DrugMAP Full Data Download File Title - DrugMAP drug to drug therapeutic target (DTT) mapping with mode of action information in raw format Version 1.01 (2022.07.20) Provided by Lab of Innovative Drug Reasearch and Bioinformatics (IDRB) College of Pharmaceutical Sciences Zhejiang University https://idrblab.org/ Any question about data provided here, please contact with: Dr. Li (lifengcheng@zju.edu.cn) and Dr. Yin (yinjiayi@zju.edu.cn) DI: Drug_ID DN: Drug_Name TI: DTT_ID TN: DTT_Name MA: MOA RN: Reference_Name RU: Reference_URL DM02A65 DI DM02A65 DM02A65 DN Temazepam DM02A65 TI TTPTXIN DM02A65 TN Translocator protein (TSPO) DM02A65 MA Modulator DM02A65 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM02A65 RU https://www.fda.gov/ DM02AWV DI DM02AWV DM02AWV DN Tolbutamide DM02AWV TI TTEF5MJ DM02AWV TN ATP-binding cassette transporter C9 (ABCC9) DM02AWV MA Blocker DM02AWV RN Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. DM02AWV RU https://pubmed.ncbi.nlm.nih.gov/19065048 DM02AWV DI DM02AWV DM02AWV DN Tolbutamide DM02AWV TI TTP835K DM02AWV TN ATP-binding cassette transporter C8 (ABCC8) DM02AWV MA Blocker DM02AWV RN Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J Clin Invest. 2009 Jan;119(1):80-90. DM02AWV RU https://pubmed.ncbi.nlm.nih.gov/19065048 DM03CP7 DI DM03CP7 DM03CP7 DN Calcipotriol DM03CP7 TI TTK59TV DM03CP7 TN Vitamin D3 receptor (VDR) DM03CP7 MA Antagonist DM03CP7 RN Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59. DM03CP7 RU https://pubmed.ncbi.nlm.nih.gov/18393827 DM04LR2 DI DM04LR2 DM04LR2 DN Floxuridine DM04LR2 TI TTU6BFZ DM04LR2 TN Candida Thymidylate synthase (Candi TMP1) DM04LR2 MA Inhibitor DM04LR2 RN Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86. DM04LR2 RU https://pubmed.ncbi.nlm.nih.gov/10482907 DM053KT DI DM053KT DM053KT DN Aprepitant DM053KT TI TTZPO1L DM053KT TN Substance-P receptor (TACR1) DM053KT MA Antagonist DM053KT RN Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46. DM053KT RU https://pubmed.ncbi.nlm.nih.gov/19354254 DM05968 DI DM05968 DM05968 DN Otilonium bromide DM05968 TI TTXHYV6 DM05968 TN Voltage-gated L-type calcium channel (L-CaC) DM05968 MA Blocker DM05968 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM05968 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM05FXR DI DM05FXR DM05FXR DN Meclofenamic acid DM05FXR TI TTK0943 DM05FXR TN Prostaglandin G/H synthase (COX) DM05FXR MA Inhibitor DM05FXR RN Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7. DM05FXR RU https://pubmed.ncbi.nlm.nih.gov/7825862 DM0659E DI DM0659E DM0659E DN Cannabidiol DM0659E TI TT94IAG DM0659E TN Cannabinoid receptor (CB) DM0659E MA Binder DM0659E RN (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106. DM0659E RU https://pubmed.ncbi.nlm.nih.gov/12450575 DM06HG5 DI DM06HG5 DM06HG5 DN Levomethadyl Acetate DM06HG5 TI TTKWM86 DM06HG5 TN Opioid receptor mu (MOP) DM06HG5 MA Agonist DM06HG5 RN Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216. DM06HG5 RU https://pubmed.ncbi.nlm.nih.gov/10911931 DM07K2I DI DM07K2I DM07K2I DN Eprosartan DM07K2I TI TT8DBY3 DM07K2I TN Angiotensin II receptor type-1 (AGTR1) DM07K2I MA Antagonist DM07K2I RN Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. DM07K2I RU https://pubmed.ncbi.nlm.nih.gov/18855637 DM07TX3 DI DM07TX3 DM07TX3 DN Cefotetan DM07TX3 TI TTJP4SM DM07TX3 TN Bacterial Penicillin binding protein (Bact PBP) DM07TX3 MA Binder DM07TX3 RN In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24. DM07TX3 RU https://pubmed.ncbi.nlm.nih.gov/17488372 DM07U2A DI DM07U2A DM07U2A DN Estradiol acetate DM07U2A TI TTZAYWL DM07U2A TN Estrogen receptor (ESR) DM07U2A MA Modulator DM07U2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM07U2A RU https://www.fda.gov/ DM08E9O DI DM08E9O DM08E9O DN Diazepam DM08E9O TI TTPTXIN DM08E9O TN Translocator protein (TSPO) DM08E9O MA Agonist DM08E9O RN Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8. DM08E9O RU https://pubmed.ncbi.nlm.nih.gov/19782064 DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 TI TTFEZ5Q DM0AQ83 TN Coagulation factor IX (F9) DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0AQ83 DI DM0AQ83 DM0AQ83 DN Emicizumab DM0AQ83 TI TTCIHJA DM0AQ83 TN Coagulation factor Xa (F10) DM0AQ83 MA Modulator DM0AQ83 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0AQ83 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0AUCH DI DM0AUCH DM0AUCH DN Reslizumab DM0AUCH TI TTPREZD DM0AUCH TN Interleukin-5 (IL5) DM0AUCH MA Modulator DM0AUCH RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DM0AUCH RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DM0BQRS DI DM0BQRS DM0BQRS DN Spinosad DM0BQRS TI TT9JZPU DM0BQRS TN Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR) DM0BQRS MA Modulator DM0BQRS RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM0BQRS RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM0C9IL DI DM0C9IL DM0C9IL DN Ranolazine DM0C9IL TI TTP86E2 DM0C9IL TN Plasminogen (PLG) DM0C9IL MA Modulator DM0C9IL RN Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. DM0C9IL RU https://pubmed.ncbi.nlm.nih.gov/23694890 DM0CVXA DI DM0CVXA DM0CVXA DN Mechlorethamine DM0CVXA TI TTUTN1I DM0CVXA TN Human Deoxyribonucleic acid (hDNA) DM0CVXA MA Intercalator DM0CVXA RN Proteomic analysis of DNA-protein cross-linking by antitumor nitrogen mustards. Chem Res Toxicol. 2009 Jun;22(6):1151-62. DM0CVXA RU https://pubmed.ncbi.nlm.nih.gov/19480393 DM0D9YJ DI DM0D9YJ DM0D9YJ DN Dirithromycin DM0D9YJ TI TTUWYEA DM0D9YJ TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM0D9YJ MA Binder DM0D9YJ RN Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98. DM0D9YJ RU https://pubmed.ncbi.nlm.nih.gov/11324679 DM0DQM5 DI DM0DQM5 DM0DQM5 DN Amlexanox DM0DQM5 TI TT78R5H DM0DQM5 TN Heat shock protein 90 alpha (HSP90A) DM0DQM5 MA Inhibitor DM0DQM5 RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM0DQM5 RU https://pubmed.ncbi.nlm.nih.gov/12803546 DM0DTF7 DI DM0DTF7 DM0DTF7 DN Zonisamide DM0DTF7 TI TTRK8B9 DM0DTF7 TN Sodium channel unspecific (NaC) DM0DTF7 MA Blocker DM0DTF7 RN Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8. DM0DTF7 RU https://pubmed.ncbi.nlm.nih.gov/18782687 DM0DXA8 DI DM0DXA8 DM0DXA8 DN Droperidol DM0DXA8 TI TTEX248 DM0DXA8 TN Dopamine D2 receptor (D2R) DM0DXA8 MA Binder DM0DXA8 RN Alpha-adrenergic blockade: a possible mechanism of tocolytic action of certain benzodiazepines in a postpartum rat model in vivo. Life Sci. 2003 Jan 24;72(10):1093-102. DM0DXA8 RU https://pubmed.ncbi.nlm.nih.gov/12505540 DM0E6S3 DI DM0E6S3 DM0E6S3 DN Suvorexant DM0E6S3 TI TT9N02I DM0E6S3 TN Orexin receptor type 2 (HCRTR2) DM0E6S3 MA Modulator DM0E6S3 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM0E6S3 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM0EP7M DI DM0EP7M DM0EP7M DN Minaprine DM0EP7M TI TT0K1SC DM0EP7M TN 5-HT 2B receptor (HTR2B) DM0EP7M MA Antagonist DM0EP7M RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DM0EP7M RU https://pubmed.ncbi.nlm.nih.gov/18045214 DM0EZ9Q DI DM0EZ9Q DM0EZ9Q DN Pramlintide DM0EZ9Q TI TTVIMDE DM0EZ9Q TN Glucagon-like peptide 1 receptor (GLP1R) DM0EZ9Q MA Agonist DM0EZ9Q RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM0EZ9Q RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM0FB1J DI DM0FB1J DM0FB1J DN Sertraline DM0FB1J TI TT3ROYC DM0FB1J TN Serotonin transporter (SERT) DM0FB1J MA Inhibitor DM0FB1J RN Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6. DM0FB1J RU https://pubmed.ncbi.nlm.nih.gov/17877739 DM0FSIM DI DM0FSIM DM0FSIM DN Diphtheria-tetanus vaccine DM0FSIM TI TTXT4D5 DM0FSIM TN Bacterial Cell membrane (Bact CM) DM0FSIM RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM0FSIM RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM0GOUD DI DM0GOUD DM0GOUD DN Urokinase DM0GOUD TI TTGY7WI DM0GOUD TN Urokinase-type plasminogen activator (PLAU) DM0GOUD MA Modulator DM0GOUD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0GOUD RU https://www.fda.gov/ DM0GQ8N DI DM0GQ8N DM0GQ8N DN Amobarbital DM0GQ8N TI TT1MPAY DM0GQ8N TN GABA(A) receptor alpha-1 (GABRA1) DM0GQ8N MA Antagonist DM0GQ8N RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM0GQ8N RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM0GUSX DI DM0GUSX DM0GUSX DN Ranitidine DM0GUSX TI TTQHJ1K DM0GUSX TN Histamine H2 receptor (H2R) DM0GUSX MA Antagonist DM0GUSX RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM0GUSX RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM0HAC8 DI DM0HAC8 DM0HAC8 DN Cerliponase Alfa DM0HAC8 TI TTOVYPT DM0HAC8 TN Tripeptidyl-peptidase I (TPP1) DM0HAC8 MA Modulator DM0HAC8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0HAC8 RU https://www.fda.gov/ DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TT6EO5L DM0HS92 TN Erbb2 tyrosine kinase receptor (HER2) DM0HS92 MA Inhibitor DM0HS92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0HS92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TTGKNB4 DM0HS92 TN Epidermal growth factor receptor (EGFR) DM0HS92 MA Inhibitor DM0HS92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0HS92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0HS92 DI DM0HS92 DM0HS92 DN Merimepodib DM0HS92 TI TTL7C8Q DM0HS92 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM0HS92 MA Inhibitor DM0HS92 RN VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. DM0HS92 RU https://pubmed.ncbi.nlm.nih.gov/11288107 DM0HXDS DI DM0HXDS DM0HXDS DN Pentostatin DM0HXDS TI TTLP57V DM0HXDS TN Adenosine deaminase (ADA) DM0HXDS MA Inhibitor DM0HXDS RN Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. DM0HXDS RU https://pubmed.ncbi.nlm.nih.gov/10887639 DM0J2ZT DI DM0J2ZT DM0J2ZT DN Safinamide mesylate DM0J2ZT TI TTGP7BY DM0J2ZT TN Monoamine oxidase type B (MAO-B) DM0J2ZT MA Inhibitor DM0J2ZT RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0J2ZT RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0JE6N DI DM0JE6N DM0JE6N DN Metixene DM0JE6N TI TTZ9SOR DM0JE6N TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0JE6N MA Modulator DM0JE6N RN Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease.J Pharmacol Exp Ther.2012 Mar;340(3):595-603. DM0JE6N RU https://www.ncbi.nlm.nih.gov/pubmed/22135383 DM0JXFL DI DM0JXFL DM0JXFL DN Temocapril hydrochloride DM0JXFL TI TTL69WB DM0JXFL TN Angiotensin-converting enzyme (ACE) DM0JXFL MA Modulator DM0JXFL RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM0JXFL RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM0KAE6 DI DM0KAE6 DM0KAE6 DN Kombiglyze XR/Komboglyze FDC DM0KAE6 TI TTDIGC1 DM0KAE6 TN Dipeptidyl peptidase 4 (DPP-4) DM0KAE6 MA Modulator DM0KAE6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DM0KAE6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DM0KYI4 DI DM0KYI4 DM0KYI4 DN Mebutamate DM0KYI4 TI TTEX6LM DM0KYI4 TN GABA(A) receptor gamma-3 (GABRG3) DM0KYI4 MA Modulator DM0KYI4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0KYI4 RU https://www.fda.gov/ DM0L594 DI DM0L594 DM0L594 DN Ivabradine DM0L594 TI TTFCQYU DM0L594 TN Sinus node I(f) channel (SA node IfC) DM0L594 MA Modulator DM0L594 RN Ivabradine - the first selective sinus node If channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006 February; 60(2): 222-228. DM0L594 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1448693/ DM0L594 DI DM0L594 DM0L594 DN Ivabradine DM0L594 TI TTKLW9S DM0L594 TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DM0L594 MA Inhibitor DM0L594 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0L594 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTAWNKZ DM0LPI9 TN Norepinephrine transporter (NET) DM0LPI9 MA Modulator DM0LPI9 RN Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/25535688 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTMQO60 DM0LPI9 TN Rho-associated protein kinase (ROCK) DM0LPI9 MA Modulator DM0LPI9 RN Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/25535688 DM0LPI9 DI DM0LPI9 DM0LPI9 DN Netarsudil DM0LPI9 TI TTZN7RP DM0LPI9 TN Rho-associated protein kinase 1 (ROCK1) DM0LPI9 MA Inhibitor DM0LPI9 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM0LPI9 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM0LRU9 DI DM0LRU9 DM0LRU9 DN Fendrix DM0LRU9 TI TT3J5ZI DM0LRU9 TN Cell mediated immunity response (CMIR) DM0LRU9 RN Revaccination with Fendrix or HBVaxPro results in better response rates than does revaccination with three doses of Engerix-B in previous non-responders. Vaccine. 2012 Nov 6;30(48):6734-7. DM0LRU9 RU https://pubmed.ncbi.nlm.nih.gov/22981848 DM0MQ35 DI DM0MQ35 DM0MQ35 DN Spectinomycin DM0MQ35 TI TTQ8KVI DM0MQ35 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM0MQ35 MA Binder DM0MQ35 RN Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. DM0MQ35 RU https://pubmed.ncbi.nlm.nih.gov/11014183 DM0N3L7 DI DM0N3L7 DM0N3L7 DN Ethopropazine DM0N3L7 TI TTTIBOJ DM0N3L7 TN Histamine H1 receptor (H1R) DM0N3L7 MA Modulator DM0N3L7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N3L7 RU https://www.fda.gov/ DM0N85H DI DM0N85H DM0N85H DN Vidarabine DM0N85H TI TTNE7KG DM0N85H TN Adenosine A2b receptor (ADORA2B) DM0N85H MA Modulator DM0N85H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N85H RU https://www.fda.gov/ DM0N9WA DI DM0N9WA DM0N9WA DN Calcitonin Human DM0N9WA TI TTLWS2O DM0N9WA TN Calcitonin receptor (CALCR) DM0N9WA MA Modulator DM0N9WA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0N9WA RU https://www.fda.gov/ DM0NATE DI DM0NATE DM0NATE DN Insulin Susp Protamine Zinc Beef/Pork DM0NATE TI TTZOPHG DM0NATE TN Insulin (INS) DM0NATE MA Modulator DM0NATE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0NATE RU https://www.fda.gov/ DM0P63W DI DM0P63W DM0P63W DN Guanidine Hydrochloride DM0P63W TI TTQ8AFT DM0P63W TN Adrenergic receptor Alpha-2 (ADRA2) DM0P63W MA Modulator DM0P63W RN Guanidine-based 2-adrenoceptor ligands: Towards selective antagonist activity.Eur J Med Chem.2014 Jul 23;82:242-54. DM0P63W RU https://www.ncbi.nlm.nih.gov/pubmed/24908653 DM0PMGJ DI DM0PMGJ DM0PMGJ DN Polyestradiol Phosphate DM0PMGJ TI TT2A0DR DM0PMGJ TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM0PMGJ MA Modulator DM0PMGJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0PMGJ RU https://www.fda.gov/ DM0Q8MZ DI DM0Q8MZ DM0Q8MZ DN Trimethadione DM0Q8MZ TI TT729IR DM0Q8MZ TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM0Q8MZ MA Blocker DM0Q8MZ RN Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. DM0Q8MZ RU https://pubmed.ncbi.nlm.nih.gov/17291698 DM0QD4W DI DM0QD4W DM0QD4W DN Aprotinin DM0QD4W TI TTEMV5X DM0QD4W TN Serine protease unspecific (SP) DM0QD4W MA Modulator DM0QD4W RN Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding Clin Trials. 2005;2(3):218-29; discussion 229-32. DM0QD4W RU https://pubmed.ncbi.nlm.nih.gov/16279145 DM0QJDC DI DM0QJDC DM0QJDC DN Lixisenatide DM0QJDC TI TTVIMDE DM0QJDC TN Glucagon-like peptide 1 receptor (GLP1R) DM0QJDC MA Modulator DM0QJDC RN GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42. DM0QJDC RU https://www.ncbi.nlm.nih.gov/pubmed/22945360 DM0QV1J DI DM0QV1J DM0QV1J DN Baclofen DM0QV1J TI TTDCVZW DM0QV1J TN Gamma-aminobutyric acid B receptor (GABBR) DM0QV1J MA Modulator DM0QV1J RN Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9. DM0QV1J RU https://pubmed.ncbi.nlm.nih.gov/10354414 DM0QZBN DI DM0QZBN DM0QZBN DN Ibandronate DM0QZBN TI TTIKWV4 DM0QZBN TN Geranyltranstransferase (FDPS) DM0QZBN MA Modulator DM0QZBN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0QZBN RU https://www.fda.gov/ DM0R4Z5 DI DM0R4Z5 DM0R4Z5 DN MCB-3837 DM0R4Z5 TI TT9SL3Q DM0R4Z5 TN Polypeptide deformylase (PDF) DM0R4Z5 MA Inhibitor DM0R4Z5 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM0R4Z5 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM0REZS DI DM0REZS DM0REZS DN Virulizin DM0REZS TI TTD2MLN DM0REZS TN Natural killer cell activation (NKA) DM0REZS MA Modulator DM0REZS RN Virulizin, a novel immunotherapy agent, activates NK cells through induction of IL-12 expression in macrophages. Cancer Immunol Immunother. 2005 Nov;54(11):1115-26. DM0REZS RU https://pubmed.ncbi.nlm.nih.gov/15891881 DM0RKS4 DI DM0RKS4 DM0RKS4 DN Bepridil DM0RKS4 TI TT5HONZ DM0RKS4 TN Calcium channel unspecific (CaC) DM0RKS4 MA Modulator DM0RKS4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0RKS4 RU https://www.fda.gov/ DM0RXF5 DI DM0RXF5 DM0RXF5 DN Hyqvia DM0RXF5 TI TTXFI1K DM0RXF5 TN Hyaluronidase (HYAL) DM0RXF5 MA Modulator DM0RXF5 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM0RXF5 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM0S9Z1 DI DM0S9Z1 DM0S9Z1 DN Nemonoxacin DM0S9Z1 TI TTN6J5F DM0S9Z1 TN Bacterial DNA gyrase (Bact gyrase) DM0S9Z1 MA Inhibitor DM0S9Z1 RN Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53. DM0S9Z1 RU https://pubmed.ncbi.nlm.nih.gov/25079302 DM0SYAN DI DM0SYAN DM0SYAN DN Almitrine DM0SYAN TI TTWK8D0 DM0SYAN TN Sodium pump subunit alpha-1 (ATP1A1) DM0SYAN MA Binder DM0SYAN RN Almitrine, a new kind of energy-transduction inhibitor acting on mitochondrial ATP synthase. Biochim Biophys Acta. 1989 Aug 3;975(3):325-9. DM0SYAN RU https://pubmed.ncbi.nlm.nih.gov/2527061 DM0T3YH DI DM0T3YH DM0T3YH DN Indinavir DM0T3YH TI TT5FNQT DM0T3YH TN Human immunodeficiency virus Protease (HIV PR) DM0T3YH MA Inhibitor DM0T3YH RN Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liq... J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):575-80. DM0T3YH RU https://pubmed.ncbi.nlm.nih.gov/19168402 DM0TI4U DI DM0TI4U DM0TI4U DN Acebutolol DM0TI4U TI TTR6W5O DM0TI4U TN Adrenergic receptor beta-1 (ADRB1) DM0TI4U MA Antagonist DM0TI4U RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DM0TI4U RU https://pubmed.ncbi.nlm.nih.gov/16268148 DM0VEC1 DI DM0VEC1 DM0VEC1 DN Ergonovine DM0VEC1 TI TTEX248 DM0VEC1 TN Dopamine D2 receptor (D2R) DM0VEC1 MA Agonist DM0VEC1 RN Agonist profile of ergometrine (ergonovine) on a population of postsynaptic alpha-adrenoceptors. J Pharm Pharmacol. 1988 Feb;40(2):137-9. DM0VEC1 RU https://pubmed.ncbi.nlm.nih.gov/2897449 DM0VQN3 DI DM0VQN3 DM0VQN3 DN Ofloxacin DM0VQN3 TI TTN6J5F DM0VQN3 TN Bacterial DNA gyrase (Bact gyrase) DM0VQN3 MA Modulator DM0VQN3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM0VQN3 RU https://www.fda.gov/ DM0WX6I DI DM0WX6I DM0WX6I DN Primidone DM0WX6I TI TT1MPAY DM0WX6I TN GABA(A) receptor alpha-1 (GABRA1) DM0WX6I MA Antagonist DM0WX6I RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM0WX6I RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM0Y49P DI DM0Y49P DM0Y49P DN Olanzapine/fluoxetine combination DM0Y49P TI TT8G3Z7 DM0Y49P TN Serotoninnorepinephrinedopamine reuptake (SNDR) DM0Y49P MA Antagonist DM0Y49P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM0Y49P RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM0YJSB DI DM0YJSB DM0YJSB DN Enflurane DM0YJSB TI TTAN6JD DM0YJSB TN Glutamate receptor AMPA (GRIA) DM0YJSB MA Suppressor DM0YJSB RN Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84. DM0YJSB RU https://pubmed.ncbi.nlm.nih.gov/11020764 DM0YWJC DI DM0YWJC DM0YWJC DN Safinamide DM0YWJC TI TTGP7BY DM0YWJC TN Monoamine oxidase type B (MAO-B) DM0YWJC MA Inhibitor DM0YWJC RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DM0YWJC RU https://pubmed.ncbi.nlm.nih.gov/17874969 DM0YZC6 DI DM0YZC6 DM0YZC6 DN Fulvestrant DM0YZC6 TI TTZAYWL DM0YZC6 TN Estrogen receptor (ESR) DM0YZC6 MA Antagonist DM0YZC6 RN Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway. Cell Motil Cytoskeleton. 2009 Jul;66(7):378-88. DM0YZC6 RU https://pubmed.ncbi.nlm.nih.gov/19466750 DM0ZRMQ DI DM0ZRMQ DM0ZRMQ DN Clomocycline DM0ZRMQ TI TTQ8KVI DM0ZRMQ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM0ZRMQ MA Binder DM0ZRMQ RN Molecular dynamics simulations of the 30S ribosomal subunit reveal a preferred tetracycline binding site. J Am Chem Soc. 2008 Jan 30;130(4):1114-5. DM0ZRMQ RU https://pubmed.ncbi.nlm.nih.gov/18219717 DM13495 DI DM13495 DM13495 DN Fesoterodine fumarate DM13495 TI TTZ9SOR DM13495 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM13495 MA Modulator DM13495 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM13495 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM13P4C DI DM13P4C DM13P4C DN Salsalate DM13P4C TI TT8NGED DM13P4C TN Prostaglandin G/H synthase 1 (COX-1) DM13P4C MA Inhibitor DM13P4C RN New non-steroidal anti-rheumatic drugs: selective inhibitors of inducible cyclooxygenase. Med Klin (Munich). 1998 Jul 15;93(7):407-15. DM13P4C RU https://pubmed.ncbi.nlm.nih.gov/9711054 DM13PQW DI DM13PQW DM13PQW DN Rilmenidine DM13PQW TI TT2NUT5 DM13PQW TN Adrenergic receptor alpha-2C (ADRA2C) DM13PQW MA Modulator DM13PQW RN Rilmenidine-induced ocular hypotension: role of imidazoline1 and alpha 2 receptors. Curr Eye Res. 1996 Sep;15(9):943-50. DM13PQW RU https://pubmed.ncbi.nlm.nih.gov/8921215 DM13VTW DI DM13VTW DM13VTW DN Flucytosine DM13VTW TI TTU6BFZ DM13VTW TN Candida Thymidylate synthase (Candi TMP1) DM13VTW MA Inhibitor DM13VTW RN Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. DM13VTW RU https://pubmed.ncbi.nlm.nih.gov/16964330 DM14MAE DI DM14MAE DM14MAE DN Pergolide DM14MAE TI TTZFYLI DM14MAE TN Dopamine D1 receptor (D1R) DM14MAE MA Modulator DM14MAE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM14MAE RU https://www.fda.gov/ DM14MAE DI DM14MAE DM14MAE DN Pergolide DM14MAE TI TTEX248 DM14MAE TN Dopamine D2 receptor (D2R) DM14MAE MA Modulator DM14MAE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM14MAE RU https://www.fda.gov/ DM14RF5 DI DM14RF5 DM14RF5 DN Secobarbital DM14RF5 TI TT1MPAY DM14RF5 TN GABA(A) receptor alpha-1 (GABRA1) DM14RF5 MA Antagonist DM14RF5 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM14RF5 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM154EB DI DM154EB DM154EB DN Lypressin DM154EB TI TTPFZJ1 DM154EB TN Vasopressin V1 receptor (V1R) DM154EB MA Modulator DM154EB RN Human pain thresholds after the application of lypressin, a vasopressin analogue. Pharmacol Toxicol. 1987 Jul;61(1):16-9. DM154EB RU https://pubmed.ncbi.nlm.nih.gov/3628176 DM15F0X DI DM15F0X DM15F0X DN Gefitinib DM15F0X TI TTGKNB4 DM15F0X TN Epidermal growth factor receptor (EGFR) DM15F0X MA Inhibitor DM15F0X RN Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72. DM15F0X RU https://pubmed.ncbi.nlm.nih.gov/14760365 DM15HAT DI DM15HAT DM15HAT DN Leuprorelin acetate DM15HAT TI TT8R70G DM15HAT TN Gonadotropin-releasing hormone receptor (GNRHR) DM15HAT MA Agonist DM15HAT RN Clinical pipeline report, company report or official report of Takeda (2009). DM15HAT RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM15HL8 DI DM15HL8 DM15HL8 DN Clindamycin DM15HL8 TI TTUWYEA DM15HL8 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM15HL8 MA Binder DM15HL8 RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM15HL8 RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM17ONX DI DM17ONX DM17ONX DN Fexofenadine DM17ONX TI TTTIBOJ DM17ONX TN Histamine H1 receptor (H1R) DM17ONX MA Antagonist DM17ONX RN Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. DM17ONX RU https://pubmed.ncbi.nlm.nih.gov/19210904 DM1A6RV DI DM1A6RV DM1A6RV DN Interferon beta-1a DM1A6RV TI TT4TZ8J DM1A6RV TN Interferon-beta (IFNB1) DM1A6RV MA Modulator DM1A6RV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1A6RV RU https://www.fda.gov/ DM1A9W3 DI DM1A9W3 DM1A9W3 DN Drospirenone DM1A9W3 TI TT26PHO DM1A9W3 TN Mineralocorticoid receptor (MR) DM1A9W3 MA Binder DM1A9W3 RN Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. DM1A9W3 RU https://pubmed.ncbi.nlm.nih.gov/16719803 DM1A9XO DI DM1A9XO DM1A9XO DN Sertaconazole DM1A9XO TI TTTSOUD DM1A9XO TN Candida Cytochrome P450 51 (Candi ERG11) DM1A9XO MA Inhibitor DM1A9XO RN Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59. DM1A9XO RU https://pubmed.ncbi.nlm.nih.gov/19275277 DM1AF5U DI DM1AF5U DM1AF5U DN Acetazolamide DM1AF5U TI TTHQPL7 DM1AF5U TN Carbonic anhydrase I (CA-I) DM1AF5U MA Modulator DM1AF5U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1AF5U RU https://www.fda.gov/ DM1AGXN DI DM1AGXN DM1AGXN DN Paromomycin DM1AGXN TI TTQ8KVI DM1AGXN TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM1AGXN MA Binder DM1AGXN RN Aminoglycoside association pathways with the 30S ribosomal subunit. J Phys Chem B. 2009 May 21;113(20):7322-30. DM1AGXN RU https://pubmed.ncbi.nlm.nih.gov/19438282 DM1BKA6 DI DM1BKA6 DM1BKA6 DN Opicapone DM1BKA6 TI TTKWFB8 DM1BKA6 TN Catechol-O-methyl-transferase (COMT) DM1BKA6 MA Inhibitor DM1BKA6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1BKA6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212489s000lbl.pdf DM1BS03 DI DM1BS03 DM1BS03 DN Sifalimumab DM1BS03 TI TTMQB37 DM1BS03 TN Interferon alpha/beta receptor 2 (IFNAR2) DM1BS03 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM1BS03 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM1BV7W DI DM1BV7W DM1BV7W DN Aliskiren DM1BV7W TI TTB2MXP DM1BV7W TN Angiotensinogenase renin (REN) DM1BV7W MA Inhibitor DM1BV7W RN Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patie... J Renin Angiotensin Aldosterone Syst. 2009 Sep;10(3):157-67. DM1BV7W RU https://pubmed.ncbi.nlm.nih.gov/19617271 DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R TI TTRA79S DM1CI9R TN Cholesterol synthesis (Chole synth) DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DM1CI9R DI DM1CI9R DM1CI9R DN Bempedoic acid DM1CI9R TI TT0Z6Y2 DM1CI9R TN ATP-citrate synthase (ACLY) DM1CI9R MA Inhibitor DM1CI9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM1CI9R RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf DM1D8XY DI DM1D8XY DM1D8XY DN Dantrolene DM1D8XY TI TT9YXM1 DM1D8XY TN Ryanodine receptor (RYR) DM1D8XY MA Modulator DM1D8XY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1D8XY RU https://www.fda.gov/ DM1D90W DI DM1D90W DM1D90W DN Tropicamide DM1D90W TI TTQ3JTF DM1D90W TN Muscarinic acetylcholine receptor M4 (CHRM4) DM1D90W MA Antagonist DM1D90W RN The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 rec... Psychopharmacology (Berl). 2007 Oct;194(3):347-59. DM1D90W RU https://pubmed.ncbi.nlm.nih.gov/17594079 DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 TI TTF1QVM DM1DBV5 TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM1DBV5 MA Inhibitor DM1DBV5 RN Clinical pipeline report, company report or official report of Takeda (2009). DM1DBV5 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM1DBV5 DI DM1DBV5 DM1DBV5 DN Dexlansoprazole DM1DBV5 TI TTLOKXP DM1DBV5 TN Gastric H(+)/K(+) ATPase (Proton pump) DM1DBV5 MA Modulator DM1DBV5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1DBV5 RU https://www.fda.gov/ DM1DP7T DI DM1DP7T DM1DP7T DN Levonorgestrel DM1DP7T TI TTUV8G9 DM1DP7T TN Progesterone receptor (PGR) DM1DP7T MA Binder DM1DP7T RN Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins. Mol Pharmacol. 2009 Jun;75(6):1317-24. DM1DP7T RU https://pubmed.ncbi.nlm.nih.gov/19289570 DM1DX4Q DI DM1DX4Q DM1DX4Q DN Eribulin DM1DX4Q TI TTML2WA DM1DX4Q TN Tubulin (TUB) DM1DX4Q MA Inhibitor DM1DX4Q RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM1DX4Q RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM1ECNJ DI DM1ECNJ DM1ECNJ DN GS-7340 DM1ECNJ TI TT84ETX DM1ECNJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1ECNJ MA Inhibitor DM1ECNJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020 DM1ECNJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208464s008lbl.pdf DM1EF73 DI DM1EF73 DM1EF73 DN Methysergide DM1EF73 TI TTWJBZ5 DM1EF73 TN 5-HT 2C receptor (HTR2C) DM1EF73 MA Antagonist DM1EF73 RN Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8. DM1EF73 RU https://pubmed.ncbi.nlm.nih.gov/18396470 DM1F42Z DI DM1F42Z DM1F42Z DN Oxatomide DM1F42Z TI TTTIBOJ DM1F42Z TN Histamine H1 receptor (H1R) DM1F42Z MA Antagonist DM1F42Z RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM1F42Z RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM1FDN8 DI DM1FDN8 DM1FDN8 DN Mizolastine DM1FDN8 TI TTTIBOJ DM1FDN8 TN Histamine H1 receptor (H1R) DM1FDN8 MA Antagonist DM1FDN8 RN Histamine H1-receptor antagonists inhibit nuclear factor-kappaB and activator protein-1 activities via H1-receptor-dependent and -independent mechanisms. Clin Exp Allergy. 2008 Jun;38(6):947-56. DM1FDN8 RU https://pubmed.ncbi.nlm.nih.gov/18498541 DM1FX74 DI DM1FX74 DM1FX74 DN Bretylium DM1FX74 TI TTR6W5O DM1FX74 TN Adrenergic receptor beta-1 (ADRB1) DM1FX74 MA Antagonist DM1FX74 RN Components of functional sympathetic control of heart rate in neonatal rats. Am J Physiol. 1985 May;248(5 Pt 2):R601-10. DM1FX74 RU https://pubmed.ncbi.nlm.nih.gov/2859811 DM1I3D5 DI DM1I3D5 DM1I3D5 DN Lepirudin DM1I3D5 TI TT6L509 DM1I3D5 TN Coagulation factor IIa (F2) DM1I3D5 MA Inhibitor DM1I3D5 RN Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50. DM1I3D5 RU https://pubmed.ncbi.nlm.nih.gov/10560805 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTQ13Z5 DM1I93C TN Muscarinic acetylcholine receptor M3 (CHRM3) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTZ9SOR DM1I93C TN Muscarinic acetylcholine receptor M1 (CHRM1) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1I93C DI DM1I93C DM1I93C DN SMT-D002 DM1I93C TI TTYEG6Q DM1I93C TN Muscarinic acetylcholine receptor M2 (CHRM2) DM1I93C MA Agonist DM1I93C RN Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. DM1I93C RU https://pubmed.ncbi.nlm.nih.gov/15540789 DM1IB4Q DI DM1IB4Q DM1IB4Q DN Zolmitriptan DM1IB4Q TI TTK8CXU DM1IB4Q TN 5-HT 1B receptor (HTR1B) DM1IB4Q MA Modulator DM1IB4Q RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1IB4Q RU https://www.fda.gov/ DM1IB4Q DI DM1IB4Q DM1IB4Q DN Zolmitriptan DM1IB4Q TI TT6MSOK DM1IB4Q TN 5-HT 1D receptor (HTR1D) DM1IB4Q MA Modulator DM1IB4Q RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1IB4Q RU https://www.fda.gov/ DM1IFGT DI DM1IFGT DM1IFGT DN Chlorproguanil DM1IFGT TI TT9SL3Q DM1IFGT TN Polypeptide deformylase (PDF) DM1IFGT MA Inhibitor DM1IFGT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM1IFGT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM1IQRP DI DM1IQRP DM1IQRP DN Udenafil DM1IQRP TI TTJ0IQB DM1IQRP TN Phosphodiesterase 5A (PDE5A) DM1IQRP MA Inhibitor DM1IQRP RN Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42. DM1IQRP RU https://pubmed.ncbi.nlm.nih.gov/19465935 DM1IS6U DI DM1IS6U DM1IS6U DN Tenofovir DM1IS6U TI TT84ETX DM1IS6U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1IS6U MA Inhibitor DM1IS6U RN Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33. DM1IS6U RU https://pubmed.ncbi.nlm.nih.gov/15125867 DM1JEGF DI DM1JEGF DM1JEGF DN Albiglutide DM1JEGF TI TTVIMDE DM1JEGF TN Glucagon-like peptide 1 receptor (GLP1R) DM1JEGF MA Modulator DM1JEGF RN GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.Nat Rev Endocrinol.2012 Dec;8(12):728-42. DM1JEGF RU https://www.ncbi.nlm.nih.gov/pubmed/22945360 DM1KS78 DI DM1KS78 DM1KS78 DN Talazoparib DM1KS78 TI TTEBCY8 DM1KS78 TN Poly [ADP-ribose] polymerase (PARP) DM1KS78 MA Inhibitor DM1KS78 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1KS78 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1M0Q4 DI DM1M0Q4 DM1M0Q4 DN Procaterol DM1M0Q4 TI TT2CJVK DM1M0Q4 TN Adrenergic receptor beta-2 (ADRB2) DM1M0Q4 MA Agonist DM1M0Q4 RN Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice. Allergol Int. 2007 Sep;56(3):285-91. DM1M0Q4 RU https://pubmed.ncbi.nlm.nih.gov/17646734 DM1MBYQ DI DM1MBYQ DM1MBYQ DN Ganciclovir DM1MBYQ TI TTIU7X1 DM1MBYQ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM1MBYQ MA Inhibitor DM1MBYQ RN Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81. DM1MBYQ RU https://pubmed.ncbi.nlm.nih.gov/19563015 DM1N62C DI DM1N62C DM1N62C DN Quetiapine DM1N62C TI TTEX248 DM1N62C TN Dopamine D2 receptor (D2R) DM1N62C MA Agonist DM1N62C RN Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. DM1N62C RU https://pubmed.ncbi.nlm.nih.gov/19217900 DM1NG5W DI DM1NG5W DM1NG5W DN Hydrogen peroxide DM1NG5W TI TTELIN2 DM1NG5W TN PTPN1 messenger RNA (PTPN1 mRNA) DM1NG5W MA Inhibitor DM1NG5W RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DM1NG5W RU https://pubmed.ncbi.nlm.nih.gov/10091683 DM1NOEK DI DM1NOEK DM1NOEK DN Metreleptin DM1NOEK TI TT0HD6V DM1NOEK TN Leptin receptor (LEPR) DM1NOEK MA Modulator DM1NOEK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM1NOEK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM1O3BY DI DM1O3BY DM1O3BY DN Mecasermin DM1O3BY TI TTHRID2 DM1O3BY TN Insulin-like growth factor I receptor (IGF1R) DM1O3BY MA Inhibitor DM1O3BY RN IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45. DM1O3BY RU https://pubmed.ncbi.nlm.nih.gov/12845531 DM1OFHN DI DM1OFHN DM1OFHN DN Meglitinides DM1OFHN TI TTCBFJO DM1OFHN TN Insulin receptor (INSR) DM1OFHN MA Stimulator DM1OFHN RN New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62. DM1OFHN RU https://pubmed.ncbi.nlm.nih.gov/18840004 DM1OFHN DI DM1OFHN DM1OFHN DN Meglitinides DM1OFHN TI TTEX248 DM1OFHN TN Dopamine D2 receptor (D2R) DM1OFHN MA Antagonist DM1OFHN RN Specific in vitro and in vivo binding of 3H-raclopride. A potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol. 1985 Jul 1;34(13):2251-9. DM1OFHN RU https://pubmed.ncbi.nlm.nih.gov/4015674 DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR TI TTROQ37 DM1P6FR TN MAPK/ERK kinase kinase (MAP3K) DM1P6FR MA Modulator DM1P6FR RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DM1P6FR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DM1P6FR DI DM1P6FR DM1P6FR DN Arry-162 DM1P6FR TI TTZCRP3 DM1P6FR TN ERK activator kinase (MEK) DM1P6FR MA Inhibitor DM1P6FR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1P6FR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1QLST DI DM1QLST DM1QLST DN Trimazosin DM1QLST TI TT34BHT DM1QLST TN Adrenergic receptor alpha-1D (ADRA1D) DM1QLST MA Modulator DM1QLST RN The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50. DM1QLST RU https://pubmed.ncbi.nlm.nih.gov/6199597 DM1R5X4 DI DM1R5X4 DM1R5X4 DN Becaplermin DM1R5X4 TI TTI7421 DM1R5X4 TN Platelet-derived growth factor receptor beta (PDGFRB) DM1R5X4 MA Modulator DM1R5X4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1R5X4 RU https://www.fda.gov/ DM1RBYG DI DM1RBYG DM1RBYG DN Nitric Oxide DM1RBYG TI TT6HPVC DM1RBYG TN Guanylate cyclase (GC) DM1RBYG MA Stimulator DM1RBYG RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DM1RBYG RU https://pubmed.ncbi.nlm.nih.gov/19618122 DM1RBYG DI DM1RBYG DM1RBYG DN Nitric Oxide DM1RBYG TI TT23PYC DM1RBYG TN Soluble guanylate cyclase (GCS) DM1RBYG MA Stimulator DM1RBYG RN Nitric oxide and nitrovasodilators: similarities, differences, and interactions. Am J Cardiol. 1996 May 30;77(13):2C-7C. DM1RBYG RU https://pubmed.ncbi.nlm.nih.gov/8638522 DM1S4AG DI DM1S4AG DM1S4AG DN Lumiracoxib DM1S4AG TI TTVKILB DM1S4AG TN Prostaglandin G/H synthase 2 (COX-2) DM1S4AG MA Inhibitor DM1S4AG RN Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8. DM1S4AG RU https://pubmed.ncbi.nlm.nih.gov/19251789 DM1SC8M DI DM1SC8M DM1SC8M DN Trimipramine DM1SC8M TI TTAWNKZ DM1SC8M TN Norepinephrine transporter (NET) DM1SC8M MA Inhibitor DM1SC8M RN Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90. DM1SC8M RU https://pubmed.ncbi.nlm.nih.gov/16388933 DM1SRQT DI DM1SRQT DM1SRQT DN Aceprometazine DM1SRQT TI TTTIBOJ DM1SRQT TN Histamine H1 receptor (H1R) DM1SRQT MA Antagonist DM1SRQT RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM1SRQT RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM1TJ8F DI DM1TJ8F DM1TJ8F DN Diethylcarbamazine DM1TJ8F TI TT2J34L DM1TJ8F TN Arachidonate 5-lipoxygenase (5-LOX) DM1TJ8F MA Inhibitor DM1TJ8F RN Inhibition of leukotriene formation by diethylcarbamazine modifies the acid-base balance in the rabbits with blast injuries of the lungs. Vojnosanit Pregl. 1999 May-Jun;56(3):243-7. DM1TJ8F RU https://pubmed.ncbi.nlm.nih.gov/10518442 DM1TMA3 DI DM1TMA3 DM1TMA3 DN Imiquimod DM1TMA3 TI TTRJ1K4 DM1TMA3 TN Toll-like receptor 7 (TLR7) DM1TMA3 MA Agonist DM1TMA3 RN Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85. DM1TMA3 RU https://pubmed.ncbi.nlm.nih.gov/19516264 DM1UE67 DI DM1UE67 DM1UE67 DN TOCOTRIENOL DM1UE67 TI TTPADOQ DM1UE67 TN HMG-CoA reductase (HMGCR) DM1UE67 MA Inhibitor DM1UE67 RN Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo). 2002 Oct;48(5):332-7. DM1UE67 RU https://pubmed.ncbi.nlm.nih.gov/12656204 DM1UJO0 DI DM1UJO0 DM1UJO0 DN Pitavastatin calcium DM1UJO0 TI TTPADOQ DM1UJO0 TN HMG-CoA reductase (HMGCR) DM1UJO0 MA Inhibitor DM1UJO0 RN Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203. DM1UJO0 RU https://pubmed.ncbi.nlm.nih.gov/11304935 DM1UV7F DI DM1UV7F DM1UV7F DN Baloxavir marboxil DM1UV7F TI TTWORX6 DM1UV7F TN Influenza Polymerase acidic endonuclease (Influ PA) DM1UV7F MA Inhibitor DM1UV7F RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1UV7F RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 TI TTK8R02 DM1V329 TN Vasopressin V2 receptor (V2R) DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DM1V329 DI DM1V329 DM1V329 DN Conivaptan DM1V329 TI TT4TFGN DM1V329 TN Vasopressin V1a receptor (V1AR) DM1V329 MA Modulator DM1V329 RN Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23. DM1V329 RU https://pubmed.ncbi.nlm.nih.gov/11705818 DM1V5ZS DI DM1V5ZS DM1V5ZS DN Felbamate DM1V5ZS TI TT9IK2Z DM1V5ZS TN N-methyl-D-aspartate receptor (NMDAR) DM1V5ZS MA Antagonist DM1V5ZS RN Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008 Mar 27;51(6):1534-45. DM1V5ZS RU https://pubmed.ncbi.nlm.nih.gov/18311896 DM1WL9O DI DM1WL9O DM1WL9O DN Glycodiazine DM1WL9O TI TTG140O DM1WL9O TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DM1WL9O MA Binder DM1WL9O RN Coupling between proximal tubular transport processes. Studies with ouabain, SITS and HCO3-free solutions. Pflugers Arch. 1977 Apr 25;368(3):245-52. DM1WL9O RU https://pubmed.ncbi.nlm.nih.gov/141035 DM1WXA6 DI DM1WXA6 DM1WXA6 DN Lofexidine DM1WXA6 TI TTQ8AFT DM1WXA6 TN Adrenergic receptor Alpha-2 (ADRA2) DM1WXA6 MA Agonist DM1WXA6 RN Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6. DM1WXA6 RU https://pubmed.ncbi.nlm.nih.gov/18821454 DM1WXA6 DI DM1WXA6 DM1WXA6 DN Lofexidine DM1WXA6 TI TTWG9A4 DM1WXA6 TN Adrenergic receptor alpha-2A (ADRA2A) DM1WXA6 MA Agonist DM1WXA6 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM1WXA6 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM1XBHS DI DM1XBHS DM1XBHS DN Pentazocine DM1XBHS TI TTN4QDT DM1XBHS TN Opioid receptor (OPR) DM1XBHS MA Antagonist DM1XBHS RN Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8. DM1XBHS RU https://pubmed.ncbi.nlm.nih.gov/10562966 DM1XBWR DI DM1XBWR DM1XBWR DN N-acetyl-D-glucosamine DM1XBWR TI TTDM6HZ DM1XBWR TN Alpha-N-acetylglucosaminidase (NAGLU) DM1XBWR MA Activator DM1XBWR RN Development of bFGF-Chitosan Matrices and Their Interactions with Human Dermal Fibroblast Cells. J Biomater Sci Polym Ed. 2009;20(10):1335-51. DM1XBWR RU https://pubmed.ncbi.nlm.nih.gov/19622275 DM1XHYJ DI DM1XHYJ DM1XHYJ DN Etidronic acid DM1XHYJ TI TTCWXFA DM1XHYJ TN Protein-tyrosine phosphatase sigma (R-PTP-sigma) DM1XHYJ MA Inhibitor DM1XHYJ RN Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43. DM1XHYJ RU https://pubmed.ncbi.nlm.nih.gov/8992885 DM1XT4N DI DM1XT4N DM1XT4N DN Tafenoquine DM1XT4N TI TTB8JQ7 DM1XT4N TN Electron transport complex III (Complex III) DM1XT4N MA Inhibitor DM1XT4N RN Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. DM1XT4N RU https://pubmed.ncbi.nlm.nih.gov/30229442 DM1XT4N DI DM1XT4N DM1XT4N DN Tafenoquine DM1XT4N TI TTULV0X DM1XT4N TN Reactive oxygen species (ROS) DM1XT4N MA Modulator DM1XT4N RN Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. DM1XT4N RU https://pubmed.ncbi.nlm.nih.gov/30229442 DM1Y2JH DI DM1Y2JH DM1Y2JH DN Inulin DM1Y2JH TI TTZOPHG DM1Y2JH TN Insulin (INS) DM1Y2JH MA Modulator DM1Y2JH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1Y2JH RU https://www.fda.gov/ DM1Y69Q DI DM1Y69Q DM1Y69Q DN Interleukin-3 DM1Y69Q TI TT5TQ2W DM1Y69Q TN Granulocyte colony-stimulating factor (CSF3) DM1Y69Q MA Modulator DM1Y69Q RN Interleukin 3: from colony-stimulating factor to pluripotent immunoregulatory cytokine. Int J Immunopharmacol. 1992 Apr;14(3):421-30. DM1Y69Q RU https://pubmed.ncbi.nlm.nih.gov/1618595 DM1YA7M DI DM1YA7M DM1YA7M DN Sulfonamides DM1YA7M TI TT4ILYC DM1YA7M TN Bacterial Dihydropteroate synthetase (Bact folP) DM1YA7M MA Binder DM1YA7M RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DM1YA7M RU https://pubmed.ncbi.nlm.nih.gov/18804175 DM1YB0R DI DM1YB0R DM1YB0R DN OZ277 DM1YB0R TI TTZVSJ2 DM1YB0R TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DM1YB0R MA Inhibitor DM1YB0R RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM1YB0R RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM1YBHK DI DM1YBHK DM1YBHK DN Rifabutin DM1YBHK TI TTHKJLN DM1YBHK TN DNA-directed RNA polymerase (RNAP) DM1YBHK MA Modulator DM1YBHK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM1YBHK RU https://www.fda.gov/ DM1YBRM DI DM1YBRM DM1YBRM DN Cyclobenzaprine DM1YBRM TI TTYSN63 DM1YBRM TN 5-HT 2 receptor (5HT2R) DM1YBRM MA Antagonist DM1YBRM RN Torticollis under Cyclobenzaprine. Pharmacology. 2009 Jul 8;84(2):91-92. DM1YBRM RU https://pubmed.ncbi.nlm.nih.gov/19590258 DM1YEPS DI DM1YEPS DM1YEPS DN Volanesorsen DM1YEPS TI TTXOZQ1 DM1YEPS TN ApoC-III messenger RNA (APOC3 mRNA) DM1YEPS MA Inhibitor DM1YEPS RN Metabolism and Disposition of Volanesorsen, a 2'- O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species. Drug Metab Dispos. 2019 Oct;47(10):1164-1173. DM1YEPS RU https://pubmed.ncbi.nlm.nih.gov/31350288 DM1YVZT DI DM1YVZT DM1YVZT DN Rituximab DM1YVZT TI TTUE541 DM1YVZT TN Leukocyte surface antigen Leu-16 (CD20) DM1YVZT RN Clinical pipeline report, company report or official report of Genentech (2009). DM1YVZT RU http://www.gene.com/gene/pipeline/status/ DM20K91 DI DM20K91 DM20K91 DN Travoprost DM20K91 TI TTT2ZAR DM20K91 TN Prostaglandin F2-alpha receptor (PTGFR) DM20K91 MA Agonist DM20K91 RN Prostaglandin subtype-selective and non-selective IOP-lowering comparison in monkeys. J Ocul Pharmacol Ther. 2009 Feb;25(1):1-8. DM20K91 RU https://pubmed.ncbi.nlm.nih.gov/19232013 DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM TI TT0MV2T DM20LIM TN Melanocortin receptor 1 (MC1R) DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DM20LIM DI DM20LIM DM20LIM DN Bremelanotide DM20LIM TI TTD0CIQ DM20LIM TN Melanocortin receptor 4 (MC4R) DM20LIM MA Agonist DM20LIM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20LIM RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf DM20R5F DI DM20R5F DM20R5F DN Spiramycin DM20R5F TI TTLFGBV DM20R5F TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM20R5F MA Binder DM20R5F RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DM20R5F RU https://pubmed.ncbi.nlm.nih.gov/11768328 DM20VMW DI DM20VMW DM20VMW DN Ethylestrenol DM20VMW TI TTS64P2 DM20VMW TN Androgen receptor (AR) DM20VMW MA Modulator DM20VMW RN Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, ... Endocrinology. 1984 Jun;114(6):2100-6. DM20VMW RU https://www.ncbi.nlm.nih.gov/pubmed/6539197 DM20VSK DI DM20VSK DM20VSK DN Istradefylline DM20VSK TI TTM2AOE DM20VSK TN Adenosine A2a receptor (ADORA2A) DM20VSK MA Modulator DM20VSK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM20VSK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022075s000lbl.pdf DM214Q8 DI DM214Q8 DM214Q8 DN Talbutal DM214Q8 TI TTEX6LM DM214Q8 TN GABA(A) receptor gamma-3 (GABRG3) DM214Q8 MA Modulator DM214Q8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM214Q8 RU https://www.fda.gov/ DM215WE DI DM215WE DM215WE DN MK-1439 DM215WE TI TT84ETX DM215WE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM215WE MA Inhibitor DM215WE RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM215WE RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM21C09 DI DM21C09 DM21C09 DN Nitrendipine DM21C09 TI TTFK1JQ DM21C09 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM21C09 MA Blocker DM21C09 RN Sulfobutyl ether-alkyl ether mixed cyclodextrin derivatives with enhanced inclusion ability. J Pharm Sci. 2009 Dec;98(12):4769-80. DM21C09 RU https://pubmed.ncbi.nlm.nih.gov/19408308 DM23D7J DI DM23D7J DM23D7J DN Tiaprofenic acid DM23D7J TI TTVKILB DM23D7J TN Prostaglandin G/H synthase 2 (COX-2) DM23D7J MA Inhibitor DM23D7J RN Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14. DM23D7J RU https://pubmed.ncbi.nlm.nih.gov/2277128 DM23HCX DI DM23HCX DM23HCX DN Dextropropoxyphene DM23HCX TI TTN4QDT DM23HCX TN Opioid receptor (OPR) DM23HCX MA Agonist DM23HCX RN Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9. DM23HCX RU https://pubmed.ncbi.nlm.nih.gov/19021937 DM25FL8 DI DM25FL8 DM25FL8 DN Methimazole DM25FL8 TI TT52XDZ DM25FL8 TN Thyroid peroxidase (TPO) DM25FL8 MA Inhibitor DM25FL8 RN Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73. DM25FL8 RU https://pubmed.ncbi.nlm.nih.gov/7952157 DM25HP1 DI DM25HP1 DM25HP1 DN Sermorelin DM25HP1 TI TTG4R8V DM25HP1 TN Growth hormone-releasing hormone receptor (GHRHR) DM25HP1 MA Binder DM25HP1 RN Sermorelin: a better approach to management of adult-onset growth hormone insufficiency Clin Interv Aging. 2006;1(4):307-8. DM25HP1 RU https://pubmed.ncbi.nlm.nih.gov/18046908 DM264B3 DI DM264B3 DM264B3 DN Dimenhydrinate DM264B3 TI TTTIBOJ DM264B3 TN Histamine H1 receptor (H1R) DM264B3 MA Antagonist DM264B3 RN Histamine 1 receptor antagonist in symptomatic treatment of renal colic accompanied by nausea: two birds with one stone Urology. 2009 Jan;73(1):32-6. DM264B3 RU https://pubmed.ncbi.nlm.nih.gov/18849063 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTTDVOJ DM26CQR TN Tropomyosin-related kinase A (TrkA) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTXABCW DM26CQR TN NT-3 growth factor receptor (TrkC) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26CQR DI DM26CQR DM26CQR DN Larotrectinib DM26CQR TI TTKN7QR DM26CQR TN BDNF/NT-3 growth factors receptor (TrkB) DM26CQR MA Inhibitor DM26CQR RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM26CQR RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM26E4B DI DM26E4B DM26E4B DN Moexipril DM26E4B TI TTL69WB DM26E4B TN Angiotensin-converting enzyme (ACE) DM26E4B MA Inhibitor DM26E4B RN Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Dig Dis Sci. 2010 Feb;55(2):476-83. DM26E4B RU https://pubmed.ncbi.nlm.nih.gov/19255851 DM26KR1 DI DM26KR1 DM26KR1 DN Copper dotatate Cu-64 DM26KR1 TI TTZ6T9E DM26KR1 TN Somatostatin receptor type 2 (SSTR2) DM26KR1 MA Binder DM26KR1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM26KR1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf DM26PRD DI DM26PRD DM26PRD DN Reboxetine DM26PRD TI TTAWNKZ DM26PRD TN Norepinephrine transporter (NET) DM26PRD MA Inhibitor DM26PRD RN Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82. DM26PRD RU https://pubmed.ncbi.nlm.nih.gov/11249515 DM27U4Y DI DM27U4Y DM27U4Y DN Desogestrel DM27U4Y TI TTUV8G9 DM27U4Y TN Progesterone receptor (PGR) DM27U4Y MA Modulator DM27U4Y RN Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40. DM27U4Y RU https://pubmed.ncbi.nlm.nih.gov/11108884 DM27Z5T DI DM27Z5T DM27Z5T DN Estradiol cypionate DM27Z5T TI TTZAYWL DM27Z5T TN Estrogen receptor (ESR) DM27Z5T MA Modulator DM27Z5T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM27Z5T RU https://www.fda.gov/ DM28D05 DI DM28D05 DM28D05 DN Oritavancin DM28D05 TI TT4ILYC DM28D05 TN Bacterial Dihydropteroate synthetase (Bact folP) DM28D05 MA Inhibitor DM28D05 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM28D05 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM28MU7 DI DM28MU7 DM28MU7 DN Tolnaftate DM28MU7 TI TTE14XG DM28MU7 TN Squalene monooxygenase (SQLE) DM28MU7 MA Inhibitor DM28MU7 RN Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81. DM28MU7 RU https://pubmed.ncbi.nlm.nih.gov/1416865 DM28UJG DI DM28UJG DM28UJG DN Dapagliflozin DM28UJG TI TTLWPVF DM28UJG TN Sodium/glucose cotransporter 2 (SGLT2) DM28UJG MA Modulator DM28UJG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM28UJG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM295PR DI DM295PR DM295PR DN Ofatumumab DM295PR TI TTUE541 DM295PR TN Leukocyte surface antigen Leu-16 (CD20) DM295PR RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM295PR RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM29GAD DI DM29GAD DM29GAD DN Lumefantrine DM29GAD TI TTWK8D0 DM29GAD TN Sodium pump subunit alpha-1 (ATP1A1) DM29GAD MA Binder DM29GAD RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM29GAD RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM2AOTZ DI DM2AOTZ DM2AOTZ DN Perazine DM2AOTZ TI TTEX248 DM2AOTZ TN Dopamine D2 receptor (D2R) DM2AOTZ MA Modulator DM2AOTZ RN Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87. DM2AOTZ RU https://pubmed.ncbi.nlm.nih.gov/15582454 DM2AQ5N DI DM2AQ5N DM2AQ5N DN Spironolactone DM2AQ5N TI TT26PHO DM2AQ5N TN Mineralocorticoid receptor (MR) DM2AQ5N MA Modulator DM2AQ5N RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2AQ5N RU https://www.fda.gov/ DM2AR7L DI DM2AR7L DM2AR7L DN Meloxicam DM2AR7L TI TTVKILB DM2AR7L TN Prostaglandin G/H synthase 2 (COX-2) DM2AR7L MA Inhibitor DM2AR7L RN Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):21-7. DM2AR7L RU https://pubmed.ncbi.nlm.nih.gov/9219316 DM2BTFN DI DM2BTFN DM2BTFN DN Desirudin Recombinant DM2BTFN TI TT6L509 DM2BTFN TN Coagulation factor IIa (F2) DM2BTFN MA Modulator DM2BTFN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2BTFN RU https://www.fda.gov/ DM2C48U DI DM2C48U DM2C48U DN Anisindione DM2C48U TI TT6L509 DM2C48U TN Coagulation factor IIa (F2) DM2C48U MA Modulator DM2C48U RN Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6. DM2C48U RU https://pubmed.ncbi.nlm.nih.gov/12680483 DM2C4RF DI DM2C4RF DM2C4RF DN Betrixaban DM2C4RF TI TTCIHJA DM2C4RF TN Coagulation factor Xa (F10) DM2C4RF MA Modulator DM2C4RF RN Company report (Portola) DM2C4RF RU https://www.portola.com/clinical-development/betrixaban-fxa-inhibitor/ DM2DMPO DI DM2DMPO DM2DMPO DN Kanamycin DM2DMPO TI TTQ8KVI DM2DMPO TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM2DMPO MA Binder DM2DMPO RN SsrA-mediated protein tagging in the presence of miscoding drugs and its physiological role in Escherichia coli. Genes Cells. 2002 Jul;7(7):629-38. DM2DMPO RU https://pubmed.ncbi.nlm.nih.gov/12081641 DM2EN6G DI DM2EN6G DM2EN6G DN Propantheline DM2EN6G TI TTZ9SOR DM2EN6G TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2EN6G MA Antagonist DM2EN6G RN Involvement of the peripheral cholinergic muscarinic system in the compensatory ovarian hypertrophy in the rat. Exp Biol Med (Maywood). 2004 Sep;229(8):793-805. DM2EN6G RU https://pubmed.ncbi.nlm.nih.gov/15337834 DM2ET1M DI DM2ET1M DM2ET1M DN Succinylcholine DM2ET1M TI TTQ13Z5 DM2ET1M TN Muscarinic acetylcholine receptor M3 (CHRM3) DM2ET1M MA Antagonist DM2ET1M RN The involvement of histaminic and muscarinic receptors in the bronchoconstriction induced by myorelaxant administration in sensitized rabbits. Anesth Analg. 2008 Dec;107(6):1899-906. DM2ET1M RU https://pubmed.ncbi.nlm.nih.gov/19020136 DM2EXC5 DI DM2EXC5 DM2EXC5 DN BOL-303259-X DM2EXC5 TI TTT2ZAR DM2EXC5 TN Prostaglandin F2-alpha receptor (PTGFR) DM2EXC5 MA Agonist DM2EXC5 RN Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2alpha agonist, in preclinical models. Exp Eye Res. 2011 Sep;93(3):250-5. DM2EXC5 RU https://pubmed.ncbi.nlm.nih.gov/21396362 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TT8NGED DM2F8XZ TN Prostaglandin G/H synthase 1 (COX-1) DM2F8XZ MA Inhibitor DM2F8XZ RN The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18612540 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTCFSPE DM2F8XZ TN Carbonic anhydrase VI (CA-VI) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTSYM0R DM2F8XZ TN Carbonic anhydrase XII (CA-XII) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTANPDJ DM2F8XZ TN Carbonic anhydrase II (CA-II) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTUNARX DM2F8XZ TN Carbonic anhydrase (CA) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18501600 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTZHA0O DM2F8XZ TN Carbonic anhydrase IV (CA-IV) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2F8XZ DI DM2F8XZ DM2F8XZ DN Salicyclic acid DM2F8XZ TI TTHQPL7 DM2F8XZ TN Carbonic anhydrase I (CA-I) DM2F8XZ MA Inhibitor DM2F8XZ RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DM2F8XZ RU https://pubmed.ncbi.nlm.nih.gov/18579385 DM2FGRT DI DM2FGRT DM2FGRT DN Clavulanate DM2FGRT TI TTHI19T DM2FGRT TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM2FGRT MA Inhibitor DM2FGRT RN A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9. DM2FGRT RU https://pubmed.ncbi.nlm.nih.gov/19505232 DM2FHG3 DI DM2FHG3 DM2FHG3 DN Pramiracetam DM2FHG3 TI TTH18TF DM2FHG3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM2FHG3 MA Modulator DM2FHG3 RN Some neurochemical properties of pramiracetam (CI-879), a new cognition-enhancing agent. Article first published online: 5 OCT 2004. DM2FHG3 RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430030503/abstract DM2G9AE DI DM2G9AE DM2G9AE DN Citalopram DM2G9AE TI TT3ROYC DM2G9AE TN Serotonin transporter (SERT) DM2G9AE MA Modulator DM2G9AE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2G9AE RU https://www.fda.gov/ DM2HG4X DI DM2HG4X DM2HG4X DN Prednisone DM2HG4X TI TTYRL6O DM2HG4X TN Glucocorticoid receptor (NR3C1) DM2HG4X MA Agonist DM2HG4X RN Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22. DM2HG4X RU https://pubmed.ncbi.nlm.nih.gov/8619627 DM2HKC4 DI DM2HKC4 DM2HKC4 DN Fluorometholone DM2HKC4 TI TTYRL6O DM2HKC4 TN Glucocorticoid receptor (NR3C1) DM2HKC4 MA Binder DM2HKC4 RN Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20. DM2HKC4 RU https://pubmed.ncbi.nlm.nih.gov/12861354 DM2HRKE DI DM2HRKE DM2HRKE DN Pentosan polysulfate DM2HRKE TI TTCEKVZ DM2HRKE TN Fibroblast growth factor-4 (FGF4) DM2HRKE MA Modulator DM2HRKE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2HRKE RU https://www.fda.gov/ DM2HU9I DI DM2HU9I DM2HU9I DN Triamterene DM2HU9I TI TTQM7TE DM2HU9I TN Amiloride-sensitive sodium channel (ENaC) DM2HU9I MA Blocker DM2HU9I RN Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18. DM2HU9I RU https://pubmed.ncbi.nlm.nih.gov/11509829 DM2JGQ3 DI DM2JGQ3 DM2JGQ3 DN Trametinib DM2JGQ3 TI TTROQ37 DM2JGQ3 TN MAPK/ERK kinase kinase (MAP3K) DM2JGQ3 MA Modulator DM2JGQ3 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM2JGQ3 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM2JTS5 DI DM2JTS5 DM2JTS5 DN Follitropin beta DM2JTS5 TI TTZFDBT DM2JTS5 TN Follicle-stimulating hormone receptor (FSHR) DM2JTS5 MA Binder DM2JTS5 RN Follitropin-alpha (Gonal-F) versus follitropin-beta (Puregon) in controlled ovarian hyperstimulation for in vitro fertilization: is there any diffe... Fertil Steril. 2009 Apr;91(4 Suppl):1522-5. DM2JTS5 RU https://pubmed.ncbi.nlm.nih.gov/18851846 DM2L3D5 DI DM2L3D5 DM2L3D5 DN Tertatolol DM2L3D5 TI TTSQIFT DM2L3D5 TN 5-HT 1A receptor (HTR1A) DM2L3D5 MA Inhibitor DM2L3D5 RN Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993). DM2L3D5 RU http://www.sciencedirect.com/science/article/pii/S0960894X0181009X DM2M3ZA DI DM2M3ZA DM2M3ZA DN Glycopyrrolate DM2M3ZA TI TTZ9SOR DM2M3ZA TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2M3ZA MA Antagonist DM2M3ZA RN Autonomic cardiovascular control during a novel pharmacologic alternative to ganglionic blockade. Clin Pharmacol Ther. 2008 May;83(5):692-701. DM2M3ZA RU https://pubmed.ncbi.nlm.nih.gov/17687267 DM2NA4K DI DM2NA4K DM2NA4K DN Ciclesonide DM2NA4K TI TTJL8VG DM2NA4K TN Corticosteroid-binding globulin (SERPINA6) DM2NA4K MA Binder DM2NA4K RN Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. DM2NA4K RU https://pubmed.ncbi.nlm.nih.gov/10634411 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTJP4SM DM2NLS9 TN Bacterial Penicillin binding protein (Bact PBP) DM2NLS9 MA Inhibitor DM2NLS9 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTU6BFZ DM2NLS9 TN Candida Thymidylate synthase (Candi TMP1) DM2NLS9 MA Inhibitor DM2NLS9 RN Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. DM2NLS9 RU https://pubmed.ncbi.nlm.nih.gov/12494465 DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTN6J5F DM2NLS9 TN Bacterial DNA gyrase (Bact gyrase) DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DM2NLS9 DI DM2NLS9 DM2NLS9 DN Ciprofloxacin XR DM2NLS9 TI TTIXTO3 DM2NLS9 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DM2NLS9 MA Modulator DM2NLS9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2NLS9 RU https://www.fda.gov/ DM2NUH3 DI DM2NUH3 DM2NUH3 DN Imipramine DM2NUH3 TI TTAWNKZ DM2NUH3 TN Norepinephrine transporter (NET) DM2NUH3 MA Inhibitor DM2NUH3 RN Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8. DM2NUH3 RU https://pubmed.ncbi.nlm.nih.gov/19059298 DM2OVDT DI DM2OVDT DM2OVDT DN Tecfidera DM2OVDT TI TTK3Q4W DM2OVDT TN NFE2-related factor 2 pathway (Nrf2 pathway) DM2OVDT MA Inhibitor DM2OVDT RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM2OVDT RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM2OZ3G DI DM2OZ3G DM2OZ3G DN Ixabepilone DM2OZ3G TI TTML2WA DM2OZ3G TN Tubulin (TUB) DM2OZ3G MA Stablizer DM2OZ3G RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM2OZ3G RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM2P6VD DI DM2P6VD DM2P6VD DN Thrombin/fibrinogen matrix patch DM2P6VD TI TTWODQF DM2P6VD TN Fibrin (FG) DM2P6VD MA Modulator DM2P6VD RN Fibrin sealant patch for repair of acute type a aortic dissection. J Card Surg. 2013 Nov;28(6):736-41. DM2P6VD RU https://pubmed.ncbi.nlm.nih.gov/23957708 DM2POTE DI DM2POTE DM2POTE DN Colchicine DM2POTE TI TTML2WA DM2POTE TN Tubulin (TUB) DM2POTE MA Binder DM2POTE RN Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74. DM2POTE RU https://pubmed.ncbi.nlm.nih.gov/19527023 DM2PSBE DI DM2PSBE DM2PSBE DN Focetria A(H1N1) DM2PSBE TI TT3J5ZI DM2PSBE TN Cell mediated immunity response (CMIR) DM2PSBE RN Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ. 2013 Feb 4;346:f393. DM2PSBE RU https://pubmed.ncbi.nlm.nih.gov/23381200 DM2PYNR DI DM2PYNR DM2PYNR DN Phenindione DM2PYNR TI TTEUC8H DM2PYNR TN Vitamin K epoxide reductase complex 1 (VKORC1) DM2PYNR MA Inhibitor DM2PYNR RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DM2PYNR RU https://pubmed.ncbi.nlm.nih.gov/17955831 DM2QBHP DI DM2QBHP DM2QBHP DN Eteplirsen DM2QBHP TI TTWLFXU DM2QBHP TN Dystrophin messenger RNA (DMD mRNA) DM2QBHP MA Modulator DM2QBHP RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM2QBHP RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM2QDX1 DI DM2QDX1 DM2QDX1 DN Oxamniquine DM2QDX1 TI TTB1TZG DM2QDX1 TN Schistosoma Deoxyribonucleic acid (Schist DNA) DM2QDX1 MA Modulator DM2QDX1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM2QDX1 RU https://www.fda.gov/ DM2QHZU DI DM2QHZU DM2QHZU DN Sulindac DM2QHZU TI TTFBNVI DM2QHZU TN Aldose reductase (AKR1B1) DM2QHZU MA Inhibitor DM2QHZU RN Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8. DM2QHZU RU https://pubmed.ncbi.nlm.nih.gov/6409111 DM2R68E DI DM2R68E DM2R68E DN Ramipril DM2R68E TI TTL69WB DM2R68E TN Angiotensin-converting enzyme (ACE) DM2R68E MA Inhibitor DM2R68E RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM2R68E RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM2R86O DI DM2R86O DM2R86O DN Siponimod DM2R86O TI TT7BQRM DM2R86O TN Sphingosine-1 phosphate receptor (S1PR) DM2R86O MA Modulator DM2R86O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM2R86O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf DM2R86O DI DM2R86O DM2R86O DN Siponimod DM2R86O TI TT9JZCK DM2R86O TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM2R86O MA Modulator DM2R86O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM2R86O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf DM2RBWK DI DM2RBWK DM2RBWK DN Belladonna DM2RBWK TI TTH18TF DM2RBWK TN Muscarinic acetylcholine receptor M5 (CHRM5) DM2RBWK MA Modulator DM2RBWK RN Plasma level of atropine after accidental ingestion of Atropa belladonna. Clin Toxicol (Phila). 2009 Jul;47(6):602-4. DM2RBWK RU https://pubmed.ncbi.nlm.nih.gov/19586361 DM2RX0I DI DM2RX0I DM2RX0I DN Abametapir DM2RX0I TI TT1GHVO DM2RX0I TN Matrix metalloproteinase (MMP) DM2RX0I MA Inhibitor DM2RX0I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM2RX0I RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206966lbl.pdf DM2SR1J DI DM2SR1J DM2SR1J DN Meningococcal groups A, C, Y and W-135 conjugate vaccine DM2SR1J TI TTY4IQ9 DM2SR1J TN Corynebacterium Mutated CRM197 (Cory mTOX) DM2SR1J MA Binder DM2SR1J RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM2SR1J RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM2TEOL DI DM2TEOL DM2TEOL DN Methotrexate DM2TEOL TI TTY8Z2E DM2TEOL TN Proton-coupled folate transporter (SLC46A1) DM2TEOL MA Modulator DM2TEOL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DM2TEOL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DM2TEOL DI DM2TEOL DM2TEOL DN Methotrexate DM2TEOL TI TT09I7D DM2TEOL TN Solute carrier family 19 member 1 (SLC19A1) DM2TEOL MA Modulator DM2TEOL RN Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11. DM2TEOL RU https://pubmed.ncbi.nlm.nih.gov/9525913 DM2TO9R DI DM2TO9R DM2TO9R DN Desflurane DM2TO9R TI TTAN6JD DM2TO9R TN Glutamate receptor AMPA (GRIA) DM2TO9R MA Antagonist DM2TO9R RN Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics. Anesth Analg. 2001 May;92(5):1182-91. DM2TO9R RU https://pubmed.ncbi.nlm.nih.gov/11323344 DM2U4XQ DI DM2U4XQ DM2U4XQ DN ALCURONIUM DM2U4XQ TI TTLA931 DM2U4XQ TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2U4XQ MA Inhibitor DM2U4XQ RN Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29. DM2U4XQ RU https://pubmed.ncbi.nlm.nih.gov/17722904 DM2WE5K DI DM2WE5K DM2WE5K DN Ceruletide DM2WE5K TI TTVFO0U DM2WE5K TN Gastrin/cholecystokinin type B receptor (CCKBR) DM2WE5K MA Agonist DM2WE5K RN Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8. DM2WE5K RU https://pubmed.ncbi.nlm.nih.gov/18537882 DM2XVNI DI DM2XVNI DM2XVNI DN Levormeloxifene DM2XVNI TI TTZAYWL DM2XVNI TN Estrogen receptor (ESR) DM2XVNI MA Modulator DM2XVNI RN Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001 Jul;21(4):302-47. DM2XVNI RU https://pubmed.ncbi.nlm.nih.gov/11410933 DM2YGNW DI DM2YGNW DM2YGNW DN Dactinomycin DM2YGNW TI TTUTN1I DM2YGNW TN Human Deoxyribonucleic acid (hDNA) DM2YGNW MA Breaker DM2YGNW RN Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. DM2YGNW RU https://pubmed.ncbi.nlm.nih.gov/10576292 DM2ZGAN DI DM2ZGAN DM2ZGAN DN Mesoridazine DM2ZGAN TI TTEX248 DM2ZGAN TN Dopamine D2 receptor (D2R) DM2ZGAN MA Agonist DM2ZGAN RN Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as... J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. DM2ZGAN RU https://pubmed.ncbi.nlm.nih.gov/16135699 DM30SGU DI DM30SGU DM30SGU DN Simvastatin DM30SGU TI TTPADOQ DM30SGU TN HMG-CoA reductase (HMGCR) DM30SGU MA Inhibitor DM30SGU RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DM30SGU RU https://pubmed.ncbi.nlm.nih.gov/11523064 DM30SXV DI DM30SXV DM30SXV DN Idursulfase DM30SXV TI TTNY2AP DM30SXV TN Iduronate 2-sulfatase (IDS) DM30SXV MA Modulator DM30SXV RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM30SXV RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM32B5U DI DM32B5U DM32B5U DN Upadacitinib DM32B5U TI TT6DM01 DM32B5U TN Janus kinase 1 (JAK-1) DM32B5U MA Modulator DM32B5U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM32B5U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf DM32GSJ DI DM32GSJ DM32GSJ DN Incruse ellipta DM32GSJ TI TTOXS3C DM32GSJ TN Muscarinic acetylcholine receptor (CHRM) DM32GSJ MA Antagonist DM32GSJ RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM32GSJ RU http://www.gsk.ca/english/html/media-centre/2014-04-17.html DM32YAI DI DM32YAI DM32YAI DN Dimethindene DM32YAI TI TTTIBOJ DM32YAI TN Histamine H1 receptor (H1R) DM32YAI MA Antagonist DM32YAI RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DM32YAI RU https://pubmed.ncbi.nlm.nih.gov/19308787 DM346QI DI DM346QI DM346QI DN Capreomycin Sulfate DM346QI TI TTIA0J5 DM346QI TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DM346QI MA Modulator DM346QI RN The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome.Nat Struct Mol Biol.2010 Mar;17(3):289-93. DM346QI RU https://www.ncbi.nlm.nih.gov/pubmed/20154709 DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO TI TTDIGC1 DM34TXO TN Dipeptidyl peptidase 4 (DPP-4) DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DM34TXO DI DM34TXO DM34TXO DN Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO TI TTLWPVF DM34TXO TN Sodium/glucose cotransporter 2 (SGLT2) DM34TXO MA Modulator DM34TXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM34TXO RU https://www.fda.gov/ DM35M8J DI DM35M8J DM35M8J DN Thioridazine DM35M8J TI TTEX248 DM35M8J TN Dopamine D2 receptor (D2R) DM35M8J MA Antagonist DM35M8J RN Antipsychotics lack alpha 1A/B adrenoceptor subtype selectivity in the rat. Eur Neuropsychopharmacol. 2005 Mar;15(2):231-4. DM35M8J RU https://pubmed.ncbi.nlm.nih.gov/15695070 DM36LAJ DI DM36LAJ DM36LAJ DN Emedastine DM36LAJ TI TTTIBOJ DM36LAJ TN Histamine H1 receptor (H1R) DM36LAJ MA Antagonist DM36LAJ RN Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases. Expert Opin Pharmacother. 2009 Aug;10(11):1859-67. DM36LAJ RU https://pubmed.ncbi.nlm.nih.gov/19558341 DM38VYQ DI DM38VYQ DM38VYQ DN Pentolinium DM38VYQ TI TT4H1MQ DM38VYQ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DM38VYQ MA Antagonist DM38VYQ RN Nicotinic and nonnicotinic receptor-mediated actions of vinblastine. Proc Soc Exp Biol Med. 1993 Jul;203(3):372-6. DM38VYQ RU https://pubmed.ncbi.nlm.nih.gov/8516349 DM3906J DI DM3906J DM3906J DN Bedaquiline DM3906J TI TT19K0L DM3906J TN Mycobacterium Proton pump (MycB Prop) DM3906J MA Modulator DM3906J RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM3906J RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM3ADGP DI DM3ADGP DM3ADGP DN Rhucin DM3ADGP TI TTJ0IQB DM3ADGP TN Phosphodiesterase 5A (PDE5A) DM3ADGP MA Inhibitor DM3ADGP RN cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91. DM3ADGP RU https://pubmed.ncbi.nlm.nih.gov/19546307 DM3ADGP DI DM3ADGP DM3ADGP DN Rhucin DM3ADGP TI TTVQ6R9 DM3ADGP TN C1 esterase inhibitor (SERPING1) DM3ADGP MA Modulator DM3ADGP RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM3ADGP RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TTGKNB4 DM3BH1Y TN Epidermal growth factor receptor (EGFR) DM3BH1Y MA Inhibitor DM3BH1Y RN Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/19365520 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TT6EO5L DM3BH1Y TN Erbb2 tyrosine kinase receptor (HER2) DM3BH1Y MA Inhibitor DM3BH1Y RN Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/19365520 DM3BH1Y DI DM3BH1Y DM3BH1Y DN Lapatinib DM3BH1Y TI TT1QFLA DM3BH1Y TN Eukaryotic elongation factor 2 kinase (eEF-2K) DM3BH1Y MA Inhibitor DM3BH1Y RN Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813. DM3BH1Y RU https://pubmed.ncbi.nlm.nih.gov/27756261 DM3BS97 DI DM3BS97 DM3BS97 DN Macrolides DM3BS97 TI TTLFGBV DM3BS97 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM3BS97 MA Binder DM3BS97 RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DM3BS97 RU https://pubmed.ncbi.nlm.nih.gov/18804175 DM3BVAE DI DM3BVAE DM3BVAE DN Obinutuzumab DM3BVAE TI TTUE541 DM3BVAE TN Leukocyte surface antigen Leu-16 (CD20) DM3BVAE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DM3BVAE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ TI TTSZLWK DM3C5GZ TN Aromatase (CYP19A1) DM3C5GZ MA Inhibitor DM3C5GZ RN Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/16279787 DM3C5GZ DI DM3C5GZ DM3C5GZ DN FADROZOLE DM3C5GZ TI TTIQUX7 DM3C5GZ TN Steroid 11-beta-hydroxylase (CYP11B1) DM3C5GZ MA Inhibitor DM3C5GZ RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM3C5GZ RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM3DSVJ DI DM3DSVJ DM3DSVJ DN Incadronate DM3DSVJ TI TTIKWV4 DM3DSVJ TN Geranyltranstransferase (FDPS) DM3DSVJ MA Inhibitor DM3DSVJ RN Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. DM3DSVJ RU https://pubmed.ncbi.nlm.nih.gov/11160603 DM3ED1A DI DM3ED1A DM3ED1A DN Tavaborole DM3ED1A TI TT37GL6 DM3ED1A TN Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) DM3ED1A MA Inhibitor DM3ED1A RN An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science. 2007 Jun 22;316(5832):1759-61. DM3ED1A RU https://pubmed.ncbi.nlm.nih.gov/17588934 DM3FXMA DI DM3FXMA DM3FXMA DN Naloxone DM3FXMA TI TTKWM86 DM3FXMA TN Opioid receptor mu (MOP) DM3FXMA MA Antagonist DM3FXMA RN OxyContin abuse and overdose. Postgrad Med. 2009 Mar;121(2):163-7. DM3FXMA RU https://pubmed.ncbi.nlm.nih.gov/19332974 DM3FXPS DI DM3FXPS DM3FXPS DN Liraglutide DM3FXPS TI TTVIMDE DM3FXPS TN Glucagon-like peptide 1 receptor (GLP1R) DM3FXPS MA Agonist DM3FXPS RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM3FXPS RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM3GB6S DI DM3GB6S DM3GB6S DN Halobetasol propionate DM3GB6S TI TTP3UTW DM3GB6S TN Steroid hormone receptor ERR (ESRR) DM3GB6S MA Modulator DM3GB6S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3GB6S RU https://www.fda.gov/ DM3JCVS DI DM3JCVS DM3JCVS DN Terazosin DM3JCVS TI TT34BHT DM3JCVS TN Adrenergic receptor alpha-1D (ADRA1D) DM3JCVS MA Antagonist DM3JCVS RN Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95. DM3JCVS RU https://pubmed.ncbi.nlm.nih.gov/12496995 DM3JDRP DI DM3JDRP DM3JDRP DN Cladribine DM3JDRP TI TTLP57V DM3JDRP TN Adenosine deaminase (ADA) DM3JDRP MA Inhibitor DM3JDRP RN Cladribine: from the bench to the bedside--focus on hairy cell leukemia. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57. DM3JDRP RU https://pubmed.ncbi.nlm.nih.gov/15485311 DM3KJBC DI DM3KJBC DM3KJBC DN Epinephrine DM3KJBC TI TTR6W5O DM3KJBC TN Adrenergic receptor beta-1 (ADRB1) DM3KJBC MA Agonist DM3KJBC RN Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77. DM3KJBC RU https://pubmed.ncbi.nlm.nih.gov/19460844 DM3KN7V DI DM3KN7V DM3KN7V DN Bifonazole DM3KN7V TI TTTSOUD DM3KN7V TN Candida Cytochrome P450 51 (Candi ERG11) DM3KN7V MA Inhibitor DM3KN7V RN Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7. DM3KN7V RU https://pubmed.ncbi.nlm.nih.gov/17027909 DM3NC4M DI DM3NC4M DM3NC4M DN Quercetin DM3NC4M TI TTPOI4B DM3NC4M TN Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) DM3NC4M MA Inhibitor DM3NC4M RN Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress. J Lipid Res. 2003 Feb;44(2):380-7. DM3NC4M RU https://pubmed.ncbi.nlm.nih.gov/12576520 DM3NF5G DI DM3NF5G DM3NF5G DN Delavirdine DM3NF5G TI TT84ETX DM3NF5G TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3NF5G MA Modulator DM3NF5G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3NF5G RU https://www.fda.gov/ DM3NUMH DI DM3NUMH DM3NUMH DN Aripiprazole DM3NUMH TI TTEX248 DM3NUMH TN Dopamine D2 receptor (D2R) DM3NUMH MA Agonist DM3NUMH RN Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. DM3NUMH RU https://pubmed.ncbi.nlm.nih.gov/17501690 DM3NXRU DI DM3NXRU DM3NXRU DN Timolol DM3NXRU TI TTR6W5O DM3NXRU TN Adrenergic receptor beta-1 (ADRB1) DM3NXRU MA Antagonist DM3NXRU RN Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95. DM3NXRU RU https://pubmed.ncbi.nlm.nih.gov/17154662 DM3O6CY DI DM3O6CY DM3O6CY DN Micardis telmisartan DM3O6CY TI TT8DBY3 DM3O6CY TN Angiotensin II receptor type-1 (AGTR1) DM3O6CY MA Antagonist DM3O6CY RN The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005 Nov;23(11):2055-61. DM3O6CY RU https://pubmed.ncbi.nlm.nih.gov/16208149 DM3O8QY DI DM3O8QY DM3O8QY DN Degarelix DM3O8QY TI TT8R70G DM3O8QY TN Gonadotropin-releasing hormone receptor (GNRHR) DM3O8QY MA Inhibitor DM3O8QY RN Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. J Med Chem. 2005 Jul 28;48(15):4851-60. DM3O8QY RU https://pubmed.ncbi.nlm.nih.gov/16033265 DM3OBQF DI DM3OBQF DM3OBQF DN Belimumab DM3OBQF TI TTWMIDN DM3OBQF TN B-cell-activating factor (TNFSF13B) DM3OBQF RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM3OBQF RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM3P5DA DI DM3P5DA DM3P5DA DN Rofecoxib DM3P5DA TI TTVKILB DM3P5DA TN Prostaglandin G/H synthase 2 (COX-2) DM3P5DA MA Inhibitor DM3P5DA RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DM3P5DA RU https://pubmed.ncbi.nlm.nih.gov/18045214 DM3P6V7 DI DM3P6V7 DM3P6V7 DN Furazolidone DM3P6V7 TI TTS1W4A DM3P6V7 TN Bacterial Deoxyribonucleic acid (Bact DNA) DM3P6V7 MA Modulator DM3P6V7 RN Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5. DM3P6V7 RU https://www.ncbi.nlm.nih.gov/pubmed/1174533 DM3PD2C DI DM3PD2C DM3PD2C DN Fluoxetine DM3PD2C TI TT3ROYC DM3PD2C TN Serotonin transporter (SERT) DM3PD2C MA Modulator DM3PD2C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM3PD2C RU https://www.fda.gov/ DM3PZXN DI DM3PZXN DM3PZXN DN Taliglucerase alfa DM3PZXN TI TT1B5PU DM3PZXN TN Glucosylceramidase (GBA) DM3PZXN MA Modulator DM3PZXN RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM3PZXN RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM3Q1SM DI DM3Q1SM DM3Q1SM DN Obeticholic acid DM3Q1SM TI TTS4UGC DM3Q1SM TN Farnesoid X-activated receptor (FXR) DM3Q1SM MA Modulator DM3Q1SM RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM3Q1SM RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM3SRJZ DI DM3SRJZ DM3SRJZ DN Belotecan hydrocholoride DM3SRJZ TI TTGTQHC DM3SRJZ TN DNA topoisomerase I (TOP1) DM3SRJZ MA Modulator DM3SRJZ RN Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43. DM3SRJZ RU https://pubmed.ncbi.nlm.nih.gov/19422222 DM3TABW DI DM3TABW DM3TABW DN Oxyphencyclimine DM3TABW TI TTH18TF DM3TABW TN Muscarinic acetylcholine receptor M5 (CHRM5) DM3TABW MA Binder DM3TABW RN Stereoselective interaction of procyclidine, hexahydro-difenidol, hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors. Eur J Pharmacol. 1992 Sep 1;227(1):33-42. DM3TABW RU https://pubmed.ncbi.nlm.nih.gov/1426023 DM3TPY8 DI DM3TPY8 DM3TPY8 DN Interferon Alfa-2b, Recombinant DM3TPY8 TI TTMQB37 DM3TPY8 TN Interferon alpha/beta receptor 2 (IFNAR2) DM3TPY8 MA Binder DM3TPY8 RN Successful treatment of relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia with T315I mutation after haplo-identical hematopoie... Leuk Res. 2009 Aug;33(8):e111-3. DM3TPY8 RU https://pubmed.ncbi.nlm.nih.gov/19362369 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTI7421 DM3U7SZ TN Platelet-derived growth factor receptor beta (PDGFRB) DM3U7SZ MA Inhibitor DM3U7SZ RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12646019 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTRLW2X DM3U7SZ TN Fibroblast growth factor receptor 1 (FGFR1) DM3U7SZ MA Inhibitor DM3U7SZ RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT8FYO9 DM3U7SZ TN Platelet-derived growth factor receptor alpha (PDGFRA) DM3U7SZ MA Inhibitor DM3U7SZ RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12646019 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTX41N9 DM3U7SZ TN Tyrosine-protein kinase Kit (KIT) DM3U7SZ MA Inhibitor DM3U7SZ RN New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/10882357 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTUTJGQ DM3U7SZ TN Vascular endothelial growth factor receptor 2 (KDR) DM3U7SZ MA Inhibitor DM3U7SZ RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT1VAUK DM3U7SZ TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM3U7SZ MA Inhibitor DM3U7SZ RN New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/10882357 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT4DXQT DM3U7SZ TN Proto-oncogene c-Ret (RET) DM3U7SZ MA Inhibitor DM3U7SZ RN Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/20117004 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TTIHYA4 DM3U7SZ TN Thrombopoietin receptor (MPL) DM3U7SZ MA Modulator DM3U7SZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DM3U7SZ DI DM3U7SZ DM3U7SZ DN Romiplostim DM3U7SZ TI TT037IE DM3U7SZ TN Aryl hydrocarbon receptor (AHR) DM3U7SZ MA Modulator DM3U7SZ RN A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83. DM3U7SZ RU https://pubmed.ncbi.nlm.nih.gov/16222321 DM3UZ95 DI DM3UZ95 DM3UZ95 DN Bisoprolol DM3UZ95 TI TTR6W5O DM3UZ95 TN Adrenergic receptor beta-1 (ADRB1) DM3UZ95 MA Antagonist DM3UZ95 RN Antiarrhythmic effect of bisoprolol, a highly selective beta1-blocker, in patients with paroxysmal atrial fibrillation. Int Heart J. 2008 May;49(3):281-93. DM3UZ95 RU https://pubmed.ncbi.nlm.nih.gov/18612186 DM3VFPD DI DM3VFPD DM3VFPD DN Troglitazone DM3VFPD TI TTZMAO3 DM3VFPD TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM3VFPD MA Agonist DM3VFPD RN Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602. DM3VFPD RU https://pubmed.ncbi.nlm.nih.gov/12594814 DM3VOGS DI DM3VOGS DM3VOGS DN Ceftizoxime DM3VOGS TI TTJP4SM DM3VOGS TN Bacterial Penicillin binding protein (Bact PBP) DM3VOGS MA Binder DM3VOGS RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM3VOGS RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM3VR1L DI DM3VR1L DM3VR1L DN Selegiline hydrochloride DM3VR1L TI TTGP7BY DM3VR1L TN Monoamine oxidase type B (MAO-B) DM3VR1L MA Modulator DM3VR1L RN Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. DM3VR1L RU https://pubmed.ncbi.nlm.nih.gov/16939381 DM3VS7Z DI DM3VS7Z DM3VS7Z DN Imidazole salicylate DM3VS7Z TI TTTEJMY DM3VS7Z TN Tromboxane A2 synthesis (TA2 synth) DM3VS7Z MA Modulator DM3VS7Z RN Tolerability of imidazole salycilate in aspirin-sensitive patients. Allergy Proc. 1995 Sep-Oct;16(5):251-4. DM3VS7Z RU https://pubmed.ncbi.nlm.nih.gov/8566739 DM3W15N DI DM3W15N DM3W15N DN Calcium carbimide DM3W15N TI TTCTAOJ DM3W15N TN Acetaldehyde dehydrogenase (ALDH) DM3W15N MA Inhibitor DM3W15N RN Disulfiram and calcium carbimide. Mode of action, adverse effects and clinical use. Tidsskr Nor Laegeforen. 1990 Apr 10;110(10):1224-8. DM3W15N RU https://pubmed.ncbi.nlm.nih.gov/2185581 DM3WKQ4 DI DM3WKQ4 DM3WKQ4 DN Rasagiline DM3WKQ4 TI TTGP7BY DM3WKQ4 TN Monoamine oxidase type B (MAO-B) DM3WKQ4 MA Inhibitor DM3WKQ4 RN Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59. DM3WKQ4 RU https://pubmed.ncbi.nlm.nih.gov/19526291 DM3XNUI DI DM3XNUI DM3XNUI DN Tazobactam DM3XNUI TI TTHI19T DM3XNUI TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM3XNUI MA Inhibitor DM3XNUI RN Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9. DM3XNUI RU https://pubmed.ncbi.nlm.nih.gov/19576305 DM3XU74 DI DM3XU74 DM3XU74 DN Dornase Alfa DM3XU74 TI TTUTN1I DM3XU74 TN Human Deoxyribonucleic acid (hDNA) DM3XU74 MA Breaker DM3XU74 RN Dornase alfa. BioDrugs. 1997 Dec;8(6):439-45. DM3XU74 RU https://pubmed.ncbi.nlm.nih.gov/18031106 DM3XYD1 DI DM3XYD1 DM3XYD1 DN Tegaserod DM3XYD1 TI TT07C3Y DM3XYD1 TN 5-HT 4 receptor (HTR4) DM3XYD1 MA Agonist DM3XYD1 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM3XYD1 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM4087K DI DM4087K DM4087K DN Saprisartan DM4087K TI TT8DBY3 DM4087K TN Angiotensin II receptor type-1 (AGTR1) DM4087K MA Antagonist DM4087K RN Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. DM4087K RU https://pubmed.ncbi.nlm.nih.gov/10579749 DM40EF6 DI DM40EF6 DM40EF6 DN Penicillamine DM40EF6 TI TTT3ZC9 DM40EF6 TN Human immunodeficiency virus Tat protein (HIV tat) DM40EF6 MA Inhibitor DM40EF6 RN Docking studies reveal a selective binding of D-penicillamine to the transactivator protein of human immunodeficiency virus type 1. FEBS Lett. 2002 Apr 10;516(1-3):43-6. DM40EF6 RU https://pubmed.ncbi.nlm.nih.gov/11959100 DM41GRA DI DM41GRA DM41GRA DN Ceftazidime DM41GRA TI TTJP4SM DM41GRA TN Bacterial Penicillin binding protein (Bact PBP) DM41GRA MA Binder DM41GRA RN New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41. DM41GRA RU https://pubmed.ncbi.nlm.nih.gov/18318877 DM42HXN DI DM42HXN DM42HXN DN Atracurium DM42HXN TI TTJSZTB DM42HXN TN Nicotinic acetylcholine receptor (nAChR) DM42HXN MA Antagonist DM42HXN RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DM42HXN RU https://pubmed.ncbi.nlm.nih.gov/19417616 DM42W1B DI DM42W1B DM42W1B DN Cefmetazole DM42W1B TI TT85JMW DM42W1B TN Bacterial Penicillin binding protein 3 (Bact mrcA) DM42W1B MA Binder DM42W1B RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM42W1B RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM43AN2 DI DM43AN2 DM43AN2 DN Fructose DM43AN2 TI TTMS54D DM43AN2 TN Fragile histidine triad protein (FHIT) DM43AN2 MA Inhibitor DM43AN2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM43AN2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM458UM DI DM458UM DM458UM DN Captopril DM458UM TI TTL69WB DM458UM TN Angiotensin-converting enzyme (ACE) DM458UM MA Inhibitor DM458UM RN Using ACE inhibitors appropriately. Am Fam Physician. 2002 Aug 1;66(3):461-8. DM458UM RU https://pubmed.ncbi.nlm.nih.gov/12182524 DM45OJN DI DM45OJN DM45OJN DN Mometasone DM45OJN TI TTYRL6O DM45OJN TN Glucocorticoid receptor (NR3C1) DM45OJN MA Agonist DM45OJN RN Mometasone furoate is a less specific glucocorticoid than fluticasone propionate. Eur Respir J. 2002 Dec;20(6):1386-92. DM45OJN RU https://pubmed.ncbi.nlm.nih.gov/12503693 DM471KJ DI DM471KJ DM471KJ DN Omeprazole DM471KJ TI TTLOKXP DM471KJ TN Gastric H(+)/K(+) ATPase (Proton pump) DM471KJ MA Modulator DM471KJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM471KJ RU https://www.fda.gov/ DM473VD DI DM473VD DM473VD DN Mivacurium DM473VD TI TTF4E0J DM473VD TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM473VD MA Antagonist DM473VD RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DM473VD RU https://pubmed.ncbi.nlm.nih.gov/19417616 DM48K0X DI DM48K0X DM48K0X DN Carfilzomib DM48K0X TI TTU7ZMG DM48K0X TN Proteasome (PS) DM48K0X MA Modulator DM48K0X RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM48K0X RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM48QOT DI DM48QOT DM48QOT DN Artemether DM48QOT TI TTWK8D0 DM48QOT TN Sodium pump subunit alpha-1 (ATP1A1) DM48QOT MA Binder DM48QOT RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DM48QOT RU https://pubmed.ncbi.nlm.nih.gov/18220771 DM49DUI DI DM49DUI DM49DUI DN Tretinoin DM49DUI TI TTOD7B3 DM49DUI TN Retinoic acid receptor (RAR) DM49DUI MA Binder DM49DUI RN Retinoids--which dermatological indications will benefit in the near future Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15. DM49DUI RU https://pubmed.ncbi.nlm.nih.gov/11586072 DM49DUI DI DM49DUI DM49DUI DN Tretinoin DM49DUI TI TT1Q3IE DM49DUI TN Retinoic acid receptor gamma (RARG) DM49DUI MA Agonist DM49DUI RN Targacept active conformation search: a new method for predicting the conformation of a ligand bound to its protein target. J Med Chem. 2004 Dec 30;47(27):6831-9. DM49DUI RU https://pubmed.ncbi.nlm.nih.gov/15615532 DM49IGF DI DM49IGF DM49IGF DN Pefloxacin DM49IGF TI TT0IHXV DM49IGF TN DNA topoisomerase II (TOP2) DM49IGF MA Inhibitor DM49IGF RN Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. DM49IGF RU https://pubmed.ncbi.nlm.nih.gov/3282749 DM49VEW DI DM49VEW DM49VEW DN Penicillin G Benzathine DM49VEW TI TTJP4SM DM49VEW TN Bacterial Penicillin binding protein (Bact PBP) DM49VEW MA Modulator DM49VEW RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DM49VEW RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DM4AK0Q DI DM4AK0Q DM4AK0Q DN Interferon alfa-n1 DM4AK0Q TI TTMQB37 DM4AK0Q TN Interferon alpha/beta receptor 2 (IFNAR2) DM4AK0Q MA Binder DM4AK0Q RN Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology. 1998 Apr;27(4):1121-7. DM4AK0Q RU https://pubmed.ncbi.nlm.nih.gov/9537453 DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ TI TTOJI4S DM4AMQZ TN Calcium-dependent chloride channel anoctamin (ANO) DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM4AMQZ DI DM4AMQZ DM4AMQZ DN Crofelemer DM4AMQZ TI TTRLZHP DM4AMQZ TN cAMP-dependent chloride channel (CFTR) DM4AMQZ MA Modulator DM4AMQZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM4AMQZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM4BDON DI DM4BDON DM4BDON DN Methylprednisolone DM4BDON TI TTYRL6O DM4BDON TN Glucocorticoid receptor (NR3C1) DM4BDON MA Modulator DM4BDON RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4BDON RU https://www.fda.gov/ DM4BOAS DI DM4BOAS DM4BOAS DN Velaglucerase alfa DM4BOAS TI TT1B5PU DM4BOAS TN Glucosylceramidase (GBA) DM4BOAS MA Modulator DM4BOAS RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM4BOAS RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM4CF18 DI DM4CF18 DM4CF18 DN Menotropins DM4CF18 TI TTZFDBT DM4CF18 TN Follicle-stimulating hormone receptor (FSHR) DM4CF18 MA Binder DM4CF18 RN The role of gonadotropins in ovulation induction. Am J Obstet Gynecol. 1995 Feb;172(2 Pt 2):759-65. DM4CF18 RU https://pubmed.ncbi.nlm.nih.gov/7872378 DM4DMBT DI DM4DMBT DM4DMBT DN Chlorthalidone DM4DMBT TI TTS087L DM4DMBT TN Solute carrier family 12 member 1 (SLC12A1) DM4DMBT MA Blocker DM4DMBT RN The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52. DM4DMBT RU https://pubmed.ncbi.nlm.nih.gov/15134800 DM4E8O9 DI DM4E8O9 DM4E8O9 DN Umeclidinium DM4E8O9 TI TTH18TF DM4E8O9 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM4E8O9 MA Modulator DM4E8O9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7354). DM4E8O9 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7354 DM4EGV0 DI DM4EGV0 DM4EGV0 DN Linaclotide DM4EGV0 TI TTLDPRG DM4EGV0 TN Guanylyl cyclase C (GUCY2C) DM4EGV0 MA Activator DM4EGV0 RN Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. DM4EGV0 RU https://pubmed.ncbi.nlm.nih.gov/17979603 DM4ES8F DI DM4ES8F DM4ES8F DN Penbutolol DM4ES8F TI TTR6W5O DM4ES8F TN Adrenergic receptor beta-1 (ADRB1) DM4ES8F MA Antagonist DM4ES8F RN beta-Adrenergic receptor blockers--a group of chiral drugs: different effects of each enantiomer. Ceska Slov Farm. 2002 May;51(3):121-8. DM4ES8F RU https://pubmed.ncbi.nlm.nih.gov/12058352 DM4EWNS DI DM4EWNS DM4EWNS DN Cinoxacin DM4EWNS TI TT0IHXV DM4EWNS TN DNA topoisomerase II (TOP2) DM4EWNS MA Inhibitor DM4EWNS RN The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. DM4EWNS RU https://pubmed.ncbi.nlm.nih.gov/10411577 DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTNDSF4 DM4F29C TN Proto-oncogene c-Met (MET) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTSZ6Y3 DM4F29C TN Proto-oncogene c-Ros (ROS1) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTPMQSO DM4F29C TN ALK tyrosine kinase receptor (ALK) DM4F29C MA Modulator DM4F29C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4F29C RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4F29C DI DM4F29C DM4F29C DN Crizotinib DM4F29C TI TTKA5LP DM4F29C TN HGF/Met signaling pathway (HGF/Met pathway) DM4F29C MA Inhibitor DM4F29C RN Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907. DM4F29C RU https://pubmed.ncbi.nlm.nih.gov/26345996 DM4I8O7 DI DM4I8O7 DM4I8O7 DN Bunazosin DM4I8O7 TI TT34BHT DM4I8O7 TN Adrenergic receptor alpha-1D (ADRA1D) DM4I8O7 MA Modulator DM4I8O7 RN Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56. DM4I8O7 RU https://pubmed.ncbi.nlm.nih.gov/15867947 DM4IAKR DI DM4IAKR DM4IAKR DN MD-1100 DM4IAKR TI TTLDPRG DM4IAKR TN Guanylyl cyclase C (GUCY2C) DM4IAKR MA Activator DM4IAKR RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM4IAKR RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM4IF32 DI DM4IF32 DM4IF32 DN Pyrazinamide DM4IF32 TI TTVTX4N DM4IF32 TN Bacterial Fatty acid synthetase I (Bact inhA) DM4IF32 MA Inhibitor DM4IF32 RN Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med. 2000 Sep;6(9):1043-7. DM4IF32 RU https://pubmed.ncbi.nlm.nih.gov/10973326 DM4K7GQ DI DM4K7GQ DM4K7GQ DN Erythromycin DM4K7GQ TI TTUWYEA DM4K7GQ TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4K7GQ MA Binder DM4K7GQ RN A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54. DM4K7GQ RU https://pubmed.ncbi.nlm.nih.gov/1945852 DM4KDYJ DI DM4KDYJ DM4KDYJ DN Nortriptyline DM4KDYJ TI TT3ROYC DM4KDYJ TN Serotonin transporter (SERT) DM4KDYJ MA Modulator DM4KDYJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4KDYJ RU https://www.fda.gov/ DM4KI7O DI DM4KI7O DM4KI7O DN Zidovudine DM4KI7O TI TT84ETX DM4KI7O TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4KI7O MA Inhibitor DM4KI7O RN Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33. DM4KI7O RU https://pubmed.ncbi.nlm.nih.gov/15125867 DM4KI7O DI DM4KI7O DM4KI7O DN Zidovudine DM4KI7O TI TTGJCWZ DM4KI7O TN Fms-like tyrosine kinase 3 (FLT-3) DM4KI7O MA Binder DM4KI7O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807). DM4KI7O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807 DM4L59B DI DM4L59B DM4L59B DN Teprotumumab DM4L59B TI TTHRID2 DM4L59B TN Insulin-like growth factor I receptor (IGF1R) DM4L59B MA Antagonist DM4L59B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM4L59B RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761143s000lbl.pdf DM4L6EU DI DM4L6EU DM4L6EU DN Trandolapril DM4L6EU TI TTL69WB DM4L6EU TN Angiotensin-converting enzyme (ACE) DM4L6EU MA Inhibitor DM4L6EU RN Selective reduction of central pulse pressure under angiotensin blockage in SHR: role of the fibronectin-alpha5beta1 integrin complex. Am J Hypertens. 2009 Jul;22(7):711-7. DM4L6EU RU https://pubmed.ncbi.nlm.nih.gov/19424161 DM4L8H3 DI DM4L8H3 DM4L8H3 DN Loracarbef DM4L8H3 TI TTJP4SM DM4L8H3 TN Bacterial Penicillin binding protein (Bact PBP) DM4L8H3 MA Binder DM4L8H3 RN Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. DM4L8H3 RU https://pubmed.ncbi.nlm.nih.gov/16940068 DM4LECQ DI DM4LECQ DM4LECQ DN Vilazodone DM4LECQ TI TT3ROYC DM4LECQ TN Serotonin transporter (SERT) DM4LECQ MA Modulator DM4LECQ RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM4LECQ RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM4LECQ DI DM4LECQ DM4LECQ DN Vilazodone DM4LECQ TI TTSQIFT DM4LECQ TN 5-HT 1A receptor (HTR1A) DM4LECQ MA Modulator DM4LECQ RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM4LECQ RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM4LOD0 DI DM4LOD0 DM4LOD0 DN Alglucosidase alfa DM4LOD0 TI TT95ICL DM4LOD0 TN Mannose-6-phosphate receptor (M6PR) DM4LOD0 MA Binder DM4LOD0 RN Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep;66(3):329-35. DM4LOD0 RU https://pubmed.ncbi.nlm.nih.gov/19542901 DM4LSNE DI DM4LSNE DM4LSNE DN Procaine DM4LSNE TI TTPC4TU DM4LSNE TN 5-HT 3A receptor (HTR3A) DM4LSNE MA Antagonist DM4LSNE RN Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70. DM4LSNE RU https://pubmed.ncbi.nlm.nih.gov/18035290 DM4LSPN DI DM4LSPN DM4LSPN DN Ibudilast DM4LSPN TI TTV5CGO DM4LSPN TN Phosphodiesterase 4 (PDE4) DM4LSPN MA Inhibitor DM4LSPN RN Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796. DM4LSPN RU https://pubmed.ncbi.nlm.nih.gov/31388135 DM4LSPN DI DM4LSPN DM4LSPN DN Ibudilast DM4LSPN TI TTZCG4L DM4LSPN TN Phosphodiesterase 3 (PDE3) DM4LSPN MA Inhibitor DM4LSPN RN Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796. DM4LSPN RU https://pubmed.ncbi.nlm.nih.gov/31388135 DM4LT8A DI DM4LT8A DM4LT8A DN Dapsone DM4LT8A TI TT6NHYC DM4LT8A TN Pneumocystis carinii Dihydropteroate synthase (PC DHPS) DM4LT8A MA Modulator DM4LT8A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4LT8A RU https://www.fda.gov/ DM4LTKV DI DM4LTKV DM4LTKV DN Dalfopristin DM4LTKV TI TTUWYEA DM4LTKV TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4LTKV MA Binder DM4LTKV RN The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9. DM4LTKV RU https://pubmed.ncbi.nlm.nih.gov/15991995 DM4M1SG DI DM4M1SG DM4M1SG DN Clarithromycin DM4M1SG TI TTUWYEA DM4M1SG TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM4M1SG MA Binder DM4M1SG RN Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21. DM4M1SG RU https://pubmed.ncbi.nlm.nih.gov/11677599 DM4MDJY DI DM4MDJY DM4MDJY DN Fluvastatin DM4MDJY TI TTPADOQ DM4MDJY TN HMG-CoA reductase (HMGCR) DM4MDJY MA Inhibitor DM4MDJY RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DM4MDJY RU https://pubmed.ncbi.nlm.nih.gov/11523064 DM4ME02 DI DM4ME02 DM4ME02 DN Ticarcillin DM4ME02 TI TTJP4SM DM4ME02 TN Bacterial Penicillin binding protein (Bact PBP) DM4ME02 MA Binder DM4ME02 RN Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7. DM4ME02 RU https://pubmed.ncbi.nlm.nih.gov/8360977 DM4NTMO DI DM4NTMO DM4NTMO DN TRYPAN BLUE DM4NTMO TI TTELIN2 DM4NTMO TN PTPN1 messenger RNA (PTPN1 mRNA) DM4NTMO MA Inhibitor DM4NTMO RN Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6. DM4NTMO RU https://pubmed.ncbi.nlm.nih.gov/15050628 DM4O2Z7 DI DM4O2Z7 DM4O2Z7 DN Cyclophosphamide DM4O2Z7 TI TTUTN1I DM4O2Z7 TN Human Deoxyribonucleic acid (hDNA) DM4O2Z7 MA Modulator DM4O2Z7 RN O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22. DM4O2Z7 RU https://www.ncbi.nlm.nih.gov/pubmed/9714064 DM4O90W DI DM4O90W DM4O90W DN Insulin-lispro DM4O90W TI TTCBFJO DM4O90W TN Insulin receptor (INSR) DM4O90W MA Binder DM4O90W RN Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2. DM4O90W RU https://pubmed.ncbi.nlm.nih.gov/10601956 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TTRMX3V DM4ONW5 TN Janus kinase 2 (JAK-2) DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TT6DM01 DM4ONW5 TN Janus kinase 1 (JAK-1) DM4ONW5 MA Modulator DM4ONW5 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM4ONW5 DI DM4ONW5 DM4ONW5 DN Baricitinib DM4ONW5 TI TTJSQEF DM4ONW5 TN Tyrosine-protein kinase (PTK) DM4ONW5 MA Inhibitor DM4ONW5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM4ONW5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM4PF81 DI DM4PF81 DM4PF81 DN Mitomycin A DM4PF81 TI TTUTN1I DM4PF81 TN Human Deoxyribonucleic acid (hDNA) DM4PF81 RN Selective activation of mitomycin A by thiols to form DNA cross-links and monoadducts: biochemical basis for the modulation of mitomycin cytotoxicity by the quinone redox potential. J Med Chem. 2001 Aug 16;44(17):2834-42. DM4PF81 RU https://pubmed.ncbi.nlm.nih.gov/11495594 DM4PRFC DI DM4PRFC DM4PRFC DN Bupivacaine DM4PRFC TI TT90XZ8 DM4PRFC TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM4PRFC MA Modulator DM4PRFC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PRFC RU https://www.fda.gov/ DM4PUDW DI DM4PUDW DM4PUDW DN L-glutamic acid DM4PUDW TI TT9IK2Z DM4PUDW TN N-methyl-D-aspartate receptor (NMDAR) DM4PUDW MA Antagonist DM4PUDW RN Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603. DM4PUDW RU https://pubmed.ncbi.nlm.nih.gov/18923069 DM4PVDY DI DM4PVDY DM4PVDY DN Durvalumab DM4PVDY TI TT8ZLTI DM4PVDY TN Programmed cell death 1 ligand 1 (PD-L1) DM4PVDY MA Modulator DM4PVDY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PVDY RU https://www.fda.gov/ DM4PXF6 DI DM4PXF6 DM4PXF6 DN Desoximetasone DM4PXF6 TI TTP3UTW DM4PXF6 TN Steroid hormone receptor ERR (ESRR) DM4PXF6 MA Modulator DM4PXF6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4PXF6 RU https://www.fda.gov/ DM4QFXJ DI DM4QFXJ DM4QFXJ DN Sodium Tetradecyl Sulfate DM4QFXJ TI TTZUXYS DM4QFXJ TN Vitamin K-dependent protein C (PROC) DM4QFXJ MA Inhibitor DM4QFXJ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM4QFXJ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM4QTBN DI DM4QTBN DM4QTBN DN Isotretinoin DM4QTBN TI TTOD7B3 DM4QTBN TN Retinoic acid receptor (RAR) DM4QTBN MA Agonist DM4QTBN RN Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402. DM4QTBN RU https://pubmed.ncbi.nlm.nih.gov/14501777 DM4RK0G DI DM4RK0G DM4RK0G DN Divalproex sodium DM4RK0G TI TTT2LD9 DM4RK0G TN GABA transaminase (ABAT) DM4RK0G MA Inhibitor DM4RK0G RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM4RK0G RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM4S3O8 DI DM4S3O8 DM4S3O8 DN Ertapenem DM4S3O8 TI TTJP4SM DM4S3O8 TN Bacterial Penicillin binding protein (Bact PBP) DM4S3O8 MA Binder DM4S3O8 RN Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24. DM4S3O8 RU https://pubmed.ncbi.nlm.nih.gov/15716453 DM4UHZF DI DM4UHZF DM4UHZF DN Vestronidase alfa DM4UHZF TI TTHS7CM DM4UHZF TN Beta-glucuronidase (GUSB) DM4UHZF MA Modulator DM4UHZF RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM4UHZF RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM4V6JA DI DM4V6JA DM4V6JA DN Cilazapril DM4V6JA TI TTL69WB DM4V6JA TN Angiotensin-converting enzyme (ACE) DM4V6JA MA Inhibitor DM4V6JA RN Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. DM4V6JA RU https://pubmed.ncbi.nlm.nih.gov/18423812 DM4V6RL DI DM4V6RL DM4V6RL DN Ritodrine DM4V6RL TI TT2CJVK DM4V6RL TN Adrenergic receptor beta-2 (ADRB2) DM4V6RL MA Modulator DM4V6RL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4V6RL RU https://www.fda.gov/ DM4VAOG DI DM4VAOG DM4VAOG DN Gadobenate dimeglumine DM4VAOG TI TTFNGC9 DM4VAOG TN Serum albumin (ALB) DM4VAOG MA Binder DM4VAOG RN Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7. DM4VAOG RU https://pubmed.ncbi.nlm.nih.gov/18655261 DM4W9B3 DI DM4W9B3 DM4W9B3 DN Fosamprenavir DM4W9B3 TI TT5FNQT DM4W9B3 TN Human immunodeficiency virus Protease (HIV PR) DM4W9B3 MA Inhibitor DM4W9B3 RN Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in ... J Antimicrob Chemother. 2009 Aug;64(2):398-410. DM4W9B3 RU https://pubmed.ncbi.nlm.nih.gov/19515730 DM4WVC5 DI DM4WVC5 DM4WVC5 DN Lifitegrast DM4WVC5 TI TTCT6F7 DM4WVC5 TN Intercellular adhesion molecule ICAM-1 (ICAM1) DM4WVC5 MA Inhibitor DM4WVC5 RN Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett. 2012 Jan 31;3(3):203-6. DM4WVC5 RU https://pubmed.ncbi.nlm.nih.gov/24900456 DM4WVC5 DI DM4WVC5 DM4WVC5 DN Lifitegrast DM4WVC5 TI TT48WR6 DM4WVC5 TN Integrin alpha-L (ITGAL) DM4WVC5 MA Modulator DM4WVC5 RN Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402. DM4WVC5 RU https://pubmed.ncbi.nlm.nih.gov/23215542 DM4YMIS DI DM4YMIS DM4YMIS DN Aldesleukin DM4YMIS TI TTF89GD DM4YMIS TN Interleukin-2 (IL2) DM4YMIS MA Modulator DM4YMIS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4YMIS RU https://www.fda.gov/ DM4YWCZ DI DM4YWCZ DM4YWCZ DN Nalmefene DM4YWCZ TI TTN4QDT DM4YWCZ TN Opioid receptor (OPR) DM4YWCZ MA Antagonist DM4YWCZ RN Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97. DM4YWCZ RU https://pubmed.ncbi.nlm.nih.gov/19001155 DM4ZBK6 DI DM4ZBK6 DM4ZBK6 DN Fedratinib DM4ZBK6 TI TTRMX3V DM4ZBK6 TN Janus kinase 2 (JAK-2) DM4ZBK6 MA Inhibitor DM4ZBK6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM4ZBK6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212327s000lbl.pdf DM4ZLFD DI DM4ZLFD DM4ZLFD DN Glucosamine DM4ZLFD TI TTRYK0X DM4ZLFD TN Interleukin-1 beta (IL1B) DM4ZLFD MA Inhibitor DM4ZLFD RN Glucosamine inhibits IL-1beta-mediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem. 2009 Oct 1;108(2):489-98. DM4ZLFD RU https://pubmed.ncbi.nlm.nih.gov/19626664 DM4ZS8M DI DM4ZS8M DM4ZS8M DN Nefazodone DM4ZS8M TI TTWJBZ5 DM4ZS8M TN 5-HT 2C receptor (HTR2C) DM4ZS8M MA Antagonist DM4ZS8M RN Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. DM4ZS8M RU https://pubmed.ncbi.nlm.nih.gov/16433010 DM50ILT DI DM50ILT DM50ILT DN Fostemsavir DM50ILT TI TTBYP1X DM50ILT TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DM50ILT MA Inhibitor DM50ILT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2020 DM50ILT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf DM50PMY DI DM50PMY DM50PMY DN Minodronate DM50PMY TI TTIKWV4 DM50PMY TN Geranyltranstransferase (FDPS) DM50PMY MA Inhibitor DM50PMY RN Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64. DM50PMY RU https://pubmed.ncbi.nlm.nih.gov/20394422 DM51FY6 DI DM51FY6 DM51FY6 DN Tacrine DM51FY6 TI TT1RS9F DM51FY6 TN Acetylcholinesterase (AChE) DM51FY6 MA Inhibitor DM51FY6 RN Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19. DM51FY6 RU https://pubmed.ncbi.nlm.nih.gov/12139368 DM51OQW DI DM51OQW DM51OQW DN Oxprenolol DM51OQW TI TTR6W5O DM51OQW TN Adrenergic receptor beta-1 (ADRB1) DM51OQW MA Antagonist DM51OQW RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DM51OQW RU https://pubmed.ncbi.nlm.nih.gov/16268148 DM51TYR DI DM51TYR DM51TYR DN Esmolol DM51TYR TI TTR6W5O DM51TYR TN Adrenergic receptor beta-1 (ADRB1) DM51TYR MA Antagonist DM51TYR RN Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart Lung. 2009 Jan-Feb;38(1):48-55. DM51TYR RU https://pubmed.ncbi.nlm.nih.gov/19150530 DM51Z9E DI DM51Z9E DM51Z9E DN Cephalothin sodium DM51Z9E TI TTJP4SM DM51Z9E TN Bacterial Penicillin binding protein (Bact PBP) DM51Z9E MA Modulator DM51Z9E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM51Z9E RU https://www.fda.gov/ DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 TI TTZA1NY DM53IP1 TN GABA(A) receptor beta-2 (GABRB2) DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM53IP1 DI DM53IP1 DM53IP1 DN Ethchlorvynol DM53IP1 TI TT1MPAY DM53IP1 TN GABA(A) receptor alpha-1 (GABRA1) DM53IP1 MA Antagonist DM53IP1 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM53IP1 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM53PV8 DI DM53PV8 DM53PV8 DN Cefoperazone DM53PV8 TI TTJP4SM DM53PV8 TN Bacterial Penicillin binding protein (Bact PBP) DM53PV8 MA Binder DM53PV8 RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DM53PV8 RU https://pubmed.ncbi.nlm.nih.gov/9841767 DM53SRA DI DM53SRA DM53SRA DN Prochlorperazine DM53SRA TI TTEX248 DM53SRA TN Dopamine D2 receptor (D2R) DM53SRA MA Antagonist DM53SRA RN In vitro and in vivo characteristics of prochlorperazine oral disintegrating film. Int J Pharm. 2009 Feb 23;368(1-2):98-102. DM53SRA RU https://pubmed.ncbi.nlm.nih.gov/18992311 DM560Y3 DI DM560Y3 DM560Y3 DN Morantel tartrate DM560Y3 TI TTHDSE2 DM560Y3 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM560Y3 MA Inhibitor DM560Y3 RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DM560Y3 RU https://pubmed.ncbi.nlm.nih.gov/11031122 DM56YN7 DI DM56YN7 DM56YN7 DN Desloratadine DM56YN7 TI TTTIBOJ DM56YN7 TN Histamine H1 receptor (H1R) DM56YN7 MA Antagonist DM56YN7 RN Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79. DM56YN7 RU https://pubmed.ncbi.nlm.nih.gov/19236123 DM57O90 DI DM57O90 DM57O90 DN Zolgensma DM57O90 TI TT8QL6X DM57O90 TN Survival motor neuron protein (SMN1) DM57O90 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DM57O90 RU https://www.fda.gov/vaccines-blood-biologics/zolgensma DM584TM DI DM584TM DM584TM DN Butacaine DM584TM TI TTRK8B9 DM584TM TN Sodium channel unspecific (NaC) DM584TM MA Modulator DM584TM RN WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers. DM584TM RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080717&CC=WO&NR=2008085711A1&KC=A1 DM58QS1 DI DM58QS1 DM58QS1 DN Botulinum Toxin Type B DM58QS1 TI TTG25NJ DM58QS1 TN Vesicle-associated membrane protein (VAMP) DM58QS1 MA Binder DM58QS1 RN Long-lasting benefits of botulinum toxin type B in Parkinson's disease-related drooling. J Neurol. 2009 Apr;256(4):563-7. DM58QS1 RU https://pubmed.ncbi.nlm.nih.gov/19401804 DM58VQX DI DM58VQX DM58VQX DN Telavancin DM58VQX TI TT7EFHR DM58VQX TN Corticotropin-releasing factor receptor 1 (CRHR1) DM58VQX MA Antagonist DM58VQX RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DM58VQX RU https://pubmed.ncbi.nlm.nih.gov/17109611 DM58WKG DI DM58WKG DM58WKG DN Panobinostat DM58WKG TI TT6R7JZ DM58WKG TN Histone deacetylase 1 (HDAC1) DM58WKG MA Inhibitor DM58WKG RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DM58WKG RU https://pubmed.ncbi.nlm.nih.gov/19721445 DM59AZT DI DM59AZT DM59AZT DN Clotiazepam DM59AZT TI TTPTXIN DM59AZT TN Translocator protein (TSPO) DM59AZT MA Agonist DM59AZT RN Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40. DM59AZT RU https://pubmed.ncbi.nlm.nih.gov/2574062 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN TI TT1290U DM59JCN TN Coagulation factor VIII (F8) DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM59JCN DI DM59JCN DM59JCN DN Drotrecogin alfa DM59JCN TI TT1O264 DM59JCN TN Coagulation factor Va (F5) DM59JCN MA Inhibitor DM59JCN RN Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96. DM59JCN RU https://pubmed.ncbi.nlm.nih.gov/19498123 DM5A31S DI DM5A31S DM5A31S DN TP-434 DM5A31S TI TTND3XS DM5A31S TN Bacterial Ribosome (Bact RIBS) DM5A31S MA Modulator DM5A31S RN Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother. 2012 May;56(5):2559-64. DM5A31S RU https://pubmed.ncbi.nlm.nih.gov/22354310 DM5A31S DI DM5A31S DM5A31S DN TP-434 DM5A31S TI TTOVFH2 DM5A31S TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM5A31S MA Inhibitor DM5A31S RN The antibiotic arms race: current and emerging therapy for Klebsiella pneumoniae carbapenemase (KPC) - producing bacteria.Expert Opin Pharmacother. 2018 Oct 22:1-13. DM5A31S RU https://pubmed.ncbi.nlm.nih.gov/30346216 DM5A38V DI DM5A38V DM5A38V DN Metharbital DM5A38V TI TTEX6LM DM5A38V TN GABA(A) receptor gamma-3 (GABRG3) DM5A38V MA Modulator DM5A38V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5A38V RU https://www.fda.gov/ DM5BS98 DI DM5BS98 DM5BS98 DN Ampiroxicam DM5BS98 TI TTK0943 DM5BS98 TN Prostaglandin G/H synthase (COX) DM5BS98 MA Modulator DM5BS98 RN Premedication with cyclooxygenase-2 inhibitor meloxicam reduced postoperative pain in patients after oral surgery. Int J Oral Maxillofac Surg. 2006 Jul;35(7):613-7. DM5BS98 RU https://pubmed.ncbi.nlm.nih.gov/16540287 DM5CL9Z DI DM5CL9Z DM5CL9Z DN Certolizumab DM5CL9Z TI TTF8CQI DM5CL9Z TN Tumor necrosis factor (TNF) DM5CL9Z MA Inhibitor DM5CL9Z RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DM5CL9Z RU https://pubmed.ncbi.nlm.nih.gov/18321156 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ TI TTAN6JD DM5D6WZ TN Glutamate receptor AMPA (GRIA) DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DM5D6WZ DI DM5D6WZ DM5D6WZ DN Dihydroergotoxine DM5D6WZ TI TTEX248 DM5D6WZ TN Dopamine D2 receptor (D2R) DM5D6WZ MA Agonist DM5D6WZ RN Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97. DM5D6WZ RU https://pubmed.ncbi.nlm.nih.gov/10084415 DM5DWMU DI DM5DWMU DM5DWMU DN Rimantadine DM5DWMU TI TTXT3PU DM5DWMU TN Influenza M2 protein (Influ M) DM5DWMU MA Inhibitor DM5DWMU RN Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104. DM5DWMU RU https://pubmed.ncbi.nlm.nih.gov/19215710 DM5EN79 DI DM5EN79 DM5EN79 DN Levamisole DM5EN79 TI TTMR5UV DM5EN79 TN Alkaline phosphatase tissue-nonspecific (ALPL) DM5EN79 MA Inhibitor DM5EN79 RN Characterization of rat heart alkaline phosphatase isoenzymes and modulation of activity. Braz J Med Biol Res. 2008 Jul;41(7):600-9. DM5EN79 RU https://pubmed.ncbi.nlm.nih.gov/18719742 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTHC7JD DM5F47O TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTMVBWH DM5F47O TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F47O DI DM5F47O DM5F47O DN Sofosbuvir + velpatasvir + voxilaprevir DM5F47O TI TTCJ2X8 DM5F47O TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM5F47O MA Inhibitor DM5F47O RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM5F47O RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM5F84A DI DM5F84A DM5F84A DN Pipecuronium DM5F84A TI TTF4E0J DM5F84A TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM5F84A MA Antagonist DM5F84A RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DM5F84A RU https://pubmed.ncbi.nlm.nih.gov/18633030 DM5FL14 DI DM5FL14 DM5FL14 DN Amifostine DM5FL14 TI TT0C9DV DM5FL14 TN Toxic reactive metabolite (TRM) DM5FL14 MA Modulator DM5FL14 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM5FL14 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM5FLTY DI DM5FLTY DM5FLTY DN Risedronate DM5FLTY TI TTIKWV4 DM5FLTY TN Geranyltranstransferase (FDPS) DM5FLTY MA Inhibitor DM5FLTY RN Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14. DM5FLTY RU https://pubmed.ncbi.nlm.nih.gov/12086478 DM5FSJA DI DM5FSJA DM5FSJA DN Glimepiride DM5FSJA TI TTEF5MJ DM5FSJA TN ATP-binding cassette transporter C9 (ABCC9) DM5FSJA MA Blocker DM5FSJA RN Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8. DM5FSJA RU https://pubmed.ncbi.nlm.nih.gov/19125764 DM5FSJA DI DM5FSJA DM5FSJA DN Glimepiride DM5FSJA TI TTP835K DM5FSJA TN ATP-binding cassette transporter C8 (ABCC8) DM5FSJA MA Blocker DM5FSJA RN Mechanism of disopyramide-induced hypoglycaemia in a patient with Type 2 diabetes. Diabet Med. 2009 Jan;26(1):76-8. DM5FSJA RU https://pubmed.ncbi.nlm.nih.gov/19125764 DM5GT1M DI DM5GT1M DM5GT1M DN EVANS BLUE DM5GT1M TI TTFNGC9 DM5GT1M TN Serum albumin (ALB) DM5GT1M MA Modulator DM5GT1M RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM5GT1M RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM5GVHU DI DM5GVHU DM5GVHU DN Quinolones DM5GVHU TI TT0IHXV DM5GVHU TN DNA topoisomerase II (TOP2) DM5GVHU MA Inhibitor DM5GVHU RN The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol. 2005;45:529-64. DM5GVHU RU https://pubmed.ncbi.nlm.nih.gov/15822188 DM5I1CE DI DM5I1CE DM5I1CE DN Valacyclovir Hydrochloride DM5I1CE TI TTIU7X1 DM5I1CE TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM5I1CE MA Modulator DM5I1CE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5I1CE RU https://www.fda.gov/ DM5I621 DI DM5I621 DM5I621 DN Methyldopa DM5I621 TI TTEX248 DM5I621 TN Dopamine D2 receptor (D2R) DM5I621 MA Agonist DM5I621 RN Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich). 2007 May;9(5):399-405. DM5I621 RU https://pubmed.ncbi.nlm.nih.gov/17485976 DM5IKUF DI DM5IKUF DM5IKUF DN Dihydroergotamine DM5IKUF TI TTEX248 DM5IKUF TN Dopamine D2 receptor (D2R) DM5IKUF MA Agonist DM5IKUF RN Current and prospective pharmacological targets in relation to antimigraine action. Naunyn Schmiedebergs Arch Pharmacol. 2008 Oct;378(4):371-94. DM5IKUF RU https://pubmed.ncbi.nlm.nih.gov/18626630 DM5IXKQ DI DM5IXKQ DM5IXKQ DN Vismodegib DM5IXKQ TI TT8J1S3 DM5IXKQ TN Smoothened homolog (SMO) DM5IXKQ MA Modulator DM5IXKQ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM5IXKQ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM5J1NH DI DM5J1NH DM5J1NH DN Alcaftadine DM5J1NH TI TTTIBOJ DM5J1NH TN Histamine H1 receptor (H1R) DM5J1NH MA Antagonist DM5J1NH RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5J1NH RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM5J64S DI DM5J64S DM5J64S DN Miglustat DM5J64S TI TTPHEX3 DM5J64S TN Ceramide glucosyltransferase (UGCG) DM5J64S MA Inhibitor DM5J64S RN Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies. Clin Ther. 2007 Aug;29(8):1645-54. DM5J64S RU https://pubmed.ncbi.nlm.nih.gov/17919546 DM5JQ0D DI DM5JQ0D DM5JQ0D DN Streptokinase DM5JQ0D TI TTP86E2 DM5JQ0D TN Plasminogen (PLG) DM5JQ0D MA Activator DM5JQ0D RN Acute anuric renal failure with streptokinase therapy in a patient with acute venous thromboembolic disease and the review of renal side effects of streptokinase. Tuberk Toraks. 2008;56(4):456-61. DM5JQ0D RU https://pubmed.ncbi.nlm.nih.gov/19123085 DM5JTPU DI DM5JTPU DM5JTPU DN Albumin Human DM5JTPU TI TTFNGC9 DM5JTPU TN Serum albumin (ALB) DM5JTPU MA Modulator DM5JTPU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5JTPU RU https://www.fda.gov/ DM5JVAN DI DM5JVAN DM5JVAN DN Fingolimod DM5JVAN TI TT9JZCK DM5JVAN TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM5JVAN MA Modulator DM5JVAN RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM5JVAN RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM5JVS3 DI DM5JVS3 DM5JVS3 DN Isoniazid DM5JVS3 TI TTVTX4N DM5JVS3 TN Bacterial Fatty acid synthetase I (Bact inhA) DM5JVS3 MA Inhibitor DM5JVS3 RN Diversity in enoyl-acyl carrier protein reductases. Cell Mol Life Sci. 2009 May;66(9):1507-17. DM5JVS3 RU https://pubmed.ncbi.nlm.nih.gov/19151923 DM5JWV9 DI DM5JWV9 DM5JWV9 DN Tiazofurin DM5JWV9 TI TTL7C8Q DM5JWV9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5JWV9 MA Inhibitor DM5JWV9 RN In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30. DM5JWV9 RU https://pubmed.ncbi.nlm.nih.gov/9703919 DM5KYPJ DI DM5KYPJ DM5KYPJ DN Butorphanol DM5KYPJ TI TT27RFC DM5KYPJ TN Opioid receptor delta (OPRD1) DM5KYPJ MA Agonist DM5KYPJ RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DM5KYPJ RU https://pubmed.ncbi.nlm.nih.gov/15942128 DM5L6HI DI DM5L6HI DM5L6HI DN Atomoxetine DM5L6HI TI TTAWNKZ DM5L6HI TN Norepinephrine transporter (NET) DM5L6HI MA Inhibitor DM5L6HI RN Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50. DM5L6HI RU https://pubmed.ncbi.nlm.nih.gov/18568443 DM5LJCI DI DM5LJCI DM5LJCI DN Eptinezumab DM5LJCI TI TTAFORY DM5LJCI TN Calcitonin gene-related peptide (CALC) DM5LJCI MA Inhibitor DM5LJCI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM5LJCI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf DM5M4NT DI DM5M4NT DM5M4NT DN Ethacrynate sodium DM5M4NT TI TTS087L DM5M4NT TN Solute carrier family 12 member 1 (SLC12A1) DM5M4NT MA Modulator DM5M4NT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5M4NT RU https://www.fda.gov/ DM5NM6E DI DM5NM6E DM5NM6E DN NADH DM5NM6E TI TTTJF7V DM5NM6E TN NADH dehydrogenase (MT-ND3) DM5NM6E MA Binder DM5NM6E RN Mechanism of cadmium-decreased glucuronidation in the rat. Biochem Pharmacol. 1992 Dec 1;44(11):2139-47. DM5NM6E RU https://pubmed.ncbi.nlm.nih.gov/1472079 DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 TI TTFBNVI DM5OGK0 TN Aldose reductase (AKR1B1) DM5OGK0 MA Inhibitor DM5OGK0 RN Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/11522497 DM5OGK0 DI DM5OGK0 DM5OGK0 DN Epalrestat DM5OGK0 TI TTXHYV6 DM5OGK0 TN Voltage-gated L-type calcium channel (L-CaC) DM5OGK0 MA Blocker DM5OGK0 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DM5OGK0 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DM5OHYE DI DM5OHYE DM5OHYE DN Bacitracin DM5OHYE TI TT2EDHU DM5OHYE TN Insulin-degrading enzyme (IDE) DM5OHYE MA Inhibitor DM5OHYE RN Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci. 2004 Oct 27;24(43):9632-7. DM5OHYE RU https://pubmed.ncbi.nlm.nih.gov/15509750 DM5OY70 DI DM5OY70 DM5OY70 DN Iron Dextran DM5OY70 TI TTQO71U DM5OY70 TN Hemoglobin (HB) DM5OY70 MA Activator DM5OY70 RN Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7. DM5OY70 RU https://pubmed.ncbi.nlm.nih.gov/18760066 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 TI TT3ROYC DM5PCS7 TN Serotonin transporter (SERT) DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DM5PCS7 DI DM5PCS7 DM5PCS7 DN Bupropion DM5PCS7 TI TTAWNKZ DM5PCS7 TN Norepinephrine transporter (NET) DM5PCS7 MA Inhibitor DM5PCS7 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DM5PCS7 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DM5PDRB DI DM5PDRB DM5PDRB DN Amikacin DM5PDRB TI TTQ8KVI DM5PDRB TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DM5PDRB MA Binder DM5PDRB RN Bacterial resistance to aminoglycosides and beta-lactams: the Tn1331 transposon paradigm. Front Biosci. 2000 Jan 1;5:D20-9. DM5PDRB RU https://pubmed.ncbi.nlm.nih.gov/10702385 DM5PFIJ DI DM5PFIJ DM5PFIJ DN Givosiran DM5PFIJ TI TTG1FXO DM5PFIJ TN ALAS1 messenger RNA (ALAS1 mRNA) DM5PFIJ MA Inhibitor DM5PFIJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM5PFIJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0212194s000lbl.pdf DM5PU6O DI DM5PU6O DM5PU6O DN Oxcarbazepine DM5PU6O TI TTN9VTF DM5PU6O TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DM5PU6O MA Blocker DM5PU6O RN Debate: Does genetic information in humans help us treat patients PRO--genetic information in humans helps us treat patients. CON--genetic information does not help at all. Epilepsia. 2008 Dec;49 Suppl 9:13-24. DM5PU6O RU https://pubmed.ncbi.nlm.nih.gov/19087113 DM5PVQE DI DM5PVQE DM5PVQE DN Paroxetine DM5PVQE TI TT3ROYC DM5PVQE TN Serotonin transporter (SERT) DM5PVQE MA Modulator DM5PVQE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5PVQE RU https://www.fda.gov/ DM5QF9V DI DM5QF9V DM5QF9V DN Tamsulosin DM5QF9V TI TTNGILX DM5QF9V TN Adrenergic receptor alpha-1A (ADRA1A) DM5QF9V MA Modulator DM5QF9V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5QF9V RU https://www.fda.gov/ DM5QWEL DI DM5QWEL DM5QWEL DN Guanabenz DM5QWEL TI TTQ8AFT DM5QWEL TN Adrenergic receptor Alpha-2 (ADRA2) DM5QWEL MA Agonist DM5QWEL RN Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5. DM5QWEL RU https://pubmed.ncbi.nlm.nih.gov/9284427 DM5SQ1G DI DM5SQ1G DM5SQ1G DN Dihydroergocristine DM5SQ1G TI TT2NUT5 DM5SQ1G TN Adrenergic receptor alpha-2C (ADRA2C) DM5SQ1G MA Modulator DM5SQ1G RN Effect of dihydroergocristine on blood pressure and activity at peripheral alpha-adrenoceptors in pithed rats. Eur J Pharmacol. 1984 Jan 13;97(1-2):21-7. DM5SQ1G RU https://pubmed.ncbi.nlm.nih.gov/6321209 DM5SXUV DI DM5SXUV DM5SXUV DN Repaglinide DM5SXUV TI TTP835K DM5SXUV TN ATP-binding cassette transporter C8 (ABCC8) DM5SXUV MA Blocker DM5SXUV RN Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. DM5SXUV RU https://pubmed.ncbi.nlm.nih.gov/19478691 DM5SXUV DI DM5SXUV DM5SXUV DN Repaglinide DM5SXUV TI TTEF5MJ DM5SXUV TN ATP-binding cassette transporter C9 (ABCC9) DM5SXUV MA Blocker DM5SXUV RN Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. DM5SXUV RU https://pubmed.ncbi.nlm.nih.gov/19478691 DM5SYZP DI DM5SYZP DM5SYZP DN Disopyramide DM5SYZP TI TTZOVE0 DM5SYZP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM5SYZP MA Blocker DM5SYZP RN Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. DM5SYZP RU https://pubmed.ncbi.nlm.nih.gov/11196553 DM5T6US DI DM5T6US DM5T6US DN Estrone DM5T6US TI TTZAYWL DM5T6US TN Estrogen receptor (ESR) DM5T6US MA Agonist DM5T6US RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DM5T6US RU https://pubmed.ncbi.nlm.nih.gov/19434891 DM5TVS3 DI DM5TVS3 DM5TVS3 DN Vinblastine DM5TVS3 TI TTJ2PTI DM5TVS3 TN Tubulin beta-2 chain (TUBB2) DM5TVS3 MA Inhibitor DM5TVS3 RN Effect of the antitumor drug vinblastine on nuclear betaII-tubulin in cultured rat kidney mesangial cells. Invest New Drugs. 2003 Feb;21(1):15-20. DM5TVS3 RU https://pubmed.ncbi.nlm.nih.gov/12795526 DM5UGDK DI DM5UGDK DM5UGDK DN Mephenytoin DM5UGDK TI TTZOVE0 DM5UGDK TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM5UGDK MA Blocker DM5UGDK RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DM5UGDK RU https://pubmed.ncbi.nlm.nih.gov/19552484 DM5URA2 DI DM5URA2 DM5URA2 DN Chlorpheniramine DM5URA2 TI TTTIBOJ DM5URA2 TN Histamine H1 receptor (H1R) DM5URA2 MA Antagonist DM5URA2 RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM5URA2 RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM5V9U1 DI DM5V9U1 DM5V9U1 DN Gadofosveset DM5V9U1 TI TTFNGC9 DM5V9U1 TN Serum albumin (ALB) DM5V9U1 MA Modulator DM5V9U1 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DM5V9U1 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTYEG6Q DM5VWOB TN Muscarinic acetylcholine receptor M2 (CHRM2) DM5VWOB MA Antagonist DM5VWOB RN Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/19565307 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTOXS3C DM5VWOB TN Muscarinic acetylcholine receptor (CHRM) DM5VWOB MA Antagonist DM5VWOB RN Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/12235229 DM5VWOB DI DM5VWOB DM5VWOB DN Methylscopolamine DM5VWOB TI TTQ13Z5 DM5VWOB TN Muscarinic acetylcholine receptor M3 (CHRM3) DM5VWOB MA Antagonist DM5VWOB RN Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94. DM5VWOB RU https://pubmed.ncbi.nlm.nih.gov/9846649 DM5WFNP DI DM5WFNP DM5WFNP DN Abarelix DM5WFNP TI TT8R70G DM5WFNP TN Gonadotropin-releasing hormone receptor (GNRHR) DM5WFNP MA Modulator DM5WFNP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5WFNP RU https://www.fda.gov/ DM5X7VY DI DM5X7VY DM5X7VY DN Pyrimethamine DM5X7VY TI TTVC37M DM5X7VY TN Folate receptor alpha (FOLR1) DM5X7VY MA Modulator DM5X7VY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5X7VY RU https://www.fda.gov/ DM5XH2C DI DM5XH2C DM5XH2C DN Methotrexate Sodium DM5XH2C TI TTYZVDJ DM5XH2C TN Dihydrofolate reductase (DHFR) DM5XH2C MA Modulator DM5XH2C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM5XH2C RU https://www.fda.gov/ DM5XHVR DI DM5XHVR DM5XHVR DN Insulin Lyspro recombinant DM5XHVR TI TTCBFJO DM5XHVR TN Insulin receptor (INSR) DM5XHVR MA Binder DM5XHVR RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DM5XHVR RU https://pubmed.ncbi.nlm.nih.gov/12509758 DM5XLTY DI DM5XLTY DM5XLTY DN Spirapril DM5XLTY TI TTL69WB DM5XLTY TN Angiotensin-converting enzyme (ACE) DM5XLTY MA Inhibitor DM5XLTY RN Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J. 2005 Sep;19(11):1474-81. DM5XLTY RU https://pubmed.ncbi.nlm.nih.gov/16126915 DM5XPIJ DI DM5XPIJ DM5XPIJ DN Leuprolide DM5XPIJ TI TT0ID4A DM5XPIJ TN Leutinizing-hormone-releasing hormone (GNRH1) DM5XPIJ MA Activator DM5XPIJ RN Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Pharmacotherapy. 2008 Dec;28(12):1511-22. DM5XPIJ RU https://pubmed.ncbi.nlm.nih.gov/19025432 DM5YBO1 DI DM5YBO1 DM5YBO1 DN Levalbuterol DM5YBO1 TI TT2CJVK DM5YBO1 TN Adrenergic receptor beta-2 (ADRB2) DM5YBO1 MA Antagonist DM5YBO1 RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DM5YBO1 RU https://pubmed.ncbi.nlm.nih.gov/19491545 DM602WT DI DM602WT DM602WT DN Idelalisib DM602WT TI TTGBPJE DM602WT TN PI3-kinase delta (PIK3CD) DM602WT MA Inhibitor DM602WT RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM602WT RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TTGP7BY DM6034S TN Monoamine oxidase type B (MAO-B) DM6034S MA Inhibitor DM6034S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DM6034S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TTZPO1L DM6034S TN Substance-P receptor (TACR1) DM6034S MA Antagonist DM6034S RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6034S RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6034S DI DM6034S DM6034S DN Selegiline DM6034S TI TT32XQJ DM6034S TN Monoamine oxidase (MAO) DM6034S MA Inhibitor DM6034S RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM6034S RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM60QMR DI DM60QMR DM60QMR DN Ethacrynic acid DM60QMR TI TTS087L DM60QMR TN Solute carrier family 12 member 1 (SLC12A1) DM60QMR MA Blocker DM60QMR RN Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74. DM60QMR RU https://pubmed.ncbi.nlm.nih.gov/7733229 DM61TA4 DI DM61TA4 DM61TA4 DN Arsenic trioxide DM61TA4 TI TTJ3E9X DM61TA4 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM61TA4 MA Inhibitor DM61TA4 RN How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002 Sep;2(9):705-13. DM61TA4 RU https://pubmed.ncbi.nlm.nih.gov/12209159 DM62B78 DI DM62B78 DM62B78 DN Olodaterol DM62B78 TI TT2CJVK DM62B78 TN Adrenergic receptor beta-2 (ADRB2) DM62B78 MA Modulator DM62B78 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM62B78 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM62MUZ DI DM62MUZ DM62MUZ DN Samarium Sm-153 Lexidronam Pentasodium DM62MUZ TI TTGXKP7 DM62MUZ TN Samarium (SAM) DM62MUZ MA Modulator DM62MUZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM62MUZ RU https://www.fda.gov/ DM62UG5 DI DM62UG5 DM62UG5 DN Vemurafenib DM62UG5 TI TTWCGQT DM62UG5 TN Serine/threonine-protein kinase B-raf (BRAF) DM62UG5 MA Modulator DM62UG5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM62UG5 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM62UHC DI DM62UHC DM62UHC DN Meropenem DM62UHC TI TTJP4SM DM62UHC TN Bacterial Penicillin binding protein (Bact PBP) DM62UHC MA Modulator DM62UHC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM62UHC RU https://www.fda.gov/ DM63QS9 DI DM63QS9 DM63QS9 DN Nystatin DM63QS9 TI TTQKWA4 DM63QS9 TN Fungal Cell membrane ergosterol (Fung CME) DM63QS9 MA Modulator DM63QS9 RN Cholesterol and Ergosterol Influence Nystatin Surface Aggregation: Relation to Pore Formation DM63QS9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1304795 DM65AGJ DI DM65AGJ DM65AGJ DN Oxymorphone DM65AGJ TI TTN4QDT DM65AGJ TN Opioid receptor (OPR) DM65AGJ MA Modulator DM65AGJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094). DM65AGJ RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7094 DM65KL8 DI DM65KL8 DM65KL8 DN Fluocinonide DM65KL8 TI TTP3UTW DM65KL8 TN Steroid hormone receptor ERR (ESRR) DM65KL8 MA Modulator DM65KL8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM65KL8 RU https://www.fda.gov/ DM671NG DI DM671NG DM671NG DN Progabide DM671NG TI TTDCVZW DM671NG TN Gamma-aminobutyric acid B receptor (GABBR) DM671NG MA Agonist DM671NG RN Interactions between dopamine and GABA in the control of ambulatory activity and neophobia in the mouse. Pharmacol Biochem Behav. 1998 Jan;59(1):239-47. DM671NG RU https://pubmed.ncbi.nlm.nih.gov/9443561 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH TI TTK0943 DM672AH TN Prostaglandin G/H synthase (COX) DM672AH MA Inhibitor DM672AH RN Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/19075637 DM672AH DI DM672AH DM672AH DN Aspirin DM672AH TI TTPADOQ DM672AH TN HMG-CoA reductase (HMGCR) DM672AH MA Inhibitor DM672AH RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DM672AH RU https://pubmed.ncbi.nlm.nih.gov/16503827 DM67VKL DI DM67VKL DM67VKL DN Prasterone DM67VKL TI TTS64P2 DM67VKL TN Androgen receptor (AR) DM67VKL MA Antagonist DM67VKL RN Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev. 2004 Apr;3(2):171-87. DM67VKL RU https://pubmed.ncbi.nlm.nih.gov/15177053 DM67VKL DI DM67VKL DM67VKL DN Prasterone DM67VKL TI TTKN8W0 DM67VKL TN Glucose-6-phosphate dehydrogenase (G6PD) DM67VKL MA Inhibitor DM67VKL RN Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5. DM67VKL RU https://pubmed.ncbi.nlm.nih.gov/3776114 DM69XMQ DI DM69XMQ DM69XMQ DN RG-7446 DM69XMQ TI TT8ZLTI DM69XMQ TN Programmed cell death 1 ligand 1 (PD-L1) DM69XMQ RN PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673. DM69XMQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3892798/ DM6A0X7 DI DM6A0X7 DM6A0X7 DN Pravastatin DM6A0X7 TI TTPADOQ DM6A0X7 TN HMG-CoA reductase (HMGCR) DM6A0X7 MA Inhibitor DM6A0X7 RN A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9. DM6A0X7 RU https://pubmed.ncbi.nlm.nih.gov/11996957 DM6A4NW DI DM6A4NW DM6A4NW DN Etoricoxib DM6A4NW TI TTVKILB DM6A4NW TN Prostaglandin G/H synthase 2 (COX-2) DM6A4NW MA Inhibitor DM6A4NW RN The effect of newer anti-rheumatic drugs on osteogenic cell proliferation: an in-vitro study. J Orthop Surg Res. 2009 May 26;4:17. DM6A4NW RU https://pubmed.ncbi.nlm.nih.gov/19470170 DM6AN32 DI DM6AN32 DM6AN32 DN Trovafloxacin DM6AN32 TI TTN6J5F DM6AN32 TN Bacterial DNA gyrase (Bact gyrase) DM6AN32 MA Modulator DM6AN32 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6AN32 RU https://www.fda.gov/ DM6AUFY DI DM6AUFY DM6AUFY DN Iloperidone DM6AUFY TI TTJQOD7 DM6AUFY TN 5-HT 2A receptor (HTR2A) DM6AUFY MA Antagonist DM6AUFY RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6AUFY RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6AUFY DI DM6AUFY DM6AUFY DN Iloperidone DM6AUFY TI TTEX248 DM6AUFY TN Dopamine D2 receptor (D2R) DM6AUFY MA Antagonist DM6AUFY RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6AUFY RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6AUHV DI DM6AUHV DM6AUHV DN Fostamatinib DM6AUHV TI TTOU65C DM6AUHV TN Tyrosine-protein kinase SYK (SYK) DM6AUHV MA Modulator DM6AUHV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). DM6AUHV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230 DM6AVR4 DI DM6AVR4 DM6AVR4 DN Hydroquinone DM6AVR4 TI TT38RM1 DM6AVR4 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM6AVR4 MA Antagonist DM6AVR4 RN Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76. DM6AVR4 RU https://pubmed.ncbi.nlm.nih.gov/9787163 DM6AVR4 DI DM6AVR4 DM6AVR4 DN Hydroquinone DM6AVR4 TI TTULVH8 DM6AVR4 TN Tyrosinase (TYR) DM6AVR4 MA Inhibitor DM6AVR4 RN Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5. DM6AVR4 RU https://pubmed.ncbi.nlm.nih.gov/19159217 DM6CLBN DI DM6CLBN DM6CLBN DN Danaparoid DM6CLBN TI TTCIHJA DM6CLBN TN Coagulation factor Xa (F10) DM6CLBN MA Inhibitor DM6CLBN RN Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6. DM6CLBN RU https://pubmed.ncbi.nlm.nih.gov/12402196 DM6D7N8 DI DM6D7N8 DM6D7N8 DN Propylthiouracil DM6D7N8 TI TTU3X26 DM6D7N8 TN Iodothyronine deiodinase type I (DIO1) DM6D7N8 MA Inhibitor DM6D7N8 RN Type 1 iodothyronine deiodinase is the major source of circulating T3 in hyperthyroidism: implications for therapy. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):740-1. DM6D7N8 RU https://pubmed.ncbi.nlm.nih.gov/17712320 DM6D7N8 DI DM6D7N8 DM6D7N8 DN Propylthiouracil DM6D7N8 TI TT52XDZ DM6D7N8 TN Thyroid peroxidase (TPO) DM6D7N8 MA Inhibitor DM6D7N8 RN Bioinorganic chemistry in thyroid gland: effect of antithyroid drugs on peroxidase-catalyzed oxidation and iodination reactions. Bioinorg Chem Appl. 2006:23214. DM6D7N8 RU https://pubmed.ncbi.nlm.nih.gov/17497002 DM6DEK9 DI DM6DEK9 DM6DEK9 DN Stavudine DM6DEK9 TI TT84ETX DM6DEK9 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6DEK9 MA Inhibitor DM6DEK9 RN Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705. DM6DEK9 RU https://pubmed.ncbi.nlm.nih.gov/15183338 DM6ECN9 DI DM6ECN9 DM6ECN9 DN Aluminium DM6ECN9 TI TTWK8D0 DM6ECN9 TN Sodium pump subunit alpha-1 (ATP1A1) DM6ECN9 MA Binder DM6ECN9 RN The inhibitory effect of aluminium on the (Na+/K+)ATPase activity of rat brain cortex synaptosomes. J Inorg Biochem. 2003 Sep 15;97(1):143-50. DM6ECN9 RU https://pubmed.ncbi.nlm.nih.gov/14507470 DM6EL5Q DI DM6EL5Q DM6EL5Q DN Glucarpidase DM6EL5Q TI TTX81QL DM6EL5Q TN Toxic methotrexate (TM) DM6EL5Q MA Modulator DM6EL5Q RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM6EL5Q RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM6EUL5 DI DM6EUL5 DM6EUL5 DN Betaxolol DM6EUL5 TI TTR6W5O DM6EUL5 TN Adrenergic receptor beta-1 (ADRB1) DM6EUL5 MA Antagonist DM6EUL5 RN beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29. DM6EUL5 RU https://pubmed.ncbi.nlm.nih.gov/19439240 DM6F1PU DI DM6F1PU DM6F1PU DN Vortioxetine DM6F1PU TI TT3ROYC DM6F1PU TN Serotonin transporter (SERT) DM6F1PU MA Inhibitor DM6F1PU RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM6F1PU RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM6FG1P DI DM6FG1P DM6FG1P DN Doxercalciferol DM6FG1P TI TTK59TV DM6FG1P TN Vitamin D3 receptor (VDR) DM6FG1P MA Antagonist DM6FG1P RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DM6FG1P RU https://pubmed.ncbi.nlm.nih.gov/19249988 DM6HX9B DI DM6HX9B DM6HX9B DN Nevirapine DM6HX9B TI TT84ETX DM6HX9B TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6HX9B MA Modulator DM6HX9B RN HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9. DM6HX9B RU https://www.ncbi.nlm.nih.gov/pubmed/22266819 DM6I2WQ DI DM6I2WQ DM6I2WQ DN Amezinium DM6I2WQ TI TT2NUT5 DM6I2WQ TN Adrenergic receptor alpha-2C (ADRA2C) DM6I2WQ MA Modulator DM6I2WQ RN Pharmacology of amezinium, a novel antihypotensive drug. III. Studies on the mechanism of action. Arzneimittelforschung. 1981;31(9a):1558-65. DM6I2WQ RU https://pubmed.ncbi.nlm.nih.gov/7197970 DM6I5GR DI DM6I5GR DM6I5GR DN Promethazine DM6I5GR TI TTTIBOJ DM6I5GR TN Histamine H1 receptor (H1R) DM6I5GR MA Antagonist DM6I5GR RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DM6I5GR RU https://pubmed.ncbi.nlm.nih.gov/18446005 DM6IR3P DI DM6IR3P DM6IR3P DN Liothyronine DM6IR3P TI TTTSEPU DM6IR3P TN Thyroid hormone receptor alpha (THRA) DM6IR3P MA Antagonist DM6IR3P RN Evaluation of thyroid hormone action in a case of generalized resistance to thyroid hormone with chronic thyroiditis: discovery of a novel heterozy... Endocr J. 2007 Dec;54(5):727-32. DM6IR3P RU https://pubmed.ncbi.nlm.nih.gov/17827792 DM6KI0D DI DM6KI0D DM6KI0D DN Repirinast DM6KI0D TI TT7CXIM DM6KI0D TN Histamine receptor (HR) DM6KI0D MA Modulator DM6KI0D RN Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90. DM6KI0D RU https://pubmed.ncbi.nlm.nih.gov/1378339 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTN6J5F DM6KZMG TN Bacterial DNA gyrase (Bact gyrase) DM6KZMG MA Modulator DM6KZMG RN In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65. DM6KZMG RU https://www.ncbi.nlm.nih.gov/pubmed/11864945 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTIXTO3 DM6KZMG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DM6KZMG MA Modulator DM6KZMG RN In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65. DM6KZMG RU https://www.ncbi.nlm.nih.gov/pubmed/11864945 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTABD5E DM6KZMG TN DNA replication (DNA repli) DM6KZMG MA Inhibitor DM6KZMG RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM6KZMG RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM6KZMG DI DM6KZMG DM6KZMG DN Ozenoxacin DM6KZMG TI TTRVWAT DM6KZMG TN Staphylococcus DNA gyrase A (Stap-coc gyrA) DM6KZMG MA Inhibitor DM6KZMG RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM6KZMG RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM6L4H2 DI DM6L4H2 DM6L4H2 DN Cobicistat DM6L4H2 TI TTIJQ3O DM6L4H2 TN Cytochrome P450 3A (CYP3A) DM6L4H2 MA Modulator DM6L4H2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7535). DM6L4H2 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7535 DM6L5VO DI DM6L5VO DM6L5VO DN Methsuximide DM6L5VO TI TT729IR DM6L5VO TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM6L5VO MA Blocker DM6L5VO RN Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. DM6L5VO RU https://pubmed.ncbi.nlm.nih.gov/11641441 DM6LOQU DI DM6LOQU DM6LOQU DN Celecoxib DM6LOQU TI TTVKILB DM6LOQU TN Prostaglandin G/H synthase 2 (COX-2) DM6LOQU MA Inhibitor DM6LOQU RN Pfizer. Product Development Pipeline. March 31 2009. DM6LOQU RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM6MO9X DI DM6MO9X DM6MO9X DN Insulin Zinc Susp Recombinant Human DM6MO9X TI TTZOPHG DM6MO9X TN Insulin (INS) DM6MO9X MA Modulator DM6MO9X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6MO9X RU https://www.fda.gov/ DM6N4PR DI DM6N4PR DM6N4PR DN Cerulenin DM6N4PR TI TT7AOUD DM6N4PR TN Fatty acid synthase (FASN) DM6N4PR MA Inhibitor DM6N4PR RN Inhibition of fatty acid biosynthesis prevents adipocyte lipotoxicity on human osteoblasts in vitro. J Cell Mol Med. 2010 Apr;14(4):982-91. DM6N4PR RU https://pubmed.ncbi.nlm.nih.gov/19382912 DM6NZ2P DI DM6NZ2P DM6NZ2P DN Pegvaliase DM6NZ2P TI TTGSVH2 DM6NZ2P TN Phenylalanine hydroxylase (PAH) DM6NZ2P MA Modulator DM6NZ2P RN Induction, titration, and maintenance dosing regimen in a phase 2 study of pegvaliase for control of blood phenylalanine in adults with phenylketonuria.Mol Genet Metab. 2018 Nov;125(3):217-227. DM6NZ2P RU https://pubmed.ncbi.nlm.nih.gov/30146451 DM6OZQV DI DM6OZQV DM6OZQV DN Daclizumab DM6OZQV TI TTF89GD DM6OZQV TN Interleukin-2 (IL2) DM6OZQV MA Modulator DM6OZQV RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM6OZQV RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM6PR40 DI DM6PR40 DM6PR40 DN Paramethasone DM6PR40 TI TTJL8VG DM6PR40 TN Corticosteroid-binding globulin (SERPINA6) DM6PR40 MA Binder DM6PR40 RN Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab. 2000 Jan;85(1):361-7. DM6PR40 RU https://pubmed.ncbi.nlm.nih.gov/10634411 DM6Q4B0 DI DM6Q4B0 DM6Q4B0 DN Anistreplase DM6Q4B0 TI TTP86E2 DM6Q4B0 TN Plasminogen (PLG) DM6Q4B0 MA Activator DM6Q4B0 RN Evaluation of thrombolytic agents. Drugs. 1997;54 Suppl 3:11-6; discussion 16-7. DM6Q4B0 RU https://pubmed.ncbi.nlm.nih.gov/9360848 DM6Q7U4 DI DM6Q7U4 DM6Q7U4 DN Lenalidomide DM6Q7U4 TI TTF8CQI DM6Q7U4 TN Tumor necrosis factor (TNF) DM6Q7U4 MA Inhibitor DM6Q7U4 RN Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351. DM6Q7U4 RU https://pubmed.ncbi.nlm.nih.gov/19370685 DM6QFSV DI DM6QFSV DM6QFSV DN Erdosteine DM6QFSV TI TT3NKIB DM6QFSV TN Pancreatic elastase 1 (CELA1) DM6QFSV MA Modulator DM6QFSV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM6QFSV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q TI TTQ8AFT DM6RZ9Q TN Adrenergic receptor Alpha-2 (ADRA2) DM6RZ9Q MA Agonist DM6RZ9Q RN Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/11164065 DM6RZ9Q DI DM6RZ9Q DM6RZ9Q DN Clonidine DM6RZ9Q TI TT7HC21 DM6RZ9Q TN Membrane copper amine oxidase (AOC3) DM6RZ9Q MA Inhibitor DM6RZ9Q RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6RZ9Q RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6S0HB DI DM6S0HB DM6S0HB DN TachoComb DM6S0HB TI TTWODQF DM6S0HB TN Fibrin (FG) DM6S0HB MA Modulator DM6S0HB RN Pancreaticojejunostomy using a fibrin adhesive sealant (TachoComb) for the prevention of pancreatic fistula after pancreaticoduodenectomy. Hepatogastroenterology. 2011 Jan-Feb;58(105):187-91. DM6S0HB RU https://pubmed.ncbi.nlm.nih.gov/21510312 DM6S157 DI DM6S157 DM6S157 DN Guanadrel Sulfate DM6S157 TI TTVIREA DM6S157 TN Adrenergic receptor (ADR) DM6S157 MA Modulator DM6S157 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6S157 RU https://www.fda.gov/ DM6T2J3 DI DM6T2J3 DM6T2J3 DN Neostigmine DM6T2J3 TI TT1RS9F DM6T2J3 TN Acetylcholinesterase (AChE) DM6T2J3 MA Inhibitor DM6T2J3 RN Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. DM6T2J3 RU https://pubmed.ncbi.nlm.nih.gov/19472276 DM6T924 DI DM6T924 DM6T924 DN Gabapentin DM6T924 TI TTDCVZW DM6T924 TN Gamma-aminobutyric acid B receptor (GABBR) DM6T924 MA Antagonist DM6T924 RN Gabapentin increases a tonic inhibitory conductance in hippocampal pyramidal neurons. Anesthesiology. 2006 Aug;105(2):325-33. DM6T924 RU https://pubmed.ncbi.nlm.nih.gov/16871066 DM6TS1N DI DM6TS1N DM6TS1N DN Phendimetrazine DM6TS1N TI TTBRKXS DM6TS1N TN Adrenergic receptor alpha-1B (ADRA1B) DM6TS1N MA Antagonist DM6TS1N RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DM6TS1N RU https://pubmed.ncbi.nlm.nih.gov/17016423 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTI2WET DM6U9CQ TN Platelet-derived growth factor receptor (PDGFR) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTUTJGQ DM6U9CQ TN Vascular endothelial growth factor receptor 2 (KDR) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6U9CQ DI DM6U9CQ DM6U9CQ DN Pazopanib HCl DM6U9CQ TI TTX41N9 DM6U9CQ TN Tyrosine-protein kinase Kit (KIT) DM6U9CQ MA Inhibitor DM6U9CQ RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM6U9CQ RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM6VM38 DI DM6VM38 DM6VM38 DN Reserpine DM6VM38 TI TTNZRI3 DM6VM38 TN Synaptic vesicle amine transporter (SLC18A2) DM6VM38 MA Blocker DM6VM38 RN Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. DM6VM38 RU https://pubmed.ncbi.nlm.nih.gov/19571144 DM6VOWQ DI DM6VOWQ DM6VOWQ DN Fomepizole DM6VOWQ TI TT5AHZ0 DM6VOWQ TN Alcohol dehydrogenase 1A (ADH1A) DM6VOWQ MA Modulator DM6VOWQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6VOWQ RU https://www.fda.gov/ DM6VZFQ DI DM6VZFQ DM6VZFQ DN Pirfenidone DM6VZFQ TI TTR9XHZ DM6VZFQ TN Transforming growth factor beta 1 (TGFB1) DM6VZFQ MA Modulator DM6VZFQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM6VZFQ RU https://www.fda.gov/ DM6W8V5 DI DM6W8V5 DM6W8V5 DN Lisdexamfetamine DM6W8V5 TI TTIU98M DM6W8V5 TN Trace amine-associated receptor-1 (TAAR1) DM6W8V5 MA Modulator DM6W8V5 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM6W8V5 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM6WJO9 DI DM6WJO9 DM6WJO9 DN Etodolac DM6WJO9 TI TTVKILB DM6WJO9 TN Prostaglandin G/H synthase 2 (COX-2) DM6WJO9 MA Inhibitor DM6WJO9 RN Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8. DM6WJO9 RU https://pubmed.ncbi.nlm.nih.gov/17603251 DM6XFHS DI DM6XFHS DM6XFHS DN SPI-1005 DM6XFHS TI TTFNGC9 DM6XFHS TN Serum albumin (ALB) DM6XFHS MA Binder DM6XFHS RN Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44. DM6XFHS RU https://pubmed.ncbi.nlm.nih.gov/7945407 DM6Y3AN DI DM6Y3AN DM6Y3AN DN Micafungin DM6Y3AN TI TT0SFXH DM6Y3AN TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DM6Y3AN MA Modulator DM6Y3AN RN An immunomodulatory activity of micafungin in preclinical aspergillosis. J Antimicrob Chemother. 2014 Apr;69(4):1065-74. DM6Y3AN RU https://pubmed.ncbi.nlm.nih.gov/24265229 DM6YWBF DI DM6YWBF DM6YWBF DN Herbimycin A DM6YWBF TI TT6PKBN DM6YWBF TN Proto-oncogene c-Src (SRC) DM6YWBF MA Inhibitor DM6YWBF RN In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73. DM6YWBF RU https://pubmed.ncbi.nlm.nih.gov/7967714 DM6ZPLQ DI DM6ZPLQ DM6ZPLQ DN Novolimus DM6ZPLQ TI TTCJG29 DM6ZPLQ TN Serine/threonine-protein kinase mTOR (mTOR) DM6ZPLQ MA Inhibitor DM6ZPLQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DM6ZPLQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DM70BU5 DI DM70BU5 DM70BU5 DN Thalidomide DM70BU5 TI TTF8CQI DM70BU5 TN Tumor necrosis factor (TNF) DM70BU5 MA Inhibitor DM70BU5 RN Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5. DM70BU5 RU https://pubmed.ncbi.nlm.nih.gov/19099634 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN TI TTJQOD7 DM70DTN TN 5-HT 2A receptor (HTR2A) DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70DTN DI DM70DTN DM70DTN DN Flibanserin DM70DTN TI TTSQIFT DM70DTN TN 5-HT 1A receptor (HTR1A) DM70DTN MA Modulator DM70DTN RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DM70DTN RU https://pubmed.ncbi.nlm.nih.gov/28919714 DM70IK5 DI DM70IK5 DM70IK5 DN Marinol DM70IK5 TI TT6OEDT DM70IK5 TN Cannabinoid receptor 1 (CB1) DM70IK5 MA Agonist DM70IK5 RN Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411. DM70IK5 RU https://pubmed.ncbi.nlm.nih.gov/19226257 DM72JXH DI DM72JXH DM72JXH DN Losartan DM72JXH TI TT8DBY3 DM72JXH TN Angiotensin II receptor type-1 (AGTR1) DM72JXH MA Antagonist DM72JXH RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DM72JXH RU https://pubmed.ncbi.nlm.nih.gov/19513646 DM749I3 DI DM749I3 DM749I3 DN Ubrogepant DM749I3 TI TTY6O0Q DM749I3 TN Calcitonin gene-related peptide receptor (CGRPR) DM749I3 MA Antagonist DM749I3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM749I3 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf DM74LZK DI DM74LZK DM74LZK DN Cromoglicate DM74LZK TI TT78R5H DM74LZK TN Heat shock protein 90 alpha (HSP90A) DM74LZK MA Inhibitor DM74LZK RN Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41. DM74LZK RU https://pubmed.ncbi.nlm.nih.gov/12803546 DM74SVE DI DM74SVE DM74SVE DN Dasiglucagon DM74SVE TI TT9O6WS DM74SVE TN Glucagon receptor (GCGR) DM74SVE MA Agonist DM74SVE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DM74SVE RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf DM75CXN DI DM75CXN DM75CXN DN Avanafil DM75CXN TI TTJ0IQB DM75CXN TN Phosphodiesterase 5A (PDE5A) DM75CXN MA Modulator DM75CXN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM75CXN RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM76VHG DI DM76VHG DM76VHG DN Regadenoson DM76VHG TI TTM2AOE DM76VHG TN Adenosine A2a receptor (ADORA2A) DM76VHG MA Modulator DM76VHG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM76VHG RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM783CH DI DM783CH DM783CH DN Levobupivacaine DM783CH TI TTRK8B9 DM783CH TN Sodium channel unspecific (NaC) DM783CH MA Blocker DM783CH RN Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505. DM783CH RU https://pubmed.ncbi.nlm.nih.gov/11094008 DM78G6F DI DM78G6F DM78G6F DN HTF 919 DM78G6F TI TT07C3Y DM78G6F TN 5-HT 4 receptor (HTR4) DM78G6F MA Agonist DM78G6F RN 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58. DM78G6F RU https://pubmed.ncbi.nlm.nih.gov/11874527 DM78IME DI DM78IME DM78IME DN Ergotidine DM78IME TI TTTIBOJ DM78IME TN Histamine H1 receptor (H1R) DM78IME MA Agonist DM78IME RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DM78IME RU https://pubmed.ncbi.nlm.nih.gov/11179434 DM78NWP DI DM78NWP DM78NWP DN Dostarlimab DM78NWP TI TTNBFWK DM78NWP TN Programmed cell death protein 1 (PD-1) DM78NWP MA Inhibitor DM78NWP RN Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer. Future Oncol. 2021 Mar;17(8):877-892. DM78NWP RU https://pubmed.ncbi.nlm.nih.gov/33251877 DM79F6G DI DM79F6G DM79F6G DN Adenosine triphosphate DM79F6G TI TT3PJMV DM79F6G TN Tyrosine-protein kinase ABL1 (ABL) DM79F6G MA Inhibitor DM79F6G RN Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. DM79F6G RU https://pubmed.ncbi.nlm.nih.gov/18056932 DM79NTF DI DM79NTF DM79NTF DN Propranolol DM79NTF TI TTR6W5O DM79NTF TN Adrenergic receptor beta-1 (ADRB1) DM79NTF MA Antagonist DM79NTF RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DM79NTF RU https://pubmed.ncbi.nlm.nih.gov/19491545 DM79NZ5 DI DM79NZ5 DM79NZ5 DN Insulin determir DM79NZ5 TI TTZOPHG DM79NZ5 TN Insulin (INS) DM79NZ5 MA Modulator DM79NZ5 RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DM79NZ5 RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DM79VXT DI DM79VXT DM79VXT DN PF-04971729 DM79VXT TI TTLWPVF DM79VXT TN Sodium/glucose cotransporter 2 (SGLT2) DM79VXT MA Modulator DM79VXT RN Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin.Diabetes Obes Metab.2015 Jun;17(6):591-8. DM79VXT RU https://www.ncbi.nlm.nih.gov/pubmed/25754396 DM79XDW DI DM79XDW DM79XDW DN Cephalosporin DM79XDW TI TTLP6GN DM79XDW TN Bacterial DD-carboxypeptidase (Bact vanYB) DM79XDW MA Binder DM79XDW RN A 1.2-A snapshot of the final step of bacterial cell wall biosynthesis. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1427-31. DM79XDW RU https://pubmed.ncbi.nlm.nih.gov/11171967 DM79Y2T DI DM79Y2T DM79Y2T DN ATryn antithrombin DM79Y2T TI TT6L509 DM79Y2T TN Coagulation factor IIa (F2) DM79Y2T MA Modulator DM79Y2T RN Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779. DM79Y2T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875262/ DM7A8TW DI DM7A8TW DM7A8TW DN Ezetimibe DM7A8TW TI TTPD1CN DM7A8TW TN Niemann-Pick C1-like protein 1 (NPC1L1) DM7A8TW MA Inhibitor DM7A8TW RN Update on patented cholesterol absorption inhibitors. Expert Opin Ther Pat. 2009 Aug;19(8):1083-107. DM7A8TW RU https://pubmed.ncbi.nlm.nih.gov/19552506 DM7AVGW DI DM7AVGW DM7AVGW DN Ocriplasmin DM7AVGW TI TTPJ921 DM7AVGW TN Fibronectin (FN1) DM7AVGW MA Inhibitor DM7AVGW RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DM7AVGW RU https://pubmed.ncbi.nlm.nih.gov/23370234 DM7BN0X DI DM7BN0X DM7BN0X DN Esomeprazole DM7BN0X TI TTLOKXP DM7BN0X TN Gastric H(+)/K(+) ATPase (Proton pump) DM7BN0X MA Modulator DM7BN0X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7BN0X RU https://www.fda.gov/ DM7C8YV DI DM7C8YV DM7C8YV DN Plicamycin DM7C8YV TI TTX2AYW DM7C8YV TN RNA synthesis (hRNA synth) DM7C8YV MA Modulator DM7C8YV RN Role of magnesium ion in mithramycin-DNA interaction: binding of mithramycin-Mg2+ complexes with DNA. Biochemistry. 1995 Jan 31;34(4):1376-85. DM7C8YV RU https://pubmed.ncbi.nlm.nih.gov/7827085 DM7DSYP DI DM7DSYP DM7DSYP DN Cefprozil DM7DSYP TI TTJP4SM DM7DSYP TN Bacterial Penicillin binding protein (Bact PBP) DM7DSYP MA Binder DM7DSYP RN Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8. DM7DSYP RU https://pubmed.ncbi.nlm.nih.gov/15949076 DM7EN8I DI DM7EN8I DM7EN8I DN Diflunisal DM7EN8I TI TTVKILB DM7EN8I TN Prostaglandin G/H synthase 2 (COX-2) DM7EN8I MA Inhibitor DM7EN8I RN Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice. J Am Dent Assoc. 2001 Apr;132(4):451-6. DM7EN8I RU https://pubmed.ncbi.nlm.nih.gov/11315375 DM7EUK3 DI DM7EUK3 DM7EUK3 DN Delapril DM7EUK3 TI TTL69WB DM7EUK3 TN Angiotensin-converting enzyme (ACE) DM7EUK3 MA Modulator DM7EUK3 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM7EUK3 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC TI TTP362L DM7EVLC TN Solute carrier family 12 member 3 (SLC12A3) DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7EVLC DI DM7EVLC DM7EVLC DN Bendroflumethiazide DM7EVLC TI TTS087L DM7EVLC TN Solute carrier family 12 member 1 (SLC12A1) DM7EVLC MA Blocker DM7EVLC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7EVLC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7F1PA DI DM7F1PA DM7F1PA DN Nebivolol DM7F1PA TI TTR6W5O DM7F1PA TN Adrenergic receptor beta-1 (ADRB1) DM7F1PA MA Antagonist DM7F1PA RN Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27. DM7F1PA RU https://pubmed.ncbi.nlm.nih.gov/19443516 DM7F5OW DI DM7F5OW DM7F5OW DN Mepyramine maleate DM7F5OW TI TTTIBOJ DM7F5OW TN Histamine H1 receptor (H1R) DM7F5OW MA Antagonist DM7F5OW RN Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54. DM7F5OW RU https://pubmed.ncbi.nlm.nih.gov/19552055 DM7G0EP DI DM7G0EP DM7G0EP DN Fosmidomycin DM7G0EP TI TTLH4J3 DM7G0EP TN Plasmodium DOXP reductoisomerase (Malaria DXR) DM7G0EP MA Binder DM7G0EP RN Structural basis of fosmidomycin action revealed by the complex with 2-C-methyl-D-erythritol 4-phosphate synthase (IspC). Implications for the cata... J Biol Chem. 2003 May 16;278(20):18401-7. DM7G0EP RU https://pubmed.ncbi.nlm.nih.gov/12621040 DM7GCVW DI DM7GCVW DM7GCVW DN Acalabrutinib DM7GCVW TI TTGM6VW DM7GCVW TN Tyrosine-protein kinase BTK (ATK) DM7GCVW MA Inhibitor DM7GCVW RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7GCVW RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7HUNW DI DM7HUNW DM7HUNW DN Testosterone DM7HUNW TI TTS64P2 DM7HUNW TN Androgen receptor (AR) DM7HUNW MA Agonist DM7HUNW RN Molecular mechanism of androgen action. Trends Endocrinol Metab. 1998 Oct 1;9(8):317-24. DM7HUNW RU https://pubmed.ncbi.nlm.nih.gov/18406296 DM7HXWT DI DM7HXWT DM7HXWT DN Nilotinib DM7HXWT TI TTS7G69 DM7HXWT TN Fusion protein Bcr-Abl (Bcr-Abl) DM7HXWT MA Modulator DM7HXWT RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM7HXWT RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM7I64Z DI DM7I64Z DM7I64Z DN Almogran DM7I64Z TI TT6MSOK DM7I64Z TN 5-HT 1D receptor (HTR1D) DM7I64Z MA Agonist DM7I64Z RN Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75. DM7I64Z RU https://pubmed.ncbi.nlm.nih.gov/11768838 DM7ICNU DI DM7ICNU DM7ICNU DN Doxycycline DM7ICNU TI TTOVFH2 DM7ICNU TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM7ICNU MA Modulator DM7ICNU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7ICNU RU https://www.fda.gov/ DM7ISKJ DI DM7ISKJ DM7ISKJ DN Nisoldipine DM7ISKJ TI TT5HONZ DM7ISKJ TN Calcium channel unspecific (CaC) DM7ISKJ MA Blocker DM7ISKJ RN RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12. DM7ISKJ RU https://pubmed.ncbi.nlm.nih.gov/19536471 DM7IW9J DI DM7IW9J DM7IW9J DN Ramelteon DM7IW9J TI TT0WAIE DM7IW9J TN Melatonin receptor type 1A (MTNR1A) DM7IW9J MA Modulator DM7IW9J RN MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85. DM7IW9J RU https://pubmed.ncbi.nlm.nih.gov/24228714 DM7IW9J DI DM7IW9J DM7IW9J DN Ramelteon DM7IW9J TI TT32JK8 DM7IW9J TN Melatonin receptor type 1B (MTNR1B) DM7IW9J MA Modulator DM7IW9J RN MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014 Apr 24;57(8):3161-85. DM7IW9J RU https://pubmed.ncbi.nlm.nih.gov/24228714 DM7J2TA DI DM7J2TA DM7J2TA DN Methazolamide DM7J2TA TI TTHQPL7 DM7J2TA TN Carbonic anhydrase I (CA-I) DM7J2TA MA Modulator DM7J2TA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597). DM7J2TA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597 DM7J6OR DI DM7J6OR DM7J6OR DN Tocilizumab DM7J6OR TI TT0E5SK DM7J6OR TN Interleukin 6 receptor (IL6R) DM7J6OR MA Modulator DM7J6OR RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM7J6OR RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM7JHX0 DI DM7JHX0 DM7JHX0 DN Butethal DM7JHX0 TI TT1MPAY DM7JHX0 TN GABA(A) receptor alpha-1 (GABRA1) DM7JHX0 MA Antagonist DM7JHX0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7JHX0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7JT24 DI DM7JT24 DM7JT24 DN Acocantherin DM7JT24 TI TTWK8D0 DM7JT24 TN Sodium pump subunit alpha-1 (ATP1A1) DM7JT24 MA Binder DM7JT24 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7JT24 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7K5GD DI DM7K5GD DM7K5GD DN Lutropin alfa DM7K5GD TI TT2O4W9 DM7K5GD TN Luteinizing hormone receptor (LHCGR) DM7K5GD MA Binder DM7K5GD RN Lutropin alfa. Drugs. 2008;68(11):1529-40. DM7K5GD RU https://pubmed.ncbi.nlm.nih.gov/18627209 DM7MDBE DI DM7MDBE DM7MDBE DN Vericiguat DM7MDBE TI TTWNFC2 DM7MDBE TN Soluble guanylyl cyclase (GUCY2D) DM7MDBE MA Modulator DM7MDBE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DM7MDBE RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214377s000lbl.pdf DM7MT6E DI DM7MT6E DM7MT6E DN Prasugrel DM7MT6E TI TTZ1DT0 DM7MT6E TN P2Y purinoceptor 12 (P2RY12) DM7MT6E MA Inhibitor DM7MT6E RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM7MT6E RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM7NKEV DI DM7NKEV DM7NKEV DN Thioguanine DM7NKEV TI TTCAQMW DM7NKEV TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DM7NKEV MA Intercalator DM7NKEV RN Immune effector cells produce lethal DNA damage in cells treated with a thiopurine. Cancer Res. 2009 Mar 15;69(6):2393-9. DM7NKEV RU https://pubmed.ncbi.nlm.nih.gov/19244103 DM7NPJS DI DM7NPJS DM7NPJS DN Paliperidone DM7NPJS TI TT85JO3 DM7NPJS TN 5-HT receptor (5HTR) DM7NPJS MA Antagonist DM7NPJS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM7NPJS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TT9V5JH DM7OKQV TN Phospholipase A2 (PLA2G1B) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TTQ6VF4 DM7OKQV TN Ferrochelatase (FECH) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OKQV DI DM7OKQV DM7OKQV DN Cholic acid DM7OKQV TI TTMF541 DM7OKQV TN Liver carboxylesterase (CES1) DM7OKQV MA Inhibitor DM7OKQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OKQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 TI TTPREZD DM7P1J4 TN Interleukin-5 (IL5) DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity a novel approach for the treatment of asthma DM7P1J4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587289 DM7P1J4 DI DM7P1J4 DM7P1J4 DN Benralizumab DM7P1J4 TI TTXH9AD DM7P1J4 TN Interleukin 5 receptor alpha (IL5RA) DM7P1J4 MA Modulator DM7P1J4 RN Benralizumab--a humanized mAb to IL-5R with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma. Expert Opin Biol Ther. 2012 Jan;12(1):113-8. DM7P1J4 RU https://www.ncbi.nlm.nih.gov/pubmed/22136436 DM7PQIK DI DM7PQIK DM7PQIK DN Nitrofurantoin DM7PQIK TI TTS1W4A DM7PQIK TN Bacterial Deoxyribonucleic acid (Bact DNA) DM7PQIK MA Breaker DM7PQIK RN On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14. DM7PQIK RU https://pubmed.ncbi.nlm.nih.gov/8607796 DM7Q41G DI DM7Q41G DM7Q41G DN Pyruvic acid DM7Q41G TI TTT2LD9 DM7Q41G TN GABA transaminase (ABAT) DM7Q41G MA Inhibitor DM7Q41G RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7Q41G RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TTRMX3V DM7Q98D TN Janus kinase 2 (JAK-2) DM7Q98D MA Modulator DM7Q98D RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TT6DM01 DM7Q98D TN Janus kinase 1 (JAK-1) DM7Q98D MA Modulator DM7Q98D RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM7Q98D DI DM7Q98D DM7Q98D DN Ruxolitinib DM7Q98D TI TTPRL03 DM7Q98D TN Urokinase plasminogen activator surface receptor (PLAUR) DM7Q98D MA Inhibitor DM7Q98D RN Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis.Cell Cycle. 2014;13(12):1958-69. DM7Q98D RU https://pubmed.ncbi.nlm.nih.gov/24763226 DM7QG0M DI DM7QG0M DM7QG0M DN Raxibacumab DM7QG0M TI TT3YGCD DM7QG0M TN Bacterial Protective antigen (Bact pagA) DM7QG0M MA Modulator DM7QG0M RN Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. DM7QG0M RU https://pubmed.ncbi.nlm.nih.gov/21383241 DM7RE8P DI DM7RE8P DM7RE8P DN Frovatriptan DM7RE8P TI TTK8CXU DM7RE8P TN 5-HT 1B receptor (HTR1B) DM7RE8P MA Modulator DM7RE8P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7RE8P RU https://www.fda.gov/ DM7RE8P DI DM7RE8P DM7RE8P DN Frovatriptan DM7RE8P TI TT6MSOK DM7RE8P TN 5-HT 1D receptor (HTR1D) DM7RE8P MA Modulator DM7RE8P RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7RE8P RU https://www.fda.gov/ DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTS7G69 DM7RJXL TN Fusion protein Bcr-Abl (Bcr-Abl) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTI2WET DM7RJXL TN Platelet-derived growth factor receptor (PDGFR) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTX41N9 DM7RJXL TN Tyrosine-protein kinase Kit (KIT) DM7RJXL MA Inhibitor DM7RJXL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM7RJXL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM7RJXL DI DM7RJXL DM7RJXL DN Imatinib DM7RJXL TI TTN6ORK DM7RJXL TN Mcl-1 messenger RNA (MCL-1 mRNA) DM7RJXL RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM7RJXL RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM7RNP3 DI DM7RNP3 DM7RNP3 DN Enbrel DM7RNP3 TI TTF8CQI DM7RNP3 TN Tumor necrosis factor (TNF) DM7RNP3 MA Modulator DM7RNP3 RN Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61. DM7RNP3 RU https://www.ncbi.nlm.nih.gov/pubmed/11451976 DM7SJD6 DI DM7SJD6 DM7SJD6 DN Methylphenidate DM7SJD6 TI TTVBI8W DM7SJD6 TN Dopamine transporter (DAT) DM7SJD6 MA Blocker DM7SJD6 RN Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5. DM7SJD6 RU https://pubmed.ncbi.nlm.nih.gov/15950015 DM7SWIA DI DM7SWIA DM7SWIA DN Triprolidine DM7SWIA TI TTTIBOJ DM7SWIA TN Histamine H1 receptor (H1R) DM7SWIA MA Antagonist DM7SWIA RN Histamine excites rat lateral vestibular nuclear neurons through activation of post-synaptic H2 receptors. Neurosci Lett. 2008 Dec 19;448(1):15-9. DM7SWIA RU https://pubmed.ncbi.nlm.nih.gov/18938221 DM7U5QJ DI DM7U5QJ DM7U5QJ DN Cinnarizine DM7U5QJ TI TTTIBOJ DM7U5QJ TN Histamine H1 receptor (H1R) DM7U5QJ MA Antagonist DM7U5QJ RN Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4. DM7U5QJ RU https://pubmed.ncbi.nlm.nih.gov/12056673 DM7UP8X DI DM7UP8X DM7UP8X DN Pegfilgrastim DM7UP8X TI TTC70AJ DM7UP8X TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DM7UP8X MA Binder DM7UP8X RN Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004 Jul;50(1):55-8. DM7UP8X RU https://pubmed.ncbi.nlm.nih.gov/15082029 DM7VTQO DI DM7VTQO DM7VTQO DN Entecavir DM7VTQO TI TTS5K1M DM7VTQO TN Hepatitis B virus Reverse transcriptase (HBV RT) DM7VTQO MA Modulator DM7VTQO RN Effect of hepatitis B virus reverse transcriptase variations on entecavir treatment response. J Infect Dis. 2014 Sep 1;210(5):701-7. DM7VTQO RU https://pubmed.ncbi.nlm.nih.gov/24610871 DM7W94S DI DM7W94S DM7W94S DN Brigatinib DM7W94S TI TTPMQSO DM7W94S TN ALK tyrosine kinase receptor (ALK) DM7W94S MA Inhibitor DM7W94S RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DM7W94S RU https://pubmed.ncbi.nlm.nih.gov/29348678 DM7WI4Q DI DM7WI4Q DM7WI4Q DN Quinagolide DM7WI4Q TI TTEX248 DM7WI4Q TN Dopamine D2 receptor (D2R) DM7WI4Q MA Agonist DM7WI4Q RN Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8. DM7WI4Q RU https://pubmed.ncbi.nlm.nih.gov/12055141 DM7YCK3 DI DM7YCK3 DM7YCK3 DN Thiabendazole DM7YCK3 TI TTHDSE2 DM7YCK3 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM7YCK3 MA Inhibitor DM7YCK3 RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DM7YCK3 RU https://pubmed.ncbi.nlm.nih.gov/11031122 DM7YMIT DI DM7YMIT DM7YMIT DN Methohexital DM7YMIT TI TT1MPAY DM7YMIT TN GABA(A) receptor alpha-1 (GABRA1) DM7YMIT MA Antagonist DM7YMIT RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM7YMIT RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM7YPM1 DI DM7YPM1 DM7YPM1 DN Enfuvirtide DM7YPM1 TI TTG90S6 DM7YPM1 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DM7YPM1 MA Modulator DM7YPM1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7YPM1 RU https://www.fda.gov/ DM7ZWNY DI DM7ZWNY DM7ZWNY DN Porfimer Sodium DM7ZWNY TI TTH0DUS DM7ZWNY TN Low-density lipoprotein receptor (LDL-R) DM7ZWNY MA Modulator DM7ZWNY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7ZWNY RU https://www.fda.gov/ DM804UR DI DM804UR DM804UR DN Hyoscyamine DM804UR TI TTH18TF DM804UR TN Muscarinic acetylcholine receptor M5 (CHRM5) DM804UR MA Antagonist DM804UR RN Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein. Biochemistry. 1987 Dec 15;26(25):8175-82. DM804UR RU https://pubmed.ncbi.nlm.nih.gov/3126798 DM80OEZ DI DM80OEZ DM80OEZ DN Iobenguane I-123 DM80OEZ TI TTAWNKZ DM80OEZ TN Norepinephrine transporter (NET) DM80OEZ MA Inhibitor DM80OEZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DM80OEZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DM80OZ5 DI DM80OZ5 DM80OZ5 DN Halothane DM80OZ5 TI TTAN6JD DM80OZ5 TN Glutamate receptor AMPA (GRIA) DM80OZ5 MA Antagonist DM80OZ5 RN Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45. DM80OZ5 RU https://pubmed.ncbi.nlm.nih.gov/17828284 DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTST7KB DM819JF TN Fibroblast growth factor receptor 3 (FGFR3) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTRLW2X DM819JF TN Fibroblast growth factor receptor 1 (FGFR1) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM819JF DI DM819JF DM819JF DN Pemigatinib DM819JF TI TTGJVQM DM819JF TN Fibroblast growth factor receptor 2 (FGFR2) DM819JF MA Inhibitor DM819JF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM819JF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213736s000lbl.pdf DM82Z30 DI DM82Z30 DM82Z30 DN Topiramate DM82Z30 TI TT0MYE2 DM82Z30 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM82Z30 MA Antagonist DM82Z30 RN Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005 May;10(2):323-43. DM82Z30 RU https://pubmed.ncbi.nlm.nih.gov/15934870 DM83MOK DI DM83MOK DM83MOK DN Glassia DM83MOK TI TTA7UJC DM83MOK TN Alpha-1-antitrypsin (SERPINA1) DM83MOK MA Inhibitor DM83MOK RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM83MOK RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM84ZXF DI DM84ZXF DM84ZXF DN Lorazepam DM84ZXF TI TTPTXIN DM84ZXF TN Translocator protein (TSPO) DM84ZXF MA Modulator DM84ZXF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM84ZXF RU https://www.fda.gov/ DM87XSN DI DM87XSN DM87XSN DN REGN-727 DM87XSN TI TTBRG7E DM87XSN TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM87XSN RN Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36. DM87XSN RU https://pubmed.ncbi.nlm.nih.gov/22633824 DM89JLN DI DM89JLN DM89JLN DN Apixaban DM89JLN TI TTCIHJA DM89JLN TN Coagulation factor Xa (F10) DM89JLN MA Inhibitor DM89JLN RN Pfizer. Product Development Pipeline. March 31 2009. DM89JLN RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM89QE1 DI DM89QE1 DM89QE1 DN Metformin DM89QE1 TI TTY84UG DM89QE1 TN Acetyl-CoA carboxylase 2 (ACACB) DM89QE1 MA Activator DM89QE1 RN AMP-activated protein kinase-dependent and -independent mechanisms underlying in vitro antiglioma action of compound C. Biochem Pharmacol. 2009 Jun 1;77(11):1684-93. DM89QE1 RU https://pubmed.ncbi.nlm.nih.gov/19428322 DM89QE1 DI DM89QE1 DM89QE1 DN Metformin DM89QE1 TI TTMHCGA DM89QE1 TN Solute carrier family 47 member 1 (SLC47A1) DM89QE1 MA Modulator DM89QE1 RN Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701. DM89QE1 RU https://pubmed.ncbi.nlm.nih.gov/16850272 DM8AI9U DI DM8AI9U DM8AI9U DN Loxapine DM8AI9U TI TTEX248 DM8AI9U TN Dopamine D2 receptor (D2R) DM8AI9U MA Antagonist DM8AI9U RN Remoxipride in Parkinson's disease: differential response in patients with dyskinesias fluctuations versus psychosis. Clin Neuropharmacol. 1995 Feb;18(1):39-45. DM8AI9U RU https://pubmed.ncbi.nlm.nih.gov/8665533 DM8ANCF DI DM8ANCF DM8ANCF DN Muromonab DM8ANCF TI TTZAT79 DM8ANCF TN T-cell surface glycoprotein CD3 epsilon (CD3E) DM8ANCF MA Binder DM8ANCF RN Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35. DM8ANCF RU https://pubmed.ncbi.nlm.nih.gov/14664658 DM8BKU9 DI DM8BKU9 DM8BKU9 DN Acitretin DM8BKU9 TI TTH8FZW DM8BKU9 TN Signal transducer and activator of transcription 3 (STAT3) DM8BKU9 MA Inhibitor DM8BKU9 RN Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4. DM8BKU9 RU https://pubmed.ncbi.nlm.nih.gov/16737614 DM8C3GN DI DM8C3GN DM8C3GN DN Denopamine DM8C3GN TI TTEX248 DM8C3GN TN Dopamine D2 receptor (D2R) DM8C3GN MA Modulator DM8C3GN RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8C3GN RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM8C43Q DI DM8C43Q DM8C43Q DN Cycrimine DM8C43Q TI TTZ9SOR DM8C43Q TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8C43Q MA Binder DM8C43Q RN Capillary gas chromatography of trihexyphenidyl, procyclidine and cycrimine in biological fluids. J Chromatogr. 1989 Sep 29;494:135-42. DM8C43Q RU https://pubmed.ncbi.nlm.nih.gov/2573609 DM8DQV9 DI DM8DQV9 DM8DQV9 DN Pelubiprofen DM8DQV9 TI TTK0943 DM8DQV9 TN Prostaglandin G/H synthase (COX) DM8DQV9 MA Modulator DM8DQV9 RN Anti-inflammatory effect of pelubiprofen, 2-[4-(oxocyclohexylidenemethyl)-phenyl]propionic acid, mediated by dual suppression of COX activity and LPS-induced inflammatory gene expression via NF- B inactivation. J Cell Biochem. 2011 Dec;112(12):3594-603. DM8DQV9 RU https://pubmed.ncbi.nlm.nih.gov/21809372 DM8DZC1 DI DM8DZC1 DM8DZC1 DN Dyphylline DM8DZC1 TI TTZ97H5 DM8DZC1 TN Phosphodiesterase 4A (PDE4A) DM8DZC1 MA Inhibitor DM8DZC1 RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DM8DZC1 RU https://pubmed.ncbi.nlm.nih.gov/7925603 DM8EU0Z DI DM8EU0Z DM8EU0Z DN Dicloxacillin DM8EU0Z TI TTJP4SM DM8EU0Z TN Bacterial Penicillin binding protein (Bact PBP) DM8EU0Z MA Binder DM8EU0Z RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DM8EU0Z RU https://pubmed.ncbi.nlm.nih.gov/6335600 DM8HBJI DI DM8HBJI DM8HBJI DN Coagulation Factor IX DM8HBJI TI TTCIHJA DM8HBJI TN Coagulation factor Xa (F10) DM8HBJI MA Activator DM8HBJI RN Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24. DM8HBJI RU https://pubmed.ncbi.nlm.nih.gov/16086639 DM8HDOL DI DM8HDOL DM8HDOL DN Phytonadione DM8HDOL TI TT76OLR DM8HDOL TN Vitamin K-dependent gamma-carboxylase (GGCX) DM8HDOL MA Cofactor DM8HDOL RN Quinone oxidoreductases and vitamin K metabolism. Vitam Horm. 2008;78:85-101. DM8HDOL RU https://pubmed.ncbi.nlm.nih.gov/18374191 DM8HJX6 DI DM8HJX6 DM8HJX6 DN Tipranavir DM8HJX6 TI TT5FNQT DM8HJX6 TN Human immunodeficiency virus Protease (HIV PR) DM8HJX6 MA Modulator DM8HJX6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8HJX6 RU https://www.fda.gov/ DM8HLO5 DI DM8HLO5 DM8HLO5 DN Canakinumab DM8HLO5 TI TTRYK0X DM8HLO5 TN Interleukin-1 beta (IL1B) DM8HLO5 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DM8HLO5 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DM8HO1L DI DM8HO1L DM8HO1L DN Pyridostigmine DM8HO1L TI TT1RS9F DM8HO1L TN Acetylcholinesterase (AChE) DM8HO1L MA Inhibitor DM8HO1L RN Neuromuscular blockade, reversal agent use, and operating room time: retrospective analysis of US inpatient surgeries. Curr Med Res Opin. 2009 Apr;25(4):943-50. DM8HO1L RU https://pubmed.ncbi.nlm.nih.gov/19257799 DM8JRH0 DI DM8JRH0 DM8JRH0 DN Cangrelor DM8JRH0 TI TTZ1DT0 DM8JRH0 TN P2Y purinoceptor 12 (P2RY12) DM8JRH0 MA Antagonist DM8JRH0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328). DM8JRH0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328 DM8JXPZ DI DM8JXPZ DM8JXPZ DN Glibenclamide DM8JXPZ TI TTP835K DM8JXPZ TN ATP-binding cassette transporter C8 (ABCC8) DM8JXPZ MA Modulator DM8JXPZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8JXPZ RU https://www.fda.gov/ DM8K1XO DI DM8K1XO DM8K1XO DN Hydrocortamate DM8K1XO TI TTYRL6O DM8K1XO TN Glucocorticoid receptor (NR3C1) DM8K1XO MA Modulator DM8K1XO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8K1XO RU https://www.fda.gov/ DM8K3EI DI DM8K3EI DM8K3EI DN Ethionamide DM8K3EI TI TTVTX4N DM8K3EI TN Bacterial Fatty acid synthetase I (Bact inhA) DM8K3EI MA Inhibitor DM8K3EI RN Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8. DM8K3EI RU https://pubmed.ncbi.nlm.nih.gov/17227913 DM8KSQH DI DM8KSQH DM8KSQH DN Phenoxybenzamine DM8KSQH TI TTEX248 DM8KSQH TN Dopamine D2 receptor (D2R) DM8KSQH MA Antagonist DM8KSQH RN Catecholamine-secreting neuroblastoma in a 4-month-old infant: perioperative management. J Clin Anesth. 2009 Feb;21(1):54-6. DM8KSQH RU https://pubmed.ncbi.nlm.nih.gov/19232942 DM8L9D4 DI DM8L9D4 DM8L9D4 DN Bestatin DM8L9D4 TI TTXZEAJ DM8L9D4 TN Leukotriene A-4 hydrolase (LTA4H) DM8L9D4 MA Inhibitor DM8L9D4 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM8L9D4 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM8LRU2 DI DM8LRU2 DM8LRU2 DN Revolade/Promacta DM8LRU2 TI TTIHYA4 DM8LRU2 TN Thrombopoietin receptor (MPL) DM8LRU2 MA Agonist DM8LRU2 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM8LRU2 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM8LX76 DI DM8LX76 DM8LX76 DN Penicillin V Potassium DM8LX76 TI TTJP4SM DM8LX76 TN Bacterial Penicillin binding protein (Bact PBP) DM8LX76 MA Modulator DM8LX76 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8LX76 RU https://www.fda.gov/ DM8MC6O DI DM8MC6O DM8MC6O DN Estradiol valerate DM8MC6O TI TTZAYWL DM8MC6O TN Estrogen receptor (ESR) DM8MC6O MA Modulator DM8MC6O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8MC6O RU https://www.fda.gov/ DM8MNVO DI DM8MNVO DM8MNVO DN Tolcapone DM8MNVO TI TTKWFB8 DM8MNVO TN Catechol-O-methyl-transferase (COMT) DM8MNVO MA Inhibitor DM8MNVO RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DM8MNVO RU https://pubmed.ncbi.nlm.nih.gov/11346021 DM8QB0T DI DM8QB0T DM8QB0T DN GSK2592984A DM8QB0T TI TT3J5ZI DM8QB0T TN Cell mediated immunity response (CMIR) DM8QB0T RN Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80. DM8QB0T RU https://pubmed.ncbi.nlm.nih.gov/20941447 DM8QB1D DI DM8QB1D DM8QB1D DN Olaparib DM8QB1D TI TTEBCY8 DM8QB1D TN Poly [ADP-ribose] polymerase (PARP) DM8QB1D MA Modulator DM8QB1D RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM8QB1D RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM8QM5U DI DM8QM5U DM8QM5U DN Anidulafungin DM8QM5U TI TT0SFXH DM8QM5U TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DM8QM5U MA Modulator DM8QM5U RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DM8QM5U RU https://pubmed.ncbi.nlm.nih.gov/17342860 DM8QTJI DI DM8QTJI DM8QTJI DN Loteprednol etabonate DM8QTJI TI TTP3UTW DM8QTJI TN Steroid hormone receptor ERR (ESRR) DM8QTJI MA Modulator DM8QTJI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8QTJI RU https://www.fda.gov/ DM8RFNJ DI DM8RFNJ DM8RFNJ DN Pitolisant DM8RFNJ TI TT9JNIC DM8RFNJ TN Histamine H3 receptor (H3R) DM8RFNJ MA Agonist DM8RFNJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DM8RFNJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211150s000lbl.pdf DM8RZ9H DI DM8RZ9H DM8RZ9H DN Eszopiclone DM8RZ9H TI TTPTXIN DM8RZ9H TN Translocator protein (TSPO) DM8RZ9H MA Agonist DM8RZ9H RN New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9. DM8RZ9H RU https://pubmed.ncbi.nlm.nih.gov/18265473 DM8S6T7 DI DM8S6T7 DM8S6T7 DN Ivosidenib DM8S6T7 TI TTV2A1R DM8S6T7 TN Oxalosuccinate decarboxylase (IDH1) DM8S6T7 MA Inhibitor DM8S6T7 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM8S6T7 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM8SMD1 DI DM8SMD1 DM8SMD1 DN Tazarotene DM8SMD1 TI TT1Q3IE DM8SMD1 TN Retinoic acid receptor gamma (RARG) DM8SMD1 MA Binder DM8SMD1 RN Recent developments in receptor-selective retinoids. Curr Pharm Des. 2000 Jun;6(9):919-31. DM8SMD1 RU https://pubmed.ncbi.nlm.nih.gov/10828316 DM8SXYG DI DM8SXYG DM8SXYG DN Lamotrigine DM8SXYG TI TTN9VTF DM8SXYG TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DM8SXYG MA Blocker DM8SXYG RN The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. DM8SXYG RU https://pubmed.ncbi.nlm.nih.gov/19579915 DM8SY60 DI DM8SY60 DM8SY60 DN Butoconazole DM8SY60 TI TTTSOUD DM8SY60 TN Candida Cytochrome P450 51 (Candi ERG11) DM8SY60 MA Inhibitor DM8SY60 RN Effects of terconazole and other azole antifungal agents on the sterol and carbohydrate composition of Candida albicans. Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):31-5. DM8SY60 RU https://pubmed.ncbi.nlm.nih.gov/2184984 DM8TUPF DI DM8TUPF DM8TUPF DN Milrinone DM8TUPF TI TTZCG4L DM8TUPF TN Phosphodiesterase 3 (PDE3) DM8TUPF MA Modulator DM8TUPF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8TUPF RU https://www.fda.gov/ DM8V75C DI DM8V75C DM8V75C DN ABIRATERONE DM8V75C TI TTRA5BZ DM8V75C TN Steroid 17-alpha-monooxygenase (S17AH) DM8V75C MA Modulator DM8V75C RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DM8V75C RU https://pubmed.ncbi.nlm.nih.gov/22293555 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTVKILB DM8VCBE TN Prostaglandin G/H synthase 2 (COX-2) DM8VCBE MA Inhibitor DM8VCBE RN Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/19379806 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTMWT8Z DM8VCBE TN C-X-C chemokine receptor type 1 (CXCR1) DM8VCBE MA Inhibitor DM8VCBE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TT30C9G DM8VCBE TN C-X-C chemokine receptor type 2 (CXCR2) DM8VCBE MA Inhibitor DM8VCBE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM8VCBE DI DM8VCBE DM8VCBE DN Ibuprofen DM8VCBE TI TTCTE1G DM8VCBE TN Interleukin-8 (IL8) DM8VCBE MA Inhibitor DM8VCBE RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DM8VCBE RU https://pubmed.ncbi.nlm.nih.gov/19560921 DM8WAHT DI DM8WAHT DM8WAHT DN Fentanyl DM8WAHT TI TTKWM86 DM8WAHT TN Opioid receptor mu (MOP) DM8WAHT MA Modulator DM8WAHT RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM8WAHT RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM8WBAH DI DM8WBAH DM8WBAH DN Dexmethylphenidate hydrochloride DM8WBAH TI TTVBI8W DM8WBAH TN Dopamine transporter (DAT) DM8WBAH MA Inhibitor DM8WBAH RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM8WBAH RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM8WCXM DI DM8WCXM DM8WCXM DN Befunolol hci DM8WCXM TI TTVIREA DM8WCXM TN Adrenergic receptor (ADR) DM8WCXM MA Modulator DM8WCXM RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM8WCXM RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM8WI3R DI DM8WI3R DM8WI3R DN Alogliptin DM8WI3R TI TTDIGC1 DM8WI3R TN Dipeptidyl peptidase 4 (DPP-4) DM8WI3R MA Inhibitor DM8WI3R RN Clinical pipeline report, company report or official report of Takeda (2009). DM8WI3R RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM8X2EH DI DM8X2EH DM8X2EH DN Everolimus DM8X2EH TI TTCJG29 DM8X2EH TN Serine/threonine-protein kinase mTOR (mTOR) DM8X2EH MA Inhibitor DM8X2EH RN Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma. Gan To Kagaku Ryoho. 2009 Jul;36(7):1076-9. DM8X2EH RU https://pubmed.ncbi.nlm.nih.gov/19620795 DM8X4A1 DI DM8X4A1 DM8X4A1 DN Methantheline DM8X4A1 TI TTH18TF DM8X4A1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8X4A1 MA Antagonist DM8X4A1 RN Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004193. DM8X4A1 RU https://pubmed.ncbi.nlm.nih.gov/19160231 DM8XI09 DI DM8XI09 DM8XI09 DN Methyldopate Hydrochloride DM8XI09 TI TTQ8AFT DM8XI09 TN Adrenergic receptor Alpha-2 (ADRA2) DM8XI09 MA Modulator DM8XI09 RN Effect of Antihypertensive Therapy with Alpha Methyldopa on Levels of Angiogenic Factors in Pregnancies with Hypertensive Disorders DM8XI09 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2447877 DM8XP26 DI DM8XP26 DM8XP26 DN Rolapitant DM8XP26 TI TTZPO1L DM8XP26 TN Substance-P receptor (TACR1) DM8XP26 MA Antagonist DM8XP26 RN Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44. DM8XP26 RU https://pubmed.ncbi.nlm.nih.gov/24969614 DM8Y2RU DI DM8Y2RU DM8Y2RU DN Cenegermin DM8Y2RU TI TTEDJN4 DM8Y2RU TN Low-affinity nerve growth factor receptor (NGFR) DM8Y2RU MA Agonist DM8Y2RU RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM8Y2RU RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM8YU2F DI DM8YU2F DM8YU2F DN Mepenzolate DM8YU2F TI TTH18TF DM8YU2F TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8YU2F MA Antagonist DM8YU2F RN Isolation of cholinergic active ingredients in aqueous extracts of Mareya micrantha using the longitudinal muscle of isolated guinea-pig ileum as a pharmacological activity marker. J Ethnopharmacol. 1995 Mar;45(3):215-22. DM8YU2F RU https://pubmed.ncbi.nlm.nih.gov/7623487 DM8YXKW DI DM8YXKW DM8YXKW DN Dihydroxyaluminium DM8YXKW TI TT8RDXP DM8YXKW TN Troponin C (TN-C) DM8YXKW MA Stimulator DM8YXKW RN A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med. 2009 Dec;9(4):303-12. DM8YXKW RU https://pubmed.ncbi.nlm.nih.gov/19350363 DM8ZHP1 DI DM8ZHP1 DM8ZHP1 DN MCI-186 DM8ZHP1 TI TTJGNVC DM8ZHP1 TN Apoptosis regulator Bcl-2 (BCL-2) DM8ZHP1 MA Regulator (upregulator) DM8ZHP1 RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DM8ZHP1 RU https://pubmed.ncbi.nlm.nih.gov/17604499 DM8ZVJ7 DI DM8ZVJ7 DM8ZVJ7 DN Calcitriol DM8ZVJ7 TI TTK59TV DM8ZVJ7 TN Vitamin D3 receptor (VDR) DM8ZVJ7 MA Agonist DM8ZVJ7 RN Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood. 2000 Nov 1;96(9):3188-94. DM8ZVJ7 RU https://pubmed.ncbi.nlm.nih.gov/11050002 DM8ZXT6 DI DM8ZXT6 DM8ZXT6 DN Oxymetazoline DM8ZXT6 TI TTQ8AFT DM8ZXT6 TN Adrenergic receptor Alpha-2 (ADRA2) DM8ZXT6 MA Agonist DM8ZXT6 RN Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. DM8ZXT6 RU https://pubmed.ncbi.nlm.nih.gov/11481271 DM90TJP DI DM90TJP DM90TJP DN Sapropterin hydrochloride DM90TJP TI TTGSVH2 DM90TJP TN Phenylalanine hydroxylase (PAH) DM90TJP MA Modulator DM90TJP RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DM90TJP RU https://pubmed.ncbi.nlm.nih.gov/18246607 DM90WJH DI DM90WJH DM90WJH DN Interferon alfacon-1 DM90WJH TI TTMQB37 DM90WJH TN Interferon alpha/beta receptor 2 (IFNAR2) DM90WJH MA Binder DM90WJH RN Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology. 2009 Jun;49(6):1838-46. DM90WJH RU https://pubmed.ncbi.nlm.nih.gov/19291790 DM92AH3 DI DM92AH3 DM92AH3 DN Cyproheptadine DM92AH3 TI TTTIBOJ DM92AH3 TN Histamine H1 receptor (H1R) DM92AH3 MA Antagonist DM92AH3 RN Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008 Aug 1;112(3):760-9. DM92AH3 RU https://pubmed.ncbi.nlm.nih.gov/18502826 DM93L4X DI DM93L4X DM93L4X DN Dexmedetomidine DM93L4X TI TTQ8AFT DM93L4X TN Adrenergic receptor Alpha-2 (ADRA2) DM93L4X MA Agonist DM93L4X RN Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95. DM93L4X RU https://pubmed.ncbi.nlm.nih.gov/12503262 DM93VBZ DI DM93VBZ DM93VBZ DN LY2835219 DM93VBZ TI TT0PG8F DM93VBZ TN Cyclin-dependent kinase 4 (CDK4) DM93VBZ MA Modulator DM93VBZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM93VBZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM93VBZ DI DM93VBZ DM93VBZ DN LY2835219 DM93VBZ TI TTO0FDJ DM93VBZ TN Cyclin-dependent kinase 6 (CDK6) DM93VBZ MA Modulator DM93VBZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM93VBZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM958QB DI DM958QB DM958QB DN Ripretinib DM958QB TI TT8FYO9 DM958QB TN Platelet-derived growth factor receptor alpha (PDGFRA) DM958QB MA Inhibitor DM958QB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM958QB RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf DM958QB DI DM958QB DM958QB DN Ripretinib DM958QB TI TTX41N9 DM958QB TN Tyrosine-protein kinase Kit (KIT) DM958QB MA Inhibitor DM958QB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DM958QB RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213973s000lbl.pdf DM96SE0 DI DM96SE0 DM96SE0 DN Haloperidol DM96SE0 TI TTEX248 DM96SE0 TN Dopamine D2 receptor (D2R) DM96SE0 MA Antagonist DM96SE0 RN Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85. DM96SE0 RU https://pubmed.ncbi.nlm.nih.gov/12112400 DM98IXF DI DM98IXF DM98IXF DN Triamcinolone DM98IXF TI TTYRL6O DM98IXF TN Glucocorticoid receptor (NR3C1) DM98IXF MA Modulator DM98IXF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM98IXF RU https://www.fda.gov/ DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M TI TT3ROYC DM9BI7M TN Serotonin transporter (SERT) DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DM9BI7M DI DM9BI7M DM9BI7M DN Duloxetine DM9BI7M TI TTAWNKZ DM9BI7M TN Norepinephrine transporter (NET) DM9BI7M MA Inhibitor DM9BI7M RN Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42. DM9BI7M RU https://pubmed.ncbi.nlm.nih.gov/17198971 DM9CIUW DI DM9CIUW DM9CIUW DN Ribociclib succinate DM9CIUW TI TT0PG8F DM9CIUW TN Cyclin-dependent kinase 4 (CDK4) DM9CIUW MA Modulator DM9CIUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM9CIUW RU https://www.fda.gov/ DM9CIUW DI DM9CIUW DM9CIUW DN Ribociclib succinate DM9CIUW TI TTO0FDJ DM9CIUW TN Cyclin-dependent kinase 6 (CDK6) DM9CIUW MA Modulator DM9CIUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM9CIUW RU https://www.fda.gov/ DM9EQC0 DI DM9EQC0 DM9EQC0 DN Oxidized glutathione DM9EQC0 TI TTEP6RV DM9EQC0 TN Glutathione reductase (GR) DM9EQC0 MA Inhibitor DM9EQC0 RN The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401. DM9EQC0 RU https://pubmed.ncbi.nlm.nih.gov/7788561 DM9FKSR DI DM9FKSR DM9FKSR DN Oxitropium bromide DM9FKSR TI TTH18TF DM9FKSR TN Muscarinic acetylcholine receptor M5 (CHRM5) DM9FKSR MA Modulator DM9FKSR RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DM9FKSR RU https://pubmed.ncbi.nlm.nih.gov/17309302 DM9G7BS DI DM9G7BS DM9G7BS DN Cyclizine DM9G7BS TI TTTIBOJ DM9G7BS TN Histamine H1 receptor (H1R) DM9G7BS MA Antagonist DM9G7BS RN Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit. 2003 Apr;25(2):192-6. DM9G7BS RU https://pubmed.ncbi.nlm.nih.gov/12657913 DM9GH25 DI DM9GH25 DM9GH25 DN Arcitumomab DM9GH25 TI TTPX7I5 DM9GH25 TN Carcinoembryonic antigen CGM1 (CD66d) DM9GH25 RN In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing tumor cells in mice. Radiology. 2008 Jun;247(3):779-87. DM9GH25 RU https://pubmed.ncbi.nlm.nih.gov/18413884 DM9GP85 DI DM9GP85 DM9GP85 DN Tesamorelin DM9GP85 TI TTG4R8V DM9GP85 TN Growth hormone-releasing hormone receptor (GHRHR) DM9GP85 MA Binder DM9GP85 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DM9GP85 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTLM12X DM9HOKG TN Matrix metalloproteinase-2 (MMP-2) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTMX39J DM9HOKG TN Matrix metalloproteinase-1 (MMP-1) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HOKG DI DM9HOKG DM9HOKG DN Prinomastat DM9HOKG TI TTMTWOS DM9HOKG TN Matrix metalloproteinase-7 (MMP-7) DM9HOKG MA Inhibitor DM9HOKG RN AG-3340 (Agouron Pharmaceuticals Inc). IDrugs. 2000 Mar;3(3):336-45. DM9HOKG RU https://pubmed.ncbi.nlm.nih.gov/16103944 DM9HPW3 DI DM9HPW3 DM9HPW3 DN Exemestane DM9HPW3 TI TTSZLWK DM9HPW3 TN Aromatase (CYP19A1) DM9HPW3 MA Inhibitor DM9HPW3 RN Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. DM9HPW3 RU https://pubmed.ncbi.nlm.nih.gov/14505258 DM9HQ5U DI DM9HQ5U DM9HQ5U DN Tagraxofusp DM9HQ5U TI TTENHJ0 DM9HQ5U TN Interleukin 3 receptor alpha (IL3RA) DM9HQ5U MA Modulator DM9HQ5U RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DM9HQ5U RU https://pubmed.ncbi.nlm.nih.gov/30710142 DM9J04X DI DM9J04X DM9J04X DN Butalbital DM9J04X TI TT1MPAY DM9J04X TN GABA(A) receptor alpha-1 (GABRA1) DM9J04X MA Antagonist DM9J04X RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DM9J04X RU https://pubmed.ncbi.nlm.nih.gov/18048412 DM9J6C2 DI DM9J6C2 DM9J6C2 DN Tetracaine DM9J6C2 TI TT90XZ8 DM9J6C2 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM9J6C2 MA Inhibitor DM9J6C2 RN Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38. DM9J6C2 RU https://pubmed.ncbi.nlm.nih.gov/14975698 DM9JOYP DI DM9JOYP DM9JOYP DN Palifermin DM9JOYP TI TTGJVQM DM9JOYP TN Fibroblast growth factor receptor 2 (FGFR2) DM9JOYP MA Binder DM9JOYP RN Keratinocyte growth factor. Expert Opin Biol Ther. 2009 Jun;9(6):779-87. DM9JOYP RU https://pubmed.ncbi.nlm.nih.gov/19456212 DM9JXB7 DI DM9JXB7 DM9JXB7 DN Retapamulin DM9JXB7 TI TTUWYEA DM9JXB7 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM9JXB7 MA Inhibitor DM9JXB7 RN Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7. DM9JXB7 RU https://pubmed.ncbi.nlm.nih.gov/17562806 DM9KHZL DI DM9KHZL DM9KHZL DN Heparin Sodium DM9KHZL TI TT4QPUL DM9KHZL TN Antithrombin-III (ATIII) DM9KHZL MA Modulator DM9KHZL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). DM9KHZL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 DM9KJLZ DI DM9KJLZ DM9KJLZ DN Foscavir DM9KJLZ TI TTIU7X1 DM9KJLZ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM9KJLZ MA Inhibitor DM9KJLZ RN Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22. DM9KJLZ RU https://pubmed.ncbi.nlm.nih.gov/19275707 DM9KZDO DI DM9KZDO DM9KZDO DN Esterified estrogens DM9KZDO TI TTZAYWL DM9KZDO TN Estrogen receptor (ESR) DM9KZDO MA Modulator DM9KZDO RN Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2011 Jan;95(1):366-8. DM9KZDO RU https://pubmed.ncbi.nlm.nih.gov/20850731 DM9NJ52 DI DM9NJ52 DM9NJ52 DN Fosinopril DM9NJ52 TI TTL69WB DM9NJ52 TN Angiotensin-converting enzyme (ACE) DM9NJ52 MA Inhibitor DM9NJ52 RN Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. Am Heart J. 2009 Feb;157(2):334.e1-8. DM9NJ52 RU https://pubmed.ncbi.nlm.nih.gov/19185642 DM9NSWT DI DM9NSWT DM9NSWT DN Guanethidine DM9NSWT TI TTT04VN DM9NSWT TN Adrenergic neuron (AD neuro) DM9NSWT MA Blocker DM9NSWT RN Characterization of bradykinin-induced endothelium-independent contraction in equine basilar artery. J Vet Pharmacol Ther. 2009 Jun;32(3):264-70. DM9NSWT RU https://pubmed.ncbi.nlm.nih.gov/19646091 DM9O8DT DI DM9O8DT DM9O8DT DN L-tyrosine DM9O8DT TI TTUHP71 DM9O8DT TN Tyrosine 3-monooxygenase (TH) DM9O8DT MA Binder DM9O8DT RN Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5. DM9O8DT RU https://pubmed.ncbi.nlm.nih.gov/16581181 DM9OZWQ DI DM9OZWQ DM9OZWQ DN Lovastatin DM9OZWQ TI TTPADOQ DM9OZWQ TN HMG-CoA reductase (HMGCR) DM9OZWQ MA Inhibitor DM9OZWQ RN Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46. DM9OZWQ RU https://pubmed.ncbi.nlm.nih.gov/12082550 DM9PLRH DI DM9PLRH DM9PLRH DN Doxazosin DM9PLRH TI TT34BHT DM9PLRH TN Adrenergic receptor alpha-1D (ADRA1D) DM9PLRH MA Antagonist DM9PLRH RN The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. DM9PLRH RU https://pubmed.ncbi.nlm.nih.gov/19002123 DM9PVX8 DI DM9PVX8 DM9PVX8 DN Rucaparib DM9PVX8 TI TTEBCY8 DM9PVX8 TN Poly [ADP-ribose] polymerase (PARP) DM9PVX8 MA Modulator DM9PVX8 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DM9PVX8 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DM9Q8SO DI DM9Q8SO DM9Q8SO DN Fibrinolysin DM9Q8SO TI TTWODQF DM9Q8SO TN Fibrin (FG) DM9Q8SO MA Modulator DM9Q8SO RN FIBRINOLYSIN, FIBRIN AND HYALINE MEMBRANES. Pediatrics. 1963 Nov;32:940-2. DM9Q8SO RU https://pubmed.ncbi.nlm.nih.gov/14075642 DM9QWAH DI DM9QWAH DM9QWAH DN Ceftolozane/tazobactam DM9QWAH TI TTHI19T DM9QWAH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM9QWAH MA Modulator DM9QWAH RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DM9QWAH RU https://pubmed.ncbi.nlm.nih.gov/25633781 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW TI TTS087L DM9S2JW TN Solute carrier family 12 member 1 (SLC12A1) DM9S2JW MA Blocker DM9S2JW RN Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/18769054 DM9S2JW DI DM9S2JW DM9S2JW DN Aldosterone DM9S2JW TI TT26PHO DM9S2JW TN Mineralocorticoid receptor (MR) DM9S2JW MA Agonist DM9S2JW RN Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42. DM9S2JW RU https://pubmed.ncbi.nlm.nih.gov/16188378 DM9U4FO DI DM9U4FO DM9U4FO DN Benzonatate DM9U4FO TI TTZOVE0 DM9U4FO TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM9U4FO MA Blocker DM9U4FO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9U4FO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9UB0P DI DM9UB0P DM9UB0P DN Oxaprozin DM9UB0P TI TTK0943 DM9UB0P TN Prostaglandin G/H synthase (COX) DM9UB0P MA Inhibitor DM9UB0P RN The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. DM9UB0P RU https://pubmed.ncbi.nlm.nih.gov/17409433 DM9UCJK DI DM9UCJK DM9UCJK DN Doripenem DM9UCJK TI TT4ILYC DM9UCJK TN Bacterial Dihydropteroate synthetase (Bact folP) DM9UCJK MA Inhibitor DM9UCJK RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM9UCJK RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM9UTDE DI DM9UTDE DM9UTDE DN Morniflumate DM9UTDE TI TTK0943 DM9UTDE TN Prostaglandin G/H synthase (COX) DM9UTDE MA Modulator DM9UTDE RN Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9. DM9UTDE RU https://pubmed.ncbi.nlm.nih.gov/1659152 DM9Y6X7 DI DM9Y6X7 DM9Y6X7 DN Clodronate DM9Y6X7 TI TTU5A6Q DM9Y6X7 TN Adenine nucleotide translocator 1 (SLC25A4) DM9Y6X7 MA Inhibitor DM9Y6X7 RN Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62. DM9Y6X7 RU https://pubmed.ncbi.nlm.nih.gov/11961144 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ TI TT3ROYC DM9YSNQ TN Serotonin transporter (SERT) DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM9YSNQ DI DM9YSNQ DM9YSNQ DN Amfepramone DM9YSNQ TI TTAWNKZ DM9YSNQ TN Norepinephrine transporter (NET) DM9YSNQ MA Inhibitor DM9YSNQ RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM9YSNQ RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM9ZMQH DI DM9ZMQH DM9ZMQH DN Clocortolone DM9ZMQH TI TT9V5JH DM9ZMQH TN Phospholipase A2 (PLA2G1B) DM9ZMQH MA Inducer DM9ZMQH RN Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis. Cutis. 1980 Jan;25(1):96-8. DM9ZMQH RU https://pubmed.ncbi.nlm.nih.gov/6986236 DMA04JS DI DMA04JS DMA04JS DN Antazoline DMA04JS TI TTTIBOJ DMA04JS TN Histamine H1 receptor (H1R) DMA04JS MA Antagonist DMA04JS RN Histamine and the convulsive threshold or effectiveness of antiepileptic drugs. Przegl Lek. 2008;65(11):803-6. DMA04JS RU https://pubmed.ncbi.nlm.nih.gov/19205365 DMA13GD DI DMA13GD DMA13GD DN Cidofovir DMA13GD TI TTIU7X1 DMA13GD TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMA13GD MA Modulator DMA13GD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA13GD RU https://www.fda.gov/ DMA16BR DI DMA16BR DMA16BR DN Vorapaxar DMA16BR TI TTL935N DMA16BR TN Proteinase activated receptor 1 (F2R) DMA16BR MA Antagonist DMA16BR RN In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8. DMA16BR RU https://pubmed.ncbi.nlm.nih.gov/19572350 DMA17D0 DI DMA17D0 DMA17D0 DN Dorzolamide DMA17D0 TI TTANPDJ DMA17D0 TN Carbonic anhydrase II (CA-II) DMA17D0 MA Inhibitor DMA17D0 RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMA17D0 RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMA2GHJ DI DMA2GHJ DMA2GHJ DN Tolperisone DMA2GHJ TI TTN9VTF DMA2GHJ TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMA2GHJ MA Modulator DMA2GHJ RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DMA2GHJ RU https://pubmed.ncbi.nlm.nih.gov/16126840 DMA2GHJ DI DMA2GHJ DMA2GHJ DN Tolperisone DMA2GHJ TI TTCRJKY DMA2GHJ TN Voltage-gated calcium channel (Cav) DMA2GHJ MA Modulator DMA2GHJ RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DMA2GHJ RU https://pubmed.ncbi.nlm.nih.gov/16126840 DMA2Z4F DI DMA2Z4F DMA2Z4F DN Minoxidil DMA2Z4F TI TT1VOHK DMA2Z4F TN Potassium channel unspecific (KC) DMA2Z4F MA Modulator DMA2Z4F RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA2Z4F RU https://www.fda.gov/ DMA47C6 DI DMA47C6 DMA47C6 DN Rimiterol DMA47C6 TI TTMXGCW DMA47C6 TN Adrenergic receptor beta-3 (ADRB3) DMA47C6 MA Modulator DMA47C6 RN Comparison of the beta2-adrenoceptor selectivity of rimiterol, salbutamol and isoprenaline by the intravenous route in man. Br J Clin Pharmacol. 1975 Feb;2(1):41-8. DMA47C6 RU https://pubmed.ncbi.nlm.nih.gov/10940 DMA4MRX DI DMA4MRX DMA4MRX DN Perphenazine DMA4MRX TI TTEX248 DMA4MRX TN Dopamine D2 receptor (D2R) DMA4MRX MA Antagonist DMA4MRX RN CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93. DMA4MRX RU https://pubmed.ncbi.nlm.nih.gov/18075468 DMA5OBU DI DMA5OBU DMA5OBU DN Human neutral insulin DMA5OBU TI TTCBFJO DMA5OBU TN Insulin receptor (INSR) DMA5OBU MA Binder DMA5OBU RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMA5OBU RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMA5QPM DI DMA5QPM DMA5QPM DN Zemaira DMA5QPM TI TTA7UJC DMA5QPM TN Alpha-1-antitrypsin (SERPINA1) DMA5QPM MA Inhibitor DMA5QPM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMA5QPM RU https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/zemaira DMA5XGH DI DMA5XGH DMA5XGH DN Isradipine DMA5XGH TI TT5HONZ DMA5XGH TN Calcium channel unspecific (CaC) DMA5XGH MA Modulator DMA5XGH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA5XGH RU https://www.fda.gov/ DMA630M DI DMA630M DMA630M DN Vaccinia immune globulin DMA630M TI TTOP3CH DMA630M TN Immunoglobulin unspecific (Ig) DMA630M MA Modulator DMA630M RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMA630M RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMA65ER DI DMA65ER DMA65ER DN Nipradilol DMA65ER TI TTMXGCW DMA65ER TN Adrenergic receptor beta-3 (ADRB3) DMA65ER MA Modulator DMA65ER RN Actions of nipradilol (K-351), a new alpha- and beta-adrenoceptor blocker, on the rabbit portal vein. Jpn J Pharmacol. 1984 Aug;35(4):359-69. DMA65ER RU https://pubmed.ncbi.nlm.nih.gov/6150128 DMA6S1D DI DMA6S1D DMA6S1D DN Ropinirole DMA6S1D TI TT4C8EA DMA6S1D TN Dopamine D3 receptor (D3R) DMA6S1D MA Modulator DMA6S1D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA6S1D RU https://www.fda.gov/ DMA6S1D DI DMA6S1D DMA6S1D DN Ropinirole DMA6S1D TI TTEX248 DMA6S1D TN Dopamine D2 receptor (D2R) DMA6S1D MA Modulator DMA6S1D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA6S1D RU https://www.fda.gov/ DMA7PEW DI DMA7PEW DMA7PEW DN Verapamil DMA7PEW TI TT729IR DMA7PEW TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMA7PEW MA Blocker DMA7PEW RN Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93. DMA7PEW RU https://pubmed.ncbi.nlm.nih.gov/15821157 DMA7QTC DI DMA7QTC DMA7QTC DN Lactoferrin DMA7QTC TI TTM1TDX DMA7QTC TN Tryptase alpha/beta-1 (Tryptase) DMA7QTC MA Inhibitor DMA7QTC RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DMA7QTC RU https://pubmed.ncbi.nlm.nih.gov/10197050 DMA8DPN DI DMA8DPN DMA8DPN DN Dexchlorpheniramine maleate DMA8DPN TI TTTIBOJ DMA8DPN TN Histamine H1 receptor (H1R) DMA8DPN MA Modulator DMA8DPN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMA8DPN RU https://www.fda.gov/ DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 TI TTW0CMT DMA8FS5 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMA8FS5 MA Blocker DMA8FS5 RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMA8FS5 DI DMA8FS5 DMA8FS5 DN Dronedarone DMA8FS5 TI TT1VOHK DMA8FS5 TN Potassium channel unspecific (KC) DMA8FS5 MA Inhibitor DMA8FS5 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMA8FS5 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMA8J1G DI DMA8J1G DMA8J1G DN Rifampin DMA8J1G TI TTIJ5EB DMA8J1G TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMA8J1G MA Inhibitor DMA8J1G RN Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67. DMA8J1G RU https://pubmed.ncbi.nlm.nih.gov/11751823 DMA8LM5 DI DMA8LM5 DMA8LM5 DN Cyclopentolate DMA8LM5 TI TTH18TF DMA8LM5 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMA8LM5 MA Antagonist DMA8LM5 RN High spatial resolution studies of muscarinic neuroeffector junctions in mouse isolated vas deferens. Neuroscience. 2009 Sep 15;162(4):1366-76. DMA8LM5 RU https://pubmed.ncbi.nlm.nih.gov/19486927 DMA9DHW DI DMA9DHW DMA9DHW DN Nalfurafine hcl DMA9DHW TI TTKWM86 DMA9DHW TN Opioid receptor mu (MOP) DMA9DHW MA Inhibitor DMA9DHW RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DMA9DHW RU https://pubmed.ncbi.nlm.nih.gov/19962305 DMA9DHW DI DMA9DHW DMA9DHW DN Nalfurafine hcl DMA9DHW TI TTQW87Y DMA9DHW TN Opioid receptor kappa (OPRK1) DMA9DHW MA Inhibitor DMA9DHW RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DMA9DHW RU https://pubmed.ncbi.nlm.nih.gov/19962305 DMA9REV DI DMA9REV DMA9REV DN Elosulfase alfa DMA9REV TI TTT9YPO DMA9REV TN N-acetylgalactosamine 6 sulfatase (GALNS) DMA9REV MA Modulator DMA9REV RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMA9REV RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAB6PM DI DMAB6PM DMAB6PM DN Factor 8 DMAB6PM TI TT1290U DMAB6PM TN Coagulation factor VIII (F8) DMAB6PM MA Modulator DMAB6PM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMAB6PM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMAB9QE DI DMAB9QE DMAB9QE DN Nivolumab DMAB9QE TI TTNBFWK DMAB9QE TN Programmed cell death protein 1 (PD-1) DMAB9QE MA Modulator DMAB9QE RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAB9QE RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMABVE9 DI DMABVE9 DMABVE9 DN Sulfanilamide DMABVE9 TI TT4ILYC DMABVE9 TN Bacterial Dihydropteroate synthetase (Bact folP) DMABVE9 MA Modulator DMABVE9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMABVE9 RU https://www.fda.gov/ DMAC130 DI DMAC130 DMAC130 DN Inotuzumab ozogamicin DMAC130 TI TTM6QSK DMAC130 TN B-cell receptor CD22 (CD22) DMAC130 RN Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36. DMAC130 RU https://pubmed.ncbi.nlm.nih.gov/23633004 DMAE6LK DI DMAE6LK DMAE6LK DN Topetecan DMAE6LK TI TTGTQHC DMAE6LK TN DNA topoisomerase I (TOP1) DMAE6LK MA Inhibitor DMAE6LK RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMAE6LK RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMAE84F DI DMAE84F DMAE84F DN Alclometasone DMAE84F TI TTJL8VG DMAE84F TN Corticosteroid-binding globulin (SERPINA6) DMAE84F MA Binder DMAE84F RN The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. DMAE84F RU https://pubmed.ncbi.nlm.nih.gov/2508442 DMAF1NB DI DMAF1NB DMAF1NB DN Isocarboxazid DMAF1NB TI TT3WG5C DMAF1NB TN Monoamine oxidase type A (MAO-A) DMAF1NB MA Inhibitor DMAF1NB RN MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219. DMAF1NB RU https://pubmed.ncbi.nlm.nih.gov/7612154 DMAFBCY DI DMAFBCY DMAFBCY DN Mequitazine DMAFBCY TI TTTIBOJ DMAFBCY TN Histamine H1 receptor (H1R) DMAFBCY MA Antagonist DMAFBCY RN Efficiency of mequitazine in the treatment of allergic rhinitis and chronic urticaria in children. A bibliographic systematic review. Rev Alerg Mex. 2008 Jan-Feb;55(1):3-9. DMAFBCY RU https://pubmed.ncbi.nlm.nih.gov/18697448 DMAGFOD DI DMAGFOD DMAGFOD DN Semaglutide DMAGFOD TI TTVIMDE DMAGFOD TN Glucagon-like peptide 1 receptor (GLP1R) DMAGFOD MA Agonist DMAGFOD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMAGFOD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMAH70G DI DMAH70G DMAH70G DN Molindone DMAH70G TI TTEX248 DMAH70G TN Dopamine D2 receptor (D2R) DMAH70G MA Binder DMAH70G RN Molindone for schizophrenia and severe mental illness. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002083. DMAH70G RU https://pubmed.ncbi.nlm.nih.gov/17253473 DMAHEFY DI DMAHEFY DMAHEFY DN Nafarelin DMAHEFY TI TT8R70G DMAHEFY TN Gonadotropin-releasing hormone receptor (GNRHR) DMAHEFY MA Agonist DMAHEFY RN Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin ... Theriogenology. 2009 Apr 15;71(7):1037-45. DMAHEFY RU https://pubmed.ncbi.nlm.nih.gov/19233456 DMAHJEF DI DMAHJEF DMAHJEF DN Betamethasone DMAHJEF TI TTYRL6O DMAHJEF TN Glucocorticoid receptor (NR3C1) DMAHJEF MA Agonist DMAHJEF RN The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur J Pharmacol. 2006 Aug 7;542(1-3):179-83. DMAHJEF RU https://pubmed.ncbi.nlm.nih.gov/16824511 DMAHMT9 DI DMAHMT9 DMAHMT9 DN Glutathione DMAHMT9 TI TT3C1VN DMAHMT9 TN Enzyme unspecific (Enz) DMAHMT9 MA Modulator DMAHMT9 RN Methionine and cysteine affect glutathione level, glutathione-related enzyme activities and the expression of glutathione S-transferase isozymes in rat hepatocytes. J Nutr. 1997 Nov;127(11):2135-41. DMAHMT9 RU https://pubmed.ncbi.nlm.nih.gov/9372907 DMAHOVJ DI DMAHOVJ DMAHOVJ DN Crizanlizumab DMAHOVJ TI TTE5VG0 DMAHOVJ TN P-selectin (SELP) DMAHOVJ MA Inhibitor DMAHOVJ RN Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84. DMAHOVJ RU https://pubmed.ncbi.nlm.nih.gov/31933169 DMAHSU0 DI DMAHSU0 DMAHSU0 DN Selexipag DMAHSU0 TI TTOFYT1 DMAHSU0 TN Prostacyclin receptor (PTGIR) DMAHSU0 MA Agonist DMAHSU0 RN Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80. DMAHSU0 RU https://pubmed.ncbi.nlm.nih.gov/22362844 DMAHZKR DI DMAHZKR DMAHZKR DN Protokylol Hydrochloride DMAHZKR TI TTR6W5O DMAHZKR TN Adrenergic receptor beta-1 (ADRB1) DMAHZKR MA Modulator DMAHZKR RN N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver. DMAHZKR RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1668481 DMAI7ZV DI DMAI7ZV DMAI7ZV DN Diltiazem DMAI7ZV TI TTFK1JQ DMAI7ZV TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMAI7ZV MA Blocker DMAI7ZV RN Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem. 2009;24(1-2):17-24. DMAI7ZV RU https://pubmed.ncbi.nlm.nih.gov/19590189 DMAKIDV DI DMAKIDV DMAKIDV DN Dydrogesterone DMAKIDV TI TTUV8G9 DMAKIDV TN Progesterone receptor (PGR) DMAKIDV MA Agonist DMAKIDV RN Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31. DMAKIDV RU https://pubmed.ncbi.nlm.nih.gov/18061638 DMAKXW9 DI DMAKXW9 DMAKXW9 DN PLEGRIDY DMAKXW9 TI TT4TZ8J DMAKXW9 TN Interferon-beta (IFNB1) DMAKXW9 MA Modulator DMAKXW9 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAKXW9 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAL4G0 DI DMAL4G0 DMAL4G0 DN Flurazepam DMAL4G0 TI TTPTXIN DMAL4G0 TN Translocator protein (TSPO) DMAL4G0 MA Modulator DMAL4G0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAL4G0 RU https://www.fda.gov/ DMALNG0 DI DMALNG0 DMALNG0 DN RHuEPO DMALNG0 TI TTAUX24 DMALNG0 TN Erythropoietin Receptor (EPOR) DMALNG0 MA Stimulator DMALNG0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DMALNG0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DMANBR7 DI DMANBR7 DMANBR7 DN L-alanyl-l-glutamine DMANBR7 TI TTI7S12 DMANBR7 TN Glutamine receptor (GluR) DMANBR7 MA Modulator DMANBR7 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMANBR7 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMANBZI DI DMANBZI DMANBZI DN Abiraterone acetate DMANBZI TI TTRA5BZ DMANBZI TN Steroid 17-alpha-monooxygenase (S17AH) DMANBZI MA Modulator DMANBZI RN CYP17A1 inhibitors in castration-resistant prostate cancer.Steroids.2015 Mar;95:80-7. DMANBZI RU https://www.ncbi.nlm.nih.gov/pubmed/25560485 DMANL0D DI DMANL0D DMANL0D DN Latamoxef DMANL0D TI TT85JMW DMANL0D TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMANL0D MA Binder DMANL0D RN Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9. DMANL0D RU https://pubmed.ncbi.nlm.nih.gov/9841767 DMAO80I DI DMAO80I DMAO80I DN Pralatrexate DMAO80I TI TT9SL3Q DMAO80I TN Polypeptide deformylase (PDF) DMAO80I MA Inhibitor DMAO80I RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMAO80I RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMAOL2S DI DMAOL2S DMAOL2S DN Voriconazole DMAOL2S TI TTTSOUD DMAOL2S TN Candida Cytochrome P450 51 (Candi ERG11) DMAOL2S MA Modulator DMAOL2S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAOL2S RU https://www.fda.gov/ DMAP58Y DI DMAP58Y DMAP58Y DN Peginterferon alfa-2b DMAP58Y TI TTSIUJ9 DMAP58Y TN Interferon-alpha 2 (IFNA2) DMAP58Y MA Modulator DMAP58Y RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAP58Y RU https://www.fda.gov/ DMAP8MV DI DMAP8MV DMAP8MV DN Iron DMAP8MV TI TTQO71U DMAP8MV TN Hemoglobin (HB) DMAP8MV MA Activator DMAP8MV RN Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008 Jul;18(7):424-7. DMAP8MV RU https://pubmed.ncbi.nlm.nih.gov/18760066 DMAPV1B DI DMAPV1B DMAPV1B DN Glatiramer acetate DMAPV1B TI TTLCMWF DMAPV1B TN MHC class II antigen DRB1*1 (HLA-DRB1) DMAPV1B MA Binder DMAPV1B RN Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14593-8. DMAPV1B RU https://pubmed.ncbi.nlm.nih.gov/15371592 DMAQ2LK DI DMAQ2LK DMAQ2LK DN Teicoplanin DMAQ2LK TI TTXT4D5 DMAQ2LK TN Bacterial Cell membrane (Bact CM) DMAQ2LK MA Inhibitor DMAQ2LK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMAQ2LK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMAQ469 DI DMAQ469 DMAQ469 DN Gonadorelin DMAQ469 TI TT8R70G DMAQ469 TN Gonadotropin-releasing hormone receptor (GNRHR) DMAQ469 MA Agonist DMAQ469 RN Use of cognitive behavior therapy for functional hypothalamic amenorrhea. Ann N Y Acad Sci. 2006 Dec;1092:114-29. DMAQ469 RU https://pubmed.ncbi.nlm.nih.gov/17308138 DMAS02L DI DMAS02L DMAS02L DN Alpha-acetyldigoxin DMAS02L TI TTYHPRQ DMAS02L TN Sodium pump (NaP) DMAS02L MA Modulator DMAS02L RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMAS02L RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 TI TTG0MT6 DMASDQ6 TN Interleukin-17 (IL17) DMASDQ6 MA Modulator DMASDQ6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMASDQ6 RU https://www.fda.gov/ DMASDQ6 DI DMASDQ6 DMASDQ6 DN Brodalumab DMASDQ6 TI TT69OHW DMASDQ6 TN Interleukin 17 receptor (IL17R) DMASDQ6 MA Antagonist DMASDQ6 RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMASDQ6 RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMAT2XH DI DMAT2XH DMAT2XH DN Nabumetone DMAT2XH TI TTVKILB DMAT2XH TN Prostaglandin G/H synthase 2 (COX-2) DMAT2XH MA Inhibitor DMAT2XH RN Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96. DMAT2XH RU https://pubmed.ncbi.nlm.nih.gov/11701998 DMAT8CG DI DMAT8CG DMAT8CG DN Goserelin DMAT8CG TI TT0ID4A DMAT8CG TN Leutinizing-hormone-releasing hormone (GNRH1) DMAT8CG MA Activator DMAT8CG RN Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):341-9. DMAT8CG RU https://pubmed.ncbi.nlm.nih.gov/19244174 DMAUHQX DI DMAUHQX DMAUHQX DN Methdilazine DMAUHQX TI TTTIBOJ DMAUHQX TN Histamine H1 receptor (H1R) DMAUHQX MA Antagonist DMAUHQX RN Effect of H1 blockers alone and in combination with morphine to produce antinociception in mice. Neuropharmacology. 1985 Jan;24(1):1-4. DMAUHQX RU https://pubmed.ncbi.nlm.nih.gov/2858829 DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN TI TTUDR0C DMAWJIN TN Iron (Fe) DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DMAWJIN DI DMAWJIN DMAWJIN DN Etidronate Disodium DMAWJIN TI TT8X5NO DMAWJIN TN Calcium (Ca) DMAWJIN MA Modulator DMAWJIN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMAWJIN RU https://www.fda.gov/ DMAWU35 DI DMAWU35 DMAWU35 DN Amtolmetin guacil DMAWU35 TI TTK0943 DMAWU35 TN Prostaglandin G/H synthase (COX) DMAWU35 MA Modulator DMAWU35 RN Gastrointestinal safety of amtolmetin guacyl in comparison with celecoxib in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005 Nov-Dec;23(6):809-18. DMAWU35 RU https://pubmed.ncbi.nlm.nih.gov/16396699 DMAY7H4 DI DMAY7H4 DMAY7H4 DN Valdecoxib DMAY7H4 TI TTVKILB DMAY7H4 TN Prostaglandin G/H synthase 2 (COX-2) DMAY7H4 MA Inhibitor DMAY7H4 RN Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78. DMAY7H4 RU https://pubmed.ncbi.nlm.nih.gov/16719803 DMAY96V DI DMAY96V DMAY96V DN Methacycline DMAY96V TI TTQ8KVI DMAY96V TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMAY96V MA Binder DMAY96V RN Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):232-6. DMAY96V RU https://pubmed.ncbi.nlm.nih.gov/18220943 DMAYEU1 DI DMAYEU1 DMAYEU1 DN Demecarium bromide DMAYEU1 TI TT1RS9F DMAYEU1 TN Acetylcholinesterase (AChE) DMAYEU1 MA Inhibitor DMAYEU1 RN The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5. DMAYEU1 RU https://pubmed.ncbi.nlm.nih.gov/12641839 DMAYL0T DI DMAYL0T DMAYL0T DN Phenylbutazone DMAYL0T TI TTVKILB DMAYL0T TN Prostaglandin G/H synthase 2 (COX-2) DMAYL0T MA Inhibitor DMAYL0T RN COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis. Pharmacol Res. 2005 Oct;52(4):302-6. DMAYL0T RU https://pubmed.ncbi.nlm.nih.gov/15939622 DMAYX6P DI DMAYX6P DMAYX6P DN Sulfoxone DMAYX6P TI TT915ZD DMAYX6P TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMAYX6P MA Inhibitor DMAYX6P RN Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54. DMAYX6P RU https://pubmed.ncbi.nlm.nih.gov/18475922 DMB08GE DI DMB08GE DMB08GE DN Sulfamethoxazole DMB08GE TI TT4ILYC DMB08GE TN Bacterial Dihydropteroate synthetase (Bact folP) DMB08GE MA Inhibitor DMB08GE RN In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs. Antimicrob Agents Chemother. 1995 Apr;39(4):948-52. DMB08GE RU https://pubmed.ncbi.nlm.nih.gov/7786001 DMB0EUX DI DMB0EUX DMB0EUX DN Gliquidone DMB0EUX TI TTG140O DMB0EUX TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMB0EUX MA Binder DMB0EUX RN Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H]glyburide binding to rat brain synaptosomes. Bioorg Med Chem. 2003 May 1;11(9):2099-113. DMB0EUX RU https://pubmed.ncbi.nlm.nih.gov/12670661 DMB0VY8 DI DMB0VY8 DMB0VY8 DN Pancuronium DMB0VY8 TI TTJSZTB DMB0VY8 TN Nicotinic acetylcholine receptor (nAChR) DMB0VY8 MA Antagonist DMB0VY8 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMB0VY8 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMB19L8 DI DMB19L8 DMB19L8 DN Trihexyphenidyl DMB19L8 TI TTZ9SOR DMB19L8 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMB19L8 MA Antagonist DMB19L8 RN The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic dr... Psychopharmacology (Berl). 2009 Apr;203(2):295-301. DMB19L8 RU https://pubmed.ncbi.nlm.nih.gov/18685832 DMB19L8 DI DMB19L8 DMB19L8 DN Trihexyphenidyl DMB19L8 TI TTMXGCW DMB19L8 TN Adrenergic receptor beta-3 (ADRB3) DMB19L8 MA Agonist DMB19L8 RN Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21. DMB19L8 RU https://pubmed.ncbi.nlm.nih.gov/19199918 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTQ8AFT DMB1CZ8 TN Adrenergic receptor Alpha-2 (ADRA2) DMB1CZ8 MA Agonist DMB1CZ8 RN Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/17874970 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TT7QNVC DMB1CZ8 TN Glucose-dependent insulinotropic receptor (GPR119) DMB1CZ8 MA Agonist DMB1CZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DMB1CZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTNET8J DMB1CZ8 TN G-protein coupled receptor 55 (GPR55) DMB1CZ8 MA Agonist DMB1CZ8 RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/17876302 DMB1CZ8 DI DMB1CZ8 DMB1CZ8 DN Guanfacine extended release DMB1CZ8 TI TTMSFAW DMB1CZ8 TN Cannabinoid receptor 2 (CB2) DMB1CZ8 MA Agonist DMB1CZ8 RN Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81. DMB1CZ8 RU https://pubmed.ncbi.nlm.nih.gov/18524639 DMB1IU4 DI DMB1IU4 DMB1IU4 DN Lenvatinib DMB1IU4 TI TTUTJGQ DMB1IU4 TN Vascular endothelial growth factor receptor 2 (KDR) DMB1IU4 MA Inhibitor DMB1IU4 RN Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. DMB1IU4 RU https://pubmed.ncbi.nlm.nih.gov/18764727 DMB39LO DI DMB39LO DMB39LO DN Metolazone DMB39LO TI TTP362L DMB39LO TN Solute carrier family 12 member 3 (SLC12A3) DMB39LO MA Blocker DMB39LO RN The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22. DMB39LO RU https://pubmed.ncbi.nlm.nih.gov/11457874 DMB3ZSK DI DMB3ZSK DMB3ZSK DN Deslanoside DMB3ZSK TI TTWK8D0 DMB3ZSK TN Sodium pump subunit alpha-1 (ATP1A1) DMB3ZSK MA Binder DMB3ZSK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB3ZSK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB47TQ DI DMB47TQ DMB47TQ DN Alseroxylon DMB47TQ TI TTNZRI3 DMB47TQ TN Synaptic vesicle amine transporter (SLC18A2) DMB47TQ MA Blocker DMB47TQ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMB47TQ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMB4AVP DI DMB4AVP DMB4AVP DN Pamidronate DMB4AVP TI TTIKWV4 DMB4AVP TN Geranyltranstransferase (FDPS) DMB4AVP MA Inhibitor DMB4AVP RN Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24. DMB4AVP RU https://pubmed.ncbi.nlm.nih.gov/18782552 DMB4HCT DI DMB4HCT DMB4HCT DN Sparfloxacin DMB4HCT TI TTN6J5F DMB4HCT TN Bacterial DNA gyrase (Bact gyrase) DMB4HCT MA Modulator DMB4HCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HCT RU https://www.fda.gov/ DMB4HCT DI DMB4HCT DMB4HCT DN Sparfloxacin DMB4HCT TI TTIXTO3 DMB4HCT TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMB4HCT MA Modulator DMB4HCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HCT RU https://www.fda.gov/ DMB4HFI DI DMB4HFI DMB4HFI DN Alkavervir DMB4HFI TI TTNZRI3 DMB4HFI TN Synaptic vesicle amine transporter (SLC18A2) DMB4HFI MA Modulator DMB4HFI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMB4HFI RU https://www.fda.gov/ DMB4OLE DI DMB4OLE DMB4OLE DN Propofol DMB4OLE TI TTDP1UC DMB4OLE TN Fatty acid amide hydrolase (FAAH) DMB4OLE MA Inhibitor DMB4OLE RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMB4OLE RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMB4SFH DI DMB4SFH DMB4SFH DN Mepyramine DMB4SFH TI TTTIBOJ DMB4SFH TN Histamine H1 receptor (H1R) DMB4SFH MA Antagonist DMB4SFH RN Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54. DMB4SFH RU https://pubmed.ncbi.nlm.nih.gov/19552055 DMB6VEG DI DMB6VEG DMB6VEG DN Nelarabine DMB6VEG TI TTUBNVO DMB6VEG TN DNA synthesis (DNA synth) DMB6VEG MA Binder DMB6VEG RN Nelarabine. Drugs. 2008;68(4):439-47. DMB6VEG RU https://pubmed.ncbi.nlm.nih.gov/18318562 DMB8CNL DI DMB8CNL DMB8CNL DN Lindane DMB8CNL TI TTAN6JD DMB8CNL TN Glutamate receptor AMPA (GRIA) DMB8CNL MA Antagonist DMB8CNL RN NMDA-induced seizure intensity is enhanced in COX-2 deficient mice. Neurotoxicology. 2008 Nov;29(6):1114-20. DMB8CNL RU https://pubmed.ncbi.nlm.nih.gov/18834901 DMB8PF3 DI DMB8PF3 DMB8PF3 DN CT-102 DMB8PF3 TI TTI2WET DMB8PF3 TN Platelet-derived growth factor receptor (PDGFR) DMB8PF3 MA Activator DMB8PF3 RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMB8PF3 RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMB920Z DI DMB920Z DMB920Z DN Ceritinib DMB920Z TI TTPMQSO DMB920Z TN ALK tyrosine kinase receptor (ALK) DMB920Z MA Modulator DMB920Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7397). DMB920Z RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7397 DMBAPFG DI DMBAPFG DMBAPFG DN Brinzolamide DMBAPFG TI TTZHA0O DMBAPFG TN Carbonic anhydrase IV (CA-IV) DMBAPFG MA Modulator DMBAPFG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBAPFG RU https://www.fda.gov/ DMBAUED DI DMBAUED DMBAUED DN Anileridine DMBAUED TI TTKWM86 DMBAUED TN Opioid receptor mu (MOP) DMBAUED MA Agonist DMBAUED RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMBAUED RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMBCM8L DI DMBCM8L DMBCM8L DN Nicergoline DMBCM8L TI TTQ8AFT DMBCM8L TN Adrenergic receptor Alpha-2 (ADRA2) DMBCM8L MA Antagonist DMBCM8L RN Effect of non-selective alpha-adrenergic receptor antagonist nicergoline on the activity of neurons in the ventral lateral thalamic nucleus. Fiziol Zh. 2005;51(4):29-35. DMBCM8L RU https://pubmed.ncbi.nlm.nih.gov/16201147 DMBCYF5 DI DMBCYF5 DMBCYF5 DN Pirmenol DMBCYF5 TI TTRK8B9 DMBCYF5 TN Sodium channel unspecific (NaC) DMBCYF5 MA Modulator DMBCYF5 RN Pirmenol, a new antiarrhythmic drug with potassium- and sodium-channel blocking activity; a voltage-clamp study in rabbit Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol. 1990 May;341(5):462-71. DMBCYF5 RU https://pubmed.ncbi.nlm.nih.gov/2164163 DMBDAZV DI DMBDAZV DMBDAZV DN Amlodipine DMBDAZV TI TTFK1JQ DMBDAZV TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMBDAZV MA Blocker DMBDAZV RN A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94. DMBDAZV RU https://pubmed.ncbi.nlm.nih.gov/18217647 DMBDPY0 DI DMBDPY0 DMBDPY0 DN Domperidone DMBDPY0 TI TTEX248 DMBDPY0 TN Dopamine D2 receptor (D2R) DMBDPY0 MA Antagonist DMBDPY0 RN Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31. DMBDPY0 RU https://pubmed.ncbi.nlm.nih.gov/18970411 DMBEP7G DI DMBEP7G DMBEP7G DN Fomivirsen sodium DMBEP7G TI TT4SCBE DMBEP7G TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMBEP7G MA Modulator DMBEP7G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBEP7G RU https://www.fda.gov/ DMBESUA DI DMBESUA DMBESUA DN Tucatinib DMBESUA TI TT6EO5L DMBESUA TN Erbb2 tyrosine kinase receptor (HER2) DMBESUA MA Inhibitor DMBESUA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBESUA RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213411s000lbl.pdf DMBEX4O DI DMBEX4O DMBEX4O DN Methylergonovine DMBEX4O TI TTZFYLI DMBEX4O TN Dopamine D1 receptor (D1R) DMBEX4O MA Antagonist DMBEX4O RN Reinforcement in an in vitro analog of appetitive classical conditioning of feeding behavior in Aplysia: blockade by a dopamine antagonist. Learn Mem. 2005 May-Jun;12(3):216-20. DMBEX4O RU https://pubmed.ncbi.nlm.nih.gov/15930499 DMBFE74 DI DMBFE74 DMBFE74 DN Milnacipran DMBFE74 TI TTAWNKZ DMBFE74 TN Norepinephrine transporter (NET) DMBFE74 MA Inhibitor DMBFE74 RN Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63. DMBFE74 RU https://pubmed.ncbi.nlm.nih.gov/19620845 DMBFZ6L DI DMBFZ6L DMBFZ6L DN Remdesivir DMBFZ6L TI TTV1095 DMBFZ6L TN COVID-19 RNA-directed RNA polymerase (RdRp) DMBFZ6L MA Inhibitor DMBFZ6L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBFZ6L RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf DMBGWPH DI DMBGWPH DMBGWPH DN Medroxyprogesterone DMBGWPH TI TTUV8G9 DMBGWPH TN Progesterone receptor (PGR) DMBGWPH MA Agonist DMBGWPH RN Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31. DMBGWPH RU https://pubmed.ncbi.nlm.nih.gov/18061638 DMBGZI3 DI DMBGZI3 DMBGZI3 DN Chlorpromazine DMBGZI3 TI TTEX248 DMBGZI3 TN Dopamine D2 receptor (D2R) DMBGZI3 MA Antagonist DMBGZI3 RN Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3. DMBGZI3 RU https://pubmed.ncbi.nlm.nih.gov/19374860 DMBHMOX DI DMBHMOX DMBHMOX DN Palonosetron DMBHMOX TI TTPC4TU DMBHMOX TN 5-HT 3A receptor (HTR3A) DMBHMOX MA Antagonist DMBHMOX RN Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34. DMBHMOX RU https://pubmed.ncbi.nlm.nih.gov/19436621 DMBHO9Y DI DMBHO9Y DMBHO9Y DN Adinazolam DMBHO9Y TI TTPTXIN DMBHO9Y TN Translocator protein (TSPO) DMBHO9Y MA Agonist DMBHO9Y RN Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol. 1999 Apr 29;371(2-3):113-22. DMBHO9Y RU https://pubmed.ncbi.nlm.nih.gov/10357248 DMBI4JG DI DMBI4JG DMBI4JG DN Isosorbide dinitrate DMBI4JG TI TT6HPVC DMBI4JG TN Guanylate cyclase (GC) DMBI4JG MA Stimulator DMBI4JG RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMBI4JG RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMBI9ZJ DI DMBI9ZJ DMBI9ZJ DN Falecalcitrol DMBI9ZJ TI TTK59TV DMBI9ZJ TN Vitamin D3 receptor (VDR) DMBI9ZJ MA Agonist DMBI9ZJ RN Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. Bioorg Med Chem. 2000 Aug;8(8):2157-66. DMBI9ZJ RU https://pubmed.ncbi.nlm.nih.gov/11003160 DMBIYNH DI DMBIYNH DMBIYNH DN ETI-204 DMBIYNH TI TTRLPUB DMBIYNH TN Bacillus anthracis Protective antigen (Anthrax PA) DMBIYNH RN Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax. Antimicrob Agents Chemother. 2015 Apr;59(4):2206-14. DMBIYNH RU https://pubmed.ncbi.nlm.nih.gov/25645849 DMBKX3C DI DMBKX3C DMBKX3C DN VESNARINONE DMBKX3C TI TT06AWU DMBKX3C TN Phosphodiesterase 3A (PDE3A) DMBKX3C MA Inhibitor DMBKX3C RN Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62. DMBKX3C RU https://pubmed.ncbi.nlm.nih.gov/20005117 DMBKX3C DI DMBKX3C DMBKX3C DN VESNARINONE DMBKX3C TI TTQ6VDM DMBKX3C TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMBKX3C MA Inhibitor DMBKX3C RN Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. DMBKX3C RU https://pubmed.ncbi.nlm.nih.gov/12873512 DMBL79I DI DMBL79I DMBL79I DN Proguanil DMBL79I TI TT9SL3Q DMBL79I TN Polypeptide deformylase (PDF) DMBL79I MA Inhibitor DMBL79I RN Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil. Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10931-6. DMBL79I RU https://pubmed.ncbi.nlm.nih.gov/9380737 DMBLX7U DI DMBLX7U DMBLX7U DN Evinacumab DMBLX7U TI TTUO98L DMBLX7U TN Angiopoietin-related protein 3 (ANGPTL3) DMBLX7U MA Inhibitor DMBLX7U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMBLX7U RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761181s000lbl.pdf DMBMUWZ DI DMBMUWZ DMBMUWZ DN Emtricitabine DMBMUWZ TI TT84ETX DMBMUWZ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBMUWZ MA Modulator DMBMUWZ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMBMUWZ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMBNI20 DI DMBNI20 DMBNI20 DN Ulipristal DMBNI20 TI TTUV8G9 DMBNI20 TN Progesterone receptor (PGR) DMBNI20 MA Modulator DMBNI20 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMBNI20 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMBNKST DI DMBNKST DMBNKST DN Nadroparin calcium DMBNKST TI TTCIHJA DMBNKST TN Coagulation factor Xa (F10) DMBNKST MA Modulator DMBNKST RN Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81. DMBNKST RU https://pubmed.ncbi.nlm.nih.gov/113585 DMBP5N3 DI DMBP5N3 DMBP5N3 DN Cantharidin DMBP5N3 TI TTFLH0E DMBP5N3 TN Serine/threonine PP1-alpha (PPP1CA) DMBP5N3 MA Inhibitor DMBP5N3 RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DMBP5N3 RU https://pubmed.ncbi.nlm.nih.gov/11881984 DMBQEGT DI DMBQEGT DMBQEGT DN Buprenorphine + naloxone DMBQEGT TI TTKWM86 DMBQEGT TN Opioid receptor mu (MOP) DMBQEGT MA Agonist DMBQEGT RN Abstracts of Poster Presentations: CNS Summit 2013: November 14-17, 2013 Boca Raton, Florida. Innov Clin Neurosci. 2013 Nov-Dec; 10(11-12 Suppl B): 1-18. DMBQEGT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051412/ DMBR01X DI DMBR01X DMBR01X DN Brilinta DMBR01X TI TTZ1DT0 DMBR01X TN P2Y purinoceptor 12 (P2RY12) DMBR01X MA Antagonist DMBR01X RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMBR01X RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMBR5Q7 DI DMBR5Q7 DMBR5Q7 DN Rolitetracycline DMBR5Q7 TI TTQ8KVI DMBR5Q7 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMBR5Q7 MA Binder DMBR5Q7 RN Reversed-phase high-performance liquid chromatography coupled to ultraviolet and electrospray time-of-flight mass spectrometry on-line detection fo... J Chromatogr A. 2008 Jun 27;1195(1-2):107-16. DMBR5Q7 RU https://pubmed.ncbi.nlm.nih.gov/18501371 DMBS370 DI DMBS370 DMBS370 DN Tofacitinib DMBS370 TI TTT7PJU DMBS370 TN Janus kinase 3 (JAK-3) DMBS370 MA Modulator DMBS370 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMBS370 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMBS632 DI DMBS632 DMBS632 DN Buspirone DMBS632 TI TTSQIFT DMBS632 TN 5-HT 1A receptor (HTR1A) DMBS632 MA Agonist DMBS632 RN Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204. DMBS632 RU https://pubmed.ncbi.nlm.nih.gov/16594259 DMBSHMF DI DMBSHMF DMBSHMF DN Boceprevir DMBSHMF TI TTHC7JD DMBSHMF TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMBSHMF MA Modulator DMBSHMF RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMBSHMF RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMBSK7X DI DMBSK7X DMBSK7X DN Isoflurophate DMBSK7X TI TT1RS9F DMBSK7X TN Acetylcholinesterase (AChE) DMBSK7X MA Inhibitor DMBSK7X RN Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502. DMBSK7X RU https://pubmed.ncbi.nlm.nih.gov/12837382 DMBSXI0 DI DMBSXI0 DMBSXI0 DN Dienestrol DMBSXI0 TI TTZAYWL DMBSXI0 TN Estrogen receptor (ESR) DMBSXI0 MA Agonist DMBSXI0 RN Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity. Bone. 2009 Jan;44(1):102-12. DMBSXI0 RU https://pubmed.ncbi.nlm.nih.gov/18976723 DMBT3AI DI DMBT3AI DMBT3AI DN Belantamab mafodotin DMBT3AI TI TTZ3P4W DMBT3AI TN B-cell maturation protein (TNFRSF17) DMBT3AI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMBT3AI RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761158s000lbl.pdf DMBT7MI DI DMBT7MI DMBT7MI DN Gentamicine sulfate DMBT7MI TI TTUWYEA DMBT7MI TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMBT7MI MA Binder DMBT7MI RN The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9. DMBT7MI RU https://pubmed.ncbi.nlm.nih.gov/12217690 DMBUH26 DI DMBUH26 DMBUH26 DN Rituximab DMBUH26 TI TTUE541 DMBUH26 TN Leukocyte surface antigen Leu-16 (CD20) DMBUH26 RN [Contribution of radioimmunotherapy to the treatment of lymphoma]. Ann Pharm Fr. 2008 Nov-Dec;66(5-6):300-8. DMBUH26 RU https://pubmed.ncbi.nlm.nih.gov/19061730 DMBUNVW DI DMBUNVW DMBUNVW DN Prednicarbate DMBUNVW TI TTP3UTW DMBUNVW TN Steroid hormone receptor ERR (ESRR) DMBUNVW MA Modulator DMBUNVW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBUNVW RU https://www.fda.gov/ DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 TI TTTSEPU DMBVEC7 TN Thyroid hormone receptor alpha (THRA) DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMBVEC7 DI DMBVEC7 DMBVEC7 DN Dextrothyroxine Sodium DMBVEC7 TI TTGER3L DMBVEC7 TN Thyroid hormone receptor beta (THRB) DMBVEC7 MA Modulator DMBVEC7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMBVEC7 RU https://www.fda.gov/ DMBW7VH DI DMBW7VH DMBW7VH DN Methyprylon DMBW7VH TI TT1MPAY DMBW7VH TN GABA(A) receptor alpha-1 (GABRA1) DMBW7VH MA Antagonist DMBW7VH RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMBW7VH RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMBXVMZ DI DMBXVMZ DMBXVMZ DN Dihydroartemisinin DMBXVMZ TI TTZVSJ2 DMBXVMZ TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMBXVMZ MA Inhibitor DMBXVMZ RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMBXVMZ RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMBXWU8 DI DMBXWU8 DMBXWU8 DN Aprindine DMBXWU8 TI TTV3NH6 DMBXWU8 TN Calmodulin (CALM) DMBXWU8 MA Inhibitor DMBXWU8 RN Aprindine inhibits calmodulin-stimulated phosphodiesterase and Ca-ATPase activities. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):151-6. DMBXWU8 RU https://pubmed.ncbi.nlm.nih.gov/6186851 DMBYCU0 DI DMBYCU0 DMBYCU0 DN Metyrosine DMBYCU0 TI TTUHP71 DMBYCU0 TN Tyrosine 3-monooxygenase (TH) DMBYCU0 MA Binder DMBYCU0 RN Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8. DMBYCU0 RU https://pubmed.ncbi.nlm.nih.gov/1677640 DMBYNW0 DI DMBYNW0 DMBYNW0 DN MK-3475 DMBYNW0 TI TTNBFWK DMBYNW0 TN Programmed cell death protein 1 (PD-1) DMBYNW0 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMBYNW0 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMBZIVP DI DMBZIVP DMBZIVP DN Tubocurarine DMBZIVP TI TTF4E0J DMBZIVP TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMBZIVP MA Antagonist DMBZIVP RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMBZIVP RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMBZWQL DI DMBZWQL DMBZWQL DN Clemastine DMBZWQL TI TTTIBOJ DMBZWQL TN Histamine H1 receptor (H1R) DMBZWQL MA Antagonist DMBZWQL RN Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91. DMBZWQL RU https://pubmed.ncbi.nlm.nih.gov/18548114 DMC0GSJ DI DMC0GSJ DMC0GSJ DN Efavirenz DMC0GSJ TI TT84ETX DMC0GSJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMC0GSJ MA Modulator DMC0GSJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC0GSJ RU https://www.fda.gov/ DMC128O DI DMC128O DMC128O DN Anileridine Hydrochloride DMC128O TI TTKWM86 DMC128O TN Opioid receptor mu (MOP) DMC128O MA Modulator DMC128O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC128O RU https://www.fda.gov/ DMC1NBW DI DMC1NBW DMC1NBW DN Thiazolidinedione DMC1NBW TI TTZMAO3 DMC1NBW TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMC1NBW MA Agonist DMC1NBW RN Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. DMC1NBW RU https://pubmed.ncbi.nlm.nih.gov/12379847 DMC3JST DI DMC3JST DMC3JST DN Clorazepate DMC3JST TI TTPTXIN DMC3JST TN Translocator protein (TSPO) DMC3JST MA Modulator DMC3JST RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMC3JST RU https://www.fda.gov/ DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA TI TTOI92F DMC3YUA TN Multidrug resistance-associated protein 1 (ABCC1) DMC3YUA MA Stimulator DMC3YUA RN Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transpo... Drug Metab Dispos. 2009 Jan;37(1):129-36. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/18845662 DMC3YUA DI DMC3YUA DMC3YUA DN Benzbromarone DMC3YUA TI TTOJI4S DMC3YUA TN Calcium-dependent chloride channel anoctamin (ANO) DMC3YUA MA Antagonist DMC3YUA RN Anoctamin Channels in Human Myometrium: A Novel Target for Tocolysis.Reprod Sci. 2018 Nov;25(11):1589-1600. DMC3YUA RU https://pubmed.ncbi.nlm.nih.gov/29471754 DMC4GEI DI DMC4GEI DMC4GEI DN Ospemifene DMC4GEI TI TTZAYWL DMC4GEI TN Estrogen receptor (ESR) DMC4GEI MA Modulator DMC4GEI RN Clinical pipeline report, company report or official report of Shionogi (2011). DMC4GEI RU http://www.shionogi.co.jp/index_e.html DMC50ME DI DMC50ME DMC50ME DN Debrisoquin DMC50ME TI TTT04VN DMC50ME TN Adrenergic neuron (AD neuro) DMC50ME MA Blocker DMC50ME RN Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604. DMC50ME RU https://pubmed.ncbi.nlm.nih.gov/5431666 DMC5AST DI DMC5AST DMC5AST DN Butabarbital DMC5AST TI TT1MPAY DMC5AST TN GABA(A) receptor alpha-1 (GABRA1) DMC5AST MA Antagonist DMC5AST RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMC5AST RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMC7XDN DI DMC7XDN DMC7XDN DN Alprazolam DMC7XDN TI TTPTXIN DMC7XDN TN Translocator protein (TSPO) DMC7XDN MA Agonist DMC7XDN RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMC7XDN RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TTS64P2 DMC8VNH TN Androgen receptor (AR) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TTVKILB DMC8VNH TN Prostaglandin G/H synthase 2 (COX-2) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TT8NGED DMC8VNH TN Prostaglandin G/H synthase 1 (COX-1) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC8VNH DI DMC8VNH DMC8VNH DN Flufenamic Acid DMC8VNH TI TT5ZWB6 DMC8VNH TN Dihydrodiol dehydrogenase type I (AKR1C3) DMC8VNH MA Inhibitor DMC8VNH RN Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51. DMC8VNH RU https://pubmed.ncbi.nlm.nih.gov/7864817 DMC9O43 DI DMC9O43 DMC9O43 DN Sevoflurane DMC9O43 TI TTAN6JD DMC9O43 TN Glutamate receptor AMPA (GRIA) DMC9O43 MA Antagonist DMC9O43 RN Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35. DMC9O43 RU https://pubmed.ncbi.nlm.nih.gov/19247760 DMCA9QP DI DMCA9QP DMCA9QP DN Papaverine DMCA9QP TI TTJ0IQB DMCA9QP TN Phosphodiesterase 5A (PDE5A) DMCA9QP MA Inhibitor DMCA9QP RN Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8. DMCA9QP RU https://pubmed.ncbi.nlm.nih.gov/12646997 DMCA9QP DI DMCA9QP DMCA9QP DN Papaverine DMCA9QP TI TTSKMI8 DMCA9QP TN Phosphodiesterase 4D (PDE4D) DMCA9QP MA Inhibitor DMCA9QP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCA9QP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCBJSR DI DMCBJSR DMCBJSR DN Sunitinib DMCBJSR TI TTUTJGQ DMCBJSR TN Vascular endothelial growth factor receptor 2 (KDR) DMCBJSR MA Modulator DMCBJSR RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMCBJSR RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMCD9YG DI DMCD9YG DMCD9YG DN Prazosin DMCD9YG TI TTG28O6 DMCD9YG TN Adrenergic receptor Alpha-1 (ADRA1) DMCD9YG MA Antagonist DMCD9YG RN Adventitia removal does not modify the alphaID-adrenoceptors response in aorta during hypertension and ageing. Auton Autacoid Pharmacol. 2009 Jul;29(3):117-33. DMCD9YG RU https://pubmed.ncbi.nlm.nih.gov/19566752 DMCDYW7 DI DMCDYW7 DMCDYW7 DN Nicardipine DMCDYW7 TI TT5HONZ DMCDYW7 TN Calcium channel unspecific (CaC) DMCDYW7 MA Blocker DMCDYW7 RN Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20. DMCDYW7 RU https://pubmed.ncbi.nlm.nih.gov/19569065 DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD TI TT3WG5C DMCEUJD TN Monoamine oxidase type A (MAO-A) DMCEUJD MA Inhibitor DMCEUJD RN Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6. DMCEUJD RU https://pubmed.ncbi.nlm.nih.gov/19423952 DMCEUJD DI DMCEUJD DMCEUJD DN Clorgyline DMCEUJD TI TT32XQJ DMCEUJD TN Monoamine oxidase (MAO) DMCEUJD MA Inhibitor DMCEUJD RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCEUJD RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCEW64 DI DMCEW64 DMCEW64 DN Ceftriaxone DMCEW64 TI TTJP4SM DMCEW64 TN Bacterial Penicillin binding protein (Bact PBP) DMCEW64 MA Modulator DMCEW64 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMCEW64 RU https://www.fda.gov/ DMCEZ1B DI DMCEZ1B DMCEZ1B DN Cotinine DMCEZ1B TI TTJSZTB DMCEZ1B TN Nicotinic acetylcholine receptor (nAChR) DMCEZ1B MA Modulator DMCEZ1B RN Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31. DMCEZ1B RU https://pubmed.ncbi.nlm.nih.gov/12008000 DMCFE9I DI DMCFE9I DMCFE9I DN Valproate DMCFE9I TI TTRZQE3 DMCFE9I TN Glycogen synthase kinase-3 alpha (GSK-3A) DMCFE9I MA Inhibitor DMCFE9I RN Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76. DMCFE9I RU https://pubmed.ncbi.nlm.nih.gov/18851693 DMCFE9I DI DMCFE9I DMCFE9I DN Valproate DMCFE9I TI TTBH0VX DMCFE9I TN Histone deacetylase (HDAC) DMCFE9I MA Inhibitor DMCFE9I RN Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086. DMCFE9I RU https://pubmed.ncbi.nlm.nih.gov/19564914 DMCH7RU DI DMCH7RU DMCH7RU DN Pheniramine DMCH7RU TI TTTIBOJ DMCH7RU TN Histamine H1 receptor (H1R) DMCH7RU MA Antagonist DMCH7RU RN Role of central histaminergic system in lorazepam withdrawal syndrome in rats. Pharmacol Biochem Behav. 2001 Apr;68(4):777-82. DMCH7RU RU https://pubmed.ncbi.nlm.nih.gov/11526976 DMCH80F DI DMCH80F DMCH80F DN Polythiazide DMCH80F TI TTP362L DMCH80F TN Solute carrier family 12 member 3 (SLC12A3) DMCH80F MA Blocker DMCH80F RN The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon. J Clin Invest. 2001 Jul;108(2):215-22. DMCH80F RU https://pubmed.ncbi.nlm.nih.gov/11457874 DMCHV4I DI DMCHV4I DMCHV4I DN Rifapentine DMCHV4I TI TTHKJLN DMCHV4I TN DNA-directed RNA polymerase (RNAP) DMCHV4I MA Binder DMCHV4I RN Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998 Jul;42(7):1853-7. DMCHV4I RU https://pubmed.ncbi.nlm.nih.gov/9661035 DMCIJBH DI DMCIJBH DMCIJBH DN DU-176B DMCIJBH TI TTCIHJA DMCIJBH TN Coagulation factor Xa (F10) DMCIJBH MA Modulator DMCIJBH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359). DMCIJBH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2359 DMCJN1P DI DMCJN1P DMCJN1P DN Plerixafor DMCJN1P TI TTBID49 DMCJN1P TN C-X-C chemokine receptor type 4 (CXCR4) DMCJN1P MA Antagonist DMCJN1P RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMCJN1P RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMCKL5V DI DMCKL5V DMCKL5V DN Efalizumab DMCKL5V TI TT48WR6 DMCKL5V TN Integrin alpha-L (ITGAL) DMCKL5V RN [Successful therapy of discoid lupus erythematosus with efalizumab]. Hautarzt. 2010 Mar;61(3):246-9. DMCKL5V RU https://pubmed.ncbi.nlm.nih.gov/19436973 DMCKPUR DI DMCKPUR DMCKPUR DN Alfaferone DMCKPUR TI TT95SOA DMCKPUR TN Interferon alpha (IFNA) DMCKPUR MA Modulator DMCKPUR RN Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7. DMCKPUR RU https://pubmed.ncbi.nlm.nih.gov/21739360 DMCKYZ5 DI DMCKYZ5 DMCKYZ5 DN Clenbuterol DMCKYZ5 TI TT2CJVK DMCKYZ5 TN Adrenergic receptor beta-2 (ADRB2) DMCKYZ5 MA Agonist DMCKYZ5 RN Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7. DMCKYZ5 RU https://pubmed.ncbi.nlm.nih.gov/19095863 DMCL2OK DI DMCL2OK DMCL2OK DN Disulfiram DMCL2OK TI TTB6UM0 DMCL2OK TN Fatty aldehyde dehydrogenase (ALDH3A2) DMCL2OK MA Inhibitor DMCL2OK RN Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76. DMCL2OK RU https://pubmed.ncbi.nlm.nih.gov/16545872 DMCLHO0 DI DMCLHO0 DMCLHO0 DN Bethanechol DMCLHO0 TI TTH18TF DMCLHO0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMCLHO0 MA Agonist DMCLHO0 RN Loss of Ca-mediated ion transport during colitis correlates with reduced ion transport responses to a Ca-activated K channel opener. Br J Pharmacol. 2009 Apr;156(7):1085-97. DMCLHO0 RU https://pubmed.ncbi.nlm.nih.gov/19298254 DMCLR6G DI DMCLR6G DMCLR6G DN Pegloticase DMCLR6G TI TTZ1SWF DMCLR6G TN Uric acid (URA) DMCLR6G MA Modulator DMCLR6G RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCLR6G RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCMBHA DI DMCMBHA DMCMBHA DN Erlotinib DMCMBHA TI TTGKNB4 DMCMBHA TN Epidermal growth factor receptor (EGFR) DMCMBHA MA Inhibitor DMCMBHA RN Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48. DMCMBHA RU https://pubmed.ncbi.nlm.nih.gov/19627157 DMCME17 DI DMCME17 DMCME17 DN Lisuride DMCME17 TI TTEX248 DMCME17 TN Dopamine D2 receptor (D2R) DMCME17 MA Agonist DMCME17 RN Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 2007 Sep;6(9):826-9. DMCME17 RU https://pubmed.ncbi.nlm.nih.gov/17706566 DMCMETN DI DMCMETN DMCMETN DN MLN9708 DMCMETN TI TTU7ZMG DMCMETN TN Proteasome (PS) DMCMETN MA Modulator DMCMETN RN Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010 Mar 1;70(5):1970-80. DMCMETN RU https://pubmed.ncbi.nlm.nih.gov/20160034 DMCN61Z DI DMCN61Z DMCN61Z DN Interferon beta-1b DMCN61Z TI TTMQB37 DMCN61Z TN Interferon alpha/beta receptor 2 (IFNAR2) DMCN61Z MA Binder DMCN61Z RN Interferon-beta(1b) Treatment in Neuromyelitis Optica. Eur Neurol. 2009 Jul 7;62(3):167-170. DMCN61Z RU https://pubmed.ncbi.nlm.nih.gov/19590215 DMCO5JZ DI DMCO5JZ DMCO5JZ DN SR141716A DMCO5JZ TI TT6OEDT DMCO5JZ TN Cannabinoid receptor 1 (CB1) DMCO5JZ MA Antagonist DMCO5JZ RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMCO5JZ RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMCOAVT DI DMCOAVT DMCOAVT DN Emepronium DMCOAVT TI TTH18TF DMCOAVT TN Muscarinic acetylcholine receptor M5 (CHRM5) DMCOAVT MA Modulator DMCOAVT RN Classification of the presynaptic muscarinic receptor subtype that regulates 3H-acetylcholine secretion in the guinea pig urinary bladder in vitro. J Pharmacol Exp Ther. 1995 Jul;274(1):458-68. DMCOAVT RU https://pubmed.ncbi.nlm.nih.gov/7616431 DMCOLUP DI DMCOLUP DMCOLUP DN Levallorphan DMCOLUP TI TTF4E0J DMCOLUP TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMCOLUP MA Antagonist DMCOLUP RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DMCOLUP RU https://pubmed.ncbi.nlm.nih.gov/18633030 DMCOZJY DI DMCOZJY DMCOZJY DN Tenapanor DMCOZJY TI TTFZVPO DMCOZJY TN Sodium/hydrogen exchanger 3 (SLC9A3) DMCOZJY MA Modulator DMCOZJY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMCOZJY RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211801s000lbl.pdf DMCR1MV DI DMCR1MV DMCR1MV DN Itraconazole DMCR1MV TI TTTSOUD DMCR1MV TN Candida Cytochrome P450 51 (Candi ERG11) DMCR1MV MA Modulator DMCR1MV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMCR1MV RU https://www.fda.gov/ DMCR1MV DI DMCR1MV DMCR1MV DN Itraconazole DMCR1MV TI TT4LXBC DMCR1MV TN Hedgehog signaling pathway (HS pathway) DMCR1MV MA Inhibitor DMCR1MV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCR1MV RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCRQHB DI DMCRQHB DMCRQHB DN Edrophonium DMCRQHB TI TT1RS9F DMCRQHB TN Acetylcholinesterase (AChE) DMCRQHB MA Inhibitor DMCRQHB RN Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56. DMCRQHB RU https://pubmed.ncbi.nlm.nih.gov/19472276 DMCS6M5 DI DMCS6M5 DMCS6M5 DN Voxelotor DMCS6M5 TI TTQO71U DMCS6M5 TN Hemoglobin (HB) DMCS6M5 MA Modulator DMCS6M5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMCS6M5 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf DMCSLZ4 DI DMCSLZ4 DMCSLZ4 DN Sodium zirconium cyclosilicate DMCSLZ4 TI TTB0SC6 DMCSLZ4 TN Potassium (K) DMCSLZ4 MA Binder DMCSLZ4 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMCSLZ4 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMCT31R DI DMCT31R DMCT31R DN Carbinoxamine DMCT31R TI TTTIBOJ DMCT31R TN Histamine H1 receptor (H1R) DMCT31R MA Antagonist DMCT31R RN Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4. DMCT31R RU https://pubmed.ncbi.nlm.nih.gov/7513381 DMCT3I8 DI DMCT3I8 DMCT3I8 DN Ifosfamide DMCT3I8 TI TTUTN1I DMCT3I8 TN Human Deoxyribonucleic acid (hDNA) DMCT3I8 MA Modulator DMCT3I8 RN Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35. DMCT3I8 RU https://www.ncbi.nlm.nih.gov/pubmed/15827549 DMCTE9R DI DMCTE9R DMCTE9R DN Mexiletine DMCTE9R TI TTZOVE0 DMCTE9R TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMCTE9R MA Blocker DMCTE9R RN Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. DMCTE9R RU https://pubmed.ncbi.nlm.nih.gov/11196553 DMCUT21 DI DMCUT21 DMCUT21 DN Ursodeoxycholic acid DMCUT21 TI TTOP832 DMCUT21 TN Solute carrier family 23 member 2 (SLC23A2) DMCUT21 MA Activator DMCUT21 RN Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36. DMCUT21 RU https://pubmed.ncbi.nlm.nih.gov/18706437 DMCUT21 DI DMCUT21 DMCUT21 DN Ursodeoxycholic acid DMCUT21 TI TTJBPN3 DMCUT21 TN Biliverdin reductase A (BLVRA) DMCUT21 MA Activator DMCUT21 RN Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal... Toxicol Appl Pharmacol. 2008 Oct 15;232(2):327-36. DMCUT21 RU https://pubmed.ncbi.nlm.nih.gov/18706437 DMCV109 DI DMCV109 DMCV109 DN Etanercept DMCV109 TI TTF8CQI DMCV109 TN Tumor necrosis factor (TNF) DMCV109 MA Modulator DMCV109 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMCV109 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 TI TTX09M4 DMCVJ86 TN Ribonucleotide reductase (RIR) DMCVJ86 MA Inhibitor DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMCVJ86 DI DMCVJ86 DMCVJ86 DN Clofarabine DMCVJ86 TI TTJP4SM DMCVJ86 TN Bacterial Penicillin binding protein (Bact PBP) DMCVJ86 MA Binder DMCVJ86 RN Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30. DMCVJ86 RU https://pubmed.ncbi.nlm.nih.gov/17852710 DMCVPXO DI DMCVPXO DMCVPXO DN Lurasidone hydrochloride DMCVPXO TI TTJQOD7 DMCVPXO TN 5-HT 2A receptor (HTR2A) DMCVPXO MA Modulator DMCVPXO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCVPXO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCVPXO DI DMCVPXO DMCVPXO DN Lurasidone hydrochloride DMCVPXO TI TTEX248 DMCVPXO TN Dopamine D2 receptor (D2R) DMCVPXO MA Modulator DMCVPXO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCVPXO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCX0K3 DI DMCX0K3 DMCX0K3 DN Cinacalcet DMCX0K3 TI TTBUYHA DMCX0K3 TN Extracellular calcium-sensing receptor (CASR) DMCX0K3 MA Agonist DMCX0K3 RN Clinical pipeline report, company report or official report of Amgen (2009). DMCX0K3 RU http://www.amgen.com/science/pipe.jsp DMCY0TI DI DMCY0TI DMCY0TI DN Carglumic acid DMCY0TI TI TT42M75 DMCY0TI TN Carbamoyl-phosphate synthetase I (CPS1) DMCY0TI MA Activator DMCY0TI RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMCY0TI RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMCY8AF DI DMCY8AF DMCY8AF DN Arbutamine DMCY8AF TI TTR6W5O DMCY8AF TN Adrenergic receptor beta-1 (ADRB1) DMCY8AF MA Stimulator DMCY8AF RN Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing. Cardiovasc Drugs Ther. 1996 Mar;10(1):39-47. DMCY8AF RU https://pubmed.ncbi.nlm.nih.gov/8723169 DMCYANK DI DMCYANK DMCYANK DN Doxapram DMCYANK TI TT6EYVN DMCYANK TN Peripheral carotid chemoreceptor (PCC) DMCYANK MA Stimulator DMCYANK RN Ovalbumin sensitization alters the ventilatory responses to chemical challenges in guinea pigs. J Appl Physiol (1985). 2005 Nov;99(5):1782-8. DMCYANK RU https://pubmed.ncbi.nlm.nih.gov/16024517 DMCYVDT DI DMCYVDT DMCYVDT DN Chlorzoxazone DMCYVDT TI TTMNI76 DMCYVDT TN Calcium-activated potassium channel (KCN) DMCYVDT MA Activator DMCYVDT RN Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. DMCYVDT RU https://pubmed.ncbi.nlm.nih.gov/16859676 DMCZGRE DI DMCZGRE DMCZGRE DN Dolutegravir DMCZGRE TI TT5FH9Y DMCZGRE TN Human immunodeficiency virus Integrase (HIV IN) DMCZGRE MA Modulator DMCZGRE RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMCZGRE RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMCZIHT DI DMCZIHT DMCZIHT DN Asasantin DMCZIHT TI TTK0943 DMCZIHT TN Prostaglandin G/H synthase (COX) DMCZIHT MA Inhibitor DMCZIHT RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMCZIHT RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMCZQGK DI DMCZQGK DMCZQGK DN Demecolcine DMCZQGK TI TT1EDJZ DMCZQGK TN Microtubule-associated protein (MAP) DMCZQGK MA Modulator DMCZQGK RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMCZQGK RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMD072M DI DMD072M DMD072M DN Fosfestrol DMD072M TI TTZAYWL DMD072M TN Estrogen receptor (ESR) DMD072M MA Modulator DMD072M RN Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009 Jul;109(7):3012-43. DMD072M RU https://pubmed.ncbi.nlm.nih.gov/19422222 DMD157S DI DMD157S DMD157S DN Montelukast DMD157S TI TTGKOY9 DMD157S TN Leukotriene CysLT1 receptor (CYSLTR1) DMD157S MA Antagonist DMD157S RN Protective potential of montelukast against hepatic ischemia/reperfusion injury in rats. J Surg Res. 2010 Mar;159(1):588-94. DMD157S RU https://pubmed.ncbi.nlm.nih.gov/19515388 DMD1B8Z DI DMD1B8Z DMD1B8Z DN Dobutamine DMD1B8Z TI TTR6W5O DMD1B8Z TN Adrenergic receptor beta-1 (ADRB1) DMD1B8Z MA Agonist DMD1B8Z RN Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16. DMD1B8Z RU https://pubmed.ncbi.nlm.nih.gov/18275933 DMD1QXW DI DMD1QXW DMD1QXW DN Ambrisentan DMD1QXW TI TTKRD0G DMD1QXW TN Endothelin A receptor (EDNRA) DMD1QXW MA Antagonist DMD1QXW RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMD1QXW RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMD1VZL DI DMD1VZL DMD1VZL DN Pemafibrate DMD1VZL TI TTJ584C DMD1VZL TN Peroxisome proliferator-activated receptor alpha (PPARA) DMD1VZL MA Agonist DMD1VZL RN Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810. DMD1VZL RU https://pubmed.ncbi.nlm.nih.gov/28929345 DMD2K4I DI DMD2K4I DMD2K4I DN Fludiazepam DMD2K4I TI TTPTXIN DMD2K4I TN Translocator protein (TSPO) DMD2K4I MA Agonist DMD2K4I RN Benzodiazepines and their metabolites: relationship between binding affinity to the benzodiazepine receptor and pharmacological activity. Life Sci. 1985 Jan 14;36(2):113-9. DMD2K4I RU https://pubmed.ncbi.nlm.nih.gov/2857046 DMD2NV7 DI DMD2NV7 DMD2NV7 DN Pindolol DMD2NV7 TI TTR6W5O DMD2NV7 TN Adrenergic receptor beta-1 (ADRB1) DMD2NV7 MA Antagonist DMD2NV7 RN Are we misunderstanding beta-blockers. Int J Cardiol. 2007 Aug 9;120(1):10-27. DMD2NV7 RU https://pubmed.ncbi.nlm.nih.gov/17433471 DMD2WPG DI DMD2WPG DMD2WPG DN Trientine DMD2WPG TI TTEYTKG DMD2WPG TN Carbonic anhydrase XIV (CA-XIV) DMD2WPG MA Inhibitor DMD2WPG RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD2WPG RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4381 DI DMD4381 DMD4381 DN Terbutaline DMD4381 TI TT2CJVK DMD4381 TN Adrenergic receptor beta-2 (ADRB2) DMD4381 MA Agonist DMD4381 RN Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Pharmacology. 1975;13(3):201-11. DMD4381 RU https://pubmed.ncbi.nlm.nih.gov/239414 DMD59GI DI DMD59GI DMD59GI DN Urapidil DMD59GI TI TTG28O6 DMD59GI TN Adrenergic receptor Alpha-1 (ADRA1) DMD59GI MA Antagonist DMD59GI RN Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55. DMD59GI RU https://pubmed.ncbi.nlm.nih.gov/9829161 DMD59GI DI DMD59GI DMD59GI DN Urapidil DMD59GI TI TTSQIFT DMD59GI TN 5-HT 1A receptor (HTR1A) DMD59GI MA Agonist DMD59GI RN Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55. DMD59GI RU https://pubmed.ncbi.nlm.nih.gov/9829161 DMD5JU8 DI DMD5JU8 DMD5JU8 DN Cephalexin DMD5JU8 TI TTJP4SM DMD5JU8 TN Bacterial Penicillin binding protein (Bact PBP) DMD5JU8 MA Binder DMD5JU8 RN Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21. DMD5JU8 RU https://pubmed.ncbi.nlm.nih.gov/14970246 DMD5LBX DI DMD5LBX DMD5LBX DN Celiprolol HCL DMD5LBX TI TTVIREA DMD5LBX TN Adrenergic receptor (ADR) DMD5LBX MA Modulator DMD5LBX RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMD5LBX RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMD7L94 DI DMD7L94 DMD7L94 DN Palbociclib DMD7L94 TI TT0PG8F DMD7L94 TN Cyclin-dependent kinase 4 (CDK4) DMD7L94 MA Modulator DMD7L94 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017 DMD7L94 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf DMD7L94 DI DMD7L94 DMD7L94 DN Palbociclib DMD7L94 TI TTO0FDJ DMD7L94 TN Cyclin-dependent kinase 6 (CDK6) DMD7L94 MA Modulator DMD7L94 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017 DMD7L94 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207103s004lbl.pdf DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O TI TT4NVEM DMD7X1O TN DNA topoisomerase II beta (TOP2B) DMD7X1O MA Inhibitor DMD7X1O RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD7X1O RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD7X1O DI DMD7X1O DMD7X1O DN Dexrazoxane DMD7X1O TI TT0IHXV DMD7X1O TN DNA topoisomerase II (TOP2) DMD7X1O MA Modulator DMD7X1O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMD7X1O RU https://www.fda.gov/ DMD8Q3J DI DMD8Q3J DMD8Q3J DN Gemfibrozil DMD8Q3J TI TTOF3WZ DMD8Q3J TN Lipoprotein lipase (LPL) DMD8Q3J MA Activator DMD8Q3J RN Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 2006 Jan;42(1):39-64. DMD8Q3J RU https://pubmed.ncbi.nlm.nih.gov/16511610 DMD9WSC DI DMD9WSC DMD9WSC DN Memantine DMD9WSC TI TT9IK2Z DMD9WSC TN N-methyl-D-aspartate receptor (NMDAR) DMD9WSC MA Modulator DMD9WSC RN The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S23-32. DMD9WSC RU https://pubmed.ncbi.nlm.nih.gov/12973747 DMDBX5F DI DMDBX5F DMDBX5F DN Ivermectin DMDBX5F TI TTSNVHO DMDBX5F TN Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) DMDBX5F MA Activator DMDBX5F RN Inhibitory neurotransmission and olfactory memory in honeybees. Neurobiol Learn Mem. 2008 Nov;90(4):589-95. DMDBX5F RU https://pubmed.ncbi.nlm.nih.gov/18755283 DMDBZMV DI DMDBZMV DMDBZMV DN Vitamin B6 DMDBZMV TI TTN451K DMDBZMV TN Aromatic-L-amino-acid decarboxylase (DDC) DMDBZMV MA Cofactor DMDBZMV RN Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2005 Aug 5;137B(1):1-4. DMDBZMV RU https://pubmed.ncbi.nlm.nih.gov/15965967 DMDEA85 DI DMDEA85 DMDEA85 DN Trimetrexate DMDEA85 TI TT9SL3Q DMDEA85 TN Polypeptide deformylase (PDF) DMDEA85 MA Inhibitor DMDEA85 RN Expression and characterization of recombinant human-derived Pneumocystis carinii dihydrofolate reductase. Antimicrob Agents Chemother. 2000 Nov;44(11):3092-6. DMDEA85 RU https://pubmed.ncbi.nlm.nih.gov/11036028 DMDEXQ0 DI DMDEXQ0 DMDEXQ0 DN Febuxostat DMDEXQ0 TI TT7RJY8 DMDEXQ0 TN Xanthine dehydrogenase/oxidase (XDH) DMDEXQ0 MA Inhibitor DMDEXQ0 RN Clinical pipeline report, company report or official report of Takeda (2009). DMDEXQ0 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMDEZI3 DI DMDEZI3 DMDEZI3 DN Pegvisomant DMDEZI3 TI TTKMAZ6 DMDEZI3 TN Growth hormone receptor (GHR) DMDEZI3 MA Antagonist DMDEZI3 RN Growth hormone receptor antagonist treatment reduces exercise performance in young males. J Clin Endocrinol Metab. 2009 Sep;94(9):3265-72. DMDEZI3 RU https://pubmed.ncbi.nlm.nih.gov/19549743 DMDF79Z DI DMDF79Z DMDF79Z DN Acetylcholine DMDF79Z TI TTOXS3C DMDF79Z TN Muscarinic acetylcholine receptor (CHRM) DMDF79Z MA Agonist DMDF79Z RN Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66. DMDF79Z RU https://pubmed.ncbi.nlm.nih.gov/14722259 DMDH9KX DI DMDH9KX DMDH9KX DN Megestrol DMDH9KX TI TTUV8G9 DMDH9KX TN Progesterone receptor (PGR) DMDH9KX MA Binder DMDH9KX RN Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8. DMDH9KX RU https://pubmed.ncbi.nlm.nih.gov/14687437 DMDHCK9 DI DMDHCK9 DMDHCK9 DN Trumenba DMDHCK9 TI TTUW6OP DMDHCK9 TN Complement factor H (CFH) DMDHCK9 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMDHCK9 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMDI269 DI DMDI269 DMDI269 DN Docetaxel DMDI269 TI TTML2WA DMDI269 TN Tubulin (TUB) DMDI269 MA Inhibitor DMDI269 RN Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31. DMDI269 RU https://pubmed.ncbi.nlm.nih.gov/16296875 DMDI6R4 DI DMDI6R4 DMDI6R4 DN Dabigatran DMDI6R4 TI TT6L509 DMDI6R4 TN Coagulation factor IIa (F2) DMDI6R4 MA Inhibitor DMDI6R4 RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMDI6R4 RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMDIC39 DI DMDIC39 DMDIC39 DN Fosfosal DMDIC39 TI TTK0943 DMDIC39 TN Prostaglandin G/H synthase (COX) DMDIC39 MA Modulator DMDIC39 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMDIC39 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMDINC4 DI DMDINC4 DMDINC4 DN Thiothixene DMDINC4 TI TTEX248 DMDINC4 TN Dopamine D2 receptor (D2R) DMDINC4 MA Antagonist DMDINC4 RN Dopaminergic stimulation of cAMP accumulation in cultured rat mesangial cells. Am J Physiol. 1987 Aug;253(2 Pt 2):H358-64. DMDINC4 RU https://pubmed.ncbi.nlm.nih.gov/3039860 DMDINFS DI DMDINFS DMDINFS DN Sanguinarine DMDINFS TI TTQ38E9 DMDINFS TN Sodium/potassium-transporting ATPase (SPT ATPase) DMDINFS MA Modulator DMDINFS RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMDINFS RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMDIYFZ DI DMDIYFZ DMDIYFZ DN Telotristat ethyl DMDIYFZ TI TTDJBV3 DMDIYFZ TN Tryptophan hydroxylase (TPH) DMDIYFZ MA Modulator DMDIYFZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMDIYFZ RU https://www.fda.gov/ DMDJMA3 DI DMDJMA3 DMDJMA3 DN Rizatriptan DMDJMA3 TI TT6MSOK DMDJMA3 TN 5-HT 1D receptor (HTR1D) DMDJMA3 MA Agonist DMDJMA3 RN An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. DMDJMA3 RU https://pubmed.ncbi.nlm.nih.gov/12434581 DMDK7T9 DI DMDK7T9 DMDK7T9 DN SBC-102 DMDK7T9 TI TTS8T1M DMDK7T9 TN Lysosomal acid lipase (LIPA) DMDK7T9 MA Modulator DMDK7T9 RN A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency. N Engl J Med. 2015 Sep 10;373(11):1010-20. DMDK7T9 RU https://pubmed.ncbi.nlm.nih.gov/26352813 DMDKE4N DI DMDKE4N DMDKE4N DN Secretin DMDKE4N TI TTOBVIN DMDKE4N TN Secretin receptor (SCT) DMDKE4N MA Binder DMDKE4N RN False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009 May;7(5):600-2. DMDKE4N RU https://pubmed.ncbi.nlm.nih.gov/19245850 DMDKF3M DI DMDKF3M DMDKF3M DN Raloxifene DMDKF3M TI TTZAYWL DMDKF3M TN Estrogen receptor (ESR) DMDKF3M MA Modulator DMDKF3M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMDKF3M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMDKXTO DI DMDKXTO DMDKXTO DN Cobicistat/darunavir DMDKXTO TI TTIJQ3O DMDKXTO TN Cytochrome P450 3A (CYP3A) DMDKXTO MA Modulator DMDKXTO RN Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014 Feb;74(2):195-206. DMDKXTO RU https://pubmed.ncbi.nlm.nih.gov/24343782 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTSCIUP DMDL27I TN Oxytocin receptor (OTR) DMDL27I MA Modulator DMDL27I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369). DMDL27I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TT4TFGN DMDL27I TN Vasopressin V1a receptor (V1AR) DMDL27I MA Agonist DMDL27I RN Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44. DMDL27I RU https://pubmed.ncbi.nlm.nih.gov/9334232 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTL9MHW DMDL27I TN Vasopressin V1b receptor (V1BR) DMDL27I MA Agonist DMDL27I RN The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22. DMDL27I RU https://pubmed.ncbi.nlm.nih.gov/9322919 DMDL27I DI DMDL27I DMDL27I DN Oxytocin DMDL27I TI TTK8R02 DMDL27I TN Vasopressin V2 receptor (V2R) DMDL27I MA Agonist DMDL27I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368). DMDL27I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368 DMDNJHG DI DMDNJHG DMDNJHG DN Aztreonam DMDNJHG TI TT85JMW DMDNJHG TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMDNJHG MA Binder DMDNJHG RN Penicillin-binding protein PBP2 of Escherichia coli localizes preferentially in the lateral wall and at mid-cell in comparison with the old cell pole. Mol Microbiol. 2003 Jan;47(2):539-47. DMDNJHG RU https://pubmed.ncbi.nlm.nih.gov/12519203 DMDO279 DI DMDO279 DMDO279 DN Phenprocoumon DMDO279 TI TTEUC8H DMDO279 TN Vitamin K epoxide reductase complex 1 (VKORC1) DMDO279 MA Inhibitor DMDO279 RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DMDO279 RU https://pubmed.ncbi.nlm.nih.gov/17955831 DMDPM7R DI DMDPM7R DMDPM7R DN Y-25130 DMDPM7R TI TTNXLKE DMDPM7R TN 5-HT 3 receptor (5HT3R) DMDPM7R MA Antagonist DMDPM7R RN The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist. Eur J Pharmacol. 1991 Apr 24;196(3):299-305. DMDPM7R RU https://pubmed.ncbi.nlm.nih.gov/1654255 DMDPYI5 DI DMDPYI5 DMDPYI5 DN Benzyl benzoate DMDPYI5 TI TTLUQ8E DMDPYI5 TN Hormone sensitive lipase (LIPE) DMDPYI5 MA Modulator DMDPYI5 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMDPYI5 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMDRKH2 DI DMDRKH2 DMDRKH2 DN Thiamphenicol DMDRKH2 TI TTLFGBV DMDRKH2 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMDRKH2 MA Modulator DMDRKH2 RN The fused TrpEG from Streptomyces venezuelae is an anthranilate synthase, not a 2-amino-2-deoxyisochorismate [corrected] (ADIC) synthase. Ethn Dis. 2008 Spring;18(2 Suppl 2):S2-9-13. DMDRKH2 RU https://pubmed.ncbi.nlm.nih.gov/18646313 DMDRQZU DI DMDRQZU DMDRQZU DN Ethanol DMDRQZU TI TT1MPAY DMDRQZU TN GABA(A) receptor alpha-1 (GABRA1) DMDRQZU MA Antagonist DMDRQZU RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDRQZU RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDRT0E DI DMDRT0E DMDRT0E DN Idoxuridine DMDRT0E TI TT4823K DMDRT0E TN Virus Deoxyribonucleic acid (Viru DNA) DMDRT0E MA Binder DMDRT0E RN Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. DMDRT0E RU https://pubmed.ncbi.nlm.nih.gov/10392098 DMDSWAG DI DMDSWAG DMDSWAG DN Methylphenobarbital DMDSWAG TI TT1MPAY DMDSWAG TN GABA(A) receptor alpha-1 (GABRA1) DMDSWAG MA Antagonist DMDSWAG RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDSWAG RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDTC7R DI DMDTC7R DMDTC7R DN Phenindamine DMDTC7R TI TTTIBOJ DMDTC7R TN Histamine H1 receptor (H1R) DMDTC7R MA Antagonist DMDTC7R RN The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor. J Med Chem. 1995 Aug 18;38(17):3351-60. DMDTC7R RU https://pubmed.ncbi.nlm.nih.gov/7650688 DMDU0BV DI DMDU0BV DMDU0BV DN Pivmecillinam DMDU0BV TI TTJP4SM DMDU0BV TN Bacterial Penicillin binding protein (Bact PBP) DMDU0BV MA Binder DMDU0BV RN Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother. 2009 Mar;53(3):912-7. DMDU0BV RU https://pubmed.ncbi.nlm.nih.gov/19104012 DMDVP3B DI DMDVP3B DMDVP3B DN Pregabalin DMDVP3B TI TTFK1JQ DMDVP3B TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMDVP3B MA Modulator DMDVP3B RN Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol. 2006 Aug;70(2):467-76. DMDVP3B RU https://pubmed.ncbi.nlm.nih.gov/16641316 DMDWICP DI DMDWICP DMDWICP DN Succinic acid DMDWICP TI TTJUWVB DMDWICP TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMDWICP MA Inhibitor DMDWICP RN Redox-switch modulation of human SSADH by dynamic catalytic loop. EMBO J. 2009 Apr 8;28(7):959-68. DMDWICP RU https://pubmed.ncbi.nlm.nih.gov/19300440 DMDX1ZC DI DMDX1ZC DMDX1ZC DN Cinolazepam DMDX1ZC TI TTPTXIN DMDX1ZC TN Translocator protein (TSPO) DMDX1ZC MA Binder DMDX1ZC RN Short-term sleep laboratory studies with cinolazepam in situational insomnia induced by traffic noise. Int J Clin Pharmacol Res. 1987;7(5):407-18. DMDX1ZC RU https://pubmed.ncbi.nlm.nih.gov/2889679 DMDYA31 DI DMDYA31 DMDYA31 DN Pretomanid DMDYA31 TI TT08ESN DMDYA31 TN Mycobacterium Mycolic acid synthase (MycB cma) DMDYA31 MA Inhibitor DMDYA31 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMDYA31 RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212862Orig1s000Lbl.pdf DMDZ9LT DI DMDZ9LT DMDZ9LT DN Ethosuximide DMDZ9LT TI TT729IR DMDZ9LT TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMDZ9LT MA Blocker DMDZ9LT RN Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. DMDZ9LT RU https://pubmed.ncbi.nlm.nih.gov/19005061 DMDZY54 DI DMDZY54 DMDZY54 DN Fremanezumab DMDZY54 TI TTY6O0Q DMDZY54 TN Calcitonin gene-related peptide receptor (CGRPR) DMDZY54 MA Modulator DMDZY54 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMDZY54 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DME0F98 DI DME0F98 DME0F98 DN Ovine corticotropin-releasing hormone DME0F98 TI TTVIREA DME0F98 TN Adrenergic receptor (ADR) DME0F98 MA Modulator DME0F98 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DME0F98 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TTZOVE0 DME0TC8 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DME0TC8 MA Inhibitor DME0TC8 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TT4FDG6 DME0TC8 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DME0TC8 MA Inhibitor DME0TC8 RN Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Feb 1;17(3):662-7. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/17134896 DME0TC8 DI DME0TC8 DME0TC8 DN Lomerizine DME0TC8 TI TTRK8B9 DME0TC8 TN Sodium channel unspecific (NaC) DME0TC8 MA Inhibitor DME0TC8 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DME0TC8 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DME1DJX DI DME1DJX DME1DJX DN Baquting DME1DJX TI TTWODQF DME1DJX TN Fibrin (FG) DME1DJX MA Modulator DME1DJX RN Baquting, enable our sales and marketing team to effectively promote our principal products and help to stimulate the sales of our other pharmaceuticals. DME1DJX RU http://www.sec.gov/Archives/edgar/data/1474952/000119312509239183/df1.htm DME1LQN DI DME1LQN DME1LQN DN Streptomycin DME1LQN TI TTQ8KVI DME1LQN TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DME1LQN MA Binder DME1LQN RN Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 2000 Sep 21;407(6802):340-8. DME1LQN RU https://pubmed.ncbi.nlm.nih.gov/11014183 DME2H5T DI DME2H5T DME2H5T DN Cilastatin DME2H5T TI TTYUENF DME2H5T TN Dehydropeptidase I (DPEP1) DME2H5T MA Inhibitor DME2H5T RN Pharmacokinetic study of pleural fluid penetration of carbapenem antibiotic agents in chemical pleurisy. Respir Med. 2006 Feb;100(2):324-31. DME2H5T RU https://pubmed.ncbi.nlm.nih.gov/16493791 DME2PY5 DI DME2PY5 DME2PY5 DN Midodrine DME2PY5 TI TTG28O6 DME2PY5 TN Adrenergic receptor Alpha-1 (ADRA1) DME2PY5 MA Agonist DME2PY5 RN Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging. 2001;18(7):495-505. DME2PY5 RU https://pubmed.ncbi.nlm.nih.gov/11482743 DME2XG3 DI DME2XG3 DME2XG3 DN Carbenicillin Indanyl Sodium DME2XG3 TI TTJP4SM DME2XG3 TN Bacterial Penicillin binding protein (Bact PBP) DME2XG3 MA Modulator DME2XG3 RN Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61. DME2XG3 RU https://www.ncbi.nlm.nih.gov/pubmed/6821456 DME4RA8 DI DME4RA8 DME4RA8 DN Amodiaquine DME4RA8 TI TT2B6EV DME4RA8 TN Histamine N-methyltransferase (HNMT) DME4RA8 MA Inhibitor DME4RA8 RN Effect of amodiaquine, a histamine N-methyltransferase inhibitor, on, Propionibacterium acnes and lipopolysaccharide-induced hepatitis in mice. Eur J Pharmacol. 2007 Mar 8;558(1-3):179-84. DME4RA8 RU https://pubmed.ncbi.nlm.nih.gov/17222819 DME5Y64 DI DME5Y64 DME5Y64 DN Tranilast DME5Y64 TI TTTIBOJ DME5Y64 TN Histamine H1 receptor (H1R) DME5Y64 MA Antagonist DME5Y64 RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DME5Y64 RU https://pubmed.ncbi.nlm.nih.gov/16083326 DME5Y64 DI DME5Y64 DME5Y64 DN Tranilast DME5Y64 TI TTHM0R1 DME5Y64 TN Steryl-sulfatase (STS) DME5Y64 MA Inhibitor DME5Y64 RN Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. Curr Med Chem. 2002 Jan;9(2):263-73. DME5Y64 RU https://pubmed.ncbi.nlm.nih.gov/11860358 DME6G97 DI DME6G97 DME6G97 DN Lefamulin DME6G97 TI TTLFGBV DME6G97 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DME6G97 MA Inhibitor DME6G97 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DME6G97 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf DME78OA DI DME78OA DME78OA DN Biperiden DME78OA TI TTZ9SOR DME78OA TN Muscarinic acetylcholine receptor M1 (CHRM1) DME78OA MA Antagonist DME78OA RN Evaluation of in vivo binding properties of 3H-NMPB and 3H-QNB in mouse brain. J Neural Transm. 1999;106(7-8):583-92. DME78OA RU https://pubmed.ncbi.nlm.nih.gov/10907719 DME7KRM DI DME7KRM DME7KRM DN Oxiconazole DME7KRM TI TTTSOUD DME7KRM TN Candida Cytochrome P450 51 (Candi ERG11) DME7KRM MA Inhibitor DME7KRM RN Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9. DME7KRM RU https://pubmed.ncbi.nlm.nih.gov/12823944 DME8FZ9 DI DME8FZ9 DME8FZ9 DN Methoxsalen DME8FZ9 TI TTAQ6ZW DME8FZ9 TN Cytochrome P450 2A6 (CYP2A6) DME8FZ9 MA Binder DME8FZ9 RN Mutagenicity and carcinogenicity of methoxsalen plus UV-A. Arch Dermatol. 1984 May;120(5):662-9. DME8FZ9 RU https://pubmed.ncbi.nlm.nih.gov/6372701 DME9JNL DI DME9JNL DME9JNL DN Propericiazine DME9JNL TI TTBRKXS DME9JNL TN Adrenergic receptor alpha-1B (ADRA1B) DME9JNL MA Binder DME9JNL RN Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. DME9JNL RU https://pubmed.ncbi.nlm.nih.gov/6149771 DMEADRK DI DMEADRK DMEADRK DN Hexylcaine DMEADRK TI TTZOVE0 DMEADRK TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMEADRK MA Blocker DMEADRK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEADRK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEAOYJ DI DMEAOYJ DMEAOYJ DN Ponesimod DMEAOYJ TI TT9JZCK DMEAOYJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMEAOYJ MA Agonist DMEAOYJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMEAOYJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213498s000lbl.pdf DMEBOFW DI DMEBOFW DMEBOFW DN Clofazimine DMEBOFW TI TTS1W4A DMEBOFW TN Bacterial Deoxyribonucleic acid (Bact DNA) DMEBOFW MA Modulator DMEBOFW RN The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4. DMEBOFW RU https://www.ncbi.nlm.nih.gov/pubmed/945233 DMEBQAO DI DMEBQAO DMEBQAO DN Lumasiran DMEBQAO TI TTS58YO DMEBQAO TN HAO1 messenger RNA (HAO1 mRNA) DMEBQAO MA Inhibitor DMEBQAO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEBQAO RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214103lbl.pdf DMEBY2D DI DMEBY2D DMEBY2D DN Beriplast-P DMEBY2D TI TTWODQF DMEBY2D TN Fibrin (FG) DMEBY2D MA Modulator DMEBY2D RN Wound healing and degradation of the fibrin sealant Beriplast P following partial liver resection in rabbits. Wound Repair Regen. 2005 May-Jun;13(3):318-23. DMEBY2D RU https://pubmed.ncbi.nlm.nih.gov/15953052 DMECB4H DI DMECB4H DMECB4H DN Levopropoxyphene Napsylate Anhydrous DMECB4H TI TTKWM86 DMECB4H TN Opioid receptor mu (MOP) DMECB4H MA Modulator DMECB4H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMECB4H RU https://www.fda.gov/ DMECB4H DI DMECB4H DMECB4H DN Levopropoxyphene Napsylate Anhydrous DMECB4H TI TT35UGH DMECB4H TN Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) DMECB4H MA Modulator DMECB4H RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMECB4H RU https://www.fda.gov/ DMECBWN DI DMECBWN DMECBWN DN Riluzole DMECBWN TI TTN9VTF DMECBWN TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMECBWN MA Blocker DMECBWN RN Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Prog Brain Res. 2002;137:177-90. DMECBWN RU https://pubmed.ncbi.nlm.nih.gov/12440368 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 TI TT6L509 DMECRX1 TN Coagulation factor IIa (F2) DMECRX1 MA Inhibitor DMECRX1 RN New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/11479484 DMECRX1 DI DMECRX1 DMECRX1 DN Bivalirudin DMECRX1 TI TTRTKPV DMECRX1 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMECRX1 MA Inhibitor DMECRX1 RN 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8. DMECRX1 RU https://pubmed.ncbi.nlm.nih.gov/12937775 DMEDU7B DI DMEDU7B DMEDU7B DN NERATINIB MALEATE DMEDU7B TI TT6EO5L DMEDU7B TN Erbb2 tyrosine kinase receptor (HER2) DMEDU7B MA Antagonist DMEDU7B RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMEDU7B RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMEDU7B DI DMEDU7B DMEDU7B DN NERATINIB MALEATE DMEDU7B TI TTGKNB4 DMEDU7B TN Epidermal growth factor receptor (EGFR) DMEDU7B MA Antagonist DMEDU7B RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMEDU7B RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMEFRTZ DI DMEFRTZ DMEFRTZ DN Lurbinectedin DMEFRTZ TI TTOVXHF DMEFRTZ TN Human Deoxyribonucleic acid minor groove (hDNA min) DMEFRTZ MA Inhibitor DMEFRTZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEFRTZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf DMEFRTZ DI DMEFRTZ DMEFRTZ DN Lurbinectedin DMEFRTZ TI TTUTN1I DMEFRTZ TN Human Deoxyribonucleic acid (hDNA) DMEFRTZ MA Inhibitor DMEFRTZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMEFRTZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf DMEGIQ6 DI DMEGIQ6 DMEGIQ6 DN Nitrazepam DMEGIQ6 TI TT1MPAY DMEGIQ6 TN GABA(A) receptor alpha-1 (GABRA1) DMEGIQ6 MA Antagonist DMEGIQ6 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMEGIQ6 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TTR6YA2 DMEH3O7 TN Bacterial RNA polymerase sigma factor SigA (Bact sigA) DMEH3O7 MA Modulator DMEH3O7 RN NCBI report DMEH3O7 RU http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TTS31JH DMEH3O7 TN Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) DMEH3O7 MA Modulator DMEH3O7 RN NCBI report DMEH3O7 RU http://www.ncbi.nlm.nih.gov/Structure/mmdb/mmdbsrv.cgi?uid=4OIR DMEH3O7 DI DMEH3O7 DMEH3O7 DN Rifamycin DMEH3O7 TI TT79JGK DMEH3O7 TN Mycobacterium RNA polymerase (MycB RNAP) DMEH3O7 MA Inhibitor DMEH3O7 RN Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.Proc Natl Acad Sci U S A. 2017 Jun 13;114(24):E4832-E4840. DMEH3O7 RU https://pubmed.ncbi.nlm.nih.gov/28559332 DMEH7YU DI DMEH7YU DMEH7YU DN Lanadelumab DMEH7YU TI TTMF8H9 DMEH7YU TN Plasma kallikrein (KLKB1) DMEH7YU MA Modulator DMEH7YU RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMEH7YU RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 TI TT3ROYC DMEHCY5 TN Serotonin transporter (SERT) DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DMEHCY5 DI DMEHCY5 DMEHCY5 DN Dextromethorphan polistirex DMEHCY5 TI TT5TPI6 DMEHCY5 TN Opioid receptor sigma 1 (OPRS1) DMEHCY5 MA Modulator DMEHCY5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEHCY5 RU https://www.fda.gov/ DMEJKRF DI DMEJKRF DMEJKRF DN Motexafin gadolinium DMEJKRF TI TTLPJWH DMEJKRF TN Thioredoxin reductase (PRDX5) DMEJKRF MA Modulator DMEJKRF RN Mechanism of inhibition of ribonucleotide reductase with motexafin gadolinium (MGd). Biochem Biophys Res Commun. 2009 Feb 13;379(3):775-9. DMEJKRF RU https://pubmed.ncbi.nlm.nih.gov/19121624 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TTQOD3G DMEMBJC TN Folate receptor (FOLR) DMEMBJC MA Binder DMEMBJC RN Gamma-glutamyl hydrolase and drug resistance. Clin Chim Acta. 2006 Dec;374(1-2):25-32. DMEMBJC RU https://pubmed.ncbi.nlm.nih.gov/16859665 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TTY8Z2E DMEMBJC TN Proton-coupled folate transporter (SLC46A1) DMEMBJC MA Modulator DMEMBJC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DMEMBJC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DMEMBJC DI DMEMBJC DMEMBJC DN Folic acid DMEMBJC TI TT09I7D DMEMBJC TN Solute carrier family 19 member 1 (SLC19A1) DMEMBJC MA Modulator DMEMBJC RN Increased activity of a novel low pH folate transporter associated with lipophilic antifolate resistance in chinese hamster ovary cells. J Biol Chem. 1998 Apr 3;273(14):8106-11. DMEMBJC RU https://pubmed.ncbi.nlm.nih.gov/9525913 DMEMV9D DI DMEMV9D DMEMV9D DN Trimeprazine DMEMV9D TI TTTIBOJ DMEMV9D TN Histamine H1 receptor (H1R) DMEMV9D MA Antagonist DMEMV9D RN Effectiveness of alimemazine in controlling retching after Nissen fundoplication. J Pediatr Surg. 2005 Nov;40(11):1737-40. DMEMV9D RU https://pubmed.ncbi.nlm.nih.gov/16291162 DMEN6X7 DI DMEN6X7 DMEN6X7 DN Atropine DMEN6X7 TI TTH18TF DMEN6X7 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMEN6X7 MA Antagonist DMEN6X7 RN Additive protective effects of donepezil and nicotine against salsolinol-induced cytotoxicity in SH-SY5Y cells. Neurotox Res. 2009 Oct;16(3):194-204. DMEN6X7 RU https://pubmed.ncbi.nlm.nih.gov/19526284 DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TT8NGED DMENSL5 TN Prostaglandin G/H synthase 1 (COX-1) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TTVKILB DMENSL5 TN Prostaglandin G/H synthase 2 (COX-2) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMENSL5 DI DMENSL5 DMENSL5 DN Aminosalicylic acid DMENSL5 TI TTYZVDJ DMENSL5 TN Dihydrofolate reductase (DHFR) DMENSL5 MA Modulator DMENSL5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMENSL5 RU https://www.fda.gov/ DMEO794 DI DMEO794 DMEO794 DN Galantamine DMEO794 TI TT1RS9F DMEO794 TN Acetylcholinesterase (AChE) DMEO794 MA Inhibitor DMEO794 RN [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. DMEO794 RU https://pubmed.ncbi.nlm.nih.gov/19504422 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTF45NW DMEPWYA TN Strychnine-binding glycine receptor (GLRA1) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TT1MPAY DMEPWYA TN GABA(A) receptor alpha-1 (GABRA1) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTZA1NY DMEPWYA TN GABA(A) receptor beta-2 (GABRB2) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTZ8EM9 DMEPWYA TN Glycine receptor (GlyR) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TTNJYV2 DMEPWYA TN Gamma-aminobutyric acid receptor (GAR) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMEPWYA DI DMEPWYA DMEPWYA DN THIOCOLCHICOSIDE DMEPWYA TI TT06RH5 DMEPWYA TN GABA(A) receptor gamma-2 (GABRG2) DMEPWYA MA Inhibitor DMEPWYA RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMEPWYA RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMER9YA DI DMER9YA DMER9YA DN Galsulfase DMER9YA TI TTESQTG DMER9YA TN N-acetylgalactosamine-4-sulfatase (G4S) DMER9YA MA Modulator DMER9YA RN Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme ) therapy. J Inherit Metab Dis. 2013 Mar;36(2):385-94. DMER9YA RU https://pubmed.ncbi.nlm.nih.gov/22669363 DMETVFJ DI DMETVFJ DMETVFJ DN Omalizumab DMETVFJ TI TTDGEC0 DMETVFJ TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMETVFJ MA Modulator DMETVFJ RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMETVFJ RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMETWAU DI DMETWAU DMETWAU DN Hyaluronidase (ovine) DMETWAU TI TTYTVXF DMETWAU TN Hyaluronic acid (HA) DMETWAU MA Modulator DMETWAU RN Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol. 2005 Oct;140(4):585-97. DMETWAU RU https://pubmed.ncbi.nlm.nih.gov/16226510 DMETYK5 DI DMETYK5 DMETYK5 DN Triazolam DMETYK5 TI TTPTXIN DMETYK5 TN Translocator protein (TSPO) DMETYK5 MA Modulator DMETYK5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMETYK5 RU https://www.fda.gov/ DMEV954 DI DMEV954 DMEV954 DN Sulfinpyrazone DMEV954 TI TTOI92F DMEV954 TN Multidrug resistance-associated protein 1 (ABCC1) DMEV954 MA Modulator DMEV954 RN Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metab Dispos. 2008 Apr;36(4):631-40. DMEV954 RU https://pubmed.ncbi.nlm.nih.gov/18180270 DMEVXY6 DI DMEVXY6 DMEVXY6 DN Heparin Calcium DMEVXY6 TI TT4QPUL DMEVXY6 TN Antithrombin-III (ATIII) DMEVXY6 MA Modulator DMEVXY6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEVXY6 RU https://www.fda.gov/ DMEWC7N DI DMEWC7N DMEWC7N DN Prazepam DMEWC7N TI TTPTXIN DMEWC7N TN Translocator protein (TSPO) DMEWC7N MA Modulator DMEWC7N RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMEWC7N RU https://www.fda.gov/ DMEWUPF DI DMEWUPF DMEWUPF DN Salmon Calcitonin DMEWUPF TI TTLWS2O DMEWUPF TN Calcitonin receptor (CALCR) DMEWUPF MA Binder DMEWUPF RN Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. Peptides. 2009 Jul;30(7):1288-95. DMEWUPF RU https://pubmed.ncbi.nlm.nih.gov/19540427 DMEXMYK DI DMEXMYK DMEXMYK DN Alpelisib DMEXMYK TI TTEUNMR DMEXMYK TN PI3-kinase alpha (PIK3CA) DMEXMYK MA Inhibitor DMEXMYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMEXMYK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212526s000lbl.pdf DMEYHG9 DI DMEYHG9 DMEYHG9 DN Elotuzumab DMEYHG9 TI TT7ILZ1 DMEYHG9 TN SLAM family member 7 SLAMF7 (CS1) DMEYHG9 RN Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. DMEYHG9 RU https://pubmed.ncbi.nlm.nih.gov/25764988 DMEYLH9 DI DMEYLH9 DMEYLH9 DN Ribavirin DMEYLH9 TI TTL7C8Q DMEYLH9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMEYLH9 MA Inhibitor DMEYLH9 RN Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006 Jan;57(1):8-13. DMEYLH9 RU https://pubmed.ncbi.nlm.nih.gov/16293677 DMEZ2KH DI DMEZ2KH DMEZ2KH DN Ocrelizumab DMEZ2KH TI TTUE541 DMEZ2KH TN Leukocyte surface antigen Leu-16 (CD20) DMEZ2KH RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMEZ2KH RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMEZFXR DI DMEZFXR DMEZFXR DN Desoxyribonuclease DMEZFXR TI TT3C1VN DMEZFXR TN Enzyme unspecific (Enz) DMEZFXR MA Modulator DMEZFXR RN Preparation of the bifunctional enzyme ribonuclease-deoxyribonuclease by cross-linkage. Biochemistry. 1979 Oct 2;18(20):4449-52. DMEZFXR RU https://pubmed.ncbi.nlm.nih.gov/486431 DMF0NQR DI DMF0NQR DMF0NQR DN Eplerenone DMF0NQR TI TT26PHO DMF0NQR TN Mineralocorticoid receptor (MR) DMF0NQR MA Modulator DMF0NQR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMF0NQR RU https://www.fda.gov/ DMF1X5P DI DMF1X5P DMF1X5P DN Proflavine DMF1X5P TI TTS1W4A DMF1X5P TN Bacterial Deoxyribonucleic acid (Bact DNA) DMF1X5P MA Binder DMF1X5P RN Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19. DMF1X5P RU https://pubmed.ncbi.nlm.nih.gov/19364280 DMF28YC DI DMF28YC DMF28YC DN Atorvastatin DMF28YC TI TTPADOQ DMF28YC TN HMG-CoA reductase (HMGCR) DMF28YC MA Inhibitor DMF28YC RN Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64. DMF28YC RU https://pubmed.ncbi.nlm.nih.gov/11523064 DMF29Q5 DI DMF29Q5 DMF29Q5 DN Connexyn DMF29Q5 TI TTWG9A4 DMF29Q5 TN Adrenergic receptor alpha-2A (ADRA2A) DMF29Q5 MA Agonist DMF29Q5 RN alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51. DMF29Q5 RU https://pubmed.ncbi.nlm.nih.gov/19527774 DMF2JDG DI DMF2JDG DMF2JDG DN Dromostanolone DMF2JDG TI TTS64P2 DMF2JDG TN Androgen receptor (AR) DMF2JDG MA Binder DMF2JDG RN Endocrinological and pathological effects of anabolic-androgenic steroid in male rats. Endocr J. 2004 Aug;51(4):425-34. DMF2JDG RU https://pubmed.ncbi.nlm.nih.gov/15351799 DMF2KLU DI DMF2KLU DMF2KLU DN Oxybutynin hydrochloride DMF2KLU TI TTOXS3C DMF2KLU TN Muscarinic acetylcholine receptor (CHRM) DMF2KLU MA Modulator DMF2KLU RN Effects of propiverine hydrochloride (propiverine) on the muscarinic receptor binding affinity in guinea pig tissues and on salivation in conscious dogs. Nihon Yakurigaku Zasshi. 1999 Mar;113(3):157-66. DMF2KLU RU https://pubmed.ncbi.nlm.nih.gov/10347840 DMF3AN7 DI DMF3AN7 DMF3AN7 DN Loratadine DMF3AN7 TI TTTIBOJ DMF3AN7 TN Histamine H1 receptor (H1R) DMF3AN7 MA Antagonist DMF3AN7 RN Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6. DMF3AN7 RU https://pubmed.ncbi.nlm.nih.gov/19452709 DMF3GM2 DI DMF3GM2 DMF3GM2 DN Somatropin recombinant DMF3GM2 TI TTKMAZ6 DMF3GM2 TN Growth hormone receptor (GHR) DMF3GM2 MA Binder DMF3GM2 RN Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006 Feb;22(2):351-7. DMF3GM2 RU https://pubmed.ncbi.nlm.nih.gov/16466607 DMF3VXA DI DMF3VXA DMF3VXA DN Zotepine DMF3VXA TI TTJQOD7 DMF3VXA TN 5-HT 2A receptor (HTR2A) DMF3VXA MA Inhibitor DMF3VXA RN Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501. DMF3VXA RU https://pubmed.ncbi.nlm.nih.gov/11170639 DMF54ZG DI DMF54ZG DMF54ZG DN Sulpiride DMF54ZG TI TTEX248 DMF54ZG TN Dopamine D2 receptor (D2R) DMF54ZG MA Antagonist DMF54ZG RN The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. DMF54ZG RU https://pubmed.ncbi.nlm.nih.gov/12083990 DMF5EK1 DI DMF5EK1 DMF5EK1 DN Vilanterol DMF5EK1 TI TT2CJVK DMF5EK1 TN Adrenergic receptor beta-2 (ADRB2) DMF5EK1 MA Modulator DMF5EK1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353). DMF5EK1 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7353 DMF5HU6 DI DMF5HU6 DMF5HU6 DN Cefotiam DMF5HU6 TI TT85JMW DMF5HU6 TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMF5HU6 MA Binder DMF5HU6 RN Genetic analyses of beta-lactamase negative ampicillin-resistant strains of Haemophilus influenzae isolated in Okinawa, Japan. Jpn J Infect Dis. 2006 Feb;59(1):36-41. DMF5HU6 RU https://pubmed.ncbi.nlm.nih.gov/16495632 DMF5XQH DI DMF5XQH DMF5XQH DN Methoxamine DMF5XQH TI TTBRKXS DMF5XQH TN Adrenergic receptor alpha-1B (ADRA1B) DMF5XQH MA Stimulator DMF5XQH RN Activation of alpha1-adrenoceptors inhibits growth hormone secretion in humans. Exp Clin Endocrinol Diabetes. 2009 Oct;117(9):460-2. DMF5XQH RU https://pubmed.ncbi.nlm.nih.gov/19373756 DMF5ZB3 DI DMF5ZB3 DMF5ZB3 DN OspA lipoprotein DMF5ZB3 TI TTM6QSK DMF5ZB3 TN B-cell receptor CD22 (CD22) DMF5ZB3 MA Binder DMF5ZB3 RN Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14. DMF5ZB3 RU https://pubmed.ncbi.nlm.nih.gov/10067697 DMF6Y0L DI DMF6Y0L DMF6Y0L DN Polatuzumab vedotin DMF6Y0L TI TTBN5I7 DMF6Y0L TN B-cell-specific glycoprotein B29 (CD79B) DMF6Y0L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMF6Y0L RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761121s000lbl.pdf DMF6Z5T DI DMF6Z5T DMF6Z5T DN Glecaprevir; pibrentasvir DMF6Z5T TI TTHC7JD DMF6Z5T TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMF6Z5T MA Inhibitor DMF6Z5T RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMF6Z5T RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMF6Z5T DI DMF6Z5T DMF6Z5T DN Glecaprevir; pibrentasvir DMF6Z5T TI TTCJ2X8 DMF6Z5T TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMF6Z5T MA Inhibitor DMF6Z5T RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMF6Z5T RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMF8DNE DI DMF8DNE DMF8DNE DN Framycetin DMF8DNE TI TTQ8KVI DMF8DNE TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMF8DNE MA Binder DMF8DNE RN Characterization of a 30S ribosomal subunit assembly intermediate found in Escherichia coli cells growing with neomycin or paromomycin. Arch Microbiol. 2008 May;189(5):441-9. DMF8DNE RU https://pubmed.ncbi.nlm.nih.gov/18060665 DMF8DNE DI DMF8DNE DMF8DNE DN Framycetin DMF8DNE TI TT38DW5 DMF8DNE TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMF8DNE MA Binder DMF8DNE RN Antistaphylococcal activity of gentamicin. Minerva Med. 1975 Dec 8;66(84):4505-26. DMF8DNE RU https://pubmed.ncbi.nlm.nih.gov/1105242 DMF8Y74 DI DMF8Y74 DMF8Y74 DN Hydroxyzine DMF8Y74 TI TTTIBOJ DMF8Y74 TN Histamine H1 receptor (H1R) DMF8Y74 MA Antagonist DMF8Y74 RN Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient ... J Pharmacol Sci. 2008 Dec;108(4):462-71. DMF8Y74 RU https://pubmed.ncbi.nlm.nih.gov/19057127 DMF9G7L DI DMF9G7L DMF9G7L DN Dibucaine DMF9G7L TI TTZOVE0 DMF9G7L TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMF9G7L MA Blocker DMF9G7L RN Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. DMF9G7L RU https://pubmed.ncbi.nlm.nih.gov/12354567 DMF9O6B DI DMF9O6B DMF9O6B DN Gallium nitrate DMF9O6B TI TTRYK0X DMF9O6B TN Interleukin-1 beta (IL1B) DMF9O6B MA Inhibitor DMF9O6B RN Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and revie... Med Hypotheses. 2005;65(6):1136-41. DMF9O6B RU https://pubmed.ncbi.nlm.nih.gov/16122880 DMFA5MY DI DMFA5MY DMFA5MY DN Metoclopramide DMFA5MY TI TTEX248 DMFA5MY TN Dopamine D2 receptor (D2R) DMFA5MY MA Antagonist DMFA5MY RN Mechanisms for metoclopramide-mediated sensitization and haloperidol-induced catalepsy in rats. Eur J Pharmacol. 2008 Jun 10;587(1-3):181-6. DMFA5MY RU https://pubmed.ncbi.nlm.nih.gov/18457824 DMFA9MV DI DMFA9MV DMFA9MV DN Efinaconazole DMFA9MV TI TTTSOUD DMFA9MV TN Candida Cytochrome P450 51 (Candi ERG11) DMFA9MV MA Inhibitor DMFA9MV RN Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. Reprod Toxicol. 2015 Apr;52:18-25. DMFA9MV RU https://pubmed.ncbi.nlm.nih.gov/25527861 DMFAOKP DI DMFAOKP DMFAOKP DN Fenoldopam DMFAOKP TI TTZFYLI DMFAOKP TN Dopamine D1 receptor (D1R) DMFAOKP MA Agonist DMFAOKP RN Etiology of iodinated radiocontrast nephrotoxicity and its attenuation by beraprost. Yakugaku Zasshi. 2008 Jul;128(7):1023-9. DMFAOKP RU https://pubmed.ncbi.nlm.nih.gov/18591870 DMFB97P DI DMFB97P DMFB97P DN Dihydrotachysterol DMFB97P TI TTK59TV DMFB97P TN Vitamin D3 receptor (VDR) DMFB97P MA Antagonist DMFB97P RN In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1 alpha,25- and 1 beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem. 1993 Jan 5;268(1):282-92. DMFB97P RU https://pubmed.ncbi.nlm.nih.gov/8380156 DMFC41K DI DMFC41K DMFC41K DN Tafluprost DMFC41K TI TTT2ZAR DMFC41K TN Prostaglandin F2-alpha receptor (PTGFR) DMFC41K MA Modulator DMFC41K RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMFC41K RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMFC71L DI DMFC71L DMFC71L DN Clozapine DMFC71L TI TTE0A2F DMFC71L TN Dopamine D4 receptor (D4R) DMFC71L MA Modulator DMFC71L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFC71L RU https://www.fda.gov/ DMFCLYW DI DMFCLYW DMFCLYW DN Moxisylyte DMFCLYW TI TT34BHT DMFCLYW TN Adrenergic receptor alpha-1D (ADRA1D) DMFCLYW MA Modulator DMFCLYW RN Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5. DMFCLYW RU https://pubmed.ncbi.nlm.nih.gov/8866639 DMFD9Q6 DI DMFD9Q6 DMFD9Q6 DN Cetrorelix DMFD9Q6 TI TT8R70G DMFD9Q6 TN Gonadotropin-releasing hormone receptor (GNRHR) DMFD9Q6 MA Antagonist DMFD9Q6 RN Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 2009 Jul 1;69(10):1025-33. DMFD9Q6 RU https://pubmed.ncbi.nlm.nih.gov/19301301 DMFDC0Q DI DMFDC0Q DMFDC0Q DN Tiotropium DMFDC0Q TI TTQ13Z5 DMFDC0Q TN Muscarinic acetylcholine receptor M3 (CHRM3) DMFDC0Q MA Antagonist DMFDC0Q RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMFDC0Q RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMFDC0Q DI DMFDC0Q DMFDC0Q DN Tiotropium DMFDC0Q TI TTOXS3C DMFDC0Q TN Muscarinic acetylcholine receptor (CHRM) DMFDC0Q MA Antagonist DMFDC0Q RN Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70. DMFDC0Q RU https://pubmed.ncbi.nlm.nih.gov/23435542 DMFEGB0 DI DMFEGB0 DMFEGB0 DN Segesterone acetate; ethinyl estradiol DMFEGB0 TI TTUV8G9 DMFEGB0 TN Progesterone receptor (PGR) DMFEGB0 MA Modulator DMFEGB0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMFEGB0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMFEGB0 DI DMFEGB0 DMFEGB0 DN Segesterone acetate; ethinyl estradiol DMFEGB0 TI TTDSB34 DMFEGB0 TN G-protein coupled estrogen receptor 1 (GPER1) DMFEGB0 MA Modulator DMFEGB0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMFEGB0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMFEHXD DI DMFEHXD DMFEHXD DN Natamycin DMFEHXD TI TTAH0B3 DMFEHXD TN Fungal Cell membrane (Fung CM) DMFEHXD MA Binder DMFEHXD RN Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401. DMFEHXD RU https://pubmed.ncbi.nlm.nih.gov/18165687 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK TI TTZVSJ2 DMFETDK TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMFETDK MA Inhibitor DMFETDK RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMFETDK DI DMFETDK DMFETDK DN Artemisinin SP DMFETDK TI TTAN6JD DMFETDK TN Glutamate receptor AMPA (GRIA) DMFETDK MA Agonist DMFETDK RN GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32. DMFETDK RU https://pubmed.ncbi.nlm.nih.gov/12171573 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 TI TTP86E2 DMFGND4 TN Plasminogen (PLG) DMFGND4 MA Inhibitor DMFGND4 RN The blockage of the high-affinity lysine binding sites of plasminogen by EACA significantly inhibits prourokinase-induced plasminogen activation. Biochim Biophys Acta. 2002 Apr 29;1596(2):182-92. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/12007600 DMFGND4 DI DMFGND4 DMFGND4 DN Aminocaproic acid DMFGND4 TI TTXAGYU DMFGND4 TN Tissue-type plasminogen activator (PLAT) DMFGND4 MA Inhibitor DMFGND4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFGND4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFGQ2S DI DMFGQ2S DMFGQ2S DN Erythrityl Tetranitrate DMFGQ2S TI TT6HPVC DMFGQ2S TN Guanylate cyclase (GC) DMFGQ2S MA Stimulator DMFGQ2S RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMFGQ2S RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMFH15Z DI DMFH15Z DMFH15Z DN Bendamustine hydrochloride DMFH15Z TI TTUTN1I DMFH15Z TN Human Deoxyribonucleic acid (hDNA) DMFH15Z MA Modulator DMFH15Z RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMFH15Z RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMFI46A DI DMFI46A DMFI46A DN Argatroban DMFI46A TI TT6L509 DMFI46A TN Coagulation factor IIa (F2) DMFI46A MA Inhibitor DMFI46A RN Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44. DMFI46A RU https://pubmed.ncbi.nlm.nih.gov/12496240 DMFI8A7 DI DMFI8A7 DMFI8A7 DN Tranexamic acid DMFI8A7 TI TTP86E2 DMFI8A7 TN Plasminogen (PLG) DMFI8A7 MA Inhibitor DMFI8A7 RN Evaluation of aprotinin and tranexamic acid in different in vitro and in vivo models of fibrinolysis, coagulation and thrombus formation. J Thromb Haemost. 2007 Oct;5(10):2113-8. DMFI8A7 RU https://pubmed.ncbi.nlm.nih.gov/17666018 DMFIC0M DI DMFIC0M DMFIC0M DN Cinalukast DMFIC0M TI TTGKOY9 DMFIC0M TN Leukotriene CysLT1 receptor (CYSLTR1) DMFIC0M MA Antagonist DMFIC0M RN Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. J Allergy Clin Immunol. 1997 Feb;99(2):210-5. DMFIC0M RU https://pubmed.ncbi.nlm.nih.gov/9042047 DMFIQ2H DI DMFIQ2H DMFIQ2H DN Migalastat DMFIQ2H TI TTIS03D DMFIQ2H TN Alpha-galactosidase A (GLA) DMFIQ2H MA Modulator DMFIQ2H RN AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br J Pharmacol. 2015 Apr;172(7):1834-45. DMFIQ2H RU https://pubmed.ncbi.nlm.nih.gov/25440006 DMFJ2OG DI DMFJ2OG DMFJ2OG DN Collagenase DMFJ2OG TI TTK982E DMFJ2OG TN Collagen (CO) DMFJ2OG MA Breaker DMFJ2OG RN Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2. DMFJ2OG RU https://pubmed.ncbi.nlm.nih.gov/17577383 DMFJ8LT DI DMFJ8LT DMFJ8LT DN Ibutamoren DMFJ8LT TI TTWDC17 DMFJ8LT TN Growth hormone secretagogue receptor 1 (GHSR) DMFJ8LT MA Modulator DMFJ8LT RN Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):7001-5. DMFJ8LT RU https://www.ncbi.nlm.nih.gov/pubmed/7624358 DMFJH5Q DI DMFJH5Q DMFJH5Q DN Mephentermine DMFJH5Q TI TTEX248 DMFJH5Q TN Dopamine D2 receptor (D2R) DMFJH5Q MA Agonist DMFJH5Q RN Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. DMFJH5Q RU https://pubmed.ncbi.nlm.nih.gov/10722 DMFJTDI DI DMFJTDI DMFJTDI DN Sibutramine DMFJTDI TI TTAWNKZ DMFJTDI TN Norepinephrine transporter (NET) DMFJTDI MA Modulator DMFJTDI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFJTDI RU https://www.fda.gov/ DMFJTDI DI DMFJTDI DMFJTDI DN Sibutramine DMFJTDI TI TT3ROYC DMFJTDI TN Serotonin transporter (SERT) DMFJTDI MA Modulator DMFJTDI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFJTDI RU https://www.fda.gov/ DMFJZN0 DI DMFJZN0 DMFJZN0 DN Romosozumab DMFJZN0 TI TTYRO4F DMFJZN0 TN Sclerostin (SOST) DMFJZN0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMFJZN0 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761062s000lbl.pdf DMFK9HG DI DMFK9HG DMFK9HG DN Escitalopram DMFK9HG TI TT3ROYC DMFK9HG TN Serotonin transporter (SERT) DMFK9HG MA Inhibitor DMFK9HG RN Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7. DMFK9HG RU https://pubmed.ncbi.nlm.nih.gov/19566691 DMFKXDY DI DMFKXDY DMFKXDY DN Fenofibrate DMFKXDY TI TTJ584C DMFKXDY TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFKXDY MA Agonist DMFKXDY RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMFKXDY RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMFLUTR DI DMFLUTR DMFLUTR DN Glucagon recombinant DMFLUTR TI TT9O6WS DMFLUTR TN Glucagon receptor (GCGR) DMFLUTR MA Binder DMFLUTR RN Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70. DMFLUTR RU https://pubmed.ncbi.nlm.nih.gov/17462598 DMFMBZ4 DI DMFMBZ4 DMFMBZ4 DN Zanamivir DMFMBZ4 TI TT50QJ3 DMFMBZ4 TN Influenza Neuraminidase (Influ NA) DMFMBZ4 MA Inhibitor DMFMBZ4 RN Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. DMFMBZ4 RU https://pubmed.ncbi.nlm.nih.gov/18328578 DMFMDOB DI DMFMDOB DMFMDOB DN Carteolol DMFMDOB TI TTR6W5O DMFMDOB TN Adrenergic receptor beta-1 (ADRB1) DMFMDOB MA Agonist DMFMDOB RN Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. DMFMDOB RU https://pubmed.ncbi.nlm.nih.gov/11138729 DMFMZ3G DI DMFMZ3G DMFMZ3G DN Choriogonadotropin alfa DMFMZ3G TI TT2O4W9 DMFMZ3G TN Luteinizing hormone receptor (LHCGR) DMFMZ3G MA Modulator DMFMZ3G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFMZ3G RU https://www.fda.gov/ DMFN07X DI DMFN07X DMFN07X DN Nilutamide DMFN07X TI TTS64P2 DMFN07X TN Androgen receptor (AR) DMFN07X MA Antagonist DMFN07X RN CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res. 2008 Mar 15;68(6):1715-22. DMFN07X RU https://pubmed.ncbi.nlm.nih.gov/18339851 DMFNAEM DI DMFNAEM DMFNAEM DN Sulfaphenazole DMFNAEM TI TTR40YJ DMFNAEM TN S-mephenytoin 4-hydroxylase (CYP2C9) DMFNAEM MA Modulator DMFNAEM RN Identification of amino acid substitutions that confer a high affinity for sulfaphenazole binding and a high catalytic efficiency for warfarin meta... Biochemistry. 1998 Nov 17;37(46):16270-9. DMFNAEM RU https://www.ncbi.nlm.nih.gov/pubmed/9819219 DMFNH7L DI DMFNH7L DMFNH7L DN Pentobarbital DMFNH7L TI TT1MPAY DMFNH7L TN GABA(A) receptor alpha-1 (GABRA1) DMFNH7L MA Antagonist DMFNH7L RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMFNH7L RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMFO843 DI DMFO843 DMFO843 DN Fluspirilene DMFO843 TI TTEX248 DMFO843 TN Dopamine D2 receptor (D2R) DMFO843 MA Antagonist DMFO843 RN Inhibition of glutamate release by fluspirilene in cerebrocortical nerve terminals (synaptosomes). Synapse. 2002 Apr;44(1):36-41. DMFO843 RU https://pubmed.ncbi.nlm.nih.gov/11842444 DMFOIA8 DI DMFOIA8 DMFOIA8 DN Nesiritide DMFOIA8 TI TTJME02 DMFOIA8 TN Atrial natriuretic peptide receptor A (NPR1) DMFOIA8 MA Binder DMFOIA8 RN The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb;19(2):391-9. DMFOIA8 RU https://pubmed.ncbi.nlm.nih.gov/14736964 DMFOTZ7 DI DMFOTZ7 DMFOTZ7 DN Racecadotril DMFOTZ7 TI TT8CYO4 DMFOTZ7 TN Endopeptidase (ENP) DMFOTZ7 MA Modulator DMFOTZ7 RN A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol. 2012 May 30;3:93. DMFOTZ7 RU https://pubmed.ncbi.nlm.nih.gov/22661949 DMFOVSD DI DMFOVSD DMFOVSD DN Brompheniramine DMFOVSD TI TTTIBOJ DMFOVSD TN Histamine H1 receptor (H1R) DMFOVSD MA Antagonist DMFOVSD RN Histamine-induced venodilation in human beings involves both H1 and H2 receptor subtypes. J Allergy Clin Immunol. 1994 Mar;93(3):606-14. DMFOVSD RU https://pubmed.ncbi.nlm.nih.gov/8151062 DMFP6MV DI DMFP6MV DMFP6MV DN Fidaxomicin DMFP6MV TI TTIJ5EB DMFP6MV TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMFP6MV MA Modulator DMFP6MV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMFP6MV RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMFQ320 DI DMFQ320 DMFQ320 DN Ipratropium DMFQ320 TI TTQ13Z5 DMFQ320 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMFQ320 MA Modulator DMFQ320 RN Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69. DMFQ320 RU https://www.ncbi.nlm.nih.gov/pubmed/22767057 DMFQCB1 DI DMFQCB1 DMFQCB1 DN Dicumarol DMFQCB1 TI TTEUC8H DMFQCB1 TN Vitamin K epoxide reductase complex 1 (VKORC1) DMFQCB1 MA Inhibitor DMFQCB1 RN Vitamin K antagonism of coumarin intoxication in the rat. Thromb Haemost. 1986 Apr 30;55(2):235-9. DMFQCB1 RU https://pubmed.ncbi.nlm.nih.gov/2424118 DMFQEA6 DI DMFQEA6 DMFQEA6 DN Pembrolizumab DMFQEA6 TI TTNBFWK DMFQEA6 TN Programmed cell death protein 1 (PD-1) DMFQEA6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMFQEA6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMFR201 DI DMFR201 DMFR201 DN Vibegron DMFR201 TI TTMXGCW DMFR201 TN Adrenergic receptor beta-3 (ADRB3) DMFR201 MA Agonist DMFR201 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMFR201 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213006s000lbl.pdf DMFRM1I DI DMFRM1I DMFRM1I DN Canagliflozin DMFRM1I TI TTLWPVF DMFRM1I TN Sodium/glucose cotransporter 2 (SGLT2) DMFRM1I MA Modulator DMFRM1I RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMFRM1I RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMFS63G DI DMFS63G DMFS63G DN Enfortumab DMFS63G TI TTPO9EG DMFS63G TN Nectin cell adhesion molecule 4 (NECTIN4) DMFS63G MA Inhibitor DMFS63G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMFS63G RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf DMFSWGH DI DMFSWGH DMFSWGH DN Econazole DMFSWGH TI TTTSOUD DMFSWGH TN Candida Cytochrome P450 51 (Candi ERG11) DMFSWGH MA Inhibitor DMFSWGH RN Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603. DMFSWGH RU https://pubmed.ncbi.nlm.nih.gov/18694951 DMFT73E DI DMFT73E DMFT73E DN Chorionic Gonadotropin DMFT73E TI TT2O4W9 DMFT73E TN Luteinizing hormone receptor (LHCGR) DMFT73E MA Modulator DMFT73E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMFT73E RU https://www.fda.gov/ DMFUAXT DI DMFUAXT DMFUAXT DN H1N1 pandemic influenza A vaccine DMFUAXT TI TT3J5ZI DMFUAXT TN Cell mediated immunity response (CMIR) DMFUAXT RN How Influenza (Flu) Vaccines Are Made. FLU.gov. 2014. DMFUAXT RU http://www.flu.gov/about_the_flu/h1n1/ DMFWKG1 DI DMFWKG1 DMFWKG1 DN Nandrolone DMFWKG1 TI TTS64P2 DMFWKG1 TN Androgen receptor (AR) DMFWKG1 MA Agonist DMFWKG1 RN Expression of androgen receptor on fibroblast and hepatocyte of rats after deep second-degree burn caused by scalding. Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 May;36(3):362-4. DMFWKG1 RU https://pubmed.ncbi.nlm.nih.gov/15931869 DMFX9O6 DI DMFX9O6 DMFX9O6 DN SM-101 DMFX9O6 TI TTXT21W DMFX9O6 TN Immunoglobulin gamma Fc receptor IIA (FCGR2A) DMFX9O6 MA Antagonist DMFX9O6 RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMFX9O6 RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMFX9O6 DI DMFX9O6 DMFX9O6 DN SM-101 DMFX9O6 TI TTYT93M DMFX9O6 TN MAP kinase p38 (MAPK12) DMFX9O6 MA Inhibitor DMFX9O6 RN Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. DMFX9O6 RU https://pubmed.ncbi.nlm.nih.gov/18764722 DMFXEWT DI DMFXEWT DMFXEWT DN Chloramphenicol DMFXEWT TI TTLFGBV DMFXEWT TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMFXEWT MA Binder DMFXEWT RN Inhibition of peptide bond formation by pleuromutilins: the structure of the 50S ribosomal subunit from Deinococcus radiodurans in complex with tiamulin. Mol Microbiol. 2004 Dec;54(5):1287-94. DMFXEWT RU https://pubmed.ncbi.nlm.nih.gov/15554968 DMFY307 DI DMFY307 DMFY307 DN Hexafluronium bromide DMFY307 TI TTEB0GD DMFY307 TN Cholinesterase (BCHE) DMFY307 MA Inhibitor DMFY307 RN Synergistic effect of acidosis and succinylcholine-induced hyperkalemia in spinal cord transected rats. Acta Anaesthesiol Scand. 1984 Feb;28(1):87-90. DMFY307 RU https://pubmed.ncbi.nlm.nih.gov/6711267 DMFYBD0 DI DMFYBD0 DMFYBD0 DN Dexibuprofen DMFYBD0 TI TTK0943 DMFYBD0 TN Prostaglandin G/H synthase (COX) DMFYBD0 MA Modulator DMFYBD0 RN Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64. DMFYBD0 RU https://pubmed.ncbi.nlm.nih.gov/12708604 DMFYZKN DI DMFYZKN DMFYZKN DN Enprofylline DMFYZKN TI TTZ97H5 DMFYZKN TN Phosphodiesterase 4A (PDE4A) DMFYZKN MA Inhibitor DMFYZKN RN Effects of enprofylline, a new xanthine derivate, on human pregnant myometrium. Am J Obstet Gynecol. 1987 Apr;156(4):958-62. DMFYZKN RU https://pubmed.ncbi.nlm.nih.gov/3034059 DMFZBMQ DI DMFZBMQ DMFZBMQ DN Chloroxine DMFZBMQ TI TTQW87Y DMFZBMQ TN Opioid receptor kappa (OPRK1) DMFZBMQ MA Inhibitor DMFZBMQ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMFZBMQ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K TI TT84ETX DMG0H8K TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMG0H8K DI DMG0H8K DMG0H8K DN Bictegravir, emtricitabine and tenofovir alafenamide DMG0H8K TI TT5FH9Y DMG0H8K TN Human immunodeficiency virus Integrase (HIV IN) DMG0H8K MA Inhibitor DMG0H8K RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMG0H8K RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMG1DTE DI DMG1DTE DMG1DTE DN Penfluridol DMG1DTE TI TT729IR DMG1DTE TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMG1DTE MA Blocker DMG1DTE RN Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. DMG1DTE RU https://pubmed.ncbi.nlm.nih.gov/11784784 DMG281S DI DMG281S DMG281S DN Carboplatin DMG281S TI TTUTN1I DMG281S TN Human Deoxyribonucleic acid (hDNA) DMG281S MA Modulator DMG281S RN Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905. DMG281S RU https://www.ncbi.nlm.nih.gov/pubmed/20719935 DMG2KI4 DI DMG2KI4 DMG2KI4 DN Fluocinolone acetonide DMG2KI4 TI TTYRL6O DMG2KI4 TN Glucocorticoid receptor (NR3C1) DMG2KI4 MA Modulator DMG2KI4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG2KI4 RU https://www.fda.gov/ DMG2KW7 DI DMG2KW7 DMG2KW7 DN Menthol DMG2KW7 TI TTELV3W DMG2KW7 TN Transformation-sensitive protein p120 (TRPA1) DMG2KW7 MA Activator DMG2KW7 RN TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10. DMG2KW7 RU https://pubmed.ncbi.nlm.nih.gov/19220220 DMG2KW7 DI DMG2KW7 DMG2KW7 DN Menthol DMG2KW7 TI TTXDKTO DMG2KW7 TN Long transient receptor potential channel 8 (TRPM8) DMG2KW7 MA Activator DMG2KW7 RN TRPV1-mediated itch in seasonal allergic rhinitis. Allergy. 2009 May;64(5):807-10. DMG2KW7 RU https://pubmed.ncbi.nlm.nih.gov/19220220 DMG2SKR DI DMG2SKR DMG2SKR DN Tedizolid DMG2SKR TI TTUWYEA DMG2SKR TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMG2SKR MA Modulator DMG2SKR RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMG2SKR RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMG2YBD DI DMG2YBD DMG2YBD DN Trifluridine DMG2YBD TI TTU6BFZ DMG2YBD TN Candida Thymidylate synthase (Candi TMP1) DMG2YBD MA Inhibitor DMG2YBD RN Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703. DMG2YBD RU https://pubmed.ncbi.nlm.nih.gov/18600528 DMG3F94 DI DMG3F94 DMG3F94 DN Mestranol DMG3F94 TI TTZAYWL DMG3F94 TN Estrogen receptor (ESR) DMG3F94 MA Agonist DMG3F94 RN Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9. DMG3F94 RU https://pubmed.ncbi.nlm.nih.gov/18374427 DMG592Q DI DMG592Q DMG592Q DN Solifenacin DMG592Q TI TTQ13Z5 DMG592Q TN Muscarinic acetylcholine receptor M3 (CHRM3) DMG592Q MA Antagonist DMG592Q RN Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. DMG592Q RU https://pubmed.ncbi.nlm.nih.gov/19446545 DMG594T DI DMG594T DMG594T DN Ibritumomab DMG594T TI TTUE541 DMG594T TN Leukocyte surface antigen Leu-16 (CD20) DMG594T RN Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. DMG594T RU https://pubmed.ncbi.nlm.nih.gov/19427037 DMG60XN DI DMG60XN DMG60XN DN Phentermine DMG60XN TI TTAWNKZ DMG60XN TN Norepinephrine transporter (NET) DMG60XN MA Inhibitor DMG60XN RN Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. DMG60XN RU https://pubmed.ncbi.nlm.nih.gov/11060745 DMG629M DI DMG629M DMG629M DN Rivastigmine DMG629M TI TT1RS9F DMG629M TN Acetylcholinesterase (AChE) DMG629M MA Modulator DMG629M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMG629M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMG6OYJ DI DMG6OYJ DMG6OYJ DN Lorcaserin DMG6OYJ TI TTWJBZ5 DMG6OYJ TN 5-HT 2C receptor (HTR2C) DMG6OYJ MA Agonist DMG6OYJ RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMG6OYJ RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMG6ZU4 DI DMG6ZU4 DMG6ZU4 DN Lanreotide acetate DMG6ZU4 TI TTZ6T9E DMG6ZU4 TN Somatostatin receptor type 2 (SSTR2) DMG6ZU4 MA Modulator DMG6ZU4 RN Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. DMG6ZU4 RU https://pubmed.ncbi.nlm.nih.gov/16262568 DMG7SQK DI DMG7SQK DMG7SQK DN Rescinnamine DMG7SQK TI TTL69WB DMG7SQK TN Angiotensin-converting enzyme (ACE) DMG7SQK MA Inhibitor DMG7SQK RN Colorimetric determination of indolic drugs. Pak J Pharm Sci. 2005 Apr;18(2):48-51. DMG7SQK RU https://pubmed.ncbi.nlm.nih.gov/16431399 DMG814N DI DMG814N DMG814N DN Saquinavir DMG814N TI TT5FNQT DMG814N TN Human immunodeficiency virus Protease (HIV PR) DMG814N MA Inhibitor DMG814N RN PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. J Med Virol. 2008 Dec;80(12):2053-63. DMG814N RU https://pubmed.ncbi.nlm.nih.gov/19040279 DMG8K57 DI DMG8K57 DMG8K57 DN Cortisone acetate DMG8K57 TI TTP3UTW DMG8K57 TN Steroid hormone receptor ERR (ESRR) DMG8K57 MA Modulator DMG8K57 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMG8K57 RU https://www.fda.gov/ DMG8MLJ DI DMG8MLJ DMG8MLJ DN Pneumococcal 13-valent conjugate vaccine DMG8MLJ TI TTY4IQ9 DMG8MLJ TN Corynebacterium Mutated CRM197 (Cory mTOX) DMG8MLJ MA Binder DMG8MLJ RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMG8MLJ RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMG9B1U DI DMG9B1U DMG9B1U DN Elvitegravir DMG9B1U TI TT5FH9Y DMG9B1U TN Human immunodeficiency virus Integrase (HIV IN) DMG9B1U MA Modulator DMG9B1U RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMG9B1U RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMG9HIA DI DMG9HIA DMG9HIA DN Urofollitropin DMG9HIA TI TTZFDBT DMG9HIA TN Follicle-stimulating hormone receptor (FSHR) DMG9HIA MA Binder DMG9HIA RN Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol. 2004;3(3):161-71. DMG9HIA RU https://pubmed.ncbi.nlm.nih.gov/16026112 DMGA9X0 DI DMGA9X0 DMGA9X0 DN Sodium nitroprusside DMGA9X0 TI TT23PYC DMGA9X0 TN Soluble guanylate cyclase (GCS) DMGA9X0 MA Modulator DMGA9X0 RN Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications.Crit Care Res Pract.2012;2012:290805. DMGA9X0 RU https://www.ncbi.nlm.nih.gov/pubmed/22482042 DMGAZHU DI DMGAZHU DMGAZHU DN Quattvaxem DMGAZHU TI TT3J5ZI DMGAZHU TN Cell mediated immunity response (CMIR) DMGAZHU RN Double-blind study comparing the immunogenicity of a licensed DTwPHib-CRM197 conjugate vaccine (Quattvaxem) with three investigational, liquid formulations using lower doses of Hib-CRM197 conjugate. Vaccine. 2005 Feb 25;23(14):1715-9. DMGAZHU RU https://pubmed.ncbi.nlm.nih.gov/15705477 DMGB035 DI DMGB035 DMGB035 DN Armodafinil DMGB035 TI TT34BHT DMGB035 TN Adrenergic receptor alpha-1D (ADRA1D) DMGB035 MA Agonist DMGB035 RN Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364. DMGB035 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2654794/ DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TT3WG5C DMGB5RE TN Monoamine oxidase type A (MAO-A) DMGB5RE MA Inhibitor DMGB5RE RN Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11. DMGB5RE RU https://pubmed.ncbi.nlm.nih.gov/19275775 DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TTGP7BY DMGB5RE TN Monoamine oxidase type B (MAO-B) DMGB5RE MA Inhibitor DMGB5RE RN Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73. DMGB5RE RU https://pubmed.ncbi.nlm.nih.gov/16927039 DMGB5RE DI DMGB5RE DMGB5RE DN Tranylcypromine DMGB5RE TI TT32XQJ DMGB5RE TN Monoamine oxidase (MAO) DMGB5RE MA Inhibitor DMGB5RE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMGB5RE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMGBKVD DI DMGBKVD DMGBKVD DN Gamma hydroxybutyric acid DMGBKVD TI TTDCVZW DMGBKVD TN Gamma-aminobutyric acid B receptor (GABBR) DMGBKVD MA Modulator DMGBKVD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGBKVD RU https://www.fda.gov/ DMGBPSH DI DMGBPSH DMGBPSH DN Homatropine Methylbromide DMGBPSH TI TTH18TF DMGBPSH TN Muscarinic acetylcholine receptor M5 (CHRM5) DMGBPSH MA Antagonist DMGBPSH RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMGBPSH RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMGC5DB DI DMGC5DB DMGC5DB DN Ciprofibrate DMGC5DB TI TTJ584C DMGC5DB TN Peroxisome proliferator-activated receptor alpha (PPARA) DMGC5DB MA Agonist DMGC5DB RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMGC5DB RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMGCHDS DI DMGCHDS DMGCHDS DN Sulfamethizole DMGCHDS TI TT4ILYC DMGCHDS TN Bacterial Dihydropteroate synthetase (Bact folP) DMGCHDS MA Inhibitor DMGCHDS RN Inhibition of bioluminescence in Photobacterium phosphoreum by sulfamethizole and its stimulation by thymine. Biochim Biophys Acta. 1990 Jun 26;1017(3):229-34. DMGCHDS RU https://pubmed.ncbi.nlm.nih.gov/2372557 DMGCSVF DI DMGCSVF DMGCSVF DN Fluticasone DMGCSVF TI TTYRL6O DMGCSVF TN Glucocorticoid receptor (NR3C1) DMGCSVF MA Antagonist DMGCSVF RN Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60. DMGCSVF RU https://pubmed.ncbi.nlm.nih.gov/18536783 DMGD3YH DI DMGD3YH DMGD3YH DN Naldemedine Tosylate DMGD3YH TI TTKWM86 DMGD3YH TN Opioid receptor mu (MOP) DMGD3YH MA Antagonist DMGD3YH RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMGD3YH RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMGDKXN DI DMGDKXN DMGDKXN DN Sitagliptin DMGDKXN TI TTDIGC1 DMGDKXN TN Dipeptidyl peptidase 4 (DPP-4) DMGDKXN MA Inhibitor DMGDKXN RN Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38. DMGDKXN RU https://pubmed.ncbi.nlm.nih.gov/19545590 DMGE0CW DI DMGE0CW DMGE0CW DN Glutethimide DMGE0CW TI TTVG215 DMGE0CW TN Debrisoquine 4-hydroxylase (CYP2D6) DMGE0CW MA Inducer DMGE0CW RN A study of the effects of large doses of glutethimide that were used for self-poisoning during pregnancy on human fetuses. Toxicol Ind Health. 2008 Feb-Mar;24(1-2):69-78. DMGE0CW RU https://pubmed.ncbi.nlm.nih.gov/18818183 DMGEATB DI DMGEATB DMGEATB DN Siltuximab DMGEATB TI TTT1V78 DMGEATB TN Interleukin-6 (IL6) DMGEATB RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGEATB RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ TI TTW640A DMGECIJ TN B-lymphocyte surface antigen B4 (CD19) DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGECIJ DI DMGECIJ DMGECIJ DN Blinatumomab DMGECIJ TI TTUN7MC DMGECIJ TN T-cell surface glycoprotein CD3 (CD3) DMGECIJ MA Modulator DMGECIJ RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMGECIJ RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMGEMB7 DI DMGEMB7 DMGEMB7 DN Hydrocortisone DMGEMB7 TI TTYRL6O DMGEMB7 TN Glucocorticoid receptor (NR3C1) DMGEMB7 MA Modulator DMGEMB7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGEMB7 RU https://www.fda.gov/ DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TTWG9A4 DMGFB0E TN Adrenergic receptor alpha-2A (ADRA2A) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TT2NUT5 DMGFB0E TN Adrenergic receptor alpha-2C (ADRA2C) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFB0E DI DMGFB0E DMGFB0E DN MOXONIDINE DMGFB0E TI TTWM4TY DMGFB0E TN Adrenergic receptor alpha-2B (ADRA2B) DMGFB0E MA Inhibitor DMGFB0E RN Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5. DMGFB0E RU https://pubmed.ncbi.nlm.nih.gov/8632424 DMGFPU2 DI DMGFPU2 DMGFPU2 DN Linezolid DMGFPU2 TI TTLFGBV DMGFPU2 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMGFPU2 MA Binder DMGFPU2 RN Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance. Genome Res. 2009 Jul;19(7):1214-23. DMGFPU2 RU https://pubmed.ncbi.nlm.nih.gov/19351617 DMGFV3Z DI DMGFV3Z DMGFV3Z DN Nizatidine DMGFV3Z TI TTQHJ1K DMGFV3Z TN Histamine H2 receptor (H2R) DMGFV3Z MA Antagonist DMGFV3Z RN Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7. DMGFV3Z RU https://pubmed.ncbi.nlm.nih.gov/18979143 DMGFWSM DI DMGFWSM DMGFWSM DN Zaleplon DMGFWSM TI TT1MPAY DMGFWSM TN GABA(A) receptor alpha-1 (GABRA1) DMGFWSM MA Modulator DMGFWSM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGFWSM RU https://www.fda.gov/ DMGIZF5 DI DMGIZF5 DMGIZF5 DN Hydroxyflutamide DMGIZF5 TI TTS64P2 DMGIZF5 TN Androgen receptor (AR) DMGIZF5 MA Antagonist DMGIZF5 RN Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. DMGIZF5 RU https://pubmed.ncbi.nlm.nih.gov/17392714 DMGKT2L DI DMGKT2L DMGKT2L DN Pro-urokinase DMGKT2L TI TTGY7WI DMGKT2L TN Urokinase-type plasminogen activator (PLAU) DMGKT2L MA Modulator DMGKT2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393). DMGKT2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393 DMGKV9D DI DMGKV9D DMGKV9D DN Hydroxocobalamin DMGKV9D TI TTCQ21Y DMGKV9D TN Methylmalonyl-CoA mutase (MMUT) DMGKV9D MA Cofactor DMGKV9D RN Vitamin B12. Nippon Rinsho. 1999 Oct;57(10):2205-10. DMGKV9D RU https://pubmed.ncbi.nlm.nih.gov/10540863 DMGL19D DI DMGL19D DMGL19D DN Enzalutamide DMGL19D TI TTS64P2 DMGL19D TN Androgen receptor (AR) DMGL19D MA Modulator DMGL19D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMGL19D RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMGLAX1 DI DMGLAX1 DMGLAX1 DN Halcinonide DMGLAX1 TI TTP3UTW DMGLAX1 TN Steroid hormone receptor ERR (ESRR) DMGLAX1 MA Modulator DMGLAX1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGLAX1 RU https://www.fda.gov/ DMGLP6S DI DMGLP6S DMGLP6S DN Sarpogrelate DMGLP6S TI TTJQOD7 DMGLP6S TN 5-HT 2A receptor (HTR2A) DMGLP6S MA Antagonist DMGLP6S RN Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30. DMGLP6S RU https://pubmed.ncbi.nlm.nih.gov/19557588 DMGLUQS DI DMGLUQS DMGLUQS DN Rilonacept DMGLUQS TI TTRYK0X DMGLUQS TN Interleukin-1 beta (IL1B) DMGLUQS MA Modulator DMGLUQS RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMGLUQS RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGLX0T DI DMGLX0T DMGLX0T DN Grepafloxacin DMGLX0T TI TTN6J5F DMGLX0T TN Bacterial DNA gyrase (Bact gyrase) DMGLX0T MA Modulator DMGLX0T RN Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5. DMGLX0T RU https://www.ncbi.nlm.nih.gov/pubmed/11796384 DMGLZ26 DI DMGLZ26 DMGLZ26 DN Practolol DMGLZ26 TI TTR6W5O DMGLZ26 TN Adrenergic receptor beta-1 (ADRB1) DMGLZ26 MA Antagonist DMGLZ26 RN Prostaglandin E2 synthesis elicited by adrenergic stimuli in guinea pig trachea is mediated primarily via activation of beta 2 adrenergic receptors. Prostaglandins. 1992 Nov;44(5):399-412. DMGLZ26 RU https://pubmed.ncbi.nlm.nih.gov/1335153 DMGM2Z6 DI DMGM2Z6 DMGM2Z6 DN Lonafarnib DMGM2Z6 TI TTXQKM3 DMGM2Z6 TN Farnesyl protein transferase (Ftase) DMGM2Z6 MA Modulator DMGM2Z6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMGM2Z6 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf DMGMB30 DI DMGMB30 DMGMB30 DN Ganirelix DMGMB30 TI TT8R70G DMGMB30 TN Gonadotropin-releasing hormone receptor (GNRHR) DMGMB30 MA Antagonist DMGMB30 RN Age attenuates testosterone secretion driven by amplitude-varying pulses of recombinant human luteinizing hormone during acute gonadotrope inhibiti... J Clin Endocrinol Metab. 2007 Sep;92(9):3626-32. DMGMB30 RU https://pubmed.ncbi.nlm.nih.gov/17579202 DMGMF6V DI DMGMF6V DMGMF6V DN Capsaicin DMGMF6V TI TTMI6F5 DMGMF6V TN Transient receptor potential cation channel V1 (TRPV1) DMGMF6V MA Agonist DMGMF6V RN Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol. 2007;(179):155-71. DMGMF6V RU https://pubmed.ncbi.nlm.nih.gov/17217056 DMGMNH3 DI DMGMNH3 DMGMNH3 DN Dalbavancin DMGMNH3 TI TTXMY0J DMGMNH3 TN Pancreatic triacylglycerol lipase (PNLIP) DMGMNH3 MA Inhibitor DMGMNH3 RN Pfizer. Product Development Pipeline. March 31 2009. DMGMNH3 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMGN1PW DI DMGN1PW DMGN1PW DN Indapamide DMGN1PW TI TT846HF DMGN1PW TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMGN1PW MA Blocker DMGN1PW RN Indapamide induces apoptosis of GH3 pituitary cells independently of its inhibition of voltage-dependent K+ currents. Eur J Pharmacol. 2006 Apr 24;536(1-2):78-84. DMGN1PW RU https://pubmed.ncbi.nlm.nih.gov/16556441 DMGN4BY DI DMGN4BY DMGN4BY DN Flurbiprofen DMGN4BY TI TTVKILB DMGN4BY TN Prostaglandin G/H synthase 2 (COX-2) DMGN4BY MA Modulator DMGN4BY RN Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35. DMGN4BY RU https://www.ncbi.nlm.nih.gov/pubmed/22714712 DMGN5QD DI DMGN5QD DMGN5QD DN Protirelin DMGN5QD TI TT4J8MF DMGN5QD TN Thyrotropin-releasing hormone receptor (TRHR) DMGN5QD MA Modulator DMGN5QD RN Company report (takeda) DMGN5QD RU https://www.takeda.com/csr/reports/pdf/index/ar2010_04_en.pdf DMGNYIH DI DMGNYIH DMGNYIH DN Retigabine DMGNYIH TI TTIVDM3 DMGNYIH TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMGNYIH MA Modulator DMGNYIH RN The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia. 2012 Apr;53(4):606-12. DMGNYIH RU https://pubmed.ncbi.nlm.nih.gov/22428574 DMGNYIH DI DMGNYIH DMGNYIH DN Retigabine DMGNYIH TI TTQ29KF DMGNYIH TN Voltage-gated potassium channel Kv7 (KCNQ) DMGNYIH MA Activator DMGNYIH RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMGNYIH RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMGO2MC DI DMGO2MC DMGO2MC DN Fenofibric acid DMGO2MC TI TTIV96N DMGO2MC TN Fatty acid-binding protein 1 (FABP1) DMGO2MC MA Inhibitor DMGO2MC RN Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64. DMGO2MC RU https://pubmed.ncbi.nlm.nih.gov/18533710 DMGO72P DI DMGO72P DMGO72P DN Oseltamivir DMGO72P TI TT50QJ3 DMGO72P TN Influenza Neuraminidase (Influ NA) DMGO72P MA Inhibitor DMGO72P RN Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. DMGO72P RU https://pubmed.ncbi.nlm.nih.gov/18328578 DMGOVHA DI DMGOVHA DMGOVHA DN Cenobamate DMGOVHA TI TTIG65Q DMGOVHA TN Voltage-gated sodium channel (Nav) DMGOVHA MA Inhibitor DMGOVHA RN Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons. Eur J Pharmacol. 2019 Jul 15;855:175-182. DMGOVHA RU https://pubmed.ncbi.nlm.nih.gov/31063770 DMGOXPQ DI DMGOXPQ DMGOXPQ DN DP-VPA DMGOXPQ TI TTNJYV2 DMGOXPQ TN Gamma-aminobutyric acid receptor (GAR) DMGOXPQ MA Modulator DMGOXPQ RN DP-VPA D-Pharm. Curr Opin Investig Drugs. 2002 Jun;3(6):921-3. DMGOXPQ RU https://pubmed.ncbi.nlm.nih.gov/12137414 DMGP8AX DI DMGP8AX DMGP8AX DN Thiopental DMGP8AX TI TTDP1UC DMGP8AX TN Fatty acid amide hydrolase (FAAH) DMGP8AX MA Inhibitor DMGP8AX RN The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13. DMGP8AX RU https://pubmed.ncbi.nlm.nih.gov/12839875 DMGQ0ZI DI DMGQ0ZI DMGQ0ZI DN Pralidoxime chloride DMGQ0ZI TI TT1RS9F DMGQ0ZI TN Acetylcholinesterase (AChE) DMGQ0ZI MA Modulator DMGQ0ZI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQ0ZI RU https://www.fda.gov/ DMGQFYB DI DMGQFYB DMGQFYB DN Mecamylamine DMGQFYB TI TTJSZTB DMGQFYB TN Nicotinic acetylcholine receptor (nAChR) DMGQFYB MA Antagonist DMGQFYB RN Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7. DMGQFYB RU https://pubmed.ncbi.nlm.nih.gov/12080428 DMGQIPT DI DMGQIPT DMGQIPT DN Caspofungin DMGQIPT TI TT0SFXH DMGQIPT TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMGQIPT MA Modulator DMGQIPT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQIPT RU https://www.fda.gov/ DMGQU0Y DI DMGQU0Y DMGQU0Y DN Piperacetazine DMGQU0Y TI TTEX248 DMGQU0Y TN Dopamine D2 receptor (D2R) DMGQU0Y MA Modulator DMGQU0Y RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGQU0Y RU https://www.fda.gov/ DMGR5Z3 DI DMGR5Z3 DMGR5Z3 DN Flunitrazepam DMGR5Z3 TI TTPTXIN DMGR5Z3 TN Translocator protein (TSPO) DMGR5Z3 MA Agonist DMGR5Z3 RN Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46. DMGR5Z3 RU https://pubmed.ncbi.nlm.nih.gov/19443999 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTYEG6Q DMGS4QH TN Muscarinic acetylcholine receptor M2 (CHRM2) DMGS4QH MA Inhibitor DMGS4QH RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTQ3JTF DMGS4QH TN Muscarinic acetylcholine receptor M4 (CHRM4) DMGS4QH MA Inhibitor DMGS4QH RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMGS4QH DI DMGS4QH DMGS4QH DN Methacholine Chloride DMGS4QH TI TTQ13Z5 DMGS4QH TN Muscarinic acetylcholine receptor M3 (CHRM3) DMGS4QH MA Modulator DMGS4QH RN Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62. DMGS4QH RU https://pubmed.ncbi.nlm.nih.gov/12540494 DMGS80V DI DMGS80V DMGS80V DN Levorphanol DMGS80V TI TTN4QDT DMGS80V TN Opioid receptor (OPR) DMGS80V MA Agonist DMGS80V RN Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22. DMGS80V RU https://pubmed.ncbi.nlm.nih.gov/14742749 DMGS80V DI DMGS80V DMGS80V DN Levorphanol DMGS80V TI TT9IK2Z DMGS80V TN N-methyl-D-aspartate receptor (NMDAR) DMGS80V MA Antagonist DMGS80V RN Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. DMGS80V RU https://pubmed.ncbi.nlm.nih.gov/12507405 DMGSRN1 DI DMGSRN1 DMGSRN1 DN Mipomersen DMGSRN1 TI TTN1IE2 DMGSRN1 TN APOB messenger RNA (APOB mRNA) DMGSRN1 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMGSRN1 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMGTW1I DI DMGTW1I DMGTW1I DN Pirarubicin DMGTW1I TI TTUTN1I DMGTW1I TN Human Deoxyribonucleic acid (hDNA) DMGTW1I MA Modulator DMGTW1I RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMGTW1I RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMGU74E DI DMGU74E DMGU74E DN Cholecalciferol DMGU74E TI TTK59TV DMGU74E TN Vitamin D3 receptor (VDR) DMGU74E MA Binder DMGU74E RN [Vitamin D2 or vitamin D3]. Rev Med Interne. 2008 Oct;29(10):815-20. DMGU74E RU https://pubmed.ncbi.nlm.nih.gov/18406498 DMGUC9T DI DMGUC9T DMGUC9T DN HEV-239 DMGUC9T TI TT3J5ZI DMGUC9T TN Cell mediated immunity response (CMIR) DMGUC9T RN The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother. 2015;11(4):908-14. DMGUC9T RU https://pubmed.ncbi.nlm.nih.gov/25714510 DMGUX67 DI DMGUX67 DMGUX67 DN Ibopamine hci DMGUX67 TI TTEX248 DMGUX67 TN Dopamine D2 receptor (D2R) DMGUX67 MA Modulator DMGUX67 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMGUX67 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMGUZ0W DI DMGUZ0W DMGUZ0W DN MELARSOPROL DMGUZ0W TI TT2SUAQ DMGUZ0W TN Cysteine protease (CYP) DMGUZ0W MA Inhibitor DMGUZ0W RN On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide s... J Med Chem. 2009 Sep 24;52(18):5662-72. DMGUZ0W RU https://pubmed.ncbi.nlm.nih.gov/19715342 DMGV8QU DI DMGV8QU DMGV8QU DN Etravirine DMGV8QU TI TT84ETX DMGV8QU TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMGV8QU MA Modulator DMGV8QU RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMGV8QU RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMGVH6N DI DMGVH6N DMGVH6N DN Axitinib DMGVH6N TI TTUTJGQ DMGVH6N TN Vascular endothelial growth factor receptor 2 (KDR) DMGVH6N MA Modulator DMGVH6N RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMGVH6N RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMGVJLB DI DMGVJLB DMGVJLB DN GMA-161 DMGVJLB TI TT7KTSR DMGVJLB TN Immunoglobulin gamma Fc receptor III (FCGR3) DMGVJLB MA Antagonist DMGVJLB RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMGVJLB RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMGVUO5 DI DMGVUO5 DMGVUO5 DN Tislelizumab DMGVUO5 TI TTNBFWK DMGVUO5 TN Programmed cell death protein 1 (PD-1) DMGVUO5 RN Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC). Expert Opin Investig Drugs. 2020 Dec;29(12):1355-1364. DMGVUO5 RU https://pubmed.ncbi.nlm.nih.gov/33044117 DMGW1ID DI DMGW1ID DMGW1ID DN Sirolimus DMGW1ID TI TTCJG29 DMGW1ID TN Serine/threonine-protein kinase mTOR (mTOR) DMGW1ID MA Inhibitor DMGW1ID RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMGW1ID RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMGW1ID DI DMGW1ID DMGW1ID DN Sirolimus DMGW1ID TI TTGQUFK DMGW1ID TN PI3K/AKT/mTOR pathway (PAm pathway) DMGW1ID MA Inhibitor DMGW1ID RN The genomic landscape of nasopharyngeal carcinoma.Nat Genet. 2014 Aug;46(8):866-71. DMGW1ID RU https://pubmed.ncbi.nlm.nih.gov/24952746 DMGWR0C DI DMGWR0C DMGWR0C DN Sintilimab DMGWR0C TI TTNBFWK DMGWR0C TN Programmed cell death protein 1 (PD-1) DMGWR0C MA Inhibitor DMGWR0C RN Sintilimab: First Global Approval. Drugs. 2019 Feb;79(3):341-346. DMGWR0C RU https://pubmed.ncbi.nlm.nih.gov/30742278 DMGXENV DI DMGXENV DMGXENV DN Saxagliptin DMGXENV TI TTDIGC1 DMGXENV TN Dipeptidyl peptidase 4 (DPP-4) DMGXENV MA Inhibitor DMGXENV RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMGXENV RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT TI TTZAYWL DMGY0UT TN Estrogen receptor (ESR) DMGY0UT MA Agonist DMGY0UT RN Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002 Mar 28;346(13):967-74. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/11919305 DMGY0UT DI DMGY0UT DMGY0UT DN Estrogen DMGY0UT TI TTOM3J0 DMGY0UT TN Estrogen receptor beta (ESR2) DMGY0UT MA Agonist DMGY0UT RN Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15133-6. DMGY0UT RU https://pubmed.ncbi.nlm.nih.gov/10611350 DMGZOVN DI DMGZOVN DMGZOVN DN Benztropine DMGZOVN TI TTZ9SOR DMGZOVN TN Muscarinic acetylcholine receptor M1 (CHRM1) DMGZOVN MA Antagonist DMGZOVN RN Formulation and biopharmaceutical evaluation of transdermal patch containing benztropine. Int J Pharm. 2008 Jun 5;357(1-2):55-60. DMGZOVN RU https://pubmed.ncbi.nlm.nih.gov/18417307 DMGZQEF DI DMGZQEF DMGZQEF DN Mifepristone DMGZQEF TI TTYRL6O DMGZQEF TN Glucocorticoid receptor (NR3C1) DMGZQEF MA Modulator DMGZQEF RN The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8. DMGZQEF RU https://pubmed.ncbi.nlm.nih.gov/17509631 DMH07Y3 DI DMH07Y3 DMH07Y3 DN Letrozole DMH07Y3 TI TTSZLWK DMH07Y3 TN Aromatase (CYP19A1) DMH07Y3 MA Inhibitor DMH07Y3 RN Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51. DMH07Y3 RU https://pubmed.ncbi.nlm.nih.gov/14505258 DMH0QKA DI DMH0QKA DMH0QKA DN GDC-0199 DMH0QKA TI TTJGNVC DMH0QKA TN Apoptosis regulator Bcl-2 (BCL-2) DMH0QKA MA Modulator DMH0QKA RN ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. DMH0QKA RU https://pubmed.ncbi.nlm.nih.gov/23291630 DMH0ZJE DI DMH0ZJE DMH0ZJE DN Mitomycin DMH0ZJE TI TTUTN1I DMH0ZJE TN Human Deoxyribonucleic acid (hDNA) DMH0ZJE MA Binder DMH0ZJE RN Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8. DMH0ZJE RU https://pubmed.ncbi.nlm.nih.gov/19608391 DMH15UV DI DMH15UV DMH15UV DN Tetrahydrofolic acid DMH15UV TI TTQOD3G DMH15UV TN Folate receptor (FOLR) DMH15UV MA Binder DMH15UV RN Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thromb Res. 2001 Apr 15;102(2):115-20. DMH15UV RU https://pubmed.ncbi.nlm.nih.gov/11323021 DMH1KMT DI DMH1KMT DMH1KMT DN Polidocanol DMH1KMT TI TTT6K3S DMH1KMT TN Endothelium of blood vessels (Endothelium) DMH1KMT MA Modulator DMH1KMT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMH1KMT RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMH1M9B DI DMH1M9B DMH1M9B DN Benazepril DMH1M9B TI TTL69WB DMH1M9B TN Angiotensin-converting enzyme (ACE) DMH1M9B MA Inhibitor DMH1M9B RN Efficacy of benazepril hydrochloride to delay the progression of occult dilated cardiomyopathy in Doberman Pinschers. J Vet Intern Med. 2009 Sep-Oct;23(5):977-83. DMH1M9B RU https://pubmed.ncbi.nlm.nih.gov/19572914 DMH2NMY DI DMH2NMY DMH2NMY DN Mepivacaine DMH2NMY TI TTRK8B9 DMH2NMY TN Sodium channel unspecific (NaC) DMH2NMY MA Blocker DMH2NMY RN Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505. DMH2NMY RU https://pubmed.ncbi.nlm.nih.gov/11094008 DMH4CFE DI DMH4CFE DMH4CFE DN Antithymocyte globulin DMH4CFE TI TTBGTFN DMH4CFE TN T-cell surface glycoprotein CD1a (CD1A) DMH4CFE MA Binder DMH4CFE RN Acute sensory neuropathy associated with rabbit antithymocyte globulin. Am J Transplant. 2007 Feb;7(2):484-6. DMH4CFE RU https://pubmed.ncbi.nlm.nih.gov/17283492 DMH4IVU DI DMH4IVU DMH4IVU DN Haloprogin DMH4IVU TI TTAH0B3 DMH4IVU TN Fungal Cell membrane (Fung CM) DMH4IVU MA Binder DMH4IVU RN Haloprogin: mode of action studies in Candida albicans. Can J Microbiol. 1974 Sep;20(9):1241-5. DMH4IVU RU https://pubmed.ncbi.nlm.nih.gov/4608935 DMH5W0G DI DMH5W0G DMH5W0G DN Dipivefrin DMH5W0G TI TTR6W5O DMH5W0G TN Adrenergic receptor beta-1 (ADRB1) DMH5W0G MA Antagonist DMH5W0G RN Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol. 1996 May;5(3):146-53. DMH5W0G RU https://pubmed.ncbi.nlm.nih.gov/8803576 DMH61ZB DI DMH61ZB DMH61ZB DN Cimetidine DMH61ZB TI TTQHJ1K DMH61ZB TN Histamine H2 receptor (H2R) DMH61ZB MA Antagonist DMH61ZB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMH61ZB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMH6IKO DI DMH6IKO DMH6IKO DN Lusutrombopag DMH6IKO TI TTIHYA4 DMH6IKO TN Thrombopoietin receptor (MPL) DMH6IKO MA Agonist DMH6IKO RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMH6IKO RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMH75KV DI DMH75KV DMH75KV DN Acenocoumarol DMH75KV TI TTEUC8H DMH75KV TN Vitamin K epoxide reductase complex 1 (VKORC1) DMH75KV MA Inhibitor DMH75KV RN Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity. Mol Biol Rep. 2010 Apr;37(4):1693-7. DMH75KV RU https://pubmed.ncbi.nlm.nih.gov/19562511 DMH7GN8 DI DMH7GN8 DMH7GN8 DN Ramosetron DMH7GN8 TI TT85JO3 DMH7GN8 TN 5-HT receptor (5HTR) DMH7GN8 MA Modulator DMH7GN8 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMH7GN8 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMH7GN8 DI DMH7GN8 DMH7GN8 DN Ramosetron DMH7GN8 TI TTNXLKE DMH7GN8 TN 5-HT 3 receptor (5HT3R) DMH7GN8 MA Modulator DMH7GN8 RN Inhibitory effect of YM060 on 5-HT3 receptor-mediated depolarization in colonic myenteric neurons of the guinea pig. Eur J Pharmacol. 1995 Sep 5;283(1-3):107-12. DMH7GN8 RU https://pubmed.ncbi.nlm.nih.gov/7498299 DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ TI TTANPDJ DMH7IDQ TN Carbonic anhydrase II (CA-II) DMH7IDQ MA Inhibitor DMH7IDQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMH7IDQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMH7IDQ DI DMH7IDQ DMH7IDQ DN Dichlorphenamide DMH7IDQ TI TTHQPL7 DMH7IDQ TN Carbonic anhydrase I (CA-I) DMH7IDQ MA Modulator DMH7IDQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMH7IDQ RU https://www.fda.gov/ DMH7MUV DI DMH7MUV DMH7MUV DN Zalcitabine DMH7MUV TI TT84ETX DMH7MUV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMH7MUV MA Inhibitor DMH7MUV RN A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54. DMH7MUV RU https://pubmed.ncbi.nlm.nih.gov/9833673 DMH7OIA DI DMH7OIA DMH7OIA DN Infliximab DMH7OIA TI TTF8CQI DMH7OIA TN Tumor necrosis factor (TNF) DMH7OIA RN Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9. DMH7OIA RU https://pubmed.ncbi.nlm.nih.gov/18414459 DMHA18P DI DMHA18P DMHA18P DN Lasofoxifene DMHA18P TI TTZAYWL DMHA18P TN Estrogen receptor (ESR) DMHA18P MA Modulator DMHA18P RN Pfizer. Product Development Pipeline. March 31 2009. DMHA18P RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMHA18P DI DMHA18P DMHA18P DN Lasofoxifene DMHA18P TI TT57ID8 DMHA18P TN Respiratory syncytial virus protein F (RSV F) DMHA18P MA Modulator DMHA18P RN Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87. DMHA18P RU https://pubmed.ncbi.nlm.nih.gov/19562644 DMHAQCO DI DMHAQCO DMHAQCO DN Trichlormethiazide DMHAQCO TI TTS087L DMHAQCO TN Solute carrier family 12 member 1 (SLC12A1) DMHAQCO MA Blocker DMHAQCO RN Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72. DMHAQCO RU https://pubmed.ncbi.nlm.nih.gov/17414671 DMHAUO0 DI DMHAUO0 DMHAUO0 DN Acetyldigitoxin DMHAUO0 TI TTWK8D0 DMHAUO0 TN Sodium pump subunit alpha-1 (ATP1A1) DMHAUO0 MA Modulator DMHAUO0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHAUO0 RU https://www.fda.gov/ DMHCI9S DI DMHCI9S DMHCI9S DN Flurandrenolide DMHCI9S TI TTP3UTW DMHCI9S TN Steroid hormone receptor ERR (ESRR) DMHCI9S MA Modulator DMHCI9S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCI9S RU https://www.fda.gov/ DMHCTAL DI DMHCTAL DMHCTAL DN Cryptenamine Acetates DMHCTAL TI TTH18TF DMHCTAL TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHCTAL MA Modulator DMHCTAL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHCTAL RU https://www.fda.gov/ DMHD4PE DI DMHD4PE DMHD4PE DN Desvenlafaxine DMHD4PE TI TT3ROYC DMHD4PE TN Serotonin transporter (SERT) DMHD4PE MA Modulator DMHD4PE RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMHD4PE RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMHDF7B DI DMHDF7B DMHDF7B DN Thiamylal DMHDF7B TI TTEX6LM DMHDF7B TN GABA(A) receptor gamma-3 (GABRG3) DMHDF7B MA Modulator DMHDF7B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHDF7B RU https://www.fda.gov/ DMHERIJ DI DMHERIJ DMHERIJ DN Capromab DMHERIJ TI TT9G4N0 DMHERIJ TN Glutamate carboxypeptidase II (GCPII) DMHERIJ RN Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med. 2007 Jan;37(1):17-28. DMHERIJ RU https://pubmed.ncbi.nlm.nih.gov/17161036 DMHF4IQ DI DMHF4IQ DMHF4IQ DN Trimethaphan DMHF4IQ TI TT4H1MQ DMHF4IQ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMHF4IQ MA Antagonist DMHF4IQ RN Mechanism of long-lasting block of ganglion nicotinic receptors by mono-ammonium compounds with long aliphatic chain. J Auton Nerv Syst. 1994 Aug;48(3):231-40. DMHF4IQ RU https://pubmed.ncbi.nlm.nih.gov/7963258 DMHFJDT DI DMHFJDT DMHFJDT DN Procyclidine DMHFJDT TI TTH18TF DMHFJDT TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHFJDT MA Antagonist DMHFJDT RN Protection against soman-induced seizures in rats: relationship among doses of prophylactics, soman, and adjuncts. Toxicol Appl Pharmacol. 2004 May 1;196(3):327-36. DMHFJDT RU https://pubmed.ncbi.nlm.nih.gov/15094303 DMHG57U DI DMHG57U DMHG57U DN OPC-34712 DMHG57U TI TTSQIFT DMHG57U TN 5-HT 1A receptor (HTR1A) DMHG57U MA Modulator DMHG57U RN Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9. DMHG57U RU https://www.ncbi.nlm.nih.gov/pubmed/24955861 DMHG57U DI DMHG57U DMHG57U DN OPC-34712 DMHG57U TI TTEX248 DMHG57U TN Dopamine D2 receptor (D2R) DMHG57U MA Modulator DMHG57U RN Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9. DMHG57U RU https://www.ncbi.nlm.nih.gov/pubmed/24955861 DMHIDCJ DI DMHIDCJ DMHIDCJ DN Octreotide DMHIDCJ TI TTZ6T9E DMHIDCJ TN Somatostatin receptor type 2 (SSTR2) DMHIDCJ MA Binder DMHIDCJ RN Versatile conjugation of octreotide to dendrimers by cycloaddition ("click") chemistry to yield high-affinity multivalent cyclic Peptide dendrimers. Bioconjug Chem. 2009 Jul;20(7):1323-31. DMHIDCJ RU https://pubmed.ncbi.nlm.nih.gov/19537708 DMHIDUE DI DMHIDUE DMHIDUE DN Phenelzine DMHIDUE TI TTGP7BY DMHIDUE TN Monoamine oxidase type B (MAO-B) DMHIDUE MA Inhibitor DMHIDUE RN Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34. DMHIDUE RU https://pubmed.ncbi.nlm.nih.gov/18539478 DMHIDUE DI DMHIDUE DMHIDUE DN Phenelzine DMHIDUE TI TT32XQJ DMHIDUE TN Monoamine oxidase (MAO) DMHIDUE MA Inhibitor DMHIDUE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMHIDUE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMHJV0X DI DMHJV0X DMHJV0X DN Pertuzumab DMHJV0X TI TT6EO5L DMHJV0X TN Erbb2 tyrosine kinase receptor (HER2) DMHJV0X MA Inhibitor DMHJV0X RN Clinical pipeline report, company report or official report of Roche (2009). DMHJV0X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMHJVOL DI DMHJVOL DMHJVOL DN Nabi-HB DMHJVOL TI TT6KSF7 DMHJVOL TN Hepatitis B virus Large envelope protein (HBV S) DMHJVOL MA Modulator DMHJVOL RN Hepatitis B Immune Globulin (Human) Nabi-HB . US Food and Drug Administration report. DMHJVOL RU http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm117658.pdf DMHKS94 DI DMHKS94 DMHKS94 DN Valaciclovir DMHKS94 TI TTIU7X1 DMHKS94 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMHKS94 MA Inhibitor DMHKS94 RN Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15. DMHKS94 RU https://pubmed.ncbi.nlm.nih.gov/19239637 DMHL7OB DI DMHL7OB DMHL7OB DN Uracil mustard DMHL7OB TI TTUTN1I DMHL7OB TN Human Deoxyribonucleic acid (hDNA) DMHL7OB MA Modulator DMHL7OB RN Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8. DMHL7OB RU https://pubmed.ncbi.nlm.nih.gov/8625472 DMHLP9C DI DMHLP9C DMHLP9C DN Felypressin DMHLP9C TI TT4TFGN DMHLP9C TN Vasopressin V1a receptor (V1AR) DMHLP9C MA Agonist DMHLP9C RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMHLP9C RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTJX3UE DMHM7JS TN Somatostatin receptor type 3 (SSTR3) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTIND6G DMHM7JS TN Somatostatin receptor type 1 (SSTR1) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 355). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=355 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TTZ6T9E DMHM7JS TN Somatostatin receptor type 2 (SSTR2) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356 DMHM7JS DI DMHM7JS DMHM7JS DN Pasireotide DMHM7JS TI TT2BC4G DMHM7JS TN Somatostatin receptor type 5 (SSTR5) DMHM7JS MA Inhibitor DMHM7JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359). DMHM7JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TT9SL3Q DMHM93Y TN Polypeptide deformylase (PDF) DMHM93Y MA Inhibitor DMHM93Y RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMHM93Y RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TT1MPAY DMHM93Y TN GABA(A) receptor alpha-1 (GABRA1) DMHM93Y MA Antagonist DMHM93Y RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMHM93Y RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMHM93Y DI DMHM93Y DMHM93Y DN Meprobamate DMHM93Y TI TTBZ7OD DMHM93Y TN Protein kinase C epsilon (PRKCE) DMHM93Y MA Stimulator DMHM93Y RN Protein kinase C, an elusive therapeutic target . Nat Rev Drug Discov. 2012 December; 11(12): 937-957. DMHM93Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760692/ DMHMP05 DI DMHMP05 DMHMP05 DN Carprofen DMHMP05 TI TTVKILB DMHMP05 TN Prostaglandin G/H synthase 2 (COX-2) DMHMP05 MA Inhibitor DMHMP05 RN Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators. J Med Chem. 2006 Dec 28;49(26):7588-91. DMHMP05 RU https://pubmed.ncbi.nlm.nih.gov/17181139 DMHN027 DI DMHN027 DMHN027 DN Levothyroxine DMHN027 TI TTTSEPU DMHN027 TN Thyroid hormone receptor alpha (THRA) DMHN027 MA Antagonist DMHN027 RN Thyroid hormone resistance and pituitary enlargement after thyroid ablation in a woman on levothyroxine treatment. Thyroid. 2008 Oct;18(10):1119-23. DMHN027 RU https://pubmed.ncbi.nlm.nih.gov/18816177 DMHNQOG DI DMHNQOG DMHNQOG DN Zafirlukast DMHNQOG TI TTGKOY9 DMHNQOG TN Leukotriene CysLT1 receptor (CYSLTR1) DMHNQOG MA Antagonist DMHNQOG RN Inhibitory effects of zafirlukast on respiratory bursts of human neutrophils. Drugs Exp Clin Res. 2002;28(4):133-45. DMHNQOG RU https://pubmed.ncbi.nlm.nih.gov/12512231 DMHO0AR DI DMHO0AR DMHO0AR DN Ergocalciferol DMHO0AR TI TTK59TV DMHO0AR TN Vitamin D3 receptor (VDR) DMHO0AR MA Antagonist DMHO0AR RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMHO0AR RU https://pubmed.ncbi.nlm.nih.gov/18525006 DMHOAUG DI DMHOAUG DMHOAUG DN Rimegepant DMHOAUG TI TTY6O0Q DMHOAUG TN Calcitonin gene-related peptide receptor (CGRPR) DMHOAUG MA Antagonist DMHOAUG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMHOAUG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf DMHP21E DI DMHP21E DMHP21E DN Hydromorphone DMHP21E TI TT27RFC DMHP21E TN Opioid receptor delta (OPRD1) DMHP21E MA Binder DMHP21E RN Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12. DMHP21E RU https://pubmed.ncbi.nlm.nih.gov/14998329 DMHP21E DI DMHP21E DMHP21E DN Hydromorphone DMHP21E TI TTKWM86 DMHP21E TN Opioid receptor mu (MOP) DMHP21E MA Inhibitor DMHP21E RN Clinical pipeline report, company report or official report of signaturerx. DMHP21E RU http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids DMHP8FI DI DMHP8FI DMHP8FI DN Methscopolamine bromide DMHP8FI TI TTQ13Z5 DMHP8FI TN Muscarinic acetylcholine receptor M3 (CHRM3) DMHP8FI MA Modulator DMHP8FI RN Agonist-regulated alteration of the affinity of pancreatic muscarinic cholinergic receptors. J Biol Chem. 1993 Oct 25;268(30):22436-43. DMHP8FI RU https://www.ncbi.nlm.nih.gov/pubmed/7693670 DMHP9BL DI DMHP9BL DMHP9BL DN Etelcalcetide DMHP9BL TI TTBUYHA DMHP9BL TN Extracellular calcium-sensing receptor (CASR) DMHP9BL MA Modulator DMHP9BL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHP9BL RU https://www.fda.gov/ DMHPRWG DI DMHPRWG DMHPRWG DN Exjade DMHPRWG TI TTUDR0C DMHPRWG TN Iron (Fe) DMHPRWG MA Modulator DMHPRWG RN Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. DMHPRWG RU https://pubmed.ncbi.nlm.nih.gov/17927285 DMHPWOM DI DMHPWOM DMHPWOM DN Diphenidol DMHPWOM TI TTQ3JTF DMHPWOM TN Muscarinic acetylcholine receptor M4 (CHRM4) DMHPWOM MA Antagonist DMHPWOM RN Diphenidol-related diamines as novel muscarinic M4 receptor antagonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2972-6. DMHPWOM RU https://pubmed.ncbi.nlm.nih.gov/18395442 DMHR8KW DI DMHR8KW DMHR8KW DN Alvimopan DMHR8KW TI TTKWM86 DMHR8KW TN Opioid receptor mu (MOP) DMHR8KW MA Antagonist DMHR8KW RN Alvimopan for postoperative ileus. Am J Health Syst Pharm. 2009 Jul 15;66(14):1267-77. DMHR8KW RU https://pubmed.ncbi.nlm.nih.gov/19574601 DMHRG8Q DI DMHRG8Q DMHRG8Q DN Carbidopa DMHRG8Q TI TTN451K DMHRG8Q TN Aromatic-L-amino-acid decarboxylase (DDC) DMHRG8Q MA Inhibitor DMHRG8Q RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DMHRG8Q RU https://pubmed.ncbi.nlm.nih.gov/11346021 DMHSJB4 DI DMHSJB4 DMHSJB4 DN Cyclacillin DMHSJB4 TI TTJP4SM DMHSJB4 TN Bacterial Penicillin binding protein (Bact PBP) DMHSJB4 MA Binder DMHSJB4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMHSJB4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TT4DXQT DMHSY1I TN Proto-oncogene c-Ret (RET) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TTUTJGQ DMHSY1I TN Vascular endothelial growth factor receptor 2 (KDR) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHSY1I DI DMHSY1I DMHSY1I DN Regorafenib DMHSY1I TI TTX41N9 DMHSY1I TN Tyrosine-protein kinase Kit (KIT) DMHSY1I MA Modulator DMHSY1I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMHSY1I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMHT34O DI DMHT34O DMHT34O DN Gemifloxacin DMHT34O TI TTN6J5F DMHT34O TN Bacterial DNA gyrase (Bact gyrase) DMHT34O MA Modulator DMHT34O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHT34O RU https://www.fda.gov/ DMHT34O DI DMHT34O DMHT34O DN Gemifloxacin DMHT34O TI TTIXTO3 DMHT34O TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMHT34O MA Modulator DMHT34O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHT34O RU https://www.fda.gov/ DMHTB31 DI DMHTB31 DMHTB31 DN Carphenazine DMHTB31 TI TTEX248 DMHTB31 TN Dopamine D2 receptor (D2R) DMHTB31 MA Antagonist DMHTB31 RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMHTB31 RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMHTEAO DI DMHTEAO DMHTEAO DN Carvedilol DMHTEAO TI TTG28O6 DMHTEAO TN Adrenergic receptor Alpha-1 (ADRA1) DMHTEAO MA Antagonist DMHTEAO RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DMHTEAO RU https://pubmed.ncbi.nlm.nih.gov/19491545 DMHTXSL DI DMHTXSL DMHTXSL DN Arbekacin DMHTXSL TI TTA4FIU DMHTXSL TN Ribosome A (hRA) DMHTXSL MA Modulator DMHTXSL RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMHTXSL RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TTC1GLB DMHTYK3 TN Interleukin-23 (IL23) DMHTYK3 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TTRTK6Y DMHTYK3 TN Interleukin-12 alpha (IL12A) DMHTYK3 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMHTYK3 DI DMHTYK3 DMHTYK3 DN Ustekinumab DMHTYK3 TI TT9SL3Q DMHTYK3 TN Polypeptide deformylase (PDF) DMHTYK3 MA Inhibitor DMHTYK3 RN Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9. DMHTYK3 RU https://pubmed.ncbi.nlm.nih.gov/12384337 DMHVBG1 DI DMHVBG1 DMHVBG1 DN Naftifine DMHVBG1 TI TTE14XG DMHVBG1 TN Squalene monooxygenase (SQLE) DMHVBG1 MA Inhibitor DMHVBG1 RN Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7. DMHVBG1 RU https://pubmed.ncbi.nlm.nih.gov/8834895 DMHVJFK DI DMHVJFK DMHVJFK DN Misoprostol DMHVJFK TI TTOFYT1 DMHVJFK TN Prostacyclin receptor (PTGIR) DMHVJFK MA Antagonist DMHVJFK RN Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. DMHVJFK RU https://pubmed.ncbi.nlm.nih.gov/12488443 DMHVL0J DI DMHVL0J DMHVL0J DN Azelaic Acid DMHVL0J TI TT2A0DR DMHVL0J TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMHVL0J MA Inhibitor DMHVL0J RN Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid. Br J Dermatol. 1988 Nov;119(5):627-32. DMHVL0J RU https://pubmed.ncbi.nlm.nih.gov/3207614 DMHVWIK DI DMHVWIK DMHVWIK DN Cefepime DMHVWIK TI TTHWB7G DMHVWIK TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMHVWIK MA Modulator DMHVWIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHVWIK RU https://www.fda.gov/ DMHWE7P DI DMHWE7P DMHWE7P DN Ampicillin DMHWE7P TI TTJP4SM DMHWE7P TN Bacterial Penicillin binding protein (Bact PBP) DMHWE7P MA Binder DMHWE7P RN Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80. DMHWE7P RU https://pubmed.ncbi.nlm.nih.gov/11959556 DMHY3IP DI DMHY3IP DMHY3IP DN Lobeglitazone DMHY3IP TI TTJ584C DMHY3IP TN Peroxisome proliferator-activated receptor alpha (PPARA) DMHY3IP MA Agonist DMHY3IP RN Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. DMHY3IP RU https://pubmed.ncbi.nlm.nih.gov/24802657 DMHY3IP DI DMHY3IP DMHY3IP DN Lobeglitazone DMHY3IP TI TTZMAO3 DMHY3IP TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMHY3IP MA Agonist DMHY3IP RN Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74. DMHY3IP RU https://pubmed.ncbi.nlm.nih.gov/24802657 DMHZCPO DI DMHZCPO DMHZCPO DN Ibrutinib DMHZCPO TI TTGM6VW DMHZCPO TN Tyrosine-protein kinase BTK (ATK) DMHZCPO MA Inhibitor DMHZCPO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). DMHZCPO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948 DMHZJCG DI DMHZJCG DMHZJCG DN Pentamidine DMHZJCG TI TTM1TDX DMHZJCG TN Tryptase alpha/beta-1 (Tryptase) DMHZJCG MA Inhibitor DMHZJCG RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DMHZJCG RU https://pubmed.ncbi.nlm.nih.gov/10197050 DMHZV7X DI DMHZV7X DMHZV7X DN Golimumab DMHZV7X TI TTF8CQI DMHZV7X TN Tumor necrosis factor (TNF) DMHZV7X RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMHZV7X RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMI0GDH DI DMI0GDH DMI0GDH DN Oxybuprocaine DMI0GDH TI TTRK8B9 DMI0GDH TN Sodium channel unspecific (NaC) DMI0GDH MA Blocker DMI0GDH RN Intrathecal oxybuprocaine and proxymetacaine produced potent and long-lasting spinal anesthesia in rats. Neurosci Lett. 2009 May 1;454(3):249-53. DMI0GDH RU https://pubmed.ncbi.nlm.nih.gov/19429093 DMI0RHA DI DMI0RHA DMI0RHA DN Inebilizumab DMI0RHA TI TTW640A DMI0RHA TN B-lymphocyte surface antigen B4 (CD19) DMI0RHA MA Inhibitor DMI0RHA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMI0RHA RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761142s000lbl.pdf DMI18HW DI DMI18HW DMI18HW DN Benzocaine DMI18HW TI TTRK8B9 DMI18HW TN Sodium channel unspecific (NaC) DMI18HW MA Blocker DMI18HW RN Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. Circ Res. 2008 Jan 4;102(1):86-94. DMI18HW RU https://pubmed.ncbi.nlm.nih.gov/17967784 DMI2QPE DI DMI2QPE DMI2QPE DN Didanosine DMI2QPE TI TT84ETX DMI2QPE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI2QPE MA Inhibitor DMI2QPE RN The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. DMI2QPE RU https://pubmed.ncbi.nlm.nih.gov/19412117 DMI347A DI DMI347A DMI347A DN Lamivudine DMI347A TI TT84ETX DMI347A TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI347A MA Modulator DMI347A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMI347A RU https://www.fda.gov/ DMI40NL DI DMI40NL DMI40NL DN Tolazoline DMI40NL TI TTEX248 DMI40NL TN Dopamine D2 receptor (D2R) DMI40NL MA Antagonist DMI40NL RN Comparative effects of tolazoline and nitroprusside on human isolated radial artery. Ann Thorac Surg. 2006 Jan;81(1):125-31. DMI40NL RU https://pubmed.ncbi.nlm.nih.gov/16368348 DMI4EL5 DI DMI4EL5 DMI4EL5 DN Ketorolac DMI4EL5 TI TTK0943 DMI4EL5 TN Prostaglandin G/H synthase (COX) DMI4EL5 MA Inhibitor DMI4EL5 RN Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32. DMI4EL5 RU https://pubmed.ncbi.nlm.nih.gov/17369458 DMI53FU DI DMI53FU DMI53FU DN Gaboxadol DMI53FU TI TTGXH6N DMI53FU TN GABA(A) receptor delta (GABRD) DMI53FU MA Modulator DMI53FU RN Gaboxadol--a new awakening in sleep.Curr Opin Pharmacol.2006 Feb;6(1):30-6. DMI53FU RU https://www.ncbi.nlm.nih.gov/pubmed/16368265 DMI5678 DI DMI5678 DMI5678 DN Pirbuterol DMI5678 TI TT2CJVK DMI5678 TN Adrenergic receptor beta-2 (ADRB2) DMI5678 MA Agonist DMI5678 RN Inhaled beta agonists. Respir Care. 2007 Jul;52(7):820-32. DMI5678 RU https://pubmed.ncbi.nlm.nih.gov/17594727 DMI5DW1 DI DMI5DW1 DMI5DW1 DN Hesperidin DMI5DW1 TI TT4FDG6 DMI5DW1 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMI5DW1 MA Inhibitor DMI5DW1 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMI5DW1 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMI5OXG DI DMI5OXG DMI5OXG DN Latanoprost DMI5OXG TI TTT2ZAR DMI5OXG TN Prostaglandin F2-alpha receptor (PTGFR) DMI5OXG MA Agonist DMI5OXG RN PGF(2alpha) FP receptor contributes to brain damage following transient focal brain ischemia. Neurotox Res. 2009 Jan;15(1):62-70. DMI5OXG RU https://pubmed.ncbi.nlm.nih.gov/19384589 DMI6E0R DI DMI6E0R DMI6E0R DN Midostaurin DMI6E0R TI TTGJCWZ DMI6E0R TN Fms-like tyrosine kinase 3 (FLT-3) DMI6E0R MA Inhibitor DMI6E0R RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMI6E0R RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMI6E0R DI DMI6E0R DMI6E0R DN Midostaurin DMI6E0R TI TTRFOXJ DMI6E0R TN Protein kinase C gamma (PRKCG) DMI6E0R MA Inhibitor DMI6E0R RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMI6E0R RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMI6GKT DI DMI6GKT DMI6GKT DN Beta-acetyldigoxin DMI6GKT TI TTYHPRQ DMI6GKT TN Sodium pump (NaP) DMI6GKT MA Modulator DMI6GKT RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMI6GKT RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMI6HUW DI DMI6HUW DMI6HUW DN Terbinafine DMI6HUW TI TTM9XSU DMI6HUW TN Candida Squalene epoxidase (Candi ERG1) DMI6HUW MA Modulator DMI6HUW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMI6HUW RU https://www.fda.gov/ DMI782S DI DMI782S DMI782S DN Erdafitinib DMI782S TI TT0LF7H DMI782S TN Fibroblast growth factor receptor (FGFR) DMI782S MA Inhibitor DMI782S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMI782S RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf DMI783H DI DMI783H DMI783H DN Vonvendi DMI783H TI TT3SZBT DMI783H TN von Willebrand factor (VWF) DMI783H MA Replacement DMI783H RN Clinical pipeline report, company report or official report of Vonvendi. DMI783H RU https://www.vonvendi.com/ DMI7DZ2 DI DMI7DZ2 DMI7DZ2 DN Prilocaine DMI7DZ2 TI TTZOVE0 DMI7DZ2 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMI7DZ2 MA Blocker DMI7DZ2 RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMI7DZ2 RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMI7FVQ DI DMI7FVQ DMI7FVQ DN Metyrapone DMI7FVQ TI TTIQUX7 DMI7FVQ TN Steroid 11-beta-hydroxylase (CYP11B1) DMI7FVQ MA Inhibitor DMI7FVQ RN Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21. DMI7FVQ RU https://pubmed.ncbi.nlm.nih.gov/11869873 DMI9FBP DI DMI9FBP DMI9FBP DN Imipenem DMI9FBP TI TTHWB7G DMI9FBP TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMI9FBP MA Binder DMI9FBP RN A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with gram-negative urosepsis. Urosepsis Study Group. J Endotoxin Res. 2000;6(1):25-31. DMI9FBP RU https://pubmed.ncbi.nlm.nih.gov/11061029 DMI9PRJ DI DMI9PRJ DMI9PRJ DN Diflorasone DMI9PRJ TI TT9V5JH DMI9PRJ TN Phospholipase A2 (PLA2G1B) DMI9PRJ MA Inhibitor DMI9PRJ RN Structures from powders: diflorasone diacetate. Steroids. 2009 Jan;74(1):102-11. DMI9PRJ RU https://pubmed.ncbi.nlm.nih.gov/19013475 DMIBH7M DI DMIBH7M DMIBH7M DN L-tryptophan DMIBH7M TI TTZJYKH DMIBH7M TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMIBH7M MA Binder DMIBH7M RN Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38. DMIBH7M RU https://pubmed.ncbi.nlm.nih.gov/16834326 DMIBNG2 DI DMIBNG2 DMIBNG2 DN Picrotoxin DMIBNG2 TI TT1MPAY DMIBNG2 TN GABA(A) receptor alpha-1 (GABRA1) DMIBNG2 MA Antagonist DMIBNG2 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMIBNG2 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMICA9H DI DMICA9H DMICA9H DN Sulfasalazine DMICA9H TI TTIMJ02 DMICA9H TN ATP-binding cassette transporter G2 (ABCG2) DMICA9H MA Inhibitor DMICA9H RN The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996 Mar 1;156(5):1937-41. DMICA9H RU https://pubmed.ncbi.nlm.nih.gov/8596047 DMICA9H DI DMICA9H DMICA9H DN Sulfasalazine DMICA9H TI TTSXVID DMICA9H TN Nuclear factor NF-kappa-B (NFKB) DMICA9H MA Activator DMICA9H RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMICA9H RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMICDLV DI DMICDLV DMICDLV DN Lorlatinib DMICDLV TI TTPMQSO DMICDLV TN ALK tyrosine kinase receptor (ALK) DMICDLV MA Inhibitor DMICDLV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMICDLV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMICDLV DI DMICDLV DMICDLV DN Lorlatinib DMICDLV TI TTSZ6Y3 DMICDLV TN Proto-oncogene c-Ros (ROS1) DMICDLV MA Inhibitor DMICDLV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMICDLV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMIEU69 DI DMIEU69 DMIEU69 DN Salmeterol DMIEU69 TI TT2CJVK DMIEU69 TN Adrenergic receptor beta-2 (ADRB2) DMIEU69 MA Agonist DMIEU69 RN Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65. DMIEU69 RU https://pubmed.ncbi.nlm.nih.gov/19059068 DMIFYLX DI DMIFYLX DMIFYLX DN Bopindolol DMIFYLX TI TTMXGCW DMIFYLX TN Adrenergic receptor beta-3 (ADRB3) DMIFYLX MA Modulator DMIFYLX RN Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes. J Cardiovasc Pharmacol. 1986;8 Suppl 6:S70-3. DMIFYLX RU https://pubmed.ncbi.nlm.nih.gov/2439825 DMIG6FY DI DMIG6FY DMIG6FY DN Amdinocillin DMIG6FY TI TTHWB7G DMIG6FY TN Bacterial Penicillin binding protein 2 (Bact mrdA) DMIG6FY MA Inhibitor DMIG6FY RN Growth of Escherichia coli: significance of peptidoglycan degradation during elongation and septation. J Bacteriol. 2008 Jun;190(11):3914-22. DMIG6FY RU https://pubmed.ncbi.nlm.nih.gov/18390656 DMIG8DW DI DMIG8DW DMIG8DW DN Dexamethasone sodium phosphate DMIG8DW TI TTYRL6O DMIG8DW TN Glucocorticoid receptor (NR3C1) DMIG8DW MA Agonist DMIG8DW RN Dexamethasone rapidly increases GABA release in the dorsal motor nucleus of the vagus via retrograde messenger-mediated enhancement of TRPV1 activity. PLoS One. 2013 Jul 30;8(7):e70505. DMIG8DW RU https://pubmed.ncbi.nlm.nih.gov/23936221 DMIHRNA DI DMIHRNA DMIHRNA DN Tolazamide DMIHRNA TI TTG140O DMIHRNA TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMIHRNA MA Blocker DMIHRNA RN Inhibition of ATP-activated potassium channels exerts pressor effects and improves survival in a rat model of severe hemorrhagic shock. Shock. 1996 Jun;5(6):391-4. DMIHRNA RU https://pubmed.ncbi.nlm.nih.gov/8799949 DMIJATC DI DMIJATC DMIJATC DN Benzphetamine DMIJATC TI TT9IK2Z DMIJATC TN N-methyl-D-aspartate receptor (NMDAR) DMIJATC MA Antagonist DMIJATC RN Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. J Pharmacol Exp Ther. 2002 Mar;300(3):1008-16. DMIJATC RU https://pubmed.ncbi.nlm.nih.gov/11861810 DMIJC9X DI DMIJC9X DMIJC9X DN Osilodrostat DMIJC9X TI TTIQUX7 DMIJC9X TN Steroid 11-beta-hydroxylase (CYP11B1) DMIJC9X MA Modulator DMIJC9X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMIJC9X RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212801s000lbl.pdf DMIJRF0 DI DMIJRF0 DMIJRF0 DN Anisotropine Methylbromide DMIJRF0 TI TTH18TF DMIJRF0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMIJRF0 MA Binder DMIJRF0 RN Anisotropine methylbromide: a new antispasmodic for gastrointestinal disorders. Curr Ther Res Clin Exp. 1963 May;5:213-8. DMIJRF0 RU https://pubmed.ncbi.nlm.nih.gov/13966843 DMIK367 DI DMIK367 DMIK367 DN Procarbazine DMIK367 TI TTUTN1I DMIK367 TN Human Deoxyribonucleic acid (hDNA) DMIK367 RN Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86. DMIK367 RU https://pubmed.ncbi.nlm.nih.gov/18840549 DMIKFEL DI DMIKFEL DMIKFEL DN Levomepromazine DMIKFEL TI TTEX248 DMIKFEL TN Dopamine D2 receptor (D2R) DMIKFEL MA Modulator DMIKFEL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIKFEL RU https://www.fda.gov/ DMIKHN0 DI DMIKHN0 DMIKHN0 DN Meticillin DMIKHN0 TI TTJP4SM DMIKHN0 TN Bacterial Penicillin binding protein (Bact PBP) DMIKHN0 MA Binder DMIKHN0 RN A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58. DMIKHN0 RU https://pubmed.ncbi.nlm.nih.gov/16946250 DMINO7Z DI DMINO7Z DMINO7Z DN Perhexiline DMINO7Z TI TTDL0NY DMINO7Z TN Carnitine O-palmitoyltransferase I (CPT1B) DMINO7Z MA Inhibitor DMINO7Z RN Perhexiline. Cardiovasc Drug Rev. 2007 Spring;25(1):76-97. DMINO7Z RU https://pubmed.ncbi.nlm.nih.gov/17445089 DMINOX3 DI DMINOX3 DMINOX3 DN Vincristine DMINOX3 TI TTYFKSZ DMINOX3 TN Tubulin beta (TUBB) DMINOX3 MA Modulator DMINOX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMINOX3 RU https://www.fda.gov/ DMINRKW DI DMINRKW DMINRKW DN Clomipramine DMINRKW TI TT3ROYC DMINRKW TN Serotonin transporter (SERT) DMINRKW MA Inhibitor DMINRKW RN Efficacy of treatments for patients with obsessive-compulsive disorder: a systematic review. J Am Acad Nurse Pract. 2009 Apr;21(4):207-13. DMINRKW RU https://pubmed.ncbi.nlm.nih.gov/19366379 DMINZ4W DI DMINZ4W DMINZ4W DN Tetrahydrobiopterin DMINZ4W TI TTUHP71 DMINZ4W TN Tyrosine 3-monooxygenase (TH) DMINZ4W MA Cofactor DMINZ4W RN Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20. DMINZ4W RU https://pubmed.ncbi.nlm.nih.gov/17982884 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTANPDJ DMIO1K0 TN Carbonic anhydrase II (CA-II) DMIO1K0 MA Inhibitor DMIO1K0 RN Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/20201556 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTSYM0R DMIO1K0 TN Carbonic anhydrase XII (CA-XII) DMIO1K0 MA Inhibitor DMIO1K0 RN Sulfonamide linked neoglycoconjugates--a new class of inhibitors for cancer-associated carbonic anhydrases. J Med Chem. 2010 Apr 8;53(7):2913-26. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/20201556 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTCFSPE DMIO1K0 TN Carbonic anhydrase VI (CA-VI) DMIO1K0 MA Inhibitor DMIO1K0 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTEYTKG DMIO1K0 TN Carbonic anhydrase XIV (CA-XIV) DMIO1K0 MA Inhibitor DMIO1K0 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTZHA0O DMIO1K0 TN Carbonic anhydrase IV (CA-IV) DMIO1K0 MA Inhibitor DMIO1K0 RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMIO1K0 DI DMIO1K0 DMIO1K0 DN Sulfamylon DMIO1K0 TI TTUNARX DMIO1K0 TN Carbonic anhydrase (CA) DMIO1K0 MA Inhibitor DMIO1K0 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIO1K0 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIO4V5 DI DMIO4V5 DMIO4V5 DN VRX496 DMIO4V5 TI TTXVOJ5 DMIO4V5 TN Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA) DMIO4V5 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMIO4V5 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU TI TTKRD0G DMIOGBU TN Endothelin A receptor (EDNRA) DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOGBU DI DMIOGBU DMIOGBU DN Bosentan DMIOGBU TI TT3ZTGU DMIOGBU TN Endothelin B receptor (EDNRB) DMIOGBU MA Modulator DMIOGBU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIOGBU RU https://www.fda.gov/ DMIOZ29 DI DMIOZ29 DMIOZ29 DN Glycine DMIOZ29 TI TTKJEMQ DMIOZ29 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMIOZ29 MA Antagonist DMIOZ29 RN Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78. DMIOZ29 RU https://pubmed.ncbi.nlm.nih.gov/19562643 DMIP3ZV DI DMIP3ZV DMIP3ZV DN Fenoterol DMIP3ZV TI TT2CJVK DMIP3ZV TN Adrenergic receptor beta-2 (ADRB2) DMIP3ZV MA Agonist DMIP3ZV RN Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75. DMIP3ZV RU https://pubmed.ncbi.nlm.nih.gov/19334040 DMIR5QP DI DMIR5QP DMIR5QP DN Azlocillin DMIR5QP TI TTJP4SM DMIR5QP TN Bacterial Penicillin binding protein (Bact PBP) DMIR5QP MA Binder DMIR5QP RN Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8. DMIR5QP RU https://pubmed.ncbi.nlm.nih.gov/2515794 DMIRMVB DI DMIRMVB DMIRMVB DN Methadyl Acetate DMIRMVB TI TTKWM86 DMIRMVB TN Opioid receptor mu (MOP) DMIRMVB MA Agonist DMIRMVB RN Acetylmethadol metabolites influence opiate receptors and adenylate cyclase in amygdala. Eur J Pharmacol. 1981 Jul 10;72(4):343-9. DMIRMVB RU https://pubmed.ncbi.nlm.nih.gov/6268422 DMISH0Z DI DMISH0Z DMISH0Z DN Mogamulizumab DMISH0Z TI TT7HQD0 DMISH0Z TN C-C chemokine receptor type 4 (CCR4) DMISH0Z MA Inhibitor DMISH0Z RN Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9. DMISH0Z RU https://pubmed.ncbi.nlm.nih.gov/21154168 DMIT8LX DI DMIT8LX DMIT8LX DN Fluphenazine DMIT8LX TI TTK8CXU DMIT8LX TN 5-HT 1B receptor (HTR1B) DMIT8LX MA Modulator DMIT8LX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIT8LX RU https://www.fda.gov/ DMITQS0 DI DMITQS0 DMITQS0 DN Lopinavir DMITQS0 TI TTLFGBV DMITQS0 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMITQS0 MA Modulator DMITQS0 RN Company report (JMI Laboratories) DMITQS0 RU http://www.jmilabs.com/data/posters/ICAAC2013%5CE-144.pdf DMITSEH DI DMITSEH DMITSEH DN Isoetharine DMITSEH TI TT2CJVK DMITSEH TN Adrenergic receptor beta-2 (ADRB2) DMITSEH MA Modulator DMITSEH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMITSEH RU https://www.fda.gov/ DMIUW25 DI DMIUW25 DMIUW25 DN Granisetron DMIUW25 TI TTNXLKE DMIUW25 TN 5-HT 3 receptor (5HT3R) DMIUW25 MA Antagonist DMIUW25 RN New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J. 2006 Sep-Oct;12(5):341-7. DMIUW25 RU https://pubmed.ncbi.nlm.nih.gov/17034670 DMIUX3D DI DMIUX3D DMIUX3D DN Methyl aminolevulinate DMIUX3D TI TTQ6VF4 DMIUX3D TN Ferrochelatase (FECH) DMIUX3D MA Activator DMIUX3D RN Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res. 2009 May 15;15(10):3333-43. DMIUX3D RU https://pubmed.ncbi.nlm.nih.gov/19447864 DMIUYFH DI DMIUYFH DMIUYFH DN Sulfapyridine DMIUYFH TI TT4ILYC DMIUYFH TN Bacterial Dihydropteroate synthetase (Bact folP) DMIUYFH MA Inhibitor DMIUYFH RN A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6. DMIUYFH RU https://pubmed.ncbi.nlm.nih.gov/19586630 DMIVJ0D DI DMIVJ0D DMIVJ0D DN Pseudoephedrine DMIVJ0D TI TTEX248 DMIVJ0D TN Dopamine D2 receptor (D2R) DMIVJ0D MA Stimulator DMIVJ0D RN Cetirizine/pseudoephedrine. Drugs. 2001;61(15):2231-40; discussion 2241-2. DMIVJ0D RU https://pubmed.ncbi.nlm.nih.gov/11772135 DMIWFRL DI DMIWFRL DMIWFRL DN Tolvaptan DMIWFRL TI TTK8R02 DMIWFRL TN Vasopressin V2 receptor (V2R) DMIWFRL MA Antagonist DMIWFRL RN Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84. DMIWFRL RU https://pubmed.ncbi.nlm.nih.gov/19196236 DMIXC7G DI DMIXC7G DMIXC7G DN Zoledronate DMIXC7G TI TTIKWV4 DMIXC7G TN Geranyltranstransferase (FDPS) DMIXC7G MA Modulator DMIXC7G RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIXC7G RU https://www.fda.gov/ DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 TI TTUTJGQ DMIYDT4 TN Vascular endothelial growth factor receptor 2 (KDR) DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMIYDT4 DI DMIYDT4 DMIYDT4 DN Cabozantinib DMIYDT4 TI TTNDSF4 DMIYDT4 TN Proto-oncogene c-Met (MET) DMIYDT4 MA Inhibitor DMIYDT4 RN Clinical pipeline report, company report or official report of Exelixis (2011). DMIYDT4 RU http://www.exelixis.com/pipeline DMIYG7Z DI DMIYG7Z DMIYG7Z DN Donepezil DMIYG7Z TI TT1RS9F DMIYG7Z TN Acetylcholinesterase (AChE) DMIYG7Z MA Modulator DMIYG7Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMIYG7Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMIYJFV DI DMIYJFV DMIYJFV DN Nicorandil DMIYJFV TI TTEF5MJ DMIYJFV TN ATP-binding cassette transporter C9 (ABCC9) DMIYJFV MA Activator DMIYJFV RN A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) chann... J Mol Cell Cardiol. 2005 Jul;39(1):1-6. DMIYJFV RU https://pubmed.ncbi.nlm.nih.gov/15978900 DMIZ1E8 DI DMIZ1E8 DMIZ1E8 DN Galcanezumab DMIZ1E8 TI TTY6O0Q DMIZ1E8 TN Calcitonin gene-related peptide receptor (CGRPR) DMIZ1E8 MA Modulator DMIZ1E8 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMIZ1E8 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMIZ6W2 DI DMIZ6W2 DMIZ6W2 DN Norfloxacin DMIZ6W2 TI TTN6J5F DMIZ6W2 TN Bacterial DNA gyrase (Bact gyrase) DMIZ6W2 MA Modulator DMIZ6W2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMIZ6W2 RU https://www.fda.gov/ DMJ01D8 DI DMJ01D8 DMJ01D8 DN Colforsin daropate hci DMJ01D8 TI TTULOB6 DMJ01D8 TN Cathelicidin antimicrobial peptide (CAMP) DMJ01D8 MA Modulator DMJ01D8 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJ01D8 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJ0QOW DI DMJ0QOW DMJ0QOW DN Rilpivirine DMJ0QOW TI TT84ETX DMJ0QOW TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJ0QOW MA Inhibitor DMJ0QOW RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMJ0QOW RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMJ0QOW DI DMJ0QOW DMJ0QOW DN Rilpivirine DMJ0QOW TI TT90XZ8 DMJ0QOW TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMJ0QOW MA Inhibitor DMJ0QOW RN Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82. DMJ0QOW RU https://pubmed.ncbi.nlm.nih.gov/15044438 DMJ13KI DI DMJ13KI DMJ13KI DN Terconazole DMJ13KI TI TTTSOUD DMJ13KI TN Candida Cytochrome P450 51 (Candi ERG11) DMJ13KI MA Inhibitor DMJ13KI RN Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9. DMJ13KI RU https://pubmed.ncbi.nlm.nih.gov/1951574 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTH029C DMJ2AH4 TN Retinoic acid receptor RXR-gamma (RXRG) DMJ2AH4 MA Binder DMJ2AH4 RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTOD7B3 DMJ2AH4 TN Retinoic acid receptor (RAR) DMJ2AH4 MA Binder DMJ2AH4 RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMJ2AH4 DI DMJ2AH4 DMJ2AH4 DN Vitamin A DMJ2AH4 TI TTRTKPV DMJ2AH4 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMJ2AH4 MA Binder DMJ2AH4 RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMJ2AH4 RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMJ2O7B DI DMJ2O7B DMJ2O7B DN Gemtuzumab ozogamicin DMJ2O7B TI TTJVYO3 DMJ2O7B TN Myeloid cell surface antigen CD33 (CD33) DMJ2O7B RN Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging. 2009;4:197-205. DMJ2O7B RU https://pubmed.ncbi.nlm.nih.gov/19503782 DMJ3I1Q DI DMJ3I1Q DMJ3I1Q DN Niflumic acid DMJ3I1Q TI TTVKILB DMJ3I1Q TN Prostaglandin G/H synthase 2 (COX-2) DMJ3I1Q MA Inhibitor DMJ3I1Q RN Rat ovulation, implantation and decidualization are severely compromised by COX-2 inhibitors. Front Biosci. 2007 May 1;12:3333-42. DMJ3I1Q RU https://pubmed.ncbi.nlm.nih.gov/17485303 DMJ47QC DI DMJ47QC DMJ47QC DN Thyrotropin DMJ47QC TI TT6NYJA DMJ47QC TN Thyrotropin receptor (TSHR) DMJ47QC MA Modulator DMJ47QC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJ47QC RU https://www.fda.gov/ DMJ4AWC DI DMJ4AWC DMJ4AWC DN Cyclothiazide DMJ4AWC TI TTANPDJ DMJ4AWC TN Carbonic anhydrase II (CA-II) DMJ4AWC MA Inhibitor DMJ4AWC RN Selective effect of thiazides on the human osteoblast-like cell line MG-63. Kidney Int. 1996 Nov;50(5):1476-82. DMJ4AWC RU https://pubmed.ncbi.nlm.nih.gov/8914012 DMJ6H1Z DI DMJ6H1Z DMJ6H1Z DN Quinestrol DMJ6H1Z TI TTZAYWL DMJ6H1Z TN Estrogen receptor (ESR) DMJ6H1Z MA Modulator DMJ6H1Z RN The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro. Bone. 2007 Mar;40(3):674-84. DMJ6H1Z RU https://pubmed.ncbi.nlm.nih.gov/17174166 DMJ7A0H DI DMJ7A0H DMJ7A0H DN Cefdinir DMJ7A0H TI TTJP4SM DMJ7A0H TN Bacterial Penicillin binding protein (Bact PBP) DMJ7A0H MA Binder DMJ7A0H RN Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60. DMJ7A0H RU https://pubmed.ncbi.nlm.nih.gov/17540669 DMJ7IQX DI DMJ7IQX DMJ7IQX DN Crestor/TriLipix DMJ7IQX TI TTPADOQ DMJ7IQX TN HMG-CoA reductase (HMGCR) DMJ7IQX MA Inhibitor DMJ7IQX RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMJ7IQX RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMJ8A3Z DI DMJ8A3Z DMJ8A3Z DN Florbetapir F-18 DMJ8A3Z TI TTE4KHA DMJ8A3Z TN Amyloid beta A4 protein (APP) DMJ8A3Z MA Modulator DMJ8A3Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMJ8A3Z RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMJ8NMC DI DMJ8NMC DMJ8NMC DN Barbital DMJ8NMC TI TT1MPAY DMJ8NMC TN GABA(A) receptor alpha-1 (GABRA1) DMJ8NMC MA Antagonist DMJ8NMC RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJ8NMC RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJ90O5 DI DMJ90O5 DMJ90O5 DN Medrysone DMJ90O5 TI TTP3UTW DMJ90O5 TN Steroid hormone receptor ERR (ESRR) DMJ90O5 MA Modulator DMJ90O5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJ90O5 RU https://www.fda.gov/ DMJ93CT DI DMJ93CT DMJ93CT DN Inotersen DMJ93CT TI TTC1I86 DMJ93CT TN Transthyretin (TTR) DMJ93CT MA Antisense DMJ93CT RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMJ93CT RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMJ9G23 DI DMJ9G23 DMJ9G23 DN ISIS 1570 DMJ9G23 TI TTA1L39 DMJ9G23 TN ICAM1 messenger RNA (ICAM1 mRNA) DMJ9G23 RN US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion. DMJ9G23 RU http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true DMJAOT1 DI DMJAOT1 DMJAOT1 DN Polyoxidonium DMJAOT1 TI TT3J5ZI DMJAOT1 TN Cell mediated immunity response (CMIR) DMJAOT1 MA Modulator DMJAOT1 RN Effect of polyoxidonium on the phagocytic activity of human peripheral blood leukocytes. Russ J Immunol. 2003 Apr;8(1):53-60. DMJAOT1 RU https://pubmed.ncbi.nlm.nih.gov/12717555 DMJAPE7 DI DMJAPE7 DMJAPE7 DN Methylene blue DMJAPE7 TI TT32XQJ DMJAPE7 TN Monoamine oxidase (MAO) DMJAPE7 RN Photoluminescence of CdTe nanocrystals modulated by methylene blue and DNA. A label-free luminescent signaling nanohybrid platform. Phys Chem Chem Phys. 2009 Jul 7;11(25):5062-9. DMJAPE7 RU https://pubmed.ncbi.nlm.nih.gov/19562136 DMJAPE7 DI DMJAPE7 DMJAPE7 DN Methylene blue DMJAPE7 TI TT6HPVC DMJAPE7 TN Guanylate cyclase (GC) DMJAPE7 MA Inhibitor DMJAPE7 RN Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82. DMJAPE7 RU https://pubmed.ncbi.nlm.nih.gov/19473193 DMJBOCR DI DMJBOCR DMJBOCR DN Levacecarnine HCL DMJBOCR TI TTDL0NY DMJBOCR TN Carnitine O-palmitoyltransferase I (CPT1B) DMJBOCR MA Activator DMJBOCR RN Central ghrelin regulates peripheral lipid metabolism in a growth hormone-independent fashion. Endocrinology. 2009 Oct;150(10):4562-74. DMJBOCR RU https://pubmed.ncbi.nlm.nih.gov/19608647 DMJCP1Y DI DMJCP1Y DMJCP1Y DN Yohimbine DMJCP1Y TI TTQ8AFT DMJCP1Y TN Adrenergic receptor Alpha-2 (ADRA2) DMJCP1Y MA Antagonist DMJCP1Y RN Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9. DMJCP1Y RU https://pubmed.ncbi.nlm.nih.gov/19640235 DMJDB0Y DI DMJDB0Y DMJDB0Y DN Dezocine DMJDB0Y TI TTQW87Y DMJDB0Y TN Opioid receptor kappa (OPRK1) DMJDB0Y MA Antagonist DMJDB0Y RN Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3. DMJDB0Y RU https://pubmed.ncbi.nlm.nih.gov/16433932 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTAN6JD DMJDYNQ TN Glutamate receptor AMPA (GRIA) DMJDYNQ MA Modulator DMJDYNQ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTVPQTF DMJDYNQ TN Glutamate receptor AMPA 1 (GRIA1) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TT9HLZ0 DMJDYNQ TN Glutamate receptor AMPA 2 (GRIA2) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TT82EZV DMJDYNQ TN Glutamate receptor AMPA 3 (GRIA3) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJDYNQ DI DMJDYNQ DMJDYNQ DN E-2007 DMJDYNQ TI TTPJR0G DMJDYNQ TN Glutamate receptor AMPA 4 (GRIA4) DMJDYNQ MA Inhibitor DMJDYNQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJDYNQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJE6KO DI DMJE6KO DMJE6KO DN Desvenalfaxine succinate DMJE6KO TI TTAWNKZ DMJE6KO TN Norepinephrine transporter (NET) DMJE6KO MA Inhibitor DMJE6KO RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMJE6KO RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT85JO3 DMJFP6G TN 5-HT receptor (5HTR) DMJFP6G MA Modulator DMJFP6G RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTWJBZ5 DMJFP6G TN 5-HT 2C receptor (HTR2C) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTK8CXU DMJFP6G TN 5-HT 1B receptor (HTR1B) DMJFP6G MA Antagonist DMJFP6G RN Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/8863519 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTCPG9S DMJFP6G TN 5-HT 1E receptor (HTR1E) DMJFP6G MA Antagonist DMJFP6G RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/14744596 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT0MI3F DMJFP6G TN 5-HT 1F receptor (HTR1F) DMJFP6G MA Antagonist DMJFP6G RN Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/9225282 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTRUFDT DMJFP6G TN 5-HT 5A receptor (HTR5A) DMJFP6G MA Antagonist DMJFP6G RN Cloning and characterisation of the human 5-HT5A serotonin receptor. FEBS Lett. 1994 Dec 5;355(3):242-6. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/7988681 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT6MSOK DMJFP6G TN 5-HT 1D receptor (HTR1D) DMJFP6G MA Antagonist DMJFP6G RN Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/1652050 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TT0K1SC DMJFP6G TN 5-HT 2B receptor (HTR2B) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFP6G DI DMJFP6G DMJFP6G DN Metergolin DMJFP6G TI TTJQOD7 DMJFP6G TN 5-HT 2A receptor (HTR2A) DMJFP6G MA Antagonist DMJFP6G RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMJFP6G RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMJFZDL DI DMJFZDL DMJFZDL DN Naphazoline DMJFZDL TI TTEX248 DMJFZDL TN Dopamine D2 receptor (D2R) DMJFZDL MA Agonist DMJFZDL RN Decongestants in treatment of nasal obstruction. Otolaryngol Pol. 1999;53(3):347-52. DMJFZDL RU https://pubmed.ncbi.nlm.nih.gov/10481510 DMJHLSD DI DMJHLSD DMJHLSD DN Famciclovir DMJHLSD TI TTIU7X1 DMJHLSD TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMJHLSD MA Inhibitor DMJHLSD RN Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8. DMJHLSD RU https://pubmed.ncbi.nlm.nih.gov/15452407 DMJHN0A DI DMJHN0A DMJHN0A DN Icosapent DMJHN0A TI TTK0943 DMJHN0A TN Prostaglandin G/H synthase (COX) DMJHN0A MA Binder DMJHN0A RN Differential modulation of Toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003 Mar;44(3):479-86. DMJHN0A RU https://pubmed.ncbi.nlm.nih.gov/12562875 DMJI3BA DI DMJI3BA DMJI3BA DN Peginterferon alfa-2a DMJI3BA TI TTSIUJ9 DMJI3BA TN Interferon-alpha 2 (IFNA2) DMJI3BA MA Modulator DMJI3BA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJI3BA RU https://www.fda.gov/ DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T TI TTAN6JD DMJIA6T TN Glutamate receptor AMPA (GRIA) DMJIA6T MA Agonist DMJIA6T RN Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/17073666 DMJIA6T DI DMJIA6T DMJIA6T DN Barbiturate DMJIA6T TI TT1MPAY DMJIA6T TN GABA(A) receptor alpha-1 (GABRA1) DMJIA6T MA Antagonist DMJIA6T RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMJIA6T RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMJIBAW DI DMJIBAW DMJIBAW DN Budesonide DMJIBAW TI TTYRL6O DMJIBAW TN Glucocorticoid receptor (NR3C1) DMJIBAW MA Antagonist DMJIBAW RN PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71. DMJIBAW RU https://pubmed.ncbi.nlm.nih.gov/19138736 DMJKROX DI DMJKROX DMJKROX DN Luvox DMJKROX TI TT3ROYC DMJKROX TN Serotonin transporter (SERT) DMJKROX MA Modulator DMJKROX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJKROX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJL10P DI DMJL10P DMJL10P DN Isoxyl DMJL10P TI TT6RIOV DMJL10P TN Acyl-CoA desaturase (SCD) DMJL10P MA Binder DMJL10P RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DMJL10P RU https://pubmed.ncbi.nlm.nih.gov/18804175 DMJMVKI DI DMJMVKI DMJMVKI DN Metipranolol DMJMVKI TI TTR6W5O DMJMVKI TN Adrenergic receptor beta-1 (ADRB1) DMJMVKI MA Antagonist DMJMVKI RN Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther. 2005 Jun;21(3):175-81. DMJMVKI RU https://pubmed.ncbi.nlm.nih.gov/15969634 DMJNV4O DI DMJNV4O DMJNV4O DN Tirbanibulin DMJNV4O TI TTHVQ4N DMJNV4O TN Tubulin polymerization (TubP) DMJNV4O MA Inhibitor DMJNV4O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMJNV4O RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213189s000lbl.pdf DMJO6GV DI DMJO6GV DMJO6GV DN Abciximab DMJO6GV TI TT38RM1 DMJO6GV TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMJO6GV MA Modulator DMJO6GV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJO6GV RU https://www.fda.gov/ DMJOQM3 DI DMJOQM3 DMJOQM3 DN Eflornithine DMJOQM3 TI TTUMGNO DMJOQM3 TN Ornithine decarboxylase (ODC1) DMJOQM3 MA Inhibitor DMJOQM3 RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DMJOQM3 RU https://pubmed.ncbi.nlm.nih.gov/3115816 DMJPD06 DI DMJPD06 DMJPD06 DN Lmw heparin DMJPD06 TI TTCIHJA DMJPD06 TN Coagulation factor Xa (F10) DMJPD06 MA Modulator DMJPD06 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMJPD06 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMJPR2B DI DMJPR2B DMJPR2B DN Glisoxepide DMJPR2B TI TTG140O DMJPR2B TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMJPR2B MA Blocker DMJPR2B RN Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther. 2006 Jan;316(1):182-8. DMJPR2B RU https://pubmed.ncbi.nlm.nih.gov/16174795 DMJSBT6 DI DMJSBT6 DMJSBT6 DN Silodosin DMJSBT6 TI TTNGILX DMJSBT6 TN Adrenergic receptor alpha-1A (ADRA1A) DMJSBT6 MA Inhibitor DMJSBT6 RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMJSBT6 RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMJTEMW DI DMJTEMW DMJTEMW DN Lubiprostone DMJTEMW TI TT30NW6 DMJTEMW TN Chloride channel protein 2 (CLC-2) DMJTEMW MA Activator DMJTEMW RN Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol. 2009 May;296(5):L811-24. DMJTEMW RU https://pubmed.ncbi.nlm.nih.gov/19233902 DMJTIYK DI DMJTIYK DMJTIYK DN Ipilimumab DMJTIYK TI TTI2S1D DMJTIYK TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJTIYK RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMJTIYK RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMJUNY5 DI DMJUNY5 DMJUNY5 DN Cefpodoxime DMJUNY5 TI TTJP4SM DMJUNY5 TN Bacterial Penicillin binding protein (Bact PBP) DMJUNY5 MA Binder DMJUNY5 RN Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45. DMJUNY5 RU https://pubmed.ncbi.nlm.nih.gov/16940068 DMJUVE6 DI DMJUVE6 DMJUVE6 DN Bulevirtide DMJUVE6 TI TTWZRY5 DMJUVE6 TN Sodium/bile acid cotransporter (SLC10A1) DMJUVE6 MA Inhibitor DMJUVE6 RN Bulevirtide: First Approval. Drugs. 2020 Oct;80(15):1601-1605. DMJUVE6 RU https://pubmed.ncbi.nlm.nih.gov/32926353 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT6PKBN DMJV2EK TN Proto-oncogene c-Src (SRC) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TTS7G69 DMJV2EK TN Fusion protein Bcr-Abl (Bcr-Abl) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT860QF DMJV2EK TN LCK tyrosine protein kinase (LCK) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJV2EK DI DMJV2EK DMJV2EK DN Dasatinib DMJV2EK TI TT2B9KF DMJV2EK TN Fyn tyrosine protein kinase (FYN) DMJV2EK MA Inhibitor DMJV2EK RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMJV2EK RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMJW0VS DI DMJW0VS DMJW0VS DN Tilidine DMJW0VS TI TTN4QDT DMJW0VS TN Opioid receptor (OPR) DMJW0VS MA Modulator DMJW0VS RN Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8. DMJW0VS RU https://pubmed.ncbi.nlm.nih.gov/15627429 DMJWRQP DI DMJWRQP DMJWRQP DN Zanubrutinib DMJWRQP TI TTGM6VW DMJWRQP TN Tyrosine-protein kinase BTK (ATK) DMJWRQP MA Inhibitor DMJWRQP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMJWRQP RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf DMJX6ZG DI DMJX6ZG DMJX6ZG DN Codeine DMJX6ZG TI TT27RFC DMJX6ZG TN Opioid receptor delta (OPRD1) DMJX6ZG MA Agonist DMJX6ZG RN Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. DMJX6ZG RU https://pubmed.ncbi.nlm.nih.gov/15942128 DMJXDGC DI DMJXDGC DMJXDGC DN Cefaclor DMJXDGC TI TTJP4SM DMJXDGC TN Bacterial Penicillin binding protein (Bact PBP) DMJXDGC MA Binder DMJXDGC RN Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74. DMJXDGC RU https://pubmed.ncbi.nlm.nih.gov/15747584 DMJXIC9 DI DMJXIC9 DMJXIC9 DN Anagliptin DMJXIC9 TI TTDIGC1 DMJXIC9 TN Dipeptidyl peptidase 4 (DPP-4) DMJXIC9 MA Modulator DMJXIC9 RN Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30. DMJXIC9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646042/ DMJYCVW DI DMJYCVW DMJYCVW DN Warfarin DMJYCVW TI TTEUC8H DMJYCVW TN Vitamin K epoxide reductase complex 1 (VKORC1) DMJYCVW MA Inhibitor DMJYCVW RN [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036. DMJYCVW RU https://pubmed.ncbi.nlm.nih.gov/17955831 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK TI TT4C8EA DMJYDVK TN Dopamine D3 receptor (D3R) DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMJYDVK DI DMJYDVK DMJYDVK DN Cariprazine DMJYDVK TI TTEX248 DMJYDVK TN Dopamine D2 receptor (D2R) DMJYDVK MA Modulator DMJYDVK RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMJYDVK RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMJYN25 DI DMJYN25 DMJYN25 DN Tenecteplase DMJYN25 TI TTP86E2 DMJYN25 TN Plasminogen (PLG) DMJYN25 MA Activator DMJYN25 RN Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. DMJYN25 RU https://pubmed.ncbi.nlm.nih.gov/15823070 DMJZHT1 DI DMJZHT1 DMJZHT1 DN Tadalafil DMJZHT1 TI TTJ0IQB DMJZHT1 TN Phosphodiesterase 5A (PDE5A) DMJZHT1 MA Inhibitor DMJZHT1 RN Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. DMJZHT1 RU https://pubmed.ncbi.nlm.nih.gov/19487219 DMK08L3 DI DMK08L3 DMK08L3 DN Amifampridine DMK08L3 TI TT1VOHK DMK08L3 TN Potassium channel unspecific (KC) DMK08L3 MA Blocker DMK08L3 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK08L3 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK0O7U DI DMK0O7U DMK0O7U DN Flutamide DMK0O7U TI TTS64P2 DMK0O7U TN Androgen receptor (AR) DMK0O7U MA Antagonist DMK0O7U RN Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002 Sep;60(3 Suppl 1):132-8; discussion 138-9. DMK0O7U RU https://pubmed.ncbi.nlm.nih.gov/12231070 DMK1GBJ DI DMK1GBJ DMK1GBJ DN Trazodone DMK1GBJ TI TT3ROYC DMK1GBJ TN Serotonin transporter (SERT) DMK1GBJ MA Modulator DMK1GBJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMK1GBJ RU https://www.fda.gov/ DMK1GBJ DI DMK1GBJ DMK1GBJ DN Trazodone DMK1GBJ TI TTSQIFT DMK1GBJ TN 5-HT 1A receptor (HTR1A) DMK1GBJ MA Modulator DMK1GBJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMK1GBJ RU https://www.fda.gov/ DMK1LZD DI DMK1LZD DMK1LZD DN Methoxy polyethylene glycol-epoetin beta DMK1LZD TI TTAUX24 DMK1LZD TN Erythropoietin Receptor (EPOR) DMK1LZD MA Activator DMK1LZD RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMK1LZD RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMK2GZX DI DMK2GZX DMK2GZX DN Avapritinib DMK2GZX TI TT8FYO9 DMK2GZX TN Platelet-derived growth factor receptor alpha (PDGFRA) DMK2GZX MA Inhibitor DMK2GZX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMK2GZX RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212608s000lbl.pdf DMK2PBD DI DMK2PBD DMK2PBD DN Palonosetron + fosnetupitant DMK2PBD TI TTZPO1L DMK2PBD TN Substance-P receptor (TACR1) DMK2PBD MA Antagonist DMK2PBD RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK2PBD RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK2PBD DI DMK2PBD DMK2PBD DN Palonosetron + fosnetupitant DMK2PBD TI TTPC4TU DMK2PBD TN 5-HT 3A receptor (HTR3A) DMK2PBD MA Antagonist DMK2PBD RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMK2PBD RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMK4OL7 DI DMK4OL7 DMK4OL7 DN Zinostatin stimalamer DMK4OL7 TI TTUTN1I DMK4OL7 TN Human Deoxyribonucleic acid (hDNA) DMK4OL7 MA Modulator DMK4OL7 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMK4OL7 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMK54YG DI DMK54YG DMK54YG DN Griseofulvin DMK54YG TI TT7PBUD DMK54YG TN Fungal Microtubule (Fung MicroTU) DMK54YG MA Inducer DMK54YG RN Dermatophyte infections. Am Fam Physician. 2003 Jan 1;67(1):101-8. DMK54YG RU https://pubmed.ncbi.nlm.nih.gov/12537173 DMK57GB DI DMK57GB DMK57GB DN Ethinamate DMK57GB TI TTANPDJ DMK57GB TN Carbonic anhydrase II (CA-II) DMK57GB MA Inhibitor DMK57GB RN Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. DMK57GB RU https://pubmed.ncbi.nlm.nih.gov/1460006 DMK659W DI DMK659W DMK659W DN Enteric-coated mycophenolate sodium DMK659W TI TTCAQMW DMK659W TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DMK659W MA Inhibitor DMK659W RN Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond). 2004 Jul;107(1):63-8. DMK659W RU https://pubmed.ncbi.nlm.nih.gov/14723604 DMK6XAV DI DMK6XAV DMK6XAV DN Bitolterol DMK6XAV TI TTMXGCW DMK6XAV TN Adrenergic receptor beta-3 (ADRB3) DMK6XAV MA Modulator DMK6XAV RN Bitolterol mesylate: a beta-adrenergic agent. Chemistry, pharmacokinetics, pharmacodynamics, adverse effects and clinical efficacy in asthma. Pharmacotherapy. 1985 May-Jun;5(3):127-37. DMK6XAV RU https://pubmed.ncbi.nlm.nih.gov/3895171 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S TI TTAWNKZ DMK7F9S TN Norepinephrine transporter (NET) DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7F9S DI DMK7F9S DMK7F9S DN Amitriptyline DMK7F9S TI TT3ROYC DMK7F9S TN Serotonin transporter (SERT) DMK7F9S MA Inhibitor DMK7F9S RN Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6. DMK7F9S RU https://pubmed.ncbi.nlm.nih.gov/18622371 DMK7HFI DI DMK7HFI DMK7HFI DN Mefenamic acid DMK7HFI TI TTVKILB DMK7HFI TN Prostaglandin G/H synthase 2 (COX-2) DMK7HFI MA Inhibitor DMK7HFI RN Systematic pharmacological approach to the characterization of NSAIDs. Prostaglandins Leukot Essent Fatty Acids. 1998 Jul;59(1):55-62. DMK7HFI RU https://pubmed.ncbi.nlm.nih.gov/9758208 DMK7IWL DI DMK7IWL DMK7IWL DN Relugolix DMK7IWL TI TT8R70G DMK7IWL TN Gonadotropin-releasing hormone receptor (GNRHR) DMK7IWL MA Antagonist DMK7IWL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMK7IWL RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214621s000lbl.pdf DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TTR6W5O DMK7MEY TN Adrenergic receptor beta-1 (ADRB1) DMK7MEY MA Agonist DMK7MEY RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TT2CJVK DMK7MEY TN Adrenergic receptor beta-2 (ADRB2) DMK7MEY MA Modulator DMK7MEY RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMK7MEY DI DMK7MEY DMK7MEY DN Isoproterenol DMK7MEY TI TTGW72V DMK7MEY TN Interleukin-12 beta (IL12B) DMK7MEY MA Modulator DMK7MEY RN A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. DMK7MEY RU https://pubmed.ncbi.nlm.nih.gov/21447719 DMK8U72 DI DMK8U72 DMK8U72 DN Labetalol DMK8U72 TI TTG28O6 DMK8U72 TN Adrenergic receptor Alpha-1 (ADRA1) DMK8U72 MA Antagonist DMK8U72 RN Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8. DMK8U72 RU https://pubmed.ncbi.nlm.nih.gov/19491545 DMKA8J4 DI DMKA8J4 DMKA8J4 DN Etonogestrel DMKA8J4 TI TTUV8G9 DMKA8J4 TN Progesterone receptor (PGR) DMKA8J4 MA Binder DMKA8J4 RN Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7. DMKA8J4 RU https://pubmed.ncbi.nlm.nih.gov/19434887 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTZFYLI DMKAEQW TN Dopamine D1 receptor (D1R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTE0A2F DMKAEQW TN Dopamine D4 receptor (D4R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTEX248 DMKAEQW TN Dopamine D2 receptor (D2R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKAEQW DI DMKAEQW DMKAEQW DN Phenyltoloxamine DMKAEQW TI TTS2PH3 DMKAEQW TN Dopamine D5 receptor (D5R) DMKAEQW MA Inhibitor DMKAEQW RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMKAEQW RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMKB79O DI DMKB79O DMKB79O DN Bromfenac DMKB79O TI TT8NGED DMKB79O TN Prostaglandin G/H synthase 1 (COX-1) DMKB79O MA Inhibitor DMKB79O RN Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. DMKB79O RU https://pubmed.ncbi.nlm.nih.gov/16846546 DMKB9FI DI DMKB9FI DMKB9FI DN Benzoic acid DMKB9FI TI TT958S6 DMKB9FI TN Ras-related protein Rab-9A (RAB9A) DMKB9FI MA Inhibitor DMKB9FI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKB9FI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP TI TTK25J1 DMKBJWP TN Adenosine A1 receptor (ADORA1) DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBJWP DI DMKBJWP DMKBJWP DN Caffeine DMKBJWP TI TTM2AOE DMKBJWP TN Adenosine A2a receptor (ADORA2A) DMKBJWP MA Antagonist DMKBJWP RN Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. DMKBJWP RU https://pubmed.ncbi.nlm.nih.gov/15095008 DMKBOS2 DI DMKBOS2 DMKBOS2 DN Levosimendan DMKBOS2 TI TT8RDXP DMKBOS2 TN Troponin C (TN-C) DMKBOS2 MA Stimulator DMKBOS2 RN Timing of levosimendan in cardiac surgery. Anadolu Kardiyol Derg. 2009 Jun;9(3):223-30. DMKBOS2 RU https://pubmed.ncbi.nlm.nih.gov/19520657 DMKBTFG DI DMKBTFG DMKBTFG DN Cefozopran DMKBTFG TI TT4ILYC DMKBTFG TN Bacterial Dihydropteroate synthetase (Bact folP) DMKBTFG MA Inhibitor DMKBTFG RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMKBTFG RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMKBW5C DI DMKBW5C DMKBW5C DN Talimogene Laherparepvec DMKBW5C TI TTNYZG2 DMKBW5C TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMKBW5C MA Modulator DMKBW5C RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKBW5C RU https://www.fda.gov/ DMKBYWI DI DMKBYWI DMKBYWI DN Trifluoperazine DMKBYWI TI TTV3NH6 DMKBYWI TN Calmodulin (CALM) DMKBYWI MA Inhibitor DMKBYWI RN Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5. DMKBYWI RU https://pubmed.ncbi.nlm.nih.gov/14531016 DMKCIUZ DI DMKCIUZ DMKCIUZ DN Daratumumab DMKCIUZ TI TTPURFN DMKCIUZ TN Cyclic ADP-ribose hydrolase 1 (CD38) DMKCIUZ RN Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015 Sep 24;373(13):1207-19. DMKCIUZ RU https://pubmed.ncbi.nlm.nih.gov/26308596 DMKDU16 DI DMKDU16 DMKDU16 DN Daptomycin DMKDU16 TI TT4ILYC DMKDU16 TN Bacterial Dihydropteroate synthetase (Bact folP) DMKDU16 MA Binder DMKDU16 RN Structural transitions as determinants of the action of the calcium-dependent antibiotic daptomycin. Chem Biol. 2004 Jul;11(7):949-57. DMKDU16 RU https://pubmed.ncbi.nlm.nih.gov/15271353 DMKE6YT DI DMKE6YT DMKE6YT DN Incobotulinum toxin A DMKE6YT TI TTZJD1B DMKE6YT TN Acetylcholine release (Ach rele) DMKE6YT MA Modulator DMKE6YT RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMKE6YT RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMKE7L9 DI DMKE7L9 DMKE7L9 DN Doxacurium DMKE7L9 TI TTS5WZF DMKE7L9 TN Neuronal acetylcholine receptor alpha (NACHRA) DMKE7L9 MA Antagonist DMKE7L9 RN Interaction of nondepolarizing muscle relaxants with M2 and M3 muscarinic receptors in guinea pig lung and heart. Anesthesiology. 1996 Jan;84(1):155-61. DMKE7L9 RU https://pubmed.ncbi.nlm.nih.gov/8572329 DMKECZD DI DMKECZD DMKECZD DN Temozolomide DMKECZD TI TTUTN1I DMKECZD TN Human Deoxyribonucleic acid (hDNA) DMKECZD MA Modulator DMKECZD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKECZD RU https://www.fda.gov/ DMKER83 DI DMKER83 DMKER83 DN Hesperetin DMKER83 TI TTF8P9I DMKER83 TN Diacylglycerol acyltransferase 1 (DGAT1) DMKER83 MA Inhibitor DMKER83 RN In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens. Planta Med. 2004 Mar;70(3):258-60. DMKER83 RU https://pubmed.ncbi.nlm.nih.gov/15114505 DMKEX7O DI DMKEX7O DMKEX7O DN Plecanatide DMKEX7O TI TTLDPRG DMKEX7O TN Guanylyl cyclase C (GUCY2C) DMKEX7O MA Modulator DMKEX7O RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKEX7O RU https://www.fda.gov/ DMKEY6S DI DMKEY6S DMKEY6S DN Margetuximab DMKEY6S TI TT6EO5L DMKEY6S TN Erbb2 tyrosine kinase receptor (HER2) DMKEY6S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMKEY6S RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf DMKFQJP DI DMKFQJP DMKFQJP DN Triflupromazine DMKFQJP TI TT0K1SC DMKFQJP TN 5-HT 2B receptor (HTR2B) DMKFQJP MA Antagonist DMKFQJP RN Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85. DMKFQJP RU https://pubmed.ncbi.nlm.nih.gov/497523 DMKGH0R DI DMKGH0R DMKGH0R DN GHRP-2 DMKGH0R TI TTZ3IFB DMKGH0R TN Phosphogluconate dehydrogenase (PGD) DMKGH0R MA Inhibitor DMKGH0R RN Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14. DMKGH0R RU https://pubmed.ncbi.nlm.nih.gov/12818683 DMKGH0R DI DMKGH0R DMKGH0R DN GHRP-2 DMKGH0R TI TTWDC17 DMKGH0R TN Growth hormone secretagogue receptor 1 (GHSR) DMKGH0R MA Agonist DMKGH0R RN GH-releasing peptide-2 increases fat mass in mice lacking NPY: indication for a crucial mediating role of hypothalamic agouti-related protein. Endocrinology. 2002 Feb;143(2):558-68. DMKGH0R RU https://pubmed.ncbi.nlm.nih.gov/11796511 DMKI2XC DI DMKI2XC DMKI2XC DN Sulfacytine DMKI2XC TI TT4ILYC DMKI2XC TN Bacterial Dihydropteroate synthetase (Bact folP) DMKI2XC MA Inhibitor DMKI2XC RN Sulfacytine in uncomplicated urinary tract infections. Double-blind comparison with sulfisoxazole. Urology. 1976 Mar;7(3):267-71. DMKI2XC RU https://pubmed.ncbi.nlm.nih.gov/769287 DMKI7RB DI DMKI7RB DMKI7RB DN Clomifene DMKI7RB TI TTZAYWL DMKI7RB TN Estrogen receptor (ESR) DMKI7RB MA Modulator DMKI7RB RN The future of the new selective estrogen receptor modulators. Menopause Int. 2007 Mar;13(1):27-34. DMKI7RB RU https://pubmed.ncbi.nlm.nih.gov/17448265 DMKINJO DI DMKINJO DMKINJO DN Gentamicin DMKINJO TI TTOVFH2 DMKINJO TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMKINJO MA Modulator DMKINJO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKINJO RU https://www.fda.gov/ DMKITQE DI DMKITQE DMKITQE DN Amoxapine DMKITQE TI TTAWNKZ DMKITQE TN Norepinephrine transporter (NET) DMKITQE MA Inhibitor DMKITQE RN Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25. DMKITQE RU https://pubmed.ncbi.nlm.nih.gov/7845548 DMKJ485 DI DMKJ485 DMKJ485 DN Pioglitazone DMKJ485 TI TTZMAO3 DMKJ485 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMKJ485 MA Agonist DMKJ485 RN Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7. DMKJ485 RU https://pubmed.ncbi.nlm.nih.gov/12379847 DMKJ8LB DI DMKJ8LB DMKJ8LB DN Josamycin DMKJ8LB TI TTUWYEA DMKJ8LB TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMKJ8LB MA Binder DMKJ8LB RN The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003 Jul 25;330(5):1005-14. DMKJ8LB RU https://pubmed.ncbi.nlm.nih.gov/12860123 DMKLAYG DI DMKLAYG DMKLAYG DN Altretamine DMKLAYG TI TTUTN1I DMKLAYG TN Human Deoxyribonucleic acid (hDNA) DMKLAYG MA Breaker DMKLAYG RN Synergy of irofulven in combination with other DNA damaging agents: synergistic interaction with altretamine, alkylating, and platinum-derived agen... Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. DMKLAYG RU https://pubmed.ncbi.nlm.nih.gov/18305940 DMKLJRD DI DMKLJRD DMKLJRD DN Fospropofol disodium DMKLJRD TI TTAN6JD DMKLJRD TN Glutamate receptor AMPA (GRIA) DMKLJRD MA Modulator DMKLJRD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMKLJRD RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMKLSHF DI DMKLSHF DMKLSHF DN Bambuterol DMKLSHF TI TT2CJVK DMKLSHF TN Adrenergic receptor beta-2 (ADRB2) DMKLSHF MA Agonist DMKLSHF RN Enantiomeric separation of beta2-agonists on macrocyclic antibiotic chiral stationary phases in high performance liquid chromatography. Pharmazie. 2007 Nov;62(11):836-40. DMKLSHF RU https://pubmed.ncbi.nlm.nih.gov/18065099 DMKM3SX DI DMKM3SX DMKM3SX DN Sulfamerazine DMKM3SX TI TT4ILYC DMKM3SX TN Bacterial Dihydropteroate synthetase (Bact folP) DMKM3SX MA Inhibitor DMKM3SX RN A confirmatory method for the simultaneous extraction, separation, identification and quantification of Tetracycline, Sulphonamide, Trimethoprim an... J Chromatogr A. 2009 Nov 13;1216(46):8110-6. DMKM3SX RU https://pubmed.ncbi.nlm.nih.gov/19586630 DMKMBES DI DMKMBES DMKMBES DN Plazomicin DMKMBES TI TTUQ7WN DMKMBES TN Mitochondrial rRNA methyltransferase 2 (MRM2) DMKMBES MA Inhibitor DMKMBES RN In vitro activity of plazomicin against -lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).J Antimicrob Chemother. 2017 Oct 1;72(10):2792-2795. DMKMBES RU https://pubmed.ncbi.nlm.nih.gov/29091224 DMKMJHE DI DMKMJHE DMKMJHE DN Cemiplimab DMKMJHE TI TTNBFWK DMKMJHE TN Programmed cell death protein 1 (PD-1) DMKMJHE MA Modulator DMKMJHE RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKMJHE RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMKMWQG DI DMKMWQG DMKMWQG DN Olopatadine DMKMWQG TI TTTIBOJ DMKMWQG TN Histamine H1 receptor (H1R) DMKMWQG MA Antagonist DMKMWQG RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMKMWQG RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMKN345 DI DMKN345 DMKN345 DN Charybdotoxin DMKN345 TI TTMNI76 DMKN345 TN Calcium-activated potassium channel (KCN) DMKN345 MA Blocker DMKN345 RN Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8. DMKN345 RU https://pubmed.ncbi.nlm.nih.gov/16741254 DMKOJSN DI DMKOJSN DMKOJSN DN Necitumumab DMKOJSN TI TTGKNB4 DMKOJSN TN Epidermal growth factor receptor (EGFR) DMKOJSN MA Modulator DMKOJSN RN Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54. DMKOJSN RU https://pubmed.ncbi.nlm.nih.gov/21154166 DMKOXFE DI DMKOXFE DMKOXFE DN Doxylamine DMKOXFE TI TTTIBOJ DMKOXFE TN Histamine H1 receptor (H1R) DMKOXFE MA Antagonist DMKOXFE RN First-generation H1 antihistamines found in pilot fatalities of civil aviation accidents, 1990-2005. Aviat Space Environ Med. 2007 May;78(5):514-22. DMKOXFE RU https://pubmed.ncbi.nlm.nih.gov/17539447 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA TI TTTIBOJ DMKQTBA TN Histamine H1 receptor (H1R) DMKQTBA MA Antagonist DMKQTBA RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMKQTBA DI DMKQTBA DMKQTBA DN Diphenhydramine DMKQTBA TI TT2B6EV DMKQTBA TN Histamine N-methyltransferase (HNMT) DMKQTBA MA Inhibitor DMKQTBA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKQTBA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKR3C5 DI DMKR3C5 DMKR3C5 DN Ergotamine DMKR3C5 TI TTG28O6 DMKR3C5 TN Adrenergic receptor Alpha-1 (ADRA1) DMKR3C5 MA Agonist DMKR3C5 RN Reversal of ergotamine-induced vasospasm following methylprednisolone. Clin Toxicol (Phila). 2008 Dec;46(10):1074-6. DMKR3C5 RU https://pubmed.ncbi.nlm.nih.gov/18763151 DMKS1DV DI DMKS1DV DMKS1DV DN SARALASIN DMKS1DV TI TTQVOEI DMKS1DV TN Angiotensin II receptor type-2 (AGTR2) DMKS1DV MA Inhibitor DMKS1DV RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMKS1DV RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMKS1DV DI DMKS1DV DMKS1DV DN SARALASIN DMKS1DV TI TT8DBY3 DMKS1DV TN Angiotensin II receptor type-1 (AGTR1) DMKS1DV MA Inhibitor DMKS1DV RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMKS1DV RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMKSQG0 DI DMKSQG0 DMKSQG0 DN Tiagabine DMKSQG0 TI TTV9MQG DMKSQG0 TN Gamma-aminobutyric acid uptake (GABAU) DMKSQG0 MA Inhibitor DMKSQG0 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMKSQG0 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMKSQG0 DI DMKSQG0 DMKSQG0 DN Tiagabine DMKSQG0 TI TTPRKM0 DMKSQG0 TN GABA transporter GAT-1 (SLC6A1) DMKSQG0 MA Inhibitor DMKSQG0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929). DMKSQG0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929 DMKSTWR DI DMKSTWR DMKSTWR DN L-Proline DMKSTWR TI TT6ZFQ4 DMKSTWR TN Rotamase B (PPIB) DMKSTWR MA Binder DMKSTWR RN Escherichia coli cyclophilin B binds a highly distorted form of trans-prolyl peptide isomer. Eur J Biochem. 2004 Sep;271(18):3794-803. DMKSTWR RU https://pubmed.ncbi.nlm.nih.gov/15355356 DMKSTWR DI DMKSTWR DMKSTWR DN L-Proline DMKSTWR TI TTL2ADK DMKSTWR TN Rotamase A (PPIA) DMKSTWR MA Binder DMKSTWR RN Mechanistic insight into the role of transition-state stabilization in cyclophilin A. J Am Chem Soc. 2009 Jan 14;131(1):147-52. DMKSTWR RU https://pubmed.ncbi.nlm.nih.gov/19128175 DMKUOQV DI DMKUOQV DMKUOQV DN Burosumab DMKUOQV TI TT2IZ4K DMKUOQV TN Fibroblast growth factor-23 (FGF23) DMKUOQV MA Modulator DMKUOQV RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMKUOQV RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMKV4NL DI DMKV4NL DMKV4NL DN Flavoxate DMKV4NL TI TTH18TF DMKV4NL TN Muscarinic acetylcholine receptor M5 (CHRM5) DMKV4NL MA Antagonist DMKV4NL RN Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats. Brain Res. 1996 Jul 15;727(1-2):91-8. DMKV4NL RU https://pubmed.ncbi.nlm.nih.gov/8842386 DMKVOYF DI DMKVOYF DMKVOYF DN Penicillin V DMKVOYF TI TTJP4SM DMKVOYF TN Bacterial Penicillin binding protein (Bact PBP) DMKVOYF MA Binder DMKVOYF RN Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol. 1995 Jul;177(13):3631-40. DMKVOYF RU https://pubmed.ncbi.nlm.nih.gov/7541399 DMKVWGE DI DMKVWGE DMKVWGE DN Dexbrompheniramine DMKVWGE TI TTTIBOJ DMKVWGE TN Histamine H1 receptor (H1R) DMKVWGE MA Antagonist DMKVWGE RN H2 histaminergic control of inhibition of eating induced by intragastric NaCl in rats. Physiol Behav. 1998 Aug;65(1):105-13. DMKVWGE RU https://pubmed.ncbi.nlm.nih.gov/9811372 DMKWB73 DI DMKWB73 DMKWB73 DN Epoetin alfa DMKWB73 TI TTAUX24 DMKWB73 TN Erythropoietin Receptor (EPOR) DMKWB73 MA Agonist DMKWB73 RN 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12. DMKWB73 RU https://pubmed.ncbi.nlm.nih.gov/19229970 DMKWFBT DI DMKWFBT DMKWFBT DN Melatonin DMKWFBT TI TT0WAIE DMKWFBT TN Melatonin receptor type 1A (MTNR1A) DMKWFBT MA Binder DMKWFBT RN The human MT1 melatonin receptor stimulates cAMP production in the human neuroblastoma cell line SH-SY5Y cells via a calcium-calmodulin signal transduction pathway. J Neuroendocrinol. 2005 Mar;17(3):170-8. DMKWFBT RU https://pubmed.ncbi.nlm.nih.gov/15796769 DMKWFBT DI DMKWFBT DMKWFBT DN Melatonin DMKWFBT TI TTJLP0R DMKWFBT TN Quinone reductase 2 (NQO2) DMKWFBT MA Inhibitor DMKWFBT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKWFBT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKXJZ7 DI DMKXJZ7 DMKXJZ7 DN Suprofen DMKXJZ7 TI TT8NGED DMKXJZ7 TN Prostaglandin G/H synthase 1 (COX-1) DMKXJZ7 MA Inhibitor DMKXJZ7 RN Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71. DMKXJZ7 RU https://pubmed.ncbi.nlm.nih.gov/11885959 DMKXY2R DI DMKXY2R DMKXY2R DN Ibutilide DMKXY2R TI TT1VOHK DMKXY2R TN Potassium channel unspecific (KC) DMKXY2R MA Modulator DMKXY2R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKXY2R RU https://www.fda.gov/ DMKY8V1 DI DMKY8V1 DMKY8V1 DN Propiomazine DMKY8V1 TI TTTIBOJ DMKY8V1 TN Histamine H1 receptor (H1R) DMKY8V1 MA Antagonist DMKY8V1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKY8V1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKYD5N DI DMKYD5N DMKYD5N DN Zuclopenthixol DMKYD5N TI TTEX248 DMKYD5N TN Dopamine D2 receptor (D2R) DMKYD5N MA Antagonist DMKYD5N RN An ethopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Methods Find Exp Clin Pharmacol. 1999 Jan-Feb;21(1):11-5. DMKYD5N RU https://pubmed.ncbi.nlm.nih.gov/10222441 DMKZEIB DI DMKZEIB DMKZEIB DN Felbinac DMKZEIB TI TTK0943 DMKZEIB TN Prostaglandin G/H synthase (COX) DMKZEIB MA Modulator DMKZEIB RN A review of the effects of fenbufen and a metabolite, biphenylacetic acid, on platelet biochemistry and function. Arzneimittelforschung. 1980;30(4A):702-7. DMKZEIB RU https://pubmed.ncbi.nlm.nih.gov/6254545 DMKZROL DI DMKZROL DMKZROL DN Saralasin Acetate DMKZROL TI TT8DBY3 DMKZROL TN Angiotensin II receptor type-1 (AGTR1) DMKZROL MA Modulator DMKZROL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMKZROL RU https://www.fda.gov/ DML0B41 DI DML0B41 DML0B41 DN Naloxegol DML0B41 TI TTKWM86 DML0B41 TN Opioid receptor mu (MOP) DML0B41 MA Modulator DML0B41 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DML0B41 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DML0D1P DI DML0D1P DML0D1P DN Reteplase DML0D1P TI TTP86E2 DML0D1P TN Plasminogen (PLG) DML0D1P MA Activator DML0D1P RN Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem. 2008 Jul;6(3):212-23. DML0D1P RU https://pubmed.ncbi.nlm.nih.gov/18673235 DML0RAE DI DML0RAE DML0RAE DN Methoxyflurane DML0RAE TI TT1MPAY DML0RAE TN GABA(A) receptor alpha-1 (GABRA1) DML0RAE MA Antagonist DML0RAE RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DML0RAE RU https://pubmed.ncbi.nlm.nih.gov/18048412 DML1538 DI DML1538 DML1538 DN Diazoxide DML1538 TI TT1VOHK DML1538 TN Potassium channel unspecific (KC) DML1538 MA Modulator DML1538 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DML1538 RU https://www.fda.gov/ DML2A03 DI DML2A03 DML2A03 DN Alosetron DML2A03 TI TTPC4TU DML2A03 TN 5-HT 3A receptor (HTR3A) DML2A03 MA Antagonist DML2A03 RN Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844. DML2A03 RU https://pubmed.ncbi.nlm.nih.gov/19471254 DML2NIB DI DML2NIB DML2NIB DN Aminophylline DML2NIB TI TT06AWU DML2NIB TN Phosphodiesterase 3A (PDE3A) DML2NIB MA Inhibitor DML2NIB RN Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3. DML2NIB RU https://pubmed.ncbi.nlm.nih.gov/17391155 DML4ZOT DI DML4ZOT DML4ZOT DN Lidocaine DML4ZOT TI TTN9VTF DML4ZOT TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DML4ZOT MA Blocker DML4ZOT RN Mechanisms of analgesia of intravenous lidocaine. Rev Bras Anestesiol. 2008 May-Jun;58(3):280-6. DML4ZOT RU https://pubmed.ncbi.nlm.nih.gov/19378524 DML53ZJ DI DML53ZJ DML53ZJ DN Mirtazapine DML53ZJ TI TTWJBZ5 DML53ZJ TN 5-HT 2C receptor (HTR2C) DML53ZJ MA Antagonist DML53ZJ RN Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulatio... Mol Pharmacol. 2008 Mar;73(3):748-57. DML53ZJ RU https://pubmed.ncbi.nlm.nih.gov/18083778 DML5VQ0 DI DML5VQ0 DML5VQ0 DN Fenoprofen DML5VQ0 TI TTK0943 DML5VQ0 TN Prostaglandin G/H synthase (COX) DML5VQ0 MA Inhibitor DML5VQ0 RN The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62. DML5VQ0 RU https://pubmed.ncbi.nlm.nih.gov/17409433 DML60TN DI DML60TN DML60TN DN Sotalol DML60TN TI TTR6W5O DML60TN TN Adrenergic receptor beta-1 (ADRB1) DML60TN MA Antagonist DML60TN RN beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. DML60TN RU https://pubmed.ncbi.nlm.nih.gov/19259968 DML6OE7 DI DML6OE7 DML6OE7 DN Tbo-Filgrastim DML6OE7 TI TTC70AJ DML6OE7 TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DML6OE7 MA Modulator DML6OE7 RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DML6OE7 RU https://pubmed.ncbi.nlm.nih.gov/23370234 DML6SRO DI DML6SRO DML6SRO DN Alacepril DML6SRO TI TTL69WB DML6SRO TN Angiotensin-converting enzyme (ACE) DML6SRO MA Modulator DML6SRO RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DML6SRO RU https://pubmed.ncbi.nlm.nih.gov/17309302 DML72VJ DI DML72VJ DML72VJ DN GW685698X DML72VJ TI TTYRL6O DML72VJ TN Glucocorticoid receptor (NR3C1) DML72VJ MA Agonist DML72VJ RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DML72VJ RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DML8KTN DI DML8KTN DML8KTN DN Danazol DML8KTN TI TTZAYWL DML8KTN TN Estrogen receptor (ESR) DML8KTN MA Antagonist DML8KTN RN Danazol suppression of luteinizing hormone in the rat: evidence for mediation by both androgen and estrogen receptors. Proc Soc Exp Biol Med. 1990 May;194(1):54-7. DML8KTN RU https://pubmed.ncbi.nlm.nih.gov/2326286 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ TI TTMXGCW DML8QSZ TN Adrenergic receptor beta-3 (ADRB3) DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DML8QSZ DI DML8QSZ DML8QSZ DN Amosulalol DML8QSZ TI TT2NUT5 DML8QSZ TN Adrenergic receptor alpha-2C (ADRA2C) DML8QSZ MA Modulator DML8QSZ RN Effects of amosulalol, a combined alpha 1- and beta-adrenoceptor-blocking agent, on ischemic myocardial energy metabolism in dogs. J Pharm Sci. 1993 Mar;82(3):291-5. DML8QSZ RU https://pubmed.ncbi.nlm.nih.gov/8095542 DML97WV DI DML97WV DML97WV DN Pemirolast DML97WV TI TTTIBOJ DML97WV TN Histamine H1 receptor (H1R) DML97WV MA Antagonist DML97WV RN The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica. 2008;222(4):232-9. DML97WV RU https://pubmed.ncbi.nlm.nih.gov/18463425 DML9TI0 DI DML9TI0 DML9TI0 DN Ombitasvir + paritaprevir + ritonavir DML9TI0 TI TTWXB3E DML9TI0 TN Hepatitis C virus NS3 helicase (HCV NS3) DML9TI0 MA Modulator DML9TI0 RN HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy DML9TI0 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632384 DMLB0EZ DI DMLB0EZ DMLB0EZ DN Tamoxifen DMLB0EZ TI TTZAYWL DMLB0EZ TN Estrogen receptor (ESR) DMLB0EZ MA Antagonist DMLB0EZ RN Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86. DMLB0EZ RU https://pubmed.ncbi.nlm.nih.gov/18991792 DMLBVKQ DI DMLBVKQ DMLBVKQ DN Entacapone DMLBVKQ TI TTKWFB8 DMLBVKQ TN Catechol-O-methyl-transferase (COMT) DMLBVKQ MA Inhibitor DMLBVKQ RN Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Clin Ther. 2001 Jun;23(6):802-32; discussion 771. DMLBVKQ RU https://pubmed.ncbi.nlm.nih.gov/11440283 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TTVBI8W DMLDQFV TN Dopamine transporter (DAT) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TTAWNKZ DMLDQFV TN Norepinephrine transporter (NET) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TT3ROYC DMLDQFV TN Serotonin transporter (SERT) DMLDQFV MA Inhibitor DMLDQFV RN Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52. DMLDQFV RU https://pubmed.ncbi.nlm.nih.gov/25948101 DMLDQFV DI DMLDQFV DMLDQFV DN Dasotraline DMLDQFV TI TT8G3Z7 DMLDQFV TN Serotoninnorepinephrinedopamine reuptake (SNDR) DMLDQFV MA Inhibitor DMLDQFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLDQFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMLE7IO DI DMLE7IO DMLE7IO DN Tigecycline DMLE7IO TI TTQ8KVI DMLE7IO TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMLE7IO MA Binder DMLE7IO RN Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110. DMLE7IO RU https://pubmed.ncbi.nlm.nih.gov/16863487 DMLEDNK DI DMLEDNK DMLEDNK DN Carbenicillin DMLEDNK TI TTJP4SM DMLEDNK TN Bacterial Penicillin binding protein (Bact PBP) DMLEDNK MA Binder DMLEDNK RN Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23. DMLEDNK RU https://pubmed.ncbi.nlm.nih.gov/2112536 DMLFX7K DI DMLFX7K DMLFX7K DN LCZ696 DMLFX7K TI TT5TKPM DMLFX7K TN Neutral endopeptidase (MME) DMLFX7K MA Modulator DMLFX7K RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMLFX7K RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMLFZHD DI DMLFZHD DMLFZHD DN Aclarubicin DMLFZHD TI TT0IHXV DMLFZHD TN DNA topoisomerase II (TOP2) DMLFZHD MA Inhibitor DMLFZHD RN Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines. Anticancer Drug Des. 2001 Dec;16(6):305-15. DMLFZHD RU https://pubmed.ncbi.nlm.nih.gov/12375883 DMLHESP DI DMLHESP DMLHESP DN Chlorothiazide DMLHESP TI TTANPDJ DMLHESP TN Carbonic anhydrase II (CA-II) DMLHESP MA Inhibitor DMLHESP RN Localization of diuretic effects along the loop of Henle: an in vivo microperfusion study in rats. Clin Sci (Lond). 2000 Apr;98(4):481-8. DMLHESP RU https://pubmed.ncbi.nlm.nih.gov/10731484 DMLHOA0 DI DMLHOA0 DMLHOA0 DN Xatral DMLHOA0 TI TTNGILX DMLHOA0 TN Adrenergic receptor alpha-1A (ADRA1A) DMLHOA0 MA Antagonist DMLHOA0 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMLHOA0 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMLHSE3 DI DMLHSE3 DMLHSE3 DN Oxtriphylline DMLHSE3 TI TTV5CGO DMLHSE3 TN Phosphodiesterase 4 (PDE4) DMLHSE3 MA Modulator DMLHSE3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLHSE3 RU https://www.fda.gov/ DMLHSE3 DI DMLHSE3 DMLHSE3 DN Oxtriphylline DMLHSE3 TI TTZCG4L DMLHSE3 TN Phosphodiesterase 3 (PDE3) DMLHSE3 MA Modulator DMLHSE3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLHSE3 RU https://www.fda.gov/ DMLJ634 DI DMLJ634 DMLJ634 DN Sodium lauryl sulfate DMLJ634 TI TTFNGC9 DMLJ634 TN Serum albumin (ALB) DMLJ634 MA Binder DMLJ634 RN Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7. DMLJ634 RU https://pubmed.ncbi.nlm.nih.gov/16085141 DMLK2QH DI DMLK2QH DMLK2QH DN Nateglinide DMLK2QH TI TT1VOHK DMLK2QH TN Potassium channel unspecific (KC) DMLK2QH MA Modulator DMLK2QH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLK2QH RU https://www.fda.gov/ DMLKFC4 DI DMLKFC4 DMLKFC4 DN Quinupristin DMLKFC4 TI TTIB7O8 DMLKFC4 TN Bacterial Integral membrane LmrP (Bact lmrP) DMLKFC4 MA Modulator DMLKFC4 RN The lactococcal secondary multidrug transporter LmrP confers resistance to lincosamides, macrolides, streptogramins and tetracyclines. Microbiology. 2001 Oct;147(Pt 10):2873-80. DMLKFC4 RU https://pubmed.ncbi.nlm.nih.gov/11577166 DMLKSE0 DI DMLKSE0 DMLKSE0 DN Hexachlorophene DMLKSE0 TI TTAO7YK DMLKSE0 TN Plasmodium Glutamate dehydrogenase (Malaria gdh) DMLKSE0 MA Inhibitor DMLKSE0 RN Novel inhibitors complexed with glutamate dehydrogenase: allosteric regulation by control of protein dynamics. J Biol Chem. 2009 Aug 21;284(34):22988-3000. DMLKSE0 RU https://pubmed.ncbi.nlm.nih.gov/19531491 DMLMXE0 DI DMLMXE0 DMLMXE0 DN Amprenavir DMLMXE0 TI TT5FNQT DMLMXE0 TN Human immunodeficiency virus Protease (HIV PR) DMLMXE0 MA Inhibitor DMLMXE0 RN Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69(4):477-503. DMLMXE0 RU https://pubmed.ncbi.nlm.nih.gov/19323590 DMLNCE0 DI DMLNCE0 DMLNCE0 DN Cetuximab DMLNCE0 TI TTGKNB4 DMLNCE0 TN Epidermal growth factor receptor (EGFR) DMLNCE0 RN Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14. DMLNCE0 RU https://pubmed.ncbi.nlm.nih.gov/12479268 DMLNMEA DI DMLNMEA DMLNMEA DN Estradiol valerate/dienogest DMLNMEA TI TTUV8G9 DMLNMEA TN Progesterone receptor (PGR) DMLNMEA MA Modulator DMLNMEA RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMLNMEA RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMLOQ1V DI DMLOQ1V DMLOQ1V DN Tasimelteon DMLOQ1V TI TT32JK8 DMLOQ1V TN Melatonin receptor type 1B (MTNR1B) DMLOQ1V MA Agonist DMLOQ1V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393). DMLOQ1V RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 DMLOQ1V DI DMLOQ1V DMLOQ1V DN Tasimelteon DMLOQ1V TI TT0WAIE DMLOQ1V TN Melatonin receptor type 1A (MTNR1A) DMLOQ1V MA Agonist DMLOQ1V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7393). DMLOQ1V RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7393 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTHBTOP DMLOS5R TN PI3-kinase gamma (PIK3CG) DMLOS5R MA Modulator DMLOS5R RN BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110 and p110 activities in tumor cell lines and xenograft models.Mol Cancer Ther.2013 Nov;12(11):2319-30. DMLOS5R RU https://www.ncbi.nlm.nih.gov/pubmed/24170767 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTGBPJE DMLOS5R TN PI3-kinase delta (PIK3CD) DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLOS5R DI DMLOS5R DMLOS5R DN Bay 80-6946 DMLOS5R TI TTEUNMR DMLOS5R TN PI3-kinase alpha (PIK3CA) DMLOS5R MA Inhibitor DMLOS5R RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMLOS5R RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMLPAOB DI DMLPAOB DMLPAOB DN Allopurinol DMLPAOB TI TT7RJY8 DMLPAOB TN Xanthine dehydrogenase/oxidase (XDH) DMLPAOB MA Inhibitor DMLPAOB RN Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1. DMLPAOB RU https://pubmed.ncbi.nlm.nih.gov/5324754 DMLPSWQ DI DMLPSWQ DMLPSWQ DN Niraparib Tosylate DMLPSWQ TI TTVDSZ0 DMLPSWQ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMLPSWQ MA Modulator DMLPSWQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLPSWQ RU https://www.fda.gov/ DMLS39E DI DMLS39E DMLS39E DN Proparacaine DMLS39E TI TT90XZ8 DMLS39E TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMLS39E MA Modulator DMLS39E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLS39E RU https://www.fda.gov/ DMLSUWZ DI DMLSUWZ DMLSUWZ DN PSI-7977 DMLSUWZ TI TTMVBWH DMLSUWZ TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMLSUWZ MA Modulator DMLSUWZ RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMLSUWZ RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMLT0E1 DI DMLT0E1 DMLT0E1 DN Conjugated estrogens DMLT0E1 TI TTOM3J0 DMLT0E1 TN Estrogen receptor beta (ESR2) DMLT0E1 MA Antagonist DMLT0E1 RN Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogens combination. Mol Endocrinol. 2009 Jan;23(1):74-85. DMLT0E1 RU https://pubmed.ncbi.nlm.nih.gov/19036900 DMLUA9D DI DMLUA9D DMLUA9D DN Simeprevir DMLUA9D TI TTHC7JD DMLUA9D TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMLUA9D MA Modulator DMLUA9D RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMLUA9D RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMLVSYX DI DMLVSYX DMLVSYX DN Remimazolam DMLVSYX TI TTEX6LM DMLVSYX TN GABA(A) receptor gamma-3 (GABRG3) DMLVSYX MA Agonist DMLVSYX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMLVSYX RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212295s000lbl.pdf DMLW57T DI DMLW57T DMLW57T DN Teniposide DMLW57T TI TT0IHXV DMLW57T TN DNA topoisomerase II (TOP2) DMLW57T MA Modulator DMLW57T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMLW57T RU https://www.fda.gov/ DMLW9HG DI DMLW9HG DMLW9HG DN Tildrakizumab DMLW9HG TI TTC1GLB DMLW9HG TN Interleukin-23 (IL23) DMLW9HG MA Modulator DMLW9HG RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMLW9HG RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMLW9HG DI DMLW9HG DMLW9HG DN Tildrakizumab DMLW9HG TI TTQTX98 DMLW9HG TN Interleukin-37 (IL37) DMLW9HG MA Inhibitor DMLW9HG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLW9HG RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 TI TT8DBY3 DMLWQ27 TN Angiotensin II receptor type-1 (AGTR1) DMLWQ27 MA Inhibitor DMLWQ27 RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMLWQ27 RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMLWQ27 DI DMLWQ27 DMLWQ27 DN Angiotensin Ii DMLWQ27 TI TTQVOEI DMLWQ27 TN Angiotensin II receptor type-2 (AGTR2) DMLWQ27 MA Inhibitor DMLWQ27 RN The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993). DMLWQ27 RU http://www.sciencedirect.com/science/article/pii/S0960894X00806885 DMLZNIQ DI DMLZNIQ DMLZNIQ DN Sarecycline DMLZNIQ TI TTOVFH2 DMLZNIQ TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMLZNIQ MA Inhibitor DMLZNIQ RN Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris.Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01297-18. DMLZNIQ RU https://pubmed.ncbi.nlm.nih.gov/30397052 DMM0HR1 DI DMM0HR1 DMM0HR1 DN Pargyline DMM0HR1 TI TTGP7BY DMM0HR1 TN Monoamine oxidase type B (MAO-B) DMM0HR1 MA Inhibitor DMM0HR1 RN Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8. DMM0HR1 RU https://pubmed.ncbi.nlm.nih.gov/19542488 DMM0HR1 DI DMM0HR1 DMM0HR1 DN Pargyline DMM0HR1 TI TT32XQJ DMM0HR1 TN Monoamine oxidase (MAO) DMM0HR1 MA Inhibitor DMM0HR1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMM0HR1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMM0PDO DI DMM0PDO DMM0PDO DN Dalfampridine DMM0PDO TI TT1VOHK DMM0PDO TN Potassium channel unspecific (KC) DMM0PDO MA Modulator DMM0PDO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMM0PDO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMM0XGL DI DMM0XGL DMM0XGL DN Idarubicin DMM0XGL TI TT0IHXV DMM0XGL TN DNA topoisomerase II (TOP2) DMM0XGL MA Modulator DMM0XGL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM0XGL RU https://www.fda.gov/ DMM13DI DI DMM13DI DMM13DI DN Tasosartan DMM13DI TI TT8DBY3 DMM13DI TN Angiotensin II receptor type-1 (AGTR1) DMM13DI MA Antagonist DMM13DI RN Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. DMM13DI RU https://pubmed.ncbi.nlm.nih.gov/11046101 DMM1JL9 DI DMM1JL9 DMM1JL9 DN Amcinonide DMM1JL9 TI TTP3UTW DMM1JL9 TN Steroid hormone receptor ERR (ESRR) DMM1JL9 MA Modulator DMM1JL9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM1JL9 RU https://www.fda.gov/ DMM2NSK DI DMM2NSK DMM2NSK DN Adenosine DMM2NSK TI TTNE7KG DMM2NSK TN Adenosine A2b receptor (ADORA2B) DMM2NSK MA Modulator DMM2NSK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM2NSK RU https://www.fda.gov/ DMM32GT DI DMM32GT DMM32GT DN Risankizumab DMM32GT TI TTC1GLB DMM32GT TN Interleukin-23 (IL23) DMM32GT MA Inhibitor DMM32GT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMM32GT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf DMM3950 DI DMM3950 DMM3950 DN Sodium chloride DMM3950 TI TTQ8AFT DMM3950 TN Adrenergic receptor Alpha-2 (ADRA2) DMM3950 MA Agonist DMM3950 RN Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403. DMM3950 RU https://pubmed.ncbi.nlm.nih.gov/11164065 DMM39BF DI DMM39BF DMM39BF DN Mitoxantrone DMM39BF TI TT0IHXV DMM39BF TN DNA topoisomerase II (TOP2) DMM39BF MA Modulator DMM39BF RN Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. DMM39BF RU https://pubmed.ncbi.nlm.nih.gov/9450803 DMM3L6Z DI DMM3L6Z DMM3L6Z DN Ketobemidone DMM3L6Z TI TTN4QDT DMM3L6Z TN Opioid receptor (OPR) DMM3L6Z MA Modulator DMM3L6Z RN The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4. DMM3L6Z RU https://pubmed.ncbi.nlm.nih.gov/8878254 DMM4FXA DI DMM4FXA DMM4FXA DN Asfotase alfa DMM4FXA TI TTMR5UV DMM4FXA TN Alkaline phosphatase tissue-nonspecific (ALPL) DMM4FXA MA Modulator DMM4FXA RN Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012 Mar 8;366(10):904-13. DMM4FXA RU https://pubmed.ncbi.nlm.nih.gov/22397652 DMM4QOJ DI DMM4QOJ DMM4QOJ DN Metadoxine DMM4QOJ TI TTPRKM0 DMM4QOJ TN GABA transporter GAT-1 (SLC6A1) DMM4QOJ MA Modulator DMM4QOJ RN Company report (Alcobra pharma) DMM4QOJ RU http://www.alcobra-pharma.com/products.cfm?productID=163127 DMM4U9G DI DMM4U9G DMM4U9G DN R0-93877 DMM4U9G TI TT07C3Y DMM4U9G TN 5-HT 4 receptor (HTR4) DMM4U9G MA Agonist DMM4U9G RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DMM4U9G RU https://pubmed.ncbi.nlm.nih.gov/11293643 DMM58JY DI DMM58JY DMM58JY DN Ziprasidone DMM58JY TI TTEX248 DMM58JY TN Dopamine D2 receptor (D2R) DMM58JY MA Agonist DMM58JY RN Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17. DMM58JY RU https://pubmed.ncbi.nlm.nih.gov/19011428 DMM58JY DI DMM58JY DMM58JY DN Ziprasidone DMM58JY TI TTLA931 DMM58JY TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMM58JY MA Binder DMM58JY RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMM58JY RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMM765C DI DMM765C DMM765C DN Nitroprusside DMM765C TI TTC9IZL DMM765C TN Inositol 1,4,5-trisphosphate receptor (ITPR) DMM765C MA Antagonist DMM765C RN Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation. J Biol Chem. 1996 Mar 8;271(10):5545-51. DMM765C RU https://pubmed.ncbi.nlm.nih.gov/8621413 DMM7CHK DI DMM7CHK DMM7CHK DN Trimethoprim DMM7CHK TI TTYZVDJ DMM7CHK TN Dihydrofolate reductase (DHFR) DMM7CHK MA Modulator DMM7CHK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM7CHK RU https://www.fda.gov/ DMM9BJD DI DMM9BJD DMM9BJD DN Tisagenlecleucel DMM9BJD TI TTUE541 DMM9BJD TN Leukocyte surface antigen Leu-16 (CD20) DMM9BJD MA Immunostimulant DMM9BJD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM9BJD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMM9BJD DI DMM9BJD DMM9BJD DN Tisagenlecleucel DMM9BJD TI TTW640A DMM9BJD TN B-lymphocyte surface antigen B4 (CD19) DMM9BJD MA Immunostimulant DMM9BJD RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMM9BJD RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMMAWLU DI DMMAWLU DMMAWLU DN Huperzine A DMMAWLU TI TT1RS9F DMMAWLU TN Acetylcholinesterase (AChE) DMMAWLU MA Inhibitor DMMAWLU RN Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70. DMMAWLU RU https://pubmed.ncbi.nlm.nih.gov/12213312 DMMAWLU DI DMMAWLU DMMAWLU DN Huperzine A DMMAWLU TI TT9IK2Z DMMAWLU TN N-methyl-D-aspartate receptor (NMDAR) DMMAWLU MA Antagonist DMMAWLU RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMMAWLU RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMMAWY1 DI DMMAWY1 DMMAWY1 DN Adefovir dipivoxil DMMAWY1 TI TT84ETX DMMAWY1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMAWY1 MA Modulator DMMAWY1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMAWY1 RU https://www.fda.gov/ DMMC345 DI DMMC345 DMMC345 DN Cefadroxil DMMC345 TI TTJP4SM DMMC345 TN Bacterial Penicillin binding protein (Bact PBP) DMMC345 MA Binder DMMC345 RN Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32. DMMC345 RU https://pubmed.ncbi.nlm.nih.gov/9352657 DMMC45B DI DMMC45B DMMC45B DN Teriparatide DMMC45B TI TT6F7GZ DMMC45B TN Parathyroid hormone (PTH) DMMC45B MA Modulator DMMC45B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMC45B RU https://www.fda.gov/ DMMD9QE DI DMMD9QE DMMD9QE DN Colistin DMMD9QE TI TT4ILYC DMMD9QE TN Bacterial Dihydropteroate synthetase (Bact folP) DMMD9QE MA Binder DMMD9QE RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMMD9QE RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTKLV96 DMME8LH TN Retinoic acid receptor RXR-beta (RXRB) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TT6PEUO DMME8LH TN Retinoic acid receptor RXR-alpha (RXRA) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTISP28 DMME8LH TN Retinoic acid receptor beta (RARB) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TTH029C DMME8LH TN Retinoic acid receptor RXR-gamma (RXRG) DMME8LH MA Agonist DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMME8LH DI DMME8LH DMME8LH DN Alitretinoin DMME8LH TI TT1Q3IE DMME8LH TN Retinoic acid receptor gamma (RARG) DMME8LH MA Modulator DMME8LH RN Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):30-4. DMME8LH RU https://pubmed.ncbi.nlm.nih.gov/8380496 DMMF8U0 DI DMMF8U0 DMMF8U0 DN Atezolizumab DMMF8U0 TI TT8ZLTI DMMF8U0 TN Programmed cell death 1 ligand 1 (PD-L1) DMMF8U0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMF8U0 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761034s018lbl.pdf DMMFCIH DI DMMFCIH DMMFCIH DN Clotrimazole DMMFCIH TI TT30C9G DMMFCIH TN C-X-C chemokine receptor type 2 (CXCR2) DMMFCIH MA Modulator DMMFCIH RN Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44. DMMFCIH RU https://www.ncbi.nlm.nih.gov/pubmed/3895959 DMMFVB3 DI DMMFVB3 DMMFVB3 DN Difluprednate DMMFVB3 TI TTUCK4B DMMFVB3 TN Phospholipase A2 inhibitory protein (PA2IP) DMMFVB3 MA Agonist DMMFVB3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMMFVB3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMMFWOJ DI DMMFWOJ DMMFWOJ DN Probenecid DMMFWOJ TI TTTQR47 DMMFWOJ TN Solute carrier family 22 member 8 (SLC22A8) DMMFWOJ MA Blocker DMMFWOJ RN Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158. DMMFWOJ RU https://pubmed.ncbi.nlm.nih.gov/12605306 DMMG26Z DI DMMG26Z DMMG26Z DN Dolasetron DMMG26Z TI TTPC4TU DMMG26Z TN 5-HT 3A receptor (HTR3A) DMMG26Z MA Antagonist DMMG26Z RN Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24. DMMG26Z RU https://pubmed.ncbi.nlm.nih.gov/19135415 DMMHNU2 DI DMMHNU2 DMMHNU2 DN (S)-(+)-Dimethindene maleate DMMHNU2 TI TTTIBOJ DMMHNU2 TN Histamine H1 receptor (H1R) DMMHNU2 MA Antagonist DMMHNU2 RN Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors. J Recept Signal Transduct Res. 2009;29(2):84-93. DMMHNU2 RU https://pubmed.ncbi.nlm.nih.gov/19308787 DMMHR1U DI DMMHR1U DMMHR1U DN Denileukin diftitox DMMHR1U TI TTAJU0S DMMHR1U TN Interleukin 2 receptor (IL2R) DMMHR1U MA Binder DMMHR1U RN Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. DMMHR1U RU https://pubmed.ncbi.nlm.nih.gov/18684057 DMMHYLB DI DMMHYLB DMMHYLB DN H5N1 influenza vaccine DMMHYLB TI TT3J5ZI DMMHYLB TN Cell mediated immunity response (CMIR) DMMHYLB RN Comparative clinical trial of vaccines against avian influenza. Zh Mikrobiol Epidemiol Immunobiol. 2007 May-Jun;(3):10-6. DMMHYLB RU https://pubmed.ncbi.nlm.nih.gov/17672124 DMMIAXO DI DMMIAXO DMMIAXO DN Betamethasone valerate DMMIAXO TI TTYRL6O DMMIAXO TN Glucocorticoid receptor (NR3C1) DMMIAXO MA Modulator DMMIAXO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMIAXO RU https://www.fda.gov/ DMMIHVP DI DMMIHVP DMMIHVP DN Dextroamphetamine DMMIHVP TI TTIU98M DMMIHVP TN Trace amine-associated receptor-1 (TAAR1) DMMIHVP MA Modulator DMMIHVP RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMMIHVP RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMMIQ20 DI DMMIQ20 DMMIQ20 DN Patiromer calcium DMMIQ20 TI TTB0SC6 DMMIQ20 TN Potassium (K) DMMIQ20 MA Binder DMMIQ20 RN Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011 Apr;32(7):820-8. DMMIQ20 RU https://pubmed.ncbi.nlm.nih.gov/21208974 DMMIQ7G DI DMMIQ7G DMMIQ7G DN Rosuvastatin DMMIQ7G TI TTPADOQ DMMIQ7G TN HMG-CoA reductase (HMGCR) DMMIQ7G MA Inhibitor DMMIQ7G RN New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10. DMMIQ7G RU https://pubmed.ncbi.nlm.nih.gov/12539816 DMMJ1IS DI DMMJ1IS DMMJ1IS DN Prolixin decanoate DMMJ1IS TI TTK8CXU DMMJ1IS TN 5-HT 1B receptor (HTR1B) DMMJ1IS MA Modulator DMMJ1IS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMJ1IS RU https://www.fda.gov/ DMMJQSH DI DMMJQSH DMMJQSH DN Lanthanum carbonate DMMJQSH TI TTHOTF6 DMMJQSH TN Phosphate (PHO) DMMJQSH MA Modulator DMMJQSH RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DMMJQSH RU https://pubmed.ncbi.nlm.nih.gov/15756752 DMMJTYW DI DMMJTYW DMMJTYW DN Darbepoetin alfa DMMJTYW TI TTAUX24 DMMJTYW TN Erythropoietin Receptor (EPOR) DMMJTYW MA Agonist DMMJTYW RN A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9. DMMJTYW RU https://pubmed.ncbi.nlm.nih.gov/10406949 DMMJVXZ DI DMMJVXZ DMMJVXZ DN LU302146 DMMJVXZ TI TTKRD0G DMMJVXZ TN Endothelin A receptor (EDNRA) DMMJVXZ MA Antagonist DMMJVXZ RN Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S. DMMJVXZ RU https://pubmed.ncbi.nlm.nih.gov/12193103 DMMKHBJ DI DMMKHBJ DMMKHBJ DN Cefotaxime DMMKHBJ TI TTLP6GN DMMKHBJ TN Bacterial DD-carboxypeptidase (Bact vanYB) DMMKHBJ MA Inhibitor DMMKHBJ RN Extended-spectrum cephalosporinases: structure, detection and epidemiology. Future Microbiol. 2007 Jun;2:297-307. DMMKHBJ RU https://pubmed.ncbi.nlm.nih.gov/17661704 DMMN36E DI DMMN36E DMMN36E DN Abacavir DMMN36E TI TT84ETX DMMN36E TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMN36E MA Inhibitor DMMN36E RN Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6. DMMN36E RU https://pubmed.ncbi.nlm.nih.gov/19442129 DMMP3Y2 DI DMMP3Y2 DMMP3Y2 DN Yn-968D1 DMMP3Y2 TI TTUTJGQ DMMP3Y2 TN Vascular endothelial growth factor receptor 2 (KDR) DMMP3Y2 MA Inhibitor DMMP3Y2 RN YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011 Jul;102(7):1374-80. DMMP3Y2 RU https://pubmed.ncbi.nlm.nih.gov/21443688 DMMP5SI DI DMMP5SI DMMP5SI DN Revefenacin DMMP5SI TI TTOXS3C DMMP5SI TN Muscarinic acetylcholine receptor (CHRM) DMMP5SI MA Antagonist DMMP5SI RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMMP5SI RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMMPCFX DI DMMPCFX DMMPCFX DN Recombinant human endostatin DMMPCFX TI TTRPKQG DMMPCFX TN Beta-catenin (CTNNB1) DMMPCFX MA Modulator DMMPCFX RN Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway. PLoS One. 2014 Sep 18;9(9):e107463. DMMPCFX RU https://pubmed.ncbi.nlm.nih.gov/25232946 DMMPG5V DI DMMPG5V DMMPG5V DN NERIDRONIC ACID DMMPG5V TI TTIKWV4 DMMPG5V TN Geranyltranstransferase (FDPS) DMMPG5V MA Inhibitor DMMPG5V RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMMPG5V RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTSZ6Y3 DMMPTLH TN Proto-oncogene c-Ros (ROS1) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTPMQSO DMMPTLH TN ALK tyrosine kinase receptor (ALK) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTKN7QR DMMPTLH TN BDNF/NT-3 growth factors receptor (TrkB) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTXABCW DMMPTLH TN NT-3 growth factor receptor (TrkC) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMPTLH DI DMMPTLH DMMPTLH DN Entrectinib DMMPTLH TI TTTDVOJ DMMPTLH TN Tropomyosin-related kinase A (TrkA) DMMPTLH MA Inhibitor DMMPTLH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMMPTLH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf DMMQ8ZG DI DMMQ8ZG DMMQ8ZG DN Furosemide DMMQ8ZG TI TTS087L DMMQ8ZG TN Solute carrier family 12 member 1 (SLC12A1) DMMQ8ZG MA Blocker DMMQ8ZG RN Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60. DMMQ8ZG RU https://pubmed.ncbi.nlm.nih.gov/17414583 DMMQHOZ DI DMMQHOZ DMMQHOZ DN Oxyphenonium DMMQHOZ TI TTZ9SOR DMMQHOZ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMMQHOZ MA Antagonist DMMQHOZ RN Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62. DMMQHOZ RU https://pubmed.ncbi.nlm.nih.gov/10430538 DMMRV29 DI DMMRV29 DMMRV29 DN Telaprevir DMMRV29 TI TTHC7JD DMMRV29 TN Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A) DMMRV29 MA Modulator DMMRV29 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMMRV29 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMMSDOY DI DMMSDOY DMMSDOY DN Stiripentol DMMSDOY TI TTEX6LM DMMSDOY TN GABA(A) receptor gamma-3 (GABRG3) DMMSDOY MA Modulator DMMSDOY RN Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006 Apr;47(4):704-16. DMMSDOY RU https://pubmed.ncbi.nlm.nih.gov/16650136 DMMSOLA DI DMMSOLA DMMSOLA DN Propoxyphene Hydrochloride DMMSOLA TI TTKWM86 DMMSOLA TN Opioid receptor mu (MOP) DMMSOLA MA Modulator DMMSOLA RN Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovasc Res. 1999 Dec;44(3):568-78. DMMSOLA RU https://www.ncbi.nlm.nih.gov/pubmed/10690289 DMMTAJC DI DMMTAJC DMMTAJC DN Potassium chloride DMMTAJC TI TTS087L DMMTAJC TN Solute carrier family 12 member 1 (SLC12A1) DMMTAJC MA Modulator DMMTAJC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMTAJC RU https://www.fda.gov/ DMMU6BJ DI DMMU6BJ DMMU6BJ DN Sodium bicarbonate DMMU6BJ TI TTZPWGN DMMU6BJ TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMMU6BJ MA Blocker DMMU6BJ RN Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001. DMMU6BJ RU https://pubmed.ncbi.nlm.nih.gov/19445797 DMMU6BJ DI DMMU6BJ DMMU6BJ DN Sodium bicarbonate DMMU6BJ TI TTPLQO0 DMMU6BJ TN Voltage-gated potassium channel Kv4.3 (KCND3) DMMU6BJ MA Blocker DMMU6BJ RN Management of cocaine-induced cardiac arrhythmias due to cardiac ion channel dysfunction. Clin Toxicol (Phila). 2009 Jan;47(1):14-23. DMMU6BJ RU https://pubmed.ncbi.nlm.nih.gov/18815938 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 TI TTVKILB DMMUCG4 TN Prostaglandin G/H synthase 2 (COX-2) DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUCG4 DI DMMUCG4 DMMUCG4 DN Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 TI TT8NGED DMMUCG4 TN Prostaglandin G/H synthase 1 (COX-1) DMMUCG4 MA Inhibitor DMMUCG4 RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMMUCG4 RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMMUOLJ DI DMMUOLJ DMMUOLJ DN Varenicline DMMUOLJ TI TTL1ATN DMMUOLJ TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMMUOLJ MA Modulator DMMUOLJ RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMMUOLJ RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMMV0KW DI DMMV0KW DMMV0KW DN Ephedrine DMMV0KW TI TTEX248 DMMV0KW TN Dopamine D2 receptor (D2R) DMMV0KW MA Agonist DMMV0KW RN The effect of alpha-2 adrenergic agonists on memory and cognitive flexibility. Cogn Behav Neurol. 2006 Dec;19(4):204-7. DMMV0KW RU https://pubmed.ncbi.nlm.nih.gov/17159617 DMMVNZ0 DI DMMVNZ0 DMMVNZ0 DN Masoprocol DMMVNZ0 TI TT6EO5L DMMVNZ0 TN Erbb2 tyrosine kinase receptor (HER2) DMMVNZ0 MA Modulator DMMVNZ0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMVNZ0 RU https://www.fda.gov/ DMMWSUL DI DMMWSUL DMMWSUL DN Lomustine DMMWSUL TI TTUTN1I DMMWSUL TN Human Deoxyribonucleic acid (hDNA) DMMWSUL MA Inhibitor DMMWSUL RN Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds. Acta Pol Pharm. 2007 Jan-Feb;64(1):27-33. DMMWSUL RU https://pubmed.ncbi.nlm.nih.gov/17665847 DMMWZET DI DMMWZET DMMWZET DN Dexamethasone DMMWZET TI TTYRL6O DMMWZET TN Glucocorticoid receptor (NR3C1) DMMWZET MA Agonist DMMWZET RN Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72. DMMWZET RU https://pubmed.ncbi.nlm.nih.gov/19375647 DMMX2E6 DI DMMX2E6 DMMX2E6 DN Pemetrexed DMMX2E6 TI TTU6BFZ DMMX2E6 TN Candida Thymidylate synthase (Candi TMP1) DMMX2E6 MA Inhibitor DMMX2E6 RN Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40. DMMX2E6 RU https://pubmed.ncbi.nlm.nih.gov/19362945 DMMYLTI DI DMMYLTI DMMYLTI DN Thyrotropin Alfa DMMYLTI TI TT6NYJA DMMYLTI TN Thyrotropin receptor (TSHR) DMMYLTI MA Binder DMMYLTI RN Pharmacological profiles and clinical effects of recombinant human thyrotropin alfa (Thyrogen) Intramuscular Injection 0.9 mg). Nippon Yakurigaku Zasshi. 2009 Jul;134(1):28-34. DMMYLTI RU https://pubmed.ncbi.nlm.nih.gov/19602784 DMMYPWO DI DMMYPWO DMMYPWO DN Alefacept DMMYPWO TI TT5KSBY DMMYPWO TN Surface glycoprotein LFA-3 (CD58) DMMYPWO MA Modulator DMMYPWO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMYPWO RU https://www.fda.gov/ DMMYZ3D DI DMMYZ3D DMMYZ3D DN Tositumomab DMMYZ3D TI TTUE541 DMMYZ3D TN Leukocyte surface antigen Leu-16 (CD20) DMMYZ3D RN Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. DMMYZ3D RU https://pubmed.ncbi.nlm.nih.gov/19427037 DMMZB0K DI DMMZB0K DMMZB0K DN Prifinium DMMZB0K TI TTH18TF DMMZB0K TN Muscarinic acetylcholine receptor M5 (CHRM5) DMMZB0K MA Modulator DMMZB0K RN Ligand binding properties of muscarinic acetylcholine receptor subtypes (m1-m5) expressed in baculovirus-infected insect cells. J Pharmacol Exp Ther. 1995 Jul;274(1):378-84. DMMZB0K RU https://pubmed.ncbi.nlm.nih.gov/7616422 DMMZPWT DI DMMZPWT DMMZPWT DN Levocabastine DMMZPWT TI TTTIBOJ DMMZPWT TN Histamine H1 receptor (H1R) DMMZPWT MA Antagonist DMMZPWT RN Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine. Biochem Pharmacol. 2008 Sep 15;76(6):751-62. DMMZPWT RU https://pubmed.ncbi.nlm.nih.gov/18680729 DMMZSXQ DI DMMZSXQ DMMZSXQ DN Azathioprine DMMZSXQ TI TTZFTY4 DMMZSXQ TN Amidophosphoribosyltransferase (PPAT) DMMZSXQ MA Inhibitor DMMZSXQ RN IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol. 2008 Jan;65(1):69-77. DMMZSXQ RU https://pubmed.ncbi.nlm.nih.gov/17662091 DMMZXIW DI DMMZXIW DMMZXIW DN Rabeprazole DMMZXIW TI TTF1QVM DMMZXIW TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMMZXIW MA Inhibitor DMMZXIW RN Review article: rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther. 1999 Oct;13 Suppl 5:17-23. DMMZXIW RU https://pubmed.ncbi.nlm.nih.gov/10555605 DMN0LP8 DI DMN0LP8 DMN0LP8 DN Polymyxin B Sulfate DMN0LP8 TI TT4ILYC DMN0LP8 TN Bacterial Dihydropteroate synthetase (Bact folP) DMN0LP8 MA Binder DMN0LP8 RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMN0LP8 RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMN0S1G DI DMN0S1G DMN0S1G DN HEGF DMN0S1G TI TTGKNB4 DMN0S1G TN Epidermal growth factor receptor (EGFR) DMN0S1G MA Activator DMN0S1G RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMN0S1G RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMN1XVC DI DMN1XVC DMN1XVC DN Lutetium Lu 177 dotatate DMN1XVC TI TTIND6G DMN1XVC TN Somatostatin receptor type 1 (SSTR1) DMN1XVC MA Antagonist DMN1XVC RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMN1XVC RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMN3E57 DI DMN3E57 DMN3E57 DN Levodopa DMN3E57 TI TTEX248 DMN3E57 TN Dopamine D2 receptor (D2R) DMN3E57 MA Modulator DMN3E57 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639). DMN3E57 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3639 DMN3GCH DI DMN3GCH DMN3GCH DN Darunavir DMN3GCH TI TT5FNQT DMN3GCH TN Human immunodeficiency virus Protease (HIV PR) DMN3GCH MA Modulator DMN3GCH RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMN3GCH RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMN3UXQ DI DMN3UXQ DMN3UXQ DN Diethylstilbestrol DMN3UXQ TI TTZAYWL DMN3UXQ TN Estrogen receptor (ESR) DMN3UXQ MA Agonist DMN3UXQ RN Effects of diethylstilbestrol on programmed oocyte death and induction of polyovular follicles in neonatal mouse ovaries. Biol Reprod. 2009 Nov;81(5):1002-9. DMN3UXQ RU https://pubmed.ncbi.nlm.nih.gov/19553606 DMN4CV5 DI DMN4CV5 DMN4CV5 DN Calcidiol DMN4CV5 TI TTK59TV DMN4CV5 TN Vitamin D3 receptor (VDR) DMN4CV5 MA Antagonist DMN4CV5 RN Vitamin D in health and disease. Clin J Am Soc Nephrol. 2008 Sep;3(5):1535-41. DMN4CV5 RU https://pubmed.ncbi.nlm.nih.gov/18525006 DMN4H2O DI DMN4H2O DMN4H2O DN Zithromax DMN4H2O TI TTUWYEA DMN4H2O TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMN4H2O MA Modulator DMN4H2O RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMN4H2O RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMN5T2A DI DMN5T2A DMN5T2A DN Ciclopirox DMN5T2A TI TTJQFBG DMN5T2A TN HIF-prolyl hydroxylase (HPH) DMN5T2A MA Modulator DMN5T2A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMN5T2A RU https://www.fda.gov/ DMN63DZ DI DMN63DZ DMN63DZ DN Moxetumomab pasudotox DMN63DZ TI TTM6QSK DMN63DZ TN B-cell receptor CD22 (CD22) DMN63DZ MA Modulator DMN63DZ RN Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405. DMN63DZ RU https://pubmed.ncbi.nlm.nih.gov/22003067 DMN6CAG DI DMN6CAG DMN6CAG DN Tiapride DMN6CAG TI TT90XZ8 DMN6CAG TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMN6CAG MA Inhibitor DMN6CAG RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMN6CAG RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMN6CAG DI DMN6CAG DMN6CAG DN Tiapride DMN6CAG TI TTEX248 DMN6CAG TN Dopamine D2 receptor (D2R) DMN6CAG MA Antagonist DMN6CAG RN The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. DMN6CAG RU https://pubmed.ncbi.nlm.nih.gov/12083990 DMN6DXL DI DMN6DXL DMN6DXL DN Risperidone DMN6DXL TI TTEX248 DMN6DXL TN Dopamine D2 receptor (D2R) DMN6DXL MA Antagonist DMN6DXL RN Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci. 2009 Jun;63(3):322-8. DMN6DXL RU https://pubmed.ncbi.nlm.nih.gov/19566763 DMN6QO5 DI DMN6QO5 DMN6QO5 DN Gliclazide DMN6QO5 TI TTP835K DMN6QO5 TN ATP-binding cassette transporter C8 (ABCC8) DMN6QO5 MA Blocker DMN6QO5 RN Structural basis for the interference between nicorandil and sulfonylurea action. Diabetes. 2001 Oct;50(10):2253-9. DMN6QO5 RU https://pubmed.ncbi.nlm.nih.gov/11574406 DMN7SDE DI DMN7SDE DMN7SDE DN Methyclothiazide DMN7SDE TI TTS087L DMN7SDE TN Solute carrier family 12 member 1 (SLC12A1) DMN7SDE MA Blocker DMN7SDE RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMN7SDE RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K TI TTNJYV2 DMN7Y9K TN Gamma-aminobutyric acid receptor (GAR) DMN7Y9K MA Inhibitor DMN7Y9K RN Synthesis and binding affinity of 2-phenylimidazo[1,2-alpha]pyridine derivatives for both central and peripheral benzodiazepine receptors. A new se... J Med Chem. 1997 Sep 12;40(19):3109-18. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/9301675 DMN7Y9K DI DMN7Y9K DMN7Y9K DN Alpidem DMN7Y9K TI TTPTXIN DMN7Y9K TN Translocator protein (TSPO) DMN7Y9K MA Inhibitor DMN7Y9K RN Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem. 2008 Sep 25;51(18):5798-806. DMN7Y9K RU https://pubmed.ncbi.nlm.nih.gov/18729350 DMN9CWF DI DMN9CWF DMN9CWF DN Salbutamol DMN9CWF TI TT2CJVK DMN9CWF TN Adrenergic receptor beta-2 (ADRB2) DMN9CWF MA Agonist DMN9CWF RN Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8. DMN9CWF RU https://pubmed.ncbi.nlm.nih.gov/11772115 DMN9RPO DI DMN9RPO DMN9RPO DN Nafcillin DMN9RPO TI TTJP4SM DMN9RPO TN Bacterial Penicillin binding protein (Bact PBP) DMN9RPO MA Binder DMN9RPO RN Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10. DMN9RPO RU https://pubmed.ncbi.nlm.nih.gov/2387996 DMNA8HM DI DMNA8HM DMNA8HM DN Pyrithione Zinc DMNA8HM TI TTG5TOX DMNA8HM TN Fungal Proton pump (FPPCM) DMNA8HM MA Modulator DMNA8HM RN Mechanism of the antimicrobial action of pyrithione: effects on membrane transport, ATP levels, and protein synthesis. Antimicrob Agents Chemother. 1978 Jul;14(1):60-8. DMNA8HM RU https://www.ncbi.nlm.nih.gov/pubmed/28693 DMNAKLY DI DMNAKLY DMNAKLY DN Remikiren DMNAKLY TI TTB2MXP DMNAKLY TN Angiotensinogenase renin (REN) DMNAKLY MA Inhibitor DMNAKLY RN Functional expression of the renin-angiotensin system in human podocytes. Am J Physiol Renal Physiol. 2006 Mar;290(3):F710-9. DMNAKLY RU https://pubmed.ncbi.nlm.nih.gov/16189286 DMNARJT DI DMNARJT DMNARJT DN Ioflupane I-123 DMNARJT TI TTVBI8W DMNARJT TN Dopamine transporter (DAT) DMNARJT MA Modulator DMNARJT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMNARJT RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMNC64R DI DMNC64R DMNC64R DN Antegren DMNC64R TI TT4BT06 DMNC64R TN Integrin alpha-4 (ITGA4) DMNC64R RN Very late antigen 4 (VLA4) antagonists as anti-inflammatory agents. Curr Opin Chem Biol. 1998 Aug;2(4):453-7. DMNC64R RU https://pubmed.ncbi.nlm.nih.gov/9736917 DMND304 DI DMND304 DMND304 DN Miltefosine DMND304 TI TT9V5JH DMND304 TN Phospholipase A2 (PLA2G1B) DMND304 MA Inhibitor DMND304 RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DMND304 RU https://pubmed.ncbi.nlm.nih.gov/19463273 DMNDJT5 DI DMNDJT5 DMNDJT5 DN Bromodiphenhydramine DMNDJT5 TI TTTIBOJ DMNDJT5 TN Histamine H1 receptor (H1R) DMNDJT5 MA Antagonist DMNDJT5 RN Studies on synergism between penicillins and ambodryl (bromodiphenhydramine HCl), an antihistamine with antimicrobial property. Indian J Exp Biol. 1990 Mar;28(3):253-8. DMNDJT5 RU https://pubmed.ncbi.nlm.nih.gov/1973150 DMNER5S DI DMNER5S DMNER5S DN Bleomycin DMNER5S TI TTUTN1I DMNER5S TN Human Deoxyribonucleic acid (hDNA) DMNER5S MA Breaker DMNER5S RN Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85. DMNER5S RU https://pubmed.ncbi.nlm.nih.gov/6177398 DMNEXZF DI DMNEXZF DMNEXZF DN Cefamandole DMNEXZF TI TTJP4SM DMNEXZF TN Bacterial Penicillin binding protein (Bact PBP) DMNEXZF MA Binder DMNEXZF RN The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54. DMNEXZF RU https://pubmed.ncbi.nlm.nih.gov/9419181 DMNF0G8 DI DMNF0G8 DMNF0G8 DN Rh-alphaglucosidase DMNF0G8 TI TTXWASR DMNF0G8 TN Intestinal maltase-glucoamylase (MGAM) DMNF0G8 MA Modulator DMNF0G8 RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMNF0G8 RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMNFUZR DI DMNFUZR DMNFUZR DN Enalapril DMNFUZR TI TTL69WB DMNFUZR TN Angiotensin-converting enzyme (ACE) DMNFUZR MA Inhibitor DMNFUZR RN Determination of bezafibrate, methotrexate, cyclophosphamide, orlistat and enalapril in waste and surface waters using on-line solid-phase extracti... J Environ Monit. 2009 Apr;11(4):830-8. DMNFUZR RU https://pubmed.ncbi.nlm.nih.gov/19557238 DMNH3PG DI DMNH3PG DMNH3PG DN Etoposide DMNH3PG TI TT0IHXV DMNH3PG TN DNA topoisomerase II (TOP2) DMNH3PG MA Modulator DMNH3PG RN Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72. DMNH3PG RU https://www.ncbi.nlm.nih.gov/pubmed/16101488 DMNHTZI DI DMNHTZI DMNHTZI DN Protriptyline DMNHTZI TI TTAWNKZ DMNHTZI TN Norepinephrine transporter (NET) DMNHTZI MA Inhibitor DMNHTZI RN Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55. DMNHTZI RU https://pubmed.ncbi.nlm.nih.gov/3494977 DMNI0KO DI DMNI0KO DMNI0KO DN Denosumab DMNI0KO TI TT9E8HR DMNI0KO TN Osteoclast differentiation factor (ODF) DMNI0KO RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMNI0KO RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMNIJT0 DI DMNIJT0 DMNIJT0 DN Adenosine monophosphate DMNIJT0 TI TTV1ZSQ DMNIJT0 TN Adenylate cyclase type 1 (ADCY1) DMNIJT0 MA Binder DMNIJT0 RN Ecto- and cytosolic 5'-nucleotidases in normal and AMP deaminase-deficient human skeletal muscle. Biol Chem. 2006 Jan;387(1):53-8. DMNIJT0 RU https://pubmed.ncbi.nlm.nih.gov/16497164 DMNKG1Z DI DMNKG1Z DMNKG1Z DN Atenolol DMNKG1Z TI TTR6W5O DMNKG1Z TN Adrenergic receptor beta-1 (ADRB1) DMNKG1Z MA Antagonist DMNKG1Z RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DMNKG1Z RU https://pubmed.ncbi.nlm.nih.gov/16268148 DMNKT8Z DI DMNKT8Z DMNKT8Z DN Pachycarpine DMNKT8Z TI TTRK8B9 DMNKT8Z TN Sodium channel unspecific (NaC) DMNKT8Z MA Modulator DMNKT8Z RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNKT8Z RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNL0E6 DI DMNL0E6 DMNL0E6 DN Pipobroman DMNL0E6 TI TTUTN1I DMNL0E6 TN Human Deoxyribonucleic acid (hDNA) DMNL0E6 MA Binder DMNL0E6 RN Effects of piposulfan (Ancyte) on protein and DNA synthesis in Ehrlich ascites carcinoma. Life Sci II. 1971 Jun 8;10(11):605-12. DMNL0E6 RU https://pubmed.ncbi.nlm.nih.gov/5556760 DMNL98G DI DMNL98G DMNL98G DN Meclofenamate sodium DMNL98G TI TT8NGED DMNL98G TN Prostaglandin G/H synthase 1 (COX-1) DMNL98G MA Modulator DMNL98G RN Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82. DMNL98G RU https://www.ncbi.nlm.nih.gov/pubmed/11592955 DMNL98G DI DMNL98G DMNL98G DN Meclofenamate sodium DMNL98G TI TTVKILB DMNL98G TN Prostaglandin G/H synthase 2 (COX-2) DMNL98G MA Modulator DMNL98G RN Role of COX-2-derived metabolites in regulation of the renal hemodynamic response to norepinephrine. Am J Physiol Renal Physiol. 2001 Nov;281(5):F975-82. DMNL98G RU https://www.ncbi.nlm.nih.gov/pubmed/11592955 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTZA1NY DMNLHAC TN GABA(A) receptor beta-2 (GABRB2) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTNJYV2 DMNLHAC TN Gamma-aminobutyric acid receptor (GAR) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/16854065 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TT06RH5 DMNLHAC TN GABA(A) receptor gamma-2 (GABRG2) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TT1MPAY DMNLHAC TN GABA(A) receptor alpha-1 (GABRA1) DMNLHAC MA Inhibitor DMNLHAC RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/15828844 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTGXH6N DMNLHAC TN GABA(A) receptor delta (GABRD) DMNLHAC MA Inhibitor DMNLHAC RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNLHAC RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNLHAC DI DMNLHAC DMNLHAC DN Allopregnanolone DMNLHAC TI TTEX6LM DMNLHAC TN GABA(A) receptor gamma-3 (GABRG3) DMNLHAC MA Modulator DMNLHAC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNLHAC RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMNMHBV DI DMNMHBV DMNMHBV DN Penicillin DMNMHBV TI TTJP4SM DMNMHBV TN Bacterial Penicillin binding protein (Bact PBP) DMNMHBV MA Modulator DMNMHBV RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMNMHBV RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMNMW9R DI DMNMW9R DMNMW9R DN Pramipexole DMNMW9R TI TT4C8EA DMNMW9R TN Dopamine D3 receptor (D3R) DMNMW9R MA Modulator DMNMW9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMW9R RU https://www.fda.gov/ DMNMW9R DI DMNMW9R DMNMW9R DN Pramipexole DMNMW9R TI TTEX248 DMNMW9R TN Dopamine D2 receptor (D2R) DMNMW9R MA Modulator DMNMW9R RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMW9R RU https://www.fda.gov/ DMNMXR8 DI DMNMXR8 DMNMXR8 DN Procainamide DMNMXR8 TI TT05DLS DMNMXR8 TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMNMXR8 MA Modulator DMNMXR8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNMXR8 RU https://www.fda.gov/ DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TT5L2VC DMNO38U TN Kallikrein-related peptidase (KLK) DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TT2WR1T DMNO38U TN Cationic trypsinogen (PRSS1) DMNO38U MA Inhibitor DMNO38U RN Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 1995 Apr 28;38(9):1511-22. DMNO38U RU https://pubmed.ncbi.nlm.nih.gov/7739010 DMNO38U DI DMNO38U DMNO38U DN Bortezomib DMNO38U TI TTU7ZMG DMNO38U TN Proteasome (PS) DMNO38U MA Modulator DMNO38U RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMNO38U RU https://www.fda.gov/ DMNOBFQ DI DMNOBFQ DMNOBFQ DN Mebeverine DMNOBFQ TI TTH18TF DMNOBFQ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMNOBFQ MA Antagonist DMNOBFQ RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMNOBFQ RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMNOKBV DI DMNOKBV DMNOKBV DN Phenytoin DMNOKBV TI TTRK8B9 DMNOKBV TN Sodium channel unspecific (NaC) DMNOKBV MA Blocker DMNOKBV RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DMNOKBV RU https://pubmed.ncbi.nlm.nih.gov/19552484 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU TI TTR6W5O DMNOSWU TN Adrenergic receptor beta-1 (ADRB1) DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNOSWU DI DMNOSWU DMNOSWU DN Anisodine DMNOSWU TI TTH18TF DMNOSWU TN Muscarinic acetylcholine receptor M5 (CHRM5) DMNOSWU MA Modulator DMNOSWU RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMNOSWU RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMNP60F DI DMNP60F DMNP60F DN Anastrozole DMNP60F TI TTSZLWK DMNP60F TN Aromatase (CYP19A1) DMNP60F MA Inhibitor DMNP60F RN Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8. DMNP60F RU https://pubmed.ncbi.nlm.nih.gov/12199354 DMNPZL4 DI DMNPZL4 DMNPZL4 DN Dacarbazine DMNPZL4 TI TTUTN1I DMNPZL4 TN Human Deoxyribonucleic acid (hDNA) DMNPZL4 MA Breaker DMNPZL4 RN Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8. DMNPZL4 RU https://pubmed.ncbi.nlm.nih.gov/19561552 DMNQXV8 DI DMNQXV8 DMNQXV8 DN LGX818 DMNQXV8 TI TTWCGQT DMNQXV8 TN Serine/threonine-protein kinase B-raf (BRAF) DMNQXV8 MA Modulator DMNQXV8 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNQXV8 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNSJ7V DI DMNSJ7V DMNSJ7V DN Tropisetron DMNSJ7V TI TTPC4TU DMNSJ7V TN 5-HT 3A receptor (HTR3A) DMNSJ7V MA Antagonist DMNSJ7V RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMNSJ7V RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMNUC42 DI DMNUC42 DMNUC42 DN Sulodexide DMNUC42 TI TT4QPUL DMNUC42 TN Antithrombin-III (ATIII) DMNUC42 MA Activator DMNUC42 RN Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide. Med Res Rev. 1998 Jan;18(1):1-20. DMNUC42 RU https://pubmed.ncbi.nlm.nih.gov/9436179 DMNUWST DI DMNUWST DMNUWST DN Flucloxacillin DMNUWST TI TTJP4SM DMNUWST TN Bacterial Penicillin binding protein (Bact PBP) DMNUWST MA Binder DMNUWST RN Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71. DMNUWST RU https://pubmed.ncbi.nlm.nih.gov/6335600 DMNVKU6 DI DMNVKU6 DMNVKU6 DN Crisaborole DMNVKU6 TI TTV5CGO DMNVKU6 TN Phosphodiesterase 4 (PDE4) DMNVKU6 MA Modulator DMNVKU6 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMNVKU6 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMNWZJG DI DMNWZJG DMNWZJG DN Leucovorin Calcium DMNWZJG TI TTYZVDJ DMNWZJG TN Dihydrofolate reductase (DHFR) DMNWZJG MA Modulator DMNWZJG RN Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.NCI Monogr.1987;(5):17-26. DMNWZJG RU https://www.ncbi.nlm.nih.gov/pubmed/2448654 DMNXY5K DI DMNXY5K DMNXY5K DN Peramivir DMNXY5K TI TT50QJ3 DMNXY5K TN Influenza Neuraminidase (Influ NA) DMNXY5K MA Inhibitor DMNXY5K RN Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13. DMNXY5K RU https://pubmed.ncbi.nlm.nih.gov/19067613 DMNYOIX DI DMNYOIX DMNYOIX DN Olaratumab DMNYOIX TI TT8FYO9 DMNYOIX TN Platelet-derived growth factor receptor alpha (PDGFRA) DMNYOIX MA Modulator DMNYOIX RN A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604. DMNYOIX RU https://pubmed.ncbi.nlm.nih.gov/24452395 DMNYPGS DI DMNYPGS DMNYPGS DN Tioconazole DMNYPGS TI TTTSOUD DMNYPGS TN Candida Cytochrome P450 51 (Candi ERG11) DMNYPGS MA Inhibitor DMNYPGS RN Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6. DMNYPGS RU https://pubmed.ncbi.nlm.nih.gov/15625110 DMNZBRY DI DMNZBRY DMNZBRY DN Capreomycin DMNZBRY TI TTIA0J5 DMNZBRY TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DMNZBRY MA Binder DMNZBRY RN Interaction between the ribosomal subunits: 16S rRNA suppressors of the lethal DeltaA1916 mutation in the 23S rRNA of Escherichia coli. Mol Genet Genomics. 2007 Sep;278(3):307-15. DMNZBRY RU https://pubmed.ncbi.nlm.nih.gov/17564727 DMNZCI1 DI DMNZCI1 DMNZCI1 DN YM443 DMNZCI1 TI TT1RS9F DMNZCI1 TN Acetylcholinesterase (AChE) DMNZCI1 MA Modulator DMNZCI1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMNZCI1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMNZSC1 DI DMNZSC1 DMNZSC1 DN Candicidin DMNZSC1 TI TTQKWA4 DMNZSC1 TN Fungal Cell membrane ergosterol (Fung CME) DMNZSC1 MA Modulator DMNZSC1 RN Mode of Action of the Polyene Antibiotic Candicidin: Binding Factors in the Wall of Candida albicans DMNZSC1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC429577 DMNZWL7 DI DMNZWL7 DMNZWL7 DN Moclobemide DMNZWL7 TI TT3WG5C DMNZWL7 TN Monoamine oxidase type A (MAO-A) DMNZWL7 MA Inhibitor DMNZWL7 RN Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5. DMNZWL7 RU https://pubmed.ncbi.nlm.nih.gov/12457375 DMNZWL7 DI DMNZWL7 DMNZWL7 DN Moclobemide DMNZWL7 TI TT32XQJ DMNZWL7 TN Monoamine oxidase (MAO) DMNZWL7 MA Inhibitor DMNZWL7 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMNZWL7 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMO091F DI DMO091F DMO091F DN Balsalazide DMO091F TI TT8NGED DMO091F TN Prostaglandin G/H synthase 1 (COX-1) DMO091F MA Inhibitor DMO091F RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMO091F RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMO14SG DI DMO14SG DMO14SG DN Mebendazole DMO14SG TI TTYFKSZ DMO14SG TN Tubulin beta (TUBB) DMO14SG MA Binder DMO14SG RN Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. DMO14SG RU https://pubmed.ncbi.nlm.nih.gov/19336257 DMO2K0J DI DMO2K0J DMO2K0J DN Pyridoxal Phosphate DMO2K0J TI TTT2LD9 DMO2K0J TN GABA transaminase (ABAT) DMO2K0J MA Inhibitor DMO2K0J RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMO2K0J RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMO2K0J DI DMO2K0J DMO2K0J DN Pyridoxal Phosphate DMO2K0J TI TT6L509 DMO2K0J TN Coagulation factor IIa (F2) DMO2K0J MA Inhibitor DMO2K0J RN New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32. DMO2K0J RU https://pubmed.ncbi.nlm.nih.gov/11794963 DMO381I DI DMO381I DMO381I DN Acamprosate DMO381I TI TTAN6JD DMO381I TN Glutamate receptor AMPA (GRIA) DMO381I MA Agonist DMO381I RN Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37. DMO381I RU https://pubmed.ncbi.nlm.nih.gov/19523047 DMO4PVE DI DMO4PVE DMO4PVE DN Apraclonidine DMO4PVE TI TTQ8AFT DMO4PVE TN Adrenergic receptor Alpha-2 (ADRA2) DMO4PVE MA Agonist DMO4PVE RN Apraclonidine attenuates the increases in spinal excitatory amino acid release in rats with adjuvant-induced inflammation. Anesth Analg. 2002 Mar;94(3):701-5; table of contents. DMO4PVE RU https://pubmed.ncbi.nlm.nih.gov/11867401 DMO50U2 DI DMO50U2 DMO50U2 DN Naratriptan DMO50U2 TI TTK8CXU DMO50U2 TN 5-HT 1B receptor (HTR1B) DMO50U2 MA Agonist DMO50U2 RN Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9. DMO50U2 RU https://pubmed.ncbi.nlm.nih.gov/18223456 DMO5SZX DI DMO5SZX DMO5SZX DN Diphenoxylate DMO5SZX TI TTKWM86 DMO5SZX TN Opioid receptor mu (MOP) DMO5SZX MA Agonist DMO5SZX RN Loperamide: a pharmacological review. Rev Gastroenterol Disord. 2007;7 Suppl 3:S11-8. DMO5SZX RU https://pubmed.ncbi.nlm.nih.gov/18192961 DMO6315 DI DMO6315 DMO6315 DN Vonoprazan DMO6315 TI TTLOKXP DMO6315 TN Gastric H(+)/K(+) ATPase (Proton pump) DMO6315 MA Modulator DMO6315 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2008 DMO6315 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020973s022lbl.pdf DMO946V DI DMO946V DMO946V DN Ticlopidine DMO946V TI TTQL5VC DMO946V TN Platelet-activating factor receptor (PTAFR) DMO946V MA Modulator DMO946V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMO946V RU https://www.fda.gov/ DMO95XI DI DMO95XI DMO95XI DN Insulin, porcine DMO95XI TI TTCBFJO DMO95XI TN Insulin receptor (INSR) DMO95XI MA Binder DMO95XI RN Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9. DMO95XI RU https://pubmed.ncbi.nlm.nih.gov/12038982 DMO9WDS DI DMO9WDS DMO9WDS DN Altropane DMO9WDS TI TTVBI8W DMO9WDS TN Dopamine transporter (DAT) DMO9WDS MA Inhibitor DMO9WDS RN Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. DMO9WDS RU https://pubmed.ncbi.nlm.nih.gov/9593103 DMOA4VW DI DMOA4VW DMOA4VW DN Insulin-detemir DMOA4VW TI TTZOPHG DMOA4VW TN Insulin (INS) DMOA4VW MA Modulator DMOA4VW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOA4VW RU https://www.fda.gov/ DMOAD2Y DI DMOAD2Y DMOAD2Y DN Dupilumab DMOAD2Y TI TTDWHC3 DMOAD2Y TN Interleukin 4 receptor alpha (IL4R) DMOAD2Y RN Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. DMOAD2Y RU https://pubmed.ncbi.nlm.nih.gov/23688323 DMOB2F3 DI DMOB2F3 DMOB2F3 DN Heptabarbital DMOB2F3 TI TTAN6JD DMOB2F3 TN Glutamate receptor AMPA (GRIA) DMOB2F3 MA Antagonist DMOB2F3 RN A computer program using disposition decomposition analysis in pharmacodynamics. Biopharm Drug Dispos. 1997 Jan;18(1):9-15. DMOB2F3 RU https://pubmed.ncbi.nlm.nih.gov/9008265 DMOB58Q DI DMOB58Q DMOB58Q DN MK-8228 DMOB58Q TI TTOGPL1 DMOB58Q TN Cytomegalovirus Terminase UL56 (CMV TRM1) DMOB58Q MA Inhibitor DMOB58Q RN The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85(20):10884-93. DMOB58Q RU https://pubmed.ncbi.nlm.nih.gov/21752907 DMOB58Q DI DMOB58Q DMOB58Q DN MK-8228 DMOB58Q TI TTZHSBO DMOB58Q TN Cytomegalovirus Terminase (CMV TRM) DMOB58Q MA Inhibitor DMOB58Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMOB58Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMOBIKY DI DMOBIKY DMOBIKY DN Bexarotene DMOBIKY TI TT6PEUO DMOBIKY TN Retinoic acid receptor RXR-alpha (RXRA) DMOBIKY MA Modulator DMOBIKY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOBIKY RU https://www.fda.gov/ DMOBLGK DI DMOBLGK DMOBLGK DN Tromethamine DMOBLGK TI TTBFROQ DMOBLGK TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMOBLGK MA Inhibitor DMOBLGK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOBLGK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMODHQI DI DMODHQI DMODHQI DN Budipine DMODHQI TI TTGP7BY DMODHQI TN Monoamine oxidase type B (MAO-B) DMODHQI MA Modulator DMODHQI RN Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105. DMODHQI RU https://pubmed.ncbi.nlm.nih.gov/10370904 DMODJ40 DI DMODJ40 DMODJ40 DN Ethinyl estradiol DMODJ40 TI TTZAYWL DMODJ40 TN Estrogen receptor (ESR) DMODJ40 MA Agonist DMODJ40 RN 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8. DMODJ40 RU https://pubmed.ncbi.nlm.nih.gov/19237207 DMOEM2I DI DMOEM2I DMOEM2I DN Estriol DMOEM2I TI TTZAYWL DMOEM2I TN Estrogen receptor (ESR) DMOEM2I MA Agonist DMOEM2I RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMOEM2I RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMOERGM DI DMOERGM DMOERGM DN Abaloparatide DMOERGM TI TTFPD47 DMOERGM TN Parathyroid hormone 1 receptor (PTH1R) DMOERGM MA Modulator DMOERGM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOERGM RU https://www.fda.gov/ DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 TI TT5L2VC DMOF2C6 TN Kallikrein-related peptidase (KLK) DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMOF2C6 DI DMOF2C6 DMOF2C6 DN Ecallantide DMOF2C6 TI TTMF8H9 DMOF2C6 TN Plasma kallikrein (KLKB1) DMOF2C6 MA Inhibitor DMOF2C6 RN Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin Biol Ther. 2008 Aug;8(8):1187-99. DMOF2C6 RU https://pubmed.ncbi.nlm.nih.gov/18613770 DMOF7AT DI DMOF7AT DMOF7AT DN Streptozocin DMOF7AT TI TTUTN1I DMOF7AT TN Human Deoxyribonucleic acid (hDNA) DMOF7AT MA Breaker DMOF7AT RN Hydrodynamics-based transfection of pancreatic duodenal homeobox 1 DNA improves hyperglycemia and is associated with limited complications in diabe... Endocr J. 2009;56(6):783-90. DMOF7AT RU https://pubmed.ncbi.nlm.nih.gov/19561381 DMOFP18 DI DMOFP18 DMOFP18 DN Ryzodeq DMOFP18 TI TTCBFJO DMOFP18 TN Insulin receptor (INSR) DMOFP18 MA Modulator DMOFP18 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMOFP18 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMOGFIX DI DMOGFIX DMOGFIX DN Eltrombopag DMOGFIX TI TTIHYA4 DMOGFIX TN Thrombopoietin receptor (MPL) DMOGFIX MA Agonist DMOGFIX RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMOGFIX RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMOGNXY DI DMOGNXY DMOGNXY DN Sarilumab DMOGNXY TI TT0E5SK DMOGNXY TN Interleukin 6 receptor (IL6R) DMOGNXY MA Modulator DMOGNXY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOGNXY RU https://www.fda.gov/ DMOGREH DI DMOGREH DMOGREH DN Suplatast tosilate DMOGREH TI TTGPK5Y DMOGREH TN T(H2) cytokine production (TH2 produ) DMOGREH MA Modulator DMOGREH RN Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol. 2000 Apr;105(4):739-45. DMOGREH RU https://pubmed.ncbi.nlm.nih.gov/10756224 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TT0JESD DMOH8VY TN Erbb4 tyrosine kinase receptor (Erbb-4) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TT6EO5L DMOH8VY TN Erbb2 tyrosine kinase receptor (HER2) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7422 DMOH8VY DI DMOH8VY DMOH8VY DN Dacomitinib DMOH8VY TI TTGKNB4 DMOH8VY TN Epidermal growth factor receptor (EGFR) DMOH8VY MA Antagonist DMOH8VY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMOH8VY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMOHK1E DI DMOHK1E DMOHK1E DN Docosanol DMOHK1E TI TT1JL7D DMOHK1E TN Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1) DMOHK1E MA Modulator DMOHK1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOHK1E RU https://www.fda.gov/ DMOHS9P DI DMOHS9P DMOHS9P DN Phenacemide DMOHS9P TI TTRK8B9 DMOHS9P TN Sodium channel unspecific (NaC) DMOHS9P MA Blocker DMOHS9P RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOHS9P RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOI1ZF DI DMOI1ZF DMOI1ZF DN Choline alfoscerate DMOI1ZF TI TTH18TF DMOI1ZF TN Muscarinic acetylcholine receptor M5 (CHRM5) DMOI1ZF MA Modulator DMOI1ZF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMOI1ZF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 TI TTEX248 DMOIFW0 TN Dopamine D2 receptor (D2R) DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DMOIFW0 DI DMOIFW0 DMOIFW0 DN Aniracetam DMOIFW0 TI TTJQOD7 DMOIFW0 TN 5-HT 2A receptor (HTR2A) DMOIFW0 MA Inhibitor DMOIFW0 RN Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43. DMOIFW0 RU https://pubmed.ncbi.nlm.nih.gov/11412837 DMOIX5S DI DMOIX5S DMOIX5S DN Azilsartan DMOIX5S TI TT8DBY3 DMOIX5S TN Angiotensin II receptor type-1 (AGTR1) DMOIX5S MA Modulator DMOIX5S RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMOIX5S RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMOJ0V6 DI DMOJ0V6 DMOJ0V6 DN Metoprolol DMOJ0V6 TI TTR6W5O DMOJ0V6 TN Adrenergic receptor beta-1 (ADRB1) DMOJ0V6 MA Antagonist DMOJ0V6 RN Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6. DMOJ0V6 RU https://pubmed.ncbi.nlm.nih.gov/16268148 DMOJ4ZI DI DMOJ4ZI DMOJ4ZI DN Butenafine DMOJ4ZI TI TTM9XSU DMOJ4ZI TN Candida Squalene epoxidase (Candi ERG1) DMOJ4ZI MA Modulator DMOJ4ZI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOJ4ZI RU https://www.fda.gov/ DMOJZQ9 DI DMOJZQ9 DMOJZQ9 DN Loperamide DMOJZQ9 TI TT27RFC DMOJZQ9 TN Opioid receptor delta (OPRD1) DMOJZQ9 MA Binder DMOJZQ9 RN Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8. DMOJZQ9 RU https://pubmed.ncbi.nlm.nih.gov/6319884 DMOK965 DI DMOK965 DMOK965 DN Prulifloxacin DMOK965 TI TTFK8YB DMOK965 TN Bacterial DNA topoisomerase 4A (Bact parC) DMOK965 MA Inhibitor DMOK965 RN Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. DMOK965 RU https://pubmed.ncbi.nlm.nih.gov/16441207 DMOK965 DI DMOK965 DMOK965 DN Prulifloxacin DMOK965 TI TTN6J5F DMOK965 TN Bacterial DNA gyrase (Bact gyrase) DMOK965 MA Inhibitor DMOK965 RN Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther. 2006 Feb;4(1):27-41. DMOK965 RU https://pubmed.ncbi.nlm.nih.gov/16441207 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI TI TTZAYWL DMOKCVI TN Estrogen receptor (ESR) DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMOKCVI DI DMOKCVI DMOKCVI DN ARZOXIFENE DMOKCVI TI TTOM3J0 DMOKCVI TN Estrogen receptor beta (ESR2) DMOKCVI MA Inhibitor DMOKCVI RN Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. J Med Chem. 2007 May 31;50(11):2682-92. DMOKCVI RU https://pubmed.ncbi.nlm.nih.gov/17489582 DMOL54H DI DMOL54H DMOL54H DN Clopidogrel DMOL54H TI TTZ1DT0 DMOL54H TN P2Y purinoceptor 12 (P2RY12) DMOL54H MA Antagonist DMOL54H RN P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. DMOL54H RU https://pubmed.ncbi.nlm.nih.gov/15199474 DMOL5IU DI DMOL5IU DMOL5IU DN Mesalazine DMOL5IU TI TT8NGED DMOL5IU TN Prostaglandin G/H synthase 1 (COX-1) DMOL5IU MA Inhibitor DMOL5IU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOL5IU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOL793 DI DMOL793 DMOL793 DN Trifarotene DMOL793 TI TT1Q3IE DMOL793 TN Retinoic acid receptor gamma (RARG) DMOL793 MA Agonist DMOL793 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMOL793 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211527s000lbl.pdf DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTH18TF DMOLNCZ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTQ3JTF DMOLNCZ TN Muscarinic acetylcholine receptor M4 (CHRM4) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTQ13Z5 DMOLNCZ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTZ9SOR DMOLNCZ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNCZ DI DMOLNCZ DMOLNCZ DN ACECLIDINE DMOLNCZ TI TTYEG6Q DMOLNCZ TN Muscarinic acetylcholine receptor M2 (CHRM2) DMOLNCZ MA Inhibitor DMOLNCZ RN Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. DMOLNCZ RU https://pubmed.ncbi.nlm.nih.gov/8464038 DMOLNHF DI DMOLNHF DMOLNHF DN Melphalan DMOLNHF TI TTUTN1I DMOLNHF TN Human Deoxyribonucleic acid (hDNA) DMOLNHF MA Modulator DMOLNHF RN Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94. DMOLNHF RU https://www.ncbi.nlm.nih.gov/pubmed/2155711 DMOM8AL DI DMOM8AL DMOM8AL DN Scopolamine DMOM8AL TI TTOXS3C DMOM8AL TN Muscarinic acetylcholine receptor (CHRM) DMOM8AL MA Antagonist DMOM8AL RN The amygdala modulates morphine-induced state-dependent memory retrieval via muscarinic acetylcholine receptors. Neuroscience. 2009 May 5;160(2):255-63. DMOM8AL RU https://pubmed.ncbi.nlm.nih.gov/19272427 DMOMBJW DI DMOMBJW DMOMBJW DN Moricizine DMOMBJW TI TTZOVE0 DMOMBJW TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMOMBJW MA Blocker DMOMBJW RN From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33. DMOMBJW RU https://pubmed.ncbi.nlm.nih.gov/8780326 DMOMK1V DI DMOMK1V DMOMK1V DN Halofantrine DMOMK1V TI TTV3NH6 DMOMK1V TN Calmodulin (CALM) DMOMK1V MA Modulator DMOMK1V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOMK1V RU https://www.fda.gov/ DMOMLHJ DI DMOMLHJ DMOMLHJ DN Lymecycline DMOMLHJ TI TTQ8KVI DMOMLHJ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMOMLHJ MA Binder DMOMLHJ RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMOMLHJ RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMOMP9U DI DMOMP9U DMOMP9U DN Cetirizine DMOMP9U TI TTTIBOJ DMOMP9U TN Histamine H1 receptor (H1R) DMOMP9U MA Antagonist DMOMP9U RN Design, synthesis and histamine H1-receptor antagonistic activity of some novel 4-amino-2-(substituted)-5-(substituted) aryl-6-[(substituted aryl) amino] pyrimidines. Arzneimittelforschung. 2009;59(5):243-7. DMOMP9U RU https://pubmed.ncbi.nlm.nih.gov/19537525 DMOP0BL DI DMOP0BL DMOP0BL DN Ambenonium DMOP0BL TI TT1RS9F DMOP0BL TN Acetylcholinesterase (AChE) DMOP0BL MA Inhibitor DMOP0BL RN Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66. DMOP0BL RU https://pubmed.ncbi.nlm.nih.gov/18033235 DMOPGHQ DI DMOPGHQ DMOPGHQ DN Indiplon DMOPGHQ TI TT1MPAY DMOPGHQ TN GABA(A) receptor alpha-1 (GABRA1) DMOPGHQ MA Agonist DMOPGHQ RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMOPGHQ RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMOPZDT DI DMOPZDT DMOPZDT DN Perindopril DMOPZDT TI TTL69WB DMOPZDT TN Angiotensin-converting enzyme (ACE) DMOPZDT MA Inhibitor DMOPZDT RN Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease. Rev Med Liege. 2009 Apr;64(4):223-7. DMOPZDT RU https://pubmed.ncbi.nlm.nih.gov/19514543 DMOQK8Z DI DMOQK8Z DMOQK8Z DN Arbidol DMOQK8Z TI TTF4CAM DMOQK8Z TN Influenza Hemagglutinin (Influ HA) DMOQK8Z MA Inhibitor DMOQK8Z RN Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers. Clin Ther. 2009 Apr;31(4):784-92. DMOQK8Z RU https://pubmed.ncbi.nlm.nih.gov/19446151 DMOQVU9 DI DMOQVU9 DMOQVU9 DN Hydroxyurea DMOQVU9 TI TTBWDI0 DMOQVU9 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMOQVU9 MA Modulator DMOQVU9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOQVU9 RU https://www.fda.gov/ DMORPBA DI DMORPBA DMORPBA DN Ergoloid mesylate DMORPBA TI TT32XQJ DMORPBA TN Monoamine oxidase (MAO) DMORPBA MA Modulator DMORPBA RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMORPBA RU https://www.fda.gov/ DMOSQGU DI DMOSQGU DMOSQGU DN Nalbuphine DMOSQGU TI TTQW87Y DMOSQGU TN Opioid receptor kappa (OPRK1) DMOSQGU MA Modulator DMOSQGU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOSQGU RU https://www.fda.gov/ DMOSW35 DI DMOSW35 DMOSW35 DN Felodipine DMOSW35 TI TT5HONZ DMOSW35 TN Calcium channel unspecific (CaC) DMOSW35 MA Blocker DMOSW35 RN Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7. DMOSW35 RU https://pubmed.ncbi.nlm.nih.gov/18974361 DMOTQ1I DI DMOTQ1I DMOTQ1I DN Ondansetron DMOTQ1I TI TTNXLKE DMOTQ1I TN 5-HT 3 receptor (5HT3R) DMOTQ1I MA Agonist DMOTQ1I RN Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70. DMOTQ1I RU https://pubmed.ncbi.nlm.nih.gov/9831410 DMOU1PK DI DMOU1PK DMOU1PK DN Praziquantel DMOU1PK TI TTCYE56 DMOU1PK TN Glutathione-dependent PGD synthase (HPGDS) DMOU1PK MA Inhibitor DMOU1PK RN X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 Mar 1;61(Pt 3):263-5. DMOU1PK RU https://pubmed.ncbi.nlm.nih.gov/16511012 DMOUC09 DI DMOUC09 DMOUC09 DN Norepinephrine DMOUC09 TI TTR6W5O DMOUC09 TN Adrenergic receptor beta-1 (ADRB1) DMOUC09 MA Stimulator DMOUC09 RN Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31. DMOUC09 RU https://pubmed.ncbi.nlm.nih.gov/10075057 DMOUMDV DI DMOUMDV DMOUMDV DN Penciclovir DMOUMDV TI TTIU7X1 DMOUMDV TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMOUMDV MA Inhibitor DMOUMDV RN Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66. DMOUMDV RU https://pubmed.ncbi.nlm.nih.gov/19228073 DMOUMDV DI DMOUMDV DMOUMDV DN Penciclovir DMOUMDV TI TTP3QRF DMOUMDV TN Thymidine kinase 1 (TK1) DMOUMDV MA Inhibitor DMOUMDV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOUMDV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOVAIX DI DMOVAIX DMOVAIX DN Meropenem + vaborbactam DMOVAIX TI TTHI19T DMOVAIX TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMOVAIX MA Inhibitor DMOVAIX RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMOVAIX RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMOVH1M DI DMOVH1M DMOVH1M DN Oxytetracycline DMOVH1M TI TTQ8KVI DMOVH1M TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMOVH1M MA Binder DMOVH1M RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMOVH1M RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMOVY05 DI DMOVY05 DMOVY05 DN Ketotifen DMOVY05 TI TTTIBOJ DMOVY05 TN Histamine H1 receptor (H1R) DMOVY05 MA Antagonist DMOVY05 RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMOVY05 RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMOWEBU DI DMOWEBU DMOWEBU DN Pegaptanib DMOWEBU TI TTIPJCB DMOWEBU TN Neuropilin-1 (NRP1) DMOWEBU RN Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32. DMOWEBU RU https://pubmed.ncbi.nlm.nih.gov/16518379 DMOWK6B DI DMOWK6B DMOWK6B DN Aprobarbital DMOWK6B TI TTAN6JD DMOWK6B TN Glutamate receptor AMPA (GRIA) DMOWK6B MA Binder DMOWK6B RN Determination of zidovudine/lamivudine/nevirapine in human plasma using ion-pair HPLC. J Pharm Biomed Anal. 2002 Jun 1;28(5):903-8. DMOWK6B RU https://pubmed.ncbi.nlm.nih.gov/12039632 DMOWLVG DI DMOWLVG DMOWLVG DN Nitazoxanide DMOWLVG TI TT0F5P8 DMOWLVG TN Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO) DMOWLVG MA Modulator DMOWLVG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOWLVG RU https://www.fda.gov/ DMOWZ6B DI DMOWZ6B DMOWZ6B DN Fluconazole DMOWZ6B TI TTTSOUD DMOWZ6B TN Candida Cytochrome P450 51 (Candi ERG11) DMOWZ6B MA Modulator DMOWZ6B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMOWZ6B RU https://www.fda.gov/ DMOX3LB DI DMOX3LB DMOX3LB DN Fosphenytoin DMOX3LB TI TTZOVE0 DMOX3LB TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMOX3LB MA Blocker DMOX3LB RN Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68. DMOX3LB RU https://pubmed.ncbi.nlm.nih.gov/19552484 DMOXJKF DI DMOXJKF DMOXJKF DN Dapiprazole DMOXJKF TI TTEX248 DMOXJKF TN Dopamine D2 receptor (D2R) DMOXJKF MA Antagonist DMOXJKF RN Effect of ibopamine on aqueous humor production in normotensive humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4853-8. DMOXJKF RU https://pubmed.ncbi.nlm.nih.gov/14578408 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 TI TT3PQ2Y DMOY7W3 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOY7W3 DI DMOY7W3 DMOY7W3 DN Artemisinin DMOY7W3 TI TTZVSJ2 DMOY7W3 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMOY7W3 MA Inhibitor DMOY7W3 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMOY7W3 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMOYJFK DI DMOYJFK DMOYJFK DN Valrubicin DMOYJFK TI TT0IHXV DMOYJFK TN DNA topoisomerase II (TOP2) DMOYJFK MA Inhibitor DMOYJFK RN Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II. NCI Monogr. 1987;(4):111-5. DMOYJFK RU https://pubmed.ncbi.nlm.nih.gov/3041237 DMP0OVQ DI DMP0OVQ DMP0OVQ DN Gestrinone DMP0OVQ TI TTZAYWL DMP0OVQ TN Estrogen receptor (ESR) DMP0OVQ MA Modulator DMP0OVQ RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMP0OVQ RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMP0UK2 DI DMP0UK2 DMP0UK2 DN Vecuronium DMP0UK2 TI TTF4E0J DMP0UK2 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMP0UK2 MA Antagonist DMP0UK2 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMP0UK2 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMP1I6Y DI DMP1I6Y DMP1I6Y DN Alectinib DMP1I6Y TI TTPMQSO DMP1I6Y TN ALK tyrosine kinase receptor (ALK) DMP1I6Y MA Inhibitor DMP1I6Y RN CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011 May 17;19(5):679-90. DMP1I6Y RU https://pubmed.ncbi.nlm.nih.gov/21575866 DMP1QTS DI DMP1QTS DMP1QTS DN Idecabtagene vicleucel DMP1QTS TI TTZ3P4W DMP1QTS TN B-cell maturation protein (TNFRSF17) DMP1QTS MA CAR-T-Cell-Therapy DMP1QTS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMP1QTS RU https://www.fda.gov/vaccines-blood-biologics/abecma-idecabtagene-vicleucel DMP2LZ8 DI DMP2LZ8 DMP2LZ8 DN MLN0002 DMP2LZ8 TI TT7ZMI1 DMP2LZ8 TN Integrin alpha-4/beta-7 (ITGA4/B7) DMP2LZ8 MA Modulator DMP2LZ8 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMP2LZ8 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMP45ME DI DMP45ME DMP45ME DN Lisocabtagene maraleucel DMP45ME TI TTW640A DMP45ME TN B-lymphocyte surface antigen B4 (CD19) DMP45ME MA CAR-T-Cell-Therapy DMP45ME RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMP45ME RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel DMP54C7 DI DMP54C7 DMP54C7 DN Bacampicillin DMP54C7 TI TTJP4SM DMP54C7 TN Bacterial Penicillin binding protein (Bact PBP) DMP54C7 MA Binder DMP54C7 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMP54C7 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMP5A4T DI DMP5A4T DMP5A4T DN Trilaciclib DMP5A4T TI TT0PG8F DMP5A4T TN Cyclin-dependent kinase 4 (CDK4) DMP5A4T MA Inhibitor DMP5A4T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMP5A4T RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf DMP5A4T DI DMP5A4T DMP5A4T DN Trilaciclib DMP5A4T TI TTO0FDJ DMP5A4T TN Cyclin-dependent kinase 6 (CDK6) DMP5A4T MA Inhibitor DMP5A4T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMP5A4T RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf DMP6G8T DI DMP6G8T DMP6G8T DN Topotecan DMP6G8T TI TTGTQHC DMP6G8T TN DNA topoisomerase I (TOP1) DMP6G8T MA Modulator DMP6G8T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMP6G8T RU https://www.fda.gov/ DMP6M1N DI DMP6M1N DMP6M1N DN Pirenzepine DMP6M1N TI TTZ9SOR DMP6M1N TN Muscarinic acetylcholine receptor M1 (CHRM1) DMP6M1N MA Antagonist DMP6M1N RN Negative crosstalk between M1 and M2 muscarinic autoreceptors involves endogenous adenosine activating A1 receptors at the rat motor endplate. Neurosci Lett. 2009 Aug 14;459(3):127-31. DMP6M1N RU https://pubmed.ncbi.nlm.nih.gov/19427366 DMP6SC2 DI DMP6SC2 DMP6SC2 DN Irinotecan DMP6SC2 TI TTGTQHC DMP6SC2 TN DNA topoisomerase I (TOP1) DMP6SC2 MA Modulator DMP6SC2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMP6SC2 RU https://www.fda.gov/ DMP79A1 DI DMP79A1 DMP79A1 DN Macitentan DMP79A1 TI TTKRD0G DMP79A1 TN Endothelin A receptor (EDNRA) DMP79A1 MA Modulator DMP79A1 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMP79A1 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMP79A1 DI DMP79A1 DMP79A1 DN Macitentan DMP79A1 TI TT3ZTGU DMP79A1 TN Endothelin B receptor (EDNRB) DMP79A1 MA Modulator DMP79A1 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMP79A1 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMP7LK1 DI DMP7LK1 DMP7LK1 DN Guggulsterone DMP7LK1 TI TTS4UGC DMP7LK1 TN Farnesoid X-activated receptor (FXR) DMP7LK1 MA Antagonist DMP7LK1 RN Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8. DMP7LK1 RU https://pubmed.ncbi.nlm.nih.gov/19102680 DMP8HEL DI DMP8HEL DMP8HEL DN Mitiglinide DMP8HEL TI TTG140O DMP8HEL TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMP8HEL MA Blocker DMP8HEL RN Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases. Biochem Pharmacol. 2007 Jun 1;73(11):1842-51. DMP8HEL RU https://pubmed.ncbi.nlm.nih.gov/17359941 DMP9HBO DI DMP9HBO DMP9HBO DN Sucralfate DMP9HBO TI TTGKIED DMP9HBO TN Fibroblast growth factor-2 (FGF2) DMP9HBO MA Modulator DMP9HBO RN Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions. Gastrointest Endosc. 1995 Feb;41(2):109-14. DMP9HBO RU https://pubmed.ncbi.nlm.nih.gov/7720996 DMPAZHC DI DMPAZHC DMPAZHC DN Cabazitaxel DMPAZHC TI TTML2WA DMPAZHC TN Tubulin (TUB) DMPAZHC MA Inhibitor DMPAZHC RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMPAZHC RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMPC1J7 DI DMPC1J7 DMPC1J7 DN Clofibrate DMPC1J7 TI TTOF3WZ DMPC1J7 TN Lipoprotein lipase (LPL) DMPC1J7 MA Activator DMPC1J7 RN Effects of clofibrate treatment in laying hens. Poult Sci. 2007 Jun;86(6):1187-95. DMPC1J7 RU https://pubmed.ncbi.nlm.nih.gov/17495091 DMPC2QY DI DMPC2QY DMPC2QY DN CNTO-1959 DMPC2QY TI TTC1GLB DMPC2QY TN Interleukin-23 (IL23) DMPC2QY RN Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4. DMPC2QY RU https://pubmed.ncbi.nlm.nih.gov/25807335 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTPTXIN DMPCG2L TN Translocator protein (TSPO) DMPCG2L MA Antagonist DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TT37EDJ DMPCG2L TN GABA(A) receptor alpha-3 (GABRA3) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTNZPQ1 DMPCG2L TN GABA(A) receptor alpha-5 (GABRA5) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTBMV1G DMPCG2L TN GABA(A) receptor alpha-2 (GABRA2) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMPCG2L DI DMPCG2L DMPCG2L DN Flumazenil DMPCG2L TI TTEX6LM DMPCG2L TN GABA(A) receptor gamma-3 (GABRG3) DMPCG2L MA Modulator (allosteric modulator) DMPCG2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMPCG2L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMPDW6T DI DMPDW6T DMPDW6T DN Epirubicin DMPDW6T TI TT0IHXV DMPDW6T TN DNA topoisomerase II (TOP2) DMPDW6T MA Modulator DMPDW6T RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPDW6T RU https://www.fda.gov/ DMPDYFR DI DMPDYFR DMPDYFR DN Cefazolin DMPDYFR TI TTJP4SM DMPDYFR TN Bacterial Penicillin binding protein (Bact PBP) DMPDYFR MA Binder DMPDYFR RN Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9. DMPDYFR RU https://pubmed.ncbi.nlm.nih.gov/18218742 DMPFN6Y DI DMPFN6Y DMPFN6Y DN Olanzapine DMPFN6Y TI TTEX248 DMPFN6Y TN Dopamine D2 receptor (D2R) DMPFN6Y MA Agonist DMPFN6Y RN Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61. DMPFN6Y RU https://pubmed.ncbi.nlm.nih.gov/11217867 DMPFWO6 DI DMPFWO6 DMPFWO6 DN Halazepam DMPFWO6 TI TTPTXIN DMPFWO6 TN Translocator protein (TSPO) DMPFWO6 MA Modulator DMPFWO6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPFWO6 RU https://www.fda.gov/ DMPGHY8 DI DMPGHY8 DMPGHY8 DN Roflumilast DMPGHY8 TI TTV5CGO DMPGHY8 TN Phosphodiesterase 4 (PDE4) DMPGHY8 MA Modulator DMPGHY8 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMPGHY8 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMPGR1E DI DMPGR1E DMPGR1E DN Clascoterone DMPGR1E TI TTS64P2 DMPGR1E TN Androgen receptor (AR) DMPGR1E MA Antagonist DMPGR1E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMPGR1E RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213433s000lbl.pdf DMPGUCF DI DMPGUCF DMPGUCF DN Dopamine DMPGUCF TI TTEX248 DMPGUCF TN Dopamine D2 receptor (D2R) DMPGUCF MA Agonist DMPGUCF RN The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74. DMPGUCF RU https://pubmed.ncbi.nlm.nih.gov/17301410 DMPHVQ1 DI DMPHVQ1 DMPHVQ1 DN Human prothrombin complex concentrate DMPHVQ1 TI TT6L509 DMPHVQ1 TN Coagulation factor IIa (F2) DMPHVQ1 MA Modulator DMPHVQ1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMPHVQ1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMPHWU6 DI DMPHWU6 DMPHWU6 DN Tandospirone DMPHWU6 TI TT85JO3 DMPHWU6 TN 5-HT receptor (5HTR) DMPHWU6 MA Modulator DMPHWU6 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMPHWU6 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI TI TTN6J5F DMPHXMI TN Bacterial DNA gyrase (Bact gyrase) DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMPHXMI DI DMPHXMI DMPHXMI DN Besifloxacin DMPHXMI TI TTIXTO3 DMPHXMI TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMPHXMI MA Modulator DMPHXMI RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMPHXMI RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMPHZQE DI DMPHZQE DMPHZQE DN Chlorpropamide DMPHZQE TI TTG140O DMPHZQE TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMPHZQE MA Blocker DMPHZQE RN Effect of the chlorpropamide and fructose-1,6-bisphosphate of soluble TNF receptor II levels. Pharmacol Res. 2004 May;49(5):449-53. DMPHZQE RU https://pubmed.ncbi.nlm.nih.gov/14998554 DMPI6Z0 DI DMPI6Z0 DMPI6Z0 DN Zopiclone DMPI6Z0 TI TTAN6JD DMPI6Z0 TN Glutamate receptor AMPA (GRIA) DMPI6Z0 MA Binder DMPI6Z0 RN Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453. DMPI6Z0 RU https://pubmed.ncbi.nlm.nih.gov/19300573 DMPI98T DI DMPI98T DMPI98T DN Doxepin DMPI98T TI TTTIBOJ DMPI98T TN Histamine H1 receptor (H1R) DMPI98T MA Inhibitor DMPI98T RN Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305. DMPI98T RU https://pubmed.ncbi.nlm.nih.gov/17685877 DMPIBJK DI DMPIBJK DMPIBJK DN Propafenone DMPIBJK TI TT05DLS DMPIBJK TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMPIBJK MA Modulator DMPIBJK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPIBJK RU https://www.fda.gov/ DMPIHLS DI DMPIHLS DMPIHLS DN Diclofenac DMPIHLS TI TTK0943 DMPIHLS TN Prostaglandin G/H synthase (COX) DMPIHLS MA Modulator DMPIHLS RN Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82. DMPIHLS RU https://pubmed.ncbi.nlm.nih.gov/11221916 DMPL395 DI DMPL395 DMPL395 DN Insulin degludec DMPL395 TI TTZOPHG DMPL395 TN Insulin (INS) DMPL395 MA Modulator DMPL395 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMPL395 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMPLY7B DI DMPLY7B DMPLY7B DN Cefmenoxime DMPLY7B TI TT85JMW DMPLY7B TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMPLY7B MA Binder DMPLY7B RN In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. Antimicrob Agents Chemother. 1988 May;32(5):693-701. DMPLY7B RU https://pubmed.ncbi.nlm.nih.gov/3134847 DMPM4SK DI DMPM4SK DMPM4SK DN Methamphetamine DMPM4SK TI TTEX248 DMPM4SK TN Dopamine D2 receptor (D2R) DMPM4SK MA Agonist DMPM4SK RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DMPM4SK RU https://pubmed.ncbi.nlm.nih.gov/15977970 DMPM4SK DI DMPM4SK DMPM4SK DN Methamphetamine DMPM4SK TI TTBRKXS DMPM4SK TN Adrenergic receptor alpha-1B (ADRA1B) DMPM4SK MA Antagonist DMPM4SK RN Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9. DMPM4SK RU https://pubmed.ncbi.nlm.nih.gov/18945553 DMPMYE8 DI DMPMYE8 DMPMYE8 DN Miconazole DMPMYE8 TI TTTSOUD DMPMYE8 TN Candida Cytochrome P450 51 (Candi ERG11) DMPMYE8 MA Modulator DMPMYE8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPMYE8 RU https://www.fda.gov/ DMPN1TW DI DMPN1TW DMPN1TW DN Dofetilide DMPN1TW TI TT1VOHK DMPN1TW TN Potassium channel unspecific (KC) DMPN1TW MA Modulator DMPN1TW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMPN1TW RU https://www.fda.gov/ DMPO0MS DI DMPO0MS DMPO0MS DN Gallamine Triethiodide DMPO0MS TI TTYEG6Q DMPO0MS TN Muscarinic acetylcholine receptor M2 (CHRM2) DMPO0MS MA Antagonist DMPO0MS RN Cholinergic regulation of the corpora allata in adult male loreyi leafworm Mythimna loreyi. Arch Insect Biochem Physiol. 2002 Apr;49(4):215-24. DMPO0MS RU https://pubmed.ncbi.nlm.nih.gov/11921079 DMPOD47 DI DMPOD47 DMPOD47 DN Ajmalicine DMPOD47 TI TTR6W5O DMPOD47 TN Adrenergic receptor beta-1 (ADRB1) DMPOD47 MA Modulator DMPOD47 RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMPOD47 RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMPOU5H DI DMPOU5H DMPOU5H DN ENASIDENIB MESYLATE DMPOU5H TI TTDTWV0 DMPOU5H TN Isocitrate dehydrogenase (IDH) DMPOU5H MA Inhibitor DMPOU5H RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMPOU5H RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMPQAGE DI DMPQAGE DMPQAGE DN Mycophenolate mofetil DMPQAGE TI TTTB4UP DMPQAGE TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMPQAGE MA Inhibitor DMPQAGE RN Clinical pipeline report, company report or official report of Roche (2009). DMPQAGE RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMPQAGE DI DMPQAGE DMPQAGE DN Mycophenolate mofetil DMPQAGE TI TT1ZAVI DMPQAGE TN Prostaglandin E2 receptor EP2 (PTGER2) DMPQAGE MA Modulator DMPQAGE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341). DMPQAGE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341 DMPRBQV DI DMPRBQV DMPRBQV DN Enalaprilat DMPRBQV TI TTL69WB DMPRBQV TN Angiotensin-converting enzyme (ACE) DMPRBQV MA Inhibitor DMPRBQV RN Analysis of Vancomycin in the Hindlimb Vascular Bed of the Rat. Am J Ther. 1996 Oct;3(10):681-687. DMPRBQV RU https://pubmed.ncbi.nlm.nih.gov/11862223 DMPRI8G DI DMPRI8G DMPRI8G DN Buprenorphine DMPRI8G TI TTKWM86 DMPRI8G TN Opioid receptor mu (MOP) DMPRI8G MA Agonist DMPRI8G RN Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8. DMPRI8G RU https://pubmed.ncbi.nlm.nih.gov/19494155 DMPSB8F DI DMPSB8F DMPSB8F DN MEPTAZINOL DMPSB8F TI TTEB0GD DMPSB8F TN Cholinesterase (BCHE) DMPSB8F MA Inhibitor DMPSB8F RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMPSB8F RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMPT74U DI DMPT74U DMPT74U DN Gramicidin D DMPT74U TI TT4ILYC DMPT74U TN Bacterial Dihydropteroate synthetase (Bact folP) DMPT74U MA Binder DMPT74U RN Structures of gramicidins A, B, and C incorporated into sodium dodecyl sulfate micelles. Biochemistry. 2001 Oct 2;40(39):11676-86. DMPT74U RU https://pubmed.ncbi.nlm.nih.gov/11570868 DMPU2WX DI DMPU2WX DMPU2WX DN Omacetaxine mepesuccinate DMPU2WX TI TTA4FIU DMPU2WX TN Ribosome A (hRA) DMPU2WX MA Modulator DMPU2WX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMPU2WX RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMPUKA7 DI DMPUKA7 DMPUKA7 DN Caplacizumab DMPUKA7 TI TT3SZBT DMPUKA7 TN von Willebrand factor (VWF) DMPUKA7 MA Inhibitor DMPUKA7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMPUKA7 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761112s000lbl.pdf DMPVRN9 DI DMPVRN9 DMPVRN9 DN Setmelanotide DMPVRN9 TI TTD0CIQ DMPVRN9 TN Melanocortin receptor 4 (MC4R) DMPVRN9 MA Agonist DMPVRN9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMPVRN9 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213793s000lbl.pdf DMPWB7T DI DMPWB7T DMPWB7T DN Maprotiline DMPWB7T TI TTAWNKZ DMPWB7T TN Norepinephrine transporter (NET) DMPWB7T MA Inhibitor DMPWB7T RN Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28. DMPWB7T RU https://pubmed.ncbi.nlm.nih.gov/15900091 DMPWCTH DI DMPWCTH DMPWCTH DN Neocarzinostatin DMPWCTH TI TTUTN1I DMPWCTH TN Human Deoxyribonucleic acid (hDNA) DMPWCTH MA Modulator DMPWCTH RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMPWCTH RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMPWGBR DI DMPWGBR DMPWGBR DN Triclabendazole DMPWGBR TI TTEAID7 DMPWGBR TN Trypanosoma Cruzipain (Trypano CYSP) DMPWGBR MA Inhibitor DMPWGBR RN Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65. DMPWGBR RU https://pubmed.ncbi.nlm.nih.gov/20426472 DMPWNDB DI DMPWNDB DMPWNDB DN Balofloxacin DMPWNDB TI TTJP4SM DMPWNDB TN Bacterial Penicillin binding protein (Bact PBP) DMPWNDB MA Inhibitor DMPWNDB RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMPWNDB RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMPWSEM DI DMPWSEM DMPWSEM DN Lercanidipine DMPWSEM TI TTFK1JQ DMPWSEM TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMPWSEM MA Blocker DMPWSEM RN Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):981-7. DMPWSEM RU https://pubmed.ncbi.nlm.nih.gov/19619074 DMPXITB DI DMPXITB DMPXITB DN Hetacillin DMPXITB TI TTJP4SM DMPXITB TN Bacterial Penicillin binding protein (Bact PBP) DMPXITB MA Modulator DMPXITB RN JBioWH: an open-source Java framework for bioinformatics data integration.Database (Oxford).2013 Jul 11;2013:bat051. DMPXITB RU https://www.ncbi.nlm.nih.gov/pubmed/23846595 DMPZI3Q DI DMPZI3Q DMPZI3Q DN Ketoconazole DMPZI3Q TI TTTSOUD DMPZI3Q TN Candida Cytochrome P450 51 (Candi ERG11) DMPZI3Q MA Inhibitor DMPZI3Q RN Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302. DMPZI3Q RU https://pubmed.ncbi.nlm.nih.gov/19566112 DMPZS7U DI DMPZS7U DMPZS7U DN Oxyphenbutazone DMPZS7U TI TTFNGC9 DMPZS7U TN Serum albumin (ALB) DMPZS7U MA Modulator DMPZS7U RN Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4. DMPZS7U RU https://www.ncbi.nlm.nih.gov/pubmed/7062254 DMQ0C2Z DI DMQ0C2Z DMQ0C2Z DN Prevnar DMQ0C2Z TI TT9GOIR DMQ0C2Z TN Streptococcus Diphtheria protein (Stre DIPP) DMQ0C2Z RN Patent WO2013131983 A1. DMQ0C2Z RU http://www.google.com/patents/WO2013131983A1?cl=en DMQ0RKZ DI DMQ0RKZ DMQ0RKZ DN Nimodipine DMQ0RKZ TI TT5HONZ DMQ0RKZ TN Calcium channel unspecific (CaC) DMQ0RKZ MA Blocker DMQ0RKZ RN Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44. DMQ0RKZ RU https://pubmed.ncbi.nlm.nih.gov/19443934 DMQ2491 DI DMQ2491 DMQ2491 DN Nitroglycerin DMQ2491 TI TTGKNB4 DMQ2491 TN Epidermal growth factor receptor (EGFR) DMQ2491 MA Activator DMQ2491 RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMQ2491 RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMQ2491 DI DMQ2491 DMQ2491 DN Nitroglycerin DMQ2491 TI TT23PYC DMQ2491 TN Soluble guanylate cyclase (GCS) DMQ2491 MA Modulator DMQ2491 RN Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14. DMQ2491 RU https://pubmed.ncbi.nlm.nih.gov/11896472 DMQ2AIJ DI DMQ2AIJ DMQ2AIJ DN Lestaurtinib DMQ2AIJ TI TTGJCWZ DMQ2AIJ TN Fms-like tyrosine kinase 3 (FLT-3) DMQ2AIJ MA Modulator DMQ2AIJ RN Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71. DMQ2AIJ RU https://pubmed.ncbi.nlm.nih.gov/17984313 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TTPADOQ DMQ2FKJ TN HMG-CoA reductase (HMGCR) DMQ2FKJ MA Inhibitor DMQ2FKJ RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TT3PQ2Y DMQ2FKJ TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMQ2FKJ MA Inhibitor DMQ2FKJ RN Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/10941801 DMQ2FKJ DI DMQ2FKJ DMQ2FKJ DN Teriflunomide DMQ2FKJ TI TTLVP78 DMQ2FKJ TN Dihydroorotate dehydrogenase (DHODH) DMQ2FKJ MA Modulator DMQ2FKJ RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMQ2FKJ RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMQ2FPC DI DMQ2FPC DMQ2FPC DN Vasopressin DMQ2FPC TI TTK8R02 DMQ2FPC TN Vasopressin V2 receptor (V2R) DMQ2FPC MA Agonist DMQ2FPC RN Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9. DMQ2FPC RU https://pubmed.ncbi.nlm.nih.gov/16738530 DMQ2JO5 DI DMQ2JO5 DMQ2JO5 DN Hydrocodone DMQ2JO5 TI TTKWM86 DMQ2JO5 TN Opioid receptor mu (MOP) DMQ2JO5 MA Modulator DMQ2JO5 RN Clinical pipeline report, company report or official report of kempharm. DMQ2JO5 RU http://www.kempharm.com/pages/pipeline/pain.php DMQ314B DI DMQ314B DMQ314B DN Hexobarbital DMQ314B TI TT1MPAY DMQ314B TN GABA(A) receptor alpha-1 (GABRA1) DMQ314B MA Antagonist DMQ314B RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMQ314B RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMQ4HIN DI DMQ4HIN DMQ4HIN DN Cabergoline DMQ4HIN TI TTEX248 DMQ4HIN TN Dopamine D2 receptor (D2R) DMQ4HIN MA Agonist DMQ4HIN RN Role of D1 and D2 receptors in the regulation of voluntary movements. Bull Exp Biol Med. 2008 Jul;146(1):14-7. DMQ4HIN RU https://pubmed.ncbi.nlm.nih.gov/19145338 DMQ4TJK DI DMQ4TJK DMQ4TJK DN Dutasteride DMQ4TJK TI TT2A0DR DMQ4TJK TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMQ4TJK MA Inhibitor DMQ4TJK RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMQ4TJK RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMQ5S6C DI DMQ5S6C DMQ5S6C DN Tebipenem pivoxil DMQ5S6C TI TTJP4SM DMQ5S6C TN Bacterial Penicillin binding protein (Bact PBP) DMQ5S6C MA Binder DMQ5S6C RN In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18. DMQ5S6C RU https://pubmed.ncbi.nlm.nih.gov/30718255 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TT6PKBN DMQ8E9R TN Proto-oncogene c-Src (SRC) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TT3PJMV DMQ8E9R TN Tyrosine-protein kinase ABL1 (ABL) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8E9R DI DMQ8E9R DMQ8E9R DN SKI-758 DMQ8E9R TI TTGKNB4 DMQ8E9R TN Epidermal growth factor receptor (EGFR) DMQ8E9R MA Inhibitor DMQ8E9R RN Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. DMQ8E9R RU https://pubmed.ncbi.nlm.nih.gov/17181170 DMQ8FR2 DI DMQ8FR2 DMQ8FR2 DN Prednisolone DMQ8FR2 TI TTYRL6O DMQ8FR2 TN Glucocorticoid receptor (NR3C1) DMQ8FR2 MA Modulator DMQ8FR2 RN Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6. DMQ8FR2 RU https://pubmed.ncbi.nlm.nih.gov/11081607 DMQ8HOJ DI DMQ8HOJ DMQ8HOJ DN lumateperone tosylate DMQ8HOJ TI TTJQOD7 DMQ8HOJ TN 5-HT 2A receptor (HTR2A) DMQ8HOJ MA Antagonist DMQ8HOJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMQ8HOJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf DMQ8HOJ DI DMQ8HOJ DMQ8HOJ DN lumateperone tosylate DMQ8HOJ TI TTEX248 DMQ8HOJ TN Dopamine D2 receptor (D2R) DMQ8HOJ MA Antagonist DMQ8HOJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMQ8HOJ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf DMQ8JIK DI DMQ8JIK DMQ8JIK DN Chenodiol DMQ8JIK TI TTS4UGC DMQ8JIK TN Farnesoid X-activated receptor (FXR) DMQ8JIK MA Modulator DMQ8JIK RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DMQ8JIK RU https://pubmed.ncbi.nlm.nih.gov/12052824 DMQ8R4E DI DMQ8R4E DMQ8R4E DN Naftopidil DMQ8R4E TI TTNGILX DMQ8R4E TN Adrenergic receptor alpha-1A (ADRA1A) DMQ8R4E MA Inhibitor DMQ8R4E RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMQ8R4E RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMQ9MVG DI DMQ9MVG DMQ9MVG DN Chlorhexidine DMQ9MVG TI TT4ILYC DMQ9MVG TN Bacterial Dihydropteroate synthetase (Bact folP) DMQ9MVG MA Breaker DMQ9MVG RN The mechanism of action of chlorhexidine. FEMS Microbiol Lett. 1992 Dec 15;79(1-3):211-5. DMQ9MVG RU https://pubmed.ncbi.nlm.nih.gov/1335944 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH TI TTQ38E9 DMQCTIH TN Sodium/potassium-transporting ATPase (SPT ATPase) DMQCTIH MA Inhibitor DMQCTIH RN Fab antibody fragments: some applications in clinical toxicology. Drug Saf. 2004;27(14):1115-33. DMQCTIH RU https://pubmed.ncbi.nlm.nih.gov/15554746 DMQCTIH DI DMQCTIH DMQCTIH DN Digoxin DMQCTIH TI TTACFNR DMQCTIH TN Organic anion transporter M1 (SLCO4C1) DMQCTIH MA Modulator DMQCTIH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1227). DMQCTIH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1227 DMQG17S DI DMQG17S DMQG17S DN Tirofiban DMQG17S TI TT38RM1 DMQG17S TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQG17S MA Modulator DMQG17S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQG17S RU https://www.fda.gov/ DMQHM2D DI DMQHM2D DMQHM2D DN Benzylpenicilloyl Polylysine DMQHM2D TI TTDGEC0 DMQHM2D TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMQHM2D MA Binder DMQHM2D RN Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60. DMQHM2D RU https://pubmed.ncbi.nlm.nih.gov/7436456 DMQI0FU DI DMQI0FU DMQI0FU DN Insulin-glulisine DMQI0FU TI TTCBFJO DMQI0FU TN Insulin receptor (INSR) DMQI0FU MA Binder DMQI0FU RN Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57. DMQI0FU RU https://pubmed.ncbi.nlm.nih.gov/19496630 DMQJHR7 DI DMQJHR7 DMQJHR7 DN Indacaterol DMQJHR7 TI TT2CJVK DMQJHR7 TN Adrenergic receptor beta-2 (ADRB2) DMQJHR7 MA Agonist DMQJHR7 RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMQJHR7 RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMQL8XJ DI DMQL8XJ DMQL8XJ DN Decitabine DMQL8XJ TI TTUTN1I DMQL8XJ TN Human Deoxyribonucleic acid (hDNA) DMQL8XJ MA Modulator DMQL8XJ RN 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101. DMQL8XJ RU https://pubmed.ncbi.nlm.nih.gov/17342860 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N TI TT2NUT5 DMQLT4N TN Adrenergic receptor alpha-2C (ADRA2C) DMQLT4N MA Modulator DMQLT4N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520). DMQLT4N RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=520 DMQLT4N DI DMQLT4N DMQLT4N DN Brimonidine DMQLT4N TI TTQ8AFT DMQLT4N TN Adrenergic receptor Alpha-2 (ADRA2) DMQLT4N MA Agonist DMQLT4N RN Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90. DMQLT4N RU https://pubmed.ncbi.nlm.nih.gov/10943881 DMQLX7O DI DMQLX7O DMQLX7O DN Arteether DMQLX7O TI TT9X7H4 DMQLX7O TN Beta-hematin formation (BHF) DMQLX7O MA Modulator DMQLX7O RN Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012 May;56(5):2546-52. DMQLX7O RU https://pubmed.ncbi.nlm.nih.gov/22354307 DMQM9S0 DI DMQM9S0 DMQM9S0 DN Palivizumab DMQM9S0 TI TT57ID8 DMQM9S0 TN Respiratory syncytial virus protein F (RSV F) DMQM9S0 MA Modulator DMQM9S0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQM9S0 RU https://www.fda.gov/ DMQMBZ1 DI DMQMBZ1 DMQMBZ1 DN Rivaroxaban DMQMBZ1 TI TTCIHJA DMQMBZ1 TN Coagulation factor Xa (F10) DMQMBZ1 MA Modulator DMQMBZ1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMQMBZ1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMQMGXV DI DMQMGXV DMQMGXV DN Loxoprofen gel DMQMGXV TI TTK0943 DMQMGXV TN Prostaglandin G/H synthase (COX) DMQMGXV MA Inhibitor DMQMGXV RN Comparative study of the clinical efficacy of the selective cyclooxygenase-2 inhibitor celecoxib compared with loxoprofen in patients with frozen shoulder. Mod Rheumatol. 2014 Jan;24(1):144-9. DMQMGXV RU https://pubmed.ncbi.nlm.nih.gov/24261771 DMQMV1B DI DMQMV1B DMQMV1B DN Adalimumab DMQMV1B TI TTF8CQI DMQMV1B TN Tumor necrosis factor (TNF) DMQMV1B RN Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7. DMQMV1B RU https://pubmed.ncbi.nlm.nih.gov/19573024 DMQNI7O DI DMQNI7O DMQNI7O DN OTL-200 DMQNI7O TI TTYQANR DMQNI7O TN Cerebroside-sulfatase (ARSA) DMQNI7O MA Replacement DMQNI7O RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DMQNI7O RU https://www.orchard-tx.com/approach/pipeline/ DMQNWRD DI DMQNWRD DMQNWRD DN Oxaliplatin DMQNWRD TI TTUTN1I DMQNWRD TN Human Deoxyribonucleic acid (hDNA) DMQNWRD MA Modulator DMQNWRD RN Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93. DMQNWRD RU https://www.ncbi.nlm.nih.gov/pubmed/23019159 DMQPD1F DI DMQPD1F DMQPD1F DN Panitumumab DMQPD1F TI TTGKNB4 DMQPD1F TN Epidermal growth factor receptor (EGFR) DMQPD1F MA Suppressor DMQPD1F RN Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. DMQPD1F RU https://pubmed.ncbi.nlm.nih.gov/19616446 DMQPTOZ DI DMQPTOZ DMQPTOZ DN Icatibant DMQPTOZ TI TTGY8IW DMQPTOZ TN B2 bradykinin receptor (BDKRB2) DMQPTOZ MA Antagonist DMQPTOZ RN Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41. DMQPTOZ RU https://pubmed.ncbi.nlm.nih.gov/19552510 DMQRPOS DI DMQRPOS DMQRPOS DN Chlorphentermine hydrochloride DMQRPOS TI TT3ROYC DMQRPOS TN Serotonin transporter (SERT) DMQRPOS MA Modulator DMQRPOS RN Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates.Implications for primary pulmonary hypertension.Circulation.1999 Aug 24;100(8):869-75. DMQRPOS RU https://www.ncbi.nlm.nih.gov/pubmed/10458725 DMQSA2V DI DMQSA2V DMQSA2V DN Valbenazine tosylate DMQSA2V TI TTNZRI3 DMQSA2V TN Synaptic vesicle amine transporter (SLC18A2) DMQSA2V MA Modulator DMQSA2V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQSA2V RU https://www.fda.gov/ DMQSGM0 DI DMQSGM0 DMQSGM0 DN Hydroxyamphetamine Hydrobromide DMQSGM0 TI TTIU98M DMQSGM0 TN Trace amine-associated receptor-1 (TAAR1) DMQSGM0 MA Modulator DMQSGM0 RN Diagnostic pharmacology of the pupil.Clin Neuropharmacol.1985;8(1):27-37. DMQSGM0 RU https://www.ncbi.nlm.nih.gov/pubmed/3884149 DMQTAGO DI DMQTAGO DMQTAGO DN BMS-201038 DMQTAGO TI TTUS1RD DMQTAGO TN Microsomal triglyceride transfer protein (MTTP) DMQTAGO MA Inhibitor DMQTAGO RN Dyslipidemia and cardiovascular diseases. Curr Opin Lipidol. 2009 Apr;20(2):157-8. DMQTAGO RU https://pubmed.ncbi.nlm.nih.gov/19276898 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO TI TTHQZV7 DMQTFAO TN Mothers against decapentaplegic homolog 3 (SMAD3) DMQTFAO MA Inhibitor DMQTFAO RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQTFAO DI DMQTFAO DMQTFAO DN Fluorescein DMQTFAO TI TTTQR47 DMQTFAO TN Solute carrier family 22 member 8 (SLC22A8) DMQTFAO MA Inhibitor DMQTFAO RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DMQTFAO RU https://pubmed.ncbi.nlm.nih.gov/17553798 DMQTJSX DI DMQTJSX DMQTJSX DN Fluvoxamine DMQTJSX TI TT3ROYC DMQTJSX TN Serotonin transporter (SERT) DMQTJSX MA Inhibitor DMQTJSX RN Changes of functional MRI findings in a patient whose pathological gambling improved with fluvoxamine. Yonsei Med J. 2009 Jun 30;50(3):441-4. DMQTJSX RU https://pubmed.ncbi.nlm.nih.gov/19568609 DMQTREB DI DMQTREB DMQTREB DN Uridine DMQTREB TI TTO0IB8 DMQTREB TN Thymidine phosphorylase (TYMP) DMQTREB MA Inhibitor DMQTREB RN Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues. Hum Cell. 2007 Nov;20(4):107-10. DMQTREB RU https://pubmed.ncbi.nlm.nih.gov/17949350 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT TI TTUTN1I DMQUSBT TN Human Deoxyribonucleic acid (hDNA) DMQUSBT MA Intercalator DMQUSBT RN 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12. DMQUSBT RU https://pubmed.ncbi.nlm.nih.gov/2472832 DMQUSBT DI DMQUSBT DMQUSBT DN Daunorubicin DMQUSBT TI TTABD5E DMQUSBT TN DNA replication (DNA repli) DMQUSBT MA Modulator DMQUSBT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQUSBT RU https://www.fda.gov/ DMQVRZH DI DMQVRZH DMQVRZH DN Vitamin B3 DMQVRZH TI TTRHEQ4 DMQVRZH TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMQVRZH MA Inhibitor DMQVRZH RN Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31. DMQVRZH RU https://pubmed.ncbi.nlm.nih.gov/12100180 DMQVRZH DI DMQVRZH DMQVRZH DN Vitamin B3 DMQVRZH TI TTWNV8U DMQVRZH TN Nicotinic acid receptor (HCAR2) DMQVRZH MA Agonist DMQVRZH RN Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31. DMQVRZH RU https://pubmed.ncbi.nlm.nih.gov/12100180 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD TI TT06AWU DMQVZJD TN Phosphodiesterase 3A (PDE3A) DMQVZJD MA Inhibitor DMQVZJD RN Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18. DMQVZJD RU https://pubmed.ncbi.nlm.nih.gov/3027339 DMQVZJD DI DMQVZJD DMQVZJD DN Enoximone DMQVZJD TI TTZCG4L DMQVZJD TN Phosphodiesterase 3 (PDE3) DMQVZJD MA Modulator DMQVZJD RN In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9. DMQVZJD RU https://www.ncbi.nlm.nih.gov/pubmed/12657857 DMQWZ0H DI DMQWZ0H DMQWZ0H DN Benzthiazide DMQWZ0H TI TTANPDJ DMQWZ0H TN Carbonic anhydrase II (CA-II) DMQWZ0H MA Inhibitor DMQWZ0H RN Nature of the inhibition of carbonic anhydrase by acetazolamide and benzthiazide. J Pharmacol Exp Ther. 1961 Mar;131:271-4. DMQWZ0H RU https://pubmed.ncbi.nlm.nih.gov/13760527 DMQXI9F DI DMQXI9F DMQXI9F DN L-Phenylalanine DMQXI9F TI TTUHP71 DMQXI9F TN Tyrosine 3-monooxygenase (TH) DMQXI9F MA Binder DMQXI9F RN Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67. DMQXI9F RU https://pubmed.ncbi.nlm.nih.gov/17305546 DMQXLD2 DI DMQXLD2 DMQXLD2 DN Cyproterone DMQXLD2 TI TTS64P2 DMQXLD2 TN Androgen receptor (AR) DMQXLD2 MA Antagonist DMQXLD2 RN Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug;74(8):669-74. DMQXLD2 RU https://pubmed.ncbi.nlm.nih.gov/19463689 DMQXTJS DI DMQXTJS DMQXTJS DN Eptifibatide DMQXTJS TI TT38RM1 DMQXTJS TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQXTJS MA Modulator DMQXTJS RN Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62. DMQXTJS RU https://pubmed.ncbi.nlm.nih.gov/2033037 DMQYJIR DI DMQYJIR DMQYJIR DN Macimorelin DMQYJIR TI TTWDC17 DMQYJIR TN Growth hormone secretagogue receptor 1 (GHSR) DMQYJIR MA Agonist DMQYJIR RN National Cancer Institute Drug Dictionary (drug id 735530). DMQYJIR RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=735530 DMQYUWG DI DMQYUWG DMQYUWG DN Toremifene DMQYUWG TI TTZAYWL DMQYUWG TN Estrogen receptor (ESR) DMQYUWG MA Modulator DMQYUWG RN Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81. DMQYUWG RU https://pubmed.ncbi.nlm.nih.gov/19468285 DMQYV60 DI DMQYV60 DMQYV60 DN Isopropamide iodide DMQYV60 TI TTOXS3C DMQYV60 TN Muscarinic acetylcholine receptor (CHRM) DMQYV60 MA Modulator DMQYV60 RN Competitive and non-competitive antagonism exhibited by 'selective' antagonists at atrial and ileal muscarinic receptor subtypes. Br J Pharmacol. 1987 Apr;90(4):701-7. DMQYV60 RU https://pubmed.ncbi.nlm.nih.gov/3580704 DMQZ9GF DI DMQZ9GF DMQZ9GF DN Trilostane DMQZ9GF TI TTOM3J0 DMQZ9GF TN Estrogen receptor beta (ESR2) DMQZ9GF MA Modulator DMQZ9GF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMQZ9GF RU https://www.fda.gov/ DMQZBXI DI DMQZBXI DMQZBXI DN Calaspargase pegol DMQZBXI TI TT4WT91 DMQZBXI TN Asparaginase (ASRGL1) DMQZBXI MA Inhibitor DMQZBXI RN Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. J Clin Oncol. 2014 Dec 1;32(34):3874-82. DMQZBXI RU https://pubmed.ncbi.nlm.nih.gov/25348002 DMR0TYK DI DMR0TYK DMR0TYK DN Fosdenopterin DMR0TYK TI TT7RJY8 DMR0TYK TN Xanthine dehydrogenase/oxidase (XDH) DMR0TYK MA Cofactor DMR0TYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMR0TYK RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214018s000lbl.pdf DMR27C8 DI DMR27C8 DMR27C8 DN Artesunate DMR27C8 TI TTZVSJ2 DMR27C8 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMR27C8 MA Inhibitor DMR27C8 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMR27C8 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMR2IQ4 DI DMR2IQ4 DMR2IQ4 DN Tizanidine DMR2IQ4 TI TTQ8AFT DMR2IQ4 TN Adrenergic receptor Alpha-2 (ADRA2) DMR2IQ4 MA Agonist DMR2IQ4 RN Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52. DMR2IQ4 RU https://pubmed.ncbi.nlm.nih.gov/9074844 DMR2J95 DI DMR2J95 DMR2J95 DN Omadacycline DMR2J95 TI TTOVFH2 DMR2J95 TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMR2J95 MA Inhibitor DMR2J95 RN Omadacycline Enters the Ring: A New Antimicrobial Contender.Pharmacotherapy. 2018 Dec;38(12):1194-1204. DMR2J95 RU https://pubmed.ncbi.nlm.nih.gov/30290000 DMR4HIW DI DMR4HIW DMR4HIW DN Insulin-glargine DMR4HIW TI TTZOPHG DMR4HIW TN Insulin (INS) DMR4HIW MA Modulator DMR4HIW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMR4HIW RU https://www.fda.gov/ DMR5QS6 DI DMR5QS6 DMR5QS6 DN Hydroxystilbamidine Isethionate DMR5QS6 TI TTS1W4A DMR5QS6 TN Bacterial Deoxyribonucleic acid (Bact DNA) DMR5QS6 MA Modulator DMR5QS6 RN Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42. DMR5QS6 RU https://www.ncbi.nlm.nih.gov/pubmed/1242363 DMR5ZUP DI DMR5ZUP DMR5ZUP DN Paramethadione DMR5ZUP TI TT729IR DMR5ZUP TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMR5ZUP MA Blocker DMR5ZUP RN Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. DMR5ZUP RU https://pubmed.ncbi.nlm.nih.gov/17291698 DMR6N7H DI DMR6N7H DMR6N7H DN Acetohexamide DMR6N7H TI TTP835K DMR6N7H TN ATP-binding cassette transporter C8 (ABCC8) DMR6N7H MA Modulator DMR6N7H RN Diabetes and insulin secretion: the ATP-sensitive K+ channel (K ATP) connection.Diabetes.2005 Nov;54(11):3065-72. DMR6N7H RU https://www.ncbi.nlm.nih.gov/pubmed/16249427 DMR6QH0 DI DMR6QH0 DMR6QH0 DN Venlafaxine DMR6QH0 TI TT3ROYC DMR6QH0 TN Serotonin transporter (SERT) DMR6QH0 MA Inhibitor DMR6QH0 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DMR6QH0 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DMR6QH0 DI DMR6QH0 DMR6QH0 DN Venlafaxine DMR6QH0 TI TTAWNKZ DMR6QH0 TN Norepinephrine transporter (NET) DMR6QH0 MA Inhibitor DMR6QH0 RN Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92. DMR6QH0 RU https://pubmed.ncbi.nlm.nih.gov/19496045 DMR7IVC DI DMR7IVC DMR7IVC DN Pimavanserin DMR7IVC TI TTJQOD7 DMR7IVC TN 5-HT 2A receptor (HTR2A) DMR7IVC MA Modulator DMR7IVC RN Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52. DMR7IVC RU https://www.ncbi.nlm.nih.gov/pubmed/22954754 DMR87LC DI DMR87LC DMR87LC DN Ethambutol DMR87LC TI TT1Q8GP DMR87LC TN Mycobacterium Arabinosyltransferase C (MycB embC) DMR87LC MA Inhibitor DMR87LC RN The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2009 Oct;53(10):4138-46. DMR87LC RU https://pubmed.ncbi.nlm.nih.gov/19596878 DMR8H31 DI DMR8H31 DMR8H31 DN Quinapril DMR8H31 TI TTL69WB DMR8H31 TN Angiotensin-converting enzyme (ACE) DMR8H31 MA Inhibitor DMR8H31 RN An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int. 2009 Feb;29 Suppl 2:S49-50. DMR8H31 RU https://pubmed.ncbi.nlm.nih.gov/19270231 DMR8ONJ DI DMR8ONJ DMR8ONJ DN Leflunomide DMR8ONJ TI TT3PQ2Y DMR8ONJ TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMR8ONJ MA Inhibitor DMR8ONJ RN Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91. DMR8ONJ RU https://pubmed.ncbi.nlm.nih.gov/10583416 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTLP6GN DMR8YD6 TN Bacterial DD-carboxypeptidase (Bact vanYB) DMR8YD6 MA Inhibitor DMR8YD6 RN Has nature already identified all useful antibacterial targets Curr Opin Microbiol. 2008 Oct;11(5):387-92. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/18804175 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTGTQHC DMR8YD6 TN DNA topoisomerase I (TOP1) DMR8YD6 MA Inhibitor DMR8YD6 RN Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J. 2002 Sep 1;366(Pt 2):653-61. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/12027807 DMR8YD6 DI DMR8YD6 DMR8YD6 DN B-Lactams DMR8YD6 TI TTPOI4B DMR8YD6 TN Acetyl-CoA:lyso-PAF acetyltransferase (PCAT) DMR8YD6 MA Inhibitor DMR8YD6 RN Inhibition of lysoPAF acetyltransferase activity by flavonoids. Inflamm Res. 1996 Nov;45(11):546-9. DMR8YD6 RU https://pubmed.ncbi.nlm.nih.gov/8951505 DMRADYL DI DMRADYL DMRADYL DN Pinacidil DMRADYL TI TT1VOHK DMRADYL TN Potassium channel unspecific (KC) DMRADYL MA Modulator DMRADYL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRADYL RU https://www.fda.gov/ DMRBJNZ DI DMRBJNZ DMRBJNZ DN Forasartan DMRBJNZ TI TT8DBY3 DMRBJNZ TN Angiotensin II receptor type-1 (AGTR1) DMRBJNZ MA Antagonist DMRBJNZ RN Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification. J Med Chem. 2003 Feb 27;46(5):716-26. DMRBJNZ RU https://pubmed.ncbi.nlm.nih.gov/12593652 DMRCLZB DI DMRCLZB DMRCLZB DN Pentagastrin DMRCLZB TI TTVFO0U DMRCLZB TN Gastrin/cholecystokinin type B receptor (CCKBR) DMRCLZB MA Agonist DMRCLZB RN Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology. 2009 Jan;34(2):509-21. DMRCLZB RU https://pubmed.ncbi.nlm.nih.gov/18580872 DMRCX8K DI DMRCX8K DMRCX8K DN Eloctate DMRCX8K TI TT1290U DMRCX8K TN Coagulation factor VIII (F8) DMRCX8K MA Modulator DMRCX8K RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRCX8K RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMRD1QK DI DMRD1QK DMRD1QK DN Netilmicin DMRD1QK TI TTQ8KVI DMRD1QK TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMRD1QK MA Binder DMRD1QK RN Ribosomal resistance in the gentamicin producer organism Micromonospora purpurea. Antimicrob Agents Chemother. 1982 Aug;22(2):231-6. DMRD1QK RU https://pubmed.ncbi.nlm.nih.gov/6927285 DMRDUC0 DI DMRDUC0 DMRDUC0 DN Elagolix sodium DMRDUC0 TI TT8R70G DMRDUC0 TN Gonadotropin-releasing hormone receptor (GNRHR) DMRDUC0 MA Antagonist DMRDUC0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMRDUC0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMREUQ6 DI DMREUQ6 DMREUQ6 DN Valsartan DMREUQ6 TI TT8DBY3 DMREUQ6 TN Angiotensin II receptor type-1 (AGTR1) DMREUQ6 MA Antagonist DMREUQ6 RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DMREUQ6 RU https://pubmed.ncbi.nlm.nih.gov/19513646 DMRF9YK DI DMRF9YK DMRF9YK DN Empagliflozin DMRF9YK TI TTLWPVF DMRF9YK TN Sodium/glucose cotransporter 2 (SGLT2) DMRF9YK MA Modulator DMRF9YK RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMRF9YK RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMRFWGK DI DMRFWGK DMRFWGK DN Novobiocin DMRFWGK TI TT0IHXV DMRFWGK TN DNA topoisomerase II (TOP2) DMRFWGK MA Inhibitor DMRFWGK RN Transcriptional responses of Bacillus subtillis and thuringiensis to antibiotics and anti-tumour drugs. Int J Mol Med. 2009 Jan;23(1):33-9. DMRFWGK RU https://pubmed.ncbi.nlm.nih.gov/19082504 DMRGZ16 DI DMRGZ16 DMRGZ16 DN Sulfamethazine DMRGZ16 TI TT4ILYC DMRGZ16 TN Bacterial Dihydropteroate synthetase (Bact folP) DMRGZ16 MA Inhibitor DMRGZ16 RN A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. J Chromatogr A. 2009 Oct 23;1216(43):7275-80. DMRGZ16 RU https://pubmed.ncbi.nlm.nih.gov/19505691 DMRH0D5 DI DMRH0D5 DMRH0D5 DN PEGylated IFN beta 1-a DMRH0D5 TI TT4TZ8J DMRH0D5 TN Interferon-beta (IFNB1) DMRH0D5 MA Modulator DMRH0D5 RN Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014 Jul;13(7):657-65. DMRH0D5 RU https://pubmed.ncbi.nlm.nih.gov/24794721 DMRH7CV DI DMRH7CV DMRH7CV DN Deserpidine DMRH7CV TI TTL69WB DMRH7CV TN Angiotensin-converting enzyme (ACE) DMRH7CV MA Inhibitor DMRH7CV RN Angiotensin II-induced modulation of endothelium-dependent relaxation in rabbit mesenteric resistance arteries. J Physiol. 2003 May 1;548(Pt 3):893-906. DMRH7CV RU https://pubmed.ncbi.nlm.nih.gov/12651915 DMRHGI9 DI DMRHGI9 DMRHGI9 DN Cisplatin DMRHGI9 TI TTUTN1I DMRHGI9 TN Human Deoxyribonucleic acid (hDNA) DMRHGI9 MA Modulator DMRHGI9 RN Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9. DMRHGI9 RU https://www.ncbi.nlm.nih.gov/pubmed/8533159 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TTUTJGQ DMRICNP TN Vascular endothelial growth factor receptor 2 (KDR) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TT4DXQT DMRICNP TN Proto-oncogene c-Ret (RET) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRICNP DI DMRICNP DMRICNP DN Vandetanib DMRICNP TI TTGKNB4 DMRICNP TN Epidermal growth factor receptor (EGFR) DMRICNP MA Inhibitor DMRICNP RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMRICNP RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMRJ3YX DI DMRJ3YX DMRJ3YX DN Alteplase DMRJ3YX TI TTP86E2 DMRJ3YX TN Plasminogen (PLG) DMRJ3YX MA Activator DMRJ3YX RN Thrombolytic therapies: the current state of affairs. J Endovasc Ther. 2005 Apr;12(2):224-32. DMRJ3YX RU https://pubmed.ncbi.nlm.nih.gov/15823070 DMRJ7D1 DI DMRJ7D1 DMRJ7D1 DN Nomegestrol acetate DMRJ7D1 TI TTZAYWL DMRJ7D1 TN Estrogen receptor (ESR) DMRJ7D1 MA Modulator DMRJ7D1 RN Regulation of rat uterine steroid receptors by nomegestrol acetate, a new 19-nor-progesterone derivative. J Pharmacol Exp Ther. 1989 Feb;248(2):758-61. DMRJ7D1 RU https://pubmed.ncbi.nlm.nih.gov/2918478 DMRJFN9 DI DMRJFN9 DMRJFN9 DN Theophylline DMRJFN9 TI TTSLI08 DMRJFN9 TN Adenosine receptor (ADOR) DMRJFN9 MA Antagonist DMRJFN9 RN Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007 Sep;12(3):479-92. DMRJFN9 RU https://pubmed.ncbi.nlm.nih.gov/17874974 DMRJLAT DI DMRJLAT DMRJLAT DN Osimertinib DMRJLAT TI TTGKNB4 DMRJLAT TN Epidermal growth factor receptor (EGFR) DMRJLAT MA Inhibitor DMRJLAT RN AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. DMRJLAT RU https://pubmed.ncbi.nlm.nih.gov/24893891 DMRJSP8 DI DMRJSP8 DMRJSP8 DN Orlistat DMRJSP8 TI TT6OEDT DMRJSP8 TN Cannabinoid receptor 1 (CB1) DMRJSP8 MA Inhibitor DMRJSP8 RN Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9. DMRJSP8 RU https://pubmed.ncbi.nlm.nih.gov/18831576 DMRJSP8 DI DMRJSP8 DMRJSP8 DN Orlistat DMRJSP8 TI TTXMY0J DMRJSP8 TN Pancreatic triacylglycerol lipase (PNLIP) DMRJSP8 MA Modulator DMRJSP8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRJSP8 RU https://www.fda.gov/ DMRK8OT DI DMRK8OT DMRK8OT DN Candesartan DMRK8OT TI TT8DBY3 DMRK8OT TN Angiotensin II receptor type-1 (AGTR1) DMRK8OT MA Antagonist DMRK8OT RN Candesartan: widening indications for this angiotensin II receptor blocker Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. DMRK8OT RU https://pubmed.ncbi.nlm.nih.gov/19563275 DMRKE63 DI DMRKE63 DMRKE63 DN Chlorambucil DMRKE63 TI TTABD5E DMRKE63 TN DNA replication (DNA repli) DMRKE63 MA Intercalator DMRKE63 RN Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23. DMRKE63 RU https://pubmed.ncbi.nlm.nih.gov/19509245 DMRKOS1 DI DMRKOS1 DMRKOS1 DN Oxilofrine DMRKOS1 TI TTVIREA DMRKOS1 TN Adrenergic receptor (ADR) DMRKOS1 MA Modulator DMRKOS1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMRKOS1 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMRKXPT DI DMRKXPT DMRKXPT DN Ketoprofen DMRKXPT TI TTVKILB DMRKXPT TN Prostaglandin G/H synthase 2 (COX-2) DMRKXPT MA Inhibitor DMRKXPT RN Probing the skin permeation of fish oil/EPA and ketoprofen-3. Effects on epidermal COX-2 and LOX. Prostaglandins Leukot Essent Fatty Acids. 2007 Jun;76(6):357-62. DMRKXPT RU https://pubmed.ncbi.nlm.nih.gov/17588732 DMRL3AB DI DMRL3AB DMRL3AB DN Famotidine DMRL3AB TI TTQHJ1K DMRL3AB TN Histamine H2 receptor (H2R) DMRL3AB MA Antagonist DMRL3AB RN Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5. DMRL3AB RU https://pubmed.ncbi.nlm.nih.gov/11180002 DMRM0JV DI DMRM0JV DMRM0JV DN Nalidixic acid DMRM0JV TI TT0IHXV DMRM0JV TN DNA topoisomerase II (TOP2) DMRM0JV MA Inhibitor DMRM0JV RN Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. DMRM0JV RU https://pubmed.ncbi.nlm.nih.gov/2847647 DMRM3AW DI DMRM3AW DMRM3AW DN Acarbose DMRM3AW TI TTXWASR DMRM3AW TN Intestinal maltase-glucoamylase (MGAM) DMRM3AW MA Modulator DMRM3AW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRM3AW RU https://www.fda.gov/ DMRMCXW DI DMRMCXW DMRMCXW DN Zotarolimus DMRMCXW TI TTCJG29 DMRMCXW TN Serine/threonine-protein kinase mTOR (mTOR) DMRMCXW MA Modulator DMRMCXW RN Natural products to drugs: natural product-derived compounds in clinical trials. Nat Prod Rep. 2008 Jun;25(3):475-516. DMRMCXW RU https://pubmed.ncbi.nlm.nih.gov/18497896 DMRMDWA DI DMRMDWA DMRMDWA DN Estropipate DMRMDWA TI TTZAYWL DMRMDWA TN Estrogen receptor (ESR) DMRMDWA MA Modulator DMRMDWA RN US patent application no. 5,004,651, Stabilizing system for solid dosage forms. DMRMDWA RU http://www.google.com/patents/US5004651 DMRMFP4 DI DMRMFP4 DMRMFP4 DN Inamrinone Lactate DMRMFP4 TI TTZCG4L DMRMFP4 TN Phosphodiesterase 3 (PDE3) DMRMFP4 MA Inhibitor DMRMFP4 RN Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8. DMRMFP4 RU https://pubmed.ncbi.nlm.nih.gov/12076859 DMRMS0L DI DMRMS0L DMRMS0L DN Morphine DMRMS0L TI TTKWM86 DMRMS0L TN Opioid receptor mu (MOP) DMRMS0L MA Modulator DMRMS0L RN Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8. DMRMS0L RU https://www.ncbi.nlm.nih.gov/pubmed/15901793 DMRMS1A DI DMRMS1A DMRMS1A DN Betamethasone Benzoate DMRMS1A TI TTYRL6O DMRMS1A TN Glucocorticoid receptor (NR3C1) DMRMS1A MA Modulator DMRMS1A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRMS1A RU https://www.fda.gov/ DMRQD04 DI DMRQD04 DMRQD04 DN Tramadol DMRQD04 TI TTWJBZ5 DMRQD04 TN 5-HT 2C receptor (HTR2C) DMRQD04 MA Modulator DMRQD04 RN The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes. Anesth Analg. 2004 May;98(5):1401-6, table of contents. DMRQD04 RU https://pubmed.ncbi.nlm.nih.gov/15105221 DMRSKMZ DI DMRSKMZ DMRSKMZ DN Satumomab Pendetide DMRSKMZ TI TTX35ZM DMRSKMZ TN Tumor-associated glycoprotein 72 (TAG-72) DMRSKMZ MA Binder DMRSKMZ RN Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. J Nucl Med Technol. 1998 Sep;26(3):155-63; quiz 170-1. DMRSKMZ RU https://pubmed.ncbi.nlm.nih.gov/9755434 DMRSX53 DI DMRSX53 DMRSX53 DN nusinersen DMRSX53 TI TTSVGQ5 DMRSX53 TN SMN1 messenger RNA (SMN1 mRNA) DMRSX53 MA Modulator DMRSX53 RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMRSX53 RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMRSZA5 DI DMRSZA5 DMRSZA5 DN Cefacetrile DMRSZA5 TI TTJP4SM DMRSZA5 TN Bacterial Penicillin binding protein (Bact PBP) DMRSZA5 MA Binder DMRSZA5 RN Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42. DMRSZA5 RU https://pubmed.ncbi.nlm.nih.gov/18665871 DMRTSGP DI DMRTSGP DMRTSGP DN Amiloride DMRTSGP TI TTRJYB6 DMRTSGP TN Acid-sensing ion channel 1 (ASIC1) DMRTSGP MA Modulator DMRTSGP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMRTSGP RU https://www.fda.gov/ DMRV7H0 DI DMRV7H0 DMRV7H0 DN Bumetanide DMRV7H0 TI TTS087L DMRV7H0 TN Solute carrier family 12 member 1 (SLC12A1) DMRV7H0 MA Blocker DMRV7H0 RN Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37. DMRV7H0 RU https://pubmed.ncbi.nlm.nih.gov/19141616 DMRVBWU DI DMRVBWU DMRVBWU DN Bentazepam DMRVBWU TI TTEX6LM DMRVBWU TN GABA(A) receptor gamma-3 (GABRG3) DMRVBWU MA Modulator DMRVBWU RN Prodynorphin gene deletion increased anxiety-like behaviours, impaired the anxiolytic effect of bromazepam and altered GABAA receptor subunits gene expression in the amygdala. J Psychopharmacol. 2011Jan;25(1):87-96. DMRVBWU RU https://pubmed.ncbi.nlm.nih.gov/20530587 DMS0AFE DI DMS0AFE DMS0AFE DN Desoxycorticosterone acetate DMS0AFE TI TT26PHO DMS0AFE TN Mineralocorticoid receptor (MR) DMS0AFE MA Modulator DMS0AFE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS0AFE RU https://www.fda.gov/ DMS104F DI DMS104F DMS104F DN Temsirolimus DMS104F TI TTCJG29 DMS104F TN Serine/threonine-protein kinase mTOR (mTOR) DMS104F MA Inhibitor DMS104F RN Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. DMS104F RU https://pubmed.ncbi.nlm.nih.gov/25312588 DMS1GYT DI DMS1GYT DMS1GYT DN Mirabegron DMS1GYT TI TTMXGCW DMS1GYT TN Adrenergic receptor beta-3 (ADRB3) DMS1GYT MA Modulator DMS1GYT RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMS1GYT RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMS2IUH DI DMS2IUH DMS2IUH DN Valganciclovir DMS2IUH TI TTIU7X1 DMS2IUH TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMS2IUH MA Inhibitor DMS2IUH RN Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22. DMS2IUH RU https://pubmed.ncbi.nlm.nih.gov/19275707 DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TT7MRDV DMS2J0Z TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TTX41N9 DMS2J0Z TN Tyrosine-protein kinase Kit (KIT) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2J0Z DI DMS2J0Z DMS2J0Z DN Pexidartinib DMS2J0Z TI TTGJCWZ DMS2J0Z TN Fms-like tyrosine kinase 3 (FLT-3) DMS2J0Z MA Inhibitor DMS2J0Z RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMS2J0Z RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211810s000lbl.pdf DMS2M7O DI DMS2M7O DMS2M7O DN Deferiprone DMS2M7O TI TTUDR0C DMS2M7O TN Iron (Fe) DMS2M7O MA Modulator DMS2M7O RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMS2M7O RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMS3508 DI DMS3508 DMS3508 DN Carboprost tromethamine DMS3508 TI TTT2ZAR DMS3508 TN Prostaglandin F2-alpha receptor (PTGFR) DMS3508 MA Modulator DMS3508 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS3508 RU https://www.fda.gov/ DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTYCILE DMS3GVE TN Vasopressin receptor (VR) DMS3GVE MA Modulator DMS3GVE RN Vasopressin V2 (SR121463A) and V1a (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 Nov 3;383(3):287-90. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/10594321 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTL9MHW DMS3GVE TN Vasopressin V1b receptor (V1BR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTK8R02 DMS3GVE TN Vasopressin V2 receptor (V2R) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TTSCIUP DMS3GVE TN Oxytocin receptor (OTR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GVE DI DMS3GVE DMS3GVE DN Desmopressin DMS3GVE TI TT4TFGN DMS3GVE TN Vasopressin V1a receptor (V1AR) DMS3GVE MA Agonist DMS3GVE RN Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88. DMS3GVE RU https://pubmed.ncbi.nlm.nih.gov/15084136 DMS3GX2 DI DMS3GX2 DMS3GX2 DN Telmisartan DMS3GX2 TI TT8DBY3 DMS3GX2 TN Angiotensin II receptor type-1 (AGTR1) DMS3GX2 MA Antagonist DMS3GX2 RN Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009 Jun;50(6):1226-35. DMS3GX2 RU https://pubmed.ncbi.nlm.nih.gov/19395110 DMS3YE9 DI DMS3YE9 DMS3YE9 DN Amantadine DMS3YE9 TI TTXT3PU DMS3YE9 TN Influenza M2 protein (Influ M) DMS3YE9 MA Inhibitor DMS3YE9 RN Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76. DMS3YE9 RU https://pubmed.ncbi.nlm.nih.gov/19469531 DMS4BLQ DI DMS4BLQ DMS4BLQ DN Aminolevulinic acid hci DMS4BLQ TI TTJHKYD DMS4BLQ TN Delta-aminolevulinic acid dehydratase (ALAD) DMS4BLQ MA Inhibitor DMS4BLQ RN Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat Biotechnol. 2003 May;21(5):566-9. DMS4BLQ RU https://pubmed.ncbi.nlm.nih.gov/12665801 DMS51VC DI DMS51VC DMS51VC DN Clomiphene citrate DMS51VC TI TTZAYWL DMS51VC TN Estrogen receptor (ESR) DMS51VC MA Modulator DMS51VC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS51VC RU https://www.fda.gov/ DMS5IEB DI DMS5IEB DMS5IEB DN Docarpamine DMS5IEB TI TTEX248 DMS5IEB TN Dopamine D2 receptor (D2R) DMS5IEB MA Modulator DMS5IEB RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMS5IEB RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMS60RB DI DMS60RB DMS60RB DN Levofloxacin DMS60RB TI TTN6J5F DMS60RB TN Bacterial DNA gyrase (Bact gyrase) DMS60RB MA Modulator DMS60RB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS60RB RU https://www.fda.gov/ DMS60RB DI DMS60RB DMS60RB DN Levofloxacin DMS60RB TI TTIXTO3 DMS60RB TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMS60RB MA Modulator DMS60RB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS60RB RU https://www.fda.gov/ DMS7OU8 DI DMS7OU8 DMS7OU8 DN Elapegademase DMS7OU8 TI TTLP57V DMS7OU8 TN Adenosine deaminase (ADA) DMS7OU8 MA Modulator DMS7OU8 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMS7OU8 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMS7T13 DI DMS7T13 DMS7T13 DN Meclizine DMS7T13 TI TTRANFM DMS7T13 TN Orphan nuclear receptor NR1I3 (NR1I3) DMS7T13 MA Modulator DMS7T13 RN Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38(1-2):51-73. DMS7T13 RU https://pubmed.ncbi.nlm.nih.gov/16684648 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTUTJGQ DMS8IFC TN Vascular endothelial growth factor receptor 2 (KDR) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTX41N9 DMS8IFC TN Tyrosine-protein kinase Kit (KIT) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTI7421 DMS8IFC TN Platelet-derived growth factor receptor beta (PDGFRB) DMS8IFC MA Modulator DMS8IFC RN Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40. DMS8IFC RU https://www.ncbi.nlm.nih.gov/pubmed/18852116 DMS8IFC DI DMS8IFC DMS8IFC DN Sorafenib DMS8IFC TI TTGKNB4 DMS8IFC TN Epidermal growth factor receptor (EGFR) DMS8IFC MA Inhibitor DMS8IFC RN Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16. DMS8IFC RU http://journalofnasopharyngealcarcinoma.org/JNPC/article/view/30/227 DMSA4B3 DI DMSA4B3 DMSA4B3 DN Desoxycorticosterone pivalate DMSA4B3 TI TT26PHO DMSA4B3 TN Mineralocorticoid receptor (MR) DMSA4B3 MA Binder DMSA4B3 RN Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51. DMSA4B3 RU https://pubmed.ncbi.nlm.nih.gov/6227474 DMSA4HZ DI DMSA4HZ DMSA4HZ DN KU-0058948 DMSA4HZ TI TTVDSZ0 DMSA4HZ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMSA4HZ MA Inhibitor DMSA4HZ RN Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009 May 14;52(9):3108-11. DMSA4HZ RU https://pubmed.ncbi.nlm.nih.gov/19354255 DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU TI TTFZDNP DMSA8RU TN Activation B7-1 antigen (CD80) DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMSA8RU DI DMSA8RU DMSA8RU DN Abatacept DMSA8RU TI TTHGXBU DMSA8RU TN T-lymphocyte activation antigen CD86 (FUN1) DMSA8RU MA Binder DMSA8RU RN Selective modulation of T-cell co-stimulation: a novel mode of action for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun;27(3):510-8. DMSA8RU RU https://pubmed.ncbi.nlm.nih.gov/19604448 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TT8J1S3 DMSB068 TN Smoothened homolog (SMO) DMSB068 MA Modulator DMSB068 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMSB068 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TT4LXBC DMSB068 TN Hedgehog signaling pathway (HS pathway) DMSB068 MA Inhibitor DMSB068 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMSB068 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMSB068 DI DMSB068 DMSB068 DN PF-04449913 DMSB068 TI TTCJG29 DMSB068 TN Serine/threonine-protein kinase mTOR (mTOR) DMSB068 MA Inhibitor DMSB068 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSB068 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMSBRUW DI DMSBRUW DMSBRUW DN Decamethonium DMSBRUW TI TT54JVQ DMSBRUW TN Neuronal acetylcholine receptor alpha-1 (CHRNA1) DMSBRUW MA Modulator DMSBRUW RN Potency of nondepolarizing muscle relaxants on muscle-type acetylcholine receptors in denervated mouse skeletal muscle.Acta Pharmacol Sin.2010 Dec;31(12):1541-6. DMSBRUW RU https://www.ncbi.nlm.nih.gov/pubmed/21102480 DMSC4A7 DI DMSC4A7 DMSC4A7 DN Indomethacin DMSC4A7 TI TTVKILB DMSC4A7 TN Prostaglandin G/H synthase 2 (COX-2) DMSC4A7 MA Modulator DMSC4A7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSC4A7 RU https://www.fda.gov/ DMSCDY9 DI DMSCDY9 DMSCDY9 DN Mannitol DMSCDY9 TI TTTX5M8 DMSCDY9 TN Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH) DMSCDY9 MA Activator DMSCDY9 RN Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82. DMSCDY9 RU https://pubmed.ncbi.nlm.nih.gov/18983992 DMSCDY9 DI DMSCDY9 DMSCDY9 DN Mannitol DMSCDY9 TI TTV0PE2 DMSCDY9 TN Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA) DMSCDY9 MA Activator DMSCDY9 RN Polyol-specific long-chain dehydrogenases/reductases of mannitol metabolism in Aspergillus fumigatus: biochemical characterization and pH studies o... Chem Biol Interact. 2009 Mar 16;178(1-3):274-82. DMSCDY9 RU https://pubmed.ncbi.nlm.nih.gov/18983992 DMSCIKZ DI DMSCIKZ DMSCIKZ DN Dopexamine DMSCIKZ TI TTEX248 DMSCIKZ TN Dopamine D2 receptor (D2R) DMSCIKZ MA Modulator DMSCIKZ RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMSCIKZ RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMSD1UN DI DMSD1UN DMSD1UN DN Bevacizumab DMSD1UN TI TTOHSBA DMSD1UN TN Vascular endothelial growth factor A (VEGFA) DMSD1UN MA Inhibitor DMSD1UN RN FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085. DMSD1UN RU https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125085 DMSE3I7 DI DMSE3I7 DMSE3I7 DN Gemcitabine DMSE3I7 TI TTBWDI0 DMSE3I7 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMSE3I7 MA Modulator DMSE3I7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSE3I7 RU https://www.fda.gov/ DMSEPK8 DI DMSEPK8 DMSEPK8 DN Brivaracetam DMSEPK8 TI TTT3P91 DMSEPK8 TN Synaptic vesicle glycoprotein 2A (SV2A) DMSEPK8 MA Inhibitor DMSEPK8 RN Pharmacological management of epilepsy: recent advances and future prospects. Drugs. 2008;68(14):1925-39. DMSEPK8 RU https://pubmed.ncbi.nlm.nih.gov/18778117 DMSF4PR DI DMSF4PR DMSF4PR DN Chlormerodrin DMSF4PR TI TTJUWVB DMSF4PR TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMSF4PR MA Modulator DMSF4PR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSF4PR RU https://www.fda.gov/ DMSFK9V DI DMSFK9V DMSFK9V DN Daclatasvir DMSFK9V TI TTCJ2X8 DMSFK9V TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMSFK9V MA Inhibitor DMSFK9V RN 2011 Pipeline of Bristol-Myers Squibb. DMSFK9V RU http://www.bms.com/pages/default.aspx DMSFQ8I DI DMSFQ8I DMSFQ8I DN Meclocycline DMSFQ8I TI TTQ8KVI DMSFQ8I TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMSFQ8I MA Binder DMSFQ8I RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMSFQ8I RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMSHPW8 DI DMSHPW8 DMSHPW8 DN Tolterodine DMSHPW8 TI TTQ13Z5 DMSHPW8 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSHPW8 MA Antagonist DMSHPW8 RN Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. DMSHPW8 RU https://pubmed.ncbi.nlm.nih.gov/14769832 DMSI5CB DI DMSI5CB DMSI5CB DN Chloroquine DMSI5CB TI TTKY2NS DMSI5CB TN Duffy antigen chemokine receptor (ACKR1) DMSI5CB MA Modulator DMSI5CB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSI5CB RU https://www.fda.gov/ DMSIMD8 DI DMSIMD8 DMSIMD8 DN Cefuroxime DMSIMD8 TI TTJP4SM DMSIMD8 TN Bacterial Penicillin binding protein (Bact PBP) DMSIMD8 MA Binder DMSIMD8 RN Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30. DMSIMD8 RU https://pubmed.ncbi.nlm.nih.gov/12615852 DMSIVND DI DMSIVND DMSIVND DN Hydroxychloroquine DMSIVND TI TTRJ1K4 DMSIVND TN Toll-like receptor 7 (TLR7) DMSIVND MA Antagonist DMSIVND RN TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35. DMSIVND RU https://pubmed.ncbi.nlm.nih.gov/18220957 DMSJDTY DI DMSJDTY DMSJDTY DN Menadione DMSJDTY TI TT3MOS2 DMSJDTY TN Aldehyde oxidase (AOX1) DMSJDTY MA Inhibitor DMSJDTY RN Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumour agent acridine carboxamide. Biochem Pharmacol. 1993 May 25;45(10):2159-62. DMSJDTY RU https://pubmed.ncbi.nlm.nih.gov/8512597 DMSJDTY DI DMSJDTY DMSJDTY DN Menadione DMSJDTY TI TTPFZJ1 DMSJDTY TN Vasopressin V1 receptor (V1R) DMSJDTY MA Agonist DMSJDTY RN Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996 May;7(5):805-10. DMSJDTY RU https://pubmed.ncbi.nlm.nih.gov/8738818 DMSJVAM DI DMSJVAM DMSJVAM DN Amisulpride DMSJVAM TI TTEX248 DMSJVAM TN Dopamine D2 receptor (D2R) DMSJVAM MA Antagonist DMSJVAM RN Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20(5):389-409. DMSJVAM RU https://pubmed.ncbi.nlm.nih.gov/16696579 DMSL679 DI DMSL679 DMSL679 DN Gatifloxacin DMSL679 TI TTN6J5F DMSL679 TN Bacterial DNA gyrase (Bact gyrase) DMSL679 MA Modulator DMSL679 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSL679 RU https://www.fda.gov/ DMSL679 DI DMSL679 DMSL679 DN Gatifloxacin DMSL679 TI TTIXTO3 DMSL679 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMSL679 MA Modulator DMSL679 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSL679 RU https://www.fda.gov/ DMSLJP4 DI DMSLJP4 DMSLJP4 DN Ziconotide DMSLJP4 TI TT4FDG6 DMSLJP4 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMSLJP4 MA Blocker DMSLJP4 RN Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. DMSLJP4 RU https://pubmed.ncbi.nlm.nih.gov/19249984 DMSM2KE DI DMSM2KE DMSM2KE DN Nitrofurazone DMSM2KE TI TTOVFH2 DMSM2KE TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMSM2KE MA Inhibitor DMSM2KE RN The antibiotic Furvina targets the P-site of 30S ribosomal subunits and inhibits translation initiation displaying start codon bias. Nucleic Acids Res. 2012 Nov 1;40(20):10366-74. DMSM2KE RU https://pubmed.ncbi.nlm.nih.gov/22941660 DMSNVGB DI DMSNVGB DMSNVGB DN Echothiophate Iodide DMSNVGB TI TT1RS9F DMSNVGB TN Acetylcholinesterase (AChE) DMSNVGB MA Modulator DMSNVGB RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSNVGB RU https://www.fda.gov/ DMSOAJ2 DI DMSOAJ2 DMSOAJ2 DN N-0923 DMSOAJ2 TI TTEX248 DMSOAJ2 TN Dopamine D2 receptor (D2R) DMSOAJ2 MA Agonist DMSOAJ2 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMSOAJ2 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMSOQK1 DI DMSOQK1 DMSOQK1 DN Chloroprocaine DMSOQK1 TI TTWK8D0 DMSOQK1 TN Sodium pump subunit alpha-1 (ATP1A1) DMSOQK1 MA Blocker DMSOQK1 RN Inhibition of the Na,K-ATPase of canine renal medulla by several local anesthetics. Pharmacol Res. 2001 Apr;43(4):399-403. DMSOQK1 RU https://pubmed.ncbi.nlm.nih.gov/11352545 DMSOURV DI DMSOURV DMSOURV DN Formoterol DMSOURV TI TT2CJVK DMSOURV TN Adrenergic receptor beta-2 (ADRB2) DMSOURV MA Agonist DMSOURV RN Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104. DMSOURV RU https://pubmed.ncbi.nlm.nih.gov/12137617 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TT3ROYC DMSOX7I TN Serotonin transporter (SERT) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TTAWNKZ DMSOX7I TN Norepinephrine transporter (NET) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSOX7I DI DMSOX7I DMSOX7I DN Cocaine DMSOX7I TI TTVBI8W DMSOX7I TN Dopamine transporter (DAT) DMSOX7I MA Inhibitor DMSOX7I RN Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81. DMSOX7I RU https://pubmed.ncbi.nlm.nih.gov/19376154 DMSP4JX DI DMSP4JX DMSP4JX DN Cetraxate DMSP4JX TI TT5L2VC DMSP4JX TN Kallikrein-related peptidase (KLK) DMSP4JX MA Modulator DMSP4JX RN A new broad spectrum inhibitor of esteroproteases, 4-(2-carboxyethyl) phenyl-trans-4-aminomethyl cyclohexane carboxylate hydrochloride (DV 1006). Tohoku J Exp Med. 1972 Mar;106(3):233-48. DMSP4JX RU https://pubmed.ncbi.nlm.nih.gov/4261023 DMSPJG2 DI DMSPJG2 DMSPJG2 DN Ropivacaine DMSPJG2 TI TT90XZ8 DMSPJG2 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMSPJG2 MA Modulator DMSPJG2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSPJG2 RU https://www.fda.gov/ DMSQ1JV DI DMSQ1JV DMSQ1JV DN LAS-34273 DMSQ1JV TI TTQ13Z5 DMSQ1JV TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSQ1JV MA Antagonist DMSQ1JV RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMSQ1JV RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMSQ8MD DI DMSQ8MD DMSQ8MD DN Anagrelide DMSQ8MD TI TT06AWU DMSQ8MD TN Phosphodiesterase 3A (PDE3A) DMSQ8MD MA Inhibitor DMSQ8MD RN Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45. DMSQ8MD RU https://pubmed.ncbi.nlm.nih.gov/16000354 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE TI TTN9VTF DMSQDLE TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMSQDLE MA Blocker DMSQDLE RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMSQDLE RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMSQDLE DI DMSQDLE DMSQDLE DN Flecainide DMSQDLE TI TT05DLS DMSQDLE TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMSQDLE MA Modulator DMSQDLE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQDLE RU https://www.fda.gov/ DMSQVD6 DI DMSQVD6 DMSQVD6 DN Ceforanide DMSQVD6 TI TTJP4SM DMSQVD6 TN Bacterial Penicillin binding protein (Bact PBP) DMSQVD6 MA Binder DMSQVD6 RN The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3. DMSQVD6 RU https://pubmed.ncbi.nlm.nih.gov/12890292 DMSQZE2 DI DMSQZE2 DMSQZE2 DN Asenapine DMSQZE2 TI TTXFI1K DMSQZE2 TN Hyaluronidase (HYAL) DMSQZE2 MA Modulator DMSQZE2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSQZE2 RU https://www.fda.gov/ DMSREPX DI DMSREPX DMSREPX DN Levobetaxolol DMSREPX TI TTR6W5O DMSREPX TN Adrenergic receptor beta-1 (ADRB1) DMSREPX MA Antagonist DMSREPX RN Binding affinities of ocular hypotensive beta-blockers levobetaxolol, levobunolol, and timolol at endogenous guinea pig beta-adrenoceptors. J Ocul Pharmacol Ther. 2004 Apr;20(2):93-9. DMSREPX RU https://pubmed.ncbi.nlm.nih.gov/15117564 DMSRZAO DI DMSRZAO DMSRZAO DN Eliglustat tartrate DMSRZAO TI TTPHEX3 DMSRZAO TN Ceramide glucosyltransferase (UGCG) DMSRZAO MA Modulator DMSRZAO RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSRZAO RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTVJ1D8 DMSTA36 TN Vascular endothelial growth factor receptor (VEGFR) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTRLW2X DMSTA36 TN Fibroblast growth factor receptor 1 (FGFR1) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTGJCWZ DMSTA36 TN Fms-like tyrosine kinase 3 (FLT-3) DMSTA36 MA Inhibitor DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSTA36 DI DMSTA36 DMSTA36 DN Intedanib DMSTA36 TI TTI2WET DMSTA36 TN Platelet-derived growth factor receptor (PDGFR) DMSTA36 MA Modulator DMSTA36 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMSTA36 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMSUVM1 DI DMSUVM1 DMSUVM1 DN Cefditoren DMSUVM1 TI TTJP4SM DMSUVM1 TN Bacterial Penicillin binding protein (Bact PBP) DMSUVM1 MA Binder DMSUVM1 RN Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7. DMSUVM1 RU https://pubmed.ncbi.nlm.nih.gov/17724158 DMSVOCZ DI DMSVOCZ DMSVOCZ DN Pantoprazole DMSVOCZ TI TTLOKXP DMSVOCZ TN Gastric H(+)/K(+) ATPase (Proton pump) DMSVOCZ MA Modulator DMSVOCZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSVOCZ RU https://www.fda.gov/ DMSVOZT DI DMSVOZT DMSVOZT DN Nifedipine DMSVOZT TI TTXHYV6 DMSVOZT TN Voltage-gated L-type calcium channel (L-CaC) DMSVOZT MA Modulator DMSVOZT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSVOZT RU https://www.fda.gov/ DMSWNJF DI DMSWNJF DMSWNJF DN Ravulizumab DMSWNJF TI TTKANGO DMSWNJF TN Complement C5 (CO5) DMSWNJF MA Inhibitor DMSWNJF RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMSWNJF RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMSWUGE DI DMSWUGE DMSWUGE DN Telbivudine DMSWUGE TI TTT4SY6 DMSWUGE TN Hepatitis B virus Polymerase (HBV P) DMSWUGE MA Inhibitor DMSWUGE RN Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol. 2008;22(6):1081-92. DMSWUGE RU https://pubmed.ncbi.nlm.nih.gov/19187868 DMSWYF5 DI DMSWYF5 DMSWYF5 DN Quinine DMSWYF5 TI TT05DLS DMSWYF5 TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMSWYF5 MA Modulator DMSWYF5 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMSWYF5 RU https://www.fda.gov/ DMSXKYG DI DMSXKYG DMSXKYG DN Gamma-homolinolenic acid DMSXKYG TI TT8NGED DMSXKYG TN Prostaglandin G/H synthase 1 (COX-1) DMSXKYG MA Inhibitor DMSXKYG RN Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96. DMSXKYG RU https://pubmed.ncbi.nlm.nih.gov/11939906 DMSY4ZG DI DMSY4ZG DMSY4ZG DN Tenofovir disoproxil fumarate DMSY4ZG TI TT84ETX DMSY4ZG TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSY4ZG MA Modulator DMSY4ZG RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMSY4ZG RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMSYFM8 DI DMSYFM8 DMSYFM8 DN Cysteamine DMSYFM8 TI TTWF7UG DMSYFM8 TN Somatostatin (SST) DMSYFM8 MA Binder DMSYFM8 RN Somatostatin, Alzheimer's disease and cognition: an old story coming of age Prog Neurobiol. 2009 Oct;89(2):153-61. DMSYFM8 RU https://pubmed.ncbi.nlm.nih.gov/19595735 DMSYPNW DI DMSYPNW DMSYPNW DN Ranibizumab DMSYPNW TI TTOHSBA DMSYPNW TN Vascular endothelial growth factor A (VEGFA) DMSYPNW RN Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70. DMSYPNW RU https://pubmed.ncbi.nlm.nih.gov/17031284 DMSYRBX DI DMSYRBX DMSYRBX DN Atazanavir DMSYRBX TI TT5FNQT DMSYRBX TN Human immunodeficiency virus Protease (HIV PR) DMSYRBX MA Modulator DMSYRBX RN Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacod... J Infect Dis. 2001 Apr 1;183(7):1126-9. DMSYRBX RU https://pubmed.ncbi.nlm.nih.gov/11237841 DMSZLJR DI DMSZLJR DMSZLJR DN Avelumab DMSZLJR TI TT8ZLTI DMSZLJR TN Programmed cell death 1 ligand 1 (PD-L1) DMSZLJR RN Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57. DMSZLJR RU https://pubmed.ncbi.nlm.nih.gov/26014098 DMSZQAK DI DMSZQAK DMSZQAK DN Amphetamine DMSZQAK TI TTIU98M DMSZQAK TN Trace amine-associated receptor-1 (TAAR1) DMSZQAK MA Modulator DMSZQAK RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMSZQAK RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TT9IK2Z DMT1I52 TN N-methyl-D-aspartate receptor (NMDAR) DMT1I52 MA Agonist DMT1I52 RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TTCS3P1 DMT1I52 TN Mycobacterium D-alanine-D-alanine ligase A (MycB ddl) DMT1I52 MA Inhibitor DMT1I52 RN Self-protection mechanism in D-cycloserine-producing Streptomyces lavendulae. Gene cloning, characterization, and kinetics of its alanine racemase ... J Biol Chem. 2004 Oct 29;279(44):46143-52. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/15302885 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TT6TMZU DMT1I52 TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT1I52 DI DMT1I52 DMT1I52 DN Cycloserine DMT1I52 TI TTLD29N DMT1I52 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMT1I52 MA Inhibitor DMT1I52 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT1I52 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT2EJP DI DMT2EJP DMT2EJP DN Podofilox DMT2EJP TI TT0IHXV DMT2EJP TN DNA topoisomerase II (TOP2) DMT2EJP MA Modulator DMT2EJP RN Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39. DMT2EJP RU https://pubmed.ncbi.nlm.nih.gov/11102564 DMT2FDC DI DMT2FDC DMT2FDC DN Desipramine DMT2FDC TI TTAWNKZ DMT2FDC TN Norepinephrine transporter (NET) DMT2FDC MA Inhibitor DMT2FDC RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMT2FDC RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMT2KRV DI DMT2KRV DMT2KRV DN Ciclosporin DMT2KRV TI TTA4LDE DMT2KRV TN Calcineurin (PPP3CA) DMT2KRV MA Inhibitor DMT2KRV RN Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007 May;19(3):238-45. DMT2KRV RU https://pubmed.ncbi.nlm.nih.gov/17414949 DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TTOHSBA DMT3D5I TN Vascular endothelial growth factor A (VEGFA) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TTPJQHE DMT3D5I TN Vascular endothelial growth factor B (VEGFB) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT3D5I DI DMT3D5I DMT3D5I DN Aflibercept DMT3D5I TI TT48I1Y DMT3D5I TN Placenta growth factor (PlGF) DMT3D5I MA Modulator DMT3D5I RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMT3D5I RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMT45MU DI DMT45MU DMT45MU DN Rosiglitazone XR DMT45MU TI TTZMAO3 DMT45MU TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMT45MU MA Agonist DMT45MU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMT45MU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMT57WC DI DMT57WC DMT57WC DN Tetrahydrozoline DMT57WC TI TT2NUT5 DMT57WC TN Adrenergic receptor alpha-2C (ADRA2C) DMT57WC MA Modulator DMT57WC RN Prolonged cardiovascular effects after unintentional ingestion of tetrahydrozoline. Clin Toxicol (Phila). 2008 Feb;46(2):171-2. DMT57WC RU https://pubmed.ncbi.nlm.nih.gov/18259967 DMT5GNL DI DMT5GNL DMT5GNL DN Romidepsin DMT5GNL TI TT6R7JZ DMT5GNL TN Histone deacetylase 1 (HDAC1) DMT5GNL MA Inhibitor DMT5GNL RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMT5GNL RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMT5HA4 DI DMT5HA4 DMT5HA4 DN Ketamine DMT5HA4 TI TT9IK2Z DMT5HA4 TN N-methyl-D-aspartate receptor (NMDAR) DMT5HA4 MA Antagonist DMT5HA4 RN Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64. DMT5HA4 RU https://pubmed.ncbi.nlm.nih.gov/19583475 DMT5RMB DI DMT5RMB DMT5RMB DN Cyclofenil DMT5RMB TI TTZAYWL DMT5RMB TN Estrogen receptor (ESR) DMT5RMB MA Modulator DMT5RMB RN Fluorine-substituted cyclofenil derivatives as estrogen receptor ligands: synthesis and structure-affinity relationship study of potential positron emission tomography agents for imaging estrogen receptors in breast cancer. J Med Chem. 2006 Apr 20;49(8):2496-511. DMT5RMB RU https://pubmed.ncbi.nlm.nih.gov/16610793 DMT6AM2 DI DMT6AM2 DMT6AM2 DN Ozanimod DMT6AM2 TI TT9JZCK DMT6AM2 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMT6AM2 MA Agonist DMT6AM2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMT6AM2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209899s000lbl.pdf DMT70RC DI DMT70RC DMT70RC DN Piperaquine DMT70RC TI TTZVSJ2 DMT70RC TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMT70RC MA Inhibitor DMT70RC RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMT70RC RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMT73J8 DI DMT73J8 DMT73J8 DN Luliconazole DMT73J8 TI TTTSOUD DMT73J8 TN Candida Cytochrome P450 51 (Candi ERG11) DMT73J8 MA Inhibitor DMT73J8 RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMT73J8 RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMT81LZ DI DMT81LZ DMT81LZ DN Arn-509 DMT81LZ TI TTS64P2 DMT81LZ TN Androgen receptor (AR) DMT81LZ MA Inhibitor DMT81LZ RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMT81LZ RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMT9FH3 DI DMT9FH3 DMT9FH3 DN Terlipressin DMT9FH3 TI TT4TFGN DMT9FH3 TN Vasopressin V1a receptor (V1AR) DMT9FH3 MA Stimulator DMT9FH3 RN Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31. DMT9FH3 RU https://pubmed.ncbi.nlm.nih.gov/19589090 DMT9K8G DI DMT9K8G DMT9K8G DN Raltitrexed DMT9K8G TI TTU6BFZ DMT9K8G TN Candida Thymidylate synthase (Candi TMP1) DMT9K8G MA Inhibitor DMT9K8G RN DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96. DMT9K8G RU https://pubmed.ncbi.nlm.nih.gov/18773878 DMTA5OE DI DMTA5OE DMTA5OE DN Azacitidine DMTA5OE TI TTHVCUP DMTA5OE TN DNA [cytosine-5]-methyltransferase (DNMT) DMTA5OE MA Inhibitor DMTA5OE RN The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28. DMTA5OE RU https://pubmed.ncbi.nlm.nih.gov/19194470 DMTAFY4 DI DMTAFY4 DMTAFY4 DN Oxacillin DMTAFY4 TI TTJP4SM DMTAFY4 TN Bacterial Penicillin binding protein (Bact PBP) DMTAFY4 MA Binder DMTAFY4 RN Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8. DMTAFY4 RU https://pubmed.ncbi.nlm.nih.gov/19433567 DMTAJQE DI DMTAJQE DMTAJQE DN Amphotericin B DMTAJQE TI TTQKWA4 DMTAJQE TN Fungal Cell membrane ergosterol (Fung CME) DMTAJQE MA Modulator DMTAJQE RN Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta. 2002 Dec 23;1567(1-2):63-78. DMTAJQE RU https://pubmed.ncbi.nlm.nih.gov/12488039 DMTAREC DI DMTAREC DMTAREC DN Rimexolone DMTAREC TI TTPNQAC DMTAREC TN Estrogen-related receptor-alpha (ESRRA) DMTAREC MA Modulator DMTAREC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DMTAREC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DMTBGW8 DI DMTBGW8 DMTBGW8 DN Vardenafil DMTBGW8 TI TTJ0IQB DMTBGW8 TN Phosphodiesterase 5A (PDE5A) DMTBGW8 MA Binder DMTBGW8 RN The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12. DMTBGW8 RU https://pubmed.ncbi.nlm.nih.gov/12475462 DMTBKF3 DI DMTBKF3 DMTBKF3 DN Piperacillin DMTBKF3 TI TTJP4SM DMTBKF3 TN Bacterial Penicillin binding protein (Bact PBP) DMTBKF3 MA Binder DMTBKF3 RN In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6. DMTBKF3 RU https://pubmed.ncbi.nlm.nih.gov/15551215 DMTBW2O DI DMTBW2O DMTBW2O DN Propylhexedrine DMTBW2O TI TT2NUT5 DMTBW2O TN Adrenergic receptor alpha-2C (ADRA2C) DMTBW2O MA Modulator DMTBW2O RN Airway compromise and delayed death following attempted central vein injection of propylhexedrine. J Emerg Med. 1994 Nov-Dec;12(6):795-7. DMTBW2O RU https://pubmed.ncbi.nlm.nih.gov/7533806 DMTGBAX DI DMTGBAX DMTGBAX DN Pomalidomide DMTGBAX TI TTDIBYJ DMTGBAX TN Angiogenesis/myeloma cell growth (AMCG) DMTGBAX MA Modulator DMTGBAX RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMTGBAX RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMTGDN8 DI DMTGDN8 DMTGDN8 DN Levetiracetam DMTGDN8 TI TTPC4TU DMTGDN8 TN 5-HT 3A receptor (HTR3A) DMTGDN8 MA Antagonist DMTGDN8 RN Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62. DMTGDN8 RU https://pubmed.ncbi.nlm.nih.gov/18321148 DMTGDN8 DI DMTGDN8 DMTGDN8 DN Levetiracetam DMTGDN8 TI TTT3P91 DMTGDN8 TN Synaptic vesicle glycoprotein 2A (SV2A) DMTGDN8 MA Modulator DMTGDN8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTGDN8 RU https://www.fda.gov/ DMTHWBI DI DMTHWBI DMTHWBI DN Nitrous oxide DMTHWBI TI TT9IK2Z DMTHWBI TN N-methyl-D-aspartate receptor (NMDAR) DMTHWBI MA Antagonist DMTHWBI RN Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79. DMTHWBI RU https://pubmed.ncbi.nlm.nih.gov/17073666 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE TI TT3PJMV DMTI8YE TN Tyrosine-protein kinase ABL1 (ABL) DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMTI8YE DI DMTI8YE DMTI8YE DN Bosutinib DMTI8YE TI TT6PKBN DMTI8YE TN Proto-oncogene c-Src (SRC) DMTI8YE MA Inhibitor DMTI8YE RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMTI8YE RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMTIGA0 DI DMTIGA0 DMTIGA0 DN Acrivastine DMTIGA0 TI TTTIBOJ DMTIGA0 TN Histamine H1 receptor (H1R) DMTIGA0 MA Antagonist DMTIGA0 RN Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet. 1999 May;36(5):329-52. DMTIGA0 RU https://pubmed.ncbi.nlm.nih.gov/10384858 DMTIQF3 DI DMTIQF3 DMTIQF3 DN Treprostinil DMTIQF3 TI TTOFYT1 DMTIQF3 TN Prostacyclin receptor (PTGIR) DMTIQF3 MA Agonist DMTIQF3 RN Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35. DMTIQF3 RU https://pubmed.ncbi.nlm.nih.gov/19332188 DMTIUFA DI DMTIUFA DMTIUFA DN Celtura DMTIUFA TI TT3J5ZI DMTIUFA TN Cell mediated immunity response (CMIR) DMTIUFA RN A prospective observational safety study on MF59( ) adjuvanted cell culture-derived vaccine, Celtura( ) during the A/H1N1 (2009) influenza pandemic. Vaccine. 2012 Oct 5;30(45):6436-43. DMTIUFA RU https://pubmed.ncbi.nlm.nih.gov/22902681 DMTIVEN DI DMTIVEN DMTIVEN DN Metronidazole DMTIVEN TI TTS1W4A DMTIVEN TN Bacterial Deoxyribonucleic acid (Bact DNA) DMTIVEN MA Modulator DMTIVEN RN DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8. DMTIVEN RU https://www.ncbi.nlm.nih.gov/pubmed/11406179 DMTK234 DI DMTK234 DMTK234 DN Piroxicam DMTK234 TI TT8NGED DMTK234 TN Prostaglandin G/H synthase 1 (COX-1) DMTK234 MA Modulator DMTK234 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTK234 RU https://www.fda.gov/ DMTK4LS DI DMTK4LS DMTK4LS DN Triptorelin DMTK4LS TI TT8R70G DMTK4LS TN Gonadotropin-releasing hormone receptor (GNRHR) DMTK4LS MA Modulator DMTK4LS RN Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44. DMTK4LS RU https://pubmed.ncbi.nlm.nih.gov/17185802 DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q TI TT6EO5L DMTKD7Q TN Erbb2 tyrosine kinase receptor (HER2) DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKD7Q DI DMTKD7Q DMTKD7Q DN BIBW 2992 DMTKD7Q TI TTGKNB4 DMTKD7Q TN Epidermal growth factor receptor (EGFR) DMTKD7Q MA Inhibitor DMTKD7Q RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMTKD7Q RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMTKU46 DI DMTKU46 DMTKU46 DN Bismuth DMTKU46 TI TTFNGC9 DMTKU46 TN Serum albumin (ALB) DMTKU46 MA Binder DMTKU46 RN Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35. DMTKU46 RU https://pubmed.ncbi.nlm.nih.gov/11110794 DMTL94F DI DMTL94F DMTL94F DN Maraviroc DMTL94F TI TT2CEJG DMTL94F TN C-C chemokine receptor type 5 (CCR5) DMTL94F MA Antagonist DMTL94F RN Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists. Antiviral Res. 2009 Jul;83(1):86-9. DMTL94F RU https://pubmed.ncbi.nlm.nih.gov/19501260 DMTL94F DI DMTL94F DMTL94F DN Maraviroc DMTL94F TI TTJIH8Q DMTL94F TN CCR5 messenger RNA (CCR5 mRNA) DMTL94F MA Antagonist DMTL94F RN Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human. Biochem Pharmacol. 2005 Dec 19;71(1-2):163-72. DMTL94F RU https://pubmed.ncbi.nlm.nih.gov/16298345 DMTL9IP DI DMTL9IP DMTL9IP DN Meprednisone DMTL9IP TI TTYRL6O DMTL9IP TN Glucocorticoid receptor (NR3C1) DMTL9IP MA Modulator DMTL9IP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTL9IP RU https://www.fda.gov/ DMTM2IK DI DMTM2IK DMTM2IK DN Mercaptopurine DMTM2IK TI TTL7C8Q DMTM2IK TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMTM2IK MA Inhibitor DMTM2IK RN Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol. 2008 Aug;64(8):753-67. DMTM2IK RU https://pubmed.ncbi.nlm.nih.gov/18506437 DMTM2IK DI DMTM2IK DMTM2IK DN Mercaptopurine DMTM2IK TI TTZFTY4 DMTM2IK TN Amidophosphoribosyltransferase (PPAT) DMTM2IK MA Breaker DMTM2IK RN 6-mercaptopurine (6-MP) induces p53-mediated apoptosis of neural progenitor cells in the developing fetal rodent brain. Neurotoxicol Teratol. 2009 Jul-Aug;31(4):198-202. DMTM2IK RU https://pubmed.ncbi.nlm.nih.gov/19281843 DMTN5XI DI DMTN5XI DMTN5XI DN Chlordiazepoxide DMTN5XI TI TTPTXIN DMTN5XI TN Translocator protein (TSPO) DMTN5XI MA Modulator DMTN5XI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTN5XI RU https://www.fda.gov/ DMTNFCQ DI DMTNFCQ DMTNFCQ DN Levobunolol DMTNFCQ TI TTR6W5O DMTNFCQ TN Adrenergic receptor beta-1 (ADRB1) DMTNFCQ MA Antagonist DMTNFCQ RN Binding of beta-adrenoceptor antagonists to rat and rabbit lung: special reference to levobunolol. Arzneimittelforschung. 1984;34(5):579-84. DMTNFCQ RU https://pubmed.ncbi.nlm.nih.gov/6147147 DMTO13J DI DMTO13J DMTO13J DN Clonazepam DMTO13J TI TTNJYV2 DMTO13J TN Gamma-aminobutyric acid receptor (GAR) DMTO13J MA Agonist DMTO13J RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMTO13J RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMTP1DC DI DMTP1DC DMTP1DC DN Irbesartan DMTP1DC TI TT8DBY3 DMTP1DC TN Angiotensin II receptor type-1 (AGTR1) DMTP1DC MA Antagonist DMTP1DC RN Radioligand binding assays: application of [(125)I]angiotensin II receptor binding. Methods Mol Biol. 2009;552:131-41. DMTP1DC RU https://pubmed.ncbi.nlm.nih.gov/19513646 DMTP2NJ DI DMTP2NJ DMTP2NJ DN Desonide DMTP2NJ TI TTP3UTW DMTP2NJ TN Steroid hormone receptor ERR (ESRR) DMTP2NJ MA Modulator DMTP2NJ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTP2NJ RU https://www.fda.gov/ DMTPAM3 DI DMTPAM3 DMTPAM3 DN Metformin arginine-hemisuccinimide DMTPAM3 TI TTCBFJO DMTPAM3 TN Insulin receptor (INSR) DMTPAM3 MA Inhibitor DMTPAM3 RN Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91. DMTPAM3 RU https://pubmed.ncbi.nlm.nih.gov/15135305 DMTPIZC DI DMTPIZC DMTPIZC DN Conjugated estrogens a DMTPIZC TI TTZAYWL DMTPIZC TN Estrogen receptor (ESR) DMTPIZC MA Modulator DMTPIZC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMTPIZC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMTQS9A DI DMTQS9A DMTQS9A DN Metaproterenol sulfate DMTQS9A TI TT2CJVK DMTQS9A TN Adrenergic receptor beta-2 (ADRB2) DMTQS9A MA Modulator DMTQS9A RN Male--female differences in the impact of beta-adrenoceptor stimulation on resistance to experimental metastasis: exploring the effects of age and ... J Neuroimmunol. 2008 Jan;193(1-2):113-9. DMTQS9A RU https://pubmed.ncbi.nlm.nih.gov/18037507 DMTS85L DI DMTS85L DMTS85L DN Capecitabine DMTS85L TI TTU6BFZ DMTS85L TN Candida Thymidylate synthase (Candi TMP1) DMTS85L MA Inhibitor DMTS85L RN UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36. DMTS85L RU https://pubmed.ncbi.nlm.nih.gov/15709193 DMTSRI6 DI DMTSRI6 DMTSRI6 DN Oprelvekin DMTSRI6 TI TTZPLJS DMTSRI6 TN Interleukin 11 receptor alpha (IL11RA) DMTSRI6 MA Binder DMTSRI6 RN Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71. DMTSRI6 RU https://pubmed.ncbi.nlm.nih.gov/18020592 DMTUKZH DI DMTUKZH DMTUKZH DN Deferoxamine mesylate DMTUKZH TI TTUDR0C DMTUKZH TN Iron (Fe) DMTUKZH MA Modulator DMTUKZH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMTUKZH RU https://www.fda.gov/ DMTW3R8 DI DMTW3R8 DMTW3R8 DN Sulfadiazine DMTW3R8 TI TT4ILYC DMTW3R8 TN Bacterial Dihydropteroate synthetase (Bact folP) DMTW3R8 MA Inhibitor DMTW3R8 RN Sulfadiazine/hydroxypropyl-beta-cyclodextrin host-guest system: Characterization, phase-solubility and molecular modeling. Bioorg Med Chem. 2008 May 15;16(10):5788-94. DMTW3R8 RU https://pubmed.ncbi.nlm.nih.gov/18434167 DMTW6IU DI DMTW6IU DMTW6IU DN Methadone DMTW6IU TI TTN4QDT DMTW6IU TN Opioid receptor (OPR) DMTW6IU MA Agonist DMTW6IU RN Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25. DMTW6IU RU https://pubmed.ncbi.nlm.nih.gov/19535889 DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TTO0FDJ DMTWS9E TN Cyclin-dependent kinase 6 (CDK6) DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TT0PG8F DMTWS9E TN Cyclin-dependent kinase 4 (CDK4) DMTWS9E MA Inhibitor DMTWS9E RN Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005. DMTWS9E RU http://www.newsrx.com/newsletters/Law-and-Health-Weekly/2005-05-14/05092005333475LH.html DMTWS9E DI DMTWS9E DMTWS9E DN Apremilast DMTWS9E TI TTV5CGO DMTWS9E TN Phosphodiesterase 4 (PDE4) DMTWS9E MA Inhibitor DMTWS9E RN Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17-26. DMTWS9E RU https://pubmed.ncbi.nlm.nih.gov/17352685 DMTWUXR DI DMTWUXR DMTWUXR DN Chlormezanone DMTWUXR TI TTPTXIN DMTWUXR TN Translocator protein (TSPO) DMTWUXR MA Agonist DMTWUXR RN Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. Curr Med Res Opin. 1982;8(1):33-8. DMTWUXR RU https://pubmed.ncbi.nlm.nih.gov/7105820 DMTX2BH DI DMTX2BH DMTX2BH DN Cefonicid DMTX2BH TI TTJP4SM DMTX2BH TN Bacterial Penicillin binding protein (Bact PBP) DMTX2BH MA Binder DMTX2BH RN Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6. DMTX2BH RU https://pubmed.ncbi.nlm.nih.gov/6376452 DMTY169 DI DMTY169 DMTY169 DN Norethindrone DMTY169 TI TTUV8G9 DMTY169 TN Progesterone receptor (PGR) DMTY169 MA Agonist DMTY169 RN Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. DMTY169 RU https://pubmed.ncbi.nlm.nih.gov/15189034 DMTY9LU DI DMTY9LU DMTY9LU DN Piperazine DMTY9LU TI TTNJYV2 DMTY9LU TN Gamma-aminobutyric acid receptor (GAR) DMTY9LU MA Antagonist DMTY9LU RN Cyclooctadepsipeptides--an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents. 2003 Sep;22(3):318-31. DMTY9LU RU https://pubmed.ncbi.nlm.nih.gov/13678839 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD TI TTT2ZAR DMTYOPD TN Prostaglandin F2-alpha receptor (PTGFR) DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMTYOPD DI DMTYOPD DMTYOPD DN Dinoprostone DMTYOPD TI TT1ZAVI DMTYOPD TN Prostaglandin E2 receptor EP2 (PTGER2) DMTYOPD MA Antagonist DMTYOPD RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMTYOPD RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMTZC5G DI DMTZC5G DMTZC5G DN Bezlotoxumab DMTZC5G TI TTQH65V DMTZC5G TN Clostridium difficile Toxin B (CD toxB) DMTZC5G MA Modulator DMTZC5G RN 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76. DMTZC5G RU https://www.ncbi.nlm.nih.gov/pubmed/28148938 DMTZNQ9 DI DMTZNQ9 DMTZNQ9 DN Interferon alfa-n3 DMTZNQ9 TI TT95SOA DMTZNQ9 TN Interferon alpha (IFNA) DMTZNQ9 MA Modulator DMTZNQ9 RN Clinical pipeline report, company report or official report of Hemispherx Biopharma. DMTZNQ9 RU http://www.hemispherx.net/content/rnd/ DMU0YP6 DI DMU0YP6 DMU0YP6 DN Flumethasone Pivalate DMU0YP6 TI TTP3UTW DMU0YP6 TN Steroid hormone receptor ERR (ESRR) DMU0YP6 MA Modulator DMU0YP6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU0YP6 RU https://www.fda.gov/ DMU1GX0 DI DMU1GX0 DMU1GX0 DN Mitotane DMU1GX0 TI TTZAYWL DMU1GX0 TN Estrogen receptor (ESR) DMU1GX0 MA Binder DMU1GX0 RN Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. DMU1GX0 RU https://pubmed.ncbi.nlm.nih.gov/15898346 DMU1XOD DI DMU1XOD DMU1XOD DN Nafamostat DMU1XOD TI TTF8CQI DMU1XOD TN Tumor necrosis factor (TNF) DMU1XOD RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMU1XOD RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMU1XOD DI DMU1XOD DMU1XOD DN Nafamostat DMU1XOD TI TTEMV5X DMU1XOD TN Serine protease unspecific (SP) DMU1XOD MA Inhibitor DMU1XOD RN Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20. DMU1XOD RU https://pubmed.ncbi.nlm.nih.gov/19513558 DMU3DNC DI DMU3DNC DMU3DNC DN Pentoxifylline DMU3DNC TI TTF8CQI DMU3DNC TN Tumor necrosis factor (TNF) DMU3DNC RN Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20. DMU3DNC RU https://pubmed.ncbi.nlm.nih.gov/15190511 DMU3FGB DI DMU3FGB DMU3FGB DN Dhaq diacetate DMU3FGB TI TT0IHXV DMU3FGB TN DNA topoisomerase II (TOP2) DMU3FGB MA Inhibitor DMU3FGB RN The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone. Cancer Res. 2009 Feb 1;69(3):940-7. DMU3FGB RU https://pubmed.ncbi.nlm.nih.gov/19176397 DMU3IET DI DMU3IET DMU3IET DN Thiethylperazine DMU3IET TI TTEX248 DMU3IET TN Dopamine D2 receptor (D2R) DMU3IET MA Antagonist DMU3IET RN Antiemetic specificity of dopamine antagonists. Psychopharmacology (Berl). 1982;78(3):210-3. DMU3IET RU https://pubmed.ncbi.nlm.nih.gov/6130555 DMU4D5Y DI DMU4D5Y DMU4D5Y DN Benzquinamide DMU4D5Y TI TT0JLSD DMU4D5Y TN Multidrug resistance protein (MDR) DMU4D5Y MA Inhibitor DMU4D5Y RN Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. Oncol Res. 1992;4(8-9):359-65. DMU4D5Y RU https://pubmed.ncbi.nlm.nih.gov/1362504 DMU4JLB DI DMU4JLB DMU4JLB DN Penicillin G Procaine DMU4JLB TI TTJP4SM DMU4JLB TN Bacterial Penicillin binding protein (Bact PBP) DMU4JLB MA Modulator DMU4JLB RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMU4JLB RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMU4ORS DI DMU4ORS DMU4ORS DN Magnesium DMU4ORS TI TT9IK2Z DMU4ORS TN N-methyl-D-aspartate receptor (NMDAR) DMU4ORS MA Antagonist DMU4ORS RN Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42. DMU4ORS RU https://pubmed.ncbi.nlm.nih.gov/19249986 DMU54C3 DI DMU54C3 DMU54C3 DN Flutropium bromide DMU54C3 TI TTH18TF DMU54C3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMU54C3 MA Modulator DMU54C3 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMU54C3 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMU54QB DI DMU54QB DMU54QB DN Treximet DMU54QB TI TTSQIFT DMU54QB TN 5-HT 1A receptor (HTR1A) DMU54QB MA Antagonist DMU54QB RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMU54QB RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMU6OFP DI DMU6OFP DMU6OFP DN Dyclonine DMU6OFP TI TTZOVE0 DMU6OFP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMU6OFP MA Blocker DMU6OFP RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMU6OFP RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMU764S DI DMU764S DMU764S DN Ritonavir DMU764S TI TT5FNQT DMU764S TN Human immunodeficiency virus Protease (HIV PR) DMU764S MA Inhibitor DMU764S RN Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009 Apr;33(4):307-20. DMU764S RU https://pubmed.ncbi.nlm.nih.gov/19108994 DMU7SF8 DI DMU7SF8 DMU7SF8 DN Conjugated estrogens b DMU7SF8 TI TTZAYWL DMU7SF8 TN Estrogen receptor (ESR) DMU7SF8 MA Modulator DMU7SF8 RN Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid. No To Shinkei. 1977 Feb;29(2):205-13. DMU7SF8 RU https://pubmed.ncbi.nlm.nih.gov/326277 DMU7YEL DI DMU7YEL DMU7YEL DN Sufentanil DMU7YEL TI TTN4QDT DMU7YEL TN Opioid receptor (OPR) DMU7YEL MA Antagonist DMU7YEL RN mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96. DMU7YEL RU https://pubmed.ncbi.nlm.nih.gov/19519662 DMU8ANS DI DMU8ANS DMU8ANS DN Ximelegatran DMU8ANS TI TT6L509 DMU8ANS TN Coagulation factor IIa (F2) DMU8ANS MA Inhibitor DMU8ANS RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMU8ANS RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMU8ANS DI DMU8ANS DMU8ANS DN Ximelegatran DMU8ANS TI TTMQO60 DMU8ANS TN Rho-associated protein kinase (ROCK) DMU8ANS MA Modulator DMU8ANS RN Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol. 2000 May;57(5):976-83. DMU8ANS RU https://www.ncbi.nlm.nih.gov/pubmed/10779382 DMU8JGH DI DMU8JGH DMU8JGH DN Hydralazine DMU8JGH TI TT7HC21 DMU8JGH TN Membrane copper amine oxidase (AOC3) DMU8JGH MA Modulator DMU8JGH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8JGH RU https://www.fda.gov/ DMU8KOD DI DMU8KOD DMU8KOD DN Anakinra DMU8KOD TI TTWOTEA DMU8KOD TN Interleukin 1 receptor type 1 (IL1R1) DMU8KOD MA Antagonist DMU8KOD RN IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. Eur Cytokine Netw. 2009 Jun 1;20(2):81-87. DMU8KOD RU https://pubmed.ncbi.nlm.nih.gov/19541594 DMU8V4S DI DMU8V4S DMU8V4S DN Moxifloxacin DMU8V4S TI TTN6J5F DMU8V4S TN Bacterial DNA gyrase (Bact gyrase) DMU8V4S MA Modulator DMU8V4S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8V4S RU https://www.fda.gov/ DMU8V4S DI DMU8V4S DMU8V4S DN Moxifloxacin DMU8V4S TI TTIXTO3 DMU8V4S TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMU8V4S MA Modulator DMU8V4S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMU8V4S RU https://www.fda.gov/ DMU92F8 DI DMU92F8 DMU92F8 DN Promestriene DMU92F8 TI TTZAYWL DMU92F8 TN Estrogen receptor (ESR) DMU92F8 MA Modulator DMU92F8 RN Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients. Anticancer Drugs. 2013 Nov;24(10):989-98. DMU92F8 RU https://pubmed.ncbi.nlm.nih.gov/24080714 DMU9C8F DI DMU9C8F DMU9C8F DN Bavencio DMU9C8F TI TT8ZLTI DMU9C8F TN Programmed cell death 1 ligand 1 (PD-L1) DMU9C8F MA Inhibitor DMU9C8F RN ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health. DMU9C8F RU https://clinicaltrials.gov/ct2/show/NCT03403777 DMU9D2F DI DMU9D2F DMU9D2F DN Gabexate DMU9D2F TI TTEMV5X DMU9D2F TN Serine protease unspecific (SP) DMU9D2F MA Inhibitor DMU9D2F RN Tryptase-positive mast cells correlate with angiogenesis in early breast cancer patients. Int J Oncol. 2009 Jul;35(1):115-20. DMU9D2F RU https://pubmed.ncbi.nlm.nih.gov/19513558 DMU9MYJ DI DMU9MYJ DMU9MYJ DN Oxandrolone DMU9MYJ TI TTS64P2 DMU9MYJ TN Androgen receptor (AR) DMU9MYJ MA Agonist DMU9MYJ RN The effect of oxandrolone treatment on human osteoblastic cells. J Burns Wounds. 2007 Mar 7;6:e4. DMU9MYJ RU https://pubmed.ncbi.nlm.nih.gov/17364004 DMUBP9O DI DMUBP9O DMUBP9O DN Voglibose DMUBP9O TI TTXWASR DMUBP9O TN Intestinal maltase-glucoamylase (MGAM) DMUBP9O MA Inhibitor DMUBP9O RN Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6. DMUBP9O RU https://pubmed.ncbi.nlm.nih.gov/19568704 DMUCWEX DI DMUCWEX DMUCWEX DN Polidocanol - BioForm Medical/Chemische Fabrik Kreussler & Co DMUCWEX TI TT42M75 DMUCWEX TN Carbamoyl-phosphate synthetase I (CPS1) DMUCWEX MA Modulator DMUCWEX RN Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. DMUCWEX RU https://pubmed.ncbi.nlm.nih.gov/21283092 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 TI TT26PHO DMUDIR8 TN Mineralocorticoid receptor (MR) DMUDIR8 MA Agonist DMUDIR8 RN Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/14570856 DMUDIR8 DI DMUDIR8 DMUDIR8 DN Fludrocortisone DMUDIR8 TI TTS64P2 DMUDIR8 TN Androgen receptor (AR) DMUDIR8 MA Inhibitor DMUDIR8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUDIR8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUDJZM DI DMUDJZM DMUDJZM DN Dextromethorphan DMUDJZM TI TT5TPI6 DMUDJZM TN Opioid receptor sigma 1 (OPRS1) DMUDJZM MA Agonist DMUDJZM RN Dextromethorphan/quinidine: AVP 923, dextromethorphan/cytochrome P450-2D6 inhibitor, quinidine/dextromethorphan. Drugs R D. 2005;6(3):174-7. DMUDJZM RU https://pubmed.ncbi.nlm.nih.gov/15869321 DMUDWP9 DI DMUDWP9 DMUDWP9 DN Mepindolol DMUDWP9 TI TTMXGCW DMUDWP9 TN Adrenergic receptor beta-3 (ADRB3) DMUDWP9 MA Modulator DMUDWP9 RN Pharmacological studies on the intrinsic sympathomimetic activity of the beta-adrenoceptor antagonist mepindolol. Arzneimittelforschung. 1986 May;36(5):811-3. DMUDWP9 RU https://pubmed.ncbi.nlm.nih.gov/2873820 DMUFGAY DI DMUFGAY DMUFGAY DN Betazole DMUFGAY TI TTQHJ1K DMUFGAY TN Histamine H2 receptor (H2R) DMUFGAY MA Antagonist DMUFGAY RN Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6. DMUFGAY RU https://pubmed.ncbi.nlm.nih.gov/2892392 DMUHCF1 DI DMUHCF1 DMUHCF1 DN Fluoxymesterone DMUHCF1 TI TTS64P2 DMUHCF1 TN Androgen receptor (AR) DMUHCF1 MA Agonist DMUHCF1 RN An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. DMUHCF1 RU https://pubmed.ncbi.nlm.nih.gov/17023534 DMUI0CH DI DMUI0CH DMUI0CH DN Tobramycin DMUI0CH TI TTOVFH2 DMUI0CH TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMUI0CH MA Modulator DMUI0CH RN Mechanism of action of aminoglycoside antibiotics.Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits.Eur J Biochem.1979 Dec;102(1):73-81. DMUI0CH RU https://www.ncbi.nlm.nih.gov/pubmed/391568 DMUIASK DI DMUIASK DMUIASK DN Cosyntropin DMUIASK TI TTPWFDX DMUIASK TN Melanocortin receptor 2 (MC2R) DMUIASK MA Antagonist DMUIASK RN Hypothalamic-pituitary-adrenal axis dysfunction in hospitalized neonatal foals. J Vet Intern Med. 2009 Jul-Aug;23(4):901-12. DMUIASK RU https://pubmed.ncbi.nlm.nih.gov/19496914 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TTK0943 DMUIE76 TN Prostaglandin G/H synthase (COX) DMUIE76 MA Inhibitor DMUIE76 RN Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/15662292 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TTAWNKZ DMUIE76 TN Norepinephrine transporter (NET) DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUIE76 DI DMUIE76 DMUIE76 DN Acetaminophen DMUIE76 TI TT3ROYC DMUIE76 TN Serotonin transporter (SERT) DMUIE76 MA Inhibitor DMUIE76 RN Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107. DMUIE76 RU https://pubmed.ncbi.nlm.nih.gov/19517098 DMUJGR1 DI DMUJGR1 DMUJGR1 DN Sorivudine DMUJGR1 TI TT84ETX DMUJGR1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMUJGR1 MA Modulator DMUJGR1 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUJGR1 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TT2Q6G1 DMUKC5L TN Vascular endothelial growth factor receptor 1 (FLT-1) DMUKC5L MA Inhibitor DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TTDCBX5 DMUKC5L TN Vascular endothelial growth factor receptor 3 (FLT-4) DMUKC5L MA Modulator DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUKC5L DI DMUKC5L DMUKC5L DN Tivozanib DMUKC5L TI TTUTJGQ DMUKC5L TN Vascular endothelial growth factor receptor 2 (KDR) DMUKC5L MA Modulator DMUKC5L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMUKC5L RU https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma DMUL45H DI DMUL45H DMUL45H DN Naltrexone DMUL45H TI TTN4QDT DMUL45H TN Opioid receptor (OPR) DMUL45H MA Antagonist DMUL45H RN An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44. DMUL45H RU https://pubmed.ncbi.nlm.nih.gov/18250251 DMUL5EW DI DMUL5EW DMUL5EW DN Posaconazole DMUL5EW TI TTTSOUD DMUL5EW TN Candida Cytochrome P450 51 (Candi ERG11) DMUL5EW MA Inhibitor DMUL5EW RN A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6. DMUL5EW RU https://pubmed.ncbi.nlm.nih.gov/16961575 DMUL7T1 DI DMUL7T1 DMUL7T1 DN Imidapril DMUL7T1 TI TTL69WB DMUL7T1 TN Angiotensin-converting enzyme (ACE) DMUL7T1 MA Modulator DMUL7T1 RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUL7T1 RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMULAI4 DI DMULAI4 DMULAI4 DN Carbimazole DMULAI4 TI TT52XDZ DMULAI4 TN Thyroid peroxidase (TPO) DMULAI4 MA Inhibitor DMULAI4 RN Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467-73. DMULAI4 RU https://pubmed.ncbi.nlm.nih.gov/7952157 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTU6BFZ DMUM7HZ TN Candida Thymidylate synthase (Candi TMP1) DMUM7HZ MA Inhibitor DMUM7HZ RN The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/14689231 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTZPS91 DMUM7HZ TN Dihydrothymine dehydrogenase (DPYD) DMUM7HZ MA Inhibitor DMUM7HZ RN Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer. 2002 Jun;38(9):1271-7. DMUM7HZ RU https://pubmed.ncbi.nlm.nih.gov/12044515 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTQY2EJ DMUM7HZ TN TERT messenger RNA (TERT mRNA) DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUM7HZ DI DMUM7HZ DMUM7HZ DN Fluorouracil DMUM7HZ TI TTP1UKZ DMUM7HZ TN Thymidylate synthase messenger RNA (TYMS mRNA) DMUM7HZ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUM7HZ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUMOEV DI DMUMOEV DMUMOEV DN Ansuvimab DMUMOEV TI TT2F0AU DMUMOEV TN Ebola virus Envelope glycoprotein (EV GP) DMUMOEV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMUMOEV RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761172s000lbl.pdf DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 TI TTZ9SOR DMUMQZ0 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMUMQZ0 MA Antagonist DMUMQZ0 RN Accidental acute clidinium toxicity. Emerg Med J. 2009 Jun;26(6):460. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/19465630 DMUMQZ0 DI DMUMQZ0 DMUMQZ0 DN Clidinium DMUMQZ0 TI TTOXS3C DMUMQZ0 TN Muscarinic acetylcholine receptor (CHRM) DMUMQZ0 MA Antagonist DMUMQZ0 RN Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7. DMUMQZ0 RU https://pubmed.ncbi.nlm.nih.gov/9454790 DMUNSWV DI DMUNSWV DMUNSWV DN Cefradine DMUNSWV TI TTJP4SM DMUNSWV TN Bacterial Penicillin binding protein (Bact PBP) DMUNSWV MA Binder DMUNSWV RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMUNSWV RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMUNTE3 DI DMUNTE3 DMUNTE3 DN Estradiol DMUNTE3 TI TTZAYWL DMUNTE3 TN Estrogen receptor (ESR) DMUNTE3 MA Agonist DMUNTE3 RN Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201. DMUNTE3 RU https://pubmed.ncbi.nlm.nih.gov/19434891 DMUOK4C DI DMUOK4C DMUOK4C DN Lisinopril DMUOK4C TI TTL69WB DMUOK4C TN Angiotensin-converting enzyme (ACE) DMUOK4C MA Inhibitor DMUOK4C RN Involvement of vascular angiotensin II-forming enzymes in the progression of aortic abdominal aneurysms in angiotensin II- infused ApoE-deficient m... J Atheroscler Thromb. 2009 Jun;16(3):164-71. DMUOK4C RU https://pubmed.ncbi.nlm.nih.gov/19556720 DMUOT9V DI DMUOT9V DMUOT9V DN Taxol DMUOT9V TI TTJGNVC DMUOT9V TN Apoptosis regulator Bcl-2 (BCL-2) DMUOT9V MA Modulator DMUOT9V RN Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. DMUOT9V RU https://pubmed.ncbi.nlm.nih.gov/19671798 DMUOT9V DI DMUOT9V DMUOT9V DN Taxol DMUOT9V TI TTYFKSZ DMUOT9V TN Tubulin beta (TUBB) DMUOT9V MA Modulator DMUOT9V RN Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14. DMUOT9V RU https://pubmed.ncbi.nlm.nih.gov/19671798 DMUPE07 DI DMUPE07 DMUPE07 DN Nicotinamide DMUPE07 TI TTVDSZ0 DMUPE07 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMUPE07 MA Binder DMUPE07 RN beta-1,2,3-Triazolyl-nucleosides as nicotinamide riboside mimics. Nucleosides Nucleotides Nucleic Acids. 2009 Mar;28(3):238-59. DMUPE07 RU https://pubmed.ncbi.nlm.nih.gov/19333861 DMUPFLI DI DMUPFLI DMUPFLI DN Deutetrabenazine DMUPFLI TI TTNZRI3 DMUPFLI TN Synaptic vesicle amine transporter (SLC18A2) DMUPFLI MA Modulator DMUPFLI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUPFLI RU https://www.fda.gov/ DMUPOGR DI DMUPOGR DMUPOGR DN Lumacaftor + Ivacaftor DMUPOGR TI TTFPKRB DMUPOGR TN cAMP-dependent chloride channel F508 deletion (CFTR del F508) DMUPOGR MA Enhancer DMUPOGR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUPOGR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUPOGR DI DMUPOGR DMUPOGR DN Lumacaftor + Ivacaftor DMUPOGR TI TTRLZHP DMUPOGR TN cAMP-dependent chloride channel (CFTR) DMUPOGR MA Enhancer DMUPOGR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUPOGR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUQ0E8 DI DMUQ0E8 DMUQ0E8 DN Tepotinib DMUQ0E8 TI TTNDSF4 DMUQ0E8 TN Proto-oncogene c-Met (MET) DMUQ0E8 MA Modulator DMUQ0E8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMUQ0E8 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf DMUR64T DI DMUR64T DMUR64T DN Lesinurad DMUR64T TI TTA592U DMUR64T TN Urate anion exchanger 1 (URAT1) DMUR64T MA Modulator DMUR64T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031). DMUR64T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031 DMUR94J DI DMUR94J DMUR94J DN Certoparin sodium DMUR94J TI TTCIHJA DMUR94J TN Coagulation factor Xa (F10) DMUR94J MA Modulator DMUR94J RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMUR94J RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMUSLW3 DI DMUSLW3 DMUSLW3 DN Carbetocin DMUSLW3 TI TTSCIUP DMUSLW3 TN Oxytocin receptor (OTR) DMUSLW3 MA Agonist DMUSLW3 RN Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512. DMUSLW3 RU https://pubmed.ncbi.nlm.nih.gov/18655903 DMUSZHD DI DMUSZHD DMUSZHD DN Hydrochlorothiazide DMUSZHD TI TTL69WB DMUSZHD TN Angiotensin-converting enzyme (ACE) DMUSZHD MA Modulator DMUSZHD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUSZHD RU https://www.fda.gov/ DMUTEX3 DI DMUTEX3 DMUTEX3 DN Amiodarone DMUTEX3 TI TT1VOHK DMUTEX3 TN Potassium channel unspecific (KC) DMUTEX3 MA Modulator DMUTEX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUTEX3 RU https://www.fda.gov/ DMUTL7O DI DMUTL7O DMUTL7O DN Cloxacillin DMUTL7O TI TTJP4SM DMUTL7O TN Bacterial Penicillin binding protein (Bact PBP) DMUTL7O MA Binder DMUTL7O RN Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303. DMUTL7O RU https://pubmed.ncbi.nlm.nih.gov/17386727 DMUTYR2 DI DMUTYR2 DMUTYR2 DN Epoprostenol DMUTYR2 TI TTOFYT1 DMUTYR2 TN Prostacyclin receptor (PTGIR) DMUTYR2 MA Agonist DMUTYR2 RN Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94. DMUTYR2 RU https://pubmed.ncbi.nlm.nih.gov/19302827 DMUTZ8S DI DMUTZ8S DMUTZ8S DN Interferon Alfa-2a, Recombinant DMUTZ8S TI TTGJVQM DMUTZ8S TN Fibroblast growth factor receptor 2 (FGFR2) DMUTZ8S MA Binder DMUTZ8S RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMUTZ8S RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMUV8OR DI DMUV8OR DMUV8OR DN Indecainide DMUV8OR TI TTZOVE0 DMUV8OR TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMUV8OR MA Blocker DMUV8OR RN Electrophysiological studies of indecainide hydrochloride, a new antiarrhythmic agent, in canine cardiac tissues. J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):614-21. DMUV8OR RU https://pubmed.ncbi.nlm.nih.gov/6206315 DMUWAM2 DI DMUWAM2 DMUWAM2 DN Pyronaridine DMUWAM2 TI TTZVSJ2 DMUWAM2 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMUWAM2 MA Inhibitor DMUWAM2 RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMUWAM2 RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMUWBIJ DI DMUWBIJ DMUWBIJ DN Propiverine DMUWBIJ TI TTH18TF DMUWBIJ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMUWBIJ MA Antagonist DMUWBIJ RN Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8. DMUWBIJ RU https://pubmed.ncbi.nlm.nih.gov/10374898 DMUXP52 DI DMUXP52 DMUXP52 DN Clobetasol DMUXP52 TI TT9V5JH DMUXP52 TN Phospholipase A2 (PLA2G1B) DMUXP52 MA Inhibitor DMUXP52 RN Utilization of epidermal phospholipase A2 inhibition to monitor topical steroid action. Br J Dermatol. 1984 Jul;111 Suppl 27:195-203. DMUXP52 RU https://pubmed.ncbi.nlm.nih.gov/6743552 DMUY2OR DI DMUY2OR DMUY2OR DN Cynarin DMUY2OR TI TTLOQ79 DMUY2OR TN Taste receptor (TASR) DMUY2OR MA Modulator DMUY2OR RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMUY2OR RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMUY35B DI DMUY35B DMUY35B DN Progesterone DMUY35B TI TTUV8G9 DMUY35B TN Progesterone receptor (PGR) DMUY35B MA Agonist DMUY35B RN Clinical pipeline report, company report or official report of lipocine. DMUY35B RU http://www.lipocine.com/pipeline/lpcn-1107/ DMUYNEI DI DMUYNEI DMUYNEI DN Amoxicillin DMUYNEI TI TTXT4D5 DMUYNEI TN Bacterial Cell membrane (Bact CM) DMUYNEI MA Modulator DMUYNEI RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUYNEI RU https://www.fda.gov/ DMUZNIG DI DMUZNIG DMUZNIG DN Troleandomycin DMUZNIG TI TTUWYEA DMUZNIG TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMUZNIG MA Binder DMUZNIG RN Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5. DMUZNIG RU https://pubmed.ncbi.nlm.nih.gov/6972981 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 TI TTUPDWN DMUZPJ5 TN Cholinergic receptor unspecific (CHR) DMUZPJ5 MA Antagonist DMUZPJ5 RN Bradycardia produced by pyridostigmine and physostigmine. Can J Anaesth. 1997 Dec;44(12):1286-92. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/9429048 DMUZPJ5 DI DMUZPJ5 DMUZPJ5 DN Cisatracurium DMUZPJ5 TI TTF4E0J DMUZPJ5 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMUZPJ5 MA Antagonist DMUZPJ5 RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMUZPJ5 RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMV05SW DI DMV05SW DMV05SW DN As-1670542 DMV05SW TI TTIHYA4 DMV05SW TN Thrombopoietin receptor (MPL) DMV05SW MA Agonist DMV05SW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DMV05SW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DMV0RNS DI DMV0RNS DMV0RNS DN Deflazacort DMV0RNS TI TTYRL6O DMV0RNS TN Glucocorticoid receptor (NR3C1) DMV0RNS MA Modulator DMV0RNS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMV0RNS RU https://www.fda.gov/ DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTAXZ0K DMV23GL TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMV23GL MA Inhibitor DMV23GL RN Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/8295214 DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTLXAKE DMV23GL TN Solute carrier family 29 member 1 (SLC29A1) DMV23GL MA Inhibitor DMV23GL RN Synthesis, flow cytometric evaluation, and identification of highly potent dipyridamole analogues as equilibrative nucleoside transporter 1 inhibit... J Med Chem. 2007 Aug 9;50(16):3906-20. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/17636949 DMV23GL DI DMV23GL DMV23GL DN Lidoflazine DMV23GL TI TTRK8B9 DMV23GL TN Sodium channel unspecific (NaC) DMV23GL MA Inhibitor DMV23GL RN Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74. DMV23GL RU https://pubmed.ncbi.nlm.nih.gov/8295214 DMV26S8 DI DMV26S8 DMV26S8 DN Levomilnacipran DMV26S8 TI TTAWNKZ DMV26S8 TN Norepinephrine transporter (NET) DMV26S8 MA Modulator DMV26S8 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMV26S8 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMV26S8 DI DMV26S8 DMV26S8 DN Levomilnacipran DMV26S8 TI TT3ROYC DMV26S8 TN Serotonin transporter (SERT) DMV26S8 MA Modulator DMV26S8 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMV26S8 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMV2JNY DI DMV2JNY DMV2JNY DN Cephapirin DMV2JNY TI TTJP4SM DMV2JNY TN Bacterial Penicillin binding protein (Bact PBP) DMV2JNY MA Binder DMV2JNY RN The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85. DMV2JNY RU https://pubmed.ncbi.nlm.nih.gov/808545 DMV3YMX DI DMV3YMX DMV3YMX DN Vedolizmab DMV3YMX TI TTLT9XQ DMV3YMX TN Integrin beta-7 (ITGB7) DMV3YMX MA Antagonist DMV3YMX RN Clinical pipeline report, company report or official report of Takeda (2009). DMV3YMX RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMV3YMX DI DMV3YMX DMV3YMX DN Vedolizmab DMV3YMX TI TT4BT06 DMV3YMX TN Integrin alpha-4 (ITGA4) DMV3YMX MA Antagonist DMV3YMX RN Clinical pipeline report, company report or official report of Takeda (2009). DMV3YMX RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMV4KOA DI DMV4KOA DMV4KOA DN GW642444 DMV4KOA TI TT2CJVK DMV4KOA TN Adrenergic receptor beta-2 (ADRB2) DMV4KOA MA Agonist DMV4KOA RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMV4KOA RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMV62ED DI DMV62ED DMV62ED DN Fotemustine DMV62ED TI TTR7UJ3 DMV62ED TN Cytoplasmic thioredoxin reductase (TXNRD1) DMV62ED MA Inhibitor DMV62ED RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV62ED RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV67QO DI DMV67QO DMV67QO DN Ibalizumab DMV67QO TI TTN2JFW DMV67QO TN T-cell surface glycoprotein CD4 (CD4) DMV67QO MA Modulator DMV67QO RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMV67QO RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMV74ZH DI DMV74ZH DMV74ZH DN Pizotyline DMV74ZH TI TT85JO3 DMV74ZH TN 5-HT receptor (5HTR) DMV74ZH MA Modulator DMV74ZH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMV74ZH RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMV7IM6 DI DMV7IM6 DMV7IM6 DN Histamine Phosphate DMV7IM6 TI TT7CXIM DMV7IM6 TN Histamine receptor (HR) DMV7IM6 MA Modulator DMV7IM6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMV7IM6 RU https://www.fda.gov/ DMV7YFT DI DMV7YFT DMV7YFT DN Darolutamide DMV7YFT TI TTS64P2 DMV7YFT TN Androgen receptor (AR) DMV7YFT MA Antagonist DMV7YFT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMV7YFT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf DMV96ZH DI DMV96ZH DMV96ZH DN Anapsos DMV96ZH TI TTXL3MF DMV96ZH TN Lymphoid cell adhesion molecule expression (LCDME) DMV96ZH MA Modulator DMV96ZH RN Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion molecules. Pharmacol Res. 2002 Aug;46(2):185-90. DMV96ZH RU https://pubmed.ncbi.nlm.nih.gov/12220959 DMV9ADG DI DMV9ADG DMV9ADG DN Pilocarpine DMV9ADG TI TTH18TF DMV9ADG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMV9ADG MA Agonist DMV9ADG RN Retinoic acid prevents virus-induced airway hyperreactivity and M2 receptor dysfunction via anti-inflammatory and antiviral effects. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L340-6. DMV9ADG RU https://pubmed.ncbi.nlm.nih.gov/19465517 DMVAIH4 DI DMVAIH4 DMVAIH4 DN Hylenex DMVAIH4 TI TTYTVXF DMVAIH4 TN Hyaluronic acid (HA) DMVAIH4 MA Modulator DMVAIH4 RN Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296. DMVAIH4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/ DMVAZP9 DI DMVAZP9 DMVAZP9 DN Tenoxicam DMVAZP9 TI TTVKILB DMVAZP9 TN Prostaglandin G/H synthase 2 (COX-2) DMVAZP9 MA Inhibitor DMVAZP9 RN The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005 Sep;16(3):138-42. DMVAZP9 RU https://pubmed.ncbi.nlm.nih.gov/16245223 DMVE3TK DI DMVE3TK DMVE3TK DN Bromocriptine DMVE3TK TI TTEX248 DMVE3TK TN Dopamine D2 receptor (D2R) DMVE3TK MA Agonist DMVE3TK RN Silymarin BIO-C, an extract from Silybum marianum fruits, induces hyperprolactinemia in intact female rats. Phytomedicine. 2009 Sep;16(9):839-44. DMVE3TK RU https://pubmed.ncbi.nlm.nih.gov/19303749 DMVEK07 DI DMVEK07 DMVEK07 DN Magnesium Sulfate DMVEK07 TI TT9IK2Z DMVEK07 TN N-methyl-D-aspartate receptor (NMDAR) DMVEK07 MA Antagonist DMVEK07 RN Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95. DMVEK07 RU https://pubmed.ncbi.nlm.nih.gov/17720112 DMVGPMX DI DMVGPMX DMVGPMX DN Fosfomycin DMVGPMX TI TTICX3S DMVGPMX TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMVGPMX MA Inhibitor DMVGPMX RN Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem. 2005 Feb 4;280(5):3757-63. DMVGPMX RU https://pubmed.ncbi.nlm.nih.gov/15531591 DMVHJLX DI DMVHJLX DMVHJLX DN Perospirone DMVHJLX TI TTYSN63 DMVHJLX TN 5-HT 2 receptor (5HT2R) DMVHJLX MA Modulator DMVHJLX RN Pharmacological effects of zotepine and other antipsychotics on the central 5-HT2 receptors. Pharmacopsychiatry. 1993 Mar;26(2):53-8. DMVHJLX RU https://pubmed.ncbi.nlm.nih.gov/7690975 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ TI TTVQ6R9 DMVIKJZ TN C1 esterase inhibitor (SERPING1) DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVIKJZ DI DMVIKJZ DMVIKJZ DN Cinryze DMVIKJZ TI TT7LRQH DMVIKJZ TN Complement C1s component (C1S) DMVIKJZ MA Modulator DMVIKJZ RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVIKJZ RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVJS2K DI DMVJS2K DMVJS2K DN Monobenzone DMVJS2K TI TTULVH8 DMVJS2K TN Tyrosinase (TYR) DMVJS2K MA Inhibitor DMVJS2K RN Identification of an Alkylhydroquinone from Rhus succedanea as an Inhibitor of Tyrosinase and Melanogenesis. J Agric Food Chem. 2009 Mar 25;57(6):2200-5. DMVJS2K RU https://pubmed.ncbi.nlm.nih.gov/19159217 DMVKA4O DI DMVKA4O DMVKA4O DN Mianserin DMVKA4O TI TTYSN63 DMVKA4O TN 5-HT 2 receptor (5HT2R) DMVKA4O MA Antagonist DMVKA4O RN 5-HT reuptake and 5-HT2 receptors modulate capsaicin-evoked hypothermia in rats. Neurosci Lett. 2008 Jan 17;430(3):191-6. DMVKA4O RU https://pubmed.ncbi.nlm.nih.gov/18155835 DMVLHNI DI DMVLHNI DMVLHNI DN Tridihexethyl DMVLHNI TI TTH18TF DMVLHNI TN Muscarinic acetylcholine receptor M5 (CHRM5) DMVLHNI MA Binder DMVLHNI RN Effect of anticholinergic agents upon acquired nystagmus: a double-blind study of trihexyphenidyl and tridihexethyl chloride. Neurology. 1991 Nov;41(11):1737-41. DMVLHNI RU https://pubmed.ncbi.nlm.nih.gov/1944902 DMVLMW6 DI DMVLMW6 DMVLMW6 DN Ketanserin DMVLMW6 TI TTYSN63 DMVLMW6 TN 5-HT 2 receptor (5HT2R) DMVLMW6 MA Antagonist DMVLMW6 RN Nordexfenfluramine causes more severe pulmonary vasoconstriction than dexfenfluramine. Am J Physiol Lung Cell Mol Physiol. 2004 Mar;286(3):L531-8. DMVLMW6 RU https://pubmed.ncbi.nlm.nih.gov/14607779 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTZCW3T DMVM6QR TN Dihydropyrimidinase related protein 2 (DPYSL2) DMVM6QR MA Modulator DMVM6QR RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTN9VTF DMVM6QR TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMVM6QR MA Inhibitor DMVM6QR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMVM6QR DI DMVM6QR DMVM6QR DN Lacosamide DMVM6QR TI TTIG65Q DMVM6QR TN Voltage-gated sodium channel (Nav) DMVM6QR MA Inhibitor DMVM6QR RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMVM6QR RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMVMQ1L DI DMVMQ1L DMVMQ1L DN Nafronyl DMVMQ1L TI TT85JO3 DMVMQ1L TN 5-HT receptor (5HTR) DMVMQ1L MA Modulator DMVMQ1L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMVMQ1L RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMVMY7K DI DMVMY7K DMVMY7K DN Arepanrix DMVMY7K TI TT3J5ZI DMVMY7K TN Cell mediated immunity response (CMIR) DMVMY7K RN Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development. Brain Behav Immun. 2015 Jul;47:44-57. DMVMY7K RU https://pubmed.ncbi.nlm.nih.gov/25452148 DMVN2E6 DI DMVN2E6 DMVN2E6 DN Vinpocetine DMVN2E6 TI TTHQENC DMVN2E6 TN Phosphodiesterase 1 (PDE1) DMVN2E6 MA Inhibitor DMVN2E6 RN Effects of phosphodiesterase inhibitors on contraction induced by endothelin-1 of isolated human prostatic tissue. Urology. 2009 Jun;73(6):1397-401. DMVN2E6 RU https://pubmed.ncbi.nlm.nih.gov/19285714 DMVN5OH DI DMVN5OH DMVN5OH DN Minocycline DMVN5OH TI TTQ8KVI DMVN5OH TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMVN5OH MA Binder DMVN5OH RN Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. DMVN5OH RU https://pubmed.ncbi.nlm.nih.gov/16723578 DMVO0UB DI DMVO0UB DMVO0UB DN Alfentanil DMVO0UB TI TTKWM86 DMVO0UB TN Opioid receptor mu (MOP) DMVO0UB MA Agonist DMVO0UB RN Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87. DMVO0UB RU https://pubmed.ncbi.nlm.nih.gov/11240090 DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED TI TTANPDJ DMVO4ED TN Carbonic anhydrase II (CA-II) DMVO4ED MA Inhibitor DMVO4ED RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVO4ED RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVO4ED DI DMVO4ED DMVO4ED DN Ethoxzolamide DMVO4ED TI TTHQPL7 DMVO4ED TN Carbonic anhydrase I (CA-I) DMVO4ED MA Modulator DMVO4ED RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVO4ED RU https://www.fda.gov/ DMVOIK1 DI DMVOIK1 DMVOIK1 DN Rosoxacin DMVOIK1 TI TT0IHXV DMVOIK1 TN DNA topoisomerase II (TOP2) DMVOIK1 MA Inhibitor DMVOIK1 RN Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598-601. DMVOIK1 RU https://pubmed.ncbi.nlm.nih.gov/3010848 DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 TI TTED8JB DMVONE6 TN Epidermal growth factor (EGF) DMVONE6 MA Modulator DMVONE6 RN Repurposing of the epidermal growth factor. Journal of Commercial Biotechnology (2011) 17, 45-52. DMVONE6 RU http://www.palgrave-journals.com/jcb/journal/v17/n1/full/jcb201028a.html DMVONE6 DI DMVONE6 DMVONE6 DN Epidermal growth factor DMVONE6 TI TTGKNB4 DMVONE6 TN Epidermal growth factor receptor (EGFR) DMVONE6 MA Modulator DMVONE6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMVONE6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE TI TTQY2EJ DMVP5YE TN TERT messenger RNA (TERT mRNA) DMVP5YE RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMVP5YE RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMVP5YE DI DMVP5YE DMVP5YE DN Doxorubicin DMVP5YE TI TT0IHXV DMVP5YE TN DNA topoisomerase II (TOP2) DMVP5YE MA Modulator DMVP5YE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVP5YE RU https://www.fda.gov/ DMVPUQI DI DMVPUQI DMVPUQI DN Hydroflumethiazide DMVPUQI TI TTS087L DMVPUQI TN Solute carrier family 12 member 1 (SLC12A1) DMVPUQI MA Blocker DMVPUQI RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMVPUQI RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMVPWLZ DI DMVPWLZ DMVPWLZ DN Terbutyline DMVPWLZ TI TTVIREA DMVPWLZ TN Adrenergic receptor (ADR) DMVPWLZ MA Modulator DMVPWLZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMVPWLZ RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMVPZBE DI DMVPZBE DMVPZBE DN Iloprost DMVPZBE TI TT1ZAVI DMVPZBE TN Prostaglandin E2 receptor EP2 (PTGER2) DMVPZBE MA Agonist DMVPZBE RN Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27. DMVPZBE RU https://pubmed.ncbi.nlm.nih.gov/17408863 DMVR628 DI DMVR628 DMVR628 DN Vindesine DMVR628 TI TTYFKSZ DMVR628 TN Tubulin beta (TUBB) DMVR628 MA Binder DMVR628 RN Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36. DMVR628 RU https://pubmed.ncbi.nlm.nih.gov/17465195 DMVRH9C DI DMVRH9C DMVRH9C DN Lomefloxacin DMVRH9C TI TT0IHXV DMVRH9C TN DNA topoisomerase II (TOP2) DMVRH9C MA Inhibitor DMVRH9C RN Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22. DMVRH9C RU https://pubmed.ncbi.nlm.nih.gov/12215656 DMVRIC2 DI DMVRIC2 DMVRIC2 DN Zileuton DMVRIC2 TI TT2J34L DMVRIC2 TN Arachidonate 5-lipoxygenase (5-LOX) DMVRIC2 MA Inhibitor DMVRIC2 RN 5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009 Oct;31(8):848-52. DMVRIC2 RU https://pubmed.ncbi.nlm.nih.gov/19309543 DMVRLT7 DI DMVRLT7 DMVRLT7 DN Fludarabine DMVRLT7 TI TTLP57V DMVRLT7 TN Adenosine deaminase (ADA) DMVRLT7 MA Inhibitor DMVRLT7 RN Purine nucleoside analogs in indolent non-Hodgkin's lymphoma. Oncology (Williston Park). 2000 Jun;14(6 Suppl 2):13-5. DMVRLT7 RU https://pubmed.ncbi.nlm.nih.gov/10887639 DMVRYT2 DI DMVRYT2 DMVRYT2 DN Nabilone DMVRYT2 TI TTMSFAW DMVRYT2 TN Cannabinoid receptor 2 (CB2) DMVRYT2 MA Inhibitor DMVRYT2 RN Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010. DMVRYT2 RU https://pubmed.ncbi.nlm.nih.gov/20925434 DMVRYT2 DI DMVRYT2 DMVRYT2 DN Nabilone DMVRYT2 TI TT6OEDT DMVRYT2 TN Cannabinoid receptor 1 (CB1) DMVRYT2 MA Inhibitor DMVRYT2 RN Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010. DMVRYT2 RU https://pubmed.ncbi.nlm.nih.gov/20925434 DMVS9WQ DI DMVS9WQ DMVS9WQ DN Nitisinone DMVS9WQ TI TT8DSFC DMVS9WQ TN Hydroxyphenylpyruvate dioxygenase (HPD) DMVS9WQ MA Inhibitor DMVS9WQ RN Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008 May;9(7):1229-36. DMVS9WQ RU https://pubmed.ncbi.nlm.nih.gov/18422479 DMVTHER DI DMVTHER DMVTHER DN Lincomycin DMVTHER TI TTUWYEA DMVTHER TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMVTHER MA Inhibitor DMVTHER RN Specific inhibition of 50S ribosomal subunit formation in Staphylococcus aureus cells by 16-membered macrolide, lincosamide, and streptogramin B antibiotics. Curr Microbiol. 2000 Aug;41(2):126-35. DMVTHER RU https://pubmed.ncbi.nlm.nih.gov/10856379 DMVTHWQ DI DMVTHWQ DMVTHWQ DN Silver sulfadiazine DMVTHWQ TI TT4ILYC DMVTHWQ TN Bacterial Dihydropteroate synthetase (Bact folP) DMVTHWQ MA Binder DMVTHWQ RN Comparative evaluation of transdermal formulations of norfloxacin with silver sulfadiazine cream, USP, for burn wound healing property. J Burns Wounds. 2006 Jun 7;5:e4. DMVTHWQ RU https://pubmed.ncbi.nlm.nih.gov/16921417 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q TI TTIXTO3 DMVTU5Q TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMVTU5Q DI DMVTU5Q DMVTU5Q DN Delafloxacin Meglumine DMVTU5Q TI TTZ82MR DMVTU5Q TN Plasmodium DNA gyrase (Malaria gyrase) DMVTU5Q MA Inhibitor DMVTU5Q RN 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85. DMVTU5Q RU https://pubmed.ncbi.nlm.nih.gov/29348678 DMVWHTG DI DMVWHTG DMVWHTG DN Afamelanotide DMVWHTG TI TT0MV2T DMVWHTG TN Melanocortin receptor 1 (MC1R) DMVWHTG MA Modulator DMVWHTG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMVWHTG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210797s000lbl.pdf DMVXFYE DI DMVXFYE DMVXFYE DN Vinorelbine DMVXFYE TI TTML2WA DMVXFYE TN Tubulin (TUB) DMVXFYE MA Inhibitor DMVXFYE RN Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9. DMVXFYE RU https://pubmed.ncbi.nlm.nih.gov/18633246 DMVY4GN DI DMVY4GN DMVY4GN DN Testolactone DMVY4GN TI TTSZLWK DMVY4GN TN Aromatase (CYP19A1) DMVY4GN MA Inhibitor DMVY4GN RN Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9. DMVY4GN RU https://pubmed.ncbi.nlm.nih.gov/11792932 DMVYSLE DI DMVYSLE DMVYSLE DN Cefalotin DMVYSLE TI TTLP6GN DMVYSLE TN Bacterial DD-carboxypeptidase (Bact vanYB) DMVYSLE MA Inhibitor DMVYSLE RN Binding of cephalothin and cefotaxime to D-ala-D-ala-peptidase reveals a functional basis of a natural mutation in a low-affinity penicillin-binding protein and in extended-spectrum beta-lactamases. Biochemistry. 1995 Jul 25;34(29):9532-40. DMVYSLE RU https://pubmed.ncbi.nlm.nih.gov/7626623 DMVYXR8 DI DMVYXR8 DMVYXR8 DN Sumatriptan DMVYXR8 TI TT6MSOK DMVYXR8 TN 5-HT 1D receptor (HTR1D) DMVYXR8 MA Agonist DMVYXR8 RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DMVYXR8 RU https://pubmed.ncbi.nlm.nih.gov/11293643 DMVZQ2M DI DMVZQ2M DMVZQ2M DN Probucol DMVZQ2M TI TTJW1GN DMVZQ2M TN ATP-binding cassette transporter A1 (ABCA1) DMVZQ2M MA Modulator DMVZQ2M RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMVZQ2M RU https://www.fda.gov/ DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 TI TT1MPAY DMW1OQ0 TN GABA(A) receptor alpha-1 (GABRA1) DMW1OQ0 MA Antagonist DMW1OQ0 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMW1OQ0 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMW1OQ0 DI DMW1OQ0 DMW1OQ0 DN Clobazam - Lundbeck DMW1OQ0 TI TTEX6LM DMW1OQ0 TN GABA(A) receptor gamma-3 (GABRG3) DMW1OQ0 MA Modulator DMW1OQ0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW1OQ0 RU https://www.fda.gov/ DMW2GEJ DI DMW2GEJ DMW2GEJ DN Mepolizumab DMW2GEJ TI TTPREZD DMW2GEJ TN Interleukin-5 (IL5) DMW2GEJ MA Modulator DMW2GEJ RN Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563. Drugs R D. 2008;9(2):125-30. DMW2GEJ RU https://www.ncbi.nlm.nih.gov/pubmed/18298130 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 TI TT5HONZ DMW4M97 TN Calcium channel unspecific (CaC) DMW4M97 MA Modulator DMW4M97 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMW4M97 DI DMW4M97 DMW4M97 DN Clevidipine butyrate DMW4M97 TI TTXHYV6 DMW4M97 TN Voltage-gated L-type calcium channel (L-CaC) DMW4M97 MA Inhibitor DMW4M97 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMW4M97 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMW4X37 DI DMW4X37 DMW4X37 DN Diphenylpyraline DMW4X37 TI TTTIBOJ DMW4X37 TN Histamine H1 receptor (H1R) DMW4X37 MA Antagonist DMW4X37 RN Transport mechanism of an H1-antagonist at the blood-brain barrier: transport mechanism of mepyramine using the carotid injection technique. Biol Pharm Bull. 1994 May;17(5):676-9. DMW4X37 RU https://pubmed.ncbi.nlm.nih.gov/7920432 DMW51AX DI DMW51AX DMW51AX DN Anisodamine DMW51AX TI TTR6W5O DMW51AX TN Adrenergic receptor beta-1 (ADRB1) DMW51AX MA Modulator DMW51AX RN Medicinal plants in therapy. Bull World Health Organ. 1985;63(6):965-81. DMW51AX RU https://pubmed.ncbi.nlm.nih.gov/3879679 DMW542E DI DMW542E DMW542E DN Orphenadrine DMW542E TI TT9IK2Z DMW542E TN N-methyl-D-aspartate receptor (NMDAR) DMW542E MA Antagonist DMW542E RN Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. Pain. 2009 Apr;142(3):225-35. DMW542E RU https://pubmed.ncbi.nlm.nih.gov/19217209 DMW5ML9 DI DMW5ML9 DMW5ML9 DN Tecovirimat DMW5ML9 TI TTG7UOF DMW5ML9 TN Variola virus Envelope phospholipase F13 (VARV p37) DMW5ML9 MA Inhibitor DMW5ML9 RN Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection.IDrugs. 2010 Mar;13(3):181-91. Review DMW5ML9 RU https://pubmed.ncbi.nlm.nih.gov/20191435 DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X TI TTK8CXU DMW649X TN 5-HT 1B receptor (HTR1B) DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW649X DI DMW649X DMW649X DN Eletriptan DMW649X TI TT6MSOK DMW649X TN 5-HT 1D receptor (HTR1D) DMW649X MA Modulator DMW649X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW649X RU https://www.fda.gov/ DMW67MU DI DMW67MU DMW67MU DN Botulinum Toxin Type A DMW67MU TI TTYQWA0 DMW67MU TN Synaptosomal-associated protein 25 (SNAP25) DMW67MU MA Inhibitor DMW67MU RN Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct duration... J Biol Chem. 2003 Jan 10;278(2):1363-71. DMW67MU RU https://pubmed.ncbi.nlm.nih.gov/12381720 DMW6F0S DI DMW6F0S DMW6F0S DN Mizoribine DMW6F0S TI TTL7C8Q DMW6F0S TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMW6F0S MA Inhibitor DMW6F0S RN VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent. J Pharm Sci. 2001 May;90(5):625-37. DMW6F0S RU https://pubmed.ncbi.nlm.nih.gov/11288107 DMW6GVL DI DMW6GVL DMW6GVL DN Nadolol DMW6GVL TI TTR6W5O DMW6GVL TN Adrenergic receptor beta-1 (ADRB1) DMW6GVL MA Modulator DMW6GVL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW6GVL RU https://www.fda.gov/ DMW6ZJI DI DMW6ZJI DMW6ZJI DN Levocetirizine dihydrochloride DMW6ZJI TI TTTIBOJ DMW6ZJI TN Histamine H1 receptor (H1R) DMW6ZJI MA Antagonist DMW6ZJI RN Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8. DMW6ZJI RU https://pubmed.ncbi.nlm.nih.gov/19210904 DMW83TP DI DMW83TP DMW83TP DN Pimozide DMW83TP TI TTEX248 DMW83TP TN Dopamine D2 receptor (D2R) DMW83TP MA Antagonist DMW83TP RN [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1. DMW83TP RU https://pubmed.ncbi.nlm.nih.gov/16924461 DMW8KI7 DI DMW8KI7 DMW8KI7 DN Insulin Susp Isophane Recombinant Human DMW8KI7 TI TTZOPHG DMW8KI7 TN Insulin (INS) DMW8KI7 MA Modulator DMW8KI7 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMW8KI7 RU https://www.fda.gov/ DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG TI TTOHSBA DMW8QNG TN Vascular endothelial growth factor A (VEGFA) DMW8QNG MA Inhibitor DMW8QNG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMW8QNG RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761125s000lbl.pdf DMW8QNG DI DMW8QNG DMW8QNG DN Brolucizumab DMW8QNG TI TT9HKJA DMW8QNG TN Vascular endothelial growth factor (VEGF) DMW8QNG MA Inhibitor DMW8QNG RN Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000. DMW8QNG RU https://pubmed.ncbi.nlm.nih.gov/31768932 DMWA24P DI DMWA24P DMWA24P DN IPI-145 DMWA24P TI TTGBPJE DMWA24P TN PI3-kinase delta (PIK3CD) DMWA24P MA Modulator DMWA24P RN PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. DMWA24P RU https://pubmed.ncbi.nlm.nih.gov/24211136 DMWA24P DI DMWA24P DMWA24P DN IPI-145 DMWA24P TI TTHBTOP DMWA24P TN PI3-kinase gamma (PIK3CG) DMWA24P MA Modulator DMWA24P RN PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol. 2013 Nov 21;20(11):1364-74. DMWA24P RU https://pubmed.ncbi.nlm.nih.gov/24211136 DMWA2DZ DI DMWA2DZ DMWA2DZ DN Berotralstat DMWA2DZ TI TTMF8H9 DMWA2DZ TN Plasma kallikrein (KLKB1) DMWA2DZ MA Inhibitor DMWA2DZ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWA2DZ RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf DMWBHRY DI DMWBHRY DMWBHRY DN Olmesartan medoxomil DMWBHRY TI TT8DBY3 DMWBHRY TN Angiotensin II receptor type-1 (AGTR1) DMWBHRY MA Antagonist DMWBHRY RN Mechanism of diastolic stiffening of the failing myocardium and its prevention by angiotensin receptor and calcium channel blockers. J Cardiovasc Pharmacol. 2009 Jul;54(1):47-56. DMWBHRY RU https://pubmed.ncbi.nlm.nih.gov/19528815 DMWBQKU DI DMWBQKU DMWBQKU DN Olprinone DMWBQKU TI TTZCG4L DMWBQKU TN Phosphodiesterase 3 (PDE3) DMWBQKU MA Inhibitor DMWBQKU RN Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74. DMWBQKU RU https://pubmed.ncbi.nlm.nih.gov/12397365 DMWCOSR DI DMWCOSR DMWCOSR DN Quinethazone DMWCOSR TI TTUNARX DMWCOSR TN Carbonic anhydrase (CA) DMWCOSR MA Inhibitor DMWCOSR RN Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for th... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. DMWCOSR RU https://pubmed.ncbi.nlm.nih.gov/18374572 DMWCQP4 DI DMWCQP4 DMWCQP4 DN Interferon alfa-2B DMWCQP4 TI TTSIUJ9 DMWCQP4 TN Interferon-alpha 2 (IFNA2) DMWCQP4 MA Modulator DMWCQP4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWCQP4 RU https://www.fda.gov/ DMWCRN1 DI DMWCRN1 DMWCRN1 DN Ispaghula DMWCRN1 TI TTH18TF DMWCRN1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMWCRN1 MA Antagonist DMWCRN1 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMWCRN1 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMWE2N4 DI DMWE2N4 DMWE2N4 DN Auranofin DMWE2N4 TI TTP3UTW DMWE2N4 TN Steroid hormone receptor ERR (ESRR) DMWE2N4 MA Modulator DMWE2N4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWE2N4 RU https://www.fda.gov/ DMWE60C DI DMWE60C DMWE60C DN Rufinamide DMWE60C TI TTRK8B9 DMWE60C TN Sodium channel unspecific (NaC) DMWE60C MA Blocker DMWE60C RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DMWE60C RU https://pubmed.ncbi.nlm.nih.gov/17874969 DMWF5R4 DI DMWF5R4 DMWF5R4 DN Melphalan flufenamide DMWF5R4 TI TTUTN1I DMWF5R4 TN Human Deoxyribonucleic acid (hDNA) DMWF5R4 MA Binder DMWF5R4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMWF5R4 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214383s000lbl.pdf DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ TI TTSYVO6 DMWFHMZ TN Cholesterol desmolase (CYP11A1) DMWFHMZ MA Inhibitor DMWFHMZ RN Breakdown of Th cell immune responses and steroidogenic CYP11A1 expression in CD4+ T cells in a murine model implanted with B16 melanoma. Cell Immunol. 2000 Nov 25;206(1):7-15. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/11161433 DMWFHMZ DI DMWFHMZ DMWFHMZ DN Aminoglutethimide DMWFHMZ TI TTSZLWK DMWFHMZ TN Aromatase (CYP19A1) DMWFHMZ MA Inhibitor DMWFHMZ RN Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45. DMWFHMZ RU https://pubmed.ncbi.nlm.nih.gov/17602675 DMWFJTR DI DMWFJTR DMWFJTR DN Linagliptin DMWFJTR TI TTDIGC1 DMWFJTR TN Dipeptidyl peptidase 4 (DPP-4) DMWFJTR MA Inhibitor DMWFJTR RN Boehringer Ingelheim. Product Development Pipeline. June 2 2009. DMWFJTR RU http://www.boehringer-ingelheim.com/corporate/research/pipeline.asp DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ TI TT1ZAVI DMWH7NQ TN Prostaglandin E2 receptor EP2 (PTGER2) DMWH7NQ MA Agonist DMWH7NQ RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMWH7NQ DI DMWH7NQ DMWH7NQ DN Alprostadil DMWH7NQ TI TT2O84V DMWH7NQ TN Thromboxane A2 receptor (TBXA2R) DMWH7NQ MA Modulator DMWH7NQ RN Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6. DMWH7NQ RU https://pubmed.ncbi.nlm.nih.gov/10509658 DMWH9CN DI DMWH9CN DMWH9CN DN Ridogrel DMWH9CN TI TT2O84V DMWH9CN TN Thromboxane A2 receptor (TBXA2R) DMWH9CN MA Binder DMWH9CN RN Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42. DMWH9CN RU https://pubmed.ncbi.nlm.nih.gov/19337130 DMWIJTN DI DMWIJTN DMWIJTN DN Voclosporin DMWIJTN TI TTA4LDE DMWIJTN TN Calcineurin (PPP3CA) DMWIJTN MA Inhibitor DMWIJTN RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMWIJTN RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213716s000lbl.pdf DMWIX23 DI DMWIX23 DMWIX23 DN Metaraminol DMWIX23 TI TTEX248 DMWIX23 TN Dopamine D2 receptor (D2R) DMWIX23 MA Agonist DMWIX23 RN Alpha1-adrenoceptor stimulation enhances experimental gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 1998 Jul 29;77(3):467-9. DMWIX23 RU https://pubmed.ncbi.nlm.nih.gov/9663612 DMWLC57 DI DMWLC57 DMWLC57 DN Brentuximab vedotin DMWLC57 TI TT2GM5R DMWLC57 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMWLC57 MA Modulator DMWLC57 RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMWLC57 RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMWLTU2 DI DMWLTU2 DMWLTU2 DN PSMA-11 Ga-68 DMWLTU2 TI TT9G4N0 DMWLTU2 TN Glutamate carboxypeptidase II (GCPII) DMWLTU2 MA Binder DMWLTU2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWLTU2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212642s000lbl.pdf DMWMCN0 DI DMWMCN0 DMWMCN0 DN Erenumab DMWMCN0 TI TTY6O0Q DMWMCN0 TN Calcitonin gene-related peptide receptor (CGRPR) DMWMCN0 MA Modulator DMWMCN0 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMWMCN0 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMWMPD4 DI DMWMPD4 DMWMPD4 DN Vorinostat DMWMPD4 TI TT6R7JZ DMWMPD4 TN Histone deacetylase 1 (HDAC1) DMWMPD4 MA Inhibitor DMWMPD4 RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DMWMPD4 RU https://pubmed.ncbi.nlm.nih.gov/19721445 DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTZOVE0 DMWMPRG TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMWMPRG MA Blocker DMWMPRG RN Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81. DMWMPRG RU https://pubmed.ncbi.nlm.nih.gov/12354567 DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTRK8B9 DMWMPRG TN Sodium channel unspecific (NaC) DMWMPRG MA Antagonist DMWMPRG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWMPRG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWMPRG DI DMWMPRG DMWMPRG DN Tetrodotoxin DMWMPRG TI TTIG65Q DMWMPRG TN Voltage-gated sodium channel (Nav) DMWMPRG MA Inhibitor DMWMPRG RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMWMPRG RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMWNHPC DI DMWNHPC DMWNHPC DN Aminolevulinic Acid Hydrochloride DMWNHPC TI TTNFMS9 DMWNHPC TN Protoporphyrinogen oxidase (PPOX) DMWNHPC MA Modulator DMWNHPC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNHPC RU https://www.fda.gov/ DMWNRZT DI DMWNRZT DMWNRZT DN Basiliximab DMWNRZT TI TT10Y9E DMWNRZT TN Interleukin 2 receptor alpha (IL2RA) DMWNRZT MA Modulator DMWNRZT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWNRZT RU https://www.fda.gov/ DMWO3N6 DI DMWO3N6 DMWO3N6 DN Indeloxazine DMWO3N6 TI TTGP7BY DMWO3N6 TN Monoamine oxidase type B (MAO-B) DMWO3N6 MA Modulator DMWO3N6 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMWO3N6 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMWOSKJ DI DMWOSKJ DMWOSKJ DN Zolpidem DMWOSKJ TI TTEX6LM DMWOSKJ TN GABA(A) receptor gamma-3 (GABRG3) DMWOSKJ MA Modulator (allosteric modulator) DMWOSKJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMWOSKJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMWOSKJ DI DMWOSKJ DMWOSKJ DN Zolpidem DMWOSKJ TI TT1MPAY DMWOSKJ TN GABA(A) receptor alpha-1 (GABRA1) DMWOSKJ MA Modulator DMWOSKJ RN Zolpidem, a selective GABA(A) receptor alpha1 subunit agonist, induces comparable Fos expression in oxytocinergic neurons of the hypothalamic paraventricular and accessory but not supraoptic nuclei in the rat.Brain Res Bull.2006 Dec 11;71(1-3):200-7. DMWOSKJ RU https://www.ncbi.nlm.nih.gov/pubmed/17113947 DMWP1BH DI DMWP1BH DMWP1BH DN Tazemetostat DMWP1BH TI TT9MZCQ DMWP1BH TN Enhancer of zeste homolog 2 (EZH2) DMWP1BH MA Inhibitor DMWP1BH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWP1BH RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf DMWQ16I DI DMWQ16I DMWQ16I DN Primaquine DMWQ16I TI TT698WO DMWQ16I TN Plasmodium Deoxyribonucleic acid (Malaria DNA) DMWQ16I RN Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107. DMWQ16I RU https://pubmed.ncbi.nlm.nih.gov/17686563 DMWQ4MZ DI DMWQ4MZ DMWQ4MZ DN Gilteritinib DMWQ4MZ TI TTGJCWZ DMWQ4MZ TN Fms-like tyrosine kinase 3 (FLT-3) DMWQ4MZ MA Inhibitor DMWQ4MZ RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMWQ4MZ RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMWQ4MZ DI DMWQ4MZ DMWQ4MZ DN Gilteritinib DMWQ4MZ TI TTZPY6J DMWQ4MZ TN Tyrosine-protein kinase UFO (AXL) DMWQ4MZ MA Inhibitor DMWQ4MZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWQ4MZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWS3FH DI DMWS3FH DMWS3FH DN Fondaparinux sodium DMWS3FH TI TTCIHJA DMWS3FH TN Coagulation factor Xa (F10) DMWS3FH MA Inhibitor DMWS3FH RN Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24. DMWS3FH RU https://pubmed.ncbi.nlm.nih.gov/13679646 DMWSA0V DI DMWSA0V DMWSA0V DN Patisiran DMWSA0V TI TTPOYU7 DMWSA0V TN Transthyretin messenger RNA (TTR mRNA) DMWSA0V RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DMWSA0V RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/ DMWSMND DI DMWSMND DMWSMND DN Cevimeline DMWSMND TI TTQ13Z5 DMWSMND TN Muscarinic acetylcholine receptor M3 (CHRM3) DMWSMND MA Agonist DMWSMND RN Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. DMWSMND RU https://pubmed.ncbi.nlm.nih.gov/18450949 DMWT905 DI DMWT905 DMWT905 DN Mefloquine DMWT905 TI TTT28H3 DMWT905 TN Plasmodium 80S ribosome (Malaria 80S) DMWT905 MA Binder DMWT905 RN An ultrastructural study of the effects of mefloquine on malaria parasites. Am J Trop Med Hyg. 1987 Jan;36(1):9-14. DMWT905 RU https://pubmed.ncbi.nlm.nih.gov/3544894 DMWTAOI DI DMWTAOI DMWTAOI DN Estramustine DMWTAOI TI TTSBFYK DMWTAOI TN Estramustine binding protein (EMBP) DMWTAOI MA Binder DMWTAOI RN Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5. DMWTAOI RU https://pubmed.ncbi.nlm.nih.gov/7703721 DMWTVAN DI DMWTVAN DMWTVAN DN Rauwolfia serpentina root DMWTVAN TI TTZIFHC DMWTVAN TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMWTVAN MA Inhibitor DMWTVAN RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMWTVAN RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMWU0I2 DI DMWU0I2 DMWU0I2 DN Pralsetinib DMWU0I2 TI TT4DXQT DMWU0I2 TN Proto-oncogene c-Ret (RET) DMWU0I2 MA Inhibitor DMWU0I2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMWU0I2 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213721s000lbl.pdf DMWUFQ4 DI DMWUFQ4 DMWUFQ4 DN Ramucirumab DMWUFQ4 TI TTUTJGQ DMWUFQ4 TN Vascular endothelial growth factor receptor 2 (KDR) DMWUFQ4 MA Modulator DMWUFQ4 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMWUFQ4 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMWUIJE DI DMWUIJE DMWUIJE DN Tolmetin DMWUIJE TI TTVKILB DMWUIJE TN Prostaglandin G/H synthase 2 (COX-2) DMWUIJE MA Inhibitor DMWUIJE RN Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44. DMWUIJE RU https://pubmed.ncbi.nlm.nih.gov/19379806 DMWUMRL DI DMWUMRL DMWUMRL DN Interferon gamma-1b DMWUMRL TI TT13TL0 DMWUMRL TN Interferon gamma receptor (IFNGR2) DMWUMRL MA Binder DMWUMRL RN Genetic polymorphisms in the promoter of the interferon gamma receptor 1 gene are associated with atopic cataracts. Invest Ophthalmol Vis Sci. 2007 Feb;48(2):583-9. DMWUMRL RU https://pubmed.ncbi.nlm.nih.gov/17251453 DMWV2AG DI DMWV2AG DMWV2AG DN Ceftibuten DMWV2AG TI TTJP4SM DMWV2AG TN Bacterial Penicillin binding protein (Bact PBP) DMWV2AG MA Binder DMWV2AG RN Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91. DMWV2AG RU https://pubmed.ncbi.nlm.nih.gov/19532086 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ TI TT2A0DR DMWV3TZ TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMWV3TZ MA Inhibitor DMWV3TZ RN The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14. DMWV3TZ RU https://pubmed.ncbi.nlm.nih.gov/19543428 DMWV3TZ DI DMWV3TZ DMWV3TZ DN Finasteride DMWV3TZ TI TTT02K8 DMWV3TZ TN Steroid 5-alpha-reductase 2 (SRD5A2) DMWV3TZ MA Inhibitor DMWV3TZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV3TZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMWVCF3 DI DMWVCF3 DMWVCF3 DN Fusidic acid DMWVCF3 TI TT6HP1T DMWVCF3 TN Streptococcus Elongation factor G (Stre-coc fusA) DMWVCF3 MA Inhibitor DMWVCF3 RN Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob Agents Chemother. 2009 May;53(5):2059-65. DMWVCF3 RU https://pubmed.ncbi.nlm.nih.gov/19289529 DMWVIGP DI DMWVIGP DMWVIGP DN Digitoxin DMWVIGP TI TTQ38E9 DMWVIGP TN Sodium/potassium-transporting ATPase (SPT ATPase) DMWVIGP MA Inhibitor DMWVIGP RN Treatment of congestive heart failure--current status of use of digitoxin. Eur J Clin Invest. 2001;31 Suppl 2:10-7. DMWVIGP RU https://pubmed.ncbi.nlm.nih.gov/11525233 DMWX5CO DI DMWX5CO DMWX5CO DN Nicotine DMWX5CO TI TTJSZTB DMWX5CO TN Nicotinic acetylcholine receptor (nAChR) DMWX5CO MA Antagonist DMWX5CO RN Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91. DMWX5CO RU https://pubmed.ncbi.nlm.nih.gov/19481556 DMWX683 DI DMWX683 DMWX683 DN Mupirocin DMWX683 TI TT6KYJ5 DMWX683 TN Bacterial Isoleucyl-tRNA synthetase (Bact ileS) DMWX683 MA Modulator DMWX683 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWX683 RU https://www.fda.gov/ DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ TI TTQ13Z5 DMWXLYZ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMWXLYZ MA Antagonist DMWXLYZ RN M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/19416629 DMWXLYZ DI DMWXLYZ DMWXLYZ DN Darifenacin DMWXLYZ TI TTOXS3C DMWXLYZ TN Muscarinic acetylcholine receptor (CHRM) DMWXLYZ MA Antagonist DMWXLYZ RN Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res. 1997 Jan-May;17(1-3):177-84. DMWXLYZ RU https://pubmed.ncbi.nlm.nih.gov/9029489 DMX0E5B DI DMX0E5B DMX0E5B DN Bimatoprost DMX0E5B TI TT9B4N3 DMX0E5B TN Prostaglandin receptor (PTGR) DMX0E5B MA Modulator DMX0E5B RN Bimatoprost-induced calcium signaling in human T-cells does not involve prostanoid FP or TP receptors. Curr Eye Res. 2009 Mar;34(3):184-95. DMX0E5B RU https://pubmed.ncbi.nlm.nih.gov/19274525 DMX0EZJ DI DMX0EZJ DMX0EZJ DN Prothionamide DMX0EZJ TI TTVTX4N DMX0EZJ TN Bacterial Fatty acid synthetase I (Bact inhA) DMX0EZJ MA Inhibitor DMX0EZJ RN Mechanism of thioamide drug action against tuberculosis and leprosy. J Exp Med. 2007 Jan 22;204(1):73-8. DMX0EZJ RU https://pubmed.ncbi.nlm.nih.gov/17227913 DMX0K3Q DI DMX0K3Q DMX0K3Q DN Epinastine DMX0K3Q TI TTTIBOJ DMX0K3Q TN Histamine H1 receptor (H1R) DMX0K3Q MA Antagonist DMX0K3Q RN Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038. DMX0K3Q RU https://pubmed.ncbi.nlm.nih.gov/19381339 DMX2358 DI DMX2358 DMX2358 DN Adapalene DMX2358 TI TTOD7B3 DMX2358 TN Retinoic acid receptor (RAR) DMX2358 MA Binder DMX2358 RN A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4. DMX2358 RU https://pubmed.ncbi.nlm.nih.gov/18848668 DMX38HQ DI DMX38HQ DMX38HQ DN Apomorphine DMX38HQ TI TTEX248 DMX38HQ TN Dopamine D2 receptor (D2R) DMX38HQ MA Agonist DMX38HQ RN Dopamine D(2/3) receptor occupancy of apomorphine in the nonhuman primate brain--a comparative PET study with [11C]raclopride and [11C]MNPA. Synapse. 2009 May;63(5):378-89. DMX38HQ RU https://pubmed.ncbi.nlm.nih.gov/19173265 DMX4GND DI DMX4GND DMX4GND DN Meperidine DMX4GND TI TTQ8AFT DMX4GND TN Adrenergic receptor Alpha-2 (ADRA2) DMX4GND MA Agonist DMX4GND RN Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7. DMX4GND RU https://pubmed.ncbi.nlm.nih.gov/18234187 DMX6OE3 DI DMX6OE3 DMX6OE3 DN Dabrafenib DMX6OE3 TI TTWCGQT DMX6OE3 TN Serine/threonine-protein kinase B-raf (BRAF) DMX6OE3 MA Inhibitor DMX6OE3 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2011). DMX6OE3 RU http://www.gsk.com/ DMX6RTG DI DMX6RTG DMX6RTG DN Trospium DMX6RTG TI TTH18TF DMX6RTG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMX6RTG MA Antagonist DMX6RTG RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMX6RTG RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMX7A5V DI DMX7A5V DMX7A5V DN Faropenem DMX7A5V TI TT4ILYC DMX7A5V TN Bacterial Dihydropteroate synthetase (Bact folP) DMX7A5V MA Inhibitor DMX7A5V RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMX7A5V RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMX7LKS DI DMX7LKS DMX7LKS DN Isovanillin DMX7LKS TI TT3MOS2 DMX7LKS TN Aldehyde oxidase (AOX1) DMX7LKS MA Inhibitor DMX7LKS RN Contribution of aldehyde oxidizing enzymes on the metabolism of 3,4-dimethoxy-2-phenylethylamine to 3,4-dimethoxyphenylacetic acid by guinea pig li... Cell Physiol Biochem. 2006;17(1-2):47-56. DMX7LKS RU https://pubmed.ncbi.nlm.nih.gov/16543721 DMX7V28 DI DMX7V28 DMX7V28 DN Insulin-aspart DMX7V28 TI TTZOPHG DMX7V28 TN Insulin (INS) DMX7V28 MA Modulator DMX7V28 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMX7V28 RU https://www.fda.gov/ DMX8CVY DI DMX8CVY DMX8CVY DN Pivampicillin DMX8CVY TI TTJP4SM DMX8CVY TN Bacterial Penicillin binding protein (Bact PBP) DMX8CVY MA Binder DMX8CVY RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMX8CVY RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMX8M26 DI DMX8M26 DMX8M26 DN Hyaluronate sodium DMX8M26 TI TTG8DNU DMX8M26 TN Hyaluronic acid receptor (LYVE1) DMX8M26 MA Modulator DMX8M26 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4954). DMX8M26 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4954 DMX9K8F DI DMX9K8F DMX9K8F DN Carbachol DMX9K8F TI TTF4E0J DMX9K8F TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMX9K8F MA Antagonist DMX9K8F RN Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. DMX9K8F RU https://pubmed.ncbi.nlm.nih.gov/18633030 DMX9PIA DI DMX9PIA DMX9PIA DN Live attenuated influenza vaccine DMX9PIA TI TT3J5ZI DMX9PIA TN Cell mediated immunity response (CMIR) DMX9PIA RN Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc. 2008 Jan;83(1):77-84. DMX9PIA RU https://pubmed.ncbi.nlm.nih.gov/18174020 DMXBLMP DI DMXBLMP DMXBLMP DN Riociguat DMXBLMP TI TTWNFC2 DMXBLMP TN Soluble guanylyl cyclase (GUCY2D) DMXBLMP MA Modulator DMXBLMP RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMXBLMP RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMXBQAM DI DMXBQAM DMXBQAM DN Miglitol DMXBQAM TI TTXWASR DMXBQAM TN Intestinal maltase-glucoamylase (MGAM) DMXBQAM MA Inhibitor DMXBQAM RN Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29. DMXBQAM RU https://pubmed.ncbi.nlm.nih.gov/9951949 DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 TI TT3NKIB DMXC1K9 TN Pancreatic elastase 1 (CELA1) DMXC1K9 MA Inhibitor DMXC1K9 RN Elastase inhibitors. J Soc Biol. 2001;195(2):143-50. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/11723826 DMXC1K9 DI DMXC1K9 DMXC1K9 DN Alpha 1-PI DMXC1K9 TI TTN9D8E DMXC1K9 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMXC1K9 MA Antagonist DMXC1K9 RN NMDA receptor stimulation induces reversible fission of the neuronal endoplasmic reticulum. PLoS One. 2009;4(4):e5250. DMXC1K9 RU https://pubmed.ncbi.nlm.nih.gov/19381304 DMXCM7H DI DMXCM7H DMXCM7H DN Cerivastatin DMXCM7H TI TTPADOQ DMXCM7H TN HMG-CoA reductase (HMGCR) DMXCM7H MA Inhibitor DMXCM7H RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMXCM7H RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMXDZAQ DI DMXDZAQ DMXDZAQ DN Bepotastine DMXDZAQ TI TTTIBOJ DMXDZAQ TN Histamine H1 receptor (H1R) DMXDZAQ MA Antagonist DMXDZAQ RN Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008 Jul 22;118(4):363-72. DMXDZAQ RU https://pubmed.ncbi.nlm.nih.gov/18606918 DMXE76K DI DMXE76K DMXE76K DN Delamanid DMXE76K TI TTXT4D5 DMXE76K TN Bacterial Cell membrane (Bact CM) DMXE76K MA Inhibitor DMXE76K RN Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update. Eur Respir J. 2021 May 20;57(5):2002483. DMXE76K RU https://pubmed.ncbi.nlm.nih.gov/33243846 DMXEACF DI DMXEACF DMXEACF DN Idarucizumab DMXEACF TI TTFDXCO DMXEACF TN Dabigatran (Dabi) DMXEACF MA Binder DMXEACF RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2015 DMXEACF RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.pdf DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK TI TTVKILB DMXGDFK TN Prostaglandin G/H synthase 2 (COX-2) DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DMXGDFK DI DMXGDFK DMXGDFK DN Fenbufen DMXGDFK TI TT8NGED DMXGDFK TN Prostaglandin G/H synthase 1 (COX-1) DMXGDFK MA Inhibitor DMXGDFK RN Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804. DMXGDFK RU https://pubmed.ncbi.nlm.nih.gov/19457595 DMXGJEI DI DMXGJEI DMXGJEI DN Chlophedianol DMXGJEI TI TTTIBOJ DMXGJEI TN Histamine H1 receptor (H1R) DMXGJEI MA Antagonist DMXGJEI RN Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. J Chromatogr. 1988 Aug 19;430(1):31-41. DMXGJEI RU https://pubmed.ncbi.nlm.nih.gov/2905706 DMXGQYZ DI DMXGQYZ DMXGQYZ DN Fleroxacin DMXGQYZ TI TT0IHXV DMXGQYZ TN DNA topoisomerase II (TOP2) DMXGQYZ MA Inhibitor DMXGQYZ RN Fleroxacin overview. Chemotherapy. 1996 Mar;42 Suppl 1:1-9. DMXGQYZ RU https://pubmed.ncbi.nlm.nih.gov/8861529 DMXIQYS DI DMXIQYS DMXIQYS DN Iodipamide DMXIQYS TI TTFNGC9 DMXIQYS TN Serum albumin (ALB) DMXIQYS MA Binder DMXIQYS RN Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. DMXIQYS RU https://pubmed.ncbi.nlm.nih.gov/18436441 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TTK982E DMXJ7O8 TN Collagen (CO) DMXJ7O8 MA Activator DMXJ7O8 RN Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009 May;15(2):214-7. DMXJ7O8 RU https://pubmed.ncbi.nlm.nih.gov/19626722 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TTOP832 DMXJ7O8 TN Solute carrier family 23 member 2 (SLC23A2) DMXJ7O8 MA Modulator DMXJ7O8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1042). DMXJ7O8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1042 DMXJ7O8 DI DMXJ7O8 DMXJ7O8 DN Vitamin C DMXJ7O8 TI TT6XAGK DMXJ7O8 TN Solute carrier family 23 member 1 (SLC23A1) DMXJ7O8 MA Modulator DMXJ7O8 RN Decreased expression of the vitamin C transporter SVCT1 by ascorbic acid in a human intestinal epithelial cell line. Br J Nutr. 2002 Feb;87(2):97-100. DMXJ7O8 RU https://pubmed.ncbi.nlm.nih.gov/11895172 DMXKJ6C DI DMXKJ6C DMXKJ6C DN Torasemide DMXKJ6C TI TTS087L DMXKJ6C TN Solute carrier family 12 member 1 (SLC12A1) DMXKJ6C MA Blocker DMXKJ6C RN Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9. DMXKJ6C RU https://pubmed.ncbi.nlm.nih.gov/17460608 DMXKZT3 DI DMXKZT3 DMXKZT3 DN Buclizine DMXKZT3 TI TTTIBOJ DMXKZT3 TN Histamine H1 receptor (H1R) DMXKZT3 MA Antagonist DMXKZT3 RN Toxicologic and clinical appraisal of buclizine, a new antihistaminic compound. J Allergy. 1956 Jan;27(1):63-7. DMXKZT3 RU https://pubmed.ncbi.nlm.nih.gov/13294975 DMXLBCQ DI DMXLBCQ DMXLBCQ DN Sodium phenylbutyrate DMXLBCQ TI TTBH0VX DMXLBCQ TN Histone deacetylase (HDAC) DMXLBCQ MA Inhibitor DMXLBCQ RN Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8. DMXLBCQ RU https://pubmed.ncbi.nlm.nih.gov/20583972 DMXLBCQ DI DMXLBCQ DMXLBCQ DN Sodium phenylbutyrate DMXLBCQ TI TTFJ8Q1 DMXLBCQ TN Protein kinase C alpha (PRKCA) DMXLBCQ MA Modulator DMXLBCQ RN Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401. DMXLBCQ RU https://pubmed.ncbi.nlm.nih.gov/23686835 DMXLKHV DI DMXLKHV DMXLKHV DN Oxycodone DMXLKHV TI TT27RFC DMXLKHV TN Opioid receptor delta (OPRD1) DMXLKHV MA Agonist DMXLKHV RN Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307. DMXLKHV RU https://pubmed.ncbi.nlm.nih.gov/17525040 DMXLKHV DI DMXLKHV DMXLKHV DN Oxycodone DMXLKHV TI TTKWM86 DMXLKHV TN Opioid receptor mu (MOP) DMXLKHV MA Modulator DMXLKHV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMXLKHV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMXLSH3 DI DMXLSH3 DMXLSH3 DN Tapentadol hydrochloride DMXLSH3 TI TTKWM86 DMXLSH3 TN Opioid receptor mu (MOP) DMXLSH3 MA Modulator DMXLSH3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMXLSH3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMXLSH3 DI DMXLSH3 DMXLSH3 DN Tapentadol hydrochloride DMXLSH3 TI TTAWNKZ DMXLSH3 TN Norepinephrine transporter (NET) DMXLSH3 MA Modulator DMXLSH3 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMXLSH3 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMXLT8C DI DMXLT8C DMXLT8C DN Sulfisoxazole DMXLT8C TI TT4ILYC DMXLT8C TN Bacterial Dihydropteroate synthetase (Bact folP) DMXLT8C MA Inhibitor DMXLT8C RN Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63. DMXLT8C RU https://pubmed.ncbi.nlm.nih.gov/7486915 DMXLVDT DI DMXLVDT DMXLVDT DN Lasmiditan DMXLVDT TI TT0MI3F DMXLVDT TN 5-HT 1F receptor (HTR1F) DMXLVDT MA Agonist DMXLVDT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMXLVDT RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211280s000lbl.pdf DMXLYQF DI DMXLYQF DMXLYQF DN Belatacept DMXLYQF TI TTQ13FT DMXLYQF TN T-cell-specific surface glycoprotein CD28 (CD28) DMXLYQF MA Inhibitor DMXLYQF RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DMXLYQF RU https://pubmed.ncbi.nlm.nih.gov/19265486 DMXNR04 DI DMXNR04 DMXNR04 DN Unoprostone DMXNR04 TI TT9B4N3 DMXNR04 TN Prostaglandin receptor (PTGR) DMXNR04 MA Modulator DMXNR04 RN Comparison of the vasoactive effects of the docosanoid unoprostone and selected prostanoids on isolated perfused retinal arterioles. Invest Ophthalmol Vis Sci. 2001 Jun;42(7):1499-504. DMXNR04 RU https://pubmed.ncbi.nlm.nih.gov/11381053 DMXNZM4 DI DMXNZM4 DMXNZM4 DN Oxazepam DMXNZM4 TI TTPTXIN DMXNZM4 TN Translocator protein (TSPO) DMXNZM4 MA Agonist DMXNZM4 RN Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9. DMXNZM4 RU https://pubmed.ncbi.nlm.nih.gov/18692521 DMXOELT DI DMXOELT DMXOELT DN Midazolam DMXOELT TI TTPTXIN DMXOELT TN Translocator protein (TSPO) DMXOELT MA Modulator DMXOELT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMXOELT RU https://www.fda.gov/ DMXQKSL DI DMXQKSL DMXQKSL DN Dinoprost Tromethamine DMXQKSL TI TTOFYT1 DMXQKSL TN Prostacyclin receptor (PTGIR) DMXQKSL MA Antagonist DMXQKSL RN Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. DMXQKSL RU https://pubmed.ncbi.nlm.nih.gov/12488443 DMXQS7K DI DMXQS7K DMXQS7K DN Cenestin DMXQS7K TI TTZAYWL DMXQS7K TN Estrogen receptor (ESR) DMXQS7K MA Agonist DMXQS7K RN Estrogen replacement therapy and cardioprotection: mechanisms and controversies. Braz J Med Biol Res. 2002 Mar;35(3):271-6. DMXQS7K RU https://pubmed.ncbi.nlm.nih.gov/11887204 DMXSVGI DI DMXSVGI DMXSVGI DN Loncastuximab tesirine DMXSVGI TI TTW640A DMXSVGI TN B-lymphocyte surface antigen B4 (CD19) DMXSVGI MA Inhibitor DMXSVGI RN Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645. DMXSVGI RU https://pubmed.ncbi.nlm.nih.gov/33211842 DMXTCVF DI DMXTCVF DMXTCVF DN Radium-223-Dichloride DMXTCVF TI TTUTN1I DMXTCVF TN Human Deoxyribonucleic acid (hDNA) DMXTCVF MA Modulator DMXTCVF RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMXTCVF RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMXTMBJ DI DMXTMBJ DMXTMBJ DN Azelastine DMXTMBJ TI TTTIBOJ DMXTMBJ TN Histamine H1 receptor (H1R) DMXTMBJ MA Antagonist DMXTMBJ RN Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79. DMXTMBJ RU https://pubmed.ncbi.nlm.nih.gov/18446005 DMXVU6D DI DMXVU6D DMXVU6D DN Diphemanil Methylsulfate DMXVU6D TI TTZ9SOR DMXVU6D TN Muscarinic acetylcholine receptor M1 (CHRM1) DMXVU6D MA Modulator DMXVU6D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMXVU6D RU https://www.fda.gov/ DMXW92T DI DMXW92T DMXW92T DN Ixekizumab DMXW92T TI TTG0MT6 DMXW92T TN Interleukin-17 (IL17) DMXW92T MA Modulator DMXW92T RN Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5. DMXW92T RU https://pubmed.ncbi.nlm.nih.gov/23013312 DMXWOCP DI DMXWOCP DMXWOCP DN Ethotoin DMXWOCP TI TTZOVE0 DMXWOCP TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMXWOCP MA Blocker DMXWOCP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXWOCP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXY30O DI DMXY30O DMXY30O DN Dipyridamole DMXY30O TI TTJ0IQB DMXY30O TN Phosphodiesterase 5A (PDE5A) DMXY30O MA Modulator DMXY30O RN Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46. DMXY30O RU https://www.ncbi.nlm.nih.gov/pubmed/21649691 DMXYJ9C DI DMXYJ9C DMXYJ9C DN Busulfan DMXYJ9C TI TTUTN1I DMXYJ9C TN Human Deoxyribonucleic acid (hDNA) DMXYJ9C MA Modulator DMXYJ9C RN DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8. DMXYJ9C RU https://www.ncbi.nlm.nih.gov/pubmed/15132775 DMXYJOB DI DMXYJOB DMXYJOB DN Phentolamine DMXYJOB TI TTEX248 DMXYJOB TN Dopamine D2 receptor (D2R) DMXYJOB MA Antagonist DMXYJOB RN Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R330-6. DMXYJOB RU https://pubmed.ncbi.nlm.nih.gov/19474390 DMXYTN9 DI DMXYTN9 DMXYTN9 DN Phenmetrazine DMXYTN9 TI TTVBI8W DMXYTN9 TN Dopamine transporter (DAT) DMXYTN9 MA Inhibitor DMXYTN9 RN Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. DMXYTN9 RU https://pubmed.ncbi.nlm.nih.gov/12106802 DMXYTN9 DI DMXYTN9 DMXYTN9 DN Phenmetrazine DMXYTN9 TI TTAWNKZ DMXYTN9 TN Norepinephrine transporter (NET) DMXYTN9 MA Inhibitor DMXYTN9 RN Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7. DMXYTN9 RU https://pubmed.ncbi.nlm.nih.gov/12106802 DMXZ84M DI DMXZ84M DMXZ84M DN Malathion DMXZ84M TI TT1RS9F DMXZ84M TN Acetylcholinesterase (AChE) DMXZ84M MA Inhibitor DMXZ84M RN Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40. DMXZ84M RU https://pubmed.ncbi.nlm.nih.gov/19444631 DMXZOCG DI DMXZOCG DMXZOCG DN Phenobarbital DMXZOCG TI TTNJYV2 DMXZOCG TN Gamma-aminobutyric acid receptor (GAR) DMXZOCG MA Antagonist DMXZOCG RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMXZOCG RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMXZRW0 DI DMXZRW0 DMXZRW0 DN DTI-015 DMXZRW0 TI TTUTN1I DMXZRW0 TN Human Deoxyribonucleic acid (hDNA) DMXZRW0 MA Binder DMXZRW0 RN Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer. 1991;27(12):1658-62. DMXZRW0 RU https://pubmed.ncbi.nlm.nih.gov/1664221 DMY0EKH DI DMY0EKH DMY0EKH DN Nemonapride DMY0EKH TI TTEX248 DMY0EKH TN Dopamine D2 receptor (D2R) DMY0EKH MA Agonist DMY0EKH RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMY0EKH RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMY0KGJ DI DMY0KGJ DMY0KGJ DN Chlorprothixene DMY0KGJ TI TTEX248 DMY0KGJ TN Dopamine D2 receptor (D2R) DMY0KGJ MA Antagonist DMY0KGJ RN Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. DMY0KGJ RU https://pubmed.ncbi.nlm.nih.gov/19091563 DMY0M8J DI DMY0M8J DMY0M8J DN Sargramostim DMY0M8J TI TT6MP2Z DMY0M8J TN GMCSFR-alpha (CSF2RA) DMY0M8J MA Binder DMY0M8J RN Stem cell transplantation and hematopoietic growth factors. Curr Hematol Rep. 2002 Nov;1(2):103-9. DMY0M8J RU https://pubmed.ncbi.nlm.nih.gov/12901131 DMY18XK DI DMY18XK DMY18XK DN Penicillin G Sodium DMY18XK TI TTJP4SM DMY18XK TN Bacterial Penicillin binding protein (Bact PBP) DMY18XK MA Modulator DMY18XK RN Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model DMY18XK RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957969 DMY2KX9 DI DMY2KX9 DMY2KX9 DN Alendronate DMY2KX9 TI TTIKWV4 DMY2KX9 TN Geranyltranstransferase (FDPS) DMY2KX9 MA Modulator DMY2KX9 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMY2KX9 RU https://www.fda.gov/ DMY4D87 DI DMY4D87 DMY4D87 DN Quazepam DMY4D87 TI TTPTXIN DMY4D87 TN Translocator protein (TSPO) DMY4D87 MA Modulator DMY4D87 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMY4D87 RU https://www.fda.gov/ DMY4UMW DI DMY4UMW DMY4UMW DN Atovaquone DMY4UMW TI TT3PQ2Y DMY4UMW TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMY4UMW MA Inhibitor DMY4UMW RN Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42. DMY4UMW RU https://pubmed.ncbi.nlm.nih.gov/15044733 DMY5JEP DI DMY5JEP DMY5JEP DN Mezlocillin DMY5JEP TI TT85JMW DMY5JEP TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMY5JEP MA Binder DMY5JEP RN Bactericidal effect of piperacillin alone and combined. Presse Med. 1986 Dec 20;15(46):2297-302. DMY5JEP RU https://pubmed.ncbi.nlm.nih.gov/2949271 DMY60I8 DI DMY60I8 DMY60I8 DN Cefixime DMY60I8 TI TTJP4SM DMY60I8 TN Bacterial Penicillin binding protein (Bact PBP) DMY60I8 MA Binder DMY60I8 RN Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51. DMY60I8 RU https://pubmed.ncbi.nlm.nih.gov/19528266 DMY62FC DI DMY62FC DMY62FC DN Tezacaftor And Ivacaftor DMY62FC TI TTRLZHP DMY62FC TN cAMP-dependent chloride channel (CFTR) DMY62FC MA Binder DMY62FC RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMY62FC RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMY6T31 DI DMY6T31 DMY6T31 DN Isoflurane DMY6T31 TI TTAN6JD DMY6T31 TN Glutamate receptor AMPA (GRIA) DMY6T31 MA Agonist DMY6T31 RN Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5. DMY6T31 RU https://pubmed.ncbi.nlm.nih.gov/15680938 DMY7ESM DI DMY7ESM DMY7ESM DN Recombinant Factor IX DMY7ESM TI TTFEZ5Q DMY7ESM TN Coagulation factor IX (F9) DMY7ESM MA Modulator DMY7ESM RN BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B. Ther Adv Hematol. 2014 Oct;5(5):168-80. DMY7ESM RU https://pubmed.ncbi.nlm.nih.gov/25324957 DMY7PED DI DMY7PED DMY7PED DN Cisapride DMY7PED TI TT07C3Y DMY7PED TN 5-HT 4 receptor (HTR4) DMY7PED MA Agonist DMY7PED RN Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90. DMY7PED RU https://pubmed.ncbi.nlm.nih.gov/18948374 DMY85QW DI DMY85QW DMY85QW DN Bazedoxifene DMY85QW TI TTZAYWL DMY85QW TN Estrogen receptor (ESR) DMY85QW MA Modulator DMY85QW RN Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009 Nov-Dec;16(6):1109-15. DMY85QW RU https://pubmed.ncbi.nlm.nih.gov/19543129 DMY9BMK DI DMY9BMK DMY9BMK DN Rocuronium DMY9BMK TI TTF4E0J DMY9BMK TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMY9BMK MA Antagonist DMY9BMK RN Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. DMY9BMK RU https://pubmed.ncbi.nlm.nih.gov/19417616 DMY9TCW DI DMY9TCW DMY9TCW DN Bromazepam DMY9TCW TI TTAN6JD DMY9TCW TN Glutamate receptor AMPA (GRIA) DMY9TCW MA Binder DMY9TCW RN Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71. DMY9TCW RU https://pubmed.ncbi.nlm.nih.gov/19099296 DMYBV3G DI DMYBV3G DMYBV3G DN Paricalcitol DMYBV3G TI TTK59TV DMYBV3G TN Vitamin D3 receptor (VDR) DMYBV3G MA Agonist DMYBV3G RN New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor... Contrib Nephrol. 2009;163:219-226. DMYBV3G RU https://pubmed.ncbi.nlm.nih.gov/19494617 DMYCXKL DI DMYCXKL DMYCXKL DN Capmatinib DMYCXKL TI TTNDSF4 DMYCXKL TN Proto-oncogene c-Met (MET) DMYCXKL MA Modulator DMYCXKL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMYCXKL RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf DMYE5LJ DI DMYE5LJ DMYE5LJ DN DEOXYCYTIDINE DMYE5LJ TI TTP3QRF DMYE5LJ TN Thymidine kinase 1 (TK1) DMYE5LJ MA Inhibitor DMYE5LJ RN Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9. DMYE5LJ RU https://pubmed.ncbi.nlm.nih.gov/7097717 DMYFBMS DI DMYFBMS DMYFBMS DN 99mTc-fanolesomab DMYFBMS TI TTNV1KZ DMYFBMS TN Fucosyltransferase IV (CD15) DMYFBMS RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DMYFBMS RU https://pubmed.ncbi.nlm.nih.gov/15756752 DMYGHX5 DI DMYGHX5 DMYGHX5 DN Moxidectin DMYGHX5 TI TTSNVHO DMYGHX5 TN Onchocerca Glutamate-gated chloride channel (Onchoc GluCl) DMYGHX5 MA Modulator DMYGHX5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMYGHX5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMYGHX5 DI DMYGHX5 DMYGHX5 DN Moxidectin DMYGHX5 TI TTNJYV2 DMYGHX5 TN Gamma-aminobutyric acid receptor (GAR) DMYGHX5 MA Modulator DMYGHX5 RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMYGHX5 RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TTGJCWZ DMYGJQO TN Fms-like tyrosine kinase 3 (FLT-3) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TT3PJMV DMYGJQO TN Tyrosine-protein kinase ABL1 (ABL) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TTX41N9 DMYGJQO TN Tyrosine-protein kinase Kit (KIT) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYGJQO DI DMYGJQO DMYGJQO DN Ponatinib DMYGJQO TI TT4DXQT DMYGJQO TN Proto-oncogene c-Ret (RET) DMYGJQO MA Modulator DMYGJQO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYGJQO RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYHBKN DI DMYHBKN DMYHBKN DN Exenatide DMYHBKN TI TTVIMDE DMYHBKN TN Glucagon-like peptide 1 receptor (GLP1R) DMYHBKN MA Binder DMYHBKN RN Improved glycemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes TechnolTher. 2009 Jun;11(6):353-9. DMYHBKN RU https://pubmed.ncbi.nlm.nih.gov/19459763 DMYHDCA DI DMYHDCA DMYHDCA DN Pranlukast DMYHDCA TI TTGKOY9 DMYHDCA TN Leukotriene CysLT1 receptor (CYSLTR1) DMYHDCA MA Antagonist DMYHDCA RN Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting. J Investig Allergol Clin Immunol. 2009;19(3):195-203. DMYHDCA RU https://pubmed.ncbi.nlm.nih.gov/19610262 DMYHN59 DI DMYHN59 DMYHN59 DN Axicabtagene ciloleucel DMYHN59 TI TTW640A DMYHN59 TN B-lymphocyte surface antigen B4 (CD19) DMYHN59 MA CAR-T-Cell-Therapy DMYHN59 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services DMYHN59 RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel DMYILBE DI DMYILBE DMYILBE DN Modafinil DMYILBE TI TTVBI8W DMYILBE TN Dopamine transporter (DAT) DMYILBE MA Modulator DMYILBE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYILBE RU https://www.fda.gov/ DMYK490 DI DMYK490 DMYK490 DN Nepafenac DMYK490 TI TTK0943 DMYK490 TN Prostaglandin G/H synthase (COX) DMYK490 MA Inhibitor DMYK490 RN Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15. DMYK490 RU https://pubmed.ncbi.nlm.nih.gov/12506103 DMYKUNR DI DMYKUNR DMYKUNR DN Moxalactam Disodium DMYKUNR TI TT85JMW DMYKUNR TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMYKUNR MA Modulator DMYKUNR RN Moxalactam (6059-S), a new 1-oxa-beta-lactam: binding affinity for penicillin-binding proteins of Escherichia coli K-12. DMYKUNR RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC283783 DMYLMU0 DI DMYLMU0 DMYLMU0 DN Isosorbide mononitrate DMYLMU0 TI TT6HPVC DMYLMU0 TN Guanylate cyclase (GC) DMYLMU0 MA Stimulator DMYLMU0 RN Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201. DMYLMU0 RU https://pubmed.ncbi.nlm.nih.gov/19618122 DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR TI TTIU7X1 DMYLOVR TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMYLOVR MA Modulator DMYLOVR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYLOVR RU https://www.fda.gov/ DMYLOVR DI DMYLOVR DMYLOVR DN Aciclovir DMYLOVR TI TTHPJTK DMYLOVR TN Varicella-zoster virus DNA polymerase (VZV ORF28) DMYLOVR MA Modulator DMYLOVR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYLOVR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYM974 DI DMYM974 DMYM974 DN Arformoterol DMYM974 TI TT2CJVK DMYM974 TN Adrenergic receptor beta-2 (ADRB2) DMYM974 MA Agonist DMYM974 RN Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9. DMYM974 RU https://pubmed.ncbi.nlm.nih.gov/19271027 DMYN59P DI DMYN59P DMYN59P DN Vildagliptin DMYN59P TI TTDIGC1 DMYN59P TN Dipeptidyl peptidase 4 (DPP-4) DMYN59P MA Inhibitor DMYN59P RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMYN59P RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMYN8MA DI DMYN8MA DMYN8MA DN Tianeptine DMYN8MA TI TT3ROYC DMYN8MA TN Serotonin transporter (SERT) DMYN8MA MA Inhibitor DMYN8MA RN Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. DMYN8MA RU https://pubmed.ncbi.nlm.nih.gov/17109609 DMYNMDP DI DMYNMDP DMYNMDP DN Tocainide DMYNMDP TI TT05DLS DMYNMDP TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMYNMDP MA Modulator DMYNMDP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYNMDP RU https://www.fda.gov/ DMYOAKS DI DMYOAKS DMYOAKS DN Teduglutide DMYOAKS TI TT1YWO5 DMYOAKS TN Glucagon-like peptide 2 receptor (GLP2R) DMYOAKS MA Modulator DMYOAKS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYOAKS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYP4XC DI DMYP4XC DMYP4XC DN Norgestimate DMYP4XC TI TTUV8G9 DMYP4XC TN Progesterone receptor (PGR) DMYP4XC MA Agonist DMYP4XC RN Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7. DMYP4XC RU https://pubmed.ncbi.nlm.nih.gov/19434887 DMYQCWT DI DMYQCWT DMYQCWT DN Tecartus DMYQCWT TI TTW640A DMYQCWT TN B-lymphocyte surface antigen B4 (CD19) DMYQCWT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. DMYQCWT RU https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel DMYQDBO DI DMYQDBO DMYQDBO DN Ademetionine DMYQDBO TI TTX2N1T DMYQDBO TN Transferase unspecific (TF) DMYQDBO MA Modulator DMYQDBO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2013 DMYQDBO RU https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205123Orig1s000MedR.pdf DMYQVGN DI DMYQVGN DMYQVGN DN Premarin/Trimegestone DMYQVGN TI TTZAYWL DMYQVGN TN Estrogen receptor (ESR) DMYQVGN MA Modulator DMYQVGN RN The Haunting of Medical Journals: How Ghostwriting Sold RT PLoS Med. 2010 September; 7(9): e1000335. DMYQVGN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2935455/ DMYRBO1 DI DMYRBO1 DMYRBO1 DN Umbralisib DMYRBO1 TI TTA8PLI DMYRBO1 TN Casein kinase I epsilon (CSNK1E) DMYRBO1 MA Inhibitor DMYRBO1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMYRBO1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf DMYRBO1 DI DMYRBO1 DMYRBO1 DN Umbralisib DMYRBO1 TI TTGBPJE DMYRBO1 TN PI3-kinase delta (PIK3CD) DMYRBO1 MA Inhibitor DMYRBO1 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 DMYRBO1 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213176s000lbl.pdf DMYRX8B DI DMYRX8B DMYRX8B DN Ardeparin DMYRX8B TI TT4QPUL DMYRX8B TN Antithrombin-III (ATIII) DMYRX8B MA Modulator DMYRX8B RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYRX8B RU https://www.fda.gov/ DMYSCIL DI DMYSCIL DMYSCIL DN Prolastin DMYSCIL TI TTZBFA0 DMYSCIL TN Protease unspecific (PRO) DMYSCIL MA Inhibitor DMYSCIL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYSCIL RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYT0OG DI DMYT0OG DMYT0OG DN Vigabatrin DMYT0OG TI TTT2LD9 DMYT0OG TN GABA transaminase (ABAT) DMYT0OG MA Inhibitor DMYT0OG RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMYT0OG RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMYT2FP DI DMYT2FP DMYT2FP DN Cellulose Sodium Phosphate DMYT2FP TI TT8X5NO DMYT2FP TN Calcium (Ca) DMYT2FP MA Modulator DMYT2FP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYT2FP RU https://www.fda.gov/ DMYTE6L DI DMYTE6L DMYTE6L DN Enoxacin DMYTE6L TI TT0IHXV DMYTE6L TN DNA topoisomerase II (TOP2) DMYTE6L MA Inhibitor DMYTE6L RN Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121. DMYTE6L RU https://pubmed.ncbi.nlm.nih.gov/3282749 DMYTXVR DI DMYTXVR DMYTXVR DN Cefoxitin DMYTXVR TI TTJP4SM DMYTXVR TN Bacterial Penicillin binding protein (Bact PBP) DMYTXVR MA Binder DMYTXVR RN Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66. DMYTXVR RU https://pubmed.ncbi.nlm.nih.gov/18725435 DMYURI6 DI DMYURI6 DMYURI6 DN Raltegravir DMYURI6 TI TT5FH9Y DMYURI6 TN Human immunodeficiency virus Integrase (HIV IN) DMYURI6 MA Modulator DMYURI6 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMYURI6 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMYVP5G DI DMYVP5G DMYVP5G DN Insulin recombinant DMYVP5G TI TTCBFJO DMYVP5G TN Insulin receptor (INSR) DMYVP5G MA Binder DMYVP5G RN Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51. DMYVP5G RU https://pubmed.ncbi.nlm.nih.gov/12509758 DMYWQ0O DI DMYWQ0O DMYWQ0O DN Tetrabenazine DMYWQ0O TI TTNZRI3 DMYWQ0O TN Synaptic vesicle amine transporter (SLC18A2) DMYWQ0O MA Blocker DMYWQ0O RN Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8. DMYWQ0O RU https://pubmed.ncbi.nlm.nih.gov/19571144 DMYX7NI DI DMYX7NI DMYX7NI DN Acetohydroxamic Acid DMYX7NI TI TTAS2UO DMYX7NI TN Bacterial Urease (Bact ureC) DMYX7NI MA Inhibitor DMYX7NI RN Enzymatic, immunological and phylogenetic characterization of Brucella suis urease. BMC Microbiol. 2008 Jul 19;8:121. DMYX7NI RU https://pubmed.ncbi.nlm.nih.gov/18638408 DMYXBV3 DI DMYXBV3 DMYXBV3 DN Dulaglutide DMYXBV3 TI TTVIMDE DMYXBV3 TN Glucagon-like peptide 1 receptor (GLP1R) DMYXBV3 MA Agonist DMYXBV3 RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMYXBV3 RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 TI TTKWM86 DMYZ0P1 TN Opioid receptor mu (MOP) DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ0P1 DI DMYZ0P1 DMYZ0P1 DN Eluxadoline DMYZ0P1 TI TT27RFC DMYZ0P1 TN Opioid receptor delta (OPRD1) DMYZ0P1 MA Modulator DMYZ0P1 RN Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56. DMYZ0P1 RU https://www.ncbi.nlm.nih.gov/pubmed/25261794 DMYZ57N DI DMYZ57N DMYZ57N DN Albendazole DMYZ57N TI TTYFKSZ DMYZ57N TN Tubulin beta (TUBB) DMYZ57N MA Binder DMYZ57N RN Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7. DMYZ57N RU https://pubmed.ncbi.nlm.nih.gov/19336257 DMYZFXN DI DMYZFXN DMYZFXN DN Lornoxicam DMYZFXN TI TTK0943 DMYZFXN TN Prostaglandin G/H synthase (COX) DMYZFXN MA Modulator DMYZFXN RN The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79. DMYZFXN RU https://pubmed.ncbi.nlm.nih.gov/10450786 DMYZITL DI DMYZITL DMYZITL DN Cephaloglycin DMYZITL TI TTJP4SM DMYZITL TN Bacterial Penicillin binding protein (Bact PBP) DMYZITL MA Modulator DMYZITL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMYZITL RU https://www.fda.gov/ DMZ0P95 DI DMZ0P95 DMZ0P95 DN Ga-68-DOTATOC DMZ0P95 TI TTZ6T9E DMZ0P95 TN Somatostatin receptor type 2 (SSTR2) DMZ0P95 MA Binder DMZ0P95 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 DMZ0P95 RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210828s000lbl.pdf DMZ0Q1G DI DMZ0Q1G DMZ0Q1G DN Permethrin DMZ0Q1G TI TTRK8B9 DMZ0Q1G TN Sodium channel unspecific (NaC) DMZ0Q1G MA Blocker DMZ0Q1G RN In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8. DMZ0Q1G RU https://pubmed.ncbi.nlm.nih.gov/14651650 DMZ1WXJ DI DMZ1WXJ DMZ1WXJ DN Vitamin B1 DMZ1WXJ TI TT8RHGB DMZ1WXJ TN Bacterial Pyruvate decarboxylase (Bact aceE) DMZ1WXJ MA Cofactor DMZ1WXJ RN Vitamins and cofactors: highlights of ESBOC 2009. Nat Chem Biol. 2009 Aug;5(8):530-3. DMZ1WXJ RU https://pubmed.ncbi.nlm.nih.gov/19620989 DMZ2WL4 DI DMZ2WL4 DMZ2WL4 DN Cefpiramide DMZ2WL4 TI TTJP4SM DMZ2WL4 TN Bacterial Penicillin binding protein (Bact PBP) DMZ2WL4 MA Binder DMZ2WL4 RN Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. DMZ2WL4 RU https://pubmed.ncbi.nlm.nih.gov/17016423 DMZ30JT DI DMZ30JT DMZ30JT DN Oxantel pamoate DMZ30JT TI TTHDSE2 DMZ30JT TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMZ30JT MA Inhibitor DMZ30JT RN Fumarate reductase is essential for Helicobacter pylori colonization of the mouse stomach. Microb Pathog. 2000 Nov;29(5):279-87. DMZ30JT RU https://pubmed.ncbi.nlm.nih.gov/11031122 DMZ36RN DI DMZ36RN DMZ36RN DN Mazindol DMZ36RN TI TTAWNKZ DMZ36RN TN Norepinephrine transporter (NET) DMZ36RN MA Modulator DMZ36RN RN Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16. DMZ36RN RU https://pubmed.ncbi.nlm.nih.gov/15300361 DMZ4P3A DI DMZ4P3A DMZ4P3A DN Telithromycin DMZ4P3A TI TTUWYEA DMZ4P3A TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMZ4P3A MA Binder DMZ4P3A RN An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47. DMZ4P3A RU https://pubmed.ncbi.nlm.nih.gov/15386111 DMZ5RGV DI DMZ5RGV DMZ5RGV DN Naproxen DMZ5RGV TI TTVKILB DMZ5RGV TN Prostaglandin G/H synthase 2 (COX-2) DMZ5RGV MA Inhibitor DMZ5RGV RN Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20. DMZ5RGV RU https://pubmed.ncbi.nlm.nih.gov/11028250 DMZ5RGV DI DMZ5RGV DMZ5RGV DN Naproxen DMZ5RGV TI TT8NGED DMZ5RGV TN Prostaglandin G/H synthase 1 (COX-1) DMZ5RGV MA Inhibitor DMZ5RGV RN Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20. DMZ5RGV RU https://pubmed.ncbi.nlm.nih.gov/11028250 DMZ65K8 DI DMZ65K8 DMZ65K8 DN Pilsicainide DMZ65K8 TI TTRK8B9 DMZ65K8 TN Sodium channel unspecific (NaC) DMZ65K8 MA Modulator DMZ65K8 RN A sodium channel blocker, pilsicainide, produces atrial post-repolarization refractoriness through the reduction of sodium channel availability. Tohoku J Exp Med. 2011;225(1):35-42. DMZ65K8 RU https://pubmed.ncbi.nlm.nih.gov/21869589 DMZ6VEY DI DMZ6VEY DMZ6VEY DN Sulfacetamide DMZ6VEY TI TT915ZD DMZ6VEY TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMZ6VEY MA Inhibitor DMZ6VEY RN Antifungal Activity of Ag(I) and Zn(II) Complexes of Sulfacetamide Derivatives. Met Based Drugs. 2000;7(1):49-54. DMZ6VEY RU https://pubmed.ncbi.nlm.nih.gov/18475922 DMZ7XNQ DI DMZ7XNQ DMZ7XNQ DN Tacrolimus DMZ7XNQ TI TTA4LDE DMZ7XNQ TN Calcineurin (PPP3CA) DMZ7XNQ MA Inhibitor DMZ7XNQ RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMZ7XNQ RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMZ80SB DI DMZ80SB DMZ80SB DN Azatadine DMZ80SB TI TTTIBOJ DMZ80SB TN Histamine H1 receptor (H1R) DMZ80SB MA Antagonist DMZ80SB RN Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis. Asian Pac J Allergy Immunol. 1990 Dec;8(2):103-7. DMZ80SB RU https://pubmed.ncbi.nlm.nih.gov/1982614 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTPFZJ1 DMZ905C TN Vasopressin V1 receptor (V1R) DMZ905C MA Antagonist DMZ905C RN Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/1337114 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTL9MHW DMZ905C TN Vasopressin V1b receptor (V1BR) DMZ905C MA Inhibitor DMZ905C RN New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/7241506 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TTK8R02 DMZ905C TN Vasopressin V2 receptor (V2R) DMZ905C MA Inhibitor DMZ905C RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/12436936 DMZ905C DI DMZ905C DMZ905C DN Mozavaptan DMZ905C TI TT4TFGN DMZ905C TN Vasopressin V1a receptor (V1AR) DMZ905C MA Inhibitor DMZ905C RN Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65. DMZ905C RU https://pubmed.ncbi.nlm.nih.gov/10376439 DMZ9BMU DI DMZ9BMU DMZ9BMU DN Colistimethate DMZ9BMU TI TT4ILYC DMZ9BMU TN Bacterial Dihydropteroate synthetase (Bact folP) DMZ9BMU MA Binder DMZ9BMU RN Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7. DMZ9BMU RU https://pubmed.ncbi.nlm.nih.gov/10492501 DMZ9FAO DI DMZ9FAO DMZ9FAO DN Somatomedin-1 DMZ9FAO TI TTHRID2 DMZ9FAO TN Insulin-like growth factor I receptor (IGF1R) DMZ9FAO MA Modulator DMZ9FAO RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DMZ9FAO RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DMZA017 DI DMZA017 DMZA017 DN Tetracycline DMZA017 TI TTQ8KVI DMZA017 TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMZA017 MA Binder DMZA017 RN The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. DMZA017 RU https://pubmed.ncbi.nlm.nih.gov/14723559 DMZA5PQ DI DMZA5PQ DMZA5PQ DN Glipizide DMZA5PQ TI TTG140O DMZA5PQ TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMZA5PQ MA Blocker DMZA5PQ RN Triggering and amplification of insulin secretion by dimethyl alpha-ketoglutarate, a membrane permeable alpha-ketoglutarate analogue. Eur J Pharmacol. 2009 Apr 1;607(1-3):41-6. DMZA5PQ RU https://pubmed.ncbi.nlm.nih.gov/19233162 DMZAL7W DI DMZAL7W DMZAL7W DN Promazine DMZAL7W TI TTH18TF DMZAL7W TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZAL7W MA Binder DMZAL7W RN Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. DMZAL7W RU https://pubmed.ncbi.nlm.nih.gov/2899826 DMZBU15 DI DMZBU15 DMZBU15 DN Tripelennamine DMZBU15 TI TTTIBOJ DMZBU15 TN Histamine H1 receptor (H1R) DMZBU15 MA Antagonist DMZBU15 RN Involvement of histamine H1 and H2 receptors in the regulation of STAT-1 phosphorylation: inverse agonism exhibited by the receptor antagonists. Int Immunopharmacol. 2005 Jul;5(7-8):1299-309. DMZBU15 RU https://pubmed.ncbi.nlm.nih.gov/15914334 DMZC1HS DI DMZC1HS DMZC1HS DN Ivacaftor DMZC1HS TI TTRLZHP DMZC1HS TN cAMP-dependent chloride channel (CFTR) DMZC1HS MA Modulator DMZC1HS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMZC1HS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMZC6GT DI DMZC6GT DMZC6GT DN Elliptinium acetate DMZC6GT TI TTABD5E DMZC6GT TN DNA replication (DNA repli) DMZC6GT MA Modulator DMZC6GT RN Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64. DMZC6GT RU https://pubmed.ncbi.nlm.nih.gov/91123 DMZD5QR DI DMZD5QR DMZD5QR DN Cytarabine DMZD5QR TI TTIU7X1 DMZD5QR TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMZD5QR MA Inhibitor DMZD5QR RN Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72. DMZD5QR RU https://pubmed.ncbi.nlm.nih.gov/19372559 DMZDCS0 DI DMZDCS0 DMZDCS0 DN Bezafibrate DMZDCS0 TI TTJ584C DMZDCS0 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMZDCS0 MA Agonist DMZDCS0 RN Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92. DMZDCS0 RU https://pubmed.ncbi.nlm.nih.gov/19124612 DMZDF0B DI DMZDF0B DMZDF0B DN Aceclofenac DMZDF0B TI TTK0943 DMZDF0B TN Prostaglandin G/H synthase (COX) DMZDF0B MA Modulator DMZDF0B RN Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35. DMZDF0B RU https://pubmed.ncbi.nlm.nih.gov/12966366 DMZDN4W DI DMZDN4W DMZDN4W DN L-alanine DMZDN4W TI TTT2LD9 DMZDN4W TN GABA transaminase (ABAT) DMZDN4W MA Inhibitor DMZDN4W RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMZDN4W RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG TI TTN6J5F DMZEONG TN Bacterial DNA gyrase (Bact gyrase) DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMZEONG DI DMZEONG DMZEONG DN Finafloxacin DMZEONG TI TTIXTO3 DMZEONG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMZEONG MA Modulator DMZEONG RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMZEONG RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMZEPFJ DI DMZEPFJ DMZEPFJ DN Demeclocycline DMZEPFJ TI TTQ8KVI DMZEPFJ TN Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) DMZEPFJ MA Binder DMZEPFJ RN Detection of tetracycline resistance genes by PCR methods. Methods Mol Biol. 2004;268:3-13. DMZEPFJ RU https://pubmed.ncbi.nlm.nih.gov/15156014 DMZFICR DI DMZFICR DMZFICR DN Bevantolol DMZFICR TI TTEX248 DMZFICR TN Dopamine D2 receptor (D2R) DMZFICR MA Antagonist DMZFICR RN Determination of bevantolol in human plasma by high performance liquid chromatography using solid phase extraction technique. Arch Pharm Res. 2007 Jul;30(7):890-7. DMZFICR RU https://pubmed.ncbi.nlm.nih.gov/17703743 DMZG5WL DI DMZG5WL DMZG5WL DN Emapalumab DMZG5WL TI TT93WF5 DMZG5WL TN Interferon-gamma (IFNG) DMZG5WL MA Modulator DMZG5WL RN 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. DMZG5WL RU https://pubmed.ncbi.nlm.nih.gov/30710142 DMZGXUM DI DMZGXUM DMZGXUM DN Estazolam DMZGXUM TI TTPTXIN DMZGXUM TN Translocator protein (TSPO) DMZGXUM MA Agonist DMZGXUM RN Design and synthesis of new 2-substituted-5-(2-benzylthiophenyl)-1,3,4-oxadiazoles as benzodiazepine receptor agonists. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3126-9. DMZGXUM RU https://pubmed.ncbi.nlm.nih.gov/15876530 DMZHPNE DI DMZHPNE DMZHPNE DN Cimetropium bromide DMZHPNE TI TTH18TF DMZHPNE TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZHPNE MA Modulator DMZHPNE RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZHPNE RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMZHUO5 DI DMZHUO5 DMZHUO5 DN Phenylephrine DMZHUO5 TI TTEX248 DMZHUO5 TN Dopamine D2 receptor (D2R) DMZHUO5 MA Agonist DMZHUO5 RN MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res. 2010 Apr;159(2):755-64. DMZHUO5 RU https://pubmed.ncbi.nlm.nih.gov/19482300 DMZI2UF DI DMZI2UF DMZI2UF DN Sulphadoxine DMZI2UF TI TT4ILYC DMZI2UF TN Bacterial Dihydropteroate synthetase (Bact folP) DMZI2UF MA Binder DMZI2UF RN The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71. DMZI2UF RU https://pubmed.ncbi.nlm.nih.gov/18220771 DMZI2UF DI DMZI2UF DMZI2UF DN Sulphadoxine DMZI2UF TI TTGP7BY DMZI2UF TN Monoamine oxidase type B (MAO-B) DMZI2UF MA Inhibitor DMZI2UF RN Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82. DMZI2UF RU https://pubmed.ncbi.nlm.nih.gov/11928718 DMZI3WO DI DMZI3WO DMZI3WO DN Etomidate DMZI3WO TI TTEX6LM DMZI3WO TN GABA(A) receptor gamma-3 (GABRG3) DMZI3WO MA Modulator DMZI3WO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZI3WO RU https://www.fda.gov/ DMZJYBW DI DMZJYBW DMZJYBW DN Metocurine Iodide DMZJYBW TI TTL1ATN DMZJYBW TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMZJYBW MA Modulator DMZJYBW RN NMR study of general anesthetic interaction with nAChR beta2 subunit.Biophys J.2008 Mar 1;94(5):1681-8. DMZJYBW RU https://www.ncbi.nlm.nih.gov/pubmed/17993502 DMZKXB7 DI DMZKXB7 DMZKXB7 DN Butylscopolamine DMZKXB7 TI TTH18TF DMZKXB7 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZKXB7 MA Modulator DMZKXB7 RN Comparison of pharmacological effects of L- and DL-n-butyl-scopolamine in rat uterus. Yao Xue Xue Bao. 1994;29(1):24-7. DMZKXB7 RU https://pubmed.ncbi.nlm.nih.gov/8036897 DMZKYIV DI DMZKYIV DMZKYIV DN Amsacrine DMZKYIV TI TT0IHXV DMZKYIV TN DNA topoisomerase II (TOP2) DMZKYIV MA Inhibitor DMZKYIV RN Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21. DMZKYIV RU https://pubmed.ncbi.nlm.nih.gov/11716434 DMZL3IV DI DMZL3IV DMZL3IV DN Alemtuzumab DMZL3IV TI TTQT5S9 DMZL3IV TN Cambridge pathology 1 antigen (CD52) DMZL3IV RN Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med. 2009 Jun 19;7:49. DMZL3IV RU https://pubmed.ncbi.nlm.nih.gov/19545375 DMZLBUO DI DMZLBUO DMZLBUO DN Lucanthone DMZLBUO TI TT0IHXV DMZLBUO TN DNA topoisomerase II (TOP2) DMZLBUO MA Inhibitor DMZLBUO RN Clonogenicity of human leukemic cells protected from cell-lethal agents by heat shock protein 70. Cell Stress Chaperones. 2005 Spring;10(1):37-45. DMZLBUO RU https://pubmed.ncbi.nlm.nih.gov/15832946 DMZLGRB DI DMZLGRB DMZLGRB DN Pimecrolimus DMZLGRB TI TTA4LDE DMZLGRB TN Calcineurin (PPP3CA) DMZLGRB MA Inhibitor DMZLGRB RN Treatment of chronic blepharokeratoconjunctivitis with local calcineurin inhibitors. Ophthalmologe. 2009 Jul;106(7):635-8. DMZLGRB RU https://pubmed.ncbi.nlm.nih.gov/19499228 DMZLHKJ DI DMZLHKJ DMZLHKJ DN Adenine DMZLHKJ TI TTUTN1I DMZLHKJ TN Human Deoxyribonucleic acid (hDNA) DMZLHKJ MA Binder DMZLHKJ RN Escherichia coli DNA adenine methyltransferase: intrasite processivity and substrate-induced dimerization and activation. Biochemistry. 2009 Aug 11;48(31):7399-410. DMZLHKJ RU https://pubmed.ncbi.nlm.nih.gov/19580332 DMZM84R DI DMZM84R DMZM84R DN Ethynodiol diacetate DMZM84R TI TTUV8G9 DMZM84R TN Progesterone receptor (PGR) DMZM84R MA Binder DMZM84R RN Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84. DMZM84R RU https://pubmed.ncbi.nlm.nih.gov/858280 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT TI TT06AWU DMZMSCT TN Phosphodiesterase 3A (PDE3A) DMZMSCT MA Inhibitor DMZMSCT RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DMZMSCT RU https://pubmed.ncbi.nlm.nih.gov/2985781 DMZMSCT DI DMZMSCT DMZMSCT DN Cilostazol DMZMSCT TI TTZCG4L DMZMSCT TN Phosphodiesterase 3 (PDE3) DMZMSCT MA Modulator DMZMSCT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZMSCT RU https://www.fda.gov/ DMZMSPF DI DMZMSPF DMZMSPF DN Bicalutamide DMZMSPF TI TTS64P2 DMZMSPF TN Androgen receptor (AR) DMZMSPF MA Antagonist DMZMSPF RN Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May;121(1):1-11. DMZMSPF RU https://pubmed.ncbi.nlm.nih.gov/19533338 DMZOLBI DI DMZOLBI DMZOLBI DN Carbamazepine DMZOLBI TI TTRK8B9 DMZOLBI TN Sodium channel unspecific (NaC) DMZOLBI MA Modulator DMZOLBI RN Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7. DMZOLBI RU https://pubmed.ncbi.nlm.nih.gov/24319110 DMZPHIK DI DMZPHIK DMZPHIK DN Beclomethasone DMZPHIK TI TTP3UTW DMZPHIK TN Steroid hormone receptor ERR (ESRR) DMZPHIK MA Modulator DMZPHIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMZPHIK RU https://www.fda.gov/ DMZPXRC DI DMZPXRC DMZPXRC DN Carzinophilin DMZPXRC TI TTY1GPO DMZPXRC TN Human Deoxyribonucleic acid major groove (hDNA maj) DMZPXRC MA Modulator DMZPXRC RN Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. DMZPXRC RU https://pubmed.ncbi.nlm.nih.gov/17309302 DMZQOUX DI DMZQOUX DMZQOUX DN Trastuzumab DMZQOUX TI TT6EO5L DMZQOUX TN Erbb2 tyrosine kinase receptor (HER2) DMZQOUX RN Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10. DMZQOUX RU https://pubmed.ncbi.nlm.nih.gov/15179190 DMZR15V DI DMZR15V DMZR15V DN Selpercatinib DMZR15V TI TT4DXQT DMZR15V TN Proto-oncogene c-Ret (RET) DMZR15V MA Inhibitor DMZR15V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020 DMZR15V RU https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf DMZR26N DI DMZR26N DMZR26N DN Ciprofloxacin+dexamethasone DMZR26N TI TT0IHXV DMZR26N TN DNA topoisomerase II (TOP2) DMZR26N MA Binder DMZR26N RN Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. DMZR26N RU https://pubmed.ncbi.nlm.nih.gov/16634700 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTRK8B9 DMZREFQ TN Sodium channel unspecific (NaC) DMZREFQ MA Blocker DMZREFQ RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTN9VTF DMZREFQ TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZREFQ DI DMZREFQ DMZREFQ DN Eslicarbazepine DMZREFQ TI TTIG65Q DMZREFQ TN Voltage-gated sodium channel (Nav) DMZREFQ MA Inhibitor DMZREFQ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZREFQ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZSDGX DI DMZSDGX DMZSDGX DN Dicyclomine DMZSDGX TI TTZ9SOR DMZSDGX TN Muscarinic acetylcholine receptor M1 (CHRM1) DMZSDGX MA Antagonist DMZSDGX RN [Characterization of muscarinic receptors in undifferentiated thyroid cells in Fisher rats]. Endocrinol Nutr. 2009 Mar;56(3):106-11. DMZSDGX RU https://pubmed.ncbi.nlm.nih.gov/19627722 DMZSWQC DI DMZSWQC DMZSWQC DN Flunisolide DMZSWQC TI TTYRL6O DMZSWQC TN Glucocorticoid receptor (NR3C1) DMZSWQC MA Agonist DMZSWQC RN The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticost... J Allergy Clin Immunol. 2009 Jun;123(6):1376-83.e7. DMZSWQC RU https://pubmed.ncbi.nlm.nih.gov/19254810 DMZT2P0 DI DMZT2P0 DMZT2P0 DN Abobotulinum toxin A DMZT2P0 TI TTZJD1B DMZT2P0 TN Acetylcholine release (Ach rele) DMZT2P0 MA Modulator DMZT2P0 RN Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. DMZT2P0 RU https://pubmed.ncbi.nlm.nih.gov/20118952 DMZT4N7 DI DMZT4N7 DMZT4N7 DN Leucovorin/5-fluorouracil DMZT4N7 TI TTU6BFZ DMZT4N7 TN Candida Thymidylate synthase (Candi TMP1) DMZT4N7 MA Inhibitor DMZT4N7 RN Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44. DMZT4N7 RU https://pubmed.ncbi.nlm.nih.gov/19383847 DMZTGN2 DI DMZTGN2 DMZTGN2 DN Methylnaltrexone bromide DMZTGN2 TI TTD0CIQ DMZTGN2 TN Melanocortin receptor 4 (MC4R) DMZTGN2 MA Agonist DMZTGN2 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMZTGN2 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMZTGN2 DI DMZTGN2 DMZTGN2 DN Methylnaltrexone bromide DMZTGN2 TI TTKWM86 DMZTGN2 TN Opioid receptor mu (MOP) DMZTGN2 MA Modulator DMZTGN2 RN 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. DMZTGN2 RU https://pubmed.ncbi.nlm.nih.gov/19180096 DMZTXCH DI DMZTXCH DMZTXCH DN Remifentanil DMZTXCH TI TTKWM86 DMZTXCH TN Opioid receptor mu (MOP) DMZTXCH MA Agonist DMZTXCH RN The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: Prevent... Pain. 2009 Jan;141(1-2):88-96. DMZTXCH RU https://pubmed.ncbi.nlm.nih.gov/19058913 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP TI TTZPWGN DMZU5JP TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMZU5JP MA Blocker DMZU5JP RN Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/19582593 DMZU5JP DI DMZU5JP DMZU5JP DN Flunarizine DMZU5JP TI TTX4QDJ DMZU5JP TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMZU5JP MA Inhibitor DMZU5JP RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZU5JP RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMZUR4N DI DMZUR4N DMZUR4N DN Triclosan DMZUR4N TI TTNX2CS DMZUR4N TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMZUR4N MA Binder DMZUR4N RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMZUR4N RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMZUW6P DI DMZUW6P DMZUW6P DN Factor viia DMZUW6P TI TTF0EGX DMZUW6P TN Coagulation factor VII (F7) DMZUW6P MA Modulator DMZUW6P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMZUW6P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMZV2PJ DI DMZV2PJ DMZV2PJ DN Acetophenazine DMZV2PJ TI TTEX248 DMZV2PJ TN Dopamine D2 receptor (D2R) DMZV2PJ MA Antagonist DMZV2PJ RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMZV2PJ RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMZVMKF DI DMZVMKF DMZVMKF DN Alfuzosin DMZVMKF TI TT34BHT DMZVMKF TN Adrenergic receptor alpha-1D (ADRA1D) DMZVMKF MA Antagonist DMZVMKF RN Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. DMZVMKF RU https://pubmed.ncbi.nlm.nih.gov/11893233 DMZW9HA DI DMZW9HA DMZW9HA DN Olsalazine DMZW9HA TI TTPZ7AG DMZW9HA TN Oxidoreductase unspecific (OR) DMZW9HA MA Modulator DMZW9HA RN Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases. Protein Cell. 2010 Aug;1(8):780-90. DMZW9HA RU https://pubmed.ncbi.nlm.nih.gov/21203919 DMZYLFC DI DMZYLFC DMZYLFC DN Viomycin sulfate DMZYLFC TI TTIA0J5 DMZYLFC TN Bacterial 70S ribosomal RNA (Bact 70S rRNA) DMZYLFC MA Modulator DMZYLFC RN The antibiotic viomycin traps the ribosome in an intermediate state of translocation.Nat Struct Mol Biol.2007 Jun;14(6):493-7. DMZYLFC RU https://www.ncbi.nlm.nih.gov/pubmed/17515906 nan DI nan nan DN nan nan TI TTIHYA4 nan TN Thrombopoietin receptor (MPL) nan MA Agonist nan RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). nan RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DM5GFIK DI DM5GFIK DM5GFIK DN Icotinib hydrochloride DM5GFIK TI TTGKNB4 DM5GFIK TN Epidermal growth factor receptor (EGFR) DM5GFIK MA Antagonist DM5GFIK RN Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202. DM5GFIK RU https://pubmed.ncbi.nlm.nih.gov/21144613 DM5GIWZ DI DM5GIWZ DM5GIWZ DN Mirogabalin DM5GIWZ TI TTFK1JQ DM5GIWZ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM5GIWZ MA Modulator DM5GIWZ RN Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61. DM5GIWZ RU https://pubmed.ncbi.nlm.nih.gov/25231896 DMBZ27L DI DMBZ27L DMBZ27L DN Favipiravir DMBZ27L TI TT79JGK DMBZ27L TN Mycobacterium RNA polymerase (MycB RNAP) DMBZ27L MA Modulator DMBZ27L RN Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54. DMBZ27L RU https://www.ncbi.nlm.nih.gov/pubmed/24084488 DMDWYUN DI DMDWYUN DMDWYUN DN HBI-8000 DMDWYUN TI TT6R7JZ DMDWYUN TN Histone deacetylase 1 (HDAC1) DMDWYUN MA Modulator DMDWYUN RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDWYUN RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDWYUN DI DMDWYUN DMDWYUN DN HBI-8000 DMDWYUN TI TTBH0VX DMDWYUN TN Histone deacetylase (HDAC) DMDWYUN MA Inhibitor DMDWYUN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDWYUN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRCOU5 DI DMRCOU5 DMRCOU5 DN Dicycloplatin DMRCOU5 TI TTUTN1I DMRCOU5 TN Human Deoxyribonucleic acid (hDNA) DMRCOU5 MA Inhibitor DMRCOU5 RN Dicycloplatin, a novel platinum analog in chemotherapy: synthesis of chinese pre-clinical and clinical profile and emerging mechanistic studies. Anticancer Res. 2014 Jan;34(1):455-63. DMRCOU5 RU https://pubmed.ncbi.nlm.nih.gov/24403501 DMY67U8 DI DMY67U8 DMY67U8 DN Trapidil DMY67U8 TI TTST7KB DMY67U8 TN Fibroblast growth factor receptor 3 (FGFR3) DMY67U8 MA Inhibitor DMY67U8 RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMY67U8 RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMY67U8 DI DMY67U8 DMY67U8 DN Trapidil DMY67U8 TI TTI2WET DMY67U8 TN Platelet-derived growth factor receptor (PDGFR) DMY67U8 MA Inhibitor DMY67U8 RN Osteitis fibrosa is mediated by Platelet-Derived Growth Factor-A via a phosphoinositide 3-kinase-dependent signaling pathway in a rat model for chr... Endocrinology. 2008 Nov;149(11):5735-46. DMY67U8 RU https://pubmed.ncbi.nlm.nih.gov/18635661 DM2M47Y DI DM2M47Y DM2M47Y DN TKM-ApoB DM2M47Y TI TTN1IE2 DM2M47Y TN APOB messenger RNA (APOB mRNA) DM2M47Y RN Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146. DM2M47Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/ DM2VOQ3 DI DM2VOQ3 DM2VOQ3 DN Mosapride DM2VOQ3 TI TT07C3Y DM2VOQ3 TN 5-HT 4 receptor (HTR4) DM2VOQ3 MA Agonist DM2VOQ3 RN The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37. DM2VOQ3 RU https://pubmed.ncbi.nlm.nih.gov/18415081 DM3S8XC DI DM3S8XC DM3S8XC DN Dihydrotestosterone DM3S8XC TI TTKPW01 DM3S8XC TN Androgen receptor messenger RNA (AR mRNA) DM3S8XC MA Agonist DM3S8XC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628). DM3S8XC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628 DM3S8XC DI DM3S8XC DM3S8XC DN Dihydrotestosterone DM3S8XC TI TTS64P2 DM3S8XC TN Androgen receptor (AR) DM3S8XC MA Modulator DM3S8XC RN Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor. Mol Endocrinol. 2002 Jul;16(7):1492-501. DM3S8XC RU https://www.ncbi.nlm.nih.gov/pubmed/12089345 DM3YH4I DI DM3YH4I DM3YH4I DN D-Serine DM3YH4I TI TTLD29N DM3YH4I TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM3YH4I MA Inhibitor DM3YH4I RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DM3YH4I RU https://pubmed.ncbi.nlm.nih.gov/11752352 DM3YH4I DI DM3YH4I DM3YH4I DN D-Serine DM3YH4I TI TTF45NW DM3YH4I TN Strychnine-binding glycine receptor (GLRA1) DM3YH4I MA Inhibitor DM3YH4I RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DM3YH4I RU https://pubmed.ncbi.nlm.nih.gov/11752352 DM4OQRD DI DM4OQRD DM4OQRD DN HIF-1alpha DM4OQRD TI TTQHWNA DM4OQRD TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM4OQRD MA Inhibitor DM4OQRD RN A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008 Nov;7(11):3598-608. DM4OQRD RU https://pubmed.ncbi.nlm.nih.gov/18974394 DM4OQRD DI DM4OQRD DM4OQRD DN HIF-1alpha DM4OQRD TI TT0LF7H DM4OQRD TN Fibroblast growth factor receptor (FGFR) DM4OQRD MA Antagonist DM4OQRD RN Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. DM4OQRD RU https://pubmed.ncbi.nlm.nih.gov/11576867 DM4TX7J DI DM4TX7J DM4TX7J DN Talipexole DM4TX7J TI TTEX248 DM4TX7J TN Dopamine D2 receptor (D2R) DM4TX7J MA Agonist DM4TX7J RN Effects of talipexole on emesis-related changes in abdominal afferent vagal activity and ileal serotonin metabolism in rats. Res Commun Mol Pathol Pharmacol. 1997 Jan;95(1):67-82. DM4TX7J RU https://pubmed.ncbi.nlm.nih.gov/9055350 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTPADOQ DM5FABJ TN HMG-CoA reductase (HMGCR) DM5FABJ MA Inhibitor DM5FABJ RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TT2O84V DM5FABJ TN Thromboxane A2 receptor (TBXA2R) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTNVEIR DM5FABJ TN Prostaglandin D2 receptor (PTGDR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTOFYT1 DM5FABJ TN Prostacyclin receptor (PTGIR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTQDMX5 DM5FABJ TN Prostaglandin D2 receptor 2 (PTGDR2) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TTT2ZAR DM5FABJ TN Prostaglandin F2-alpha receptor (PTGFR) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM5FABJ DI DM5FABJ DM5FABJ DN LAROPIPRANT DM5FABJ TI TT1ZAVI DM5FABJ TN Prostaglandin E2 receptor EP2 (PTGER2) DM5FABJ MA Inhibitor DM5FABJ RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM5FABJ RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM6VFO1 DI DM6VFO1 DM6VFO1 DN Pregnenolone DM6VFO1 TI TTPNQAC DM6VFO1 TN Estrogen-related receptor-alpha (ESRRA) DM6VFO1 MA Agonist DM6VFO1 RN Suppression of adrenal function by low-dose prednisone: assessment with 24-hour urinary steroid hormone profiles--a review of five cases. Altern Med Rev. 2006 Mar;11(1):40-6. DM6VFO1 RU https://pubmed.ncbi.nlm.nih.gov/16597193 DM8EKSV DI DM8EKSV DM8EKSV DN Anti-MIF antibodies DM8EKSV TI TT2AST1 DM8EKSV TN Macrophage migration inhibitory factor (MIF) DM8EKSV MA Inhibitor DM8EKSV RN Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the beta-Sheet Structure of MIF. J Biol Chem. 2012 March 2; 287(10): 7446-7455. DM8EKSV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293543/ DM8NWFD DI DM8NWFD DM8NWFD DN Hypericum DM8NWFD TI TTAWNKZ DM8NWFD TN Norepinephrine transporter (NET) DM8NWFD MA Inhibitor DM8NWFD RN The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8. DM8NWFD RU https://pubmed.ncbi.nlm.nih.gov/10483049 DM92S6N DI DM92S6N DM92S6N DN Levamlodipine DM92S6N TI TTXHYV6 DM92S6N TN Voltage-gated L-type calcium channel (L-CaC) DM92S6N MA Modulator DM92S6N RN Effects of (S)-amlodipine and (R)-amlodipine on L-type calcium channel current of rat ventricular myocytes and cytosolic calcium of aortic smooth muscle cells. Pharmazie. 2008 Jun;63(6):470-4. DM92S6N RU https://pubmed.ncbi.nlm.nih.gov/18604992 DMB0FWL DI DMB0FWL DMB0FWL DN Dihydrocodeine DMB0FWL TI TTN4QDT DMB0FWL TN Opioid receptor (OPR) DMB0FWL MA Modulator DMB0FWL RN Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63. DMB0FWL RU https://pubmed.ncbi.nlm.nih.gov/12420793 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TT4TFGN DMB7WYM TN Vasopressin V1a receptor (V1AR) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTSCIUP DMB7WYM TN Oxytocin receptor (OTR) DMB7WYM MA Inhibitor DMB7WYM RN Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):954-9. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/16297621 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTL9MHW DMB7WYM TN Vasopressin V1b receptor (V1BR) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMB7WYM DI DMB7WYM DMB7WYM DN ATOSIBAN DMB7WYM TI TTK8R02 DMB7WYM TN Vasopressin V2 receptor (V2R) DMB7WYM MA Inhibitor DMB7WYM RN The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4. DMB7WYM RU https://pubmed.ncbi.nlm.nih.gov/18032036 DMBPN7T DI DMBPN7T DMBPN7T DN Rupatadine DMBPN7T TI TTQL5VC DMBPN7T TN Platelet-activating factor receptor (PTAFR) DMBPN7T MA Inhibitor DMBPN7T RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBPN7T RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMBPN7T DI DMBPN7T DMBPN7T DN Rupatadine DMBPN7T TI TTTIBOJ DMBPN7T TN Histamine H1 receptor (H1R) DMBPN7T MA Inhibitor DMBPN7T RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBPN7T RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMC5Q8X DI DMC5Q8X DMC5Q8X DN Berberine DMC5Q8X TI TTUJFD0 DMC5Q8X TN Telomerase reverse transcriptase (TERT) DMC5Q8X MA Inhibitor DMC5Q8X RN Stage specificity of Plasmodium falciparum telomerase and its inhibition by berberine. Parasitol Int. 2002 Mar;51(1):99-103. DMC5Q8X RU https://pubmed.ncbi.nlm.nih.gov/11880232 DMDN4A1 DI DMDN4A1 DMDN4A1 DN Glitazone DMDN4A1 TI TTZMAO3 DMDN4A1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMDN4A1 MA Agonist DMDN4A1 RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMDN4A1 RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMF8CJ9 DI DMF8CJ9 DMF8CJ9 DN Pyridine DMF8CJ9 TI TTKNWZ4 DMF8CJ9 TN Thromboxane-A synthase (TBXAS1) DMF8CJ9 MA Inhibitor DMF8CJ9 RN Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55. DMF8CJ9 RU https://pubmed.ncbi.nlm.nih.gov/7199089 DMHEAB1 DI DMHEAB1 DMHEAB1 DN Neupro DMHEAB1 TI TTWFZ1N DMHEAB1 TN Dopamine receptor (DR) DMHEAB1 MA Agonist DMHEAB1 RN Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019 Jul;33(7):707-718. DMHEAB1 RU https://pubmed.ncbi.nlm.nih.gov/31243728 DMIGKA1 DI DMIGKA1 DMIGKA1 DN Ozagrel DMIGKA1 TI TTQBR95 DMIGKA1 TN Stress-activated protein kinase 2a (p38 alpha) DMIGKA1 MA Inhibitor DMIGKA1 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMIGKA1 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMIV8CT DI DMIV8CT DMIV8CT DN Parecoxib DMIV8CT TI TTSZDQU DMIV8CT TN Lactotransferrin (LTF) DMIV8CT MA Inhibitor DMIV8CT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIV8CT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKV32D DI DMKV32D DMKV32D DN Xylometazoline DMKV32D TI TT2NUT5 DMKV32D TN Adrenergic receptor alpha-2C (ADRA2C) DMKV32D MA Modulator DMKV32D RN Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. DMKV32D RU https://pubmed.ncbi.nlm.nih.gov/20030735 DMN2Q5I DI DMN2Q5I DMN2Q5I DN Diacerein DMN2Q5I TI TTRYK0X DMN2Q5I TN Interleukin-1 beta (IL1B) DMN2Q5I MA Inhibitor DMN2Q5I RN Non-surgical treatment of osteoarthritis of large joints - new aspects. Wien Med Wochenschr. 2009;159(3-4):76-86. DMN2Q5I RU https://pubmed.ncbi.nlm.nih.gov/19247594 DMOSJD0 DI DMOSJD0 DMOSJD0 DN Sivelestat sodium hydrate DMOSJD0 TI TTPLTSQ DMOSJD0 TN Neutrophil elastase (NE) DMOSJD0 MA Inhibitor DMOSJD0 RN Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. DMOSJD0 RU https://pubmed.ncbi.nlm.nih.gov/17874973 DMOSJD0 DI DMOSJD0 DMOSJD0 DN Sivelestat sodium hydrate DMOSJD0 TI TTEMV5X DMOSJD0 TN Serine protease unspecific (SP) DMOSJD0 MA Inhibitor DMOSJD0 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMOSJD0 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMTV7XH DI DMTV7XH DMTV7XH DN SPN-812 DMTV7XH TI TTAWNKZ DMTV7XH TN Norepinephrine transporter (NET) DMTV7XH MA Antagonist DMTV7XH RN New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. DMTV7XH RU https://pubmed.ncbi.nlm.nih.gov/32943948 DMTV7XH DI DMTV7XH DMTV7XH DN SPN-812 DMTV7XH TI TT0K1SC DMTV7XH TN 5-HT 2B receptor (HTR2B) DMTV7XH MA Antagonist DMTV7XH RN New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. DMTV7XH RU https://pubmed.ncbi.nlm.nih.gov/32943948 DMVILAD DI DMVILAD DMVILAD DN MOTILIN DMVILAD TI TT953CX DMVILAD TN Motilin receptor (MLNR) DMVILAD MA Inhibitor DMVILAD RN Discovery of a new class of macrocyclic antagonists to the human motilin receptor. J Med Chem. 2006 Nov 30;49(24):7190-7. DMVILAD RU https://pubmed.ncbi.nlm.nih.gov/17125271 DMVPLNC DI DMVPLNC DMVPLNC DN Ingrezza DMVPLNC TI TTNZRI3 DMVPLNC TN Synaptic vesicle amine transporter (SLC18A2) DMVPLNC MA Antagonist DMVPLNC RN VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111. DMVPLNC RU https://pubmed.ncbi.nlm.nih.gov/29680151 DMVXLOD DI DMVXLOD DMVXLOD DN Imrecoxib DMVXLOD TI TT8NGED DMVXLOD TN Prostaglandin G/H synthase 1 (COX-1) DMVXLOD MA Inhibitor DMVXLOD RN Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. DMVXLOD RU https://pubmed.ncbi.nlm.nih.gov/19286379 DMVXLOD DI DMVXLOD DMVXLOD DN Imrecoxib DMVXLOD TI TTVKILB DMVXLOD TN Prostaglandin G/H synthase 2 (COX-2) DMVXLOD MA Inhibitor DMVXLOD RN Synthesis and anti-inflammatory activity of the major metabolites of imrecoxib. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2270-2. DMVXLOD RU https://pubmed.ncbi.nlm.nih.gov/19286379 DMVZL26 DI DMVZL26 DMVZL26 DN 3,4-Dihydroxycinnamic Acid DMVZL26 TI TT2AST1 DMVZL26 TN Macrophage migration inhibitory factor (MIF) DMVZL26 MA Inhibitor DMVZL26 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVZL26 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVZL26 DI DMVZL26 DMVZL26 DN 3,4-Dihydroxycinnamic Acid DMVZL26 TI TT2J34L DMVZL26 TN Arachidonate 5-lipoxygenase (5-LOX) DMVZL26 MA Inhibitor DMVZL26 RN Phenidone protects the nigral dopaminergic neurons from LPS-induced neurotoxicity. Neurosci Lett. 2008 Nov 7;445(1):1-6. DMVZL26 RU https://pubmed.ncbi.nlm.nih.gov/18760329 DMWDEN0 DI DMWDEN0 DMWDEN0 DN Amylin DMWDEN0 TI TTD0CIQ DMWDEN0 TN Melanocortin receptor 4 (MC4R) DMWDEN0 MA Agonist DMWDEN0 RN Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26. DMWDEN0 RU https://pubmed.ncbi.nlm.nih.gov/11060745 DMWL182 DI DMWL182 DMWL182 DN Beraprost DMWL182 TI TTOFYT1 DMWL182 TN Prostacyclin receptor (PTGIR) DMWL182 MA Agonist DMWL182 RN Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174. DMWL182 RU https://pubmed.ncbi.nlm.nih.gov/25584359 DMXBYQR DI DMXBYQR DMXBYQR DN Silymarin DMXBYQR TI TT2J34L DMXBYQR TN Arachidonate 5-lipoxygenase (5-LOX) DMXBYQR MA Inhibitor DMXBYQR RN Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine. 2000 Mar;7(1):21-4. DMXBYQR RU https://pubmed.ncbi.nlm.nih.gov/10782486 DMY2AEF DI DMY2AEF DMY2AEF DN PAI-1 DMY2AEF TI TTGY7WI DMY2AEF TN Urokinase-type plasminogen activator (PLAU) DMY2AEF MA Inhibitor DMY2AEF RN Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6. DMY2AEF RU https://pubmed.ncbi.nlm.nih.gov/7563153 DMYGEH7 DI DMYGEH7 DMYGEH7 DN Ceftolozane sulfate DMYGEH7 TI TTJP4SM DMYGEH7 TN Bacterial Penicillin binding protein (Bact PBP) DMYGEH7 MA Modulator DMYGEH7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYGEH7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYOC29 DI DMYOC29 DMYOC29 DN Hirudin DMYOC29 TI TT6L509 DMYOC29 TN Coagulation factor IIa (F2) DMYOC29 MA Inhibitor DMYOC29 RN Probing the hirudin-thrombin interaction by incorporation of noncoded amino acids and molecular dynamics simulation. Biochemistry. 2002 Nov 19;41(46):13556-69. DMYOC29 RU https://pubmed.ncbi.nlm.nih.gov/12427016 DMZ5Y1P DI DMZ5Y1P DMZ5Y1P DN Dichloroacetate DMZ5Y1P TI TTCZOF2 DMZ5Y1P TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMZ5Y1P MA Inhibitor DMZ5Y1P RN Comparison of Antitumor Effects of Combined and Separate Treatment with NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate. Bull Exp Biol Med. 2019 Nov;168(1):92-94. DMZ5Y1P RU https://pubmed.ncbi.nlm.nih.gov/31768777 DMXIRA0 DI DMXIRA0 DMXIRA0 DN RLX030 DMXIRA0 TI TTMAHD1 DMXIRA0 TN Relaxin receptor 1 (RXFP1) DMXIRA0 MA Modulator DMXIRA0 RN Design of the RELAXin in acute heart failure study. Am Heart J. 2012 Feb;163(2):149-55.e1. DMXIRA0 RU https://pubmed.ncbi.nlm.nih.gov/22305830 DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TTCGSZ4 DMOML9Q TN Pancreatic alpha-amylase (AMY2A) DMOML9Q MA Modulator DMOML9Q RN Clinical pipeline report, company report or official report of Digestive Care. DMOML9Q RU http://www.digestivecare.com/release102708.shtm DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TT7MRGU DMOML9Q TN Chymotrypsin (CTR) DMOML9Q MA Modulator DMOML9Q RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DMOML9Q RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DMOML9Q DI DMOML9Q DMOML9Q DN Pancrecarb DMOML9Q TI TTXMY0J DMOML9Q TN Pancreatic triacylglycerol lipase (PNLIP) DMOML9Q MA Modulator DMOML9Q RN Clinical pipeline report, company report or official report of Digestive Care. DMOML9Q RU http://www.digestivecare.com/release102708.shtm DM26I8H DI DM26I8H DM26I8H DN TK-DLI DM26I8H TI TTP3QRF DM26I8H TN Thymidine kinase 1 (TK1) DM26I8H MA Modulator DM26I8H RN Company report (Takara Bio) DM26I8H RU http://www.takara-bio.com/news_e/2008/10/07.htm DMBRFUQ DI DMBRFUQ DMBRFUQ DN B-cell lymphoma vaccine DMBRFUQ TI TT6MP2Z DMBRFUQ TN GMCSFR-alpha (CSF2RA) DMBRFUQ RN Idiotypevaccinetherapy (BiovaxID) infollicularlymphomain first complete remission: Phase III clinical trial results, Journal of Clinical Oncology, Vol 27, No 18S (June 20 Supplement), 2009: 2. DMBRFUQ RU http://meeting.ascopubs.org/cgi/content/abstract/27/18S/2?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=Idiotype+vaccine+therapy+(BiovaxID)+in+follicular+lymphoma+&searchid=1&FIRSTINDEX=0&volume=27&issue=18S&resourcetype=HWCIT DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT9W8GU DMF2O4T TN Gamma-secretase (GS) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT8JRS7 DMF2O4T TN Beta-secretase (BACE) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTWN3F4 DMF2O4T TN Presenilin 2 (PSEN2) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTVKILB DMF2O4T TN Prostaglandin G/H synthase 2 (COX-2) DMF2O4T MA Inhibitor DMF2O4T RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TT8NGED DMF2O4T TN Prostaglandin G/H synthase 1 (COX-1) DMF2O4T MA Inhibitor DMF2O4T RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMF2O4T DI DMF2O4T DMF2O4T DN (S)-FLURBIPROFEN DMF2O4T TI TTZ3S8C DMF2O4T TN Presenilin 1 (PSEN1) DMF2O4T MA Inhibitor DMF2O4T RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMF2O4T RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMLRKJX DI DMLRKJX DMLRKJX DN Neugranin DMLRKJX TI TT5TQ2W DMLRKJX TN Granulocyte colony-stimulating factor (CSF3) DMLRKJX MA Modulator DMLRKJX RN Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia pastoris. PLoS One. 2014; 9(12): e115840. DMLRKJX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275271/ DMP5O1U DI DMP5O1U DMP5O1U DN GSK2696273 DMP5O1U TI TTLP57V DMP5O1U TN Adenosine deaminase (ADA) DMP5O1U MA Modulator DMP5O1U RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMP5O1U RU https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/ DMUY09W DI DMUY09W DMUY09W DN SK-NBP601 DMUY09W TI TT1290U DMUY09W TN Coagulation factor VIII (F8) DMUY09W MA Inhibitor DMUY09W RN Clinical pipeline report, company report or official report of SK Chemicals. DMUY09W RU http://www.skchemicals.com/en/about/rd_result.asp DMXSDJU DI DMXSDJU DMXSDJU DN MPL-containing Pollinex allergy desensitization vaccine DMXSDJU TI TTISGCA DMXSDJU TN Toll-like receptor 4 (TLR4) DMXSDJU RN Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006. DMXSDJU RU http://miranda.hemscott.com/ir/agy/ir.jsp?page=news_regulatory&article=36483600159086 DMYA6TR DI DMYA6TR DMYA6TR DN Human coagulation factor X DMYA6TR TI TTCIHJA DMYA6TR TN Coagulation factor Xa (F10) DMYA6TR MA Modulator DMYA6TR RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMYA6TR RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM02BVQ DI DM02BVQ DM02BVQ DN ARQ-087 DM02BVQ TI TTRLW2X DM02BVQ TN Fibroblast growth factor receptor 1 (FGFR1) DM02BVQ MA Inhibitor DM02BVQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). DM02BVQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808 DM02BVQ DI DM02BVQ DM02BVQ DN ARQ-087 DM02BVQ TI TT0LF7H DM02BVQ TN Fibroblast growth factor receptor (FGFR) DM02BVQ MA Antagonist DM02BVQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM02BVQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM06KRC DI DM06KRC DM06KRC DN Oregovomab DM06KRC TI TTC1PS3 DM06KRC TN Ovarian carcinoma antigen CA125 (MUC16) DM06KRC RN MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014; 13: 129. DM06KRC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046138/ DM0762O DI DM0762O DM0762O DN Fenfluramine DM0762O TI TT85JO3 DM0762O TN 5-HT receptor (5HTR) DM0762O MA Antagonist DM0762O RN Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418. DM0762O RU https://pubmed.ncbi.nlm.nih.gov/15977970 DM07653 DI DM07653 DM07653 DN SULTHIAME DM07653 TI TTANPDJ DM07653 TN Carbonic anhydrase II (CA-II) DM07653 MA Inhibitor DM07653 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM07653 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM08XIN DI DM08XIN DM08XIN DN EPIANDROSTERONE DM08XIN TI TTKN8W0 DM08XIN TN Glucose-6-phosphate dehydrogenase (G6PD) DM08XIN MA Inhibitor DM08XIN RN Inhibition of Trypanosoma brucei glucose-6-phosphate dehydrogenase by human steroids and their effects on the viability of cultured parasites. Bioorg Med Chem. 2009 Mar 15;17(6):2483-9. DM08XIN RU https://pubmed.ncbi.nlm.nih.gov/19231202 DM097UP DI DM097UP DM097UP DN CBT-1 DM097UP TI TT3OT40 DM097UP TN Multidrug resistance protein 1 (ABCB1) DM097UP MA Modulator DM097UP RN A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors. Oncologist.2012;17(4):512. DM097UP RU https://www.ncbi.nlm.nih.gov/pubmed/22416063 DM09M3H DI DM09M3H DM09M3H DN BAY 94-9027 DM09M3H TI TT1290U DM09M3H TN Coagulation factor VIII (F8) DM09M3H MA Modulator DM09M3H RN Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96. DM09M3H RU https://pubmed.ncbi.nlm.nih.gov/24843882 DM09RKB DI DM09RKB DM09RKB DN LC-150444 DM09RKB TI TTDIGC1 DM09RKB TN Dipeptidyl peptidase 4 (DPP-4) DM09RKB MA Inhibitor DM09RKB RN Clinical pipeline report, company report or official report of ShangHai APIs Chemical. DM09RKB RU http://www.apischemical.com/APIsproducts4/850649-62-6,Alogliptin(SYR-322).htm DM09TVB DI DM09TVB DM09TVB DN Zimura DM09TVB TI TTKANGO DM09TVB TN Complement C5 (CO5) DM09TVB MA Inhibitor DM09TVB RN C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576-586. DM09TVB RU https://pubmed.ncbi.nlm.nih.gov/32882310 DM0AEDT DI DM0AEDT DM0AEDT DN BIIB067 DM0AEDT TI TT6RVLG DM0AEDT TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DM0AEDT MA Inhibitor DM0AEDT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0AEDT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0DIEZ DI DM0DIEZ DM0DIEZ DN UNI-rhIL-11 DM0DIEZ TI TTZPLJS DM0DIEZ TN Interleukin 11 receptor alpha (IL11RA) DM0DIEZ MA Modulator DM0DIEZ RN Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5. DM0DIEZ RU https://pubmed.ncbi.nlm.nih.gov/12478901 DM0EQ9X DI DM0EQ9X DM0EQ9X DN Av 133 DM0EQ9X TI TTNZRI3 DM0EQ9X TN Synaptic vesicle amine transporter (SLC18A2) DM0EQ9X MA Enhancer DM0EQ9X RN Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952. DM0EQ9X RU https://pubmed.ncbi.nlm.nih.gov/24098749 DM0GUV2 DI DM0GUV2 DM0GUV2 DN DE-766 DM0GUV2 TI TTGKNB4 DM0GUV2 TN Epidermal growth factor receptor (EGFR) DM0GUV2 MA Modulator DM0GUV2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM0GUV2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM0HIU5 DI DM0HIU5 DM0HIU5 DN Solanezumab DM0HIU5 TI TTE4KHA DM0HIU5 TN Amyloid beta A4 protein (APP) DM0HIU5 MA Modulator DM0HIU5 RN Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21. DM0HIU5 RU https://pubmed.ncbi.nlm.nih.gov/24450890 DM0JA9N DI DM0JA9N DM0JA9N DN Cyrtominetin DM0JA9N TI TT5FLYB DM0JA9N TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DM0JA9N MA Modulator DM0JA9N RN Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8. DM0JA9N RU https://pubmed.ncbi.nlm.nih.gov/23376250 DM0LQ94 DI DM0LQ94 DM0LQ94 DN GnRH DM0LQ94 TI TT8R70G DM0LQ94 TN Gonadotropin-releasing hormone receptor (GNRHR) DM0LQ94 MA Modulator DM0LQ94 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DM0LQ94 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DM0MI81 DI DM0MI81 DM0MI81 DN Bevacizumab + Erlotinib DM0MI81 TI TTGKNB4 DM0MI81 TN Epidermal growth factor receptor (EGFR) DM0MI81 MA Inhibitor DM0MI81 RN Clinical pipeline report, company report or official report of Roche (2009). DM0MI81 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM0MI81 DI DM0MI81 DM0MI81 DN Bevacizumab + Erlotinib DM0MI81 TI TTOHSBA DM0MI81 TN Vascular endothelial growth factor A (VEGFA) DM0MI81 MA Inhibitor DM0MI81 RN Clinical pipeline report, company report or official report of Roche (2009). DM0MI81 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM0Q6CM DI DM0Q6CM DM0Q6CM DN CIGB-300 DM0Q6CM TI TTZ5NI7 DM0Q6CM TN Casein kinase II (CSNK2) DM0Q6CM MA Modulator DM0Q6CM RN Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models. Mol Clin Oncol. 2014 Nov;2(6):935-944. DM0Q6CM RU https://pubmed.ncbi.nlm.nih.gov/25279177 DM0QNF4 DI DM0QNF4 DM0QNF4 DN TRx0237 DM0QNF4 TI TTS87KH DM0QNF4 TN Microtubule-associated protein tau (MAPT) DM0QNF4 MA Inhibitor DM0QNF4 RN Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296. DM0QNF4 RU https://pubmed.ncbi.nlm.nih.gov/32091331 DM0QV27 DI DM0QV27 DM0QV27 DN NN5401 DM0QV27 TI TTCBFJO DM0QV27 TN Insulin receptor (INSR) DM0QV27 MA Modulator DM0QV27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM0QV27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM0TWCY DI DM0TWCY DM0TWCY DN PF-04950615 DM0TWCY TI TTBRG7E DM0TWCY TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM0TWCY RN Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8. DM0TWCY RU https://pubmed.ncbi.nlm.nih.gov/24316621 DM0ZOGX DI DM0ZOGX DM0ZOGX DN Linopirdine DM0ZOGX TI TTIVDM3 DM0ZOGX TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DM0ZOGX MA Modulator DM0ZOGX RN The M-channel blocker linopirdine is an agonist of the capsaicin receptor TRPV1. J Pharmacol Sci. 2010;114(3):332-40. DM0ZOGX RU https://pubmed.ncbi.nlm.nih.gov/21099148 DM103O8 DI DM103O8 DM103O8 DN Ligelizumab DM103O8 TI TTYJQTF DM103O8 TN Immunoglobulin E (IgE) DM103O8 MA Inhibitor DM103O8 RN Clinical pipeline report, company report or official report of Novartis. DM103O8 RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=Ligelizumab&field_pipeline_filing_date=All DM13V0P DI DM13V0P DM13V0P DN Rivoceranib DM13V0P TI TTUTJGQ DM13V0P TN Vascular endothelial growth factor receptor 2 (KDR) DM13V0P MA Antagonist DM13V0P RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM13V0P RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM15ZIB DI DM15ZIB DM15ZIB DN Mosunetuzumab DM15ZIB TI TTUN7MC DM15ZIB TN T-cell surface glycoprotein CD3 (CD3) DM15ZIB MA Inhibitor DM15ZIB RN Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. DM15ZIB RU https://pubmed.ncbi.nlm.nih.gov/32859946 DM15ZIB DI DM15ZIB DM15ZIB DN Mosunetuzumab DM15ZIB TI TTUE541 DM15ZIB TN Leukocyte surface antigen Leu-16 (CD20) DM15ZIB MA Inhibitor DM15ZIB RN Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28. DM15ZIB RU https://pubmed.ncbi.nlm.nih.gov/32859946 DM180DM DI DM180DM DM180DM DN ARGX-113 DM180DM TI TTKLPHO DM180DM TN Neonatal Fc receptor (FCGRT) DM180DM MA Antagonist DM180DM RN Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019 Jun 4;92(23):e2661-e2673. DM180DM RU https://pubmed.ncbi.nlm.nih.gov/31118245 DM1874J DI DM1874J DM1874J DN TRC105 DM1874J TI TTB30LE DM1874J TN Endoglin CD105 (ENG) DM1874J MA Modulator DM1874J RN An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26. DM1874J RU https://pubmed.ncbi.nlm.nih.gov/25261556 DM18B72 DI DM18B72 DM18B72 DN Rosiglitazone + simvastatin DM18B72 TI TTZMAO3 DM18B72 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM18B72 MA Agonist DM18B72 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM18B72 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM1975O DI DM1975O DM1975O DN Cilnidipine DM1975O TI TTXHYV6 DM1975O TN Voltage-gated L-type calcium channel (L-CaC) DM1975O MA Blocker DM1975O RN N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000. DM1975O RU https://pubmed.ncbi.nlm.nih.gov/12011661 DM1975O DI DM1975O DM1975O DN Cilnidipine DM1975O TI TT4FDG6 DM1975O TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM1975O MA Blocker DM1975O RN N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens. 2002 May;20(5):993-1000. DM1975O RU https://pubmed.ncbi.nlm.nih.gov/12011661 DM19CFZ DI DM19CFZ DM19CFZ DN DIMS-0150 DM19CFZ TI TTKLNRV DM19CFZ TN NFKB messenger RNA (NFKB mRNA) DM19CFZ RN News and Analysis. Nature Reviews Drug Discovery 12, 179 (March 2013). DM19CFZ RU http://www.nature.com/nrd/journal/v12/n3/full/nrd3963.html DM1ARHT DI DM1ARHT DM1ARHT DN BYM338 DM1ARHT TI TTX2DRI DM1ARHT TN Activin receptor type IIA (ACVR2A) DM1ARHT MA Inhibitor DM1ARHT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1ARHT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM1BXMY DI DM1BXMY DM1BXMY DN LY2605541 DM1BXMY TI TTZOPHG DM1BXMY TN Insulin (INS) DM1BXMY MA Modulator DM1BXMY RN LY2605541--a preferential hepato-specific insulin analogue. Diabetes. 2014 Feb;63(2):390-2. DM1BXMY RU https://pubmed.ncbi.nlm.nih.gov/24464715 DM1C95G DI DM1C95G DM1C95G DN DARE-BV1 DM1C95G TI TTUWYEA DM1C95G TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM1C95G RN Characterization of Escherichia coli 50S ribosomal protein L31. FEMS Microbiol Lett. 1999 Nov 15;180(2):345-9. DM1C95G RU https://pubmed.ncbi.nlm.nih.gov/10556732 DM1EO3G DI DM1EO3G DM1EO3G DN Odanacatib DM1EO3G TI TTDZN01 DM1EO3G TN Cathepsin K (CTSK) DM1EO3G MA Inhibitor DM1EO3G RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM1EO3G RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTGPQ0F DM1IZ5D TN Prolyl endopeptidase FAP (FAP) DM1IZ5D MA Inhibitor DM1IZ5D RN Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9. DM1IZ5D RU https://pubmed.ncbi.nlm.nih.gov/18032930 DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTJGLZF DM1IZ5D TN Dipeptidyl peptidase 8 (DPP-8) DM1IZ5D MA Inhibitor DM1IZ5D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1IZ5D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1IZ5D DI DM1IZ5D DM1IZ5D DN Talabostat DM1IZ5D TI TTNDUL7 DM1IZ5D TN Dipeptidyl peptidase 9 (DPP-9) DM1IZ5D MA Inhibitor DM1IZ5D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1IZ5D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1JCW8 DI DM1JCW8 DM1JCW8 DN Xaliproden DM1JCW8 TI TTSQIFT DM1JCW8 TN 5-HT 1A receptor (HTR1A) DM1JCW8 MA Antagonist DM1JCW8 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM1JCW8 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM1K78U DI DM1K78U DM1K78U DN Apricitabine DM1K78U TI TT84ETX DM1K78U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1K78U MA Modulator DM1K78U RN Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38. DM1K78U RU https://www.ncbi.nlm.nih.gov/pubmed/18211121 DM1NQDW DI DM1NQDW DM1NQDW DN SGI110 DM1NQDW TI TT6S2FE DM1NQDW TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM1NQDW MA Modulator DM1NQDW RN Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts. Epigenetics. 2015;10(3):237-46. DM1NQDW RU https://pubmed.ncbi.nlm.nih.gov/25793777 DM1NTVQ DI DM1NTVQ DM1NTVQ DN Tadekinig alfa DM1NTVQ TI TTRICUF DM1NTVQ TN Interleukin-18 (IL18) DM1NTVQ MA Inhibitor DM1NTVQ RN Clinical pipeline report, company report or official report of AB2 Bio. DM1NTVQ RU http://www.ab2bio.com/en/products.36.html DM1ODMR DI DM1ODMR DM1ODMR DN SR46349B DM1ODMR TI TTJQOD7 DM1ODMR TN 5-HT 2A receptor (HTR2A) DM1ODMR MA Modulator DM1ODMR RN SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41. DM1ODMR RU https://www.ncbi.nlm.nih.gov/pubmed/12225700 DM1ODMR DI DM1ODMR DM1ODMR DN SR46349B DM1ODMR TI TTWJBZ5 DM1ODMR TN 5-HT 2C receptor (HTR2C) DM1ODMR MA Modulator DM1ODMR RN SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology. 2002 Sep;27(3):430-41. DM1ODMR RU https://www.ncbi.nlm.nih.gov/pubmed/12225700 DM1PI9G DI DM1PI9G DM1PI9G DN NN8717 DM1PI9G TI TTAXGIP DM1PI9G TN Coagulation factor XIII (F13B) DM1PI9G MA Modulator DM1PI9G RN Topical recombinant thrombin at a concentration of 1000 IU/mL reliably shortens in vivo TTH and delivers durable hemostasis in the presence of heparin anticoagulation and clopidogrel platelet inhibition in a rabbit model of vascular bleeding. Ann Surg Innov Res. 2009; 3: 14. DM1PI9G RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786906/ DM1PRT6 DI DM1PRT6 DM1PRT6 DN M710 DM1PRT6 TI TT9HKJA DM1PRT6 TN Vascular endothelial growth factor (VEGF) DM1PRT6 MA Inhibitor DM1PRT6 RN ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health. DM1PRT6 RU https://clinicaltrials.gov/ct2/show/NCT03610646 DM1RMF5 DI DM1RMF5 DM1RMF5 DN Acadesine DM1RMF5 TI TTLAFZV DM1RMF5 TN AMP-activated protein kinase (AMPK) DM1RMF5 MA Modulator DM1RMF5 RN Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44. DM1RMF5 RU https://pubmed.ncbi.nlm.nih.gov/18671468 DM1RWMY DI DM1RWMY DM1RWMY DN Plasma derived factor VIII PEGylated liposomal DM1RWMY TI TT1290U DM1RWMY TN Coagulation factor VIII (F8) DM1RWMY MA Modulator DM1RWMY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM1RWMY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM1SMAI DI DM1SMAI DM1SMAI DN Eperisone DM1SMAI TI TTCRJKY DM1SMAI TN Voltage-gated calcium channel (Cav) DM1SMAI MA Modulator DM1SMAI RN Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305. DM1SMAI RU https://pubmed.ncbi.nlm.nih.gov/2555204 DM1T6ZN DI DM1T6ZN DM1T6ZN DN Pacritinib DM1T6ZN TI TTGJCWZ DM1T6ZN TN Fms-like tyrosine kinase 3 (FLT-3) DM1T6ZN MA Modulator DM1T6ZN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807). DM1T6ZN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807 DM1T6ZN DI DM1T6ZN DM1T6ZN DN Pacritinib DM1T6ZN TI TTRMX3V DM1T6ZN TN Janus kinase 2 (JAK-2) DM1T6ZN MA Modulator DM1T6ZN RN National Cancer Institute Drug Dictionary (drug id 609888). DM1T6ZN RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=609888 DM1TJXA DI DM1TJXA DM1TJXA DN Chloride DM1TJXA TI TTTSOUD DM1TJXA TN Candida Cytochrome P450 51 (Candi ERG11) DM1TJXA MA Modulator DM1TJXA RN Isavuconazonium: first global approval. Drugs. 2015 May;75(7):817-22. DM1TJXA RU https://pubmed.ncbi.nlm.nih.gov/25902926 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTGBPJE DM1WEHC TN PI3-kinase delta (PIK3CD) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTHBTOP DM1WEHC TN PI3-kinase gamma (PIK3CG) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTTHBCA DM1WEHC TN PI3-kinase beta (PIK3CB) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WEHC DI DM1WEHC DM1WEHC DN Buparlisib DM1WEHC TI TTEUNMR DM1WEHC TN PI3-kinase alpha (PIK3CA) DM1WEHC MA Inhibitor DM1WEHC RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1WEHC RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1WMOK DI DM1WMOK DM1WMOK DN Generx DM1WMOK TI TTCEKVZ DM1WMOK TN Fibroblast growth factor-4 (FGF4) DM1WMOK MA Replacement DM1WMOK RN Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll Cardiol. 2007 Sep 11;50(11):1038-46. DM1WMOK RU https://pubmed.ncbi.nlm.nih.gov/17825712 DM1WNGJ DI DM1WNGJ DM1WNGJ DN DFP-10917 DM1WNGJ TI TTABD5E DM1WNGJ TN DNA replication (DNA repli) DM1WNGJ MA Inhibitor DM1WNGJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1WNGJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1YVLM DI DM1YVLM DM1YVLM DN FST-201 DM1YVLM TI TTYRL6O DM1YVLM TN Glucocorticoid receptor (NR3C1) DM1YVLM MA Agonist DM1YVLM RN A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009 Aug;26(8):776-83. DM1YVLM RU https://pubmed.ncbi.nlm.nih.gov/19756415 DM20KYR DI DM20KYR DM20KYR DN Ruxolitinib DM20KYR TI TTWKB01 DM20KYR TN HUMAN janus kinase 1 (JAK-1) DM20KYR MA Inhibitor DM20KYR RN The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393. DM20KYR RU https://pubmed.ncbi.nlm.nih.gov/32222466 DM20KYR DI DM20KYR DM20KYR DN Ruxolitinib DM20KYR TI TT0F5HE DM20KYR TN HUMAN janus kinase 2 (JAK-2) DM20KYR MA Inhibitor DM20KYR RN The Use of Anti-Inflammatory Drugs in the Treatment of People With Severe Coronavirus Disease 2019 (COVID-19): The Perspectives of Clinical Immunologists From China. Clin Immunol. 2020 May;214:108393. DM20KYR RU https://pubmed.ncbi.nlm.nih.gov/32222466 DM23BUP DI DM23BUP DM23BUP DN PF-05280014 DM23BUP TI TT6EO5L DM23BUP TN Erbb2 tyrosine kinase receptor (HER2) DM23BUP MA Antagonist DM23BUP RN Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin( )). BioDrugs. 2014 Oct;28(5):451-9. DM23BUP RU https://pubmed.ncbi.nlm.nih.gov/25001079 DM25TMP DI DM25TMP DM25TMP DN Rubraca rucaparib DM25TMP TI TTEBCY8 DM25TMP TN Poly [ADP-ribose] polymerase (PARP) DM25TMP MA Inhibitor DM25TMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM25TMP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM29XGY DI DM29XGY DM29XGY DN HMPL-004 DM29XGY TI TTBD054 DM29XGY TN Inflammation pathogenesis (IP) DM29XGY MA Antagonist DM29XGY RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DM29XGY RU http://www.hmplglobal.com/en/hmpl-004/ DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTXWASR DM2ATZB TN Intestinal maltase-glucoamylase (MGAM) DM2ATZB MA Inhibitor DM2ATZB RN Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/7966130 DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTHCF4J DM2ATZB TN Alpha-glucosidase (GLA) DM2ATZB MA Inhibitor DM2ATZB RN Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/7966130 DM2ATZB DI DM2ATZB DM2ATZB DN Deoxynojirimycin DM2ATZB TI TTLPC70 DM2ATZB TN Lysosomal alpha-glucosidase (GAA) DM2ATZB MA Inhibitor DM2ATZB RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DM2ATZB RU https://pubmed.ncbi.nlm.nih.gov/18595718 DM2EJM3 DI DM2EJM3 DM2EJM3 DN AKB-6548 DM2EJM3 TI TTJQFBG DM2EJM3 TN HIF-prolyl hydroxylase (HPH) DM2EJM3 MA Modulator DM2EJM3 RN DOI: 10.1038/nrd4422 DM2EJM3 RU http://www.nature.com/nrd/journal/v13/n11/fig_tab/nrd4422_T2.html DM2F9YO DI DM2F9YO DM2F9YO DN Anakinra DM2F9YO TI TTT7FOP DM2F9YO TN HUMAN interleukin-1 receptor 1 (IL1R1) DM2F9YO MA Antagonist DM2F9YO RN FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166. DM2F9YO RU http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Addlsearch_drug_name DM2FV5N DI DM2FV5N DM2FV5N DN Darunavir + cobicistat DM2FV5N TI TT1D53B DM2FV5N TN COVID-19 3C-like protease (3CLpro) DM2FV5N MA Inhibitor DM2FV5N RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DM2FV5N RU https://pubmed.ncbi.nlm.nih.gov/32205870 DM2GF14 DI DM2GF14 DM2GF14 DN PF-06410293 DM2GF14 TI TTF8CQI DM2GF14 TN Tumor necrosis factor (TNF) DM2GF14 RN Apoptosis and the FLIP and NF-kappa B proteins as pharmacodynamic criteria for biosimilar TNF-alpha antagonists. Biologics. 2014 Jul 31;8:211-20. DM2GF14 RU https://pubmed.ncbi.nlm.nih.gov/25114503 DM2GHCR DI DM2GHCR DM2GHCR DN Rebamipide DM2GHCR TI TT5Y4EM DM2GHCR TN N-formyl peptide receptor (FPR1) DM2GHCR MA Antagonist DM2GHCR RN Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. J Pharmacol Exp Ther. 2001 Apr;297(1):388-94. DM2GHCR RU https://pubmed.ncbi.nlm.nih.gov/11259567 DM2H8FZ DI DM2H8FZ DM2H8FZ DN TAK-700 DM2H8FZ TI TTRA5BZ DM2H8FZ TN Steroid 17-alpha-monooxygenase (S17AH) DM2H8FZ MA Modulator DM2H8FZ RN Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28. DM2H8FZ RU https://pubmed.ncbi.nlm.nih.gov/22249003 DM2J4YB DI DM2J4YB DM2J4YB DN ABP 501 DM2J4YB TI TTF8CQI DM2J4YB TN Tumor necrosis factor (TNF) DM2J4YB RN Case study: biosimilar anti TNFalpha (Adalimumab) analysis of Fc effector functions. BMC Proc. 2013; 7(Suppl 6): P30. DM2J4YB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980296/ DM2OBNW DI DM2OBNW DM2OBNW DN Bococizumab DM2OBNW TI TTBRG7E DM2OBNW TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DM2OBNW RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DM2OBNW RU https://pubmed.ncbi.nlm.nih.gov/25323928 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTZ97H5 DM2R15Q TN Phosphodiesterase 4A (PDE4A) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTSKMI8 DM2R15Q TN Phosphodiesterase 4D (PDE4D) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2R15Q DI DM2R15Q DM2R15Q DN DENBUFYLLINE DM2R15Q TI TTVIAT9 DM2R15Q TN Phosphodiesterase 4B (PDE4B) DM2R15Q MA Inhibitor DM2R15Q RN Pyrazolopyrimidine-2,4-dione sulfonamides: novel and selective calcitonin inducers. J Med Chem. 2002 May 23;45(11):2342-5. DM2R15Q RU https://pubmed.ncbi.nlm.nih.gov/12014973 DM2RTGP DI DM2RTGP DM2RTGP DN Alpha-glucosidase DM2RTGP TI TTXWASR DM2RTGP TN Intestinal maltase-glucoamylase (MGAM) DM2RTGP MA Modulator DM2RTGP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627). DM2RTGP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627 DM2TNJ1 DI DM2TNJ1 DM2TNJ1 DN Molgramostim DM2TNJ1 TI TT6MP2Z DM2TNJ1 TN GMCSFR-alpha (CSF2RA) DM2TNJ1 MA Agonist DM2TNJ1 RN Clinical pipeline report, company report or official report of gensci-china. DM2TNJ1 RU http://www.gensci-china.com/gensci/cp1_somatropinAQ.asp?MaxID=3 DM2XSG0 DI DM2XSG0 DM2XSG0 DN GMA105 DM2XSG0 TI TTVIMDE DM2XSG0 TN Glucagon-like peptide 1 receptor (GLP1R) DM2XSG0 MA Inhibitor DM2XSG0 RN Clinical pipeline report, company report or official report of Gmax Biopharm. DM2XSG0 RU http://www.gmaxbiopharm.com/wap_product_detailen/id/3.html DM2YQK8 DI DM2YQK8 DM2YQK8 DN AR-301 DM2YQK8 TI TT5FLYB DM2YQK8 TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DM2YQK8 MA Inhibitor DM2YQK8 RN Clinical pipeline report, company report or official report of Aridis Pharmaceuticals. DM2YQK8 RU https://www.aridispharma.com/ar-301/ DM3274D DI DM3274D DM3274D DN Fostamatinib disodium DM3274D TI TTOU65C DM3274D TN Tyrosine-protein kinase SYK (SYK) DM3274D MA Inhibitor DM3274D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3274D RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM34GOF DI DM34GOF DM34GOF DN REL-1017 DM34GOF TI TT9IK2Z DM34GOF TN N-methyl-D-aspartate receptor (NMDAR) DM34GOF MA Antagonist DM34GOF RN N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects. Neuropsychopharmacology. 2019 Dec;44(13):2230-2238. DM34GOF RU https://pubmed.ncbi.nlm.nih.gov/31454827 DM35GBS DI DM35GBS DM35GBS DN Favipiravir DM35GBS TI TTV1095 DM35GBS TN COVID-19 RNA-directed RNA polymerase (RdRp) DM35GBS MA Inhibitor DM35GBS RN Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020. DM35GBS RU https://doi.org/10.1101/2020.03.17.20037432 DM35T1O DI DM35T1O DM35T1O DN Epristeride DM35T1O TI TT2A0DR DM35T1O TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM35T1O MA Inhibitor DM35T1O RN Discovery of a novel hybrid from finasteride and epristeride as 5alpha-reductase inhibitor. Bioorg Med Chem Lett. 2011 Jan 1;21(1):475-8. DM35T1O RU https://pubmed.ncbi.nlm.nih.gov/21094046 DM36C17 DI DM36C17 DM36C17 DN Blonanserin DM36C17 TI TTEX248 DM36C17 TN Dopamine D2 receptor (D2R) DM36C17 MA Antagonist DM36C17 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM36C17 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM36C17 DI DM36C17 DM36C17 DN Blonanserin DM36C17 TI TTJQOD7 DM36C17 TN 5-HT 2A receptor (HTR2A) DM36C17 MA Antagonist DM36C17 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM36C17 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM376WT DI DM376WT DM376WT DN NKTR 214 DM376WT TI TT9721Y DM376WT TN Interleukin 2 receptor beta (IL2RB) DM376WT MA Agonist DM376WT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM376WT RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM3A701 DI DM3A701 DM3A701 DN IDP-122 DM3A701 TI TTP3UTW DM3A701 TN Steroid hormone receptor ERR (ESRR) DM3A701 MA Agonist DM3A701 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3A701 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3BK2Y DI DM3BK2Y DM3BK2Y DN OTL-103 DM3BK2Y TI TTE8T73 DM3BK2Y TN Wiskott-Aldrich syndrome protein (WAS) DM3BK2Y MA Replacement DM3BK2Y RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DM3BK2Y RU https://www.orchard-tx.com/approach/pipeline/ DM3BO8G DI DM3BO8G DM3BO8G DN SUVN-G3031 DM3BO8G TI TT9JNIC DM3BO8G TN Histamine H3 receptor (H3R) DM3BO8G MA Antagonist DM3BO8G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3BO8G RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3DG5C DI DM3DG5C DM3DG5C DN THX-TS01 DM3DG5C TI TT94IAG DM3DG5C TN Cannabinoid receptor (CB) DM3DG5C MA Modulator DM3DG5C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3DG5C RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3FIC2 DI DM3FIC2 DM3FIC2 DN ABT-761 DM3FIC2 TI TT2J34L DM3FIC2 TN Arachidonate 5-lipoxygenase (5-LOX) DM3FIC2 MA Inhibitor DM3FIC2 RN Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging. 2010 May;3(3):298-307. DM3FIC2 RU https://pubmed.ncbi.nlm.nih.gov/20190281 DM3FPAQ DI DM3FPAQ DM3FPAQ DN Anifrolumab DM3FPAQ TI TTMQB37 DM3FPAQ TN Interferon alpha/beta receptor 2 (IFNAR2) DM3FPAQ MA Antagonist DM3FPAQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3FPAQ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3G74J DI DM3G74J DM3G74J DN Tamibarotene DM3G74J TI TTISP28 DM3G74J TN Retinoic acid receptor beta (RARB) DM3G74J MA Modulator DM3G74J RN Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12. DM3G74J RU https://pubmed.ncbi.nlm.nih.gov/22863914 DM3G74J DI DM3G74J DM3G74J DN Tamibarotene DM3G74J TI TTW38KT DM3G74J TN Retinoic acid receptor alpha (RARA) DM3G74J MA Modulator DM3G74J RN Tamibarotene: a candidate retinoid drug for Alzheimer's disease. Biol Pharm Bull. 2012;35(8):1206-12. DM3G74J RU https://pubmed.ncbi.nlm.nih.gov/22863914 DM3GTAL DI DM3GTAL DM3GTAL DN Maribavir DM3GTAL TI TTXQ04B DM3GTAL TN Cytomegalovirus Ganciclovir kinase (CMV UL97) DM3GTAL MA Inhibitor DM3GTAL RN The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003 Jan;77(2):905-14. DM3GTAL RU https://pubmed.ncbi.nlm.nih.gov/12502806 DM3H2U4 DI DM3H2U4 DM3H2U4 DN Patrome DM3H2U4 TI TTN451K DM3H2U4 TN Aromatic-L-amino-acid decarboxylase (DDC) DM3H2U4 MA Modulator DM3H2U4 RN The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000 Nov;6(11):4365-72. DM3H2U4 RU https://pubmed.ncbi.nlm.nih.gov/11106255 DM3IWS8 DI DM3IWS8 DM3IWS8 DN Laquinimod DM3IWS8 TI TTSXVID DM3IWS8 TN Nuclear factor NF-kappa-B (NFKB) DM3IWS8 MA Modulator DM3IWS8 RN Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24. DM3IWS8 RU https://pubmed.ncbi.nlm.nih.gov/22766690 DM3L2GT DI DM3L2GT DM3L2GT DN O6-Benzylguanine alkylade DM3L2GT TI TTJ8DV7 DM3L2GT TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DM3L2GT MA Modulator DM3L2GT RN Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol. 2009 Mar 10;27(8):1262-7. DM3L2GT RU https://pubmed.ncbi.nlm.nih.gov/19204199 DM3MAYQ DI DM3MAYQ DM3MAYQ DN BMS-986205 DM3MAYQ TI TTZJYKH DM3MAYQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM3MAYQ MA Inhibitor DM3MAYQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3MAYQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3MXT8 DI DM3MXT8 DM3MXT8 DN BI 201335 DM3MXT8 TI TT5FNQT DM3MXT8 TN Human immunodeficiency virus Protease (HIV PR) DM3MXT8 MA Inhibitor DM3MXT8 RN 2011 Pipeline of Boehringer Ingelheim Pharma. DM3MXT8 RU http://www.boehringer-ingelheim.com/ DM3OU54 DI DM3OU54 DM3OU54 DN ICI 118,551 DM3OU54 TI TT2CJVK DM3OU54 TN Adrenergic receptor beta-2 (ADRB2) DM3OU54 MA Antagonist DM3OU54 RN Selective beta 2-adrenoceptor antagonists: derivatives of ICI 118,551 and a binary aryloxypropanolamine. J Pharm Pharmacol. 1988 Nov;40(11):803-5. DM3OU54 RU https://pubmed.ncbi.nlm.nih.gov/2907563 DM3PA8H DI DM3PA8H DM3PA8H DN THVD-201 DM3PA8H TI TTOXS3C DM3PA8H TN Muscarinic acetylcholine receptor (CHRM) DM3PA8H MA Agonist DM3PA8H RN Future therapies: Early trials and basic science. Can Urol Assoc J. 2013 Sep-Oct; 7(9-10 Suppl 4): S179-S180. DM3PA8H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919188/ DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TT9HKJA DM3PS2E TN Vascular endothelial growth factor (VEGF) DM3PS2E MA Modulator DM3PS2E RN Clinical pipeline report, company report or official report of Ohr Pharmaceutical. DM3PS2E RU http://www.ohrpharmaceutical.com/research/squalamine DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TTGKIED DM3PS2E TN Fibroblast growth factor-2 (FGF2) DM3PS2E MA Modulator DM3PS2E RN Clinical pipeline report, company report or official report of Ohr Pharmaceutical. DM3PS2E RU http://www.ohrpharmaceutical.com/research/squalamine DM3PS2E DI DM3PS2E DM3PS2E DN Squalamine DM3PS2E TI TTSM78N DM3PS2E TN Platelet-derived growth factor A (PDGFA) DM3PS2E MA Inhibitor DM3PS2E RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PS2E RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM3PSUF DI DM3PSUF DM3PSUF DN MK-3102 DM3PSUF TI TTDIGC1 DM3PSUF TN Dipeptidyl peptidase 4 (DPP-4) DM3PSUF MA Modulator DM3PSUF RN Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12. DM3PSUF RU https://pubmed.ncbi.nlm.nih.gov/24660890 DM3QLK2 DI DM3QLK2 DM3QLK2 DN Atamestane + Toremifene DM3QLK2 TI TTSZLWK DM3QLK2 TN Aromatase (CYP19A1) DM3QLK2 MA Modulator DM3QLK2 RN Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7. DM3QLK2 RU https://pubmed.ncbi.nlm.nih.gov/17942301 DM3RWXL DI DM3RWXL DM3RWXL DN Resveratrol DM3RWXL TI TT8NGED DM3RWXL TN Prostaglandin G/H synthase 1 (COX-1) DM3RWXL MA Modulator DM3RWXL RN Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J Biol Chem. 2004 May 21;279(21):22727-37. DM3RWXL RU https://pubmed.ncbi.nlm.nih.gov/15020596 DM3RWXL DI DM3RWXL DM3RWXL DN Resveratrol DM3RWXL TI TTUF2HO DM3RWXL TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM3RWXL MA Inhibitor DM3RWXL RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM3RWXL RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM3UQ9K DI DM3UQ9K DM3UQ9K DN Acolbifene DM3UQ9K TI TTZAYWL DM3UQ9K TN Estrogen receptor (ESR) DM3UQ9K MA Modulator DM3UQ9K RN Bioactivation of the selective estrogen receptor modulator acolbifene to quinone methides. Chem Res Toxicol. 2005 Feb;18(2):174-82. DM3UQ9K RU https://pubmed.ncbi.nlm.nih.gov/15720121 DM3WP0N DI DM3WP0N DM3WP0N DN Al3818 DM3WP0N TI TT6PKBN DM3WP0N TN Proto-oncogene c-Src (SRC) DM3WP0N MA Inhibitor DM3WP0N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3WP0N RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3YEV0 DI DM3YEV0 DM3YEV0 DN 131I-labelled aCD45 DM3YEV0 TI TTUS45N DM3YEV0 TN Leukocyte common antigen (PTPRC) DM3YEV0 RN 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 1;107(5):2184-91. DM3YEV0 RU https://pubmed.ncbi.nlm.nih.gov/16254140 DM3YXP8 DI DM3YXP8 DM3YXP8 DN Remacemide DM3YXP8 TI TT9IK2Z DM3YXP8 TN N-methyl-D-aspartate receptor (NMDAR) DM3YXP8 MA Agonist DM3YXP8 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DM3YXP8 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DM3ZL7D DI DM3ZL7D DM3ZL7D DN Edotecarin DM3ZL7D TI TTGTQHC DM3ZL7D TN DNA topoisomerase I (TOP1) DM3ZL7D MA Inhibitor DM3ZL7D RN Edotecarin: a novel topoisomerase I inhibitor. Clin Colorectal Cancer. 2005 May;5(1):27-36. DM3ZL7D RU https://pubmed.ncbi.nlm.nih.gov/15929804 DM407I6 DI DM407I6 DM407I6 DN BAY 853934 DM407I6 TI TTJQFBG DM407I6 TN HIF-prolyl hydroxylase (HPH) DM407I6 MA Inhibitor DM407I6 RN Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003. DM407I6 RU https://pubmed.ncbi.nlm.nih.gov/29485740 DM408GM DI DM408GM DM408GM DN S-474474 DM408GM TI TT8DBY3 DM408GM TN Angiotensin II receptor type-1 (AGTR1) DM408GM MA Blocker DM408GM RN Clinical pipeline report, company report or official report of Shionogi (2011). DM408GM RU http://www.shionogi.co.jp/index_e.html DM42GP9 DI DM42GP9 DM42GP9 DN Bicifadine DM42GP9 TI TTAWNKZ DM42GP9 TN Norepinephrine transporter (NET) DM42GP9 MA Modulator DM42GP9 RN Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine DM42GP9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431 DM42GP9 DI DM42GP9 DM42GP9 DN Bicifadine DM42GP9 TI TT3ROYC DM42GP9 TN Serotonin transporter (SERT) DM42GP9 MA Modulator DM42GP9 RN Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine DM42GP9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202431 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTRLW2X DM42PFT TN Fibroblast growth factor receptor 1 (FGFR1) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTGJVQM DM42PFT TN Fibroblast growth factor receptor 2 (FGFR2) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTUTJGQ DM42PFT TN Vascular endothelial growth factor receptor 2 (KDR) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TT8FYO9 DM42PFT TN Platelet-derived growth factor receptor alpha (PDGFRA) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTST7KB DM42PFT TN Fibroblast growth factor receptor 3 (FGFR3) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTDCBX5 DM42PFT TN Vascular endothelial growth factor receptor 3 (FLT-4) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TTI7421 DM42PFT TN Platelet-derived growth factor receptor beta (PDGFRB) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM42PFT DI DM42PFT DM42PFT DN E-3810 DM42PFT TI TT2Q6G1 DM42PFT TN Vascular endothelial growth factor receptor 1 (FLT-1) DM42PFT MA Inhibitor DM42PFT RN E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405. DM42PFT RU https://pubmed.ncbi.nlm.nih.gov/21212416 DM45DS8 DI DM45DS8 DM45DS8 DN NKTR-181 DM45DS8 TI TTKWM86 DM45DS8 TN Opioid receptor mu (MOP) DM45DS8 MA Agonist DM45DS8 RN A Review of Abuse-Deterrent Opioids For Chronic Nonmalignant Pain. P T. 2012 July; 37(7): 412-418. DM45DS8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411218/ DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTOA6YT DM49IGE TN MERS-CoV RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/31924756 DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTKXI53 DM49IGE TN SARS-CoV RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/31924756 DM49IGE DI DM49IGE DM49IGE DN Remdesivir DM49IGE TI TTV1095 DM49IGE TN COVID-19 RNA-directed RNA polymerase (RdRp) DM49IGE MA Inhibitor DM49IGE RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM49IGE RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM4CGH5 DI DM4CGH5 DM4CGH5 DN verubecestat DM4CGH5 TI TT8JRS7 DM4CGH5 TN Beta-secretase (BACE) DM4CGH5 MA Modulator DM4CGH5 RN BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. DM4CGH5 RU https://pubmed.ncbi.nlm.nih.gov/25621019 DM4CGH5 DI DM4CGH5 DM4CGH5 DN verubecestat DM4CGH5 TI TTJUNZF DM4CGH5 TN Beta-secretase 1 (BACE1) DM4CGH5 MA Inhibitor DM4CGH5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4CGH5 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DM4CSDH DI DM4CSDH DM4CSDH DN CS-8958 DM4CSDH TI TT50QJ3 DM4CSDH TN Influenza Neuraminidase (Influ NA) DM4CSDH MA Inhibitor DM4CSDH RN Developing new antiviral agents for influenza treatment: what does the future hold Clin Infect Dis. 2009 Jan 1;48 Suppl 1:S3-13. DM4CSDH RU https://pubmed.ncbi.nlm.nih.gov/19067613 DM4E9PK DI DM4E9PK DM4E9PK DN AM-111 DM4E9PK TI TTR2TXZ DM4E9PK TN Jun N terminal kinase (JNK) DM4E9PK MA Modulator DM4E9PK RN The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985. DM4E9PK RU https://www.ncbi.nlm.nih.gov/pubmed/22427801 DM4EGPN DI DM4EGPN DM4EGPN DN Lanperisone DM4EGPN TI TT84DRB DM4EGPN TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DM4EGPN MA Modulator DM4EGPN RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DM4EGPN RU https://pubmed.ncbi.nlm.nih.gov/16126840 DM4FHQR DI DM4FHQR DM4FHQR DN Canfosfamide DM4FHQR TI TT40K12 DM4FHQR TN Glutathione S-transferase P (GSTP1) DM4FHQR MA Modulator DM4FHQR RN Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA). Biochemistry. 2013 Nov 12;52(45):8069-78. DM4FHQR RU https://pubmed.ncbi.nlm.nih.gov/24066958 DM4FPM3 DI DM4FPM3 DM4FPM3 DN Amediplase DM4FPM3 TI TTGY7WI DM4FPM3 TN Urokinase-type plasminogen activator (PLAU) DM4FPM3 MA Activator DM4FPM3 RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DM4FPM3 RU https://pubmed.ncbi.nlm.nih.gov/16503827 DM4GWL7 DI DM4GWL7 DM4GWL7 DN Gefapixant DM4GWL7 TI TT2THBD DM4GWL7 TN P2X purinoceptor 3 (P2RX3) DM4GWL7 MA Inhibitor DM4GWL7 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM4GWL7 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM4GXW3 DI DM4GXW3 DM4GXW3 DN Ataluren DM4GXW3 TI TT2TNRM DM4GXW3 TN Dystrophin nonsense mutant (DMD) DM4GXW3 MA Modulator DM4GXW3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7341). DM4GXW3 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7341 DM4HK8Z DI DM4HK8Z DM4HK8Z DN ASTX727 DM4HK8Z TI TTHVCUP DM4HK8Z TN DNA [cytosine-5]-methyltransferase (DNMT) DM4HK8Z MA Inhibitor DM4HK8Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4HK8Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4HQ52 DI DM4HQ52 DM4HQ52 DN APL-2 DM4HQ52 TI TTJGY7A DM4HQ52 TN Complement C3 (CO3) DM4HQ52 MA Inhibitor DM4HQ52 RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DM4HQ52 RU https://pubmed.ncbi.nlm.nih.gov/30072728 DM4HYMS DI DM4HYMS DM4HYMS DN ABT-888 DM4HYMS TI TTEBCY8 DM4HYMS TN Poly [ADP-ribose] polymerase (PARP) DM4HYMS MA Modulator DM4HYMS RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4HYMS RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4K9WH DI DM4K9WH DM4K9WH DN R1678 DM4K9WH TI TTHJTF7 DM4K9WH TN Glycine transporter GlyT-1 (SLC6A9) DM4K9WH MA Blocker DM4K9WH RN Clinical pipeline report, company report or official report of Roche (2009). DM4K9WH RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM4N1SP DI DM4N1SP DM4N1SP DN Shigamabs DM4N1SP TI TT1HYOF DM4N1SP TN Bacterial Shiga toxin 2 subunit B (Bact stxII) DM4N1SP MA Modulator DM4N1SP RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DM4N1SP RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DM4NX0C DI DM4NX0C DM4NX0C DN Fevipiprant DM4NX0C TI TTQDMX5 DM4NX0C TN Prostaglandin D2 receptor 2 (PTGDR2) DM4NX0C MA Antagonist DM4NX0C RN Fevipiprant in the treatment of asthma. Expert Opin Investig Drugs. 2018 Feb;27(2):199-207. DM4NX0C RU https://pubmed.ncbi.nlm.nih.gov/29363343 DM4OAIU DI DM4OAIU DM4OAIU DN LMI070 DM4OAIU TI TT8QL6X DM4OAIU TN Survival motor neuron protein (SMN1) DM4OAIU MA Modulator DM4OAIU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4OAIU RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4OHMP DI DM4OHMP DM4OHMP DN A-3309 DM4OHMP TI TTPI1M5 DM4OHMP TN Ileal sodium/bile acid cotransporter (SLC10A2) DM4OHMP MA Inhibitor DM4OHMP RN Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84. DM4OHMP RU https://pubmed.ncbi.nlm.nih.gov/23215781 DM4P5UJ DI DM4P5UJ DM4P5UJ DN VM-501 DM4P5UJ TI TTGUYTR DM4P5UJ TN Interleukin-11 (IL11) DM4P5UJ MA Agonist DM4P5UJ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033052) DM4P5UJ RU http://adisinsight.springer.com/drugs/800033052 DM4SKYI DI DM4SKYI DM4SKYI DN PAMAQUESIDE DM4SKYI TI TT61VTP DM4SKYI TN Cholesterol uptake (Chole uptake) DM4SKYI MA Modulator DM4SKYI RN Comparison of synthetic saponin cholesterol absorption inhibitors in rabbits: evidence for a non-stoichiometric, intestinal mechanism of action. J Lipid Res. 1999 Mar;40(3):464-74. DM4SKYI RU https://pubmed.ncbi.nlm.nih.gov/10064735 DM4TOEQ DI DM4TOEQ DM4TOEQ DN Spartalizumab DM4TOEQ TI TTNBFWK DM4TOEQ TN Programmed cell death protein 1 (PD-1) DM4TOEQ RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM4TOEQ RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM4U5NF DI DM4U5NF DM4U5NF DN ISIS-TTR DM4U5NF TI TTPOYU7 DM4U5NF TN Transthyretin messenger RNA (TTR mRNA) DM4U5NF RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DM4U5NF RU http://www.isispharm.com/index.htm DM4VJ5Q DI DM4VJ5Q DM4VJ5Q DN ATG-Fresenius S DM4VJ5Q TI TTXQYT6 DM4VJ5Q TN T-cells (T-cells) DM4VJ5Q RN Clinical pipeline report, company report or official report of Neovii Biotech. DM4VJ5Q RU http://www.neoviibiotech.com/products-and-pipeline/atg-fresenius.html DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TT6L509 DM4W8RE TN Coagulation factor IIa (F2) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 2: optimization of the P2-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2648-53. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16460939 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TTP86E2 DM4W8RE TN Plasminogen (PLG) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TT2WR1T DM4W8RE TN Cationic trypsinogen (PRSS1) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4W8RE DI DM4W8RE DM4W8RE DN Melagatran DM4W8RE TI TTCIHJA DM4W8RE TN Coagulation factor Xa (F10) DM4W8RE MA Inhibitor DM4W8RE RN Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. DM4W8RE RU https://pubmed.ncbi.nlm.nih.gov/16517159 DM4XBM7 DI DM4XBM7 DM4XBM7 DN DiaPep-277 DM4XBM7 TI TT9HL5R DM4XBM7 TN Mitochondrial matrix protein P1 (HSPD1) DM4XBM7 MA Modulator DM4XBM7 RN Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev. 2007 May;23(4):269-75. DM4XBM7 RU https://pubmed.ncbi.nlm.nih.gov/17024692 DM4XSQ2 DI DM4XSQ2 DM4XSQ2 DN FG-4592 DM4XSQ2 TI TT9ISBX DM4XSQ2 TN HIF-prolyl hydroxylase 2 (HPH-2) DM4XSQ2 MA Inhibitor DM4XSQ2 RN Crystalline forms of a prolyl hydroxylase inhibitor. US9115085. DM4XSQ2 RU http://www.freepatentsonline.com/US9115085.html DM4XSQ2 DI DM4XSQ2 DM4XSQ2 DN FG-4592 DM4XSQ2 TI TTMHFRY DM4XSQ2 TN HIF-prolyl hydroxylase 1 (HPH-1) DM4XSQ2 MA Inhibitor DM4XSQ2 RN The latest advances in kidney diseases and related disorders. Drug News Perspect. 2007 Dec;20(10):647-54. DM4XSQ2 RU https://pubmed.ncbi.nlm.nih.gov/18301799 DM4Y1SP DI DM4Y1SP DM4Y1SP DN Carisbamate DM4Y1SP TI TTRK8B9 DM4Y1SP TN Sodium channel unspecific (NaC) DM4Y1SP MA Blocker DM4Y1SP RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DM4Y1SP RU https://pubmed.ncbi.nlm.nih.gov/19008076 DM4Y7WV DI DM4Y7WV DM4Y7WV DN GRASPA DM4Y7WV TI TT4WT91 DM4Y7WV TN Asparaginase (ASRGL1) DM4Y7WV MA Modulator DM4Y7WV RN l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol. 2011 Apr;153(1):58-65. DM4Y7WV RU https://pubmed.ncbi.nlm.nih.gov/21332712 DM4YDAJ DI DM4YDAJ DM4YDAJ DN Sildenafil DM4YDAJ TI TTRYFSB DM4YDAJ TN HUMAN phosphodiesterase type 5 (PDE5) DM4YDAJ MA Inhibitor DM4YDAJ RN Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol. 2005 Feb;79(3):1966-9. doi: 10.1128/JVI.79.3.1966-1969.2005. DM4YDAJ RU https://pubmed.ncbi.nlm.nih.gov/15650225 DM4YGWA DI DM4YGWA DM4YGWA DN Esonarimod DM4YGWA TI TTGD6BY DM4YGWA TN TNF-alpha/IL-1 beta production (TNFA/IL1B produ) DM4YGWA MA Modulator DM4YGWA RN KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line. Drugs Exp Clin Res. 2002;28(5):197-205. DM4YGWA RU https://pubmed.ncbi.nlm.nih.gov/12635495 DM4Z9QI DI DM4Z9QI DM4Z9QI DN Olokizumab DM4Z9QI TI TTT1V78 DM4Z9QI TN Interleukin-6 (IL6) DM4Z9QI MA Modulator DM4Z9QI RN Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study. Ann Rheum Dis. 2014 September; 73(9): 1607-1615. DM4Z9QI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4145439/ DM50SNX DI DM50SNX DM50SNX DN Bucelipase alfa DM50SNX TI TTTRNQW DM50SNX TN Bile-salt-activated lipase (CEL) DM50SNX MA Modulator DM50SNX RN ClinicalTrials.gov (NCT00743483) Efficacy of Bucelipase Alfa (BSSL) in Patients With Cystic Fibrosis and Pancreatic Insufficiency. U.S. National Institutes of Health. DM50SNX RU https://clinicaltrials.gov/ct2/show/NCT00743483 DM51JW4 DI DM51JW4 DM51JW4 DN BIIB037 DM51JW4 TI TTE4KHA DM51JW4 TN Amyloid beta A4 protein (APP) DM51JW4 MA Modulator DM51JW4 RN Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18. DM51JW4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/ DM52QEZ DI DM52QEZ DM52QEZ DN Zalutumumab DM52QEZ TI TTGKNB4 DM52QEZ TN Epidermal growth factor receptor (EGFR) DM52QEZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM52QEZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM53J6B DI DM53J6B DM53J6B DN PDR001 DM53J6B TI TTNBFWK DM53J6B TN Programmed cell death protein 1 (PD-1) DM53J6B MA Antagonist DM53J6B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM53J6B RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM57B9J DI DM57B9J DM57B9J DN Biferonex DM57B9J TI TT4TZ8J DM57B9J TN Interferon-beta (IFNB1) DM57B9J MA Modulator DM57B9J RN Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs. 2009;23(6):453-62. DM57B9J RU https://pubmed.ncbi.nlm.nih.gov/19480465 DM5DAP3 DI DM5DAP3 DM5DAP3 DN PGF2ALPHA-IE DM5DAP3 TI TTT2ZAR DM5DAP3 TN Prostaglandin F2-alpha receptor (PTGFR) DM5DAP3 MA Modulator DM5DAP3 RN Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994 Oct;59(4):401-7. DM5DAP3 RU https://pubmed.ncbi.nlm.nih.gov/7532135 DM5DRMY DI DM5DRMY DM5DRMY DN P1101 DM5DRMY TI TT95SOA DM5DRMY TN Interferon alpha (IFNA) DM5DRMY MA Inhibitor DM5DRMY RN Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94. DM5DRMY RU https://pubmed.ncbi.nlm.nih.gov/25545244 DM5E73H DI DM5E73H DM5E73H DN Revusiran DM5E73H TI TTPOYU7 DM5E73H TN Transthyretin messenger RNA (TTR mRNA) DM5E73H RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DM5E73H RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fac/ DM5FZH4 DI DM5FZH4 DM5FZH4 DN ProstaVac DM5FZH4 TI TTS78AZ DM5FZH4 TN Prostate specific antigen (KLK3) DM5FZH4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DM5FZH4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTYPXQF DM5H0R9 TN Protein kinase C beta (PRKCB) DM5H0R9 MA Modulator DM5H0R9 RN The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83. DM5H0R9 RU https://pubmed.ncbi.nlm.nih.gov/18452078 DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTWTSCV DM5H0R9 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM5H0R9 MA Inhibitor DM5H0R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5H0R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5H0R9 DI DM5H0R9 DM5H0R9 DN Enzastaurin DM5H0R9 TI TTHBTOP DM5H0R9 TN PI3-kinase gamma (PIK3CG) DM5H0R9 MA Inhibitor DM5H0R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5H0R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5K6J4 DI DM5K6J4 DM5K6J4 DN AJM-300 DM5K6J4 TI TT6S84X DM5K6J4 TN Integrin alpha-4/beta-1 (ITGA4/B1) DM5K6J4 MA Modulator DM5K6J4 RN Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42. DM5K6J4 RU https://pubmed.ncbi.nlm.nih.gov/23623333 DM5KL8E DI DM5KL8E DM5KL8E DN IBI-308 DM5KL8E TI TTNBFWK DM5KL8E TN Programmed cell death protein 1 (PD-1) DM5KL8E RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM5KL8E RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM5L8QT DI DM5L8QT DM5L8QT DN INO-1001 DM5L8QT TI TTEBCY8 DM5L8QT TN Poly [ADP-ribose] polymerase (PARP) DM5L8QT MA Modulator DM5L8QT RN Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12. DM5L8QT RU https://pubmed.ncbi.nlm.nih.gov/20395771 DM5LQHB DI DM5LQHB DM5LQHB DN CCX-168 DM5LQHB TI TTHXFA1 DM5LQHB TN C5a anaphylatoxin chemotactic receptor (C5AR1) DM5LQHB MA Antagonist DM5LQHB RN Clinical pipeline report, company report or official report of ChemoCentryx. DM5LQHB RU http://www.chemocentryx.com/pipeline/orphan-and-rare-diseases/ DM5N1OB DI DM5N1OB DM5N1OB DN Asp-2151 DM5N1OB TI TTKCVJR DM5N1OB TN Herpes simplex virus Helicase-primase (HSV UL8) DM5N1OB MA Inhibitor DM5N1OB RN Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res. 2012 Feb;93(2):301-4. DM5N1OB RU https://pubmed.ncbi.nlm.nih.gov/22155691 DM5PRLA DI DM5PRLA DM5PRLA DN Fasinumab DM5PRLA TI TTDN3LF DM5PRLA TN Nerve growth factor (NGF) DM5PRLA MA Inhibitor DM5PRLA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5PRLA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM5S4DL DI DM5S4DL DM5S4DL DN Forigerimod DM5S4DL TI TTPVYKI DM5S4DL TN Signal transduction unspecific (ST) DM5S4DL MA Modulator DM5S4DL RN Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial. Arthritis Rheum. 2008 Dec;58(12):3873-83. DM5S4DL RU https://pubmed.ncbi.nlm.nih.gov/19035498 DM5S4LX DI DM5S4LX DM5S4LX DN Mirvetuximab soravtansine DM5S4LX TI TTVC37M DM5S4LX TN Folate receptor alpha (FOLR1) DM5S4LX MA Antagonist DM5S4LX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5S4LX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5ST9Z DI DM5ST9Z DM5ST9Z DN Zolbetuximab DM5ST9Z TI TT6PKBX DM5ST9Z TN Claudin-18 (CLDN18) DM5ST9Z RN FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021 May;32(5):609-619. DM5ST9Z RU https://pubmed.ncbi.nlm.nih.gov/33610734 DM5T4IS DI DM5T4IS DM5T4IS DN VP-102 DM5T4IS TI TTHTKNY DM5T4IS TN Serine/threonine PP2A-alpha (PPP2CA) DM5T4IS MA Inhibitor DM5T4IS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5T4IS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5T4IS DI DM5T4IS DM5T4IS DN VP-102 DM5T4IS TI TTLA7IX DM5T4IS TN Protein phosphatase 1A (PPM1A) DM5T4IS MA Inhibitor DM5T4IS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5T4IS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5VH6U DI DM5VH6U DM5VH6U DN Serlopitant DM5VH6U TI TTZPO1L DM5VH6U TN Substance-P receptor (TACR1) DM5VH6U MA Antagonist DM5VH6U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5VH6U RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM5WCV4 DI DM5WCV4 DM5WCV4 DN JX-594 DM5WCV4 TI TTNYZG2 DM5WCV4 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM5WCV4 MA Modulator DM5WCV4 RN Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther. 2006 Sep;14(3):361-70. DM5WCV4 RU https://pubmed.ncbi.nlm.nih.gov/16905462 DM5X7DJ DI DM5X7DJ DM5X7DJ DN Chlorpromazine DM5X7DJ TI TTAIY2U DM5X7DJ TN HUMAN clathrin-mediated endocytosis (RME) DM5X7DJ MA Inhibitor DM5X7DJ RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM5X7DJ RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM5X849 DI DM5X849 DM5X849 DN MEDI4736 DM5X849 TI TT8ZLTI DM5X849 TN Programmed cell death 1 ligand 1 (PD-L1) DM5X849 MA Modulator DM5X849 RN National Cancer Institute Drug Dictionary (drug id 740856). DM5X849 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=740856 DM5XUQL DI DM5XUQL DM5XUQL DN CPI-613 DM5XUQL TI TTH8T6I DM5XUQL TN Alpha-ketoglutarate dehydrogenase (OGDH) DM5XUQL MA Modulator DM5XUQL RN A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab. 2014 Mar 10;2(1):4. DM5XUQL RU https://pubmed.ncbi.nlm.nih.gov/24612826 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TTD16BI DM5Y4Q2 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TTZGK1R DM5Y4Q2 TN HUMAN glycosylation of host receptor (GHR) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DM5Y4Q2 DI DM5Y4Q2 DM5Y4Q2 DN Azithromycin + hydroxychloroquine DM5Y4Q2 TI TT3A1EZ DM5Y4Q2 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DM5Y4Q2 MA Inhibitor DM5Y4Q2 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DM5Y4Q2 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DM60TVK DI DM60TVK DM60TVK DN CQA 206-291 DM60TVK TI TTEX248 DM60TVK TN Dopamine D2 receptor (D2R) DM60TVK MA Agonist DM60TVK RN The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist. Clin Neuropharmacol. 1989 Feb;12(1):55-9. DM60TVK RU https://pubmed.ncbi.nlm.nih.gov/2565766 DM624TW DI DM624TW DM624TW DN Omecamtiv mecarbil DM624TW TI TT9WOBN DM624TW TN Cardiac myosin (MYBPC3) DM624TW MA Modulator DM624TW RN CK-1827452, a sarcomere-directed cardiac myosin activator for acute and chronic heart disease. IDrugs. 2009 Apr;12(4):243-51. DM624TW RU https://pubmed.ncbi.nlm.nih.gov/19350469 DM62E7C DI DM62E7C DM62E7C DN CPL-7075 DM62E7C TI TTF8CQI DM62E7C TN Tumor necrosis factor (TNF) DM62E7C MA Inhibitor DM62E7C RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM62E7C RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM62QTW DI DM62QTW DM62QTW DN RTB101 DM62QTW TI TT4GO0F DM62QTW TN CREB-regulated transcription coactivator 1 (TORC1) DM62QTW MA Inhibitor DM62QTW RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DM62QTW RU https://pubmed.ncbi.nlm.nih.gov/30072728 DM64QG9 DI DM64QG9 DM64QG9 DN Diquafosol DM64QG9 TI TTOZHQC DM64QG9 TN P2Y purinoceptor 2 (P2RY2) DM64QG9 MA Agonist DM64QG9 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM64QG9 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM64WYC DI DM64WYC DM64WYC DN Atx-101 DM64WYC TI TTLG1PD DM64WYC TN Proliferating cell nuclear antigen (PCNA) DM64WYC MA Immunomodulator DM64WYC RN Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7):e70430. DM64WYC RU https://pubmed.ncbi.nlm.nih.gov/23936203 DM67P0F DI DM67P0F DM67P0F DN CS-038 DM67P0F TI TTZMAO3 DM67P0F TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM67P0F MA Modulator DM67P0F RN Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9. DM67P0F RU https://www.ncbi.nlm.nih.gov/pubmed/18065097 DM67P0F DI DM67P0F DM67P0F DN CS-038 DM67P0F TI TTJ584C DM67P0F TN Peroxisome proliferator-activated receptor alpha (PPARA) DM67P0F MA Modulator DM67P0F RN Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9. DM67P0F RU https://www.ncbi.nlm.nih.gov/pubmed/18065097 DM6BU57 DI DM6BU57 DM6BU57 DN Eraxis/Vfend DM6BU57 TI TTZMS1L DM6BU57 TN Fungal Papulacandin B resistance protein 1 (Fung FKS1) DM6BU57 MA Inhibitor DM6BU57 RN Pfizer. Product Development Pipeline. March 31 2009. DM6BU57 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM6BZCV DI DM6BZCV DM6BZCV DN Sivelestat DM6BZCV TI TTPLTSQ DM6BZCV TN Neutrophil elastase (NE) DM6BZCV MA Inhibitor DM6BZCV RN Neutrophil elastase inhibitor (sivelestat) reduces the levels of inflammatory mediators by inhibiting NF-kB. Inflamm Res. 2009 Apr;58(4):198-203. DM6BZCV RU https://pubmed.ncbi.nlm.nih.gov/19169649 DM6BZCV DI DM6BZCV DM6BZCV DN Sivelestat DM6BZCV TI TT3NKIB DM6BZCV TN Pancreatic elastase 1 (CELA1) DM6BZCV MA Inhibitor DM6BZCV RN Sivelestat (selective neutrophil elastase inhibitor) improves the mortality rate of sepsis associated with both acute respiratory distress syndrome... Shock. 2010 Jan;33(1):14-8. DM6BZCV RU https://pubmed.ncbi.nlm.nih.gov/19487982 DM6CHNJ DI DM6CHNJ DM6CHNJ DN Camptothecin DM6CHNJ TI TTGTQHC DM6CHNJ TN DNA topoisomerase I (TOP1) DM6CHNJ MA Modulator DM6CHNJ RN Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802. DM6CHNJ RU https://pubmed.ncbi.nlm.nih.gov/16990856 DM6ENSJ DI DM6ENSJ DM6ENSJ DN Tralokinumab DM6ENSJ TI TTMPZ7V DM6ENSJ TN Interleukin 13 receptor alpha-2 (IL13RA2) DM6ENSJ MA Modulator DM6ENSJ RN Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.Am J Respir Cell Mol Biol.2014 May;50(5):985-94. DM6ENSJ RU https://www.ncbi.nlm.nih.gov/pubmed/24325475 DM6ENSJ DI DM6ENSJ DM6ENSJ DN Tralokinumab DM6ENSJ TI TT0GVCH DM6ENSJ TN Interleukin-13 (IL13) DM6ENSJ MA Inhibitor DM6ENSJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6ENSJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM6HXTS DI DM6HXTS DM6HXTS DN Anamorelin DM6HXTS TI TTWDC17 DM6HXTS TN Growth hormone secretagogue receptor 1 (GHSR) DM6HXTS MA Stimulator DM6HXTS RN Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 2009 Jun;19(3):267-73. DM6HXTS RU https://pubmed.ncbi.nlm.nih.gov/19196529 DM6HXTS DI DM6HXTS DM6HXTS DN Anamorelin DM6HXTS TI TTHCF4J DM6HXTS TN Alpha-glucosidase (GLA) DM6HXTS MA Modulator DM6HXTS RN Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87. DM6HXTS RU https://www.ncbi.nlm.nih.gov/pubmed/23378626 DM6KRLW DI DM6KRLW DM6KRLW DN BQ788 DM6KRLW TI TT3ZTGU DM6KRLW TN Endothelin B receptor (EDNRB) DM6KRLW MA Antagonist DM6KRLW RN BQ788, an endothelin ET(B) receptor antagonist, attenuates stab wound injury-induced reactive astrocytes in rat brain. Glia. 1999 May;26(3):268-71. DM6KRLW RU https://pubmed.ncbi.nlm.nih.gov/10340767 DM6L4ZT DI DM6L4ZT DM6L4ZT DN SB-742457 DM6L4ZT TI TTJS8PY DM6L4ZT TN 5-HT 6 receptor (HTR6) DM6L4ZT MA Antagonist DM6L4ZT RN 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15. DM6L4ZT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/ DM6L5ZQ DI DM6L5ZQ DM6L5ZQ DN Vercirnon DM6L5ZQ TI TTIPS8B DM6L5ZQ TN C-C chemokine receptor type 9 (CCR9) DM6L5ZQ MA Modulator DM6L5ZQ RN GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs. 2010 Jul;13(7):472-81. DM6L5ZQ RU https://pubmed.ncbi.nlm.nih.gov/20582872 DM6LVCQ DI DM6LVCQ DM6LVCQ DN LY-CoV555 DM6LVCQ TI TTZ3COY DM6LVCQ TN COVID-19 spike glycoprotein (S) DM6LVCQ MA Inhibitor DM6LVCQ RN Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply. N Engl J Med. 2021 Jan 14;384(2):189. DM6LVCQ RU https://pubmed.ncbi.nlm.nih.gov/33378611 DM6P8HU DI DM6P8HU DM6P8HU DN Dutasteride + tamsulosin DM6P8HU TI TTNGILX DM6P8HU TN Adrenergic receptor alpha-1A (ADRA1A) DM6P8HU MA Antagonist DM6P8HU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6P8HU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6P8HU DI DM6P8HU DM6P8HU DN Dutasteride + tamsulosin DM6P8HU TI TT2A0DR DM6P8HU TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM6P8HU MA Inhibitor DM6P8HU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6P8HU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6PMNR DI DM6PMNR DM6PMNR DN Ulocuplumab DM6PMNR TI TTBID49 DM6PMNR TN C-X-C chemokine receptor type 4 (CXCR4) DM6PMNR MA Antagonist DM6PMNR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6PMNR RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTUTJGQ DM6QOVN TN Vascular endothelial growth factor receptor 2 (KDR) DM6QOVN MA Inhibitor DM6QOVN RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17416531 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTR5TV4 DM6QOVN TN ERBB2 messenger RNA (HER2 mRNA) DM6QOVN MA Inhibitor DM6QOVN RN Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/18077425 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TTGKNB4 DM6QOVN TN Epidermal growth factor receptor (EGFR) DM6QOVN MA Inhibitor DM6QOVN RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17416531 DM6QOVN DI DM6QOVN DM6QOVN DN HKI-272 DM6QOVN TI TT6EO5L DM6QOVN TN Erbb2 tyrosine kinase receptor (HER2) DM6QOVN MA Inhibitor DM6QOVN RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM6QOVN RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM6QZIA DI DM6QZIA DM6QZIA DN Solithromycin DM6QZIA TI TTUWYEA DM6QZIA TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM6QZIA MA Modulator DM6QZIA RN Company report (cempra) DM6QZIA RU http://www.cempra.com/products/Solithromycin-cem-101/ DM6R2XF DI DM6R2XF DM6R2XF DN FKB238 DM6R2XF TI TT9HKJA DM6R2XF TN Vascular endothelial growth factor (VEGF) DM6R2XF MA Inhibitor DM6R2XF RN Clinical pipeline report, company report or official report of Fujifilm. DM6R2XF RU https://fujifilmkyowakirin-biologics.com/en/pipeline/ DM6RUKX DI DM6RUKX DM6RUKX DN BVT.2733 DM6RUKX TI TTN7BL9 DM6RUKX TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM6RUKX MA Inhibitor DM6RUKX RN Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology. 2003 Nov;144(11):4755-62. DM6RUKX RU https://pubmed.ncbi.nlm.nih.gov/12960099 DM6RWBN DI DM6RWBN DM6RWBN DN Beperminogene perplasmid DM6RWBN TI TTNDSF4 DM6RWBN TN Proto-oncogene c-Met (MET) DM6RWBN MA Modulator DM6RWBN RN Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56. DM6RWBN RU https://pubmed.ncbi.nlm.nih.gov/25190335 DM6S4R2 DI DM6S4R2 DM6S4R2 DN DA-3031 DM6S4R2 TI TT5TQ2W DM6S4R2 TN Granulocyte colony-stimulating factor (CSF3) DM6S4R2 MA Modulator DM6S4R2 RN A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.Invest New Drugs.2013 Oct;31(5):1300-6. DM6S4R2 RU https://www.ncbi.nlm.nih.gov/pubmed/23677653 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTMTWOS DM6V34C TN Matrix metalloproteinase-7 (MMP-7) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTMX39J DM6V34C TN Matrix metalloproteinase-1 (MMP-1) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6V34C DI DM6V34C DM6V34C DN Marimastat DM6V34C TI TTLM12X DM6V34C TN Matrix metalloproteinase-2 (MMP-2) DM6V34C MA Inhibitor DM6V34C RN Metalloelastase (MMP-12) induced inflammatory response in mice airways: effects of dexamethasone, rolipram and marimastat. Eur J Pharmacol. 2007 Mar 15;559(1):75-81. DM6V34C RU https://pubmed.ncbi.nlm.nih.gov/17234180 DM6WZG8 DI DM6WZG8 DM6WZG8 DN AXS-05 DM6WZG8 TI TT9IK2Z DM6WZG8 TN N-methyl-D-aspartate receptor (NMDAR) DM6WZG8 MA Antagonist DM6WZG8 RN Clinical pipeline report, company report or official report of Axsome Therapeutics. DM6WZG8 RU https://axsome.com/axs-pipeline/about-axs-05/ DM71CK8 DI DM71CK8 DM71CK8 DN Beloranib DM71CK8 TI TTZL0OI DM71CK8 TN Methionine aminopeptidase 2 (METAP2) DM71CK8 MA Inhibitor DM71CK8 RN 2011 Pipeline of Zafgen. DM71CK8 RU http://www.zafgen.com/approach-pipeline.html DM71GPM DI DM71GPM DM71GPM DN Grippol Plus DM71GPM TI TT3J5ZI DM71GPM TN Cell mediated immunity response (CMIR) DM71GPM RN Clinical pipeline report, company report or official report of Petrovax. DM71GPM RU http://petrovax.com/medication/catalog/grippallplus/ DM71ZL6 DI DM71ZL6 DM71ZL6 DN TZTX-001 DM71ZL6 TI TTZAYWL DM71ZL6 TN Estrogen receptor (ESR) DM71ZL6 MA Modulator DM71ZL6 RN Clinical pipeline report, company report or official report of Pharmabiz. DM71ZL6 RU http://www.pharmabiz.com/PrintArticle.aspx?aid=77569&sid=2 DM735FA DI DM735FA DM735FA DN IMO-2125 DM735FA TI TTSHG0T DM735FA TN Toll-like receptor 9 (TLR9) DM735FA MA Agonist DM735FA RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011). DM735FA RU http://www.iderapharma.com/ DM76GZ0 DI DM76GZ0 DM76GZ0 DN Angiotensin-(1-7) DM76GZ0 TI TTOISYB DM76GZ0 TN Proto-oncogene Mas (MAS) DM76GZ0 MA Agonist DM76GZ0 RN New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8. DM76GZ0 RU https://pubmed.ncbi.nlm.nih.gov/23166114 DM7BCWT DI DM7BCWT DM7BCWT DN Imiglitazar DM7BCWT TI TTZMAO3 DM7BCWT TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM7BCWT MA Modulator DM7BCWT RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM7BCWT RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM7BCWT DI DM7BCWT DM7BCWT DN Imiglitazar DM7BCWT TI TTJ584C DM7BCWT TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7BCWT MA Modulator DM7BCWT RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM7BCWT RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM7BSRH DI DM7BSRH DM7BSRH DN Tramiprosate DM7BSRH TI TTE4KHA DM7BSRH TN Amyloid beta A4 protein (APP) DM7BSRH MA Antagonist DM7BSRH RN Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47. DM7BSRH RU https://pubmed.ncbi.nlm.nih.gov/16675063 DM7EBH9 DI DM7EBH9 DM7EBH9 DN ALX-0081 DM7EBH9 TI TT3SZBT DM7EBH9 TN von Willebrand factor (VWF) DM7EBH9 MA Binder DM7EBH9 RN Clinical pipeline report, company report or official report of Ablynx DM7EBH9 RU http://hugin.info/137912/R/1338761/319541.pdf DM7EOBQ DI DM7EOBQ DM7EOBQ DN Entacapone+levodopa+carbidopa DM7EOBQ TI TTKWFB8 DM7EOBQ TN Catechol-O-methyl-transferase (COMT) DM7EOBQ MA Inhibitor DM7EOBQ RN Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. DM7EOBQ RU https://pubmed.ncbi.nlm.nih.gov/16083328 DM7EOBQ DI DM7EOBQ DM7EOBQ DN Entacapone+levodopa+carbidopa DM7EOBQ TI TTEX248 DM7EOBQ TN Dopamine D2 receptor (D2R) DM7EOBQ MA Agonist DM7EOBQ RN Emerging drugs for restless legs syndrome. Expert Opin Emerg Drugs. 2005 Aug;10(3):537-52. DM7EOBQ RU https://pubmed.ncbi.nlm.nih.gov/16083328 DM7EVUF DI DM7EVUF DM7EVUF DN ABL001 DM7EVUF TI TTS7G69 DM7EVUF TN Fusion protein Bcr-Abl (Bcr-Abl) DM7EVUF MA Inhibitor DM7EVUF RN Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019 Dec 12;381(24):2315-2326. DM7EVUF RU https://pubmed.ncbi.nlm.nih.gov/31826340 DM7F2VG DI DM7F2VG DM7F2VG DN SA-237 DM7F2VG TI TT0E5SK DM7F2VG TN Interleukin 6 receptor (IL6R) DM7F2VG MA Antagonist DM7F2VG RN IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA. MAbs. 2013 March 1; 5(2): 178-201. DM7F2VG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893229/ DM7HQNX DI DM7HQNX DM7HQNX DN Renzapride DM7HQNX TI TT07C3Y DM7HQNX TN 5-HT 4 receptor (HTR4) DM7HQNX MA Modulator DM7HQNX RN Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. DM7HQNX RU https://www.ncbi.nlm.nih.gov/pubmed/18095752 DM7HQNX DI DM7HQNX DM7HQNX DN Renzapride DM7HQNX TI TTNXLKE DM7HQNX TN 5-HT 3 receptor (5HT3R) DM7HQNX MA Modulator DM7HQNX RN Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63. DM7HQNX RU https://www.ncbi.nlm.nih.gov/pubmed/18095752 DM7JFDO DI DM7JFDO DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO TI TT3SZBT DM7JFDO TN von Willebrand factor (VWF) DM7JFDO MA Modulator DM7JFDO RN 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418. DM7JFDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/ DM7JFDO DI DM7JFDO DM7JFDO DN Recombinant von Willebrand factor/recombinant Factor VIII complex DM7JFDO TI TT1290U DM7JFDO TN Coagulation factor VIII (F8) DM7JFDO MA Modulator DM7JFDO RN 6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418. DM7JFDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997296/ DM7KI4E DI DM7KI4E DM7KI4E DN Oblimersen DM7KI4E TI TTJGNVC DM7KI4E TN Apoptosis regulator Bcl-2 (BCL-2) DM7KI4E MA Inhibitor DM7KI4E RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM7KI4E RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM7NJYC DI DM7NJYC DM7NJYC DN BGB-A317 DM7NJYC TI TTNBFWK DM7NJYC TN Programmed cell death protein 1 (PD-1) DM7NJYC MA Inhibitor DM7NJYC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7NJYC RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM7NV1I DI DM7NV1I DM7NV1I DN SPD-465 DM7NV1I TI TTIU98M DM7NV1I TN Trace amine-associated receptor-1 (TAAR1) DM7NV1I MA Agonist DM7NV1I RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DM7NV1I RU https://pubmed.ncbi.nlm.nih.gov/24950453 DM7OSHC DI DM7OSHC DM7OSHC DN Pinaverium bromide DM7OSHC TI TTXHYV6 DM7OSHC TN Voltage-gated L-type calcium channel (L-CaC) DM7OSHC MA Blocker DM7OSHC RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM7OSHC RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM7QI29 DI DM7QI29 DM7QI29 DN Crenezumab DM7QI29 TI TTE4KHA DM7QI29 TN Amyloid beta A4 protein (APP) DM7QI29 MA Modulator DM7QI29 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM7QI29 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM7R145 DI DM7R145 DM7R145 DN Otesaconazole DM7R145 TI TTTSOUD DM7R145 TN Candida Cytochrome P450 51 (Candi ERG11) DM7R145 MA Inhibitor DM7R145 RN Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis. Antimicrob Agents Chemother. 2015 Sep;59(9):5567-73. DM7R145 RU https://pubmed.ncbi.nlm.nih.gov/26124165 DM7R3N5 DI DM7R3N5 DM7R3N5 DN Mirikizumab DM7R3N5 TI TTRTK6Y DM7R3N5 TN Interleukin-12 alpha (IL12A) DM7R3N5 MA Inhibitor DM7R3N5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7R3N5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7V9LH DI DM7V9LH DM7V9LH DN Blisibimod DM7V9LH TI TTWMIDN DM7V9LH TN B-cell-activating factor (TNFSF13B) DM7V9LH MA Inhibitor DM7V9LH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7V9LH RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM7WORZ DI DM7WORZ DM7WORZ DN LY-686017 DM7WORZ TI TTZPO1L DM7WORZ TN Substance-P receptor (TACR1) DM7WORZ MA Antagonist DM7WORZ RN Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498. DM7WORZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2804869/ DM7WYXJ DI DM7WYXJ DM7WYXJ DN P-1101 DM7WYXJ TI TTSIUJ9 DM7WYXJ TN Interferon-alpha 2 (IFNA2) DM7WYXJ MA Modulator DM7WYXJ RN Effects of PEG-interferon-alpha-2A on Schistosoma mansoni infection in mice. J Parasitol. 2010 Aug;96(4):703-8. DM7WYXJ RU https://pubmed.ncbi.nlm.nih.gov/20486736 DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TT9B4N3 DM7YNV9 TN Prostaglandin receptor (PTGR) DM7YNV9 MA Modulator DM7YNV9 RN Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677. DM7YNV9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/ DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TTV8DM2 DM7YNV9 TN Bacterial Dihydrofolate reductase (Bact DHFR) DM7YNV9 MA Modulator DM7YNV9 RN Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.Future Microbiol.2009 Mar;4(2):131-44. DM7YNV9 RU https://www.ncbi.nlm.nih.gov/pubmed/19257839 DM7YNV9 DI DM7YNV9 DM7YNV9 DN Iclaprim DM7YNV9 TI TTYZVDJ DM7YNV9 TN Dihydrofolate reductase (DHFR) DM7YNV9 MA Inhibitor DM7YNV9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7YNV9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTJQOD7 DM7ZFBA TN 5-HT 2A receptor (HTR2A) DM7ZFBA MA Antagonist DM7ZFBA RN Antagonism of 5-hydroxytryptamine(2a) receptors attenuates the behavioral effects of cocaine in rats. J Pharmacol Exp Ther. 2001 Apr;297(1):357-63. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/11259563 DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTQ6VDM DM7ZFBA TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM7ZFBA MA Inhibitor DM7ZFBA RN Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/20493697 DM7ZFBA DI DM7ZFBA DM7ZFBA DN M100907 DM7ZFBA TI TTWJBZ5 DM7ZFBA TN 5-HT 2C receptor (HTR2C) DM7ZFBA MA Inhibitor DM7ZFBA RN Non-basic ligands for aminergic GPCRs: the discovery and development diaryl sulfones as selective, orally bioavailable 5-HT2A receptor antagonists ... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3708-12. DM7ZFBA RU https://pubmed.ncbi.nlm.nih.gov/20493697 DM7ZOAE DI DM7ZOAE DM7ZOAE DN GFT-505 DM7ZOAE TI TT2JWF6 DM7ZOAE TN Peroxisome proliferator-activated receptor delta (PPARD) DM7ZOAE MA Modulator DM7ZOAE RN Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30. DM7ZOAE RU https://www.ncbi.nlm.nih.gov/pubmed/23715754 DM7ZOAE DI DM7ZOAE DM7ZOAE DN GFT-505 DM7ZOAE TI TTJ584C DM7ZOAE TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7ZOAE MA Modulator DM7ZOAE RN Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30. DM7ZOAE RU https://www.ncbi.nlm.nih.gov/pubmed/23715754 DM803GL DI DM803GL DM803GL DN CIPEMASTAT DM803GL TI TTGA1IV DM803GL TN Matrix metalloproteinase-8 (MMP-8) DM803GL MA Modulator DM803GL RN Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. DM803GL RU https://pubmed.ncbi.nlm.nih.gov/24491581 DM803GL DI DM803GL DM803GL DN CIPEMASTAT DM803GL TI TTMX39J DM803GL TN Matrix metalloproteinase-1 (MMP-1) DM803GL MA Modulator DM803GL RN Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infect Immun. 2014 Apr;82(4):1710-8. DM803GL RU https://pubmed.ncbi.nlm.nih.gov/24491581 DM823WQ DI DM823WQ DM823WQ DN FP-1201 DM823WQ TI TT4TZ8J DM823WQ TN Interferon-beta (IFNB1) DM823WQ MA Modulator DM823WQ RN The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.Lancet Respir Med. 2014 Feb;2(2):98-107. DM823WQ RU https://www.ncbi.nlm.nih.gov/pubmed/24503265 DM83EBP DI DM83EBP DM83EBP DN Alisporivir DM83EBP TI TTATDGJ DM83EBP TN Calcium signal-modulating cyclophilin ligand (CAML) DM83EBP MA Inhibitor DM83EBP RN DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687. DM83EBP RU https://pubmed.ncbi.nlm.nih.gov/21060866 DM83SEB DI DM83SEB DM83SEB DN Faricimab DM83SEB TI TTOHSBA DM83SEB TN Vascular endothelial growth factor A (VEGFA) DM83SEB RN Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DM83SEB RU https://pubmed.ncbi.nlm.nih.gov/33471572 DM83SEB DI DM83SEB DM83SEB DN Faricimab DM83SEB TI TTKLQTJ DM83SEB TN Angiopoietin-2 (ANGPT2) DM83SEB RN Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200. DM83SEB RU https://pubmed.ncbi.nlm.nih.gov/33471572 DM84AD1 DI DM84AD1 DM84AD1 DN Arofylline DM84AD1 TI TTV5CGO DM84AD1 TN Phosphodiesterase 4 (PDE4) DM84AD1 MA Inhibitor DM84AD1 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM84AD1 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM84LO5 DI DM84LO5 DM84LO5 DN MK-8109 DM84LO5 TI TTVC37M DM84LO5 TN Folate receptor alpha (FOLR1) DM84LO5 MA Modulator DM84LO5 RN A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996. DM84LO5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560517/ DM8D13S DI DM8D13S DM8D13S DN MABp1 DM8D13S TI TTPM6HI DM8D13S TN Interleukin-1 alpha (IL1A) DM8D13S MA Inhibitor DM8D13S RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8D13S RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8E51L DI DM8E51L DM8E51L DN FASORACETAM DM8E51L TI TTAN6JD DM8E51L TN Glutamate receptor AMPA (GRIA) DM8E51L MA Modulator DM8E51L RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM8E51L RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM8FSPV DI DM8FSPV DM8FSPV DN JTZ-951 DM8FSPV TI TTJQFBG DM8FSPV TN HIF-prolyl hydroxylase (HPH) DM8FSPV MA Modulator DM8FSPV RN DOI: 10.1038/nrneph.2015.82 DM8FSPV RU http://www.nature.com/nrneph/journal/v11/n7/fig_tab/nrneph.2015.82_T1.html DM8GFEV DI DM8GFEV DM8GFEV DN Atacicept DM8GFEV TI TTOI1RM DM8GFEV TN A proliferation-inducing ligand (APRIL) DM8GFEV MA Modulator DM8GFEV RN Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis. Nervenarzt. 2009 Dec;80(12):1462-72. DM8GFEV RU https://pubmed.ncbi.nlm.nih.gov/19779889 DM8HCFD DI DM8HCFD DM8HCFD DN Sarilumab DM8HCFD TI TTDVAKP DM8HCFD TN HUMAN interleukin-6 receptor (IL6R) DM8HCFD MA Blocker DM8HCFD RN IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015 May;16(5):448-57. DM8HCFD RU https://pubmed.ncbi.nlm.nih.gov/25898198 DM8HVNR DI DM8HVNR DM8HVNR DN Recombinant acidic fibroblast growth factor DM8HVNR TI TT5HU6Z DM8HVNR TN Fibroblast growth factor (FGF) DM8HVNR MA Modulator DM8HVNR RN Molecular characterization of recombinant human acidic fibroblast growth factor produced in E. coli: comparative studies with human basic fibroblast growth factor. Mol Endocrinol. 1990 Jun;4(6):869-79. DM8HVNR RU https://pubmed.ncbi.nlm.nih.gov/1700280 DM8J29L DI DM8J29L DM8J29L DN PF-04965842 DM8J29L TI TTJSQEF DM8J29L TN Tyrosine-protein kinase (PTK) DM8J29L MA Inhibitor DM8J29L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8J29L RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8JWNA DI DM8JWNA DM8JWNA DN NVP-LAQ824 DM8JWNA TI TT6R7JZ DM8JWNA TN Histone deacetylase 1 (HDAC1) DM8JWNA MA Inhibitor DM8JWNA RN NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22. DM8JWNA RU https://pubmed.ncbi.nlm.nih.gov/12816865 DM8JWNA DI DM8JWNA DM8JWNA DN NVP-LAQ824 DM8JWNA TI TTBH0VX DM8JWNA TN Histone deacetylase (HDAC) DM8JWNA MA Inhibitor DM8JWNA RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM8JWNA RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM8K5Z6 DI DM8K5Z6 DM8K5Z6 DN Motexafin lutetium DM8K5Z6 TI TTS78AZ DM8K5Z6 TN Prostate specific antigen (KLK3) DM8K5Z6 MA Modulator DM8K5Z6 RN Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen. Clin Cancer Res. 2008 Aug 1;14(15):4869-76. DM8K5Z6 RU https://pubmed.ncbi.nlm.nih.gov/18676760 DM8L3JU DI DM8L3JU DM8L3JU DN Fosclin DM8L3JU TI TTLH4J3 DM8L3JU TN Plasmodium DOXP reductoisomerase (Malaria DXR) DM8L3JU MA Inhibitor DM8L3JU RN Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis. 2004 Mar 1;189(5):901-8. DM8L3JU RU https://pubmed.ncbi.nlm.nih.gov/14976608 DM8L7JD DI DM8L7JD DM8L7JD DN Zoniporide hydrochloride DM8L7JD TI TTGSEFH DM8L7JD TN Sodium/hydrogen exchanger 1 (SLC9A1) DM8L7JD MA Inhibitor DM8L7JD RN Zoniporde: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1). Cardiovasc Drug Rev. 2003 Spring;21(1):17-32. DM8L7JD RU https://pubmed.ncbi.nlm.nih.gov/12595915 DM8M2N3 DI DM8M2N3 DM8M2N3 DN Glycyrrhizin DM8M2N3 TI TTN7BL9 DM8M2N3 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM8M2N3 MA Inhibitor DM8M2N3 RN Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. Bioorg Med Chem. 2009 Aug 1;17(15):5722-32. DM8M2N3 RU https://pubmed.ncbi.nlm.nih.gov/19574056 DM8QIRN DI DM8QIRN DM8QIRN DN AMT-011 DM8QIRN TI TTOF3WZ DM8QIRN TN Lipoprotein lipase (LPL) DM8QIRN MA Modulator DM8QIRN RN Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70. DM8QIRN RU https://pubmed.ncbi.nlm.nih.gov/23527320 DM8RBHJ DI DM8RBHJ DM8RBHJ DN Esomeprazole magnesium + Aspirin DM8RBHJ TI TTF1QVM DM8RBHJ TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM8RBHJ MA Inhibitor DM8RBHJ RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM8RBHJ RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM8RLJ5 DI DM8RLJ5 DM8RLJ5 DN RAD-1901 DM8RLJ5 TI TTZAYWL DM8RLJ5 TN Estrogen receptor (ESR) DM8RLJ5 MA Modulator DM8RLJ5 RN RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models. Anticancer Drugs. 2015 Oct;26(9):948-56. DM8RLJ5 RU https://pubmed.ncbi.nlm.nih.gov/26164151 DM8SYTE DI DM8SYTE DM8SYTE DN AIR-insulin DM8SYTE TI TTF89GD DM8SYTE TN Interleukin-2 (IL2) DM8SYTE MA Modulator DM8SYTE RN The AIR inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther. 2007 Jun;9 Suppl 1:S41-7. DM8SYTE RU https://pubmed.ncbi.nlm.nih.gov/17563303 DM8VO16 DI DM8VO16 DM8VO16 DN KH-902 DM8VO16 TI TTVJ1D8 DM8VO16 TN Vascular endothelial growth factor receptor (VEGFR) DM8VO16 MA Modulator DM8VO16 RN Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53. DM8VO16 RU https://pubmed.ncbi.nlm.nih.gov/22340191 DM8Y12A DI DM8Y12A DM8Y12A DN PH-80 DM8Y12A TI TTOASGR DM8Y12A TN Neuroepithelial receptor (NR) DM8Y12A MA Modulator DM8Y12A RN Patents by Assignee Pherin Corporation. DM8Y12A RU http://patents.justia.com/assignee/pherin-corporation DM8Y4JS DI DM8Y4JS DM8Y4JS DN AC220 DM8Y4JS TI TTGJCWZ DM8Y4JS TN Fms-like tyrosine kinase 3 (FLT-3) DM8Y4JS MA Inhibitor DM8Y4JS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8Y4JS RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8Z0I3 DI DM8Z0I3 DM8Z0I3 DN MF-101 DM8Z0I3 TI TTOM3J0 DM8Z0I3 TN Estrogen receptor beta (ESR2) DM8Z0I3 MA Antagonist DM8Z0I3 RN MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause. 2009 May-Jun;16(3):458-65. DM8Z0I3 RU https://pubmed.ncbi.nlm.nih.gov/19182698 DM90AG2 DI DM90AG2 DM90AG2 DN Ularitide DM90AG2 TI TTJME02 DM90AG2 TN Atrial natriuretic peptide receptor A (NPR1) DM90AG2 MA Modulator DM90AG2 RN Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. Eur Heart J. 2015 Mar 21;36(12):715-23. DM90AG2 RU https://pubmed.ncbi.nlm.nih.gov/25670819 DM91LGU DI DM91LGU DM91LGU DN Abexinostat DM91LGU TI TTBH0VX DM91LGU TN Histone deacetylase (HDAC) DM91LGU MA Modulator DM91LGU RN Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31. DM91LGU RU https://pubmed.ncbi.nlm.nih.gov/25600050 DM936V7 DI DM936V7 DM936V7 DN GS-9674 DM936V7 TI TTS4UGC DM936V7 TN Farnesoid X-activated receptor (FXR) DM936V7 MA Agonist DM936V7 RN The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801. DM936V7 RU https://pubmed.ncbi.nlm.nih.gov/30661255 DM942HP DI DM942HP DM942HP DN Brivanib DM942HP TI TTUTJGQ DM942HP TN Vascular endothelial growth factor receptor 2 (KDR) DM942HP MA Modulator DM942HP RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM942HP RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM94Y6O DI DM94Y6O DM94Y6O DN BMN-701 DM94Y6O TI TTLPC70 DM94Y6O TN Lysosomal alpha-glucosidase (GAA) DM94Y6O MA Modulator DM94Y6O RN Clinical pipeline report, company report or official report of BioMarin Pharma. DM94Y6O RU https://www.bmrn.com/pipeline/igf2-gaa-for-pompe-disease.php DM95IPS DI DM95IPS DM95IPS DN Tivanisiran DM95IPS TI TT50OG3 DM95IPS TN TRPV1 messenger RNA (TRPV1 mRNA) DM95IPS MA Inhibitor DM95IPS RN Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018 Apr;27(4):421-426. DM95IPS RU https://pubmed.ncbi.nlm.nih.gov/29569947 DM97S10 DI DM97S10 DM97S10 DN DP-b99 DM97S10 TI TT6X50U DM97S10 TN Matrix metalloproteinase-9 (MMP-9) DM97S10 MA Inhibitor DM97S10 RN DP-b99 modulates matrix metalloproteinase activity and neuronal plasticity. PLoS One. 2014 Jun 11;9(6):e99789. DM97S10 RU https://pubmed.ncbi.nlm.nih.gov/24918931 DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TTOHSBA DM9CEI5 TN Vascular endothelial growth factor A (VEGFA) DM9CEI5 MA Inhibitor DM9CEI5 RN Clinical pipeline report, company report or official report of Roche (2009). DM9CEI5 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TT6EO5L DM9CEI5 TN Erbb2 tyrosine kinase receptor (HER2) DM9CEI5 RN Clinical pipeline report, company report or official report of Roche (2009). DM9CEI5 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9CEI5 DI DM9CEI5 DM9CEI5 DN Bevacizumab + Trastuzumab DM9CEI5 TI TTS4UGC DM9CEI5 TN Farnesoid X-activated receptor (FXR) DM9CEI5 MA Antagonist DM9CEI5 RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DM9CEI5 RU https://pubmed.ncbi.nlm.nih.gov/12052824 DM9CMI3 DI DM9CMI3 DM9CMI3 DN H5N1 influenza vaccine DM9CMI3 TI TT3J5ZI DM9CMI3 TN Cell mediated immunity response (CMIR) DM9CMI3 RN Characterization of a whole, inactivated influenza (H5N1) vaccine. Influenza and Other Respiratory Viruses Volume 2, Issue 6, pages 261-266, November 2008. DM9CMI3 RU http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2008.00066.x/full DM9DEYL DI DM9DEYL DM9DEYL DN SD-6010 DM9DEYL TI TTF10I9 DM9DEYL TN Nitric-oxide synthase inducible (NOS2) DM9DEYL MA Inhibitor DM9DEYL RN A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95. DM9DEYL RU https://pubmed.ncbi.nlm.nih.gov/23144445 DM9EXGI DI DM9EXGI DM9EXGI DN Bevacizumab + Rituximab DM9EXGI TI TTUE541 DM9EXGI TN Leukocyte surface antigen Leu-16 (CD20) DM9EXGI RN Clinical pipeline report, company report or official report of Roche (2009). DM9EXGI RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9EXGI DI DM9EXGI DM9EXGI DN Bevacizumab + Rituximab DM9EXGI TI TTOHSBA DM9EXGI TN Vascular endothelial growth factor A (VEGFA) DM9EXGI MA Inhibitor DM9EXGI RN Clinical pipeline report, company report or official report of Roche (2009). DM9EXGI RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9EZM0 DI DM9EZM0 DM9EZM0 DN LNP023 DM9EZM0 TI TTA0P7K DM9EZM0 TN Complement factor B (CFB) DM9EZM0 MA Inhibitor DM9EZM0 RN Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem. 2020 Jun 11;63(11):5697-5722. DM9EZM0 RU https://pubmed.ncbi.nlm.nih.gov/32073845 DM9FAJM DI DM9FAJM DM9FAJM DN D-5519 DM9FAJM TI TTPNQAC DM9FAJM TN Estrogen-related receptor-alpha (ESRRA) DM9FAJM MA Modulator DM9FAJM RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007199) DM9FAJM RU http://adisinsight.springer.com/drugs/800007199 DM9G5XD DI DM9G5XD DM9G5XD DN IB-MECA DM9G5XD TI TTJFY5U DM9G5XD TN Adenosine A3 receptor (ADORA3) DM9G5XD MA Agonist DM9G5XD RN A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. FEBS Lett. 1993 Dec 20;336(1):57-60. DM9G5XD RU https://pubmed.ncbi.nlm.nih.gov/8262217 DM9GSVQ DI DM9GSVQ DM9GSVQ DN Tasquinimod DM9GSVQ TI TT0TMQG DM9GSVQ TN Calgranulin B (S100A9) DM9GSVQ MA Modulator DM9GSVQ RN Mechanisms of action of tasquinimod on the tumour microenvironment. Cancer Chemother Pharmacol. 2014; 73(1): 1-8. DM9GSVQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3889691/ DM9HUYP DI DM9HUYP DM9HUYP DN ZANOTERONE DM9HUYP TI TTS64P2 DM9HUYP TN Androgen receptor (AR) DM9HUYP MA Inhibitor DM9HUYP RN Antiandrogenic steroidal sulfonyl heterocycles. Utility of electrostatic complementarity in defining bioisosteric sulfonyl heterocycles. J Med Chem. 1992 May 15;35(10):1663-70. DM9HUYP RU https://pubmed.ncbi.nlm.nih.gov/1588549 DM9J0KD DI DM9J0KD DM9J0KD DN K-103-IP DM9J0KD TI TTK0943 DM9J0KD TN Prostaglandin G/H synthase (COX) DM9J0KD MA Modulator DM9J0KD RN ClinicalTrials.gov (NCT02089425) An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.. U.S. National Institutes of Health. DM9J0KD RU https://clinicaltrials.gov/ct2/show/NCT02089425 DM9J5Q4 DI DM9J5Q4 DM9J5Q4 DN VAL-083 DM9J5Q4 TI TTUTN1I DM9J5Q4 TN Human Deoxyribonucleic acid (hDNA) DM9J5Q4 MA Modulator DM9J5Q4 RN Effect of 1,2:5,6-dianhydrogalactitol and 1,2:5,6-dianhydro-3,4-diacetylgalactitol on DNA synthesis in the cells of melanoma B16, bone marrow, small intestine epithelium, spleen and liver of mice. Biull Eksp Biol Med. 1984 Sep;98(9):301-3. DM9J5Q4 RU https://pubmed.ncbi.nlm.nih.gov/6487788 DM9K3LM DI DM9K3LM DM9K3LM DN MPDL-3280A DM9K3LM TI TT8ZLTI DM9K3LM TN Programmed cell death 1 ligand 1 (PD-L1) DM9K3LM MA Modulator DM9K3LM RN Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47. DM9K3LM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014795/ DM9L1AC DI DM9L1AC DM9L1AC DN SYR-472 DM9L1AC TI TTDIGC1 DM9L1AC TN Dipeptidyl peptidase 4 (DPP-4) DM9L1AC MA Inhibitor DM9L1AC RN SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32. DM9L1AC RU https://pubmed.ncbi.nlm.nih.gov/24622716 DM9LH10 DI DM9LH10 DM9LH10 DN Vadastuximab talirine DM9LH10 TI TTJVYO3 DM9LH10 TN Myeloid cell surface antigen CD33 (CD33) DM9LH10 MA Antagonist DM9LH10 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9LH10 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TT4C8EA DM9PVHX TN Dopamine D3 receptor (D3R) DM9PVHX MA Inhibitor DM9PVHX RN Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/9617505 DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TTGP7BY DM9PVHX TN Monoamine oxidase type B (MAO-B) DM9PVHX MA Inhibitor DM9PVHX RN Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. Am J Geriatr Pharmacother. 2006 Dec;4(4):330-46. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/17296539 DM9PVHX DI DM9PVHX DM9PVHX DN P2B-001 DM9PVHX TI TTEX248 DM9PVHX TN Dopamine D2 receptor (D2R) DM9PVHX MA Inhibitor DM9PVHX RN Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51. DM9PVHX RU https://pubmed.ncbi.nlm.nih.gov/9617505 DM9QPOU DI DM9QPOU DM9QPOU DN Epoetin zeta DM9QPOU TI TTAUX24 DM9QPOU TN Erythropoietin Receptor (EPOR) DM9QPOU MA Modulator DM9QPOU RN Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28. DM9QPOU RU https://pubmed.ncbi.nlm.nih.gov/18931828 DM9R2SD DI DM9R2SD DM9R2SD DN Alilusem DM9R2SD TI TTYJL7K DM9R2SD TN Sodium/potassium transport (Na/K trans) DM9R2SD MA Modulator DM9R2SD RN US patent application no. 8,067,031, Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use. DM9R2SD RU http://www.google.lv/patents/US8067031 DM9R5J6 DI DM9R5J6 DM9R5J6 DN Tezepelumab DM9R5J6 TI TTHMW3T DM9R5J6 TN Thymic stromal lymphopoietin (TSLP) DM9R5J6 RN Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017 Sep 7;377(10):936-946. DM9R5J6 RU https://pubmed.ncbi.nlm.nih.gov/28877011 DM9SKW8 DI DM9SKW8 DM9SKW8 DN AZD5363 DM9SKW8 TI TTAZ05C DM9SKW8 TN RAC-gamma serine/threonine-protein kinase (AKT3) DM9SKW8 MA Modulator DM9SKW8 RN The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood. 2014 Oct 2;124(14):2190-5. DM9SKW8 RU https://pubmed.ncbi.nlm.nih.gov/25075128 DM9SKW8 DI DM9SKW8 DM9SKW8 DN AZD5363 DM9SKW8 TI TTWTSCV DM9SKW8 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM9SKW8 MA Inhibitor DM9SKW8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9SKW8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9T8OF DI DM9T8OF DM9T8OF DN RQ-00000004 DM9T8OF TI TTLOKXP DM9T8OF TN Gastric H(+)/K(+) ATPase (Proton pump) DM9T8OF MA Modulator DM9T8OF RN N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther. 2009 Feb;328(2):671-9. DM9T8OF RU https://pubmed.ncbi.nlm.nih.gov/18981288 DM9Y3B5 DI DM9Y3B5 DM9Y3B5 DN CMX-001 DM9Y3B5 TI TTATL6Y DM9Y3B5 TN DNA-dependent DNA polymerase (DPOL) DM9Y3B5 MA Inhibitor DM9Y3B5 RN Detection of Molluscum Contagiosum Virus (MCV) DNA in the Plasma of an Immunocompromised Patient and Possible Reduction of MCV DNA With CMX-001. J Infect Dis. 2012 March 1; 205(5): 794-797. DM9Y3B5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274371/ DM9Y3EG DI DM9Y3EG DM9Y3EG DN Guadecitabine DM9Y3EG TI TT6S2FE DM9Y3EG TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM9Y3EG MA Inhibitor DM9Y3EG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Y3EG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9YI2C DI DM9YI2C DM9YI2C DN ErepoXen DM9YI2C TI TTAUX24 DM9YI2C TN Erythropoietin Receptor (EPOR) DM9YI2C MA Agonist DM9YI2C RN Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83. DM9YI2C RU https://pubmed.ncbi.nlm.nih.gov/16885048 DM9Z4N5 DI DM9Z4N5 DM9Z4N5 DN RA101495 DM9Z4N5 TI TTKANGO DM9Z4N5 TN Complement C5 (CO5) DM9Z4N5 MA Inhibitor DM9Z4N5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Z4N5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMA0WEK DI DMA0WEK DMA0WEK DN Coprexa DMA0WEK TI TT6RVLG DMA0WEK TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMA0WEK MA Inhibitor DMA0WEK RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DMA0WEK RU https://pubmed.ncbi.nlm.nih.gov/16914587 DMA16IL DI DMA16IL DMA16IL DN NU-100 DMA16IL TI TT4TZ8J DMA16IL TN Interferon-beta (IFNB1) DMA16IL MA Modulator DMA16IL RN PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138. DMA16IL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ DMA25NO DI DMA25NO DMA25NO DN MK-4214 DMA25NO TI TT5TQ2W DMA25NO TN Granulocyte colony-stimulating factor (CSF3) DMA25NO MA Modulator DMA25NO RN DOI: 10.1038/nbt0710-636a DMA25NO RU http://www.nature.com/nbt/journal/v28/n7/full/nbt0710-636a.html DMA2NYS DI DMA2NYS DMA2NYS DN Lampalizumab DMA2NYS TI TT8D13I DMA2NYS TN Complement factor D (CFD) DMA2NYS MA Inhibitor DMA2NYS RN In Vivo Stability Profiles of Anti-factor D Molecules Support Long-Acting Delivery Approaches. Mol Pharm. 2019 Jan 7;16(1):86-95. DMA2NYS RU https://pubmed.ncbi.nlm.nih.gov/30444371 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTOHSBA DMA86FL TN Vascular endothelial growth factor A (VEGFA) DMA86FL MA Inhibitor DMA86FL RN Clinical pipeline report, company report or official report of Genentech (2009). DMA86FL RU http://www.gene.com/gene/pipeline/status/ DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TT3PQ2Y DMA86FL TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMA86FL MA Inhibitor DMA86FL RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTG8HIM DMA86FL TN Dual specificity protein phosphatase 1 (DUSP1) DMA86FL MA Inhibitor DMA86FL RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TT2J34L DMA86FL TN Arachidonate 5-lipoxygenase (5-LOX) DMA86FL MA Inhibitor DMA86FL RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTR0SWN DMA86FL TN M-phase inducer phosphatase 2 (MPIP2) DMA86FL MA Inhibitor DMA86FL RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTZJYKH DMA86FL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMA86FL MA Inhibitor DMA86FL RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMA86FL DI DMA86FL DMA86FL DN Avastin+/-Tarceva DMA86FL TI TTJNTSI DMA86FL TN Rotamase Pin1 (PIN1) DMA86FL MA Inhibitor DMA86FL RN Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.PLoS One. 2016 Jun 3;11(6):e0156833. DMA86FL RU https://pubmed.ncbi.nlm.nih.gov/27258148 DMACVEI DI DMACVEI DMACVEI DN SPI-2012 DMACVEI TI TT5TQ2W DMACVEI TN Granulocyte colony-stimulating factor (CSF3) DMACVEI MA Modulator DMACVEI RN Company report (Sppirx) DMACVEI RU http://www.sppirx.com/338-spectrum-products-development-spi2012.html DMACYW6 DI DMACYW6 DMACYW6 DN NKTR-214 DMACYW6 TI TT9721Y DMACYW6 TN Interleukin 2 receptor beta (IL2RB) DMACYW6 MA Agonist DMACYW6 RN Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 Jan 31;11(1):661. DMACYW6 RU https://pubmed.ncbi.nlm.nih.gov/32005826 DMAD2OZ DI DMAD2OZ DMAD2OZ DN Palovarotene DMAD2OZ TI TT1Q3IE DMAD2OZ TN Retinoic acid receptor gamma (RARG) DMAD2OZ MA Agonist DMAD2OZ RN Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor. Eur Respir J. 2012 Aug;40(2):306-12. DMAD2OZ RU https://pubmed.ncbi.nlm.nih.gov/22282548 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TTGP7BY DMAFPHB TN Monoamine oxidase type B (MAO-B) DMAFPHB MA Inhibitor DMAFPHB RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TTJQOD7 DMAFPHB TN 5-HT 2A receptor (HTR2A) DMAFPHB MA Inhibitor DMAFPHB RN Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/3543362 DMAFPHB DI DMAFPHB DMAFPHB DN TRYPTAMINE DMAFPHB TI TT3WG5C DMAFPHB TN Monoamine oxidase type A (MAO-A) DMAFPHB MA Inhibitor DMAFPHB RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMAFPHB RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMAFUIR DI DMAFUIR DMAFUIR DN DWP-431 DMAFUIR TI TTP3IGX DMAFUIR TN Bone morphogenetic protein 2 (BMP2) DMAFUIR MA Modulator DMAFUIR RN Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery. Spine J. 2014 Mar 1;14(3):552-9. DMAFUIR RU https://pubmed.ncbi.nlm.nih.gov/24412416 DMAJM12 DI DMAJM12 DMAJM12 DN LATIN T1D DMAJM12 TI TTVIMDE DMAJM12 TN Glucagon-like peptide 1 receptor (GLP1R) DMAJM12 MA Agonist DMAJM12 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMAJM12 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMALFKX DI DMALFKX DMALFKX DN Savolitinib DMALFKX TI TTNDSF4 DMALFKX TN Proto-oncogene c-Met (MET) DMALFKX MA Inhibitor DMALFKX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMALFKX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAMTGI DI DMAMTGI DMAMTGI DN SD-101 DMAMTGI TI TTSHG0T DMAMTGI TN Toll-like receptor 9 (TLR9) DMAMTGI RN Novel drugs targeting Toll-like receptors for antiviral therapy. Future Virol. 2014 September; 9(9): 811-829. DMAMTGI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4303062/ DMANKTO DI DMANKTO DMANKTO DN Vatreptacog alfa (activated) DMANKTO TI TTF0EGX DMANKTO TN Coagulation factor VII (F7) DMANKTO MA Modulator DMANKTO RN Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9. DMANKTO RU https://pubmed.ncbi.nlm.nih.gov/22470921 DMAPRWV DI DMAPRWV DMAPRWV DN SaxaDapa FDC DMAPRWV TI TTDIGC1 DMAPRWV TN Dipeptidyl peptidase 4 (DPP-4) DMAPRWV MA Modulator DMAPRWV RN Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. DMAPRWV RU https://pubmed.ncbi.nlm.nih.gov/20539105 DMAPRWV DI DMAPRWV DMAPRWV DN SaxaDapa FDC DMAPRWV TI TTN7Y4P DMAPRWV TN Sodium/glucose cotransporter 2 (SLC5A4) DMAPRWV MA Modulator DMAPRWV RN Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7. DMAPRWV RU https://pubmed.ncbi.nlm.nih.gov/20539105 DMAR1YS DI DMAR1YS DMAR1YS DN BMS-986165 DMAR1YS TI TTBYWP2 DMAR1YS TN TYK2 tyrosine kinase (TYK2) DMAR1YS MA Inhibitor DMAR1YS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAR1YS RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTVBI8W DMAR9ND TN Dopamine transporter (DAT) DMAR9ND MA Inhibitor DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTAWNKZ DMAR9ND TN Norepinephrine transporter (NET) DMAR9ND MA Inhibitor DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMAR9ND DI DMAR9ND DMAR9ND DN Bupropion+Naltrexone DMAR9ND TI TTN4QDT DMAR9ND TN Opioid receptor (OPR) DMAR9ND MA Antagonist DMAR9ND RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMAR9ND RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TT4C8EA DMASPWR TN Dopamine D3 receptor (D3R) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TT5TPI6 DMASPWR TN Opioid receptor sigma 1 (OPRS1) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TTSQIFT DMASPWR TN 5-HT 1A receptor (HTR1A) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMASPWR DI DMASPWR DMASPWR DN CM-2395 DMASPWR TI TTE0A2F DMASPWR TN Dopamine D4 receptor (D4R) DMASPWR MA Agonist DMASPWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127) DMASPWR RU http://adisinsight.springer.com/drugs/800031127 DMATC14 DI DMATC14 DMATC14 DN Tozadenant DMATC14 TI TTM2AOE DMATC14 TN Adenosine A2a receptor (ADORA2A) DMATC14 MA Antagonist DMATC14 RN Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76. DMATC14 RU https://pubmed.ncbi.nlm.nih.gov/25008546 DMAXTFO DI DMAXTFO DMAXTFO DN H1N1 influenza vaccine DMAXTFO TI TT3J5ZI DMAXTFO TN Cell mediated immunity response (CMIR) DMAXTFO RN Clinical pipeline report, company report or official report of Sanofi Pasteur. DMAXTFO RU http://www.sanofipasteur.com/en/articles/sanofi-pasteur-s-a-h1n1-vaccine-humenza-recommended-by-european-medicines-agency.aspx DMAYC76 DI DMAYC76 DMAYC76 DN Levomequitazine DMAYC76 TI TT7CXIM DMAYC76 TN Histamine receptor (HR) DMAYC76 MA Antagonist DMAYC76 RN Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther. 1998 Feb;284(2):437-42. DMAYC76 RU https://pubmed.ncbi.nlm.nih.gov/9454781 DMAYO46 DI DMAYO46 DMAYO46 DN AEZS-108 DMAYO46 TI TT8R70G DMAYO46 TN Gonadotropin-releasing hormone receptor (GNRHR) DMAYO46 MA Modulator DMAYO46 RN Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinicalstudies. Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):829-34. DMAYO46 RU https://pubmed.ncbi.nlm.nih.gov/10639165 DMAYTIH DI DMAYTIH DMAYTIH DN S-06911 DMAYTIH TI TTK59TV DMAYTIH TN Vitamin D3 receptor (VDR) DMAYTIH MA Inhibitor DMAYTIH RN Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73. DMAYTIH RU https://pubmed.ncbi.nlm.nih.gov/12520525 DMB06MU DI DMB06MU DMB06MU DN HC-1119 DMB06MU TI TTS64P2 DMB06MU TN Androgen receptor (AR) DMB06MU MA Inhibitor DMB06MU RN Clinical pipeline report, company report or official report of Hinova Pharmaceuticals. DMB06MU RU http://www.hinovapharma.com/en/chanpinxianguan.html DMB147A DI DMB147A DMB147A DN BAX-817 DMB147A TI TTF0EGX DMB147A TN Coagulation factor VII (F7) DMB147A MA Inhibitor DMB147A RN Clinical pipeline report, company report or official report of Baxter. DMB147A RU http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-newsArticle&id=2025563 DMB24H7 DI DMB24H7 DMB24H7 DN Motavizumab DMB24H7 TI TT57ID8 DMB24H7 TN Respiratory syncytial virus protein F (RSV F) DMB24H7 MA Modulator DMB24H7 RN Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591. DMB24H7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/ DMB2C0E DI DMB2C0E DMB2C0E DN Elagolix DMB2C0E TI TT8R70G DMB2C0E TN Gonadotropin-releasing hormone receptor (GNRHR) DMB2C0E MA Antagonist DMB2C0E RN Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond Engl). 2015 Jan;11(1):19-28. DMB2C0E RU https://pubmed.ncbi.nlm.nih.gov/25581052 DMB34TZ DI DMB34TZ DMB34TZ DN Grippol TC DMB34TZ TI TT3J5ZI DMB34TZ TN Cell mediated immunity response (CMIR) DMB34TZ RN Clinical pipeline report, company report or official report of Petrovax. DMB34TZ RU http://petrovax.com/medication/catalog/grippallplus/ DMB4JPG DI DMB4JPG DMB4JPG DN CNTX-4975 DMB4JPG TI TTMI6F5 DMB4JPG TN Transient receptor potential cation channel V1 (TRPV1) DMB4JPG MA Agonist DMB4JPG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB4JPG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMB9587 DI DMB9587 DMB9587 DN Amocarzine DMB9587 TI TT1RS9F DMB9587 TN Acetylcholinesterase (AChE) DMB9587 MA Inhibitor DMB9587 RN Activity, mechanism of action and pharmacokinetics of 2-tert-butylbenzothiazole and CGP 6140 (amocarzine) antifilarial drugs. Acta Trop. 1992 Aug;51(3-4):195-211. DMB9587 RU https://pubmed.ncbi.nlm.nih.gov/1359747 DMBD4K3 DI DMBD4K3 DMBD4K3 DN Selinexor DMBD4K3 TI TTCJUR4 DMBD4K3 TN Exportin-1 (XPO1) DMBD4K3 MA Inhibitor DMBD4K3 RN Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73. DMBD4K3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511/ DMBEL3Q DI DMBEL3Q DMBEL3Q DN GDC-0853 DMBEL3Q TI TTGM6VW DMBEL3Q TN Tyrosine-protein kinase BTK (ATK) DMBEL3Q MA Inhibitor DMBEL3Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBEL3Q RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMBER0Q DI DMBER0Q DMBER0Q DN Hu5F9-G4 DMBER0Q TI TT28S46 DMBER0Q TN Leukocyte surface antigen CD47 (CD47) DMBER0Q MA Inhibitor DMBER0Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBER0Q RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBFE4K DI DMBFE4K DMBFE4K DN Tirapazamine DMBFE4K TI TT0IHXV DMBFE4K TN DNA topoisomerase II (TOP2) DMBFE4K MA Modulator DMBFE4K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBFE4K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBH4FL DI DMBH4FL DMBH4FL DN BI 655066 DMBH4FL TI TTC1GLB DMBH4FL TN Interleukin-23 (IL23) DMBH4FL RN Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015 Jul;136(1):116-124.e7. DMBH4FL RU https://pubmed.ncbi.nlm.nih.gov/25769911 DMBIZ7H DI DMBIZ7H DMBIZ7H DN ICT-107 DMBIZ7H TI TTMPZ7V DMBIZ7H TN Interleukin 13 receptor alpha-2 (IL13RA2) DMBIZ7H RN Clinical pipeline report, company report or official report of ImmunoCellular Therapeutics. DMBIZ7H RU http://www.imuc.com/pipeline/ict-107 DMBJTVL DI DMBJTVL DMBJTVL DN Isotretinoin DMBJTVL TI TTNHMO8 DMBJTVL TN COVID-19 papain-like proteinase (PL-PRO) DMBJTVL MA Inhibitor DMBJTVL RN ClinicalTrials.gov (NCT04361422) Isotretinoin in Treatment of COVID-19. U.S. National Institutes of Health. DMBJTVL RU https://clinicaltrials.gov/ct2/show/NCT04361422 DMBKWAF DI DMBKWAF DMBKWAF DN Peg-G-CSF DMBKWAF TI TTC70AJ DMBKWAF TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMBKWAF MA Stimulator DMBKWAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMBKWAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMBPY9Z DI DMBPY9Z DMBPY9Z DN MBG453 DMBPY9Z TI TT1RWL7 DMBPY9Z TN Hepatitis A virus cellular receptor 2 (TIM3) DMBPY9Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBPY9Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBQK0X DI DMBQK0X DMBQK0X DN Algenpantucel-L DMBQK0X TI TTPJ1I3 DMBQK0X TN Galactosyltransferase (GALT) DMBQK0X RN Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. J Gastrointest Cancer. 2014; 45(2): 190-201. DMBQK0X RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4024386/ DMBRQF5 DI DMBRQF5 DMBRQF5 DN ApoC-III DMBRQF5 TI TT3GKN5 DMBRQF5 TN Lipase unspecific (LIP) DMBRQF5 MA Inhibitor DMBRQF5 RN An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor Int J Clin Pract. 2008 May;62(5):799-809. DMBRQF5 RU https://pubmed.ncbi.nlm.nih.gov/18201179 DMBS3UG DI DMBS3UG DMBS3UG DN CORT-125134 DMBS3UG TI TTYRL6O DMBS3UG TN Glucocorticoid receptor (NR3C1) DMBS3UG MA Antagonist DMBS3UG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBS3UG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTJX3UE DMBWO5T TN Somatostatin receptor type 3 (SSTR3) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TT2BC4G DMBWO5T TN Somatostatin receptor type 5 (SSTR5) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTZ6T9E DMBWO5T TN Somatostatin receptor type 2 (SSTR2) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTAE1BR DMBWO5T TN Somatostatin receptor type 4 (SSTR4) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBWO5T DI DMBWO5T DMBWO5T DN ODT-8 DMBWO5T TI TTIND6G DMBWO5T TN Somatostatin receptor type 1 (SSTR1) DMBWO5T MA Inhibitor DMBWO5T RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMBWO5T RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMBXR23 DI DMBXR23 DMBXR23 DN BMN-110 DMBXR23 TI TTT9YPO DMBXR23 TN N-acetylgalactosamine 6 sulfatase (GALNS) DMBXR23 MA Modulator DMBXR23 RN Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014 Nov;37(6):979-90. DMBXR23 RU https://pubmed.ncbi.nlm.nih.gov/24810369 DMBY31K DI DMBY31K DMBY31K DN Rivoglitazone DMBY31K TI TTZMAO3 DMBY31K TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMBY31K MA Agonist DMBY31K RN A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13. DMBY31K RU https://pubmed.ncbi.nlm.nih.gov/21492364 DMBY56U DI DMBY56U DMBY56U DN EXISULIND DMBY56U TI TTJ0IQB DMBY56U TN Phosphodiesterase 5A (PDE5A) DMBY56U MA Modulator DMBY56U RN Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42. DMBY56U RU https://pubmed.ncbi.nlm.nih.gov/10910034 DMC4X7L DI DMC4X7L DMC4X7L DN CMS-024-02 DMC4X7L TI TTBH0VX DMC4X7L TN Histone deacetylase (HDAC) DMC4X7L MA Modulator DMC4X7L RN US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery. DMC4X7L RU http://www.google.com/patents/US20120302505 DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTROQ37 DMC7W6R TN MAPK/ERK kinase kinase (MAP3K) DMC7W6R MA Modulator DMC7W6R RN Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Br J Cancer.2012 May 8;106(10):1648-59. DMC7W6R RU https://www.ncbi.nlm.nih.gov/pubmed/22569000 DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTIDAPM DMC7W6R TN ERK activator kinase 1 (MEK1) DMC7W6R MA Inhibitor DMC7W6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC7W6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMC7W6R DI DMC7W6R DMC7W6R DN Selumetinib DMC7W6R TI TTTW2NY DMC7W6R TN ERK activator kinase 2 (MEK2) DMC7W6R MA Inhibitor DMC7W6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC7W6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCA6BW DI DMCA6BW DMCA6BW DN Pixykine DMCA6BW TI TT6MP2Z DMCA6BW TN GMCSFR-alpha (CSF2RA) DMCA6BW MA Modulator DMCA6BW RN Phase I/II trial of PIXY321 (granulocyte-macrophage colony stimulating factor/interleukin-3 fusion protein) for treatment of inherited and acquired... Br J Haematol. 1998 Nov;103(2):304-7. DMCA6BW RU https://www.ncbi.nlm.nih.gov/pubmed/9827896 DMCA7FN DI DMCA7FN DMCA7FN DN Exatecan DMCA7FN TI TTGTQHC DMCA7FN TN DNA topoisomerase I (TOP1) DMCA7FN MA Inhibitor DMCA7FN RN Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 2001 Dec;7(12):3963-70. DMCA7FN RU https://pubmed.ncbi.nlm.nih.gov/11751488 DMCDZ15 DI DMCDZ15 DMCDZ15 DN Evacetrapib DMCDZ15 TI TTFQAYR DMCDZ15 TN Cholesteryl ester transfer protein (CETP) DMCDZ15 MA Inhibitor DMCDZ15 RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMCDZ15 RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMCF6SX DI DMCF6SX DMCF6SX DN TAK-491 DMCF6SX TI TT8DBY3 DMCF6SX TN Angiotensin II receptor type-1 (AGTR1) DMCF6SX MA Modulator DMCF6SX RN 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. DMCF6SX RU https://pubmed.ncbi.nlm.nih.gov/22293555 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTHPFTS DMCGWBJ TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TT7AOUD DMCGWBJ TN Fatty acid synthase (FASN) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TT84ETX DMCGWBJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMCGWBJ MA Inhibitor DMCGWBJ RN Simplified catechin-gallate inhibitors of HIV-1 reverse transcriptase. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2763-7. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/11591519 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTBE4IR DMCGWBJ TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMCGWBJ MA Inhibitor DMCGWBJ RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTJ4QE7 DMCGWBJ TN Matrix metalloproteinase-14 (MMP-14) DMCGWBJ MA Inhibitor DMCGWBJ RN Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/19524436 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTNX2CS DMCGWBJ TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMCGWBJ MA Inhibitor DMCGWBJ RN Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/17263522 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTLM12X DMCGWBJ TN Matrix metalloproteinase-2 (MMP-2) DMCGWBJ MA Inhibitor DMCGWBJ RN Regioselective synthesis of methylated epigallocatechin gallate via nitrobenzenesulfonyl (Ns) protecting group. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4171-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/19524436 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTE14XG DMCGWBJ TN Squalene monooxygenase (SQLE) DMCGWBJ MA Inhibitor DMCGWBJ RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMCGWBJ DI DMCGWBJ DMCGWBJ DN Epigallocatechin gallate DMCGWBJ TI TTPLTSQ DMCGWBJ TN Neutrophil elastase (NE) DMCGWBJ MA Inhibitor DMCGWBJ RN Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5. DMCGWBJ RU https://pubmed.ncbi.nlm.nih.gov/20004577 DMCHA27 DI DMCHA27 DMCHA27 DN Almonertinib DMCHA27 TI TTGKNB4 DMCHA27 TN Epidermal growth factor receptor (EGFR) DMCHA27 MA Inhibitor DMCHA27 RN Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918. DMCHA27 RU https://pubmed.ncbi.nlm.nih.gov/32916310 DMCJRL1 DI DMCJRL1 DMCJRL1 DN MGN-1703 DMCJRL1 TI TTSHG0T DMCJRL1 TN Toll-like receptor 9 (TLR9) DMCJRL1 MA Agonist DMCJRL1 RN Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24. DMCJRL1 RU https://pubmed.ncbi.nlm.nih.gov/24816725 DMCJY35 DI DMCJY35 DMCJY35 DN MIN-101 DMCJY35 TI TTJQOD7 DMCJY35 TN 5-HT 2A receptor (HTR2A) DMCJY35 MA Antagonist DMCJY35 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMCJY35 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMCJY35 DI DMCJY35 DMCJY35 DN MIN-101 DMCJY35 TI TT9NXW4 DMCJY35 TN Sigma intracellular receptor 2 (TMEM97) DMCJY35 MA Antagonist DMCJY35 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCJY35 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMCKPG4 DI DMCKPG4 DMCKPG4 DN ABC294640 DMCKPG4 TI TTCN0M9 DMCKPG4 TN Sphingosine kinase 2 (SPHK2) DMCKPG4 MA Modulator DMCKPG4 RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMCKPG4 RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMCMDVR DI DMCMDVR DMCMDVR DN Triptolide DMCMDVR TI TTSXVID DMCMDVR TN Nuclear factor NF-kappa-B (NFKB) DMCMDVR MA Inhibitor DMCMDVR RN Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18. DMCMDVR RU https://pubmed.ncbi.nlm.nih.gov/11753684 DMCMIJ1 DI DMCMIJ1 DMCMIJ1 DN NT0202 DMCMIJ1 TI TTIU98M DMCMIJ1 TN Trace amine-associated receptor-1 (TAAR1) DMCMIJ1 MA Agonist DMCMIJ1 RN Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct;85:499-507. DMCMIJ1 RU https://pubmed.ncbi.nlm.nih.gov/24950453 DMCMJRA DI DMCMJRA DMCMJRA DN EGF816 DMCMJRA TI TTGKNB4 DMCMJRA TN Epidermal growth factor receptor (EGFR) DMCMJRA MA Inhibitor DMCMJRA RN Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15. DMCMJRA RU https://pubmed.ncbi.nlm.nih.gov/24065731 DMCRGY4 DI DMCRGY4 DMCRGY4 DN Karenitecin DMCRGY4 TI TTGTQHC DMCRGY4 TN DNA topoisomerase I (TOP1) DMCRGY4 MA Inhibitor DMCRGY4 RN Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9. DMCRGY4 RU https://pubmed.ncbi.nlm.nih.gov/10692484 DMCRGY4 DI DMCRGY4 DMCRGY4 DN Karenitecin DMCRGY4 TI TT2GPK3 DMCRGY4 TN DNA topoisomerase (TOP) DMCRGY4 MA Inhibitor DMCRGY4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCRGY4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCWM03 DI DMCWM03 DMCWM03 DN Unfractionated heparin DMCWM03 TI TT4QPUL DMCWM03 TN Antithrombin-III (ATIII) DMCWM03 MA Modulator DMCWM03 RN Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma. Thromb Res. 1982 Nov 15;28(4):487-97. DMCWM03 RU https://pubmed.ncbi.nlm.nih.gov/7164033 DMD1FTP DI DMD1FTP DMD1FTP DN PRO-140 DMD1FTP TI TT2CEJG DMD1FTP TN C-C chemokine receptor type 5 (CCR5) DMD1FTP MA Antagonist DMD1FTP RN Agonist-induced internalization of CC chemokine receptor 5 as a mechanism to inhibit HIV replication. J Pharmacol Exp Ther. 2011 Jun;337(3):655-62. DMD1FTP RU https://pubmed.ncbi.nlm.nih.gov/21389095 DMD2O0L DI DMD2O0L DMD2O0L DN UX-001 DMD2O0L TI TT50QJ3 DMD2O0L TN Influenza Neuraminidase (Influ NA) DMD2O0L MA Inhibitor DMD2O0L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD2O0L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD2O0L DI DMD2O0L DMD2O0L DN UX-001 DMD2O0L TI TTQ8J1V DMD2O0L TN Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) DMD2O0L MA Inhibitor DMD2O0L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD2O0L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD5QRS DI DMD5QRS DMD5QRS DN Ranirestat DMD5QRS TI TTFBNVI DMD5QRS TN Aldose reductase (AKR1B1) DMD5QRS MA Inhibitor DMD5QRS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DMD5QRS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DMD6AUX DI DMD6AUX DMD6AUX DN Tat-NR2B9c DMD6AUX TI TT9PB26 DMD6AUX TN Presynaptic density protein 95 (DLG4) DMD6AUX MA Inhibitor DMD6AUX RN Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7. DMD6AUX RU https://pubmed.ncbi.nlm.nih.gov/22388811 DMD7K9X DI DMD7K9X DMD7K9X DN Davunetide DMD7K9X TI TTS87KH DMD7K9X TN Microtubule-associated protein tau (MAPT) DMD7K9X MA Modulator DMD7K9X RN Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. DMD7K9X RU https://pubmed.ncbi.nlm.nih.gov/21902667 DMD7L48 DI DMD7L48 DMD7L48 DN Plinabulin DMD7L48 TI TTYFKSZ DMD7L48 TN Tubulin beta (TUBB) DMD7L48 MA Modulator DMD7L48 RN NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31. DMD7L48 RU https://www.ncbi.nlm.nih.gov/pubmed/16317287 DMD7L48 DI DMD7L48 DMD7L48 DN Plinabulin DMD7L48 TI TTKIGZF DMD7L48 TN Guanine nucleotide exchange factor (GNEF) DMD7L48 MA Stimulator DMD7L48 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD7L48 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMD7XWS DI DMD7XWS DMD7XWS DN AS-013 DMD7XWS TI TTG1QMU DMD7XWS TN Prostaglandin E2 receptor EP1 (PTGER1) DMD7XWS MA Agonist DMD7XWS RN Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7. DMD7XWS RU https://pubmed.ncbi.nlm.nih.gov/9844994 DMD8QTC DI DMD8QTC DMD8QTC DN Apadenoson DMD8QTC TI TTM2AOE DMD8QTC TN Adenosine A2a receptor (ADORA2A) DMD8QTC MA Agonist DMD8QTC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290). DMD8QTC RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3290 DMDAN8H DI DMDAN8H DMDAN8H DN BMS-582664 DMDAN8H TI TTST7KB DMDAN8H TN Fibroblast growth factor receptor 3 (FGFR3) DMDAN8H MA Inhibitor DMDAN8H RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMDAN8H RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMDBY30 DI DMDBY30 DMDBY30 DN Nelipepimut S DMDBY30 TI TT6EO5L DMDBY30 TN Erbb2 tyrosine kinase receptor (HER2) DMDBY30 MA Inhibitor DMDBY30 RN The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31. DMDBY30 RU https://pubmed.ncbi.nlm.nih.gov/24896623 DMDC7OH DI DMDC7OH DMDC7OH DN PH94B NS DMDC7OH TI TTCI43M DMDC7OH TN GABA(A) receptor (GABAR) DMDC7OH MA Modulator DMDC7OH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDC7OH RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMDCFXJ DI DMDCFXJ DMDCFXJ DN Vaborbactam DMDCFXJ TI TTHI19T DMDCFXJ TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMDCFXJ MA Inhibitor DMDCFXJ RN Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17. DMDCFXJ RU https://pubmed.ncbi.nlm.nih.gov/28848018 DMDCQW0 DI DMDCQW0 DMDCQW0 DN Quinotolast DMDCQW0 TI TT7KY5U DMDCQW0 TN Histamine/peptide leukotriene release (His/p-LT rele) DMDCQW0 MA Modulator DMDCQW0 RN Effects of quinotolast, a new orally active antiallergic drug, on experimental allergic models. Jpn J Pharmacol. 1993 Sep;63(1):73-81. DMDCQW0 RU https://pubmed.ncbi.nlm.nih.gov/7505860 DMDEJX9 DI DMDEJX9 DMDEJX9 DN Reproxalap DMDEJX9 TI TTZEX7Y DMDEJX9 TN Malondialdehyde (MDA) DMDEJX9 MA Inhibitor DMDEJX9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDEJX9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMDGK83 DI DMDGK83 DMDGK83 DN NN1841 DMDGK83 TI TTAXGIP DMDGK83 TN Coagulation factor XIII (F13B) DMDGK83 MA Modulator DMDGK83 RN Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency. J Blood Med. 2014 Jul 9;5:107-13. DMDGK83 RU https://pubmed.ncbi.nlm.nih.gov/25031548 DMDJLY9 DI DMDJLY9 DMDJLY9 DN NM-702 DMDJLY9 TI TTUST1O DMDJLY9 TN Phosphodiesterase (PDE) DMDJLY9 MA Inhibitor DMDJLY9 RN The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. DMDJLY9 RU https://pubmed.ncbi.nlm.nih.gov/17174195 DMDJLY9 DI DMDJLY9 DMDJLY9 DN NM-702 DMDJLY9 TI TTKNWZ4 DMDJLY9 TN Thromboxane-A synthase (TBXAS1) DMDJLY9 MA Inhibitor DMDJLY9 RN The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45. DMDJLY9 RU https://pubmed.ncbi.nlm.nih.gov/17174195 DMDLU4Z DI DMDLU4Z DMDLU4Z DN Desmoteplase DMDLU4Z TI TTP86E2 DMDLU4Z TN Plasminogen (PLG) DMDLU4Z MA Activator DMDLU4Z RN Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke. 2003 Feb;34(2):537-43. DMDLU4Z RU https://pubmed.ncbi.nlm.nih.gov/12574572 DMDMAE4 DI DMDMAE4 DMDMAE4 DN SAR438584 DMDMAE4 TI TT57ID8 DMDMAE4 TN Respiratory syncytial virus protein F (RSV F) DMDMAE4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040470) DMDMAE4 RU http://adisinsight.springer.com/drugs/800040470 DMDN4ZP DI DMDN4ZP DMDN4ZP DN Lixivaptan DMDN4ZP TI TTV9GOF DMDN4ZP TN Histidine decarboxylase (HDC) DMDN4ZP MA Inhibitor DMDN4ZP RN Clinical pipeline report, company report or official report of Biofrontera (2009). DMDN4ZP RU http://www.biofrontera.com/index.php?id=5 DMDN4ZP DI DMDN4ZP DMDN4ZP DN Lixivaptan DMDN4ZP TI TTK8R02 DMDN4ZP TN Vasopressin V2 receptor (V2R) DMDN4ZP MA Antagonist DMDN4ZP RN Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95. DMDN4ZP RU https://pubmed.ncbi.nlm.nih.gov/17355215 DMDTGWQ DI DMDTGWQ DMDTGWQ DN GMI-1271 DMDTGWQ TI TTAU4D6 DMDTGWQ TN E-selectin (SELE) DMDTGWQ MA Inhibitor DMDTGWQ RN Clinical pipeline report, company report or official report of glycomimetics. DMDTGWQ RU http://www.glycomimetics.com/programs-pipeline/gmi-1271/ DMDU5Y2 DI DMDU5Y2 DMDU5Y2 DN QPI-1002 DMDU5Y2 TI TT7SBF5 DMDU5Y2 TN Cellular tumor antigen p53 (TP53) DMDU5Y2 MA Modulator DMDU5Y2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDU5Y2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDV4EP DI DMDV4EP DMDV4EP DN MRTX849 DMDV4EP TI TT3LH46 DMDV4EP TN KRAS G12C mutant (KRAS G12C) DMDV4EP MA Inhibitor DMDV4EP RN Clinical pipeline report, company report or official report of Mirati Therapeutics. DMDV4EP RU https://www.mirati.com/science/pipeline/ DMDVAFP DI DMDVAFP DMDVAFP DN RG7601 DMDVAFP TI TTJGNVC DMDVAFP TN Apoptosis regulator Bcl-2 (BCL-2) DMDVAFP MA Modulator DMDVAFP RN ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8. DMDVAFP RU https://pubmed.ncbi.nlm.nih.gov/23291630 DMDWU1S DI DMDWU1S DMDWU1S DN Rubitecan DMDWU1S TI TTGTQHC DMDWU1S TN DNA topoisomerase I (TOP1) DMDWU1S MA Inhibitor DMDWU1S RN Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9. DMDWU1S RU https://pubmed.ncbi.nlm.nih.gov/16370935 DMDXE4I DI DMDXE4I DMDXE4I DN ABP959 DMDXE4I TI TTKANGO DMDXE4I TN Complement C5 (CO5) DMDXE4I MA Inhibitor DMDXE4I RN A randomized, double-blind, single-dose, three-arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris ?) in healthy male subjects. Eur J Haematol. 2020 Jul;105(1):66-74. DMDXE4I RU https://pubmed.ncbi.nlm.nih.gov/32196749 DMDZ6Q3 DI DMDZ6Q3 DMDZ6Q3 DN Napabucasin DMDZ6Q3 TI TTH8FZW DMDZ6Q3 TN Signal transducer and activator of transcription 3 (STAT3) DMDZ6Q3 MA Inhibitor DMDZ6Q3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDZ6Q3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDZW8K DI DMDZW8K DMDZW8K DN RBT-101 DMDZW8K TI TTX4GLS DMDZW8K TN Mammalian target of rapamycin complex 1 (mTORC1) DMDZW8K MA Inhibitor DMDZW8K RN Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533. DMDZW8K RU https://pubmed.ncbi.nlm.nih.gov/30057410 DME5PN3 DI DME5PN3 DME5PN3 DN Satavaptan DME5PN3 TI TTK8R02 DME5PN3 TN Vasopressin V2 receptor (V2R) DME5PN3 MA Antagonist DME5PN3 RN Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17. DME5PN3 RU https://pubmed.ncbi.nlm.nih.gov/19196237 DME617W DI DME617W DME617W DN Neucardin DME617W TI TTEH395 DME617W TN Pro-neuregulin-1 (Pro-NRG1) DME617W MA Modulator DME617W RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DME617W RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DME76AP DI DME76AP DME76AP DN Bis(olanzapine) pamoate monohydrate DME76AP TI TTEX248 DME76AP TN Dopamine D2 receptor (D2R) DME76AP MA Modulator DME76AP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DME76AP RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DME76AP DI DME76AP DME76AP DN Bis(olanzapine) pamoate monohydrate DME76AP TI TTYSN63 DME76AP TN 5-HT 2 receptor (5HT2R) DME76AP MA Modulator DME76AP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DME76AP RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DME9QGW DI DME9QGW DME9QGW DN Marizomib DME9QGW TI TTU7ZMG DME9QGW TN Proteasome (PS) DME9QGW MA Inhibitor DME9QGW RN Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets. 2011 Mar;11(3):254-84. DME9QGW RU https://pubmed.ncbi.nlm.nih.gov/21247382 DMEAOZ0 DI DMEAOZ0 DMEAOZ0 DN Cilengitide DMEAOZ0 TI TT69TQN DMEAOZ0 TN Integrin alpha-V/beta-3 (ITGAV/B3) DMEAOZ0 MA Modulator DMEAOZ0 RN The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.PLoS One.2009;4(2):e4449. DMEAOZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/19212436 DMEDSVJ DI DMEDSVJ DMEDSVJ DN Ociperlimab DMEDSVJ TI TTWNL74 DMEDSVJ TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMEDSVJ MA Inhibitor DMEDSVJ RN Clinical pipeline report, company report or official report of BeiGene. DMEDSVJ RU https://www.beigene.com/science-and-product-portfolio/pipeline/ociperlimab DMEFCTP DI DMEFCTP DMEFCTP DN Glufosfamide DMEFCTP TI TTUTN1I DMEFCTP TN Human Deoxyribonucleic acid (hDNA) DMEFCTP MA Modulator DMEFCTP RN A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo. Neoplasia. 2007 Aug;9(8):625-33. DMEFCTP RU https://www.ncbi.nlm.nih.gov/pubmed/17786181 DMEFCTP DI DMEFCTP DMEFCTP DN Glufosfamide DMEFCTP TI TTUBNVO DMEFCTP TN DNA synthesis (DNA synth) DMEFCTP MA Inhibitor DMEFCTP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEFCTP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMEH641 DI DMEH641 DMEH641 DN PRX-302 DMEH641 TI TTS78AZ DMEH641 TN Prostate specific antigen (KLK3) DMEH641 MA Modulator DMEH641 RN Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2011 May;59(5):747-54. DMEH641 RU https://pubmed.ncbi.nlm.nih.gov/21129846 DMEKAYI DI DMEKAYI DMEKAYI DN Netupitant DMEKAYI TI TTZPO1L DMEKAYI TN Substance-P receptor (TACR1) DMEKAYI MA Antagonist DMEKAYI RN Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44. DMEKAYI RU https://pubmed.ncbi.nlm.nih.gov/24969614 DMENDP6 DI DMENDP6 DMENDP6 DN OBI-1 DMENDP6 TI TT1290U DMENDP6 TN Coagulation factor VIII (F8) DMENDP6 MA Modulator DMENDP6 RN Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70. DMENDP6 RU https://pubmed.ncbi.nlm.nih.gov/25623166 DMER75Y DI DMER75Y DMER75Y DN RG6013 DMER75Y TI TTFEZ5Q DMER75Y TN Coagulation factor IX (F9) DMER75Y RN Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation. J Thromb Haemost. 2014 Feb;12(2):206-13. DMER75Y RU https://pubmed.ncbi.nlm.nih.gov/24738137 DMESAZK DI DMESAZK DMESAZK DN Peretinoin DMESAZK TI TTOD7B3 DMESAZK TN Retinoic acid receptor (RAR) DMESAZK MA Modulator DMESAZK RN Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191. DMESAZK RU https://pubmed.ncbi.nlm.nih.gov/23587162 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTEYTKG DMEW5Z8 TN Carbonic anhydrase XIV (CA-XIV) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTCFSPE DMEW5Z8 TN Carbonic anhydrase VI (CA-VI) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TT2LVK8 DMEW5Z8 TN Carbonic anhydrase IX (CA-IX) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTSYM0R DMEW5Z8 TN Carbonic anhydrase XII (CA-XII) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTANPDJ DMEW5Z8 TN Carbonic anhydrase II (CA-II) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTUNARX DMEW5Z8 TN Carbonic anhydrase (CA) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTZHA0O DMEW5Z8 TN Carbonic anhydrase IV (CA-IV) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEW5Z8 DI DMEW5Z8 DMEW5Z8 DN PARABEN DMEW5Z8 TI TTHQPL7 DMEW5Z8 TN Carbonic anhydrase I (CA-I) DMEW5Z8 MA Inhibitor DMEW5Z8 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMEW5Z8 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMEWRXA DI DMEWRXA DMEWRXA DN SHP647 DMEWRXA TI TTBD6I7 DMEWRXA TN Mucosal addressin cell adhesion molecule 1 (MADCAM1) DMEWRXA MA Inhibitor DMEWRXA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEWRXA RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEX86V DI DMEX86V DMEX86V DN Epcoritamab DMEX86V TI TTUN7MC DMEX86V TN T-cell surface glycoprotein CD3 (CD3) DMEX86V MA Inhibitor DMEX86V RN Clinical pipeline report, company report or official report of Genmab. DMEX86V RU https://www.genmab.com/pipeline/ DMEX86V DI DMEX86V DMEX86V DN Epcoritamab DMEX86V TI TTUE541 DMEX86V TN Leukocyte surface antigen Leu-16 (CD20) DMEX86V MA Inhibitor DMEX86V RN Clinical pipeline report, company report or official report of Genmab. DMEX86V RU https://www.genmab.com/pipeline/ DMEY1F3 DI DMEY1F3 DMEY1F3 DN Zabofloxacin DMEY1F3 TI TTN6J5F DMEY1F3 TN Bacterial DNA gyrase (Bact gyrase) DMEY1F3 MA Modulator DMEY1F3 RN DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8. DMEY1F3 RU https://www.ncbi.nlm.nih.gov/pubmed/20403681 DMEY1F3 DI DMEY1F3 DMEY1F3 DN Zabofloxacin DMEY1F3 TI TTIXTO3 DMEY1F3 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMEY1F3 MA Modulator DMEY1F3 RN DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8. DMEY1F3 RU https://www.ncbi.nlm.nih.gov/pubmed/20403681 DMEZ0H5 DI DMEZ0H5 DMEZ0H5 DN LY2963016 DMEZ0H5 TI TTZOPHG DMEZ0H5 TN Insulin (INS) DMEZ0H5 MA Agonist DMEZ0H5 RN Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus ) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study. Diabetes Obes Metab.2015 Aug;17(8):726-33. DMEZ0H5 RU https://pubmed.ncbi.nlm.nih.gov/25974640 DMF0NA9 DI DMF0NA9 DMF0NA9 DN KX-01 DMF0NA9 TI TT6PKBN DMF0NA9 TN Proto-oncogene c-Src (SRC) DMF0NA9 MA Inhibitor DMF0NA9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF0NA9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMF30HL DI DMF30HL DMF30HL DN Zarnestra DMF30HL TI TTXQKM3 DMF30HL TN Farnesyl protein transferase (Ftase) DMF30HL MA Modulator DMF30HL RN Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia. Biologics. 2008 Sep;2(3):491-500. DMF30HL RU https://www.ncbi.nlm.nih.gov/pubmed/19707379 DMF30HL DI DMF30HL DMF30HL DN Zarnestra DMF30HL TI TTIKWV4 DMF30HL TN Geranyltranstransferase (FDPS) DMF30HL MA Inhibitor DMF30HL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF30HL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMF3V01 DI DMF3V01 DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine DMF3V01 TI TTD16BI DMF3V01 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMF3V01 MA Inhibitor DMF3V01 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMF3V01 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMF3V01 DI DMF3V01 DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine DMF3V01 TI TTZGK1R DMF3V01 TN HUMAN glycosylation of host receptor (GHR) DMF3V01 MA Inhibitor DMF3V01 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMF3V01 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMF3V01 DI DMF3V01 DMF3V01 DN Darunavir + ritonavir + favipiravir + hydroxychloroquine DMF3V01 TI TT3A1EZ DMF3V01 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMF3V01 MA Inhibitor DMF3V01 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMF3V01 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMF50XJ DI DMF50XJ DMF50XJ DN Amitriptyline+ketamine DMF50XJ TI TT9IK2Z DMF50XJ TN N-methyl-D-aspartate receptor (NMDAR) DMF50XJ MA Antagonist DMF50XJ RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMF50XJ RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMF5GZI DI DMF5GZI DMF5GZI DN RG7388 DMF5GZI TI TT08GJW DMF5GZI TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMF5GZI MA Modulator DMF5GZI RN Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma. Oncotarget. 2015 Apr 30;6(12):10207-21. DMF5GZI RU https://pubmed.ncbi.nlm.nih.gov/25844600 DMF5GZI DI DMF5GZI DMF5GZI DN RG7388 DMF5GZI TI TT0JESD DMF5GZI TN Erbb4 tyrosine kinase receptor (Erbb-4) DMF5GZI MA Inhibitor DMF5GZI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1799). DMF5GZI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1799 DMF98Q0 DI DMF98Q0 DMF98Q0 DN Momelotinib DMF98Q0 TI TTRMX3V DMF98Q0 TN Janus kinase 2 (JAK-2) DMF98Q0 MA Modulator DMF98Q0 RN Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4. DMF98Q0 RU https://www.ncbi.nlm.nih.gov/pubmed/25322686 DMFBNA3 DI DMFBNA3 DMFBNA3 DN Nicaraven DMFBNA3 TI TTVDSZ0 DMFBNA3 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMFBNA3 MA Modulator DMFBNA3 RN Inhibition of poly (ADP-ribose) polymerase as a protective effect of nicaraven in ionizing radiation- and ara-C-induced cell death. Anticancer Res. 2006 Sep-Oct;26(5A):3421-7. DMFBNA3 RU https://pubmed.ncbi.nlm.nih.gov/17094462 DMFD249 DI DMFD249 DMFD249 DN Nebracetam DMFD249 TI TTZ9SOR DMFD249 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMFD249 MA Agonist DMFD249 RN Effects of nebracetam (WEB 1881 FU), a novel nootropic, as a M1-muscarinic agonist. Jpn J Pharmacol. 1991 Jan;55(1):177-80. DMFD249 RU https://pubmed.ncbi.nlm.nih.gov/2041225 DMFDNT0 DI DMFDNT0 DMFDNT0 DN Tocilizumab DMFDNT0 TI TTDVAKP DMFDNT0 TN HUMAN interleukin-6 receptor (IL6R) DMFDNT0 MA Inhibitor DMFDNT0 RN Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020 Apr 2. pii: S0923-7534(20)36387-0. DMFDNT0 RU https://pubmed.ncbi.nlm.nih.gov/32247642 DMFIP35 DI DMFIP35 DMFIP35 DN Adhexil DMFIP35 TI TTWODQF DMFIP35 TN Fibrin (FG) DMFIP35 MA Modulator DMFIP35 RN Evaluation of a fibrin preparation containing tranexamic acid (Adhexil) in a rabbit uterine horn model of adhesions with and without bleeding and in a model with two surgical loci. Fertil Steril. 2010 Mar 1;93(4):1045-51. DMFIP35 RU https://pubmed.ncbi.nlm.nih.gov/19147133 DMFJLB6 DI DMFJLB6 DMFJLB6 DN Lanabecestat DMFJLB6 TI TT8JRS7 DMFJLB6 TN Beta-secretase (BACE) DMFJLB6 MA Inhibitor DMFJLB6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFJLB6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFKOR9 DI DMFKOR9 DMFKOR9 DN Pafuramidine DMFKOR9 TI TTUTN1I DMFKOR9 TN Human Deoxyribonucleic acid (hDNA) DMFKOR9 MA Modulator DMFKOR9 RN DNA Minor Groove Induced Dimerization of Heterocyclic Cations: Compound Structure, Binding Affinity and Specificity for a TTAA Site DMFKOR9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988403 DMFLJHQ DI DMFLJHQ DMFLJHQ DN LCQ908 DMFLJHQ TI TTF8P9I DMFLJHQ TN Diacylglycerol acyltransferase 1 (DGAT1) DMFLJHQ MA Modulator DMFLJHQ RN DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96. DMFLJHQ RU https://pubmed.ncbi.nlm.nih.gov/20597032 DMFLWX1 DI DMFLWX1 DMFLWX1 DN Farletuzumab DMFLWX1 TI TTVC37M DMFLWX1 TN Folate receptor alpha (FOLR1) DMFLWX1 MA Modulator DMFLWX1 RN Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8. DMFLWX1 RU https://www.ncbi.nlm.nih.gov/pubmed/23474348 DMFMWYC DI DMFMWYC DMFMWYC DN Resatorvid DMFMWYC TI TTISGCA DMFMWYC TN Toll-like receptor 4 (TLR4) DMFMWYC MA Antagonist DMFMWYC RN Clinical pipeline report, company report or official report of Takeda (2009). DMFMWYC RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMFQ1WX DI DMFQ1WX DMFQ1WX DN CLS006 DMFQ1WX TI TTL3N71 DMFQ1WX TN Virus Replication (Viru Repli) DMFQ1WX MA Inhibitor DMFQ1WX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFQ1WX RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMFSHEM DI DMFSHEM DMFSHEM DN Ragaglitazar DMFSHEM TI TTZMAO3 DMFSHEM TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMFSHEM MA Modulator DMFSHEM RN Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56. DMFSHEM RU https://pubmed.ncbi.nlm.nih.gov/14551179 DMFSHEM DI DMFSHEM DMFSHEM DN Ragaglitazar DMFSHEM TI TTJ584C DMFSHEM TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFSHEM MA Modulator DMFSHEM RN Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56. DMFSHEM RU https://pubmed.ncbi.nlm.nih.gov/14551179 DMFUOM7 DI DMFUOM7 DMFUOM7 DN ALN-TTRsc DMFUOM7 TI TTC1I86 DMFUOM7 TN Transthyretin (TTR) DMFUOM7 MA Inhibitor DMFUOM7 RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc. DMFUOM7 RU http://www.alnylam.com/product-pipeline/ttr-amyloidosis-fap/ DMFWE9S DI DMFWE9S DMFWE9S DN Mobocertinib DMFWE9S TI TT2M7YX DMFWE9S TN EGFR Exon20ins mutant (EGFR Exon20ins) DMFWE9S MA Inhibitor DMFWE9S RN Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Feb 25;candisc.1683.2020. DMFWE9S RU https://pubmed.ncbi.nlm.nih.gov/33632773 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TT1MPAY DMFWMKZ TN GABA(A) receptor alpha-1 (GABRA1) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TTZA1NY DMFWMKZ TN GABA(A) receptor beta-2 (GABRB2) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TT06RH5 DMFWMKZ TN GABA(A) receptor gamma-2 (GABRG2) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFWMKZ DI DMFWMKZ DMFWMKZ DN ZK-93423 DMFWMKZ TI TTNJYV2 DMFWMKZ TN Gamma-aminobutyric acid receptor (GAR) DMFWMKZ MA Inhibitor DMFWMKZ RN Structural requirements for agonist actions at the benzodiazepine receptor: studies with analogues of 6-(benzyloxy)-4-(methoxymethyl)-beta-carbolin... J Med Chem. 1990 Mar;33(3):1062-9. DMFWMKZ RU https://pubmed.ncbi.nlm.nih.gov/1968513 DMFZ81T DI DMFZ81T DMFZ81T DN Fidanacogene elaparvovec DMFZ81T TI TTFEZ5Q DMFZ81T TN Coagulation factor IX (F9) DMFZ81T MA Replacement DMFZ81T RN Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua. J Thromb Haemost. 2021 May;19(5):1212-1218. DMFZ81T RU https://pubmed.ncbi.nlm.nih.gov/33636038 DMFZBNE DI DMFZBNE DMFZBNE DN ITF2357 DMFZBNE TI TT6R7JZ DMFZBNE TN Histone deacetylase 1 (HDAC1) DMFZBNE MA Inhibitor DMFZBNE RN Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. DMFZBNE RU https://pubmed.ncbi.nlm.nih.gov/19552608 DMFZBNE DI DMFZBNE DMFZBNE DN ITF2357 DMFZBNE TI TTRMX3V DMFZBNE TN Janus kinase 2 (JAK-2) DMFZBNE MA Inhibitor DMFZBNE RN Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. DMFZBNE RU https://pubmed.ncbi.nlm.nih.gov/19552608 DMFZBNE DI DMFZBNE DMFZBNE DN ITF2357 DMFZBNE TI TTBH0VX DMFZBNE TN Histone deacetylase (HDAC) DMFZBNE MA Inhibitor DMFZBNE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFZBNE RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMG2QP4 DI DMG2QP4 DMG2QP4 DN SEP-363856 DMG2QP4 TI TTSQIFT DMG2QP4 TN 5-HT 1A receptor (HTR1A) DMG2QP4 MA Agonist DMG2QP4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG2QP4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMG2QP4 DI DMG2QP4 DMG2QP4 DN SEP-363856 DMG2QP4 TI TTIU98M DMG2QP4 TN Trace amine-associated receptor-1 (TAAR1) DMG2QP4 MA Agonist DMG2QP4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG2QP4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMG324Y DI DMG324Y DMG324Y DN AMG 145 DMG324Y TI TTBRG7E DMG324Y TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMG324Y MA Modulator DMG324Y RN PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40. DMG324Y RU https://pubmed.ncbi.nlm.nih.gov/25282519 DMG3NFZ DI DMG3NFZ DMG3NFZ DN Muraglitazar DMG3NFZ TI TTZMAO3 DMG3NFZ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMG3NFZ MA Modulator DMG3NFZ RN Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95. DMG3NFZ RU https://www.ncbi.nlm.nih.gov/pubmed/16199244 DMG3NFZ DI DMG3NFZ DMG3NFZ DN Muraglitazar DMG3NFZ TI TTJ584C DMG3NFZ TN Peroxisome proliferator-activated receptor alpha (PPARA) DMG3NFZ MA Modulator DMG3NFZ RN Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95. DMG3NFZ RU https://www.ncbi.nlm.nih.gov/pubmed/16199244 DMG4UJ6 DI DMG4UJ6 DMG4UJ6 DN EVK-001 DMG4UJ6 TI TTWFZ1N DMG4UJ6 TN Dopamine receptor (DR) DMG4UJ6 MA Antagonist DMG4UJ6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG4UJ6 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMG5BTD DI DMG5BTD DMG5BTD DN ALZT-OP1 DMG5BTD TI TTE4KHA DMG5BTD TN Amyloid beta A4 protein (APP) DMG5BTD MA Inhibitor DMG5BTD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG5BTD RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMG8U6M DI DMG8U6M DMG8U6M DN DIPROTEVERINE HYDROCHLORIDE DMG8U6M TI TT5HONZ DMG8U6M TN Calcium channel unspecific (CaC) DMG8U6M MA Antagonist DMG8U6M RN Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9. DMG8U6M RU https://pubmed.ncbi.nlm.nih.gov/8998385 DMGF8MZ DI DMGF8MZ DMGF8MZ DN FPL-62064 DMGF8MZ TI TT2J34L DMGF8MZ TN Arachidonate 5-lipoxygenase (5-LOX) DMGF8MZ MA Modulator DMGF8MZ RN FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor. Agents Actions. 1990 Jun;30(3-4):432-42. DMGF8MZ RU https://pubmed.ncbi.nlm.nih.gov/2117338 DMGFULM DI DMGFULM DMGFULM DN Heparin low molecular weight DMGFULM TI TT4QPUL DMGFULM TN Antithrombin-III (ATIII) DMGFULM MA Modulator DMGFULM RN Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8. DMGFULM RU https://pubmed.ncbi.nlm.nih.gov/8588200 DMGJQVI DI DMGJQVI DMGJQVI DN GS-6615 DMGJQVI TI TT40BO8 DMGJQVI TN Late inward sodium current (LISC) DMGJQVI MA Modulator DMGJQVI RN Clinical pipeline report, company report or official report of Gilead. DMGJQVI RU http://www.gilead.com/news/press-releases/2014/5/gilead-announces-phase-1-data-for-investigational-therapy-gs6615-in-patients-with-long-qt3-syndrome DMGKBZH DI DMGKBZH DMGKBZH DN TD-1792 DMGKBZH TI TTLP6GN DMGKBZH TN Bacterial DD-carboxypeptidase (Bact vanYB) DMGKBZH MA Inhibitor DMGKBZH RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMGKBZH RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMGMNUE DI DMGMNUE DMGMNUE DN AM0010 DMGMNUE TI TTT0Q1F DMGMNUE TN Interleukin-10 (IL10) DMGMNUE MA Modulator DMGMNUE RN Clinical pipeline report, company report or official report of ARMO BioSciences. DMGMNUE RU http://www.armobio.com/drug-development DMGNC6T DI DMGNC6T DMGNC6T DN M-0011 DMGNC6T TI TTT2KE3 DMGNC6T TN Alpha-mannosidase (MANA) DMGNC6T MA Modulator DMGNC6T RN ClinicalTrials.gov (NCT01681953) A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis. U.S. National Institutes of Health. DMGNC6T RU https://clinicaltrials.gov/ct2/show/NCT01681953 DMGNHC2 DI DMGNHC2 DMGNHC2 DN MK-3415A DMGNHC2 TI TTQH65V DMGNHC2 TN Clostridium difficile Toxin B (CD toxB) DMGNHC2 RN ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health. DMGNHC2 RU https://clinicaltrials.gov/ct2/show/NCT01513239 DMGNHC2 DI DMGNHC2 DMGNHC2 DN MK-3415A DMGNHC2 TI TT64H8L DMGNHC2 TN Clostridium difficile Toxin A (CD toxA) DMGNHC2 RN ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health. DMGNHC2 RU https://clinicaltrials.gov/ct2/show/NCT01513239 DMGOTK4 DI DMGOTK4 DMGOTK4 DN Rhumab Beta7 DMGOTK4 TI TTLT9XQ DMGOTK4 TN Integrin beta-7 (ITGB7) DMGOTK4 RN A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013 Aug;62(8):1122-30. DMGOTK4 RU https://pubmed.ncbi.nlm.nih.gov/22717454 DMGQ1TV DI DMGQ1TV DMGQ1TV DN ASP1941 DMGQ1TV TI TTLWPVF DMGQ1TV TN Sodium/glucose cotransporter 2 (SGLT2) DMGQ1TV MA Modulator DMGQ1TV RN Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44. DMGQ1TV RU https://www.ncbi.nlm.nih.gov/pubmed/25685284 DMGR98T DI DMGR98T DMGR98T DN SAGE-217 DMGR98T TI TTEX6LM DMGR98T TN GABA(A) receptor gamma-3 (GABRG3) DMGR98T MA Modulator DMGR98T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGR98T RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMGRBN5 DI DMGRBN5 DMGRBN5 DN TESAGLITAZAR DMGRBN5 TI TTZMAO3 DMGRBN5 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMGRBN5 MA Modulator DMGRBN5 RN Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32. DMGRBN5 RU https://www.ncbi.nlm.nih.gov/pubmed/22131108 DMGRBN5 DI DMGRBN5 DMGRBN5 DN TESAGLITAZAR DMGRBN5 TI TTJ584C DMGRBN5 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMGRBN5 MA Modulator DMGRBN5 RN Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32. DMGRBN5 RU https://www.ncbi.nlm.nih.gov/pubmed/22131108 DMGTCI0 DI DMGTCI0 DMGTCI0 DN Rilimogene galvacirepvec DMGTCI0 TI TTS78AZ DMGTCI0 TN Prostate specific antigen (KLK3) DMGTCI0 MA Modulator DMGTCI0 RN Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105. DMGTCI0 RU https://pubmed.ncbi.nlm.nih.gov/20100959 DMGWVLX DI DMGWVLX DMGWVLX DN Itolizumab DMGWVLX TI TTMF6KC DMGWVLX TN T-cell differentiation antigen CD6 (TP120) DMGWVLX RN Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. J Am Acad Dermatol. 2014 Sep;71(3):484-92. DMGWVLX RU https://pubmed.ncbi.nlm.nih.gov/24703722 DMGYK2N DI DMGYK2N DMGYK2N DN Tilsotolimod DMGYK2N TI TTSHG0T DMGYK2N TN Toll-like receptor 9 (TLR9) DMGYK2N MA Agonist DMGYK2N RN Tilsotolimod with ipilimumab drives tumor responses in anti-PD-1 refractory melanoma. Cancer Discov. 2021 Mar 11;candisc.1546.2020. DMGYK2N RU https://pubmed.ncbi.nlm.nih.gov/33707233 DMGZPX6 DI DMGZPX6 DMGZPX6 DN PI-88 DMGZPX6 TI TTDCBX5 DMGZPX6 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMGZPX6 MA Modulator DMGZPX6 RN Company report (Medigen) DMGZPX6 RU http://www.medigen.com.tw/en/muparfostat-pi-88/ DMH2EA1 DI DMH2EA1 DMH2EA1 DN Laromustine DMH2EA1 TI TTUTN1I DMH2EA1 TN Human Deoxyribonucleic acid (hDNA) DMH2EA1 MA Binder DMH2EA1 RN Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):211-6. DMH2EA1 RU https://pubmed.ncbi.nlm.nih.gov/20511167 DMH2FN1 DI DMH2FN1 DMH2FN1 DN Suronacrine maleate DMH2FN1 TI TTAWNKZ DMH2FN1 TN Norepinephrine transporter (NET) DMH2FN1 MA Modulator DMH2FN1 RN Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7. DMH2FN1 RU https://www.ncbi.nlm.nih.gov/pubmed/1776748 DMH2FN1 DI DMH2FN1 DMH2FN1 DN Suronacrine maleate DMH2FN1 TI TT1RS9F DMH2FN1 TN Acetylcholinesterase (AChE) DMH2FN1 MA Modulator DMH2FN1 RN Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7. DMH2FN1 RU https://www.ncbi.nlm.nih.gov/pubmed/1776748 DMH3XDR DI DMH3XDR DMH3XDR DN BI 425809 DMH3XDR TI TTHJTF7 DMH3XDR TN Glycine transporter GlyT-1 (SLC6A9) DMH3XDR MA Inhibitor DMH3XDR RN Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021 Mar;8(3):191-201. DMH3XDR RU https://pubmed.ncbi.nlm.nih.gov/33610228 DMH7W9X DI DMH7W9X DMH7W9X DN SNDX-275 DMH7W9X TI TT6R7JZ DMH7W9X TN Histone deacetylase 1 (HDAC1) DMH7W9X MA Inhibitor DMH7W9X RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMH7W9X RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMH7W9X DI DMH7W9X DMH7W9X DN SNDX-275 DMH7W9X TI TTBH0VX DMH7W9X TN Histone deacetylase (HDAC) DMH7W9X MA Inhibitor DMH7W9X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH7W9X RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH8IT5 DI DMH8IT5 DMH8IT5 DN Donaperminogene seltoplasmid DMH8IT5 TI TT4V2JM DMH8IT5 TN Hepatocyte growth factor (HGF) DMH8IT5 MA Replacement DMH8IT5 RN Clinical pipeline report, company report or official report of ViroMed. DMH8IT5 RU http://menu.itooza.com/cmsupload/contdown.php?sn=20190912100403_fd_image_119_65_142__1669.pdf&rsn=ViroMed_May_30_2018.pdf DMH9EUA DI DMH9EUA DMH9EUA DN Nemolizumab DMH9EUA TI TT9HPX0 DMH9EUA TN Interleukin 31 receptor (IL31R) DMH9EUA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH9EUA RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHDNK0 DI DMHDNK0 DMHDNK0 DN TroVax DMHDNK0 TI TT70MLA DMHDNK0 TN Oncotrophoblast glycoprotein 5T4 (TPBG) DMHDNK0 RN Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47. DMHDNK0 RU https://pubmed.ncbi.nlm.nih.gov/20881001 DMHFBOG DI DMHFBOG DMHFBOG DN SAR231893 DMHFBOG TI TTDWHC3 DMHFBOG TN Interleukin 4 receptor alpha (IL4R) DMHFBOG MA Modulator DMHFBOG RN Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. DMHFBOG RU https://pubmed.ncbi.nlm.nih.gov/23688323 DMHJCGV DI DMHJCGV DMHJCGV DN Candoxatril DMHJCGV TI TT5TKPM DMHJCGV TN Neutral endopeptidase (MME) DMHJCGV MA Inhibitor DMHJCGV RN Neutral endopeptidase inhibitor suppresses the early phase of atrial electrical remodeling in a canine rapid atrial pacing model. Indian Pacing Electrophysiol J. 2008 Apr 1;8(2):102-13. DMHJCGV RU https://pubmed.ncbi.nlm.nih.gov/18379655 DMHKCIS DI DMHKCIS DMHKCIS DN Aldoxorubicin DMHKCIS TI TT0IHXV DMHKCIS TN DNA topoisomerase II (TOP2) DMHKCIS MA Modulator DMHKCIS RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHKCIS RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHKZLF DI DMHKZLF DMHKZLF DN OSI-906 DMHKZLF TI TTHRID2 DMHKZLF TN Insulin-like growth factor I receptor (IGF1R) DMHKZLF MA Inhibitor DMHKZLF RN Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5. DMHKZLF RU https://pubmed.ncbi.nlm.nih.gov/20346655 DMHN3PG DI DMHN3PG DMHN3PG DN GRT-6005 DMHN3PG TI TTKWM86 DMHN3PG TN Opioid receptor mu (MOP) DMHN3PG MA Modulator DMHN3PG RN Cebranopadol: a first in-class example of a nociceptin/orphanin FQ receptor and opioid receptor agonist. Br J Anaesth. 2015 Mar;114(3):364-6. DMHN3PG RU https://pubmed.ncbi.nlm.nih.gov/25248647 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TT2Q6G1 DMHOSCQ TN Vascular endothelial growth factor receptor 1 (FLT-1) DMHOSCQ MA Inhibitor DMHOSCQ RN Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. DMHOSCQ RU https://pubmed.ncbi.nlm.nih.gov/25482937 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TTUTJGQ DMHOSCQ TN Vascular endothelial growth factor receptor 2 (KDR) DMHOSCQ MA Inhibitor DMHOSCQ RN Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. DMHOSCQ RU https://pubmed.ncbi.nlm.nih.gov/25482937 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TTDCBX5 DMHOSCQ TN Vascular endothelial growth factor receptor 3 (FLT-4) DMHOSCQ MA Inhibitor DMHOSCQ RN Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45. DMHOSCQ RU https://pubmed.ncbi.nlm.nih.gov/25482937 DMHOSCQ DI DMHOSCQ DMHOSCQ DN Fruquintinib DMHOSCQ TI TTVJ1D8 DMHOSCQ TN Vascular endothelial growth factor receptor (VEGFR) DMHOSCQ MA Inhibitor DMHOSCQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHOSCQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHQ5GK DI DMHQ5GK DMHQ5GK DN Bapineuzumab DMHQ5GK TI TTE4KHA DMHQ5GK TN Amyloid beta A4 protein (APP) DMHQ5GK RN Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82. DMHQ5GK RU https://pubmed.ncbi.nlm.nih.gov/21091109 DMHQRYE DI DMHQRYE DMHQRYE DN Tenidap DMHQRYE TI TT2J34L DMHQRYE TN Arachidonate 5-lipoxygenase (5-LOX) DMHQRYE MA Modulator DMHQRYE RN The in vitro free radical scavenging activity of tenidap, a new dual cyclo-oxygenase and 5-1ipoxygenase inhibitor. Mediators Inflamm. 1992;1(2):141-3. DMHQRYE RU https://pubmed.ncbi.nlm.nih.gov/18475454 DMHTY9W DI DMHTY9W DMHTY9W DN Ublituximab DMHTY9W TI TTUE541 DMHTY9W TN Leukocyte surface antigen Leu-16 (CD20) DMHTY9W RN The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51. DMHTY9W RU https://pubmed.ncbi.nlm.nih.gov/25552707 DMHULRK DI DMHULRK DMHULRK DN GV1001 DMHULRK TI TTUJFD0 DMHULRK TN Telomerase reverse transcriptase (TERT) DMHULRK RN Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82. DMHULRK RU https://pubmed.ncbi.nlm.nih.gov/17060934 DMHXTAQ DI DMHXTAQ DMHXTAQ DN Pazufloxacin DMHXTAQ TI TTN6J5F DMHXTAQ TN Bacterial DNA gyrase (Bact gyrase) DMHXTAQ MA Inhibitor DMHXTAQ RN Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. DMHXTAQ RU https://www.ncbi.nlm.nih.gov/pubmed/11709337 DMHXTAQ DI DMHXTAQ DMHXTAQ DN Pazufloxacin DMHXTAQ TI TTFK8YB DMHXTAQ TN Bacterial DNA topoisomerase 4A (Bact parC) DMHXTAQ MA Inhibitor DMHXTAQ RN Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother. 2001 Dec;45(12):3544-7. DMHXTAQ RU https://www.ncbi.nlm.nih.gov/pubmed/11709337 DMHZBEO DI DMHZBEO DMHZBEO DN Difelikefalin DMHZBEO TI TTQW87Y DMHZBEO TN Opioid receptor kappa (OPRK1) DMHZBEO MA Agonist DMHZBEO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHZBEO RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMI1R5S DI DMI1R5S DMI1R5S DN SAIT101 DMI1R5S TI TTUE541 DMI1R5S TN Leukocyte surface antigen Leu-16 (CD20) DMI1R5S RN Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy. Front Oncol. 2018 Jun 4;8:163. DMI1R5S RU https://pubmed.ncbi.nlm.nih.gov/29915719 DMI1ZXV DI DMI1ZXV DMI1ZXV DN Epratuzumab DMI1ZXV TI TTM6QSK DMI1ZXV TN B-cell receptor CD22 (CD22) DMI1ZXV RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DMI1ZXV RU https://pubmed.ncbi.nlm.nih.gov/19265486 DMI3YLK DI DMI3YLK DMI3YLK DN LA-EP2006 DMI3YLK TI TT5TQ2W DMI3YLK TN Granulocyte colony-stimulating factor (CSF3) DMI3YLK MA Modulator DMI3YLK RN National Cancer Institute Drug Dictionary (drug id 724518). DMI3YLK RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=724518 DMIC56X DI DMIC56X DMIC56X DN NASVAC DMIC56X TI TTRF7Q8 DMIC56X TN Natural killer cell receptor (NKCR) DMIC56X RN In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7. DMIC56X RU https://pubmed.ncbi.nlm.nih.gov/25193323 DMIC56X DI DMIC56X DMIC56X DN NASVAC DMIC56X TI TT6KSF7 DMIC56X TN Hepatitis B virus Large envelope protein (HBV S) DMIC56X RN In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. Mol Immunol. 2015 Feb;63(2):320-7. DMIC56X RU https://pubmed.ncbi.nlm.nih.gov/25193323 DMIE1WY DI DMIE1WY DMIE1WY DN AG-881 DMIE1WY TI TTDTWV0 DMIE1WY TN Isocitrate dehydrogenase (IDH) DMIE1WY MA Inhibitor DMIE1WY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIE1WY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIG4OX DI DMIG4OX DMIG4OX DN SOTB07 DMIG4OX TI TTVIAT9 DMIG4OX TN Phosphodiesterase 4B (PDE4B) DMIG4OX MA Inhibitor DMIG4OX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DMIG4OX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DMIG4OX DI DMIG4OX DMIG4OX DN SOTB07 DMIG4OX TI TTSKMI8 DMIG4OX TN Phosphodiesterase 4D (PDE4D) DMIG4OX MA Inhibitor DMIG4OX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DMIG4OX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DMIG4OX DI DMIG4OX DMIG4OX DN SOTB07 DMIG4OX TI TTZ97H5 DMIG4OX TN Phosphodiesterase 4A (PDE4A) DMIG4OX MA Inhibitor DMIG4OX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DMIG4OX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DMIGFOR DI DMIGFOR DMIGFOR DN I3C DMIGFOR TI TTSHAEB DMIGFOR TN NF-kappa-B inhibitor alpha (NFKBIA) DMIGFOR MA Inhibitor DMIGFOR RN Protective effect of Indole-3-carbinol, an NF-B inhibitor in experimental paradigm of Parkinson's disease: In silico and in vivo studies. Brain Behav Immun. 2020 Nov;90:108-137. DMIGFOR RU https://pubmed.ncbi.nlm.nih.gov/32800927 DMIGX84 DI DMIGX84 DMIGX84 DN Cethromycin DMIGX84 TI TTLFGBV DMIGX84 TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMIGX84 MA Inhibitor DMIGX84 RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMIGX84 RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMIJGT9 DI DMIJGT9 DMIJGT9 DN INCB24360 DMIJGT9 TI TTZJYKH DMIJGT9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMIJGT9 MA Inhibitor DMIJGT9 RN Incyte. Product Development Pipeline. DMIJGT9 RU http://www.incyte.com/drugs_product_pipeline.html DMIKDCQ DI DMIKDCQ DMIKDCQ DN Ensartinib DMIKDCQ TI TTPMQSO DMIKDCQ TN ALK tyrosine kinase receptor (ALK) DMIKDCQ MA Inhibitor DMIKDCQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIKDCQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIKMA9 DI DMIKMA9 DMIKMA9 DN CG-100649 DMIKMA9 TI TTVKILB DMIKMA9 TN Prostaglandin G/H synthase 2 (COX-2) DMIKMA9 MA Inhibitor DMIKMA9 RN Pharmacokinetic, pharmacodynamic, and safety/tolerability profiles of CG100649, a novel COX-2 inhibitor: results of a phase i, randomized, multiple-dose study in healthy Korean men and women. Clin Ther. 2015 Jan 1;37(1):197-210. DMIKMA9 RU https://pubmed.ncbi.nlm.nih.gov/25097102 DMIKMA9 DI DMIKMA9 DMIKMA9 DN CG-100649 DMIKMA9 TI TTHQPL7 DMIKMA9 TN Carbonic anhydrase I (CA-I) DMIKMA9 MA Inhibitor DMIKMA9 RN Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12. DMIKMA9 RU https://pubmed.ncbi.nlm.nih.gov/26095375 DMIKMA9 DI DMIKMA9 DMIKMA9 DN CG-100649 DMIKMA9 TI TTANPDJ DMIKMA9 TN Carbonic anhydrase II (CA-II) DMIKMA9 MA Inhibitor DMIKMA9 RN Understanding the Dual Inhibition of COX-2 and Carbonic Anhydrase-II by Celecoxib and CG100649 Using Density Functional Theory Calculations and other Molecular Modelling Approaches. Protein Pept Lett. 2015;22(10):903-12. DMIKMA9 RU https://pubmed.ncbi.nlm.nih.gov/26095375 DMIL37Z DI DMIL37Z DMIL37Z DN Losmapimod DMIL37Z TI TTQBR95 DMIL37Z TN Stress-activated protein kinase 2a (p38 alpha) DMIL37Z MA Inhibitor DMIL37Z RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMIL37Z RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMIM5AP DI DMIM5AP DMIM5AP DN TAK-875 DMIM5AP TI TTB8FUC DMIM5AP TN Free fatty acid receptor 1 (GPR40) DMIM5AP MA Modulator DMIM5AP RN Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81. DMIM5AP RU https://pubmed.ncbi.nlm.nih.gov/25787200 DMIPNBG DI DMIPNBG DMIPNBG DN Nemonaxacin DMIPNBG TI TTIXTO3 DMIPNBG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMIPNBG MA Modulator DMIPNBG RN In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.J Antimicrob Chemother.2009 Dec;64(6):1226-9. DMIPNBG RU https://www.ncbi.nlm.nih.gov/pubmed/19833635 DMIQ31Y DI DMIQ31Y DMIQ31Y DN Custirsen DMIQ31Y TI TTRL76H DMIQ31Y TN Clusterin messenger RNA (Clusterin mRNA) DMIQ31Y RN Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. Eur J Cancer. 2009 Jul;45(10):1846-54. DMIQ31Y RU https://pubmed.ncbi.nlm.nih.gov/19342222 DMIQCFG DI DMIQCFG DMIQCFG DN Ulinastatin DMIQCFG TI TT2WR1T DMIQCFG TN Cationic trypsinogen (PRSS1) DMIQCFG MA Modulator DMIQCFG RN Intravenous administration of ulinastatin (human urinary trypsin inhibitor) in severe sepsis: a multicenter randomized controlled study. Intensive Care Med. 2014 Jun;40(6):830-8. DMIQCFG RU https://pubmed.ncbi.nlm.nih.gov/24737258 DMIRYU9 DI DMIRYU9 DMIRYU9 DN Pancopride DMIRYU9 TI TTNXLKE DMIRYU9 TN 5-HT 3 receptor (5HT3R) DMIRYU9 MA Inhibitor DMIRYU9 RN Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64. DMIRYU9 RU https://pubmed.ncbi.nlm.nih.gov/1451737 DMITJAK DI DMITJAK DMITJAK DN Androsterone DMITJAK TI TTNJYV2 DMITJAK TN Gamma-aminobutyric acid receptor (GAR) DMITJAK MA Inhibitor DMITJAK RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DMITJAK RU https://pubmed.ncbi.nlm.nih.gov/16854065 DMITJRU DI DMITJRU DMITJRU DN Epothilon DMITJRU TI TTML2WA DMITJRU TN Tubulin (TUB) DMITJRU MA Stablizer DMITJRU RN Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. DMITJRU RU https://pubmed.ncbi.nlm.nih.gov/18764727 DMIWLJE DI DMIWLJE DMIWLJE DN Guanine DMIWLJE TI TTLSWP6 DMIWLJE TN GTP cyclohydrolase-I (GCH1) DMIWLJE MA Inhibitor DMIWLJE RN GTP cyclohydrolase I feedback regulatory protein-dependent and -independent inhibitors of GTP cyclohydrolase I. Arch Biochem Biophys. 2001 Apr 1;388(1):67-73. DMIWLJE RU https://pubmed.ncbi.nlm.nih.gov/11361142 DMIZJ8M DI DMIZJ8M DMIZJ8M DN Psoralen DMIZJ8M TI TTGP7BY DMIZJ8M TN Monoamine oxidase type B (MAO-B) DMIZJ8M MA Inhibitor DMIZJ8M RN Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80. DMIZJ8M RU https://pubmed.ncbi.nlm.nih.gov/11169165 DMIZJ8M DI DMIZJ8M DMIZJ8M DN Psoralen DMIZJ8M TI TT3WG5C DMIZJ8M TN Monoamine oxidase type A (MAO-A) DMIZJ8M MA Inhibitor DMIZJ8M RN Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80. DMIZJ8M RU https://pubmed.ncbi.nlm.nih.gov/11169165 DMJ2KIE DI DMJ2KIE DMJ2KIE DN NI-101 DMJ2KIE TI TTE4KHA DMJ2KIE TN Amyloid beta A4 protein (APP) DMJ2KIE RN Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479. DMJ2KIE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862506/ DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TTAU4D6 DMJ432G TN E-selectin (SELE) DMJ432G MA Inhibitor DMJ432G RN Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. DMJ432G RU https://pubmed.ncbi.nlm.nih.gov/22129980 DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TT2IYXF DMJ432G TN L-selectin (SELL) DMJ432G MA Inhibitor DMJ432G RN Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. DMJ432G RU https://pubmed.ncbi.nlm.nih.gov/22129980 DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TTE5VG0 DMJ432G TN P-selectin (SELP) DMJ432G MA Inhibitor DMJ432G RN Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890. DMJ432G RU https://pubmed.ncbi.nlm.nih.gov/22129980 DMJ432G DI DMJ432G DMJ432G DN GMI-1070 DMJ432G TI TTBGONL DMJ432G TN Selectin (SEL) DMJ432G MA Antagonist DMJ432G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ432G RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMJ6F5C DI DMJ6F5C DMJ6F5C DN XL019 DMJ6F5C TI TTRMX3V DMJ6F5C TN Janus kinase 2 (JAK-2) DMJ6F5C MA Inhibitor DMJ6F5C RN Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. DMJ6F5C RU https://pubmed.ncbi.nlm.nih.gov/19552608 DMJ7IKW DI DMJ7IKW DMJ7IKW DN PF-4494700 DMJ7IKW TI TTMO9HF DMJ7IKW TN Advanced glycosylation end product receptor (AGER) DMJ7IKW MA Antagonist DMJ7IKW RN Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9. DMJ7IKW RU https://pubmed.ncbi.nlm.nih.gov/25586103 DMJ8AUE DI DMJ8AUE DMJ8AUE DN Plitidepsin DMJ8AUE TI TTSQC14 DMJ8AUE TN Palmitoyl-protein thioesterase 1 (PPT1) DMJ8AUE MA Modulator DMJ8AUE RN Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B DMJ8AUE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433765 DMJ9ZIY DI DMJ9ZIY DMJ9ZIY DN CK-2017357 DMJ9ZIY TI TTYUMF5 DMJ9ZIY TN Fast skeletal muscle troponin complex (TNNC2) DMJ9ZIY MA Modulator DMJ9ZIY RN Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5. DMJ9ZIY RU https://pubmed.ncbi.nlm.nih.gov/22344294 DMJBHO0 DI DMJBHO0 DMJBHO0 DN PC-DAC:Insulin DMJBHO0 TI TTZOPHG DMJBHO0 TN Insulin (INS) DMJBHO0 MA Modulator DMJBHO0 RN Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin. J Diabetes Sci Technol. 2010 May; 4(3): 532-539. DMJBHO0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901028/ DMJBU9V DI DMJBU9V DMJBU9V DN Velimogene aliplasmid DMJBU9V TI TTGS10J DMJBU9V TN HLA class I antigen B-7 (HLA-B) DMJBU9V MA Modulator DMJBU9V RN Velimogene aliplasmid. Expert Opin Biol Ther. 2010 May;10(5):841-51. DMJBU9V RU https://pubmed.ncbi.nlm.nih.gov/20367461 DMJBXO3 DI DMJBXO3 DMJBXO3 DN VX-661 DMJBXO3 TI TTRLZHP DMJBXO3 TN cAMP-dependent chloride channel (CFTR) DMJBXO3 MA Regulator DMJBXO3 RN CFTR Modulators for the Treatment of Cystic Fibrosis. P T. 2014 Jul;39(7):500-11. DMJBXO3 RU https://pubmed.ncbi.nlm.nih.gov/25083129 DMJCF1O DI DMJCF1O DMJCF1O DN Maralixibat DMJCF1O TI TTPI1M5 DMJCF1O TN Ileal sodium/bile acid cotransporter (SLC10A2) DMJCF1O MA Inhibitor DMJCF1O RN Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689. DMJCF1O RU https://pubmed.ncbi.nlm.nih.gov/32653991 DMJFD2I DI DMJFD2I DMJFD2I DN ABT-492 DMJFD2I TI TTIXTO3 DMJFD2I TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMJFD2I MA Modulator DMJFD2I RN Contrasting Effects of Acidic pH on the Extracellular and Intracellular Activities of the Anti-Gram-Positive Fluoroquinolones Moxifloxacin and Delafloxacin against Staphylococcus aureus DMJFD2I RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028753 DMJFNR9 DI DMJFNR9 DMJFNR9 DN Viramidine DMJFNR9 TI TTL7C8Q DMJFNR9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMJFNR9 MA Inhibitor DMJFNR9 RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMJFNR9 RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMJKWMA DI DMJKWMA DMJKWMA DN Tanezumab DMJKWMA TI TTDN3LF DMJKWMA TN Nerve growth factor (NGF) DMJKWMA MA Inhibitor DMJKWMA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJKWMA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMJNSLU DI DMJNSLU DMJNSLU DN AAV2-hRPE65v2 DMJNSLU TI TTBOH16 DMJNSLU TN Retinal pigment epithelium protein (RPE65) DMJNSLU MA Modulator DMJNSLU RN AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012 Feb 8;4(120):120ra15. DMJNSLU RU https://pubmed.ncbi.nlm.nih.gov/22323828 DMJPGUA DI DMJPGUA DMJPGUA DN Manidipine DMJPGUA TI TTEAID7 DMJPGUA TN Trypanosoma Cruzipain (Trypano CYSP) DMJPGUA MA Inhibitor DMJPGUA RN Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65. DMJPGUA RU https://pubmed.ncbi.nlm.nih.gov/20426472 DMJRFYB DI DMJRFYB DMJRFYB DN RG7201 DMJRFYB TI TTN7Y4P DMJRFYB TN Sodium/glucose cotransporter 2 (SLC5A4) DMJRFYB MA Modulator DMJRFYB RN Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014 Mar 28;13:65. DMJRFYB RU https://pubmed.ncbi.nlm.nih.gov/24678906 DMJRQDG DI DMJRQDG DMJRQDG DN AG-SPT201 DMJRQDG TI TTF1QVM DMJRQDG TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMJRQDG MA Modulator DMJRQDG RN Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. DMJRQDG RU https://pubmed.ncbi.nlm.nih.gov/10197495 DMJS8V3 DI DMJS8V3 DMJS8V3 DN Disufenton sodium DMJS8V3 TI TT8E7Z0 DMJS8V3 TN Free radical (FRD) DMJS8V3 MA Modulator DMJS8V3 RN NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001 Jan;32(1):190-8. DMJS8V3 RU https://pubmed.ncbi.nlm.nih.gov/11136936 DMK0QW6 DI DMK0QW6 DMK0QW6 DN Albinterferon alfa-2b DMK0QW6 TI TTSIUJ9 DMK0QW6 TN Interferon-alpha 2 (IFNA2) DMK0QW6 MA Modulator DMK0QW6 RN Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin. 2009 Apr;25(4):991-1002. DMK0QW6 RU https://pubmed.ncbi.nlm.nih.gov/19275518 DMK1IPV DI DMK1IPV DMK1IPV DN SCY-078 DMK1IPV TI TT0SFXH DMK1IPV TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMK1IPV MA Inhibitor DMK1IPV RN Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015 Feb;59(2):1265-72. DMK1IPV RU https://pubmed.ncbi.nlm.nih.gov/25512406 DMK2Y4V DI DMK2Y4V DMK2Y4V DN Ancrod DMK2Y4V TI TTZUXYS DMK2Y4V TN Vitamin K-dependent protein C (PROC) DMK2Y4V MA Modulator DMK2Y4V RN Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology. 1989 Dec;71(6):870-7. DMK2Y4V RU https://pubmed.ncbi.nlm.nih.gov/2589675 DMK301H DI DMK301H DMK301H DN MK-8742 DMK301H TI TTCJ2X8 DMK301H TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMK301H MA Modulator DMK301H RN Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. ChemMedChem. 2013 Dec;8(12):1930-40. DMK301H RU https://pubmed.ncbi.nlm.nih.gov/24127258 DMK34MZ DI DMK34MZ DMK34MZ DN Xilonix DMK34MZ TI TTPM6HI DMK34MZ TN Interleukin-1 alpha (IL1A) DMK34MZ MA Modulator DMK34MZ RN Clinical pipeline report, company report or official report of xbiotech. DMK34MZ RU http://www.xbiotech.com/clinical/oncology.html DMK38MV DI DMK38MV DMK38MV DN Fulranumab DMK38MV TI TTEDJN4 DMK38MV TN Low-affinity nerve growth factor receptor (NGFR) DMK38MV MA Antagonist DMK38MV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMK38MV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMK56G0 DI DMK56G0 DMK56G0 DN Bexagliflozin DMK56G0 TI TTF8JAT DMK56G0 TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMK56G0 MA Inhibitor DMK56G0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK56G0 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMK6OFY DI DMK6OFY DMK6OFY DN Peginterferon lambda-1a DMK6OFY TI TTM624L DMK6OFY TN Interleukin-29 (IL29) DMK6OFY MA Agonist DMK6OFY RN Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5. DMK6OFY RU https://pubmed.ncbi.nlm.nih.gov/20645873 DMK6QBZ DI DMK6QBZ DMK6QBZ DN OMS721 DMK6QBZ TI TTR01E9 DMK6QBZ TN Mannan-binding lectin serine protease-2 (MASP2) DMK6QBZ MA Inhibitor DMK6QBZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK6QBZ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMK8AQP DI DMK8AQP DMK8AQP DN Sirukumab DMK8AQP TI TT0E5SK DMK8AQP TN Interleukin 6 receptor (IL6R) DMK8AQP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310). DMK8AQP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310 DMK8AQP DI DMK8AQP DMK8AQP DN Sirukumab DMK8AQP TI TTT1V78 DMK8AQP TN Interleukin-6 (IL6) DMK8AQP MA Inhibitor DMK8AQP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK8AQP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMK9BP2 DI DMK9BP2 DMK9BP2 DN Mavacamten DMK9BP2 TI TTITSMB DMK9BP2 TN Myosin (MYO) DMK9BP2 MA Inhibitor DMK9BP2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK9BP2 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMKA2PI DI DMKA2PI DMKA2PI DN Efpeglenatide DMKA2PI TI TTVIMDE DMKA2PI TN Glucagon-like peptide 1 receptor (GLP1R) DMKA2PI MA Agonist DMKA2PI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKA2PI RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMKB4ZY DI DMKB4ZY DMKB4ZY DN Zanolimumab DMKB4ZY TI TTN2JFW DMKB4ZY TN T-cell surface glycoprotein CD4 (CD4) DMKB4ZY RN Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62. DMKB4ZY RU https://pubmed.ncbi.nlm.nih.gov/17311990 DMKD2BQ DI DMKD2BQ DMKD2BQ DN Creatine ALS-08 DMKD2BQ TI TTZ1DV7 DMKD2BQ TN Mitochondrial function (MF) DMKD2BQ MA Modulator DMKD2BQ RN The therapeutic role of creatine in Huntington's disease. Pharmacol Ther. 2005 Nov;108(2):193-207. DMKD2BQ RU https://pubmed.ncbi.nlm.nih.gov/16055197 DMKE187 DI DMKE187 DMKE187 DN Telmisartan DMKE187 TI TTPKMXQ DMKE187 TN HUMAN type-1 angiotensin II receptor (AGTR1) DMKE187 MA Blocker DMKE187 RN Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3. DMKE187 RU https://pubmed.ncbi.nlm.nih.gov/32246101 DMKHLRT DI DMKHLRT DMKHLRT DN SAND-26 DMKHLRT TI TTDIGC1 DMKHLRT TN Dipeptidyl peptidase 4 (DPP-4) DMKHLRT RN Clinical pipeline report, company report or official report of Siesonline. DMKHLRT RU http://www.siesonline.it/en/wp-content/uploads/2013/05/21.pdf DMKL5AT DI DMKL5AT DMKL5AT DN Flurpiridaz F 18 DMKL5AT TI TTRU1NG DMKL5AT TN Mitochondrial complex I (NDUFA13) DMKL5AT MA Inhibitor DMKL5AT RN The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med. 2011 Jul;41(4):305-13. DMKL5AT RU https://pubmed.ncbi.nlm.nih.gov/21624564 DMKL9QO DI DMKL9QO DMKL9QO DN Seocalcitol DMKL9QO TI TTK59TV DMKL9QO TN Vitamin D3 receptor (VDR) DMKL9QO MA Inhibitor DMKL9QO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKL9QO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKLBHX DI DMKLBHX DMKLBHX DN ALO-02 DMKLBHX TI TTN4QDT DMKLBHX TN Opioid receptor (OPR) DMKLBHX MA Modulator DMKLBHX RN Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex. J Pain. 2005 Jun;6(6):392-9. DMKLBHX RU https://pubmed.ncbi.nlm.nih.gov/15943961 DMKMTDG DI DMKMTDG DMKMTDG DN Balovaptan DMKMTDG TI TT4TFGN DMKMTDG TN Vasopressin V1a receptor (V1AR) DMKMTDG MA Antagonist DMKMTDG RN Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525. DMKMTDG RU https://pubmed.ncbi.nlm.nih.gov/31951127 DMKNCVM DI DMKNCVM DMKNCVM DN Dalcetrapib DMKNCVM TI TTFQAYR DMKNCVM TN Cholesteryl ester transfer protein (CETP) DMKNCVM MA Inhibitor DMKNCVM RN Clinical pipeline report, company report or official report of Roche (2009). DMKNCVM RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMKP45D DI DMKP45D DMKP45D DN Naproxcinod DMKP45D TI TTK0943 DMKP45D TN Prostaglandin G/H synthase (COX) DMKP45D MA Modulator DMKP45D RN Naproxcinod, a new cyclooxygenase-inhibiting nitric oxide donator (CINOD). Expert Opin Biol Ther. 2009 May;9(5):649-57. DMKP45D RU https://pubmed.ncbi.nlm.nih.gov/19392579 DMKQZ0L DI DMKQZ0L DMKQZ0L DN ERITORAN DMKQZ0L TI TTISGCA DMKQZ0L TN Toll-like receptor 4 (TLR4) DMKQZ0L MA Inhibitor DMKQZ0L RN Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6. DMKQZ0L RU https://pubmed.ncbi.nlm.nih.gov/18828583 DMKSAG1 DI DMKSAG1 DMKSAG1 DN Tabalumab DMKSAG1 TI TTWMIDN DMKSAG1 TN B-cell-activating factor (TNFSF13B) DMKSAG1 MA Modulator DMKSAG1 RN Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors. Ann Rheum Dis. 2013 Sep 1;72(9):1461-8. DMKSAG1 RU https://pubmed.ncbi.nlm.nih.gov/23268367 DMKTS2M DI DMKTS2M DMKTS2M DN Rifaximin DR DMKTS2M TI TTHKJLN DMKTS2M TN DNA-directed RNA polymerase (RNAP) DMKTS2M MA Inhibitor DMKTS2M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKTS2M RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMKUOVP DI DMKUOVP DMKUOVP DN Ublituximab + umbralisib DMKUOVP TI TTUE541 DMKUOVP TN Leukocyte surface antigen Leu-16 (CD20) DMKUOVP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUOVP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKWBJR DI DMKWBJR DMKWBJR DN ISIS-PKK DMKWBJR TI TTN0PCX DMKWBJR TN Plasma kallikrein messenger RNA (KLKB1 mRNA) DMKWBJR RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMKWBJR RU https://www.isispharm.com/pipeline/isis-pkkrx/ DMKWV4B DI DMKWV4B DMKWV4B DN Golnerminogene pradenovac DMKWV4B TI TTF8CQI DMKWV4B TN Tumor necrosis factor (TNF) DMKWV4B MA Modulator DMKWV4B RN TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30. DMKWV4B RU https://pubmed.ncbi.nlm.nih.gov/16132372 DMKZRBP DI DMKZRBP DMKZRBP DN Litoxetine DMKZRBP TI TT3ROYC DMKZRBP TN Serotonin transporter (SERT) DMKZRBP MA Modulator DMKZRBP RN Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45. DMKZRBP RU https://www.ncbi.nlm.nih.gov/pubmed/8385615 DMKZRBP DI DMKZRBP DMKZRBP DN Litoxetine DMKZRBP TI TTNXLKE DMKZRBP TN 5-HT 3 receptor (5HT3R) DMKZRBP MA Modulator DMKZRBP RN Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45. DMKZRBP RU https://www.ncbi.nlm.nih.gov/pubmed/8385615 DML1KTO DI DML1KTO DML1KTO DN PT2977 DML1KTO TI TTDMLNT DML1KTO TN Hypoxia-inducible factor 2 alpha (HIF-2A) DML1KTO MA Inhibitor DML1KTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML1KTO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML61S4 DI DML61S4 DML61S4 DN ARQ-151 DML61S4 TI TTV5CGO DML61S4 TN Phosphodiesterase 4 (PDE4) DML61S4 MA Inhibitor DML61S4 RN Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239. DML61S4 RU https://pubmed.ncbi.nlm.nih.gov/32668113 DML6GAN DI DML6GAN DML6GAN DN Taxol/Paraplatin/Herceptin DML6GAN TI TTJGNVC DML6GAN TN Apoptosis regulator Bcl-2 (BCL-2) DML6GAN MA Modulator DML6GAN RN Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. DML6GAN RU https://pubmed.ncbi.nlm.nih.gov/16381626 DML6GAN DI DML6GAN DML6GAN DN Taxol/Paraplatin/Herceptin DML6GAN TI TT6EO5L DML6GAN TN Erbb2 tyrosine kinase receptor (HER2) DML6GAN MA Inhibitor DML6GAN RN Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32. DML6GAN RU https://pubmed.ncbi.nlm.nih.gov/16381626 DML6GAN DI DML6GAN DML6GAN DN Taxol/Paraplatin/Herceptin DML6GAN TI TTUTN1I DML6GAN TN Human Deoxyribonucleic acid (hDNA) DML6GAN MA Binder DML6GAN RN Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20;24(18):2786-92. DML6GAN RU https://pubmed.ncbi.nlm.nih.gov/16782917 DML83IW DI DML83IW DML83IW DN Semagacestat DML83IW TI TT9W8GU DML83IW TN Gamma-secretase (GS) DML83IW MA Modulator DML83IW RN A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. DML83IW RU https://pubmed.ncbi.nlm.nih.gov/23883379 DMLA1ER DI DMLA1ER DMLA1ER DN EC20 DMLA1ER TI TTVC37M DMLA1ER TN Folate receptor alpha (FOLR1) DMLA1ER MA Modulator DMLA1ER RN EP patent application no. 2822386, Folate receptor alpha binding ligands. DMLA1ER RU http://www.google.com/patents/EP2822386A1?cl=en DMLAYTP DI DMLAYTP DMLAYTP DN Soluble ferric pyrophosphate DMLAYTP TI TTUDR0C DMLAYTP TN Iron (Fe) DMLAYTP MA Modulator DMLAYTP RN A micronised, dispersible ferric pyrophosphate with high relative bioavailability in man. Br J Nutr. 2004 Jan;91(1):107-12. DMLAYTP RU https://pubmed.ncbi.nlm.nih.gov/14748943 DMLB3I4 DI DMLB3I4 DMLB3I4 DN Trastuzumab-DM1 DMLB3I4 TI TT6EO5L DMLB3I4 TN Erbb2 tyrosine kinase receptor (HER2) DMLB3I4 RN Clinical pipeline report, company report or official report of Genentech (2009). DMLB3I4 RU http://www.gene.com/gene/pipeline/status/ DMLBYRA DI DMLBYRA DMLBYRA DN ADX N05 DMLBYRA TI TT5TPI6 DMLBYRA TN Opioid receptor sigma 1 (OPRS1) DMLBYRA MA Modulator DMLBYRA RN Clinical pipeline report, company report or official report of SK BioPhamaceuticals. DMLBYRA RU http://www.skbp.com/etc/news_view_14.asp DMLCXPD DI DMLCXPD DMLCXPD DN TG-C DMLCXPD TI TTR9XHZ DMLCXPD TN Transforming growth factor beta 1 (TGFB1) DMLCXPD MA Modulator DMLCXPD RN Clinical pipeline report, company report or official report of Tissue Gene, Inc. DMLCXPD RU http://www.tissuegene.com/products/cartilage.html DMLDB1X DI DMLDB1X DMLDB1X DN Andecaliximab DMLDB1X TI TT6X50U DMLDB1X TN Matrix metalloproteinase-9 (MMP-9) DMLDB1X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLDB1X RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLG96Z DI DMLG96Z DMLG96Z DN INM-176 DMLG96Z TI TT1RS9F DMLG96Z TN Acetylcholinesterase (AChE) DMLG96Z MA Inhibitor DMLG96Z RN The memory ameliorating effects of INM-176, an ethanolic extract of Angelica gigas, against scopolamine- or Abeta(1-42)-induced cognitive dysfunction in mice. J Ethnopharmacol. 2012 Sep 28;143(2):611-20. DMLG96Z RU https://pubmed.ncbi.nlm.nih.gov/22846435 DMLHEU7 DI DMLHEU7 DMLHEU7 DN Ridaforolimus DMLHEU7 TI TTCJG29 DMLHEU7 TN Serine/threonine-protein kinase mTOR (mTOR) DMLHEU7 MA Inhibitor DMLHEU7 RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMLHEU7 RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMLIMEA DI DMLIMEA DMLIMEA DN Varespladib methyl DMLIMEA TI TT2XHSJ DMLIMEA TN Secretory phospholipase A2 (sPLA2) DMLIMEA MA Modulator DMLIMEA RN Varespladib. Am J Cardiovasc Drugs. 2011;11(2):137-43. DMLIMEA RU https://pubmed.ncbi.nlm.nih.gov/21446779 DMLKI2B DI DMLKI2B DMLKI2B DN Trafermin DMLKI2B TI TTGJVQM DMLKI2B TN Fibroblast growth factor receptor 2 (FGFR2) DMLKI2B MA Activator DMLKI2B RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMLKI2B RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMLMN2F DI DMLMN2F DMLMN2F DN CM-AT DMLMN2F TI TT7MRGU DMLMN2F TN Chymotrypsin (CTR) DMLMN2F MA Modulator DMLMN2F RN Drugmakers dance with autism. Nat Biotechnol. 2010 Aug;28(8):772-4. DMLMN2F RU https://pubmed.ncbi.nlm.nih.gov/20697394 DMLMS6J DI DMLMS6J DMLMS6J DN OTL-101 DMLMS6J TI TTLP57V DMLMS6J TN Adenosine deaminase (ADA) DMLMS6J MA Replacement DMLMS6J RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DMLMS6J RU https://www.orchard-tx.com/approach/pipeline/ DMLO0KD DI DMLO0KD DMLO0KD DN Vicineum DMLO0KD TI TTZ8WH4 DMLO0KD TN Tumor-associated calcium signal transducer 1 (EPCAM) DMLO0KD RN Clinical pipeline report, company report or official report of Sesen Bio. DMLO0KD RU https://sesenbio.com/our-programs/ DMLQO7F DI DMLQO7F DMLQO7F DN EVP-6124 DMLQO7F TI TTLA931 DMLQO7F TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMLQO7F MA Modulator DMLQO7F RN Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24. DMLQO7F RU https://pubmed.ncbi.nlm.nih.gov/24419307 DMLRHM5 DI DMLRHM5 DMLRHM5 DN [3H](R)-(-)-baclofen DMLRHM5 TI TTDCVZW DMLRHM5 TN Gamma-aminobutyric acid B receptor (GABBR) DMLRHM5 MA Agonist DMLRHM5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242). DMLRHM5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242 DMLSOB7 DI DMLSOB7 DMLSOB7 DN Premarin/Pravachol DMLSOB7 TI TTOM3J0 DMLSOB7 TN Estrogen receptor beta (ESR2) DMLSOB7 MA Modulator DMLSOB7 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMLSOB7 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMLSOB7 DI DMLSOB7 DMLSOB7 DN Premarin/Pravachol DMLSOB7 TI TTZAYWL DMLSOB7 TN Estrogen receptor (ESR) DMLSOB7 MA Modulator DMLSOB7 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMLSOB7 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMLSOB7 DI DMLSOB7 DMLSOB7 DN Premarin/Pravachol DMLSOB7 TI TTPADOQ DMLSOB7 TN HMG-CoA reductase (HMGCR) DMLSOB7 MA Modulator DMLSOB7 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMLSOB7 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMLSV74 DI DMLSV74 DMLSV74 DN Sotorasib DMLSV74 TI TT3LH46 DMLSV74 TN KRAS G12C mutant (KRAS G12C) DMLSV74 MA Inhibitor DMLSV74 RN Clinical pipeline report, company report or official report of Amgen. DMLSV74 RU https://www.amgenpipeline.com/ DMLU8NX DI DMLU8NX DMLU8NX DN Benserazide DMLU8NX TI TTN451K DMLU8NX TN Aromatic-L-amino-acid decarboxylase (DDC) DMLU8NX MA Inhibitor DMLU8NX RN Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease. Semin Neurol. 2001;21(1):15-22. DMLU8NX RU https://pubmed.ncbi.nlm.nih.gov/11346021 DMLVNTA DI DMLVNTA DMLVNTA DN Besipirdine DMLVNTA TI TTNGILX DMLVNTA TN Adrenergic receptor alpha-1A (ADRA1A) DMLVNTA MA Antagonist DMLVNTA RN Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46. DMLVNTA RU https://pubmed.ncbi.nlm.nih.gov/9103515 DMLWIU4 DI DMLWIU4 DMLWIU4 DN Cefluprenam DMLWIU4 TI TTJP4SM DMLWIU4 TN Bacterial Penicillin binding protein (Bact PBP) DMLWIU4 MA Inhibitor DMLWIU4 RN Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7. DMLWIU4 RU https://pubmed.ncbi.nlm.nih.gov/1804003 DMLY0H5 DI DMLY0H5 DMLY0H5 DN Astuprotimut-R DMLY0H5 TI TTWSKHD DMLY0H5 TN Melanoma-associated antigen 3 (MAGEA3) DMLY0H5 MA Modulator DMLY0H5 RN National Cancer Institute Drug Dictionary (drug id 600553). DMLY0H5 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=600553 DMLY9F1 DI DMLY9F1 DMLY9F1 DN Azetirelin DMLY9F1 TI TT4J8MF DMLY9F1 TN Thyrotropin-releasing hormone receptor (TRHR) DMLY9F1 MA Modulator DMLY9F1 RN Intestinal absorption of azetirelin, a new thyrotropin-releasing hormone (TRH) analogue. II. In situ and in vitro absorption characteristics of azetirelin from the rat intestine. Biol Pharm Bull. 1995 Jul;18(7):976-9. DMLY9F1 RU https://pubmed.ncbi.nlm.nih.gov/7581253 DMLYGH4 DI DMLYGH4 DMLYGH4 DN MK-4827 DMLYGH4 TI TTEBCY8 DMLYGH4 TN Poly [ADP-ribose] polymerase (PARP) DMLYGH4 MA Modulator DMLYGH4 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMLYGH4 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMM0HAE DI DMM0HAE DMM0HAE DN DSC-127 DMM0HAE TI TTOISYB DMM0HAE TN Proto-oncogene Mas (MAS) DMM0HAE MA Agonist DMM0HAE RN New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 Dec;13(4):505-8. DMM0HAE RU https://pubmed.ncbi.nlm.nih.gov/23166114 DMM0VO3 DI DMM0VO3 DMM0VO3 DN BSI-201 DMM0VO3 TI TTEBCY8 DMM0VO3 TN Poly [ADP-ribose] polymerase (PARP) DMM0VO3 MA Modulator DMM0VO3 RN Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012 Mar 15;18(6):1655-62. DMM0VO3 RU https://pubmed.ncbi.nlm.nih.gov/22291137 DMM1YC4 DI DMM1YC4 DMM1YC4 DN E-101 DMM1YC4 TI TTVCZPI DMM1YC4 TN Myeloperoxidase (MPO) DMM1YC4 MA Modulator DMM1YC4 RN In vitro antibacterial activity of E-101 Solution, a novel myeloperoxidase-mediated antimicrobial, against Gram-positive and Gram-negative pathogens. J Antimicrob Chemother. 2011 Feb;66(2):335-42. DMM1YC4 RU https://pubmed.ncbi.nlm.nih.gov/21118915 DMM1Z9G DI DMM1Z9G DMM1Z9G DN Vutrisiran DMM1Z9G TI TTPOYU7 DMM1Z9G TN Transthyretin messenger RNA (TTR mRNA) DMM1Z9G MA Inhibitor DMM1Z9G RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. DMM1Z9G RU https://www.alnylam.com/alnylam-rnai-pipeline/ DMM2JXP DI DMM2JXP DMM2JXP DN VX-787 DMM2JXP TI TT62KQV DMM2JXP TN Influenza Polymerase basic protein 2 (Influ PB2) DMM2JXP MA Inhibitor DMM2JXP RN Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J Med Chem. 2014 Aug 14;57(15):6668-78. DMM2JXP RU https://pubmed.ncbi.nlm.nih.gov/25019388 DMM2LTC DI DMM2LTC DMM2LTC DN KSI-301 DMM2LTC TI TT9HKJA DMM2LTC TN Vascular endothelial growth factor (VEGF) DMM2LTC MA Inhibitor DMM2LTC RN Clinical pipeline report, company report or official report of Kodiak Sciences. DMM2LTC RU https://kodiak.com/our-pipeline/ DMM2OZH DI DMM2OZH DMM2OZH DN Ushercell DMM2OZH TI TTAUG8D DMM2OZH TN Human immunodeficiency virus Transmission (HIV Tran) DMM2OZH MA Modulator DMM2OZH RN Short Communication: Enhancement of HIV Infection by Cellulose Sulfate. AIDS Res Hum Retroviruses. 2008 July; 24(7): 925-929. DMM2OZH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2927036/ DMM4C95 DI DMM4C95 DMM4C95 DN PF-06438179 DMM4C95 TI TTF8CQI DMM4C95 TN Tumor necrosis factor (TNF) DMM4C95 MA Inhibitor DMM4C95 RN Biosimilars in the therapy of inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2014 Jun;26(6):581-7. DMM4C95 RU https://pubmed.ncbi.nlm.nih.gov/24722561 DMM4FJ3 DI DMM4FJ3 DMM4FJ3 DN Finerenone DMM4FJ3 TI TT26PHO DMM4FJ3 TN Mineralocorticoid receptor (MR) DMM4FJ3 MA Antagonist DMM4FJ3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM4FJ3 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMM5VTA DI DMM5VTA DMM5VTA DN Dutogliptin DMM5VTA TI TTDIGC1 DMM5VTA TN Dipeptidyl peptidase 4 (DPP-4) DMM5VTA MA Inhibitor DMM5VTA RN Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55. DMM5VTA RU https://pubmed.ncbi.nlm.nih.gov/20380656 DMM6G5D DI DMM6G5D DMM6G5D DN AZD0914 DMM6G5D TI TTN6J5F DMM6G5D TN Bacterial DNA gyrase (Bact gyrase) DMM6G5D MA Modulator DMM6G5D RN High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea.Antimicrob Agents Chemother.2014 Sep;58(9):5585-8. DMM6G5D RU https://www.ncbi.nlm.nih.gov/pubmed/24982070 DMM74PK DI DMM74PK DMM74PK DN Atrasentan DMM74PK TI TTKRD0G DMM74PK TN Endothelin A receptor (EDNRA) DMM74PK MA Antagonist DMM74PK RN Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S. DMM74PK RU https://pubmed.ncbi.nlm.nih.gov/12193124 DMM76GL DI DMM76GL DMM76GL DN Ceftobiprole DMM76GL TI TTJP4SM DMM76GL TN Bacterial Penicillin binding protein (Bact PBP) DMM76GL MA Modulator DMM76GL RN Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4. DMM76GL RU https://www.ncbi.nlm.nih.gov/pubmed/17470659 DMM9JEF DI DMM9JEF DMM9JEF DN Imatinib DMM9JEF TI TTE63HY DMM9JEF TN HUMAN fusion protein Bcr-Abl (Bcr-Abl) DMM9JEF MA Inhibitor DMM9JEF RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMM9JEF RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMM9XL2 DI DMM9XL2 DMM9XL2 DN BMN-111 DMM9XL2 TI TTRK0B9 DMM9XL2 TN C-type natriuretic peptide (NPPC) DMM9XL2 MA Modulator DMM9XL2 RN Clinical pipeline report, company report or official report of Biomarin. DMM9XL2 RU https://www.bmrn.com/pipeline/clinical-trials/achondroplasia.php DMMA0C7 DI DMMA0C7 DMMA0C7 DN Laquinamod DMMA0C7 TI TTZF0K2 DMMA0C7 TN C-X-C motif chemokine 2 (CXCL2) DMMA0C7 MA Modulator DMMA0C7 RN Multiple sclerosis: current and future treatment options. Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):292-9. DMMA0C7 RU https://pubmed.ncbi.nlm.nih.gov/18220950 DMMBC5W DI DMMBC5W DMMBC5W DN PDGF-BB DMMBC5W TI TTQA6SX DMMBC5W TN Platelet-derived growth factor B (PDGFB) DMMBC5W MA Modulator DMMBC5W RN Clinical pipeline report, company report or official report of Adocia. DMMBC5W RU http://www.adocia.fr/WP/products/bc-pdgf-bb-en/ DMMBJYC DI DMMBJYC DMMBJYC DN ZYH-1 DMMBJYC TI TTZMAO3 DMMBJYC TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMMBJYC MA Modulator DMMBJYC RN Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. DMMBJYC RU https://pubmed.ncbi.nlm.nih.gov/24062180 DMMBJYC DI DMMBJYC DMMBJYC DN ZYH-1 DMMBJYC TI TTJ584C DMMBJYC TN Peroxisome proliferator-activated receptor alpha (PPARA) DMMBJYC MA Modulator DMMBJYC RN Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. DMMBJYC RU https://pubmed.ncbi.nlm.nih.gov/24062180 DMMC3Y8 DI DMMC3Y8 DMMC3Y8 DN NPC-01 DMMC3Y8 TI TTZAYWL DMMC3Y8 TN Estrogen receptor (ESR) DMMC3Y8 MA Modulator DMMC3Y8 RN ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health. DMMC3Y8 RU https://clinicaltrials.gov/ct2/show/NCT01246791 DMMC3Y8 DI DMMC3Y8 DMMC3Y8 DN NPC-01 DMMC3Y8 TI TTUV8G9 DMMC3Y8 TN Progesterone receptor (PGR) DMMC3Y8 MA Agonist DMMC3Y8 RN ClinicalTrials.gov (NCT01246791) Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers. U.S. National Institutes of Health. DMMC3Y8 RU https://clinicaltrials.gov/ct2/show/NCT01246791 DMMD856 DI DMMD856 DMMD856 DN Sulopenem DMMD856 TI TTJP4SM DMMD856 TN Bacterial Penicillin binding protein (Bact PBP) DMMD856 MA Modulator DMMD856 RN In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37. DMMD856 RU https://pubmed.ncbi.nlm.nih.gov/8786624 DMME6GJ DI DMME6GJ DMME6GJ DN SB12 DMME6GJ TI TTKANGO DMME6GJ TN Complement C5 (CO5) DMME6GJ MA Inhibitor DMME6GJ RN Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. DMME6GJ RU https://pubmed.ncbi.nlm.nih.gov/31324874 DMMEAOL DI DMMEAOL DMMEAOL DN Coversin DMMEAOL TI TTKANGO DMMEAOL TN Complement C5 (CO5) DMMEAOL MA Inhibitor DMMEAOL RN Use of the complement inhibitor Coversin to treat HSCT-associated TMA. Blood Adv. 2017 Jul 3;1(16):1254-1258. DMMEAOL RU https://pubmed.ncbi.nlm.nih.gov/29296765 DMMF5K4 DI DMMF5K4 DMMF5K4 DN ABL 001 DMMF5K4 TI TTS7G69 DMMF5K4 TN Fusion protein Bcr-Abl (Bcr-Abl) DMMF5K4 MA Inhibitor DMMF5K4 RN ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia, NorthBuilding, 2014, 120-125. DMMF5K4 RU https://ash.confex.com/ash/2014/webprogram/Paper76344.html DMMIWCE DI DMMIWCE DMMIWCE DN Sifuvirtide DMMIWCE TI TTG90S6 DMMIWCE TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMMIWCE MA Modulator DMMIWCE RN Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide.J Biol Chem.2012 Feb 24;287(9):6788-96. DMMIWCE RU https://www.ncbi.nlm.nih.gov/pubmed/22228771 DMMJ63A DI DMMJ63A DMMJ63A DN PT-304 DMMJ63A TI TT84ETX DMMJ63A TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMJ63A MA Inhibitor DMMJ63A RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMMJ63A RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMMKE2H DI DMMKE2H DMMKE2H DN Valoctocogene roxaparvovec DMMKE2H TI TT1290U DMMKE2H TN Coagulation factor VIII (F8) DMMKE2H MA Replacement DMMKE2H RN Clinical pipeline report, company report or official report of BioMarin Pharmaceutical. DMMKE2H RU https://www.biomarin.com/our-treatments/pipeline/ DMMKGBP DI DMMKGBP DMMKGBP DN D-Methionine DMMKGBP TI TTZL0OI DMMKGBP TN Methionine aminopeptidase 2 (METAP2) DMMKGBP MA Inhibitor DMMKGBP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMKGBP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMLXA9 DI DMMLXA9 DMMLXA9 DN LX-4211 DMMLXA9 TI TT2UE56 DMMLXA9 TN Sodium/glucose cotransporter 1 (SGLT1) DMMLXA9 MA Modulator DMMLXA9 RN LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. DMMLXA9 RU https://pubmed.ncbi.nlm.nih.gov/22739142 DMMLXA9 DI DMMLXA9 DMMLXA9 DN LX-4211 DMMLXA9 TI TTLWPVF DMMLXA9 TN Sodium/glucose cotransporter 2 (SGLT2) DMMLXA9 MA Modulator DMMLXA9 RN LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69. DMMLXA9 RU https://pubmed.ncbi.nlm.nih.gov/22739142 DMMNP2F DI DMMNP2F DMMNP2F DN G17DT DMMNP2F TI TT4LRVO DMMNP2F TN Gastrin (GAST) DMMNP2F RN G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404. DMMNP2F RU https://pubmed.ncbi.nlm.nih.gov/17309331 DMMO6P0 DI DMMO6P0 DMMO6P0 DN Tifacogin DMMO6P0 TI TT068JH DMMO6P0 TN Tissue factor pathway inhibitor (TFPI) DMMO6P0 MA Inhibitor DMMO6P0 RN Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47. DMMO6P0 RU https://pubmed.ncbi.nlm.nih.gov/12851279 DMMP51W DI DMMP51W DMMP51W DN sparsentan DMMP51W TI TT8DBY3 DMMP51W TN Angiotensin II receptor type-1 (AGTR1) DMMP51W MA Antagonist DMMP51W RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMMP51W RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMMP51W DI DMMP51W DMMP51W DN sparsentan DMMP51W TI TTKRD0G DMMP51W TN Endothelin A receptor (EDNRA) DMMP51W MA Antagonist DMMP51W RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMMP51W RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMMQ2U9 DI DMMQ2U9 DMMQ2U9 DN VGX-3100 DMMQ2U9 TI TTE2N95 DMMQ2U9 TN Human papillomavirus protein E6 (HPV E6) DMMQ2U9 MA Modulator DMMQ2U9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMQ2U9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMQ2U9 DI DMMQ2U9 DMMQ2U9 DN VGX-3100 DMMQ2U9 TI TT3CPZW DMMQ2U9 TN Human papillomavirus protein E7 (HPV E7) DMMQ2U9 MA Modulator DMMQ2U9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMQ2U9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMQ7BY DI DMMQ7BY DMMQ7BY DN Fitusiran DMMQ7BY TI TTZ4MD5 DMMQ7BY TN SERPINC1 messenger RNA (SERPINC1 mRNA) DMMQ7BY MA Inhibitor DMMQ7BY RN Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy. N Engl J Med. 2017 Aug 31;377(9):819-828. DMMQ7BY RU https://pubmed.ncbi.nlm.nih.gov/28691885 DMMTKC6 DI DMMTKC6 DMMTKC6 DN TEV-48125 DMMTKC6 TI TTAFORY DMMTKC6 TN Calcitonin gene-related peptide (CALC) DMMTKC6 RN TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. Neurology. 2016 Jul 5;87(1):41-8. DMMTKC6 RU https://pubmed.ncbi.nlm.nih.gov/27281531 DMMTW9K DI DMMTW9K DMMTW9K DN Vicriviroc DMMTW9K TI TT2CEJG DMMTW9K TN C-C chemokine receptor type 5 (CCR5) DMMTW9K MA Antagonist DMMTW9K RN HIV entry: new insights and implications for patient management. Curr Opin Infect Dis. 2009 Feb;22(1):35-42. DMMTW9K RU https://pubmed.ncbi.nlm.nih.gov/19532079 DMMWO7V DI DMMWO7V DMMWO7V DN ABBV-951 DMMWO7V TI TTWFZ1N DMMWO7V TN Dopamine receptor (DR) DMMWO7V MA Activator DMMWO7V RN Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Ann Neurol. 2021 Jul;90(1):52-61. DMMWO7V RU https://pubmed.ncbi.nlm.nih.gov/33772855 DMMX75K DI DMMX75K DMMX75K DN LEE011 DMMX75K TI TT0PG8F DMMX75K TN Cyclin-dependent kinase 4 (CDK4) DMMX75K MA Modulator DMMX75K RN Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. DMMX75K RU https://pubmed.ncbi.nlm.nih.gov/24045179 DMMX75K DI DMMX75K DMMX75K DN LEE011 DMMX75K TI TTO0FDJ DMMX75K TN Cyclin-dependent kinase 6 (CDK6) DMMX75K MA Modulator DMMX75K RN Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. DMMX75K RU https://pubmed.ncbi.nlm.nih.gov/24045179 DMMZDJ6 DI DMMZDJ6 DMMZDJ6 DN Captopril DMMZDJ6 TI TTGFNPD DMMZDJ6 TN HUMAN angiotensin-converting enzyme (ACE) DMMZDJ6 MA Inhibitor DMMZDJ6 RN Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31. DMMZDJ6 RU https://pubmed.ncbi.nlm.nih.gov/32291526 DMMZS2T DI DMMZS2T DMMZS2T DN 177-Lu-oxodotreotide DMMZS2T TI TTOMNR9 DMMZS2T TN Somatostatin receptor (SSTR) DMMZS2T MA Agonist DMMZS2T RN Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12. DMMZS2T RU https://pubmed.ncbi.nlm.nih.gov/22388631 DMN1ZEU DI DMN1ZEU DMN1ZEU DN Radiosensitizer gene therapy DMN1ZEU TI TTP3QRF DMN1ZEU TN Thymidine kinase 1 (TK1) DMN1ZEU MA Inhibitor DMN1ZEU RN Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res. 1997 Nov;3(11):2081-8. DMN1ZEU RU https://pubmed.ncbi.nlm.nih.gov/9815600 DMN4E7T DI DMN4E7T DMN4E7T DN Guaiacol DMN4E7T TI TTANPDJ DMN4E7T TN Carbonic anhydrase II (CA-II) DMN4E7T MA Inhibitor DMN4E7T RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMN4E7T RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMN72OM DI DMN72OM DMN72OM DN U300 DMN72OM TI TTZOPHG DMN72OM TN Insulin (INS) DMN72OM MA Modulator DMN72OM RN U300, a novel long-acting insulin formulation. Expert Opin Biol Ther. 2014 Dec;14(12):1849-60. DMN72OM RU https://pubmed.ncbi.nlm.nih.gov/25311556 DMN8DQH DI DMN8DQH DMN8DQH DN Darusentan DMN8DQH TI TTKRD0G DMN8DQH TN Endothelin A receptor (EDNRA) DMN8DQH MA Antagonist DMN8DQH RN Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62. DMN8DQH RU https://pubmed.ncbi.nlm.nih.gov/16633090 DMN9BO3 DI DMN9BO3 DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine DMN9BO3 TI TTD16BI DMN9BO3 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMN9BO3 MA Inhibitor DMN9BO3 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMN9BO3 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMN9BO3 DI DMN9BO3 DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine DMN9BO3 TI TTZGK1R DMN9BO3 TN HUMAN glycosylation of host receptor (GHR) DMN9BO3 MA Inhibitor DMN9BO3 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMN9BO3 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMN9BO3 DI DMN9BO3 DMN9BO3 DN Darunavir + ritonavir + oseltamivir + hydroxychloroquine DMN9BO3 TI TT3A1EZ DMN9BO3 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMN9BO3 MA Inhibitor DMN9BO3 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMN9BO3 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMN9ETB DI DMN9ETB DMN9ETB DN Contusugene ladenovec DMN9ETB TI TT7SBF5 DMN9ETB TN Cellular tumor antigen p53 (TP53) DMN9ETB MA Modulator DMN9ETB RN A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther. 2009 Feb;11(1):54-61. DMN9ETB RU https://pubmed.ncbi.nlm.nih.gov/19169960 DMNAYUJ DI DMNAYUJ DMNAYUJ DN Lu AF35700 DMNAYUJ TI TTEX248 DMNAYUJ TN Dopamine D2 receptor (D2R) DMNAYUJ MA Modulator DMNAYUJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNAYUJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMNCY1I DI DMNCY1I DMNCY1I DN (-)-Phenserine DMNCY1I TI TT1RS9F DMNCY1I TN Acetylcholinesterase (AChE) DMNCY1I MA Inhibitor DMNCY1I RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMNCY1I RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMNCY1I DI DMNCY1I DMNCY1I DN (-)-Phenserine DMNCY1I TI TTEB0GD DMNCY1I TN Cholinesterase (BCHE) DMNCY1I MA Inhibitor DMNCY1I RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMNCY1I RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMND3AB DI DMND3AB DMND3AB DN Asimadoline DMND3AB TI TTQW87Y DMND3AB TN Opioid receptor kappa (OPRK1) DMND3AB MA Agonist DMND3AB RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMND3AB RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMNDCFY DI DMNDCFY DMNDCFY DN MPL-S DMNDCFY TI TTF10I9 DMNDCFY TN Nitric-oxide synthase inducible (NOS2) DMNDCFY MA Modulator DMNDCFY RN Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47. DMNDCFY RU https://pubmed.ncbi.nlm.nih.gov/9234781 DMNDGWE DI DMNDGWE DMNDGWE DN IT-101 DMNDGWE TI TTQHWNA DMNDGWE TN Hypoxia-inducible factor 1 alpha (HIF-1A) DMNDGWE MA Inhibitor DMNDGWE RN CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat. 2015 Apr;150(3):559-67. DMNDGWE RU https://pubmed.ncbi.nlm.nih.gov/25833208 DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTJGNVC DMNE56X TN Apoptosis regulator Bcl-2 (BCL-2) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of Roche (2009). DMNE56X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTU1E82 DMNE56X TN Apoptosis regulator Bcl-xL (BCL-xL) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of Roche (2009). DMNE56X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTQ79W8 DMNE56X TN Apoptosis regulator Bcl-W (BCL-W) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of Roche (2009). DMNE56X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMNE56X DI DMNE56X DMNE56X DN ABT-263 DMNE56X TI TTFCJ7S DMNE56X TN G1/S-specific cyclin-D1 (CCND1) DMNE56X MA Inhibitor DMNE56X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNE56X RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNF4UH DI DMNF4UH DMNF4UH DN Liprotamase DMNF4UH TI TTCGSZ4 DMNF4UH TN Pancreatic alpha-amylase (AMY2A) DMNF4UH MA Modulator DMNF4UH RN Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. DMNF4UH RU http://investor.anthera.com/releasedetail.cfm?releaseid=859598 DMNF4UH DI DMNF4UH DMNF4UH DN Liprotamase DMNF4UH TI TTXMY0J DMNF4UH TN Pancreatic triacylglycerol lipase (PNLIP) DMNF4UH MA Modulator DMNF4UH RN Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. DMNF4UH RU http://investor.anthera.com/releasedetail.cfm?releaseid=859598 DMNF4UH DI DMNF4UH DMNF4UH DN Liprotamase DMNF4UH TI TT7MRGU DMNF4UH TN Chymotrypsin (CTR) DMNF4UH MA Modulator DMNF4UH RN Clinical pipeline report, company report or official report of Anthera Pharmaceuticals. DMNF4UH RU http://investor.anthera.com/releasedetail.cfm?releaseid=859598 DMNGCAD DI DMNGCAD DMNGCAD DN Rova-T DMNGCAD TI TT1C9K6 DMNGCAD TN Delta-like protein 3 (DLL3) DMNGCAD MA Inhibitor DMNGCAD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNGCAD RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMNKBEC DI DMNKBEC DMNKBEC DN BGJ398 DMNKBEC TI TTRLW2X DMNKBEC TN Fibroblast growth factor receptor 1 (FGFR1) DMNKBEC MA Modulator DMNKBEC RN Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res. 2013 Apr;28(4):899-911. DMNKBEC RU https://pubmed.ncbi.nlm.nih.gov/23129509 DMNKBEC DI DMNKBEC DMNKBEC DN BGJ398 DMNKBEC TI TT0LF7H DMNKBEC TN Fibroblast growth factor receptor (FGFR) DMNKBEC MA Inhibitor DMNKBEC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNKBEC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNM93X DI DMNM93X DMNM93X DN Linagliptin DMNM93X TI TTF928K DMNM93X TN HUMAN dipeptidyl peptidase 4 (DPP-4) DMNM93X MA Inhibitor DMNM93X RN DPP4 inhibition: preventing SARS-CoV-2 infection and/or progression of COVID-19 Diabetes Metab Res Rev. 2020 Apr 26. DMNM93X RU https://pubmed.ncbi.nlm.nih.gov/32336007 DMNQ869 DI DMNQ869 DMNQ869 DN ABT-267 DMNQ869 TI TTCJ2X8 DMNQ869 TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMNQ869 MA Modulator DMNQ869 RN Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014 Mar 13;57(5):2047-57. DMNQ869 RU https://pubmed.ncbi.nlm.nih.gov/24400777 DMNVP8Q DI DMNVP8Q DMNVP8Q DN Tivantinib DMNVP8Q TI TTNDSF4 DMNVP8Q TN Proto-oncogene c-Met (MET) DMNVP8Q MA Inhibitor DMNVP8Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948). DMNVP8Q RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7948 DMNY05F DI DMNY05F DMNY05F DN Lopinavir + ritonavir + oseltamivir DMNY05F TI TT1D53B DMNY05F TN COVID-19 3C-like protease (3CLpro) DMNY05F MA Inhibitor DMNY05F RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMNY05F RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMNZOCK DI DMNZOCK DMNZOCK DN PF-05280586 DMNZOCK TI TTUE541 DMNZOCK TN Leukocyte surface antigen Leu-16 (CD20) DMNZOCK MA Antagonist DMNZOCK RN Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera ). Toxicol Pathol. 2014 Oct;42(7):1069-81. DMNZOCK RU https://pubmed.ncbi.nlm.nih.gov/24604381 DMO1234 DI DMO1234 DMO1234 DN TNX-102 DMO1234 TI TT2NUT5 DMO1234 TN Adrenergic receptor alpha-2C (ADRA2C) DMO1234 MA Antagonist DMO1234 RN Clinical pipeline report, company report or official report of Tonix Pharmaceuticals. DMO1234 RU http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia DMO1234 DI DMO1234 DMO1234 DN TNX-102 DMO1234 TI TTJQOD7 DMO1234 TN 5-HT 2A receptor (HTR2A) DMO1234 MA Antagonist DMO1234 RN Clinical pipeline report, company report or official report of Tonix Pharmaceuticals. DMO1234 RU http://www.tonixpharma.com/research-development/tnx-102-sl-for-fibromyalgia DMO3ITF DI DMO3ITF DMO3ITF DN GASTRAZOLE DMO3ITF TI TTVFO0U DMO3ITF TN Gastrin/cholecystokinin type B receptor (CCKBR) DMO3ITF MA Antagonist DMO3ITF RN Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 April 24; 94(8): 1107-1115. DMO3ITF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361246/ DMO628K DI DMO628K DMO628K DN Arbaclofen placarbil DMO628K TI TTDCVZW DMO628K TN Gamma-aminobutyric acid B receptor (GABBR) DMO628K MA Modulator DMO628K RN Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.J Pharmacol Exp Ther.2009 Sep;330(3):911-21. DMO628K RU https://www.ncbi.nlm.nih.gov/pubmed/19502531 DMO628K DI DMO628K DMO628K DN Arbaclofen placarbil DMO628K TI TTEX6LM DMO628K TN GABA(A) receptor gamma-3 (GABRG3) DMO628K MA Agonist DMO628K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO628K RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMO7BQS DI DMO7BQS DMO7BQS DN DMP-444 DMO7BQS TI TT38RM1 DMO7BQS TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMO7BQS MA Modulator DMO7BQS RN Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4. DMO7BQS RU https://pubmed.ncbi.nlm.nih.gov/12911097 DMO8PT9 DI DMO8PT9 DMO8PT9 DN MLN8237 DMO8PT9 TI TTPS3C0 DMO8PT9 TN Aurora kinase A (AURKA) DMO8PT9 MA Inhibitor DMO8PT9 RN Effect of Aurora A kinase inhibitor MLN8237 combined with rituximab on antitumor activity in preclinical B-cell non-Hodgkin's lymphoma models. Journal of Clinical Oncology, 2009:8553. DMO8PT9 RU http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8553 DMODA2X DI DMODA2X DMODA2X DN Bardoxolone methyl DMODA2X TI TTT2SVW DMODA2X TN PPAR-gamma messenger RNA (PPARG mRNA) DMODA2X MA Antagonist DMODA2X RN A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6. DMODA2X RU https://pubmed.ncbi.nlm.nih.gov/11043571 DMOF0CA DI DMOF0CA DMOF0CA DN Nolatrexed DMOF0CA TI TTU6BFZ DMOF0CA TN Candida Thymidylate synthase (Candi TMP1) DMOF0CA MA Inhibitor DMOF0CA RN A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20. DMOF0CA RU https://pubmed.ncbi.nlm.nih.gov/10070890 DMOFH1M DI DMOFH1M DMOFH1M DN Volasertib DMOFH1M TI TTIYVQP DMOFH1M TN Polo-like kinase 1 (PLK1) DMOFH1M MA Modulator DMOFH1M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168). DMOFH1M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168 DMOFIBM DI DMOFIBM DMOFIBM DN LMT-X DMOFIBM TI TTS87KH DMOFIBM TN Microtubule-associated protein tau (MAPT) DMOFIBM MA Inhibitor DMOFIBM RN Clinical pipeline report, company report or official report of TauRx. DMOFIBM RU http://taurx.com/press-releases-announcements.html DMOFIBM DI DMOFIBM DMOFIBM DN LMT-X DMOFIBM TI TTZGF8B DMOFIBM TN Tau protein aggregation (TauA) DMOFIBM MA Modulator DMOFIBM RN Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease. Correction in: volume 31 on page 81. DMOFIBM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000701/ DMOFIBM DI DMOFIBM DMOFIBM DN LMT-X DMOFIBM TI TT9RZ03 DMOFIBM TN TAR DNA binding protein 43 (TARDBP) DMOFIBM MA Inhibitor DMOFIBM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOFIBM RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMOG2X1 DI DMOG2X1 DMOG2X1 DN Trebananib DMOG2X1 TI TTKLQTJ DMOG2X1 TN Angiopoietin-2 (ANGPT2) DMOG2X1 MA Inhibitor DMOG2X1 RN Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069. DMOG2X1 RU https://pubmed.ncbi.nlm.nih.gov/28751444 DMOG2X1 DI DMOG2X1 DMOG2X1 DN Trebananib DMOG2X1 TI TTWNQ1T DMOG2X1 TN Angiopoietin-1 (ANGPT1) DMOG2X1 MA Inhibitor DMOG2X1 RN Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15;23(20):6062-6069. DMOG2X1 RU https://pubmed.ncbi.nlm.nih.gov/28751444 DMOHUR2 DI DMOHUR2 DMOHUR2 DN GLYX-13 DMOHUR2 TI TT9IK2Z DMOHUR2 TN N-methyl-D-aspartate receptor (NMDAR) DMOHUR2 MA Agonist DMOHUR2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOHUR2 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMOJQGT DI DMOJQGT DMOJQGT DN ICARIIN DMOJQGT TI TTJ0IQB DMOJQGT TN Phosphodiesterase 5A (PDE5A) DMOJQGT MA Inhibitor DMOJQGT RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DMOJQGT RU https://pubmed.ncbi.nlm.nih.gov/18778098 DMOKQV7 DI DMOKQV7 DMOKQV7 DN XOMA 052 DMOKQV7 TI TTRYK0X DMOKQV7 TN Interleukin-1 beta (IL1B) DMOKQV7 RN Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010 Dec;12(6):755-69. DMOKQV7 RU https://pubmed.ncbi.nlm.nih.gov/21154167 DMOKT7Y DI DMOKT7Y DMOKT7Y DN FARGLITAZAR DMOKT7Y TI TTZMAO3 DMOKT7Y TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMOKT7Y MA Modulator DMOKT7Y RN Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999 Jul;40(7):1177-84. DMOKT7Y RU https://www.ncbi.nlm.nih.gov/pubmed/10393202 DMOLR5W DI DMOLR5W DMOLR5W DN Yttrium (90Y) clivatuzumab tetraxetan DMOLR5W TI TTBHFYQ DMOLR5W TN Mucin-1 (MUC1) DMOLR5W RN Clinical pipeline report, company report or official report of Immunomedics. DMOLR5W RU http://www.immunomedics.com/clivatuzumab-demo.shtml DMOMDXI DI DMOMDXI DMOMDXI DN Pratosartan DMOMDXI TI TT8DBY3 DMOMDXI TN Angiotensin II receptor type-1 (AGTR1) DMOMDXI MA Antagonist DMOMDXI RN Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients. Hypertens Res. 2008 Feb;31(2):281-7. DMOMDXI RU https://pubmed.ncbi.nlm.nih.gov/18360048 DMOQ9H1 DI DMOQ9H1 DMOQ9H1 DN Tremelimumab DMOQ9H1 TI TTI2S1D DMOQ9H1 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMOQ9H1 MA Modulator DMOQ9H1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743). DMOQ9H1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743 DMOQKAD DI DMOQKAD DMOQKAD DN SNF472 DMOQKAD TI TTGUHMF DMOQKAD TN Hydroxyapatite (HA) DMOQKAD MA Binder DMOQKAD RN Clinical pipeline report, company report or official report of Sanifit. DMOQKAD RU https://www.sanifit.com/lead-compound-snf472/ DMORSFB DI DMORSFB DMORSFB DN Chloroquine DMORSFB TI TTD16BI DMORSFB TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMORSFB MA Inhibitor DMORSFB RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMORSFB RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMORSFB DI DMORSFB DMORSFB DN Chloroquine DMORSFB TI TTZGK1R DMORSFB TN HUMAN glycosylation of host receptor (GHR) DMORSFB MA Inhibitor DMORSFB RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMORSFB RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMOSTXF DI DMOSTXF DMOSTXF DN Rigosertib DMOSTXF TI TTIYVQP DMOSTXF TN Polo-like kinase 1 (PLK1) DMOSTXF MA Modulator DMOSTXF RN Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. DMOSTXF RU https://pubmed.ncbi.nlm.nih.gov/24493827 DMOSTXF DI DMOSTXF DMOSTXF DN Rigosertib DMOSTXF TI TTHBTOP DMOSTXF TN PI3-kinase gamma (PIK3CG) DMOSTXF MA Modulator DMOSTXF RN Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15;20(6):1656-65. DMOSTXF RU https://pubmed.ncbi.nlm.nih.gov/24493827 DMOTCIU DI DMOTCIU DMOTCIU DN Lerisetron DMOTCIU TI TTNXLKE DMOTCIU TN 5-HT 3 receptor (5HT3R) DMOTCIU MA Antagonist DMOTCIU RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMOTCIU RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMOTH6V DI DMOTH6V DMOTH6V DN Interferon alpha 2a DMOTH6V TI TTSIUJ9 DMOTH6V TN Interferon-alpha 2 (IFNA2) DMOTH6V MA Modulator DMOTH6V RN Hairy cell leukemia associated with large granular lymphocyte leukemia: immunologic and genomic study, effect of interferon treatment. Blood. 1988 Aug;72(2):655-60. DMOTH6V RU https://pubmed.ncbi.nlm.nih.gov/2840988 DMOUGX1 DI DMOUGX1 DMOUGX1 DN Diamyd DMOUGX1 TI TT7UY6K DMOUGX1 TN Glutamate decarboxylase 2 (GAD2) DMOUGX1 MA Immunomodulator DMOUGX1 RN Clinical pipeline report, company report or official report of Diamyd Medical. DMOUGX1 RU http://www.diamyd.com/docs/gadProducts.aspx?section=products DMOVEDH DI DMOVEDH DMOVEDH DN SYM-004 DMOVEDH TI TTGKNB4 DMOVEDH TN Epidermal growth factor receptor (EGFR) DMOVEDH RN Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206. DMOVEDH RU https://pubmed.ncbi.nlm.nih.gov/24204198 DMOWINT DI DMOWINT DMOWINT DN Reloxaliase DMOWINT TI TTMDQIJ DMOWINT TN Oxalate absorption (Oxalate absor) DMOWINT MA Replacement DMOWINT RN Clinical pipeline report, company report or official report of Allena Pharmaceuticals. DMOWINT RU https://www.allenapharma.com/reloxaliase DMOWQAF DI DMOWQAF DMOWQAF DN Recombinant human iduronate-2-sulfatase DMOWQAF TI TTNY2AP DMOWQAF TN Iduronate 2-sulfatase (IDS) DMOWQAF MA Modulator DMOWQAF RN The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II. PLoS One. 2014 Jan 13;9(1):e85074. DMOWQAF RU https://pubmed.ncbi.nlm.nih.gov/24454794 DMOYGZF DI DMOYGZF DMOYGZF DN Retosiban DMOYGZF TI TTSCIUP DMOYGZF TN Oxytocin receptor (OTR) DMOYGZF MA Modulator DMOYGZF RN The Effect of an Oxytocin Receptor Antagonist (Retosiban, GSK221149A) on the Response of Human Myometrial Explants to Prolonged Mechanical Stretch.Endocrinology.2015 Oct;156(10):3511-6. DMOYGZF RU https://www.ncbi.nlm.nih.gov/pubmed/26207346 DMP0NGX DI DMP0NGX DMP0NGX DN Cilansetron DMP0NGX TI TTPC4TU DMP0NGX TN 5-HT 3A receptor (HTR3A) DMP0NGX MA Modulator DMP0NGX RN Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93. DMP0NGX RU https://www.ncbi.nlm.nih.gov/pubmed/15757394 DMP2BFG DI DMP2BFG DMP2BFG DN Anacetrapib DMP2BFG TI TTFQAYR DMP2BFG TN Cholesteryl ester transfer protein (CETP) DMP2BFG MA Inhibitor DMP2BFG RN Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (C... Br J Clin Pharmacol. 2009 May;67(5):520-6. DMP2BFG RU https://pubmed.ncbi.nlm.nih.gov/19552746 DMP2SGN DI DMP2SGN DMP2SGN DN Dabelotine DMP2SGN TI TTVIREA DMP2SGN TN Adrenergic receptor (ADR) DMP2SGN MA Modulator DMP2SGN RN US patent application no. 2007,0049,576, Neurogenesis by muscarinic receptor modulation. DMP2SGN RU http://www.google.nl/patents/US20070049576 DMP36KD DI DMP36KD DMP36KD DN MLN4924 DMP36KD TI TTVKOPM DMP36KD TN NEDD8-activating enzyme (NAE) DMP36KD MA Modulator DMP36KD RN Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.Cell Death Dis.2012 Sep 6;3:e386. DMP36KD RU https://www.ncbi.nlm.nih.gov/pubmed/22951983 DMP36KD DI DMP36KD DMP36KD DN MLN4924 DMP36KD TI TTNDC4K DMP36KD TN Ubiquitin-like protein Nedd8 (NEDD8) DMP36KD MA Inhibitor DMP36KD RN Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.Cell Death Dis. 2017 Jun 1;8(6):e2834. DMP36KD RU https://pubmed.ncbi.nlm.nih.gov/28569775 DMP3GI2 DI DMP3GI2 DMP3GI2 DN KW-3357 DMP3GI2 TI TT4QPUL DMP3GI2 TN Antithrombin-III (ATIII) DMP3GI2 MA Modulator DMP3GI2 RN Company report (kyowa-kirin) DMP3GI2 RU http://www.kyowa-kirin.com/news_releases/2014/e20140801_01.html DMP5G1K DI DMP5G1K DMP5G1K DN KPS-0373 DMP5G1K TI TT2Z39D DMP5G1K TN Thyrotropin-releasing hormone (TRH) DMP5G1K MA Modulator DMP5G1K RN DOI: 10.1002/mdc3.12057 DMP5G1K RU http://www.movementdisorders.org/MDS/Journals/Clinical-Practice-E-Journal-Overview/Movement-Disorders-Clinical-Practice-E-Journal-Volume-1-Issue-4/Treatment-Options-in-Degenerative-Cerebellar-Ataxia-A-Systematic-Review.htm DMP5L8S DI DMP5L8S DMP5L8S DN 177Lu-DOTA-octreotate DMP5L8S TI TTOMNR9 DMP5L8S TN Somatostatin receptor (SSTR) DMP5L8S MA Modulator DMP5L8S RN Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25. DMP5L8S RU https://pubmed.ncbi.nlm.nih.gov/24632546 DMP61YB DI DMP61YB DMP61YB DN ISRAPAFANT DMP61YB TI TTQL5VC DMP61YB TN Platelet-activating factor receptor (PTAFR) DMP61YB MA Antagonist DMP61YB RN Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40. DMP61YB RU https://pubmed.ncbi.nlm.nih.gov/20007715 DMP6IMQ DI DMP6IMQ DMP6IMQ DN Rindopepimut DMP6IMQ TI TTGKNB4 DMP6IMQ TN Epidermal growth factor receptor (EGFR) DMP6IMQ MA Modulator DMP6IMQ RN Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54. DMP6IMQ RU https://pubmed.ncbi.nlm.nih.gov/21154166 DMP83UZ DI DMP83UZ DMP83UZ DN Fumaric acid DMP83UZ TI TT93WF5 DMP83UZ TN Interferon-gamma (IFNG) DMP83UZ MA Binder DMP83UZ RN Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. DMP83UZ RU https://pubmed.ncbi.nlm.nih.gov/18764723 DMP8ESD DI DMP8ESD DMP8ESD DN Zicronapine DMP8ESD TI TTEX248 DMP8ESD TN Dopamine D2 receptor (D2R) DMP8ESD MA Modulator DMP8ESD RN Clinical pipeline report, company report or official report of Lundbeck. DMP8ESD RU http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605 DMP8ESD DI DMP8ESD DMP8ESD DN Zicronapine DMP8ESD TI TTZFYLI DMP8ESD TN Dopamine D1 receptor (D1R) DMP8ESD MA Modulator DMP8ESD RN Clinical pipeline report, company report or official report of Lundbeck. DMP8ESD RU http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605 DMP8ESD DI DMP8ESD DMP8ESD DN Zicronapine DMP8ESD TI TTJQOD7 DMP8ESD TN 5-HT 2A receptor (HTR2A) DMP8ESD MA Modulator DMP8ESD RN Clinical pipeline report, company report or official report of Lundbeck. DMP8ESD RU http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605 DMP8MDW DI DMP8MDW DMP8MDW DN GS-5745 DMP8MDW TI TT6X50U DMP8MDW TN Matrix metalloproteinase-9 (MMP-9) DMP8MDW MA Modulator DMP8MDW RN National Cancer Institute Drug Dictionary (drug id 747683). DMP8MDW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747683 DMPBA0D DI DMPBA0D DMPBA0D DN Sofpironium bromide DMPBA0D TI TTUPDWN DMPBA0D TN Cholinergic receptor unspecific (CHR) DMPBA0D MA Antagonist DMPBA0D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPBA0D RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMPBJ8W DI DMPBJ8W DMPBJ8W DN Turoctocog alfa DMPBJ8W TI TT1290U DMPBJ8W TN Coagulation factor VIII (F8) DMPBJ8W MA Modulator DMPBJ8W RN The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight ), in patients with hemophilia A. J Thromb Haemost. 2015 Mar;13(3):370-9. DMPBJ8W RU https://pubmed.ncbi.nlm.nih.gov/25495795 DMPCFXN DI DMPCFXN DMPCFXN DN QAW-039 DMPCFXN TI TTNVEIR DMPCFXN TN Prostaglandin D2 receptor (PTGDR) DMPCFXN MA Antagonist DMPCFXN RN Effect Of QAW039, An Oral Prostaglandin D2 Receptor (DP2/CRTh2) Antagonist, Upon Sputum And Bronchial Eosinophilic Inflammation And Clinical Outcomes In Treatment-Resistant Asthma: A Phase 2a Randomized Placebo-Controlled Trial. American Thoracic Society Journals. 2015. DMPCFXN RU http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A6361 DMPDQ8T DI DMPDQ8T DMPDQ8T DN AB-103 DMPDQ8T TI TTQ13FT DMPDQ8T TN T-cell-specific surface glycoprotein CD28 (CD28) DMPDQ8T MA Antagonist DMPDQ8T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPDQ8T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMPG4OM DI DMPG4OM DMPG4OM DN CAZ AVI DMPG4OM TI TTHI19T DMPG4OM TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMPG4OM MA Modulator DMPG4OM RN NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7. DMPG4OM RU https://pubmed.ncbi.nlm.nih.gov/22587688 DMPGH7N DI DMPGH7N DMPGH7N DN ThermoProfen DMPGH7N TI TT8NGED DMPGH7N TN Prostaglandin G/H synthase 1 (COX-1) DMPGH7N MA Inhibitor DMPGH7N RN Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49. DMPGH7N RU https://pubmed.ncbi.nlm.nih.gov/20210866 DMPGH7N DI DMPGH7N DMPGH7N DN ThermoProfen DMPGH7N TI TTVKILB DMPGH7N TN Prostaglandin G/H synthase 2 (COX-2) DMPGH7N MA Inhibitor DMPGH7N RN Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010 Apr;11(4):535-49. DMPGH7N RU https://pubmed.ncbi.nlm.nih.gov/20210866 DMPH1RK DI DMPH1RK DMPH1RK DN Alferminogene tadenovec DMPH1RK TI TTCEKVZ DMPH1RK TN Fibroblast growth factor-4 (FGF4) DMPH1RK MA Modulator DMPH1RK RN Alferminogene tadenovec, an angiogenic FGF4 gene therapy for coronary artery disease. IDrugs. 2008 Apr;11(4):283-93. DMPH1RK RU https://pubmed.ncbi.nlm.nih.gov/18379964 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTZMAO3 DMPIDXT TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMPIDXT MA Agonist DMPIDXT RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMPIDXT RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTI2WET DMPIDXT TN Platelet-derived growth factor receptor (PDGFR) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTUTJGQ DMPIDXT TN Vascular endothelial growth factor receptor 2 (KDR) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTPS3C0 DMPIDXT TN Aurora kinase A (AURKA) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TTRLW2X DMPIDXT TN Fibroblast growth factor receptor 1 (FGFR1) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPIDXT DI DMPIDXT DMPIDXT DN Rosiglitazone + metformin DMPIDXT TI TT5LS6T DMPIDXT TN Aurora kinase B (AURKB) DMPIDXT MA Inhibitor DMPIDXT RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMPIDXT RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMPJTZ1 DI DMPJTZ1 DMPJTZ1 DN RBP-7000 DMPJTZ1 TI TTEX248 DMPJTZ1 TN Dopamine D2 receptor (D2R) DMPJTZ1 MA Modulator DMPJTZ1 RN Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment. Clin Pharmacokinet. 2014 Jun;53(6):533-43. DMPJTZ1 RU https://pubmed.ncbi.nlm.nih.gov/24464285 DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TT2Q6G1 DMPOTM4 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTRLW2X DMPOTM4 TN Fibroblast growth factor receptor 1 (FGFR1) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTUTJGQ DMPOTM4 TN Vascular endothelial growth factor receptor 2 (KDR) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTDCBX5 DMPOTM4 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of Hutchison Medi Pharma. DMPOTM4 RU http://www.hmplglobal.com/en/sulfatinib/ DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TT7MRDV DMPOTM4 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPOTM4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPOTM4 DI DMPOTM4 DMPOTM4 DN Sulfatinib DMPOTM4 TI TTVJ1D8 DMPOTM4 TN Vascular endothelial growth factor receptor (VEGFR) DMPOTM4 MA Inhibitor DMPOTM4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPOTM4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPQR1D DI DMPQR1D DMPQR1D DN Claudiximab DMPQR1D TI TT6PKBX DMPQR1D TN Claudin-18 (CLDN18) DMPQR1D RN Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014 Feb 1;134(3):731-9. DMPQR1D RU https://pubmed.ncbi.nlm.nih.gov/23900716 DMPRI14 DI DMPRI14 DMPRI14 DN Baricitinib DMPRI14 TI TT0AGBL DMPRI14 TN HUMAN cyclin G-associated kinase (GAK) DMPRI14 MA Inhibitor DMPRI14 RN Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. DMPRI14 RU https://pubmed.ncbi.nlm.nih.gov/32032529 DMPRI14 DI DMPRI14 DMPRI14 DN Baricitinib DMPRI14 TI TTN9A16 DMPRI14 TN HUMAN adaptor-associated kinase 1 (AAK1) DMPRI14 MA Inhibitor DMPRI14 RN Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. DMPRI14 RU https://pubmed.ncbi.nlm.nih.gov/32032529 DMPSG4D DI DMPSG4D DMPSG4D DN Flobufen DMPSG4D TI TT2J34L DMPSG4D TN Arachidonate 5-lipoxygenase (5-LOX) DMPSG4D MA Modulator DMPSG4D RN Pharmacological profile of the novel potent antirheumatic 4-(2',4'-difluorobiphenyl-4-yl)-2-methyl-4-oxobutanoic acid. Arzneimittelforschung. 1997 May;47(5):648-52. DMPSG4D RU https://pubmed.ncbi.nlm.nih.gov/9205780 DMPTCYB DI DMPTCYB DMPTCYB DN Cadi-05 DMPTCYB TI TTSHG0T DMPTCYB TN Toll-like receptor 9 (TLR9) DMPTCYB RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMPTCYB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMPTCYB DI DMPTCYB DMPTCYB DN Cadi-05 DMPTCYB TI TTY7ZHS DMPTCYB TN Toll-like receptor 2 (TLR2) DMPTCYB RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMPTCYB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMPTCYB DI DMPTCYB DMPTCYB DN Cadi-05 DMPTCYB TI TTISGCA DMPTCYB TN Toll-like receptor 4 (TLR4) DMPTCYB RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMPTCYB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMPV6B2 DI DMPV6B2 DMPV6B2 DN BA-058 DMPV6B2 TI TTEPJL5 DMPV6B2 TN Parathyroid hormone receptor (PTH2R) DMPV6B2 MA Modulator DMPV6B2 RN Emerging therapies for the treatment of osteoporosis. J Midlife Health. 2013 Jul-Sep; 4(3): 147-152. DMPV6B2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3952405/ DMPVW6H DI DMPVW6H DMPVW6H DN Morphine-6-glucuronide DMPVW6H TI TTKWM86 DMPVW6H TN Opioid receptor mu (MOP) DMPVW6H MA Agonist DMPVW6H RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DMPVW6H RU https://pubmed.ncbi.nlm.nih.gov/15757410 DMPW5SB DI DMPW5SB DMPW5SB DN Bay 86-9766 DMPW5SB TI TTROQ37 DMPW5SB TN MAPK/ERK kinase kinase (MAP3K) DMPW5SB MA Modulator DMPW5SB RN RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.Cancer Res.2009 Sep 1;69(17):6839-47. DMPW5SB RU https://www.ncbi.nlm.nih.gov/pubmed/19706763 DMPW5UF DI DMPW5UF DMPW5UF DN Avalglucosidase alfa DMPW5UF TI TTLPC70 DMPW5UF TN Lysosomal alpha-glucosidase (GAA) DMPW5UF MA Replacement DMPW5UF RN ClinicalTrials.gov (NCT02782741) Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease (COMET). U.S. National Institutes of Health. DMPW5UF RU https://clinicaltrials.gov/ct2/show/NCT02782741 DMPXOYJ DI DMPXOYJ DMPXOYJ DN CPI-0610 DMPXOYJ TI TTRA6BO DMPXOYJ TN Bromodomain-containing protein 4 (BRD4) DMPXOYJ MA Modulator DMPXOYJ RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMPXOYJ RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMPXOYJ DI DMPXOYJ DMPXOYJ DN CPI-0610 DMPXOYJ TI TTE4BSY DMPXOYJ TN Bromodomain and extraterminal domain protein (BET) DMPXOYJ MA Inhibitor DMPXOYJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPXOYJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPYET9 DI DMPYET9 DMPYET9 DN Taspoglutide DMPYET9 TI TTVIMDE DMPYET9 TN Glucagon-like peptide 1 receptor (GLP1R) DMPYET9 MA Agonist DMPYET9 RN Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabet Med. 2009 Nov;26(11):1156-64. DMPYET9 RU https://pubmed.ncbi.nlm.nih.gov/19929995 DMQ0IZ6 DI DMQ0IZ6 DMQ0IZ6 DN 177Lu-labelled PSMA-617 DMQ0IZ6 TI TT9G4N0 DMQ0IZ6 TN Glutamate carboxypeptidase II (GCPII) DMQ0IZ6 RN [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer]. Nuklearmedizin. 2016 Jun 28;55(3):123-8. DMQ0IZ6 RU https://pubmed.ncbi.nlm.nih.gov/27350005 DMQ38JZ DI DMQ38JZ DMQ38JZ DN HB-AS02V DMQ38JZ TI TT3J5ZI DMQ38JZ TN Cell mediated immunity response (CMIR) DMQ38JZ RN Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin. 2010 Jul;6(7):578-84. DMQ38JZ RU https://pubmed.ncbi.nlm.nih.gov/20523113 DMQ4CSX DI DMQ4CSX DMQ4CSX DN Rezafungin DMQ4CSX TI TT0SFXH DMQ4CSX TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMQ4CSX MA Inhibitor DMQ4CSX RN Antifungal drugs: What brings the future?. Med Mycol. 2019 Jun 1;57(Supplement_3):S328-S343. DMQ4CSX RU https://pubmed.ncbi.nlm.nih.gov/31292663 DMQ509J DI DMQ509J DMQ509J DN Alicaforsen DMQ509J TI TTA1L39 DMQ509J TN ICAM1 messenger RNA (ICAM1 mRNA) DMQ509J RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMQ509J RU http://www.isispharm.com/Pipeline/index.htm DMQ509J DI DMQ509J DMQ509J DN Alicaforsen DMQ509J TI TTCT6F7 DMQ509J TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMQ509J MA Antagonist DMQ509J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ509J RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQ94CT DI DMQ94CT DMQ94CT DN AT9283 DMQ94CT TI TT5LS6T DMQ94CT TN Aurora kinase B (AURKB) DMQ94CT MA Modulator DMQ94CT RN A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73. DMQ94CT RU https://pubmed.ncbi.nlm.nih.gov/25370467 DMQ94CT DI DMQ94CT DMQ94CT DN AT9283 DMQ94CT TI TTPS3C0 DMQ94CT TN Aurora kinase A (AURKA) DMQ94CT MA Modulator DMQ94CT RN A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study. Clin Cancer Res. 2015 Jan 15;21(2):267-73. DMQ94CT RU https://pubmed.ncbi.nlm.nih.gov/25370467 DMQBF7O DI DMQBF7O DMQBF7O DN MK-3222 DMQBF7O TI TTC1GLB DMQBF7O TN Interleukin-23 (IL23) DMQBF7O RN Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. DMQBF7O RU https://pubmed.ncbi.nlm.nih.gov/26042589 DMQCZ4N DI DMQCZ4N DMQCZ4N DN Glyminox DMQCZ4N TI TT84ETX DMQCZ4N TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQCZ4N MA Inhibitor DMQCZ4N RN Glyminox Biosyn. Curr Opin Investig Drugs. 2004 Feb;5(2):222-31. DMQCZ4N RU https://pubmed.ncbi.nlm.nih.gov/15043398 DMQEC6Z DI DMQEC6Z DMQEC6Z DN Melanoma vaccine DMQEC6Z TI TTULVH8 DMQEC6Z TN Tyrosinase (TYR) DMQEC6Z RN National Cancer Institute Drug Dictionary (drug id 685201). DMQEC6Z RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201 DMQEC6Z DI DMQEC6Z DMQEC6Z DN Melanoma vaccine DMQEC6Z TI TT8MK59 DMQEC6Z TN Melanocytes lineage-specific antigen GP100 (PMEL) DMQEC6Z RN National Cancer Institute Drug Dictionary (drug id 685201). DMQEC6Z RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201 DMQEC6Z DI DMQEC6Z DMQEC6Z DN Melanoma vaccine DMQEC6Z TI TT362RB DMQEC6Z TN MART-1 melanoma antigen (MLANA) DMQEC6Z RN National Cancer Institute Drug Dictionary (drug id 685201). DMQEC6Z RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=685201 DMQG7ZM DI DMQG7ZM DMQG7ZM DN Belagenpumatucel-L DMQG7ZM TI TTI0KH6 DMQG7ZM TN TGF beta-2 messenger RNA (TGFB2 mRNA) DMQG7ZM RN National Cancer Institute Drug Dictionary (drug id 590662). DMQG7ZM RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=590662 DMQGR45 DI DMQGR45 DMQGR45 DN Pixantrone DMQGR45 TI TT0IHXV DMQGR45 TN DNA topoisomerase II (TOP2) DMQGR45 MA Modulator DMQGR45 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQGR45 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQGV5P DI DMQGV5P DMQGV5P DN VLB-01 DMQGV5P TI TT32JK8 DMQGV5P TN Melatonin receptor type 1B (MTNR1B) DMQGV5P MA Modulator DMQGV5P RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQGV5P RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQHX1Y DI DMQHX1Y DMQHX1Y DN Etirinotecan pegol DMQHX1Y TI TTGTQHC DMQHX1Y TN DNA topoisomerase I (TOP1) DMQHX1Y MA Inhibitor DMQHX1Y RN Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014 Dec;74(6):1125-37. DMQHX1Y RU https://pubmed.ncbi.nlm.nih.gov/25228368 DMQIE7U DI DMQIE7U DMQIE7U DN GMA102 DMQIE7U TI TTVIMDE DMQIE7U TN Glucagon-like peptide 1 receptor (GLP1R) DMQIE7U MA Inhibitor DMQIE7U RN Clinical pipeline report, company report or official report of Gmax Biopharm. DMQIE7U RU http://www.gmaxbiopharm.com/wap_product_detailen/id/2.html DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTN4QDT DMQJXL4 TN Opioid receptor (OPR) DMQJXL4 MA Agonist DMQJXL4 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQJXL4 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTLA931 DMQJXL4 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMQJXL4 MA Agonist DMQJXL4 RN Clinical pipeline report, company report or official report of Roche (2009). DMQJXL4 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TT9W8GU DMQJXL4 TN Gamma-secretase (GS) DMQJXL4 MA Inhibitor DMQJXL4 RN Clinical pipeline report, company report or official report of Roche (2009). DMQJXL4 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTD0CIQ DMQJXL4 TN Melanocortin receptor 4 (MC4R) DMQJXL4 MA Agonist DMQJXL4 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMQJXL4 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTBW580 DMQJXL4 TN TAX transcriptionally-activated glycoprotein 1 (OX40) DMQJXL4 MA Modulator DMQJXL4 RN Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68. DMQJXL4 RU https://www.ncbi.nlm.nih.gov/pubmed/23334208 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTKLQTJ DMQJXL4 TN Angiopoietin-2 (ANGPT2) DMQJXL4 MA Modulator DMQJXL4 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQJXL4 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQJXL4 DI DMQJXL4 DMQJXL4 DN AMG 386 DMQJXL4 TI TTWNQ1T DMQJXL4 TN Angiopoietin-1 (ANGPT1) DMQJXL4 MA Modulator DMQJXL4 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQJXL4 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQL0KF DI DMQL0KF DMQL0KF DN Vanadate DMQL0KF TI TTZVSJ2 DMQL0KF TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMQL0KF MA Inhibitor DMQL0KF RN Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem. 2001 Apr 6;276(14):10782-7. DMQL0KF RU https://pubmed.ncbi.nlm.nih.gov/11145964 DMQLSMB DI DMQLSMB DMQLSMB DN Dociparstat sodium DMQLSMB TI TT4UGTF DMQLSMB TN Stromal cell-derived factor 1 (CXCL12) DMQLSMB MA Inhibitor DMQLSMB RN Clinical pipeline report, company report or official report of Chimerix. DMQLSMB RU https://www.chimerix.com/our-science/dstat/ DMQLSMB DI DMQLSMB DMQLSMB DN Dociparstat sodium DMQLSMB TI TTSG7Q5 DMQLSMB TN Platelet factor 4 (PF4) DMQLSMB MA Inhibitor DMQLSMB RN Clinical pipeline report, company report or official report of Chimerix. DMQLSMB RU https://www.chimerix.com/our-science/dstat/ DMQM2FH DI DMQM2FH DMQM2FH DN RRx-001 DMQM2FH TI TT8E7Z0 DMQM2FH TN Free radical (FRD) DMQM2FH MA Modulator DMQM2FH RN Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012 May 15;72(10):2600-8. DMQM2FH RU https://pubmed.ncbi.nlm.nih.gov/22589277 DMQNMAT DI DMQNMAT DMQNMAT DN Tirzepatide DMQNMAT TI TTVIMDE DMQNMAT TN Glucagon-like peptide 1 receptor (GLP1R) DMQNMAT MA Agonist DMQNMAT RN Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. J Clin Endocrinol Metab. 2021 Jan 23;106(2):388-396. DMQNMAT RU https://pubmed.ncbi.nlm.nih.gov/33236115 DMQNVR8 DI DMQNVR8 DMQNVR8 DN Lopinavir + ritonavir DMQNVR8 TI TT1D53B DMQNVR8 TN COVID-19 3C-like protease (3CLpro) DMQNVR8 MA Inhibitor DMQNVR8 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMQNVR8 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMQOCD8 DI DMQOCD8 DMQOCD8 DN RUBOXISTAURIN HYDROCHLORIDE DMQOCD8 TI TTYPXQF DMQOCD8 TN Protein kinase C beta (PRKCB) DMQOCD8 MA Modulator DMQOCD8 RN Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9. DMQOCD8 RU https://pubmed.ncbi.nlm.nih.gov/17472415 DMQP0X5 DI DMQP0X5 DMQP0X5 DN Lebrikizumab DMQP0X5 TI TT0GVCH DMQP0X5 TN Interleukin-13 (IL13) DMQP0X5 MA Modulator DMQP0X5 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMQP0X5 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT0JLSD DMQPH29 TN Multidrug resistance protein (MDR) DMQPH29 MA Inhibitor DMQPH29 RN Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/19442032 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTANPDJ DMQPH29 TN Carbonic anhydrase II (CA-II) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTSYM0R DMQPH29 TN Carbonic anhydrase XII (CA-XII) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTCFSPE DMQPH29 TN Carbonic anhydrase VI (CA-VI) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT2LVK8 DMQPH29 TN Carbonic anhydrase IX (CA-IX) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTXV4FI DMQPH29 TN Albendazole monooxygenase (CYP3A4) DMQPH29 MA Inhibitor DMQPH29 RN Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/18249473 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTF10I9 DMQPH29 TN Nitric-oxide synthase inducible (NOS2) DMQPH29 MA Inhibitor DMQPH29 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTEYTKG DMQPH29 TN Carbonic anhydrase XIV (CA-XIV) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTHQPL7 DMQPH29 TN Carbonic anhydrase I (CA-I) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTHVCUP DMQPH29 TN DNA [cytosine-5]-methyltransferase (DNMT) DMQPH29 MA Inhibitor DMQPH29 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTHY57M DMQPH29 TN Matrix metalloproteinase-13 (MMP-13) DMQPH29 MA Inhibitor DMQPH29 RN High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/18358729 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT6VZ78 DMQPH29 TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMQPH29 MA Inhibitor DMQPH29 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT7RJY8 DMQPH29 TN Xanthine dehydrogenase/oxidase (XDH) DMQPH29 MA Inhibitor DMQPH29 RN Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/19388706 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT8NGED DMQPH29 TN Prostaglandin G/H synthase 1 (COX-1) DMQPH29 MA Inhibitor DMQPH29 RN Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/15780608 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TT6X50U DMQPH29 TN Matrix metalloproteinase-9 (MMP-9) DMQPH29 MA Inhibitor DMQPH29 RN Synthesis and biological evaluation of curcuminoid pyrazoles as new therapeutic agents in inflammatory bowel disease: effect on matrix metalloprote... Bioorg Med Chem. 2009 Feb 1;17(3):1290-6. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/19128977 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTVKILB DMQPH29 TN Prostaglandin G/H synthase 2 (COX-2) DMQPH29 MA Inhibitor DMQPH29 RN Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/15780608 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTZHA0O DMQPH29 TN Carbonic anhydrase IV (CA-IV) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTE4KHA DMQPH29 TN Amyloid beta A4 protein (APP) DMQPH29 MA Inhibitor DMQPH29 RN Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/17004725 DMQPH29 DI DMQPH29 DMQPH29 DN Curcumin DMQPH29 TI TTUNARX DMQPH29 TN Carbonic anhydrase (CA) DMQPH29 MA Inhibitor DMQPH29 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMQPH29 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMQRL2Y DI DMQRL2Y DMQRL2Y DN AC0010 DMQRL2Y TI TTG96HZ DMQRL2Y TN EGFR messenger RNA (EGFR mRNA) DMQRL2Y MA Inhibitor DMQRL2Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQRL2Y RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQSBX4 DI DMQSBX4 DMQSBX4 DN Clazosentan DMQSBX4 TI TTKRD0G DMQSBX4 TN Endothelin A receptor (EDNRA) DMQSBX4 MA Antagonist DMQSBX4 RN Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918. DMQSBX4 RU https://pubmed.ncbi.nlm.nih.gov/17700991 DMQSBX4 DI DMQSBX4 DMQSBX4 DN Clazosentan DMQSBX4 TI TTCV6O0 DMQSBX4 TN Endothelin receptor (EDNR) DMQSBX4 MA Antagonist DMQSBX4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQSBX4 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMQTLVB DI DMQTLVB DMQTLVB DN Hebergel DMQTLVB TI TTSIUJ9 DMQTLVB TN Interferon-alpha 2 (IFNA2) DMQTLVB MA Modulator DMQTLVB RN Evaluation of recombinant human interferon alpha-2b structure and stability by in-gel tryptic digestion, H/D exchange and mass spectrometry. J Pharm Biomed Anal. 2006 Feb 24;40(3):781-7. DMQTLVB RU https://pubmed.ncbi.nlm.nih.gov/16316735 DMQZI7K DI DMQZI7K DMQZI7K DN ISIS 23722 DMQZI7K TI TTTPU1G DMQZI7K TN Apoptosis inhibitor survivin (BIRC5) DMQZI7K MA Modulator DMQZI7K RN Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression.Eur J Cancer.2012 Mar;48(5):763-71. DMQZI7K RU https://www.ncbi.nlm.nih.gov/pubmed/22088485 DMR0EWV DI DMR0EWV DMR0EWV DN SAR342434 DMR0EWV TI TTZOPHG DMR0EWV TN Insulin (INS) DMR0EWV MA Modulator DMR0EWV RN Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015 May; 17(5): 445-451. DMR0EWV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403967/ DMR21Q3 DI DMR21Q3 DMR21Q3 DN Clevudine DMR21Q3 TI TTS5K1M DMR21Q3 TN Hepatitis B virus Reverse transcriptase (HBV RT) DMR21Q3 MA Inhibitor DMR21Q3 RN 2011 Pipeline of Bukwang. DMR21Q3 RU http://bkmedical.en.ecplaza.net/ DMR23M1 DI DMR23M1 DMR23M1 DN Mapracorat DMR23M1 TI TTYRL6O DMR23M1 TN Glucocorticoid receptor (NR3C1) DMR23M1 MA Agonist DMR23M1 RN Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases. Br J Pharmacol. 2009 Oct;158(4):1088-103. DMR23M1 RU https://pubmed.ncbi.nlm.nih.gov/19422381 DMR2JD4 DI DMR2JD4 DMR2JD4 DN Darotropium + 642444 DMR2JD4 TI TTZ9SOR DMR2JD4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMR2JD4 MA Agonist DMR2JD4 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMR2JD4 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMR6YH3 DI DMR6YH3 DMR6YH3 DN GLP-1 DMR6YH3 TI TTVIMDE DMR6YH3 TN Glucagon-like peptide 1 receptor (GLP1R) DMR6YH3 MA Modulator DMR6YH3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMR6YH3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMR71ST DI DMR71ST DMR71ST DN ASP1929 DMR71ST TI TTGKNB4 DMR71ST TN Epidermal growth factor receptor (EGFR) DMR71ST MA Inhibitor DMR71ST RN ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health. DMR71ST RU https://clinicaltrials.gov/ct2/show/NCT04305795 DMR9TF1 DI DMR9TF1 DMR9TF1 DN Bimekizumab DMR9TF1 TI TT2B6PS DMR9TF1 TN Cytokine ML-1 (IL17F) DMR9TF1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR9TF1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMR9TF1 DI DMR9TF1 DMR9TF1 DN Bimekizumab DMR9TF1 TI TTG0MT6 DMR9TF1 TN Interleukin-17 (IL17) DMR9TF1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR9TF1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMRD5SP DI DMRD5SP DMRD5SP DN Fenretinide DMRD5SP TI TTOD7B3 DMRD5SP TN Retinoic acid receptor (RAR) DMRD5SP MA Modulator DMRD5SP RN National Cancer Institute Drug Dictionary (drug id 39582). DMRD5SP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=39582 DMREDYP DI DMREDYP DMREDYP DN ABT-869 DMREDYP TI TTDCBX5 DMREDYP TN Vascular endothelial growth factor receptor 3 (FLT-4) DMREDYP MA Modulator DMREDYP RN Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2006 Apr;5(4):995-1006. DMREDYP RU https://pubmed.ncbi.nlm.nih.gov/16648571 DMRG1X3 DI DMRG1X3 DMRG1X3 DN Pirtobrutinib DMRG1X3 TI TTGM6VW DMRG1X3 TN Tyrosine-protein kinase BTK (ATK) DMRG1X3 MA Inhibitor DMRG1X3 RN Targeting BTK in CLL: Beyond Ibrutinib. Curr Hematol Malig Rep. 2019 Jun;14(3):197-205. DMRG1X3 RU https://pubmed.ncbi.nlm.nih.gov/31028669 DMRH291 DI DMRH291 DMRH291 DN Dexanabinol DMRH291 TI TT9IK2Z DMRH291 TN N-methyl-D-aspartate receptor (NMDAR) DMRH291 MA Antagonist DMRH291 RN Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84. DMRH291 RU https://pubmed.ncbi.nlm.nih.gov/19249984 DMRJK3U DI DMRJK3U DMRJK3U DN Avotermin DMRJK3U TI TTWOMY8 DMRJK3U TN Transforming growth factor beta 3 (TGFB3) DMRJK3U MA Modulator DMRJK3U RN Discovery and development of avotermin (recombinant human transforming growth factor beta 3): a new class of prophylactic therapeutic for the improvement of scarring. Wound Repair Regen. 2011 Sep;19 Suppl 1:s38-48. DMRJK3U RU https://pubmed.ncbi.nlm.nih.gov/21793965 DMRKTCP DI DMRKTCP DMRKTCP DN MGA012 DMRKTCP TI TTNBFWK DMRKTCP TN Programmed cell death protein 1 (PD-1) DMRKTCP MA Inhibitor DMRKTCP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRKTCP RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMRLVUD DI DMRLVUD DMRLVUD DN Imagabalin DMRLVUD TI TTFK1JQ DMRLVUD TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMRLVUD MA Agonist DMRLVUD RN Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology. Brain Res. 2011 Jul 15;1401:1-9. DMRLVUD RU https://pubmed.ncbi.nlm.nih.gov/21664606 DMRNGD2 DI DMRNGD2 DMRNGD2 DN GSK1278863 DMRNGD2 TI TTMHFRY DMRNGD2 TN HIF-prolyl hydroxylase 1 (HPH-1) DMRNGD2 MA Inhibitor DMRNGD2 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMRNGD2 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMRSI1M DI DMRSI1M DMRSI1M DN NAV5001 DMRSI1M TI TTVBI8W DMRSI1M TN Dopamine transporter (DAT) DMRSI1M MA Modulator DMRSI1M RN Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41. DMRSI1M RU https://pubmed.ncbi.nlm.nih.gov/9593103 DMRSNEU DI DMRSNEU DMRSNEU DN Masitinib DMRSNEU TI TT6PKBN DMRSNEU TN Proto-oncogene c-Src (SRC) DMRSNEU MA Inhibitor DMRSNEU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRSNEU RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMRSNEU DI DMRSNEU DMRSNEU DN Masitinib DMRSNEU TI TTJSQEF DMRSNEU TN Tyrosine-protein kinase (PTK) DMRSNEU MA Inhibitor DMRSNEU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRSNEU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRUEKC DI DMRUEKC DMRUEKC DN Synthetic conjugated estrogen DMRUEKC TI TTZAYWL DMRUEKC TN Estrogen receptor (ESR) DMRUEKC MA Modulator DMRUEKC RN Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. Obstet Gynecol. 2004 Feb;103(2):245-53. DMRUEKC RU https://pubmed.ncbi.nlm.nih.gov/14754691 DMRV4DT DI DMRV4DT DMRV4DT DN AT1001 DMRV4DT TI TTLC8E1 DMRV4DT TN Haptoglobin (HP) DMRV4DT MA Modulator DMRV4DT RN Zonulin, regulation of tight junctions, and autoimmune diseases DMRV4DT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384703 DMS0ZBI DI DMS0ZBI DMS0ZBI DN Ag-221 DMS0ZBI TI TTDTWV0 DMS0ZBI TN Isocitrate dehydrogenase (IDH) DMS0ZBI MA Inhibitor DMS0ZBI RN New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma. Int J Med Sci. 2015; 12(3): 201-213. DMS0ZBI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4323358/ DMS1EQ7 DI DMS1EQ7 DMS1EQ7 DN PF-1228305 DMS1EQ7 TI TTKRD0G DMS1EQ7 TN Endothelin A receptor (EDNRA) DMS1EQ7 MA Antagonist DMS1EQ7 RN Pfizer. Product Development Pipeline. March 31 2009. DMS1EQ7 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMS1X67 DI DMS1X67 DMS1X67 DN Amitifadine DMS1X67 TI TT3ROYC DMS1X67 TN Serotonin transporter (SERT) DMS1X67 MA Inhibitor DMS1X67 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928). DMS1X67 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=928 DMS1X67 DI DMS1X67 DMS1X67 DN Amitifadine DMS1X67 TI TTVBI8W DMS1X67 TN Dopamine transporter (DAT) DMS1X67 MA Inhibitor DMS1X67 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927). DMS1X67 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=927 DMS1X67 DI DMS1X67 DMS1X67 DN Amitifadine DMS1X67 TI TTAWNKZ DMS1X67 TN Norepinephrine transporter (NET) DMS1X67 MA Inhibitor DMS1X67 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DMS1X67 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DMS2GA1 DI DMS2GA1 DMS2GA1 DN Bindarit DMS2GA1 TI TTNAY0P DMS2GA1 TN Monocyte chemotactic and activating factor (CCL2) DMS2GA1 MA Inhibitor DMS2GA1 RN Bindarit: an anti-inflammatory small molecule that modulates the NF B pathway. Cell Cycle. 2012 Jan 1;11(1):159-69. DMS2GA1 RU https://pubmed.ncbi.nlm.nih.gov/22189654 DMS2WV3 DI DMS2WV3 DMS2WV3 DN AIDSVAX DMS2WV3 TI TTBYP1X DMS2WV3 TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMS2WV3 RN HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen. Drugs R D. 2003;4(4):249-53. DMS2WV3 RU https://pubmed.ncbi.nlm.nih.gov/12848591 DMS57DJ DI DMS57DJ DMS57DJ DN Trimegestone/ethinyl estradiol DMS57DJ TI TTZAYWL DMS57DJ TN Estrogen receptor (ESR) DMS57DJ MA Modulator DMS57DJ RN Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. J Steroid Biochem Mol Biol. 2005 Mar;94(4):361-8. DMS57DJ RU https://pubmed.ncbi.nlm.nih.gov/15857755 DMS9503 DI DMS9503 DMS9503 DN Benzylpenicillin DMS9503 TI TT85JMW DMS9503 TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMS9503 MA Binder DMS9503 RN Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother. 2001 Jun;45(6):1693-9. DMS9503 RU https://pubmed.ncbi.nlm.nih.gov/11353613 DMS9503 DI DMS9503 DMS9503 DN Benzylpenicillin DMS9503 TI TTTKCMH DMS9503 TN Bacterial Penicillin binding protein 1 (Bact pbp) DMS9503 MA Binder DMS9503 RN Overexpression, purification and biochemical characterization of a class A high-molecular-mass penicillin-binding protein (PBP), PBP1* and its soluble derivative from Mycobacterium tuberculosis. Biochem J. 2002 Feb 1;361(Pt 3):635-9. DMS9503 RU https://pubmed.ncbi.nlm.nih.gov/11802794 DMS9GE1 DI DMS9GE1 DMS9GE1 DN MyoCell SDF-1 DMS9GE1 TI TT4UGTF DMS9GE1 TN Stromal cell-derived factor 1 (CXCL12) DMS9GE1 MA Modulator DMS9GE1 RN Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011 Feb;11(2):189-97. DMS9GE1 RU https://pubmed.ncbi.nlm.nih.gov/21219236 DMS9R43 DI DMS9R43 DMS9R43 DN Ecopipam DMS9R43 TI TTZFYLI DMS9R43 TN Dopamine D1 receptor (D1R) DMS9R43 MA Modulator DMS9R43 RN A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome.Clin Neuropharmacol.2014 Jan-Feb;37(1):26-30. DMS9R43 RU https://www.ncbi.nlm.nih.gov/pubmed/24434529 DMSCGM8 DI DMSCGM8 DMSCGM8 DN LentiGlobin DMSCGM8 TI TTM6HK1 DMSCGM8 TN Hemoglobin subunit beta (HBB) DMSCGM8 MA Modulator DMSCGM8 RN Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of beta-thalassemia and sickle cell disease. Curr Gene Ther. 2015;15(1):64-81. DMSCGM8 RU https://pubmed.ncbi.nlm.nih.gov/25429463 DMSDBPG DI DMSDBPG DMSDBPG DN KN046 DMSDBPG TI TTI2S1D DMSDBPG TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMSDBPG MA Inhibitor DMSDBPG RN Clinical pipeline report, company report or official report of Alphamab Oncology. DMSDBPG RU http://www.alphamabonc.com/pipeline/kn046.html DMSDBPG DI DMSDBPG DMSDBPG DN KN046 DMSDBPG TI TT8ZLTI DMSDBPG TN Programmed cell death 1 ligand 1 (PD-L1) DMSDBPG MA Inhibitor DMSDBPG RN Clinical pipeline report, company report or official report of Alphamab Oncology. DMSDBPG RU http://www.alphamabonc.com/pipeline/kn046.html DMSFX75 DI DMSFX75 DMSFX75 DN QVA-149 DMSFX75 TI TT2CJVK DMSFX75 TN Adrenergic receptor beta-2 (ADRB2) DMSFX75 MA Agonist DMSFX75 RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMSFX75 RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMSMFN2 DI DMSMFN2 DMSMFN2 DN GSK2140944 DMSMFN2 TI TT0IHXV DMSMFN2 TN DNA topoisomerase II (TOP2) DMSMFN2 MA Inhibitor DMSMFN2 RN Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent. J Clin Microbiol. 2014 Jul;52(7):2629-32. DMSMFN2 RU https://pubmed.ncbi.nlm.nih.gov/24759716 DMSO02K DI DMSO02K DMSO02K DN AMT-061 DMSO02K TI TTFEZ5Q DMSO02K TN Coagulation factor IX (F9) DMSO02K RN Clinical pipeline report, company report or official report of uniQure. DMSO02K RU http://uniqure.com/gene-therapy/hemophilia.php DMSP0X8 DI DMSP0X8 DMSP0X8 DN IDAZOXAN HYDROCHLORIDE DMSP0X8 TI TT2NUT5 DMSP0X8 TN Adrenergic receptor alpha-2C (ADRA2C) DMSP0X8 MA Modulator DMSP0X8 RN Different sites of action for alpha 2-adrenoceptor antagonists in the modulation of noradrenaline release and contraction response in the vas deferens of the rat. J Pharm Pharmacol. 1992 Mar;44(3):231-4. DMSP0X8 RU https://pubmed.ncbi.nlm.nih.gov/1354730 DMSPN58 DI DMSPN58 DMSPN58 DN Clomethiazole DMSPN58 TI TTEX6LM DMSPN58 TN GABA(A) receptor gamma-3 (GABRG3) DMSPN58 MA Modulator DMSPN58 RN Electrophysiological actions of gamma-aminobutyric acid and clomethiazole on recombinant GABA(A) receptors. Eur J Pharmacol. 2002 Oct 11;452(3):255-62. DMSPN58 RU https://www.ncbi.nlm.nih.gov/pubmed/12359265 DMSRIT4 DI DMSRIT4 DMSRIT4 DN Lenzilumab DMSRIT4 TI TTPZGYX DMSRIT4 TN HUMAN colony-stimulating factor (GM-CSF) DMSRIT4 MA Inhibitor DMSRIT4 RN The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468. DMSRIT4 RU https://pubmed.ncbi.nlm.nih.gov/32317220 DMSW80U DI DMSW80U DMSW80U DN VM-202 DMSW80U TI TT4V2JM DMSW80U TN Hepatocyte growth factor (HGF) DMSW80U MA Modulator DMSW80U RN Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63. DMSW80U RU https://pubmed.ncbi.nlm.nih.gov/18620865 DMSY0NE DI DMSY0NE DMSY0NE DN CS1001 DMSY0NE TI TT8ZLTI DMSY0NE TN Programmed cell death 1 ligand 1 (PD-L1) DMSY0NE RN GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015. DMSY0NE RU https://pubmed.ncbi.nlm.nih.gov/33209620 DMSZPR3 DI DMSZPR3 DMSZPR3 DN Rolofylline DMSZPR3 TI TTK25J1 DMSZPR3 TN Adenosine A1 receptor (ADORA1) DMSZPR3 MA Antagonist DMSZPR3 RN Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72. DMSZPR3 RU https://pubmed.ncbi.nlm.nih.gov/19196240 DMT0A3Y DI DMT0A3Y DMT0A3Y DN APD-334 DMT0A3Y TI TT9JZCK DMT0A3Y TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMT0A3Y MA Agonist DMT0A3Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT0A3Y RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMT4K0Z DI DMT4K0Z DMT4K0Z DN L-citrulline DMT4K0Z TI TTI1PRE DMT4K0Z TN G-protein coupled receptor GPCR33 (GPRC6A) DMT4K0Z MA Agonist DMT4K0Z RN Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97. DMT4K0Z RU https://pubmed.ncbi.nlm.nih.gov/15576628 DMT4QHD DI DMT4QHD DMT4QHD DN GDC-0032 DMT4QHD TI TTEUNMR DMT4QHD TN PI3-kinase alpha (PIK3CA) DMT4QHD MA Modulator DMT4QHD RN Company report (BioOncology) DMT4QHD RU http://www.biooncology.com/pipeline-molecules/taselisib-gdc-0032 DMT4QHD DI DMT4QHD DMT4QHD DN GDC-0032 DMT4QHD TI TTHBTOP DMT4QHD TN PI3-kinase gamma (PIK3CG) DMT4QHD MA Inhibitor DMT4QHD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT4QHD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMT67EH DI DMT67EH DMT67EH DN Ibodutant DMT67EH TI TTYO0A3 DMT67EH TN Substance-K receptor (TACR2) DMT67EH MA Antagonist DMT67EH RN Antagonist profile of ibodutant at the tachykinin NK2 receptor in guinea pig isolated bronchi. Eur J Pharmacol. 2013 Nov 15;720(1-3):180-5. DMT67EH RU https://pubmed.ncbi.nlm.nih.gov/24436990 DMT71EX DI DMT71EX DMT71EX DN SSR-126517E DMT71EX TI TTCIHJA DMT71EX TN Coagulation factor Xa (F10) DMT71EX MA Inhibitor DMT71EX RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMT71EX RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMT8IAJ DI DMT8IAJ DMT8IAJ DN MK-8808 DMT8IAJ TI TTUE541 DMT8IAJ TN Leukocyte surface antigen Leu-16 (CD20) DMT8IAJ MA Agonist DMT8IAJ RN Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003 Oct 20;22(47):7359-68. DMT8IAJ RU https://pubmed.ncbi.nlm.nih.gov/14576843 DMT8J0I DI DMT8J0I DMT8J0I DN GSK1265744 DMT8J0I TI TT5FH9Y DMT8J0I TN Human immunodeficiency virus Integrase (HIV IN) DMT8J0I MA Inhibitor DMT8J0I RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMT8J0I RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMTCR2O DI DMTCR2O DMTCR2O DN Tecarfarin DMTCR2O TI TTEUC8H DMTCR2O TN Vitamin K epoxide reductase complex 1 (VKORC1) DMTCR2O MA Inhibitor DMTCR2O RN Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74. DMTCR2O RU https://pubmed.ncbi.nlm.nih.gov/20622200 DMTD7AB DI DMTD7AB DMTD7AB DN Pracinostat DMTD7AB TI TTBH0VX DMTD7AB TN Histone deacetylase (HDAC) DMTD7AB MA Modulator DMTD7AB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365). DMTD7AB RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8365 DMTGYSO DI DMTGYSO DMTGYSO DN Fasiglifam hemihydrate DMTGYSO TI TTB8FUC DMTGYSO TN Free fatty acid receptor 1 (GPR40) DMTGYSO MA Modulator DMTGYSO RN A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280. DMTGYSO RU https://pubmed.ncbi.nlm.nih.gov/24130766 DMTKRY1 DI DMTKRY1 DMTKRY1 DN Netivudine DMTKRY1 TI TTIU7X1 DMTKRY1 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMTKRY1 MA Modulator DMTKRY1 RN Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs. 1999 Feb;57(2):187-206. DMTKRY1 RU https://pubmed.ncbi.nlm.nih.gov/10188760 DMTL5Q0 DI DMTL5Q0 DMTL5Q0 DN Losartan DMTL5Q0 TI TTPKMXQ DMTL5Q0 TN HUMAN type-1 angiotensin II receptor (AGTR1) DMTL5Q0 MA Blocker DMTL5Q0 RN Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3. DMTL5Q0 RU https://pubmed.ncbi.nlm.nih.gov/32246101 DMTNQB0 DI DMTNQB0 DMTNQB0 DN CC-486 DMTNQB0 TI TTVDSZ0 DMTNQB0 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTNQB0 MA Inhibitor DMTNQB0 RN Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2003 Jan 16;46(2):210-3. DMTNQB0 RU https://pubmed.ncbi.nlm.nih.gov/12519059 DMTNQB0 DI DMTNQB0 DMTNQB0 DN CC-486 DMTNQB0 TI TT6S2FE DMTNQB0 TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMTNQB0 MA Inhibitor DMTNQB0 RN Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes. Leukemia. 2016 Apr;30(4):889-96. DMTNQB0 RU https://pubmed.ncbi.nlm.nih.gov/26442612 DMTNUJ8 DI DMTNUJ8 DMTNUJ8 DN E-2609 DMTNUJ8 TI TT8JRS7 DMTNUJ8 TN Beta-secretase (BACE) DMTNUJ8 MA Inhibitor DMTNUJ8 RN Targeting the beta secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 2014 March; 13(3): 319-329. DMTNUJ8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086426/ DMTNUJ8 DI DMTNUJ8 DMTNUJ8 DN E-2609 DMTNUJ8 TI TTJUNZF DMTNUJ8 TN Beta-secretase 1 (BACE1) DMTNUJ8 MA Inhibitor DMTNUJ8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTNUJ8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMTQJE0 DI DMTQJE0 DMTQJE0 DN RG3638 DMTQJE0 TI TTNDSF4 DMTQJE0 TN Proto-oncogene c-Met (MET) DMTQJE0 MA Modulator DMTQJE0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMTQJE0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMTSN8L DI DMTSN8L DMTSN8L DN PT005 DMTSN8L TI TT2CJVK DMTSN8L TN Adrenergic receptor beta-2 (ADRB2) DMTSN8L MA Agonist DMTSN8L RN Clinical pipeline report, company report or official report of Pearl Therapeutics. DMTSN8L RU http://www.pearltherapeutics.com/PT005 DMTSONL DI DMTSONL DMTSONL DN Claritin/Singulair DMTSONL TI TTGKOY9 DMTSONL TN Leukotriene CysLT1 receptor (CYSLTR1) DMTSONL MA Modulator DMTSONL RN Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001 Sep;108(3):E48. DMTSONL RU https://pubmed.ncbi.nlm.nih.gov/11533366 DMTUV7L DI DMTUV7L DMTUV7L DN GED-0301 DMTUV7L TI TT0J32Z DMTUV7L TN Smad7 messenger RNA (Smad7 mRNA) DMTUV7L MA Inhibitor DMTUV7L RN A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease. Aliment Pharmacol Ther. 2012 Nov;36(9):850-7. DMTUV7L RU https://pubmed.ncbi.nlm.nih.gov/22971085 DMTUV7L DI DMTUV7L DMTUV7L DN GED-0301 DMTUV7L TI TTW06P4 DMTUV7L TN Mothers against decapentaplegic homolog 7 (SMAD7) DMTUV7L MA Inhibitor DMTUV7L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTUV7L RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMTV7ZM DI DMTV7ZM DMTV7ZM DN Eptastigmine DMTV7ZM TI TT1RS9F DMTV7ZM TN Acetylcholinesterase (AChE) DMTV7ZM MA Inhibitor DMTV7ZM RN Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies. CNS Drug Rev. 2001 Winter;7(4):369-86. DMTV7ZM RU https://pubmed.ncbi.nlm.nih.gov/11830755 DMTV7ZM DI DMTV7ZM DMTV7ZM DN Eptastigmine DMTV7ZM TI TTEB0GD DMTV7ZM TN Cholinesterase (BCHE) DMTV7ZM MA Inhibitor DMTV7ZM RN Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85. DMTV7ZM RU https://pubmed.ncbi.nlm.nih.gov/16570913 DMTZ1A5 DI DMTZ1A5 DMTZ1A5 DN 13-cis-retinoic acid DMTZ1A5 TI TTOD7B3 DMTZ1A5 TN Retinoic acid receptor (RAR) DMTZ1A5 MA Modulator DMTZ1A5 RN 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000 Aug;115(2):321-7. DMTZ1A5 RU https://pubmed.ncbi.nlm.nih.gov/10951254 DMU2J7Y DI DMU2J7Y DMU2J7Y DN Ciltacabtagene autoleucel DMU2J7Y TI TTZ3P4W DMU2J7Y TN B-cell maturation protein (TNFRSF17) DMU2J7Y RN ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health. DMU2J7Y RU https://clinicaltrials.gov/ct2/show/NCT04181827 DMU2ZFK DI DMU2ZFK DMU2ZFK DN CT-2584 DMU2ZFK TI TTUAIKM DMU2ZFK TN Cholinephosphate cytidylyltransferase (PCYT1B) DMU2ZFK MA Modulator DMU2ZFK RN Pharmacological inhibition of phosphatidylcholine biosynthesis is associated with induction of phosphatidylinositol accumulation and cytolysis of neoplastic cell lines. Cancer Res. 2000 Sep 15;60(18):5204-13. DMU2ZFK RU https://pubmed.ncbi.nlm.nih.gov/11016649 DMU72KL DI DMU72KL DMU72KL DN ICP-022 DMU72KL TI TTGM6VW DMU72KL TN Tyrosine-protein kinase BTK (ATK) DMU72KL MA Inhibitor DMU72KL RN Clinical pipeline report, company report or official report of InnoCare Pharma. DMU72KL RU https://www.innocarepharma.com/en/pipeline/our-pipeline/ DMUE843 DI DMUE843 DMUE843 DN Hematide DMUE843 TI TTAUX24 DMUE843 TN Erythropoietin Receptor (EPOR) DMUE843 MA Agonist DMUE843 RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMUE843 RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMUES7Y DI DMUES7Y DMUES7Y DN AB154 DMUES7Y TI TTWNL74 DMUES7Y TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMUES7Y MA Inhibitor DMUES7Y RN Clinical pipeline report, company report or official report of Arcus Biosciences. DMUES7Y RU https://arcusbio.com/domvanalimab/ DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTF4E0J DMUF0BJ TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMUF0BJ MA Inhibitor DMUF0BJ RN Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16640326 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TT4H1MQ DMUF0BJ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMUF0BJ MA Inhibitor DMUF0BJ RN Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16934977 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTTVAFQ DMUF0BJ TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMUF0BJ MA Inhibitor DMUF0BJ RN Deconstructing cytisine: The syntheses of (+/-)-cyfusine and (+/-)-cyclopropylcyfusine, fused ring analogs of cytisine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2316-9. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/18356044 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TT5KPZR DMUF0BJ TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMUF0BJ MA Inhibitor DMUF0BJ RN Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16934977 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTLA931 DMUF0BJ TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMUF0BJ MA Inhibitor DMUF0BJ RN 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97. DMUF0BJ RU https://pubmed.ncbi.nlm.nih.gov/16171993 DMUF0BJ DI DMUF0BJ DMUF0BJ DN CYTISINE DMUF0BJ TI TTJSZTB DMUF0BJ TN Nicotinic acetylcholine receptor (nAChR) DMUF0BJ MA Antagonist DMUF0BJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUF0BJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMUHS5Q DI DMUHS5Q DMUHS5Q DN E-913 DMUHS5Q TI TT2CEJG DMUHS5Q TN C-C chemokine receptor type 5 (CCR5) DMUHS5Q MA Antagonist DMUHS5Q RN Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34. DMUHS5Q RU https://pubmed.ncbi.nlm.nih.gov/17920529 DMUIBV8 DI DMUIBV8 DMUIBV8 DN Azimilide DMUIBV8 TI TT1VOHK DMUIBV8 TN Potassium channel unspecific (KC) DMUIBV8 MA Modulator DMUIBV8 RN Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9. DMUIBV8 RU https://www.ncbi.nlm.nih.gov/pubmed/10730550 DMUNBMA DI DMUNBMA DMUNBMA DN MT-1621 DMUNBMA TI TT7KNZQ DMUNBMA TN Thymidine kinase 2 (Mt-TK2) DMUNBMA MA Replacement DMUNBMA RN Clinical pipeline report, company report or official report of Modis Therapeutics. DMUNBMA RU https://www.modistx.com/product/ DMUNMY0 DI DMUNMY0 DMUNMY0 DN Ralfinamide DMUNMY0 TI TT4FDG6 DMUNMY0 TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMUNMY0 MA Blocker DMUNMY0 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMUNMY0 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMUNMY0 DI DMUNMY0 DMUNMY0 DN Ralfinamide DMUNMY0 TI TTRK8B9 DMUNMY0 TN Sodium channel unspecific (NaC) DMUNMY0 MA Blocker DMUNMY0 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMUNMY0 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMUOFAC DI DMUOFAC DMUOFAC DN Balixafortide DMUOFAC TI TTBID49 DMUOFAC TN C-X-C chemokine receptor type 4 (CXCR4) DMUOFAC MA Antagonist DMUOFAC RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DMUOFAC RU https://pubmed.ncbi.nlm.nih.gov/30072728 DMUP5Z0 DI DMUP5Z0 DMUP5Z0 DN PF-03084014 DMUP5Z0 TI TT9W8GU DMUP5Z0 TN Gamma-secretase (GS) DMUP5Z0 MA Modulator DMUP5Z0 RN Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.J Pharmacol Exp Ther.2010 Jul;334(1):269-77. DMUP5Z0 RU https://www.ncbi.nlm.nih.gov/pubmed/20363853 DMUP5Z0 DI DMUP5Z0 DMUP5Z0 DN PF-03084014 DMUP5Z0 TI TTE4KHA DMUP5Z0 TN Amyloid beta A4 protein (APP) DMUP5Z0 MA Inhibitor DMUP5Z0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUP5Z0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMUQ1DO DI DMUQ1DO DMUQ1DO DN ITI-007 DMUQ1DO TI TT3ROYC DMUQ1DO TN Serotonin transporter (SERT) DMUQ1DO MA Antagonist DMUQ1DO RN Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc. DMUQ1DO RU http://www.intracellulartherapies.com/products-technology/iti-007.html DMUQ1DO DI DMUQ1DO DMUQ1DO DN ITI-007 DMUQ1DO TI TTJQOD7 DMUQ1DO TN 5-HT 2A receptor (HTR2A) DMUQ1DO MA Antagonist DMUQ1DO RN Clinical pipeline report, company report or official report of Intra-Cellular Therapies, Inc. DMUQ1DO RU http://www.intracellulartherapies.com/products-technology/iti-007.html DMUQ1DO DI DMUQ1DO DMUQ1DO DN ITI-007 DMUQ1DO TI TT85JO3 DMUQ1DO TN 5-HT receptor (5HTR) DMUQ1DO MA Antagonist DMUQ1DO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUQ1DO RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMUQ390 DI DMUQ390 DMUQ390 DN Murepavadin DMUQ390 TI TTJZ7GF DMUQ390 TN Pseudomonas LPS-assembly protein LptD (Pseudo lptD) DMUQ390 MA Antagonist DMUQ390 RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DMUQ390 RU https://pubmed.ncbi.nlm.nih.gov/30072728 DMUS1F8 DI DMUS1F8 DMUS1F8 DN Inolimomab DMUS1F8 TI TT10Y9E DMUS1F8 TN Interleukin 2 receptor alpha (IL2RA) DMUS1F8 MA Modulator DMUS1F8 RN Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease.Biol Blood Marrow Transplant.2006 Nov;12(11):1135-41. DMUS1F8 RU https://www.ncbi.nlm.nih.gov/pubmed/17085306 DMUVMWZ DI DMUVMWZ DMUVMWZ DN Carebastine DMUVMWZ TI TTTIBOJ DMUVMWZ TN Histamine H1 receptor (H1R) DMUVMWZ MA Antagonist DMUVMWZ RN Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20. DMUVMWZ RU https://pubmed.ncbi.nlm.nih.gov/16083326 DMUVSG4 DI DMUVSG4 DMUVSG4 DN Sasanlimab DMUVSG4 TI TTNBFWK DMUVSG4 TN Programmed cell death protein 1 (PD-1) DMUVSG4 RN Pharmacologic Properties and Preclinical Activity of Sasanlimab, A High-affinity Engineered Anti-Human PD-1 Antibody. Mol Cancer Ther. 2020 Oct;19(10):2105-2116. DMUVSG4 RU https://pubmed.ncbi.nlm.nih.gov/32847983 DMUVZAO DI DMUVZAO DMUVZAO DN GSK642444 DMUVZAO TI TT2CJVK DMUVZAO TN Adrenergic receptor beta-2 (ADRB2) DMUVZAO MA Agonist DMUVZAO RN Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651. DMUVZAO RU https://pubmed.ncbi.nlm.nih.gov/28919714 DMUWXEB DI DMUWXEB DMUWXEB DN QPI-1007 DMUWXEB TI TT12VNG DMUWXEB TN Caspase 2 messenger RNA (CASP2 mRNA) DMUWXEB RN Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014 Aug;24(4):258-66. DMUWXEB RU https://pubmed.ncbi.nlm.nih.gov/25054518 DMUX7Z8 DI DMUX7Z8 DMUX7Z8 DN DE-117 DMUX7Z8 TI TT1ZAVI DMUX7Z8 TN Prostaglandin E2 receptor EP2 (PTGER2) DMUX7Z8 MA Agonist DMUX7Z8 RN Clinical pipeline report, company report or official report of Santen Pharmaceutical. DMUX7Z8 RU http://www.santeninc.com/research/moa/ DMUYOC8 DI DMUYOC8 DMUYOC8 DN AP12009 DMUYOC8 TI TTY9TWO DMUYOC8 TN Transforming growth factor beta 2 (TGFB2) DMUYOC8 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMUYOC8 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMV1SOR DI DMV1SOR DMV1SOR DN AVP-786 DMV1SOR TI TT3ROYC DMV1SOR TN Serotonin transporter (SERT) DMV1SOR MA Modulator DMV1SOR RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMV1SOR RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMV1SOR DI DMV1SOR DMV1SOR DN AVP-786 DMV1SOR TI TT5TPI6 DMV1SOR TN Opioid receptor sigma 1 (OPRS1) DMV1SOR MA Modulator DMV1SOR RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMV1SOR RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMV3DHQ DI DMV3DHQ DMV3DHQ DN IDDBCP161883 DMV3DHQ TI TTDIGC1 DMV3DHQ TN Dipeptidyl peptidase 4 (DPP-4) DMV3DHQ MA Inhibitor DMV3DHQ RN Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2013 May 6;6:187-95. DMV3DHQ RU https://pubmed.ncbi.nlm.nih.gov/23671395 DMV574J DI DMV574J DMV574J DN CSL312 DMV574J TI TTMXD0O DMV574J TN Coagulation factor XII (F12) DMV574J MA Inhibitor DMV574J RN Clinical pipeline report, company report or official report of CSL Behring. DMV574J RU https://www.cslbehring.com/r-and-d/product-pipeline DMV7T64 DI DMV7T64 DMV7T64 DN Talactoferrin DMV7T64 TI TTSZDQU DMV7T64 TN Lactotransferrin (LTF) DMV7T64 MA Modulator DMV7T64 RN Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study. Am J Surg. 2007 Jan;193(1):49-54. DMV7T64 RU https://pubmed.ncbi.nlm.nih.gov/17188087 DMV8EXG DI DMV8EXG DMV8EXG DN PolyHeme DMV8EXG TI TTQO71U DMV8EXG TN Hemoglobin (HB) DMV8EXG MA Modulator DMV8EXG RN Blood substitutes- the polyheme trials. Mcgill J Med. 2008 January; 11(1): 59-65. DMV8EXG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2322929/ DMVA8KU DI DMVA8KU DMVA8KU DN ASP0113 DMVA8KU TI TTK938H DMVA8KU TN Cytomegalovirus Deoxyribonucleic acid (CMV DNA) DMVA8KU RN VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr Opin Mol Ther. 2009 Oct;11(5):572-8. DMVA8KU RU https://pubmed.ncbi.nlm.nih.gov/19806506 DMVBA7I DI DMVBA7I DMVBA7I DN Reparixin DMVBA7I TI TT30C9G DMVBA7I TN C-X-C chemokine receptor type 2 (CXCR2) DMVBA7I MA Modulator DMVBA7I RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMVBA7I RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMVBA7I DI DMVBA7I DMVBA7I DN Reparixin DMVBA7I TI TTMWT8Z DMVBA7I TN C-X-C chemokine receptor type 1 (CXCR1) DMVBA7I MA Modulator DMVBA7I RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMVBA7I RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMVDCGZ DI DMVDCGZ DMVDCGZ DN Pyridoxamine DMVDCGZ TI TTMO9HF DMVDCGZ TN Advanced glycosylation end product receptor (AGER) DMVDCGZ MA Inhibitor DMVDCGZ RN Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett. 2010 Sep;17(9):1177-81. DMVDCGZ RU https://pubmed.ncbi.nlm.nih.gov/20441560 DMVEHM4 DI DMVEHM4 DMVEHM4 DN Phentermine+topiramate DMVEHM4 TI TTNJYV2 DMVEHM4 TN Gamma-aminobutyric acid receptor (GAR) DMVEHM4 MA Modulator DMVEHM4 RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMVEHM4 RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMVEHM4 DI DMVEHM4 DMVEHM4 DN Phentermine+topiramate DMVEHM4 TI TTUNARX DMVEHM4 TN Carbonic anhydrase (CA) DMVEHM4 MA Inhibitor DMVEHM4 RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMVEHM4 RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMVHF8G DI DMVHF8G DMVHF8G DN Binodenoson DMVHF8G TI TTM2AOE DMVHF8G TN Adenosine A2a receptor (ADORA2A) DMVHF8G MA Agonist DMVHF8G RN Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12. DMVHF8G RU https://pubmed.ncbi.nlm.nih.gov/17531571 DMVHRL8 DI DMVHRL8 DMVHRL8 DN Alfimeprase DMVHRL8 TI TTWODQF DMVHRL8 TN Fibrin (FG) DMVHRL8 MA Modulator DMVHRL8 RN Disulfide structure of alfimeprase: A recombinant analog of fibrolase. Protein Sci. 2001 June; 10(6): 1264-1267. DMVHRL8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374009/ DMVHZDP DI DMVHZDP DMVHZDP DN PF-06439535 DMVHZDP TI TT9HKJA DMVHZDP TN Vascular endothelial growth factor (VEGF) DMVHZDP RN National Cancer Institute Drug Dictionary (drug id 43234). DMVHZDP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=43234 DMVJNFI DI DMVJNFI DMVJNFI DN Spermidine DMVJNFI TI TTR7UJ3 DMVJNFI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMVJNFI MA Inhibitor DMVJNFI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVJNFI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTS74QB DMVJW0S TN Inhibitor of apoptosis protein (hIAP) DMVJW0S MA Modulator DMVJW0S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7729). DMVJW0S RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7729 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTIRY6K DMVJW0S TN Cellular inhibitor of apoptosis 2 (BIRC3) DMVJW0S MA Inhibitor DMVJW0S RN Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51. DMVJW0S RU https://pubmed.ncbi.nlm.nih.gov/25520882 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTR7B60 DMVJW0S TN X-linked inhibitor of apoptosis protein (XIAP) DMVJW0S MA Inhibitor DMVJW0S RN Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51. DMVJW0S RU https://pubmed.ncbi.nlm.nih.gov/25520882 DMVJW0S DI DMVJW0S DMVJW0S DN AT-406 DMVJW0S TI TTQ5LRD DMVJW0S TN Cellular inhibitor of apoptosis 1 (BIRC2) DMVJW0S MA Inhibitor DMVJW0S RN Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung c... Am J Cancer Res. 2014 Nov 19;4(6):943-51. DMVJW0S RU https://pubmed.ncbi.nlm.nih.gov/25520882 DMVKL3B DI DMVKL3B DMVKL3B DN Ravulizumab DMVKL3B TI TTN0GJ5 DMVKL3B TN HUMAN complement C5 protein (C5) DMVKL3B MA Inhibitor DMVKL3B RN Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. DMVKL3B RU https://pubmed.ncbi.nlm.nih.gov/32327719 DMVLKDX DI DMVLKDX DMVLKDX DN Streptokinase rectal suppository DMVLKDX TI TT2VCLI DMVLKDX TN Streptococcus Streptokinase (Stre-coc skc) DMVLKDX MA Modulator DMVLKDX RN Pharmacovigilance program to monitor adverse reactions of recombinant streptokinase in acute myocardial infarction. BMC Clin Pharmacol. 2005 Nov 2;5:5. DMVLKDX RU https://www.ncbi.nlm.nih.gov/pubmed/16262910 DMVLWG7 DI DMVLWG7 DMVLWG7 DN Ad5FGF-4 DMVLWG7 TI TTCEKVZ DMVLWG7 TN Fibroblast growth factor-4 (FGF4) DMVLWG7 MA Modulator DMVLWG7 RN Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am J Cardiol. 2003 Nov 7;92(9B):24N-31N. DMVLWG7 RU https://pubmed.ncbi.nlm.nih.gov/14615023 DMVO1C0 DI DMVO1C0 DMVO1C0 DN NBI-98854 DMVO1C0 TI TTNZRI3 DMVO1C0 TN Synaptic vesicle amine transporter (SLC18A2) DMVO1C0 MA Inhibitor DMVO1C0 RN NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7. DMVO1C0 RU https://pubmed.ncbi.nlm.nih.gov/26346941 DMVO7UW DI DMVO7UW DMVO7UW DN Siltuximab DMVO7UW TI TTJH4Y5 DMVO7UW TN HUMAN interleukin 6 (IL6) DMVO7UW MA Inhibitor DMVO7UW RN Siltuximab. In: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. 2018 Dec 3. DMVO7UW RU https://pubmed.ncbi.nlm.nih.gov/29999789 DMVOY6B DI DMVOY6B DMVOY6B DN AMD-070 DMVOY6B TI TTBID49 DMVOY6B TN C-X-C chemokine receptor type 4 (CXCR4) DMVOY6B MA Antagonist DMVOY6B RN Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):559-65. DMVOY6B RU https://pubmed.ncbi.nlm.nih.gov/18362694 DMVP7HI DI DMVP7HI DMVP7HI DN Nestorone DMVP7HI TI TTUV8G9 DMVP7HI TN Progesterone receptor (PGR) DMVP7HI MA Agonist DMVP7HI RN Efficacy of the selective progesterone receptor agonist Nestorone for chronic experimental autoimmune encephalomyelitis. J Neuroimmunol. 2014 Nov 15;276(1-2):89-97. DMVP7HI RU https://pubmed.ncbi.nlm.nih.gov/25200475 DMVQ5X1 DI DMVQ5X1 DMVQ5X1 DN Roclatan DMVQ5X1 TI TTAWNKZ DMVQ5X1 TN Norepinephrine transporter (NET) DMVQ5X1 MA Modulator DMVQ5X1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMVQ5X1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMVQ5X1 DI DMVQ5X1 DMVQ5X1 DN Roclatan DMVQ5X1 TI TTMQO60 DMVQ5X1 TN Rho-associated protein kinase (ROCK) DMVQ5X1 MA Modulator DMVQ5X1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMVQ5X1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMVSX6O DI DMVSX6O DMVSX6O DN Tebipenem DMVSX6O TI TT6OEDT DMVSX6O TN Cannabinoid receptor 1 (CB1) DMVSX6O MA Antagonist DMVSX6O RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMVSX6O RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMVU687 DI DMVU687 DMVU687 DN Esketamine DMVU687 TI TT9IK2Z DMVU687 TN N-methyl-D-aspartate receptor (NMDAR) DMVU687 MA Antagonist DMVU687 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVU687 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMVU8RW DI DMVU8RW DMVU8RW DN PRT4445 DMVU8RW TI TTCIHJA DMVU8RW TN Coagulation factor Xa (F10) DMVU8RW MA Modulator DMVU8RW RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMVU8RW RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMVXUR0 DI DMVXUR0 DMVXUR0 DN Magrolimab DMVXUR0 TI TTN2JFW DMVXUR0 TN T-cell surface glycoprotein CD4 (CD4) DMVXUR0 MA Inhibitor DMVXUR0 RN Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791. DMVXUR0 RU https://pubmed.ncbi.nlm.nih.gov/33423844 DMVY0BU DI DMVY0BU DMVY0BU DN Apaziquone DMVY0BU TI TTUTN1I DMVY0BU TN Human Deoxyribonucleic acid (hDNA) DMVY0BU MA Modulator DMVY0BU RN EO9 (Apaziquone): from the clinic to the laboratory and back again DMVY0BU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569998 DMVZ57G DI DMVZ57G DMVZ57G DN MD1003 DMVZ57G TI TTSXVID DMVZ57G TN Nuclear factor NF-kappa-B (NFKB) DMVZ57G MA Inhibitor DMVZ57G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVZ57G RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMW34B1 DI DMW34B1 DMW34B1 DN BL-8040 DMW34B1 TI TTBID49 DMW34B1 TN C-X-C chemokine receptor type 4 (CXCR4) DMW34B1 MA Antagonist DMW34B1 RN The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells. November 15, 2013; Blood: 122 (21). DMW34B1 RU http://www.bloodjournal.org/content/122/21/3939?sso-checked=true DMW5PHL DI DMW5PHL DMW5PHL DN Taberminogene vadenovec DMW5PHL TI TTDCBX5 DMW5PHL TN Vascular endothelial growth factor receptor 3 (FLT-4) DMW5PHL MA Modulator DMW5PHL RN Advances in kinase targeting: current clinical use and clinical trials. Trends Pharmacol Sci. 2014 Nov;35(11):604-20. DMW5PHL RU https://pubmed.ncbi.nlm.nih.gov/25312588 DMW63TQ DI DMW63TQ DMW63TQ DN PF-06741086 DMW63TQ TI TT068JH DMW63TQ TN Tissue factor pathway inhibitor (TFPI) DMW63TQ MA Inhibitor DMW63TQ RN Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46. DMW63TQ RU https://pubmed.ncbi.nlm.nih.gov/30927117 DMW6C81 DI DMW6C81 DMW6C81 DN Eltoprazine DMW6C81 TI TTSQIFT DMW6C81 TN 5-HT 1A receptor (HTR1A) DMW6C81 MA Agonist DMW6C81 RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMW6C81 RU http://www.jazzpharma.com/products/ DMW6C81 DI DMW6C81 DMW6C81 DN Eltoprazine DMW6C81 TI TTWJBZ5 DMW6C81 TN 5-HT 2C receptor (HTR2C) DMW6C81 MA Antagonist DMW6C81 RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMW6C81 RU http://www.jazzpharma.com/products/ DMW6C81 DI DMW6C81 DMW6C81 DN Eltoprazine DMW6C81 TI TTK8CXU DMW6C81 TN 5-HT 1B receptor (HTR1B) DMW6C81 MA Agonist DMW6C81 RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMW6C81 RU http://www.jazzpharma.com/products/ DMWA74Y DI DMWA74Y DMWA74Y DN Radotinib DMWA74Y TI TTS7G69 DMWA74Y TN Fusion protein Bcr-Abl (Bcr-Abl) DMWA74Y MA Modulator DMWA74Y RN Danusertib, an aurora kinase inhibitor.Expert Opin Investig Drugs.2012 Mar;21(3):383-93. DMWA74Y RU https://www.ncbi.nlm.nih.gov/pubmed/22242557 DMWAHTN DI DMWAHTN DMWAHTN DN Cetilistat DMWAHTN TI TTKYZA9 DMWAHTN TN Gastric triacylglycerol lipase (LIPF) DMWAHTN MA Modulator DMWAHTN RN Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9. DMWAHTN RU https://pubmed.ncbi.nlm.nih.gov/16953261 DMWAL73 DI DMWAL73 DMWAL73 DN Albutropin DMWAL73 TI TTT3YKH DMWAL73 TN Somatotropin (GH1) DMWAL73 MA Modulator DMWAL73 RN Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur J Pharmacol. 2002 Dec 5;456(1-3):149-58. DMWAL73 RU https://pubmed.ncbi.nlm.nih.gov/12450581 DMWBZJD DI DMWBZJD DMWBZJD DN GDC-0068 DMWBZJD TI TTWTSCV DMWBZJD TN RAC-alpha serine/threonine-protein kinase (AKT1) DMWBZJD MA Inhibitor DMWBZJD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWBZJD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWD3IV DI DMWD3IV DMWD3IV DN Oseltamivir + hydroxychloroquine DMWD3IV TI TTD16BI DMWD3IV TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMWD3IV MA Inhibitor DMWD3IV RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMWD3IV RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMWD3IV DI DMWD3IV DMWD3IV DN Oseltamivir + hydroxychloroquine DMWD3IV TI TTZGK1R DMWD3IV TN HUMAN glycosylation of host receptor (GHR) DMWD3IV MA Inhibitor DMWD3IV RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMWD3IV RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMWD3IV DI DMWD3IV DMWD3IV DN Oseltamivir + hydroxychloroquine DMWD3IV TI TT3A1EZ DMWD3IV TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMWD3IV MA Inhibitor DMWD3IV RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMWD3IV RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMWDEFC DI DMWDEFC DMWDEFC DN Zatosetron maleate DMWDEFC TI TTNXLKE DMWDEFC TN 5-HT 3 receptor (5HT3R) DMWDEFC MA Modulator DMWDEFC RN Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999 Apr;19(2):125-31. DMWDEFC RU https://www.ncbi.nlm.nih.gov/pubmed/10211913 DMWE3SC DI DMWE3SC DMWE3SC DN ASC09 + ritonavir + oseltamivir DMWE3SC TI TT1D53B DMWE3SC TN COVID-19 3C-like protease (3CLpro) DMWE3SC MA Inhibitor DMWE3SC RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMWE3SC RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMWGRQD DI DMWGRQD DMWGRQD DN LU AE58054 DMWGRQD TI TTJS8PY DMWGRQD TN 5-HT 6 receptor (HTR6) DMWGRQD MA Enhancer DMWGRQD RN Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. DMWGRQD RU https://pubmed.ncbi.nlm.nih.gov/20569520 DMWL2XD DI DMWL2XD DMWL2XD DN GSK2402968 DMWL2XD TI TTWLFXU DMWL2XD TN Dystrophin messenger RNA (DMD mRNA) DMWL2XD MA Modulator DMWL2XD RN Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014 Oct;13(10):987-96. DMWL2XD RU https://pubmed.ncbi.nlm.nih.gov/25209738 DMWLF2X DI DMWLF2X DMWLF2X DN Ceftobiprole medocaril DMWLF2X TI TTJP4SM DMWLF2X TN Bacterial Penicillin binding protein (Bact PBP) DMWLF2X MA Binder DMWLF2X RN Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018 Sep;19(13):1503-1509. DMWLF2X RU https://pubmed.ncbi.nlm.nih.gov/30198789 DMWM4D0 DI DMWM4D0 DMWM4D0 DN TAS-120 DMWM4D0 TI TT0LF7H DMWM4D0 TN Fibroblast growth factor receptor (FGFR) DMWM4D0 MA Antagonist DMWM4D0 RN TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270. DMWM4D0 RU http://mct.aacrjournals.org/content/12/11_Supplement/A270.short DMWM4D0 DI DMWM4D0 DMWM4D0 DN TAS-120 DMWM4D0 TI TT5HU6Z DMWM4D0 TN Fibroblast growth factor (FGF) DMWM4D0 MA Inhibitor DMWM4D0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWM4D0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWMT5N DI DMWMT5N DMWMT5N DN VRS-317 DMWMT5N TI TTT3YKH DMWMT5N TN Somatotropin (GH1) DMWMT5N MA Modulator DMWMT5N RN Company report (Versartis) DMWMT5N RU http://www.versartis.com/content/productpipeline/vrs-317.htm DMWO5ZR DI DMWO5ZR DMWO5ZR DN Cediranib DMWO5ZR TI TTUTJGQ DMWO5ZR TN Vascular endothelial growth factor receptor 2 (KDR) DMWO5ZR MA Inhibitor DMWO5ZR RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMWO5ZR RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMWOF1E DI DMWOF1E DMWOF1E DN SKY59 DMWOF1E TI TTKANGO DMWOF1E TN Complement C5 (CO5) DMWOF1E MA Inhibitor DMWOF1E RN The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920. DMWOF1E RU https://pubmed.ncbi.nlm.nih.gov/31978221 DMWPA4L DI DMWPA4L DMWPA4L DN PF-07055480 DMWPA4L TI TT1290U DMWPA4L TN Coagulation factor VIII (F8) DMWPA4L MA Replacement DMWPA4L RN Clinical pipeline report, company report or official report of Pfizer. DMWPA4L RU https://www.pfizer.com/science/rare-diseases/pipeline DMWTPCA DI DMWTPCA DMWTPCA DN L-651582 DMWTPCA TI TTH18TF DMWTPCA TN Muscarinic acetylcholine receptor M5 (CHRM5) DMWTPCA MA Modulator DMWTPCA RN The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release. J Pharmacol Exp Ther. 1991 Jun;257(3):967-71. DMWTPCA RU https://pubmed.ncbi.nlm.nih.gov/1646332 DMWUN1S DI DMWUN1S DMWUN1S DN Drisapersen DMWUN1S TI TTWLFXU DMWUN1S TN Dystrophin messenger RNA (DMD mRNA) DMWUN1S RN PRO-051, an antisense oligonucleotide for the potential treatment of Duchenne muscular dystrophy. Curr Opin Mol Ther. 2010 Aug;12(4):478-86. DMWUN1S RU https://pubmed.ncbi.nlm.nih.gov/20677099 DMWX90U DI DMWX90U DMWX90U DN Gantenerumab DMWX90U TI TTE4KHA DMWX90U TN Amyloid beta A4 protein (APP) DMWX90U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWX90U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWYPZF DI DMWYPZF DMWYPZF DN BAY-35-3377 DMWYPZF TI TTN6J5F DMWYPZF TN Bacterial DNA gyrase (Bact gyrase) DMWYPZF MA Inhibitor DMWYPZF RN Antibiotics in the clinical pipeline in 2013. J Antibiot (Tokyo). 2013 Oct;66(10):571-91. DMWYPZF RU https://pubmed.ncbi.nlm.nih.gov/24002361 DMWZ2TU DI DMWZ2TU DMWZ2TU DN CO-1686 DMWZ2TU TI TTGKNB4 DMWZ2TU TN Epidermal growth factor receptor (EGFR) DMWZ2TU MA Modulator DMWZ2TU RN Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9. DMWZ2TU RU https://pubmed.ncbi.nlm.nih.gov/25923550 DMWZIRJ DI DMWZIRJ DMWZIRJ DN LY404039 DMWZIRJ TI TT8A9EF DMWZIRJ TN Metabotropic glutamate receptor 3 (mGluR3) DMWZIRJ MA Agonist DMWZIRJ RN Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia. Expert Opin Ther Pat. 2009 Sep;19(9):1259-75. DMWZIRJ RU https://pubmed.ncbi.nlm.nih.gov/19552508 DMX04CA DI DMX04CA DMX04CA DN VB-111 DMX04CA TI TTF0RCZ DMX04CA TN Apoptosis mediating surface antigen FAS (FAS) DMX04CA MA Modulator DMX04CA RN Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007. DMX04CA RU https://www.ncbi.nlm.nih.gov/pubmed/23589178 DMX04CA DI DMX04CA DMX04CA DN VB-111 DMX04CA TI TTG043C DMX04CA TN Tumor necrosis factor receptor type I (TNF-R1) DMX04CA MA Modulator DMX04CA RN Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.Clin Cancer Res.2013 Jul 15;19(14):3996-4007. DMX04CA RU https://www.ncbi.nlm.nih.gov/pubmed/23589178 DMX0O9U DI DMX0O9U DMX0O9U DN Lopinavir + ritonavir + favipiravir DMX0O9U TI TT1D53B DMX0O9U TN COVID-19 3C-like protease (3CLpro) DMX0O9U MA Inhibitor DMX0O9U RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMX0O9U RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMX0PWV DI DMX0PWV DMX0PWV DN Anti-IL-23 DMX0PWV TI TT6H4QR DMX0PWV TN Interleukin 23 receptor (IL23R) DMX0PWV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293). DMX0PWV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293 DMX178V DI DMX178V DMX178V DN 177-Lu-PSMA-617 DMX178V TI TT9G4N0 DMX178V TN Glutamate carboxypeptidase II (GCPII) DMX178V MA Agonist DMX178V RN Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus. 2020 Jun 30;12(6):e8921. DMX178V RU https://pubmed.ncbi.nlm.nih.gov/32760622 DMX36BH DI DMX36BH DMX36BH DN Andolast DMX36BH TI TT1VOHK DMX36BH TN Potassium channel unspecific (KC) DMX36BH MA Opener DMX36BH RN BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46. DMX36BH RU https://pubmed.ncbi.nlm.nih.gov/18473808 DMX7BM4 DI DMX7BM4 DMX7BM4 DN Efaproxyn DMX7BM4 TI TTQO71U DMX7BM4 TN Hemoglobin (HB) DMX7BM4 MA Inhibitor DMX7BM4 RN Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1503-9. DMX7BM4 RU https://pubmed.ncbi.nlm.nih.gov/15817356 DMX9K3W DI DMX9K3W DMX9K3W DN Cetraxal Otic DMX9K3W TI TT1WJCI DMX9K3W TN Streptococcus Topoisomerase IV A (Stre-coc parC) DMX9K3W MA Modulator DMX9K3W RN DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33. DMX9K3W RU https://pubmed.ncbi.nlm.nih.gov/20534341 DMX9K3W DI DMX9K3W DMX9K3W DN Cetraxal Otic DMX9K3W TI TTE72ID DMX9K3W TN Haemophilus influenzae DNA gyrase A (Hae-influ gyrA) DMX9K3W MA Modulator DMX9K3W RN DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010 May 28;17(5):421-33. DMX9K3W RU https://pubmed.ncbi.nlm.nih.gov/20534341 DMX9YLR DI DMX9YLR DMX9YLR DN Pridopidine DMX9YLR TI TTEX248 DMX9YLR TN Dopamine D2 receptor (D2R) DMX9YLR MA Modulator DMX9YLR RN Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease. Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4. DMX9YLR RU https://pubmed.ncbi.nlm.nih.gov/20616707 DMXAO4J DI DMXAO4J DMXAO4J DN SAR153191 DMXAO4J TI TT0E5SK DMXAO4J TN Interleukin 6 receptor (IL6R) DMXAO4J MA Antagonist DMXAO4J RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMXAO4J RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMXAZ47 DI DMXAZ47 DMXAZ47 DN HGH-CTP DMXAZ47 TI TTT3YKH DMXAZ47 TN Somatotropin (GH1) DMXAZ47 MA Agonist DMXAZ47 RN Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9: 3527-3538. DMXAZ47 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122423/ DMXBHR6 DI DMXBHR6 DMXBHR6 DN Balaglitazone DMXBHR6 TI TTZMAO3 DMXBHR6 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMXBHR6 MA Modulator DMXBHR6 RN Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97. DMXBHR6 RU https://www.ncbi.nlm.nih.gov/pubmed/22372600 DMXGE3O DI DMXGE3O DMXGE3O DN SAR408701 DMXGE3O TI TTY6DTE DMXGE3O TN Carcinoembryonic antigen CEA (CD66e) DMXGE3O RN ClinicalTrials.gov (NCT02187848) Evaluation of SAR408701 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. DMXGE3O RU https://clinicaltrials.gov/ct2/show/NCT02187848 DMXHI89 DI DMXHI89 DMXHI89 DN Velac Gel DMXHI89 TI TTOD7B3 DMXHI89 TN Retinoic acid receptor (RAR) DMXHI89 MA Inhibitor DMXHI89 RN Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74. DMXHI89 RU https://pubmed.ncbi.nlm.nih.gov/1652368 DMXJMKF DI DMXJMKF DMXJMKF DN Ganaxolone DMXJMKF TI TTGXH6N DMXJMKF TN GABA(A) receptor delta (GABRD) DMXJMKF MA Modulator DMXJMKF RN Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence. Ann Neurol. 1998 Oct;44(4):688-91. DMXJMKF RU https://www.ncbi.nlm.nih.gov/pubmed/9778270 DMXJMKF DI DMXJMKF DMXJMKF DN Ganaxolone DMXJMKF TI TTEX6LM DMXJMKF TN GABA(A) receptor gamma-3 (GABRG3) DMXJMKF MA Agonist DMXJMKF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXJMKF RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMXLGED DI DMXLGED DMXLGED DN esuberaprost DMXLGED TI TTOFYT1 DMXLGED TN Prostacyclin receptor (PTGIR) DMXLGED MA Agonist DMXLGED RN Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9. DMXLGED RU https://pubmed.ncbi.nlm.nih.gov/2665758 DMXNZQK DI DMXNZQK DMXNZQK DN SUN-101 DMXNZQK TI TTOXS3C DMXNZQK TN Muscarinic acetylcholine receptor (CHRM) DMXNZQK MA Inhibitor DMXNZQK RN Long-acting bronchodilators in COPD: Where are we now and where are we going Breathe 06/2014; 10(2):110-120. DMXNZQK RU http://breathe.ersjournals.com/content/10/2/110 DMXU4ON DI DMXU4ON DMXU4ON DN Synthetic hypericin DMXU4ON TI TTYVX59 DMXU4ON TN Protein kinase C (PRKC) DMXU4ON MA Inhibitor DMXU4ON RN Characterization of the interaction of hypericin with protein kinase C in U-87 MG human glioma cells. Photochem Photobiol. 2006 May-Jun;82(3):720-8. DMXU4ON RU https://pubmed.ncbi.nlm.nih.gov/16396605 DMXY34J DI DMXY34J DMXY34J DN S-110 DMXY34J TI TT6S2FE DMXY34J TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMXY34J MA Inhibitor DMXY34J RN S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth. Mol Cancer Ther. 2010 May;9(5):1443-50. DMXY34J RU https://pubmed.ncbi.nlm.nih.gov/20442312 DMXY34J DI DMXY34J DMXY34J DN S-110 DMXY34J TI TTHVCUP DMXY34J TN DNA [cytosine-5]-methyltransferase (DNMT) DMXY34J MA Inhibitor DMXY34J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXY34J RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMXYM1H DI DMXYM1H DMXYM1H DN Visilizumab DMXYM1H TI TTBMAOZ DMXYM1H TN Regulatory protein unspecific (RGP) DMXYM1H RN Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol. 2008 Jun;127(3):322-9. DMXYM1H RU https://pubmed.ncbi.nlm.nih.gov/18424236 DMXYRPO DI DMXYRPO DMXYRPO DN Act1 DMXYRPO TI TT4F7SL DMXYRPO TN Gap junction alpha-1 protein (GJA1) DMXYRPO MA Modulator DMXYRPO RN Company report (FirstString Research) DMXYRPO RU http://firststringresearch.com/platform-technology/ DMXZ9T3 DI DMXZ9T3 DMXZ9T3 DN AC-170 DMXZ9T3 TI TTTIBOJ DMXZ9T3 TN Histamine H1 receptor (H1R) DMXZ9T3 MA Antagonist DMXZ9T3 RN Clinical pipeline report, company report or official report of NicOx SA. DMXZ9T3 RU http://www.nicox.com/rd/ac-170/ DMXZAL2 DI DMXZAL2 DMXZAL2 DN Hydroxychloroquine DMXZAL2 TI TTD16BI DMXZAL2 TN HUMAN pH-dependent viral fusion/replication (pH-DVF/R) DMXZAL2 MA Inhibitor DMXZAL2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMXZAL2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMXZAL2 DI DMXZAL2 DMXZAL2 DN Hydroxychloroquine DMXZAL2 TI TTZGK1R DMXZAL2 TN HUMAN glycosylation of host receptor (GHR) DMXZAL2 MA Inhibitor DMXZAL2 RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMXZAL2 RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMXZAL2 DI DMXZAL2 DMXZAL2 DN Hydroxychloroquine DMXZAL2 TI TT3A1EZ DMXZAL2 TN HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway) DMXZAL2 MA Inhibitor DMXZAL2 RN Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155-166. DMXZAL2 RU https://pubmed.ncbi.nlm.nih.gov/32034323 DMY60DT DI DMY60DT DMY60DT DN N8-GP DMY60DT TI TT1290U DMY60DT TN Coagulation factor VIII (F8) DMY60DT MA Modulator DMY60DT RN Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8. DMY60DT RU https://pubmed.ncbi.nlm.nih.gov/23398640 DMY7WH1 DI DMY7WH1 DMY7WH1 DN Sutimlimab DMY7WH1 TI TT7LRQH DMY7WH1 TN Complement C1s component (C1S) DMY7WH1 MA Inhibitor DMY7WH1 RN Antibodies to watch in 2020. MAbs. Jan-Dec 2020;12(1):1703531. DMY7WH1 RU https://pubmed.ncbi.nlm.nih.gov/31847708 DMY96O3 DI DMY96O3 DMY96O3 DN acelarin DMY96O3 TI TTUBNVO DMY96O3 TN DNA synthesis (DNA synth) DMY96O3 MA Inhibitor DMY96O3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY96O3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYA41S DI DMYA41S DMYA41S DN TNX-355 DMYA41S TI TTN2JFW DMYA41S TN T-cell surface glycoprotein CD4 (CD4) DMYA41S MA Binder DMYA41S RN Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. DMYA41S RU https://pubmed.ncbi.nlm.nih.gov/16182193 DMYHSO2 DI DMYHSO2 DMYHSO2 DN ABT-874 DMYHSO2 TI TTGW72V DMYHSO2 TN Interleukin-12 beta (IL12B) DMYHSO2 MA Modulator DMYHSO2 RN Briakinumab for the treatment of plaque psoriasis.BioDrugs.2012 Feb 1;26(1):9-20. DMYHSO2 RU https://www.ncbi.nlm.nih.gov/pubmed/22077474 DMYHV17 DI DMYHV17 DMYHV17 DN Sumanirole DMYHV17 TI TTEX248 DMYHV17 TN Dopamine D2 receptor (D2R) DMYHV17 MA Agonist DMYHV17 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMYHV17 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMYJ2QB DI DMYJ2QB DMYJ2QB DN D2A21 DMYJ2QB TI TTXT4D5 DMYJ2QB TN Bacterial Cell membrane (Bact CM) DMYJ2QB MA Modulator DMYJ2QB RN In Vitro Microbicidal Activities of Cecropin Peptides D2A21 and D4E1 and Gel Formulations Containing 0.1 to 2% D2A21 against Chlamydia trachomatis. Antimicrob Agents Chemother. 2002 January; 46(1): 34-41. DMYJ2QB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC126975/ DMYLT67 DI DMYLT67 DMYLT67 DN TKI258 DMYLT67 TI TTST7KB DMYLT67 TN Fibroblast growth factor receptor 3 (FGFR3) DMYLT67 MA Inhibitor DMYLT67 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMYLT67 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMYLT67 DI DMYLT67 DMYLT67 DN TKI258 DMYLT67 TI TTI2WET DMYLT67 TN Platelet-derived growth factor receptor (PDGFR) DMYLT67 MA Inhibitor DMYLT67 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMYLT67 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMYN391 DI DMYN391 DMYN391 DN Odevixibat DMYN391 TI TTPI1M5 DMYN391 TN Ileal sodium/bile acid cotransporter (SLC10A2) DMYN391 MA Inhibitor DMYN391 RN Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020 Sep;14(5):677-689. DMYN391 RU https://pubmed.ncbi.nlm.nih.gov/32653991 DMYN3IH DI DMYN3IH DMYN3IH DN AGI-1067 DMYN3IH TI TT1AVS7 DMYN3IH TN Second phase insulin secretion (SPI secr) DMYN3IH MA Inhibitor DMYN3IH RN AGI-1067, a novel antioxidant and anti-inflammatory agent, enhances insulin release and protects mouse islets. Mol Cell Endocrinol. 2010 Jul 29;323(2):246-55. DMYN3IH RU https://pubmed.ncbi.nlm.nih.gov/20211684 DMYNJHI DI DMYNJHI DMYNJHI DN Arc029 DMYNJHI TI TT7RGTM DMYNJHI TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMYNJHI MA Inhibitor DMYNJHI RN Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406. DMYNJHI RU https://pubmed.ncbi.nlm.nih.gov/2552119 DMYNJHI DI DMYNJHI DMYNJHI DN Arc029 DMYNJHI TI TTZIFHC DMYNJHI TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMYNJHI MA Inhibitor DMYNJHI RN Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406. DMYNJHI RU https://pubmed.ncbi.nlm.nih.gov/2552119 DMYTC4I DI DMYTC4I DMYTC4I DN NeuVax DMYTC4I TI TT6EO5L DMYTC4I TN Erbb2 tyrosine kinase receptor (HER2) DMYTC4I RN The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6(5):519-31. DMYTC4I RU https://pubmed.ncbi.nlm.nih.gov/24896623 DMYVBF6 DI DMYVBF6 DMYVBF6 DN Edasalonexent DMYVBF6 TI TTSXVID DMYVBF6 TN Nuclear factor NF-kappa-B (NFKB) DMYVBF6 MA Inhibitor DMYVBF6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYVBF6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMYX7VI DI DMYX7VI DMYX7VI DN Rintatolimod DMYX7VI TI TTD24Y0 DMYX7VI TN Toll-like receptor 3 (TLR3) DMYX7VI RN A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome. PLoS One. 2012;7(3):e31334. DMYX7VI RU https://pubmed.ncbi.nlm.nih.gov/22431963 DMYXOHV DI DMYXOHV DMYXOHV DN Rifalazil DMYXOHV TI TTIJ5EB DMYXOHV TN Bacterial RNA polymerase switch region (Bact RNAP-SR) DMYXOHV MA Inhibitor DMYXOHV RN Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. DMYXOHV RU https://pubmed.ncbi.nlm.nih.gov/17691942 DMZ1UOI DI DMZ1UOI DMZ1UOI DN Asp-015K DMZ1UOI TI TTT7PJU DMZ1UOI TN Janus kinase 3 (JAK-3) DMZ1UOI MA Inhibitor DMZ1UOI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). DMZ1UOI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049 DMZ1UOI DI DMZ1UOI DMZ1UOI DN Asp-015K DMZ1UOI TI TT6DM01 DMZ1UOI TN Janus kinase 1 (JAK-1) DMZ1UOI MA Inhibitor DMZ1UOI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047). DMZ1UOI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047 DMZ1UOI DI DMZ1UOI DMZ1UOI DN Asp-015K DMZ1UOI TI TTJSQEF DMZ1UOI TN Tyrosine-protein kinase (PTK) DMZ1UOI MA Inhibitor DMZ1UOI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ1UOI RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZ3P6C DI DMZ3P6C DMZ3P6C DN Teplizumab DMZ3P6C TI TTBMAOZ DMZ3P6C TN Regulatory protein unspecific (RGP) DMZ3P6C RN Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol. 2010 Oct;40(10):2891-901. DMZ3P6C RU https://pubmed.ncbi.nlm.nih.gov/21038470 DMZ3P6C DI DMZ3P6C DMZ3P6C DN Teplizumab DMZ3P6C TI TTV3XPL DMZ3P6C TN T-cell surface glycoprotein CD3 gamma (CD3G) DMZ3P6C MA Inhibitor DMZ3P6C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ3P6C RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMZ61IA DI DMZ61IA DMZ61IA DN Setipiprant DMZ61IA TI TTQDMX5 DMZ61IA TN Prostaglandin D2 receptor 2 (PTGDR2) DMZ61IA MA Antagonist DMZ61IA RN Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52. DMZ61IA RU https://pubmed.ncbi.nlm.nih.gov/24964348 DMZ61IA DI DMZ61IA DMZ61IA DN Setipiprant DMZ61IA TI TTNVEIR DMZ61IA TN Prostaglandin D2 receptor (PTGDR) DMZ61IA MA Antagonist DMZ61IA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ61IA RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMZ6VD5 DI DMZ6VD5 DMZ6VD5 DN M-518101 DMZ6VD5 TI TTUST1O DMZ6VD5 TN Phosphodiesterase (PDE) DMZ6VD5 MA Inhibitor DMZ6VD5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ6VD5 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZ7AMY DI DMZ7AMY DMZ7AMY DN Amivantamab DMZ7AMY TI TTNDSF4 DMZ7AMY TN Proto-oncogene c-Met (MET) DMZ7AMY MA Inhibitor DMZ7AMY RN Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. DMZ7AMY RU https://pubmed.ncbi.nlm.nih.gov/32414908 DMZ7AMY DI DMZ7AMY DMZ7AMY DN Amivantamab DMZ7AMY TI TTGKNB4 DMZ7AMY TN Epidermal growth factor receptor (EGFR) DMZ7AMY MA Inhibitor DMZ7AMY RN Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. DMZ7AMY RU https://pubmed.ncbi.nlm.nih.gov/32414908 DMZA2K0 DI DMZA2K0 DMZA2K0 DN INCSHR1210 DMZA2K0 TI TTNBFWK DMZA2K0 TN Programmed cell death protein 1 (PD-1) DMZA2K0 MA Inhibitor DMZA2K0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZA2K0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZA47Y DI DMZA47Y DMZA47Y DN Iomab-B DMZA47Y TI TTUS45N DMZA47Y TN Leukocyte common antigen (PTPRC) DMZA47Y RN Clinical pipeline report, company report or official report of Actinium Pharmaceuticals. DMZA47Y RU http://www.actiniumpharma.com/products/pipeline/iomab-b/ DMZARP1 DI DMZARP1 DMZARP1 DN FV-100 DMZARP1 TI TTP3QRF DMZARP1 TN Thymidine kinase 1 (TK1) DMZARP1 MA Inhibitor DMZARP1 RN Specific recognition of the bicyclic pyrimidine nucleoside analogs, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase. Mol Pharmacol. 2002 Feb;61(2):249-54. DMZARP1 RU https://pubmed.ncbi.nlm.nih.gov/11809847 DMZB9RI DI DMZB9RI DMZB9RI DN Arabaclofen DMZB9RI TI TTDCVZW DMZB9RI TN Gamma-aminobutyric acid B receptor (GABBR) DMZB9RI MA Agonist DMZB9RI RN Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84. DMZB9RI RU https://pubmed.ncbi.nlm.nih.gov/23436129 DMZBGI8 DI DMZBGI8 DMZBGI8 DN Tilarginine acetate DMZBGI8 TI TTCM4B3 DMZBGI8 TN Nitric-oxide synthase endothelial (NOS3) DMZBGI8 MA Modulator DMZBGI8 RN Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66. DMZBGI8 RU https://pubmed.ncbi.nlm.nih.gov/17387132 DMZE2JO DI DMZE2JO DMZE2JO DN SNS-595 DMZE2JO TI TT0IHXV DMZE2JO TN DNA topoisomerase II (TOP2) DMZE2JO MA Modulator DMZE2JO RN A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.Haematologica.2015 Feb;100(2):231-7. DMZE2JO RU https://www.ncbi.nlm.nih.gov/pubmed/25381131 DMZHN5B DI DMZHN5B DMZHN5B DN MIM-D3 DMZHN5B TI TTTDVOJ DMZHN5B TN Tropomyosin-related kinase A (TrkA) DMZHN5B MA Agonist DMZHN5B RN Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285. DMZHN5B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699314/ DMZIM37 DI DMZIM37 DMZIM37 DN CP-868596 DMZIM37 TI TT8FYO9 DMZIM37 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMZIM37 MA Modulator DMZIM37 RN The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9. DMZIM37 RU https://www.ncbi.nlm.nih.gov/pubmed/25597754 DMZIM37 DI DMZIM37 DMZIM37 DN CP-868596 DMZIM37 TI TT6PKBN DMZIM37 TN Proto-oncogene c-Src (SRC) DMZIM37 MA Inhibitor DMZIM37 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZIM37 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZJGVL DI DMZJGVL DMZJGVL DN CSL-654 DMZJGVL TI TTFEZ5Q DMZJGVL TN Coagulation factor IX (F9) DMZJGVL MA Modulator DMZJGVL RN Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood. 2012 September 20; 120(12): 2405-2411. DMZJGVL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448255/ DMZKGPV DI DMZKGPV DMZKGPV DN Gemigliptin DMZKGPV TI TTDIGC1 DMZKGPV TN Dipeptidyl peptidase 4 (DPP-4) DMZKGPV MA Inhibitor DMZKGPV RN Evaluation of the pharmacokinetics of the DPP-4 inhibitor gemigliptin when coadministered with rosuvastatin or irbesartan to healthy subjects. Curr Med Res Opin. 2015 Feb;31(2):229-41. DMZKGPV RU https://pubmed.ncbi.nlm.nih.gov/25350224 DMZKTYJ DI DMZKTYJ DMZKTYJ DN Enmetazobactam DMZKTYJ TI TTHI19T DMZKTYJ TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMZKTYJ MA Inhibitor DMZKTYJ RN Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20. DMZKTYJ RU https://pubmed.ncbi.nlm.nih.gov/32253209 DMZL1I8 DI DMZL1I8 DMZL1I8 DN Fidarestat DMZL1I8 TI TTFBNVI DMZL1I8 TN Aldose reductase (AKR1B1) DMZL1I8 MA Inhibitor DMZL1I8 RN Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82. DMZL1I8 RU https://pubmed.ncbi.nlm.nih.gov/11574441 DMZPEHY DI DMZPEHY DMZPEHY DN Multi-epitope peptide melanoma vaccine DMZPEHY TI TT362RB DMZPEHY TN MART-1 melanoma antigen (MLANA) DMZPEHY RN Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. DMZPEHY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/ DMZPEHY DI DMZPEHY DMZPEHY DN Multi-epitope peptide melanoma vaccine DMZPEHY TI TT8MK59 DMZPEHY TN Melanocytes lineage-specific antigen GP100 (PMEL) DMZPEHY RN Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. DMZPEHY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/ DMZPEHY DI DMZPEHY DMZPEHY DN Multi-epitope peptide melanoma vaccine DMZPEHY TI TTULVH8 DMZPEHY TN Tyrosinase (TYR) DMZPEHY RN Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650. DMZPEHY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483091/ DMZS2R7 DI DMZS2R7 DMZS2R7 DN Granexin gel DMZS2R7 TI TT4F7SL DMZS2R7 TN Gap junction alpha-1 protein (GJA1) DMZS2R7 MA Modulator DMZS2R7 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMZS2R7 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0798Z DI DM0798Z DM0798Z DN NLG8189 DM0798Z TI TTZJYKH DM0798Z TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM0798Z MA Inhibitor DM0798Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0798Z RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0ASTP DI DM0ASTP DM0ASTP DN Verapamil DM0ASTP TI TTHQJ2Y DM0ASTP TN HUMAN two pore channel subtype 2 (TPC2) DM0ASTP MA Blocker DM0ASTP RN Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. DM0ASTP RU https://pubmed.ncbi.nlm.nih.gov/32221306 DM0EFQS DI DM0EFQS DM0EFQS DN Plasminogen DM0EFQS TI TTP86E2 DM0EFQS TN Plasminogen (PLG) DM0EFQS MA Modulator DM0EFQS RN Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005 Apr;93(4):647-54. DM0EFQS RU https://pubmed.ncbi.nlm.nih.gov/15841308 DM0JETC DI DM0JETC DM0JETC DN Genistein DM0JETC TI TTOM3J0 DM0JETC TN Estrogen receptor beta (ESR2) DM0JETC MA Modulator DM0JETC RN Company report (Axcentua) DM0JETC RU http://axcentua.com/science/genistein/ DM0NZDT DI DM0NZDT DM0NZDT DN Pactimibe DM0NZDT TI TTMF541 DM0NZDT TN Liver carboxylesterase (CES1) DM0NZDT MA Inhibitor DM0NZDT RN Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and b... J Med Chem. 2008 Aug 14;51(15):4823-33. DM0NZDT RU https://pubmed.ncbi.nlm.nih.gov/18620381 DM12UX6 DI DM12UX6 DM12UX6 DN 131 I-omburtamab DM12UX6 TI TT6CQUM DM12UX6 TN B7 homolog 3 (CD276) DM12UX6 MA Inhibitor DM12UX6 RN IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177. DM12UX6 RU https://pubmed.ncbi.nlm.nih.gov/33047248 DM15VBJ DI DM15VBJ DM15VBJ DN Artemisone DM15VBJ TI TT9X7H4 DM15VBJ TN Beta-hematin formation (BHF) DM15VBJ MA Modulator DM15VBJ RN Anticancer Properties of Distinct Antimalarial Drug Classes. PLoS One. 2013; 8(12): e82962. DM15VBJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877007/ DM1LFUN DI DM1LFUN DM1LFUN DN Ravidasvir DM1LFUN TI TTCJ2X8 DM1LFUN TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM1LFUN MA Inhibitor DM1LFUN RN Clinical pipeline report, company report or official report of Presidio Pharmaceuticals. DM1LFUN RU http://www.presidiopharma.com/ DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTHQPL7 DM1QSM3 TN Carbonic anhydrase I (CA-I) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTZHA0O DM1QSM3 TN Carbonic anhydrase IV (CA-IV) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTUNARX DM1QSM3 TN Carbonic anhydrase (CA) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTSYM0R DM1QSM3 TN Carbonic anhydrase XII (CA-XII) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTANPDJ DM1QSM3 TN Carbonic anhydrase II (CA-II) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TTEYTKG DM1QSM3 TN Carbonic anhydrase XIV (CA-XIV) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1QSM3 DI DM1QSM3 DM1QSM3 DN Phenol DM1QSM3 TI TT2LVK8 DM1QSM3 TN Carbonic anhydrase IX (CA-IX) DM1QSM3 MA Inhibitor DM1QSM3 RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM1QSM3 RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM1SV8I DI DM1SV8I DM1SV8I DN PHN-131 DM1SV8I TI TTQW87Y DM1SV8I TN Opioid receptor kappa (OPRK1) DM1SV8I MA Agonist DM1SV8I RN Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402. DM1SV8I RU https://pubmed.ncbi.nlm.nih.gov/2826773 DM23ARP DI DM23ARP DM23ARP DN V-710 DM23ARP TI TTE0AHP DM23ARP TN Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB) DM23ARP RN Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA. 2013 Apr 3;309(13):1368-78. DM23ARP RU https://pubmed.ncbi.nlm.nih.gov/23549582 DM2U3MX DI DM2U3MX DM2U3MX DN VX-509 DM2U3MX TI TTT7PJU DM2U3MX TN Janus kinase 3 (JAK-3) DM2U3MX MA Inhibitor DM2U3MX RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DM2U3MX RU https://pubmed.ncbi.nlm.nih.gov/24818516 DM2YNMI DI DM2YNMI DM2YNMI DN MK-1654 DM2YNMI TI TT57ID8 DM2YNMI TN Respiratory syncytial virus protein F (RSV F) DM2YNMI MA Inhibitor DM2YNMI RN A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153. DM2YNMI RU https://pubmed.ncbi.nlm.nih.gov/31515478 DM30JWZ DI DM30JWZ DM30JWZ DN SM04554 DM30JWZ TI TTFPSHI DM30JWZ TN Wnt signaling pathway (Wnt pathway) DM30JWZ MA Modulator DM30JWZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM30JWZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM31L9K DI DM31L9K DM31L9K DN Sepofarsen DM31L9K TI TT3XBOV DM31L9K TN CEP290 messenger RNA (CEP290 mRNA) DM31L9K MA Inhibitor DM31L9K RN Clinical pipeline report, company report or official report of ProQR Therapeutics. DM31L9K RU https://www.proqr.com/pipeline DM31VZT DI DM31VZT DM31VZT DN CAD-106 DM31VZT TI TTE4KHA DM31VZT TN Amyloid beta A4 protein (APP) DM31VZT RN The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31. DM31VZT RU https://pubmed.ncbi.nlm.nih.gov/21697382 DM32148 DI DM32148 DM32148 DN CD19 CAR T cells DM32148 TI TTW640A DM32148 TN B-lymphocyte surface antigen B4 (CD19) DM32148 MA CAR-T-Cell-Therapy DM32148 RN ClinicalTrials.gov (NCT03391726) CART-19 Cells for R/R B-cell Lymphoma DM32148 RU https://clinicaltrials.gov/ct2/show/NCT03391726 DM36HBS DI DM36HBS DM36HBS DN ALXN1101 DM36HBS TI TTH13AB DM36HBS TN Cyclic pyranopterin monophosphate synthase (MOCS1) DM36HBS MA Modulator DM36HBS RN ClinicalTrials.gov (NCT02047461) Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP. U.S. National Institutes of Health. DM36HBS RU https://clinicaltrials.gov/ct2/show/NCT02047461 DM3827C DI DM3827C DM3827C DN AZD4547 DM3827C TI TTRLW2X DM3827C TN Fibroblast growth factor receptor 1 (FGFR1) DM3827C MA Modulator DM3827C RN AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012 Apr 15;72(8):2045-56. DM3827C RU https://pubmed.ncbi.nlm.nih.gov/22369928 DM3827C DI DM3827C DM3827C DN AZD4547 DM3827C TI TT0LF7H DM3827C TN Fibroblast growth factor receptor (FGFR) DM3827C MA Inhibitor DM3827C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3827C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3MJUS DI DM3MJUS DM3MJUS DN NBTX-001 DM3MJUS TI TT9IK2Z DM3MJUS TN N-methyl-D-aspartate receptor (NMDAR) DM3MJUS MA Antagonist DM3MJUS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3MJUS RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM45Z3P DI DM45Z3P DM45Z3P DN CD123/CLL1 CAR-T Cells DM45Z3P TI TTENHJ0 DM45Z3P TN Interleukin 3 receptor alpha (IL3RA) DM45Z3P MA CAR-T-Cell-Therapy(Dual specific) DM45Z3P RN ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML DM45Z3P RU https://clinicaltrials.gov/ct2/show/NCT03631576 DM45Z3P DI DM45Z3P DM45Z3P DN CD123/CLL1 CAR-T Cells DM45Z3P TI TT70N8V DM45Z3P TN Myeloid inhibitory C-type lectin-like receptor (CD371) DM45Z3P MA CAR-T-Cell-Therapy(Dual specific) DM45Z3P RN ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML DM45Z3P RU https://clinicaltrials.gov/ct2/show/NCT03631576 DM4H78P DI DM4H78P DM4H78P DN NT-501 DM4H78P TI TTT2F9E DM4H78P TN Ciliary neurotrophic factor receptor alpha (CNTFR) DM4H78P MA Modulator DM4H78P RN Clinical pipeline report, company report or official report of Neurotech. DM4H78P RU http://www.neurotechusa.com/cntfrenexus.html DM4OYXE DI DM4OYXE DM4OYXE DN LIAROZOLE DM4OYXE TI TTD7Q0R DM4OYXE TN Cytochrome P450 26 (CYP26A1) DM4OYXE MA Inhibitor DM4OYXE RN Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem. 2008 Sep 1;16(17):8301-13. DM4OYXE RU https://pubmed.ncbi.nlm.nih.gov/18722776 DM4OYXE DI DM4OYXE DM4OYXE DN LIAROZOLE DM4OYXE TI TTSZLWK DM4OYXE TN Aromatase (CYP19A1) DM4OYXE MA Inhibitor DM4OYXE RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM4OYXE RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM4WQBO DI DM4WQBO DM4WQBO DN VM-1500 DM4WQBO TI TT84ETX DM4WQBO TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4WQBO MA Inhibitor DM4WQBO RN 127 afety, pharmokinetics and efficacy of VM-1500, a novel reverse transcriptase inhibitor, In healthy volunteers and HIV-infected patients. J Acquir Immune Defic Syndr. 2014 April; 65(Suppl 2): 52. DM4WQBO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149639/ DM5G1NT DI DM5G1NT DM5G1NT DN VX-210 DM5G1NT TI TTXEVN8 DM5G1NT TN Transforming protein Rho (RHO) DM5G1NT MA Inhibitor DM5G1NT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5G1NT RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM5UJ9P DI DM5UJ9P DM5UJ9P DN IMU-838 DM5UJ9P TI TT3UY29 DM5UJ9P TN HUMAN dihydroorotate dehydrogenase (DHODH) DM5UJ9P MA Inhibitor DM5UJ9P RN IMU-838 Targeting DHODH DM5UJ9P RU https://www.immunic-therapeutics.com/imu838/ DM5WQ2U DI DM5WQ2U DM5WQ2U DN SR-123781A DM5WQ2U TI TTCIHJA DM5WQ2U TN Coagulation factor Xa (F10) DM5WQ2U MA Modulator DM5WQ2U RN SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60. DM5WQ2U RU https://pubmed.ncbi.nlm.nih.gov/11372679 DM5WQ2U DI DM5WQ2U DM5WQ2U DN SR-123781A DM5WQ2U TI TT6L509 DM5WQ2U TN Coagulation factor IIa (F2) DM5WQ2U MA Modulator DM5WQ2U RN SR123781A, a synthetic heparin mimetic. Thromb Haemost. 2001 May;85(5):852-60. DM5WQ2U RU https://pubmed.ncbi.nlm.nih.gov/11372679 DM5YHU2 DI DM5YHU2 DM5YHU2 DN Avoralstat DM5YHU2 TI TTJLNAW DM5YHU2 TN Tissue kallikrein (KLK2) DM5YHU2 MA Inhibitor DM5YHU2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5YHU2 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM5YHU2 DI DM5YHU2 DM5YHU2 DN Avoralstat DM5YHU2 TI TTDJ4MY DM5YHU2 TN Kininogen (KNG1) DM5YHU2 MA Inhibitor DM5YHU2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5YHU2 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM6GTMD DI DM6GTMD DM6GTMD DN ADX-48621 DM6GTMD TI TTHS256 DM6GTMD TN Metabotropic glutamate receptor 5 (mGluR5) DM6GTMD MA Modulator DM6GTMD RN Pipeline of Addex Pharma. Addex Pharma. 2009. DM6GTMD RU http://www.addexpharma.com/pipeline-old/adx48621/ DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTNDSF4 DM752PU TN Proto-oncogene c-Met (MET) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTDCBX5 DM752PU TN Vascular endothelial growth factor receptor 3 (FLT-4) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTUTJGQ DM752PU TN Vascular endothelial growth factor receptor 2 (KDR) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TT4DXQT DM752PU TN Proto-oncogene c-Ret (RET) DM752PU MA Inhibitor DM752PU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185). DM752PU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTNDSF4 DM752PU TN Proto-oncogene c-Met (MET) DM752PU MA Inhibitor DM752PU RN Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011 May 1;17(9):2638-45. DM752PU RU https://pubmed.ncbi.nlm.nih.gov/21242122 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TT4DXQT DM752PU TN Proto-oncogene c-Ret (RET) DM752PU MA Inhibitor DM752PU RN Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res. 2011 May 1;17(9):2638-45. DM752PU RU https://pubmed.ncbi.nlm.nih.gov/21242122 DM752PU DI DM752PU DM752PU DN MGCD516 DM752PU TI TTU8W4S DM752PU TN Protein kinase (PK) DM752PU MA Inhibitor DM752PU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM752PU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8D6O2 DI DM8D6O2 DM8D6O2 DN Nafamostat DM8D6O2 TI TTZ3COY DM8D6O2 TN COVID-19 spike glycoprotein (S) DM8D6O2 MA Inhibitor DM8D6O2 RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DM8D6O2 RU https://pubmed.ncbi.nlm.nih.gov/32127666 DM8D6O2 DI DM8D6O2 DM8D6O2 DN Nafamostat DM8D6O2 TI TT85VHW DM8D6O2 TN MERS-CoV spike glycoprotein (S) DM8D6O2 MA Inhibitor DM8D6O2 RN Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539. DM8D6O2 RU https://pubmed.ncbi.nlm.nih.gov/27550352 DM901ZW DI DM901ZW DM901ZW DN Naptumomab estafenatox DM901ZW TI TT70MLA DM901ZW TN Oncotrophoblast glycoprotein 5T4 (TPBG) DM901ZW MA Immunomodulator DM901ZW RN Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370. DM901ZW RU https://pubmed.ncbi.nlm.nih.gov/24445502 DM948AP DI DM948AP DM948AP DN MAb114 DM948AP TI TT2F0AU DM948AP TN Ebola virus Envelope glycoprotein (EV GP) DM948AP RN Ansuvimab: First Approval. Drugs. 2021 Apr;81(5):595-598. DM948AP RU https://pubmed.ncbi.nlm.nih.gov/33751449 DMB8UQ3 DI DMB8UQ3 DMB8UQ3 DN Ramatroban DMB8UQ3 TI TT2O84V DMB8UQ3 TN Thromboxane A2 receptor (TBXA2R) DMB8UQ3 MA Antagonist DMB8UQ3 RN Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7. DMB8UQ3 RU https://pubmed.ncbi.nlm.nih.gov/17761352 DMB8UQ3 DI DMB8UQ3 DMB8UQ3 DN Ramatroban DMB8UQ3 TI TTQDMX5 DMB8UQ3 TN Prostaglandin D2 receptor 2 (PTGDR2) DMB8UQ3 MA Antagonist DMB8UQ3 RN CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. DMB8UQ3 RU https://pubmed.ncbi.nlm.nih.gov/16256979 DMBFOAZ DI DMBFOAZ DMBFOAZ DN AMG520 DMBFOAZ TI TTJUNZF DMBFOAZ TN Beta-secretase 1 (BACE1) DMBFOAZ MA Inhibitor DMBFOAZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBFOAZ RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMBIO6E DI DMBIO6E DMBIO6E DN Meclinertant DMBIO6E TI TTTUMEP DMBIO6E TN Neurotensin receptor type 1 (NTSR1) DMBIO6E MA Antagonist DMBIO6E RN Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23. DMBIO6E RU https://pubmed.ncbi.nlm.nih.gov/19118604 DMBJ15R DI DMBJ15R DMBJ15R DN Pexacerfont DMBJ15R TI TT7EFHR DMBJ15R TN Corticotropin-releasing factor receptor 1 (CRHR1) DMBJ15R MA Antagonist DMBJ15R RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMBJ15R RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMBJ4IZ DI DMBJ4IZ DMBJ4IZ DN LECOZOTAN HYDROCHLORIDE DMBJ4IZ TI TTSQIFT DMBJ4IZ TN 5-HT 1A receptor (HTR1A) DMBJ4IZ MA Antagonist DMBJ4IZ RN A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in... Clin Pharmacol Ther. 2008 Jan;83(1):86-96. DMBJ4IZ RU https://pubmed.ncbi.nlm.nih.gov/17507923 DMC3794 DI DMC3794 DMC3794 DN Indium-111 DMC3794 TI TTGKNB4 DMC3794 TN Epidermal growth factor receptor (EGFR) DMC3794 RN Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. DMC3794 RU https://pubmed.ncbi.nlm.nih.gov/25731184 DMCA2PJ DI DMCA2PJ DMCA2PJ DN ONO-2506 DMCA2PJ TI TTMXGCW DMCA2PJ TN Adrenergic receptor beta-3 (ADRB3) DMCA2PJ MA Agonist DMCA2PJ RN FR149175, a beta 3-adrenoceptor-selective agonist, is a possible therapeutic agent for non-insulin-dependent diabetes mellitus. Jpn J Pharmacol. 1997 May;74(1):109-12. DMCA2PJ RU https://pubmed.ncbi.nlm.nih.gov/9195306 DMCA2PJ DI DMCA2PJ DMCA2PJ DN ONO-2506 DMCA2PJ TI TTQ0V86 DMCA2PJ TN S100 calcium-binding protein B (S100B) DMCA2PJ MA Modulator DMCA2PJ RN Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B.Curr Drug Targets CNS Neurol Disord.2005 Apr;4(2):127-42. DMCA2PJ RU https://www.ncbi.nlm.nih.gov/pubmed/15857298 DMCGK6X DI DMCGK6X DMCGK6X DN PRO 140 DMCGK6X TI TT2CEJG DMCGK6X TN C-C chemokine receptor type 5 (CCR5) DMCGK6X MA Inhibitor DMCGK6X RN The return of PRO 140, a CCR5-directed mAb. Curr Opin HIV AIDS. 2018 Jul;13(4):346-353. DMCGK6X RU https://pubmed.ncbi.nlm.nih.gov/29708899 DMCTRLN DI DMCTRLN DMCTRLN DN OT-101 DMCTRLN TI TTI0KH6 DMCTRLN TN TGF beta-2 messenger RNA (TGFB2 mRNA) DMCTRLN MA Inhibitor DMCTRLN RN Clinical pipeline report, company report or official report of Oncotelic. DMCTRLN RU https://www.oncotelic.com/pipeline/ DMD5AEB DI DMD5AEB DMD5AEB DN NAL-GLU DMD5AEB TI TT0ID4A DMD5AEB TN Leutinizing-hormone-releasing hormone (GNRH1) DMD5AEB RN The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am J Obstet Gynecol. 1991 Dec;165(6Pt 1):1811-7. DMD5AEB RU https://pubmed.ncbi.nlm.nih.gov/1750480 DMD741P DI DMD741P DMD741P DN Alagebrium chloride DMD741P TI TTMO9HF DMD741P TN Advanced glycosylation end product receptor (AGER) DMD741P MA Breaker DMD741P RN Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage. Trans Am Ophthalmol Soc. 2009 Dec;107:146-58. DMD741P RU https://pubmed.ncbi.nlm.nih.gov/20126491 DMD9ISG DI DMD9ISG DMD9ISG DN SM-88 DMD9ISG TI TT8E7Z0 DMD9ISG TN Free radical (FRD) DMD9ISG MA Stimulator DMD9ISG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD9ISG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDG8Q3 DI DMDG8Q3 DMDG8Q3 DN Varlitinib DMDG8Q3 TI TTGKNB4 DMDG8Q3 TN Epidermal growth factor receptor (EGFR) DMDG8Q3 MA Modulator DMDG8Q3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDG8Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDG8Q3 DI DMDG8Q3 DMDG8Q3 DN Varlitinib DMDG8Q3 TI TT6EO5L DMDG8Q3 TN Erbb2 tyrosine kinase receptor (HER2) DMDG8Q3 MA Modulator DMDG8Q3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDG8Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDLGRO DI DMDLGRO DMDLGRO DN Aramchol DMDLGRO TI TT6RIOV DMDLGRO TN Acyl-CoA desaturase (SCD) DMDLGRO MA Inhibitor DMDLGRO RN The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014 Dec;12(12):2085-91.e1. DMDLGRO RU https://pubmed.ncbi.nlm.nih.gov/24815326 DMDQOWT DI DMDQOWT DMDQOWT DN MOR-208 DMDQOWT TI TTW640A DMDQOWT TN B-lymphocyte surface antigen B4 (CD19) DMDQOWT RN A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60. DMDQOWT RU https://pubmed.ncbi.nlm.nih.gov/25301708 DMEUGZL DI DMEUGZL DMEUGZL DN Legumain-cleavable doxorubicin prodrugs DMEUGZL TI TTPTWV5 DMEUGZL TN Legumain (LGMN) DMEUGZL MA Modulator DMEUGZL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2380). DMEUGZL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2380 DMFCLT6 DI DMFCLT6 DMFCLT6 DN CE-224535 DMFCLT6 TI TT473XN DMFCLT6 TN P2X purinoceptor 7 (P2RX7) DMFCLT6 MA Antagonist DMFCLT6 RN Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol. 2012 Apr;39(4):720-7. DMFCLT6 RU https://pubmed.ncbi.nlm.nih.gov/22382341 DMFE0P1 DI DMFE0P1 DMFE0P1 DN Metformin glycinate DMFE0P1 TI TTCBFJO DMFE0P1 TN Insulin receptor (INSR) DMFE0P1 MA Inhibitor DMFE0P1 RN Effect of Metformin Glycinate on Glycated Hemoglobin A1c Concentration and Insulin Sensitivity in Drug-Naive Adult Patients with Type 2 Diabetes Mellitus. Diabetes Technol Ther. 2012 December; 14(12): 1140-1144. DMFE0P1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521136/ DMGC970 DI DMGC970 DMGC970 DN AG-013 DMGC970 TI TTNOJIZ DMGC970 TN Trefoil factor-1 (TFF1) DMGC970 MA Modulator DMGC970 RN AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol. 2010 Jul;46(7):564-70. DMGC970 RU https://pubmed.ncbi.nlm.nih.gov/20542722 DMGKRAJ DI DMGKRAJ DMGKRAJ DN VB4-845 DMGKRAJ TI TTZ8WH4 DMGKRAJ TN Tumor-associated calcium signal transducer 1 (EPCAM) DMGKRAJ RN A bispecific EpCAM/CD133 targeted toxin is effective against carcinoma. Target Oncol. 2014 September; 9(3): 239-249. DMGKRAJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994189/ DMGPJ5U DI DMGPJ5U DMGPJ5U DN JNJ-54861911 DMGPJ5U TI TT8JRS7 DMGPJ5U TN Beta-secretase (BACE) DMGPJ5U MA Inhibitor DMGPJ5U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGPJ5U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMH7CSQ DI DMH7CSQ DMH7CSQ DN Gavilimomab DMH7CSQ TI TT5UJWD DMH7CSQ TN Basigin (BSG) DMH7CSQ RN National Cancer Institute Drug Dictionary (drug id 38221). DMH7CSQ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=38221 DMH7IPW DI DMH7IPW DMH7IPW DN Sarizotan DMH7IPW TI TTSQIFT DMH7IPW TN 5-HT 1A receptor (HTR1A) DMH7IPW MA Modulator DMH7IPW RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMH7IPW RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMH7IPW DI DMH7IPW DMH7IPW DN Sarizotan DMH7IPW TI TTEX248 DMH7IPW TN Dopamine D2 receptor (D2R) DMH7IPW MA Modulator DMH7IPW RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMH7IPW RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMH8VMP DI DMH8VMP DMH8VMP DN Emixustat DMH8VMP TI TTBOH16 DMH8VMP TN Retinal pigment epithelium protein (RPE65) DMH8VMP MA Inhibitor DMH8VMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH8VMP RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMHWE5R DI DMHWE5R DMHWE5R DN Batabulin DMHWE5R TI TTYFKSZ DMHWE5R TN Tubulin beta (TUBB) DMHWE5R MA Inhibitor DMHWE5R RN Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605. DMHWE5R RU https://pubmed.ncbi.nlm.nih.gov/11606124 DMHWY2G DI DMHWY2G DMHWY2G DN Pagoclone DMHWY2G TI TTEX6LM DMHWY2G TN GABA(A) receptor gamma-3 (GABRG3) DMHWY2G MA Modulator DMHWY2G RN Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73. DMHWY2G RU https://pubmed.ncbi.nlm.nih.gov/16702891 DMHXJ68 DI DMHXJ68 DMHXJ68 DN WVE-210201 DMHXJ68 TI TT48MP6 DMHXJ68 TN Dystrophin (DMD) DMHXJ68 MA Modulator DMHXJ68 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHXJ68 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMI215P DI DMI215P DMI215P DN Lopinavir + ritonavir + interferon beta-1b DMI215P TI TTWOH4Q DMI215P TN MERS-CoV 3C-like proteinase (3CLpro) DMI215P MA Inhibitor DMI215P RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMI215P RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMIUA3M DI DMIUA3M DMIUA3M DN Imprime PGG DMIUA3M TI TTJGY7A DMIUA3M TN Complement C3 (CO3) DMIUA3M MA Modulator DMIUA3M RN National Cancer Institute Drug Dictionary (drug id 599816). DMIUA3M RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816 DMJQHXD DI DMJQHXD DMJQHXD DN AZD3293 DMJQHXD TI TT8JRS7 DMJQHXD TN Beta-secretase (BACE) DMJQHXD MA Modulator DMJQHXD RN AZD3293 A novel BACE1 inhibitor: safety, tolerability, and effects on plasma and CSF A-beta peptides following single- and multiple-dose administration. Neurobiology of Aging. May 20, 2008. DMJQHXD RU http://www.neurobiologyofaging.org/article/S0197-4580(08)00131-0/abstract DMJRU3A DI DMJRU3A DMJRU3A DN AMO-02 DMJRU3A TI TTRSMW9 DMJRU3A TN Glycogen synthase kinase-3 beta (GSK-3B) DMJRU3A MA Inhibitor DMJRU3A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJRU3A RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMJYTUQ DI DMJYTUQ DMJYTUQ DN CR-845 DMJYTUQ TI TTQW87Y DMJYTUQ TN Opioid receptor kappa (OPRK1) DMJYTUQ MA Agonist DMJYTUQ RN Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322. DMJYTUQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2691465/ DMKGQF0 DI DMKGQF0 DMKGQF0 DN Suvodirsen DMKGQF0 TI TTWLFXU DMKGQF0 TN Dystrophin messenger RNA (DMD mRNA) DMKGQF0 MA Inhibitor DMKGQF0 RN Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694. DMKGQF0 RU https://pubmed.ncbi.nlm.nih.gov/32782413 DMKMZW2 DI DMKMZW2 DMKMZW2 DN MTC-DOX DMKMZW2 TI TT0IHXV DMKMZW2 TN DNA topoisomerase II (TOP2) DMKMZW2 MA Modulator DMKMZW2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMKMZW2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMKT16N DI DMKT16N DMKT16N DN Bevacizumab DMKT16N TI TT140V6 DMKT16N TN HUMAN vascular endothelial growth factor (VEGF) DMKT16N MA Inhibitor DMKT16N RN ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP) DMKT16N RU https://clinicaltrials.gov/ct2/show/NCT04275414 DMKY9GI DI DMKY9GI DMKY9GI DN Activated recombinant FVII-albumin fusion protein DMKY9GI TI TTF0EGX DMKY9GI TN Coagulation factor VII (F7) DMKY9GI MA Modulator DMKY9GI RN ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health. DMKY9GI RU https://clinicaltrials.gov/ct2/show/NCT01542619 DMKY9GI DI DMKY9GI DMKY9GI DN Activated recombinant FVII-albumin fusion protein DMKY9GI TI TTFNGC9 DMKY9GI TN Serum albumin (ALB) DMKY9GI MA Modulator DMKY9GI RN ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health. DMKY9GI RU https://clinicaltrials.gov/ct2/show/NCT01542619 DML906E DI DML906E DML906E DN CY-1503 DML906E TI TTE5VG0 DML906E TN P-selectin (SELP) DML906E MA Modulator DML906E RN Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9. DML906E RU https://pubmed.ncbi.nlm.nih.gov/7543381 DML906E DI DML906E DML906E DN CY-1503 DML906E TI TTAU4D6 DML906E TN E-selectin (SELE) DML906E MA Modulator DML906E RN Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9. DML906E RU https://pubmed.ncbi.nlm.nih.gov/7543381 DML9FD4 DI DML9FD4 DML9FD4 DN Rinfabate DML9FD4 TI TTHRID2 DML9FD4 TN Insulin-like growth factor I receptor (IGF1R) DML9FD4 MA Modulator DML9FD4 RN Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7. DML9FD4 RU https://pubmed.ncbi.nlm.nih.gov/15777106 DMMHSLC DI DMMHSLC DMMHSLC DN Afq056 DMMHSLC TI TTHS256 DMMHSLC TN Metabotropic glutamate receptor 5 (mGluR5) DMMHSLC MA Modulator DMMHSLC RN Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. Drug Metab Dispos. 2013 Sep;41(9):1626-41. DMMHSLC RU https://pubmed.ncbi.nlm.nih.gov/23775850 DMMTL7V DI DMMTL7V DMMTL7V DN Hemoglobin raffimer DMMTL7V TI TTQO71U DMMTL7V TN Hemoglobin (HB) DMMTL7V MA Modulator DMMTL7V RN Use of hemoglobin raffimer for postoperative life-threatening anemia in a Jehovah's Witness. Can J Anaesth. 2005 Apr;52(4):369-73. DMMTL7V RU https://pubmed.ncbi.nlm.nih.gov/15814750 DMN6F1W DI DMN6F1W DMN6F1W DN Amiodarone DMN6F1W TI TTHQJ2Y DMN6F1W TN HUMAN two pore channel subtype 2 (TPC2) DMN6F1W MA Blocker DMN6F1W RN Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. DMN6F1W RU https://pubmed.ncbi.nlm.nih.gov/32221306 DMNIYSZ DI DMNIYSZ DMNIYSZ DN RP101 DMNIYSZ TI TTP3QRF DMNIYSZ TN Thymidine kinase 1 (TK1) DMNIYSZ MA Inhibitor DMNIYSZ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMNIYSZ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMNTCV4 DI DMNTCV4 DMNTCV4 DN MBX-8025 DMNTCV4 TI TT2JWF6 DMNTCV4 TN Peroxisome proliferator-activated receptor delta (PPARD) DMNTCV4 MA Agonist DMNTCV4 RN ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008. DMNTCV4 RU https://clinicaltrials.gov/ct2/show/NCT00701883 DMOJLCV DI DMOJLCV DMOJLCV DN SAR164877 DMOJLCV TI TTDN3LF DMOJLCV TN Nerve growth factor (NGF) DMOJLCV MA Modulator DMOJLCV RN Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. DMOJLCV RU https://www.ncbi.nlm.nih.gov/pubmed/21389990 DMONWJ4 DI DMONWJ4 DMONWJ4 DN Imetelstat DMONWJ4 TI TTUJFD0 DMONWJ4 TN Telomerase reverse transcriptase (TERT) DMONWJ4 MA Inhibitor DMONWJ4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMONWJ4 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMONYS9 DI DMONYS9 DMONYS9 DN MBX-102 DMONYS9 TI TTZMAO3 DMONYS9 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMONYS9 MA Agonist DMONYS9 RN MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. DMONYS9 RU https://pubmed.ncbi.nlm.nih.gov/19389808 DMP8HW1 DI DMP8HW1 DMP8HW1 DN LY2157299 DMP8HW1 TI TTP4520 DMP8HW1 TN TGF-beta receptor type I (TGFBR1) DMP8HW1 MA Modulator DMP8HW1 RN Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23. DMP8HW1 RU https://pubmed.ncbi.nlm.nih.gov/25488804 DMP8HW1 DI DMP8HW1 DMP8HW1 DN LY2157299 DMP8HW1 TI TTR9XHZ DMP8HW1 TN Transforming growth factor beta 1 (TGFB1) DMP8HW1 MA Inhibitor DMP8HW1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP8HW1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPDA17 DI DMPDA17 DMPDA17 DN Omburtamab I-131 DMPDA17 TI TT6CQUM DMPDA17 TN B7 homolog 3 (CD276) DMPDA17 MA Inhibitor DMPDA17 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPDA17 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPLQ1V DI DMPLQ1V DMPLQ1V DN IFX-1 DMPLQ1V TI TTRJ91Q DMPLQ1V TN HUMAN complement C5 alpha (C5A) DMPLQ1V MA Inhibitor DMPLQ1V RN 03-2020-InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRxs anti-C5a Technology DMPLQ1V RU https://www.inflarx.de/Home/Investors/Press-Releases/03-2020-InflaRx-Doses-First-Patient-in-Multicenter-Randomized-Clinical-Trial-in-Severe-Progressed-COVID-19-Pneumonia-in-Europe-upon-Receipt-of-Initial-Positive-Human-Data-with-InflaRx-s-anti-C5a-Technology.html DMPWH30 DI DMPWH30 DMPWH30 DN Pimagedine HCl DMPWH30 TI TTF10I9 DMPWH30 TN Nitric-oxide synthase inducible (NOS2) DMPWH30 MA Inhibitor DMPWH30 RN Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49. DMPWH30 RU https://pubmed.ncbi.nlm.nih.gov/18639532 DMQ1FU8 DI DMQ1FU8 DMQ1FU8 DN Montelukast DMQ1FU8 TI TTSB6CA DMQ1FU8 TN HUMAN cysteinyl leukotriene receptor (CysLTR) DMQ1FU8 MA Antagonist DMQ1FU8 RN As a potential treatment of COVID-19: Montelukast. Med Hypotheses. 2020 May 11;142:109828. DMQ1FU8 RU https://pubmed.ncbi.nlm.nih.gov/32416408 DMRZ1F2 DI DMRZ1F2 DMRZ1F2 DN Padsevonil DMRZ1F2 TI TTT3P91 DMRZ1F2 TN Synaptic vesicle glycoprotein 2A (SV2A) DMRZ1F2 MA Inhibitor DMRZ1F2 RN Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20. DMRZ1F2 RU https://pubmed.ncbi.nlm.nih.gov/31619464 DMRZ1F2 DI DMRZ1F2 DMRZ1F2 DN Padsevonil DMRZ1F2 TI TTCI43M DMRZ1F2 TN GABA(A) receptor (GABAR) DMRZ1F2 MA Inhibitor DMRZ1F2 RN Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models. J Pharmacol Exp Ther. 2020 Jan;372(1):11-20. DMRZ1F2 RU https://pubmed.ncbi.nlm.nih.gov/31619464 DMS8QF9 DI DMS8QF9 DMS8QF9 DN Arimoclomol DMS8QF9 TI TTG91S4 DMS8QF9 TN Heat shock protein (HSP) DMS8QF9 MA Modulator DMS8QF9 RN Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Jul;13(7):482-96. DMS8QF9 RU https://pubmed.ncbi.nlm.nih.gov/20582873 DMSR7D2 DI DMSR7D2 DMSR7D2 DN CX-516 DMSR7D2 TI TTAN6JD DMSR7D2 TN Glutamate receptor AMPA (GRIA) DMSR7D2 MA Modulator DMSR7D2 RN Autism spectrum disorders: emerging pharmacotherapy. Expert Opin Emerg Drugs. 2005 Aug;10(3):521-36. DMSR7D2 RU https://pubmed.ncbi.nlm.nih.gov/16083327 DMST3FM DI DMST3FM DMST3FM DN CART-19 DMST3FM TI TTW640A DMST3FM TN B-lymphocyte surface antigen B4 (CD19) DMST3FM MA CAR-T-Cell-Therapy DMST3FM RN ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL DMST3FM RU https://clinicaltrials.gov/ct2/show/NCT03027739 DMT13UA DI DMT13UA DMT13UA DN Olokizumab DMT13UA TI TTJH4Y5 DMT13UA TN HUMAN interleukin 6 (IL6) DMT13UA MA Inhibitor DMT13UA RN Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82. DMT13UA RU https://pubmed.ncbi.nlm.nih.gov/24670876 DMTIESG DI DMTIESG DMTIESG DN Omburtamab DMTIESG TI TT6CQUM DMTIESG TN B7 homolog 3 (CD276) DMTIESG MA Inhibitor DMTIESG RN Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3. DMTIESG RU https://pubmed.ncbi.nlm.nih.gov/33533945 DMUOMBZ DI DMUOMBZ DMUOMBZ DN CLL1 CAR-T Cell DMUOMBZ TI TT70N8V DMUOMBZ TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMUOMBZ MA CAR-T-Cell-Therapy(Dual specific) DMUOMBZ RN ClinicalTrials.gov (NCT03631576) CD123/CLL1 CAR-T Cells for R/R AML DMUOMBZ RU https://clinicaltrials.gov/ct2/show/NCT03631576 DMUQWRD DI DMUQWRD DMUQWRD DN LYS-SAF302 DMUQWRD TI TTPJ2SH DMUQWRD TN N-sulphoglucosamine sulphohydrolase (SGSH) DMUQWRD MA Replacement DMUQWRD RN Clinical pipeline report, company report or official report of Lysogene. DMUQWRD RU https://www.lysogene.com/lys-saf302/ DMURH4X DI DMURH4X DMURH4X DN Oxypurinol DMURH4X TI TT7RJY8 DMURH4X TN Xanthine dehydrogenase/oxidase (XDH) DMURH4X MA Inhibitor DMURH4X RN Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52. DMURH4X RU https://pubmed.ncbi.nlm.nih.gov/2829916 DMUSJ3D DI DMUSJ3D DMUSJ3D DN BIIB-088 DMUSJ3D TI TTHBDA9 DMUSJ3D TN X-linked retinitis pigmentosa GTPase regulator (RPGR) DMUSJ3D RN ClinicalTrials.gov (NCT04850118) A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health. DMUSJ3D RU https://clinicaltrials.gov/ct2/show/NCT04850118 DMV52CP DI DMV52CP DMV52CP DN Bucindolol DMV52CP TI TT2CJVK DMV52CP TN Adrenergic receptor beta-2 (ADRB2) DMV52CP MA Modulator DMV52CP RN Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9. DMV52CP RU https://www.ncbi.nlm.nih.gov/pubmed/2412063 DMV52CP DI DMV52CP DMV52CP DN Bucindolol DMV52CP TI TTR6W5O DMV52CP TN Adrenergic receptor beta-1 (ADRB1) DMV52CP MA Modulator DMV52CP RN Bucindolol has serotonin and alpha-adrenoceptor blocking properties. J Cardiovasc Pharmacol. 1985;7 Suppl 7:S67-9. DMV52CP RU https://www.ncbi.nlm.nih.gov/pubmed/2412063 DMVB4OS DI DMVB4OS DMVB4OS DN AVN 211 DMVB4OS TI TTJS8PY DMVB4OS TN 5-HT 6 receptor (HTR6) DMVB4OS MA Modulator DMVB4OS RN Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91. DMVB4OS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/ DMVDTR2 DI DMVDTR2 DMVDTR2 DN Thymoquinone DMVDTR2 TI TT7SBF5 DMVDTR2 TN Cellular tumor antigen p53 (TP53) DMVDTR2 MA Inhibitor DMVDTR2 RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMVDTR2 RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMVDTR2 DI DMVDTR2 DMVDTR2 DN Thymoquinone DMVDTR2 TI TTJGNVC DMVDTR2 TN Apoptosis regulator Bcl-2 (BCL-2) DMVDTR2 MA Inhibitor DMVDTR2 RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMVDTR2 RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMVDTR2 DI DMVDTR2 DMVDTR2 DN Thymoquinone DMVDTR2 TI TTQ57WJ DMVDTR2 TN Apoptosis regulator BAX (BAX) DMVDTR2 MA Inhibitor DMVDTR2 RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMVDTR2 RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMVSIN2 DI DMVSIN2 DMVSIN2 DN Emapalumab DMVSIN2 TI TTR10KI DMVSIN2 TN HUMAN interferon gamma (IFNG) DMVSIN2 MA Inhibitor DMVSIN2 RN Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011. DMVSIN2 RU https://pubmed.ncbi.nlm.nih.gov/15476870 DMW7TZV DI DMW7TZV DMW7TZV DN GS-6207 DMW7TZV TI TTTWS2G DMW7TZV TN Human immunodeficiency virus Capsid p24 (HIV p24) DMW7TZV MA Inhibitor DMW7TZV RN Clinical pipeline report, company report or official report of Gilead Sciences. DMW7TZV RU https://www.gilead.com/science-and-medicine/pipeline DMWE3GB DI DMWE3GB DMWE3GB DN TG-4010 DMWE3GB TI TTBHFYQ DMWE3GB TN Mucin-1 (MUC1) DMWE3GB MA Modulator DMWE3GB RN A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44. DMWE3GB RU https://pubmed.ncbi.nlm.nih.gov/18594319 DMWE3GB DI DMWE3GB DMWE3GB DN TG-4010 DMWE3GB TI TTF89GD DMWE3GB TN Interleukin-2 (IL2) DMWE3GB MA Modulator DMWE3GB RN A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44. DMWE3GB RU https://pubmed.ncbi.nlm.nih.gov/18594319 DMWZ6DK DI DMWZ6DK DMWZ6DK DN Roledumab DMWZ6DK TI TTLCKI8 DMWZ6DK TN Blood group Rh(D) polypeptide (RHD) DMWZ6DK RN Pharmacokinetics and safety of roledumab, a novel human recombinant monoclonal anti-RhD antibody with an optimized Fc for improved engagement of FCgammaRIII, in healthy volunteers. Vox Sang. 2012 Oct;103(3):213-22. DMWZ6DK RU https://pubmed.ncbi.nlm.nih.gov/22568808 DMX9V8K DI DMX9V8K DMX9V8K DN Contigoside B DMX9V8K TI TTFBNVI DMX9V8K TN Aldose reductase (AKR1B1) DMX9V8K MA Inhibitor DMX9V8K RN Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5. DMX9V8K RU https://pubmed.ncbi.nlm.nih.gov/8699190 DMX9V8K DI DMX9V8K DMX9V8K DN Contigoside B DMX9V8K TI TTL69WB DMX9V8K TN Angiotensin-converting enzyme (ACE) DMX9V8K MA Inhibitor DMX9V8K RN Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3. DMX9V8K RU https://pubmed.ncbi.nlm.nih.gov/3430165 DMXCD69 DI DMXCD69 DMXCD69 DN CEP1347 DMXCD69 TI TTUNSIX DMXCD69 TN Mixed lineage kinase 1 (MAP3K9) DMXCD69 MA Inhibitor DMXCD69 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMXCD69 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMYFQJL DI DMYFQJL DMYFQJL DN BNV-222 DMYFQJL TI TTFBNVI DMYFQJL TN Aldose reductase (AKR1B1) DMYFQJL MA Inhibitor DMYFQJL RN ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health. DMYFQJL RU https://clinicaltrials.gov/ct2/show/NCT02332005 DMYKNME DI DMYKNME DMYKNME DN PF-06651600 DMYKNME TI TTT7PJU DMYKNME TN Janus kinase 3 (JAK-3) DMYKNME MA Inhibitor DMYKNME RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYKNME RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMYVKM5 DI DMYVKM5 DMYVKM5 DN Darbufelone DMYVKM5 TI TT2J34L DMYVKM5 TN Arachidonate 5-lipoxygenase (5-LOX) DMYVKM5 MA Modulator DMYVKM5 RN Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9. DMYVKM5 RU https://pubmed.ncbi.nlm.nih.gov/23517721 DMYVKM5 DI DMYVKM5 DMYVKM5 DN Darbufelone DMYVKM5 TI TTVKILB DMYVKM5 TN Prostaglandin G/H synthase 2 (COX-2) DMYVKM5 MA Modulator DMYVKM5 RN Novel dual cyclooxygenase and lipoxygenase inhibitors targeting hyaluronan-CD44v6 pathway and inducing cytotoxicity in colon cancer cells. Bioorg Med Chem. 2013 May 1;21(9):2551-9. DMYVKM5 RU https://pubmed.ncbi.nlm.nih.gov/23517721 DMZ0T24 DI DMZ0T24 DMZ0T24 DN Abagovomab DMZ0T24 TI TTC1PS3 DMZ0T24 TN Ovarian carcinoma antigen CA125 (MUC16) DMZ0T24 RN Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer. Immunotherapy. 2011 Feb;3(2):153-62. DMZ0T24 RU https://pubmed.ncbi.nlm.nih.gov/21322756 DMZGKXW DI DMZGKXW DMZGKXW DN Atogepant DMZGKXW TI TTQ4ESF DMZGKXW TN Calgranulin D (S100A12) DMZGKXW MA Antagonist DMZGKXW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZGKXW RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZV3SY DI DMZV3SY DMZV3SY DN Denagliptin DMZV3SY TI TTDIGC1 DMZV3SY TN Dipeptidyl peptidase 4 (DPP-4) DMZV3SY MA Inhibitor DMZV3SY RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMZV3SY RU https://pubmed.ncbi.nlm.nih.gov/19149538 DM78DOT DI DM78DOT DM78DOT DN AllerB DM78DOT TI TT9V5JH DM78DOT TN Phospholipase A2 (PLA2G1B) DM78DOT MA Inhibitor DM78DOT RN Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol. 1998 Jun;101(6 Pt 1):747-54. DM78DOT RU https://pubmed.ncbi.nlm.nih.gov/9648701 DMEARCM DI DMEARCM DMEARCM DN OrM3 DMEARCM TI TTH18TF DMEARCM TN Muscarinic acetylcholine receptor M5 (CHRM5) DMEARCM MA Antagonist DMEARCM RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMEARCM RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMJM9LZ DI DMJM9LZ DMJM9LZ DN LB80380 DMJM9LZ TI TTS5K1M DMJM9LZ TN Hepatitis B virus Reverse transcriptase (HBV RT) DMJM9LZ MA Inhibitor DMJM9LZ RN 2011 Pipeline of LG Life Sciences. DMJM9LZ RU http://www.lgls.com/ DMOE582 DI DMOE582 DMOE582 DN TZP-101 DMOE582 TI TTWDC17 DMOE582 TN Growth hormone secretagogue receptor 1 (GHSR) DMOE582 MA Agonist DMOE582 RN Contribution of protein binding to the pharmacokinetics of the ghrelin receptor agonist TZP-101 in healthy volunteers and adults with symptomatic gastroparesis: two randomized, double-blind studies and a binding profile study. Clin Drug Investig. 2009;29(6):409-18. DMOE582 RU https://pubmed.ncbi.nlm.nih.gov/19432500 DMXB4NL DI DMXB4NL DMXB4NL DN MEDI4893 DMXB4NL TI TT5FLYB DMXB4NL TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DMXB4NL RN Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80. DMXB4NL RU https://pubmed.ncbi.nlm.nih.gov/25210036 DM0TH9A DI DM0TH9A DM0TH9A DN Bimosiamose DM0TH9A TI TTAU4D6 DM0TH9A TN E-selectin (SELE) DM0TH9A MA Inhibitor DM0TH9A RN Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82. DM0TH9A RU https://pubmed.ncbi.nlm.nih.gov/18598003 DMGM1IR DI DMGM1IR DMGM1IR DN RhuDex DMGM1IR TI TTFZDNP DMGM1IR TN Activation B7-1 antigen (CD80) DMGM1IR MA Inhibitor DMGM1IR RN A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005. DMGM1IR RU https://pubmed.ncbi.nlm.nih.gov/21447719 DMJBDL0 DI DMJBDL0 DMJBDL0 DN BIIB104 DMJBDL0 TI TTAN6JD DMJBDL0 TN Glutamate receptor AMPA (GRIA) DMJBDL0 MA Activator DMJBDL0 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJBDL0 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMKJDR6 DI DMKJDR6 DMKJDR6 DN VX-702 DMKJDR6 TI TTQBR95 DMKJDR6 TN Stress-activated protein kinase 2a (p38 alpha) DMKJDR6 MA Modulator DMKJDR6 RN Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41. DMKJDR6 RU https://pubmed.ncbi.nlm.nih.gov/19404957 DMLQ3PO DI DMLQ3PO DMLQ3PO DN INCB13739 DMLQ3PO TI TTN7BL9 DMLQ3PO TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMLQ3PO MA Inhibitor DMLQ3PO RN Incyte's Selective Oral Inhibitor Of 11beta-HSD1 Demonstrates Improvements In Insulin Sensitivity And Lowers Cholesterol Levels In Type 2 Diabetics. Incyte. 2008. DMLQ3PO RU http://www.medicalnewstoday.com/articles/110647.php DMLQ3PO DI DMLQ3PO DMLQ3PO DN INCB13739 DMLQ3PO TI TTWC6MY DMLQ3PO TN Protein tyrosine phosphatase (PTP) DMLQ3PO MA Inhibitor DMLQ3PO RN Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9. DMLQ3PO RU https://pubmed.ncbi.nlm.nih.gov/9341756 DMMWC6F DI DMMWC6F DMMWC6F DN INCB9471 DMMWC6F TI TT2CEJG DMMWC6F TN C-C chemokine receptor type 5 (CCR5) DMMWC6F MA Antagonist DMMWC6F RN Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34. DMMWC6F RU https://pubmed.ncbi.nlm.nih.gov/17920529 DMR6LXM DI DMR6LXM DMR6LXM DN CAP-232 DMR6LXM TI TT4LOT8 DMR6LXM TN Pyruvate kinase M2 (PKM) DMR6LXM MA Modulator DMR6LXM RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMR6LXM RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMSC8YW DI DMSC8YW DMSC8YW DN ANA773 DMSC8YW TI TTRJ1K4 DMSC8YW TN Toll-like receptor 7 (TLR7) DMSC8YW MA Agonist DMSC8YW RN Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011). DMSC8YW RU http://www.anadyspharma.com/ DMUB8WN DI DMUB8WN DMUB8WN DN Aerovant DMUB8WN TI TTDWHC3 DMUB8WN TN Interleukin 4 receptor alpha (IL4R) DMUB8WN MA Antagonist DMUB8WN RN Aerovance starts trial of Aerovant for uncontrolled asthma. Aerovance. March 3, 2009. DMUB8WN RU http://www.news-medical.net/news/2009/03/03/46411.aspx DMYZU6G DI DMYZU6G DMYZU6G DN MEM-1003 DMYZU6G TI TTXHYV6 DMYZU6G TN Voltage-gated L-type calcium channel (L-CaC) DMYZU6G MA Modulator DMYZU6G RN Efficacy of MEM 1003, a novel calcium channel blocker, in delay and trace eyeblink conditioning in older rabbits. Neurobiol Aging. 2007 May;28(5):766-73. DMYZU6G RU https://pubmed.ncbi.nlm.nih.gov/16621170 DM0157T DI DM0157T DM0157T DN DM199 DM0157T TI TTGY8IW DM0157T TN B2 bradykinin receptor (BDKRB2) DM0157T MA Activator DM0157T RN Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119. DM0157T RU https://pubmed.ncbi.nlm.nih.gov/26038695 DM01SR6 DI DM01SR6 DM01SR6 DN L-NAME DM01SR6 TI TTCM4B3 DM01SR6 TN Nitric-oxide synthase endothelial (NOS3) DM01SR6 MA Inhibitor DM01SR6 RN Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61. DM01SR6 RU https://pubmed.ncbi.nlm.nih.gov/19586617 DM0298B DI DM0298B DM0298B DN Salvicine DM0298B TI TT0IHXV DM0298B TN DNA topoisomerase II (TOP2) DM0298B MA Modulator DM0298B RN Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5. DM0298B RU https://pubmed.ncbi.nlm.nih.gov/17723179 DM03NQS DI DM03NQS DM03NQS DN GTP-200 DM03NQS TI TTWDC17 DM03NQS TN Growth hormone secretagogue receptor 1 (GHSR) DM03NQS MA Agonist DM03NQS RN Orphan GPCR research. Br J Pharmacol. 2008 March; 153(Suppl 1): S339-S346. DM03NQS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2268047/ DM047HI DI DM047HI DM047HI DN VBP15 DM047HI TI TTOZRK6 DM047HI TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM047HI MA Agonist DM047HI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM047HI RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM0568C DI DM0568C DM0568C DN MK-0873 DM0568C TI TTZ97H5 DM0568C TN Phosphodiesterase 4A (PDE4A) DM0568C MA Inhibitor DM0568C RN MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7. DM0568C RU https://pubmed.ncbi.nlm.nih.gov/18321743 DM0568C DI DM0568C DM0568C DN MK-0873 DM0568C TI TTVIAT9 DM0568C TN Phosphodiesterase 4B (PDE4B) DM0568C MA Inhibitor DM0568C RN MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7. DM0568C RU https://pubmed.ncbi.nlm.nih.gov/18321743 DM0568C DI DM0568C DM0568C DN MK-0873 DM0568C TI TTSKMI8 DM0568C TN Phosphodiesterase 4D (PDE4D) DM0568C MA Inhibitor DM0568C RN MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulm Pharmacol Ther. 2008;21(3):573-7. DM0568C RU https://pubmed.ncbi.nlm.nih.gov/18321743 DM059CZ DI DM059CZ DM059CZ DN DPK-060 DM059CZ TI TTXT4D5 DM059CZ TN Bacterial Cell membrane (Bact CM) DM059CZ MA Enhancer DM059CZ RN The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov. 2015 Feb;14(2):111-29. DM059CZ RU https://pubmed.ncbi.nlm.nih.gov/25614221 DM05TBE DI DM05TBE DM05TBE DN KLS-0611 DM05TBE TI TTHBUXE DM05TBE TN Mucin (MUC) DM05TBE MA Stimulator DM05TBE RN WO patent application no. 2011,1034,23, Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors. DM05TBE RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110825&CC=WO&NR=2011103423A1&KC=A1 DM05WIU DI DM05WIU DM05WIU DN PBI-05204 DM05WIU TI TTQ38E9 DM05WIU TN Sodium/potassium-transporting ATPase (SPT ATPase) DM05WIU MA Inhibitor DM05WIU RN First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf- beta and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec;32(6):1204-12. DM05WIU RU https://pubmed.ncbi.nlm.nih.gov/24919855 DM06GDC DI DM06GDC DM06GDC DN T2c-001 DM06GDC TI TTXQYT6 DM06GDC TN T-cells (T-cells) DM06GDC MA Modulator DM06GDC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM06GDC RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM08F12 DI DM08F12 DM08F12 DN KT6-971 DM08F12 TI TTNA5ZS DM08F12 TN Cholesterol absorption (Chole absorp) DM08F12 MA Inhibitor DM08F12 RN Intestinal and Hepatic Niemann-Pick C1-Like 1. Correction in: Diabetes Metab J. 2013 December; 37(6): 486-487. DM08F12 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753488/ DM094UH DI DM094UH DM094UH DN CB-839 DM094UH TI TTCW0KX DM094UH TN Glutaminase (GLS) DM094UH MA Modulator DM094UH RN Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901. DM094UH RU https://pubmed.ncbi.nlm.nih.gov/24523301 DM0AOID DI DM0AOID DM0AOID DN MB-CART19.1 DM0AOID TI TTW640A DM0AOID TN B-lymphocyte surface antigen B4 (CD19) DM0AOID MA CAR-T-Cell-Therapy DM0AOID RN ClinicalTrials.gov (NCT03321123) MB-CART19.1 in Patients With R/R ALL DM0AOID RU https://clinicaltrials.gov/ct2/show/NCT03321123 DM0BFJ5 DI DM0BFJ5 DM0BFJ5 DN RPSGL-Ig DM0BFJ5 TI TTE5VG0 DM0BFJ5 TN P-selectin (SELP) DM0BFJ5 MA Inhibitor DM0BFJ5 RN rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6. DM0BFJ5 RU https://pubmed.ncbi.nlm.nih.gov/25817339 DM0CL4I DI DM0CL4I DM0CL4I DN MCS-110 DM0CL4I TI TT731LW DM0CL4I TN Colony stimulating factor-1 receptor (CSF-1R) DM0CL4I MA Modulator DM0CL4I RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM0CL4I RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM0DRAZ DI DM0DRAZ DM0DRAZ DN AMG 479 DM0DRAZ TI TTHRID2 DM0DRAZ TN Insulin-like growth factor I receptor (IGF1R) DM0DRAZ MA Inhibitor DM0DRAZ RN Clinical pipeline report, company report or official report of Amgen (2009). DM0DRAZ RU http://www.amgen.com/science/pipe.jsp DM0DT45 DI DM0DT45 DM0DT45 DN CYSTEMUSTINE DM0DT45 TI TTUTN1I DM0DT45 TN Human Deoxyribonucleic acid (hDNA) DM0DT45 MA Binder DM0DT45 RN A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models. J Pharmacol Exp Ther. 2008 Jul;326(1):171-7. DM0DT45 RU https://pubmed.ncbi.nlm.nih.gov/18411412 DM0EDHJ DI DM0EDHJ DM0EDHJ DN CC-90011 DM0EDHJ TI TTNR0UQ DM0EDHJ TN Lysine-specific histone demethylase 1 (LSD) DM0EDHJ MA Inhibitor DM0EDHJ RN Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529. DM0EDHJ RU https://pubmed.ncbi.nlm.nih.gov/33034194 DM0EZWI DI DM0EZWI DM0EZWI DN MDX-1100 DM0EZWI TI TTQOVYA DM0EZWI TN C-X-C motif chemokine 10 (CXCL10) DM0EZWI RN A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9. DM0EZWI RU https://pubmed.ncbi.nlm.nih.gov/22147649 DM0FGDO DI DM0FGDO DM0FGDO DN ACCLAIM DM0FGDO TI TTCM4B3 DM0FGDO TN Nitric-oxide synthase endothelial (NOS3) DM0FGDO MA Stimulator DM0FGDO RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DM0FGDO RU http://www.centerwatch.com/ DM0FJIE DI DM0FJIE DM0FJIE DN Ontuxizumab DM0FJIE TI TTYJWT7 DM0FJIE TN Endosialin (CD248) DM0FJIE MA Inhibitor DM0FJIE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0FJIE RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM0FXMZ DI DM0FXMZ DM0FXMZ DN APG-101 DM0FXMZ TI TTF0RCZ DM0FXMZ TN Apoptosis mediating surface antigen FAS (FAS) DM0FXMZ MA Inhibitor DM0FXMZ RN Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol. 2012 May;13(1):93-100. DM0FXMZ RU https://pubmed.ncbi.nlm.nih.gov/22446296 DM0G5O6 DI DM0G5O6 DM0G5O6 DN Flumatinib DM0G5O6 TI TT3PJMV DM0G5O6 TN Tyrosine-protein kinase ABL1 (ABL) DM0G5O6 MA Inhibitor DM0G5O6 RN Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2014 Jan;105(1):117-25. DM0G5O6 RU https://pubmed.ncbi.nlm.nih.gov/24205792 DM0GZTD DI DM0GZTD DM0GZTD DN L-ornithine phenylacetate DM0GZTD TI TTSXVID DM0GZTD TN Nuclear factor NF-kappa-B (NFKB) DM0GZTD MA Modulator DM0GZTD RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM0GZTD RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM0K8U7 DI DM0K8U7 DM0K8U7 DN YSIL6 DM0K8U7 TI TTT1V78 DM0K8U7 TN Interleukin-6 (IL6) DM0K8U7 MA Inhibitor DM0K8U7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020380) DM0K8U7 RU http://adisinsight.springer.com/drugs/800020380 DM0KBML DI DM0KBML DM0KBML DN REGN-COV2 DM0KBML TI TTZ3COY DM0KBML TN COVID-19 spike glycoprotein (S) DM0KBML MA Inhibitor DM0KBML RN REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):238-251. DM0KBML RU https://pubmed.ncbi.nlm.nih.gov/33332778 DM0KJDY DI DM0KJDY DM0KJDY DN LY2801653 DM0KJDY TI TTNDSF4 DM0KJDY TN Proto-oncogene c-Met (MET) DM0KJDY MA Modulator DM0KJDY RN Clinical pipeline report, company report or official report of Eli Lilly. DM0KJDY RU http://www.lillyoncologypipeline.com/met-inhibitor.aspx DM0KJDY DI DM0KJDY DM0KJDY DN LY2801653 DM0KJDY TI TTU8W4S DM0KJDY TN Protein kinase (PK) DM0KJDY MA Inhibitor DM0KJDY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0KJDY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0KRLJ DI DM0KRLJ DM0KRLJ DN PF-885706 DM0KRLJ TI TT07C3Y DM0KRLJ TN 5-HT 4 receptor (HTR4) DM0KRLJ MA Agonist DM0KRLJ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025579) DM0KRLJ RU http://adisinsight.springer.com/drugs/800025579 DM0KVJC DI DM0KVJC DM0KVJC DN EC-145 DM0KVJC TI TTVC37M DM0KVJC TN Folate receptor alpha (FOLR1) DM0KVJC MA Modulator DM0KVJC RN Significance of Folate Receptor alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small Cell Lung Cancer treated with Pemetrexed. J Thorac Oncol. 2013 January; 8(1): 19-30. DM0KVJC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645936/ DM0LA6E DI DM0LA6E DM0LA6E DN HGTV43 DM0LA6E TI TT6S84O DM0LA6E TN Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element) DM0LA6E RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM0LA6E RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM0LA6E DI DM0LA6E DM0LA6E DN HGTV43 DM0LA6E TI TTFP96H DM0LA6E TN Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA) DM0LA6E RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM0LA6E RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM0LA6E DI DM0LA6E DM0LA6E DN HGTV43 DM0LA6E TI TTRP4JT DM0LA6E TN Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA) DM0LA6E RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM0LA6E RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM0M7QW DI DM0M7QW DM0M7QW DN AZD-8848 DM0M7QW TI TTRJ1K4 DM0M7QW TN Toll-like receptor 7 (TLR7) DM0M7QW MA Agonist DM0M7QW RN Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53. DM0M7QW RU https://pubmed.ncbi.nlm.nih.gov/22726593 DM0MO8I DI DM0MO8I DM0MO8I DN BQ-123 DM0MO8I TI TTKRD0G DM0MO8I TN Endothelin A receptor (EDNRA) DM0MO8I MA Antagonist DM0MO8I RN Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4. DM0MO8I RU https://pubmed.ncbi.nlm.nih.gov/9068384 DM0MTP8 DI DM0MTP8 DM0MTP8 DN CN-105 DM0MTP8 TI TTKS9CB DM0MTP8 TN Apolipoprotein E (APOE) DM0MTP8 MA Agonist DM0MTP8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0MTP8 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM0NFMS DI DM0NFMS DM0NFMS DN XEN-2174 DM0NFMS TI TTAWNKZ DM0NFMS TN Norepinephrine transporter (NET) DM0NFMS MA Inhibitor DM0NFMS RN Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6. DM0NFMS RU https://pubmed.ncbi.nlm.nih.gov/15661433 DM0NJWG DI DM0NJWG DM0NJWG DN Human interleukin-2 DM0NJWG TI TTF89GD DM0NJWG TN Interleukin-2 (IL2) DM0NJWG MA Modulator DM0NJWG RN Clinical pipeline report, company report or official report of Immunservice. DM0NJWG RU http://www.immunservice.com/index.php?page=regulatory DM0OHX3 DI DM0OHX3 DM0OHX3 DN LB-30870 DM0OHX3 TI TT6L509 DM0OHX3 TN Coagulation factor IIa (F2) DM0OHX3 MA Inhibitor DM0OHX3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM0OHX3 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTFQI4H DM0OVZ2 TN Tankyrase-2 (TNKS-2) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTVUSO7 DM0OVZ2 TN Tankyrase-1 (TNKS-1) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTVDSZ0 DM0OVZ2 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OVZ2 DI DM0OVZ2 DM0OVZ2 DN PMID27841036-Compound-37 DM0OVZ2 TI TTQ4V96 DM0OVZ2 TN Poly [ADP-ribose] polymerase 2 (PARP2) DM0OVZ2 MA Inhibitor DM0OVZ2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM0OVZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM0OYLQ DI DM0OYLQ DM0OYLQ DN I-vation DM0OYLQ TI TTJL8VG DM0OYLQ TN Corticosteroid-binding globulin (SERPINA6) DM0OYLQ MA Modulator DM0OYLQ RN Cortisol binding in rat skeletal muscle. J Biol Chem. 1975 Feb 25;250(4):1207-11. DM0OYLQ RU https://pubmed.ncbi.nlm.nih.gov/163248 DM0PFNC DI DM0PFNC DM0PFNC DN AZD6738 DM0PFNC TI TT8ZYBQ DM0PFNC TN Serine/threonine-protein kinase ATR (FRP1) DM0PFNC MA Inhibitor DM0PFNC RN National Cancer Institute Drug Dictionary (drug id 754022). DM0PFNC RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754022 DM0POWG DI DM0POWG DM0POWG DN Vidofludimus DM0POWG TI TTLVP78 DM0POWG TN Dihydroorotate dehydrogenase (DHODH) DM0POWG MA Modulator DM0POWG RN Company report (4SC) DM0POWG RU http://www.4sc.de/product-pipeline/clinical/vidofludimus DM0RA8F DI DM0RA8F DM0RA8F DN Oleoyl-estrone DM0RA8F TI TT8A9EF DM0RA8F TN Metabotropic glutamate receptor 3 (mGluR3) DM0RA8F MA Agonist DM0RA8F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0RA8F RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0RA8F DI DM0RA8F DM0RA8F DN Oleoyl-estrone DM0RA8F TI TTXJ47W DM0RA8F TN Metabotropic glutamate receptor 2 (mGluR2) DM0RA8F MA Agonist DM0RA8F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0RA8F RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0RPY5 DI DM0RPY5 DM0RPY5 DN ACH-3102 DM0RPY5 TI TTCJ2X8 DM0RPY5 TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM0RPY5 MA Modulator DM0RPY5 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM0RPY5 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM0TZEP DI DM0TZEP DM0TZEP DN Bamosiran DM0TZEP TI TTG8ZWP DM0TZEP TN ADRB2 messenger RNA (ADRB2 mRNA) DM0TZEP MA Inhibitor DM0TZEP RN Clinical pipeline report, company report or official report of Sylentis. DM0TZEP RU https://www.sylentis.com/index.php/en/pipeline/bamosiran DM0VGDC DI DM0VGDC DM0VGDC DN ARRY-382 DM0VGDC TI TT731LW DM0VGDC TN Colony stimulating factor-1 receptor (CSF-1R) DM0VGDC MA Modulator DM0VGDC RN Company report (Array) DM0VGDC RU http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-382/ DM0VGDC DI DM0VGDC DM0VGDC DN ARRY-382 DM0VGDC TI TT7MRDV DM0VGDC TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM0VGDC MA Inhibitor DM0VGDC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0VGDC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0W3R7 DI DM0W3R7 DM0W3R7 DN MCLA-128 DM0W3R7 TI TT6EO5L DM0W3R7 TN Erbb2 tyrosine kinase receptor (HER2) DM0W3R7 MA Antagonist DM0W3R7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0W3R7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0WY3H DI DM0WY3H DM0WY3H DN JNJ-39220675 DM0WY3H TI TT9JNIC DM0WY3H TN Histamine H3 receptor (H3R) DM0WY3H MA Antagonist DM0WY3H RN JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41. DM0WY3H RU https://pubmed.ncbi.nlm.nih.gov/21086115 DM0Y8JP DI DM0Y8JP DM0Y8JP DN DAS-181 DM0Y8JP TI TT50QJ3 DM0Y8JP TN Influenza Neuraminidase (Influ NA) DM0Y8JP MA Inhibitor DM0Y8JP RN Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS One. 2009 Nov 6;4(11):e7838. DM0Y8JP RU https://pubmed.ncbi.nlm.nih.gov/19893749 DM0YCPL DI DM0YCPL DM0YCPL DN Bemcentinib DM0YCPL TI TTZPY6J DM0YCPL TN Tyrosine-protein kinase UFO (AXL) DM0YCPL MA Inhibitor DM0YCPL RN AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. J Thorac Oncol. 2020 Jun;15(6):973-999. DM0YCPL RU https://pubmed.ncbi.nlm.nih.gov/32018052 DM0YO4Q DI DM0YO4Q DM0YO4Q DN Urocortin 2 DM0YO4Q TI TTIY658 DM0YO4Q TN Corticotropin-releasing factor receptor 2 (CRHR2) DM0YO4Q MA Antagonist DM0YO4Q RN Evolution of complementary peptide systems: teneurin C-terminal-associated peptides and corticotropin-releasing factor superfamilies. Ann N Y Acad Sci. 2009 Apr;1163:215-20. DM0YO4Q RU https://pubmed.ncbi.nlm.nih.gov/19456342 DM0YWQ4 DI DM0YWQ4 DM0YWQ4 DN VB 1953 DM0YWQ4 TI TTFK8YB DM0YWQ4 TN Bacterial DNA topoisomerase 4A (Bact parC) DM0YWQ4 MA Inhibitor DM0YWQ4 RN Clinical pipeline report, company report or official report of Vyome Therapeutics. DM0YWQ4 RU https://www.vyometx.com/platform-strategy.html DM0YWQ4 DI DM0YWQ4 DM0YWQ4 DN VB 1953 DM0YWQ4 TI TTN6J5F DM0YWQ4 TN Bacterial DNA gyrase (Bact gyrase) DM0YWQ4 MA Inhibitor DM0YWQ4 RN Clinical pipeline report, company report or official report of Vyome Therapeutics. DM0YWQ4 RU https://www.vyometx.com/platform-strategy.html DM0ZIT2 DI DM0ZIT2 DM0ZIT2 DN PTX-200 DM0ZIT2 TI TTWTSCV DM0ZIT2 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM0ZIT2 MA Inhibitor DM0ZIT2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0ZIT2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM104SP DI DM104SP DM104SP DN Vericigiuat DM104SP TI TTLBYH1 DM104SP TN Guanylate cyclase soluble beta-1 (GUCY1B1) DM104SP MA Modulator DM104SP RN Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026-38. DM104SP RU https://pubmed.ncbi.nlm.nih.gov/25056511 DM129T7 DI DM129T7 DM129T7 DN CROMOGLYCATE LISETIL HYDROCHLORIDE DM129T7 TI TTE87WJ DM129T7 TN Calcium-activated potassium channel KCa1.1 (KCNMA1) DM129T7 MA Modulator DM129T7 RN The significance of chloride in the inhibitory action of disodium cromoglycate on immunologically-stimulated rat peritoneal mast cells. Biochim Biophys Acta. 2011 Sep;1810(9):867-74. DM129T7 RU https://pubmed.ncbi.nlm.nih.gov/21635937 DM13G5R DI DM13G5R DM13G5R DN TRK-170 DM13G5R TI TT7ZMI1 DM13G5R TN Integrin alpha-4/beta-7 (ITGA4/B7) DM13G5R MA Modulator DM13G5R RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM13G5R RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM13G5R DI DM13G5R DM13G5R DN TRK-170 DM13G5R TI TT6S84X DM13G5R TN Integrin alpha-4/beta-1 (ITGA4/B1) DM13G5R MA Modulator DM13G5R RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM13G5R RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM13OVF DI DM13OVF DM13OVF DN REMD 477 DM13OVF TI TT9O6WS DM13OVF TN Glucagon receptor (GCGR) DM13OVF MA Antagonist DM13OVF RN Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305. DM13OVF RU https://pubmed.ncbi.nlm.nih.gov/29283470 DM157U0 DI DM157U0 DM157U0 DN Sofinicline DM157U0 TI TTL1ATN DM157U0 TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DM157U0 MA Modulator DM157U0 RN Sofinicline: a novel nicotinic acetylcholine receptor agonist in the treatment of attention-deficit/hyperactivity disorder. Expert Opin Investig Drugs. 2014 Aug;23(8):1157-63. DM157U0 RU https://pubmed.ncbi.nlm.nih.gov/24965900 DM15MRZ DI DM15MRZ DM15MRZ DN IMR-687 DM15MRZ TI TTZOEBC DM15MRZ TN Phosphodiesterase 9 (PDE9) DM15MRZ MA Inhibitor DM15MRZ RN Clinical pipeline report, company report or official report of Imara. DM15MRZ RU https://imaratx.com/our-programs/ DM15QL9 DI DM15QL9 DM15QL9 DN ROXINDOLE DM15QL9 TI TTEX248 DM15QL9 TN Dopamine D2 receptor (D2R) DM15QL9 MA Inhibitor DM15QL9 RN Indolebutylamines as selective 5-HT(1A) agonists. J Med Chem. 2004 Sep 9;47(19):4677-83. DM15QL9 RU https://pubmed.ncbi.nlm.nih.gov/15341483 DM15RZO DI DM15RZO DM15RZO DN KYMRIAH DM15RZO TI TTW640A DM15RZO TN B-lymphocyte surface antigen B4 (CD19) DM15RZO MA CAR-T-Cell-Therapy DM15RZO RN ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies DM15RZO RU https://clinicaltrials.gov/ct2/show/NCT03642626 DM16IMT DI DM16IMT DM16IMT DN CRYPTOPHYCIN 52 DM16IMT TI TTML2WA DM16IMT TN Tubulin (TUB) DM16IMT MA Inhibitor DM16IMT RN Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer. 2003 Feb;39(2):197-9. DM16IMT RU https://pubmed.ncbi.nlm.nih.gov/12581573 DM16KJ3 DI DM16KJ3 DM16KJ3 DN CNS-5161 DM16KJ3 TI TT9IK2Z DM16KJ3 TN N-methyl-D-aspartate receptor (NMDAR) DM16KJ3 MA Antagonist DM16KJ3 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM16KJ3 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM16RIC DI DM16RIC DM16RIC DN Oprozomib DM16RIC TI TTU7ZMG DM16RIC TN Proteasome (PS) DM16RIC MA Modulator DM16RIC RN A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 2;116(23):4906-15. DM16RIC RU https://pubmed.ncbi.nlm.nih.gov/20805366 DM17469 DI DM17469 DM17469 DN ARRY-502 DM17469 TI TTQDMX5 DM17469 TN Prostaglandin D2 receptor 2 (PTGDR2) DM17469 MA Modulator DM17469 RN Clinical pipeline report, company report or official report of Array BioPharma (Drug: ARRY-502). DM17469 RU http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-502/ DM17JSI DI DM17JSI DM17JSI DN CGC-11047 DM17JSI TI TTUTN1I DM17JSI TN Human Deoxyribonucleic acid (hDNA) DM17JSI MA Modulator DM17JSI RN Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75. DM17JSI RU https://pubmed.ncbi.nlm.nih.gov/19487545 DM17OZM DI DM17OZM DM17OZM DN GL-0817 DM17OZM TI TTWSKHD DM17OZM TN Melanoma-associated antigen 3 (MAGEA3) DM17OZM MA Immunomodulator DM17OZM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM17OZM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM180VX DI DM180VX DM180VX DN SC-49483 DM180VX TI TTXWASR DM180VX TN Intestinal maltase-glucoamylase (MGAM) DM180VX MA Inhibitor DM180VX RN Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8. DM180VX RU https://pubmed.ncbi.nlm.nih.gov/8923673 DM1945H DI DM1945H DM1945H DN JTT-251 DM1945H TI TT3UNDH DM1945H TN Pyruvate dehydrogenase kinase (PDHK) DM1945H MA Inhibitor DM1945H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1945H RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM19GUH DI DM19GUH DM19GUH DN TVB-2640 DM19GUH TI TT7AOUD DM19GUH TN Fatty acid synthase (FASN) DM19GUH MA Inhibitor DM19GUH RN Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117. DM19GUH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027139/ DM1AQLW DI DM1AQLW DM1AQLW DN Otilimab DM1AQLW TI TTPZGYX DM1AQLW TN HUMAN colony-stimulating factor (GM-CSF) DM1AQLW MA Inhibitor DM1AQLW RN The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468. DM1AQLW RU https://pubmed.ncbi.nlm.nih.gov/32317220 DM1B8IT DI DM1B8IT DM1B8IT DN Apadoline DM1B8IT TI TTQW87Y DM1B8IT TN Opioid receptor kappa (OPRK1) DM1B8IT MA Agonist DM1B8IT RN Novel developments with selective, non-peptidic kappa-opioid receptor agonists. Expert Opin Investig Drugs. 1997 Oct;6(10):1351-68. DM1B8IT RU https://pubmed.ncbi.nlm.nih.gov/15989506 DM1BYNF DI DM1BYNF DM1BYNF DN THRX-198321 DM1BYNF TI TT2CJVK DM1BYNF TN Adrenergic receptor beta-2 (ADRB2) DM1BYNF MA Modulator DM1BYNF RN THRX-198321 is a bifunctional muscarinic receptor antagonist and beta2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol. 2011 Mar;79(3):389-99. DM1BYNF RU https://pubmed.ncbi.nlm.nih.gov/21139051 DM1C9NQ DI DM1C9NQ DM1C9NQ DN SCY-635 DM1C9NQ TI TTATDGJ DM1C9NQ TN Calcium signal-modulating cyclophilin ligand (CAML) DM1C9NQ MA Modulator DM1C9NQ RN SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010 Feb;54(2):660-72. DM1C9NQ RU https://pubmed.ncbi.nlm.nih.gov/19933795 DM1CLKO DI DM1CLKO DM1CLKO DN ASKP-1240 DM1CLKO TI TTN6Y9A DM1CLKO TN CD40L receptor (CD40) DM1CLKO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874). DM1CLKO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874 DM1E4VP DI DM1E4VP DM1E4VP DN IL-21 DM1E4VP TI TT9QEJ6 DM1E4VP TN Interleukin-21 (IL21) DM1E4VP MA Modulator DM1E4VP RN National Cancer Institute Drug Dictionary (drug id 409696). DM1E4VP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=409696 DM1EK5D DI DM1EK5D DM1EK5D DN Ortataxel DM1EK5D TI TT0JLSD DM1EK5D TN Multidrug resistance protein (MDR) DM1EK5D MA Modulator DM1EK5D RN Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009). DM1EK5D RU http://www.spectrumpharm.com/products_Spectrum.html DM1EK5D DI DM1EK5D DM1EK5D DN Ortataxel DM1EK5D TI TTF8CQI DM1EK5D TN Tumor necrosis factor (TNF) DM1EK5D MA Inhibitor DM1EK5D RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DM1EK5D RU https://pubmed.ncbi.nlm.nih.gov/19265486 DM1EPMF DI DM1EPMF DM1EPMF DN GSK1322322 DM1EPMF TI TTICO5G DM1EPMF TN Staphylococcus Peptide deformylase (Stap-coc def) DM1EPMF MA Modulator DM1EPMF RN Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36. DM1EPMF RU https://pubmed.ncbi.nlm.nih.gov/25174923 DM1FCDH DI DM1FCDH DM1FCDH DN EV-077 DM1FCDH TI TTKNWZ4 DM1FCDH TN Thromboxane-A synthase (TBXAS1) DM1FCDH MA Modulator DM1FCDH RN Company report (Pharmaceuticalintelligence) DM1FCDH RU http://pharmaceuticalintelligence.com/tag/diabetic-nephropathy/ DM1FJ2B DI DM1FJ2B DM1FJ2B DN AFP464 DM1FJ2B TI TT2QPV9 DM1FJ2B TN Aryl hydrocarbon receptor signaling pathway (AhR pathway) DM1FJ2B MA Suppressor DM1FJ2B RN Clinical pipeline report, company report or official report of AFP464. DM1FJ2B RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/afp464 DM1FS2W DI DM1FS2W DM1FS2W DN Revamilast DM1FS2W TI TTSKMI8 DM1FS2W TN Phosphodiesterase 4D (PDE4D) DM1FS2W MA Inhibitor DM1FS2W RN WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate . DM1FS2W RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1 DM1FS2W DI DM1FS2W DM1FS2W DN Revamilast DM1FS2W TI TTVIAT9 DM1FS2W TN Phosphodiesterase 4B (PDE4B) DM1FS2W MA Inhibitor DM1FS2W RN WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate . DM1FS2W RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1 DM1FS2W DI DM1FS2W DM1FS2W DN Revamilast DM1FS2W TI TTZ97H5 DM1FS2W TN Phosphodiesterase 4A (PDE4A) DM1FS2W MA Inhibitor DM1FS2W RN WO patent application no. 2012,1109,46, Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate . DM1FS2W RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120823&CC=WO&NR=2012110946A1&KC=A1 DM1G6ME DI DM1G6ME DM1G6ME DN VIS410 DM1G6ME TI TTF4CAM DM1G6ME TN Influenza Hemagglutinin (Influ HA) DM1G6ME MA Inhibitor DM1G6ME RN Clinical pipeline report, company report or official report of Visterra. DM1G6ME RU http://www.visterrainc.com/#pipeline DM1GRCU DI DM1GRCU DM1GRCU DN JNJ-17216498 DM1GRCU TI TT9JNIC DM1GRCU TN Histamine H3 receptor (H3R) DM1GRCU MA Antagonist DM1GRCU RN Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61. DM1GRCU RU https://pubmed.ncbi.nlm.nih.gov/15466448 DM1H7UK DI DM1H7UK DM1H7UK DN Dectrekumab DM1H7UK TI TT0GVCH DM1H7UK TN Interleukin-13 (IL13) DM1H7UK MA Inhibitor DM1H7UK RN Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. DM1H7UK RU https://pubmed.ncbi.nlm.nih.gov/25226850 DM1HC9R DI DM1HC9R DM1HC9R DN MGL-3196 DM1HC9R TI TTGER3L DM1HC9R TN Thyroid hormone receptor beta (THRB) DM1HC9R MA Agonist DM1HC9R RN Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-beta agonist. Atherosclerosis. 2013 Oct;230(2):373-80. DM1HC9R RU https://pubmed.ncbi.nlm.nih.gov/24075770 DM1HG3U DI DM1HG3U DM1HG3U DN DM-99 DM1HG3U TI TTCBFJO DM1HG3U TN Insulin receptor (INSR) DM1HG3U MA Agonist DM1HG3U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM1HG3U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM1IBRT DI DM1IBRT DM1IBRT DN OPN-305 DM1IBRT TI TTY7ZHS DM1IBRT TN Toll-like receptor 2 (TLR2) DM1IBRT RN Treatment with OPN-305, a humanized anti-Toll-Like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv. 2012 Apr;5(2):279-87. DM1IBRT RU https://pubmed.ncbi.nlm.nih.gov/22354933 DM1JBD8 DI DM1JBD8 DM1JBD8 DN OC-000459 DM1JBD8 TI TTQDMX5 DM1JBD8 TN Prostaglandin D2 receptor 2 (PTGDR2) DM1JBD8 MA Antagonist DM1JBD8 RN Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013 Mar;68(3):375-85. DM1JBD8 RU https://pubmed.ncbi.nlm.nih.gov/23379537 DM1JNDV DI DM1JNDV DM1JNDV DN PRX00933 DM1JNDV TI TTWJBZ5 DM1JNDV TN 5-HT 2C receptor (HTR2C) DM1JNDV MA Agonist DM1JNDV RN 2011 Pipeline of Proximagen Group plc. DM1JNDV RU http://www.proximagen.com/science/pipeline/ DM1KGS7 DI DM1KGS7 DM1KGS7 DN Tesofensine DM1KGS7 TI TTCBFJO DM1KGS7 TN Insulin receptor (INSR) DM1KGS7 MA Inhibitor DM1KGS7 RN The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol. 2010 Jun 25;636(1-3):88-95. DM1KGS7 RU https://pubmed.ncbi.nlm.nih.gov/20385125 DM1LDIP DI DM1LDIP DM1LDIP DN Econail DM1LDIP TI TTTSOUD DM1LDIP TN Candida Cytochrome P450 51 (Candi ERG11) DM1LDIP MA Inhibitor DM1LDIP RN Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother. 2010 Oct;54(10):4235-45. DM1LDIP RU https://pubmed.ncbi.nlm.nih.gov/20625155 DM1M0PR DI DM1M0PR DM1M0PR DN Saruplase DM1M0PR TI TTGY7WI DM1M0PR TN Urokinase-type plasminogen activator (PLAU) DM1M0PR MA Activator DM1M0PR RN Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4. DM1M0PR RU https://pubmed.ncbi.nlm.nih.gov/7534946 DM1M57I DI DM1M57I DM1M57I DN MK-2578 DM1M57I TI TTQG4NR DM1M57I TN Erythropoietin (EPO) DM1M57I MA Agonist DM1M57I RN Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636. DM1M57I RU https://pubmed.ncbi.nlm.nih.gov/20622817 DM1NCUY DI DM1NCUY DM1NCUY DN CMI-392 DM1NCUY TI TT2J34L DM1NCUY TN Arachidonate 5-lipoxygenase (5-LOX) DM1NCUY MA Modulator DM1NCUY RN Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. DM1NCUY RU https://pubmed.ncbi.nlm.nih.gov/11529688 DM1NCUY DI DM1NCUY DM1NCUY DN CMI-392 DM1NCUY TI TTQL5VC DM1NCUY TN Platelet-activating factor receptor (PTAFR) DM1NCUY MA Modulator DM1NCUY RN Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20. DM1NCUY RU https://pubmed.ncbi.nlm.nih.gov/11529688 DM1NMGJ DI DM1NMGJ DM1NMGJ DN BI 456906 DM1NMGJ TI TTVIMDE DM1NMGJ TN Glucagon-like peptide 1 receptor (GLP1R) DM1NMGJ MA Agonist DM1NMGJ RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DM1NMGJ RU https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-and-zealand-pharma-advance-dual-acting-glp-1glucagon-agonist-bi DM1O0DV DI DM1O0DV DM1O0DV DN Pradefovir DM1O0DV TI TTS5K1M DM1O0DV TN Hepatitis B virus Reverse transcriptase (HBV RT) DM1O0DV MA Modulator DM1O0DV RN DOI: 10.1128/AAC.01566-05 DM1O0DV RU http://aac.asm.org/content/50/9/2926.full DM1ODP6 DI DM1ODP6 DM1ODP6 DN VA-106483 DM1ODP6 TI TTK8R02 DM1ODP6 TN Vasopressin V2 receptor (V2R) DM1ODP6 MA Inhibitor DM1ODP6 RN New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists. J Med Chem. 2008 Dec 25;51(24):8124-34. DM1ODP6 RU https://pubmed.ncbi.nlm.nih.gov/19053774 DM1P60V DI DM1P60V DM1P60V DN NYX-2925 DM1P60V TI TT9IK2Z DM1P60V TN N-methyl-D-aspartate receptor (NMDAR) DM1P60V MA Modulator DM1P60V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1P60V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM1S2FZ DI DM1S2FZ DM1S2FZ DN Cemdisiran DM1S2FZ TI TT2LJRF DM1S2FZ TN C5 messenger RNA (C5 mRNA) DM1S2FZ MA Inhibitor DM1S2FZ RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. DM1S2FZ RU https://www.alnylam.com/alnylam-rnai-pipeline/ DM1S489 DI DM1S489 DM1S489 DN E6005 DM1S489 TI TTV5CGO DM1S489 TN Phosphodiesterase 4 (PDE4) DM1S489 MA Inhibitor DM1S489 RN Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12. DM1S489 RU https://pubmed.ncbi.nlm.nih.gov/23674603 DM1SB94 DI DM1SB94 DM1SB94 DN Tiprelestat DM1SB94 TI TT5MLC4 DM1SB94 TN Leukocyte proteinase-3 (PRTN3) DM1SB94 MA Modulator DM1SB94 RN Company report (Proteo Biotech AG) DM1SB94 RU http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html DM1SB94 DI DM1SB94 DM1SB94 DN Tiprelestat DM1SB94 TI TTPLTSQ DM1SB94 TN Neutrophil elastase (NE) DM1SB94 MA Modulator DM1SB94 RN Company report (Proteo Biotech AG) DM1SB94 RU http://proteo.us/proteo-inc/r-und-d/lead-product-elafin.html DM1T3KQ DI DM1T3KQ DM1T3KQ DN AMG-714 DM1T3KQ TI TTJFA35 DM1T3KQ TN Interleukin-15 (IL15) DM1T3KQ RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DM1T3KQ RU https://pubmed.ncbi.nlm.nih.gov/18321156 DM1TKG4 DI DM1TKG4 DM1TKG4 DN RDEA3170 DM1TKG4 TI TTA592U DM1TKG4 TN Urate anion exchanger 1 (URAT1) DM1TKG4 MA Modulator DM1TKG4 RN The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164. DM1TKG4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750299/ DM1TSHL DI DM1TSHL DM1TSHL DN Taprenepag DM1TSHL TI TT1ZAVI DM1TSHL TN Prostaglandin E2 receptor EP2 (PTGER2) DM1TSHL MA Agonist DM1TSHL RN A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17. DM1TSHL RU https://pubmed.ncbi.nlm.nih.gov/21851167 DM1TWIE DI DM1TWIE DM1TWIE DN CFZ533 DM1TWIE TI TTN6Y9A DM1TWIE TN CD40L receptor (CD40) DM1TWIE MA Inhibitor DM1TWIE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1TWIE RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM1UO4S DI DM1UO4S DM1UO4S DN Descartes-11 DM1UO4S TI TTZ3P4W DM1UO4S TN B-cell maturation protein (TNFRSF17) DM1UO4S RN Clinical pipeline report, company report or official report of Cartesian Therapeutics. DM1UO4S RU https://www.cartesiantherapeutics.com/clinical-trials/ DM1USXR DI DM1USXR DM1USXR DN AQ-13 DM1USXR TI TTKY2NS DM1USXR TN Duffy antigen chemokine receptor (ACKR1) DM1USXR MA Modulator DM1USXR RN From control to eradication of malaria: the end of being stuck in second gear . Asian Pacific Journal of Tropical Medicine Volume 3, Issue 5, May 2010, Pages 412-420. DM1USXR RU http://www.sciencedirect.com/science/article/pii/S1995764510601010 DM1VITS DI DM1VITS DM1VITS DN APD-403 DM1VITS TI TTEX248 DM1VITS TN Dopamine D2 receptor (D2R) DM1VITS MA Antagonist DM1VITS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215). DM1VITS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215 DM1VK96 DI DM1VK96 DM1VK96 DN LANEPITANT DM1VK96 TI TTZPO1L DM1VK96 TN Substance-P receptor (TACR1) DM1VK96 MA Antagonist DM1VK96 RN NK1 receptor antagonists as a new treatment for corneal neovascularization. Invest Ophthalmol Vis Sci. 2014 Sep 16;55(10):6783-94. DM1VK96 RU https://pubmed.ncbi.nlm.nih.gov/25228541 DM1X3L0 DI DM1X3L0 DM1X3L0 DN BGB-3245 DM1X3L0 TI TTB18GJ DM1X3L0 TN Proto-oncogene c-RAF (c-RAF) DM1X3L0 MA Inhibitor DM1X3L0 RN Clinical pipeline report, company report or official report of BeiGene. DM1X3L0 RU https://www.beigene.com/science-and-product-portfolio/pipeline DM1YAK6 DI DM1YAK6 DM1YAK6 DN GDC0941 DM1YAK6 TI TTHBTOP DM1YAK6 TN PI3-kinase gamma (PIK3CG) DM1YAK6 MA Inhibitor DM1YAK6 RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DM1YAK6 RU https://pubmed.ncbi.nlm.nih.gov/19644473 DM1ZJYS DI DM1ZJYS DM1ZJYS DN Dusigitumab DM1ZJYS TI TTE8WGO DM1ZJYS TN Insulin-like growth factor-II (IGF2) DM1ZJYS MA Inhibitor DM1ZJYS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1ZJYS RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1ZOCK DI DM1ZOCK DM1ZOCK DN Bryostatin-1 DM1ZOCK TI TTBZ7OD DM1ZOCK TN Protein kinase C epsilon (PRKCE) DM1ZOCK MA Activator DM1ZOCK RN Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8. DM1ZOCK RU https://pubmed.ncbi.nlm.nih.gov/11490365 DM1ZQEN DI DM1ZQEN DM1ZQEN DN TRAXOPRODIL MESYLATE DM1ZQEN TI TT9IK2Z DM1ZQEN TN N-methyl-D-aspartate receptor (NMDAR) DM1ZQEN MA Modulator DM1ZQEN RN The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury. J Neurotrauma. 2005 Dec;22(12):1428-43. DM1ZQEN RU https://pubmed.ncbi.nlm.nih.gov/16379581 DM20ATW DI DM20ATW DM20ATW DN Diflomotecan DM20ATW TI TTGTQHC DM20ATW TN DNA topoisomerase I (TOP1) DM20ATW MA Inhibitor DM20ATW RN Diflomotecan, a promising homocamptothecin for cancer therapy. Expert Opin Investig Drugs. 2009 Jan;18(1):69-75. DM20ATW RU https://pubmed.ncbi.nlm.nih.gov/19053883 DM20CIM DI DM20CIM DM20CIM DN RNF43-721 DM20CIM TI TTD91BL DM20CIM TN RING finger protein 43 (RNF43) DM20CIM MA Modulator DM20CIM RN Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer. Exp Ther Med. 2011 Jan-Feb; 2(1): 73-79. DM20CIM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440656/ DM20MDU DI DM20MDU DM20MDU DN Danoprevir DM20MDU TI TT5FNQT DM20MDU TN Human immunodeficiency virus Protease (HIV PR) DM20MDU MA Inhibitor DM20MDU RN 2011 Pipeline of InterMune. DM20MDU RU http://www.intermune.com/pipeline DM219SF DI DM219SF DM219SF DN JNJ-40346527 DM219SF TI TT731LW DM219SF TN Colony stimulating factor-1 receptor (CSF-1R) DM219SF MA Modulator DM219SF RN An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma. Clin Cancer Res. 2015 Apr 15;21(8):1843-50. DM219SF RU https://pubmed.ncbi.nlm.nih.gov/25628399 DM21Z68 DI DM21Z68 DM21Z68 DN Nimacimab DM21Z68 TI TT6OEDT DM21Z68 TN Cannabinoid receptor 1 (CB1) DM21Z68 MA Antagonist DM21Z68 RN Clinical pipeline report, company report or official report of Bird Rock Bio. DM21Z68 RU http://www.birdrockbio.com/our-pipeline/nimacimab/ DM23UQ9 DI DM23UQ9 DM23UQ9 DN ABT-122 DM23UQ9 TI TTF8CQI DM23UQ9 TN Tumor necrosis factor (TNF) DM23UQ9 MA Modulator DM23UQ9 RN DOI: 10.1136/annrheumdis-2015-eular.4042 DM23UQ9 RU http://ard.bmj.com/content/74/Suppl_2/479.2.abstract DM23UQ9 DI DM23UQ9 DM23UQ9 DN ABT-122 DM23UQ9 TI TTG0MT6 DM23UQ9 TN Interleukin-17 (IL17) DM23UQ9 MA Modulator DM23UQ9 RN DOI: 10.1136/annrheumdis-2015-eular.4042 DM23UQ9 RU http://ard.bmj.com/content/74/Suppl_2/479.2.abstract DM23Y6K DI DM23Y6K DM23Y6K DN LYS228 DM23Y6K TI TT85JMW DM23Y6K TN Bacterial Penicillin binding protein 3 (Bact mrcA) DM23Y6K MA Binder DM23Y6K RN Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In Vitro Susceptibility in Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 Sep 24;62(10):e01200-18. DM23Y6K RU https://pubmed.ncbi.nlm.nih.gov/30061293 DM2458E DI DM2458E DM2458E DN Matuzumab DM2458E TI TTGKNB4 DM2458E TN Epidermal growth factor receptor (EGFR) DM2458E RN Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73. DM2458E RU https://pubmed.ncbi.nlm.nih.gov/18394559 DM24I0N DI DM24I0N DM24I0N DN PF-4878691 DM24I0N TI TTRJ1K4 DM24I0N TN Toll-like receptor 7 (TLR7) DM24I0N MA Agonist DM24I0N RN The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9. DM24I0N RU https://pubmed.ncbi.nlm.nih.gov/21451504 DM24SOL DI DM24SOL DM24SOL DN MLN1202 DM24SOL TI TTFZYTO DM24SOL TN C-C chemokine receptor type 2 (CCR2) DM24SOL MA Antagonist DM24SOL RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM24SOL RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM24SOL DI DM24SOL DM24SOL DN MLN1202 DM24SOL TI TTUPB12 DM24SOL TN Measles virus Fusion glycoprotein (MeV F) DM24SOL MA Inhibitor DM24SOL RN Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17. DM24SOL RU https://pubmed.ncbi.nlm.nih.gov/19453286 DM2570B DI DM2570B DM2570B DN Poly-ICLC DM2570B TI TTD24Y0 DM2570B TN Toll-like receptor 3 (TLR3) DM2570B MA Inducer DM2570B RN Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med. 2007 Feb 12;5:10. DM2570B RU https://pubmed.ncbi.nlm.nih.gov/17295916 DM25VY8 DI DM25VY8 DM25VY8 DN Mydicar DM25VY8 TI TTE6THL DM25VY8 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) DM25VY8 MA Modulator DM25VY8 RN Clinical pipeline report, company report or official report of Celladon. DM25VY8 RU http://www.celladon.com/mydicar/ DM25YLM DI DM25YLM DM25YLM DN GSK2981278 DM25YLM TI TTGV6LY DM25YLM TN Nuclear receptor ROR-gamma (RORG) DM25YLM MA Agonist DM25YLM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM25YLM RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM263RP DI DM263RP DM263RP DN BIIB092 DM263RP TI TTS87KH DM263RP TN Microtubule-associated protein tau (MAPT) DM263RP MA Inhibitor DM263RP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM263RP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM26IH8 DI DM26IH8 DM26IH8 DN S-297995 DM26IH8 TI TTN4QDT DM26IH8 TN Opioid receptor (OPR) DM26IH8 MA Antagonist DM26IH8 RN Clinical pipeline report, company report or official report of Shionogi (2011). DM26IH8 RU http://www.shionogi.co.jp/index_e.html DM26YJ1 DI DM26YJ1 DM26YJ1 DN PEGPH20 DM26YJ1 TI TTXFI1K DM26YJ1 TN Hyaluronidase (HYAL) DM26YJ1 MA Modulator DM26YJ1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM26YJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM276N1 DI DM276N1 DM276N1 DN Piritrexim DM276N1 TI TTYZVDJ DM276N1 TN Dihydrofolate reductase (DHFR) DM276N1 MA Modulator DM276N1 RN Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling ... Eur J Med Chem. 2004 Dec;39(12):1079-88. DM276N1 RU https://www.ncbi.nlm.nih.gov/pubmed/15571870 DM27D4J DI DM27D4J DM27D4J DN PD-0325901 DM27D4J TI TTROQ37 DM27D4J TN MAPK/ERK kinase kinase (MAP3K) DM27D4J MA Modulator DM27D4J RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DM27D4J RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DM27KFY DI DM27KFY DM27KFY DN SB-207266A DM27KFY TI TT07C3Y DM27KFY TN 5-HT 4 receptor (HTR4) DM27KFY MA Antagonist DM27KFY RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DM27KFY RU https://pubmed.ncbi.nlm.nih.gov/11293643 DM28A5D DI DM28A5D DM28A5D DN CAR-T cells targeting CD19 DM28A5D TI TTW640A DM28A5D TN B-lymphocyte surface antigen B4 (CD19) DM28A5D MA CAR-T-Cell-Therapy DM28A5D RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DM28A5D RU https://clinicaltrials.gov/ct2/show/NCT03196830 DM28M6I DI DM28M6I DM28M6I DN TV-1102 DM28M6I TI TT2VIZQ DM28M6I TN ITGAV messenger RNA (ITGAV mRNA) DM28M6I RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM28M6I RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM293JT DI DM293JT DM293JT DN BIIB 033 DM293JT TI TTZYQ80 DM293JT TN Leucine-rich repeat neuronal protein 1 (LINGO1) DM293JT RN Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014 Aug 21;1(2):e18. DM293JT RU https://pubmed.ncbi.nlm.nih.gov/25340070 DM2C1YN DI DM2C1YN DM2C1YN DN MEGF0444A DM2C1YN TI TT7WD0H DM2C1YN TN Epidermal growth factor-like protein 7 (EGFL7) DM2C1YN MA Modulator DM2C1YN RN A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614. DM2C1YN RU http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/2614 DM2CJ4O DI DM2CJ4O DM2CJ4O DN Rebmab-100 DM2CJ4O TI TTUPAD7 DM2CJ4O TN Galactoside 3(4)-L-fucosyltransferase (FUT3) DM2CJ4O RN A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecol Oncol. 2015 Aug;138(2):272-7. DM2CJ4O RU https://pubmed.ncbi.nlm.nih.gov/26026738 DM2CJB4 DI DM2CJB4 DM2CJB4 DN MK-0773 DM2CJB4 TI TTS64P2 DM2CJB4 TN Androgen receptor (AR) DM2CJB4 MA Modulator DM2CJB4 RN Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiology. J Biol Chem. 2010 May 28;285(22):17054-64. DM2CJB4 RU https://pubmed.ncbi.nlm.nih.gov/20356837 DM2CUS0 DI DM2CUS0 DM2CUS0 DN F901318 DM2CUS0 TI TTTSUI2 DM2CUS0 TN Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH) DM2CUS0 MA Inhibitor DM2CUS0 RN Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00231-18. DM2CUS0 RU https://pubmed.ncbi.nlm.nih.gov/29891595 DM2HDTM DI DM2HDTM DM2HDTM DN Tosagestin DM2HDTM TI TTUV8G9 DM2HDTM TN Progesterone receptor (PGR) DM2HDTM MA Agonist DM2HDTM RN Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions. J Steroid Biochem Mol Biol. 1992 Jun;42(5):457-65. DM2HDTM RU https://pubmed.ncbi.nlm.nih.gov/1616875 DM2IFJQ DI DM2IFJQ DM2IFJQ DN GBL-310 DM2IFJQ TI TTVOE6D DM2IFJQ TN Mitogen-activated protein kinase (MAPK) DM2IFJQ MA Inhibitor DM2IFJQ RN WO patent application no. 2010,0456,51, Methods for analyzing drug response. DM2IFJQ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100422&CC=WO&NR=2010045651A1&KC=A1 DM2IFYZ DI DM2IFYZ DM2IFYZ DN CB-10-01 DM2IFYZ TI TTUJFD0 DM2IFYZ TN Telomerase reverse transcriptase (TERT) DM2IFYZ RN Telomerase immunity from bench to bedside: round one. J Transl Med. 2007 Feb 26;5:12. DM2IFYZ RU https://pubmed.ncbi.nlm.nih.gov/17324292 DM2J36F DI DM2J36F DM2J36F DN BILN-2061 DM2J36F TI TTWXB3E DM2J36F TN Hepatitis C virus NS3 helicase (HCV NS3) DM2J36F MA Inhibitor DM2J36F RN Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5. DM2J36F RU https://pubmed.ncbi.nlm.nih.gov/15732092 DM2K5VP DI DM2K5VP DM2K5VP DN Coxsackievirus A21 DM2K5VP TI TT5Z9WY DM2K5VP TN Complement decay-accelerating factor (CD55) DM2K5VP MA Inhibitor DM2K5VP RN Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007 Apr;137(2):133-41. DM2K5VP RU https://pubmed.ncbi.nlm.nih.gov/17391493 DM2KQ71 DI DM2KQ71 DM2KQ71 DN Sutezolid DM2KQ71 TI TT2VX74 DM2KQ71 TN Bacterial Protein synthesis (Bact PROS) DM2KQ71 MA Modulator DM2KQ71 RN Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob Agents Chemother. 2010 Jun;54(6):2549-59. DM2KQ71 RU https://pubmed.ncbi.nlm.nih.gov/20385852 DM2L9CO DI DM2L9CO DM2L9CO DN Ezatiostat DM2L9CO TI TT40K12 DM2L9CO TN Glutathione S-transferase P (GSTP1) DM2L9CO MA Modulator DM2L9CO RN National Cancer Institute Drug Dictionary (drug id 485244). DM2L9CO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=485244 DM2LBC3 DI DM2LBC3 DM2LBC3 DN TEW-7197 DM2LBC3 TI TTP4520 DM2LBC3 TN TGF-beta receptor type I (TGFBR1) DM2LBC3 MA Modulator DM2LBC3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM2LBC3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM2LBC3 DI DM2LBC3 DM2LBC3 DN TEW-7197 DM2LBC3 TI TTO3HT7 DM2LBC3 TN Transforming growth factor beta (TGFB) DM2LBC3 MA Antagonist DM2LBC3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2LBC3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM2LBHN DI DM2LBHN DM2LBHN DN JTE-051 DM2LBHN TI TT3C80U DM2LBHN TN T-cell-specific kinase (ITK) DM2LBHN MA Inhibitor DM2LBHN RN Characterisation of a K390R ITK Kinase Dead Transgenic Mouse - Implications for ITK as a Therapeutic Target. PLoS One. 2014; 9(9): e107490. DM2LBHN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4174519/ DM2LZIY DI DM2LZIY DM2LZIY DN BT-061 DM2LZIY TI TTN2JFW DM2LZIY TN T-cell surface glycoprotein CD4 (CD4) DM2LZIY RN Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2. DM2LZIY RU https://pubmed.ncbi.nlm.nih.gov/25666094 DM2M80G DI DM2M80G DM2M80G DN Z 360 DM2M80G TI TTVFO0U DM2M80G TN Gastrin/cholecystokinin type B receptor (CCKBR) DM2M80G MA Modulator DM2M80G RN Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gen... Biol Pharm Bull. 2010;33(2):216-22. DM2M80G RU https://www.ncbi.nlm.nih.gov/pubmed/20118543 DM2MSGF DI DM2MSGF DM2MSGF DN ASP9831 DM2MSGF TI TTV5CGO DM2MSGF TN Phosphodiesterase 4 (PDE4) DM2MSGF MA Inhibitor DM2MSGF RN Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. DM2MSGF RU https://pubmed.ncbi.nlm.nih.gov/24530600 DM2N0Z3 DI DM2N0Z3 DM2N0Z3 DN KUR-211 DM2N0Z3 TI TTWODQF DM2N0Z3 TN Fibrin (FG) DM2N0Z3 MA Modulator DM2N0Z3 RN Clinical pipeline report, company report or official report of Kuros. DM2N0Z3 RU http://www.kuros.ch/cms/front_content.php?idcat=78 DM2NF6X DI DM2NF6X DM2NF6X DN MIV-210 DM2NF6X TI TTS5K1M DM2NF6X TN Hepatitis B virus Reverse transcriptase (HBV RT) DM2NF6X MA Modulator DM2NF6X RN Emerging antivirals for the treatment of hepatitis B DM2NF6X RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069299 DM2NJYC DI DM2NJYC DM2NJYC DN Patidegib DM2NJYC TI TT4LXBC DM2NJYC TN Hedgehog signaling pathway (HS pathway) DM2NJYC MA Inhibitor DM2NJYC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2NJYC RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM2O4MI DI DM2O4MI DM2O4MI DN UK-432097 DM2O4MI TI TTM2AOE DM2O4MI TN Adenosine A2a receptor (ADORA2A) DM2O4MI MA Agonist DM2O4MI RN Structure of an agonist-bound human A2A adenosine receptor. Science. 2011 Apr 15;332(6027):322-7. DM2O4MI RU https://pubmed.ncbi.nlm.nih.gov/21393508 DM2O7NM DI DM2O7NM DM2O7NM DN FKB01MD DM2O7NM TI TT6MSOK DM2O7NM TN 5-HT 1D receptor (HTR1D) DM2O7NM MA Agonist DM2O7NM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2O7NM RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM2O7NM DI DM2O7NM DM2O7NM DN FKB01MD DM2O7NM TI TTYSN63 DM2O7NM TN 5-HT 2 receptor (5HT2R) DM2O7NM MA Inhibitor DM2O7NM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2O7NM RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM2O7NM DI DM2O7NM DM2O7NM DN FKB01MD DM2O7NM TI TTSQIFT DM2O7NM TN 5-HT 1A receptor (HTR1A) DM2O7NM MA Modulator DM2O7NM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2O7NM RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM2OS51 DI DM2OS51 DM2OS51 DN ABT-126 DM2OS51 TI TTLA931 DM2OS51 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2OS51 MA Modulator DM2OS51 RN A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90. DM2OS51 RU http://www.sciencedirect.com/science/article/pii/S2352873715000104 DM2PEU5 DI DM2PEU5 DM2PEU5 DN CNSB-001 DM2PEU5 TI TTQ29KF DM2PEU5 TN Voltage-gated potassium channel Kv7 (KCNQ) DM2PEU5 MA Agonist DM2PEU5 RN The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72. DM2PEU5 RU https://pubmed.ncbi.nlm.nih.gov/20433607 DM2PEU5 DI DM2PEU5 DM2PEU5 DN CNSB-001 DM2PEU5 TI TTN4QDT DM2PEU5 TN Opioid receptor (OPR) DM2PEU5 MA Agonist DM2PEU5 RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM2PEU5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM2POHA DI DM2POHA DM2POHA DN AGS-16C3F DM2POHA TI TTD4TKP DM2POHA TN Phosphodiesterase I beta (ENPP3) DM2POHA MA Inhibitor DM2POHA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2POHA RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM2Q50G DI DM2Q50G DM2Q50G DN Belnacasan DM2Q50G TI TTCQIBE DM2Q50G TN Caspase-1 (CASP1) DM2Q50G MA Inhibitor DM2Q50G RN (S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydr... J Pharmacol Exp Ther. 2007 May;321(2):509-16. DM2Q50G RU https://pubmed.ncbi.nlm.nih.gov/17289835 DM2QBDS DI DM2QBDS DM2QBDS DN Disitertide DM2QBDS TI TTR9XHZ DM2QBDS TN Transforming growth factor beta 1 (TGFB1) DM2QBDS MA Inhibitor DM2QBDS RN Perspectives of TGF-beta inhibition in pancreatic and hepatocellular carcinomas. Oncotarget. 2014 January; 5(1): 78-94. DM2QBDS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960190/ DM2QIN1 DI DM2QIN1 DM2QIN1 DN HT-100 DM2QIN1 TI TTXYCDZ DM2QIN1 TN Bifunctional aminoacyl-tRNA synthetase (EPRS) DM2QIN1 MA Modulator DM2QIN1 RN Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8(3):311-7. DM2QIN1 RU https://pubmed.ncbi.nlm.nih.gov/22327401 DM2RJ4D DI DM2RJ4D DM2RJ4D DN MM-141 DM2RJ4D TI TTHRID2 DM2RJ4D TN Insulin-like growth factor I receptor (IGF1R) DM2RJ4D MA Modulator DM2RJ4D RN MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25. DM2RJ4D RU https://pubmed.ncbi.nlm.nih.gov/24282274 DM2RJ4D DI DM2RJ4D DM2RJ4D DN MM-141 DM2RJ4D TI TTDC8N2 DM2RJ4D TN Erbb3 tyrosine kinase receptor (Erbb-3) DM2RJ4D MA Modulator DM2RJ4D RN MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25. DM2RJ4D RU https://pubmed.ncbi.nlm.nih.gov/24282274 DM2RJ4D DI DM2RJ4D DM2RJ4D DN MM-141 DM2RJ4D TI TTCJG29 DM2RJ4D TN Serine/threonine-protein kinase mTOR (mTOR) DM2RJ4D MA Inhibitor DM2RJ4D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2RJ4D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM2RS0V DI DM2RS0V DM2RS0V DN Isofagomine tartrate DM2RS0V TI TT1B5PU DM2RS0V TN Glucosylceramidase (GBA) DM2RS0V MA Inhibitor DM2RS0V RN Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. Chembiochem. 2008 Nov 3;9(16):2650-62. DM2RS0V RU https://pubmed.ncbi.nlm.nih.gov/18972510 DM2SWI8 DI DM2SWI8 DM2SWI8 DN RG7888 DM2SWI8 TI TTBW580 DM2SWI8 TN TAX transcriptionally-activated glycoprotein 1 (OX40) DM2SWI8 RN Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models. J Immunother Cancer. 2014; 2(Suppl 3): P105. DM2SWI8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288389/ DM2TSMD DI DM2TSMD DM2TSMD DN 177Lu-labelled NeoBOMB1 DM2TSMD TI TTC1MVT DM2TSMD TN Gastrin-releasing peptide receptor (GRPR) DM2TSMD RN 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299. DM2TSMD RU https://pubmed.ncbi.nlm.nih.gov/27609789 DM2U45Q DI DM2U45Q DM2U45Q DN Danegaptide DM2U45Q TI TTJO6E9 DM2U45Q TN Gap junction protein (GJP) DM2U45Q MA Modulator DM2U45Q RN The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. DM2U45Q RU https://pubmed.ncbi.nlm.nih.gov/19252062 DM2U530 DI DM2U530 DM2U530 DN ALD-401 DM2U530 TI TTFLN4T DM2U530 TN Mitochondrial aldehyde dehydrogenase (ALDH2) DM2U530 MA Modulator DM2U530 RN A novel aldehyde dehydrogenase-3 activator leads to adult salivary stem cell enrichment in vivo. Clin Cancer Res. 2011 Dec 1;17(23):7265-72. DM2U530 RU https://pubmed.ncbi.nlm.nih.gov/21998334 DM2UGT7 DI DM2UGT7 DM2UGT7 DN RG-101 DM2UGT7 TI TTP03CE DM2UGT7 TN Hepatitis C virus microRNA miR-122 (HCV MIR122) DM2UGT7 MA Modulator DM2UGT7 RN Company report (Isis Pharmaceuticals) DM2UGT7 RU https://www.isispharm.com/pipeline/rg-101/ DM2UJ1H DI DM2UJ1H DM2UJ1H DN NW-3509 DM2UJ1H TI TTRK8B9 DM2UJ1H TN Sodium channel unspecific (NaC) DM2UJ1H MA Blocker DM2UJ1H RN Clinical pipeline report, company report or official report of Newron. DM2UJ1H RU http://www.newron.com/eng/Default.aspx?SEZ=3&PAG=52 DM2UKJV DI DM2UKJV DM2UKJV DN SP-333 DM2UKJV TI TTLDPRG DM2UKJV TN Guanylyl cyclase C (GUCY2C) DM2UKJV MA Agonist DM2UKJV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2UKJV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM2UOSN DI DM2UOSN DM2UOSN DN Conatumumab DM2UOSN TI TT6OEDT DM2UOSN TN Cannabinoid receptor 1 (CB1) DM2UOSN MA Agonist DM2UOSN RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM2UOSN RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM2UOSN DI DM2UOSN DM2UOSN DN Conatumumab DM2UOSN TI TTW20TU DM2UOSN TN TRAIL receptor 2 (TRAIL-R2) DM2UOSN MA Agonist DM2UOSN RN Clinical pipeline report, company report or official report of Amgen (2009). DM2UOSN RU http://www.amgen.com/science/pipe.jsp DM2UOSN DI DM2UOSN DM2UOSN DN Conatumumab DM2UOSN TI TT90XZ8 DM2UOSN TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM2UOSN MA Binder DM2UOSN RN Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12. DM2UOSN RU https://pubmed.ncbi.nlm.nih.gov/10762603 DM2UP6Z DI DM2UP6Z DM2UP6Z DN ARO-AAT DM2UP6Z TI TT2L4TV DM2UP6Z TN SERPINA1 messenger RNA (SERPINA1 mRNA) DM2UP6Z RN Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals. DM2UP6Z RU https://arrowheadpharma.com/pipeline/ DM2USXP DI DM2USXP DM2USXP DN Remlarsen DM2USXP TI TTO60BY DM2USXP TN microRNA hsa-miR-29b (MIR29b) DM2USXP MA Replacement DM2USXP RN A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin. J Invest Dermatol. 2019 May;139(5):1073-1081. DM2USXP RU https://pubmed.ncbi.nlm.nih.gov/30472058 DM2VO97 DI DM2VO97 DM2VO97 DN RK-023 DM2VO97 TI TT30NW6 DM2VO97 TN Chloride channel protein 2 (CLC-2) DM2VO97 MA Modulator DM2VO97 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM2VO97 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM2VO9T DI DM2VO9T DM2VO9T DN GBR 830 DM2VO9T TI TTL31H0 DM2VO9T TN OX40L receptor (CD134) DM2VO9T MA Antagonist DM2VO9T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2VO9T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM2WP8F DI DM2WP8F DM2WP8F DN HT-0712 DM2WP8F TI TTSKMI8 DM2WP8F TN Phosphodiesterase 4D (PDE4D) DM2WP8F MA Inhibitor DM2WP8F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DM2WP8F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DM2WP8F DI DM2WP8F DM2WP8F DN HT-0712 DM2WP8F TI TTZ97H5 DM2WP8F TN Phosphodiesterase 4A (PDE4A) DM2WP8F MA Inhibitor DM2WP8F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DM2WP8F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DM2WP8F DI DM2WP8F DM2WP8F DN HT-0712 DM2WP8F TI TTVIAT9 DM2WP8F TN Phosphodiesterase 4B (PDE4B) DM2WP8F MA Inhibitor DM2WP8F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DM2WP8F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DM2X0SP DI DM2X0SP DM2X0SP DN VIR-2218 DM2X0SP TI TTINUYD DM2X0SP TN Hepatitis B virus Large envelope protein (HBV S) DM2X0SP MA Inhibitor DM2X0SP RN Clinical pipeline report, company report or official report of Vir Biotechnology. DM2X0SP RU https://www.vir.bio/pipeline/ DM2XE80 DI DM2XE80 DM2XE80 DN BAY-X-7195 DM2XE80 TI TTGKOY9 DM2XE80 TN Leukotriene CysLT1 receptor (CYSLTR1) DM2XE80 MA Modulator DM2XE80 RN The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85. DM2XE80 RU https://www.ncbi.nlm.nih.gov/pubmed/8838238 DM2XE80 DI DM2XE80 DM2XE80 DN BAY-X-7195 DM2XE80 TI TT0PZR5 DM2XE80 TN Leukotriene CysLT2 receptor (CYSLTR2) DM2XE80 MA Modulator DM2XE80 RN The effect of a novel leukotriene C4/D4 antagonist, BAY-x-7195, on experimental allergic reactions. Prostaglandins. 1995 Nov-Dec;50(5-6):269-85. DM2XE80 RU https://www.ncbi.nlm.nih.gov/pubmed/8838238 DM2YIOE DI DM2YIOE DM2YIOE DN SDZ-MAR-327 DM2YIOE TI TTSQIFT DM2YIOE TN 5-HT 1A receptor (HTR1A) DM2YIOE MA Modulator DM2YIOE RN DOI: 10.1038/sj.mp.4002062 DM2YIOE RU http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html DM2YIOE DI DM2YIOE DM2YIOE DN SDZ-MAR-327 DM2YIOE TI TTEX248 DM2YIOE TN Dopamine D2 receptor (D2R) DM2YIOE MA Modulator DM2YIOE RN DOI: 10.1038/sj.mp.4002062 DM2YIOE RU http://www.nature.com/mp/journal/v12/n10/fig_tab/4002062t1.html DM2YIZH DI DM2YIZH DM2YIZH DN NCX-1000 DM2YIZH TI TTZY5KP DM2YIZH TN Caspase (CASP) DM2YIZH MA Modulator DM2YIZH RN Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br J Pharmacol. 2004 Sep;143(1):33-42. DM2YIZH RU https://pubmed.ncbi.nlm.nih.gov/15345658 DM2ZLWH DI DM2ZLWH DM2ZLWH DN TG-0054 DM2ZLWH TI TTBID49 DM2ZLWH TN C-X-C chemokine receptor type 4 (CXCR4) DM2ZLWH MA Inhibitor DM2ZLWH RN CXCR4 Antagonist TG-0054 Mobilizes Mesenchymal Stem Cells, Attenuates Inflammation, and Preserves Cardiac Systolic Function in a Porcine Model of Myocardial Infarction. Cell Transplant. 2015;24(7):1313-28. DM2ZLWH RU https://pubmed.ncbi.nlm.nih.gov/24823505 DM2ZUXK DI DM2ZUXK DM2ZUXK DN Lu-AA34893 DM2ZUXK TI TT3ROYC DM2ZUXK TN Serotonin transporter (SERT) DM2ZUXK MA Modulator DM2ZUXK RN Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105). DM2ZUXK RU https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false DM2ZUXK DI DM2ZUXK DM2ZUXK DN Lu-AA34893 DM2ZUXK TI TT85JO3 DM2ZUXK TN 5-HT receptor (5HTR) DM2ZUXK MA Modulator DM2ZUXK RN Encyclopedia of Psychopharmacology. Ian Stolerman. 2010. Page(105). DM2ZUXK RU https://books.google.com.hk/books?id=qoyYobgX0uwC&pg=PA105&lpg=PA105&dq=Lu-AA34893++Serotonin+transporter&source=bl&ots=Y8wHg_Wpnq&sig=QOjSsHQcRslsmIZnyU6GU1bGY_s&hl=zh-CN&sa=X&ved=0CDAQ6AEwA2oVChMIwZvmieS7yAIVAsKOCh2rAgWU#v=onepage&q=Lu-AA34893%20%20Serotonin%20transporter&f=false DM32NWD DI DM32NWD DM32NWD DN LIK-066 DM32NWD TI TT2UE56 DM32NWD TN Sodium/glucose cotransporter 1 (SGLT1) DM32NWD MA Inhibitor DM32NWD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915). DM32NWD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915 DM32NWD DI DM32NWD DM32NWD DN LIK-066 DM32NWD TI TTLWPVF DM32NWD TN Sodium/glucose cotransporter 2 (SGLT2) DM32NWD MA Inhibitor DM32NWD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM32NWD RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM32UOC DI DM32UOC DM32UOC DN EDP-938 DM32UOC TI TT25A0I DM32UOC TN Respiratory syncytial virus protein N (RSV N) DM32UOC MA Inhibitor DM32UOC RN EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model. PLoS Pathog. 2021 Mar 15;17(3):e1009428. DM32UOC RU https://pubmed.ncbi.nlm.nih.gov/33720995 DM32YTJ DI DM32YTJ DM32YTJ DN APN-301 DM32YTJ TI TTF89GD DM32YTJ TN Interleukin-2 (IL2) DM32YTJ MA Modulator DM32YTJ RN Clinical pipeline report, company report or official report of APEIRON Biologics. DM32YTJ RU http://www.apeiron-biologics.com/index.php/projects/apn301-hu14-18-il2.html DM347TQ DI DM347TQ DM347TQ DN MK-3697 DM347TQ TI TT9N02I DM347TQ TN Orexin receptor type 2 (HCRTR2) DM347TQ MA Modulator DM347TQ RN Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. Bioorg Med Chem Lett. 2014 Oct 15;24(20):4884-90. DM347TQ RU https://pubmed.ncbi.nlm.nih.gov/25248679 DM34FWR DI DM34FWR DM34FWR DN Lu-AA39959 DM34FWR TI TTM7WCE DM34FWR TN Ion channel unspecific (IC) DM34FWR MA Modulator DM34FWR RN Lundbeck: leading the way in the treatment of CNS disorders. DM34FWR RU http://onlinelibrary.wiley.com/doi/10.1002/fps.78/pdf DM35KDA DI DM35KDA DM35KDA DN Ataciguat DM35KDA TI TTJME02 DM35KDA TN Atrial natriuretic peptide receptor A (NPR1) DM35KDA MA Activator DM35KDA RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM35KDA RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM35S2I DI DM35S2I DM35S2I DN ASM-024 DM35S2I TI TTJSZTB DM35S2I TN Nicotinic acetylcholine receptor (nAChR) DM35S2I MA Agonist DM35S2I RN Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4. DM35S2I RU https://pubmed.ncbi.nlm.nih.gov/26252534 DM37CX4 DI DM37CX4 DM37CX4 DN IC14 DM37CX4 TI TTCLGZ8 DM37CX4 TN HUAMN monocyte differentiation antigen CD14 (CD14) DM37CX4 MA Inhibitor DM37CX4 RN IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19) DM37CX4 RU https://clinicaltrials.gov/ct2/show/NCT04391309 DM3816P DI DM3816P DM3816P DN PAC-14028 DM3816P TI TTMI6F5 DM3816P TN Transient receptor potential cation channel V1 (TRPV1) DM3816P MA Antagonist DM3816P RN Development of PAC-14028, a novel transient receptor potential vanilloid type 1 (TRPV1) channel antagonist as a new drug for refractory skin diseases. Arch Pharm Res. 2012 Mar;35(3):393-6. DM3816P RU https://pubmed.ncbi.nlm.nih.gov/22477184 DM38ARE DI DM38ARE DM38ARE DN Gp100:209-217(210M) peptide vaccine DM38ARE TI TT8MK59 DM38ARE TN Melanocytes lineage-specific antigen GP100 (PMEL) DM38ARE RN National Cancer Institute Drug Dictionary (drug id 476335). DM38ARE RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=476335 DM39RXO DI DM39RXO DM39RXO DN SiG12D-LODER DM39RXO TI TT9TVNM DM39RXO TN KRAS G12D mutant messenger RNA (KRAS mRNA) DM39RXO MA Inhibitor DM39RXO RN Clinical pipeline report, company report or official report of Silenseed. DM39RXO RU https://www.silenseed.com/kras-loder-for-pancreatic-cancer/ DM3AIF7 DI DM3AIF7 DM3AIF7 DN TNF alpha kinoid DM3AIF7 TI TTF8CQI DM3AIF7 TN Tumor necrosis factor (TNF) DM3AIF7 RN Modulation of Anti-Tumor Necrosis Factor Alpha (TNF-alpha) Antibody Secretion in Mice Immunized with TNF-alpha Kinoid. Clin Vaccine Immunol. 2012 May; 19(5): 699-703. DM3AIF7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346328/ DM3BN4W DI DM3BN4W DM3BN4W DN CFI-400945 DM3BN4W TI TTGPNZQ DM3BN4W TN Polo-like kinase 4 (PLK4) DM3BN4W MA Inhibitor DM3BN4W RN Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76. DM3BN4W RU https://pubmed.ncbi.nlm.nih.gov/25043604 DM3C8GQ DI DM3C8GQ DM3C8GQ DN PF-489791 DM3C8GQ TI TTJ0IQB DM3C8GQ TN Phosphodiesterase 5A (PDE5A) DM3C8GQ MA Inhibitor DM3C8GQ RN Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358. DM3C8GQ RU https://www.smr.org.uk/smr/archive/pastmeetings/Downloads/SMR_Dec_09_Report.pdf DM3C9F8 DI DM3C9F8 DM3C9F8 DN RVT-505 DM3C9F8 TI TT037IE DM3C9F8 TN Aryl hydrocarbon receptor (AHR) DM3C9F8 MA Modulator DM3C9F8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3C9F8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM3C9NV DI DM3C9NV DM3C9NV DN TD-8954 DM3C9NV TI TT07C3Y DM3C9NV TN 5-HT 4 receptor (HTR4) DM3C9NV MA Modulator DM3C9NV RN The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25. DM3C9NV RU https://pubmed.ncbi.nlm.nih.gov/21687517 DM3CVHQ DI DM3CVHQ DM3CVHQ DN FE-202158 DM3CVHQ TI TT4TFGN DM3CVHQ TN Vasopressin V1a receptor (V1AR) DM3CVHQ MA Agonist DM3CVHQ RN The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*. Crit Care Med. 2014 Jul;42(7):e525-33. DM3CVHQ RU https://pubmed.ncbi.nlm.nih.gov/24674922 DM3D52L DI DM3D52L DM3D52L DN TAS-114 DM3D52L TI TTH6MBO DM3D52L TN dUTP pyrophosphatase (DUT) DM3D52L MA Inhibitor DM3D52L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3D52L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3DQXG DI DM3DQXG DM3DQXG DN NPSP-795 DM3DQXG TI TTEPJL5 DM3DQXG TN Parathyroid hormone receptor (PTH2R) DM3DQXG MA Modulator DM3DQXG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332). DM3DQXG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332 DM3DWKN DI DM3DWKN DM3DWKN DN PF-4191834 DM3DWKN TI TT2J34L DM3DWKN TN Arachidonate 5-lipoxygenase (5-LOX) DM3DWKN MA Inhibitor DM3DWKN RN Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain. J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. DM3DWKN RU https://pubmed.ncbi.nlm.nih.gov/20378715 DM3FS1G DI DM3FS1G DM3FS1G DN RT-001 DM3FS1G TI TTB52WU DM3FS1G TN Bacterial Botulinum toxin A (Bact botA) DM3FS1G MA Modulator DM3FS1G RN Clinical pipeline report, company report or official report of Revance Therapeutics. DM3FS1G RU http://www.revance.com/mechanism-of-action-rt001/ DM3GEHC DI DM3GEHC DM3GEHC DN CX-8998 DM3GEHC TI TTT6NKW DM3GEHC TN Voltage-gated T-type calcium channel (T-CaC) DM3GEHC MA Modulator DM3GEHC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3GEHC RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3GRKY DI DM3GRKY DM3GRKY DN S-707106 DM3GRKY TI TTCBFJO DM3GRKY TN Insulin receptor (INSR) DM3GRKY MA Modulator DM3GRKY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM3GRKY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM3H0IX DI DM3H0IX DM3H0IX DN AMG 890 DM3H0IX TI TTU9LGY DM3H0IX TN Apolipoprotein A messenger RNA (LPA mRNA) DM3H0IX MA Inhibitor DM3H0IX RN Clinical pipeline report, company report or official report of Amgen. DM3H0IX RU https://www.amgenpipeline.com/ DM3H82Q DI DM3H82Q DM3H82Q DN NS-7 DM3H82Q TI TTRK8B9 DM3H82Q TN Sodium channel unspecific (NaC) DM3H82Q MA Modulator DM3H82Q RN Preferential inhibition by a novel Na(+)/Ca(2+) channel blocker NS-7 of severe to mild hypoxic injury in rat cerebrocortical slices: A possible involvement of a highly voltage-dependent blockade of Ca(2+) channel. J Pharmacol Exp Ther. 2000 May;293(2):522-9. DM3H82Q RU https://pubmed.ncbi.nlm.nih.gov/10773024 DM3I71U DI DM3I71U DM3I71U DN MKT-077 DM3I71U TI TTMTPG3 DM3I71U TN Mortalin (HSPA9) DM3I71U MA Modulator DM3I71U RN Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function. Cancer Res. 2000 Dec 15;60(24):6818-21. DM3I71U RU https://pubmed.ncbi.nlm.nih.gov/11156371 DM3ICO6 DI DM3ICO6 DM3ICO6 DN JNJ-74494550 DM3ICO6 TI TTNCIE0 DM3ICO6 TN CD70 antigen (CD27-L) DM3ICO6 RN Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467. DM3ICO6 RU https://pubmed.ncbi.nlm.nih.gov/32601337 DM3ICYL DI DM3ICYL DM3ICYL DN AP-301-IH DM3ICYL TI TTF8CQI DM3ICYL TN Tumor necrosis factor (TNF) DM3ICYL MA Inhibitor DM3ICYL RN AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013 Jun;26(3):356-63. DM3ICYL RU https://pubmed.ncbi.nlm.nih.gov/23313096 DM3IEHP DI DM3IEHP DM3IEHP DN NN8555 DM3IEHP TI TTLRN4A DM3IEHP TN NKG2 D activating NK receptor (KLRK1) DM3IEHP MA Antagonist DM3IEHP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3IEHP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3JFZ2 DI DM3JFZ2 DM3JFZ2 DN CXL DM3JFZ2 TI TTHI19T DM3JFZ2 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM3JFZ2 MA Modulator DM3JFZ2 RN Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215. DM3JFZ2 RU http://www.mdpi.com/2079-6382/3/2/193 DM3JNXS DI DM3JNXS DM3JNXS DN AN-1792 DM3JNXS TI TTE4KHA DM3JNXS TN Amyloid beta A4 protein (APP) DM3JNXS MA Inhibitor DM3JNXS RN Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63. DM3JNXS RU https://pubmed.ncbi.nlm.nih.gov/16936277 DM3JSFK DI DM3JSFK DM3JSFK DN AZD-5069 DM3JSFK TI TT30C9G DM3JSFK TN C-X-C chemokine receptor type 2 (CXCR2) DM3JSFK MA Inhibitor DM3JSFK RN Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50. DM3JSFK RU https://pubmed.ncbi.nlm.nih.gov/25736418 DM3L51O DI DM3L51O DM3L51O DN Rilopirox DM3L51O TI TT2J34L DM3L51O TN Arachidonate 5-lipoxygenase (5-LOX) DM3L51O MA Inhibitor DM3L51O RN Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses. 1991;34 Suppl 1:91-3. DM3L51O RU https://pubmed.ncbi.nlm.nih.gov/1840158 DM3ORVD DI DM3ORVD DM3ORVD DN Neramexane DM3ORVD TI TT9IK2Z DM3ORVD TN N-methyl-D-aspartate receptor (NMDAR) DM3ORVD MA Antagonist DM3ORVD RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DM3ORVD RU https://pubmed.ncbi.nlm.nih.gov/15757410 DM3P91Z DI DM3P91Z DM3P91Z DN Alacizumab pegol DM3P91Z TI TTUTJGQ DM3P91Z TN Vascular endothelial growth factor receptor 2 (KDR) DM3P91Z RN Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res. 2007 Dec 1;13(23):7113-8. DM3P91Z RU https://pubmed.ncbi.nlm.nih.gov/18056191 DM3POT6 DI DM3POT6 DM3POT6 DN ATL1102 DM3POT6 TI TTJMF9P DM3POT6 TN ITGA4 messenger RNA (ITGA4 mRNA) DM3POT6 MA Modulator DM3POT6 RN CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.Neurology.2014 Nov 11;83(20):1780-8. DM3POT6 RU https://www.ncbi.nlm.nih.gov/pubmed/25239835 DM3QDA6 DI DM3QDA6 DM3QDA6 DN Polynoma-1 DM3QDA6 TI TTULVH8 DM3QDA6 TN Tyrosinase (TYR) DM3QDA6 RN An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015. DM3QDA6 RU http://www.polynoma.com/ DM3QDA6 DI DM3QDA6 DM3QDA6 DN Polynoma-1 DM3QDA6 TI TTWSKHD DM3QDA6 TN Melanoma-associated antigen 3 (MAGEA3) DM3QDA6 RN An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015. DM3QDA6 RU http://www.polynoma.com/ DM3QDA6 DI DM3QDA6 DM3QDA6 DN Polynoma-1 DM3QDA6 TI TT362RB DM3QDA6 TN MART-1 melanoma antigen (MLANA) DM3QDA6 RN An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015. DM3QDA6 RU http://www.polynoma.com/ DM3RBJW DI DM3RBJW DM3RBJW DN MB-11055 DM3RBJW TI TTLAFZV DM3RBJW TN AMP-activated protein kinase (AMPK) DM3RBJW MA Modulator DM3RBJW RN Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72. DM3RBJW RU https://www.ncbi.nlm.nih.gov/pubmed/17429005 DM3RU0A DI DM3RU0A DM3RU0A DN CAR-T cells targeting CD20 DM3RU0A TI TTUE541 DM3RU0A TN Leukocyte surface antigen Leu-16 (CD20) DM3RU0A MA CAR-T-Cell-Therapy DM3RU0A RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DM3RU0A RU https://clinicaltrials.gov/ct2/show/NCT03196830 DM3SYOK DI DM3SYOK DM3SYOK DN CTP-543 DM3SYOK TI TTRMX3V DM3SYOK TN Janus kinase 2 (JAK-2) DM3SYOK MA Inhibitor DM3SYOK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3SYOK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3SYOK DI DM3SYOK DM3SYOK DN CTP-543 DM3SYOK TI TT6DM01 DM3SYOK TN Janus kinase 1 (JAK-1) DM3SYOK MA Inhibitor DM3SYOK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3SYOK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3TN1A DI DM3TN1A DM3TN1A DN ASP7991 DM3TN1A TI TTBUYHA DM3TN1A TN Extracellular calcium-sensing receptor (CASR) DM3TN1A MA Agonist DM3TN1A RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616) DM3TN1A RU http://adisinsight.springer.com/drugs/800035616 DM3TRF7 DI DM3TRF7 DM3TRF7 DN Brasofensine DM3TRF7 TI TT3ROYC DM3TRF7 TN Serotonin transporter (SERT) DM3TRF7 MA Modulator DM3TRF7 RN Brasofensine NeuroSearch. Curr Opin Investig Drugs. 2000 Dec;1(4):504-7. DM3TRF7 RU https://pubmed.ncbi.nlm.nih.gov/11249705 DM3TUBR DI DM3TUBR DM3TUBR DN Acalabrutinib DM3TUBR TI TTOWPER DM3TUBR TN HUMAN bruton tyrosine kinase (BTK) DM3TUBR MA Inhibitor DM3TUBR RN AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19 DM3TUBR RU https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-initiates-calavi-clinical-trial-with-calquence-against-covid-19.html DM3U9BY DI DM3U9BY DM3U9BY DN RO-5126766 DM3U9BY TI TTROQ37 DM3U9BY TN MAPK/ERK kinase kinase (MAP3K) DM3U9BY MA Modulator DM3U9BY RN The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217. DM3U9BY RU https://www.ncbi.nlm.nih.gov/pubmed/25422890 DM3U9BY DI DM3U9BY DM3U9BY DN RO-5126766 DM3U9BY TI TTQ9K3Y DM3U9BY TN Serine/threonine-protein kinase Raf (RAF) DM3U9BY MA Modulator DM3U9BY RN The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.PLoS One.2014 Nov 25;9(11):e113217. DM3U9BY RU https://www.ncbi.nlm.nih.gov/pubmed/25422890 DM3V7QO DI DM3V7QO DM3V7QO DN Vatelizumab DM3V7QO TI TTMSB0A DM3V7QO TN Integrin alpha-2/beta-1 (ITGA2/B1) DM3V7QO RN Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146. DM3V7QO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/ DM3VP19 DI DM3VP19 DM3VP19 DN APC-8015F DM3VP19 TI TTCT6F7 DM3VP19 TN Intercellular adhesion molecule ICAM-1 (ICAM1) DM3VP19 MA Modulator DM3VP19 RN National Cancer Institute Drug Dictionary (drug id 561410). DM3VP19 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=561410 DM3WCL4 DI DM3WCL4 DM3WCL4 DN Baltaleucel-T DM3WCL4 TI TTXQYT6 DM3WCL4 TN T-cells (T-cells) DM3WCL4 MA Immunomodulator DM3WCL4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3WCL4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM3WDZ5 DI DM3WDZ5 DM3WDZ5 DN MK-1775 DM3WDZ5 TI TTJFOAL DM3WDZ5 TN Wee1-like protein kinase (WEE1) DM3WDZ5 MA Inhibitor DM3WDZ5 RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DM3WDZ5 RU https://pubmed.ncbi.nlm.nih.gov/23467907 DM3WSDR DI DM3WSDR DM3WSDR DN IXT-m200 DM3WSDR TI TT3UEY0 DM3WSDR TN Methamphetamine (Meth) DM3WSDR MA Antagonist DM3WSDR RN Clinical pipeline report, company report or official report of InterveXion Therapeutics. DM3WSDR RU http://intervexion.com/research-development/anti-methamphetamine-products/ DM3WSL2 DI DM3WSL2 DM3WSL2 DN HPH-116 DM3WSL2 TI TT8Z1OP DM3WSL2 TN Human immunodeficiency virus Nucleocapsid p7 (HIV p7) DM3WSL2 MA Modulator DM3WSL2 RN Clinical pipeline report, company report or official report of H-Phar. DM3WSL2 RU http://www.h-phar.com/Projects_Projet_1.php DM3WX0K DI DM3WX0K DM3WX0K DN HQK-1004 DM3WX0K TI TTP3QRF DM3WX0K TN Thymidine kinase 1 (TK1) DM3WX0K MA Modulator DM3WX0K RN Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol. 2001 Sep;13(5):360-7. DM3WX0K RU https://pubmed.ncbi.nlm.nih.gov/11555713 DM3WY0B DI DM3WY0B DM3WY0B DN LAS-41002 DM3WY0B TI TTYRL6O DM3WY0B TN Glucocorticoid receptor (NR3C1) DM3WY0B MA Modulator DM3WY0B RN Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives. Dermatol Res Pract. 2012; 2012: 923134. DM3WY0B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432345/ DM3XRUH DI DM3XRUH DM3XRUH DN LJN452 DM3XRUH TI TTS4UGC DM3XRUH TN Farnesoid X-activated receptor (FXR) DM3XRUH MA Agonist DM3XRUH RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DM3XRUH RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DM3XT5V DI DM3XT5V DM3XT5V DN APD371 DM3XT5V TI TTMSFAW DM3XT5V TN Cannabinoid receptor 2 (CB2) DM3XT5V MA Agonist DM3XT5V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3XT5V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3YB2C DI DM3YB2C DM3YB2C DN CDP-6038 DM3YB2C TI TTT1V78 DM3YB2C TN Interleukin-6 (IL6) DM3YB2C MA Modulator DM3YB2C RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM3YB2C RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM3YIKR DI DM3YIKR DM3YIKR DN PF-4523655 DM3YIKR TI TTVEOY6 DM3YIKR TN RTP801 messenger RNA (RTP801 mRNA) DM3YIKR RN DNA-damage-inducible transcript 4 (DDIT4; RTP801). SciBX 3(20); doi:10.1038/scibx.2010.629. May 20 2010 DM3YIKR RU http://www.nature.com/scibx/journal/v3/n20/full/scibx.2010.629.html DM3YVKQ DI DM3YVKQ DM3YVKQ DN YT-146 DM3YVKQ TI TTNE7KG DM3YVKQ TN Adenosine A2b receptor (ADORA2B) DM3YVKQ MA Agonist DM3YVKQ RN Identification of adenosine A2 receptor-cAMP system in human aortic endothelial cells. Biochem Biophys Res Commun. 1994 Mar 15;199(2):905-10. DM3YVKQ RU https://pubmed.ncbi.nlm.nih.gov/8135838 DM3Z6IQ DI DM3Z6IQ DM3Z6IQ DN CLR-3001 DM3Z6IQ TI TTEX248 DM3Z6IQ TN Dopamine D2 receptor (D2R) DM3Z6IQ MA Modulator DM3Z6IQ RN Clinical pipeline report, company report or official report of Clera Inc. DM3Z6IQ RU http://clera.com/cognition/ DM3Z6IQ DI DM3Z6IQ DM3Z6IQ DN CLR-3001 DM3Z6IQ TI TT3ROYC DM3Z6IQ TN Serotonin transporter (SERT) DM3Z6IQ MA Inhibitor DM3Z6IQ RN Clinical pipeline report, company report or official report of Clera Inc. DM3Z6IQ RU http://clera.com/cognition/ DM3ZEYL DI DM3ZEYL DM3ZEYL DN Piboserod DM3ZEYL TI TT07C3Y DM3ZEYL TN 5-HT 4 receptor (HTR4) DM3ZEYL MA Antagonist DM3ZEYL RN Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32. DM3ZEYL RU https://pubmed.ncbi.nlm.nih.gov/11293643 DM3ZL2O DI DM3ZL2O DM3ZL2O DN GSK-557296 DM3ZL2O TI TTSCIUP DM3ZL2O TN Oxytocin receptor (OTR) DM3ZL2O MA Antagonist DM3ZL2O RN Inhibition of ejaculation by the non-peptide oxytocin receptor antagonist GSK557296: a multi-level site of action. Br J Pharmacol. 2013 Aug;169(7):1477-85. DM3ZL2O RU https://pubmed.ncbi.nlm.nih.gov/23530818 DM40HOY DI DM40HOY DM40HOY DN KLH-2109 DM40HOY TI TT8R70G DM40HOY TN Gonadotropin-releasing hormone receptor (GNRHR) DM40HOY MA Agonist DM40HOY RN Clinical pipeline report, company report or official report of Avarx. DM40HOY RU http://www.avarx.com/AvaRx/SubDomains/bucket2705902527756613996/Listings/bucket5664821816690947691/Public.Listing.display.html DM42B0C DI DM42B0C DM42B0C DN BMS-986253 DM42B0C TI TTCTE1G DM42B0C TN Interleukin-8 (IL8) DM42B0C MA Inhibitor DM42B0C RN Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019 Sep 5;7(1):240. DM42B0C RU https://pubmed.ncbi.nlm.nih.gov/31488216 DM43O9N DI DM43O9N DM43O9N DN LY-334370 DM43O9N TI TT0MI3F DM43O9N TN 5-HT 1F receptor (HTR1F) DM43O9N MA Modulator DM43O9N RN Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001 Oct 13;358(9289):1230-4. DM43O9N RU https://www.ncbi.nlm.nih.gov/pubmed/11675061 DM450XS DI DM450XS DM450XS DN BAY 2253651 DM450XS TI TTGR91N DM450XS TN TWIK-related acid-sensitive potassium channel 1 (TASK1) DM450XS MA Inhibitor DM450XS RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM450XS RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM452RF DI DM452RF DM452RF DN RG7880 DM452RF TI TTLDX4N DM452RF TN Interleukin-22 (IL22) DM452RF MA Modulator DM452RF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM452RF RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM457XO DI DM457XO DM457XO DN IW-1701 DM457XO TI TT6HPVC DM457XO TN Guanylate cyclase (GC) DM457XO MA Stimulator DM457XO RN Clinical pipeline report, company report or official report of Cyclerion Therapeutics. DM457XO RU https://www.cyclerion.com/other-clinical-assets/ DM489FT DI DM489FT DM489FT DN GW-870086-X DM489FT TI TTYRL6O DM489FT TN Glucocorticoid receptor (NR3C1) DM489FT MA Agonist DM489FT RN Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7. DM489FT RU https://pubmed.ncbi.nlm.nih.gov/23462748 DM48DPS DI DM48DPS DM48DPS DN AB-729 DM48DPS TI TT43YWN DM48DPS TN Hepatitis B virus messenger RNA (HBV mRNA) DM48DPS MA Inhibitor DM48DPS RN Clinical pipeline report, company report or official report of Arbutus Biopharma. DM48DPS RU http://www.arbutusbio.com/portfolio/ab-729-galnac-rnai.php DM4AC2F DI DM4AC2F DM4AC2F DN RGI-2001 DM4AC2F TI TT7AKW1 DM4AC2F TN T-cell receptor (TCR) DM4AC2F MA Modulator DM4AC2F RN Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68. DM4AC2F RU https://pubmed.ncbi.nlm.nih.gov/21145405 DM4BLJM DI DM4BLJM DM4BLJM DN Thymoctonan DM4BLJM TI TTF89GD DM4BLJM TN Interleukin-2 (IL2) DM4BLJM MA Modulator DM4BLJM RN Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B. J Hepatol. 1995 Jul;23(1):21-7. DM4BLJM RU https://pubmed.ncbi.nlm.nih.gov/8530805 DM4BTH8 DI DM4BTH8 DM4BTH8 DN GSK2330672 DM4BTH8 TI TTPI1M5 DM4BTH8 TN Ileal sodium/bile acid cotransporter (SLC10A2) DM4BTH8 MA Modulator DM4BTH8 RN Discovery of a highly potent, nonabsorbable apical sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. DM4BTH8 RU https://pubmed.ncbi.nlm.nih.gov/23678871 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTV9A7R DM4C7E6 TN Lactoylglutathione lyase (GLO1) DM4C7E6 MA Inhibitor DM4C7E6 RN Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/18258440 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTF8CQI DM4C7E6 TN Tumor necrosis factor (TNF) DM4C7E6 MA Inhibitor DM4C7E6 RN Discovery of the inhibitors of tumor necrosis factor alpha with structure-based virtual screening. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6195-8. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/20850306 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TT7RJY8 DM4C7E6 TN Xanthine dehydrogenase/oxidase (XDH) DM4C7E6 MA Inhibitor DM4C7E6 RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/3379415 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TT2IYXF DM4C7E6 TN L-selectin (SELL) DM4C7E6 MA Inhibitor DM4C7E6 RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/17302397 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTNGKET DM4C7E6 TN Prolyl endopeptidase (PREP) DM4C7E6 MA Inhibitor DM4C7E6 RN Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/18650094 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TTE5VG0 DM4C7E6 TN P-selectin (SELP) DM4C7E6 MA Inhibitor DM4C7E6 RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/17302397 DM4C7E6 DI DM4C7E6 DM4C7E6 DN BAICALEIN DM4C7E6 TI TT2J34L DM4C7E6 TN Arachidonate 5-lipoxygenase (5-LOX) DM4C7E6 MA Inhibitor DM4C7E6 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM4C7E6 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM4CIKA DI DM4CIKA DM4CIKA DN RDP58 DM4CIKA TI TTF8CQI DM4CIKA TN Tumor necrosis factor (TNF) DM4CIKA MA Inhibitor DM4CIKA RN RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Inflamm Res. 2002 Nov;51(11):522-31. DM4CIKA RU https://pubmed.ncbi.nlm.nih.gov/12540016 DM4CJNE DI DM4CJNE DM4CJNE DN AYX-1 DM4CJNE TI TTUQREN DM4CJNE TN Early growth response protein 1 (EGR-1) DM4CJNE MA Inhibitor DM4CJNE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4CJNE RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4EF9Y DI DM4EF9Y DM4EF9Y DN LY-2608204 DM4EF9Y TI TTDLNGZ DM4EF9Y TN Glucokinase (GCK) DM4EF9Y MA Activator DM4EF9Y RN Clinical pipeline report, company report or official report of Eli Lilly. DM4EF9Y RU http://www.lillytrials.com/initiated/initiated.html DM4EHVB DI DM4EHVB DM4EHVB DN PPI-668 DM4EHVB TI TTCJ2X8 DM4EHVB TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM4EHVB MA Modulator DM4EHVB RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4EHVB RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4EP6Y DI DM4EP6Y DM4EP6Y DN 13-DEOXYADRIAMYCIN HYDROCHLORIDE DM4EP6Y TI TTUTN1I DM4EP6Y TN Human Deoxyribonucleic acid (hDNA) DM4EP6Y MA Modulator DM4EP6Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4EP6Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4EP6Y DI DM4EP6Y DM4EP6Y DN 13-DEOXYADRIAMYCIN HYDROCHLORIDE DM4EP6Y TI TT0IHXV DM4EP6Y TN DNA topoisomerase II (TOP2) DM4EP6Y MA Modulator DM4EP6Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4EP6Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4FBUH DI DM4FBUH DM4FBUH DN EXC 001 DM4FBUH TI TTCJVNE DM4FBUH TN CTGF messenger RNA (CTGF mRNA) DM4FBUH RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DM4FBUH RU http://www.isispharm.com/index.htm DM4FIWC DI DM4FIWC DM4FIWC DN PI-88/Taxotere DM4FIWC TI TTJGNVC DM4FIWC TN Apoptosis regulator Bcl-2 (BCL-2) DM4FIWC MA Modulator DM4FIWC RN Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7. DM4FIWC RU https://pubmed.ncbi.nlm.nih.gov/19917571 DM4FIWC DI DM4FIWC DM4FIWC DN PI-88/Taxotere DM4FIWC TI TT63KYR DM4FIWC TN Tubulin beta-1 chain (TUBB1) DM4FIWC MA Modulator DM4FIWC RN Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7. DM4FIWC RU https://pubmed.ncbi.nlm.nih.gov/19917571 DM4H8EZ DI DM4H8EZ DM4H8EZ DN IFN-alpha DM4H8EZ TI TT95SOA DM4H8EZ TN Interferon alpha (IFNA) DM4H8EZ MA Modulator DM4H8EZ RN WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same. DM4H8EZ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2 DM4I6XK DI DM4I6XK DM4I6XK DN TB-402 DM4I6XK TI TT1290U DM4I6XK TN Coagulation factor VIII (F8) DM4I6XK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM4I6XK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM4JFMZ DI DM4JFMZ DM4JFMZ DN T-82 DM4JFMZ TI TT1RS9F DM4JFMZ TN Acetylcholinesterase (AChE) DM4JFMZ MA Inhibitor DM4JFMZ RN Effects of T-82, a novel acetylcholinesterase inhibitor, on impaired learning and memory in passive avoidance task in rats. Eur J Pharmacol. 2003 Mar 28;465(1-2):97-103. DM4JFMZ RU https://pubmed.ncbi.nlm.nih.gov/12650838 DM4JGNH DI DM4JGNH DM4JGNH DN BAY 1067197 DM4JGNH TI TTK25J1 DM4JGNH TN Adenosine A1 receptor (ADORA1) DM4JGNH MA Modulator DM4JGNH RN Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619. DM4JGNH RU http://www.pnas.org/content/111/12/4614 DM4KOAC DI DM4KOAC DM4KOAC DN AGN-241751 DM4KOAC TI TT9IK2Z DM4KOAC TN N-methyl-D-aspartate receptor (NMDAR) DM4KOAC MA Modulator DM4KOAC RN Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons. Neuropsychopharmacology. 2021 Mar;46(4):799-808. DM4KOAC RU https://pubmed.ncbi.nlm.nih.gov/33059355 DM4KTN6 DI DM4KTN6 DM4KTN6 DN ASP-3652 DM4KTN6 TI TTMXGCW DM4KTN6 TN Adrenergic receptor beta-3 (ADRB3) DM4KTN6 MA Agonist DM4KTN6 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029610) DM4KTN6 RU http://adisinsight.springer.com/drugs/800029610 DM4KWEF DI DM4KWEF DM4KWEF DN S-0509 DM4KWEF TI TTVFO0U DM4KWEF TN Gastrin/cholecystokinin type B receptor (CCKBR) DM4KWEF MA Antagonist DM4KWEF RN Selective action of a CCK-B/gastrin receptor antagonist, S-0509, on pentagastrin-, peptone meal- and beer-stimulated gastric acid secretion in dogs. Aliment Pharmacol Ther. 2000 Apr;14(4):479-88. DM4KWEF RU https://pubmed.ncbi.nlm.nih.gov/10759628 DM4L5VJ DI DM4L5VJ DM4L5VJ DN R-phenserine DM4L5VJ TI TT1RS9F DM4L5VJ TN Acetylcholinesterase (AChE) DM4L5VJ MA Inhibitor DM4L5VJ RN An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul;2(3):281-90. DM4L5VJ RU https://pubmed.ncbi.nlm.nih.gov/15974893 DM4LJH8 DI DM4LJH8 DM4LJH8 DN CYT003 DM4LJH8 TI TTSHG0T DM4LJH8 TN Toll-like receptor 9 (TLR9) DM4LJH8 MA Agonist DM4LJH8 RN CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015 Sep;70(9):1160-8. DM4LJH8 RU https://pubmed.ncbi.nlm.nih.gov/26042362 DM4LKFO DI DM4LKFO DM4LKFO DN NELOTANSERIN DM4LKFO TI TTJQOD7 DM4LKFO TN 5-HT 2A receptor (HTR2A) DM4LKFO MA Modulator DM4LKFO RN Nelotanserin, a novel selective human 5-hydroxytryptamine2A inverse agonist for the treatment of insomnia.J Pharmacol Exp Ther.2010 Jan;332(1):281-90. DM4LKFO RU https://www.ncbi.nlm.nih.gov/pubmed/19841476 DM4MF9V DI DM4MF9V DM4MF9V DN proglumide DM4MF9V TI TTCG0AL DM4MF9V TN Cholecystokinin receptor type A (CCKAR) DM4MF9V MA Antagonist DM4MF9V RN Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists. Arzneimittelforschung. 1987 Nov;37(11):1265-8. DM4MF9V RU https://pubmed.ncbi.nlm.nih.gov/3440035 DM4MSLY DI DM4MSLY DM4MSLY DN ZN-c3 DM4MSLY TI TTJFOAL DM4MSLY TN Wee1-like protein kinase (WEE1) DM4MSLY MA Inhibitor DM4MSLY RN Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals. DM4MSLY RU https://zentalis.com/our-pipeline/pipeline/ DM4N2O0 DI DM4N2O0 DM4N2O0 DN Apilimod dimesylate DM4N2O0 TI TTA4M1N DM4N2O0 TN Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) DM4N2O0 MA Inhibitor DM4N2O0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4N2O0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4N6EK DI DM4N6EK DM4N6EK DN LY293558 DM4N6EK TI TT0MYE2 DM4N6EK TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM4N6EK MA Modulator DM4N6EK RN Pharmacogenetics of new analgesics. Br J Pharmacol. 2011 Jun;163(3):447-60. DM4N6EK RU https://pubmed.ncbi.nlm.nih.gov/20942817 DM4N6PF DI DM4N6PF DM4N6PF DN RP-49356 DM4N6PF TI TT1VOHK DM4N6PF TN Potassium channel unspecific (KC) DM4N6PF MA Opener DM4N6PF RN Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol. 1990 Mar;99(3):487-92. DM4N6PF RU https://pubmed.ncbi.nlm.nih.gov/2158844 DM4NXWE DI DM4NXWE DM4NXWE DN UB-311 DM4NXWE TI TTE4KHA DM4NXWE TN Amyloid beta A4 protein (APP) DM4NXWE MA Modulator DM4NXWE RN Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7. DM4NXWE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979042/ DM4NY58 DI DM4NY58 DM4NY58 DN SB-623 DM4NY58 TI TT6R7JZ DM4NY58 TN Histone deacetylase 1 (HDAC1) DM4NY58 MA Inhibitor DM4NY58 RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM4NY58 RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM4O17U DI DM4O17U DM4O17U DN VLTS-589 DM4O17U TI TT69TQN DM4O17U TN Integrin alpha-V/beta-3 (ITGAV/B3) DM4O17U MA Modulator DM4O17U RN AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35. DM4O17U RU http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1914/html DM4OT29 DI DM4OT29 DM4OT29 DN POL-6326 DM4OT29 TI TTBID49 DM4OT29 TN C-X-C chemokine receptor type 4 (CXCR4) DM4OT29 MA Antagonist DM4OT29 RN CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov. 2012 Sep;7(3):251-64. DM4OT29 RU https://pubmed.ncbi.nlm.nih.gov/22376154 DM4QHZS DI DM4QHZS DM4QHZS DN BMS-986177 DM4QHZS TI TTDM4ZU DM4QHZS TN Factor XI messenger RNA (F11 mRNA) DM4QHZS MA Inhibitor DM4QHZS RN Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017 Dec;12(12):1195-1205. DM4QHZS RU https://pubmed.ncbi.nlm.nih.gov/28952381 DM4R23C DI DM4R23C DM4R23C DN TPM-1/Morphine DM4R23C TI TTQW87Y DM4R23C TN Opioid receptor kappa (OPRK1) DM4R23C MA Inhibitor DM4R23C RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM4R23C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM4R23C DI DM4R23C DM4R23C DN TPM-1/Morphine DM4R23C TI TT27RFC DM4R23C TN Opioid receptor delta (OPRD1) DM4R23C MA Inhibitor DM4R23C RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM4R23C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM4R23C DI DM4R23C DM4R23C DN TPM-1/Morphine DM4R23C TI TTKWM86 DM4R23C TN Opioid receptor mu (MOP) DM4R23C MA Inhibitor DM4R23C RN Molecular Mechanisms of Opioid Receptor-Dependent Signaling and Behavior. Anesthesiology. 2011 December; 115(6): 1363-1381. DM4R23C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698859/ DM4RXDQ DI DM4RXDQ DM4RXDQ DN ISIS-HBV DM4RXDQ TI TT43YWN DM4RXDQ TN Hepatitis B virus messenger RNA (HBV mRNA) DM4RXDQ RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DM4RXDQ RU https://www.isispharm.com/pipeline/isis-hbvrx/ DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTN7BL9 DM4SOAW TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM4SOAW MA Inhibitor DM4SOAW RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/20100662 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TT9V5JH DM4SOAW TN Phospholipase A2 (PLA2G1B) DM4SOAW MA Inhibitor DM4SOAW RN Synthesis of benzoyl phenyl benzoates as effective inhibitors for phospholipase A2 and hyaluronidase enzymes. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4100-4. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/15993585 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTIU7X1 DM4SOAW TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM4SOAW MA Inhibitor DM4SOAW RN DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/10654412 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTZHY6R DM4SOAW TN Glycogen phosphorylase muscle form (GP) DM4SOAW MA Inhibitor DM4SOAW RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/19642687 DM4SOAW DI DM4SOAW DM4SOAW DN URSOLIC ACID DM4SOAW TI TTELIN2 DM4SOAW TN PTPN1 messenger RNA (PTPN1 mRNA) DM4SOAW MA Inhibitor DM4SOAW RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DM4SOAW RU https://pubmed.ncbi.nlm.nih.gov/19836230 DM4T9RS DI DM4T9RS DM4T9RS DN ATN-161 DM4T9RS TI TT69TQN DM4T9RS TN Integrin alpha-V/beta-3 (ITGAV/B3) DM4T9RS MA Antagonist DM4T9RS RN A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80. DM4T9RS RU https://pubmed.ncbi.nlm.nih.gov/16985061 DM4T9RS DI DM4T9RS DM4T9RS DN ATN-161 DM4T9RS TI TTH4QIS DM4T9RS TN Integrin alpha-5/beta-1 (ITGA5/B1) DM4T9RS MA Antagonist DM4T9RS RN A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther. 2006 Sep;5(9):2271-80. DM4T9RS RU https://pubmed.ncbi.nlm.nih.gov/16985061 DM4V8WF DI DM4V8WF DM4V8WF DN Cenicriviroc DM4V8WF TI TT2CEJG DM4V8WF TN C-C chemokine receptor type 5 (CCR5) DM4V8WF MA Modulator DM4V8WF RN The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline. J Antimicrob Chemother. 2015 Mar;70(3):750-6. DM4V8WF RU https://pubmed.ncbi.nlm.nih.gov/25433008 DM4V8WF DI DM4V8WF DM4V8WF DN Cenicriviroc DM4V8WF TI TTFZYTO DM4V8WF TN C-C chemokine receptor type 2 (CCR2) DM4V8WF MA Antagonist DM4V8WF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4V8WF RU http://phrma-docs.phrma.org/files/dmfile/2017-HIV-AIDS-MID-Drug-List.pdf DM4VWXI DI DM4VWXI DM4VWXI DN [131I]-Metuximab DM4VWXI TI TT5UJWD DM4VWXI TN Basigin (BSG) DM4VWXI RN Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase I/II trials. Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):435-44. DM4VWXI RU https://pubmed.ncbi.nlm.nih.gov/16690431 DM4W28K DI DM4W28K DM4W28K DN NCX 1022 DM4W28K TI TTK0943 DM4W28K TN Prostaglandin G/H synthase (COX) DM4W28K MA Modulator DM4W28K RN Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol. 2004 Nov;143(5):618-25. DM4W28K RU https://pubmed.ncbi.nlm.nih.gov/15313880 DM4WHOS DI DM4WHOS DM4WHOS DN KPP203 DM4WHOS TI TT7BQRM DM4WHOS TN Sphingosine-1 phosphate receptor (S1PR) DM4WHOS MA Agonist DM4WHOS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WHOS RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM4XMF7 DI DM4XMF7 DM4XMF7 DN LY2606368 DM4XMF7 TI TTTU902 DM4XMF7 TN Checkpoint kinase-1 (CHK1) DM4XMF7 MA Inhibitor DM4XMF7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4XMF7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4ZIDH DI DM4ZIDH DM4ZIDH DN Xentuzumab DM4ZIDH TI TTT6LOU DM4ZIDH TN Insulin-like growth factor-I (IGF1) DM4ZIDH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4ZIDH RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM4ZIDH DI DM4ZIDH DM4ZIDH DN Xentuzumab DM4ZIDH TI TTE8WGO DM4ZIDH TN Insulin-like growth factor-II (IGF2) DM4ZIDH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4ZIDH RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM4ZLTY DI DM4ZLTY DM4ZLTY DN ABBV-2222 DM4ZLTY TI TTRLZHP DM4ZLTY TN cAMP-dependent chloride channel (CFTR) DM4ZLTY MA Modulator DM4ZLTY RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM4ZLTY RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM50M2R DI DM50M2R DM50M2R DN JTT-654 DM50M2R TI TTN7BL9 DM50M2R TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM50M2R MA Inhibitor DM50M2R RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DM50M2R RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DM50Z4U DI DM50Z4U DM50Z4U DN Milataxel DM50Z4U TI TTML2WA DM50Z4U TN Tubulin (TUB) DM50Z4U MA Inhibitor DM50Z4U RN J Clin Oncol 28, 2010 (suppl; abstr e13075). DM50Z4U RU http://meetinglibrary.asco.org/content/54296-74 DM51LTG DI DM51LTG DM51LTG DN BMS-708163 DM51LTG TI TT9W8GU DM51LTG TN Gamma-secretase (GS) DM51LTG MA Modulator DM51LTG RN Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol. 2012 Nov;69(11):1430-40. DM51LTG RU https://pubmed.ncbi.nlm.nih.gov/22892585 DM524GR DI DM524GR DM524GR DN ICP-192 DM524GR TI TT0LF7H DM524GR TN Fibroblast growth factor receptor (FGFR) DM524GR MA Inhibitor DM524GR RN Clinical pipeline report, company report or official report of InnoCare Pharma. DM524GR RU https://www.innocarepharma.com/en/pipeline/our-pipeline/ DM52HUD DI DM52HUD DM52HUD DN Dexloxiglumide DM52HUD TI TTVFO0U DM52HUD TN Gastrin/cholecystokinin type B receptor (CCKBR) DM52HUD MA Inhibitor DM52HUD RN Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7. DM52HUD RU https://pubmed.ncbi.nlm.nih.gov/9341915 DM52HUD DI DM52HUD DM52HUD DN Dexloxiglumide DM52HUD TI TTCG0AL DM52HUD TN Cholecystokinin receptor type A (CCKAR) DM52HUD MA Inhibitor DM52HUD RN Full agonists of CCK8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem. 1989 Feb;32(2):445-9. DM52HUD RU https://pubmed.ncbi.nlm.nih.gov/2464062 DM548TK DI DM548TK DM548TK DN KD025 DM548TK TI TTGWKQJ DM548TK TN Rho-associated protein kinase 2 (ROCK2) DM548TK MA Inhibitor DM548TK RN Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. DM548TK RU https://pubmed.ncbi.nlm.nih.gov/25385601 DM54MAJ DI DM54MAJ DM54MAJ DN YF-476 DM54MAJ TI TTVFO0U DM54MAJ TN Gastrin/cholecystokinin type B receptor (CCKBR) DM54MAJ MA Inhibitor DM54MAJ RN CCK-B receptor antagonist YF476 inhibits pancreatic enzyme secretion at a duodenal level in pigs. Scand J Gastroenterol. 2004 Sep;39(9):886-90. DM54MAJ RU https://pubmed.ncbi.nlm.nih.gov/15513388 DM563NC DI DM563NC DM563NC DN Fasitibant chloride DM563NC TI TTGY8IW DM563NC TN B2 bradykinin receptor (BDKRB2) DM563NC MA Antagonist DM563NC RN Fasitibant chloride, a kinin B receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10. DM563NC RU https://pubmed.ncbi.nlm.nih.gov/22251015 DM57TY3 DI DM57TY3 DM57TY3 DN 9-ING-41 DM57TY3 TI TTRSMW9 DM57TY3 TN Glycogen synthase kinase-3 beta (GSK-3B) DM57TY3 MA Inhibitor DM57TY3 RN 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977. DM57TY3 RU https://pubmed.ncbi.nlm.nih.gov/31882719 DM58HR7 DI DM58HR7 DM58HR7 DN SC-75416 DM58HR7 TI TTVKILB DM58HR7 TN Prostaglandin G/H synthase 2 (COX-2) DM58HR7 MA Inhibitor DM58HR7 RN Modeling and simulation to support dose selection and clinical development of SC-75416, a selective COX-2 inhibitor for the treatment of acute and ... Clin Pharmacol Ther. 2008 Jun;83(6):857-66. DM58HR7 RU https://pubmed.ncbi.nlm.nih.gov/17882158 DM59OJ2 DI DM59OJ2 DM59OJ2 DN Abicipar pegol DM59OJ2 TI TTOHSBA DM59OJ2 TN Vascular endothelial growth factor A (VEGFA) DM59OJ2 MA Inhibitor DM59OJ2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM59OJ2 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM5BL4C DI DM5BL4C DM5BL4C DN Veltuzumab DM5BL4C TI TTUE541 DM5BL4C TN Leukocyte surface antigen Leu-16 (CD20) DM5BL4C MA Modulator DM5BL4C RN Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura. Curr Opin Mol Ther. 2009 Apr;11(2):200-7. DM5BL4C RU https://pubmed.ncbi.nlm.nih.gov/19330725 DM5C70M DI DM5C70M DM5C70M DN T-607 DM5C70M TI TTYFKSZ DM5C70M TN Tubulin beta (TUBB) DM5C70M MA Inhibitor DM5C70M RN Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476. DM5C70M RU http://www.sciencedirect.com/science/article/pii/0040402072880293 DM5CB8U DI DM5CB8U DM5CB8U DN DELTIBANT DM5CB8U TI TTGY8IW DM5CB8U TN B2 bradykinin receptor (BDKRB2) DM5CB8U MA Modulator DM5CB8U RN CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992;38 ( Pt 3):413-20. DM5CB8U RU https://pubmed.ncbi.nlm.nih.gov/1462875 DM5D6Y7 DI DM5D6Y7 DM5D6Y7 DN OBI-3424 DM5D6Y7 TI TTUTN1I DM5D6Y7 TN Human Deoxyribonucleic acid (hDNA) DM5D6Y7 RN OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-4503. DM5D6Y7 RU https://pubmed.ncbi.nlm.nih.gov/31015346 DM5DSGJ DI DM5DSGJ DM5DSGJ DN MD-0727 DM5DSGJ TI TTNA5ZS DM5DSGJ TN Cholesterol absorption (Chole absorp) DM5DSGJ MA Modulator DM5DSGJ RN Th-P16:297 Early clinical characterization of MD-0727, a novel cholesterol absorption inhibitor, in healthy subjects. Atherosclerosis Supplements Volume 7, Issue 3, 2006, Pages 558-559. DM5DSGJ RU http://www.sciencedirect.com/science/article/pii/S1567568806822555 DM5EFXZ DI DM5EFXZ DM5EFXZ DN Alpha-1 antitrypsin DM5EFXZ TI TT2WR1T DM5EFXZ TN Cationic trypsinogen (PRSS1) DM5EFXZ MA Modulator DM5EFXZ RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DM5EFXZ RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DM5F0QY DI DM5F0QY DM5F0QY DN IONIS-416858 DM5F0QY TI TTDM4ZU DM5F0QY TN Factor XI messenger RNA (F11 mRNA) DM5F0QY MA Inhibitor DM5F0QY RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM5F0QY RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM5GAC4 DI DM5GAC4 DM5GAC4 DN SRD-441 DM5GAC4 TI TTZBFA0 DM5GAC4 TN Protease unspecific (PRO) DM5GAC4 MA Inhibitor DM5GAC4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029807) DM5GAC4 RU http://adisinsight.springer.com/drugs/800029807 DM5GKYD DI DM5GKYD DM5GKYD DN CDX-3379 DM5GKYD TI TTDC8N2 DM5GKYD TN Erbb3 tyrosine kinase receptor (Erbb-3) DM5GKYD MA Antagonist DM5GKYD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5GKYD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM5GQD7 DI DM5GQD7 DM5GQD7 DN Metoprine DM5GQD7 TI TT9SL3Q DM5GQD7 TN Polypeptide deformylase (PDF) DM5GQD7 MA Inhibitor DM5GQD7 RN Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. DM5GQD7 RU https://pubmed.ncbi.nlm.nih.gov/16612649 DM5GQD7 DI DM5GQD7 DM5GQD7 DN Metoprine DM5GQD7 TI TT2B6EV DM5GQD7 TN Histamine N-methyltransferase (HNMT) DM5GQD7 MA Inhibitor DM5GQD7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5GQD7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5H8V1 DI DM5H8V1 DM5H8V1 DN PF-06826647 DM5H8V1 TI TTBYWP2 DM5H8V1 TN TYK2 tyrosine kinase (TYK2) DM5H8V1 MA Inhibitor DM5H8V1 RN Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases. J Med Chem. 2020 Nov 25;63(22):13561-13577. DM5H8V1 RU https://pubmed.ncbi.nlm.nih.gov/32787094 DM5HMTB DI DM5HMTB DM5HMTB DN Porphobilinogen DM5HMTB TI TTJHKYD DM5HMTB TN Delta-aminolevulinic acid dehydratase (ALAD) DM5HMTB MA Inhibitor DM5HMTB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5HMTB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5HPZU DI DM5HPZU DM5HPZU DN NOX-H94 DM5HPZU TI TTPCG5T DM5HPZU TN Hepcidin (HAMP) DM5HPZU MA Inhibitor DM5HPZU RN The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 Mar 21;121(12):2311-5. DM5HPZU RU https://pubmed.ncbi.nlm.nih.gov/23349391 DM5IX9M DI DM5IX9M DM5IX9M DN LY-156735 DM5IX9M TI TT0WAIE DM5IX9M TN Melatonin receptor type 1A (MTNR1A) DM5IX9M MA Agonist DM5IX9M RN Melatonin and sleep in aging population. Exp Gerontol. 2005 Dec;40(12):911-25. DM5IX9M RU https://pubmed.ncbi.nlm.nih.gov/16183237 DM5LM3O DI DM5LM3O DM5LM3O DN IONIS-DNM2-2.5Rx DM5LM3O TI TTVRA5G DM5LM3O TN DNM2 messenger RNA (DNM2 mRNA) DM5LM3O MA Inhibitor DM5LM3O RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM5LM3O RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM5LQEI DI DM5LQEI DM5LQEI DN Leuvectin DM5LQEI TI TTF89GD DM5LQEI TN Interleukin-2 (IL2) DM5LQEI MA Modulator DM5LQEI RN Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J Urol. 2000 Apr;18(2):152-6. DM5LQEI RU https://pubmed.ncbi.nlm.nih.gov/10854152 DM5N4OA DI DM5N4OA DM5N4OA DN KVD824 DM5N4OA TI TTMF8H9 DM5N4OA TN Plasma kallikrein (KLKB1) DM5N4OA MA Inhibitor DM5N4OA RN Clinical pipeline report, company report or official report of KalVista Pharmaceuticals. DM5N4OA RU https://www.kalvista.com/products-pipeline/kvd824-hae DM5NC39 DI DM5NC39 DM5NC39 DN SAGE-324 DM5NC39 TI TTCI43M DM5NC39 TN GABA(A) receptor (GABAR) DM5NC39 MA Modulator DM5NC39 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM5NC39 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM5O6GC DI DM5O6GC DM5O6GC DN ONO-9054 DM5O6GC TI TTT2ZAR DM5O6GC TN Prostaglandin F2-alpha receptor (PTGFR) DM5O6GC MA Modulator DM5O6GC RN IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52. DM5O6GC RU https://pubmed.ncbi.nlm.nih.gov/25788650 DM5O6GC DI DM5O6GC DM5O6GC DN ONO-9054 DM5O6GC TI TTPNGDE DM5O6GC TN Prostaglandin E2 receptor EP3 (PTGER3) DM5O6GC MA Modulator DM5O6GC RN IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52. DM5O6GC RU https://pubmed.ncbi.nlm.nih.gov/25788650 DM5OU2W DI DM5OU2W DM5OU2W DN BMS-986253 DM5OU2W TI TT3JF7X DM5OU2W TN HUMAN interleukin 8 (IL8) DM5OU2W MA Inhibitor DM5OU2W RN ClinicalTrials.gov (NCT04347226) Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19. U.S. National Institutes of Health. DM5OU2W RU https://clinicaltrials.gov/ct2/show/NCT04347226 DM5PBLM DI DM5PBLM DM5PBLM DN EYP001 DM5PBLM TI TTS4UGC DM5PBLM TN Farnesoid X-activated receptor (FXR) DM5PBLM MA Agonist DM5PBLM RN Clinical pipeline report, company report or official report of ENYO Pharma. DM5PBLM RU http://www.enyopharma.com/pipeline/eyp001-in-nash/ DM5Q9RY DI DM5Q9RY DM5Q9RY DN OX-914 DM5Q9RY TI TTVIAT9 DM5Q9RY TN Phosphodiesterase 4B (PDE4B) DM5Q9RY MA Inhibitor DM5Q9RY RN Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009. DM5Q9RY RU http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf DM5Q9RY DI DM5Q9RY DM5Q9RY DN OX-914 DM5Q9RY TI TTSKMI8 DM5Q9RY TN Phosphodiesterase 4D (PDE4D) DM5Q9RY MA Inhibitor DM5Q9RY RN Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009. DM5Q9RY RU http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf DM5Q9RY DI DM5Q9RY DM5Q9RY DN OX-914 DM5Q9RY TI TTZ97H5 DM5Q9RY TN Phosphodiesterase 4A (PDE4A) DM5Q9RY MA Inhibitor DM5Q9RY RN Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009. DM5Q9RY RU http://feed.ne.cision.com/wpyfs/00/00/00/00/00/0E/79/F6/wkr0003.pdf DM5R89X DI DM5R89X DM5R89X DN SARIPIDEM DM5R89X TI TTEX6LM DM5R89X TN GABA(A) receptor gamma-3 (GABRG3) DM5R89X MA Modulator DM5R89X RN Behavioural effects of novel benzodiazepine (omega) receptor agonists and partial agonists: increases in punished responding and antagonism of the pentylenetetrazole cue. Behav Pharmacol. 1995 Mar;6(2):116-126. DM5R89X RU https://pubmed.ncbi.nlm.nih.gov/11224318 DM5RAB9 DI DM5RAB9 DM5RAB9 DN RG-7234 DM5RAB9 TI TT9H85R DM5RAB9 TN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DM5RAB9 MA Inhibitor DM5RAB9 RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DM5RAB9 RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DM5TC43 DI DM5TC43 DM5TC43 DN AR-12286 DM5TC43 TI TTMQO60 DM5TC43 TN Rho-associated protein kinase (ROCK) DM5TC43 MA Modulator DM5TC43 RN Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1. DM5TC43 RU https://pubmed.ncbi.nlm.nih.gov/21794845 DM5TMYC DI DM5TMYC DM5TMYC DN iOWH032 DM5TMYC TI TTRLZHP DM5TMYC TN cAMP-dependent chloride channel (CFTR) DM5TMYC MA Inhibitor DM5TMYC RN Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem. 2011 Aug;3(10):1317-25. DM5TMYC RU https://pubmed.ncbi.nlm.nih.gov/21859305 DM5UFRO DI DM5UFRO DM5UFRO DN Itriglumide DM5UFRO TI TTVFO0U DM5UFRO TN Gastrin/cholecystokinin type B receptor (CCKBR) DM5UFRO MA Antagonist DM5UFRO RN Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem. 2007; 7(12): 1211-1231. DM5UFRO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718729/ DM5WK0J DI DM5WK0J DM5WK0J DN ARQ 092 DM5WK0J TI TTAZ05C DM5WK0J TN RAC-gamma serine/threonine-protein kinase (AKT3) DM5WK0J MA Modulator DM5WK0J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5WK0J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5WK0J DI DM5WK0J DM5WK0J DN ARQ 092 DM5WK0J TI TTWTSCV DM5WK0J TN RAC-alpha serine/threonine-protein kinase (AKT1) DM5WK0J MA Inhibitor DM5WK0J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5WK0J RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM5WZ0O DI DM5WZ0O DM5WZ0O DN EDP-420 DM5WZ0O TI TTLFGBV DM5WZ0O TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DM5WZ0O MA Inhibitor DM5WZ0O RN EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium. Antimicrob Agents Chemother. 2007 May; 51(5): 1666-1670. DM5WZ0O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855536/ DM5XRMA DI DM5XRMA DM5XRMA DN Tipapkinogene sovacivec DM5XRMA TI TTE2N95 DM5XRMA TN Human papillomavirus protein E6 (HPV E6) DM5XRMA MA Modulator DM5XRMA RN Immune therapy for human papillomaviruses-related cancers DM5XRMA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927 DM5XRMA DI DM5XRMA DM5XRMA DN Tipapkinogene sovacivec DM5XRMA TI TT3CPZW DM5XRMA TN Human papillomavirus protein E7 (HPV E7) DM5XRMA MA Modulator DM5XRMA RN Immune therapy for human papillomaviruses-related cancers DM5XRMA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259927 DM5XT3G DI DM5XT3G DM5XT3G DN DE-098 DM5XT3G TI TTF0RCZ DM5XT3G TN Apoptosis mediating surface antigen FAS (FAS) DM5XT3G RN ARG098, a novel anti-human Fas antibody, suppresses synovial hyperplasia and prevents cartilage destruction in a severe combined immunodeficient-HuRAg mouse model. BMC Musculoskeletal Disorders 2010,11:221. DM5XT3G RU http://www.biomedcentral.com/1471-2474/11/221 DM5XYFH DI DM5XYFH DM5XYFH DN SGS742 DM5XYFH TI TTDCVZW DM5XYFH TN Gamma-aminobutyric acid B receptor (GABBR) DM5XYFH MA Modulator DM5XYFH RN SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol. 2004 Oct 15;68(8):1479-87. DM5XYFH RU https://pubmed.ncbi.nlm.nih.gov/15451390 DM5Z34K DI DM5Z34K DM5Z34K DN UCB-35440 DM5Z34K TI TT2J34L DM5Z34K TN Arachidonate 5-lipoxygenase (5-LOX) DM5Z34K MA Modulator DM5Z34K RN The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71. DM5Z34K RU https://pubmed.ncbi.nlm.nih.gov/15627437 DM5Z34K DI DM5Z34K DM5Z34K DN UCB-35440 DM5Z34K TI TTTIBOJ DM5Z34K TN Histamine H1 receptor (H1R) DM5Z34K MA Modulator DM5Z34K RN The effect of a novel, dual function histamine H1 receptor antagonist/5-lipoxygenase enzyme inhibitor on in vivo dermal inflammation and extravasat... Eur J Pharmacol. 2005 Jan 4;506(3):265-71. DM5Z34K RU https://pubmed.ncbi.nlm.nih.gov/15627437 DM5Z3VP DI DM5Z3VP DM5Z3VP DN Ertumaxomab DM5Z3VP TI TTV3XPL DM5Z3VP TN T-cell surface glycoprotein CD3 gamma (CD3G) DM5Z3VP RN Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. DM5Z3VP RU https://pubmed.ncbi.nlm.nih.gov/22820509 DM5Z3VP DI DM5Z3VP DM5Z3VP DN Ertumaxomab DM5Z3VP TI TTZAT79 DM5Z3VP TN T-cell surface glycoprotein CD3 epsilon (CD3E) DM5Z3VP RN Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. DM5Z3VP RU https://pubmed.ncbi.nlm.nih.gov/22820509 DM5Z3VP DI DM5Z3VP DM5Z3VP DN Ertumaxomab DM5Z3VP TI TT6EO5L DM5Z3VP TN Erbb2 tyrosine kinase receptor (HER2) DM5Z3VP RN Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. DM5Z3VP RU https://pubmed.ncbi.nlm.nih.gov/22820509 DM5ZTE4 DI DM5ZTE4 DM5ZTE4 DN PRO-001 DM5ZTE4 TI TT2EDHU DM5ZTE4 TN Insulin-degrading enzyme (IDE) DM5ZTE4 MA Modulator DM5ZTE4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2371). DM5ZTE4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2371 DM60G5O DI DM60G5O DM60G5O DN KB002/003 DM60G5O TI TTNYZG2 DM60G5O TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM60G5O MA Modulator DM60G5O RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM60G5O RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM63P1W DI DM63P1W DM63P1W DN Descartes-08 DM63P1W TI TTZ3P4W DM63P1W TN B-cell maturation protein (TNFRSF17) DM63P1W MA CAR-T-Cell-Therapy DM63P1W RN ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma DM63P1W RU https://clinicaltrials.gov/ct2/show/NCT03448978 DM63QY0 DI DM63QY0 DM63QY0 DN SAR292833 DM63QY0 TI TT946IA DM63QY0 TN Transient receptor potential cation channel V3 (TRPV3) DM63QY0 MA Modulator DM63QY0 RN Pharmacological profiling of the TRPV3 channel in recombinant and native assays. Br J Pharmacol. 2014 May;171(10):2631-44. DM63QY0 RU https://pubmed.ncbi.nlm.nih.gov/23848361 DM64NYP DI DM64NYP DM64NYP DN TRN-157 DM64NYP TI TTQ13Z5 DM64NYP TN Muscarinic acetylcholine receptor M3 (CHRM3) DM64NYP MA Antagonist DM64NYP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15). DM64NYP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15 DM64ZYM DI DM64ZYM DM64ZYM DN GPI-1485 DM64ZYM TI TTMW94E DM64ZYM TN FK506-binding protein 1A (FKBP1A) DM64ZYM MA Binder DM64ZYM RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DM64ZYM RU https://pubmed.ncbi.nlm.nih.gov/18991661 DM652CM DI DM652CM DM652CM DN RV-568 DM652CM TI TTU8W4S DM652CM TN Protein kinase (PK) DM652CM MA Inhibitor DM652CM RN Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. DM652CM RU https://pubmed.ncbi.nlm.nih.gov/25599809 DM65PTO DI DM65PTO DM65PTO DN AMG 232 DM65PTO TI TT08GJW DM65PTO TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DM65PTO MA Modulator DM65PTO RN Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41. DM65PTO RU https://pubmed.ncbi.nlm.nih.gov/24967612 DM67EMK DI DM67EMK DM67EMK DN SCH-900776 DM67EMK TI TTTU902 DM67EMK TN Checkpoint kinase-1 (CHK1) DM67EMK MA Inhibitor DM67EMK RN Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602. DM67EMK RU https://pubmed.ncbi.nlm.nih.gov/21321066 DM68K39 DI DM68K39 DM68K39 DN ETIPREDNOL DICLOACETATE DM68K39 TI TTYRL6O DM68K39 TN Glucocorticoid receptor (NR3C1) DM68K39 MA Modulator DM68K39 RN Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate.Int J Inflam.2012;2012:789623. DM68K39 RU https://www.ncbi.nlm.nih.gov/pubmed/22536546 DM69NF1 DI DM69NF1 DM69NF1 DN EP-101 DM69NF1 TI TTOXS3C DM69NF1 TN Muscarinic acetylcholine receptor (CHRM) DM69NF1 MA Antagonist DM69NF1 RN Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013 Jun;26(3):307-17. DM69NF1 RU https://pubmed.ncbi.nlm.nih.gov/23274274 DM6ABD9 DI DM6ABD9 DM6ABD9 DN ATHX-105 DM6ABD9 TI TTWJBZ5 DM6ABD9 TN 5-HT 2C receptor (HTR2C) DM6ABD9 MA Agonist DM6ABD9 RN Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60. DM6ABD9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/ DM6AI9N DI DM6AI9N DM6AI9N DN AZD-2927 DM6AI9N TI TTM7WCE DM6AI9N TN Ion channel unspecific (IC) DM6AI9N MA Modulator DM6AI9N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7704). DM6AI9N RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7704 DM6AJKC DI DM6AJKC DM6AJKC DN AFN-1720 DM6AJKC TI TTVTX4N DM6AJKC TN Bacterial Fatty acid synthetase I (Bact inhA) DM6AJKC MA Inhibitor DM6AJKC RN Affinium Pharmaceuticals Announces the Initiation of a Phase 1 Intravenous Clinical Trial of a New Antibiotic Prodrug, and the Closing of a Follow-on Financing Round. PR Newswire Sep. 4, 2013 10:16 PM. DM6AJKC RU http://www.virtualizationconference.com/node/2779672 DM6B9HP DI DM6B9HP DM6B9HP DN Apomine DM6B9HP TI TTS4UGC DM6B9HP TN Farnesoid X-activated receptor (FXR) DM6B9HP MA Agonist DM6B9HP RN The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59. DM6B9HP RU https://pubmed.ncbi.nlm.nih.gov/11254888 DM6BKG2 DI DM6BKG2 DM6BKG2 DN VVP-808 DM6BKG2 TI TTCBFJO DM6BKG2 TN Insulin receptor (INSR) DM6BKG2 MA Modulator DM6BKG2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM6BKG2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM6CNFW DI DM6CNFW DM6CNFW DN RG7686 DM6CNFW TI TTJTSX4 DM6CNFW TN Glypican-3 (GPC3) DM6CNFW RN First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8. DM6CNFW RU https://pubmed.ncbi.nlm.nih.gov/23362325 DM6CVZ5 DI DM6CVZ5 DM6CVZ5 DN Bavisant DM6CVZ5 TI TT9JNIC DM6CVZ5 TN Histamine H3 receptor (H3R) DM6CVZ5 MA Antagonist DM6CVZ5 RN Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34. DM6CVZ5 RU https://pubmed.ncbi.nlm.nih.gov/22519922 DM6DK9A DI DM6DK9A DM6DK9A DN PVX-410 DM6DK9A TI TT7ILZ1 DM6DK9A TN SLAM family member 7 SLAMF7 (CS1) DM6DK9A MA Modulator DM6DK9A RN Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228. DM6DK9A RU https://pubmed.ncbi.nlm.nih.gov/25764988 DM6DKF9 DI DM6DKF9 DM6DKF9 DN GSK961081 DM6DKF9 TI TT2CJVK DM6DKF9 TN Adrenergic receptor beta-2 (ADRB2) DM6DKF9 MA Modulator DM6DKF9 RN Pharmacologic characterization of GSK-961081 (TD-5959), a first-in-class inhaled bifunctional bronchodilator possessing muscarinic receptor antagonist and 2-adrenoceptor agonist properties.J Pharmacol Exp Ther.2014 Oct;351(1):190-9. DM6DKF9 RU https://www.ncbi.nlm.nih.gov/pubmed/25100753 DM6DL5K DI DM6DL5K DM6DL5K DN Leridistim DM6DL5K TI TTPYS82 DM6DL5K TN Interleukin 3 receptor (CSF2RB) DM6DL5K MA Agonist DM6DL5K RN Leridistim, a chimeric dual G-CSF and IL-3 receptor agonist, enhances multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression: effect of schedule, dose, and route of administration. Stem Cells. 2001;19(6):522-33. DM6DL5K RU https://pubmed.ncbi.nlm.nih.gov/11713344 DM6EIZG DI DM6EIZG DM6EIZG DN BIM23A760 DM6EIZG TI TT2J34L DM6EIZG TN Arachidonate 5-lipoxygenase (5-LOX) DM6EIZG MA Inhibitor DM6EIZG RN Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. DM6EIZG RU https://pubmed.ncbi.nlm.nih.gov/10940813 DM6EIZG DI DM6EIZG DM6EIZG DN BIM23A760 DM6EIZG TI TTEX248 DM6EIZG TN Dopamine D2 receptor (D2R) DM6EIZG MA Modulator DM6EIZG RN BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. DM6EIZG RU https://pubmed.ncbi.nlm.nih.gov/16625841 DM6F5EV DI DM6F5EV DM6F5EV DN PD-360324 DM6F5EV TI TT731LW DM6F5EV TN Colony stimulating factor-1 receptor (CSF-1R) DM6F5EV MA Modulator DM6F5EV RN Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70. DM6F5EV RU https://www.ncbi.nlm.nih.gov/pubmed/26376111 DM6HBGN DI DM6HBGN DM6HBGN DN GSK-1399686 DM6HBGN TI TTUWYEA DM6HBGN TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM6HBGN MA Modulator DM6HBGN RN Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015 March; 8(2): 66-82. DM6HBGN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314302/ DM6HJ3V DI DM6HJ3V DM6HJ3V DN ASP0819 DM6HJ3V TI TT7M9I6 DM6HJ3V TN Calcium-activated potassium channel KCa3.1 (KCNN4) DM6HJ3V MA Activator DM6HJ3V RN Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369. DM6HJ3V RU https://pubmed.ncbi.nlm.nih.gov/33328761 DM6IQ3V DI DM6IQ3V DM6IQ3V DN IMO-2055 DM6IQ3V TI TTSHG0T DM6IQ3V TN Toll-like receptor 9 (TLR9) DM6IQ3V MA Agonist DM6IQ3V RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011). DM6IQ3V RU http://www.iderapharma.com/ DM6JTSZ DI DM6JTSZ DM6JTSZ DN MB-07811 DM6JTSZ TI TTGER3L DM6JTSZ TN Thyroid hormone receptor beta (THRB) DM6JTSZ MA Modulator DM6JTSZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 589). DM6JTSZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=589 DM6L5TR DI DM6L5TR DM6L5TR DN EGEN-001 DM6L5TR TI TTGW72V DM6L5TR TN Interleukin-12 beta (IL12B) DM6L5TR MA Modulator DM6L5TR RN National Cancer Institute Drug Dictionary (drug id 454593). DM6L5TR RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=454593 DM6MUCX DI DM6MUCX DM6MUCX DN CpG-10101 DM6MUCX TI TTSHG0T DM6MUCX TN Toll-like receptor 9 (TLR9) DM6MUCX MA Agonist DM6MUCX RN Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007;12(5):741-51. DM6MUCX RU https://pubmed.ncbi.nlm.nih.gov/17713157 DM6N05H DI DM6N05H DM6N05H DN BIO-11006 DM6N05H TI TTHRM39 DM6N05H TN Myristoylated alanine-rich C-kinase substrate (MARCKS) DM6N05H MA Inhibitor DM6N05H RN Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation. Exp Lung Res. 2010 Mar;36(2):75-84. DM6N05H RU https://pubmed.ncbi.nlm.nih.gov/20205598 DM6OC53 DI DM6OC53 DM6OC53 DN PDX-101 DM6OC53 TI TTBH0VX DM6OC53 TN Histone deacetylase (HDAC) DM6OC53 MA Modulator DM6OC53 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM6OC53 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM6OFJ8 DI DM6OFJ8 DM6OFJ8 DN Indibulin DM6OFJ8 TI TTML2WA DM6OFJ8 TN Tubulin (TUB) DM6OFJ8 MA Stablizer DM6OFJ8 RN 2011 Pipeline of ZioPharm. DM6OFJ8 RU http://www.ziopharm.com/clinical_dev.php DM6OLGC DI DM6OLGC DM6OLGC DN MK-3207 DM6OLGC TI TTY6O0Q DM6OLGC TN Calcitonin gene-related peptide receptor (CGRPR) DM6OLGC MA Antagonist DM6OLGC RN Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60. DM6OLGC RU https://pubmed.ncbi.nlm.nih.gov/20065019 DM6P91T DI DM6P91T DM6P91T DN INGN-241 DM6P91T TI TT1EPXZ DM6P91T TN Interleukin-24 (IL24) DM6P91T MA Inhibitor DM6P91T RN Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther. 2005 Jan;11(1):160-72. DM6P91T RU https://pubmed.ncbi.nlm.nih.gov/15585417 DM6PBUM DI DM6PBUM DM6PBUM DN Birinapant DM6PBUM TI TTR7B60 DM6PBUM TN X-linked inhibitor of apoptosis protein (XIAP) DM6PBUM MA Modulator DM6PBUM RN cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72. DM6PBUM RU https://pubmed.ncbi.nlm.nih.gov/24497535 DM6PBUM DI DM6PBUM DM6PBUM DN Birinapant DM6PBUM TI TTQ5LRD DM6PBUM TN Cellular inhibitor of apoptosis 1 (BIRC2) DM6PBUM MA Modulator DM6PBUM RN cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood. 2014 Apr 17;123(16):2562-72. DM6PBUM RU https://pubmed.ncbi.nlm.nih.gov/24497535 DM6PDX2 DI DM6PDX2 DM6PDX2 DN IONIS-C9Rx DM6PDX2 TI TTA4SHR DM6PDX2 TN C9orf72 messenger RNA (C9orf72 mRNA) DM6PDX2 MA Inhibitor DM6PDX2 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM6PDX2 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM6PTIX DI DM6PTIX DM6PTIX DN ABT-981 DM6PTIX TI TTPM6HI DM6PTIX TN Interleukin-1 alpha (IL1A) DM6PTIX MA Modulator DM6PTIX RN Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19. DM6PTIX RU https://pubmed.ncbi.nlm.nih.gov/25764208 DM6PTIX DI DM6PTIX DM6PTIX DN ABT-981 DM6PTIX TI TTRYK0X DM6PTIX TN Interleukin-1 beta (IL1B) DM6PTIX MA Modulator DM6PTIX RN Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1alpha and IL-1beta. MAbs. 2015;7(3):605-19. DM6PTIX RU https://pubmed.ncbi.nlm.nih.gov/25764208 DM6Q295 DI DM6Q295 DM6Q295 DN SAR566658 DM6Q295 TI TTCFSPE DM6Q295 TN Carbonic anhydrase VI (CA-VI) DM6Q295 MA Inhibitor DM6Q295 RN An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. Mol Cancer Ther. 2020 Aug;19(8):1660-1669. DM6Q295 RU https://pubmed.ncbi.nlm.nih.gov/32451330 DM6RBYT DI DM6RBYT DM6RBYT DN ALD-403 DM6RBYT TI TTAFORY DM6RBYT TN Calcitonin gene-related peptide (CALC) DM6RBYT MA Modulator DM6RBYT RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM6RBYT RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM6RKG3 DI DM6RKG3 DM6RKG3 DN Fadolmidine DM6RKG3 TI TT2NUT5 DM6RKG3 TN Adrenergic receptor alpha-2C (ADRA2C) DM6RKG3 MA Agonist DM6RKG3 RN Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev. 2004 Summer;10(2):117-26. DM6RKG3 RU https://pubmed.ncbi.nlm.nih.gov/15179442 DM6RKG3 DI DM6RKG3 DM6RKG3 DN Fadolmidine DM6RKG3 TI TTQ8AFT DM6RKG3 TN Adrenergic receptor Alpha-2 (ADRA2) DM6RKG3 MA Agonist DM6RKG3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6RKG3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM6RQXB DI DM6RQXB DM6RQXB DN CNTO-6785 DM6RQXB TI TTG0MT6 DM6RQXB TN Interleukin-17 (IL17) DM6RQXB RN Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2. DM6RQXB RU https://pubmed.ncbi.nlm.nih.gov/25549584 DM6RQXB DI DM6RQXB DM6RQXB DN CNTO-6785 DM6RQXB TI TT69OHW DM6RQXB TN Interleukin 17 receptor (IL17R) DM6RQXB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6RQXB RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM6RTVG DI DM6RTVG DM6RTVG DN Urelumab DM6RTVG TI TTPW9LJ DM6RTVG TN Co-stimulatory molecule 4-1BB (CD137) DM6RTVG MA Agonist DM6RTVG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6RTVG RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM6S83X DI DM6S83X DM6S83X DN NDDP DM6S83X TI TTUTN1I DM6S83X TN Human Deoxyribonucleic acid (hDNA) DM6S83X MA Binder DM6S83X RN Cell death and DNA fragmentation induced by liposomal platinum(II) complex, L-NDDP in A2780 and A2780/PDD cells. Anticancer Res. 1994 Mar-Apr;14(2A):421-6. DM6S83X RU https://pubmed.ncbi.nlm.nih.gov/8017841 DM6SANW DI DM6SANW DM6SANW DN TD-5108 DM6SANW TI TT07C3Y DM6SANW TN 5-HT 4 receptor (HTR4) DM6SANW MA Agonist DM6SANW RN The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37. DM6SANW RU https://pubmed.ncbi.nlm.nih.gov/18415081 DM6TAFE DI DM6TAFE DM6TAFE DN TTAC-0001 DM6TAFE TI TTUTJGQ DM6TAFE TN Vascular endothelial growth factor receptor 2 (KDR) DM6TAFE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM6TAFE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM6UGHA DI DM6UGHA DM6UGHA DN DSP-6952 DM6UGHA TI TT07C3Y DM6UGHA TN 5-HT 4 receptor (HTR4) DM6UGHA MA Agonist DM6UGHA RN DSP-6952, a high affinity serotonin (5-HT4) receptor partial agonist. Sumitomo Dainippon Pharma Co. Ltd. DM6UGHA RU http://www.biocentury.com/products/dsp-6952 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TTI3NXG DM6UQNW TN Human immunodeficiency virus Matrix p17 (HIV MA) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TT84ETX DM6UQNW TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TT4NXYM DM6UQNW TN Human immunodeficiency virus Negative factor (HIV nef) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6UQNW DI DM6UQNW DM6UQNW DN F4co vaccine DM6UQNW TI TTTWS2G DM6UQNW TN Human immunodeficiency virus Capsid p24 (HIV p24) DM6UQNW RN EP patent application no. 2621528, Vaccine. DM6UQNW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130807&CC=EP&NR=2621528A1&KC=A1 DM6VPIO DI DM6VPIO DM6VPIO DN MM36 DM6VPIO TI TT0JLSD DM6VPIO TN Multidrug resistance protein (MDR) DM6VPIO MA Inhibitor DM6VPIO RN Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. DM6VPIO RU https://pubmed.ncbi.nlm.nih.gov/19442032 DM6VQTF DI DM6VQTF DM6VQTF DN ZEN-3694 DM6VQTF TI TTE4BSY DM6VQTF TN Bromodomain and extraterminal domain protein (BET) DM6VQTF MA Inhibitor DM6VQTF RN Clinical pipeline report, company report or official report of Zenith Epigenetics. DM6VQTF RU https://www.zenithepigenetics.com/programs/pipeline DM6WN2D DI DM6WN2D DM6WN2D DN ABT-308 DM6WN2D TI TTMPZ7V DM6WN2D TN Interleukin 13 receptor alpha-2 (IL13RA2) DM6WN2D MA Antagonist DM6WN2D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6WN2D RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM6X70G DI DM6X70G DM6X70G DN ABI-H2158 DM6X70G TI TTM42UJ DM6X70G TN Hepatitis B virus Capsid protein (HBV C) DM6X70G MA Inhibitor DM6X70G RN Clinical pipeline report, company report or official report of Assembly Biosciences. DM6X70G RU https://www.assemblybio.com/pipeline/ DM6XJ9S DI DM6XJ9S DM6XJ9S DN SB-743921 DM6XJ9S TI TTTRP0H DM6XJ9S TN Kinesin-like protein KIF11 (KIF11) DM6XJ9S MA Inhibitor DM6XJ9S RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Jan-Feb;31(1):47-57. DM6XJ9S RU https://pubmed.ncbi.nlm.nih.gov/19357798 DM6XN4C DI DM6XN4C DM6XN4C DN CAR-T cells targeting CD22 DM6XN4C TI TTM6QSK DM6XN4C TN B-cell receptor CD22 (CD22) DM6XN4C MA CAR-T-Cell-Therapy DM6XN4C RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DM6XN4C RU https://clinicaltrials.gov/ct2/show/NCT03196830 DM6YI5T DI DM6YI5T DM6YI5T DN Tegobuvir DM6YI5T TI TTMVBWH DM6YI5T TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM6YI5T MA Inhibitor DM6YI5T RN Clinical pipeline report, company report or official report of Gilead (2011). DM6YI5T RU http://www.gilead.com/ DM6Z9BV DI DM6Z9BV DM6Z9BV DN CeaVac DM6Z9BV TI TTY6DTE DM6Z9BV TN Carcinoembryonic antigen CEA (CD66e) DM6Z9BV RN Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5. DM6Z9BV RU https://pubmed.ncbi.nlm.nih.gov/10561367 DM6ZIES DI DM6ZIES DM6ZIES DN A-6 DM6ZIES TI TTWFBT7 DM6ZIES TN Extracellular matrix receptor III (CD44) DM6ZIES MA Modulator DM6ZIES RN Modulation of CD44 Activity by A6-Peptide.Front Immunol.2015 Mar 30;6:135. DM6ZIES RU https://www.ncbi.nlm.nih.gov/pubmed/25870596 DM6ZOUV DI DM6ZOUV DM6ZOUV DN Clazakizumab DM6ZOUV TI TTJH4Y5 DM6ZOUV TN HUMAN interleukin 6 (IL6) DM6ZOUV MA Inhibitor DM6ZOUV RN Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS) J Autoimmun. 2020 Apr 10:102452. DM6ZOUV RU https://pubmed.ncbi.nlm.nih.gov/32291137 DM7063I DI DM7063I DM7063I DN LADIRUBICIN DM7063I TI TTUTN1I DM7063I TN Human Deoxyribonucleic acid (hDNA) DM7063I MA Binder DM7063I RN The power and potential of doxorubicin-DNA adducts. IUBMB Life. 2005 Feb;57(2):73-81. DM7063I RU https://pubmed.ncbi.nlm.nih.gov/16036566 DM71BZV DI DM71BZV DM71BZV DN Etamicastat DM71BZV TI TTYIP79 DM71BZV TN Dopamine beta hydroxylase (DBH) DM71BZV MA Inhibitor DM71BZV RN Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-beta-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects. Drugs R D. 2010;10(4):225-42. DM71BZV RU https://pubmed.ncbi.nlm.nih.gov/21171669 DM71HVW DI DM71HVW DM71HVW DN PH-794428 DM71HVW TI TTKMAZ6 DM71HVW TN Growth hormone receptor (GHR) DM71HVW MA Modulator DM71HVW RN PEGylation of somatropin (recombinant human growth hormone): impact on its clearance in humans.Xenobiotica.2008 Oct;38(10):1340-51. DM71HVW RU https://www.ncbi.nlm.nih.gov/pubmed/18802875 DM725UG DI DM725UG DM725UG DN DN24-02 DM725UG TI TT6EO5L DM725UG TN Erbb2 tyrosine kinase receptor (HER2) DM725UG MA Modulator DM725UG RN Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20;25(24):3680-7. DM725UG RU https://pubmed.ncbi.nlm.nih.gov/17704416 DM726HX DI DM726HX DM726HX DN MGCD-0103 DM726HX TI TT6R7JZ DM726HX TN Histone deacetylase 1 (HDAC1) DM726HX MA Inhibitor DM726HX RN Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32. DM726HX RU https://pubmed.ncbi.nlm.nih.gov/19721445 DM726HX DI DM726HX DM726HX DN MGCD-0103 DM726HX TI TTBH0VX DM726HX TN Histone deacetylase (HDAC) DM726HX MA Inhibitor DM726HX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM726HX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM72GZO DI DM72GZO DM72GZO DN JNJ-42165279 DM72GZO TI TTDP1UC DM72GZO TN Fatty acid amide hydrolase (FAAH) DM72GZO MA Inhibitor DM72GZO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM72GZO RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM72O6F DI DM72O6F DM72O6F DN GI-6207 DM72O6F TI TTY6DTE DM72O6F TN Carcinoembryonic antigen CEA (CD66e) DM72O6F MA Modulator DM72O6F RN Clinical pipeline report, company report or official report of GlobeImmune. DM72O6F RU https://www.globeimmune.com/cancer/gi-6207/ DM73UTG DI DM73UTG DM73UTG DN PRALNACASAN DM73UTG TI TTCQIBE DM73UTG TN Caspase-1 (CASP1) DM73UTG MA Modulator DM73UTG RN Pralnacasan, an inhibitor of interleukin-1beta converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. 2003 Oct;11(10):738-46. DM73UTG RU https://pubmed.ncbi.nlm.nih.gov/13129693 DM73XNG DI DM73XNG DM73XNG DN EVT302 DM73XNG TI TTGP7BY DM73XNG TN Monoamine oxidase type B (MAO-B) DM73XNG MA Inhibitor DM73XNG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM73XNG RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM740BS DI DM740BS DM740BS DN BI 1358894 DM740BS TI TT32NQ1 DM740BS TN Short transient receptor potential channel 5 (TRPC5) DM740BS MA Inhibitor DM740BS RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DM740BS RU https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop DM740BS DI DM740BS DM740BS DN BI 1358894 DM740BS TI TTX0H5W DM740BS TN Short transient receptor potential channel 4 (TRPC4) DM740BS MA Inhibitor DM740BS RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DM740BS RU https://www.boehringer-ingelheim.pt/press-release/hydra-biosciences-and-boehringer-ingelheim-announce-worldwide-collaboration-develop DM740LV DI DM740LV DM740LV DN YKP-GI DM740LV TI TT07C3Y DM740LV TN 5-HT 4 receptor (HTR4) DM740LV MA Agonist DM740LV RN A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1. DM740LV RU https://pubmed.ncbi.nlm.nih.gov/25148765 DM74KIM DI DM74KIM DM74KIM DN KB-003 DM74KIM TI TTNYZG2 DM74KIM TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM74KIM RN US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast. DM74KIM RU https://www.google.com/patents/US20100158905 DM74ZKN DI DM74ZKN DM74ZKN DN HBI-3000 DM74ZKN TI TT5HONZ DM74ZKN TN Calcium channel unspecific (CaC) DM74ZKN MA Blocker DM74ZKN RN Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85. DM74ZKN RU https://pubmed.ncbi.nlm.nih.gov/20980921 DM74ZKN DI DM74ZKN DM74ZKN DN HBI-3000 DM74ZKN TI TT1VOHK DM74ZKN TN Potassium channel unspecific (KC) DM74ZKN MA Blocker DM74ZKN RN Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85. DM74ZKN RU https://pubmed.ncbi.nlm.nih.gov/20980921 DM74ZKN DI DM74ZKN DM74ZKN DN HBI-3000 DM74ZKN TI TTRK8B9 DM74ZKN TN Sodium channel unspecific (NaC) DM74ZKN MA Inhibitor DM74ZKN RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM74ZKN RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM753H8 DI DM753H8 DM753H8 DN EB8018 DM753H8 TI TTTCRU2 DM753H8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM753H8 MA Inhibitor DM753H8 RN Clinical pipeline report, company report or official report of Enterome Biosciences. DM753H8 RU https://www.enterome.com/#pipeline DM756GE DI DM756GE DM756GE DN APH-0812 DM756GE TI TTYVX59 DM756GE TN Protein kinase C (PRKC) DM756GE MA Inhibitor DM756GE RN Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. DM756GE RU https://pubmed.ncbi.nlm.nih.gov/17585335 DM756GE DI DM756GE DM756GE DN APH-0812 DM756GE TI TTBH0VX DM756GE TN Histone deacetylase (HDAC) DM756GE MA Inhibitor DM756GE RN Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62. DM756GE RU https://pubmed.ncbi.nlm.nih.gov/17585335 DM7583A DI DM7583A DM7583A DN Beta-caryophyllene DM7583A TI TTMSFAW DM7583A TN Cannabinoid receptor 2 (CB2) DM7583A MA Agonist DM7583A RN The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20. DM7583A RU https://pubmed.ncbi.nlm.nih.gov/24210682 DM7586F DI DM7586F DM7586F DN Bafetinib DM7586F TI TT1RWNJ DM7586F TN Tyrosine-protein kinase Lyn (JTK8) DM7586F MA Modulator DM7586F RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7586F RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7586F DI DM7586F DM7586F DN Bafetinib DM7586F TI TTS7G69 DM7586F TN Fusion protein Bcr-Abl (Bcr-Abl) DM7586F MA Modulator DM7586F RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7586F RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM75RFJ DI DM75RFJ DM75RFJ DN Siplizumab DM75RFJ TI TTJDUNO DM75RFJ TN T-cell surface antigen CD2 (CD2) DM75RFJ RN Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52. DM75RFJ RU https://pubmed.ncbi.nlm.nih.gov/15757402 DM79YAS DI DM79YAS DM79YAS DN Racotumomab DM79YAS TI TTSFNKW DM79YAS TN Tumor antigen NGcGM3 (NGcGM3) DM79YAS MA Modulator DM79YAS RN Racotumomab: an anti-idiotype vaccine related to N-glycolyl-containing gangliosides - preclinical and clinical data. Front Oncol. 2012; 2: 150. DM79YAS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478665/ DM7ADGX DI DM7ADGX DM7ADGX DN Carfentanil DM7ADGX TI TT27RFC DM7ADGX TN Opioid receptor delta (OPRD1) DM7ADGX MA Agonist DM7ADGX RN Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. DM7ADGX RU https://pubmed.ncbi.nlm.nih.gov/12712038 DM7ADGX DI DM7ADGX DM7ADGX DN Carfentanil DM7ADGX TI TTQW87Y DM7ADGX TN Opioid receptor kappa (OPRK1) DM7ADGX MA Agonist DM7ADGX RN Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. DM7ADGX RU https://pubmed.ncbi.nlm.nih.gov/12712038 DM7ADGX DI DM7ADGX DM7ADGX DN Carfentanil DM7ADGX TI TTKWM86 DM7ADGX TN Opioid receptor mu (MOP) DM7ADGX MA Agonist DM7ADGX RN Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5. DM7ADGX RU https://pubmed.ncbi.nlm.nih.gov/12712038 DM7AFJ8 DI DM7AFJ8 DM7AFJ8 DN Diannexin DM7AFJ8 TI TT2Z83I DM7AFJ8 TN Annexin A5 (ANXA5) DM7AFJ8 MA Modulator DM7AFJ8 RN Expression and purification of recombinant human annexin V in Escherichia coli. Prep Biochem Biotechnol. 2000 Nov;30(4):305-12. DM7AFJ8 RU https://pubmed.ncbi.nlm.nih.gov/11065275 DM7B1AR DI DM7B1AR DM7B1AR DN AZD-1446 DM7B1AR TI TTL1ATN DM7B1AR TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DM7B1AR MA Modulator DM7B1AR RN A randomized, double-blind, placebo-controlled crossover study of 4 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder.Psychopharmacology (Berl). 2014 Mar;231(6):1251-65. DM7B1AR RU https://www.ncbi.nlm.nih.gov/pubmed/23640072 DM7BN5W DI DM7BN5W DM7BN5W DN LPN023 DM7BN5W TI TTA0P7K DM7BN5W TN Complement factor B (CFB) DM7BN5W MA Inhibitor DM7BN5W RN Complement Inhibitors in Clinical Trials for Glomerular Diseases. Front Immunol. 2019 Sep 27;10:2166. DM7BN5W RU https://pubmed.ncbi.nlm.nih.gov/31611870 DM7EJ8S DI DM7EJ8S DM7EJ8S DN PF-06882961 DM7EJ8S TI TTVIMDE DM7EJ8S TN Glucagon-like peptide 1 receptor (GLP1R) DM7EJ8S MA Agonist DM7EJ8S RN Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Mol Cell. 2020 Nov 5;80(3):485-500.e7. DM7EJ8S RU https://pubmed.ncbi.nlm.nih.gov/33027691 DM7G4Y9 DI DM7G4Y9 DM7G4Y9 DN Ralinepag DM7G4Y9 TI TTOFYT1 DM7G4Y9 TN Prostacyclin receptor (PTGIR) DM7G4Y9 MA Agonist DM7G4Y9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7G4Y9 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM7GELO DI DM7GELO DM7GELO DN CMVpp65-A0201 DM7GELO TI TTNDHVE DM7GELO TN Cytomegalovirus 65kDa phosphoprotein (HCV UL83) DM7GELO RN National Cancer Institute Drug Dictionary (drug id 599982). DM7GELO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599982 DM7GPMB DI DM7GPMB DM7GPMB DN Depatuxizumab DM7GPMB TI TTGKNB4 DM7GPMB TN Epidermal growth factor receptor (EGFR) DM7GPMB MA Antagonist DM7GPMB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7GPMB RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM7HNFV DI DM7HNFV DM7HNFV DN GSK2982772 DM7HNFV TI TTAIQSN DM7HNFV TN Receptor-interacting protein 1 (RIPK1) DM7HNFV MA Inhibitor DM7HNFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7HNFV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM7I0MT DI DM7I0MT DM7I0MT DN MT203 DM7I0MT TI TTNYZG2 DM7I0MT TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM7I0MT MA Modulator DM7I0MT RN GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential. Expert Rev Clin Immunol. 2015 Apr;11(4):457-65. DM7I0MT RU https://pubmed.ncbi.nlm.nih.gov/25748625 DM7I56B DI DM7I56B DM7I56B DN ATM AVI DM7I56B TI TTUE541 DM7I56B TN Leukocyte surface antigen Leu-16 (CD20) DM7I56B MA Modulator DM7I56B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DM7I56B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DM7IFNB DI DM7IFNB DM7IFNB DN LY3202626 DM7IFNB TI TT8JRS7 DM7IFNB TN Beta-secretase (BACE) DM7IFNB MA Inhibitor DM7IFNB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7IFNB RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7IGO9 DI DM7IGO9 DM7IGO9 DN Apimostinel DM7IGO9 TI TT9IK2Z DM7IGO9 TN N-methyl-D-aspartate receptor (NMDAR) DM7IGO9 MA Partial agonist DM7IGO9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7IGO9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM7IH48 DI DM7IH48 DM7IH48 DN Dapansutrile DM7IH48 TI TT4EN8X DM7IH48 TN Caterpiller protein 1.1 (NLRP3) DM7IH48 MA Inhibitor DM7IH48 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7IH48 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7K4YR DI DM7K4YR DM7K4YR DN MIS-416 DM7K4YR TI TTSHG0T DM7K4YR TN Toll-like receptor 9 (TLR9) DM7K4YR MA Modulator DM7K4YR RN DOI: 10.1371/journal.pone.0087712 DM7K4YR RU http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712 DM7K4YR DI DM7K4YR DM7K4YR DN MIS-416 DM7K4YR TI TTYPUHA DM7K4YR TN Pattern recognition receptor NOD2 (NOD2) DM7K4YR MA Modulator DM7K4YR RN DOI: 10.1371/journal.pone.0087712 DM7K4YR RU http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087712 DM7KR4C DI DM7KR4C DM7KR4C DN YM-934 DM7KR4C TI TT1VOHK DM7KR4C TN Potassium channel unspecific (KC) DM7KR4C MA Blocker DM7KR4C RN Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea pig airways. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1379-83. DM7KR4C RU https://pubmed.ncbi.nlm.nih.gov/7524979 DM7MBV6 DI DM7MBV6 DM7MBV6 DN Lancovutide DM7MBV6 TI TTCYAXN DM7MBV6 TN Chloride channel unspecific (ClC) DM7MBV6 MA Modulator DM7MBV6 RN Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother. 2011 Jan;45(1):49-59. DM7MBV6 RU https://pubmed.ncbi.nlm.nih.gov/21156814 DM7NHLC DI DM7NHLC DM7NHLC DN BAY-85-3934 DM7NHLC TI TTMHFRY DM7NHLC TN HIF-prolyl hydroxylase 1 (HPH-1) DM7NHLC MA Inhibitor DM7NHLC RN Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014 Nov 13;9(11):e111838. DM7NHLC RU https://pubmed.ncbi.nlm.nih.gov/25392999 DM7NJWY DI DM7NJWY DM7NJWY DN Spiroglumide DM7NJWY TI TTVBI8W DM7NJWY TN Dopamine transporter (DAT) DM7NJWY MA Inhibitor DM7NJWY RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM7NJWY RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM7NJWY DI DM7NJWY DM7NJWY DN Spiroglumide DM7NJWY TI TTAWNKZ DM7NJWY TN Norepinephrine transporter (NET) DM7NJWY MA Inhibitor DM7NJWY RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM7NJWY RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM7NJWY DI DM7NJWY DM7NJWY DN Spiroglumide DM7NJWY TI TTVFO0U DM7NJWY TN Gastrin/cholecystokinin type B receptor (CCKBR) DM7NJWY MA Antagonist DM7NJWY RN Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9. DM7NJWY RU https://pubmed.ncbi.nlm.nih.gov/8791971 DM7OTQS DI DM7OTQS DM7OTQS DN JNJ-10311795 DM7OTQS TI TT8VUE0 DM7OTQS TN Chymase (CYM) DM7OTQS MA Inhibitor DM7OTQS RN Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30. DM7OTQS RU https://pubmed.ncbi.nlm.nih.gov/17361995 DM7OTQS DI DM7OTQS DM7OTQS DN JNJ-10311795 DM7OTQS TI TTQAJF1 DM7OTQS TN Cathepsin G (CTSG) DM7OTQS MA Inhibitor DM7OTQS RN Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30. DM7OTQS RU https://pubmed.ncbi.nlm.nih.gov/17361995 DM7P0WR DI DM7P0WR DM7P0WR DN NAI-acne DM7P0WR TI TTYQIFM DM7P0WR TN Staphylococcus Elongation factor Tu (Stap-coc tuf) DM7P0WR MA Modulator DM7P0WR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031008) DM7P0WR RU http://adisinsight.springer.com/drugs/800031008 DM7PCLY DI DM7PCLY DM7PCLY DN ARC1779 DM7PCLY TI TT3SZBT DM7PCLY TN von Willebrand factor (VWF) DM7PCLY MA Inhibitor DM7PCLY RN Short-Acting Anti-VWF (von Willebrand Factor) Aptamer Improves the Recovery, Survival, and Hemostatic Functions of Refrigerated Platelets. Arterioscler Thromb Vasc Biol. 2019 Oct;39(10):2028-2037. DM7PCLY RU https://pubmed.ncbi.nlm.nih.gov/31315441 DM7PT8R DI DM7PT8R DM7PT8R DN BioE-743 DM7PT8R TI TT8XK6L DM7PT8R TN Quinone reductase 1 (NQO1) DM7PT8R MA Modulator DM7PT8R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7PT8R RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7QUN0 DI DM7QUN0 DM7QUN0 DN HQK-1001 DM7QUN0 TI TTQO71U DM7QUN0 TN Hemoglobin (HB) DM7QUN0 MA Inducer DM7QUN0 RN A phase 2 study of HQK-1001, an oral fetal haemoglobin inducer, in beta-thalassaemia intermedia. Br J Haematol. 2014 Feb;164(3):456-8. DM7QUN0 RU https://pubmed.ncbi.nlm.nih.gov/24224649 DM7RYL4 DI DM7RYL4 DM7RYL4 DN FG-2216 DM7RYL4 TI TTJQFBG DM7RYL4 TN HIF-prolyl hydroxylase (HPH) DM7RYL4 MA Modulator DM7RYL4 RN Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD DM7RYL4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014028 DM7USVA DI DM7USVA DM7USVA DN Duvelisib DM7USVA TI TTK5FVJ DM7USVA TN HUMAN PI3-kinase delta (PIK3CD) DM7USVA MA Inhibitor DM7USVA RN ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health. DM7USVA RU https://clinicaltrials.gov/ct2/show/NCT04372602 DM7USVA DI DM7USVA DM7USVA DN Duvelisib DM7USVA TI TTHXGLJ DM7USVA TN HUMAN PI3-kinase gamma (PIK3CG) DM7USVA MA Inhibitor DM7USVA RN ClinicalTrials.gov (NCT04372602) Duvelisib to Combat COVID-19. U.S. National Institutes of Health. DM7USVA RU https://clinicaltrials.gov/ct2/show/NCT04372602 DM7V96W DI DM7V96W DM7V96W DN GSK2798745 DM7V96W TI TTKP2SU DM7V96W TN Transient receptor potential cation channel V4 (TRPV4) DM7V96W MA Antagonist DM7V96W RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM7V96W RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM7VG8L DI DM7VG8L DM7VG8L DN MTC-896 DM7VG8L TI TT6QAJ3 DM7VG8L TN Melanocortin receptor 5 (MC5R) DM7VG8L MA Antagonist DM7VG8L RN Clinical pipeline report, company report or official report of Avarx. DM7VG8L RU http://www.avarx.com/AvaRx/SubDomains/Company231/Listings/231/Public.Listing.display.html DM7VJE1 DI DM7VJE1 DM7VJE1 DN IONIS-TMPRSS6-LRx DM7VJE1 TI TTNIUKC DM7VJE1 TN TMPRSS6 messenger RNA (TMPRSS6 mRNA) DM7VJE1 MA Inhibitor DM7VJE1 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM7VJE1 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM7W0JE DI DM7W0JE DM7W0JE DN LEO 124249 DM7W0JE TI TTJSQEF DM7W0JE TN Tyrosine-protein kinase (PTK) DM7W0JE MA Inhibitor DM7W0JE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7W0JE RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM7X54F DI DM7X54F DM7X54F DN ABT-288 DM7X54F TI TT9JNIC DM7X54F TN Histamine H3 receptor (H3R) DM7X54F MA Modulator DM7X54F RN A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71. DM7X54F RU https://www.ncbi.nlm.nih.gov/pubmed/25024314 DM7XIAJ DI DM7XIAJ DM7XIAJ DN ID-93/GLA-SE DM7XIAJ TI TTVH0YQ DM7XIAJ TN Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens) DM7XIAJ MA Modulator DM7XIAJ RN US patent application no. US20150182612 A1. DM7XIAJ RU https://www.google.co.in/patents/US20150182612 DM7XV4R DI DM7XV4R DM7XV4R DN BMS-954561 DM7XV4R TI TTJSZTB DM7XV4R TN Nicotinic acetylcholine receptor (nAChR) DM7XV4R MA Modulator DM7XV4R RN EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders. DM7XV4R RU http://www.google.com/patents/EP2774991A1?cl=en DM7XZY5 DI DM7XZY5 DM7XZY5 DN Triapine DM7XZY5 TI TTBWDI0 DM7XZY5 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DM7XZY5 MA Modulator DM7XZY5 RN PAN-811 inhibits oxidative stress-induced cell death of human Alzheimer's disease-derived and age-matched olfactory neuroepithelial cells via suppression of intracellular reactive oxygen species. J Alzheimers Dis. 2009;17(3):611-9. DM7XZY5 RU https://pubmed.ncbi.nlm.nih.gov/19433896 DM7Y60I DI DM7Y60I DM7Y60I DN Plevitrexed DM7Y60I TI TTU6BFZ DM7Y60I TN Candida Thymidylate synthase (Candi TMP1) DM7Y60I MA Inhibitor DM7Y60I RN Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30. DM7Y60I RU https://pubmed.ncbi.nlm.nih.gov/17297914 DM7YWVT DI DM7YWVT DM7YWVT DN PRX-321 DM7YWVT TI TTDWHC3 DM7YWVT TN Interleukin 4 receptor alpha (IL4R) DM7YWVT MA Agonist DM7YWVT RN Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring. J Pharmacol Exp Ther. 2009 Aug;330(2):520-5. DM7YWVT RU https://pubmed.ncbi.nlm.nih.gov/19478131 DM7ZM1H DI DM7ZM1H DM7ZM1H DN BHT-3009 DM7ZM1H TI TT2RY5P DM7ZM1H TN Myelin basic protein (MBP) DM7ZM1H RN BHT-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr Opin Mol Ther. 2009 Aug;11(4):463-70. DM7ZM1H RU https://pubmed.ncbi.nlm.nih.gov/19649992 DM7ZQAT DI DM7ZQAT DM7ZQAT DN ALZ-801 DM7ZQAT TI TTE4KHA DM7ZQAT TN Amyloid beta A4 protein (APP) DM7ZQAT MA Inhibitor DM7ZQAT RN Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012. DM7ZQAT RU http://www.alzheon.com/?page_id=280 DM80HOV DI DM80HOV DM80HOV DN SDF-1 DM80HOV TI TT4UGTF DM80HOV TN Stromal cell-derived factor 1 (CXCL12) DM80HOV MA Inhibitor DM80HOV RN SDF-1 in myocardial repair. Gene Ther. 2012 Jun;19(6):583-7. DM80HOV RU https://pubmed.ncbi.nlm.nih.gov/22673496 DM819CO DI DM819CO DM819CO DN ADMVA DM819CO TI TTFBNVI DM819CO TN Aldose reductase (AKR1B1) DM819CO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DM819CO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DM81D4I DI DM81D4I DM81D4I DN PF-4447943 DM81D4I TI TTZOEBC DM81D4I TN Phosphodiesterase 9 (PDE9) DM81D4I MA Inhibitor DM81D4I RN A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr Alzheimer Res. 2014;11(5):413-21. DM81D4I RU https://pubmed.ncbi.nlm.nih.gov/24801218 DM81SDB DI DM81SDB DM81SDB DN Niravoline DM81SDB TI TTQW87Y DM81SDB TN Opioid receptor kappa (OPRK1) DM81SDB MA Modulator DM81SDB RN Effect of niravoline (RU51599), a kappa-opioid receptor agonist, on tumour-origin brain oedema. Acta Neurochir (Wien). 1999;141(7):771-8. DM81SDB RU https://www.ncbi.nlm.nih.gov/pubmed/10481790 DM81UAZ DI DM81UAZ DM81UAZ DN TAK-272 DM81UAZ TI TTB2MXP DM81UAZ TN Angiotensinogenase renin (REN) DM81UAZ MA Modulator DM81UAZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033655) DM81UAZ RU http://adisinsight.springer.com/drugs/800033655 DM81UJW DI DM81UJW DM81UJW DN LY-2590443 DM81UJW TI TTZPO1L DM81UJW TN Substance-P receptor (TACR1) DM81UJW MA Antagonist DM81UJW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360). DM81UJW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360 DM821BS DI DM821BS DM821BS DN Adipiplon DM821BS TI TT37EDJ DM821BS TN GABA(A) receptor alpha-3 (GABRA3) DM821BS MA Modulator DM821BS RN Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3. DM821BS RU https://pubmed.ncbi.nlm.nih.gov/21762686 DM826SW DI DM826SW DM826SW DN PF-04236921 DM826SW TI TTF6I40 DM826SW TN Interleukin (IL) DM826SW MA Inhibitor DM826SW RN US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast. DM826SW RU https://www.google.com/patents/US20100158905 DM826SW DI DM826SW DM826SW DN PF-04236921 DM826SW TI TTT1V78 DM826SW TN Interleukin-6 (IL6) DM826SW MA Inhibitor DM826SW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM826SW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM83IYE DI DM83IYE DM83IYE DN BAY1193397 DM83IYE TI TT2NUT5 DM83IYE TN Adrenergic receptor alpha-2C (ADRA2C) DM83IYE MA Antagonist DM83IYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM83IYE RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM83QCL DI DM83QCL DM83QCL DN Ro 31-7453 DM83QCL TI TT0PG8F DM83QCL TN Cyclin-dependent kinase 4 (CDK4) DM83QCL MA Inhibitor DM83QCL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM83QCL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM83QCL DI DM83QCL DM83QCL DN Ro 31-7453 DM83QCL TI TT7HF4W DM83QCL TN Cyclin-dependent kinase 2 (CDK2) DM83QCL MA Inhibitor DM83QCL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM83QCL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM83QCL DI DM83QCL DM83QCL DN Ro 31-7453 DM83QCL TI TTH6V3D DM83QCL TN Cyclin-dependent kinase 1 (CDK1) DM83QCL MA Inhibitor DM83QCL RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM83QCL RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM85WID DI DM85WID DM85WID DN Crobenetine DM85WID TI TTRK8B9 DM85WID TN Sodium channel unspecific (NaC) DM85WID MA Antagonist DM85WID RN Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol. 2001 Dec;134(8):1742-8. DM85WID RU https://pubmed.ncbi.nlm.nih.gov/11739251 DM867BJ DI DM867BJ DM867BJ DN SLV320 DM867BJ TI TTK25J1 DM867BJ TN Adenosine A1 receptor (ADORA1) DM867BJ MA Antagonist DM867BJ RN Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64. DM867BJ RU https://pubmed.ncbi.nlm.nih.gov/19196241 DM89ASO DI DM89ASO DM89ASO DN JCAR015 DM89ASO TI TTW640A DM89ASO TN B-lymphocyte surface antigen B4 (CD19) DM89ASO MA CAR-T-Cell-Therapy DM89ASO RN ClinicalTrials.gov (NCT02535364) Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL). DM89ASO RU https://clinicaltrials.gov/ct2/show/NCT02535364 DM89D6C DI DM89D6C DM89D6C DN DNL758 DM89D6C TI TTAIQSN DM89D6C TN Receptor-interacting protein 1 (RIPK1) DM89D6C MA Inhibitor DM89D6C RN Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. DM89D6C RU https://pubmed.ncbi.nlm.nih.gov/32669658 DM89QXT DI DM89QXT DM89QXT DN MET409 DM89QXT TI TTS4UGC DM89QXT TN Farnesoid X-activated receptor (FXR) DM89QXT MA Agonist DM89QXT RN Clinical pipeline report, company report or official report of Metacrine. DM89QXT RU https://www.metacrine.com/programs/ DM8A120 DI DM8A120 DM8A120 DN RO7121661 DM8A120 TI TTNBFWK DM8A120 TN Programmed cell death protein 1 (PD-1) DM8A120 MA Inhibitor DM8A120 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM8A120 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM8A120 DI DM8A120 DM8A120 DN RO7121661 DM8A120 TI TT1RWL7 DM8A120 TN Hepatitis A virus cellular receptor 2 (TIM3) DM8A120 MA Inhibitor DM8A120 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM8A120 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM8A71F DI DM8A71F DM8A71F DN AR-67 DM8A71F TI TTGTQHC DM8A71F TN DNA topoisomerase I (TOP1) DM8A71F MA Inhibitor DM8A71F RN Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans. Cancer Chemother Pharmacol. 2014 Jul;74(1):45-54. DM8A71F RU https://pubmed.ncbi.nlm.nih.gov/24807458 DM8AM60 DI DM8AM60 DM8AM60 DN TC-5214 DM8AM60 TI TT35UGH DM8AM60 TN Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) DM8AM60 MA Antagonist DM8AM60 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8AM60 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8AM60 DI DM8AM60 DM8AM60 DN TC-5214 DM8AM60 TI TT5KPZR DM8AM60 TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM8AM60 MA Antagonist DM8AM60 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8AM60 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8ARQW DI DM8ARQW DM8ARQW DN ORM-12741 DM8ARQW TI TT2NUT5 DM8ARQW TN Adrenergic receptor alpha-2C (ADRA2C) DM8ARQW MA Antagonist DM8ARQW RN A double-blind, randomized, placebo-controlled crossover trial of the alpha2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis. Rheumatology (Oxford). 2014 May;53(5):948-52. DM8ARQW RU https://pubmed.ncbi.nlm.nih.gov/24489014 DM8C1H4 DI DM8C1H4 DM8C1H4 DN PF-06823859 DM8C1H4 TI TT4TZ8J DM8C1H4 TN Interferon-beta (IFNB1) DM8C1H4 MA Blocker DM8C1H4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8C1H4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8CWL0 DI DM8CWL0 DM8CWL0 DN BVT.28949 DM8CWL0 TI TTJQOD7 DM8CWL0 TN 5-HT 2A receptor (HTR2A) DM8CWL0 MA Antagonist DM8CWL0 RN Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011; 5: 667-677. DM8CWL0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104796/ DM8DVC9 DI DM8DVC9 DM8DVC9 DN RT-400 DM8DVC9 TI TTIY658 DM8DVC9 TN Corticotropin-releasing factor receptor 2 (CRHR2) DM8DVC9 MA Agonist DM8DVC9 RN Advances in therapeutic peptides targeting G protein-coupled receptors. Nat Rev Drug Discov. 2020 Jun;19(6):389-413. DM8DVC9 RU https://pubmed.ncbi.nlm.nih.gov/32494050 DM8DZKI DI DM8DZKI DM8DZKI DN TNP-2092 DM8DZKI TI TTN6J5F DM8DZKI TN Bacterial DNA gyrase (Bact gyrase) DM8DZKI MA Inhibitor DM8DZKI RN Clinical pipeline report, company report or official report of TenNor Therapeutics. DM8DZKI RU http://www.tennorx.com/en/h-col-158.html DM8DZKI DI DM8DZKI DM8DZKI DN TNP-2092 DM8DZKI TI TTFK8YB DM8DZKI TN Bacterial DNA topoisomerase 4A (Bact parC) DM8DZKI MA Inhibitor DM8DZKI RN Clinical pipeline report, company report or official report of TenNor Therapeutics. DM8DZKI RU http://www.tennorx.com/en/h-col-158.html DM8FZOG DI DM8FZOG DM8FZOG DN AZD-2327 DM8FZOG TI TT27RFC DM8FZOG TN Opioid receptor delta (OPRD1) DM8FZOG MA Agonist DM8FZOG RN Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204. DM8FZOG RU https://pubmed.ncbi.nlm.nih.gov/21444630 DM8GHIX DI DM8GHIX DM8GHIX DN ADC-3680 DM8GHIX TI TTQDMX5 DM8GHIX TN Prostaglandin D2 receptor 2 (PTGDR2) DM8GHIX MA Antagonist DM8GHIX RN Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66. DM8GHIX RU https://pubmed.ncbi.nlm.nih.gov/24073896 DM8H7OA DI DM8H7OA DM8H7OA DN Netoglitazone DM8H7OA TI TTZMAO3 DM8H7OA TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM8H7OA MA Modulator DM8H7OA RN Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone. 2006 Jan;38(1):74-84. DM8H7OA RU https://www.ncbi.nlm.nih.gov/pubmed/16137931 DM8HBUI DI DM8HBUI DM8HBUI DN ADU-S100 DM8HBUI TI TTT402Y DM8HBUI TN Stimulator of interferon genes protein (TMEM173) DM8HBUI MA Activator DM8HBUI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8HBUI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8J9DC DI DM8J9DC DM8J9DC DN RG7221 DM8J9DC TI TTOHSBA DM8J9DC TN Vascular endothelial growth factor A (VEGFA) DM8J9DC MA Modulator DM8J9DC RN Bispecific antibodies and their applications DM8J9DC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687327 DM8J9DC DI DM8J9DC DM8J9DC DN RG7221 DM8J9DC TI TTKLQTJ DM8J9DC TN Angiopoietin-2 (ANGPT2) DM8J9DC MA Modulator DM8J9DC RN Company report (Roche pipeline: July 27, 2017) DM8J9DC RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DM8JMNL DI DM8JMNL DM8JMNL DN RG7155 DM8JMNL TI TT731LW DM8JMNL TN Colony stimulating factor-1 receptor (CSF-1R) DM8JMNL MA Modulator DM8JMNL RN Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59. DM8JMNL RU https://pubmed.ncbi.nlm.nih.gov/24898549 DM8JMNL DI DM8JMNL DM8JMNL DN RG7155 DM8JMNL TI TT0IQER DM8JMNL TN Macrophage colony-stimulating factor 1 (CSF1) DM8JMNL MA Antagonist DM8JMNL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8JMNL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8JQZC DI DM8JQZC DM8JQZC DN BNZ-1 DM8JQZC TI TTJFA35 DM8JQZC TN Interleukin-15 (IL15) DM8JQZC MA Inhibitor DM8JQZC RN Clinical pipeline report, company report or official report of Bioniz Therapeutics. DM8JQZC RU https://bioniz.com/pipeline/bnz-1/ DM8JQZC DI DM8JQZC DM8JQZC DN BNZ-1 DM8JQZC TI TTF89GD DM8JQZC TN Interleukin-2 (IL2) DM8JQZC MA Inhibitor DM8JQZC RN Clinical pipeline report, company report or official report of Bioniz Therapeutics. DM8JQZC RU https://bioniz.com/pipeline/bnz-1/ DM8JQZC DI DM8JQZC DM8JQZC DN BNZ-1 DM8JQZC TI TT0JTFD DM8JQZC TN Interleukin-9 (IL9) DM8JQZC MA Inhibitor DM8JQZC RN Clinical pipeline report, company report or official report of Bioniz Therapeutics. DM8JQZC RU https://bioniz.com/pipeline/bnz-1/ DM8JVIB DI DM8JVIB DM8JVIB DN 18F-LMI-1195 DM8JVIB TI TTAWNKZ DM8JVIB TN Norepinephrine transporter (NET) DM8JVIB MA Enhancer DM8JVIB RN Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6. DM8JVIB RU https://pubmed.ncbi.nlm.nih.gov/23670901 DM8K5IF DI DM8K5IF DM8K5IF DN E7850 DM8K5IF TI TT9ABMF DM8K5IF TN Serine/threonine-protein kinase Chk2 (RAD53) DM8K5IF MA Modulator DM8K5IF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1988). DM8K5IF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1988 DM8LBUK DI DM8LBUK DM8LBUK DN UNI-PH (1-34) DM8LBUK TI TTEPJL5 DM8LBUK TN Parathyroid hormone receptor (PTH2R) DM8LBUK MA Modulator DM8LBUK RN Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ. 2006 July 4; 175(1): 52-59. DM8LBUK RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1482742/ DM8LBYT DI DM8LBYT DM8LBYT DN NIS793 DM8LBYT TI TTO3HT7 DM8LBYT TN Transforming growth factor beta (TGFB) DM8LBYT MA Inhibitor DM8LBYT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8LBYT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8MJ3F DI DM8MJ3F DM8MJ3F DN PB1046 DM8MJ3F TI TT4O5P0 DM8MJ3F TN Helodermin-preferring VIP receptor (VIPR2) DM8MJ3F MA Agonist DM8MJ3F RN Clinical pipeline report, company report or official report of PhaseBio Pharmaceuticals. DM8MJ3F RU http://phasebio.com/clinical-development-pipeline/vasomera/ DM8N3OQ DI DM8N3OQ DM8N3OQ DN GT-AADC DM8N3OQ TI TTN451K DM8N3OQ TN Aromatic-L-amino-acid decarboxylase (DDC) DM8N3OQ MA Replacement DM8N3OQ RN Clinical pipeline report, company report or official report of PTC Therapeutics. DM8N3OQ RU https://www.ptcbio.com/our-pipeline/areas-of-interest/additional-areas/ DM8N3ZQ DI DM8N3ZQ DM8N3ZQ DN XP-21279 DM8N3ZQ TI TTEX248 DM8N3ZQ TN Dopamine D2 receptor (D2R) DM8N3ZQ MA Agonist DM8N3ZQ RN Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014 Jan;29(1):75-82. DM8N3ZQ RU https://pubmed.ncbi.nlm.nih.gov/24339234 DM8NLDI DI DM8NLDI DM8NLDI DN Endostatin DM8NLDI TI TTBPXMA DM8NLDI TN Prolactin receptor (PRLR) DM8NLDI MA Modulator DM8NLDI RN Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer. Cancer Res. 2003 Jul 1;63(13):3598-604. DM8NLDI RU https://pubmed.ncbi.nlm.nih.gov/12839947 DM8NODR DI DM8NODR DM8NODR DN ATI-502 DM8NODR TI TTT7PJU DM8NODR TN Janus kinase 3 (JAK-3) DM8NODR MA Inhibitor DM8NODR RN ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health. DM8NODR RU https://clinicaltrials.gov/ct2/show/NCT03759340 DM8NODR DI DM8NODR DM8NODR DN ATI-502 DM8NODR TI TT6DM01 DM8NODR TN Janus kinase 1 (JAK-1) DM8NODR MA Inhibitor DM8NODR RN ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health. DM8NODR RU https://clinicaltrials.gov/ct2/show/NCT03759340 DM8OG0J DI DM8OG0J DM8OG0J DN LY-517717 DM8OG0J TI TTCIHJA DM8OG0J TN Coagulation factor Xa (F10) DM8OG0J MA Inhibitor DM8OG0J RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DM8OG0J RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM8QGPE DI DM8QGPE DM8QGPE DN HepaStem DM8QGPE TI TTGSVH2 DM8QGPE TN Phenylalanine hydroxylase (PAH) DM8QGPE MA Modulator DM8QGPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240). DM8QGPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240 DM8QXEY DI DM8QXEY DM8QXEY DN Evt201 DM8QXEY TI TTCI43M DM8QXEY TN GABA(A) receptor (GABAR) DM8QXEY MA Modulator DM8QXEY RN The partial positive allosteric GABA(A) receptor modulator EVT 201 is efficacious and safe in the treatment of adult primary insomnia patients. Sleep Med. 2009 Sep;10(8):859-64. DM8QXEY RU https://pubmed.ncbi.nlm.nih.gov/19345644 DM8R71T DI DM8R71T DM8R71T DN BL-22 DM8R71T TI TTM6QSK DM8R71T TN B-cell receptor CD22 (CD22) DM8R71T RN Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903. DM8R71T RU https://pubmed.ncbi.nlm.nih.gov/20215554 DM8SNEM DI DM8SNEM DM8SNEM DN BAY 11-42524 DM8SNEM TI TT8VUE0 DM8SNEM TN Chymase (CYM) DM8SNEM MA Inhibitor DM8SNEM RN ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction. DM8SNEM RU https://clinicaltrials.gov/ct2/show/NCT02452515 DM8SVIY DI DM8SVIY DM8SVIY DN AZD4635 DM8SVIY TI TTM2AOE DM8SVIY TN Adenosine A2a receptor (ADORA2A) DM8SVIY MA Antagonist DM8SVIY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8SVIY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8T6KQ DI DM8T6KQ DM8T6KQ DN PF-232798 DM8T6KQ TI TT2CEJG DM8T6KQ TN C-C chemokine receptor type 5 (CCR5) DM8T6KQ MA Antagonist DM8T6KQ RN An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798). J Med Chem. 2011 Jan 13;54(1):67-77. DM8T6KQ RU https://pubmed.ncbi.nlm.nih.gov/21128663 DM8TDBY DI DM8TDBY DM8TDBY DN OCFENTANIL DM8TDBY TI TTN4QDT DM8TDBY TN Opioid receptor (OPR) DM8TDBY MA Modulator DM8TDBY RN Comparison of ocfentanil and fentanyl as supplements to general anesthesia. Anesth Analg. 1991 Nov;73(5):622-6. DM8TDBY RU https://pubmed.ncbi.nlm.nih.gov/1952145 DM8TKG5 DI DM8TKG5 DM8TKG5 DN SB-265610 DM8TKG5 TI TT30C9G DM8TKG5 TN C-X-C chemokine receptor type 2 (CXCR2) DM8TKG5 MA Antagonist DM8TKG5 RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM8TKG5 RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM8TOS0 DI DM8TOS0 DM8TOS0 DN HER-2 Protein AutoVac DM8TOS0 TI TT6EO5L DM8TOS0 TN Erbb2 tyrosine kinase receptor (HER2) DM8TOS0 MA Inhibitor DM8TOS0 RN Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32. DM8TOS0 RU https://pubmed.ncbi.nlm.nih.gov/22124364 DM8UCNK DI DM8UCNK DM8UCNK DN Telisotuzumab vedotin DM8UCNK TI TTNDSF4 DM8UCNK TN Proto-oncogene c-Met (MET) DM8UCNK RN Clinical pipeline report, company report or official report of AbbVie. DM8UCNK RU https://www.abbvie.com/our-science/pipeline/abbv-399.html DM8UQJG DI DM8UQJG DM8UQJG DN CDX-1307 DM8UQJG TI TTUH273 DM8UQJG TN Choriogonadotropin beta (CG-beta) DM8UQJG RN CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011 Jun;10(6):733-42. DM8UQJG RU https://pubmed.ncbi.nlm.nih.gov/21692696 DM8VWPH DI DM8VWPH DM8VWPH DN Doxorubicin-eluting beads DM8VWPH TI TT0IHXV DM8VWPH TN DNA topoisomerase II (TOP2) DM8VWPH MA Modulator DM8VWPH RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8VWPH RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8W4N9 DI DM8W4N9 DM8W4N9 DN Apratastat DM8W4N9 TI TTMX39J DM8W4N9 TN Matrix metalloproteinase-1 (MMP-1) DM8W4N9 MA Inhibitor DM8W4N9 RN Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. DM8W4N9 RU https://pubmed.ncbi.nlm.nih.gov/16426848 DM8W4N9 DI DM8W4N9 DM8W4N9 DN Apratastat DM8W4N9 TI TTHY57M DM8W4N9 TN Matrix metalloproteinase-13 (MMP-13) DM8W4N9 MA Modulator DM8W4N9 RN Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. DM8W4N9 RU https://pubmed.ncbi.nlm.nih.gov/16426848 DM8W4N9 DI DM8W4N9 DM8W4N9 DN Apratastat DM8W4N9 TI TT6AZXG DM8W4N9 TN TNF alpha converting enzyme (ADAM17) DM8W4N9 MA Modulator DM8W4N9 RN Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1605-9. DM8W4N9 RU https://pubmed.ncbi.nlm.nih.gov/16426848 DM8WU3O DI DM8WU3O DM8WU3O DN Drug 2862277 DM8WU3O TI TTG043C DM8WU3O TN Tumor necrosis factor receptor type I (TNF-R1) DM8WU3O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870). DM8WU3O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870 DM8X5Q1 DI DM8X5Q1 DM8X5Q1 DN CP101 DM8X5Q1 TI TT9IK2Z DM8X5Q1 TN N-methyl-D-aspartate receptor (NMDAR) DM8X5Q1 MA Antagonist DM8X5Q1 RN The neuroprotective effect of the forebrain-selective NMDA antagonist CP101,606 upon focal ischemic brain damage caused by acute subdural hematoma in the rat. J Neurotrauma. 1997 Jun;14(6):409-17. DM8X5Q1 RU https://pubmed.ncbi.nlm.nih.gov/9219855 DM8XH3S DI DM8XH3S DM8XH3S DN H-1152 DM8XH3S TI TTZN7RP DM8XH3S TN Rho-associated protein kinase 1 (ROCK1) DM8XH3S MA Inhibitor DM8XH3S RN Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. DM8XH3S RU https://pubmed.ncbi.nlm.nih.gov/17064221 DM8YF01 DI DM8YF01 DM8YF01 DN Interferon-alpha lozenge DM8YF01 TI TT95SOA DM8YF01 TN Interferon alpha (IFNA) DM8YF01 MA Modulator DM8YF01 RN Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7. DM8YF01 RU https://pubmed.ncbi.nlm.nih.gov/12090541 DM8ZTW7 DI DM8ZTW7 DM8ZTW7 DN MK-1029 DM8ZTW7 TI TTNVEIR DM8ZTW7 TN Prostaglandin D2 receptor (PTGDR) DM8ZTW7 MA Inhibitor DM8ZTW7 RN Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs. Expert Opin Investig Drugs. 2014 Jan;23(1):55-66. DM8ZTW7 RU https://pubmed.ncbi.nlm.nih.gov/24073896 DM90DTM DI DM90DTM DM90DTM DN Sirukumab DM90DTM TI TTJH4Y5 DM90DTM TN HUMAN interleukin 6 (IL6) DM90DTM MA Inhibitor DM90DTM RN Sirukumab: A Potential Treatment for Mood Disorders Adv Ther. 2017 Jan;34(1):78-90. DM90DTM RU https://pubmed.ncbi.nlm.nih.gov/27913990 DM91U0R DI DM91U0R DM91U0R DN ABX-EGF DM91U0R TI TTGKNB4 DM91U0R TN Epidermal growth factor receptor (EGFR) DM91U0R RN Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611. DM91U0R RU https://pubmed.ncbi.nlm.nih.gov/11920518 DM92X7N DI DM92X7N DM92X7N DN ASN002 DM92X7N TI TT2HUPM DM92X7N TN SYK messenger RNA (SYK mRNA) DM92X7N MA Inhibitor DM92X7N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM92X7N RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM93CTQ DI DM93CTQ DM93CTQ DN AR08 DM93CTQ TI TTVIREA DM93CTQ TN Adrenergic receptor (ADR) DM93CTQ MA Modulator DM93CTQ RN Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov. 2014 June; 9(6): 579-594. DM93CTQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287224/ DM93YKJ DI DM93YKJ DM93YKJ DN VX-680 DM93YKJ TI TTPS3C0 DM93YKJ TN Aurora kinase A (AURKA) DM93YKJ MA Inhibitor DM93YKJ RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM93YKJ RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM93YKJ DI DM93YKJ DM93YKJ DN VX-680 DM93YKJ TI TT860QF DM93YKJ TN LCK tyrosine protein kinase (LCK) DM93YKJ MA Inhibitor DM93YKJ RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM93YKJ RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM93YKJ DI DM93YKJ DM93YKJ DN VX-680 DM93YKJ TI TT5LS6T DM93YKJ TN Aurora kinase B (AURKB) DM93YKJ MA Inhibitor DM93YKJ RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DM93YKJ RU https://pubmed.ncbi.nlm.nih.gov/17692029 DM94NBE DI DM94NBE DM94NBE DN PF-04991532 DM94NBE TI TTDLNGZ DM94NBE TN Glucokinase (GCK) DM94NBE MA Activator DM94NBE RN The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One. 2014 May 23;9(5):e97139. DM94NBE RU https://pubmed.ncbi.nlm.nih.gov/24858947 DM95FR3 DI DM95FR3 DM95FR3 DN Tarextumab DM95FR3 TI TTVX7IA DM95FR3 TN Notch-3 receptor (NOTCH3) DM95FR3 MA Modulator DM95FR3 RN Company report (OncoMed Pharmaceuticals) DM95FR3 RU http://www.oncomed.com/Pipeline.html DM95FR3 DI DM95FR3 DM95FR3 DN Tarextumab DM95FR3 TI TT82FVD DM95FR3 TN Notch-2 receptor (NOTCH2) DM95FR3 MA Modulator DM95FR3 RN Company report (OncoMed Pharmaceuticals) DM95FR3 RU http://www.oncomed.com/Pipeline.html DM96NCR DI DM96NCR DM96NCR DN Eniluracil DM96NCR TI TTZPS91 DM96NCR TN Dihydrothymine dehydrogenase (DPYD) DM96NCR MA Modulator DM96NCR RN Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs. 2000 Jul;9(7):1635-49. DM96NCR RU https://pubmed.ncbi.nlm.nih.gov/11060767 DM96NHM DI DM96NHM DM96NHM DN Dimiracetam DM96NHM TI TT9IK2Z DM96NHM TN N-methyl-D-aspartate receptor (NMDAR) DM96NHM MA Antagonist DM96NHM RN Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain. Neuropharmacology. 2014 Jun;81:85-94. DM96NHM RU https://pubmed.ncbi.nlm.nih.gov/24486381 DM96VWD DI DM96VWD DM96VWD DN PINOCEMBRIN DM96VWD TI TTI84H7 DM96VWD TN Cytochrome P450 1B1 (CYP1B1) DM96VWD MA Inhibitor DM96VWD RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM96VWD RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM973N4 DI DM973N4 DM973N4 DN AMG 853 DM973N4 TI TTQDMX5 DM973N4 TN Prostaglandin D2 receptor 2 (PTGDR2) DM973N4 MA Modulator DM973N4 RN Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45. DM973N4 RU https://www.ncbi.nlm.nih.gov/pubmed/23174659 DM973N4 DI DM973N4 DM973N4 DN AMG 853 DM973N4 TI TTNVEIR DM973N4 TN Prostaglandin D2 receptor (PTGDR) DM973N4 MA Modulator DM973N4 RN Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients.J Allergy Clin Immunol.2013 Feb;131(2):339-45. DM973N4 RU https://www.ncbi.nlm.nih.gov/pubmed/23174659 DM98RW0 DI DM98RW0 DM98RW0 DN Cirmtuzumab DM98RW0 TI TTDEJAU DM98RW0 TN Neurotrophic tyrosine kinase ROR1 (ROR1) DM98RW0 MA Antagonist DM98RW0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM98RW0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9AWSO DI DM9AWSO DM9AWSO DN Telapristone DM9AWSO TI TTUV8G9 DM9AWSO TN Progesterone receptor (PGR) DM9AWSO MA Antagonist DM9AWSO RN In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88. DM9AWSO RU https://pubmed.ncbi.nlm.nih.gov/15120421 DM9BREJ DI DM9BREJ DM9BREJ DN MYK-491 DM9BREJ TI TTITSMB DM9BREJ TN Myosin (MYO) DM9BREJ MA Activator DM9BREJ RN Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial. Eur J Heart Fail. 2020 Sep;22(9):1649-1658. DM9BREJ RU https://pubmed.ncbi.nlm.nih.gov/32558989 DM9DJL2 DI DM9DJL2 DM9DJL2 DN P276-00 DM9DJL2 TI TT1LVF2 DM9DJL2 TN Cyclin-dependent kinase 9 (CDK9) DM9DJL2 MA Inhibitor DM9DJL2 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DM9DJL2 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DM9DJL2 DI DM9DJL2 DM9DJL2 DN P276-00 DM9DJL2 TI TTH6V3D DM9DJL2 TN Cyclin-dependent kinase 1 (CDK1) DM9DJL2 MA Inhibitor DM9DJL2 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DM9DJL2 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DM9DJL2 DI DM9DJL2 DM9DJL2 DN P276-00 DM9DJL2 TI TT0PG8F DM9DJL2 TN Cyclin-dependent kinase 4 (CDK4) DM9DJL2 MA Inhibitor DM9DJL2 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DM9DJL2 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DM9EFH0 DI DM9EFH0 DM9EFH0 DN NS 1209 DM9EFH0 TI TT0MYE2 DM9EFH0 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM9EFH0 MA Modulator DM9EFH0 RN The efficacy of the AMPA receptor antagonist NS1209 and lidocaine in nerve injury pain: a randomized, double-blind, placebo-controlled, three-way crossover study. Anesth Analg. 2009 Apr;108(4):1311-9. DM9EFH0 RU https://pubmed.ncbi.nlm.nih.gov/19299805 DM9FHV8 DI DM9FHV8 DM9FHV8 DN CK-2127107 DM9FHV8 TI TTYUMF5 DM9FHV8 TN Fast skeletal muscle troponin complex (TNNC2) DM9FHV8 MA Modulator DM9FHV8 RN Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012 Feb 19;18(3):452-5. DM9FHV8 RU https://pubmed.ncbi.nlm.nih.gov/22344294 DM9FXU7 DI DM9FXU7 DM9FXU7 DN MDL-27192 DM9FXU7 TI TT9IK2Z DM9FXU7 TN N-methyl-D-aspartate receptor (NMDAR) DM9FXU7 MA Modulator DM9FXU7 RN Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties. Epilepsy Res. 1997 Apr;27(1):41-54. DM9FXU7 RU https://pubmed.ncbi.nlm.nih.gov/9169290 DM9FZYT DI DM9FZYT DM9FZYT DN BI-655130 DM9FZYT TI TTUS18T DM9FZYT TN IL-1 receptor-like 2 (IL1RL2) DM9FZYT MA Antagonist DM9FZYT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FZYT RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM9GRTK DI DM9GRTK DM9GRTK DN ACYLINE DM9GRTK TI TT8R70G DM9GRTK TN Gonadotropin-releasing hormone receptor (GNRHR) DM9GRTK MA Inhibitor DM9GRTK RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM9GRTK RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM9GZW6 DI DM9GZW6 DM9GZW6 DN Vabicaserin DM9GZW6 TI TT0K1SC DM9GZW6 TN 5-HT 2B receptor (HTR2B) DM9GZW6 MA Modulator DM9GZW6 RN Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111. DM9GZW6 RU https://www.ncbi.nlm.nih.gov/pubmed/24759548 DM9GZW6 DI DM9GZW6 DM9GZW6 DN Vabicaserin DM9GZW6 TI TTWJBZ5 DM9GZW6 TN 5-HT 2C receptor (HTR2C) DM9GZW6 MA Modulator DM9GZW6 RN Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111. DM9GZW6 RU https://www.ncbi.nlm.nih.gov/pubmed/24759548 DM9IMEZ DI DM9IMEZ DM9IMEZ DN Seviteronel DM9IMEZ TI TTRA5BZ DM9IMEZ TN Steroid 17-alpha-monooxygenase (S17AH) DM9IMEZ MA Inhibitor DM9IMEZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9IMEZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9JGTQ DI DM9JGTQ DM9JGTQ DN PH10 nasal spray DM9JGTQ TI TT3FOGT DM9JGTQ TN Chemosensory receptor (CheR) DM9JGTQ MA Modulator DM9JGTQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9JGTQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM9KB7A DI DM9KB7A DM9KB7A DN ZGN-1061 DM9KB7A TI TTZL0OI DM9KB7A TN Methionine aminopeptidase 2 (METAP2) DM9KB7A MA Inhibitor DM9KB7A RN The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219. DM9KB7A RU https://pubmed.ncbi.nlm.nih.gov/32077231 DM9KL7P DI DM9KL7P DM9KL7P DN ALT-801 DM9KL7P TI TT7SBF5 DM9KL7P TN Cellular tumor antigen p53 (TP53) DM9KL7P MA Immunomodulator (Immunostimulant) DM9KL7P RN Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15;17(24):7765-75. DM9KL7P RU https://pubmed.ncbi.nlm.nih.gov/21994418 DM9KNJT DI DM9KNJT DM9KNJT DN Vobarilizumab DM9KNJT TI TTFNGC9 DM9KNJT TN Serum albumin (ALB) DM9KNJT MA Inhibitor DM9KNJT RN Clinical pipeline report, company report or official report of Ablynx. DM9KNJT RU https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf DM9KNJT DI DM9KNJT DM9KNJT DN Vobarilizumab DM9KNJT TI TT0E5SK DM9KNJT TN Interleukin 6 receptor (IL6R) DM9KNJT MA Inhibitor DM9KNJT RN Clinical pipeline report, company report or official report of Ablynx. DM9KNJT RU https://www.ablynx.com/uploads/data/files/160706%20alx-0061%20c202%20webcast_final.pdf DM9KTSG DI DM9KTSG DM9KTSG DN S-1360 DM9KTSG TI TT5FH9Y DM9KTSG TN Human immunodeficiency virus Integrase (HIV IN) DM9KTSG MA Inhibitor DM9KTSG RN HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D. 2007;8(3):155-68. DM9KTSG RU https://pubmed.ncbi.nlm.nih.gov/17472411 DM9L15R DI DM9L15R DM9L15R DN Dextofisopam DM9L15R TI TTPTXIN DM9L15R TN Translocator protein (TSPO) DM9L15R MA Agonist DM9L15R RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM9L15R RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM9L15R DI DM9L15R DM9L15R DN Dextofisopam DM9L15R TI TTNJYV2 DM9L15R TN Gamma-aminobutyric acid receptor (GAR) DM9L15R MA Agonist DM9L15R RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DM9L15R RU https://pubmed.ncbi.nlm.nih.gov/16634703 DM9LKYP DI DM9LKYP DM9LKYP DN AZ-40140 DM9LKYP TI TTMXGCW DM9LKYP TN Adrenergic receptor beta-3 (ADRB3) DM9LKYP MA Agonist DM9LKYP RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM9LKYP RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM9LNXS DI DM9LNXS DM9LNXS DN ARI-3037MO DM9LNXS TI TTRHEQ4 DM9LNXS TN Diacylglycerol O-acyltransferase 2 (DGAT2) DM9LNXS MA Inhibitor DM9LNXS RN 2011 Pipeline of Arisaph Pharmaceuticals. DM9LNXS RU http://www.arisaph.com/ DM9LNXS DI DM9LNXS DM9LNXS DN ARI-3037MO DM9LNXS TI TTWNV8U DM9LNXS TN Nicotinic acid receptor (HCAR2) DM9LNXS MA Agonist DM9LNXS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9LNXS RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM9LNXS DI DM9LNXS DM9LNXS DN ARI-3037MO DM9LNXS TI TT8WFXV DM9LNXS TN Hydroxycarboxylic acid receptor 3 (HCAR3) DM9LNXS MA Agonist DM9LNXS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9LNXS RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM9LZ0M DI DM9LZ0M DM9LZ0M DN APD-515 DM9LZ0M TI TTOXS3C DM9LZ0M TN Muscarinic acetylcholine receptor (CHRM) DM9LZ0M MA Agonist DM9LZ0M RN Clinical pipeline report, company report or official report of Acacia Pharma. DM9LZ0M RU http://www.acaciapharma.com/pipeline/apd515 DM9M5WV DI DM9M5WV DM9M5WV DN MRG-201 DM9M5WV TI TTK982E DM9M5WV TN Collagen (CO) DM9M5WV MA Modulator DM9M5WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9M5WV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM9M5WV DI DM9M5WV DM9M5WV DN MRG-201 DM9M5WV TI TT1GNRQ DM9M5WV TN microRNA hsa-miR-155 (MIR155) DM9M5WV MA Modulator DM9M5WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9M5WV RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM9MKQ5 DI DM9MKQ5 DM9MKQ5 DN Hu3F8 mAb DM9MKQ5 TI TT80ARU DM9MKQ5 TN Ganglioside GD2 (GD2) DM9MKQ5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9MKQ5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9OPK3 DI DM9OPK3 DM9OPK3 DN SPD-556 DM9OPK3 TI TTK8R02 DM9OPK3 TN Vasopressin V2 receptor (V2R) DM9OPK3 MA Antagonist DM9OPK3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368). DM9OPK3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368 DM9ORUW DI DM9ORUW DM9ORUW DN FRM-0962 DM9ORUW TI TTE4KHA DM9ORUW TN Amyloid beta A4 protein (APP) DM9ORUW MA Modulator DM9ORUW RN Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014 DM9ORUW RU http://www.nature.com/scibx/journal/v7/n40/full/scibx.2014.1175.html DM9OXEJ DI DM9OXEJ DM9OXEJ DN BIIB 023 DM9OXEJ TI TTBTDM1 DM9OXEJ TN TNF-related weak inducer of apoptosis (TWEAK) DM9OXEJ MA Modulator DM9OXEJ RN ClinicalTrials.gov (NCT00771329) BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. DM9OXEJ RU https://clinicaltrials.gov/ct2/show/NCT00771329 DM9OZU5 DI DM9OZU5 DM9OZU5 DN Heat shock protein vaccine DM9OZU5 TI TTG91S4 DM9OZU5 TN Heat shock protein (HSP) DM9OZU5 RN Heat shock proteins (HSPs) based anti-cancer vaccines. Curr Mol Med. 2012 Nov 1;12(9):1183-97. DM9OZU5 RU https://pubmed.ncbi.nlm.nih.gov/22804241 DM9PVNJ DI DM9PVNJ DM9PVNJ DN TCN-032 DM9PVNJ TI TTXT3PU DM9PVNJ TN Influenza M2 protein (Influ M) DM9PVNJ RN Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010 July 13; 107(28): 12658-12663. DM9PVNJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2906546/ DM9Q2B6 DI DM9Q2B6 DM9Q2B6 DN GS-9876 DM9Q2B6 TI TTOU65C DM9Q2B6 TN Tyrosine-protein kinase SYK (SYK) DM9Q2B6 MA Inhibitor DM9Q2B6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9Q2B6 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM9QF65 DI DM9QF65 DM9QF65 DN GR-MD-02 DM9QF65 TI TTFPQV7 DM9QF65 TN Galectin-3 (LGALS3) DM9QF65 MA Inhibitor DM9QF65 RN Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013 Dec 18;8(12):e83481. DM9QF65 RU https://pubmed.ncbi.nlm.nih.gov/24367597 DM9QFW2 DI DM9QFW2 DM9QFW2 DN Tau-binding PET tracer DM9QFW2 TI TTS87KH DM9QFW2 TN Microtubule-associated protein tau (MAPT) DM9QFW2 MA Modulator DM9QFW2 RN Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. DM9QFW2 RU https://pubmed.ncbi.nlm.nih.gov/21902667 DM9RC7D DI DM9RC7D DM9RC7D DN SAGE-718 DM9RC7D TI TT9IK2Z DM9RC7D TN N-methyl-D-aspartate receptor (NMDAR) DM9RC7D MA Modulator DM9RC7D RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM9RC7D RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM9REBL DI DM9REBL DM9REBL DN DDP-225 DM9REBL TI TTNXLKE DM9REBL TN 5-HT 3 receptor (5HT3R) DM9REBL MA Modulator DM9REBL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM9REBL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM9RW6H DI DM9RW6H DM9RW6H DN JNJ-56136379 DM9RW6H TI TTM42UJ DM9RW6H TN Hepatitis B virus Capsid protein (HBV C) DM9RW6H MA Inhibitor DM9RW6H RN JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection. Gastroenterology. 2020 Aug;159(2):521-533.e9. DM9RW6H RU https://pubmed.ncbi.nlm.nih.gov/32343960 DM9S3P7 DI DM9S3P7 DM9S3P7 DN PF-06473871 DM9S3P7 TI TTIL516 DM9S3P7 TN CCN2 messenger RNA (CCN2 mRNA) DM9S3P7 MA Inhibitor DM9S3P7 RN A Placebo-controlled Study of PF-06473871 (Anti-Connective Tissue Growth Factor Antisense Oligonucleotide) in Reducing Hypertrophic Skin Scarring. Plast Reconstr Surg Glob Open. 2018 Sep 6;6(9):e1861. DM9S3P7 RU https://pubmed.ncbi.nlm.nih.gov/30349773 DM9SX6Y DI DM9SX6Y DM9SX6Y DN Indisulam DM9SX6Y TI TT2LVK8 DM9SX6Y TN Carbonic anhydrase IX (CA-IX) DM9SX6Y MA Modulator DM9SX6Y RN Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-assoc... Bioorg Med Chem Lett. 2004 Jan 5;14(1):217-23. DM9SX6Y RU https://www.ncbi.nlm.nih.gov/pubmed/14684331 DM9T8A2 DI DM9T8A2 DM9T8A2 DN LGD-4665 DM9T8A2 TI TTIHYA4 DM9T8A2 TN Thrombopoietin receptor (MPL) DM9T8A2 MA Agonist DM9T8A2 RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DM9T8A2 RU https://pubmed.ncbi.nlm.nih.gov/18537519 DM9UMIO DI DM9UMIO DM9UMIO DN JNJ-38518168 DM9UMIO TI TTXJ178 DM9UMIO TN Histamine H4 receptor (H4R) DM9UMIO MA Antagonist DM9UMIO RN The histamine H4 receptor: from orphan to the clinic. Front Pharmacol. 2015; 6: 65. DM9UMIO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379874/ DM9UMSJ DI DM9UMSJ DM9UMSJ DN AM001 DM9UMSJ TI TTOE7I0 DM9UMSJ TN Rap guanine nucleotide exchange factor 3 (RAPGEF3) DM9UMSJ MA Inhibitor DM9UMSJ RN Identification of a pharmacological inhibitor of Epac1 that protects the heart against acute and chronic models of cardiac stress. Cardiovasc Res. 2019 Oct 1;115(12):1766-1777. DM9UMSJ RU https://pubmed.ncbi.nlm.nih.gov/30873562 DM9VEAL DI DM9VEAL DM9VEAL DN NPC-1C DM9VEAL TI TT34I9F DM9VEAL TN Neoplasm antigen (NA) DM9VEAL RN National Cancer Institute Drug Dictionary (drug id 663436). DM9VEAL RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=663436 DM9XKJU DI DM9XKJU DM9XKJU DN J 591 Lu-177 DM9XKJU TI TT9G4N0 DM9XKJU TN Glutamate carboxypeptidase II (GCPII) DM9XKJU MA Modulator DM9XKJU RN Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013 Sep 15;19(18):5182-91. DM9XKJU RU https://pubmed.ncbi.nlm.nih.gov/23714732 DM9Y1XB DI DM9Y1XB DM9Y1XB DN ABT-RTA-408 DM9Y1XB TI TTA6ZN2 DM9Y1XB TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9Y1XB MA Modulator DM9Y1XB RN National Cancer Institute Drug Dictionary (drug id 756624). DM9Y1XB RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756624 DM9ZHRS DI DM9ZHRS DM9ZHRS DN LIM-0705 DM9ZHRS TI TTK8XD6 DM9ZHRS TN ATP-binding cassette transporter (ABCA) DM9ZHRS MA Activator DM9ZHRS RN WO patent application no. 2010,0428,86, Pyrone analogs for therapeutic treatment. DM9ZHRS RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100415&CC=WO&NR=2010042886A2&KC=A2 DMA04DE DI DMA04DE DMA04DE DN Topiroxostat DMA04DE TI TT7RJY8 DMA04DE TN Xanthine dehydrogenase/oxidase (XDH) DMA04DE MA Inhibitor DMA04DE RN QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52. DMA04DE RU https://pubmed.ncbi.nlm.nih.gov/24214189 DMA0DSJ DI DMA0DSJ DMA0DSJ DN L-694,458 DMA0DSJ TI TTPLTSQ DMA0DSJ TN Neutrophil elastase (NE) DMA0DSJ MA Inhibitor DMA0DSJ RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DMA0DSJ RU https://pubmed.ncbi.nlm.nih.gov/12084007 DMA0QZH DI DMA0QZH DMA0QZH DN SSR-180575 DMA0QZH TI TTPTXIN DMA0QZH TN Translocator protein (TSPO) DMA0QZH MA Inhibitor DMA0QZH RN SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a peripheral benzodiazepine receptor ligand, promotes neuronal survival and repair. J PharmacolExp Ther. 2002 Jun;301(3):1067-78. DMA0QZH RU https://pubmed.ncbi.nlm.nih.gov/12023539 DMA0RI9 DI DMA0RI9 DMA0RI9 DN LIDORESTAT DMA0RI9 TI TTFBNVI DMA0RI9 TN Aldose reductase (AKR1B1) DMA0RI9 MA Inhibitor DMA0RI9 RN Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52. DMA0RI9 RU https://pubmed.ncbi.nlm.nih.gov/15857120 DMA12HB DI DMA12HB DMA12HB DN SEP--4199 DMA12HB TI TTEX248 DMA12HB TN Dopamine D2 receptor (D2R) DMA12HB MA Antagonist DMA12HB RN ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health. DMA12HB RU https://clinicaltrials.gov/ct2/show/NCT03543410 DMA12HB DI DMA12HB DMA12HB DN SEP--4199 DMA12HB TI TT85JO3 DMA12HB TN 5-HT receptor (5HTR) DMA12HB MA Antagonist DMA12HB RN ClinicalTrials.gov (NCT03543410) A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression. U.S. National Institutes of Health. DMA12HB RU https://clinicaltrials.gov/ct2/show/NCT03543410 DMA2IXQ DI DMA2IXQ DMA2IXQ DN GSK2586184 DMA2IXQ TI TT6DM01 DMA2IXQ TN Janus kinase 1 (JAK-1) DMA2IXQ MA Modulator DMA2IXQ RN DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184. Lupus. 2015 May;24(6):648-9. DMA2IXQ RU https://pubmed.ncbi.nlm.nih.gov/25724932 DMA2UYE DI DMA2UYE DMA2UYE DN Ro-24-7429 DMA2UYE TI TTT3ZC9 DMA2UYE TN Human immunodeficiency virus Tat protein (HIV tat) DMA2UYE MA Modulator DMA2UYE RN A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52. DMA2UYE RU https://pubmed.ncbi.nlm.nih.gov/7594660 DMA42BV DI DMA42BV DMA42BV DN AVE-2268 DMA42BV TI TTLWPVF DMA42BV TN Sodium/glucose cotransporter 2 (SGLT2) DMA42BV MA Modulator DMA42BV RN Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80. DMA42BV RU https://pubmed.ncbi.nlm.nih.gov/19137908 DMA4LNE DI DMA4LNE DMA4LNE DN SGN-LIV1A DMA4LNE TI TTZN1CF DMA4LNE TN Solute carrier family 39 member 6 (SLC39A6) DMA4LNE RN SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. DMA4LNE RU https://pubmed.ncbi.nlm.nih.gov/25253783 DMA4OGL DI DMA4OGL DMA4OGL DN OMS824 DMA4OGL TI TTJW4LU DMA4OGL TN Phosphodiesterase 10A (PDE10) DMA4OGL MA Inhibitor DMA4OGL RN New Drugs/Drug News. P T. 2013 November; 38(11): 667-672. DMA4OGL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875261/ DMA5D6T DI DMA5D6T DMA5D6T DN CX1789 DMA5D6T TI TTAN6JD DMA5D6T TN Glutamate receptor AMPA (GRIA) DMA5D6T MA Agonist DMA5D6T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA5D6T RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMA6HQJ DI DMA6HQJ DMA6HQJ DN HO/03/03 DMA6HQJ TI TTYVX59 DMA6HQJ TN Protein kinase C (PRKC) DMA6HQJ MA Modulator DMA6HQJ RN WO patent application no. 2014,0853,81, Pharmaceutical combinations. DMA6HQJ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140605&CC=WO&NR=2014085381A1&KC=A1 DMA6RBF DI DMA6RBF DMA6RBF DN GSK1325756 DMA6RBF TI TT30C9G DMA6RBF TN C-X-C chemokine receptor type 2 (CXCR2) DMA6RBF MA Modulator DMA6RBF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMA6RBF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMA75FG DI DMA75FG DMA75FG DN BAY 794980 DMA75FG TI TT1290U DMA75FG TN Coagulation factor VIII (F8) DMA75FG MA Modulator DMA75FG RN Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study. Thromb Haemost. 2012 Nov;108(5):913-22. DMA75FG RU https://pubmed.ncbi.nlm.nih.gov/23014711 DMA7ISF DI DMA7ISF DMA7ISF DN Tarloxotinib DMA7ISF TI TT6EO5L DMA7ISF TN Erbb2 tyrosine kinase receptor (HER2) DMA7ISF MA Inhibitor DMA7ISF RN Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475. DMA7ISF RU https://pubmed.ncbi.nlm.nih.gov/33355298 DMA7ISF DI DMA7ISF DMA7ISF DN Tarloxotinib DMA7ISF TI TTGKNB4 DMA7ISF TN Epidermal growth factor receptor (EGFR) DMA7ISF MA Inhibitor DMA7ISF RN Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475. DMA7ISF RU https://pubmed.ncbi.nlm.nih.gov/33355298 DMA9238 DI DMA9238 DMA9238 DN BTRX-246040 DMA9238 TI TTNT7K8 DMA9238 TN Nociceptin receptor (OPRL1) DMA9238 MA Antagonist DMA9238 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA9238 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMA9FKY DI DMA9FKY DMA9FKY DN AG140699 DMA9FKY TI TTVDSZ0 DMA9FKY TN Poly [ADP-ribose] polymerase 1 (PARP1) DMA9FKY MA Inhibitor DMA9FKY RN Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. DMA9FKY RU https://pubmed.ncbi.nlm.nih.gov/15864271 DMA9MBR DI DMA9MBR DMA9MBR DN PF-04523655 DMA9MBR TI TT0AWFK DMA9MBR TN HIF-1 responsive protein RTP801 (DDIT4) DMA9MBR RN Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. DMA9MBR RU https://pubmed.ncbi.nlm.nih.gov/19568274 DMA9SEY DI DMA9SEY DMA9SEY DN GDC-0084 DMA9SEY TI TTHBTOP DMA9SEY TN PI3-kinase gamma (PIK3CG) DMA9SEY MA Inhibitor DMA9SEY RN Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol. 2012 July; 14(7): 819-829. DMA9SEY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3379803/ DMA9VGW DI DMA9VGW DMA9VGW DN Sitafloxacin DMA9VGW TI TTN6J5F DMA9VGW TN Bacterial DNA gyrase (Bact gyrase) DMA9VGW MA Inhibitor DMA9VGW RN Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. DMA9VGW RU https://pubmed.ncbi.nlm.nih.gov/18390884 DMA9VGW DI DMA9VGW DMA9VGW DN Sitafloxacin DMA9VGW TI TTFK8YB DMA9VGW TN Bacterial DNA topoisomerase 4A (Bact parC) DMA9VGW MA Inhibitor DMA9VGW RN Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 2008 Jul;62(1):98-104. DMA9VGW RU https://pubmed.ncbi.nlm.nih.gov/18390884 DMABRXY DI DMABRXY DMABRXY DN IDM-2101 DMABRXY TI TTY6DTE DMABRXY TN Carcinoembryonic antigen CEA (CD66e) DMABRXY RN Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. DMABRXY RU https://pubmed.ncbi.nlm.nih.gov/18802154 DMABRXY DI DMABRXY DMABRXY DN IDM-2101 DMABRXY TI TTWSKHD DMABRXY TN Melanoma-associated antigen 3 (MAGEA3) DMABRXY RN Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25. DMABRXY RU https://pubmed.ncbi.nlm.nih.gov/18802154 DMAC457 DI DMAC457 DMAC457 DN LY3127804 DMAC457 TI TT0APVH DMAC457 TN HUMAN angiopoietin-2 (ANG-2) DMAC457 MA Inhibitor DMAC457 RN Updates: Lilly's Global COVID-19 Response DMAC457 RU https://www.lilly.com/news/stories/coronavirus-covid19-global-response DMACTBM DI DMACTBM DMACTBM DN DAC-060 DMACTBM TI TTBH0VX DMACTBM TN Histone deacetylase (HDAC) DMACTBM MA Inhibitor DMACTBM RN Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369. DMACTBM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341130/ DMAEB9O DI DMAEB9O DMAEB9O DN Valomaciclovir stearate DMAEB9O TI TTIU7X1 DMAEB9O TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMAEB9O MA Modulator DMAEB9O RN Progress in the Development of New Therapies for Herpesvirus Infections. Curr Opin Virol. 2011 December 1; 1(6): 548-554. DMAEB9O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3230035/ DMAEWS1 DI DMAEWS1 DMAEWS1 DN GAM-501 DMAEWS1 TI TTQA6SX DMAEWS1 TN Platelet-derived growth factor B (PDGFB) DMAEWS1 MA Modulator DMAEWS1 RN Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen. 2009 Nov-Dec;17(6):772-9. DMAEWS1 RU https://pubmed.ncbi.nlm.nih.gov/19821960 DMAFUHK DI DMAFUHK DMAFUHK DN QGC-001 DMAFUHK TI TT9PBIL DMAFUHK TN Glutamyl aminopeptidase (ENPEP) DMAFUHK MA Inhibitor DMAFUHK RN Clinical pipeline report, company report or official report of Quantum Genomics. DMAFUHK RU http://www.quantum-genomics.com/www/en/science/programme-qgc001/ DMAFUHK DI DMAFUHK DMAFUHK DN QGC-001 DMAFUHK TI TTGMFY7 DMAFUHK TN Aspartyl aminopeptidase (DNPEP) DMAFUHK MA Inhibitor DMAFUHK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAFUHK RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMAFZ84 DI DMAFZ84 DMAFZ84 DN PIKAMILONE DMAFZ84 TI TTNJYV2 DMAFZ84 TN Gamma-aminobutyric acid receptor (GAR) DMAFZ84 MA Modulator DMAFZ84 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMAFZ84 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMAG4SX DI DMAG4SX DMAG4SX DN BILR-355 DMAG4SX TI TT84ETX DMAG4SX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMAG4SX MA Inhibitor DMAG4SX RN Evaluation of steady-state pharmacokinetic interactions between ritonavir-boosted BILR 355, a non-nucleoside reverse transcriptase inhibitor, and lamivudine/zidovudine in healthy subjects. J Clin Pharm Ther. 2012 Feb;37(1):81-8. DMAG4SX RU https://pubmed.ncbi.nlm.nih.gov/21128991 DMAHGKE DI DMAHGKE DMAHGKE DN E7016 DMAHGKE TI TTEBCY8 DMAHGKE TN Poly [ADP-ribose] polymerase (PARP) DMAHGKE MA Modulator DMAHGKE RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMAHGKE RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMAHOEP DI DMAHOEP DMAHOEP DN GRNVAC1 DMAHOEP TI TTUJFD0 DMAHOEP TN Telomerase reverse transcriptase (TERT) DMAHOEP RN Targeting telomerase-expressing cancer cells. J Cell Mol Med. 2011 Jul;15(7):1433-42. DMAHOEP RU https://pubmed.ncbi.nlm.nih.gov/21332640 DMAIGTE DI DMAIGTE DMAIGTE DN SurVaxM DMAIGTE TI TTTPU1G DMAIGTE TN Apoptosis inhibitor survivin (BIRC5) DMAIGTE MA Inhibitor DMAIGTE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAIGTE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAIW6C DI DMAIW6C DMAIW6C DN Clazakizumab DMAIW6C TI TTT1V78 DMAIW6C TN Interleukin-6 (IL6) DMAIW6C MA Inhibitor DMAIW6C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAIW6C RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAJ6YL DI DMAJ6YL DMAJ6YL DN TNX-1300 DMAJ6YL TI TTX7ZJ3 DMAJ6YL TN Cocaine (Coca) DMAJ6YL MA Degrader DMAJ6YL RN Clinical pipeline report, company report or official report of Tonix Pharmaceuticals. DMAJ6YL RU https://www.tonixpharma.com/pipeline/overview DMAJ85O DI DMAJ85O DMAJ85O DN VDA-1102 DMAJ85O TI TTK02H8 DMAJ85O TN Hexokinase-2 (HK2) DMAJ85O MA Modulator DMAJ85O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAJ85O RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAJ85O DI DMAJ85O DMAJ85O DN VDA-1102 DMAJ85O TI TTAMKGB DMAJ85O TN Voltage-dependent anion-selective channel 1 (VDAC1) DMAJ85O MA Modulator DMAJ85O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAJ85O RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAJH75 DI DMAJH75 DMAJH75 DN RSV-604 DMAJH75 TI TT25A0I DMAJH75 TN Respiratory syncytial virus protein N (RSV N) DMAJH75 MA Inhibitor DMAJH75 RN Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7. DMAJH75 RU https://pubmed.ncbi.nlm.nih.gov/25451060 DMAKSMX DI DMAKSMX DMAKSMX DN Camicinal DMAKSMX TI TT953CX DMAKSMX TN Motilin receptor (MLNR) DMAKSMX MA Modulator DMAKSMX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297). DMAKSMX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297 DMANC59 DI DMANC59 DMANC59 DN AZD-3241 DMANC59 TI TTVCZPI DMANC59 TN Myeloperoxidase (MPO) DMANC59 MA Inhibitor DMANC59 RN Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700. DMANC59 RU https://pubmed.ncbi.nlm.nih.gov/26137956 DMANRGW DI DMANRGW DMANRGW DN IP10 C8 DMANRGW TI TTDIGC1 DMANRGW TN Dipeptidyl peptidase 4 (DPP-4) DMANRGW MA Modulator DMANRGW RN Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61. DMANRGW RU https://pubmed.ncbi.nlm.nih.gov/19327105 DMANRGW DI DMANRGW DMANRGW DN IP10 C8 DMANRGW TI TTPHMWB DMANRGW TN Aminopeptidase N (ANPEP) DMANRGW MA Modulator DMANRGW RN Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61. DMANRGW RU https://pubmed.ncbi.nlm.nih.gov/19327105 DMAOUZV DI DMAOUZV DMAOUZV DN Nivatrotamab DMAOUZV TI TTUN7MC DMAOUZV TN T-cell surface glycoprotein CD3 (CD3) DMAOUZV MA Inhibitor DMAOUZV RN Clinical pipeline report, company report or official report of Y-mAbs Therapeutics. DMAOUZV RU https://ymabs.com/research-development/pipeline/ DMAOUZV DI DMAOUZV DMAOUZV DN Nivatrotamab DMAOUZV TI TT80ARU DMAOUZV TN Ganglioside GD2 (GD2) DMAOUZV MA Inhibitor DMAOUZV RN Clinical pipeline report, company report or official report of Y-mAbs Therapeutics. DMAOUZV RU https://ymabs.com/research-development/pipeline/ DMAQW9M DI DMAQW9M DMAQW9M DN SFX-01 DMAQW9M TI TTA6ZN2 DMAQW9M TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAQW9M MA Activator DMAQW9M RN Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. DMAQW9M RU https://pubmed.ncbi.nlm.nih.gov/30610225 DMARIQK DI DMARIQK DMARIQK DN AT-527 DMARIQK TI TTSUKYD DMARIQK TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMARIQK MA Inhibitor DMARIQK RN AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19. Antimicrob Agents Chemother. 2021 Mar 18;65(4):e02479-20. DMARIQK RU https://pubmed.ncbi.nlm.nih.gov/33558299 DMARQ0H DI DMARQ0H DMARQ0H DN JKB-122 DMARQ0H TI TTN4QDT DMARQ0H TN Opioid receptor (OPR) DMARQ0H MA Modulator DMARQ0H RN WO patent application no. 2011,1401,90, Tetrazolones as inhibitors of fatty acid synthase. DMARQ0H RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20111110&CC=WO&NR=2011140190A1&KC=A1 DMARVFG DI DMARVFG DMARVFG DN Talacotuzumab DMARVFG TI TTENHJ0 DMARVFG TN Interleukin 3 receptor alpha (IL3RA) DMARVFG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMARVFG RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMASRP3 DI DMASRP3 DMASRP3 DN AVA-101 DMASRP3 TI TT9HKJA DMASRP3 TN Vascular endothelial growth factor (VEGF) DMASRP3 MA Modulator DMASRP3 RN Clinical pipeline report, company report or official report of Avalanche Biotechnologies. DMASRP3 RU http://www.avalanchebiotech.com/ DMAUN15 DI DMAUN15 DMAUN15 DN Carlumab DMAUN15 TI TTNAY0P DMAUN15 TN Monocyte chemotactic and activating factor (CCL2) DMAUN15 RN Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. Target Oncol. 2015 Mar;10(1):111-23. DMAUN15 RU https://pubmed.ncbi.nlm.nih.gov/24928772 DMAV426 DI DMAV426 DMAV426 DN (S)-oxybutynin DMAV426 TI TTZ9SOR DMAV426 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMAV426 MA Antagonist DMAV426 RN Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991 Feb;256(2):562-7. DMAV426 RU https://pubmed.ncbi.nlm.nih.gov/1993995 DMAVM2E DI DMAVM2E DMAVM2E DN NYX-783 DMAVM2E TI TT9IK2Z DMAVM2E TN N-methyl-D-aspartate receptor (NMDAR) DMAVM2E MA Modulator DMAVM2E RN Clinical pipeline report, company report or official report of Aptinyx. DMAVM2E RU https://www.aptinyx.com/pipeline/ DMAVQR1 DI DMAVQR1 DMAVQR1 DN THR-184 DMAVQR1 TI TTKOBRA DMAVQR1 TN Bone morphogenetic protein 7 (BMP7) DMAVQR1 MA Agonist DMAVQR1 RN Perioperative THR-184 and AKI after Cardiac Surgery. J Am Soc Nephrol. 2018 Feb;29(2):670-679. DMAVQR1 RU https://pubmed.ncbi.nlm.nih.gov/29203473 DMAW4EL DI DMAW4EL DMAW4EL DN CLR-1404 DMAW4EL TI TTHBTOP DMAW4EL TN PI3-kinase gamma (PIK3CG) DMAW4EL MA Inhibitor DMAW4EL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMAW4EL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMAWKSM DI DMAWKSM DMAWKSM DN CetuGEX DMAWKSM TI TTGKNB4 DMAWKSM TN Epidermal growth factor receptor (EGFR) DMAWKSM RN Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92. DMAWKSM RU https://pubmed.ncbi.nlm.nih.gov/21293176 DMAWLVB DI DMAWLVB DMAWLVB DN TPI ASM8 DMAWLVB TI TTPYS82 DMAWLVB TN Interleukin 3 receptor (CSF2RB) DMAWLVB MA Modulator DMAWLVB RN Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res.2012 Nov;40(21):10585-95. DMAWLVB RU https://www.ncbi.nlm.nih.gov/pubmed/22989709 DMAWXJT DI DMAWXJT DMAWXJT DN ORG-13011 DMAWXJT TI TTSQIFT DMAWXJT TN 5-HT 1A receptor (HTR1A) DMAWXJT MA Antagonist DMAWXJT RN Antagonism of the 5-HT1A receptor stimulus in a conditioned taste aversion procedure. Eur Neuropsychopharmacol. 1999 Jun;9(4):345-9. DMAWXJT RU https://pubmed.ncbi.nlm.nih.gov/10422896 DMAX632 DI DMAX632 DMAX632 DN HDV-interferon DMAX632 TI TTV2CN0 DMAX632 TN Interferon receptor (IFNR) DMAX632 MA Modulator DMAX632 RN Interferon in HDV infection. Antiviral Res. 1994 Jul;24(2-3):165-74. DMAX632 RU https://pubmed.ncbi.nlm.nih.gov/7979316 DMAYWXD DI DMAYWXD DMAYWXD DN VA-111913 DMAYWXD TI TT4TFGN DMAYWXD TN Vasopressin V1a receptor (V1AR) DMAYWXD MA Antagonist DMAYWXD RN Clinical pipeline report, company report or official report of Avarx. DMAYWXD RU http://www.avarx.com/AvaRx/SubDomains/bucket304f365f4d5c821c892abf2b5eb4/Listings/bucket3e0f28b94cc197c9e1c49f1451ad/Public.Listing.display.html DMAZ2L6 DI DMAZ2L6 DMAZ2L6 DN TROXACITABINE DMAZ2L6 TI TTUTN1I DMAZ2L6 TN Human Deoxyribonucleic acid (hDNA) DMAZ2L6 MA Binder DMAZ2L6 RN Troxacitabine. Bull Cancer. 2004 Mar;91(3):213-8. DMAZ2L6 RU https://pubmed.ncbi.nlm.nih.gov/15171046 DMAZ460 DI DMAZ460 DMAZ460 DN Pankomab-GEX DMAZ460 TI TTBHFYQ DMAZ460 TN Mucin-1 (MUC1) DMAZ460 RN Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44. DMAZ460 RU https://pubmed.ncbi.nlm.nih.gov/23275306 DMAZHT0 DI DMAZHT0 DMAZHT0 DN TA-8995 DMAZHT0 TI TTFQAYR DMAZHT0 TN Cholesteryl ester transfer protein (CETP) DMAZHT0 MA Inhibitor DMAZHT0 RN Amgen To Acquire Privately-Held Dezima Pharma DMAZHT0 RU http://www.amgen.com/media/media_pr_detail.jsp?releaseID=2088272 DMAZIND DI DMAZIND DMAZIND DN Otlertuzumab DMAZIND TI TTFCW29 DMAZIND TN Leukocyte antigen CD37 (CD37) DMAZIND MA Inhibitor DMAZIND RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAZIND RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAZNVX DI DMAZNVX DMAZNVX DN YM-264 DMAZNVX TI TTQL5VC DMAZNVX TN Platelet-activating factor receptor (PTAFR) DMAZNVX MA Antagonist DMAZNVX RN Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5. DMAZNVX RU https://pubmed.ncbi.nlm.nih.gov/2025290 DMB0CXT DI DMB0CXT DMB0CXT DN GSK2330811 DMB0CXT TI TTIVXSE DMB0CXT TN Oncostatin-M (OSM) DMB0CXT MA Inhibitor DMB0CXT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0CXT RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMB0TNL DI DMB0TNL DMB0TNL DN AC-201 DMB0TNL TI TTRYK0X DMB0TNL TN Interleukin-1 beta (IL1B) DMB0TNL MA Inhibitor DMB0TNL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0TNL RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMB0TNL DI DMB0TNL DMB0TNL DN AC-201 DMB0TNL TI TTCQIBE DMB0TNL TN Caspase-1 (CASP1) DMB0TNL MA Inhibitor DMB0TNL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0TNL RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMB0UF9 DI DMB0UF9 DMB0UF9 DN Bb2121 DMB0UF9 TI TTZ3P4W DMB0UF9 TN B-cell maturation protein (TNFRSF17) DMB0UF9 MA Immunomodulator DMB0UF9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB0UF9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMB1UYV DI DMB1UYV DMB1UYV DN IC-485 DMB1UYV TI TTV5CGO DMB1UYV TN Phosphodiesterase 4 (PDE4) DMB1UYV MA Inhibitor DMB1UYV RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMB1UYV RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMB1WF3 DI DMB1WF3 DMB1WF3 DN OPC-14523 DMB1WF3 TI TT5TPI6 DMB1WF3 TN Opioid receptor sigma 1 (OPRS1) DMB1WF3 MA Modulator DMB1WF3 RN Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88. DMB1WF3 RU https://www.ncbi.nlm.nih.gov/pubmed/11747902 DMB1WF3 DI DMB1WF3 DMB1WF3 DN OPC-14523 DMB1WF3 TI TTSQIFT DMB1WF3 TN 5-HT 1A receptor (HTR1A) DMB1WF3 MA Modulator DMB1WF3 RN Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523. Neuropharmacology. 2001 Dec;41(8):976-88. DMB1WF3 RU https://www.ncbi.nlm.nih.gov/pubmed/11747902 DMB38KH DI DMB38KH DMB38KH DN Elisidepsin DMB38KH TI TTDC8N2 DMB38KH TN Erbb3 tyrosine kinase receptor (Erbb-3) DMB38KH MA Inhibitor DMB38KH RN Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer. 2009 Jul;45(10):1855-64. DMB38KH RU https://pubmed.ncbi.nlm.nih.gov/19346126 DMB4A8I DI DMB4A8I DMB4A8I DN MANOALIDE DMB4A8I TI TT9V5JH DMB4A8I TN Phospholipase A2 (PLA2G1B) DMB4A8I MA Modulator DMB4A8I RN Manoalide, a phospholipase A2 inhibitor, inhibits arachidonate incorporation and turnover in brain phospholipids of the awake rat. Neurochem Res. 1998 Oct;23(10):1251-7. DMB4A8I RU https://www.ncbi.nlm.nih.gov/pubmed/9804280 DMB4GD9 DI DMB4GD9 DMB4GD9 DN IONIS-GCGR-Rx DMB4GD9 TI TTLMJSC DMB4GD9 TN Glucagon receptor messenger RNA (GCGR mRNA) DMB4GD9 MA Inhibitor DMB4GD9 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMB4GD9 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMB4HCY DI DMB4HCY DMB4HCY DN KUR-212 DMB4HCY TI TTWODQF DMB4HCY TN Fibrin (FG) DMB4HCY MA Modulator DMB4HCY RN Clinical pipeline report, company report or official report of Kuros. DMB4HCY RU http://www.kuros.ch/cms/front_content.php?idcat=80 DMB4M6O DI DMB4M6O DMB4M6O DN RG7314 DMB4M6O TI TT4TFGN DMB4M6O TN Vasopressin V1a receptor (V1AR) DMB4M6O MA Modulator DMB4M6O RN Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30. DMB4M6O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/ DMB5L6Q DI DMB5L6Q DMB5L6Q DN LY-2940094 DMB5L6Q TI TTNT7K8 DMB5L6Q TN Nociceptin receptor (OPRL1) DMB5L6Q MA Modulator DMB5L6Q RN Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology Volume 95, Issue 2, 15 May 2015, Pages 81-97. DMB5L6Q RU http://www.sciencedirect.com/science/article/pii/S0006295215001562 DMB7CPG DI DMB7CPG DMB7CPG DN Elsiglutide DMB7CPG TI TT1YWO5 DMB7CPG TN Glucagon-like peptide 2 receptor (GLP2R) DMB7CPG MA Modulator DMB7CPG RN Poster Abstracts. Volume 10, Issue Supplement S8, pages 126-209, December 2014. DMB7CPG RU http://onlinelibrary.wiley.com/doi/10.1111/ajco.12305/abstract DMB7WT1 DI DMB7WT1 DMB7WT1 DN L-697,661 DMB7WT1 TI TT84ETX DMB7WT1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMB7WT1 MA Modulator DMB7WT1 RN Mechanism of resistance to U-90152S and sensitization to L-697,661 by a proline to leucine change at residue 236 of human immunodeficiency virus ty... FEBS Lett. 1995 Feb 13;359(2-3):233-8. DMB7WT1 RU https://www.ncbi.nlm.nih.gov/pubmed/7532595 DMB87M3 DI DMB87M3 DMB87M3 DN AZD9668 DMB87M3 TI TTPLTSQ DMB87M3 TN Neutrophil elastase (NE) DMB87M3 MA Inhibitor DMB87M3 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMB87M3 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMB9ADM DI DMB9ADM DMB9ADM DN FolateImmune DMB9ADM TI TTVC37M DMB9ADM TN Folate receptor alpha (FOLR1) DMB9ADM MA Modulator DMB9ADM RN Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91. DMB9ADM RU https://pubmed.ncbi.nlm.nih.gov/19738218 DMB9LRJ DI DMB9LRJ DMB9LRJ DN Bintrafusp alfa DMB9LRJ TI TTO3HT7 DMB9LRJ TN Transforming growth factor beta (TGFB) DMB9LRJ RN Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. DMB9LRJ RU https://pubmed.ncbi.nlm.nih.gov/32173464 DMB9LRJ DI DMB9LRJ DMB9LRJ DN Bintrafusp alfa DMB9LRJ TI TT8ZLTI DMB9LRJ TN Programmed cell death 1 ligand 1 (PD-L1) DMB9LRJ RN Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222. DMB9LRJ RU https://pubmed.ncbi.nlm.nih.gov/32173464 DMBADQV DI DMBADQV DMBADQV DN ASP-3291 DMBADQV TI TTEOSZT DMBADQV TN Melanocortin receptor (MCR) DMBADQV MA Modulator DMBADQV RN Clinical pipeline report, company report or official report of Drais Pharmaceuticals. DMBADQV RU http://www.draispharma.com/press.php DMBC7HZ DI DMBC7HZ DMBC7HZ DN DM-CHOC-PEN DMBC7HZ TI TTUTN1I DMBC7HZ TN Human Deoxyribonucleic acid (hDNA) DMBC7HZ MA Modulator DMBC7HZ RN Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents. Cancer Chemother Pharmacol. 2009 September; 64(4): 829-835. DMBC7HZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717391/ DMBDFN7 DI DMBDFN7 DMBDFN7 DN GS-4977 DMBDFN7 TI TTOQCD8 DMBDFN7 TN Apoptosis signal-regulating kinase 1 (MAP3K5) DMBDFN7 MA Inhibitor DMBDFN7 RN Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33. DMBDFN7 RU https://pubmed.ncbi.nlm.nih.gov/25531162 DMBFPO1 DI DMBFPO1 DMBFPO1 DN F-8-IL-10 fusion protein DMBFPO1 TI TTT0Q1F DMBFPO1 TN Interleukin-10 (IL10) DMBFPO1 MA Modulator DMBFPO1 RN Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142. DMBFPO1 RU https://pubmed.ncbi.nlm.nih.gov/19781067 DMBFZET DI DMBFZET DMBFZET DN DX-890 DMBFZET TI TTPLTSQ DMBFZET TN Neutrophil elastase (NE) DMBFZET MA Inhibitor DMBFZET RN Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2007 Sep;12(3):461-77. DMBFZET RU https://pubmed.ncbi.nlm.nih.gov/17874973 DMBFZSX DI DMBFZSX DMBFZSX DN RALURIDINE DMBFZSX TI TT84ETX DMBFZSX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBFZSX MA Inhibitor DMBFZSX RN 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob Agents Chemother. 1994 Jul;38(7):1590-603. DMBFZSX RU https://pubmed.ncbi.nlm.nih.gov/7526782 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTK25J1 DMBH316 TN Adenosine A1 receptor (ADORA1) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTNE7KG DMBH316 TN Adenosine A2b receptor (ADORA2B) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTM2AOE DMBH316 TN Adenosine A2a receptor (ADORA2A) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH316 DI DMBH316 DMBH316 DN Tonapofylline DMBH316 TI TTJFY5U DMBH316 TN Adenosine A3 receptor (ADORA3) DMBH316 MA Inhibitor DMBH316 RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMBH316 RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMBH7XI DI DMBH7XI DMBH7XI DN Pramiconazole DMBH7XI TI TTTSOUD DMBH7XI TN Candida Cytochrome P450 51 (Candi ERG11) DMBH7XI MA Modulator DMBH7XI RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBH7XI RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBHN4K DI DMBHN4K DMBHN4K DN RQ-00000005 DMBHN4K TI TTWDC17 DMBHN4K TN Growth hormone secretagogue receptor 1 (GHSR) DMBHN4K MA Agonist DMBHN4K RN Hypotensive effects of ghrelin receptor agonists mediated through a novel receptor. Br J Pharmacol. 2014 Mar;171(5):1275-86. DMBHN4K RU https://pubmed.ncbi.nlm.nih.gov/24670149 DMBHP56 DI DMBHP56 DMBHP56 DN Efungumab DMBHP56 TI TT78R5H DMBHP56 TN Heat shock protein 90 alpha (HSP90A) DMBHP56 RN Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23. DMBHP56 RU https://pubmed.ncbi.nlm.nih.gov/19773528 DMBHPDW DI DMBHPDW DMBHPDW DN Phenylbutyrate DMBHPDW TI TTRK8B9 DMBHPDW TN Sodium channel unspecific (NaC) DMBHPDW MA Blocker DMBHPDW RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMBHPDW RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMBHPDW DI DMBHPDW DMBHPDW DN Phenylbutyrate DMBHPDW TI TTNJYV2 DMBHPDW TN Gamma-aminobutyric acid receptor (GAR) DMBHPDW MA Agonist DMBHPDW RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMBHPDW RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMBHPDW DI DMBHPDW DMBHPDW DN Phenylbutyrate DMBHPDW TI TT6R7JZ DMBHPDW TN Histone deacetylase 1 (HDAC1) DMBHPDW MA Inhibitor DMBHPDW RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMBHPDW RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMBJ3GL DI DMBJ3GL DMBJ3GL DN Nerenone DMBJ3GL TI TT26PHO DMBJ3GL TN Mineralocorticoid receptor (MR) DMBJ3GL MA Antagonist DMBJ3GL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626). DMBJ3GL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626 DMBJMZC DI DMBJMZC DMBJMZC DN GSK239512 DMBJMZC TI TT9JNIC DMBJMZC TN Histamine H3 receptor (H3R) DMBJMZC MA Antagonist DMBJMZC RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMBJMZC RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMBJN19 DI DMBJN19 DMBJN19 DN Rontalizumab DMBJN19 TI TT95SOA DMBJN19 TN Interferon alpha (IFNA) DMBJN19 RN Clinical pipeline report, company report or official report of Genentech (2011). DMBJN19 RU http://www.gene.com/gene/index.jsp DMBJU2G DI DMBJU2G DMBJU2G DN SAR-260093 DMBJU2G TI TT7QNVC DMBJU2G TN Glucose-dependent insulinotropic receptor (GPR119) DMBJU2G MA Agonist DMBJU2G RN GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59. DMBJU2G RU https://pubmed.ncbi.nlm.nih.gov/19780700 DMBJY1Z DI DMBJY1Z DMBJY1Z DN SCH-900271 DMBJY1Z TI TTWNV8U DMBJY1Z TN Nicotinic acid receptor (HCAR2) DMBJY1Z MA Modulator DMBJY1Z RN Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8. DMBJY1Z RU https://pubmed.ncbi.nlm.nih.gov/24900372 DMBKQSZ DI DMBKQSZ DMBKQSZ DN TTP399 DMBKQSZ TI TTDLNGZ DMBKQSZ TN Glucokinase (GCK) DMBKQSZ MA Activator DMBKQSZ RN Clinical pipeline report, company report or official report of vTv Therapeutics. DMBKQSZ RU https://vtvtherapeutics.com/pipeline/ttp399/ DMBL3VD DI DMBL3VD DMBL3VD DN PF-05212384 DMBL3VD TI TTCJG29 DMBL3VD TN Serine/threonine-protein kinase mTOR (mTOR) DMBL3VD MA Modulator DMBL3VD RN First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95. DMBL3VD RU https://pubmed.ncbi.nlm.nih.gov/25652454 DMBL3VD DI DMBL3VD DMBL3VD DN PF-05212384 DMBL3VD TI TTHBTOP DMBL3VD TN PI3-kinase gamma (PIK3CG) DMBL3VD MA Modulator DMBL3VD RN First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer. Clin Cancer Res. 2015 Apr 15;21(8):1888-95. DMBL3VD RU https://pubmed.ncbi.nlm.nih.gov/25652454 DMBLHGP DI DMBLHGP DMBLHGP DN Saracatinib DMBLHGP TI TT6PKBN DMBLHGP TN Proto-oncogene c-Src (SRC) DMBLHGP MA Modulator DMBLHGP RN Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45. DMBLHGP RU https://www.ncbi.nlm.nih.gov/pubmed/20557276 DMBLHGP DI DMBLHGP DMBLHGP DN Saracatinib DMBLHGP TI TT3PJMV DMBLHGP TN Tyrosine-protein kinase ABL1 (ABL) DMBLHGP MA Modulator DMBLHGP RN Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45. DMBLHGP RU https://www.ncbi.nlm.nih.gov/pubmed/20557276 DMBM2I9 DI DMBM2I9 DMBM2I9 DN LY-518674 DMBM2I9 TI TTJ584C DMBM2I9 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMBM2I9 MA Agonist DMBM2I9 RN Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2009 Jan;29(1):140-6. DMBM2I9 RU https://pubmed.ncbi.nlm.nih.gov/18988892 DMBM47Z DI DMBM47Z DMBM47Z DN Oxazolidinones DMBM47Z TI TTLFGBV DMBM47Z TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMBM47Z MA Inhibitor DMBM47Z RN Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46. DMBM47Z RU https://pubmed.ncbi.nlm.nih.gov/10411137 DMBM47Z DI DMBM47Z DMBM47Z DN Oxazolidinones DMBM47Z TI TT38DW5 DMBM47Z TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMBM47Z MA Inhibitor DMBM47Z RN Ribosomal RNA is the target for oxazolidinones, a novel class of translational inhibitors. RNA. 1999 Jul;5(7):939-46. DMBM47Z RU https://pubmed.ncbi.nlm.nih.gov/10411137 DMBNU1W DI DMBNU1W DMBNU1W DN TTP-054 DMBNU1W TI TTVIMDE DMBNU1W TN Glucagon-like peptide 1 receptor (GLP1R) DMBNU1W MA Modulator DMBNU1W RN Small Molecule Drug Discovery at the Glucagon-Like Peptide-1 Receptor. Exp Diabetes Res. 2012; 2012: 709893. DMBNU1W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352573/ DMBO021 DI DMBO021 DMBO021 DN THR-18 DMBO021 TI TTTO43N DMBO021 TN Endothelial plasminogen activator inhibitor (SERPINE1) DMBO021 MA Activator DMBO021 RN THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models. Neurol Res. 2011 Nov;33(9):983-90. DMBO021 RU https://pubmed.ncbi.nlm.nih.gov/22081002 DMBOL4K DI DMBOL4K DMBOL4K DN 264W94 DMBOL4K TI TTPI1M5 DMBOL4K TN Ileal sodium/bile acid cotransporter (SLC10A2) DMBOL4K MA Modulator DMBOL4K RN Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76. DMBOL4K RU https://pubmed.ncbi.nlm.nih.gov/21934041 DMBOZPH DI DMBOZPH DMBOZPH DN RX-5902 DMBOZPH TI TTOTSW1 DMBOZPH TN ATP-dependent RNA helicase DDX5 (DDX5) DMBOZPH MA Modulator DMBOZPH RN Company report (Rexahn) DMBOZPH RU http://investors.rexahn.com/releasedetail.cfm?releaseid=895381 DMBOZPH DI DMBOZPH DMBOZPH DN RX-5902 DMBOZPH TI TTZKPVC DMBOZPH TN Phosphorylated p68 RNA helicase (pDDX5) DMBOZPH MA Inhibitor DMBOZPH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBOZPH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBPJ9U DI DMBPJ9U DMBPJ9U DN PEGylated pitrakinra DMBPJ9U TI TTLGTKB DMBPJ9U TN Interleukin-4 (IL4) DMBPJ9U MA Modulator DMBPJ9U RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMBPJ9U RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMBPJ9U DI DMBPJ9U DMBPJ9U DN PEGylated pitrakinra DMBPJ9U TI TT0GVCH DMBPJ9U TN Interleukin-13 (IL13) DMBPJ9U MA Modulator DMBPJ9U RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMBPJ9U RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMBQC3L DI DMBQC3L DMBQC3L DN Verubulin DMBQC3L TI TTYFKSZ DMBQC3L TN Tubulin beta (TUBB) DMBQC3L MA Modulator DMBQC3L RN Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.ChemMedChem.2014 Apr;9(4):847-54. DMBQC3L RU https://www.ncbi.nlm.nih.gov/pubmed/24678059 DMBQD9H DI DMBQD9H DMBQD9H DN TAK-906 DMBQD9H TI TT4C8EA DMBQD9H TN Dopamine D3 receptor (D3R) DMBQD9H MA Inhibitor DMBQD9H RN Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18. DMBQD9H RU https://pubmed.ncbi.nlm.nih.gov/33462988 DMBQD9H DI DMBQD9H DMBQD9H DN TAK-906 DMBQD9H TI TTEX248 DMBQD9H TN Dopamine D2 receptor (D2R) DMBQD9H MA Inhibitor DMBQD9H RN Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18. DMBQD9H RU https://pubmed.ncbi.nlm.nih.gov/33462988 DMBR0QK DI DMBR0QK DMBR0QK DN Atorvastatin DMBR0QK TI TTDJB68 DMBR0QK TN HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) DMBR0QK MA Inhibitor DMBR0QK RN Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042. DMBR0QK RU https://pubmed.ncbi.nlm.nih.gov/32347925 DMBR8NF DI DMBR8NF DMBR8NF DN MLN2480 DMBR8NF TI TT0EOB8 DMBR8NF TN B-Raf messenger RNA (BRAF mRNA) DMBR8NF MA Inhibitor DMBR8NF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943). DMBR8NF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943 DMBR8NF DI DMBR8NF DMBR8NF DN MLN2480 DMBR8NF TI TTAN5W2 DMBR8NF TN Raf messenger RNA (Raf mRNA) DMBR8NF MA Inhibitor DMBR8NF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184). DMBR8NF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184 DMBR8NF DI DMBR8NF DMBR8NF DN MLN2480 DMBR8NF TI TTQ9K3Y DMBR8NF TN Serine/threonine-protein kinase Raf (RAF) DMBR8NF MA Inhibitor DMBR8NF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBR8NF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBRKZ7 DI DMBRKZ7 DMBRKZ7 DN CT1812 DMBRKZ7 TI TT9NXW4 DMBRKZ7 TN Sigma intracellular receptor 2 (TMEM97) DMBRKZ7 MA Antagonist DMBRKZ7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBRKZ7 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMBRL19 DI DMBRL19 DMBRL19 DN Bimakalim DMBRL19 TI TT1VOHK DMBRL19 TN Potassium channel unspecific (KC) DMBRL19 MA Agonist DMBRL19 RN Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46. DMBRL19 RU https://pubmed.ncbi.nlm.nih.gov/15115902 DMBSXR9 DI DMBSXR9 DMBSXR9 DN rhACE2 DMBSXR9 TI TTYRG7F DMBSXR9 TN HUMAN angiotensin-converting enzyme 2 (ACE2) DMBSXR9 MA Inhibitor DMBSXR9 RN ClinicalTrials.gov (NCT04287686) Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 DMBSXR9 RU https://clinicaltrials.gov/ct2/show/NCT04346797 DMBT46Y DI DMBT46Y DMBT46Y DN CTP-543 DMBT46Y TI TTRMX3V DMBT46Y TN Janus kinase 2 (JAK-2) DMBT46Y MA Inhibitor DMBT46Y RN Clinical pipeline report, company report or official report of Concert Pharmaceuticals. DMBT46Y RU https://www.concertpharma.com/product-pipeline/ctp-543/ DMBT46Y DI DMBT46Y DMBT46Y DN CTP-543 DMBT46Y TI TT6DM01 DMBT46Y TN Janus kinase 1 (JAK-1) DMBT46Y MA Inhibitor DMBT46Y RN Clinical pipeline report, company report or official report of Concert Pharmaceuticals. DMBT46Y RU https://www.concertpharma.com/product-pipeline/ctp-543/ DMBTVFE DI DMBTVFE DMBTVFE DN MEDI-551 DMBTVFE TI TTW640A DMBTVFE TN B-lymphocyte surface antigen B4 (CD19) DMBTVFE RN Clinical pipeline report, company report or official report of MedImmune (2011). DMBTVFE RU http://www.medimmune.com/research_pipeline.aspx DMBUSNL DI DMBUSNL DMBUSNL DN Pumosetrag DMBUSNL TI TTNXLKE DMBUSNL TN 5-HT 3 receptor (5HT3R) DMBUSNL MA Modulator DMBUSNL RN Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.Neurogastroenterol Motil.2014 Jan;26(1):13-20. DMBUSNL RU https://www.ncbi.nlm.nih.gov/pubmed/24001105 DMBVI6E DI DMBVI6E DMBVI6E DN Ostabolin-C DMBVI6E TI TT6F7GZ DMBVI6E TN Parathyroid hormone (PTH) DMBVI6E MA Modulator DMBVI6E RN ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. IDrugs. 2008 Nov;11(11):827-40. DMBVI6E RU https://www.ncbi.nlm.nih.gov/pubmed/18988128 DMBWNX5 DI DMBWNX5 DMBWNX5 DN AMA-76 DMBWNX5 TI TTMQO60 DMBWNX5 TN Rho-associated protein kinase (ROCK) DMBWNX5 MA Modulator DMBWNX5 RN AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16. DMBWNX5 RU https://pubmed.ncbi.nlm.nih.gov/24474276 DMBWPZJ DI DMBWPZJ DMBWPZJ DN GSK2245035 DMBWPZJ TI TTRJ1K4 DMBWPZJ TN Toll-like receptor 7 (TLR7) DMBWPZJ MA Modulator DMBWPZJ RN Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80. DMBWPZJ RU https://pubmed.ncbi.nlm.nih.gov/26044169 DMBX2RE DI DMBX2RE DMBX2RE DN MN-221 DMBX2RE TI TT2CJVK DMBX2RE TN Adrenergic receptor beta-2 (ADRB2) DMBX2RE MA Agonist DMBX2RE RN Investigation of beta(2)-adrenoceptor subtype selectivity and organ specificity for bedoradrine (KUR-1246), a novel tocolytic beta-adrenergic receptor stimulant. J Obstet Gynaecol Res. 2009 Jun;35(3):405-13. DMBX2RE RU https://pubmed.ncbi.nlm.nih.gov/19527375 DMBX9C0 DI DMBX9C0 DMBX9C0 DN GW-427353 DMBX9C0 TI TTMXGCW DMBX9C0 TN Adrenergic receptor beta-3 (ADRB3) DMBX9C0 MA Agonist DMBX9C0 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMBX9C0 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMBXEG9 DI DMBXEG9 DMBXEG9 DN Intetumumab DMBXEG9 TI TT69TQN DMBXEG9 TN Integrin alpha-V/beta-3 (ITGAV/B3) DMBXEG9 MA Modulator DMBXEG9 RN A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011 Jul 26;105(3):346-52. DMBXEG9 RU https://pubmed.ncbi.nlm.nih.gov/21750555 DMBXWJ5 DI DMBXWJ5 DMBXWJ5 DN JNJ 63723283 DMBXWJ5 TI TTNBFWK DMBXWJ5 TN Programmed cell death protein 1 (PD-1) DMBXWJ5 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMBXWJ5 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMBYDNE DI DMBYDNE DMBYDNE DN Managlinat dialanetil DMBYDNE TI TTWHDVK DMBYDNE TN Fructose-1,6-bisphosphatase (FBP) DMBYDNE MA Modulator DMBYDNE RN MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A. 2005 May 31;102(22):7970-5. DMBYDNE RU https://pubmed.ncbi.nlm.nih.gov/15911772 DMBYJ92 DI DMBYJ92 DMBYJ92 DN Dilmapimod DMBYJ92 TI TTQBR95 DMBYJ92 TN Stress-activated protein kinase 2a (p38 alpha) DMBYJ92 MA Inhibitor DMBYJ92 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMBYJ92 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMBZ6CP DI DMBZ6CP DMBZ6CP DN PRN1008 DMBZ6CP TI TTGM6VW DMBZ6CP TN Tyrosine-protein kinase BTK (ATK) DMBZ6CP MA Inhibitor DMBZ6CP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBZ6CP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMBZK3P DI DMBZK3P DMBZK3P DN ISF35 DMBZK3P TI TTIJP3Q DMBZK3P TN TNF related activation protein (CD40LG) DMBZK3P MA Binder DMBZK3P RN Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25. DMBZK3P RU https://pubmed.ncbi.nlm.nih.gov/25382101 DMBZO8N DI DMBZO8N DMBZO8N DN Sabarubicin DMBZO8N TI TT0IHXV DMBZO8N TN DNA topoisomerase II (TOP2) DMBZO8N MA Modulator DMBZO8N RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBZO8N RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBZQS7 DI DMBZQS7 DMBZQS7 DN ASP-8477 DMBZQS7 TI TTVJ1D8 DMBZQS7 TN Vascular endothelial growth factor receptor (VEGFR) DMBZQS7 MA Modulator DMBZQS7 RN ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health. DMBZQS7 RU https://clinicaltrials.gov/ct2/show/NCT02065349 DMC04SR DI DMC04SR DMC04SR DN LB-100 DMC04SR TI TTHTKNY DMC04SR TN Serine/threonine PP2A-alpha (PPP2CA) DMC04SR MA Inhibitor DMC04SR RN Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72. DMC04SR RU https://pubmed.ncbi.nlm.nih.gov/24867249 DMC04SR DI DMC04SR DMC04SR DN LB-100 DMC04SR TI TTRKDL6 DMC04SR TN Serine/threonine PP2A (PP2A) DMC04SR MA Inhibitor DMC04SR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC04SR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMC13BQ DI DMC13BQ DMC13BQ DN ICO-25 DMC13BQ TI TTBHFYQ DMC13BQ TN Mucin-1 (MUC1) DMC13BQ RN The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5. DMC13BQ RU https://pubmed.ncbi.nlm.nih.gov/12534220 DMC1F2T DI DMC1F2T DMC1F2T DN FP-1097 DMC1F2T TI TTZ9SOR DMC1F2T TN Muscarinic acetylcholine receptor M1 (CHRM1) DMC1F2T MA Antagonist DMC1F2T RN Clinical pipeline report, company report or official report of FemmePharma. DMC1F2T RU http://femmepharma.com/ DMC1F2T DI DMC1F2T DMC1F2T DN FP-1097 DMC1F2T TI TTYEG6Q DMC1F2T TN Muscarinic acetylcholine receptor M2 (CHRM2) DMC1F2T MA Antagonist DMC1F2T RN Clinical pipeline report, company report or official report of FemmePharma. DMC1F2T RU http://femmepharma.com/ DMC1I56 DI DMC1I56 DMC1I56 DN Exherin DMC1I56 TI TT1WS0T DMC1I56 TN Neural cadherin (CDH2) DMC1I56 MA Binder DMC1I56 RN Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5. DMC1I56 RU https://pubmed.ncbi.nlm.nih.gov/19190075 DMC2FAL DI DMC2FAL DMC2FAL DN PF-3893787 DMC2FAL TI TTXJ178 DMC2FAL TN Histamine H4 receptor (H4R) DMC2FAL MA Antagonist DMC2FAL RN Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett. 2011 Nov 1;21(21):6596-602. DMC2FAL RU https://pubmed.ncbi.nlm.nih.gov/21920751 DMC3P45 DI DMC3P45 DMC3P45 DN Terameprocol DMC3P45 TI TTZEP6S DMC3P45 TN Transcription factor Sp1 (SP1) DMC3P45 MA Modulator DMC3P45 RN Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14. DMC3P45 RU https://pubmed.ncbi.nlm.nih.gov/18311658 DMC3PJS DI DMC3PJS DMC3PJS DN Oxytrex DMC3PJS TI TTN4QDT DMC3PJS TN Opioid receptor (OPR) DMC3PJS MA Modulator DMC3PJS RN Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. Expert Opin Investig Drugs. 2007 Aug;16(8):1277-83. DMC3PJS RU https://pubmed.ncbi.nlm.nih.gov/17685875 DMC3T2S DI DMC3T2S DMC3T2S DN PIRODOMAST DMC3T2S TI TTTWGIX DMC3T2S TN Leukotriene receptor (LTR) DMC3T2S MA Modulator DMC3T2S RN Antiallergy activity of Sch 37224, a new inhibitor of leukotriene formation. J Pharmacol Exp Ther. 1988 Dec;247(3):997-1003. DMC3T2S RU https://pubmed.ncbi.nlm.nih.gov/2462630 DMC48SP DI DMC48SP DMC48SP DN AZD-7268 DMC48SP TI TTN4QDT DMC48SP TN Opioid receptor (OPR) DMC48SP MA Modulator DMC48SP RN EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders. DMC48SP RU http://www.google.com/patents/EP2774991A1?cl=en DMC56T4 DI DMC56T4 DMC56T4 DN RAF265 DMC56T4 TI TTUTJGQ DMC56T4 TN Vascular endothelial growth factor receptor 2 (KDR) DMC56T4 MA Modulator DMC56T4 RN RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs. 2013 Feb;31(1):200-5. DMC56T4 RU https://pubmed.ncbi.nlm.nih.gov/22773056 DMC5MQD DI DMC5MQD DMC5MQD DN M2951 DMC5MQD TI TTGM6VW DMC5MQD TN Tyrosine-protein kinase BTK (ATK) DMC5MQD MA Inhibitor DMC5MQD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC5MQD RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMC5PB2 DI DMC5PB2 DMC5PB2 DN E-4716 DMC5PB2 TI TTTIBOJ DMC5PB2 TN Histamine H1 receptor (H1R) DMC5PB2 MA Modulator DMC5PB2 RN Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. Br J Clin Pharmacol. 2005 Jan;59(1):43-53. DMC5PB2 RU https://pubmed.ncbi.nlm.nih.gov/15606439 DMC5TV6 DI DMC5TV6 DMC5TV6 DN TPI-287 DMC5TV6 TI TT1WDO0 DMC5TV6 TN Microtubule (MicroTu) DMC5TV6 MA Stabilizer DMC5TV6 RN TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol Cancer Ther. 2012 Sep;11(9):1959-67. DMC5TV6 RU https://pubmed.ncbi.nlm.nih.gov/22622283 DMC8NAO DI DMC8NAO DMC8NAO DN ADXS-HPV DMC8NAO TI TT3CPZW DMC8NAO TN Human papillomavirus protein E7 (HPV E7) DMC8NAO RN ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer. Journal for ImmunoTherapy of Cancer, 2013, 1(Suppl 1):P231. DMC8NAO RU http://www.immunotherapyofcancer.org/content/1/S1/P231 DMCA8G1 DI DMCA8G1 DMCA8G1 DN VTP-43742 DMCA8G1 TI TTGV6LY DMCA8G1 TN Nuclear receptor ROR-gamma (RORG) DMCA8G1 MA Inhibitor DMCA8G1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCA8G1 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMCAFVN DI DMCAFVN DMCAFVN DN IRT-102 DMCAFVN TI TT6IEYX DMCAFVN TN Opioid receptor zeta (OGFR) DMCAFVN MA Modulator DMCAFVN RN The opiate receptor binding interactions of 3H-methionine enkephalin, an opioid peptide. Eur J Pharmacol. 1978 Feb 1;47(3):319-31. DMCAFVN RU https://pubmed.ncbi.nlm.nih.gov/204498 DMCAFXM DI DMCAFXM DMCAFXM DN ALX-101 DMCAFXM TI TTM1EQF DMCAFXM TN Oxysterols receptor LXR (NR1H) DMCAFXM MA Agonist DMCAFXM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCAFXM RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMCATH2 DI DMCATH2 DMCATH2 DN Dilpacimab DMCATH2 TI TTV23LH DMCATH2 TN Delta-like protein 4 (DLL4) DMCATH2 RN Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35. DMCATH2 RU https://pubmed.ncbi.nlm.nih.gov/21473903 DMCATH2 DI DMCATH2 DMCATH2 DN Dilpacimab DMCATH2 TI TT9HKJA DMCATH2 TN Vascular endothelial growth factor (VEGF) DMCATH2 RN Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35. DMCATH2 RU https://pubmed.ncbi.nlm.nih.gov/21473903 DMCBEYH DI DMCBEYH DMCBEYH DN P54 DMCBEYH TI TTUIZKC DMCBEYH TN DNA-binding factor KBF1 (p105) DMCBEYH MA Modulator DMCBEYH RN Identification of p54(nrb) and the 14-3-3 Protein HS1 as TNF-alpha-inducible genes related to cell cycle control and apoptosis in human arterial endothelial cells. J Biochem Mol Biol. 2005 Jul 31;38(4):447-56. DMCBEYH RU https://pubmed.ncbi.nlm.nih.gov/16053712 DMCD6G1 DI DMCD6G1 DMCD6G1 DN SMT-C1100 DMCD6G1 TI TTNO1VA DMCD6G1 TN Utrophin (UTRN) DMCD6G1 MA Regulator (upregulator) DMCD6G1 RN Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol.2015 Jun;55(6):698-707. DMCD6G1 RU https://pubmed.ncbi.nlm.nih.gov/25651188 DMCDAVK DI DMCDAVK DMCDAVK DN GSK3036656 DMCDAVK TI TT46T5G DMCDAVK TN Mycobacterium Leucine-tRNA ligase (MycB leuS) DMCDAVK MA Inhibitor DMCDAVK RN Discovery of a Potent and Specific M. tuberculosis Leucyl-tRNA Synthetase Inhibitor: (S)-3-(Aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem. 2017 Oct 12;60(19):8011-8026. DMCDAVK RU https://pubmed.ncbi.nlm.nih.gov/28953378 DMCDMFP DI DMCDMFP DMCDMFP DN TT-223 DMCDMFP TI TTVFO0U DMCDMFP TN Gastrin/cholecystokinin type B receptor (CCKBR) DMCDMFP MA Modulator DMCDMFP RN The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98. DMCDMFP RU https://pubmed.ncbi.nlm.nih.gov/10757621 DMCDON3 DI DMCDON3 DMCDON3 DN SLV 306 DMCDON3 TI TT5TKPM DMCDON3 TN Neutral endopeptidase (MME) DMCDON3 MA Modulator DMCDON3 RN The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. DMCDON3 RU https://pubmed.ncbi.nlm.nih.gov/22480515 DMCDON3 DI DMCDON3 DMCDON3 DN SLV 306 DMCDON3 TI TT1BGDH DMCDON3 TN Endothelin-converting enzyme (ECE) DMCDON3 MA Modulator DMCDON3 RN The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. DMCDON3 RU https://pubmed.ncbi.nlm.nih.gov/22480515 DMCEPUA DI DMCEPUA DMCEPUA DN ERB-041 DMCEPUA TI TTOM3J0 DMCEPUA TN Estrogen receptor beta (ESR2) DMCEPUA MA Agonist DMCEPUA RN Erb-041, an estrogen receptor-beta agonist, inhibits skin photocarcinogenesis in SKH-1 hairless mice by downregulating the WNT signaling pathway. Cancer Prev Res (Phila). 2014 Feb;7(2):186-98. DMCEPUA RU https://pubmed.ncbi.nlm.nih.gov/24217507 DMCEUOH DI DMCEUOH DMCEUOH DN Fluoropeptide vaccine DMCEUOH TI TTN2JFW DMCEUOH TN T-cell surface glycoprotein CD4 (CD4) DMCEUOH RN A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402. DMCEUOH RU https://pubmed.ncbi.nlm.nih.gov/24928790 DMCEUOH DI DMCEUOH DMCEUOH DN Fluoropeptide vaccine DMCEUOH TI TTMHA6L DMCEUOH TN T-cell surface glycoprotein CD8 (CD8) DMCEUOH RN A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402. DMCEUOH RU https://pubmed.ncbi.nlm.nih.gov/24928790 DMCF5E0 DI DMCF5E0 DMCF5E0 DN Vaniprevir DMCF5E0 TI TT5FNQT DMCF5E0 TN Human immunodeficiency virus Protease (HIV PR) DMCF5E0 MA Inhibitor DMCF5E0 RN Clinical pipeline report, company report or official report of Merck (2011). DMCF5E0 RU http://www.merck.com/index.html DMCFGP3 DI DMCFGP3 DMCFGP3 DN LKA651 DMCFGP3 TI TTQG4NR DMCFGP3 TN Erythropoietin (EPO) DMCFGP3 RN Clinical pipeline report, company report or official report of Novartis. DMCFGP3 RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=LKA651&field_pipeline_filing_date=All DMCFLRH DI DMCFLRH DMCFLRH DN Cibinetide DMCFLRH TI TTAUX24 DMCFLRH TN Erythropoietin Receptor (EPOR) DMCFLRH MA Agonist DMCFLRH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCFLRH RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCFPBE DI DMCFPBE DMCFPBE DN NN8765 DMCFPBE TI TTC4IMS DMCFPBE TN NKG2-A/B-activating NK receptor (NKG2A) DMCFPBE MA Modulator DMCFPBE RN Handbook of Therapeutic Antibodies. 2014. 1. Page(1098). DMCFPBE RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA2173&lpg=PA2173&dq=%22NN-8765%22+++drug&source=bl&ots=OSgek3Ubee&sig=uPqJzQ0sfWmrddc5W83GKlUI4JQ&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI3cTx8NTGyAIVTgWOCh29iQZt DMCGK9H DI DMCGK9H DMCGK9H DN VT-1129 DMCGK9H TI TT3C1VN DMCGK9H TN Enzyme unspecific (Enz) DMCGK9H MA Inhibitor DMCGK9H RN The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob Agents Chemother. 2014 Dec;58(12):7121-7. DMCGK9H RU https://pubmed.ncbi.nlm.nih.gov/25224009 DMCGK9H DI DMCGK9H DMCGK9H DN VT-1129 DMCGK9H TI TT67TDP DMCGK9H TN Lanosterol 14-alpha demethylase (CYP51A1) DMCGK9H MA Inhibitor DMCGK9H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCGK9H RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMCGNJ6 DI DMCGNJ6 DMCGNJ6 DN CDX-1401 DMCGNJ6 TI TTE5ITK DMCGNJ6 TN Cancer/testis antigen 1 (NY-ESO-1) DMCGNJ6 MA Modulator DMCGNJ6 RN National Cancer Institute Drug Dictionary (drug id 651880). DMCGNJ6 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=651880 DMCH3G5 DI DMCH3G5 DMCH3G5 DN AQX-1125 DMCH3G5 TI TTTP2Z1 DMCH3G5 TN SH2 domain inositol 5'-phosphatase 1 (INPP5D) DMCH3G5 MA Agonist DMCH3G5 RN Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo. Br J Pharmacol. 2013 Mar;168(6):1519-29. DMCH3G5 RU https://pubmed.ncbi.nlm.nih.gov/23121409 DMCHFB0 DI DMCHFB0 DMCHFB0 DN YH-4808 DMCHFB0 TI TTLOKXP DMCHFB0 TN Gastric H(+)/K(+) ATPase (Proton pump) DMCHFB0 MA Modulator DMCHFB0 RN Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil.2012 Aug;24(8):697-704. DMCHFB0 RU https://www.ncbi.nlm.nih.gov/pubmed/22783985 DMCHWX1 DI DMCHWX1 DMCHWX1 DN DCR-PHXC DMCHWX1 TI TTW76JE DMCHWX1 TN LDHA messenger RNA (LDHA mRNA) DMCHWX1 MA Inhibitor DMCHWX1 RN Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6(4):1088-1098. DMCHWX1 RU https://pubmed.ncbi.nlm.nih.gov/33912759 DMCHZAN DI DMCHZAN DMCHZAN DN RGH-896 DMCHZAN TI TTN9D8E DMCHZAN TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMCHZAN MA Antagonist DMCHZAN RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMCHZAN RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMCIGRB DI DMCIGRB DMCIGRB DN Fialuridine DMCIGRB TI TTIU7X1 DMCIGRB TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMCIGRB MA Modulator DMCIGRB RN Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3592-7. DMCIGRB RU https://pubmed.ncbi.nlm.nih.gov/8622980 DMCIGRW DI DMCIGRW DMCIGRW DN GSK2838232 DMCIGRW TI TT5TOX7 DMCIGRW TN Human immunodeficiency virus Maturation (HIV Mat) DMCIGRW MA Modulator DMCIGRW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762) DMCIGRW RU http://adisinsight.springer.com/drugs/800037762 DMCJX79 DI DMCJX79 DMCJX79 DN ITV-1 DMCJX79 TI TTG90S6 DMCJX79 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMCJX79 RN Clinical pipeline report, company report or official report of Immunotech Laboratories. DMCJX79 RU http://www.immunotechlab.com/ipf/ DMCK8SX DI DMCK8SX DMCK8SX DN MDX-1097 DMCK8SX TI TT1HM0R DMCK8SX TN Kappa myeloma antigen (KMA) DMCK8SX RN MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide. Br J Haematol. 2015 May;169(3):333-43. DMCK8SX RU https://pubmed.ncbi.nlm.nih.gov/25653020 DMCKNBA DI DMCKNBA DMCKNBA DN Lufironil DMCKNBA TI TTNH25W DMCKNBA TN Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1) DMCKNBA MA Modulator DMCKNBA RN Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, Lufironil. Eur J Clin Chem Clin Biochem. 1994Jul;32(7):515-20. DMCKNBA RU https://pubmed.ncbi.nlm.nih.gov/7981331 DMCLEXM DI DMCLEXM DMCLEXM DN SAR-110894 DMCLEXM TI TT9JNIC DMCLEXM TN Histamine H3 receptor (H3R) DMCLEXM MA Antagonist DMCLEXM RN SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14. DMCLEXM RU https://pubmed.ncbi.nlm.nih.gov/22542742 DMCLT2F DI DMCLT2F DMCLT2F DN Emepepimut-S DMCLT2F TI TTBHFYQ DMCLT2F TN Mucin-1 (MUC1) DMCLT2F RN Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7. DMCLT2F RU https://pubmed.ncbi.nlm.nih.gov/21689064 DMCLWDJ DI DMCLWDJ DMCLWDJ DN Lumacaftor DMCLWDJ TI TTRLZHP DMCLWDJ TN cAMP-dependent chloride channel (CFTR) DMCLWDJ MA Regulator DMCLWDJ RN A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38. DMCLWDJ RU https://pubmed.ncbi.nlm.nih.gov/24973281 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TTL9MHW DMCMD93 TN Vasopressin V1b receptor (V1BR) DMCMD93 MA Antagonist DMCMD93 RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TTK8R02 DMCMD93 TN Vasopressin V2 receptor (V2R) DMCMD93 MA Inhibitor DMCMD93 RN Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/19800231 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TTSCIUP DMCMD93 TN Oxytocin receptor (OTR) DMCMD93 MA Inhibitor DMCMD93 RN Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/19800231 DMCMD93 DI DMCMD93 DMCMD93 DN SSR149415 DMCMD93 TI TT4TFGN DMCMD93 TN Vasopressin V1a receptor (V1AR) DMCMD93 MA Inhibitor DMCMD93 RN Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22. DMCMD93 RU https://pubmed.ncbi.nlm.nih.gov/19800231 DMCN4H6 DI DMCN4H6 DMCN4H6 DN Flezelastine DMCN4H6 TI TTEWNM1 DMCN4H6 TN IL-1 synthesis/release (IL-1 synth/rele) DMCN4H6 MA Modulator DMCN4H6 RN Effects of flezelastine and its enantiomers on LPS-induced IL-1 beta generation in vitro and LPS-induced pyrexia in vivo. Agents Actions. 1994 Mar;41(1-2):99-100. DMCN4H6 RU https://pubmed.ncbi.nlm.nih.gov/7915872 DMCN9GX DI DMCN9GX DMCN9GX DN CVX-045 DMCN9GX TI TTKI0H1 DMCN9GX TN Thrombospondin-1 (THBS1) DMCN9GX MA Agonist DMCN9GX RN Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. Transl Oncol. 2011 Aug;4(4):249-57. DMCN9GX RU https://pubmed.ncbi.nlm.nih.gov/21804921 DMCNL7Z DI DMCNL7Z DMCNL7Z DN MT-3724 DMCNL7Z TI TTUE541 DMCNL7Z TN Leukocyte surface antigen Leu-16 (CD20) DMCNL7Z MA Inhibitor DMCNL7Z RN Clinical pipeline report, company report or official report of Molecular Templates. DMCNL7Z RU https://www.mtem.com/pipeline/mt-3724 DMCNTFW DI DMCNTFW DMCNTFW DN Ad-RTS-hIL-12 DMCNTFW TI TTG68FB DMCNTFW TN Interleukine 12 (IL-12) DMCNTFW MA Replacement DMCNTFW RN Clinical pipeline report, company report or official report of Ziopharm Oncology. DMCNTFW RU https://ziopharm.com/controlled-il-12/ DMCO8UZ DI DMCO8UZ DMCO8UZ DN KP-496 DMCO8UZ TI TTGKOY9 DMCO8UZ TN Leukotriene CysLT1 receptor (CYSLTR1) DMCO8UZ MA Modulator DMCO8UZ RN Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10. DMCO8UZ RU https://pubmed.ncbi.nlm.nih.gov/17130683 DMCO8UZ DI DMCO8UZ DMCO8UZ DN KP-496 DMCO8UZ TI TT2O84V DMCO8UZ TN Thromboxane A2 receptor (TBXA2R) DMCO8UZ MA Modulator DMCO8UZ RN Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10. DMCO8UZ RU https://pubmed.ncbi.nlm.nih.gov/17130683 DMCPUKG DI DMCPUKG DMCPUKG DN BAY 85-8501 DMCPUKG TI TTPLTSQ DMCPUKG TN Neutrophil elastase (NE) DMCPUKG MA Modulator DMCPUKG RN Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 5-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem. 2015 Jul;10(7):1163-73. DMCPUKG RU https://pubmed.ncbi.nlm.nih.gov/26083237 DMCQARM DI DMCQARM DMCQARM DN TTP889 DMCQARM TI TTFEZ5Q DMCQARM TN Coagulation factor IX (F9) DMCQARM MA Inhibitor DMCQARM RN Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008 Mar;6(3):457-63. DMCQARM RU https://pubmed.ncbi.nlm.nih.gov/18088349 DMCQARM DI DMCQARM DMCQARM DN TTP889 DMCQARM TI TTUPB12 DMCQARM TN Measles virus Fusion glycoprotein (MeV F) DMCQARM MA Inhibitor DMCQARM RN Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17. DMCQARM RU https://pubmed.ncbi.nlm.nih.gov/19453286 DMCQBFT DI DMCQBFT DMCQBFT DN Parthenolide DMCQBFT TI TTJ3E9X DMCQBFT TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMCQBFT MA Inhibitor DMCQBFT RN The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol. 2001 Aug;8(8):759-66. DMCQBFT RU https://pubmed.ncbi.nlm.nih.gov/11514225 DMCQBFT DI DMCQBFT DMCQBFT DN Parthenolide DMCQBFT TI TTSXVID DMCQBFT TN Nuclear factor NF-kappa-B (NFKB) DMCQBFT MA Inhibitor DMCQBFT RN Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15. DMCQBFT RU https://pubmed.ncbi.nlm.nih.gov/15630139 DMCQL5I DI DMCQL5I DMCQL5I DN DE-110 DMCQL5I TI TTYRL6O DMCQL5I TN Glucocorticoid receptor (NR3C1) DMCQL5I MA Agonist DMCQL5I RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031667) DMCQL5I RU http://adisinsight.springer.com/drugs/800031667 DMCSGJ2 DI DMCSGJ2 DMCSGJ2 DN BAY1163877 DMCSGJ2 TI TT0LF7H DMCSGJ2 TN Fibroblast growth factor receptor (FGFR) DMCSGJ2 MA Antagonist DMCSGJ2 RN Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739. DMCSGJ2 RU http://cancerres.aacrjournals.org/content/74/19_Supplement/1739 DMCSN69 DI DMCSN69 DMCSN69 DN PT2385 DMCSN69 TI TTWPA54 DMCSN69 TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMCSN69 MA Inhibitor DMCSN69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCSN69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCSN69 DI DMCSN69 DMCSN69 DN PT2385 DMCSN69 TI TTSN6QU DMCSN69 TN HIF1-alpha messenger RNA (HIF1A mRNA) DMCSN69 MA Inhibitor DMCSN69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCSN69 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCSN69 DI DMCSN69 DMCSN69 DN PT2385 DMCSN69 TI TTDMLNT DMCSN69 TN Hypoxia-inducible factor 2 alpha (HIF-2A) DMCSN69 MA Inhibitor DMCSN69 RN Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236. DMCSN69 RU https://pubmed.ncbi.nlm.nih.gov/30089425 DMCSR8I DI DMCSR8I DMCSR8I DN Recoflavone DMCSR8I TI TTSXVID DMCSR8I TN Nuclear factor NF-kappa-B (NFKB) DMCSR8I MA Modulator DMCSR8I RN DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91. DMCSR8I RU https://pubmed.ncbi.nlm.nih.gov/18222973 DMCSXI4 DI DMCSXI4 DMCSXI4 DN Elezanumab DMCSXI4 TI TTURJV4 DMCSXI4 TN Repulsive guidance molecule A (RGMA) DMCSXI4 MA Inhibitor DMCSXI4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCSXI4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCT08V DI DMCT08V DMCT08V DN Domagrozumab DMCT08V TI TTSWPH8 DMCT08V TN Growth/differentiation factor 8 (GDF-8) DMCT08V MA Inhibitor DMCT08V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCT08V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCT1RQ DI DMCT1RQ DMCT1RQ DN LFG-316 DMCT1RQ TI TTKANGO DMCT1RQ TN Complement C5 (CO5) DMCT1RQ RN Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29. DMCT1RQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017905/ DMCT8EY DI DMCT8EY DMCT8EY DN Cenderitide DMCT8EY TI TTJME02 DMCT8EY TN Atrial natriuretic peptide receptor A (NPR1) DMCT8EY MA Agonist DMCT8EY RN 2011 Pipeline of Nile Therapeutics. DMCT8EY RU http://www.nilethera.com/pipeline.html DMCTWIB DI DMCTWIB DMCTWIB DN AL102 DMCTWIB TI TT9W8GU DMCTWIB TN Gamma-secretase (GS) DMCTWIB MA Inhibitor DMCTWIB RN Clinical pipeline report, company report or official report of Ayala Pharmaceuticals. DMCTWIB RU https://www.ayalapharma.com/pipeline/investigational-therapies-al101-and-al102 DMCU74R DI DMCU74R DMCU74R DN Daporinad DMCU74R TI TTD1WIG DMCU74R TN Nicotinamide phosphoribosyltransferase (NAMPT) DMCU74R MA Inhibitor DMCU74R RN Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. DMCU74R RU https://pubmed.ncbi.nlm.nih.gov/18201551 DMCUGI8 DI DMCUGI8 DMCUGI8 DN ONO-AE1-437 DMCUGI8 TI TT79WV3 DMCUGI8 TN Prostaglandin E2 receptor EP4 (PTGER4) DMCUGI8 MA Agonist DMCUGI8 RN An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90. DMCUGI8 RU https://pubmed.ncbi.nlm.nih.gov/15295094 DMCV602 DI DMCV602 DMCV602 DN LY2523355 DMCV602 TI TTTRP0H DMCV602 TN Kinesin-like protein KIF11 (KIF11) DMCV602 MA Modulator DMCV602 RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DMCV602 RU https://pubmed.ncbi.nlm.nih.gov/22825217 DMCXNIP DI DMCXNIP DMCXNIP DN MORAb-009 DMCXNIP TI TT4RXME DMCXNIP TN Mesothelin (MSLN) DMCXNIP RN Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 1;20(23):5927-36. DMCXNIP RU https://pubmed.ncbi.nlm.nih.gov/25231400 DMCXRZF DI DMCXRZF DMCXRZF DN LY2603618 DMCXRZF TI TTTU902 DMCXRZF TN Checkpoint kinase-1 (CHK1) DMCXRZF MA Modulator DMCXRZF RN Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26. DMCXRZF RU https://pubmed.ncbi.nlm.nih.gov/24114124 DMCY785 DI DMCY785 DMCY785 DN SB-656933 DMCY785 TI TT30C9G DMCY785 TN C-X-C chemokine receptor type 2 (CXCR2) DMCY785 MA Antagonist DMCY785 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMCY785 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMCY9PO DI DMCY9PO DMCY9PO DN Itarnafloxin DMCY9PO TI TTCSZH7 DMCY9PO TN Nucleolin (NCL) DMCY9PO MA Inhibitor DMCY9PO RN Targeting G-quadruplexes in gene promoters: a novel anticancer strategy . Nat Rev Drug Discov. 2011 April; 10(4): 261-275. DMCY9PO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119469/ DMCZFMS DI DMCZFMS DMCZFMS DN ABX-IL8 DMCZFMS TI TTCTE1G DMCZFMS TN Interleukin-8 (IL8) DMCZFMS RN Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002 Jul;161(1):125-34. DMCZFMS RU https://pubmed.ncbi.nlm.nih.gov/12107097 DMCZH5B DI DMCZH5B DMCZH5B DN GS-9256 DMCZH5B TI TT5FNQT DMCZH5B TN Human immunodeficiency virus Protease (HIV PR) DMCZH5B MA Inhibitor DMCZH5B RN Clinical pipeline report, company report or official report of Gilead (2011). DMCZH5B RU http://www.gilead.com/ DMD09CT DI DMD09CT DMD09CT DN LY-362884 DMD09CT TI TTMXGCW DMD09CT TN Adrenergic receptor beta-3 (ADRB3) DMD09CT MA Agonist DMD09CT RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMD09CT RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMD0E8U DI DMD0E8U DMD0E8U DN Naveglitazar DMD0E8U TI TTZMAO3 DMD0E8U TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMD0E8U MA Modulator DMD0E8U RN The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61. DMD0E8U RU https://pubmed.ncbi.nlm.nih.gov/17012539 DMD0E8U DI DMD0E8U DMD0E8U DN Naveglitazar DMD0E8U TI TTJ584C DMD0E8U TN Peroxisome proliferator-activated receptor alpha (PPARA) DMD0E8U MA Modulator DMD0E8U RN The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats... Drug Metab Dispos. 2007 Jan;35(1):51-61. DMD0E8U RU https://pubmed.ncbi.nlm.nih.gov/17012539 DMD0I29 DI DMD0I29 DMD0I29 DN ATL-104 DMD0I29 TI TTDB5IS DMD0I29 TN Receptor unspecific (Rec) DMD0I29 MA Modulator DMD0I29 RN Treatment of oral mucositis after peripheral blood SCT with ATL-104 mouthwash: results from a randomized, double-blind, placebo-controlled trial. Bone Marrow Transplant. 2009 Apr;43(7):563-9. DMD0I29 RU https://pubmed.ncbi.nlm.nih.gov/18997832 DMD275X DI DMD275X DMD275X DN Pardoprunox DMD275X TI TTEX248 DMD275X TN Dopamine D2 receptor (D2R) DMD275X MA Agonist DMD275X RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMD275X RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMD2RFO DI DMD2RFO DMD2RFO DN AQW-051 DMD2RFO TI TTLA931 DMD2RFO TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMD2RFO MA Agonist DMD2RFO RN AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23. DMD2RFO RU https://pubmed.ncbi.nlm.nih.gov/25172125 DMD3RU8 DI DMD3RU8 DMD3RU8 DN GFT14 DMD3RU8 TI TTJ584C DMD3RU8 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMD3RU8 MA Agonist DMD3RU8 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024296) DMD3RU8 RU http://adisinsight.springer.com/drugs/800024296 DMD3WNP DI DMD3WNP DMD3WNP DN RO5520985 DMD3WNP TI TTOHSBA DMD3WNP TN Vascular endothelial growth factor A (VEGFA) DMD3WNP MA Modulator DMD3WNP RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMD3WNP RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMD3WNP DI DMD3WNP DMD3WNP DN RO5520985 DMD3WNP TI TTKLQTJ DMD3WNP TN Angiopoietin-2 (ANGPT2) DMD3WNP MA Modulator DMD3WNP RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMD3WNP RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMD3XMG DI DMD3XMG DMD3XMG DN AFTVac DMD3XMG TI TT6MP2Z DMD3XMG TN GMCSFR-alpha (CSF2RA) DMD3XMG RN Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9. DMD3XMG RU https://pubmed.ncbi.nlm.nih.gov/15014006 DMD3XMG DI DMD3XMG DMD3XMG DN AFTVac DMD3XMG TI TT9721Y DMD3XMG TN Interleukin 2 receptor beta (IL2RB) DMD3XMG RN Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res. 2004 Mar 1;10(5):1574-9. DMD3XMG RU https://pubmed.ncbi.nlm.nih.gov/15014006 DMD4KAU DI DMD4KAU DMD4KAU DN LIRIMILAST DMD4KAU TI TTVIAT9 DMD4KAU TN Phosphodiesterase 4B (PDE4B) DMD4KAU MA Inhibitor DMD4KAU RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMD4KAU RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMD4KAU DI DMD4KAU DMD4KAU DN LIRIMILAST DMD4KAU TI TTSKMI8 DMD4KAU TN Phosphodiesterase 4D (PDE4D) DMD4KAU MA Inhibitor DMD4KAU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMD4KAU RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMD4KAU DI DMD4KAU DMD4KAU DN LIRIMILAST DMD4KAU TI TTZ97H5 DMD4KAU TN Phosphodiesterase 4A (PDE4A) DMD4KAU MA Inhibitor DMD4KAU RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMD4KAU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMD4OK0 DI DMD4OK0 DMD4OK0 DN K-134 DMD4OK0 TI TTZCG4L DMD4OK0 TN Phosphodiesterase 3 (PDE3) DMD4OK0 MA Modulator DMD4OK0 RN A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication. J Vasc Surg. 2012 Feb;55(2):381-389.e1. DMD4OK0 RU https://pubmed.ncbi.nlm.nih.gov/22119244 DMD4YRG DI DMD4YRG DMD4YRG DN EQ-917 DMD4YRG TI TTGTQHC DMD4YRG TN DNA topoisomerase I (TOP1) DMD4YRG MA Inhibitor DMD4YRG RN The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J Chemother. 2010 Jun;22(3):197-200. DMD4YRG RU https://pubmed.ncbi.nlm.nih.gov/20566426 DMD51RN DI DMD51RN DMD51RN DN TAK-448 DMD51RN TI TTU2O6T DMD51RN TN Metastasis-suppressor KiSS-1 (KISS1) DMD51RN MA Modulator DMD51RN RN Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.Eur J Pharmacol.2014 Jul 15;735:77-85. DMD51RN RU https://www.ncbi.nlm.nih.gov/pubmed/24747751 DMD6E5W DI DMD6E5W DMD6E5W DN MK-8342 DMD6E5W TI TTUV8G9 DMD6E5W TN Progesterone receptor (PGR) DMD6E5W MA Agonist DMD6E5W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627). DMD6E5W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627 DMD72F4 DI DMD72F4 DMD72F4 DN T-817MA DMD72F4 TI TTV0YFR DMD72F4 TN Lipid peroxidation (LPO) DMD72F4 MA Modulator DMD72F4 RN A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. Neuropharmacology. 2008 Oct;55(5):654-60. DMD72F4 RU https://pubmed.ncbi.nlm.nih.gov/18573265 DMD72F4 DI DMD72F4 DMD72F4 DN T-817MA DMD72F4 TI TTE4KHA DMD72F4 TN Amyloid beta A4 protein (APP) DMD72F4 MA Inhibitor DMD72F4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD72F4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMD74BJ DI DMD74BJ DMD74BJ DN PF-05089771 DMD74BJ TI TT4G2JS DMD74BJ TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMD74BJ MA Blocker DMD74BJ RN Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127. DMD74BJ RU https://pubmed.ncbi.nlm.nih.gov/26419464 DMD8GNB DI DMD8GNB DMD8GNB DN BXT-51072 DMD8GNB TI TTF10I9 DMD8GNB TN Nitric-oxide synthase inducible (NOS2) DMD8GNB MA Modulator DMD8GNB RN Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8. DMD8GNB RU https://pubmed.ncbi.nlm.nih.gov/11078703 DMD8RU0 DI DMD8RU0 DMD8RU0 DN SEphB4-HSA DMD8RU0 TI TTKPV6O DMD8RU0 TN Ephrin type-B receptor 2 (EPHB2) DMD8RU0 MA Inhibitor DMD8RU0 RN National Cancer Institute Drug Dictionary (drug name SEphB4-HSA). DMD8RU0 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-ephb4-hsa-fusion-protein DMD8XOY DI DMD8XOY DMD8XOY DN S-38093 DMD8XOY TI TT9JNIC DMD8XOY TN Histamine H3 receptor (H3R) DMD8XOY MA Antagonist DMD8XOY RN Histamine H3 Receptors and Sleep-Wake Regulation. JPET January 2011 vol. 336 no. 1 17-23. DMD8XOY RU http://jpet.aspetjournals.org/content/336/1/17.full DMD9KYF DI DMD9KYF DMD9KYF DN LY3023414 DMD9KYF TI TTCJG29 DMD9KYF TN Serine/threonine-protein kinase mTOR (mTOR) DMD9KYF MA Modulator DMD9KYF RN Company report (Lilly) DMD9KYF RU http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx DMD9KYF DI DMD9KYF DMD9KYF DN LY3023414 DMD9KYF TI TTEUNMR DMD9KYF TN PI3-kinase alpha (PIK3CA) DMD9KYF MA Modulator DMD9KYF RN Company report (Lilly) DMD9KYF RU http://www.lillyoncologypipeline.com/pi3kmtor-dual-inhibitor.aspx DMD9RV3 DI DMD9RV3 DMD9RV3 DN INCB039110 DMD9RV3 TI TTRMX3V DMD9RV3 TN Janus kinase 2 (JAK-2) DMD9RV3 MA Inhibitor DMD9RV3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). DMD9RV3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048 DMD9RV3 DI DMD9RV3 DMD9RV3 DN INCB039110 DMD9RV3 TI TT6DM01 DMD9RV3 TN Janus kinase 1 (JAK-1) DMD9RV3 MA Inhibitor DMD9RV3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047). DMD9RV3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2047 DMDAHL6 DI DMDAHL6 DMDAHL6 DN GS-5806 DMDAHL6 TI TT57ID8 DMDAHL6 TN Respiratory syncytial virus protein F (RSV F) DMDAHL6 MA Inhibitor DMDAHL6 RN Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-43. DMDAHL6 RU https://pubmed.ncbi.nlm.nih.gov/25574686 DMDAKZW DI DMDAKZW DMDAKZW DN Vacc-4x DMDAKZW TI TTTWS2G DMDAKZW TN Human immunodeficiency virus Capsid p24 (HIV p24) DMDAKZW RN Clinical pipeline report, company report or official report of Bionor Pharma. DMDAKZW RU http://www.bionorpharma.com/en/News/2011/Scientific/Vacc-4x+results+presented+in+Bangkok.b7C_wljS1c.ips DMDB4EJ DI DMDB4EJ DMDB4EJ DN Tarafenacin DMDB4EJ TI TTQ13Z5 DMDB4EJ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMDB4EJ MA Antagonist DMDB4EJ RN In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17. DMDB4EJ RU https://pubmed.ncbi.nlm.nih.gov/19222482 DMDEL3F DI DMDEL3F DMDEL3F DN EMZ701 DMDEL3F TI TTSYFMA DMDEL3F TN Interferon alpha/beta receptor 1 (IFNAR1) DMDEL3F MA Modulator DMDEL3F RN Patent EP2766021 A1. DMDEL3F RU http://www.google.com/patents/EP2766021A1?cl=en DMDF7XB DI DMDF7XB DMDF7XB DN SYN120 DMDF7XB TI TTJS8PY DMDF7XB TN 5-HT 6 receptor (HTR6) DMDF7XB MA Antagonist DMDF7XB RN Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822. DMDF7XB RU https://pubmed.ncbi.nlm.nih.gov/30262889 DMDF7XB DI DMDF7XB DMDF7XB DN SYN120 DMDF7XB TI TTJQOD7 DMDF7XB TN 5-HT 2A receptor (HTR2A) DMDF7XB MA Antagonist DMDF7XB RN Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822. DMDF7XB RU https://pubmed.ncbi.nlm.nih.gov/30262889 DMDFZK8 DI DMDFZK8 DMDFZK8 DN LY3113593 DMDFZK8 TI TT07RIB DMDFZK8 TN Bone morphogenetic protein 6 (BMP6) DMDFZK8 MA Inhibitor DMDFZK8 RN Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol. 2019 May;85(5):935-948. DMDFZK8 RU https://pubmed.ncbi.nlm.nih.gov/30677788 DMDGPKS DI DMDGPKS DMDGPKS DN RG7625 DMDGPKS TI TTUMQVO DMDGPKS TN Cathepsin S (CTSS) DMDGPKS MA Antagonist DMDGPKS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDGPKS RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMDGZ1C DI DMDGZ1C DMDGZ1C DN FE-202767 DMDGZ1C TI TTSCIUP DMDGZ1C TN Oxytocin receptor (OTR) DMDGZ1C MA Agonist DMDGZ1C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369). DMDGZ1C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369 DMDI43Y DI DMDI43Y DMDI43Y DN BGB-324 DMDI43Y TI TTZPY6J DMDI43Y TN Tyrosine-protein kinase UFO (AXL) DMDI43Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1835). DMDI43Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1835 DMDJRU1 DI DMDJRU1 DMDJRU1 DN MM-121 DMDJRU1 TI TTDC8N2 DMDJRU1 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMDJRU1 MA Modulator DMDJRU1 RN Company report (Merrimack) DMDJRU1 RU http://investors.merrimack.com/releasedetail.cfm?releaseid=897168 DMDJUWG DI DMDJUWG DMDJUWG DN DLX-105 DMDJUWG TI TTF8CQI DMDJUWG TN Tumor necrosis factor (TNF) DMDJUWG RN Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element binding protein. Mol Pharmacol. 2003 Mar;63(3):690-8. DMDJUWG RU https://pubmed.ncbi.nlm.nih.gov/12606779 DMDK0HX DI DMDK0HX DMDK0HX DN INCB54707 DMDK0HX TI TT6DM01 DMDK0HX TN Janus kinase 1 (JAK-1) DMDK0HX MA Inhibitor DMDK0HX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDK0HX RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMDK7CL DI DMDK7CL DMDK7CL DN AN-2898 DMDK7CL TI TTSKMI8 DMDK7CL TN Phosphodiesterase 4D (PDE4D) DMDK7CL MA Inhibitor DMDK7CL RN An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. DMDK7CL RU https://pubmed.ncbi.nlm.nih.gov/23625818 DMDK7CL DI DMDK7CL DMDK7CL DN AN-2898 DMDK7CL TI TTVIAT9 DMDK7CL TN Phosphodiesterase 4B (PDE4B) DMDK7CL MA Inhibitor DMDK7CL RN An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. DMDK7CL RU https://pubmed.ncbi.nlm.nih.gov/23625818 DMDK7CL DI DMDK7CL DMDK7CL DN AN-2898 DMDK7CL TI TTZ97H5 DMDK7CL TN Phosphodiesterase 4A (PDE4A) DMDK7CL MA Inhibitor DMDK7CL RN An assessment of the genetic toxicology of novel boron-containing therapeutic agents. Environ Mol Mutagen. 2013 Jun;54(5):338-46. DMDK7CL RU https://pubmed.ncbi.nlm.nih.gov/23625818 DMDKRS3 DI DMDKRS3 DMDKRS3 DN Antistasin DMDKRS3 TI TTCIHJA DMDKRS3 TN Coagulation factor Xa (F10) DMDKRS3 MA Inhibitor DMDKRS3 RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DMDKRS3 RU https://pubmed.ncbi.nlm.nih.gov/11804648 DMDKWA3 DI DMDKWA3 DMDKWA3 DN Vx-001 DMDKWA3 TI TTUJFD0 DMDKWA3 TN Telomerase reverse transcriptase (TERT) DMDKWA3 RN Clinical pipeline report, company report or official report of Vaxon-biotech. DMDKWA3 RU http://vaxon-biotech.com/ DMDL9WU DI DMDL9WU DMDL9WU DN AV-201 DMDL9WU TI TTN451K DMDL9WU TN Aromatic-L-amino-acid decarboxylase (DDC) DMDL9WU MA Modulator DMDL9WU RN UCSF report DMDL9WU RU http://pdcenter.neurology.ucsf.edu/research/learn-about-closed-studies/gene-therapy-aadc-phase-i DMDLOBZ DI DMDLOBZ DMDLOBZ DN Selinexor oral DMDLOBZ TI TTCJUR4 DMDLOBZ TN Exportin-1 (XPO1) DMDLOBZ MA Inhibitor DMDLOBZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDLOBZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMDMQW0 DI DMDMQW0 DMDMQW0 DN SAR-100842 DMDMQW0 TI TTQ6S1K DMDMQW0 TN Lysophosphatidic acid receptor 1 (LPAR1) DMDMQW0 MA Modulator DMDMQW0 RN Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11. DMDMQW0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/ DMDMQW0 DI DMDMQW0 DMDMQW0 DN SAR-100842 DMDMQW0 TI TTE2YJR DMDMQW0 TN Lysophosphatidate-3 receptor (LPAR3) DMDMQW0 MA Modulator DMDMQW0 RN Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11. DMDMQW0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286743/ DMDMXKQ DI DMDMXKQ DMDMXKQ DN GSK1292263 DMDMXKQ TI TT7QNVC DMDMXKQ TN Glucose-dependent insulinotropic receptor (GPR119) DMDMXKQ MA Modulator DMDMXKQ RN Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494. DMDMXKQ RU https://www.ncbi.nlm.nih.gov/pubmed/24699248 DMDN6FO DI DMDN6FO DMDN6FO DN MVI-816 DMDN6FO TI TTBRZQS DMDN6FO TN Prostatic acid phosphatase (ACPP) DMDN6FO MA Modulator DMDN6FO RN Company report (Madisonvaccine) DMDN6FO RU http://www.madisonvaccinesinc.com/Home/News DMDNHRA DI DMDNHRA DMDNHRA DN Ilodecakin DMDNHRA TI TTT0Q1F DMDNHRA TN Interleukin-10 (IL10) DMDNHRA MA Modulator DMDNHRA RN Ilodecakin. Schering-Plough Corp. IDrugs. 1999 Oct;2(10):1045-58. DMDNHRA RU https://pubmed.ncbi.nlm.nih.gov/16118714 DMDNJ18 DI DMDNJ18 DMDNJ18 DN F-627 DMDNJ18 TI TT5TQ2W DMDNJ18 TN Granulocyte colony-stimulating factor (CSF3) DMDNJ18 MA Modulator DMDNJ18 RN Clinical pipeline report, company report or official report of Generon (Shanghai) Corporation Ltd. DMDNJ18 RU http://www.generonbiomed.com/html/en/index.php?ac=article&at=list&tid=29 DMDNRU1 DI DMDNRU1 DMDNRU1 DN RNS-60 DMDNRU1 TI TTO7FVG DMDNRU1 TN Heat shock protein 90 (HSP90) DMDNRU1 MA Modulator DMDNRU1 RN Clinical pipeline report, company report or official report of Revalesio. DMDNRU1 RU http://revalesio.com/about-our-technology/ DMDPBMH DI DMDPBMH DMDPBMH DN TB-403 DMDPBMH TI TT48I1Y DMDPBMH TN Placenta growth factor (PlGF) DMDPBMH MA Inhibitor DMDPBMH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDPBMH RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMDPFTB DI DMDPFTB DMDPFTB DN V-101 DMDPFTB TI TT2NUT5 DMDPFTB TN Adrenergic receptor alpha-2C (ADRA2C) DMDPFTB MA Agonist DMDPFTB RN Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012 Dec;17(10):1-4. DMDPFTB RU https://pubmed.ncbi.nlm.nih.gov/23223767 DMDPLEM DI DMDPLEM DMDPLEM DN BMS-184476 DMDPLEM TI TTML2WA DMDPLEM TN Tubulin (TUB) DMDPLEM MA Inhibitor DMDPLEM RN Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days. Br J Cancer. 2004 July 19; 91(2): 213-218. DMDPLEM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409820/ DMDPNCJ DI DMDPNCJ DMDPNCJ DN IMO-8400 DMDPNCJ TI TTOK0LR DMDPNCJ TN Toll-like receptor (TLR) DMDPNCJ MA Antagonist DMDPNCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDPNCJ RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMDPQV5 DI DMDPQV5 DMDPQV5 DN BMS-599626 DMDPQV5 TI TTGKNB4 DMDPQV5 TN Epidermal growth factor receptor (EGFR) DMDPQV5 MA Inhibitor DMDPQV5 RN AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61. DMDPQV5 RU https://pubmed.ncbi.nlm.nih.gov/20119866 DMDPQV5 DI DMDPQV5 DMDPQV5 DN BMS-599626 DMDPQV5 TI TT6EO5L DMDPQV5 TN Erbb2 tyrosine kinase receptor (HER2) DMDPQV5 MA Inhibitor DMDPQV5 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMDPQV5 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMDQH9A DI DMDQH9A DMDQH9A DN ADL-5859 DMDQH9A TI TT27RFC DMDQH9A TN Opioid receptor delta (OPRD1) DMDQH9A MA Agonist DMDQH9A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMDQH9A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMDQS4W DI DMDQS4W DMDQS4W DN ASC-J9 DMDQS4W TI TTS64P2 DMDQS4W TN Androgen receptor (AR) DMDQS4W MA Inhibitor DMDQS4W RN New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol. 2013 Feb;182(2):460-73. DMDQS4W RU https://pubmed.ncbi.nlm.nih.gov/23219429 DMDR2SZ DI DMDR2SZ DMDR2SZ DN MCT-125 DMDR2SZ TI TTAWNKZ DMDR2SZ TN Norepinephrine transporter (NET) DMDR2SZ MA Inhibitor DMDR2SZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DMDR2SZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DMDS20X DI DMDS20X DMDS20X DN Enoblituzumab DMDS20X TI TT6CQUM DMDS20X TN B7 homolog 3 (CD276) DMDS20X MA Inhibitor DMDS20X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDS20X RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMDSNIR DI DMDSNIR DMDSNIR DN BBI503 DMDSNIR TI TTPV9O1 DMDSNIR TN Cancer stemness kinase (CSK) DMDSNIR MA Inhibitor DMDSNIR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDSNIR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDSNIR DI DMDSNIR DMDSNIR DN BBI503 DMDSNIR TI TTPMIQ9 DMDSNIR TN Serine/threonine-protein kinase (STK) DMDSNIR MA Inhibitor DMDSNIR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDSNIR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDTI0L DI DMDTI0L DMDTI0L DN Masilukast DMDTI0L TI TTGKOY9 DMDTI0L TN Leukotriene CysLT1 receptor (CYSLTR1) DMDTI0L MA Modulator DMDTI0L RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDTI0L RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDTNOS DI DMDTNOS DMDTNOS DN NNC-0123-0000-0338 DMDTNOS TI TTZOPHG DMDTNOS TN Insulin (INS) DMDTNOS MA Modulator DMDTNOS RN ClinicalTrials.gov (NCT01334034) Safety of NNC 0123-0000-0338 in Healthy Subjects. U.S. National Institutes of Health. DMDTNOS RU https://clinicaltrials.gov/ct2/show/NCT01334034 DMDUV1S DI DMDUV1S DMDUV1S DN DOLASTATIN-10 DMDUV1S TI TTML2WA DMDUV1S TN Tubulin (TUB) DMDUV1S MA Inhibitor DMDUV1S RN Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30. DMDUV1S RU https://pubmed.ncbi.nlm.nih.gov/9554885 DMDUV1S DI DMDUV1S DMDUV1S DN DOLASTATIN-10 DMDUV1S TI TTYFKSZ DMDUV1S TN Tubulin beta (TUBB) DMDUV1S MA Inhibitor DMDUV1S RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMDUV1S RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMDUV1S DI DMDUV1S DMDUV1S DN DOLASTATIN-10 DMDUV1S TI TTJ2PTI DMDUV1S TN Tubulin beta-2 chain (TUBB2) DMDUV1S MA Inhibitor DMDUV1S RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMDUV1S RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTVWAGF DMDUVCZ TN MHC class I NK cell receptor 2DS1 (CD158h) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TT4UXPE DMDUVCZ TN MHC class I NK cell receptor 2DL1 (CD158A) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTU0P73 DMDUVCZ TN MHC class I NK cell receptor 2DL2 (CD158b1) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTEX3SI DMDUVCZ TN MHC class I NK cell receptor 2DL3 (CD158b2) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDUVCZ DI DMDUVCZ DMDUVCZ DN IPH-2101 DMDUVCZ TI TTV3CFI DMDUVCZ TN MHC class I NK cell receptor 2DS2 (CD158j) DMDUVCZ MA Modulator DMDUVCZ RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMDUVCZ RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMDV8MK DI DMDV8MK DMDV8MK DN CALDARET HYDRATE DMDV8MK TI TT619TC DMDV8MK TN Sodium/calcium exchanger (SLC) DMDV8MK MA Modulator DMDV8MK RN Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. J Pharmacol Sci. 2007 Feb;103(2):222-33. DMDV8MK RU https://pubmed.ncbi.nlm.nih.gov/17299242 DMDW5ZC DI DMDW5ZC DMDW5ZC DN SER-100 DMDW5ZC TI TTNT7K8 DMDW5ZC TN Nociceptin receptor (OPRL1) DMDW5ZC MA Agonist DMDW5ZC RN Clinical pipeline report, company report or official report of Serodus ASA. DMDW5ZC RU http://www.serodus.com/Pipeline/SER100TRISH DMDWG36 DI DMDWG36 DMDWG36 DN Codrituzumab DMDWG36 TI TTJTSX4 DMDWG36 TN Glypican-3 (GPC3) DMDWG36 MA Inhibitor DMDWG36 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDWG36 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMDWP0U DI DMDWP0U DMDWP0U DN BTA-798 DMDWP0U TI TT8R3VP DMDWP0U TN Rhinovirus Capsid protein (HRV VP) DMDWP0U MA Inhibitor DMDWP0U RN Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol. 2012 Jan 15;83(2):185-92. DMDWP0U RU https://pubmed.ncbi.nlm.nih.gov/21889497 DMDWYZS DI DMDWYZS DMDWYZS DN GTx-758 DMDWYZS TI TTZAYWL DMDWYZS TN Estrogen receptor (ESR) DMDWYZS MA Modulator DMDWYZS RN Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334-41. DMDWYZS RU https://pubmed.ncbi.nlm.nih.gov/24968970 DMDY01J DI DMDY01J DMDY01J DN NHS-IL2-LT DMDY01J TI TTUTN1I DMDY01J TN Human Deoxyribonucleic acid (hDNA) DMDY01J MA Modulator DMDY01J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDY01J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDYVN8 DI DMDYVN8 DMDYVN8 DN MEDI-528 DMDYVN8 TI TT0JTFD DMDYVN8 TN Interleukin-9 (IL9) DMDYVN8 MA Inhibitor DMDYVN8 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMDYVN8 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMDYWM8 DI DMDYWM8 DMDYWM8 DN E-10030 DMDYWM8 TI TTQA6SX DMDYWM8 TN Platelet-derived growth factor B (PDGFB) DMDYWM8 MA Antagonist DMDYWM8 RN Aptamers as therapeutics. Nat Rev Drug Discov. 2010 Jul;9(7):537-50. DMDYWM8 RU https://pubmed.ncbi.nlm.nih.gov/20592747 DMDYZRS DI DMDYZRS DMDYZRS DN BPS-804 DMDYZRS TI TTYRO4F DMDYZRS TN Sclerostin (SOST) DMDYZRS RN WO patent application no. 2010,1001,79, Self-forming gel system for sustained drug delivery. DMDYZRS RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100910&CC=WO&NR=2010100179A2&KC=A2 DMDZ4R2 DI DMDZ4R2 DMDZ4R2 DN Org-30029 DMDZ4R2 TI TTZCG4L DMDZ4R2 TN Phosphodiesterase 3 (PDE3) DMDZ4R2 MA Modulator DMDZ4R2 RN Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606. DMDZ4R2 RU https://pubmed.ncbi.nlm.nih.gov/8431987 DMDZE3B DI DMDZE3B DMDZE3B DN HGT-1111 DMDZE3B TI TTYQANR DMDZE3B TN Cerebroside-sulfatase (ARSA) DMDZE3B MA Modulator DMDZE3B RN ClinicalTrials.gov (NCT00681811) Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD. U.S. National Institutes of Health. DMDZE3B RU https://clinicaltrials.gov/ct2/show/NCT00681811 DMDZWPL DI DMDZWPL DMDZWPL DN ITCA-638 DMDZWPL TI TTS2TGF DMDZWPL TN Interferon-omega (IFNW1) DMDZWPL MA Modulator DMDZWPL RN Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20. DMDZWPL RU https://pubmed.ncbi.nlm.nih.gov/19319841 DME01HT DI DME01HT DME01HT DN Fluciclatide F-18 DME01HT TI TT69TQN DME01HT TN Integrin alpha-V/beta-3 (ITGAV/B3) DME01HT MA Modulator DME01HT RN Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.J Nucl Med.2009 Jan;50(1):116-22. DME01HT RU https://www.ncbi.nlm.nih.gov/pubmed/19091899 DME0JMV DI DME0JMV DME0JMV DN AZX-100 DME0JMV TI TT5IP87 DME0JMV TN Heat shock protein 20 (HSP20) DME0JMV MA Modulator DME0JMV RN Internalization and intracellular trafficking of a PTD-conjugated anti-fibrotic peptide, AZX100, in human dermal keloid fibroblasts. J Pharm Sci. 2010 Jul;99(7):3100-21. DME0JMV RU https://pubmed.ncbi.nlm.nih.gov/20140957 DME1WV2 DI DME1WV2 DME1WV2 DN KD-7040 DME1WV2 TI TTF10I9 DME1WV2 TN Nitric-oxide synthase inducible (NOS2) DME1WV2 MA Inhibitor DME1WV2 RN WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration. DME1WV2 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140206&CC=WO&NR=2014021408A1&KC=A1 DME1YMX DI DME1YMX DME1YMX DN RG7935 DME1YMX TI TT08OSU DME1YMX TN Synuclein alpha (SNCA) DME1YMX RN alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med. 2012 February; 2(2): a009399. DME1YMX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281589/ DME25TI DI DME25TI DME25TI DN Prosaptide TX14(A) DME25TI TI TTDB5IS DME25TI TN Receptor unspecific (Rec) DME25TI MA Modulator DME25TI RN Central action of prosaptide TX14(A) against gp120-induced allodynia in rats. European Journal of Pain Volume 12, Issue 1, January 2008, Pages 76-81. DME25TI RU http://www.sciencedirect.com/science/article/pii/S1090380107000584 DME26RS DI DME26RS DME26RS DN LTB4 DME26RS TI TTN53ZF DME26RS TN Leukotriene B4 receptor 1 (LTB4R) DME26RS MA Agonist DME26RS RN LTB4 promotes insulin resistance in obese mice by acting on macrophages, hepatocytes and myocytes. Nat Med. 2015 Mar;21(3):239-47. DME26RS RU https://pubmed.ncbi.nlm.nih.gov/25706874 DME26RS DI DME26RS DME26RS DN LTB4 DME26RS TI TTVJX54 DME26RS TN Leukotriene B4 receptor 2 (LTB4R2) DME26RS MA Inhibitor DME26RS RN Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993). DME26RS RU http://www.sciencedirect.com/science/article/pii/S0960894X01810003 DME2S4D DI DME2S4D DME2S4D DN JNJ-61393215 DME2S4D TI TT60Q8D DME2S4D TN Orexin receptor type 1 (HCRTR1) DME2S4D MA Antagonist DME2S4D RN Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Transl Psychiatry. 2020 Sep 7;10(1):308. DME2S4D RU https://pubmed.ncbi.nlm.nih.gov/32895369 DME321B DI DME321B DME321B DN VX-944 DME321B TI TTCAQMW DME321B TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DME321B MA Inhibitor DME321B RN Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1;24(38):5888-96. DME321B RU https://pubmed.ncbi.nlm.nih.gov/15940263 DME321B DI DME321B DME321B DN VX-944 DME321B TI TTL7C8Q DME321B TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DME321B MA Inhibitor DME321B RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DME321B RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DME384W DI DME384W DME384W DN AdPEDR DME384W TI TTR59S1 DME384W TN Pigment epithelium-derived factor (SERPINF1) DME384W MA Inhibitor DME384W RN Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35. DME384W RU https://pubmed.ncbi.nlm.nih.gov/15757408 DME3POC DI DME3POC DME3POC DN Imisopasem manganese DME3POC TI TT9O4C5 DME3POC TN Superoxide dismutase Mn (SOD Mn) DME3POC MA Modulator DME3POC RN The manganese superoxide dismutase mimetic, M40403, protects adult mice from lethal total body irradiation. Free Radic Res. 2010 May;44(5):529-40. DME3POC RU https://pubmed.ncbi.nlm.nih.gov/20298121 DME3ZYC DI DME3ZYC DME3ZYC DN ALKS 4230 DME3ZYC TI TTAJU0S DME3ZYC TN Interleukin 2 receptor (IL2R) DME3ZYC MA Agonist DME3ZYC RN ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673. DME3ZYC RU https://pubmed.ncbi.nlm.nih.gov/32317293 DME4LA1 DI DME4LA1 DME4LA1 DN Tideglusib DME4LA1 TI TTRSMW9 DME4LA1 TN Glycogen synthase kinase-3 beta (GSK-3B) DME4LA1 MA Inhibitor DME4LA1 RN Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904. DME4LA1 RU https://pubmed.ncbi.nlm.nih.gov/22102280 DME53YS DI DME53YS DME53YS DN Sotrastaurin acetate DME53YS TI TT8QL1J DME53YS TN Protein kinase C theta (PRKCQ) DME53YS MA Inhibitor DME53YS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DME53YS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DME53YS DI DME53YS DME53YS DN Sotrastaurin acetate DME53YS TI TTYPXQF DME53YS TN Protein kinase C beta (PRKCB) DME53YS MA Inhibitor DME53YS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DME53YS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DME53YS DI DME53YS DME53YS DN Sotrastaurin acetate DME53YS TI TTFJ8Q1 DME53YS TN Protein kinase C alpha (PRKCA) DME53YS MA Inhibitor DME53YS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DME53YS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DME5CSV DI DME5CSV DME5CSV DN Mibampator DME5CSV TI TTAN6JD DME5CSV TN Glutamate receptor AMPA (GRIA) DME5CSV MA Agonist DME5CSV RN Mibampator (LY451395) Randomized Clinical Trial for Agitation/Aggression in Alzheimer's disease. Int Psychogeriatr. 2013 May; 25(5): 707-719. DME5CSV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938603/ DME6I03 DI DME6I03 DME6I03 DN VDA-1102 DME6I03 TI TTJLNAW DME6I03 TN Tissue kallikrein (KLK2) DME6I03 MA Modulator DME6I03 RN Clinical pipeline report, company report or official report of Vidac Pharma. DME6I03 RU http://www.vidacpharma.com/vda-1102-iv-vidac-pharma DME6I03 DI DME6I03 DME6I03 DN VDA-1102 DME6I03 TI TTPZI04 DME6I03 TN Voltage-dependent anion channel (VDAC) DME6I03 MA Modulator DME6I03 RN Clinical pipeline report, company report or official report of Vidac Pharma. DME6I03 RU http://www.vidacpharma.com/vda-1102-iv-vidac-pharma DME6KAF DI DME6KAF DME6KAF DN NPC-15199 DME6KAF TI TTW6MKR DME6KAF TN Calcium release (Ca rele) DME6KAF MA Modulator DME6KAF RN NPC-15199, a novel anti-inflammatory agent, mobilizes intracellular Ca2+ in bladder female transitional carcinoma (BFTC) cells. Chin J Physiol. 2000 Mar 31;43(1):29-33. DME6KAF RU https://pubmed.ncbi.nlm.nih.gov/10857466 DME6QH1 DI DME6QH1 DME6QH1 DN AMG 557 DME6QH1 TI TTB9Z8R DME6QH1 TN B7-related protein 1 (B7RP1) DME6QH1 MA Modulator DME6QH1 RN Administration Of AMG 557, A Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study. San Diego, CA October 25-30, 2013 DME6QH1 RU http://www.blackwellpublishing.com/acrmeeting/abstract.asp?MeetingID=799&id=109110 DME6X27 DI DME6X27 DME6X27 DN UR-63325 DME6X27 TI TTXJ178 DME6X27 TN Histamine H4 receptor (H4R) DME6X27 MA Antagonist DME6X27 RN Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012 Jan 1;4:967-87. DME6X27 RU https://pubmed.ncbi.nlm.nih.gov/22202103 DME71WA DI DME71WA DME71WA DN Q301 DME71WA TI TT2J34L DME71WA TN Arachidonate 5-lipoxygenase (5-LOX) DME71WA MA Inhibitor DME71WA RN Clinical pipeline report, company report or official report of Qurient. DME71WA RU http://www.qurient.com/bbs/content.php?co_id=q301 DME7VZD DI DME7VZD DME7VZD DN Vilaprisan DME7VZD TI TTUV8G9 DME7VZD TN Progesterone receptor (PGR) DME7VZD MA Antagonist DME7VZD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033939) DME7VZD RU http://adisinsight.springer.com/drugs/800033939 DME8ARP DI DME8ARP DME8ARP DN RX-3117 DME8ARP TI TT6S2FE DME8ARP TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DME8ARP MA Inhibitor DME8ARP RN Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360). Invest New Drugs. 2013 Dec;31(6):1444-57. DME8ARP RU https://pubmed.ncbi.nlm.nih.gov/24048768 DME8IFQ DI DME8IFQ DME8IFQ DN Noberastine DME8IFQ TI TTTIBOJ DME8IFQ TN Histamine H1 receptor (H1R) DME8IFQ MA Antagonist DME8IFQ RN A double-blind placebo controlled dose response study of noberastine on histamine induced weal and flare. Eur J Clin Pharmacol. 1991;40(1):83-5. DME8IFQ RU https://pubmed.ncbi.nlm.nih.gov/1676366 DME8O5K DI DME8O5K DME8O5K DN LOU064 DME8O5K TI TTGM6VW DME8O5K TN Tyrosine-protein kinase BTK (ATK) DME8O5K MA Inhibitor DME8O5K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME8O5K RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DME8PFQ DI DME8PFQ DME8PFQ DN TMX-049 DME8PFQ TI TT7RJY8 DME8PFQ TN Xanthine dehydrogenase/oxidase (XDH) DME8PFQ MA Inhibitor DME8PFQ RN Clinical pipeline report, company report or official report of Teijin Pharma. DME8PFQ RU https://www.teijin.com/news/2019/20190920_3737.html DME8XD7 DI DME8XD7 DME8XD7 DN ASP-1707 DME8XD7 TI TT8R70G DME8XD7 TN Gonadotropin-releasing hormone receptor (GNRHR) DME8XD7 MA Antagonist DME8XD7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032657) DME8XD7 RU http://adisinsight.springer.com/drugs/800032657 DME8Z5M DI DME8Z5M DME8Z5M DN AZD-3199 DME8Z5M TI TT2CJVK DME8Z5M TN Adrenergic receptor beta-2 (ADRB2) DME8Z5M MA Agonist DME8Z5M RN Clinical pharmacokinetics of AZD3199, an inhaled ultra-long-acting beta2-adrenoreceptor agonist (uLABA). Drug Des Devel Ther. 2015; 9: 753-762. DME8Z5M RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4330041/ DMEB3T9 DI DMEB3T9 DMEB3T9 DN Amdoxovir DMEB3T9 TI TT84ETX DMEB3T9 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMEB3T9 MA Modulator DMEB3T9 RN Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-1-infected subjects failing current therapy (AACTG A5118). Antivir Ther. 2006;11(5):619-23. DMEB3T9 RU https://www.ncbi.nlm.nih.gov/pubmed/16964830 DMED5J6 DI DMED5J6 DMED5J6 DN JTT-851 DMED5J6 TI TTB8FUC DMED5J6 TN Free fatty acid receptor 1 (GPR40) DMED5J6 MA Agonist DMED5J6 RN Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137. DMED5J6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/ DMEDITW DI DMEDITW DMEDITW DN MK-1454 DMEDITW TI TTT402Y DMEDITW TN Stimulator of interferon genes protein (TMEM173) DMEDITW MA Agonist DMEDITW RN National Cancer Institute Drug Dictionary (drug name MK1454). DMEDITW RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-1454 DMEFD0B DI DMEFD0B DMEFD0B DN RG6100 DMEFD0B TI TTS87KH DMEFD0B TN Microtubule-associated protein tau (MAPT) DMEFD0B MA Inhibitor DMEFD0B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEFD0B RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMEFW3G DI DMEFW3G DMEFW3G DN KD019 DMEFW3G TI TTI4ZX2 DMEFW3G TN Ephrin type-B receptor 4 (EPHB4) DMEFW3G MA Modulator DMEFW3G RN XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol. 2012 Jan;7(1):219-26. DMEFW3G RU https://pubmed.ncbi.nlm.nih.gov/22011666 DMEFW3G DI DMEFW3G DMEFW3G DN KD019 DMEFW3G TI TTJSQEF DMEFW3G TN Tyrosine-protein kinase (PTK) DMEFW3G MA Inhibitor DMEFW3G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEFW3G RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMEG4TC DI DMEG4TC DMEG4TC DN Stannsoporfin DMEG4TC TI TTI6V2A DMEG4TC TN Heme oxygenase 1 (HMOX1) DMEG4TC MA Inhibitor DMEG4TC RN Chemoprevention of severe neonatal hyperbilirubinemia. Semin Perinatol. 2004 Oct;28(5):365-8. DMEG4TC RU https://pubmed.ncbi.nlm.nih.gov/15686268 DMEGDWA DI DMEGDWA DMEGDWA DN BNC-210 DMEGDWA TI TTNJYV2 DMEGDWA TN Gamma-aminobutyric acid receptor (GAR) DMEGDWA MA Modulator DMEGDWA RN 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. DMEGDWA RU https://pubmed.ncbi.nlm.nih.gov/23989795 DMEGNHZ DI DMEGNHZ DMEGNHZ DN SAR279356 DMEGNHZ TI TTAFD3Y DMEGNHZ TN Poly-N-acetyl glucosamine (PNAG) DMEGNHZ MA Modulator DMEGNHZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMEGNHZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMEGTH1 DI DMEGTH1 DMEGTH1 DN Ozarelix DMEGTH1 TI TT8R70G DMEGTH1 TN Gonadotropin-releasing hormone receptor (GNRHR) DMEGTH1 MA Modulator DMEGTH1 RN Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate. 2010 Sep 1;70(12):1340-9. DMEGTH1 RU https://pubmed.ncbi.nlm.nih.gov/20623634 DMEHOI1 DI DMEHOI1 DMEHOI1 DN Novaferon DMEHOI1 TI TTSIUJ9 DMEHOI1 TN Interferon-alpha 2 (IFNA2) DMEHOI1 MA Modulator DMEHOI1 RN Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int. 2014; 14: 8. DMEHOI1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3976097/ DMEJICQ DI DMEJICQ DMEJICQ DN Aprocitentan DMEJICQ TI TTCV6O0 DMEJICQ TN Endothelin receptor (EDNR) DMEJICQ MA Antagonist DMEJICQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEJICQ RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMEK580 DI DMEK580 DMEK580 DN CD19 CAR T cells DMEK580 TI TTW640A DMEK580 TN B-lymphocyte surface antigen B4 (CD19) DMEK580 MA CAR-T-Cell-Therapy DMEK580 RN ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies DMEK580 RU https://clinicaltrials.gov/ct2/show/NCT02846584 DMEL15U DI DMEL15U DMEL15U DN FK-143 DMEL15U TI TT2A0DR DMEL15U TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMEL15U MA Modulator DMEL15U RN FK143, a novel nonsteroidal inhibitor of steroid 5 alpha-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol. 1995 Apr;52(4):357-63. DMEL15U RU https://www.ncbi.nlm.nih.gov/pubmed/7734404 DMEL5SV DI DMEL5SV DMEL5SV DN FR139317 DMEL5SV TI TTZPO1L DMEL5SV TN Substance-P receptor (TACR1) DMEL5SV MA Antagonist DMEL5SV RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMEL5SV RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMEL5SV DI DMEL5SV DMEL5SV DN FR139317 DMEL5SV TI TTKRD0G DMEL5SV TN Endothelin A receptor (EDNRA) DMEL5SV MA Antagonist DMEL5SV RN Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002 Aug 1;64(3):497-505. DMEL5SV RU https://pubmed.ncbi.nlm.nih.gov/12147302 DMELUAK DI DMELUAK DMELUAK DN MP470 DMELUAK TI TT8FYO9 DMELUAK TN Platelet-derived growth factor receptor alpha (PDGFRA) DMELUAK MA Modulator DMELUAK RN Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. DMELUAK RU https://pubmed.ncbi.nlm.nih.gov/24849582 DMELUAK DI DMELUAK DMELUAK DN MP470 DMELUAK TI TTX41N9 DMELUAK TN Tyrosine-protein kinase Kit (KIT) DMELUAK MA Modulator DMELUAK RN Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204. DMELUAK RU https://pubmed.ncbi.nlm.nih.gov/24849582 DMELUYN DI DMELUYN DMELUYN DN XP-23829 DMELUYN TI TTSXVID DMELUYN TN Nuclear factor NF-kappa-B (NFKB) DMELUYN MA Inhibitor DMELUYN RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036491) DMELUYN RU http://adisinsight.springer.com/drugs/800036491 DMEN5KA DI DMEN5KA DMEN5KA DN GTS-21 DMEN5KA TI TTLA931 DMEN5KA TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMEN5KA MA Agonist DMEN5KA RN The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81. DMEN5KA RU https://pubmed.ncbi.nlm.nih.gov/10942043 DMEO9Y7 DI DMEO9Y7 DMEO9Y7 DN INGAP peptide DMEO9Y7 TI TTGMYVE DMEO9Y7 TN Phosphofructokinase 2 (PFK2) DMEO9Y7 MA Modulator DMEO9Y7 RN A Pentadecapeptide Fragment of Islet Neogenesis-Associated Protein Increases Beta-Cell Mass and Reverses Diabetes in C57BL/6J Mice. Ann Surg. 2004 November; 240(5): 875-884. DMEO9Y7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1356495/ DMER82Z DI DMER82Z DMER82Z DN COR-1 DMER82Z TI TTR6W5O DMER82Z TN Adrenergic receptor beta-1 (ADRB1) DMER82Z MA Antagonist DMER82Z RN Administration of the cyclic peptide COR-1 in humans (phase I study): ex vivo measurements of anti-beta1-adrenergic receptor antibody neutralization and of immune parameters. Eur J Heart Fail. 2012 Nov;14(11):1230-9. DMER82Z RU https://pubmed.ncbi.nlm.nih.gov/22968742 DMESMHU DI DMESMHU DMESMHU DN AVE-0657 DMESMHU TI TTFZVPO DMESMHU TN Sodium/hydrogen exchanger 3 (SLC9A3) DMESMHU MA Inhibitor DMESMHU RN Inhibition of central Na(+)/H(+) exchanger type 3 can alleviate sleep apnea in Sprague-Dawley rats. Chin Med J (Engl). 2014;127(1):48-53. DMESMHU RU https://pubmed.ncbi.nlm.nih.gov/24384423 DMEVARK DI DMEVARK DMEVARK DN GSK561679 DMEVARK TI TT7EFHR DMEVARK TN Corticotropin-releasing factor receptor 1 (CRHR1) DMEVARK MA Antagonist DMEVARK RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMEVARK RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMEVXS1 DI DMEVXS1 DMEVXS1 DN PRX-3140 DMEVXS1 TI TT07C3Y DMEVXS1 TN 5-HT 4 receptor (HTR4) DMEVXS1 MA Modulator DMEVXS1 RN Clinical pipeline report, company report or official report of Nanotherapeutics. DMEVXS1 RU http://www.nanotherapeutics.com/prx-3140/ DMEW3K9 DI DMEW3K9 DMEW3K9 DN AZD7624 DMEW3K9 TI TTWELHI DMEW3K9 TN Stress-activated protein kinase (p38) DMEW3K9 MA Inhibitor DMEW3K9 RN Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. DMEW3K9 RU https://pubmed.ncbi.nlm.nih.gov/25599809 DMEW62S DI DMEW62S DMEW62S DN AB-106 DMEW62S TI TTSZ6Y3 DMEW62S TN Proto-oncogene c-Ros (ROS1) DMEW62S MA Inhibitor DMEW62S RN Clinical pipeline report, company report or official report of AnHeart Therapeutics. DMEW62S RU https://anhearttherapeutics.com/pipeline/ DMEW62S DI DMEW62S DMEW62S DN AB-106 DMEW62S TI TTJOCTY DMEW62S TN Tropomyosin receptor kinase (Trk) DMEW62S MA Inhibitor DMEW62S RN Clinical pipeline report, company report or official report of AnHeart Therapeutics. DMEW62S RU https://anhearttherapeutics.com/pipeline/ DMEWQ4X DI DMEWQ4X DMEWQ4X DN ABT-639 DMEWQ4X TI TTZPWGN DMEWQ4X TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMEWQ4X MA Modulator DMEWQ4X RN Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83. DMEWQ4X RU https://pubmed.ncbi.nlm.nih.gov/26035253 DMEXKF4 DI DMEXKF4 DMEXKF4 DN GSK3196165 DMEXKF4 TI TTNYZG2 DMEXKF4 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMEXKF4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEXKF4 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEXMV5 DI DMEXMV5 DMEXMV5 DN Virexxa DMEXMV5 TI TTUV8G9 DMEXMV5 TN Progesterone receptor (PGR) DMEXMV5 MA Inducer DMEXMV5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627). DMEXMV5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627 DMEXN7V DI DMEXN7V DMEXN7V DN APN401 DMEXN7V TI TTHRAIJ DMEXN7V TN CBLB messenger RNA (CBLB mRNA) DMEXN7V MA Inhibitor DMEXN7V RN Clinical pipeline report, company report or official report of Apeiron Biologics. DMEXN7V RU https://www.apeiron-biologics.com/science/#apn401 DMEYIVW DI DMEYIVW DMEYIVW DN CAP1-6D DMEYIVW TI TTY6DTE DMEYIVW TN Carcinoembryonic antigen CEA (CD66e) DMEYIVW MA Modulator DMEYIVW RN Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7. DMEYIVW RU https://pubmed.ncbi.nlm.nih.gov/9377571 DMEYKRN DI DMEYKRN DMEYKRN DN TAK-379 DMEYKRN TI TTCBFJO DMEYKRN TN Insulin receptor (INSR) DMEYKRN MA Modulator DMEYKRN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMEYKRN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMEYMTX DI DMEYMTX DMEYMTX DN CP-461 DMEYMTX TI TTJGW1Z DMEYMTX TN Phosphodiesterase 2A (PDE2A) DMEYMTX MA Inhibitor DMEYMTX RN Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83. DMEYMTX RU https://pubmed.ncbi.nlm.nih.gov/11569947 DMEYNQA DI DMEYNQA DMEYNQA DN ALN-RSV01 DMEYNQA TI TTWSF5D DMEYNQA TN HRSV Nucleoprotein messenger RNA (HRSV N mRNA) DMEYNQA MA Inhibitor DMEYNQA RN Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 2008 Mar;77(3):225-31. DMEYNQA RU https://pubmed.ncbi.nlm.nih.gov/18242722 DMEYQPN DI DMEYQPN DMEYQPN DN P-1736 DMEYQPN TI TTB8FUC DMEYQPN TN Free fatty acid receptor 1 (GPR40) DMEYQPN MA Modulator DMEYQPN RN Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946. DMEYQPN RU https://pubmed.ncbi.nlm.nih.gov/24194903 DMEZLFT DI DMEZLFT DMEZLFT DN Camsirubicin DMEZLFT TI TTCGY2K DMEZLFT TN DNA topoisomerase II alpha (TOP2A) DMEZLFT MA Inhibitor DMEZLFT RN Clinical pipeline report, company report or official report of Monopar Therapeutics. DMEZLFT RU https://www.monopartx.com/pipeline/Camsirubicin DMF34UY DI DMF34UY DMF34UY DN AZD-2423 DMF34UY TI TTFZYTO DMF34UY TN C-C chemokine receptor type 2 (CCR2) DMF34UY MA Antagonist DMF34UY RN CA patent application no. 841416, Method of selecting therapeutic indications. DMF34UY RU http://www.google.com/patents/CA2841416A1?cl=en DMF3MV1 DI DMF3MV1 DMF3MV1 DN GDC-0980/RG7422 DMF3MV1 TI TTCJG29 DMF3MV1 TN Serine/threonine-protein kinase mTOR (mTOR) DMF3MV1 MA Modulator DMF3MV1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMF3MV1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMF3MV1 DI DMF3MV1 DMF3MV1 DN GDC-0980/RG7422 DMF3MV1 TI TTHBTOP DMF3MV1 TN PI3-kinase gamma (PIK3CG) DMF3MV1 MA Modulator DMF3MV1 RN GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther. 2011 Dec;10(12):2426-36. DMF3MV1 RU https://pubmed.ncbi.nlm.nih.gov/21998291 DMF3QN1 DI DMF3QN1 DMF3QN1 DN ALKS33 DMF3QN1 TI TTKWM86 DMF3QN1 TN Opioid receptor mu (MOP) DMF3QN1 MA Inhibitor DMF3QN1 RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMF3QN1 RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMF46PD DI DMF46PD DMF46PD DN BMS-911543 DMF46PD TI TTRMX3V DMF46PD TN Janus kinase 2 (JAK-2) DMF46PD MA Modulator DMF46PD RN Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. DMF46PD RU https://pubmed.ncbi.nlm.nih.gov/22015772 DMF4MX9 DI DMF4MX9 DMF4MX9 DN Cobomarsen DMF4MX9 TI TT1GNRQ DMF4MX9 TN microRNA hsa-miR-155 (MIR155) DMF4MX9 MA Inhibitor DMF4MX9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF4MX9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMF5YEN DI DMF5YEN DMF5YEN DN PG-102 DMF5YEN TI TTIJP3Q DMF5YEN TN TNF related activation protein (CD40LG) DMF5YEN MA Modulator DMF5YEN RN Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27. DMF5YEN RU https://www.ncbi.nlm.nih.gov/pubmed/25795759 DMF61ML DI DMF61ML DMF61ML DN TF0023 DMF61ML TI TT6L509 DMF61ML TN Coagulation factor IIa (F2) DMF61ML MA Inhibitor DMF61ML RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF61ML RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMF6CTI DI DMF6CTI DMF6CTI DN KHK-6188 DMF6CTI TI TTMSFAW DMF6CTI TN Cannabinoid receptor 2 (CB2) DMF6CTI MA Agonist DMF6CTI RN Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2). DMF6CTI RU http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands DMF7J6D DI DMF7J6D DMF7J6D DN INGN-225 DMF7J6D TI TT7SBF5 DMF7J6D TN Cellular tumor antigen p53 (TP53) DMF7J6D RN INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010 Jun;10(6):983-91. DMF7J6D RU https://pubmed.ncbi.nlm.nih.gov/20420527 DMF86P2 DI DMF86P2 DMF86P2 DN BI 655064 DMF86P2 TI TTIJP3Q DMF86P2 TN TNF related activation protein (CD40LG) DMF86P2 RN FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study DMF86P2 RU http://ard.bmj.com/content/74/Suppl_2/483.3.abstract DMF86P2 DI DMF86P2 DMF86P2 DN BI 655064 DMF86P2 TI TTN6Y9A DMF86P2 TN CD40L receptor (CD40) DMF86P2 MA Inhibitor DMF86P2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF86P2 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMF910Q DI DMF910Q DMF910Q DN GS-9451 DMF910Q TI TTWXB3E DMF910Q TN Hepatitis C virus NS3 helicase (HCV NS3) DMF910Q MA Modulator DMF910Q RN Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295. DMF910Q RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457362/ DMF93RQ DI DMF93RQ DMF93RQ DN INS-37217 DMF93RQ TI TTOZHQC DMF93RQ TN P2Y purinoceptor 2 (P2RY2) DMF93RQ MA Agonist DMF93RQ RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMF93RQ RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMF95KD DI DMF95KD DMF95KD DN SAR-407899 DMF95KD TI TTZN7RP DMF95KD TN Rho-associated protein kinase 1 (ROCK1) DMF95KD MA Inhibitor DMF95KD RN The Rho kinase inhibitor SAR407899 potently inhibits endothelin-1-induced constriction of renal resistance arteries. J Hypertens. 2012 May;30(5):980-9. DMF95KD RU https://pubmed.ncbi.nlm.nih.gov/22388233 DMF9RB4 DI DMF9RB4 DMF9RB4 DN Procysteine DMF9RB4 TI TTULV0X DMF9RB4 TN Reactive oxygen species (ROS) DMF9RB4 MA Modulator DMF9RB4 RN Protective effect of procysteine on Acinetobacter pneumonia in hyperoxic conditions. J Antimicrob Chemother. 2013 Oct;68(10):2305-10. DMF9RB4 RU https://pubmed.ncbi.nlm.nih.gov/23681269 DMF9Z2T DI DMF9Z2T DMF9Z2T DN T-2007 DMF9Z2T TI TTEX6LM DMF9Z2T TN GABA(A) receptor gamma-3 (GABRG3) DMF9Z2T MA Agonist DMF9Z2T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMF9Z2T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMFAKGR DI DMFAKGR DMFAKGR DN CG-400549 DMFAKGR TI TTZBRVL DMFAKGR TN Staphylococcus Enoyl ACP reductase (Stap-coc fabI) DMFAKGR MA Inhibitor DMFAKGR RN In vitro activities of CG400549, a novel FabI inhibitor, against recently isolated clinical staphylococcal strains in Korea. Antimicrob Agents Chemother. 2007 Jul;51(7):2591-3. DMFAKGR RU https://pubmed.ncbi.nlm.nih.gov/17420210 DMFAO5G DI DMFAO5G DMFAO5G DN S-PRAnt DMFAO5G TI TTUV8G9 DMFAO5G TN Progesterone receptor (PGR) DMFAO5G MA Antagonist DMFAO5G RN BAY 1002670: a novel, highly potent and selective progesterone receptor modulator for gynaecological therapies. Hum Reprod. 2013 Aug;28(8):2253-64. DMFAO5G RU https://pubmed.ncbi.nlm.nih.gov/23739217 DMFAU3Z DI DMFAU3Z DMFAU3Z DN GSK249320 DMFAU3Z TI TT9XFON DMFAU3Z TN Myelin-associated glycoprotein (MAG) DMFAU3Z RN First-time-in-human study with GSK249320, a myelin-associated glycoprotein inhibitor, in healthy volunteers. Clin Pharmacol Ther. 2013 Feb;93(2):163-9. DMFAU3Z RU https://pubmed.ncbi.nlm.nih.gov/23267856 DMFCIKN DI DMFCIKN DMFCIKN DN Polivy DMFCIKN TI TTBN5I7 DMFCIKN TN B-cell-specific glycoprotein B29 (CD79B) DMFCIKN MA Agonist DMFCIKN RN Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475. DMFCIKN RU https://pubmed.ncbi.nlm.nih.gov/31352604 DMFDA4Y DI DMFDA4Y DMFDA4Y DN SR-2640 DMFDA4Y TI TTTWGIX DMFDA4Y TN Leukotriene receptor (LTR) DMFDA4Y MA Modulator DMFDA4Y RN Effect of the leukotriene LTD4/LTE4 antagonist, SR 2640, in ulcerative colitis: an open clinical study. Prostaglandins Leukot Essent Fatty Acids. 1991 Mar;42(3):181-4. DMFDA4Y RU https://pubmed.ncbi.nlm.nih.gov/1677467 DMFG8TI DI DMFG8TI DMFG8TI DN INCB00928 DMFG8TI TI TTJNBQA DMFG8TI TN Activin receptor-like kinase 2 (ALK-2) DMFG8TI MA Inhibitor DMFG8TI RN Clinical pipeline report, company report or official report of Incyte. DMFG8TI RU https://www.incyte.com/what-we-do/pharmaceutical-portfolio DMFGNB4 DI DMFGNB4 DMFGNB4 DN LY-2623091 DMFGNB4 TI TT26PHO DMFGNB4 TN Mineralocorticoid receptor (MR) DMFGNB4 MA Antagonist DMFGNB4 RN Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. DMFGNB4 RU https://pubmed.ncbi.nlm.nih.gov/26083526 DMFI5J4 DI DMFI5J4 DMFI5J4 DN Dextromethorphan+quinidine DMFI5J4 TI TTSZLWK DMFI5J4 TN Aromatase (CYP19A1) DMFI5J4 MA Inhibitor DMFI5J4 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMFI5J4 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMFI5J4 DI DMFI5J4 DMFI5J4 DN Dextromethorphan+quinidine DMFI5J4 TI TT9IK2Z DMFI5J4 TN N-methyl-D-aspartate receptor (NMDAR) DMFI5J4 MA Antagonist DMFI5J4 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMFI5J4 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TT9W8GU DMFIVSR TN Gamma-secretase (GS) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TT8JRS7 DMFIVSR TN Beta-secretase (BACE) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TTWN3F4 DMFIVSR TN Presenilin 2 (PSEN2) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFIVSR DI DMFIVSR DMFIVSR DN R-flurbiprofen DMFIVSR TI TTZ3S8C DMFIVSR TN Presenilin 1 (PSEN1) DMFIVSR MA Inhibitor DMFIVSR RN The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2219-23. DMFIVSR RU https://pubmed.ncbi.nlm.nih.gov/16455248 DMFL96Z DI DMFL96Z DMFL96Z DN Pegamotecan DMFL96Z TI TTGTQHC DMFL96Z TN DNA topoisomerase I (TOP1) DMFL96Z MA Inhibitor DMFL96Z RN A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70. DMFL96Z RU https://pubmed.ncbi.nlm.nih.gov/18398613 DMFLCW4 DI DMFLCW4 DMFLCW4 DN AZD8931 DMFLCW4 TI TT6EO5L DMFLCW4 TN Erbb2 tyrosine kinase receptor (HER2) DMFLCW4 MA Inhibitor DMFLCW4 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMFLCW4 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMFLZPC DI DMFLZPC DMFLZPC DN VER 50589 DMFLZPC TI TT78R5H DMFLZPC TN Heat shock protein 90 alpha (HSP90A) DMFLZPC MA Inhibitor DMFLZPC RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMFLZPC RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMFM6OU DI DMFM6OU DMFM6OU DN PerioPatch DMFM6OU TI TTHS7CM DMFM6OU TN Beta-glucuronidase (GUSB) DMFM6OU MA Modulator DMFM6OU RN Clinical pipeline report, company report or official report of Izun Pharmaceuticals. DMFM6OU RU http://izunpharma.com/products/periopatch/ DMFMKQ3 DI DMFMKQ3 DMFMKQ3 DN LY3015014 DMFMKQ3 TI TTBRG7E DMFMKQ3 TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMFMKQ3 RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMFMKQ3 RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMFNDBC DI DMFNDBC DMFNDBC DN Otelixizumab DMFNDBC TI TTUN7MC DMFNDBC TN T-cell surface glycoprotein CD3 (CD3) DMFNDBC MA Modulator DMFNDBC RN Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54. DMFNDBC RU https://www.ncbi.nlm.nih.gov/pubmed/25011949 DMFNZPY DI DMFNZPY DMFNZPY DN SSR-240612 DMFNZPY TI TTG5QIA DMFNZPY TN B1 bradykinin receptor (BDKRB1) DMFNZPY MA Antagonist DMFNZPY RN The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br J Pharmacol. 2007 September; 152(2): 280-287. DMFNZPY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1978253/ DMFO2G5 DI DMFO2G5 DMFO2G5 DN Afabicin DMFO2G5 TI TTZBRVL DMFO2G5 TN Staphylococcus Enoyl ACP reductase (Stap-coc fabI) DMFO2G5 MA Inhibitor DMFO2G5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFO2G5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMFO6MH DI DMFO6MH DMFO6MH DN Kevetrin DMFO6MH TI TT7SBF5 DMFO6MH TN Cellular tumor antigen p53 (TP53) DMFO6MH MA Stimulator DMFO6MH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFO6MH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFORDT DI DMFORDT DMFORDT DN Afimoxifene DMFORDT TI TTZAYWL DMFORDT TN Estrogen receptor (ESR) DMFORDT MA Modulator DMFORDT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMFORDT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMFT5D6 DI DMFT5D6 DMFT5D6 DN Telcagepant DMFT5D6 TI TTY6O0Q DMFT5D6 TN Calcitonin gene-related peptide receptor (CGRPR) DMFT5D6 MA Antagonist DMFT5D6 RN CGRP antagonists: novel concept for treatment of migraine. Med Monatsschr Pharm. 2009 May;32(5):182-5. DMFT5D6 RU https://pubmed.ncbi.nlm.nih.gov/19469188 DMFU0JY DI DMFU0JY DMFU0JY DN TH-302 DMFU0JY TI TTUTN1I DMFU0JY TN Human Deoxyribonucleic acid (hDNA) DMFU0JY MA Modulator DMFU0JY RN Company report (Threshold Pharmaceuticals) DMFU0JY RU http://www.thresholdpharm.com/what-is-th-302 DMFVL5J DI DMFVL5J DMFVL5J DN AZD-4877 DMFVL5J TI TTTRP0H DMFVL5J TN Kinesin-like protein KIF11 (KIF11) DMFVL5J MA Inhibitor DMFVL5J RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DMFVL5J RU https://pubmed.ncbi.nlm.nih.gov/22825217 DMFVNSB DI DMFVNSB DMFVNSB DN WY-50295-tromethamine DMFVNSB TI TT2J34L DMFVNSB TN Arachidonate 5-lipoxygenase (5-LOX) DMFVNSB MA Inhibitor DMFVNSB RN WY-50295 tromethamine: a 5-lipoxygenase inhibitor without activity in human whole blood. Prostaglandins Leukot Essent Fatty Acids. 1999 Jan;60(1):31-41. DMFVNSB RU https://pubmed.ncbi.nlm.nih.gov/10319915 DMFW860 DI DMFW860 DMFW860 DN ABT-450 DMFW860 TI TT5FNQT DMFW860 TN Human immunodeficiency virus Protease (HIV PR) DMFW860 MA Inhibitor DMFW860 RN Clinical pipeline report, company report or official report of Abbott Laboratories (2011) DMFW860 RU http://www.abbott.com/index2.htm DMFWZ2U DI DMFWZ2U DMFWZ2U DN Valopicitabine dihydrochloride DMFWZ2U TI TTMVBWH DMFWZ2U TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMFWZ2U MA Modulator DMFWZ2U RN Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8. DMFWZ2U RU https://pubmed.ncbi.nlm.nih.gov/17328231 DMFX3P1 DI DMFX3P1 DMFX3P1 DN ONO-5129 DMFX3P1 TI TTZMAO3 DMFX3P1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMFX3P1 MA Modulator DMFX3P1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFX3P1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFX3P1 DI DMFX3P1 DMFX3P1 DN ONO-5129 DMFX3P1 TI TTJ584C DMFX3P1 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFX3P1 MA Modulator DMFX3P1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFX3P1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFXN2T DI DMFXN2T DMFXN2T DN AMG 745 DMFXN2T TI TTSWPH8 DMFXN2T TN Growth/differentiation factor 8 (GDF-8) DMFXN2T MA Antagonist DMFXN2T RN The role of myostatin in muscle wasting: an overview. J Cachexia Sarcopenia Muscle. 2011 September; 2(3): 143-151. DMFXN2T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177043/ DMFYABR DI DMFYABR DMFYABR DN PRO-044 DMFYABR TI TTWLFXU DMFYABR TN Dystrophin messenger RNA (DMD mRNA) DMFYABR RN Update on neuromuscular disorders in pediatric orthopaedics: Duchenne muscular dystrophy, myelomeningocele, and cerebral palsy. J Pediatr Orthop. 2014 Oct-Nov;34 Suppl 1:S44-8. DMFYABR RU https://pubmed.ncbi.nlm.nih.gov/25207736 DMFZ084 DI DMFZ084 DMFZ084 DN Fresolimumab DMFZ084 TI TTO3HT7 DMFZ084 TN Transforming growth factor beta (TGFB) DMFZ084 MA Inhibitor DMFZ084 RN Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504. DMFZ084 RU https://pubmed.ncbi.nlm.nih.gov/29476019 DMFZULI DI DMFZULI DMFZULI DN Upamostat DMFZULI TI TTGY7WI DMFZULI TN Urokinase-type plasminogen activator (PLAU) DMFZULI MA Inhibitor DMFZULI RN Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70. DMFZULI RU https://pubmed.ncbi.nlm.nih.gov/23412098 DMG1LVA DI DMG1LVA DMG1LVA DN BLZ-945 DMG1LVA TI TTC70AJ DMG1LVA TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMG1LVA MA Inhibitor DMG1LVA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMG1LVA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMG1LVA DI DMG1LVA DMG1LVA DN BLZ-945 DMG1LVA TI TT7MRDV DMG1LVA TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMG1LVA MA Antagonist DMG1LVA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG1LVA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG1VXR DI DMG1VXR DMG1VXR DN SBC-014 DMG1VXR TI TTC70AJ DMG1VXR TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMG1VXR MA Modulator DMG1VXR RN A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2. DMG1VXR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639539/ DMG3O2Z DI DMG3O2Z DMG3O2Z DN Girentuximab I-124 DMG3O2Z TI TT2LVK8 DMG3O2Z TN Carbonic anhydrase IX (CA-IX) DMG3O2Z MA Enhancer DMG3O2Z RN Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. Biologics. 2012;6:395-407. DMG3O2Z RU https://pubmed.ncbi.nlm.nih.gov/23204838 DMG3ON2 DI DMG3ON2 DMG3ON2 DN BIA 3-202 DMG3ON2 TI TTKWFB8 DMG3ON2 TN Catechol-O-methyl-transferase (COMT) DMG3ON2 MA Inhibitor DMG3ON2 RN Chemical synthesis and characterization of conjugates of a novel catechol-O-methyltransferase inhibitor. Bioconjug Chem. 2002 Sep-Oct;13(5):1112-8. DMG3ON2 RU https://pubmed.ncbi.nlm.nih.gov/12236793 DMG439E DI DMG439E DMG439E DN Fipamezole DMG439E TI TTQ8AFT DMG439E TN Adrenergic receptor Alpha-2 (ADRA2) DMG439E MA Antagonist DMG439E RN Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17. DMG439E RU https://pubmed.ncbi.nlm.nih.gov/16939381 DMG5C8D DI DMG5C8D DMG5C8D DN GS-9620 DMG5C8D TI TTRJ1K4 DMG5C8D TN Toll-like receptor 7 (TLR7) DMG5C8D MA Modulator DMG5C8D RN Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105. DMG5C8D RU https://pubmed.ncbi.nlm.nih.gov/24133297 DMG5Q7F DI DMG5Q7F DMG5Q7F DN IPI-549 DMG5Q7F TI TTHBTOP DMG5Q7F TN PI3-kinase gamma (PIK3CG) DMG5Q7F MA Inhibitor DMG5Q7F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG5Q7F RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG65WH DI DMG65WH DMG65WH DN Ficlatuzumab DMG65WH TI TT4V2JM DMG65WH TN Hepatocyte growth factor (HGF) DMG65WH MA Inhibitor DMG65WH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG65WH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG6KXB DI DMG6KXB DMG6KXB DN MK-8245 DMG6KXB TI TT6RIOV DMG6KXB TN Acyl-CoA desaturase (SCD) DMG6KXB MA Inhibitor DMG6KXB RN Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. J Med Chem. 2011 Jul 28;54(14):5082-96. DMG6KXB RU https://pubmed.ncbi.nlm.nih.gov/21661758 DMG7IEN DI DMG7IEN DMG7IEN DN Anatibant DMG7IEN TI TTGY8IW DMG7IEN TN B2 bradykinin receptor (BDKRB2) DMG7IEN MA Antagonist DMG7IEN RN Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med. 2009 Jul;37(7):2228-34. DMG7IEN RU https://pubmed.ncbi.nlm.nih.gov/19487935 DMG7PDY DI DMG7PDY DMG7PDY DN XEN-D0501 DMG7PDY TI TTMI6F5 DMG7PDY TN Transient receptor potential cation channel V1 (TRPV1) DMG7PDY MA Antagonist DMG7PDY RN An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN-D0501 in healthy subjects. Br J Clin Pharmacol. 2011 Dec;72(6):921-31. DMG7PDY RU https://pubmed.ncbi.nlm.nih.gov/21676011 DMG7RAV DI DMG7RAV DMG7RAV DN LMB-2 DMG7RAV TI TT10Y9E DMG7RAV TN Interleukin 2 receptor alpha (IL2RA) DMG7RAV MA Modulator DMG7RAV RN Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36. DMG7RAV RU https://pubmed.ncbi.nlm.nih.gov/10764422 DMG7XOC DI DMG7XOC DMG7XOC DN NIC5-15 DMG7XOC TI TTE4KHA DMG7XOC TN Amyloid beta A4 protein (APP) DMG7XOC MA Inhibitor DMG7XOC RN Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20. DMG7XOC RU https://pubmed.ncbi.nlm.nih.gov/25325702 DMG7YI9 DI DMG7YI9 DMG7YI9 DN ZYH7 DMG7YI9 TI TTJ584C DMG7YI9 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMG7YI9 MA Agonist DMG7YI9 RN Clinical pipeline report, company report or official report of Zydus Cadila. DMG7YI9 RU https://zyduscadila.com/public/pdf/investorpresentation/Investor_Presentation_February_2020.pdf DMG7YQL DI DMG7YQL DMG7YQL DN GSK2245840 DMG7YQL TI TTUF2HO DMG7YQL TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMG7YQL MA Modulator DMG7YQL RN Sirtuin 1 activator SRT2104 protects Huntington's disease mice. Ann Clin Transl Neurol. 2014 Dec;1(12):1047-52. DMG7YQL RU https://pubmed.ncbi.nlm.nih.gov/25574479 DMG8NLI DI DMG8NLI DMG8NLI DN P-9808 DMG8NLI TI TTT0HW3 DMG8NLI TN Porphobilinogen deaminase (HMBS) DMG8NLI MA Modulator DMG8NLI RN Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49. DMG8NLI RU https://pubmed.ncbi.nlm.nih.gov/17375984 DMG9MN2 DI DMG9MN2 DMG9MN2 DN SAR97276 DMG9MN2 TI TTQ2GJ0 DMG9MN2 TN Plasmodial phospholipid metabolism (PPP metab) DMG9MN2 MA Antagonist DMG9MN2 RN Transport and pharmacodynamics of albitiazolium, an antimalarial drug candidate. Br J Pharmacol. 2012 August; 166(8): 2263-2276. DMG9MN2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437492/ DMGBLI3 DI DMGBLI3 DMGBLI3 DN VS-6063 DMGBLI3 TI TTON5IT DMGBLI3 TN Focal adhesion kinase 1 (FAK) DMGBLI3 MA Inhibitor DMGBLI3 RN Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95. DMGBLI3 RU https://pubmed.ncbi.nlm.nih.gov/24062525 DMGBPME DI DMGBPME DMGBPME DN 2-Methoxyestradiol DMGBPME TI TTQHWNA DMGBPME TN Hypoxia-inducible factor 1 alpha (HIF-1A) DMGBPME MA Modulator DMGBPME RN 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squam... Clin Cancer Res. 2004 Dec 15;10(24):8665-73. DMGBPME RU https://www.ncbi.nlm.nih.gov/pubmed/15623651 DMGCRKY DI DMGCRKY DMGCRKY DN Midismase DMGCRKY TI TT6RVLG DMGCRKY TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMGCRKY MA Modulator DMGCRKY RN A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis DMGCRKY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364 DMGCTX5 DI DMGCTX5 DMGCTX5 DN Combined PR1/WT1 vaccine DMGCTX5 TI TT5MLC4 DMGCTX5 TN Leukocyte proteinase-3 (PRTN3) DMGCTX5 RN Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. DMGCTX5 RU https://pubmed.ncbi.nlm.nih.gov/17875804 DMGCTX5 DI DMGCTX5 DMGCTX5 DN Combined PR1/WT1 vaccine DMGCTX5 TI TTZ8UT4 DMGCTX5 TN Wilms tumor protein (WT1) DMGCTX5 RN Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008 Jan 1;111(1):236-42. DMGCTX5 RU https://pubmed.ncbi.nlm.nih.gov/17875804 DMGD1YP DI DMGD1YP DMGD1YP DN MEDI9929 DMGD1YP TI TTHMW3T DMGD1YP TN Thymic stromal lymphopoietin (TSLP) DMGD1YP MA Modulator DMGD1YP RN Human immunoglobulin G2Lambda monoclonal antibody directed against thymic stromal lymphopoietin (MEDI9929). European medicines agency science medicines health (EMEA-001613-PIP01-14). European Union. 2015. DMGD1YP RU http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/pips/EMEA-001613-PIP01-14/pip_001268.jsp&mid=WC0b01ac058001d129 DMGD3XT DI DMGD3XT DMGD3XT DN DRL-17822 DMGD3XT TI TTFQAYR DMGD3XT TN Cholesteryl ester transfer protein (CETP) DMGD3XT MA Inhibitor DMGD3XT RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMGD3XT RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMGDB21 DI DMGDB21 DMGDB21 DN VX-150 DMGDB21 TI TT90XZ8 DMGDB21 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMGDB21 MA Inhibitor DMGDB21 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGDB21 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMGDF2X DI DMGDF2X DMGDF2X DN ASP-7147 DMGDF2X TI TTC1MVT DMGDF2X TN Gastrin-releasing peptide receptor (GRPR) DMGDF2X MA Antagonist DMGDF2X RN Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion DMGDF2X RU http://www.astellas.com/en/corporate/news/detail/astellas-and-drais-partner-to-.html DMGE058 DI DMGE058 DMGE058 DN Cabiralizumab DMGE058 TI TT7MRDV DMGE058 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMGE058 MA Antagonist DMGE058 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGE058 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGE058 DI DMGE058 DMGE058 DN Cabiralizumab DMGE058 TI TTNYZG2 DMGE058 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMGE058 MA Antagonist DMGE058 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGE058 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGE8FK DI DMGE8FK DMGE8FK DN AMR-001 DMGE8FK TI TTZAVYN DMGE8FK TN Hematopoietic progenitor cell antigen CD34 (CD34) DMGE8FK MA Modulator DMGE8FK RN National Cancer Institute Drug Dictionary (drug id 743421). DMGE8FK RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=743421 DMGEAM6 DI DMGEAM6 DMGEAM6 DN Cinaciguat DMGEAM6 TI TTLBYH1 DMGEAM6 TN Guanylate cyclase soluble beta-1 (GUCY1B1) DMGEAM6 MA Activator DMGEAM6 RN Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009 Jun 2;119(21):2781-8. DMGEAM6 RU https://pubmed.ncbi.nlm.nih.gov/19451356 DMGFZOL DI DMGFZOL DMGFZOL DN Enadoline DMGFZOL TI TTQW87Y DMGFZOL TN Opioid receptor kappa (OPRK1) DMGFZOL MA Agonist DMGFZOL RN Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. Pain. 1999 Mar;80(1-2):383-9. DMGFZOL RU https://pubmed.ncbi.nlm.nih.gov/10204752 DMGHQ37 DI DMGHQ37 DMGHQ37 DN Icaritin DMGHQ37 TI TTZAYWL DMGHQ37 TN Estrogen receptor (ESR) DMGHQ37 MA Modulator DMGHQ37 RN A novel prenylflavone restricts breast cancer cell growth through AhR-mediated destabilization of ER protein.Carcinogenesis.2012 May;33(5):1089-97. DMGHQ37 RU https://www.ncbi.nlm.nih.gov/pubmed/22345291 DMGIRM1 DI DMGIRM1 DMGIRM1 DN SH-529 DMGIRM1 TI TT470F3 DMGIRM1 TN TNF alpha production (TNFA produ) DMGIRM1 MA Modulator DMGIRM1 RN Particulate beta-glucan induces TNF-alpha production in wound macrophages via a redox-sensitive NF- beta-dependent pathway. Wound Repair Regen. 2011 May-Jun;19(3):411-9. DMGIRM1 RU https://pubmed.ncbi.nlm.nih.gov/21518092 DMGJ1X2 DI DMGJ1X2 DMGJ1X2 DN Aplindore fumarate DMGJ1X2 TI TTEX248 DMGJ1X2 TN Dopamine D2 receptor (D2R) DMGJ1X2 MA Agonist DMGJ1X2 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMGJ1X2 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMGJ71F DI DMGJ71F DMGJ71F DN ALT-836 DMGJ71F TI TT38MDJ DMGJ71F TN Tissue factor (F3) DMGJ71F MA Inhibitor DMGJ71F RN ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1295-303. DMGJ71F RU https://pubmed.ncbi.nlm.nih.gov/25801992 DMGJEB8 DI DMGJEB8 DMGJEB8 DN SSR125543 DMGJEB8 TI TT7EFHR DMGJEB8 TN Corticotropin-releasing factor receptor 1 (CRHR1) DMGJEB8 MA Antagonist DMGJEB8 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMGJEB8 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMGJYZ8 DI DMGJYZ8 DMGJYZ8 DN EDP-305 DMGJYZ8 TI TTS4UGC DMGJYZ8 TN Farnesoid X-activated receptor (FXR) DMGJYZ8 MA Agonist DMGJYZ8 RN A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669. DMGJYZ8 RU https://pubmed.ncbi.nlm.nih.gov/32329946 DMGK1JE DI DMGK1JE DMGK1JE DN MORAb-004 DMGK1JE TI TTYJWT7 DMGK1JE TN Endosialin (CD248) DMGK1JE MA Modulator DMGK1JE RN A first-in-human phase I study of MORAb-004, a monoclonal antibody to endosialin in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 15;21(6):1281-8. DMGK1JE RU https://pubmed.ncbi.nlm.nih.gov/25398449 DMGLCVU DI DMGLCVU DMGLCVU DN R-salbutamol sulphate DMGLCVU TI TT2CJVK DMGLCVU TN Adrenergic receptor beta-2 (ADRB2) DMGLCVU MA Agonist DMGLCVU RN Pharmacokinetics and extrapulmonary beta 2 adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 1997 Oct;52(10):849-52. DMGLCVU RU https://pubmed.ncbi.nlm.nih.gov/9404370 DMGLVBI DI DMGLVBI DMGLVBI DN JTT-302 DMGLVBI TI TTFQAYR DMGLVBI TN Cholesteryl ester transfer protein (CETP) DMGLVBI MA Inhibitor DMGLVBI RN The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. DMGLVBI RU https://pubmed.ncbi.nlm.nih.gov/25323928 DMGMC8H DI DMGMC8H DMGMC8H DN LY333531 DMGMC8H TI TT9SL3Q DMGMC8H TN Polypeptide deformylase (PDF) DMGMC8H MA Inhibitor DMGMC8H RN Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. J Mol Biol. 2000 Jan 14;295(2):307-23. DMGMC8H RU https://pubmed.ncbi.nlm.nih.gov/10623528 DMGMC8H DI DMGMC8H DMGMC8H DN LY333531 DMGMC8H TI TTYPXQF DMGMC8H TN Protein kinase C beta (PRKCB) DMGMC8H MA Inhibitor DMGMC8H RN Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8. DMGMC8H RU https://pubmed.ncbi.nlm.nih.gov/12540629 DMGNFBC DI DMGNFBC DMGNFBC DN APN301 DMGNFBC TI TT80ARU DMGNFBC TN Ganglioside GD2 (GD2) DMGNFBC MA Inhibitor DMGNFBC RN Clinical pipeline report, company report or official report of Apeiron Biologics. DMGNFBC RU https://www.apeiron-biologics.com/childrens-oncology-group-and-apeiron-to-jointly-conduct-phase-ii-study-in-neuroblastoma-with-hu14-18-il2-apn301/ DMGNK67 DI DMGNK67 DMGNK67 DN TETRAPLATIN TETRANITRATE DMGNK67 TI TTUTN1I DMGNK67 TN Human Deoxyribonucleic acid (hDNA) DMGNK67 MA Binder DMGNK67 RN Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines. Anticancer Drugs. 1993 Apr;4(2):251-8. DMGNK67 RU https://pubmed.ncbi.nlm.nih.gov/8490203 DMGO45I DI DMGO45I DMGO45I DN FR-146687 DMGO45I TI TTTU72V DMGO45I TN Steroid 5-alpha-reductase 1 (SRD5A1) DMGO45I MA Inhibitor DMGO45I RN Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94. DMGO45I RU https://pubmed.ncbi.nlm.nih.gov/12236849 DMGO7QT DI DMGO7QT DMGO7QT DN INK128 DMGO7QT TI TTCJG29 DMGO7QT TN Serine/threonine-protein kinase mTOR (mTOR) DMGO7QT MA Inhibitor DMGO7QT RN 2011 Pipeline of Intellikine. DMGO7QT RU http://www.intellikine.com/pipeline/ DMGOFL3 DI DMGOFL3 DMGOFL3 DN AMG 151 DMGOFL3 TI TTDLNGZ DMGOFL3 TN Glucokinase (GCK) DMGOFL3 MA Inhibitor DMGOFL3 RN This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009 DMGOFL3 RU http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf DMGP9VN DI DMGP9VN DMGP9VN DN PDC-1421 DMGP9VN TI TTAWNKZ DMGP9VN TN Norepinephrine transporter (NET) DMGP9VN MA Inhibitor DMGP9VN RN Clinical pipeline report, company report or official report of BioInvent. DMGP9VN RU https://www.biolite.com.tw/tw/medicine/bli1005.html DMGQ175 DI DMGQ175 DMGQ175 DN Mapatumumab DMGQ175 TI TT5WLRX DMGQ175 TN TRAIL receptor 1 (TRAIL-R1) DMGQ175 MA Modulator DMGQ175 RN National Cancer Institute Drug Dictionary (drug id 486626). DMGQ175 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=486626 DMGQSVX DI DMGQSVX DMGQSVX DN AZD-2115 DMGQSVX TI TTOXS3C DMGQSVX TN Muscarinic acetylcholine receptor (CHRM) DMGQSVX MA Agonist DMGQSVX RN Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83. DMGQSVX RU https://pubmed.ncbi.nlm.nih.gov/22917191 DMGQSVX DI DMGQSVX DMGQSVX DN AZD-2115 DMGQSVX TI TT2CJVK DMGQSVX TN Adrenergic receptor beta-2 (ADRB2) DMGQSVX MA Agonist DMGQSVX RN Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115. Expert Opin Ther Pat. 2012 Nov;22(11):1377-83. DMGQSVX RU https://pubmed.ncbi.nlm.nih.gov/22917191 DMGROQP DI DMGROQP DMGROQP DN FK-505 DMGROQP TI TTFH2RS DMGROQP TN FK506-binding protein (FKBP) DMGROQP MA Modulator DMGROQP RN Prevention of Cardiac Hypertrophy by Calcineurin Inhibition. Circulation Research. 1999; 84: 623-632. DMGROQP RU http://circres.ahajournals.org/content/84/6/623.full.html DMGTB2Q DI DMGTB2Q DMGTB2Q DN SSR411298 DMGTB2Q TI TTDP1UC DMGTB2Q TN Fatty acid amide hydrolase (FAAH) DMGTB2Q MA Inhibitor DMGTB2Q RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMGTB2Q RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMGTJUP DI DMGTJUP DMGTJUP DN IONIS-PTP1BRX DMGTJUP TI TTMS7KP DMGTJUP TN Protein-tyrosine phosphatase 1B (PTP1B) DMGTJUP MA Inhibitor DMGTJUP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGTJUP RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMGU05N DI DMGU05N DMGU05N DN GSK598809 DMGU05N TI TT4C8EA DMGU05N TN Dopamine D3 receptor (D3R) DMGU05N MA Antagonist DMGU05N RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMGU05N RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMGUI51 DI DMGUI51 DMGUI51 DN MSDC-0602 DMGUI51 TI TTCBFJO DMGUI51 TN Insulin receptor (INSR) DMGUI51 MA Modulator DMGUI51 RN Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J Biol Chem. 2012 Jul 6;287(28):23537-48. DMGUI51 RU https://pubmed.ncbi.nlm.nih.gov/22621923 DMGUTPN DI DMGUTPN DMGUTPN DN ABT-414 DMGUTPN TI TTGKNB4 DMGUTPN TN Epidermal growth factor receptor (EGFR) DMGUTPN RN Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278. DMGUTPN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/ DMGVKHQ DI DMGVKHQ DMGVKHQ DN ADX10059 DMGVKHQ TI TTHS256 DMGVKHQ TN Metabotropic glutamate receptor 5 (mGluR5) DMGVKHQ MA Modulator DMGVKHQ RN A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and... Gut. 2009 Sep;58(9):1192-9. DMGVKHQ RU https://pubmed.ncbi.nlm.nih.gov/19460767 DMGVQI8 DI DMGVQI8 DMGVQI8 DN AM-001 DMGVQI8 TI TTRLW2X DMGVQI8 TN Fibroblast growth factor receptor 1 (FGFR1) DMGVQI8 MA Antagonist DMGVQI8 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029917) DMGVQI8 RU http://adisinsight.springer.com/drugs/800029917 DMGWE4H DI DMGWE4H DMGWE4H DN TGFK09SD DMGWE4H TI TTSQIFT DMGWE4H TN 5-HT 1A receptor (HTR1A) DMGWE4H MA Modulator DMGWE4H RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032503) DMGWE4H RU http://adisinsight.springer.com/drugs/800032503 DMGWNCJ DI DMGWNCJ DMGWNCJ DN Ifabotuzumab DMGWNCJ TI TTHS2LR DMGWNCJ TN Ephrin type-A receptor 3 (EPHA3) DMGWNCJ MA Antagonist DMGWNCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGWNCJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGWP8L DI DMGWP8L DMGWP8L DN TLC-388 DMGWP8L TI TTGTQHC DMGWP8L TN DNA topoisomerase I (TOP1) DMGWP8L MA Inhibitor DMGWP8L RN Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12. DMGWP8L RU https://pubmed.ncbi.nlm.nih.gov/9885371 DMGWZ93 DI DMGWZ93 DMGWZ93 DN Lulizumab pegol DMGWZ93 TI TTQ13FT DMGWZ93 TN T-cell-specific surface glycoprotein CD28 (CD28) DMGWZ93 MA Modulator DMGWZ93 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGWZ93 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMGXTOP DI DMGXTOP DMGXTOP DN JTX-2011 DMGXTOP TI TTE5VP6 DMGXTOP TN Inducible T-cell costimulator (ICOS) DMGXTOP MA Agonist DMGXTOP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGXTOP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGY5JC DI DMGY5JC DMGY5JC DN Pentacea DMGY5JC TI TTY6DTE DMGY5JC TN Carcinoembryonic antigen CEA (CD66e) DMGY5JC RN Antibody fragments: Hope and hype. MAbs. 2010 Jan-Feb; 2(1): 77-83. DMGY5JC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828581/ DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TTLYXIT DMGYBZI TN Aurora kinase C (AURKC) DMGYBZI MA Inhibitor DMGYBZI RN Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/15828847 DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TT9RTBL DMGYBZI TN Aurora B messenger RNA (AURKB mRNA) DMGYBZI MA Inhibitor DMGYBZI RN Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/15828847 DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TT5LS6T DMGYBZI TN Aurora kinase B (AURKB) DMGYBZI MA Inhibitor DMGYBZI RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMGYBZI DI DMGYBZI DMGYBZI DN PHA-739358 DMGYBZI TI TTPS3C0 DMGYBZI TN Aurora kinase A (AURKA) DMGYBZI MA Inhibitor DMGYBZI RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMGYBZI RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMGYSZ0 DI DMGYSZ0 DMGYSZ0 DN TVI-Kidney-1 DMGYSZ0 TI TTXQYT6 DMGYSZ0 TN T-cells (T-cells) DMGYSZ0 RN Clinical pipeline report, company report or official report of TVAX Biomedical. DMGYSZ0 RU http://www.tvaxbiomedical.com/tvi-kidney.shtml DMGYXFP DI DMGYXFP DMGYXFP DN BMS-582949 DMGYXFP TI TTGFK5X DMGYXFP TN Protein kinase unspecific (PK) DMGYXFP MA Modulator DMGYXFP RN Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33. DMGYXFP RU https://pubmed.ncbi.nlm.nih.gov/23578688 DMGYXFP DI DMGYXFP DMGYXFP DN BMS-582949 DMGYXFP TI TTWELHI DMGYXFP TN Stress-activated protein kinase (p38) DMGYXFP MA Inhibitor DMGYXFP RN Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38alpha inhibitor. Bioorg Med Chem Lett. 2013 May 15;23(10):3028-33. DMGYXFP RU https://pubmed.ncbi.nlm.nih.gov/23578688 DMH0C8J DI DMH0C8J DMH0C8J DN GW-813893 DMH0C8J TI TTCIHJA DMH0C8J TN Coagulation factor Xa (F10) DMH0C8J MA Inhibitor DMH0C8J RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMH0C8J RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMH0LM2 DI DMH0LM2 DMH0LM2 DN POT-4 DMH0LM2 TI TTJGY7A DMH0LM2 TN Complement C3 (CO3) DMH0LM2 MA Inhibitor DMH0LM2 RN Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292. DMH0LM2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2700864/ DMH1DYU DI DMH1DYU DMH1DYU DN MSC1936369B DMH1DYU TI TTROQ37 DMH1DYU TN MAPK/ERK kinase kinase (MAP3K) DMH1DYU MA Modulator DMH1DYU RN Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer. 2013 Nov;133(9):2089-101. DMH1DYU RU https://pubmed.ncbi.nlm.nih.gov/23629727 DMH2VS0 DI DMH2VS0 DMH2VS0 DN CLP-1001 DMH2VS0 TI TTWN7KV DMH2VS0 TN Na-K-Cl cotransporter (NKCC) DMH2VS0 MA Modulator DMH2VS0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034446) DMH2VS0 RU http://adisinsight.springer.com/drugs/800034446 DMH3YKJ DI DMH3YKJ DMH3YKJ DN LY2382770 DMH3YKJ TI TTO3HT7 DMH3YKJ TN Transforming growth factor beta (TGFB) DMH3YKJ MA Inhibitor DMH3YKJ RN A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31. DMH3YKJ RU https://pubmed.ncbi.nlm.nih.gov/25270361 DMH4BFD DI DMH4BFD DMH4BFD DN TN-871 DMH4BFD TI TTTD45S DMH4BFD TN Neurotransmitter release (NT rele) DMH4BFD MA Modulator DMH4BFD RN Effects of an indene-derivative, TN-871, on synaptic transmission in a sympathetic ganglion: presynaptic actions on neurotransmitter release. Bull Tokyo Med Dent Univ. 1995 Mar;42(1):19-29. DMH4BFD RU https://pubmed.ncbi.nlm.nih.gov/7895315 DMH4C3M DI DMH4C3M DMH4C3M DN STA-5326 DMH4C3M TI TTRTK6Y DMH4C3M TN Interleukin-12 alpha (IL12A) DMH4C3M MA Inhibitor DMH4C3M RN Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122. DMH4C3M RU https://pubmed.ncbi.nlm.nih.gov/18847496 DMH5CAL DI DMH5CAL DMH5CAL DN ARQ 761 DMH5CAL TI TT8XK6L DMH5CAL TN Quinone reductase 1 (NQO1) DMH5CAL MA Inhibitor DMH5CAL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH5CAL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH5GQU DI DMH5GQU DMH5GQU DN CO-101 DMH5GQU TI TTUTN1I DMH5GQU TN Human Deoxyribonucleic acid (hDNA) DMH5GQU MA Inhibitor DMH5GQU RN Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12. DMH5GQU RU https://pubmed.ncbi.nlm.nih.gov/16807468 DMH5GQU DI DMH5GQU DMH5GQU DN CO-101 DMH5GQU TI TTBWDI0 DMH5GQU TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMH5GQU MA Inhibitor DMH5GQU RN Cellular pharmacology of gemcitabine. Ann Oncol. 2006 May;17 Suppl 5:v7-12. DMH5GQU RU https://pubmed.ncbi.nlm.nih.gov/16807468 DMH5LFR DI DMH5LFR DMH5LFR DN ALXN6000 DMH5LFR TI TT0BE68 DMH5LFR TN Membrane glycoprotein OX2 (CD200) DMH5LFR RN American Society of Hematology, 52nd Annual Meeting and Exposition. P T. 2011 February; 36(2): 100-103. DMH5LFR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086088/ DMH5MVE DI DMH5MVE DMH5MVE DN Sodium stibogluconate DMH5MVE TI TTNJKC3 DMH5MVE TN Leishmania DNA topoisomerase I (Leishm TOP1) DMH5MVE MA Modulator DMH5MVE RN Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J Parasitol. 2004 Oct;90(5):1155-62. DMH5MVE RU https://pubmed.ncbi.nlm.nih.gov/15562618 DMH6XJG DI DMH6XJG DMH6XJG DN WCK-2349 DMH6XJG TI TTIXTO3 DMH6XJG TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMH6XJG MA Modulator DMH6XJG RN DOI: 10.1038/ja.2013.86 DMH6XJG RU http://www.nature.com/ja/journal/v66/n10/fig_tab/ja201386t3.html DMH7Q4E DI DMH7Q4E DMH7Q4E DN Bimagrumab DMH7Q4E TI TTRG4QN DMH7Q4E TN Activin receptor type II (ACVR2) DMH7Q4E MA Inhibitor DMH7Q4E RN Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol (Oxf). 2018 Jun;88(6):908-919. DMH7Q4E RU https://pubmed.ncbi.nlm.nih.gov/29566437 DMH7RJ1 DI DMH7RJ1 DMH7RJ1 DN BIIB014 DMH7RJ1 TI TTM2AOE DMH7RJ1 TN Adenosine A2a receptor (ADORA2A) DMH7RJ1 MA Antagonist DMH7RJ1 RN Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. DMH7RJ1 RU https://pubmed.ncbi.nlm.nih.gov/17016425 DMH85M0 DI DMH85M0 DMH85M0 DN ZD-6126 DMH85M0 TI TTYFKSZ DMH85M0 TN Tubulin beta (TUBB) DMH85M0 MA Inhibitor DMH85M0 RN Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008 Apr;26(2):159-67. DMH85M0 RU https://pubmed.ncbi.nlm.nih.gov/18219445 DMH96JW DI DMH96JW DMH96JW DN Dersalazine DMH96JW TI TTQL5VC DMH96JW TN Platelet-activating factor receptor (PTAFR) DMH96JW MA Inhibitor DMH96JW RN The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740. DMH96JW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315044/ DMH97XA DI DMH97XA DMH97XA DN Igmesine DMH97XA TI TTA7UJC DMH97XA TN Alpha-1-antitrypsin (SERPINA1) DMH97XA MA Modulator DMH97XA RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMH97XA RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMH97XA DI DMH97XA DMH97XA DN Igmesine DMH97XA TI TT5TPI6 DMH97XA TN Opioid receptor sigma 1 (OPRS1) DMH97XA MA Agonist DMH97XA RN Antiamnesic and neuroprotective effects of donepezil against learning impairments induced in mice by exposure to carbon monoxide gas. J Pharmacol Exp Ther. 2006 Jun;317(3):1307-19. DMH97XA RU https://pubmed.ncbi.nlm.nih.gov/16551835 DMH9JFZ DI DMH9JFZ DMH9JFZ DN NBI-5788 DMH9JFZ TI TT2RY5P DMH9JFZ TN Myelin basic protein (MBP) DMH9JFZ MA Binder DMH9JFZ RN NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann Neurol. 2000 Nov;48(5):758-65. DMH9JFZ RU https://pubmed.ncbi.nlm.nih.gov/11079539 DMH9RTV DI DMH9RTV DMH9RTV DN Omigapil DMH9RTV TI TTUGSWA DMH9RTV TN Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DMH9RTV MA Modulator DMH9RTV RN Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3887-9. DMH9RTV RU https://pubmed.ncbi.nlm.nih.gov/16505364 DMHBN8X DI DMHBN8X DMHBN8X DN 60P002 DMHBN8X TI TTQL5VC DMHBN8X TN Platelet-activating factor receptor (PTAFR) DMHBN8X MA Antagonist DMHBN8X RN Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals. DMHBN8X RU https://60degreespharma.com/research-development/clinical-pipeline/ DMHBOUX DI DMHBOUX DMHBOUX DN CORT125281 DMHBOUX TI TTOZRK6 DMHBOUX TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMHBOUX MA Antagonist DMHBOUX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHBOUX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHC2AW DI DMHC2AW DMHC2AW DN SPI-205 DMHC2AW TI TTEDJN4 DMHC2AW TN Low-affinity nerve growth factor receptor (NGFR) DMHC2AW MA Modulator DMHC2AW RN AIT-082 NeoTherapeutics Inc. IDrugs. 1998 Oct;1(6):694-9. DMHC2AW RU https://www.ncbi.nlm.nih.gov/pubmed/18465624 DMHET8R DI DMHET8R DMHET8R DN VRC-HIVDNA016-00-VP DMHET8R TI TTUIFO6 DMHET8R TN Human immunodeficiency virus Adenovector Ad35 (HIV Ad35) DMHET8R RN ClinicalTrials.gov (NCT00123968) Safety of and Immune Response to an HIV-1 Vaccine (VRC-HIVDNA016-00-VP) and a Vaccine Booster (VRC-HIVADV014-00-VP) in HIV Uninfected East African Adults. U.S. National Institutes of Health. DMHET8R RU https://clinicaltrials.gov/ct2/show/NCT00123968 DMHETPI DI DMHETPI DMHETPI DN ISIS-FXI DMHETPI TI TTDM4ZU DMHETPI TN Factor XI messenger RNA (F11 mRNA) DMHETPI RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMHETPI RU http://www.isispharm.com/index.htm DMHEWT7 DI DMHEWT7 DMHEWT7 DN TRU-015 DMHEWT7 TI TTUE541 DMHEWT7 TN Leukocyte surface antigen Leu-16 (CD20) DMHEWT7 MA Antagonist DMHEWT7 RN TRU-015, a small modular immunopharmaceutical (SMIP drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis. Arthritis Res Ther. 2007; 9(Suppl 3): P32. DMHEWT7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061958/ DMHFUJT DI DMHFUJT DMHFUJT DN AZ-01, PEGylated interferon-beta DMHFUJT TI TT4TZ8J DMHFUJT TN Interferon-beta (IFNB1) DMHFUJT MA Modulator DMHFUJT RN PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138. DMHFUJT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ DMHG3UR DI DMHG3UR DMHG3UR DN NOX-E36 DMHG3UR TI TTNAY0P DMHG3UR TN Monocyte chemotactic and activating factor (CCL2) DMHG3UR MA Inhibitor DMHG3UR RN Crystal structure of a mirror-image L-RNA aptamer (Spiegelmer) in complex with the natural L-protein target CCL2. Nat Commun. 2015 Apr 22;6:6923. DMHG3UR RU https://pubmed.ncbi.nlm.nih.gov/25901662 DMHI36A DI DMHI36A DMHI36A DN IFX-1 DMHI36A TI TTKANGO DMHI36A TN Complement C5 (CO5) DMHI36A MA Inhibitor DMHI36A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHI36A RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHI6GE DI DMHI6GE DMHI6GE DN Pirsidomine DMHI6GE TI TT6HPVC DMHI6GE TN Guanylate cyclase (GC) DMHI6GE MA Modulator DMHI6GE RN Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998 Jul;54(1):207-12. DMHI6GE RU https://pubmed.ncbi.nlm.nih.gov/9658207 DMHJEZS DI DMHJEZS DMHJEZS DN CR-3294 DMHJEZS TI TTF10I9 DMHJEZS TN Nitric-oxide synthase inducible (NOS2) DMHJEZS MA Inhibitor DMHJEZS RN Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827. DMHJEZS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2926937/ DMHJTR2 DI DMHJTR2 DMHJTR2 DN XL880 DMHJTR2 TI TTUTJGQ DMHJTR2 TN Vascular endothelial growth factor receptor 2 (KDR) DMHJTR2 MA Modulator DMHJTR2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHJTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHJTR2 DI DMHJTR2 DMHJTR2 DN XL880 DMHJTR2 TI TTNDSF4 DMHJTR2 TN Proto-oncogene c-Met (MET) DMHJTR2 MA Modulator DMHJTR2 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHJTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHKIOF DI DMHKIOF DMHKIOF DN OT551 DMHKIOF TI TTA6ZN2 DMHKIOF TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMHKIOF MA Activator DMHKIOF RN Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. DMHKIOF RU https://pubmed.ncbi.nlm.nih.gov/26594225 DMHKTGX DI DMHKTGX DMHKTGX DN BAY 1142524 DMHKTGX TI TT8VUE0 DMHKTGX TN Chymase (CYM) DMHKTGX MA Inhibitor DMHKTGX RN Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479. DMHKTGX RU https://pubmed.ncbi.nlm.nih.gov/29878583 DMHLXUY DI DMHLXUY DMHLXUY DN ASP8273 DMHLXUY TI TTGKNB4 DMHLXUY TN Epidermal growth factor receptor (EGFR) DMHLXUY MA Inhibitor DMHLXUY RN Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083. DMHLXUY RU http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8083 DMHMV6E DI DMHMV6E DMHMV6E DN BMS-986020 DMHMV6E TI TTQ6S1K DMHMV6E TN Lysophosphatidic acid receptor 1 (LPAR1) DMHMV6E MA Antagonist DMHMV6E RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHMV6E RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMHNIGB DI DMHNIGB DMHNIGB DN GPX-150D DMHNIGB TI TT0IHXV DMHNIGB TN DNA topoisomerase II (TOP2) DMHNIGB MA Modulator DMHNIGB RN Company report (Gem pharmaceuticals) DMHNIGB RU http://www.gempharmaceuticals.com/targeted-therapy-approach.shtml DMHNYWP DI DMHNYWP DMHNYWP DN ISIS-GCGR DMHNYWP TI TTLMJSC DMHNYWP TN Glucagon receptor messenger RNA (GCGR mRNA) DMHNYWP RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMHNYWP RU http://www.isispharm.com/index.htm DMHOF7T DI DMHOF7T DMHOF7T DN MEHD-7945A DMHOF7T TI TTGKNB4 DMHOF7T TN Epidermal growth factor receptor (EGFR) DMHOF7T MA Modulator DMHOF7T RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHOF7T RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHOF7T DI DMHOF7T DMHOF7T DN MEHD-7945A DMHOF7T TI TTDC8N2 DMHOF7T TN Erbb3 tyrosine kinase receptor (Erbb-3) DMHOF7T MA Modulator DMHOF7T RN Company report (Biooncology) DMHOF7T RU http://www.biooncology.com/pipeline-molecules/anti-her3 DMHOJ8W DI DMHOJ8W DMHOJ8W DN Isatoribine DMHOJ8W TI TTRJ1K4 DMHOJ8W TN Toll-like receptor 7 (TLR7) DMHOJ8W MA Agonist DMHOJ8W RN Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40. DMHOJ8W RU https://pubmed.ncbi.nlm.nih.gov/18066870 DMHOLB7 DI DMHOLB7 DMHOLB7 DN A-85380 DMHOLB7 TI TTJSZTB DMHOLB7 TN Nicotinic acetylcholine receptor (nAChR) DMHOLB7 MA Agonist DMHOLB7 RN The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30. DMHOLB7 RU https://pubmed.ncbi.nlm.nih.gov/11772288 DMHPEFS DI DMHPEFS DMHPEFS DN TAK-128 DMHPEFS TI TT2O84V DMHPEFS TN Thromboxane A2 receptor (TBXA2R) DMHPEFS MA Modulator DMHPEFS RN ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health. DMHPEFS RU https://clinicaltrials.gov/ct2/show/NCT00229437 DMHQKN6 DI DMHQKN6 DMHQKN6 DN CART-19 DMHQKN6 TI TTW640A DMHQKN6 TN B-lymphocyte surface antigen B4 (CD19) DMHQKN6 MA CAR-T-Cell-Therapy DMHQKN6 RN ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy DMHQKN6 RU https://clinicaltrials.gov/ct2/show/NCT01029366 DMHQV6R DI DMHQV6R DMHQV6R DN GS-4059 DMHQV6R TI TTGM6VW DMHQV6R TN Tyrosine-protein kinase BTK (ATK) DMHQV6R MA Inhibitor DMHQV6R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHQV6R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHSL87 DI DMHSL87 DMHSL87 DN Methoxyestradiol DMHSL87 TI TT6RVLG DMHSL87 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMHSL87 MA Inhibitor DMHSL87 RN Antitumor effects of photodynamic therapy are potentiated by 2-methoxyestradiol. A superoxide dismutase inhibitor. J Biol Chem. 2003 Jan 3;278(1):407-14. DMHSL87 RU https://pubmed.ncbi.nlm.nih.gov/12409296 DMHTIGU DI DMHTIGU DMHTIGU DN MK-5442 DMHTIGU TI TTBUYHA DMHTIGU TN Extracellular calcium-sensing receptor (CASR) DMHTIGU MA Modulator DMHTIGU RN Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93. DMHTIGU RU https://pubmed.ncbi.nlm.nih.gov/21187599 DMHU8SJ DI DMHU8SJ DMHU8SJ DN MB07803 DMHU8SJ TI TTWHDVK DMHU8SJ TN Fructose-1,6-bisphosphatase (FBP) DMHU8SJ MA Modulator DMHU8SJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHU8SJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHUCQS DI DMHUCQS DMHUCQS DN PL-3994 DMHUCQS TI TTJME02 DMHUCQS TN Atrial natriuretic peptide receptor A (NPR1) DMHUCQS MA Agonist DMHUCQS RN In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH2) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator. Pulm Pharmacol Ther. 2013 April; 26(2): 229-238. DMHUCQS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070431/ DMHVEGJ DI DMHVEGJ DMHVEGJ DN CC-930 DMHVEGJ TI TTR2TXZ DMHVEGJ TN Jun N terminal kinase (JNK) DMHVEGJ MA Modulator DMHVEGJ RN In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80. DMHVEGJ RU https://pubmed.ncbi.nlm.nih.gov/25475995 DMHVJZ6 DI DMHVJZ6 DMHVJZ6 DN SAM-531 DMHVJZ6 TI TTJS8PY DMHVJZ6 TN 5-HT 6 receptor (HTR6) DMHVJZ6 MA Antagonist DMHVJZ6 RN Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9. DMHVJZ6 RU https://pubmed.ncbi.nlm.nih.gov/23336058 DMHVZ27 DI DMHVZ27 DMHVZ27 DN Anti-CD137 DMHVZ27 TI TTPW9LJ DMHVZ27 TN Co-stimulatory molecule 4-1BB (CD137) DMHVZ27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878). DMHVZ27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878 DMHYZEK DI DMHYZEK DMHYZEK DN BIBH 1 DMHYZEK TI TTGPQ0F DMHYZEK TN Prolyl endopeptidase FAP (FAP) DMHYZEK RN A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47. DMHYZEK RU https://pubmed.ncbi.nlm.nih.gov/12738716 DMHZ4JI DI DMHZ4JI DMHZ4JI DN HGT-1410 DMHZ4JI TI TTPJ2SH DMHZ4JI TN N-sulphoglucosamine sulphohydrolase (SGSH) DMHZ4JI MA Modulator DMHZ4JI RN ClinicalTrials.gov (NCT01155778) Safety, Tolerability, Ascending Dose and Dose Frequency Study of rhHNS Via an IDDD in MPS IIIA Patients. U.S. National Institutes of Health. DMHZ4JI RU https://clinicaltrials.gov/ct2/show/NCT01155778 DMHZIFJ DI DMHZIFJ DMHZIFJ DN PS-938285 DMHZIFJ TI TT30C9G DMHZIFJ TN C-X-C chemokine receptor type 2 (CXCR2) DMHZIFJ MA Antagonist DMHZIFJ RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMHZIFJ RU http://www.centerwatch.com/ DMI2GSK DI DMI2GSK DMI2GSK DN Coluracetam DMI2GSK TI TTAN6JD DMI2GSK TN Glutamate receptor AMPA (GRIA) DMI2GSK MA Modulator DMI2GSK RN MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats. J Neural Transm. 2008 Jul;115(7):1027-35. DMI2GSK RU https://pubmed.ncbi.nlm.nih.gov/18446264 DMI2XP1 DI DMI2XP1 DMI2XP1 DN L19-IL-2 fusion protein DMI2XP1 TI TTF89GD DMI2XP1 TN Interleukin-2 (IL2) DMI2XP1 RN National Cancer Institute Drug Dictionary (drug id 665656). DMI2XP1 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=665656 DMI3WFG DI DMI3WFG DMI3WFG DN AMG 334 DMI3WFG TI TTY6O0Q DMI3WFG TN Calcitonin gene-related peptide receptor (CGRPR) DMI3WFG MA Modulator DMI3WFG RN EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP receptor. J Headache Pain. 2014; 15(Suppl 1): G43. DMI3WFG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182181/ DMI4C90 DI DMI4C90 DMI4C90 DN HF-0220 DMI4C90 TI TTCYE56 DMI4C90 TN Glutathione-dependent PGD synthase (HPGDS) DMI4C90 MA Stimulator DMI4C90 RN US patent application no. 2009,0062,529, Multi-cyclic compounds. DMI4C90 RU http://www.google.st/patents/US20090062529 DMI4E9K DI DMI4E9K DMI4E9K DN MLN0264 DMI4E9K TI TTLDPRG DMI4E9K TN Guanylyl cyclase C (GUCY2C) DMI4E9K MA Modulator DMI4E9K RN J Clin Oncol 31, 2013 (suppl; abstr TPS3646). DMI4E9K RU http://meetinglibrary.asco.org/content/111779-132 DMI57ZA DI DMI57ZA DMI57ZA DN TGWOOAA DMI57ZA TI TTYSN63 DMI57ZA TN 5-HT 2 receptor (5HT2R) DMI57ZA MA Antagonist DMI57ZA RN Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. DMI57ZA RU http://www.fabrekramer.com/?page_id=70 DMI57ZA DI DMI57ZA DMI57ZA DN TGWOOAA DMI57ZA TI TTSQIFT DMI57ZA TN 5-HT 1A receptor (HTR1A) DMI57ZA MA Antagonist DMI57ZA RN Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. DMI57ZA RU http://www.fabrekramer.com/?page_id=70 DMI5HFU DI DMI5HFU DMI5HFU DN NS 2359 DMI5HFU TI TTVBI8W DMI5HFU TN Dopamine transporter (DAT) DMI5HFU MA Inhibitor DMI5HFU RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMI5HFU RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMI5HFU DI DMI5HFU DMI5HFU DN NS 2359 DMI5HFU TI TTAWNKZ DMI5HFU TN Norepinephrine transporter (NET) DMI5HFU MA Inhibitor DMI5HFU RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMI5HFU RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMI5HFU DI DMI5HFU DMI5HFU DN NS 2359 DMI5HFU TI TT3ROYC DMI5HFU TN Serotonin transporter (SERT) DMI5HFU MA Inhibitor DMI5HFU RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMI5HFU RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMI5TXZ DI DMI5TXZ DMI5TXZ DN AEM-28 DMI5TXZ TI TTKS9CB DMI5TXZ TN Apolipoprotein E (APOE) DMI5TXZ MA Modulator DMI5TXZ RN Clinical pipeline report, company report or official report of LipimetiX. DMI5TXZ RU http://www.lipimetix.com/technology.html DMI69E5 DI DMI69E5 DMI69E5 DN DS-3201b DMI69E5 TI TTNJA0C DMI69E5 TN Enhancer of zeste homolog 1 (EZH1) DMI69E5 MA Inhibitor DMI69E5 RN Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. DMI69E5 RU https://pubmed.ncbi.nlm.nih.gov/30658046 DMI69E5 DI DMI69E5 DMI69E5 DN DS-3201b DMI69E5 TI TT9MZCQ DMI69E5 TN Enhancer of zeste homolog 2 (EZH2) DMI69E5 MA Inhibitor DMI69E5 RN Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. DMI69E5 RU https://pubmed.ncbi.nlm.nih.gov/30658046 DMI874B DI DMI874B DMI874B DN Iratumumab DMI874B TI TT2GM5R DMI874B TN Lymphocyte activation antigen CD30 (TNFRSF8) DMI874B RN Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2. DMI874B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3337265/ DMI9WVM DI DMI9WVM DMI9WVM DN MEDI-575 DMI9WVM TI TT8FYO9 DMI9WVM TN Platelet-derived growth factor receptor alpha (PDGFRA) DMI9WVM RN Clinical pipeline report, company report or official report of MedImmune (2011). DMI9WVM RU http://www.medimmune.com/research_pipeline.aspx DMIAZ13 DI DMIAZ13 DMIAZ13 DN Ponezumab DMIAZ13 TI TTE4KHA DMIAZ13 TN Amyloid beta A4 protein (APP) DMIAZ13 RN Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36. DMIAZ13 RU https://pubmed.ncbi.nlm.nih.gov/22197375 DMIBXK0 DI DMIBXK0 DMIBXK0 DN AZD-7009 DMIBXK0 TI TT1VOHK DMIBXK0 TN Potassium channel unspecific (KC) DMIBXK0 MA Modulator DMIBXK0 RN Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. J Electrocardiol. 2014 May-Jun;47(3):316-23. DMIBXK0 RU https://pubmed.ncbi.nlm.nih.gov/24508473 DMICMNU DI DMICMNU DMICMNU DN ISIS-GCCR DMICMNU TI TTOZRK6 DMICMNU TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMICMNU RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMICMNU RU http://www.isispharm.com/index.htm DMICMXE DI DMICMXE DMICMXE DN Ferroquine DMICMXE TI TT0OV9N DMICMXE TN Haematin (HA) DMICMXE MA Inhibitor DMICMXE RN Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol Pharm. 2005 May-Jun;2(3):185-93. DMICMXE RU https://www.ncbi.nlm.nih.gov/pubmed/15934779 DMIEPJG DI DMIEPJG DMIEPJG DN BTT-1023 DMIEPJG TI TT7HC21 DMIEPJG TN Membrane copper amine oxidase (AOC3) DMIEPJG RN Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9. DMIEPJG RU https://pubmed.ncbi.nlm.nih.gov/23847292 DMIERPK DI DMIERPK DMIERPK DN UE-2343 DMIERPK TI TTN7BL9 DMIERPK TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMIERPK MA Inhibitor DMIERPK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIERPK RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMIEXUM DI DMIEXUM DMIEXUM DN GSK768974 DMIEXUM TI TTEPJL5 DMIEXUM TN Parathyroid hormone receptor (PTH2R) DMIEXUM MA Agonist DMIEXUM RN Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone. 2000 Oct;27(4):471-8. DMIEXUM RU https://pubmed.ncbi.nlm.nih.gov/11033441 DMIEZUB DI DMIEZUB DMIEZUB DN L-DOS47 DMIEZUB TI TTUTJGQ DMIEZUB TN Vascular endothelial growth factor receptor 2 (KDR) DMIEZUB RN Clinical pipeline report, company report or official report of Helix BioPharma. DMIEZUB RU https://www.helixbiopharma.com/pipeline/ DMIFA0L DI DMIFA0L DMIFA0L DN APG-115 DMIFA0L TI TT08GJW DMIFA0L TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMIFA0L MA Inhibitor DMIFA0L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIFA0L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIFA0L DI DMIFA0L DMIFA0L DN APG-115 DMIFA0L TI TT7SBF5 DMIFA0L TN Cellular tumor antigen p53 (TP53) DMIFA0L MA Inhibitor DMIFA0L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIFA0L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIFGLY DI DMIFGLY DMIFGLY DN Leukemia cancer vaccine DMIFGLY TI TT6MP2Z DMIFGLY TN GMCSFR-alpha (CSF2RA) DMIFGLY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DMIFGLY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DMIG98L DI DMIG98L DMIG98L DN RC-3095 DMIG98L TI TTC1MVT DMIG98L TN Gastrin-releasing peptide receptor (GRPR) DMIG98L MA Inhibitor DMIG98L RN Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005 Aug 4;24(33):5262-8. DMIG98L RU https://pubmed.ncbi.nlm.nih.gov/15940257 DMIHQ5G DI DMIHQ5G DMIHQ5G DN IL-2/CD40L-expressing leukemia vaccine DMIHQ5G TI TTF89GD DMIHQ5G TN Interleukin-2 (IL2) DMIHQ5G RN Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41. DMIHQ5G RU https://pubmed.ncbi.nlm.nih.gov/16249392 DMIHQ5G DI DMIHQ5G DMIHQ5G DN IL-2/CD40L-expressing leukemia vaccine DMIHQ5G TI TTIJP3Q DMIHQ5G TN TNF related activation protein (CD40LG) DMIHQ5G RN Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41. DMIHQ5G RU https://pubmed.ncbi.nlm.nih.gov/16249392 DMIJNLG DI DMIJNLG DMIJNLG DN Semapimod DMIJNLG TI TTB18GJ DMIJNLG TN Proto-oncogene c-RAF (c-RAF) DMIJNLG MA Modulator DMIJNLG RN Specific inhibition of c-Raf activity by semapimod induces clinical remission in severe Crohn's disease. J Immunol. 2005 Aug 15;175(4):2293-300. DMIJNLG RU https://pubmed.ncbi.nlm.nih.gov/16081798 DMIK2AD DI DMIK2AD DMIK2AD DN OPC-64005 DMIK2AD TI TT8G3Z7 DMIK2AD TN Serotoninnorepinephrinedopamine reuptake (SNDR) DMIK2AD MA Inhibitor DMIK2AD RN Clinical pipeline report, company report or official report of Otsuka Pharmaceutical. DMIK2AD RU https://www.otsuka.co.jp/en/research-and-development/pipeline/ DMIKH67 DI DMIKH67 DMIKH67 DN Valetizumab DMIKH67 TI TTMSB0A DMIKH67 TN Integrin alpha-2/beta-1 (ITGA2/B1) DMIKH67 RN Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146. DMIKH67 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492762/ DMIM1U9 DI DMIM1U9 DMIM1U9 DN Vorolanib DMIM1U9 TI TTVJ1D8 DMIM1U9 TN Vascular endothelial growth factor receptor (VEGFR) DMIM1U9 MA Inhibitor DMIM1U9 RN Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114. DMIM1U9 RU https://pubmed.ncbi.nlm.nih.gov/33707933 DMIM1U9 DI DMIM1U9 DMIM1U9 DN Vorolanib DMIM1U9 TI TTI2WET DMIM1U9 TN Platelet-derived growth factor receptor (PDGFR) DMIM1U9 MA Inhibitor DMIM1U9 RN Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114. DMIM1U9 RU https://pubmed.ncbi.nlm.nih.gov/33707933 DMIN0SV DI DMIN0SV DMIN0SV DN GSK2269557 DMIN0SV TI TTWELHI DMIN0SV TN Stress-activated protein kinase (p38) DMIN0SV MA Inhibitor DMIN0SV RN Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557. Expert Opin Ther Pat. 2012 Aug;22(8):965-70. DMIN0SV RU https://pubmed.ncbi.nlm.nih.gov/22765651 DMINQP1 DI DMINQP1 DMINQP1 DN NEUROPEPTIDE-Y DMINQP1 TI TTRK9JT DMINQP1 TN Neuropeptide Y receptor type 1 (NPY1R) DMINQP1 MA Inhibitor DMINQP1 RN 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6. DMINQP1 RU https://pubmed.ncbi.nlm.nih.gov/19916528 DMINQP1 DI DMINQP1 DMINQP1 DN NEUROPEPTIDE-Y DMINQP1 TI TTJ6WK9 DMINQP1 TN Neuropeptide Y receptor type 2 (NPY2R) DMINQP1 MA Inhibitor DMINQP1 RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMINQP1 RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMIO59F DI DMIO59F DMIO59F DN ORG-34517 DMIO59F TI TTYRL6O DMIO59F TN Glucocorticoid receptor (NR3C1) DMIO59F MA Antagonist DMIO59F RN Differential effects of the new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on glucocorticoid receptor nuclear translocation in the AtT20 cell line. Ann N Y Acad Sci. 2008 Dec;1148:536-41. DMIO59F RU https://pubmed.ncbi.nlm.nih.gov/19120154 DMIOGZM DI DMIOGZM DMIOGZM DN ELIPRODIL DMIOGZM TI TTLD29N DMIOGZM TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMIOGZM MA Inhibitor DMIOGZM RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DMIOGZM RU https://pubmed.ncbi.nlm.nih.gov/10425109 DMIOGZM DI DMIOGZM DMIOGZM DN ELIPRODIL DMIOGZM TI TTN9D8E DMIOGZM TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMIOGZM MA Inhibitor DMIOGZM RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DMIOGZM RU https://pubmed.ncbi.nlm.nih.gov/10425109 DMIOUEY DI DMIOUEY DMIOUEY DN AMG 337 DMIOUEY TI TTNDSF4 DMIOUEY TN Proto-oncogene c-Met (MET) DMIOUEY MA Modulator DMIOUEY RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2508). DMIOUEY RU http://meetinglibrary.asco.org/content/127112-144 DMIQB13 DI DMIQB13 DMIQB13 DN SHAPE DMIQB13 TI TTBH0VX DMIQB13 TN Histone deacetylase (HDAC) DMIQB13 MA Inhibitor DMIQB13 RN Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals. DMIQB13 RU http://tetralogicpharma.com/shape/ DMIQDFW DI DMIQDFW DMIQDFW DN Neu-P11 DMIQDFW TI TTSQIFT DMIQDFW TN 5-HT 1A receptor (HTR1A) DMIQDFW MA Agonist DMIQDFW RN Clinical pipeline report, company report or official report of Neurim Pharmaceuticals. DMIQDFW RU http://www.neurim.com/products/ DMIQDFW DI DMIQDFW DMIQDFW DN Neu-P11 DMIQDFW TI TT6MSOK DMIQDFW TN 5-HT 1D receptor (HTR1D) DMIQDFW MA Agonist DMIQDFW RN Clinical pipeline report, company report or official report of Neurim Pharmaceuticals. DMIQDFW RU http://www.neurim.com/products/ DMIQDFW DI DMIQDFW DMIQDFW DN Neu-P11 DMIQDFW TI TT0WAIE DMIQDFW TN Melatonin receptor type 1A (MTNR1A) DMIQDFW MA Agonist DMIQDFW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 288). DMIQDFW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288 DMIRPSA DI DMIRPSA DMIRPSA DN Mitoglitazone DMIRPSA TI TTCBFJO DMIRPSA TN Insulin receptor (INSR) DMIRPSA MA Modulator DMIRPSA RN An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73. DMIRPSA RU https://pubmed.ncbi.nlm.nih.gov/24931567 DMIRPSA DI DMIRPSA DMIRPSA DN Mitoglitazone DMIRPSA TI TTSJH2W DMIRPSA TN Mitochondrial protein unspecific (MP) DMIRPSA MA Modulator DMIRPSA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIRPSA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMIRSWE DI DMIRSWE DMIRSWE DN CYT-006-AngQb DMIRSWE TI TTGN1ZA DMIRSWE TN Angiotensin II receptor (AGTR) DMIRSWE RN CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs. 2009 Mar;10(3):269-75. DMIRSWE RU https://pubmed.ncbi.nlm.nih.gov/19333885 DMISETH DI DMISETH DMISETH DN HER2/neu peptide vaccine DMISETH TI TT6EO5L DMISETH TN Erbb2 tyrosine kinase receptor (HER2) DMISETH RN N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells. Anticancer Res. 2009 Jul;29(7):2427-35. DMISETH RU https://pubmed.ncbi.nlm.nih.gov/19596910 DMISQOZ DI DMISQOZ DMISQOZ DN AP-761 DMISQOZ TI TTQDMX5 DMISQOZ TN Prostaglandin D2 receptor 2 (PTGDR2) DMISQOZ MA Antagonist DMISQOZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028464) DMISQOZ RU http://adisinsight.springer.com/drugs/800028464 DMIU19E DI DMIU19E DMIU19E DN CP-101,606 DMIU19E TI TTN9D8E DMIU19E TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMIU19E MA Antagonist DMIU19E RN NMDA receptors as targets for drug action in neuropathic pain. Eur J Pharmacol. 2001 Oct 19;429(1-3):71-8. DMIU19E RU https://pubmed.ncbi.nlm.nih.gov/11698028 DMIUC3M DI DMIUC3M DMIUC3M DN IMGN901 DMIUC3M TI TTUBJQ3 DMIUC3M TN Neural cell adhesion molecule (NCAM) DMIUC3M MA Modulator DMIUC3M RN Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs. 2014 Mar-Apr;6(2):556-66. DMIUC3M RU https://pubmed.ncbi.nlm.nih.gov/24492307 DMIUS5X DI DMIUS5X DMIUS5X DN R1507 DMIUS5X TI TTHRID2 DMIUS5X TN Insulin-like growth factor I receptor (IGF1R) DMIUS5X MA Inhibitor DMIUS5X RN Clinical pipeline report, company report or official report of Roche (2009). DMIUS5X RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMIV9ZE DI DMIV9ZE DMIV9ZE DN LOXORIBINE DMIV9ZE TI TTRJ1K4 DMIV9ZE TN Toll-like receptor 7 (TLR7) DMIV9ZE MA Agonist DMIV9ZE RN The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97. DMIV9ZE RU https://pubmed.ncbi.nlm.nih.gov/14579267 DMIVR9K DI DMIVR9K DMIVR9K DN MER-3001 DMIVR9K TI TTZOPHG DMIVR9K TN Insulin (INS) DMIVR9K MA Modulator DMIVR9K RN Clinical pipeline report, company report or official report of Mercia Pharma Inc. DMIVR9K RU http://merciapharma.com/?page_id=81 DMIVUFL DI DMIVUFL DMIVUFL DN ACH-1625 DMIVUFL TI TT5FNQT DMIVUFL TN Human immunodeficiency virus Protease (HIV PR) DMIVUFL MA Inhibitor DMIVUFL RN Clinical pipeline report, company report or official report of Achillion (2011). DMIVUFL RU http://www.achillion.com/main.aspx?pn=ProductPipeline&fl=l DMIVZ3M DI DMIVZ3M DMIVZ3M DN AME-133v DMIVZ3M TI TTUE541 DMIVZ3M TN Leukocyte surface antigen Leu-16 (CD20) DMIVZ3M RN Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgammaRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res. 2012 Mar 1;18(5):1395-403. DMIVZ3M RU https://pubmed.ncbi.nlm.nih.gov/22223529 DMIW453 DI DMIW453 DMIW453 DN Pelitinib DMIW453 TI TTGKNB4 DMIW453 TN Epidermal growth factor receptor (EGFR) DMIW453 MA Modulator DMIW453 RN EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12. DMIW453 RU https://www.ncbi.nlm.nih.gov/pubmed/23379415 DMIXT2Y DI DMIXT2Y DMIXT2Y DN MGAH22 DMIXT2Y TI TT6EO5L DMIXT2Y TN Erbb2 tyrosine kinase receptor (HER2) DMIXT2Y MA Modulator DMIXT2Y RN Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6): R123. DMIXT2Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3326565/ DMIYFWA DI DMIYFWA DMIYFWA DN Dapirolizumab pegol DMIYFWA TI TTIJP3Q DMIYFWA TN TNF related activation protein (CD40LG) DMIYFWA MA Inhibitor DMIYFWA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIYFWA RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMIZKEC DI DMIZKEC DMIZKEC DN BMS-986036 DMIZKEC TI TTQ916P DMIZKEC TN Fibroblast growth factor-21 (FGF21) DMIZKEC MA Agonist DMIZKEC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIZKEC RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMIZYV1 DI DMIZYV1 DMIZYV1 DN QAV-680 DMIZYV1 TI TTQDMX5 DMIZYV1 TN Prostaglandin D2 receptor 2 (PTGDR2) DMIZYV1 MA Antagonist DMIZYV1 RN Discovery and characterization of NVP-QAV680, a potent and selective CRTh2 receptor antagonist suitable for clinical testing in allergic diseases. Bioorg Med Chem. 2013 Nov 1;21(21):6582-91. DMIZYV1 RU https://pubmed.ncbi.nlm.nih.gov/24021582 DMJ1DIB DI DMJ1DIB DMJ1DIB DN S-tenatoprazole DMJ1DIB TI TTLOKXP DMJ1DIB TN Gastric H(+)/K(+) ATPase (Proton pump) DMJ1DIB MA Modulator DMJ1DIB RN Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in heal... Aliment Pharmacol Ther. 2004 Mar 15;19(6):655-62. DMJ1DIB RU https://www.ncbi.nlm.nih.gov/pubmed/15023167 DMJ1FXL DI DMJ1FXL DMJ1FXL DN JNJ-53718678 DMJ1FXL TI TT57ID8 DMJ1FXL TN Respiratory syncytial virus protein F (RSV F) DMJ1FXL MA Inhibitor DMJ1FXL RN Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756. DMJ1FXL RU https://pubmed.ncbi.nlm.nih.gov/29684148 DMJ2763 DI DMJ2763 DMJ2763 DN IONIS-FB-LRx DMJ2763 TI TT3SGK7 DMJ2763 TN CFB messenger RNA (CFB mRNA) DMJ2763 MA Inhibitor DMJ2763 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMJ2763 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMJ2FTU DI DMJ2FTU DMJ2FTU DN TGBA01AD DMJ2FTU TI TT6MSOK DMJ2FTU TN 5-HT 1D receptor (HTR1D) DMJ2FTU MA Modulator DMJ2FTU RN Company report (Fabrekramer) DMJ2FTU RU http://www.fabrekramer.com/?page_id=66 DMJ2FTU DI DMJ2FTU DMJ2FTU DN TGBA01AD DMJ2FTU TI TTSQIFT DMJ2FTU TN 5-HT 1A receptor (HTR1A) DMJ2FTU MA Modulator DMJ2FTU RN Company report (Fabrekramer) DMJ2FTU RU http://www.fabrekramer.com/?page_id=66 DMJ2REU DI DMJ2REU DMJ2REU DN Berubicin DMJ2REU TI TT0IHXV DMJ2REU TN DNA topoisomerase II (TOP2) DMJ2REU MA Modulator DMJ2REU RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJ2REU RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJ34G6 DI DMJ34G6 DMJ34G6 DN SAR-125844 DMJ34G6 TI TTNDSF4 DMJ34G6 TN Proto-oncogene c-Met (MET) DMJ34G6 MA Inhibitor DMJ34G6 RN The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94. DMJ34G6 RU https://pubmed.ncbi.nlm.nih.gov/25504634 DMJ37UX DI DMJ37UX DMJ37UX DN Revacept DMJ37UX TI TTTJUVZ DMJ37UX TN Platelet glycoprotein VI (GP6) DMJ37UX MA Inhibitor DMJ37UX RN Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation.2011 May 3;123(17):1891-9. DMJ37UX RU https://pubmed.ncbi.nlm.nih.gov/21502572 DMJ3KPO DI DMJ3KPO DMJ3KPO DN TD-101 DMJ3KPO TI TT2FX8W DMJ3KPO TN Keratin 6A messenger RNA (KRT6A mRNA) DMJ3KPO RN First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010 Feb;18(2):442-6. DMJ3KPO RU https://pubmed.ncbi.nlm.nih.gov/19935778 DMJ48AB DI DMJ48AB DMJ48AB DN ARRY-797 DMJ48AB TI TTYT93M DMJ48AB TN MAP kinase p38 (MAPK12) DMJ48AB MA Inhibitor DMJ48AB RN Array BioPharmas ARRY-797 Meets Primary Endpoint in Clinical Proof of Concept Trial in Osteoarthritis Patients Whose Pain is Poorly Controlled by NSAIDs DMJ48AB RU http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1720505&highlight= DMJ48AB DI DMJ48AB DMJ48AB DN ARRY-797 DMJ48AB TI TTWELHI DMJ48AB TN Stress-activated protein kinase (p38) DMJ48AB MA Inhibitor DMJ48AB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ48AB RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMJ4BKT DI DMJ4BKT DMJ4BKT DN F-16-IL-2 fusion protein DMJ4BKT TI TTUCPMY DMJ4BKT TN Tenascin (TNC) DMJ4BKT MA Modulator DMJ4BKT RN National Cancer Institute Drug Dictionary (drug id 674718). DMJ4BKT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=674718 DMJ4GPR DI DMJ4GPR DMJ4GPR DN AMP-579 DMJ4GPR TI TTM2AOE DMJ4GPR TN Adenosine A2a receptor (ADORA2A) DMJ4GPR MA Modulator DMJ4GPR RN Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53. DMJ4GPR RU https://pubmed.ncbi.nlm.nih.gov/15271662 DMJ4GPR DI DMJ4GPR DMJ4GPR DN AMP-579 DMJ4GPR TI TTK25J1 DMJ4GPR TN Adenosine A1 receptor (ADORA1) DMJ4GPR MA Modulator DMJ4GPR RN Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53. DMJ4GPR RU https://pubmed.ncbi.nlm.nih.gov/15271662 DMJ7QP8 DI DMJ7QP8 DMJ7QP8 DN AN-019 DMJ7QP8 TI TTS7G69 DMJ7QP8 TN Fusion protein Bcr-Abl (Bcr-Abl) DMJ7QP8 MA Inhibitor DMJ7QP8 RN Design, synthesis and preclinical evaluation of NRC-AN-019. Int J Oncol. 2013 Jan;42(1):168-78. DMJ7QP8 RU https://pubmed.ncbi.nlm.nih.gov/23151973 DMJ8V3K DI DMJ8V3K DMJ8V3K DN AZD5312 DMJ8V3K TI TTS64P2 DMJ8V3K TN Androgen receptor (AR) DMJ8V3K MA Modulator DMJ8V3K RN Company report (Astrazeneca) DMJ8V3K RU https://www.astrazeneca.com/our-company/media-centre/press-releases/2014/astrazeneca-isis-pharmaceuticals-oligonucleotide-oncology-cardiovascular-metabolic-diseases-13112014.html DMJ94L0 DI DMJ94L0 DMJ94L0 DN ZK-91587 DMJ94L0 TI TT26PHO DMJ94L0 TN Mineralocorticoid receptor (MR) DMJ94L0 MA Antagonist DMJ94L0 RN ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43. DMJ94L0 RU https://pubmed.ncbi.nlm.nih.gov/3193846 DMJ9M5D DI DMJ9M5D DMJ9M5D DN SGN-30 DMJ9M5D TI TT2GM5R DMJ9M5D TN Lymphocyte activation antigen CD30 (TNFRSF8) DMJ9M5D RN The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42. DMJ9M5D RU https://pubmed.ncbi.nlm.nih.gov/12097283 DMJ9RN8 DI DMJ9RN8 DMJ9RN8 DN SAR-339658 DMJ9RN8 TI TTMSB0A DMJ9RN8 TN Integrin alpha-2/beta-1 (ITGA2/B1) DMJ9RN8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578). DMJ9RN8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578 DMJ9XCO DI DMJ9XCO DMJ9XCO DN CCX-140 DMJ9XCO TI TTFZYTO DMJ9XCO TN C-C chemokine receptor type 2 (CCR2) DMJ9XCO MA Antagonist DMJ9XCO RN Present and future in the treatment of diabetic kidney disease. J Diabetes Res. 2015;2015:801348. DMJ9XCO RU https://pubmed.ncbi.nlm.nih.gov/25945357 DMJAEG6 DI DMJAEG6 DMJAEG6 DN VX-745 DMJAEG6 TI TTYT93M DMJAEG6 TN MAP kinase p38 (MAPK12) DMJAEG6 MA Inhibitor DMJAEG6 RN P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis. J Inflamm (Lond). 2008 Dec 4;5:22. DMJAEG6 RU https://pubmed.ncbi.nlm.nih.gov/19055838 DMJAEG6 DI DMJAEG6 DMJAEG6 DN VX-745 DMJAEG6 TI TTQBR95 DMJAEG6 TN Stress-activated protein kinase 2a (p38 alpha) DMJAEG6 MA Inhibitor DMJAEG6 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMJAEG6 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMJAEG6 DI DMJAEG6 DMJAEG6 DN VX-745 DMJAEG6 TI TT73U6C DMJAEG6 TN Stress-activated protein kinase 2b (p38 beta) DMJAEG6 MA Inhibitor DMJAEG6 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMJAEG6 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMJC8DR DI DMJC8DR DMJC8DR DN BNC-105 DMJC8DR TI TTYFKSZ DMJC8DR TN Tubulin beta (TUBB) DMJC8DR MA Modulator DMJC8DR RN The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60. DMJC8DR RU https://www.ncbi.nlm.nih.gov/pubmed/25482941 DMJCULI DI DMJCULI DMJCULI DN M7824 DMJCULI TI TTO3HT7 DMJCULI TN Transforming growth factor beta (TGFB) DMJCULI MA Inhibitor DMJCULI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJCULI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJCULI DI DMJCULI DMJCULI DN M7824 DMJCULI TI TT8ZLTI DMJCULI TN Programmed cell death 1 ligand 1 (PD-L1) DMJCULI MA Inhibitor DMJCULI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJCULI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJCULI DI DMJCULI DMJCULI DN M7824 DMJCULI TI TTNBFWK DMJCULI TN Programmed cell death protein 1 (PD-1) DMJCULI RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMJCULI RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMJD7H4 DI DMJD7H4 DMJD7H4 DN CX-1739 DMJD7H4 TI TTAN6JD DMJD7H4 TN Glutamate receptor AMPA (GRIA) DMJD7H4 MA Agonist DMJD7H4 RN AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology. 2013 Jan;64:268-82. DMJD7H4 RU https://pubmed.ncbi.nlm.nih.gov/22801296 DMJFDS0 DI DMJFDS0 DMJFDS0 DN BI-409306 DMJFDS0 TI TTZOEBC DMJFDS0 TN Phosphodiesterase 9 (PDE9) DMJFDS0 MA Inhibitor DMJFDS0 RN Clinical pipeline report, company report or official report of Boehringer Ingelheim pipeline. DMJFDS0 RU https://www.boehringer-ingelheim.com/research_development/drug_discovery/pipeline.html DMJFLBC DI DMJFLBC DMJFLBC DN AVN 101 DMJFLBC TI TTJS8PY DMJFLBC TN 5-HT 6 receptor (HTR6) DMJFLBC MA Modulator DMJFLBC RN Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91. DMJFLBC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/ DMJGL72 DI DMJGL72 DMJGL72 DN KW-2478 DMJGL72 TI TT78R5H DMJGL72 TN Heat shock protein 90 alpha (HSP90A) DMJGL72 MA Modulator DMJGL72 RN Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68. DMJGL72 RU https://pubmed.ncbi.nlm.nih.gov/22829970 DMJGVXT DI DMJGVXT DMJGVXT DN ISIS-PTP1Brx DMJGVXT TI TTELIN2 DMJGVXT TN PTPN1 messenger RNA (PTPN1 mRNA) DMJGVXT MA Modulator DMJGVXT RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMJGVXT RU https://www.isispharm.com/pipeline/isis-ptp1brx/ DMJGYPK DI DMJGYPK DMJGYPK DN AZD9056 DMJGYPK TI TT473XN DMJGYPK TN P2X purinoceptor 7 (P2RX7) DMJGYPK MA Antagonist DMJGYPK RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMJGYPK RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMJH2AC DI DMJH2AC DMJH2AC DN SPD-557 DMJH2AC TI TT07C3Y DMJH2AC TN 5-HT 4 receptor (HTR4) DMJH2AC MA Agonist DMJH2AC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMJH2AC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMJH3U0 DI DMJH3U0 DMJH3U0 DN TAK-659 DMJH3U0 TI TTOU65C DMJH3U0 TN Tyrosine-protein kinase SYK (SYK) DMJH3U0 MA Inhibitor DMJH3U0 RN J Clin Oncol 32:5s, 2014 (suppl; abstr 8580). DMJH3U0 RU http://meetinglibrary.asco.org/content/134551-144 DMJH3U0 DI DMJH3U0 DMJH3U0 DN TAK-659 DMJH3U0 TI TTGJCWZ DMJH3U0 TN Fms-like tyrosine kinase 3 (FLT-3) DMJH3U0 MA Inhibitor DMJH3U0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJH3U0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJH6EL DI DMJH6EL DMJH6EL DN Selurampanel DMJH6EL TI TTAN6JD DMJH6EL TN Glutamate receptor AMPA (GRIA) DMJH6EL MA Antagonist DMJH6EL RN BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs. 2014 Jan;23(1):107-13. DMJH6EL RU https://pubmed.ncbi.nlm.nih.gov/24147649 DMJHA6Q DI DMJHA6Q DMJHA6Q DN Ar9281 DMJHA6Q TI TT7WVHI DMJHA6Q TN Soluble epoxide hydrolase (EPHX2) DMJHA6Q MA Inhibitor DMJHA6Q RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DMJHA6Q RU https://pubmed.ncbi.nlm.nih.gov/17616115 DMJHVZC DI DMJHVZC DMJHVZC DN MLN-591RL DMJHVZC TI TT9G4N0 DMJHVZC TN Glutamate carboxypeptidase II (GCPII) DMJHVZC RN Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI Res. 2015 Apr 29;5:28. DMJHVZC RU https://pubmed.ncbi.nlm.nih.gov/25984435 DMJIB89 DI DMJIB89 DMJIB89 DN Remetinostat DMJIB89 TI TTBH0VX DMJIB89 TN Histone deacetylase (HDAC) DMJIB89 MA Inhibitor DMJIB89 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJIB89 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJIBSG DI DMJIBSG DMJIBSG DN OBE-101 DMJIBSG TI TTTIBOJ DMJIBSG TN Histamine H1 receptor (H1R) DMJIBSG MA Modulator DMJIBSG RN Betahistine in the treatment of M ni re's disease. Neuropsychiatr Dis Treat. 2007 August; 3(4): 429-440. DMJIBSG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655085/ DMJIMXH DI DMJIMXH DMJIMXH DN Puerarin DMJIMXH TI TTWJBZ5 DMJIMXH TN 5-HT 2C receptor (HTR2C) DMJIMXH MA Modulator DMJIMXH RN NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists. Pharmacol Biochem Behav. 2003 Jun;75(3):619-25. DMJIMXH RU https://www.ncbi.nlm.nih.gov/pubmed/12895679 DMJK5CT DI DMJK5CT DMJK5CT DN STX-140 DMJK5CT TI TTHM0R1 DMJK5CT TN Steryl-sulfatase (STS) DMJK5CT MA Inhibitor DMJK5CT RN 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96. DMJK5CT RU https://pubmed.ncbi.nlm.nih.gov/17181151 DMJK5CT DI DMJK5CT DMJK5CT DN STX-140 DMJK5CT TI TTANPDJ DMJK5CT TN Carbonic anhydrase II (CA-II) DMJK5CT MA Inhibitor DMJK5CT RN Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308. DMJK5CT RU https://pubmed.ncbi.nlm.nih.gov/18260615 DMJK8L1 DI DMJK8L1 DMJK8L1 DN MRG002 DMJK8L1 TI TT6EO5L DMJK8L1 TN Erbb2 tyrosine kinase receptor (HER2) DMJK8L1 RN ClinicalTrials.gov (NCT04839510) A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer. U.S. National Institutes of Health. DMJK8L1 RU https://clinicaltrials.gov/ct2/show/NCT04839510 DMJKBAY DI DMJKBAY DMJKBAY DN NGX-267 DMJKBAY TI TTZ9SOR DMJKBAY TN Muscarinic acetylcholine receptor M1 (CHRM1) DMJKBAY MA Agonist DMJKBAY RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMJKBAY RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMJKHVX DI DMJKHVX DMJKHVX DN Mazapertine succinate DMJKHVX TI TTSQIFT DMJKHVX TN 5-HT 1A receptor (HTR1A) DMJKHVX MA Modulator DMJKHVX RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMJKHVX RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMJKHVX DI DMJKHVX DMJKHVX DN Mazapertine succinate DMJKHVX TI TTEX248 DMJKHVX TN Dopamine D2 receptor (D2R) DMJKHVX MA Modulator DMJKHVX RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMJKHVX RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMJKLHU DI DMJKLHU DMJKLHU DN CAP-7.1 DMJKLHU TI TT0IHXV DMJKLHU TN DNA topoisomerase II (TOP2) DMJKLHU MA Modulator DMJKLHU RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJKLHU RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJL4A7 DI DMJL4A7 DMJL4A7 DN O-desulfated heparin DMJL4A7 TI TT4QPUL DMJL4A7 TN Antithrombin-III (ATIII) DMJL4A7 MA Modulator DMJL4A7 RN Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest. 1981 Jan;67(1):223-8. DMJL4A7 RU https://pubmed.ncbi.nlm.nih.gov/6778897 DMJLNZQ DI DMJLNZQ DMJLNZQ DN K-828-AB DMJLNZQ TI TTT2LD9 DMJLNZQ TN GABA transaminase (ABAT) DMJLNZQ MA Inhibitor DMJLNZQ RN Phase II clinical trial of K-828-AB for treating behavioral and psychological symptoms of dementia. Kowa Co. Ltd. DMJLNZQ RU http://www.biocentury.com/products/k-828-ab DMJN09S DI DMJN09S DMJN09S DN GEN-1 DMJN09S TI TTG68FB DMJN09S TN Interleukine 12 (IL-12) DMJN09S MA Replacement DMJN09S RN Clinical pipeline report, company report or official report of Celsion. DMJN09S RU https://celsion.com/gen-1/ DMJN3BA DI DMJN3BA DMJN3BA DN Zalospirone DMJN3BA TI TTSQIFT DMJN3BA TN 5-HT 1A receptor (HTR1A) DMJN3BA MA Agonist DMJN3BA RN The serotonin 5-HT receptor agonist tandospirone improves executive function in common marmosets. Behav Brain Res. 2015 Jul 1;287:120-6. DMJN3BA RU https://pubmed.ncbi.nlm.nih.gov/25804359 DMJN9PU DI DMJN9PU DMJN9PU DN INCB86550 DMJN9PU TI TT8ZLTI DMJN9PU TN Programmed cell death 1 ligand 1 (PD-L1) DMJN9PU MA Inhibitor DMJN9PU RN National Cancer Institute Drug Dictionary (drug name INCB086550). DMJN9PU RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pd-l1-inhibitor-incb086550 DMJNO3D DI DMJNO3D DMJNO3D DN Follicle stimulating hormone DMJNO3D TI TT13GFV DMJNO3D TN Follicle stimulating hormone (FSHB) DMJNO3D MA Modulator DMJNO3D RN Company report (Glycotope) DMJNO3D RU http://www.glycotope.com/glycotopes-fully-human-and-glycooptimized-recombinant-fsh-gextm-showed-superior-activity-and-excellent-tolerability-in-a-phase-ii-clinical-trial-for-in-vitro-fertilisation DMJO402 DI DMJO402 DMJO402 DN Anti-LAG3 DMJO402 TI TTNVXAW DMJO402 TN Lymphocyte activation gene 3 protein (LAG3) DMJO402 MA Inhibitor DMJO402 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJO402 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMJOM5L DI DMJOM5L DMJOM5L DN Talampanel DMJOM5L TI TTAN6JD DMJOM5L TN Glutamate receptor AMPA (GRIA) DMJOM5L MA Antagonist DMJOM5L RN Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model. Epilepsia. 2009 Apr;50(4):694-701. DMJOM5L RU https://pubmed.ncbi.nlm.nih.gov/19220413 DMJOYNZ DI DMJOYNZ DMJOYNZ DN Lu AF11167 DMJOYNZ TI TTJW4LU DMJOYNZ TN Phosphodiesterase 10A (PDE10) DMJOYNZ MA Inhibitor DMJOYNZ RN PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178. DMJOYNZ RU https://pubmed.ncbi.nlm.nih.gov/33551724 DMJPE61 DI DMJPE61 DMJPE61 DN PF-02545920 DMJPE61 TI TTJW4LU DMJPE61 TN Phosphodiesterase 10A (PDE10) DMJPE61 MA Inhibitor DMJPE61 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJPE61 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMJPV5X DI DMJPV5X DMJPV5X DN Alovudine DMJPV5X TI TT84ETX DMJPV5X TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJPV5X MA Modulator DMJPV5X RN Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clin Drug Investig. 2008;28(2):129-38. DMJPV5X RU https://www.ncbi.nlm.nih.gov/pubmed/18211121 DMJPZDC DI DMJPZDC DMJPZDC DN Anti-PSCA mab DMJPZDC TI TT9T4AV DMJPZDC TN Prostate stem cell antigen (PSCA) DMJPZDC MA Modulator DMJPZDC RN Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemother Pharmacol. 2012 Mar;69(3):763-71. DMJPZDC RU https://pubmed.ncbi.nlm.nih.gov/22020316 DMJR9H0 DI DMJR9H0 DMJR9H0 DN CC-292 DMJR9H0 TI TTGM6VW DMJR9H0 TN Tyrosine-protein kinase BTK (ATK) DMJR9H0 MA Modulator DMJR9H0 RN Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans. J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. DMJR9H0 RU https://pubmed.ncbi.nlm.nih.gov/23709115 DMJRD7A DI DMJRD7A DMJRD7A DN GSK3326595 DMJRD7A TI TTR1D7X DMJRD7A TN Protein arginine methyltransferase 5 (PRMT5) DMJRD7A MA Inhibitor DMJRD7A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJRD7A RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJRK6D DI DMJRK6D DMJRK6D DN SB-9200 DMJRK6D TI TTVB0O3 DMJRK6D TN Retinoic acid-inducible gene-1 (RIG-1) DMJRK6D MA Modulator DMJRK6D RN Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200) DMJRK6D RU http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/ DMJRK6D DI DMJRK6D DMJRK6D DN SB-9200 DMJRK6D TI TTYPUHA DMJRK6D TN Pattern recognition receptor NOD2 (NOD2) DMJRK6D MA Modulator DMJRK6D RN Company reprot (Spring Bank Pharmaceuticals) (drug: SB 9200) DMJRK6D RU http://springbankpharm.com/spring-bank-pharmaceuticals-presents-preclinical-and-clinical-data-on-immunomodulatory-agent-sb-9200-at-the-2015-annual-meeting-of-the-european-association-for-the-study-of-the-liver/ DMJSADP DI DMJSADP DMJSADP DN BI 2536 DMJSADP TI TTIYVQP DMJSADP TN Polo-like kinase 1 (PLK1) DMJSADP MA Inhibitor DMJSADP RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMJSADP RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMJSD5W DI DMJSD5W DMJSD5W DN FK-070 DMJSD5W TI TT2O84V DMJSD5W TN Thromboxane A2 receptor (TBXA2R) DMJSD5W MA Modulator DMJSD5W RN Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5. DMJSD5W RU https://pubmed.ncbi.nlm.nih.gov/8794987 DMJSD5W DI DMJSD5W DMJSD5W DN FK-070 DMJSD5W TI TTKNWZ4 DMJSD5W TN Thromboxane-A synthase (TBXAS1) DMJSD5W MA Modulator DMJSD5W RN Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5. DMJSD5W RU https://pubmed.ncbi.nlm.nih.gov/8794987 DMJSVRL DI DMJSVRL DMJSVRL DN JM216 DMJSVRL TI TTUTN1I DMJSVRL TN Human Deoxyribonucleic acid (hDNA) DMJSVRL MA Modulator DMJSVRL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJSVRL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJSWXL DI DMJSWXL DMJSWXL DN Ad-p53 DMJSWXL TI TT7SBF5 DMJSWXL TN Cellular tumor antigen p53 (TP53) DMJSWXL MA Modulator DMJSWXL RN Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. 2003 Mar;10(3):224-38. DMJSWXL RU https://pubmed.ncbi.nlm.nih.gov/12637944 DMJSY3Q DI DMJSY3Q DMJSY3Q DN Ladostigil DMJSY3Q TI TTGP7BY DMJSY3Q TN Monoamine oxidase type B (MAO-B) DMJSY3Q MA Inhibitor DMJSY3Q RN Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94. DMJSY3Q RU https://pubmed.ncbi.nlm.nih.gov/22280345 DMJSY3Q DI DMJSY3Q DMJSY3Q DN Ladostigil DMJSY3Q TI TT3WG5C DMJSY3Q TN Monoamine oxidase type A (MAO-A) DMJSY3Q MA Inhibitor DMJSY3Q RN Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94. DMJSY3Q RU https://pubmed.ncbi.nlm.nih.gov/22280345 DMJSY3Q DI DMJSY3Q DMJSY3Q DN Ladostigil DMJSY3Q TI TT1RS9F DMJSY3Q TN Acetylcholinesterase (AChE) DMJSY3Q MA Inhibitor DMJSY3Q RN Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94. DMJSY3Q RU https://pubmed.ncbi.nlm.nih.gov/22280345 DMJTU8D DI DMJTU8D DMJTU8D DN OGX-427 DMJTU8D TI TTMG98T DMJTU8D TN Heat shock protein 27 (HSP27) DMJTU8D MA Modulator DMJTU8D RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJTU8D RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJTYO4 DI DMJTYO4 DMJTYO4 DN PGL-2 DMJTYO4 TI TTHM0R1 DMJTYO4 TN Steryl-sulfatase (STS) DMJTYO4 MA Inhibitor DMJTYO4 RN Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65. DMJTYO4 RU https://pubmed.ncbi.nlm.nih.gov/24604234 DMJUSM8 DI DMJUSM8 DMJUSM8 DN VX-759 DMJUSM8 TI TTMVBWH DMJUSM8 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMJUSM8 MA Inhibitor DMJUSM8 RN 2011 Pipeline of Vertex. DMJUSM8 RU http://www.vrtx.com/current-projects.html DMJUV6C DI DMJUV6C DMJUV6C DN BMS-223131 DMJUV6C TI TT1AQ50 DMJUV6C TN Charybdotoxin receptor beta-4 (BKbeta4) DMJUV6C MA Modulator DMJUV6C RN Effect of 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinolin-2(1H)-one (BMS-223131), a novel opener of large conductance ... J Pharmacol Exp Ther. 2005 May;313(2):840-7. DMJUV6C RU https://pubmed.ncbi.nlm.nih.gov/15701710 DMJV3AX DI DMJV3AX DMJV3AX DN IVA337 DMJV3AX TI TTRMIZ7 DMJV3AX TN Peroxisome proliferator-activated receptor (PPAR) DMJV3AX MA Agonist DMJV3AX RN Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann Rheum Dis. 2017 Nov;76(11):1931-1940. DMJV3AX RU https://pubmed.ncbi.nlm.nih.gov/28801346 DMJVN89 DI DMJVN89 DMJVN89 DN AEB07 DMJVN89 TI TTYVX59 DMJVN89 TN Protein kinase C (PRKC) DMJVN89 MA Inhibitor DMJVN89 RN What's next in the pipeline. Am J Transplant. 2008 Oct;8(10):1972-81. DMJVN89 RU https://pubmed.ncbi.nlm.nih.gov/18828764 DMJVU7Y DI DMJVU7Y DMJVU7Y DN MBL-HCV1 DMJVU7Y TI TTDBG95 DMJVU7Y TN Hepatitis C virus Envelope glycoprotein E2 (HCV NS1) DMJVU7Y MA Modulator DMJVU7Y RN Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013 Apr;13(4):1047-54. DMJVU7Y RU https://pubmed.ncbi.nlm.nih.gov/23356386 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTLU5FO DMJWD62 TN Calcium-activated potassium channel KCa4.2 (KCNT2) DMJWD62 MA Inhibitor (gating inhibitor) DMJWD62 RN Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/16687497 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTKP2SU DMJWD62 TN Transient receptor potential cation channel V4 (TRPV4) DMJWD62 MA Activator DMJWD62 RN Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002 Apr 19;277(16):13569-77. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/11827975 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTGJFK1 DMJWD62 TN Calcium-activated potassium channel KCa4.1 (KCNT1) DMJWD62 MA Activator DMJWD62 RN Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/16687497 DMJWD62 DI DMJWD62 DMJWD62 DN phorbol 12-myristate 13-acetate DMJWD62 TI TTEO25X DMJWD62 TN Inward rectifier potassium channel Kir3.4 (KCNJ5) DMJWD62 MA Inhibitor (gating inhibitor) DMJWD62 RN Molecular basis for the inhibition of G protein-coupled inward rectifier K(+) channels by protein kinase C. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1087-92. DMJWD62 RU https://pubmed.ncbi.nlm.nih.gov/14732702 DMJWE3I DI DMJWE3I DMJWE3I DN Gossypol DMJWE3I TI TTJGNVC DMJWE3I TN Apoptosis regulator Bcl-2 (BCL-2) DMJWE3I MA Regulator DMJWE3I RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMJWE3I RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMJX2P4 DI DMJX2P4 DMJX2P4 DN Fezakinumab DMJX2P4 TI TTLDX4N DMJX2P4 TN Interleukin-22 (IL22) DMJX2P4 RN Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16. DMJX2P4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/ DMJX3O8 DI DMJX3O8 DMJX3O8 DN OSI-027 DMJX3O8 TI TTCJG29 DMJX3O8 TN Serine/threonine-protein kinase mTOR (mTOR) DMJX3O8 MA Inhibitor DMJX3O8 RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DMJX3O8 RU https://pubmed.ncbi.nlm.nih.gov/19644473 DMJY2TM DI DMJY2TM DMJY2TM DN Gabapentin enacarbil DMJY2TM TI TT61XTV DMJY2TM TN Sodium-dependent multivitamin transporter (SLC5A6) DMJY2TM MA Modulator DMJY2TM RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMJY2TM RU https://www.fda.gov/ DMJZVPB DI DMJZVPB DMJZVPB DN ENMD-2076 DMJZVPB TI TTPS3C0 DMJZVPB TN Aurora kinase A (AURKA) DMJZVPB MA Inhibitor DMJZVPB RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMJZVPB RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMJZVPB DI DMJZVPB DMJZVPB DN ENMD-2076 DMJZVPB TI TTU8W4S DMJZVPB TN Protein kinase (PK) DMJZVPB MA Inhibitor DMJZVPB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJZVPB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMK0MJP DI DMK0MJP DMK0MJP DN Odelepran DMK0MJP TI TTN4QDT DMK0MJP TN Opioid receptor (OPR) DMK0MJP MA Antagonist DMK0MJP RN A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence. Alcohol Clin Exp Res. 2014 Feb;38(2):511-20. DMK0MJP RU https://pubmed.ncbi.nlm.nih.gov/24010675 DMK0NGB DI DMK0NGB DMK0NGB DN Rozanolixizumab DMK0NGB TI TTPY4SE DMK0NGB TN Immunoglobulin Fc receptor (FCR) DMK0NGB MA Antagonist DMK0NGB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK0NGB RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMK10ZC DI DMK10ZC DMK10ZC DN PLECONARIL DMK10ZC TI TT87Q2D DMK10ZC TN Picornavirus Capsid protein VP1 (PicVir VP1) DMK10ZC MA Modulator DMK10ZC RN Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother. 2005 Nov;49(11):4492-9. DMK10ZC RU https://pubmed.ncbi.nlm.nih.gov/16251287 DMK2E0N DI DMK2E0N DMK2E0N DN RAXOFELAST DMK2E0N TI TTV0YFR DMK2E0N TN Lipid peroxidation (LPO) DMK2E0N MA Modulator DMK2E0N RN Lipid peroxidation inhibition by raxofelast improves angiogenesis and wound healing in experimental burn wounds. Shock. 2005 Jul;24(1):85-91. DMK2E0N RU https://pubmed.ncbi.nlm.nih.gov/15988325 DMK2LGM DI DMK2LGM DMK2LGM DN AVN 322 DMK2LGM TI TTJS8PY DMK2LGM TN 5-HT 6 receptor (HTR6) DMK2LGM MA Modulator DMK2LGM RN 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15. DMK2LGM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706851/ DMK2T7J DI DMK2T7J DMK2T7J DN IW-1973 DMK2T7J TI TT23PYC DMK2T7J TN Soluble guanylate cyclase (GCS) DMK2T7J MA Agonist DMK2T7J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK2T7J RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMK3RL8 DI DMK3RL8 DMK3RL8 DN Somatropin intranasal rhGH DMK3RL8 TI TTT3YKH DMK3RL8 TN Somatotropin (GH1) DMK3RL8 MA Modulator DMK3RL8 RN Long-term efficacy and safety of somatropin for adult growth hormone deficiency.Treat Endocrinol.2003;2(2):109-20. DMK3RL8 RU https://www.ncbi.nlm.nih.gov/pubmed/15871547 DMK3U1X DI DMK3U1X DMK3U1X DN ALT-803 DMK3U1X TI TTGN89I DMK3U1X TN Interleukin 15 receptor alpha (IL15RA) DMK3U1X MA Agonist DMK3U1X RN Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 2013 May 15;73(10):3075-86. DMK3U1X RU https://pubmed.ncbi.nlm.nih.gov/23644531 DMK3VYU DI DMK3VYU DMK3VYU DN ATI-502 DMK3VYU TI TTJSQEF DMK3VYU TN Tyrosine-protein kinase (PTK) DMK3VYU MA Inhibitor DMK3VYU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK3VYU RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMK4FRU DI DMK4FRU DMK4FRU DN CBLB-502 DMK4FRU TI TTCXP8J DMK4FRU TN Toll-like receptor 5 (TLR5) DMK4FRU MA Agonist DMK4FRU RN Recombinant TLR5 agonist CBLB502 promotes NK cell-mediated anti-CMV immunity in mice. PLoS One. 2014 May 30;9(5):e96165. DMK4FRU RU https://pubmed.ncbi.nlm.nih.gov/24879439 DMK4VOU DI DMK4VOU DMK4VOU DN KVD001 DMK4VOU TI TTMF8H9 DMK4VOU TN Plasma kallikrein (KLKB1) DMK4VOU MA Inhibitor DMK4VOU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK4VOU RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMK5PYS DI DMK5PYS DMK5PYS DN RG7745 DMK5PYS TI TTF4CAM DMK5PYS TN Influenza Hemagglutinin (Influ HA) DMK5PYS RN Clinical pipeline report, company report or official report of Roche. DMK5PYS RU http://www.roche.com/irp2q13e-annex.pdf DMK6FYR DI DMK6FYR DMK6FYR DN DiabeCell DMK6FYR TI TTXQYT6 DMK6FYR TN T-cells (T-cells) DMK6FYR MA Modulator DMK6FYR RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMK6FYR RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMK7CYX DI DMK7CYX DMK7CYX DN Vadimezan DMK7CYX TI TTSXVID DMK7CYX TN Nuclear factor NF-kappa-B (NFKB) DMK7CYX MA Modulator DMK7CYX RN Auckland Cancer Society Research Centre report DMK7CYX RU https://www.fmhs.auckland.ac.nz/en/sms/about/our-departments/oncology/cancer-trials-nz/trials-and-research-projects/closed/asa404.html DMK7DFM DI DMK7DFM DMK7DFM DN CPX-POM DMK7DFM TI TTX09M4 DMK7DFM TN Ribonucleotide reductase (RIR) DMK7DFM MA Inhibitor DMK7DFM RN Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159. DMK7DFM RU https://pubmed.ncbi.nlm.nih.gov/31113837 DMK7OHI DI DMK7OHI DMK7OHI DN INCAGN01949 DMK7OHI TI TTL31H0 DMK7OHI TN OX40L receptor (CD134) DMK7OHI MA Agonist DMK7OHI RN Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. Gynecol Oncol Rep. 2020 Oct 1;34:100655. DMK7OHI RU https://pubmed.ncbi.nlm.nih.gov/33083509 DMK8PTH DI DMK8PTH DMK8PTH DN PRM-151 DMK8PTH TI TTNJ5A6 DMK8PTH TN Neuronal pentraxin-2 (NPTX2) DMK8PTH MA Modulator DMK8PTH RN PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect. 2010 Jun;23(5):305-15. DMK8PTH RU https://pubmed.ncbi.nlm.nih.gov/20603654 DMK8SY6 DI DMK8SY6 DMK8SY6 DN E2027 DMK8SY6 TI TTZOEBC DMK8SY6 TN Phosphodiesterase 9 (PDE9) DMK8SY6 MA Antagonist DMK8SY6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK8SY6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMK9NQI DI DMK9NQI DMK9NQI DN CPP-115 DMK9NQI TI TTT2LD9 DMK9NQI TN GABA transaminase (ABAT) DMK9NQI MA Inhibitor DMK9NQI RN Clinical pipeline report, company report or official report of Catalyst Pharma. DMK9NQI RU http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588 DMKA705 DI DMKA705 DMKA705 DN PGL-2001 DMKA705 TI TTHM0R1 DMKA705 TN Steryl-sulfatase (STS) DMKA705 MA Inhibitor DMKA705 RN Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65. DMKA705 RU https://pubmed.ncbi.nlm.nih.gov/24604234 DMKAUM9 DI DMKAUM9 DMKAUM9 DN Eculizumab DMKAUM9 TI TTN0GJ5 DMKAUM9 TN HUMAN complement C5 protein (C5) DMKAUM9 MA Inhibitor DMKAUM9 RN Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. DMKAUM9 RU https://pubmed.ncbi.nlm.nih.gov/32327719 DMKBIPR DI DMKBIPR DMKBIPR DN Actimab-A DMKBIPR TI TTJVYO3 DMKBIPR TN Myeloid cell surface antigen CD33 (CD33) DMKBIPR MA Inhibitor DMKBIPR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKBIPR RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMKBRDL DI DMKBRDL DMKBRDL DN BEZ235 DMKBRDL TI TTCJG29 DMKBRDL TN Serine/threonine-protein kinase mTOR (mTOR) DMKBRDL MA Modulator DMKBRDL RN The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43. DMKBRDL RU https://www.ncbi.nlm.nih.gov/pubmed/22355272 DMKBRDL DI DMKBRDL DMKBRDL DN BEZ235 DMKBRDL TI TTHBTOP DMKBRDL TN PI3-kinase gamma (PIK3CG) DMKBRDL MA Modulator DMKBRDL RN The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012 Jan;14(1):34-43. DMKBRDL RU https://www.ncbi.nlm.nih.gov/pubmed/22355272 DMKCBSM DI DMKCBSM DMKCBSM DN SOM3355 DMKCBSM TI TTNZRI3 DMKCBSM TN Synaptic vesicle amine transporter (SLC18A2) DMKCBSM MA Inhibitor DMKCBSM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKCBSM RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMKD5ZO DI DMKD5ZO DMKD5ZO DN NN-8226 DMKD5ZO TI TTNZMY2 DMKD5ZO TN Interleukin-20 (IL20) DMKD5ZO RN Handbook of Therapeutic Antibodies. 2014. 1. Page(995). DMKD5ZO RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA995&lpg=PA995&dq=NN-8828++++++ANTI&source=bl&ots=OSgek3Ucgf&sig=8iYcf4GKsCAvCCC1QHsKqxZK3YQ&hl=zh-CN&sa=X&ved=0CEwQ6AEwBmoVChMIyrS7qtXGyAIVA0COCh20lgxt#v=onepage&q=NN-8828%20%20%20%20%20%20ANTI&f=false DMKDGI8 DI DMKDGI8 DMKDGI8 DN BP-100-1-01 DMKDGI8 TI TTEYRJ9 DMKDGI8 TN GRB2 messenger RNA (GRB2 mRNA) DMKDGI8 MA Modulator DMKDGI8 RN ClinicalTrials.gov (NCT01159028) Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS. U.S. National Institutes of Health. DMKDGI8 RU https://clinicaltrials.gov/ct2/show/NCT01159028 DMKDN1C DI DMKDN1C DMKDN1C DN MVA-85A DMKDN1C TI TTZYJ8U DMKDN1C TN Mycobacterium Antigen complex 85A (MycB fbpA) DMKDN1C RN MVA-85A, a novel candidate booster vaccine for the prevention of tuberculosis in children and adults. Curr Opin Mol Ther. 2010 Feb;12(1):124-34. DMKDN1C RU https://pubmed.ncbi.nlm.nih.gov/20140824 DMKDP57 DI DMKDP57 DMKDP57 DN Safotibant DMKDP57 TI TTG5QIA DMKDP57 TN B1 bradykinin receptor (BDKRB1) DMKDP57 MA Modulator DMKDP57 RN The role of kinin receptors in cancer and therapeutic opportunities. Cancer Letters Volume 345, Issue 1, 1 April 2014, Pages 27-38. DMKDP57 RU http://www.sciencedirect.com/science/article/pii/S030438351300829X DMKEV7N DI DMKEV7N DMKEV7N DN PK1 DMKEV7N TI TTCGY2K DMKEV7N TN DNA topoisomerase II alpha (TOP2A) DMKEV7N MA Modulator DMKEV7N RN Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol. 2009 Jun;34(6):1629-36. DMKEV7N RU https://pubmed.ncbi.nlm.nih.gov/19424581 DMKFJXP DI DMKFJXP DMKFJXP DN BDB001 DMKFJXP TI TTOK0LR DMKFJXP TN Toll-like receptor (TLR) DMKFJXP MA Agonist DMKFJXP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKFJXP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKGM42 DI DMKGM42 DMKGM42 DN BREQUINAR DMKGM42 TI TTLVP78 DMKGM42 TN Dihydroorotate dehydrogenase (DHODH) DMKGM42 MA Modulator DMKGM42 RN DOI: 10.1203/00006450-198807000-00137 DMKGM42 RU http://www.nature.com/pr/journal/v24/n1/abs/pr1988506a.html DMKH4PI DI DMKH4PI DMKH4PI DN BMS 791325 DMKH4PI TI TTMVBWH DMKH4PI TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMKH4PI MA Inhibitor DMKH4PI RN 2011 Pipeline of Bristol-Myers Squibb. DMKH4PI RU http://www.bms.com/pages/default.aspx DMKHNXA DI DMKHNXA DMKHNXA DN G100 DMKHNXA TI TTISGCA DMKHNXA TN Toll-like receptor 4 (TLR4) DMKHNXA MA Antagonist DMKHNXA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKHNXA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKICA3 DI DMKICA3 DMKICA3 DN BIO-1211 DMKICA3 TI TT4BT06 DMKICA3 TN Integrin alpha-4 (ITGA4) DMKICA3 MA Antagonist DMKICA3 RN A small-molecule, tight-binding inhibitor of the integrin alpha(4)beta(1) blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):603-11. DMKICA3 RU https://pubmed.ncbi.nlm.nih.gov/10934094 DMKIE9C DI DMKIE9C DMKIE9C DN JNJ-26481585 DMKIE9C TI TTBH0VX DMKIE9C TN Histone deacetylase (HDAC) DMKIE9C MA Modulator DMKIE9C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503). DMKIE9C RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7503 DMKIZAL DI DMKIZAL DMKIZAL DN ONO-1603 DMKIZAL TI TTNGKET DMKIZAL TN Prolyl endopeptidase (PREP) DMKIZAL MA Modulator DMKIZAL RN ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4. DMKIZAL RU https://pubmed.ncbi.nlm.nih.gov/8878106 DMKJ9LU DI DMKJ9LU DMKJ9LU DN SPD602 DMKJ9LU TI TTUDR0C DMKJ9LU TN Iron (Fe) DMKJ9LU MA Modulator DMKJ9LU RN ClinicalTrials.gov (NCT01604941) Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy. U.S. National Institutes of Health. DMKJ9LU RU https://clinicaltrials.gov/ct2/show/NCT01604941 DMKJF6H DI DMKJF6H DMKJF6H DN YM-430 DMKJF6H TI TTMXGCW DMKJF6H TN Adrenergic receptor beta-3 (ADRB3) DMKJF6H MA Modulator DMKJF6H RN Cardiovascular effects of YM430, a 1,4-dihydropyridine derivative with beta-adrenoceptor blocking activity, in dogs and rats. Biol Pharm Bull. 1997 Mar;20(3):230-6. DMKJF6H RU https://pubmed.ncbi.nlm.nih.gov/9084878 DMKJFDM DI DMKJFDM DMKJFDM DN CP-601927 DMKJFDM TI TTL1ATN DMKJFDM TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMKJFDM MA Modulator DMKJFDM RN Toxicity study in juvenile rats with the alpha4beta2 nicotinic acetylcholine receptor partial agonist CP-601,927. Birth Defects Res B Dev Reprod Toxicol. 2011 Aug;92(4):323-32. DMKJFDM RU https://pubmed.ncbi.nlm.nih.gov/21594972 DMKJIDU DI DMKJIDU DMKJIDU DN TZI-41078 DMKJIDU TI TTG3K2U DMKJIDU TN Lipoxygenase (ALOX) DMKJIDU MA Modulator DMKJIDU RN Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10. DMKJIDU RU https://pubmed.ncbi.nlm.nih.gov/8581424 DMKJIDU DI DMKJIDU DMKJIDU DN TZI-41078 DMKJIDU TI TTK0943 DMKJIDU TN Prostaglandin G/H synthase (COX) DMKJIDU MA Modulator DMKJIDU RN Hydroxylamine analogs of 2,6-di-t-butylphenols: dual inhibitors of cyclooxygenase and 5-lipoxygenase or selective 5-lipoxygenase inhibitors. Bioorg Med Chem. 1995 Apr;3(4):403-10. DMKJIDU RU https://pubmed.ncbi.nlm.nih.gov/8581424 DMKLJMI DI DMKLJMI DMKLJMI DN NIC-002 DMKLJMI TI TTJSZTB DMKLJMI TN Nicotinic acetylcholine receptor (nAChR) DMKLJMI RN Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106. DMKLJMI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513862/ DMKLMG6 DI DMKLMG6 DMKLMG6 DN KN035 DMKLMG6 TI TT8ZLTI DMKLMG6 TN Programmed cell death 1 ligand 1 (PD-L1) DMKLMG6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMKLMG6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMKM7EW DI DMKM7EW DMKM7EW DN PF-06463922 DMKM7EW TI TTPMQSO DMKM7EW TN ALK tyrosine kinase receptor (ALK) DMKM7EW MA Inhibitor DMKM7EW RN PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models. Cancer Cell. 2015 Jul 13;28(1):70-81. DMKM7EW RU https://pubmed.ncbi.nlm.nih.gov/26144315 DMKMSC4 DI DMKMSC4 DMKMSC4 DN MDX-1342 DMKMSC4 TI TTW640A DMKMSC4 TN B-lymphocyte surface antigen B4 (CD19) DMKMSC4 RN A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65. DMKMSC4 RU https://pubmed.ncbi.nlm.nih.gov/19657637 DMKNIVG DI DMKNIVG DMKNIVG DN Sodium butyrate DMKNIVG TI TT6R7JZ DMKNIVG TN Histone deacetylase 1 (HDAC1) DMKNIVG MA Inhibitor DMKNIVG RN Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. DMKNIVG RU https://pubmed.ncbi.nlm.nih.gov/16955068 DMKNRYH DI DMKNRYH DMKNRYH DN AKB-9778 DMKNRYH TI TT64I9Q DMKNRYH TN Protein tyrosine phosphatase beta (PTPRB) DMKNRYH MA Modulator DMKNRYH RN Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression.J Natl Cancer Inst.2013 Aug 21;105(16):1188-201. DMKNRYH RU https://www.ncbi.nlm.nih.gov/pubmed/23899555 DMKNRYH DI DMKNRYH DMKNRYH DN AKB-9778 DMKNRYH TI TT9VGXW DMKNRYH TN Angiopoietin 1 receptor (TEK) DMKNRYH MA Activator DMKNRYH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKNRYH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMKO0BQ DI DMKO0BQ DMKO0BQ DN BLD-2660 DMKO0BQ TI TT45V0U DMKO0BQ TN HUMAN calpain-1/calpain small subunit 1 heterodimer (CAPN1/CAPNS1) DMKO0BQ MA Inhibitor DMKO0BQ RN ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health. DMKO0BQ RU https://clinicaltrials.gov/ct2/show/NCT04334460 DMKO0BQ DI DMKO0BQ DMKO0BQ DN BLD-2660 DMKO0BQ TI TTO361H DMKO0BQ TN HUMAN calpain-2/calpain small subunit 1 heterodimer (CAPN2/CAPNS1) DMKO0BQ MA Inhibitor DMKO0BQ RN ClinicalTrials.gov (NCT04334460) Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects. U.S. National Institutes of Health. DMKO0BQ RU https://clinicaltrials.gov/ct2/show/NCT04334460 DMKOTUJ DI DMKOTUJ DMKOTUJ DN SRX246 DMKOTUJ TI TT4TFGN DMKOTUJ TN Vasopressin V1a receptor (V1AR) DMKOTUJ MA Antagonist DMKOTUJ RN Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. J Clin Med. 2020 Nov 16;9(11):3682. DMKOTUJ RU https://pubmed.ncbi.nlm.nih.gov/33207828 DMKP3SJ DI DMKP3SJ DMKP3SJ DN F-351 DMKP3SJ TI TTRAXK5 DMKP3SJ TN Aminotransferase (AT) DMKP3SJ MA Inhibitor DMKP3SJ RN Expansion of the clavulanic acid gene cluster: identification and in vivo functional analysis of three new genes required for biosynthesis of clavulanic acid by Streptomyces clavuligerus. J Bacteriol. 2000 Jul;182(14):4087-95. DMKP3SJ RU https://pubmed.ncbi.nlm.nih.gov/10869089 DMKPZ0Q DI DMKPZ0Q DMKPZ0Q DN Mitoquinone DMKPZ0Q TI TTULV0X DMKPZ0Q TN Reactive oxygen species (ROS) DMKPZ0Q MA Inhibitor DMKPZ0Q RN Mitoquinone (MitoQ) Inhibits Platelet Activation Steps by Reducing ROS Levels. Int J Mol Sci. 2020 Aug 27;21(17):6192. DMKPZ0Q RU https://pubmed.ncbi.nlm.nih.gov/32867213 DMKQ3MC DI DMKQ3MC DMKQ3MC DN Human interferon alpha oral DMKQ3MC TI TT95SOA DMKQ3MC TN Interferon alpha (IFNA) DMKQ3MC MA Modulator DMKQ3MC RN Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9. DMKQ3MC RU https://pubmed.ncbi.nlm.nih.gov/1388878 DMKQXDB DI DMKQXDB DMKQXDB DN Rostafuroxin DMKQXDB TI TTQ38E9 DMKQXDB TN Sodium/potassium-transporting ATPase (SPT ATPase) DMKQXDB MA Modulator DMKQXDB RN Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 2006 Mar;290(3):R529-35. DMKQXDB RU https://pubmed.ncbi.nlm.nih.gov/16467500 DMKRFCO DI DMKRFCO DMKRFCO DN CDX-301 DMKRFCO TI TTGJCWZ DMKRFCO TN Fms-like tyrosine kinase 3 (FLT-3) DMKRFCO MA Inhibitor DMKRFCO RN Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers. Bone Marrow Transplant. 2015 Jul;50(7):924-30. DMKRFCO RU https://pubmed.ncbi.nlm.nih.gov/25915810 DMKRGVJ DI DMKRGVJ DMKRGVJ DN INS-1 DMKRGVJ TI TTZ7WFL DMKRGVJ TN Glucose metabolism (Glucose metab) DMKRGVJ MA Modulator DMKRGVJ RN Herbal constituent sequoyitol improves hyperglycemia and glucose intolerance by targeting hepatocytes, adipocytes, and beta-cells. Am J Physiol Endocrinol Metab. 2012 April 15; 302(8): E932-E940. DMKRGVJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3330724/ DMKS7RJ DI DMKS7RJ DMKS7RJ DN CGS-15873A DMKS7RJ TI TTEX248 DMKS7RJ TN Dopamine D2 receptor (D2R) DMKS7RJ MA Modulator DMKS7RJ RN Biochemical and pharmacological characterization of the putative dopamine autoreceptor agonist benzopyranopyridine, CGS 15873A. Article first published online: 5 OCT 2004. DMKS7RJ RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430180303/abstract DMKSUOI DI DMKSUOI DMKSUOI DN Flavopiridol DMKSUOI TI TTMBO1Z DMKSUOI TN Cyclin-dependent kinase (CDK) DMKSUOI MA Inhibitor DMKSUOI RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMKSUOI RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMKSUOI DI DMKSUOI DMKSUOI DN Flavopiridol DMKSUOI TI TT31JXP DMKSUOI TN Myophosphorylase (PYGM) DMKSUOI MA Inhibitor DMKSUOI RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMKSUOI RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMKSUOI DI DMKSUOI DMKSUOI DN Flavopiridol DMKSUOI TI TT1LVF2 DMKSUOI TN Cyclin-dependent kinase 9 (CDK9) DMKSUOI MA Inhibitor DMKSUOI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKSUOI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKTLSD DI DMKTLSD DMKTLSD DN S-15535 DMKTLSD TI TTSQIFT DMKTLSD TN 5-HT 1A receptor (HTR1A) DMKTLSD MA Antagonist DMKTLSD RN S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Br J Pharmacol. 1999 Nov;128(6):1207-14. DMKTLSD RU https://pubmed.ncbi.nlm.nih.gov/10578133 DMKTP8E DI DMKTP8E DMKTP8E DN PRX002 DMKTP8E TI TT08OSU DMKTP8E TN Synuclein alpha (SNCA) DMKTP8E MA Inhibitor DMKTP8E RN Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-alpha-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 Oct 1;75(10):1206-1214. DMKTP8E RU https://pubmed.ncbi.nlm.nih.gov/29913017 DMKU6MW DI DMKU6MW DMKU6MW DN JB991 DMKU6MW TI TT9B4N3 DMKU6MW TN Prostaglandin receptor (PTGR) DMKU6MW MA Agonist DMKU6MW RN US patent application no. 2006,0041,016, Composition and method for the treatment of psoriasis. DMKU6MW RU http://www.google.com/patents/US20060041016 DMKU93J DI DMKU93J DMKU93J DN VAS-203 DMKU93J TI TTCM4B3 DMKU93J TN Nitric-oxide synthase endothelial (NOS3) DMKU93J MA Inhibitor DMKU93J RN Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606. DMKU93J RU https://pubmed.ncbi.nlm.nih.gov/24831445 DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTSQIFT DMKUE8O TN 5-HT 1A receptor (HTR1A) DMKUE8O MA Antagonist DMKUE8O RN Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271 DMKUE8O RU http://link.springer.com/article/10.1007%2Fs40290-014-0070-6 DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTEX248 DMKUE8O TN Dopamine D2 receptor (D2R) DMKUE8O MA Antagonist DMKUE8O RN Drug Development in Schizophrenia: Summary and Table. Pharmaceutical Medicine October 2014, Volume 28, Issue 5, pp 265-271 DMKUE8O RU http://link.springer.com/article/10.1007%2Fs40290-014-0070-6 DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TT4C8EA DMKUE8O TN Dopamine D3 receptor (D3R) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTE0A2F DMKUE8O TN Dopamine D4 receptor (D4R) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTJQOD7 DMKUE8O TN 5-HT 2A receptor (HTR2A) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TT8G3Z7 DMKUE8O TN Serotoninnorepinephrinedopamine reuptake (SNDR) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTTIBOJ DMKUE8O TN Histamine H1 receptor (H1R) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKUE8O DI DMKUE8O DMKUE8O DN RP5063 DMKUE8O TI TTO9X1H DMKUE8O TN 5-HT 7 receptor (HTR7) DMKUE8O MA Partial agonist DMKUE8O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUE8O RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMKV5UM DI DMKV5UM DMKV5UM DN TM-601 DMKV5UM TI TTCYAXN DMKV5UM TN Chloride channel unspecific (ClC) DMKV5UM MA Inhibitor DMKV5UM RN NMR sequential assignments and solution structure of chlorotoxin, a small scorpion toxin that blocks chloride channels. Biochemistry. 1995 Jan 10;34(1):13-21. DMKV5UM RU https://pubmed.ncbi.nlm.nih.gov/7819188 DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTVDSZ0 DMKVBL8 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTFQI4H DMKVBL8 TN Tankyrase-2 (TNKS-2) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTVUSO7 DMKVBL8 TN Tankyrase-1 (TNKS-1) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVBL8 DI DMKVBL8 DMKVBL8 DN Stenoparib DMKVBL8 TI TTQ4V96 DMKVBL8 TN Poly [ADP-ribose] polymerase 2 (PARP2) DMKVBL8 MA Inhibitor DMKVBL8 RN Clinical pipeline report, company report or official report of Allarity Therapeutics. DMKVBL8 RU https://allarity.com/pipeline/stenoparib/ DMKVIWM DI DMKVIWM DMKVIWM DN QR-333 DMKVIWM TI TTFBNVI DMKVIWM TN Aldose reductase (AKR1B1) DMKVIWM MA Inhibitor DMKVIWM RN A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53. DMKVIWM RU https://pubmed.ncbi.nlm.nih.gov/16112498 DMKVP7E DI DMKVP7E DMKVP7E DN Apolizumab DMKVP7E TI TTYA75N DMKVP7E TN MHC class II antigen DR (HLA-DR) DMKVP7E MA Modulator DMKVP7E RN A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. DMKVP7E RU https://www.ncbi.nlm.nih.gov/pubmed/17071489 DMKVXYS DI DMKVXYS DMKVXYS DN FK-409 DMKVXYS TI TTWNFC2 DMKVXYS TN Soluble guanylyl cyclase (GUCY2D) DMKVXYS MA Modulator DMKVXYS RN Vasorelaxant mechanism of the new vasodilator, FK409. Eur J Pharmacol. 1993 Aug 15;246(3):205-12. DMKVXYS RU https://www.ncbi.nlm.nih.gov/pubmed/7901040 DMKWCTR DI DMKWCTR DMKWCTR DN GS-9973 DMKWCTR TI TTOU65C DMKWCTR TN Tyrosine-protein kinase SYK (SYK) DMKWCTR MA Modulator DMKWCTR RN An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. DMKWCTR RU https://pubmed.ncbi.nlm.nih.gov/25696919 DMKWGS1 DI DMKWGS1 DMKWGS1 DN PBT-2 DMKWGS1 TI TTS87KH DMKWGS1 TN Microtubule-associated protein tau (MAPT) DMKWGS1 MA Modulator DMKWGS1 RN PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16. DMKWGS1 RU https://pubmed.ncbi.nlm.nih.gov/20164561 DMKY638 DI DMKY638 DMKY638 DN BMS-813160 DMKY638 TI TTFZYTO DMKY638 TN C-C chemokine receptor type 2 (CCR2) DMKY638 MA Modulator DMKY638 RN A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24. DMKY638 RU https://pubmed.ncbi.nlm.nih.gov/21936726 DMKY638 DI DMKY638 DMKY638 DN BMS-813160 DMKY638 TI TT2CEJG DMKY638 TN C-C chemokine receptor type 5 (CCR5) DMKY638 MA Modulator DMKY638 RN A dual CCR2/CCR5 chemokine antagonist, BMS-813160. Expert Opin Ther Pat. 2011 Dec;21(12):1919-24. DMKY638 RU https://pubmed.ncbi.nlm.nih.gov/21936726 DMKYMS2 DI DMKYMS2 DMKYMS2 DN LY-2428757 DMKYMS2 TI TTVIMDE DMKYMS2 TN Glucagon-like peptide 1 receptor (GLP1R) DMKYMS2 MA Stimulator DMKYMS2 RN Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes Metab Syndr Obes. 2009; 2: 37-49. DMKYMS2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818016/ DMKZN3A DI DMKZN3A DMKZN3A DN Golotimod DMKZN3A TI TTH8FZW DMKZN3A TN Signal transducer and activator of transcription 3 (STAT3) DMKZN3A MA Inhibitor DMKZN3A RN National Cancer Institute Drug Dictionary (drug id 617379). DMKZN3A RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=617379 DMKZUVC DI DMKZUVC DMKZUVC DN INS-50589 DMKZUVC TI TTZ1DT0 DMKZUVC TN P2Y purinoceptor 12 (P2RY12) DMKZUVC MA Modulator DMKZUVC RN Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589. Platelets. 2007 Aug;18(5):346-56. DMKZUVC RU https://pubmed.ncbi.nlm.nih.gov/17654304 DML0I2Z DI DML0I2Z DML0I2Z DN M118 DML0I2Z TI TT4QPUL DML0I2Z TN Antithrombin-III (ATIII) DML0I2Z MA Inhibitor DML0I2Z RN Clinical pipeline report, company report or official report of Momentapharma. DML0I2Z RU http://www.momentapharma.com/pipeline/adomiparin.php DML0KWM DI DML0KWM DML0KWM DN CAR-T cells targeting CD30 DML0KWM TI TT2GM5R DML0KWM TN Lymphocyte activation antigen CD30 (TNFRSF8) DML0KWM MA CAR-T-Cell-Therapy DML0KWM RN ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL DML0KWM RU https://clinicaltrials.gov/ct2/show/NCT03196830 DML10K3 DI DML10K3 DML10K3 DN SF1126 DML10K3 TI TTHBTOP DML10K3 TN PI3-kinase gamma (PIK3CG) DML10K3 MA Modulator DML10K3 RN An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.Cancer Chemother Pharmacol.2013 Apr;71(4):867-81. DML10K3 RU https://www.ncbi.nlm.nih.gov/pubmed/23355037 DML10K3 DI DML10K3 DML10K3 DN SF1126 DML10K3 TI TTCJG29 DML10K3 TN Serine/threonine-protein kinase mTOR (mTOR) DML10K3 MA Inhibitor DML10K3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML10K3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML1CK2 DI DML1CK2 DML1CK2 DN BMS-188797 DML1CK2 TI TTML2WA DML1CK2 TN Tubulin (TUB) DML1CK2 MA Inhibitor DML1CK2 RN Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94. DML1CK2 RU https://pubmed.ncbi.nlm.nih.gov/14613998 DML27AE DI DML27AE DML27AE DN Arverapamil DML27AE TI TT5HONZ DML27AE TN Calcium channel unspecific (CaC) DML27AE MA Modulator DML27AE RN BJMP 2010;3(4):a342 DML27AE RU http://bjmp.org/files/2010-3-4/bjmp-2010-3-4-a342.pdf DML2CPW DI DML2CPW DML2CPW DN VAY736 DML2CPW TI TT7NJSE DML2CPW TN B-cell-activating factor receptor (TNFRSF13C) DML2CPW RN National Cancer Institute Drug Dictionary (drug id 762784). DML2CPW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762784 DML2D30 DI DML2D30 DML2D30 DN S-16924 DML2D30 TI TTSQIFT DML2D30 TN 5-HT 1A receptor (HTR1A) DML2D30 MA Modulator DML2D30 RN S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther. 1998 Sep;286(3):1341-55. DML2D30 RU https://pubmed.ncbi.nlm.nih.gov/9732398 DML2D8Q DI DML2D8Q DML2D8Q DN Bevirimat DML2D8Q TI TTFGZB6 DML2D8Q TN Human immunodeficiency virus GAG protein (HIV gag) DML2D8Q MA Inhibitor DML2D8Q RN Synthesis and biological evaluation of a new derivative of bevirimat that targets the Gag CA-SP1 cleavage site. Eur J Med Chem. 2013 Apr;62:453-65. DML2D8Q RU https://pubmed.ncbi.nlm.nih.gov/23399723 DML2ZWR DI DML2ZWR DML2ZWR DN Solubilized type 1 native bovine collagen DML2ZWR TI TTUABC1 DML2ZWR TN Collagen I (COL1A2) DML2ZWR MA Modulator DML2ZWR RN Company report (Argentisrx) DML2ZWR RU http://www.argentisrx.com/arg201-development-to-date.html DML38VU DI DML38VU DML38VU DN PF-446687 DML38VU TI TTD0CIQ DML38VU TN Melanocortin receptor 4 (MC4R) DML38VU MA Modulator DML38VU RN Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65. DML38VU RU https://pubmed.ncbi.nlm.nih.gov/25652247 DML3PJF DI DML3PJF DML3PJF DN ARN-810 DML3PJF TI TTZAYWL DML3PJF TN Estrogen receptor (ESR) DML3PJF MA Modulator DML3PJF RN Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts. J Med Chem.2015 Jun 25;58(12):4888-904. DML3PJF RU https://pubmed.ncbi.nlm.nih.gov/25879485 DML4GU1 DI DML4GU1 DML4GU1 DN 99mTc-MIP-1404 DML4GU1 TI TT9G4N0 DML4GU1 TN Glutamate carboxypeptidase II (GCPII) DML4GU1 MA Modulator DML4GU1 RN 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76. DML4GU1 RU https://pubmed.ncbi.nlm.nih.gov/23733925 DML4PMG DI DML4PMG DML4PMG DN Dendritic cell vaccine DML4PMG TI TTUJFD0 DML4PMG TN Telomerase reverse transcriptase (TERT) DML4PMG RN In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells. J Immunotoxicol. 2009 Dec;6(4):243-8. DML4PMG RU https://pubmed.ncbi.nlm.nih.gov/19908943 DML4RCG DI DML4RCG DML4RCG DN HS-110 DML4RCG TI TTFZDNP DML4RCG TN Activation B7-1 antigen (CD80) DML4RCG RN Clinical pipeline report, company report or official report of Heat Biologics. DML4RCG RU http://www.heatbio.com/product-pipeline/hs-110 DML4RCG DI DML4RCG DML4RCG DN HS-110 DML4RCG TI TTFPKXQ DML4RCG TN Endoplasmin (HSP90B1) DML4RCG RN Clinical pipeline report, company report or official report of Heat Biologics. DML4RCG RU http://www.heatbio.com/product-pipeline/hs-110 DML5AE4 DI DML5AE4 DML5AE4 DN FK-3311 DML5AE4 TI TTVKILB DML5AE4 TN Prostaglandin G/H synthase 2 (COX-2) DML5AE4 MA Modulator DML5AE4 RN Effects of the COX-2 inhibitor FK3311 on ischemia - reperfusion injury in the rat lung. J Invest Surg. 2007 May-Jun;20(3):175-80. DML5AE4 RU https://pubmed.ncbi.nlm.nih.gov/17613692 DML5S71 DI DML5S71 DML5S71 DN Nexopamil DML5S71 TI TT5HONZ DML5S71 TN Calcium channel unspecific (CaC) DML5S71 MA Blocker DML5S71 RN Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. DML5S71 RU https://pubmed.ncbi.nlm.nih.gov/7506319 DML5S71 DI DML5S71 DML5S71 DN Nexopamil DML5S71 TI TTYSN63 DML5S71 TN 5-HT 2 receptor (5HT2R) DML5S71 MA Modulator DML5S71 RN Inhibition by the combined Ca2+ and 5-HT2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimal damage. J Cardiovasc Pharmacol. 1993 Nov;22(5):687-94. DML5S71 RU https://pubmed.ncbi.nlm.nih.gov/7506319 DML6PO5 DI DML6PO5 DML6PO5 DN GM-CSF cancer vaccine DML6PO5 TI TT6MP2Z DML6PO5 TN GMCSFR-alpha (CSF2RA) DML6PO5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DML6PO5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DML6TAS DI DML6TAS DML6TAS DN OPI-1002 DML6TAS TI TT12KOD DML6TAS TN P53 messenger RNA (TP53 mRNA) DML6TAS RN 2011 Pipeline of Quark Pharm. DML6TAS RU http://www.quarkpharma.com/qbi-en/home/homepage/ DML6XSP DI DML6XSP DML6XSP DN Resiquimod DML6XSP TI TTRJ1K4 DML6XSP TN Toll-like receptor 7 (TLR7) DML6XSP MA Modulator DML6XSP RN TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70. DML6XSP RU https://www.ncbi.nlm.nih.gov/pubmed/16081189 DML6XSP DI DML6XSP DML6XSP DN Resiquimod DML6XSP TI TT8CWFK DML6XSP TN Toll-like receptor 8 (TLR8) DML6XSP MA Modulator DML6XSP RN TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70. DML6XSP RU https://www.ncbi.nlm.nih.gov/pubmed/16081189 DML6XWR DI DML6XWR DML6XWR DN LY2944876 DML6XWR TI TTVIMDE DML6XWR TN Glucagon-like peptide 1 receptor (GLP1R) DML6XWR MA Modulator DML6XWR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML6XWR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML6XWR DI DML6XWR DML6XWR DN LY2944876 DML6XWR TI TT9O6WS DML6XWR TN Glucagon receptor (GCGR) DML6XWR MA Modulator DML6XWR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML6XWR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML7N4B DI DML7N4B DML7N4B DN MUC1-Poly-ICLC DML7N4B TI TTBHFYQ DML7N4B TN Mucin-1 (MUC1) DML7N4B RN Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429. DML7N4B RU https://pubmed.ncbi.nlm.nih.gov/23802084 DML7WP0 DI DML7WP0 DML7WP0 DN Eldacimibe DML7WP0 TI TTMF541 DML7WP0 TN Liver carboxylesterase (CES1) DML7WP0 MA Modulator DML7WP0 RN Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46. DML7WP0 RU https://pubmed.ncbi.nlm.nih.gov/7621974 DML84CN DI DML84CN DML84CN DN ISIS-CRPRx DML84CN TI TTWRN6M DML84CN TN CRP messenger RNA (CRP mRNA) DML84CN MA Modulator DML84CN RN Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. J Pharmacol Toxicol Methods. 2014 Jan-Feb;69(1):49-60. DML84CN RU https://pubmed.ncbi.nlm.nih.gov/24211663 DML8N3Y DI DML8N3Y DML8N3Y DN Recifercept DML8N3Y TI TTST7KB DML8N3Y TN Fibroblast growth factor receptor 3 (FGFR3) DML8N3Y RN In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368. DML8N3Y RU https://pubmed.ncbi.nlm.nih.gov/33370388 DML97KB DI DML97KB DML97KB DN TAS-106 DML97KB TI TT79JGK DML97KB TN Mycobacterium RNA polymerase (MycB RNAP) DML97KB MA Modulator DML97KB RN Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.Invest New Drugs.2012 Feb;30(1):316-26. DML97KB RU https://www.ncbi.nlm.nih.gov/pubmed/20839029 DML9AVG DI DML9AVG DML9AVG DN IMG-7289 DML9AVG TI TTNR0UQ DML9AVG TN Lysine-specific histone demethylase 1 (LSD) DML9AVG MA Inhibitor DML9AVG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML9AVG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML9M5S DI DML9M5S DML9M5S DN AZD-4017 DML9M5S TI TTN7BL9 DML9M5S TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DML9M5S MA Inhibitor DML9M5S RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DML9M5S RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMLA8H3 DI DMLA8H3 DMLA8H3 DN LX2931 DMLA8H3 TI TT618Q2 DMLA8H3 TN Sphingosine-1-phosphate lyase 1 (SGPL1) DMLA8H3 MA Inhibitor DMLA8H3 RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMLA8H3 RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMLAOHX DI DMLAOHX DMLAOHX DN Avdoralimab DMLAOHX TI TTQLO2H DMLAOHX TN HUMAN C5a receptor (C5aR) DMLAOHX MA Inhibitor DMLAOHX RN Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24;7(1):77. DMLAOHX RU https://pubmed.ncbi.nlm.nih.gov/29691378 DMLBD5I DI DMLBD5I DMLBD5I DN LXE408 DMLBD5I TI TTSVQWU DMLBD5I TN Leishmania major Proteasome (Leishm Proteasome) DMLBD5I MA Inhibitor DMLBD5I RN Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases. J Med Chem. 2020 Oct 8;63(19):10773-10781. DMLBD5I RU https://pubmed.ncbi.nlm.nih.gov/32667203 DMLBWT1 DI DMLBWT1 DMLBWT1 DN ALRN-6924 DMLBWT1 TI TT08GJW DMLBWT1 TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMLBWT1 MA Antagonist DMLBWT1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLBWT1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLBWT1 DI DMLBWT1 DMLBWT1 DN ALRN-6924 DMLBWT1 TI TT9OUDQ DMLBWT1 TN p53-binding protein Mdm4 (MDM4) DMLBWT1 MA Inhibitor DMLBWT1 RN Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612. DMLBWT1 RU https://pubmed.ncbi.nlm.nih.gov/30072728 DMLCUAS DI DMLCUAS DMLCUAS DN TOFIMILAST DMLCUAS TI TTVIAT9 DMLCUAS TN Phosphodiesterase 4B (PDE4B) DMLCUAS MA Inhibitor DMLCUAS RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMLCUAS RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMLCUAS DI DMLCUAS DMLCUAS DN TOFIMILAST DMLCUAS TI TTSKMI8 DMLCUAS TN Phosphodiesterase 4D (PDE4D) DMLCUAS MA Inhibitor DMLCUAS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMLCUAS RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMLCUAS DI DMLCUAS DMLCUAS DN TOFIMILAST DMLCUAS TI TTZ97H5 DMLCUAS TN Phosphodiesterase 4A (PDE4A) DMLCUAS MA Inhibitor DMLCUAS RN GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther. 2011 Apr;337(1):145-54. DMLCUAS RU https://pubmed.ncbi.nlm.nih.gov/21205923 DMLD4VQ DI DMLD4VQ DMLD4VQ DN RPL-554 DMLD4VQ TI TTZCG4L DMLD4VQ TN Phosphodiesterase 3 (PDE3) DMLD4VQ MA Modulator DMLD4VQ RN Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27. DMLD4VQ RU https://www.ncbi.nlm.nih.gov/pubmed/24429275 DMLD80M DI DMLD80M DMLD80M DN Brivoligide DMLD80M TI TTE8LGD DMLD80M TN EGR1 messenger RNA (EGR1 mRNA) DMLD80M MA Inhibitor DMLD80M RN ClinicalTrials.gov (NCT04104919) Study to Evaluate a Preop Dose of Brivoligide Injection for Pain After Mastectomy in Patients With High PCS Scores. U.S. National Institutes of Health. DMLD80M RU https://clinicaltrials.gov/ct2/show/NCT04104919 DMLDBQ5 DI DMLDBQ5 DMLDBQ5 DN SEN-196 DMLDBQ5 TI TTUF2HO DMLDBQ5 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMLDBQ5 MA Inhibitor DMLDBQ5 RN Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011 Dec;16(10):1153-69. DMLDBQ5 RU https://pubmed.ncbi.nlm.nih.gov/22086720 DMLEO2Z DI DMLEO2Z DMLEO2Z DN ABT-652 DMLEO2Z TI TT9JNIC DMLEO2Z TN Histamine H3 receptor (H3R) DMLEO2Z MA Modulator DMLEO2Z RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225) DMLEO2Z RU http://adisinsight.springer.com/drugs/800032225 DMLEX1D DI DMLEX1D DMLEX1D DN Lexibulin DMLEX1D TI TTYFKSZ DMLEX1D TN Tubulin beta (TUBB) DMLEX1D MA Inhibitor DMLEX1D RN National Cancer Institute Drug Dictionary (drug id 598799). DMLEX1D RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=598799 DMLFGHX DI DMLFGHX DMLFGHX DN BRL 35135 DMLFGHX TI TTR6W5O DMLFGHX TN Adrenergic receptor beta-1 (ADRB1) DMLFGHX MA Agonist DMLFGHX RN Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol. 1996 Sep;42(3):291-300. DMLFGHX RU https://pubmed.ncbi.nlm.nih.gov/8877018 DMLFI7Q DI DMLFI7Q DMLFI7Q DN GSK-2251052 DMLFI7Q TI TT37GL6 DMLFI7Q TN Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) DMLFI7Q MA Inhibitor DMLFI7Q RN Bacterial resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98. DMLFI7Q RU https://pubmed.ncbi.nlm.nih.gov/25348524 DMLFSMX DI DMLFSMX DMLFSMX DN GK1-399 DMLFSMX TI TTDLNGZ DMLFSMX TN Glucokinase (GCK) DMLFSMX MA Inhibitor DMLFSMX RN Clinical pipeline report, company report or official report of vTv Therapeutics, NCT02405260. DMLFSMX RU http://vtvtherapeutics.com/pipeline/ttp399 DMLHPVW DI DMLHPVW DMLHPVW DN L1-79 DMLHPVW TI TTUHP71 DMLHPVW TN Tyrosine 3-monooxygenase (TH) DMLHPVW MA Inhibitor DMLHPVW RN Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981. DMLHPVW RU https://pubmed.ncbi.nlm.nih.gov/31492568 DMLIPY1 DI DMLIPY1 DMLIPY1 DN Xmab 5871 DMLIPY1 TI TT5RWKQ DMLIPY1 TN Immunoglobulin gamma Fc receptor IIB (FCGR2B) DMLIPY1 MA Modulator DMLIPY1 RN CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. DMLIPY1 RU https://pubmed.ncbi.nlm.nih.gov/22820352 DMLIPY1 DI DMLIPY1 DMLIPY1 DN Xmab 5871 DMLIPY1 TI TTW640A DMLIPY1 TN B-lymphocyte surface antigen B4 (CD19) DMLIPY1 MA Modulator DMLIPY1 RN Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fc receptor IIb inhibitory receptor.Arthritis Rheumatol.2014 May;66(5):1153-64. DMLIPY1 RU https://www.ncbi.nlm.nih.gov/pubmed/24782179 DMLK59M DI DMLK59M DMLK59M DN AZD1480 DMLK59M TI TTRMX3V DMLK59M TN Janus kinase 2 (JAK-2) DMLK59M MA Modulator DMLK59M RN The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-97. DMLK59M RU https://pubmed.ncbi.nlm.nih.gov/19962667 DMLMNFX DI DMLMNFX DMLMNFX DN Omaveloxolone DMLMNFX TI TTA6ZN2 DMLMNFX TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMLMNFX MA Activator DMLMNFX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLMNFX RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMLMV0O DI DMLMV0O DMLMV0O DN MK-7655 DMLMV0O TI TTHI19T DMLMV0O TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMLMV0O MA Inhibitor DMLMV0O RN Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5. DMLMV0O RU https://pubmed.ncbi.nlm.nih.gov/24433862 DMLMZ6Q DI DMLMZ6Q DMLMZ6Q DN NP-2 DMLMZ6Q TI TTN4QDT DMLMZ6Q TN Opioid receptor (OPR) DMLMZ6Q MA Antagonist DMLMZ6Q RN Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. J Biol Chem. 2001 Jun 1;276(22):18688-94. DMLMZ6Q RU https://pubmed.ncbi.nlm.nih.gov/11278319 DMLNKX7 DI DMLNKX7 DMLNKX7 DN STX-107 DMLNKX7 TI TTHS256 DMLNKX7 TN Metabotropic glutamate receptor 5 (mGluR5) DMLNKX7 MA Antagonist DMLNKX7 RN Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents. J Can Acad Child Adolesc Psychiatry. 2014 February; 23(1):20-30. DMLNKX7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917666/ DMLO18H DI DMLO18H DMLO18H DN BAY-Y-5959 DMLO18H TI TTXHYV6 DMLO18H TN Voltage-gated L-type calcium channel (L-CaC) DMLO18H MA Modulator DMLO18H RN Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6. DMLO18H RU https://pubmed.ncbi.nlm.nih.gov/9694931 DMLPEZS DI DMLPEZS DMLPEZS DN Venglustat DMLPEZS TI TTPHEX3 DMLPEZS TN Ceramide glucosyltransferase (UGCG) DMLPEZS MA Inhibitor DMLPEZS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPEZS RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMLPNVS DI DMLPNVS DMLPNVS DN MB-102 DMLPNVS TI TTENHJ0 DMLPNVS TN Interleukin 3 receptor alpha (IL3RA) DMLPNVS MA CAR-T-Cell-Therapy DMLPNVS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPNVS RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLPRZJ DI DMLPRZJ DMLPRZJ DN Ensaculin hydrochloride DMLPRZJ TI TTSQIFT DMLPRZJ TN 5-HT 1A receptor (HTR1A) DMLPRZJ MA Modulator DMLPRZJ RN Ensaculin (KA-672 HCl): a multitransmitter approach to dementia treatment. CNS Drug Rev. 2002 Summer;8(2):143-58. DMLPRZJ RU https://pubmed.ncbi.nlm.nih.gov/12177685 DMLQ3OK DI DMLQ3OK DMLQ3OK DN PF-05175157 DMLQ3OK TI TTY84UG DMLQ3OK TN Acetyl-CoA carboxylase 2 (ACACB) DMLQ3OK MA Inhibitor DMLQ3OK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264). DMLQ3OK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264 DMLQDBH DI DMLQDBH DMLQDBH DN HM-5016504 DMLQDBH TI TTNDSF4 DMLQDBH TN Proto-oncogene c-Met (MET) DMLQDBH MA Inhibitor DMLQDBH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMLQDBH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMLQK6E DI DMLQK6E DMLQK6E DN PYM-50028 DMLQK6E TI TTSMLOH DMLQK6E TN Brain-derived neurotrophic factor (BDNF) DMLQK6E MA Agonist DMLQK6E RN PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008 Jul;22(7):2488-97. DMLQK6E RU https://pubmed.ncbi.nlm.nih.gov/18364399 DMLQRFO DI DMLQRFO DMLQRFO DN AGN-2979 DMLQRFO TI TTZSJHV DMLQRFO TN Tryptophan 5-hydroxylase 1 (TPH1) DMLQRFO MA Modulator DMLQRFO RN Antidepressant-like action of AGN 2979, a tryptophan hydroxylase activation inhibitor, in a chronic mild stress model of depression in rats. Eur Neuropsychopharmacol. 2001 Oct;11(5):351-7. DMLQRFO RU https://pubmed.ncbi.nlm.nih.gov/11597821 DMLQRYH DI DMLQRYH DMLQRYH DN CH-4051 DMLQRYH TI TTYZVDJ DMLQRYH TN Dihydrofolate reductase (DHFR) DMLQRYH MA Inhibitor DMLQRYH RN CH-1504, a metabolically inert antifolate for the potential treatment of rheumatoid arthritis. IDrugs. 2010 Aug;13(8):559-67. DMLQRYH RU https://pubmed.ncbi.nlm.nih.gov/20721827 DMLRTN1 DI DMLRTN1 DMLRTN1 DN CI-1012 DMLRTN1 TI TT3NH7G DMLRTN1 TN Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA) DMLRTN1 MA Inhibitor DMLRTN1 RN WO patent application no. 2006,0835,53, Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase. DMLRTN1 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060810&CC=WO&NR=2006083553A2&KC=A2 DMLRU9I DI DMLRU9I DMLRU9I DN Lunacalcipol DMLRU9I TI TT82UI1 DMLRU9I TN Cytochrome P450 24 (CYP24A1) DMLRU9I MA Inhibitor DMLRU9I RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022679) DMLRU9I RU http://adisinsight.springer.com/drugs/800022679 DMLS269 DI DMLS269 DMLS269 DN E-1224 DMLS269 TI TTTSOUD DMLS269 TN Candida Cytochrome P450 51 (Candi ERG11) DMLS269 MA Inhibitor DMLS269 RN Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease. Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242. DMLS269 RU https://pubmed.ncbi.nlm.nih.gov/23277882 DMLSK01 DI DMLSK01 DMLSK01 DN Altrakincept DMLSK01 TI TTDWHC3 DMLSK01 TN Interleukin 4 receptor alpha (IL4R) DMLSK01 MA Modulator DMLSK01 RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMLSK01 RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMLT7JV DI DMLT7JV DMLT7JV DN CNV-2197944 DMLT7JV TI TT4FDG6 DMLT7JV TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMLT7JV MA Blocker DMLT7JV RN Clinical pipeline report, company report or official report of Convergence Pharmaceuticals Ltd. DMLT7JV RU http://www.convergencepharma.com/index.asp?page_id=30 DMLT94F DI DMLT94F DMLT94F DN VLS-101 DMLT94F TI TTDEJAU DMLT94F TN Neurotrophic tyrosine kinase ROR1 (ROR1) DMLT94F RN Clinical pipeline report, company report or official report of VelosBio. DMLT94F RU https://velosbio.com/our-science/pipeline DMLTAES DI DMLTAES DMLTAES DN MK-0752 DMLTAES TI TT9W8GU DMLTAES TN Gamma-secretase (GS) DMLTAES MA Modulator DMLTAES RN Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Sep 1;878(25):2348-52. DMLTAES RU https://pubmed.ncbi.nlm.nih.gov/20702149 DMLTI39 DI DMLTI39 DMLTI39 DN Lumiliximab DMLTI39 TI TTCH6MU DMLTI39 TN Lymphocyte IgE receptor (CD23) DMLTI39 RN Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol. 2005 Oct;116(4):780-8. DMLTI39 RU https://pubmed.ncbi.nlm.nih.gov/16210051 DMLTSDC DI DMLTSDC DMLTSDC DN LY-2456302 DMLTSDC TI TTQW87Y DMLTSDC TN Opioid receptor kappa (OPRK1) DMLTSDC MA Antagonist DMLTSDC RN LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 2014 Feb;77:131-44. DMLTSDC RU https://pubmed.ncbi.nlm.nih.gov/24071566 DMLUM3Y DI DMLUM3Y DMLUM3Y DN ONO-4641 DMLUM3Y TI TT9JZCK DMLUM3Y TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMLUM3Y MA Agonist DMLUM3Y RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMLUM3Y RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMLV1ET DI DMLV1ET DMLV1ET DN BIIB074 DMLV1ET TI TT4G2JS DMLV1ET TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMLV1ET MA Inhibitor DMLV1ET RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMLV1ET RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMLV9GS DI DMLV9GS DMLV9GS DN AD04 DMLV9GS TI TTNXLKE DMLV9GS TN 5-HT 3 receptor (5HT3R) DMLV9GS MA Antagonist DMLV9GS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLV9GS RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMLVCZR DI DMLVCZR DMLVCZR DN ACH-4471 DMLVCZR TI TT8D13I DMLVCZR TN Complement factor D (CFD) DMLVCZR MA Inhibitor DMLVCZR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLVCZR RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMLVHAJ DI DMLVHAJ DMLVHAJ DN PX-12 DMLVHAJ TI TTZJ5U9 DMLVHAJ TN Thioredoxin (TXN) DMLVHAJ MA Inhibitor DMLVHAJ RN 2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Mol Cancer Ther. 2008 Jan;7(1):143-51. DMLVHAJ RU https://pubmed.ncbi.nlm.nih.gov/18202017 DMLVQKF DI DMLVQKF DMLVQKF DN MRX-6 DMLVQKF TI TT9V5JH DMLVQKF TN Phospholipase A2 (PLA2G1B) DMLVQKF MA Inhibitor DMLVQKF RN A novel treatment of contact dermatitis by topical application of phospholipase A2 inhibitor: a double-blind placebo-controlled pilot study. Int J Immunopathol Pharmacol. 2007 Jan-Mar;20(1):191-5. DMLVQKF RU https://pubmed.ncbi.nlm.nih.gov/17346444 DMLWKZ7 DI DMLWKZ7 DMLWKZ7 DN GO-203-2c DMLWKZ7 TI TTBHFYQ DMLWKZ7 TN Mucin-1 (MUC1) DMLWKZ7 MA Inhibitor DMLWKZ7 RN Clinical pipeline report, company report or official report of Genus Oncology. DMLWKZ7 RU http://www.genusoncology.com/phase-1-trial-GO-203-2c.php DMLWM4G DI DMLWM4G DMLWM4G DN VX-15 DMLWM4G TI TT5UT28 DMLWM4G TN Semaphorin-4D (SEMA4D) DMLWM4G RN Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Soli... Clin Cancer Res. 2016 Feb 15;22(4):827-36. DMLWM4G RU https://pubmed.ncbi.nlm.nih.gov/26446947 DMLWM4G DI DMLWM4G DMLWM4G DN VX-15 DMLWM4G TI TT5TKPM DMLWM4G TN Neutral endopeptidase (MME) DMLWM4G MA Inhibitor DMLWM4G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLWM4G RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLXFM6 DI DMLXFM6 DMLXFM6 DN AZD-8683 DMLXFM6 TI TTOXS3C DMLXFM6 TN Muscarinic acetylcholine receptor (CHRM) DMLXFM6 MA Antagonist DMLXFM6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17). DMLXFM6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17 DMLYIPA DI DMLYIPA DMLYIPA DN SGT-53 DMLYIPA TI TT7SBF5 DMLYIPA TN Cellular tumor antigen p53 (TP53) DMLYIPA MA Stimulator DMLYIPA RN Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr;20(4):222-8. DMLYIPA RU https://pubmed.ncbi.nlm.nih.gov/23470564 DMM02VJ DI DMM02VJ DMM02VJ DN JI-101 DMM02VJ TI TT0JESD DMM02VJ TN Erbb4 tyrosine kinase receptor (Erbb-4) DMM02VJ MA Modulator DMM02VJ RN A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.Invest New Drugs.2015 Dec;33(6):1217-24. DMM02VJ RU https://www.ncbi.nlm.nih.gov/pubmed/26365907 DMM0N1F DI DMM0N1F DMM0N1F DN AZD-0865 DMM0N1F TI TTLOKXP DMM0N1F TN Gastric H(+)/K(+) ATPase (Proton pump) DMM0N1F MA Modulator DMM0N1F RN Mechanism of action of AZD0865, a K+-competitive inhibitor of gastric H+,K+-ATPase. Biochem Pharmacol. 2007 Jan 15;73(2):198-205. DMM0N1F RU https://pubmed.ncbi.nlm.nih.gov/17081503 DMM15RI DI DMM15RI DMM15RI DN Ranpirnase DMM15RI TI TTRBUYN DMM15RI TN Ribonuclease (RNase) DMM15RI MA Modulator DMM15RI RN Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy.Expert Opin Biol Ther. 2008 Jun;8(6):813-27. DMM15RI RU https://pubmed.ncbi.nlm.nih.gov/18476793 DMM3AI8 DI DMM3AI8 DMM3AI8 DN SLx-4090 DMM3AI8 TI TTUS1RD DMM3AI8 TN Microsomal triglyceride transfer protein (MTTP) DMM3AI8 MA Modulator DMM3AI8 RN A small-molecule inhibitor of enterocytic microsomal triglyceride transfer protein, SLx-4090: biochemical, pharmacodynamic, pharmacokinetic, and safety profile. J Pharmacol Exp Ther. 2011 Jun;337(3):775-85. DMM3AI8 RU https://pubmed.ncbi.nlm.nih.gov/21406547 DMM3BPL DI DMM3BPL DMM3BPL DN DAS-431 DMM3BPL TI TTZFYLI DMM3BPL TN Dopamine D1 receptor (D1R) DMM3BPL MA Agonist DMM3BPL RN Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16. DMM3BPL RU https://pubmed.ncbi.nlm.nih.gov/11607045 DMM4EJI DI DMM4EJI DMM4EJI DN Resten-NG DMM4EJI TI TTNQ5ZP DMM4EJI TN Myc messenger RNA (MYC mRNA) DMM4EJI RN Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. DMM4EJI RU https://pubmed.ncbi.nlm.nih.gov/11590694 DMM549D DI DMM549D DMM549D DN IMO-3100 DMM549D TI TTSHG0T DMM549D TN Toll-like receptor 9 (TLR9) DMM549D MA Modulator DMM549D RN Company report (Iderapharma) DMM549D RU http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887 DMM549D DI DMM549D DMM549D DN IMO-3100 DMM549D TI TTRJ1K4 DMM549D TN Toll-like receptor 7 (TLR7) DMM549D MA Modulator DMM549D RN Company report (Iderapharma) DMM549D RU http://ir.iderapharma.com/phoenix.zhtml?c=208904&p=irol-newsArticle&ID=1816887 DMM5BVG DI DMM5BVG DMM5BVG DN TBR-760 DMM5BVG TI TTZ6T9E DMM5BVG TN Somatostatin receptor type 2 (SSTR2) DMM5BVG MA Agonist DMM5BVG RN TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101. DMM5BVG RU https://pubmed.ncbi.nlm.nih.gov/32591776 DMM5BVG DI DMM5BVG DMM5BVG DN TBR-760 DMM5BVG TI TTEX248 DMM5BVG TN Dopamine D2 receptor (D2R) DMM5BVG MA Agonist DMM5BVG RN TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101. DMM5BVG RU https://pubmed.ncbi.nlm.nih.gov/32591776 DMM5JAN DI DMM5JAN DMM5JAN DN LY2495655 DMM5JAN TI TTSWPH8 DMM5JAN TN Growth/differentiation factor 8 (GDF-8) DMM5JAN MA Modulator DMM5JAN RN Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. DMM5JAN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/ DMM5SCF DI DMM5SCF DMM5SCF DN ONC201 DMM5SCF TI TT4C8EA DMM5SCF TN Dopamine D3 receptor (D3R) DMM5SCF MA Antagonist DMM5SCF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM5SCF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMM5SCF DI DMM5SCF DMM5SCF DN ONC201 DMM5SCF TI TTWFZ1N DMM5SCF TN Dopamine receptor (DR) DMM5SCF MA Antagonist DMM5SCF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM5SCF RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMM5SCF DI DMM5SCF DMM5SCF DN ONC201 DMM5SCF TI TTEX248 DMM5SCF TN Dopamine D2 receptor (D2R) DMM5SCF MA Antagonist DMM5SCF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM5SCF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMM65W1 DI DMM65W1 DMM65W1 DN CX-717 DMM65W1 TI TTAN6JD DMM65W1 TN Glutamate receptor AMPA (GRIA) DMM65W1 MA Modulator DMM65W1 RN Acute sleep deprivation: the effects of the AMPAKINE compound CX717 on human cognitive performance, alertness and recovery sleep. J Psychopharmacol. 2012 Aug;26(8):1047-57. DMM65W1 RU https://pubmed.ncbi.nlm.nih.gov/21940760 DMM6B2Y DI DMM6B2Y DMM6B2Y DN ADU- S100 DMM6B2Y TI TTT402Y DMM6B2Y TN Stimulator of interferon genes protein (TMEM173) DMM6B2Y MA Agonist DMM6B2Y RN Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. DMM6B2Y RU https://pubmed.ncbi.nlm.nih.gov/30540940 DMM6J5Z DI DMM6J5Z DMM6J5Z DN PQ-912 DMM6J5Z TI TTJ7YTV DMM6J5Z TN Glutaminyl cyclase (QPCT) DMM6J5Z MA Inhibitor DMM6J5Z RN Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer s Disease ImmunotherapyRoxanna Perez-Garmendia, Goar Gevorkian. Curr Neuropharmacol. 2013 September; 11(5): 491-498. DMM6J5Z RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763757/ DMM6KZR DI DMM6KZR DMM6KZR DN Mutant ras vaccine DMM6KZR TI TTW2R9X DMM6KZR TN GTPase NRas (NRAS) DMM6KZR RN The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014 Feb 24;12:55. DMM6KZR RU https://pubmed.ncbi.nlm.nih.gov/24565030 DMM7F1E DI DMM7F1E DMM7F1E DN PRUVANSERIN DMM7F1E TI TTJQOD7 DMM7F1E TN 5-HT 2A receptor (HTR2A) DMM7F1E MA Modulator DMM7F1E RN 5-HT(2A) inverse-agonists for the treatment of insomnia. Curr Top Med Chem. 2008;8(11):969-76. DMM7F1E RU https://www.ncbi.nlm.nih.gov/pubmed/18673166 DMM7Q68 DI DMM7Q68 DMM7Q68 DN BAY-2253651 DMM7Q68 TI TTGR91N DMM7Q68 TN TWIK-related acid-sensitive potassium channel 1 (TASK1) DMM7Q68 MA Inhibitor DMM7Q68 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMM7Q68 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMM7Z6K DI DMM7Z6K DMM7Z6K DN CXA10 DMM7Z6K TI TT3Z6Y9 DMM7Z6K TN Cysteines of Keap1 (KEAP1 Cysteines) DMM7Z6K MA Inactivator DMM7Z6K RN The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56. DMM7Z6K RU https://pubmed.ncbi.nlm.nih.gov/28510041 DMM7Z6K DI DMM7Z6K DMM7Z6K DN CXA10 DMM7Z6K TI TTA6ZN2 DMM7Z6K TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMM7Z6K MA Activator DMM7Z6K RN The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56. DMM7Z6K RU https://pubmed.ncbi.nlm.nih.gov/28510041 DMM8IAQ DI DMM8IAQ DMM8IAQ DN PNU-142731A DMM8IAQ TI TT26HJ8 DMM8IAQ TN Eosinophil/lymphocyte-rich accumulation (ELR accum) DMM8IAQ MA Modulator DMM8IAQ RN Preclinical evaluation of anti-inflammatory activities of the novel pyrrolopyrimidine PNU-142731A, a potential treatment for asthma. J Pharmacol Exp Ther. 1999 Jul;290(1):188-95. DMM8IAQ RU https://pubmed.ncbi.nlm.nih.gov/10381775 DMM8Z3Q DI DMM8Z3Q DMM8Z3Q DN Encequidar DMM8Z3Q TI TTJUXV6 DMM8Z3Q TN Multidrug resistance protein 3 (ABCB4) DMM8Z3Q MA Inhibitor DMM8Z3Q RN Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. J Med Chem. 2021 Apr 8;64(7):3677-3693. DMM8Z3Q RU https://pubmed.ncbi.nlm.nih.gov/33729781 DMM9F25 DI DMM9F25 DMM9F25 DN LDE225 DMM9F25 TI TT8J1S3 DMM9F25 TN Smoothened homolog (SMO) DMM9F25 MA Modulator DMM9F25 RN Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer. 2014 Sep 9;111(6):1168-79. DMM9F25 RU https://pubmed.ncbi.nlm.nih.gov/25093491 DMMAIY2 DI DMMAIY2 DMMAIY2 DN GSK-256073 DMMAIY2 TI TTWNV8U DMMAIY2 TN Nicotinic acid receptor (HCAR2) DMMAIY2 MA Agonist DMMAIY2 RN GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21. DMMAIY2 RU https://pubmed.ncbi.nlm.nih.gov/23701262 DMMBAIH DI DMMBAIH DMMBAIH DN NXN-188 DMMBAIH TI TTK8CXU DMMBAIH TN 5-HT 1B receptor (HTR1B) DMMBAIH MA Modulator DMMBAIH RN Company report (NeurAxon) DMMBAIH RU http://www.neuraxon.com/103110.html DMMBAIH DI DMMBAIH DMMBAIH DN NXN-188 DMMBAIH TI TT6MSOK DMMBAIH TN 5-HT 1D receptor (HTR1D) DMMBAIH MA Modulator DMMBAIH RN Company report (NeurAxon) DMMBAIH RU http://www.neuraxon.com/103110.html DMMBAIH DI DMMBAIH DMMBAIH DN NXN-188 DMMBAIH TI TTZUFI5 DMMBAIH TN Nitric-oxide synthase brain (NOS1) DMMBAIH MA Inhibitor DMMBAIH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMBAIH RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMMBVCJ DI DMMBVCJ DMMBVCJ DN ASCJ-9 DMMBVCJ TI TTS64P2 DMMBVCJ TN Androgen receptor (AR) DMMBVCJ MA Enhancer DMMBVCJ RN Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis. 2013 Aug 8;4:e764. DMMBVCJ RU https://pubmed.ncbi.nlm.nih.gov/23928703 DMMC3XR DI DMMC3XR DMMC3XR DN DPV-001 DMMC3XR TI TTOK0LR DMMC3XR TN Toll-like receptor (TLR) DMMC3XR MA Modulator DMMC3XR RN UbiVac's DRibble, autophagosome-enriched vaccines: Applications for cancer and infectious disease. UbiVac. 2013. DMMC3XR RU http://ubivac.com/zap/?page_id=2668 DMMCA9V DI DMMCA9V DMMCA9V DN SAR-113945 DMMCA9V TI TTJ3E9X DMMCA9V TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMMCA9V MA Inhibitor DMMCA9V RN The NF B pathway: a therapeutic target in glioblastoma. Oncotarget. 2011 August; 2(8): 646-653. DMMCA9V RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248209/ DMMCL9F DI DMMCL9F DMMCL9F DN AZD1981 DMMCL9F TI TTQDMX5 DMMCL9F TN Prostaglandin D2 receptor 2 (PTGDR2) DMMCL9F MA Antagonist DMMCL9F RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMMCL9F RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMMCYZ8 DI DMMCYZ8 DMMCYZ8 DN PQR309 DMMCYZ8 TI TTCJG29 DMMCYZ8 TN Serine/threonine-protein kinase mTOR (mTOR) DMMCYZ8 MA Inhibitor DMMCYZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMMCYZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMMCYZ8 DI DMMCYZ8 DMMCYZ8 DN PQR309 DMMCYZ8 TI TTHBTOP DMMCYZ8 TN PI3-kinase gamma (PIK3CG) DMMCYZ8 MA Inhibitor DMMCYZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMMCYZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMMCYZ8 DI DMMCYZ8 DMMCYZ8 DN PQR309 DMMCYZ8 TI TTTHBCA DMMCYZ8 TN PI3-kinase beta (PIK3CB) DMMCYZ8 MA Inhibitor DMMCYZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2154). DMMCYZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2154 DMMEAGO DI DMMEAGO DMMEAGO DN BMS-955176 DMMEAGO TI TT5TOX7 DMMEAGO TN Human immunodeficiency virus Maturation (HIV Mat) DMMEAGO MA Inhibitor DMMEAGO RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMMEAGO RU http://news.bms.com/press-release/study-next-generation-investigational-hiv-1-maturation-inhibitor-shows-positive-result DMMEL6B DI DMMEL6B DMMEL6B DN PRO22 DMMEL6B TI TTSXVID DMMEL6B TN Nuclear factor NF-kappa-B (NFKB) DMMEL6B MA Inhibitor DMMEL6B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMEL6B RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMFLXN DI DMMFLXN DMMFLXN DN AD-452 DMMFLXN TI TTXM6JN DMMFLXN TN Cytokine receptor unspecific (CRF) DMMFLXN MA Modulator DMMFLXN RN Detection of apoptosis by RT-PCR array in mefloquine-induced cochlear damage. Journal of Otology Volume 6, Issue 1, June 2011, Pages 1-9. DMMFLXN RU http://www.sciencedirect.com/science/article/pii/S1672293011500017 DMMG61B DI DMMG61B DMMG61B DN ACT-GRO-777 DMMG61B TI TTCSZH7 DMMG61B TN Nucleolin (NCL) DMMG61B RN Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma. J Cancer Ther. 2013 June 1; 4(4): 872-890. DMMG61B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104705/ DMMGAUK DI DMMGAUK DMMGAUK DN AGN-XX/YY DMMGAUK TI TT2NUT5 DMMGAUK TN Adrenergic receptor alpha-2C (ADRA2C) DMMGAUK MA Agonist DMMGAUK RN Patent WO2008058220 A2. DMMGAUK RU http://www.google.com/patents/WO2008058220A2?cl=en DMMGSFV DI DMMGSFV DMMGSFV DN PF-06700841 DMMGSFV TI TT6DM01 DMMGSFV TN Janus kinase 1 (JAK-1) DMMGSFV MA Inhibitor DMMGSFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMGSFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMGSFV DI DMMGSFV DMMGSFV DN PF-06700841 DMMGSFV TI TTBYWP2 DMMGSFV TN TYK2 tyrosine kinase (TYK2) DMMGSFV MA Inhibitor DMMGSFV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMGSFV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TT8FYO9 DMMHX9K TN Platelet-derived growth factor receptor alpha (PDGFRA) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TTX41N9 DMMHX9K TN Tyrosine-protein kinase Kit (KIT) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TTVJ1D8 DMMHX9K TN Vascular endothelial growth factor receptor (VEGFR) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMHX9K DI DMMHX9K DMMHX9K DN XL-820 DMMHX9K TI TTI7421 DMMHX9K TN Platelet-derived growth factor receptor beta (PDGFRB) DMMHX9K MA Inhibitor DMMHX9K RN National Cancer Institute Drug Dictionary (drug id 452042). DMMHX9K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=452042 DMMI0RH DI DMMI0RH DMMI0RH DN LY-2599506 DMMI0RH TI TTDLNGZ DMMI0RH TN Glucokinase (GCK) DMMI0RH MA Inhibitor DMMI0RH RN This week in therapeutics Endocrine disease. SciBX 2(37); doi:10.1038/scibx.2009.1408. Sept. 24, 2009 DMMI0RH RU http://www.nature.com/scibx/journal/v2/n37/pdf/scibx.2009.1408.pdf DMMI84K DI DMMI84K DMMI84K DN Beta-lapachone DMMI84K TI TTGTQHC DMMI84K TN DNA topoisomerase I (TOP1) DMMI84K MA Modulator DMMI84K RN Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002 Sep;2(3):227-42. DMMI84K RU https://pubmed.ncbi.nlm.nih.gov/12188909 DMMIHSO DI DMMIHSO DMMIHSO DN ENERGI-F701 DMMIHSO TI TTLAFZV DMMIHSO TN AMP-activated protein kinase (AMPK) DMMIHSO MA Activator DMMIHSO RN Clinical pipeline report, company report or official report of Energenesis Biomedical. DMMIHSO RU https://www.energenesis-biomedical.com/_en/tech_detail.php?id=186 DMMIYZ7 DI DMMIYZ7 DMMIYZ7 DN Palifosfamide DMMIYZ7 TI TT6S2FE DMMIYZ7 TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMMIYZ7 MA Inhibitor DMMIYZ7 RN Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012 Feb;23(2):173-84. DMMIYZ7 RU https://pubmed.ncbi.nlm.nih.gov/22027537 DMMJUHD DI DMMJUHD DMMJUHD DN P-276 DMMJUHD TI TT0PG8F DMMJUHD TN Cyclin-dependent kinase 4 (CDK4) DMMJUHD MA Inhibitor DMMJUHD RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DMMJUHD RU https://pubmed.ncbi.nlm.nih.gov/21253554 DMMJUHD DI DMMJUHD DMMJUHD DN P-276 DMMJUHD TI TTH6V3D DMMJUHD TN Cyclin-dependent kinase 1 (CDK1) DMMJUHD MA Inhibitor DMMJUHD RN P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34. DMMJUHD RU https://pubmed.ncbi.nlm.nih.gov/17363487 DMMK6IT DI DMMK6IT DMMK6IT DN Testogen TDS DMMK6IT TI TTS64P2 DMMK6IT TN Androgen receptor (AR) DMMK6IT MA Modulator DMMK6IT RN Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26. DMMK6IT RU https://pubmed.ncbi.nlm.nih.gov/2912689 DMMKASG DI DMMKASG DMMKASG DN AGTC-0106 DMMKASG TI TTA7UJC DMMKASG TN Alpha-1-antitrypsin (SERPINA1) DMMKASG MA Modulator DMMKASG RN First gene therapy nears landmark European market authorization. Nat Biotechnol. 2012 Sep;30(9):807-9. DMMKASG RU https://pubmed.ncbi.nlm.nih.gov/22965030 DMMKCJ6 DI DMMKCJ6 DMMKCJ6 DN BC-7013 DMMKCJ6 TI TTUWYEA DMMKCJ6 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMMKCJ6 MA Modulator DMMKCJ6 RN Company report (briva) DMMKCJ6 RU http://www.nabriva.com/fileadmin/content/ICAAC_2009/F1-1521_In_vitro_antibacterial_spectrum_of_BC-7013.pdf DMMKOPX DI DMMKOPX DMMKOPX DN PM-00104 DMMKOPX TI TTUTN1I DMMKOPX TN Human Deoxyribonucleic acid (hDNA) DMMKOPX MA Modulator DMMKOPX RN Zalypsis has in vitro activity in acute myeloid blasts and leukemic progenitor cells through the induction of a DNA damage response. Haematologica. 2011 May;96(5):687-95. DMMKOPX RU https://pubmed.ncbi.nlm.nih.gov/21330323 DMMKW8L DI DMMKW8L DMMKW8L DN ASTX660 DMMKW8L TI TTK3WBU DMMKW8L TN XIAP messenger RNA (XIAP mRNA) DMMKW8L MA Inhibitor DMMKW8L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMKW8L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMML7BE DI DMML7BE DMML7BE DN Xl147 DMML7BE TI TTHBTOP DMML7BE TN PI3-kinase gamma (PIK3CG) DMML7BE MA Modulator DMML7BE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156). DMML7BE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156 DMMN21R DI DMMN21R DMMN21R DN Cenersen DMMN21R TI TT12KOD DMMN21R TN P53 messenger RNA (TP53 mRNA) DMMN21R RN Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27. DMMN21R RU https://pubmed.ncbi.nlm.nih.gov/21717444 DMMNTOW DI DMMNTOW DMMNTOW DN TTP435 DMMNTOW TI TT4DE1O DMMNTOW TN Agouti-related protein (AGRP) DMMNTOW MA Inhibitor DMMNTOW RN Clinical pipeline report, company report or official report of TransTech Pharma (2011). DMMNTOW RU http://www.ttpharma.com/ DMMNXIW DI DMMNXIW DMMNXIW DN TS-022 DMMNXIW TI TTNVEIR DMMNXIW TN Prostaglandin D2 receptor (PTGDR) DMMNXIW MA Agonist DMMNXIW RN Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis... Eur J Pharmacol. 2007 Feb 5;556(1-3):207-14. DMMNXIW RU https://pubmed.ncbi.nlm.nih.gov/17141215 DMMO46E DI DMMO46E DMMO46E DN Pidilizumab DMMO46E TI TT8ZLTI DMMO46E TN Programmed cell death 1 ligand 1 (PD-L1) DMMO46E RN PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun;34(5):409-18. DMMO46E RU https://pubmed.ncbi.nlm.nih.gov/21577144 DMMOHUA DI DMMOHUA DMMOHUA DN Contezolid acefosamil DMMOHUA TI TTLIZBJ DMMOHUA TN Protein synthesis (hPRO synth) DMMOHUA MA Inhibitor DMMOHUA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMOHUA RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMMOWT9 DI DMMOWT9 DMMOWT9 DN GSK3640254 DMMOWT9 TI TT5TOX7 DMMOWT9 TN Human immunodeficiency virus Maturation (HIV Mat) DMMOWT9 MA Inhibitor DMMOWT9 RN Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. Pharmacol Res Perspect. 2020 Dec;8(6):e00671. DMMOWT9 RU https://pubmed.ncbi.nlm.nih.gov/33200887 DMMPC6W DI DMMPC6W DMMPC6W DN CTL019 DMMPC6W TI TTW640A DMMPC6W TN B-lymphocyte surface antigen B4 (CD19) DMMPC6W MA CAR-T-Cell-Therapy DMMPC6W RN ClinicalTrials.gov (NCT02445248) Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients. U.S. National Institutes of Health. DMMPC6W RU https://clinicaltrials.gov/ct2/show/NCT02445248 DMMQ1YU DI DMMQ1YU DMMQ1YU DN FLUASTERONE DMMQ1YU TI TT3V81G DMMQ1YU TN Nuclear receptor unspecific (NR) DMMQ1YU MA Modulator DMMQ1YU RN Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem. 2002 Jun 14;277(24):21379-88. DMMQ1YU RU https://pubmed.ncbi.nlm.nih.gov/11934890 DMMQ6VT DI DMMQ6VT DMMQ6VT DN Leronlimab DMMQ6VT TI TTH91NV DMMQ6VT TN HUMAN C-C chemokine receptor 5 (CCR5) DMMQ6VT MA Inhibitor DMMQ6VT RN Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19 DMMQ6VT RU https://www.medrxiv.org/content/10.1101/2020.05.02.20084673v1.full.pdf DMMQFG2 DI DMMQFG2 DMMQFG2 DN Imeglimin DMMQFG2 TI TTLAFZV DMMQFG2 TN AMP-activated protein kinase (AMPK) DMMQFG2 MA Modulator DMMQFG2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542) DMMQFG2 RU http://adisinsight.springer.com/drugs/800032542 DMMQY0O DI DMMQY0O DMMQY0O DN GED-0507-34-Levo DMMQY0O TI TTZMAO3 DMMQY0O TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMMQY0O MA Agonist DMMQY0O RN PPAR-gamma in ulcerative colitis: a novel target for intervention. Curr Drug Targets. 2013 Nov;14(12):1501-7. DMMQY0O RU https://pubmed.ncbi.nlm.nih.gov/23651165 DMMQYF6 DI DMMQYF6 DMMQYF6 DN TRO-19622 DMMQYF6 TI TTAN6JD DMMQYF6 TN Glutamate receptor AMPA (GRIA) DMMQYF6 MA Antagonist DMMQYF6 RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMMQYF6 RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMMQZ3I DI DMMQZ3I DMMQZ3I DN HMR59 DMMQZ3I TI TTBGTEJ DMMQZ3I TN Membrane inhibitor of reactive lysis (CD59) DMMQZ3I MA Replacement DMMQZ3I RN Clinical pipeline report, company report or official report of Hemera Biosciences. DMMQZ3I RU https://www.hemerabiosciences.com/hmr59/ DMMRKPF DI DMMRKPF DMMRKPF DN CHS-131 DMMRKPF TI TTZMAO3 DMMRKPF TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMMRKPF MA Modulator DMMRKPF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMRKPF RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMMRYEK DI DMMRYEK DMMRYEK DN MPSK3169A DMMRYEK TI TTNIZ2B DMMRYEK TN PCSK9 messenger RNA (PCSK9 mRNA) DMMRYEK MA Modulator DMMRYEK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388). DMMRYEK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2388 DMMSBW5 DI DMMSBW5 DMMSBW5 DN LY-545694 DMMSBW5 TI TTDXZ24 DMMSBW5 TN Glutamate receptor ionotropic (GRI) DMMSBW5 MA Antagonist DMMSBW5 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019739) DMMSBW5 RU http://adisinsight.springer.com/drugs/800019739 DMMSGAT DI DMMSGAT DMMSGAT DN BI 207127 DMMSGAT TI TTMVBWH DMMSGAT TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMMSGAT MA Inhibitor DMMSGAT RN 2011 Pipeline of Boehringer Ingelheim Pharma. DMMSGAT RU http://www.boehringer-ingelheim.com/ DMMSIG7 DI DMMSIG7 DMMSIG7 DN DM-71 DMMSIG7 TI TTCBFJO DMMSIG7 TN Insulin receptor (INSR) DMMSIG7 MA Modulator DMMSIG7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMMSIG7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMMSTCF DI DMMSTCF DMMSTCF DN K-832 DMMSTCF TI TTSD92E DMMSTCF TN Interleukin-1 (IL1) DMMSTCF MA Inhibitor DMMSTCF RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMMSTCF RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMMU41F DI DMMU41F DMMU41F DN SRX-246 DMMU41F TI TT4TFGN DMMU41F TN Vasopressin V1a receptor (V1AR) DMMU41F MA Antagonist DMMU41F RN Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-43. DMMU41F RU https://pubmed.ncbi.nlm.nih.gov/23471831 DMMUPTN DI DMMUPTN DMMUPTN DN ADL-5747 DMMUPTN TI TT27RFC DMMUPTN TN Opioid receptor delta (OPRD1) DMMUPTN MA Agonist DMMUPTN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMMUPTN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMMUR6V DI DMMUR6V DMMUR6V DN NS-2710 DMMUR6V TI TT37EDJ DMMUR6V TN GABA(A) receptor alpha-3 (GABRA3) DMMUR6V MA Modulator DMMUR6V RN GABAA receptor subtype-selective modulators. I. alpha2/alpha3-selective agonists as non-sedating anxiolytics. Curr Top Med Chem. 2011;11(9):1176-202. DMMUR6V RU https://pubmed.ncbi.nlm.nih.gov/21050172 DMMVFRC DI DMMVFRC DMMVFRC DN Mavrilimumab DMMVFRC TI TT6MP2Z DMMVFRC TN GMCSFR-alpha (CSF2RA) DMMVFRC RN Clinical pipeline report, company report or official report of MedImmune (2011). DMMVFRC RU http://www.medimmune.com/research_pipeline.aspx DMMVFRC DI DMMVFRC DMMVFRC DN Mavrilimumab DMMVFRC TI TTNYZG2 DMMVFRC TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMMVFRC MA Antagonist DMMVFRC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMVFRC RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMMWCZS DI DMMWCZS DMMWCZS DN SCH 420814 DMMWCZS TI TTM2AOE DMMWCZS TN Adenosine A2a receptor (ADORA2A) DMMWCZS MA Antagonist DMMWCZS RN Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. DMMWCZS RU https://pubmed.ncbi.nlm.nih.gov/17016425 DMMWIHC DI DMMWIHC DMMWIHC DN CYT 99007 DMMWIHC TI TTAWI51 DMMWIHC TN Interleukin 7 receptor alpha (IL7R) DMMWIHC MA Binder DMMWIHC RN Perspectives on interleukin-7 therapy in HIV infection. Curr Opin HIV AIDS. 2007 May;2(3):228-33. DMMWIHC RU https://pubmed.ncbi.nlm.nih.gov/19372891 DMMWPSQ DI DMMWPSQ DMMWPSQ DN TA-2005 DMMWPSQ TI TT2CJVK DMMWPSQ TN Adrenergic receptor beta-2 (ADRB2) DMMWPSQ MA Agonist DMMWPSQ RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMMWPSQ RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMMX1EJ DI DMMX1EJ DMMX1EJ DN AS-1402 DMMX1EJ TI TTBHFYQ DMMX1EJ TN Mucin-1 (MUC1) DMMX1EJ RN Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73. DMMX1EJ RU https://pubmed.ncbi.nlm.nih.gov/19811637 DMMYTRU DI DMMYTRU DMMYTRU DN RQ-00000007 (oral) DMMYTRU TI TT79WV3 DMMYTRU TN Prostaglandin E2 receptor EP4 (PTGER4) DMMYTRU MA Antagonist DMMYTRU RN Clinical pipeline report, company report or official report of Avarx. DMMYTRU RU http://www.avarx.com/AvaRx/SubDomains/bucket5733245651167129819/Listings/bucket2137138075456035728/Public.Listing.display.html DMMZOYN DI DMMZOYN DMMZOYN DN ABT-348 DMMZOYN TI TTLYXIT DMMZOYN TN Aurora kinase C (AURKC) DMMZOYN MA Modulator DMMZOYN RN Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. DMMZOYN RU https://pubmed.ncbi.nlm.nih.gov/22935731 DMMZOYN DI DMMZOYN DMMZOYN DN ABT-348 DMMZOYN TI TTPS3C0 DMMZOYN TN Aurora kinase A (AURKA) DMMZOYN MA Modulator DMMZOYN RN Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. DMMZOYN RU https://pubmed.ncbi.nlm.nih.gov/22935731 DMMZOYN DI DMMZOYN DMMZOYN DN ABT-348 DMMZOYN TI TT5LS6T DMMZOYN TN Aurora kinase B (AURKB) DMMZOYN MA Modulator DMMZOYN RN Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27. DMMZOYN RU https://pubmed.ncbi.nlm.nih.gov/22935731 DMMZQ7V DI DMMZQ7V DMMZQ7V DN Granotapide DMMZQ7V TI TTUS1RD DMMZQ7V TN Microsomal triglyceride transfer protein (MTTP) DMMZQ7V MA Inhibitor DMMZQ7V RN JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses food intake and gastric emptying with the elevation of plasma peptide YY and glucagon-like peptide-1 in a dietary fat-dependent manner. J Pharmacol Exp Ther. 2011 Mar;336(3):850-6. DMMZQ7V RU https://pubmed.ncbi.nlm.nih.gov/21139060 DMN0VS2 DI DMN0VS2 DMN0VS2 DN Lopinavir + ritonavir + ribavirin + interferon beta-1b DMN0VS2 TI TT1D53B DMN0VS2 TN COVID-19 3C-like protease (3CLpro) DMN0VS2 MA Inhibitor DMN0VS2 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMN0VS2 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMN0VS2 DI DMN0VS2 DMN0VS2 DN Lopinavir + ritonavir + ribavirin + interferon beta-1b DMN0VS2 TI TTV1095 DMN0VS2 TN COVID-19 RNA-directed RNA polymerase (RdRp) DMN0VS2 MA Inhibitor DMN0VS2 RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DMN0VS2 RU https://pubmed.ncbi.nlm.nih.gov/32127666 DMN1EFR DI DMN1EFR DMN1EFR DN RhGDF-5 DMN1EFR TI TT37XV9 DMN1EFR TN Growth/differentiation factor 5 (GDF-5) DMN1EFR MA Modulator DMN1EFR RN Superior effect of MD05, beta-tricalcium phosphate coated with recombinant human growth/differentiation factor-5, compared to conventional bone substitutes in the rat calvarial defect model. J Periodontol. 2006 Sep;77(9):1582-90. DMN1EFR RU https://pubmed.ncbi.nlm.nih.gov/16945037 DMN1SWB DI DMN1SWB DMN1SWB DN EGS-21 DMN1SWB TI TTCBFJO DMN1SWB TN Insulin receptor (INSR) DMN1SWB MA Modulator DMN1SWB RN Ceramides and glucosylceramides are independent antagonists of insulin signaling. J Biol Chem. 2014 Jan 10;289(2):723-34. DMN1SWB RU https://pubmed.ncbi.nlm.nih.gov/24214972 DMN28WK DI DMN28WK DMN28WK DN BMS-919373 DMN28WK TI TTW0CMT DMN28WK TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMN28WK MA Inhibitor DMN28WK RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504) DMN28WK RU http://adisinsight.springer.com/drugs/800035504 DMN3S1B DI DMN3S1B DMN3S1B DN ABT-229 DMN3S1B TI TTQ6VDM DMN3S1B TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMN3S1B MA Inhibitor DMN3S1B RN 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8. DMN3S1B RU https://pubmed.ncbi.nlm.nih.gov/20869254 DMN45IC DI DMN45IC DMN45IC DN AFM13 DMN45IC TI TTIFOC0 DMN45IC TN Immunoglobulin gamma Fc receptor IIIA (FCGR3A) DMN45IC RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMN45IC RU https://www.affimed.com/rock-platform/pipeline/ DMN45IC DI DMN45IC DMN45IC DN AFM13 DMN45IC TI TT2GM5R DMN45IC TN Lymphocyte activation antigen CD30 (TNFRSF8) DMN45IC RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMN45IC RU https://www.affimed.com/rock-platform/pipeline/ DMN45RI DI DMN45RI DMN45RI DN MIJ821 DMN45RI TI TTN9D8E DMN45RI TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMN45RI MA Modulator DMN45RI RN Clinical pipeline report, company report or official report of Cadent Therapeutics. DMN45RI RU https://www.cipherbio.com/data-viz/organization/Cadent%2BTherapeutics/products DMN5JCX DI DMN5JCX DMN5JCX DN Carboxyamidotriazole orotate DMN5JCX TI TTF89GD DMN5JCX TN Interleukin-2 (IL2) DMN5JCX MA Inhibitor DMN5JCX RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2071). DMN5JCX RU http://meetinglibrary.asco.org/content/132006-144 DMN68ZL DI DMN68ZL DMN68ZL DN Multi-epitope tyrosinase/gp100 vaccine DMN68ZL TI TT8MK59 DMN68ZL TN Melanocytes lineage-specific antigen GP100 (PMEL) DMN68ZL RN ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health. DMN68ZL RU https://clinicaltrials.gov/ct2/show/NCT00003362 DMN68ZL DI DMN68ZL DMN68ZL DN Multi-epitope tyrosinase/gp100 vaccine DMN68ZL TI TTULVH8 DMN68ZL TN Tyrosinase (TYR) DMN68ZL RN ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health. DMN68ZL RU https://clinicaltrials.gov/ct2/show/NCT00003362 DMN6IDO DI DMN6IDO DMN6IDO DN GTP-010 DMN6IDO TI TTVIMDE DMN6IDO TN Glucagon-like peptide 1 receptor (GLP1R) DMN6IDO MA Agonist DMN6IDO RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMN6IDO RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMN6J18 DI DMN6J18 DMN6J18 DN Vupanorsen DMN6J18 TI TT59GO7 DMN6J18 TN ANGPTL3 messenger RNA (ANGPTL3 mRNA) DMN6J18 MA Inhibitor DMN6J18 RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMN6J18 RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMN6TKI DI DMN6TKI DMN6TKI DN Carmoterol DMN6TKI TI TT2CJVK DMN6TKI TN Adrenergic receptor beta-2 (ADRB2) DMN6TKI MA Agonist DMN6TKI RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMN6TKI RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMN7EUO DI DMN7EUO DMN7EUO DN N6022 DMN7EUO TI TTVG0SN DMN7EUO TN S-nitrosoglutathione reductase (CBR1) DMN7EUO MA Inhibitor DMN7EUO RN Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase. Biochemistry. 2012 Mar 13;51(10):2157-68. DMN7EUO RU https://pubmed.ncbi.nlm.nih.gov/22335564 DMN7VK1 DI DMN7VK1 DMN7VK1 DN AV-101 DMN7VK1 TI TT9IK2Z DMN7VK1 TN N-methyl-D-aspartate receptor (NMDAR) DMN7VK1 MA Antagonist DMN7VK1 RN Clinical pipeline report, company report or official report of VistaGen Therapeutics, Inc. DMN7VK1 RU http://www.vistagen.com/?page_id=198 DMN94QM DI DMN94QM DMN94QM DN PF-06291874 DMN94QM TI TT9O6WS DMN94QM TN Glucagon receptor (GCGR) DMN94QM MA Antagonist DMN94QM RN Clinical pipeline report, company report or official report of pfizer. DMN94QM RU http://www.pfizer.com/sites/default/files/product-pipeline/110614_Pipeline_Update.pdf DMNABMU DI DMNABMU DMNABMU DN GS-4997 DMNABMU TI TTOQCD8 DMNABMU TN Apoptosis signal-regulating kinase 1 (MAP3K5) DMNABMU MA Inhibitor DMNABMU RN Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129(1):29-33. DMNABMU RU https://pubmed.ncbi.nlm.nih.gov/25531162 DMNAECP DI DMNAECP DMNAECP DN SR-147778 DMNAECP TI TT6OEDT DMNAECP TN Cannabinoid receptor 1 (CB1) DMNAECP MA Modulator DMNAECP RN Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77. DMNAECP RU https://www.ncbi.nlm.nih.gov/pubmed/23278647 DMNAU1V DI DMNAU1V DMNAU1V DN ABT-436 DMNAU1V TI TTL9MHW DMNAU1V TN Vasopressin V1b receptor (V1BR) DMNAU1V MA Modulator DMNAU1V RN The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115. DMNAU1V RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016603/ DMNB4P1 DI DMNB4P1 DMNB4P1 DN TAK-653 DMNB4P1 TI TTAN6JD DMNB4P1 TN Glutamate receptor AMPA (GRIA) DMNB4P1 MA Activator DMNB4P1 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNB4P1 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNB4XK DI DMNB4XK DMNB4XK DN BVD-523 DMNB4XK TI TT1MG9E DMNB4XK TN Extracellular signal-regulated kinase 1 (ERK1) DMNB4XK MA Modulator DMNB4XK RN DOI: 10.1158/1538-7445.AM2015-4693 DMNB4XK RU http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693 DMNB4XK DI DMNB4XK DMNB4XK DN BVD-523 DMNB4XK TI TT4TQBX DMNB4XK TN Extracellular signal-regulated kinase 2 (ERK2) DMNB4XK MA Modulator DMNB4XK RN DOI: 10.1158/1538-7445.AM2015-4693 DMNB4XK RU http://cancerres.aacrjournals.org/content/75/15_Supplement/4693?cited-by=yes&legid=canres;75/15_Supplement/4693 DMNB4XK DI DMNB4XK DMNB4XK DN BVD-523 DMNB4XK TI TTKPV6O DMNB4XK TN Ephrin type-B receptor 2 (EPHB2) DMNB4XK MA Inhibitor DMNB4XK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNB4XK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNC1AF DI DMNC1AF DMNC1AF DN CR-665 DMNC1AF TI TTQW87Y DMNC1AF TN Opioid receptor kappa (OPRK1) DMNC1AF MA Agonist DMNC1AF RN Analgesic efficacy of peripheral kappa-opioid receptor agonist CR665 compared to oxycodone in a multi-modal, multi-tissue experimental human pain model: selective effect on visceral pain. Anesthesiology. 2009 Sep;111(3):616-24. DMNC1AF RU https://pubmed.ncbi.nlm.nih.gov/19672186 DMNC76I DI DMNC76I DMNC76I DN COL-1077 DMNC76I TI TTRK8B9 DMNC76I TN Sodium channel unspecific (NaC) DMNC76I MA Antagonist DMNC76I RN Clinical pipeline report, company report or official report of Columbia Laboratories. DMNC76I RU http://companies.einnews.com/news/columbia-laboratories-news DMNE1FR DI DMNE1FR DMNE1FR DN Resminostat DMNE1FR TI TT6R7JZ DMNE1FR TN Histone deacetylase 1 (HDAC1) DMNE1FR MA Inhibitor DMNE1FR RN 2011 Pipeline of 4SC AG. DMNE1FR RU http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html DMNE7L3 DI DMNE7L3 DMNE7L3 DN CC-220 DMNE7L3 TI TTDKGTC DMNE7L3 TN Protein cereblon (CRBN) DMNE7L3 MA Inhibitor DMNE7L3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNE7L3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNEHY1 DI DMNEHY1 DMNEHY1 DN OI338GT DMNEHY1 TI TTVIMDE DMNEHY1 TN Glucagon-like peptide 1 receptor (GLP1R) DMNEHY1 MA Modulator DMNEHY1 RN Clinical pipeline report, company report or official report of Novo Nordisk A/S. DMNEHY1 RU http://www.novonordisk.com/bin/getPDF.1781915.pdf DMNF38S DI DMNF38S DMNF38S DN 16,16-dimethyl-PGE2 DMNF38S TI TTPNGDE DMNF38S TN Prostaglandin E2 receptor EP3 (PTGER3) DMNF38S MA Agonist DMNF38S RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMNF38S RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMNF38S DI DMNF38S DMNF38S DN 16,16-dimethyl-PGE2 DMNF38S TI TT1ZAVI DMNF38S TN Prostaglandin E2 receptor EP2 (PTGER2) DMNF38S MA Agonist DMNF38S RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMNF38S RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMNF38S DI DMNF38S DMNF38S DN 16,16-dimethyl-PGE2 DMNF38S TI TT79WV3 DMNF38S TN Prostaglandin E2 receptor EP4 (PTGER4) DMNF38S MA Agonist DMNF38S RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMNF38S RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMNFADH DI DMNFADH DMNFADH DN APR-246 DMNFADH TI TT7SBF5 DMNFADH TN Cellular tumor antigen p53 (TP53) DMNFADH MA Stimulator DMNFADH RN APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. DMNFADH RU https://pubmed.ncbi.nlm.nih.gov/24157875 DMNFKVW DI DMNFKVW DMNFKVW DN BR-4628 DMNFKVW TI TT26PHO DMNFKVW TN Mineralocorticoid receptor (MR) DMNFKVW MA Antagonist DMNFKVW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626). DMNFKVW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626 DMNFP21 DI DMNFP21 DMNFP21 DN TC-6987 DMNFP21 TI TTLA931 DMNFP21 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMNFP21 MA Modulator DMNFP21 RN ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health. DMNFP21 RU https://clinicaltrials.gov/ct2/show/NCT01293669 DMNFVKC DI DMNFVKC DMNFVKC DN Vapitadine DMNFVKC TI TTTIBOJ DMNFVKC TN Histamine H1 receptor (H1R) DMNFVKC MA Antagonist DMNFVKC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020866) DMNFVKC RU http://adisinsight.springer.com/drugs/800020866 DMNFZYE DI DMNFZYE DMNFZYE DN WT1-targeted autologous dendritic cell vaccine DMNFZYE TI TTZ8UT4 DMNFZYE TN Wilms tumor protein (WT1) DMNFZYE RN ClinicalTrials.gov (NCT01686334) Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission. U.S. National Institutes of Health. DMNFZYE RU https://clinicaltrials.gov/ct2/show/NCT01686334 DMNG35S DI DMNG35S DMNG35S DN ABT-751 DMNG35S TI TTYFKSZ DMNG35S TN Tubulin beta (TUBB) DMNG35S MA Modulator DMNG35S RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNG35S RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNGT89 DI DMNGT89 DMNGT89 DN Lirilumab DMNGT89 TI TTAZF9M DMNGT89 TN RAS-like protein KIR (GEM) DMNGT89 MA Modulator DMNGT89 RN Anti-tumoral efficacy of therapeutic human anti-KIR antibody (Lirilumab/BMS-986015/IPH2102) in a preclinical xenograft tumor model. J Immunother Cancer. 2013; 1(Suppl 1): P40. DMNGT89 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991278/ DMNJ491 DI DMNJ491 DMNJ491 DN IMGN529 DMNJ491 TI TTFCW29 DMNJ491 TN Leukocyte antigen CD37 (CD37) DMNJ491 RN The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia. 2014 Jul;28(7):1501-10. DMNJ491 RU https://pubmed.ncbi.nlm.nih.gov/24445867 DMNKAFQ DI DMNKAFQ DMNKAFQ DN Instiladrin DMNKAFQ TI TTSIUJ9 DMNKAFQ TN Interferon-alpha 2 (IFNA2) DMNKAFQ MA Modulator DMNKAFQ RN ClinicalTrials.gov (NCT01687244) Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. U.S. National Institutes of Health. DMNKAFQ RU https://clinicaltrials.gov/ct2/show/NCT01687244 DMNL9HO DI DMNL9HO DMNL9HO DN Tabimorelin DMNL9HO TI TTWDC17 DMNL9HO TN Growth hormone secretagogue receptor 1 (GHSR) DMNL9HO MA Modulator DMNL9HO RN Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur J Endocrinol. 1999 Aug;141(2):180-9. DMNL9HO RU https://pubmed.ncbi.nlm.nih.gov/10427162 DMNLH9W DI DMNLH9W DMNLH9W DN KN026 DMNLH9W TI TT6EO5L DMNLH9W TN Erbb2 tyrosine kinase receptor (HER2) DMNLH9W MA Inhibitor DMNLH9W RN Clinical pipeline report, company report or official report of Alphamab Oncology. DMNLH9W RU http://www.alphamabonc.com/pipeline/kn026.html DMNLQHK DI DMNLQHK DMNLQHK DN Tanespimycin DMNLQHK TI TT78R5H DMNLQHK TN Heat shock protein 90 alpha (HSP90A) DMNLQHK MA Inhibitor DMNLQHK RN Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8. DMNLQHK RU https://pubmed.ncbi.nlm.nih.gov/19466875 DMNM4CK DI DMNM4CK DMNM4CK DN PF-00734200 DMNM4CK TI TTDIGC1 DMNM4CK TN Dipeptidyl peptidase 4 (DPP-4) DMNM4CK MA Modulator DMNM4CK RN Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.Diabet Med.2011 Apr;28(4):464-9. DMNM4CK RU https://www.ncbi.nlm.nih.gov/pubmed/21392067 DMNM9DZ DI DMNM9DZ DMNM9DZ DN Nepicastat oral DMNM9DZ TI TTYIP79 DMNM9DZ TN Dopamine beta hydroxylase (DBH) DMNM9DZ MA Inhibitor DMNM9DZ RN Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol. 1997 Aug;121(8):1803-9. DMNM9DZ RU https://pubmed.ncbi.nlm.nih.gov/9283721 DMNO5UE DI DMNO5UE DMNO5UE DN Labetuzumab I-131 DMNO5UE TI TTY6DTE DMNO5UE TN Carcinoembryonic antigen CEA (CD66e) DMNO5UE RN National Cancer Institute Drug Dictionary (drug id 692828). DMNO5UE RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=692828 DMNO7BC DI DMNO7BC DMNO7BC DN AeroLEF DMNO7BC TI TTN4QDT DMNO7BC TN Opioid receptor (OPR) DMNO7BC MA Agonist DMNO7BC RN Current Research on Opioid Receptor Function. Curr Drug Targets. 2012 February; 13(2): 230-246. DMNO7BC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371376/ DMNOMV2 DI DMNOMV2 DMNOMV2 DN HP-184 DMNOMV2 TI TTQ6VDM DMNOMV2 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMNOMV2 MA Blocker DMNOMV2 RN Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80. DMNOMV2 RU https://pubmed.ncbi.nlm.nih.gov/18321149 DMNOMV2 DI DMNOMV2 DMNOMV2 DN HP-184 DMNOMV2 TI TTN9VTF DMNOMV2 TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMNOMV2 MA Blocker DMNOMV2 RN Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80. DMNOMV2 RU https://pubmed.ncbi.nlm.nih.gov/18321149 DMNPRMC DI DMNPRMC DMNPRMC DN SPI-1620 DMNPRMC TI TT3ZTGU DMNPRMC TN Endothelin B receptor (EDNRB) DMNPRMC MA Agonist DMNPRMC RN Clinical pipeline report, company report or official report of Spectrum Phamaceuticals (2009). DMNPRMC RU http://www.spectrumpharm.com/products_Spectrum.html DMNQ5T2 DI DMNQ5T2 DMNQ5T2 DN AG-858 DMNQ5T2 TI TTHYBIX DMNQ5T2 TN Heat shock protein 70 (HSP70) DMNQ5T2 RN Preparation of a Heat Shock Proteins 70-based Vaccine from DC-tumor fusion cells. Methods Mol Biol. 2011; 787: 255-265. DMNQ5T2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088345/ DMNQ7DV DI DMNQ7DV DMNQ7DV DN APD-209 DMNQ7DV TI TT2CJVK DMNQ7DV TN Adrenergic receptor beta-2 (ADRB2) DMNQ7DV MA Agonist DMNQ7DV RN Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Retraction in: Drug Des Devel Ther. 2013; 7: 1385. DMNQ7DV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746778/ DMNQG24 DI DMNQG24 DMNQG24 DN Volociximab DMNQG24 TI TTH4QIS DMNQG24 TN Integrin alpha-5/beta-1 (ITGA5/B1) DMNQG24 RN Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J Exp Ther Oncol. 2006;5(4):273-86. DMNQG24 RU https://pubmed.ncbi.nlm.nih.gov/17024968 DMNRHMX DI DMNRHMX DMNRHMX DN SKF-110679 DMNRHMX TI TTKMAZ6 DMNRHMX TN Growth hormone receptor (GHR) DMNRHMX MA Modulator DMNRHMX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1093). DMNRHMX RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1093 DMNRYPF DI DMNRYPF DMNRYPF DN Cixutumumab DMNRYPF TI TTHRID2 DMNRYPF TN Insulin-like growth factor I receptor (IGF1R) DMNRYPF MA Modulator DMNRYPF RN Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015 Jul;26(7):1459-64. DMNRYPF RU https://pubmed.ncbi.nlm.nih.gov/25858498 DMNSRY7 DI DMNSRY7 DMNSRY7 DN PXL-770 DMNSRY7 TI TTLAFZV DMNSRY7 TN AMP-activated protein kinase (AMPK) DMNSRY7 MA Activator DMNSRY7 RN Clinical pipeline report, company report or official report of Poxel SA. DMNSRY7 RU https://www.poxelpharma.com/en_us/product-pipeline/pxl770 DMNST69 DI DMNST69 DMNST69 DN Metaiodobenzylguanidine I-131 DMNST69 TI TTAWNKZ DMNST69 TN Norepinephrine transporter (NET) DMNST69 MA Modulator DMNST69 RN Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91. DMNST69 RU https://pubmed.ncbi.nlm.nih.gov/24573553 DMNSYXB DI DMNSYXB DMNSYXB DN Filibuvir DMNSYXB TI TTMVBWH DMNSYXB TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMNSYXB MA Inhibitor DMNSYXB RN Clinical pipeline report, company report or official report of Pfizer (2011). DMNSYXB RU http://www.pfizer.com/home/ DMNTC7O DI DMNTC7O DMNTC7O DN RO-4995819 DMNTC7O TI TT8A9EF DMNTC7O TN Metabotropic glutamate receptor 3 (mGluR3) DMNTC7O MA Modulator DMNTC7O RN Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112. DMNTC7O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/ DMNTC7O DI DMNTC7O DMNTC7O DN RO-4995819 DMNTC7O TI TTXJ47W DMNTC7O TN Metabotropic glutamate receptor 2 (mGluR2) DMNTC7O MA Modulator DMNTC7O RN Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat. 2013; 9: 1101-1112. DMNTC7O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747027/ DMNU48O DI DMNU48O DMNU48O DN Peptide YY 3-36 DMNU48O TI TTVFJLX DMNU48O TN Peptide tyrosine tyrosine PYY (PYY) DMNU48O MA Modulator DMNU48O RN Clinical pipeline report, company report or official report of Emisphere. DMNU48O RU http://ir.emisphere.com/releasedetail.cfm?releaseid=356364 DMNUXKA DI DMNUXKA DMNUXKA DN INCAGN01876 DMNUXKA TI TTG6LA7 DMNUXKA TN Activation-inducible TNFR family receptor (TNFRSF18) DMNUXKA MA Agonist DMNUXKA RN Clinical pipeline report, company report or official report of Agenus. DMNUXKA RU https://agenusbio.com/pipeline/ DMNVFZA DI DMNVFZA DMNVFZA DN AC-1202 DMNVFZA TI TTNHYJL DMNVFZA TN Ketogenesis (KG) DMNVFZA MA Modulator DMNVFZA RN Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond). 2009 Aug 10;6:31. DMNVFZA RU https://pubmed.ncbi.nlm.nih.gov/19664276 DMNVU28 DI DMNVU28 DMNVU28 DN ASB17061 DMNVU28 TI TT8VUE0 DMNVU28 TN Chymase (CYM) DMNVU28 MA Modulator DMNVU28 RN Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82. DMNVU28 RU https://pubmed.ncbi.nlm.nih.gov/23889510 DMNVZDT DI DMNVZDT DMNVZDT DN ISIS-FGFR4 DMNVZDT TI TT1KX2S DMNVZDT TN FGFR4 messenger RNA (FGFR4 mRNA) DMNVZDT RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMNVZDT RU http://www.isispharm.com/index.htm DMNW0DG DI DMNW0DG DMNW0DG DN Iodine-131-tositumomab DMNW0DG TI TTUE541 DMNW0DG TN Leukocyte surface antigen Leu-16 (CD20) DMNW0DG RN Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008 Aug 1;112(3):830-5. DMNW0DG RU https://pubmed.ncbi.nlm.nih.gov/18502830 DMNW5I9 DI DMNW5I9 DMNW5I9 DN CERE-110 DMNW5I9 TI TTDN3LF DMNW5I9 TN Nerve growth factor (NGF) DMNW5I9 MA Modulator DMNW5I9 RN CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease. Curr Opin Mol Ther. 2010 Apr;12(2):240-7. DMNW5I9 RU https://pubmed.ncbi.nlm.nih.gov/20373268 DMNWYHD DI DMNWYHD DMNWYHD DN RDEA-684 DMNWYHD TI TTA592U DMNWYHD TN Urate anion exchanger 1 (URAT1) DMNWYHD MA Inhibitor DMNWYHD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031). DMNWYHD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1031 DMNXJ5B DI DMNXJ5B DMNXJ5B DN TGFK08AA DMNXJ5B TI TTSQIFT DMNXJ5B TN 5-HT 1A receptor (HTR1A) DMNXJ5B MA Modulator DMNXJ5B RN 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov. 2013 Sep;12(9):667-87. DMNXJ5B RU https://pubmed.ncbi.nlm.nih.gov/23989795 DMNY3J0 DI DMNY3J0 DMNY3J0 DN VTB-38543 DMNY3J0 TI TTXA6PH DMNY3J0 TN Oxysterols receptor LXR-beta (NR1H2) DMNY3J0 MA Agonist DMNY3J0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNY3J0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMNZ35F DI DMNZ35F DMNZ35F DN HP-228 DMNZ35F TI TTF10I9 DMNZ35F TN Nitric-oxide synthase inducible (NOS2) DMNZ35F MA Modulator DMNZ35F RN HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91. DMNZ35F RU https://pubmed.ncbi.nlm.nih.gov/7473142 DMO02LU DI DMO02LU DMO02LU DN PF-3463275 DMO02LU TI TTHJTF7 DMO02LU TN Glycine transporter GlyT-1 (SLC6A9) DMO02LU MA Inhibitor DMO02LU RN Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85. DMO02LU RU https://pubmed.ncbi.nlm.nih.gov/24172334 DMO0C5R DI DMO0C5R DMO0C5R DN NU300 DMO0C5R TI TTC6JZQ DMO0C5R TN Haemophilus influenzae CRM197 (Hae-influ CRM197) DMO0C5R MA Modulator DMO0C5R RN ClinicalTrials.gov (NCT02140047) Exploratory Clinical Study of MT-2301. U.S. National Institutes of Health. DMO0C5R RU https://clinicaltrials.gov/ct2/show/NCT02140047 DMO0VGH DI DMO0VGH DMO0VGH DN Coenzyme Q10 analog DMO0VGH TI TT8XK6L DMO0VGH TN Quinone reductase 1 (NQO1) DMO0VGH MA Modulator DMO0VGH RN Therapeutic strategies for Leber's hereditary optic neuropathy: A current update. Intractable Rare Dis Res. 2013 November; 2(4): 130-135. DMO0VGH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204556/ DMO10JI DI DMO10JI DMO10JI DN HibTITER DMO10JI TI TTC6JZQ DMO10JI TN Haemophilus influenzae CRM197 (Hae-influ CRM197) DMO10JI RN Immunogenicity and safety of Haemophilus influenzae type b conjugate vaccine (HibTITER) and a combination vaccine of diphtheria, tetanus, pertussis and HibTITER (TETRAMUNE) in two-month-old infants. J Microbiol Immunol Infect. 1998 Sep;31(3):180-6. DMO10JI RU https://pubmed.ncbi.nlm.nih.gov/10496155 DMO1VHC DI DMO1VHC DMO1VHC DN ALX-0061 DMO1VHC TI TT0E5SK DMO1VHC TN Interleukin 6 receptor (IL6R) DMO1VHC RN The preclinical pharmacology of the high affinity anti-IL-6R Nanobody ALX-0061 supports its clinical development in rheumatoid arthritis. Arthritis Res Ther. 2015 May 20;17:135. DMO1VHC RU https://pubmed.ncbi.nlm.nih.gov/25994180 DMO1XUK DI DMO1XUK DMO1XUK DN Myeloma cancer vaccine DMO1XUK TI TT6MP2Z DMO1XUK TN GMCSFR-alpha (CSF2RA) DMO1XUK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DMO1XUK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DMO1ZGX DI DMO1ZGX DMO1ZGX DN CRILVASTATIN DMO1ZGX TI TTPADOQ DMO1ZGX TN HMG-CoA reductase (HMGCR) DMO1ZGX MA Inhibitor DMO1ZGX RN Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Br J Pharmacol. 1996 Aug;118(7):1862-8. DMO1ZGX RU https://pubmed.ncbi.nlm.nih.gov/8842455 DMO2TYL DI DMO2TYL DMO2TYL DN Ramipril DMO2TYL TI TTGFNPD DMO2TYL TN HUMAN angiotensin-converting enzyme (ACE) DMO2TYL MA Inhibitor DMO2TYL RN Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Curr Cardiol Rep. 2020 Apr 14;22(5):31. DMO2TYL RU https://pubmed.ncbi.nlm.nih.gov/32291526 DMO3U4W DI DMO3U4W DMO3U4W DN VX-222 DMO3U4W TI TTMVBWH DMO3U4W TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMO3U4W MA Inhibitor DMO3U4W RN 2011 Pipeline of Vertex. DMO3U4W RU http://www.vrtx.com/current-projects.html DMO4EYX DI DMO4EYX DMO4EYX DN Soblidotin DMO4EYX TI TTML2WA DMO4EYX TN Tubulin (TUB) DMO4EYX MA Modulator DMO4EYX RN Antitumor activity of TZT-1027 (Soblidotin). Anticancer Res. 2006 May-Jun;26(3A):1973-81. DMO4EYX RU https://pubmed.ncbi.nlm.nih.gov/16827132 DMO4I61 DI DMO4I61 DMO4I61 DN H5N1 influenza vaccine DMO4I61 TI TT3J5ZI DMO4I61 TN Cell mediated immunity response (CMIR) DMO4I61 RN Anti-influenza agents from Traditional Chinese Medicine. Nat Prod Rep. 2010 Jan;27(12):1758-80. DMO4I61 RU https://pubmed.ncbi.nlm.nih.gov/20941447 DMO4MNQ DI DMO4MNQ DMO4MNQ DN BGS-649 DMO4MNQ TI TTSZLWK DMO4MNQ TN Aromatase (CYP19A1) DMO4MNQ MA Inhibitor DMO4MNQ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111) DMO4MNQ RU http://adisinsight.springer.com/drugs/800032111 DMO5JS3 DI DMO5JS3 DMO5JS3 DN GSK3389404 DMO5JS3 TI TTSJVOI DMO5JS3 TN Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) DMO5JS3 MA Inhibitor DMO5JS3 RN A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801. DMO5JS3 RU https://pubmed.ncbi.nlm.nih.gov/30861337 DMO72IF DI DMO72IF DMO72IF DN AMG 301 DMO72IF TI TT5OREU DMO72IF TN PACAP type I receptor (PAC1R) DMO72IF MA Inhibitor DMO72IF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO72IF RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMO7MBS DI DMO7MBS DMO7MBS DN MM-111 DMO7MBS TI TT6EO5L DMO7MBS TN Erbb2 tyrosine kinase receptor (HER2) DMO7MBS MA Modulator DMO7MBS RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMO7MBS RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMO84TL DI DMO84TL DMO84TL DN ME-3407 DMO84TL TI TT18ETS DMO84TL TN Myosin light kinase (MYLK) DMO84TL MA Inhibitor DMO84TL RN ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. Am J Physiol. 1997 May;272(5 Pt 1):G1122-34. DMO84TL RU https://pubmed.ncbi.nlm.nih.gov/9176222 DMO8IEZ DI DMO8IEZ DMO8IEZ DN LY-2828360 DMO8IEZ TI TTMSFAW DMO8IEZ TN Cannabinoid receptor 2 (CB2) DMO8IEZ MA Agonist DMO8IEZ RN Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2). DMO8IEZ RU http://www.researchgate.net/publication/258114758_Recent_Development_of_CB2_Selective_and_Peripheral_CB1CB2_Cannabinoid_Receptor_Ligands DMO9LBE DI DMO9LBE DMO9LBE DN SUN N4057 DMO9LBE TI TTSQIFT DMO9LBE TN 5-HT 1A receptor (HTR1A) DMO9LBE MA Agonist DMO9LBE RN Experimental study of pharmacological hypothermia: enhanced neuroprotective effect of a novel 5-HT 1 A agonist SUN N4057 by the pharmacological hypothermia. No To Shinkei. 2001 Sep;53(9):853-8. DMO9LBE RU https://pubmed.ncbi.nlm.nih.gov/11596480 DMO9QB8 DI DMO9QB8 DMO9QB8 DN R-IFN-1a DMO9QB8 TI TTSYFMA DMO9QB8 TN Interferon alpha/beta receptor 1 (IFNAR1) DMO9QB8 MA Modulator DMO9QB8 RN Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b. J Neurol Sci.1999 Oct 15;168(2):131-6. DMO9QB8 RU https://pubmed.ncbi.nlm.nih.gov/10526196 DMOB01U DI DMOB01U DMOB01U DN Amsilarotene DMOB01U TI TTOD7B3 DMOB01U TN Retinoic acid receptor (RAR) DMOB01U MA Antagonist DMOB01U RN Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002 Aug 15;20(16):3522-32. DMOB01U RU https://pubmed.ncbi.nlm.nih.gov/12177113 DMOB1EM DI DMOB1EM DMOB1EM DN Plasmin DMOB1EM TI TTWODQF DMOB1EM TN Fibrin (FG) DMOB1EM MA Modulator DMOB1EM RN ClinicalTrials.gov (NCT01014975) A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. U.S. National Institutes of Health. DMOB1EM RU https://clinicaltrials.gov/ct2/show/NCT01014975 DMOCID7 DI DMOCID7 DMOCID7 DN Etazolate DMOCID7 TI TTEX6LM DMOCID7 TN GABA(A) receptor gamma-3 (GABRG3) DMOCID7 MA Modulator DMOCID7 RN Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem. 2008 Jul;106(1):392-404. DMOCID7 RU https://pubmed.ncbi.nlm.nih.gov/18397369 DMOCRYB DI DMOCRYB DMOCRYB DN GLPG-1837 DMOCRYB TI TTRLZHP DMOCRYB TN cAMP-dependent chloride channel (CFTR) DMOCRYB MA Enhancer DMOCRYB RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMOCRYB RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMODJTX DI DMODJTX DMODJTX DN AMG-181 DMODJTX TI TTLT9XQ DMODJTX TN Integrin beta-7 (ITGB7) DMODJTX RN Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013 May;169(1):51-68. DMODJTX RU https://pubmed.ncbi.nlm.nih.gov/23425116 DMODJTX DI DMODJTX DMODJTX DN AMG-181 DMODJTX TI TT4BT06 DMODJTX TN Integrin alpha-4 (ITGA4) DMODJTX MA Inhibitor DMODJTX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMODJTX RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMODLN7 DI DMODLN7 DMODLN7 DN IRX-2 DMODLN7 TI TTXM6JN DMODLN7 TN Cytokine receptor unspecific (CRF) DMODLN7 MA Modulator DMODLN7 RN Clinical pipeline report, company report or official report of IRX Therapeutics. DMODLN7 RU http://www.irxtherapeutics.com/prod_irx2.html DMOEARH DI DMOEARH DMOEARH DN Azd2014 DMOEARH TI TTCJG29 DMOEARH TN Serine/threonine-protein kinase mTOR (mTOR) DMOEARH MA Inhibitor DMOEARH RN Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014. Biochem Biophys Res Commun. 2014 Jan 10;443(2):406-12. DMOEARH RU https://pubmed.ncbi.nlm.nih.gov/24309100 DMOEARH DI DMOEARH DMOEARH DN Azd2014 DMOEARH TI TTX4GLS DMOEARH TN Mammalian target of rapamycin complex 1 (mTORC1) DMOEARH MA Inhibitor DMOEARH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOEARH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOEARH DI DMOEARH DMOEARH DN Azd2014 DMOEARH TI TTWDKCL DMOEARH TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DMOEARH MA Inhibitor DMOEARH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOEARH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOFTRE DI DMOFTRE DMOFTRE DN Cizolirtine DMOFTRE TI TTVSFJW DMOFTRE TN Calcitonin gene-related peptide 1 (CALCA) DMOFTRE MA Inhibitor DMOFTRE RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMOFTRE RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMOGDCQ DI DMOGDCQ DMOGDCQ DN Ab-01 DMOGDCQ TI TTZO9B0 DMOGDCQ TN Interleukin 21 receptor (IL21R) DMOGDCQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2304). DMOGDCQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2304 DMOGFNI DI DMOGFNI DMOGFNI DN AVN-101 DMOGFNI TI TTO9X1H DMOGFNI TN 5-HT 7 receptor (HTR7) DMOGFNI MA Antagonist DMOGFNI RN AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620. DMOGFNI RU https://pubmed.ncbi.nlm.nih.gov/27232215 DMOGYQ0 DI DMOGYQ0 DMOGYQ0 DN ONO-2952 DMOGYQ0 TI TTPTXIN DMOGYQ0 TN Translocator protein (TSPO) DMOGYQ0 MA Antagonist DMOGYQ0 RN Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Jul 17;99:51-66. DMOGYQ0 RU https://pubmed.ncbi.nlm.nih.gov/26189762 DMOH8LD DI DMOH8LD DMOH8LD DN Senktide DMOH8LD TI TTBPGLU DMOH8LD TN Neuromedin-K receptor (TACR3) DMOH8LD MA Agonist DMOH8LD RN Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63. DMOH8LD RU https://pubmed.ncbi.nlm.nih.gov/12598409 DMOH8LD DI DMOH8LD DMOH8LD DN Senktide DMOH8LD TI TT4BT06 DMOH8LD TN Integrin alpha-4 (ITGA4) DMOH8LD MA Inhibitor DMOH8LD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOH8LD RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMOHAS2 DI DMOHAS2 DMOHAS2 DN GPC-3298306 DMOHAS2 TI TTJTSX4 DMOHAS2 TN Glypican-3 (GPC3) DMOHAS2 RN Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91. DMOHAS2 RU https://pubmed.ncbi.nlm.nih.gov/18974622 DMOHT5V DI DMOHT5V DMOHT5V DN DKN-01 DMOHT5V TI TTE3RAC DMOHT5V TN Dickkopf-related protein 1 (DKK1) DMOHT5V MA Inhibitor DMOHT5V RN The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer. Expert Opin Investig Drugs. 2020 Jul;29(7):639-644. DMOHT5V RU https://pubmed.ncbi.nlm.nih.gov/32408777 DMOI9EL DI DMOI9EL DMOI9EL DN Radezolid DMOI9EL TI TT2VX74 DMOI9EL TN Bacterial Protein synthesis (Bact PROS) DMOI9EL MA Inhibitor DMOI9EL RN Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo). 2011 Jun;64(6):413-25. DMOI9EL RU https://pubmed.ncbi.nlm.nih.gov/21587262 DMOJ7QA DI DMOJ7QA DMOJ7QA DN Mitemcinal fumarate DMOJ7QA TI TT953CX DMOJ7QA TN Motilin receptor (MLNR) DMOJ7QA MA Agonist DMOJ7QA RN Clinical pipeline report, company report or official report of Roche (2009). DMOJ7QA RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMOJA5G DI DMOJA5G DMOJA5G DN Nuplazid DMOJA5G TI TTJQOD7 DMOJA5G TN 5-HT 2A receptor (HTR2A) DMOJA5G MA Agonist DMOJA5G RN The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091. DMOJA5G RU https://pubmed.ncbi.nlm.nih.gov/30288594 DMOJA5G DI DMOJA5G DMOJA5G DN Nuplazid DMOJA5G TI TTWJBZ5 DMOJA5G TN 5-HT 2C receptor (HTR2C) DMOJA5G MA Agonist DMOJA5G RN The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug. Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091. DMOJA5G RU https://pubmed.ncbi.nlm.nih.gov/30288594 DMOKUA5 DI DMOKUA5 DMOKUA5 DN XR-5000 DMOKUA5 TI TTGTQHC DMOKUA5 TN DNA topoisomerase I (TOP1) DMOKUA5 MA Modulator DMOKUA5 RN Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80. DMOKUA5 RU https://pubmed.ncbi.nlm.nih.gov/12075748 DMOKUA5 DI DMOKUA5 DMOKUA5 DN XR-5000 DMOKUA5 TI TT0IHXV DMOKUA5 TN DNA topoisomerase II (TOP2) DMOKUA5 MA Modulator DMOKUA5 RN Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol. 2002 May;13(5):777-80. DMOKUA5 RU https://pubmed.ncbi.nlm.nih.gov/12075748 DMOLTAD DI DMOLTAD DMOLTAD DN SM-04690 DMOLTAD TI TTFPSHI DMOLTAD TN Wnt signaling pathway (Wnt pathway) DMOLTAD MA Modulator DMOLTAD RN Clinical pipeline report, company report or official report of Phrma.org Arthritis 2014. DMOLTAD RU http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-arthritis.pdf DMOMDA4 DI DMOMDA4 DMOMDA4 DN B-701 DMOMDA4 TI TTST7KB DMOMDA4 TN Fibroblast growth factor receptor 3 (FGFR3) DMOMDA4 MA Antagonist DMOMDA4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOMDA4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMOMI97 DI DMOMI97 DMOMI97 DN UNI-rE-4 DMOMI97 TI TTVIMDE DMOMI97 TN Glucagon-like peptide 1 receptor (GLP1R) DMOMI97 MA Modulator DMOMI97 RN Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. DMOMI97 RU https://pubmed.ncbi.nlm.nih.gov/19748064 DMOMS7R DI DMOMS7R DMOMS7R DN GI-6301 DMOMS7R TI TTBXAHS DMOMS7R TN T-box transcription factor T (TBXT) DMOMS7R RN Clinical pipeline report, company report or official report of GlobeImmune. DMOMS7R RU https://www.globeimmune.com/cancer/gi-6301/ DMOPWSX DI DMOPWSX DMOPWSX DN Ibrolipim DMOPWSX TI TTOF3WZ DMOPWSX TN Lipoprotein lipase (LPL) DMOPWSX MA Modulator DMOPWSX RN NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats. Metabolism. 2005 Dec;54(12):1587-92. DMOPWSX RU https://pubmed.ncbi.nlm.nih.gov/16311090 DMOQ7YI DI DMOQ7YI DMOQ7YI DN GPD-1116 DMOQ7YI TI TTVIAT9 DMOQ7YI TN Phosphodiesterase 4B (PDE4B) DMOQ7YI MA Inhibitor DMOQ7YI RN Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204. DMOQ7YI RU https://pubmed.ncbi.nlm.nih.gov/17993591 DMOQ7YI DI DMOQ7YI DMOQ7YI DN GPD-1116 DMOQ7YI TI TTSKMI8 DMOQ7YI TN Phosphodiesterase 4D (PDE4D) DMOQ7YI MA Inhibitor DMOQ7YI RN Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204. DMOQ7YI RU https://pubmed.ncbi.nlm.nih.gov/17993591 DMOQ7YI DI DMOQ7YI DMOQ7YI DN GPD-1116 DMOQ7YI TI TTZ97H5 DMOQ7YI TN Phosphodiesterase 4A (PDE4A) DMOQ7YI MA Inhibitor DMOQ7YI RN Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 s... Am J Physiol Lung Cell Mol Physiol. 2008 Feb;294(2):L196-204. DMOQ7YI RU https://pubmed.ncbi.nlm.nih.gov/17993591 DMOR8SY DI DMOR8SY DMOR8SY DN CNT0-1959 DMOR8SY TI TTC1GLB DMOR8SY TN Interleukin-23 (IL23) DMOR8SY RN Interleukin-23 in the pathogenesis and treatment of psoriasis. Skin Therapy Lett. 2015 Mar-Apr;20(2):1-4. DMOR8SY RU https://pubmed.ncbi.nlm.nih.gov/25807335 DMORFZD DI DMORFZD DMORFZD DN Tolamba DMORFZD TI TTSHG0T DMORFZD TN Toll-like receptor 9 (TLR9) DMORFZD RN Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol. 2009 August; 146(3): 282-291. DMORFZD RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747261/ DMORJD4 DI DMORJD4 DMORJD4 DN AVB-500 DMORJD4 TI TT69QD2 DMORJD4 TN AXL receptor tyrosine kinase ligand (GAS6) DMORJD4 MA Inhibitor DMORJD4 RN Clinical pipeline report, company report or official report of Aravive. DMORJD4 RU https://aravive.com/pipeline/ DMORNVB DI DMORNVB DMORNVB DN NU-172 DMORNVB TI TT6L509 DMORNVB TN Coagulation factor IIa (F2) DMORNVB MA Inhibitor DMORNVB RN Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011; 18(27): 4206-4214. DMORNVB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260938/ DMOS5JZ DI DMOS5JZ DMOS5JZ DN Lexatumumab DMOS5JZ TI TTW20TU DMOS5JZ TN TRAIL receptor 2 (TRAIL-R2) DMOS5JZ RN National Cancer Institute Drug Dictionary (drug id 528015). DMOS5JZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=528015 DMOSCBF DI DMOSCBF DMOSCBF DN SAR-3419 DMOSCBF TI TTW640A DMOSCBF TN B-lymphocyte surface antigen B4 (CD19) DMOSCBF RN A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2014 Jan 1;20(1):213-20. DMOSCBF RU https://pubmed.ncbi.nlm.nih.gov/24132920 DMOSL9P DI DMOSL9P DMOSL9P DN E6201 DMOSL9P TI TTROQ37 DMOSL9P TN MAPK/ERK kinase kinase (MAP3K) DMOSL9P MA Modulator DMOSL9P RN E6201, a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase-1: in vivo effects on cutaneous inflammatory responses by topical administration. J Pharmacol Exp Ther. 2010 Oct;335(1):23-31. DMOSL9P RU https://pubmed.ncbi.nlm.nih.gov/20627998 DMOT0M7 DI DMOT0M7 DMOT0M7 DN JTX-4014 DMOT0M7 TI TTNBFWK DMOT0M7 TN Programmed cell death protein 1 (PD-1) DMOT0M7 MA Inhibitor DMOT0M7 RN Clinical pipeline report, company report or official report of Jounce Therapeutics. DMOT0M7 RU https://jouncetx.com/our-pipeline/ DMOT0WR DI DMOT0WR DMOT0WR DN ONO-2333Ms DMOT0WR TI TT7EFHR DMOT0WR TN Corticotropin-releasing factor receptor 1 (CRHR1) DMOT0WR MA Antagonist DMOT0WR RN Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86. DMOT0WR RU https://pubmed.ncbi.nlm.nih.gov/23294766 DMOV0AP DI DMOV0AP DMOV0AP DN 842166X DMOV0AP TI TTMSFAW DMOV0AP TN Cannabinoid receptor 2 (CB2) DMOV0AP MA Agonist DMOV0AP RN The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49. DMOV0AP RU https://pubmed.ncbi.nlm.nih.gov/24358778 DMOVB3Y DI DMOVB3Y DMOVB3Y DN GKT-137831 DMOVB3Y TI TTQRBSJ DMOVB3Y TN NADPH oxidase 4 (NOX4) DMOVB3Y MA Modulator DMOVB3Y RN Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327. DMOVB3Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/ DMOVB3Y DI DMOVB3Y DMOVB3Y DN GKT-137831 DMOVB3Y TI TTFQVUT DMOVB3Y TN NADPH oxidase (NOX) DMOVB3Y MA Modulator DMOVB3Y RN Nicotinamide Adenine Dinucleotide Phosphate Oxidase (NOX) in Experimental Liver Fibrosis: GKT137831 as a Novel Potential Therapeutic Agent. Hepatology. 2012 December; 56(6): 2316-2327. DMOVB3Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493679/ DMOVQP8 DI DMOVQP8 DMOVQP8 DN SPP-600 DMOVQP8 TI TTB2MXP DMOVQP8 TN Angiotensinogenase renin (REN) DMOVQP8 MA Inhibitor DMOVQP8 RN Effect of SPP 635, a renin inhibitor, on intraocular pressure in glaucomatous monkey eyes. Exp Eye Res. 2012 Jan;94(1):146-9. DMOVQP8 RU https://pubmed.ncbi.nlm.nih.gov/22173206 DMOW9X2 DI DMOW9X2 DMOW9X2 DN KRP-203 DMOW9X2 TI TT9JZCK DMOW9X2 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMOW9X2 MA Agonist DMOW9X2 RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMOW9X2 RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMOX1CU DI DMOX1CU DMOX1CU DN NCX-4016 DMOX1CU TI TTK0943 DMOX1CU TN Prostaglandin G/H synthase (COX) DMOX1CU MA Inhibitor DMOX1CU RN Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90. DMOX1CU RU https://pubmed.ncbi.nlm.nih.gov/16503827 DMOXKIC DI DMOXKIC DMOXKIC DN MEDI3902 DMOXKIC TI TTLK9NJ DMOXKIC TN Pseudomonas PcrV protein type III (Pseudo pcrV) DMOXKIC RN A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155. DMOXKIC RU https://pubmed.ncbi.nlm.nih.gov/25391481 DMOXKIC DI DMOXKIC DMOXKIC DN MEDI3902 DMOXKIC TI TTTPDRC DMOXKIC TN Pseudomonas Psl exopolysaccharide (Pseudo pslG) DMOXKIC RN A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci Transl Med. 2014 Nov 12;6(262):262ra155. DMOXKIC RU https://pubmed.ncbi.nlm.nih.gov/25391481 DMOYS8A DI DMOYS8A DMOYS8A DN PTG-300 DMOYS8A TI TTPCG5T DMOYS8A TN Hepcidin (HAMP) DMOYS8A MA Replacement DMOYS8A RN Clinical pipeline report, company report or official report of Protagonist Therapeutics. DMOYS8A RU https://www.protagonist-inc.com/pipeline/#overview DMOZ04X DI DMOZ04X DMOZ04X DN AZD-5213 DMOZ04X TI TT9JNIC DMOZ04X TN Histamine H3 receptor (H3R) DMOZ04X MA Antagonist DMOZ04X RN SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14. DMOZ04X RU https://pubmed.ncbi.nlm.nih.gov/22542742 DMOZAMN DI DMOZAMN DMOZAMN DN TAK-935 DMOZAMN TI TT4EB85 DMOZAMN TN Cholesterol 24-hydroxylase (CYP46A1) DMOZAMN MA Inhibitor DMOZAMN RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040983) DMOZAMN RU http://adisinsight.springer.com/drugs/800040983 DMOZW4C DI DMOZW4C DMOZW4C DN Neublastin DMOZW4C TI TT63XRS DMOZW4C TN GDNF receptor alpha-3 (GFRA3) DMOZW4C MA Modulator DMOZW4C RN First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica. PLoSOne. 2015 May 11;10(5):e0125034. DMOZW4C RU https://pubmed.ncbi.nlm.nih.gov/25962165 DMP05GL DI DMP05GL DMP05GL DN LYC-30937 DMP05GL TI TT5WKM8 DMP05GL TN ATP phosphatase (ATPase) DMP05GL MA Modulator DMP05GL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP05GL RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMP0LST DI DMP0LST DMP0LST DN APL-101 DMP0LST TI TTNDSF4 DMP0LST TN Proto-oncogene c-Met (MET) DMP0LST MA Inhibitor DMP0LST RN Clinical pipeline report, company report or official report of Apollomics. DMP0LST RU https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-101/ DMP1873 DI DMP1873 DMP1873 DN TAK-063 DMP1873 TI TTJW4LU DMP1873 TN Phosphodiesterase 10A (PDE10) DMP1873 MA Inhibitor DMP1873 RN Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197. DMP1873 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376699/ DMP1W9Z DI DMP1W9Z DMP1W9Z DN NP-01 DMP1W9Z TI TTCBFJO DMP1W9Z TN Insulin receptor (INSR) DMP1W9Z MA Agonist DMP1W9Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMP1W9Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMP2BWX DI DMP2BWX DMP2BWX DN Ispinesib DMP2BWX TI TTTRP0H DMP2BWX TN Kinesin-like protein KIF11 (KIF11) DMP2BWX MA Inhibitor DMP2BWX RN Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2009 Dec 15;53(7):1255-63. DMP2BWX RU https://pubmed.ncbi.nlm.nih.gov/19554570 DMP2DNS DI DMP2DNS DMP2DNS DN Rambazole DMP2DNS TI TTD7Q0R DMP2DNS TN Cytochrome P450 26 (CYP26A1) DMP2DNS MA Inhibitor DMP2DNS RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DMP2DNS RU https://pubmed.ncbi.nlm.nih.gov/19249988 DMP2DNS DI DMP2DNS DMP2DNS DN Rambazole DMP2DNS TI TTYO0A3 DMP2DNS TN Substance-K receptor (TACR2) DMP2DNS MA Antagonist DMP2DNS RN Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005 Jun 1;516(2):104-11. DMP2DNS RU https://pubmed.ncbi.nlm.nih.gov/15925360 DMP30SA DI DMP30SA DMP30SA DN TVB-2640 DMP30SA TI TT7AOUD DMP30SA TN Fatty acid synthase (FASN) DMP30SA MA Inhibitor DMP30SA RN Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities. Hepatology. 2020 Jul;72(1):103-118. DMP30SA RU https://pubmed.ncbi.nlm.nih.gov/31630414 DMP42W1 DI DMP42W1 DMP42W1 DN IW-6118 DMP42W1 TI TTDP1UC DMP42W1 TN Fatty acid amide hydrolase (FAAH) DMP42W1 MA Modulator DMP42W1 RN The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685. DMP42W1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146581/ DMP56WJ DI DMP56WJ DMP56WJ DN CF102 DMP56WJ TI TTJFY5U DMP56WJ TN Adenosine A3 receptor (ADORA3) DMP56WJ MA Agonist DMP56WJ RN 2011 Pipeline of Can-Fite BioPharm. DMP56WJ RU http://www.canfite.com/pipeline.html DMP5Y1A DI DMP5Y1A DMP5Y1A DN AGN-199981 DMP5Y1A TI TTWM4TY DMP5Y1A TN Adrenergic receptor alpha-2B (ADRA2B) DMP5Y1A MA Agonist DMP5Y1A RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMP5Y1A RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMP5Z9N DI DMP5Z9N DMP5Z9N DN SAN-300 DMP5Z9N TI TTPERWV DMP5Z9N TN Integrin alpha-1 (VLA-1) DMP5Z9N MA Antagonist DMP5Z9N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP5Z9N RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMP62L5 DI DMP62L5 DMP62L5 DN Resiniferatoxin DMP62L5 TI TTMI6F5 DMP62L5 TN Transient receptor potential cation channel V1 (TRPV1) DMP62L5 MA Activator DMP62L5 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMP62L5 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMP6B59 DI DMP6B59 DMP6B59 DN Ocaperidone DMP6B59 TI TTSECX1 DMP6B59 TN Connective tissue growth factor (CTGF) DMP6B59 MA Inhibitor DMP6B59 RN Current and emerging drugs for idiopathic pulmonary fibrosis. Expert Opin Emerg Drugs. 2007 Nov;12(4):627-46. DMP6B59 RU https://pubmed.ncbi.nlm.nih.gov/17979604 DMP6B59 DI DMP6B59 DMP6B59 DN Ocaperidone DMP6B59 TI TTJQOD7 DMP6B59 TN 5-HT 2A receptor (HTR2A) DMP6B59 MA Modulator DMP6B59 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMP6B59 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMP6B59 DI DMP6B59 DMP6B59 DN Ocaperidone DMP6B59 TI TTEX248 DMP6B59 TN Dopamine D2 receptor (D2R) DMP6B59 MA Modulator DMP6B59 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMP6B59 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMP6MH9 DI DMP6MH9 DMP6MH9 DN DA-8031 DMP6MH9 TI TT3ROYC DMP6MH9 TN Serotonin transporter (SERT) DMP6MH9 MA Inhibitor DMP6MH9 RN Effect of DA-8031, a novel oral compound for premature ejaculation, on male rat sexual behavior. Int J Urol. 2014 Mar;21(3):325-9. DMP6MH9 RU https://pubmed.ncbi.nlm.nih.gov/23968141 DMP7J0S DI DMP7J0S DMP7J0S DN R411 DMP7J0S TI TT6S84X DMP7J0S TN Integrin alpha-4/beta-1 (ITGA4/B1) DMP7J0S MA Modulator DMP7J0S RN Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010 Oct;9(10):804-20. DMP7J0S RU https://pubmed.ncbi.nlm.nih.gov/20885411 DMP925B DI DMP925B DMP925B DN ICA-105665 DMP925B TI TTIVDM3 DMP925B TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMP925B MA Activator DMP925B RN New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008 Jul;8(4):345-52. DMP925B RU https://pubmed.ncbi.nlm.nih.gov/18590620 DMP9TKE DI DMP9TKE DMP9TKE DN PTC299 DMP9TKE TI TT2J34L DMP9TKE TN Arachidonate 5-lipoxygenase (5-LOX) DMP9TKE MA Inhibitor DMP9TKE RN Therapeutic intervention in a rat model of ARDS: I. Dual inhibition of arachidonic acid metabolism. Circ Shock. 1990 Nov;32(3):231-42. DMP9TKE RU https://pubmed.ncbi.nlm.nih.gov/2124522 DMP9TKE DI DMP9TKE DMP9TKE DN PTC299 DMP9TKE TI TTOHSBA DMP9TKE TN Vascular endothelial growth factor A (VEGFA) DMP9TKE MA Modulator DMP9TKE RN Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24. DMP9TKE RU https://www.ncbi.nlm.nih.gov/pubmed/25407389 DMPAJ41 DI DMPAJ41 DMPAJ41 DN BIIB-021 DMPAJ41 TI TT78R5H DMPAJ41 TN Heat shock protein 90 alpha (HSP90A) DMPAJ41 MA Inhibitor DMPAJ41 RN BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9. DMPAJ41 RU https://pubmed.ncbi.nlm.nih.gov/19372565 DMPBK8N DI DMPBK8N DMPBK8N DN GSK3228836 DMPBK8N TI TTSJVOI DMPBK8N TN Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) DMPBK8N MA Inhibitor DMPBK8N RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMPBK8N RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMPBKUZ DI DMPBKUZ DMPBKUZ DN SCH-900978 DMPBKUZ TI TTZPO1L DMPBKUZ TN Substance-P receptor (TACR1) DMPBKUZ MA Antagonist DMPBKUZ RN Clinical pipeline report, company report or official report of OPKO Health, Inc. DMPBKUZ RU http://investor.opko.com/secfiling.cfm?filingID=950123-10-54487&CIK=944809 DMPBR0D DI DMPBR0D DMPBR0D DN IPH-2102 DMPBR0D TI TTU0P73 DMPBR0D TN MHC class I NK cell receptor 2DL2 (CD158b1) DMPBR0D MA Antagonist DMPBR0D RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMPBR0D RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMPBR0D DI DMPBR0D DMPBR0D DN IPH-2102 DMPBR0D TI TTEX3SI DMPBR0D TN MHC class I NK cell receptor 2DL3 (CD158b2) DMPBR0D MA Antagonist DMPBR0D RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMPBR0D RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMPBR0D DI DMPBR0D DMPBR0D DN IPH-2102 DMPBR0D TI TT4UXPE DMPBR0D TN MHC class I NK cell receptor 2DL1 (CD158A) DMPBR0D MA Antagonist DMPBR0D RN Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. DMPBR0D RU https://pubmed.ncbi.nlm.nih.gov/25510242 DMPBTVK DI DMPBTVK DMPBTVK DN MGB-BP-3 DMPBTVK TI TTS1W4A DMPBTVK TN Bacterial Deoxyribonucleic acid (Bact DNA) DMPBTVK MA Binder DMPBTVK RN Clinical pipeline report, company report or official report of MGB Biopharma. DMPBTVK RU https://www.mgb-biopharma.com/wp-content/uploads/SMi-MGB-Biopharma-Presentation.pdf DMPBV9D DI DMPBV9D DMPBV9D DN Flupirtine DMPBV9D TI TTQ29KF DMPBV9D TN Voltage-gated potassium channel Kv7 (KCNQ) DMPBV9D MA Modulator DMPBV9D RN Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249. DMPBV9D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743843/ DMPC4EK DI DMPC4EK DMPC4EK DN EP-217609 DMPC4EK TI TTCIHJA DMPC4EK TN Coagulation factor Xa (F10) DMPC4EK MA Modulator DMPC4EK RN Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95. DMPC4EK RU https://www.ncbi.nlm.nih.gov/pubmed/22144183 DMPC4EK DI DMPC4EK DMPC4EK DN EP-217609 DMPC4EK TI TT6L509 DMPC4EK TN Coagulation factor IIa (F2) DMPC4EK MA Modulator DMPC4EK RN Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.Blood.2012 Mar 8;119(10):2187-95. DMPC4EK RU https://www.ncbi.nlm.nih.gov/pubmed/22144183 DMPD3X6 DI DMPD3X6 DMPD3X6 DN Pegmusirudin DMPD3X6 TI TT6L509 DMPD3X6 TN Coagulation factor IIa (F2) DMPD3X6 MA Modulator DMPD3X6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMPD3X6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMPDVM8 DI DMPDVM8 DMPDVM8 DN ABT-510 DMPDVM8 TI TTKI0H1 DMPDVM8 TN Thrombospondin-1 (THBS1) DMPDVM8 MA Modulator DMPDVM8 RN A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9. DMPDVM8 RU https://pubmed.ncbi.nlm.nih.gov/17551310 DMPE2B9 DI DMPE2B9 DMPE2B9 DN ZD-7288 DMPE2B9 TI TTKLW9S DMPE2B9 TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DMPE2B9 MA Modulator DMPE2B9 RN ZD 7288, an HCN channel blocker, attenuates chronic visceral pain in irritable bowel syndrome-like rats. World J Gastroenterol. 2014 Feb 28;20(8):2091-7. DMPE2B9 RU https://pubmed.ncbi.nlm.nih.gov/24587682 DMPER4A DI DMPER4A DMPER4A DN NIR178 DMPER4A TI TTSLI08 DMPER4A TN Adenosine receptor (ADOR) DMPER4A MA Antagonist DMPER4A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPER4A RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPF9ZM DI DMPF9ZM DMPF9ZM DN Obatoclax DMPF9ZM TI TTJGNVC DMPF9ZM TN Apoptosis regulator Bcl-2 (BCL-2) DMPF9ZM MA Inhibitor DMPF9ZM RN Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. DMPF9ZM RU https://pubmed.ncbi.nlm.nih.gov/20709666 DMPF9ZM DI DMPF9ZM DMPF9ZM DN Obatoclax DMPF9ZM TI TTU1E82 DMPF9ZM TN Apoptosis regulator Bcl-xL (BCL-xL) DMPF9ZM MA Inhibitor DMPF9ZM RN Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. DMPF9ZM RU https://pubmed.ncbi.nlm.nih.gov/20709666 DMPF9ZM DI DMPF9ZM DMPF9ZM DN Obatoclax DMPF9ZM TI TTL53M6 DMPF9ZM TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMPF9ZM MA Inhibitor DMPF9ZM RN Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9. DMPF9ZM RU https://pubmed.ncbi.nlm.nih.gov/20709666 DMPFG7H DI DMPFG7H DMPFG7H DN JNJ-16269110 DMPFG7H TI TTUS1RD DMPFG7H TN Microsomal triglyceride transfer protein (MTTP) DMPFG7H MA Inhibitor DMPFG7H RN ClinicalTrials.gov (NCT00672386) A Study of the Safety and Effectiveness of a R256918 in Patients With Type 2 Diabetes. U.S. National Institutes of Health. DMPFG7H RU https://clinicaltrials.gov/ct2/show/NCT00672386 DMPFVJB DI DMPFVJB DMPFVJB DN 5-hydroxymethyl-2-furfural DMPFVJB TI TTQO71U DMPFVJB TN Hemoglobin (HB) DMPFVJB MA Modulator DMPFVJB RN 5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. Br J Haematol. 2005 Feb;128(4):552-61. DMPFVJB RU https://pubmed.ncbi.nlm.nih.gov/15686467 DMPH1AG DI DMPH1AG DMPH1AG DN TG100801 DMPH1AG TI TT9HKJA DMPH1AG TN Vascular endothelial growth factor (VEGF) DMPH1AG MA Inhibitor DMPH1AG RN Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37. DMPH1AG RU https://pubmed.ncbi.nlm.nih.gov/18330892 DMPHCDL DI DMPHCDL DMPHCDL DN GLPG-0634 DMPHCDL TI TT6DM01 DMPHCDL TN Janus kinase 1 (JAK-1) DMPHCDL MA Modulator DMPHCDL RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DMPHCDL RU https://pubmed.ncbi.nlm.nih.gov/24818516 DMPI6N0 DI DMPI6N0 DMPI6N0 DN XZK-monascus DMPI6N0 TI TTPADOQ DMPI6N0 TN HMG-CoA reductase (HMGCR) DMPI6N0 MA Modulator DMPI6N0 RN NMR evaluation of total statin content and HMG-CoA reductase inhibition in red yeast rice (Monascus spp.) food supplements. Chin Med. 2012 Mar 22;7:8. DMPI6N0 RU https://pubmed.ncbi.nlm.nih.gov/22439629 DMPJQZG DI DMPJQZG DMPJQZG DN NSC-645809 DMPJQZG TI TTJLP0R DMPJQZG TN Quinone reductase 2 (NQO2) DMPJQZG MA Inhibitor DMPJQZG RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMPJQZG RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMPK34E DI DMPK34E DMPK34E DN Sun13834 DMPK34E TI TTV5CGO DMPK34E TN Phosphodiesterase 4 (PDE4) DMPK34E MA Inhibitor DMPK34E RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DMPK34E RU https://pubmed.ncbi.nlm.nih.gov/7925603 DMPK34E DI DMPK34E DMPK34E DN Sun13834 DMPK34E TI TT8VUE0 DMPK34E TN Chymase (CYM) DMPK34E MA Modulator DMPK34E RN Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91. DMPK34E RU https://www.ncbi.nlm.nih.gov/pubmed/18996112 DMPKWR3 DI DMPKWR3 DMPKWR3 DN MEDI-546 DMPKWR3 TI TTSYFMA DMPKWR3 TN Interferon alpha/beta receptor 1 (IFNAR1) DMPKWR3 MA Modulator DMPKWR3 RN Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-alpha receptor 1 antibody. MAbs. 2015;7(2):428-39. DMPKWR3 RU https://pubmed.ncbi.nlm.nih.gov/25606664 DMPL9KG DI DMPL9KG DMPL9KG DN LGD-6972 DMPL9KG TI TT9O6WS DMPL9KG TN Glucagon receptor (GCGR) DMPL9KG MA Antagonist DMPL9KG RN Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31. DMPL9KG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/ DMPLKAH DI DMPLKAH DMPLKAH DN GSK-706769 DMPLKAH TI TT2CEJG DMPLKAH TN C-C chemokine receptor type 5 (CCR5) DMPLKAH MA Antagonist DMPLKAH RN Tapping into combination pills for HIV. Nat Rev Drug Discov. 2009 Jun;8(6):439-40. DMPLKAH RU https://pubmed.ncbi.nlm.nih.gov/19483700 DMPMO6G DI DMPMO6G DMPMO6G DN CC-401 DMPMO6G TI TTR2TXZ DMPMO6G TN Jun N terminal kinase (JNK) DMPMO6G MA Modulator DMPMO6G RN Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49. DMPMO6G RU https://www.ncbi.nlm.nih.gov/pubmed/19629069 DMPMU38 DI DMPMU38 DMPMU38 DN JVRS-100 DMPMU38 TI TTSHG0T DMPMU38 TN Toll-like receptor 9 (TLR9) DMPMU38 RN Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone ) increases antibody response, cellular immunity, and antigenically drifted protection. Vaccine. 2009 June 12; 27(29):3811-3820. DMPMU38 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690618/ DMPN314 DI DMPN314 DMPN314 DN SNA-120 DMPN314 TI TTTDVOJ DMPN314 TN Tropomyosin-related kinase A (TrkA) DMPN314 MA Inhibitor DMPN314 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPN314 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMPNDYU DI DMPNDYU DMPNDYU DN MEM-3454 DMPNDYU TI TTLA931 DMPNDYU TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMPNDYU MA Antagonist DMPNDYU RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMPNDYU RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMPNYXQ DI DMPNYXQ DMPNYXQ DN BIO-11006 DMPNYXQ TI TTHRM39 DMPNYXQ TN Myristoylated alanine-rich C-kinase substrate (MARCKS) DMPNYXQ MA Inhibitor DMPNYXQ RN An Inhaled Inhibitor of Myristoylated Alanine-Rich C Kinase Substrate Reverses LPS-Induced Acute Lung Injury in Mice. Am J Respir Cell Mol Biol. 2016 Nov;55(5):617-622. DMPNYXQ RU https://pubmed.ncbi.nlm.nih.gov/27556883 DMPO4M1 DI DMPO4M1 DMPO4M1 DN Paquinimod DMPO4M1 TI TT0TMQG DMPO4M1 TN Calgranulin B (S100A9) DMPO4M1 MA Inhibitor DMPO4M1 RN Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis. Ann Rheum Dis. 2015 Dec;74(12):2254-8. DMPO4M1 RU https://pubmed.ncbi.nlm.nih.gov/25969431 DMPO7UG DI DMPO7UG DMPO7UG DN AGEN2034 DMPO7UG TI TTNBFWK DMPO7UG TN Programmed cell death protein 1 (PD-1) DMPO7UG MA Inhibitor DMPO7UG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPO7UG RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMPQHOR DI DMPQHOR DMPQHOR DN AMG 208 DMPQHOR TI TTNDSF4 DMPQHOR TN Proto-oncogene c-Met (MET) DMPQHOR MA Modulator DMPQHOR RN A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30;6(21):18693-706. DMPQHOR RU https://pubmed.ncbi.nlm.nih.gov/26155941 DMPR8E9 DI DMPR8E9 DMPR8E9 DN ACP-001 DMPR8E9 TI TTT3YKH DMPR8E9 TN Somatotropin (GH1) DMPR8E9 MA Modulator DMPR8E9 RN ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health. DMPR8E9 RU https://clinicaltrials.gov/ct2/show/NCT01947907 DMPRIHK DI DMPRIHK DMPRIHK DN Anti-CD3 and anti-Her2/neu bispecific antibody-armed activated T cells DMPRIHK TI TT6EO5L DMPRIHK TN Erbb2 tyrosine kinase receptor (HER2) DMPRIHK RN Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors. J Hematother Stem Cell Res. 2001 Apr;10(2):247-60. DMPRIHK RU https://pubmed.ncbi.nlm.nih.gov/11359672 DMPRYU1 DI DMPRYU1 DMPRYU1 DN PF-04457845 DMPRYU1 TI TTDP1UC DMPRYU1 TN Fatty acid amide hydrolase (FAAH) DMPRYU1 MA Inhibitor DMPRYU1 RN Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96. DMPRYU1 RU https://pubmed.ncbi.nlm.nih.gov/21666860 DMPRZX4 DI DMPRZX4 DMPRZX4 DN LAS 100977 DMPRZX4 TI TT2CJVK DMPRZX4 TN Adrenergic receptor beta-2 (ADRB2) DMPRZX4 MA Agonist DMPRZX4 RN Pharmacological characterization of abediterol, a novel inhaled beta(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models. J Pharmacol Exp Ther. 2012 Aug;342(2):497-509. DMPRZX4 RU https://pubmed.ncbi.nlm.nih.gov/22588259 DMPSBTL DI DMPSBTL DMPSBTL DN VY-AADC DMPSBTL TI TTN451K DMPSBTL TN Aromatic-L-amino-acid decarboxylase (DDC) DMPSBTL MA Replacement DMPSBTL RN Clinical pipeline report, company report or official report of Voyager Therapeutics. DMPSBTL RU https://www.voyagertherapeutics.com/our-approach-programs/clinical-trials/ DMPSCVY DI DMPSCVY DMPSCVY DN CMX-2043 DMPSCVY TI TTWTSCV DMPSCVY TN RAC-alpha serine/threonine-protein kinase (AKT1) DMPSCVY MA Modulator DMPSCVY RN Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64. DMPSCVY RU https://pubmed.ncbi.nlm.nih.gov/24751172 DMPSCVY DI DMPSCVY DMPSCVY DN CMX-2043 DMPSCVY TI TTNDSF4 DMPSCVY TN Proto-oncogene c-Met (MET) DMPSCVY MA Modulator DMPSCVY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPSCVY RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMPUAOE DI DMPUAOE DMPUAOE DN SCH-527123 DMPUAOE TI TTBD6I7 DMPUAOE TN Mucosal addressin cell adhesion molecule 1 (MADCAM1) DMPUAOE RN Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59. DMPUAOE RU https://pubmed.ncbi.nlm.nih.gov/17355213 DMPUAOE DI DMPUAOE DMPUAOE DN SCH-527123 DMPUAOE TI TT30C9G DMPUAOE TN C-X-C chemokine receptor type 2 (CXCR2) DMPUAOE MA Modulator DMPUAOE RN CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11. DMPUAOE RU https://www.ncbi.nlm.nih.gov/pubmed/25695403 DMPUAOE DI DMPUAOE DMPUAOE DN SCH-527123 DMPUAOE TI TTMWT8Z DMPUAOE TN C-X-C chemokine receptor type 1 (CXCR1) DMPUAOE MA Antagonist DMPUAOE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPUAOE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPVAUT DI DMPVAUT DMPVAUT DN CCX872 DMPVAUT TI TTFZYTO DMPVAUT TN C-C chemokine receptor type 2 (CCR2) DMPVAUT MA Inhibitor DMPVAUT RN Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet Volume 383, Supplement 1, 26 February 2014, Pages S78. DMPVAUT RU http://www.sciencedirect.com/science/article/pii/S014067361460341X DMPVQYR DI DMPVQYR DMPVQYR DN PF-05212377 DMPVQYR TI TTJS8PY DMPVQYR TN 5-HT 6 receptor (HTR6) DMPVQYR MA Antagonist DMPVQYR RN PF-05212377 Alzheimer's Disease (Phase 2). Pfizer. DMPVQYR RU http://www.alzforum.org/therapeutics/pf-05212377 DMPW0UL DI DMPW0UL DMPW0UL DN SYN-120 DMPW0UL TI TTJS8PY DMPW0UL TN 5-HT 6 receptor (HTR6) DMPW0UL MA Antagonist DMPW0UL RN The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168. DMPW0UL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268149/ DMPW28M DI DMPW28M DMPW28M DN PD-200390 DMPW28M TI TT729IR DMPW28M TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMPW28M MA Modulator DMPW28M RN Pfizer. Product Development Pipeline. March 31 2009. DMPW28M RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMPWSBL DI DMPWSBL DMPWSBL DN ALD-518 DMPWSBL TI TTT1V78 DMPWSBL TN Interleukin-6 (IL6) DMPWSBL MA Modulator DMPWSBL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMPWSBL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMPXH7N DI DMPXH7N DMPXH7N DN FKW00GA DMPXH7N TI TTJQOD7 DMPXH7N TN 5-HT 2A receptor (HTR2A) DMPXH7N MA Antagonist DMPXH7N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPXH7N RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMPXH7N DI DMPXH7N DMPXH7N DN FKW00GA DMPXH7N TI TTSQIFT DMPXH7N TN 5-HT 1A receptor (HTR1A) DMPXH7N MA Antagonist DMPXH7N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPXH7N RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMPXK27 DI DMPXK27 DMPXK27 DN PBI-4050 DMPXK27 TI TTB8FUC DMPXK27 TN Free fatty acid receptor 1 (GPR40) DMPXK27 MA Agonist DMPXK27 RN Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663. DMPXK27 RU https://pubmed.ncbi.nlm.nih.gov/30578394 DMPXK27 DI DMPXK27 DMPXK27 DN PBI-4050 DMPXK27 TI TTG0MQD DMPXK27 TN Inflammation-related GPCR EX33 (GPR84) DMPXK27 MA Antagonist DMPXK27 RN Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663. DMPXK27 RU https://pubmed.ncbi.nlm.nih.gov/30578394 DMPZ67G DI DMPZ67G DMPZ67G DN SDZ-281-240 DMPZ67G TI TTMW94E DMPZ67G TN FK506-binding protein 1A (FKBP1A) DMPZ67G MA Modulator DMPZ67G RN Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol. 1996 Apr;106(4):701-10. DMPZ67G RU https://pubmed.ncbi.nlm.nih.gov/8618008 DMPZ97S DI DMPZ97S DMPZ97S DN NNZ-2566 DMPZ97S TI TT9RTYG DMPZ97S TN Neuropeptide receptor (NPR) DMPZ97S MA Modulator DMPZ97S RN NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. J Neuroinflammation. 2009 Aug 5;6:19. DMPZ97S RU https://pubmed.ncbi.nlm.nih.gov/19656406 DMQ08AJ DI DMQ08AJ DMQ08AJ DN Edotreotide DMQ08AJ TI TTOMNR9 DMQ08AJ TN Somatostatin receptor (SSTR) DMQ08AJ MA Modulator DMQ08AJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQ08AJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQ0XZE DI DMQ0XZE DMQ0XZE DN GI-4000 + gemcitabine DMQ0XZE TI TTRHMTC DMQ0XZE TN Mutated KRAS (mKRAS) DMQ0XZE MA Modulator DMQ0XZE RN Clinical pipeline report, company report or official report of GlobeImmune. DMQ0XZE RU https://www.globeimmune.com/cancer/gi-4000/ DMQ1GH4 DI DMQ1GH4 DMQ1GH4 DN AEF0117 DMQ1GH4 TI TT6OEDT DMQ1GH4 TN Cannabinoid receptor 1 (CB1) DMQ1GH4 MA Antagonist DMQ1GH4 RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMQ1GH4 RU https://brain.labex.u-bordeaux.fr/Actions/Focus/CannaPreg-i6901.html DMQ2O8V DI DMQ2O8V DMQ2O8V DN CHF-3381 DMQ2O8V TI TTGP7BY DMQ2O8V TN Monoamine oxidase type B (MAO-B) DMQ2O8V MA Inhibitor DMQ2O8V RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQ2O8V RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQ2O8V DI DMQ2O8V DMQ2O8V DN CHF-3381 DMQ2O8V TI TT9IK2Z DMQ2O8V TN N-methyl-D-aspartate receptor (NMDAR) DMQ2O8V MA Antagonist DMQ2O8V RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQ2O8V RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQ2O8V DI DMQ2O8V DMQ2O8V DN CHF-3381 DMQ2O8V TI TT3WG5C DMQ2O8V TN Monoamine oxidase type A (MAO-A) DMQ2O8V MA Inhibitor DMQ2O8V RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQ2O8V RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQ30X2 DI DMQ30X2 DMQ30X2 DN HQP1351 DMQ30X2 TI TTS7G69 DMQ30X2 TN Fusion protein Bcr-Abl (Bcr-Abl) DMQ30X2 MA Inhibitor DMQ30X2 RN Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci. 2019 Oct 26;9:88. DMQ30X2 RU https://pubmed.ncbi.nlm.nih.gov/31673329 DMQ3C05 DI DMQ3C05 DMQ3C05 DN ISIS-APO(a) DMQ3C05 TI TTU9LGY DMQ3C05 TN Apolipoprotein A messenger RNA (LPA mRNA) DMQ3C05 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMQ3C05 RU https://www.isispharm.com/pipeline/isis-apoarx/ DMQ3RWN DI DMQ3RWN DMQ3RWN DN Iralukast DMQ3RWN TI TTGKOY9 DMQ3RWN TN Leukotriene CysLT1 receptor (CYSLTR1) DMQ3RWN MA Modulator DMQ3RWN RN Pharmacological characterization of the cysteinyl-leukotriene antagonists CGP 45715A (iralukast) and CGP 57698 in human airways in vitro. Br J Pharmacol. 1998 Feb;123(3):590-8. DMQ3RWN RU https://pubmed.ncbi.nlm.nih.gov/9504401 DMQ47U6 DI DMQ47U6 DMQ47U6 DN CR8020 DMQ47U6 TI TTF4CAM DMQ47U6 TN Influenza Hemagglutinin (Influ HA) DMQ47U6 RN Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014 Dec;88(23):13580-92. DMQ47U6 RU https://pubmed.ncbi.nlm.nih.gov/25210195 DMQ58YH DI DMQ58YH DMQ58YH DN Anti-LT alpha DMQ58YH TI TTP73TM DMQ58YH TN Lymphotoxin-alpha (LTA) DMQ58YH RN Clinical pipeline report, company report or official report of Genentech (2011). DMQ58YH RU http://www.gene.com/gene/index.jsp DMQ6ANE DI DMQ6ANE DMQ6ANE DN TGOF02N DMQ6ANE TI TTYSN63 DMQ6ANE TN 5-HT 2 receptor (5HT2R) DMQ6ANE MA Modulator DMQ6ANE RN Clinical pipeline report, company report or official report of Fabre-Kramer Pharmaceuticals. DMQ6ANE RU http://www.fabrekramer.com/?page_id=76 DMQ6KZM DI DMQ6KZM DMQ6KZM DN ABI-009 DMQ6KZM TI TTCJG29 DMQ6KZM TN Serine/threonine-protein kinase mTOR (mTOR) DMQ6KZM MA Inhibitor DMQ6KZM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ6KZM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQ73AY DI DMQ73AY DMQ73AY DN Reovirus DMQ73AY TI TTW2R9X DMQ73AY TN GTPase NRas (NRAS) DMQ73AY MA Modulator DMQ73AY RN Reovirus (Reolysin) as a potential therapy for malignant peripheral nerve sheath tumors. DMQ73AY RU http://cancerres.aacrjournals.org/content/72/8_Supplement/2488.short DMQ7UL8 DI DMQ7UL8 DMQ7UL8 DN Camostat DMQ7UL8 TI TTEMV5X DMQ7UL8 TN Serine protease unspecific (SP) DMQ7UL8 MA Inhibitor DMQ7UL8 RN Camostat mesilate inhibits prostasin activity and reduces blood pressure and renal injury in salt-sensitive hypertension. J Hypertens. 2009 Jan;27(1):181-9. DMQ7UL8 RU https://pubmed.ncbi.nlm.nih.gov/19145783 DMQ874W DI DMQ874W DMQ874W DN CC-1088 DMQ874W TI TTVIAT9 DMQ874W TN Phosphodiesterase 4B (PDE4B) DMQ874W MA Inhibitor DMQ874W RN Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. DMQ874W RU https://pubmed.ncbi.nlm.nih.gov/9873600 DMQ874W DI DMQ874W DMQ874W DN CC-1088 DMQ874W TI TTSKMI8 DMQ874W TN Phosphodiesterase 4D (PDE4D) DMQ874W MA Inhibitor DMQ874W RN Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. DMQ874W RU https://pubmed.ncbi.nlm.nih.gov/9873600 DMQ874W DI DMQ874W DMQ874W DN CC-1088 DMQ874W TI TTZ97H5 DMQ874W TN Phosphodiesterase 4A (PDE4A) DMQ874W MA Inhibitor DMQ874W RN Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2669-74. DMQ874W RU https://pubmed.ncbi.nlm.nih.gov/9873600 DMQ8J0U DI DMQ8J0U DMQ8J0U DN Basmisanil DMQ8J0U TI TTNZPQ1 DMQ8J0U TN GABA(A) receptor alpha-5 (GABRA5) DMQ8J0U MA Modulator DMQ8J0U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ8J0U RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMQ8K93 DI DMQ8K93 DMQ8K93 DN RFT-5.dgA DMQ8K93 TI TT10Y9E DMQ8K93 TN Interleukin 2 receptor alpha (IL2RA) DMQ8K93 MA Modulator DMQ8K93 RN Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol. 2003 May;14(5):729-36. DMQ8K93 RU https://www.ncbi.nlm.nih.gov/pubmed/12702527 DMQA3MV DI DMQA3MV DMQA3MV DN MNX-100 DMQA3MV TI TT2MN5K DMQA3MV TN Phosphorylated protein kinase B (pAKT) DMQA3MV MA Modulator DMQA3MV RN Clinical pipeline report, company report or official report of MetronomX. DMQA3MV RU http://www.metronomxgroup.com/mnx-100.php DMQBP7R DI DMQBP7R DMQBP7R DN CAT 1004 DMQBP7R TI TTUIZKC DMQBP7R TN DNA-binding factor KBF1 (p105) DMQBP7R MA Inhibitor DMQBP7R RN Clinical pipeline report, company report or official report of Catabasis Pharmaceuticals Inc. DMQBP7R RU http://www.catabasis.com/clinical-trials-cat-1004-movedmd.php DMQBP7R DI DMQBP7R DMQBP7R DN CAT 1004 DMQBP7R TI TTSXVID DMQBP7R TN Nuclear factor NF-kappa-B (NFKB) DMQBP7R MA Inhibitor DMQBP7R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQBP7R RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMQCFSM DI DMQCFSM DMQCFSM DN BGB-3112 DMQCFSM TI TTGM6VW DMQCFSM TN Tyrosine-protein kinase BTK (ATK) DMQCFSM MA Inhibitor DMQCFSM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQCFSM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQD1GN DI DMQD1GN DMQD1GN DN JNJ-32729463 DMQD1GN TI TTN6J5F DMQD1GN TN Bacterial DNA gyrase (Bact gyrase) DMQD1GN MA Inhibitor DMQD1GN RN Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. DMQD1GN RU https://pubmed.ncbi.nlm.nih.gov/21911562 DMQD1GN DI DMQD1GN DMQD1GN DN JNJ-32729463 DMQD1GN TI TTFK8YB DMQD1GN TN Bacterial DNA topoisomerase 4A (Bact parC) DMQD1GN MA Inhibitor DMQD1GN RN Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. DMQD1GN RU https://pubmed.ncbi.nlm.nih.gov/21911562 DMQD5NA DI DMQD5NA DMQD5NA DN TD-9855 DMQD5NA TI TTAWNKZ DMQD5NA TN Norepinephrine transporter (NET) DMQD5NA MA Modulator DMQD5NA RN Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. DMQD5NA RU https://pubmed.ncbi.nlm.nih.gov/25522383 DMQD5NA DI DMQD5NA DMQD5NA DN TD-9855 DMQD5NA TI TT3ROYC DMQD5NA TN Serotonin transporter (SERT) DMQD5NA MA Modulator DMQD5NA RN Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027. DMQD5NA RU https://pubmed.ncbi.nlm.nih.gov/25522383 DMQD753 DI DMQD753 DMQD753 DN SUVN-502 DMQD753 TI TTJS8PY DMQD753 TN 5-HT 6 receptor (HTR6) DMQD753 MA Antagonist DMQD753 RN Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344. DMQD753 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007800/ DMQDLVW DI DMQDLVW DMQDLVW DN KRP-104 DMQDLVW TI TTDIGC1 DMQDLVW TN Dipeptidyl peptidase 4 (DPP-4) DMQDLVW MA Modulator DMQDLVW RN Clinical pipeline report, company report or official report of Activx. DMQDLVW RU http://www.activx.com/press/news_20080821.html DMQEC9P DI DMQEC9P DMQEC9P DN GW-870086-X DMQEC9P TI TTYRL6O DMQEC9P TN Glucocorticoid receptor (NR3C1) DMQEC9P MA Agonist DMQEC9P RN Unique response profile of trabecular meshwork cells to the novel selective glucocorticoid receptor agonist, GW870086X. Invest Ophthalmol Vis Sci. 2013 Mar 1;54(3):2100-7. DMQEC9P RU https://pubmed.ncbi.nlm.nih.gov/23462748 DMQERC6 DI DMQERC6 DMQERC6 DN E5555 DMQERC6 TI TTL935N DMQERC6 TN Proteinase activated receptor 1 (F2R) DMQERC6 MA Antagonist DMQERC6 RN Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53. DMQERC6 RU https://pubmed.ncbi.nlm.nih.gov/21502577 DMQFU1R DI DMQFU1R DMQFU1R DN Anti-M1 prime DMQFU1R TI TTA5LWY DMQFU1R TN M1-prime segment of membrane-expressed IgE (M1 IgE) DMQFU1R RN Clinical pipeline report, company report or official report of Genentech (2011). DMQFU1R RU http://www.gene.com/gene/index.jsp DMQGBM1 DI DMQGBM1 DMQGBM1 DN EVT-201 DMQGBM1 TI TTEX6LM DMQGBM1 TN GABA(A) receptor gamma-3 (GABRG3) DMQGBM1 MA Modulator DMQGBM1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMQGBM1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMQGBM1 DI DMQGBM1 DMQGBM1 DN EVT-201 DMQGBM1 TI TT1MPAY DMQGBM1 TN GABA(A) receptor alpha-1 (GABRA1) DMQGBM1 MA Modulator DMQGBM1 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMQGBM1 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMQGI73 DI DMQGI73 DMQGI73 DN AVI-4557 DMQGI73 TI TTWP7HQ DMQGI73 TN CYP3A4 messenger RNA (CYP3A4 mRNA) DMQGI73 RN Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos. 2002 Jul;30(7):757-62. DMQGI73 RU https://pubmed.ncbi.nlm.nih.gov/12065433 DMQGI8R DI DMQGI8R DMQGI8R DN CD20 CAR T cells DMQGI8R TI TTUE541 DMQGI8R TN Leukocyte surface antigen Leu-16 (CD20) DMQGI8R MA CAR-T-Cell-Therapy DMQGI8R RN ClinicalTrials.gov (NCT02846584) a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies DMQGI8R RU https://clinicaltrials.gov/ct2/show/NCT02846584 DMQGO74 DI DMQGO74 DMQGO74 DN ONO-3307 DMQGO74 TI TTZBFA0 DMQGO74 TN Protease unspecific (PRO) DMQGO74 MA Modulator DMQGO74 RN Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63. DMQGO74 RU https://pubmed.ncbi.nlm.nih.gov/2515329 DMQGPLO DI DMQGPLO DMQGPLO DN GSK-1070806 DMQGPLO TI TTRICUF DMQGPLO TN Interleukin-18 (IL18) DMQGPLO RN Targeting the IL-1 family members in skin inflammation. Curr Opin Investig Drugs. 2010 November; 11(11): 1211-1220. DMQGPLO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059231/ DMQH1NV DI DMQH1NV DMQH1NV DN Emivirine DMQH1NV TI TT84ETX DMQH1NV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQH1NV MA Modulator DMQH1NV RN Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.Clin Ther.2009 Apr;31(4):692-704. DMQH1NV RU https://www.ncbi.nlm.nih.gov/pubmed/19446143 DMQH2SF DI DMQH2SF DMQH2SF DN IPH4102 DMQH2SF TI TTQH3N0 DMQH2SF TN MHC class I NK cell receptor 3DL2 (CD158k) DMQH2SF MA Antagonist DMQH2SF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQH2SF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQHBSX DI DMQHBSX DMQHBSX DN NITD609 DMQHBSX TI TTJFY5U DMQHBSX TN Adenosine A3 receptor (ADORA3) DMQHBSX MA Inhibitor DMQHBSX RN Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80. DMQHBSX RU https://pubmed.ncbi.nlm.nih.gov/20813948 DMQHBSX DI DMQHBSX DMQHBSX DN NITD609 DMQHBSX TI TTQ6VDM DMQHBSX TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMQHBSX MA Inhibitor DMQHBSX RN Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80. DMQHBSX RU https://pubmed.ncbi.nlm.nih.gov/20813948 DMQHS6B DI DMQHS6B DMQHS6B DN MK-866 DMQHS6B TI TT2J34L DMQHS6B TN Arachidonate 5-lipoxygenase (5-LOX) DMQHS6B MA Modulator DMQHS6B RN Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats DMQHS6B RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1574003 DMQI43G DI DMQI43G DMQI43G DN BMS 650032 DMQI43G TI TT5FNQT DMQI43G TN Human immunodeficiency virus Protease (HIV PR) DMQI43G MA Inhibitor DMQI43G RN 2011 Pipeline of Bristol-Myers Squibb. DMQI43G RU http://www.bms.com/pages/default.aspx DMQJ5DV DI DMQJ5DV DMQJ5DV DN ATN-224 DMQJ5DV TI TT6RVLG DMQJ5DV TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMQJ5DV MA Inhibitor DMQJ5DV RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DMQJ5DV RU https://pubmed.ncbi.nlm.nih.gov/16914587 DMQJBUK DI DMQJBUK DMQJBUK DN CD19-targeting CAR T cells DMQJBUK TI TTW640A DMQJBUK TN B-lymphocyte surface antigen B4 (CD19) DMQJBUK MA CAR-T-Cell-Therapy DMQJBUK RN ClinicalTrials.gov (NCT02132624) CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. DMQJBUK RU https://clinicaltrials.gov/ct2/show/NCT02132624 DMQKSGI DI DMQKSGI DMQKSGI DN Myo-inositol DMQKSGI TI TTI0TCK DMQKSGI TN Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA) DMQKSGI MA Inhibitor DMQKSGI RN Phosphatidylinositol synthesis in mycobacteria. Biochim Biophys Acta. 1999 Jan 4;1436(3):437-50. DMQKSGI RU https://pubmed.ncbi.nlm.nih.gov/9989274 DMQKSGI DI DMQKSGI DMQKSGI DN Myo-inositol DMQKSGI TI TTE4KHA DMQKSGI TN Amyloid beta A4 protein (APP) DMQKSGI MA Inhibitor DMQKSGI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQKSGI RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMQKU2F DI DMQKU2F DMQKU2F DN DWP-05195 DMQKU2F TI TTMI6F5 DMQKU2F TN Transient receptor potential cation channel V1 (TRPV1) DMQKU2F MA Antagonist DMQKU2F RN TRPV1 Antagonists as Analgesic Agents. The Open Pain Journal, 2013, 6, (Suppl 1: M11), 108-118 . DMQKU2F RU http://benthamopen.com/contents/pdf/TOPAINJ/TOPAINJ-6-108.pdf DMQKZDT DI DMQKZDT DMQKZDT DN Talnetant DMQKZDT TI TTBPGLU DMQKZDT TN Neuromedin-K receptor (TACR3) DMQKZDT MA Antagonist DMQKZDT RN Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67. DMQKZDT RU https://pubmed.ncbi.nlm.nih.gov/19540857 DMQL3VS DI DMQL3VS DMQL3VS DN BMS-275183 DMQL3VS TI TTML2WA DMQL3VS TN Tubulin (TUB) DMQL3VS MA Inhibitor DMQL3VS RN A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Invest New Drugs. 2011 Dec;29(6):1426-31. DMQL3VS RU https://pubmed.ncbi.nlm.nih.gov/20680660 DMQLZOF DI DMQLZOF DMQLZOF DN PF-06252616 DMQLZOF TI TTSWPH8 DMQLZOF TN Growth/differentiation factor 8 (GDF-8) DMQLZOF RN Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. DMQLZOF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/ DMQM3IX DI DMQM3IX DMQM3IX DN SELODENOSON DMQM3IX TI TTK25J1 DMQM3IX TN Adenosine A1 receptor (ADORA1) DMQM3IX MA Agonist DMQM3IX RN Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308. DMQM3IX RU https://pubmed.ncbi.nlm.nih.gov/21185259 DMQM7IL DI DMQM7IL DMQM7IL DN SAR245409 DMQM7IL TI TTHBTOP DMQM7IL TN PI3-kinase gamma (PIK3CG) DMQM7IL MA Inhibitor DMQM7IL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156). DMQM7IL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156 DMQM7IL DI DMQM7IL DMQM7IL DN SAR245409 DMQM7IL TI TTCJG29 DMQM7IL TN Serine/threonine-protein kinase mTOR (mTOR) DMQM7IL MA Inhibitor DMQM7IL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMQM7IL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMQMF4O DI DMQMF4O DMQMF4O DN PF-04937319 DMQMF4O TI TTDLNGZ DMQMF4O TN Glucokinase (GCK) DMQMF4O MA Modulator DMQMF4O RN Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes. Diabetes Obes Metab. 2015 Aug;17(8):751-9. DMQMF4O RU https://pubmed.ncbi.nlm.nih.gov/25885172 DMQMTO1 DI DMQMTO1 DMQMTO1 DN MBX-2044 DMQMTO1 TI TTZMAO3 DMQMTO1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMQMTO1 MA Agonist DMQMTO1 RN MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol. 2009 Jul;23(7):975-88. DMQMTO1 RU https://pubmed.ncbi.nlm.nih.gov/19389808 DMQMV9F DI DMQMV9F DMQMV9F DN Apaxifylline DMQMV9F TI TTK25J1 DMQMV9F TN Adenosine A1 receptor (ADORA1) DMQMV9F MA Antagonist DMQMV9F RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779) DMQMV9F RU http://adisinsight.springer.com/drugs/800004779 DMQMYP5 DI DMQMYP5 DMQMYP5 DN VOFOPITANT HYDROCHLORIDE DMQMYP5 TI TTZPO1L DMQMYP5 TN Substance-P receptor (TACR1) DMQMYP5 MA Antagonist DMQMYP5 RN Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58. DMQMYP5 RU https://pubmed.ncbi.nlm.nih.gov/19428297 DMQO2IT DI DMQO2IT DMQO2IT DN G1T38 DMQO2IT TI TT0PG8F DMQO2IT TN Cyclin-dependent kinase 4 (CDK4) DMQO2IT MA Inhibitor DMQO2IT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQO2IT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQO2IT DI DMQO2IT DMQO2IT DN G1T38 DMQO2IT TI TTO0FDJ DMQO2IT TN Cyclin-dependent kinase 6 (CDK6) DMQO2IT MA Inhibitor DMQO2IT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQO2IT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQOBH4 DI DMQOBH4 DMQOBH4 DN mab 1-7F9 DMQOBH4 TI TTU0P73 DMQOBH4 TN MHC class I NK cell receptor 2DL2 (CD158b1) DMQOBH4 RN Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. DMQOBH4 RU https://pubmed.ncbi.nlm.nih.gov/19561305 DMQOBH4 DI DMQOBH4 DMQOBH4 DN mab 1-7F9 DMQOBH4 TI TT4UXPE DMQOBH4 TN MHC class I NK cell receptor 2DL1 (CD158A) DMQOBH4 RN Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. DMQOBH4 RU https://pubmed.ncbi.nlm.nih.gov/19561305 DMQOBH4 DI DMQOBH4 DMQOBH4 DN mab 1-7F9 DMQOBH4 TI TTEX3SI DMQOBH4 TN MHC class I NK cell receptor 2DL3 (CD158b2) DMQOBH4 RN Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84. DMQOBH4 RU https://pubmed.ncbi.nlm.nih.gov/19561305 DMQOTHP DI DMQOTHP DMQOTHP DN AZD9833 DMQOTHP TI TTZAYWL DMQOTHP TN Estrogen receptor (ESR) DMQOTHP MA Degrader DMQOTHP RN Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist. J Med Chem. 2020 Dec 10;63(23):14530-14559. DMQOTHP RU https://pubmed.ncbi.nlm.nih.gov/32910656 DMQOXNL DI DMQOXNL DMQOXNL DN LMB763 DMQOXNL TI TTS4UGC DMQOXNL TN Farnesoid X-activated receptor (FXR) DMQOXNL MA Agonist DMQOXNL RN Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880. DMQOXNL RU https://pubmed.ncbi.nlm.nih.gov/31940200 DMQR23W DI DMQR23W DMQR23W DN MRE-0094 DMQR23W TI TTM2AOE DMQR23W TN Adenosine A2a receptor (ADORA2A) DMQR23W MA Agonist DMQR23W RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMQR23W RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMQR9I8 DI DMQR9I8 DMQR9I8 DN G-202 DMQR9I8 TI TT9G4N0 DMQR9I8 TN Glutamate carboxypeptidase II (GCPII) DMQR9I8 MA Inhibitor DMQR9I8 RN National Cancer Institute Drug Dictionary (drug id 666090). DMQR9I8 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=666090 DMQRCX5 DI DMQRCX5 DMQRCX5 DN DCDS-4501A DMQRCX5 TI TTBN5I7 DMQRCX5 TN B-cell-specific glycoprotein B29 (CD79B) DMQRCX5 RN Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278. DMQRCX5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/ DMQSA7H DI DMQSA7H DMQSA7H DN Interferon beta 1a DMQSA7H TI TT4TZ8J DMQSA7H TN Interferon-beta (IFNB1) DMQSA7H MA Modulator DMQSA7H RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMQSA7H RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMQSC5O DI DMQSC5O DMQSC5O DN Varlilumab DMQSC5O TI TTDO1MV DMQSC5O TN T-cell activation antigen CD27 (CD27) DMQSC5O MA Inhibitor DMQSC5O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQSC5O RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMQSIY1 DI DMQSIY1 DMQSIY1 DN CLS003 DMQSIY1 TI TTL3N71 DMQSIY1 TN Virus Replication (Viru Repli) DMQSIY1 MA Inhibitor DMQSIY1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQSIY1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQSN7B DI DMQSN7B DMQSN7B DN SR-31747 DMQSN7B TI TT4VQZX DMQSN7B TN Cholestenol delta-isomerase (EBP) DMQSN7B MA Modulator DMQSN7B RN Both the immunosuppressant SR31747 and the antiestrogen tamoxifen bind to an emopamil-insensitive site of mammalian Delta8-Delta7 sterol isomerase. J Pharmacol Exp Ther. 1998 Jun;285(3):1296-302. DMQSN7B RU https://pubmed.ncbi.nlm.nih.gov/9618436 DMQSO4L DI DMQSO4L DMQSO4L DN ML-04 DMQSO4L TI TT2O4W9 DMQSO4L TN Luteinizing hormone receptor (LHCGR) DMQSO4L MA Modulator DMQSO4L RN Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol. 2007 Jan;34(1):55-70. DMQSO4L RU https://pubmed.ncbi.nlm.nih.gov/17210462 DMQTREC DI DMQTREC DMQTREC DN Her2-targeted autologous T-cell therapy DMQTREC TI TT6EO5L DMQTREC TN Erbb2 tyrosine kinase receptor (HER2) DMQTREC MA Inhibitor DMQTREC RN A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res. 2014;2014:326545. DMQTREC RU https://pubmed.ncbi.nlm.nih.gov/25009822 DMQUWXY DI DMQUWXY DMQUWXY DN CRLX101 DMQUWXY TI TTGTQHC DMQUWXY TN DNA topoisomerase I (TOP1) DMQUWXY MA Modulator DMQUWXY RN Company report (Ceruleanrx) DMQUWXY RU http://ceruleanrx.com/platform-pipeline/crlx101.php DMQV1OU DI DMQV1OU DMQV1OU DN LY-2875358 DMQV1OU TI TTNDSF4 DMQV1OU TN Proto-oncogene c-Met (MET) DMQV1OU RN Clinical pipeline report, company report or official report of Eli Lilly. DMQV1OU RU http://www.lillyoncologypipeline.com/met-antibody.aspx DMQVC3E DI DMQVC3E DMQVC3E DN Salvianolic acid B DMQVC3E TI TTZHNQA DMQVC3E TN Insulin-like growth factor-binding protein 3 (IGFBP3) DMQVC3E MA Inhibitor DMQVC3E RN Salvianolic acid B improves myocardial function in diabetic cardiomyopathy by suppressing IGFBP3. J Mol Cell Cardiol. 2020 Feb;139:98-112. DMQVC3E RU https://pubmed.ncbi.nlm.nih.gov/31982427 DMQVN6P DI DMQVN6P DMQVN6P DN K-604 DMQVN6P TI TTMF541 DMQVN6P TN Liver carboxylesterase (CES1) DMQVN6P MA Inhibitor DMQVN6P RN A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis. 2007 Apr;191(2):290-7. DMQVN6P RU https://pubmed.ncbi.nlm.nih.gov/16820149 DMQX5UA DI DMQX5UA DMQX5UA DN FLX-787 DMQX5UA TI TTFRV98 DMQX5UA TN Melanoma antigen gp75 (TYRP1) DMQX5UA MA Activator DMQX5UA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQX5UA RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQX5UA DI DMQX5UA DMQX5UA DN FLX-787 DMQX5UA TI TT79AOF DMQX5UA TN Transient receptor potential channel (TRP channel) DMQX5UA MA Agonist DMQX5UA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQX5UA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQXL1T DI DMQXL1T DMQXL1T DN CT 327 DMQXL1T TI TTTDVOJ DMQXL1T TN Tropomyosin-related kinase A (TrkA) DMQXL1T MA Inhibitor DMQXL1T RN Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis. Acta Derm Venereol. 2015 May;95(5):542-8. DMQXL1T RU https://pubmed.ncbi.nlm.nih.gov/25594427 DMQXYRG DI DMQXYRG DMQXYRG DN 9-AMINOCAMPTOTHECIN DMQXYRG TI TTGTQHC DMQXYRG TN DNA topoisomerase I (TOP1) DMQXYRG MA Inhibitor DMQXYRG RN Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin. Ann N Y Acad Sci. 2000;922:178-87. DMQXYRG RU https://pubmed.ncbi.nlm.nih.gov/11193893 DMQZ5HF DI DMQZ5HF DMQZ5HF DN KNI-272 DMQZ5HF TI TT5FNQT DMQZ5HF TN Human immunodeficiency virus Protease (HIV PR) DMQZ5HF MA Modulator DMQZ5HF RN Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activit... Antimicrob Agents Chemother. 2002 Feb;46(2):402-8. DMQZ5HF RU https://www.ncbi.nlm.nih.gov/pubmed/11796349 DMQZJNA DI DMQZJNA DMQZJNA DN LCAR-B38M CAR-T Cell DMQZJNA TI TTZ3P4W DMQZJNA TN B-cell maturation protein (TNFRSF17) DMQZJNA MA CAR-T-Cell-Therapy DMQZJNA RN ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma DMQZJNA RU https://clinicaltrials.gov/ct2/show/NCT03758417 DMQZWYE DI DMQZWYE DMQZWYE DN MRX-4 DMQZWYE TI TT9V5JH DMQZWYE TN Phospholipase A2 (PLA2G1B) DMQZWYE MA Inhibitor DMQZWYE RN Phospholipase A2, group IVA (cytosolic, calcium-dependent) (PLA2G4A). SciBX 1(41); doi:10.1038/scibx.2008.999. Nov. 13 2008 DMQZWYE RU http://www.nature.com/scibx/journal/v1/n41/full/scibx.2008.999.html DMQZXDW DI DMQZXDW DMQZXDW DN Lum001 DMQZXDW TI TTPI1M5 DMQZXDW TN Ileal sodium/bile acid cotransporter (SLC10A2) DMQZXDW MA Inhibitor DMQZXDW RN Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb; 4(1): 1-6. DMQZXDW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322589/ DMQZXDW DI DMQZXDW DMQZXDW DN Lum001 DMQZXDW TI TTWZRY5 DMQZXDW TN Sodium/bile acid cotransporter (SLC10A1) DMQZXDW MA Inhibitor DMQZXDW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQZXDW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMR09IH DI DMR09IH DMR09IH DN SRP-9001 DMR09IH TI TT48MP6 DMR09IH TN Dystrophin (DMD) DMR09IH MA Replacement DMR09IH RN Clinical pipeline report, company report or official report of Sarepta Therapeutics. DMR09IH RU https://www.sarepta.com/products-pipeline/pipeline DMR0N74 DI DMR0N74 DMR0N74 DN LAM-002 DMR0N74 TI TTA4M1N DMR0N74 TN Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) DMR0N74 MA Inhibitor DMR0N74 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR0N74 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR1MIV DI DMR1MIV DMR1MIV DN ASP8062 DMR1MIV TI TTDCVZW DMR1MIV TN Gamma-aminobutyric acid B receptor (GABBR) DMR1MIV MA Modulator DMR1MIV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR1MIV RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMR1MQW DI DMR1MQW DMR1MQW DN Lenzilumab DMR1MQW TI TTNYZG2 DMR1MQW TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMR1MQW MA Antagonist DMR1MQW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR1MQW RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMR2YPF DI DMR2YPF DMR2YPF DN ALG-1001 DMR2YPF TI TT9HKJA DMR2YPF TN Vascular endothelial growth factor (VEGF) DMR2YPF MA Modulator DMR2YPF RN Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070. DMR2YPF RU https://pubmed.ncbi.nlm.nih.gov/25802751 DMR37X8 DI DMR37X8 DMR37X8 DN TTP-448 DMR37X8 TI TTMO9HF DMR37X8 TN Advanced glycosylation end product receptor (AGER) DMR37X8 MA Modulator DMR37X8 RN Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease. Expert Opin Investig Drugs. 2015 Mar;24(3):393-9. DMR37X8 RU https://pubmed.ncbi.nlm.nih.gov/25586103 DMR3952 DI DMR3952 DMR3952 DN FBS-0701 DMR3952 TI TTQO71U DMR3952 TN Hemoglobin (HB) DMR3952 MA Modulator DMR3952 RN A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 1;15(23):7144-52. DMR3952 RU https://pubmed.ncbi.nlm.nih.gov/22919029 DMR3P98 DI DMR3P98 DMR3P98 DN ORG 34517/34850 DMR3P98 TI TTYRL6O DMR3P98 TN Glucocorticoid receptor (NR3C1) DMR3P98 MA Antagonist DMR3P98 RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMR3P98 RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMR3P98 DI DMR3P98 DMR3P98 DN ORG 34517/34850 DMR3P98 TI TTBFROQ DMR3P98 TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMR3P98 MA Inhibitor DMR3P98 RN A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer. 2000 Sep;83(5):594-601. DMR3P98 RU https://pubmed.ncbi.nlm.nih.gov/10944598 DMR4YEG DI DMR4YEG DMR4YEG DN Tesidolumab DMR4YEG TI TTKANGO DMR4YEG TN Complement C5 (CO5) DMR4YEG MA Inhibitor DMR4YEG RN Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant. 2020 Sep;20(9):2581-2588. DMR4YEG RU https://pubmed.ncbi.nlm.nih.gov/32301258 DMR50I7 DI DMR50I7 DMR50I7 DN Elsamitrucin DMR50I7 TI TT0IHXV DMR50I7 TN DNA topoisomerase II (TOP2) DMR50I7 MA Modulator DMR50I7 RN Elsamicin A binding to DNA. A comparative thermodynamic characterization. FEBS Lett. 2004 Oct 8;576(1-2):68-72. DMR50I7 RU https://pubmed.ncbi.nlm.nih.gov/15474012 DMR59I4 DI DMR59I4 DMR59I4 DN BBI-5000 DMR59I4 TI TTQDMX5 DMR59I4 TN Prostaglandin D2 receptor 2 (PTGDR2) DMR59I4 MA Antagonist DMR59I4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR59I4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMR5GSB DI DMR5GSB DMR5GSB DN Tetrahydrouridine DMR5GSB TI TTQ12RK DMR5GSB TN Cytidine deaminase (CDA) DMR5GSB MA Modulator DMR5GSB RN Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels. PLoS One. 2012;7(5):e37424. DMR5GSB RU https://pubmed.ncbi.nlm.nih.gov/22616006 DMR5J6K DI DMR5J6K DMR5J6K DN DAPITANT DMR5J6K TI TTZPO1L DMR5J6K TN Substance-P receptor (TACR1) DMR5J6K MA Antagonist DMR5J6K RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004225) DMR5J6K RU http://adisinsight.springer.com/drugs/800004225 DMR69CG DI DMR69CG DMR69CG DN XEN-402 DMR69CG TI TT4G2JS DMR69CG TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMR69CG MA Inhibitor DMR69CG RN Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5. DMR69CG RU https://pubmed.ncbi.nlm.nih.gov/22035805 DMR6USG DI DMR6USG DMR6USG DN PELITREXOL DMR6USG TI TTEXB9Z DMR6USG TN Glycinamide ribonucleotide formyltransferase (GART) DMR6USG MA Inhibitor DMR6USG RN Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors. J Clin Oncol (Meeting Abstracts) July 2004 vol. 22 no. 14_suppl 3075. DMR6USG RU http://meeting.ascopubs.org/cgi/content/short/22/14_suppl/3075 DMR7H2V DI DMR7H2V DMR7H2V DN PRX-08066 DMR7H2V TI TT0K1SC DMR7H2V TN 5-HT 2B receptor (HTR2B) DMR7H2V MA Antagonist DMR7H2V RN Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. DMR7H2V RU https://pubmed.ncbi.nlm.nih.gov/17064221 DMR8W7Y DI DMR8W7Y DMR8W7Y DN AKCEA-ANGPTL3-LRX DMR8W7Y TI TTUO98L DMR8W7Y TN Angiopoietin-related protein 3 (ANGPTL3) DMR8W7Y MA Inhibitor DMR8W7Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR8W7Y RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMR8Y4F DI DMR8Y4F DMR8Y4F DN Troplasminogen alfa DMR8Y4F TI TTP86E2 DMR8Y4F TN Plasminogen (PLG) DMR8Y4F MA Modulator DMR8Y4F RN V-10153 (Vernalis). Curr Opin Investig Drugs. 2005 Sep;6(9):951-5. DMR8Y4F RU https://pubmed.ncbi.nlm.nih.gov/16187695 DMR9COG DI DMR9COG DMR9COG DN STX-100 DMR9COG TI TTIQSVM DMR9COG TN Integrin alpha-V/beta-6 (ITGAV/B6) DMR9COG MA Antagonist DMR9COG RN Integrin-mediated regulation of TGFbeta in fibrosis. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease Volume 1832, Issue 7, July 2013, Pages 891-896. DMR9COG RU http://www.sciencedirect.com/science/article/pii/S0925443912002281 DMRA3T2 DI DMRA3T2 DMRA3T2 DN GSK2339345 DMRA3T2 TI TTRK8B9 DMRA3T2 TN Sodium channel unspecific (NaC) DMRA3T2 MA Modulator DMRA3T2 RN ClinicalTrials.gov (NCT01494636) The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects. U.S. National Institutes of Health. DMRA3T2 RU https://clinicaltrials.gov/ct2/show/NCT01494636 DMRAFBK DI DMRAFBK DMRAFBK DN PF-04958242 DMRAFBK TI TTAN6JD DMRAFBK TN Glutamate receptor AMPA (GRIA) DMRAFBK MA Activator DMRAFBK RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMRAFBK RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMRC0EQ DI DMRC0EQ DMRC0EQ DN Bertilimumab DMRC0EQ TI TTCF05Y DMRC0EQ TN Small-inducible cytokine A11 (CCL11) DMRC0EQ MA Modulator DMRC0EQ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRC0EQ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRDEKZ DI DMRDEKZ DMRDEKZ DN LY2928057 DMRDEKZ TI TT6Y1PG DMRDEKZ TN Solute carrier family 40 member 1 (SLC40A1) DMRDEKZ MA Modulator DMRDEKZ RN Targeting the Hepcidin-Ferroportin Axis to Develop New Treatment Strategies for Anemia of Chronic Disease and Anemia of Inflammation. Am J Hematol. 2012 April; 87(4): 392-400. DMRDEKZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653431/ DMRFK0B DI DMRFK0B DMRFK0B DN SAGE-217b DMRFK0B TI TTGXH6N DMRFK0B TN GABA(A) receptor delta (GABRD) DMRFK0B MA Immunostimulant DMRFK0B RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMRFK0B RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMRFO34 DI DMRFO34 DMRFO34 DN SR 16234 DMRFO34 TI TTZAYWL DMRFO34 TN Estrogen receptor (ESR) DMRFO34 MA Modulator DMRFO34 RN National Cancer Institute Drug Dictionary (drug id 599816). DMRFO34 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599816 DMRFY7I DI DMRFY7I DMRFY7I DN ICA-17043 DMRFY7I TI TTMNI76 DMRFY7I TN Calcium-activated potassium channel (KCN) DMRFY7I MA Inhibitor DMRFY7I RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMRFY7I RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMRFY7I DI DMRFY7I DMRFY7I DN ICA-17043 DMRFY7I TI TT7M9I6 DMRFY7I TN Calcium-activated potassium channel KCa3.1 (KCNN4) DMRFY7I MA Modulator DMRFY7I RN Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9. DMRFY7I RU https://www.ncbi.nlm.nih.gov/pubmed/19236269 DMRG0A3 DI DMRG0A3 DMRG0A3 DN ARQ 531 DMRG0A3 TI TTGM6VW DMRG0A3 TN Tyrosine-protein kinase BTK (ATK) DMRG0A3 MA Inhibitor DMRG0A3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRG0A3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRGQVZ DI DMRGQVZ DMRGQVZ DN Antroquinonol DMRGQVZ TI TT6S2FE DMRGQVZ TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMRGQVZ MA Inhibitor DMRGQVZ RN Antroquinonol D, isolated from Antrodia camphorata, with DNA demethylation and anticancer potential. J Agric Food Chem. 2014 Jun 18;62(24):5625-35. DMRGQVZ RU https://pubmed.ncbi.nlm.nih.gov/24784321 DMRGTZ2 DI DMRGTZ2 DMRGTZ2 DN SSTarbaclofen DMRGTZ2 TI TTDCVZW DMRGTZ2 TN Gamma-aminobutyric acid B receptor (GABBR) DMRGTZ2 MA Modulator DMRGTZ2 RN Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med. 2012 Sep 19;4(152):152ra128. DMRGTZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/22993295 DMRHD6B DI DMRHD6B DMRHD6B DN SKL-NP DMRHD6B TI TTKLW9S DMRHD6B TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DMRHD6B MA Modulator DMRHD6B RN A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons. Korean J Physiol Pharmacol. 2012 Aug;16(4):237-41. DMRHD6B RU https://pubmed.ncbi.nlm.nih.gov/22915988 DMRIO6D DI DMRIO6D DMRIO6D DN ORMD-0901 DMRIO6D TI TTVIMDE DMRIO6D TN Glucagon-like peptide 1 receptor (GLP1R) DMRIO6D MA Agonist DMRIO6D RN Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models. J Diabetes Sci Technol. 2010 Nov 1;4(6):1516-23. DMRIO6D RU https://pubmed.ncbi.nlm.nih.gov/21129350 DMRJ5LP DI DMRJ5LP DMRJ5LP DN Vasoactive intestinal peptide DMRJ5LP TI TTCL30I DMRJ5LP TN Vasoactive intestinal polypeptide receptor 1 (VIPR1) DMRJ5LP MA Antagonist DMRJ5LP RN Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. DMRJ5LP RU https://pubmed.ncbi.nlm.nih.gov/17064221 DMRN543 DI DMRN543 DMRN543 DN ISIS-EIF4E DMRN543 TI TTNBTCW DMRN543 TN eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) DMRN543 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMRN543 RU http://www.isispharm.com/index.htm DMRO6XT DI DMRO6XT DMRO6XT DN BGB-290 DMRO6XT TI TTKSAQZ DMRO6XT TN Tankyrase (TNKS) DMRO6XT MA Modulator DMRO6XT RN National Cancer Institute Drug Dictionary (drug id 769217). DMRO6XT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=769217 DMRO6XT DI DMRO6XT DMRO6XT DN BGB-290 DMRO6XT TI TTEBCY8 DMRO6XT TN Poly [ADP-ribose] polymerase (PARP) DMRO6XT MA Inhibitor DMRO6XT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRO6XT RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRP3CV DI DMRP3CV DMRP3CV DN Phenylalanine hydroxylase DMRP3CV TI TTGSVH2 DMRP3CV TN Phenylalanine hydroxylase (PAH) DMRP3CV MA Modulator DMRP3CV RN Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014 Jul 5;384(9937):37-44. DMRP3CV RU https://pubmed.ncbi.nlm.nih.gov/24743000 DMRPCF2 DI DMRPCF2 DMRPCF2 DN MGCD265 DMRPCF2 TI TTZPY6J DMRPCF2 TN Tyrosine-protein kinase UFO (AXL) DMRPCF2 MA Modulator DMRPCF2 RN Company report (Mirati Therapeutics: formerly MethylGene) DMRPCF2 RU http://www.mirati.com/programs/mgcd265/ DMRPCF2 DI DMRPCF2 DMRPCF2 DN MGCD265 DMRPCF2 TI TTU8W4S DMRPCF2 TN Protein kinase (PK) DMRPCF2 MA Inhibitor DMRPCF2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRPCF2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRQ0SA DI DMRQ0SA DMRQ0SA DN TT-401 DMRQ0SA TI TTVIMDE DMRQ0SA TN Glucagon-like peptide 1 receptor (GLP1R) DMRQ0SA MA Modulator DMRQ0SA RN Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration. Am J Ophthalmol. 2013 Dec;156(6):1176-83. DMRQ0SA RU https://pubmed.ncbi.nlm.nih.gov/24083687 DMRQ0SA DI DMRQ0SA DMRQ0SA DN TT-401 DMRQ0SA TI TT9O6WS DMRQ0SA TN Glucagon receptor (GCGR) DMRQ0SA MA Agonist DMRQ0SA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRQ0SA RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMRQGMZ DI DMRQGMZ DMRQGMZ DN HD-003 DMRQGMZ TI TT20DOQ DMRQGMZ TN Hydroxy radical elimination (HYRE) DMRQGMZ MA Modulator DMRQGMZ RN Creatinine and HMH (5-hydroxy-1-methylhydantoin, NZ-419) as intrinsic hydroxyl radical scavengers. Drug Discov Ther. 2011 Aug;5(4):162-75. DMRQGMZ RU https://pubmed.ncbi.nlm.nih.gov/22466296 DMRQUH4 DI DMRQUH4 DMRQUH4 DN NI-0801 DMRQUH4 TI TTQOVYA DMRQUH4 TN C-X-C motif chemokine 10 (CXCL10) DMRQUH4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267) DMRQUH4 RU http://adisinsight.springer.com/drugs/800029267 DMRSG31 DI DMRSG31 DMRSG31 DN BCX-3408 DMRSG31 TI TTMCF1Y DMRSG31 TN Purine nucleoside phosphorylase (PNP) DMRSG31 MA Inhibitor DMRSG31 RN BCX-4208 (RO5092888), a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Is a Novel, Potent Orally Active Anti-T-Cell and B-Cell Agent. 50th ASH Annual Meeting and Exposition. 2008. DMRSG31 RU http://ash.confex.com/ash/2008/webprogram/Paper7315.html DMRSK2I DI DMRSK2I DMRSK2I DN MGCD290 DMRSK2I TI TTVO9RI DMRSK2I TN Fungal Probable histone deacetylase HOS2 (Fung HOS2) DMRSK2I MA Inhibitor DMRSK2I RN Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2009 Dec;47(12):3797-804. DMRSK2I RU https://pubmed.ncbi.nlm.nih.gov/19794038 DMRSN2C DI DMRSN2C DMRSN2C DN MB-12066 DMRSN2C TI TTUF2HO DMRSN2C TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMRSN2C MA Modulator DMRSN2C RN Pharmacological activation of Sirt1 ameliorates polyglutamine-induced toxicity through the regulation of autophagy.PLoS One.2013 Jun 10;8(6):e64953. DMRSN2C RU https://www.ncbi.nlm.nih.gov/pubmed/23762270 DMRSU4X DI DMRSU4X DMRSU4X DN Salirasib DMRSU4X TI TTW2R9X DMRSU4X TN GTPase NRas (NRAS) DMRSU4X MA Antagonist DMRSU4X RN The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. Methods Enzymol. 2008;439:467-89. DMRSU4X RU https://pubmed.ncbi.nlm.nih.gov/18374183 DMRSU4X DI DMRSU4X DMRSU4X DN Salirasib DMRSU4X TI TTCJG29 DMRSU4X TN Serine/threonine-protein kinase mTOR (mTOR) DMRSU4X MA Modulator DMRSU4X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMRSU4X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMRT28X DI DMRT28X DMRT28X DN ONO-6126 DMRT28X TI TTV5CGO DMRT28X TN Phosphodiesterase 4 (PDE4) DMRT28X MA Inhibitor DMRT28X RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMRT28X RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMRT8K4 DI DMRT8K4 DMRT8K4 DN MK-0812 DMRT8K4 TI TTFZYTO DMRT8K4 TN C-C chemokine receptor type 2 (CCR2) DMRT8K4 MA Antagonist DMRT8K4 RN Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J Immunol Methods. 2010 Jan 31;352(1-2):101-10. DMRT8K4 RU https://pubmed.ncbi.nlm.nih.gov/19913021 DMRTD7I DI DMRTD7I DMRTD7I DN PLX8394 DMRTD7I TI TTWCGQT DMRTD7I TN Serine/threonine-protein kinase B-raf (BRAF) DMRTD7I MA Inhibitor DMRTD7I RN Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014 Mar;27(2):253-62. DMRTD7I RU https://pubmed.ncbi.nlm.nih.gov/24283590 DMRVEHY DI DMRVEHY DMRVEHY DN LY3012212 DMRVEHY TI TT2Q6G1 DMRVEHY TN Vascular endothelial growth factor receptor 1 (FLT-1) DMRVEHY MA Modulator DMRVEHY RN Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study. Invest New Drugs. 2014 Apr;32(2):303-11. DMRVEHY RU https://pubmed.ncbi.nlm.nih.gov/23903897 DMRWE5D DI DMRWE5D DMRWE5D DN SB-728-T DMRWE5D TI TT2CEJG DMRWE5D TN C-C chemokine receptor type 5 (CCR5) DMRWE5D MA Modulator DMRWE5D RN Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV. N Engl J Med. 2014 March 6; 370(10): 901-910. DMRWE5D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084652/ DMRWG8B DI DMRWG8B DMRWG8B DN BNT321 DMRWG8B TI TTD9I12 DMRWG8B TN Carbohydrate antigen 19-9 (CA 19-9) DMRWG8B MA Inhibitor DMRWG8B RN Clinical pipeline report, company report or official report of BioNTech. DMRWG8B RU https://biontech.de/science/pipeline DMRXCUQ DI DMRXCUQ DMRXCUQ DN SPL-108 DMRXCUQ TI TTWFBT7 DMRXCUQ TN Extracellular matrix receptor III (CD44) DMRXCUQ MA Inhibitor DMRXCUQ RN Clinical pipeline report, company report or official report of Splash Pharmaceuticals. DMRXCUQ RU http://www.splashpharma.com/new-page DMRYH3M DI DMRYH3M DMRYH3M DN ADP-A2M4 DMRYH3M TI TT9EQUY DMRYH3M TN Melanoma-associated antigen 4 (MAGEA4) DMRYH3M RN Clinical pipeline report, company report or official report of Adaptimmune. DMRYH3M RU https://www.adaptimmune.com/pipeline/adp-a2m4 DMRYHWI DI DMRYHWI DMRYHWI DN SB-705498 DMRYHWI TI TTMI6F5 DMRYHWI TN Transient receptor potential cation channel V1 (TRPV1) DMRYHWI MA Blocker DMRYHWI RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMRYHWI RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMRYLBW DI DMRYLBW DMRYLBW DN NTO-1151 DMRYLBW TI TTRBUYN DMRYLBW TN Ribonuclease (RNase) DMRYLBW MA Modulator DMRYLBW RN Clinical pipeline report, company report or official report of Nanotherapeutics. DMRYLBW RU http://www.nanotherapeutics.com/triapine/ DMRZA6G DI DMRZA6G DMRZA6G DN S-8921 DMRZA6G TI TTPI1M5 DMRZA6G TN Ileal sodium/bile acid cotransporter (SLC10A2) DMRZA6G MA Inhibitor DMRZA6G RN Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1304-11. DMRZA6G RU https://pubmed.ncbi.nlm.nih.gov/9714138 DMRZBPI DI DMRZBPI DMRZBPI DN YM-543 DMRZBPI TI TTLWPVF DMRZBPI TN Sodium/glucose cotransporter 2 (SGLT2) DMRZBPI MA Modulator DMRZBPI RN Pharmacological Characterization of YM543, a Newly Synthesized, Orally Active SGLT2 Selective Inhibitor. Endocr Res. 2013 Aug;38(3):168-183. DMRZBPI RU https://www.ncbi.nlm.nih.gov/pubmed/23374077 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTUV8G9 DMRZLU4 TN Progesterone receptor (PGR) DMRZLU4 MA Inhibitor DMRZLU4 RN Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/11150172 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTYRL6O DMRZLU4 TN Glucocorticoid receptor (NR3C1) DMRZLU4 MA Inhibitor DMRZLU4 RN Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/11150172 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTKPW01 DMRZLU4 TN Androgen receptor messenger RNA (AR mRNA) DMRZLU4 MA Inhibitor DMRZLU4 RN Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J Med Chem. 2000 Dec 28;43(26):5010-6. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/11150172 DMRZLU4 DI DMRZLU4 DMRZLU4 DN BAY 86-5044 DMRZLU4 TI TTHL6YX DMRZLU4 TN Progesterone (PG) DMRZLU4 MA Antagonist DMRZLU4 RN Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol. 2013 Oct;24(10):2543-8. DMRZLU4 RU https://pubmed.ncbi.nlm.nih.gov/23788750 DMS01AX DI DMS01AX DMS01AX DN CERE-120 DMS01AX TI TTWFC4G DMS01AX TN Netrin (NET) DMS01AX MA Modulator DMS01AX RN Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther. 2007 Jan;15(1):62-8. DMS01AX RU https://pubmed.ncbi.nlm.nih.gov/17164776 DMS0GA6 DI DMS0GA6 DMS0GA6 DN AMY-101 DMS0GA6 TI TTJGY7A DMS0GA6 TN Complement C3 (CO3) DMS0GA6 MA Inhibitor DMS0GA6 RN The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450. DMS0GA6 RU https://pubmed.ncbi.nlm.nih.gov/32360516 DMS1YPZ DI DMS1YPZ DMS1YPZ DN SAR391786 DMS1YPZ TI TTSWPH8 DMS1YPZ TN Growth/differentiation factor 8 (GDF-8) DMS1YPZ RN Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010 Mar;10(1):56-63. DMS1YPZ RU https://pubmed.ncbi.nlm.nih.gov/20190380 DMS2MQ5 DI DMS2MQ5 DMS2MQ5 DN BGC-20-1531 DMS2MQ5 TI TT79WV3 DMS2MQ5 TN Prostaglandin E2 receptor EP4 (PTGER4) DMS2MQ5 MA Antagonist DMS2MQ5 RN BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327. DMS2MQ5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697835/ DMS2Q9G DI DMS2Q9G DMS2Q9G DN PHA848125 DMS2Q9G TI TT7HF4W DMS2Q9G TN Cyclin-dependent kinase 2 (CDK2) DMS2Q9G MA Inhibitor DMS2Q9G RN Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63. DMS2Q9G RU https://pubmed.ncbi.nlm.nih.gov/19603809 DMS2WB5 DI DMS2WB5 DMS2WB5 DN CX157 DMS2WB5 TI TT3WG5C DMS2WB5 TN Monoamine oxidase type A (MAO-A) DMS2WB5 MA Inhibitor DMS2WB5 RN Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31. DMS2WB5 RU https://pubmed.ncbi.nlm.nih.gov/19890267 DMS2WIN DI DMS2WIN DMS2WIN DN Delphinidin DMS2WIN TI TTUTJGQ DMS2WIN TN Vascular endothelial growth factor receptor 2 (KDR) DMS2WIN MA Modulator DMS2WIN RN Delphinidin, a dietary anthocyanidin, inhibits vascular endothelial growth factor receptor-2 phosphorylation. Carcinogenesis. 2006 May;27(5):989-96. DMS2WIN RU https://pubmed.ncbi.nlm.nih.gov/16308314 DMS34YO DI DMS34YO DMS34YO DN PM184 DMS34YO TI TTHVQ4N DMS34YO TN Tubulin polymerization (TubP) DMS34YO MA Inhibitor DMS34YO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS34YO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMS4XFI DI DMS4XFI DMS4XFI DN OPT-302 DMS4XFI TI TT0QUFV DMS4XFI TN Vascular endothelial growth factor C (VEGFC) DMS4XFI MA Inhibitor DMS4XFI RN Clinical pipeline report, company report or official report of Opthea. DMS4XFI RU https://opthea.com/ DMS4XFI DI DMS4XFI DMS4XFI DN OPT-302 DMS4XFI TI TTOM5H4 DMS4XFI TN Vascular endothelial growth factor D (VEGFD) DMS4XFI MA Inhibitor DMS4XFI RN Clinical pipeline report, company report or official report of Opthea. DMS4XFI RU https://opthea.com/ DMS610L DI DMS610L DMS610L DN PF-04691502 DMS610L TI TTCJG29 DMS610L TN Serine/threonine-protein kinase mTOR (mTOR) DMS610L MA Modulator DMS610L RN PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99. DMS610L RU https://www.ncbi.nlm.nih.gov/pubmed/21750219 DMS610L DI DMS610L DMS610L DN PF-04691502 DMS610L TI TTHBTOP DMS610L TN PI3-kinase gamma (PIK3CG) DMS610L MA Modulator DMS610L RN PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.Mol Cancer Ther.2011 Nov;10(11):2189-99. DMS610L RU https://www.ncbi.nlm.nih.gov/pubmed/21750219 DMS6E9J DI DMS6E9J DMS6E9J DN Lefitolimod DMS6E9J TI TTSHG0T DMS6E9J TN Toll-like receptor 9 (TLR9) DMS6E9J MA Agonist DMS6E9J RN Beneficial modulation of the tumor microenvironment and generation of anti-tumor responses by TLR9 agonist lefitolimod alone and in combination with checkpoint inhibitors. Oncoimmunology. 2019 Sep 20;8(12):e1659096. DMS6E9J RU https://pubmed.ncbi.nlm.nih.gov/31741757 DMS6ZA0 DI DMS6ZA0 DMS6ZA0 DN BTD-001 DMS6ZA0 TI TTCI43M DMS6ZA0 TN GABA(A) receptor (GABAR) DMS6ZA0 MA Antagonist DMS6ZA0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS6ZA0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMS7609 DI DMS7609 DMS7609 DN YM-358 DMS7609 TI TT8DBY3 DMS7609 TN Angiotensin II receptor type-1 (AGTR1) DMS7609 MA Antagonist DMS7609 RN Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81. DMS7609 RU https://pubmed.ncbi.nlm.nih.gov/10706380 DMS7FRI DI DMS7FRI DMS7FRI DN Methanesulfonyl fluoride DMS7FRI TI TT1RS9F DMS7FRI TN Acetylcholinesterase (AChE) DMS7FRI MA Inhibitor DMS7FRI RN A randomized phase I study of methanesulfonyl fluoride, an irreversible cholinesterase inhibitor, for the treatment of Alzheimer's disease. Br J Clin Pharmacol. 2013 May;75(5):1231-9. DMS7FRI RU https://pubmed.ncbi.nlm.nih.gov/23116458 DMS8Q7A DI DMS8Q7A DMS8Q7A DN Ontazolast DMS8Q7A TI TTTWGIX DMS8Q7A TN Leukotriene receptor (LTR) DMS8Q7A MA Modulator DMS8Q7A RN Effects of progesterone and leukotriene receptor antagonists in experimental models of P-glycoprotein-related resistance. Eur J Med Res. 1997 Apr 21;2(4):159-64. DMS8Q7A RU https://pubmed.ncbi.nlm.nih.gov/9110922 DMS9BDQ DI DMS9BDQ DMS9BDQ DN Tipelukast DMS9BDQ TI TT2J34L DMS9BDQ TN Arachidonate 5-lipoxygenase (5-LOX) DMS9BDQ MA Modulator DMS9BDQ RN Company report (MediciNova) DMS9BDQ RU http://medicinova.com/clinical-development/core/mn-001-nash/ DMS9BDQ DI DMS9BDQ DMS9BDQ DN Tipelukast DMS9BDQ TI TTZCG4L DMS9BDQ TN Phosphodiesterase 3 (PDE3) DMS9BDQ MA Modulator DMS9BDQ RN Company report (MediciNova) DMS9BDQ RU http://medicinova.com/clinical-development/core/mn-001-nash/ DMS9Y1T DI DMS9Y1T DMS9Y1T DN DG-17 DMS9Y1T TI TT5FNQT DMS9Y1T TN Human immunodeficiency virus Protease (HIV PR) DMS9Y1T MA Inhibitor DMS9Y1T RN Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 1999 April 16; 13(6): 661-667. DMS9Y1T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2566777/ DMSA2LZ DI DMSA2LZ DMSA2LZ DN TPI-1020 DMSA2LZ TI TTYRL6O DMSA2LZ TN Glucocorticoid receptor (NR3C1) DMSA2LZ MA Antagonist DMSA2LZ RN Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol. Br J Pharmacol. 2012 Oct;167(3):515-26. DMSA2LZ RU https://pubmed.ncbi.nlm.nih.gov/22563753 DMSABRI DI DMSABRI DMSABRI DN CERC-301 DMSABRI TI TTN9D8E DMSABRI TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMSABRI MA Antagonist DMSABRI RN Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Nov 5;766:1-8. DMSABRI RU https://pubmed.ncbi.nlm.nih.gov/26325093 DMSBLOU DI DMSBLOU DMSBLOU DN AEG-33773 DMSBLOU TI TTHYBIX DMSBLOU TN Heat shock protein 70 (HSP70) DMSBLOU MA Inhibitor DMSBLOU RN Mitogen-activated protein kinase kinase kinase 12 (MAP3K12; DLK); c-jun N-terminal kinase (JNK). SciBX 2(11); doi:10.1038/scibx.2009.462. March 19 2009 DMSBLOU RU http://www.nature.com/scibx/journal/v2/n11/full/scibx.2009.462.html DMSBNTZ DI DMSBNTZ DMSBNTZ DN CBX-129801 DMSBNTZ TI TTKF4WV DMSBNTZ TN Connecting peptide (C-peptide) DMSBNTZ MA Modulator DMSBNTZ RN ClinicalTrials.gov (NCT01681290) Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes. U.S. National Institutes of Health. DMSBNTZ RU https://clinicaltrials.gov/ct2/show/NCT01681290 DMSBPJI DI DMSBPJI DMSBPJI DN BL-7040 DMSBPJI TI TTSHG0T DMSBPJI TN Toll-like receptor 9 (TLR9) DMSBPJI MA Activator DMSBPJI RN Gut feeling: MicroRNA discriminators of the intestinal TLR9-cholinergic links. Int Immunopharmacol. 2015 Nov;29(1):8-14. DMSBPJI RU https://pubmed.ncbi.nlm.nih.gov/26003847 DMSC7TN DI DMSC7TN DMSC7TN DN Rimacalib DMSC7TN TI TTFYL58 DMSC7TN TN CaM-kinase II (CAMK2) DMSC7TN MA Modulator DMSC7TN RN Role for CaMKII inhibition in rheumatoid arthritis: effects on HIF-1-induced VEGF production by rheumatoid synovial fibroblasts. Ann N Y Acad Sci. 2009 Sep;1173:706-11. DMSC7TN RU https://pubmed.ncbi.nlm.nih.gov/19758219 DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TTRMX3V DMSCR2H TN Janus kinase 2 (JAK-2) DMSCR2H MA Modulator DMSCR2H RN Company report (Portola Pharmaceuticals) DMSCR2H RU https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/ DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TTOU65C DMSCR2H TN Tyrosine-protein kinase SYK (SYK) DMSCR2H MA Modulator DMSCR2H RN Company report (Portola Pharmaceuticals) DMSCR2H RU https://www.portola.com/blog/cerdulatinib-a-unique-and-promising-investigational-treatment-for-patients-with-hematologic-cancers/ DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TTT7PJU DMSCR2H TN Janus kinase 3 (JAK-3) DMSCR2H MA Inhibitor DMSCR2H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSCR2H RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSCR2H DI DMSCR2H DMSCR2H DN Cerdulatinib DMSCR2H TI TT6DM01 DMSCR2H TN Janus kinase 1 (JAK-1) DMSCR2H MA Inhibitor DMSCR2H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSCR2H RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSE9TH DI DMSE9TH DMSE9TH DN MT-1303 DMSE9TH TI TT9JZCK DMSE9TH TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMSE9TH MA Modulator DMSE9TH RN Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75. DMSE9TH RU https://pubmed.ncbi.nlm.nih.gov/26239599 DMSEVBH DI DMSEVBH DMSEVBH DN Lersivirine DMSEVBH TI TT84ETX DMSEVBH TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSEVBH MA Inhibitor DMSEVBH RN Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clin Ther.2010 Oct;32(11):1889-95. DMSEVBH RU https://pubmed.ncbi.nlm.nih.gov/21095483 DMSF10P DI DMSF10P DMSF10P DN RGN-259 DMSF10P TI TTH5WZF DMSF10P TN Actin (ACT) DMSF10P MA Modulator DMSF10P RN Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491-6. DMSF10P RU https://pubmed.ncbi.nlm.nih.gov/25826322 DMSF7WJ DI DMSF7WJ DMSF7WJ DN CL-329167 DMSF7WJ TI TT8DBY3 DMSF7WJ TN Angiotensin II receptor type-1 (AGTR1) DMSF7WJ MA Antagonist DMSF7WJ RN Distribution and function of cardiac angiotensin AT1- and AT2-receptor subtypes in hypertrophied rat hearts. Am J Physiol. 1994 Aug;267(2 Pt 2):H844-52. DMSF7WJ RU https://pubmed.ncbi.nlm.nih.gov/8067441 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TT8FYO9 DMSFWT7 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTGJCWZ DMSFWT7 TN Fms-like tyrosine kinase 3 (FLT-3) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTX41N9 DMSFWT7 TN Tyrosine-protein kinase Kit (KIT) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTI7421 DMSFWT7 TN Platelet-derived growth factor receptor beta (PDGFRB) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TT2Q6G1 DMSFWT7 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTDCBX5 DMSFWT7 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSFWT7 DI DMSFWT7 DMSFWT7 DN Famitinib DMSFWT7 TI TTUTJGQ DMSFWT7 TN Vascular endothelial growth factor receptor 2 (KDR) DMSFWT7 MA Inhibitor DMSFWT7 RN Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706. DMSFWT7 RU https://pubmed.ncbi.nlm.nih.gov/23126373 DMSGFOY DI DMSGFOY DMSGFOY DN Coltuximab ravtansine DMSGFOY TI TTW640A DMSGFOY TN B-lymphocyte surface antigen B4 (CD19) DMSGFOY MA Inhibitor DMSGFOY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSGFOY RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TT7HF4W DMSH108 TN Cyclin-dependent kinase 2 (CDK2) DMSH108 MA Inhibitor DMSH108 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TTQYF7G DMSH108 TN Cyclin-dependent kinase 7 (CDK7) DMSH108 MA Inhibitor DMSH108 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TTH6V3D DMSH108 TN Cyclin-dependent kinase 1 (CDK1) DMSH108 MA Inhibitor DMSH108 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMSH108 DI DMSH108 DMSH108 DN R-roscovitine DMSH108 TI TTMBO1Z DMSH108 TN Cyclin-dependent kinase (CDK) DMSH108 MA Inhibitor DMSH108 RN Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma.Clin Cancer Res. 2009 Jun 1;15(11):3716-24. DMSH108 RU https://pubmed.ncbi.nlm.nih.gov/19470731 DMSHE70 DI DMSHE70 DMSHE70 DN GSK2141795 DMSHE70 TI TTAZ05C DMSHE70 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMSHE70 MA Modulator DMSHE70 RN Inhibiting the akt pathway in cancer treatment: three leading candidates. P T. 2011 Apr;36(4):225-7. DMSHE70 RU https://pubmed.ncbi.nlm.nih.gov/21572779 DMSHGWN DI DMSHGWN DMSHGWN DN Lintopride DMSHGWN TI TT07C3Y DMSHGWN TN 5-HT 4 receptor (HTR4) DMSHGWN MA Modulator DMSHGWN RN The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9. DMSHGWN RU https://pubmed.ncbi.nlm.nih.gov/8580279 DMSHGWN DI DMSHGWN DMSHGWN DN Lintopride DMSHGWN TI TTNXLKE DMSHGWN TN 5-HT 3 receptor (5HT3R) DMSHGWN MA Modulator DMSHGWN RN The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9. DMSHGWN RU https://pubmed.ncbi.nlm.nih.gov/8580279 DMSHV9C DI DMSHV9C DMSHV9C DN CCX-354 DMSHV9C TI TTC24WT DMSHV9C TN C-C chemokine receptor type 1 (CCR1) DMSHV9C MA Antagonist DMSHV9C RN Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann Rheum Dis. 2013 Mar;72(3):337-44. DMSHV9C RU https://pubmed.ncbi.nlm.nih.gov/22589376 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TT6EO5L DMSI8N3 TN Erbb2 tyrosine kinase receptor (HER2) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TT0JESD DMSI8N3 TN Erbb4 tyrosine kinase receptor (Erbb-4) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TTGKNB4 DMSI8N3 TN Epidermal growth factor receptor (EGFR) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSI8N3 DI DMSI8N3 DMSI8N3 DN CI-1033 DMSI8N3 TI TTWTSCV DMSI8N3 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMSI8N3 MA Inhibitor DMSI8N3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMSI8N3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMSIGAB DI DMSIGAB DMSIGAB DN L-alanosine DMSIGAB TI TTEWTCR DMSIGAB TN Adenine synthesis (Adeni synth) DMSIGAB MA Modulator DMSIGAB RN Circadian pharmacology of L-alanosine (SDX-102) in mice. Mol Cancer Ther. 2006 Feb;5(2):337-46. DMSIGAB RU https://pubmed.ncbi.nlm.nih.gov/16505107 DMSIXG4 DI DMSIXG4 DMSIXG4 DN TT-173 DMSIXG4 TI TT38MDJ DMSIXG4 TN Tissue factor (F3) DMSIXG4 MA Modulator DMSIXG4 RN TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. Clin Oral Investig. 2016 Jun;20(5):1055-63. DMSIXG4 RU https://pubmed.ncbi.nlm.nih.gov/26374745 DMSJ3Z5 DI DMSJ3Z5 DMSJ3Z5 DN REGN1979 DMSJ3Z5 TI TTUE541 DMSJ3Z5 TN Leukocyte surface antigen Leu-16 (CD20) DMSJ3Z5 MA Inhibitor DMSJ3Z5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSJ3Z5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMSJOE3 DI DMSJOE3 DMSJOE3 DN LM-030 DMSJOE3 TI TT5L2VC DMSJOE3 TN Kallikrein-related peptidase (KLK) DMSJOE3 MA Inhibitor DMSJOE3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSJOE3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSJU5B DI DMSJU5B DMSJU5B DN RP-L102 DMSJU5B TI TTV5HJS DMSJU5B TN Fanconi anemia group A protein (FANCA) DMSJU5B MA Replacement DMSJU5B RN Clinical pipeline report, company report or official report of Rocket Pharmaceuticals. DMSJU5B RU https://rocketpharma.com/our-disease-focus/ DMSKMET DI DMSKMET DMSKMET DN Gimatecan DMSKMET TI TTGTQHC DMSKMET TN DNA topoisomerase I (TOP1) DMSKMET MA Inhibitor DMSKMET RN Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. Biochem Pharmacol. 2013 May 15;85(10):1433-40. DMSKMET RU https://pubmed.ncbi.nlm.nih.gov/23466420 DMSL3DX DI DMSL3DX DMSL3DX DN GS-5885 DMSL3DX TI TTCJ2X8 DMSL3DX TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMSL3DX MA Modulator DMSL3DX RN Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033-46. DMSL3DX RU https://pubmed.ncbi.nlm.nih.gov/24320933 DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TTSQIFT DMSLIW6 TN 5-HT 1A receptor (HTR1A) DMSLIW6 MA Antagonist DMSLIW6 RN Company report (Minerva Neurosciences),MIN-101,Schizophrenia, 6 trials completed; Once a day formulation completed , Phase IIa completed; Phase IIb enrollment ongoing and expected to continue over the last 3 quarters of 2015. DMSLIW6 RU http://minervaneurosciences.com/ DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TT3ROYC DMSLIW6 TN Serotonin transporter (SERT) DMSLIW6 MA Inhibitor DMSLIW6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSLIW6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TTVBI8W DMSLIW6 TN Dopamine transporter (DAT) DMSLIW6 MA Inhibitor DMSLIW6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSLIW6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMSLIW6 DI DMSLIW6 DMSLIW6 DN MIN-117 DMSLIW6 TI TT85JO3 DMSLIW6 TN 5-HT receptor (5HTR) DMSLIW6 MA Antagonist DMSLIW6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSLIW6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMSLMY7 DI DMSLMY7 DMSLMY7 DN 11C-PBR-28 DMSLMY7 TI TTPTXIN DMSLMY7 TN Translocator protein (TSPO) DMSLMY7 MA Binder DMSLMY7 RN PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat. Neurosci Lett. 2007 Jan 16;411(3):200-5. DMSLMY7 RU https://pubmed.ncbi.nlm.nih.gov/17127001 DMSMCXN DI DMSMCXN DMSMCXN DN HBV vaccine DMSMCXN TI TT3J5ZI DMSMCXN TN Cell mediated immunity response (CMIR) DMSMCXN RN ClinicalTrials.gov (NCT00508833) Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615). U.S. National Institutes of Health. DMSMCXN RU https://clinicaltrials.gov/ct2/show/NCT00508833 DMSO846 DI DMSO846 DMSO846 DN Orvepitant DMSO846 TI TTZPO1L DMSO846 TN Substance-P receptor (TACR1) DMSO846 MA Antagonist DMSO846 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMSO846 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMSOPAU DI DMSOPAU DMSOPAU DN Pyrazoloacridine DMSOPAU TI TT0IHXV DMSOPAU TN DNA topoisomerase II (TOP2) DMSOPAU MA Modulator DMSOPAU RN Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res. 1998 Mar;4(3):683-91. DMSOPAU RU https://pubmed.ncbi.nlm.nih.gov/9533538 DMSPWX6 DI DMSPWX6 DMSPWX6 DN MK-5172 DMSPWX6 TI TT5FNQT DMSPWX6 TN Human immunodeficiency virus Protease (HIV PR) DMSPWX6 MA Inhibitor DMSPWX6 RN Clinical pipeline report, company report or official report of Merck (2011). DMSPWX6 RU http://www.merck.com/index.html DMSRC5D DI DMSRC5D DMSRC5D DN IDX899 DMSRC5D TI TT84ETX DMSRC5D TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSRC5D MA Modulator DMSRC5D RN Unexpected finding of delayed-onset seizures in HIV-positive, treatment-experienced subjects in the Phase IIb evaluation of fosdevirine (GSK2248761).Antivir Ther.2014;19(1):69-78. DMSRC5D RU https://www.ncbi.nlm.nih.gov/pubmed/24158593 DMSROM4 DI DMSROM4 DMSROM4 DN BHQ880 DMSROM4 TI TTE3RAC DMSROM4 TN Dickkopf-related protein 1 (DKK1) DMSROM4 MA Inhibitor DMSROM4 RN Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9. DMSROM4 RU https://pubmed.ncbi.nlm.nih.gov/19417213 DMSRVXO DI DMSRVXO DMSRVXO DN BMS-986263 DMSRVXO TI TTPSWQG DMSRVXO TN SERPINH1 messenger RNA (SERPINH1 mRNA) DMSRVXO MA Inhibitor DMSRVXO RN A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance. AAPS J. 2019 Jul 22;21(5):92. DMSRVXO RU https://pubmed.ncbi.nlm.nih.gov/31332587 DMST4OR DI DMST4OR DMST4OR DN Selgantolimod DMST4OR TI TT8CWFK DMST4OR TN Toll-like receptor 8 (TLR8) DMST4OR MA Agonist DMST4OR RN Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203. DMST4OR RU https://pubmed.ncbi.nlm.nih.gov/32407112 DMSTH01 DI DMSTH01 DMSTH01 DN Rocilinostat DMSTH01 TI TTBH0VX DMSTH01 TN Histone deacetylase (HDAC) DMSTH01 MA Inhibitor DMSTH01 RN National Cancer Institute Drug Dictionary (drug id 698408). DMSTH01 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=698408 DMSTHG1 DI DMSTHG1 DMSTHG1 DN VX-371 DMSTHG1 TI TTQM7TE DMSTHG1 TN Amiloride-sensitive sodium channel (ENaC) DMSTHG1 MA Inhibitor DMSTHG1 RN The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652. DMSTHG1 RU https://pubmed.ncbi.nlm.nih.gov/29599187 DMSTJ6Q DI DMSTJ6Q DMSTJ6Q DN INX-189 DMSTJ6Q TI TTMVBWH DMSTJ6Q TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMSTJ6Q MA Inhibitor DMSTJ6Q RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMSTJ6Q RU http://news.bms.com/press-release/financial-news/bristol-myers-squibb-discontinues-development-bms-986094-investigationa DMSUB64 DI DMSUB64 DMSUB64 DN BAY 57-1293 DMSUB64 TI TTKCVJR DMSUB64 TN Herpes simplex virus Helicase-primase (HSV UL8) DMSUB64 MA Inhibitor DMSUB64 RN Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir Chem Chemother. 2004 May;15(3):135-40. DMSUB64 RU https://pubmed.ncbi.nlm.nih.gov/15266895 DMSUQFJ DI DMSUQFJ DMSUQFJ DN SBI-087 DMSUQFJ TI TTUE541 DMSUQFJ TN Leukocyte surface antigen Leu-16 (CD20) DMSUQFJ MA Inhibitor DMSUQFJ RN Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009 August; 157(2): 198-208. DMSUQFJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730845/ DMSV60C DI DMSV60C DMSV60C DN MEDI0382 DMSV60C TI TT0NUFM DMSV60C TN Glucagon (GCG) DMSV60C MA Agonist DMSV60C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSV60C RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMSVWI7 DI DMSVWI7 DMSVWI7 DN Neladenoson bialanate DMSVWI7 TI TT92EIB DMSVWI7 TN ADORA1 messenger RNA (ADORA1 mRNA) DMSVWI7 MA Agonist DMSVWI7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSVWI7 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMSW5XJ DI DMSW5XJ DMSW5XJ DN RV521 DMSW5XJ TI TT57ID8 DMSW5XJ TN Respiratory syncytial virus protein F (RSV F) DMSW5XJ MA Inhibitor DMSW5XJ RN Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676. DMSW5XJ RU https://pubmed.ncbi.nlm.nih.gov/33729773 DMSWLM5 DI DMSWLM5 DMSWLM5 DN CP-122721 DMSWLM5 TI TTZPO1L DMSWLM5 TN Substance-P receptor (TACR1) DMSWLM5 MA Antagonist DMSWLM5 RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DMSWLM5 RU https://pubmed.ncbi.nlm.nih.gov/17109611 DMSWPA6 DI DMSWPA6 DMSWPA6 DN Superoxide dismutase DMSWPA6 TI TT6RVLG DMSWPA6 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMSWPA6 MA Modulator DMSWPA6 RN Polyhemoglobin-superoxide dismutase-catalase-carbonic anhydrase: a novel biotechnology-based blood substitute that transports both oxygen and carbon dioxide and also acts as an antioxidant.Artif Cells Blood Substit Immobil Biotechnol.2011 Jun;39(3):127-36. DMSWPA6 RU https://www.ncbi.nlm.nih.gov/pubmed/21574914 DMSWUNX DI DMSWUNX DMSWUNX DN Naratuximab emtansine DMSWUNX TI TTFCW29 DMSWUNX TN Leukocyte antigen CD37 (CD37) DMSWUNX MA Inhibitor DMSWUNX RN Clinical pipeline report, company report or official report of Debiopharm. DMSWUNX RU https://www.debiopharm.com/drug-development/pipeline/debio-1562/ DMSZFTP DI DMSZFTP DMSZFTP DN Met-enkephalin DMSZFTP TI TT27RFC DMSZFTP TN Opioid receptor delta (OPRD1) DMSZFTP MA Agonist DMSZFTP RN Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9. DMSZFTP RU https://pubmed.ncbi.nlm.nih.gov/7813576 DMSZFTP DI DMSZFTP DMSZFTP DN Met-enkephalin DMSZFTP TI TTKWM86 DMSZFTP TN Opioid receptor mu (MOP) DMSZFTP MA Inhibitor DMSZFTP RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMSZFTP RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMSZOXQ DI DMSZOXQ DMSZOXQ DN Baminercept DMSZOXQ TI TTFO0PM DMSZOXQ TN Lymphotoxin beta receptor (LTBR) DMSZOXQ MA Antagonist DMSZOXQ RN ClinicalTrials.gov (NCT01552681) Baminercept in Sj ren's Syndrome. U.S. National Institutes of Health. DMSZOXQ RU https://clinicaltrials.gov/ct2/show/NCT01552681 DMSZQHX DI DMSZQHX DMSZQHX DN BI-505 DMSZQHX TI TTCT6F7 DMSZQHX TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMSZQHX RN A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013 Apr 15;23(4):502-15. DMSZQHX RU https://pubmed.ncbi.nlm.nih.gov/23597564 DMSZQHX DI DMSZQHX DMSZQHX DN BI-505 DMSZQHX TI TTZPY6J DMSZQHX TN Tyrosine-protein kinase UFO (AXL) DMSZQHX MA Inhibitor DMSZQHX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSZQHX RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMT0K4F DI DMT0K4F DMT0K4F DN MTR105 DMT0K4F TI TTCM4B3 DMT0K4F TN Nitric-oxide synthase endothelial (NOS3) DMT0K4F MA Inhibitor DMT0K4F RN Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7. DMT0K4F RU https://pubmed.ncbi.nlm.nih.gov/18434722 DMT1OZ6 DI DMT1OZ6 DMT1OZ6 DN MK-2206 DMT1OZ6 TI TTAZ05C DMT1OZ6 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMT1OZ6 MA Modulator DMT1OZ6 RN First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol.2011 Dec 10;29(35):4688-95. DMT1OZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/22025163 DMT1OZ6 DI DMT1OZ6 DMT1OZ6 DN MK-2206 DMT1OZ6 TI TT0A1R8 DMT1OZ6 TN E2 ubiquitin-conjugating enzyme T (UBE2T) DMT1OZ6 MA Inhibitor DMT1OZ6 RN UBE2T promotes nasopharyngeal carcinoma cell proliferation, invasion, and metastasis by activating the AKT/GSK3/-catenin pathway.Oncotarget. 2016 Mar 22;7(12):15161-72. DMT1OZ6 RU https://pubmed.ncbi.nlm.nih.gov/26943030 DMT1ZX0 DI DMT1ZX0 DMT1ZX0 DN RG1577 DMT1ZX0 TI TTGP7BY DMT1ZX0 TN Monoamine oxidase type B (MAO-B) DMT1ZX0 MA Modulator DMT1ZX0 RN Sembragiline Alzheimer's Disease (Phase 2). Evotech AG, Roche. DMT1ZX0 RU http://www.alzforum.org/therapeutics/sembragiline DMT3KB4 DI DMT3KB4 DMT3KB4 DN Lobeline DMT3KB4 TI TTNZRI3 DMT3KB4 TN Synaptic vesicle amine transporter (SLC18A2) DMT3KB4 MA Inhibitor DMT3KB4 RN Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27. DMT3KB4 RU https://pubmed.ncbi.nlm.nih.gov/21050177 DMT3ORQ DI DMT3ORQ DMT3ORQ DN CP-80794 DMT3ORQ TI TTB2MXP DMT3ORQ TN Angiotensinogenase renin (REN) DMT3ORQ MA Inhibitor DMT3ORQ RN Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril. J Cardiovasc Pharmacol. 1992 Jul;20(1):75-82. DMT3ORQ RU https://pubmed.ncbi.nlm.nih.gov/1383634 DMT3S10 DI DMT3S10 DMT3S10 DN AN0128 DMT3S10 TI TTF8CQI DMT3S10 TN Tumor necrosis factor (TNF) DMT3S10 MA Inhibitor DMT3S10 RN Inhibition of experimental periodontitis by a topical boron-based antimicrobial. J Dent Res. 2008 Feb;87(2):148-52. DMT3S10 RU https://pubmed.ncbi.nlm.nih.gov/18218841 DMT4FI5 DI DMT4FI5 DMT4FI5 DN SAR-566658 DMT4FI5 TI TTBHFYQ DMT4FI5 TN Mucin-1 (MUC1) DMT4FI5 RN Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73. DMT4FI5 RU http://mct.aacrjournals.org/content/12/11_Supplement/A73.short DMT4MKF DI DMT4MKF DMT4MKF DN Emibetuzumab DMT4MKF TI TTNDSF4 DMT4MKF TN Proto-oncogene c-Met (MET) DMT4MKF MA Inhibitor DMT4MKF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT4MKF RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMT4OPL DI DMT4OPL DMT4OPL DN Tonabersat DMT4OPL TI TT6MSOK DMT4OPL TN 5-HT 1D receptor (HTR1D) DMT4OPL MA Agonist DMT4OPL RN The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia. 2000 Jul;20(6):538-45. DMT4OPL RU https://pubmed.ncbi.nlm.nih.gov/11075836 DMT4QRD DI DMT4QRD DMT4QRD DN RG-4929 DMT4QRD TI TTN7BL9 DMT4QRD TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMT4QRD MA Inhibitor DMT4QRD RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DMT4QRD RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMT4UC1 DI DMT4UC1 DMT4UC1 DN Sibrotuzumab DMT4UC1 TI TTGPQ0F DMT4UC1 TN Prolyl endopeptidase FAP (FAP) DMT4UC1 MA Inhibitor DMT4UC1 RN A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47. DMT4UC1 RU https://pubmed.ncbi.nlm.nih.gov/12738716 DMT5QSD DI DMT5QSD DMT5QSD DN Resimmune DMT5QSD TI TTZAT79 DMT5QSD TN T-cell surface glycoprotein CD3 epsilon (CD3E) DMT5QSD MA Modulator DMT5QSD RN Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800. DMT5QSD RU https://www.ncbi.nlm.nih.gov/pubmed/25795722 DMT5QYJ DI DMT5QYJ DMT5QYJ DN ATI-2173 DMT5QYJ TI TTT4SY6 DMT5QYJ TN Hepatitis B virus Polymerase (HBV P) DMT5QYJ MA Inhibitor DMT5QYJ RN ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens. Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00836-20. DMT5QYJ RU https://pubmed.ncbi.nlm.nih.gov/32540975 DMT5YK7 DI DMT5YK7 DMT5YK7 DN GSK2890457 DMT5YK7 TI TTF5WCR DMT5YK7 TN Endogenous gut peptide (EGP) DMT5YK7 MA Modulator DMT5YK7 RN Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies. Expert Opin Investig Drugs. 2014 Aug;23(8):1055-66. DMT5YK7 RU https://pubmed.ncbi.nlm.nih.gov/25000213 DMT6E5N DI DMT6E5N DMT6E5N DN Onapristone DMT6E5N TI TTUV8G9 DMT6E5N TN Progesterone receptor (PGR) DMT6E5N MA Modulator DMT6E5N RN Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer. Eur J Cancer. 1999 Feb;35(2):214-8. DMT6E5N RU https://www.ncbi.nlm.nih.gov/pubmed/10448262 DMT6H3J DI DMT6H3J DMT6H3J DN AbGn-168 DMT6H3J TI TTS5K8U DMT6H3J TN P-selectin glycoprotein ligand 1 (SELPLG) DMT6H3J RN Clinical pipeline report, company report or official report of Avarx. DMT6H3J RU http://www.avarx.com/AvaRx/SubDomains/bucket3739906636580370793/Listings/bucket460336945731305549/Public.Listing.display.html DMT6O2E DI DMT6O2E DMT6O2E DN NC318 DMT6O2E TI TTBSZPF DMT6O2E TN Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15) DMT6O2E MA Inhibitor DMT6O2E RN Clinical pipeline report, company report or official report of NextCure. DMT6O2E RU http://www.nextcure.com/pipeline/ DMT8GVU DI DMT8GVU DMT8GVU DN 177Lu-DOTATATE DMT8GVU TI TTOMNR9 DMT8GVU TN Somatostatin receptor (SSTR) DMT8GVU MA Modulator DMT8GVU RN Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25. DMT8GVU RU https://pubmed.ncbi.nlm.nih.gov/24632546 DMT8GVU DI DMT8GVU DMT8GVU DN 177Lu-DOTATATE DMT8GVU TI TTAE1BR DMT8GVU TN Somatostatin receptor type 4 (SSTR4) DMT8GVU MA Inhibitor DMT8GVU RN New Drug in Development Shows Improved Progression-Free Survival for Patients with Advanced Metastatic Midgut Neuroendocrine Tumors DMT8GVU RU https://www.cancercommons.org/tag/177lu-dotatate/ DMT8L6P DI DMT8L6P DMT8L6P DN BMS-817399 DMT8L6P TI TTC24WT DMT8L6P TN C-C chemokine receptor type 1 (CCR1) DMT8L6P MA Modulator DMT8L6P RN Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritis. J Med Chem. 2014 Sep 25;57(18):7550-64. DMT8L6P RU https://pubmed.ncbi.nlm.nih.gov/25101488 DMT8SMO DI DMT8SMO DMT8SMO DN TKA-731 DMT8SMO TI TTZPO1L DMT8SMO TN Substance-P receptor (TACR1) DMT8SMO MA Antagonist DMT8SMO RN The NK1-receptor antagonist TKA731 in painful diabetic neuropathy: a randomised, controlled trial. Eur J Pain. 2006 Aug;10(6):567-71. DMT8SMO RU https://pubmed.ncbi.nlm.nih.gov/16199188 DMT9QI2 DI DMT9QI2 DMT9QI2 DN OCV-101 DMT9QI2 TI TT2Q6G1 DMT9QI2 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMT9QI2 MA Modulator DMT9QI2 RN Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.Cancer Sci.2013 Jan;104(1):98-104. DMT9QI2 RU https://www.ncbi.nlm.nih.gov/pubmed/23020774 DMTAEMB DI DMTAEMB DMTAEMB DN AX-200 DMTAEMB TI TTC70AJ DMTAEMB TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMTAEMB MA Modulator DMTAEMB RN Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7. DMTAEMB RU https://pubmed.ncbi.nlm.nih.gov/23963331 DMTAX8B DI DMTAX8B DMTAX8B DN S-2150 DMTAX8B TI TT5HONZ DMTAX8B TN Calcium channel unspecific (CaC) DMTAX8B MA Modulator DMTAX8B RN Pharmacodynamics of S-2150, a simultaneous calcium-blocking and alpha1-inhibiting antihypertensive drug, in rats. J Pharm Pharmacol. 2000 Mar;52(3):273-80. DMTAX8B RU https://pubmed.ncbi.nlm.nih.gov/10757414 DMTB63Q DI DMTB63Q DMTB63Q DN Estetrol DMTB63Q TI TTZAYWL DMTB63Q TN Estrogen receptor (ESR) DMTB63Q MA Modulator DMTB63Q RN Clinical pipeline report, company report or official report of Pantarhei Bioscience. DMTB63Q RU http://pantarheibio.com/pipeline/estetrol.htm DMTBAV3 DI DMTBAV3 DMTBAV3 DN RX-0201 DMTBAV3 TI TTWTSCV DMTBAV3 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMTBAV3 MA Inhibitor DMTBAV3 RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMTBAV3 RU http://www.centerwatch.com/ DMTBFE4 DI DMTBFE4 DMTBFE4 DN LY2090314 DMTBFE4 TI TTRZQE3 DMTBFE4 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMTBFE4 MA Modulator DMTBFE4 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMTBFE4 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMTBFE4 DI DMTBFE4 DMTBFE4 DN LY2090314 DMTBFE4 TI TTRSMW9 DMTBFE4 TN Glycogen synthase kinase-3 beta (GSK-3B) DMTBFE4 MA Modulator DMTBFE4 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMTBFE4 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMTBFXW DI DMTBFXW DMTBFXW DN CART 19 DMTBFXW TI TTW640A DMTBFXW TN B-lymphocyte surface antigen B4 (CD19) DMTBFXW MA CAR-T-Cell-Therapy DMTBFXW RN ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL DMTBFXW RU https://clinicaltrials.gov/ct2/show/NCT02935543 DMTBRPO DI DMTBRPO DMTBRPO DN REGN910-3 DMTBRPO TI TTKLQTJ DMTBRPO TN Angiopoietin-2 (ANGPT2) DMTBRPO MA Inhibitor DMTBRPO RN ClinicalTrials.gov (NCT02713204) Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX). U.S. National Institutes of Health. DMTBRPO RU https://clinicaltrials.gov/ct2/show/NCT02713204 DMTCXSG DI DMTCXSG DMTCXSG DN Abituzumab DMTCXSG TI TTT1R2L DMTCXSG TN Integrin alpha-V (ITGAV) DMTCXSG RN Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. Ann Oncol. 2015 Jan;26(1):132-40. DMTCXSG RU https://pubmed.ncbi.nlm.nih.gov/25319061 DMTDANB DI DMTDANB DMTDANB DN Pegsunercept DMTDANB TI TTF8CQI DMTDANB TN Tumor necrosis factor (TNF) DMTDANB MA Inhibitor DMTDANB RN Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy. Am J Pathol. 2008 May;172(5):1411-8. DMTDANB RU https://pubmed.ncbi.nlm.nih.gov/18403591 DMTE071 DI DMTE071 DMTE071 DN CHF-5074 DMTE071 TI TT9W8GU DMTE071 TN Gamma-secretase (GS) DMTE071 MA Modulator DMTE071 RN CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.Br J Pharmacol.2009 Mar;156(6):982-93. DMTE071 RU https://www.ncbi.nlm.nih.gov/pubmed/19239474 DMTE8DC DI DMTE8DC DMTE8DC DN Pozelimab DMTE8DC TI TTKANGO DMTE8DC TN Complement C5 (CO5) DMTE8DC MA Inhibitor DMTE8DC RN Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892. DMTE8DC RU https://pubmed.ncbi.nlm.nih.gov/32384086 DMTF24A DI DMTF24A DMTF24A DN ASP-7035 DMTF24A TI TTK8R02 DMTF24A TN Vasopressin V2 receptor (V2R) DMTF24A MA Agonist DMTF24A RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285) DMTF24A RU http://adisinsight.springer.com/drugs/800030285 DMTFE9Y DI DMTFE9Y DMTFE9Y DN AFN-1252 DMTFE9Y TI TTZBRVL DMTFE9Y TN Staphylococcus Enoyl ACP reductase (Stap-coc fabI) DMTFE9Y MA Inhibitor DMTFE9Y RN Activity of AFN-1252, a novel FabI inhibitor, against Staphylococcus aureus in an in vitro pharmacodynamic model simulating human pharmacokinetics. J Chemother. 2013 Feb;25(1):32-5. DMTFE9Y RU https://pubmed.ncbi.nlm.nih.gov/23433442 DMTG2O0 DI DMTG2O0 DMTG2O0 DN Anrukinzumab DMTG2O0 TI TT0GVCH DMTG2O0 TN Interleukin-13 (IL13) DMTG2O0 MA Modulator DMTG2O0 RN Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900. DMTG2O0 RU https://www.ncbi.nlm.nih.gov/pubmed/25567115 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTJW4LU DMTGNWU TN Phosphodiesterase 10A (PDE10) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTZCG4L DMTGNWU TN Phosphodiesterase 3 (PDE3) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTZ97H5 DMTGNWU TN Phosphodiesterase 4A (PDE4A) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGNWU DI DMTGNWU DMTGNWU DN Tofisopam DMTGNWU TI TTJGW1Z DMTGNWU TN Phosphodiesterase 2A (PDE2A) DMTGNWU MA Inhibitor DMTGNWU RN The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25. DMTGNWU RU https://pubmed.ncbi.nlm.nih.gov/20967473 DMTGR25 DI DMTGR25 DMTGR25 DN L-745,870 DMTGR25 TI TTE0A2F DMTGR25 TN Dopamine D4 receptor (D4R) DMTGR25 MA Antagonist DMTGR25 RN Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77. DMTGR25 RU https://pubmed.ncbi.nlm.nih.gov/18604600 DMTGU6K DI DMTGU6K DMTGU6K DN REN-1654 DMTGU6K TI TT7KPH1 DMTGU6K TN MAPK/ERK signaling pathway (MAPK pathway) DMTGU6K MA Modulator DMTGU6K RN US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases. DMTGU6K RU http://www.google.com/patents/US20060270742 DMTGU6K DI DMTGU6K DMTGU6K DN REN-1654 DMTGU6K TI TTX1JEN DMTGU6K TN JNK signaling pathway (JNK pathway) DMTGU6K MA Modulator DMTGU6K RN US patent application no. 2006,0270,742, Compositions and methods for the treatment of neurodegenerative diseases. DMTGU6K RU http://www.google.com/patents/US20060270742 DMTHR4U DI DMTHR4U DMTHR4U DN ASM8 DMTHR4U TI TTU3Y87 DMTHR4U TN CCR3 messenger RNA (CCR3 mRNA) DMTHR4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 60). DMTHR4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=60 DMTIED1 DI DMTIED1 DMTIED1 DN 131I-TM-601 DMTIED1 TI TTCYAXN DMTIED1 TN Chloride channel unspecific (ClC) DMTIED1 MA Inhibitor DMTIED1 RN Imaging glioma extent with 131I-TM-601. J Nucl Med. 2005 Apr;46(4):580-6. DMTIED1 RU https://pubmed.ncbi.nlm.nih.gov/15809479 DMTJMK5 DI DMTJMK5 DMTJMK5 DN TD-1211 DMTJMK5 TI TTKWM86 DMTJMK5 TN Opioid receptor mu (MOP) DMTJMK5 MA Modulator DMTJMK5 RN The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386(6):479-91. DMTJMK5 RU https://pubmed.ncbi.nlm.nih.gov/23549670 DMTJOEL DI DMTJOEL DMTJOEL DN DIADENOSINE TETRAPHOSPHATE DMTJOEL TI TTSLI08 DMTJOEL TN Adenosine receptor (ADOR) DMTJOEL MA Modulator DMTJOEL RN Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors. Br J Pharmacol. 1996 Nov;119(5):835-44. DMTJOEL RU https://pubmed.ncbi.nlm.nih.gov/8922729 DMTJOQX DI DMTJOQX DMTJOQX DN SMP-986 DMTJOQX TI TTRK8B9 DMTJOQX TN Sodium channel unspecific (NaC) DMTJOQX MA Antagonist DMTJOQX RN DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129. DMTJOQX RU http://www.sciencedirect.com/science/article/pii/S0022534708603717 DMTJOQX DI DMTJOQX DMTJOQX DN SMP-986 DMTJOQX TI TTOXS3C DMTJOQX TN Muscarinic acetylcholine receptor (CHRM) DMTJOQX MA Antagonist DMTJOQX RN DUAL INHIBITION OF Na+-CHANNEL AND MUSCARINIC RECEPTORS BY SMP-986 EFFICIENTLY IMPROVED VOIDING FUNCTION COMPARED TO ANTI-MUSCARINIC AGENTS IN TWO CONSCIOUS RAT MODELS OF DETRUSOR OVERACTIVITY. The Journal of Urology Volume 179, Issue 4, Supplement, April 2008, Pages 129. DMTJOQX RU http://www.sciencedirect.com/science/article/pii/S0022534708603717 DMTJWNE DI DMTJWNE DMTJWNE DN PF-03446962 DMTJWNE TI TTGYPTC DMTJWNE TN Activin receptor-like kinase-1 (ACVRL1) DMTJWNE MA Modulator DMTJWNE RN ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood. 2011 June 30; 117(26): 6999-7006. DMTJWNE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3143549/ DMTKDIP DI DMTKDIP DMTKDIP DN BMS-986141 DMTKDIP TI TT3I4WV DMTKDIP TN Prostate apoptosis response-4 (PAWR) DMTKDIP MA Antagonist DMTKDIP RN Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents. Eur J Med Chem. 2021 Jan 1;209:112893. DMTKDIP RU https://pubmed.ncbi.nlm.nih.gov/33049608 DMTKSVA DI DMTKSVA DMTKSVA DN CIMICOXIB DMTKSVA TI TTVKILB DMTKSVA TN Prostaglandin G/H synthase 2 (COX-2) DMTKSVA MA Modulator DMTKSVA RN Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs.Vet J.2014 Apr;200(1):77-81. DMTKSVA RU https://www.ncbi.nlm.nih.gov/pubmed/24461644 DMTL39C DI DMTL39C DMTL39C DN Plevitrexed (R)-isomer DMTL39C TI TTU6BFZ DMTL39C TN Candida Thymidylate synthase (Candi TMP1) DMTL39C MA Inhibitor DMTL39C RN Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30. DMTL39C RU https://pubmed.ncbi.nlm.nih.gov/17297914 DMTL39C DI DMTL39C DMTL39C DN Plevitrexed (R)-isomer DMTL39C TI TT5FOMZ DMTL39C TN Thymidylate synthase (TYMS) DMTL39C MA Inhibitor DMTL39C RN Differential effect of 1,10-phenanthroline on mammalian, yeast, and parasite glycosylphosphatidylinositol anchor synthesis. Biochem Biophys Res Commun. 2001 Nov 16;288(5):1112-8. DMTL39C RU https://pubmed.ncbi.nlm.nih.gov/11700026 DMTLB92 DI DMTLB92 DMTLB92 DN DI-Leu16-IL2 DMTLB92 TI TTUE541 DMTLB92 TN Leukocyte surface antigen Leu-16 (CD20) DMTLB92 MA Modulator DMTLB92 RN National Cancer Institute Drug Dictionary (drug id 599668). DMTLB92 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599668 DMTLR6Y DI DMTLR6Y DMTLR6Y DN 3K3A-APC DMTLR6Y TI TTZUXYS DMTLR6Y TN Vitamin K-dependent protein C (PROC) DMTLR6Y MA Modulator DMTLR6Y RN Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des. 2012;18(27):4215-22. DMTLR6Y RU https://pubmed.ncbi.nlm.nih.gov/22632606 DMTM4QA DI DMTM4QA DMTM4QA DN LCL161 DMTM4QA TI TTS74QB DMTM4QA TN Inhibitor of apoptosis protein (hIAP) DMTM4QA MA Modulator DMTM4QA RN National Cancer Institute Drug Dictionary (drug id 670651). DMTM4QA RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=670651 DMTMCPZ DI DMTMCPZ DMTMCPZ DN KB001A DMTMCPZ TI TTLK9NJ DMTMCPZ TN Pseudomonas PcrV protein type III (Pseudo pcrV) DMTMCPZ MA Inhibitor DMTMCPZ RN KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484-491. DMTMCPZ RU https://pubmed.ncbi.nlm.nih.gov/29292092 DMTN16K DI DMTN16K DMTN16K DN Implitapide DMTN16K TI TTUS1RD DMTN16K TN Microsomal triglyceride transfer protein (MTTP) DMTN16K MA Inhibitor DMTN16K RN Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan;11(1):67-70. DMTN16K RU https://pubmed.ncbi.nlm.nih.gov/19080731 DMTNDM2 DI DMTNDM2 DMTNDM2 DN Setrobuvir DMTNDM2 TI TTMVBWH DMTNDM2 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMTNDM2 MA Inhibitor DMTNDM2 RN Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011). DMTNDM2 RU http://www.anadyspharma.com/ DMTNOXQ DI DMTNOXQ DMTNOXQ DN OT-551 DMTNOXQ TI TTA6ZN2 DMTNOXQ TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMTNOXQ MA Inhibitor DMTNOXQ RN New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2. DMTNOXQ RU https://pubmed.ncbi.nlm.nih.gov/23812264 DMTOCIV DI DMTOCIV DMTOCIV DN SR-43845 DMTOCIV TI TTB2MXP DMTOCIV TN Angiotensinogenase renin (REN) DMTOCIV MA Inhibitor DMTOCIV RN Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca. J Hypertens Suppl. 1989 Apr;7(2):S33-5. DMTOCIV RU https://pubmed.ncbi.nlm.nih.gov/2666612 DMTOI7S DI DMTOI7S DMTOI7S DN ARRY-520 DMTOI7S TI TTTRP0H DMTOI7S TN Kinesin-like protein KIF11 (KIF11) DMTOI7S MA Inhibitor DMTOI7S RN Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia. 2009 Oct;23(10):1755-62. DMTOI7S RU https://pubmed.ncbi.nlm.nih.gov/19458629 DMTPQUA DI DMTPQUA DMTPQUA DN LY-2624803 DMTPQUA TI TTTIBOJ DMTPQUA TN Histamine H1 receptor (H1R) DMTPQUA MA Modulator DMTPQUA RN Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11. DMTPQUA RU https://pubmed.ncbi.nlm.nih.gov/25423562 DMTQ1Y3 DI DMTQ1Y3 DMTQ1Y3 DN AXL-1717 DMTQ1Y3 TI TTHRID2 DMTQ1Y3 TN Insulin-like growth factor I receptor (IGF1R) DMTQ1Y3 MA Inhibitor DMTQ1Y3 RN Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7. DMTQ1Y3 RU https://pubmed.ncbi.nlm.nih.gov/20698809 DMTQ2K0 DI DMTQ2K0 DMTQ2K0 DN SelG1 DMTQ2K0 TI TTE5VG0 DMTQ2K0 TN P-selectin (SELP) DMTQ2K0 RN Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011). DMTQ2K0 RU http://www.selexys.com/product_pipeline.asp DMTRONK DI DMTRONK DMTRONK DN BZL-101 DMTRONK TI TT34ECM DMTRONK TN Cell cycle (CC) DMTRONK MA Inhibitor DMTRONK RN BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype. Cancer Biol Ther. 2010 Aug 15;10(4):397-405. DMTRONK RU https://www.ncbi.nlm.nih.gov/pubmed/20574166 DMTROUI DI DMTROUI DMTROUI DN Vazegepant DMTROUI TI TT67OLB DMTROUI TN HUMAN calcitonin gene-related peptide type 1 receptor (CALCRL) DMTROUI MA Inhibitor DMTROUI RN Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen DMTROUI RU https://clinicaltrials.gov/ct2/show/NCT04346615 DMTSVJM DI DMTSVJM DMTSVJM DN CJM112 DMTSVJM TI TTG0MT6 DMTSVJM TN Interleukin-17 (IL17) DMTSVJM MA Inhibitor DMTSVJM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTSVJM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTUMYX DI DMTUMYX DMTUMYX DN AS-902330 DMTUMYX TI TT6ICRA DMTUMYX TN Fibroblast growth factor-18 (FGF18) DMTUMYX MA Modulator DMTUMYX RN Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014 Jul;66(7):1820-31. DMTUMYX RU https://pubmed.ncbi.nlm.nih.gov/24740822 DMTVGMZ DI DMTVGMZ DMTVGMZ DN NKP 608 DMTVGMZ TI TTZPO1L DMTVGMZ TN Substance-P receptor (TACR1) DMTVGMZ MA Antagonist DMTVGMZ RN Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study. Aliment Pharmacol Ther.2012 Feb;35(3):360-7. DMTVGMZ RU https://pubmed.ncbi.nlm.nih.gov/22221140 DMTVGY7 DI DMTVGY7 DMTVGY7 DN BMS-770767 DMTVGY7 TI TTN7BL9 DMTVGY7 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMTVGY7 MA Modulator DMTVGY7 RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DMTVGY7 RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMTVS3A DI DMTVS3A DMTVS3A DN Somatoprim DMTVS3A TI TTOMNR9 DMTVS3A TN Somatostatin receptor (SSTR) DMTVS3A MA Modulator DMTVS3A RN DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34. DMTVS3A RU https://www.ncbi.nlm.nih.gov/pubmed/22065857 DMTVU2Q DI DMTVU2Q DMTVU2Q DN LY2541546 DMTVU2Q TI TTYRO4F DMTVU2Q TN Sclerostin (SOST) DMTVU2Q RN Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. DMTVU2Q RU https://pubmed.ncbi.nlm.nih.gov/22106037 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT06RH5 DMTW79H TN GABA(A) receptor gamma-2 (GABRG2) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTDCVZW DMTW79H TN Gamma-aminobutyric acid B receptor (GABBR) DMTW79H MA Inhibitor DMTW79H RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/1652022 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT8RXO5 DMTW79H TN GABA transporter-3 (SLC6A11) DMTW79H MA Inhibitor DMTW79H RN Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/6268788 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTBMV1G DMTW79H TN GABA(A) receptor alpha-2 (GABRA2) DMTW79H MA Inhibitor DMTW79H RN New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/7392039 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT37EDJ DMTW79H TN GABA(A) receptor alpha-3 (GABRA3) DMTW79H MA Inhibitor DMTW79H RN New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/7392039 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTNJYV2 DMTW79H TN Gamma-aminobutyric acid receptor (GAR) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTZA1NY DMTW79H TN GABA(A) receptor beta-2 (GABRB2) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT1MPAY DMTW79H TN GABA(A) receptor alpha-1 (GABRA1) DMTW79H MA Inhibitor DMTW79H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTNZPQ1 DMTW79H TN GABA(A) receptor alpha-5 (GABRA5) DMTW79H MA Inhibitor DMTW79H RN New anticonvulsants: Schiff bases of gamma-aminobutyric acid and gamma-aminobutyramide. J Med Chem. 1980 Jun;23(6):702-4. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/7392039 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TTPRKM0 DMTW79H TN GABA transporter GAT-1 (SLC6A1) DMTW79H MA Inhibitor DMTW79H RN Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/15509161 DMTW79H DI DMTW79H DMTW79H DN GSK683699 DMTW79H TI TT4BT06 DMTW79H TN Integrin alpha-4 (ITGA4) DMTW79H MA Binder DMTW79H RN Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59. DMTW79H RU https://pubmed.ncbi.nlm.nih.gov/17355213 DMTX8IZ DI DMTX8IZ DMTX8IZ DN Endoxifen DMTX8IZ TI TTZAYWL DMTX8IZ TN Estrogen receptor (ESR) DMTX8IZ MA Modulator DMTX8IZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMTX8IZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMTXCUS DI DMTXCUS DMTXCUS DN Galiximab DMTXCUS TI TTFZDNP DMTXCUS TN Activation B7-1 antigen (CD80) DMTXCUS RN Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8. DMTXCUS RU https://pubmed.ncbi.nlm.nih.gov/15994148 DMTXHJ9 DI DMTXHJ9 DMTXHJ9 DN Sirolimus DMTXHJ9 TI TT7HQAF DMTXHJ9 TN HUMAN mammalian target of rapamycin (mTOR) DMTXHJ9 MA Inhibitor DMTXHJ9 RN Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14. DMTXHJ9 RU https://pubmed.ncbi.nlm.nih.gov/32194980 DMTXNZK DI DMTXNZK DMTXNZK DN Icofungipen DMTXNZK TI TT2GPK3 DMTXNZK TN DNA topoisomerase (TOP) DMTXNZK MA Inhibitor DMTXNZK RN Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2. Biochim Biophys Acta. 2003 Jan 3;1625(1):27-9. DMTXNZK RU https://pubmed.ncbi.nlm.nih.gov/12527422 DMTXNZK DI DMTXNZK DMTXNZK DN Icofungipen DMTXNZK TI TTBZHDM DMTXNZK TN Fungal Isoleucyl t-RNA synthetase (Fung ILS1) DMTXNZK MA Modulator DMTXNZK RN Efficacy, plasma pharmacokinetics, and safety of icofungipen, an inhibitor of Candida isoleucyl-tRNA synthetase, in treatment of experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother. 2005 May;49(5):2084-92. DMTXNZK RU https://pubmed.ncbi.nlm.nih.gov/15855534 DMTY4KN DI DMTY4KN DMTY4KN DN Dexefaroxan DMTY4KN TI TTM2AOE DMTY4KN TN Adenosine A2a receptor (ADORA2A) DMTY4KN MA Agonist DMTY4KN RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMTY4KN RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMTY4KN DI DMTY4KN DMTY4KN DN Dexefaroxan DMTY4KN TI TTJSZTB DMTY4KN TN Nicotinic acetylcholine receptor (nAChR) DMTY4KN MA Agonist DMTY4KN RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMTY4KN RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMTY4PG DI DMTY4PG DMTY4PG DN GI-4000 DMTY4PG TI TTW2R9X DMTY4PG TN GTPase NRas (NRAS) DMTY4PG RN Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation. Clin Lung Cancer. 2014 Nov;15(6):405-10. DMTY4PG RU https://pubmed.ncbi.nlm.nih.gov/25044103 DMTY6OF DI DMTY6OF DMTY6OF DN ATI-501 DMTY6OF TI TTT7PJU DMTY6OF TN Janus kinase 3 (JAK-3) DMTY6OF MA Inhibitor DMTY6OF RN Clinical pipeline report, company report or official report of Aclaris Therapeutics. DMTY6OF RU https://www.aclaristx.com/pipeline/ DMTY6OF DI DMTY6OF DMTY6OF DN ATI-501 DMTY6OF TI TT6DM01 DMTY6OF TN Janus kinase 1 (JAK-1) DMTY6OF MA Inhibitor DMTY6OF RN Clinical pipeline report, company report or official report of Aclaris Therapeutics. DMTY6OF RU https://www.aclaristx.com/pipeline/ DMTYD8Q DI DMTYD8Q DMTYD8Q DN ZD2079 DMTYD8Q TI TTMXGCW DMTYD8Q TN Adrenergic receptor beta-3 (ADRB3) DMTYD8Q MA Agonist DMTYD8Q RN Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70. DMTYD8Q RU https://pubmed.ncbi.nlm.nih.gov/10207980 DMTYXQF DI DMTYXQF DMTYXQF DN NVP-AUY922 DMTYXQF TI TT78R5H DMTYXQF TN Heat shock protein 90 alpha (HSP90A) DMTYXQF MA Inhibitor DMTYXQF RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMTYXQF RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMU0812 DI DMU0812 DMU0812 DN PAZ-320 DMU0812 TI TTXWASR DMU0812 TN Intestinal maltase-glucoamylase (MGAM) DMU0812 MA Modulator DMU0812 RN Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022. DMU0812 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455361/ DMU1MR9 DI DMU1MR9 DMU1MR9 DN IMD-1041 DMU1MR9 TI TTJ3E9X DMU1MR9 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMU1MR9 MA Inhibitor DMU1MR9 RN Inhibition of I B phosphorylation prevents load-induced cardiac dysfunction in mice. Am J Physiol Heart Circ Physiol. 2012 Dec 15;303(12):H1435-45. DMU1MR9 RU https://pubmed.ncbi.nlm.nih.gov/23042949 DMU1XZD DI DMU1XZD DMU1XZD DN Erteberel DMU1XZD TI TTOM3J0 DMU1XZD TN Estrogen receptor beta (ESR2) DMU1XZD MA Agonist DMU1XZD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031986) DMU1XZD RU http://adisinsight.springer.com/drugs/800031986 DMU2GP4 DI DMU2GP4 DMU2GP4 DN DT-1687 DMU2GP4 TI TTICZ1O DMU2GP4 TN Metabotropic glutamate receptor 4 (mGluR4) DMU2GP4 MA Modulator DMU2GP4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292). DMU2GP4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292 DMU3KOH DI DMU3KOH DMU3KOH DN NNC-0151-0000-0000 DMU3KOH TI TTKANGO DMU3KOH TN Complement C5 (CO5) DMU3KOH RN Complement-targeted therapeutics. Nat Biotechnol. 2007 Nov;25(11):1265-75. DMU3KOH RU https://pubmed.ncbi.nlm.nih.gov/17989689 DMU3P1K DI DMU3P1K DMU3P1K DN Cenerimod DMU3P1K TI TT2DLFI DMU3P1K TN Lysosphingolipid receptor (LSPR) DMU3P1K MA Agonist DMU3P1K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU3P1K RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMU3XJP DI DMU3XJP DMU3XJP DN Pascolizumab DMU3XJP TI TTLGTKB DMU3XJP TN Interleukin-4 (IL4) DMU3XJP MA Modulator DMU3XJP RN The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. DMU3XJP RU https://www.ncbi.nlm.nih.gov/pubmed/23197041 DMU4CS8 DI DMU4CS8 DMU4CS8 DN MEDI6012 DMU4CS8 TI TTGZ91P DMU4CS8 TN Lecithin-cholesterol acyltransferase (LCAT) DMU4CS8 MA Modulator DMU4CS8 RN Familial lecithin-cholesterol acyltransferase (LCAT) deficiency; a differential of proteinuria. J Nephropathol. 2015 January; 4(1): 25-28. DMU4CS8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316582/ DMU5EVR DI DMU5EVR DMU5EVR DN GSK2586881 DMU5EVR TI TTUI5H7 DMU5EVR TN Angiotensin-converting enzyme 2 (ACE2) DMU5EVR MA Modulator DMU5EVR RN New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. DMU5EVR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/ DMU5H3A DI DMU5H3A DMU5H3A DN PZ-128 DMU5H3A TI TTL935N DMU5H3A TN Proteinase activated receptor 1 (F2R) DMU5H3A MA Antagonist DMU5H3A RN PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003. DMU5H3A RU https://pubmed.ncbi.nlm.nih.gov/33028101 DMU5SZP DI DMU5SZP DMU5SZP DN Inecalcitol oral DMU5SZP TI TTK59TV DMU5SZP TN Vitamin D3 receptor (VDR) DMU5SZP MA Agonist DMU5SZP RN Inecalcitol, an analog of 1,25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle. 2013 Mar 1;12(5):743-52. DMU5SZP RU https://pubmed.ncbi.nlm.nih.gov/23388458 DMU62I8 DI DMU62I8 DMU62I8 DN CX2009 DMU62I8 TI TT2AFT6 DMU62I8 TN Activated leukocyte cell adhesionmolecule (ALCAM) DMU62I8 RN Clinical pipeline report, company report or official report of CytomX Therapeutics. DMU62I8 RU https://cytomx.com/pipeline/ DMU6NBO DI DMU6NBO DMU6NBO DN APX3330 DMU6NBO TI TTHGL48 DMU6NBO TN AP endonuclease 1 (APEX1) DMU6NBO MA Inhibitor DMU6NBO RN Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic. NPJ Precis Oncol. 2017;1:19. DMU6NBO RU https://pubmed.ncbi.nlm.nih.gov/28825044 DMU6R3O DI DMU6R3O DMU6R3O DN CLG561 DMU6R3O TI TTLA0VS DMU6R3O TN Complement factor P (CFP) DMU6R3O MA Inhibitor DMU6R3O RN Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342. DMU6R3O RU https://pubmed.ncbi.nlm.nih.gov/30686077 DMU7ZMH DI DMU7ZMH DMU7ZMH DN S-364735 DMU7ZMH TI TT5FH9Y DMU7ZMH TN Human immunodeficiency virus Integrase (HIV IN) DMU7ZMH MA Inhibitor DMU7ZMH RN The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother. 2008 Mar;52(3):901-8. DMU7ZMH RU https://pubmed.ncbi.nlm.nih.gov/18160521 DMU81BH DI DMU81BH DMU81BH DN LY-2189102 DMU81BH TI TTRYK0X DMU81BH TN Interleukin-1 beta (IL1B) DMU81BH RN Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 2013Aug;36(8):2239-46. DMU81BH RU https://pubmed.ncbi.nlm.nih.gov/23514733 DMUA0XC DI DMUA0XC DMUA0XC DN ALF-5755 DMUA0XC TI TTL4H8N DMUA0XC TN Regenerating human pro-islet peptide (REG3A) DMUA0XC MA Modulator DMUA0XC RN HIP/PAP prevents excitotoxic neuronal death and promotes plasticity. Ann Clin Transl Neurol. 2014 October; 1(10): 739-754. DMUA0XC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241802/ DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TTBWX8P DMUAOFM TN Staphylococcus Manganese transporter C (Stap-coc MntC) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TTE6QWF DMUAOFM TN Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TT4SVB7 DMUAOFM TN Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAOFM DI DMUAOFM DMUAOFM DN PF-06290510 DMUAOFM TI TTWGZ64 DMUAOFM TN Staphylococcus Clumping factor A (Stap-coc ClfA) DMUAOFM RN ClinicalTrials.gov (NCT01364571) Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years. U.S. National Institutes of Health. DMUAOFM RU https://clinicaltrials.gov/ct2/show/NCT01364571 DMUAXS5 DI DMUAXS5 DMUAXS5 DN FP-1039 DMUAXS5 TI TTRLW2X DMUAXS5 TN Fibroblast growth factor receptor 1 (FGFR1) DMUAXS5 MA Antagonist DMUAXS5 RN FGF1-gold nanoparticle conjugates targeting FGFR efficiently decrease cell viability upon NIR irradiation. Int J Nanomedicine. 2012; 7: 5915-5927. DMUAXS5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514973/ DMUB3OY DI DMUB3OY DMUB3OY DN RO-5323441 DMUB3OY TI TT48I1Y DMUB3OY TN Placenta growth factor (PlGF) DMUB3OY MA Inhibitor DMUB3OY RN RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011. DMUB3OY RU http://cancerres.aacrjournals.org/content/70/8_Supplement/1370.abstract DMUDMHA DI DMUDMHA DMUDMHA DN CZEN-002 DMUDMHA TI TTSXVID DMUDMHA TN Nuclear factor NF-kappa-B (NFKB) DMUDMHA MA Modulator DMUDMHA RN US patent application no. US20100278784 A1. DMUDMHA RU https://www.google.com.ar/patents/US20100278784 DMUE0AK DI DMUE0AK DMUE0AK DN Saratin DMUE0AK TI TTE5Q4N DMUE0AK TN VWF-dependent platelet-collagen conversion (VDDPCC) DMUE0AK MA Inhibitor DMUE0AK RN Antithrombotic effects of saratin on human atherosclerotic plaques. Thromb Haemost. 2004 Jul;92(1):191-200. DMUE0AK RU https://pubmed.ncbi.nlm.nih.gov/15213861 DMUE90I DI DMUE90I DMUE90I DN AZD1656 DMUE90I TI TTDLNGZ DMUE90I TN Glucokinase (GCK) DMUE90I MA Activator DMUE90I RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMUE90I RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMUFCQG DI DMUFCQG DMUFCQG DN IC14 DMUFCQG TI TT6I7DC DMUFCQG TN Monocyte differentiation antigen CD14 (CD14) DMUFCQG RN IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res. 2001;7(4):310-4. DMUFCQG RU https://pubmed.ncbi.nlm.nih.gov/11717588 DMUFY4K DI DMUFY4K DMUFY4K DN BCT303 DMUFY4K TI TTTSEPU DMUFY4K TN Thyroid hormone receptor alpha (THRA) DMUFY4K MA Modulator DMUFY4K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUFY4K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUFY4K DI DMUFY4K DMUFY4K DN BCT303 DMUFY4K TI TTGER3L DMUFY4K TN Thyroid hormone receptor beta (THRB) DMUFY4K MA Modulator DMUFY4K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUFY4K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUGBQK DI DMUGBQK DMUGBQK DN DVC1-0101 DMUGBQK TI TTGKIED DMUGBQK TN Fibroblast growth factor-2 (FGF2) DMUGBQK MA Modulator DMUGBQK RN DVC1-0101 to treat peripheral arterial disease: a Phase I/IIa open-label dose-escalation clinical trial. Mol Ther. 2013 Mar;21(3):707-14. DMUGBQK RU https://pubmed.ncbi.nlm.nih.gov/23319060 DMUGN4B DI DMUGN4B DMUGN4B DN MN-305 DMUGN4B TI TTSQIFT DMUGN4B TN 5-HT 1A receptor (HTR1A) DMUGN4B MA Agonist DMUGN4B RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMUGN4B RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMUHDX3 DI DMUHDX3 DMUHDX3 DN PC-SOD DMUHDX3 TI TT6RVLG DMUHDX3 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMUHDX3 MA Modulator DMUHDX3 RN A lecithinized superoxide dismutase (PC-SOD) improves ulcerative colitis DMUHDX3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659364 DMUI5PA DI DMUI5PA DMUI5PA DN Brostallicin DMUI5PA TI TTOVXHF DMUI5PA TN Human Deoxyribonucleic acid minor groove (hDNA min) DMUI5PA MA Inhibitor DMUI5PA RN Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs. 2009 Dec;18(12):1939-46. DMUI5PA RU https://pubmed.ncbi.nlm.nih.gov/19938904 DMUICJD DI DMUICJD DMUICJD DN SAR-156597 DMUICJD TI TTDWHC3 DMUICJD TN Interleukin 4 receptor alpha (IL4R) DMUICJD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697). DMUICJD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697 DMUICJD DI DMUICJD DMUICJD DN SAR-156597 DMUICJD TI TTLGTKB DMUICJD TN Interleukin-4 (IL4) DMUICJD MA Modulator DMUICJD RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMUICJD RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMUICJD DI DMUICJD DMUICJD DN SAR-156597 DMUICJD TI TT0GVCH DMUICJD TN Interleukin-13 (IL13) DMUICJD MA Modulator DMUICJD RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMUICJD RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMUJ0W7 DI DMUJ0W7 DMUJ0W7 DN CP-724714 DMUJ0W7 TI TT6EO5L DMUJ0W7 TN Erbb2 tyrosine kinase receptor (HER2) DMUJ0W7 MA Inhibitor DMUJ0W7 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMUJ0W7 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMUJ1WV DI DMUJ1WV DMUJ1WV DN IMCgp100 DMUJ1WV TI TT8MK59 DMUJ1WV TN Melanocytes lineage-specific antigen GP100 (PMEL) DMUJ1WV MA Modulator DMUJ1WV RN Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors DMUJ1WV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624013 DMUJ1WV DI DMUJ1WV DMUJ1WV DN IMCgp100 DMUJ1WV TI TTV3XPL DMUJ1WV TN T-cell surface glycoprotein CD3 gamma (CD3G) DMUJ1WV MA Inhibitor DMUJ1WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUJ1WV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMUJ1WV DI DMUJ1WV DMUJ1WV DN IMCgp100 DMUJ1WV TI TT7AKW1 DMUJ1WV TN T-cell receptor (TCR) DMUJ1WV MA Modulator DMUJ1WV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUJ1WV RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMUK6HC DI DMUK6HC DMUK6HC DN N-5984 DMUK6HC TI TTMXGCW DMUK6HC TN Adrenergic receptor beta-3 (ADRB3) DMUK6HC MA Agonist DMUK6HC RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMUK6HC RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMUL6GY DI DMUL6GY DMUL6GY DN BEMORADAN DMUL6GY TI TT06AWU DMUL6GY TN Phosphodiesterase 3A (PDE3A) DMUL6GY MA Inhibitor DMUL6GY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMUL6GY RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMULZ4W DI DMULZ4W DMULZ4W DN CHR-2797 DMULZ4W TI TT371QC DMULZ4W TN Puromycin-sensitive aminopeptidase (NPEPPS) DMULZ4W MA Inhibitor DMULZ4W RN CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008 Aug 15;68(16):6669-79. DMULZ4W RU https://pubmed.ncbi.nlm.nih.gov/18701491 DMULZ4W DI DMULZ4W DMULZ4W DN CHR-2797 DMULZ4W TI TTWLEZV DMULZ4W TN Aminopeptidase (AMP) DMULZ4W MA Inhibitor DMULZ4W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMULZ4W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMUM2KA DI DMUM2KA DMUM2KA DN BN82451 DMUM2KA TI TTRK8B9 DMUM2KA TN Sodium channel unspecific (NaC) DMUM2KA MA Blocker DMUM2KA RN Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97. DMUM2KA RU https://pubmed.ncbi.nlm.nih.gov/19453283 DMUM2KA DI DMUM2KA DMUM2KA DN BN82451 DMUM2KA TI TTK0943 DMUM2KA TN Prostaglandin G/H synthase (COX) DMUM2KA MA Inhibitor DMUM2KA RN Emerging drug therapies in Huntington's disease. Expert Opin Emerg Drugs. 2009 Jun;14(2):273-97. DMUM2KA RU https://pubmed.ncbi.nlm.nih.gov/19453283 DMUM370 DI DMUM370 DMUM370 DN MSH-1001 DMUM370 TI TT1VOHK DMUM370 TN Potassium channel unspecific (KC) DMUM370 MA Opener DMUM370 RN KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci. 2009 Apr;109(4):511-7. DMUM370 RU https://pubmed.ncbi.nlm.nih.gov/19372634 DMUMCB9 DI DMUMCB9 DMUMCB9 DN Amelubant DMUMCB9 TI TTN53ZF DMUMCB9 TN Leukotriene B4 receptor 1 (LTB4R) DMUMCB9 MA Antagonist DMUMCB9 RN Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects. Paediatr Drugs. 2005;7(6):353-63. DMUMCB9 RU https://pubmed.ncbi.nlm.nih.gov/16356023 DMUMCWS DI DMUMCWS DMUMCWS DN MEMP1972A DMUMCWS TI TTYJQTF DMUMCWS TN Immunoglobulin E (IgE) DMUMCWS RN International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011 DMUMCWS RU http://www.who.int/medicines/publications/druginformation/innlists/Final_PL106.pdf DMUNJZB DI DMUNJZB DMUNJZB DN UCN-01 DMUNJZB TI TTTU902 DMUNJZB TN Checkpoint kinase-1 (CHK1) DMUNJZB MA Inhibitor DMUNJZB RN Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30. DMUNJZB RU https://pubmed.ncbi.nlm.nih.gov/19473860 DMUOEKM DI DMUOEKM DMUOEKM DN JNJ-39393406 DMUOEKM TI TTLA931 DMUOEKM TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMUOEKM MA Modulator DMUOEKM RN Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204. DMUOEKM RU https://pubmed.ncbi.nlm.nih.gov/22766391 DMUOYQR DI DMUOYQR DMUOYQR DN AVI-5126 DMUOYQR TI TTNQ5ZP DMUOYQR TN Myc messenger RNA (MYC mRNA) DMUOYQR RN Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201. DMUOYQR RU https://pubmed.ncbi.nlm.nih.gov/22149555 DMUPD4G DI DMUPD4G DMUPD4G DN ISIS 113715 DMUPD4G TI TTELIN2 DMUPD4G TN PTPN1 messenger RNA (PTPN1 mRNA) DMUPD4G RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMUPD4G RU http://www.isispharm.com/Pipeline/index.htm DMUPJWH DI DMUPJWH DMUPJWH DN YM-598 DMUPJWH TI TTKRD0G DMUPJWH TN Endothelin A receptor (EDNRA) DMUPJWH MA Antagonist DMUPJWH RN Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol. 2011 May; 163(2): 220-233. DMUPJWH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087127/ DMUPZFO DI DMUPZFO DMUPZFO DN Neihulizumab DMUPZFO TI TTS5K8U DMUPZFO TN P-selectin glycoprotein ligand 1 (SELPLG) DMUPZFO MA Inhibitor DMUPZFO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUPZFO RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMUQH78 DI DMUQH78 DMUQH78 DN Tempol DMUQH78 TI TT6RVLG DMUQH78 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMUQH78 MA Modulator DMUQH78 RN The superoxide dismutase mimetic, tempol, reduces the bioavailability of nitric oxide and does not alter L-NAME-induced hypertension in rats. Basic Clin Pharmacol Toxicol. 2005 Jul;97(1):29-34. DMUQH78 RU https://www.ncbi.nlm.nih.gov/pubmed/15943756 DMUQZT4 DI DMUQZT4 DMUQZT4 DN VPI-2690B DMUQZT4 TI TTHRID2 DMUQZT4 TN Insulin-like growth factor I receptor (IGF1R) DMUQZT4 MA Antagonist DMUQZT4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUQZT4 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMURX4B DI DMURX4B DMURX4B DN Recombinant batroxobin DMURX4B TI TTWODQF DMURX4B TN Fibrin (FG) DMURX4B MA Modulator DMURX4B RN Functional characterization of recombinant batroxobin, a snake venom thrombin-like enzyme, expressed from Pichia pastoris. FEBS Lett. 2004 Jul 30;571(1-3):67-73. DMURX4B RU https://pubmed.ncbi.nlm.nih.gov/15280019 DMURXMJ DI DMURXMJ DMURXMJ DN HTI-101 DMURXMJ TI TT3C1VN DMURXMJ TN Enzyme unspecific (Enz) DMURXMJ MA Antagonist DMURXMJ RN Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference. Halozyme Therapeutics. JULY 12, 2006. DMURXMJ RU http://www.prnewswire.com/news-releases/halozyme-therapeutics-announces-new-studies-from-hti-101-presented-at-proteoglycan-research-conference-56000982.html DMUT9OE DI DMUT9OE DMUT9OE DN Zadaxin/lamivudine DMUT9OE TI TTSYFMA DMUT9OE TN Interferon alpha/beta receptor 1 (IFNAR1) DMUT9OE MA Modulator DMUT9OE RN Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7. DMUT9OE RU https://pubmed.ncbi.nlm.nih.gov/15992078 DMUT9OE DI DMUT9OE DMUT9OE DN Zadaxin/lamivudine DMUT9OE TI TTSHG0T DMUT9OE TN Toll-like receptor 9 (TLR9) DMUT9OE MA Modulator DMUT9OE RN Zadaxin (thymosin alpha1) for the treatment of viral hepatitis. Expert Opin Investig Drugs. 1999 Mar;8(3):281-7. DMUT9OE RU https://pubmed.ncbi.nlm.nih.gov/15992078 DMUTS1W DI DMUTS1W DMUTS1W DN BMS-936557 DMUTS1W TI TTQOVYA DMUTS1W TN C-X-C motif chemokine 10 (CXCL10) DMUTS1W RN Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50. DMUTS1W RU https://pubmed.ncbi.nlm.nih.gov/23461895 DMUVMY9 DI DMUVMY9 DMUVMY9 DN BI-836858 DMUVMY9 TI TTJVYO3 DMUVMY9 TN Myeloid cell surface antigen CD33 (CD33) DMUVMY9 RN The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53. DMUVMY9 RU https://pubmed.ncbi.nlm.nih.gov/24809231 DMUVON0 DI DMUVON0 DMUVON0 DN PNT-2258 DMUVON0 TI TTFOUV4 DMUVON0 TN BCL-2 messenger RNA (BCL2 mRNA) DMUVON0 RN Clinical pipeline report, company report or official report of ProNAi. DMUVON0 RU http://pronai.com/pnt2258-targeting-bcl2/ DMUWFI7 DI DMUWFI7 DMUWFI7 DN QAX-576 DMUWFI7 TI TT0GVCH DMUWFI7 TN Interleukin-13 (IL13) DMUWFI7 MA Modulator DMUWFI7 RN Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7. DMUWFI7 RU https://pubmed.ncbi.nlm.nih.gov/25226850 DMUWJI4 DI DMUWJI4 DMUWJI4 DN E-6700 DMUWJI4 TI TT2J34L DMUWJI4 TN Arachidonate 5-lipoxygenase (5-LOX) DMUWJI4 MA Modulator DMUWJI4 RN Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57. DMUWJI4 RU https://pubmed.ncbi.nlm.nih.gov/8759636 DMUWJI4 DI DMUWJI4 DMUWJI4 DN E-6700 DMUWJI4 TI TTKNWZ4 DMUWJI4 TN Thromboxane-A synthase (TBXAS1) DMUWJI4 MA Modulator DMUWJI4 RN Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57. DMUWJI4 RU https://pubmed.ncbi.nlm.nih.gov/8759636 DMUX8JZ DI DMUX8JZ DMUX8JZ DN Nivocasan DMUX8JZ TI TTCQIBE DMUX8JZ TN Caspase-1 (CASP1) DMUX8JZ MA Modulator DMUX8JZ RN Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis. 2013 Dec;18(12):1481-91. DMUX8JZ RU https://pubmed.ncbi.nlm.nih.gov/24045874 DMUXDGZ DI DMUXDGZ DMUXDGZ DN EPX-300 DMUXDGZ TI TT85JO3 DMUXDGZ TN 5-HT receptor (5HTR) DMUXDGZ MA Modulator DMUXDGZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUXDGZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMUXIRM DI DMUXIRM DMUXIRM DN DS-8500 DMUXIRM TI TT7QNVC DMUXIRM TN Glucose-dependent insulinotropic receptor (GPR119) DMUXIRM MA Modulator DMUXIRM RN Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31. DMUXIRM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/ DMV0A28 DI DMV0A28 DMV0A28 DN Recombinant RGD-hirudin DMV0A28 TI TT6L509 DMV0A28 TN Coagulation factor IIa (F2) DMV0A28 MA Modulator DMV0A28 RN The NMR solution structure of recombinant RGD-hirudin. Biochem Biophys Res Commun. 2007 Aug 17;360(1):103-8. DMV0A28 RU https://pubmed.ncbi.nlm.nih.gov/17585879 DMV0MZ3 DI DMV0MZ3 DMV0MZ3 DN FK-962 DMV0MZ3 TI TTOMNR9 DMV0MZ3 TN Somatostatin receptor (SSTR) DMV0MZ3 MA Modulator DMV0MZ3 RN FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7. DMV0MZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/11172755 DMV14LM DI DMV14LM DMV14LM DN LY2886721 DMV14LM TI TT8JRS7 DMV14LM TN Beta-secretase (BACE) DMV14LM MA Modulator DMV14LM RN Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9. DMV14LM RU https://www.ncbi.nlm.nih.gov/pubmed/24530026 DMV17HK DI DMV17HK DMV17HK DN PTI-125 DMV17HK TI TTSTRZY DMV17HK TN Filamin A (FLNA) DMV17HK MA Inhibitor DMV17HK RN Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A. J Neurosci. 2012 Jul 18;32(29):9773-84. DMV17HK RU https://pubmed.ncbi.nlm.nih.gov/22815492 DMV1T59 DI DMV1T59 DMV1T59 DN JNJ-18038683 DMV1T59 TI TTO9X1H DMV1T59 TN 5-HT 7 receptor (HTR7) DMV1T59 MA Antagonist DMV1T59 RN Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453. DMV1T59 RU https://pubmed.ncbi.nlm.nih.gov/25642174 DMV27SP DI DMV27SP DMV27SP DN Panobacumab DMV27SP TI TT4ESMB DMV27SP TN Pseudomonas Lipopolysaccharide (Pseudo LPS) DMV27SP MA Modulator DMV27SP RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DMV27SP RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DMV2YDK DI DMV2YDK DMV2YDK DN LEISH-F1 DMV2YDK TI TT3J5ZI DMV2YDK TN Cell mediated immunity response (CMIR) DMV2YDK RN A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine. 2011 Apr 27;29(19):3531-7. DMV2YDK RU https://pubmed.ncbi.nlm.nih.gov/21414377 DMV319J DI DMV319J DMV319J DN RO-4905417 DMV319J TI TTS5K8U DMV319J TN P-selectin glycoprotein ligand 1 (SELPLG) DMV319J RN WO patent application no. 2013,0144,05, Methods. DMV319J RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130131&CC=WO&NR=2013014405A2&KC=A2 DMV3TO4 DI DMV3TO4 DMV3TO4 DN GSK3810109 DMV3TO4 TI TT2ISQT DMV3TO4 TN Human immunodeficiency virus Attachment (HIV att) DMV3TO4 MA Inhibitor DMV3TO4 RN Clinical pipeline report, company report or official report of ViiV Healthcare. DMV3TO4 RU https://viivhealthcare.com/en-us/medicines-in-development/ DMV41P5 DI DMV41P5 DMV41P5 DN JNJ-37822681 DMV41P5 TI TTEX248 DMV41P5 TN Dopamine D2 receptor (D2R) DMV41P5 MA Agonist DMV41P5 RN Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15. DMV41P5 RU https://pubmed.ncbi.nlm.nih.gov/23754735 DMV50R1 DI DMV50R1 DMV50R1 DN HE3235 DMV50R1 TI TTYA7V2 DMV50R1 TN Prostate cance cell (PCC) DMV50R1 MA Inhibitor DMV50R1 RN 17alpha-alkynyl 3alpha, 17beta-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism. Invest New Drugs. 2012 Feb;30(1):59-78. DMV50R1 RU https://pubmed.ncbi.nlm.nih.gov/20814732 DMV6SNU DI DMV6SNU DMV6SNU DN GSK4069889 DMV6SNU TI TT1RWL7 DMV6SNU TN Hepatitis A virus cellular receptor 2 (TIM3) DMV6SNU MA Inhibitor DMV6SNU RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMV6SNU RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMV7ZU0 DI DMV7ZU0 DMV7ZU0 DN GS-6624 DMV7ZU0 TI TTFSUHX DMV7ZU0 TN Lysyl oxidase homolog 2 (LOXL2) DMV7ZU0 RN National Cancer Institute Drug Dictionary (drug id 681814). DMV7ZU0 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=681814 DMV84OK DI DMV84OK DMV84OK DN DTI-0009 DMV84OK TI TTK25J1 DMV84OK TN Adenosine A1 receptor (ADORA1) DMV84OK MA Agonist DMV84OK RN Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308. DMV84OK RU https://pubmed.ncbi.nlm.nih.gov/21185259 DMV86DY DI DMV86DY DMV86DY DN [131I]-BC8 DMV86DY TI TTUS45N DMV86DY TN Leukocyte common antigen (PTPRC) DMV86DY RN Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995 Feb 15;85(4):1122-31. DMV86DY RU https://pubmed.ncbi.nlm.nih.gov/7849300 DMV8WU9 DI DMV8WU9 DMV8WU9 DN LYC-55716 DMV8WU9 TI TTGV6LY DMV8WU9 TN Nuclear receptor ROR-gamma (RORG) DMV8WU9 MA Agonist DMV8WU9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV8WU9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMV934L DI DMV934L DMV934L DN ALX-40-4C DMV934L TI TTT3ZC9 DMV934L TN Human immunodeficiency virus Tat protein (HIV tat) DMV934L MA Modulator DMV934L RN Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions. J Virol. 1996 May;70(5):2825-31. DMV934L RU https://pubmed.ncbi.nlm.nih.gov/8627756 DMV96BY DI DMV96BY DMV96BY DN ETS-6218 DMV96BY TI TT7CXIM DMV96BY TN Histamine receptor (HR) DMV96BY MA Modulator DMV96BY RN Clinical pipeline report, company report or official report of e-Therapeutics. DMV96BY RU http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf DMVA5NS DI DMVA5NS DMVA5NS DN BAY-57-9352 DMVA5NS TI TTI2WET DMVA5NS TN Platelet-derived growth factor receptor (PDGFR) DMVA5NS MA Inhibitor DMVA5NS RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMVA5NS RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMVA5NS DI DMVA5NS DMVA5NS DN BAY-57-9352 DMVA5NS TI TTUTJGQ DMVA5NS TN Vascular endothelial growth factor receptor 2 (KDR) DMVA5NS MA Inhibitor DMVA5NS RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMVA5NS RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMVA5NS DI DMVA5NS DMVA5NS DN BAY-57-9352 DMVA5NS TI TTVJ1D8 DMVA5NS TN Vascular endothelial growth factor receptor (VEGFR) DMVA5NS MA Inhibitor DMVA5NS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVA5NS RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMVACTU DI DMVACTU DMVACTU DN Interferon alpha-2b DMVACTU TI TTSIUJ9 DMVACTU TN Interferon-alpha 2 (IFNA2) DMVACTU MA Modulator DMVACTU RN Clinical pipeline report, company report or official report of Avarx. DMVACTU RU http://www.avarx.com/AvaRx/SubDomains/Company271/Listings/bucketc9a4f99040669fa206037a416235/Public.Listing.display.html DMVADGZ DI DMVADGZ DMVADGZ DN AWD-12-281 DMVADGZ TI TTVIAT9 DMVADGZ TN Phosphodiesterase 4B (PDE4B) DMVADGZ MA Inhibitor DMVADGZ RN The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17. DMVADGZ RU https://pubmed.ncbi.nlm.nih.gov/16354405 DMVADGZ DI DMVADGZ DMVADGZ DN AWD-12-281 DMVADGZ TI TTSKMI8 DMVADGZ TN Phosphodiesterase 4D (PDE4D) DMVADGZ MA Inhibitor DMVADGZ RN The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17. DMVADGZ RU https://pubmed.ncbi.nlm.nih.gov/16354405 DMVADGZ DI DMVADGZ DMVADGZ DN AWD-12-281 DMVADGZ TI TTZ97H5 DMVADGZ TN Phosphodiesterase 4A (PDE4A) DMVADGZ MA Inhibitor DMVADGZ RN The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005 Dec;57(12):1609-17. DMVADGZ RU https://pubmed.ncbi.nlm.nih.gov/16354405 DMVB8EO DI DMVB8EO DMVB8EO DN XLCART001 DMVB8EO TI TTW640A DMVB8EO TN B-lymphocyte surface antigen B4 (CD19) DMVB8EO MA CAR-T-Cell-Therapy DMVB8EO RN ClinicalTrials.gov (NCT03598179) XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects DMVB8EO RU https://clinicaltrials.gov/ct2/show/NCT03598179 DMVC90W DI DMVC90W DMVC90W DN Oglemilast DMVC90W TI TTZ97H5 DMVC90W TN Phosphodiesterase 4A (PDE4A) DMVC90W MA Inhibitor DMVC90W RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMVC90W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMVC90W DI DMVC90W DMVC90W DN Oglemilast DMVC90W TI TTVIAT9 DMVC90W TN Phosphodiesterase 4B (PDE4B) DMVC90W MA Inhibitor DMVC90W RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMVC90W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMVC90W DI DMVC90W DMVC90W DN Oglemilast DMVC90W TI TTSKMI8 DMVC90W TN Phosphodiesterase 4D (PDE4D) DMVC90W MA Inhibitor DMVC90W RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking . Br J Pharmacol. 2008 October; 155(3): 288-290. DMVC90W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567889/ DMVCXZK DI DMVCXZK DMVCXZK DN Rupintrivir DMVCXZK TI TTGW0DV DMVCXZK TN Rhinovirus Protease 3C (HRV P3C) DMVCXZK MA Modulator DMVCXZK RN Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011 Oct;85(19):10319-31. DMVCXZK RU https://pubmed.ncbi.nlm.nih.gov/21795339 DMVDO93 DI DMVDO93 DMVDO93 DN BL-1020 DMVDO93 TI TTEX248 DMVDO93 TN Dopamine D2 receptor (D2R) DMVDO93 MA Antagonist DMVDO93 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMVDO93 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMVDO93 DI DMVDO93 DMVDO93 DN BL-1020 DMVDO93 TI TTNJYV2 DMVDO93 TN Gamma-aminobutyric acid receptor (GAR) DMVDO93 MA Agonist DMVDO93 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMVDO93 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMVIRN3 DI DMVIRN3 DMVIRN3 DN N-DESMETHYLCLOZAPINE DMVIRN3 TI TTZ9SOR DMVIRN3 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMVIRN3 MA Modulator DMVIRN3 RN N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarin... Neuropsychopharmacology. 2005 Nov;30(11):1986-95. DMVIRN3 RU https://www.ncbi.nlm.nih.gov/pubmed/15900318 DMVIWNK DI DMVIWNK DMVIWNK DN SFV IL-12 gene therapy DMVIWNK TI TTGW72V DMVIWNK TN Interleukin-12 beta (IL12B) DMVIWNK MA Modulator DMVIWNK RN Clinical pipeline report, company report or official report of Trademarkia. DMVIWNK RU http://www.trademarkia.com/lipovil-12-79009798.html DMVJ6WS DI DMVJ6WS DMVJ6WS DN Melogliptin DMVJ6WS TI TTDIGC1 DMVJ6WS TN Dipeptidyl peptidase 4 (DPP-4) DMVJ6WS MA Inhibitor DMVJ6WS RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMVJ6WS RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMVJB09 DI DMVJB09 DMVJB09 DN MK-1903 DMVJB09 TI TTWNV8U DMVJB09 TN Nicotinic acid receptor (HCAR2) DMVJB09 MA Agonist DMVJB09 RN Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115. DMVJB09 RU https://pubmed.ncbi.nlm.nih.gov/22914621 DMVJD2W DI DMVJD2W DMVJD2W DN Pazopanib + Tyverb/Tykerb DMVJD2W TI TTGKNB4 DMVJD2W TN Epidermal growth factor receptor (EGFR) DMVJD2W MA Inhibitor DMVJD2W RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMVJD2W RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMVJD2W DI DMVJD2W DMVJD2W DN Pazopanib + Tyverb/Tykerb DMVJD2W TI TT6EO5L DMVJD2W TN Erbb2 tyrosine kinase receptor (HER2) DMVJD2W MA Inhibitor DMVJD2W RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMVJD2W RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMVJWPR DI DMVJWPR DMVJWPR DN TOK-001 DMVJWPR TI TTS64P2 DMVJWPR TN Androgen receptor (AR) DMVJWPR MA Inhibitor DMVJWPR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8638). DMVJWPR RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8638 DMVJXOH DI DMVJXOH DMVJXOH DN BMS-986012 DMVJXOH TI TTW7KYV DMVJXOH TN Fucosyl GM1 (FucGM1) DMVJXOH MA Inhibitor DMVJXOH RN A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer. Clin Cancer Res. 2018 Oct 15;24(20):5178-5189. DMVJXOH RU https://pubmed.ncbi.nlm.nih.gov/30021910 DMVKPEZ DI DMVKPEZ DMVKPEZ DN AZD-9164 DMVKPEZ TI TTOXS3C DMVKPEZ TN Muscarinic acetylcholine receptor (CHRM) DMVKPEZ MA Antagonist DMVKPEZ RN The discovery of AZD9164, a novel muscarinic M3 antagonist. Bioorg Med Chem Lett. 2011 Dec 15;21(24):7440-6. DMVKPEZ RU https://pubmed.ncbi.nlm.nih.gov/22047691 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTZHA0O DMVKW0N TN Carbonic anhydrase IV (CA-IV) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTUNARX DMVKW0N TN Carbonic anhydrase (CA) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTHQPL7 DMVKW0N TN Carbonic anhydrase I (CA-I) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTEYTKG DMVKW0N TN Carbonic anhydrase XIV (CA-XIV) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TT2LVK8 DMVKW0N TN Carbonic anhydrase IX (CA-IX) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTCFSPE DMVKW0N TN Carbonic anhydrase VI (CA-VI) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTHM0R1 DMVKW0N TN Steryl-sulfatase (STS) DMVKW0N MA Inhibitor DMVKW0N RN Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/20148564 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTSYM0R DMVKW0N TN Carbonic anhydrase XII (CA-XII) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTSZLWK DMVKW0N TN Aromatase (CYP19A1) DMVKW0N MA Inhibitor DMVKW0N RN Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/20148564 DMVKW0N DI DMVKW0N DMVKW0N DN Coumate DMVKW0N TI TTANPDJ DMVKW0N TN Carbonic anhydrase II (CA-II) DMVKW0N MA Inhibitor DMVKW0N RN Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-r... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. DMVKW0N RU https://pubmed.ncbi.nlm.nih.gov/18640037 DMVLXMG DI DMVLXMG DMVLXMG DN Camostat mesylate DMVLXMG TI TT3FDB1 DMVLXMG TN HUMAN transmembrane protease serine 2 (TMPRSS2) DMVLXMG MA Inhibitor DMVLXMG RN SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. DMVLXMG RU https://pubmed.ncbi.nlm.nih.gov/32142651 DMVM13R DI DMVM13R DMVM13R DN LJPC-401 DMVM13R TI TTPCG5T DMVM13R TN Hepcidin (HAMP) DMVM13R MA Agonist DMVM13R RN ClinicalTrials.gov (NCT03395704) A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis. U.S. National Institutes of Health. DMVM13R RU https://clinicaltrials.gov/ct2/show/NCT03395704 DMVNAYE DI DMVNAYE DMVNAYE DN MK-8521 DMVNAYE TI TT0NUFM DMVNAYE TN Glucagon (GCG) DMVNAYE MA Co-agonist DMVNAYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVNAYE RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMVNAYE DI DMVNAYE DMVNAYE DN MK-8521 DMVNAYE TI TT9O6WS DMVNAYE TN Glucagon receptor (GCGR) DMVNAYE MA Co-agonist DMVNAYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVNAYE RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMVO5DR DI DMVO5DR DMVO5DR DN CP-331684 DMVO5DR TI TTMXGCW DMVO5DR TN Adrenergic receptor beta-3 (ADRB3) DMVO5DR MA Agonist DMVO5DR RN CN patent application no. 1717230, Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor. DMVO5DR RU https://www.google.com/patents/CN1717230A?cl=en DMVQARP DI DMVQARP DMVQARP DN WCK-771 DMVQARP TI TTN6J5F DMVQARP TN Bacterial DNA gyrase (Bact gyrase) DMVQARP MA Modulator DMVQARP RN Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models DMVQARP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196 DMVQARP DI DMVQARP DMVQARP DN WCK-771 DMVQARP TI TTIXTO3 DMVQARP TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMVQARP MA Modulator DMVQARP RN Antistaphylococcal Activity of WCK 771, a Tricyclic Fluoroquinolone, in Animal Infection Models DMVQARP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC529196 DMVQHBK DI DMVQHBK DMVQHBK DN Anti-GD2 CART DMVQHBK TI TT80ARU DMVQHBK TN Ganglioside GD2 (GD2) DMVQHBK MA CAR-T-Cell-Therapy DMVQHBK RN ClinicalTrials.gov (NCT02765243) Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma DMVQHBK RU https://clinicaltrials.gov/ct2/show/NCT02765243 DMVR6OM DI DMVR6OM DMVR6OM DN Flotetuzumab DMVR6OM TI TTENHJ0 DMVR6OM TN Interleukin 3 receptor alpha (IL3RA) DMVR6OM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVR6OM RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMVRNAO DI DMVRNAO DMVRNAO DN Anti-IP10 DMVRNAO TI TTQOVYA DMVRNAO TN C-X-C motif chemokine 10 (CXCL10) DMVRNAO RN Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50. DMVRNAO RU https://pubmed.ncbi.nlm.nih.gov/23461895 DMVS61L DI DMVS61L DMVS61L DN Tepoxalin DMVS61L TI TTLGTKB DMVS61L TN Interleukin-4 (IL4) DMVS61L MA Inhibitor DMVS61L RN Therapeutic interference with interferon-gamma (IFN-gamma) and soluble IL-4 receptor (sIL-4R) in allergic diseases. Behring Inst Mitt. 1995 Jun;(96):118-30. DMVS61L RU https://pubmed.ncbi.nlm.nih.gov/7575347 DMVS61L DI DMVS61L DMVS61L DN Tepoxalin DMVS61L TI TT2J34L DMVS61L TN Arachidonate 5-lipoxygenase (5-LOX) DMVS61L MA Inhibitor DMVS61L RN Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundam Appl Toxicol. 1996 Sep;33(1):38-48. DMVS61L RU https://pubmed.ncbi.nlm.nih.gov/8812216 DMVSUH1 DI DMVSUH1 DMVSUH1 DN JNJ-64565111 DMVSUH1 TI TT0NUFM DMVSUH1 TN Glucagon (GCG) DMVSUH1 MA Agonist DMVSUH1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVSUH1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMVU1R9 DI DMVU1R9 DMVU1R9 DN RM-1929 DMVU1R9 TI TTGKNB4 DMVU1R9 TN Epidermal growth factor receptor (EGFR) DMVU1R9 MA Antagonist DMVU1R9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVU1R9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVUGF7 DI DMVUGF7 DMVUGF7 DN PUR-0110 DMVUGF7 TI TT4EWFY DMVUGF7 TN TNF/IL-10 release (TNF/IL10 rele) DMVUGF7 MA Modulator DMVUGF7 RN PCT-233, a novel modulator of pro- and anti-inflammatory cytokine production. Clin Exp Immunol. 2004 Mar;135(3):440-7. DMVUGF7 RU https://pubmed.ncbi.nlm.nih.gov/15008976 DMVUX1C DI DMVUX1C DMVUX1C DN BFH-772 DMVUX1C TI TTVJ1D8 DMVUX1C TN Vascular endothelial growth factor receptor (VEGFR) DMVUX1C MA Agonist DMVUX1C RN CA patent application no. 841416, Method of selecting therapeutic indications. DMVUX1C RU http://www.google.com/patents/CA2841416A1?cl=en DMVW5KR DI DMVW5KR DMVW5KR DN Olcegepant DMVW5KR TI TTY6O0Q DMVW5KR TN Calcitonin gene-related peptide receptor (CGRPR) DMVW5KR MA Modulator DMVW5KR RN Olcegepant, a non-peptide CGRP1 antagonist for migraine treatment. IDrugs. 2007 Aug;10(8):566-74. DMVW5KR RU https://www.ncbi.nlm.nih.gov/pubmed/17665333 DMVX6H0 DI DMVX6H0 DMVX6H0 DN TRV027 DMVX6H0 TI TT8DBY3 DMVX6H0 TN Angiotensin II receptor type-1 (AGTR1) DMVX6H0 MA Antagonist DMVX6H0 RN First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2013 Sep;53(9):892-9. DMVX6H0 RU https://pubmed.ncbi.nlm.nih.gov/23813302 DMVXGU0 DI DMVXGU0 DMVXGU0 DN RG7596 DMVXGU0 TI TTBN5I7 DMVXGU0 TN B-cell-specific glycoprotein B29 (CD79B) DMVXGU0 MA Modulator DMVXGU0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852). DMVXGU0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2852 DMVXLQ7 DI DMVXLQ7 DMVXLQ7 DN TLN-4601 DMVXLQ7 TI TTPTXIN DMVXLQ7 TN Translocator protein (TSPO) DMVXLQ7 MA Modulator DMVXLQ7 RN TLN-4601 peripheral benzodiazepine receptor (PBR/TSPO) binding properties do not mediate apoptosis but confer tumor-specific accumulation.Biochem Pharmacol.2010 Nov 15;80(10):1572-9. DMVXLQ7 RU https://www.ncbi.nlm.nih.gov/pubmed/20655882 DMVXZC4 DI DMVXZC4 DMVXZC4 DN OBP-601 DMVXZC4 TI TT84ETX DMVXZC4 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMVXZC4 MA Inhibitor DMVXZC4 RN Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2012 Oct;56(10):5000-8. DMVXZC4 RU https://pubmed.ncbi.nlm.nih.gov/22733071 DMVXZJ4 DI DMVXZJ4 DMVXZJ4 DN RetinoStat DMVXZJ4 TI TT63DI9 DMVXZJ4 TN Endostatin (COL18A1) DMVXZJ4 MA Modulator DMVXZJ4 RN Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91. DMVXZJ4 RU https://pubmed.ncbi.nlm.nih.gov/22716662 DMVXZJ4 DI DMVXZJ4 DMVXZJ4 DN RetinoStat DMVXZJ4 TI TTP86E2 DMVXZJ4 TN Plasminogen (PLG) DMVXZJ4 MA Modulator DMVXZJ4 RN Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat( ), for age-related macular degeneration. Hum Gene Ther. 2012 Sep;23(9):980-91. DMVXZJ4 RU https://pubmed.ncbi.nlm.nih.gov/22716662 DMVZ01T DI DMVZ01T DMVZ01T DN SSR240600 DMVZ01T TI TTZPO1L DMVZ01T TN Substance-P receptor (TACR1) DMVZ01T MA Antagonist DMVZ01T RN SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1171-9. DMVZ01T RU https://pubmed.ncbi.nlm.nih.gov/12438541 DMVZT2I DI DMVZT2I DMVZT2I DN CX-072 DMVZT2I TI TT8ZLTI DMVZT2I TN Programmed cell death 1 ligand 1 (PD-L1) DMVZT2I MA Inhibitor DMVZT2I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVZT2I RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMW03YD DI DMW03YD DMW03YD DN BAN2401 DMW03YD TI TTE4KHA DMW03YD TN Amyloid beta A4 protein (APP) DMW03YD MA Modulator DMW03YD RN The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88. DMW03YD RU https://pubmed.ncbi.nlm.nih.gov/25096615 DMW145U DI DMW145U DMW145U DN TMC-310911 DMW145U TI TT5FNQT DMW145U TN Human immunodeficiency virus Protease (HIV PR) DMW145U MA Inhibitor DMW145U RN Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry & Biology Volume 21, Issue 9, 18 September 2014, Pages 1115-1142. DMW145U RU http://www.sciencedirect.com/science/article/pii/S1074552114002890 DMW17KS DI DMW17KS DMW17KS DN TOL-3021 DMW17KS TI TTUTN1I DMW17KS TN Human Deoxyribonucleic acid (hDNA) DMW17KS MA Modulator DMW17KS RN Clinical pipeline report, company report or official report of Tolerion. DMW17KS RU http://www.tolerioninc.com/TOL-3021_press_release.html DMW1NKO DI DMW1NKO DMW1NKO DN X-82 DMW1NKO TI TTI2WET DMW1NKO TN Platelet-derived growth factor receptor (PDGFR) DMW1NKO MA Modulator DMW1NKO RN National Cancer Institute Drug Dictionary (drug id 695817). DMW1NKO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817 DMW1NKO DI DMW1NKO DMW1NKO DN X-82 DMW1NKO TI TT2Q6G1 DMW1NKO TN Vascular endothelial growth factor receptor 1 (FLT-1) DMW1NKO MA Modulator DMW1NKO RN National Cancer Institute Drug Dictionary (drug id 695817). DMW1NKO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=695817 DMW1NKO DI DMW1NKO DMW1NKO DN X-82 DMW1NKO TI TTVJ1D8 DMW1NKO TN Vascular endothelial growth factor receptor (VEGFR) DMW1NKO MA Inhibitor DMW1NKO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW1NKO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW1OI6 DI DMW1OI6 DMW1OI6 DN P32/98 DMW1OI6 TI TTDIGC1 DMW1OI6 TN Dipeptidyl peptidase 4 (DPP-4) DMW1OI6 MA Inhibitor DMW1OI6 RN Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes. 2002 Apr;51(4):943-50. DMW1OI6 RU https://pubmed.ncbi.nlm.nih.gov/11916911 DMW2IF9 DI DMW2IF9 DMW2IF9 DN IR502 DMW2IF9 TI TT7AKW1 DMW2IF9 TN T-cell receptor (TCR) DMW2IF9 MA Modulator DMW2IF9 RN WO patent application no. 2004,0677,06, Production of multimeric proteins. DMW2IF9 RU http://www.google.com/patents/WO2004067706A2?cl=en DMW2QYT DI DMW2QYT DMW2QYT DN Firategrast DMW2QYT TI TT6S84X DMW2QYT TN Integrin alpha-4/beta-1 (ITGA4/B1) DMW2QYT MA Modulator DMW2QYT RN Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.2012 Feb;11(2):131-9. DMW2QYT RU https://www.ncbi.nlm.nih.gov/pubmed/22226929 DMW4LTI DI DMW4LTI DMW4LTI DN Votucalis DMW4LTI TI TT7CXIM DMW4LTI TN Histamine receptor (HR) DMW4LTI MA Antagonist DMW4LTI RN CA patent application no. 520580, Histamine binding compounds for treatment method for disease conditions mediated by neutrophils. DMW4LTI RU http://www.google.com.ar/patents/CA2520580A1?cl=en DMW4YK1 DI DMW4YK1 DMW4YK1 DN Remogliflozin etabonate DMW4YK1 TI TTN7Y4P DMW4YK1 TN Sodium/glucose cotransporter 2 (SLC5A4) DMW4YK1 MA Blocker DMW4YK1 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMW4YK1 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMW4YK1 DI DMW4YK1 DMW4YK1 DN Remogliflozin etabonate DMW4YK1 TI TTLWPVF DMW4YK1 TN Sodium/glucose cotransporter 2 (SGLT2) DMW4YK1 MA Inhibitor DMW4YK1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW4YK1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMW50NF DI DMW50NF DMW50NF DN LE-SN38 DMW50NF TI TTGTQHC DMW50NF TN DNA topoisomerase I (TOP1) DMW50NF MA Inhibitor DMW50NF RN Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines. Anticancer Res. 2012 Nov;32(11):4823-32. DMW50NF RU https://pubmed.ncbi.nlm.nih.gov/23155248 DMW6NMP DI DMW6NMP DMW6NMP DN L19-TNF-alpha DMW6NMP TI TTPJ921 DMW6NMP TN Fibronectin (FN1) DMW6NMP RN National Cancer Institute Drug Dictionary (drug id 686947). DMW6NMP RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=686947 DMW6UA3 DI DMW6UA3 DMW6UA3 DN SR-46559A DMW6UA3 TI TTZ9SOR DMW6UA3 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMW6UA3 MA Agonist DMW6UA3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMW6UA3 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMW6VA0 DI DMW6VA0 DMW6VA0 DN LM-1507.NA DMW6VA0 TI TTGKOY9 DMW6VA0 TN Leukotriene CysLT1 receptor (CYSLTR1) DMW6VA0 MA Antagonist DMW6VA0 RN Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem Pharmacol. 2002 Apr 15;63(8):1537-46. DMW6VA0 RU https://pubmed.ncbi.nlm.nih.gov/11996896 DMW7L0Y DI DMW7L0Y DMW7L0Y DN PUL-042 DMW7L0Y TI TT2LBCR DMW7L0Y TN HUMAN toll-like receptor 9 (TLR9) DMW7L0Y MA Agonist DMW7L0Y RN Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. DMW7L0Y RU https://pulmotect.com/product/ DMW7L0Y DI DMW7L0Y DMW7L0Y DN PUL-042 DMW7L0Y TI TTAVUMS DMW7L0Y TN HUMAN toll-like receptor 2 (TLR2) DMW7L0Y MA Agonist DMW7L0Y RN Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. DMW7L0Y RU https://pulmotect.com/product/ DMW7L0Y DI DMW7L0Y DMW7L0Y DN PUL-042 DMW7L0Y TI TTLSU52 DMW7L0Y TN HUMAN toll-like receptor 6 (TLR6) DMW7L0Y MA Agonist DMW7L0Y RN Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. DMW7L0Y RU https://pulmotect.com/product/ DMW7PFS DI DMW7PFS DMW7PFS DN Turosteride DMW7PFS TI TT2A0DR DMW7PFS TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMW7PFS MA Inhibitor DMW7PFS RN Hormonal effects of turosteride, a 5 alpha-reductase inhibitor, in the rat. J Steroid Biochem Mol Biol. 1993 Nov;46(5):549-55. DMW7PFS RU https://pubmed.ncbi.nlm.nih.gov/8240976 DMW8X05 DI DMW8X05 DMW8X05 DN THR-149 DMW8X05 TI TTMF8H9 DMW8X05 TN Plasma kallikrein (KLKB1) DMW8X05 MA Inhibitor DMW8X05 RN Clinical pipeline report, company report or official report of Oxurion. DMW8X05 RU https://www.oxurion.com/product/thr-149-pkal-inhibitor DMW9F1G DI DMW9F1G DMW9F1G DN CKD602 DMW9F1G TI TTGTQHC DMW9F1G TN DNA topoisomerase I (TOP1) DMW9F1G MA Inhibitor DMW9F1G RN Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998 Oct;21(5):581-90. DMW9F1G RU https://pubmed.ncbi.nlm.nih.gov/9875499 DMWAD93 DI DMWAD93 DMWAD93 DN Leniolisib DMWAD93 TI TTGBPJE DMWAD93 TN PI3-kinase delta (PIK3CD) DMWAD93 MA Inhibitor DMWAD93 RN Effective "activated PI3K syndrome"-targeted therapy with the PI3K inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307-2316. DMWAD93 RU https://pubmed.ncbi.nlm.nih.gov/28972011 DMWB94K DI DMWB94K DMWB94K DN Evenamide DMWB94K TI TTIG65Q DMWB94K TN Voltage-gated sodium channel (Nav) DMWB94K MA Blocker DMWB94K RN Clinical pipeline report, company report or official report of Newron Pharmaceuticals. DMWB94K RU https://www.newron.com/science#evenamide DMWC36Y DI DMWC36Y DMWC36Y DN OMS405 DMWC36Y TI TTZMAO3 DMWC36Y TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMWC36Y MA Agonist DMWC36Y RN Clinical pipeline report, company report or official report of Avarx. DMWC36Y RU http://www.avarx.com/AvaRx/SubDomains/bucket4984694478449561395/Listings/bucket4040741479008611375/Public.Listing.display.html DMWCBY7 DI DMWCBY7 DMWCBY7 DN Odiparcil DMWCBY7 TI TT6L509 DMWCBY7 TN Coagulation factor IIa (F2) DMWCBY7 MA Inhibitor DMWCBY7 RN A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96. DMWCBY7 RU https://pubmed.ncbi.nlm.nih.gov/16961606 DMWDJ15 DI DMWDJ15 DMWDJ15 DN UFT/leucovorin calcium DMWDJ15 TI TTU6BFZ DMWDJ15 TN Candida Thymidylate synthase (Candi TMP1) DMWDJ15 MA Modulator DMWDJ15 RN Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer. 1989 Mar 15;63(6 Suppl):1008-12. DMWDJ15 RU https://pubmed.ncbi.nlm.nih.gov/2521810 DMWE7B9 DI DMWE7B9 DMWE7B9 DN CX-4945 DMWE7B9 TI TTZ5NI7 DMWE7B9 TN Casein kinase II (CSNK2) DMWE7B9 MA Modulator DMWE7B9 RN CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway. Leukemia. 2013 Oct;27(10):2094-6. DMWE7B9 RU https://pubmed.ncbi.nlm.nih.gov/23900138 DMWE7B9 DI DMWE7B9 DMWE7B9 DN CX-4945 DMWE7B9 TI TTER6YH DMWE7B9 TN Casein kinase II alpha (CSNK2A1) DMWE7B9 MA Inhibitor DMWE7B9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWE7B9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWEB07 DI DMWEB07 DMWEB07 DN XOMA-629 DMWEB07 TI TTXCSDR DMWEB07 TN Protein bactericidal permeability-increasing (BPI) DMWEB07 MA Inhibitor DMWEB07 RN Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012 Mar 16;10(4):243-54. DMWEB07 RU https://pubmed.ncbi.nlm.nih.gov/22421877 DMWFTRJ DI DMWFTRJ DMWFTRJ DN MK-0354 DMWFTRJ TI TTWNV8U DMWFTRJ TN Nicotinic acid receptor (HCAR2) DMWFTRJ MA Inhibitor DMWFTRJ RN GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4. DMWFTRJ RU https://pubmed.ncbi.nlm.nih.gov/20615702 DMWH7Z5 DI DMWH7Z5 DMWH7Z5 DN BI-836826 DMWH7Z5 TI TTFCW29 DMWH7Z5 TN Leukocyte antigen CD37 (CD37) DMWH7Z5 RN Anti-CD37 antibodies for chronic lymphocytic leukemia. Expert Opin Biol Ther. 2014 May;14(5):651-61. DMWH7Z5 RU https://pubmed.ncbi.nlm.nih.gov/24555705 DMWI0X3 DI DMWI0X3 DMWI0X3 DN Barusiban DMWI0X3 TI TTSCIUP DMWI0X3 TN Oxytocin receptor (OTR) DMWI0X3 MA Antagonist DMWI0X3 RN The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol. 2009 Jun;200(6):627.e1-10. DMWI0X3 RU https://pubmed.ncbi.nlm.nih.gov/19306963 DMWJMFZ DI DMWJMFZ DMWJMFZ DN Miravirsen DMWJMFZ TI TTP03CE DMWJMFZ TN Hepatitis C virus microRNA miR-122 (HCV MIR122) DMWJMFZ MA Modulator DMWJMFZ RN Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.Nucleic Acids Res.2014 Jan;42(1):609-21. DMWJMFZ RU https://www.ncbi.nlm.nih.gov/pubmed/24068553 DMWK26Q DI DMWK26Q DMWK26Q DN EPX-200 DMWK26Q TI TT85JO3 DMWK26Q TN 5-HT receptor (5HTR) DMWK26Q MA Modulator DMWK26Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWK26Q RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWK9BX DI DMWK9BX DMWK9BX DN SQ-109 DMWK9BX TI TTTLB3R DMWK9BX TN Mycobacterium Membrane protein mmpL3 (MycB mmpL3) DMWK9BX MA Modulator DMWK9BX RN SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012 Apr;56(4):1797-809. DMWK9BX RU https://pubmed.ncbi.nlm.nih.gov/22252828 DMWLIPJ DI DMWLIPJ DMWLIPJ DN MAXY-G34 DMWLIPJ TI TTC70AJ DMWLIPJ TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMWLIPJ MA Agonist DMWLIPJ RN Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors. Health Phys. 2014 Jan;106(1):21-38. DMWLIPJ RU https://pubmed.ncbi.nlm.nih.gov/24276547 DMWN2EC DI DMWN2EC DMWN2EC DN ORG-25935 DMWN2EC TI TTHJTF7 DMWN2EC TN Glycine transporter GlyT-1 (SLC6A9) DMWN2EC MA Inhibitor DMWN2EC RN The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014 Apr;34(2):190-8. DMWN2EC RU https://pubmed.ncbi.nlm.nih.gov/24525661 DMWNYIE DI DMWNYIE DMWNYIE DN Bemarituzumab DMWNYIE TI TTGKIED DMWNYIE TN Fibroblast growth factor-2 (FGF2) DMWNYIE MA Antagonist DMWNYIE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWNYIE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TTM7WCE DMWP59B TN Ion channel unspecific (IC) DMWP59B MA Antagonist DMWP59B RN A randomized trial of budiodarone in paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2012 Jun;34(1):1-9. DMWP59B RU https://pubmed.ncbi.nlm.nih.gov/22205496 DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TTRK8B9 DMWP59B TN Sodium channel unspecific (NaC) DMWP59B MA Agonist DMWP59B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWP59B RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TT5HONZ DMWP59B TN Calcium channel unspecific (CaC) DMWP59B MA Agonist DMWP59B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWP59B RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMWP59B DI DMWP59B DMWP59B DN ATI-2042 DMWP59B TI TT1VOHK DMWP59B TN Potassium channel unspecific (KC) DMWP59B MA Agonist DMWP59B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWP59B RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMWPDUZ DI DMWPDUZ DMWPDUZ DN BTRX-335140 DMWPDUZ TI TTQW87Y DMWPDUZ TN Opioid receptor kappa (OPRK1) DMWPDUZ MA Antagonist DMWPDUZ RN Clinical pipeline report, company report or official report of BlackThorn Therapeutics. DMWPDUZ RU https://www.blackthornrx.com/btrx-335140-kappa-opioid-receptor-antagonist/ DMWPGB8 DI DMWPGB8 DMWPGB8 DN Amg 747 DMWPGB8 TI TTHJTF7 DMWPGB8 TN Glycine transporter GlyT-1 (SLC6A9) DMWPGB8 MA Modulator DMWPGB8 RN Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov. 2013 Nov;12(11):866-85. DMWPGB8 RU https://pubmed.ncbi.nlm.nih.gov/24172334 DMWPGLS DI DMWPGLS DMWPGLS DN ASN100 DMWPGLS TI TTKE96O DMWPGLS TN Staphylococcus Five leukocidin toxins (Stap-coc lukF) DMWPGLS MA Modulator DMWPGLS RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DMWPGLS RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DMWPGLS DI DMWPGLS DMWPGLS DN ASN100 DMWPGLS TI TT5FLYB DMWPGLS TN Staphylococcus Alpha-hemolysin (Stap-coc hly) DMWPGLS MA Modulator DMWPGLS RN Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8. DMWPGLS RU https://www.ncbi.nlm.nih.gov/pubmed/26514853 DMWPI2U DI DMWPI2U DMWPI2U DN TC-6499-12 DMWPI2U TI TTL1ATN DMWPI2U TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMWPI2U MA Modulator DMWPI2U RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWPI2U RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWPSJR DI DMWPSJR DMWPSJR DN TAK-831 DMWPSJR TI TT7Y3EJ DMWPSJR TN D-amino acid oxidase (DAO) DMWPSJR MA Inhibitor DMWPSJR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWPSJR RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMWT73D DI DMWT73D DMWT73D DN PMX-60056 DMWT73D TI TT4QPUL DMWT73D TN Antithrombin-III (ATIII) DMWT73D MA Antagonist DMWT73D RN Parenteral Anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Correction in: Chest. 2013 August; 144(2): 721. DMWT73D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278070/ DMWU41P DI DMWU41P DMWU41P DN TRIDMAC DMWU41P TI TTJSZTB DMWU41P TN Nicotinic acetylcholine receptor (nAChR) DMWU41P MA Antagonist DMWU41P RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMWU41P RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMWUQI9 DI DMWUQI9 DMWUQI9 DN CER-001 DMWUQI9 TI TT7GN3U DMWUQI9 TN Apolipoprotein A-I (APOA1) DMWUQI9 MA Modulator DMWUQI9 RN Clinical pipeline report, company report or official report of Cerenis. DMWUQI9 RU http://www.cerenis.com/en/our-therapies/cer-001 DMWV2N1 DI DMWV2N1 DMWV2N1 DN IONIS-GCCRRX DMWV2N1 TI TTYRL6O DMWV2N1 TN Glucocorticoid receptor (NR3C1) DMWV2N1 MA Antagonist DMWV2N1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV2N1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMWVBS2 DI DMWVBS2 DMWVBS2 DN NXN-462 DMWVBS2 TI TTZUFI5 DMWVBS2 TN Nitric-oxide synthase brain (NOS1) DMWVBS2 MA Inhibitor DMWVBS2 RN ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health. DMWVBS2 RU https://clinicaltrials.gov/ct2/show/NCT01748877 DMWVBTQ DI DMWVBTQ DMWVBTQ DN PD-145065 DMWVBTQ TI TTKRD0G DMWVBTQ TN Endothelin A receptor (EDNRA) DMWVBTQ MA Modulator DMWVBTQ RN Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13. DMWVBTQ RU https://pubmed.ncbi.nlm.nih.gov/8032643 DMWVBTQ DI DMWVBTQ DMWVBTQ DN PD-145065 DMWVBTQ TI TT3ZTGU DMWVBTQ TN Endothelin B receptor (EDNRB) DMWVBTQ MA Modulator DMWVBTQ RN Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ-123 and PD 145065. Br J Pharmacol. 1994 May;112(1):207-13. DMWVBTQ RU https://pubmed.ncbi.nlm.nih.gov/8032643 DMWVPO0 DI DMWVPO0 DMWVPO0 DN BPN14770 DMWVPO0 TI TTSKMI8 DMWVPO0 TN Phosphodiesterase 4D (PDE4D) DMWVPO0 MA Inhibitor DMWVPO0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWVPO0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMWXJSZ DI DMWXJSZ DMWXJSZ DN GRC-15300 DMWXJSZ TI TTMI6F5 DMWXJSZ TN Transient receptor potential cation channel V1 (TRPV1) DMWXJSZ MA Antagonist DMWXJSZ RN The discovery and development of analgesics: new mechanisms, new modalities. J Clin Invest. 2010 November 1; 120(11): 3753-3759. DMWXJSZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966322/ DMWY0V1 DI DMWY0V1 DMWY0V1 DN LIPO-5 DMWY0V1 TI TTFGZB6 DMWY0V1 TN Human immunodeficiency virus GAG protein (HIV gag) DMWY0V1 RN HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9. DMWY0V1 RU https://pubmed.ncbi.nlm.nih.gov/25839103 DMWY0V1 DI DMWY0V1 DMWY0V1 DN LIPO-5 DMWY0V1 TI TT4NXYM DMWY0V1 TN Human immunodeficiency virus Negative factor (HIV nef) DMWY0V1 RN HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations. Vaccine. 2015 May 11;33(20):2354-9. DMWY0V1 RU https://pubmed.ncbi.nlm.nih.gov/25839103 DMWY609 DI DMWY609 DMWY609 DN CG201 DMWY609 TI TT0ID4A DMWY609 TN Leutinizing-hormone-releasing hormone (GNRH1) DMWY609 MA Modulator DMWY609 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWY609 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWYMJN DI DMWYMJN DMWYMJN DN ALN-CC5 DMWYMJN TI TT2LJRF DMWYMJN TN C5 messenger RNA (C5 mRNA) DMWYMJN MA Inhibitor DMWYMJN RN Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019 May 10;13:484-492. DMWYMJN RU https://pubmed.ncbi.nlm.nih.gov/31193726 DMX04O8 DI DMX04O8 DMX04O8 DN NYX-2925 DMX04O8 TI TT9IK2Z DMX04O8 TN N-methyl-D-aspartate receptor (NMDAR) DMX04O8 MA Modulator DMX04O8 RN NYX-2925 Is a Novel N-Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain. J Pharmacol Exp Ther. 2018 Sep;366(3):485-497. DMX04O8 RU https://pubmed.ncbi.nlm.nih.gov/29986951 DMX054A DI DMX054A DMX054A DN CP-547632 DMX054A TI TTUTJGQ DMX054A TN Vascular endothelial growth factor receptor 2 (KDR) DMX054A MA Inhibitor DMX054A RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMX054A RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMX1KDM DI DMX1KDM DMX1KDM DN ABI-H0731 DMX1KDM TI TTM42UJ DMX1KDM TN Hepatitis B virus Capsid protein (HBV C) DMX1KDM MA Inhibitor DMX1KDM RN Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020 Feb;5(2):152-166. DMX1KDM RU https://pubmed.ncbi.nlm.nih.gov/31711752 DMX27IT DI DMX27IT DMX27IT DN DTRM-555 DMX27IT TI TTGM6VW DMX27IT TN Tyrosine-protein kinase BTK (ATK) DMX27IT MA Inhibitor DMX27IT RN ClinicalTrials.gov (NCT04305444) Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas. U.S. National Institutes of Health. DMX27IT RU https://clinicaltrials.gov/ct2/show/NCT04305444 DMX27Q1 DI DMX27Q1 DMX27Q1 DN GSK933776A DMX27Q1 TI TTE4KHA DMX27Q1 TN Amyloid beta A4 protein (APP) DMX27Q1 MA Modulator DMX27Q1 RN Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569. DMX27Q1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832388/ DMX2LO3 DI DMX2LO3 DMX2LO3 DN 99mTc-RP-128 DMX2LO3 TI TTYG378 DMX2LO3 TN Tuftsin receptor (TR) DMX2LO3 MA Modulator DMX2LO3 RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMX2LO3 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMX2P5G DI DMX2P5G DMX2P5G DN APX005M DMX2P5G TI TTN6Y9A DMX2P5G TN CD40L receptor (CD40) DMX2P5G MA Agonist DMX2P5G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX2P5G RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTUTJGQ DMX302C TN Vascular endothelial growth factor receptor 2 (KDR) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTGKNB4 DMX302C TN Epidermal growth factor receptor (EGFR) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTR5TV4 DMX302C TN ERBB2 messenger RNA (HER2 mRNA) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX302C DI DMX302C DMX302C DN BMS-690514 DMX302C TI TTGJCWZ DMX302C TN Fms-like tyrosine kinase 3 (FLT-3) DMX302C MA Inhibitor DMX302C RN Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. DMX302C RU https://pubmed.ncbi.nlm.nih.gov/20166197 DMX4DQH DI DMX4DQH DMX4DQH DN Delanzomib DMX4DQH TI TTU7ZMG DMX4DQH TN Proteasome (PS) DMX4DQH MA Modulator DMX4DQH RN Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol. 2012 Jan;12(1):257-70. DMX4DQH RU https://pubmed.ncbi.nlm.nih.gov/22178195 DMX4MVP DI DMX4MVP DMX4MVP DN ONO-4053 DMX4MVP TI TTNVEIR DMX4MVP TN Prostaglandin D2 receptor (PTGDR) DMX4MVP MA Antagonist DMX4MVP RN Effect of ONO-4053, a DP1 (prostaglandin D2 receptor) Antagonist, on Prostaglandin D2-Induced Nasal Congestion. Journal of Allergy and Clinical Immunology Volume 135, Issue 2, Supplement, February 2015, Pages AB219. DMX4MVP RU http://www.sciencedirect.com/science/article/pii/S0091674914034332 DMX4RSD DI DMX4RSD DMX4RSD DN EFEGATRAN SULFATE HYDRATE DMX4RSD TI TT6L509 DMX4RSD TN Coagulation factor IIa (F2) DMX4RSD MA Inhibitor DMX4RSD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMX4RSD RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMX4U0B DI DMX4U0B DMX4U0B DN MCS-18 DMX4U0B TI TTY7ZHS DMX4U0B TN Toll-like receptor 2 (TLR2) DMX4U0B MA Modulator DMX4U0B RN The novel arthritis-drug substance MCS-18 attenuates the antibody production in vivo. Acta Microbiol Immunol Hung. 2008 Mar;55(1):15-31. DMX4U0B RU https://pubmed.ncbi.nlm.nih.gov/18507149 DMX5SG7 DI DMX5SG7 DMX5SG7 DN AZD1772//RDX5791 DMX5SG7 TI TTFZVPO DMX5SG7 TN Sodium/hydrogen exchanger 3 (SLC9A3) DMX5SG7 MA Modulator DMX5SG7 RN RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99. DMX5SG7 RU http://www.gastrojournal.org/article/S0016-5085(11)60405-8/pdf DMX6B95 DI DMX6B95 DMX6B95 DN HER1-VSSP vaccine DMX6B95 TI TTGKNB4 DMX6B95 TN Epidermal growth factor receptor (EGFR) DMX6B95 RN Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9. DMX6B95 RU https://pubmed.ncbi.nlm.nih.gov/16841332 DMX6RZG DI DMX6RZG DMX6RZG DN EFT508 DMX6RZG TI TTEZAUX DMX6RZG TN MAPK signal-integrating kinase 1 (MKNK1) DMX6RZG MA Inhibitor DMX6RZG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX6RZG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX6RZG DI DMX6RZG DMX6RZG DN EFT508 DMX6RZG TI TTRECN3 DMX6RZG TN MAP kinase signal-integrating kinase 2 (MKNK2) DMX6RZG MA Inhibitor DMX6RZG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX6RZG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX8C6J DI DMX8C6J DMX8C6J DN HCB1019 DMX8C6J TI TT4F7SL DMX8C6J TN Gap junction alpha-1 protein (GJA1) DMX8C6J MA Inhibitor DMX8C6J RN Clinical pipeline report, company report or official report of OcuNexus Therapeutics. DMX8C6J RU https://ocunexus.com/ophthalmic DMX8JYN DI DMX8JYN DMX8JYN DN RG-7090 DMX8JYN TI TTHS256 DMX8JYN TN Metabotropic glutamate receptor 5 (mGluR5) DMX8JYN MA Antagonist DMX8JYN RN The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6): 1237-1250. DMX8JYN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932172/ DMX8ZAQ DI DMX8ZAQ DMX8ZAQ DN Paliroden DMX8ZAQ TI TT9HLZ0 DMX8ZAQ TN Glutamate receptor AMPA 2 (GRIA2) DMX8ZAQ MA Modulator DMX8ZAQ RN Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS Chem Neurosci.2013 Apr 17;4(4):635-44. DMX8ZAQ RU https://www.ncbi.nlm.nih.gov/pubmed/23402301 DMX9MSL DI DMX9MSL DMX9MSL DN 2X-121 DMX9MSL TI TTEBCY8 DMX9MSL TN Poly [ADP-ribose] polymerase (PARP) DMX9MSL MA Inhibitor DMX9MSL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX9MSL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX9MSL DI DMX9MSL DMX9MSL DN 2X-121 DMX9MSL TI TTKSAQZ DMX9MSL TN Tankyrase (TNKS) DMX9MSL MA Inhibitor DMX9MSL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX9MSL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTWG9A4 DMX9Y7V TN Adrenergic receptor alpha-2A (ADRA2A) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTBRKXS DMX9Y7V TN Adrenergic receptor alpha-1B (ADRA1B) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TT34BHT DMX9Y7V TN Adrenergic receptor alpha-1D (ADRA1D) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTWM4TY DMX9Y7V TN Adrenergic receptor alpha-2B (ADRA2B) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TTNGILX DMX9Y7V TN Adrenergic receptor alpha-1A (ADRA1A) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9Y7V DI DMX9Y7V DMX9Y7V DN MEDETOMIDINE DMX9Y7V TI TT2NUT5 DMX9Y7V TN Adrenergic receptor alpha-2C (ADRA2C) DMX9Y7V MA Inhibitor DMX9Y7V RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMX9Y7V RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMX9ZM4 DI DMX9ZM4 DMX9ZM4 DN PEG-SN38 DMX9ZM4 TI TTGTQHC DMX9ZM4 TN DNA topoisomerase I (TOP1) DMX9ZM4 MA Inhibitor DMX9ZM4 RN EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLoS One. 2012;7(9):e45248. DMX9ZM4 RU https://pubmed.ncbi.nlm.nih.gov/23028879 DMXA6B3 DI DMXA6B3 DMXA6B3 DN RO-4929097 DMXA6B3 TI TT9W8GU DMXA6B3 TN Gamma-secretase (GS) DMXA6B3 MA Modulator DMXA6B3 RN Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012 Jul 1;30(19):2348-53. DMXA6B3 RU https://pubmed.ncbi.nlm.nih.gov/22529266 DMXAH4G DI DMXAH4G DMXAH4G DN PD-143188 DMXAH4G TI TTEX248 DMXAH4G TN Dopamine D2 receptor (D2R) DMXAH4G MA Modulator DMXAH4G RN Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci. 1998;62(7):649-63. DMXAH4G RU https://pubmed.ncbi.nlm.nih.gov/9472724 DMXB6KG DI DMXB6KG DMXB6KG DN FAD-104 DMXB6KG TI TTUTN1I DMXB6KG TN Human Deoxyribonucleic acid (hDNA) DMXB6KG MA Binder DMXB6KG RN Biological activities of new anthracyclines containing fluorine, FAD104 and its metabolites. J Antibiot (Tokyo). 1990 May;43(5):556-65. DMXB6KG RU https://pubmed.ncbi.nlm.nih.gov/1694165 DMXB9RS DI DMXB9RS DMXB9RS DN ROTIGAPTIDE DMXB9RS TI TTJO6E9 DMXB9RS TN Gap junction protein (GJP) DMXB9RS MA Modulator DMXB9RS RN The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol. 2006 Mar;147(5):486-95. DMXB9RS RU https://pubmed.ncbi.nlm.nih.gov/16415913 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TTL69WB DMXBR27 TN Angiotensin-converting enzyme (ACE) DMXBR27 MA Inhibitor DMXBR27 RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TT5TKPM DMXBR27 TN Neutral endopeptidase (MME) DMXBR27 MA Inhibitor DMXBR27 RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TTE6THL DMXBR27 TN Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2) DMXBR27 MA Inhibitor DMXBR27 RN Interaction of D-600 with the transmembrane domain of the sarcoplasmic reticulum Ca(2+)-ATPase. Am J Physiol Cell Physiol. 2000 Jul;279(1):C166-72. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/10898728 DMXBR27 DI DMXBR27 DMXBR27 DN Gallopamil DMXBR27 TI TTXHYV6 DMXBR27 TN Voltage-gated L-type calcium channel (L-CaC) DMXBR27 MA Blocker DMXBR27 RN Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15. DMXBR27 RU https://pubmed.ncbi.nlm.nih.gov/18258561 DMXCJKY DI DMXCJKY DMXCJKY DN SLV-334 DMXCJKY TI TT5TKPM DMXCJKY TN Neutral endopeptidase (MME) DMXCJKY MA Modulator DMXCJKY RN Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26. DMXCJKY RU https://www.ncbi.nlm.nih.gov/pubmed/20129503 DMXCJKY DI DMXCJKY DMXCJKY DN SLV-334 DMXCJKY TI TT1BGDH DMXCJKY TN Endothelin-converting enzyme (ECE) DMXCJKY MA Modulator DMXCJKY RN Clinical trials in traumatic brain injury: past experience and current developments.Neurotherapeutics.2010 Jan;7(1):115-26. DMXCJKY RU https://www.ncbi.nlm.nih.gov/pubmed/20129503 DMXDVNZ DI DMXDVNZ DMXDVNZ DN S-555739 DMXDVNZ TI TTNVEIR DMXDVNZ TN Prostaglandin D2 receptor (PTGDR) DMXDVNZ MA Antagonist DMXDVNZ RN Clinical pipeline report, company report or official report of Shionogi (2011). DMXDVNZ RU http://www.shionogi.co.jp/index_e.html DMXEQ0R DI DMXEQ0R DMXEQ0R DN LTX-109 DMXEQ0R TI TTXT4D5 DMXEQ0R TN Bacterial Cell membrane (Bact CM) DMXEQ0R MA Modulator DMXEQ0R RN A synthetic antimicrobial peptidomimetic (LTX 109): stereochemical impact on membrane disruption. J Med Chem. 2011 Aug 25;54(16):5786-95. DMXEQ0R RU https://pubmed.ncbi.nlm.nih.gov/21732630 DMXF26Y DI DMXF26Y DMXF26Y DN AZD7325 DMXF26Y TI TTAN6JD DMXF26Y TN Glutamate receptor AMPA (GRIA) DMXF26Y MA Agonist DMXF26Y RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMXF26Y RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMXG5WU DI DMXG5WU DMXG5WU DN Xanomeline tartrate DMXG5WU TI TTZ9SOR DMXG5WU TN Muscarinic acetylcholine receptor M1 (CHRM1) DMXG5WU MA Agonist DMXG5WU RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMXG5WU RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMXG9ES DI DMXG9ES DMXG9ES DN RXI-109 DMXG9ES TI TTIL516 DMXG9ES TN CCN2 messenger RNA (CCN2 mRNA) DMXG9ES MA Inhibitor DMXG9ES RN The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019 Jun;18(6):421-446. DMXG9ES RU https://pubmed.ncbi.nlm.nih.gov/30846871 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TTSC2YM DMXH1KC TN Mitochondrial uncoupling protein 2 (UCP2) DMXH1KC MA Inducer DMXH1KC RN Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/9150705 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TTMXGCW DMXH1KC TN Adrenergic receptor beta-3 (ADRB3) DMXH1KC MA Agonist DMXH1KC RN Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans. Curr Pharm Des. 2001 Sep;7(14):1433-49. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/11472270 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TTI12YJ DMXH1KC TN Mitochondrial uncoupling protein 1 (UCP1) DMXH1KC MA Inducer DMXH1KC RN Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/9150705 DMXH1KC DI DMXH1KC DMXH1KC DN CL-316,243 DMXH1KC TI TT12RJK DMXH1KC TN Mitochondrial uncoupling protein 3 (UCP3) DMXH1KC MA Inducer DMXH1KC RN Anti-obesity and anti-diabetic effects of CL316,243, a highly specific beta 3-adrenoceptor agonist, in Otsuka Long-Evans Tokushima Fatty rats: induction of uncoupling protein and activation of glucose transporter 4 in white fat. Eur J Endocrinol. 1997 Apr;136(4):429-37. DMXH1KC RU https://pubmed.ncbi.nlm.nih.gov/9150705 DMXI9BP DI DMXI9BP DMXI9BP DN Brilacidin DMXI9BP TI TTXT4D5 DMXI9BP TN Bacterial Cell membrane (Bact CM) DMXI9BP MA Enhancer DMXI9BP RN Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16. Antimicrob Agents Chemother. 2014 Sep;58(9):5136-45. DMXI9BP RU https://pubmed.ncbi.nlm.nih.gov/24936592 DMXJ8Z4 DI DMXJ8Z4 DMXJ8Z4 DN AK104 DMXJ8Z4 TI TTI2S1D DMXJ8Z4 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMXJ8Z4 MA Inhibitor DMXJ8Z4 RN Clinical pipeline report, company report or official report of Akeso Biopharma. DMXJ8Z4 RU https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/ DMXJ8Z4 DI DMXJ8Z4 DMXJ8Z4 DN AK104 DMXJ8Z4 TI TTNBFWK DMXJ8Z4 TN Programmed cell death protein 1 (PD-1) DMXJ8Z4 MA Inhibitor DMXJ8Z4 RN Clinical pipeline report, company report or official report of Akeso Biopharma. DMXJ8Z4 RU https://akesobio-umb.azurewebsites.net/en/rd-and-science/pipelines/ DMXJWNS DI DMXJWNS DMXJWNS DN MM-093 DMXJWNS TI TTCFEA1 DMXJWNS TN Alpha-fetoprotein (AFP) DMXJWNS MA Modulator DMXJWNS RN MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. Curr Opin Mol Ther. 2007 Dec;9(6):603-10. DMXJWNS RU https://pubmed.ncbi.nlm.nih.gov/18041671 DMXKOW6 DI DMXKOW6 DMXKOW6 DN MKC-1106-MT DMXKOW6 TI TT362RB DMXKOW6 TN MART-1 melanoma antigen (MLANA) DMXKOW6 MA Modulator DMXKOW6 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXKOW6 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXKOW6 DI DMXKOW6 DMXKOW6 DN MKC-1106-MT DMXKOW6 TI TTULVH8 DMXKOW6 TN Tyrosinase (TYR) DMXKOW6 MA Modulator DMXKOW6 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXKOW6 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXL7HO DI DMXL7HO DMXL7HO DN OLX10010 DMXL7HO TI TTIL516 DMXL7HO TN CCN2 messenger RNA (CCN2 mRNA) DMXL7HO MA Inhibitor DMXL7HO RN Clinical pipeline report, company report or official report of Olix Pharmaceuticals. DMXL7HO RU https://www.olixpharma.com/eng/rnd/rnd03_olx101a.php DMXLAPF DI DMXLAPF DMXLAPF DN UCB-11056 DMXLAPF TI TT0QZ8R DMXLAPF TN cAMP formation (cAMP form) DMXLAPF MA Modulator DMXLAPF RN ucb 11056, a new potential nootropic drug, amplifies induced cyclic AMP formation in rat brain tissue. J Neurochem. 1993 Dec;61(6):2256-61. DMXLAPF RU https://pubmed.ncbi.nlm.nih.gov/8245976 DMXLE71 DI DMXLE71 DMXLE71 DN SYL-040012 DMXLE71 TI TTG8ZWP DMXLE71 TN ADRB2 messenger RNA (ADRB2 mRNA) DMXLE71 RN In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014 Jan;22(1):81-91. DMXLE71 RU https://pubmed.ncbi.nlm.nih.gov/24025749 DMXM34I DI DMXM34I DMXM34I DN O-304 DMXM34I TI TTLAFZV DMXM34I TN AMP-activated protein kinase (AMPK) DMXM34I MA Activator DMXM34I RN Clinical pipeline report, company report or official report of Betagenon. DMXM34I RU https://betagenon.com/research-development/o304-our-ampk-activator DMXMC8I DI DMXMC8I DMXMC8I DN FGF-1 DMXMC8I TI TTRLW2X DMXMC8I TN Fibroblast growth factor receptor 1 (FGFR1) DMXMC8I MA Binder DMXMC8I RN Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer. 2002 Jun 17;86(12):1864-70. DMXMC8I RU https://pubmed.ncbi.nlm.nih.gov/12085177 DMXO4T8 DI DMXO4T8 DMXO4T8 DN GLPG0974 DMXO4T8 TI TT0FYAN DMXO4T8 TN Free fatty acid receptor 2 (FFAR2) DMXO4T8 MA Antagonist DMXO4T8 RN Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic. J Med Chem. 2014 Dec 11;57(23):10044-57. DMXO4T8 RU https://pubmed.ncbi.nlm.nih.gov/25380412 DMXOTMP DI DMXOTMP DMXOTMP DN FPI-01 DMXOTMP TI TTZ8UT4 DMXOTMP TN Wilms tumor protein (WT1) DMXOTMP RN Clinical pipeline report, company report or official report of Formula Pharmaceuticals. DMXOTMP RU http://www.formulapharma.com/fp1_01/default.asp DMXR8WN DI DMXR8WN DMXR8WN DN CYCLOPLATAM DMXR8WN TI TTYVX59 DMXR8WN TN Protein kinase C (PRKC) DMXR8WN MA Inhibitor DMXR8WN RN Effect of anti-tumor agents cisplatin and cycloplatam on membrane protein kinase C activity in murine T-lymphocytes. Biokhimiia. 1996 Oct;61(10):1866-73. DMXR8WN RU https://pubmed.ncbi.nlm.nih.gov/9011234 DMXROM7 DI DMXROM7 DMXROM7 DN Polyglutamate camptothecin DMXROM7 TI TTGTQHC DMXROM7 TN DNA topoisomerase I (TOP1) DMXROM7 MA Inhibitor DMXROM7 RN Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006 Oct;6(10):789-802. DMXROM7 RU https://pubmed.ncbi.nlm.nih.gov/16990856 DMXSFA0 DI DMXSFA0 DMXSFA0 DN ALV-003 DMXSFA0 TI TTNGKET DMXSFA0 TN Prolyl endopeptidase (PREP) DMXSFA0 MA Modulator DMXSFA0 RN The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95. DMXSFA0 RU https://pubmed.ncbi.nlm.nih.gov/19942485 DMXSZA4 DI DMXSZA4 DMXSZA4 DN MT-3995 DMXSZA4 TI TT26PHO DMXSZA4 TN Mineralocorticoid receptor (MR) DMXSZA4 MA Antagonist DMXSZA4 RN Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. DMXSZA4 RU https://pubmed.ncbi.nlm.nih.gov/26083526 DMXTKCR DI DMXTKCR DMXTKCR DN JT02 DMXTKCR TI TTQOVYA DMXTKCR TN C-X-C motif chemokine 10 (CXCL10) DMXTKCR MA Inhibitor DMXTKCR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXTKCR RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMXTOVE DI DMXTOVE DMXTOVE DN Sampatrilat DMXTOVE TI TT5TKPM DMXTOVE TN Neutral endopeptidase (MME) DMXTOVE MA Modulator DMXTOVE RN Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71. DMXTOVE RU https://pubmed.ncbi.nlm.nih.gov/10371365 DMXU5LZ DI DMXU5LZ DMXU5LZ DN CRS-207 DMXU5LZ TI TT4RXME DMXU5LZ TN Mesothelin (MSLN) DMXU5LZ RN Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33. DMXU5LZ RU https://pubmed.ncbi.nlm.nih.gov/25584002 DMXUCG3 DI DMXUCG3 DMXUCG3 DN GSK233705 DMXUCG3 TI TTH18TF DMXUCG3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMXUCG3 MA Antagonist DMXUCG3 RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMXUCG3 RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMXY0H2 DI DMXY0H2 DMXY0H2 DN QAX-028 DMXY0H2 TI TTOXS3C DMXY0H2 TN Muscarinic acetylcholine receptor (CHRM) DMXY0H2 MA Antagonist DMXY0H2 RN EP patent application no. 2398798, Triazolopyridine derivatives as p38 map kinase inhibitors. DMXY0H2 RU http://www.google.com/patents/EP2398798A1?cl=en DMXYLTI DI DMXYLTI DMXYLTI DN CDP323 DMXYLTI TI TT6S84X DMXYLTI TN Integrin alpha-4/beta-1 (ITGA4/B1) DMXYLTI MA Modulator DMXYLTI RN Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438. DMXYLTI RU https://www.ncbi.nlm.nih.gov/pubmed/23472197 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TTDCBX5 DMY0UEQ TN Vascular endothelial growth factor receptor 3 (FLT-4) DMY0UEQ MA Inhibitor DMY0UEQ RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TTGKNB4 DMY0UEQ TN Epidermal growth factor receptor (EGFR) DMY0UEQ MA Inhibitor DMY0UEQ RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/17416531 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TTUTJGQ DMY0UEQ TN Vascular endothelial growth factor receptor 2 (KDR) DMY0UEQ MA Inhibitor DMY0UEQ RN Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/17416531 DMY0UEQ DI DMY0UEQ DMY0UEQ DN VATALANIB DMY0UEQ TI TT1VAUK DMY0UEQ TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMY0UEQ MA Inhibitor DMY0UEQ RN Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9. DMY0UEQ RU https://pubmed.ncbi.nlm.nih.gov/16460936 DMY1UGV DI DMY1UGV DMY1UGV DN Bc-3781 intravenous DMY1UGV TI TT2VX74 DMY1UGV TN Bacterial Protein synthesis (Bact PROS) DMY1UGV MA Modulator DMY1UGV RN Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother. 2013 Sep;57(9):4489-95. DMY1UGV RU https://pubmed.ncbi.nlm.nih.gov/23836172 DMY1XJH DI DMY1XJH DMY1XJH DN AMG 570 DMY1XJH TI TTWMIDN DMY1XJH TN B-cell-activating factor (TNFSF13B) DMY1XJH MA Inhibitor DMY1XJH RN Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914. DMY1XJH RU https://pubmed.ncbi.nlm.nih.gov/30789152 DMY1XJH DI DMY1XJH DMY1XJH DN AMG 570 DMY1XJH TI TTB9Z8R DMY1XJH TN B7-related protein 1 (B7RP1) DMY1XJH MA Inhibitor DMY1XJH RN Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914. DMY1XJH RU https://pubmed.ncbi.nlm.nih.gov/30789152 DMY2L7V DI DMY2L7V DMY2L7V DN Lucatumumab DMY2L7V TI TTIJP3Q DMY2L7V TN TNF related activation protein (CD40LG) DMY2L7V MA Modulator DMY2L7V RN Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42. DMY2L7V RU https://www.ncbi.nlm.nih.gov/pubmed/22475052 DMY3KSU DI DMY3KSU DMY3KSU DN GW-42004 DMY3KSU TI TTMSFAW DMY3KSU TN Cannabinoid receptor 2 (CB2) DMY3KSU MA Modulator DMY3KSU RN Company report (Gwpharm) DMY3KSU RU http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx DMY3KSU DI DMY3KSU DMY3KSU DN GW-42004 DMY3KSU TI TT6OEDT DMY3KSU TN Cannabinoid receptor 1 (CB1) DMY3KSU MA Modulator DMY3KSU RN Company report (Gwpharm) DMY3KSU RU http://www.gwpharm.com/GW%20Pharmaceuticals%20Provides%20Update%20on%20Cannabinoid%20Pipeline.aspx DMY4IWC DI DMY4IWC DMY4IWC DN LCB-2183 DMY4IWC TI TT7CXIM DMY4IWC TN Histamine receptor (HR) DMY4IWC MA Modulator DMY4IWC RN LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity. Int J Immunopharmacol. 1994 Aug;16(8):675-83. DMY4IWC RU https://pubmed.ncbi.nlm.nih.gov/7989136 DMY4OMS DI DMY4OMS DMY4OMS DN Carabersat DMY4OMS TI TTSB7ZR DMY4OMS TN Trigeminal ganglion stimulation-induced response (TGSR) DMY4OMS MA Modulator DMY4OMS RN Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br J Pharmacol. 2001 April; 132(7): 1549-1557. DMY4OMS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572685/ DMY53PL DI DMY53PL DMY53PL DN GW 597599 DMY53PL TI TTZPO1L DMY53PL TN Substance-P receptor (TACR1) DMY53PL MA Antagonist DMY53PL RN Application of LC-NMR to the identification of bulk drug impurities in NK1 antagonist GW597599 (vestipitant). Magn Reson Chem. 2010 Jul;48(7):523-30. DMY53PL RU https://pubmed.ncbi.nlm.nih.gov/20535779 DMY5IX4 DI DMY5IX4 DMY5IX4 DN BTL-TML-001 DMY5IX4 TI TTL3N71 DMY5IX4 TN Virus Replication (Viru Repli) DMY5IX4 MA Inhibitor DMY5IX4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY5IX4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMY5NUR DI DMY5NUR DMY5NUR DN VK-2809 DMY5NUR TI TTGER3L DMY5NUR TN Thyroid hormone receptor beta (THRB) DMY5NUR MA Agonist DMY5NUR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY5NUR RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMY61TJ DI DMY61TJ DMY61TJ DN FK-614 DMY61TJ TI TTZMAO3 DMY61TJ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMY61TJ MA Agonist DMY61TJ RN FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs. Metabolism. 2005 Sep;54(9):1250-8. DMY61TJ RU https://pubmed.ncbi.nlm.nih.gov/16125538 DMY6WUV DI DMY6WUV DMY6WUV DN GDC-0077 DMY6WUV TI TTHBTOP DMY6WUV TN PI3-kinase gamma (PIK3CG) DMY6WUV MA Inhibitor DMY6WUV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY6WUV RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY7Q3I DI DMY7Q3I DMY7Q3I DN JNJ-10229570 DMY7Q3I TI TT6QAJ3 DMY7Q3I TN Melanocortin receptor 5 (MC5R) DMY7Q3I MA Antagonist DMY7Q3I RN A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011 Jul;63(1):23-32. DMY7Q3I RU https://pubmed.ncbi.nlm.nih.gov/21602033 DMY89BN DI DMY89BN DMY89BN DN URC102 DMY89BN TI TTA592U DMY89BN TN Urate anion exchanger 1 (URAT1) DMY89BN MA Inhibitor DMY89BN RN Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013). DMY89BN RU http://www.chugai-pharm.co.jp/english/ir/reports_downloads/pipeline.html DMY9ZGN DI DMY9ZGN DMY9ZGN DN VT-111a DMY9ZGN TI TTEMV5X DMY9ZGN TN Serine protease unspecific (SP) DMY9ZGN MA Modulator DMY9ZGN RN Viral Serpin Therapeutics: From Concept to Clinic. Methods Enzymol. 2011; 499: 301-329. DMY9ZGN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558843/ DMYAQV2 DI DMYAQV2 DMYAQV2 DN ATL101 DMYAQV2 TI TT9G4N0 DMYAQV2 TN Glutamate carboxypeptidase II (GCPII) DMYAQV2 MA Modulator DMYAQV2 RN Clinical pipeline report, company report or official report of Atlab pharma. DMYAQV2 RU http://www.atlab-pharma.com/pipeline_atl101.html DMYAXNM DI DMYAXNM DMYAXNM DN SRK-015 DMYAXNM TI TTM8I2X DMYAXNM TN Myostatin (MSTN) DMYAXNM MA Inhibitor DMYAXNM RN Clinical pipeline report, company report or official report of Scholar Rock. DMYAXNM RU https://scholarrock.com/our-pipeline/spinal-muscular-atrophy/ DMYBIFS DI DMYBIFS DMYBIFS DN Parsaclisib DMYBIFS TI TTGBPJE DMYBIFS TN PI3-kinase delta (PIK3CD) DMYBIFS MA Inhibitor DMYBIFS RN Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752. DMYBIFS RU https://pubmed.ncbi.nlm.nih.gov/30803990 DMYBQEF DI DMYBQEF DMYBQEF DN AP26113 DMYBQEF TI TTPMQSO DMYBQEF TN ALK tyrosine kinase receptor (ALK) DMYBQEF MA Modulator DMYBQEF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYBQEF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYC2LE DI DMYC2LE DMYC2LE DN Disufenton DMYC2LE TI TTLQTHB DMYC2LE TN Extracellular sulfatase Sulf-2 (SULF2) DMYC2LE MA Inhibitor DMYC2LE RN The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer. 2013 Mar;52(3):225-36. DMYC2LE RU https://pubmed.ncbi.nlm.nih.gov/23109092 DMYCITZ DI DMYCITZ DMYCITZ DN MP-101 DMYCITZ TI TT8A9EF DMYCITZ TN Metabotropic glutamate receptor 3 (mGluR3) DMYCITZ MA Agonist DMYCITZ RN ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health. DMYCITZ RU https://clinicaltrials.gov/ct2/show/NCT03044249 DMYCITZ DI DMYCITZ DMYCITZ DN MP-101 DMYCITZ TI TTXJ47W DMYCITZ TN Metabotropic glutamate receptor 2 (mGluR2) DMYCITZ MA Agonist DMYCITZ RN ClinicalTrials.gov (NCT03044249) A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression. U.S. National Institutes of Health. DMYCITZ RU https://clinicaltrials.gov/ct2/show/NCT03044249 DMYDM68 DI DMYDM68 DMYDM68 DN BGP-15 DMYDM68 TI TTEBCY8 DMYDM68 TN Poly [ADP-ribose] polymerase (PARP) DMYDM68 MA Modulator DMYDM68 RN BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37. DMYDM68 RU https://pubmed.ncbi.nlm.nih.gov/22350755 DMYDM68 DI DMYDM68 DMYDM68 DN BGP-15 DMYDM68 TI TTR2TXZ DMYDM68 TN Jun N terminal kinase (JNK) DMYDM68 MA Inhibitor DMYDM68 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYDM68 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYEGRH DI DMYEGRH DMYEGRH DN IL-4R DMYEGRH TI TTLGTKB DMYEGRH TN Interleukin-4 (IL4) DMYEGRH MA Inhibitor DMYEGRH RN Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001 Jun;107(6):963-70. DMYEGRH RU https://pubmed.ncbi.nlm.nih.gov/11398072 DMYEIOH DI DMYEIOH DMYEIOH DN ARQ-154 DMYEIOH TI TTV5CGO DMYEIOH TN Phosphodiesterase 4 (PDE4) DMYEIOH MA Inhibitor DMYEIOH RN Clinical pipeline report, company report or official report of Arcutis Biotherapeutics. DMYEIOH RU https://arcutis.com/trial/arq-154/ DMYEZ5J DI DMYEZ5J DMYEZ5J DN Romilkimab DMYEZ5J TI TTLGTKB DMYEZ5J TN Interleukin-4 (IL4) DMYEZ5J MA Inhibitor DMYEZ5J RN A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607. DMYEZ5J RU https://pubmed.ncbi.nlm.nih.gov/32963047 DMYEZ5J DI DMYEZ5J DMYEZ5J DN Romilkimab DMYEZ5J TI TT0GVCH DMYEZ5J TN Interleukin-13 (IL13) DMYEZ5J MA Inhibitor DMYEZ5J RN A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607. DMYEZ5J RU https://pubmed.ncbi.nlm.nih.gov/32963047 DMYFRTB DI DMYFRTB DMYFRTB DN PCM-075 DMYFRTB TI TTIYVQP DMYFRTB TN Polo-like kinase 1 (PLK1) DMYFRTB MA Inhibitor DMYFRTB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYFRTB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYG1ZQ DI DMYG1ZQ DMYG1ZQ DN OPNT001 DMYG1ZQ TI TTKWM86 DMYG1ZQ TN Opioid receptor mu (MOP) DMYG1ZQ MA Antagonist DMYG1ZQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYG1ZQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMYILGK DI DMYILGK DMYILGK DN RP6530 DMYILGK TI TTGBPJE DMYILGK TN PI3-kinase delta (PIK3CD) DMYILGK MA Inhibitor DMYILGK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYILGK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYISJK DI DMYISJK DMYISJK DN PX-866 DMYISJK TI TTHBTOP DMYISJK TN PI3-kinase gamma (PIK3CG) DMYISJK MA Inhibitor DMYISJK RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DMYISJK RU https://pubmed.ncbi.nlm.nih.gov/19644473 DMYK1DR DI DMYK1DR DMYK1DR DN BLI-1005 DMYK1DR TI TTAWNKZ DMYK1DR TN Norepinephrine transporter (NET) DMYK1DR MA Inhibitor DMYK1DR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYK1DR RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMYK1JU DI DMYK1JU DMYK1JU DN ASP8232 DMYK1JU TI TT7HC21 DMYK1JU TN Membrane copper amine oxidase (AOC3) DMYK1JU MA Inhibitor DMYK1JU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYK1JU RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYL7VR DI DMYL7VR DMYL7VR DN Piclamilast DMYL7VR TI TTZ97H5 DMYL7VR TN Phosphodiesterase 4A (PDE4A) DMYL7VR MA Inhibitor DMYL7VR RN Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77. DMYL7VR RU https://pubmed.ncbi.nlm.nih.gov/15765929 DMYL7VR DI DMYL7VR DMYL7VR DN Piclamilast DMYL7VR TI TTSKMI8 DMYL7VR TN Phosphodiesterase 4D (PDE4D) DMYL7VR MA Inhibitor DMYL7VR RN Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77. DMYL7VR RU https://pubmed.ncbi.nlm.nih.gov/15765929 DMYL7VR DI DMYL7VR DMYL7VR DN Piclamilast DMYL7VR TI TTVIAT9 DMYL7VR TN Phosphodiesterase 4B (PDE4B) DMYL7VR MA Inhibitor DMYL7VR RN Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients. Lung. 2004;182(6):369-77. DMYL7VR RU https://pubmed.ncbi.nlm.nih.gov/15765929 DMYLBOU DI DMYLBOU DMYLBOU DN SB-649868 DMYLBOU TI TT60Q8D DMYLBOU TN Orexin receptor type 1 (HCRTR1) DMYLBOU MA Antagonist DMYLBOU RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMYLBOU RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMYNTQV DI DMYNTQV DMYNTQV DN CGP-28014 DMYNTQV TI TTKWFB8 DMYNTQV TN Catechol-O-methyl-transferase (COMT) DMYNTQV MA Modulator DMYNTQV RN CGP 28014, a new inhibitor of cerebral catechol-O-methylation with a non-catechol structure. Naunyn Schmiedebergs Arch Pharmacol. 1990 Sep;342(3):305-11. DMYNTQV RU https://pubmed.ncbi.nlm.nih.gov/1980718 DMYO185 DI DMYO185 DMYO185 DN BT-062 DMYO185 TI TTYDSVG DMYO185 TN Syndecan-1 (SDC1) DMYO185 RN The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15;15(12):4028-37. DMYO185 RU https://pubmed.ncbi.nlm.nih.gov/19509164 DMYOUB6 DI DMYOUB6 DMYOUB6 DN EMA-401 DMYOUB6 TI TTQVOEI DMYOUB6 TN Angiotensin II receptor type-2 (AGTR2) DMYOUB6 MA Antagonist DMYOUB6 RN Clinical pipeline report, company report or official report of Spinifex. DMYOUB6 RU http://www.spinifexpharma.com/EMA401-DEVELOPMENT.html DMYP7TO DI DMYP7TO DMYP7TO DN Trametinib + 2141795 DMYP7TO TI TTWTSCV DMYP7TO TN RAC-alpha serine/threonine-protein kinase (AKT1) DMYP7TO MA Modulator DMYP7TO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMYP7TO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMYPXQ2 DI DMYPXQ2 DMYPXQ2 DN CVBT-141H DMYPXQ2 TI TTMY81X DMYPXQ2 TN Heparin-binding growth factor 1 (FGF1) DMYPXQ2 MA Modulator DMYPXQ2 RN Clinical pipeline report, company report or official report of CVBT. DMYPXQ2 RU http://cvbt.com/index.php?pr=Severe_CHD DMYRIHZ DI DMYRIHZ DMYRIHZ DN PCL-016 DMYRIHZ TI TT3J1EK DMYRIHZ TN Zinc finger protein (ZNF) DMYRIHZ MA Modulator DMYRIHZ RN US patent application no. 2005,0239,723, Compositions and methods useful for treatment of acne. DMYRIHZ RU http://www.google.com/patents/US20050239723 DMYS6MW DI DMYS6MW DMYS6MW DN GCS-100 DMYS6MW TI TTX1OI0 DMYS6MW TN Galectin (LGALS) DMYS6MW MA Modulator DMYS6MW RN GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood. 2010 May 13;115(19):3939-48. DMYS6MW RU https://pubmed.ncbi.nlm.nih.gov/20190189 DMYSQMW DI DMYSQMW DMYSQMW DN BAY-1902607 DMYSQMW TI TT2THBD DMYSQMW TN P2X purinoceptor 3 (P2RX3) DMYSQMW MA Inhibitor DMYSQMW RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMYSQMW RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMYT470 DI DMYT470 DMYT470 DN Seribantumab DMYT470 TI TTDC8N2 DMYT470 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMYT470 MA Antagonist DMYT470 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYT470 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMYTKF5 DI DMYTKF5 DMYTKF5 DN Interferon DMYTKF5 TI TT6ONYI DMYTKF5 TN Interferon (IFN) DMYTKF5 MA Modulator DMYTKF5 RN Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year. Influenza Other Respir Viruses. 2013 Sep;7(5):854-62. DMYTKF5 RU https://pubmed.ncbi.nlm.nih.gov/23398960 DMYU6P5 DI DMYU6P5 DMYU6P5 DN GS-9857 DMYU6P5 TI TTWXB3E DMYU6P5 TN Hepatitis C virus NS3 helicase (HCV NS3) DMYU6P5 MA Inhibitor DMYU6P5 RN Clinical pipeline report, company report or official report of Gilead. DMYU6P5 RU http://www.gilead.com/research/pipeline DMYUNXP DI DMYUNXP DMYUNXP DN AZD2811 DMYUNXP TI TTCY4SB DMYUNXP TN Aurora kinase (AURK) DMYUNXP MA Inhibitor DMYUNXP RN Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo. Sci Transl Med. 2016 Feb 10;8(325):325ra17. DMYUNXP RU https://pubmed.ncbi.nlm.nih.gov/26865565 DMYUO6B DI DMYUO6B DMYUO6B DN PlaMavax DMYUO6B TI TTDUK07 DMYUO6B TN Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP) DMYUO6B RN Lipid kinase enters the malaria stage. SciBX 6(48); doi:10.1038/scibx.2013.1373. Dec. 19 2013 DMYUO6B RU http://www.nature.com/scibx/journal/v6/n48/full/scibx.2013.1373.html DMYWA0Z DI DMYWA0Z DMYWA0Z DN GORALATIDE DMYWA0Z TI TTLK6DR DMYWA0Z TN Cyclin D1 synthesis (CCND1 synthesis) DMYWA0Z MA Modulator DMYWA0Z RN Reduction of heat-induced haemotoxicity in a hyperthermic purging protocol of murine acute myeloid leukaemic stem cells by AcSDKP. Br J Haematol. 1997 Dec;99(3):692-8. DMYWA0Z RU https://pubmed.ncbi.nlm.nih.gov/9401086 DMYWO62 DI DMYWO62 DMYWO62 DN Capadenoson DMYWO62 TI TTK25J1 DMYWO62 TN Adenosine A1 receptor (ADORA1) DMYWO62 MA Agonist DMYWO62 RN A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10. DMYWO62 RU https://pubmed.ncbi.nlm.nih.gov/19012505 DMYXOU2 DI DMYXOU2 DMYXOU2 DN NRX-4204 DMYXOU2 TI TTH029C DMYXOU2 TN Retinoic acid receptor RXR-gamma (RXRG) DMYXOU2 MA Modulator DMYXOU2 RN DOI: 10.1038/scibx.2010.766 DMYXOU2 RU http://www.nature.com/scibx/journal/v3/n25/full/scibx.2010.766.html DMYZWDC DI DMYZWDC DMYZWDC DN ESBA-105 DMYZWDC TI TTF8CQI DMYZWDC TN Tumor necrosis factor (TNF) DMYZWDC RN Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci. 2009 Feb;50(2):771-8. DMYZWDC RU https://pubmed.ncbi.nlm.nih.gov/18757508 DMZ0DMY DI DMZ0DMY DMZ0DMY DN LY2874455 DMZ0DMY TI TTGJVQM DMZ0DMY TN Fibroblast growth factor receptor 2 (FGFR2) DMZ0DMY MA Modulator DMZ0DMY RN Company report (Eli Lilly) (drug: LY2874455) DMZ0DMY RU http://www.lillyoncologypipeline.com/fgfr-inhibitor.aspx DMZ0F65 DI DMZ0F65 DMZ0F65 DN Contezolid DMZ0F65 TI TTLIZBJ DMZ0F65 TN Protein synthesis (hPRO synth) DMZ0F65 MA Inhibitor DMZ0F65 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ0F65 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMZ2XAP DI DMZ2XAP DMZ2XAP DN LX-1031 DMZ2XAP TI TT7ZK9C DMZ2XAP TN Tryptophan 5-hydroxylase (TPH) DMZ2XAP MA Inhibitor DMZ2XAP RN LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010 Dec;13(12):921-8. DMZ2XAP RU https://pubmed.ncbi.nlm.nih.gov/21154152 DMZ2YBE DI DMZ2YBE DMZ2YBE DN Lexipafant DMZ2YBE TI TT84ETX DMZ2YBE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMZ2YBE MA Inhibitor DMZ2YBE RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMZ2YBE RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMZ2YBE DI DMZ2YBE DMZ2YBE DN Lexipafant DMZ2YBE TI TTQL5VC DMZ2YBE TN Platelet-activating factor receptor (PTAFR) DMZ2YBE MA Modulator DMZ2YBE RN Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9. DMZ2YBE RU https://www.ncbi.nlm.nih.gov/pubmed/12440758 DMZ3BER DI DMZ3BER DMZ3BER DN HM-78136B DMZ3BER TI TT6EO5L DMZ3BER TN Erbb2 tyrosine kinase receptor (HER2) DMZ3BER MA Inhibitor DMZ3BER RN Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54. DMZ3BER RU https://pubmed.ncbi.nlm.nih.gov/21732342 DMZ3BER DI DMZ3BER DMZ3BER DN HM-78136B DMZ3BER TI TTGKNB4 DMZ3BER TN Epidermal growth factor receptor (EGFR) DMZ3BER MA Inhibitor DMZ3BER RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ3BER RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ3FE8 DI DMZ3FE8 DMZ3FE8 DN VX-135 DMZ3FE8 TI TTMVBWH DMZ3FE8 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMZ3FE8 MA Inhibitor DMZ3FE8 RN All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11. DMZ3FE8 RU https://pubmed.ncbi.nlm.nih.gov/23722330 DMZ3OU6 DI DMZ3OU6 DMZ3OU6 DN Lithium DMZ3OU6 TI TTRSMW9 DMZ3OU6 TN Glycogen synthase kinase-3 beta (GSK-3B) DMZ3OU6 MA Inhibitor DMZ3OU6 RN The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874. DMZ3OU6 RU https://pubmed.ncbi.nlm.nih.gov/29212798 DMZ3OU6 DI DMZ3OU6 DMZ3OU6 DN Lithium DMZ3OU6 TI TTRZQE3 DMZ3OU6 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMZ3OU6 MA Inhibitor DMZ3OU6 RN The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874. DMZ3OU6 RU https://pubmed.ncbi.nlm.nih.gov/29212798 DMZ4MCG DI DMZ4MCG DMZ4MCG DN KB-6806 DMZ4MCG TI TTNXLKE DMZ4MCG TN 5-HT 3 receptor (5HT3R) DMZ4MCG MA Antagonist DMZ4MCG RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMZ4MCG RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMZ571Y DI DMZ571Y DMZ571Y DN TG-2349 DMZ571Y TI TTRHUKY DMZ571Y TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMZ571Y MA Modulator DMZ571Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMZ571Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMZ67Q0 DI DMZ67Q0 DMZ67Q0 DN WT1 peptide vaccine DMZ67Q0 TI TTZ8UT4 DMZ67Q0 TN Wilms tumor protein (WT1) DMZ67Q0 RN Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3beta sequence associated with remission in one patient is detectable in other vaccinated patients. Cancer ImmunolImmunother. 2012 Mar;61(3):313-22. DMZ67Q0 RU https://pubmed.ncbi.nlm.nih.gov/21898091 DMZ6RG2 DI DMZ6RG2 DMZ6RG2 DN TTP273 DMZ6RG2 TI TTVIMDE DMZ6RG2 TN Glucagon-like peptide 1 receptor (GLP1R) DMZ6RG2 MA Agonist DMZ6RG2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ6RG2 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMZ6Y0T DI DMZ6Y0T DMZ6Y0T DN LEO-32731 DMZ6Y0T TI TTV5CGO DMZ6Y0T TN Phosphodiesterase 4 (PDE4) DMZ6Y0T MA Inhibitor DMZ6Y0T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ6Y0T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMZ70GE DI DMZ70GE DMZ70GE DN BOS-228 DMZ70GE TI TTJP4SM DMZ70GE TN Bacterial Penicillin binding protein (Bact PBP) DMZ70GE MA Inhibitor DMZ70GE RN Clinical pipeline report, company report or official report of Boston Pharmaceuticals. DMZ70GE RU https://www.bostonpharmaceuticals.com/infectious-disease DMZ7I51 DI DMZ7I51 DMZ7I51 DN TA-270 DMZ7I51 TI TT2J34L DMZ7I51 TN Arachidonate 5-lipoxygenase (5-LOX) DMZ7I51 MA Inhibitor DMZ7I51 RN TA-270 [4-hydroxy-1-methyl-3-octyloxy-7-sinapinoylamino-2(1H)-quinolinone], an anti-asthmatic agent, inhibits leukotriene production induced by IgE... J Pharmacol Exp Ther. 2003 Nov;307(2):583-8. DMZ7I51 RU https://pubmed.ncbi.nlm.nih.gov/12970384 DMZ7YX3 DI DMZ7YX3 DMZ7YX3 DN M-16209 DMZ7YX3 TI TTFBNVI DMZ7YX3 TN Aldose reductase (AKR1B1) DMZ7YX3 MA Inhibitor DMZ7YX3 RN Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91. DMZ7YX3 RU https://pubmed.ncbi.nlm.nih.gov/1828768 DMZ8PY0 DI DMZ8PY0 DMZ8PY0 DN ACE-031 DMZ8PY0 TI TTSWPH8 DMZ8PY0 TN Growth/differentiation factor 8 (GDF-8) DMZ8PY0 MA Inhibitor DMZ8PY0 RN A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve. 2013 Mar;47(3):416-23. DMZ8PY0 RU https://pubmed.ncbi.nlm.nih.gov/23169607 DMZASMP DI DMZASMP DMZASMP DN LY2784544 DMZASMP TI TTRMX3V DMZASMP TN Janus kinase 2 (JAK-2) DMZASMP MA Modulator DMZASMP RN Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109. DMZASMP RU https://pubmed.ncbi.nlm.nih.gov/23584399 DMZB8AJ DI DMZB8AJ DMZB8AJ DN BMS-986142 DMZB8AJ TI TTGM6VW DMZB8AJ TN Tyrosine-protein kinase BTK (ATK) DMZB8AJ MA Inhibitor DMZB8AJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZB8AJ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZC4V0 DI DMZC4V0 DMZC4V0 DN Buproprion+zonisamide DMZC4V0 TI TTTQR47 DMZC4V0 TN Solute carrier family 22 member 8 (SLC22A8) DMZC4V0 MA Blocker DMZC4V0 RN Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50. DMZC4V0 RU https://pubmed.ncbi.nlm.nih.gov/18473708 DMZCA0K DI DMZCA0K DMZCA0K DN TBC-3711 DMZCA0K TI TTKRD0G DMZCA0K TN Endothelin A receptor (EDNRA) DMZCA0K MA Antagonist DMZCA0K RN TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res. 2001 Sep;50(3):374-83. DMZCA0K RU https://pubmed.ncbi.nlm.nih.gov/11518825 DMZCG91 DI DMZCG91 DMZCG91 DN CSL-112 DMZCG91 TI TT7GN3U DMZCG91 TN Apolipoprotein A-I (APOA1) DMZCG91 MA Modulator DMZCG91 RN CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 2014 Jan;232(1):110-8. DMZCG91 RU https://pubmed.ncbi.nlm.nih.gov/24401224 DMZCI04 DI DMZCI04 DMZCI04 DN PB-1023 DMZCI04 TI TTVIMDE DMZCI04 TN Glucagon-like peptide 1 receptor (GLP1R) DMZCI04 MA Modulator DMZCI04 RN On-target Effects of GLP-1 Receptor Agonists on Thyroid C-cells in Rats and Mice. Toxicol Pathol February 2013 vol. 41 no. 2 303-309. DMZCI04 RU http://tpx.sagepub.com/content/41/2/303.full DMZCI04 DI DMZCI04 DMZCI04 DN PB-1023 DMZCI04 TI TT0NUFM DMZCI04 TN Glucagon (GCG) DMZCI04 MA Agonist DMZCI04 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZCI04 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMZCU7I DI DMZCU7I DMZCU7I DN LY-377604 DMZCU7I TI TTMXGCW DMZCU7I TN Adrenergic receptor beta-3 (ADRB3) DMZCU7I MA Agonist DMZCU7I RN Combination of a Beta Adrenoceptor Modulator and a Norepinephrine-Serotonin Uptake Inhibitor for the Treatment of Obesity. ACS Med Chem Lett. 2011 August 11; 2(8): 583-586. DMZCU7I RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018109/ DMZCVD7 DI DMZCVD7 DMZCVD7 DN K-201 DMZCVD7 TI TT1VOHK DMZCVD7 TN Potassium channel unspecific (KC) DMZCVD7 MA Modulator DMZCVD7 RN Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy DMZCVD7 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340112 DMZE6Y9 DI DMZE6Y9 DMZE6Y9 DN TT-100 DMZE6Y9 TI TTGKNB4 DMZE6Y9 TN Epidermal growth factor receptor (EGFR) DMZE6Y9 MA Inhibitor DMZE6Y9 RN BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009. DMZE6Y9 RU http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html DMZE6Y9 DI DMZE6Y9 DMZE6Y9 DN TT-100 DMZE6Y9 TI TTHRID2 DMZE6Y9 TN Insulin-like growth factor I receptor (IGF1R) DMZE6Y9 MA Inhibitor DMZE6Y9 RN BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009. DMZE6Y9 RU http://globenewswire.com/news-release/2009/09/10/404398/173021/en/BiPar-Sciences-Co-founder-Reunites-Management-Team-At-TriAct-Therapeutics-to-Advance-Clinical-Stage-Cancer-Programs.html DMZEJLB DI DMZEJLB DMZEJLB DN CP-533536 DMZEJLB TI TT1ZAVI DMZEJLB TN Prostaglandin E2 receptor EP2 (PTGER2) DMZEJLB MA Agonist DMZEJLB RN Pfizer. Product Development Pipeline. March 31 2009. DMZEJLB RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMZEU6M DI DMZEU6M DMZEU6M DN TAK-831 DMZEU6M TI TT7Y3EJ DMZEU6M TN D-amino acid oxidase (DAO) DMZEU6M MA Inhibitor DMZEU6M RN Mechanistic Multilayer Quantitative Model for Nonlinear Pharmacokinetics, Target Occupancy and Pharmacodynamics (PK/TO/PD) Relationship of D-Amino Acid Oxidase Inhibitor, TAK-831 in Mice. Pharm Res. 2020 Aug 5;37(8):164. DMZEU6M RU https://pubmed.ncbi.nlm.nih.gov/32901384 DMZF68E DI DMZF68E DMZF68E DN Ascrolimus DMZF68E TI TTFH2RS DMZF68E TN FK506-binding protein (FKBP) DMZF68E MA Modulator DMZF68E RN Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17(6):584-91. DMZF68E RU https://pubmed.ncbi.nlm.nih.gov/8588225 DMZFV3E DI DMZFV3E DMZFV3E DN Remogli ozin-etabonate DMZFV3E TI TTN7Y4P DMZFV3E TN Sodium/glucose cotransporter 2 (SLC5A4) DMZFV3E MA Modulator DMZFV3E RN Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol.2013 Apr 30;14:25. DMZFV3E RU https://pubmed.ncbi.nlm.nih.gov/23631443 DMZFW8V DI DMZFW8V DMZFW8V DN MIN-202 DMZFW8V TI TT9N02I DMZFW8V TN Orexin receptor type 2 (HCRTR2) DMZFW8V MA Antagonist DMZFW8V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZFW8V RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMZGNOJ DI DMZGNOJ DMZGNOJ DN S-777469 DMZGNOJ TI TTMSFAW DMZGNOJ TN Cannabinoid receptor 2 (CB2) DMZGNOJ MA Agonist DMZGNOJ RN Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79. DMZGNOJ RU https://pubmed.ncbi.nlm.nih.gov/19216704 DMZHB37 DI DMZHB37 DMZHB37 DN GSK2110183 DMZHB37 TI TTWTSCV DMZHB37 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMZHB37 MA Modulator DMZHB37 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMZHB37 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMZIC4Q DI DMZIC4Q DMZIC4Q DN SPN-812 DMZIC4Q TI TTAWNKZ DMZIC4Q TN Norepinephrine transporter (NET) DMZIC4Q MA Inhibitor DMZIC4Q RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZIC4Q RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMZIQ8G DI DMZIQ8G DMZIQ8G DN Prolarix DMZIQ8G TI TTJLP0R DMZIQ8G TN Quinone reductase 2 (NQO2) DMZIQ8G MA Inhibitor DMZIQ8G RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMZIQ8G RU http://www.centerwatch.com/ DMZJP2T DI DMZJP2T DMZJP2T DN INCB50465 DMZJP2T TI TTGBPJE DMZJP2T TN PI3-kinase delta (PIK3CD) DMZJP2T MA Inhibitor DMZJP2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZJP2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZJREM DI DMZJREM DMZJREM DN RO-4998452 DMZJREM TI TTLWPVF DMZJREM TN Sodium/glucose cotransporter 2 (SGLT2) DMZJREM MA Modulator DMZJREM RN A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.Diabetes Obes Metab.2015 Oct;17(10):984-93. DMZJREM RU https://www.ncbi.nlm.nih.gov/pubmed/26179482 DMZKBMG DI DMZKBMG DMZKBMG DN Lenapenem hydrochloride hydrate DMZKBMG TI TTJP4SM DMZKBMG TN Bacterial Penicillin binding protein (Bact PBP) DMZKBMG MA Inhibitor DMZKBMG RN Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods. J Antibiot (Tokyo). 1997 Feb;50(2):139-42. DMZKBMG RU https://pubmed.ncbi.nlm.nih.gov/9099223 DMZKPI8 DI DMZKPI8 DMZKPI8 DN TAK-715 DMZKPI8 TI TTWELHI DMZKPI8 TN Stress-activated protein kinase (p38) DMZKPI8 MA Inhibitor DMZKPI8 RN Inhibition of Wnt/beta-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Idelta/ . Chem Biol. 2011 Apr 22;18(4):485-94. DMZKPI8 RU https://pubmed.ncbi.nlm.nih.gov/21513885 DMZKYNO DI DMZKYNO DMZKYNO DN Juvidex DMZKYNO TI TTPNE41 DMZKYNO TN CI Man-6-P receptor (IGF2R) DMZKYNO MA Modulator DMZKYNO RN Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies. Mol Med. 2011 Jan-Feb; 17(1-2): 113-125. DMZKYNO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3022978/ DMZL48U DI DMZL48U DMZL48U DN KUR-111 DMZL48U TI TT6F7GZ DMZL48U TN Parathyroid hormone (PTH) DMZL48U MA Modulator DMZL48U RN Company report (Cytos) DMZL48U RU http://www.cytos.com/kur-111/ DMZLBAW DI DMZLBAW DMZLBAW DN Fucoxanthin DMZLBAW TI TTSHAEB DMZLBAW TN NF-kappa-B inhibitor alpha (NFKBIA) DMZLBAW MA Inhibitor DMZLBAW RN Fucoxanthin inhibits the inflammatory response by suppressing the activation of NF-B and MAPKs in lipopolysaccharide-induced RAW 264.7 macrophages. Eur J Pharmacol. 2010 Dec 15;649(1-3):369-75. DMZLBAW RU https://pubmed.ncbi.nlm.nih.gov/20868674 DMZLGQV DI DMZLGQV DMZLGQV DN AZD2624 DMZLGQV TI TTBPGLU DMZLGQV TN Neuromedin-K receptor (TACR3) DMZLGQV MA Modulator DMZLGQV RN The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.J Clin Psychopharmacol.2014 Apr;34(2):199-204. DMZLGQV RU https://www.ncbi.nlm.nih.gov/pubmed/24525659 DMZMCB1 DI DMZMCB1 DMZMCB1 DN GW274150 DMZMCB1 TI TTF10I9 DMZMCB1 TN Nitric-oxide synthase inducible (NOS2) DMZMCB1 MA Modulator DMZMCB1 RN GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65. DMZMCB1 RU https://www.ncbi.nlm.nih.gov/pubmed/12631066 DMZMSQJ DI DMZMSQJ DMZMSQJ DN AUS-131 DMZMSQJ TI TTOM3J0 DMZMSQJ TN Estrogen receptor beta (ESR2) DMZMSQJ MA Agonist DMZMSQJ RN S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 2005 May;81(5):1072-9. DMZMSQJ RU https://pubmed.ncbi.nlm.nih.gov/15883431 DMZMUIL DI DMZMUIL DMZMUIL DN PF-04518600 DMZMUIL TI TTL31H0 DMZMUIL TN OX40L receptor (CD134) DMZMUIL MA Agonist DMZMUIL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZMUIL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZO2SY DI DMZO2SY DMZO2SY DN BIIB054 DMZO2SY TI TT08OSU DMZO2SY TN Synuclein alpha (SNCA) DMZO2SY MA Inhibitor DMZO2SY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZO2SY RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZOA2L DI DMZOA2L DMZOA2L DN ETX-9101 DMZOA2L TI TT7CXIM DMZOA2L TN Histamine receptor (HR) DMZOA2L MA Modulator DMZOA2L RN Clinical pipeline report, company report or official report of e-Therapeutics. DMZOA2L RU http://www.etherapeutics.co.uk/wp-content/uploads/2014/12/etp-10594-ar-08-web.pdf DMZOIP4 DI DMZOIP4 DMZOIP4 DN LY-2409021 DMZOIP4 TI TT9O6WS DMZOIP4 TN Glucagon receptor (GCGR) DMZOIP4 MA Antagonist DMZOIP4 RN Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22. DMZOIP4 RU https://pubmed.ncbi.nlm.nih.gov/25656305 DMZP84Y DI DMZP84Y DMZP84Y DN Ifetroban sodium DMZP84Y TI TT2O84V DMZP84Y TN Thromboxane A2 receptor (TBXA2R) DMZP84Y MA Antagonist DMZP84Y RN AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9. DMZP84Y RU https://pubmed.ncbi.nlm.nih.gov/15613065 DMZQBCL DI DMZQBCL DMZQBCL DN LR3001 DMZQBCL TI TT8V13P DMZQBCL TN Myb messenger RNA (MYB mRNA) DMZQBCL RN Genta obtains orphan drug designation for C-Myb Antisense (LR3001) in chronic myelocytic leukemia. Genta. 2005. DMZQBCL RU http://www.drugs.com/news/genta-obtains-orphan-designation-c-myb-antisense-lr3001-chronic-myelocytic-leukemia-3031.html DMZR9OU DI DMZR9OU DMZR9OU DN BI-44370 DMZR9OU TI TTY6O0Q DMZR9OU TN Calcitonin gene-related peptide receptor (CGRPR) DMZR9OU MA Antagonist DMZR9OU RN BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573-84. DMZR9OU RU https://pubmed.ncbi.nlm.nih.gov/21172952 DMZRXTL DI DMZRXTL DMZRXTL DN E7820 DMZRXTL TI TTSJ542 DMZRXTL TN Integrin alpha-2 (ITGA2) DMZRXTL MA Inhibitor DMZRXTL RN Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin Cancer Res. 2011 Jan 1;17(1):193-200. DMZRXTL RU https://pubmed.ncbi.nlm.nih.gov/21208908 DMZT7EP DI DMZT7EP DMZT7EP DN EPI 589 DMZT7EP TI TTIB5LO DMZT7EP TN Quinone reductase (NQO) DMZT7EP MA Modulator DMZT7EP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZT7EP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZT8FS DI DMZT8FS DMZT8FS DN Preverex DMZT8FS TI TTU5CF1 DMZT8FS TN Actin polymerization (Actin poly) DMZT8FS MA Modulator DMZT8FS RN Chronic hypoxia differentially up-regulates protein kinase C-mediated ovine uterine arterial contraction via actin polymerization signaling in pregnancy. Biol Reprod. 2012 Dec 21;87(6):142. DMZT8FS RU https://pubmed.ncbi.nlm.nih.gov/23136295 DMZTAJL DI DMZTAJL DMZTAJL DN TA-7906 DMZTAJL TI TTSKMI8 DMZTAJL TN Phosphodiesterase 4D (PDE4D) DMZTAJL MA Inhibitor DMZTAJL RN Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6. DMZTAJL RU https://pubmed.ncbi.nlm.nih.gov/12067300 DMZTAJL DI DMZTAJL DMZTAJL DN TA-7906 DMZTAJL TI TTVIAT9 DMZTAJL TN Phosphodiesterase 4B (PDE4B) DMZTAJL MA Inhibitor DMZTAJL RN Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6. DMZTAJL RU https://pubmed.ncbi.nlm.nih.gov/12067300 DMZTAJL DI DMZTAJL DMZTAJL DN TA-7906 DMZTAJL TI TTZ97H5 DMZTAJL TN Phosphodiesterase 4A (PDE4A) DMZTAJL MA Inhibitor DMZTAJL RN Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol. 2002 Jun;128(3):460-6. DMZTAJL RU https://pubmed.ncbi.nlm.nih.gov/12067300 DMZTOJ6 DI DMZTOJ6 DMZTOJ6 DN TBA-7371 DMZTOJ6 TI TTLOHU4 DMZTOJ6 TN Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) DMZTOJ6 MA Inhibitor DMZTOJ6 RN Clinical pipeline report, company report or official report of TB Alliance. DMZTOJ6 RU https://www.tballiance.org/portfolio/trial/12010 DMZUAH2 DI DMZUAH2 DMZUAH2 DN ASP-4901 DMZUAH2 TI TTZOEBC DMZUAH2 TN Phosphodiesterase 9 (PDE9) DMZUAH2 MA Inhibitor DMZUAH2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033070) DMZUAH2 RU http://adisinsight.springer.com/drugs/800033070 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTNT7K8 DMZUAJ4 TN Nociceptin receptor (OPRL1) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTD0CIQ DMZUAJ4 TN Melanocortin receptor 4 (MC4R) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTXV4FI DMZUAJ4 TN Albendazole monooxygenase (CYP3A4) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTYO0A3 DMZUAJ4 TN Substance-K receptor (TACR2) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TT4TFGN DMZUAJ4 TN Vasopressin V1a receptor (V1AR) DMZUAJ4 MA Inhibitor DMZUAJ4 RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMZUAJ4 RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMZUAJ4 DI DMZUAJ4 DMZUAJ4 DN PMX-53 DMZUAJ4 TI TTHXFA1 DMZUAJ4 TN C5a anaphylatoxin chemotactic receptor (C5AR1) DMZUAJ4 MA Modulator DMZUAJ4 RN Company report (Arana Therapeutics) DMZUAJ4 RU http://www.asx.com.au/asxpdf/20090219/pdf/31g4hr7254nxxr.pdf DMZUV7T DI DMZUV7T DMZUV7T DN CART-19 cells DMZUV7T TI TTW640A DMZUV7T TN B-lymphocyte surface antigen B4 (CD19) DMZUV7T MA CAR-T-Cell-Therapy DMZUV7T RN ClinicalTrials.gov (NCT01551043) Allo CART-19 Protocol DMZUV7T RU https://clinicaltrials.gov/ct2/show/NCT01551043 DMZV27P DI DMZV27P DMZV27P DN SXC-2023 DMZV27P TI TTBZMIO DMZV27P TN Cystine/glutamate transporter (SLC7A11) DMZV27P MA Activator DMZV27P RN Clinical pipeline report, company report or official report of Promentis Pharmaceuticals. DMZV27P RU https://promentispharma.com/technology/sxc-2023/ DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TT0LF7H DMZW50O TN Fibroblast growth factor receptor (FGFR) DMZW50O MA Modulator DMZW50O RN The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58. DMZW50O RU https://pubmed.ncbi.nlm.nih.gov/25169980 DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TTRLW2X DMZW50O TN Fibroblast growth factor receptor 1 (FGFR1) DMZW50O MA Inhibitor DMZW50O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZW50O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TTGJVQM DMZW50O TN Fibroblast growth factor receptor 2 (FGFR2) DMZW50O MA Inhibitor DMZW50O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZW50O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZW50O DI DMZW50O DMZW50O DN Debio 1347 DMZW50O TI TTST7KB DMZW50O TN Fibroblast growth factor receptor 3 (FGFR3) DMZW50O MA Inhibitor DMZW50O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZW50O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZWNQF DI DMZWNQF DMZWNQF DN 2'3'-Dideoxyinosine DMZWNQF TI TTMCF1Y DMZWNQF TN Purine nucleoside phosphorylase (PNP) DMZWNQF MA Inhibitor DMZWNQF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZWNQF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZX0VF DI DMZX0VF DMZX0VF DN Tavokinogene telseplasmid DMZX0VF TI TTG68FB DMZX0VF TN Interleukine 12 (IL-12) DMZX0VF MA Replacement DMZX0VF RN Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Ann Oncol. 2020 Apr;31(4):532-540. DMZX0VF RU https://pubmed.ncbi.nlm.nih.gov/32147213 DM824EG DI DM824EG DM824EG DN COVA322 DM824EG TI TTF8CQI DM824EG TN Tumor necrosis factor (TNF) DM824EG MA Modulator DM824EG RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM824EG RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DM824EG DI DM824EG DM824EG DN COVA322 DM824EG TI TTG0MT6 DM824EG TN Interleukin-17 (IL17) DM824EG MA Modulator DM824EG RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM824EG RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMJ1NG4 DI DMJ1NG4 DMJ1NG4 DN Dalazatide DMJ1NG4 TI TTY3UE6 DMJ1NG4 TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMJ1NG4 MA Inhibitor DMJ1NG4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ1NG4 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMTXBUV DI DMTXBUV DMTXBUV DN BT1718 DMTXBUV TI TTJ4QE7 DMTXBUV TN Matrix metalloproteinase-14 (MMP-14) DMTXBUV MA Inhibitor DMTXBUV RN ClinicalTrials.gov (NCT03486730) BT1718 in Patients With Advanced Solid Tumours.. U.S. National Institutes of Health. DMTXBUV RU https://clinicaltrials.gov/ct2/show/NCT03486730 DMV401D DI DMV401D DMV401D DN Debio-0824 DMV401D TI TTY3UE6 DMV401D TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMV401D MA Inhibitor DMV401D RN Durable Pharmacological Responses from the Peptide ShK-186, a Specific Kv1.3 Channel Inhibitor That Suppresses T Cell Mediators of Autoimmune Disease. J Pharmacol Exp Ther. 2012 September; 342(3): 642-653. DMV401D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422530/ DM03GDJ DI DM03GDJ DM03GDJ DN Pepinemab DM03GDJ TI TT5UT28 DM03GDJ TN Semaphorin-4D (SEMA4D) DM03GDJ MA Inhibitor DM03GDJ RN Clinical pipeline report, company report or official report of Vaccinex. DM03GDJ RU https://vaccinex.com/pipeline/pepinemab-immuno-oncology/ DM03LWZ DI DM03LWZ DM03LWZ DN CVX-060 DM03LWZ TI TTKLQTJ DM03LWZ TN Angiopoietin-2 (ANGPT2) DM03LWZ RN Clinical pipeline report, company report or official report of CovX (2011). DM03LWZ RU http://www.covx.com/pipeline.html DM04HNB DI DM04HNB DM04HNB DN Anti-CD19 CAR-T DM04HNB TI TTW640A DM04HNB TN B-lymphocyte surface antigen B4 (CD19) DM04HNB MA CAR-T-Cell-Therapy DM04HNB RN ClinicalTrials.gov (NCT02685670) Competitive Transfer of CD19-TCRz-CD28 and CD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma DM04HNB RU https://clinicaltrials.gov/ct2/show/NCT02685670 DM059OH DI DM059OH DM059OH DN GSK3145095 DM059OH TI TTAIQSN DM059OH TN Receptor-interacting protein 1 (RIPK1) DM059OH MA Inhibitor DM059OH RN Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer. ACS Med Chem Lett. 2019 May 9;10(6):857-862. DM059OH RU https://pubmed.ncbi.nlm.nih.gov/31223438 DM08TH3 DI DM08TH3 DM08TH3 DN ITI-214 DM08TH3 TI TTHQENC DM08TH3 TN Phosphodiesterase 1 (PDE1) DM08TH3 MA Inhibitor DM08TH3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM08TH3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM095HQ DI DM095HQ DM095HQ DN LM11A-31 DM095HQ TI TTEDJN4 DM095HQ TN Low-affinity nerve growth factor receptor (NGFR) DM095HQ MA Modulator DM095HQ RN Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinal vascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. DM095HQ RU https://pubmed.ncbi.nlm.nih.gov/31073629 DM09JOZ DI DM09JOZ DM09JOZ DN ImMucin DM09JOZ TI TTBHFYQ DM09JOZ TN Mucin-1 (MUC1) DM09JOZ RN Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56. DM09JOZ RU https://pubmed.ncbi.nlm.nih.gov/25496030 DM0C1IX DI DM0C1IX DM0C1IX DN Anti-MUC1 CAR T Cells DM0C1IX TI TTBHFYQ DM0C1IX TN Mucin-1 (MUC1) DM0C1IX MA CAR-T-Cell-Therapy DM0C1IX RN ClinicalTrials.gov (NCT02587689) Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor DM0C1IX RU https://clinicaltrials.gov/ct2/show/NCT02587689 DM0C5MV DI DM0C5MV DM0C5MV DN HH2710 DM0C5MV TI TT1MG9E DM0C5MV TN Extracellular signal-regulated kinase 1 (ERK1) DM0C5MV MA Inhibitor DM0C5MV RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DM0C5MV RU https://www.haihepharma.com/en/research DM0C5MV DI DM0C5MV DM0C5MV DN HH2710 DM0C5MV TI TT4TQBX DM0C5MV TN Extracellular signal-regulated kinase 2 (ERK2) DM0C5MV MA Inhibitor DM0C5MV RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DM0C5MV RU https://www.haihepharma.com/en/research DM0CJAN DI DM0CJAN DM0CJAN DN AAV-CNGB3 DM0CJAN TI TT0LJCG DM0CJAN TN Cyclic nucleotide-gated channel beta-3 (CNGB3) DM0CJAN RN Clinical pipeline report, company report or official report of MeiraGTx. DM0CJAN RU https://meiragtx.com/research-development/pipeline/ DM0F9CD DI DM0F9CD DM0F9CD DN CCT301-59 (targeting ROR2) DM0F9CD TI TTUDPCI DM0F9CD TN Neurotrophic tyrosine kinase ROR2 (ROR2) DM0F9CD MA CAR-T-Cell-Therapy DM0F9CD RN ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma DM0F9CD RU https://clinicaltrials.gov/ct2/show/NCT03393936 DM0HSJK DI DM0HSJK DM0HSJK DN FF-10501-01 DM0HSJK TI TTF63Z1 DM0HSJK TN Cell differentiation (CD) DM0HSJK MA Stimulator DM0HSJK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0HSJK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0HTEF DI DM0HTEF DM0HTEF DN PRI-724 DM0HTEF TI TTFRCTK DM0HTEF TN CREB-binding protein (CREBBP) DM0HTEF MA Modulator DM0HTEF RN Inhibition of Wnt/beta-catenin/CREB binding protein (CBP) signaling reverses pulmonary fibrosis. Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14309-14. DM0HTEF RU https://pubmed.ncbi.nlm.nih.gov/20660310 DM0I5LM DI DM0I5LM DM0I5LM DN DdRNAi therapy rHIV7-shl-TAR-CCR5RZ, stem cells DM0I5LM TI TTJIH8Q DM0I5LM TN CCR5 messenger RNA (CCR5 mRNA) DM0I5LM RN Progress on RNAi-based molecular medicines. Int J Nanomedicine. 2012; 7: 3971-3980. DM0I5LM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418169/ DM0MCTJ DI DM0MCTJ DM0MCTJ DN CART-123 cells DM0MCTJ TI TTENHJ0 DM0MCTJ TN Interleukin 3 receptor alpha (IL3RA) DM0MCTJ MA CAR-T-Cell-Therapy DM0MCTJ RN ClinicalTrials.gov (NCT03556982) CART-123 FOR Relapsed/Refractory Acute Myelocytic LeukemiaAML DM0MCTJ RU https://clinicaltrials.gov/ct2/show/NCT03556982 DM0NZYC DI DM0NZYC DM0NZYC DN KO-539 DM0NZYC TI TT0CZBQ DM0NZYC TN Menin-MLL1 interaction (MEN1-KMT2A PPI) DM0NZYC MA Inhibitor DM0NZYC RN Clinical pipeline report, company report or official report of Kura Oncology. DM0NZYC RU https://kuraoncology.com/pipeline/#ko539 DM0PWX2 DI DM0PWX2 DM0PWX2 DN AUTO2 DM0PWX2 TI TTL9OD4 DM0PWX2 TN Transmembrane activator and CAML interactor (TNFRSF13B) DM0PWX2 MA CAR-T-Cell-Therapy(Dual specific) DM0PWX2 RN ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma DM0PWX2 RU https://clinicaltrials.gov/ct2/show/NCT03287804 DM0PWX2 DI DM0PWX2 DM0PWX2 DN AUTO2 DM0PWX2 TI TTZ3P4W DM0PWX2 TN B-cell maturation protein (TNFRSF17) DM0PWX2 MA CAR-T-Cell-Therapy(Dual specific) DM0PWX2 RN ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma DM0PWX2 RU https://clinicaltrials.gov/ct2/show/NCT03287804 DM0S24D DI DM0S24D DM0S24D DN GTU-TB vaccine DM0S24D TI TTUTN1I DM0S24D TN Human Deoxyribonucleic acid (hDNA) DM0S24D RN Clinical pipeline report, company report or official report of hightechfinland. DM0S24D RU http://www.hightechfinland.com/wwwdata/pdf/2013/Fitbiotech.pdf DM0USBX DI DM0USBX DM0USBX DN CD38 CAR-T Cell DM0USBX TI TTPURFN DM0USBX TN Cyclic ADP-ribose hydrolase 1 (CD38) DM0USBX MA CAR-T-Cell-Therapy DM0USBX RN ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy DM0USBX RU https://clinicaltrials.gov/ct2/show/NCT03754764 DM0VXIM DI DM0VXIM DM0VXIM DN TJ003234 DM0VXIM TI TTPZGYX DM0VXIM TN HUMAN colony-stimulating factor (GM-CSF) DM0VXIM MA Inhibitor DM0VXIM RN The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. J Autoimmun. 2020 Apr 17:102468. DM0VXIM RU https://pubmed.ncbi.nlm.nih.gov/32317220 DM0Y6WU DI DM0Y6WU DM0Y6WU DN REGN5678 DM0Y6WU TI TTQ13FT DM0Y6WU TN T-cell-specific surface glycoprotein CD28 (CD28) DM0Y6WU MA Inhibitor DM0Y6WU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM0Y6WU RU https://www.regeneron.com/science/pipeline DM0Y6WU DI DM0Y6WU DM0Y6WU DN REGN5678 DM0Y6WU TI TT9G4N0 DM0Y6WU TN Glutamate carboxypeptidase II (GCPII) DM0Y6WU MA Inhibitor DM0Y6WU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM0Y6WU RU https://www.regeneron.com/science/pipeline DM129VT DI DM129VT DM129VT DN 514G3 DM129VT TI TTOWKQ9 DM129VT TN Staphylococcus IgG binding protein A (Stap-coc SpA) DM129VT MA Inhibitor DM129VT RN A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia. PLoS One. 2018 Jan 24;13(1):e0190537. DM129VT RU https://pubmed.ncbi.nlm.nih.gov/29364906 DM13AH8 DI DM13AH8 DM13AH8 DN TAS-0728 DM13AH8 TI TT6EO5L DM13AH8 TN Erbb2 tyrosine kinase receptor (HER2) DM13AH8 MA Inhibitor DM13AH8 RN TAS0728, A Covalent-binding, HER2-selective Kinase Inhibitor Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2019 Apr;18(4):733-742. DM13AH8 RU https://pubmed.ncbi.nlm.nih.gov/30787176 DM148HX DI DM148HX DM148HX DN XToll DM148HX TI TTWYMFE DM148HX TN Mitochondrial 10kDa heat shock protein (HSPE1) DM148HX MA Modulator DM148HX RN XToll, a recombinant chaperonin 10 as an anti-inflammatory immunomodulator. Curr Opin Investig Drugs. 2008 May;9(5):523-33. DM148HX RU https://pubmed.ncbi.nlm.nih.gov/18465663 DM18ZLW DI DM18ZLW DM18ZLW DN IMP-321 DM18ZLW TI TTNVXAW DM18ZLW TN Lymphocyte activation gene 3 protein (LAG3) DM18ZLW MA Immunomodulator DM18ZLW RN A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11. DM18ZLW RU https://pubmed.ncbi.nlm.nih.gov/17785860 DM1AB4L DI DM1AB4L DM1AB4L DN Talotrexin DM1AB4L TI TTVC37M DM1AB4L TN Folate receptor alpha (FOLR1) DM1AB4L MA Antagonist DM1AB4L RN Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301. DM1AB4L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033035/ DM1CG47 DI DM1CG47 DM1CG47 DN IL-2 XL DM1CG47 TI TTF89GD DM1CG47 TN Interleukin-2 (IL2) DM1CG47 MA Modulator DM1CG47 RN Pharmacokinetics (PK) and immunologic responses in a phase I/II study of a sustained release formulation of IL-2 in renal cell carcinoma (RCC) patients. J Clin Oncol (Meeting Abstracts) June 2006 vol. 24 no. 18_suppl 2558. DM1CG47 RU http://meeting.ascopubs.org/cgi/content/short/24/18_suppl/2558 DM1D6BT DI DM1D6BT DM1D6BT DN PEGylated hyaluronidase (human recombinant) DM1D6BT TI TTXFI1K DM1D6BT TN Hyaluronidase (HYAL) DM1D6BT MA Modulator DM1D6BT RN Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov. 2011 September; 1(4): 291-296. DM1D6BT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3204883/ DM1DHPO DI DM1DHPO DM1DHPO DN BCMA CAR-T DM1DHPO TI TTZ3P4W DM1DHPO TN B-cell maturation protein (TNFRSF17) DM1DHPO MA CAR-T-Cell-Therapy DM1DHPO RN ClinicalTrials.gov (NCT03322735) Study of BCMA CAR-T in Multiple Myeloma DM1DHPO RU https://clinicaltrials.gov/ct2/show/NCT03322735 DM1EH9D DI DM1EH9D DM1EH9D DN Anti-CD19 CAR-T cells DM1EH9D TI TTW640A DM1EH9D TN B-lymphocyte surface antigen B4 (CD19) DM1EH9D MA CAR-T-Cell-Therapy DM1EH9D RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM1EH9D RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM1FJW6 DI DM1FJW6 DM1FJW6 DN BT8009 DM1FJW6 TI TTPO9EG DM1FJW6 TN Nectin cell adhesion molecule 4 (NECTIN4) DM1FJW6 RN Clinical pipeline report, company report or official report of Bicycle Therapeutics. DM1FJW6 RU https://www.bicycletherapeutics.com/wp-content/uploads/BT8009-AACR-4479-Rigby.pdf DM1FY97 DI DM1FY97 DM1FY97 DN T3D-959 DM1FY97 TI TT2JWF6 DM1FY97 TN Peroxisome proliferator-activated receptor delta (PPARD) DM1FY97 MA Modulator DM1FY97 RN Phrma report (2013 Alzheimers disease) DM1FY97 RU http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf DM1FY97 DI DM1FY97 DM1FY97 DN T3D-959 DM1FY97 TI TTZMAO3 DM1FY97 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM1FY97 MA Modulator DM1FY97 RN Phrma report (2013 Alzheimers disease) DM1FY97 RU http://www.phrma.org/sites/default/files/Alzheimer's%202013.pdf DM1GE67 DI DM1GE67 DM1GE67 DN GS-4224 DM1GE67 TI TT8ZLTI DM1GE67 TN Programmed cell death 1 ligand 1 (PD-L1) DM1GE67 MA Inhibitor DM1GE67 RN Clinical pipeline report, company report or official report of Gilead Sciences. DM1GE67 RU https://www.gilead.com/science-and-medicine/pipeline DM1KZW0 DI DM1KZW0 DM1KZW0 DN MGC018 DM1KZW0 TI TT6CQUM DM1KZW0 TN B7 homolog 3 (CD276) DM1KZW0 RN Clinical pipeline report, company report or official report of MacroGenics. DM1KZW0 RU https://www.macrogenics.com/mgc018-b7-h3/ DM1LO8K DI DM1LO8K DM1LO8K DN RVX-208 DM1LO8K TI TTRA6BO DM1LO8K TN Bromodomain-containing protein 4 (BRD4) DM1LO8K MA Modulator DM1LO8K RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DM1LO8K RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DM1PQJO DI DM1PQJO DM1PQJO DN Enapotamab vedotin DM1PQJO TI TTZPY6J DM1PQJO TN Tyrosine-protein kinase UFO (AXL) DM1PQJO MA Inhibitor DM1PQJO RN Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer. JCI Insight. 2019 Nov 1;4(21):e128199. DM1PQJO RU https://pubmed.ncbi.nlm.nih.gov/31600169 DM1U6VX DI DM1U6VX DM1U6VX DN HER-2-targeting CAR T Cells DM1U6VX TI TT6EO5L DM1U6VX TN Erbb2 tyrosine kinase receptor (HER2) DM1U6VX MA CAR-T-Cell-Therapy DM1U6VX RN ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer DM1U6VX RU https://clinicaltrials.gov/ct2/show/NCT02547961 DM1W7LV DI DM1W7LV DM1W7LV DN CAR-T cells targeting MAGE-A1 DM1W7LV TI TT63M7Q DM1W7LV TN Melanoma-associated antigen 1 (MAGEA1) DM1W7LV MA CAR-T-Cell-Therapy DM1W7LV RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DM1W7LV RU https://clinicaltrials.gov/ct2/show/NCT03356808 DM1WB8H DI DM1WB8H DM1WB8H DN Anti-CD19-CAR PBL DM1WB8H TI TTW640A DM1WB8H TN B-lymphocyte surface antigen B4 (CD19) DM1WB8H MA CAR-T-Cell-Therapy DM1WB8H RN ClinicalTrials.gov (NCT00924326) CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma DM1WB8H RU https://clinicaltrials.gov/ct2/show/NCT00924326 DM1WD8F DI DM1WD8F DM1WD8F DN ISB 1302 DM1WD8F TI TT6EO5L DM1WD8F TN Erbb2 tyrosine kinase receptor (HER2) DM1WD8F MA Inhibitor DM1WD8F RN Clinical pipeline report, company report or official report of Ichnos Sciences. DM1WD8F RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DM1WD8F DI DM1WD8F DM1WD8F DN ISB 1302 DM1WD8F TI TTUN7MC DM1WD8F TN T-cell surface glycoprotein CD3 (CD3) DM1WD8F MA Inhibitor DM1WD8F RN Clinical pipeline report, company report or official report of Ichnos Sciences. DM1WD8F RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DM1XIMU DI DM1XIMU DM1XIMU DN FF-10101 DM1XIMU TI TTGJCWZ DM1XIMU TN Fms-like tyrosine kinase 3 (FLT-3) DM1XIMU MA Inhibitor DM1XIMU RN A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018 Jan 25;131(4):426-438. DM1XIMU RU https://pubmed.ncbi.nlm.nih.gov/29187377 DM1ZGUX DI DM1ZGUX DM1ZGUX DN CPHPC DM1ZGUX TI TTB7VAT DM1ZGUX TN Serum amyloid P-component (APCS) DM1ZGUX MA Modulator DM1ZGUX RN Interaction of serum amyloid P component with hexanoyl bis(D-proline) (CPHPC).Acta Crystallogr D Biol Crystallogr.2014 Aug;70(Pt 8):2232-40. DM1ZGUX RU https://www.ncbi.nlm.nih.gov/pubmed/25084341 DM1ZHML DI DM1ZHML DM1ZHML DN HPN328 DM1ZHML TI TT1C9K6 DM1ZHML TN Delta-like protein 3 (DLL3) DM1ZHML RN Clinical pipeline report, company report or official report of Harpoon Therapeutics. DM1ZHML RU https://www.harpoontx.com/pipeline/ DM1ZK4W DI DM1ZK4W DM1ZK4W DN TRBC1 DM1ZK4W TI TT1DHW2 DM1ZK4W TN T-cell receptor beta constant 1 (TRBC1) DM1ZK4W MA CAR-T-Cell-Therapy DM1ZK4W RN ClinicalTrials.gov (NCT03590574) Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma DM1ZK4W RU https://clinicaltrials.gov/ct2/show/NCT03590574 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTDCBX5 DM21WBH TN Vascular endothelial growth factor receptor 3 (FLT-4) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTO7LKR DM21WBH TN Tyrosine-protein kinase Mer (MERTK) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTGJCWZ DM21WBH TN Fms-like tyrosine kinase 3 (FLT-3) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTNDSF4 DM21WBH TN Proto-oncogene c-Met (MET) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTRLW2X DM21WBH TN Fibroblast growth factor receptor 1 (FGFR1) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTI7421 DM21WBH TN Platelet-derived growth factor receptor beta (PDGFRB) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTUTJGQ DM21WBH TN Vascular endothelial growth factor receptor 2 (KDR) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TT1VAUK DM21WBH TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTST7KB DM21WBH TN Fibroblast growth factor receptor 3 (FGFR3) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTXABCW DM21WBH TN NT-3 growth factor receptor (TrkC) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTKN7QR DM21WBH TN BDNF/NT-3 growth factors receptor (TrkB) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTGJVQM DM21WBH TN Fibroblast growth factor receptor 2 (FGFR2) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM21WBH DI DM21WBH DM21WBH DN MK-2461 DM21WBH TI TTBQ3OC DM21WBH TN Macrophage-stimulating protein receptor (RON) DM21WBH MA Inhibitor DM21WBH RN MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33. DM21WBH RU https://pubmed.ncbi.nlm.nih.gov/20145145 DM25QKC DI DM25QKC DM25QKC DN MK-1308 DM25QKC TI TTI2S1D DM25QKC TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM25QKC MA Inhibitor DM25QKC RN Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403. DM25QKC RU https://pubmed.ncbi.nlm.nih.gov/33276076 DM26VCZ DI DM26VCZ DM26VCZ DN Anti-NY-ESO-1 CAR-T cells DM26VCZ TI TTE5ITK DM26VCZ TN Cancer/testis antigen 1 (NY-ESO-1) DM26VCZ MA CAR-T-Cell-Therapy DM26VCZ RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM26VCZ RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM276Y8 DI DM276Y8 DM276Y8 DN ARV-471 DM276Y8 TI TTS64P2 DM276Y8 TN Androgen receptor (AR) DM276Y8 MA Degrader DM276Y8 RN Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689. DM276Y8 RU https://pubmed.ncbi.nlm.nih.gov/32829249 DM27RXS DI DM27RXS DM27RXS DN ORIN1001 DM27RXS TI TTOJ9QL DM27RXS TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM27RXS MA Inhibitor DM27RXS RN Clinical pipeline report, company report or official report of Orinove. DM27RXS RU http://www.orinove.com/about261.html DM2910G DI DM2910G DM2910G DN Anti-VEGFR2 CD8 cell therapy DM2910G TI TTUTJGQ DM2910G TN Vascular endothelial growth factor receptor 2 (KDR) DM2910G MA Modulator DM2910G RN Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. DM2910G RU https://pubmed.ncbi.nlm.nih.gov/23045683 DM2910G DI DM2910G DM2910G DN Anti-VEGFR2 CD8 cell therapy DM2910G TI TTMHA6L DM2910G TN T-cell surface glycoprotein CD8 (CD8) DM2910G MA Modulator DM2910G RN Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17561-6. DM2910G RU https://pubmed.ncbi.nlm.nih.gov/23045683 DM2B1V0 DI DM2B1V0 DM2B1V0 DN CCT301-38 (targeting ROR2) DM2B1V0 TI TTUDPCI DM2B1V0 TN Neurotrophic tyrosine kinase ROR2 (ROR2) DM2B1V0 MA CAR-T-Cell-Therapy DM2B1V0 RN ClinicalTrials.gov (NCT03393936) Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma DM2B1V0 RU https://clinicaltrials.gov/ct2/show/NCT03393936 DM2BXDU DI DM2BXDU DM2BXDU DN CFG920 DM2BXDU TI TTRA5BZ DM2BXDU TN Steroid 17-alpha-monooxygenase (S17AH) DM2BXDU MA Inhibitor DM2BXDU RN Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013 Jul 4;14(7):13958-78. DM2BXDU RU https://pubmed.ncbi.nlm.nih.gov/23880851 DM2CDLS DI DM2CDLS DM2CDLS DN QLT-091568 DM2CDLS TI TTMXGCW DM2CDLS TN Adrenergic receptor beta-3 (ADRB3) DM2CDLS MA Antagonist DM2CDLS RN Clinical pipeline report, company report or official report of QLT Inc. DM2CDLS RU http://www.qltinc.com/newsCenter/2009/091230.htm DM2DHJS DI DM2DHJS DM2DHJS DN ONC1-13B DM2DHJS TI TTS64P2 DM2DHJS TN Androgen receptor (AR) DM2DHJS MA Antagonist DM2DHJS RN Preclinical Development of ONC1-13B, Novel Antiandrogen for Prostate Cancer Treatment. J Cancer. 2014 Jan 21;5(2):133-42. DM2DHJS RU https://pubmed.ncbi.nlm.nih.gov/24494031 DM2FSM5 DI DM2FSM5 DM2FSM5 DN CLR-1401 DM2FSM5 TI TTHBTOP DM2FSM5 TN PI3-kinase gamma (PIK3CG) DM2FSM5 MA Inhibitor DM2FSM5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DM2FSM5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DM2HRYD DI DM2HRYD DM2HRYD DN AEG35156 DM2HRYD TI TTK3WBU DM2HRYD TN XIAP messenger RNA (XIAP mRNA) DM2HRYD RN Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. DM2HRYD RU https://pubmed.ncbi.nlm.nih.gov/19568274 DM2LU8M DI DM2LU8M DM2LU8M DN AP1903 DM2LU8M TI TTMW94E DM2LU8M TN FK506-binding protein 1A (FKBP1A) DM2LU8M MA Modulator DM2LU8M RN Using gene transfer to circumvent off-target effects. Gene Ther. 2008 May;15(10):759-64. DM2LU8M RU https://pubmed.ncbi.nlm.nih.gov/18356813 DM2LYIN DI DM2LYIN DM2LYIN DN LX-7101 DM2LYIN TI TTU8W4S DM2LYIN TN Protein kinase (PK) DM2LYIN MA Inhibitor DM2LYIN RN Design, synthesis and biological characterization of selective LIMK inhibitors. Bioorg Med Chem Lett. 2015 Sep 15;25(18):4005-10. DM2LYIN RU https://pubmed.ncbi.nlm.nih.gov/26233434 DM2LZ8F DI DM2LZ8F DM2LZ8F DN Taurocholic acid DM2LZ8F TI TTPI1M5 DM2LZ8F TN Ileal sodium/bile acid cotransporter (SLC10A2) DM2LZ8F MA Modulator DM2LZ8F RN Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter. Am J Physiol. 1998 Jan;274(1 Pt 1):G157-69. DM2LZ8F RU https://pubmed.ncbi.nlm.nih.gov/9458785 DM2LZ8F DI DM2LZ8F DM2LZ8F DN Taurocholic acid DM2LZ8F TI TTTRNQW DM2LZ8F TN Bile-salt-activated lipase (CEL) DM2LZ8F MA Inhibitor DM2LZ8F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2LZ8F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2X3BR DI DM2X3BR DM2X3BR DN SNN-0031 DM2X3BR TI TTI7421 DM2X3BR TN Platelet-derived growth factor receptor beta (PDGFRB) DM2X3BR MA Modulator DM2X3BR RN Company report (Neuronova) DM2X3BR RU http://www.neuronova.com/index.php?option=com_content&task=view&id=41 DM2YTGQ DI DM2YTGQ DM2YTGQ DN Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes DM2YTGQ TI TTW640A DM2YTGQ TN B-lymphocyte surface antigen B4 (CD19) DM2YTGQ MA CAR-T-Cell-Therapy DM2YTGQ RN ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia DM2YTGQ RU https://clinicaltrials.gov/ct2/show/NCT01865617 DM31NJU DI DM31NJU DM31NJU DN ABY-025 DM31NJU TI TT6EO5L DM31NJU TN Erbb2 tyrosine kinase receptor (HER2) DM31NJU MA Enhancer DM31NJU RN Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010 Jul;51(7):1131-8. DM31NJU RU https://pubmed.ncbi.nlm.nih.gov/20554729 DM32AKH DI DM32AKH DM32AKH DN G-207 virus construct DM32AKH TI TTX09M4 DM32AKH TN Ribonucleotide reductase (RIR) DM32AKH MA Inhibitor DM32AKH RN Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer. 2011 Dec;30(12):831-41. DM32AKH RU https://pubmed.ncbi.nlm.nih.gov/22059912 DM35XCT DI DM35XCT DM35XCT DN CD56-specific gene-engineered T cells DM35XCT TI TTVXPHT DM35XCT TN Neural cell adhesion molecule 1 (NCAM1) DM35XCT MA CAR-T-Cell-Therapy DM35XCT RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DM35XCT RU https://clinicaltrials.gov/ct2/show/NCT03222674 DM35YFC DI DM35YFC DM35YFC DN MS-1819 DM35YFC TI TTXMY0J DM35YFC TN Pancreatic triacylglycerol lipase (PNLIP) DM35YFC MA Modulator DM35YFC RN Clinical pipeline report, company report or official report of AzurRx. DM35YFC RU http://www.azurrx.com/news-events/press-releases/10-news-2014/58-http-www-azurrx-com-administrator-index-php-option-com-content-view-article-layout-edit DM3FIMD DI DM3FIMD DM3FIMD DN WT-4869 DM3FIMD TI TTZ8UT4 DM3FIMD TN Wilms tumor protein (WT1) DM3FIMD MA Modulator DM3FIMD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033385) DM3FIMD RU http://adisinsight.springer.com/drugs/800033385 DM3GO0J DI DM3GO0J DM3GO0J DN Sodium taurocholate DM3GO0J TI TTSDVTR DM3GO0J TN G-protein coupled bile acid receptor 1 (GPBAR1) DM3GO0J MA Modulator DM3GO0J RN Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism.Acta Pharmaceutica Sinica B Volume 5, Issue 2, March 2015, Pages 151-157. DM3GO0J RU http://www.sciencedirect.com/science/article/pii/S2211383514001300 DM3I267 DI DM3I267 DM3I267 DN CART-EGFR DM3I267 TI TTGKNB4 DM3I267 TN Epidermal growth factor receptor (EGFR) DM3I267 MA CAR-T-Cell-Therapy DM3I267 RN ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR) DM3I267 RU https://clinicaltrials.gov/ct2/show/NCT01869166 DM3KXMG DI DM3KXMG DM3KXMG DN IZONSTERIDE DM3KXMG TI TT2A0DR DM3KXMG TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM3KXMG MA Modulator DM3KXMG RN Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible... Urology. 2004 Jan;63(1):114-9. DM3KXMG RU https://www.ncbi.nlm.nih.gov/pubmed/14751361 DM3XWJ8 DI DM3XWJ8 DM3XWJ8 DN CPI-1205 DM3XWJ8 TI TT9MZCQ DM3XWJ8 TN Enhancer of zeste homolog 2 (EZH2) DM3XWJ8 MA Inhibitor DM3XWJ8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3XWJ8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3ZN6Y DI DM3ZN6Y DM3ZN6Y DN FPA-008 DM3ZN6Y TI TT731LW DM3ZN6Y TN Colony stimulating factor-1 receptor (CSF-1R) DM3ZN6Y MA Modulator DM3ZN6Y RN Company report (Five Prime Therapeutics) DM3ZN6Y RU http://www.fiveprime.com/pipeline/fpa008 DM3ZN6Y DI DM3ZN6Y DM3ZN6Y DN FPA-008 DM3ZN6Y TI TT7MRDV DM3ZN6Y TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM3ZN6Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3ZN6Y RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM40NEB DI DM40NEB DM40NEB DN CD22 CAR-T DM40NEB TI TTM6QSK DM40NEB TN B-cell receptor CD22 (CD22) DM40NEB MA CAR-T-Cell-Therapy DM40NEB RN ClinicalTrials.gov (NCT02794961) CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies DM40NEB RU https://clinicaltrials.gov/ct2/show/NCT02794961 DM43ICH DI DM43ICH DM43ICH DN IMSA101 DM43ICH TI TTT402Y DM43ICH TN Stimulator of interferon genes protein (TMEM173) DM43ICH MA Agonist DM43ICH RN Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics. DM43ICH RU http://www.immunesensor.com/ DM471ZH DI DM471ZH DM471ZH DN ORE-1001 DM471ZH TI TTUI5H7 DM471ZH TN Angiotensin-converting enzyme 2 (ACE2) DM471ZH MA Inhibitor DM471ZH RN Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice. Inflamm Res. 2009 Nov;58(11):819-27. DM471ZH RU https://pubmed.ncbi.nlm.nih.gov/19517214 DM49BX1 DI DM49BX1 DM49BX1 DN F-16-131I DM49BX1 TI TTUCPMY DM49BX1 TN Tenascin (TNC) DM49BX1 RN Tumor-Associated Fibroblasts and their Matrix. Springer. Margareta M. Mueller,Norbert E. Fusenig, 2011. Page(775). DM49BX1 RU https://books.google.com.hk/books?id=NthWAAAAcAAJ&pg=PA775&lpg=PA775&dq=%22F-16-131I%22&source=bl&ots=lx9eNOrJ9J&sig=TSJZ44F1Vb9V3iKhqn2bmzR0H4E&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIgayw4crGyAIVDEiOCh1b7Q2U#v=onepage&q=%22F-16-131I%22&f=false DM4D3YF DI DM4D3YF DM4D3YF DN Anti-BCMA CAR-T cells DM4D3YF TI TTZ3P4W DM4D3YF TN B-cell maturation protein (TNFRSF17) DM4D3YF MA CAR-T-Cell-Therapy DM4D3YF RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM4D3YF RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM4H7UY DI DM4H7UY DM4H7UY DN Milatuzumab DM4H7UY TI TTCMYP9 DM4H7UY TN HLA-DR antigens-associated invariant (CD74) DM4H7UY RN Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011 Apr 28;117(17):4530-41. DM4H7UY RU https://pubmed.ncbi.nlm.nih.gov/21228331 DM4L28K DI DM4L28K DM4L28K DN Ad35-GRIN DM4L28K TI TT84ETX DM4L28K TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4L28K RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DM4L28K RU https://pubmed.ncbi.nlm.nih.gov/22870265 DM4L28K DI DM4L28K DM4L28K DN Ad35-GRIN DM4L28K TI TTFGZB6 DM4L28K TN Human immunodeficiency virus GAG protein (HIV gag) DM4L28K RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DM4L28K RU https://pubmed.ncbi.nlm.nih.gov/22870265 DM4L28K DI DM4L28K DM4L28K DN Ad35-GRIN DM4L28K TI TT4NXYM DM4L28K TN Human immunodeficiency virus Negative factor (HIV nef) DM4L28K RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DM4L28K RU https://pubmed.ncbi.nlm.nih.gov/22870265 DM4MBUI DI DM4MBUI DM4MBUI DN CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells DM4MBUI TI TTM6QSK DM4MBUI TN B-cell receptor CD22 (CD22) DM4MBUI MA CAR-T-Cell-Therapy(Dual specific) DM4MBUI RN ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy DM4MBUI RU https://clinicaltrials.gov/ct2/show/NCT02903810 DM4MBUI DI DM4MBUI DM4MBUI DN CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells DM4MBUI TI TTW640A DM4MBUI TN B-lymphocyte surface antigen B4 (CD19) DM4MBUI MA CAR-T-Cell-Therapy(Dual specific) DM4MBUI RN ClinicalTrials.gov (NCT02903810) Combination Transfer of CD19-TCRz-41BB and CD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy DM4MBUI RU https://clinicaltrials.gov/ct2/show/NCT02903810 DM4NK3J DI DM4NK3J DM4NK3J DN SF0166 DM4NK3J TI TT69TQN DM4NK3J TN Integrin alpha-V/beta-3 (ITGAV/B3) DM4NK3J MA Antagonist DM4NK3J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4NK3J RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM4NMBW DI DM4NMBW DM4NMBW DN Anti-Mesothelin CAR-T cells DM4NMBW TI TT4RXME DM4NMBW TN Mesothelin (MSLN) DM4NMBW MA CAR-T-Cell-Therapy DM4NMBW RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM4NMBW RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM4WEZL DI DM4WEZL DM4WEZL DN Anti-CD20 CAR-T cells DM4WEZL TI TTUE541 DM4WEZL TN Leukocyte surface antigen Leu-16 (CD20) DM4WEZL MA CAR-T-Cell-Therapy(Dual specific) DM4WEZL RN ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) DM4WEZL RU https://clinicaltrials.gov/ct2/show/NCT02737085 DM4WEZL DI DM4WEZL DM4WEZL DN Anti-CD20 CAR-T cells DM4WEZL TI TTW640A DM4WEZL TN B-lymphocyte surface antigen B4 (CD19) DM4WEZL MA CAR-T-Cell-Therapy(Dual specific) DM4WEZL RN ClinicalTrials.gov (NCT02737085) the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) DM4WEZL RU https://clinicaltrials.gov/ct2/show/NCT02737085 DM581CS DI DM581CS DM581CS DN CD19 and CD22 CAR-T Cells DM581CS TI TTM6QSK DM581CS TN B-cell receptor CD22 (CD22) DM581CS MA CAR-T-Cell-Therapy(Dual specific) DM581CS RN ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma DM581CS RU https://clinicaltrials.gov/ct2/show/NCT03468153 DM581CS DI DM581CS DM581CS DN CD19 and CD22 CAR-T Cells DM581CS TI TTW640A DM581CS TN B-lymphocyte surface antigen B4 (CD19) DM581CS MA CAR-T-Cell-Therapy(Dual specific) DM581CS RN ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma DM581CS RU https://clinicaltrials.gov/ct2/show/NCT03468153 DM5AIKR DI DM5AIKR DM5AIKR DN RGX-104 DM5AIKR TI TTM1EQF DM5AIKR TN Oxysterols receptor LXR (NR1H) DM5AIKR MA Agonist DM5AIKR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5AIKR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5DZEL DI DM5DZEL DM5DZEL DN PLX9486 DM5DZEL TI TTX41N9 DM5DZEL TN Tyrosine-protein kinase Kit (KIT) DM5DZEL MA Inhibitor DM5DZEL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5DZEL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5FCO4 DI DM5FCO4 DM5FCO4 DN Elpamotide DM5FCO4 TI TTUTJGQ DM5FCO4 TN Vascular endothelial growth factor receptor 2 (KDR) DM5FCO4 RN Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors. Cancer Sci. 2012 Dec;103(12):2135-8. DM5FCO4 RU https://pubmed.ncbi.nlm.nih.gov/22957712 DM5FKU1 DI DM5FKU1 DM5FKU1 DN CAR-T cells targeting Muc1 DM5FKU1 TI TTBHFYQ DM5FKU1 TN Mucin-1 (MUC1) DM5FKU1 MA CAR-T-Cell-Therapy DM5FKU1 RN ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer DM5FKU1 RU https://clinicaltrials.gov/ct2/show/NCT03356795 DM5HUY8 DI DM5HUY8 DM5HUY8 DN BMS-863233 DM5HUY8 TI TTSMTDI DM5HUY8 TN CDC7-related kinase (CDC7) DM5HUY8 MA Modulator DM5HUY8 RN Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31. DM5HUY8 RU https://pubmed.ncbi.nlm.nih.gov/22560567 DM5MFHO DI DM5MFHO DM5MFHO DN REIC gene therapy DM5MFHO TI TTY2ZV6 DM5MFHO TN Dickkopf-related protein 3 (DKK3) DM5MFHO MA Modulator DM5MFHO RN Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. J Gastroenterol Hepatol. 2014 May;29(5):973-83. DM5MFHO RU https://pubmed.ncbi.nlm.nih.gov/24372695 DM5N04G DI DM5N04G DM5N04G DN LT-1951 DM5N04G TI TTF10I9 DM5N04G TN Nitric-oxide synthase inducible (NOS2) DM5N04G MA Modulator DM5N04G RN Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14. DM5N04G RU https://pubmed.ncbi.nlm.nih.gov/12742995 DM5NICF DI DM5NICF DM5NICF DN TBI-1501 DM5NICF TI TTW640A DM5NICF TN B-lymphocyte surface antigen B4 (CD19) DM5NICF MA CAR-T-Cell-Therapy DM5NICF RN ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia DM5NICF RU https://clinicaltrials.gov/ct2/show/NCT03155191 DM5O4GR DI DM5O4GR DM5O4GR DN NB1011 DM5O4GR TI TTU6BFZ DM5O4GR TN Candida Thymidylate synthase (Candi TMP1) DM5O4GR MA Binder DM5O4GR RN Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochem Biophys Res Commun. 2003 Jul 25;307(2):297-300. DM5O4GR RU https://pubmed.ncbi.nlm.nih.gov/12859954 DM5U3IF DI DM5U3IF DM5U3IF DN KB-004 DM5U3IF TI TTHS2LR DM5U3IF TN Ephrin type-A receptor 3 (EPHA3) DM5U3IF RN Clinical pipeline report, company report or official report of Kalobios. DM5U3IF RU http://kalobios.com/kb004 DM5VF04 DI DM5VF04 DM5VF04 DN GD2-CART01 DM5VF04 TI TT80ARU DM5VF04 TN Ganglioside GD2 (GD2) DM5VF04 MA CAR-T-Cell-Therapy DM5VF04 RN ClinicalTrials.gov (NCT03373097) Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma DM5VF04 RU https://clinicaltrials.gov/ct2/show/NCT03373097 DM5VG6S DI DM5VG6S DM5VG6S DN BGB-A333 DM5VG6S TI TT8ZLTI DM5VG6S TN Programmed cell death 1 ligand 1 (PD-L1) DM5VG6S RN Clinical pipeline report, company report or official report of BeiGene. DM5VG6S RU https://www.beigene.com/science-and-product-portfolio/pipeline DM5YDSU DI DM5YDSU DM5YDSU DN ACI-24 DM5YDSU TI TTE4KHA DM5YDSU TN Amyloid beta A4 protein (APP) DM5YDSU RN Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36. DM5YDSU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015631/ DM6078F DI DM6078F DM6078F DN CT84.66 DM6078F TI TTY6DTE DM6078F TN Carcinoembryonic antigen CEA (CD66e) DM6078F RN Technology evaluation: cT84.66, City of Hope. Curr Opin Mol Ther. 2004 Feb;6(1):90-5. DM6078F RU https://pubmed.ncbi.nlm.nih.gov/15011786 DM614BA DI DM614BA DM614BA DN Re-188-P-2045 DM614BA TI TTZ6T9E DM614BA TN Somatostatin receptor type 2 (SSTR2) DM614BA MA Modulator DM614BA RN The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med. 2014 Dec;55(12):2020-5. DM614BA RU https://pubmed.ncbi.nlm.nih.gov/25359879 DM61MBG DI DM61MBG DM61MBG DN CD22-Targeted CAR-T cells DM61MBG TI TTM6QSK DM61MBG TN B-cell receptor CD22 (CD22) DM61MBG MA CAR-T-Cell-Therapy DM61MBG RN ClinicalTrials.gov (NCT02935153) A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies DM61MBG RU https://clinicaltrials.gov/ct2/show/NCT02935153 DM64FY7 DI DM64FY7 DM64FY7 DN CLR457 DM64FY7 TI TTHBTOP DM64FY7 TN PI3-kinase gamma (PIK3CG) DM64FY7 MA Modulator DM64FY7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM64FY7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM64PM7 DI DM64PM7 DM64PM7 DN EXO-230 DM64PM7 TI TT8NGED DM64PM7 TN Prostaglandin G/H synthase 1 (COX-1) DM64PM7 MA Agonist DM64PM7 RN Inhibiting Amadori-modified albumin formation improves biomarkers of podocyte damage in diabetic rats. Physiol Rep. 2013 September; 1(4): e00083. DM64PM7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831899/ DM65MEL DI DM65MEL DM65MEL DN LXS196 DM65MEL TI TTYVX59 DM65MEL TN Protein kinase C (PRKC) DM65MEL MA Inhibitor DM65MEL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM65MEL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM69A1W DI DM69A1W DM69A1W DN CD19 CART DM69A1W TI TTW640A DM69A1W TN B-lymphocyte surface antigen B4 (CD19) DM69A1W MA CAR-T-Cell-Therapy DM69A1W RN ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL DM69A1W RU https://clinicaltrials.gov/ct2/show/NCT03232619 DM6AXV9 DI DM6AXV9 DM6AXV9 DN TOL-101 DM6AXV9 TI TT7AKW1 DM6AXV9 TN T-cell receptor (TCR) DM6AXV9 RN First-in-Human Study of the Safety and Efficacy of TOL101 Induction to Prevent Kidney Transplant Rejection. Am J Transplant. 2014 June; 14(6): 1346-1355. DM6AXV9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404309/ DM6H1MQ DI DM6H1MQ DM6H1MQ DN CAR-T cells targeting GPC3 DM6H1MQ TI TTJTSX4 DM6H1MQ TN Glypican-3 (GPC3) DM6H1MQ MA CAR-T-Cell-Therapy DM6H1MQ RN ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy DM6H1MQ RU https://clinicaltrials.gov/ct2/show/NCT02959151 DM6H3YS DI DM6H3YS DM6H3YS DN MAGE-A10 TCR DM6H3YS TI TT7AKW1 DM6H3YS TN T-cell receptor (TCR) DM6H3YS MA Immunomodulator DM6H3YS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6H3YS RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM6HPEC DI DM6HPEC DM6HPEC DN USL311 DM6HPEC TI TTBID49 DM6HPEC TN C-X-C chemokine receptor type 4 (CXCR4) DM6HPEC MA Antagonist DM6HPEC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6HPEC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6JLNT DI DM6JLNT DM6JLNT DN 177-Lu-NeoB DM6JLNT TI TTC1MVT DM6JLNT TN Gastrin-releasing peptide receptor (GRPR) DM6JLNT MA Antagonist DM6JLNT RN 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. J Nucl Med. 2017 Feb;58(2):293-299. DM6JLNT RU https://pubmed.ncbi.nlm.nih.gov/27609789 DM6JN19 DI DM6JN19 DM6JN19 DN ME-344 DM6JN19 TI TTCJG29 DM6JN19 TN Serine/threonine-protein kinase mTOR (mTOR) DM6JN19 MA Inhibitor DM6JN19 RN National Cancer Institute Drug Dictionary (drug id 728650). DM6JN19 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=728650 DM6JN19 DI DM6JN19 DM6JN19 DN ME-344 DM6JN19 TI TTX4GLS DM6JN19 TN Mammalian target of rapamycin complex 1 (mTORC1) DM6JN19 MA Inhibitor DM6JN19 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6JN19 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6JN19 DI DM6JN19 DM6JN19 DN ME-344 DM6JN19 TI TTWDKCL DM6JN19 TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DM6JN19 MA Inhibitor DM6JN19 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6JN19 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6LDI4 DI DM6LDI4 DM6LDI4 DN BMS-986158 DM6LDI4 TI TTE4BSY DM6LDI4 TN Bromodomain and extraterminal domain protein (BET) DM6LDI4 MA Inhibitor DM6LDI4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6LDI4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6M8O4 DI DM6M8O4 DM6M8O4 DN SAR440234 DM6M8O4 TI TTUN7MC DM6M8O4 TN T-cell surface glycoprotein CD3 (CD3) DM6M8O4 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM6M8O4 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM6M8O4 DI DM6M8O4 DM6M8O4 DN SAR440234 DM6M8O4 TI TTENHJ0 DM6M8O4 TN Interleukin 3 receptor alpha (IL3RA) DM6M8O4 RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DM6M8O4 RU https://pubmed.ncbi.nlm.nih.gov/31175342 DM6V5OB DI DM6V5OB DM6V5OB DN P-552-02 DM6V5OB TI TTRK8B9 DM6V5OB TN Sodium channel unspecific (NaC) DM6V5OB MA Blocker DM6V5OB RN US patent application no. 2014,0221,286, Sodium channel blockers reduce glucagon secretion. DM6V5OB RU https://www.google.com/patents/US20140221286 DM6VCPX DI DM6VCPX DM6VCPX DN CAR-T cells targeting CEA DM6VCPX TI TTY6DTE DM6VCPX TN Carcinoembryonic antigen CEA (CD66e) DM6VCPX MA CAR-T-Cell-Therapy DM6VCPX RN ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy DM6VCPX RU https://clinicaltrials.gov/ct2/show/NCT02959151 DM6VGO3 DI DM6VGO3 DM6VGO3 DN OPB-31121 DM6VGO3 TI TTH8FZW DM6VGO3 TN Signal transducer and activator of transcription 3 (STAT3) DM6VGO3 MA Inhibitor DM6VGO3 RN OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52. DM6VGO3 RU https://pubmed.ncbi.nlm.nih.gov/23402820 DM6ZXWY DI DM6ZXWY DM6ZXWY DN CAR.CD30 cells DM6ZXWY TI TT2GM5R DM6ZXWY TN Lymphocyte activation antigen CD30 (TNFRSF8) DM6ZXWY MA CAR-T-Cell-Therapy DM6ZXWY RN ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas DM6ZXWY RU https://clinicaltrials.gov/ct2/show/NCT02663297 DM71BFM DI DM71BFM DM71BFM DN DNA-Ad DM71BFM TI TTQZW34 DM71BFM TN Plasmodium Apical membrane protein (Malaria AMA-1) DM71BFM RN Sterile immunity to malaria after DNA prime/adenovirus boost immunization is associated with effector memory CD8+T cells targeting AMA1 class I epitopes. PLoS One. 2014 Sep 11;9(9):e106241. DM71BFM RU https://pubmed.ncbi.nlm.nih.gov/25211344 DM71I53 DI DM71I53 DM71I53 DN APC-100 DM71I53 TI TTS64P2 DM71I53 TN Androgen receptor (AR) DM71I53 MA Inhibitor DM71I53 RN 2011 Pipeline of Adamis Pharmaceuticals. DM71I53 RU http://www.adamispharmaceuticals.com/ DM72DU3 DI DM72DU3 DM72DU3 DN DZD9008 DM72DU3 TI TT2M7YX DM72DU3 TN EGFR Exon20ins mutant (EGFR Exon20ins) DM72DU3 MA Inhibitor DM72DU3 RN Clinical pipeline report, company report or official report of Dizal Pharmaceuticals. DM72DU3 RU http://www.dizalpharma.com/innovation/science DM72JE4 DI DM72JE4 DM72JE4 DN FF-10502 DM72JE4 TI TTA0XPV DM72JE4 TN DNA polymerase beta (POLB) DM72JE4 MA Inhibitor DM72JE4 RN FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells. J Pharmacol Exp Ther. 2018 Jul;366(1):125-135. DM72JE4 RU https://pubmed.ncbi.nlm.nih.gov/29653962 DM75QY9 DI DM75QY9 DM75QY9 DN ATL-313 DM75QY9 TI TTM2AOE DM75QY9 TN Adenosine A2a receptor (ADORA2A) DM75QY9 MA Agonist DM75QY9 RN Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis. Infect Immun. 2006 May;74(5):2606-12. DM75QY9 RU https://pubmed.ncbi.nlm.nih.gov/16622196 DM76S3X DI DM76S3X DM76S3X DN ARO-HBV DM76S3X TI TT43YWN DM76S3X TN Hepatitis B virus messenger RNA (HBV mRNA) DM76S3X MA Inhibitor DM76S3X RN Clinical pipeline report, company report or official report of Arrowhead Pharmaceuticals. DM76S3X RU https://arrowheadpharma.com/pipeline/ DM78KMT DI DM78KMT DM78KMT DN NPB-001-056 DM78KMT TI TTS7G69 DM78KMT TN Fusion protein Bcr-Abl (Bcr-Abl) DM78KMT MA Inhibitor DM78KMT RN NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells. Front Biosci (Elite Ed). 2011 Jun 1;3:1273-88. DM78KMT RU https://pubmed.ncbi.nlm.nih.gov/21622134 DM79GPF DI DM79GPF DM79GPF DN CD19.CAR T Cells DM79GPF TI TTW640A DM79GPF TN B-lymphocyte surface antigen B4 (CD19) DM79GPF MA CAR-T-Cell-Therapy DM79GPF RN ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR DM79GPF RU https://clinicaltrials.gov/ct2/show/NCT03676504 DM7C1AJ DI DM7C1AJ DM7C1AJ DN HT-2157 DM7C1AJ TI TTOPAY7 DM7C1AJ TN Galanin receptor (GAL-R) DM7C1AJ MA Antagonist DM7C1AJ RN Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94. DM7C1AJ RU https://pubmed.ncbi.nlm.nih.gov/16287967 DM7CLEZ DI DM7CLEZ DM7CLEZ DN Eltanexor oral DM7CLEZ TI TTCJUR4 DM7CLEZ TN Exportin-1 (XPO1) DM7CLEZ MA Inhibitor DM7CLEZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7CLEZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7DWLY DI DM7DWLY DM7DWLY DN GLR2007 DM7DWLY TI TT0PG8F DM7DWLY TN Cyclin-dependent kinase 4 (CDK4) DM7DWLY MA Inhibitor DM7DWLY RN Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals. DM7DWLY RU http://www.ganlee.com/en/index.php?optionid=681&auto_id=68 DM7DWLY DI DM7DWLY DM7DWLY DN GLR2007 DM7DWLY TI TTO0FDJ DM7DWLY TN Cyclin-dependent kinase 6 (CDK6) DM7DWLY MA Inhibitor DM7DWLY RN Clinical pipeline report, company report or official report of Gan & Lee Pharmaceuticals. DM7DWLY RU http://www.ganlee.com/en/index.php?optionid=681&auto_id=68 DM7IWTF DI DM7IWTF DM7IWTF DN ACP-319 DM7IWTF TI TTGM6VW DM7IWTF TN Tyrosine-protein kinase BTK (ATK) DM7IWTF MA Inhibitor DM7IWTF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). DM7IWTF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948 DM7LOSK DI DM7LOSK DM7LOSK DN REGN4018 DM7LOSK TI TTC1PS3 DM7LOSK TN Ovarian carcinoma antigen CA125 (MUC16) DM7LOSK MA Inhibitor DM7LOSK RN A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. DM7LOSK RU https://pubmed.ncbi.nlm.nih.gov/31217340 DM7LOSK DI DM7LOSK DM7LOSK DN REGN4018 DM7LOSK TI TTUN7MC DM7LOSK TN T-cell surface glycoprotein CD3 (CD3) DM7LOSK MA Inhibitor DM7LOSK RN A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534. DM7LOSK RU https://pubmed.ncbi.nlm.nih.gov/31217340 DM7NKWQ DI DM7NKWQ DM7NKWQ DN PBCAR20A DM7NKWQ TI TTUE541 DM7NKWQ TN Leukocyte surface antigen Leu-16 (CD20) DM7NKWQ RN Clinical pipeline report, company report or official report of Precision Biosciences. DM7NKWQ RU https://precisionbiosciences.com/pipeline/ DM7O29W DI DM7O29W DM7O29W DN AVX901 DM7O29W TI TT6EO5L DM7O29W TN Erbb2 tyrosine kinase receptor (HER2) DM7O29W MA Inhibitor DM7O29W RN ClinicalTrials.gov (NCT01526473) A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901. U.S. National Institutes of Health. DM7O29W RU https://clinicaltrials.gov/ct2/show/NCT01526473 DM7O89Q DI DM7O89Q DM7O89Q DN AT-777 DM7O89Q TI TTMVBWH DM7O89Q TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM7O89Q MA Inhibitor DM7O89Q RN Clinical pipeline report, company report or official report of Atea Pharmaceuticals. DM7O89Q RU https://ateapharma.com/about-us/hepatitis-c/ DM7OE3X DI DM7OE3X DM7OE3X DN INCAGN1949 DM7OE3X TI TTL31H0 DM7OE3X TN OX40L receptor (CD134) DM7OE3X MA Agonist DM7OE3X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7OE3X RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM7RNKM DI DM7RNKM DM7RNKM DN AMT-060 DM7RNKM TI TTFEZ5Q DM7RNKM TN Coagulation factor IX (F9) DM7RNKM MA Modulator DM7RNKM RN Phase I/II clinical trial of AMT-060 for treating hemophilia B. uniQure N.V. DM7RNKM RU http://www.biocentury.com/products/amt-060 DM7SMNJ DI DM7SMNJ DM7SMNJ DN NKTR-255 DM7SMNJ TI TTGN89I DM7SMNJ TN Interleukin 15 receptor alpha (IL15RA) DM7SMNJ MA Agonist DM7SMNJ RN Clinical pipeline report, company report or official report of Nektar Therapeutics. DM7SMNJ RU https://www.nektar.com/pipeline/rd-pipeline/nktr-255 DM7T1CR DI DM7T1CR DM7T1CR DN LY3016859 DM7T1CR TI TTTLQFR DM7T1CR TN Transforming growth factor alpha (TGFA) DM7T1CR MA Modulator DM7T1CR RN Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43. DM7T1CR RU https://pubmed.ncbi.nlm.nih.gov/24518034 DM7T1CR DI DM7T1CR DM7T1CR DN LY3016859 DM7T1CR TI TTYSB89 DM7T1CR TN Epiregulin (EREG) DM7T1CR MA Modulator DM7T1CR RN Generation and activity of a humanized monoclonal antibody that selectively neutralizes the epidermal growth factor receptor ligands transforming growth factor-alpha and epiregulin. J Pharmacol Exp Ther. 2014 May;349(2):330-43. DM7T1CR RU https://pubmed.ncbi.nlm.nih.gov/24518034 DM7TF49 DI DM7TF49 DM7TF49 DN AAV-RPGR DM7TF49 TI TTHBDA9 DM7TF49 TN X-linked retinitis pigmentosa GTPase regulator (RPGR) DM7TF49 RN Clinical pipeline report, company report or official report of MeiraGTx. DM7TF49 RU https://meiragtx.com/research-development/pipeline/ DM7TZL0 DI DM7TZL0 DM7TZL0 DN INCB054329 DM7TZL0 TI TTE4BSY DM7TZL0 TN Bromodomain and extraterminal domain protein (BET) DM7TZL0 MA Inhibitor DM7TZL0 RN The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. Clin Cancer Res. 2019 Jan 1;25(1):300-311. DM7TZL0 RU https://pubmed.ncbi.nlm.nih.gov/30206163 DM7U458 DI DM7U458 DM7U458 DN IDX-184 DM7U458 TI TTE3PC9 DM7U458 TN Hepatitis C virus Non-structural 5 (HCV NS5) DM7U458 MA Inhibitor DM7U458 RN Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus. Antimicrob Agents Chemother. 2012 June; 56(6): 3359-3368. DM7U458 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370800/ DM7WK6N DI DM7WK6N DM7WK6N DN DSP-0509 DM7WK6N TI TTRJ1K4 DM7WK6N TN Toll-like receptor 7 (TLR7) DM7WK6N MA Agonist DM7WK6N RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DM7WK6N RU https://www.ds-pharma.com/rd/clinical/pipeline.html DM8124R DI DM8124R DM8124R DN INCB01158 DM8124R TI TTSANDR DM8124R TN Arginase (ARG) DM8124R MA Inhibitor DM8124R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8124R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8139V DI DM8139V DM8139V DN Anti-CD30 CAR T cells DM8139V TI TT2GM5R DM8139V TN Lymphocyte activation antigen CD30 (TNFRSF8) DM8139V MA CAR-T-Cell-Therapy DM8139V RN ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273) DM8139V RU https://clinicaltrials.gov/ct2/show/NCT02274584 DM81JIT DI DM81JIT DM81JIT DN CART33 cells DM81JIT TI TTJVYO3 DM81JIT TN Myeloid cell surface antigen CD33 (CD33) DM81JIT MA CAR-T-Cell-Therapy DM81JIT RN ClinicalTrials.gov (NCT01864902) Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33 DM81JIT RU https://clinicaltrials.gov/ct2/show/NCT01864902 DM84YEC DI DM84YEC DM84YEC DN Atiprimod DM84YEC TI TTH8FZW DM84YEC TN Signal transducer and activator of transcription 3 (STAT3) DM84YEC MA Inhibitor DM84YEC RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM84YEC RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM86OJ0 DI DM86OJ0 DM86OJ0 DN HPN536 DM86OJ0 TI TT4RXME DM86OJ0 TN Mesothelin (MSLN) DM86OJ0 RN Clinical pipeline report, company report or official report of Harpoon Therapeutics. DM86OJ0 RU https://www.harpoontx.com/pipeline/ DM87H0S DI DM87H0S DM87H0S DN ADG106 DM87H0S TI TTPW9LJ DM87H0S TN Co-stimulatory molecule 4-1BB (CD137) DM87H0S MA Inhibitor DM87H0S RN Clinical pipeline report, company report or official report of Adagene. DM87H0S RU https://www.adagene.com/pipeline/adg106/ DM8A5E0 DI DM8A5E0 DM8A5E0 DN Vecabrutinib DM8A5E0 TI TTGM6VW DM8A5E0 TN Tyrosine-protein kinase BTK (ATK) DM8A5E0 MA Inhibitor DM8A5E0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8A5E0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8CMUW DI DM8CMUW DM8CMUW DN 4SCAR19 and 4SCAR22 DM8CMUW TI TTM6QSK DM8CMUW TN B-cell receptor CD22 (CD22) DM8CMUW MA CAR-T-Cell-Therapy(Dual specific) DM8CMUW RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DM8CMUW RU https://clinicaltrials.gov/ct2/show/NCT03125577 DM8CMUW DI DM8CMUW DM8CMUW DN 4SCAR19 and 4SCAR22 DM8CMUW TI TTW640A DM8CMUW TN B-lymphocyte surface antigen B4 (CD19) DM8CMUW MA CAR-T-Cell-Therapy(Dual specific) DM8CMUW RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DM8CMUW RU https://clinicaltrials.gov/ct2/show/NCT03125577 DM8D2LC DI DM8D2LC DM8D2LC DN Tractinostat DM8D2LC TI TTBH0VX DM8D2LC TN Histone deacetylase (HDAC) DM8D2LC MA Inhibitor DM8D2LC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8D2LC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8E3N6 DI DM8E3N6 DM8E3N6 DN IPP-204106 DM8E3N6 TI TTHBS98 DM8E3N6 TN Nucleophosmin (NPM1) DM8E3N6 MA Modulator DM8E3N6 RN Company report (ImmuPharma) DM8E3N6 RU http://www.immupharma.org/cancer-treatment DM8E3N6 DI DM8E3N6 DM8E3N6 DN IPP-204106 DM8E3N6 TI TTCSZH7 DM8E3N6 TN Nucleolin (NCL) DM8E3N6 MA Modulator DM8E3N6 RN Company report (ImmuPharma) DM8E3N6 RU http://www.immupharma.org/cancer-treatment DM8EAGV DI DM8EAGV DM8EAGV DN Anti-EGFR V III CAR-T cells DM8EAGV TI TTZ6B2I DM8EAGV TN Epidermal growth factor receptor variant III (EGFR vIII) DM8EAGV MA CAR-T-Cell-Therapy DM8EAGV RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM8EAGV RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM8ENKS DI DM8ENKS DM8ENKS DN Anti-Factor D DM8ENKS TI TT8D13I DM8ENKS TN Complement factor D (CFD) DM8ENKS RN Association for Research in Vision and Ophthalmology (ARVO)--2010 Annual Meeting. For Sight: The Future of Eye and Vision Research--part 1. IDrugs. 2010 Jul;13(7):427-9. DM8ENKS RU https://pubmed.ncbi.nlm.nih.gov/20582862 DM8IC5H DI DM8IC5H DM8IC5H DN Triciribine DM8IC5H TI TT84ETX DM8IC5H TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM8IC5H MA Inhibitor DM8IC5H RN Design, synthesis and antiviral activity of novel 4,5-disubstituted 7-(beta-D-ribofuranosyl)pyrrolo[2,3-d][1,2,3]triazines and the novel 3-amino-5-... J Med Chem. 2005 Jun 2;48(11):3840-51. DM8IC5H RU https://pubmed.ncbi.nlm.nih.gov/15916436 DM8J5H1 DI DM8J5H1 DM8J5H1 DN PRLX93936 DM8J5H1 TI TTT48SQ DM8J5H1 TN Voltage-dependent anion-selective channel 3 (VDAC3) DM8J5H1 MA Modulator DM8J5H1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8J5H1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8K0PR DI DM8K0PR DM8K0PR DN DSP-107 DM8K0PR TI TT28S46 DM8K0PR TN Leukocyte surface antigen CD47 (CD47) DM8K0PR RN Clinical pipeline report, company report or official report of KAHR Medical. DM8K0PR RU https://kahrbio.com/technology/#pipeline DM8K7CN DI DM8K7CN DM8K7CN DN SPK-8011 DM8K7CN TI TT1290U DM8K7CN TN Coagulation factor VIII (F8) DM8K7CN MA Replacement DM8K7CN RN Clinical pipeline report, company report or official report of Spark Therapeutics. DM8K7CN RU https://sparktx.com/scientific-platform-programs/ DM8KESD DI DM8KESD DM8KESD DN CD19 CAR-T lymphocytes DM8KESD TI TTW640A DM8KESD TN B-lymphocyte surface antigen B4 (CD19) DM8KESD MA CAR-T-Cell-Therapy DM8KESD RN ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL DM8KESD RU https://clinicaltrials.gov/ct2/show/NCT03467256 DM8M71U DI DM8M71U DM8M71U DN DTX301 DM8M71U TI TT5KIO9 DM8M71U TN Ornithine transcarbamylase (OTC) DM8M71U MA Replacement DM8M71U RN Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical. DM8M71U RU https://www.ultragenyx.com/pipeline/dtx-301-for-otc/ DM8O3R9 DI DM8O3R9 DM8O3R9 DN APG-1252 DM8O3R9 TI TTJGNVC DM8O3R9 TN Apoptosis regulator Bcl-2 (BCL-2) DM8O3R9 MA Inhibitor DM8O3R9 RN Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206. DM8O3R9 RU https://pubmed.ncbi.nlm.nih.gov/32346976 DM8O3R9 DI DM8O3R9 DM8O3R9 DN APG-1252 DM8O3R9 TI TTU1E82 DM8O3R9 TN Apoptosis regulator Bcl-xL (BCL-xL) DM8O3R9 MA Inhibitor DM8O3R9 RN Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206. DM8O3R9 RU https://pubmed.ncbi.nlm.nih.gov/32346976 DM8P7FC DI DM8P7FC DM8P7FC DN JCARH125 DM8P7FC TI TTZ3P4W DM8P7FC TN B-cell maturation protein (TNFRSF17) DM8P7FC MA CAR-T-Cell-Therapy DM8P7FC RN ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product DM8P7FC RU https://clinicaltrials.gov/ct2/show/NCT03436771 DM8RJTB DI DM8RJTB DM8RJTB DN LY3295668 DM8RJTB TI TTPS3C0 DM8RJTB TN Aurora kinase A (AURKA) DM8RJTB MA Inhibitor DM8RJTB RN Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol Cancer Ther. 2019 Dec;18(12):2207-2219. DM8RJTB RU https://pubmed.ncbi.nlm.nih.gov/31530649 DM8RXFB DI DM8RXFB DM8RXFB DN CD19 targeted chimeric antigen receptor T cells DM8RXFB TI TTW640A DM8RXFB TN B-lymphocyte surface antigen B4 (CD19) DM8RXFB MA CAR-T-Cell-Therapy DM8RXFB RN ClinicalTrials.gov (NCT03118180) CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma DM8RXFB RU https://clinicaltrials.gov/ct2/show/NCT03118180 DM8V0UL DI DM8V0UL DM8V0UL DN ASP-9521 DM8V0UL TI TT5ZWB6 DM8V0UL TN Dihydrodiol dehydrogenase type I (AKR1C3) DM8V0UL MA Modulator DM8V0UL RN Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004. DM8V0UL RU https://pubmed.ncbi.nlm.nih.gov/24771350 DM8XN4A DI DM8XN4A DM8XN4A DN INCAGN1876 DM8XN4A TI TTG6LA7 DM8XN4A TN Activation-inducible TNFR family receptor (TNFRSF18) DM8XN4A MA Agonist DM8XN4A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8XN4A RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM90BUD DI DM90BUD DM90BUD DN ChronSeal DM90BUD TI TTNDSF4 DM90BUD TN Proto-oncogene c-Met (MET) DM90BUD MA Inhibitor DM90BUD RN Clinical pipeline report, company report or official report of Kringle Pharma. DM90BUD RU http://www.kringle-pharma.com/en/news.html DM90XQC DI DM90XQC DM90XQC DN CTX001 DM90XQC TI TTR61MW DM90XQC TN B-cell lymphoma/leukemia 11A (BCL11A) DM90XQC RN Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199. DM90XQC RU https://pubmed.ncbi.nlm.nih.gov/31900462 DM92CUG DI DM92CUG DM92CUG DN Anti-CD19 CAR-T cells DM92CUG TI TTW640A DM92CUG TN B-lymphocyte surface antigen B4 (CD19) DM92CUG MA CAR-T-Cell-Therapy DM92CUG RN ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies DM92CUG RU https://clinicaltrials.gov/ct2/show/NCT03366324 DM95XR8 DI DM95XR8 DM95XR8 DN CTCE-9908 DM95XR8 TI TTBID49 DM95XR8 TN C-X-C chemokine receptor type 4 (CXCR4) DM95XR8 MA Modulator DM95XR8 RN A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009 Aug;155(2):231-6. DM95XR8 RU https://pubmed.ncbi.nlm.nih.gov/19482312 DM98YFK DI DM98YFK DM98YFK DN SB-913 DM98YFK TI TTNY2AP DM98YFK TN Iduronate 2-sulfatase (IDS) DM98YFK MA Replacement DM98YFK RN ClinicalTrials.gov (NCT03041324) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II. U.S. National Institutes of Health. DM98YFK RU https://clinicaltrials.gov/ct2/show/NCT03041324 DM9B7Z5 DI DM9B7Z5 DM9B7Z5 DN Sym015 DM9B7Z5 TI TTNDSF4 DM9B7Z5 TN Proto-oncogene c-Met (MET) DM9B7Z5 MA Inhibitor DM9B7Z5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9B7Z5 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9B7Z5 DI DM9B7Z5 DM9B7Z5 DN Sym015 DM9B7Z5 TI TTGKNB4 DM9B7Z5 TN Epidermal growth factor receptor (EGFR) DM9B7Z5 MA Antagonist DM9B7Z5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9B7Z5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9DR13 DI DM9DR13 DM9DR13 DN PCAR-019 DM9DR13 TI TTW640A DM9DR13 TN B-lymphocyte surface antigen B4 (CD19) DM9DR13 MA CAR-T-Cell-Therapy DM9DR13 RN ClinicalTrials.gov (NCT02819583) CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma DM9DR13 RU https://clinicaltrials.gov/ct2/show/NCT02819583 DM9EM5G DI DM9EM5G DM9EM5G DN ASTX295 DM9EM5G TI TT08GJW DM9EM5G TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DM9EM5G MA Antagonist DM9EM5G RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DM9EM5G RU https://astx.com/research-development/clinical-pipeline/astx295-oral-murine-double-minute-2-mdm2-antagonist-solid-tumors/ DM9FB2T DI DM9FB2T DM9FB2T DN TPX-0005 DM9FB2T TI TTTDVOJ DM9FB2T TN Tropomyosin-related kinase A (TrkA) DM9FB2T MA Inhibitor DM9FB2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FB2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9FB2T DI DM9FB2T DM9FB2T DN TPX-0005 DM9FB2T TI TTPMQSO DM9FB2T TN ALK tyrosine kinase receptor (ALK) DM9FB2T MA Inhibitor DM9FB2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FB2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9FB2T DI DM9FB2T DM9FB2T DN TPX-0005 DM9FB2T TI TTSZ6Y3 DM9FB2T TN Proto-oncogene c-Ros (ROS1) DM9FB2T MA Inhibitor DM9FB2T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9FB2T RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9FNC8 DI DM9FNC8 DM9FNC8 DN RP-3500 DM9FNC8 TI TT8ZYBQ DM9FNC8 TN Serine/threonine-protein kinase ATR (FRP1) DM9FNC8 MA Inhibitor DM9FNC8 RN Clinical pipeline report, company report or official report of Repare Therapeutics. DM9FNC8 RU https://www.reparerx.com/pipeline/ DM9IQ4A DI DM9IQ4A DM9IQ4A DN TRU-016 DM9IQ4A TI TTFCW29 DM9IQ4A TN Leukocyte antigen CD37 (CD37) DM9IQ4A MA Modulator DM9IQ4A RN TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr Opin Investig Drugs. 2009 Dec;10(12):1383-90. DM9IQ4A RU https://pubmed.ncbi.nlm.nih.gov/19943209 DM9MF08 DI DM9MF08 DM9MF08 DN OBP-301 DM9MF08 TI TTUJFD0 DM9MF08 TN Telomerase reverse transcriptase (TERT) DM9MF08 MA Inhibitor DM9MF08 RN Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):285-92. DM9MF08 RU https://pubmed.ncbi.nlm.nih.gov/14734481 DM9NPF6 DI DM9NPF6 DM9NPF6 DN Anti-CD33 CAR-T cells DM9NPF6 TI TTJVYO3 DM9NPF6 TN Myeloid cell surface antigen CD33 (CD33) DM9NPF6 MA CAR-T-Cell-Therapy DM9NPF6 RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DM9NPF6 RU https://clinicaltrials.gov/ct2/show/NCT03638206 DM9PJZT DI DM9PJZT DM9PJZT DN Ipamorelin DM9PJZT TI TTWDC17 DM9PJZT TN Growth hormone secretagogue receptor 1 (GHSR) DM9PJZT MA Modulator DM9PJZT RN Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.J Pharmacol Exp Ther.2009 Jun;329(3):1110-6. DM9PJZT RU https://www.ncbi.nlm.nih.gov/pubmed/19289567 DM9S5I1 DI DM9S5I1 DM9S5I1 DN TC-210 DM9S5I1 TI TT4RXME DM9S5I1 TN Mesothelin (MSLN) DM9S5I1 RN Clinical pipeline report, company report or official report of TCR2 Therapeutics. DM9S5I1 RU https://www.tcr2.com/solid-tumors#tc210 DM9UZM1 DI DM9UZM1 DM9UZM1 DN CCS1477 DM9UZM1 TI TTFRCTK DM9UZM1 TN CREB-binding protein (CREBBP) DM9UZM1 MA Inhibitor DM9UZM1 RN Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. DM9UZM1 RU https://pubmed.ncbi.nlm.nih.gov/33431496 DM9UZM1 DI DM9UZM1 DM9UZM1 DN CCS1477 DM9UZM1 TI TTGH73N DM9UZM1 TN Histone acetyltransferase p300 (EP300) DM9UZM1 MA Inhibitor DM9UZM1 RN Targeting the p300/CBP Axis in Lethal Prostate Cancer. Cancer Discov. 2021 May;11(5):1118-1137. DM9UZM1 RU https://pubmed.ncbi.nlm.nih.gov/33431496 DMA1CSR DI DMA1CSR DMA1CSR DN LY3499446 DMA1CSR TI TT3LH46 DMA1CSR TN KRAS G12C mutant (KRAS G12C) DMA1CSR MA Inhibitor DMA1CSR RN KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070. DMA1CSR RU https://pubmed.ncbi.nlm.nih.gov/32711246 DMA41DO DI DMA41DO DMA41DO DN Isunakinra DMA41DO TI TT5BFT0 DMA41DO TN Interleukin-1 receptor (IL1R) DMA41DO MA Inhibitor DMA41DO RN Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease. Eye Contact Lens. 2017 Sep;43(5):287-296. DMA41DO RU https://pubmed.ncbi.nlm.nih.gov/27466718 DMA5B1S DI DMA5B1S DMA5B1S DN KRN-330 DMA5B1S TI TT96HUR DMA5B1S TN Cell surface A33 antigen (GPA33) DMA5B1S RN Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90. DMA5B1S RU https://pubmed.ncbi.nlm.nih.gov/24691674 DMA8Z4N DI DMA8Z4N DMA8Z4N DN SB-318 DMA8Z4N TI TT0IUKX DMA8Z4N TN Alpha-L-iduronidase (IDUA) DMA8Z4N MA Replacement DMA8Z4N RN ClinicalTrials.gov (NCT02702115) Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I. U.S. National Institutes of Health. DMA8Z4N RU https://clinicaltrials.gov/ct2/show/NCT02702115 DMA9MP5 DI DMA9MP5 DMA9MP5 DN BN-2629 DMA9MP5 TI TTUTN1I DMA9MP5 TN Human Deoxyribonucleic acid (hDNA) DMA9MP5 MA Binder DMA9MP5 RN Single-Nucleotide Polymorphisms in Rv2629 Are Specific for Mycobacterium tuberculosis Genotypes Beijing and Ghana but Not Associated with Rifampin Resistance . J Clin Microbiol. 2009 January; 47(1): 223-226. DMA9MP5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2620844/ DMACPQO DI DMACPQO DMACPQO DN Dihydrexidine DMACPQO TI TTZFYLI DMACPQO TN Dopamine D1 receptor (D1R) DMACPQO MA Inhibitor DMACPQO RN trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization o... J Med Chem. 2006 Nov 16;49(23):6848-57. DMACPQO RU https://pubmed.ncbi.nlm.nih.gov/17154515 DMADEHZ DI DMADEHZ DMADEHZ DN LY2880070 DMADEHZ TI TTTU902 DMADEHZ TN Checkpoint kinase-1 (CHK1) DMADEHZ MA Inhibitor DMADEHZ RN A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581. DMADEHZ RU https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3581 DMADNY3 DI DMADNY3 DMADNY3 DN SHR-1314 DMADNY3 TI TTG0MT6 DMADNY3 TN Interleukin-17 (IL17) DMADNY3 MA Inhibitor DMADNY3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMADNY3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMAGE91 DI DMAGE91 DMAGE91 DN RG7800 DMAGE91 TI TT8QL6X DMAGE91 TN Survival motor neuron protein (SMN1) DMAGE91 MA Modulator DMAGE91 RN Assays for the Identification and Prioritization of Drug Candidates for Spinal Muscular Atrophy. Assay Drug Dev Technol. 2014 August 1; 12(6): 315-341. DMAGE91 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142828/ DMAGX0Q DI DMAGX0Q DMAGX0Q DN REGN5458 DMAGX0Q TI TTUN7MC DMAGX0Q TN T-cell surface glycoprotein CD3 (CD3) DMAGX0Q MA Inhibitor DMAGX0Q RN A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304. DMAGX0Q RU https://pubmed.ncbi.nlm.nih.gov/33651100 DMAGX0Q DI DMAGX0Q DMAGX0Q DN REGN5458 DMAGX0Q TI TTZ3P4W DMAGX0Q TN B-cell maturation protein (TNFRSF17) DMAGX0Q MA Inhibitor DMAGX0Q RN A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304. DMAGX0Q RU https://pubmed.ncbi.nlm.nih.gov/33651100 DMAH6UJ DI DMAH6UJ DMAH6UJ DN AAV-RPE65 DMAH6UJ TI TTBOH16 DMAH6UJ TN Retinal pigment epithelium protein (RPE65) DMAH6UJ RN Clinical pipeline report, company report or official report of MeiraGTx. DMAH6UJ RU https://meiragtx.com/research-development/pipeline/ DMAHWLR DI DMAHWLR DMAHWLR DN MGD007 DMAHWLR TI TTV3XPL DMAHWLR TN T-cell surface glycoprotein CD3 gamma (CD3G) DMAHWLR MA Modulator DMAHWLR RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMAHWLR RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMAHWLR DI DMAHWLR DMAHWLR DN MGD007 DMAHWLR TI TT96HUR DMAHWLR TN Cell surface A33 antigen (GPA33) DMAHWLR MA Modulator DMAHWLR RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMAHWLR RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMAMIU4 DI DMAMIU4 DMAMIU4 DN VIR-201 DMAMIU4 TI TT93WF5 DMAMIU4 TN Interferon-gamma (IFNG) DMAMIU4 MA Modulator DMAMIU4 RN EP patent application no. 17782511, Nucleoside phosphonate conjugates as anti hiv agents. DMAMIU4 RU http://www.google.com.ar/patents/EP1778251B1?cl=en DMAN21O DI DMAN21O DMAN21O DN VG-101 DMAN21O TI TTOM3J0 DMAN21O TN Estrogen receptor beta (ESR2) DMAN21O MA Agonist DMAN21O RN Update on alternative therapies for vulvovaginal atrophy. Patient Prefer Adherence. 2011; 5: 533-536. DMAN21O RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218114/ DMAO04B DI DMAO04B DMAO04B DN CEP-32496 DMAO04B TI TTWCGQT DMAO04B TN Serine/threonine-protein kinase B-raf (BRAF) DMAO04B MA Inhibitor DMAO04B RN Clinical pipeline report, company report or official report of Ambit Biosciences. DMAO04B RU http://www.ambitbio.com/CEP32496 DMAO04B DI DMAO04B DMAO04B DN CEP-32496 DMAO04B TI TT4DXQT DMAO04B TN Proto-oncogene c-Ret (RET) DMAO04B MA Inhibitor DMAO04B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAO04B RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAP5B4 DI DMAP5B4 DMAP5B4 DN AGEN1884 DMAP5B4 TI TTI2S1D DMAP5B4 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMAP5B4 MA Antagonist DMAP5B4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAP5B4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMAPUZY DI DMAPUZY DMAPUZY DN AAV1-FS344 DMAPUZY TI TTM8I2X DMAPUZY TN Myostatin (MSTN) DMAPUZY MA Modulator DMAPUZY RN Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med. 2009 November 11; 1(6): 6ra15. DMAPUZY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852878/ DMB19IO DI DMB19IO DMB19IO DN Ad-IL-12 DNA therapeutic DMB19IO TI TTGW72V DMB19IO TN Interleukin-12 beta (IL12B) DMB19IO MA Modulator DMB19IO RN National Cancer Institute Drug Dictionary (drug id 710508). DMB19IO RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=710508 DMB2NP8 DI DMB2NP8 DMB2NP8 DN T-1249 DMB2NP8 TI TTG90S6 DMB2NP8 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMB2NP8 MA Inhibitor DMB2NP8 RN HIV entry inhibitors in clinical development. Curr Opin Pharmacol. 2002 Oct;2(5):523-8. DMB2NP8 RU https://pubmed.ncbi.nlm.nih.gov/12324253 DMB4HEW DI DMB4HEW DMB4HEW DN CART-138 cells DMB4HEW TI TTYDSVG DMB4HEW TN Syndecan-1 (SDC1) DMB4HEW MA CAR-T-Cell-Therapy DMB4HEW RN ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma DMB4HEW RU https://clinicaltrials.gov/ct2/show/NCT03196414 DMB5KRA DI DMB5KRA DMB5KRA DN CFI-402411 DMB5KRA TI TTSHWUP DMB5KRA TN MEK kinase kinase 1 (MAP4K1) DMB5KRA MA Inhibitor DMB5KRA RN Clinical pipeline report, company report or official report of Treadwell Therapeutics. DMB5KRA RU https://treadwelltx.com/pipeline/ DMB5X7Z DI DMB5X7Z DMB5X7Z DN ATG002 DMB5X7Z TI TTJSZTB DMB5X7Z TN Nicotinic acetylcholine receptor (nAChR) DMB5X7Z MA Agonist DMB5X7Z RN Athenagen Advances Angiogenesis Drug to Clinical Testing. Athenagen. JUNE 21, 2006. DMB5X7Z RU http://www.prnewswire.com/news-releases/athenagen-advances-angiogenesis-drug-to-clinical-testing-56212977.html DMBCIXL DI DMBCIXL DMBCIXL DN Stamulumab DMBCIXL TI TTSWPH8 DMBCIXL TN Growth/differentiation factor 8 (GDF-8) DMBCIXL RN Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders. Curr Opin Support Palliat Care. 2013 November; 7(4): 352-360. DMBCIXL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819341/ DMBEQ08 DI DMBEQ08 DMBEQ08 DN L-377202 DMBEQ08 TI TT0IHXV DMBEQ08 TN DNA topoisomerase II (TOP2) DMBEQ08 MA Modulator DMBEQ08 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBEQ08 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBFUOI DI DMBFUOI DMBFUOI DN SECTA belomycin DMBFUOI TI TTUTN1I DMBFUOI TN Human Deoxyribonucleic acid (hDNA) DMBFUOI MA Binder DMBFUOI RN Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13. DMBFUOI RU https://pubmed.ncbi.nlm.nih.gov/14624648 DMBGA35 DI DMBGA35 DMBGA35 DN AP-1030 DMBGA35 TI TT0MV2T DMBGA35 TN Melanocortin receptor 1 (MC1R) DMBGA35 MA Modulator DMBGA35 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBGA35 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBGA35 DI DMBGA35 DMBGA35 DN AP-1030 DMBGA35 TI TTD0CIQ DMBGA35 TN Melanocortin receptor 4 (MC4R) DMBGA35 MA Modulator DMBGA35 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBGA35 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBGU7V DI DMBGU7V DMBGU7V DN INCB57643 DMBGU7V TI TTRA6BO DMBGU7V TN Bromodomain-containing protein 4 (BRD4) DMBGU7V MA Inhibitor DMBGU7V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBGU7V RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBGXH5 DI DMBGXH5 DMBGXH5 DN AdCh63-MSP1 DMBGXH5 TI TT68ZYJ DMBGXH5 TN Plasmodium Merozoite surface protein 1 (Malaria MSP-1) DMBGXH5 RN Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection. Immunology. 2014 Apr;141(4):628-44. DMBGXH5 RU https://pubmed.ncbi.nlm.nih.gov/24303947 DMBN1XS DI DMBN1XS DMBN1XS DN Triciribine prodrug DMBN1XS TI TTWTSCV DMBN1XS TN RAC-alpha serine/threonine-protein kinase (AKT1) DMBN1XS MA Inhibitor DMBN1XS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMBN1XS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMBPN4K DI DMBPN4K DMBPN4K DN CAR-T cells targeting MucI DMBPN4K TI TTBHFYQ DMBPN4K TN Mucin-1 (MUC1) DMBPN4K MA CAR-T-Cell-Therapy DMBPN4K RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMBPN4K RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMBQRGV DI DMBQRGV DMBQRGV DN NT-501 CNTF DMBQRGV TI TTGEM5Q DMBQRGV TN Ciliary neurotrophic factor (CNTF) DMBQRGV MA Modulator DMBQRGV RN Clinical pipeline report, company report or official report of Neurotech. DMBQRGV RU http://www.neurotechusa.com/cntfrenexus.html DMBUJVX DI DMBUJVX DMBUJVX DN Phenoxodiol DMBUJVX TI TTR7B60 DMBUJVX TN X-linked inhibitor of apoptosis protein (XIAP) DMBUJVX MA Modulator DMBUJVX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBUJVX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBUJVX DI DMBUJVX DMBUJVX DN Phenoxodiol DMBUJVX TI TTOHFIY DMBUJVX TN Sphingosine kinase 1 (SPHK1) DMBUJVX MA Modulator DMBUJVX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBUJVX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBUYIK DI DMBUYIK DMBUYIK DN CWP232291 DMBUYIK TI TTFPSHI DMBUYIK TN Wnt signaling pathway (Wnt pathway) DMBUYIK MA Inhibitor DMBUYIK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBUYIK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMBZ68C DI DMBZ68C DMBZ68C DN MALP-2S DMBZ68C TI TTWRI8V DMBZ68C TN Toll-like receptor 6 (TLR6) DMBZ68C MA Modulator DMBZ68C RN Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8. DMBZ68C RU https://pubmed.ncbi.nlm.nih.gov/21172450 DMBZ68C DI DMBZ68C DMBZ68C DN MALP-2S DMBZ68C TI TTY7ZHS DMBZ68C TN Toll-like receptor 2 (TLR2) DMBZ68C MA Modulator DMBZ68C RN Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2. Microbes Infect. 2011 Apr;13(4):350-8. DMBZ68C RU https://pubmed.ncbi.nlm.nih.gov/21172450 DMC1XHK DI DMC1XHK DMC1XHK DN AVR-RD-01 DMC1XHK TI TTIS03D DMC1XHK TN Alpha-galactosidase A (GLA) DMC1XHK RN Clinical pipeline report, company report or official report of Avrobio. DMC1XHK RU https://www.avrobio.com/our-pipeline/ DMC284G DI DMC284G DMC284G DN EGFRvIII CAR DMC284G TI TTZ6B2I DMC284G TN Epidermal growth factor receptor variant III (EGFR vIII) DMC284G MA Modulator DMC284G RN EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res. 2014 Feb 15;20(4):972-84. DMC284G RU https://pubmed.ncbi.nlm.nih.gov/24352643 DMC4ZQD DI DMC4ZQD DMC4ZQD DN ACHM-CNGB3 DMC4ZQD TI TT0LJCG DMC4ZQD TN Cyclic nucleotide-gated channel beta-3 (CNGB3) DMC4ZQD RN Clinical pipeline report, company report or official report of Applied Genetic Technologies. DMC4ZQD RU https://agtc.com/programs/achromatopsia/ DMC5NSO DI DMC5NSO DMC5NSO DN AUTO3 DMC5NSO TI TTM6QSK DMC5NSO TN B-cell receptor CD22 (CD22) DMC5NSO MA CAR-T-Cell-Therapy(Dual specific) DMC5NSO RN ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL DMC5NSO RU https://clinicaltrials.gov/ct2/show/NCT03289455 DMC5NSO DI DMC5NSO DMC5NSO DN AUTO3 DMC5NSO TI TTW640A DMC5NSO TN B-lymphocyte surface antigen B4 (CD19) DMC5NSO MA CAR-T-Cell-Therapy(Dual specific) DMC5NSO RN ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL DMC5NSO RU https://clinicaltrials.gov/ct2/show/NCT03289455 DMC5SAW DI DMC5SAW DMC5SAW DN LY3039478 DMC5SAW TI TTXDIK2 DMC5SAW TN Notch-4 receptor (NOTCH4) DMC5SAW MA Inhibitor DMC5SAW RN J Clin Oncol 33, 2015 (suppl; abstr 2533). DMC5SAW RU http://meetinglibrary.asco.org/content/144588-156 DMC5SAW DI DMC5SAW DMC5SAW DN LY3039478 DMC5SAW TI TTB1STW DMC5SAW TN Notch-1 receptor (NOTCH1) DMC5SAW MA Inhibitor DMC5SAW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC5SAW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCAUKW DI DMCAUKW DMCAUKW DN EMB-01 DMCAUKW TI TTGKNB4 DMCAUKW TN Epidermal growth factor receptor (EGFR) DMCAUKW MA Inhibitor DMCAUKW RN Clinical pipeline report, company report or official report of EpimAb Biotherapeutics. DMCAUKW RU https://www.epimab.com/en/pipeline/1 DMCBQTF DI DMCBQTF DMCBQTF DN S-3304 DMCBQTF TI TT1GHVO DMCBQTF TN Matrix metalloproteinase (MMP) DMCBQTF MA Inhibitor DMCBQTF RN Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93. DMCBQTF RU https://pubmed.ncbi.nlm.nih.gov/15968885 DMCDQX0 DI DMCDQX0 DMCDQX0 DN ND-0801 DMCDQX0 TI TTJSZTB DMCDQX0 TN Nicotinic acetylcholine receptor (nAChR) DMCDQX0 MA Modulator DMCDQX0 RN Drugs in Clinical Development for Attention-Deficit/Hyperactivity Disorder: Summary and Table, 2013, Volume 27, Issue 4, 245-248. DMCDQX0 RU http://link.springer.com/article/10.1007/s40290-013-0026-2 DMCDUJY DI DMCDUJY DMCDUJY DN Anti-CD20-CAR vector-transduced autologous T cells DMCDUJY TI TTUE541 DMCDUJY TN Leukocyte surface antigen Leu-16 (CD20) DMCDUJY MA CAR-T-Cell-Therapy DMCDUJY RN ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy DMCDUJY RU https://clinicaltrials.gov/ct2/show/NCT01735604 DMCEGP2 DI DMCEGP2 DMCEGP2 DN BrevaRex DMCEGP2 TI TTBHFYQ DMCEGP2 TN Mucin-1 (MUC1) DMCEGP2 RN Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity. Ann Oncol. 2004 Dec;15(12):1825-33. DMCEGP2 RU https://pubmed.ncbi.nlm.nih.gov/15550589 DMCFSZ5 DI DMCFSZ5 DMCFSZ5 DN TAI-GPC3-CART cells DMCFSZ5 TI TTJTSX4 DMCFSZ5 TN Glypican-3 (GPC3) DMCFSZ5 MA CAR-T-Cell-Therapy DMCFSZ5 RN ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC DMCFSZ5 RU https://clinicaltrials.gov/ct2/show/NCT02715362 DMCGX9Y DI DMCGX9Y DMCGX9Y DN SNDX-5613 DMCGX9Y TI TT0CZBQ DMCGX9Y TN Menin-MLL1 interaction (MEN1-KMT2A PPI) DMCGX9Y MA Inhibitor DMCGX9Y RN Clinical pipeline report, company report or official report of Syndax Pharmaceuticals. DMCGX9Y RU https://syndax.com/pipeline/sndx-5613/ DMCH98G DI DMCH98G DMCH98G DN CD38-specific gene-engineered T cells DMCH98G TI TTPURFN DMCH98G TN Cyclic ADP-ribose hydrolase 1 (CD38) DMCH98G MA CAR-T-Cell-Therapy DMCH98G RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMCH98G RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMCJ10K DI DMCJ10K DMCJ10K DN LM11A-31 DMCJ10K TI TTEDJN4 DMCJ10K TN Low-affinity nerve growth factor receptor (NGFR) DMCJ10K MA Modulator DMCJ10K RN Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model.Neurobiol Aging.2013 Aug;34(8):2052-63. DMCJ10K RU https://www.ncbi.nlm.nih.gov/pubmed/23545424 DMCLKA4 DI DMCLKA4 DMCLKA4 DN 2-hydroxyoleic acid DMCLKA4 TI TTBOE28 DMCLKA4 TN Sphingomyelin synthase (SMS) DMCLKA4 MA Modulator DMCLKA4 RN Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19569-74. DMCLKA4 RU https://pubmed.ncbi.nlm.nih.gov/22106271 DMCMT4V DI DMCMT4V DMCMT4V DN Dexamethasone palmitate DMCMT4V TI TTPNQAC DMCMT4V TN Estrogen-related receptor-alpha (ESRRA) DMCMT4V MA Agonist DMCMT4V RN Dexamethasone treatment in childhood bacterial meningitis in Malawi: a randomised controlled trial. Lancet. 2002 Jul 20;360(9328):211-8. DMCMT4V RU https://pubmed.ncbi.nlm.nih.gov/12133656 DMCP8F3 DI DMCP8F3 DMCP8F3 DN SPK-8016 DMCP8F3 TI TT1290U DMCP8F3 TN Coagulation factor VIII (F8) DMCP8F3 MA Replacement DMCP8F3 RN Clinical pipeline report, company report or official report of Spark Therapeutics. DMCP8F3 RU https://sparktx.com/scientific-platform-programs/ DMCPM92 DI DMCPM92 DMCPM92 DN CAR-T cells targeting CLL1 DMCPM92 TI TT70N8V DMCPM92 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMCPM92 MA CAR-T-Cell-Therapy DMCPM92 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMCPM92 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TT70MLA DMCPZYT TN Oncotrophoblast glycoprotein 5T4 (TPBG) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TTKGUEB DMCPZYT TN Melanoma-associated antigen C2 (MAGEC2) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TTTPU1G DMCPZYT TN Apoptosis inhibitor survivin (BIRC5) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TT9M6NA DMCPZYT TN Cancer/testis antigen MAGE-C1/CT7 (MAGEC1) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCPZYT DI DMCPZYT DMCPZYT DN CV-9201 DMCPZYT TI TTE5ITK DMCPZYT TN Cancer/testis antigen 1 (NY-ESO-1) DMCPZYT RN National Cancer Institute Drug Dictionary (drug id 648549). DMCPZYT RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=648549 DMCR7EF DI DMCR7EF DMCR7EF DN CEQ-508 DMCR7EF TI TTRPKQG DMCR7EF TN Beta-catenin (CTNNB1) DMCR7EF RN Current Progress of siRNA/shRNA Therapeutics in Clinical Trials. Biotechnol J. 2011 September; 6(9): 1130-1146. DMCR7EF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388104/ DMCSGNU DI DMCSGNU DMCSGNU DN CD138 CAR T cells DMCSGNU TI TTYDSVG DMCSGNU TN Syndecan-1 (SDC1) DMCSGNU MA CAR-T-Cell-Therapy DMCSGNU RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMCSGNU RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMCT917 DI DMCT917 DMCT917 DN CLL1-specific gene-engineered T cells DMCT917 TI TT70N8V DMCT917 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMCT917 MA CAR-T-Cell-Therapy DMCT917 RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMCT917 RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMCT9NG DI DMCT9NG DMCT9NG DN GB1275 DMCT9NG TI TTB69FJ DMCT9NG TN Integrin alpha-M (ITGAM) DMCT9NG MA Agonist DMCT9NG RN National Cancer Institute Drug Dictionary (drug name GB1275). DMCT9NG RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cd11b-agonist-gb1275 DMCVBQD DI DMCVBQD DMCVBQD DN MLN1117 DMCVBQD TI TTEUNMR DMCVBQD TN PI3-kinase alpha (PIK3CA) DMCVBQD MA Inhibitor DMCVBQD RN National Cancer Institute Drug Dictionary (drug id 714372). DMCVBQD RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=714372 DMCVMUL DI DMCVMUL DMCVMUL DN MGD013 DMCVMUL TI TTNBFWK DMCVMUL TN Programmed cell death protein 1 (PD-1) DMCVMUL RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMCVMUL RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMCWVPU DI DMCWVPU DMCWVPU DN CBP-501 DMCWVPU TI TT3DCYJ DMCWVPU TN Microtubule affinity regulating kinase 3 (MARK3) DMCWVPU MA Inhibitor DMCWVPU RN National Cancer Institute Drug Dictionary (drug id 577812). DMCWVPU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812 DMCWVPU DI DMCWVPU DMCWVPU DN CBP-501 DMCWVPU TI TTMUG9D DMCWVPU TN MAPK-activated protein kinase 2 (MAPKAPK2) DMCWVPU MA Inhibitor DMCWVPU RN National Cancer Institute Drug Dictionary (drug id 577812). DMCWVPU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=577812 DMD1V7I DI DMD1V7I DMD1V7I DN Celgosivir DMD1V7I TI TTXWASR DMD1V7I TN Intestinal maltase-glucoamylase (MGAM) DMD1V7I MA Modulator DMD1V7I RN Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70. DMD1V7I RU https://www.ncbi.nlm.nih.gov/pubmed/19649930 DMD20YH DI DMD20YH DMD20YH DN SAR-650984 DMD20YH TI TTPURFN DMD20YH TN Cyclic ADP-ribose hydrolase 1 (CD38) DMD20YH RN Clinical pipeline report, company report or official report of Sanofi-Aventis. DMD20YH RU https://www.sanofioncology.com/m/pipeline/SAR650984.aspx DMD2L1U DI DMD2L1U DMD2L1U DN OBI-888 DMD2L1U TI TT4UXTG DMD2L1U TN Globohexaosylceramide (Globo H) DMD2L1U RN Clinical pipeline report, company report or official report of OBI Pharma. DMD2L1U RU https://www.obipharma.com/obi-888-mab/ DMD37Q5 DI DMD37Q5 DMD37Q5 DN SEL24 DMD37Q5 TI TTA7WGU DMD37Q5 TN Serine/threonine-protein kinase pim (PIM) DMD37Q5 MA Inhibitor DMD37Q5 RN A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931. DMD37Q5 RU https://pubmed.ncbi.nlm.nih.gov/29682194 DMD37Q5 DI DMD37Q5 DMD37Q5 DN SEL24 DMD37Q5 TI TTGJCWZ DMD37Q5 TN Fms-like tyrosine kinase 3 (FLT-3) DMD37Q5 MA Inhibitor DMD37Q5 RN A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931. DMD37Q5 RU https://pubmed.ncbi.nlm.nih.gov/29682194 DMD3XMW DI DMD3XMW DMD3XMW DN Cethrin DMD3XMW TI TTMQO60 DMD3XMW TN Rho-associated protein kinase (ROCK) DMD3XMW MA Modulator DMD3XMW RN A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96. DMD3XMW RU https://pubmed.ncbi.nlm.nih.gov/21381984 DMD8RLY DI DMD8RLY DMD8RLY DN GEN3009 DMD8RLY TI TTFCW29 DMD8RLY TN Leukocyte antigen CD37 (CD37) DMD8RLY RN Clinical pipeline report, company report or official report of AbbVie. DMD8RLY RU https://www.abbvie.com/our-science/pipeline/gen-3009.html DMD9X6U DI DMD9X6U DMD9X6U DN JNJ-68284528 DMD9X6U TI TTZ3P4W DMD9X6U TN B-cell maturation protein (TNFRSF17) DMD9X6U MA CAR-T-Cell-Therapy DMD9X6U RN ClinicalTrials.gov (NCT03548207) A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma DMD9X6U RU https://clinicaltrials.gov/ct2/show/NCT03548207 DMD9Y5T DI DMD9Y5T DMD9Y5T DN AZD7648 DMD9Y5T TI TTK3PY9 DMD9Y5T TN DNA-dependent protein kinase catalytic (PRKDC) DMD9Y5T MA Inhibitor DMD9Y5T RN AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. Nat Commun. 2019 Nov 7;10(1):5065. DMD9Y5T RU https://pubmed.ncbi.nlm.nih.gov/31699977 DMDASRW DI DMDASRW DMDASRW DN Norleucine DMDASRW TI TT01M3K DMDASRW TN Hepatocyte nuclear factor 1-alpha (HNF1A) DMDASRW MA Inhibitor DMDASRW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMDASRW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMDCHM7 DI DMDCHM7 DMDCHM7 DN BMS-986016 DMDCHM7 TI TTNVXAW DMDCHM7 TN Lymphocyte activation gene 3 protein (LAG3) DMDCHM7 MA Modulator DMDCHM7 RN Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96. DMDCHM7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4346216/ DMDFG1O DI DMDFG1O DMDFG1O DN HLF 1-11 DMDFG1O TI TTSZDQU DMDFG1O TN Lactotransferrin (LTF) DMDFG1O MA Modulator DMDFG1O RN The synthetic N-terminal peptide of human lactoferrin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2004 Dec;48(12):4919-21. DMDFG1O RU https://pubmed.ncbi.nlm.nih.gov/15561882 DMDHJNV DI DMDHJNV DMDHJNV DN Annamycin DMDHJNV TI TTCGY2K DMDHJNV TN DNA topoisomerase II alpha (TOP2A) DMDHJNV RN Effect of structural modification at the 4, 3', and 2' positions of doxorubicin on topoisomerase II poisoning, apoptosis, and cytotoxicity in human melanoma cells. Arch Immunol Ther Exp (Warsz). May-Jun 2007;55(3):193-8. DMDHJNV RU https://pubmed.ncbi.nlm.nih.gov/17557149 DMDHKN1 DI DMDHKN1 DMDHKN1 DN Anti-MUC1 CAR T Cells DMDHKN1 TI TTBHFYQ DMDHKN1 TN Mucin-1 (MUC1) DMDHKN1 MA CAR-T-Cell-Therapy DMDHKN1 RN ClinicalTrials.gov (NCT03525782) Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC DMDHKN1 RU https://clinicaltrials.gov/ct2/show/NCT03525782 DMDJLX7 DI DMDJLX7 DMDJLX7 DN Timcodar dimesilate DMDJLX7 TI TTFH2RS DMDJLX7 TN FK506-binding protein (FKBP) DMDJLX7 MA Modulator DMDJLX7 RN Analysis of FK506, timcodar (VX-853) and FKBP51 and FKBP52 chaperones in control of glucocorticoid receptor activity and phosphorylation. Pharmacol Res Perspect. 2014 December; 2(6): e00076. DMDJLX7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186452/ DMDJSOH DI DMDJSOH DMDJSOH DN ZK-001 DMDJSOH TI TTVB0Q9 DMDJSOH TN Platelet glycoprotein Ib alpha (CD42b) DMDJSOH MA Modulator DMDJSOH RN Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2014 Feb;111(2):279-89. DMDJSOH RU https://pubmed.ncbi.nlm.nih.gov/24172860 DMDKTYU DI DMDKTYU DMDKTYU DN Anti-EGFRvIII CAR transduced PBL DMDKTYU TI TTZ6B2I DMDKTYU TN Epidermal growth factor receptor variant III (EGFR vIII) DMDKTYU MA CAR-T-Cell-Therapy DMDKTYU RN ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health. DMDKTYU RU https://clinicaltrials.gov/ct2/show/NCT01454596 DMDNJP5 DI DMDNJP5 DMDNJP5 DN NM21-1480 DMDNJP5 TI TTPW9LJ DMDNJP5 TN Co-stimulatory molecule 4-1BB (CD137) DMDNJP5 MA Modulator DMDNJP5 RN Clinical pipeline report, company report or official report of Numab Therapeutics. DMDNJP5 RU https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf DMDNJP5 DI DMDNJP5 DMDNJP5 DN NM21-1480 DMDNJP5 TI TT8ZLTI DMDNJP5 TN Programmed cell death 1 ligand 1 (PD-L1) DMDNJP5 MA Modulator DMDNJP5 RN Clinical pipeline report, company report or official report of Numab Therapeutics. DMDNJP5 RU https://www.numab.com/wp-content/uploads/2019/03/190330_PRE_Numab_AACR-Poster-2019.pdf DMDO6J1 DI DMDO6J1 DMDO6J1 DN Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs DMDO6J1 TI TTJTSX4 DMDO6J1 TN Glypican-3 (GPC3) DMDO6J1 MA CAR-T-Cell-Therapy DMDO6J1 RN ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) DMDO6J1 RU https://clinicaltrials.gov/ct2/show/NCT03084380 DMDOXMN DI DMDOXMN DMDOXMN DN AB928 DMDOXMN TI TTM2AOE DMDOXMN TN Adenosine A2a receptor (ADORA2A) DMDOXMN MA Antagonist DMDOXMN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDOXMN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDOXMN DI DMDOXMN DMDOXMN DN AB928 DMDOXMN TI TTNE7KG DMDOXMN TN Adenosine A2b receptor (ADORA2B) DMDOXMN MA Antagonist DMDOXMN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDOXMN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDQO0S DI DMDQO0S DMDQO0S DN BMS-753493 DMDQO0S TI TTVC37M DMDQO0S TN Folate receptor alpha (FOLR1) DMDQO0S MA Modulator DMDQO0S RN A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31. DMDQO0S RU https://pubmed.ncbi.nlm.nih.gov/25380635 DMDRYZK DI DMDRYZK DMDRYZK DN Anti-CD19 CAR-T cells DMDRYZK TI TTW640A DMDRYZK TN B-lymphocyte surface antigen B4 (CD19) DMDRYZK MA CAR-T-Cell-Therapy DMDRYZK RN ClinicalTrials.gov (NCT02851589) Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma DMDRYZK RU https://clinicaltrials.gov/ct2/show/NCT02851589 DMDSKR2 DI DMDSKR2 DMDSKR2 DN CAR-T cells targeting Glypican-3 (GPC3) DMDSKR2 TI TTJTSX4 DMDSKR2 TN Glypican-3 (GPC3) DMDSKR2 MA CAR-T-Cell-Therapy DMDSKR2 RN ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3 DMDSKR2 RU https://clinicaltrials.gov/ct2/show/NCT02723942 DMDTNFB DI DMDTNFB DMDTNFB DN ISIS-STAT3 DMDTNFB TI TTHJT3X DMDTNFB TN STAT3 messenger RNA (STAT3 mRNA) DMDTNFB RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMDTNFB RU http://www.isispharm.com/index.htm DMDWCOF DI DMDWCOF DMDWCOF DN EGFR CART DMDWCOF TI TTGKNB4 DMDWCOF TN Epidermal growth factor receptor (EGFR) DMDWCOF MA CAR-T-Cell-Therapy DMDWCOF RN ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer DMDWCOF RU https://clinicaltrials.gov/ct2/show/NCT03152435 DME2W4T DI DME2W4T DME2W4T DN Forodesine DME2W4T TI TTMCF1Y DME2W4T TN Purine nucleoside phosphorylase (PNP) DME2W4T MA Inhibitor DME2W4T RN Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 an... Blood. 2009 Aug 20;114(8):1563-75. DME2W4T RU https://pubmed.ncbi.nlm.nih.gov/19541822 DME6NMJ DI DME6NMJ DME6NMJ DN CYT-0851 DME6NMJ TI TTC0G1L DME6NMJ TN DNA repair protein RAD51 homolog 1 (RAD51) DME6NMJ MA Inhibitor DME6NMJ RN National Cancer Institute Drug Dictionary (drug name CYT0851). DME6NMJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rad51-inhibitor-cyt-0851 DME6PB0 DI DME6PB0 DME6PB0 DN MG7-CART DME6PB0 TI TTPXOQN DME6PB0 TN Gastric carcinoma-associated antigen MG7 (MG7) DME6PB0 MA CAR-T-Cell-Therapy DME6PB0 RN ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART) DME6PB0 RU https://clinicaltrials.gov/ct2/show/NCT02862704 DME6PB0 DI DME6PB0 DME6PB0 DN MG7-CART DME6PB0 TI TTPW9LJ DME6PB0 TN Co-stimulatory molecule 4-1BB (CD137) DME6PB0 MA CAR-T-Cell-Therapy DME6PB0 RN ClinicalTrials.gov (NCT02862704) A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART) DME6PB0 RU https://clinicaltrials.gov/ct2/show/NCT02862704 DME7PBN DI DME7PBN DME7PBN DN mRNA-3704 DME7PBN TI TTCQ21Y DME7PBN TN Methylmalonyl-CoA mutase (MMUT) DME7PBN MA Replacement DME7PBN RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DME7PBN RU https://www.modernatx.com/mrna-3705 DME8JW1 DI DME8JW1 DME8JW1 DN KTE-C19 CAR DME8JW1 TI TTW640A DME8JW1 TN B-lymphocyte surface antigen B4 (CD19) DME8JW1 MA Inhibitor DME8JW1 RN Clinical pipeline report, company report or official report of Kite Pharma. DME8JW1 RU http://ir.kitepharma.com/releasedetail.cfm?releaseid=867609 DMECGKO DI DMECGKO DMECGKO DN CD19 CAR-T Cells DMECGKO TI TTW640A DMECGKO TN B-lymphocyte surface antigen B4 (CD19) DMECGKO MA CAR-T-Cell-Therapy DMECGKO RN ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. DMECGKO RU https://clinicaltrials.gov/ct2/show/NCT03263208 DMED9QV DI DMED9QV DMED9QV DN INCB40093 DMED9QV TI TTGBPJE DMED9QV TN PI3-kinase delta (PIK3CD) DMED9QV MA Inhibitor DMED9QV RN INCB40093 is a selective PI3Kdelta inhibitor with potent antiproliferative activity against human B-cell tumors. DMED9QV RU http://cancerres.aacrjournals.org/content/74/19_Supplement/4531.short DMEF4L5 DI DMEF4L5 DMEF4L5 DN AMG888/U3-1287 DMEF4L5 TI TTDC8N2 DMEF4L5 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMEF4L5 MA Modulator DMEF4L5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). DMEF4L5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798 DMEGPSW DI DMEGPSW DMEGPSW DN AdCh63 AMA1 DMEGPSW TI TTQZW34 DMEGPSW TN Plasmodium Apical membrane protein (Malaria AMA-1) DMEGPSW RN ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health. DMEGPSW RU https://clinicaltrials.gov/ct2/show/NCT01142765 DMEGSU5 DI DMEGSU5 DMEGSU5 DN 4SCAR-GD2 DMEGSU5 TI TT80ARU DMEGSU5 TN Ganglioside GD2 (GD2) DMEGSU5 MA CAR-T-Cell-Therapy DMEGSU5 RN ClinicalTrials.gov (NCT02992210) Study on GD2 Positive Solid Tumors by 4SCAR-GD2 DMEGSU5 RU https://clinicaltrials.gov/ct2/show/NCT02992210 DMEJT5Z DI DMEJT5Z DMEJT5Z DN SN-32793 DMEJT5Z TI TTGKNB4 DMEJT5Z TN Epidermal growth factor receptor (EGFR) DMEJT5Z MA Inhibitor DMEJT5Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMEJT5Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMELJDI DI DMELJDI DMELJDI DN KAI-9803 DMELJDI TI TT9WJ8U DMELJDI TN Protein kinase C delta (PRKCD) DMELJDI MA Inhibitor DMELJDI RN PKC delta and epsilon in drug targeting and therapeutics. Recent Pat DNA Gene Seq. 2009;3(2):96-101. DMELJDI RU https://pubmed.ncbi.nlm.nih.gov/19519579 DMELJIV DI DMELJIV DMELJIV DN OPA-6566 DMELJIV TI TTM2AOE DMELJIV TN Adenosine A2a receptor (ADORA2A) DMELJIV MA Agonist DMELJIV RN Clinical pipeline report, company report or official report of Acucela. DMELJIV RU http://www.acucela.com/Read-About-Us/Press-Releases/Acucela-and-Otsuka-Pharmaceutical-Announce-the-(1) DMEMRW0 DI DMEMRW0 DMEMRW0 DN Lipoteichoic acid DMEMRW0 TI TTY7ZHS DMEMRW0 TN Toll-like receptor 2 (TLR2) DMEMRW0 MA Modulator DMEMRW0 RN Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccha... J Biol Chem. 2003 May 2;278(18):15587-94. DMEMRW0 RU https://pubmed.ncbi.nlm.nih.gov/12594207 DMEN2L7 DI DMEN2L7 DMEN2L7 DN AG019 DMEN2L7 TI TTT0Q1F DMEN2L7 TN Interleukin-10 (IL10) DMEN2L7 RN ClinicalTrials.gov (NCT03751007) A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D). U.S. National Institutes of Health. DMEN2L7 RU https://clinicaltrials.gov/ct2/show/NCT03751007 DMENF5K DI DMENF5K DMENF5K DN Liatermin DMENF5K TI TTF23ML DMENF5K TN Glial cell line-derived neurotrophic factor (GDNF) DMENF5K MA Modulator DMENF5K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMENF5K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMENFD6 DI DMENFD6 DMENFD6 DN Metelimumab DMENFD6 TI TTP4520 DMENFD6 TN TGF-beta receptor type I (TGFBR1) DMENFD6 RN Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22. DMENFD6 RU https://pubmed.ncbi.nlm.nih.gov/15573100 DMENIQ7 DI DMENIQ7 DMENIQ7 DN CAR-T cells targeting BCMA DMENIQ7 TI TTZ3P4W DMENIQ7 TN B-cell maturation protein (TNFRSF17) DMENIQ7 MA CAR-T-Cell-Therapy DMENIQ7 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMENIQ7 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMEOLVP DI DMEOLVP DMEOLVP DN NI-0401 DMEOLVP TI TTBMAOZ DMEOLVP TN Regulatory protein unspecific (RGP) DMEOLVP RN Clinical pipeline report, company report or official report of NovImmune. DMEOLVP RU http://www.novimmune.com/pipeline/ni-0401.html DMEOS5K DI DMEOS5K DMEOS5K DN AEE-788 DMEOS5K TI TTGJVQM DMEOS5K TN Fibroblast growth factor receptor 2 (FGFR2) DMEOS5K MA Inhibitor DMEOS5K RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMEOS5K RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMEOS5K DI DMEOS5K DMEOS5K DN AEE-788 DMEOS5K TI TTST7KB DMEOS5K TN Fibroblast growth factor receptor 3 (FGFR3) DMEOS5K MA Inhibitor DMEOS5K RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMEOS5K RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMEU86T DI DMEU86T DMEU86T DN ACT017 DMEU86T TI TTTJUVZ DMEU86T TN Platelet glycoprotein VI (GP6) DMEU86T MA Inhibitor DMEU86T RN Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT017, an Antiplatelet GPVI (Glycoprotein VI) Fab. Arterioscler Thromb Vasc Biol. 2019 May;39(5):956-964. DMEU86T RU https://pubmed.ncbi.nlm.nih.gov/31017822 DMEVGI9 DI DMEVGI9 DMEVGI9 DN SPK-7001 DMEVGI9 TI TTOA18V DMEVGI9 TN Rab proteins geranylgeranyltransferase component A 1 (CHM) DMEVGI9 MA Replacement DMEVGI9 RN Clinical pipeline report, company report or official report of Spark Therapeutics. DMEVGI9 RU https://sparktx.com/scientific-platform-programs/ DMEWXFK DI DMEWXFK DMEWXFK DN C 82 DMEWXFK TI TTFRCTK DMEWXFK TN CREB-binding protein (CREBBP) DMEWXFK MA Inhibitor DMEWXFK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEWXFK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEWXFK DI DMEWXFK DMEWXFK DN C 82 DMEWXFK TI TTRPKQG DMEWXFK TN Beta-catenin (CTNNB1) DMEWXFK MA Inhibitor DMEWXFK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEWXFK RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMF4AOE DI DMF4AOE DMF4AOE DN 177-Lu-PSMA-R2 DMF4AOE TI TT9G4N0 DMF4AOE TN Glutamate carboxypeptidase II (GCPII) DMF4AOE MA Agonist DMF4AOE RN National Cancer Institute Drug Dictionary (drug name Lu-177-PSMA-R2). DMF4AOE RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/lutetium-lu-177-psma-r2 DMF7EX8 DI DMF7EX8 DMF7EX8 DN EGFR antisense DNA DMF7EX8 TI TTG96HZ DMF7EX8 TN EGFR messenger RNA (EGFR mRNA) DMF7EX8 RN Antitumor Effects of EGFR Antisense Guanidine-Based Peptide Nucleic Acids in Cancer Models. ACS Chem Biol. 2013 February 15; 8(2): 345-352. DMF7EX8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684443/ DMFA4CK DI DMFA4CK DMFA4CK DN BAY 1902607 DMFA4CK TI TT2THBD DMFA4CK TN P2X purinoceptor 3 (P2RX3) DMFA4CK MA Antagonist DMFA4CK RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFA4CK RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFAMNH DI DMFAMNH DMFAMNH DN 99mTc-rBitistatin DMFAMNH TI TT38RM1 DMFAMNH TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMFAMNH MA Modulator DMFAMNH RN Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63. DMFAMNH RU https://pubmed.ncbi.nlm.nih.gov/17921036 DMFCPG0 DI DMFCPG0 DMFCPG0 DN CAR-T cells targeting GD2 DMFCPG0 TI TT80ARU DMFCPG0 TN Ganglioside GD2 (GD2) DMFCPG0 MA CAR-T-Cell-Therapy DMFCPG0 RN ClinicalTrials.gov (NCT03252171) CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients DMFCPG0 RU https://clinicaltrials.gov/ct2/show/NCT03252171 DMFHV9L DI DMFHV9L DMFHV9L DN Leber's congenital amaurosis gene therapy DMFHV9L TI TTBOH16 DMFHV9L TN Retinal pigment epithelium protein (RPE65) DMFHV9L MA Modulator DMFHV9L RN ClinicalTrials.gov (NCT00749957) Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis. U.S. National Institutes of Health. DMFHV9L RU https://clinicaltrials.gov/ct2/show/NCT00749957 DMFJB35 DI DMFJB35 DMFJB35 DN ABO-102 DMFJB35 TI TTPJ2SH DMFJB35 TN N-sulphoglucosamine sulphohydrolase (SGSH) DMFJB35 RN Clinical pipeline report, company report or official report of Abeona Therapeutics. DMFJB35 RU https://www.abeonatherapeutics.com/science DMFK5IX DI DMFK5IX DMFK5IX DN MAK683 DMFK5IX TI TTFNJ4R DMFK5IX TN Embryonic ectoderm development protein (EED) DMFK5IX MA Inhibitor DMFK5IX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFK5IX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFKA4G DI DMFKA4G DMFKA4G DN BLZ-100 DMFKA4G TI TTCYAXN DMFKA4G TN Chloride channel unspecific (ClC) DMFKA4G MA Inhibitor DMFKA4G RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFKA4G RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFKA4G DI DMFKA4G DMFKA4G DN BLZ-100 DMFKA4G TI TT1GHVO DMFKA4G TN Matrix metalloproteinase (MMP) DMFKA4G MA Inhibitor DMFKA4G RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFKA4G RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFKA4G DI DMFKA4G DMFKA4G DN BLZ-100 DMFKA4G TI TT6X50U DMFKA4G TN Matrix metalloproteinase-9 (MMP-9) DMFKA4G MA Inhibitor DMFKA4G RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMFKA4G RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMFOR9Y DI DMFOR9Y DMFOR9Y DN TSR-011 DMFOR9Y TI TTPMQSO DMFOR9Y TN ALK tyrosine kinase receptor (ALK) DMFOR9Y MA Inhibitor DMFOR9Y RN Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 2012 Oct;136(10):1201-4. DMFOR9Y RU https://pubmed.ncbi.nlm.nih.gov/23020724 DMFTZX0 DI DMFTZX0 DMFTZX0 DN AFM24 DMFTZX0 TI TTIFOC0 DMFTZX0 TN Immunoglobulin gamma Fc receptor IIIA (FCGR3A) DMFTZX0 RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMFTZX0 RU https://www.affimed.com/rock-platform/pipeline/ DMFTZX0 DI DMFTZX0 DMFTZX0 DN AFM24 DMFTZX0 TI TTGKNB4 DMFTZX0 TN Epidermal growth factor receptor (EGFR) DMFTZX0 RN Clinical pipeline report, company report or official report of Affimed Therapeutics. DMFTZX0 RU https://www.affimed.com/rock-platform/pipeline/ DMFUDHM DI DMFUDHM DMFUDHM DN MUC-1 CART cell immunotherapy DMFUDHM TI TTBHFYQ DMFUDHM TN Mucin-1 (MUC1) DMFUDHM MA CAR-T-Cell-Therapy DMFUDHM RN ClinicalTrials.gov (NCT03633773) Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma DMFUDHM RU https://clinicaltrials.gov/ct2/show/NCT03633773 DMFV6TY DI DMFV6TY DMFV6TY DN Anti-CD123-CAR-transduced T cells DMFV6TY TI TTENHJ0 DMFV6TY TN Interleukin 3 receptor alpha (IL3RA) DMFV6TY MA CAR-T-Cell-Therapy DMFV6TY RN ClinicalTrials.gov (NCT02937103) A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies DMFV6TY RU https://clinicaltrials.gov/ct2/show/NCT02937103 DMFVTSG DI DMFVTSG DMFVTSG DN 4SCAR19 and 4SCAR20 DMFVTSG TI TTUE541 DMFVTSG TN Leukocyte surface antigen Leu-16 (CD20) DMFVTSG MA CAR-T-Cell-Therapy(Dual specific) DMFVTSG RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMFVTSG RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMFVTSG DI DMFVTSG DMFVTSG DN 4SCAR19 and 4SCAR20 DMFVTSG TI TTW640A DMFVTSG TN B-lymphocyte surface antigen B4 (CD19) DMFVTSG MA CAR-T-Cell-Therapy(Dual specific) DMFVTSG RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMFVTSG RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMFZS8A DI DMFZS8A DMFZS8A DN CD38 and BCMA CAR-T Cells DMFZS8A TI TTZ3P4W DMFZS8A TN B-cell maturation protein (TNFRSF17) DMFZS8A MA CAR-T-Cell-Therapy(Dual specific) DMFZS8A RN ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma DMFZS8A RU https://clinicaltrials.gov/ct2/show/NCT03767751 DMFZS8A DI DMFZS8A DMFZS8A DN CD38 and BCMA CAR-T Cells DMFZS8A TI TTPURFN DMFZS8A TN Cyclic ADP-ribose hydrolase 1 (CD38) DMFZS8A MA CAR-T-Cell-Therapy(Dual specific) DMFZS8A RN ClinicalTrials.gov (NCT03767751) A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma DMFZS8A RU https://clinicaltrials.gov/ct2/show/NCT03767751 DMG107N DI DMG107N DMG107N DN ISB 1342 DMG107N TI TTPURFN DMG107N TN Cyclic ADP-ribose hydrolase 1 (CD38) DMG107N MA Inhibitor DMG107N RN Clinical pipeline report, company report or official report of Ichnos Sciences. DMG107N RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DMG107N DI DMG107N DMG107N DN ISB 1342 DMG107N TI TTUN7MC DMG107N TN T-cell surface glycoprotein CD3 (CD3) DMG107N MA Inhibitor DMG107N RN Clinical pipeline report, company report or official report of Ichnos Sciences. DMG107N RU https://ichnossciences.com/wp-content/uploads/Ichnos-Sciences-Corporate-Deck-Sept-25-2020-FINAL.pdf DMG48WN DI DMG48WN DMG48WN DN G0-203-2c DMG48WN TI TTBHFYQ DMG48WN TN Mucin-1 (MUC1) DMG48WN MA Modulator DMG48WN RN Clinical pipeline report, company report or official report of Genus Oncology. DMG48WN RU http://www.genusoncology.com/phase-1-trial-GO-203-2c.php DMG65CV DI DMG65CV DMG65CV DN INCB057643 DMG65CV TI TTE4BSY DMG65CV TN Bromodomain and extraterminal domain protein (BET) DMG65CV MA Inhibitor DMG65CV RN Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 Mar 15;26(6):1247-1257. DMG65CV RU https://pubmed.ncbi.nlm.nih.gov/31527168 DMG7XHE DI DMG7XHE DMG7XHE DN Monalizumab DMG7XHE TI TTC4IMS DMG7XHE TN NKG2-A/B-activating NK receptor (NKG2A) DMG7XHE MA Antagonist DMG7XHE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG7XHE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG8JLC DI DMG8JLC DMG8JLC DN SRP-9003 DMG8JLC TI TTEDCQ0 DMG8JLC TN Beta-sarcoglycan (SGCB) DMG8JLC MA Replacement DMG8JLC RN Clinical pipeline report, company report or official report of Sarepta Therapeutics. DMG8JLC RU https://www.sarepta.com/products-pipeline/pipeline DMG9OAV DI DMG9OAV DMG9OAV DN AUTO1 DMG9OAV TI TTW640A DMG9OAV TN B-lymphocyte surface antigen B4 (CD19) DMG9OAV RN Clinical pipeline report, company report or official report of Autolus Therapeutics. DMG9OAV RU https://www.autolus.com/pipeline/ DMGC96P DI DMGC96P DMGC96P DN MLN-2704 DMGC96P TI TT9G4N0 DMGC96P TN Glutamate carboxypeptidase II (GCPII) DMGC96P RN Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol. 2008 May 1;26(13):2147-54. DMGC96P RU https://pubmed.ncbi.nlm.nih.gov/18362364 DMGDK9C DI DMGDK9C DMGDK9C DN CD19 specific CAR T cells DMGDK9C TI TTW640A DMGDK9C TN B-lymphocyte surface antigen B4 (CD19) DMGDK9C MA CAR-T-Cell-Therapy DMGDK9C RN ClinicalTrials.gov (NCT02028455) A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia DMGDK9C RU https://clinicaltrials.gov/ct2/show/NCT02028455 DMGEZVF DI DMGEZVF DMGEZVF DN JS016 DMGEZVF TI TTZ3COY DMGEZVF TN COVID-19 spike glycoprotein (S) DMGEZVF MA Inhibitor DMGEZVF RN Clinical pipeline report, company report or official report of Lilly. DMGEZVF RU https://www.lilly.com/discovery/clinical-development-pipeline# DMGF2PU DI DMGF2PU DMGF2PU DN BNT411 DMGF2PU TI TTRJ1K4 DMGF2PU TN Toll-like receptor 7 (TLR7) DMGF2PU MA Agonist DMGF2PU RN Clinical pipeline report, company report or official report of BioNTech. DMGF2PU RU https://biontech.de/science/pipeline DMGFPQ0 DI DMGFPQ0 DMGFPQ0 DN PBF509 DMGFPQ0 TI TTM2AOE DMGFPQ0 TN Adenosine A2a receptor (ADORA2A) DMGFPQ0 MA Antagonist DMGFPQ0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGFPQ0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGIN7J DI DMGIN7J DMGIN7J DN Onyvax-105 DMGIN7J TI TT5Z9WY DMGIN7J TN Complement decay-accelerating factor (CD55) DMGIN7J RN Technology evaluation: Onyvax-105, Onyvax. Curr Opin Mol Ther. 2003 Dec;5(6):668-72. DMGIN7J RU https://pubmed.ncbi.nlm.nih.gov/14755894 DMGM7QD DI DMGM7QD DMGM7QD DN BMS-777607 DMGM7QD TI TTNDSF4 DMGM7QD TN Proto-oncogene c-Met (MET) DMGM7QD MA Inhibitor DMGM7QD RN Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607... J Med Chem. 2009 Mar 12;52(5):1251-4. DMGM7QD RU https://pubmed.ncbi.nlm.nih.gov/19260711 DMGN679 DI DMGN679 DMGN679 DN GPC3-CART cells DMGN679 TI TTJTSX4 DMGN679 TN Glypican-3 (GPC3) DMGN679 MA CAR-T-Cell-Therapy DMGN679 RN ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) DMGN679 RU https://clinicaltrials.gov/ct2/show/NCT03130712 DMGQX0U DI DMGQX0U DMGQX0U DN ALX148 DMGQX0U TI TT28S46 DMGQX0U TN Leukocyte surface antigen CD47 (CD47) DMGQX0U MA Inhibitor DMGQX0U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGQX0U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGTB5N DI DMGTB5N DMGTB5N DN LJM716 DMGTB5N TI TTDC8N2 DMGTB5N TN Erbb3 tyrosine kinase receptor (Erbb-3) DMGTB5N RN An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res. 2013 Oct 1;73(19):6024-35. DMGTB5N RU https://pubmed.ncbi.nlm.nih.gov/23928993 DMGTOIX DI DMGTOIX DMGTOIX DN A166 DMGTOIX TI TT6EO5L DMGTOIX TN Erbb2 tyrosine kinase receptor (HER2) DMGTOIX RN Clinical pipeline report, company report or official report of KLUS Pharma. DMGTOIX RU https://www.kluspharma.com/pipeline DMH064K DI DMH064K DMH064K DN SEL-24 DMH064K TI TTTN5QW DMH064K TN Serine/threonine-protein kinase pim-1 (PIM1) DMH064K MA Inhibitor DMH064K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158). DMH064K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2158 DMH064K DI DMH064K DMH064K DN SEL-24 DMH064K TI TTGJCWZ DMH064K TN Fms-like tyrosine kinase 3 (FLT-3) DMH064K MA Inhibitor DMH064K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH064K RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH0ROP DI DMH0ROP DMH0ROP DN Maltose DMH0ROP TI TTXWASR DMH0ROP TN Intestinal maltase-glucoamylase (MGAM) DMH0ROP MA Inhibitor DMH0ROP RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMH0ROP RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMH0ROP DI DMH0ROP DMH0ROP DN Maltose DMH0ROP TI TTHCF4J DMH0ROP TN Alpha-glucosidase (GLA) DMH0ROP MA Inhibitor DMH0ROP RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMH0ROP RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMH2NKD DI DMH2NKD DMH2NKD DN EB-101 DMH2NKD TI TTE4KHA DMH2NKD TN Amyloid beta A4 protein (APP) DMH2NKD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMH2NKD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMH32LC DI DMH32LC DMH32LC DN ISIS-DMPK DMH32LC TI TTZQTY2 DMH32LC TN DMPK messenger RNA (DMPK mRNA) DMH32LC RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DMH32LC RU https://www.isispharm.com/pipeline/isis-dmpkrx/ DMH70A9 DI DMH70A9 DMH70A9 DN BCMA CAR T cells DMH70A9 TI TTZ3P4W DMH70A9 TN B-cell maturation protein (TNFRSF17) DMH70A9 MA CAR-T-Cell-Therapy DMH70A9 RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMH70A9 RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMH9RGV DI DMH9RGV DMH9RGV DN TTP-814 DMH9RGV TI TTMS7KP DMH9RGV TN Protein-tyrosine phosphatase 1B (PTP1B) DMH9RGV MA Inhibitor DMH9RGV RN Protein tyrosine phosphatase 1B (PTP-1B; PTPN1). SciBX 5(7); doi:10.1038/scibx.2012.176. Feb. 16 2012 DMH9RGV RU http://www.nature.com/scibx/journal/v5/n7/full/scibx.2012.176.html DMHIQDC DI DMHIQDC DMHIQDC DN CUDC-907 DMHIQDC TI TTHBTOP DMHIQDC TN PI3-kinase gamma (PIK3CG) DMHIQDC MA Modulator DMHIQDC RN Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.Clin Cancer Res.2012 Aug 1;18(15):4104-13. DMHIQDC RU https://www.ncbi.nlm.nih.gov/pubmed/22693356 DMHIQDC DI DMHIQDC DMHIQDC DN CUDC-907 DMHIQDC TI TTBH0VX DMHIQDC TN Histone deacetylase (HDAC) DMHIQDC MA Inhibitor DMHIQDC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHIQDC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHMC19 DI DMHMC19 DMHMC19 DN CD137 CAR-T Cell DMHMC19 TI TTPW9LJ DMHMC19 TN Co-stimulatory molecule 4-1BB (CD137) DMHMC19 MA CAR-T-Cell-Therapy DMHMC19 RN ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies DMHMC19 RU https://clinicaltrials.gov/ct2/show/NCT02965092 DMHNFXR DI DMHNFXR DMHNFXR DN Chimeric Antigen Receptor Modified T cells Targeting CD19 DMHNFXR TI TTW640A DMHNFXR TN B-lymphocyte surface antigen B4 (CD19) DMHNFXR MA CAR-T-Cell-Therapy DMHNFXR RN ClinicalTrials.gov (NCT02349698) A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma DMHNFXR RU https://clinicaltrials.gov/ct2/show/NCT02349698 DMHOWU5 DI DMHOWU5 DMHOWU5 DN CD123-specific gene-engineered T cells DMHOWU5 TI TTENHJ0 DMHOWU5 TN Interleukin 3 receptor alpha (IL3RA) DMHOWU5 MA CAR-T-Cell-Therapy DMHOWU5 RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMHOWU5 RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMHPZ8G DI DMHPZ8G DMHPZ8G DN CD20-Specific CAR T Cells DMHPZ8G TI TTUE541 DMHPZ8G TN Leukocyte surface antigen Leu-16 (CD20) DMHPZ8G MA CAR-T-Cell-Therapy DMHPZ8G RN ClinicalTrials.gov (NCT03277729) A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas DMHPZ8G RU https://clinicaltrials.gov/ct2/show/NCT03277729 DMHQ2U8 DI DMHQ2U8 DMHQ2U8 DN IMC-F106C DMHQ2U8 TI TTPH7T0 DMHQ2U8 TN Tumor expressed melanoma antigen (PRAME) DMHQ2U8 RN Clinical pipeline report, company report or official report of Immunocore. DMHQ2U8 RU https://www.immunocore.com/news/immunocore-announces-dosing-first-patient-fourth-immtac DMHRCQI DI DMHRCQI DMHRCQI DN eFT226 DMHRCQI TI TTIGYVZ DMHRCQI TN HUMAN eukaryotic initiation factor-4A (eIF4A) DMHRCQI MA Inhibitor DMHRCQI RN Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. J Med Chem. 2020 Jun 11;63(11):5879-5955. DMHRCQI RU https://pubmed.ncbi.nlm.nih.gov/32470302 DMHSLVJ DI DMHSLVJ DMHSLVJ DN Anti-CD19 CAR transduced T cells DMHSLVJ TI TTW640A DMHSLVJ TN B-lymphocyte surface antigen B4 (CD19) DMHSLVJ MA CAR-T-Cell-Therapy DMHSLVJ RN ClinicalTrials.gov (NCT03191773) A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies DMHSLVJ RU https://clinicaltrials.gov/ct2/show/NCT03191773 DMHTG8P DI DMHTG8P DMHTG8P DN TP-0903 DMHTG8P TI TTZPY6J DMHTG8P TN Tyrosine-protein kinase UFO (AXL) DMHTG8P MA Inhibitor DMHTG8P RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHTG8P RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMHW289 DI DMHW289 DMHW289 DN DCC-3014 DMHW289 TI TT7MRDV DMHW289 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMHW289 MA Inhibitor DMHW289 RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMHW289 RU https://www.deciphera.com/pipeline/dcc-3014/ DMHXTNW DI DMHXTNW DMHXTNW DN LY-2228820 DMHXTNW TI TTWELHI DMHXTNW TN Stress-activated protein kinase (p38) DMHXTNW MA Inhibitor DMHXTNW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7959). DMHXTNW RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7959 DMHZUF8 DI DMHZUF8 DMHZUF8 DN AGN-208397 DMHZUF8 TI TT6EO5L DMHZUF8 TN Erbb2 tyrosine kinase receptor (HER2) DMHZUF8 MA Inhibitor DMHZUF8 RN New hope for dry AMD. Nat Rev Drug Discov. 2013 Jul;12(7):501-2. DMHZUF8 RU https://pubmed.ncbi.nlm.nih.gov/23812264 DMI0H3B DI DMI0H3B DMI0H3B DN UshStat DMI0H3B TI TTNIMDP DMI0H3B TN Myosin-7 (MYH7) DMI0H3B MA Modulator DMI0H3B RN EIAV-based retinal gene therapy in the shaker1 mouse model for usher syndrome type 1B: development of UshStat. PLoS One. 2014 Apr 4;9(4):e94272. DMI0H3B RU https://pubmed.ncbi.nlm.nih.gov/24705452 DMI17NX DI DMI17NX DMI17NX DN ART621 DMI17NX TI TTF8CQI DMI17NX TN Tumor necrosis factor (TNF) DMI17NX MA Inhibitor DMI17NX RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DMI17NX RU https://pubmed.ncbi.nlm.nih.gov/19249988 DMI27RF DI DMI27RF DMI27RF DN AAV-AQP1 DMI27RF TI TTSF1KH DMI27RF TN Aquaporin-1 (AQP1) DMI27RF RN Clinical pipeline report, company report or official report of MeiraGTx. DMI27RF RU https://meiragtx.com/research-development/pipeline/ DMI2OVA DI DMI2OVA DMI2OVA DN CD19-targeting CAR T Cells DMI2OVA TI TTW640A DMI2OVA TN B-lymphocyte surface antigen B4 (CD19) DMI2OVA MA CAR-T-Cell-Therapy DMI2OVA RN ClinicalTrials.gov (NCT02547948) CD19-targeting CAR T Cells for B Cell Lymphoma DMI2OVA RU https://clinicaltrials.gov/ct2/show/NCT02547948 DMI42Q0 DI DMI42Q0 DMI42Q0 DN BGB-A425 DMI42Q0 TI TT1RWL7 DMI42Q0 TN Hepatitis A virus cellular receptor 2 (TIM3) DMI42Q0 RN Clinical pipeline report, company report or official report of BeiGene. DMI42Q0 RU https://www.beigene.com/science-and-product-portfolio/pipeline DMI71FN DI DMI71FN DMI71FN DN EDO-S101 DMI71FN TI TTBH0VX DMI71FN TN Histone deacetylase (HDAC) DMI71FN MA Inhibitor DMI71FN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI71FN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI7S39 DI DMI7S39 DMI7S39 DN FLX475 DMI7S39 TI TT7HQD0 DMI7S39 TN C-C chemokine receptor type 4 (CCR4) DMI7S39 MA Antagonist DMI7S39 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI7S39 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI8RG1 DI DMI8RG1 DMI8RG1 DN OTX-015 DMI8RG1 TI TTRA6BO DMI8RG1 TN Bromodomain-containing protein 4 (BRD4) DMI8RG1 MA Modulator DMI8RG1 RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMI8RG1 RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMI8RG1 DI DMI8RG1 DMI8RG1 DN OTX-015 DMI8RG1 TI TTDP48B DMI8RG1 TN Bromodomain-containing protein 2 (BRD2) DMI8RG1 MA Modulator DMI8RG1 RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMI8RG1 RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMI8RG1 DI DMI8RG1 DMI8RG1 DN OTX-015 DMI8RG1 TI TTE4BSY DMI8RG1 TN Bromodomain and extraterminal domain protein (BET) DMI8RG1 MA Inhibitor DMI8RG1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI8RG1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI8TW3 DI DMI8TW3 DMI8TW3 DN 4SCAR19/22 T cells DMI8TW3 TI TTM6QSK DMI8TW3 TN B-cell receptor CD22 (CD22) DMI8TW3 MA CAR-T-Cell-Therapy(Dual specific) DMI8TW3 RN ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies DMI8TW3 RU https://clinicaltrials.gov/ct2/show/NCT03098355 DMI8TW3 DI DMI8TW3 DMI8TW3 DN 4SCAR19/22 T cells DMI8TW3 TI TTW640A DMI8TW3 TN B-lymphocyte surface antigen B4 (CD19) DMI8TW3 MA CAR-T-Cell-Therapy(Dual specific) DMI8TW3 RN ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies DMI8TW3 RU https://clinicaltrials.gov/ct2/show/NCT03098355 DMI9FXE DI DMI9FXE DMI9FXE DN KBP-5074 DMI9FXE TI TT26PHO DMI9FXE TN Mineralocorticoid receptor (MR) DMI9FXE MA Antagonist DMI9FXE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI9FXE RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMIA9JD DI DMIA9JD DMIA9JD DN YSCMA DMIA9JD TI TTDIGC1 DMIA9JD TN Dipeptidyl peptidase 4 (DPP-4) DMIA9JD RN Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol. 2014 Feb 6;9:30. DMIA9JD RU https://pubmed.ncbi.nlm.nih.gov/24502396 DMIFCY2 DI DMIFCY2 DMIFCY2 DN H3B-6545 DMIFCY2 TI TTZAYWL DMIFCY2 TN Estrogen receptor (ESR) DMIFCY2 MA Antagonist DMIFCY2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIFCY2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIM9TZ DI DMIM9TZ DMIM9TZ DN CAR-T cells targeting CD19 DMIM9TZ TI TTW640A DMIM9TZ TN B-lymphocyte surface antigen B4 (CD19) DMIM9TZ MA CAR-T-Cell-Therapy DMIM9TZ RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMIM9TZ RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMIMA4V DI DMIMA4V DMIMA4V DN BPX-501 DMIMA4V TI TTXQYT6 DMIMA4V TN T-cells (T-cells) DMIMA4V MA Immunomodulator DMIMA4V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIMA4V RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMIOUFK DI DMIOUFK DMIOUFK DN Emfilermin DMIOUFK TI TTID542 DMIOUFK TN Leukemia inhibitory factor receptor (LIFR) DMIOUFK MA Inhibitor DMIOUFK RN Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer. Br J Clin Pharmacol. 2004 May; 57(5): 576-585. DMIOUFK RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884498/ DMIREUZ DI DMIREUZ DMIREUZ DN Ex vivo adenosine deaminase-transduced hematopoietic stem cell therapy DMIREUZ TI TTLP57V DMIREUZ TN Adenosine deaminase (ADA) DMIREUZ MA Modulator DMIREUZ RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMIREUZ RU https://www.gsk.com/en-gb/media/press-releases/2015/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/ DMIRG15 DI DMIRG15 DMIRG15 DN MaC46/M87o DMIRG15 TI TTG90S6 DMIRG15 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMIRG15 MA Modulator DMIRG15 RN DOI: 10.1038/mt.sj.6300124 DMIRG15 RU http://www.nature.com/mt/journal/v15/n5/full/6300124a.html DMIRGTZ DI DMIRGTZ DMIRGTZ DN ACHM-CNGA3 DMIRGTZ TI TTW0QOV DMIRGTZ TN Cyclic nucleotide-gated channel alpha-3 (CNGA3) DMIRGTZ RN Clinical pipeline report, company report or official report of Applied Genetic Technologies. DMIRGTZ RU https://agtc.com/programs/achromatopsia/ DMIS75V DI DMIS75V DMIS75V DN MTL-CEPBA DMIS75V TI TT5LWG1 DMIS75V TN CEBPA messenger RNA (CEBPA mRNA) DMIS75V MA Activator DMIS75V RN MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-alpha, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. Clin Cancer Res. 2020 Aug 1;26(15):3936-3946. DMIS75V RU https://pubmed.ncbi.nlm.nih.gov/32357963 DMIU0VP DI DMIU0VP DMIU0VP DN SNX-5422 DMIU0VP TI TT78R5H DMIU0VP TN Heat shock protein 90 alpha (HSP90A) DMIU0VP MA Inhibitor DMIU0VP RN SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55. DMIU0VP RU https://pubmed.ncbi.nlm.nih.gov/18948577 DMIU0VP DI DMIU0VP DMIU0VP DN SNX-5422 DMIU0VP TI TTH5YN2 DMIU0VP TN Heat shock protein 90 beta (HSP90B) DMIU0VP MA Inhibitor DMIU0VP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIU0VP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIU1HY DI DMIU1HY DMIU1HY DN HuM-195-Ac-225 DMIU1HY TI TTJVYO3 DMIU1HY TN Myeloid cell surface antigen CD33 (CD33) DMIU1HY MA Inhibitor DMIU1HY RN J Clin Oncol 29: 2011 (suppl; abstr 6516). DMIU1HY RU http://meetinglibrary.asco.org/content/77232-102 DMIU26T DI DMIU26T DMIU26T DN OP-1250 DMIU26T TI TTZAYWL DMIU26T TN Estrogen receptor (ESR) DMIU26T MA Antagonist DMIU26T RN Clinical pipeline report, company report or official report of Olema Pharmaceuticals. DMIU26T RU https://olema.com/pipeline/ DMIVE67 DI DMIVE67 DMIVE67 DN TPX-0046 DMIVE67 TI TT4DXQT DMIVE67 TN Proto-oncogene c-Ret (RET) DMIVE67 MA Inhibitor DMIVE67 RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMIVE67 RU https://tptherapeutics.com/pipeline/tpx-0046/ DMIVE67 DI DMIVE67 DMIVE67 DN TPX-0046 DMIVE67 TI TT6PKBN DMIVE67 TN Proto-oncogene c-Src (SRC) DMIVE67 MA Inhibitor DMIVE67 RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMIVE67 RU https://tptherapeutics.com/pipeline/tpx-0046/ DMIXPNG DI DMIXPNG DMIXPNG DN CHR-3996 DMIXPNG TI TTSHTOI DMIXPNG TN Histone deacetylase 2 (HDAC2) DMIXPNG MA Inhibitor DMIXPNG RN A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. DMIXPNG RU https://pubmed.ncbi.nlm.nih.gov/22553374 DMIXPNG DI DMIXPNG DMIXPNG DN CHR-3996 DMIXPNG TI TT6R7JZ DMIXPNG TN Histone deacetylase 1 (HDAC1) DMIXPNG MA Inhibitor DMIXPNG RN A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. DMIXPNG RU https://pubmed.ncbi.nlm.nih.gov/22553374 DMIXPNG DI DMIXPNG DMIXPNG DN CHR-3996 DMIXPNG TI TT4YWTO DMIXPNG TN Histone deacetylase 3 (HDAC3) DMIXPNG MA Inhibitor DMIXPNG RN A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. DMIXPNG RU https://pubmed.ncbi.nlm.nih.gov/22553374 DMIY1ZB DI DMIY1ZB DMIY1ZB DN 4SCAR19 cells DMIY1ZB TI TTW640A DMIY1ZB TN B-lymphocyte surface antigen B4 (CD19) DMIY1ZB MA CAR-T-Cell-Therapy DMIY1ZB RN ClinicalTrials.gov (NCT03050190) A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies DMIY1ZB RU https://clinicaltrials.gov/ct2/show/NCT03050190 DMJ42E6 DI DMJ42E6 DMJ42E6 DN ProSavin DMJ42E6 TI TTLSWP6 DMJ42E6 TN GTP cyclohydrolase-I (GCH1) DMJ42E6 MA Modulator DMJ42E6 RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMJ42E6 RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/ DMJ42E6 DI DMJ42E6 DMJ42E6 DN ProSavin DMJ42E6 TI TTN451K DMJ42E6 TN Aromatic-L-amino-acid decarboxylase (DDC) DMJ42E6 MA Modulator DMJ42E6 RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMJ42E6 RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/ DMJ42E6 DI DMJ42E6 DMJ42E6 DN ProSavin DMJ42E6 TI TTUHP71 DMJ42E6 TN Tyrosine 3-monooxygenase (TH) DMJ42E6 MA Modulator DMJ42E6 RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMJ42E6 RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-completion-of-prosavin-r-phase-i-ii-study-in-parkinson-s-disease/ DMJ5MPG DI DMJ5MPG DMJ5MPG DN BDC-1001 DMJ5MPG TI TTY6DTE DMJ5MPG TN Carcinoembryonic antigen CEA (CD66e) DMJ5MPG RN Clinical pipeline report, company report or official report of Bolt Biotherapeutics. DMJ5MPG RU https://www.boltbio.com/pipeline/ DMJ7LP0 DI DMJ7LP0 DMJ7LP0 DN CTX110 DMJ7LP0 TI TTQO71U DMJ7LP0 TN Hemoglobin (HB) DMJ7LP0 RN Clinical pipeline report, company report or official report of CRISPR Therapeutics. DMJ7LP0 RU http://www.crisprtx.com/programs/pipeline DMJ9CY4 DI DMJ9CY4 DMJ9CY4 DN IL-2/gene-modified lymphocytes DMJ9CY4 TI TTF89GD DMJ9CY4 TN Interleukin-2 (IL2) DMJ9CY4 MA Modulator DMJ9CY4 RN Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica. 2012 November; 97(11): 1622-1631. DMJ9CY4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487433/ DMJBQ96 DI DMJBQ96 DMJBQ96 DN Cetrelimab DMJBQ96 TI TTNBFWK DMJBQ96 TN Programmed cell death protein 1 (PD-1) DMJBQ96 RN Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update. Int J Mol Sci. 2018 Dec 7;19(12):3924. DMJBQ96 RU https://pubmed.ncbi.nlm.nih.gov/30544512 DMJC2RU DI DMJC2RU DMJC2RU DN PBCAR0191 DMJC2RU TI TTW640A DMJC2RU TN B-lymphocyte surface antigen B4 (CD19) DMJC2RU MA CAR-T-Cell-Therapy DMJC2RU RN ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL DMJC2RU RU https://clinicaltrials.gov/ct2/show/NCT03666000 DMJDV0K DI DMJDV0K DMJDV0K DN SPR720 DMJDV0K TI TTS7LWX DMJDV0K TN Bacterial DNA gyrase B (Bact gyrB) DMJDV0K MA Inhibitor DMJDV0K RN Advancement of GyrB Inhibitors for Treatment of Infections Caused by Mycobacterium tuberculosis and Non-tuberculous Mycobacteria. ACS Infect Dis. 2020 Jun 12;6(6):1323-1331. DMJDV0K RU https://pubmed.ncbi.nlm.nih.gov/32183511 DMJDVCW DI DMJDVCW DMJDVCW DN HL-085 DMJDVCW TI TTZCRP3 DMJDVCW TN ERK activator kinase (MEK) DMJDVCW MA Inhibitor DMJDVCW RN Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551. DMJDVCW RU https://pubmed.ncbi.nlm.nih.gov/28954413 DMJEXLI DI DMJEXLI DMJEXLI DN CPI-0209 DMJEXLI TI TT9MZCQ DMJEXLI TN Enhancer of zeste homolog 2 (EZH2) DMJEXLI MA Inhibitor DMJEXLI RN ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health. DMJEXLI RU https://clinicaltrials.gov/ct2/show/NCT04104776 DMJKFNU DI DMJKFNU DMJKFNU DN DCC-2036 DMJKFNU TI TT3PJMV DMJKFNU TN Tyrosine-protein kinase ABL1 (ABL) DMJKFNU MA Modulator DMJKFNU RN Company report (Deciphera Pharmaceuticals: Tumor-Targeted Programs and Indications) DMJKFNU RU http://www.deciphera.com/pipeline DMJKFNU DI DMJKFNU DMJKFNU DN DCC-2036 DMJKFNU TI TT9VGXW DMJKFNU TN Angiopoietin 1 receptor (TEK) DMJKFNU MA Inhibitor DMJKFNU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJKFNU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJLMEF DI DMJLMEF DMJLMEF DN AP-30663 DMJLMEF TI TTKU9YD DMJLMEF TN Calcium-activated potassium channel KCa2 (KCNN) DMJLMEF MA Inhibitor DMJLMEF RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJLMEF RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJPSIL DI DMJPSIL DMJPSIL DN Dapivirine DMJPSIL TI TT84ETX DMJPSIL TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJPSIL MA Inhibitor DMJPSIL RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMJPSIL RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMJSQXT DI DMJSQXT DMJSQXT DN TAK-007 DMJSQXT TI TTW640A DMJSQXT TN B-lymphocyte surface antigen B4 (CD19) DMJSQXT RN Clinical pipeline report, company report or official report of Takeda. DMJSQXT RU https://www.takeda.com/newsroom/newsreleases/2020/takeda-opens-new-rd-cell-therapy-manufacturing-facility-to--support-expansion-of-next-generation-clinical-programs/ DMJV2IF DI DMJV2IF DMJV2IF DN JCAR017 DMJV2IF TI TTW640A DMJV2IF TN B-lymphocyte surface antigen B4 (CD19) DMJV2IF MA CAR-T-Cell-Therapy DMJV2IF RN ClinicalTrials.gov (NCT03436771) Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product DMJV2IF RU https://clinicaltrials.gov/ct2/show/NCT03436771 DMJVENR DI DMJVENR DMJVENR DN CAR-T cells targeting CD2 DMJVENR TI TT80ARU DMJVENR TN Ganglioside GD2 (GD2) DMJVENR MA CAR-T-Cell-Therapy DMJVENR RN ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer DMJVENR RU https://clinicaltrials.gov/ct2/show/NCT03356795 DMJVFK7 DI DMJVFK7 DMJVFK7 DN Meplazumab DMJVFK7 TI TTG21IS DMJVFK7 TN HUMAN basigin (BSG) DMJVFK7 MA Inhibitor DMJVFK7 RN Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial DMJVFK7 RU https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1 DMJVGIH DI DMJVGIH DMJVGIH DN AIGIV DMJVGIH TI TTRLPUB DMJVGIH TN Bacillus anthracis Protective antigen (Anthrax PA) DMJVGIH MA Modulator DMJVGIH RN Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother. 2013 Nov;57(11):5684-92. DMJVGIH RU https://pubmed.ncbi.nlm.nih.gov/23979731 DMK095Z DI DMK095Z DMK095Z DN SRP-9004 DMK095Z TI TTS9Q5V DMK095Z TN Sarcoglycan alpha (SGCA) DMK095Z MA Replacement DMK095Z RN Clinical pipeline report, company report or official report of Sarepta Therapeutics. DMK095Z RU https://www.sarepta.com/products-pipeline/pipeline DMK2L38 DI DMK2L38 DMK2L38 DN M3814 DMK2L38 TI TTK3PY9 DMK2L38 TN DNA-dependent protein kinase catalytic (PRKDC) DMK2L38 MA Inhibitor DMK2L38 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK2L38 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMK2RIB DI DMK2RIB DMK2RIB DN GTB-3550 DMK2RIB TI TTJVYO3 DMK2RIB TN Myeloid cell surface antigen CD33 (CD33) DMK2RIB MA Inhibitor DMK2RIB RN Clinical pipeline report, company report or official report of GT Biopharma. DMK2RIB RU https://www.gtbiopharma.com/product-pipeline/gtb-3550 DMK2RIB DI DMK2RIB DMK2RIB DN GTB-3550 DMK2RIB TI TT7KTSR DMK2RIB TN Immunoglobulin gamma Fc receptor III (FCGR3) DMK2RIB MA Inhibitor DMK2RIB RN Clinical pipeline report, company report or official report of GT Biopharma. DMK2RIB RU https://www.gtbiopharma.com/product-pipeline/gtb-3550 DMK4VY9 DI DMK4VY9 DMK4VY9 DN DS-7300 DMK4VY9 TI TTGTQHC DMK4VY9 TN DNA topoisomerase I (TOP1) DMK4VY9 MA Inhibitor DMK4VY9 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMK4VY9 RU https://www.daiichisankyo.com/rd/pipeline/ DMK4VY9 DI DMK4VY9 DMK4VY9 DN DS-7300 DMK4VY9 TI TT6CQUM DMK4VY9 TN B7 homolog 3 (CD276) DMK4VY9 MA Inhibitor DMK4VY9 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMK4VY9 RU https://www.daiichisankyo.com/rd/pipeline/ DMKC8F9 DI DMKC8F9 DMKC8F9 DN 4SCAR19 and 4SCAR70 DMKC8F9 TI TTW640A DMKC8F9 TN B-lymphocyte surface antigen B4 (CD19) DMKC8F9 MA CAR-T-Cell-Therapy(Dual specific) DMKC8F9 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMKC8F9 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMKC8F9 DI DMKC8F9 DMKC8F9 DN 4SCAR19 and 4SCAR70 DMKC8F9 TI TTNCIE0 DMKC8F9 TN CD70 antigen (CD27-L) DMKC8F9 MA CAR-T-Cell-Therapy(Dual specific) DMKC8F9 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMKC8F9 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMKCJ75 DI DMKCJ75 DMKCJ75 DN CBL0102 DMKCJ75 TI TTETDKQ DMKCJ75 TN Facilitates chromatin transcription complex (FACT) DMKCJ75 MA Modulator DMKCJ75 RN Company report (Incuron) DMKCJ75 RU http://www.incuron.ru/en/news-en/item/2-incuron-announce-cbl0102-orphan-drug-status-for-hepatocellular-carcinoma DMKGU5F DI DMKGU5F DMKGU5F DN CART20 DMKGU5F TI TTUE541 DMKGU5F TN Leukocyte surface antigen Leu-16 (CD20) DMKGU5F MA CAR-T-Cell-Therapy DMKGU5F RN ClinicalTrials.gov (NCT02965157) Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma DMKGU5F RU https://clinicaltrials.gov/ct2/show/NCT02965157 DMKMSP2 DI DMKMSP2 DMKMSP2 DN INCB53914 DMKMSP2 TI TTA7WGU DMKMSP2 TN Serine/threonine-protein kinase pim (PIM) DMKMSP2 MA Inhibitor DMKMSP2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKMSP2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKNA94 DI DMKNA94 DMKNA94 DN INO-8875 DMKNA94 TI TTK25J1 DMKNA94 TN Adenosine A1 receptor (ADORA1) DMKNA94 MA Agonist DMKNA94 RN INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. J Pharmacol Exp Ther. 2013 Jan;344(1):59-67. DMKNA94 RU https://pubmed.ncbi.nlm.nih.gov/23055540 DMKQRUJ DI DMKQRUJ DMKQRUJ DN CD19-directed CAR-T cells DMKQRUJ TI TTW640A DMKQRUJ TN B-lymphocyte surface antigen B4 (CD19) DMKQRUJ MA CAR-T-Cell-Therapy DMKQRUJ RN ClinicalTrials.gov (NCT02537977) CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy DMKQRUJ RU https://clinicaltrials.gov/ct2/show/NCT02537977 DMKV5D6 DI DMKV5D6 DMKV5D6 DN IM19 CAR-T DMKV5D6 TI TTW640A DMKV5D6 TN B-lymphocyte surface antigen B4 (CD19) DMKV5D6 MA CAR-T-Cell-Therapy DMKV5D6 RN ClinicalTrials.gov (NCT03142646) Safety and Efficacy Evaluation of IM19 CAR-T Cells DMKV5D6 RU https://clinicaltrials.gov/ct2/show/NCT03142646 DMKVMWO DI DMKVMWO DMKVMWO DN RP-L201 DMKVMWO TI TTIJWR7 DMKVMWO TN Integrin beta-2 (ITGB2) DMKVMWO MA Replacement DMKVMWO RN Clinical pipeline report, company report or official report of Rocket Pharmaceuticals. DMKVMWO RU https://rocketpharma.com/our-disease-focus/ DML0GIU DI DML0GIU DML0GIU DN AIV001 DML0GIU TI TTVJ1D8 DML0GIU TN Vascular endothelial growth factor receptor (VEGFR) DML0GIU MA Inhibitor DML0GIU RN Clinical pipeline report, company report or official report of AiViva BioPharma. DML0GIU RU https://aiviva.com/aiv001 DML29RF DI DML29RF DML29RF DN KP-100 DML29RF TI TTWC6MY DML29RF TN Protein tyrosine phosphatase (PTP) DML29RF MA Inhibitor DML29RF RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010512) DML29RF RU http://adisinsight.springer.com/drugs/800010512 DML54PD DI DML54PD DML54PD DN TriCAR-T-CD19 DML54PD TI TTW640A DML54PD TN B-lymphocyte surface antigen B4 (CD19) DML54PD MA CAR-T-Cell-Therapy DML54PD RN ClinicalTrials.gov (NCT03497533) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19 DML54PD RU https://clinicaltrials.gov/ct2/show/NCT03497533 DML6EVJ DI DML6EVJ DML6EVJ DN F-14512 DML6EVJ TI TT0IHXV DML6EVJ TN DNA topoisomerase II (TOP2) DML6EVJ MA Modulator DML6EVJ RN Regulation by survivin of cancer cell death induced by F14512, a polyamine-containing inhibitor of DNA topoisomerase II.Apoptosis.2012 Apr;17(4):364-76. DML6EVJ RU https://www.ncbi.nlm.nih.gov/pubmed/22127645 DML8US9 DI DML8US9 DML8US9 DN CLIC-1901 DML8US9 TI TTW640A DML8US9 TN B-lymphocyte surface antigen B4 (CD19) DML8US9 MA CAR-T-Cell-Therapy DML8US9 RN ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies DML8US9 RU https://clinicaltrials.gov/ct2/show/NCT03765177 DMLAKPI DI DMLAKPI DMLAKPI DN AU101 DMLAKPI TI TTQ13FT DMLAKPI TN T-cell-specific surface glycoprotein CD28 (CD28) DMLAKPI MA Immunomodulator DMLAKPI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLAKPI RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLE8T9 DI DMLE8T9 DMLE8T9 DN CART30 DMLE8T9 TI TT2GM5R DMLE8T9 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMLE8T9 MA CAR-T-Cell-Therapy DMLE8T9 RN ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas DMLE8T9 RU https://clinicaltrials.gov/ct2/show/NCT02259556 DMLEVFW DI DMLEVFW DMLEVFW DN IFN alpha kinoid DMLEVFW TI TT95SOA DMLEVFW TN Interferon alpha (IFNA) DMLEVFW MA Modulator DMLEVFW RN Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56. DMLEVFW RU https://pubmed.ncbi.nlm.nih.gov/23203821 DMLFB25 DI DMLFB25 DMLFB25 DN Anti-CD19 and Anti-CD20 CAR-T Cells DMLFB25 TI TTUE541 DMLFB25 TN Leukocyte surface antigen Leu-16 (CD20) DMLFB25 MA CAR-T-Cell-Therapy(Dual specific) DMLFB25 RN ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma DMLFB25 RU https://clinicaltrials.gov/ct2/show/NCT03207178 DMLFB25 DI DMLFB25 DMLFB25 DN Anti-CD19 and Anti-CD20 CAR-T Cells DMLFB25 TI TTW640A DMLFB25 TN B-lymphocyte surface antigen B4 (CD19) DMLFB25 MA CAR-T-Cell-Therapy(Dual specific) DMLFB25 RN ClinicalTrials.gov (NCT03207178) Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma DMLFB25 RU https://clinicaltrials.gov/ct2/show/NCT03207178 DMLOGI4 DI DMLOGI4 DMLOGI4 DN Autologous CD19-targeting CAR T cells DMLOGI4 TI TTW640A DMLOGI4 TN B-lymphocyte surface antigen B4 (CD19) DMLOGI4 MA CAR-T-Cell-Therapy DMLOGI4 RN ClinicalTrials.gov (NCT02963038) CAR T Cells for Refractory B Cell Malignancy DMLOGI4 RU https://clinicaltrials.gov/ct2/show/NCT02963038 DMLPTOF DI DMLPTOF DMLPTOF DN PEN-866 DMLPTOF TI TTGTQHC DMLPTOF TN DNA topoisomerase I (TOP1) DMLPTOF MA Inhibitor DMLPTOF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPTOF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLROMP DI DMLROMP DMLROMP DN TKM-PLK1 DMLROMP TI TTH4IP0 DMLROMP TN PLK1 messenger RNA (PLK1 mRNA) DMLROMP RN Clinical pipeline report, company report or official report of Arbutus Biopharma. DMLROMP RU http://arbutusbio.com/portfolio/tkm-plk1.php DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTTHBCA DMLSYJQ TN PI3-kinase beta (PIK3CB) DMLSYJQ MA Inhibitor DMLSYJQ RN The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. DMLSYJQ RU https://pubmed.ncbi.nlm.nih.gov/21558396 DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTGBPJE DMLSYJQ TN PI3-kinase delta (PIK3CD) DMLSYJQ MA Inhibitor DMLSYJQ RN The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. DMLSYJQ RU https://pubmed.ncbi.nlm.nih.gov/21558396 DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTEUNMR DMLSYJQ TN PI3-kinase alpha (PIK3CA) DMLSYJQ MA Inhibitor DMLSYJQ RN The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011 May 15;17(10):3272-81. DMLSYJQ RU https://pubmed.ncbi.nlm.nih.gov/21558396 DMLSYJQ DI DMLSYJQ DMLSYJQ DN PA-799 DMLSYJQ TI TTHBTOP DMLSYJQ TN PI3-kinase gamma (PIK3CG) DMLSYJQ MA Modulator DMLSYJQ RN Company report (Chugai-pharm) DMLSYJQ RU http://www.chugai-pharm.co.jp/html/meeting/pdf/140424ePresentation.pdf DMLV4U1 DI DMLV4U1 DMLV4U1 DN ZN-e4 DMLV4U1 TI TTGKNB4 DMLV4U1 TN Epidermal growth factor receptor (EGFR) DMLV4U1 MA Inhibitor DMLV4U1 RN Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals. DMLV4U1 RU https://zentalis.com/our-pipeline/pipeline/ DMM10J4 DI DMM10J4 DMM10J4 DN BMS-986288 DMM10J4 TI TTI2S1D DMM10J4 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMM10J4 MA Inhibitor DMM10J4 RN Clinical pipeline report, company report or official report of CytomX Therapeutics. DMM10J4 RU https://cytomx.com/pipeline/ DMM35D2 DI DMM35D2 DMM35D2 DN CD33-specific gene-engineered T cells DMM35D2 TI TTJVYO3 DMM35D2 TN Myeloid cell surface antigen CD33 (CD33) DMM35D2 MA CAR-T-Cell-Therapy DMM35D2 RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMM35D2 RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMM8J5W DI DMM8J5W DMM8J5W DN 4SCAR-PSMA DMM8J5W TI TT9G4N0 DMM8J5W TN Glutamate carboxypeptidase II (GCPII) DMM8J5W MA CAR-T-Cell-Therapy DMM8J5W RN ClinicalTrials.gov (NCT03185468) Intervention of Bladder Cancer by CAR-T DMM8J5W RU https://clinicaltrials.gov/ct2/show/NCT03185468 DMM9L1R DI DMM9L1R DMM9L1R DN PEP-223/CoVaccine HT DMM9L1R TI TT8R70G DMM9L1R TN Gonadotropin-releasing hormone receptor (GNRHR) DMM9L1R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DMM9L1R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DMMAQJ7 DI DMMAQJ7 DMMAQJ7 DN CAR-T cells targeting Mesothelin DMMAQJ7 TI TT4RXME DMMAQJ7 TN Mesothelin (MSLN) DMMAQJ7 MA CAR-T-Cell-Therapy DMMAQJ7 RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMMAQJ7 RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMMAUOK DI DMMAUOK DMMAUOK DN PEN-221 DMMAUOK TI TTZ6T9E DMMAUOK TN Somatostatin receptor type 2 (SSTR2) DMMAUOK MA Modulator DMMAUOK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMAUOK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMB5CV DI DMMB5CV DMMB5CV DN Medusa IL-2 DMMB5CV TI TTF89GD DMMB5CV TN Interleukin-2 (IL2) DMMB5CV MA Modulator DMMB5CV RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMB5CV RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMD10S DI DMMD10S DMMD10S DN EMD 55900 DMMD10S TI TTGKNB4 DMMD10S TN Epidermal growth factor receptor (EGFR) DMMD10S RN Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611. DMMD10S RU https://pubmed.ncbi.nlm.nih.gov/11920518 DMMHLJQ DI DMMHLJQ DMMHLJQ DN CD19 CAR T cells DMMHLJQ TI TTW640A DMMHLJQ TN B-lymphocyte surface antigen B4 (CD19) DMMHLJQ MA CAR-T-Cell-Therapy DMMHLJQ RN ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies DMMHLJQ RU https://clinicaltrials.gov/ct2/show/NCT02772198 DMMNIBY DI DMMNIBY DMMNIBY DN Aflunov DMMNIBY TI TT3J5ZI DMMNIBY TN Cell mediated immunity response (CMIR) DMMNIBY RN Aflunov( ): a prepandemic influenza vaccine. Expert Rev Vaccines. 2012 Feb;11(2):145-57. DMMNIBY RU https://pubmed.ncbi.nlm.nih.gov/22309663 DMMOA2X DI DMMOA2X DMMOA2X DN Nikkomycin Z DMMOA2X TI TTBGVF1 DMMOA2X TN Candida Chitin synthase 3 (Candi CHS3) DMMOA2X MA Modulator DMMOA2X RN Inhibitory effect of nikkomycin Z on chitin synthases in Candida albicans. Yeast. 2002 Mar 15;19(4):341-9. DMMOA2X RU https://pubmed.ncbi.nlm.nih.gov/11870857 DMMQGPE DI DMMQGPE DMMQGPE DN Zenocutuzomab DMMQGPE TI TT6EO5L DMMQGPE TN Erbb2 tyrosine kinase receptor (HER2) DMMQGPE MA Inhibitor DMMQGPE RN Clinical pipeline report, company report or official report of Merus. DMMQGPE RU https://merus.nl/pipeline/ DMMQGPE DI DMMQGPE DMMQGPE DN Zenocutuzomab DMMQGPE TI TTDC8N2 DMMQGPE TN Erbb3 tyrosine kinase receptor (Erbb-3) DMMQGPE MA Inhibitor DMMQGPE RN Clinical pipeline report, company report or official report of Merus. DMMQGPE RU https://merus.nl/pipeline/ DMMQYL9 DI DMMQYL9 DMMQYL9 DN CC-223 DMMQYL9 TI TTCJG29 DMMQYL9 TN Serine/threonine-protein kinase mTOR (mTOR) DMMQYL9 MA Modulator DMMQYL9 RN CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther. 2015 Jun;14(6):1295-305. DMMQYL9 RU https://pubmed.ncbi.nlm.nih.gov/25855786 DMMTDK1 DI DMMTDK1 DMMTDK1 DN CART-HER-2 DMMTDK1 TI TT6EO5L DMMTDK1 TN Erbb2 tyrosine kinase receptor (HER2) DMMTDK1 MA CAR-T-Cell-Therapy DMMTDK1 RN ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors DMMTDK1 RU https://clinicaltrials.gov/ct2/show/NCT01935843 DMMUCH0 DI DMMUCH0 DMMUCH0 DN SHR2554 DMMUCH0 TI TT9MZCQ DMMUCH0 TN Enhancer of zeste homolog 2 (EZH2) DMMUCH0 MA Inhibitor DMMUCH0 RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMMUCH0 RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMMUSHR DI DMMUSHR DMMUSHR DN Anti-CD19/22-CAR vector-transduced T cells DMMUSHR TI TTM6QSK DMMUSHR TN B-cell receptor CD22 (CD22) DMMUSHR MA CAR-T-Cell-Therapy(Dual specific) DMMUSHR RN ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 DMMUSHR RU https://clinicaltrials.gov/ct2/show/NCT03185494 DMMUSHR DI DMMUSHR DMMUSHR DN Anti-CD19/22-CAR vector-transduced T cells DMMUSHR TI TTW640A DMMUSHR TN B-lymphocyte surface antigen B4 (CD19) DMMUSHR MA CAR-T-Cell-Therapy(Dual specific) DMMUSHR RN ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 DMMUSHR RU https://clinicaltrials.gov/ct2/show/NCT03185494 DMMVWSY DI DMMVWSY DMMVWSY DN CK-101 DMMVWSY TI TTG96HZ DMMVWSY TN EGFR messenger RNA (EGFR mRNA) DMMVWSY MA Inhibitor DMMVWSY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMVWSY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMZSIB DI DMMZSIB DMMZSIB DN Interferon alpha 5 DMMZSIB TI TTLHGSF DMMZSIB TN Interferon-alpha 5 (IFNA5) DMMZSIB MA Modulator DMMZSIB RN Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20. DMMZSIB RU https://pubmed.ncbi.nlm.nih.gov/19319841 DMN0EMP DI DMN0EMP DMN0EMP DN Epicatechin DMN0EMP TI TT8NGED DMN0EMP TN Prostaglandin G/H synthase 1 (COX-1) DMN0EMP MA Inhibitor DMN0EMP RN Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82. DMN0EMP RU https://pubmed.ncbi.nlm.nih.gov/15568761 DMN0EMP DI DMN0EMP DMN0EMP DN Epicatechin DMN0EMP TI TTPZ7AG DMN0EMP TN Oxidoreductase unspecific (OR) DMN0EMP MA Modulator DMN0EMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMN0EMP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMN0EMP DI DMN0EMP DMN0EMP DN Epicatechin DMN0EMP TI TTSJH2W DMN0EMP TN Mitochondrial protein unspecific (MP) DMN0EMP MA Modulator DMN0EMP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMN0EMP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMN0ZQ5 DI DMN0ZQ5 DMN0ZQ5 DN OTSGC-A24 DMN0ZQ5 TI TT2Q6G1 DMN0ZQ5 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMN0ZQ5 RN J Clin Oncol 33, 2015 (suppl 3; abstr 65). DMN0ZQ5 RU http://meetinglibrary.asco.org/content/140443-158 DMN0ZQ5 DI DMN0ZQ5 DMN0ZQ5 DN OTSGC-A24 DMN0ZQ5 TI TTUTJGQ DMN0ZQ5 TN Vascular endothelial growth factor receptor 2 (KDR) DMN0ZQ5 RN J Clin Oncol 33, 2015 (suppl 3; abstr 65). DMN0ZQ5 RU http://meetinglibrary.asco.org/content/140443-158 DMN2FS3 DI DMN2FS3 DMN2FS3 DN EPZ-5676 DMN2FS3 TI TTSZ8T1 DMN2FS3 TN Histone-lysine N-methyltransferase (HLNM) DMN2FS3 MA Modulator DMN2FS3 RN Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood. 2013 August 8; 122(6): 1017-1025. DMN2FS3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739029/ DMN3C2I DI DMN3C2I DMN3C2I DN CAR-T cells targeting EphA2 DMN3C2I TI TTRJB2G DMN3C2I TN Ephrin type-A receptor 2 (EPHA2) DMN3C2I MA CAR-T-Cell-Therapy DMN3C2I RN ClinicalTrials.gov (NCT02575261) CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients DMN3C2I RU https://clinicaltrials.gov/ct2/show/NCT02575261 DMN62MP DI DMN62MP DMN62MP DN WASP gene therapy DMN62MP TI TTE8T73 DMN62MP TN Wiskott-Aldrich syndrome protein (WAS) DMN62MP MA Modulator DMN62MP RN ClinicalTrials.gov (NCT01347242) Gene Therapy for Wiskott-Aldrich Syndrome (WAS). U.S. National Institutes of Health. DMN62MP RU https://clinicaltrials.gov/ct2/show/NCT01347242 DMN7QBE DI DMN7QBE DMN7QBE DN GANTACURIUM CHLORIDE DMN7QBE TI TTJSZTB DMN7QBE TN Nicotinic acetylcholine receptor (nAChR) DMN7QBE MA Modulator DMN7QBE RN Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in guinea pigs. Anesthesiology. 2010 April; 112(4): 892-899. DMN7QBE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2854830/ DMNHE43 DI DMNHE43 DMNHE43 DN HTU-PA DMNHE43 TI TTGY7WI DMNHE43 TN Urokinase-type plasminogen activator (PLAU) DMNHE43 MA Activator DMNHE43 RN Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7. DMNHE43 RU https://pubmed.ncbi.nlm.nih.gov/2936742 DMNHZS4 DI DMNHZS4 DMNHZS4 DN IMX-110 DMNHZS4 TI TTH8FZW DMNHZS4 TN Signal transducer and activator of transcription 3 (STAT3) DMNHZS4 MA Inhibitor DMNHZS4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNHZS4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNKLZM DI DMNKLZM DMNKLZM DN TgAAG76 DMNKLZM TI TTBOH16 DMNKLZM TN Retinal pigment epithelium protein (RPE65) DMNKLZM MA Modulator DMNKLZM RN tgAAG76, an adeno-associated virus delivered gene therapy for the potential treatment of vision loss caused by RPE65 gene abnormalities. Curr Opin Mol Ther. 2010 Aug;12(4):471-7. DMNKLZM RU https://pubmed.ncbi.nlm.nih.gov/20677098 DMNMV0D DI DMNMV0D DMNMV0D DN JAB-3312 DMNMV0D TI TT7WUAV DMNMV0D TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMNMV0D MA Inhibitor DMNMV0D RN Clinical pipeline report, company report or official report of AbbVie. DMNMV0D RU https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html DMNTP23 DI DMNTP23 DMNTP23 DN Anti-CD19-CAR-T cells DMNTP23 TI TTW640A DMNTP23 TN B-lymphocyte surface antigen B4 (CD19) DMNTP23 MA CAR-T-Cell-Therapy DMNTP23 RN ClinicalTrials.gov (NCT02672501) A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia DMNTP23 RU https://clinicaltrials.gov/ct2/show/NCT02672501 DMNV8SY DI DMNV8SY DMNV8SY DN SNN-0029 DMNV8SY TI TTOHSBA DMNV8SY TN Vascular endothelial growth factor A (VEGFA) DMNV8SY MA Modulator DMNV8SY RN Clinical pipeline report, company report or official report of Neuronova. DMNV8SY RU http://www.neuronova.com/index.php?option=com_content&task=view&id=40&Itemid=71 DMNXLOT DI DMNXLOT DMNXLOT DN ALAMIFOVIR DMNXLOT TI TTMR83K DMNXLOT TN Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS) DMNXLOT MA Modulator DMNXLOT RN Noncompetitive Inhibition of Hepatitis B Virus Reverse Transcriptase Protein Priming and DNA Synthesis by the Nucleoside Analog Clevudine. Correction in: Antimicrob Agents Chemother. 2013 November; 57(11): 5788. DMNXLOT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754288/ DMNZ6VA DI DMNZ6VA DMNZ6VA DN Erythropoietin-transfected autologous cell therapy DMNZ6VA TI TTQG4NR DMNZ6VA TN Erythropoietin (EPO) DMNZ6VA MA Modulator DMNZ6VA RN Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipients. Mol Ther. 2009 Feb;17(2):369-72. DMNZ6VA RU https://pubmed.ncbi.nlm.nih.gov/19088705 DMNZ7F2 DI DMNZ7F2 DMNZ7F2 DN CD19.CAR-T cells DMNZ7F2 TI TTW640A DMNZ7F2 TN B-lymphocyte surface antigen B4 (CD19) DMNZ7F2 MA CAR-T-Cell-Therapy DMNZ7F2 RN ClinicalTrials.gov (NCT02652910) Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma DMNZ7F2 RU https://clinicaltrials.gov/ct2/show/NCT02652910 DMNZJAE DI DMNZJAE DMNZJAE DN AAV-CNGA3 DMNZJAE TI TTW0QOV DMNZJAE TN Cyclic nucleotide-gated channel alpha-3 (CNGA3) DMNZJAE RN Clinical pipeline report, company report or official report of MeiraGTx. DMNZJAE RU https://meiragtx.com/research-development/pipeline/ DMOCHVE DI DMOCHVE DMOCHVE DN SL-401 DMOCHVE TI TTPYS82 DMOCHVE TN Interleukin 3 receptor (CSF2RB) DMOCHVE MA Inhibitor DMOCHVE RN Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17;124(3):385-92. DMOCHVE RU https://pubmed.ncbi.nlm.nih.gov/24859366 DMODTX5 DI DMODTX5 DMODTX5 DN BDTX-189 DMODTX5 TI TT6EO5L DMODTX5 TN Erbb2 tyrosine kinase receptor (HER2) DMODTX5 MA Inhibitor DMODTX5 RN Clinical pipeline report, company report or official report of Black Diamond Therapeutics. DMODTX5 RU https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/ DMODTX5 DI DMODTX5 DMODTX5 DN BDTX-189 DMODTX5 TI TTGKNB4 DMODTX5 TN Epidermal growth factor receptor (EGFR) DMODTX5 MA Inhibitor DMODTX5 RN Clinical pipeline report, company report or official report of Black Diamond Therapeutics. DMODTX5 RU https://www.blackdiamondtherapeutics.com/pipeline/bdtx-189/ DMOI5PB DI DMOI5PB DMOI5PB DN CARCIK-CD19 DMOI5PB TI TTW640A DMOI5PB TN B-lymphocyte surface antigen B4 (CD19) DMOI5PB MA CAR-T-Cell-Therapy DMOI5PB RN ClinicalTrials.gov (NCT03389035) Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT DMOI5PB RU https://clinicaltrials.gov/ct2/show/NCT03389035 DMOKVJD DI DMOKVJD DMOKVJD DN ODM-207 DMOKVJD TI TTE4BSY DMOKVJD TN Bromodomain and extraterminal domain protein (BET) DMOKVJD MA Inhibitor DMOKVJD RN First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours. Br J Cancer. 2020 Dec;123(12):1730-1736. DMOKVJD RU https://pubmed.ncbi.nlm.nih.gov/32989226 DMON4IL DI DMON4IL DMON4IL DN TG100-115 DMON4IL TI TTHBTOP DMON4IL TN PI3-kinase gamma (PIK3CG) DMON4IL MA Inhibitor DMON4IL RN Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic can... J Pharmacol Exp Ther. 2009 Mar;328(3):758-65. DMON4IL RU https://pubmed.ncbi.nlm.nih.gov/19056934 DMOPVET DI DMOPVET DMOPVET DN ADXS-PSA DMOPVET TI TTS78AZ DMOPVET TN Prostate specific antigen (KLK3) DMOPVET MA Modulator DMOPVET RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DMOPVET RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DMOPVIQ DI DMOPVIQ DMOPVIQ DN AVX701 DMOPVIQ TI TTY6DTE DMOPVIQ TN Carcinoembryonic antigen CEA (CD66e) DMOPVIQ MA Modulator DMOPVIQ RN Viral vector-based therapeutic cancer vaccines. Cancer J. 2011 Sep-Oct;17(5):359-71. DMOPVIQ RU https://pubmed.ncbi.nlm.nih.gov/21952287 DMOUW65 DI DMOUW65 DMOUW65 DN PRX-102 DMOUW65 TI TTIS03D DMOUW65 TN Alpha-galactosidase A (GLA) DMOUW65 MA Modulator DMOUW65 RN Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67. DMOUW65 RU https://pubmed.ncbi.nlm.nih.gov/25155442 DMOVF6E DI DMOVF6E DMOVF6E DN Humanized CD19 CAR-T cells DMOVF6E TI TTW640A DMOVF6E TN B-lymphocyte surface antigen B4 (CD19) DMOVF6E MA CAR-T-Cell-Therapy DMOVF6E RN ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia DMOVF6E RU https://clinicaltrials.gov/ct2/show/NCT03275493 DMOYS1N DI DMOYS1N DMOYS1N DN NT219 DMOYS1N TI TTADRX7 DMOYS1N TN Insulin receptor substrate-1 (IRS1) DMOYS1N MA Inhibitor DMOYS1N RN Clinical pipeline report, company report or official report of Purple Biotech. DMOYS1N RU https://purple-biotech.com/pipeline/#1NT-219 DMOYS1N DI DMOYS1N DMOYS1N DN NT219 DMOYS1N TI TTH8FZW DMOYS1N TN Signal transducer and activator of transcription 3 (STAT3) DMOYS1N MA Inhibitor DMOYS1N RN Clinical pipeline report, company report or official report of Purple Biotech. DMOYS1N RU https://purple-biotech.com/pipeline/#1NT-219 DMOYS1N DI DMOYS1N DMOYS1N DN NT219 DMOYS1N TI TTF95B8 DMOYS1N TN Insulin receptor substrate 2 (IRS2) DMOYS1N MA Inhibitor DMOYS1N RN Clinical pipeline report, company report or official report of Purple Biotech. DMOYS1N RU https://purple-biotech.com/pipeline/#1NT-219 DMPAZ3U DI DMPAZ3U DMPAZ3U DN AU105 DMPAZ3U TI TT6EO5L DMPAZ3U TN Erbb2 tyrosine kinase receptor (HER2) DMPAZ3U MA Immunomodulator DMPAZ3U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPAZ3U RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMPB9OD DI DMPB9OD DMPB9OD DN OBI-999 DMPB9OD TI TT4UXTG DMPB9OD TN Globohexaosylceramide (Globo H) DMPB9OD RN Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate. Mol Cancer Ther. 2021 Jun;20(6):1121-1132. DMPB9OD RU https://pubmed.ncbi.nlm.nih.gov/33722855 DMPFGL8 DI DMPFGL8 DMPFGL8 DN BAL-101553 DMPFGL8 TI TTYFKSZ DMPFGL8 TN Tubulin beta (TUBB) DMPFGL8 MA Inhibitor DMPFGL8 RN Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2015 Jun;62(6):1106-9. DMPFGL8 RU https://pubmed.ncbi.nlm.nih.gov/25407467 DMPFGL8 DI DMPFGL8 DMPFGL8 DN BAL-101553 DMPFGL8 TI TTML2WA DMPFGL8 TN Tubulin (TUB) DMPFGL8 MA Inhibitor DMPFGL8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPFGL8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPJLS4 DI DMPJLS4 DMPJLS4 DN CAD-1883 DMPJLS4 TI TTKU9YD DMPJLS4 TN Calcium-activated potassium channel KCa2 (KCNN) DMPJLS4 MA Activator DMPJLS4 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMPJLS4 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMPK35H DI DMPK35H DMPK35H DN CAR-T cells targeting mesothelin DMPK35H TI TT4RXME DMPK35H TN Mesothelin (MSLN) DMPK35H MA CAR-T-Cell-Therapy DMPK35H RN ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy DMPK35H RU https://clinicaltrials.gov/ct2/show/NCT02959151 DMPLBDF DI DMPLBDF DMPLBDF DN Omburtamab I-124 DMPLBDF TI TT6CQUM DMPLBDF TN B7 homolog 3 (CD276) DMPLBDF MA Inhibitor DMPLBDF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPLBDF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPMF6L DI DMPMF6L DMPMF6L DN Nepadutant DMPMF6L TI TTYO0A3 DMPMF6L TN Substance-K receptor (TACR2) DMPMF6L MA Antagonist DMPMF6L RN Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. DMPMF6L RU https://pubmed.ncbi.nlm.nih.gov/17979603 DMPNR0J DI DMPNR0J DMPNR0J DN Muc1-specific gene-engineered T cells DMPNR0J TI TTBHFYQ DMPNR0J TN Mucin-1 (MUC1) DMPNR0J MA CAR-T-Cell-Therapy DMPNR0J RN ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia DMPNR0J RU https://clinicaltrials.gov/ct2/show/NCT03222674 DMPS3I6 DI DMPS3I6 DMPS3I6 DN CD38 CAR T cells DMPS3I6 TI TTPURFN DMPS3I6 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMPS3I6 MA CAR-T-Cell-Therapy DMPS3I6 RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMPS3I6 RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMPWBM2 DI DMPWBM2 DMPWBM2 DN APG-2575 DMPWBM2 TI TTJGNVC DMPWBM2 TN Apoptosis regulator Bcl-2 (BCL-2) DMPWBM2 MA Inhibitor DMPWBM2 RN A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma. Oncol Res. 2020 Sep 1;28(4):331-344. DMPWBM2 RU https://pubmed.ncbi.nlm.nih.gov/32093809 DMPWHU6 DI DMPWHU6 DMPWHU6 DN V81444 DMPWHU6 TI TTM2AOE DMPWHU6 TN Adenosine A2a receptor (ADORA2A) DMPWHU6 MA Antagonist DMPWHU6 RN Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. CNS Drugs. 2014 May;28(5):455-74. DMPWHU6 RU https://pubmed.ncbi.nlm.nih.gov/24687255 DMPXOGD DI DMPXOGD DMPXOGD DN SAR-161271 DMPXOGD TI TTZOPHG DMPXOGD TN Insulin (INS) DMPXOGD MA Modulator DMPXOGD RN Clinical pipeline report, company report or official report of sanofi-aventis. DMPXOGD RU http://en.sanofi.com/img/content/study/TDU10987_summary.pdf DMPYW28 DI DMPYW28 DMPYW28 DN CG-806 DMPYW28 TI TTGM6VW DMPYW28 TN Tyrosine-protein kinase BTK (ATK) DMPYW28 MA Inhibitor DMPYW28 RN Clinical pipeline report, company report or official report of Aptose Biosciences. DMPYW28 RU https://www.aptose.com/product-pipeline/cg-806-for-b-cell DMPZE2G DI DMPZE2G DMPZE2G DN ZPL521 DMPZE2G TI TTT1JVS DMPZE2G TN Cytosolic phospholipase A2 (GIVA cPLA2) DMPZE2G MA Inhibitor DMPZE2G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPZE2G RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQ5EYJ DI DMQ5EYJ DMQ5EYJ DN ISA-P53-01 DMQ5EYJ TI TT7SBF5 DMQ5EYJ TN Cellular tumor antigen p53 (TP53) DMQ5EYJ RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMQ5EYJ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMQ8VUW DI DMQ8VUW DMQ8VUW DN FCN-437 DMQ8VUW TI TT0PG8F DMQ8VUW TN Cyclin-dependent kinase 4 (CDK4) DMQ8VUW MA Inhibitor DMQ8VUW RN Clinical pipeline report, company report or official report of Fochon Pharmaceuticals. DMQ8VUW RU http://fochon.com/what-we-do/fcn-411/ DMQ8VUW DI DMQ8VUW DMQ8VUW DN FCN-437 DMQ8VUW TI TTO0FDJ DMQ8VUW TN Cyclin-dependent kinase 6 (CDK6) DMQ8VUW MA Inhibitor DMQ8VUW RN Clinical pipeline report, company report or official report of Fochon Pharmaceuticals. DMQ8VUW RU http://fochon.com/what-we-do/fcn-411/ DMQB7SZ DI DMQB7SZ DMQB7SZ DN CD19 and CD22 CAR-T Cells DMQB7SZ TI TTM6QSK DMQB7SZ TN B-cell receptor CD22 (CD22) DMQB7SZ MA CAR-T-Cell-Therapy(Dual specific) DMQB7SZ RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMQB7SZ RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMQB7SZ DI DMQB7SZ DMQB7SZ DN CD19 and CD22 CAR-T Cells DMQB7SZ TI TTW640A DMQB7SZ TN B-lymphocyte surface antigen B4 (CD19) DMQB7SZ MA CAR-T-Cell-Therapy(Dual specific) DMQB7SZ RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMQB7SZ RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMQD6B9 DI DMQD6B9 DMQD6B9 DN Anti-HER2 CAR-T DMQD6B9 TI TT6EO5L DMQD6B9 TN Erbb2 tyrosine kinase receptor (HER2) DMQD6B9 MA CAR-T-Cell-Therapy DMQD6B9 RN ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer DMQD6B9 RU https://clinicaltrials.gov/ct2/show/NCT02713984 DMQE7TW DI DMQE7TW DMQE7TW DN CD19-CAR T cell DMQE7TW TI TTW640A DMQE7TW TN B-lymphocyte surface antigen B4 (CD19) DMQE7TW MA CAR-T-Cell-Therapy DMQE7TW RN ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL DMQE7TW RU https://clinicaltrials.gov/ct2/show/NCT03373071 DMQJ6YL DI DMQJ6YL DMQJ6YL DN CD19 CAR Gene Transduced T Lymphocytes DMQJ6YL TI TTW640A DMQJ6YL TN B-lymphocyte surface antigen B4 (CD19) DMQJ6YL MA CAR-T-Cell-Therapy DMQJ6YL RN ClinicalTrials.gov (NCT02134262) Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes DMQJ6YL RU https://clinicaltrials.gov/ct2/show/NCT02134262 DMQN9ME DI DMQN9ME DMQN9ME DN LGH-447 DMQN9ME TI TT69J2Z DMQN9ME TN Serine/threonine-protein kinase pim-2 (PIM2) DMQN9ME MA Modulator DMQN9ME RN Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers. Clin Cancer Res. 2014 Apr 1;20(7):1834-45. DMQN9ME RU https://pubmed.ncbi.nlm.nih.gov/24474669 DMQO5UF DI DMQO5UF DMQO5UF DN INCB62079 DMQO5UF TI TT5BR7T DMQO5UF TN Fibroblast growth factor receptor 4 (FGFR4) DMQO5UF MA Inhibitor DMQO5UF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQO5UF RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQOW0H DI DMQOW0H DMQOW0H DN PP-1420 DMQOW0H TI TTIB95A DMQOW0H TN Pancreatic hormone (PH) DMQOW0H MA Modulator DMQOW0H RN Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. Br J Clin Pharmacol. 2012 Feb;73(2):232-9. DMQOW0H RU https://pubmed.ncbi.nlm.nih.gov/21834938 DMQS5DY DI DMQS5DY DMQS5DY DN TRX-518 DMQS5DY TI TTG6LA7 DMQS5DY TN Activation-inducible TNFR family receptor (TNFRSF18) DMQS5DY RN Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5. DMQS5DY RU https://pubmed.ncbi.nlm.nih.gov/26153987 DMQSF5C DI DMQSF5C DMQSF5C DN FBT-A05 DMQSF5C TI TTUE541 DMQSF5C TN Leukocyte surface antigen Leu-16 (CD20) DMQSF5C RN Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial. J Transl Med. 2013 Jul 2;11:160. DMQSF5C RU https://pubmed.ncbi.nlm.nih.gov/23815981 DMQU4EI DI DMQU4EI DMQU4EI DN Galnobax DMQU4EI TI TTR6W5O DMQU4EI TN Adrenergic receptor beta-1 (ADRB1) DMQU4EI MA Agonist DMQU4EI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQU4EI RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMQWI7V DI DMQWI7V DMQWI7V DN Hematopoietic stem cell gene therapy DMQWI7V TI TTE8T73 DMQWI7V TN Wiskott-Aldrich syndrome protein (WAS) DMQWI7V MA Modulator DMQWI7V RN Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr Opin Mol Ther. 2006 Oct;8(5):390-5. DMQWI7V RU https://pubmed.ncbi.nlm.nih.gov/17078381 DMQXU4C DI DMQXU4C DMQXU4C DN Anti-CD19-CAR vector-transduced T cells DMQXU4C TI TTW640A DMQXU4C TN B-lymphocyte surface antigen B4 (CD19) DMQXU4C MA CAR-T-Cell-Therapy DMQXU4C RN ClinicalTrials.gov (NCT02081937) CART-19 Immunotherapy in Mantle Cell Lymphoma DMQXU4C RU https://clinicaltrials.gov/ct2/show/NCT02081937 DMQZJ3B DI DMQZJ3B DMQZJ3B DN Anti-HIV ribozyme therapy DMQZJ3B TI TTT3ZC9 DMQZJ3B TN Human immunodeficiency virus Tat protein (HIV tat) DMQZJ3B MA Modulator DMQZJ3B RN Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Methods Mol Biol. 2004;252:581-98. DMQZJ3B RU https://pubmed.ncbi.nlm.nih.gov/15017082 DMR3VCY DI DMR3VCY DMR3VCY DN MP0250 DMR3VCY TI TTOHSBA DMR3VCY TN Vascular endothelial growth factor A (VEGFA) DMR3VCY MA Inhibitor DMR3VCY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR3VCY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR3VCY DI DMR3VCY DMR3VCY DN MP0250 DMR3VCY TI TT4V2JM DMR3VCY TN Hepatocyte growth factor (HGF) DMR3VCY MA Inhibitor DMR3VCY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR3VCY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR65X7 DI DMR65X7 DMR65X7 DN TC-110 DMR65X7 TI TTW640A DMR65X7 TN B-lymphocyte surface antigen B4 (CD19) DMR65X7 RN Clinical pipeline report, company report or official report of TCR2 Therapeutics. DMR65X7 RU https://www.tcr2.com/hematological-malignancies#tc110 DMR8AHJ DI DMR8AHJ DMR8AHJ DN MOR-202 DMR8AHJ TI TTPURFN DMR8AHJ TN Cyclic ADP-ribose hydrolase 1 (CD38) DMR8AHJ RN Clinical pipeline report, company report or official report of MorphoSys. DMR8AHJ RU https://www.morphosys.com/pipeline/proprietary-product-portfolio/mor202 DMR8EPF DI DMR8EPF DMR8EPF DN BIIB-087 DMR8EPF TI TTT2CZY DMR8EPF TN Retinoschisin (RS1) DMR8EPF RN ClinicalTrials.gov (NCT02416622) Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS). U.S. National Institutes of Health. DMR8EPF RU https://clinicaltrials.gov/ct2/show/NCT02416622 DMR9H6B DI DMR9H6B DMR9H6B DN AMXI 5001 DMR9H6B TI TTVDSZ0 DMR9H6B TN Poly [ADP-ribose] polymerase 1 (PARP1) DMR9H6B MA Inhibitor DMR9H6B RN AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. DMR9H6B RU https://pubmed.ncbi.nlm.nih.gov/32905466 DMR9H6B DI DMR9H6B DMR9H6B DN AMXI 5001 DMR9H6B TI TTQ4V96 DMR9H6B TN Poly [ADP-ribose] polymerase 2 (PARP2) DMR9H6B MA Inhibitor DMR9H6B RN AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. DMR9H6B RU https://pubmed.ncbi.nlm.nih.gov/32905466 DMR9H6B DI DMR9H6B DMR9H6B DN AMXI 5001 DMR9H6B TI TTU1SOM DMR9H6B TN Microtubule polymerization (MicroTu poly) DMR9H6B MA Inhibitor DMR9H6B RN AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020 Aug 1;10(8):2649-2676. DMR9H6B RU https://pubmed.ncbi.nlm.nih.gov/32905466 DMRABOS DI DMRABOS DMRABOS DN WX-554 DMRABOS TI TTROQ37 DMRABOS TN MAPK/ERK kinase kinase (MAP3K) DMRABOS MA Modulator DMRABOS RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DMRABOS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DMRC7PI DI DMRC7PI DMRC7PI DN SGN-CD33A DMRC7PI TI TTJVYO3 DMRC7PI TN Myeloid cell surface antigen CD33 (CD33) DMRC7PI RN SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63. DMRC7PI RU https://pubmed.ncbi.nlm.nih.gov/23770776 DMRE0LU DI DMRE0LU DMRE0LU DN REGN5459 DMRE0LU TI TTUN7MC DMRE0LU TN T-cell surface glycoprotein CD3 (CD3) DMRE0LU MA Inhibitor DMRE0LU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DMRE0LU RU https://www.regeneron.com/science/pipeline DMRE0LU DI DMRE0LU DMRE0LU DN REGN5459 DMRE0LU TI TTZ3P4W DMRE0LU TN B-cell maturation protein (TNFRSF17) DMRE0LU MA Inhibitor DMRE0LU RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DMRE0LU RU https://www.regeneron.com/science/pipeline DMREQCF DI DMREQCF DMREQCF DN CAR-T Cells targeting EpCAM DMREQCF TI TTZ8WH4 DMREQCF TN Tumor-associated calcium signal transducer 1 (EPCAM) DMREQCF MA CAR-T-Cell-Therapy DMREQCF RN ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer DMREQCF RU https://clinicaltrials.gov/ct2/show/NCT03013712 DMRET3H DI DMRET3H DMRET3H DN AG-013958 DMRET3H TI TTVJ1D8 DMRET3H TN Vascular endothelial growth factor receptor (VEGFR) DMRET3H MA Inhibitor DMRET3H RN Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933. DMRET3H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1995411/ DMRHOFB DI DMRHOFB DMRHOFB DN Ferritarg P DMRHOFB TI TT975ZT DMRHOFB TN Ferritin (FTH1) DMRHOFB RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019964) DMRHOFB RU http://adisinsight.springer.com/drugs/800019964 DMRJ3ND DI DMRJ3ND DMRJ3ND DN CD19 and CD20 CAR-T Cells DMRJ3ND TI TTUE541 DMRJ3ND TN Leukocyte surface antigen Leu-16 (CD20) DMRJ3ND MA CAR-T-Cell-Therapy(Dual specific) DMRJ3ND RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMRJ3ND RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMRJ3ND DI DMRJ3ND DMRJ3ND DN CD19 and CD20 CAR-T Cells DMRJ3ND TI TTW640A DMRJ3ND TN B-lymphocyte surface antigen B4 (CD19) DMRJ3ND MA CAR-T-Cell-Therapy(Dual specific) DMRJ3ND RN ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma DMRJ3ND RU https://clinicaltrials.gov/ct2/show/NCT03398967 DMRJK26 DI DMRJK26 DMRJK26 DN UCART019 DMRJK26 TI TTW640A DMRJK26 TN B-lymphocyte surface antigen B4 (CD19) DMRJK26 MA CAR-T-Cell-Therapy DMRJK26 RN ClinicalTrials.gov (NCT03166878) A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma DMRJK26 RU https://clinicaltrials.gov/ct2/show/NCT03166878 DMRLV7G DI DMRLV7G DMRLV7G DN INCB59872 DMRLV7G TI TTNR0UQ DMRLV7G TN Lysine-specific histone demethylase 1 (LSD) DMRLV7G MA Inhibitor DMRLV7G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRLV7G RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRS58M DI DMRS58M DMRS58M DN Avrina DMRS58M TI TTSXVID DMRS58M TN Nuclear factor NF-kappa-B (NFKB) DMRS58M MA Modulator DMRS58M RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRS58M RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRSI1O DI DMRSI1O DMRSI1O DN ChronVac-C hepatitis C DNA vaccine DMRSI1O TI TTZYW5V DMRSI1O TN Hepatitis C virus Deoxyribonucleic acid (HCV DNA) DMRSI1O RN Clinical pipeline report, company report or official report of Inovio Pharmaceuticals. DMRSI1O RU http://ir.inovio.com/news/news-releases/news-releases-details/2013/Inovio-Collaborator-ChronTech-Reports-Interim-Phase-II-Clinical-Study-Results-from-ChronVac-C-Vaccine-for-Hepatitis-C-Infection/default.aspx DMRXQCL DI DMRXQCL DMRXQCL DN DT388IL-3 DMRXQCL TI TTPYS82 DMRXQCL TN Interleukin 3 receptor (CSF2RB) DMRXQCL MA Inhibitor DMRXQCL RN Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunol Immunother. 2005 Aug;54(8):799-806. DMRXQCL RU https://pubmed.ncbi.nlm.nih.gov/15614527 DMS0L6J DI DMS0L6J DMS0L6J DN NY-ESO-TCR DMS0L6J TI TT7AKW1 DMS0L6J TN T-cell receptor (TCR) DMS0L6J MA CAR-T-Cell-Therapy DMS0L6J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS0L6J RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMS19IH DI DMS19IH DMS19IH DN MBO7133 DMS19IH TI TTUTN1I DMS19IH TN Human Deoxyribonucleic acid (hDNA) DMS19IH MA Binder DMS19IH RN Novel Cox-2 Inhibitor for Breast Cancer Therapy. Temple University School of Medicine Philadelphia, Pennsylvania 19140. July 2004. DMS19IH RU http://www.dtic.mil/get-tr-doc/pdf?AD=ADA431390 DMS1NMO DI DMS1NMO DMS1NMO DN SCRI-huCAR19v1 DMS1NMO TI TTW640A DMS1NMO TN B-lymphocyte surface antigen B4 (CD19) DMS1NMO MA CAR-T-Cell-Therapy DMS1NMO RN ClinicalTrials.gov (NCT03684889) CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma DMS1NMO RU https://clinicaltrials.gov/ct2/show/NCT03684889 DMS326R DI DMS326R DMS326R DN Anti-CD19 CAR T cells DMS326R TI TTW640A DMS326R TN B-lymphocyte surface antigen B4 (CD19) DMS326R MA CAR-T-Cell-Therapy DMS326R RN ClinicalTrials.gov (NCT02842138) Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma DMS326R RU https://clinicaltrials.gov/ct2/show/NCT02842138 DMS5OL0 DI DMS5OL0 DMS5OL0 DN CD56 CAR T cells DMS5OL0 TI TTVXPHT DMS5OL0 TN Neural cell adhesion molecule 1 (NCAM1) DMS5OL0 MA CAR-T-Cell-Therapy DMS5OL0 RN ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma DMS5OL0 RU https://clinicaltrials.gov/ct2/show/NCT03271632 DMSDZ8U DI DMSDZ8U DMSDZ8U DN Rintatolimod DMSDZ8U TI TT1CN09 DMSDZ8U TN HUMAN toll-like receptor 3 (TLR3) DMSDZ8U MA Agonist DMSDZ8U RN Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Expert Rev Clin Pharmacol. 2016 Jun;9(6):755-70. DMSDZ8U RU https://pubmed.ncbi.nlm.nih.gov/27045557 DMSFEOC DI DMSFEOC DMSFEOC DN Anti-CD19 CAR-T cells DMSFEOC TI TTW640A DMSFEOC TN B-lymphocyte surface antigen B4 (CD19) DMSFEOC MA CAR-T-Cell-Therapy DMSFEOC RN ClinicalTrials.gov (NCT02782351) Humanized CAR-T Therapy for Treatment of B Cell Malignancy DMSFEOC RU https://clinicaltrials.gov/ct2/show/NCT02782351 DMSGM2L DI DMSGM2L DMSGM2L DN PBCAR269A DMSGM2L TI TTZ3P4W DMSGM2L TN B-cell maturation protein (TNFRSF17) DMSGM2L RN Clinical pipeline report, company report or official report of Precision Biosciences. DMSGM2L RU https://precisionbiosciences.com/pipeline/ DMSJ54W DI DMSJ54W DMSJ54W DN PC14586 DMSJ54W TI TTJC50M DMSJ54W TN P53 Y220C mutant (TP53 Y220C) DMSJ54W MA Reactivator DMSJ54W RN Clinical pipeline report, company report or official report of PMV Pharmaceuticals. DMSJ54W RU https://www.pmvpharma.com/pipeline/ DMSOQ6E DI DMSOQ6E DMSOQ6E DN AT-342 DMSOQ6E TI TT34ZAF DMSOQ6E TN UDP-glucuronosyltransferase 1A1 (UGT1A1) DMSOQ6E MA Replacement DMSOQ6E RN ClinicalTrials.gov (NCT03223194) Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS). U.S. National Institutes of Health. DMSOQ6E RU https://clinicaltrials.gov/ct2/show/NCT03223194 DMSOX57 DI DMSOX57 DMSOX57 DN SJCAR19 DMSOX57 TI TTW640A DMSOX57 TN B-lymphocyte surface antigen B4 (CD19) DMSOX57 MA CAR-T-Cell-Therapy DMSOX57 RN ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia DMSOX57 RU https://clinicaltrials.gov/ct2/show/NCT03573700 DMST6A3 DI DMST6A3 DMST6A3 DN Sodium pyruvate DMST6A3 TI TTULV0X DMST6A3 TN Reactive oxygen species (ROS) DMST6A3 MA Antagonist DMST6A3 RN A molecular mechanism of pyruvate protection against cytotoxicity of reactive oxygen species in osteoblasts. Mol Pharmacol. 2006 Sep;70(3):925-35. DMST6A3 RU https://pubmed.ncbi.nlm.nih.gov/16766717 DMST6A3 DI DMST6A3 DMST6A3 DN Sodium pyruvate DMST6A3 TI TTZHA0O DMST6A3 TN Carbonic anhydrase IV (CA-IV) DMST6A3 MA Inhibitor DMST6A3 RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8. DMST6A3 RU https://pubmed.ncbi.nlm.nih.gov/15664815 DMSTEFK DI DMSTEFK DMSTEFK DN SKB264 DMSTEFK TI TTP2HE5 DMSTEFK TN Tumor associated calcium signal transducer 2 (TACSTD2) DMSTEFK RN ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health. DMSTEFK RU https://clinicaltrials.gov/ct2/show/NCT04152499 DMT17XU DI DMT17XU DMT17XU DN 131I-radretumab DMT17XU TI TTBVIQC DMT17XU TN Integrin beta-1 (ITGB1) DMT17XU RN Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43. DMT17XU RU https://pubmed.ncbi.nlm.nih.gov/24777501 DMT2FAP DI DMT2FAP DMT2FAP DN AZD-2836 DMT2FAP TI TTCJ2X8 DMT2FAP TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMT2FAP MA Modulator DMT2FAP RN TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711. DMT2FAP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/ DMT89K2 DI DMT89K2 DMT89K2 DN CAR-T cells targeting GD2 DMT89K2 TI TT80ARU DMT89K2 TN Ganglioside GD2 (GD2) DMT89K2 MA CAR-T-Cell-Therapy DMT89K2 RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMT89K2 RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMTAODR DI DMTAODR DMTAODR DN NBE-002 DMTAODR TI TTDEJAU DMTAODR TN Neurotrophic tyrosine kinase ROR1 (ROR1) DMTAODR RN Clinical pipeline report, company report or official report of NBE-Therapeutics. DMTAODR RU https://www.nbe-therapeutics.com/technology/overview DMTCADJ DI DMTCADJ DMTCADJ DN McN3377 DMTCADJ TI TTHS256 DMTCADJ TN Metabotropic glutamate receptor 5 (mGluR5) DMTCADJ MA Modulator DMTCADJ RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMTCADJ RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMTEY1L DI DMTEY1L DMTEY1L DN BMS-986315 DMTEY1L TI TTC4IMS DMTEY1L TN NKG2-A/B-activating NK receptor (NKG2A) DMTEY1L MA Inhibitor DMTEY1L RN ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. DMTEY1L RU https://clinicaltrials.gov/ct2/show/NCT04349267 DMTH75R DI DMTH75R DMTH75R DN OXY-111A DMTH75R TI TTQO71U DMTH75R TN Hemoglobin (HB) DMTH75R MA Enhancer DMTH75R RN Modulating the oxygen affinity of human fetal haemoglobin with synthetic allosteric modulators. Br J Haematol. 1998 Sep;102(5):1165-71. DMTH75R RU https://pubmed.ncbi.nlm.nih.gov/9753039 DMTJQ8S DI DMTJQ8S DMTJQ8S DN GS-9219 DMTJQ8S TI TTIU7X1 DMTJQ8S TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMTJQ8S MA Inhibitor DMTJQ8S RN GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma. Clin Cancer Res. 2008 May 1;14(9):2824-32. DMTJQ8S RU https://pubmed.ncbi.nlm.nih.gov/18451250 DMTJWIQ DI DMTJWIQ DMTJWIQ DN LY2940680 DMTJWIQ TI TT8J1S3 DMTJWIQ TN Smoothened homolog (SMO) DMTJWIQ MA Modulator DMTJWIQ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTJWIQ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTMVEW DI DMTMVEW DMTMVEW DN JCAR014 DMTMVEW TI TTW640A DMTMVEW TN B-lymphocyte surface antigen B4 (CD19) DMTMVEW MA CAR-T-Cell-Therapy DMTMVEW RN ClinicalTrials.gov (NCT02706405) JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma DMTMVEW RU https://clinicaltrials.gov/ct2/show/NCT02706405 DMTO9VF DI DMTO9VF DMTO9VF DN Anti-CD22-CAR-transduced T cells DMTO9VF TI TTM6QSK DMTO9VF TN B-cell receptor CD22 (CD22) DMTO9VF MA CAR-T-Cell-Therapy DMTO9VF RN ClinicalTrials.gov (NCT03262298) Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies DMTO9VF RU https://clinicaltrials.gov/ct2/show/NCT03262298 DMTOMWB DI DMTOMWB DMTOMWB DN BI 1206 DMTOMWB TI TT5RWKQ DMTOMWB TN Immunoglobulin gamma Fc receptor IIB (FCGR2B) DMTOMWB RN Clinical pipeline report, company report or official report of BioInvent. DMTOMWB RU https://www.bioinvent.com/pipeline/bi-1206-in-solid-tumors/ DMTQIB2 DI DMTQIB2 DMTQIB2 DN Anti-MUC1 CAR-T cells DMTQIB2 TI TTBHFYQ DMTQIB2 TN Mucin-1 (MUC1) DMTQIB2 MA CAR-T-Cell-Therapy DMTQIB2 RN ClinicalTrials.gov (NCT02617134) CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor DMTQIB2 RU https://clinicaltrials.gov/ct2/show/NCT02617134 DMTS51C DI DMTS51C DMTS51C DN AGTC-501 DMTS51C TI TTHBDA9 DMTS51C TN X-linked retinitis pigmentosa GTPase regulator (RPGR) DMTS51C RN ClinicalTrials.gov (NCT03316560) Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations. U.S. National Institutes of Health. DMTS51C RU https://clinicaltrials.gov/ct2/show/NCT03316560 DMTV42K DI DMTV42K DMTV42K DN G1 DMTV42K TI TTDSB34 DMTV42K TN G-protein coupled estrogen receptor 1 (GPER1) DMTV42K MA Agonist DMTV42K RN Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006 Apr;2(4):207-12. DMTV42K RU https://pubmed.ncbi.nlm.nih.gov/16520733 DMTV4L7 DI DMTV4L7 DMTV4L7 DN CHS-828 DMTV4L7 TI TTD1WIG DMTV4L7 TN Nicotinamide phosphoribosyltransferase (NAMPT) DMTV4L7 MA Inhibitor DMTV4L7 RN Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804. DMTV4L7 RU https://pubmed.ncbi.nlm.nih.gov/18201551 DMTVXBY DI DMTVXBY DMTVXBY DN Anti-CD38 CAR-T cells DMTVXBY TI TTPURFN DMTVXBY TN Cyclic ADP-ribose hydrolase 1 (CD38) DMTVXBY MA CAR-T-Cell-Therapy DMTVXBY RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMTVXBY RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMTY96S DI DMTY96S DMTY96S DN Eptacog beta DMTY96S TI TTLPJWH DMTY96S TN Thioredoxin reductase (PRDX5) DMTY96S MA Inhibitor DMTY96S RN APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881. DMTY96S RU https://pubmed.ncbi.nlm.nih.gov/24157875 DMTZSPJ DI DMTZSPJ DMTZSPJ DN Anti-CD30-CAR-transduced T cells DMTZSPJ TI TT2GM5R DMTZSPJ TN Lymphocyte activation antigen CD30 (TNFRSF8) DMTZSPJ MA CAR-T-Cell-Therapy DMTZSPJ RN ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies DMTZSPJ RU https://clinicaltrials.gov/ct2/show/NCT02958410 DMU348C DI DMU348C DMU348C DN CD19 CART DMU348C TI TTW640A DMU348C TN B-lymphocyte surface antigen B4 (CD19) DMU348C MA CAR-T-Cell-Therapy DMU348C RN ClinicalTrials.gov (NCT03146533) CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma. DMU348C RU https://clinicaltrials.gov/ct2/show/NCT03146533 DMU3PD7 DI DMU3PD7 DMU3PD7 DN RGX-121 DMU3PD7 TI TTNY2AP DMU3PD7 TN Iduronate 2-sulfatase (IDS) DMU3PD7 MA Replacement DMU3PD7 RN Clinical pipeline report, company report or official report of REGENXBIO. DMU3PD7 RU https://www.regenxbio.com/rgx-121/ DMU6MJ1 DI DMU6MJ1 DMU6MJ1 DN NAHE-001 DMU6MJ1 TI TTLHGSF DMU6MJ1 TN Interferon-alpha 5 (IFNA5) DMU6MJ1 MA Modulator DMU6MJ1 RN Interferons and viral infections. Biofactors. 2009 Jan-Feb;35(1):14-20. DMU6MJ1 RU https://pubmed.ncbi.nlm.nih.gov/19319841 DMU6TG7 DI DMU6TG7 DMU6TG7 DN XMT-1592 DMU6TG7 TI TTQPZTM DMU6TG7 TN Sodium/phosphate cotransporter 2B (SLC34A2) DMU6TG7 RN Clinical pipeline report, company report or official report of Mersana Therapeutics. DMU6TG7 RU https://www.mersana.com/pipeline/xmt-1592/ DMU9BCD DI DMU9BCD DMU9BCD DN NS-018 DMU9BCD TI TTRMX3V DMU9BCD TN Janus kinase 2 (JAK-2) DMU9BCD MA Modulator DMU9BCD RN Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4:e174. DMU9BCD RU https://pubmed.ncbi.nlm.nih.gov/24413068 DMUARWH DI DMUARWH DMUARWH DN CD19 CAR T Cells DMUARWH TI TTW640A DMUARWH TN B-lymphocyte surface antigen B4 (CD19) DMUARWH MA CAR-T-Cell-Therapy DMUARWH RN ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant DMUARWH RU https://clinicaltrials.gov/ct2/show/NCT01475058 DMUBEX4 DI DMUBEX4 DMUBEX4 DN CAR-T cells targeting MAGE-A4 DMUBEX4 TI TT9EQUY DMUBEX4 TN Melanoma-associated antigen 4 (MAGEA4) DMUBEX4 MA CAR-T-Cell-Therapy DMUBEX4 RN ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer DMUBEX4 RU https://clinicaltrials.gov/ct2/show/NCT03356808 DMUBLC3 DI DMUBLC3 DMUBLC3 DN ABO-101 DMUBLC3 TI TTDM6HZ DMUBLC3 TN Alpha-N-acetylglucosaminidase (NAGLU) DMUBLC3 RN Clinical pipeline report, company report or official report of Abeona Therapeutics. DMUBLC3 RU https://www.abeonatherapeutics.com/science DMUGHWR DI DMUGHWR DMUGHWR DN WP-1066 DMUGHWR TI TTKAWRQ DMUGHWR TN JAK-STAT signaling pathway (JAK-STAT pathway) DMUGHWR MA Inhibitor DMUGHWR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7972). DMUGHWR RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7972 DMUGHWR DI DMUGHWR DMUGHWR DN WP-1066 DMUGHWR TI TTH8FZW DMUGHWR TN Signal transducer and activator of transcription 3 (STAT3) DMUGHWR MA Inhibitor DMUGHWR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUGHWR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMUGMFN DI DMUGMFN DMUGMFN DN CXB-909 DMUGMFN TI TTDN3LF DMUGMFN TN Nerve growth factor (NGF) DMUGMFN MA Modulator DMUGMFN RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUGMFN RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUNM4D DI DMUNM4D DMUNM4D DN ESR0114 DMUNM4D TI TTGV6LY DMUNM4D TN Nuclear receptor ROR-gamma (RORG) DMUNM4D MA Inhibitor DMUNM4D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUNM4D RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMUP52Y DI DMUP52Y DMUP52Y DN SB-FIX DMUP52Y TI TTFEZ5Q DMUP52Y TN Coagulation factor IX (F9) DMUP52Y MA Replacement DMUP52Y RN ClinicalTrials.gov (NCT02695160) Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B. U.S. National Institutes of Health. DMUP52Y RU https://clinicaltrials.gov/ct2/show/NCT02695160 DMUS79V DI DMUS79V DMUS79V DN CART-138 cells DMUS79V TI TTYDSVG DMUS79V TN Syndecan-1 (SDC1) DMUS79V MA CAR-T-Cell-Therapy DMUS79V RN ClinicalTrials.gov (NCT01886976) Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138 DMUS79V RU https://clinicaltrials.gov/ct2/show/NCT01886976 DMUYFS1 DI DMUYFS1 DMUYFS1 DN 4SCAR19 and 4SCAR30 DMUYFS1 TI TT2GM5R DMUYFS1 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMUYFS1 MA CAR-T-Cell-Therapy(Dual specific) DMUYFS1 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMUYFS1 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMUYFS1 DI DMUYFS1 DMUYFS1 DN 4SCAR19 and 4SCAR30 DMUYFS1 TI TTW640A DMUYFS1 TN B-lymphocyte surface antigen B4 (CD19) DMUYFS1 MA CAR-T-Cell-Therapy(Dual specific) DMUYFS1 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMUYFS1 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMUZIRY DI DMUZIRY DMUZIRY DN Cal-1 DMUZIRY TI TT2CEJG DMUZIRY TN C-C chemokine receptor type 5 (CCR5) DMUZIRY MA Modulator DMUZIRY RN Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor. Mol Ther Methods Clin Dev. 2014 Feb 12;1:11. DMUZIRY RU https://pubmed.ncbi.nlm.nih.gov/26015947 DMV1EA9 DI DMV1EA9 DMV1EA9 DN BIL010t DMV1EA9 TI TT473XN DMV1EA9 TN P2X purinoceptor 7 (P2RX7) DMV1EA9 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMV1EA9 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMV1SDA DI DMV1SDA DMV1SDA DN HM43239 DMV1SDA TI TTOU65C DMV1SDA TN Tyrosine-protein kinase SYK (SYK) DMV1SDA MA Inhibitor DMV1SDA RN Clinical pipeline report, company report or official report of Hanmi Pharmaceutical. DMV1SDA RU https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD DMV1SDA DI DMV1SDA DMV1SDA DN HM43239 DMV1SDA TI TTGJCWZ DMV1SDA TN Fms-like tyrosine kinase 3 (FLT-3) DMV1SDA MA Inhibitor DMV1SDA RN Clinical pipeline report, company report or official report of Hanmi Pharmaceutical. DMV1SDA RU https://www.hanmipharm.com/ehanmi/handler/Rnd-FocusedPipelineD DMV5H0S DI DMV5H0S DMV5H0S DN Anti-C-met CAR-T cells DMV5H0S TI TTNDSF4 DMV5H0S TN Proto-oncogene c-Met (MET) DMV5H0S MA CAR-T-Cell-Therapy DMV5H0S RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMV5H0S RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMV6GX7 DI DMV6GX7 DMV6GX7 DN ONO-7475 DMV6GX7 TI TTO7LKR DMV6GX7 TN Tyrosine-protein kinase Mer (MERTK) DMV6GX7 MA Inhibitor DMV6GX7 RN Clinical pipeline report, company report or official report of Ono Pharmaceutical. DMV6GX7 RU https://www.ono-pharma.com/ir/library/pipeline.html DMV6GX7 DI DMV6GX7 DMV6GX7 DN ONO-7475 DMV6GX7 TI TTZPY6J DMV6GX7 TN Tyrosine-protein kinase UFO (AXL) DMV6GX7 MA Inhibitor DMV6GX7 RN Clinical pipeline report, company report or official report of Ono Pharmaceutical. DMV6GX7 RU https://www.ono-pharma.com/ir/library/pipeline.html DMV7Q6X DI DMV7Q6X DMV7Q6X DN APN-201 DMV7Q6X TI TT6RVLG DMV7Q6X TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMV7Q6X MA Modulator DMV7Q6X RN Peyronie's disease: a critical appraisal of current diagnosis and treatment. Int J Impot Res. 2008 Sep-Oct;20(5):445-59. DMV7Q6X RU https://pubmed.ncbi.nlm.nih.gov/18650828 DMV9QGW DI DMV9QGW DMV9QGW DN BPX-601 DMV9QGW TI TT9T4AV DMV9QGW TN Prostate stem cell antigen (PSCA) DMV9QGW MA CAR-T-Cell-Therapy DMV9QGW RN ClinicalTrials.gov (NCT02744287) Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors DMV9QGW RU https://clinicaltrials.gov/ct2/show/NCT02744287 DMVFHL9 DI DMVFHL9 DMVFHL9 DN CAR-T cells targeting CD22 DMVFHL9 TI TTM6QSK DMVFHL9 TN B-cell receptor CD22 (CD22) DMVFHL9 MA CAR-T-Cell-Therapy DMVFHL9 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMVFHL9 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMVG4OC DI DMVG4OC DMVG4OC DN ZN-c5 DMVG4OC TI TTZAYWL DMVG4OC TN Estrogen receptor (ESR) DMVG4OC MA Degrader DMVG4OC RN Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals. DMVG4OC RU https://zentalis.com/our-pipeline/pipeline/ DMVKQT8 DI DMVKQT8 DMVKQT8 DN SALACINOL DMVKQT8 TI TTXWASR DMVKQT8 TN Intestinal maltase-glucoamylase (MGAM) DMVKQT8 MA Inhibitor DMVKQT8 RN Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8. DMVKQT8 RU https://pubmed.ncbi.nlm.nih.gov/20970346 DMVKQT8 DI DMVKQT8 DMVKQT8 DN SALACINOL DMVKQT8 TI TTLPC70 DMVKQT8 TN Lysosomal alpha-glucosidase (GAA) DMVKQT8 MA Inhibitor DMVKQT8 RN Alpha-glucosidase inhibitor from Kothala-himbutu (Salacia reticulata WIGHT). J Nat Prod. 2008 Jun;71(6):981-4. DMVKQT8 RU https://pubmed.ncbi.nlm.nih.gov/18547114 DMVNCSK DI DMVNCSK DMVNCSK DN ASC-101 DMVNCSK TI TT3C1VN DMVNCSK TN Enzyme unspecific (Enz) DMVNCSK MA Modulator DMVNCSK RN ClinicalTrials.gov (NCT01983761) Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation. U.S. National Institutes of Health. DMVNCSK RU https://clinicaltrials.gov/ct2/show/NCT01983761 DMVW1GY DI DMVW1GY DMVW1GY DN CART-19/BCMA DMVW1GY TI TTZ3P4W DMVW1GY TN B-cell maturation protein (TNFRSF17) DMVW1GY MA CAR-T-Cell-Therapy(Dual specific) DMVW1GY RN ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT DMVW1GY RU https://clinicaltrials.gov/ct2/show/NCT03455972 DMVW1GY DI DMVW1GY DMVW1GY DN CART-19/BCMA DMVW1GY TI TTW640A DMVW1GY TN B-lymphocyte surface antigen B4 (CD19) DMVW1GY MA CAR-T-Cell-Therapy(Dual specific) DMVW1GY RN ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT DMVW1GY RU https://clinicaltrials.gov/ct2/show/NCT03455972 DMVYTG7 DI DMVYTG7 DMVYTG7 DN BGB-283 DMVYTG7 TI TTWCGQT DMVYTG7 TN Serine/threonine-protein kinase B-raf (BRAF) DMVYTG7 MA Inhibitor DMVYTG7 RN BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97. DMVYTG7 RU https://pubmed.ncbi.nlm.nih.gov/26208524 DMVZ9XL DI DMVZ9XL DMVZ9XL DN 177Lu-labelled DOTA-JR11 DMVZ9XL TI TTOMNR9 DMVZ9XL TN Somatostatin receptor (SSTR) DMVZ9XL RN Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398. DMVZ9XL RU https://pubmed.ncbi.nlm.nih.gov/32859703 DMVZXIA DI DMVZXIA DMVZXIA DN ASTX029 DMVZXIA TI TT1MG9E DMVZXIA TN Extracellular signal-regulated kinase 1 (ERK1) DMVZXIA MA Inhibitor DMVZXIA RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DMVZXIA RU https://astx.com/research-development/clinical-pipeline/ DMVZXIA DI DMVZXIA DMVZXIA DN ASTX029 DMVZXIA TI TT4TQBX DMVZXIA TN Extracellular signal-regulated kinase 2 (ERK2) DMVZXIA MA Inhibitor DMVZXIA RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DMVZXIA RU https://astx.com/research-development/clinical-pipeline/ DMW340V DI DMW340V DMW340V DN CAR-T cells targeting PSMA DMW340V TI TT9G4N0 DMW340V TN Glutamate carboxypeptidase II (GCPII) DMW340V MA CAR-T-Cell-Therapy DMW340V RN ClinicalTrials.gov (NCT03356795) Intervention of CAR-T Against Cervical Cancer DMW340V RU https://clinicaltrials.gov/ct2/show/NCT03356795 DMWCJ1F DI DMWCJ1F DMWCJ1F DN OT-58 DMWCJ1F TI TTVZJ7G DMWCJ1F TN Cystathionine beta-synthase (CBS) DMWCJ1F MA Replacement DMWCJ1F RN Classical homocystinuria: From cystathionine beta-synthase deficiency to novel enzyme therapies. Biochimie. 2020 Jun;173:48-56. DMWCJ1F RU https://pubmed.ncbi.nlm.nih.gov/31857119 DMWE205 DI DMWE205 DMWE205 DN DCR-MYC DMWE205 TI TTVW4XU DMWE205 TN MYCBP messenger RNA (MYCBP mRNA) DMWE205 RN National Cancer Institute Drug Dictionary (drug id 759983). DMWE205 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=759983 DMWEJ0C DI DMWEJ0C DMWEJ0C DN FGF401 DMWEJ0C TI TT1KX2S DMWEJ0C TN FGFR4 messenger RNA (FGFR4 mRNA) DMWEJ0C MA Antagonist DMWEJ0C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWEJ0C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWIH59 DI DMWIH59 DMWIH59 DN T2c-003 DMWIH59 TI TTFBNVI DMWIH59 TN Aldose reductase (AKR1B1) DMWIH59 MA Modulator DMWIH59 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DMWIH59 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DMWLZI6 DI DMWLZI6 DMWLZI6 DN AZD0466 DMWLZI6 TI TTJGNVC DMWLZI6 TN Apoptosis regulator Bcl-2 (BCL-2) DMWLZI6 MA Inhibitor DMWLZI6 RN Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112. DMWLZI6 RU https://pubmed.ncbi.nlm.nih.gov/33495510 DMWLZI6 DI DMWLZI6 DMWLZI6 DN AZD0466 DMWLZI6 TI TTU1E82 DMWLZI6 TN Apoptosis regulator Bcl-xL (BCL-xL) DMWLZI6 MA Inhibitor DMWLZI6 RN Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112. DMWLZI6 RU https://pubmed.ncbi.nlm.nih.gov/33495510 DMWOYNT DI DMWOYNT DMWOYNT DN CART-BCMA cells DMWOYNT TI TTZ3P4W DMWOYNT TN B-cell maturation protein (TNFRSF17) DMWOYNT MA CAR-T-Cell-Therapy DMWOYNT RN ClinicalTrials.gov (NCT03196414) Study of CART-138/BCMA Therapy for R/R Multiple Myeloma DMWOYNT RU https://clinicaltrials.gov/ct2/show/NCT03196414 DMWPD7N DI DMWPD7N DMWPD7N DN 177Lu-labelled PSMA-R2 DMWPD7N TI TT9G4N0 DMWPD7N TN Glutamate carboxypeptidase II (GCPII) DMWPD7N RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DMWPD7N RU https://pubmed.ncbi.nlm.nih.gov/32728208 DMWSGZU DI DMWSGZU DMWSGZU DN Epithalon DMWSGZU TI TTUJFD0 DMWSGZU TN Telomerase reverse transcriptase (TERT) DMWSGZU MA Modulator DMWSGZU RN Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003 Jun;135(6):590-2. DMWSGZU RU https://pubmed.ncbi.nlm.nih.gov/12937682 DMWYT4K DI DMWYT4K DMWYT4K DN CART-19 cells DMWYT4K TI TTW640A DMWYT4K TN B-lymphocyte surface antigen B4 (CD19) DMWYT4K MA CAR-T-Cell-Therapy DMWYT4K RN ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL DMWYT4K RU https://clinicaltrials.gov/ct2/show/NCT03544021 DMWZOD7 DI DMWZOD7 DMWZOD7 DN CNVN-202 DMWZOD7 TI TTJ8O14 DMWZOD7 TN Tumor suppressor candidate 2 (TUSC2) DMWZOD7 MA Suppressor DMWZOD7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018766) DMWZOD7 RU http://adisinsight.springer.com/drugs/800018766 DMX0R1E DI DMX0R1E DMX0R1E DN CART-19/22 DMX0R1E TI TTM6QSK DMX0R1E TN B-cell receptor CD22 (CD22) DMX0R1E MA CAR-T-Cell-Therapy(Dual specific) DMX0R1E RN ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. DMX0R1E RU https://clinicaltrials.gov/ct2/show/NCT03614858 DMX0R1E DI DMX0R1E DMX0R1E DN CART-19/22 DMX0R1E TI TTW640A DMX0R1E TN B-lymphocyte surface antigen B4 (CD19) DMX0R1E MA CAR-T-Cell-Therapy(Dual specific) DMX0R1E RN ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. DMX0R1E RU https://clinicaltrials.gov/ct2/show/NCT03614858 DMX168L DI DMX168L DMX168L DN PLX2853 DMX168L TI TTRA6BO DMX168L TN Bromodomain-containing protein 4 (BRD4) DMX168L MA Inhibitor DMX168L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX168L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX3CNS DI DMX3CNS DMX3CNS DN Stargen DMX3CNS TI TTLB52K DMX3CNS TN ATP-binding cassette transporter A4 (ABCA4) DMX3CNS MA Modulator DMX3CNS RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMX3CNS RU http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-positive-dsmb-review-of-ongoing-retinostat-r-and-stargen-clinical-studies/ DMXF9DM DI DMXF9DM DMXF9DM DN OXB-102 DMXF9DM TI TTLSWP6 DMXF9DM TN GTP cyclohydrolase-I (GCH1) DMXF9DM RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMXF9DM RU https://www.oxb.com/pipeline DMXF9DM DI DMXF9DM DMXF9DM DN OXB-102 DMXF9DM TI TTN451K DMXF9DM TN Aromatic-L-amino-acid decarboxylase (DDC) DMXF9DM RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMXF9DM RU https://www.oxb.com/pipeline DMXF9DM DI DMXF9DM DMXF9DM DN OXB-102 DMXF9DM TI TTUHP71 DMXF9DM TN Tyrosine 3-monooxygenase (TH) DMXF9DM RN Clinical pipeline report, company report or official report of Oxford BioMedica. DMXF9DM RU https://www.oxb.com/pipeline DMXI03L DI DMXI03L DMXI03L DN Anti-mesothelin CAR transduced PBL DMXI03L TI TT4RXME DMXI03L TN Mesothelin (MSLN) DMXI03L MA CAR-T-Cell-Therapy DMXI03L RN ClinicalTrials.gov (NCT01583686) CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer DMXI03L RU https://clinicaltrials.gov/ct2/show/NCT01583686 DMXI8CD DI DMXI8CD DMXI8CD DN TRC-253 DMXI8CD TI TTKPW01 DMXI8CD TN Androgen receptor messenger RNA (AR mRNA) DMXI8CD MA Antagonist DMXI8CD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXI8CD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXJ683 DI DMXJ683 DMXJ683 DN KY1044 DMXJ683 TI TTE5VP6 DMXJ683 TN Inducible T-cell costimulator (ICOS) DMXJ683 MA Inhibitor DMXJ683 RN Clinical pipeline report, company report or official report of Kymab. DMXJ683 RU https://www.kymab.com/pipeline/ky1044/ DMXKDUL DI DMXKDUL DMXKDUL DN BGT226 DMXKDUL TI TTCJG29 DMXKDUL TN Serine/threonine-protein kinase mTOR (mTOR) DMXKDUL MA Modulator DMXKDUL RN Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8. DMXKDUL RU https://pubmed.ncbi.nlm.nih.gov/21959532 DMXKDUL DI DMXKDUL DMXKDUL DN BGT226 DMXKDUL TI TTHBTOP DMXKDUL TN PI3-kinase gamma (PIK3CG) DMXKDUL MA Modulator DMXKDUL RN Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. Anticancer Drugs. 2012 Jan;23(1):131-8. DMXKDUL RU https://pubmed.ncbi.nlm.nih.gov/21959532 DMXKOUC DI DMXKOUC DMXKOUC DN Neu-120 DMXKOUC TI TTRSMW9 DMXKOUC TN Glycogen synthase kinase-3 beta (GSK-3B) DMXKOUC MA Modulator DMXKOUC RN Company report (Neurim Pharmaceuticals) DMXKOUC RU http://www.neurim.com/products/ DMXKOUC DI DMXKOUC DMXKOUC DN Neu-120 DMXKOUC TI TTGP7BY DMXKOUC TN Monoamine oxidase type B (MAO-B) DMXKOUC MA Modulator DMXKOUC RN Company report (Neurim Pharmaceuticals) DMXKOUC RU http://www.neurim.com/products/ DMXLPYE DI DMXLPYE DMXLPYE DN ONO-7579 DMXLPYE TI TTTDVOJ DMXLPYE TN Tropomyosin-related kinase A (TrkA) DMXLPYE MA Inhibitor DMXLPYE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXLPYE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXMK30 DI DMXMK30 DMXMK30 DN Anti-CD20-CAR-transduced T cells DMXMK30 TI TTUE541 DMXMK30 TN Leukocyte surface antigen Leu-16 (CD20) DMXMK30 MA CAR-T-Cell-Therapy DMXMK30 RN ClinicalTrials.gov (NCT02710149) A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies DMXMK30 RU https://clinicaltrials.gov/ct2/show/NCT02710149 DMXNTR7 DI DMXNTR7 DMXNTR7 DN SOBI003 DMXNTR7 TI TTPJ2SH DMXNTR7 TN N-sulphoglucosamine sulphohydrolase (SGSH) DMXNTR7 MA Replacement DMXNTR7 RN Clinical pipeline report, company report or official report of Swedish Orphan Biovitrum. DMXNTR7 RU https://www.sobi.com/en/press-releases/fda-accepts-investigational-new-drug-application-and-grants-fast-track-status DMXSEHF DI DMXSEHF DMXSEHF DN Y-39983 DMXSEHF TI TTMQO60 DMXSEHF TN Rho-associated protein kinase (ROCK) DMXSEHF MA Modulator DMXSEHF RN Effects of Y-39983, a selective Rho-associated protein kinase inhibitor, on blood flow in optic nerve head in rabbits and axonal regeneration of retinal ganglion cells in rats.Curr Eye Res. 2011 Oct;36(10):964-70. DMXSEHF RU https://www.ncbi.nlm.nih.gov/pubmed/21950703 DMXU7P6 DI DMXU7P6 DMXU7P6 DN MB-CART20.1 DMXU7P6 TI TTUE541 DMXU7P6 TN Leukocyte surface antigen Leu-16 (CD20) DMXU7P6 MA CAR-T-Cell-Therapy DMXU7P6 RN ClinicalTrials.gov (NCT03664635) MB-CART20.1 Lymphoma DMXU7P6 RU https://clinicaltrials.gov/ct2/show/NCT03664635 DMXU98C DI DMXU98C DMXU98C DN AO-176 DMXU98C TI TT28S46 DMXU98C TN Leukocyte surface antigen CD47 (CD47) DMXU98C MA Inhibitor DMXU98C RN Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. Mol Cancer Ther. 2020 Mar;19(3):835-846. DMXU98C RU https://pubmed.ncbi.nlm.nih.gov/31879362 DMXV6YP DI DMXV6YP DMXV6YP DN Fus-1 tumor suppressor gene therapy DMXV6YP TI TTJ8O14 DMXV6YP TN Tumor suppressor candidate 2 (TUSC2) DMXV6YP MA Suppressor DMXV6YP RN INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87. DMXV6YP RU https://pubmed.ncbi.nlm.nih.gov/17472413 DMXVIQN DI DMXVIQN DMXVIQN DN MOR-103 DMXVIQN TI TT6MP2Z DMXVIQN TN GMCSFR-alpha (CSF2RA) DMXVIQN RN MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. 2015 Jun;74(6):1058-64. DMXVIQN RU https://pubmed.ncbi.nlm.nih.gov/24534756 DMXVRI0 DI DMXVRI0 DMXVRI0 DN Beclanorsen DMXVRI0 TI TTFOUV4 DMXVRI0 TN BCL-2 messenger RNA (BCL2 mRNA) DMXVRI0 RN Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8. DMXVRI0 RU https://pubmed.ncbi.nlm.nih.gov/25589916 DMXYHC7 DI DMXYHC7 DMXYHC7 DN RU-101 DMXYHC7 TI TTFNGC9 DMXYHC7 TN Serum albumin (ALB) DMXYHC7 MA Modulator DMXYHC7 RN Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol. 2003 October; 87(10): 1279-1283. DMXYHC7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920766/ DMXYOTP DI DMXYOTP DMXYOTP DN Anti-MUC1 CAR-T cells DMXYOTP TI TTBHFYQ DMXYOTP TN Mucin-1 (MUC1) DMXYOTP MA CAR-T-Cell-Therapy DMXYOTP RN ClinicalTrials.gov (NCT03706326) CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer DMXYOTP RU https://clinicaltrials.gov/ct2/show/NCT03706326 DMY1CP9 DI DMY1CP9 DMY1CP9 DN GLG-801 DMY1CP9 TI TTH8FZW DMY1CP9 TN Signal transducer and activator of transcription 3 (STAT3) DMY1CP9 MA Inhibitor DMY1CP9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY1CP9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY3TAD DI DMY3TAD DMY3TAD DN Recombinant factor VIIa PEGylated liposomal DMY3TAD TI TTF0EGX DMY3TAD TN Coagulation factor VII (F7) DMY3TAD MA Modulator DMY3TAD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMY3TAD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMY6U8R DI DMY6U8R DMY6U8R DN Anti-CD22 CAR-T cells DMY6U8R TI TTM6QSK DMY6U8R TN B-cell receptor CD22 (CD22) DMY6U8R MA CAR-T-Cell-Therapy DMY6U8R RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMY6U8R RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMY8NUF DI DMY8NUF DMY8NUF DN CEP-9722 DMY8NUF TI TTEBCY8 DMY8NUF TN Poly [ADP-ribose] polymerase (PARP) DMY8NUF MA Modulator DMY8NUF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMY8NUF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYBKMV DI DMYBKMV DMYBKMV DN BT5528 DMYBKMV TI TTRJB2G DMYBKMV TN Ephrin type-A receptor 2 (EPHA2) DMYBKMV RN MMAE Delivery Using the Bicycle Toxin Conjugate BT5528. Mol Cancer Ther. 2020 Jul;19(7):1385-1394. DMYBKMV RU https://pubmed.ncbi.nlm.nih.gov/32398269 DMYCID5 DI DMYCID5 DMYCID5 DN ARV-110 DMYCID5 TI TTS64P2 DMYCID5 TN Androgen receptor (AR) DMYCID5 MA Degrader DMYCID5 RN Clinical pipeline report, company report or official report of Arvinas. DMYCID5 RU https://www.arvinas.com/pipeline-programs/androgen-receptor DMYEAB1 DI DMYEAB1 DMYEAB1 DN PIPERINE DMYEAB1 TI TT3WG5C DMYEAB1 TN Monoamine oxidase type A (MAO-A) DMYEAB1 MA Inhibitor DMYEAB1 RN Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40. DMYEAB1 RU https://pubmed.ncbi.nlm.nih.gov/19969454 DMYEAB1 DI DMYEAB1 DMYEAB1 DN PIPERINE DMYEAB1 TI TTGP7BY DMYEAB1 TN Monoamine oxidase type B (MAO-B) DMYEAB1 MA Inhibitor DMYEAB1 RN Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40. DMYEAB1 RU https://pubmed.ncbi.nlm.nih.gov/19969454 DMYGK1D DI DMYGK1D DMYGK1D DN OTL-300 DMYGK1D TI TTM6HK1 DMYGK1D TN Hemoglobin subunit beta (HBB) DMYGK1D RN Clinical pipeline report, company report or official report of Orchard Therapeutics. DMYGK1D RU https://www.orchard-tx.com/approach/pipeline/ DMYGNDI DI DMYGNDI DMYGNDI DN LMP1-CAR-T cells DMYGNDI TI TT0BI4Q DMYGNDI TN Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) DMYGNDI MA CAR-T-Cell-Therapy DMYGNDI RN ClinicalTrials.gov (NCT02980315) A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application DMYGNDI RU https://clinicaltrials.gov/ct2/show/NCT02980315 DMYKZB3 DI DMYKZB3 DMYKZB3 DN Anti-DR5 cells DMYKZB3 TI TTW20TU DMYKZB3 TN TRAIL receptor 2 (TRAIL-R2) DMYKZB3 MA CAR-T-Cell-Therapy DMYKZB3 RN ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies DMYKZB3 RU https://clinicaltrials.gov/ct2/show/NCT03638206 DMYOMSC DI DMYOMSC DMYOMSC DN Aderbasib DMYOMSC TI TTOMWSY DMYOMSC TN Mammalian disintegrin-metalloprotease (ADAM10) DMYOMSC MA Modulator DMYOMSC RN Company report (Incyte) DMYOMSC RU http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDQwNjgzfENoaWxkSUQ9NDYyNTAzfFR5cGU9MQ==&t=1 DMYOMSC DI DMYOMSC DMYOMSC DN Aderbasib DMYOMSC TI TT6AZXG DMYOMSC TN TNF alpha converting enzyme (ADAM17) DMYOMSC MA Modulator DMYOMSC RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMYOMSC RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYPQT4 DI DMYPQT4 DMYPQT4 DN 4SCAR19 and 4SCAR123 DMYPQT4 TI TTENHJ0 DMYPQT4 TN Interleukin 3 receptor alpha (IL3RA) DMYPQT4 MA CAR-T-Cell-Therapy(Dual specific) DMYPQT4 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMYPQT4 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMYPQT4 DI DMYPQT4 DMYPQT4 DN 4SCAR19 and 4SCAR123 DMYPQT4 TI TTW640A DMYPQT4 TN B-lymphocyte surface antigen B4 (CD19) DMYPQT4 MA CAR-T-Cell-Therapy(Dual specific) DMYPQT4 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMYPQT4 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMYR8LF DI DMYR8LF DMYR8LF DN NKTR-262 DMYR8LF TI TTRJ1K4 DMYR8LF TN Toll-like receptor 7 (TLR7) DMYR8LF MA Agonist DMYR8LF RN Clinical pipeline report, company report or official report of Nektar Therapeutics. DMYR8LF RU https://www.nektar.com/pipeline/rd-pipeline/nktr-262 DMYR8LF DI DMYR8LF DMYR8LF DN NKTR-262 DMYR8LF TI TT8CWFK DMYR8LF TN Toll-like receptor 8 (TLR8) DMYR8LF MA Agonist DMYR8LF RN Clinical pipeline report, company report or official report of Nektar Therapeutics. DMYR8LF RU https://www.nektar.com/pipeline/rd-pipeline/nktr-262 DMZ18IO DI DMZ18IO DMZ18IO DN Anti-BCMA-CAR-transduced T cells DMZ18IO TI TTZ3P4W DMZ18IO TN B-cell maturation protein (TNFRSF17) DMZ18IO MA CAR-T-Cell-Therapy DMZ18IO RN ClinicalTrials.gov (NCT02954445) A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies DMZ18IO RU https://clinicaltrials.gov/ct2/show/NCT02954445 DMZ416B DI DMZ416B DMZ416B DN KD020 DMZ416B TI TTUS1RD DMZ416B TN Microsomal triglyceride transfer protein (MTTP) DMZ416B MA Modulator DMZ416B RN Clinical pipeline report, company report or official report of Kadmon Pharmaceuticals. DMZ416B RU http://kadmon.com/press/kadmon-corporation-presents-encouraging-nonclinical-data-on-tesevatinib-kd019-at-aacr-annual-meeting/ DMZ9VCF DI DMZ9VCF DMZ9VCF DN X-396 DMZ9VCF TI TTPMQSO DMZ9VCF TN ALK tyrosine kinase receptor (ALK) DMZ9VCF MA Inhibitor DMZ9VCF RN Clinical pipeline report, company report or official report of Xcovery. DMZ9VCF RU http://www.xcovery.com/our-science/alk-inhibitor/ DMZABYH DI DMZABYH DMZABYH DN GEN3013 DMZABYH TI TTUN7MC DMZABYH TN T-cell surface glycoprotein CD3 (CD3) DMZABYH RN DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625. DMZABYH RU https://pubmed.ncbi.nlm.nih.gov/31981978 DMZABYH DI DMZABYH DMZABYH DN GEN3013 DMZABYH TI TTUE541 DMZABYH TN Leukocyte surface antigen Leu-16 (CD20) DMZABYH RN DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625. DMZABYH RU https://pubmed.ncbi.nlm.nih.gov/31981978 DMZB6LO DI DMZB6LO DMZB6LO DN OPC-167832 DMZB6LO TI TTLOHU4 DMZB6LO TN Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) DMZB6LO MA Inhibitor DMZB6LO RN OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19. DMZB6LO RU https://pubmed.ncbi.nlm.nih.gov/32229496 DMZD7OA DI DMZD7OA DMZD7OA DN Quaratusugene ozeplasmid DMZD7OA TI TTJ8O14 DMZD7OA TN Tumor suppressor candidate 2 (TUSC2) DMZD7OA RN Clinical pipeline report, company report or official report of Genprex. DMZD7OA RU https://www.genprex.com/technology/reqorsa/ DMZEA9X DI DMZEA9X DMZEA9X DN BIW-8962 DMZEA9X TI TTGOFW6 DMZEA9X TN Ganglioside GM2 activator (GM2A) DMZEA9X RN Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 2011 Dec;102(12):2157-63. DMZEA9X RU https://pubmed.ncbi.nlm.nih.gov/21895875 DMZFIGQ DI DMZFIGQ DMZFIGQ DN TG02 DMZFIGQ TI TT7HF4W DMZFIGQ TN Cyclin-dependent kinase 2 (CDK2) DMZFIGQ MA Modulator DMZFIGQ RN Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42. DMZFIGQ RU https://pubmed.ncbi.nlm.nih.gov/22372550 DMZFIGQ DI DMZFIGQ DMZFIGQ DN TG02 DMZFIGQ TI TTMBO1Z DMZFIGQ TN Cyclin-dependent kinase (CDK) DMZFIGQ MA Inhibitor DMZFIGQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZFIGQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZFIGQ DI DMZFIGQ DMZFIGQ DN TG02 DMZFIGQ TI TTU8W4S DMZFIGQ TN Protein kinase (PK) DMZFIGQ MA Inhibitor DMZFIGQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZFIGQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZHJV8 DI DMZHJV8 DMZHJV8 DN CAR-T cells targeting CD30 DMZHJV8 TI TT2GM5R DMZHJV8 TN Lymphocyte activation antigen CD30 (TNFRSF8) DMZHJV8 MA CAR-T-Cell-Therapy DMZHJV8 RN ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMZHJV8 RU https://clinicaltrials.gov/ct2/show/NCT03312205 DMZK7IT DI DMZK7IT DMZK7IT DN BCT-100 DMZK7IT TI TTSANDR DMZK7IT TN Arginase (ARG) DMZK7IT MA Modulator DMZK7IT RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMZK7IT RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMZKFJO DI DMZKFJO DMZKFJO DN PAT-SC1 DMZKFJO TI TT5Z9WY DMZKFJO TN Complement decay-accelerating factor (CD55) DMZKFJO RN Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep. 2014 Mar;31(3):1059-66. DMZKFJO RU https://pubmed.ncbi.nlm.nih.gov/24452482 DMZKFU7 DI DMZKFU7 DMZKFU7 DN 4SCAR19 and 4SCAR38 DMZKFU7 TI TTW640A DMZKFU7 TN B-lymphocyte surface antigen B4 (CD19) DMZKFU7 MA CAR-T-Cell-Therapy(Dual specific) DMZKFU7 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMZKFU7 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMZKFU7 DI DMZKFU7 DMZKFU7 DN 4SCAR19 and 4SCAR38 DMZKFU7 TI TTPURFN DMZKFU7 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMZKFU7 MA CAR-T-Cell-Therapy(Dual specific) DMZKFU7 RN ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies DMZKFU7 RU https://clinicaltrials.gov/ct2/show/NCT03125577 DMZM6I2 DI DMZM6I2 DMZM6I2 DN Sym013 DMZM6I2 TI TT6EO5L DMZM6I2 TN Erbb2 tyrosine kinase receptor (HER2) DMZM6I2 MA Inhibitor DMZM6I2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM6I2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZM6I2 DI DMZM6I2 DMZM6I2 DN Sym013 DMZM6I2 TI TTGKNB4 DMZM6I2 TN Epidermal growth factor receptor (EGFR) DMZM6I2 MA Antagonist DMZM6I2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM6I2 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZM6I2 DI DMZM6I2 DMZM6I2 DN Sym013 DMZM6I2 TI TTDC8N2 DMZM6I2 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMZM6I2 MA Inhibitor DMZM6I2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM6I2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZSIV1 DI DMZSIV1 DMZSIV1 DN NC410 DMZSIV1 TI TTSI7A8 DMZSIV1 TN Leukocyte-associated Ig-like receptor 1 (LAIR1) DMZSIV1 MA Inhibitor DMZSIV1 RN Clinical pipeline report, company report or official report of NextCure. DMZSIV1 RU http://www.nextcure.com/pipeline/ DMZTQD8 DI DMZTQD8 DMZTQD8 DN Sirna-027 DMZTQD8 TI TT1VAUK DMZTQD8 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMZTQD8 RN 2011 Pipeline of Sirna Therapeutics. DMZTQD8 RU http://www.sirna.com/ DM459Q7 DI DM459Q7 DM459Q7 DN BMS-833923 DM459Q7 TI TT8J1S3 DM459Q7 TN Smoothened homolog (SMO) DM459Q7 MA Inhibitor DM459Q7 RN Clinical pipeline report, company report or official report of Exelixis (2011). DM459Q7 RU http://www.exelixis.com/pipeline DMNCOE1 DI DMNCOE1 DMNCOE1 DN FRM-6308 DMNCOE1 TI TTJW4LU DMNCOE1 TN Phosphodiesterase 10A (PDE10) DMNCOE1 MA Inhibitor DMNCOE1 RN Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2. DMNCOE1 RU https://pubmed.ncbi.nlm.nih.gov/25131831 DMQGH76 DI DMQGH76 DMQGH76 DN S-222611 DMQGH76 TI TT6EO5L DMQGH76 TN Erbb2 tyrosine kinase receptor (HER2) DMQGH76 MA Inhibitor DMQGH76 RN Clinical pipeline report, company report or official report of Shionogi (2011). DMQGH76 RU http://www.shionogi.co.jp/index_e.html DMQGH76 DI DMQGH76 DMQGH76 DN S-222611 DMQGH76 TI TTGKNB4 DMQGH76 TN Epidermal growth factor receptor (EGFR) DMQGH76 MA Inhibitor DMQGH76 RN Clinical pipeline report, company report or official report of Shionogi (2011). DMQGH76 RU http://www.shionogi.co.jp/index_e.html DMVWYOU DI DMVWYOU DMVWYOU DN GGF DMVWYOU TI TTEH395 DMVWYOU TN Pro-neuregulin-1 (Pro-NRG1) DMVWYOU MA Modulator DMVWYOU RN Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol. 2001 Mar 19;152(6):1289-99. DMVWYOU RU https://pubmed.ncbi.nlm.nih.gov/11257128 DM01JU8 DI DM01JU8 DM01JU8 DN JTE-451 DM01JU8 TI TTGV6LY DM01JU8 TN Nuclear receptor ROR-gamma (RORG) DM01JU8 MA Antagonist DM01JU8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM01JU8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM029TQ DI DM029TQ DM029TQ DN DS-1150b DM029TQ TI TTP6MT5 DM029TQ TN Glucose transporter type 4 (SLC2A4) DM029TQ MA Modulator DM029TQ RN Sanford-Burnham goes fourth. SciBX 7(22); doi:10.1038/scibx.2014.633. June 5 2014 DM029TQ RU http://www.nature.com/scibx/journal/v7/n22/full/scibx.2014.633.html DM0351T DI DM0351T DM0351T DN 5-FP DM0351T TI TTUTN1I DM0351T TN Human Deoxyribonucleic acid (hDNA) DM0351T MA Binder DM0351T RN Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time. Clin Cancer Res. 2003 Apr;9(4):1235-9. DM0351T RU https://pubmed.ncbi.nlm.nih.gov/12684389 DM035LO DI DM035LO DM035LO DN GP-3269 DM035LO TI TTL732K DM035LO TN Adenosine kinase (ADK) DM035LO MA Inhibitor DM035LO RN Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20. DM035LO RU https://pubmed.ncbi.nlm.nih.gov/16302820 DM03O8T DI DM03O8T DM03O8T DN PSMA-VRP DM03O8T TI TT9G4N0 DM03O8T TN Glutamate carboxypeptidase II (GCPII) DM03O8T RN A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine. 2013 Jan 30;31(6):943-9. DM03O8T RU https://pubmed.ncbi.nlm.nih.gov/23246260 DM049IX DI DM049IX DM049IX DN CDRI-97/78 DM049IX TI TTQ2GJ0 DM049IX TN Plasmodial phospholipid metabolism (PPP metab) DM049IX MA Modulator DM049IX RN Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug. Malar Res Treat. 2014;2014:372521. DM049IX RU https://pubmed.ncbi.nlm.nih.gov/24800100 DM056JD DI DM056JD DM056JD DN PF-06648671 DM056JD TI TT9W8GU DM056JD TN Gamma-secretase (GS) DM056JD MA Modulator DM056JD RN Pharmacokinetic and Pharmacodynamic Effects of a -Secretase Modulator, PF-06648671, on CSF Amyloid- Peptides in Randomized Phase I Studies. Clin Pharmacol Ther. 2020 Jan;107(1):211-220. DM056JD RU https://pubmed.ncbi.nlm.nih.gov/31314925 DM05R4C DI DM05R4C DM05R4C DN CLN-081 DM05R4C TI TTGKNB4 DM05R4C TN Epidermal growth factor receptor (EGFR) DM05R4C MA Inhibitor DM05R4C RN TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658. DM05R4C RU https://pubmed.ncbi.nlm.nih.gov/29748209 DM09SW6 DI DM09SW6 DM09SW6 DN CD4CAR DM09SW6 TI TTN2JFW DM09SW6 TN T-cell surface glycoprotein CD4 (CD4) DM09SW6 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DM09SW6 RU https://icellgene.com/our-pipeline.html DM0A6N9 DI DM0A6N9 DM0A6N9 DN PTI-80 DM0A6N9 TI TTS87KH DM0A6N9 TN Microtubule-associated protein tau (MAPT) DM0A6N9 MA Inhibitor DM0A6N9 RN Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014. DM0A6N9 RU http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-older-americans.pdf DM0BNLC DI DM0BNLC DM0BNLC DN PENNVAX-6 DM0BNLC TI TTEC2T3 DM0BNLC TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DM0BNLC MA Modulator DM0BNLC RN Company report (Inovio) DM0BNLC RU http://www.inovio.com/products/infectious-disease-vaccines/hiv/pennvax-g/ DM0DJPE DI DM0DJPE DM0DJPE DN Drug 2838232 DM0DJPE TI TTMCA52 DM0DJPE TN Viral Maturation (VM) DM0DJPE MA Modulator DM0DJPE RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037762) DM0DJPE RU http://adisinsight.springer.com/drugs/800037762 DM0E37K DI DM0E37K DM0E37K DN Pegdinetanib DM0E37K TI TTUTJGQ DM0E37K TN Vascular endothelial growth factor receptor 2 (KDR) DM0E37K MA Modulator DM0E37K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM0E37K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM0E3ZG DI DM0E3ZG DM0E3ZG DN REGN3048 DM0E3ZG TI TTZ3COY DM0E3ZG TN COVID-19 spike glycoprotein (S) DM0E3ZG MA Inhibitor DM0E3ZG RN Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71. DM0E3ZG RU https://pubmed.ncbi.nlm.nih.gov/29885377 DM0EKUQ DI DM0EKUQ DM0EKUQ DN NY-ESO-1 vaccine DM0EKUQ TI TTE5ITK DM0EKUQ TN Cancer/testis antigen 1 (NY-ESO-1) DM0EKUQ RN Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822. DM0EKUQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151653/ DM0EWMT DI DM0EWMT DM0EWMT DN SRK-181 DM0EWMT TI TTR9XHZ DM0EWMT TN Transforming growth factor beta 1 (TGFB1) DM0EWMT MA Inhibitor DM0EWMT RN Clinical pipeline report, company report or official report of Scholar Rock. DM0EWMT RU https://scholarrock.com/our-pipeline/oncology/ DM0EZ69 DI DM0EZ69 DM0EZ69 DN SYN004 DM0EZ69 TI TTGKNB4 DM0EZ69 TN Epidermal growth factor receptor (EGFR) DM0EZ69 MA Inhibitor DM0EZ69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0EZ69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM0H5JD DI DM0H5JD DM0H5JD DN MEDI3617 DM0H5JD TI TTKLQTJ DM0H5JD TN Angiopoietin-2 (ANGPT2) DM0H5JD MA Inhibitor DM0H5JD RN Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 Jun 15;24(12):2749-2757. DM0H5JD RU https://pubmed.ncbi.nlm.nih.gov/29559563 DM0HKU7 DI DM0HKU7 DM0HKU7 DN Macozinone DM0HKU7 TI TTLOHU4 DM0HKU7 TN Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1) DM0HKU7 MA Inhibitor DM0HKU7 RN Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. ACS Med Chem Lett. 2019 Feb 23;10(3):348-351. DM0HKU7 RU https://pubmed.ncbi.nlm.nih.gov/30891138 DM0I8RZ DI DM0I8RZ DM0I8RZ DN Affitope AD-01 DM0I8RZ TI TTE4KHA DM0I8RZ TN Amyloid beta A4 protein (APP) DM0I8RZ RN Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. Int J Alzheimers Dis. 2012; 2012: 369808. DM0I8RZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313573/ DM0IVGU DI DM0IVGU DM0IVGU DN PLX7486 DM0IVGU TI TTTDVOJ DM0IVGU TN Tropomyosin-related kinase A (TrkA) DM0IVGU MA Inhibitor DM0IVGU RN National Cancer Institute Drug Dictionary (drug id 747694). DM0IVGU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747694 DM0IVGU DI DM0IVGU DM0IVGU DN PLX7486 DM0IVGU TI TTC70AJ DM0IVGU TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DM0IVGU MA Inhibitor DM0IVGU RN National Cancer Institute Drug Dictionary (drug id 747694). DM0IVGU RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=747694 DM0IVGU DI DM0IVGU DM0IVGU DN PLX7486 DM0IVGU TI TT7MRDV DM0IVGU TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM0IVGU MA Inhibitor DM0IVGU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0IVGU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0J7UR DI DM0J7UR DM0J7UR DN MEDI9197 DM0J7UR TI TTRJ1K4 DM0J7UR TN Toll-like receptor 7 (TLR7) DM0J7UR MA Agonist DM0J7UR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0J7UR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0J7UR DI DM0J7UR DM0J7UR DN MEDI9197 DM0J7UR TI TT8CWFK DM0J7UR TN Toll-like receptor 8 (TLR8) DM0J7UR MA Agonist DM0J7UR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0J7UR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0JT9C DI DM0JT9C DM0JT9C DN DN1508052 DM0JT9C TI TT8CWFK DM0JT9C TN Toll-like receptor 8 (TLR8) DM0JT9C MA Agonist DM0JT9C RN Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech. DM0JT9C RU http://www.denovo-sh.com/En/technology.aspx?BaseInfoCateID=48&CateID=48 DM0LKHV DI DM0LKHV DM0LKHV DN B7-2/GM-CSF DM0LKHV TI TTZ9SOR DM0LKHV TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0LKHV MA Agonist DM0LKHV RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM0LKHV RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM0LKHV DI DM0LKHV DM0LKHV DN B7-2/GM-CSF DM0LKHV TI TTQWUPT DM0LKHV TN Thyroid hormone receptor (THR) DM0LKHV MA Agonist DM0LKHV RN Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail Rev. 2010 Mar;15(2):177-82. DM0LKHV RU https://pubmed.ncbi.nlm.nih.gov/19002578 DM0O2N4 DI DM0O2N4 DM0O2N4 DN pbi-shRNA EWS-FLI-Type 1 DM0O2N4 TI TTHOM2S DM0O2N4 TN EWS-FLI1 fusion gene mRNA (EWS-FLI1 mRNA) DM0O2N4 MA Inhibitor DM0O2N4 RN National Cancer Institute Drug Dictionary (drug id 780967). DM0O2N4 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/780967 DM0P729 DI DM0P729 DM0P729 DN GSK461364 DM0P729 TI TTIYVQP DM0P729 TN Polo-like kinase 1 (PLK1) DM0P729 MA Inhibitor DM0P729 RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DM0P729 RU https://pubmed.ncbi.nlm.nih.gov/19474163 DM0PYEQ DI DM0PYEQ DM0PYEQ DN NIP-004 DM0PYEQ TI TTIHYA4 DM0PYEQ TN Thrombopoietin receptor (MPL) DM0PYEQ MA Agonist DM0PYEQ RN A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7. DM0PYEQ RU https://pubmed.ncbi.nlm.nih.gov/16484588 DM0Q7NO DI DM0Q7NO DM0Q7NO DN AMG 176 DM0Q7NO TI TTL53M6 DM0Q7NO TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM0Q7NO MA Inhibitor DM0Q7NO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0Q7NO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM0QH9K DI DM0QH9K DM0QH9K DN FS118 DM0QH9K TI TTNVXAW DM0QH9K TN Lymphocyte activation gene 3 protein (LAG3) DM0QH9K RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM0QH9K RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM0QH9K DI DM0QH9K DM0QH9K DN FS118 DM0QH9K TI TT8ZLTI DM0QH9K TN Programmed cell death 1 ligand 1 (PD-L1) DM0QH9K RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM0QH9K RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM0QZJX DI DM0QZJX DM0QZJX DN JNJ-55308942 DM0QZJX TI TT473XN DM0QZJX TN P2X purinoceptor 7 (P2RX7) DM0QZJX MA Inhibitor DM0QZJX RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0QZJX RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0RD4F DI DM0RD4F DM0RD4F DN DS-6051 DM0RD4F TI TTTDVOJ DM0RD4F TN Tropomyosin-related kinase A (TrkA) DM0RD4F MA Inhibitor DM0RD4F RN National Cancer Institute Drug Dictionary (drug id 766123). DM0RD4F RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123 DM0RD4F DI DM0RD4F DM0RD4F DN DS-6051 DM0RD4F TI TTSZ6Y3 DM0RD4F TN Proto-oncogene c-Ros (ROS1) DM0RD4F MA Inhibitor DM0RD4F RN National Cancer Institute Drug Dictionary (drug id 766123). DM0RD4F RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=766123 DM0RIQF DI DM0RIQF DM0RIQF DN MDX-1203 DM0RIQF TI TTNCIE0 DM0RIQF TN CD70 antigen (CD27-L) DM0RIQF RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2558). DM0RIQF RU http://meetinglibrary.asco.org/content/130447-144 DM0S9OT DI DM0S9OT DM0S9OT DN VRC07-523LS DM0S9OT TI TTN2JFW DM0S9OT TN T-cell surface glycoprotein CD4 (CD4) DM0S9OT RN Clinical pipeline report, company report or official report of TaiMed Biologics. DM0S9OT RU http://www.taimedbiologics.com/pipeline/44 DM0SRAN DI DM0SRAN DM0SRAN DN CC-122 DM0SRAN TI TTDKGTC DM0SRAN TN Protein cereblon (CRBN) DM0SRAN MA Modulator DM0SRAN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0SRAN RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM0UL47 DI DM0UL47 DM0UL47 DN Anti-PD-L1 DM0UL47 TI TT8ZLTI DM0UL47 TN Programmed cell death 1 ligand 1 (PD-L1) DM0UL47 RN Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455-65. DM0UL47 RU https://pubmed.ncbi.nlm.nih.gov/22658128 DM0UOA9 DI DM0UOA9 DM0UOA9 DN NV-52 DM0UOA9 TI TTKNWZ4 DM0UOA9 TN Thromboxane-A synthase (TBXAS1) DM0UOA9 MA Inhibitor DM0UOA9 RN Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66. DM0UOA9 RU https://pubmed.ncbi.nlm.nih.gov/18457468 DM0W275 DI DM0W275 DM0W275 DN Human CD19 targeted T Cells DM0W275 TI TTW640A DM0W275 TN B-lymphocyte surface antigen B4 (CD19) DM0W275 MA CAR-T-Cell-Therapy DM0W275 RN ClinicalTrials.gov (NCT03720457) Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. DM0W275 RU https://clinicaltrials.gov/ct2/show/NCT03720457 DM0WCR4 DI DM0WCR4 DM0WCR4 DN AZD-6088 DM0WCR4 TI TTZ9SOR DM0WCR4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0WCR4 MA Agonist DM0WCR4 RN Evaluation of an Innovative Population Pharmacokinetic-Based Design for Behavioral Pharmacodynamic Endpoints. AAPS J. 2012 December; 14(4): 657-663. DM0WCR4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475849/ DM0WTMD DI DM0WTMD DM0WTMD DN DSP-2230 DM0WTMD TI TT4G2JS DM0WTMD TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM0WTMD MA Inhibitor DM0WTMD RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0WTMD RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0WTMD DI DM0WTMD DM0WTMD DN DSP-2230 DM0WTMD TI TT90XZ8 DM0WTMD TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM0WTMD MA Inhibitor DM0WTMD RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DM0WTMD RU https://pubmed.ncbi.nlm.nih.gov/30728472 DM0XDYT DI DM0XDYT DM0XDYT DN CD10-CART DM0XDYT TI TT5TKPM DM0XDYT TN Neutral endopeptidase (MME) DM0XDYT MA CAR-T-Cell-Therapy(Dual specific) DM0XDYT RN ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL DM0XDYT RU https://clinicaltrials.gov/ct2/show/NCT03407859 DM0YCG3 DI DM0YCG3 DM0YCG3 DN RVT-103+RVT-104 DM0YCG3 TI TTEB0GD DM0YCG3 TN Cholinesterase (BCHE) DM0YCG3 MA Inhibitor DM0YCG3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0YCG3 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DM0Z3JS DI DM0Z3JS DM0Z3JS DN ASG-22ME DM0Z3JS TI TTPO9EG DM0Z3JS TN Nectin cell adhesion molecule 4 (NECTIN4) DM0Z3JS RN 2011 Pipeline of Seattle Genetics. DM0Z3JS RU http://www.seagen.com/product_pipeline.php DM0ZDJ5 DI DM0ZDJ5 DM0ZDJ5 DN Anti-EGFL7 DM0ZDJ5 TI TT7WD0H DM0ZDJ5 TN Epidermal growth factor-like protein 7 (EGFL7) DM0ZDJ5 RN Clinical pipeline report, company report or official report of Genentech (2009). DM0ZDJ5 RU http://www.gene.com/gene/pipeline/status/ DM0ZMNI DI DM0ZMNI DM0ZMNI DN REGN6569 DM0ZMNI TI TTG6LA7 DM0ZMNI TN Activation-inducible TNFR family receptor (TNFRSF18) DM0ZMNI MA Inhibitor DM0ZMNI RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM0ZMNI RU https://www.regeneron.com/science/pipeline DM0ZNAR DI DM0ZNAR DM0ZNAR DN Belvarafenib DM0ZNAR TI TTB18GJ DM0ZNAR TN Proto-oncogene c-RAF (c-RAF) DM0ZNAR MA Inhibitor DM0ZNAR RN Clinical pipeline report, company report or official report of Hanmi Pharmaceutical. DM0ZNAR RU https://www.hanmipharm.com/ehanmi/handler/Rnd-Pipeline DM0ZQ48 DI DM0ZQ48 DM0ZQ48 DN GPI-16072 DM0ZQ48 TI TT9G4N0 DM0ZQ48 TN Glutamate carboxypeptidase II (GCPII) DM0ZQ48 MA Inhibitor DM0ZQ48 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DM0ZQ48 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DM0ZQ7J DI DM0ZQ7J DM0ZQ7J DN TAK-041 DM0ZQ7J TI TTOL9B0 DM0ZQ7J TN G-protein-coupled receptor PGR3 (GPR139) DM0ZQ7J MA Agonist DM0ZQ7J RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM0ZQ7J RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM12GN7 DI DM12GN7 DM12GN7 DN CB-5083 DM12GN7 TI TTHNLSB DM12GN7 TN Valosin-containing protein p97 (VCP) DM12GN7 MA Inhibitor DM12GN7 RN Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells. BMC Cancer. 2015; 15: 479. DM12GN7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4479320/ DM132EG DI DM132EG DM132EG DN M802 DM132EG TI TT6EO5L DM132EG TN Erbb2 tyrosine kinase receptor (HER2) DM132EG MA Inhibitor DM132EG RN A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355. DM132EG RU https://pubmed.ncbi.nlm.nih.gov/31412896 DM132EG DI DM132EG DM132EG DN M802 DM132EG TI TTUN7MC DM132EG TN T-cell surface glycoprotein CD3 (CD3) DM132EG MA Inhibitor DM132EG RN A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355. DM132EG RU https://pubmed.ncbi.nlm.nih.gov/31412896 DM13YK0 DI DM13YK0 DM13YK0 DN Ferroportin mab DM13YK0 TI TT6Y1PG DM13YK0 TN Solute carrier family 40 member 1 (SLC40A1) DM13YK0 RN The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. DM13YK0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/ DM14XQN DI DM14XQN DM14XQN DN BAY 79-4620 DM14XQN TI TT2LVK8 DM14XQN TN Carbonic anhydrase IX (CA-IX) DM14XQN RN Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9. DM14XQN RU https://pubmed.ncbi.nlm.nih.gov/22147747 DM15PG9 DI DM15PG9 DM15PG9 DN SAR351034 DM15PG9 TI TT2JWF6 DM15PG9 TN Peroxisome proliferator-activated receptor delta (PPARD) DM15PG9 MA Modulator DM15PG9 RN Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31. DM15PG9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428473/ DM16IX2 DI DM16IX2 DM16IX2 DN LY-2979165 DM16IX2 TI TTXJ47W DM16IX2 TN Metabotropic glutamate receptor 2 (mGluR2) DM16IX2 MA Modulator DM16IX2 RN Annual Reports in Medicinal Chemistry. Volume 47, 2012, Page(78). DM16IX2 RU https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=Annual+Reports+in+Medicinal+Chemistry++LY-2979165&source=bl&ots=oPRAtBeGRL&sig=la4YgUxL9zkXRln2i4EVFFFVzUg&hl=zh-CN&sa=X&ved=0CB4Q6AEwAGoVChMIsbb8qP3FyAIVC1iOCh3bcgiX#v=onepage&q=Annual%20Reports%20in%20Medicinal%20Chemistry%20%20LY-2979165&f=false DM16QSG DI DM16QSG DM16QSG DN Adaphostin DM16QSG TI TTS7G69 DM16QSG TN Fusion protein Bcr-Abl (Bcr-Abl) DM16QSG MA Inhibitor DM16QSG RN Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002 Jan 15;99(2):664-71. DM16QSG RU https://pubmed.ncbi.nlm.nih.gov/11781252 DM195JA DI DM195JA DM195JA DN BAY-86-7548 DM195JA TI TTHYDUM DM195JA TN Bombesin receptor (BS) DM195JA MA Enhancer DM195JA RN Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013 Jun;54(6):867-72. DM195JA RU https://pubmed.ncbi.nlm.nih.gov/23564761 DM19UTO DI DM19UTO DM19UTO DN Acebilustat DM19UTO TI TTXZEAJ DM19UTO TN Leukotriene A-4 hydrolase (LTA4H) DM19UTO MA Inhibitor DM19UTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM19UTO RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM1AKNI DI DM1AKNI DM1AKNI DN TAK-252 DM1AKNI TI TTL31H0 DM1AKNI TN OX40L receptor (CD134) DM1AKNI MA Agonist DM1AKNI RN Clinical pipeline report, company report or official report of Shattuck Labs. DM1AKNI RU https://www.shattucklabs.com/pipeline/overview/ DM1AKNI DI DM1AKNI DM1AKNI DN TAK-252 DM1AKNI TI TT8ZLTI DM1AKNI TN Programmed cell death 1 ligand 1 (PD-L1) DM1AKNI MA Agonist DM1AKNI RN Clinical pipeline report, company report or official report of Shattuck Labs. DM1AKNI RU https://www.shattucklabs.com/pipeline/overview/ DM1ALHT DI DM1ALHT DM1ALHT DN MEDl-551 DM1ALHT TI TTW640A DM1ALHT TN B-lymphocyte surface antigen B4 (CD19) DM1ALHT RN CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. DM1ALHT RU https://pubmed.ncbi.nlm.nih.gov/22820352 DM1ALY9 DI DM1ALY9 DM1ALY9 DN TAK-931 DM1ALY9 TI TTSMTDI DM1ALY9 TN CDC7-related kinase (CDC7) DM1ALY9 MA Inhibitor DM1ALY9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1ALY9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1B3UM DI DM1B3UM DM1B3UM DN GDC-0152 DM1B3UM TI TTR7B60 DM1B3UM TN X-linked inhibitor of apoptosis protein (XIAP) DM1B3UM MA Modulator DM1B3UM RN Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem. 2012 May 10;55(9):4101-13. DM1B3UM RU https://pubmed.ncbi.nlm.nih.gov/22413863 DM1B4CQ DI DM1B4CQ DM1B4CQ DN RTL-1000 DM1B4CQ TI TTXQYT6 DM1B4CQ TN T-cells (T-cells) DM1B4CQ MA Binder DM1B4CQ RN RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14. DM1B4CQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026883/ DM1C4UM DI DM1C4UM DM1C4UM DN LAMB3-transduced autologous epidermal stem cells DM1C4UM TI TT2WOUQ DM1C4UM TN Laminin beta-3 chain (LAMB3) DM1C4UM MA Modulator DM1C4UM RN Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006 Dec;12(12):1397-402. DM1C4UM RU https://pubmed.ncbi.nlm.nih.gov/17115047 DM1CZSJ DI DM1CZSJ DM1CZSJ DN (+)-JQ1 DM1CZSJ TI TT7CPI5 DM1CZSJ TN Bromodomain testis-specific protein (BRDT) DM1CZSJ MA Inhibitor DM1CZSJ RN Small-molecule inhibition of BRDT for male contraception. Cell. 2012 Aug 17;150(4):673-84. DM1CZSJ RU https://pubmed.ncbi.nlm.nih.gov/22901802 DM1CZSJ DI DM1CZSJ DM1CZSJ DN (+)-JQ1 DM1CZSJ TI TTRA6BO DM1CZSJ TN Bromodomain-containing protein 4 (BRD4) DM1CZSJ MA Inhibitor DM1CZSJ RN Selective inhibition of BET bromodomains. Nature. 2010 Dec 23;468(7327):1067-73. DM1CZSJ RU https://pubmed.ncbi.nlm.nih.gov/20871596 DM1CZSJ DI DM1CZSJ DM1CZSJ DN (+)-JQ1 DM1CZSJ TI TTE4BSY DM1CZSJ TN Bromodomain and extraterminal domain protein (BET) DM1CZSJ MA Inhibitor DM1CZSJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1CZSJ RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM1D2O0 DI DM1D2O0 DM1D2O0 DN KML-001 DM1D2O0 TI TTUJFD0 DM1D2O0 TN Telomerase reverse transcriptase (TERT) DM1D2O0 MA Inhibitor DM1D2O0 RN National Cancer Institute Drug Dictionary (drug id 672554). DM1D2O0 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=672554 DM1DISM DI DM1DISM DM1DISM DN MDAM (y-methylene-10-deazaaminopterin) DM1DISM TI TTYZVDJ DM1DISM TN Dihydrofolate reductase (DHFR) DM1DISM MA Inhibitor DM1DISM RN Evaluation of the importance of hydrophobic interactions in drug binding to dihydrofolate reductase. J Med Chem. 1988 Jan;31(1):129-37. DM1DISM RU https://pubmed.ncbi.nlm.nih.gov/3275776 DM1DIVY DI DM1DIVY DM1DIVY DN TRemelimumab + MEDI0562 DM1DIVY TI TTI2S1D DM1DIVY TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM1DIVY MA Agonist DM1DIVY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1DIVY RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1DIVY DI DM1DIVY DM1DIVY DN TRemelimumab + MEDI0562 DM1DIVY TI TTL31H0 DM1DIVY TN OX40L receptor (CD134) DM1DIVY MA Agonist DM1DIVY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1DIVY RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1EBRK DI DM1EBRK DM1EBRK DN FPA144 DM1EBRK TI TTGKIED DM1EBRK TN Fibroblast growth factor-2 (FGF2) DM1EBRK MA Antagonist DM1EBRK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1EBRK RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1F50I DI DM1F50I DM1F50I DN ABT-110 DM1F50I TI TTDN3LF DM1F50I TN Nerve growth factor (NGF) DM1F50I MA Modulator DM1F50I RN Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. DM1F50I RU https://www.ncbi.nlm.nih.gov/pubmed/21389990 DM1FJ9C DI DM1FJ9C DM1FJ9C DN AMG 876 DM1FJ9C TI TTUPB12 DM1FJ9C TN Measles virus Fusion glycoprotein (MeV F) DM1FJ9C MA Modulator DM1FJ9C RN Clinical pipeline report, company report or official report of Amgen. DM1FJ9C RU http://www.amgenpipeline.com/pipeline/ DM1FLXD DI DM1FLXD DM1FLXD DN CAN04 DM1FLXD TI TTWS50K DM1FLXD TN Interleukin 1 receptor accessory protein (IL1RAP) DM1FLXD MA Inhibitor DM1FLXD RN A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors (CANFOUR) DM1FLXD RU https://clinicaltrials.gov/ct2/show/NCT03267316 DM1FTEC DI DM1FTEC DM1FTEC DN ARQ-171 DM1FTEC TI TTVJDNB DM1FTEC TN E2F transcription factor 1 (E2F1) DM1FTEC MA Modulator DM1FTEC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025396) DM1FTEC RU http://adisinsight.springer.com/drugs/800025396 DM1FUAR DI DM1FUAR DM1FUAR DN MV-CEA DM1FUAR TI TTY6DTE DM1FUAR TN Carcinoembryonic antigen CEA (CD66e) DM1FUAR MA Modulator DM1FUAR RN Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 2010 Feb 1;70(3):875-82. DM1FUAR RU https://pubmed.ncbi.nlm.nih.gov/20103634 DM1FW0C DI DM1FW0C DM1FW0C DN AZD7762 DM1FW0C TI TTTU902 DM1FW0C TN Checkpoint kinase-1 (CHK1) DM1FW0C MA Inhibitor DM1FW0C RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM1FW0C RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM1FX09 DI DM1FX09 DM1FX09 DN DT-TX-30 DM1FX09 TI TT2O84V DM1FX09 TN Thromboxane A2 receptor (TBXA2R) DM1FX09 MA Antagonist DM1FX09 RN DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs. Basic Res Cardiol. 1997 Jun;92(3):181-90. DM1FX09 RU https://pubmed.ncbi.nlm.nih.gov/9226103 DM1GV6O DI DM1GV6O DM1GV6O DN CC-90011 DM1GV6O TI TTNR0UQ DM1GV6O TN Lysine-specific histone demethylase 1 (LSD) DM1GV6O MA Inhibitor DM1GV6O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1GV6O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1H75D DI DM1H75D DM1H75D DN Z-100 DM1H75D TI TTV2CN0 DM1H75D TN Interferon receptor (IFNR) DM1H75D MA Modulator DM1H75D RN Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. J Gen Virol. 2004 Sep;85(Pt 9):2603-13. DM1H75D RU https://pubmed.ncbi.nlm.nih.gov/15302954 DM1HUA3 DI DM1HUA3 DM1HUA3 DN RHIgM12B7 DM1HUA3 TI TTYOVWN DM1HUA3 TN Programmed cell death protein 2 (PD-2) DM1HUA3 RN National Cancer Institute Drug Dictionary (drug id 593681). DM1HUA3 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=593681 DM1ITDN DI DM1ITDN DM1ITDN DN NsG-0202 DM1ITDN TI TTDN3LF DM1ITDN TN Nerve growth factor (NGF) DM1ITDN MA Modulator DM1ITDN RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM1ITDN RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTGTQHC DM1KD7U TN DNA topoisomerase I (TOP1) DM1KD7U MA Modulator DM1KD7U RN Company report (Indena) DM1KD7U RU http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/ DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTYFKSZ DM1KD7U TN Tubulin beta (TUBB) DM1KD7U MA Modulator DM1KD7U RN Company report (Indena) DM1KD7U RU http://cn.indena.com/news/indena-nerviano-medical-sciences-agree-scale-new-high-potency-molecules-4/ DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTOHSBA DM1KD7U TN Vascular endothelial growth factor A (VEGFA) DM1KD7U MA Inhibitor DM1KD7U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1KD7U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TTB8Y9K DM1KD7U TN Angiogenesis (AGG) DM1KD7U MA Inhibitor DM1KD7U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1KD7U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1KD7U DI DM1KD7U DM1KD7U DN ABI-011 DM1KD7U TI TT4V2JM DM1KD7U TN Hepatocyte growth factor (HGF) DM1KD7U MA Inhibitor DM1KD7U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1KD7U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM1M4B8 DI DM1M4B8 DM1M4B8 DN CC-93269 DM1M4B8 TI TTZ3P4W DM1M4B8 TN B-cell maturation protein (TNFRSF17) DM1M4B8 RN T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. Oncotarget. 2020 Nov 10;11(45):4076-4081. DM1M4B8 RU https://pubmed.ncbi.nlm.nih.gov/33227097 DM1MY26 DI DM1MY26 DM1MY26 DN IGN523 DM1MY26 TI TT5CZSM DM1MY26 TN Lymphocyte activation antigen 4F2 (SLC3A2) DM1MY26 RN Antitumor activity of an anti-CD98 antibody. Int J Cancer. 2015 Aug 1;137(3):710-20. DM1MY26 RU https://pubmed.ncbi.nlm.nih.gov/25556716 DM1N8PZ DI DM1N8PZ DM1N8PZ DN rAAV1.tMCK.human-alpha-sarcoglycan DM1N8PZ TI TTS9Q5V DM1N8PZ TN Sarcoglycan alpha (SGCA) DM1N8PZ MA Modulator DM1N8PZ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM1N8PZ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1N9YS DI DM1N9YS DM1N9YS DN MSX-122 DM1N9YS TI TTBID49 DM1N9YS TN C-X-C chemokine receptor type 4 (CXCR4) DM1N9YS MA Antagonist DM1N9YS RN Comparative evaluation of CC chemokine-induced migration of murine CD8alpha+ and CD8alpha- dendritic cells and their in vivo trafficking. J Leukoc Biol. 2004 Feb;75(2):275-85. DM1N9YS RU https://pubmed.ncbi.nlm.nih.gov/14597730 DM1NHEA DI DM1NHEA DM1NHEA DN RG7450 DM1NHEA TI TT9E64S DM1NHEA TN Metalloreductase STEAP1 (STEAP1) DM1NHEA MA Modulator DM1NHEA RN Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278. DM1NHEA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3917273/ DM1O2X6 DI DM1O2X6 DM1O2X6 DN KPG-818 DM1O2X6 TI TTEZQ39 DM1O2X6 TN Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase) DM1O2X6 MA Modulator DM1O2X6 RN Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals. DM1O2X6 RU https://www.kangpugroup.com/research_development/pipeline.html DM1PK0T DI DM1PK0T DM1PK0T DN GLYCAR T cells DM1PK0T TI TTJTSX4 DM1PK0T TN Glypican-3 (GPC3) DM1PK0T MA CAR-T-Cell-Therapy DM1PK0T RN ClinicalTrials.gov (NCT02905188) Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) DM1PK0T RU https://clinicaltrials.gov/ct2/show/NCT02905188 DM1R4MQ DI DM1R4MQ DM1R4MQ DN RG7893 DM1R4MQ TI TT4G2JS DM1R4MQ TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM1R4MQ MA Inhibitor DM1R4MQ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740) DM1R4MQ RU http://adisinsight.springer.com/drugs/800041740 DM1R8P4 DI DM1R8P4 DM1R8P4 DN CART-19 DM1R8P4 TI TTW640A DM1R8P4 TN B-lymphocyte surface antigen B4 (CD19) DM1R8P4 MA CAR-T-Cell-Therapy DM1R8P4 RN ClinicalTrials.gov (NCT03101709) The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma DM1R8P4 RU https://clinicaltrials.gov/ct2/show/NCT03101709 DM1RBT8 DI DM1RBT8 DM1RBT8 DN NN-9926 DM1RBT8 TI TTVIMDE DM1RBT8 TN Glucagon-like peptide 1 receptor (GLP1R) DM1RBT8 MA Agonist DM1RBT8 RN Clinical pipeline report, company report or official report of Addex Pharmaceuticals. DM1RBT8 RU https://www.google.com.hk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=6&ved=0CEkQFjAFahUKEwiqkvGZp7nIAhWRBo4KHcHbD4U&url=http%3a%2f%2fwww%2eedisoninvestmentresearch%2ecom%2f%3fACT%3d18%26ID%3d6480&usg=AFQjCNHEg3ua1DahAa3uYwDK0pG0MPee7Q DM1RD0T DI DM1RD0T DM1RD0T DN ASP-4058 DM1RD0T TI TT9JZCK DM1RD0T TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM1RD0T MA Modulator DM1RD0T RN ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819. DM1RD0T RU https://pubmed.ncbi.nlm.nih.gov/25347187 DM1RD0T DI DM1RD0T DM1RD0T DN ASP-4058 DM1RD0T TI TTDZCKV DM1RD0T TN Sphingosine-1-phosphate receptor 5 (S1PR5) DM1RD0T MA Modulator DM1RD0T RN ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. PLoS One. 2014 Oct 27;9(10):e110819. DM1RD0T RU https://pubmed.ncbi.nlm.nih.gov/25347187 DM1RNT7 DI DM1RNT7 DM1RNT7 DN IDR-1018 DM1RNT7 TI TTXT4D5 DM1RNT7 TN Bacterial Cell membrane (Bact CM) DM1RNT7 MA Regulator DM1RNT7 RN Innate Defense Regulator Peptide 1018 in Wound Healing and Wound Infection. PLoS One. 2012; 7(8): e39373. DM1RNT7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412849/ DM1T8KN DI DM1T8KN DM1T8KN DN JCAR020 DM1T8KN TI TTC1PS3 DM1T8KN TN Ovarian carcinoma antigen CA125 (MUC16) DM1T8KN MA Immunomodulator DM1T8KN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM1T8KN RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM1UEBR DI DM1UEBR DM1UEBR DN CC-99712 DM1UEBR TI TTZ3P4W DM1UEBR TN B-cell maturation protein (TNFRSF17) DM1UEBR RN ClinicalTrials.gov (NCT04036461) A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma. U.S. National Institutes of Health. DM1UEBR RU https://clinicaltrials.gov/ct2/show/NCT04036461 DM1UIOA DI DM1UIOA DM1UIOA DN XB-947 DM1UIOA TI TT4NVEM DM1UIOA TN DNA topoisomerase II beta (TOP2B) DM1UIOA MA Modulator DM1UIOA RN XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A. 1999 October 12; 96(21): 12168-12173. DM1UIOA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC18430/ DM1UIQP DI DM1UIQP DM1UIQP DN SAFIRONIL DM1UIQP TI TTNH25W DM1UIQP TN Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1) DM1UIQP MA Modulator DM1UIQP RN Antifibrogenic therapies in chronic HCV infection. Curr Drug Targets Infect Disord. 2001 Aug;1(2):227-40. DM1UIQP RU https://pubmed.ncbi.nlm.nih.gov/12455417 DM1UQ4Y DI DM1UQ4Y DM1UQ4Y DN GSK3845097 DM1UQ4Y TI TTE5ITK DM1UQ4Y TN Cancer/testis antigen 1 (NY-ESO-1) DM1UQ4Y RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM1UQ4Y RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DM1V9YG DI DM1V9YG DM1V9YG DN BRL-52656 DM1V9YG TI TTQW87Y DM1V9YG TN Opioid receptor kappa (OPRK1) DM1V9YG MA Agonist DM1V9YG RN Kappa-opioid receptors behind the blood-brain barrier are involved in the anti-hypertensive effects of systemically administered kappa-agonists in the conscious spontaneously hypertensive rat. J Pharm Pharmacol. 1999 Nov;51(11):1251-6. DM1V9YG RU https://pubmed.ncbi.nlm.nih.gov/10632082 DM1XOZK DI DM1XOZK DM1XOZK DN ZYT-1 DM1XOZK TI TTGER3L DM1XOZK TN Thyroid hormone receptor beta (THRB) DM1XOZK MA Modulator DM1XOZK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM1XOZK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1YSMD DI DM1YSMD DM1YSMD DN MEDI6383 DM1YSMD TI TTBW580 DM1YSMD TN TAX transcriptionally-activated glycoprotein 1 (OX40) DM1YSMD RN J Clin Oncol 33, 2015 (suppl; abstr 3056). DM1YSMD RU http://meetinglibrary.asco.org/content/150554-156 DM1ZY6M DI DM1ZY6M DM1ZY6M DN 227Th-labelled MSLN-TTC DM1ZY6M TI TT4RXME DM1ZY6M TN Mesothelin (MSLN) DM1ZY6M RN Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. DM1ZY6M RU https://pubmed.ncbi.nlm.nih.gov/31064781 DM20HS7 DI DM20HS7 DM20HS7 DN GTP-004 DM20HS7 TI TT1RS9F DM20HS7 TN Acetylcholinesterase (AChE) DM20HS7 MA Inhibitor DM20HS7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM20HS7 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM23K45 DI DM23K45 DM23K45 DN Pc4 DM23K45 TI TTJGNVC DM23K45 TN Apoptosis regulator Bcl-2 (BCL-2) DM23K45 MA Agonist DM23K45 RN Association between the photodynamic loss of Bcl-2 and the sensitivity to apoptosis caused by phthalocyanine photodynamic therapy. Photochem Photobiol. 2003 Jul;78(1):1-8. DM23K45 RU https://pubmed.ncbi.nlm.nih.gov/12929741 DM2594H DI DM2594H DM2594H DN PS-178990 DM2594H TI TTS64P2 DM2594H TN Androgen receptor (AR) DM2594H MA Binder DM2594H RN Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008; 6: e010. DM2594H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602589/ DM25CBW DI DM25CBW DM25CBW DN A-348441 DM25CBW TI TTOZRK6 DM25CBW TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM25CBW MA Inhibitor DM25CBW RN Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2006 Dec 1;16(23):6086-90. DM25CBW RU https://pubmed.ncbi.nlm.nih.gov/16987661 DM25GIA DI DM25GIA DM25GIA DN REC-01 DM25GIA TI TTDIGC1 DM25GIA TN Dipeptidyl peptidase 4 (DPP-4) DM25GIA MA Inhibitor DM25GIA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM25GIA RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM27J3D DI DM27J3D DM27J3D DN BLU-554 DM27J3D TI TT1KX2S DM27J3D TN FGFR4 messenger RNA (FGFR4 mRNA) DM27J3D MA Inhibitor DM27J3D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM27J3D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM289Z4 DI DM289Z4 DM289Z4 DN LY2624587 DM289Z4 TI TTBID49 DM289Z4 TN C-X-C chemokine receptor type 4 (CXCR4) DM289Z4 MA Antagonist DM289Z4 RN Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016 Mar 8;11(3):e0150585. DM289Z4 RU https://pubmed.ncbi.nlm.nih.gov/26954567 DM2AHXW DI DM2AHXW DM2AHXW DN CD171 specific CAR T cells expressing EGFRt DM2AHXW TI TTC9D3K DM2AHXW TN Neural cell adhesion molecule L1 (L1CAM) DM2AHXW MA CAR-T-Cell-Therapy DM2AHXW RN ClinicalTrials.gov (NCT02311621) Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 DM2AHXW RU https://clinicaltrials.gov/ct2/show/NCT02311621 DM2B0TJ DI DM2B0TJ DM2B0TJ DN Leukocyte interleukin DM2B0TJ TI TT9721Y DM2B0TJ TN Interleukin 2 receptor beta (IL2RB) DM2B0TJ MA Modulator DM2B0TJ RN Leukocyte Interleukin, Inj. (LI) augmentation of natural killer cells and cytolytic T-lymphocytes. Immunopharmacol Immunotoxicol. 1995 May;17(2):247-64. DM2B0TJ RU https://pubmed.ncbi.nlm.nih.gov/7650289 DM2B9E0 DI DM2B9E0 DM2B9E0 DN AT13387 DM2B9E0 TI TT78R5H DM2B9E0 TN Heat shock protein 90 alpha (HSP90A) DM2B9E0 MA Inhibitor DM2B9E0 RN Astex Presents Updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference. Astex. 2008. DM2B9E0 RU http://www.drugs.com/clinical_trials/astex-presents-updates-at13387-hsp90-inhibitor-at9283-multi-targeted-kinase-inhibitor-eortc-nci-5775.html DM2BYWI DI DM2BYWI DM2BYWI DN MGD019 DM2BYWI TI TTI2S1D DM2BYWI TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM2BYWI MA Inhibitor DM2BYWI RN Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. DM2BYWI RU https://pubmed.ncbi.nlm.nih.gov/33377134 DM2BYWI DI DM2BYWI DM2BYWI DN MGD019 DM2BYWI TI TTNBFWK DM2BYWI TN Programmed cell death protein 1 (PD-1) DM2BYWI MA Inhibitor DM2BYWI RN Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule. Cell Rep Med. 2020 Dec 22;1(9):100163. DM2BYWI RU https://pubmed.ncbi.nlm.nih.gov/33377134 DM2D7Z0 DI DM2D7Z0 DM2D7Z0 DN PPC-5650 DM2D7Z0 TI TTRJYB6 DM2D7Z0 TN Acid-sensing ion channel 1 (ASIC1) DM2D7Z0 MA Modulator DM2D7Z0 RN ClinicalTrials.gov (NCT01449487) Investigation of Efficacy and Safety of PPC-5650 to Experimental Induced Sensation and Pain in the Rectosigmoid. U.S. National Institutes of Health. DM2D7Z0 RU https://clinicaltrials.gov/ct2/show/NCT01449487 DM2E5Z7 DI DM2E5Z7 DM2E5Z7 DN RG7882 DM2E5Z7 TI TT4RXME DM2E5Z7 TN Mesothelin (MSLN) DM2E5Z7 RN Molecular Imaging As a Tool for Drug Development and Trial Design. JCO July 13, 2015 JCO.2015.61.6425 DM2E5Z7 RU http://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.61.6425.full DM2FH10 DI DM2FH10 DM2FH10 DN INBRX-105 DM2FH10 TI TTPW9LJ DM2FH10 TN Co-stimulatory molecule 4-1BB (CD137) DM2FH10 MA Agonist DM2FH10 RN Clinical pipeline report, company report or official report of Inhibrx. DM2FH10 RU https://inhibrx.com/inbrx-105/ DM2FH10 DI DM2FH10 DM2FH10 DN INBRX-105 DM2FH10 TI TT8ZLTI DM2FH10 TN Programmed cell death 1 ligand 1 (PD-L1) DM2FH10 MA Inhibitor DM2FH10 RN Clinical pipeline report, company report or official report of Inhibrx. DM2FH10 RU https://inhibrx.com/inbrx-105/ DM2GHIP DI DM2GHIP DM2GHIP DN FFC-14A DM2GHIP TI TTUTN1I DM2GHIP TN Human Deoxyribonucleic acid (hDNA) DM2GHIP MA Binder DM2GHIP RN The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett. 2005 Aug 26;226(2):115-21. DM2GHIP RU https://pubmed.ncbi.nlm.nih.gov/16039951 DM2HES0 DI DM2HES0 DM2HES0 DN CTCE-0214 DM2HES0 TI TTBID49 DM2HES0 TN C-X-C chemokine receptor type 4 (CXCR4) DM2HES0 MA Agonist DM2HES0 RN Beneficial effect of a CXCR4 agonist in murine models of systemic inflammation. Inflammation. 2012 Feb;35(1):130-7. DM2HES0 RU https://pubmed.ncbi.nlm.nih.gov/21274742 DM2IDQ9 DI DM2IDQ9 DM2IDQ9 DN RG-7103 DM2IDQ9 TI TT4O5P0 DM2IDQ9 TN Helodermin-preferring VIP receptor (VIPR2) DM2IDQ9 MA Agonist DM2IDQ9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027925) DM2IDQ9 RU http://adisinsight.springer.com/drugs/800027925 DM2IEB7 DI DM2IEB7 DM2IEB7 DN Anti-CD30-CAR T cells DM2IEB7 TI TT2GM5R DM2IEB7 TN Lymphocyte activation antigen CD30 (TNFRSF8) DM2IEB7 MA CAR-T-Cell-Therapy DM2IEB7 RN ClinicalTrials.gov (NCT03049449) T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas DM2IEB7 RU https://clinicaltrials.gov/ct2/show/NCT03049449 DM2KCIP DI DM2KCIP DM2KCIP DN GSK3179106 DM2KCIP TI TT4DXQT DM2KCIP TN Proto-oncogene c-Ret (RET) DM2KCIP MA Inhibitor DM2KCIP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2KCIP RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM2KVM0 DI DM2KVM0 DM2KVM0 DN BI-44847 DM2KVM0 TI TTLWPVF DM2KVM0 TN Sodium/glucose cotransporter 2 (SGLT2) DM2KVM0 MA Modulator DM2KVM0 RN Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes DM2KVM0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437808 DM2L7TH DI DM2L7TH DM2L7TH DN GSK1521498 DM2L7TH TI TTKWM86 DM2L7TH TN Opioid receptor mu (MOP) DM2L7TH MA Agonist DM2L7TH RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM2L7TH RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM2LHPU DI DM2LHPU DM2LHPU DN ZK-200775 DM2LHPU TI TTAN6JD DM2LHPU TN Glutamate receptor AMPA (GRIA) DM2LHPU MA Inhibitor DM2LHPU RN Synthesis of anticonvulsive AMPA antagonists: 4-oxo-10-substituted-imidaz. Bioorg Med Chem Lett. 2001 May 7;11(9):1205-10. DM2LHPU RU https://pubmed.ncbi.nlm.nih.gov/11354378 DM2MILF DI DM2MILF DM2MILF DN GPA-TriMAR-T cells DM2MILF TI TT9VL2N DM2MILF TN Gp100[209-217] peptide (PMEL) DM2MILF MA CAR-T-Cell-Therapy DM2MILF RN ClinicalTrials.gov (NCT03649529) Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy DM2MILF RU https://clinicaltrials.gov/ct2/show/NCT03649529 DM2NBC7 DI DM2NBC7 DM2NBC7 DN EZN-2968 DM2NBC7 TI TTQHWNA DM2NBC7 TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM2NBC7 MA Modulator DM2NBC7 RN Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1), in patients with refractory solid tumors.Cancer Chemother Pharmacol.2014 Feb;73(2):343-8. DM2NBC7 RU https://www.ncbi.nlm.nih.gov/pubmed/24292632 DM2NTBL DI DM2NTBL DM2NTBL DN PF-05241328 DM2NTBL TI TT4G2JS DM2NTBL TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM2NTBL MA Inhibitor DM2NTBL RN Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9. DM2NTBL RU https://pubmed.ncbi.nlm.nih.gov/25060923 DM2OB6S DI DM2OB6S DM2OB6S DN CI-8993 DM2OB6S TI TT51SK8 DM2OB6S TN V-set immunoregulatory receptor (VSIR) DM2OB6S MA Antagonist DM2OB6S RN Clinical pipeline report, company report or official report of Curis. DM2OB6S RU https://www.curis.com/pipeline/ci-8993/ DM2OEQ9 DI DM2OEQ9 DM2OEQ9 DN CD19-directed CAR-T cells DM2OEQ9 TI TTW640A DM2OEQ9 TN B-lymphocyte surface antigen B4 (CD19) DM2OEQ9 MA CAR-T-Cell-Therapy DM2OEQ9 RN ClinicalTrials.gov (NCT03483688) A Phaseb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects DM2OEQ9 RU https://clinicaltrials.gov/ct2/show/NCT03483688 DM2POGY DI DM2POGY DM2POGY DN AMG 509 DM2POGY TI TT9E64S DM2POGY TN Metalloreductase STEAP1 (STEAP1) DM2POGY MA Inhibitor DM2POGY RN Clinical pipeline report, company report or official report of Amgen. DM2POGY RU https://www.amgenpipeline.com/ DM2PVLH DI DM2PVLH DM2PVLH DN MGA271 DM2PVLH TI TT6CQUM DM2PVLH TN B7 homolog 3 (CD276) DM2PVLH MA Modulator DM2PVLH RN T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236. DM2PVLH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107447/ DM2PYE0 DI DM2PYE0 DM2PYE0 DN DSP-8658 DM2PYE0 TI TTZMAO3 DM2PYE0 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM2PYE0 MA Modulator DM2PYE0 RN Effects of DSP-8658, a Novel Selective Peroxisome Proliferator-activated Receptors a/gamma Modulator, on Adipogenesis and Glucose Metabolism in Diabetic Obese Mice. Exp Clin Endocrinol Diabetes. 2015Sep;123(8):492-9. DM2PYE0 RU https://pubmed.ncbi.nlm.nih.gov/26011171 DM2QBMI DI DM2QBMI DM2QBMI DN CLP-1004 DM2QBMI TI TT1VOHK DM2QBMI TN Potassium channel unspecific (KC) DM2QBMI MA Binder DM2QBMI RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783) DM2QBMI RU http://adisinsight.springer.com/drugs/800036783 DM2S04R DI DM2S04R DM2S04R DN Zemab DM2S04R TI TT6EO5L DM2S04R TN Erbb2 tyrosine kinase receptor (HER2) DM2S04R RN Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components. Toxins (Basel) 2011 July; 3(7): 848-883. DM2S04R RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202854/ DM2SALJ DI DM2SALJ DM2SALJ DN Flanvotumab DM2SALJ TI TTFRV98 DM2SALJ TN Melanoma antigen gp75 (TYRP1) DM2SALJ RN National Cancer Institute Drug Dictionary (drug id 675217). DM2SALJ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=675217 DM2SQBF DI DM2SQBF DM2SQBF DN 225Ac-labelled aCD33 DM2SQBF TI TTJVYO3 DM2SQBF TN Myeloid cell surface antigen CD33 (CD33) DM2SQBF RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DM2SQBF RU https://pubmed.ncbi.nlm.nih.gov/32728208 DM2TAUR DI DM2TAUR DM2TAUR DN MK-0731 DM2TAUR TI TTTRP0H DM2TAUR TN Kinesin-like protein KIF11 (KIF11) DM2TAUR MA Inhibitor DM2TAUR RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DM2TAUR RU https://pubmed.ncbi.nlm.nih.gov/22825217 DM2TFUD DI DM2TFUD DM2TFUD DN Anti-BCMA CAR-T cells DM2TFUD TI TTZ3P4W DM2TFUD TN B-cell maturation protein (TNFRSF17) DM2TFUD MA CAR-T-Cell-Therapy DM2TFUD RN ClinicalTrials.gov (NCT03093168) BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma DM2TFUD RU https://clinicaltrials.gov/ct2/show/NCT03093168 DM2THBX DI DM2THBX DM2THBX DN OM-174 DM2THBX TI TTISGCA DM2THBX TN Toll-like receptor 4 (TLR4) DM2THBX MA Modulator DM2THBX RN Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172. DM2THBX RU https://pubmed.ncbi.nlm.nih.gov/23547558 DM2THBX DI DM2THBX DM2THBX DN OM-174 DM2THBX TI TTY7ZHS DM2THBX TN Toll-like receptor 2 (TLR2) DM2THBX MA Modulator DM2THBX RN Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172. DM2THBX RU https://pubmed.ncbi.nlm.nih.gov/23547558 DM2UMGE DI DM2UMGE DM2UMGE DN Ad5-TRAIL DM2UMGE TI TTA5MS9 DM2UMGE TN TNF related apoptosis inducing ligand (TNFSF10) DM2UMGE MA Modulator DM2UMGE RN Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006 Jun;13(6):628-32. DM2UMGE RU https://pubmed.ncbi.nlm.nih.gov/16456549 DM2V4EO DI DM2V4EO DM2V4EO DN BCMA CART and huCART19 DM2V4EO TI TTZ3P4W DM2V4EO TN B-cell maturation protein (TNFRSF17) DM2V4EO MA CAR-T-Cell-Therapy(Dual specific) DM2V4EO RN ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma DM2V4EO RU https://clinicaltrials.gov/ct2/show/NCT03549442 DM2V4EO DI DM2V4EO DM2V4EO DN BCMA CART and huCART19 DM2V4EO TI TTW640A DM2V4EO TN B-lymphocyte surface antigen B4 (CD19) DM2V4EO MA CAR-T-Cell-Therapy(Dual specific) DM2V4EO RN ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma DM2V4EO RU https://clinicaltrials.gov/ct2/show/NCT03549442 DM2WMJ7 DI DM2WMJ7 DM2WMJ7 DN BMS-816336 DM2WMJ7 TI TTN7BL9 DM2WMJ7 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM2WMJ7 MA Inhibitor DM2WMJ7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027626) DM2WMJ7 RU http://adisinsight.springer.com/drugs/800027626 DM2WZ86 DI DM2WZ86 DM2WZ86 DN TRV250 DM2WZ86 TI TT27RFC DM2WZ86 TN Opioid receptor delta (OPRD1) DM2WZ86 MA Modulator DM2WZ86 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2WZ86 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM2XIRW DI DM2XIRW DM2XIRW DN NMS-03305293 DM2XIRW TI TTVDSZ0 DM2XIRW TN Poly [ADP-ribose] polymerase 1 (PARP1) DM2XIRW MA Inhibitor DM2XIRW RN NMS-P293, a PARP-1 selective inhibitor with no trapping activity and high CNS penetration, possesses potent in vivo efficacy and represents a novel therapeutic option for brain localized metastases and glioblastoma. Cancer Res 2018;78(13 Suppl):Abstract nr 4843. DM2XIRW RU https://cancerres.aacrjournals.org/content/78/13_Supplement/4843 DM2Y4D7 DI DM2Y4D7 DM2Y4D7 DN UCARTCS1 DM2Y4D7 TI TT7ILZ1 DM2Y4D7 TN SLAM family member 7 SLAMF7 (CS1) DM2Y4D7 RN ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health. DM2Y4D7 RU https://clinicaltrials.gov/ct2/show/NCT04142619 DM2Y4FG DI DM2Y4FG DM2Y4FG DN PHA-793887 DM2Y4FG TI TT7HF4W DM2Y4FG TN Cyclin-dependent kinase 2 (CDK2) DM2Y4FG MA Inhibitor DM2Y4FG RN A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70. DM2Y4FG RU https://pubmed.ncbi.nlm.nih.gov/21368575 DM2Y4FG DI DM2Y4FG DM2Y4FG DN PHA-793887 DM2Y4FG TI TT0PG8F DM2Y4FG TN Cyclin-dependent kinase 4 (CDK4) DM2Y4FG MA Inhibitor DM2Y4FG RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DM2Y4FG RU https://pubmed.ncbi.nlm.nih.gov/21253554 DM2Y4FG DI DM2Y4FG DM2Y4FG DN PHA-793887 DM2Y4FG TI TTH6V3D DM2Y4FG TN Cyclin-dependent kinase 1 (CDK1) DM2Y4FG MA Inhibitor DM2Y4FG RN A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70. DM2Y4FG RU https://pubmed.ncbi.nlm.nih.gov/21368575 DM2Z4YQ DI DM2Z4YQ DM2Z4YQ DN BI 907828 DM2Z4YQ TI TT08GJW DM2Z4YQ TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DM2Z4YQ MA Inhibitor DM2Z4YQ RN MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020 Nov;34(11):2858-2874. DM2Z4YQ RU https://pubmed.ncbi.nlm.nih.gov/32651541 DM2ZJ1C DI DM2ZJ1C DM2ZJ1C DN PF-06747143 DM2ZJ1C TI TTBID49 DM2ZJ1C TN C-X-C chemokine receptor type 4 (CXCR4) DM2ZJ1C MA Antagonist DM2ZJ1C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM2ZJ1C RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM31FOP DI DM31FOP DM31FOP DN NI-0101 DM31FOP TI TTISGCA DM31FOP TN Toll-like receptor 4 (TLR4) DM31FOP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DM31FOP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DM31RQS DI DM31RQS DM31RQS DN BAY 86-8050 DM31RQS TI TTYCILE DM31RQS TN Vasopressin receptor (VR) DM31RQS MA Modulator DM31RQS RN WO patent application no. 2015,0365,63, Disubstituted trifluormethyl pyrimidinones and use thereof as ccr2 antagonists. DM31RQS RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20150319&CC=WO&NR=2015036563A1&KC=A1 DM31VNC DI DM31VNC DM31VNC DN DS-8895 DM31VNC TI TTRJB2G DM31VNC TN Ephrin type-A receptor 2 (EPHA2) DM31VNC RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DM31VNC RU http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf DM324RM DI DM324RM DM324RM DN JCAR023 DM324RM TI TTC9D3K DM324RM TN Neural cell adhesion molecule L1 (L1CAM) DM324RM MA CAR-T-Cell-Therapy DM324RM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM324RM RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM32TFO DI DM32TFO DM32TFO DN CP-870,893 DM32TFO TI TTN6Y9A DM32TFO TN CD40L receptor (CD40) DM32TFO MA Agonist DM32TFO RN Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007 Mar 1;25(7):876-83. DM32TFO RU https://pubmed.ncbi.nlm.nih.gov/17327609 DM32VKQ DI DM32VKQ DM32VKQ DN NI-0701 DM32VKQ TI TT9DWLC DM32VKQ TN T-cell-specific protein RANTES (CCL5) DM32VKQ MA Inhibitor DM32VKQ RN Handbook of Therapeutic Antibodies. Stefan D bel, Janice M. Reichert, 2014. Page(1021). DM32VKQ RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA1021&lpg=PA1021&dq=%E2%80%9CNI-0701%E2%80%9D++RANTES&source=bl&ots=OSgek1U9gk&sig=gMuc7gZ8ZO4IH9EIdhuDhOrHTaU&hl=zh-CN&sa=X&ved=0CC8Q6AEwA2oVChMItuDj3InGyAIVzQmOCh0QPQ3H#v=onepage&q=%E2%80%9CNI-0701%E2%80%9D%20%20RANTES&f=false DM3402P DI DM3402P DM3402P DN MDX-1411 DM3402P TI TTNCIE0 DM3402P TN CD70 antigen (CD27-L) DM3402P RN Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3. DM3402P RU https://pubmed.ncbi.nlm.nih.gov/19741612 DM3415L DI DM3415L DM3415L DN BAX-499 DM3415L TI TT068JH DM3415L TN Tissue factor pathway inhibitor (TFPI) DM3415L MA Inhibitor DM3415L RN Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45. DM3415L RU https://pubmed.ncbi.nlm.nih.gov/23528042 DM3427C DI DM3427C DM3427C DN PF-4427429 DM3427C TI TTAFORY DM3427C TN Calcitonin gene-related peptide (CALC) DM3427C MA Modulator DM3427C RN Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic Migraine Study Meeting Primary and Secondary Endpoints DM3427C RU http://www.tevapharm.com/news/teva_announces_positive_results_for_tev_48125_in_phase_iib_chronic_migraine_study_meeting_primary_and_secondary_endpoints_02_15.aspx DM36EY7 DI DM36EY7 DM36EY7 DN AZD4721 DM36EY7 TI TT30C9G DM36EY7 TN C-X-C chemokine receptor type 2 (CXCR2) DM36EY7 MA Antagonist DM36EY7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038326) DM36EY7 RU http://adisinsight.springer.com/drugs/800038326 DM36FOG DI DM36FOG DM36FOG DN APD-597 DM36FOG TI TT7QNVC DM36FOG TN Glucose-dependent insulinotropic receptor (GPR119) DM36FOG MA Agonist DM36FOG RN Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5. DM36FOG RU https://pubmed.ncbi.nlm.nih.gov/22264481 DM36ONA DI DM36ONA DM36ONA DN Turofexorate isopropyl DM36ONA TI TTS4UGC DM36ONA TN Farnesoid X-activated receptor (FXR) DM36ONA MA Modulator DM36ONA RN A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G543-52. DM36ONA RU https://pubmed.ncbi.nlm.nih.gov/19136377 DM36PKZ DI DM36PKZ DM36PKZ DN PF-3758309 DM36PKZ TI TT7Y3BZ DM36PKZ TN PAK-4 protein kinase (PAK4) DM36PKZ MA Inhibitor DM36PKZ RN Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9446-51. DM36PKZ RU https://pubmed.ncbi.nlm.nih.gov/20439741 DM36WTQ DI DM36WTQ DM36WTQ DN AC-262271 DM36WTQ TI TTZ9SOR DM36WTQ TN Muscarinic acetylcholine receptor M1 (CHRM1) DM36WTQ MA Agonist DM36WTQ RN Phase I clinical trial of muscarinic agonist (AC-262271) for treating glaucoma. Acadia Pharmaceuticals. DM36WTQ RU http://www.biocentury.com/products/ac-262271 DM3720L DI DM3720L DM3720L DN REGN5093 DM3720L TI TTNDSF4 DM3720L TN Proto-oncogene c-Met (MET) DM3720L MA Inhibitor DM3720L RN Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals. DM3720L RU https://www.regeneron.com/science/pipeline DM37OJN DI DM37OJN DM37OJN DN CD20-CAR-T Cells DM37OJN TI TTUE541 DM37OJN TN Leukocyte surface antigen Leu-16 (CD20) DM37OJN MA CAR-T-Cell-Therapy DM37OJN RN ClinicalTrials.gov (NCT03576807) The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma DM37OJN RU https://clinicaltrials.gov/ct2/show/NCT03576807 DM38F50 DI DM38F50 DM38F50 DN PTX-35 DM38F50 TI TTDV6BQ DM38F50 TN Tumor necrosis factor receptor member 25 (TNFRSF25) DM38F50 MA Agonist DM38F50 RN Clinical pipeline report, company report or official report of Pelican Therapeutics. DM38F50 RU https://www.pelicantherapeutics.com/products DM38JZU DI DM38JZU DM38JZU DN EMD-1204831 DM38JZU TI TTNDSF4 DM38JZU TN Proto-oncogene c-Met (MET) DM38JZU MA Inhibitor DM38JZU RN 2012 ASCO Annual Meeting. DM38JZU RU http://meetinglibrary.asco.org/subcategories/2012%20ASCO%20Annual%20Meeting DM39LPN DI DM39LPN DM39LPN DN CarVAC DM39LPN TI TTW640A DM39LPN TN B-lymphocyte surface antigen B4 (CD19) DM39LPN RN ClinicalTrials.gov (NCT04156243) CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies. U.S. National Institutes of Health. DM39LPN RU https://clinicaltrials.gov/ct2/show/NCT04156243 DM39PSZ DI DM39PSZ DM39PSZ DN ME1100 DM39PSZ TI TTOVFH2 DM39PSZ TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM39PSZ MA Inhibitor DM39PSZ RN ClinicalTrials.gov (NCT01961830) Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers. U.S. National Institutes of Health. DM39PSZ RU https://clinicaltrials.gov/ct2/show/NCT01961830 DM39QWN DI DM39QWN DM39QWN DN ANS-6637 DM39QWN TI TTFLN4T DM39QWN TN Mitochondrial aldehyde dehydrogenase (ALDH2) DM39QWN MA Inhibitor DM39QWN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM39QWN RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM3AD65 DI DM3AD65 DM3AD65 DN EGFR806-specific CAR T cell DM3AD65 TI TTGKNB4 DM3AD65 TN Epidermal growth factor receptor (EGFR) DM3AD65 MA CAR-T-Cell-Therapy DM3AD65 RN ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors DM3AD65 RU https://clinicaltrials.gov/ct2/show/NCT03638167 DM3AHNX DI DM3AHNX DM3AHNX DN CAR-T Cells targeting CD19 DM3AHNX TI TTW640A DM3AHNX TN B-lymphocyte surface antigen B4 (CD19) DM3AHNX MA CAR-T-Cell-Therapy DM3AHNX RN ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia DM3AHNX RU https://clinicaltrials.gov/ct2/show/NCT03186118 DM3DUHL DI DM3DUHL DM3DUHL DN TESTOSTERONE BUCICLATE DM3DUHL TI TTS64P2 DM3DUHL TN Androgen receptor (AR) DM3DUHL MA Agonist DM3DUHL RN Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26. DM3DUHL RU https://pubmed.ncbi.nlm.nih.gov/2912689 DM3E20L DI DM3E20L DM3E20L DN Nagrestipen DM3E20L TI TT8I4WB DM3E20L TN Macrophage inflammatory protein 1-alpha (CCL3) DM3E20L MA Modulator DM3E20L RN Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy. Cancer Res. 2014 Sep 15;74(18):5070-8. DM3E20L RU https://pubmed.ncbi.nlm.nih.gov/25038226 DM3E2IY DI DM3E2IY DM3E2IY DN 225Ac-labelled aCD38 DM3E2IY TI TTPURFN DM3E2IY TN Cyclic ADP-ribose hydrolase 1 (CD38) DM3E2IY RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DM3E2IY RU https://pubmed.ncbi.nlm.nih.gov/32728208 DM3EWUX DI DM3EWUX DM3EWUX DN AZD8701 DM3EWUX TI TT1X3QF DM3EWUX TN FOXP3 messenger RNA (FOXP3 mRNA) DM3EWUX MA Inhibitor DM3EWUX RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DM3EWUX RU https://www.ionispharma.com/ionis-innovation/pipeline/ DM3GSB2 DI DM3GSB2 DM3GSB2 DN TPST-1495 DM3GSB2 TI TT79WV3 DM3GSB2 TN Prostaglandin E2 receptor EP4 (PTGER4) DM3GSB2 MA Antagonist DM3GSB2 RN Clinical pipeline report, company report or official report of Tempest Therapeutics. DM3GSB2 RU https://www.tempesttx.com/pipeline/ DM3GSB2 DI DM3GSB2 DM3GSB2 DN TPST-1495 DM3GSB2 TI TT1ZAVI DM3GSB2 TN Prostaglandin E2 receptor EP2 (PTGER2) DM3GSB2 MA Antagonist DM3GSB2 RN Clinical pipeline report, company report or official report of Tempest Therapeutics. DM3GSB2 RU https://www.tempesttx.com/pipeline/ DM3GSPR DI DM3GSPR DM3GSPR DN GEM3PSCA DM3GSPR TI TT9T4AV DM3GSPR TN Prostate stem cell antigen (PSCA) DM3GSPR MA Inhibitor DM3GSPR RN Clinical pipeline report, company report or official report of Gemoab. DM3GSPR RU https://www.gemoab.com/gem3psca DM3H6YC DI DM3H6YC DM3H6YC DN G-619 DM3H6YC TI TT2O84V DM3H6YC TN Thromboxane A2 receptor (TBXA2R) DM3H6YC MA Modulator DM3H6YC RN G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9. DM3H6YC RU https://pubmed.ncbi.nlm.nih.gov/8566149 DM3H6YC DI DM3H6YC DM3H6YC DN G-619 DM3H6YC TI TTKNWZ4 DM3H6YC TN Thromboxane-A synthase (TBXAS1) DM3H6YC MA Modulator DM3H6YC RN G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9. DM3H6YC RU https://pubmed.ncbi.nlm.nih.gov/8566149 DM3HOUX DI DM3HOUX DM3HOUX DN OPL-CCL2-LPM DM3HOUX TI TTFZYTO DM3HOUX TN C-C chemokine receptor type 2 (CCR2) DM3HOUX MA Modulator DM3HOUX RN Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol. 2009 February; 155(2): 295-303. DM3HOUX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675261/ DM3IJQ5 DI DM3IJQ5 DM3IJQ5 DN MEDI5117 DM3IJQ5 TI TTT1V78 DM3IJQ5 TN Interleukin-6 (IL6) DM3IJQ5 MA Modulator DM3IJQ5 RN Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807. DM3IJQ5 RU https://pubmed.ncbi.nlm.nih.gov/21723291 DM3IPSX DI DM3IPSX DM3IPSX DN ATLCAR.CD30.CCR4 cells DM3IPSX TI TT2GM5R DM3IPSX TN Lymphocyte activation antigen CD30 (TNFRSF8) DM3IPSX MA CAR-T-Cell-Therapy(Dual specific) DM3IPSX RN ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL DM3IPSX RU https://clinicaltrials.gov/ct2/show/NCT03602157 DM3IPSX DI DM3IPSX DM3IPSX DN ATLCAR.CD30.CCR4 cells DM3IPSX TI TT7HQD0 DM3IPSX TN C-C chemokine receptor type 4 (CCR4) DM3IPSX MA CAR-T-Cell-Therapy(Dual specific) DM3IPSX RN ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL DM3IPSX RU https://clinicaltrials.gov/ct2/show/NCT03602157 DM3IT6R DI DM3IT6R DM3IT6R DN N9-GP DM3IT6R TI TTFEZ5Q DM3IT6R TN Coagulation factor IX (F9) DM3IT6R MA Modulator DM3IT6R RN Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011 Sep 8;118(10):2695-701. DM3IT6R RU https://pubmed.ncbi.nlm.nih.gov/21555744 DM3J1T9 DI DM3J1T9 DM3J1T9 DN CPC-212 DM3J1T9 TI TT1RS9F DM3J1T9 TN Acetylcholinesterase (AChE) DM3J1T9 MA Inhibitor DM3J1T9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3J1T9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM3JOIX DI DM3JOIX DM3JOIX DN BI-754091 DM3JOIX TI TTNBFWK DM3JOIX TN Programmed cell death protein 1 (PD-1) DM3JOIX RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM3JOIX RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM3JUXW DI DM3JUXW DM3JUXW DN MVA HER-2 AutoVac DM3JUXW TI TT6EO5L DM3JUXW TN Erbb2 tyrosine kinase receptor (HER2) DM3JUXW RN Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013 Jul;24(7):1740-8. DM3JUXW RU https://pubmed.ncbi.nlm.nih.gov/23585514 DM3K4FY DI DM3K4FY DM3K4FY DN TG-1801 DM3K4FY TI TTW640A DM3K4FY TN B-lymphocyte surface antigen B4 (CD19) DM3K4FY RN Clinical pipeline report, company report or official report of TG Theraputics. DM3K4FY RU https://www.tgtherapeutics.com/our-pipeline/tg-1801/ DM3K4FY DI DM3K4FY DM3K4FY DN TG-1801 DM3K4FY TI TT28S46 DM3K4FY TN Leukocyte surface antigen CD47 (CD47) DM3K4FY RN Clinical pipeline report, company report or official report of TG Theraputics. DM3K4FY RU https://www.tgtherapeutics.com/our-pipeline/tg-1801/ DM3K8VM DI DM3K8VM DM3K8VM DN BMS-908662 DM3K8VM TI TTWCGQT DM3K8VM TN Serine/threonine-protein kinase B-raf (BRAF) DM3K8VM MA Inhibitor DM3K8VM RN Clinical pipeline report, company report or official report of Exelixis (2011). DM3K8VM RU http://www.exelixis.com/pipeline DM3KARJ DI DM3KARJ DM3KARJ DN GSK2647544 DM3KARJ TI TTDNFMT DM3KARJ TN Platelet-activating factor acetylhydrolase (PLA2G7) DM3KARJ MA Modulator DM3KARJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1432). DM3KARJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432 DM3KYO4 DI DM3KYO4 DM3KYO4 DN ZD-9379 DM3KYO4 TI TTZ8EM9 DM3KYO4 TN Glycine receptor (GlyR) DM3KYO4 MA Modulator DM3KYO4 RN Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res. 2002 Mar;4(2):119-26. DM3KYO4 RU https://pubmed.ncbi.nlm.nih.gov/12829411 DM3LOF1 DI DM3LOF1 DM3LOF1 DN E 7974 DM3LOF1 TI TTML2WA DM3LOF1 TN Tubulin (TUB) DM3LOF1 MA Inhibitor DM3LOF1 RN Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36. DM3LOF1 RU https://pubmed.ncbi.nlm.nih.gov/18764727 DM3LRAC DI DM3LRAC DM3LRAC DN XL092 DM3LRAC TI TTVJ1D8 DM3LRAC TN Vascular endothelial growth factor receptor (VEGFR) DM3LRAC MA Inhibitor DM3LRAC RN Clinical pipeline report, company report or official report of Exelixis. DM3LRAC RU https://www.exelixis.com/pipeline/ DM3LRAC DI DM3LRAC DM3LRAC DN XL092 DM3LRAC TI TTNDSF4 DM3LRAC TN Proto-oncogene c-Met (MET) DM3LRAC MA Inhibitor DM3LRAC RN Clinical pipeline report, company report or official report of Exelixis. DM3LRAC RU https://www.exelixis.com/pipeline/ DM3LRAF DI DM3LRAF DM3LRAF DN CD19CAT-41BBZ CAR T-cells DM3LRAF TI TTW640A DM3LRAF TN B-lymphocyte surface antigen B4 (CD19) DM3LRAF MA CAR-T-Cell-Therapy DM3LRAF RN ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19 DM3LRAF RU https://clinicaltrials.gov/ct2/show/NCT02935257 DM3O52N DI DM3O52N DM3O52N DN RLY-4008 DM3O52N TI TTGJVQM DM3O52N TN Fibroblast growth factor receptor 2 (FGFR2) DM3O52N MA Inhibitor DM3O52N RN Clinical pipeline report, company report or official report of Relay Therapeutics. DM3O52N RU https://relaytx.com/pipeline/ DM3OFZC DI DM3OFZC DM3OFZC DN Anti-BCMA CAR T cells DM3OFZC TI TTZ3P4W DM3OFZC TN B-cell maturation protein (TNFRSF17) DM3OFZC MA CAR-T-Cell-Therapy DM3OFZC RN ClinicalTrials.gov (NCT03559764) Study of BCMA CAR-T in Multiple Myeloma DM3OFZC RU https://clinicaltrials.gov/ct2/show/NCT03559764 DM3OP41 DI DM3OP41 DM3OP41 DN LXR 623 DM3OP41 TI TTM1EQF DM3OP41 TN Oxysterols receptor LXR (NR1H) DM3OP41 MA Modulator DM3OP41 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DM3OP41 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DM3P0H1 DI DM3P0H1 DM3P0H1 DN Duvortuxizumab DM3P0H1 TI TTW640A DM3P0H1 TN B-lymphocyte surface antigen B4 (CD19) DM3P0H1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3P0H1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM3PC0J DI DM3PC0J DM3PC0J DN N-8295 DM3PC0J TI TTSHG0T DM3PC0J TN Toll-like receptor 9 (TLR9) DM3PC0J RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019871) DM3PC0J RU http://adisinsight.springer.com/drugs/800019871 DM3PJSE DI DM3PJSE DM3PJSE DN TP-271 DM3PJSE TI TTOVFH2 DM3PJSE TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM3PJSE MA Inhibitor DM3PJSE RN Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. DM3PJSE RU https://www.tphase.com/products/pipeline/ DM3PVBJ DI DM3PVBJ DM3PVBJ DN M2698 DM3PVBJ TI TTWTSCV DM3PVBJ TN RAC-alpha serine/threonine-protein kinase (AKT1) DM3PVBJ MA Inhibitor DM3PVBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PVBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3PVBJ DI DM3PVBJ DM3PVBJ DN M2698 DM3PVBJ TI TTAZ05C DM3PVBJ TN RAC-gamma serine/threonine-protein kinase (AKT3) DM3PVBJ MA Inhibitor DM3PVBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PVBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3PVBJ DI DM3PVBJ DM3PVBJ DN M2698 DM3PVBJ TI TTG0U4H DM3PVBJ TN Ribosomal protein S6 kinase beta-1 (S6K1) DM3PVBJ MA Inhibitor DM3PVBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3PVBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM3RSMF DI DM3RSMF DM3RSMF DN Sgx523 DM3RSMF TI TTNDSF4 DM3RSMF TN Proto-oncogene c-Met (MET) DM3RSMF MA Inhibitor DM3RSMF RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DM3RSMF RU http://www.centerwatch.com/ DM3U2VY DI DM3U2VY DM3U2VY DN CG-200745 DM3U2VY TI TTBH0VX DM3U2VY TN Histone deacetylase (HDAC) DM3U2VY MA Inhibitor DM3U2VY RN Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379. DM3U2VY RU https://pubmed.ncbi.nlm.nih.gov/25781604 DM3VC6T DI DM3VC6T DM3VC6T DN EW-A-401 DM3VC6T TI TT2Q6G1 DM3VC6T TN Vascular endothelial growth factor receptor 1 (FLT-1) DM3VC6T MA Modulator DM3VC6T RN DOI: http://dx.doi.org/10.1016/j.tips.2014.09.007 DM3VC6T RU http://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(14)00160-6 DM3WP70 DI DM3WP70 DM3WP70 DN MEDI-547 DM3WP70 TI TTRJB2G DM3WP70 TN Ephrin type-A receptor 2 (EPHA2) DM3WP70 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1822). DM3WP70 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1822 DM3YZCV DI DM3YZCV DM3YZCV DN ICAR30 T cells DM3YZCV TI TT2GM5R DM3YZCV TN Lymphocyte activation antigen CD30 (TNFRSF8) DM3YZCV MA CAR-T-Cell-Therapy DM3YZCV RN ClinicalTrials.gov (NCT03383965) CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas DM3YZCV RU https://clinicaltrials.gov/ct2/show/NCT03383965 DM3Z07E DI DM3Z07E DM3Z07E DN TP-1287 DM3Z07E TI TT1LVF2 DM3Z07E TN Cyclin-dependent kinase 9 (CDK9) DM3Z07E MA Inhibitor DM3Z07E RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DM3Z07E RU https://www.sdponcology.com/pipeline/ DM3Z2JB DI DM3Z2JB DM3Z2JB DN GDC-0349 DM3Z2JB TI TTCJG29 DM3Z2JB TN Serine/threonine-protein kinase mTOR (mTOR) DM3Z2JB MA Inhibitor DM3Z2JB RN Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Med Chem Lett. 2012 Nov 29;4(1):103-7. DM3Z2JB RU https://pubmed.ncbi.nlm.nih.gov/24900569 DM3ZW6A DI DM3ZW6A DM3ZW6A DN VAN-10-4-eluting stent DM3ZW6A TI TT4TQBX DM3ZW6A TN Extracellular signal-regulated kinase 2 (ERK2) DM3ZW6A MA Inhibitor DM3ZW6A RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DM3ZW6A RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DM3ZW6A DI DM3ZW6A DM3ZW6A DN VAN-10-4-eluting stent DM3ZW6A TI TT1MG9E DM3ZW6A TN Extracellular signal-regulated kinase 1 (ERK1) DM3ZW6A MA Inhibitor DM3ZW6A RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DM3ZW6A RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DM42KZW DI DM42KZW DM42KZW DN DS-1093 DM42KZW TI TTJQFBG DM42KZW TN HIF-prolyl hydroxylase (HPH) DM42KZW MA Modulator DM42KZW RN Company report (Daiichisankyo) DM42KZW RU http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf DM43GPX DI DM43GPX DM43GPX DN BVI-007 DM43GPX TI TTIHYA4 DM43GPX TN Thrombopoietin receptor (MPL) DM43GPX MA Antagonist DM43GPX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DM43GPX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DM43GPX DI DM43GPX DM43GPX DN BVI-007 DM43GPX TI TTCG5PE DM43GPX TN Thrombopoietin (THPO) DM43GPX MA Inhibitor DM43GPX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM43GPX RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM43RV5 DI DM43RV5 DM43RV5 DN BM-ca DM43RV5 TI TTUE541 DM43RV5 TN Leukocyte surface antigen Leu-16 (CD20) DM43RV5 RN BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties. Int J Oncol. 2011 Feb;38(2):335-44. DM43RV5 RU https://pubmed.ncbi.nlm.nih.gov/21152859 DM43X0Q DI DM43X0Q DM43X0Q DN IM19 DM43X0Q TI TTW640A DM43X0Q TN B-lymphocyte surface antigen B4 (CD19) DM43X0Q MA CAR-T-Cell-Therapy DM43X0Q RN ClinicalTrials.gov (NCT03528421) Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients DM43X0Q RU https://clinicaltrials.gov/ct2/show/NCT03528421 DM4581B DI DM4581B DM4581B DN CC-94676 DM4581B TI TTS64P2 DM4581B TN Androgen receptor (AR) DM4581B MA Degrader DM4581B RN ClinicalTrials.gov (NCT04428788) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer. U.S. National Institutes of Health. DM4581B RU https://clinicaltrials.gov/ct2/show/NCT04428788 DM45BHM DI DM45BHM DM45BHM DN CEA CAR-T DM45BHM TI TTY6DTE DM45BHM TN Carcinoembryonic antigen CEA (CD66e) DM45BHM RN Clinical pipeline report, company report or official report of Sorrento Therapeutics. DM45BHM RU https://sorrentotherapeutics.com/research/immuno-oncology/car-t/ DM45HT6 DI DM45HT6 DM45HT6 DN RG6062 DM45HT6 TI TTUE541 DM45HT6 TN Leukocyte surface antigen Leu-16 (CD20) DM45HT6 MA Modulator DM45HT6 RN Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. J Clin Oncol. 2021 Jun 20;39(18):1959-1970. DM45HT6 RU https://pubmed.ncbi.nlm.nih.gov/33739857 DM45MR0 DI DM45MR0 DM45MR0 DN HIP-2B DM45MR0 TI TTL4H8N DM45MR0 TN Regenerating human pro-islet peptide (REG3A) DM45MR0 MA Modulator DM45MR0 RN Hepatocarcinoma-intestine-pancreas/pancreatic associated protein (HIP/PAP) is expressed and secreted by proliferating ductules as well as by hepatocarcinoma and cholangiocarcinoma cells. Am J Pathol.1999 Nov;155(5):1525-33. DM45MR0 RU https://pubmed.ncbi.nlm.nih.gov/10550309 DM45SGE DI DM45SGE DM45SGE DN JNJ-39439335 DM45SGE TI TTMI6F5 DM45SGE TN Transient receptor potential cation channel V1 (TRPV1) DM45SGE MA Antagonist DM45SGE RN Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem. 2015 May 14;58(9):3859-74. DM45SGE RU https://pubmed.ncbi.nlm.nih.gov/25850459 DM491NI DI DM491NI DM491NI DN SM04755 DM491NI TI TTFPSHI DM491NI TN Wnt signaling pathway (Wnt pathway) DM491NI MA Modulator DM491NI RN A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer. DM491NI RU https://clinicaltrials.gov/ct2/show/NCT02191761?term=NCT02191761&rank=1 DM4953W DI DM4953W DM4953W DN KOS-2187 DM4953W TI TT953CX DM4953W TN Motilin receptor (MLNR) DM4953W MA Agonist DM4953W RN Kosan Announces Selection of KOS-2187 As Motilide Clinical Candidate at World Congress of Gastroenterology Meeting. Kosan. 2006. DM4953W RU http://www.redorbit.com/news/health/237602/kosan_announces_selection_of_kos2187_as_motilide_clinical_candidate_at/ DM49O6Y DI DM49O6Y DM49O6Y DN ABBV-323 DM49O6Y TI TTN6Y9A DM49O6Y TN CD40L receptor (CD40) DM49O6Y MA Antagonist DM49O6Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM49O6Y RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM49RAT DI DM49RAT DM49RAT DN CD19 Redirected Autologous T Cells DM49RAT TI TTW640A DM49RAT TN B-lymphocyte surface antigen B4 (CD19) DM49RAT MA CAR-T-Cell-Therapy DM49RAT RN ClinicalTrials.gov (NCT03030976) A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE) DM49RAT RU https://clinicaltrials.gov/ct2/show/NCT03030976 DM49RI7 DI DM49RI7 DM49RI7 DN EP-51216 DM49RI7 TI TTKMAZ6 DM49RI7 TN Growth hormone receptor (GHR) DM49RI7 MA Agonist DM49RI7 RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM49RI7 RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM49VWQ DI DM49VWQ DM49VWQ DN JNJ-3534 DM49VWQ TI TTGV6LY DM49VWQ TN Nuclear receptor ROR-gamma (RORG) DM49VWQ MA Modulator DM49VWQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM49VWQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM4A3U7 DI DM4A3U7 DM4A3U7 DN DAVLB-HYDRAZIDE DM4A3U7 TI TTYFKSZ DM4A3U7 TN Tubulin beta (TUBB) DM4A3U7 MA Modulator DM4A3U7 RN An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971. DM4A3U7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667160/ DM4AU8K DI DM4AU8K DM4AU8K DN PX-478 DM4AU8K TI TTQHWNA DM4AU8K TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM4AU8K MA Inhibitor DM4AU8K RN The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects. Mol Cancer Ther. 2009 Apr;8(4):947-58. DM4AU8K RU https://pubmed.ncbi.nlm.nih.gov/19372568 DM4AXPT DI DM4AXPT DM4AXPT DN VMD-928 DM4AXPT TI TTTDVOJ DM4AXPT TN Tropomyosin-related kinase A (TrkA) DM4AXPT MA Inhibitor DM4AXPT RN ClinicalTrials.gov (NCT03556228) Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma. U.S. National Institutes of Health. DM4AXPT RU https://clinicaltrials.gov/ct2/show/NCT03556228 DM4BD5U DI DM4BD5U DM4BD5U DN E2730 DM4BD5U TI TTPW8EF DM4BD5U TN Synaptic transmission (ST) DM4BD5U MA Modulator DM4BD5U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4BD5U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4CXE2 DI DM4CXE2 DM4CXE2 DN CAR-20/19-T Cells DM4CXE2 TI TTUE541 DM4CXE2 TN Leukocyte surface antigen Leu-16 (CD20) DM4CXE2 MA CAR-T-Cell-Therapy(Dual specific) DM4CXE2 RN ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells DM4CXE2 RU https://clinicaltrials.gov/ct2/show/NCT03375619 DM4CXE2 DI DM4CXE2 DM4CXE2 DN CAR-20/19-T Cells DM4CXE2 TI TTW640A DM4CXE2 TN B-lymphocyte surface antigen B4 (CD19) DM4CXE2 MA CAR-T-Cell-Therapy(Dual specific) DM4CXE2 RN ClinicalTrials.gov (NCT03375619) Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells DM4CXE2 RU https://clinicaltrials.gov/ct2/show/NCT03375619 DM4CY2G DI DM4CY2G DM4CY2G DN PEDF gene therapy DM4CY2G TI TTR59S1 DM4CY2G TN Pigment epithelium-derived factor (SERPINF1) DM4CY2G MA Inhibitor DM4CY2G RN Adenovector pigment epithelium-derived factor (AdPEDF) delivery for wet age-related macular degeneration. Retina. 2005 Dec;25(8 Suppl):S48-S49. DM4CY2G RU https://pubmed.ncbi.nlm.nih.gov/16374334 DM4CZ2Y DI DM4CZ2Y DM4CZ2Y DN ARX-424 DM4CZ2Y TI TT4TZ8J DM4CZ2Y TN Interferon-beta (IFNB1) DM4CZ2Y MA Modulator DM4CZ2Y RN PEGylated interferon beta-1a in the treatment of multiple sclerosis - an update. Biologics. 2013; 7: 131-138. DM4CZ2Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ DM4D85V DI DM4D85V DM4D85V DN ARN-6039 DM4D85V TI TTGV6LY DM4D85V TN Nuclear receptor ROR-gamma (RORG) DM4D85V MA Agonist DM4D85V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4D85V RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM4F8AU DI DM4F8AU DM4F8AU DN HuCART-meso cells DM4F8AU TI TT4RXME DM4F8AU TN Mesothelin (MSLN) DM4F8AU MA CAR-T-Cell-Therapy DM4F8AU RN ClinicalTrials.gov (NCT03323944) CAR T Cell Immunotherapy for Pancreatic Cancer DM4F8AU RU https://clinicaltrials.gov/ct2/show/NCT03323944 DM4FOX0 DI DM4FOX0 DM4FOX0 DN AK107 DM4FOX0 TI TTV8N19 DM4FOX0 TN Immune checkpoint (ICH) DM4FOX0 MA Inhibitor DM4FOX0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4FOX0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4FW2E DI DM4FW2E DM4FW2E DN LMP400 DM4FW2E TI TTGTQHC DM4FW2E TN DNA topoisomerase I (TOP1) DM4FW2E MA Inhibitor DM4FW2E RN Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. DM4FW2E RU https://pubmed.ncbi.nlm.nih.gov/31227499 DM4G1SP DI DM4G1SP DM4G1SP DN AMG 596 DM4G1SP TI TTUN7MC DM4G1SP TN T-cell surface glycoprotein CD3 (CD3) DM4G1SP MA Inhibitor DM4G1SP RN Clinical pipeline report, company report or official report of Amgen. DM4G1SP RU https://www.amgenpipeline.com/ DM4G1SP DI DM4G1SP DM4G1SP DN AMG 596 DM4G1SP TI TTZ6B2I DM4G1SP TN Epidermal growth factor receptor variant III (EGFR vIII) DM4G1SP MA Inhibitor DM4G1SP RN Clinical pipeline report, company report or official report of Amgen. DM4G1SP RU https://www.amgenpipeline.com/ DM4GJ50 DI DM4GJ50 DM4GJ50 DN CXR-1002 DM4GJ50 TI TTTN5QW DM4GJ50 TN Serine/threonine-protein kinase pim-1 (PIM1) DM4GJ50 MA Inhibitor DM4GJ50 RN 123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46. DM4GJ50 RU http://www.researchgate.net/publication/251668212_123_Antitumor_activity_of_CXR1002_a_novel_anti-cancer_clinical_phase_compound_that_induces_ER_stress_and_inhibits_PIM_kinases_Human_tumor_xenograft_efficacy_and_in_vitro_mode_of_action DM4GKV2 DI DM4GKV2 DM4GKV2 DN TAK-243 DM4GKV2 TI TTU8HT1 DM4GKV2 TN Ubiquitin-activating enzyme (UBA) DM4GKV2 MA Inhibitor DM4GKV2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4GKV2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4I02O DI DM4I02O DM4I02O DN NJA-730 DM4I02O TI TT1ERKL DM4I02O TN CD40 messenger RNA (CD40 mRNA) DM4I02O MA Inhibitor DM4I02O RN Clinical pipeline report, company report or official report of NapaJen Pharma. DM4I02O RU https://www.napajen.com/en/study/nja-730/ DM4I92Z DI DM4I92Z DM4I92Z DN SKI-G-801 DM4I92Z TI TTGJCWZ DM4I92Z TN Fms-like tyrosine kinase 3 (FLT-3) DM4I92Z MA Inhibitor DM4I92Z RN Clinical pipeline report, company report or official report of Genosco. DM4I92Z RU http://genosco.com/pipeline/ski-g-801/ DM4IG16 DI DM4IG16 DM4IG16 DN ZYGK-1 DM4IG16 TI TTDLNGZ DM4IG16 TN Glucokinase (GCK) DM4IG16 MA Activator DM4IG16 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798). DM4IG16 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798 DM4JG0B DI DM4JG0B DM4JG0B DN DA-3607 DM4JG0B TI TTA5MS9 DM4JG0B TN TNF related apoptosis inducing ligand (TNFSF10) DM4JG0B MA Binder DM4JG0B RN Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther. 2006 Feb;13(4):330-8. DM4JG0B RU https://pubmed.ncbi.nlm.nih.gov/16195699 DM4KLNA DI DM4KLNA DM4KLNA DN SM08502 DM4KLNA TI TTFPSHI DM4KLNA TN Wnt signaling pathway (Wnt pathway) DM4KLNA MA Inhibitor DM4KLNA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4KLNA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4KPV0 DI DM4KPV0 DM4KPV0 DN ABT-413 DM4KPV0 TI TTS9BDA DM4KPV0 TN Spectrin non-erythroid beta chain 1 (SPTBN1) DM4KPV0 RN The Discovery of Novel Selective D1 Dopaminergic Agonists: A-68930, A-77636, A-86929, and ABT-413. International Journal of Medicinal Chemistry Volume 2011 (2011), Article ID 424535, Page(8). DM4KPV0 RU http://www.hindawi.com/journals/ijmc/2011/424535/ DM4LR0Y DI DM4LR0Y DM4LR0Y DN GSK-958108 DM4LR0Y TI TTSQIFT DM4LR0Y TN 5-HT 1A receptor (HTR1A) DM4LR0Y MA Antagonist DM4LR0Y RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM4LR0Y RU https://gsk.sylogent.com/files/24664.pdf DM4MDCH DI DM4MDCH DM4MDCH DN XMT-1001 DM4MDCH TI TTGTQHC DM4MDCH TN DNA topoisomerase I (TOP1) DM4MDCH MA Inhibitor DM4MDCH RN Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res. 2012 May 1;18(9):2591-602. DM4MDCH RU https://pubmed.ncbi.nlm.nih.gov/22392910 DM4MY9C DI DM4MY9C DM4MY9C DN IM156 DM4MY9C TI TTLAFZV DM4MY9C TN AMP-activated protein kinase (AMPK) DM4MY9C MA Inhibitor DM4MY9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4MY9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM4O07Q DI DM4O07Q DM4O07Q DN RWJ-68023 DM4O07Q TI TT953CX DM4O07Q TN Motilin receptor (MLNR) DM4O07Q MA Antagonist DM4O07Q RN Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function. Br J Clin Pharmacol. 2004 Apr;57(4):393-401. DM4O07Q RU https://pubmed.ncbi.nlm.nih.gov/15025736 DM4OTWL DI DM4OTWL DM4OTWL DN DA-1229 DM4OTWL TI TTDIGC1 DM4OTWL TN Dipeptidyl peptidase 4 (DPP-4) DM4OTWL MA Inhibitor DM4OTWL RN DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes. Life Sci. 2012 Jan 2;90(1-2):21-9. DM4OTWL RU https://pubmed.ncbi.nlm.nih.gov/22056373 DM4OWJ8 DI DM4OWJ8 DM4OWJ8 DN CART-ddBCMA DM4OWJ8 TI TTZ3P4W DM4OWJ8 TN B-cell maturation protein (TNFRSF17) DM4OWJ8 RN Clinical pipeline report, company report or official report of Arcellx. DM4OWJ8 RU https://arcellx.com/pipeline/overview/ DM4PWNU DI DM4PWNU DM4PWNU DN CD19 CAR T DM4PWNU TI TTW640A DM4PWNU TN B-lymphocyte surface antigen B4 (CD19) DM4PWNU MA CAR-T-Cell-Therapy DM4PWNU RN ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies DM4PWNU RU https://clinicaltrials.gov/ct2/show/NCT03559439 DM4QIOH DI DM4QIOH DM4QIOH DN JSM 6427 DM4QIOH TI TTHIZP9 DM4QIOH TN Integrin alpha-5 (ITGA5) DM4QIOH MA Antagonist DM4QIOH RN An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85. DM4QIOH RU https://pubmed.ncbi.nlm.nih.gov/18804537 DM4QIOH DI DM4QIOH DM4QIOH DN JSM 6427 DM4QIOH TI TTBVIQC DM4QIOH TN Integrin beta-1 (ITGB1) DM4QIOH MA Antagonist DM4QIOH RN An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85. DM4QIOH RU https://pubmed.ncbi.nlm.nih.gov/18804537 DM4QPT0 DI DM4QPT0 DM4QPT0 DN PF-05105679 DM4QPT0 TI TTXDKTO DM4QPT0 TN Long transient receptor potential channel 8 (TRPM8) DM4QPT0 MA Modulator DM4QPT0 RN Inhibition of TRPM8 channels reduces pain in the cold pressor test in humans. J Pharmacol Exp Ther. 2014 Nov;351(2):259-69. DM4QPT0 RU https://pubmed.ncbi.nlm.nih.gov/25125580 DM4QV8Y DI DM4QV8Y DM4QV8Y DN TT-301 DM4QV8Y TI TTRYK0X DM4QV8Y TN Interleukin-1 beta (IL1B) DM4QV8Y MA Inhibitor DM4QV8Y RN A Swell in the Armamentarium of Antiepileptic Drug Targets. Epilepsy Curr. 2011 Nov-Dec; 11(6): 172-176. DM4QV8Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220427/ DM4R6UV DI DM4R6UV DM4R6UV DN Bradykinin DM4R6UV TI TTGY8IW DM4R6UV TN B2 bradykinin receptor (BDKRB2) DM4R6UV MA Inhibitor DM4R6UV RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DM4R6UV RU https://pubmed.ncbi.nlm.nih.gov/10882364 DM4RHM5 DI DM4RHM5 DM4RHM5 DN Allogeneic CART-33 DM4RHM5 TI TTJVYO3 DM4RHM5 TN Myeloid cell surface antigen CD33 (CD33) DM4RHM5 MA CAR-T-Cell-Therapy DM4RHM5 RN ClinicalTrials.gov (NCT02799680) Allogeneic CART-33 for Relapsed/Refractory CD33+ AML DM4RHM5 RU https://clinicaltrials.gov/ct2/show/NCT02799680 DM4RK6P DI DM4RK6P DM4RK6P DN AR-12 DM4RK6P TI TT9QBI6 DM4RK6P TN Phosphoinositide dependent protein kinase-1 (PDPK1) DM4RK6P MA Modulator DM4RK6P RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM4RK6P RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM4SNK8 DI DM4SNK8 DM4SNK8 DN CARD-024 DM4SNK8 TI TTB2MXP DM4SNK8 TN Angiotensinogenase renin (REN) DM4SNK8 MA Agonist DM4SNK8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2413). DM4SNK8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413 DM4T5LH DI DM4T5LH DM4T5LH DN Guanosine DM4T5LH TI TTIU7X1 DM4T5LH TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM4T5LH MA Inhibitor DM4T5LH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4T5LH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4T5LH DI DM4T5LH DM4T5LH DN Guanosine DM4T5LH TI TT1U2YM DM4T5LH TN Cytomegalovirus DNA polymerase (CMV UL54) DM4T5LH MA Inhibitor DM4T5LH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4T5LH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4T5LH DI DM4T5LH DM4T5LH DN Guanosine DM4T5LH TI TTMCF1Y DM4T5LH TN Purine nucleoside phosphorylase (PNP) DM4T5LH MA Inhibitor DM4T5LH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4T5LH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4T916 DI DM4T916 DM4T916 DN BI-836845 DM4T916 TI TTT6LOU DM4T916 TN Insulin-like growth factor-I (IGF1) DM4T916 MA Modulator DM4T916 RN Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin.Mol Cancer Ther.2014 Feb;13(2):399-409. DM4T916 RU https://www.ncbi.nlm.nih.gov/pubmed/24296829 DM4TN6W DI DM4TN6W DM4TN6W DN ABI-H3733 DM4TN6W TI TTM42UJ DM4TN6W TN Hepatitis B virus Capsid protein (HBV C) DM4TN6W MA Inhibitor DM4TN6W RN Clinical pipeline report, company report or official report of Assembly Biosciences. DM4TN6W RU https://www.assemblybio.com/pipeline/ DM4UAPD DI DM4UAPD DM4UAPD DN Clemizole DM4UAPD TI TTALKDS DM4UAPD TN Hepatitis C virus Non-structural 4B (HCV NS4B) DM4UAPD MA Modulator DM4UAPD RN The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J Infect Dis. 2010 Jul 1;202(1):65-74. DM4UAPD RU https://pubmed.ncbi.nlm.nih.gov/20486856 DM4UOY5 DI DM4UOY5 DM4UOY5 DN TEN010 DM4UOY5 TI TTRA6BO DM4UOY5 TN Bromodomain-containing protein 4 (BRD4) DM4UOY5 MA Modulator DM4UOY5 RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DM4UOY5 RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DM4UVTO DI DM4UVTO DM4UVTO DN SYN125 DM4UVTO TI TTNBFWK DM4UVTO TN Programmed cell death protein 1 (PD-1) DM4UVTO RN Clinical pipeline report, company report or official report of Symphogen. DM4UVTO RU https://www.synermore.com/pipeline DM4VCJA DI DM4VCJA DM4VCJA DN CD30 CAR T Cells DM4VCJA TI TT2GM5R DM4VCJA TN Lymphocyte activation antigen CD30 (TNFRSF8) DM4VCJA MA CAR-T-Cell-Therapy DM4VCJA RN ClinicalTrials.gov (NCT02917083) CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) DM4VCJA RU https://clinicaltrials.gov/ct2/show/NCT02917083 DM4VTX6 DI DM4VTX6 DM4VTX6 DN RASV-Sp DM4VTX6 TI TTHI19T DM4VTX6 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM4VTX6 RN WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae. DM4VTX6 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100422&CC=WO&NR=2010045620A1&KC=A1 DM4W7Z0 DI DM4W7Z0 DM4W7Z0 DN Emactuzumab DM4W7Z0 TI TT0IQER DM4W7Z0 TN Macrophage colony-stimulating factor 1 (CSF1) DM4W7Z0 MA Antagonist DM4W7Z0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4W7Z0 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM4W92J DI DM4W92J DM4W92J DN TC-2216 DM4W92J TI TTL1ATN DM4W92J TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DM4W92J MA Modulator DM4W92J RN TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity.CNS Neurosci Ther.2008 Winter;14(4):266-77. DM4W92J RU https://www.ncbi.nlm.nih.gov/pubmed/19040552 DM4WAC2 DI DM4WAC2 DM4WAC2 DN APL-501 DM4WAC2 TI TTNBFWK DM4WAC2 TN Programmed cell death protein 1 (PD-1) DM4WAC2 MA Inhibitor DM4WAC2 RN Clinical pipeline report, company report or official report of Apollomics. DM4WAC2 RU https://www.apollomicsinc.com/zh-hans/pipeline-drugs/apl-501/ DM4WSHG DI DM4WSHG DM4WSHG DN DSP-1200 DM4WSHG TI TTWG9A4 DM4WSHG TN Adrenergic receptor alpha-2A (ADRA2A) DM4WSHG MA Antagonist DM4WSHG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WSHG RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM4WSHG DI DM4WSHG DM4WSHG DN DSP-1200 DM4WSHG TI TTJQOD7 DM4WSHG TN 5-HT 2A receptor (HTR2A) DM4WSHG MA Antagonist DM4WSHG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WSHG RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM4WSHG DI DM4WSHG DM4WSHG DN DSP-1200 DM4WSHG TI TTEX248 DM4WSHG TN Dopamine D2 receptor (D2R) DM4WSHG MA Antagonist DM4WSHG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4WSHG RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DM4XETK DI DM4XETK DM4XETK DN RX108 DM4XETK TI TTQ38E9 DM4XETK TN Sodium/potassium-transporting ATPase (SPT ATPase) DM4XETK MA Inhibitor DM4XETK RN ClinicalTrials.gov (NCT03646071) A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors. U.S. National Institutes of Health. DM4XETK RU https://clinicaltrials.gov/ct2/show/NCT03646071 DM4XT15 DI DM4XT15 DM4XT15 DN CART22-65s cells DM4XT15 TI TTM6QSK DM4XT15 TN B-cell receptor CD22 (CD22) DM4XT15 MA CAR-T-Cell-Therapy DM4XT15 RN ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL DM4XT15 RU https://clinicaltrials.gov/ct2/show/NCT03620058 DM4XZY9 DI DM4XZY9 DM4XZY9 DN DWP-09031 DM4XZY9 TI TTE4KHA DM4XZY9 TN Amyloid beta A4 protein (APP) DM4XZY9 MA Inhibitor DM4XZY9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM4XZY9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM4YA0D DI DM4YA0D DM4YA0D DN LBR-101 DM4YA0D TI TTY6O0Q DM4YA0D TN Calcitonin gene-related peptide receptor (CGRPR) DM4YA0D RN Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. Cephalalgia. 2013 Dec 23;34(7):483-492. DM4YA0D RU https://pubmed.ncbi.nlm.nih.gov/24366980 DM4YIWK DI DM4YIWK DM4YIWK DN VBY-129 DM4YIWK TI TTUMQVO DM4YIWK TN Cathepsin S (CTSS) DM4YIWK MA Inhibitor DM4YIWK RN Clinical pipeline report, company report or official report of ViroBay. DM4YIWK RU http://www.virobayinc.com/VBY-129.php DM4Z1CH DI DM4Z1CH DM4Z1CH DN 4-aminosalicylate sodium DM4Z1CH TI TTK0943 DM4Z1CH TN Prostaglandin G/H synthase (COX) DM4Z1CH MA Modulator DM4Z1CH RN 5-aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res. 2012 Apr;32(4):1193-202. DM4Z1CH RU https://pubmed.ncbi.nlm.nih.gov/22493349 DM4ZCY0 DI DM4ZCY0 DM4ZCY0 DN DSP-0337 DM4ZCY0 TI TTH8FZW DM4ZCY0 TN Signal transducer and activator of transcription 3 (STAT3) DM4ZCY0 MA Inhibitor DM4ZCY0 RN Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019 Jul 5;38(1):289. DM4ZCY0 RU https://pubmed.ncbi.nlm.nih.gov/31277685 DM4ZDOE DI DM4ZDOE DM4ZDOE DN DpC DM4ZDOE TI TTUDR0C DM4ZDOE TN Iron (Fe) DM4ZDOE MA Chelator DM4ZDOE RN Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development. Antioxid Redox Signal. 2019 Mar 10;30(8):1062-1082. DM4ZDOE RU https://pubmed.ncbi.nlm.nih.gov/29334758 DM4ZIRK DI DM4ZIRK DM4ZIRK DN VTX-1463 DM4ZIRK TI TT8CWFK DM4ZIRK TN Toll-like receptor 8 (TLR8) DM4ZIRK MA Agonist DM4ZIRK RN VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6. DM4ZIRK RU https://pubmed.ncbi.nlm.nih.gov/21548830 DM4ZK6G DI DM4ZK6G DM4ZK6G DN GSK3050002 DM4ZK6G TI TT2XAZY DM4ZK6G TN Liver and activation-regulated chemokine (CCL20) DM4ZK6G MA Inhibitor DM4ZK6G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM4ZK6G RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM4ZN8M DI DM4ZN8M DM4ZN8M DN N-803 DM4ZN8M TI TTJFA35 DM4ZN8M TN Interleukin-15 (IL15) DM4ZN8M MA Agonist DM4ZN8M RN The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339. DM4ZN8M RU https://pubmed.ncbi.nlm.nih.gov/32163523 DM51MSD DI DM51MSD DM51MSD DN BPX-101 DM51MSD TI TTIJP3Q DM51MSD TN TNF related activation protein (CD40LG) DM51MSD RN Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363. DM51MSD RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382847/ DM529QO DI DM529QO DM529QO DN pbi-shRNA STMN1 DM529QO TI TT7W5OT DM529QO TN STMN1 messenger RNA (STMN1 mRNA) DM529QO MA Inhibitor DM529QO RN Clinical pipeline report, company report or official report of Gradalis. DM529QO RU https://www.gradalisinc.com/product/development-pipeline DM52O7W DI DM52O7W DM52O7W DN GBR1302 DM52O7W TI TT6EO5L DM52O7W TN Erbb2 tyrosine kinase receptor (HER2) DM52O7W MA Inhibitor DM52O7W RN Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals. DM52O7W RU https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf DM52O7W DI DM52O7W DM52O7W DN GBR1302 DM52O7W TI TTUN7MC DM52O7W TN T-cell surface glycoprotein CD3 (CD3) DM52O7W MA Inhibitor DM52O7W RN Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals. DM52O7W RU https://glenmarkpharma-us.com/wp-content/uploads/GBR-1302_Pharmacology_ASCO-18_-FINAL.pdf DM53IPE DI DM53IPE DM53IPE DN SAR425899 DM53IPE TI TTVIMDE DM53IPE TN Glucagon-like peptide 1 receptor (GLP1R) DM53IPE MA Modulator DM53IPE RN Company report (Sanofi) (drug: LIXisenatide) DM53IPE RU http://www.sanofi.com/Images/38980_IR_Call_ADA2015_FINAL.pdf DM53IPE DI DM53IPE DM53IPE DN SAR425899 DM53IPE TI TT9O6WS DM53IPE TN Glucagon receptor (GCGR) DM53IPE MA Modulator DM53IPE RN Company report (Sanofi) (drug: LIXisenatide) DM53IPE RU http://www.sanofi.com/Images/38980_IR_Call_ADA2015_FINAL.pdf DM53IPE DI DM53IPE DM53IPE DN SAR425899 DM53IPE TI TT0NUFM DM53IPE TN Glucagon (GCG) DM53IPE MA Agonist DM53IPE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM53IPE RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM56PFL DI DM56PFL DM56PFL DN TSR-042 DM56PFL TI TTNBFWK DM56PFL TN Programmed cell death protein 1 (PD-1) DM56PFL RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM56PFL RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM56VG2 DI DM56VG2 DM56VG2 DN AVE0897 DM56VG2 TI TTJ584C DM56VG2 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM56VG2 MA Agonist DM56VG2 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM56VG2 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM572ZL DI DM572ZL DM572ZL DN BBP-398 DM572ZL TI TT7WUAV DM572ZL TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DM572ZL MA Inhibitor DM572ZL RN ClinicalTrials.gov (NCT04528836) First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. DM572ZL RU https://clinicaltrials.gov/ct2/show/NCT04528836 DM57FHW DI DM57FHW DM57FHW DN WF-11605 DM57FHW TI TTTWGIX DM57FHW TN Leukotriene receptor (LTR) DM57FHW MA Modulator DM57FHW RN WF11605, an antagonist of leukotriene B4 produced by a fungus. II. Structure determination. J Antibiot (Tokyo). 1992 May;45(5):704-8. DM57FHW RU https://pubmed.ncbi.nlm.nih.gov/1320602 DM58J7E DI DM58J7E DM58J7E DN Tedalinab DM58J7E TI TTMSFAW DM58J7E TN Cannabinoid receptor 2 (CB2) DM58J7E MA Agonist DM58J7E RN Cannabinoid CB2 receptor (CNR2). SciBX 3(46); doi:10.1038/scibx.2010.1384. Dec. 2 2010 DM58J7E RU http://www.nature.com/scibx/journal/v3/n46/full/scibx.2010.1384.html DM59EUY DI DM59EUY DM59EUY DN ADCI DM59EUY TI TT9IK2Z DM59EUY TN N-methyl-D-aspartate receptor (NMDAR) DM59EUY MA Modulator DM59EUY RN The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70. DM59EUY RU https://pubmed.ncbi.nlm.nih.gov/10714396 DM59EUY DI DM59EUY DM59EUY DN ADCI DM59EUY TI TTRK8B9 DM59EUY TN Sodium channel unspecific (NaC) DM59EUY MA Modulator DM59EUY RN The anticonvulsant SGB-017 (ADCI) blocks voltage-gated sodium channels in rat and human neurons: comparison with carbamazepine. Epilepsia. 2000 Mar;41(3):263-70. DM59EUY RU https://pubmed.ncbi.nlm.nih.gov/10714396 DM59TI2 DI DM59TI2 DM59TI2 DN M9831 DM59TI2 TI TTK3PY9 DM59TI2 TN DNA-dependent protein kinase catalytic (PRKDC) DM59TI2 MA Inhibitor DM59TI2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM59TI2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM59ZDN DI DM59ZDN DM59ZDN DN Nesvacumab DM59ZDN TI TTKLQTJ DM59ZDN TN Angiopoietin-2 (ANGPT2) DM59ZDN MA Inhibitor DM59ZDN RN Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. DM59ZDN RU https://pubmed.ncbi.nlm.nih.gov/31513439 DM5AGKV DI DM5AGKV DM5AGKV DN DTRMWXHS-12 DM5AGKV TI TTGM6VW DM5AGKV TN Tyrosine-protein kinase BTK (ATK) DM5AGKV MA Inhibitor DM5AGKV RN ClinicalTrials.gov (NCT02900716) Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas. U.S. National Institutes of Health. DM5AGKV RU https://clinicaltrials.gov/ct2/show/NCT02900716 DM5AW7J DI DM5AW7J DM5AW7J DN BIIB 015 DM5AW7J TI TTN7HMG DM5AW7J TN Teratocarcinoma-derived growth factor 1 (TDGF1) DM5AW7J RN An antibody-cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours. Eur J Cancer. 2011 Jul;47(11):1736-46. DM5AW7J RU https://pubmed.ncbi.nlm.nih.gov/21458984 DM5AWK1 DI DM5AWK1 DM5AWK1 DN NKP-1339 DM5AWK1 TI TTW26OG DM5AWK1 TN Endoplasmic reticulum chaperone BiP (HSPA5) DM5AWK1 MA Inhibitor DM5AWK1 RN NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82. DM5AWK1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/ DM5AWK1 DI DM5AWK1 DM5AWK1 DN NKP-1339 DM5AWK1 TI TT0K6EO DM5AWK1 TN Stress-activated protein kinase JNK1 (JNK1) DM5AWK1 MA Inhibitor DM5AWK1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496). DM5AWK1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1496 DM5BIM1 DI DM5BIM1 DM5BIM1 DN Anti-mesothelin CAR T Cells DM5BIM1 TI TT4RXME DM5BIM1 TN Mesothelin (MSLN) DM5BIM1 MA CAR-T-Cell-Therapy DM5BIM1 RN ClinicalTrials.gov (NCT02930993) Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors DM5BIM1 RU https://clinicaltrials.gov/ct2/show/NCT02930993 DM5BMIO DI DM5BMIO DM5BMIO DN YTB323 DM5BMIO TI TTW640A DM5BMIO TN B-lymphocyte surface antigen B4 (CD19) DM5BMIO RN Clinical pipeline report, company report or official report of Novartis. DM5BMIO RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=YTB323&field_pipeline_filing_date=All DM5BQK3 DI DM5BQK3 DM5BQK3 DN NBI-34041 DM5BQK3 TI TTIY658 DM5BQK3 TN Corticotropin-releasing factor receptor 2 (CRHR2) DM5BQK3 MA Antagonist DM5BQK3 RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM5BQK3 RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM5E9LX DI DM5E9LX DM5E9LX DN GSK586529 DM5E9LX TI TT7EFHR DM5E9LX TN Corticotropin-releasing factor receptor 1 (CRHR1) DM5E9LX MA Antagonist DM5E9LX RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM5E9LX RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM5EFPS DI DM5EFPS DM5EFPS DN MK-3134 DM5EFPS TI TT9JNIC DM5EFPS TN Histamine H3 receptor (H3R) DM5EFPS MA Agonist DM5EFPS RN Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. Psychopharmacology (Berl). 2011 Dec;218(3):513-24. DM5EFPS RU https://pubmed.ncbi.nlm.nih.gov/21644059 DM5EM04 DI DM5EM04 DM5EM04 DN CLL1-CD33 cCART cell therapy DM5EM04 TI TTJVYO3 DM5EM04 TN Myeloid cell surface antigen CD33 (CD33) DM5EM04 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DM5EM04 RU http://icellgene.com/our-pipeline.html DM5EM04 DI DM5EM04 DM5EM04 DN CLL1-CD33 cCART cell therapy DM5EM04 TI TT70N8V DM5EM04 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DM5EM04 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DM5EM04 RU http://icellgene.com/our-pipeline.html DM5EUIY DI DM5EUIY DM5EUIY DN ROR1 CAR-specific Autologous T-Lymphocytes DM5EUIY TI TTDEJAU DM5EUIY TN Neurotrophic tyrosine kinase ROR1 (ROR1) DM5EUIY MA CAR-T-Cell-Therapy DM5EUIY RN ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies DM5EUIY RU https://clinicaltrials.gov/ct2/show/NCT02706392 DM5EXJV DI DM5EXJV DM5EXJV DN LY-2881835 DM5EXJV TI TTB8FUC DM5EXJV TN Free fatty acid receptor 1 (GPR40) DM5EXJV MA Modulator DM5EXJV RN Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137. DM5EXJV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/ DM5INE7 DI DM5INE7 DM5INE7 DN NM-3 DM5INE7 TI TT9HKJA DM5INE7 TN Vascular endothelial growth factor (VEGF) DM5INE7 MA Inhibitor DM5INE7 RN 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-42. DM5INE7 RU https://pubmed.ncbi.nlm.nih.gov/16644677 DM5INZP DI DM5INZP DM5INZP DN LEQ-506 DM5INZP TI TT8J1S3 DM5INZP TN Smoothened homolog (SMO) DM5INZP MA Inhibitor DM5INZP RN Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem. 2013 Aug;8(8):1261-5. DM5INZP RU https://pubmed.ncbi.nlm.nih.gov/23821351 DM5IPHE DI DM5IPHE DM5IPHE DN 1192U90 DM5IPHE TI TTEX248 DM5IPHE TN Dopamine D2 receptor (D2R) DM5IPHE MA Antagonist DM5IPHE RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM5IPHE RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM5IPHE DI DM5IPHE DM5IPHE DN 1192U90 DM5IPHE TI TTSQIFT DM5IPHE TN 5-HT 1A receptor (HTR1A) DM5IPHE MA Agonist DM5IPHE RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM5IPHE RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM5IPHE DI DM5IPHE DM5IPHE DN 1192U90 DM5IPHE TI TTJQOD7 DM5IPHE TN 5-HT 2A receptor (HTR2A) DM5IPHE MA Antagonist DM5IPHE RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM5IPHE RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM5IPUS DI DM5IPUS DM5IPUS DN SPI-014 DM5IPUS TI TT9W8GU DM5IPUS TN Gamma-secretase (GS) DM5IPUS MA Modulator DM5IPUS RN Modulation of gamma-secretase for the treatment of Alzheimer's disease. Int J Alzheimers Dis. 2012;2012:210756. DM5IPUS RU https://pubmed.ncbi.nlm.nih.gov/23320246 DM5KBDY DI DM5KBDY DM5KBDY DN PF-06263507 DM5KBDY TI TT70MLA DM5KBDY TN Oncotrophoblast glycoprotein 5T4 (TPBG) DM5KBDY RN National Cancer Institute Drug Dictionary (drug id 751006). DM5KBDY RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751006 DM5KDGI DI DM5KDGI DM5KDGI DN TAK-901 DM5KDGI TI TT5LS6T DM5KDGI TN Aurora kinase B (AURKB) DM5KDGI MA Inhibitor DM5KDGI RN Clinical pipeline report, company report or official report of Takeda (2009). DM5KDGI RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM5KI6X DI DM5KI6X DM5KI6X DN PRX003 DM5KI6X TI TTD26RC DM5KI6X TN Cell adhesion molecule (CADM) DM5KI6X MA Inhibitor DM5KI6X RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5KI6X RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM5KMYQ DI DM5KMYQ DM5KMYQ DN Actimab-M DM5KMYQ TI TTJVYO3 DM5KMYQ TN Myeloid cell surface antigen CD33 (CD33) DM5KMYQ MA Inhibitor DM5KMYQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5KMYQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM5KU30 DI DM5KU30 DM5KU30 DN BAL-30072 DM5KU30 TI TTJP4SM DM5KU30 TN Bacterial Penicillin binding protein (Bact PBP) DM5KU30 MA Inhibitor DM5KU30 RN In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302. DM5KU30 RU https://pubmed.ncbi.nlm.nih.gov/20308379 DM5M48F DI DM5M48F DM5M48F DN BMS214662 DM5M48F TI TTXQKM3 DM5M48F TN Farnesyl protein transferase (Ftase) DM5M48F MA Modulator DM5M48F RN Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. Leukemia. 2004 Oct;18(10):1599-604. DM5M48F RU https://www.ncbi.nlm.nih.gov/pubmed/15356656 DM5OP86 DI DM5OP86 DM5OP86 DN LY3127804 DM5OP86 TI TTKLQTJ DM5OP86 TN Angiopoietin-2 (ANGPT2) DM5OP86 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5OP86 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5OTGR DI DM5OTGR DM5OTGR DN RG7461 DM5OTGR TI TTGPQ0F DM5OTGR TN Prolyl endopeptidase FAP (FAP) DM5OTGR MA Antagonist DM5OTGR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5OTGR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM5OWXA DI DM5OWXA DM5OWXA DN NBM-BMX DM5OWXA TI TTT6LFV DM5OWXA TN Histone deacetylase 8 (HDAC8) DM5OWXA MA Inhibitor DM5OWXA RN Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals. DM5OWXA RU https://www.naturewise.com.tw/#_index2 DM5OXPZ DI DM5OXPZ DM5OXPZ DN RPI-MN DM5OXPZ TI TTJSZTB DM5OXPZ TN Nicotinic acetylcholine receptor (nAChR) DM5OXPZ MA Antagonist DM5OXPZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM5OXPZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM5PUO0 DI DM5PUO0 DM5PUO0 DN PF-00337210 DM5PUO0 TI TTUTJGQ DM5PUO0 TN Vascular endothelial growth factor receptor 2 (KDR) DM5PUO0 MA Modulator DM5PUO0 RN Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function. Diabetes. 2013 August; 62(8): 2870-2878. DM5PUO0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717875/ DM5QHID DI DM5QHID DM5QHID DN NSD-788 DM5QHID TI TTEX6LM DM5QHID TN GABA(A) receptor gamma-3 (GABRG3) DM5QHID MA Modulator DM5QHID RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DM5QHID RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DM5QO1A DI DM5QO1A DM5QO1A DN LY3415244 DM5QO1A TI TT1RWL7 DM5QO1A TN Hepatitis A virus cellular receptor 2 (TIM3) DM5QO1A MA Inhibitor DM5QO1A RN Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. DM5QO1A RU https://pubmed.ncbi.nlm.nih.gov/33441294 DM5QO1A DI DM5QO1A DM5QO1A DN LY3415244 DM5QO1A TI TT8ZLTI DM5QO1A TN Programmed cell death 1 ligand 1 (PD-L1) DM5QO1A MA Inhibitor DM5QO1A RN Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2021 May 15;27(10):2773-2781. DM5QO1A RU https://pubmed.ncbi.nlm.nih.gov/33441294 DM5R7VI DI DM5R7VI DM5R7VI DN ARN-6039 DM5R7VI TI TTGV6LY DM5R7VI TN Nuclear receptor ROR-gamma (RORG) DM5R7VI MA Agonist DM5R7VI RN Clinical pipeline report, company report or official report of Arrien Pharmaceuticals. DM5R7VI RU https://www.arrienpharma.com/arn-6039.html DM5RIT8 DI DM5RIT8 DM5RIT8 DN TP-6076 DM5RIT8 TI TTOVFH2 DM5RIT8 TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DM5RIT8 RN Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. DM5RIT8 RU https://www.tphase.com/wp-content/uploads/2019/04/IDWeek-2018-TP-6076-Pipeline-FINAL-website.pdf DM5RLM4 DI DM5RLM4 DM5RLM4 DN 4SCAR19 cells DM5RLM4 TI TTW640A DM5RLM4 TN B-lymphocyte surface antigen B4 (CD19) DM5RLM4 MA CAR-T-Cell-Therapy DM5RLM4 RN ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia DM5RLM4 RU https://clinicaltrials.gov/ct2/show/NCT02968472 DM5SJO9 DI DM5SJO9 DM5SJO9 DN ACHN-975 DM5SJO9 TI TT2D1J6 DM5SJO9 TN Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC) DM5SJO9 MA Modulator DM5SJO9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5SJO9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5SN0A DI DM5SN0A DM5SN0A DN MT-5111 DM5SN0A TI TT6EO5L DM5SN0A TN Erbb2 tyrosine kinase receptor (HER2) DM5SN0A MA Inhibitor DM5SN0A RN Clinical pipeline report, company report or official report of Molecular Templates. DM5SN0A RU https://www.mtem.com/pipeline/mt-5111 DM5SO1T DI DM5SO1T DM5SO1T DN INCAGN2390 DM5SO1T TI TT1RWL7 DM5SO1T TN Hepatitis A virus cellular receptor 2 (TIM3) DM5SO1T MA Inhibitor DM5SO1T RN Clinical pipeline report, company report or official report of Agenus. DM5SO1T RU https://agenusbio.com/pipeline/ DM5SZAK DI DM5SZAK DM5SZAK DN JNJ-63709178 DM5SZAK TI TTUN7MC DM5SZAK TN T-cell surface glycoprotein CD3 (CD3) DM5SZAK MA Inhibitor DM5SZAK RN Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145. DM5SZAK RU https://pubmed.ncbi.nlm.nih.gov/29206680 DM5SZAK DI DM5SZAK DM5SZAK DN JNJ-63709178 DM5SZAK TI TTENHJ0 DM5SZAK TN Interleukin 3 receptor alpha (IL3RA) DM5SZAK MA Inhibitor DM5SZAK RN Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145. DM5SZAK RU https://pubmed.ncbi.nlm.nih.gov/29206680 DM5TB76 DI DM5TB76 DM5TB76 DN DACRA 089 DM5TB76 TI TTAT87F DM5TB76 TN Amylin receptor (IAPPR) DM5TB76 MA Agonist DM5TB76 RN A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602. DM5TB76 RU https://pubmed.ncbi.nlm.nih.gov/28109166 DM5TB76 DI DM5TB76 DM5TB76 DN DACRA 089 DM5TB76 TI TTLWS2O DM5TB76 TN Calcitonin receptor (CALCR) DM5TB76 MA Agonist DM5TB76 RN A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference. Br J Pharmacol. 2017 Apr;174(7):591-602. DM5TB76 RU https://pubmed.ncbi.nlm.nih.gov/28109166 DM5TLAP DI DM5TLAP DM5TLAP DN PRX-07034 DM5TLAP TI TTJS8PY DM5TLAP TN 5-HT 6 receptor (HTR6) DM5TLAP MA Antagonist DM5TLAP RN Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects. Can J Physiol Pharmacol. 2015 Jan;93(1):13-21. DM5TLAP RU https://pubmed.ncbi.nlm.nih.gov/25429515 DM5UQA9 DI DM5UQA9 DM5UQA9 DN Anti-meso-CAR vector transduced T cells DM5UQA9 TI TT4RXME DM5UQA9 TN Mesothelin (MSLN) DM5UQA9 MA CAR-T-Cell-Therapy DM5UQA9 RN ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso DM5UQA9 RU https://clinicaltrials.gov/ct2/show/NCT02580747 DM5UXAB DI DM5UXAB DM5UXAB DN SAR442085 DM5UXAB TI TTPURFN DM5UXAB TN Cyclic ADP-ribose hydrolase 1 (CD38) DM5UXAB MA Inhibitor DM5UXAB RN Clinical pipeline report, company report or official report of Sanofi. DM5UXAB RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DM5VEN9 DI DM5VEN9 DM5VEN9 DN Minnelide 001 DM5VEN9 TI TTHYBIX DM5VEN9 TN Heat shock protein 70 (HSP70) DM5VEN9 MA Modulator DM5VEN9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5VEN9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5VS7B DI DM5VS7B DM5VS7B DN GSK-2241658A DM5VS7B TI TTE5ITK DM5VS7B TN Cancer/testis antigen 1 (NY-ESO-1) DM5VS7B RN ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health. DM5VS7B RU https://clinicaltrials.gov/ct2/show/NCT01213472 DM5VSZR DI DM5VSZR DM5VSZR DN HPP-607 DM5VSZR TI TTLYXIT DM5VSZR TN Aurora kinase C (AURKC) DM5VSZR MA Inhibitor DM5VSZR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DM5VSZR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DM5VSZR DI DM5VSZR DM5VSZR DN HPP-607 DM5VSZR TI TTPS3C0 DM5VSZR TN Aurora kinase A (AURKA) DM5VSZR MA Inhibitor DM5VSZR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DM5VSZR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DM5VSZR DI DM5VSZR DM5VSZR DN HPP-607 DM5VSZR TI TT5LS6T DM5VSZR TN Aurora kinase B (AURKB) DM5VSZR MA Inhibitor DM5VSZR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DM5VSZR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DM5VXWO DI DM5VXWO DM5VXWO DN MP-157 DM5VXWO TI TTQVOEI DM5VXWO TN Angiotensin II receptor type-2 (AGTR2) DM5VXWO MA Agonist DM5VXWO RN As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard DM5VXWO RU http://blogs.nature.com/spoonful/2014/02/as-drug-target-reemerges-the-question-is-to-block-or-stimulate-it.html DM5VY23 DI DM5VY23 DM5VY23 DN ONC206 DM5VY23 TI TTEX248 DM5VY23 TN Dopamine D2 receptor (D2R) DM5VY23 MA Antagonist DM5VY23 RN ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro. Front Oncol. 2020 Oct 20;10:577141. DM5VY23 RU https://pubmed.ncbi.nlm.nih.gov/33194693 DM5WCBM DI DM5WCBM DM5WCBM DN ING-1 DM5WCBM TI TTZ8WH4 DM5WCBM TN Tumor-associated calcium signal transducer 1 (EPCAM) DM5WCBM RN ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res. 2004 Nov 15;10(22):7555-65. DM5WCBM RU https://pubmed.ncbi.nlm.nih.gov/15569986 DM5WDKY DI DM5WDKY DM5WDKY DN TAS-103 DM5WDKY TI TT0IHXV DM5WDKY TN DNA topoisomerase II (TOP2) DM5WDKY MA Modulator DM5WDKY RN Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemother Pharmacol. 2000;45(1):78-84. DM5WDKY RU https://www.ncbi.nlm.nih.gov/pubmed/10647506 DM5WKU1 DI DM5WKU1 DM5WKU1 DN Cardiotrophin-1 DM5WKU1 TI TTXGTZU DM5WKU1 TN Cardiotrophin-1 (CTF1) DM5WKU1 MA Stimulator DM5WKU1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM5WKU1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM5XCRQ DI DM5XCRQ DM5XCRQ DN R552 DM5XCRQ TI TTAIQSN DM5XCRQ TN Receptor-interacting protein 1 (RIPK1) DM5XCRQ MA Inhibitor DM5XCRQ RN Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. DM5XCRQ RU https://pubmed.ncbi.nlm.nih.gov/32669658 DM5XMHB DI DM5XMHB DM5XMHB DN UC-781 DM5XMHB TI TT84ETX DM5XMHB TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM5XMHB MA Inhibitor DM5XMHB RN The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86. DM5XMHB RU https://pubmed.ncbi.nlm.nih.gov/16103169 DM5YUOM DI DM5YUOM DM5YUOM DN Irofulven/Taxotere DM5YUOM TI TT63KYR DM5YUOM TN Tubulin beta-1 chain (TUBB1) DM5YUOM MA Modulator DM5YUOM RN Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32. DM5YUOM RU https://pubmed.ncbi.nlm.nih.gov/14991863 DM5YUOM DI DM5YUOM DM5YUOM DN Irofulven/Taxotere DM5YUOM TI TTJGNVC DM5YUOM TN Apoptosis regulator Bcl-2 (BCL-2) DM5YUOM MA Modulator DM5YUOM RN Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate. 2004 Apr 1;59(1):22-32. DM5YUOM RU https://pubmed.ncbi.nlm.nih.gov/14991863 DM5ZC0E DI DM5ZC0E DM5ZC0E DN 124I-8H9 DM5ZC0E TI TT6CQUM DM5ZC0E TN B7 homolog 3 (CD276) DM5ZC0E RN National Cancer Institute Drug Dictionary (drug id 722029). DM5ZC0E RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=722029 DM5ZR4Q DI DM5ZR4Q DM5ZR4Q DN PSI-938 DM5ZR4Q TI TTMVBWH DM5ZR4Q TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM5ZR4Q MA Inhibitor DM5ZR4Q RN 2011 Pipeline of Pharmasset. DM5ZR4Q RU http://www.pharmasset.com/pipeline/default.aspx DM601GL DI DM601GL DM601GL DN INNO-105 DM601GL TI TT6IEYX DM601GL TN Opioid receptor zeta (OGFR) DM601GL MA Modulator DM601GL RN National Cancer Institute Drug Dictionary (drug id 428488). DM601GL RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=428488 DM61JH5 DI DM61JH5 DM61JH5 DN BIWA 4 DM61JH5 TI TTWFBT7 DM61JH5 TN Extracellular matrix receptor III (CD44) DM61JH5 RN A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. DM61JH5 RU https://pubmed.ncbi.nlm.nih.gov/17062682 DM64LVS DI DM64LVS DM64LVS DN ICT-121 DM64LVS TI TTXMZ81 DM64LVS TN Prominin-1 (PROM1) DM64LVS RN Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 2015; 19(1A): A52-A59. DM64LVS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322523/ DM64U1Y DI DM64U1Y DM64U1Y DN R-1663 DM64U1Y TI TTCIHJA DM64U1Y TN Coagulation factor Xa (F10) DM64U1Y MA Inhibitor DM64U1Y RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DM64U1Y RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM65B7G DI DM65B7G DM65B7G DN MCP-202 DM65B7G TI TT27RFC DM65B7G TN Opioid receptor delta (OPRD1) DM65B7G MA Agonist DM65B7G RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018026) DM65B7G RU http://adisinsight.springer.com/drugs/800018026 DM674MP DI DM674MP DM674MP DN CLT030 DM674MP TI TT70N8V DM674MP TN Myeloid inhibitory C-type lectin-like receptor (CD371) DM674MP RN Clinical pipeline report, company report or official report of Cellerant Therapeutics. DM674MP RU https://www.cellerant.com/programs/clt030/ DM67OU4 DI DM67OU4 DM67OU4 DN ANAVEX 2-73 DM67OU4 TI TT5TPI6 DM67OU4 TN Opioid receptor sigma 1 (OPRS1) DM67OU4 MA Agonist DM67OU4 RN 2011 Pipeline of Anavex. DM67OU4 RU http://anavex.com/pipeline.html DM67OU4 DI DM67OU4 DM67OU4 DN ANAVEX 2-73 DM67OU4 TI TTZ9SOR DM67OU4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM67OU4 MA Agonist DM67OU4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM67OU4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM68D3O DI DM68D3O DM68D3O DN PG-545 DM68D3O TI TTR7GJO DM68D3O TN Heparanase (HPSE) DM68D3O MA Modulator DM68D3O RN PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br J Cancer. 2011 Feb 15;104(4):635-42. DM68D3O RU https://pubmed.ncbi.nlm.nih.gov/21285983 DM68I93 DI DM68I93 DM68I93 DN CTS-21166 DM68I93 TI TT8JRS7 DM68I93 TN Beta-secretase (BACE) DM68I93 MA Inhibitor DM68I93 RN ClinicalTrials.gov (NCT00621010) Safety Study of CTS21166 to Treat Alzheimer Disease. U. S. National Institutes of Health. 2008. DM68I93 RU https://clinicaltrials.gov/ct2/show/NCT00621010 DM695QT DI DM695QT DM695QT DN HMR-1031 DM695QT TI TT6S84X DM695QT TN Integrin alpha-4/beta-1 (ITGA4/B1) DM695QT MA Modulator DM695QT RN Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler. Am J Ther. 2004 Mar-Apr;11(2):103-13. DM695QT RU https://pubmed.ncbi.nlm.nih.gov/14999362 DM69YM1 DI DM69YM1 DM69YM1 DN CC-98633 DM69YM1 TI TTZ3P4W DM69YM1 TN B-cell maturation protein (TNFRSF17) DM69YM1 RN ClinicalTrials.gov (NCT04394650) A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health. DM69YM1 RU https://clinicaltrials.gov/ct2/show/NCT04394650 DM69ZBU DI DM69ZBU DM69ZBU DN DST-2970 DM69ZBU TI TTRA5BZ DM69ZBU TN Steroid 17-alpha-monooxygenase (S17AH) DM69ZBU MA Inhibitor DM69ZBU RN Clinical pipeline report, company report or official report of DisperSol Technologies. DM69ZBU RU https://www.dispersoltech.com/pipeline/ DM6ADMG DI DM6ADMG DM6ADMG DN MEDI-557 DM6ADMG TI TT57ID8 DM6ADMG TN Respiratory syncytial virus protein F (RSV F) DM6ADMG RN Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591. DM6ADMG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759493/ DM6AMKZ DI DM6AMKZ DM6AMKZ DN Embeconazole DM6AMKZ TI TTTSOUD DM6AMKZ TN Candida Cytochrome P450 51 (Candi ERG11) DM6AMKZ MA Inhibitor DM6AMKZ RN CS-758. Antifungal lanosterol 14alpha-demethylase inhibitor, 003, vol28, no3, 217-223. DM6AMKZ RU http://cat.inist.fr/?aModele=afficheN&cpsidt=14796964 DM6DULC DI DM6DULC DM6DULC DN CAR-T Cells targeting Mesothelin DM6DULC TI TT4RXME DM6DULC TN Mesothelin (MSLN) DM6DULC MA CAR-T-Cell-Therapy DM6DULC RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DM6DULC RU https://clinicaltrials.gov/ct2/show/NCT03267173 DM6ER9L DI DM6ER9L DM6ER9L DN Pfizer 10 DM6ER9L TI TT4C8EA DM6ER9L TN Dopamine D3 receptor (D3R) DM6ER9L MA Agonist DM6ER9L RN Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. DM6ER9L RU https://pubmed.ncbi.nlm.nih.gov/17826689 DM6GKMU DI DM6GKMU DM6GKMU DN ATI-9242 DM6GKMU TI TTO9X1H DM6GKMU TN 5-HT 7 receptor (HTR7) DM6GKMU MA Modulator DM6GKMU RN Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12. DM6GKMU RU http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12 DM6GKMU DI DM6GKMU DM6GKMU DN ATI-9242 DM6GKMU TI TTEX248 DM6GKMU TN Dopamine D2 receptor (D2R) DM6GKMU MA Modulator DM6GKMU RN Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12. DM6GKMU RU http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12 DM6GKMU DI DM6GKMU DM6GKMU DN ATI-9242 DM6GKMU TI TTJQOD7 DM6GKMU TN 5-HT 2A receptor (HTR2A) DM6GKMU MA Modulator DM6GKMU RN Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12. DM6GKMU RU http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/773.12 DM6GKYF DI DM6GKYF DM6GKYF DN TTX-080 DM6GKYF TI TTLKFB3 DM6GKYF TN MHC class I antigen G (HLA-G) DM6GKYF MA Inhibitor DM6GKYF RN Clinical pipeline report, company report or official report of Tizona Therapeutics. DM6GKYF RU https://www.tizonatx.com/science/ DM6GNDP DI DM6GNDP DM6GNDP DN CD19 CAR-T cells DM6GNDP TI TTW640A DM6GNDP TN B-lymphocyte surface antigen B4 (CD19) DM6GNDP MA CAR-T-Cell-Therapy DM6GNDP RN ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. DM6GNDP RU https://clinicaltrials.gov/ct2/show/NCT03671460 DM6GRNC DI DM6GRNC DM6GRNC DN CAR-T cells targeting MUC1 DM6GRNC TI TTBHFYQ DM6GRNC TN Mucin-1 (MUC1) DM6GRNC MA CAR-T-Cell-Therapy DM6GRNC RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DM6GRNC RU https://clinicaltrials.gov/ct2/show/NCT03198052 DM6IT3M DI DM6IT3M DM6IT3M DN AMG 701 DM6IT3M TI TTUN7MC DM6IT3M TN T-cell surface glycoprotein CD3 (CD3) DM6IT3M MA Inhibitor DM6IT3M RN Clinical pipeline report, company report or official report of Amgen. DM6IT3M RU https://www.amgenpipeline.com/ DM6IT3M DI DM6IT3M DM6IT3M DN AMG 701 DM6IT3M TI TTZ3P4W DM6IT3M TN B-cell maturation protein (TNFRSF17) DM6IT3M MA Inhibitor DM6IT3M RN Clinical pipeline report, company report or official report of Amgen. DM6IT3M RU https://www.amgenpipeline.com/ DM6J085 DI DM6J085 DM6J085 DN M6223 DM6J085 TI TTWNL74 DM6J085 TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DM6J085 MA Inhibitor DM6J085 RN ClinicalTrials.gov (NCT04457778) First in Human Study of M6223. U.S. National Institutes of Health. DM6J085 RU https://clinicaltrials.gov/ct2/show/NCT04457778 DM6K3JQ DI DM6K3JQ DM6K3JQ DN COTI-2 DM6K3JQ TI TT7SBF5 DM6K3JQ TN Cellular tumor antigen p53 (TP53) DM6K3JQ MA Modulator DM6K3JQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6K3JQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM6K47B DI DM6K47B DM6K47B DN DC/I540/KLH vaccine DM6K47B TI TTUJFD0 DM6K47B TN Telomerase reverse transcriptase (TERT) DM6K47B RN Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004 Feb 1;10(3):828-39. DM6K47B RU https://pubmed.ncbi.nlm.nih.gov/14871958 DM6KE4G DI DM6KE4G DM6KE4G DN GSK2849330 DM6KE4G TI TTDC8N2 DM6KE4G TN Erbb3 tyrosine kinase receptor (Erbb-3) DM6KE4G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). DM6KE4G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798 DM6KOBZ DI DM6KOBZ DM6KOBZ DN TAK-285 DM6KOBZ TI TT6EO5L DM6KOBZ TN Erbb2 tyrosine kinase receptor (HER2) DM6KOBZ MA Inhibitor DM6KOBZ RN Clinical pipeline report, company report or official report of Takeda (2009). DM6KOBZ RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM6KU93 DI DM6KU93 DM6KU93 DN Alvespimycin hydrochloride DM6KU93 TI TT78R5H DM6KU93 TN Heat shock protein 90 alpha (HSP90A) DM6KU93 MA Inhibitor DM6KU93 RN Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41. DM6KU93 RU https://pubmed.ncbi.nlm.nih.gov/18260120 DM6L5IP DI DM6L5IP DM6L5IP DN Axitirome DM6L5IP TI TTGER3L DM6L5IP TN Thyroid hormone receptor beta (THRB) DM6L5IP MA Modulator DM6L5IP RN Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors alpha-1 and beta-1. FEBS Open Bio. 2012; 2: 247-253. DM6L5IP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3642162/ DM6LQIU DI DM6LQIU DM6LQIU DN VIR-2482 DM6LQIU TI TTF4CAM DM6LQIU TN Influenza Hemagglutinin (Influ HA) DM6LQIU RN Clinical pipeline report, company report or official report of Vir Biotechnology. DM6LQIU RU https://www.vir.bio/pipeline/ DM6NG3C DI DM6NG3C DM6NG3C DN CMV glycoprotein B subunit vaccine DM6NG3C TI TTUR18Y DM6NG3C TN Cytomegalovirus Glycoprotein B (CMV gB) DM6NG3C RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DM6NG3C RU http://www.gsk-clinicalstudyregister.com/study/108890#ps DM6NUCA DI DM6NUCA DM6NUCA DN ADR-851 DM6NUCA TI TTNXLKE DM6NUCA TN 5-HT 3 receptor (5HT3R) DM6NUCA MA Modulator DM6NUCA RN Analgesic effects of S and R isomers of the novel 5-HT3 receptor antagonists ADR-851 and ADR-882 in rats. Eur J Pharmacol. 1991 Oct 29;204(1):117-9. DM6NUCA RU https://pubmed.ncbi.nlm.nih.gov/1804661 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTNDSF4 DM6NVTR TN Proto-oncogene c-Met (MET) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTO7LKR DM6NVTR TN Tyrosine-protein kinase Mer (MERTK) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTZPY6J DM6NVTR TN Tyrosine-protein kinase UFO (AXL) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6NVTR DI DM6NVTR DM6NVTR DN RXDX-106 DM6NVTR TI TTIEMFN DM6NVTR TN TYRO3 tyrosine kinase receptor (TYRO3) DM6NVTR MA Inhibitor DM6NVTR RN National Cancer Institute Drug Dictionary (drug name RXDX106). DM6NVTR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tam-c-met-inhibitor-rxdx-106 DM6O0TM DI DM6O0TM DM6O0TM DN ATA2271 DM6O0TM TI TT4RXME DM6O0TM TN Mesothelin (MSLN) DM6O0TM RN Clinical pipeline report, company report or official report of Atara Biotherapeutics. DM6O0TM RU https://www.atarabio.com/pipeline/ata2271-ata3271/ DM6OJI1 DI DM6OJI1 DM6OJI1 DN DIAPLASININ DM6OJI1 TI TTTO43N DM6OJI1 TN Endothelial plasminogen activator inhibitor (SERPINE1) DM6OJI1 MA Inhibitor DM6OJI1 RN Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis. J Thromb Haemost. 2010 Jun;8(6):1333-9. DM6OJI1 RU https://pubmed.ncbi.nlm.nih.gov/20345708 DM6OKH4 DI DM6OKH4 DM6OKH4 DN TAK-020 DM6OKH4 TI TTGM6VW DM6OKH4 TN Tyrosine-protein kinase BTK (ATK) DM6OKH4 MA Inhibitor DM6OKH4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6OKH4 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM6P93J DI DM6P93J DM6P93J DN API-023 DM6P93J TI TTF1QVM DM6P93J TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM6P93J MA Inhibitor DM6P93J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DM6P93J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DM6PFCN DI DM6PFCN DM6PFCN DN LY3009120 DM6PFCN TI TTQ9K3Y DM6PFCN TN Serine/threonine-protein kinase Raf (RAF) DM6PFCN MA Modulator DM6PFCN RN Company report (eli lily) DM6PFCN RU http://www.lillyoncologypipeline.com/pan-raf-inhibitor.aspx DM6PI5B DI DM6PI5B DM6PI5B DN M3258 DM6PI5B TI TTEAD9J DM6PI5B TN Proteasome beta-8 (PS beta-8) DM6PI5B MA Inhibitor DM6PI5B RN Clinical pipeline report, company report or official report of EMD Serono. DM6PI5B RU https://medical.emdserono.com/en_US/home/oncology/m3258.html DM6PN4H DI DM6PN4H DM6PN4H DN AjvW2 DM6PN4H TI TT38RM1 DM6PN4H TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM6PN4H RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DM6PN4H RU https://pubmed.ncbi.nlm.nih.gov/11804648 DM6PN4H DI DM6PN4H DM6PN4H DN AjvW2 DM6PN4H TI TT0IHXV DM6PN4H TN DNA topoisomerase II (TOP2) DM6PN4H MA Inhibitor DM6PN4H RN The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82. DM6PN4H RU https://pubmed.ncbi.nlm.nih.gov/12423680 DM6QENU DI DM6QENU DM6QENU DN Anti-FGFR3 DM6QENU TI TTST7KB DM6QENU TN Fibroblast growth factor receptor 3 (FGFR3) DM6QENU RN Clinical pipeline report, company report or official report of Genentech (2011). DM6QENU RU http://www.gene.com/gene/index.jsp DM6R4DO DI DM6R4DO DM6R4DO DN GC-1008 DM6R4DO TI TT5BDCY DM6R4DO TN TGF-beta receptor (TGFBR) DM6R4DO MA Modulator DM6R4DO RN Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma.PLoS One.2014 Mar 11;9(3):e90353. DM6R4DO RU https://www.ncbi.nlm.nih.gov/pubmed/24618589 DM6SCUK DI DM6SCUK DM6SCUK DN CI-959 DM6SCUK TI TT4IN7L DM6SCUK TN Histamine release (His rele) DM6SCUK MA Modulator DM6SCUK RN Cytoprotective effects of CI-959 in the rat gastric mucosa: modulation of leukocyte adhesion. Gastroenterology. 1995 Oct;109(4):1224-33. DM6SCUK RU https://pubmed.ncbi.nlm.nih.gov/7557089 DM6TLPD DI DM6TLPD DM6TLPD DN RG6115 DM6TLPD TI TTRJ1K4 DM6TLPD TN Toll-like receptor 7 (TLR7) DM6TLPD MA Agonist DM6TLPD RN Clinical pipeline report, company report or official report of Roche. DM6TLPD RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DM6UN42 DI DM6UN42 DM6UN42 DN SAR444245 DM6UN42 TI TTF89GD DM6UN42 TN Interleukin-2 (IL2) DM6UN42 RN Clinical pipeline report, company report or official report of Sanofi. DM6UN42 RU https://www.sanofi.com/en/media-room/press-releases/2020/2020-10-29-07-00-00 DM6UOXF DI DM6UOXF DM6UOXF DN AZD1419 DM6UOXF TI TTSHG0T DM6UOXF TN Toll-like receptor 9 (TLR9) DM6UOXF MA Agonist DM6UOXF RN Clinical pipeline report, company report or official report of dynavax. DM6UOXF RU http://investors.dynavax.com/releasedetail.cfm?releaseid=611310 DM6URNJ DI DM6URNJ DM6URNJ DN JNJ-67856633 DM6URNJ TI TTCI81G DM6URNJ TN MALT lymphoma-associated translocation (MALT1) DM6URNJ MA Inhibitor DM6URNJ RN National Cancer Institute Drug Dictionary (drug name JNJ67856633). DM6URNJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/malt1-inhibitor-jnj-67856633 DM6V0KY DI DM6V0KY DM6V0KY DN Xmab-2513 DM6V0KY TI TT2GM5R DM6V0KY TN Lymphocyte activation antigen CD30 (TNFRSF8) DM6V0KY RN Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. J Clin Oncol (Meeting Abstracts) May 2009 vol. 27 no. 15S 8531. DM6V0KY RU http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8531 DM6VR13 DI DM6VR13 DM6VR13 DN JNJ-69086420 DM6VR13 TI TTJLNAW DM6VR13 TN Tissue kallikrein (KLK2) DM6VR13 MA Inhibitor DM6VR13 RN ClinicalTrials.gov (NCT04644770) A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer. U.S. National Institutes of Health. DM6VR13 RU https://clinicaltrials.gov/ct2/show/NCT04644770 DM6WN9X DI DM6WN9X DM6WN9X DN DS-3801 DM6WN9X TI TT953CX DM6WN9X TN Motilin receptor (MLNR) DM6WN9X MA Agonist DM6WN9X RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DM6WN9X RU http://www.daiichisankyo.com/rd/pipeline/pdf/Pipeline_EN.pdf DM6X82R DI DM6X82R DM6X82R DN CART22 cells DM6X82R TI TTM6QSK DM6X82R TN B-cell receptor CD22 (CD22) DM6X82R MA CAR-T-Cell-Therapy DM6X82R RN ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia DM6X82R RU https://clinicaltrials.gov/ct2/show/NCT02588456 DM6XC8H DI DM6XC8H DM6XC8H DN MSC110 DM6XC8H TI TT0IQER DM6XC8H TN Macrophage colony-stimulating factor 1 (CSF1) DM6XC8H MA Inhibitor DM6XC8H RN Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes. J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. DM6XC8H RU https://pubmed.ncbi.nlm.nih.gov/30894455 DM6XTZL DI DM6XTZL DM6XTZL DN MSC-1 DM6XTZL TI TTGZ5WN DM6XTZL TN Leukemia inhibitory factor (LIF) DM6XTZL RN National Cancer Institute Drug Dictionary (drug name MSC-1). DM6XTZL RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-lif-monoclonal-antibody-msc-1 DM6XVCO DI DM6XVCO DM6XVCO DN RG7116 DM6XVCO TI TTDC8N2 DM6XVCO TN Erbb3 tyrosine kinase receptor (Erbb-3) DM6XVCO MA Modulator DM6XVCO RN RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res. 2013 Aug 15;73(16):5183-94. DM6XVCO RU https://pubmed.ncbi.nlm.nih.gov/23780344 DM6XWV4 DI DM6XWV4 DM6XWV4 DN EGFRvIII CAR T cells DM6XWV4 TI TTZ6B2I DM6XWV4 TN Epidermal growth factor receptor variant III (EGFR vIII) DM6XWV4 MA CAR-T-Cell-Therapy DM6XWV4 RN ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma DM6XWV4 RU https://clinicaltrials.gov/ct2/show/NCT02664363 DM6XZRL DI DM6XZRL DM6XZRL DN SA-5845 DM6XZRL TI TT5TPI6 DM6XZRL TN Opioid receptor sigma 1 (OPRS1) DM6XZRL MA Binder DM6XZRL RN Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med. 2004 Nov;45(11):1939-45. DM6XZRL RU https://pubmed.ncbi.nlm.nih.gov/15534066 DM6YAGE DI DM6YAGE DM6YAGE DN RWJ-67657 DM6YAGE TI TTVKILB DM6YAGE TN Prostaglandin G/H synthase 2 (COX-2) DM6YAGE MA Inhibitor DM6YAGE RN Monocyte intracellular cytokine production during human endotoxaemia with or without a second in vitro LPS challenge: effect of RWJ-67657, a p38 MAP-kinase inhibitor, on LPS-hyporesponsiveness. Clin Exp Immunol. 2002 Feb;127(2):337-43. DM6YAGE RU https://pubmed.ncbi.nlm.nih.gov/11876759 DM6Z7AD DI DM6Z7AD DM6Z7AD DN CAR-T cells targeting CD80/86 DM6Z7AD TI TTFZDNP DM6Z7AD TN Activation B7-1 antigen (CD80) DM6Z7AD MA CAR-T-Cell-Therapy DM6Z7AD RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DM6Z7AD RU https://clinicaltrials.gov/ct2/show/NCT03198052 DM6ZOD2 DI DM6ZOD2 DM6ZOD2 DN SUVN-D4010 DM6ZOD2 TI TT07C3Y DM6ZOD2 TN 5-HT 4 receptor (HTR4) DM6ZOD2 MA Agonist DM6ZOD2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM6ZOD2 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM70DYV DI DM70DYV DM70DYV DN GSK311739 DM70DYV TI TTBH0VX DM70DYV TN Histone deacetylase (HDAC) DM70DYV MA Modulator DM70DYV RN Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014. DM70DYV RU http://www.phrma.org/sites/default/files/pdf/2014-meds-in-dev-older-americans.pdf DM71HLX DI DM71HLX DM71HLX DN FAZ053 DM71HLX TI TT8ZLTI DM71HLX TN Programmed cell death 1 ligand 1 (PD-L1) DM71HLX MA Inhibitor DM71HLX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM71HLX RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM71Q69 DI DM71Q69 DM71Q69 DN ABBV-184 DM71Q69 TI TTUN7MC DM71Q69 TN T-cell surface glycoprotein CD3 (CD3) DM71Q69 RN Clinical pipeline report, company report or official report of AbbVie. DM71Q69 RU https://www.abbvie.com/our-science/pipeline/abbv-184.html DM72FOD DI DM72FOD DM72FOD DN Azd-3839 DM72FOD TI TT8JRS7 DM72FOD TN Beta-secretase (BACE) DM72FOD MA Inhibitor DM72FOD RN Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease. J Biol Chem. 2012 Nov 30;287(49):41245-57. DM72FOD RU https://pubmed.ncbi.nlm.nih.gov/23048024 DM72GZV DI DM72GZV DM72GZV DN ZEN003694 DM72GZV TI TTE4BSY DM72GZV TN Bromodomain and extraterminal domain protein (BET) DM72GZV MA Inhibitor DM72GZV RN Clinical pipeline report, company report or official report of Zenith Epigenetics. DM72GZV RU https://www.zenithepigenetics.com/programs/pipeline DM73920 DI DM73920 DM73920 DN Anti-EGFRvIII CAR T cells DM73920 TI TTZ6B2I DM73920 TN Epidermal growth factor receptor variant III (EGFR vIII) DM73920 MA CAR-T-Cell-Therapy DM73920 RN ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme DM73920 RU https://clinicaltrials.gov/ct2/show/NCT02844062 DM73YG5 DI DM73YG5 DM73YG5 DN SM09419 DM73YG5 TI TT6K9BV DM73YG5 TN Cdc-like kinase (CLK) DM73YG5 MA Inhibitor DM73YG5 RN SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Acute Myeloid Leukemia Models. Blood; 2019,134 (Supplement_1):1377. DM73YG5 RU https://doi.org/10.1182/blood-2019-130500 DM74YO8 DI DM74YO8 DM74YO8 DN PDC-41 DM74YO8 TI TTT2ZAR DM74YO8 TN Prostaglandin F2-alpha receptor (PTGFR) DM74YO8 MA Antagonist DM74YO8 RN THG113: a novel selective FP antagonist that delays preterm labor. Semin Perinatol. 2002 Dec;26(6):389-97. DM74YO8 RU https://pubmed.ncbi.nlm.nih.gov/12537309 DM75FWO DI DM75FWO DM75FWO DN PSI-697 DM75FWO TI TTE5VG0 DM75FWO TN P-selectin (SELP) DM75FWO MA Inhibitor DM75FWO RN Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007. DM75FWO RU https://pubmed.ncbi.nlm.nih.gov/23525448 DM760FA DI DM760FA DM760FA DN OPB-51602 DM760FA TI TTH8FZW DM760FA TN Signal transducer and activator of transcription 3 (STAT3) DM760FA MA Inhibitor DM760FA RN Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005. DM760FA RU https://pubmed.ncbi.nlm.nih.gov/25609248 DM796RI DI DM796RI DM796RI DN ZYAN1 DM796RI TI TTJQFBG DM796RI TN HIF-prolyl hydroxylase (HPH) DM796RI MA Inhibitor DM796RI RN Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12. DM796RI RU https://pubmed.ncbi.nlm.nih.gov/26367279 DM79W8K DI DM79W8K DM79W8K DN ICo-007 DM79W8K TI TTAN5W2 DM79W8K TN Raf messenger RNA (Raf mRNA) DM79W8K RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DM79W8K RU http://www.isispharm.com/Pipeline/index.htm DM79XGM DI DM79XGM DM79XGM DN BIBX-1382 DM79XGM TI TTGKNB4 DM79XGM TN Epidermal growth factor receptor (EGFR) DM79XGM MA Antagonist DM79XGM RN Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. DM79XGM RU https://pubmed.ncbi.nlm.nih.gov/12008195 DM7A6R5 DI DM7A6R5 DM7A6R5 DN SCH-900117 DM7A6R5 TI TTG0MT6 DM7A6R5 TN Interleukin-17 (IL17) DM7A6R5 MA Modulator DM7A6R5 RN Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. DM7A6R5 RU https://pubmed.ncbi.nlm.nih.gov/23023676 DM7B2JC DI DM7B2JC DM7B2JC DN PF-05190457 DM7B2JC TI TTWDC17 DM7B2JC TN Growth hormone secretagogue receptor 1 (GHSR) DM7B2JC MA Modulator DM7B2JC RN A gift for research. SciBX 7(6); doi:10.1038/scibx.2014.160. Feb. 13 2014 DM7B2JC RU http://www.nature.com/scibx/journal/v7/n6/full/scibx.2014.160.html DM7B650 DI DM7B650 DM7B650 DN RG-2833 DM7B650 TI TT6R7JZ DM7B650 TN Histone deacetylase 1 (HDAC1) DM7B650 MA Modulator DM7B650 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7B650 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TT7HF4W DM7BMD6 TN Cyclin-dependent kinase 2 (CDK2) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TTGJCWZ DM7BMD6 TN Fms-like tyrosine kinase 3 (FLT-3) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TT0PG8F DM7BMD6 TN Cyclin-dependent kinase 4 (CDK4) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BMD6 DI DM7BMD6 DM7BMD6 DN FN-1501 DM7BMD6 TI TTO0FDJ DM7BMD6 TN Cyclin-dependent kinase 6 (CDK6) DM7BMD6 MA Inhibitor DM7BMD6 RN Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518. DM7BMD6 RU https://pubmed.ncbi.nlm.nih.gov/29357250 DM7BOFR DI DM7BOFR DM7BOFR DN PF-06939999 DM7BOFR TI TTR1D7X DM7BOFR TN Protein arginine methyltransferase 5 (PRMT5) DM7BOFR MA Inhibitor DM7BOFR RN National Cancer Institute Drug Dictionary (drug name PF-06939999). DM7BOFR RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/protein-arginine-methyltransferase-5-inhibitor-pf-06939999 DM7C062 DI DM7C062 DM7C062 DN RTA-901 DM7C062 TI TT78R5H DM7C062 TN Heat shock protein 90 alpha (HSP90A) DM7C062 MA Modulator DM7C062 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7C062 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM7C4U9 DI DM7C4U9 DM7C4U9 DN DS-7309 DM7C4U9 TI TTDLNGZ DM7C4U9 TN Glucokinase (GCK) DM7C4U9 MA Inhibitor DM7C4U9 RN Glucokinase alternative. SciBX 6(45); doi:10.1038/scibx.2013.1279. Nov. 21 2013 DM7C4U9 RU http://www.nature.com/scibx/journal/v6/n45/full/scibx.2013.1279.html DM7C68W DI DM7C68W DM7C68W DN AST-008 DM7C68W TI TTSHG0T DM7C68W TN Toll-like receptor 9 (TLR9) DM7C68W MA Agonist DM7C68W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7C68W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7CD8Z DI DM7CD8Z DM7CD8Z DN AMAP-102 DM7CD8Z TI TTYSN63 DM7CD8Z TN 5-HT 2 receptor (5HT2R) DM7CD8Z MA Antagonist DM7CD8Z RN Clinical pipeline report, company report or official report of Anamar. DM7CD8Z RU http://anamar.com/rd/project-amap102/ DM7CHZ2 DI DM7CHZ2 DM7CHZ2 DN TTC-352 DM7CHZ2 TI TTZAYWL DM7CHZ2 TN Estrogen receptor (ESR) DM7CHZ2 MA Agonist DM7CHZ2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7CHZ2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7CIN4 DI DM7CIN4 DM7CIN4 DN GSK-625433 DM7CIN4 TI TTMVBWH DM7CIN4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM7CIN4 MA Inhibitor DM7CIN4 RN Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase . Antimicrob Agents Chemother. 2009 June; 53(6): 2544-2552. DM7CIN4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687230/ DM7CNTG DI DM7CNTG DM7CNTG DN AMG 397 DM7CNTG TI TTL53M6 DM7CNTG TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM7CNTG MA Inhibitor DM7CNTG RN Clinical pipeline report, company report or official report of Amgen. DM7CNTG RU https://www.amgenpipeline.com/ DM7DAKX DI DM7DAKX DM7DAKX DN SRT2379 DM7DAKX TI TTUF2HO DM7DAKX TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM7DAKX MA Modulator DM7DAKX RN SRT2379, a small-molecule SIRT1 activator, fails to reduce cytokine release in a human endotoxemia model. Critical Care 2013, 17(Suppl 4):P8. DM7DAKX RU http://www.ccforum.com/content/17/S4/P8 DM7DFBL DI DM7DFBL DM7DFBL DN TAK-441 DM7DFBL TI TT8J1S3 DM7DFBL TN Smoothened homolog (SMO) DM7DFBL MA Modulator DM7DFBL RN TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer. 2013 Oct 15;133(8):1955-66. DM7DFBL RU https://pubmed.ncbi.nlm.nih.gov/23564295 DM7E1W0 DI DM7E1W0 DM7E1W0 DN CC-95251 DM7E1W0 TI TTBRJS9 DM7E1W0 TN Inhibitory receptor SHPS-1 (SIRPA) DM7E1W0 RN ClinicalTrials.gov (NCT03783403) A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPalpha, in Subjects With Advanced Solid and Hematologic Cancers. U.S. National Institutes of Health. DM7E1W0 RU https://clinicaltrials.gov/ct2/show/NCT03783403 DM7E6V2 DI DM7E6V2 DM7E6V2 DN TTC-352 DM7E6V2 TI TTZAYWL DM7E6V2 TN Estrogen receptor (ESR) DM7E6V2 MA Agonist DM7E6V2 RN Clinical pipeline report, company report or official report of TTC Oncology. DM7E6V2 RU https://ttconcology.com/our-product/ DM7EAG8 DI DM7EAG8 DM7EAG8 DN Cilobradine DM7EAG8 TI TTKLW9S DM7EAG8 TN Hyperpolarization cyclic nucleotide-gated channel (HCN) DM7EAG8 MA Modulator DM7EAG8 RN Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol. 2003 Oct 8;478(2-3):161-71. DM7EAG8 RU https://pubmed.ncbi.nlm.nih.gov/14575801 DM7ER9J DI DM7ER9J DM7ER9J DN MS-553 DM7ER9J TI TTYPXQF DM7ER9J TN Protein kinase C beta (PRKCB) DM7ER9J MA Inhibitor DM7ER9J RN ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health. DM7ER9J RU https://clinicaltrials.gov/ct2/show/NCT03492125 DM7FN12 DI DM7FN12 DM7FN12 DN GSK2256294 DM7FN12 TI TT7WVHI DM7FN12 TN Soluble epoxide hydrolase (EPHX2) DM7FN12 MA Modulator DM7FN12 RN In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. DM7FN12 RU https://pubmed.ncbi.nlm.nih.gov/23434473 DM7GSZL DI DM7GSZL DM7GSZL DN PF-05230907 DM7GSZL TI TTGKNB4 DM7GSZL TN Epidermal growth factor receptor (EGFR) DM7GSZL MA Inhibitor DM7GSZL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7GSZL RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM7GUH3 DI DM7GUH3 DM7GUH3 DN SEA-TGT DM7GUH3 TI TTWNL74 DM7GUH3 TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DM7GUH3 MA Inhibitor DM7GUH3 RN Clinical pipeline report, company report or official report of Seagen. DM7GUH3 RU https://www.seagen.com/science/pipeline DM7H6XI DI DM7H6XI DM7H6XI DN RO6870810 DM7H6XI TI TTE4BSY DM7H6XI TN Bromodomain and extraterminal domain protein (BET) DM7H6XI MA Inhibitor DM7H6XI RN A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021 Feb;124(4):744-753. DM7H6XI RU https://pubmed.ncbi.nlm.nih.gov/33311588 DM7I1AQ DI DM7I1AQ DM7I1AQ DN GSK1614235 DM7I1AQ TI TT2UE56 DM7I1AQ TN Sodium/glucose cotransporter 1 (SGLT1) DM7I1AQ MA Blocker DM7I1AQ RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM7I1AQ RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM7I39W DI DM7I39W DM7I39W DN CSL-362-AML DM7I39W TI TTENHJ0 DM7I39W TN Interleukin 3 receptor alpha (IL3RA) DM7I39W RN Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28. DM7I39W RU https://pubmed.ncbi.nlm.nih.gov/24363400 DM7JNHU DI DM7JNHU DM7JNHU DN LAM-001 DM7JNHU TI TTCJG29 DM7JNHU TN Serine/threonine-protein kinase mTOR (mTOR) DM7JNHU MA Inhibitor DM7JNHU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7JNHU RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DM7JW0B DI DM7JW0B DM7JW0B DN BMS-903452 DM7JW0B TI TT7QNVC DM7JW0B TN Glucose-dependent insulinotropic receptor (GPR119) DM7JW0B MA Modulator DM7JW0B RN Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508. DM7JW0B RU https://pubmed.ncbi.nlm.nih.gov/25208139 DM7L45S DI DM7L45S DM7L45S DN 227Th-labelled PSMA-TTC DM7L45S TI TT9G4N0 DM7L45S TN Glutamate carboxypeptidase II (GCPII) DM7L45S RN Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models. Clin Cancer Res. 2021 May 25. DM7L45S RU https://pubmed.ncbi.nlm.nih.gov/34035067 DM7L91K DI DM7L91K DM7L91K DN BAY1179470 DM7L91K TI TTGJVQM DM7L91K TN Fibroblast growth factor receptor 2 (FGFR2) DM7L91K MA Antagonist DM7L91K RN National Cancer Institute Drug Dictionary (drug id 751593). DM7L91K RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751593 DM7LIV2 DI DM7LIV2 DM7LIV2 DN REGN3051 DM7LIV2 TI TTZ3COY DM7LIV2 TN COVID-19 spike glycoprotein (S) DM7LIV2 MA Inhibitor DM7LIV2 RN Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71. DM7LIV2 RU https://pubmed.ncbi.nlm.nih.gov/29885377 DM7MS10 DI DM7MS10 DM7MS10 DN WVT078 DM7MS10 TI TTUN7MC DM7MS10 TN T-cell surface glycoprotein CD3 (CD3) DM7MS10 RN ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health. DM7MS10 RU https://clinicaltrials.gov/ct2/show/NCT04123418 DM7MS10 DI DM7MS10 DM7MS10 DN WVT078 DM7MS10 TI TTZ3P4W DM7MS10 TN B-cell maturation protein (TNFRSF17) DM7MS10 RN ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health. DM7MS10 RU https://clinicaltrials.gov/ct2/show/NCT04123418 DM7MWX0 DI DM7MWX0 DM7MWX0 DN ARQ 751 DM7MWX0 TI TTWTSCV DM7MWX0 TN RAC-alpha serine/threonine-protein kinase (AKT1) DM7MWX0 MA Inhibitor DM7MWX0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7MWX0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7OC9K DI DM7OC9K DM7OC9K DN PF-05230905 DM7OC9K TI TTF8CQI DM7OC9K TN Tumor necrosis factor (TNF) DM7OC9K MA Inhibitor DM7OC9K RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033173) DM7OC9K RU http://adisinsight.springer.com/drugs/800033173 DM7PLMJ DI DM7PLMJ DM7PLMJ DN AG-707 DM7PLMJ TI TTHYBIX DM7PLMJ TN Heat shock protein 70 (HSP70) DM7PLMJ MA Modulator DM7PLMJ RN A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Vaccine. 2011 Nov 3;29(47):8530-41. DM7PLMJ RU https://pubmed.ncbi.nlm.nih.gov/21767588 DM7Q4EX DI DM7Q4EX DM7Q4EX DN Temanogrel DM7Q4EX TI TTJQOD7 DM7Q4EX TN 5-HT 2A receptor (HTR2A) DM7Q4EX MA Agonist DM7Q4EX RN Clinical pipeline report, company report or official report of Arena Pharmaceuticals. DM7Q4EX RU http://www.arenapharm.com/temanogrel DM7QGHO DI DM7QGHO DM7QGHO DN AZD5991 DM7QGHO TI TTL53M6 DM7QGHO TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM7QGHO MA Inhibitor DM7QGHO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7QGHO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7QO05 DI DM7QO05 DM7QO05 DN SAR438335 DM7QO05 TI TTVIMDE DM7QO05 TN Glucagon-like peptide 1 receptor (GLP1R) DM7QO05 MA Agonist DM7QO05 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7QO05 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM7QO05 DI DM7QO05 DM7QO05 DN SAR438335 DM7QO05 TI TTYMKBE DM7QO05 TN Gastric inhibitory polypeptide receptor (GIPR) DM7QO05 MA Agonist DM7QO05 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7QO05 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DM7QTIC DI DM7QTIC DM7QTIC DN BGB-11417 DM7QTIC TI TTJGNVC DM7QTIC TN Apoptosis regulator Bcl-2 (BCL-2) DM7QTIC MA Inhibitor DM7QTIC RN Clinical pipeline report, company report or official report of BeiGene. DM7QTIC RU https://www.beigenemedical.com/CongressDocuments/Hu%20BGB-11417%20AACR%20Poster%202020.pdf DM7RPSG DI DM7RPSG DM7RPSG DN BF-1 DM7RPSG TI TT85JO3 DM7RPSG TN 5-HT receptor (5HTR) DM7RPSG MA Modulator DM7RPSG RN Serotonin (5-HT2B) receptor. SciBX 4(19); doi:10.1038/scibx.2011.534. May 12 2011 DM7RPSG RU http://www.nature.com/scibx/journal/v4/n19/full/scibx.2011.534.html DM7TOWX DI DM7TOWX DM7TOWX DN ABT-333 DM7TOWX TI TTMVBWH DM7TOWX TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM7TOWX MA Inhibitor DM7TOWX RN Clinical pipeline report, company report or official report of Abbott Laboratories (2011) DM7TOWX RU http://www.abbott.com/index2.htm DM7UJ6E DI DM7UJ6E DM7UJ6E DN HER2-specific T cells DM7UJ6E TI TT6EO5L DM7UJ6E TN Erbb2 tyrosine kinase receptor (HER2) DM7UJ6E MA CAR-T-Cell-Therapy DM7UJ6E RN ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma DM7UJ6E RU https://clinicaltrials.gov/ct2/show/NCT02442297 DM7V2OM DI DM7V2OM DM7V2OM DN D-3263 DM7V2OM TI TTXDKTO DM7V2OM TN Long transient receptor potential channel 8 (TRPM8) DM7V2OM MA Modulator DM7V2OM RN Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring; 11(2): 82-107. DM7V2OM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2725309/ DM7W5N2 DI DM7W5N2 DM7W5N2 DN BI 894999 DM7W5N2 TI TTE4BSY DM7W5N2 TN Bromodomain and extraterminal domain protein (BET) DM7W5N2 MA Inhibitor DM7W5N2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM7W5N2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM7WKTM DI DM7WKTM DM7WKTM DN SLV-338 DM7WKTM TI TT5TKPM DM7WKTM TN Neutral endopeptidase (MME) DM7WKTM MA Modulator DM7WKTM RN Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15. DM7WKTM RU https://pubmed.ncbi.nlm.nih.gov/21888014 DM7WKTM DI DM7WKTM DM7WKTM DN SLV-338 DM7WKTM TI TT1BGDH DM7WKTM TN Endothelin-converting enzyme (ECE) DM7WKTM MA Modulator DM7WKTM RN Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. Clin Lab. 2011;57(7-8):507-15. DM7WKTM RU https://pubmed.ncbi.nlm.nih.gov/21888014 DM7X2HK DI DM7X2HK DM7X2HK DN AE-08 DM7X2HK TI TT8MK59 DM7X2HK TN Melanocytes lineage-specific antigen GP100 (PMEL) DM7X2HK RN Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7. DM7X2HK RU https://pubmed.ncbi.nlm.nih.gov/20355185 DM7XAV1 DI DM7XAV1 DM7XAV1 DN JBH492 DM7XAV1 TI TT2GIDQ DM7XAV1 TN C-C chemokine receptor type 7 (CCR7) DM7XAV1 RN ClinicalTrials.gov (NCT04240704) Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL). U.S. National Institutes of Health. DM7XAV1 RU https://clinicaltrials.gov/ct2/show/NCT04240704 DM7XES6 DI DM7XES6 DM7XES6 DN ANX-042 DM7XES6 TI TTWVLS6 DM7XES6 TN Natriuretic peptide receptor (NPR3) DM7XES6 MA Modulator DM7XES6 RN Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation: Novel Therapeutic Concepts to Combat Heart Failure. Circ Heart Fail. 2013 May; 6(3): 594-605. DM7XES6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3981104/ DM7YFW5 DI DM7YFW5 DM7YFW5 DN OPB-111077 DM7YFW5 TI TTH8FZW DM7YFW5 TN Signal transducer and activator of transcription 3 (STAT3) DM7YFW5 MA Inhibitor DM7YFW5 RN Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. Cancer Res Treat. 2019 Apr;51(2):510-518. DM7YFW5 RU https://pubmed.ncbi.nlm.nih.gov/29898591 DM7YX8G DI DM7YX8G DM7YX8G DN Pennvax-G DM7YX8G TI TTUTN1I DM7YX8G TN Human Deoxyribonucleic acid (hDNA) DM7YX8G RN Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601. DM7YX8G RU https://pubmed.ncbi.nlm.nih.gov/25531694 DM7Z8NP DI DM7Z8NP DM7Z8NP DN AM-461 DM7Z8NP TI TTQDMX5 DM7Z8NP TN Prostaglandin D2 receptor 2 (PTGDR2) DM7Z8NP MA Antagonist DM7Z8NP RN A novel DP2 receptor antagonist (AM-461): a patent evaluation of WO2011085033. Expert Opin Ther Pat. 2011 Dec;21(12):1931-6. DM7Z8NP RU https://pubmed.ncbi.nlm.nih.gov/22082220 DM7ZU3B DI DM7ZU3B DM7ZU3B DN AXT-914 DM7ZU3B TI TTBUYHA DM7ZU3B TN Extracellular calcium-sensing receptor (CASR) DM7ZU3B MA Antagonist DM7ZU3B RN AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10. DM7ZU3B RU https://pubmed.ncbi.nlm.nih.gov/24769332 DM82KWY DI DM82KWY DM82KWY DN Ronomilast DM82KWY TI TTVIAT9 DM82KWY TN Phosphodiesterase 4B (PDE4B) DM82KWY MA Inhibitor DM82KWY RN Clinical pipeline report, company report or official report of Avarx. DM82KWY RU http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html DM82KWY DI DM82KWY DM82KWY DN Ronomilast DM82KWY TI TTSKMI8 DM82KWY TN Phosphodiesterase 4D (PDE4D) DM82KWY MA Inhibitor DM82KWY RN Clinical pipeline report, company report or official report of Avarx. DM82KWY RU http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html DM82KWY DI DM82KWY DM82KWY DN Ronomilast DM82KWY TI TTZ97H5 DM82KWY TN Phosphodiesterase 4A (PDE4A) DM82KWY MA Inhibitor DM82KWY RN Clinical pipeline report, company report or official report of Avarx. DM82KWY RU http://www.avarx.com/AvaRx/SubDomains/bucket3609200049721832467/Listings/bucket3113046654580504235/Public.Listing.display.html DM82OS7 DI DM82OS7 DM82OS7 DN Anti-CD123 CAR-T treatment DM82OS7 TI TTENHJ0 DM82OS7 TN Interleukin 3 receptor alpha (IL3RA) DM82OS7 MA CAR-T-Cell-Therapy DM82OS7 RN ClinicalTrials.gov (NCT03672851) Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia DM82OS7 RU https://clinicaltrials.gov/ct2/show/NCT03672851 DM830EN DI DM830EN DM830EN DN NEO-201 DM830EN TI TTY6DTE DM830EN TN Carcinoembryonic antigen CEA (CD66e) DM830EN MA Inhibitor DM830EN RN The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198. DM830EN RU https://pubmed.ncbi.nlm.nih.gov/31928422 DM830EN DI DM830EN DM830EN DN NEO-201 DM830EN TI TTA9CK4 DM830EN TN Biliary glycoprotein 1 (CEACAM1) DM830EN MA Inhibitor DM830EN RN The Monoclonal Antibody NEO-201 Enhances Natural Killer Cell Cytotoxicity Against Tumor Cells Through Blockade of the Inhibitory CEACAM5/CEACAM1 Immune Checkpoint Pathway. Cancer Biother Radiopharm. 2020 Apr;35(3):190-198. DM830EN RU https://pubmed.ncbi.nlm.nih.gov/31928422 DM83E5B DI DM83E5B DM83E5B DN Synthetic neutrophil inhibitor peptide DM83E5B TI TTHQGFL DM83E5B TN PMN apoptosis and chemotaxis (PMNAC) DM83E5B MA Inhibitor DM83E5B RN Attenuation of interleukin 8-induced nasal inflammation by an inhibitor peptide. Am J Respir Crit Care Med. 2001 Apr;163(5):1198-205. DM83E5B RU https://pubmed.ncbi.nlm.nih.gov/11316659 DM84LXE DI DM84LXE DM84LXE DN BGB-10188 DM84LXE TI TTGBPJE DM84LXE TN PI3-kinase delta (PIK3CD) DM84LXE MA Inhibitor DM84LXE RN ClinicalTrials.gov (NCT04282018) Brief Title: Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab. U.S. National Institutes of Health. DM84LXE RU https://clinicaltrials.gov/ct2/show/NCT04282018 DM84WXZ DI DM84WXZ DM84WXZ DN AZD-7295 DM84WXZ TI TTCJ2X8 DM84WXZ TN Hepatitis C virus Non-structural 5A (HCV NS5A) DM84WXZ MA Modulator DM84WXZ RN TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION. Drugs Future. 2011 September; 36(9): 691-711. DM84WXZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558953/ DM85AXS DI DM85AXS DM85AXS DN MBS301 DM85AXS TI TT6EO5L DM85AXS TN Erbb2 tyrosine kinase receptor (HER2) DM85AXS MA Inhibitor DM85AXS RN Clinical pipeline report, company report or official report of Beijing Mabworks Biotech. DM85AXS RU http://www.mab-works.com/product/5.html DM86CZJ DI DM86CZJ DM86CZJ DN C-CAR011 DM86CZJ TI TTW640A DM86CZJ TN B-lymphocyte surface antigen B4 (CD19) DM86CZJ MA CAR-T-Cell-Therapy DM86CZJ RN ClinicalTrials.gov (NCT03299738) A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL DM86CZJ RU https://clinicaltrials.gov/ct2/show/NCT03299738 DM87SM9 DI DM87SM9 DM87SM9 DN ABBV-467 DM87SM9 TI TTL53M6 DM87SM9 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM87SM9 MA Inhibitor DM87SM9 RN Clinical pipeline report, company report or official report of AbbVie. DM87SM9 RU https://www.abbvie.com/our-science/pipeline/abbv-467.html DM89DHO DI DM89DHO DM89DHO DN ALN-VSP DM89DHO TI TTBGTCW DM89DHO TN Kinesin spindle messenger RNA (KIF11 mRNA) DM89DHO RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011). DM89DHO RU http://www.alnylam.com/Programs-and-Pipeline/index.php DM89NML DI DM89NML DM89NML DN XL652/XL014 DM89NML TI TTM1EQF DM89NML TN Oxysterols receptor LXR (NR1H) DM89NML MA Modulator DM89NML RN Clinical pipeline report, company report or official report of Exelixis (2011). DM89NML RU http://www.exelixis.com/pipeline DM8ANIM DI DM8ANIM DM8ANIM DN Lactermin DM8ANIM TI TTDB5IS DM8ANIM TN Receptor unspecific (Rec) DM8ANIM MA Modulator DM8ANIM RN Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci. 2005 Nov;62(22):2560-75. DM8ANIM RU https://pubmed.ncbi.nlm.nih.gov/16261254 DM8B2WQ DI DM8B2WQ DM8B2WQ DN AN-2718 DM8B2WQ TI TT37GL6 DM8B2WQ TN Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS) DM8B2WQ MA Inhibitor DM8B2WQ RN Metalloid compounds as drugs. Res Pharm Sci. 2013 Jul-Sep; 8(3): 145-158. DM8B2WQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3764666/ DM8B40M DI DM8B40M DM8B40M DN ONC-392 DM8B40M TI TTI2S1D DM8B40M TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM8B40M MA Inhibitor DM8B40M RN Clinical pipeline report, company report or official report of OncoImmune. DM8B40M RU https://www.oncoc4.com/index.php/product-development/onc-392 DM8BG0M DI DM8BG0M DM8BG0M DN FP-253-GDEPT DM8BG0M TI TTVYIH7 DM8BG0M TN Schistosoma Purine nucleoside phosphorylase (sch PNP) DM8BG0M MA Modulator DM8BG0M RN Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med. 2004 Dec;6(12):1343-57. DM8BG0M RU https://pubmed.ncbi.nlm.nih.gov/15493036 DM8BXDI DI DM8BXDI DM8BXDI DN MEDI7814 DM8BXDI TI TTKANGO DM8BXDI TN Complement C5 (CO5) DM8BXDI MA Modulator DM8BXDI RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8BXDI RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8CGUV DI DM8CGUV DM8CGUV DN MCLA-145 DM8CGUV TI TTPW9LJ DM8CGUV TN Co-stimulatory molecule 4-1BB (CD137) DM8CGUV MA Agonist DM8CGUV RN Clinical pipeline report, company report or official report of Merus. DM8CGUV RU https://merus.nl/publication-category/mcla-145/ DM8CGUV DI DM8CGUV DM8CGUV DN MCLA-145 DM8CGUV TI TT8ZLTI DM8CGUV TN Programmed cell death 1 ligand 1 (PD-L1) DM8CGUV MA Agonist DM8CGUV RN Clinical pipeline report, company report or official report of Merus. DM8CGUV RU https://merus.nl/pipeline/ DM8CYJ1 DI DM8CYJ1 DM8CYJ1 DN AVP-13358 DM8CYJ1 TI TTYJQTF DM8CYJ1 TN Immunoglobulin E (IgE) DM8CYJ1 MA Inhibitor DM8CYJ1 RN Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4. DM8CYJ1 RU https://pubmed.ncbi.nlm.nih.gov/15588078 DM8DBT6 DI DM8DBT6 DM8DBT6 DN ASP-0777 DM8DBT6 TI TT9IK2Z DM8DBT6 TN N-methyl-D-aspartate receptor (NMDAR) DM8DBT6 MA Modulator DM8DBT6 RN US patent application no. 2011,0262,442, Compositions for treating cns disorders. DM8DBT6 RU https://www.google.com/patents/US20110262442 DM8DMI0 DI DM8DMI0 DM8DMI0 DN AZD-8165 DM8DMI0 TI TT6L509 DM8DMI0 TN Coagulation factor IIa (F2) DM8DMI0 MA Inhibitor DM8DMI0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DM8DMI0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DM8DWOL DI DM8DWOL DM8DWOL DN CDNA vaccine DM8DWOL TI TTNYZG2 DM8DWOL TN Granulocyte-macrophage colony-stimulating factor (CSF2) DM8DWOL MA Modulator DM8DWOL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8DWOL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8FQPX DI DM8FQPX DM8FQPX DN KTN3379 DM8FQPX TI TTDC8N2 DM8FQPX TN Erbb3 tyrosine kinase receptor (Erbb-3) DM8FQPX RN A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK. Am J Transl Res. 2015; 7(4): 733-750. DM8FQPX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455348/ DM8GC65 DI DM8GC65 DM8GC65 DN RG3039 DM8GC65 TI TTLSW9V DM8GC65 TN Scavenger decapping enzyme DcpS (DCPS) DM8GC65 MA Inhibitor DM8GC65 RN 2011 Pipeline of Repligen. DM8GC65 RU http://www.repligen.com/products/pipeline DM8H2AG DI DM8H2AG DM8H2AG DN TTX-030 DM8H2AG TI TTYM8DJ DM8H2AG TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DM8H2AG MA Inhibitor DM8H2AG RN Clinical pipeline report, company report or official report of AbbVie. DM8H2AG RU https://www.abbvie.com/our-science/pipeline/ttx-030.html DM8I4G0 DI DM8I4G0 DM8I4G0 DN AEB701 DM8I4G0 TI TTYVX59 DM8I4G0 TN Protein kinase C (PRKC) DM8I4G0 MA Inhibitor DM8I4G0 RN Changes in Serum Cytokine Profile after AEB071 (Sotrastaurin) or Tacrolimus versus Their Combinations in Rat Heterotopic Cardiac Allografts. J Korean Soc Transplant. 2012 Dec;26(4):248-253. DM8I4G0 RU http://synapse.koreamed.org/DOIx.php?id=10.4285/jkstn.2012.26.4.248 DM8J3WE DI DM8J3WE DM8J3WE DN Nibentan DM8J3WE TI TT1VOHK DM8J3WE TN Potassium channel unspecific (KC) DM8J3WE MA Blocker DM8J3WE RN Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation. Kardiologiia. 2005;45(3):19-23. DM8J3WE RU https://pubmed.ncbi.nlm.nih.gov/15821703 DM8KRA3 DI DM8KRA3 DM8KRA3 DN EDP-514 DM8KRA3 TI TTM42UJ DM8KRA3 TN Hepatitis B virus Capsid protein (HBV C) DM8KRA3 MA Inhibitor DM8KRA3 RN Clinical pipeline report, company report or official report of Enanta Pharmaceuticals. DM8KRA3 RU https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Clinical-Trial-Progress-for-EDP-514-its-Lead-Core-Inhibitor-for-Hepatitis-B-Virus/default.aspx DM8L1GJ DI DM8L1GJ DM8L1GJ DN SNA-125 DM8L1GJ TI TTT7PJU DM8L1GJ TN Janus kinase 3 (JAK-3) DM8L1GJ MA Inhibitor DM8L1GJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8L1GJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8L36X DI DM8L36X DM8L36X DN CNTO-3649 DM8L36X TI TTVIMDE DM8L36X TN Glucagon-like peptide 1 receptor (GLP1R) DM8L36X MA Agonist DM8L36X RN GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One. 2012;7(11):e49152. DM8L36X RU https://pubmed.ncbi.nlm.nih.gov/23133675 DM8LG2I DI DM8LG2I DM8LG2I DN AF-130 DM8LG2I TI TT2THBD DM8LG2I TN P2X purinoceptor 3 (P2RX3) DM8LG2I MA Antagonist DM8LG2I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8LG2I RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DM8LGWR DI DM8LGWR DM8LGWR DN LY-2811376 DM8LGWR TI TT8JRS7 DM8LGWR TN Beta-secretase (BACE) DM8LGWR MA Inhibitor DM8LGWR RN Neurodegenerative disease: Inhibiting beta-secretase in humans. Nature Reviews Drug Discovery 11, 21 (January 2012). DM8LGWR RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DM8MGSH DI DM8MGSH DM8MGSH DN GPRC5D CAR-T cell therapy DM8MGSH TI TTHRAPJ DM8MGSH TN G-protein coupled receptor C 5D (GPRC5D) DM8MGSH RN GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019 Mar 27;11(485):eaau7746. DM8MGSH RU https://pubmed.ncbi.nlm.nih.gov/30918115 DM8NLPI DI DM8NLPI DM8NLPI DN CAR CD30 T cells DM8NLPI TI TT2GM5R DM8NLPI TN Lymphocyte activation antigen CD30 (TNFRSF8) DM8NLPI MA CAR-T-Cell-Therapy DM8NLPI RN ClinicalTrials.gov (NCT01316146) Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) DM8NLPI RU https://clinicaltrials.gov/ct2/show/NCT01316146 DM8O2AQ DI DM8O2AQ DM8O2AQ DN SPN-803 DM8O2AQ TI TTAN5W2 DM8O2AQ TN Raf messenger RNA (Raf mRNA) DM8O2AQ MA Inhibitor DM8O2AQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184). DM8O2AQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184 DM8O2AQ DI DM8O2AQ DM8O2AQ DN SPN-803 DM8O2AQ TI TT0EOB8 DM8O2AQ TN B-Raf messenger RNA (BRAF mRNA) DM8O2AQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943). DM8O2AQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943 DM8P3N5 DI DM8P3N5 DM8P3N5 DN ISIS-AR DM8P3N5 TI TTKPW01 DM8P3N5 TN Androgen receptor messenger RNA (AR mRNA) DM8P3N5 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DM8P3N5 RU https://www.isispharm.com/pipeline/isis-arrx/ DM8R2ZX DI DM8R2ZX DM8R2ZX DN CART-19 DM8R2ZX TI TTW640A DM8R2ZX TN B-lymphocyte surface antigen B4 (CD19) DM8R2ZX MA CAR-T-Cell-Therapy DM8R2ZX RN ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia DM8R2ZX RU https://clinicaltrials.gov/ct2/show/NCT02810223 DM8RD4T DI DM8RD4T DM8RD4T DN EC0489 DM8RD4T TI TTVC37M DM8RD4T TN Folate receptor alpha (FOLR1) DM8RD4T MA Modulator DM8RD4T RN National Cancer Institute Drug Dictionary (drug id 638649). DM8RD4T RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=638649 DM8RNSB DI DM8RNSB DM8RNSB DN WP1220 DM8RNSB TI TTH8FZW DM8RNSB TN Signal transducer and activator of transcription 3 (STAT3) DM8RNSB MA Inhibitor DM8RNSB RN Clinical pipeline report, company report or official report of Moleculin Biotech. DM8RNSB RU https://www.moleculin.com/technology/wp1220/ DM8SINB DI DM8SINB DM8SINB DN SDZ-LAV-694 DM8SINB TI TTML2WA DM8SINB TN Tubulin (TUB) DM8SINB MA Inhibitor DM8SINB RN Recent Patents Reveal Microtubules as Persistent Promising Target for Novel Drug Development for Cancers. Recent Patents on Anti-Infective Drug Discovery 12/2009; 4(3):164-82. DM8SINB RU http://www.researchgate.net/profile/Harish_Joshi/publication/26735183_Recent_patents_reveal_microtubules_as_persistent_promising_target_for_novel_drug_development_for_cancers/links/0deec5192b302d6e79000000.pdf DM8T2KA DI DM8T2KA DM8T2KA DN CI-966 DM8T2KA TI TTPRKM0 DM8T2KA TN GABA transporter GAT-1 (SLC6A1) DM8T2KA MA Modulator DM8T2KA RN Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol. 1994 Oct 14;269(2):219-24. DM8T2KA RU https://pubmed.ncbi.nlm.nih.gov/7851497 DM8TU5R DI DM8TU5R DM8TU5R DN E7766 DM8TU5R TI TTT402Y DM8TU5R TN Stimulator of interferon genes protein (TMEM173) DM8TU5R MA Agonist DM8TU5R RN E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743. DM8TU5R RU https://pubmed.ncbi.nlm.nih.gov/33522135 DM8U23L DI DM8U23L DM8U23L DN GGTI-2418 DM8U23L TI TTXQKM3 DM8U23L TN Farnesyl protein transferase (Ftase) DM8U23L MA Modulator DM8U23L RN Company report (Prescient) DM8U23L RU http://prescienttherapeutics.com/ptx-100/ DM8U2IE DI DM8U2IE DM8U2IE DN FGI-101-1A6 DM8U2IE TI TTHU7JA DM8U2IE TN Tumor susceptibility gene protein 101 (TSG101) DM8U2IE RN ClinicalTrials.gov (NCT01299142) Safety and Pharmacokinetics Study of Human Monoclonal Antibody (FGI-101-1A6). U.S. National Institutes of Health. DM8U2IE RU https://clinicaltrials.gov/ct2/show/NCT01299142 DM8U3Q2 DI DM8U3Q2 DM8U3Q2 DN BAY-1075553 DM8U3Q2 TI TT9G4N0 DM8U3Q2 TN Glutamate carboxypeptidase II (GCPII) DM8U3Q2 MA Modulator DM8U3Q2 RN Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):89-101. DM8U3Q2 RU https://pubmed.ncbi.nlm.nih.gov/23955632 DM8UTPJ DI DM8UTPJ DM8UTPJ DN VX-500 DM8UTPJ TI TT5FNQT DM8UTPJ TN Human immunodeficiency virus Protease (HIV PR) DM8UTPJ MA Inhibitor DM8UTPJ RN 2011 Pipeline of Vertex. DM8UTPJ RU http://www.vrtx.com/current-projects.html DM8V62T DI DM8V62T DM8V62T DN BAY1834845 DM8V62T TI TTKFVXR DM8V62T TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM8V62T MA Inhibitor DM8V62T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8V62T RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM8VGRX DI DM8VGRX DM8VGRX DN RGX-202 DM8VGRX TI TTYUHB5 DM8VGRX TN Solute carrier family 6 member 8 (SLC6A8) DM8VGRX MA Inhibitor DM8VGRX RN Clinical pipeline report, company report or official report of Rgenix. DM8VGRX RU https://rgenix.com/rgx-202/ DM8VQ1S DI DM8VQ1S DM8VQ1S DN AD-337 DM8VQ1S TI TT3ROYC DM8VQ1S TN Serotonin transporter (SERT) DM8VQ1S MA Modulator DM8VQ1S RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8VQ1S RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8WBNF DI DM8WBNF DM8WBNF DN DTX401 DM8WBNF TI TTBQMJ8 DM8WBNF TN Glucose-6-phosphatase (G6PC) DM8WBNF MA Replacement DM8WBNF RN Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical. DM8WBNF RU https://www.ultragenyx.com/pipeline/dtx-401-for-gsd1a/ DM8XM72 DI DM8XM72 DM8XM72 DN CIGB-500 DM8XM72 TI TTSTYLU DM8XM72 TN Growth hormone secretion (GH secr) DM8XM72 MA Modulator DM8XM72 RN Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab. 1993 Nov;77(5):1393-7. DM8XM72 RU https://pubmed.ncbi.nlm.nih.gov/8077339 DM8XMPT DI DM8XMPT DM8XMPT DN 4SC-203 DM8XMPT TI TTGJCWZ DM8XMPT TN Fms-like tyrosine kinase 3 (FLT-3) DM8XMPT MA Modulator DM8XMPT RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8XMPT RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8Y1M9 DI DM8Y1M9 DM8Y1M9 DN PSMA CAR-T cell therapy DM8Y1M9 TI TT9G4N0 DM8Y1M9 TN Glutamate carboxypeptidase II (GCPII) DM8Y1M9 RN Clinical pipeline report, company report or official report of Tmunity. DM8Y1M9 RU https://www.tmunity.com/pipeline DM8YNI6 DI DM8YNI6 DM8YNI6 DN SKL-PSY DM8YNI6 TI TTSQIFT DM8YNI6 TN 5-HT 1A receptor (HTR1A) DM8YNI6 MA Modulator DM8YNI6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1). DM8YNI6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1 DM8ZROW DI DM8ZROW DM8ZROW DN SNDX-6352 DM8ZROW TI TT7MRDV DM8ZROW TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DM8ZROW MA Antagonist DM8ZROW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM8ZROW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM8ZS7T DI DM8ZS7T DM8ZS7T DN LX2761 DM8ZS7T TI TT2UE56 DM8ZS7T TN Sodium/glucose cotransporter 1 (SGLT1) DM8ZS7T MA Inhibitor DM8ZS7T RN Clinical pipeline report, company report or official report of Lexicon Pharmaceuticals. DM8ZS7T RU https://www.lexpharma.com/pipeline/lx2761 DM90EO3 DI DM90EO3 DM90EO3 DN ABBV-621 DM90EO3 TI TTA5MS9 DM90EO3 TN TNF related apoptosis inducing ligand (TNFSF10) DM90EO3 MA Agonist DM90EO3 RN Clinical pipeline report, company report or official report of AbbVie. DM90EO3 RU https://www.abbvie.com/our-science/pipeline/abbv-621.html DM90P1K DI DM90P1K DM90P1K DN INO-3401 DM90P1K TI TTUTN1I DM90P1K TN Human Deoxyribonucleic acid (hDNA) DM90P1K RN ClinicalTrials.gov (NCT01403155) A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001. U.S. National Institutes of Health. DM90P1K RU https://clinicaltrials.gov/ct2/show/NCT01403155 DM90QPK DI DM90QPK DM90QPK DN CART-meso cells DM90QPK TI TT4RXME DM90QPK TN Mesothelin (MSLN) DM90QPK MA CAR-T-Cell-Therapy DM90QPK RN ClinicalTrials.gov (NCT02159716) CART-meso in Mesothelin Expressing Cancers DM90QPK RU https://clinicaltrials.gov/ct2/show/NCT02159716 DM926CH DI DM926CH DM926CH DN CTX130 DM926CH TI TTNCIE0 DM926CH TN CD70 antigen (CD27-L) DM926CH RN Clinical pipeline report, company report or official report of CRISPR Therapeutics. DM926CH RU http://www.crisprtx.com/programs/pipeline DM92RQT DI DM92RQT DM92RQT DN AAB-003/PF-05236812 DM92RQT TI TTE4KHA DM92RQT TN Amyloid beta A4 protein (APP) DM92RQT MA Modulator DM92RQT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM92RQT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM92YWD DI DM92YWD DM92YWD DN AMG 282 DM92YWD TI TT5MD4P DM92YWD TN Interleukin-33 (IL33) DM92YWD RN Clinical pipeline report, company report or official report of Amgen. DM92YWD RU http://www.amgenpipeline.com/pipeline/ DM93AJW DI DM93AJW DM93AJW DN LY2780301 DM93AJW TI TT7M3PI DM93AJW TN Ribosomal protein S6 kinase (S6K) DM93AJW MA Modulator DM93AJW RN A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9. DM93AJW RU https://pubmed.ncbi.nlm.nih.gov/25902900 DM93AJW DI DM93AJW DM93AJW DN LY2780301 DM93AJW TI TTAZ05C DM93AJW TN RAC-gamma serine/threonine-protein kinase (AKT3) DM93AJW MA Modulator DM93AJW RN A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015 Jun;33(3):710-9. DM93AJW RU https://pubmed.ncbi.nlm.nih.gov/25902900 DM93LMS DI DM93LMS DM93LMS DN PF-01247324 DM93LMS TI TT90XZ8 DM93LMS TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM93LMS MA Blocker DM93LMS RN Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067. DM93LMS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352054/ DM93QP2 DI DM93QP2 DM93QP2 DN Insulin transdermal DM93QP2 TI TTCBFJO DM93QP2 TN Insulin receptor (INSR) DM93QP2 MA Modulator DM93QP2 RN Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet. 2003;42(5):461-74. DM93QP2 RU https://pubmed.ncbi.nlm.nih.gov/12739984 DM94E6W DI DM94E6W DM94E6W DN LTT462 DM94E6W TI TTVOE6D DM94E6W TN Mitogen-activated protein kinase (MAPK) DM94E6W MA Inhibitor DM94E6W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM94E6W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM95F8B DI DM95F8B DM95F8B DN RO-14 DM95F8B TI TT4QPUL DM95F8B TN Antithrombin-III (ATIII) DM95F8B MA Modulator DM95F8B RN Pharmacological effects and clinical applications of ultra low molecular weight heparins. Drug Discov Ther. 2014 Feb;8(1):1-10. DM95F8B RU https://pubmed.ncbi.nlm.nih.gov/24647152 DM96JTX DI DM96JTX DM96JTX DN ATEVIRDINE DM96JTX TI TT84ETX DM96JTX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM96JTX MA Modulator DM96JTX RN Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum ... J Med Chem. 1996 Sep 13;39(19):3769-89. DM96JTX RU https://pubmed.ncbi.nlm.nih.gov/8809165 DM98EP5 DI DM98EP5 DM98EP5 DN BAY 2701439 DM98EP5 TI TT6EO5L DM98EP5 TN Erbb2 tyrosine kinase receptor (HER2) DM98EP5 MA Inhibitor DM98EP5 RN National Cancer Institute Drug Dictionary (drug name BAY2701439). DM98EP5 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/thorium-th-227-anti-her2-monoclonal-antibody-bay2701439 DM9B68S DI DM9B68S DM9B68S DN POL-6014 DM9B68S TI TTPLTSQ DM9B68S TN Neutrophil elastase (NE) DM9B68S MA Inhibitor DM9B68S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358). DM9B68S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358 DM9BJ3G DI DM9BJ3G DM9BJ3G DN ENMD-1198 DM9BJ3G TI TTQHWNA DM9BJ3G TN Hypoxia-inducible factor 1 alpha (HIF-1A) DM9BJ3G MA Inhibitor DM9BJ3G RN ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther. 2010 May;9(5):1408-18. DM9BJ3G RU https://pubmed.ncbi.nlm.nih.gov/20442304 DM9CDPO DI DM9CDPO DM9CDPO DN TBC-M4 DM9CDPO TI TTEC2T3 DM9CDPO TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DM9CDPO RN A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. DM9CDPO RU https://pubmed.ncbi.nlm.nih.gov/19943789 DM9CDPO DI DM9CDPO DM9CDPO DN TBC-M4 DM9CDPO TI TTFGZB6 DM9CDPO TN Human immunodeficiency virus GAG protein (HIV gag) DM9CDPO RN A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. DM9CDPO RU https://pubmed.ncbi.nlm.nih.gov/19943789 DM9ERH1 DI DM9ERH1 DM9ERH1 DN Capravirine DM9ERH1 TI TT84ETX DM9ERH1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9ERH1 MA Inhibitor DM9ERH1 RN Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. Drug Metab Dispos. 2004 Jul;32(7):689-98. DM9ERH1 RU https://pubmed.ncbi.nlm.nih.gov/15205383 DM9F15C DI DM9F15C DM9F15C DN MAU868 DM9F15C TI TT09JLE DM9F15C TN BV virus Major capsid protein VP1 (BKV VP1) DM9F15C MA Inhibitor DM9F15C RN Clinical pipeline report, company report or official report of Amplyx Pharmaceuticals. DM9F15C RU https://amplyx.com/our-pipeline/ DM9GC4R DI DM9GC4R DM9GC4R DN VGX-100 DM9GC4R TI TT0QUFV DM9GC4R TN Vascular endothelial growth factor C (VEGFC) DM9GC4R MA Modulator DM9GC4R RN National Cancer Institute Drug Dictionary (drug id 724066). DM9GC4R RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=724066 DM9GLHO DI DM9GLHO DM9GLHO DN Ad-OC-hsvTK/valacyclovir DM9GLHO TI TTP3QRF DM9GLHO TN Thymidine kinase 1 (TK1) DM9GLHO MA Inhibitor DM9GLHO RN Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003 Feb 10;14(3):227-41. DM9GLHO RU https://pubmed.ncbi.nlm.nih.gov/12639303 DM9IDUH DI DM9IDUH DM9IDUH DN TRX518 DM9IDUH TI TTG6LA7 DM9IDUH TN Activation-inducible TNFR family receptor (TNFRSF18) DM9IDUH RN Clinical pipeline report, company report or official report of Leap Therapeutics. DM9IDUH RU https://www.leaptx.com/our-pipeline DM9JU8L DI DM9JU8L DM9JU8L DN AKP-501 DM9JU8L TI TT13GFV DM9JU8L TN Follicle stimulating hormone (FSHB) DM9JU8L MA Modulator DM9JU8L RN AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009 Apr;82(4):247-54. DM9JU8L RU https://pubmed.ncbi.nlm.nih.gov/19183407 DM9JV80 DI DM9JV80 DM9JV80 DN Gp41 HIV-1 vaccine DM9JV80 TI TTG90S6 DM9JV80 TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DM9JV80 MA Modulator DM9JV80 RN Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617. DM9JV80 RU https://pubmed.ncbi.nlm.nih.gov/20111582 DM9JXMD DI DM9JXMD DM9JXMD DN KPT-9274 DM9JXMD TI TT7Y3BZ DM9JXMD TN PAK-4 protein kinase (PAK4) DM9JXMD MA Inhibitor DM9JXMD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9JXMD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9KS1A DI DM9KS1A DM9KS1A DN DA-727 DM9KS1A TI TTGN1ZA DM9KS1A TN Angiotensin II receptor (AGTR) DM9KS1A MA Modulator DM9KS1A RN WO patent application no. 2009,0880,06, Combined pharmaceutical agent. DM9KS1A RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090716&CC=WO&NR=2009088006A1&KC=A1 DM9L0D8 DI DM9L0D8 DM9L0D8 DN BOS172738 DM9L0D8 TI TT4DXQT DM9L0D8 TN Proto-oncogene c-Ret (RET) DM9L0D8 MA Inhibitor DM9L0D8 RN National Cancer Institute Drug Dictionary (drug name Zeteletinib). DM9L0D8 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/zeteletinib DM9LYXQ DI DM9LYXQ DM9LYXQ DN Leflunomide DM9LYXQ TI TT3UY29 DM9LYXQ TN HUMAN dihydroorotate dehydrogenase (DHODH) DM9LYXQ MA Inhibitor DM9LYXQ RN On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. 2013 Apr 25;56(8):3148-67. doi: 10.1021/jm301848w. DM9LYXQ RU https://pubmed.ncbi.nlm.nih.gov/23452331 DM9NYHT DI DM9NYHT DM9NYHT DN LY2787106 DM9NYHT TI TTPCG5T DM9NYHT TN Hepcidin (HAMP) DM9NYHT MA Inhibitor DM9NYHT RN A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia. J Hematol Oncol. 2017 Mar 21;10(1):73. DM9NYHT RU https://www.ncbi.nlm.nih.gov/pubmed/28327200 DM9O3RY DI DM9O3RY DM9O3RY DN Rosmantuzumab DM9O3RY TI TT7HJTF DM9O3RY TN R-spondin-3 (RSPO3) DM9O3RY MA Inhibitor DM9O3RY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9O3RY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9OA35 DI DM9OA35 DM9OA35 DN Long-acting erythropoietin conjugate DM9OA35 TI TTQG4NR DM9OA35 TN Erythropoietin (EPO) DM9OA35 MA Modulator DM9OA35 RN Company report (Pharmexcil) DM9OA35 RU http://www.pharmexcil.com/v1/docs/KoreanCompanies/hanmi.pdf DM9ODT6 DI DM9ODT6 DM9ODT6 DN CYC065 DM9ODT6 TI TT1LVF2 DM9ODT6 TN Cyclin-dependent kinase 9 (CDK9) DM9ODT6 MA Inhibitor DM9ODT6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9ODT6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9ODT6 DI DM9ODT6 DM9ODT6 DN CYC065 DM9ODT6 TI TT7HF4W DM9ODT6 TN Cyclin-dependent kinase 2 (CDK2) DM9ODT6 MA Inhibitor DM9ODT6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9ODT6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9P0NA DI DM9P0NA DM9P0NA DN AMG 319 DM9P0NA TI TTGBPJE DM9P0NA TN PI3-kinase delta (PIK3CD) DM9P0NA MA Inhibitor DM9P0NA RN National Cancer Institute Drug Dictionary (drug id 696292). DM9P0NA RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=696292 DM9PNR6 DI DM9PNR6 DM9PNR6 DN WST-057 DM9PNR6 TI TTZ9SOR DM9PNR6 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM9PNR6 MA Antagonist DM9PNR6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9PNR6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM9PQ2N DI DM9PQ2N DM9PQ2N DN RO-23-7553 DM9PQ2N TI TTK59TV DM9PQ2N TN Vitamin D3 receptor (VDR) DM9PQ2N MA Agonist DM9PQ2N RN Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res. 1997 Aug;3(8):1331-8. DM9PQ2N RU https://pubmed.ncbi.nlm.nih.gov/9815816 DM9QNMB DI DM9QNMB DM9QNMB DN RG6084 DM9QNMB TI TTFAOU7 DM9QNMB TN CD274 messenger RNA (CD274 mRNA) DM9QNMB MA Inhibitor DM9QNMB RN Clinical pipeline report, company report or official report of Roche. DM9QNMB RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DM9R0VA DI DM9R0VA DM9R0VA DN Belerofon DM9R0VA TI TTSYFMA DM9R0VA TN Interferon alpha/beta receptor 1 (IFNAR1) DM9R0VA MA Modulator DM9R0VA RN WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same. DM9R0VA RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090129&CC=WO&NR=2009015336A2&KC=A2 DM9RTXM DI DM9RTXM DM9RTXM DN LY3164530 DM9RTXM TI TTGKNB4 DM9RTXM TN Epidermal growth factor receptor (EGFR) DM9RTXM MA Modulator DM9RTXM RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM9RTXM RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DM9RTXM DI DM9RTXM DM9RTXM DN LY3164530 DM9RTXM TI TTNDSF4 DM9RTXM TN Proto-oncogene c-Met (MET) DM9RTXM MA Modulator DM9RTXM RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DM9RTXM RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DM9SCME DI DM9SCME DM9SCME DN IRX4204 DM9SCME TI TTH029C DM9SCME TN Retinoic acid receptor RXR-gamma (RXRG) DM9SCME MA Modulator DM9SCME RN Selective brain penetrable Nurr1 transactivator for treating Parkinson's disease.Oncotarget.2016 Feb 16;7(7):7469-79. DM9SCME RU https://www.ncbi.nlm.nih.gov/pubmed/26862735 DM9SCME DI DM9SCME DM9SCME DN IRX4204 DM9SCME TI TTP7WQM DM9SCME TN Retinoic acid receptor RXR (RXR) DM9SCME MA Agonist DM9SCME RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9SCME RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DM9SYVJ DI DM9SYVJ DM9SYVJ DN ABX-1431 DM9SYVJ TI TTZ963I DM9SYVJ TN Monoglyceride lipase (MAGL) DM9SYVJ MA Inhibitor DM9SYVJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9SYVJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DM9TD2N DI DM9TD2N DM9TD2N DN GD2 T cells DM9TD2N TI TT80ARU DM9TD2N TN Ganglioside GD2 (GD2) DM9TD2N MA CAR-T-Cell-Therapy DM9TD2N RN ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma DM9TD2N RU https://clinicaltrials.gov/ct2/show/NCT01953900 DM9UZTO DI DM9UZTO DM9UZTO DN PF-06444752 DM9UZTO TI TTYJQTF DM9UZTO TN Immunoglobulin E (IgE) DM9UZTO MA Modulator DM9UZTO RN ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health. DM9UZTO RU https://clinicaltrials.gov/ct2/show/NCT01723254 DM9VB4I DI DM9VB4I DM9VB4I DN Hu-CART meso cells DM9VB4I TI TT4RXME DM9VB4I TN Mesothelin (MSLN) DM9VB4I MA CAR-T-Cell-Therapy DM9VB4I RN ClinicalTrials.gov (NCT03054298) CAR T Cells in Mesothelin Expressing Cancers DM9VB4I RU https://clinicaltrials.gov/ct2/show/NCT03054298 DM9W0B6 DI DM9W0B6 DM9W0B6 DN VTR-297 DM9W0B6 TI TTBH0VX DM9W0B6 TN Histone deacetylase (HDAC) DM9W0B6 MA Inhibitor DM9W0B6 RN Clinical pipeline report, company report or official report of Vanda Pharmaceuticals. DM9W0B6 RU https://vandapharmaceuticalsinc.gcs-web.com/news-releases/news-release-details/vanda-pharmaceuticals-reports-third-quarter-2019-financial DM9W1BS DI DM9W1BS DM9W1BS DN Anti-CD19 CAR-T DM9W1BS TI TTW640A DM9W1BS TN B-lymphocyte surface antigen B4 (CD19) DM9W1BS MA CAR-T-Cell-Therapy DM9W1BS RN ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma DM9W1BS RU https://clinicaltrials.gov/ct2/show/NCT03110640 DM9X20P DI DM9X20P DM9X20P DN AZD-8418 DM9X20P TI TTAN6JD DM9X20P TN Glutamate receptor AMPA (GRIA) DM9X20P MA Modulator DM9X20P RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031633) DM9X20P RU http://adisinsight.springer.com/drugs/800031633 DM9Y51T DI DM9Y51T DM9Y51T DN ISIS-ANGPTL3 DM9Y51T TI TT59GO7 DM9Y51T TN ANGPTL3 messenger RNA (ANGPTL3 mRNA) DM9Y51T RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals. DM9Y51T RU https://www.isispharm.com/pipeline/isis-angptl3rx/ DM9YNTO DI DM9YNTO DM9YNTO DN ERY974 DM9YNTO TI TTJTSX4 DM9YNTO TN Glypican-3 (GPC3) DM9YNTO MA Inhibitor DM9YNTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM9YNTO RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DM9ZOMD DI DM9ZOMD DM9ZOMD DN CUDC-101 DM9ZOMD TI TTGKNB4 DM9ZOMD TN Epidermal growth factor receptor (EGFR) DM9ZOMD MA Modulator DM9ZOMD RN A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. DM9ZOMD RU https://pubmed.ncbi.nlm.nih.gov/25573383 DM9ZOMD DI DM9ZOMD DM9ZOMD DN CUDC-101 DM9ZOMD TI TT6EO5L DM9ZOMD TN Erbb2 tyrosine kinase receptor (HER2) DM9ZOMD MA Modulator DM9ZOMD RN A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. DM9ZOMD RU https://pubmed.ncbi.nlm.nih.gov/25573383 DMA1EDN DI DMA1EDN DMA1EDN DN MK-8033 DMA1EDN TI TTNDSF4 DMA1EDN TN Proto-oncogene c-Met (MET) DMA1EDN MA Inhibitor DMA1EDN RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMA1EDN RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMA1I04 DI DMA1I04 DMA1I04 DN AMG 211 DMA1I04 TI TTY6DTE DMA1I04 TN Carcinoembryonic antigen CEA (CD66e) DMA1I04 MA Immunomodulator DMA1I04 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA1I04 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMA1KQV DI DMA1KQV DMA1KQV DN MEM-1414 DMA1KQV TI TTVIAT9 DMA1KQV TN Phosphodiesterase 4B (PDE4B) DMA1KQV MA Inhibitor DMA1KQV RN The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166. DMA1KQV RU https://pubmed.ncbi.nlm.nih.gov/25351474 DMA1KQV DI DMA1KQV DMA1KQV DN MEM-1414 DMA1KQV TI TTSKMI8 DMA1KQV TN Phosphodiesterase 4D (PDE4D) DMA1KQV MA Inhibitor DMA1KQV RN The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166. DMA1KQV RU https://pubmed.ncbi.nlm.nih.gov/25351474 DMA1KQV DI DMA1KQV DMA1KQV DN MEM-1414 DMA1KQV TI TTZ97H5 DMA1KQV TN Phosphodiesterase 4A (PDE4A) DMA1KQV MA Inhibitor DMA1KQV RN The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthma. BMC Pulm Med. 2014 Oct 28;14:166. DMA1KQV RU https://pubmed.ncbi.nlm.nih.gov/25351474 DMA1QUC DI DMA1QUC DMA1QUC DN CAD-1833 DMA1QUC TI TTKU9YD DMA1QUC TN Calcium-activated potassium channel KCa2 (KCNN) DMA1QUC MA Modulator DMA1QUC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA1QUC RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMA2B5Y DI DMA2B5Y DMA2B5Y DN DS-3032 DMA2B5Y TI TT08GJW DMA2B5Y TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMA2B5Y MA Inhibitor DMA2B5Y RN Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36. DMA2B5Y RU https://pubmed.ncbi.nlm.nih.gov/24577402 DMA368V DI DMA368V DMA368V DN MGD010 DMA368V TI TT5RWKQ DMA368V TN Immunoglobulin gamma Fc receptor IIB (FCGR2B) DMA368V MA Modulator DMA368V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA368V RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMA368V DI DMA368V DMA368V DN MGD010 DMA368V TI TTBN5I7 DMA368V TN B-cell-specific glycoprotein B29 (CD79B) DMA368V MA Modulator DMA368V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA368V RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMA3B9T DI DMA3B9T DMA3B9T DN AMG 673 DMA3B9T TI TTJVYO3 DMA3B9T TN Myeloid cell surface antigen CD33 (CD33) DMA3B9T MA Inhibitor DMA3B9T RN Clinical pipeline report, company report or official report of Amgen. DMA3B9T RU https://www.amgenpipeline.com/ DMA3B9T DI DMA3B9T DMA3B9T DN AMG 673 DMA3B9T TI TTUN7MC DMA3B9T TN T-cell surface glycoprotein CD3 (CD3) DMA3B9T MA Inhibitor DMA3B9T RN Clinical pipeline report, company report or official report of Amgen. DMA3B9T RU https://www.amgenpipeline.com/ DMA41JD DI DMA41JD DMA41JD DN GSK-1827771 DMA41JD TI TT51DEV DMA41JD TN Interleukin 1 receptor type 2 (IL1R2) DMA41JD RN WO patent application no. 2013,0077,63, Modulators of the nlrp3 inflammasome il-1ss pathway for the prevention and treatment of acne. DMA41JD RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130117&CC=WO&NR=2013007763A1&KC=A1 DMA46DO DI DMA46DO DMA46DO DN INS-117548 DMA46DO TI TTGWKQJ DMA46DO TN Rho-associated protein kinase 2 (ROCK2) DMA46DO MA Modulator DMA46DO RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMA46DO RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMA46DO DI DMA46DO DMA46DO DN INS-117548 DMA46DO TI TTZN7RP DMA46DO TN Rho-associated protein kinase 1 (ROCK1) DMA46DO MA Modulator DMA46DO RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMA46DO RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMA46RN DI DMA46RN DMA46RN DN EGFRvIII-CARs DMA46RN TI TTZ6B2I DMA46RN TN Epidermal growth factor receptor variant III (EGFR vIII) DMA46RN MA CAR-T-Cell-Therapy DMA46RN RN ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM DMA46RN RU https://clinicaltrials.gov/ct2/show/NCT03283631 DMA4BRV DI DMA4BRV DMA4BRV DN Elinogrel DMA4BRV TI TTZ1DT0 DMA4BRV TN P2Y purinoceptor 12 (P2RY12) DMA4BRV MA Antagonist DMA4BRV RN Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8. DMA4BRV RU https://pubmed.ncbi.nlm.nih.gov/20178048 DMA4WEO DI DMA4WEO DMA4WEO DN ABSK021 DMA4WEO TI TT7MRDV DMA4WEO TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMA4WEO MA Inhibitor DMA4WEO RN Clinical pipeline report, company report or official report of Abbisko Therapeutics. DMA4WEO RU http://www.abbisko.com/page104?_l=en DMA6JME DI DMA6JME DMA6JME DN RTA 901 DMA6JME TI TTO7FVG DMA6JME TN Heat shock protein 90 (HSP90) DMA6JME MA Inhibitor DMA6JME RN Clinical pipeline report, company report or official report of Reata Pharmaceuticals. DMA6JME RU https://www.reatapharma.com/our-science/default.aspx DMA6O9R DI DMA6O9R DMA6O9R DN SAR-389644 DMA6O9R TI TTNVEIR DMA6O9R TN Prostaglandin D2 receptor (PTGDR) DMA6O9R MA Antagonist DMA6O9R RN US patent application no. 2008,0300,217, Combination therapy with fumaric acid esters for the treatment of autoimmune and,or inflammatory disorders. DMA6O9R RU http://www.google.com/patents/US20080300217 DMA71OL DI DMA71OL DMA71OL DN ASP8374 DMA71OL TI TTWNL74 DMA71OL TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMA71OL MA Antagonist DMA71OL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA71OL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMA7L3O DI DMA7L3O DMA7L3O DN Anti-CEA CAR-T cells DMA7L3O TI TTY6DTE DMA7L3O TN Carcinoembryonic antigen CEA (CD66e) DMA7L3O MA CAR-T-Cell-Therapy DMA7L3O RN ClinicalTrials.gov (NCT02416466) CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases DMA7L3O RU https://clinicaltrials.gov/ct2/show/NCT02416466 DMA7PWX DI DMA7PWX DMA7PWX DN Combotox DMA7PWX TI TTM6QSK DMA7PWX TN B-cell receptor CD22 (CD22) DMA7PWX MA Modulator DMA7PWX RN A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6. DMA7PWX RU https://www.ncbi.nlm.nih.gov/pubmed/21732928 DMA7PWX DI DMA7PWX DMA7PWX DN Combotox DMA7PWX TI TTW640A DMA7PWX TN B-lymphocyte surface antigen B4 (CD19) DMA7PWX MA Modulator DMA7PWX RN A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.Br J Haematol.2011 Aug;154(4):471-6. DMA7PWX RU https://www.ncbi.nlm.nih.gov/pubmed/21732928 DMA9M81 DI DMA9M81 DMA9M81 DN CAR138 T Cells DMA9M81 TI TTYDSVG DMA9M81 TN Syndecan-1 (SDC1) DMA9M81 MA CAR-T-Cell-Therapy DMA9M81 RN ClinicalTrials.gov (NCT03672318) Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma DMA9M81 RU https://clinicaltrials.gov/ct2/show/NCT03672318 DMA9UX2 DI DMA9UX2 DMA9UX2 DN Gerilimzumab DMA9UX2 TI TTT1V78 DMA9UX2 TN Interleukin-6 (IL6) DMA9UX2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMA9UX2 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAC5F2 DI DMAC5F2 DMAC5F2 DN SNS-314 DMAC5F2 TI TTLYXIT DMAC5F2 TN Aurora kinase C (AURKC) DMAC5F2 MA Inhibitor DMAC5F2 RN SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. DMAC5F2 RU https://pubmed.ncbi.nlm.nih.gov/19649632 DMAC5F2 DI DMAC5F2 DMAC5F2 DN SNS-314 DMAC5F2 TI TTPS3C0 DMAC5F2 TN Aurora kinase A (AURKA) DMAC5F2 MA Inhibitor DMAC5F2 RN SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. DMAC5F2 RU https://pubmed.ncbi.nlm.nih.gov/19649632 DMAC5F2 DI DMAC5F2 DMAC5F2 DN SNS-314 DMAC5F2 TI TT5LS6T DMAC5F2 TN Aurora kinase B (AURKB) DMAC5F2 MA Inhibitor DMAC5F2 RN SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17. DMAC5F2 RU https://pubmed.ncbi.nlm.nih.gov/19649632 DMACLIH DI DMACLIH DMACLIH DN RG7813 DMACLIH TI TTY6DTE DMACLIH TN Carcinoembryonic antigen CEA (CD66e) DMACLIH MA Inhibitor DMACLIH RN Clinical pipeline report, company report or official report of Roche. DMACLIH RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMAD6HS DI DMAD6HS DMAD6HS DN SPC4955 DMAD6HS TI TT2718H DMAD6HS TN Apolipoprotein B-100 (APOB) DMAD6HS MA Inhibitor DMAD6HS RN 2011 Pipeline of Santaris Pharma. DMAD6HS RU http://www.santaris.com/product-pipeline DMAE9I0 DI DMAE9I0 DMAE9I0 DN Dexpirronium DMAE9I0 TI TTH18TF DMAE9I0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMAE9I0 MA Antagonist DMAE9I0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMAE9I0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMAEK3L DI DMAEK3L DMAEK3L DN PF-05082566 DMAEK3L TI TTPW9LJ DMAEK3L TN Co-stimulatory molecule 4-1BB (CD137) DMAEK3L MA Modulator DMAEK3L RN Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother. 2012 Oct;61(10):1721-33. DMAEK3L RU https://pubmed.ncbi.nlm.nih.gov/22406983 DMAESIY DI DMAESIY DMAESIY DN ANX005 DMAESIY TI TT7LRQH DMAESIY TN Complement C1s component (C1S) DMAESIY MA Inhibitor DMAESIY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAESIY RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMAESQI DI DMAESQI DMAESQI DN MCY-M11 DMAESQI TI TT4RXME DMAESQI TN Mesothelin (MSLN) DMAESQI RN Clinical pipeline report, company report or official report of MaxCyte. DMAESQI RU https://maxcyte.com/carma-cell-therapies-expands-phase-i-trial-of-anti-mesothelin-mrna-car-pbmc-cell-therapy-mcy-m11/ DMAG6BV DI DMAG6BV DMAG6BV DN LGK974 DMAG6BV TI TTNFBTO DMAG6BV TN Protein-serine O-palmitoleoyltransferase porcupine (PORCN) DMAG6BV MA Inhibitor DMAG6BV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAG6BV RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAGCHE DI DMAGCHE DMAGCHE DN Multi-envelope HIV vaccine DMAGCHE TI TTBYP1X DMAGCHE TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMAGCHE RN An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428. DMAGCHE RU https://pubmed.ncbi.nlm.nih.gov/18826331 DMAGCHE DI DMAGCHE DMAGCHE DN Multi-envelope HIV vaccine DMAGCHE TI TTG90S6 DMAGCHE TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMAGCHE RN An assessment of the role of chimpanzees in AIDS vaccine research. Altern Lab Anim. 2008 Sep;36(4):381-428. DMAGCHE RU https://pubmed.ncbi.nlm.nih.gov/18826331 DMAH12E DI DMAH12E DMAH12E DN F-15845 DMAH12E TI TTZOVE0 DMAH12E TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMAH12E MA Inhibitor DMAH12E RN Selective inhibition of persistent sodium current by F 15845 prevents ischaemia-induced arrhythmias. Br J Pharmacol. 2010 Sep;161(1):79-91. DMAH12E RU https://pubmed.ncbi.nlm.nih.gov/20718741 DMAI0SH DI DMAI0SH DMAI0SH DN TNB-383B DMAI0SH TI TTUN7MC DMAI0SH TN T-cell surface glycoprotein CD3 (CD3) DMAI0SH RN Clinical pipeline report, company report or official report of AbbVie. DMAI0SH RU https://www.abbvie.com/our-science/pipeline/tnb-383b.html DMAI0SH DI DMAI0SH DMAI0SH DN TNB-383B DMAI0SH TI TTZ3P4W DMAI0SH TN B-cell maturation protein (TNFRSF17) DMAI0SH RN Clinical pipeline report, company report or official report of AbbVie. DMAI0SH RU https://www.abbvie.com/our-science/pipeline/tnb-383b.html DMAJ2T4 DI DMAJ2T4 DMAJ2T4 DN VX-916 DMAJ2T4 TI TTMVBWH DMAJ2T4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAJ2T4 MA Inhibitor DMAJ2T4 RN 2011 Pipeline of Vertex. DMAJ2T4 RU http://www.vrtx.com/current-projects.html DMAJPOX DI DMAJPOX DMAJPOX DN Balapiravir DMAJPOX TI TTMVBWH DMAJPOX TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAJPOX MA Inhibitor DMAJPOX RN R-1626, a specific oral NS5B polymerase inhibitor of hepatitis C virus. IDrugs. 2008 Oct;11(10):738-49. DMAJPOX RU https://pubmed.ncbi.nlm.nih.gov/18828074 DMAK89L DI DMAK89L DMAK89L DN GSK2661380 DMAK89L TI TTNBFWK DMAK89L TN Programmed cell death protein 1 (PD-1) DMAK89L MA Inhibitor DMAK89L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2760). DMAK89L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2760 DMAKD0I DI DMAKD0I DMAKD0I DN AVX-470 DMAKD0I TI TTG043C DMAKD0I TN Tumor necrosis factor receptor type I (TNF-R1) DMAKD0I RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DMAKD0I RU https://pubmed.ncbi.nlm.nih.gov/15507622 DMAKD0I DI DMAKD0I DMAKD0I DN AVX-470 DMAKD0I TI TTF8CQI DMAKD0I TN Tumor necrosis factor (TNF) DMAKD0I MA Inhibitor DMAKD0I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAKD0I RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAKWQD DI DMAKWQD DMAKWQD DN EVT100 DMAKWQD TI TTN9D8E DMAKWQD TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMAKWQD MA Antagonist DMAKWQD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAKWQD RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMAKZTW DI DMAKZTW DMAKZTW DN CART-117 cells DMAKZTW TI TTX41N9 DMAKZTW TN Tyrosine-protein kinase Kit (KIT) DMAKZTW MA CAR-T-Cell-Therapy DMAKZTW RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMAKZTW RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMALK7F DI DMALK7F DMALK7F DN KW-5092 DMALK7F TI TT1RS9F DMALK7F TN Acetylcholinesterase (AChE) DMALK7F MA Inhibitor DMALK7F RN Oral administration of KW-5092, a novel gastroprokinetic agent with acetylcholinesterase inhibitory and acetylcholine release enhancing activities, causes a dose-dependent increase in the blood acetylcholine content of beagle dogs. Neurosci Lett. 1997 Mar 28;225(1):25-8. DMALK7F RU https://pubmed.ncbi.nlm.nih.gov/9143009 DMAOJBX DI DMAOJBX DMAOJBX DN Tetrandrine DMAOJBX TI TT5HONZ DMAOJBX TN Calcium channel unspecific (CaC) DMAOJBX MA Antagonist DMAOJBX RN Tetrandrine: a novel calcium channel antagonist inhibits type I calcium channels in neuroblastoma cells. Neuropharmacology. 1991 Dec;30(12A):1325-31. DMAOJBX RU https://pubmed.ncbi.nlm.nih.gov/1787886 DMAOV7M DI DMAOV7M DMAOV7M DN TMC649128 DMAOV7M TI TTMVBWH DMAOV7M TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAOV7M MA Inhibitor DMAOV7M RN Clinical pipeline report, company report or official report of Medivir (2011). DMAOV7M RU http://www.medivir.se/v4/en/ DMAP6CS DI DMAP6CS DMAP6CS DN RBN-2397 DMAP6CS TI TT2FRAN DMAP6CS TN Protein mono-ADP-ribosyltransferase TIPARP (TIPARP) DMAP6CS MA Inhibitor DMAP6CS RN Clinical pipeline report, company report or official report of Ribon Therapeutics. DMAP6CS RU https://ribontx.com/rbn-2397/ DMAQ24G DI DMAQ24G DMAQ24G DN MDCO-216 DMAQ24G TI TT7GN3U DMAQ24G TN Apolipoprotein A-I (APOA1) DMAQ24G MA Modulator DMAQ24G RN MDCO-216 (Apo A-I Milano/POPC Complex) Administered to Cynomolgus Monkeys Induces Pronounced Changes in Plasma Lipids and Apolipoproteins. Circulation. 2011; 124: A10978. DMAQ24G RU https://circ.ahajournals.org/cgi/content/meeting_abstract/124/21_MeetingAbstracts/A10978 DMAQJHO DI DMAQJHO DMAQJHO DN Monohydroxyethylrutoside DMAQJHO TI TTUDR0C DMAQJHO TN Iron (Fe) DMAQJHO MA Modulator DMAQJHO RN Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res. 1997 Oct;3(10):1747-54. DMAQJHO RU https://pubmed.ncbi.nlm.nih.gov/9815559 DMAQYRL DI DMAQYRL DMAQYRL DN Eptacog alfa DMAQYRL TI TTF0EGX DMAQYRL TN Coagulation factor VII (F7) DMAQYRL MA Modulator DMAQYRL RN Recombinant factor VIIa (eptacog alfa): a review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. BioDrugs. 2008;22(2):121-36. DMAQYRL RU https://pubmed.ncbi.nlm.nih.gov/18345709 DMARHU4 DI DMARHU4 DMARHU4 DN UCART-22 DMARHU4 TI TTM6QSK DMARHU4 TN B-cell receptor CD22 (CD22) DMARHU4 RN Clinical pipeline report, company report or official report of Cellectis. DMARHU4 RU https://www.cellectis.com/en/products/product-candidates/ DMARYFK DI DMARYFK DMARYFK DN Autologous melanoma cell vaccine DMARYFK TI TTNYZG2 DMARYFK TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMARYFK MA Modulator DMARYFK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMARYFK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMAS1RB DI DMAS1RB DMAS1RB DN MK-8776 DMAS1RB TI TTTU902 DMAS1RB TN Checkpoint kinase-1 (CHK1) DMAS1RB MA Inhibitor DMAS1RB RN Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095. DMAS1RB RU https://pubmed.ncbi.nlm.nih.gov/31443367 DMASGXJ DI DMASGXJ DMASGXJ DN AMG 900 DMASGXJ TI TTLYXIT DMASGXJ TN Aurora kinase C (AURKC) DMASGXJ MA Modulator DMASGXJ RN Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. DMASGXJ RU https://pubmed.ncbi.nlm.nih.gov/20935223 DMASGXJ DI DMASGXJ DMASGXJ DN AMG 900 DMASGXJ TI TT5LS6T DMASGXJ TN Aurora kinase B (AURKB) DMASGXJ MA Modulator DMASGXJ RN Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. DMASGXJ RU https://pubmed.ncbi.nlm.nih.gov/20935223 DMASGXJ DI DMASGXJ DMASGXJ DN AMG 900 DMASGXJ TI TTPS3C0 DMASGXJ TN Aurora kinase A (AURKA) DMASGXJ MA Modulator DMASGXJ RN Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. DMASGXJ RU https://pubmed.ncbi.nlm.nih.gov/20935223 DMASKX9 DI DMASKX9 DMASKX9 DN PF-06342674 DMASKX9 TI TTAWI51 DMASKX9 TN Interleukin 7 receptor alpha (IL7R) DMASKX9 MA Antagonist DMASKX9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMASKX9 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMATJL9 DI DMATJL9 DMATJL9 DN SGN-B6A DMATJL9 TI TTKQSXZ DMATJL9 TN Integrin beta-6 (ITGB6) DMATJL9 RN Clinical pipeline report, company report or official report of Seagen. DMATJL9 RU https://www.seagen.com/science/pipeline DMAU8L9 DI DMAU8L9 DMAU8L9 DN ZW49 DMAU8L9 TI TT6EO5L DMAU8L9 TN Erbb2 tyrosine kinase receptor (HER2) DMAU8L9 MA Inhibitor DMAU8L9 RN Clinical pipeline report, company report or official report of Zymeworks. DMAU8L9 RU https://www.zymeworks.com/pipeline#zw49 DMAV86R DI DMAV86R DMAV86R DN CTT1403 DMAV86R TI TT9G4N0 DMAV86R TN Glutamate carboxypeptidase II (GCPII) DMAV86R MA Inhibitor DMAV86R RN 177 Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 2017 Apr 27;7(7):1928-1939. DMAV86R RU https://pubmed.ncbi.nlm.nih.gov/28638478 DMAWO5I DI DMAWO5I DMAWO5I DN PTX-100 DMAWO5I TI TT4P2VW DMAWO5I TN Geranylgeranyl transferase (GGTase) DMAWO5I MA Inhibitor DMAWO5I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAWO5I RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAWVTX DI DMAWVTX DMAWVTX DN Cyclopentenylcytosine DMAWVTX TI TTN12BZ DMAWVTX TN CTP synthase (CTPS1) DMAWVTX MA Inhibitor DMAWVTX RN Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75. DMAWVTX RU https://pubmed.ncbi.nlm.nih.gov/8250543 DMAXHC0 DI DMAXHC0 DMAXHC0 DN AZD9567 DMAXHC0 TI TTOZRK6 DMAXHC0 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMAXHC0 MA Modulator DMAXHC0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAXHC0 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMAXVZ1 DI DMAXVZ1 DMAXVZ1 DN AGEN2373 DMAXVZ1 TI TTPW9LJ DMAXVZ1 TN Co-stimulatory molecule 4-1BB (CD137) DMAXVZ1 MA Activator DMAXVZ1 RN Clinical pipeline report, company report or official report of Agenus. DMAXVZ1 RU https://agenusbio.com/agen2373-alpha-cd137/ DMAY6X2 DI DMAY6X2 DMAY6X2 DN CZ-48 DMAY6X2 TI TTGTQHC DMAY6X2 TN DNA topoisomerase I (TOP1) DMAY6X2 MA Inhibitor DMAY6X2 RN Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216-23. DMAY6X2 RU https://pubmed.ncbi.nlm.nih.gov/11193897 DMAY8I4 DI DMAY8I4 DMAY8I4 DN CGTG-102 DMAY8I4 TI TTNYZG2 DMAY8I4 TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMAY8I4 MA Modulator DMAY8I4 RN Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer. 2014 Aug 1;135(3):720-30. DMAY8I4 RU https://pubmed.ncbi.nlm.nih.gov/24374597 DMAYD7O DI DMAYD7O DMAYD7O DN IT-141 DMAYD7O TI TTGTQHC DMAYD7O TN DNA topoisomerase I (TOP1) DMAYD7O MA Inhibitor DMAYD7O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAYD7O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMAYHT4 DI DMAYHT4 DMAYHT4 DN CC-31244 DMAYHT4 TI TTMVBWH DMAYHT4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMAYHT4 MA Inhibitor DMAYHT4 RN Clinical pipeline report, company report or official report of Cocrystal Pharma. DMAYHT4 RU https://www.cocrystalpharma.com/development-pipeline/hepatitis-c/cc-31244 DMAYSFK DI DMAYSFK DMAYSFK DN BL-1021 DMAYSFK TI TTAWNKZ DMAYSFK TN Norepinephrine transporter (NET) DMAYSFK MA Modulator DMAYSFK RN Company report (BioLineRx) DMAYSFK RU http://www.biolinerx.com/default.asp?pageid=13&itemid=13 DMAYSFK DI DMAYSFK DMAYSFK DN BL-1021 DMAYSFK TI TT3ROYC DMAYSFK TN Serotonin transporter (SERT) DMAYSFK MA Modulator DMAYSFK RN Company report (BioLineRx) DMAYSFK RU http://www.biolinerx.com/default.asp?pageid=13&itemid=13 DMAYTRK DI DMAYTRK DMAYTRK DN H3B-6527 DMAYTRK TI TT1KX2S DMAYTRK TN FGFR4 messenger RNA (FGFR4 mRNA) DMAYTRK MA Inhibitor DMAYTRK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMAYTRK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMB01L5 DI DMB01L5 DMB01L5 DN ABBV-3067 DMB01L5 TI TTRLZHP DMB01L5 TN cAMP-dependent chloride channel (CFTR) DMB01L5 MA Modulator DMB01L5 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMB01L5 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMB1MZS DI DMB1MZS DMB1MZS DN SCO-120 DMB1MZS TI TTZAYWL DMB1MZS TN Estrogen receptor (ESR) DMB1MZS MA Degrader DMB1MZS RN Clinical pipeline report, company report or official report of Sun Pharma Advanced Research Company. DMB1MZS RU https://www.sparc.life/research-programs/sco-120 DMB2MKU DI DMB2MKU DMB2MKU DN CIGB-128 DMB2MKU TI TTSIUJ9 DMB2MKU TN Interferon-alpha 2 (IFNA2) DMB2MKU MA Modulator DMB2MKU RN Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20. DMB2MKU RU https://www.ncbi.nlm.nih.gov/pubmed/23272809 DMB2MKU DI DMB2MKU DMB2MKU DN CIGB-128 DMB2MKU TI TT93WF5 DMB2MKU TN Interferon-gamma (IFNG) DMB2MKU MA Modulator DMB2MKU RN Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial.BMC Pharmacol Toxicol.2012 Dec 28;13:20. DMB2MKU RU https://www.ncbi.nlm.nih.gov/pubmed/23272809 DMB3I04 DI DMB3I04 DMB3I04 DN VM-206 DMB3I04 TI TT6EO5L DMB3I04 TN Erbb2 tyrosine kinase receptor (HER2) DMB3I04 RN WO patent application no. 2014,1441,21, Classification and actionability indices for lung cancer. DMB3I04 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140918&CC=WO&NR=2014144121A2&KC=A2 DMB3LQU DI DMB3LQU DMB3LQU DN HuA33 DMB3LQU TI TT96HUR DMB3LQU TN Cell surface A33 antigen (GPA33) DMB3LQU RN (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80. DMB3LQU RU https://pubmed.ncbi.nlm.nih.gov/21764796 DMB3WJF DI DMB3WJF DMB3WJF DN Solulin DMB3WJF TI TT6L509 DMB3WJF TN Coagulation factor IIa (F2) DMB3WJF MA Modulator DMB3WJF RN The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011 Jun;9(6):1174-82. DMB3WJF RU https://pubmed.ncbi.nlm.nih.gov/21645225 DMB3YZJ DI DMB3YZJ DMB3YZJ DN Sonepcizumab DMB3YZJ TI TT9JZCK DMB3YZJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMB3YZJ RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMB3YZJ RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMB51K2 DI DMB51K2 DMB51K2 DN LY3405105 DMB51K2 TI TTQYF7G DMB51K2 TN Cyclin-dependent kinase 7 (CDK7) DMB51K2 MA Inhibitor DMB51K2 RN CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823. DMB51K2 RU https://pubmed.ncbi.nlm.nih.gov/32385714 DMB5A63 DI DMB5A63 DMB5A63 DN AC0058TA DMB5A63 TI TTGM6VW DMB5A63 TN Tyrosine-protein kinase BTK (ATK) DMB5A63 MA Inhibitor DMB5A63 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB5A63 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMB5JWX DI DMB5JWX DMB5JWX DN Pegadricase DMB5JWX TI TTZ1SWF DMB5JWX TN Uric acid (URA) DMB5JWX MA Modulator DMB5JWX RN Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002 Sep;29(9):1942-9. DMB5JWX RU https://pubmed.ncbi.nlm.nih.gov/12233890 DMB6FMH DI DMB6FMH DMB6FMH DN BMTP-11 DMB6FMH TI TTZPLJS DMB6FMH TN Interleukin 11 receptor alpha (IL11RA) DMB6FMH MA Modulator DMB6FMH RN Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 1;21(13):3041-51. DMB6FMH RU https://pubmed.ncbi.nlm.nih.gov/25779950 DMB6M1P DI DMB6M1P DMB6M1P DN PT-112 DMB6M1P TI TT84ETX DMB6M1P TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMB6M1P MA Inhibitor DMB6M1P RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DMB6M1P RU https://pubmed.ncbi.nlm.nih.gov/8863804 DMB6Q19 DI DMB6Q19 DMB6Q19 DN AMG 820 DMB6Q19 TI TT731LW DMB6Q19 TN Colony stimulating factor-1 receptor (CSF-1R) DMB6Q19 MA Modulator DMB6Q19 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMB6Q19 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMB6Q19 DI DMB6Q19 DMB6Q19 DN AMG 820 DMB6Q19 TI TTC70AJ DMB6Q19 TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMB6Q19 MA Inhibitor DMB6Q19 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMB6Q19 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMB83V4 DI DMB83V4 DMB83V4 DN IBI318 DMB83V4 TI TTNBFWK DMB83V4 TN Programmed cell death protein 1 (PD-1) DMB83V4 MA Inhibitor DMB83V4 RN Clinical pipeline report, company report or official report of Innovent. DMB83V4 RU http://innoventbio.com/#/news/208 DMB83V4 DI DMB83V4 DMB83V4 DN IBI318 DMB83V4 TI TT8ZLTI DMB83V4 TN Programmed cell death 1 ligand 1 (PD-L1) DMB83V4 MA Inhibitor DMB83V4 RN Clinical pipeline report, company report or official report of Innovent. DMB83V4 RU http://innoventbio.com/#/news/208 DMB8RI6 DI DMB8RI6 DMB8RI6 DN CD19 CAR T cells DMB8RI6 TI TTW640A DMB8RI6 TN B-lymphocyte surface antigen B4 (CD19) DMB8RI6 MA CAR-T-Cell-Therapy DMB8RI6 RN ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia DMB8RI6 RU https://clinicaltrials.gov/ct2/show/NCT02975687 DMB9861 DI DMB9861 DMB9861 DN Rilapladib DMB9861 TI TTDNFMT DMB9861 TN Platelet-activating factor acetylhydrolase (PLA2G7) DMB9861 MA Inhibitor DMB9861 RN Phospholipase A2 inhibitors. Curr Opin Lipidol. 2009 Aug;20(4):327-32. DMB9861 RU https://pubmed.ncbi.nlm.nih.gov/19550325 DMB9861 DI DMB9861 DMB9861 DN Rilapladib DMB9861 TI TTP3QRF DMB9861 TN Thymidine kinase 1 (TK1) DMB9861 MA Inhibitor DMB9861 RN Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22. DMB9861 RU https://pubmed.ncbi.nlm.nih.gov/9693096 DMB9861 DI DMB9861 DMB9861 DN Rilapladib DMB9861 TI TT9V5JH DMB9861 TN Phospholipase A2 (PLA2G1B) DMB9861 MA Modulator DMB9861 RN Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.J Am Coll Cardiol.2014 Jan 7-14;63(1):86-8. DMB9861 RU https://www.ncbi.nlm.nih.gov/pubmed/23973698 DMB9N4J DI DMB9N4J DMB9N4J DN ABT-957 DMB9N4J TI TTG5QB7 DMB9N4J TN Calpain-2 (CAPN2) DMB9N4J MA Modulator DMB9N4J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMB9N4J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBCATZ DI DMBCATZ DMBCATZ DN ATR-107 DMBCATZ TI TTZO9B0 DMBCATZ TN Interleukin 21 receptor (IL21R) DMBCATZ RN Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study. J Clin Pharmacol. 2014 Jan;54(1):14-22. DMBCATZ RU https://pubmed.ncbi.nlm.nih.gov/23913720 DMBCJW6 DI DMBCJW6 DMBCJW6 DN CT053 DMBCJW6 TI TTZ3P4W DMBCJW6 TN B-cell maturation protein (TNFRSF17) DMBCJW6 RN ClinicalTrials.gov (NCT03915184) Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2). U.S. National Institutes of Health. DMBCJW6 RU https://clinicaltrials.gov/ct2/show/NCT03915184 DMBDW93 DI DMBDW93 DMBDW93 DN GW-695634 DMBDW93 TI TT84ETX DMBDW93 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBDW93 MA Inhibitor DMBDW93 RN Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs. 2006 Feb;7(2):128-35. DMBDW93 RU https://pubmed.ncbi.nlm.nih.gov/16499282 DMBEA6V DI DMBEA6V DMBEA6V DN AZD1208 DMBEA6V TI TT69J2Z DMBEA6V TN Serine/threonine-protein kinase pim-2 (PIM2) DMBEA6V MA Modulator DMBEA6V RN AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014 Feb 6;123(6):905-13. DMBEA6V RU https://pubmed.ncbi.nlm.nih.gov/24363397 DMBFYSR DI DMBFYSR DMBFYSR DN Hepcidin mab DMBFYSR TI TTPCG5T DMBFYSR TN Hepcidin (HAMP) DMBFYSR RN The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. DMBFYSR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978192/ DMBG534 DI DMBG534 DMBG534 DN Org-25435 DMBG534 TI TTEX6LM DMBG534 TN GABA(A) receptor gamma-3 (GABRG3) DMBG534 MA Modulator DMBG534 RN First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial. BMC Anesthesiol. 2010 Jun 29;10:10. DMBG534 RU https://pubmed.ncbi.nlm.nih.gov/20587019 DMBG9HI DI DMBG9HI DMBG9HI DN AB023 DMBG9HI TI TTJCPUT DMBG9HI TN Coagulation factor XI (F11) DMBG9HI MA Inhibitor DMBG9HI RN Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial. Arterioscler Thromb Vasc Biol. 2019 Apr;39(4):799-809. DMBG9HI RU https://pubmed.ncbi.nlm.nih.gov/30700130 DMBGI74 DI DMBGI74 DMBGI74 DN ALX-0141 DMBGI74 TI TT9E8HR DMBGI74 TN Osteoclast differentiation factor (ODF) DMBGI74 MA Inhibitor DMBGI74 RN Clinical pipeline report, company report or official report of Ablynx. DMBGI74 RU http://www.ablynx.com/rd-portfolio/clinical-programmes/alx-0141/ DMBGUDR DI DMBGUDR DMBGUDR DN Safingol DMBGUDR TI TTYVX59 DMBGUDR TN Protein kinase C (PRKC) DMBGUDR MA Inhibitor DMBGUDR RN The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells. Int J Oncol. 2009 Dec;35(6):1463-71. DMBGUDR RU https://pubmed.ncbi.nlm.nih.gov/19885570 DMBHCSL DI DMBHCSL DMBHCSL DN CART-33 cells DMBHCSL TI TTJVYO3 DMBHCSL TN Myeloid cell surface antigen CD33 (CD33) DMBHCSL MA CAR-T-Cell-Therapy DMBHCSL RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMBHCSL RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMBI4EN DI DMBI4EN DMBI4EN DN MEDI4212 DMBI4EN TI TTYJQTF DMBI4EN TN Immunoglobulin E (IgE) DMBI4EN MA Modulator DMBI4EN RN A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64. DMBI4EN RU https://pubmed.ncbi.nlm.nih.gov/24583620 DMBIPQL DI DMBIPQL DMBIPQL DN Enavatuzumab DMBIPQL TI TTKPS7V DMBIPQL TN TNF superfamily receptor 12A (TNFRSF12A) DMBIPQL RN Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25. DMBIPQL RU https://pubmed.ncbi.nlm.nih.gov/23073510 DMBK9AM DI DMBK9AM DMBK9AM DN PLX-4720 DMBK9AM TI TT0EOB8 DMBK9AM TN B-Raf messenger RNA (BRAF mRNA) DMBK9AM MA Inhibitor DMBK9AM RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DMBK9AM RU https://pubmed.ncbi.nlm.nih.gov/22037378 DMBK9AM DI DMBK9AM DMBK9AM DN PLX-4720 DMBK9AM TI TTUTJGQ DMBK9AM TN Vascular endothelial growth factor receptor 2 (KDR) DMBK9AM MA Inhibitor DMBK9AM RN In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003 Jan;9(1):327-37. DMBK9AM RU https://pubmed.ncbi.nlm.nih.gov/12538485 DMBKL6O DI DMBKL6O DMBKL6O DN SOR-C13 DMBKL6O TI TTBK14N DMBKL6O TN Transient receptor potential cation channel V6 (TRPV6) DMBKL6O MA Inhibitor DMBKL6O RN In vivo detection of human TRPV6-rich tumors with anti-cancer peptides derived from soricidin. PLoS One. 2013;8(3):e58866. DMBKL6O RU https://pubmed.ncbi.nlm.nih.gov/23554944 DMBKO2W DI DMBKO2W DMBKO2W DN ATI-355 DMBKO2W TI TT7GXMU DMBKO2W TN Reticulon-4 (RTN4) DMBKO2W RN Limiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation. Brain. 2012 June; 135(6): 1794-1818. DMBKO2W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589918/ DMBL7CW DI DMBL7CW DMBL7CW DN PRT-062607 DMBL7CW TI TTOU65C DMBL7CW TN Tyrosine-protein kinase SYK (SYK) DMBL7CW MA Inhibitor DMBL7CW RN Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243. DMBL7CW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106228/ DMBOXA1 DI DMBOXA1 DMBOXA1 DN [3H]fenobam DMBOXA1 TI TTHS256 DMBOXA1 TN Metabotropic glutamate receptor 5 (mGluR5) DMBOXA1 MA Modulator (allosteric modulator) DMBOXA1 RN Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agon... J Pharmacol Exp Ther. 2005 Nov;315(2):711-21. DMBOXA1 RU https://pubmed.ncbi.nlm.nih.gov/16040814 DMBPV9W DI DMBPV9W DMBPV9W DN IT-139 DMBPV9W TI TTW26OG DMBPV9W TN Endoplasmic reticulum chaperone BiP (HSPA5) DMBPV9W MA Inhibitor DMBPV9W RN NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BMC Pharmacol Toxicol. 2012; 13(Suppl 1): A82. DMBPV9W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506350/ DMBQ2TF DI DMBQ2TF DMBQ2TF DN AZD-5438 DMBQ2TF TI TT7HF4W DMBQ2TF TN Cyclin-dependent kinase 2 (CDK2) DMBQ2TF MA Modulator DMBQ2TF RN AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.Int J Radiat Oncol Biol Phys.2012 Nov 15;84(4):e507-14. DMBQ2TF RU https://www.ncbi.nlm.nih.gov/pubmed/22795803 DMBQ6XY DI DMBQ6XY DMBQ6XY DN TP-3654 DMBQ6XY TI TTA7WGU DMBQ6XY TN Serine/threonine-protein kinase pim (PIM) DMBQ6XY MA Inhibitor DMBQ6XY RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMBQ6XY RU https://www.sdponcology.com/pipeline/ DMBQWVR DI DMBQWVR DMBQWVR DN ARQ-751 DMBQWVR TI TTQ7UAP DMBQWVR TN RAC serine/threonine-protein kinase (AKT) DMBQWVR MA Inhibitor DMBQWVR RN Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479. DMBQWVR RU https://pubmed.ncbi.nlm.nih.gov/26469692 DMBRN2G DI DMBRN2G DMBRN2G DN DA-697b DMBRN2G TI TT3SZBT DMBRN2G TN von Willebrand factor (VWF) DMBRN2G MA Inhibitor DMBRN2G RN A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost. 2010 Jan;103(1):205-12. DMBRN2G RU https://pubmed.ncbi.nlm.nih.gov/20062928 DMBRYZ7 DI DMBRYZ7 DMBRYZ7 DN RG6292 DMBRYZ7 TI TT10Y9E DMBRYZ7 TN Interleukin 2 receptor alpha (IL2RA) DMBRYZ7 MA Inhibitor DMBRYZ7 RN Clinical pipeline report, company report or official report of Roche. DMBRYZ7 RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMBSI6Y DI DMBSI6Y DMBSI6Y DN KITE-718 DMBSI6Y TI TTWSKHD DMBSI6Y TN Melanoma-associated antigen 3 (MAGEA3) DMBSI6Y RN ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health. DMBSI6Y RU https://clinicaltrials.gov/ct2/show/NCT03139370 DMBSI6Y DI DMBSI6Y DMBSI6Y DN KITE-718 DMBSI6Y TI TTJIWMO DMBSI6Y TN Melanoma-associated antigen 6 (MAGEA6) DMBSI6Y RN ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health. DMBSI6Y RU https://clinicaltrials.gov/ct2/show/NCT03139370 DMBSQH9 DI DMBSQH9 DMBSQH9 DN PBF-999 DMBSQH9 TI TTM2AOE DMBSQH9 TN Adenosine A2a receptor (ADORA2A) DMBSQH9 MA Antagonist DMBSQH9 RN Clinical pipeline report, company report or official report of Palobiofarma. DMBSQH9 RU https://www.palobiofarma.com/pipeline-2/ DMBSQH9 DI DMBSQH9 DMBSQH9 DN PBF-999 DMBSQH9 TI TTJW4LU DMBSQH9 TN Phosphodiesterase 10A (PDE10) DMBSQH9 MA Inhibitor DMBSQH9 RN Clinical pipeline report, company report or official report of Palobiofarma. DMBSQH9 RU https://www.palobiofarma.com/pipeline-2/ DMBSXZ1 DI DMBSXZ1 DMBSXZ1 DN MK-7162 DMBSXZ1 TI TTZJYKH DMBSXZ1 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBSXZ1 MA Inhibitor DMBSXZ1 RN ClinicalTrials.gov (NCT03364049) Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002). U.S. National Institutes of Health. DMBSXZ1 RU https://clinicaltrials.gov/ct2/show/NCT03364049 DMBTL2M DI DMBTL2M DMBTL2M DN TP-1454 DMBTL2M TI TT4LOT8 DMBTL2M TN Pyruvate kinase M2 (PKM) DMBTL2M MA Activator DMBTL2M RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMBTL2M RU https://www.ds-pharma.com/rd/clinical/pipeline.html DMBTSZD DI DMBTSZD DMBTSZD DN BIMU-1 DMBTSZD TI TT07C3Y DMBTSZD TN 5-HT 4 receptor (HTR4) DMBTSZD MA Modulator DMBTSZD RN Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. DMBTSZD RU https://pubmed.ncbi.nlm.nih.gov/8058105 DMBTSZD DI DMBTSZD DMBTSZD DN BIMU-1 DMBTSZD TI TTNXLKE DMBTSZD TN 5-HT 3 receptor (5HT3R) DMBTSZD MA Modulator DMBTSZD RN Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1994 Apr;349(4):338-45. DMBTSZD RU https://pubmed.ncbi.nlm.nih.gov/8058105 DMBUI2A DI DMBUI2A DMBUI2A DN BETULINIC ACID DMBUI2A TI TTIU7X1 DMBUI2A TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMBUI2A MA Inhibitor DMBUI2A RN DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3. DMBUI2A RU https://pubmed.ncbi.nlm.nih.gov/10654414 DMBUOX4 DI DMBUOX4 DMBUOX4 DN ADX71149 DMBUOX4 TI TTXJ47W DMBUOX4 TN Metabotropic glutamate receptor 2 (mGluR2) DMBUOX4 MA Modulator DMBUOX4 RN MGlu2 receptor-mediated modulation of conditioned avoidance behavior in rats. European journal of pharmacology. 01/2014; 727(1). DMBUOX4 RU http://www.researchgate.net/publication/260023632_MGlu2_receptor-mediated_modulation_of_conditioned_avoidance_behavior_in_rats DMBV3P8 DI DMBV3P8 DMBV3P8 DN JNJ-54728518 DMBV3P8 TI TTVIMDE DMBV3P8 TN Glucagon-like peptide 1 receptor (GLP1R) DMBV3P8 MA Agonist DMBV3P8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMBV3P8 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMBVM1Q DI DMBVM1Q DMBVM1Q DN AlphaMedix DMBVM1Q TI TTOMNR9 DMBVM1Q TN Somatostatin receptor (SSTR) DMBVM1Q MA Activator DMBVM1Q RN Clinical pipeline report, company report or official report of Orano Med. DMBVM1Q RU https://www.oranomed.com/en/pipeline DMBVUFL DI DMBVUFL DMBVUFL DN Anti-GD2 T-cells (1RG-CART) DMBVUFL TI TT80ARU DMBVUFL TN Ganglioside GD2 (GD2) DMBVUFL MA CAR-T-Cell-Therapy DMBVUFL RN ClinicalTrials.gov (NCT02761915) A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART) DMBVUFL RU https://clinicaltrials.gov/ct2/show/NCT02761915 DMBVZND DI DMBVZND DMBVZND DN ONYX-015 DMBVZND TI TT7SBF5 DMBVZND TN Cellular tumor antigen p53 (TP53) DMBVZND MA Modulator DMBVZND RN Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23. DMBVZND RU https://pubmed.ncbi.nlm.nih.gov/15607965 DMBZ2QT DI DMBZ2QT DMBZ2QT DN PHE885 DMBZ2QT TI TTZ3P4W DMBZ2QT TN B-cell maturation protein (TNFRSF17) DMBZ2QT RN ClinicalTrials.gov (NCT04318327) BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and/or Refractory Multiple Myeloma. U.S. National Institutes of Health. DMBZ2QT RU https://clinicaltrials.gov/ct2/show/NCT04318327 DMC0VJF DI DMC0VJF DMC0VJF DN Laevo-Bambuterol DMC0VJF TI TTMXGCW DMC0VJF TN Adrenergic receptor beta-3 (ADRB3) DMC0VJF MA Modulator DMC0VJF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29). DMC0VJF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29 DMC14KV DI DMC14KV DMC14KV DN GSK1995057 DMC14KV TI TTG043C DMC14KV TN Tumor necrosis factor receptor type I (TNF-R1) DMC14KV RN Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1. J Clin Immunol. 2013 Oct;33(7):1192-203. DMC14KV RU https://pubmed.ncbi.nlm.nih.gov/23832582 DMC1AZP DI DMC1AZP DMC1AZP DN SAR-405838 DMC1AZP TI TT7SBF5 DMC1AZP TN Cellular tumor antigen p53 (TP53) DMC1AZP MA Modulator DMC1AZP RN SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. Cancer Res. 2014 Oct 15;74(20):5855-65. DMC1AZP RU https://pubmed.ncbi.nlm.nih.gov/25145672 DMC1BXV DI DMC1BXV DMC1BXV DN AZD-3514 DMC1BXV TI TTS64P2 DMC1BXV TN Androgen receptor (AR) DMC1BXV MA Antagonist DMC1BXV RN AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013 Sep;12(9):1715-27. DMC1BXV RU https://pubmed.ncbi.nlm.nih.gov/23861347 DMC1HRA DI DMC1HRA DMC1HRA DN Thiarabine DMC1HRA TI TTUTN1I DMC1HRA TN Human Deoxyribonucleic acid (hDNA) DMC1HRA MA Inhibitor DMC1HRA RN Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. Chem Rev. 2009 July; 109(7): 2880-2893. DMC1HRA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827868/ DMC29LV DI DMC29LV DMC29LV DN ONO-4059 DMC29LV TI TTGM6VW DMC29LV TN Tyrosine-protein kinase BTK (ATK) DMC29LV MA Modulator DMC29LV RN ONO-4059, a novel oral Bruton's tyrosine kinase (Btk) inhibitor that demonstrates potent pharmacodynamic activity through Phosphorylated Btk (P-Btk) inhibition, in addition to effective anti-tumour activity in a TMD-8 (DLBCL) xenograft model. Cancer Research. 08/2013; 73(8 Supplement):2452-2452. DMC29LV RU http://cancerres.aacrjournals.org/content/73/8_Supplement/2452 DMC2IJN DI DMC2IJN DMC2IJN DN TPX-0022 DMC2IJN TI TT7MRDV DMC2IJN TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMC2IJN MA Inhibitor DMC2IJN RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMC2IJN RU https://tptherapeutics.com/pipeline/tpx-0022/ DMC2IJN DI DMC2IJN DMC2IJN DN TPX-0022 DMC2IJN TI TTNDSF4 DMC2IJN TN Proto-oncogene c-Met (MET) DMC2IJN MA Inhibitor DMC2IJN RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMC2IJN RU https://tptherapeutics.com/pipeline/tpx-0022/ DMC2IJN DI DMC2IJN DMC2IJN DN TPX-0022 DMC2IJN TI TT6PKBN DMC2IJN TN Proto-oncogene c-Src (SRC) DMC2IJN MA Inhibitor DMC2IJN RN Clinical pipeline report, company report or official report of Turning Point Therapeutics. DMC2IJN RU https://tptherapeutics.com/pipeline/tpx-0022/ DMC3G2E DI DMC3G2E DMC3G2E DN AMG 330 DMC3G2E TI TTJVYO3 DMC3G2E TN Myeloid cell surface antigen CD33 (CD33) DMC3G2E MA Inhibitor DMC3G2E RN Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57. DMC3G2E RU https://pubmed.ncbi.nlm.nih.gov/24674885 DMC3G2E DI DMC3G2E DMC3G2E DN AMG 330 DMC3G2E TI TTUN7MC DMC3G2E TN T-cell surface glycoprotein CD3 (CD3) DMC3G2E MA Inhibitor DMC3G2E RN Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57. DMC3G2E RU https://pubmed.ncbi.nlm.nih.gov/24674885 DMC47M9 DI DMC47M9 DMC47M9 DN GSK2831781 DMC47M9 TI TTNVXAW DMC47M9 TN Lymphocyte activation gene 3 protein (LAG3) DMC47M9 MA Inhibitor DMC47M9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC47M9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMC4RNA DI DMC4RNA DMC4RNA DN TAK-733 DMC4RNA TI TTROQ37 DMC4RNA TN MAPK/ERK kinase kinase (MAP3K) DMC4RNA MA Modulator DMC4RNA RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DMC4RNA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DMC5HXI DI DMC5HXI DMC5HXI DN STRO-002 DMC5HXI TI TTVC37M DMC5HXI TN Folate receptor alpha (FOLR1) DMC5HXI RN Clinical pipeline report, company report or official report of Sutro Biopharma. DMC5HXI RU https://www.sutrobio.com/pipeline/ DMC60S8 DI DMC60S8 DMC60S8 DN MDL-27531 DMC60S8 TI TTZ8EM9 DMC60S8 TN Glycine receptor (GlyR) DMC60S8 MA Modulator DMC60S8 RN MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neurosci Lett. 1992 Nov 23;147(1):101-5. DMC60S8 RU https://pubmed.ncbi.nlm.nih.gov/1480315 DMC6PKJ DI DMC6PKJ DMC6PKJ DN CYC140 DMC6PKJ TI TTIYVQP DMC6PKJ TN Polo-like kinase 1 (PLK1) DMC6PKJ MA Inhibitor DMC6PKJ RN Clinical pipeline report, company report or official report of Cyclacel Pharmaceuticals. DMC6PKJ RU https://cyclacel.com/research_programs_oncology_cyc140.shtml DMC6QE4 DI DMC6QE4 DMC6QE4 DN GSK1795091 DMC6QE4 TI TTISGCA DMC6QE4 TN Toll-like receptor 4 (TLR4) DMC6QE4 MA Agonist DMC6QE4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC6QE4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMC7Y5F DI DMC7Y5F DMC7Y5F DN CAR-T cells recognizing EpCAM DMC7Y5F TI TTZ8WH4 DMC7Y5F TN Tumor-associated calcium signal transducer 1 (EPCAM) DMC7Y5F MA CAR-T-Cell-Therapy DMC7Y5F RN ClinicalTrials.gov (NCT02915445) EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer DMC7Y5F RU https://clinicaltrials.gov/ct2/show/NCT02915445 DMC80LV DI DMC80LV DMC80LV DN ASP1948 DMC80LV TI TTIPJCB DMC80LV TN Neuropilin-1 (NRP1) DMC80LV MA Inhibitor DMC80LV RN National Cancer Institute Drug Dictionary (drug name ASP1948). DMC80LV RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-nrp1-antibody-asp1948 DMC84Y9 DI DMC84Y9 DMC84Y9 DN Tepoditamab DMC84Y9 TI TTUN7MC DMC84Y9 TN T-cell surface glycoprotein CD3 (CD3) DMC84Y9 RN MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733. DMC84Y9 RU https://pubmed.ncbi.nlm.nih.gov/31286786 DMC84Y9 DI DMC84Y9 DMC84Y9 DN Tepoditamab DMC84Y9 TI TT70N8V DMC84Y9 TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMC84Y9 RN MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733. DMC84Y9 RU https://pubmed.ncbi.nlm.nih.gov/31286786 DMC8J0G DI DMC8J0G DMC8J0G DN VX-128 DMC8J0G TI TT90XZ8 DMC8J0G TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMC8J0G MA Inhibitor DMC8J0G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMC8J0G RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMC8XHQ DI DMC8XHQ DMC8XHQ DN BTX-A51 DMC8XHQ TI TTFQEMX DMC8XHQ TN Casein kinase I alpha (CSNK1A1) DMC8XHQ MA Inhibitor DMC8XHQ RN Clinical pipeline report, company report or official report of BioTheryX. DMC8XHQ RU https://www.biotheryx.com/pipeline/ DMC8XHQ DI DMC8XHQ DMC8XHQ DN BTX-A51 DMC8XHQ TI TT1LVF2 DMC8XHQ TN Cyclin-dependent kinase 9 (CDK9) DMC8XHQ MA Inhibitor DMC8XHQ RN Clinical pipeline report, company report or official report of BioTheryX. DMC8XHQ RU https://www.biotheryx.com/pipeline/ DMC8XHQ DI DMC8XHQ DMC8XHQ DN BTX-A51 DMC8XHQ TI TTQYF7G DMC8XHQ TN Cyclin-dependent kinase 7 (CDK7) DMC8XHQ MA Inhibitor DMC8XHQ RN Clinical pipeline report, company report or official report of BioTheryX. DMC8XHQ RU https://www.biotheryx.com/pipeline/ DMC9N7D DI DMC9N7D DMC9N7D DN VYR 006 DMC9N7D TI TTYZVDJ DMC9N7D TN Dihydrofolate reductase (DHFR) DMC9N7D MA Inhibitor DMC9N7D RN Clinical pipeline report, company report or official report of Vyera Pharmaceuticals. DMC9N7D RU https://www.vyera.com/news-center/vyera-pharmaceuticals-has-initiated-a-phase-1-study-of-a-new-dihydrofolate-reductase-inhibitor-designed-as-a-potential-treatment-for-toxoplasmosis DMCA1NX DI DMCA1NX DMCA1NX DN MK-4280 DMCA1NX TI TTNVXAW DMCA1NX TN Lymphocyte activation gene 3 protein (LAG3) DMCA1NX MA Inhibitor DMCA1NX RN Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018 May;456:7-14. DMCA1NX RU https://pubmed.ncbi.nlm.nih.gov/29427592 DMCABUR DI DMCABUR DMCABUR DN Anti-CD19 anti-CD20 Bispecific CAR-T DMCABUR TI TTUE541 DMCABUR TN Leukocyte surface antigen Leu-16 (CD20) DMCABUR MA CAR-T-Cell-Therapy(Dual specific) DMCABUR RN ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL DMCABUR RU https://clinicaltrials.gov/ct2/show/NCT03271515 DMCABUR DI DMCABUR DMCABUR DN Anti-CD19 anti-CD20 Bispecific CAR-T DMCABUR TI TTW640A DMCABUR TN B-lymphocyte surface antigen B4 (CD19) DMCABUR MA CAR-T-Cell-Therapy(Dual specific) DMCABUR RN ClinicalTrials.gov (NCT03271515) Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL DMCABUR RU https://clinicaltrials.gov/ct2/show/NCT03271515 DMCBGLW DI DMCBGLW DMCBGLW DN GSK2636771 DMCBGLW TI TTTHBCA DMCBGLW TN PI3-kinase beta (PIK3CB) DMCBGLW MA Inhibitor DMCBGLW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7967). DMCBGLW RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7967 DMCBV20 DI DMCBV20 DMCBV20 DN LY-2334737 DMCBV20 TI TTBWDI0 DMCBV20 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMCBV20 MA Modulator DMCBV20 RN Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55. DMCBV20 RU https://pubmed.ncbi.nlm.nih.gov/23616084 DMCBV20 DI DMCBV20 DMCBV20 DN LY-2334737 DMCBV20 TI TTUTN1I DMCBV20 TN Human Deoxyribonucleic acid (hDNA) DMCBV20 MA Modulator DMCBV20 RN Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jun;71(6):1645-55. DMCBV20 RU https://pubmed.ncbi.nlm.nih.gov/23616084 DMCDMPW DI DMCDMPW DMCDMPW DN ASP9801 DMCDMPW TI TT8FRMO DMCDMPW TN Interleukin-7 (IL7) DMCDMPW RN Clinical pipeline report, company report or official report of Astellas Pharma. DMCDMPW RU https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf DMCDMPW DI DMCDMPW DMCDMPW DN ASP9801 DMCDMPW TI TTF89GD DMCDMPW TN Interleukin-2 (IL2) DMCDMPW RN Clinical pipeline report, company report or official report of Astellas Pharma. DMCDMPW RU https://www.astellas.com/system/files/2020-03/rdmeeting2019_pre_en2.pdf DMCE08M DI DMCE08M DMCE08M DN AT7519 DMCE08M TI TT7HF4W DMCE08M TN Cyclin-dependent kinase 2 (CDK2) DMCE08M MA Inhibitor DMCE08M RN Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther. 2009 Feb;8(2):324-32. DMCE08M RU https://pubmed.ncbi.nlm.nih.gov/19174555 DMCED9U DI DMCED9U DMCED9U DN IRX-5183 DMCED9U TI TTW38KT DMCED9U TN Retinoic acid receptor alpha (RARA) DMCED9U MA Agonist DMCED9U RN Retinoic acid receptor alpha and retinoid X receptor specific agonists reduce renal injury in established chronic glomerulonephritis of the rat. J Mol Med (Berl). 2004 Feb;82(2):116-25. DMCED9U RU https://pubmed.ncbi.nlm.nih.gov/14712350 DMCED9U DI DMCED9U DMCED9U DN IRX-5183 DMCED9U TI TTP7WQM DMCED9U TN Retinoic acid receptor RXR (RXR) DMCED9U MA Agonist DMCED9U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCED9U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCFGD4 DI DMCFGD4 DMCFGD4 DN TM38837 DMCFGD4 TI TT6OEDT DMCFGD4 TN Cannabinoid receptor 1 (CB1) DMCFGD4 MA Antagonist DMCFGD4 RN 2011 Pipeline of 7TM Pharma. DMCFGD4 RU http://www.7tm.com/Pipeline.aspx DMCFJM3 DI DMCFJM3 DMCFJM3 DN DS-7423 DMCFJM3 TI TTCJG29 DMCFJM3 TN Serine/threonine-protein kinase mTOR (mTOR) DMCFJM3 MA Modulator DMCFJM3 RN Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220. DMCFJM3 RU https://pubmed.ncbi.nlm.nih.gov/24504419 DMCFJM3 DI DMCFJM3 DMCFJM3 DN DS-7423 DMCFJM3 TI TTHBTOP DMCFJM3 TN PI3-kinase gamma (PIK3CG) DMCFJM3 MA Modulator DMCFJM3 RN Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One. 2014 Feb 4;9(2):e87220. DMCFJM3 RU https://pubmed.ncbi.nlm.nih.gov/24504419 DMCFMHR DI DMCFMHR DMCFMHR DN CCR5 mab DMCFMHR TI TT2CEJG DMCFMHR TN C-C chemokine receptor type 5 (CCR5) DMCFMHR RN CCR5 Monoclonal Antibodies for HIV-1 Therapy. Curr Opin HIV AIDS. 2009 March; 4(2): 104-111. DMCFMHR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760828/ DMCFPX8 DI DMCFPX8 DMCFPX8 DN 123-Iodine-labeled MFE-23 DMCFPX8 TI TTY6DTE DMCFPX8 TN Carcinoembryonic antigen CEA (CD66e) DMCFPX8 RN Crystal structure of the anti-(carcinoembryonic antigen) single-chain Fv antibody MFE-23 and a model for antigen binding based on intermolecular contacts.. Biochem J. 2000 March 1; 346(Pt 2): 519-528. DMCFPX8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1220881/ DMCG01R DI DMCG01R DMCG01R DN TTP-4000 DMCG01R TI TTMO9HF DMCG01R TN Advanced glycosylation end product receptor (AGER) DMCG01R MA Inhibitor DMCG01R RN Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases. Future Neurol. 2009; 4(2): 167-177. DMCG01R RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2709862/ DMCG7XL DI DMCG7XL DMCG7XL DN AMG 910 DMCG7XL TI TTUN7MC DMCG7XL TN T-cell surface glycoprotein CD3 (CD3) DMCG7XL MA Inhibitor DMCG7XL RN Clinical pipeline report, company report or official report of Amgen. DMCG7XL RU https://www.amgenpipeline.com/ DMCG7XL DI DMCG7XL DMCG7XL DN AMG 910 DMCG7XL TI TT6PKBX DMCG7XL TN Claudin-18 (CLDN18) DMCG7XL MA Inhibitor DMCG7XL RN Clinical pipeline report, company report or official report of Amgen. DMCG7XL RU https://www.amgenpipeline.com/ DMCGPU8 DI DMCGPU8 DMCGPU8 DN SNX281 DMCGPU8 TI TTT402Y DMCGPU8 TN Stimulator of interferon genes protein (TMEM173) DMCGPU8 MA Inhibitor DMCGPU8 RN Clinical pipeline report, company report or official report of Silicon Therapeutics. DMCGPU8 RU https://silicontx.com/therapeutics-and-pipeline/targets/sting-agonist/ DMCJFLS DI DMCJFLS DMCJFLS DN MEDI-570 DMCJFLS TI TTE5VP6 DMCJFLS TN Inducible T-cell costimulator (ICOS) DMCJFLS MA Modulator DMCJFLS RN B-cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1:S4. DMCJFLS RU https://pubmed.ncbi.nlm.nih.gov/23566679 DMCJNRL DI DMCJNRL DMCJNRL DN BAY1251152 DMCJNRL TI TTQ7ABG DMCJNRL TN Positive transcription elongation factor b (P-TEFb) DMCJNRL MA Inhibitor DMCJNRL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCJNRL RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCJUI9 DI DMCJUI9 DMCJUI9 DN GSK1070916A DMCJUI9 TI TT5LS6T DMCJUI9 TN Aurora kinase B (AURKB) DMCJUI9 MA Modulator DMCJUI9 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMCJUI9 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMCJUI9 DI DMCJUI9 DMCJUI9 DN GSK1070916A DMCJUI9 TI TTLYXIT DMCJUI9 TN Aurora kinase C (AURKC) DMCJUI9 MA Modulator DMCJUI9 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMCJUI9 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMCK2YR DI DMCK2YR DMCK2YR DN Sym022 DMCK2YR TI TTNVXAW DMCK2YR TN Lymphocyte activation gene 3 protein (LAG3) DMCK2YR MA Inhibitor DMCK2YR RN Clinical pipeline report, company report or official report of Symphogen. DMCK2YR RU http://www.symphogen.com/pipeline/products/sym022/ DMCK3OI DI DMCK3OI DMCK3OI DN FT-7051 DMCK3OI TI TTFRCTK DMCK3OI TN CREB-binding protein (CREBBP) DMCK3OI MA Inhibitor DMCK3OI RN Clinical pipeline report, company report or official report of FORMA Therapeutics. DMCK3OI RU https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/ DMCK3OI DI DMCK3OI DMCK3OI DN FT-7051 DMCK3OI TI TTGH73N DMCK3OI TN Histone acetyltransferase p300 (EP300) DMCK3OI MA Inhibitor DMCK3OI RN Clinical pipeline report, company report or official report of FORMA Therapeutics. DMCK3OI RU https://www.formatherapeutics.com/programs/metastatic-castration-resistant-prostate-cancer/ DMCKE90 DI DMCKE90 DMCKE90 DN Lopinavir + ritonavir + interferon apha + traditional chinese medicines granules DMCKE90 TI TT1D53B DMCKE90 TN COVID-19 3C-like protease (3CLpro) DMCKE90 MA Inhibitor DMCKE90 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMCKE90 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMCKF5J DI DMCKF5J DMCKF5J DN TAK-676 DMCKF5J TI TTT402Y DMCKF5J TN Stimulator of interferon genes protein (TMEM173) DMCKF5J MA Agonist DMCKF5J RN National Cancer Institute Drug Dictionary (drug name TAK676). DMCKF5J RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-tak-676 DMCKNJX DI DMCKNJX DMCKNJX DN GSK3052230 DMCKNJX TI TT5HU6Z DMCKNJX TN Fibroblast growth factor (FGF) DMCKNJX MA Inhibitor DMCKNJX RN National Cancer Institute Drug Dictionary (drug id 599037). DMCKNJX RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=599037 DMCKZUT DI DMCKZUT DMCKZUT DN GlyT1 PET radiotracers DMCKZUT TI TTHJTF7 DMCKZUT TN Glycine transporter GlyT-1 (SLC6A9) DMCKZUT MA Modulator DMCKZUT RN Glycine Transport Inhibitors for the Treatment of Schizophrenia. Open Med Chem J. 2010; 4: 10-19. DMCKZUT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023951/ DMCM0K6 DI DMCM0K6 DMCM0K6 DN YPEG-Somatropin DMCM0K6 TI TTT3YKH DMCM0K6 TN Somatotropin (GH1) DMCM0K6 MA Modulator DMCM0K6 RN Somatropin therapy in adults with Prader-Willi syndrome. Treat Endocrinol. 2004;3(3):153-60. DMCM0K6 RU https://pubmed.ncbi.nlm.nih.gov/16026111 DMCMYPX DI DMCMYPX DMCMYPX DN MEDI-2338 DMCMYPX TI TTRICUF DMCMYPX TN Interleukin-18 (IL18) DMCMYPX MA Modulator DMCMYPX RN Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2014; 9: 397-412. DMCMYPX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010626/ DMCN7WI DI DMCN7WI DMCN7WI DN AST-005 DMCN7WI TI TTF8CQI DMCN7WI TN Tumor necrosis factor (TNF) DMCN7WI MA Inhibitor DMCN7WI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCN7WI RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMCNFZG DI DMCNFZG DMCNFZG DN Anti-GD2-CAR engineered T cells DMCNFZG TI TT80ARU DMCNFZG TN Ganglioside GD2 (GD2) DMCNFZG MA CAR-T-Cell-Therapy DMCNFZG RN ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors DMCNFZG RU https://clinicaltrials.gov/ct2/show/NCT02107963 DMCNV0M DI DMCNV0M DMCNV0M DN ARRY-380 DMCNV0M TI TT6EO5L DMCNV0M TN Erbb2 tyrosine kinase receptor (HER2) DMCNV0M MA Modulator DMCNV0M RN ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice DMCNV0M RU http://arraybiopharma.com/publications/arry-380-potent-small-molecule-inhibitor-erbb2-increases-survival-intracranial-erbb2-xenograft-models-mice/ DMCOJM7 DI DMCOJM7 DMCOJM7 DN CNTX-6970 DMCOJM7 TI TTFZYTO DMCOJM7 TN C-C chemokine receptor type 2 (CCR2) DMCOJM7 MA Antagonist DMCOJM7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCOJM7 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMCOUHT DI DMCOUHT DMCOUHT DN PF-2413873 DMCOUHT TI TTUV8G9 DMCOUHT TN Progesterone receptor (PGR) DMCOUHT MA Antagonist DMCOUHT RN Unusual base-catalyzed exchange in the synthesis of deuterated PF-2413873. Journal of Labelled Compounds. 08/2009; 52(10):435 - 442. DMCOUHT RU http://onlinelibrary.wiley.com/doi/10.1002/jlcr.1657/abstract DMCP7SD DI DMCP7SD DMCP7SD DN Seclidemstat DMCP7SD TI TTNR0UQ DMCP7SD TN Lysine-specific histone demethylase 1 (LSD) DMCP7SD MA Inhibitor DMCP7SD RN Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196. DMCP7SD RU https://pubmed.ncbi.nlm.nih.gov/33042135 DMCPF90 DI DMCPF90 DMCPF90 DN Mivebresib DMCPF90 TI TTE4BSY DMCPF90 TN Bromodomain and extraterminal domain protein (BET) DMCPF90 MA Inhibitor DMCPF90 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCPF90 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMCQEL6 DI DMCQEL6 DMCQEL6 DN BAY 94-9343 DMCQEL6 TI TT4RXME DMCQEL6 TN Mesothelin (MSLN) DMCQEL6 MA Modulator DMCQEL6 RN National Cancer Institute Drug Dictionary (drug id 712853). DMCQEL6 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=712853 DMCQTLG DI DMCQTLG DMCQTLG DN INB03 DMCQTLG TI TTF8CQI DMCQTLG TN Tumor necrosis factor (TNF) DMCQTLG MA Inhibitor DMCQTLG RN Clinical pipeline report, company report or official report of INmune Bio. DMCQTLG RU https://inmunebio.com/index.php/en/science/inb03/overview DMCRLQZ DI DMCRLQZ DMCRLQZ DN ARQ 621 DMCRLQZ TI TTTRP0H DMCRLQZ TN Kinesin-like protein KIF11 (KIF11) DMCRLQZ MA Modulator DMCRLQZ RN Kinesins and cancer. Nat Rev Cancer. 2012 Jul 24;12(8):527-39. DMCRLQZ RU https://pubmed.ncbi.nlm.nih.gov/22825217 DMCSEUY DI DMCSEUY DMCSEUY DN ALN-TTR01 DMCSEUY TI TTPOYU7 DMCSEUY TN Transthyretin messenger RNA (TTR mRNA) DMCSEUY MA Inhibitor DMCSEUY RN Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29. DMCSEUY RU https://pubmed.ncbi.nlm.nih.gov/23984729 DMCT37W DI DMCT37W DMCT37W DN MK-4830 DMCT37W TI TTHC6XU DMCT37W TN Leukocyte immunoglobulin-like receptor B2 (LILRB2) DMCT37W MA Inhibitor DMCT37W RN National Cancer Institute Drug Dictionary (drug name MK4830). DMCT37W RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-ilt4-monoclonal-antibody-mk-4830 DMCT4BA DI DMCT4BA DMCT4BA DN DMUC-5754A DMCT4BA TI TTC1PS3 DMCT4BA TN Ovarian carcinoma antigen CA125 (MUC16) DMCT4BA RN Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013 May;12(5):329-32. DMCT4BA RU https://pubmed.ncbi.nlm.nih.gov/23629491 DMCU54M DI DMCU54M DMCU54M DN Posiphen R-phenserine DMCU54M TI TT08OSU DMCU54M TN Synuclein alpha (SNCA) DMCU54M MA Modulator DMCU54M RN The Anticholinesterase Phenserine and Its Enantiomer Posiphen as 5 ntranslated-Region-Directed Translation Blockers of the Parkinson's Alpha Synuclein Expression. Parkinson's Disease Volume 2012 (2012), Article ID 142372, Page(13). DMCU54M RU http://www.hindawi.com/journals/pd/2012/142372/ DMCUBFR DI DMCUBFR DMCUBFR DN CD19 CAR T Cells DMCUBFR TI TTW640A DMCUBFR TN B-lymphocyte surface antigen B4 (CD19) DMCUBFR MA CAR-T-Cell-Therapy DMCUBFR RN ClinicalTrials.gov (NCT01853631) Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) DMCUBFR RU https://clinicaltrials.gov/ct2/show/NCT01853631 DMCUBZO DI DMCUBZO DMCUBZO DN RG7828 DMCUBZO TI TTUE541 DMCUBZO TN Leukocyte surface antigen Leu-16 (CD20) DMCUBZO MA Stimulator DMCUBZO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCUBZO RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMCUE71 DI DMCUE71 DMCUE71 DN PRGN-3005 DMCUE71 TI TTC1PS3 DMCUE71 TN Ovarian carcinoma antigen CA125 (MUC16) DMCUE71 RN Clinical pipeline report, company report or official report of Precigen. DMCUE71 RU https://precigen.com/pipeline/ DMCVO2Y DI DMCVO2Y DMCVO2Y DN MLN-576 DMCVO2Y TI TTGTQHC DMCVO2Y TN DNA topoisomerase I (TOP1) DMCVO2Y MA Modulator DMCVO2Y RN In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28. DMCVO2Y RU https://pubmed.ncbi.nlm.nih.gov/11914637 DMCVO2Y DI DMCVO2Y DMCVO2Y DN MLN-576 DMCVO2Y TI TT0IHXV DMCVO2Y TN DNA topoisomerase II (TOP2) DMCVO2Y MA Modulator DMCVO2Y RN In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28. DMCVO2Y RU https://pubmed.ncbi.nlm.nih.gov/11914637 DMCW71N DI DMCW71N DMCW71N DN BMS-830216 DMCW71N TI TTX4RTB DMCW71N TN Melanin-concentrating hormone receptor 1 (MCHR1) DMCW71N MA Antagonist DMCW71N RN 2011 Pipeline of Bristol-Myers Squibb. DMCW71N RU http://www.bms.com/pages/default.aspx DMCWVS7 DI DMCWVS7 DMCWVS7 DN CCX-025 DMCWVS7 TI TTIPS8B DMCWVS7 TN C-C chemokine receptor type 9 (CCR9) DMCWVS7 MA Antagonist DMCWVS7 RN Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29. DMCWVS7 RU https://pubmed.ncbi.nlm.nih.gov/22946654 DMCX0H7 DI DMCX0H7 DMCX0H7 DN BMS-820132 DMCX0H7 TI TTDLNGZ DMCX0H7 TN Glucokinase (GCK) DMCX0H7 MA Inhibitor DMCX0H7 RN Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities. Toxicol Pathol. 2015 Aug;43(6):825-37. DMCX0H7 RU https://pubmed.ncbi.nlm.nih.gov/26085543 DMCYV26 DI DMCYV26 DMCYV26 DN Allogeneic CART-19 DMCYV26 TI TTW640A DMCYV26 TN B-lymphocyte surface antigen B4 (CD19) DMCYV26 MA CAR-T-Cell-Therapy DMCYV26 RN ClinicalTrials.gov (NCT02799550) Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL DMCYV26 RU https://clinicaltrials.gov/ct2/show/NCT02799550 DMCZ3A2 DI DMCZ3A2 DMCZ3A2 DN CD19-targeted CART cells DMCZ3A2 TI TTW640A DMCZ3A2 TN B-lymphocyte surface antigen B4 (CD19) DMCZ3A2 MA CAR-T-Cell-Therapy DMCZ3A2 RN ClinicalTrials.gov (NCT03599375) Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia DMCZ3A2 RU https://clinicaltrials.gov/ct2/show/NCT03599375 DMCZI8L DI DMCZI8L DMCZI8L DN ABBV-257 DMCZI8L TI TTF8CQI DMCZI8L TN Tumor necrosis factor (TNF) DMCZI8L MA Inhibitor DMCZI8L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCZI8L RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMCZI8L DI DMCZI8L DMCZI8L DN ABBV-257 DMCZI8L TI TTG0MT6 DMCZI8L TN Interleukin-17 (IL17) DMCZI8L MA Inhibitor DMCZI8L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMCZI8L RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMCZQNJ DI DMCZQNJ DMCZQNJ DN IMC-EB10 DMCZQNJ TI TTGJCWZ DMCZQNJ TN Fms-like tyrosine kinase 3 (FLT-3) DMCZQNJ RN IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples. Cancer Res. 2006 May 1;66(9):4843-51. DMCZQNJ RU https://pubmed.ncbi.nlm.nih.gov/16651440 DMD0BMN DI DMD0BMN DMD0BMN DN ASG-5ME DMD0BMN TI TT0NYDG DMD0BMN TN Choline transporter-like protein 4 (SLC44A4) DMD0BMN RN 2011 Pipeline of Seattle Genetics. DMD0BMN RU http://www.seagen.com/product_pipeline.php DMD0NA1 DI DMD0NA1 DMD0NA1 DN TP 6076 DMD0NA1 TI TTOVFH2 DMD0NA1 TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMD0NA1 MA Inhibitor DMD0NA1 RN Clinical pipeline report, company report or official report of Tetraphase Pharmaceuticals. DMD0NA1 RU https://www.tphase.com/wp-content/uploads/2019/04/IDWeek-2018-TP-6076-Pipeline-FINAL-website.pdf DMD0XWR DI DMD0XWR DMD0XWR DN CART123 cells DMD0XWR TI TTENHJ0 DMD0XWR TN Interleukin 3 receptor alpha (IL3RA) DMD0XWR MA CAR-T-Cell-Therapy DMD0XWR RN ClinicalTrials.gov (NCT03766126) Lentivirally Redirected CD123 Autologous T Cells in AML DMD0XWR RU https://clinicaltrials.gov/ct2/show/NCT03766126 DMD16JK DI DMD16JK DMD16JK DN RG-7816 DMD16JK TI TTNZPQ1 DMD16JK TN GABA(A) receptor alpha-5 (GABRA5) DMD16JK MA Modulator DMD16JK RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMD16JK RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMD23AX DI DMD23AX DMD23AX DN Systebryl DMD23AX TI TTE4KHA DMD23AX TN Amyloid beta A4 protein (APP) DMD23AX MA Inhibitor DMD23AX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMD23AX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMD2BIT DI DMD2BIT DMD2BIT DN AT001/r84 DMD2BIT TI TTOHSBA DMD2BIT TN Vascular endothelial growth factor A (VEGFA) DMD2BIT RN Clinical pipeline report, company report or official report of Affitech (2011). DMD2BIT RU http://www.affitech.com/ DMD2GKF DI DMD2GKF DMD2GKF DN SFLT-01 DMD2GKF TI TTOHSBA DMD2GKF TN Vascular endothelial growth factor A (VEGFA) DMD2GKF MA Modulator DMD2GKF RN sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15. DMD2GKF RU https://pubmed.ncbi.nlm.nih.gov/21252283 DMD2GKF DI DMD2GKF DMD2GKF DN SFLT-01 DMD2GKF TI TT48I1Y DMD2GKF TN Placenta growth factor (PlGF) DMD2GKF MA Modulator DMD2GKF RN sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15. DMD2GKF RU https://pubmed.ncbi.nlm.nih.gov/21252283 DMD2VRY DI DMD2VRY DMD2VRY DN SAR-115740 DMD2VRY TI TTMI6F5 DMD2VRY TN Transient receptor potential cation channel V1 (TRPV1) DMD2VRY MA Antagonist DMD2VRY RN Clinical pipeline report, company report or official report of Sanofi. DMD2VRY RU https://ncats.nih.gov/files/SAR115740.pdf DMD51GC DI DMD51GC DMD51GC DN LY3321367 DMD51GC TI TT1RWL7 DMD51GC TN Hepatitis A virus cellular receptor 2 (TIM3) DMD51GC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMD51GC RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMD6H8B DI DMD6H8B DMD6H8B DN GMZ-2 DMD6H8B TI TT3J5ZI DMD6H8B TN Cell mediated immunity response (CMIR) DMD6H8B RN Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Malar J. 2011; 10: 359. DMD6H8B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265551/ DMD751X DI DMD751X DMD751X DN 1614235 + 2330672 DMD751X TI TT2UE56 DMD751X TN Sodium/glucose cotransporter 1 (SGLT1) DMD751X MA Modulator DMD751X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 915). DMD751X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=915 DMD751X DI DMD751X DMD751X DN 1614235 + 2330672 DMD751X TI TTPI1M5 DMD751X TN Ileal sodium/bile acid cotransporter (SLC10A2) DMD751X MA Modulator DMD751X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 960). DMD751X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=960 DMD79TX DI DMD79TX DMD79TX DN TAK-102 DMD79TX TI TTJTSX4 DMD79TX TN Glypican-3 (GPC3) DMD79TX RN ClinicalTrials.gov (NCT04405778) A Study of TAK-102 in Adult With Previously-Treated Solid Tumors. U.S. National Institutes of Health. DMD79TX RU https://clinicaltrials.gov/ct2/show/NCT04405778 DMD7LHM DI DMD7LHM DMD7LHM DN ION 224 DMD7LHM TI TT8N5V1 DMD7LHM TN DGAT2 messenger RNA (DGAT2 mRNA) DMD7LHM MA Inhibitor DMD7LHM RN Clinical pipeline report, company report or official report of Ionis Pharmaceuticals. DMD7LHM RU https://www.ionispharma.com/ionis-innovation/pipeline/ DMD83WO DI DMD83WO DMD83WO DN AST-1306 DMD83WO TI TTGKNB4 DMD83WO TN Epidermal growth factor receptor (EGFR) DMD83WO MA Modulator DMD83WO RN AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. DMD83WO RU https://pubmed.ncbi.nlm.nih.gov/21789172 DMD9N12 DI DMD9N12 DMD9N12 DN BAY 2416964 DMD9N12 TI TT037IE DMD9N12 TN Aryl hydrocarbon receptor (AHR) DMD9N12 MA Antagonist DMD9N12 RN ClinicalTrials.gov (NCT04069026) A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer. U.S. National Institutes of Health. DMD9N12 RU https://clinicaltrials.gov/ct2/show/NCT04069026 DMD9OVI DI DMD9OVI DMD9OVI DN MEDI1191 DMD9OVI TI TTG68FB DMD9OVI TN Interleukine 12 (IL-12) DMD9OVI MA Replacement DMD9OVI RN Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment. Clin Cancer Res. 2020 Dec 1;26(23):6284-6298. DMD9OVI RU https://pubmed.ncbi.nlm.nih.gov/32817076 DMD9U5Q DI DMD9U5Q DMD9U5Q DN IMA 203 DMD9U5Q TI TTPH7T0 DMD9U5Q TN Tumor expressed melanoma antigen (PRAME) DMD9U5Q RN Clinical pipeline report, company report or official report of Immatics. DMD9U5Q RU https://immatics.com/our-pipeline/ DMDA1UB DI DMDA1UB DMDA1UB DN AI-850 DMDA1UB TI TTJGNVC DMDA1UB TN Apoptosis regulator Bcl-2 (BCL-2) DMDA1UB MA Modulator DMDA1UB RN Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. DMDA1UB RU https://pubmed.ncbi.nlm.nih.gov/15835739 DMDA1UB DI DMDA1UB DMDA1UB DN AI-850 DMDA1UB TI TT63KYR DMDA1UB TN Tubulin beta-1 chain (TUBB1) DMDA1UB MA Modulator DMDA1UB RN Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. DMDA1UB RU https://pubmed.ncbi.nlm.nih.gov/15835739 DMDAHEL DI DMDAHEL DMDAHEL DN SGM-1019 DMDAHEL TI TT473XN DMDAHEL TN P2X purinoceptor 7 (P2RX7) DMDAHEL MA Modulator DMDAHEL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDAHEL RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMDB3OK DI DMDB3OK DMDB3OK DN MLN-3126 DMDB3OK TI TTIPS8B DMDB3OK TN C-C chemokine receptor type 9 (CCR9) DMDB3OK MA Antagonist DMDB3OK RN Targeting T-cell migration in inflammatory bowel disease. J Intern Med. 2012 Nov;272(5):411-29. DMDB3OK RU https://pubmed.ncbi.nlm.nih.gov/22946654 DMDB7KU DI DMDB7KU DMDB7KU DN ISO-1 DMDB7KU TI TT2AST1 DMDB7KU TN Macrophage migration inhibitory factor (MIF) DMDB7KU MA Inhibitor DMDB7KU RN The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82. DMDB7KU RU https://pubmed.ncbi.nlm.nih.gov/11997397 DMDBW2N DI DMDBW2N DMDBW2N DN JNJ-64619178 DMDBW2N TI TTR1D7X DMDBW2N TN Protein arginine methyltransferase 5 (PRMT5) DMDBW2N MA Inhibitor DMDBW2N RN A patent review of arginine methyltransferase inhibitors (2010-2018). Expert Opin Ther Pat. 2019 Feb;29(2):97-114. DMDBW2N RU https://pubmed.ncbi.nlm.nih.gov/30640571 DMDC9TB DI DMDC9TB DMDC9TB DN P-BCMA-101 CAR-T cells DMDC9TB TI TTZ3P4W DMDC9TB TN B-cell maturation protein (TNFRSF17) DMDC9TB MA CAR-T-Cell-Therapy DMDC9TB RN ClinicalTrials.gov (NCT03288493) P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) DMDC9TB RU https://clinicaltrials.gov/ct2/show/NCT03288493 DMDE9I6 DI DMDE9I6 DMDE9I6 DN PF-06801591 DMDE9I6 TI TTNBFWK DMDE9I6 TN Programmed cell death protein 1 (PD-1) DMDE9I6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMDE9I6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMDER9S DI DMDER9S DMDER9S DN Minnelide DMDER9S TI TTHYBIX DMDER9S TN Heat shock protein 70 (HSP70) DMDER9S MA Inhibitor DMDER9S RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDER9S RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDF29A DI DMDF29A DMDF29A DN STM 434 DMDF29A TI TTMQO60 DMDF29A TN Rho-associated protein kinase (ROCK) DMDF29A MA Inhibitor DMDF29A RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMDF29A RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMDF29A DI DMDF29A DMDF29A DN STM 434 DMDF29A TI TT9RV4P DMDF29A TN Activin (ACT) DMDF29A MA Inhibitor DMDF29A RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDF29A RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMDFA3E DI DMDFA3E DMDFA3E DN 349U85.HCL DMDFA3E TI TTZCG4L DMDFA3E TN Phosphodiesterase 3 (PDE3) DMDFA3E MA Modulator DMDFA3E RN Pharmacokinetics and pharmacodynamics of a new cardiotonic vasodilator agent, 349U85, in normal subjects. Clin Pharmacol Ther. 1994 Jan;55(1):55-63. DMDFA3E RU https://pubmed.ncbi.nlm.nih.gov/8299318 DMDFC2Y DI DMDFC2Y DMDFC2Y DN VIC-1911 DMDFC2Y TI TTPS3C0 DMDFC2Y TN Aurora kinase A (AURKA) DMDFC2Y MA Inhibitor DMDFC2Y RN Clinical pipeline report, company report or official report of VITRAC Therapeutics. DMDFC2Y RU https://vitractherapeutics.com/ DMDFY1R DI DMDFY1R DMDFY1R DN CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells DMDFY1R TI TTENHJ0 DMDFY1R TN Interleukin 3 receptor alpha (IL3RA) DMDFY1R MA CAR-T-Cell-Therapy DMDFY1R RN ClinicalTrials.gov (NCT03114670) Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT DMDFY1R RU https://clinicaltrials.gov/ct2/show/NCT03114670 DMDG30Q DI DMDG30Q DMDG30Q DN VOB560 DMDG30Q TI TTJGNVC DMDG30Q TN Apoptosis regulator Bcl-2 (BCL-2) DMDG30Q MA Inhibitor DMDG30Q RN Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer. Cells. 2020 May 21;9(5):1287. DMDG30Q RU https://pubmed.ncbi.nlm.nih.gov/32455818 DMDGCHR DI DMDGCHR DMDGCHR DN NN-1218 DMDGCHR TI TTCBFJO DMDGCHR TN Insulin receptor (INSR) DMDGCHR MA Modulator DMDGCHR RN Ultrafast-Acting Insulins: State of the Art. J Diabetes Sci Technol. 2012 July; 6(4): 728-742. DMDGCHR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3440142/ DMDHQYA DI DMDHQYA DMDHQYA DN SAM-6 DMDHQYA TI TTW26OG DMDHQYA TN Endoplasmic reticulum chaperone BiP (HSPA5) DMDHQYA RN A new tumor-specific variant of GRP78 as target for antibody-based therapy. Lab Invest. 2008 Apr;88(4):375-86. DMDHQYA RU https://pubmed.ncbi.nlm.nih.gov/18268478 DMDIPW8 DI DMDIPW8 DMDIPW8 DN JNJ-38877605 DMDIPW8 TI TTNDSF4 DMDIPW8 TN Proto-oncogene c-Met (MET) DMDIPW8 MA Inhibitor DMDIPW8 RN The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-304. DMDIPW8 RU https://pubmed.ncbi.nlm.nih.gov/25745036 DMDK4MG DI DMDK4MG DMDK4MG DN M7583 DMDK4MG TI TTGM6VW DMDK4MG TN Tyrosine-protein kinase BTK (ATK) DMDK4MG MA Inhibitor DMDK4MG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDK4MG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDKAIC DI DMDKAIC DMDKAIC DN ISIS-SGLT2 DMDKAIC TI TTF8JAT DMDKAIC TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMDKAIC RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMDKAIC RU http://www.isispharm.com/index.htm DMDLJM1 DI DMDLJM1 DMDLJM1 DN NKR-2 CAR-T Cells DMDLJM1 TI TTLRN4A DMDLJM1 TN NKG2 D activating NK receptor (KLRK1) DMDLJM1 MA CAR-T-Cell-Therapy DMDLJM1 RN ClinicalTrials.gov (NCT03612739) EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 DMDLJM1 RU https://clinicaltrials.gov/ct2/show/NCT03612739 DMDLTCU DI DMDLTCU DMDLTCU DN Lotilibcin DMDLTCU TI TTXT4D5 DMDLTCU TN Bacterial Cell membrane (Bact CM) DMDLTCU MA Modulator DMDLTCU RN Bioactive natural products from Lysobacter. Nat Prod Rep. 2012 November 8; 29(11): 1277-1287. DMDLTCU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3468324/ DMDM85L DI DMDM85L DMDM85L DN RH 1 DMDM85L TI TTUTN1I DMDM85L TN Human Deoxyribonucleic acid (hDNA) DMDM85L MA Modulator DMDM85L RN Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent RH1 DMDM85L RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2612562 DMDMKVL DI DMDMKVL DMDMKVL DN GEM333 DMDMKVL TI TTJVYO3 DMDMKVL TN Myeloid cell surface antigen CD33 (CD33) DMDMKVL MA Inhibitor DMDMKVL RN Clinical pipeline report, company report or official report of Gemoab. DMDMKVL RU https://www.gemoab.com/gem333 DMDMKVL DI DMDMKVL DMDMKVL DN GEM333 DMDMKVL TI TTUN7MC DMDMKVL TN T-cell surface glycoprotein CD3 (CD3) DMDMKVL MA Inhibitor DMDMKVL RN Clinical pipeline report, company report or official report of Gemoab. DMDMKVL RU https://www.gemoab.com/gem333 DMDMNJ6 DI DMDMNJ6 DMDMNJ6 DN Anti-HER3/EGFR DAF DMDMNJ6 TI TTGKNB4 DMDMNJ6 TN Epidermal growth factor receptor (EGFR) DMDMNJ6 MA Modulator DMDMNJ6 RN Company report (Biooncology) DMDMNJ6 RU http://www.biooncology.com/pipeline-molecules/anti-her3 DMDMNJ6 DI DMDMNJ6 DMDMNJ6 DN Anti-HER3/EGFR DAF DMDMNJ6 TI TTDC8N2 DMDMNJ6 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMDMNJ6 MA Modulator DMDMNJ6 RN Company report (Biooncology) DMDMNJ6 RU http://www.biooncology.com/pipeline-molecules/anti-her3 DMDMPKC DI DMDMPKC DMDMPKC DN GGF-2 DMDMPKC TI TTEH395 DMDMPKC TN Pro-neuregulin-1 (Pro-NRG1) DMDMPKC MA Modulator DMDMPKC RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDMPKC RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDNPAV DI DMDNPAV DMDNPAV DN TTI-621 DMDNPAV TI TT28S46 DMDNPAV TN Leukocyte surface antigen CD47 (CD47) DMDNPAV MA Inhibitor DMDNPAV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDNPAV RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMDOCNW DI DMDOCNW DMDOCNW DN E-7050 DMDOCNW TI TTUTJGQ DMDOCNW TN Vascular endothelial growth factor receptor 2 (KDR) DMDOCNW MA Modulator DMDOCNW RN E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5. DMDOCNW RU https://pubmed.ncbi.nlm.nih.gov/19832844 DMDOCNW DI DMDOCNW DMDOCNW DN E-7050 DMDOCNW TI TTNDSF4 DMDOCNW TN Proto-oncogene c-Met (MET) DMDOCNW MA Modulator DMDOCNW RN E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. Cancer Sci. 2010 Jan;101(1):210-5. DMDOCNW RU https://pubmed.ncbi.nlm.nih.gov/19832844 DMDOSL0 DI DMDOSL0 DMDOSL0 DN SUN-N8075 DMDOSL0 TI TTC0BEN DMDOSL0 TN Oxidative stress (OS) DMDOSL0 MA Inhibitor DMDOSL0 RN Protective effect of SUN N8075, a free radical scavenger, against excessive light-induced retinal damage in mice. Biol Pharm Bull. 2014;37(3):424-30. DMDOSL0 RU https://pubmed.ncbi.nlm.nih.gov/24583861 DMDP6UF DI DMDP6UF DMDP6UF DN SCH-721015 DMDP6UF TI TTSIUJ9 DMDP6UF TN Interferon-alpha 2 (IFNA2) DMDP6UF MA Modulator DMDP6UF RN Toxicity and exposure of an adenovirus containing human interferon alpha-2b following intracystic administration in cynomolgus monkeys. Gene Ther. 2012 Jul;19(7):742-51. DMDP6UF RU https://pubmed.ncbi.nlm.nih.gov/21900961 DMDPGCS DI DMDPGCS DMDPGCS DN EGT-0001474 DMDPGCS TI TTLWPVF DMDPGCS TN Sodium/glucose cotransporter 2 (SGLT2) DMDPGCS MA Modulator DMDPGCS RN PhRMA report DMDPGCS RU http://www.phrma.org/sites/default/files/pdf/diabetes2012.pdf DMDQG4Y DI DMDQG4Y DMDQG4Y DN CPC-250 DMDQG4Y TI TT1RS9F DMDQG4Y TN Acetylcholinesterase (AChE) DMDQG4Y MA Inhibitor DMDQG4Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDQG4Y RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMDQJEZ DI DMDQJEZ DMDQJEZ DN PF-06952229 DMDQJEZ TI TTP4520 DMDQJEZ TN TGF-beta receptor type I (TGFBR1) DMDQJEZ MA Inhibitor DMDQJEZ RN Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31. DMDQJEZ RU https://pubmed.ncbi.nlm.nih.gov/25444759 DMDQRWT DI DMDQRWT DMDQRWT DN S-265744 LAP DMDQRWT TI TT5FH9Y DMDQRWT TN Human immunodeficiency virus Integrase (HIV IN) DMDQRWT MA Inhibitor DMDQRWT RN Long-acting shot prevents infection with HIV analogue. Nature. doi:10.1038/nature.2014.14819. 04 March 2014 DMDQRWT RU http://www.nature.com/news/long-acting-shot-prevents-infection-with-hiv-analogue-1.14819 DMDRBNJ DI DMDRBNJ DMDRBNJ DN ROCICLOVIR DMDRBNJ TI TTIU7X1 DMDRBNJ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMDRBNJ MA Modulator DMDRBNJ RN Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405-11. DMDRBNJ RU https://pubmed.ncbi.nlm.nih.gov/2540193 DMDSC63 DI DMDSC63 DMDSC63 DN VEL-0230 DMDSC63 TI TTDZN01 DMDSC63 TN Cathepsin K (CTSK) DMDSC63 MA Inhibitor DMDSC63 RN Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4. DMDSC63 RU https://pubmed.ncbi.nlm.nih.gov/11677133 DMDSCQG DI DMDSCQG DMDSCQG DN PF-04840082 DMDSCQG TI TTE3RAC DMDSCQG TN Dickkopf-related protein 1 (DKK1) DMDSCQG MA Modulator DMDSCQG RN The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis. J Pharmacol Exp Ther. 2010 Apr;333(1):2-13. DMDSCQG RU https://pubmed.ncbi.nlm.nih.gov/20089807 DMDSF0Q DI DMDSF0Q DMDSF0Q DN TROVIRDINE HYDROCHLORIDE DMDSF0Q TI TT84ETX DMDSF0Q TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMDSF0Q MA Modulator DMDSF0Q RN Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives tr... Antiviral Res. 1995 Dec;28(4):331-42. DMDSF0Q RU https://www.ncbi.nlm.nih.gov/pubmed/8669892 DMDSFEB DI DMDSFEB DMDSFEB DN SI-B001 DMDSFEB TI TTGKNB4 DMDSFEB TN Epidermal growth factor receptor (EGFR) DMDSFEB RN Clinical pipeline report, company report or official report of SystImmune. DMDSFEB RU https://systimmune.com/pipeline.html DMDSFEB DI DMDSFEB DMDSFEB DN SI-B001 DMDSFEB TI TTDC8N2 DMDSFEB TN Erbb3 tyrosine kinase receptor (Erbb-3) DMDSFEB RN Clinical pipeline report, company report or official report of SystImmune. DMDSFEB RU https://systimmune.com/pipeline.html DMDSVRP DI DMDSVRP DMDSVRP DN DV-1179 DMDSVRP TI TTSHG0T DMDSVRP TN Toll-like receptor 9 (TLR9) DMDSVRP MA Modulator DMDSVRP RN Company report (Dynavax) DMDSVRP RU http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/ DMDSVRP DI DMDSVRP DMDSVRP DN DV-1179 DMDSVRP TI TTRJ1K4 DMDSVRP TN Toll-like receptor 7 (TLR7) DMDSVRP MA Modulator DMDSVRP RN Company report (Dynavax) DMDSVRP RU http://www.dynavax.com/our-pipeline/immune-mediated-diseases/dv1179/ DMDSZNC DI DMDSZNC DMDSZNC DN INCAGN2385 DMDSZNC TI TTNVXAW DMDSZNC TN Lymphocyte activation gene 3 protein (LAG3) DMDSZNC MA Inhibitor DMDSZNC RN Clinical pipeline report, company report or official report of Agenus. DMDSZNC RU https://agenusbio.com/pipeline/ DMDU54Y DI DMDU54Y DMDU54Y DN IK-175 DMDU54Y TI TT037IE DMDU54Y TN Aryl hydrocarbon receptor (AHR) DMDU54Y MA Antagonist DMDU54Y RN Clinical pipeline report, company report or official report of Ikena Oncology. DMDU54Y RU https://ikenaoncology.com/pipeline/immunotherapy/ahr-antagonist-program/ DMDUIO4 DI DMDUIO4 DMDUIO4 DN AGS-348 DMDUIO4 TI TTABNSJ DMDUIO4 TN Pyruvate kinase (PK) DMDUIO4 MA Modulator DMDUIO4 RN Clinical pipeline report, company report or official report of Agios Pharmaceuticals. DMDUIO4 RU http://investor.agios.com/phoenix.zhtml?c=251862&p=irol-newsArticle&ID=1919588 DMDXFBJ DI DMDXFBJ DMDXFBJ DN LOXO-195 DMDXFBJ TI TTTDVOJ DMDXFBJ TN Tropomyosin-related kinase A (TrkA) DMDXFBJ MA Inhibitor DMDXFBJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMDXFBJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMDY08K DI DMDY08K DMDY08K DN GDC-0623 DMDY08K TI TTZCRP3 DMDY08K TN ERK activator kinase (MEK) DMDY08K MA Inhibitor DMDY08K RN Clinical pipeline report, company report or official report of Genentech (2011). DMDY08K RU http://www.gene.com/gene/index.jsp DMDZ26X DI DMDZ26X DMDZ26X DN GDC-0425 DMDZ26X TI TTTU902 DMDZ26X TN Checkpoint kinase-1 (CHK1) DMDZ26X MA Modulator DMDZ26X RN Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199). DMDZ26X RU http://cancerres.aacrjournals.org/content/75/15_Supplement/6 DMDZBTY DI DMDZBTY DMDZBTY DN HuM195/rGel DMDZBTY TI TTJVYO3 DMDZBTY TN Myeloid cell surface antigen CD33 (CD33) DMDZBTY RN Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb;98(2):217-21. DMDZBTY RU https://pubmed.ncbi.nlm.nih.gov/22875630 DMDZQ23 DI DMDZQ23 DMDZQ23 DN HF-0299 DMDZQ23 TI TTHRID2 DMDZQ23 TN Insulin-like growth factor I receptor (IGF1R) DMDZQ23 MA Modulator DMDZQ23 RN A primary adrenal steroid, 11beta-hydroxyandrostenedione, has an osteotropic effect and little androgenic activity. J Steroid Biochem Mol Biol. 2000 Nov 15;74(4):203-11. DMDZQ23 RU https://pubmed.ncbi.nlm.nih.gov/11162926 DMDZR0V DI DMDZR0V DMDZR0V DN Anti-CEA CAR-T cells DMDZR0V TI TTY6DTE DMDZR0V TN Carcinoembryonic antigen CEA (CD66e) DMDZR0V MA CAR-T-Cell-Therapy DMDZR0V RN ClinicalTrials.gov (NCT03682744) CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) DMDZR0V RU https://clinicaltrials.gov/ct2/show/NCT03682744 DME0CJ9 DI DME0CJ9 DME0CJ9 DN R763 DME0CJ9 TI TT5LS6T DME0CJ9 TN Aurora kinase B (AURKB) DME0CJ9 MA Inhibitor DME0CJ9 RN Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113. DME0CJ9 RU https://pubmed.ncbi.nlm.nih.gov/19609559 DME0CJ9 DI DME0CJ9 DME0CJ9 DN R763 DME0CJ9 TI TTPS3C0 DME0CJ9 TN Aurora kinase A (AURKA) DME0CJ9 MA Inhibitor DME0CJ9 RN Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113. DME0CJ9 RU https://pubmed.ncbi.nlm.nih.gov/19609559 DME0F5W DI DME0F5W DME0F5W DN XL418 DME0F5W TI TT7M3PI DME0F5W TN Ribosomal protein S6 kinase (S6K) DME0F5W MA Modulator DME0F5W RN Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer DME0F5W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142564 DME0F5W DI DME0F5W DME0F5W DN XL418 DME0F5W TI TTAZ05C DME0F5W TN RAC-gamma serine/threonine-protein kinase (AKT3) DME0F5W MA Modulator DME0F5W RN Targeting the phosphoinositide 3-kinase (PI3K) pathway in cancer DME0F5W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142564 DME0WX2 DI DME0WX2 DME0WX2 DN Org-43902 DME0WX2 TI TT2O4W9 DME0WX2 TN Luteinizing hormone receptor (LHCGR) DME0WX2 MA Agonist DME0WX2 RN First evidence of ovulation induced by oral LH agonists in healthy female volunteers of reproductive age. J Clin Endocrinol Metab. 2013 Apr;98(4):1558-66. DME0WX2 RU https://pubmed.ncbi.nlm.nih.gov/23515453 DME18UM DI DME18UM DME18UM DN MER-102 DME18UM TI TT4QPUL DME18UM TN Antithrombin-III (ATIII) DME18UM MA Inhibitor DME18UM RN Clinical pipeline report, company report or official report of Merrion's GIPET technology. DME18UM RU http://www.merrionpharma.com/content/portfolio/mer102.asp DME1Y9W DI DME1Y9W DME1Y9W DN Protexia DME1Y9W TI TTEB0GD DME1Y9W TN Cholinesterase (BCHE) DME1Y9W MA Modulator DME1Y9W RN In vitro and in vivo characterization of recombinant human butyrylcholinesterase (Protexia) as a potential nerve agent bioscavenger. Chem Biol Interact. 2005 Dec 15;157-158:363-5. DME1Y9W RU https://pubmed.ncbi.nlm.nih.gov/16429486 DME1ZAH DI DME1ZAH DME1ZAH DN MK-1496 DME1ZAH TI TTIYVQP DME1ZAH TN Polo-like kinase 1 (PLK1) DME1ZAH MA Inhibitor DME1ZAH RN J Clin Oncol 29: 2011 (suppl; abstr 3012). DME1ZAH RU http://meetinglibrary.asco.org/content/73894-102 DME2QUZ DI DME2QUZ DME2QUZ DN NOV1501 DME2QUZ TI TTV23LH DME2QUZ TN Delta-like protein 4 (DLL4) DME2QUZ MA Inhibitor DME2QUZ RN Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538. DME2QUZ RU https://pubmed.ncbi.nlm.nih.gov/32580836 DME2QUZ DI DME2QUZ DME2QUZ DN NOV1501 DME2QUZ TI TT9HKJA DME2QUZ TN Vascular endothelial growth factor (VEGF) DME2QUZ MA Inhibitor DME2QUZ RN Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538. DME2QUZ RU https://pubmed.ncbi.nlm.nih.gov/32580836 DME3BJL DI DME3BJL DME3BJL DN PF-07062119 DME3BJL TI TTUN7MC DME3BJL TN T-cell surface glycoprotein CD3 (CD3) DME3BJL MA Inhibitor DME3BJL RN Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395. DME3BJL RU https://pubmed.ncbi.nlm.nih.gov/33459147 DME3BJL DI DME3BJL DME3BJL DN PF-07062119 DME3BJL TI TTLDPRG DME3BJL TN Guanylyl cyclase C (GUCY2C) DME3BJL MA Inhibitor DME3BJL RN Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395. DME3BJL RU https://pubmed.ncbi.nlm.nih.gov/33459147 DME3VU8 DI DME3VU8 DME3VU8 DN REGN1400 DME3VU8 TI TTDC8N2 DME3VU8 TN Erbb3 tyrosine kinase receptor (Erbb-3) DME3VU8 RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2516). DME3VU8 RU http://meetinglibrary.asco.org/content/131992-144 DME4B8I DI DME4B8I DME4B8I DN MGD009 DME4B8I TI TT6CQUM DME4B8I TN B7 homolog 3 (CD276) DME4B8I MA Immunomodulator DME4B8I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME4B8I RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DME4D7H DI DME4D7H DME4D7H DN HM71224 DME4D7H TI TTGM6VW DME4D7H TN Tyrosine-protein kinase BTK (ATK) DME4D7H MA Inhibitor DME4D7H RN HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19(1):211. DME4D7H RU https://pubmed.ncbi.nlm.nih.gov/28950886 DME630T DI DME630T DME630T DN AV4025 DME630T TI TTCJ2X8 DME630T TN Hepatitis C virus Non-structural 5A (HCV NS5A) DME630T MA Modulator DME630T RN Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J Med Chem. 2014 Sep 25;57(18):7716-30. DME630T RU https://pubmed.ncbi.nlm.nih.gov/25148100 DME63VK DI DME63VK DME63VK DN ONO-4578 DME63VK TI TT79WV3 DME63VK TN Prostaglandin E2 receptor EP4 (PTGER4) DME63VK MA Antagonist DME63VK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME63VK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DME6UNO DI DME6UNO DME6UNO DN M012 DME6UNO TI TT6Y1PG DME6UNO TN Solute carrier family 40 member 1 (SLC40A1) DME6UNO MA Agonist DME6UNO RN Hepcidin agonists as therapeutic tools. Blood. 2018 Apr 19;131(16):1790-1794. DME6UNO RU https://pubmed.ncbi.nlm.nih.gov/29523504 DME6VX4 DI DME6VX4 DME6VX4 DN GZ402668 DME6VX4 TI TTQT5S9 DME6VX4 TN Cambridge pathology 1 antigen (CD52) DME6VX4 RN Characterization of a Next Generation Anti-CD52 Antibody. Neurology. April 6, 2015 vol. 84 no. 14. DME6VX4 RU http://www.neurology.org/content/84/14_Supplement/S20.006 DME7BMT DI DME7BMT DME7BMT DN MEDI4920 DME7BMT TI TTIJP3Q DME7BMT TN TNF related activation protein (CD40LG) DME7BMT MA Inhibitor DME7BMT RN ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health. DME7BMT RU https://clinicaltrials.gov/ct2/show/NCT02151110 DME7IVL DI DME7IVL DME7IVL DN Xmab-7195 DME7IVL TI TTYJQTF DME7IVL TN Immunoglobulin E (IgE) DME7IVL MA Inhibitor DME7IVL RN Clinical pipeline report, company report or official report of Xencor. DME7IVL RU http://www.xencor.com/pipeline/xmab7195/ DME7JFM DI DME7JFM DME7JFM DN MR1-1 DME7JFM TI TTGKNB4 DME7JFM TN Epidermal growth factor receptor (EGFR) DME7JFM MA Modulator DME7JFM RN A Phase I Study of Immunotoxin, MR1-1. Duke University report. DME7JFM RU http://www.cancer.duke.edu/btc/modules/ClinicalTrials4/index.php?id=72 DME8DUV DI DME8DUV DME8DUV DN KM-023 DME8DUV TI TT84ETX DME8DUV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DME8DUV MA Inhibitor DME8DUV RN Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects. Drug Des Devel Ther. 2014 Sep 26;8:1613-9. DME8DUV RU https://pubmed.ncbi.nlm.nih.gov/25302016 DME9NYV DI DME9NYV DME9NYV DN BI 905711 DME9NYV TI TTW20TU DME9NYV TN TRAIL receptor 2 (TRAIL-R2) DME9NYV MA Activator DME9NYV RN Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108. DME9NYV RU https://pubmed.ncbi.nlm.nih.gov/33037135 DME9UTO DI DME9UTO DME9UTO DN RP4010 DME9UTO TI TTE76YK DME9UTO TN Calcium-release activated calcium channel (CRACM) DME9UTO MA Inhibitor DME9UTO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DME9UTO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMECVP9 DI DMECVP9 DMECVP9 DN OP-0595 DMECVP9 TI TTHI19T DMECVP9 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMECVP9 MA Inhibitor DMECVP9 RN OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86. DMECVP9 RU https://pubmed.ncbi.nlm.nih.gov/26089439 DMED2WN DI DMED2WN DMED2WN DN PLX73086 DMED2WN TI TT0IQER DMED2WN TN Macrophage colony-stimulating factor 1 (CSF1) DMED2WN MA Antagonist DMED2WN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMED2WN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMED4AJ DI DMED4AJ DMED4AJ DN BGC-20-1259 DMED4AJ TI TT3ROYC DMED4AJ TN Serotonin transporter (SERT) DMED4AJ MA Modulator DMED4AJ RN Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86. DMED4AJ RU https://www.ncbi.nlm.nih.gov/pubmed/21521422 DMEFUSJ DI DMEFUSJ DMEFUSJ DN RG6296 DMEFUSJ TI TTIFOC0 DMEFUSJ TN Immunoglobulin gamma Fc receptor IIIA (FCGR3A) DMEFUSJ MA Inhibitor DMEFUSJ RN Clinical pipeline report, company report or official report of Genentech. DMEFUSJ RU https://www.genentechoncology.com/pipeline-molecules/bcma-x-cd16a.html DMEFUSJ DI DMEFUSJ DMEFUSJ DN RG6296 DMEFUSJ TI TTZ3P4W DMEFUSJ TN B-cell maturation protein (TNFRSF17) DMEFUSJ MA Inhibitor DMEFUSJ RN Clinical pipeline report, company report or official report of Genentech. DMEFUSJ RU https://www.genentechoncology.com/pipeline-molecules/bcma-x-cd16a.html DMEGN5I DI DMEGN5I DMEGN5I DN HMPL-689 DMEGN5I TI TTGBPJE DMEGN5I TN PI3-kinase delta (PIK3CD) DMEGN5I MA Inhibitor DMEGN5I RN Clinical pipeline report, company report or official report of Hutchison MediPharma. DMEGN5I RU https://www.hutch-med.com/pipeline-and-products/our-pipeline/ DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TT1LVF2 DMEGOQP TN Cyclin-dependent kinase 9 (CDK9) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TTMYWL7 DMEGOQP TN Cyclin-dependent kinase 3 (CDK3) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TTH6V3D DMEGOQP TN Cyclin-dependent kinase 1 (CDK1) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TT7HF4W DMEGOQP TN Cyclin-dependent kinase 2 (CDK2) DMEGOQP MA Inhibitor DMEGOQP RN Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/23807770 DMEGOQP DI DMEGOQP DMEGOQP DN RGB-286638 DMEGOQP TI TT0PG8F DMEGOQP TN Cyclin-dependent kinase 4 (CDK4) DMEGOQP MA Inhibitor DMEGOQP RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DMEGOQP RU https://pubmed.ncbi.nlm.nih.gov/21253554 DMEHOVF DI DMEHOVF DMEHOVF DN AMG-139 DMEHOVF TI TTC1GLB DMEHOVF TN Interleukin-23 (IL23) DMEHOVF RN Preclinical development of AMG 139, a human antibody specifically targeting IL-23. Br J Pharmacol. 2015 Jan;172(1):159-72. DMEHOVF RU https://pubmed.ncbi.nlm.nih.gov/25205227 DMEHWPC DI DMEHWPC DMEHWPC DN IMO-9200 DMEHWPC TI TTOK0LR DMEHWPC TN Toll-like receptor (TLR) DMEHWPC MA Antagonist DMEHWPC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEHWPC RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMEIM5G DI DMEIM5G DMEIM5G DN IPI-940 DMEIM5G TI TTDP1UC DMEIM5G TN Fatty acid amide hydrolase (FAAH) DMEIM5G MA Inhibitor DMEIM5G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400). DMEIM5G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400 DMEIMBP DI DMEIMBP DMEIMBP DN AMG 811 DMEIMBP TI TT93WF5 DMEIMBP TN Interferon-gamma (IFNG) DMEIMBP MA Modulator DMEIMBP RN Pharmacokinetic and pharmacodynamic relationship of AMG 811, an anti-IFN-gamma IgG1 monoclonal antibody, in patients with systemic lupus erythematosus. Pharm Res. 2015 Feb;32(2):640-53. DMEIMBP RU https://pubmed.ncbi.nlm.nih.gov/25213774 DMEITAS DI DMEITAS DMEITAS DN SNS-032 DMEITAS TI TT1LVF2 DMEITAS TN Cyclin-dependent kinase 9 (CDK9) DMEITAS MA Inhibitor DMEITAS RN Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. DMEITAS RU https://pubmed.ncbi.nlm.nih.gov/19234140 DMEITAS DI DMEITAS DMEITAS DN SNS-032 DMEITAS TI TT7HF4W DMEITAS TN Cyclin-dependent kinase 2 (CDK2) DMEITAS MA Inhibitor DMEITAS RN Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. DMEITAS RU https://pubmed.ncbi.nlm.nih.gov/19234140 DMEITAS DI DMEITAS DMEITAS DN SNS-032 DMEITAS TI TTQYF7G DMEITAS TN Cyclin-dependent kinase 7 (CDK7) DMEITAS MA Inhibitor DMEITAS RN Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. DMEITAS RU https://pubmed.ncbi.nlm.nih.gov/19234140 DMEJ4B7 DI DMEJ4B7 DMEJ4B7 DN ISIS 325568 DMEJ4B7 TI TTLMJSC DMEJ4B7 TN Glucagon receptor messenger RNA (GCGR mRNA) DMEJ4B7 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMEJ4B7 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMEJ4C1 DI DMEJ4C1 DMEJ4C1 DN MVT-5873 DMEJ4C1 TI TT80ARU DMEJ4C1 TN Ganglioside GD2 (GD2) DMEJ4C1 MA Modulator DMEJ4C1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMEJ4C1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMEJMTR DI DMEJMTR DMEJMTR DN GSK1440115 DMEJMTR TI TTW5UDX DMEJMTR TN Urotensin II receptor (UTS2R) DMEJMTR MA Antagonist DMEJMTR RN Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma. Front Pharmacol. 2013; 4: 54. DMEJMTR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3638148/ DMEMQ5J DI DMEMQ5J DMEMQ5J DN ME-1071 DMEMQ5J TI TTHI19T DMEMQ5J TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMEMQ5J MA Inhibitor DMEMQ5J RN Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38. DMEMQ5J RU https://pubmed.ncbi.nlm.nih.gov/23489027 DMEN6YF DI DMEN6YF DMEN6YF DN CART-123 cells DMEN6YF TI TTENHJ0 DMEN6YF TN Interleukin 3 receptor alpha (IL3RA) DMEN6YF MA CAR-T-Cell-Therapy DMEN6YF RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMEN6YF RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMEOJUN DI DMEOJUN DMEOJUN DN PPI-383 DMEOJUN TI TTMVBWH DMEOJUN TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMEOJUN MA Inhibitor DMEOJUN RN 1173 IDENTIFICATION AND CHARACTERIZATION OF PPI-383, A NEXT GENERATION HCV NS5B NON-NUCLEOSIDE INHIBITOR WITH POTENT ACTIVITY AGAINST ALL MAJOR HCV GENOTYPES. Journal of Hepatology Volume 56, Supplement 2, April 2012, Pages S464. DMEOJUN RU http://www.sciencedirect.com/science/article/pii/S0168827812611854 DMEP321 DI DMEP321 DMEP321 DN BVT-74316 DMEP321 TI TTJS8PY DMEP321 TN 5-HT 6 receptor (HTR6) DMEP321 MA Antagonist DMEP321 RN Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60. DMEP321 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670022/ DMEP7HO DI DMEP7HO DMEP7HO DN MSH-372 DMEP7HO TI TT84ETX DMEP7HO TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMEP7HO MA Inhibitor DMEP7HO RN WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors. DMEP7HO RU http://www.google.com/patents/WO2004029042A1?cl=en DMEPHMR DI DMEPHMR DMEPHMR DN BCMA-CS1 cCAR DMEPHMR TI TTZ3P4W DMEPHMR TN B-cell maturation protein (TNFRSF17) DMEPHMR RN ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health. DMEPHMR RU https://clinicaltrials.gov/ct2/show/NCT04156269 DMEPHMR DI DMEPHMR DMEPHMR DN BCMA-CS1 cCAR DMEPHMR TI TT7ILZ1 DMEPHMR TN SLAM family member 7 SLAMF7 (CS1) DMEPHMR RN ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health. DMEPHMR RU https://clinicaltrials.gov/ct2/show/NCT04156269 DMEPJ7C DI DMEPJ7C DMEPJ7C DN BI 905677 DMEPJ7C TI TTSXOWE DMEPJ7C TN LDL receptor related protein-6 (LRP-6) DMEPJ7C MA Antagonist DMEPJ7C RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMEPJ7C RU https://www.inoncology.com/ourpipeline/lrp56-antagonist DMEPJ7C DI DMEPJ7C DMEPJ7C DN BI 905677 DMEPJ7C TI TT7VMG4 DMEPJ7C TN Low-density lipoprotein receptor-related protein 5 (LRP5) DMEPJ7C MA Antagonist DMEPJ7C RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMEPJ7C RU https://www.inoncology.com/ourpipeline/lrp56-antagonist DMEQY4Z DI DMEQY4Z DMEQY4Z DN DZD1516 DMEQY4Z TI TT6EO5L DMEQY4Z TN Erbb2 tyrosine kinase receptor (HER2) DMEQY4Z MA Inhibitor DMEQY4Z RN ClinicalTrials.gov (NCT04509596) DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer. U.S. National Institutes of Health. DMEQY4Z RU https://clinicaltrials.gov/ct2/show/NCT04509596 DMERDMV DI DMERDMV DMERDMV DN OI362GT DMERDMV TI TTZOPHG DMERDMV TN Insulin (INS) DMERDMV MA Modulator DMERDMV RN Novo Nordisk increased operating profit in local currencies by 15% in the first quarter of 2014 DMERDMV RU https://www.novonordisk.com/bin/getPDF.1781915.pdf DMERJ6V DI DMERJ6V DMERJ6V DN PHX-1766 DMERJ6V TI TTRHUKY DMERJ6V TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMERJ6V MA Modulator DMERJ6V RN Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design. Antivir Ther. 2012;17(2):365-75. DMERJ6V RU https://pubmed.ncbi.nlm.nih.gov/22293533 DMESZQU DI DMESZQU DMESZQU DN Litenimod DMESZQU TI TTSHG0T DMESZQU TN Toll-like receptor 9 (TLR9) DMESZQU MA Modulator DMESZQU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759). DMESZQU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759 DMET0H4 DI DMET0H4 DMET0H4 DN IQB-9302 DMET0H4 TI TTW0CMT DMET0H4 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMET0H4 MA Opener DMET0H4 RN Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92. DMET0H4 RU https://pubmed.ncbi.nlm.nih.gov/11159686 DMETGAQ DI DMETGAQ DMETGAQ DN CD19-directed CAR-T cells DMETGAQ TI TTW640A DMETGAQ TN B-lymphocyte surface antigen B4 (CD19) DMETGAQ MA CAR-T-Cell-Therapy DMETGAQ RN ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia DMETGAQ RU https://clinicaltrials.gov/ct2/show/NCT03463928 DMETIBD DI DMETIBD DMETIBD DN MK-8719 DMETIBD TI TT2I6UX DMETIBD TN Beta-N-acetylhexosaminidase (OGA) DMETIBD MA Inhibitor DMETIBD RN Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097. DMETIBD RU https://pubmed.ncbi.nlm.nih.gov/31487175 DMEWRNZ DI DMEWRNZ DMEWRNZ DN GEN1046 DMEWRNZ TI TTPW9LJ DMEWRNZ TN Co-stimulatory molecule 4-1BB (CD137) DMEWRNZ MA Agonist DMEWRNZ RN Clinical pipeline report, company report or official report of Genmab. DMEWRNZ RU https://www.genmab.com/pipeline/ DMEWRNZ DI DMEWRNZ DMEWRNZ DN GEN1046 DMEWRNZ TI TT8ZLTI DMEWRNZ TN Programmed cell death 1 ligand 1 (PD-L1) DMEWRNZ MA Agonist DMEWRNZ RN Clinical pipeline report, company report or official report of Genmab. DMEWRNZ RU https://www.genmab.com/pipeline/ DMEXT97 DI DMEXT97 DMEXT97 DN ADG116 DMEXT97 TI TTI2S1D DMEXT97 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMEXT97 MA Inhibitor DMEXT97 RN Clinical pipeline report, company report or official report of Adagene. DMEXT97 RU https://www.adagene.com/pipeline/adg116/ DMEY2LK DI DMEY2LK DMEY2LK DN LCAR-B4822M CAR-T Cell DMEY2LK TI TTZ3P4W DMEY2LK TN B-cell maturation protein (TNFRSF17) DMEY2LK MA CAR-T-Cell-Therapy DMEY2LK RN ClinicalTrials.gov (NCT03674463) LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma DMEY2LK RU https://clinicaltrials.gov/ct2/show/NCT03674463 DMF0O3X DI DMF0O3X DMF0O3X DN MCLA-158 DMF0O3X TI TTTSGRH DMF0O3X TN Leucine-rich repeat-containing GPCR 5 (LGR5) DMF0O3X MA Inhibitor DMF0O3X RN Clinical pipeline report, company report or official report of Merus. DMF0O3X RU https://merus.nl/pipeline/ DMF0O3X DI DMF0O3X DMF0O3X DN MCLA-158 DMF0O3X TI TTGKNB4 DMF0O3X TN Epidermal growth factor receptor (EGFR) DMF0O3X MA Inhibitor DMF0O3X RN Clinical pipeline report, company report or official report of Merus. DMF0O3X RU https://merus.nl/pipeline/ DMF21XQ DI DMF21XQ DMF21XQ DN NGM120 DMF21XQ TI TTE61UB DMF21XQ TN GDNF family receptor alpha-like (GFRAL) DMF21XQ MA Antagonist DMF21XQ RN Clinical pipeline report, company report or official report of NGM Biopharmaceuticals. DMF21XQ RU https://www.ngmbio.com/pipeline/ DMF2CZ9 DI DMF2CZ9 DMF2CZ9 DN OSI-930 DMF2CZ9 TI TTUTJGQ DMF2CZ9 TN Vascular endothelial growth factor receptor 2 (KDR) DMF2CZ9 MA Modulator DMF2CZ9 RN OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74. DMF2CZ9 RU https://pubmed.ncbi.nlm.nih.gov/22750060 DMF2CZ9 DI DMF2CZ9 DMF2CZ9 DN OSI-930 DMF2CZ9 TI TTX41N9 DMF2CZ9 TN Tyrosine-protein kinase Kit (KIT) DMF2CZ9 MA Modulator DMF2CZ9 RN OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochem Pharmacol. 2012 Sep 15;84(6):766-74. DMF2CZ9 RU https://pubmed.ncbi.nlm.nih.gov/22750060 DMF3IBC DI DMF3IBC DMF3IBC DN Plasma derived human butyrylcholinesterase DMF3IBC TI TTEB0GD DMF3IBC TN Cholinesterase (BCHE) DMF3IBC MA Modulator DMF3IBC RN Acetylcholinesterase-Fc Fusion Protein (AChE-Fc): A Novel Potential Organophosphate Bioscavenger with Extended Plasma Half-Life. Bioconjug Chem. 2015 Aug 19;26(8):1753-8. DMF3IBC RU https://pubmed.ncbi.nlm.nih.gov/26121420 DMF3MN1 DI DMF3MN1 DMF3MN1 DN NBXT-001+Nobilis inhalation device DMF3MN1 TI TT9IK2Z DMF3MN1 TN N-methyl-D-aspartate receptor (NMDAR) DMF3MN1 MA Antagonist DMF3MN1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF3MN1 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMF5KNO DI DMF5KNO DMF5KNO DN OTSSP167 DMF5KNO TI TTBZOTY DMF5KNO TN Tyrosine-protein kinase MELK (MELK) DMF5KNO MA Inhibitor DMF5KNO RN Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget. 2012 Dec;3(12):1629-40. DMF5KNO RU https://pubmed.ncbi.nlm.nih.gov/23283305 DMF5KNO DI DMF5KNO DMF5KNO DN OTSSP167 DMF5KNO TI TT5MN2U DMF5KNO TN Maternal embryonic leucine zipper kinase (MELK) DMF5KNO MA Inhibitor DMF5KNO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMF5KNO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMF89ZT DI DMF89ZT DMF89ZT DN SEP-228432 DMF89ZT TI TT3ROYC DMF89ZT TN Serotonin transporter (SERT) DMF89ZT MA Inhibitor DMF89ZT RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028715) DMF89ZT RU http://adisinsight.springer.com/drugs/800028715 DMF8WAT DI DMF8WAT DMF8WAT DN CNTO-5825 DMF8WAT TI TT0GVCH DMF8WAT TN Interleukin-13 (IL13) DMF8WAT RN Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98. DMF8WAT RU https://pubmed.ncbi.nlm.nih.gov/23043368 DMF93T2 DI DMF93T2 DMF93T2 DN Anti-CD19/BCMA CAR-T cells DMF93T2 TI TTZ3P4W DMF93T2 TN B-cell maturation protein (TNFRSF17) DMF93T2 MA CAR-T-Cell-Therapy(Dual specific) DMF93T2 RN ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM DMF93T2 RU https://clinicaltrials.gov/ct2/show/NCT03706547 DMF93T2 DI DMF93T2 DMF93T2 DN Anti-CD19/BCMA CAR-T cells DMF93T2 TI TTW640A DMF93T2 TN B-lymphocyte surface antigen B4 (CD19) DMF93T2 MA CAR-T-Cell-Therapy(Dual specific) DMF93T2 RN ClinicalTrials.gov (NCT03706547) Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM DMF93T2 RU https://clinicaltrials.gov/ct2/show/NCT03706547 DMF9ALP DI DMF9ALP DMF9ALP DN BAY 1817080 DMF9ALP TI TT2THBD DMF9ALP TN P2X purinoceptor 3 (P2RX3) DMF9ALP MA Antagonist DMF9ALP RN Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. Eur Respir J. 2021 May 13;2004240. DMF9ALP RU https://pubmed.ncbi.nlm.nih.gov/33986030 DMFA2XQ DI DMFA2XQ DMFA2XQ DN GQ1001 DMFA2XQ TI TT6EO5L DMFA2XQ TN Erbb2 tyrosine kinase receptor (HER2) DMFA2XQ RN Clinical pipeline report, company report or official report of GeneQuantum Healthcare. DMFA2XQ RU http://www.genequantum.com/#/common/product?pid=12&id=13&type=7 DMFBMU7 DI DMFBMU7 DMFBMU7 DN Axatilamab DMFBMU7 TI TT7MRDV DMFBMU7 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMFBMU7 MA Antagonist DMFBMU7 RN Clinical pipeline report, company report or official report of Syndax Pharmaceuticals. DMFBMU7 RU https://syndax.com/pipeline/axatilimab/ DMFBOQ7 DI DMFBOQ7 DMFBOQ7 DN Xanthine DMFBOQ7 TI TTNE7KG DMFBOQ7 TN Adenosine A2b receptor (ADORA2B) DMFBOQ7 MA Antagonist DMFBOQ7 RN Role of adenosine in asthma. Drug Dev Res. 1996;39:333-6. DMFBOQ7 RU https://pubmed.ncbi.nlm.nih.gov/11542498 DMFC2OY DI DMFC2OY DMFC2OY DN GDC-0994 DMFC2OY TI TT1MG9E DMFC2OY TN Extracellular signal-regulated kinase 1 (ERK1) DMFC2OY MA Modulator DMFC2OY RN ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors DMFC2OY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142 DMFC2OY DI DMFC2OY DMFC2OY DN GDC-0994 DMFC2OY TI TT4TQBX DMFC2OY TN Extracellular signal-regulated kinase 2 (ERK2) DMFC2OY MA Modulator DMFC2OY RN ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors DMFC2OY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300142 DMFDAY7 DI DMFDAY7 DMFDAY7 DN LY3214996 DMFDAY7 TI TT4TQBX DMFDAY7 TN Extracellular signal-regulated kinase 2 (ERK2) DMFDAY7 MA Inhibitor DMFDAY7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFDAY7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFDBV5 DI DMFDBV5 DMFDBV5 DN NPT200-11 DMFDBV5 TI TT08OSU DMFDBV5 TN Synuclein alpha (SNCA) DMFDBV5 MA Inhibitor DMFDBV5 RN The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Sci Rep. 2018 Nov 1;8(1):16165. DMFDBV5 RU https://pubmed.ncbi.nlm.nih.gov/30385782 DMFDKS7 DI DMFDKS7 DMFDKS7 DN RG-7348 DMFDKS7 TI TTMVBWH DMFDKS7 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMFDKS7 MA Modulator DMFDKS7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFDKS7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFEI6T DI DMFEI6T DMFEI6T DN IPH5201 DMFEI6T TI TTYM8DJ DMFEI6T TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DMFEI6T MA Inhibitor DMFEI6T RN ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health. DMFEI6T RU https://clinicaltrials.gov/ct2/show/NCT04261075 DMFELMQ DI DMFELMQ DMFELMQ DN AMEP DMFELMQ TI TT69TQN DMFELMQ TN Integrin alpha-V/beta-3 (ITGAV/B3) DMFELMQ MA Modulator DMFELMQ RN Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90. DMFELMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25781650 DMFELMQ DI DMFELMQ DMFELMQ DN AMEP DMFELMQ TI TTH4QIS DMFELMQ TN Integrin alpha-5/beta-1 (ITGA5/B1) DMFELMQ MA Modulator DMFELMQ RN Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma.Gene Ther.2015 Jul;22(7):578-90. DMFELMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25781650 DMFEORD DI DMFEORD DMFEORD DN DNL201 DMFEORD TI TTK0FEA DMFEORD TN Leucine-rich repeat kinase 2 (LRRK2) DMFEORD MA Inhibitor DMFEORD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFEORD RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFG1YA DI DMFG1YA DMFG1YA DN 177Lu-AMBA DMFG1YA TI TTC1MVT DMFG1YA TN Gastrin-releasing peptide receptor (GRPR) DMFG1YA MA Agonist DMFG1YA RN Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res. 2010 Oct;30(10):4039-48. DMFG1YA RU https://pubmed.ncbi.nlm.nih.gov/21036718 DMFG6ML DI DMFG6ML DMFG6ML DN TAS3681 DMFG6ML TI TTS64P2 DMFG6ML TN Androgen receptor (AR) DMFG6ML MA Antagonist DMFG6ML RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFG6ML RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFGQXB DI DMFGQXB DMFGQXB DN CD28 and CD137 CAR-T Cells DMFGQXB TI TTQ13FT DMFGQXB TN T-cell-specific surface glycoprotein CD28 (CD28) DMFGQXB MA CAR-T-Cell-Therapy(Dual specific) DMFGQXB RN ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia DMFGQXB RU https://clinicaltrials.gov/ct2/show/NCT02186860 DMFGQXB DI DMFGQXB DMFGQXB DN CD28 and CD137 CAR-T Cells DMFGQXB TI TTPW9LJ DMFGQXB TN Co-stimulatory molecule 4-1BB (CD137) DMFGQXB MA CAR-T-Cell-Therapy(Dual specific) DMFGQXB RN ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia DMFGQXB RU https://clinicaltrials.gov/ct2/show/NCT02186860 DMFGR98 DI DMFGR98 DMFGR98 DN RG-7351 DMFGR98 TI TTIU98M DMFGR98 TN Trace amine-associated receptor-1 (TAAR1) DMFGR98 MA Agonist DMFGR98 RN Clinical pipeline report, company report or official report of Roche. DMFGR98 RU http://www.roche.com/roche_group_pipeline_2010-02-18.pdf DMFGYKS DI DMFGYKS DMFGYKS DN MK-5108 DMFGYKS TI TT5LS6T DMFGYKS TN Aurora kinase B (AURKB) DMFGYKS MA Inhibitor DMFGYKS RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMFGYKS RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMFGYKS DI DMFGYKS DMFGYKS DN MK-5108 DMFGYKS TI TTPS3C0 DMFGYKS TN Aurora kinase A (AURKA) DMFGYKS MA Inhibitor DMFGYKS RN A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. DMFGYKS RU https://pubmed.ncbi.nlm.nih.gov/23467907 DMFH3JM DI DMFH3JM DMFH3JM DN ABT-767 DMFH3JM TI TTEBCY8 DMFH3JM TN Poly [ADP-ribose] polymerase (PARP) DMFH3JM MA Modulator DMFH3JM RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFH3JM RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMFIS4D DI DMFIS4D DMFIS4D DN MCD-386 DMFIS4D TI TTZ9SOR DMFIS4D TN Muscarinic acetylcholine receptor M1 (CHRM1) DMFIS4D MA Agonist DMFIS4D RN The processing of the selective M1 agonist CDD-0102-J by human hepatic drug metabolizing enzymes. Am J Ther. 2005 Jul-Aug;12(4):300-5. DMFIS4D RU https://pubmed.ncbi.nlm.nih.gov/16041192 DMFJGUL DI DMFJGUL DMFJGUL DN BI 3011441 DMFJGUL TI TTZCRP3 DMFJGUL TN ERK activator kinase (MEK) DMFJGUL MA Inhibitor DMFJGUL RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMFJGUL RU https://www.inoncology.com/ourpipeline/mek-inhibitor DMFJXDZ DI DMFJXDZ DMFJXDZ DN IGM-8444 DMFJXDZ TI TTW20TU DMFJXDZ TN TRAIL receptor 2 (TRAIL-R2) DMFJXDZ MA Agonist DMFJXDZ RN Clinical pipeline report, company report or official report of IGM Biosciences. DMFJXDZ RU https://igmbio.com/pipeline/death-receptor-5/ DMFJZK3 DI DMFJZK3 DMFJZK3 DN Arecoline DMFJZK3 TI TTZ9SOR DMFJZK3 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMFJZK3 MA Inhibitor DMFJZK3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFJZK3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFK7UR DI DMFK7UR DMFK7UR DN Simotaxel DMFK7UR TI TTYFKSZ DMFK7UR TN Tubulin beta (TUBB) DMFK7UR MA Inhibitor DMFK7UR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMFK7UR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMFKEVO DI DMFKEVO DMFKEVO DN KA2237 DMFKEVO TI TTHBTOP DMFKEVO TN PI3-kinase gamma (PIK3CG) DMFKEVO MA Inhibitor DMFKEVO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFKEVO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFLP21 DI DMFLP21 DMFLP21 DN MK 8719 DMFLP21 TI TT2I6UX DMFLP21 TN Beta-N-acetylhexosaminidase (OGA) DMFLP21 MA Inhibitor DMFLP21 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFLP21 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFMGZR DI DMFMGZR DMFMGZR DN CPL207-280CA DMFMGZR TI TTB8FUC DMFMGZR TN Free fatty acid receptor 1 (GPR40) DMFMGZR MA Agonist DMFMGZR RN Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. DMFMGZR RU https://pubmed.ncbi.nlm.nih.gov/31548636 DMFMW5C DI DMFMW5C DMFMW5C DN MVA-BN Breast DMFMW5C TI TTS78AZ DMFMW5C TN Prostate specific antigen (KLK3) DMFMW5C MA Antagonist DMFMW5C RN Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011 Aug 1;71(15):5235-44. DMFMW5C RU https://pubmed.ncbi.nlm.nih.gov/21670078 DMFMWLQ DI DMFMWLQ DMFMWLQ DN JS004 DMFMWLQ TI TTER58P DMFMWLQ TN B- and T-lymphocyte attenuator (BTLA) DMFMWLQ MA Inhibitor DMFMWLQ RN Clinical pipeline report, company report or official report of Junshi Biosciences. DMFMWLQ RU https://www.junshipharma.com/en/Treatment.html DMFNSHM DI DMFNSHM DMFNSHM DN LHF-535 DMFNSHM TI TTD2IK3 DMFNSHM TN Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC) DMFNSHM MA Inhibitor DMFNSHM RN A potent Lassa virus antiviral targets an arenavirus virulence determinant. PLoS Pathog. 2018 Dec 21;14(12):e1007439. DMFNSHM RU https://pubmed.ncbi.nlm.nih.gov/30576397 DMFNYQ9 DI DMFNYQ9 DMFNYQ9 DN ME-401 DMFNYQ9 TI TTGBPJE DMFNYQ9 TN PI3-kinase delta (PIK3CD) DMFNYQ9 MA Inhibitor DMFNYQ9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFNYQ9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFO7RP DI DMFO7RP DMFO7RP DN KW-2449 DMFO7RP TI TT3PJMV DMFO7RP TN Tyrosine-protein kinase ABL1 (ABL) DMFO7RP RN KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17. DMFO7RP RU https://pubmed.ncbi.nlm.nih.gov/19541823 DMFO7RP DI DMFO7RP DMFO7RP DN KW-2449 DMFO7RP TI TTGJCWZ DMFO7RP TN Fms-like tyrosine kinase 3 (FLT-3) DMFO7RP RN KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17. DMFO7RP RU https://pubmed.ncbi.nlm.nih.gov/19541823 DMFO7RP DI DMFO7RP DMFO7RP DN KW-2449 DMFO7RP TI TTRLW2X DMFO7RP TN Fibroblast growth factor receptor 1 (FGFR1) DMFO7RP RN KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009 Aug 20;114(8):1607-17. DMFO7RP RU https://pubmed.ncbi.nlm.nih.gov/19541823 DMFOXGB DI DMFOXGB DMFOXGB DN INCB81776 DMFOXGB TI TTO7LKR DMFOXGB TN Tyrosine-protein kinase Mer (MERTK) DMFOXGB MA Inhibitor DMFOXGB RN A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477. DMFOXGB RU https://pubmed.ncbi.nlm.nih.gov/33425754 DMFOXGB DI DMFOXGB DMFOXGB DN INCB81776 DMFOXGB TI TTZPY6J DMFOXGB TN Tyrosine-protein kinase UFO (AXL) DMFOXGB MA Inhibitor DMFOXGB RN A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity. Front Oncol. 2020 Dec 7;10:598477. DMFOXGB RU https://pubmed.ncbi.nlm.nih.gov/33425754 DMFRM15 DI DMFRM15 DMFRM15 DN HX-100 DMFRM15 TI TTELV3W DMFRM15 TN Transformation-sensitive protein p120 (TRPA1) DMFRM15 MA Inhibitor DMFRM15 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFRM15 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMFSMCB DI DMFSMCB DMFSMCB DN Patritumab DMFSMCB TI TTDC8N2 DMFSMCB TN Erbb3 tyrosine kinase receptor (Erbb-3) DMFSMCB RN Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):511-6. DMFSMCB RU https://pubmed.ncbi.nlm.nih.gov/24442032 DMFTAWU DI DMFTAWU DMFTAWU DN mRNA-2416 DMFTAWU TI TTBW580 DMFTAWU TN TAX transcriptionally-activated glycoprotein 1 (OX40) DMFTAWU MA Replacement DMFTAWU RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMFTAWU RU https://www.modernatx.com/mrna-2416 DMFTGHX DI DMFTGHX DMFTGHX DN Ad5CMV-NIS DMFTGHX TI TTW7HI9 DMFTGHX TN Sodium/iodide cotransporter (SLC5A5) DMFTGHX MA Modulator DMFTGHX RN Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter. Mol Ther. 2009 December; 17(12): 2041-2048. DMFTGHX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810133/ DMFU0H5 DI DMFU0H5 DMFU0H5 DN LY3410738 DMFU0H5 TI TTV2A1R DMFU0H5 TN Oxalosuccinate decarboxylase (IDH1) DMFU0H5 MA Inhibitor DMFU0H5 RN LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML). Cancer Res 2020;80(16 Suppl):Abstract nr 6417. DMFU0H5 RU https://cancerres.aacrjournals.org/content/80/16_Supplement/6417 DMFU58V DI DMFU58V DMFU58V DN AG2034 DMFU58V TI TTCSJBZ DMFU58V TN GAR transformylase (GART) DMFU58V MA Modulator DMFU58V RN Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol. 2000;45(5):423-7. DMFU58V RU https://pubmed.ncbi.nlm.nih.gov/10803927 DMFVT43 DI DMFVT43 DMFVT43 DN E7046 DMFVT43 TI TT79WV3 DMFVT43 TN Prostaglandin E2 receptor EP4 (PTGER4) DMFVT43 MA Antagonist DMFVT43 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMFVT43 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMFWPLQ DI DMFWPLQ DMFWPLQ DN MEDI-565 DMFWPLQ TI TTV3XPL DMFWPLQ TN T-cell surface glycoprotein CD3 gamma (CD3G) DMFWPLQ MA Modulator DMFWPLQ RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMFWPLQ RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMFYKDX DI DMFYKDX DMFYKDX DN UK-396082 DMFYKDX TI TTP18AY DMFYKDX TN Carboxypeptidase B2 (CPB2) DMFYKDX MA Inhibitor DMFYKDX RN Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6. DMFYKDX RU https://pubmed.ncbi.nlm.nih.gov/19954973 DMFZ52G DI DMFZ52G DMFZ52G DN Anti-OX40 mab DMFZ52G TI TTL31H0 DMFZ52G TN OX40L receptor (CD134) DMFZ52G MA Modulator DMFZ52G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1873). DMFZ52G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873 DMG0Q27 DI DMG0Q27 DMG0Q27 DN MK-3281 DMG0Q27 TI TTMVBWH DMG0Q27 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMG0Q27 MA Inhibitor DMG0Q27 RN Clinical pipeline report, company report or official report of Merck (2011). DMG0Q27 RU http://www.merck.com/index.html DMG0SPO DI DMG0SPO DMG0SPO DN CS-0777 DMG0SPO TI TT9JZCK DMG0SPO TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMG0SPO MA Modulator DMG0SPO RN Discovery of CS-0777: A Potent, Selective, and Orally Active S1P1 Agonist. ACS Med Chem Lett. 2011 Mar 2;2(5):368-72. DMG0SPO RU https://pubmed.ncbi.nlm.nih.gov/24900318 DMG0SWE DI DMG0SWE DMG0SWE DN NBF-006 DMG0SWE TI TT48Z3K DMG0SWE TN GSTP1 messenger RNA (GSTP1 mRNA) DMG0SWE MA Inhibitor DMG0SWE RN Clinical pipeline report, company report or official report of Nitto Biopharma. DMG0SWE RU https://www.nittobiopharma.com/index.php DMG2IE5 DI DMG2IE5 DMG2IE5 DN PF-3732010 DMG2IE5 TI TTARMD9 DMG2IE5 TN Placental cadherin (CDH3) DMG2IE5 RN National Cancer Institute Drug Dictionary (drug id 580366). DMG2IE5 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=580366 DMG3J6C DI DMG3J6C DMG3J6C DN BMS-933043 DMG3J6C TI TTLA931 DMG3J6C TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMG3J6C MA Modulator DMG3J6C RN Clinical pipeline report, company report or official report of Phrma.org Alzheimers 2012. DMG3J6C RU http://phrma.org/sites/default/files/pdf/alzheimers2012.pdf DMG4H9Y DI DMG4H9Y DMG4H9Y DN ABT-072 DMG4H9Y TI TTMVBWH DMG4H9Y TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMG4H9Y MA Inhibitor DMG4H9Y RN Clinical pipeline report, company report or official report of Abbott Laboratories (2011) DMG4H9Y RU http://www.abbott.com/index2.htm DMG4QDT DI DMG4QDT DMG4QDT DN MUC-1 dendritic cancer vaccine DMG4QDT TI TTBHFYQ DMG4QDT TN Mucin-1 (MUC1) DMG4QDT RN Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med. 2003 Oct;12(4):493-502. DMG4QDT RU https://pubmed.ncbi.nlm.nih.gov/12964025 DMG4RK0 DI DMG4RK0 DMG4RK0 DN AAD-2004 DMG4RK0 TI TTYLQ8V DMG4RK0 TN Prostaglandin E synthase (PTGES) DMG4RK0 MA Inhibitor DMG4RK0 RN Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012 Sep;122(5):952-61. DMG4RK0 RU https://pubmed.ncbi.nlm.nih.gov/22537108 DMG4U32 DI DMG4U32 DMG4U32 DN TPST-1120 DMG4U32 TI TTJ584C DMG4U32 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMG4U32 MA Antagonist DMG4U32 RN Clinical pipeline report, company report or official report of Tempest Therapeutics. DMG4U32 RU https://www.tempesttx.com/pipeline/ DMG64PE DI DMG64PE DMG64PE DN AMG 506 DMG64PE TI TTGPQ0F DMG64PE TN Prolyl endopeptidase FAP (FAP) DMG64PE MA Inhibitor DMG64PE RN Clinical pipeline report, company report or official report of Amgen. DMG64PE RU https://www.amgenpipeline.com/ DMG64PE DI DMG64PE DMG64PE DN AMG 506 DMG64PE TI TTPW9LJ DMG64PE TN Co-stimulatory molecule 4-1BB (CD137) DMG64PE MA Inhibitor DMG64PE RN Clinical pipeline report, company report or official report of Amgen. DMG64PE RU https://www.amgenpipeline.com/ DMG6HLE DI DMG6HLE DMG6HLE DN LY3303560 DMG6HLE TI TTS87KH DMG6HLE TN Microtubule-associated protein tau (MAPT) DMG6HLE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG6HLE RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMG6NI8 DI DMG6NI8 DMG6NI8 DN SSR-125329A DMG6NI8 TI TT5TPI6 DMG6NI8 TN Opioid receptor sigma 1 (OPRS1) DMG6NI8 MA Binder DMG6NI8 RN SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002 Dec 5;456(1-3):123-31. DMG6NI8 RU https://pubmed.ncbi.nlm.nih.gov/12450578 DMG6S8U DI DMG6S8U DMG6S8U DN INNO-305 DMG6S8U TI TTZ8UT4 DMG6S8U TN Wilms tumor protein (WT1) DMG6S8U MA Modulator DMG6S8U RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023753) DMG6S8U RU http://adisinsight.springer.com/drugs/800023753 DMG74BY DI DMG74BY DMG74BY DN (-)-3PPP, Maryland DMG74BY TI TTEX248 DMG74BY TN Dopamine D2 receptor (D2R) DMG74BY MA Agonist DMG74BY RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMG74BY RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMG75P3 DI DMG75P3 DMG75P3 DN 4SC-205 DMG75P3 TI TTTRP0H DMG75P3 TN Kinesin-like protein KIF11 (KIF11) DMG75P3 MA Inhibitor DMG75P3 RN 2011 Pipeline of 4SC AG. DMG75P3 RU http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html DMG7FLI DI DMG7FLI DMG7FLI DN UCART123 DMG7FLI TI TTENHJ0 DMG7FLI TN Interleukin 3 receptor alpha (IL3RA) DMG7FLI MA CAR-T-Cell-Therapy DMG7FLI RN ClinicalTrials.gov (NCT03190278) Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia DMG7FLI RU https://clinicaltrials.gov/ct2/show/NCT03190278 DMG7I5J DI DMG7I5J DMG7I5J DN DS-3078 DMG7I5J TI TTCJG29 DMG7I5J TN Serine/threonine-protein kinase mTOR (mTOR) DMG7I5J MA Modulator DMG7I5J RN A first-in-human Phase I study of DS-3078a, an oral TORC1/2 inhibitor, in patients with advanced solid tumors: Preliminary results, Mol Cancer Ther November,2013, 12, C173. DMG7I5J RU http://mct.aacrjournals.org/content/12/11_Supplement/C173.abstract DMG7XKP DI DMG7XKP DMG7XKP DN SKF-105494 DMG7XKP TI TTYCILE DMG7XKP TN Vasopressin receptor (VR) DMG7XKP MA Modulator DMG7XKP RN Modulation of vasopressin antidiuretic action by alpha 2-adrenoceptors is species specific. Am J Physiol. 1991 Nov;261(5 Pt 2):R1242-6. DMG7XKP RU https://pubmed.ncbi.nlm.nih.gov/1659234 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TT84ETX DMG82ZA TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TTEC2T3 DMG82ZA TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TT4NXYM DMG82ZA TN Human immunodeficiency virus Negative factor (HIV nef) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TTF7I5O DMG82ZA TN Human immunodeficiency virus Rev protein (HIV rev) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG82ZA DI DMG82ZA DMG82ZA DN Ad35-GRIN/ENV DMG82ZA TI TTFGZB6 DMG82ZA TN Human immunodeficiency virus GAG protein (HIV gag) DMG82ZA RN A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936. DMG82ZA RU https://pubmed.ncbi.nlm.nih.gov/22870265 DMG98QO DI DMG98QO DMG98QO DN M3541 DMG98QO TI TTKBM7V DMG98QO TN ATM serine/threonine kinase (ATM) DMG98QO MA Inhibitor DMG98QO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMG98QO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMG9C4I DI DMG9C4I DMG9C4I DN Galidesivir DMG9C4I TI TTOA6YT DMG9C4I TN MERS-CoV RNA-directed RNA polymerase (RdRp) DMG9C4I MA Inhibitor DMG9C4I RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMG9C4I RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMG9C4I DI DMG9C4I DMG9C4I DN Galidesivir DMG9C4I TI TTKXI53 DMG9C4I TN SARS-CoV RNA-directed RNA polymerase (RdRp) DMG9C4I MA Inhibitor DMG9C4I RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMG9C4I RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMG9C4I DI DMG9C4I DMG9C4I DN Galidesivir DMG9C4I TI TTV1095 DMG9C4I TN COVID-19 RNA-directed RNA polymerase (RdRp) DMG9C4I MA Blocker DMG9C4I RN BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19 DMG9C4I RU https://www.biospace.com/article/releases/biocryst-begins-clinical-trial-with-galidesivir-for-treatment-of-patients-with-covid-19/ DMGA1DS DI DMGA1DS DMGA1DS DN D-0502 DMGA1DS TI TTZAYWL DMGA1DS TN Estrogen receptor (ESR) DMGA1DS MA Degrader DMGA1DS RN Clinical pipeline report, company report or official report of InventisBio. DMGA1DS RU http://www.inventisbio.com/en/product.html?id=1 DMGAKR9 DI DMGAKR9 DMGAKR9 DN AVL-3288 DMGAKR9 TI TTLA931 DMGAKR9 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMGAKR9 MA Modulator DMGAKR9 RN Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PLoS One. 2011;6(11):e27014. DMGAKR9 RU https://pubmed.ncbi.nlm.nih.gov/22096516 DMGAP53 DI DMGAP53 DMGAP53 DN BDD-10103 DMGAP53 TI TTRK8B9 DMGAP53 TN Sodium channel unspecific (NaC) DMGAP53 MA Modulator DMGAP53 RN Clinical pipeline report, company report or official report of Birds Pharma AG. DMGAP53 RU http://www.birdspharma.com/projects/bdd_10103/ DMGAR9Y DI DMGAR9Y DMGAR9Y DN BIT225 DMGAR9Y TI TT5FNQT DMGAR9Y TN Human immunodeficiency virus Protease (HIV PR) DMGAR9Y MA Inhibitor DMGAR9Y RN 2011 Pipeline of Biotron. DMGAR9Y RU http://www.biotron.com.au/ DMGAW0H DI DMGAW0H DMGAW0H DN CER-522 DMGAW0H TI TT7GN3U DMGAW0H TN Apolipoprotein A-I (APOA1) DMGAW0H MA Modulator DMGAW0H RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033541) DMGAW0H RU http://adisinsight.springer.com/drugs/800033541 DMGB32Z DI DMGB32Z DMGB32Z DN PF-06427878 DMGB32Z TI TTRHEQ4 DMGB32Z TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMGB32Z MA Inhibitor DMGB32Z RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGB32Z RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMGBKCJ DI DMGBKCJ DMGBKCJ DN ONO-7475 DMGBKCJ TI TTO7LKR DMGBKCJ TN Tyrosine-protein kinase Mer (MERTK) DMGBKCJ MA Inhibitor DMGBKCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGBKCJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGBKCJ DI DMGBKCJ DMGBKCJ DN ONO-7475 DMGBKCJ TI TTZPY6J DMGBKCJ TN Tyrosine-protein kinase UFO (AXL) DMGBKCJ MA Inhibitor DMGBKCJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGBKCJ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGC2AT DI DMGC2AT DMGC2AT DN TR1801-ADC DMGC2AT TI TTNDSF4 DMGC2AT TN Proto-oncogene c-Met (MET) DMGC2AT RN TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors. Mol Oncol. 2020 Jan;14(1):54-68. DMGC2AT RU https://pubmed.ncbi.nlm.nih.gov/31736230 DMGDARN DI DMGDARN DMGDARN DN AP32788 DMGDARN TI TTGKNB4 DMGDARN TN Epidermal growth factor receptor (EGFR) DMGDARN MA Inhibitor DMGDARN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGDARN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMGDJQR DI DMGDJQR DMGDJQR DN BMS-394136 DMGDJQR TI TTW0CMT DMGDJQR TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMGDJQR MA Modulator DMGDJQR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMGDJQR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMGE3DY DI DMGE3DY DMGE3DY DN 18-MC DMGE3DY TI TT35UGH DMGE3DY TN Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4) DMGE3DY MA Antagonist DMGE3DY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGE3DY RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMGF71W DI DMGF71W DMGF71W DN GRN163 DMGF71W TI TTUJFD0 DMGF71W TN Telomerase reverse transcriptase (TERT) DMGF71W MA Inhibitor DMGF71W RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMGF71W RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMGFABM DI DMGFABM DMGFABM DN BC-3205 DMGFABM TI TTUWYEA DMGFABM TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMGFABM MA Modulator DMGFABM RN Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics. J Clin Microbiol. 2012 October; 50(10): 3361-3364. DMGFABM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3457460/ DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TT0EOB8 DMGFAVQ TN B-Raf messenger RNA (BRAF mRNA) DMGFAVQ MA Inhibitor DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TT5TURO DMGFAVQ TN A-Raf messenger RNA (ARAF mRNA) DMGFAVQ MA Inhibitor DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TTROQ37 DMGFAVQ TN MAPK/ERK kinase kinase (MAP3K) DMGFAVQ MA Inhibitor DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TTAN5W2 DMGFAVQ TN Raf messenger RNA (Raf mRNA) DMGFAVQ MA Modulator DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TTZCRP3 DMGFAVQ TN ERK activator kinase (MEK) DMGFAVQ MA Modulator DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFAVQ DI DMGFAVQ DMGFAVQ DN RG7304 DMGFAVQ TI TT1EDJZ DMGFAVQ TN Microtubule-associated protein (MAP) DMGFAVQ MA Modulator DMGFAVQ RN Clinical pipeline report, company report or official report of Roche. DMGFAVQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGFH7T DI DMGFH7T DMGFH7T DN BI-836880 DMGFH7T TI TT9HKJA DMGFH7T TN Vascular endothelial growth factor (VEGF) DMGFH7T MA Inhibitor DMGFH7T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGFH7T RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMGFTAI DI DMGFTAI DMGFTAI DN SHR0534 DMGFTAI TI TTB8FUC DMGFTAI TN Free fatty acid receptor 1 (GPR40) DMGFTAI MA Agonist DMGFTAI RN Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. DMGFTAI RU https://pubmed.ncbi.nlm.nih.gov/31548636 DMGFTAI DI DMGFTAI DMGFTAI DN SHR0534 DMGFTAI TI TTG0MQD DMGFTAI TN Inflammation-related GPCR EX33 (GPR84) DMGFTAI MA Agonist DMGFTAI RN Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75. DMGFTAI RU https://pubmed.ncbi.nlm.nih.gov/31548636 DMGFVYL DI DMGFVYL DMGFVYL DN ALO-1567 DMGFVYL TI TTFBNVI DMGFVYL TN Aldose reductase (AKR1B1) DMGFVYL MA Inhibitor DMGFVYL RN Metabolism of the aldose reductase inhibitor ALO1567 in man. Br J Clin Pharmacol. 1991 Aug;32(2):221-7. DMGFVYL RU https://pubmed.ncbi.nlm.nih.gov/1931471 DMGHN98 DI DMGHN98 DMGHN98 DN GS-9901 DMGHN98 TI TTGBPJE DMGHN98 TN PI3-kinase delta (PIK3CD) DMGHN98 MA Inhibitor DMGHN98 RN Clinical pipeline report, company report or official report of Gilead. DMGHN98 RU http://www.gilead.com/research/pipeline DMGI58S DI DMGI58S DMGI58S DN CAR-T cells targeting Lewis-Y DMGI58S TI TTV75BJ DMGI58S TN Carbohydrate antigen Lewis-Y (Lewis-Y) DMGI58S MA CAR-T-Cell-Therapy DMGI58S RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMGI58S RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMGIAND DI DMGIAND DMGIAND DN ALLO-501 DMGIAND TI TTW640A DMGIAND TN B-lymphocyte surface antigen B4 (CD19) DMGIAND RN Clinical pipeline report, company report or official report of Allogene Therapeutics. DMGIAND RU https://www.allogene.com/pipeline#all0-501/501A DMGJ7A4 DI DMGJ7A4 DMGJ7A4 DN A/Anhui/05 DMGJ7A4 TI TTF4CAM DMGJ7A4 TN Influenza Hemagglutinin (Influ HA) DMGJ7A4 RN A Human Antibody Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses. J Virol. 2012 March; 86(6): 2978-2989. DMGJ7A4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3302345/ DMGJCDR DI DMGJCDR DMGJCDR DN Teneligliptin DMGJCDR TI TTDIGC1 DMGJCDR TN Dipeptidyl peptidase 4 (DPP-4) DMGJCDR MA Modulator DMGJCDR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DMGJCDR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DMGJNTQ DI DMGJNTQ DMGJNTQ DN FT-819 DMGJNTQ TI TTW640A DMGJNTQ TN B-lymphocyte surface antigen B4 (CD19) DMGJNTQ RN Clinical pipeline report, company report or official report of Fate Therapeutics. DMGJNTQ RU https://fatetherapeutics.com/pipeline/immuno-oncology-candidates/ft819/ DMGLEM1 DI DMGLEM1 DMGLEM1 DN PF9601N DMGLEM1 TI TTGP7BY DMGLEM1 TN Monoamine oxidase type B (MAO-B) DMGLEM1 MA Inhibitor DMGLEM1 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMGLEM1 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMGLHYU DI DMGLHYU DMGLHYU DN Enkastim-ev DMGLHYU TI TTHYBIX DMGLHYU TN Heat shock protein 70 (HSP70) DMGLHYU MA Modulator DMGLHYU RN Company report (Multimmune) DMGLHYU RU http://www.multimmune.com/mi-THERAPEUTICS-PIPELINE/ DMGLTE2 DI DMGLTE2 DMGLTE2 DN LY2922470 DMGLTE2 TI TTB8FUC DMGLTE2 TN Free fatty acid receptor 1 (GPR40) DMGLTE2 MA Agonist DMGLTE2 RN The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916. DMGLTE2 RU https://pubmed.ncbi.nlm.nih.gov/27749056 DMGLXQ9 DI DMGLXQ9 DMGLXQ9 DN RG7854 DMGLXQ9 TI TTRJ1K4 DMGLXQ9 TN Toll-like receptor 7 (TLR7) DMGLXQ9 MA Agonist DMGLXQ9 RN Clinical pipeline report, company report or official report of Roche. DMGLXQ9 RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMGMEH7 DI DMGMEH7 DMGMEH7 DN VGX-3400 DMGMEH7 TI TTF4CAM DMGMEH7 TN Influenza Hemagglutinin (Influ HA) DMGMEH7 RN Clinical pipeline report, company report or official report of Inovio Pharmaceuticals. DMGMEH7 RU http://www.inovio.com/products/infectious-disease-vaccines/influenza/pandemic/ DMGMFXJ DI DMGMFXJ DMGMFXJ DN BI 1701963 DMGMFXJ TI TTB1RA4 DMGMFXJ TN GTPase KRas (KRAS) DMGMFXJ MA Inhibitor DMGMFXJ RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMGMFXJ RU https://www.boehringer-ingelheim.com/press-release/first-pan-kras-inhibitor-advances-clinical-testing DMGMI8P DI DMGMI8P DMGMI8P DN CMP-001 DMGMI8P TI TTSHG0T DMGMI8P TN Toll-like receptor 9 (TLR9) DMGMI8P MA Agonist DMGMI8P RN Clinical pipeline report, company report or official report of Checkmate Pharmaceuticals. DMGMI8P RU https://checkmatepharma.com/pipeline/ DMGN96R DI DMGN96R DMGN96R DN Ipafricept DMGN96R TI TTVZ87F DMGN96R TN Wnt protein (WNT) DMGN96R MA Modulator DMGN96R RN Clinical pipeline report, company report or official report of OncoMed Pharmaceuticals. DMGN96R RU http://www.oncomed.com/Pipeline.html DMGO4XJ DI DMGO4XJ DMGO4XJ DN DFP-14927 DMGO4XJ TI TTATL6Y DMGO4XJ TN DNA-dependent DNA polymerase (DPOL) DMGO4XJ MA Inhibitor DMGO4XJ RN National Cancer Institute Drug Dictionary (drug name DFP14927). DMGO4XJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927 DMGO4XJ DI DMGO4XJ DMGO4XJ DN DFP-14927 DMGO4XJ TI TTUTN1I DMGO4XJ TN Human Deoxyribonucleic acid (hDNA) DMGO4XJ MA Inhibitor DMGO4XJ RN National Cancer Institute Drug Dictionary (drug name DFP14927). DMGO4XJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/pegylated-deoxycytidine-analogue-dfp-14927 DMGO6M1 DI DMGO6M1 DMGO6M1 DN GZ402666 DMGO6M1 TI TTLPC70 DMGO6M1 TN Lysosomal alpha-glucosidase (GAA) DMGO6M1 MA Modulator DMGO6M1 RN ClinicalTrials.gov (NCT01898364) Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.. U.S. National Institutes of Health. DMGO6M1 RU https://clinicaltrials.gov/ct2/show/NCT01898364 DMGONUE DI DMGONUE DMGONUE DN AB680 DMGONUE TI TTK0O6Y DMGONUE TN Ecto-5'-nucleotidase (CD73) DMGONUE MA Inhibitor DMGONUE RN Discovery of AB680: A Potent and Selective Inhibitor of CD73. J Med Chem. 2020 Oct 22;63(20):11448-11468. DMGONUE RU https://pubmed.ncbi.nlm.nih.gov/32614585 DMGPIV0 DI DMGPIV0 DMGPIV0 DN STA-5312 DMGPIV0 TI TTYFKSZ DMGPIV0 TN Tubulin beta (TUBB) DMGPIV0 MA Inhibitor DMGPIV0 RN Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 11/2006; 16(19):5164-8. DMGPIV0 RU http://pubs.acs.org/doi/abs/10.1021/op6002852 DMGPR1C DI DMGPR1C DMGPR1C DN CART-EGFRvIII T cells DMGPR1C TI TTZ6B2I DMGPR1C TN Epidermal growth factor receptor variant III (EGFR vIII) DMGPR1C MA CAR-T-Cell-Therapy DMGPR1C RN ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma DMGPR1C RU https://clinicaltrials.gov/ct2/show/NCT02209376 DMGSDPL DI DMGSDPL DMGSDPL DN NK-314 DMGSDPL TI TT0IHXV DMGSDPL TN DNA topoisomerase II (TOP2) DMGSDPL MA Modulator DMGSDPL RN NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. DMGSDPL RU https://pubmed.ncbi.nlm.nih.gov/18596031 DMGSEB0 DI DMGSEB0 DMGSEB0 DN CKD-516 DMGSEB0 TI TTYFKSZ DMGSEB0 TN Tubulin beta (TUBB) DMGSEB0 MA Inhibitor DMGSEB0 RN CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model. Invest New Drugs. 2014 Jun;32(3):400-11. DMGSEB0 RU https://pubmed.ncbi.nlm.nih.gov/24202729 DMGTL8Z DI DMGTL8Z DMGTL8Z DN ZP-1848 DMGTL8Z TI TT1YWO5 DMGTL8Z TN Glucagon-like peptide 2 receptor (GLP2R) DMGTL8Z MA Modulator DMGTL8Z RN US patent application no. 8,580,918, Peptidic glp-2 agonists. DMGTL8Z RU http://www.google.com/patents/US8580918 DMGUKRN DI DMGUKRN DMGUKRN DN PF-06648671 DMGUKRN TI TT9W8GU DMGUKRN TN Gamma-secretase (GS) DMGUKRN MA Modulator DMGUKRN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMGUKRN RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMGUM90 DI DMGUM90 DMGUM90 DN Anti-CD133-CAR vector-transduced T cells DMGUM90 TI TTXMZ81 DMGUM90 TN Prominin-1 (PROM1) DMGUM90 MA CAR-T-Cell-Therapy DMGUM90 RN ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133 DMGUM90 RU https://clinicaltrials.gov/ct2/show/NCT02541370 DMGUQ8V DI DMGUQ8V DMGUQ8V DN CD19+ CAR T Cells DMGUQ8V TI TTW640A DMGUQ8V TN B-lymphocyte surface antigen B4 (CD19) DMGUQ8V MA CAR-T-Cell-Therapy DMGUQ8V RN ClinicalTrials.gov (NCT02529813) CD19+ CAR T Cells for Lymphoid Malignancies DMGUQ8V RU https://clinicaltrials.gov/ct2/show/NCT02529813 DMGWC86 DI DMGWC86 DMGWC86 DN OMP-52M51 DMGWC86 TI TTB1STW DMGWC86 TN Notch-1 receptor (NOTCH1) DMGWC86 RN National Cancer Institute Drug Dictionary (drug id 741867). DMGWC86 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=741867 DMGXS8L DI DMGXS8L DMGXS8L DN CD20Bi aATC DMGXS8L TI TTUN7MC DMGXS8L TN T-cell surface glycoprotein CD3 (CD3) DMGXS8L MA Modulator DMGXS8L RN CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. DMGXS8L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/ DMGXS8L DI DMGXS8L DMGXS8L DN CD20Bi aATC DMGXS8L TI TTUE541 DMGXS8L TN Leukocyte surface antigen Leu-16 (CD20) DMGXS8L MA Modulator DMGXS8L RN CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. DMGXS8L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794673/ DMH0D5M DI DMH0D5M DMH0D5M DN OI287GT DMH0D5M TI TTZOPHG DMH0D5M TN Insulin (INS) DMH0D5M MA Modulator DMH0D5M RN Company report (Novonordisk) DMH0D5M RU http://www.novonordisk.com/bin/getPDF.1698237.pdf DMH1NXO DI DMH1NXO DMH1NXO DN FP-025 DMH1NXO TI TTXZ0KQ DMH1NXO TN Matrix metalloproteinase-12 (MMP-12) DMH1NXO MA Inhibitor DMH1NXO RN Potential clinical implications of recent matrix metalloproteinase inhibitor design strategies. Expert Rev Proteomics. 2015;12(5):445-7. DMH1NXO RU https://www.ncbi.nlm.nih.gov/pubmed/26174966 DMH3E5C DI DMH3E5C DMH3E5C DN TMB-365 DMH3E5C TI TTN2JFW DMH3E5C TN T-cell surface glycoprotein CD4 (CD4) DMH3E5C RN Clinical pipeline report, company report or official report of TaiMed Biologics. DMH3E5C RU http://www.taimedbiologics.com/pipeline/36 DMH6SNO DI DMH6SNO DMH6SNO DN OP-R003 DMH6SNO TI TTT1V78 DMH6SNO TN Interleukin-6 (IL6) DMH6SNO MA Modulator DMH6SNO RN A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma DMH6SNO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787636 DMH701Q DI DMH701Q DMH701Q DN CFI-402257 DMH701Q TI TTP7EGM DMH701Q TN Dual specificity protein kinase TTK (MPS1) DMH701Q MA Inhibitor DMH701Q RN Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer. Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3127-3132. DMH701Q RU https://pubmed.ncbi.nlm.nih.gov/28270606 DMH76KD DI DMH76KD DMH76KD DN Syntropin DMH76KD TI TTKMAZ6 DMH76KD TN Growth hormone receptor (GHR) DMH76KD MA Modulator DMH76KD RN Late feedback effects of hypothalamic-pituitary-adrenal axis hormones in healthy subjects. Psychoneuroendocrinology. 1998 May;23(4):371-83. DMH76KD RU https://pubmed.ncbi.nlm.nih.gov/9695137 DMH789J DI DMH789J DMH789J DN AntiCD19 CART DMH789J TI TTW640A DMH789J TN B-lymphocyte surface antigen B4 (CD19) DMH789J MA CAR-T-Cell-Therapy DMH789J RN ClinicalTrials.gov (NCT03434769) AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma DMH789J RU https://clinicaltrials.gov/ct2/show/NCT03434769 DMH86KO DI DMH86KO DMH86KO DN PCSK9 Adnectin DMH86KO TI TTBRG7E DMH86KO TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMH86KO MA Modulator DMH86KO RN Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J Pharmacol Exp Ther. 2014 Aug;350(2):412-24. DMH86KO RU https://pubmed.ncbi.nlm.nih.gov/24917546 DMH8UF0 DI DMH8UF0 DMH8UF0 DN SY-1425 DMH8UF0 TI TTW38KT DMH8UF0 TN Retinoic acid receptor alpha (RARA) DMH8UF0 MA Agonist DMH8UF0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMH8UF0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMH8VXE DI DMH8VXE DMH8VXE DN MSB2311 DMH8VXE TI TT8ZLTI DMH8VXE TN Programmed cell death 1 ligand 1 (PD-L1) DMH8VXE RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMH8VXE RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMH8Z9W DI DMH8Z9W DMH8Z9W DN ADVAX DMH8Z9W TI TTRPO9Z DMH8Z9W TN TNF-alpha signaling pathway (TNFA pathway) DMH8Z9W MA Modulator DMH8Z9W RN Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617. DMH8Z9W RU https://pubmed.ncbi.nlm.nih.gov/20111582 DMH9M62 DI DMH9M62 DMH9M62 DN AMP-224 DMH9M62 TI TTNBFWK DMH9M62 TN Programmed cell death protein 1 (PD-1) DMH9M62 MA Modulator DMH9M62 RN National Cancer Institute Drug Dictionary (drug id 700595). DMH9M62 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=700595 DMHARE7 DI DMHARE7 DMHARE7 DN NP-500 DMHARE7 TI TTZOPHG DMHARE7 TN Insulin (INS) DMHARE7 MA Modulator DMHARE7 RN Napo Receives Commitments for a Private Placement of Common Shares and Enters into Binding Letter of Intent for Intellectual Property License. Napo. JANUARY 08, 2007 DMHARE7 RU http://www.prnewswire.com/news-releases/napo-receives-commitments-for-a-private-placement-of-common-shares-and-enters-into-binding-letter-of-intent-for-intellectual-property-license-53349492.html DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTV9A7R DMHAZLM TN Lactoylglutathione lyase (GLO1) DMHAZLM MA Inhibitor DMHAZLM RN Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/18258440 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTOM3J0 DMHAZLM TN Estrogen receptor beta (ESR2) DMHAZLM MA Inhibitor DMHAZLM RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTI84H7 DMHAZLM TN Cytochrome P450 1B1 (CYP1B1) DMHAZLM MA Inhibitor DMHAZLM RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTSZLWK DMHAZLM TN Aromatase (CYP19A1) DMHAZLM MA Inhibitor DMHAZLM RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMHAZLM DI DMHAZLM DMHAZLM DN Naringenin DMHAZLM TI TTIWB6L DMHAZLM TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMHAZLM MA Inhibitor DMHAZLM RN Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99. DMHAZLM RU https://pubmed.ncbi.nlm.nih.gov/18533708 DMHBD3T DI DMHBD3T DMHBD3T DN SBT6050 DMHBD3T TI TT6EO5L DMHBD3T TN Erbb2 tyrosine kinase receptor (HER2) DMHBD3T RN Clinical pipeline report, company report or official report of Silverback Therapeutics. DMHBD3T RU https://silverbacktx.com/pipeline/#sbt6050 DMHBD3T DI DMHBD3T DMHBD3T DN SBT6050 DMHBD3T TI TT8CWFK DMHBD3T TN Toll-like receptor 8 (TLR8) DMHBD3T MA Agonist DMHBD3T RN Clinical pipeline report, company report or official report of Silverback Therapeutics. DMHBD3T RU https://silverbacktx.com/pipeline/#sbt6050 DMHBEKM DI DMHBEKM DMHBEKM DN AZD0284 DMHBEKM TI TTGV6LY DMHBEKM TN Nuclear receptor ROR-gamma (RORG) DMHBEKM MA Agonist DMHBEKM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHBEKM RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHBK6L DI DMHBK6L DMHBK6L DN CTAP-201 DMHBK6L TI TTK59TV DMHBK6L TN Vitamin D3 receptor (VDR) DMHBK6L MA Agonist DMHBK6L RN Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. Br J Pharmacol. 2009 April; 156(8): 1267-1278. DMHBK6L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697742/ DMHBNKP DI DMHBNKP DMHBNKP DN C-Met/PD-L1 CAR-T Cell DMHBNKP TI TTNDSF4 DMHBNKP TN Proto-oncogene c-Met (MET) DMHBNKP MA CAR-T-Cell-Therapy(Dual specific) DMHBNKP RN ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC DMHBNKP RU https://clinicaltrials.gov/ct2/show/NCT03672305 DMHBNKP DI DMHBNKP DMHBNKP DN C-Met/PD-L1 CAR-T Cell DMHBNKP TI TT8ZLTI DMHBNKP TN Programmed cell death 1 ligand 1 (PD-L1) DMHBNKP MA CAR-T-Cell-Therapy(Dual specific) DMHBNKP RN ClinicalTrials.gov (NCT03672305) Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC DMHBNKP RU https://clinicaltrials.gov/ct2/show/NCT03672305 DMHBUMZ DI DMHBUMZ DMHBUMZ DN AFP TCR DMHBUMZ TI TT7AKW1 DMHBUMZ TN T-cell receptor (TCR) DMHBUMZ MA Immunomodulator DMHBUMZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHBUMZ RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMHCBI0 DI DMHCBI0 DMHCBI0 DN AIP-303 DMHCBI0 TI TT6EO5L DMHCBI0 TN Erbb2 tyrosine kinase receptor (HER2) DMHCBI0 RN Clinical pipeline report, company report or official report of Adagene. DMHCBI0 RU https://www.advancedinnovativepartners.com/technology DMHCUZV DI DMHCUZV DMHCUZV DN SEL120 DMHCUZV TI TTBJR4L DMHCUZV TN Cyclin-dependent kinase 8 (CDK8) DMHCUZV MA Inhibitor DMHCUZV RN Clinical pipeline report, company report or official report of Ryvu Therapeutics. DMHCUZV RU https://ryvu.com/pipeline/ DMHCUZV DI DMHCUZV DMHCUZV DN SEL120 DMHCUZV TI TTNABU9 DMHCUZV TN Cyclin-dependent kinase 19 (CDK19) DMHCUZV MA Inhibitor DMHCUZV RN Clinical pipeline report, company report or official report of Ryvu Therapeutics. DMHCUZV RU https://ryvu.com/pipeline/ DMHD615 DI DMHD615 DMHD615 DN ALB-109564(a) DMHD615 TI TTYFKSZ DMHD615 TN Tubulin beta (TUBB) DMHD615 MA Modulator DMHD615 RN 2010 ASCO Annual Meeting DMHD615 RU http://meetinglibrary.asco.org/content/41250-74 DMHD6PA DI DMHD6PA DMHD6PA DN TnMUC-1 CAR-T cell therapy DMHD6PA TI TTBHFYQ DMHD6PA TN Mucin-1 (MUC1) DMHD6PA MA Inhibitor DMHD6PA RN ClinicalTrials.gov (NCT04025216) A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers. U.S. National Institutes of Health. DMHD6PA RU https://clinicaltrials.gov/ct2/show/NCT04025216 DMHD8CF DI DMHD8CF DMHD8CF DN TRV734 DMHD8CF TI TTKWM86 DMHD8CF TN Opioid receptor mu (MOP) DMHD8CF MA Agonist DMHD8CF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHD8CF RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMHDCSL DI DMHDCSL DMHDCSL DN LZM009 DMHDCSL TI TTNBFWK DMHDCSL TN Programmed cell death protein 1 (PD-1) DMHDCSL RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMHDCSL RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMHDSYF DI DMHDSYF DMHDSYF DN CRX-675 DMHDSYF TI TTISGCA DMHDSYF TN Toll-like receptor 4 (TLR4) DMHDSYF MA Agonist DMHDSYF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DMHDSYF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DMHE3MD DI DMHE3MD DMHE3MD DN ALLO-715 DMHE3MD TI TTZ3P4W DMHE3MD TN B-cell maturation protein (TNFRSF17) DMHE3MD RN Clinical pipeline report, company report or official report of Allogene Therapeutics. DMHE3MD RU https://www.allogene.com/pipeline#all0-501/501A DMHELFU DI DMHELFU DMHELFU DN BF-389 DMHELFU TI TT2J34L DMHELFU TN Arachidonate 5-lipoxygenase (5-LOX) DMHELFU MA Modulator DMHELFU RN Antiarthritic profile of BF-389--a novel anti-inflammatory agent with low ulcerogenic liability. Agents Actions. 1992 Sep;37(1-2):90-8. DMHELFU RU https://pubmed.ncbi.nlm.nih.gov/1456184 DMHG4Q9 DI DMHG4Q9 DMHG4Q9 DN ICAR19 CAR-T cells DMHG4Q9 TI TTW640A DMHG4Q9 TN B-lymphocyte surface antigen B4 (CD19) DMHG4Q9 MA CAR-T-Cell-Therapy DMHG4Q9 RN ClinicalTrials.gov (NCT03383952) A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia DMHG4Q9 RU https://clinicaltrials.gov/ct2/show/NCT03383952 DMHG7DZ DI DMHG7DZ DMHG7DZ DN UltraCD40L DMHG7DZ TI TTIJP3Q DMHG7DZ TN TNF related activation protein (CD40LG) DMHG7DZ MA Modulator DMHG7DZ RN CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357. DMHG7DZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3569584/ DMHI8RS DI DMHI8RS DMHI8RS DN HCBE-11 DMHI8RS TI TTFO0PM DMHI8RS TN Lymphotoxin beta receptor (LTBR) DMHI8RS RN Lymphotoxin beta receptor activation on macrophages induces cross-tolerance to TLR4 and TLR9 ligands. J Immunol. 2012 Apr 1;188(7):3426-33. DMHI8RS RU https://pubmed.ncbi.nlm.nih.gov/22357629 DMHIA7Y DI DMHIA7Y DMHIA7Y DN TAS-1440 DMHIA7Y TI TTNR0UQ DMHIA7Y TN Lysine-specific histone demethylase 1 (LSD) DMHIA7Y MA Inhibitor DMHIA7Y RN Clinical pipeline report, company report or official report of Astex Pharmaceuticals. DMHIA7Y RU https://astx.com/tas1440-oral-lsd1-inhibitor-hematological-malignancies/ DMHIPF5 DI DMHIPF5 DMHIPF5 DN ADV-1002401 DMHIPF5 TI TTDLNGZ DMHIPF5 TN Glucokinase (GCK) DMHIPF5 MA Inhibitor DMHIPF5 RN The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats. PLoS One. 2014; 9(5): e97139. DMHIPF5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4032240/ DMHIS3M DI DMHIS3M DMHIS3M DN PRAX-330 DMHIS3M TI TT54ERL DMHIS3M TN Voltage-gated sodium channel alpha Nav1.6 (SCN8A) DMHIS3M MA Inhibitor DMHIS3M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHIS3M RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMHJLB6 DI DMHJLB6 DMHJLB6 DN CC-90006 DMHJLB6 TI TTNBFWK DMHJLB6 TN Programmed cell death protein 1 (PD-1) DMHJLB6 MA Antagonist DMHJLB6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHJLB6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMHK9WR DI DMHK9WR DMHK9WR DN CTX-101 DMHK9WR TI TTW640A DMHK9WR TN B-lymphocyte surface antigen B4 (CD19) DMHK9WR RN Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199. DMHK9WR RU https://pubmed.ncbi.nlm.nih.gov/31900462 DMHMDC0 DI DMHMDC0 DMHMDC0 DN JWCAR029 DMHMDC0 TI TTW640A DMHMDC0 TN B-lymphocyte surface antigen B4 (CD19) DMHMDC0 MA CAR-T-Cell-Therapy DMHMDC0 RN ClinicalTrials.gov (NCT03344367) Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma DMHMDC0 RU https://clinicaltrials.gov/ct2/show/NCT03344367 DMHMG6X DI DMHMG6X DMHMG6X DN SX-682 DMHMG6X TI TTMWT8Z DMHMG6X TN C-X-C chemokine receptor type 1 (CXCR1) DMHMG6X MA Inhibitor DMHMG6X RN Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. DMHMG6X RU https://pubmed.ncbi.nlm.nih.gov/31848188 DMHMG6X DI DMHMG6X DMHMG6X DN SX-682 DMHMG6X TI TT30C9G DMHMG6X TN C-X-C chemokine receptor type 2 (CXCR2) DMHMG6X MA Inhibitor DMHMG6X RN Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431. DMHMG6X RU https://pubmed.ncbi.nlm.nih.gov/31848188 DMHMPK1 DI DMHMPK1 DMHMPK1 DN CD22-CART DMHMPK1 TI TTM6QSK DMHMPK1 TN B-cell receptor CD22 (CD22) DMHMPK1 MA CAR-T-Cell-Therapy(Dual specific) DMHMPK1 RN ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL DMHMPK1 RU https://clinicaltrials.gov/ct2/show/NCT03407859 DMHMZC7 DI DMHMZC7 DMHMZC7 DN GCC-4401 DMHMZC7 TI TTCIHJA DMHMZC7 TN Coagulation factor Xa (F10) DMHMZC7 MA Inhibitor DMHMZC7 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMHMZC7 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMHNZ3U DI DMHNZ3U DMHNZ3U DN PRT543 DMHNZ3U TI TTR1D7X DMHNZ3U TN Protein arginine methyltransferase 5 (PRMT5) DMHNZ3U MA Inhibitor DMHNZ3U RN Clinical pipeline report, company report or official report of Prelude Therapeutics. DMHNZ3U RU https://preludetx.com/science/prmt5/prt543/ DMHO6XP DI DMHO6XP DMHO6XP DN MyoDys DMHO6XP TI TT48MP6 DMHO6XP TN Dystrophin (DMD) DMHO6XP MA Modulator DMHO6XP RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009280) DMHO6XP RU http://adisinsight.springer.com/drugs/800009280 DMHP71R DI DMHP71R DMHP71R DN IQ-DAA DMHP71R TI TT3YGCD DMHP71R TN Bacterial Protective antigen (Bact pagA) DMHP71R MA Modulator DMHP71R RN Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43. DMHP71R RU https://www.ncbi.nlm.nih.gov/pubmed/19207098 DMHP71R DI DMHP71R DMHP71R DN IQ-DAA DMHP71R TI TTIQSC1 DMHP71R TN Bacterial Lethal factor (Bact lef) DMHP71R MA Modulator DMHP71R RN Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax.Future Microbiol.2009 Feb;4(1):35-43. DMHP71R RU https://www.ncbi.nlm.nih.gov/pubmed/19207098 DMHR7D4 DI DMHR7D4 DMHR7D4 DN REGN-910 DMHR7D4 TI TTKLQTJ DMHR7D4 TN Angiopoietin-2 (ANGPT2) DMHR7D4 RN Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013 Jan 1;73(1):108-18. DMHR7D4 RU https://pubmed.ncbi.nlm.nih.gov/23149917 DMHRY8A DI DMHRY8A DMHRY8A DN THR-687 DMHRY8A TI TTQFP08 DMHRY8A TN Integrin (ITG) DMHRY8A MA Antagonist DMHRY8A RN The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Exp Eye Res. 2019 Mar;180:43-52. DMHRY8A RU https://pubmed.ncbi.nlm.nih.gov/30472075 DMHS29U DI DMHS29U DMHS29U DN Iboctadekin DMHS29U TI TTRICUF DMHS29U TN Interleukin-18 (IL18) DMHS29U MA Modulator DMHS29U RN Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res. 2013 Sep;1(3):168-78. DMHS29U RU https://pubmed.ncbi.nlm.nih.gov/24777679 DMHS79I DI DMHS79I DMHS79I DN MK-1092 DMHS79I TI TTNVEIR DMHS79I TN Prostaglandin D2 receptor (PTGDR) DMHS79I MA Antagonist DMHS79I RN The challenge of modulating -cell autoimmunity in type 1 diabetes. Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64. DMHS79I RU https://pubmed.ncbi.nlm.nih.gov/30528099 DMHT3CB DI DMHT3CB DMHT3CB DN LC-350189 DMHT3CB TI TT7RJY8 DMHT3CB TN Xanthine dehydrogenase/oxidase (XDH) DMHT3CB MA Inhibitor DMHT3CB RN Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49. DMHT3CB RU https://pubmed.ncbi.nlm.nih.gov/26357467 DMHT5XV DI DMHT5XV DMHT5XV DN REC-02 DMHT5XV TI TT4UGTF DMHT5XV TN Stromal cell-derived factor 1 (CXCL12) DMHT5XV MA Modulator DMHT5XV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHT5XV RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMHTEZ8 DI DMHTEZ8 DMHTEZ8 DN BMS-986249 DMHTEZ8 TI TTI2S1D DMHTEZ8 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMHTEZ8 RN Clinical pipeline report, company report or official report of CytomX Therapeutics. DMHTEZ8 RU https://cytomx.com/pipeline/ DMHTNLJ DI DMHTNLJ DMHTNLJ DN CD7.CAR/28zeta CAR T cells DMHTNLJ TI TTP6B8O DMHTNLJ TN T-cell antigen CD7 (CD7) DMHTNLJ MA CAR-T-Cell-Therapy DMHTNLJ RN ClinicalTrials.gov (NCT03690011) Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells DMHTNLJ RU https://clinicaltrials.gov/ct2/show/NCT03690011 DMHTWBL DI DMHTWBL DMHTWBL DN MK-8504 DMHTWBL TI TT84ETX DMHTWBL TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMHTWBL MA Inhibitor DMHTWBL RN ClinicalTrials.gov (NCT03188523) Activity of MK-8504 in Anti-retroviral-naive, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002). U.S. National Institutes of Health. DMHTWBL RU https://clinicaltrials.gov/ct2/show/NCT03188523 DMHV58T DI DMHV58T DMHV58T DN Peldesine DMHV58T TI TTMCF1Y DMHV58T TN Purine nucleoside phosphorylase (PNP) DMHV58T MA Inhibitor DMHV58T RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHV58T RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHVIZC DI DMHVIZC DMHVIZC DN NN-7415 DMHVIZC TI TT068JH DMHVIZC TN Tissue factor pathway inhibitor (TFPI) DMHVIZC MA Modulator DMHVIZC RN Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.J Thromb Haemost.2015 May;13(5):743-54. DMHVIZC RU https://www.ncbi.nlm.nih.gov/pubmed/25641556 DMHW1LI DI DMHW1LI DMHW1LI DN Iptakalim DMHW1LI TI TT1VOHK DMHW1LI TN Potassium channel unspecific (KC) DMHW1LI MA Opener DMHW1LI RN Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4. DMHW1LI RU https://pubmed.ncbi.nlm.nih.gov/22368410 DMHWVY1 DI DMHWVY1 DMHWVY1 DN CART-19 cells DMHWVY1 TI TTW640A DMHWVY1 TN B-lymphocyte surface antigen B4 (CD19) DMHWVY1 MA CAR-T-Cell-Therapy DMHWVY1 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMHWVY1 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMHXA79 DI DMHXA79 DMHXA79 DN Mesothelin-targeted T cells DMHXA79 TI TT4RXME DMHXA79 TN Mesothelin (MSLN) DMHXA79 MA CAR-T-Cell-Therapy DMHXA79 RN ClinicalTrials.gov (NCT02792114) T-Cell Therapy for Advanced Breast Cancer DMHXA79 RU https://clinicaltrials.gov/ct2/show/NCT02792114 DMHYO38 DI DMHYO38 DMHYO38 DN AT-787 DMHYO38 TI TTMVBWH DMHYO38 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMHYO38 MA Inhibitor DMHYO38 RN Clinical pipeline report, company report or official report of Atea Pharmaceuticals. DMHYO38 RU https://ateapharma.com/about-us/hepatitis-c/ DMHZ24N DI DMHZ24N DMHZ24N DN RP-A501 DMHZ24N TI TTULDG7 DMHZ24N TN Lysosome-associated membrane glycoprotein 2 (LAMP2) DMHZ24N MA Replacement DMHZ24N RN ClinicalTrials.gov (NCT03882437) Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B. U.S. National Institutes of Health. DMHZ24N RU https://clinicaltrials.gov/ct2/show/NCT03882437 DMI0KQW DI DMI0KQW DMI0KQW DN HPN217 DMI0KQW TI TTZ3P4W DMI0KQW TN B-cell maturation protein (TNFRSF17) DMI0KQW RN Clinical pipeline report, company report or official report of AbbVie. DMI0KQW RU https://www.abbvie.com/our-science/pipeline/hpn-217.html DMI24RF DI DMI24RF DMI24RF DN OT-82 DMI24RF TI TTD1WIG DMI24RF TN Nicotinamide phosphoribosyltransferase (NAMPT) DMI24RF MA Inhibitor DMI24RF RN OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. Leukemia. 2020 Jul;34(7):1828-1839. DMI24RF RU https://pubmed.ncbi.nlm.nih.gov/31896781 DMI319T DI DMI319T DMI319T DN GS 9667 DMI319T TI TTK25J1 DMI319T TN Adenosine A1 receptor (ADORA1) DMI319T MA Agonist DMI319T RN Reduction of free fatty acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial agonist. J Clin Pharmacol. 2013 Apr;53(4):385-92. DMI319T RU https://pubmed.ncbi.nlm.nih.gov/23427000 DMI3FU6 DI DMI3FU6 DMI3FU6 DN GSK4074386 DMI3FU6 TI TTNVXAW DMI3FU6 TN Lymphocyte activation gene 3 protein (LAG3) DMI3FU6 MA Inhibitor DMI3FU6 RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMI3FU6 RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMI4O92 DI DMI4O92 DMI4O92 DN LFA-102 DMI4O92 TI TTBPXMA DMI4O92 TN Prolactin receptor (PRLR) DMI4O92 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1721). DMI4O92 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1721 DMI4TEC DI DMI4TEC DMI4TEC DN HTI-1090 DMI4TEC TI TTXNCBV DMI4TEC TN Tryptophan 2,3-dioxygenase (TDO) DMI4TEC MA Inhibitor DMI4TEC RN Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263. DMI4TEC RU https://pubmed.ncbi.nlm.nih.gov/30734612 DMI4TEC DI DMI4TEC DMI4TEC DN HTI-1090 DMI4TEC TI TTZJYKH DMI4TEC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMI4TEC MA Inhibitor DMI4TEC RN Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263. DMI4TEC RU https://pubmed.ncbi.nlm.nih.gov/30734612 DMI4UY3 DI DMI4UY3 DMI4UY3 DN BNC375 DMI4UY3 TI TTLA931 DMI4UY3 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMI4UY3 MA Modulator DMI4UY3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI4UY3 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMI5UEB DI DMI5UEB DMI5UEB DN Unacylated ghrelin DMI5UEB TI TT1OCL0 DMI5UEB TN Ghrelin (GHRL) DMI5UEB MA Inhibitor DMI5UEB RN Alize Pharma signs research collaboration and license option agreement with Lilly. Lyon, France, January 25, 2010. DMI5UEB RU http://www.alz-pharma.com/actualite/alize-pharma-signs-research-collaboration-and-license-option-agreement-with-lilly DMI6EUB DI DMI6EUB DMI6EUB DN Cyclolignan picropodophyllin DMI6EUB TI TTHRID2 DMI6EUB TN Insulin-like growth factor I receptor (IGF1R) DMI6EUB MA Inhibitor DMI6EUB RN The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg. 2007 Jul;46(1):108-15. DMI6EUB RU https://pubmed.ncbi.nlm.nih.gov/17606126 DMI7JO6 DI DMI7JO6 DMI7JO6 DN AMG 427 DMI7JO6 TI TTUN7MC DMI7JO6 TN T-cell surface glycoprotein CD3 (CD3) DMI7JO6 MA Inhibitor DMI7JO6 RN Clinical pipeline report, company report or official report of Amgen. DMI7JO6 RU https://www.amgenpipeline.com/ DMI7JO6 DI DMI7JO6 DMI7JO6 DN AMG 427 DMI7JO6 TI TTGJCWZ DMI7JO6 TN Fms-like tyrosine kinase 3 (FLT-3) DMI7JO6 MA Inhibitor DMI7JO6 RN Clinical pipeline report, company report or official report of Amgen. DMI7JO6 RU https://www.amgenpipeline.com/ DMI7XMU DI DMI7XMU DMI7XMU DN CT 868 DMI7XMU TI TTVIMDE DMI7XMU TN Glucagon-like peptide 1 receptor (GLP1R) DMI7XMU MA Modulator DMI7XMU RN Clinical pipeline report, company report or official report of Carmot Therapeutics. DMI7XMU RU http://carmot-therapeutics.us/pipeline/ DMI7XMU DI DMI7XMU DMI7XMU DN CT 868 DMI7XMU TI TTYMKBE DMI7XMU TN Gastric inhibitory polypeptide receptor (GIPR) DMI7XMU MA Modulator DMI7XMU RN Clinical pipeline report, company report or official report of Carmot Therapeutics. DMI7XMU RU http://carmot-therapeutics.us/pipeline/ DMI7ZK3 DI DMI7ZK3 DMI7ZK3 DN NKTT-120 DMI7ZK3 TI TTA6ZER DMI7ZK3 TN Immunoglobulin G1k (IgG1k) DMI7ZK3 RN Advances in Sickle Cell Therapies in the Hydroxyurea Era. Mol Med. 2014; 20(Suppl 1): S37-S42. DMI7ZK3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374518/ DMI826O DI DMI826O DMI826O DN BP1002 DMI826O TI TTFOUV4 DMI826O TN BCL-2 messenger RNA (BCL2 mRNA) DMI826O MA Inhibitor DMI826O RN Clinical pipeline report, company report or official report of Bio-Path Holdings. DMI826O RU http://dnabilize.com/bp1002/ DMI8795 DI DMI8795 DMI8795 DN UK-371800 DMI8795 TI TTJ0IQB DMI8795 TN Phosphodiesterase 5A (PDE5A) DMI8795 MA Inhibitor DMI8795 RN Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6033-6. DMI8795 RU https://pubmed.ncbi.nlm.nih.gov/18951784 DMI8QNB DI DMI8QNB DMI8QNB DN DFP 13318 DMI8QNB TI TTGTQHC DMI8QNB TN DNA topoisomerase I (TOP1) DMI8QNB MA Inhibitor DMI8QNB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMI8QNB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMI9A1Z DI DMI9A1Z DMI9A1Z DN FPI-1434 DMI9A1Z TI TTHRID2 DMI9A1Z TN Insulin-like growth factor I receptor (IGF1R) DMI9A1Z RN Clinical pipeline report, company report or official report of Fusion Pharmaceuticals. DMI9A1Z RU https://fusionpharma.com/fusion-pipeline/ DMIAK9P DI DMIAK9P DMIAK9P DN ROR1R-CAR-T Cell DMIAK9P TI TTDEJAU DMIAK9P TN Neurotrophic tyrosine kinase ROR1 (ROR1) DMIAK9P MA CAR-T-Cell-Therapy DMIAK9P RN ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) DMIAK9P RU https://clinicaltrials.gov/ct2/show/NCT02194374 DMIAOU6 DI DMIAOU6 DMIAOU6 DN SLN124 DMIAOU6 TI TTNIUKC DMIAOU6 TN TMPRSS6 messenger RNA (TMPRSS6 mRNA) DMIAOU6 MA Inhibitor DMIAOU6 RN SLN124, a GalNAc-siRNA Conjugate Targeting TMPRSS6, Efficiently Prevents Iron Overload in Hereditary Haemochromatosis Type 1. Hemasphere. 2019 Oct 1;3(6):e301. DMIAOU6 RU https://pubmed.ncbi.nlm.nih.gov/31976476 DMIAVBL DI DMIAVBL DMIAVBL DN Ki23819 DMIAVBL TI TTGJCWZ DMIAVBL TN Fms-like tyrosine kinase 3 (FLT-3) DMIAVBL MA Inhibitor DMIAVBL RN Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia. 2005 Jun;19(6):930-5. DMIAVBL RU https://pubmed.ncbi.nlm.nih.gov/15815726 DMICUPT DI DMICUPT DMICUPT DN 11C-6-Me-BTA-1 DMICUPT TI TTE4KHA DMICUPT TN Amyloid beta A4 protein (APP) DMICUPT MA Modulator DMICUPT RN Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklearmedizin. 2007;46(6):271-80. DMICUPT RU https://pubmed.ncbi.nlm.nih.gov/18084683 DMICW7D DI DMICW7D DMICW7D DN AZD-3161 DMICW7D TI TTRK8B9 DMICW7D TN Sodium channel unspecific (NaC) DMICW7D MA Modulator DMICW7D RN Recent progress in sodium channel modulators for pain.Bioorganic & Medicinal Chemistry Letters Volume 24, Issue 16, 15 August 2014, Pages 3690-3699. DMICW7D RU http://www.sciencedirect.com/science/article/pii/S0960894X14006660 DMIDEKB DI DMIDEKB DMIDEKB DN AAV2-hFIX16 DMIDEKB TI TTFEZ5Q DMIDEKB TN Coagulation factor IX (F9) DMIDEKB MA Modulator DMIDEKB RN Assessing the potential for AAV vector genotoxicity in a murine model. Correction in: Blood. 2011 June 16; 117(24): 6739. DMIDEKB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069673/ DMIEAMU DI DMIEAMU DMIEAMU DN GSK-356278 DMIEAMU TI TTSKMI8 DMIEAMU TN Phosphodiesterase 4D (PDE4D) DMIEAMU MA Inhibitor DMIEAMU RN GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. DMIEAMU RU https://pubmed.ncbi.nlm.nih.gov/24784567 DMIEAMU DI DMIEAMU DMIEAMU DN GSK-356278 DMIEAMU TI TTVIAT9 DMIEAMU TN Phosphodiesterase 4B (PDE4B) DMIEAMU MA Inhibitor DMIEAMU RN GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. DMIEAMU RU https://pubmed.ncbi.nlm.nih.gov/24784567 DMIEAMU DI DMIEAMU DMIEAMU DN GSK-356278 DMIEAMU TI TTZ97H5 DMIEAMU TN Phosphodiesterase 4A (PDE4A) DMIEAMU MA Inhibitor DMIEAMU RN GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. DMIEAMU RU https://pubmed.ncbi.nlm.nih.gov/24784567 DMIEJ0W DI DMIEJ0W DMIEJ0W DN Radiolabelled-huA33 DMIEJ0W TI TT96HUR DMIEJ0W TN Cell surface A33 antigen (GPA33) DMIEJ0W RN (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80. DMIEJ0W RU https://pubmed.ncbi.nlm.nih.gov/21764796 DMIEKTF DI DMIEKTF DMIEKTF DN Alofanib DMIEKTF TI TTGJVQM DMIEKTF TN Fibroblast growth factor receptor 2 (FGFR2) DMIEKTF MA Inhibitor DMIEKTF RN Corrigendum to 'Targeting FGFR2 with alofanib (RPT835) shows potent activity in tumour models' [Eur J Cancer 61 (2016) 20-28]. Eur J Cancer. 2017 Jan;70:156. DMIEKTF RU https://pubmed.ncbi.nlm.nih.gov/27919550 DMIF8RY DI DMIF8RY DMIF8RY DN SUN-K0706 DMIF8RY TI TT6PKBN DMIF8RY TN Proto-oncogene c-Src (SRC) DMIF8RY MA Inhibitor DMIF8RY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIF8RY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIF9DZ DI DMIF9DZ DMIF9DZ DN BGB-3113 DMIF9DZ TI TTGM6VW DMIF9DZ TN Tyrosine-protein kinase BTK (ATK) DMIF9DZ MA Inhibitor DMIF9DZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIF9DZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIFJZD DI DMIFJZD DMIFJZD DN AFM11 DMIFJZD TI TTW640A DMIFJZD TN B-lymphocyte surface antigen B4 (CD19) DMIFJZD MA Inhibitor DMIFJZD RN A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604. DMIFJZD RU https://pubmed.ncbi.nlm.nih.gov/25875246 DMIFJZD DI DMIFJZD DMIFJZD DN AFM11 DMIFJZD TI TTUN7MC DMIFJZD TN T-cell surface glycoprotein CD3 (CD3) DMIFJZD MA Inhibitor DMIFJZD RN A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604. DMIFJZD RU https://pubmed.ncbi.nlm.nih.gov/25875246 DMIFSN2 DI DMIFSN2 DMIFSN2 DN GMX1777 DMIFSN2 TI TTD1WIG DMIFSN2 TN Nicotinamide phosphoribosyltransferase (NAMPT) DMIFSN2 MA Modulator DMIFSN2 RN The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-... Mol Cell Biol. 2009 Nov;29(21):5872-88. DMIFSN2 RU https://pubmed.ncbi.nlm.nih.gov/19703994 DMIHC4R DI DMIHC4R DMIHC4R DN RG6146 DMIHC4R TI TTE4BSY DMIHC4R TN Bromodomain and extraterminal domain protein (BET) DMIHC4R MA Inhibitor DMIHC4R RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIHC4R RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIJSDO DI DMIJSDO DMIJSDO DN AVI-6003 DMIJSDO TI TT3Z102 DMIJSDO TN Ebola virus VP35 messenger RNA (EV VP35 mRNA) DMIJSDO MA Modulator DMIJSDO RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMIJSDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMIJSDO DI DMIJSDO DMIJSDO DN AVI-6003 DMIJSDO TI TTDJLWQ DMIJSDO TN Ebola virus VP24 messenger RNA (EV VP24 mRNA) DMIJSDO MA Modulator DMIJSDO RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMIJSDO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMIKE0O DI DMIKE0O DMIKE0O DN PRT1419 DMIKE0O TI TTL53M6 DMIKE0O TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMIKE0O MA Inhibitor DMIKE0O RN Clinical pipeline report, company report or official report of Prelude Therapeutics. DMIKE0O RU https://preludetx.com/science/mcl1/prt1419/ DMIKV9W DI DMIKV9W DMIKV9W DN Utomilumab DMIKV9W TI TTPW9LJ DMIKV9W TN Co-stimulatory molecule 4-1BB (CD137) DMIKV9W MA Agonist DMIKV9W RN First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20 + Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534. DMIKV9W RU https://pubmed.ncbi.nlm.nih.gov/32144134 DMIKX01 DI DMIKX01 DMIKX01 DN CTP-298 DMIKX01 TI TT5FNQT DMIKX01 TN Human immunodeficiency virus Protease (HIV PR) DMIKX01 MA Inhibitor DMIKX01 RN Avanir Licenses Concert's Deuterium-Modified Dextromethorphan Products in Potential US$200 M Deal. Vol 2012 Issue 3 Page(38). DMIKX01 RU http://ojs.pharmadeals.net:5555/index.php/pdr/article/view/cr1696/html DMILHMC DI DMILHMC DMILHMC DN CC8464 DMILHMC TI TT4G2JS DMILHMC TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMILHMC MA Inhibitor DMILHMC RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMILHMC RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMIMH8L DI DMIMH8L DMIMH8L DN ATD transdermal gel DMIMH8L TI TTZAYWL DMIMH8L TN Estrogen receptor (ESR) DMIMH8L MA Inhibitor DMIMH8L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMIMH8L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMIMK84 DI DMIMK84 DMIMK84 DN D2C7 DMIMK84 TI TTGKNB4 DMIMK84 TN Epidermal growth factor receptor (EGFR) DMIMK84 RN Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142. DMIMK84 RU https://pubmed.ncbi.nlm.nih.gov/31142380 DMIMK84 DI DMIMK84 DMIMK84 DN D2C7 DMIMK84 TI TTZ6B2I DMIMK84 TN Epidermal growth factor receptor variant III (EGFR vIII) DMIMK84 RN Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142. DMIMK84 RU https://pubmed.ncbi.nlm.nih.gov/31142380 DMIMVEX DI DMIMVEX DMIMVEX DN MMI-0100 DMIMVEX TI TTMUG9D DMIMVEX TN MAPK-activated protein kinase 2 (MAPKAPK2) DMIMVEX MA Inhibitor DMIMVEX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2094). DMIMVEX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2094 DMIQXDJ DI DMIQXDJ DMIQXDJ DN ABBV-151 DMIQXDJ TI TTR9XHZ DMIQXDJ TN Transforming growth factor beta 1 (TGFB1) DMIQXDJ MA Inhibitor DMIQXDJ RN Clinical pipeline report, company report or official report of AbbVie. DMIQXDJ RU https://www.abbvie.com/our-science/pipeline/abbv-151.html DMIR21F DI DMIR21F DMIR21F DN PFK-158 DMIR21F TI TTTHMQJ DMIR21F TN Renal carcinoma antigen NY-REN-56 (PFKFB3) DMIR21F MA Inhibitor DMIR21F RN Discovery of a PFKFB3 inhibitor for phase I trial testing that synergizes with the B-Raf inhibitor vemurafenib. Cancer Metab. 2014; 2(Suppl 1): P14. DMIR21F RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072985/ DMIRX3Z DI DMIRX3Z DMIRX3Z DN BM-212 DMIRX3Z TI TTTLB3R DMIRX3Z TN Mycobacterium Membrane protein mmpL3 (MycB mmpL3) DMIRX3Z MA Modulator DMIRX3Z RN MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother. 2012 Jan;56(1):324-31. DMIRX3Z RU https://pubmed.ncbi.nlm.nih.gov/22024828 DMIRYM8 DI DMIRYM8 DMIRYM8 DN ALX-0651 DMIRYM8 TI TTBID49 DMIRYM8 TN C-X-C chemokine receptor type 4 (CXCR4) DMIRYM8 MA Inhibitor DMIRYM8 RN Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606. DMIRYM8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3011214/ DMIS8BV DI DMIS8BV DMIS8BV DN PMD-026 DMIS8BV TI TTMVQXO DMIS8BV TN Ribosomal protein S6 kinase beta-2 (RPS6KB2) DMIS8BV MA Inhibitor DMIS8BV RN ClinicalTrials.gov (NCT04115306) Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer. U.S. National Institutes of Health. DMIS8BV RU https://clinicaltrials.gov/ct2/show/NCT04115306 DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TTQOVYA DMITVHM TN C-X-C motif chemokine 10 (CXCL10) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TT95SOA DMITVHM TN Interferon alpha (IFNA) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TTGPQ0F DMITVHM TN Prolyl endopeptidase FAP (FAP) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMITVHM DI DMITVHM DMITVHM DN NG-641 DMITVHM TI TTWE5PB DMITVHM TN C-X-C motif chemokine 9 (CXCL9) DMITVHM RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMITVHM RU https://psioxus.com/technology-products/ng-641/ DMIV04R DI DMIV04R DMIV04R DN Elpetrigine DMIV04R TI TT5HONZ DMIV04R TN Calcium channel unspecific (CaC) DMIV04R MA Blocker DMIV04R RN Clinical pipeline report, company report or official report of Jazz Pharmaceuticals. DMIV04R RU http://www.jazzpharma.com/products/ DMIVGYK DI DMIVGYK DMIVGYK DN SL-801 DMIVGYK TI TTCJUR4 DMIVGYK TN Exportin-1 (XPO1) DMIVGYK MA Inhibitor DMIVGYK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIVGYK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIVHDN DI DMIVHDN DMIVHDN DN GSK2618960 DMIVHDN TI TT8FRMO DMIVHDN TN Interleukin-7 (IL7) DMIVHDN MA Modulator DMIVHDN RN ClinicalTrials.gov (NCT02293161) Single Ascending Doses Study of Anti- Interleukin-7 Receptor alpha Monoclonal Antibody (GSK2618960) in Healthy Volunteers. U.S. National Institutes of Health. DMIVHDN RU https://clinicaltrials.gov/ct2/show/NCT02293161 DMIVUX1 DI DMIVUX1 DMIVUX1 DN Anti-EGFR CAR T DMIVUX1 TI TTGKNB4 DMIVUX1 TN Epidermal growth factor receptor (EGFR) DMIVUX1 MA CAR-T-Cell-Therapy DMIVUX1 RN ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR DMIVUX1 RU https://clinicaltrials.gov/ct2/show/NCT02331693 DMIW5NG DI DMIW5NG DMIW5NG DN RG7342 DMIW5NG TI TTHS256 DMIW5NG TN Metabotropic glutamate receptor 5 (mGluR5) DMIW5NG MA Agonist DMIW5NG RN Clinical pipeline report, company report or official report of Roche. DMIW5NG RU http://www.roche.com/irp2q14e-annex.pdf DMIX5HF DI DMIX5HF DMIX5HF DN AAV2/8-LSPhGAA DMIX5HF TI TTHCF4J DMIX5HF TN Alpha-glucosidase (GLA) DMIX5HF RN ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health. DMIX5HF RU https://clinicaltrials.gov/ct2/show/NCT03533673 DMIXABW DI DMIXABW DMIXABW DN Genz-644282 DMIXABW TI TTGTQHC DMIXABW TN DNA topoisomerase I (TOP1) DMIXABW MA Inhibitor DMIXABW RN Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. Clin Cancer Res. 2011 May 1;17(9):2777-87. DMIXABW RU https://pubmed.ncbi.nlm.nih.gov/21415217 DMIXMQE DI DMIXMQE DMIXMQE DN GAP T cells DMIXMQE TI TTJTSX4 DMIXMQE TN Glypican-3 (GPC3) DMIXMQE MA CAR-T-Cell-Therapy DMIXMQE RN ClinicalTrials.gov (NCT02932956) Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) DMIXMQE RU https://clinicaltrials.gov/ct2/show/NCT02932956 DMIYHAW DI DMIYHAW DMIYHAW DN PU-H71 DMIYHAW TI TTH5YN2 DMIYHAW TN Heat shock protein 90 beta (HSP90B) DMIYHAW MA Inhibitor DMIYHAW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMIYHAW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMIYQEM DI DMIYQEM DMIYQEM DN P-7170 DMIYQEM TI TTHBTOP DMIYQEM TN PI3-kinase gamma (PIK3CG) DMIYQEM MA Inhibitor DMIYQEM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMIYQEM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMJ0Y86 DI DMJ0Y86 DMJ0Y86 DN DV281 DMJ0Y86 TI TTSHG0T DMJ0Y86 TN Toll-like receptor 9 (TLR9) DMJ0Y86 MA Agonist DMJ0Y86 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJ0Y86 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJ1E24 DI DMJ1E24 DMJ1E24 DN MEDI5752 DMJ1E24 TI TTI2S1D DMJ1E24 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJ1E24 MA Inhibitor DMJ1E24 RN Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010. DMJ1E24 RU https://pubmed.ncbi.nlm.nih.gov/33947716 DMJ1E24 DI DMJ1E24 DMJ1E24 DN MEDI5752 DMJ1E24 TI TTNBFWK DMJ1E24 TN Programmed cell death protein 1 (PD-1) DMJ1E24 MA Inhibitor DMJ1E24 RN Bispecific Antibodies to PD-1 and CTLA4: Doubling Down on T Cells to Decouple Efficacy from Toxicity. Cancer Discov. 2021 May;11(5):1008-1010. DMJ1E24 RU https://pubmed.ncbi.nlm.nih.gov/33947716 DMJ1SQY DI DMJ1SQY DMJ1SQY DN 19-28z T CELLS DMJ1SQY TI TTW640A DMJ1SQY TN B-lymphocyte surface antigen B4 (CD19) DMJ1SQY MA CAR-T-Cell-Therapy DMJ1SQY RN ClinicalTrials.gov (NCT01840566) High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma DMJ1SQY RU https://clinicaltrials.gov/ct2/show/NCT01840566 DMJ2Q6H DI DMJ2Q6H DMJ2Q6H DN MK-7288 DMJ2Q6H TI TT9JNIC DMJ2Q6H TN Histamine H3 receptor (H3R) DMJ2Q6H MA Agonist DMJ2Q6H RN Early-stage comparative effectiveness: randomized controlled trial with histamine inverse agonist MK-7288 in excessive daytime sleepiness patients. J Clin Pharmacol. 2013 Dec;53(12):1294-302. DMJ2Q6H RU https://pubmed.ncbi.nlm.nih.gov/24122944 DMJ2R69 DI DMJ2R69 DMJ2R69 DN W-198 DMJ2R69 TI TT3OT40 DMJ2R69 TN Multidrug resistance protein 1 (ABCB1) DMJ2R69 MA Modulator DMJ2R69 RN Mechanisms of tetrandrine and 5-bromotetrandrine in reversing multidrug resistance may relate to down-regulation of multidrug resistance associated protein 7 expression. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Jun;20(3):558-63. DMJ2R69 RU https://pubmed.ncbi.nlm.nih.gov/22739155 DMJ36YH DI DMJ36YH DMJ36YH DN ACE-011 DMJ36YH TI TTO3HT7 DMJ36YH TN Transforming growth factor beta (TGFB) DMJ36YH MA Inhibitor DMJ36YH RN Clinical pipeline report, company report or official report of Acceleron Pharma (2011). DMJ36YH RU http://www.acceleronpharma.com/ DMJ37LH DI DMJ37LH DMJ37LH DN BCMA CART DMJ37LH TI TTZ3P4W DMJ37LH TN B-cell maturation protein (TNFRSF17) DMJ37LH MA CAR-T-Cell-Therapy DMJ37LH RN ClinicalTrials.gov (NCT03549442) Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma DMJ37LH RU https://clinicaltrials.gov/ct2/show/NCT03549442 DMJ3HQY DI DMJ3HQY DMJ3HQY DN Salvinorin A DMJ3HQY TI TTKWM86 DMJ3HQY TN Opioid receptor mu (MOP) DMJ3HQY MA Inhibitor DMJ3HQY RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMJ3HQY RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMJ3HQY DI DMJ3HQY DMJ3HQY DN Salvinorin A DMJ3HQY TI TT27RFC DMJ3HQY TN Opioid receptor delta (OPRD1) DMJ3HQY MA Inhibitor DMJ3HQY RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMJ3HQY RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMJ3HQY DI DMJ3HQY DMJ3HQY DN Salvinorin A DMJ3HQY TI TTQW87Y DMJ3HQY TN Opioid receptor kappa (OPRK1) DMJ3HQY MA Inhibitor DMJ3HQY RN Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. J Med Chem. 2008 Mar 27;51(6):1824-30. DMJ3HQY RU https://pubmed.ncbi.nlm.nih.gov/18293909 DMJ3PNS DI DMJ3PNS DMJ3PNS DN P-2745 DMJ3PNS TI TTP4520 DMJ3PNS TN TGF-beta receptor type I (TGFBR1) DMJ3PNS MA Modulator DMJ3PNS RN Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822. DMJ3PNS RU http://cancerres.aacrjournals.org/content/72/8_Supplement/1822.short DMJ4W5V DI DMJ4W5V DMJ4W5V DN BCMA CAR-T Cells DMJ4W5V TI TTZ3P4W DMJ4W5V TN B-cell maturation protein (TNFRSF17) DMJ4W5V MA CAR-T-Cell-Therapy DMJ4W5V RN ClinicalTrials.gov (NCT03661554) BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma DMJ4W5V RU https://clinicaltrials.gov/ct2/show/NCT03661554 DMJ52F9 DI DMJ52F9 DMJ52F9 DN HER2p63-71 peptide vaccine DMJ52F9 TI TT6EO5L DMJ52F9 TN Erbb2 tyrosine kinase receptor (HER2) DMJ52F9 RN Development of a cancer vaccine: peptides, proteins, and DNA. Cancer Chemother Pharmacol. 2000;46 Suppl:S77-82. DMJ52F9 RU https://pubmed.ncbi.nlm.nih.gov/10950153 DMJ56MS DI DMJ56MS DMJ56MS DN BUTYLATEDHYDROXYTOLUENE DMJ56MS TI TTANPDJ DMJ56MS TN Carbonic anhydrase II (CA-II) DMJ56MS MA Inhibitor DMJ56MS RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMJ56MS RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMJ7WRI DI DMJ7WRI DMJ7WRI DN GCC-1290K DMJ7WRI TI TTCRJKY DMJ7WRI TN Voltage-gated calcium channel (Cav) DMJ7WRI MA Modulator DMJ7WRI RN Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34. DMJ7WRI RU https://pubmed.ncbi.nlm.nih.gov/19428798 DMJ7WRI DI DMJ7WRI DMJ7WRI DN GCC-1290K DMJ7WRI TI TTYVX59 DMJ7WRI TN Protein kinase C (PRKC) DMJ7WRI MA Modulator DMJ7WRI RN Inhibitory effect of glutamate release from rat cerebrocortical synaptosomes by dextromethorphan and its metabolite 3-hydroxymorphinan. Neurochem Int. 2009 Jul;54(8):526-34. DMJ7WRI RU https://pubmed.ncbi.nlm.nih.gov/19428798 DMJ83Z7 DI DMJ83Z7 DMJ83Z7 DN CYT-609 DMJ83Z7 TI TTF8CQI DMJ83Z7 TN Tumor necrosis factor (TNF) DMJ83Z7 MA Modulator DMJ83Z7 RN Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine. Clin Cancer Res. 2010 December 15; 16(24): 6139-6149. DMJ83Z7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004980/ DMJ8ACF DI DMJ8ACF DMJ8ACF DN ALX-0761 DMJ8ACF TI TTG0MT6 DMJ8ACF TN Interleukin-17 (IL17) DMJ8ACF MA Modulator DMJ8ACF RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMJ8ACF RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMJ8ACF DI DMJ8ACF DMJ8ACF DN ALX-0761 DMJ8ACF TI TTVMO5W DMJ8ACF TN Interleukin-25 (IL25) DMJ8ACF MA Modulator DMJ8ACF RN Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. DMJ8ACF RU https://www.ncbi.nlm.nih.gov/pubmed/25359367 DMJA27W DI DMJA27W DMJA27W DN GDC-5573 DMJA27W TI TTB18GJ DMJA27W TN Proto-oncogene c-RAF (c-RAF) DMJA27W MA Inhibitor DMJA27W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJA27W RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJA3H1 DI DMJA3H1 DMJA3H1 DN Anti-CEA-CAR T DMJA3H1 TI TTY6DTE DMJA3H1 TN Carcinoembryonic antigen CEA (CD66e) DMJA3H1 MA CAR-T-Cell-Therapy DMJA3H1 RN ClinicalTrials.gov (NCT02349724) A Clinical Research of CAR T Cells Targeting CEA Positive Cancer DMJA3H1 RU https://clinicaltrials.gov/ct2/show/NCT02349724 DMJAPRK DI DMJAPRK DMJAPRK DN STX 64 DMJAPRK TI TTHM0R1 DMJAPRK TN Steryl-sulfatase (STS) DMJAPRK MA Inhibitor DMJAPRK RN Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res. 2006 Mar 1;12(5):1585-92. DMJAPRK RU https://pubmed.ncbi.nlm.nih.gov/16533785 DMJAVN7 DI DMJAVN7 DMJAVN7 DN GSK3186899 DMJAVN7 TI TTJ21A9 DMJAVN7 TN Cyclin-dependent kinase 12 (CDK12) DMJAVN7 MA Inhibitor DMJAVN7 RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMJAVN7 RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMJB6E2 DI DMJB6E2 DMJB6E2 DN 99mTc-MIP-1405 DMJB6E2 TI TT9G4N0 DMJB6E2 TN Glutamate carboxypeptidase II (GCPII) DMJB6E2 MA Modulator DMJB6E2 RN 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013 Aug;54(8):1369-76. DMJB6E2 RU https://pubmed.ncbi.nlm.nih.gov/23733925 DMJCIGN DI DMJCIGN DMJCIGN DN CC-95775 DMJCIGN TI TTE4BSY DMJCIGN TN Bromodomain and extraterminal domain protein (BET) DMJCIGN MA Inhibitor DMJCIGN RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMJCIGN RU https://www.bms.com/researchers-and-partners/in-the-pipeline.html DMJCQKA DI DMJCQKA DMJCQKA DN Sphingosine-1-Phosphate DMJCQKA TI TT9JZCK DMJCQKA TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMJCQKA MA Inhibitor DMJCQKA RN Exploration of amino alcohol derivatives as novel, potent, and highly selective sphingosine-1-phosphate receptor subtype-1 agonists. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2520-4. DMJCQKA RU https://pubmed.ncbi.nlm.nih.gov/20304639 DMJCT6Q DI DMJCT6Q DMJCT6Q DN CD19 CAR T-cells DMJCT6Q TI TTW640A DMJCT6Q TN B-lymphocyte surface antigen B4 (CD19) DMJCT6Q MA CAR-T-Cell-Therapy DMJCT6Q RN ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies DMJCT6Q RU https://clinicaltrials.gov/ct2/show/NCT02443831 DMJCX6D DI DMJCX6D DMJCX6D DN ASN003 DMJCX6D TI TTWCGQT DMJCX6D TN Serine/threonine-protein kinase B-raf (BRAF) DMJCX6D MA Inhibitor DMJCX6D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJCX6D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMJDP0E DI DMJDP0E DMJDP0E DN DSP-1053 DMJDP0E TI TTSQIFT DMJDP0E TN 5-HT 1A receptor (HTR1A) DMJDP0E MA Antagonist DMJDP0E RN DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats. Pharmacol Res Perspect. 2015 Jun;3(3):e00142. DMJDP0E RU https://pubmed.ncbi.nlm.nih.gov/26171224 DMJDVW4 DI DMJDVW4 DMJDVW4 DN GSK2816126 DMJDVW4 TI TT9MZCQ DMJDVW4 TN Enhancer of zeste homolog 2 (EZH2) DMJDVW4 MA Modulator DMJDVW4 RN National Cancer Institute Drug Dictionary (drug id 756211). DMJDVW4 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=756211 DMJEACT DI DMJEACT DMJEACT DN LC-1 DMJEACT TI TTSXVID DMJEACT TN Nuclear factor NF-kappa-B (NFKB) DMJEACT MA Inhibitor DMJEACT RN A water soluble parthenolide analogue suppresses in vivo tumor growth of two tobacco associated cancers, lung and bladder cancer, by targeting NF- B and generating reactive oxygen species. Int J Cancer. 2011 May 15; 128(10): 2481-2494. DMJEACT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982935/ DMJEBK8 DI DMJEBK8 DMJEBK8 DN TCD-717 DMJEBK8 TI TT10AWB DMJEBK8 TN Choline kinase (CHKA) DMJEBK8 MA Inhibitor DMJEBK8 RN National Cancer Institute Drug Dictionary (drug id 687183). DMJEBK8 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=687183 DMJFK6X DI DMJFK6X DMJFK6X DN JNJ-63898081 DMJFK6X TI TT9G4N0 DMJFK6X TN Glutamate carboxypeptidase II (GCPII) DMJFK6X MA Inhibitor DMJFK6X RN Clinical pipeline report, company report or official report of Genmab. DMJFK6X RU https://www.genmab.com/pipeline/ DMJFKW3 DI DMJFKW3 DMJFKW3 DN AMG 595 DMJFKW3 TI TTGKNB4 DMJFKW3 TN Epidermal growth factor receptor (EGFR) DMJFKW3 MA Modulator DMJFKW3 RN AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24. DMJFKW3 RU https://pubmed.ncbi.nlm.nih.gov/25931519 DMJFM3O DI DMJFM3O DMJFM3O DN RG6139 DMJFM3O TI TTNBFWK DMJFM3O TN Programmed cell death protein 1 (PD-1) DMJFM3O MA Inhibitor DMJFM3O RN Clinical pipeline report, company report or official report of Genentech. DMJFM3O RU https://www.genentechoncology.com/pipeline-molecules/pd-1-x-lag3.html DMJFM3O DI DMJFM3O DMJFM3O DN RG6139 DMJFM3O TI TTNVXAW DMJFM3O TN Lymphocyte activation gene 3 protein (LAG3) DMJFM3O MA Inhibitor DMJFM3O RN Clinical pipeline report, company report or official report of Genentech. DMJFM3O RU https://www.genentechoncology.com/pipeline-molecules/pd-1-x-lag3.html DMJFPK6 DI DMJFPK6 DMJFPK6 DN CIGB-228 DMJFPK6 TI TT3CPZW DMJFPK6 TN Human papillomavirus protein E7 (HPV E7) DMJFPK6 RN Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol. 2011; 2011: 292951. DMJFPK6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3118643/ DMJFWPR DI DMJFWPR DMJFWPR DN ABT-102 DMJFWPR TI TTMI6F5 DMJFWPR TN Transient receptor potential cation channel V1 (TRPV1) DMJFWPR MA Blocker DMJFWPR RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMJFWPR RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMJG7AY DI DMJG7AY DMJG7AY DN TD-1473 DMJG7AY TI TTJSQEF DMJG7AY TN Tyrosine-protein kinase (PTK) DMJG7AY MA Inhibitor DMJG7AY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJG7AY RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMJIH83 DI DMJIH83 DMJIH83 DN XmAb20717 DMJIH83 TI TTI2S1D DMJIH83 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJIH83 RN Clinical pipeline report, company report or official report of Xencor. DMJIH83 RU https://xencor.com/pipeline/xmab20717/ DMJIH83 DI DMJIH83 DMJIH83 DN XmAb20717 DMJIH83 TI TTNBFWK DMJIH83 TN Programmed cell death protein 1 (PD-1) DMJIH83 RN Clinical pipeline report, company report or official report of Xencor. DMJIH83 RU https://xencor.com/pipeline/xmab20717/ DMJIW5Z DI DMJIW5Z DMJIW5Z DN CD19-CAR-T Cells DMJIW5Z TI TTW640A DMJIW5Z TN B-lymphocyte surface antigen B4 (CD19) DMJIW5Z MA CAR-T-Cell-Therapy DMJIW5Z RN ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL DMJIW5Z RU https://clinicaltrials.gov/ct2/show/NCT03574168 DMJK1R0 DI DMJK1R0 DMJK1R0 DN CAR-T cells targeting CD19 DMJK1R0 TI TTW640A DMJK1R0 TN B-lymphocyte surface antigen B4 (CD19) DMJK1R0 MA CAR-T-Cell-Therapy DMJK1R0 RN ClinicalTrials.gov (NCT03086954) Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma DMJK1R0 RU https://clinicaltrials.gov/ct2/show/NCT03086954 DMJK7V0 DI DMJK7V0 DMJK7V0 DN Ge2270a DMJK7V0 TI TTG45NU DMJK7V0 TN Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1) DMJK7V0 MA Inhibitor DMJK7V0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJK7V0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJKBWO DI DMJKBWO DMJKBWO DN HER2-specific CAR T cell DMJKBWO TI TT6EO5L DMJKBWO TN Erbb2 tyrosine kinase receptor (HER2) DMJKBWO MA CAR-T-Cell-Therapy DMJKBWO RN ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors DMJKBWO RU https://clinicaltrials.gov/ct2/show/NCT03500991 DMJLIQ2 DI DMJLIQ2 DMJLIQ2 DN GALAMUSTINE HYDROCHLORIDE DMJLIQ2 TI TTUTN1I DMJLIQ2 TN Human Deoxyribonucleic acid (hDNA) DMJLIQ2 MA Antagonist DMJLIQ2 RN 6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity. Cancer Res. 1987 Feb 1;47(3):696-9. DMJLIQ2 RU https://pubmed.ncbi.nlm.nih.gov/3802075 DMJLNEF DI DMJLNEF DMJLNEF DN Cipatinib DMJLNEF TI TTGKNB4 DMJLNEF TN Epidermal growth factor receptor (EGFR) DMJLNEF MA Modulator DMJLNEF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJLNEF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJLNEF DI DMJLNEF DMJLNEF DN Cipatinib DMJLNEF TI TT6EO5L DMJLNEF TN Erbb2 tyrosine kinase receptor (HER2) DMJLNEF MA Modulator DMJLNEF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJLNEF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJLZ8T DI DMJLZ8T DMJLZ8T DN CHT-25 DMJLZ8T TI TT10Y9E DMJLZ8T TN Interleukin 2 receptor alpha (IL2RA) DMJLZ8T MA Modulator DMJLZ8T RN A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. Clin Cancer Res. 2009 Dec 15;15(24):7701-7710. DMJLZ8T RU https://pubmed.ncbi.nlm.nih.gov/20008855 DMJNFI2 DI DMJNFI2 DMJNFI2 DN BMEC-1217B DMJNFI2 TI TTFTSHD DMJNFI2 TN Cytokine unspecific (CYK) DMJNFI2 MA Regulator DMJNFI2 RN ClinicalTrials.gov (NCT00425971) Safety Study of Anti-Asthma Agent BMEC-1217B. U.S. National Institutes of Health. DMJNFI2 RU https://clinicaltrials.gov/ct2/show/NCT00425971 DMJO0BP DI DMJO0BP DMJO0BP DN PU3 DMJO0BP TI TT78R5H DMJO0BP TN Heat shock protein 90 alpha (HSP90A) DMJO0BP MA Inhibitor DMJO0BP RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMJO0BP RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMJOMD4 DI DMJOMD4 DMJOMD4 DN MP-0112 DMJOMD4 TI TTOHSBA DMJOMD4 TN Vascular endothelial growth factor A (VEGFA) DMJOMD4 MA Inhibitor DMJOMD4 RN Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014 Oct;158(4):724-732.e2. DMJOMD4 RU https://pubmed.ncbi.nlm.nih.gov/24907435 DMJP83V DI DMJP83V DMJP83V DN Gene therapy, IFN-b DMJP83V TI TT4TZ8J DMJP83V TN Interferon-beta (IFNB1) DMJP83V MA Modulator DMJP83V RN Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci. 2004 Nov;95(11):858-65. DMJP83V RU https://pubmed.ncbi.nlm.nih.gov/15546502 DMJPCHK DI DMJPCHK DMJPCHK DN LY309887 DMJPCHK TI TTEXB9Z DMJPCHK TN Glycinamide ribonucleotide formyltransferase (GART) DMJPCHK MA Inhibitor DMJPCHK RN New antimetabolites in cancer chemotherapy and their clinical impact. Br J Cancer. 1998;78 Suppl 3:1-7. DMJPCHK RU https://pubmed.ncbi.nlm.nih.gov/9717984 DMJPEVA DI DMJPEVA DMJPEVA DN CNTX-0290 DMJPEVA TI TTAE1BR DMJPEVA TN Somatostatin receptor type 4 (SSTR4) DMJPEVA MA Agonist DMJPEVA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMJPEVA RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMJPUDW DI DMJPUDW DMJPUDW DN DS-8273 DMJPUDW TI TTW20TU DMJPUDW TN TRAIL receptor 2 (TRAIL-R2) DMJPUDW MA Agonist DMJPUDW RN First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306. DMJPUDW RU https://pubmed.ncbi.nlm.nih.gov/28050790 DMJPXZ4 DI DMJPXZ4 DMJPXZ4 DN GSK618334 DMJPXZ4 TI TT4C8EA DMJPXZ4 TN Dopamine D3 receptor (D3R) DMJPXZ4 MA Antagonist DMJPXZ4 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMJPXZ4 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMJPXZ4 DI DMJPXZ4 DMJPXZ4 DN GSK618334 DMJPXZ4 TI TTOHFIY DMJPXZ4 TN Sphingosine kinase 1 (SPHK1) DMJPXZ4 MA Inhibitor DMJPXZ4 RN Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma.Oncotarget. 2016 Dec 6;7(49):80586-80598. DMJPXZ4 RU https://pubmed.ncbi.nlm.nih.gov/27811359 DMJQDUC DI DMJQDUC DMJQDUC DN Aminoguanidine DMJQDUC TI TTFZYTO DMJQDUC TN C-C chemokine receptor type 2 (CCR2) DMJQDUC MA Antagonist DMJQDUC RN Incyte Announces Second Quarter 2005 Financial Results; Reports Positive Phase IIb Results for Reverset in Treatment-Experienced HIV Patients. Incyte Corporation. 2005. DMJQDUC RU http://www.aegis.com/news/bw/2005/BW050801.html DMJQDUC DI DMJQDUC DMJQDUC DN Aminoguanidine DMJQDUC TI TTF10I9 DMJQDUC TN Nitric-oxide synthase inducible (NOS2) DMJQDUC MA Inhibitor DMJQDUC RN Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800. DMJQDUC RU https://pubmed.ncbi.nlm.nih.gov/19572977 DMJQG25 DI DMJQG25 DMJQG25 DN CLX-0921 DMJQG25 TI TTZMAO3 DMJQG25 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJQG25 MA Agonist DMJQG25 RN A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential. Metabolism. 2003 Aug;52(8):1012-8. DMJQG25 RU https://pubmed.ncbi.nlm.nih.gov/12898466 DMJQHTN DI DMJQHTN DMJQHTN DN WCK-1152 DMJQHTN TI TTIXTO3 DMJQHTN TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMJQHTN MA Modulator DMJQHTN RN DOI: 10.1093/jac/dki361 DMJQHTN RU http://jac.oxfordjournals.org/content/56/6/1130.full.pdf DMJR6TC DI DMJR6TC DMJR6TC DN 90Y-cG250 DMJR6TC TI TT2LVK8 DMJR6TC TN Carbonic anhydrase IX (CA-IX) DMJR6TC RN Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23. DMJR6TC RU https://pubmed.ncbi.nlm.nih.gov/23759990 DMJRALD DI DMJRALD DMJRALD DN LIPO-4 DMJRALD TI TTN2JFW DMJRALD TN T-cell surface glycoprotein CD4 (CD4) DMJRALD RN Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15. DMJRALD RU https://pubmed.ncbi.nlm.nih.gov/23850610 DMJRALD DI DMJRALD DMJRALD DN LIPO-4 DMJRALD TI TTMHA6L DMJRALD TN T-cell surface glycoprotein CD8 (CD8) DMJRALD RN Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15. DMJRALD RU https://pubmed.ncbi.nlm.nih.gov/23850610 DMJSFTX DI DMJSFTX DMJSFTX DN CPI-006 DMJSFTX TI TTK0O6Y DMJSFTX TN Ecto-5'-nucleotidase (CD73) DMJSFTX RN Clinical pipeline report, company report or official report of Corvus Pharmaceuticals. DMJSFTX RU https://www.corvuspharma.com/our-science/our-pipeline/ DMJSX9N DI DMJSX9N DMJSX9N DN V-24343 DMJSX9N TI TT6OEDT DMJSX9N TN Cannabinoid receptor 1 (CB1) DMJSX9N MA Antagonist DMJSX9N RN Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis. Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65. DMJSX9N RU https://pubmed.ncbi.nlm.nih.gov/19249987 DMJVCS1 DI DMJVCS1 DMJVCS1 DN RWJ-671818 DMJVCS1 TI TT6L509 DMJVCS1 TN Coagulation factor IIa (F2) DMJVCS1 MA Modulator DMJVCS1 RN Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RW... J Med Chem. 2010 Feb 25;53(4):1843-56. DMJVCS1 RU https://pubmed.ncbi.nlm.nih.gov/20102150 DMJVL57 DI DMJVL57 DMJVL57 DN XEN1101 DMJVL57 TI TTIVDM3 DMJVL57 TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMJVL57 MA Activator DMJVL57 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMJVL57 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMJVZBC DI DMJVZBC DMJVZBC DN TP-0184 DMJVZBC TI TTJNBQA DMJVZBC TN Activin receptor-like kinase 2 (ALK-2) DMJVZBC MA Inhibitor DMJVZBC RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMJVZBC RU https://www.sdponcology.com/pipeline/ DMJVZBC DI DMJVZBC DMJVZBC DN TP-0184 DMJVZBC TI TTP4520 DMJVZBC TN TGF-beta receptor type I (TGFBR1) DMJVZBC MA Inhibitor DMJVZBC RN Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma. DMJVZBC RU https://www.sdponcology.com/pipeline/ DMJW4TP DI DMJW4TP DMJW4TP DN Autologous ET1402L1-CART cells DMJW4TP TI TT3WAD0 DMJW4TP TN HLA-A02/AFP complex (HLA-A02/AFP) DMJW4TP MA CAR-T-Cell-Therapy DMJW4TP RN ClinicalTrials.gov (NCT03349255) Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma DMJW4TP RU https://clinicaltrials.gov/ct2/show/NCT03349255 DMJW5R0 DI DMJW5R0 DMJW5R0 DN SI-B003 DMJW5R0 TI TTI2S1D DMJW5R0 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMJW5R0 RN Clinical pipeline report, company report or official report of SystImmune. DMJW5R0 RU https://systimmune.com/pipeline.html DMJW5R0 DI DMJW5R0 DMJW5R0 DN SI-B003 DMJW5R0 TI TTNBFWK DMJW5R0 TN Programmed cell death protein 1 (PD-1) DMJW5R0 RN Clinical pipeline report, company report or official report of SystImmune. DMJW5R0 RU https://systimmune.com/pipeline.html DMJX6SM DI DMJX6SM DMJX6SM DN CKD-712 DMJX6SM TI TTKAWRQ DMJX6SM TN JAK-STAT signaling pathway (JAK-STAT pathway) DMJX6SM MA Inhibitor DMJX6SM RN HO-1 and JAK-2/STAT-1 signals are involved in preferential inhibition of iNOS over COX-2 gene expression by newly synthesized tetrahydroisoquinoline alkaloid, CKD712, in cells activated with lipopolysacchride. Cell Signal. 2008 Oct;20(10):1839-47. DMJX6SM RU https://pubmed.ncbi.nlm.nih.gov/18634870 DMJXBVP DI DMJXBVP DMJXBVP DN TAS-119 DMJXBVP TI TTPS3C0 DMJXBVP TN Aurora kinase A (AURKA) DMJXBVP MA Inhibitor DMJXBVP RN TAS-119, a selective Aurora A inhibitor, enhanced the antitumor efficacy of taxanes in multiple human tumor cell lines including paclitaxel-resistant cells. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A268-A268. DMJXBVP RU http://mct.aacrjournals.org/content/12/11_Supplement/A268.short DMJY15D DI DMJY15D DMJY15D DN PWT-33597 DMJY15D TI TTCJG29 DMJY15D TN Serine/threonine-protein kinase mTOR (mTOR) DMJY15D MA Modulator DMJY15D RN PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials DMJY15D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537862 DMJY15D DI DMJY15D DMJY15D DN PWT-33597 DMJY15D TI TTEUNMR DMJY15D TN PI3-kinase alpha (PIK3CA) DMJY15D MA Modulator DMJY15D RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMJY15D RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMJY35M DI DMJY35M DMJY35M DN AVE1701 DMJY35M TI TTC24WT DMJY35M TN C-C chemokine receptor type 1 (CCR1) DMJY35M MA Antagonist DMJY35M RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMJY35M RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMJY9TW DI DMJY9TW DMJY9TW DN DRF-1042 DMJY9TW TI TTGTQHC DMJY9TW TN DNA topoisomerase I (TOP1) DMJY9TW MA Inhibitor DMJY9TW RN Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study. J Clin Pharmacol. 2005 Apr;45(4):453-60. DMJY9TW RU https://pubmed.ncbi.nlm.nih.gov/15778426 DMK09D4 DI DMK09D4 DMK09D4 DN ASC09 + ritonavir DMK09D4 TI TT1D53B DMK09D4 TN COVID-19 3C-like protease (3CLpro) DMK09D4 MA Inhibitor DMK09D4 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMK09D4 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMK0AW6 DI DMK0AW6 DMK0AW6 DN XOMA-3AB DMK0AW6 TI TTB52WU DMK0AW6 TN Bacterial Botulinum toxin A (Bact botA) DMK0AW6 RN Clinical pipeline report, company report or official report of XOMA. DMK0AW6 RU http://www.xoma.com/content/pipeline/biodefense.htm DMK0BTN DI DMK0BTN DMK0BTN DN KQ-791 DMK0BTN TI TTMS7KP DMK0BTN TN Protein-tyrosine phosphatase 1B (PTP1B) DMK0BTN MA Antagonist DMK0BTN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK0BTN RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMK0QDO DI DMK0QDO DMK0QDO DN CC-90002 DMK0QDO TI TT28S46 DMK0QDO TN Leukocyte surface antigen CD47 (CD47) DMK0QDO MA Inhibitor DMK0QDO RN National Cancer Institute Drug Dictionary (drug name CC 90002). DMK0QDO RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd47-monoclonal-antibody-cc-90002 DMK19V6 DI DMK19V6 DMK19V6 DN PF-06671008 DMK19V6 TI TTARMD9 DMK19V6 TN Placental cadherin (CDH3) DMK19V6 MA Immunomodulator DMK19V6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK19V6 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMK25QD DI DMK25QD DMK25QD DN Anti-BCMA CAR-T cells DMK25QD TI TTZ3P4W DMK25QD TN B-cell maturation protein (TNFRSF17) DMK25QD MA CAR-T-Cell-Therapy DMK25QD RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMK25QD RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMK3S9J DI DMK3S9J DMK3S9J DN GSK1144814 DMK3S9J TI TTBPGLU DMK3S9J TN Neuromedin-K receptor (TACR3) DMK3S9J MA Modulator DMK3S9J RN Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39. DMK3S9J RU https://www.ncbi.nlm.nih.gov/pubmed/23067311 DMK3S9J DI DMK3S9J DMK3S9J DN GSK1144814 DMK3S9J TI TTZPO1L DMK3S9J TN Substance-P receptor (TACR1) DMK3S9J MA Modulator DMK3S9J RN Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39. DMK3S9J RU https://www.ncbi.nlm.nih.gov/pubmed/23067311 DMK48PM DI DMK48PM DMK48PM DN SY-1365 DMK48PM TI TTQYF7G DMK48PM TN Cyclin-dependent kinase 7 (CDK7) DMK48PM MA Inhibitor DMK48PM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMK48PM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMK4GIS DI DMK4GIS DMK4GIS DN Anti-hCD70 CAR transduced PBL DMK4GIS TI TTNCIE0 DMK4GIS TN CD70 antigen (CD27-L) DMK4GIS MA CAR-T-Cell-Therapy DMK4GIS RN ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers DMK4GIS RU https://clinicaltrials.gov/ct2/show/NCT02830724 DMK4PWM DI DMK4PWM DMK4PWM DN PLX-5622 DMK4PWM TI TTC70AJ DMK4PWM TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMK4PWM MA Inhibitor DMK4PWM RN Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol Med. 2012; 18(1): 519-527. DMK4PWM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356419/ DMK6P9J DI DMK6P9J DMK6P9J DN RG7741 DMK6P9J TI TTTU902 DMK6P9J TN Checkpoint kinase-1 (CHK1) DMK6P9J MA Modulator DMK6P9J RN National Cancer Institute Drug Dictionary (drug id 730054). DMK6P9J RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=730054 DMK7BND DI DMK7BND DMK7BND DN Briciclib DMK7BND TI TTFCJ7S DMK7BND TN G1/S-specific cyclin-D1 (CCND1) DMK7BND MA Inhibitor DMK7BND RN Clinical pipeline report, company report or official report of Onconova. DMK7BND RU http://www.onconova.com/product-pipeline/briciclib.php DMK7UNL DI DMK7UNL DMK7UNL DN M-0004 DMK7UNL TI TT07C3Y DMK7UNL TN 5-HT 4 receptor (HTR4) DMK7UNL MA Agonist DMK7UNL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMK7UNL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMK96CE DI DMK96CE DMK96CE DN GC-1113 DMK96CE TI TTQG4NR DMK96CE TN Erythropoietin (EPO) DMK96CE MA Modulator DMK96CE RN A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia. Arch Pharm Res. 2012 May;35(5):757-9. DMK96CE RU https://pubmed.ncbi.nlm.nih.gov/22644842 DMK9XUQ DI DMK9XUQ DMK9XUQ DN XmAb23104 DMK9XUQ TI TTNBFWK DMK9XUQ TN Programmed cell death protein 1 (PD-1) DMK9XUQ RN Clinical pipeline report, company report or official report of Xencor. DMK9XUQ RU https://xencor.com/pipeline/xmab23104/ DMK9XUQ DI DMK9XUQ DMK9XUQ DN XmAb23104 DMK9XUQ TI TTE5VP6 DMK9XUQ TN Inducible T-cell costimulator (ICOS) DMK9XUQ RN Clinical pipeline report, company report or official report of Xencor. DMK9XUQ RU https://xencor.com/pipeline/xmab23104/ DMK9Y71 DI DMK9Y71 DMK9Y71 DN Recombinant human Erbb3 fragment therapeutic tumor vaccine DMK9Y71 TI TTDC8N2 DMK9Y71 TN Erbb3 tyrosine kinase receptor (Erbb-3) DMK9Y71 RN Clinical pipeline report, company report or official report of Zensun. DMK9Y71 RU http://www.zensunusa.com/research/ DMK9Y71 DI DMK9Y71 DMK9Y71 DN Recombinant human Erbb3 fragment therapeutic tumor vaccine DMK9Y71 TI TT6EO5L DMK9Y71 TN Erbb2 tyrosine kinase receptor (HER2) DMK9Y71 RN Clinical pipeline report, company report or official report of Zensun. DMK9Y71 RU http://www.zensunusa.com/research/ DMKA2FL DI DMKA2FL DMKA2FL DN CD19/CD22 CAR T-Cells DMKA2FL TI TTM6QSK DMKA2FL TN B-cell receptor CD22 (CD22) DMKA2FL MA CAR-T-Cell-Therapy(Dual specific) DMKA2FL RN ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies DMKA2FL RU https://clinicaltrials.gov/ct2/show/NCT03448393 DMKA2FL DI DMKA2FL DMKA2FL DN CD19/CD22 CAR T-Cells DMKA2FL TI TTW640A DMKA2FL TN B-lymphocyte surface antigen B4 (CD19) DMKA2FL MA CAR-T-Cell-Therapy(Dual specific) DMKA2FL RN ClinicalTrials.gov (NCT03448393) CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies DMKA2FL RU https://clinicaltrials.gov/ct2/show/NCT03448393 DMKCRMD DI DMKCRMD DMKCRMD DN AVB-S6-500 DMKCRMD TI TTZPY6J DMKCRMD TN Tyrosine-protein kinase UFO (AXL) DMKCRMD MA Inhibitor DMKCRMD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKCRMD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKF1O2 DI DMKF1O2 DMKF1O2 DN AMG 119 DMKF1O2 TI TT1C9K6 DMKF1O2 TN Delta-like protein 3 (DLL3) DMKF1O2 MA Inhibitor DMKF1O2 RN Clinical pipeline report, company report or official report of Amgen. DMKF1O2 RU https://www.amgenpipeline.com/ DMKFVX5 DI DMKFVX5 DMKFVX5 DN KUL-7211 DMKFVX5 TI TT2CJVK DMKFVX5 TN Adrenergic receptor beta-2 (ADRB2) DMKFVX5 MA Modulator DMKFVX5 RN The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14. DMKFVX5 RU https://www.ncbi.nlm.nih.gov/pubmed/16133579 DMKFVX5 DI DMKFVX5 DMKFVX5 DN KUL-7211 DMKFVX5 TI TTMXGCW DMKFVX5 TN Adrenergic receptor beta-3 (ADRB3) DMKFVX5 MA Modulator DMKFVX5 RN The potency of KUL-7211, a selective ureteral relaxant, in isolated canine ureter: comparison with various spasmolytics.Urol Res.2005 Dec;33(6):409-14. DMKFVX5 RU https://www.ncbi.nlm.nih.gov/pubmed/16133579 DMKH3Z9 DI DMKH3Z9 DMKH3Z9 DN CC-90010 DMKH3Z9 TI TTE4BSY DMKH3Z9 TN Bromodomain and extraterminal domain protein (BET) DMKH3Z9 MA Inhibitor DMKH3Z9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKH3Z9 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMKHM7O DI DMKHM7O DMKHM7O DN SAR-126119 DMKHM7O TI TTP18AY DMKHM7O TN Carboxypeptidase B2 (CPB2) DMKHM7O MA Inhibitor DMKHM7O RN TAFIa inhibitors in the treatment of thrombosis. Curr Opin Drug Discov Devel. 2008 Jul;11(4):480-6. DMKHM7O RU https://pubmed.ncbi.nlm.nih.gov/18600565 DMKHVNE DI DMKHVNE DMKHVNE DN YKP-1358 DMKHVNE TI TTJQOD7 DMKHVNE TN 5-HT 2A receptor (HTR2A) DMKHVNE MA Modulator DMKHVNE RN Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8. DMKHVNE RU https://pubmed.ncbi.nlm.nih.gov/17259948 DMKHVNE DI DMKHVNE DMKHVNE DN YKP-1358 DMKHVNE TI TTEX248 DMKHVNE TN Dopamine D2 receptor (D2R) DMKHVNE MA Modulator DMKHVNE RN Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers. Clin Pharmacol Ther. 2007 Feb;81(2):252-8. DMKHVNE RU https://pubmed.ncbi.nlm.nih.gov/17259948 DMKJRQS DI DMKJRQS DMKJRQS DN NCX-1015 DMKJRQS TI TTYRL6O DMKJRQS TN Glucocorticoid receptor (NR3C1) DMKJRQS MA Modulator DMKJRQS RN Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol. 2003 Sep 15;171(6):3245-52. DMKJRQS RU https://pubmed.ncbi.nlm.nih.gov/12960354 DMKL92E DI DMKL92E DMKL92E DN Anti-CD22 CAR-T cells DMKL92E TI TTM6QSK DMKL92E TN B-cell receptor CD22 (CD22) DMKL92E MA CAR-T-Cell-Therapy DMKL92E RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMKL92E RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMKMN5R DI DMKMN5R DMKMN5R DN KUR-501 DMKMN5R TI TT80ARU DMKMN5R TN Ganglioside GD2 (GD2) DMKMN5R RN Clinical pipeline report, company report or official report of Kuur Therapeutics. DMKMN5R RU https://kuurtx.com/product-overview/ DMKMR2X DI DMKMR2X DMKMR2X DN ERB-257 DMKMR2X TI TTOM3J0 DMKMR2X TN Estrogen receptor beta (ESR2) DMKMR2X MA Agonist DMKMR2X RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030075) DMKMR2X RU http://adisinsight.springer.com/drugs/800030075 DMKMU2S DI DMKMU2S DMKMU2S DN GNX102 DMKMU2S TI TTZUFEL DMKMU2S TN Tumor-associated glycan antigen (TAGA) DMKMU2S RN Clinical pipeline report, company report or official report of GlycoNex. DMKMU2S RU http://www.glyconex.com.tw/index.php/en-us/product-pipeline-us DMKN8XD DI DMKN8XD DMKN8XD DN CART-38 cells DMKN8XD TI TTPURFN DMKN8XD TN Cyclic ADP-ribose hydrolase 1 (CD38) DMKN8XD MA CAR-T-Cell-Therapy DMKN8XD RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMKN8XD RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMKNH8B DI DMKNH8B DMKNH8B DN MK-2118 DMKNH8B TI TTT402Y DMKNH8B TN Stimulator of interferon genes protein (TMEM173) DMKNH8B MA Agonist DMKNH8B RN National Cancer Institute Drug Dictionary (drug name ML2118). DMKNH8B RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-mk-2118 DMKNMAE DI DMKNMAE DMKNMAE DN Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 DMKNMAE TI TTZ3P4W DMKNMAE TN B-cell maturation protein (TNFRSF17) DMKNMAE MA CAR-T-Cell-Therapy DMKNMAE RN ClinicalTrials.gov (NCT03338972) Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma DMKNMAE RU https://clinicaltrials.gov/ct2/show/NCT03338972 DMKO7EA DI DMKO7EA DMKO7EA DN ISF-402 DMKO7EA TI TTCBFJO DMKO7EA TN Insulin receptor (INSR) DMKO7EA MA Modulator DMKO7EA RN Ability of GHTD-amide and analogs to enhance insulin activity through zinc chelation and dispersal of insulin oligomers. Peptides. 2009 Jun;30(6):1088-97. DMKO7EA RU https://pubmed.ncbi.nlm.nih.gov/19463741 DMKOE84 DI DMKOE84 DMKOE84 DN PF-4603629 DMKOE84 TI TTVIMDE DMKOE84 TN Glucagon-like peptide 1 receptor (GLP1R) DMKOE84 MA Modulator DMKOE84 RN Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. DMKOE84 RU https://pubmed.ncbi.nlm.nih.gov/19748064 DMKPAOD DI DMKPAOD DMKPAOD DN DA-6886 DMKPAOD TI TT07C3Y DMKPAOD TN 5-HT 4 receptor (HTR4) DMKPAOD MA Agonist DMKPAOD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMKPAOD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMKPBVX DI DMKPBVX DMKPBVX DN Englitazone sodium DMKPBVX TI TTZMAO3 DMKPBVX TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMKPBVX MA Agonist DMKPBVX RN PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy. Int J Obes Relat Metab Disord. 2003 Feb;27(2):147-61. DMKPBVX RU https://pubmed.ncbi.nlm.nih.gov/12586994 DMKQHE5 DI DMKQHE5 DMKQHE5 DN BI-11634 DMKQHE5 TI TTCIHJA DMKQHE5 TN Coagulation factor Xa (F10) DMKQHE5 MA Inhibitor DMKQHE5 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMKQHE5 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMKR3GD DI DMKR3GD DMKR3GD DN EP-42675 DMKR3GD TI TTCIHJA DMKR3GD TN Coagulation factor Xa (F10) DMKR3GD MA Modulator DMKR3GD RN EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33. DMKR3GD RU https://pubmed.ncbi.nlm.nih.gov/24237610 DMKR3GD DI DMKR3GD DMKR3GD DN EP-42675 DMKR3GD TI TT6L509 DMKR3GD TN Coagulation factor IIa (F2) DMKR3GD MA Modulator DMKR3GD RN EP42675, a synthetic parenteral dual-action anticoagulant: pharmacokinetics, pharmacodynamics, and absence of interactions with antiplatelet drugs. J Thromb Haemost. 2014 Jan;12(1):24-33. DMKR3GD RU https://pubmed.ncbi.nlm.nih.gov/24237610 DMKR8S1 DI DMKR8S1 DMKR8S1 DN BMS-779788 DMKR8S1 TI TTM1EQF DMKR8S1 TN Oxysterols receptor LXR (NR1H) DMKR8S1 MA Modulator DMKR8S1 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DMKR8S1 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DMKSU35 DI DMKSU35 DMKSU35 DN PU-AD DMKSU35 TI TT78R5H DMKSU35 TN Heat shock protein 90 alpha (HSP90A) DMKSU35 MA Inhibitor DMKSU35 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKSU35 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMKUT08 DI DMKUT08 DMKUT08 DN TAK-071 DMKUT08 TI TTZ9SOR DMKUT08 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMKUT08 MA Modulator DMKUT08 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMKUT08 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMKUXB5 DI DMKUXB5 DMKUXB5 DN CDT-fenofibrate DMKUXB5 TI TTJ584C DMKUXB5 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMKUXB5 MA Agonist DMKUXB5 RN Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998 Nov 10;98(19):2088-93. DMKUXB5 RU https://pubmed.ncbi.nlm.nih.gov/9808609 DMKVE8X DI DMKVE8X DMKVE8X DN Acriflavine DMKVE8X TI TT5FH9Y DMKVE8X TN Human immunodeficiency virus Integrase (HIV IN) DMKVE8X MA Modulator DMKVE8X RN Why have ten or so nontoxic, retrovirus integrase inhibitors not been made available for AIDS treatment. Biomed Pharmacother. 1999 Dec;53(10):484-6. DMKVE8X RU https://pubmed.ncbi.nlm.nih.gov/10665342 DMKVIS5 DI DMKVIS5 DMKVIS5 DN RG7907 DMKVIS5 TI TTM42UJ DMKVIS5 TN Hepatitis B virus Capsid protein (HBV C) DMKVIS5 MA Inhibitor DMKVIS5 RN Clinical pipeline report, company report or official report of Roche. DMKVIS5 RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMKW10G DI DMKW10G DMKW10G DN SGN-CD30C DMKW10G TI TT2GM5R DMKW10G TN Lymphocyte activation antigen CD30 (TNFRSF8) DMKW10G RN Clinical pipeline report, company report or official report of Seagen. DMKW10G RU https://www.seagen.com/science/pipeline DMKW27X DI DMKW27X DMKW27X DN CART-19 cells DMKW27X TI TTW640A DMKW27X TN B-lymphocyte surface antigen B4 (CD19) DMKW27X MA CAR-T-Cell-Therapy DMKW27X RN ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL). DMKW27X RU https://clinicaltrials.gov/ct2/show/NCT02924753 DMKW4AJ DI DMKW4AJ DMKW4AJ DN Tasidotin hydrochloride DMKW4AJ TI TTYFKSZ DMKW4AJ TN Tubulin beta (TUBB) DMKW4AJ MA Binder DMKW4AJ RN Intracellular activation and deactivation of tasidotin, an analog of dolastatin 15: correlation with cytotoxicity. Mol Pharmacol. 2009 Jan;75(1):218-26. DMKW4AJ RU https://pubmed.ncbi.nlm.nih.gov/18927208 DMKWSFI DI DMKWSFI DMKWSFI DN CR-002 DMKWSFI TI TTQA6SX DMKWSFI TN Platelet-derived growth factor B (PDGFB) DMKWSFI MA Modulator DMKWSFI RN A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int J Clin Pharmacol Ther. 2008 May;46(5):236-44. DMKWSFI RU https://www.ncbi.nlm.nih.gov/pubmed/18538109 DMKX174 DI DMKX174 DMKX174 DN FOR46 DMKX174 TI TTMS7DF DMKX174 TN Membrane cofactor protein (CD46) DMKX174 RN Clinical pipeline report, company report or official report of Fortis Therapeutics. DMKX174 RU https://fortistx.com/for46-pipeline/ DMKY1L4 DI DMKY1L4 DMKY1L4 DN Glucose-6-phosphate DMKY1L4 TI TTC67I0 DMKY1L4 TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMKY1L4 MA Inhibitor DMKY1L4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKY1L4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKZVLH DI DMKZVLH DMKZVLH DN Lefradafiban DMKZVLH TI TT38RM1 DMKZVLH TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMKZVLH MA Modulator DMKZVLH RN Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50. DMKZVLH RU https://pubmed.ncbi.nlm.nih.gov/11250974 DML028U DI DML028U DML028U DN G1T28-1 DML028U TI TT0PG8F DML028U TN Cyclin-dependent kinase 4 (CDK4) DML028U MA Modulator DML028U RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML028U RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML028U DI DML028U DML028U DN G1T28-1 DML028U TI TTO0FDJ DML028U TN Cyclin-dependent kinase 6 (CDK6) DML028U MA Modulator DML028U RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML028U RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML07UZ DI DML07UZ DML07UZ DN CD19-CAR-T2 Cells DML07UZ TI TTW640A DML07UZ TN B-lymphocyte surface antigen B4 (CD19) DML07UZ MA CAR-T-Cell-Therapy DML07UZ RN ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia DML07UZ RU https://clinicaltrials.gov/ct2/show/NCT02822326 DML0OCD DI DML0OCD DML0OCD DN PF-3864086 DML0OCD TI TTMI6F5 DML0OCD TN Transient receptor potential cation channel V1 (TRPV1) DML0OCD MA Antagonist DML0OCD RN Clinical pipeline report, company report or official report of pfizer. DML0OCD RU https://www.pfizer.com/files/investors/presentations/acr_102808_v2.pdf DML1KSA DI DML1KSA DML1KSA DN GMI-1359 DML1KSA TI TTAU4D6 DML1KSA TN E-selectin (SELE) DML1KSA MA Antagonist DML1KSA RN Clinical pipeline report, company report or official report of GlycoMimetics. DML1KSA RU http://glycomimetics.com/pipeline/programs/gmi-1359/ DML1KSA DI DML1KSA DML1KSA DN GMI-1359 DML1KSA TI TTBID49 DML1KSA TN C-X-C chemokine receptor type 4 (CXCR4) DML1KSA MA Antagonist DML1KSA RN Clinical pipeline report, company report or official report of GlycoMimetics. DML1KSA RU http://glycomimetics.com/pipeline/programs/gmi-1359/ DML3K9N DI DML3K9N DML3K9N DN XTL-6865 DML3K9N TI TTDBG95 DML3K9N TN Hepatitis C virus Envelope glycoprotein E2 (HCV NS1) DML3K9N MA Modulator DML3K9N RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DML3K9N RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DML3M0O DI DML3M0O DML3M0O DN TAK-701 DML3M0O TI TT4V2JM DML3M0O TN Hepatocyte growth factor (HGF) DML3M0O MA Modulator DML3M0O RN Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103. DML3M0O RU https://www.ncbi.nlm.nih.gov/pubmed/22270953 DML3WT6 DI DML3WT6 DML3WT6 DN PF-06821497 DML3WT6 TI TT9MZCQ DML3WT6 TN Enhancer of zeste homolog 2 (EZH2) DML3WT6 MA Inhibitor DML3WT6 RN Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665. DML3WT6 RU https://pubmed.ncbi.nlm.nih.gov/29211475 DML4C3Q DI DML4C3Q DML4C3Q DN RO-5212054 DML4C3Q TI TTWCGQT DML4C3Q TN Serine/threonine-protein kinase B-raf (BRAF) DML4C3Q MA Inhibitor DML4C3Q RN National Cancer Institute Drug Dictionary (drug id 680347). DML4C3Q RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=680347 DML4H05 DI DML4H05 DML4H05 DN KX2-361 DML4H05 TI TT6PKBN DML4H05 TN Proto-oncogene c-Src (SRC) DML4H05 MA Inhibitor DML4H05 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2206). DML4H05 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2206 DML4JXZ DI DML4JXZ DML4JXZ DN F-7TG DML4JXZ TI TTF0EGX DML4JXZ TN Coagulation factor VII (F7) DML4JXZ MA Modulator DML4JXZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DML4JXZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DML4SIE DI DML4SIE DML4SIE DN Atu-027 DML4SIE TI TTW3P4R DML4SIE TN Protein kinase N3 (PKN3) DML4SIE MA Modulator DML4SIE RN Company report (Silence Therapeutics) DML4SIE RU http://www.silence-therapeutics.com/pipeline/?doing_wp_cron=1455613779.0401461124420166015625#AboutAtu027 DML5FX2 DI DML5FX2 DML5FX2 DN MDX-018 DML5FX2 TI TTCTE1G DML5FX2 TN Interleukin-8 (IL8) DML5FX2 MA Modulator DML5FX2 RN Company report (Genmab) DML5FX2 RU http://www.genmab.com/product-pipeline/products-in-development/humax-il8 DML5O7T DI DML5O7T DML5O7T DN IM23 DML5O7T TI TTENHJ0 DML5O7T TN Interleukin 3 receptor alpha (IL3RA) DML5O7T MA CAR-T-Cell-Therapy DML5O7T RN ClinicalTrials.gov (NCT03585517) Safety and Efficacy Evaluation of IM23 CAR-T Cells (IM23CAR-T) DML5O7T RU https://clinicaltrials.gov/ct2/show/NCT03585517 DML5V76 DI DML5V76 DML5V76 DN MK-4166 DML5V76 TI TTG6LA7 DML5V76 TN Activation-inducible TNFR family receptor (TNFRSF18) DML5V76 RN Immuno-oncology moves beyond PD-1. Nat Biotechnol. 2015 Jul;33(7):673-5. DML5V76 RU https://pubmed.ncbi.nlm.nih.gov/26153987 DML6QJN DI DML6QJN DML6QJN DN SDZ-MKS-492 DML6QJN TI TTZCG4L DML6QJN TN Phosphodiesterase 3 (PDE3) DML6QJN MA Modulator DML6QJN RN Effects of a cyclic nucleotide phosphodiesterase isoenzyme type III inhibitor, SDZ MKS 492 on airway responsiveness in beagles. Arerugi. 1993 Aug;42(8):920-5. DML6QJN RU https://pubmed.ncbi.nlm.nih.gov/8250732 DML781M DI DML781M DML781M DN BAY1895344 DML781M TI TT8ZYBQ DML781M TN Serine/threonine-protein kinase ATR (FRP1) DML781M MA Inhibitor DML781M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DML781M RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DML79KE DI DML79KE DML79KE DN AGT-182 DML79KE TI TTCBFJO DML79KE TN Insulin receptor (INSR) DML79KE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DML79KE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DML8M3B DI DML8M3B DML8M3B DN LY-2584702 DML8M3B TI TT7M3PI DML8M3B TN Ribosomal protein S6 kinase (S6K) DML8M3B MA Modulator DML8M3B RN A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.Eur J Cancer.2014 Mar;50(5):876-84. DML8M3B RU https://www.ncbi.nlm.nih.gov/pubmed/24456794 DMLA1QD DI DMLA1QD DMLA1QD DN MB-101 DMLA1QD TI TTMPZ7V DMLA1QD TN Interleukin 13 receptor alpha-2 (IL13RA2) DMLA1QD MA Immunomodulator DMLA1QD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLA1QD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMLAP8F DI DMLAP8F DMLAP8F DN AMG 424 DMLAP8F TI TTPURFN DMLAP8F TN Cyclic ADP-ribose hydrolase 1 (CD38) DMLAP8F MA Inhibitor DMLAP8F RN Clinical pipeline report, company report or official report of Amgen. DMLAP8F RU https://www.amgenpipeline.com/ DMLAP8F DI DMLAP8F DMLAP8F DN AMG 424 DMLAP8F TI TTUN7MC DMLAP8F TN T-cell surface glycoprotein CD3 (CD3) DMLAP8F MA Inhibitor DMLAP8F RN Clinical pipeline report, company report or official report of Amgen. DMLAP8F RU https://www.amgenpipeline.com/ DMLBKZV DI DMLBKZV DMLBKZV DN CER-002 DMLBKZV TI TT2JWF6 DMLBKZV TN Peroxisome proliferator-activated receptor delta (PPARD) DMLBKZV MA Agonist DMLBKZV RN Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899. DMLBKZV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997800/ DMLCTI5 DI DMLCTI5 DMLCTI5 DN MK-8353 DMLCTI5 TI TTKPV6O DMLCTI5 TN Ephrin type-B receptor 2 (EPHB2) DMLCTI5 MA Inhibitor DMLCTI5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLCTI5 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLDSX8 DI DMLDSX8 DMLDSX8 DN TT-30 DMLDSX8 TI TT0HUN7 DMLDSX8 TN Complement receptor type 2 (CD21) DMLDSX8 MA Modulator DMLDSX8 RN The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16. DMLDSX8 RU https://pubmed.ncbi.nlm.nih.gov/22577173 DMLDSX8 DI DMLDSX8 DMLDSX8 DN TT-30 DMLDSX8 TI TTUW6OP DMLDSX8 TN Complement factor H (CFH) DMLDSX8 MA Modulator DMLDSX8 RN The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012 Jun 28;119(26):6307-16. DMLDSX8 RU https://pubmed.ncbi.nlm.nih.gov/22577173 DMLDZX1 DI DMLDZX1 DMLDZX1 DN PfAMA-1 DMLDZX1 TI TTQZW34 DMLDZX1 TN Plasmodium Apical membrane protein (Malaria AMA-1) DMLDZX1 RN Plasmodium falciparum apical membrane antigen 1 (PfAMA-1) is translocated within micronemes along subpellicular microtubules during merozoite devel... J Cell Sci. 2003 Sep 15;116(Pt 18):3825-34. DMLDZX1 RU https://pubmed.ncbi.nlm.nih.gov/12902400 DMLEKUY DI DMLEKUY DMLEKUY DN APG-1387 DMLEKUY TI TTS74QB DMLEKUY TN Inhibitor of apoptosis protein (hIAP) DMLEKUY MA Inhibitor DMLEKUY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLEKUY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLEKUY DI DMLEKUY DMLEKUY DN APG-1387 DMLEKUY TI TTR7B60 DMLEKUY TN X-linked inhibitor of apoptosis protein (XIAP) DMLEKUY MA Antagonist DMLEKUY RN XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells.Theranostics. 2018 Feb 5;8(6):1494-1510. DMLEKUY RU https://pubmed.ncbi.nlm.nih.gov/29556337 DMLGD0V DI DMLGD0V DMLGD0V DN PF-04776548 DMLGD0V TI TT5FNQT DMLGD0V TN Human immunodeficiency virus Protease (HIV PR) DMLGD0V MA Modulator DMLGD0V RN ClinicalTrials.gov (NCT01045317) A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body. U.S. National Institutes of Health. DMLGD0V RU https://clinicaltrials.gov/ct2/show/NCT01045317 DMLGJKE DI DMLGJKE DMLGJKE DN CART-22 cells DMLGJKE TI TTM6QSK DMLGJKE TN B-cell receptor CD22 (CD22) DMLGJKE MA CAR-T-Cell-Therapy DMLGJKE RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMLGJKE RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMLH2Q6 DI DMLH2Q6 DMLH2Q6 DN Figopitant DMLH2Q6 TI TTZPO1L DMLH2Q6 TN Substance-P receptor (TACR1) DMLH2Q6 MA Antagonist DMLH2Q6 RN Investigation of figopitant and its metabolites in rat tissue by combining whole-body autoradiography with liquid extraction surface analysis mass spectrometry. Drug Metab Dispos. 2012 Mar;40(3):419-25. DMLH2Q6 RU https://pubmed.ncbi.nlm.nih.gov/22184457 DMLHIMO DI DMLHIMO DMLHIMO DN REV-576 DMLHIMO TI TTKANGO DMLHIMO TN Complement C5 (CO5) DMLHIMO MA Inhibitor DMLHIMO RN Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus. 2014 Oct;23(12):1324-6. DMLHIMO RU https://pubmed.ncbi.nlm.nih.gov/25228739 DMLI5VG DI DMLI5VG DMLI5VG DN CAR-T cells targeting HER2 DMLI5VG TI TT6EO5L DMLI5VG TN Erbb2 tyrosine kinase receptor (HER2) DMLI5VG MA CAR-T-Cell-Therapy DMLI5VG RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMLI5VG RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMLI9U6 DI DMLI9U6 DMLI9U6 DN AVI-7537 DMLI9U6 TI TTDJLWQ DMLI9U6 TN Ebola virus VP24 messenger RNA (EV VP24 mRNA) DMLI9U6 RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMLI9U6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMLJHM2 DI DMLJHM2 DMLJHM2 DN PD-L1 t-haNK DMLJHM2 TI TT8ZLTI DMLJHM2 TN Programmed cell death 1 ligand 1 (PD-L1) DMLJHM2 RN ClinicalTrials.gov (NCT04050709) QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers. U.S. National Institutes of Health. DMLJHM2 RU https://clinicaltrials.gov/ct2/show/NCT04050709 DMLJOAF DI DMLJOAF DMLJOAF DN BI-135585 DMLJOAF TI TTN7BL9 DMLJOAF TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMLJOAF MA Modulator DMLJOAF RN New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). DMLJOAF RU https://books.google.com.hk/books?id=0rmlVGhlJ0IC&pg=PA131&lpg=PA131&dq=RG-7234++New+Therapeutic+Strategies+for+Type+2+Diabetes&source=bl&ots=toqK7w4uiI&sig=sx5iyfQWH2bTCSZmT5aUQiKfPuM&hl=zh-CN&sa=X&ved=0CB0Q6AEwAGoVChMIsZ_k6dDGyAIViLeOCh0oUQpr#v=onepage&q=RG-7234%20%20New%20Therapeutic%20Strategies%20for%20Type%202%20Diabetes&f=false DMLJWPN DI DMLJWPN DMLJWPN DN Alx-5407 DMLJWPN TI TTHJTF7 DMLJWPN TN Glycine transporter GlyT-1 (SLC6A9) DMLJWPN MA Blocker DMLJWPN RN ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol. 2001 Dec;60(6):1414-20. DMLJWPN RU https://pubmed.ncbi.nlm.nih.gov/11723250 DMLKF3H DI DMLKF3H DMLKF3H DN Prolanta DMLKF3H TI TTBPXMA DMLKF3H TN Prolactin receptor (PRLR) DMLKF3H MA Antagonist DMLKF3H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLKF3H RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLKS7W DI DMLKS7W DMLKS7W DN NV-5138 DMLKS7W TI TTX4GLS DMLKS7W TN Mammalian target of rapamycin complex 1 (mTORC1) DMLKS7W MA Activator DMLKS7W RN Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation. J Clin Invest. 2019 Apr 16;129(6):2542-2554. DMLKS7W RU https://pubmed.ncbi.nlm.nih.gov/30990795 DMLONJG DI DMLONJG DMLONJG DN CC-97540 DMLONJG TI TTW640A DMLONJG TN B-lymphocyte surface antigen B4 (CD19) DMLONJG RN A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma DMLONJG RU https://clinicaltrials.gov/ct2/show/NCT04231747 DMLPB0X DI DMLPB0X DMLPB0X DN SB-436811 DMLPB0X TI TTW5UDX DMLPB0X TN Urotensin II receptor (UTS2R) DMLPB0X MA Inhibitor DMLPB0X RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DMLPB0X RU https://pubmed.ncbi.nlm.nih.gov/20043680 DMLPBVF DI DMLPBVF DMLPBVF DN SUVN-911 DMLPBVF TI TT5KPZR DMLPBVF TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMLPBVF MA Antagonist DMLPBVF RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLPBVF RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMLQJ5P DI DMLQJ5P DMLQJ5P DN AMG 228 DMLQJ5P TI TTG6LA7 DMLQJ5P TN Activation-inducible TNFR family receptor (TNFRSF18) DMLQJ5P MA Agonist DMLQJ5P RN Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. J Immunother Cancer. 2018 Sep 25;6(1):93. DMLQJ5P RU https://pubmed.ncbi.nlm.nih.gov/30253804 DMLQOF1 DI DMLQOF1 DMLQOF1 DN MK-7246 DMLQOF1 TI TTQDMX5 DMLQOF1 TN Prostaglandin D2 receptor 2 (PTGDR2) DMLQOF1 MA Modulator DMLQOF1 RN Discovery of MK-7246, a selective CRTH2 antagonist for the treatment of respiratory diseases. Bioorg Med Chem Lett. 2011 Jan 1;21(1):288-93. DMLQOF1 RU https://pubmed.ncbi.nlm.nih.gov/21106375 DMLQYVD DI DMLQYVD DMLQYVD DN ELND-004 DMLQYVD TI TT4BT06 DMLQYVD TN Integrin alpha-4 (ITGA4) DMLQYVD MA Inhibitor DMLQYVD RN Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8. DMLQYVD RU https://pubmed.ncbi.nlm.nih.gov/12794117 DMLRGX1 DI DMLRGX1 DMLRGX1 DN BAY 1082439 DMLRGX1 TI TTTHBCA DMLRGX1 TN PI3-kinase beta (PIK3CB) DMLRGX1 MA Modulator DMLRGX1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMLRGX1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMLSUQ8 DI DMLSUQ8 DMLSUQ8 DN KHK2455 DMLSUQ8 TI TTZJYKH DMLSUQ8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMLSUQ8 MA Inhibitor DMLSUQ8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLSUQ8 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLUOVS DI DMLUOVS DMLUOVS DN TJC4 DMLUOVS TI TT28S46 DMLUOVS TN Leukocyte surface antigen CD47 (CD47) DMLUOVS RN Clinical pipeline report, company report or official report of I-MAB Biopharma. DMLUOVS RU https://i-mabbiopharma.com/en/Pipeline.aspx DMLUYAJ DI DMLUYAJ DMLUYAJ DN OPK-0018 DMLUYAJ TI TT4QPUL DMLUYAJ TN Antithrombin-III (ATIII) DMLUYAJ MA Antagonist DMLUYAJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). DMLUYAJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 DMLVG9D DI DMLVG9D DMLVG9D DN DCC-3014 DMLVG9D TI TT7MRDV DMLVG9D TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMLVG9D MA Inhibitor DMLVG9D RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLVG9D RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLVNWO DI DMLVNWO DMLVNWO DN Oleclumab DMLVNWO TI TTK0O6Y DMLVNWO TN Ecto-5'-nucleotidase (CD73) DMLVNWO MA Inhibitor DMLVNWO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMLVNWO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMLXGAI DI DMLXGAI DMLXGAI DN LYS-6KAKT1 DMLXGAI TI TT7M3PI DMLXGAI TN Ribosomal protein S6 kinase (S6K) DMLXGAI MA Modulator DMLXGAI RN DOI: 10.1016/S1359-6349(10)71767-5 DMLXGAI RU https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer DMLXGAI DI DMLXGAI DMLXGAI DN LYS-6KAKT1 DMLXGAI TI TTAZ05C DMLXGAI TN RAC-gamma serine/threonine-protein kinase (AKT3) DMLXGAI MA Modulator DMLXGAI RN DOI: 10.1016/S1359-6349(10)71767-5 DMLXGAI RU https://www.researchgate.net/publication/251667787_62_Preclinical_evaluation_of_LYS6KAKT1_a_novel_highly_selective_orally_bioavailable_dual_inhibitor_of_p70_S6_Kinase_and_AKT_currently_in_phase_I_clinical_trials_for_cancer DMLYAGD DI DMLYAGD DMLYAGD DN JNJ-64264681 DMLYAGD TI TTGM6VW DMLYAGD TN Tyrosine-protein kinase BTK (ATK) DMLYAGD MA Inhibitor DMLYAGD RN A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia DMLYAGD RU https://clinicaltrials.gov/ct2/show/NCT04657224 DMLYP2N DI DMLYP2N DMLYP2N DN AMG 757 DMLYP2N TI TTUN7MC DMLYP2N TN T-cell surface glycoprotein CD3 (CD3) DMLYP2N MA Inhibitor DMLYP2N RN Clinical pipeline report, company report or official report of Amgen. DMLYP2N RU https://www.amgenpipeline.com/ DMLYP2N DI DMLYP2N DMLYP2N DN AMG 757 DMLYP2N TI TT1C9K6 DMLYP2N TN Delta-like protein 3 (DLL3) DMLYP2N MA Inhibitor DMLYP2N RN Clinical pipeline report, company report or official report of Amgen. DMLYP2N RU https://www.amgenpipeline.com/ DMLZDVR DI DMLZDVR DMLZDVR DN HPN424 DMLZDVR TI TT9G4N0 DMLZDVR TN Glutamate carboxypeptidase II (GCPII) DMLZDVR RN Clinical pipeline report, company report or official report of Harpoon Therapeutics. DMLZDVR RU https://www.harpoontx.com/pipeline/ DMM0HNF DI DMM0HNF DMM0HNF DN AMG 160 DMM0HNF TI TTUN7MC DMM0HNF TN T-cell surface glycoprotein CD3 (CD3) DMM0HNF MA Inhibitor DMM0HNF RN Clinical pipeline report, company report or official report of Amgen. DMM0HNF RU https://www.amgenpipeline.com/ DMM0HNF DI DMM0HNF DMM0HNF DN AMG 160 DMM0HNF TI TT9G4N0 DMM0HNF TN Glutamate carboxypeptidase II (GCPII) DMM0HNF MA Inhibitor DMM0HNF RN Clinical pipeline report, company report or official report of Amgen. DMM0HNF RU https://www.amgenpipeline.com/ DMM0VBU DI DMM0VBU DMM0VBU DN BCA101 DMM0VBU TI TTO3HT7 DMM0VBU TN Transforming growth factor beta (TGFB) DMM0VBU MA Inhibitor DMM0VBU RN ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health. DMM0VBU RU https://clinicaltrials.gov/ct2/show/NCT04429542 DMM0VBU DI DMM0VBU DMM0VBU DN BCA101 DMM0VBU TI TTGKNB4 DMM0VBU TN Epidermal growth factor receptor (EGFR) DMM0VBU MA Inhibitor DMM0VBU RN ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health. DMM0VBU RU https://clinicaltrials.gov/ct2/show/NCT04429542 DMM1N5C DI DMM1N5C DMM1N5C DN VGX-1027 DMM1N5C TI TTXT2VN DMM1N5C TN NF-kappa-B-p38 signaling pathway (NFKB-p38 pathway) DMM1N5C MA Inhibitor DMM1N5C RN Effects of the immunomodulator, VGX-1027, in endotoxin-induced uveitis in Lewis rats. Br J Pharmacol. 2008 Nov;155(5):722-30. DMM1N5C RU https://pubmed.ncbi.nlm.nih.gov/18776919 DMM1RB6 DI DMM1RB6 DMM1RB6 DN GW-328267 DMM1RB6 TI TTM2AOE DMM1RB6 TN Adenosine A2a receptor (ADORA2A) DMM1RB6 MA Modulator DMM1RB6 RN ADENOSINE RECEPTORS AS TARGETS FOR THERAPEUTIC INTERVENTION IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE DMM1RB6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778268 DMM1Y8F DI DMM1Y8F DMM1Y8F DN NGD 94-1 DMM1Y8F TI TTE0A2F DMM1Y8F TN Dopamine D4 receptor (D4R) DMM1Y8F MA Antagonist DMM1Y8F RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMM1Y8F RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMM1Y8F DI DMM1Y8F DMM1Y8F DN NGD 94-1 DMM1Y8F TI TT729IR DMM1Y8F TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMM1Y8F MA Blocker DMM1Y8F RN Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403. DMM1Y8F RU https://pubmed.ncbi.nlm.nih.gov/11784784 DMM2EZW DI DMM2EZW DMM2EZW DN BHV-5000 DMM2EZW TI TT9IK2Z DMM2EZW TN N-methyl-D-aspartate receptor (NMDAR) DMM2EZW MA Antagonist DMM2EZW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM2EZW RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMM2SNG DI DMM2SNG DMM2SNG DN NC-4016 DMM2SNG TI TTUTN1I DMM2SNG TN Human Deoxyribonucleic acid (hDNA) DMM2SNG MA Inhibitor DMM2SNG RN Effects of Treatment with Platinum Azidothymidine and Azidothymidine on Telomerase Activity and Bcl-2 Concentration in Hepatocellular Carcinoma- Induced Rats. Avicenna J Med Biotechnol. 2014 Oct-Dec;6(4): 200-209. DMM2SNG RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224659/ DMM2V74 DI DMM2V74 DMM2V74 DN 177Lu-labelled CTT-1403 DMM2V74 TI TT9G4N0 DMM2V74 TN Glutamate carboxypeptidase II (GCPII) DMM2V74 RN Clinical pipeline report, company report or official report of Cancer Targeted Technologies. DMM2V74 RU https://www.cancertargetedtechnology.com/pipeline/ctt1403/ DMM3DBU DI DMM3DBU DMM3DBU DN BMS-986301 DMM3DBU TI TTT402Y DMM3DBU TN Stimulator of interferon genes protein (TMEM173) DMM3DBU MA Agonist DMM3DBU RN Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323. DMM3DBU RU https://pubmed.ncbi.nlm.nih.gov/33081170 DMM3U2Q DI DMM3U2Q DMM3U2Q DN TJ4309 DMM3U2Q TI TTK0O6Y DMM3U2Q TN Ecto-5'-nucleotidase (CD73) DMM3U2Q RN ClinicalTrials.gov (NCT04322006) A Phase I/II Study of TJ004309 for Advanced Solid Tumor. U.S. National Institutes of Health. DMM3U2Q RU https://clinicaltrials.gov/ct2/show/NCT04322006 DMM45P9 DI DMM45P9 DMM45P9 DN Ad-IFN-alpha DMM45P9 TI TT95SOA DMM45P9 TN Interferon alpha (IFNA) DMM45P9 MA Modulator DMM45P9 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMM45P9 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMM57CS DI DMM57CS DMM57CS DN Drug 2849330 DMM57CS TI TTDC8N2 DMM57CS TN Erbb3 tyrosine kinase receptor (Erbb-3) DMM57CS RN National Cancer Institute Drug Dictionary (drug id 754219). DMM57CS RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=754219 DMM5N8P DI DMM5N8P DMM5N8P DN MRX-2843 DMM5N8P TI TTO7LKR DMM5N8P TN Tyrosine-protein kinase Mer (MERTK) DMM5N8P MA Inhibitor DMM5N8P RN The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630. DMM5N8P RU https://pubmed.ncbi.nlm.nih.gov/27158668 DMM5N8P DI DMM5N8P DMM5N8P DN MRX-2843 DMM5N8P TI TTGJCWZ DMM5N8P TN Fms-like tyrosine kinase 3 (FLT-3) DMM5N8P MA Inhibitor DMM5N8P RN The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016 Mar;1(3):e85630. DMM5N8P RU https://pubmed.ncbi.nlm.nih.gov/27158668 DMM7RC5 DI DMM7RC5 DMM7RC5 DN NCX-6560 DMM7RC5 TI TTPADOQ DMM7RC5 TN HMG-CoA reductase (HMGCR) DMM7RC5 MA Inhibitor DMM7RC5 RN Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. DMM7RC5 RU https://pubmed.ncbi.nlm.nih.gov/12815379 DMM7TBO DI DMM7TBO DMM7TBO DN MORAb-022 DMM7TBO TI TTNYZG2 DMM7TBO TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMM7TBO RN Clinical pipeline report, company report or official report of Morphotek. DMM7TBO RU http://www.morphotek.com/pipeline/MORAb-022.aspx DMM7TBO DI DMM7TBO DMM7TBO DN MORAb-022 DMM7TBO TI TT0T5HK DMM7TBO TN Immunoglobulin gamma-1 heavy NIE (NIE) DMM7TBO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM7TBO RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMM7VOB DI DMM7VOB DMM7VOB DN Hepapoietin DMM7VOB TI TTNDSF4 DMM7VOB TN Proto-oncogene c-Met (MET) DMM7VOB MA Inhibitor DMM7VOB RN Pharmacokinetics and biochemical effects of hepapoietin in patients with chronic liver disease. Alimentary Pharmacology & Therapeutics Volume 16, Issue 2, pages 235-242, February 2002. DMM7VOB RU http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2002.01110.x/full DMM7ZXR DI DMM7ZXR DMM7ZXR DN GSK2126458 DMM7ZXR TI TTHBTOP DMM7ZXR TN PI3-kinase gamma (PIK3CG) DMM7ZXR MA Modulator DMM7ZXR RN Company report (GSK) DMM7ZXR RU http://www.gsk-clinicalstudyregister.com/study/113794#ps DMM86OH DI DMM86OH DMM86OH DN DSP-6745 DMM86OH TI TT85JO3 DMM86OH TN 5-HT receptor (5HTR) DMM86OH MA Antagonist DMM86OH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMM86OH RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMM8GZT DI DMM8GZT DMM8GZT DN DL-017 DMM8GZT TI TT34BHT DMM8GZT TN Adrenergic receptor alpha-1D (ADRA1D) DMM8GZT MA Modulator DMM8GZT RN Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9. DMM8GZT RU https://pubmed.ncbi.nlm.nih.gov/11707693 DMM95XS DI DMM95XS DMM95XS DN CART19 cell DMM95XS TI TTW640A DMM95XS TN B-lymphocyte surface antigen B4 (CD19) DMM95XS MA CAR-T-Cell-Therapy DMM95XS RN ClinicalTrials.gov (NCT03685786) CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT DMM95XS RU https://clinicaltrials.gov/ct2/show/NCT03685786 DMM9ORD DI DMM9ORD DMM9ORD DN ASG-15ME DMM9ORD TI TTTVEKI DMM9ORD TN SLIT and NTRK-like family member 6 (SLITRK6) DMM9ORD RN Clinical pipeline report, company report or official report of Seattle Genetics. DMM9ORD RU http://www.seattlegenetics.com/asg15me DMM9S51 DI DMM9S51 DMM9S51 DN ELND-002 DMM9S51 TI TT4BT06 DMM9S51 TN Integrin alpha-4 (ITGA4) DMM9S51 MA Antagonist DMM9S51 RN Paxillin binding to the alpha 4 integrin subunit stimulates LFA-1 (integrin alpha L beta 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol. 2003 Jun 15;170(12):5912-8. DMM9S51 RU https://pubmed.ncbi.nlm.nih.gov/12794117 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTANPDJ DMMAS3K TN Carbonic anhydrase II (CA-II) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TT2LVK8 DMMAS3K TN Carbonic anhydrase IX (CA-IX) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/15664814 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTHQPL7 DMMAS3K TN Carbonic anhydrase I (CA-I) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTZHA0O DMMAS3K TN Carbonic anhydrase IV (CA-IV) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMMAS3K DI DMMAS3K DMMAS3K DN SULFAMIDE DMMAS3K TI TTUNARX DMMAS3K TN Carbonic anhydrase (CA) DMMAS3K MA Inhibitor DMMAS3K RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMMAS3K RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMMBQ20 DI DMMBQ20 DMMBQ20 DN CPI-818 DMMBQ20 TI TT3C80U DMMBQ20 TN T-cell-specific kinase (ITK) DMMBQ20 MA Inhibitor DMMBQ20 RN Clinical pipeline report, company report or official report of Corvus Pharmaceuticals. DMMBQ20 RU https://www.corvuspharma.com/our-science/our-pipeline/ DMMBQV3 DI DMMBQV3 DMMBQV3 DN Ad5-ENVA-48 DMMBQV3 TI TTEC2T3 DMMBQV3 TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DMMBQV3 RN ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health. DMMBQV3 RU https://clinicaltrials.gov/ct2/show/NCT00695877 DMMC6YR DI DMMC6YR DMMC6YR DN CM2489 DMMC6YR TI TT5HONZ DMMC6YR TN Calcium channel unspecific (CaC) DMMC6YR MA Modulator DMMC6YR RN Molecular pharmacology of store-operated CRAC channels DMMC6YR RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913763 DMME5P8 DI DMME5P8 DMME5P8 DN Pfizer 4 DMME5P8 TI TT5TKPM DMME5P8 TN Neutral endopeptidase (MME) DMME5P8 MA Inhibitor DMME5P8 RN Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. DMME5P8 RU https://pubmed.ncbi.nlm.nih.gov/17826689 DMMEFO0 DI DMMEFO0 DMMEFO0 DN COH29 DMMEFO0 TI TTX09M4 DMMEFO0 TN Ribonucleotide reductase (RIR) DMMEFO0 MA Inhibitor DMMEFO0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMEFO0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMEPKR DI DMMEPKR DMMEPKR DN PEG-Interferon lambda (IL-29) DMMEPKR TI TTM624L DMMEPKR TN Interleukin-29 (IL29) DMMEPKR MA Agonist DMMEPKR RN Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5. DMMEPKR RU https://pubmed.ncbi.nlm.nih.gov/20645873 DMMETU8 DI DMMETU8 DMMETU8 DN PF-4418948 DMMETU8 TI TT1ZAVI DMMETU8 TN Prostaglandin E2 receptor EP2 (PTGER2) DMMETU8 MA Antagonist DMMETU8 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMMETU8 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMMF0J3 DI DMMF0J3 DMMF0J3 DN CMX-157 DMMF0J3 TI TT84ETX DMMF0J3 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMF0J3 MA Inhibitor DMMF0J3 RN Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors. Drug Discov Today Technol. 2012 Autumn; 9(3): e183-e193. DMMF0J3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612025/ DMMF6UB DI DMMF6UB DMMF6UB DN GE-1170A DMMF6UB TI TTYQIFM DMMF6UB TN Staphylococcus Elongation factor Tu (Stap-coc tuf) DMMF6UB MA Inhibitor DMMF6UB RN GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol. 2000 Dec 15;304(5):995-1005. DMMF6UB RU https://pubmed.ncbi.nlm.nih.gov/11124042 DMMFL2P DI DMMFL2P DMMFL2P DN Anti-CD7 CAR-T cells DMMFL2P TI TTP6B8O DMMFL2P TN T-cell antigen CD7 (CD7) DMMFL2P MA CAR-T-Cell-Therapy DMMFL2P RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMMFL2P RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMMI4XR DI DMMI4XR DMMI4XR DN JNJ-17305600 DMMI4XR TI TTHJTF7 DMMI4XR TN Glycine transporter GlyT-1 (SLC6A9) DMMI4XR MA Inhibitor DMMI4XR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DMMI4XR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DMMJ1PO DI DMMJ1PO DMMJ1PO DN SGN-CD70A DMMJ1PO TI TTNCIE0 DMMJ1PO TN CD70 antigen (CD27-L) DMMJ1PO RN SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647. DMMJ1PO RU http://cancerres.aacrjournals.org/content/74/19_Supplement/2647 DMMJXAR DI DMMJXAR DMMJXAR DN Entolimod DMMJXAR TI TTCXP8J DMMJXAR TN Toll-like receptor 5 (TLR5) DMMJXAR MA Agonist DMMJXAR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMJXAR RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMMJZ2E DI DMMJZ2E DMMJZ2E DN PF-07104091 DMMJZ2E TI TT7HF4W DMMJZ2E TN Cyclin-dependent kinase 2 (CDK2) DMMJZ2E MA Inhibitor DMMJZ2E RN ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health. DMMJZ2E RU https://clinicaltrials.gov/ct2/show/NCT04553133 DMMKN4Q DI DMMKN4Q DMMKN4Q DN NOX-A12 DMMKN4Q TI TT4UGTF DMMKN4Q TN Stromal cell-derived factor 1 (CXCL12) DMMKN4Q MA Inhibitor DMMKN4Q RN SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy. Transpl Int. 2015 Dec;28(12):1426-35. DMMKN4Q RU https://pubmed.ncbi.nlm.nih.gov/26265085 DMMKUOZ DI DMMKUOZ DMMKUOZ DN VCH-286 DMMKUOZ TI TT2CEJG DMMKUOZ TN C-C chemokine receptor type 5 (CCR5) DMMKUOZ MA Antagonist DMMKUOZ RN The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets. Mol Biol Int. 2012;2012:401965. DMMKUOZ RU https://pubmed.ncbi.nlm.nih.gov/22848825 DMMKZYV DI DMMKZYV DMMKZYV DN Namitecan DMMKZYV TI TTGTQHC DMMKZYV TN DNA topoisomerase I (TOP1) DMMKZYV MA Inhibitor DMMKZYV RN Namitecan: a hydrophilic camptothecin with a promising preclinical profile. Curr Med Chem. 2012;19(21):3488-501. DMMKZYV RU https://pubmed.ncbi.nlm.nih.gov/22680917 DMMO2EJ DI DMMO2EJ DMMO2EJ DN CD19.CAR-aNKT cells DMMO2EJ TI TTW640A DMMO2EJ TN B-lymphocyte surface antigen B4 (CD19) DMMO2EJ MA CAR-T-Cell-Therapy DMMO2EJ RN ClinicalTrials.gov (NCT03774654) CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) DMMO2EJ RU https://clinicaltrials.gov/ct2/show/NCT03774654 DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTCJG29 DMMO3G5 TN Serine/threonine-protein kinase mTOR (mTOR) DMMO3G5 MA Modulator DMMO3G5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMMO3G5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTHBTOP DMMO3G5 TN PI3-kinase gamma (PIK3CG) DMMO3G5 MA Modulator DMMO3G5 RN VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther. 2013 Feb;12(2):151-61. DMMO3G5 RU https://pubmed.ncbi.nlm.nih.gov/23270925 DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTX4GLS DMMO3G5 TN Mammalian target of rapamycin complex 1 (mTORC1) DMMO3G5 MA Inhibitor DMMO3G5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMO3G5 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMMO3G5 DI DMMO3G5 DMMO3G5 DN VS-5584 DMMO3G5 TI TTWDKCL DMMO3G5 TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DMMO3G5 MA Inhibitor DMMO3G5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMMO3G5 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMMP7XG DI DMMP7XG DMMP7XG DN MAXY-4 DMMP7XG TI TTHGXBU DMMP7XG TN T-lymphocyte activation antigen CD86 (FUN1) DMMP7XG MA Inhibitor DMMP7XG RN Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3. DMMP7XG RU https://pubmed.ncbi.nlm.nih.gov/21474713 DMMP7XG DI DMMP7XG DMMP7XG DN MAXY-4 DMMP7XG TI TTFZDNP DMMP7XG TN Activation B7-1 antigen (CD80) DMMP7XG MA Inhibitor DMMP7XG RN Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011 Apr 29;332(6029):600-3. DMMP7XG RU https://pubmed.ncbi.nlm.nih.gov/21474713 DMMPFZO DI DMMPFZO DMMPFZO DN IC9.GD2.CAR.IL-15 T-cells DMMPFZO TI TT80ARU DMMPFZO TN Ganglioside GD2 (GD2) DMMPFZO MA CAR-T-Cell-Therapy DMMPFZO RN ClinicalTrials.gov (NCT03721068) Phase I Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma DMMPFZO RU https://clinicaltrials.gov/ct2/show/NCT03721068 DMMPINS DI DMMPINS DMMPINS DN IGM-2323 DMMPINS TI TTUN7MC DMMPINS TN T-cell surface glycoprotein CD3 (CD3) DMMPINS MA Inhibitor DMMPINS RN Clinical pipeline report, company report or official report of IGM Biosciences. DMMPINS RU https://igmbio.com/pipeline/cd20-x-dc3/ DMMPINS DI DMMPINS DMMPINS DN IGM-2323 DMMPINS TI TTUE541 DMMPINS TN Leukocyte surface antigen Leu-16 (CD20) DMMPINS MA Inhibitor DMMPINS RN Clinical pipeline report, company report or official report of IGM Biosciences. DMMPINS RU https://igmbio.com/pipeline/cd20-x-dc3/ DMMPKN3 DI DMMPKN3 DMMPKN3 DN CTX-471 DMMPKN3 TI TTPW9LJ DMMPKN3 TN Co-stimulatory molecule 4-1BB (CD137) DMMPKN3 MA Agonist DMMPKN3 RN Clinical pipeline report, company report or official report of Compass Therapeutics. DMMPKN3 RU https://www.compasstherapeutics.com/candidates/ctx-471-cd137-agonist/ DMMPTCK DI DMMPTCK DMMPTCK DN ARRY-300 DMMPTCK TI TTROQ37 DMMPTCK TN MAPK/ERK kinase kinase (MAP3K) DMMPTCK MA Modulator DMMPTCK RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013 Apr 12;6:27. DMMPTCK RU https://pubmed.ncbi.nlm.nih.gov/23587417 DMMQ12N DI DMMQ12N DMMQ12N DN BI 860585 DMMQ12N TI TTCJG29 DMMQ12N TN Serine/threonine-protein kinase mTOR (mTOR) DMMQ12N MA Inhibitor DMMQ12N RN Clinical pipeline report, company report or official report of tatcongress. DMMQ12N RU http://tatcongress.org/wp-content/uploads/2014/05/tat2014-abstracts-poster-session-6_140217.pdf DMMR4E7 DI DMMR4E7 DMMR4E7 DN PBSVax DMMR4E7 TI TT3NH7G DMMR4E7 TN Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA) DMMR4E7 MA Modulator DMMR4E7 RN ClinicalTrials.gov (NCT01578889) Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults. U.S. National Institutes of Health. DMMR4E7 RU https://clinicaltrials.gov/ct2/show/NCT01578889 DMMR7CH DI DMMR7CH DMMR7CH DN Insulin oral sublingual DMMR7CH TI TTCBFJO DMMR7CH TN Insulin receptor (INSR) DMMR7CH MA Modulator DMMR7CH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMMR7CH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMMRANJ DI DMMRANJ DMMRANJ DN Anti-CD19-CAR T DMMRANJ TI TTW640A DMMRANJ TN B-lymphocyte surface antigen B4 (CD19) DMMRANJ MA CAR-T-Cell-Therapy DMMRANJ RN ClinicalTrials.gov (NCT02546739) Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL DMMRANJ RU https://clinicaltrials.gov/ct2/show/NCT02546739 DMMRDUN DI DMMRDUN DMMRDUN DN TrasGEX DMMRDUN TI TT6EO5L DMMRDUN TN Erbb2 tyrosine kinase receptor (HER2) DMMRDUN RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2515). DMMRDUN RU http://meetinglibrary.asco.org/content/131582-144 DMMVXGR DI DMMVXGR DMMVXGR DN H3B-8800 DMMVXGR TI TTXR78S DMMVXGR TN SF3b complex (SF3b) DMMVXGR MA Modulator DMMVXGR RN Clinical pipeline report, company report or official report of H3 Biomedicine. DMMVXGR RU https://www.h3biomedicine.com/science/ DMMW72C DI DMMW72C DMMW72C DN AZD-1152-HQPA DMMW72C TI TT5LS6T DMMW72C TN Aurora kinase B (AURKB) DMMW72C MA Modulator DMMW72C RN Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Invest New Drugs.2013 Apr;31(2):370-80. DMMW72C RU https://www.ncbi.nlm.nih.gov/pubmed/22661287 DMMWEH6 DI DMMWEH6 DMMWEH6 DN AVP-21D9 DMMWEH6 TI TT3YGCD DMMWEH6 TN Bacterial Protective antigen (Bact pagA) DMMWEH6 RN Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrob Agents Chemother. 2014 July; 58(7): 3618-3625. DMMWEH6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068543/ DMMWNQP DI DMMWNQP DMMWNQP DN TAK-329 DMMWNQP TI TTDLNGZ DMMWNQP TN Glucokinase (GCK) DMMWNQP MA Inhibitor DMMWNQP RN Clinical pipeline report, company report or official report of Takeda. DMMWNQP RU https://www.takeda.com/csr/reports/pdf/index/ar2011_16_en.pdf DMMWS3O DI DMMWS3O DMMWS3O DN RG-7010 DMMWS3O TI TTHRID2 DMMWS3O TN Insulin-like growth factor I receptor (IGF1R) DMMWS3O MA Modulator DMMWS3O RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031207) DMMWS3O RU http://adisinsight.springer.com/drugs/800031207 DMMYRHV DI DMMYRHV DMMYRHV DN NOX-700 DMMYRHV TI TTUO9SZ DMMYRHV TN Nitric oxide elimination (NOE) DMMYRHV MA Modulator DMMYRHV RN Inhibition of nitrosylation, nitration, lymphocyte proliferation, and gene expression in acute and delayed cardiac allograft rejection by an orally active dithiocarbamate. J Cardiovasc Pharmacol. 2004 Apr;43(4):522-30. DMMYRHV RU https://pubmed.ncbi.nlm.nih.gov/15085063 DMN3D72 DI DMN3D72 DMN3D72 DN SL-172154 DMN3D72 TI TTN6Y9A DMN3D72 TN CD40L receptor (CD40) DMN3D72 MA Inhibitor DMN3D72 RN Clinical pipeline report, company report or official report of Shattuck Labs. DMN3D72 RU https://www.shattucklabs.com/pipeline/overview/ DMN3D72 DI DMN3D72 DMN3D72 DN SL-172154 DMN3D72 TI TT28S46 DMN3D72 TN Leukocyte surface antigen CD47 (CD47) DMN3D72 MA Inhibitor DMN3D72 RN Clinical pipeline report, company report or official report of Shattuck Labs. DMN3D72 RU https://www.shattucklabs.com/pipeline/overview/ DMN40DU DI DMN40DU DMN40DU DN MK-4621 DMN40DU TI TTVB0O3 DMN40DU TN Retinoic acid-inducible gene-1 (RIG-1) DMN40DU MA Agonist DMN40DU RN National Cancer Institute Drug Dictionary (drug name RGT100). DMN40DU RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rig-i-selective-ligand-rgt100 DMN4D3A DI DMN4D3A DMN4D3A DN ARI-2243 DMN4D3A TI TTDIGC1 DMN4D3A TN Dipeptidyl peptidase 4 (DPP-4) DMN4D3A MA Modulator DMN4D3A RN Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors. Mayo Clin Proc. 2010 December; 85(12 Suppl): S27-S37. DMN4D3A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996165/ DMN4I7P DI DMN4I7P DMN4I7P DN GSK3901961 DMN4I7P TI TTE5ITK DMN4I7P TN Cancer/testis antigen 1 (NY-ESO-1) DMN4I7P RN Clinical pipeline report, company report or official report of GlaxoSmithKline. DMN4I7P RU https://www.gsk.com/en-gb/research-and-development/our-pipeline/ DMN4LMT DI DMN4LMT DMN4LMT DN Oxeglitazar DMN4LMT TI TTZMAO3 DMN4LMT TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMN4LMT MA Modulator DMN4LMT RN Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. DMN4LMT RU https://pubmed.ncbi.nlm.nih.gov/20653327 DMN4LMT DI DMN4LMT DMN4LMT DN Oxeglitazar DMN4LMT TI TTJ584C DMN4LMT TN Peroxisome proliferator-activated receptor alpha (PPARA) DMN4LMT MA Modulator DMN4LMT RN Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16. DMN4LMT RU https://pubmed.ncbi.nlm.nih.gov/20653327 DMN4OGH DI DMN4OGH DMN4OGH DN TAK-960 DMN4OGH TI TTIYVQP DMN4OGH TN Polo-like kinase 1 (PLK1) DMN4OGH MA Modulator DMN4OGH RN TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Mol Cancer Ther. 2012 Mar;11(3):700-9. DMN4OGH RU https://pubmed.ncbi.nlm.nih.gov/22188812 DMN8I5Q DI DMN8I5Q DMN8I5Q DN CDP-7657 DMN8I5Q TI TTIJP3Q DMN8I5Q TN TNF related activation protein (CD40LG) DMN8I5Q RN CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234. DMN8I5Q RU https://pubmed.ncbi.nlm.nih.gov/26335795 DMN9JCD DI DMN9JCD DMN9JCD DN VS-4718 DMN9JCD TI TTON5IT DMN9JCD TN Focal adhesion kinase 1 (FAK) DMN9JCD MA Inhibitor DMN9JCD RN FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61. DMN9JCD RU https://pubmed.ncbi.nlm.nih.gov/24899686 DMN9MPX DI DMN9MPX DMN9MPX DN 212Pb-labelled DOTAMTATE DMN9MPX TI TTOMNR9 DMN9MPX TN Somatostatin receptor (SSTR) DMN9MPX RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DMN9MPX RU https://pubmed.ncbi.nlm.nih.gov/32728208 DMNAR29 DI DMNAR29 DMNAR29 DN HuCART19 DMNAR29 TI TTW640A DMNAR29 TN B-lymphocyte surface antigen B4 (CD19) DMNAR29 MA CAR-T-Cell-Therapy DMNAR29 RN ClinicalTrials.gov (NCT02374333) Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy DMNAR29 RU https://clinicaltrials.gov/ct2/show/NCT02374333 DMNBPKS DI DMNBPKS DMNBPKS DN Iofolastat I-124 DMNBPKS TI TT9G4N0 DMNBPKS TN Glutamate carboxypeptidase II (GCPII) DMNBPKS MA Inhibitor DMNBPKS RN 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med. 2011 Jul;52(7):1087-93. DMNBPKS RU https://pubmed.ncbi.nlm.nih.gov/21680691 DMNCBIU DI DMNCBIU DMNCBIU DN IC9-CAR19 T cells DMNCBIU TI TTW640A DMNCBIU TN B-lymphocyte surface antigen B4 (CD19) DMNCBIU MA CAR-T-Cell-Therapy DMNCBIU RN ClinicalTrials.gov (NCT03696784) Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma DMNCBIU RU https://clinicaltrials.gov/ct2/show/NCT03696784 DMNDACU DI DMNDACU DMNDACU DN CD19 CAR-T cells DMNDACU TI TTW640A DMNDACU TN B-lymphocyte surface antigen B4 (CD19) DMNDACU MA CAR-T-Cell-Therapy DMNDACU RN ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia DMNDACU RU https://clinicaltrials.gov/ct2/show/NCT03064269 DMNDGPT DI DMNDGPT DMNDGPT DN DS-2969 DMNDGPT TI TTPBZUO DMNDGPT TN Clostridium difficile DNA gyrase (CD gyr) DMNDGPT MA Inhibitor DMNDGPT RN In Vitro and In Vivo Activities of DS-2969b, a Novel GyrB Inhibitor, against Clostridium difficile. Antimicrob Agents Chemother. 2018 Mar 27;62(4):e02157-17. DMNDGPT RU https://pubmed.ncbi.nlm.nih.gov/29439962 DMNDHKL DI DMNDHKL DMNDHKL DN TG-1701 DMNDHKL TI TTGM6VW DMNDHKL TN Tyrosine-protein kinase BTK (ATK) DMNDHKL MA Inhibitor DMNDHKL RN Clinical pipeline report, company report or official report of TG Therapeutics. DMNDHKL RU https://www.tgtherapeutics.com/our-pipeline/tg-1701/ DMNE9Z0 DI DMNE9Z0 DMNE9Z0 DN T-0128 DMNE9Z0 TI TTUTN1I DMNE9Z0 TN Human Deoxyribonucleic acid (hDNA) DMNE9Z0 MA Inhibitor DMNE9Z0 RN Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128). Cancer Res. 2000 Jun 1;60(11):2988-95. DMNE9Z0 RU https://pubmed.ncbi.nlm.nih.gov/10850447 DMNEFQ6 DI DMNEFQ6 DMNEFQ6 DN AMG 529 DMNEFQ6 TI TTYM94H DMNEFQ6 TN Asialoglycoprotein receptor 1 (ASGR1) DMNEFQ6 MA Inhibitor DMNEFQ6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNEFQ6 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMNEVKA DI DMNEVKA DMNEVKA DN E2012 DMNEVKA TI TT9W8GU DMNEVKA TN Gamma-secretase (GS) DMNEVKA MA Modulator DMNEVKA RN Chemical Biology, Molecular Mechanism and Clinical Perspective of -Secretase Modulators in Alzheimer's Disease.Curr Neuropharmacol.2011 Dec;9(4):598-622. DMNEVKA RU https://www.ncbi.nlm.nih.gov/pubmed/22798753 DMNF09S DI DMNF09S DMNF09S DN NV-04 DMNF09S TI TTXPQW1 DMNF09S TN Hormone unspecific (HOM) DMNF09S MA Modulator DMNF09S RN US patent application no. 2011,0201,626, 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase. DMNF09S RU https://www.google.com/patents/US20110201626 DMNF3GW DI DMNF3GW DMNF3GW DN Afeletecan DMNF3GW TI TTGTQHC DMNF3GW TN DNA topoisomerase I (TOP1) DMNF3GW MA Inhibitor DMNF3GW RN The fate of camptothecin glycoconjugate: report of a clinical hold during a phase II study of BAY 56-3722 (formerly BAY 38-3441), in patients with recurrent or metastatic colorectal cancer resistant/refractory to irinotecan. Invest New Drugs. 2012 June; 30(3): 1208-1210. DMNF3GW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3348469/ DMNFDYE DI DMNFDYE DMNFDYE DN KD3010 DMNFDYE TI TT2JWF6 DMNFDYE TN Peroxisome proliferator-activated receptor delta (PPARD) DMNFDYE MA Agonist DMNFDYE RN Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007. DMNFDYE RU http://www.newsrx.com/newsletters/Health-Business-Week/2006-10-27/102320063331046HBW.html DMNFEC6 DI DMNFEC6 DMNFEC6 DN Drug 2878175 DMNFEC6 TI TTMVBWH DMNFEC6 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMNFEC6 MA Inhibitor DMNFEC6 RN P1224 GSK2878175, A POTENT NON-NUCLEOSIDE INHIBITOR OF HCV NS5B WITH PAN-GENOTYPIC ACTIVITY. Journal of Hepatology Volume 60, Issue 1, Supplement, April 2014, Pages S496. DMNFEC6 RU http://www.sciencedirect.com/science/article/pii/S0168827814613842 DMNFO2B DI DMNFO2B DMNFO2B DN Anti-BCMA CAR T cells DMNFO2B TI TTZ3P4W DMNFO2B TN B-cell maturation protein (TNFRSF17) DMNFO2B MA CAR-T-Cell-Therapy DMNFO2B RN ClinicalTrials.gov (NCT02215967) Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma DMNFO2B RU https://clinicaltrials.gov/ct2/show/NCT02215967 DMNFZOT DI DMNFZOT DMNFZOT DN TAK-593 DMNFZOT TI TTUTJGQ DMNFZOT TN Vascular endothelial growth factor receptor 2 (KDR) DMNFZOT MA Modulator DMNFZOT RN Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. DMNFZOT RU https://www.ncbi.nlm.nih.gov/pubmed/21182308 DMNFZOT DI DMNFZOT DMNFZOT DN TAK-593 DMNFZOT TI TTI7421 DMNFZOT TN Platelet-derived growth factor receptor beta (PDGFRB) DMNFZOT MA Modulator DMNFZOT RN Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51. DMNFZOT RU https://www.ncbi.nlm.nih.gov/pubmed/21182308 DMNH1Y5 DI DMNH1Y5 DMNH1Y5 DN CAR-T Cells targeting MUCI DMNH1Y5 TI TTBHFYQ DMNH1Y5 TN Mucin-1 (MUC1) DMNH1Y5 MA CAR-T-Cell-Therapy DMNH1Y5 RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMNH1Y5 RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMNHBMC DI DMNHBMC DMNHBMC DN AIC-292 DMNHBMC TI TT84ETX DMNHBMC TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMNHBMC MA Inhibitor DMNHBMC RN In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9. DMNHBMC RU https://pubmed.ncbi.nlm.nih.gov/23959304 DMNHPOT DI DMNHPOT DMNHPOT DN LErafAON DMNHPOT TI TTAN5W2 DMNHPOT TN Raf messenger RNA (Raf mRNA) DMNHPOT RN Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53. DMNHPOT RU https://pubmed.ncbi.nlm.nih.gov/15014358 DMNHSI8 DI DMNHSI8 DMNHSI8 DN PCO371 DMNHSI8 TI TTFPD47 DMNHSI8 TN Parathyroid hormone 1 receptor (PTH1R) DMNHSI8 MA Agonist DMNHSI8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNHSI8 RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMNI60O DI DMNI60O DMNI60O DN MEDI4276 DMNI60O TI TT6EO5L DMNI60O TN Erbb2 tyrosine kinase receptor (HER2) DMNI60O MA Modulator DMNI60O RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNI60O RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNICD4 DI DMNICD4 DMNICD4 DN CYT-013-IL1bQb DMNICD4 TI TTRYK0X DMNICD4 TN Interleukin-1 beta (IL1B) DMNICD4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623). DMNICD4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2623 DMNIVFJ DI DMNIVFJ DMNIVFJ DN AVN-322 DMNIVFJ TI TTJS8PY DMNIVFJ TN 5-HT 6 receptor (HTR6) DMNIVFJ MA Antagonist DMNIVFJ RN AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Curr Alzheimer Res. 2017;14(3):268-294. DMNIVFJ RU https://pubmed.ncbi.nlm.nih.gov/27829340 DMNJTLC DI DMNJTLC DMNJTLC DN Neu-2000 DMNJTLC TI TTN9D8E DMNJTLC TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMNJTLC MA Antagonist DMNJTLC RN Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug News Perspect. 2010 Nov;23(9):549-56. DMNJTLC RU https://pubmed.ncbi.nlm.nih.gov/21152450 DMNKV3O DI DMNKV3O DMNKV3O DN XEN007 DMNKV3O TI TTX4QDJ DMNKV3O TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMNKV3O MA Inhibitor DMNKV3O RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNKV3O RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNL5G7 DI DMNL5G7 DMNL5G7 DN BAY-1817080 DMNL5G7 TI TT2THBD DMNL5G7 TN P2X purinoceptor 3 (P2RX3) DMNL5G7 MA Inhibitor DMNL5G7 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMNL5G7 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMNL8MO DI DMNL8MO DMNL8MO DN MEDI-573 DMNL8MO TI TTT6LOU DMNL8MO TN Insulin-like growth factor-I (IGF1) DMNL8MO MA Modulator DMNL8MO RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNL8MO RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNLK5Y DI DMNLK5Y DMNLK5Y DN PF-06647020 DMNLK5Y TI TTXH2ZN DMNLK5Y TN Inactive tyrosine-protein kinase 7 (PTK7) DMNLK5Y MA Inhibitor DMNLK5Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNLK5Y RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMNLY9R DI DMNLY9R DMNLY9R DN YM-16151-4 DMNLY9R TI TTR6W5O DMNLY9R TN Adrenergic receptor beta-1 (ADRB1) DMNLY9R MA Modulator DMNLY9R RN Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. DMNLY9R RU https://pubmed.ncbi.nlm.nih.gov/7685438 DMNLY9R DI DMNLY9R DMNLY9R DN YM-16151-4 DMNLY9R TI TT5HONZ DMNLY9R TN Calcium channel unspecific (CaC) DMNLY9R MA Modulator DMNLY9R RN Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8. DMNLY9R RU https://pubmed.ncbi.nlm.nih.gov/7685438 DMNO91Q DI DMNO91Q DMNO91Q DN PTI-202 DMNO91Q TI TTN4QDT DMNO91Q TN Opioid receptor (OPR) DMNO91Q MA Modulator DMNO91Q RN Clinical pipeline report, company report or official report of Pain Therapeutics, Inc. DMNO91Q RU http://www.paintrials.com/pti-202.html DMNOSYW DI DMNOSYW DMNOSYW DN BI-853520 DMNOSYW TI TTON5IT DMNOSYW TN Focal adhesion kinase 1 (FAK) DMNOSYW MA Modulator DMNOSYW RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNOSYW RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNP6T3 DI DMNP6T3 DMNP6T3 DN GEN1042 DMNP6T3 TI TTN6Y9A DMNP6T3 TN CD40L receptor (CD40) DMNP6T3 MA Agonist DMNP6T3 RN Clinical pipeline report, company report or official report of Genmab. DMNP6T3 RU https://www.genmab.com/pipeline/ DMNP6T3 DI DMNP6T3 DMNP6T3 DN GEN1042 DMNP6T3 TI TTPW9LJ DMNP6T3 TN Co-stimulatory molecule 4-1BB (CD137) DMNP6T3 MA Agonist DMNP6T3 RN Clinical pipeline report, company report or official report of Genmab. DMNP6T3 RU https://www.genmab.com/pipeline/ DMNPS59 DI DMNPS59 DMNPS59 DN EZN-4176 DMNPS59 TI TTKPW01 DMNPS59 TN Androgen receptor messenger RNA (AR mRNA) DMNPS59 RN 2011 Pipeline of Santaris Pharma. DMNPS59 RU http://www.santaris.com/product-pipeline DMNSC0O DI DMNSC0O DMNSC0O DN DNL747 DMNSC0O TI TTAIQSN DMNSC0O TN Receptor-interacting protein 1 (RIPK1) DMNSC0O MA Inhibitor DMNSC0O RN Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020 Aug;19(8):553-571. DMNSC0O RU https://pubmed.ncbi.nlm.nih.gov/32669658 DMNSJ3C DI DMNSJ3C DMNSJ3C DN JNJ-26854165 DMNSJ3C TI TT08GJW DMNSJ3C TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMNSJ3C MA Modulator DMNSJ3C RN Serdemetan antagonizes the Mdm2-HIF1alpha axis leading to decreased levels of glycolytic enzymes. PLoS One. 2013 Sep 6;8(9):e74741. DMNSJ3C RU https://pubmed.ncbi.nlm.nih.gov/24040331 DMNTVUK DI DMNTVUK DMNTVUK DN TS01 DMNTVUK TI TT7LRQH DMNTVUK TN Complement C1s component (C1S) DMNTVUK MA Modulator DMNTVUK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNTVUK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNUY32 DI DMNUY32 DMNUY32 DN BI-811283 DMNUY32 TI TT5LS6T DMNUY32 TN Aurora kinase B (AURKB) DMNUY32 MA Inhibitor DMNUY32 RN Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs. 2012 Dec;30(6):2411-32. DMNUY32 RU https://pubmed.ncbi.nlm.nih.gov/22350019 DMNVDI2 DI DMNVDI2 DMNVDI2 DN RAD-140 DMNVDI2 TI TTS64P2 DMNVDI2 TN Androgen receptor (AR) DMNVDI2 MA Modulator DMNVDI2 RN Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Med Chem Lett. 2010 Dec 2;2(2):124-9. DMNVDI2 RU https://pubmed.ncbi.nlm.nih.gov/24900290 DMNVPI1 DI DMNVPI1 DMNVPI1 DN BAY 1905254 DMNVPI1 TI TT0R2QD DMNVPI1 TN Ig-like domain-containing receptor 2 (ILDR2) DMNVPI1 MA Inhibitor DMNVPI1 RN Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2). Cancer Immunol Res. 2020 Jul;8(7):895-911. DMNVPI1 RU https://pubmed.ncbi.nlm.nih.gov/32312711 DMNW3LH DI DMNW3LH DMNW3LH DN SY-5609 DMNW3LH TI TTQYF7G DMNW3LH TN Cyclin-dependent kinase 7 (CDK7) DMNW3LH MA Inhibitor DMNW3LH RN Clinical pipeline report, company report or official report of Syros Pharmaceuticals. DMNW3LH RU https://www.syros.com/programs/sy-5609 DMNWPMO DI DMNWPMO DMNWPMO DN IDH305 DMNWPMO TI TTV2A1R DMNWPMO TN Oxalosuccinate decarboxylase (IDH1) DMNWPMO MA Inhibitor DMNWPMO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMNWPMO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMNX0V7 DI DMNX0V7 DMNX0V7 DN CD38 CAR-T DMNX0V7 TI TTPURFN DMNX0V7 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMNX0V7 RN Clinical pipeline report, company report or official report of Sorrento Therapeutics. DMNX0V7 RU https://sorrentotherapeutics.com/research/pipeline/ DMNX3US DI DMNX3US DMNX3US DN GS-9820 DMNX3US TI TTGBPJE DMNX3US TN PI3-kinase delta (PIK3CD) DMNX3US MA Inhibitor DMNX3US RN National Cancer Institute Drug Dictionary (drug id 741949). DMNX3US RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=741949 DMNY0U5 DI DMNY0U5 DMNY0U5 DN BPI-9016 M DMNY0U5 TI TTNDSF4 DMNY0U5 TN Proto-oncogene c-Met (MET) DMNY0U5 MA Inhibitor DMNY0U5 RN First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6. DMNY0U5 RU https://pubmed.ncbi.nlm.nih.gov/31948451 DMNY0U5 DI DMNY0U5 DMNY0U5 DN BPI-9016 M DMNY0U5 TI TTZPY6J DMNY0U5 TN Tyrosine-protein kinase UFO (AXL) DMNY0U5 MA Inhibitor DMNY0U5 RN First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. J Hematol Oncol. 2020 Jan 16;13(1):6. DMNY0U5 RU https://pubmed.ncbi.nlm.nih.gov/31948451 DMNYGB8 DI DMNYGB8 DMNYGB8 DN GSK-1322888 DMNYGB8 TI TT953CX DMNYGB8 TN Motilin receptor (MLNR) DMNYGB8 MA Agonist DMNYGB8 RN ClinicalTrials.gov (NCT01294566) FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers. U.S. National Institutes of Health. DMNYGB8 RU https://clinicaltrials.gov/ct2/show/NCT01294566 DMNZ6XH DI DMNZ6XH DMNZ6XH DN VNRX-5133 DMNZ6XH TI TTHI19T DMNZ6XH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMNZ6XH MA Inhibitor DMNZ6XH RN Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801. DMNZ6XH RU https://pubmed.ncbi.nlm.nih.gov/31765155 DMNZQU5 DI DMNZQU5 DMNZQU5 DN P-7435 DMNZQU5 TI TTF8P9I DMNZQU5 TN Diacylglycerol acyltransferase 1 (DGAT1) DMNZQU5 MA Inhibitor DMNZQU5 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033014) DMNZQU5 RU http://adisinsight.springer.com/drugs/800033014 DMO0AJE DI DMO0AJE DMO0AJE DN CC-90010 DMO0AJE TI TTE4BSY DMO0AJE TN Bromodomain and extraterminal domain protein (BET) DMO0AJE MA Inhibitor DMO0AJE RN Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma. Ann Oncol. 2020 Jun;31(6):780-788. DMO0AJE RU https://pubmed.ncbi.nlm.nih.gov/32240793 DMO0CA8 DI DMO0CA8 DMO0CA8 DN SHP616 DMO0CA8 TI TT7LRQH DMO0CA8 TN Complement C1s component (C1S) DMO0CA8 MA Inhibitor DMO0CA8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO0CA8 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMO0JP1 DI DMO0JP1 DMO0JP1 DN OMS527 DMO0JP1 TI TT1APCZ DMO0JP1 TN Phosphodiesterase 7 (PDE7) DMO0JP1 MA Inhibitor DMO0JP1 RN Clinical pipeline report, company report or official report of Omeros. DMO0JP1 RU https://www.omeros.com/pipeline/ DMO1FTI DI DMO1FTI DMO1FTI DN Sphingosine DMO1FTI TI TTUAIKM DMO1FTI TN Cholinephosphate cytidylyltransferase (PCYT1B) DMO1FTI MA Inhibitor DMO1FTI RN Sphingosine inhibits the activity of rat liver CTP:phosphocholine cytidylyltransferase. J Biol Chem. 1990 Jul 15;265(20):11746-50. DMO1FTI RU https://pubmed.ncbi.nlm.nih.gov/2164014 DMO1N8A DI DMO1N8A DMO1N8A DN SRX-251 DMO1N8A TI TT4TFGN DMO1N8A TN Vasopressin V1a receptor (V1AR) DMO1N8A MA Antagonist DMO1N8A RN Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol Biochem Behav. 2006 Feb;83(2):169-74. DMO1N8A RU https://pubmed.ncbi.nlm.nih.gov/16504276 DMO23R0 DI DMO23R0 DMO23R0 DN CVX 096 DMO23R0 TI TTVIMDE DMO23R0 TN Glucagon-like peptide 1 receptor (GLP1R) DMO23R0 MA Modulator DMO23R0 RN Chemically programmed antibodies. Trends Biotechnol. 2014 April; 32(4): 186-197. DMO23R0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978777/ DMO2WYX DI DMO2WYX DMO2WYX DN ZT-1 DMO2WYX TI TT1RS9F DMO2WYX TN Acetylcholinesterase (AChE) DMO2WYX MA Inhibitor DMO2WYX RN A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(6):651-6. DMO2WYX RU https://pubmed.ncbi.nlm.nih.gov/15052575 DMO4SD2 DI DMO4SD2 DMO4SD2 DN ONO-4232 DMO4SD2 TI TT79WV3 DMO4SD2 TN Prostaglandin E2 receptor EP4 (PTGER4) DMO4SD2 MA Agonist DMO4SD2 RN ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345. DMO4SD2 RU http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A15345 DMO53AD DI DMO53AD DMO53AD DN Cavrotolimod DMO53AD TI TTSHG0T DMO53AD TN Toll-like receptor 9 (TLR9) DMO53AD MA Agonist DMO53AD RN Clinical pipeline report, company report or official report of Exicure. DMO53AD RU https://www.exicuretx.com/pipeline/index.php DMO548K DI DMO548K DMO548K DN LX9211 DMO548K TI TT0Z32T DMO548K TN Adaptor-associated kinase 1 (AAK1) DMO548K MA Inhibitor DMO548K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO548K RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMO5760 DI DMO5760 DMO5760 DN SR13668 DMO5760 TI TTAZ05C DMO5760 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMO5760 MA Modulator DMO5760 RN Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila). 2011 Mar;4(3):347-53. DMO5760 RU https://pubmed.ncbi.nlm.nih.gov/21372034 DMO7TES DI DMO7TES DMO7TES DN CCX507 DMO7TES TI TTIPS8B DMO7TES TN C-C chemokine receptor type 9 (CCR9) DMO7TES MA Antagonist DMO7TES RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO7TES RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMO87YS DI DMO87YS DMO87YS DN GSK065 DMO87YS TI TTIY56R DMO87YS TN Kynurenine 3-hydroxylase (KMO) DMO87YS MA Inhibitor DMO87YS RN Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827. DMO87YS RU https://pubmed.ncbi.nlm.nih.gov/28604669 DMO8L6T DI DMO8L6T DMO8L6T DN TD-0714 DMO8L6T TI TT5TKPM DMO8L6T TN Neutral endopeptidase (MME) DMO8L6T MA Inhibitor DMO8L6T RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMO8L6T RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMO8QY1 DI DMO8QY1 DMO8QY1 DN SAR-21609 DMO8QY1 TI TTSHG0T DMO8QY1 TN Toll-like receptor 9 (TLR9) DMO8QY1 MA Agonist DMO8QY1 RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMO8QY1 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMO8SGD DI DMO8SGD DMO8SGD DN Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy DMO8SGD TI TTP3QRF DMO8SGD TN Thymidine kinase 1 (TK1) DMO8SGD MA Modulator DMO8SGD RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMO8SGD RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMO8Z1D DI DMO8Z1D DMO8Z1D DN UK-66914 DMO8Z1D TI TT1VOHK DMO8Z1D TN Potassium channel unspecific (KC) DMO8Z1D MA Blocker DMO8Z1D RN Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1991 Mar;17(3):376-85. DMO8Z1D RU https://pubmed.ncbi.nlm.nih.gov/1711597 DMO97RV DI DMO97RV DMO97RV DN CSL-362 DMO97RV TI TTPYS82 DMO97RV TN Interleukin 3 receptor (CSF2RB) DMO97RV RN Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood. 2014 Feb 20;123(8):1218-28. DMO97RV RU https://pubmed.ncbi.nlm.nih.gov/24363400 DMO9BGI DI DMO9BGI DMO9BGI DN RG6076 DMO9BGI TI TTPW9LJ DMO9BGI TN Co-stimulatory molecule 4-1BB (CD137) DMO9BGI RN Clinical pipeline report, company report or official report of Roche. DMO9BGI RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMO9KZE DI DMO9KZE DMO9KZE DN XR-5944 DMO9KZE TI TT0IHXV DMO9KZE TN DNA topoisomerase II (TOP2) DMO9KZE MA Modulator DMO9KZE RN Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs. 2001 Apr;12(4):359-67. DMO9KZE RU https://pubmed.ncbi.nlm.nih.gov/11335793 DMOAET3 DI DMOAET3 DMOAET3 DN Autologous T-cell therapy DMOAET3 TI TTV3XPL DMOAET3 TN T-cell surface glycoprotein CD3 gamma (CD3G) DMOAET3 RN Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. DMOAET3 RU https://pubmed.ncbi.nlm.nih.gov/23256796 DMOAET3 DI DMOAET3 DMOAET3 DN Autologous T-cell therapy DMOAET3 TI TTZAT79 DMOAET3 TN T-cell surface glycoprotein CD3 epsilon (CD3E) DMOAET3 RN Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. DMOAET3 RU https://pubmed.ncbi.nlm.nih.gov/23256796 DMOAET3 DI DMOAET3 DMOAET3 DN Autologous T-cell therapy DMOAET3 TI TT9G4N0 DMOAET3 TN Glutamate carboxypeptidase II (GCPII) DMOAET3 RN Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38. DMOAET3 RU https://pubmed.ncbi.nlm.nih.gov/23256796 DMOCQ4K DI DMOCQ4K DMOCQ4K DN TTI-622 DMOCQ4K TI TT28S46 DMOCQ4K TN Leukocyte surface antigen CD47 (CD47) DMOCQ4K MA Blocker DMOCQ4K RN Clinical pipeline report, company report or official report of Trillium Therapeutics. DMOCQ4K RU https://trilliumtherapeutics.com/pipeline/ DMODGJU DI DMODGJU DMODGJU DN KRN633 DMODGJU TI TTUTJGQ DMODGJU TN Vascular endothelial growth factor receptor 2 (KDR) DMODGJU MA Inhibitor DMODGJU RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMODGJU RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMOE5NQ DI DMOE5NQ DMOE5NQ DN RG7347 DMOE5NQ TI TTIPJCB DMOE5NQ TN Neuropilin-1 (NRP1) DMOE5NQ MA Modulator DMOE5NQ RN Neuropilin-1 as Therapeutic Target for Malignant Melanoma. Front Oncol. 2015; 5: 125. DMOE5NQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453476/ DMOE5SZ DI DMOE5SZ DMOE5SZ DN GW-409544 DMOE5SZ TI TTZMAO3 DMOE5SZ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMOE5SZ MA Modulator DMOE5SZ RN Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546. DMOE5SZ RU https://pubmed.ncbi.nlm.nih.gov/22685582 DMOE5SZ DI DMOE5SZ DMOE5SZ DN GW-409544 DMOE5SZ TI TTJ584C DMOE5SZ TN Peroxisome proliferator-activated receptor alpha (PPARA) DMOE5SZ MA Modulator DMOE5SZ RN Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. PLoS One. 2012;7(6):e38546. DMOE5SZ RU https://pubmed.ncbi.nlm.nih.gov/22685582 DMOFSLE DI DMOFSLE DMOFSLE DN IMD-0354 DMOFSLE TI TTJ3E9X DMOFSLE TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMOFSLE MA Inhibitor DMOFSLE RN I B kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy. 2011 Jan;41(1):104-15. DMOFSLE RU https://pubmed.ncbi.nlm.nih.gov/20573155 DMOFT1V DI DMOFT1V DMOFT1V DN C-2507 DMOFT1V TI TT5FH9Y DMOFT1V TN Human immunodeficiency virus Integrase (HIV IN) DMOFT1V MA Inhibitor DMOFT1V RN Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother. 2009 Oct 19;20(2):79-85. DMOFT1V RU https://pubmed.ncbi.nlm.nih.gov/19843978 DMOG8IE DI DMOG8IE DMOG8IE DN EVT 401 DMOG8IE TI TT473XN DMOG8IE TN P2X purinoceptor 7 (P2RX7) DMOG8IE MA Antagonist DMOG8IE RN Molecular and functional properties of P2X receptors ecent progress and persisting challenges. Purinergic Signal. 2012 September; 8(3): 375-417. DMOG8IE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360091/ DMOHACZ DI DMOHACZ DMOHACZ DN CD19-TriCAR-T DMOHACZ TI TTW640A DMOHACZ TN B-lymphocyte surface antigen B4 (CD19) DMOHACZ MA CAR-T-Cell-Therapy DMOHACZ RN ClinicalTrials.gov (NCT03720496) Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCAR-T Cell Therapy DMOHACZ RU https://clinicaltrials.gov/ct2/show/NCT03720496 DMOIE05 DI DMOIE05 DMOIE05 DN 609A DMOIE05 TI TTNBFWK DMOIE05 TN Programmed cell death protein 1 (PD-1) DMOIE05 MA Inhibitor DMOIE05 RN Clinical pipeline report, company report or official report of 3SBio. DMOIE05 RU http://www.3sbio.com/en/news/details.aspx?id=111 DMOJ1AH DI DMOJ1AH DMOJ1AH DN CART22-65s cells and huCART19 Cells DMOJ1AH TI TTM6QSK DMOJ1AH TN B-cell receptor CD22 (CD22) DMOJ1AH MA CAR-T-Cell-Therapy(Dual specific) DMOJ1AH RN ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL DMOJ1AH RU https://clinicaltrials.gov/ct2/show/NCT03620058 DMOJ1AH DI DMOJ1AH DMOJ1AH DN CART22-65s cells and huCART19 Cells DMOJ1AH TI TTW640A DMOJ1AH TN B-lymphocyte surface antigen B4 (CD19) DMOJ1AH MA CAR-T-Cell-Therapy(Dual specific) DMOJ1AH RN ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL DMOJ1AH RU https://clinicaltrials.gov/ct2/show/NCT03620058 DMOJA7N DI DMOJA7N DMOJA7N DN SSR-128428 DMOJA7N TI TTCIHJA DMOJA7N TN Coagulation factor Xa (F10) DMOJA7N MA Modulator DMOJA7N RN Company report (Sanofi) (drug: FY2008) DMOJA7N RU http://en.sanofi.com/events/ceo_interview/docs/FY2008_EN_V5.pdf DMOJA7N DI DMOJA7N DMOJA7N DN SSR-128428 DMOJA7N TI TT6L509 DMOJA7N TN Coagulation factor IIa (F2) DMOJA7N MA Modulator DMOJA7N RN Company report (Sanofi) (drug: FY2008) DMOJA7N RU http://en.sanofi.com/events/ceo_interview/docs/FY2008_EN_V5.pdf DMOJEXG DI DMOJEXG DMOJEXG DN CART-Muc1 cells DMOJEXG TI TTBHFYQ DMOJEXG TN Mucin-1 (MUC1) DMOJEXG MA CAR-T-Cell-Therapy DMOJEXG RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMOJEXG RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMOJZUE DI DMOJZUE DMOJZUE DN BI-831266 DMOJZUE TI TT5LS6T DMOJZUE TN Aurora kinase B (AURKB) DMOJZUE MA Modulator DMOJZUE RN A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):409-22. DMOJZUE RU https://pubmed.ncbi.nlm.nih.gov/25529193 DMOL9JR DI DMOL9JR DMOL9JR DN JNJ-42491293 DMOL9JR TI TTXJ47W DMOL9JR TN Metabotropic glutamate receptor 2 (mGluR2) DMOL9JR MA Binder DMOL9JR RN Opportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders. Nat Rev Drug Discov. 2014 Sep;13(9):692-708. DMOL9JR RU https://pubmed.ncbi.nlm.nih.gov/25176435 DMOLFAU DI DMOLFAU DMOLFAU DN Thiopilocarpine DMOLFAU TI TTZ9SOR DMOLFAU TN Muscarinic acetylcholine receptor M1 (CHRM1) DMOLFAU MA Agonist DMOLFAU RN SDZ ENS 163, a selective muscarinic M1 receptor agonist, facilitates the induction of long-term potentiation in rat hippocampal slices. Eur J Pharmacol. 1992 Nov 3;222(1):21-5. DMOLFAU RU https://pubmed.ncbi.nlm.nih.gov/1468496 DMONZ1L DI DMONZ1L DMONZ1L DN LY3381916 DMONZ1L TI TTZJYKH DMONZ1L TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMONZ1L MA Inhibitor DMONZ1L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMONZ1L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOPGXM DI DMOPGXM DMOPGXM DN PBF-1129 DMOPGXM TI TTNE7KG DMOPGXM TN Adenosine A2b receptor (ADORA2B) DMOPGXM MA Antagonist DMOPGXM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOPGXM RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOQ2GB DI DMOQ2GB DMOQ2GB DN BR6819 DMOQ2GB TI TTYCILE DMOQ2GB TN Vasopressin receptor (VR) DMOQ2GB MA Antagonist DMOQ2GB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOQ2GB RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMORN60 DI DMORN60 DMORN60 DN CBL0137 DMORN60 TI TTETDKQ DMORN60 TN Facilitates chromatin transcription complex (FACT) DMORN60 MA Modulator DMORN60 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMORN60 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMOSCQ9 DI DMOSCQ9 DMOSCQ9 DN DNL104 DMOSCQ9 TI TTAIQSN DMOSCQ9 TN Receptor-interacting protein 1 (RIPK1) DMOSCQ9 MA Inhibitor DMOSCQ9 RN DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020 Feb;107(2):406-414. DMOSCQ9 RU https://pubmed.ncbi.nlm.nih.gov/31437302 DMOSRFZ DI DMOSRFZ DMOSRFZ DN OC-10X DMOSRFZ TI TT9K83W DMOSRFZ TN Tubulin receptor (TUBR) DMOSRFZ MA Inhibitor DMOSRFZ RN ClinicalTrials.gov (NCT01869933) Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X. U.S. National Institutes of Health. DMOSRFZ RU https://clinicaltrials.gov/ct2/show/NCT01869933 DMOTLN4 DI DMOTLN4 DMOTLN4 DN CBT-101 DMOTLN4 TI TTNDSF4 DMOTLN4 TN Proto-oncogene c-Met (MET) DMOTLN4 MA Inhibitor DMOTLN4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOTLN4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOUHR4 DI DMOUHR4 DMOUHR4 DN CA-170 DMOUHR4 TI TT8ZLTI DMOUHR4 TN Programmed cell death 1 ligand 1 (PD-L1) DMOUHR4 MA Inhibitor DMOUHR4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOUHR4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOUHR4 DI DMOUHR4 DMOUHR4 DN CA-170 DMOUHR4 TI TT51SK8 DMOUHR4 TN V-set immunoregulatory receptor (VSIR) DMOUHR4 MA Inhibitor DMOUHR4 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMOUHR4 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMOUVE7 DI DMOUVE7 DMOUVE7 DN BAY-85-8102 DMOUVE7 TI TTPTXIN DMOUVE7 TN Translocator protein (TSPO) DMOUVE7 MA Agonist DMOUVE7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMOUVE7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMOV2ML DI DMOV2ML DMOV2ML DN LY3300054 DMOV2ML TI TT8ZLTI DMOV2ML TN Programmed cell death 1 ligand 1 (PD-L1) DMOV2ML RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOV2ML RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOV2ZD DI DMOV2ZD DMOV2ZD DN C188-9 DMOV2ZD TI TTHJT3X DMOV2ZD TN STAT3 messenger RNA (STAT3 mRNA) DMOV2ZD MA Inhibitor DMOV2ZD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOV2ZD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOWTRL DI DMOWTRL DMOWTRL DN GSK-2315698 DMOWTRL TI TTB7VAT DMOWTRL TN Serum amyloid P-component (APCS) DMOWTRL RN Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis. CPT Pharmacometrics Syst Pharmacol. 2015 February; 4(2): e15. DMOWTRL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360666/ DMOWYKS DI DMOWYKS DMOWYKS DN RG6346 DMOWYKS TI TTSJVOI DMOWYKS TN Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) DMOWYKS MA Inhibitor DMOWYKS RN Clinical pipeline report, company report or official report of Dicerna Pharmaceuticals. DMOWYKS RU https://dicerna.com/pipeline/rg6346/ DMOX6EJ DI DMOX6EJ DMOX6EJ DN PF-06840003 DMOX6EJ TI TTZJYKH DMOX6EJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOX6EJ MA Inhibitor DMOX6EJ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOX6EJ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMOXDIY DI DMOXDIY DMOXDIY DN CB-5339 DMOXDIY TI TTHNLSB DMOXDIY TN Valosin-containing protein p97 (VCP) DMOXDIY MA Inhibitor DMOXDIY RN Clinical pipeline report, company report or official report of Cleave Therapeutics. DMOXDIY RU https://www.casipharmaceuticals.com/product-pipeline/cb-5339/ DMOYPTK DI DMOYPTK DMOYPTK DN AZD4573 DMOYPTK TI TT1LVF2 DMOYPTK TN Cyclin-dependent kinase 9 (CDK9) DMOYPTK MA Inhibitor DMOYPTK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMOYPTK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMOYUPM DI DMOYUPM DMOYUPM DN PPL-100 DMOYUPM TI TT5FNQT DMOYUPM TN Human immunodeficiency virus Protease (HIV PR) DMOYUPM MA Inhibitor DMOYUPM RN Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Res. 2006 Jun;70(2):17-20. DMOYUPM RU https://pubmed.ncbi.nlm.nih.gov/16473417 DMOYX6W DI DMOYX6W DMOYX6W DN PSMA-targeted tubulysin B conjugates DMOYX6W TI TT9G4N0 DMOYX6W TN Glutamate carboxypeptidase II (GCPII) DMOYX6W MA Modulator DMOYX6W RN Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm. 2009 May-Jun;6(3):780-9. DMOYX6W RU https://pubmed.ncbi.nlm.nih.gov/19361233 DMOZ3AT DI DMOZ3AT DMOZ3AT DN ACT-178882 DMOZ3AT TI TTB2MXP DMOZ3AT TN Angiotensinogenase renin (REN) DMOZ3AT MA Inhibitor DMOZ3AT RN Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects. Clin Drug Investig. 2013 Mar;33(3):207-13. DMOZ3AT RU https://pubmed.ncbi.nlm.nih.gov/23381958 DMP1ZF8 DI DMP1ZF8 DMP1ZF8 DN IC9-CAR19 cells DMP1ZF8 TI TTW640A DMP1ZF8 TN B-lymphocyte surface antigen B4 (CD19) DMP1ZF8 MA CAR-T-Cell-Therapy DMP1ZF8 RN ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia DMP1ZF8 RU https://clinicaltrials.gov/ct2/show/NCT03016377 DMP3QSA DI DMP3QSA DMP3QSA DN Quinazoline derivative 9 DMP3QSA TI TTQFRP0 DMP3QSA TN MEK kinase kinase 2 (MAP4K2) DMP3QSA MA Inhibitor DMP3QSA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP3QSA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP3QSA DI DMP3QSA DMP3QSA DN Quinazoline derivative 9 DMP3QSA TI TTRHJA3 DMP3QSA TN SPS1/STE20-related protein kinase YSK4 (YSK4) DMP3QSA MA Inhibitor DMP3QSA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP3QSA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP5CLY DI DMP5CLY DMP5CLY DN PRT6207 DMP5CLY TI TTOU65C DMP5CLY TN Tyrosine-protein kinase SYK (SYK) DMP5CLY MA Modulator DMP5CLY RN Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243. DMP5CLY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106228/ DMP5V83 DI DMP5V83 DMP5V83 DN CD22-specific CAR T-cells also expressing an EGFRt DMP5V83 TI TTM6QSK DMP5V83 TN B-cell receptor CD22 (CD22) DMP5V83 MA CAR-T-Cell-Therapy DMP5V83 RN ClinicalTrials.gov (NCT03244306) A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma DMP5V83 RU https://clinicaltrials.gov/ct2/show/NCT03244306 DMP6I9T DI DMP6I9T DMP6I9T DN INO-3510 DMP6I9T TI TTUTN1I DMP6I9T TN Human Deoxyribonucleic acid (hDNA) DMP6I9T RN Inovio Receives U.S. Patent for SynCon H1N1 Influenza Universal Vaccine. Inovio. March 26, 2012. DMP6I9T RU http://www.prnewswire.com/news-releases/inovio-receives-us-patent-for-syncon-h1n1-influenza-universal-vaccine-144185625.html DMP70FI DI DMP70FI DMP70FI DN BIBT986 DMP70FI TI TTCIHJA DMP70FI TN Coagulation factor Xa (F10) DMP70FI MA Inhibitor DMP70FI RN Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa. J Thromb Haemost. 2006 Jul;4(7):1502-9. DMP70FI RU https://pubmed.ncbi.nlm.nih.gov/16839346 DMP8QY2 DI DMP8QY2 DMP8QY2 DN M1774 DMP8QY2 TI TT8ZYBQ DMP8QY2 TN Serine/threonine-protein kinase ATR (FRP1) DMP8QY2 MA Inhibitor DMP8QY2 RN National Cancer Institute Drug Dictionary (drug name M1774). DMP8QY2 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atr-kinase-inhibitor-m1774 DMP9J5V DI DMP9J5V DMP9J5V DN NLG802 DMP9J5V TI TTZJYKH DMP9J5V TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMP9J5V MA Inhibitor DMP9J5V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMP9J5V RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMP9UO0 DI DMP9UO0 DMP9UO0 DN Lu-AE04621 DMP9UO0 TI TTEX248 DMP9UO0 TN Dopamine D2 receptor (D2R) DMP9UO0 MA Modulator DMP9UO0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031909) DMP9UO0 RU http://adisinsight.springer.com/drugs/800031909 DMP9VXQ DI DMP9VXQ DMP9VXQ DN ALPHA-FMH DMP9VXQ TI TTV9GOF DMP9VXQ TN Histidine decarboxylase (HDC) DMP9VXQ MA Modulator DMP9VXQ RN Alpha-Fluoromethylhistidine. Kinetics of uptake and inhibition of histamine synthesis in basophil (2H3) cell cultures. Mol Pharmacol. 1985 Aug;28(2):191-9. DMP9VXQ RU https://pubmed.ncbi.nlm.nih.gov/2410770 DMP9ZT1 DI DMP9ZT1 DMP9ZT1 DN ARQ 736 DMP9ZT1 TI TTWCGQT DMP9ZT1 TN Serine/threonine-protein kinase B-raf (BRAF) DMP9ZT1 MA Modulator DMP9ZT1 RN National Cancer Institute Drug Dictionary (drug id 688029). DMP9ZT1 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=688029 DMPADR1 DI DMPADR1 DMPADR1 DN CD19/CD22 Chimeric Antigen Receptor T Cells DMPADR1 TI TTM6QSK DMPADR1 TN B-cell receptor CD22 (CD22) DMPADR1 MA CAR-T-Cell-Therapy(Dual specific) DMPADR1 RN ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia DMPADR1 RU https://clinicaltrials.gov/ct2/show/NCT03233854 DMPADR1 DI DMPADR1 DMPADR1 DN CD19/CD22 Chimeric Antigen Receptor T Cells DMPADR1 TI TTW640A DMPADR1 TN B-lymphocyte surface antigen B4 (CD19) DMPADR1 MA CAR-T-Cell-Therapy(Dual specific) DMPADR1 RN ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia DMPADR1 RU https://clinicaltrials.gov/ct2/show/NCT03233854 DMPAWBN DI DMPAWBN DMPAWBN DN GSK525762 DMPAWBN TI TTRA6BO DMPAWBN TN Bromodomain-containing protein 4 (BRD4) DMPAWBN MA Modulator DMPAWBN RN Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. DMPAWBN RU https://www.ncbi.nlm.nih.gov/pubmed/24751816 DMPAWBN DI DMPAWBN DMPAWBN DN GSK525762 DMPAWBN TI TTE4BSY DMPAWBN TN Bromodomain and extraterminal domain protein (BET) DMPAWBN MA Inhibitor DMPAWBN RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPAWBN RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPCUN5 DI DMPCUN5 DMPCUN5 DN MT-110 DMPCUN5 TI TTV3XPL DMPCUN5 TN T-cell surface glycoprotein CD3 gamma (CD3G) DMPCUN5 RN EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. DMPCUN5 RU https://pubmed.ncbi.nlm.nih.gov/22096026 DMPCUN5 DI DMPCUN5 DMPCUN5 DN MT-110 DMPCUN5 TI TTZAT79 DMPCUN5 TN T-cell surface glycoprotein CD3 epsilon (CD3E) DMPCUN5 RN EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. DMPCUN5 RU https://pubmed.ncbi.nlm.nih.gov/22096026 DMPCUN5 DI DMPCUN5 DMPCUN5 DN MT-110 DMPCUN5 TI TTZ8WH4 DMPCUN5 TN Tumor-associated calcium signal transducer 1 (EPCAM) DMPCUN5 RN EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. DMPCUN5 RU https://pubmed.ncbi.nlm.nih.gov/22096026 DMPD0KL DI DMPD0KL DMPD0KL DN ABBV-428 DMPD0KL TI TTIJP3Q DMPD0KL TN TNF related activation protein (CD40LG) DMPD0KL MA Stimulator DMPD0KL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPD0KL RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMPE0KD DI DMPE0KD DMPE0KD DN MB-110 DMPE0KD TI TTCJ2X8 DMPE0KD TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMPE0KD MA Inhibitor DMPE0KD RN Clinical pipeline report, company report or official report of Microbio. DMPE0KD RU https://www.microbio.com.tw/home_03.php?p=7&a=15 DMPENAL DI DMPENAL DMPENAL DN FSI-189 DMPENAL TI TTBRJS9 DMPENAL TN Inhibitory receptor SHPS-1 (SIRPA) DMPENAL RN T cells bring unconventional cancer-targeting to the clinic - again. Nat Biotechnol. 2020 Apr;38(4):389-391. DMPENAL RU https://pubmed.ncbi.nlm.nih.gov/32265560 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTLD29N DMPHZI5 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/11543685 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TT0MYE2 DMPHZI5 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMPHZI5 MA Inhibitor DMPHZI5 RN 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/10843235 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTAN6JD DMPHZI5 TN Glutamate receptor AMPA (GRIA) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil r... J Med Chem. 2007 Apr 5;50(7):1558-70. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/17348638 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTKJEMQ DMPHZI5 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/11543685 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTVPQTF DMPHZI5 TN Glutamate receptor AMPA 1 (GRIA1) DMPHZI5 MA Inhibitor DMPHZI5 RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/17004715 DMPHZI5 DI DMPHZI5 DMPHZI5 DN NBQX DMPHZI5 TI TTN9D8E DMPHZI5 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMPHZI5 MA Inhibitor DMPHZI5 RN Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. DMPHZI5 RU https://pubmed.ncbi.nlm.nih.gov/11543685 DMPJA64 DI DMPJA64 DMPJA64 DN DA-1241 DMPJA64 TI TT7QNVC DMPJA64 TN Glucose-dependent insulinotropic receptor (GPR119) DMPJA64 MA Agonist DMPJA64 RN ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health. DMPJA64 RU https://clinicaltrials.gov/ct2/show/NCT03646721 DMPJBCR DI DMPJBCR DMPJBCR DN APO-010 DMPJBCR TI TTF0RCZ DMPJBCR TN Apoptosis mediating surface antigen FAS (FAS) DMPJBCR MA Binder DMPJBCR RN APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64. DMPJBCR RU https://pubmed.ncbi.nlm.nih.gov/21183510 DMPJMB7 DI DMPJMB7 DMPJMB7 DN NLX-101 DMPJMB7 TI TTSQIFT DMPJMB7 TN 5-HT 1A receptor (HTR1A) DMPJMB7 MA Modulator DMPJMB7 RN In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.Psychopharmacology (Berl).2012 May;221(2):261-72. DMPJMB7 RU https://www.ncbi.nlm.nih.gov/pubmed/22147258 DMPK32V DI DMPK32V DMPK32V DN BMS-754807 DMPK32V TI TTWTSCV DMPK32V TN RAC-alpha serine/threonine-protein kinase (AKT1) DMPK32V MA Inhibitor DMPK32V RN Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in cli... J Med Chem. 2009 Dec 10;52(23):7360-3. DMPK32V RU https://pubmed.ncbi.nlm.nih.gov/19778024 DMPKH6Y DI DMPKH6Y DMPKH6Y DN IPL 550,260 DMPKH6Y TI TTO0YVN DMPKH6Y TN Leukocyte (WBC) DMPKH6Y MA Modulator DMPKH6Y RN WO patent application no. 2005,0792,17, Oligonucleotide decoys and methods of use. DMPKH6Y RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050901&CC=WO&NR=2005079217A2&KC=A2 DMPKO84 DI DMPKO84 DMPKO84 DN PF-07220060 DMPKO84 TI TT0PG8F DMPKO84 TN Cyclin-dependent kinase 4 (CDK4) DMPKO84 MA Inhibitor DMPKO84 RN ClinicalTrials.gov (NCT04557449) Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (CDK4). U.S. National Institutes of Health. DMPKO84 RU https://clinicaltrials.gov/ct2/show/NCT04557449 DMPLFBV DI DMPLFBV DMPLFBV DN MEDI0680 DMPLFBV TI TTNBFWK DMPLFBV TN Programmed cell death protein 1 (PD-1) DMPLFBV RN A Phase Ib/II open-label study to evaluate the safety and efficacy of MEDI-551 in combination with immunomodulating therapy in patients with relapsed or refractory aggressive B cell lymphomas. J Immunother Cancer. 2014; 2(Suppl 3): P73. DMPLFBV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288733/ DMPLHBI DI DMPLHBI DMPLHBI DN ARI-0001 cells DMPLHBI TI TTW640A DMPLHBI TN B-lymphocyte surface antigen B4 (CD19) DMPLHBI MA CAR-T-Cell-Therapy DMPLHBI RN ClinicalTrials.gov (NCT03144583) Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy DMPLHBI RU https://clinicaltrials.gov/ct2/show/NCT03144583 DMPLV9G DI DMPLV9G DMPLV9G DN OBP-801 DMPLV9G TI TT6R7JZ DMPLV9G TN Histone deacetylase 1 (HDAC1) DMPLV9G MA Inhibitor DMPLV9G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2658). DMPLV9G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2658 DMPLV9G DI DMPLV9G DMPLV9G DN OBP-801 DMPLV9G TI TTBH0VX DMPLV9G TN Histone deacetylase (HDAC) DMPLV9G MA Inhibitor DMPLV9G RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPLV9G RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPMDTH DI DMPMDTH DMPMDTH DN Azd9496 DMPMDTH TI TTZAYWL DMPMDTH TN Estrogen receptor (ESR) DMPMDTH MA Antagonist DMPMDTH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPMDTH RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPNBJ1 DI DMPNBJ1 DMPNBJ1 DN BAY1436032 DMPNBJ1 TI TTXDKHT DMPNBJ1 TN Mutated oxalosuccinate decarboxylase (mIDH1) DMPNBJ1 MA Inhibitor DMPNBJ1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPNBJ1 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMPQ1TM DI DMPQ1TM DMPQ1TM DN CA-011 DMPQ1TM TI TTMI6F5 DMPQ1TM TN Transient receptor potential cation channel V1 (TRPV1) DMPQ1TM MA Agonist DMPQ1TM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMPQ1TM RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMPQ5XC DI DMPQ5XC DMPQ5XC DN BMS-824383 DMPQ5XC TI TTCJ2X8 DMPQ5XC TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMPQ5XC MA Inhibitor DMPQ5XC RN 2011 Pipeline of Bristol-Myers Squibb. DMPQ5XC RU http://www.bms.com/pages/default.aspx DMPQE2S DI DMPQE2S DMPQE2S DN LVGN6051 DMPQE2S TI TTPW9LJ DMPQE2S TN Co-stimulatory molecule 4-1BB (CD137) DMPQE2S MA Activator DMPQE2S RN Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcR affinity. Nat Commun. 2019 May 20;10(1):2141. DMPQE2S RU https://pubmed.ncbi.nlm.nih.gov/31105267 DMPR3A6 DI DMPR3A6 DMPR3A6 DN DS-1055 DMPR3A6 TI TT0FAYT DMPR3A6 TN Transforming growth factor beta activator LRRC32 (LRRC32) DMPR3A6 MA Inhibitor DMPR3A6 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMPR3A6 RU https://www.daiichisankyo.com/media/press_release/detail/index_4081.html DMPS6U9 DI DMPS6U9 DMPS6U9 DN AC430 DMPS6U9 TI TTRMX3V DMPS6U9 TN Janus kinase 2 (JAK-2) DMPS6U9 MA Modulator DMPS6U9 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DMPS6U9 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DMPTYE6 DI DMPTYE6 DMPTYE6 DN CCW702 DMPTYE6 TI TTUN7MC DMPTYE6 TN T-cell surface glycoprotein CD3 (CD3) DMPTYE6 RN Clinical pipeline report, company report or official report of AbbVie. DMPTYE6 RU https://www.abbvie.com/our-science/pipeline/ccw702.html DMPTYE6 DI DMPTYE6 DMPTYE6 DN CCW702 DMPTYE6 TI TT9G4N0 DMPTYE6 TN Glutamate carboxypeptidase II (GCPII) DMPTYE6 RN Clinical pipeline report, company report or official report of AbbVie. DMPTYE6 RU https://www.abbvie.com/our-science/pipeline/ccw702.html DMPVUGE DI DMPVUGE DMPVUGE DN CDX-1127 DMPVUGE TI TTDO1MV DMPVUGE TN T-cell activation antigen CD27 (CD27) DMPVUGE MA Modulator DMPVUGE RN Clinical pipeline report, company report or official report of Celldex Therapeutics. DMPVUGE RU http://www.celldex.com/pipeline/cdx-1127.php DMPW21Z DI DMPW21Z DMPW21Z DN MEDI-578 DMPW21Z TI TTDN3LF DMPW21Z TN Nerve growth factor (NGF) DMPW21Z MA Modulator DMPW21Z RN Fate of novel painkiller mAbs hangs in balance.Nat Biotechnol.2011 Mar;29(3):173-4. DMPW21Z RU https://www.ncbi.nlm.nih.gov/pubmed/21389990 DMPWOH9 DI DMPWOH9 DMPWOH9 DN DKY709 DMPWOH9 TI TTKT5NV DMPWOH9 TN Zinc finger protein Helios (IKZF2) DMPWOH9 MA Degrader DMPWOH9 RN Targeted protein degraders crowd into the clinic. Nat Rev Drug Discov. 2021 Apr;20(4):247-250. DMPWOH9 RU https://pubmed.ncbi.nlm.nih.gov/33737725 DMPXDL6 DI DMPXDL6 DMPXDL6 DN ABBV-CLS-579 DMPXDL6 TI TTY8PUS DMPXDL6 TN Tyrosine-protein phosphatase non-receptor type 2 (PTPN2) DMPXDL6 MA Inhibitor DMPXDL6 RN Clinical pipeline report, company report or official report of Calico Life Sciences. DMPXDL6 RU https://www.calicolabs.com/press/calico-and-abbvie-share-update-on-early-stage-clinical-programs DMPXLMB DI DMPXLMB DMPXLMB DN Demobesin DMPXLMB TI TTHYDUM DMPXLMB TN Bombesin receptor (BS) DMPXLMB MA Antagonist DMPXLMB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38). DMPXLMB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38 DMPXOVA DI DMPXOVA DMPXOVA DN IN10018 DMPXOVA TI TTON5IT DMPXOVA TN Focal adhesion kinase 1 (FAK) DMPXOVA MA Inhibitor DMPXOVA RN Clinical pipeline report, company report or official report of InxMed. DMPXOVA RU http://en.inxmed.com/intro/3.html DMQ01MP DI DMQ01MP DMQ01MP DN ILV-095 DMQ01MP TI TTLDX4N DMQ01MP TN Interleukin-22 (IL22) DMQ01MP RN Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16. DMQ01MP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510410/ DMQ0F5P DI DMQ0F5P DMQ0F5P DN NUC-3373 DMQ0F5P TI TT5FOMZ DMQ0F5P TN Thymidylate synthase (TYMS) DMQ0F5P MA Inhibitor DMQ0F5P RN Clinical pipeline report, company report or official report of NuCana. DMQ0F5P RU http://www.nucana.com/nuc3373.html DMQ0K95 DI DMQ0K95 DMQ0K95 DN Lu-02-750 DMQ0K95 TI TTEX248 DMQ0K95 TN Dopamine D2 receptor (D2R) DMQ0K95 MA Agonist DMQ0K95 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031195) DMQ0K95 RU http://adisinsight.springer.com/drugs/800031195 DMQ0N5Z DI DMQ0N5Z DMQ0N5Z DN AMG 562 DMQ0N5Z TI TTW640A DMQ0N5Z TN B-lymphocyte surface antigen B4 (CD19) DMQ0N5Z MA Inhibitor DMQ0N5Z RN Clinical pipeline report, company report or official report of Amgen. DMQ0N5Z RU https://www.amgenpipeline.com/ DMQ0RXA DI DMQ0RXA DMQ0RXA DN 11C-GSK-215083 DMQ0RXA TI TTJS8PY DMQ0RXA TN 5-HT 6 receptor (HTR6) DMQ0RXA MA Antagonist DMQ0RXA RN Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012 Feb;53(2):295-303. DMQ0RXA RU https://pubmed.ncbi.nlm.nih.gov/22223878 DMQ1OX4 DI DMQ1OX4 DMQ1OX4 DN AZD1979 DMQ1OX4 TI TTX4RTB DMQ1OX4 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMQ1OX4 MA Modulator DMQ1OX4 RN Phase I clinical trial of AZD1979 for treating obesity. AstraZeneca plc DMQ1OX4 RU http://www.biocentury.com/products/azd1979 DMQ2K1V DI DMQ2K1V DMQ2K1V DN SCH-442416 DMQ2K1V TI TTJFY5U DMQ2K1V TN Adenosine A3 receptor (ADORA3) DMQ2K1V MA Inhibitor DMQ2K1V RN Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5690-4. DMQ2K1V RU https://pubmed.ncbi.nlm.nih.gov/20801028 DMQ2K1V DI DMQ2K1V DMQ2K1V DN SCH-442416 DMQ2K1V TI TTM2AOE DMQ2K1V TN Adenosine A2a receptor (ADORA2A) DMQ2K1V MA Inhibitor DMQ2K1V RN Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using p... J Med Chem. 2000 Nov 16;43(23):4359-62. DMQ2K1V RU https://pubmed.ncbi.nlm.nih.gov/11087559 DMQ2K1V DI DMQ2K1V DMQ2K1V DN SCH-442416 DMQ2K1V TI TTK25J1 DMQ2K1V TN Adenosine A1 receptor (ADORA1) DMQ2K1V MA Inhibitor DMQ2K1V RN Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using p... J Med Chem. 2000 Nov 16;43(23):4359-62. DMQ2K1V RU https://pubmed.ncbi.nlm.nih.gov/11087559 DMQ2OP0 DI DMQ2OP0 DMQ2OP0 DN CA-170 DMQ2OP0 TI TT8ZLTI DMQ2OP0 TN Programmed cell death 1 ligand 1 (PD-L1) DMQ2OP0 MA Inhibitor DMQ2OP0 RN CA-170 - A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules. 2019 Aug 1;24(15):2804. DMQ2OP0 RU https://pubmed.ncbi.nlm.nih.gov/31374878 DMQ2Y1J DI DMQ2Y1J DMQ2Y1J DN CAR-T cells targeting EpCAM DMQ2Y1J TI TTZ8WH4 DMQ2Y1J TN Tumor-associated calcium signal transducer 1 (EPCAM) DMQ2Y1J MA CAR-T-Cell-Therapy DMQ2Y1J RN ClinicalTrials.gov (NCT03563326) Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART) DMQ2Y1J RU https://clinicaltrials.gov/ct2/show/NCT03563326 DMQ3O1U DI DMQ3O1U DMQ3O1U DN ABT-165 DMQ3O1U TI TTV23LH DMQ3O1U TN Delta-like protein 4 (DLL4) DMQ3O1U MA Inhibitor DMQ3O1U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ3O1U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQ3O1U DI DMQ3O1U DMQ3O1U DN ABT-165 DMQ3O1U TI TT9HKJA DMQ3O1U TN Vascular endothelial growth factor (VEGF) DMQ3O1U MA Inhibitor DMQ3O1U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ3O1U RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQ46DN DI DMQ46DN DMQ46DN DN GW-796406 DMQ46DN TI TT5TKPM DMQ46DN TN Neutral endopeptidase (MME) DMQ46DN MA Modulator DMQ46DN RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMQ46DN RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMQ46DN DI DMQ46DN DMQ46DN DN GW-796406 DMQ46DN TI TTL69WB DMQ46DN TN Angiotensin-converting enzyme (ACE) DMQ46DN MA Modulator DMQ46DN RN Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13. DMQ46DN RU https://pubmed.ncbi.nlm.nih.gov/16144980 DMQ4UJ6 DI DMQ4UJ6 DMQ4UJ6 DN CART-10 cells DMQ4UJ6 TI TT5TKPM DMQ4UJ6 TN Neutral endopeptidase (MME) DMQ4UJ6 MA CAR-T-Cell-Therapy DMQ4UJ6 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMQ4UJ6 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMQ4Z1P DI DMQ4Z1P DMQ4Z1P DN Peginterferon beta DMQ4Z1P TI TTRMX3V DMQ4Z1P TN Janus kinase 2 (JAK-2) DMQ4Z1P MA Inhibitor DMQ4Z1P RN Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008 Jul;22(7):1320-34. DMQ4Z1P RU https://pubmed.ncbi.nlm.nih.gov/18528425 DMQ5ZND DI DMQ5ZND DMQ5ZND DN Anti-MUC1 mab DMQ5ZND TI TTBHFYQ DMQ5ZND TN Mucin-1 (MUC1) DMQ5ZND MA Modulator DMQ5ZND RN Characterization of an anti-MUC1 monoclonal antibody with potential as a cancer vaccine. Hybrid Hybridomics. 2001;20(5-6):313-24. DMQ5ZND RU https://pubmed.ncbi.nlm.nih.gov/11839249 DMQ5ZVK DI DMQ5ZVK DMQ5ZVK DN JNJ-54175446 DMQ5ZVK TI TT473XN DMQ5ZVK TN P2X purinoceptor 7 (P2RX7) DMQ5ZVK MA Antagonist DMQ5ZVK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ5ZVK RU http://phrma-docs.phrma.org/files/dmfile/MID_Mental-Illness-2017-Drug-List_Final.pdf DMQ65YW DI DMQ65YW DMQ65YW DN RO-09-4889 DMQ65YW TI TTZPS91 DMQ65YW TN Dihydrothymine dehydrogenase (DPYD) DMQ65YW MA Modulator DMQ65YW RN Single ascending dose tolerability, pharmacokinetic-pharmacodynamic study of dihydropyrimidine dehydrogenase inhibitor Ro 09-4889. Clin Cancer Res. 2004 Apr 1;10(7):2327-35. DMQ65YW RU https://pubmed.ncbi.nlm.nih.gov/15073108 DMQ6DLZ DI DMQ6DLZ DMQ6DLZ DN KF-17837 DMQ6DLZ TI TTK25J1 DMQ6DLZ TN Adenosine A1 receptor (ADORA1) DMQ6DLZ MA Inhibitor DMQ6DLZ RN 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9. DMQ6DLZ RU https://pubmed.ncbi.nlm.nih.gov/11170626 DMQ6DLZ DI DMQ6DLZ DMQ6DLZ DN KF-17837 DMQ6DLZ TI TTM2AOE DMQ6DLZ TN Adenosine A2a receptor (ADORA2A) DMQ6DLZ MA Inhibitor DMQ6DLZ RN Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3. DMQ6DLZ RU https://pubmed.ncbi.nlm.nih.gov/8246243 DMQ6DLZ DI DMQ6DLZ DMQ6DLZ DN KF-17837 DMQ6DLZ TI TTNE7KG DMQ6DLZ TN Adenosine A2b receptor (ADORA2B) DMQ6DLZ MA Inhibitor DMQ6DLZ RN Photoisomerization of a potent and selective adenosine A2 antagonist, (E)-1,3-Dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine. J Med Chem. 1993 Nov 12;36(23):3731-3. DMQ6DLZ RU https://pubmed.ncbi.nlm.nih.gov/8246243 DMQ6GUY DI DMQ6GUY DMQ6GUY DN EOS100850 DMQ6GUY TI TTM2AOE DMQ6GUY TN Adenosine A2a receptor (ADORA2A) DMQ6GUY MA Antagonist DMQ6GUY RN National Cancer Institute Drug Dictionary (drug name EOS100850). DMQ6GUY RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/a2a-receptor-antagonist-eos100850 DMQ6YAZ DI DMQ6YAZ DMQ6YAZ DN EMD-534085 DMQ6YAZ TI TTBGTCW DMQ6YAZ TN Kinesin spindle messenger RNA (KIF11 mRNA) DMQ6YAZ MA Inhibitor DMQ6YAZ RN The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1491-5. DMQ6YAZ RU https://pubmed.ncbi.nlm.nih.gov/20149654 DMQ76B4 DI DMQ76B4 DMQ76B4 DN BCL11a shRNA DMQ76B4 TI TTPLHYK DMQ76B4 TN BCL11A messenger RNA (BCL11A mRNA) DMQ76B4 MA Inhibitor DMQ76B4 RN Clinical pipeline report, company report or official report of bluebird bio. DMQ76B4 RU https://www.bluebirdbio.com/our-science/pipeline DMQ789Z DI DMQ789Z DMQ789Z DN 8H9 DMQ789Z TI TTUCPMY DMQ789Z TN Tenascin (TNC) DMQ789Z RN In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res. 2004 Feb 15;64(4):1419-24. DMQ789Z RU https://pubmed.ncbi.nlm.nih.gov/14973056 DMQ7UN6 DI DMQ7UN6 DMQ7UN6 DN Trodusquemine DMQ7UN6 TI TTMS7KP DMQ7UN6 TN Protein-tyrosine phosphatase 1B (PTP1B) DMQ7UN6 MA Inhibitor DMQ7UN6 RN Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice. Obesity (Silver Spring). 2010 Aug;18(8):1516-23. DMQ7UN6 RU https://pubmed.ncbi.nlm.nih.gov/20075852 DMQ7WJI DI DMQ7WJI DMQ7WJI DN CAF-01 DMQ7WJI TI TT3J5ZI DMQ7WJI TN Cell mediated immunity response (CMIR) DMQ7WJI MA Modulator DMQ7WJI RN Mechanisms of Action of Adjuvants. Front Immunol. 2013; 4: 114. DMQ7WJI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3655441/ DMQ82SH DI DMQ82SH DMQ82SH DN PMZ-2123 DMQ82SH TI TTKRD0G DMQ82SH TN Endothelin A receptor (EDNRA) DMQ82SH MA Antagonist DMQ82SH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQ82SH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMQ8ACY DI DMQ8ACY DMQ8ACY DN DCCCyB DMQ8ACY TI TTHJTF7 DMQ8ACY TN Glycine transporter GlyT-1 (SLC6A9) DMQ8ACY MA Modulator DMQ8ACY RN Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. ACS Med Chem Lett. 2010 October 14; 1(7): 350-354. DMQ8ACY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007840/ DMQ8NTZ DI DMQ8NTZ DMQ8NTZ DN 192C86 DMQ8NTZ TI TTNVEIR DMQ8NTZ TN Prostaglandin D2 receptor (PTGDR) DMQ8NTZ MA Modulator DMQ8NTZ RN Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009 September; 158(1): 104-145. DMQ8NTZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2795261/ DMQ8YKR DI DMQ8YKR DMQ8YKR DN TAK-648 DMQ8YKR TI TTV5CGO DMQ8YKR TN Phosphodiesterase 4 (PDE4) DMQ8YKR MA Inhibitor DMQ8YKR RN Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction. Clin Transl Sci. 2017 May;10(3):185-193. DMQ8YKR RU https://pubmed.ncbi.nlm.nih.gov/28088839 DMQ9317 DI DMQ9317 DMQ9317 DN GEN1044 DMQ9317 TI TT70MLA DMQ9317 TN Oncotrophoblast glycoprotein 5T4 (TPBG) DMQ9317 RN Clinical pipeline report, company report or official report of AbbVie. DMQ9317 RU https://www.abbvie.com/our-science/pipeline/gen-1044.html DMQ9317 DI DMQ9317 DMQ9317 DN GEN1044 DMQ9317 TI TTUN7MC DMQ9317 TN T-cell surface glycoprotein CD3 (CD3) DMQ9317 RN Clinical pipeline report, company report or official report of AbbVie. DMQ9317 RU https://www.abbvie.com/our-science/pipeline/gen-1044.html DMQ98MW DI DMQ98MW DMQ98MW DN SAR164653 DMQ98MW TI TT5NILS DMQ98MW TN Cathepsin A (CTSA) DMQ98MW MA Modulator DMQ98MW RN Tolerability, safety and pharmacokinetics of the novel Cathepsin A inhibitor SAR164653 in healthy subjects.Clinical Pharmacology in Drug Development 05/2015. DMQ98MW RU http://www.researchgate.net/publication/276150796_Tolerability_safety_and_pharmacokinetics_of_the_novel_Cathepsin_A_inhibitor_SAR164653_in_healthy_subjects DMQ9KZW DI DMQ9KZW DMQ9KZW DN Biomed 101 DMQ9KZW TI TTN53ZF DMQ9KZW TN Leukotriene B4 receptor 1 (LTB4R) DMQ9KZW MA Binder DMQ9KZW RN Biomed 101, a leukotriene B4 inhibitor, may decrease IL-2 toxicity. 2003 ASCO Annual Meeting. 2003. DMQ9KZW RU http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=101740 DMQ9KZW DI DMQ9KZW DMQ9KZW DN Biomed 101 DMQ9KZW TI TTVJX54 DMQ9KZW TN Leukotriene B4 receptor 2 (LTB4R2) DMQ9KZW MA Inhibitor DMQ9KZW RN Diaryl ether/carboxylic acid derivatives of LY255283: Receptor antagonists of leukotriene B4, Bioorg. Med. Chem. Lett. 3(10):1985-1990 (1993). DMQ9KZW RU http://www.sciencedirect.com/science/article/pii/S0960894X01810003 DMQ9ZY0 DI DMQ9ZY0 DMQ9ZY0 DN SAR-104772 DMQ9ZY0 TI TTP18AY DMQ9ZY0 TN Carboxypeptidase B2 (CPB2) DMQ9ZY0 MA Inhibitor DMQ9ZY0 RN Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy . Journal of Thrombosis and Haemostasis Volume 7, Issue 12, pages 1962-1971, December 2009. DMQ9ZY0 RU http://onlinelibrary.wiley.com/doi/10.1111/j.1538-7836.2009.03596.x/full DMQA1VT DI DMQA1VT DMQA1VT DN Autologous cell based gene therapy DMQA1VT TI TTCM4B3 DMQA1VT TN Nitric-oxide synthase endothelial (NOS3) DMQA1VT MA Modulator DMQA1VT RN Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8. DMQA1VT RU https://pubmed.ncbi.nlm.nih.gov/12231180 DMQAIU1 DI DMQAIU1 DMQAIU1 DN RGLS4326 DMQAIU1 TI TTMGJ19 DMQAIU1 TN microRNA hsa-miR-17 (MIR17) DMQAIU1 MA Inhibitor DMQAIU1 RN Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat Commun. 2019 Sep 12;10(1):4148. DMQAIU1 RU https://pubmed.ncbi.nlm.nih.gov/31515477 DMQB3HD DI DMQB3HD DMQB3HD DN XmAb22841 DMQB3HD TI TTI2S1D DMQB3HD TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMQB3HD RN Clinical pipeline report, company report or official report of Xencor. DMQB3HD RU https://xencor.com/pipeline/xmab22841/ DMQB3HD DI DMQB3HD DMQB3HD DN XmAb22841 DMQB3HD TI TTNVXAW DMQB3HD TN Lymphocyte activation gene 3 protein (LAG3) DMQB3HD RN Clinical pipeline report, company report or official report of Xencor. DMQB3HD RU https://xencor.com/pipeline/xmab22841/ DMQB4VN DI DMQB4VN DMQB4VN DN MGD006 DMQB4VN TI TTUN7MC DMQB4VN TN T-cell surface glycoprotein CD3 (CD3) DMQB4VN MA Modulator DMQB4VN RN A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87. DMQB4VN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288763/ DMQB4VN DI DMQB4VN DMQB4VN DN MGD006 DMQB4VN TI TTENHJ0 DMQB4VN TN Interleukin 3 receptor alpha (IL3RA) DMQB4VN MA Modulator DMQB4VN RN A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.Sci Transl Med.2015 May 27;7(289):289ra82. DMQB4VN RU https://www.ncbi.nlm.nih.gov/pubmed/26019218 DMQBEYV DI DMQBEYV DMQBEYV DN GC021109 DMQBEYV TI TTNVSKA DMQBEYV TN P2Y purinoceptor 6 (P2RY6) DMQBEYV MA Agonist DMQBEYV RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQBEYV RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQBO3V DI DMQBO3V DMQBO3V DN M4344 DMQBO3V TI TT8ZYBQ DMQBO3V TN Serine/threonine-protein kinase ATR (FRP1) DMQBO3V MA Inhibitor DMQBO3V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQBO3V RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQCHU3 DI DMQCHU3 DMQCHU3 DN CPP -15 DMQCHU3 TI TTT2LD9 DMQCHU3 TN GABA transaminase (ABAT) DMQCHU3 MA Modulator DMQCHU3 RN Clinical pipeline report, company report or official report of Catalyst Pharma. DMQCHU3 RU http://ir.catalystpharma.com/releasedetail.cfm?ReleaseID=633588 DMQDBSU DI DMQDBSU DMQDBSU DN MEDI1341 DMQDBSU TI TT08OSU DMQDBSU TN Synuclein alpha (SNCA) DMQDBSU MA Inhibitor DMQDBSU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQDBSU RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQDKYV DI DMQDKYV DMQDKYV DN E-2212 DMQDKYV TI TT9W8GU DMQDKYV TN Gamma-secretase (GS) DMQDKYV MA Modulator DMQDKYV RN Development and mechanism of gamma-secretase modulators for Alzheimer's disease. Biochemistry. 2013 May 14;52(19):3197-216. DMQDKYV RU https://pubmed.ncbi.nlm.nih.gov/23614767 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TTWRN6M DMQDUG4 TN CRP messenger RNA (CRP mRNA) DMQDUG4 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMQDUG4 RU http://www.isispharm.com/Pipeline/index.htm DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT6TH8V DMQDUG4 TN Tyrosine-protein kinase BRK (PTK6) DMQDUG4 MA Inhibitor DMQDUG4 RN Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res. 2004 Apr 1;10(7):2307-18. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/15073106 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT860QF DMQDUG4 TN LCK tyrosine protein kinase (LCK) DMQDUG4 MA Inhibitor DMQDUG4 RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT3PJMV DMQDUG4 TN Tyrosine-protein kinase ABL1 (ABL) DMQDUG4 MA Inhibitor DMQDUG4 RN Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008 Mar 13;51(5):1252-9. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/18257513 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TT6PKBN DMQDUG4 TN Proto-oncogene c-Src (SRC) DMQDUG4 MA Inhibitor DMQDUG4 RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQDUG4 DI DMQDUG4 DMQDUG4 DN ISIS-CRP DMQDUG4 TI TTCQ2E5 DMQDUG4 TN RIP2 messenger RNA (RIP2 mRNA) DMQDUG4 MA Inhibitor DMQDUG4 RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQDUG4 RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQE4IX DI DMQE4IX DMQE4IX DN MG-1102 DMQE4IX TI TTGUMYS DMQE4IX TN Apolipoprotein(a) (LPA) DMQE4IX MA Modulator DMQE4IX RN Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model. Neoplasia. 2012 Apr;14(4):335-43. DMQE4IX RU https://pubmed.ncbi.nlm.nih.gov/22577348 DMQE9PS DI DMQE9PS DMQE9PS DN LXH254 DMQE9PS TI TTAN5W2 DMQE9PS TN Raf messenger RNA (Raf mRNA) DMQE9PS MA Inhibitor DMQE9PS RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQE9PS RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQEO4V DI DMQEO4V DMQEO4V DN AZD-5122 DMQEO4V TI TT30C9G DMQEO4V TN C-X-C chemokine receptor type 2 (CXCR2) DMQEO4V MA Modulator DMQEO4V RN Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589. DMQEO4V RU http://www.mdpi.com/1424-8247/4/4/567 DMQEOD6 DI DMQEOD6 DMQEOD6 DN VTP-27999 DMQEOD6 TI TTB2MXP DMQEOD6 TN Angiotensinogenase renin (REN) DMQEOD6 MA Inhibitor DMQEOD6 RN New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. DMQEOD6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/ DMQF982 DI DMQF982 DMQF982 DN AEW-541 DMQF982 TI TTHRID2 DMQF982 TN Insulin-like growth factor I receptor (IGF1R) DMQF982 MA Inhibitor DMQF982 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMQF982 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMQF982 DI DMQF982 DMQF982 DN AEW-541 DMQF982 TI TTCBFJO DMQF982 TN Insulin receptor (INSR) DMQF982 MA Inhibitor DMQF982 RN Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009 Aug 27;52(16):4981-5004. DMQF982 RU https://pubmed.ncbi.nlm.nih.gov/19610618 DMQFX8R DI DMQFX8R DMQFX8R DN DN1406131 DMQFX8R TI TTXNCBV DMQFX8R TN Tryptophan 2,3-dioxygenase (TDO) DMQFX8R MA Inhibitor DMQFX8R RN ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health. DMQFX8R RU https://clinicaltrials.gov/ct2/show/NCT03641794 DMQFX8R DI DMQFX8R DMQFX8R DN DN1406131 DMQFX8R TI TTZJYKH DMQFX8R TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQFX8R MA Inhibitor DMQFX8R RN ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health. DMQFX8R RU https://clinicaltrials.gov/ct2/show/NCT03641794 DMQGPRE DI DMQGPRE DMQGPRE DN ABBV-399 DMQGPRE TI TTNDSF4 DMQGPRE TN Proto-oncogene c-Met (MET) DMQGPRE MA Inhibitor DMQGPRE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQGPRE RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMQH2DK DI DMQH2DK DMQH2DK DN CAR-GPC3 T Cells DMQH2DK TI TTJTSX4 DMQH2DK TN Glypican-3 (GPC3) DMQH2DK MA CAR-T-Cell-Therapy DMQH2DK RN ClinicalTrials.gov (NCT02876978) Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma DMQH2DK RU https://clinicaltrials.gov/ct2/show/NCT02876978 DMQHPME DI DMQHPME DMQHPME DN MK-8583 DMQHPME TI TT84ETX DMQHPME TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQHPME MA Inhibitor DMQHPME RN ClinicalTrials.gov (NCT03552536) MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002). U.S. National Institutes of Health. DMQHPME RU https://clinicaltrials.gov/ct2/show/NCT03552536 DMQHWMJ DI DMQHWMJ DMQHWMJ DN LAM-003 DMQHWMJ TI TTO7FVG DMQHWMJ TN Heat shock protein 90 (HSP90) DMQHWMJ MA Inhibitor DMQHWMJ RN LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673. DMQHWMJ RU https://pubmed.ncbi.nlm.nih.gov/31751472 DMQI970 DI DMQI970 DMQI970 DN Lumoxiti DMQI970 TI TTM6QSK DMQI970 TN B-cell receptor CD22 (CD22) DMQI970 MA Inhibitor DMQI970 RN Clinical pipeline report, company report or official report of Innate Pharma. DMQI970 RU https://www.innate-pharma.com/fr/produits/lumoxiti DMQIE58 DI DMQIE58 DMQIE58 DN HH2853 DMQIE58 TI TTNJA0C DMQIE58 TN Enhancer of zeste homolog 1 (EZH1) DMQIE58 MA Inhibitor DMQIE58 RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DMQIE58 RU https://www.haihepharma.com/en/news/details/215 DMQIE58 DI DMQIE58 DMQIE58 DN HH2853 DMQIE58 TI TT9MZCQ DMQIE58 TN Enhancer of zeste homolog 2 (EZH2) DMQIE58 MA Inhibitor DMQIE58 RN Clinical pipeline report, company report or official report of HaiHe Biopharma. DMQIE58 RU https://www.haihepharma.com/en/news/details/215 DMQIEFB DI DMQIEFB DMQIEFB DN Debio 0827 DMQIEFB TI TT5TKPM DMQIEFB TN Neutral endopeptidase (MME) DMQIEFB MA Inhibitor DMQIEFB RN Clinical pipeline report, company report or official report of Debiopharm (2011). DMQIEFB RU http://www.debiopharm.com/our-business/pipeline.html DMQIKZG DI DMQIKZG DMQIKZG DN BAY 1834942 DMQIKZG TI TTIGH2W DMQIKZG TN Normal cross-reacting antigen (CD66c) DMQIKZG MA Blocker DMQIKZG RN ClinicalTrials.gov (NCT03596372) Study of BAY1834942 in Patients With Solid Tumors. U.S. National Institutes of Health. DMQIKZG RU https://clinicaltrials.gov/ct2/show/NCT03596372 DMQK5ET DI DMQK5ET DMQK5ET DN NG-350A DMQK5ET TI TTN6Y9A DMQK5ET TN CD40L receptor (CD40) DMQK5ET MA Agonist DMQK5ET RN Clinical pipeline report, company report or official report of PsiOxus Therapeutics. DMQK5ET RU https://psioxus.com/technology-products/ng-350a/ DMQKDJZ DI DMQKDJZ DMQKDJZ DN DWJ-208 DMQKDJZ TI TT4G2JS DMQKDJZ TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMQKDJZ MA Antagonist DMQKDJZ RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMQKDJZ RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMQLODU DI DMQLODU DMQLODU DN Citarinostat DMQLODU TI TT5ZKDI DMQLODU TN Histone deacetylase 6 (HDAC6) DMQLODU MA Inhibitor DMQLODU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQLODU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQMEDH DI DMQMEDH DMQMEDH DN BGB-A445 DMQMEDH TI TTL31H0 DMQMEDH TN OX40L receptor (CD134) DMQMEDH RN Clinical pipeline report, company report or official report of BeiGene. DMQMEDH RU https://www.beigene.com/science-and-product-portfolio/pipeline DMQMO4N DI DMQMO4N DMQMO4N DN SRF388 DMQMO4N TI TTC5LTG DMQMO4N TN Interleukin-27 (IL27) DMQMO4N RN Clinical pipeline report, company report or official report of Surface oncology. DMQMO4N RU https://www.surfaceoncology.com/pipeline-programs/ DMQNRGE DI DMQNRGE DMQNRGE DN PTG-100 DMQNRGE TI TTLT9XQ DMQNRGE TN Integrin beta-7 (ITGB7) DMQNRGE MA Antagonist DMQNRGE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQNRGE RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQNRGE DI DMQNRGE DMQNRGE DN PTG-100 DMQNRGE TI TT4BT06 DMQNRGE TN Integrin alpha-4 (ITGA4) DMQNRGE MA Antagonist DMQNRGE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQNRGE RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMQNS51 DI DMQNS51 DMQNS51 DN PRN2246 DMQNS51 TI TTGM6VW DMQNS51 TN Tyrosine-protein kinase BTK (ATK) DMQNS51 MA Inhibitor DMQNS51 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQNS51 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMQOHRA DI DMQOHRA DMQOHRA DN JNJ-67571244 DMQOHRA TI TTJVYO3 DMQOHRA TN Myeloid cell surface antigen CD33 (CD33) DMQOHRA MA Inhibitor DMQOHRA RN Clinical pipeline report, company report or official report of Genmab. DMQOHRA RU https://www.genmab.com/pipeline/ DMQOM5V DI DMQOM5V DMQOM5V DN GSK2646264 DMQOM5V TI TTOU65C DMQOM5V TN Tyrosine-protein kinase SYK (SYK) DMQOM5V MA Inhibitor DMQOM5V RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQOM5V RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQP6VB DI DMQP6VB DMQP6VB DN LY3200882 DMQP6VB TI TTP4520 DMQP6VB TN TGF-beta receptor type I (TGFBR1) DMQP6VB MA Inhibitor DMQP6VB RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQP6VB RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMQPI4V DI DMQPI4V DMQPI4V DN ELOMOTECAN HYDROCHLORIDE DMQPI4V TI TTGTQHC DMQPI4V TN DNA topoisomerase I (TOP1) DMQPI4V MA Modulator DMQPI4V RN The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann N Y Acad Sci. 2000;922:303-5. DMQPI4V RU https://www.ncbi.nlm.nih.gov/pubmed/11193907 DMQR4HA DI DMQR4HA DMQR4HA DN DABIS MALEATE DMQR4HA TI TTUTN1I DMQR4HA TN Human Deoxyribonucleic acid (hDNA) DMQR4HA MA Binder DMQR4HA RN DNA damage and sequence specificity of DNA binding of the new anti-cancer agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate)Broggini M1, Hartley JA, Mattes WB, Ponti M, Kohn KW, D'Incalci M.Author information1Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.Erratum inBr J Cancer 1990 Jul;62(1):172. AbstractThe DNA damage and the sequence specificity of guanine-N7 alkylation produced by the novel, positively charged, antineoplastic agent 1,4-bis(2'-chloroethyl)-1,4-diazabicyclo-[2.2.1] heptane dimaleate (Dabis maleate) and its uncharged tertiary amine analogue 1,4-bis(2'-chloroethyl)-1,4-diazacyclohexane (Dabis analogue) were investigated in L1210 cells and isolated DNA. Both compounds are cytotoxic in vitro causing an arrest of L1210 cells in G2/M phase of the cell cycle. In isolated DNA, Dabis maleate alkylates guanine at the N7-position with some differences in specificity compared to other alkylating agents (e.g. nitrogen mustard). Significant differences are also evident between Dabis maleate and Dabis analogue, suggesting that Dabis analogue is not the sole alkylating species of Dabis maleate. Using the alkaline elution technique a moderate number of DNA interstrand cross-links were detected in L1210 cells treated with both compounds, which were completely repaired within 24 h. Dabis maleate and Dabis analogue do not cause DNA single strand breaks or DNA protein cross-links at the doses at which DNA interstrand cross-links were detected.PMID: 2393411 [PubMed - indexed for MEDLINE] PMCID: PMC1971404 Free PMC ArticleSharePublication Types, MeSH Terms, SubstancesPublication TypesResearch Support, Non-U.S. Gov'tMeSH TermsAnimalsAntineoplastic Agents/pharmacology*Base SequenceBicycloCompounds/pharmacology*Bicyclo Compounds, Heterocyclic*Bridged Compounds/pharmacology*Cell Survival/drug effectsDNA Damage*DNA, Neoplasm/drug effects*Dose-Response Relationship, DrugHumansInterphase/drug effectsLeukemia L1210/pathologyTumor Cells, Cultured/drug effectsSubstancesAntineoplastic AgentsBicyclo CompoundsBicyclo Compounds, HeterocyclicBridged CompoundsDNA, Neoplasm1,4-bis(2'-chloroethyl)-1,4-diazabicyclo(2.2.1)heptaneLinkOut - more resourcesFull Text SourcesEurope PubMed CentralPubMed CentralPubMed Central CanadaOther Literature SourcesCOS Scholar UniverseAccess more work from the authors - ResearchGateMiscellaneousNCI CPTAC Assay PortalPubMed Commons home Br J Cancer. 1990 Feb;61(2):285-9. DMQR4HA RU https://pubmed.ncbi.nlm.nih.gov/2393411 DMQRKXP DI DMQRKXP DMQRKXP DN AEA-35p DMQRKXP TI TTYA75N DMQRKXP TN MHC class II antigen DR (HLA-DR) DMQRKXP RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMQRKXP RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMQRNTG DI DMQRNTG DMQRNTG DN MP-124 DMQRNTG TI TTEBCY8 DMQRNTG TN Poly [ADP-ribose] polymerase (PARP) DMQRNTG MA Modulator DMQRNTG RN Company report (Mitsubishi Tanabe Pharma) DMQRNTG RU http://www.mt-pharma-america.com/development.php DMQSJ9T DI DMQSJ9T DMQSJ9T DN Meso-CART DMQSJ9T TI TT4RXME DMQSJ9T TN Mesothelin (MSLN) DMQSJ9T MA CAR-T-Cell-Therapy DMQSJ9T RN ClinicalTrials.gov (NCT02706782) A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma DMQSJ9T RU https://clinicaltrials.gov/ct2/show/NCT02706782 DMQTOBF DI DMQTOBF DMQTOBF DN CART-56 cells DMQTOBF TI TTVXPHT DMQTOBF TN Neural cell adhesion molecule 1 (NCAM1) DMQTOBF MA CAR-T-Cell-Therapy DMQTOBF RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMQTOBF RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMQTUH8 DI DMQTUH8 DMQTUH8 DN Calanolide A DMQTUH8 TI TT84ETX DMQTUH8 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQTUH8 MA Inhibitor DMQTUH8 RN Calanolide A: a natural non-nucleoside reverse transcriptase inhibitor. BETA. 1999 Apr;12(2):8-9. DMQTUH8 RU https://pubmed.ncbi.nlm.nih.gov/11366704 DMQUFNY DI DMQUFNY DMQUFNY DN ARM210 DMQUFNY TI TT9YXM1 DMQUFNY TN Ryanodine receptor (RYR) DMQUFNY MA Modulator DMQUFNY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQUFNY RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMQUNRW DI DMQUNRW DMQUNRW DN PF-06763809 DMQUNRW TI TTRX125 DMQUNRW TN Transcription factor unspecific (TF) DMQUNRW MA Inhibitor DMQUNRW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMQUNRW RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMQVEZB DI DMQVEZB DMQVEZB DN Adjustable basal insulin DMQVEZB TI TTZOPHG DMQVEZB TN Insulin (INS) DMQVEZB MA Modulator DMQVEZB RN The future of basal insulin supplementation. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S103-8. DMQVEZB RU https://pubmed.ncbi.nlm.nih.gov/21568722 DMQYBSH DI DMQYBSH DMQYBSH DN PF-05231023 DMQYBSH TI TTQ916P DMQYBSH TN Fibroblast growth factor-21 (FGF21) DMQYBSH RN Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos. 2015 Jun;43(6):803-11. DMQYBSH RU https://pubmed.ncbi.nlm.nih.gov/25805881 DMQZSXD DI DMQZSXD DMQZSXD DN GSK3117391 DMQZSXD TI TTBH0VX DMQZSXD TN Histone deacetylase (HDAC) DMQZSXD MA Modulator DMQZSXD RN The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42. DMQZSXD RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215088/ DMR0S8U DI DMR0S8U DMR0S8U DN C326 DMR0S8U TI TTT1V78 DMR0S8U TN Interleukin-6 (IL6) DMR0S8U MA Inhibitor DMR0S8U RN The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009 Jul 9;114(2):437-43. DMR0S8U RU https://pubmed.ncbi.nlm.nih.gov/19383972 DMR0U4V DI DMR0U4V DMR0U4V DN XEN-D0103 DMR0U4V TI TTW0CMT DMR0U4V TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMR0U4V MA Inhibitor DMR0U4V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542). DMR0U4V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542 DMR0Z65 DI DMR0Z65 DMR0Z65 DN CART-20 cells DMR0Z65 TI TTUE541 DMR0Z65 TN Leukocyte surface antigen Leu-16 (CD20) DMR0Z65 MA CAR-T-Cell-Therapy DMR0Z65 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMR0Z65 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMR12S0 DI DMR12S0 DMR12S0 DN ORIC-101 DMR12S0 TI TTOZRK6 DMR12S0 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMR12S0 MA Antagonist DMR12S0 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR12S0 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR14VE DI DMR14VE DMR14VE DN KH-901 DMR14VE TI TT6MP2Z DMR14VE TN GMCSFR-alpha (CSF2RA) DMR14VE RN Effects of KH901, a tumor-specific oncolytic recombinant adenovirus, on antitumor and expressing GM-CSF in xenograft tumor models. Sichuan Da Xue Xue Bao Yi Xue Ban. 2007 Jun;38(3):386-90. DMR14VE RU https://pubmed.ncbi.nlm.nih.gov/17593813 DMR17YI DI DMR17YI DMR17YI DN Isoquine DMR17YI TI TTQ6VDM DMR17YI TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMR17YI MA Inhibitor DMR17YI RN Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15. DMR17YI RU https://pubmed.ncbi.nlm.nih.gov/19222165 DMR17YI DI DMR17YI DMR17YI DN Isoquine DMR17YI TI TTVG215 DMR17YI TN Debrisoquine 4-hydroxylase (CYP2D6) DMR17YI MA Inhibitor DMR17YI RN Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15. DMR17YI RU https://pubmed.ncbi.nlm.nih.gov/19222165 DMR24MI DI DMR24MI DMR24MI DN GSK-2256098 DMR24MI TI TTON5IT DMR24MI TN Focal adhesion kinase 1 (FAK) DMR24MI MA Inhibitor DMR24MI RN A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9. DMR24MI RU https://pubmed.ncbi.nlm.nih.gov/25486573 DMR35U4 DI DMR35U4 DMR35U4 DN AMXT1501 DMR35U4 TI TTJR4Z5 DMR35U4 TN Polyamine transport (Poly trans) DMR35U4 MA Inhibitor DMR35U4 RN AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport. Int J Cancer. 2013 Sep 15;133(6):1323-33. DMR35U4 RU https://pubmed.ncbi.nlm.nih.gov/23457004 DMR38M4 DI DMR38M4 DMR38M4 DN UNBS-1450 DMR38M4 TI TTWK8D0 DMR38M4 TN Sodium pump subunit alpha-1 (ATP1A1) DMR38M4 MA Inhibitor DMR38M4 RN Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. Cell Death Dis. 2015 Jun 11;6:e1782. DMR38M4 RU https://pubmed.ncbi.nlm.nih.gov/26068790 DMR3E4L DI DMR3E4L DMR3E4L DN Irdabisant DMR3E4L TI TT9JNIC DMR3E4L TN Histamine H3 receptor (H3R) DMR3E4L MA Antagonist DMR3E4L RN CEP-26401 (irdabisant), a potent and selective histamine H receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther. 2012 Jan;340(1):124-33. DMR3E4L RU https://pubmed.ncbi.nlm.nih.gov/22001260 DMR3SO5 DI DMR3SO5 DMR3SO5 DN JCAR018 DMR3SO5 TI TTM6QSK DMR3SO5 TN B-cell receptor CD22 (CD22) DMR3SO5 MA Immunomodulator DMR3SO5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR3SO5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMR5ATX DI DMR5ATX DMR5ATX DN NKR-2 cells DMR5ATX TI TTLRN4A DMR5ATX TN NKG2 D activating NK receptor (KLRK1) DMR5ATX MA CAR-T-Cell-Therapy DMR5ATX RN ClinicalTrials.gov (NCT03310008) Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases DMR5ATX RU https://clinicaltrials.gov/ct2/show/NCT03310008 DMR6T8L DI DMR6T8L DMR6T8L DN COM902 DMR6T8L TI TTWNL74 DMR6T8L TN V-set and immunoglobulin domain-containing protein 9 (TIGIT) DMR6T8L RN COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade. Cancer Immunol Immunother. 2021 Apr 26. DMR6T8L RU https://pubmed.ncbi.nlm.nih.gov/33903974 DMR7BAO DI DMR7BAO DMR7BAO DN PRN1371 DMR7BAO TI TT0LF7H DMR7BAO TN Fibroblast growth factor receptor (FGFR) DMR7BAO MA Inhibitor DMR7BAO RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMR7BAO RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMR7EF6 DI DMR7EF6 DMR7EF6 DN KHK-2866 DMR7EF6 TI TT15SL0 DMR7EF6 TN Proheparin-binding EGF-like growth factor (HBEGF) DMR7EF6 RN ClinicalTrials.gov (NCT01279291) Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer. U.S. National Institutes of Health. DMR7EF6 RU https://clinicaltrials.gov/ct2/show/NCT01279291 DMR7LKC DI DMR7LKC DMR7LKC DN LM-CD45 DMR7LKC TI TTUS45N DMR7LKC TN Leukocyte common antigen (PTPRC) DMR7LKC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002932) DMR7LKC RU http://adisinsight.springer.com/drugs/800002932 DMR7OGL DI DMR7OGL DMR7OGL DN ABT-239 DMR7OGL TI TT9JNIC DMR7OGL TN Histamine H3 receptor (H3R) DMR7OGL MA Antagonist DMR7OGL RN Use of the H3 receptor antagonist radioligand [3H]-A-349821 to reveal in vivo receptor occupancy of cognition enhancing H3 receptor antagonists. Br J Pharmacol. 2009 May;157(1):139-49. DMR7OGL RU https://pubmed.ncbi.nlm.nih.gov/19413577 DMR8OG2 DI DMR8OG2 DMR8OG2 DN IMGN-853 DMR8OG2 TI TTVC37M DMR8OG2 TN Folate receptor alpha (FOLR1) DMR8OG2 MA Inhibitor DMR8OG2 RN Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010 Jan;21(1):84-92. DMR8OG2 RU https://pubmed.ncbi.nlm.nih.gov/19891424 DMR93S5 DI DMR93S5 DMR93S5 DN ATL1103 DMR93S5 TI TTHJWYD DMR93S5 TN GHR messenger RNA (GHR mRNA) DMR93S5 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMR93S5 RU http://www.isispharm.com/Pipeline/index.htm DMR9PCT DI DMR9PCT DMR9PCT DN VX-970 DMR9PCT TI TT8ZYBQ DMR9PCT TN Serine/threonine-protein kinase ATR (FRP1) DMR9PCT MA Inhibitor DMR9PCT RN ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79. DMR9PCT RU https://pubmed.ncbi.nlm.nih.gov/25269479 DMRAWGC DI DMRAWGC DMRAWGC DN KM-819 DMRAWGC TI TTSKL3G DMRAWGC TN FAS-associated factor 1 (FAF1) DMRAWGC MA Inhibitor DMRAWGC RN A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers. Drug Des Devel Ther. 2019 Mar 29;13:1011-1022. DMRAWGC RU https://pubmed.ncbi.nlm.nih.gov/30992659 DMRAXFH DI DMRAXFH DMRAXFH DN SRT3025 DMRAXFH TI TTUF2HO DMRAXFH TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMRAXFH MA Modulator DMRAXFH RN The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. DMRAXFH RU https://pubmed.ncbi.nlm.nih.gov/26226624 DMRBVHE DI DMRBVHE DMRBVHE DN GSK690693 DMRBVHE TI TTAZ05C DMRBVHE TN RAC-gamma serine/threonine-protein kinase (AKT3) DMRBVHE MA Modulator DMRBVHE RN Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity.Cancer Res.2008 Apr 1;68(7):2366-74. DMRBVHE RU https://www.ncbi.nlm.nih.gov/pubmed/18381444 DMRCHOU DI DMRCHOU DMRCHOU DN H-103 DMRCHOU TI TTHYBIX DMRCHOU TN Heat shock protein 70 (HSP70) DMRCHOU MA Modulator DMRCHOU RN A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients. Gene Ther. 2009 Mar;16(3):376-82. DMRCHOU RU https://pubmed.ncbi.nlm.nih.gov/19092859 DMRD1IW DI DMRD1IW DMRD1IW DN SCO-088 DMRD1IW TI TTS7G69 DMRD1IW TN Fusion protein Bcr-Abl (Bcr-Abl) DMRD1IW MA Inhibitor DMRD1IW RN Clinical pipeline report, company report or official report of Sun Pharma Advanced Research Company. DMRD1IW RU https://www.sparc.life/research-programs/sco-088 DMRD2B0 DI DMRD2B0 DMRD2B0 DN CXD-101 DMRD2B0 TI TTBH0VX DMRD2B0 TN Histone deacetylase (HDAC) DMRD2B0 MA Inhibitor DMRD2B0 RN Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7. DMRD2B0 RU https://pubmed.ncbi.nlm.nih.gov/20002107 DMRDNPC DI DMRDNPC DMRDNPC DN GS-6620 DMRDNPC TI TTMVBWH DMRDNPC TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMRDNPC MA Inhibitor DMRDNPC RN Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother. 2014;58(4):1930-42. DMRDNPC RU https://pubmed.ncbi.nlm.nih.gov/24419349 DMRDY0G DI DMRDY0G DMRDY0G DN ACV-1 DMRDY0G TI TTJ49OM DMRDY0G TN Neuronal acetylcholine receptor alpha-10 (CHRNA10) DMRDY0G MA Modulator DMRDY0G RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRDY0G RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRE6UT DI DMRE6UT DMRE6UT DN IBC-VS01 DMRE6UT TI TTZOPHG DMRE6UT TN Insulin (INS) DMRE6UT MA Modulator DMRE6UT RN Prevention of Type 1 Diabetes Mellitus using a Novel Vaccine. Ther Adv Endocrinol Metab. 2011 February; 2(1): 9-16. DMRE6UT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3474625/ DMRGF9Q DI DMRGF9Q DMRGF9Q DN APD-916 DMRGF9Q TI TT9JNIC DMRGF9Q TN Histamine H3 receptor (H3R) DMRGF9Q MA Antagonist DMRGF9Q RN Identification of biaryl sulfone derivatives as antagonists of the histamine H receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916). Bioorg Med Chem Lett. 2012 Jan 1;22(1):71-5. DMRGF9Q RU https://pubmed.ncbi.nlm.nih.gov/22172695 DMRGHKN DI DMRGHKN DMRGHKN DN RG7827 DMRGHKN TI TTPW9LJ DMRGHKN TN Co-stimulatory molecule 4-1BB (CD137) DMRGHKN MA Agonist DMRGHKN RN Clinical pipeline report, company report or official report of Roche. DMRGHKN RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMRGP72 DI DMRGP72 DMRGP72 DN G1T-48 DMRGP72 TI TTZAYWL DMRGP72 TN Estrogen receptor (ESR) DMRGP72 MA Degrader DMRGP72 RN G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Res Treat. 2020 Apr;180(3):635-646. DMRGP72 RU https://pubmed.ncbi.nlm.nih.gov/32130619 DMRGVT9 DI DMRGVT9 DMRGVT9 DN PF-06826647 DMRGVT9 TI TTBYWP2 DMRGVT9 TN TYK2 tyrosine kinase (TYK2) DMRGVT9 MA Inhibitor DMRGVT9 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRGVT9 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMRGWDB DI DMRGWDB DMRGWDB DN PZ01 CAR-T cells DMRGWDB TI TTW640A DMRGWDB TN B-lymphocyte surface antigen B4 (CD19) DMRGWDB MA CAR-T-Cell-Therapy DMRGWDB RN ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma DMRGWDB RU https://clinicaltrials.gov/ct2/show/NCT03281551 DMRH740 DI DMRH740 DMRH740 DN CS-8080 DMRH740 TI TTM1EQF DMRH740 TN Oxysterols receptor LXR (NR1H) DMRH740 MA Modulator DMRH740 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DMRH740 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DMRHQTU DI DMRHQTU DMRHQTU DN PSMA subunit vaccine DMRHQTU TI TT9G4N0 DMRHQTU TN Glutamate carboxypeptidase II (GCPII) DMRHQTU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMRHQTU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMRI6YT DI DMRI6YT DMRI6YT DN BI 836880 DMRI6YT TI TTKLQTJ DMRI6YT TN Angiopoietin-2 (ANGPT2) DMRI6YT MA Blocker DMRI6YT RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMRI6YT RU https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor DMRI6YT DI DMRI6YT DMRI6YT DN BI 836880 DMRI6YT TI TT9HKJA DMRI6YT TN Vascular endothelial growth factor (VEGF) DMRI6YT MA Blocker DMRI6YT RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMRI6YT RU https://www.inoncology.com/ourpipeline/vegf-ang2-inhibitor DMRIH0S DI DMRIH0S DMRIH0S DN SAR113244 DMRIH0S TI TTIW59R DMRIH0S TN C-X-C chemokine receptor type 5 (CXCR5) DMRIH0S MA Modulator DMRIH0S RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRIH0S RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRINBJ DI DMRINBJ DMRINBJ DN TAK-169 DMRINBJ TI TTPURFN DMRINBJ TN Cyclic ADP-ribose hydrolase 1 (CD38) DMRINBJ MA Inhibitor DMRINBJ RN Clinical pipeline report, company report or official report of Molecular Templates. DMRINBJ RU https://www.mtem.com/pipeline/tak-169 DMRJEXM DI DMRJEXM DMRJEXM DN NN-414 DMRJEXM TI TTP835K DMRJEXM TN ATP-binding cassette transporter C8 (ABCC8) DMRJEXM MA Modulator DMRJEXM RN Attenuation of hyperinsulinemia by NN414, a SUR1/Kir6.2 selective K-adenosine triphosphate channel opener, improves glucose tolerance and lipid profile in obese Zucker rats.Metabolism.2004 Apr;53(4):441-7. DMRJEXM RU https://www.ncbi.nlm.nih.gov/pubmed/15045689 DMRJF2Q DI DMRJF2Q DMRJF2Q DN Citatuzumab bogatox DMRJF2Q TI TTZ8WH4 DMRJF2Q TN Tumor-associated calcium signal transducer 1 (EPCAM) DMRJF2Q RN Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. Cancer Biother Radiopharm. 2012 Nov;27(9):582-92. DMRJF2Q RU https://pubmed.ncbi.nlm.nih.gov/22856424 DMRL6W5 DI DMRL6W5 DMRL6W5 DN BAY2402234 DMRL6W5 TI TTLVP78 DMRL6W5 TN Dihydroorotate dehydrogenase (DHODH) DMRL6W5 MA Inhibitor DMRL6W5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRL6W5 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRLPFG DI DMRLPFG DMRLPFG DN DS-3201 DMRLPFG TI TTNJA0C DMRLPFG TN Enhancer of zeste homolog 1 (EZH1) DMRLPFG MA Inhibitor DMRLPFG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRLPFG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRLPFG DI DMRLPFG DMRLPFG DN DS-3201 DMRLPFG TI TT9MZCQ DMRLPFG TN Enhancer of zeste homolog 2 (EZH2) DMRLPFG MA Inhibitor DMRLPFG RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRLPFG RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRMC7U DI DMRMC7U DMRMC7U DN AMG 579 DMRMC7U TI TTJW4LU DMRMC7U TN Phosphodiesterase 10A (PDE10) DMRMC7U MA Inhibitor DMRMC7U RN Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41. DMRMC7U RU https://pubmed.ncbi.nlm.nih.gov/25062128 DMRNIB9 DI DMRNIB9 DMRNIB9 DN CART-34 cells DMRNIB9 TI TTZAVYN DMRNIB9 TN Hematopoietic progenitor cell antigen CD34 (CD34) DMRNIB9 MA CAR-T-Cell-Therapy DMRNIB9 RN ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS DMRNIB9 RU https://clinicaltrials.gov/ct2/show/NCT03291444 DMRP3N8 DI DMRP3N8 DMRP3N8 DN AZD4831 DMRP3N8 TI TTVCZPI DMRP3N8 TN Myeloperoxidase (MPO) DMRP3N8 MA Modulator DMRP3N8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRP3N8 RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMRP4BM DI DMRP4BM DMRP4BM DN MB-104 DMRP4BM TI TT7ILZ1 DMRP4BM TN SLAM family member 7 SLAMF7 (CS1) DMRP4BM RN Clinical pipeline report, company report or official report of Mustang Bio. DMRP4BM RU https://www.mustangbio.com/pipeline/ DMRP9YF DI DMRP9YF DMRP9YF DN XEN901 DMRP9YF TI TT54ERL DMRP9YF TN Voltage-gated sodium channel alpha Nav1.6 (SCN8A) DMRP9YF MA Inhibitor DMRP9YF RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMRP9YF RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMRQ32K DI DMRQ32K DMRQ32K DN AX-024 DMRQ32K TI TTXQYT6 DMRQ32K TN T-cells (T-cells) DMRQ32K MA Inhibitor DMRQ32K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRQ32K RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMRQ32K DI DMRQ32K DMRQ32K DN AX-024 DMRQ32K TI TTMA3VF DMRQ32K TN NCK adaptor protein 1 (NCK1) DMRQ32K MA Modulator DMRQ32K RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRQ32K RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMRQ4L6 DI DMRQ4L6 DMRQ4L6 DN HHCYH33 DMRQ4L6 TI TTEUNMR DMRQ4L6 TN PI3-kinase alpha (PIK3CA) DMRQ4L6 MA Inhibitor DMRQ4L6 RN Adaptive resistance to PI3Kalpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells. Cell Death Dis. 2021 Jan 14;12(1):85. DMRQ4L6 RU https://pubmed.ncbi.nlm.nih.gov/33446653 DMRQ5YT DI DMRQ5YT DMRQ5YT DN PTH(7-34) liposomal cream DMRQ5YT TI TTEPJL5 DMRQ5YT TN Parathyroid hormone receptor (PTH2R) DMRQ5YT MA Modulator DMRQ5YT RN Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone. 2008 Dec;43(6):1022-30. DMRQ5YT RU https://pubmed.ncbi.nlm.nih.gov/18761112 DMRQX9H DI DMRQX9H DMRQX9H DN CJ-12255 DMRQX9H TI TTZPO1L DMRQX9H TN Substance-P receptor (TACR1) DMRQX9H MA Antagonist DMRQX9H RN Neurokinin-1 receptor, a new modulator of lymphangiogenesis in obese-asthma phenotype. Life Sci. 2013 Aug 6;93(4):169-77. DMRQX9H RU https://pubmed.ncbi.nlm.nih.gov/23792204 DMRSG04 DI DMRSG04 DMRSG04 DN CAR-T cells targeting EGFRviii DMRSG04 TI TTZ6B2I DMRSG04 TN Epidermal growth factor receptor variant III (EGFR vIII) DMRSG04 MA CAR-T-Cell-Therapy DMRSG04 RN ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme DMRSG04 RU https://clinicaltrials.gov/ct2/show/NCT03170141 DMRU4YV DI DMRU4YV DMRU4YV DN GSK-2018682 DMRU4YV TI TT9JZCK DMRU4YV TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMRU4YV MA Agonist DMRU4YV RN Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702. DMRU4YV RU https://pubmed.ncbi.nlm.nih.gov/23954895 DMRVDUM DI DMRVDUM DMRVDUM DN ZP2929 DMRVDUM TI TTVIMDE DMRVDUM TN Glucagon-like peptide 1 receptor (GLP1R) DMRVDUM MA Modulator DMRVDUM RN Company report (Zealandpharma) DMRVDUM RU http://www.zealandpharma.com/product-pipeline/proprietary-pipeline/zp2929 DMRVDUM DI DMRVDUM DMRVDUM DN ZP2929 DMRVDUM TI TT9O6WS DMRVDUM TN Glucagon receptor (GCGR) DMRVDUM MA Modulator DMRVDUM RN Company report (Zealandpharma) DMRVDUM RU http://www.zealandpharma.com/product-pipeline/proprietary-pipeline/zp2929 DMRVDUM DI DMRVDUM DMRVDUM DN ZP2929 DMRVDUM TI TT0NUFM DMRVDUM TN Glucagon (GCG) DMRVDUM MA Agonist DMRVDUM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRVDUM RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMRWI7E DI DMRWI7E DMRWI7E DN Anti-N3pG-Abeta antibody DMRWI7E TI TTE4KHA DMRWI7E TN Amyloid beta A4 protein (APP) DMRWI7E RN LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co. DMRWI7E RU http://www.alzforum.org/therapeutics/ly3002813 DMRWTFG DI DMRWTFG DMRWTFG DN A-337 DMRWTFG TI TTZ8WH4 DMRWTFG TN Tumor-associated calcium signal transducer 1 (EPCAM) DMRWTFG MA Inhibitor DMRWTFG RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DMRWTFG RU https://pubmed.ncbi.nlm.nih.gov/31175342 DMRWTFG DI DMRWTFG DMRWTFG DN A-337 DMRWTFG TI TTUN7MC DMRWTFG TN T-cell surface glycoprotein CD3 (CD3) DMRWTFG MA Inhibitor DMRWTFG RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DMRWTFG RU https://pubmed.ncbi.nlm.nih.gov/31175342 DMRX530 DI DMRX530 DMRX530 DN TAS-116 DMRX530 TI TTH5YN2 DMRX530 TN Heat shock protein 90 beta (HSP90B) DMRX530 MA Inhibitor DMRX530 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRX530 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMRXDN3 DI DMRXDN3 DMRXDN3 DN BCI-838 DMRXDN3 TI TTXJ47W DMRXDN3 TN Metabotropic glutamate receptor 2 (mGluR2) DMRXDN3 MA Modulator DMRXDN3 RN Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010 DMRXDN3 RU http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html DMRXDN3 DI DMRXDN3 DMRXDN3 DN BCI-838 DMRXDN3 TI TT8A9EF DMRXDN3 TN Metabotropic glutamate receptor 3 (mGluR3) DMRXDN3 MA Modulator DMRXDN3 RN Metabotropic glutamate receptor subtype 2 (GRM2; MGLUR2); GRM3 (MGLUR3). SciBX 3(13); doi:10.1038/scibx.2010.413. April 1 2010 DMRXDN3 RU http://www.nature.com/scibx/journal/v3/n13/full/scibx.2010.413.html DMRXW9P DI DMRXW9P DMRXW9P DN GSK-2130579A DMRXW9P TI TTZ8UT4 DMRXW9P TN Wilms tumor protein (WT1) DMRXW9P RN Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012. DMRXW9P RU http://science.thomsonreuters.com.cn/media/spotlight_on_report_Q22012.pdf DMRYHWA DI DMRYHWA DMRYHWA DN IC9-GD2-CD28-OX40 DMRYHWA TI TT80ARU DMRYHWA TN Ganglioside GD2 (GD2) DMRYHWA MA CAR-T-Cell-Therapy DMRYHWA RN ClinicalTrials.gov (NCT01822652) 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN DMRYHWA RU https://clinicaltrials.gov/ct2/show/NCT01822652 DMRYM03 DI DMRYM03 DMRYM03 DN HMS5552 DMRYM03 TI TTDLNGZ DMRYM03 TN Glucokinase (GCK) DMRYM03 MA Activator DMRYM03 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRYM03 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMRYNJD DI DMRYNJD DMRYNJD DN GSK3745417 DMRYNJD TI TTT402Y DMRYNJD TN Stimulator of interferon genes protein (TMEM173) DMRYNJD MA Agonist DMRYNJD RN National Cancer Institute Drug Dictionary (drug name GSK3745417). DMRYNJD RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/sting-agonist-gsk3745417 DMRZHV6 DI DMRZHV6 DMRZHV6 DN PF-06873600 DMRZHV6 TI TTMBO1Z DMRZHV6 TN Cyclin-dependent kinase (CDK) DMRZHV6 MA Inhibitor DMRZHV6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMRZHV6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMS0P5O DI DMS0P5O DMS0P5O DN MB-103 DMS0P5O TI TT6EO5L DMS0P5O TN Erbb2 tyrosine kinase receptor (HER2) DMS0P5O RN Clinical pipeline report, company report or official report of Mustang Bio. DMS0P5O RU https://www.mustangbio.com/pipeline/ DMS1HR3 DI DMS1HR3 DMS1HR3 DN ABM-1310 DMS1HR3 TI TTWCGQT DMS1HR3 TN Serine/threonine-protein kinase B-raf (BRAF) DMS1HR3 MA Inhibitor DMS1HR3 RN Clinical pipeline report, company report or official report of ABM Therapeutics. DMS1HR3 RU http://www.abmtx.com/site/development3 DMS1NC8 DI DMS1NC8 DMS1NC8 DN DZ-2640 DMS1NC8 TI TTJP4SM DMS1NC8 TN Bacterial Penicillin binding protein (Bact PBP) DMS1NC8 MA Modulator DMS1NC8 RN In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J Antimicrob Chemother. 2000 Jul;46(1):101-8. DMS1NC8 RU https://pubmed.ncbi.nlm.nih.gov/10882697 DMS1O56 DI DMS1O56 DMS1O56 DN FF-10101-01 DMS1O56 TI TTGJCWZ DMS1O56 TN Fms-like tyrosine kinase 3 (FLT-3) DMS1O56 MA Inhibitor DMS1O56 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS1O56 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMS20X6 DI DMS20X6 DMS20X6 DN CDX-1135 DMS20X6 TI TTEA8OW DMS20X6 TN Complement receptor type 1 (CR1) DMS20X6 MA Modulator DMS20X6 RN Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol Immunol. 2013 Nov;56(1-2):91-7. DMS20X6 RU https://pubmed.ncbi.nlm.nih.gov/23685261 DMS25DL DI DMS25DL DMS25DL DN GS-1423 DMS25DL TI TTO3HT7 DMS25DL TN Transforming growth factor beta (TGFB) DMS25DL RN Clinical pipeline report, company report or official report of Agenus. DMS25DL RU https://agenusbio.com/pipeline/ DMS25DL DI DMS25DL DMS25DL DN GS-1423 DMS25DL TI TTK0O6Y DMS25DL TN Ecto-5'-nucleotidase (CD73) DMS25DL RN Clinical pipeline report, company report or official report of Agenus. DMS25DL RU https://agenusbio.com/pipeline/ DMS31YW DI DMS31YW DMS31YW DN YM-57158 DMS31YW TI TTGKOY9 DMS31YW TN Leukotriene CysLT1 receptor (CYSLTR1) DMS31YW MA Modulator DMS31YW RN In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9. DMS31YW RU https://pubmed.ncbi.nlm.nih.gov/9808690 DMS31YW DI DMS31YW DMS31YW DN YM-57158 DMS31YW TI TT2O84V DMS31YW TN Thromboxane A2 receptor (TBXA2R) DMS31YW MA Modulator DMS31YW RN In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9. DMS31YW RU https://pubmed.ncbi.nlm.nih.gov/9808690 DMS3915 DI DMS3915 DMS3915 DN AC 165198 DMS3915 TI TTUPB12 DMS3915 TN Measles virus Fusion glycoprotein (MeV F) DMS3915 MA Modulator DMS3915 RN WO patent application no. 2013,1306,83, Xten conjugate compositions and methods of making same. DMS3915 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130906&CC=WO&NR=2013130683A2&KC=A2 DMS436I DI DMS436I DMS436I DN ETX201 DMS436I TI TTZXH48 DMS436I TN TNF receptor (TNFR) DMS436I MA Antagonist DMS436I RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMS436I RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMS4H1J DI DMS4H1J DMS4H1J DN BMS-936564 DMS4H1J TI TTBID49 DMS4H1J TN C-X-C chemokine receptor type 4 (CXCR4) DMS4H1J MA Modulator DMS4H1J RN BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. DMS4H1J RU https://pubmed.ncbi.nlm.nih.gov/23213054 DMS4H30 DI DMS4H30 DMS4H30 DN BT-063 DMS4H30 TI TTDB5IS DMS4H30 TN Receptor unspecific (Rec) DMS4H30 RN Clinical pipeline report, company report or official report of Biotest. DMS4H30 RU http://www.biotest.com/de/en/r_d/pipeline/bt063.cfm DMS4P6K DI DMS4P6K DMS4P6K DN Biostrophin DMS4P6K TI TT48MP6 DMS4P6K TN Dystrophin (DMD) DMS4P6K MA Modulator DMS4P6K RN Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet. 2013 Jun;14(6):373-8. DMS4P6K RU https://pubmed.ncbi.nlm.nih.gov/23609411 DMS6DPF DI DMS6DPF DMS6DPF DN ADPT01 DMS6DPF TI TTNBFWK DMS6DPF TN Programmed cell death protein 1 (PD-1) DMS6DPF MA Inhibitor DMS6DPF RN Clinical pipeline report, company report or official report of Novartis. DMS6DPF RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All DMS6DPF DI DMS6DPF DMS6DPF DN ADPT01 DMS6DPF TI TTNVXAW DMS6DPF TN Lymphocyte activation gene 3 protein (LAG3) DMS6DPF MA Inhibitor DMS6DPF RN Clinical pipeline report, company report or official report of Novartis. DMS6DPF RU https://www.novartis.com/our-science/novartis-global-pipeline?search_api_views_fulltext=ADPT01&field_pipeline_filing_date=All DMS72GN DI DMS72GN DMS72GN DN AMG 172 DMS72GN TI TTNCIE0 DMS72GN TN CD70 antigen (CD27-L) DMS72GN MA Modulator DMS72GN RN National Cancer Institute Drug Dictionary (drug id 721679). DMS72GN RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=721679 DMS8NM5 DI DMS8NM5 DMS8NM5 DN OS2966 DMS8NM5 TI TTBVIQC DMS8NM5 TN Integrin beta-1 (ITGB1) DMS8NM5 MA Inhibitor DMS8NM5 RN Convection-Enhanced Delivery of a First-in-Class Anti-beta1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec 30;13(1):40. DMS8NM5 RU https://pubmed.ncbi.nlm.nih.gov/33396712 DMS9EKG DI DMS9EKG DMS9EKG DN VCL-1M01 DMS9EKG TI TTF89GD DMS9EKG TN Interleukin-2 (IL2) DMS9EKG MA Modulator DMS9EKG RN Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 1995 Mar;2(2):164-7. DMS9EKG RU https://pubmed.ncbi.nlm.nih.gov/7719933 DMS9I6A DI DMS9I6A DMS9I6A DN AZD7687 DMS9I6A TI TTF8P9I DMS9I6A TN Diacylglycerol acyltransferase 1 (DGAT1) DMS9I6A MA Inhibitor DMS9I6A RN Clinical pipeline report, company report or official report of AstraZeneca (2011). DMS9I6A RU http://www.astrazeneca.com/Home DMS9LVC DI DMS9LVC DMS9LVC DN KUR-502 DMS9LVC TI TTW640A DMS9LVC TN B-lymphocyte surface antigen B4 (CD19) DMS9LVC RN Clinical pipeline report, company report or official report of Kuur Therapeutics. DMS9LVC RU https://kuurtx.com/product-overview/ DMS9WXG DI DMS9WXG DMS9WXG DN HGS-1029 DMS9WXG TI TTR7B60 DMS9WXG TN X-linked inhibitor of apoptosis protein (XIAP) DMS9WXG MA Antagonist DMS9WXG RN Clinical pipeline report, company report or official report of Aegera Therapeutics Inc. DMS9WXG RU http://www.aegera.com/aeg40826.php DMSA27Z DI DMSA27Z DMSA27Z DN MK-6186 DMSA27Z TI TT84ETX DMSA27Z TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSA27Z MA Inhibitor DMSA27Z RN Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. DMSA27Z RU https://pubmed.ncbi.nlm.nih.gov/22391531 DMSAQBC DI DMSAQBC DMSAQBC DN PPI-2458 DMSAQBC TI TTZL0OI DMSAQBC TN Methionine aminopeptidase 2 (METAP2) DMSAQBC MA Inhibitor DMSAQBC RN Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26. DMSAQBC RU https://pubmed.ncbi.nlm.nih.gov/23355637 DMSBM6A DI DMSBM6A DMSBM6A DN BNC-101 DMSBM6A TI TTTSGRH DMSBM6A TN Leucine-rich repeat-containing GPCR 5 (LGR5) DMSBM6A MA Inhibitor DMSBM6A RN Clinical pipeline report, company report or official report of Bionomics. DMSBM6A RU https://www.bionomics.com.au/research-development/pipeline/oncology DMSBWAQ DI DMSBWAQ DMSBWAQ DN Bb21217 DMSBWAQ TI TTZ3P4W DMSBWAQ TN B-cell maturation protein (TNFRSF17) DMSBWAQ MA CAR-T-Cell-Therapy DMSBWAQ RN ClinicalTrials.gov (NCT03274219) Study of bb21217 in Multiple Myeloma DMSBWAQ RU https://clinicaltrials.gov/ct2/show/NCT03274219 DMSCV02 DI DMSCV02 DMSCV02 DN [N-methyl-3H(3)]AZ-10419369 DMSCV02 TI TTK8CXU DMSCV02 TN 5-HT 1B receptor (HTR1B) DMSCV02 MA Antagonist DMSCV02 RN 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43. DMSCV02 RU https://pubmed.ncbi.nlm.nih.gov/25841787 DMSCXB7 DI DMSCXB7 DMSCXB7 DN UK-240455 DMSCXB7 TI TTZ8EM9 DMSCXB7 TN Glycine receptor (GlyR) DMSCXB7 MA Modulator DMSCXB7 RN UK-315716/UK-240455. Pfizer. Curr Opin Investig Drugs. 2001 Dec;2(12):1737-9. DMSCXB7 RU https://pubmed.ncbi.nlm.nih.gov/11892937 DMSDNU1 DI DMSDNU1 DMSDNU1 DN CHF 5407 DMSDNU1 TI TTQ13Z5 DMSDNU1 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSDNU1 MA Modulator DMSDNU1 RN Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyc... J Pharmacol Exp Ther. 2010 Dec;335(3):622-35. DMSDNU1 RU https://www.ncbi.nlm.nih.gov/pubmed/20805306 DMSE19U DI DMSE19U DMSE19U DN GDC0134 DMSE19U TI TTF4AVB DMSE19U TN Protein delta homolog 1 (DLK1) DMSE19U MA Inhibitor DMSE19U RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSE19U RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMSENTW DI DMSENTW DMSENTW DN NJH395 DMSENTW TI TT6EO5L DMSENTW TN Erbb2 tyrosine kinase receptor (HER2) DMSENTW RN ClinicalTrials.gov (NCT03696771) Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer. U.S. National Institutes of Health. DMSENTW RU https://clinicaltrials.gov/ct2/show/NCT03696771 DMSGEU6 DI DMSGEU6 DMSGEU6 DN JAB-3068 DMSGEU6 TI TT7WUAV DMSGEU6 TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMSGEU6 MA Inhibitor DMSGEU6 RN Clinical pipeline report, company report or official report of AbbVie. DMSGEU6 RU https://www.abbvie.com/our-science/pipeline/jab-3068-jab-3312.html DMSGNVK DI DMSGNVK DMSGNVK DN GSK2793660 DMSGNVK TI TT4H0V2 DMSGNVK TN Dipeptidyl peptidase I (CTSC) DMSGNVK MA Modulator DMSGNVK RN ClinicalTrials.gov (NCT02058407) A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects. U.S. National Institutes of Health. DMSGNVK RU https://clinicaltrials.gov/ct2/show/NCT02058407 DMSGRA7 DI DMSGRA7 DMSGRA7 DN CIGB-M3 DMSGRA7 TI TTY6DTE DMSGRA7 TN Carcinoembryonic antigen CEA (CD66e) DMSGRA7 RN Phase I clinical trial of the (131)I-labeled anticarcinoembryonic antigen CIGB-M3 multivalent antibody fragment. Cancer Biother Radiopharm. 2011 Jun;26(3):353-63. DMSGRA7 RU https://pubmed.ncbi.nlm.nih.gov/21711100 DMSHK23 DI DMSHK23 DMSHK23 DN AMG-191 DMSHK23 TI TTX41N9 DMSHK23 TN Tyrosine-protein kinase Kit (KIT) DMSHK23 MA Inhibitor DMSHK23 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029529) DMSHK23 RU http://adisinsight.springer.com/drugs/800029529 DMSJBUZ DI DMSJBUZ DMSJBUZ DN CD20-CART DMSJBUZ TI TTUE541 DMSJBUZ TN Leukocyte surface antigen Leu-16 (CD20) DMSJBUZ MA CAR-T-Cell-Therapy(Dual specific) DMSJBUZ RN ClinicalTrials.gov (NCT03407859) Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL DMSJBUZ RU https://clinicaltrials.gov/ct2/show/NCT03407859 DMSJOTL DI DMSJOTL DMSJOTL DN PF-06817024 DMSJOTL TI TTFTSHD DMSJOTL TN Cytokine unspecific (CYK) DMSJOTL MA Modulator DMSJOTL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSJOTL RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMSJVX3 DI DMSJVX3 DMSJVX3 DN CM3.1-AC100 DMSJVX3 TI TTVIMDE DMSJVX3 TN Glucagon-like peptide 1 receptor (GLP1R) DMSJVX3 MA Agonist DMSJVX3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMSJVX3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMSJWTE DI DMSJWTE DMSJWTE DN OKI 179 DMSJWTE TI TTBH0VX DMSJWTE TN Histone deacetylase (HDAC) DMSJWTE MA Inhibitor DMSJWTE RN Clinical pipeline report, company report or official report of OnKure Therapeutics. DMSJWTE RU http://onkuretherapeutics.com/pipeline/ DMSKF29 DI DMSKF29 DMSKF29 DN TNT009 DMSKF29 TI TT7LRQH DMSKF29 TN Complement C1s component (C1S) DMSKF29 MA Inhibitor DMSKF29 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSKF29 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMSKHIC DI DMSKHIC DMSKHIC DN R4996 DMSKHIC TI TTLA931 DMSKHIC TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMSKHIC MA Agonist DMSKHIC RN Clinical pipeline report, company report or official report of Roche (2009). DMSKHIC RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMSKI8W DI DMSKI8W DMSKI8W DN KPG-121 DMSKI8W TI TTEZQ39 DMSKI8W TN Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase) DMSKI8W MA Modulator DMSKI8W RN Clinical pipeline report, company report or official report of Kangpu Biopharmaceuticals. DMSKI8W RU https://www.kangpugroup.com/research_development/pipeline.html DMSLDHG DI DMSLDHG DMSLDHG DN HPP-854 DMSLDHG TI TT8JRS7 DMSLDHG TN Beta-secretase (BACE) DMSLDHG MA Modulator DMSLDHG RN BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. DMSLDHG RU https://pubmed.ncbi.nlm.nih.gov/25621019 DMSLE03 DI DMSLE03 DMSLE03 DN PF-562271 DMSLE03 TI TTON5IT DMSLE03 TN Focal adhesion kinase 1 (FAK) DMSLE03 MA Inhibitor DMSLE03 RN Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45. DMSLE03 RU https://pubmed.ncbi.nlm.nih.gov/21903606 DMSLPTO DI DMSLPTO DMSLPTO DN ZY01 DMSLPTO TI TT6OEDT DMSLPTO TN Cannabinoid receptor 1 (CB1) DMSLPTO MA Antagonist DMSLPTO RN 2011 Pipeline of Zydus Cadila Group. DMSLPTO RU http://www.zyduscadila.com/ DMSLQW2 DI DMSLQW2 DMSLQW2 DN TRPH-222 DMSLQW2 TI TTM6QSK DMSLQW2 TN B-cell receptor CD22 (CD22) DMSLQW2 RN Clinical pipeline report, company report or official report of Triphase Accelerator. DMSLQW2 RU http://triphaseco.com/trph-222/ DMSM0IJ DI DMSM0IJ DMSM0IJ DN RG6279 DMSM0IJ TI TTNBFWK DMSM0IJ TN Programmed cell death protein 1 (PD-1) DMSM0IJ RN Clinical pipeline report, company report or official report of Roche. DMSM0IJ RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMSM42V DI DMSM42V DMSM42V DN CYAD-101 DMSM42V TI TTLRN4A DMSM42V TN NKG2 D activating NK receptor (KLRK1) DMSM42V MA CAR-T-Cell-Therapy DMSM42V RN ClinicalTrials.gov (NCT03692429) alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells DMSM42V RU https://clinicaltrials.gov/ct2/show/NCT03692429 DMSMNRQ DI DMSMNRQ DMSMNRQ DN PF-07265807 DMSMNRQ TI TTO7LKR DMSMNRQ TN Tyrosine-protein kinase Mer (MERTK) DMSMNRQ MA Inhibitor DMSMNRQ RN National Cancer Institute Drug Dictionary (drug name PF-07265807). DMSMNRQ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axl-mer-inhibitor-pf-07265807 DMSMNRQ DI DMSMNRQ DMSMNRQ DN PF-07265807 DMSMNRQ TI TTZPY6J DMSMNRQ TN Tyrosine-protein kinase UFO (AXL) DMSMNRQ MA Inhibitor DMSMNRQ RN National Cancer Institute Drug Dictionary (drug name PF-07265807). DMSMNRQ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/axl-mer-inhibitor-pf-07265807 DMSMRC1 DI DMSMRC1 DMSMRC1 DN 1069C DMSMRC1 TI TTYFKSZ DMSMRC1 TN Tubulin beta (TUBB) DMSMRC1 MA Modulator DMSMRC1 RN Patent WO2005108424 A1. DMSMRC1 RU http://www.google.com/patents/WO2005108424A1?cl=en DMSO3JA DI DMSO3JA DMSO3JA DN C7R-GD2.CART cells DMSO3JA TI TT80ARU DMSO3JA TN Ganglioside GD2 (GD2) DMSO3JA MA CAR-T-Cell-Therapy DMSO3JA RN ClinicalTrials.gov (NCT03635632) C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma (GAIL-N) DMSO3JA RU https://clinicaltrials.gov/ct2/show/NCT03635632 DMSOB5D DI DMSOB5D DMSOB5D DN Chi Lob 7/4 DMSOB5D TI TTIJP3Q DMSOB5D TN TNF related activation protein (CD40LG) DMSOB5D MA Modulator DMSOB5D RN Agonistic CD40 antibodies and cancer therapy DMSOB5D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590838 DMSPBOW DI DMSPBOW DMSPBOW DN AIC100 DMSPBOW TI TTCT6F7 DMSPBOW TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMSPBOW RN Clinical pipeline report, company report or official report of AffyImmune Therapeutics. DMSPBOW RU https://affyimmune.com/pipeline/ DMSPQDM DI DMSPQDM DMSPQDM DN JNJ-61610588 DMSPQDM TI TT51SK8 DMSPQDM TN V-set immunoregulatory receptor (VSIR) DMSPQDM MA Inhibitor DMSPQDM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSPQDM RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT1RWNJ DMSQ3AZ TN Tyrosine-protein kinase Lyn (JTK8) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TTGKNB4 DMSQ3AZ TN Epidermal growth factor receptor (EGFR) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TTDCBX5 DMSQ3AZ TN Vascular endothelial growth factor receptor 3 (FLT-4) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT2B9KF DMSQ3AZ TN Fyn tyrosine protein kinase (FYN) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT6EO5L DMSQ3AZ TN Erbb2 tyrosine kinase receptor (HER2) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT860QF DMSQ3AZ TN LCK tyrosine protein kinase (LCK) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT0SQ8J DMSQ3AZ TN Yes tyrosine kinase (YES) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQ3AZ DI DMSQ3AZ DMSQ3AZ DN JNJ-26483327 DMSQ3AZ TI TT0JESD DMSQ3AZ TN Erbb4 tyrosine kinase receptor (Erbb-4) DMSQ3AZ MA Inhibitor DMSQ3AZ RN National Cancer Institute Drug Dictionary (drug id 596693). DMSQ3AZ RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=596693 DMSQZEP DI DMSQZEP DMSQZEP DN TAR-200 DMSQZEP TI TTUBNVO DMSQZEP TN DNA synthesis (DNA synth) DMSQZEP MA Inhibitor DMSQZEP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMSQZEP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMSR5HD DI DMSR5HD DMSR5HD DN GSI-136 DMSR5HD TI TT9W8GU DMSR5HD TN Gamma-secretase (GS) DMSR5HD MA Modulator DMSR5HD RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMSR5HD RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMSR91U DI DMSR91U DMSR91U DN AVE0118 DMSR91U TI TT1VOHK DMSR91U TN Potassium channel unspecific (KC) DMSR91U MA Modulator DMSR91U RN Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.Basic Clin Pharmacol Toxicol.2014 Oct;115(4):315-20. DMSR91U RU https://www.ncbi.nlm.nih.gov/pubmed/24629214 DMSRICG DI DMSRICG DMSRICG DN TNB-486 DMSRICG TI TTW640A DMSRICG TN B-lymphocyte surface antigen B4 (CD19) DMSRICG RN Clinical pipeline report, company report or official report of Teneobio. DMSRICG RU https://teneobio.com/our-pipeline/ DMSRICG DI DMSRICG DMSRICG DN TNB-486 DMSRICG TI TTUN7MC DMSRICG TN T-cell surface glycoprotein CD3 (CD3) DMSRICG RN Clinical pipeline report, company report or official report of Teneobio. DMSRICG RU https://teneobio.com/our-pipeline/ DMSUFW6 DI DMSUFW6 DMSUFW6 DN SSR-125047 DMSUFW6 TI TT5TPI6 DMSUFW6 TN Opioid receptor sigma 1 (OPRS1) DMSUFW6 MA Binder DMSUFW6 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMSUFW6 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMSUFW6 DI DMSUFW6 DMSUFW6 DN SSR-125047 DMSUFW6 TI TTFBNVI DMSUFW6 TN Aldose reductase (AKR1B1) DMSUFW6 MA Inhibitor DMSUFW6 RN Aldose reductase inhibitors: an update. Ann Pharmacother. 1993 Jun;27(6):751-4. DMSUFW6 RU https://pubmed.ncbi.nlm.nih.gov/8329799 DMSVD2R DI DMSVD2R DMSVD2R DN SGN-CD228A DMSVD2R TI TT8OBT3 DMSVD2R TN Melanotransferrin (MELTF) DMSVD2R RN Clinical pipeline report, company report or official report of Seagen. DMSVD2R RU https://www.seagen.com/science/pipeline DMSVO92 DI DMSVO92 DMSVO92 DN Tigapotide DMSVO92 TI TTYH1ZK DMSVO92 TN Beta-microseminoprotein (MSMB) DMSVO92 MA Inhibitor DMSVO92 RN National Cancer Institute Drug Dictionary (drug id 600185). DMSVO92 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=600185 DMSWJ6D DI DMSWJ6D DMSWJ6D DN NU-206 DMSWJ6D TI TTI9HL4 DMSWJ6D TN Roof plate-specific spondin-1 (RSPO1) DMSWJ6D MA Modulator DMSWJ6D RN R-spondin1 and FOXL2 act into two distinct cellular types during goat ovarian differentiation.BMC Dev Biol.2008 Apr 2;8:36. DMSWJ6D RU https://www.ncbi.nlm.nih.gov/pubmed/18384673 DMSX24U DI DMSX24U DMSX24U DN AFO-18 DMSX24U TI TT3J5ZI DMSX24U TN Cell mediated immunity response (CMIR) DMSX24U RN ClinicalTrials.gov (NCT01009762) Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection. U.S. National Institutes of Health. DMSX24U RU https://clinicaltrials.gov/ct2/show/NCT01009762 DMSX5NJ DI DMSX5NJ DMSX5NJ DN RG6330 DMSX5NJ TI TT3LH46 DMSX5NJ TN KRAS G12C mutant (KRAS G12C) DMSX5NJ MA Inhibitor DMSX5NJ RN Clinical pipeline report, company report or official report of Roche. DMSX5NJ RU https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMSYB83 DI DMSYB83 DMSYB83 DN IMGN-388 DMSYB83 TI TTT1R2L DMSYB83 TN Integrin alpha-V (ITGAV) DMSYB83 RN Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010 Oct 1;70(19):7591-9. DMSYB83 RU https://pubmed.ncbi.nlm.nih.gov/20841470 DMSZ8HT DI DMSZ8HT DMSZ8HT DN MazF gene therapy DMSZ8HT TI TTRBUYN DMSZ8HT TN Ribonuclease (RNase) DMSZ8HT MA Modulator DMSZ8HT RN Clinical pipeline report, company report or official report of Takara Bio. DMSZ8HT RU http://www.takara-bio.com/medi_e/ DMSZIP5 DI DMSZIP5 DMSZIP5 DN SB-639 DMSZIP5 TI TT6R7JZ DMSZIP5 TN Histone deacetylase 1 (HDAC1) DMSZIP5 MA Inhibitor DMSZIP5 RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMSZIP5 RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMT0EBU DI DMT0EBU DMT0EBU DN MT-112 DMT0EBU TI TT9G4N0 DMT0EBU TN Glutamate carboxypeptidase II (GCPII) DMT0EBU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMT0EBU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMT27PA DI DMT27PA DMT27PA DN AMV564 DMT27PA TI TTJVYO3 DMT27PA TN Myeloid cell surface antigen CD33 (CD33) DMT27PA MA Modulator DMT27PA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMT27PA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMT35N2 DI DMT35N2 DMT35N2 DN C-CAR088 DMT35N2 TI TTZ3P4W DMT35N2 TN B-cell maturation protein (TNFRSF17) DMT35N2 MA CAR-T-Cell-Therapy DMT35N2 RN ClinicalTrials.gov (NCT03751293) A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma DMT35N2 RU https://clinicaltrials.gov/ct2/show/NCT03751293 DMT3HKZ DI DMT3HKZ DMT3HKZ DN HL-018 DMT3HKZ TI TT0FYAN DMT3HKZ TN Free fatty acid receptor 2 (FFAR2) DMT3HKZ MA Inhibitor DMT3HKZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 226). DMT3HKZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=226 DMT3V2W DI DMT3V2W DMT3V2W DN GSK2879552 DMT3V2W TI TTNR0UQ DMT3V2W TN Lysine-specific histone demethylase 1 (LSD) DMT3V2W MA Inhibitor DMT3V2W RN A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69. DMT3V2W RU https://pubmed.ncbi.nlm.nih.gov/26175415 DMT4Z5B DI DMT4Z5B DMT4Z5B DN CALAA-01 DMT4Z5B TI TTBWDI0 DMT4Z5B TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMT4Z5B MA Modulator DMT4Z5B RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT4Z5B RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT4Z5B DI DMT4Z5B DMT4Z5B DN CALAA-01 DMT4Z5B TI TTV5YEH DMT4Z5B TN Transferrin (TF) DMT4Z5B MA Modulator DMT4Z5B RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT4Z5B RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT5AEF DI DMT5AEF DMT5AEF DN TST-10088 DMT5AEF TI TTJ073B DMT5AEF TN Ribosome (hRBS) DMT5AEF MA Immunomodulator (Immunostimulant) DMT5AEF RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Nov;31(9):597-633. DMT5AEF RU https://pubmed.ncbi.nlm.nih.gov/20094643 DMT5Z84 DI DMT5Z84 DMT5Z84 DN ATI-0917 DMT5Z84 TI TTF7I5O DMT5Z84 TN Human immunodeficiency virus Rev protein (HIV rev) DMT5Z84 MA Inhibitor DMT5Z84 RN Antiretroviral drugs in development. A report from HIV DART 2008: Frontiers in Drug Development for Antiretroviral Therapies, 9-12 December 2008, Rio Grande, Puerto Rico. Expert Opin Investig Drugs. 2009 Apr;18(4):549-53. DMT5Z84 RU https://pubmed.ncbi.nlm.nih.gov/19335283 DMT7L30 DI DMT7L30 DMT7L30 DN CR-3465 DMT7L30 TI TTGKOY9 DMT7L30 TN Leukotriene CysLT1 receptor (CYSLTR1) DMT7L30 MA Modulator DMT7L30 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT7L30 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT7YOU DI DMT7YOU DMT7YOU DN CD19t-haNK DMT7YOU TI TTW640A DMT7YOU TN B-lymphocyte surface antigen B4 (CD19) DMT7YOU RN ClinicalTrials.gov (NCT04052061) QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma. U.S. National Institutes of Health. DMT7YOU RU https://clinicaltrials.gov/ct2/show/NCT04052061 DMT9MHE DI DMT9MHE DMT9MHE DN IMGN289 DMT9MHE TI TTGKNB4 DMT9MHE TN Epidermal growth factor receptor (EGFR) DMT9MHE MA Inhibitor DMT9MHE RN World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29. DMT9MHE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929441/ DMTAOPC DI DMTAOPC DMTAOPC DN SAR442720 DMTAOPC TI TT7WUAV DMTAOPC TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMTAOPC MA Inhibitor DMTAOPC RN Clinical pipeline report, company report or official report of Revolution Medicines. DMTAOPC RU https://www.revmed.com/pipeline/rmc-4630 DMTB4R8 DI DMTB4R8 DMTB4R8 DN BAY1125976 DMTB4R8 TI TTAZ05C DMTB4R8 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMTB4R8 MA Modulator DMTB4R8 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTB4R8 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTCB8I DI DMTCB8I DMTCB8I DN CART-19 T cells DMTCB8I TI TTW640A DMTCB8I TN B-lymphocyte surface antigen B4 (CD19) DMTCB8I MA CAR-T-Cell-Therapy DMTCB8I RN ClinicalTrials.gov (NCT02135406) CART-19 for Multiple Myeloma DMTCB8I RU https://clinicaltrials.gov/ct2/show/NCT02135406 DMTCLM3 DI DMTCLM3 DMTCLM3 DN CGM097 DMTCLM3 TI TT7SBF5 DMTCLM3 TN Cellular tumor antigen p53 (TP53) DMTCLM3 MA Modulator DMTCLM3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTCLM3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTD4EF DI DMTD4EF DMTD4EF DN ALPN-202 DMTD4EF TI TTI2S1D DMTD4EF TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMTD4EF MA Inhibitor DMTD4EF RN Clinical pipeline report, company report or official report of Alpine Immune Sciences. DMTD4EF RU https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf DMTD4EF DI DMTD4EF DMTD4EF DN ALPN-202 DMTD4EF TI TT8ZLTI DMTD4EF TN Programmed cell death 1 ligand 1 (PD-L1) DMTD4EF MA Inhibitor DMTD4EF RN Clinical pipeline report, company report or official report of Alpine Immune Sciences. DMTD4EF RU https://www.alpineimmunesciences.com/wp-content/uploads/2020/06/ALPN-202_AACR20_NEON-1_TIP.pdf DMTD57A DI DMTD57A DMTD57A DN AZD8329 DMTD57A TI TTN7BL9 DMTD57A TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMTD57A MA Inhibitor DMTD57A RN Clinical pipeline report, company report or official report of AstraZeneca (2011). DMTD57A RU http://www.astrazeneca.com/Home DMTDWIE DI DMTDWIE DMTDWIE DN BRX-005 DMTDWIE TI TTHYBIX DMTDWIE TN Heat shock protein 70 (HSP70) DMTDWIE MA Modulator DMTDWIE RN Cardiovascular effects of BRX-005 comparison to bimoclomol. Life Sci. 2000 Aug 25;67(14):1783-9. DMTDWIE RU https://pubmed.ncbi.nlm.nih.gov/11021362 DMTE18G DI DMTE18G DMTE18G DN CHF-4227 DMTE18G TI TTZAYWL DMTE18G TN Estrogen receptor (ESR) DMTE18G MA Modulator DMTE18G RN Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen. J Pharmacol Exp Ther. 2002 Oct;303(1):196-203. DMTE18G RU https://pubmed.ncbi.nlm.nih.gov/12235251 DMTEA9C DI DMTEA9C DMTEA9C DN ABBV-744 DMTEA9C TI TTRA6BO DMTEA9C TN Bromodomain-containing protein 4 (BRD4) DMTEA9C MA Inhibitor DMTEA9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTEA9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTEA9C DI DMTEA9C DMTEA9C DN ABBV-744 DMTEA9C TI TTHE657 DMTEA9C TN Bromodomain-containing protein 3 (BRD3) DMTEA9C MA Inhibitor DMTEA9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTEA9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTEA9C DI DMTEA9C DMTEA9C DN ABBV-744 DMTEA9C TI TTDP48B DMTEA9C TN Bromodomain-containing protein 2 (BRD2) DMTEA9C MA Inhibitor DMTEA9C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTEA9C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTEG6B DI DMTEG6B DMTEG6B DN PENCLOMEDINE DMTEG6B TI TTUTN1I DMTEG6B TN Human Deoxyribonucleic acid (hDNA) DMTEG6B MA Modulator DMTEG6B RN The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum. Invest New Drugs. 2003 Aug;21(3):269-79. DMTEG6B RU https://www.ncbi.nlm.nih.gov/pubmed/14578677 DMTFAGU DI DMTFAGU DMTFAGU DN SAR228810 DMTFAGU TI TTE4KHA DMTFAGU TN Amyloid beta A4 protein (APP) DMTFAGU RN SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's & Dementia Volume 9, Issue 4, Supplement, July 2013, Pages P808-P809. DMTFAGU RU http://www.sciencedirect.com/science/article/pii/S1552526013023352 DMTFU8Q DI DMTFU8Q DMTFU8Q DN OMP-131R10 DMTFU8Q TI TT7HJTF DMTFU8Q TN R-spondin-3 (RSPO3) DMTFU8Q RN Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs. PLoS One. 2020 Mar 11;15(3):e0229445. DMTFU8Q RU https://pubmed.ncbi.nlm.nih.gov/32160239 DMTFUM4 DI DMTFUM4 DMTFUM4 DN IMMU-114 DMTFUM4 TI TTYA75N DMTFUM4 TN MHC class II antigen DR (HLA-DR) DMTFUM4 RN The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD. Bone Marrow Transplant. 2012 Jul;47(7):967-80. DMTFUM4 RU https://pubmed.ncbi.nlm.nih.gov/22020022 DMTFWLE DI DMTFWLE DMTFWLE DN KUC-7483 DMTFWLE TI TTMXGCW DMTFWLE TN Adrenergic receptor beta-3 (ADRB3) DMTFWLE MA Agonist DMTFWLE RN Effects of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163-8. DMTFWLE RU https://pubmed.ncbi.nlm.nih.gov/22511202 DMTG9EV DI DMTG9EV DMTG9EV DN ATRC-101 DMTG9EV TI TTHC8EF DMTG9EV TN Polyadenylate-binding protein 1 (PABPC1) DMTG9EV RN Clinical pipeline report, company report or official report of Atreca. DMTG9EV RU https://www.atreca.com/pipeline/ DMTG9WM DI DMTG9WM DMTG9WM DN BBI-6000 DMTG9WM TI TTGV6LY DMTG9WM TN Nuclear receptor ROR-gamma (RORG) DMTG9WM MA Inhibitor DMTG9WM RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTG9WM RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMTGLOY DI DMTGLOY DMTGLOY DN TK216 DMTGLOY TI TT9AH0M DMTGLOY TN Protein C-ets-2 (ETS2) DMTGLOY MA Inhibitor DMTGLOY RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTGLOY RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMTGZN8 DI DMTGZN8 DMTGZN8 DN AMG 780 DMTGZN8 TI TTWNQ1T DMTGZN8 TN Angiopoietin-1 (ANGPT1) DMTGZN8 MA Modulator DMTGZN8 RN Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2). Cancer Research. 10/2014; 74(19 Supplement):1022-1022. DMTGZN8 RU http://cancerres.aacrjournals.org/content/74/19_Supplement/1022 DMTK1BV DI DMTK1BV DMTK1BV DN SRF617 DMTK1BV TI TTYM8DJ DMTK1BV TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DMTK1BV RN Clinical pipeline report, company report or official report of Surface oncology. DMTK1BV RU https://www.surfaceoncology.com/pipeline-programs/ DMTK78L DI DMTK78L DMTK78L DN Anti-CD30 CAR-T cells DMTK78L TI TT2GM5R DMTK78L TN Lymphocyte activation antigen CD30 (TNFRSF8) DMTK78L MA CAR-T-Cell-Therapy DMTK78L RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMTK78L RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMTKPH4 DI DMTKPH4 DMTKPH4 DN VBY- 891 DMTKPH4 TI TTUMQVO DMTKPH4 TN Cathepsin S (CTSS) DMTKPH4 MA Modulator DMTKPH4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DMTKPH4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DMTKZ1Q DI DMTKZ1Q DMTKZ1Q DN DS-6157 DMTKZ1Q TI TTGTQHC DMTKZ1Q TN DNA topoisomerase I (TOP1) DMTKZ1Q MA Inhibitor DMTKZ1Q RN Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523. DMTKZ1Q RU https://pubmed.ncbi.nlm.nih.gov/33579785 DMTKZ1Q DI DMTKZ1Q DMTKZ1Q DN DS-6157 DMTKZ1Q TI TT26C7Z DMTKZ1Q TN G-protein coupled receptor 20 (GPR20) DMTKZ1Q MA Inhibitor DMTKZ1Q RN Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 Jun;11(6):1508-1523. DMTKZ1Q RU https://pubmed.ncbi.nlm.nih.gov/33579785 DMTLNGV DI DMTLNGV DMTLNGV DN Umespirone DMTLNGV TI TTEX248 DMTLNGV TN Dopamine D2 receptor (D2R) DMTLNGV MA Antagonist DMTLNGV RN The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav. 1991 Sep;40(1):89-96. DMTLNGV RU https://pubmed.ncbi.nlm.nih.gov/1685786 DMTLNGV DI DMTLNGV DMTLNGV DN Umespirone DMTLNGV TI TTSQIFT DMTLNGV TN 5-HT 1A receptor (HTR1A) DMTLNGV MA Antagonist DMTLNGV RN The effects of umespirone as a potential anxiolytic and antipsychotic agent. Pharmacol Biochem Behav. 1991 Sep;40(1):89-96. DMTLNGV RU https://pubmed.ncbi.nlm.nih.gov/1685786 DMTLP1N DI DMTLP1N DMTLP1N DN Combinectin DMTLP1N TI TTG90S6 DMTLP1N TN Human immunodeficiency virus Glycoprotein 41 (HIV gp41) DMTLP1N MA Inhibitor DMTLP1N RN Clinical pipeline report, company report or official report of ViiV Healthcare. DMTLP1N RU https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf DMTLP1N DI DMTLP1N DMTLP1N DN Combinectin DMTLP1N TI TTN2JFW DMTLP1N TN T-cell surface glycoprotein CD4 (CD4) DMTLP1N MA Inhibitor DMTLP1N RN Clinical pipeline report, company report or official report of ViiV Healthcare. DMTLP1N RU https://jvi.asm.org/content/jvi/early/2019/07/25/JVI.00907-19.full.pdf DMTLU37 DI DMTLU37 DMTLU37 DN Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 DMTLU37 TI TT4RXME DMTLU37 TN Mesothelin (MSLN) DMTLU37 MA CAR-T-Cell-Therapy DMTLU37 RN ClinicalTrials.gov (NCT01897415) Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer DMTLU37 RU https://clinicaltrials.gov/ct2/show/NCT01897415 DMTMUWJ DI DMTMUWJ DMTMUWJ DN BMS-986299 DMTMUWJ TI TT4EN8X DMTMUWJ TN Caterpiller protein 1.1 (NLRP3) DMTMUWJ MA Agonist DMTMUWJ RN National Cancer Institute Drug Dictionary (drug name BMS-986299). DMTMUWJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nlrp3-agonist-bms-986299 DMTNUA4 DI DMTNUA4 DMTNUA4 DN ZL-1201 DMTNUA4 TI TT28S46 DMTNUA4 TN Leukocyte surface antigen CD47 (CD47) DMTNUA4 RN Clinical pipeline report, company report or official report of ZAI Lab. DMTNUA4 RU http://www.zailaboratory.com/pipeline/list.aspx DMTNYIB DI DMTNYIB DMTNYIB DN IM21 CART DMTNYIB TI TTZ3P4W DMTNYIB TN B-cell maturation protein (TNFRSF17) DMTNYIB MA CAR-T-Cell-Therapy DMTNYIB RN ClinicalTrials.gov (NCT03711864) Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma DMTNYIB RU https://clinicaltrials.gov/ct2/show/NCT03711864 DMTOLI5 DI DMTOLI5 DMTOLI5 DN Pomaglumetad DMTOLI5 TI TT8A9EF DMTOLI5 TN Metabotropic glutamate receptor 3 (mGluR3) DMTOLI5 MA Modulator DMTOLI5 RN LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45. DMTOLI5 RU https://pubmed.ncbi.nlm.nih.gov/20571979 DMTOLI5 DI DMTOLI5 DMTOLI5 DN Pomaglumetad DMTOLI5 TI TTXJ47W DMTOLI5 TN Metabotropic glutamate receptor 2 (mGluR2) DMTOLI5 MA Modulator DMTOLI5 RN LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45. DMTOLI5 RU https://pubmed.ncbi.nlm.nih.gov/20571979 DMTOUY9 DI DMTOUY9 DMTOUY9 DN Suramin DMTOUY9 TI TTZFDBT DMTOUY9 TN Follicle-stimulating hormone receptor (FSHR) DMTOUY9 MA Antagonist DMTOUY9 RN Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem. 2008 Nov;8(13):1384-94. DMTOUY9 RU https://pubmed.ncbi.nlm.nih.gov/18991754 DMTOUY9 DI DMTOUY9 DMTOUY9 DN Suramin DMTOUY9 TI TTR7GJO DMTOUY9 TN Heparanase (HPSE) DMTOUY9 MA Inhibitor DMTOUY9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1728). DMTOUY9 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1728 DMTOXLG DI DMTOXLG DMTOXLG DN PPI-461 DMTOXLG TI TTCJ2X8 DMTOXLG TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMTOXLG MA Modulator DMTOXLG RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTOXLG RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTP9ER DI DMTP9ER DMTP9ER DN D-20133 DMTP9ER TI TT1UZQH DMTP9ER TN Phospholipase C (PLC) DMTP9ER MA Inhibitor DMTP9ER RN Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain. Curr Med Chem. 2011; 18(18): 2727-2742. DMTP9ER RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091980/ DMTQ4PN DI DMTQ4PN DMTQ4PN DN Metastat DMTQ4PN TI TTLM12X DMTQ4PN TN Matrix metalloproteinase-2 (MMP-2) DMTQ4PN MA Inhibitor DMTQ4PN RN Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. DMTQ4PN RU https://pubmed.ncbi.nlm.nih.gov/12209155 DMTR7EH DI DMTR7EH DMTR7EH DN Desoxypeganine DMTR7EH TI TT1RS9F DMTR7EH TN Acetylcholinesterase (AChE) DMTR7EH MA Modulator DMTR7EH RN Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7. DMTR7EH RU https://pubmed.ncbi.nlm.nih.gov/18560630 DMTR7EH DI DMTR7EH DMTR7EH DN Desoxypeganine DMTR7EH TI TT3WG5C DMTR7EH TN Monoamine oxidase type A (MAO-A) DMTR7EH MA Modulator DMTR7EH RN Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):141-7. DMTR7EH RU https://pubmed.ncbi.nlm.nih.gov/18560630 DMTRF71 DI DMTRF71 DMTRF71 DN BIIB 028 DMTRF71 TI TT78R5H DMTRF71 TN Heat shock protein 90 alpha (HSP90A) DMTRF71 MA Inhibitor DMTRF71 RN Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 1;19(17):4824-31. DMTRF71 RU https://pubmed.ncbi.nlm.nih.gov/23873691 DMTS5VF DI DMTS5VF DMTS5VF DN MGN-1706 DMTS5VF TI TTSHG0T DMTS5VF TN Toll-like receptor 9 (TLR9) DMTS5VF MA Agonist DMTS5VF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759). DMTS5VF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759 DMTSIYZ DI DMTSIYZ DMTSIYZ DN CVN058 DMTSIYZ TI TTNXLKE DMTSIYZ TN 5-HT 3 receptor (5HT3R) DMTSIYZ MA Antagonist DMTSIYZ RN Clinical pipeline report, company report or official report of Cerevance. DMTSIYZ RU https://cerevance.com/pipeline/ DMTSKXR DI DMTSKXR DMTSKXR DN SKI-O-703 DMTSKXR TI TTOU65C DMTSKXR TN Tyrosine-protein kinase SYK (SYK) DMTSKXR MA Inhibitor DMTSKXR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTSKXR RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMTUKW9 DI DMTUKW9 DMTUKW9 DN MORAb-066 DMTUKW9 TI TT38MDJ DMTUKW9 TN Tissue factor (F3) DMTUKW9 RN Clinical pipeline report, company report or official report of Morphotek. DMTUKW9 RU http://www.morphotek.com/pipeline/MORAb-066.aspx DMTULGS DI DMTULGS DMTULGS DN Demogastrin DMTULGS TI TTVFO0U DMTULGS TN Gastrin/cholecystokinin type B receptor (CCKBR) DMTULGS MA Modulator DMTULGS RN Demonstration of new sites of expression of the CCK-B/gastrin receptor in pancreatic acinar AR42J cells using immunoelectron microscopy. Regul Pept. 1999 Oct 22;84(1-3):81-9. DMTULGS RU https://pubmed.ncbi.nlm.nih.gov/10535412 DMTUVCG DI DMTUVCG DMTUVCG DN MIK665 DMTUVCG TI TTL53M6 DMTUVCG TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMTUVCG MA Inhibitor DMTUVCG RN MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 Jun 8;11(6):443. DMTUVCG RU https://pubmed.ncbi.nlm.nih.gov/32513939 DMTV09A DI DMTV09A DMTV09A DN Cyt-1010 DMTV09A TI TTKWM86 DMTV09A TN Opioid receptor mu (MOP) DMTV09A MA Agonist DMTV09A RN Endomorphin-2: A Biased Agonist at the -Opioid Receptor. Mol Pharmacol. 2012 August; 82(2): 178-188. DMTV09A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400840/ DMTVQH2 DI DMTVQH2 DMTVQH2 DN NGP 555 DMTVQH2 TI TT9W8GU DMTVQH2 TN Gamma-secretase (GS) DMTVQH2 MA Modulator DMTVQH2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMTVQH2 RU http://phrma-docs.phrma.org/files/dmfile/MID-Update_Alzheimers-Disease_2017-Drug-List.pdf DMTWNLY DI DMTWNLY DMTWNLY DN GZ402674 DMTWNLY TI TTGTQHC DMTWNLY TN DNA topoisomerase I (TOP1) DMTWNLY MA Modulator DMTWNLY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMTWNLY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMTWSM2 DI DMTWSM2 DMTWSM2 DN RG7129 DMTWSM2 TI TT8JRS7 DMTWSM2 TN Beta-secretase (BACE) DMTWSM2 MA Modulator DMTWSM2 RN BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther. 2014 Dec 24;6(9):89. DMTWSM2 RU https://pubmed.ncbi.nlm.nih.gov/25621019 DMTXE19 DI DMTXE19 DMTXE19 DN TAK-114 DMTXE19 TI TTH8FZW DMTXE19 TN Signal transducer and activator of transcription 3 (STAT3) DMTXE19 MA Modulator DMTXE19 RN Clinical pipeline report, company report or official report of Gastroenterology. DMTXE19 RU https://www.takeda.com/siteassets/system/investors/report/quarterlyannouncements/fy2014/takeda-ir-event--a-global-leader-in-gastroenterology-held-on-march-9-2015/qr2014_q3_p_en.pdf DMTXIZ1 DI DMTXIZ1 DMTXIZ1 DN MBX-700 DMTXIZ1 TI TTMVBWH DMTXIZ1 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMTXIZ1 MA Inhibitor DMTXIZ1 RN Clinical pipeline report, company report or official report of Microbiotix Inc. DMTXIZ1 RU http://www.microbiotix.com/therapeutic-programs-hcv.htm DMTYGWV DI DMTYGWV DMTYGWV DN NSC-639829 DMTYGWV TI TTYFKSZ DMTYGWV TN Tubulin beta (TUBB) DMTYGWV MA Modulator DMTYGWV RN Solubilization of NSC-639829. Int J Pharm. 2001 Aug 28;225(1-2):41-7. DMTYGWV RU https://pubmed.ncbi.nlm.nih.gov/11489553 DMTYNRB DI DMTYNRB DMTYNRB DN KD033 DMTYNRB TI TT8ZLTI DMTYNRB TN Programmed cell death 1 ligand 1 (PD-L1) DMTYNRB MA Inhibitor DMTYNRB RN Clinical pipeline report, company report or official report of Kadmon. DMTYNRB RU https://kadmon.com/clinical-pipeline/pipeline/kd033/ DMTZ3A6 DI DMTZ3A6 DMTZ3A6 DN BMS-196085 DMTZ3A6 TI TTMXGCW DMTZ3A6 TN Adrenergic receptor beta-3 (ADRB3) DMTZ3A6 MA Inhibitor DMTZ3A6 RN Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4290-6. DMTZ3A6 RU https://pubmed.ncbi.nlm.nih.gov/17533126 DMTZ983 DI DMTZ983 DMTZ983 DN SER-101 DMTZ983 TI TT07C3Y DMTZ983 TN 5-HT 4 receptor (HTR4) DMTZ983 MA Antagonist DMTZ983 RN Phase I clinical trail of SER101 (RO1160367) for treating heart failure leukemia. Roche. DMTZ983 RU http://www.biocentury.com/products/ser101 DMTZADW DI DMTZADW DMTZADW DN CAR-T cells targeting BCMA DMTZADW TI TTZ3P4W DMTZADW TN B-cell maturation protein (TNFRSF17) DMTZADW MA CAR-T-Cell-Therapy DMTZADW RN ClinicalTrials.gov (NCT03672253) CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma DMTZADW RU https://clinicaltrials.gov/ct2/show/NCT03672253 DMTZXSO DI DMTZXSO DMTZXSO DN CAR-T cells targeting Mesothelin DMTZXSO TI TT4RXME DMTZXSO TN Mesothelin (MSLN) DMTZXSO MA CAR-T-Cell-Therapy DMTZXSO RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMTZXSO RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMU03WD DI DMU03WD DMU03WD DN IO-202 DMU03WD TI TTREOKA DMU03WD TN Leukocyte immunoglobulin-like receptor B4 (LILRB4) DMU03WD MA Inhibitor DMU03WD RN Clinical pipeline report, company report or official report of Immune-Onc Therapeutics. DMU03WD RU https://www.immune-onc.com/news/2020-09-16-io-202-fpi DMU0Q6L DI DMU0Q6L DMU0Q6L DN SDX-7320 DMU0Q6L TI TTZL0OI DMU0Q6L TN Methionine aminopeptidase 2 (METAP2) DMU0Q6L MA Inhibitor DMU0Q6L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU0Q6L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMU0V45 DI DMU0V45 DMU0V45 DN XEN-D0101 DMU0V45 TI TTW0CMT DMU0V45 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMU0V45 MA Modulator DMU0V45 RN Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15. DMU0V45 RU https://pubmed.ncbi.nlm.nih.gov/23364608 DMU1X8K DI DMU1X8K DMU1X8K DN GSK2820151 DMU1X8K TI TTE4BSY DMU1X8K TN Bromodomain and extraterminal domain protein (BET) DMU1X8K MA Inhibitor DMU1X8K RN ClinicalTrials.gov (NCT02630251) Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors. U.S. National Institutes of Health. DMU1X8K RU https://clinicaltrials.gov/ct2/show/NCT02630251 DMU21JF DI DMU21JF DMU21JF DN AGS-009 DMU21JF TI TT95SOA DMU21JF TN Interferon alpha (IFNA) DMU21JF RN Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221. DMU21JF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3358492/ DMU263R DI DMU263R DMU263R DN VBY-376 DMU263R TI TTWXB3E DMU263R TN Hepatitis C virus NS3 helicase (HCV NS3) DMU263R MA Inhibitor DMU263R RN Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765. DMU263R RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185733/ DMU26OE DI DMU26OE DMU26OE DN PIM447 DMU26OE TI TTA7WGU DMU26OE TN Serine/threonine-protein kinase pim (PIM) DMU26OE MA Inhibitor DMU26OE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU26OE RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMU2A6D DI DMU2A6D DMU2A6D DN PF-4217903 DMU2A6D TI TTNDSF4 DMU2A6D TN Proto-oncogene c-Met (MET) DMU2A6D MA Inhibitor DMU2A6D RN Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. DMU2A6D RU https://pubmed.ncbi.nlm.nih.gov/22389468 DMU2D0B DI DMU2D0B DMU2D0B DN ZYDPLA 1 DMU2D0B TI TTDIGC1 DMU2D0B TN Dipeptidyl peptidase 4 (DPP-4) DMU2D0B MA Inhibitor DMU2D0B RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU2D0B RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMU4G9J DI DMU4G9J DMU4G9J DN CAR-T cells targeting PSCA DMU4G9J TI TT9T4AV DMU4G9J TN Prostate stem cell antigen (PSCA) DMU4G9J MA CAR-T-Cell-Therapy DMU4G9J RN ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers DMU4G9J RU https://clinicaltrials.gov/ct2/show/NCT03198052 DMU67HD DI DMU67HD DMU67HD DN ATR-01 DMU67HD TI TTK3C21 DMU67HD TN Acetoacetyl-CoA thiolase (ACAT1) DMU67HD MA Inhibitor DMU67HD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU67HD RU http://phrma-docs.phrma.org/sites/default/files/pdf/medicines-in-development-drug-list-rare-diseases.pdf DMU6CQ7 DI DMU6CQ7 DMU6CQ7 DN NHS-IL 12 DMU6CQ7 TI TTGW72V DMU6CQ7 TN Interleukin-12 beta (IL12B) DMU6CQ7 MA Modulator DMU6CQ7 RN The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014 Apr 15;5(7):1869-84. DMU6CQ7 RU https://pubmed.ncbi.nlm.nih.gov/24681847 DMU6K37 DI DMU6K37 DMU6K37 DN ABBV-2737 DMU6K37 TI TTRLZHP DMU6K37 TN cAMP-dependent chloride channel (CFTR) DMU6K37 MA Modulator DMU6K37 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMU6K37 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMU6ZMX DI DMU6ZMX DMU6ZMX DN Carmoxirole DMU6ZMX TI TTEX248 DMU6ZMX TN Dopamine D2 receptor (D2R) DMU6ZMX MA Agonist DMU6ZMX RN Neurohumoral response to carmoxirole, a selective dopamine (D2) receptor agonist, in patients with chronic moderate heart failure. Cardiovasc Drugs Ther. 1998 Sep;12(4):387-94. DMU6ZMX RU https://pubmed.ncbi.nlm.nih.gov/9825185 DMU790L DI DMU790L DMU790L DN BOS172722 DMU790L TI TTP7EGM DMU790L TN Dual specificity protein kinase TTK (MPS1) DMU790L MA Inhibitor DMU790L RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMU790L RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMU87HW DI DMU87HW DMU87HW DN RGX-111 DMU87HW TI TT0IUKX DMU87HW TN Alpha-L-iduronidase (IDUA) DMU87HW MA Replacement DMU87HW RN Clinical pipeline report, company report or official report of REGENXBIO. DMU87HW RU https://regenxbio.com/rgx-111/ DMU8OCN DI DMU8OCN DMU8OCN DN CS1-CAR T Therapy DMU8OCN TI TT7ILZ1 DMU8OCN TN SLAM family member 7 SLAMF7 (CS1) DMU8OCN MA CAR-T-Cell-Therapy DMU8OCN RN ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma DMU8OCN RU https://clinicaltrials.gov/ct2/show/NCT03710421 DMU8QD2 DI DMU8QD2 DMU8QD2 DN Apramycin DMU8QD2 TI TT38DW5 DMU8QD2 TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMU8QD2 MA Inhibitor DMU8QD2 RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMU8QD2 RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMU901D DI DMU901D DMU901D DN L-MDAM DMU901D TI TTYZVDJ DMU901D TN Dihydrofolate reductase (DHFR) DMU901D MA Inhibitor DMU901D RN Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity. Clin Cancer Res. 1996 Apr;2(4):707-12. DMU901D RU https://pubmed.ncbi.nlm.nih.gov/9816221 DMU9VDS DI DMU9VDS DMU9VDS DN Mibefradil DMU9VDS TI TTZPWGN DMU9VDS TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMU9VDS MA Inhibitor DMU9VDS RN Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8. DMU9VDS RU https://pubmed.ncbi.nlm.nih.gov/10991994 DMU9ZGN DI DMU9ZGN DMU9ZGN DN SDZ-GPI-562 DMU9ZGN TI TT38RM1 DMU9ZGN TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMU9ZGN MA Modulator DMU9ZGN RN Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost. 1999;25 Suppl 1:67-75. DMU9ZGN RU https://www.ncbi.nlm.nih.gov/pubmed/10357155 DMUAJZD DI DMUAJZD DMUAJZD DN SAR247799 DMUAJZD TI TT9JZCK DMUAJZD TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMUAJZD MA Agonist DMUAJZD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUAJZD RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMUAMZY DI DMUAMZY DMUAMZY DN APVO436 DMUAMZY TI TTUN7MC DMUAMZY TN T-cell surface glycoprotein CD3 (CD3) DMUAMZY MA Inhibitor DMUAMZY RN Clinical pipeline report, company report or official report of Aptevo. DMUAMZY RU https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/ DMUAMZY DI DMUAMZY DMUAMZY DN APVO436 DMUAMZY TI TTENHJ0 DMUAMZY TN Interleukin 3 receptor alpha (IL3RA) DMUAMZY MA Inhibitor DMUAMZY RN Clinical pipeline report, company report or official report of Aptevo. DMUAMZY RU https://aptevotherapeutics.com/apvo436-anti-cd123-x-anti-cd3/ DMUANF3 DI DMUANF3 DMUANF3 DN MLN8054 DMUANF3 TI TTPS3C0 DMUANF3 TN Aurora kinase A (AURKA) DMUANF3 MA Inhibitor DMUANF3 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMUANF3 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMUANF9 DI DMUANF9 DMUANF9 DN PHE-377 DMUANF9 TI TTMI6F5 DMUANF9 TN Transient receptor potential cation channel V1 (TRPV1) DMUANF9 MA Antagonist DMUANF9 RN Clinical pipeline report, company report or official report of Pharmeste. DMUANF9 RU http://www.pharmeste.com/home.asp?op=interna&id=1 DMUB3H9 DI DMUB3H9 DMUB3H9 DN KITE-439 DMUB3H9 TI TT3CPZW DMUB3H9 TN Human papillomavirus protein E7 (HPV E7) DMUB3H9 MA Inhibitor DMUB3H9 RN ClinicalTrials.gov (NCT03912831) Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ Cancers. U.S. National Institutes of Health. DMUB3H9 RU https://clinicaltrials.gov/ct2/show/NCT03912831 DMUBMN5 DI DMUBMN5 DMUBMN5 DN BIBV 308 DMUBMN5 TI TT2O84V DMUBMN5 TN Thromboxane A2 receptor (TBXA2R) DMUBMN5 MA Antagonist DMUBMN5 RN AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9. DMUBMN5 RU https://pubmed.ncbi.nlm.nih.gov/15613065 DMUBP0V DI DMUBP0V DMUBP0V DN CNTO888 DMUBP0V TI TTNAY0P DMUBP0V TN Monocyte chemotactic and activating factor (CCL2) DMUBP0V RN CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007 Jul;9(7):556-62. DMUBP0V RU https://pubmed.ncbi.nlm.nih.gov/17710158 DMUBTC6 DI DMUBTC6 DMUBTC6 DN ND7001 DMUBTC6 TI TTJGW1Z DMUBTC6 TN Phosphodiesterase 2A (PDE2A) DMUBTC6 MA Modulator DMUBTC6 RN Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212. DMUBTC6 RU https://pubmed.ncbi.nlm.nih.gov/22947663 DMUBYFM DI DMUBYFM DMUBYFM DN ACE-041 DMUBYFM TI TTAP4T1 DMUBYFM TN Growth/differentiation factor 2 (GDF2) DMUBYFM MA Modulator DMUBYFM RN Company report (Acceleron Pharma) DMUBYFM RU http://www.acceleronpharma.com/products/dalantercept/ DMUC6EP DI DMUC6EP DMUC6EP DN BIIB095 DMUC6EP TI TT4G2JS DMUC6EP TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUC6EP MA Inhibitor DMUC6EP RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUC6EP RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUCF9L DI DMUCF9L DMUCF9L DN ABBV-2451 DMUCF9L TI TTRLZHP DMUCF9L TN cAMP-dependent chloride channel (CFTR) DMUCF9L MA Modulator DMUCF9L RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMUCF9L RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMUCQYW DI DMUCQYW DMUCQYW DN LMP744 DMUCQYW TI TTGTQHC DMUCQYW TN DNA topoisomerase I (TOP1) DMUCQYW MA Inhibitor DMUCQYW RN Targeting Topoisomerase I in the Era of Precision Medicine. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. DMUCQYW RU https://pubmed.ncbi.nlm.nih.gov/31227499 DMUETI2 DI DMUETI2 DMUETI2 DN AMG 167 DMUETI2 TI TTYRO4F DMUETI2 TN Sclerostin (SOST) DMUETI2 MA Modulator DMUETI2 RN Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013; 7: 435-448. DMUETI2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686324/ DMUEZ7V DI DMUEZ7V DMUEZ7V DN HPP404 DMUEZ7V TI TT9JNIC DMUEZ7V TN Histamine H3 receptor (H3R) DMUEZ7V MA Antagonist DMUEZ7V RN Clinical pipeline report, company report or official report of TransTech Pharma (2011). DMUEZ7V RU http://www.ttpharma.com/ DMUF6W9 DI DMUF6W9 DMUF6W9 DN PF-05186462 DMUF6W9 TI TT4G2JS DMUF6W9 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUF6W9 MA Inhibitor DMUF6W9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026875) DMUF6W9 RU http://adisinsight.springer.com/drugs/800026875 DMUFN29 DI DMUFN29 DMUFN29 DN EPI-7386 DMUFN29 TI TTS64P2 DMUFN29 TN Androgen receptor (AR) DMUFN29 MA Inhibitor DMUFN29 RN Clinical pipeline report, company report or official report of ESSA Pharma. DMUFN29 RU https://www.essapharma.com/pipeline/ DMUFRDK DI DMUFRDK DMUFRDK DN Anti-CD22 DMUFRDK TI TTM6QSK DMUFRDK TN B-cell receptor CD22 (CD22) DMUFRDK RN 2011 Pipeline of Seattle Genetics. DMUFRDK RU http://www.seagen.com/product_pipeline.php DMUGN0J DI DMUGN0J DMUGN0J DN CDX-1140 DMUGN0J TI TTN6Y9A DMUGN0J TN CD40L receptor (CD40) DMUGN0J MA Agonist DMUGN0J RN Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2019 Feb;68(2):233-245. DMUGN0J RU https://pubmed.ncbi.nlm.nih.gov/30382327 DMUHOJP DI DMUHOJP DMUHOJP DN MK-2637 DMUHOJP TI TTHJTF7 DMUHOJP TN Glycine transporter GlyT-1 (SLC6A9) DMUHOJP MA Modulator DMUHOJP RN Characterization of the novel GlyT1 PET tracer [18F]MK-6577 in humans. Synapse. 2015 Jan;69(1):33-40. DMUHOJP RU https://pubmed.ncbi.nlm.nih.gov/25196464 DMUI8F3 DI DMUI8F3 DMUI8F3 DN Friulimicin DMUI8F3 TI TTXT4D5 DMUI8F3 TN Bacterial Cell membrane (Bact CM) DMUI8F3 MA Inhibitor DMUI8F3 RN Model membrane approaches to determine the role of calcium for the antimicrobial activity of friulimicin. Int J Antimicrob Agents. 2011 Mar;37(3):256-60. DMUI8F3 RU https://pubmed.ncbi.nlm.nih.gov/21306875 DMUJ1EL DI DMUJ1EL DMUJ1EL DN BI 113823 DMUJ1EL TI TTG5QIA DMUJ1EL TN B1 bradykinin receptor (BDKRB1) DMUJ1EL MA Modulator DMUJ1EL RN The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons. Eur J Pain. 2015 Jan;19(1):132-42. DMUJ1EL RU https://pubmed.ncbi.nlm.nih.gov/25088373 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTUTJGQ DMUJCBT TN Vascular endothelial growth factor receptor 2 (KDR) DMUJCBT MA Antagonist DMUJCBT RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMUJCBT RU http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TT9VGXW DMUJCBT TN Angiopoietin 1 receptor (TEK) DMUJCBT MA Inhibitor DMUJCBT RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMUJCBT RU http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTNDSF4 DMUJCBT TN Proto-oncogene c-Met (MET) DMUJCBT MA Inhibitor DMUJCBT RN Clinical pipeline report, company report or official report of Deciphera Pharmaceuticals. DMUJCBT RU http://www.deciphera.com/article/deciphera-pharmaceuticals-announces-initiation-phase-1-cancer-trial-altiratinib-dcc-2701 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTTDVOJ DMUJCBT TN Tropomyosin-related kinase A (TrkA) DMUJCBT MA Inhibitor DMUJCBT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMUJCBT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMUJCBT DI DMUJCBT DMUJCBT DN Altiratinib DMUJCBT TI TTXABCW DMUJCBT TN NT-3 growth factor receptor (TrkC) DMUJCBT MA Inhibitor DMUJCBT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMUJCBT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMUJF9T DI DMUJF9T DMUJF9T DN CD123-CD33 Ccar DMUJF9T TI TTJVYO3 DMUJF9T TN Myeloid cell surface antigen CD33 (CD33) DMUJF9T RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUJF9T RU http://icellgene.com/our-pipeline.html DMUJF9T DI DMUJF9T DMUJF9T DN CD123-CD33 Ccar DMUJF9T TI TTENHJ0 DMUJF9T TN Interleukin 3 receptor alpha (IL3RA) DMUJF9T RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUJF9T RU http://icellgene.com/our-pipeline.html DMUK6YM DI DMUK6YM DMUK6YM DN BAY1161909 DMUK6YM TI TTP7EGM DMUK6YM TN Dual specificity protein kinase TTK (MPS1) DMUK6YM MA Inhibitor DMUK6YM RN National Cancer Institute Drug Dictionary (drug id 761238). DMUK6YM RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761238 DMUKBI2 DI DMUKBI2 DMUKBI2 DN mRNA-2752 DMUKBI2 TI TTC1GLB DMUKBI2 TN Interleukin-23 (IL23) DMUKBI2 MA Replacement DMUKBI2 RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMUKBI2 RU https://www.modernatx.com/mrna-2752 DMUKBI2 DI DMUKBI2 DMUKBI2 DN mRNA-2752 DMUKBI2 TI TTBW580 DMUKBI2 TN TAX transcriptionally-activated glycoprotein 1 (OX40) DMUKBI2 MA Replacement DMUKBI2 RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMUKBI2 RU https://www.modernatx.com/mrna-2752 DMUKBI2 DI DMUKBI2 DMUKBI2 DN mRNA-2752 DMUKBI2 TI TT8SLDN DMUKBI2 TN Interleukin-36 gamma (IL36G) DMUKBI2 MA Replacement DMUKBI2 RN Clinical pipeline report, company report or official report of Moderna Therapeutics. DMUKBI2 RU https://www.modernatx.com/mrna-2752 DMUKFCG DI DMUKFCG DMUKFCG DN Anti-Mesothelin CAR-T cells DMUKFCG TI TT4RXME DMUKFCG TN Mesothelin (MSLN) DMUKFCG MA CAR-T-Cell-Therapy DMUKFCG RN ClinicalTrials.gov (NCT03545815) Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. DMUKFCG RU https://clinicaltrials.gov/ct2/show/NCT03545815 DMUKNDO DI DMUKNDO DMUKNDO DN Anti-BCMA CART Cells DMUKNDO TI TTZ3P4W DMUKNDO TN B-cell maturation protein (TNFRSF17) DMUKNDO MA CAR-T-Cell-Therapy DMUKNDO RN ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma DMUKNDO RU https://clinicaltrials.gov/ct2/show/NCT03767725 DMULBZM DI DMULBZM DMULBZM DN Cosibelimab DMULBZM TI TT8ZLTI DMULBZM TN Programmed cell death 1 ligand 1 (PD-L1) DMULBZM RN Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers DMULBZM RU https://clinicaltrials.gov/ct2/show/NCT03212404 DMULRYC DI DMULRYC DMULRYC DN VBY- 036 DMULRYC TI TTUMQVO DMULRYC TN Cathepsin S (CTSS) DMULRYC MA Inhibitor DMULRYC RN Clinical pipeline report, company report or official report of ViroBay. DMULRYC RU http://virobayinc.com/VBY-036.php DMUMHXT DI DMUMHXT DMUMHXT DN CYC116 DMUMHXT TI TT5LS6T DMUMHXT TN Aurora kinase B (AURKB) DMUMHXT MA Inhibitor DMUMHXT RN Clinical pipeline report, company report or official report of Cyclacel. DMUMHXT RU http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011 DMUMHXT DI DMUMHXT DMUMHXT DN CYC116 DMUMHXT TI TTUTJGQ DMUMHXT TN Vascular endothelial growth factor receptor 2 (KDR) DMUMHXT MA Inhibitor DMUMHXT RN Clinical pipeline report, company report or official report of Cyclacel. DMUMHXT RU http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011 DMUMHXT DI DMUMHXT DMUMHXT DN CYC116 DMUMHXT TI TTPS3C0 DMUMHXT TN Aurora kinase A (AURKA) DMUMHXT MA Inhibitor DMUMHXT RN Clinical pipeline report, company report or official report of Cyclacel. DMUMHXT RU http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=625011 DMUMVXK DI DMUMVXK DMUMVXK DN ATR-101 DMUMVXK TI TT4V7ST DMUMVXK TN Sterol O-acyltransferase (SOAT) DMUMVXK MA Modulator DMUMVXK RN Company report (Atterocor) DMUMVXK RU http://atterocor.com/pdf/Atterocor-ENDO-PR-61214.pdf DMUMWFK DI DMUMWFK DMUMWFK DN Anti-GPC3 CAR T DMUMWFK TI TTJTSX4 DMUMWFK TN Glypican-3 (GPC3) DMUMWFK MA CAR-T-Cell-Therapy DMUMWFK RN ClinicalTrials.gov (NCT02395250) Anti-GPC3 CAR T for Treating Patients With Advanced HCC DMUMWFK RU https://clinicaltrials.gov/ct2/show/NCT02395250 DMUN7EQ DI DMUN7EQ DMUN7EQ DN SKF-105809 DMUN7EQ TI TTK0943 DMUN7EQ TN Prostaglandin G/H synthase (COX) DMUN7EQ MA Modulator DMUN7EQ RN Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. DMUN7EQ RU https://pubmed.ncbi.nlm.nih.gov/1906235 DMUN7EQ DI DMUN7EQ DMUN7EQ DN SKF-105809 DMUN7EQ TI TT2J34L DMUN7EQ TN Arachidonate 5-lipoxygenase (5-LOX) DMUN7EQ MA Inhibitor DMUN7EQ RN Analgetic activity of SK&F 105809, a dual inhibitor of arachidonic acid metabolism. Agents Actions Suppl. 1991;32:113-7. DMUN7EQ RU https://pubmed.ncbi.nlm.nih.gov/1906235 DMUNFEP DI DMUNFEP DMUNFEP DN GDC0310 DMUNFEP TI TT4G2JS DMUNFEP TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUNFEP MA Inhibitor DMUNFEP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMUNFEP RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMUNSPI DI DMUNSPI DMUNSPI DN INBRX-109 DMUNSPI TI TTW20TU DMUNSPI TN TRAIL receptor 2 (TRAIL-R2) DMUNSPI RN Clinical pipeline report, company report or official report of Inhibrx. DMUNSPI RU https://inhibrx.com/inbrx-109/ DMUNVXR DI DMUNVXR DMUNVXR DN GSK-2239633 DMUNVXR TI TT7HQD0 DMUNVXR TN C-C chemokine receptor type 4 (CCR4) DMUNVXR MA Antagonist DMUNVXR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61). DMUNVXR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61 DMUP6M5 DI DMUP6M5 DMUP6M5 DN BGB-15025 DMUP6M5 TI TTSHWUP DMUP6M5 TN MEK kinase kinase 1 (MAP4K1) DMUP6M5 MA Inhibitor DMUP6M5 RN ClinicalTrials.gov (NCT04649385) BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health. DMUP6M5 RU https://clinicaltrials.gov/ct2/show/NCT04649385 DMUPA7C DI DMUPA7C DMUPA7C DN NOCICEPTIN DMUPA7C TI TTKWM86 DMUPA7C TN Opioid receptor mu (MOP) DMUPA7C MA Inhibitor DMUPA7C RN Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. J Med Chem. 2008 Feb 28;51(4):1058-62. DMUPA7C RU https://pubmed.ncbi.nlm.nih.gov/18232652 DMUPA7C DI DMUPA7C DMUPA7C DN NOCICEPTIN DMUPA7C TI TTNT7K8 DMUPA7C TN Nociceptin receptor (OPRL1) DMUPA7C MA Inhibitor DMUPA7C RN Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1. J Pharmacol Exp Ther. 1997 Nov;283(2):735-41. DMUPA7C RU https://pubmed.ncbi.nlm.nih.gov/9353393 DMUPQ70 DI DMUPQ70 DMUPQ70 DN SPC5001 DMUPQ70 TI TTBRG7E DMUPQ70 TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMUPQ70 MA Inhibitor DMUPQ70 RN 2011 Pipeline of Santaris Pharma. DMUPQ70 RU http://www.santaris.com/product-pipeline DMUQ3C1 DI DMUQ3C1 DMUQ3C1 DN Anti-CD19 CAR-T cells DMUQ3C1 TI TTW640A DMUQ3C1 TN B-lymphocyte surface antigen B4 (CD19) DMUQ3C1 MA CAR-T-Cell-Therapy DMUQ3C1 RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMUQ3C1 RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMUR1MN DI DMUR1MN DMUR1MN DN CD19-CAR and CD28-CAR T Cells DMUR1MN TI TTQ13FT DMUR1MN TN T-cell-specific surface glycoprotein CD28 (CD28) DMUR1MN MA CAR-T-Cell-Therapy(Dual specific) DMUR1MN RN ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia DMUR1MN RU https://clinicaltrials.gov/ct2/show/NCT02146924 DMUR1MN DI DMUR1MN DMUR1MN DN CD19-CAR and CD28-CAR T Cells DMUR1MN TI TTW640A DMUR1MN TN B-lymphocyte surface antigen B4 (CD19) DMUR1MN MA CAR-T-Cell-Therapy(Dual specific) DMUR1MN RN ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia DMUR1MN RU https://clinicaltrials.gov/ct2/show/NCT02146924 DMUR49N DI DMUR49N DMUR49N DN Begacestat DMUR49N TI TT9W8GU DMUR49N TN Gamma-secretase (GS) DMUR49N MA Modulator DMUR49N RN Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. DMUR49N RU https://pubmed.ncbi.nlm.nih.gov/19671883 DMURO94 DI DMURO94 DMURO94 DN GNE Lipoplex DMURO94 TI TT4DP5S DMURO94 TN N-acetylmannosamine kinase (GNE) DMURO94 MA Inhibitor DMURO94 RN Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum Gene Ther. 2011 Nov;22(11):1331-41. DMURO94 RU https://pubmed.ncbi.nlm.nih.gov/21517694 DMURVPF DI DMURVPF DMURVPF DN Dendritic cell vaccine DMURVPF TI TT7SBF5 DMURVPF TN Cellular tumor antigen p53 (TP53) DMURVPF RN Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. DMURVPF RU https://pubmed.ncbi.nlm.nih.gov/14985857 DMUSOM9 DI DMUSOM9 DMUSOM9 DN ABBV-CX-2029 DMUSOM9 TI TT8MG4S DMUSOM9 TN Transferrin receptor protein 1 (TFRC) DMUSOM9 RN Clinical pipeline report, company report or official report of AbbVie. DMUSOM9 RU https://www.abbvie.com/our-science/pipeline/abbv-2029.html DMUSPW5 DI DMUSPW5 DMUSPW5 DN NCO-48 DMUSPW5 TI TTT4SY6 DMUSPW5 TN Hepatitis B virus Polymerase (HBV P) DMUSPW5 MA Inhibitor DMUSPW5 RN Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects DMUSPW5 RU https://clinicaltrials.gov/ct2/show/NCT04309526 DMUT4YZ DI DMUT4YZ DMUT4YZ DN RLY-1971 DMUT4YZ TI TT7WUAV DMUT4YZ TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMUT4YZ MA Inhibitor DMUT4YZ RN Clinical pipeline report, company report or official report of Relay Therapeutics. DMUT4YZ RU https://relaytx.com/pipeline/ DMUTISK DI DMUTISK DMUTISK DN Pennvax-B DMUTISK TI TTUTN1I DMUTISK TN Human Deoxyribonucleic acid (hDNA) DMUTISK RN Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals. Mol Ther. 2015 Mar;23(3):591-601. DMUTISK RU https://pubmed.ncbi.nlm.nih.gov/25531694 DMUVGMS DI DMUVGMS DMUVGMS DN MRG-110 DMUVGMS TI TTIXJ2S DMUVGMS TN microRNA hsa-miR-92 (MIR92) DMUVGMS MA Inhibitor DMUVGMS RN Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study. Nucleic Acid Ther. 2020 Dec;30(6):335-345. DMUVGMS RU https://pubmed.ncbi.nlm.nih.gov/32707001 DMUVLC4 DI DMUVLC4 DMUVLC4 DN IMGC936 DMUVLC4 TI TTTYQNS DMUVLC4 TN Cellular disintegrin-related protein (ADAM9) DMUVLC4 MA Inhibitor DMUVLC4 RN Clinical pipeline report, company report or official report of ImmunoGen. DMUVLC4 RU https://www.immunogen.com/category/imgc936/ DMUVYC5 DI DMUVYC5 DMUVYC5 DN Anti-CD19 EBV CTL therapy DMUVYC5 TI TTW640A DMUVYC5 TN B-lymphocyte surface antigen B4 (CD19) DMUVYC5 RN Cytotoxic T cells transduced with chimeric anti-CD19 receptors prevent engraftment of primary lymphoblastic leukemia in vivo. Leukemia. 2010 May;24(5):1080-4. DMUVYC5 RU https://pubmed.ncbi.nlm.nih.gov/20220773 DMUXAP1 DI DMUXAP1 DMUXAP1 DN TAK-573 DMUXAP1 TI TTPURFN DMUXAP1 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMUXAP1 RN Clinical pipeline report, company report or official report of Takeda. DMUXAP1 RU https://www.takeda.com/what-we-do/research-and-development/our-pipeline/ DMUYN26 DI DMUYN26 DMUYN26 DN IMC-CS4 DMUYN26 TI TT731LW DMUYN26 TN Colony stimulating factor-1 receptor (CSF-1R) DMUYN26 MA Modulator DMUYN26 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMUYN26 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMUYTW3 DI DMUYTW3 DMUYTW3 DN CD20-CD19 cCAR DMUYTW3 TI TTW640A DMUYTW3 TN B-lymphocyte surface antigen B4 (CD19) DMUYTW3 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUYTW3 RU http://icellgene.com/our-pipeline.html DMUYTW3 DI DMUYTW3 DMUYTW3 DN CD20-CD19 cCAR DMUYTW3 TI TTUE541 DMUYTW3 TN Leukocyte surface antigen Leu-16 (CD20) DMUYTW3 RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMUYTW3 RU http://icellgene.com/our-pipeline.html DMUZFVH DI DMUZFVH DMUZFVH DN ONT-10 DMUZFVH TI TTBHFYQ DMUZFVH TN Mucin-1 (MUC1) DMUZFVH RN Clinical pipeline report, company report or official report of Oncothyreon. DMUZFVH RU http://www.oncothyreon.com/product_pipeline/ont-10.html DMV0AH8 DI DMV0AH8 DMV0AH8 DN TCN-P DMV0AH8 TI TTAZ05C DMV0AH8 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMV0AH8 MA Modulator DMV0AH8 RN Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT.Invest New Drugs.2011 Dec;29(6):1381-9. DMV0AH8 RU https://www.ncbi.nlm.nih.gov/pubmed/20644979 DMV0MHI DI DMV0MHI DMV0MHI DN EP-7041 DMV0MHI TI TTJCPUT DMV0MHI TN Coagulation factor XI (F11) DMV0MHI MA Inhibitor DMV0MHI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV0MHI RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMV1BTP DI DMV1BTP DMV1BTP DN ISIS-SOD1 DMV1BTP TI TTP9K3Q DMV1BTP TN SOD1 messenger RNA (SOD1 mRNA) DMV1BTP RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMV1BTP RU http://www.isispharm.com/index.htm DMV3L62 DI DMV3L62 DMV3L62 DN Sym023 DMV3L62 TI TT1RWL7 DMV3L62 TN Hepatitis A virus cellular receptor 2 (TIM3) DMV3L62 MA Inhibitor DMV3L62 RN Clinical pipeline report, company report or official report of Symphogen. DMV3L62 RU http://www.symphogen.com/pipeline/products/sym023/ DMV5LGJ DI DMV5LGJ DMV5LGJ DN Tedatioxetine DMV5LGJ TI TTNXLKE DMV5LGJ TN 5-HT 3 receptor (5HT3R) DMV5LGJ MA Modulator DMV5LGJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMV5LGJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMV5LGJ DI DMV5LGJ DMV5LGJ DN Tedatioxetine DMV5LGJ TI TTWJBZ5 DMV5LGJ TN 5-HT 2C receptor (HTR2C) DMV5LGJ MA Modulator DMV5LGJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMV5LGJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMV5PEK DI DMV5PEK DMV5PEK DN ARO-HIF2 DMV5PEK TI TTWPA54 DMV5PEK TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMV5PEK MA Inhibitor DMV5PEK RN National Cancer Institute Drug Dictionary (drug name ARO-HIF2). DMV5PEK RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/hif2a-rnai-aro-hif2 DMV5X8M DI DMV5X8M DMV5X8M DN PTI-125 DMV5X8M TI TTSTRZY DMV5X8M TN Filamin A (FLNA) DMV5X8M MA Inhibitor DMV5X8M RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV5X8M RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMV632P DI DMV632P DMV632P DN CEP-37440 DMV632P TI TTON5IT DMV632P TN Focal adhesion kinase 1 (FAK) DMV632P MA Modulator DMV632P RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMV632P RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMV6DF3 DI DMV6DF3 DMV6DF3 DN AZD5658 DMV6DF3 TI TTDLNGZ DMV6DF3 TN Glucokinase (GCK) DMV6DF3 MA Activator DMV6DF3 RN Clinical pipeline report, company report or official report of AstraZeneca (2011). DMV6DF3 RU http://www.astrazeneca.com/Home DMV6JFK DI DMV6JFK DMV6JFK DN AGEN1181 DMV6JFK TI TTI2S1D DMV6JFK TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMV6JFK MA Inhibitor DMV6JFK RN Clinical pipeline report, company report or official report of Agenus. DMV6JFK RU https://agenusbio.com/agen1181-second-generation-anti-ctla-4/ DMV74JC DI DMV74JC DMV74JC DN CVX-241 DMV74JC TI TTKLQTJ DMV74JC TN Angiopoietin-2 (ANGPT2) DMV74JC MA Modulator DMV74JC RN Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A. 2010 December 28; 107(52): 22611-22616. DMV74JC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012461/ DMV80DP DI DMV80DP DMV80DP DN LAS-186323 DMV80DP TI TTLVP78 DMV80DP TN Dihydroorotate dehydrogenase (DHODH) DMV80DP MA Inhibitor DMV80DP RN Clinical pipeline report, company report or official report of Aslanpharma. DMV80DP RU http://www.aslanpharma.com/download/Press%20Release%20-%20Almirall-ASLAN%20Licensing.pdf DMV84ZR DI DMV84ZR DMV84ZR DN CARTmeso/19 DMV84ZR TI TTW640A DMV84ZR TN B-lymphocyte surface antigen B4 (CD19) DMV84ZR MA CAR-T-Cell-Therapy(Dual specific) DMV84ZR RN ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer DMV84ZR RU https://clinicaltrials.gov/ct2/show/NCT03497819 DMV84ZR DI DMV84ZR DMV84ZR DN CARTmeso/19 DMV84ZR TI TT4RXME DMV84ZR TN Mesothelin (MSLN) DMV84ZR MA CAR-T-Cell-Therapy(Dual specific) DMV84ZR RN ClinicalTrials.gov (NCT03497819) Autologous CARTmeso/19 Against Pancreatic Cancer DMV84ZR RU https://clinicaltrials.gov/ct2/show/NCT03497819 DMV8BI4 DI DMV8BI4 DMV8BI4 DN MK-6325 DMV8BI4 TI TTRHUKY DMV8BI4 TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMV8BI4 MA Modulator DMV8BI4 RN Synthesis of bis-macrocyclic HCV protease inhibitor MK-6325 via intramolecular sp -sp Suzuki-Miyaura coupling and ring closing metathesis. Org Lett. 2015 Mar 20;17(6):1533-6. DMV8BI4 RU https://pubmed.ncbi.nlm.nih.gov/25754231 DMV8IQW DI DMV8IQW DMV8IQW DN Tafluposide DMV8IQW TI TTGTQHC DMV8IQW TN DNA topoisomerase I (TOP1) DMV8IQW MA Modulator DMV8IQW RN Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73. DMV8IQW RU https://pubmed.ncbi.nlm.nih.gov/12853890 DMV8IQW DI DMV8IQW DMV8IQW DN Tafluposide DMV8IQW TI TT0IHXV DMV8IQW TN DNA topoisomerase II (TOP2) DMV8IQW MA Modulator DMV8IQW RN Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73. DMV8IQW RU https://pubmed.ncbi.nlm.nih.gov/12853890 DMV8IWJ DI DMV8IWJ DMV8IWJ DN GEN1029 DMV8IWJ TI TTW20TU DMV8IWJ TN TRAIL receptor 2 (TRAIL-R2) DMV8IWJ MA Agonist DMV8IWJ RN National Cancer Institute Drug Dictionary (drug name Tilogotamab). DMV8IWJ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/tilogotamab DMV9FTH DI DMV9FTH DMV9FTH DN FP-045 DMV9FTH TI TTFLN4T DMV9FTH TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMV9FTH MA Agonist DMV9FTH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMV9FTH RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMVA186 DI DMVA186 DMVA186 DN R7334 DMVA186 TI TT48I1Y DMVA186 TN Placenta growth factor (PlGF) DMVA186 RN Clinical pipeline report, company report or official report of Roche (2009). DMVA186 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMVBQ2L DI DMVBQ2L DMVBQ2L DN SGN LIV1A DMVBQ2L TI TTZN1CF DMVBQ2L TN Solute carrier family 39 member 6 (SLC39A6) DMVBQ2L RN SGN-LIV1A: a novel antibody-drug conjugate targeting LIV-1 for the treatment of metastatic breast cancer. Mol Cancer Ther. 2014 Dec;13(12):2991-3000. DMVBQ2L RU https://pubmed.ncbi.nlm.nih.gov/25253783 DMVD327 DI DMVD327 DMVD327 DN AVI-7288 DMVD327 TI TT1E5A4 DMVD327 TN Marburg virus NP messenger RNA (MV NP mRNA) DMVD327 RN AVI-7288 for Marburg Virus in Nonhuman Primates and Humans. N Engl J Med. 2015 Jul 23;373(4):339-48. DMVD327 RU https://pubmed.ncbi.nlm.nih.gov/26200980 DMVDIWO DI DMVDIWO DMVDIWO DN CDX-527 DMVDIWO TI TTNBFWK DMVDIWO TN Programmed cell death protein 1 (PD-1) DMVDIWO MA Inhibitor DMVDIWO RN Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137. DMVDIWO RU https://pubmed.ncbi.nlm.nih.gov/32451681 DMVDIWO DI DMVDIWO DMVDIWO DN CDX-527 DMVDIWO TI TTDO1MV DMVDIWO TN T-cell activation antigen CD27 (CD27) DMVDIWO MA Activator DMVDIWO RN Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy. Cancer Immunol Immunother. 2020 Oct;69(10):2125-2137. DMVDIWO RU https://pubmed.ncbi.nlm.nih.gov/32451681 DMVDYTG DI DMVDYTG DMVDYTG DN CPG 52364 DMVDYTG TI TTRJ1K4 DMVDYTG TN Toll-like receptor 7 (TLR7) DMVDYTG MA Antagonist DMVDYTG RN Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007. DMVDYTG RU http://www.lifesciencesworld.com/news/view/51194 DMVDYTG DI DMVDYTG DMVDYTG DN CPG 52364 DMVDYTG TI TTSHG0T DMVDYTG TN Toll-like receptor 9 (TLR9) DMVDYTG MA Antagonist DMVDYTG RN Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007. DMVDYTG RU http://www.lifesciencesworld.com/news/view/51194 DMVDYTG DI DMVDYTG DMVDYTG DN CPG 52364 DMVDYTG TI TT8CWFK DMVDYTG TN Toll-like receptor 8 (TLR8) DMVDYTG MA Antagonist DMVDYTG RN Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007. DMVDYTG RU http://www.lifesciencesworld.com/news/view/51194 DMVEGND DI DMVEGND DMVEGND DN GSK3368715 DMVEGND TI TTVOJAI DMVEGND TN Protein arginine methyltransferase 1 (PRMT1) DMVEGND MA Inhibitor DMVEGND RN National Cancer Institute Drug Dictionary (drug name GSK6097608). DMVEGND RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/prmt1-inhibitor-gsk3368715 DMVGBA1 DI DMVGBA1 DMVGBA1 DN HuMNC2-CAR44 T cells DMVGBA1 TI TTBHFYQ DMVGBA1 TN Mucin-1 (MUC1) DMVGBA1 RN Clinical pipeline report, company report or official report of Minerva Biotechnologies. DMVGBA1 RU https://www.minervabio.com/minervabio.com/pipeline/ DMVGN42 DI DMVGN42 DMVGN42 DN TRX-818 DMVGN42 TI TTB8Y9K DMVGN42 TN Angiogenesis (AGG) DMVGN42 MA Inhibitor DMVGN42 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVGN42 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVGTP6 DI DMVGTP6 DMVGTP6 DN MB-105 DMVGTP6 TI TT9T4AV DMVGTP6 TN Prostate stem cell antigen (PSCA) DMVGTP6 RN Clinical pipeline report, company report or official report of Mustang Bio. DMVGTP6 RU https://www.mustangbio.com/pipeline/ DMVHPOX DI DMVHPOX DMVHPOX DN AGN-242266 DMVHPOX TI TTS4UGC DMVHPOX TN Farnesoid X-activated receptor (FXR) DMVHPOX MA Agonist DMVHPOX RN Clinical pipeline report, company report or official report of AbbVie. DMVHPOX RU https://www.abbvie.com/our-science/pipeline/agn-242266-fxr-agonist.html DMVIMQX DI DMVIMQX DMVIMQX DN ZSTK474 DMVIMQX TI TTHBTOP DMVIMQX TN PI3-kinase gamma (PIK3CG) DMVIMQX MA Modulator DMVIMQX RN Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013 Oct;15(10):1172-83. DMVIMQX RU https://pubmed.ncbi.nlm.nih.gov/24204196 DMVJMF1 DI DMVJMF1 DMVJMF1 DN RGD-891 DMVJMF1 TI TT38RM1 DMVJMF1 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMVJMF1 MA Modulator DMVJMF1 RN Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56. DMVJMF1 RU https://pubmed.ncbi.nlm.nih.gov/11075310 DMVJWBS DI DMVJWBS DMVJWBS DN JSI-1187 DMVJWBS TI TT1MG9E DMVJWBS TN Extracellular signal-regulated kinase 1 (ERK1) DMVJWBS MA Inhibitor DMVJWBS RN National Cancer Institute Drug Dictionary (drug name JSI1187). DMVJWBS RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187 DMVJWBS DI DMVJWBS DMVJWBS DN JSI-1187 DMVJWBS TI TT4TQBX DMVJWBS TN Extracellular signal-regulated kinase 2 (ERK2) DMVJWBS MA Inhibitor DMVJWBS RN National Cancer Institute Drug Dictionary (drug name JSI1187). DMVJWBS RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/erk1-2-inhibitor-jsi-1187 DMVK3M2 DI DMVK3M2 DMVK3M2 DN CART-BCMA DMVK3M2 TI TTZ3P4W DMVK3M2 TN B-cell maturation protein (TNFRSF17) DMVK3M2 MA CAR-T-Cell-Therapy DMVK3M2 RN ClinicalTrials.gov (NCT02546167) CART-BCMA Cells for Multiple Myeloma DMVK3M2 RU https://clinicaltrials.gov/ct2/show/NCT02546167 DMVL87N DI DMVL87N DMVL87N DN AV-965 DMVL87N TI TTSQIFT DMVL87N TN 5-HT 1A receptor (HTR1A) DMVL87N MA Antagonist DMVL87N RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025412) DMVL87N RU http://adisinsight.springer.com/drugs/800025412 DMVLPRT DI DMVLPRT DMVLPRT DN ABT-700 DMVLPRT TI TTNDSF4 DMVLPRT TN Proto-oncogene c-Met (MET) DMVLPRT MA Modulator DMVLPRT RN J Clin Oncol 32:5s, 2014 (suppl; abstr 2507). DMVLPRT RU http://meetinglibrary.asco.org/content/134301-144 DMVMIBY DI DMVMIBY DMVMIBY DN AGG-523 DMVMIBY TI TTXSU2Y DMVMIBY TN Aggrecanase (ADAMTS5) DMVMIBY MA Inhibitor DMVMIBY RN Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage. 2011 Mar;19(3):315-23. DMVMIBY RU https://pubmed.ncbi.nlm.nih.gov/21163358 DMVNLGW DI DMVNLGW DMVNLGW DN MR-1817 DMVNLGW TI TTMI6F5 DMVNLGW TN Transient receptor potential cation channel V1 (TRPV1) DMVNLGW MA Antagonist DMVNLGW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030745) DMVNLGW RU http://adisinsight.springer.com/drugs/800030745 DMVONF0 DI DMVONF0 DMVONF0 DN CD19/CD22 CAR T cells DMVONF0 TI TTM6QSK DMVONF0 TN B-cell receptor CD22 (CD22) DMVONF0 MA CAR-T-Cell-Therapy(Dual specific) DMVONF0 RN ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia DMVONF0 RU https://clinicaltrials.gov/ct2/show/NCT03241940 DMVONF0 DI DMVONF0 DMVONF0 DN CD19/CD22 CAR T cells DMVONF0 TI TTW640A DMVONF0 TN B-lymphocyte surface antigen B4 (CD19) DMVONF0 MA CAR-T-Cell-Therapy(Dual specific) DMVONF0 RN ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia DMVONF0 RU https://clinicaltrials.gov/ct2/show/NCT03241940 DMVPAZ7 DI DMVPAZ7 DMVPAZ7 DN BAY1143572 DMVPAZ7 TI TTQ7ABG DMVPAZ7 TN Positive transcription elongation factor b (P-TEFb) DMVPAZ7 MA Modulator DMVPAZ7 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMVPAZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMVQAEK DI DMVQAEK DMVQAEK DN ND-1.1 DMVQAEK TI TTF4CAM DMVQAEK TN Influenza Hemagglutinin (Influ HA) DMVQAEK RN An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013 Jan;20(1):85-94. DMVQAEK RU https://pubmed.ncbi.nlm.nih.gov/23155123 DMVQJOS DI DMVQJOS DMVQJOS DN PXS-25 DMVQJOS TI TTPNE41 DMVQJOS TN CI Man-6-P receptor (IGF2R) DMVQJOS MA Inhibitor DMVQJOS RN Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol.2011 Jul;301(1):F84-93. DMVQJOS RU https://pubmed.ncbi.nlm.nih.gov/21478477 DMVQX5K DI DMVQX5K DMVQX5K DN AMG 404 DMVQX5K TI TTNBFWK DMVQX5K TN Programmed cell death protein 1 (PD-1) DMVQX5K MA Inhibitor DMVQX5K RN ClinicalTrials.gov (NCT03853109) AMG 404 in Patients With Advanced Solid Tumors.. U.S. National Institutes of Health. DMVQX5K RU https://clinicaltrials.gov/ct2/show/NCT03853109 DMVRTCW DI DMVRTCW DMVRTCW DN HDM201 DMVRTCW TI TT7SBF5 DMVRTCW TN Cellular tumor antigen p53 (TP53) DMVRTCW MA Inhibitor DMVRTCW RN National Cancer Institute Drug Dictionary (drug id 761551). DMVRTCW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=761551 DMVRTCW DI DMVRTCW DMVRTCW DN HDM201 DMVRTCW TI TT08GJW DMVRTCW TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMVRTCW MA Inhibitor DMVRTCW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVRTCW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVS87W DI DMVS87W DMVS87W DN BIIB068 DMVS87W TI TTGM6VW DMVS87W TN Tyrosine-protein kinase BTK (ATK) DMVS87W MA Inhibitor DMVS87W RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVS87W RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMVSPZM DI DMVSPZM DMVSPZM DN Anti-CD38 CAR-T cells DMVSPZM TI TTPURFN DMVSPZM TN Cyclic ADP-ribose hydrolase 1 (CD38) DMVSPZM MA CAR-T-Cell-Therapy DMVSPZM RN ClinicalTrials.gov (NCT03464916) Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients DMVSPZM RU https://clinicaltrials.gov/ct2/show/NCT03464916 DMVUL1H DI DMVUL1H DMVUL1H DN Sleeping Beauty CAR-TCR DMVUL1H TI TTW640A DMVUL1H TN B-lymphocyte surface antigen B4 (CD19) DMVUL1H RN Clinical pipeline report, company report or official report of Ziopharm Oncology. DMVUL1H RU https://ziopharm.com/pipeline/ DMVUW8A DI DMVUW8A DMVUW8A DN AVI-6002 DMVUW8A TI TT3Z102 DMVUW8A TN Ebola virus VP35 messenger RNA (EV VP35 mRNA) DMVUW8A MA Modulator DMVUW8A RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMVUW8A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMVUW8A DI DMVUW8A DMVUW8A DN AVI-6002 DMVUW8A TI TTDJLWQ DMVUW8A TN Ebola virus VP24 messenger RNA (EV VP24 mRNA) DMVUW8A MA Modulator DMVUW8A RN Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses. 2012 November; 4(11): 2806-2830. DMVUW8A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3509674/ DMVWHS1 DI DMVWHS1 DMVWHS1 DN GPC3 targeting CAR-T cells DMVWHS1 TI TTJTSX4 DMVWHS1 TN Glypican-3 (GPC3) DMVWHS1 MA CAR-T-Cell-Therapy DMVWHS1 RN ClinicalTrials.gov (NCT03198546) GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression DMVWHS1 RU https://clinicaltrials.gov/ct2/show/NCT03198546 DMVWMUK DI DMVWMUK DMVWMUK DN AZD4785 DMVWMUK TI TTB1RA4 DMVWMUK TN GTPase KRas (KRAS) DMVWMUK MA Inhibitor DMVWMUK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVWMUK RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVXLS5 DI DMVXLS5 DMVXLS5 DN Sym021 DMVXLS5 TI TTNBFWK DMVXLS5 TN Programmed cell death protein 1 (PD-1) DMVXLS5 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMVXLS5 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMVXQ5W DI DMVXQ5W DMVXQ5W DN RO-5458640 DMVXQ5W TI TTBTDM1 DMVXQ5W TN TNF-related weak inducer of apoptosis (TWEAK) DMVXQ5W MA Modulator DMVXQ5W RN A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs. 2014 January 1; 6(1): 297-308. DMVXQ5W RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929451/ DMVXRYC DI DMVXRYC DMVXRYC DN AM-211 DMVXRYC TI TTQDMX5 DMVXRYC TN Prostaglandin D2 receptor 2 (PTGDR2) DMVXRYC MA Antagonist DMVXRYC RN Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammation. J Pharmacol Exp Ther. 2011 Jul;338(1):290-301. DMVXRYC RU https://pubmed.ncbi.nlm.nih.gov/21487069 DMVYEFZ DI DMVYEFZ DMVYEFZ DN TAK-202 DMVYEFZ TI TTFZYTO DMVYEFZ TN C-C chemokine receptor type 2 (CCR2) DMVYEFZ MA Antagonist DMVYEFZ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMVYEFZ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMVYO41 DI DMVYO41 DMVYO41 DN XK-469 DMVYO41 TI TT4NVEM DMVYO41 TN DNA topoisomerase II beta (TOP2B) DMVYO41 MA Modulator DMVYO41 RN A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.Pharmacogenet Genomics.2014 Feb;24(2):129-32. DMVYO41 RU https://www.ncbi.nlm.nih.gov/pubmed/24300566 DMVYRH2 DI DMVYRH2 DMVYRH2 DN Perifosine DMVYRH2 TI TTHBTOP DMVYRH2 TN PI3-kinase gamma (PIK3CG) DMVYRH2 MA Modulator DMVYRH2 RN Company report (Aezsinc) DMVYRH2 RU http://www.aezsinc.com/en/page.php?p=60&q=504 DMW0H9Y DI DMW0H9Y DMW0H9Y DN KA2507 DMW0H9Y TI TT5ZKDI DMW0H9Y TN Histone deacetylase 6 (HDAC6) DMW0H9Y MA Inhibitor DMW0H9Y RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW0H9Y RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW0ZDF DI DMW0ZDF DMW0ZDF DN BCMA-specific CAR-expressing T Lymphocytes DMW0ZDF TI TTZ3P4W DMW0ZDF TN B-cell maturation protein (TNFRSF17) DMW0ZDF MA CAR-T-Cell-Therapy DMW0ZDF RN ClinicalTrials.gov (NCT03502577) BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma DMW0ZDF RU https://clinicaltrials.gov/ct2/show/NCT03502577 DMW10HM DI DMW10HM DMW10HM DN Tak-220 DMW10HM TI TT2CEJG DMW10HM TN C-C chemokine receptor type 5 (CCR5) DMW10HM MA Binder DMW10HM RN Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. DMW10HM RU https://pubmed.ncbi.nlm.nih.gov/16182193 DMW16VR DI DMW16VR DMW16VR DN CT-200 DMW16VR TI TTBH0VX DMW16VR TN Histone deacetylase (HDAC) DMW16VR MA Inhibitor DMW16VR RN Clinical pipeline report, company report or official report of Celleron. DMW16VR RU http://cellerontherapeutics.com/ DMW1OKT DI DMW1OKT DMW1OKT DN CBT-501 DMW1OKT TI TTNBFWK DMW1OKT TN Programmed cell death protein 1 (PD-1) DMW1OKT MA Modulator DMW1OKT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW1OKT RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMW1ZAM DI DMW1ZAM DMW1ZAM DN Iboctadekin + Doxil DMW1ZAM TI TT0IHXV DMW1ZAM TN DNA topoisomerase II (TOP2) DMW1ZAM MA Inhibitor DMW1ZAM RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMW1ZAM RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMW1ZAM DI DMW1ZAM DMW1ZAM DN Iboctadekin + Doxil DMW1ZAM TI TTRICUF DMW1ZAM TN Interleukin-18 (IL18) DMW1ZAM MA Modulator DMW1ZAM RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMW1ZAM RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMW2HS8 DI DMW2HS8 DMW2HS8 DN YM-116 DMW2HS8 TI TTC8NQ2 DMW2HS8 TN Lyase unspecific (LYA) DMW2HS8 MA Inhibitor DMW2HS8 RN YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma cells. Jpn J Pharmacol. 1999 Feb;79(2):213-20. DMW2HS8 RU https://pubmed.ncbi.nlm.nih.gov/10202857 DMW2O5D DI DMW2O5D DMW2O5D DN MK-3328 DMW2O5D TI TTHS256 DMW2O5D TN Metabotropic glutamate receptor 5 (mGluR5) DMW2O5D MA Modulator DMW2O5D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). DMW2O5D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 DMW3MCX DI DMW3MCX DMW3MCX DN PRT811 DMW3MCX TI TTR1D7X DMW3MCX TN Protein arginine methyltransferase 5 (PRMT5) DMW3MCX MA Inhibitor DMW3MCX RN Clinical pipeline report, company report or official report of Prelude Therapeutics. DMW3MCX RU https://preludetx.com/science/prmt5/prt811/ DMW43DL DI DMW43DL DMW43DL DN TAK-828 DMW43DL TI TTGV6LY DMW43DL TN Nuclear receptor ROR-gamma (RORG) DMW43DL MA Agonist DMW43DL RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW43DL RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMW4GM2 DI DMW4GM2 DMW4GM2 DN AZD5153 DMW4GM2 TI TTRA6BO DMW4GM2 TN Bromodomain-containing protein 4 (BRD4) DMW4GM2 MA Inhibitor DMW4GM2 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW4GM2 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW4JRY DI DMW4JRY DMW4JRY DN OBT076 DMW4JRY TI TTG180Q DMW4JRY TN Lymphocyte antigen 75 (LY75) DMW4JRY RN MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Mol Cancer Ther. 2019 Sep;18(9):1533-1543. DMW4JRY RU https://pubmed.ncbi.nlm.nih.gov/31227646 DMW4VQF DI DMW4VQF DMW4VQF DN AZD6423 DMW4VQF TI TT9IK2Z DMW4VQF TN N-methyl-D-aspartate receptor (NMDAR) DMW4VQF MA Antagonist DMW4VQF RN Biology of the NMDA Receptor. Marie L. Blanke and Antonius M.J. VanDongen. 2009. DMW4VQF RU http://www.ncbi.nlm.nih.gov/books/NBK5283/ DMW549Y DI DMW549Y DMW549Y DN Anti-CD19 CART Cells DMW549Y TI TTW640A DMW549Y TN B-lymphocyte surface antigen B4 (CD19) DMW549Y MA CAR-T-Cell-Therapy DMW549Y RN ClinicalTrials.gov (NCT03767725) Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma DMW549Y RU https://clinicaltrials.gov/ct2/show/NCT03767725 DMW5J9B DI DMW5J9B DMW5J9B DN JX-929 DMW5J9B TI TTKRTP6 DMW5J9B TN Cytosine deaminase (AICDA) DMW5J9B MA Modulator DMW5J9B RN Micromanaging oncolytic viruses. SciBX 1(42); doi:10.1038/scibx.2008.1014. Nov. 20 2008 DMW5J9B RU http://www.nature.com/scibx/journal/v1/n42/full/scibx.2008.1014.html DMW64UZ DI DMW64UZ DMW64UZ DN SKL-10406 DMW64UZ TI TTEX248 DMW64UZ TN Dopamine D2 receptor (D2R) DMW64UZ MA Binder DMW64UZ RN Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793. DMW64UZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783788/ DMW64UZ DI DMW64UZ DMW64UZ DN SKL-10406 DMW64UZ TI TTJQOD7 DMW64UZ TN 5-HT 2A receptor (HTR2A) DMW64UZ MA Binder DMW64UZ RN Bi-directional modulation of BNST neurons by 5-HT: Molecular expression and functional properties of excitatory 5-HT receptor subtypes. Neuroscience. 2009 December 29; 164(4): 1776-1793. DMW64UZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2783788/ DMW6X0O DI DMW6X0O DMW6X0O DN ACH-2684 DMW6X0O TI TTWXB3E DMW6X0O TN Hepatitis C virus NS3 helicase (HCV NS3) DMW6X0O MA Modulator DMW6X0O RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMW6X0O RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMW72NJ DI DMW72NJ DMW72NJ DN ASP3026 DMW72NJ TI TTPMQSO DMW72NJ TN ALK tyrosine kinase receptor (ALK) DMW72NJ MA Modulator DMW72NJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7740). DMW72NJ RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7740 DMW739O DI DMW739O DMW739O DN EP-51389 DMW739O TI TTKMAZ6 DMW739O TN Growth hormone receptor (GHR) DMW739O MA Agonist DMW739O RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DMW739O RU https://pubmed.ncbi.nlm.nih.gov/16634704 DMW7CLY DI DMW7CLY DMW7CLY DN INCB15050 DMW7CLY TI TT2CEJG DMW7CLY TN C-C chemokine receptor type 5 (CCR5) DMW7CLY MA Antagonist DMW7CLY RN Incyte. Product Development Pipeline. DMW7CLY RU http://www.incyte.com/drugs_product_pipeline.html DMW7K39 DI DMW7K39 DMW7K39 DN Pyrotinib DMW7K39 TI TTG96HZ DMW7K39 TN EGFR messenger RNA (EGFR mRNA) DMW7K39 MA Inhibitor DMW7K39 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMW7K39 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMW7VGZ DI DMW7VGZ DMW7VGZ DN PegCNTF DMW7VGZ TI TTT2F9E DMW7VGZ TN Ciliary neurotrophic factor receptor alpha (CNTFR) DMW7VGZ MA Agonist DMW7VGZ RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMW7VGZ RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMW7VGZ DI DMW7VGZ DMW7VGZ DN PegCNTF DMW7VGZ TI TTQL5VC DMW7VGZ TN Platelet-activating factor receptor (PTAFR) DMW7VGZ MA Modulator DMW7VGZ RN Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21. DMW7VGZ RU https://pubmed.ncbi.nlm.nih.gov/1793070 DMW8VEH DI DMW8VEH DMW8VEH DN BMY-43748 DMW8VEH TI TT0IHXV DMW8VEH TN DNA topoisomerase II (TOP2) DMW8VEH MA Modulator DMW8VEH RN Comparative metabolism of tosufloxacin and BMY 43748 in hepatocytes from rat, dog, monkey and man. Toxicol In Vitro. 1993 Jul;7(4):499-503. DMW8VEH RU https://pubmed.ncbi.nlm.nih.gov/20732241 DMW9YOJ DI DMW9YOJ DMW9YOJ DN MCP-201 DMW9YOJ TI TT27RFC DMW9YOJ TN Opioid receptor delta (OPRD1) DMW9YOJ MA Agonist DMW9YOJ RN US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. DMW9YOJ RU http://www.google.com/patents/US6924288 DMW9YOJ DI DMW9YOJ DMW9YOJ DN MCP-201 DMW9YOJ TI TTKWM86 DMW9YOJ TN Opioid receptor mu (MOP) DMW9YOJ MA Agonist DMW9YOJ RN US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. DMW9YOJ RU http://www.google.com/patents/US6924288 DMW9YOJ DI DMW9YOJ DMW9YOJ DN MCP-201 DMW9YOJ TI TTQW87Y DMW9YOJ TN Opioid receptor kappa (OPRK1) DMW9YOJ MA Agonist DMW9YOJ RN US patent application no. 6,924,288, Enantiomerically pure opioid diarylmethylpiperzine and methods of using same. DMW9YOJ RU http://www.google.com/patents/US6924288 DMW9ZFS DI DMW9ZFS DMW9ZFS DN AIKO-150 DMW9ZFS TI TTKWM86 DMW9ZFS TN Opioid receptor mu (MOP) DMW9ZFS MA Antagonist DMW9ZFS RN Clinical pipeline report, company report or official report of signaturerx. DMW9ZFS RU http://www.signaturerx.com/view.cfm/59/Abuse-Resistant-Opioids DMW9ZFS DI DMW9ZFS DMW9ZFS DN AIKO-150 DMW9ZFS TI TT27RFC DMW9ZFS TN Opioid receptor delta (OPRD1) DMW9ZFS MA Inhibitor DMW9ZFS RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMW9ZFS RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMW9ZFS DI DMW9ZFS DMW9ZFS DN AIKO-150 DMW9ZFS TI TTQW87Y DMW9ZFS TN Opioid receptor kappa (OPRK1) DMW9ZFS MA Inhibitor DMW9ZFS RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMW9ZFS RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMWAMNT DI DMWAMNT DMWAMNT DN CAR-T Cells targeting EGFRvIII DMWAMNT TI TTZ6B2I DMWAMNT TN Epidermal growth factor receptor variant III (EGFR vIII) DMWAMNT MA CAR-T-Cell-Therapy DMWAMNT RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMWAMNT RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMWBA1S DI DMWBA1S DMWBA1S DN PT-302 DMWBA1S TI TT84ETX DMWBA1S TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMWBA1S MA Inhibitor DMWBA1S RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMWBA1S RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMWBQ2Z DI DMWBQ2Z DMWBQ2Z DN TGF-BR2 mab DMWBQ2Z TI TTZE3P7 DMWBQ2Z TN TGF-beta receptor type II (TGFBR2) DMWBQ2Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1795). DMWBQ2Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1795 DMWCJEU DI DMWCJEU DMWCJEU DN AZD0156 DMWCJEU TI TTKBM7V DMWCJEU TN ATM serine/threonine kinase (ATM) DMWCJEU MA Inhibitor DMWCJEU RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWCJEU RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWDQOV DI DMWDQOV DMWDQOV DN GSK1482160 DMWDQOV TI TT473XN DMWDQOV TN P2X purinoceptor 7 (P2RX7) DMWDQOV MA Antagonist DMWDQOV RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMWDQOV RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMWG2K6 DI DMWG2K6 DMWG2K6 DN AMG 199 DMWG2K6 TI TTUN7MC DMWG2K6 TN T-cell surface glycoprotein CD3 (CD3) DMWG2K6 MA Inhibitor DMWG2K6 RN Clinical pipeline report, company report or official report of Amgen. DMWG2K6 RU https://www.amgenpipeline.com/ DMWG2K6 DI DMWG2K6 DMWG2K6 DN AMG 199 DMWG2K6 TI TTVO0JU DMWG2K6 TN Mucin-17 (MUC17) DMWG2K6 MA Inhibitor DMWG2K6 RN Clinical pipeline report, company report or official report of Amgen. DMWG2K6 RU https://www.amgenpipeline.com/ DMWGKHZ DI DMWGKHZ DMWGKHZ DN ATF-936 DMWGKHZ TI TTBUYHA DMWGKHZ TN Extracellular calcium-sensing receptor (CASR) DMWGKHZ MA Antagonist DMWGKHZ RN ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41. DMWGKHZ RU https://pubmed.ncbi.nlm.nih.gov/21514409 DMWHZEG DI DMWHZEG DMWHZEG DN OMN-54 DMWHZEG TI TTPVYKI DMWHZEG TN Signal transduction unspecific (ST) DMWHZEG MA Inhibitor DMWHZEG RN Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. Mol Oncol. 2014 Mar;8(2):311-22. DMWHZEG RU https://pubmed.ncbi.nlm.nih.gov/24388358 DMWHZFS DI DMWHZFS DMWHZFS DN BI 754091 DMWHZFS TI TTNBFWK DMWHZFS TN Programmed cell death protein 1 (PD-1) DMWHZFS MA Inhibitor DMWHZFS RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMWHZFS RU https://www.inoncology.com/ourpipeline/pd1-inhibitor DMWI0AL DI DMWI0AL DMWI0AL DN GSK6097608 DMWI0AL TI TT83C4X DMWI0AL TN T-cell surface protein tactile (CD96) DMWI0AL MA Antagonist DMWI0AL RN National Cancer Institute Drug Dictionary (drug name GSK6097608). DMWI0AL RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cd96-monoclonal-antibody-gsk6097608 DMWIEC1 DI DMWIEC1 DMWIEC1 DN OTSA-101-DTPA-90Y DMWIEC1 TI TTP1S2F DMWIEC1 TN Frizzled-10 (FZD10) DMWIEC1 RN A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646. DMWIEC1 RU https://pubmed.ncbi.nlm.nih.gov/29884132 DMWIJL1 DI DMWIJL1 DMWIJL1 DN Anti-PD-L1 CSR T cells DMWIJL1 TI TT8ZLTI DMWIJL1 TN Programmed cell death 1 ligand 1 (PD-L1) DMWIJL1 MA CAR-T-Cell-Therapy DMWIJL1 RN ClinicalTrials.gov (NCT02937844) Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme DMWIJL1 RU https://clinicaltrials.gov/ct2/show/NCT02937844 DMWIXLC DI DMWIXLC DMWIXLC DN CAR-T Cells targeting PSCA DMWIXLC TI TT9T4AV DMWIXLC TN Prostate stem cell antigen (PSCA) DMWIXLC MA CAR-T-Cell-Therapy DMWIXLC RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMWIXLC RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMWJ0IH DI DMWJ0IH DMWJ0IH DN REGN-421 DMWJ0IH TI TTV23LH DMWJ0IH TN Delta-like protein 4 (DLL4) DMWJ0IH RN J Clin Oncol 31, 2013 (suppl; abstr 2502). DMWJ0IH RU http://meetinglibrary.asco.org/content/113836-132 DMWK679 DI DMWK679 DMWK679 DN OMP-18R5 DMWK679 TI TTUQMO5 DMWK679 TN Frizzled-7 receptor (FZD7) DMWK679 MA Inhibitor DMWK679 RN Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22. DMWK679 RU https://pubmed.ncbi.nlm.nih.gov/22753465 DMWK951 DI DMWK951 DMWK951 DN MLN7243 DMWK951 TI TTU8HT1 DMWK951 TN Ubiquitin-activating enzyme (UBA) DMWK951 MA Modulator DMWK951 RN National Cancer Institute Drug Dictionary (drug id 757275). DMWK951 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=757275 DMWKDOQ DI DMWKDOQ DMWKDOQ DN MRX34 DMWKDOQ TI TT96IGO DMWKDOQ TN microRNA hsa-miR-34 (MIR34) DMWKDOQ MA Modulator DMWKDOQ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWKDOQ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWKYSM DI DMWKYSM DMWKYSM DN Anti-CD19-CAR DMWKYSM TI TTW640A DMWKYSM TN B-lymphocyte surface antigen B4 (CD19) DMWKYSM MA CAR-T-Cell-Therapy DMWKYSM RN ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma DMWKYSM RU https://clinicaltrials.gov/ct2/show/NCT01593696 DMWN2FP DI DMWN2FP DMWN2FP DN NZV930 DMWN2FP TI TTK0O6Y DMWN2FP TN Ecto-5'-nucleotidase (CD73) DMWN2FP MA Inhibitor DMWN2FP RN Clinical pipeline report, company report or official report of Surface oncology. DMWN2FP RU https://www.surfaceoncology.com/pipeline/the-srf373-nzv930-program/ DMWN7D3 DI DMWN7D3 DMWN7D3 DN ABT-354 DMWN7D3 TI TTJS8PY DMWN7D3 TN 5-HT 6 receptor (HTR6) DMWN7D3 MA Modulator DMWN7D3 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035134) DMWN7D3 RU http://adisinsight.springer.com/drugs/800035134 DMWOE62 DI DMWOE62 DMWOE62 DN U3-1565 DMWOE62 TI TT15SL0 DMWOE62 TN Proheparin-binding EGF-like growth factor (HBEGF) DMWOE62 MA Modulator DMWOE62 RN J Clin Oncol 31, 2013 (suppl; abstr 2519). DMWOE62 RU http://meetinglibrary.asco.org/content/111447-132 DMWP3G1 DI DMWP3G1 DMWP3G1 DN Debio 0932 DMWP3G1 TI TT78R5H DMWP3G1 TN Heat shock protein 90 alpha (HSP90A) DMWP3G1 MA Inhibitor DMWP3G1 RN Clinical pipeline report, company report or official report of Debiopharm (2011). DMWP3G1 RU http://www.debiopharm.com/our-business/pipeline.html DMWR93D DI DMWR93D DMWR93D DN Genaconazole DMWR93D TI TTTSOUD DMWR93D TN Candida Cytochrome P450 51 (Candi ERG11) DMWR93D MA Modulator DMWR93D RN New targets and delivery systems for antifungal therapy. Med Mycol. 2000;38 Suppl 1:335-47. DMWR93D RU https://pubmed.ncbi.nlm.nih.gov/11204162 DMWS40H DI DMWS40H DMWS40H DN CTX120 DMWS40H TI TTZ3P4W DMWS40H TN B-cell maturation protein (TNFRSF17) DMWS40H RN Clinical pipeline report, company report or official report of CRISPR Therapeutics. DMWS40H RU http://www.crisprtx.com/programs/pipeline DMWSC5L DI DMWSC5L DMWSC5L DN L-778123 DMWSC5L TI TTXQKM3 DMWSC5L TN Farnesyl protein transferase (Ftase) DMWSC5L MA Modulator DMWSC5L RN Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58. DMWSC5L RU https://www.ncbi.nlm.nih.gov/pubmed/12479371 DMWSC5L DI DMWSC5L DMWSC5L DN L-778123 DMWSC5L TI TTX20QP DMWSC5L TN Geranylgeranyl transferase I (GGTase-I) DMWSC5L MA Modulator DMWSC5L RN Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein trans... Mol Cancer Ther. 2002 Jul;1(9):747-58. DMWSC5L RU https://www.ncbi.nlm.nih.gov/pubmed/12479371 DMWSI04 DI DMWSI04 DMWSI04 DN IMC-002 DMWSI04 TI TT28S46 DMWSI04 TN Leukocyte surface antigen CD47 (CD47) DMWSI04 MA Blocker DMWSI04 RN Clinical pipeline report, company report or official report of ImmuneOncia Therapeutics. DMWSI04 RU http://www.immuneoncia.com/immun/index.php/pipeline/ DMWT5RS DI DMWT5RS DMWT5RS DN Daniquidone DMWT5RS TI TTGTQHC DMWT5RS TN DNA topoisomerase I (TOP1) DMWT5RS MA Modulator DMWT5RS RN Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23. DMWT5RS RU https://www.ncbi.nlm.nih.gov/pubmed/23912694 DMWT5RS DI DMWT5RS DMWT5RS DN Daniquidone DMWT5RS TI TT0IHXV DMWT5RS TN DNA topoisomerase II (TOP2) DMWT5RS MA Modulator DMWT5RS RN Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.Cancer Chemother Pharmacol.2013 Oct;72(4):917-23. DMWT5RS RU https://www.ncbi.nlm.nih.gov/pubmed/23912694 DMWT8RI DI DMWT8RI DMWT8RI DN PRX-105 DMWT8RI TI TT1RS9F DMWT8RI TN Acetylcholinesterase (AChE) DMWT8RI MA Inhibitor DMWT8RI RN Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R. Toxicol Appl Pharmacol. 2015 Sep 15;287(3):202-9. DMWT8RI RU https://pubmed.ncbi.nlm.nih.gov/26051873 DMWTVM1 DI DMWTVM1 DMWTVM1 DN EDP-322 DMWTVM1 TI TT3OT40 DMWTVM1 TN Multidrug resistance protein 1 (ABCB1) DMWTVM1 MA Inhibitor DMWTVM1 RN In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. J Antimicrob Chemother. 2015 Jan;70(1):173-7. DMWTVM1 RU https://pubmed.ncbi.nlm.nih.gov/25182063 DMWU682 DI DMWU682 DMWU682 DN PX-102 DMWU682 TI TTS4UGC DMWU682 TN Farnesoid X-activated receptor (FXR) DMWU682 MA Agonist DMWU682 RN An FXR Agonist Reduces Bile Acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Gastroenterology. 2018 Oct;155(4):1012-1016. DMWU682 RU https://pubmed.ncbi.nlm.nih.gov/29928896 DMWU71N DI DMWU71N DMWU71N DN SAN-134 DMWU71N TI TT1YWO5 DMWU71N TN Glucagon-like peptide 2 receptor (GLP2R) DMWU71N MA Inhibitor DMWU71N RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020865) DMWU71N RU http://adisinsight.springer.com/drugs/800020865 DMWV8C6 DI DMWV8C6 DMWV8C6 DN CA-4948 DMWV8C6 TI TTKFVXR DMWV8C6 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMWV8C6 MA Inhibitor DMWV8C6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWV8C6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWXQC9 DI DMWXQC9 DMWXQC9 DN Drug 2881078 DMWXQC9 TI TTS64P2 DMWXQC9 TN Androgen receptor (AR) DMWXQC9 MA Modulator DMWXQC9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800039743) DMWXQC9 RU http://adisinsight.springer.com/drugs/800039743 DMWYEDX DI DMWYEDX DMWYEDX DN ON-01210.Na DMWYEDX TI TTGQUFK DMWYEDX TN PI3K/AKT/mTOR pathway (PAm pathway) DMWYEDX MA Inhibitor DMWYEDX RN ON01210.Na (Ex-RAD ) mitigates radiation damage through activation of the AKT pathway. PLoS One. 2013;8(3):e58355. DMWYEDX RU https://pubmed.ncbi.nlm.nih.gov/23505494 DMWYF1H DI DMWYF1H DMWYF1H DN AZD8186 DMWYF1H TI TTTHBCA DMWYF1H TN PI3-kinase beta (PIK3CB) DMWYF1H MA Inhibitor DMWYF1H RN National Cancer Institute Drug Dictionary (drug id 751594). DMWYF1H RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=751594 DMWYF1H DI DMWYF1H DMWYF1H DN AZD8186 DMWYF1H TI TTHBTOP DMWYF1H TN PI3-kinase gamma (PIK3CG) DMWYF1H MA Inhibitor DMWYF1H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMWYF1H RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMWYHXG DI DMWYHXG DMWYHXG DN AZD-9819 DMWYHXG TI TTPLTSQ DMWYHXG TN Neutrophil elastase (NE) DMWYHXG MA Inhibitor DMWYHXG RN Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos. 2015 Oct;43(10):1441-9. DMWYHXG RU https://pubmed.ncbi.nlm.nih.gov/26203069 DMX05W8 DI DMX05W8 DMX05W8 DN SYN-1001 DMX05W8 TI TTN4QDT DMX05W8 TN Opioid receptor (OPR) DMX05W8 MA Agonist DMX05W8 RN Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy. J Pharmacol Exp Ther. 2005 May;313(2):712-9. DMX05W8 RU https://pubmed.ncbi.nlm.nih.gov/15647327 DMX0DUH DI DMX0DUH DMX0DUH DN MEDI2228 DMX0DUH TI TTZ3P4W DMX0DUH TN B-cell maturation protein (TNFRSF17) DMX0DUH MA Inhibitor DMX0DUH RN A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 Aug;34(8):2150-2162. DMX0DUH RU https://pubmed.ncbi.nlm.nih.gov/32060401 DMX0JLI DI DMX0JLI DMX0JLI DN A-837093 DMX0JLI TI TTMVBWH DMX0JLI TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMX0JLI MA Inhibitor DMX0JLI RN Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. DMX0JLI RU https://pubmed.ncbi.nlm.nih.gov/18321145 DMX1D0S DI DMX1D0S DMX1D0S DN OMP-21M18 DMX1D0S TI TTV23LH DMX1D0S TN Delta-like protein 4 (DLL4) DMX1D0S MA Modulator DMX1D0S RN National Cancer Institute Drug Dictionary (drug id 614677). DMX1D0S RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=614677 DMX2J57 DI DMX2J57 DMX2J57 DN GT103 DMX2J57 TI TTUW6OP DMX2J57 TN Complement factor H (CFH) DMX2J57 MA Inhibitor DMX2J57 RN Clinical pipeline report, company report or official report of Grid Therapeutics. DMX2J57 RU https://gridtherapeutics.com/research-development/gt103/ DMX3FN4 DI DMX3FN4 DMX3FN4 DN ISIS-APOCIII DMX3FN4 TI TTXOZQ1 DMX3FN4 TN ApoC-III messenger RNA (APOC3 mRNA) DMX3FN4 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMX3FN4 RU http://www.isispharm.com/index.htm DMX4PWV DI DMX4PWV DMX4PWV DN ASP1951 DMX4PWV TI TTG6LA7 DMX4PWV TN Activation-inducible TNFR family receptor (TNFRSF18) DMX4PWV MA Agonist DMX4PWV RN ClinicalTrials.gov (NCT03799003) A Study of ASP1951 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. DMX4PWV RU https://clinicaltrials.gov/ct2/show/NCT03799003 DMX4ZDY DI DMX4ZDY DMX4ZDY DN CAR-T Cells targeting CEA DMX4ZDY TI TTY6DTE DMX4ZDY TN Carcinoembryonic antigen CEA (CD66e) DMX4ZDY MA CAR-T-Cell-Therapy DMX4ZDY RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMX4ZDY RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMX5290 DI DMX5290 DMX5290 DN FF-10502-01 DMX5290 TI TTUBNVO DMX5290 TN DNA synthesis (DNA synth) DMX5290 MA Inhibitor DMX5290 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX5290 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMX5LB7 DI DMX5LB7 DMX5LB7 DN PUR0200 DMX5LB7 TI TTOXS3C DMX5LB7 TN Muscarinic acetylcholine receptor (CHRM) DMX5LB7 MA Modulator DMX5LB7 RN Clinical pipeline report, company report or official report of pulmatrix pipeline. DMX5LB7 RU http://pulmatrix.com/pipeline.html DMX6AJ8 DI DMX6AJ8 DMX6AJ8 DN ZM-H1505R DMX6AJ8 TI TTM42UJ DMX6AJ8 TN Hepatitis B virus Capsid protein (HBV C) DMX6AJ8 MA Inhibitor DMX6AJ8 RN Clinical pipeline report, company report or official report of Shanghai Zhimeng Biopharma. DMX6AJ8 RU http://www.core-biopharma.com/pipeline.html DMX6V1L DI DMX6V1L DMX6V1L DN ST-1141 DMX6V1L TI TTWDC17 DMX6V1L TN Growth hormone secretagogue receptor 1 (GHSR) DMX6V1L MA Agonist DMX6V1L RN The Prokinetic Face of Ghrelin. International Journal of Peptides Volume 2010 (2010), Article ID 493614, Page(11). DMX6V1L RU http://www.hindawi.com/journals/ijpep/2010/493614/ DMX8LY4 DI DMX8LY4 DMX8LY4 DN NS-8 DMX8LY4 TI TT1VOHK DMX8LY4 TN Potassium channel unspecific (KC) DMX8LY4 MA Agonist DMX8LY4 RN Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol. 2014 Jul 15;735:68-76. DMX8LY4 RU https://pubmed.ncbi.nlm.nih.gov/24747752 DMX8YO1 DI DMX8YO1 DMX8YO1 DN RG6125 DMX8YO1 TI TTRGWZC DMX8YO1 TN Osteoblast cadherin (CDH11) DMX8YO1 MA Inhibitor DMX8YO1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMX8YO1 RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMX94YF DI DMX94YF DMX94YF DN SEA-CD70 DMX94YF TI TTNCIE0 DMX94YF TN CD70 antigen (CD27-L) DMX94YF MA Inhibitor DMX94YF RN Clinical pipeline report, company report or official report of Seagen. DMX94YF RU https://www.seagen.com/science/pipeline DMX9AK6 DI DMX9AK6 DMX9AK6 DN PACAP38 DMX9AK6 TI TTW4LYC DMX9AK6 TN Pituitary adenylate cyclase-activating 38 (PACAP-38) DMX9AK6 MA Modulator DMX9AK6 RN Pituitary adenylate cyclase-activating polypeptides, PACAP-38 and PACAP-27, regulation of sympathetic neuron catecholamine, and neuropeptide Y expr... Ann N Y Acad Sci. 1996 Dec 26;805:204-16; discussion 217-8. DMX9AK6 RU https://pubmed.ncbi.nlm.nih.gov/8993404 DMX9EA0 DI DMX9EA0 DMX9EA0 DN TAK-058 DMX9EA0 TI TTNXLKE DMX9EA0 TN 5-HT 3 receptor (5HT3R) DMX9EA0 MA Antagonist DMX9EA0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040805) DMX9EA0 RU http://adisinsight.springer.com/drugs/800040805 DMX9ER7 DI DMX9ER7 DMX9ER7 DN BIZELESIN DMX9ER7 TI TTUTN1I DMX9ER7 TN Human Deoxyribonucleic acid (hDNA) DMX9ER7 MA Inhibitor DMX9ER7 RN Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30. DMX9ER7 RU https://pubmed.ncbi.nlm.nih.gov/8180230 DMXA7W9 DI DMXA7W9 DMXA7W9 DN SGN-70 DMXA7W9 TI TTNCIE0 DMXA7W9 TN CD70 antigen (CD27-L) DMXA7W9 RN 2011 Pipeline of Seattle Genetics. DMXA7W9 RU http://www.seagen.com/product_pipeline.php DMXAUB7 DI DMXAUB7 DMXAUB7 DN EI1071 DMXAUB7 TI TT7MRDV DMXAUB7 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMXAUB7 MA Inhibitor DMXAUB7 RN Clinical pipeline report, company report or official report of Elixiron Immunotherapeutics. DMXAUB7 RU https://www.elixiron.com/ DMXBS6U DI DMXBS6U DMXBS6U DN RG7775 DMXBS6U TI TT08GJW DMXBS6U TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DMXBS6U MA Inhibitor DMXBS6U RN Phase I clinical trail of RG7775 for treating Acute myelogenous leukemia. Roche. DMXBS6U RU http://www.biocentury.com/products/rg7775 DMXCJP8 DI DMXCJP8 DMXCJP8 DN STP1002 DMXCJP8 TI TTKSAQZ DMXCJP8 TN Tankyrase (TNKS) DMXCJP8 MA Inhibitor DMXCJP8 RN Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171. DMXCJP8 RU https://cancerres.aacrjournals.org/content/77/13_Supplement/5171 DMXCN37 DI DMXCN37 DMXCN37 DN DS-1040 DMXCN37 TI TTP18AY DMXCN37 TN Carboxypeptidase B2 (CPB2) DMXCN37 MA Modulator DMXCN37 RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMXCN37 RU http://www.daiichisankyo.com/rd/pipeline/development_pipeline/index.html#details01 DMXD4TC DI DMXD4TC DMXD4TC DN CAR19 T cells carrying cytoplasmic activated PD-1 DMXD4TC TI TTW640A DMXD4TC TN B-lymphocyte surface antigen B4 (CD19) DMXD4TC MA CAR-T-Cell-Therapy DMXD4TC RN ClinicalTrials.gov (NCT03540303) Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma DMXD4TC RU https://clinicaltrials.gov/ct2/show/NCT03540303 DMXD5QP DI DMXD5QP DMXD5QP DN SAR442257 DMXD5QP TI TTPURFN DMXD5QP TN Cyclic ADP-ribose hydrolase 1 (CD38) DMXD5QP MA Inhibitor DMXD5QP RN Clinical pipeline report, company report or official report of Sanofi. DMXD5QP RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DMXD5QP DI DMXD5QP DMXD5QP DN SAR442257 DMXD5QP TI TTUN7MC DMXD5QP TN T-cell surface glycoprotein CD3 (CD3) DMXD5QP MA Inhibitor DMXD5QP RN Clinical pipeline report, company report or official report of Sanofi. DMXD5QP RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DMXD5QP DI DMXD5QP DMXD5QP DN SAR442257 DMXD5QP TI TTQ13FT DMXD5QP TN T-cell-specific surface glycoprotein CD28 (CD28) DMXD5QP MA Inhibitor DMXD5QP RN Clinical pipeline report, company report or official report of Sanofi. DMXD5QP RU https://www.sanofi.com/en/science-and-innovation/research-and-development/rd-pipeline DMXDMH5 DI DMXDMH5 DMXDMH5 DN APVO414 DMXDMH5 TI TT9G4N0 DMXDMH5 TN Glutamate carboxypeptidase II (GCPII) DMXDMH5 MA Inhibitor DMXDMH5 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXDMH5 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMXETUQ DI DMXETUQ DMXETUQ DN HER-2/HER-1 vaccine DMXETUQ TI TTGKNB4 DMXETUQ TN Epidermal growth factor receptor (EGFR) DMXETUQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMXETUQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMXFY18 DI DMXFY18 DMXFY18 DN EZN-3042 DMXFY18 TI TTTPU1G DMXFY18 TN Apoptosis inhibitor survivin (BIRC5) DMXFY18 MA Modulator DMXFY18 RN SPC3042: a proapoptotic survivin inhibitor.Mol Cancer Ther.2008 Sep;7(9):2736-45. DMXFY18 RU https://www.ncbi.nlm.nih.gov/pubmed/18790754 DMXFYN0 DI DMXFYN0 DMXFYN0 DN AZD-3043 DMXFYN0 TI TTEX6LM DMXFYN0 TN GABA(A) receptor gamma-3 (GABRG3) DMXFYN0 MA Modulator DMXFYN0 RN AZD-3043: a novel, metabolically labile sedative-hypnotic agent with rapid and predictable emergence from hypnosis. Anesthesiology. 2012 Jun;116(6):1267-77. DMXFYN0 RU https://pubmed.ncbi.nlm.nih.gov/22531340 DMXG3T1 DI DMXG3T1 DMXG3T1 DN GS-6637 DMXG3T1 TI TTFLN4T DMXG3T1 TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMXG3T1 MA Inhibitor DMXG3T1 RN Clinical pipeline report, company report or official report of Gilead. DMXG3T1 RU http://www.gilead.com/~/media/Files/pdfs/other/Gilead_Sciences_Company_Overview_FactSheet_080514.pdf DMXHKYJ DI DMXHKYJ DMXHKYJ DN P1446A-05 DMXHKYJ TI TT0PG8F DMXHKYJ TN Cyclin-dependent kinase 4 (CDK4) DMXHKYJ MA Inhibitor DMXHKYJ RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMXHKYJ RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMXI5ON DI DMXI5ON DMXI5ON DN IMC-3C5 DMXI5ON TI TTDCBX5 DMXI5ON TN Vascular endothelial growth factor receptor 3 (FLT-4) DMXI5ON MA Modulator DMXI5ON RN Bevacizumab and breast cancer: what does the future hold . Future Oncol. 2012 April; 8(4): 403-414. DMXI5ON RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464486/ DMXI9P4 DI DMXI9P4 DMXI9P4 DN EPX-100 DMXI9P4 TI TT85JO3 DMXI9P4 TN 5-HT receptor (5HTR) DMXI9P4 MA Modulator DMXI9P4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXI9P4 RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMXIDWE DI DMXIDWE DMXIDWE DN BAY-60-5521 DMXIDWE TI TTFQAYR DMXIDWE TN Cholesteryl ester transfer protein (CETP) DMXIDWE MA Inhibitor DMXIDWE RN Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein. Br J Clin Pharmacol. 2012 Feb;73(2):210-8. DMXIDWE RU https://pubmed.ncbi.nlm.nih.gov/21838789 DMXIKYR DI DMXIKYR DMXIKYR DN APTO-253 DMXIKYR TI TTTI53X DMXIKYR TN Kruppel like factor 4 (KLF4) DMXIKYR MA Inhibitor DMXIKYR RN Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92. DMXIKYR RU https://pubmed.ncbi.nlm.nih.gov/26268924 DMXIMQT DI DMXIMQT DMXIMQT DN APX-3330 DMXIMQT TI TTHGL48 DMXIMQT TN AP endonuclease 1 (APEX1) DMXIMQT MA Inhibitor DMXIMQT RN Inhibition of APE1/Ref-1 redox activity with APX3330 blocks retinal angiogenesis in vitro and in vivo. Vision Res. 2011 Jan;51(1):93-100. DMXIMQT RU https://pubmed.ncbi.nlm.nih.gov/20937296 DMXKFOQ DI DMXKFOQ DMXKFOQ DN RPI-78M DMXKFOQ TI TTJSZTB DMXKFOQ TN Nicotinic acetylcholine receptor (nAChR) DMXKFOQ MA Antagonist DMXKFOQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXKFOQ RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMXKO1L DI DMXKO1L DMXKO1L DN L-796568 DMXKO1L TI TT2CJVK DMXKO1L TN Adrenergic receptor beta-2 (ADRB2) DMXKO1L MA Inhibitor DMXKO1L RN Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. DMXKO1L RU https://pubmed.ncbi.nlm.nih.gov/20181479 DMXKO1L DI DMXKO1L DMXKO1L DN L-796568 DMXKO1L TI TTR6W5O DMXKO1L TN Adrenergic receptor beta-1 (ADRB1) DMXKO1L MA Inhibitor DMXKO1L RN Heterocyclic acetamide and benzamide derivatives as potent and selective beta3-adrenergic receptor agonists with improved rodent pharmacokinetic pr... Bioorg Med Chem Lett. 2010 Mar 15;20(6):1895-9. DMXKO1L RU https://pubmed.ncbi.nlm.nih.gov/20181479 DMXLHVW DI DMXLHVW DMXLHVW DN PLX51107 DMXLHVW TI TTE4BSY DMXLHVW TN Bromodomain and extraterminal domain protein (BET) DMXLHVW MA Inhibitor DMXLHVW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXLHVW RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXMK5S DI DMXMK5S DMXMK5S DN Alfa-interferon DMXMK5S TI TTMQB37 DMXMK5S TN Interferon alpha/beta receptor 2 (IFNAR2) DMXMK5S MA Stimulator DMXMK5S RN New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. DMXMK5S RU https://pubmed.ncbi.nlm.nih.gov/18616415 DMXO3PV DI DMXO3PV DMXO3PV DN BI 905681 DMXO3PV TI TT7VMG4 DMXO3PV TN Low-density lipoprotein receptor-related protein 5 (LRP5) DMXO3PV MA Antagonist DMXO3PV RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMXO3PV RU https://www.inoncology.com/ourpipeline/lrp56-antagonist DMXPLMN DI DMXPLMN DMXPLMN DN INTOPLICINE DMXPLMN TI TTGTQHC DMXPLMN TN DNA topoisomerase I (TOP1) DMXPLMN MA Modulator DMXPLMN RN Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol Pharmacol. 1993 Oct;44(4):767-74. DMXPLMN RU https://www.ncbi.nlm.nih.gov/pubmed/8232227 DMXQ4NO DI DMXQ4NO DMXQ4NO DN Palomid-529 DMXQ4NO TI TTX4GLS DMXQ4NO TN Mammalian target of rapamycin complex 1 (mTORC1) DMXQ4NO MA Inhibitor DMXQ4NO RN Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33. DMXQ4NO RU https://pubmed.ncbi.nlm.nih.gov/23436212 DMXQ4NO DI DMXQ4NO DMXQ4NO DN Palomid-529 DMXQ4NO TI TTWDKCL DMXQ4NO TN Target of rapamycin complex 2 MAPKAP1 (MTORC2) DMXQ4NO MA Inhibitor DMXQ4NO RN Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer. 2013 Sep 1;133(5):1222-33. DMXQ4NO RU https://pubmed.ncbi.nlm.nih.gov/23436212 DMXQF1T DI DMXQF1T DMXQF1T DN SSR-181507 DMXQF1T TI TTSQIFT DMXQF1T TN 5-HT 1A receptor (HTR1A) DMXQF1T MA Modulator DMXQF1T RN SSR181507, a dopamine D receptor and 5-HT() receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.Pharmacol Biochem Behav.2011 Jan;97(3):428-35. DMXQF1T RU https://www.ncbi.nlm.nih.gov/pubmed/20920519 DMXQF1T DI DMXQF1T DMXQF1T DN SSR-181507 DMXQF1T TI TTEX248 DMXQF1T TN Dopamine D2 receptor (D2R) DMXQF1T MA Modulator DMXQF1T RN SSR181507, a dopamine D receptor and 5-HT() receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.Pharmacol Biochem Behav.2011 Jan;97(3):428-35. DMXQF1T RU https://www.ncbi.nlm.nih.gov/pubmed/20920519 DMXQGKL DI DMXQGKL DMXQGKL DN CB-813 DMXQGKL TI TTF0EGX DMXQGKL TN Coagulation factor VII (F7) DMXQGKL MA Modulator DMXQGKL RN Clinical pipeline report, company report or official report of Catalyst Biosciences. DMXQGKL RU http://www.catalystbiosciences.com/news/15-06-24/ DMXQHZC DI DMXQHZC DMXQHZC DN MM-151 DMXQHZC TI TTDC8N2 DMXQHZC TN Erbb3 tyrosine kinase receptor (Erbb-3) DMXQHZC MA Modulator DMXQHZC RN MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25. DMXQHZC RU https://pubmed.ncbi.nlm.nih.gov/24282274 DMXQHZC DI DMXQHZC DMXQHZC DN MM-151 DMXQHZC TI TTGKNB4 DMXQHZC TN Epidermal growth factor receptor (EGFR) DMXQHZC MA Antagonist DMXQHZC RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXQHZC RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMXQOHV DI DMXQOHV DMXQOHV DN COM701 DMXQOHV TI TTOGCNT DMXQOHV TN Transmembrane protein PVRIG (PVRIG) DMXQOHV RN Clinical pipeline report, company report or official report of Compugen. DMXQOHV RU https://cgen.com/pipeline/com701-pvrig/ DMXR6HI DI DMXR6HI DMXR6HI DN KITE-585 DMXR6HI TI TTZ3P4W DMXR6HI TN B-cell maturation protein (TNFRSF17) DMXR6HI MA CAR-T-Cell-Therapy DMXR6HI RN ClinicalTrials.gov (NCT03318861) A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma DMXR6HI RU https://clinicaltrials.gov/ct2/show/NCT03318861 DMXRPT6 DI DMXRPT6 DMXRPT6 DN GSK1070916 DMXRPT6 TI TT5LS6T DMXRPT6 TN Aurora kinase B (AURKB) DMXRPT6 MA Modulator DMXRPT6 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMXRPT6 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMXRPT6 DI DMXRPT6 DMXRPT6 DN GSK1070916 DMXRPT6 TI TTLYXIT DMXRPT6 TN Aurora kinase C (AURKC) DMXRPT6 MA Modulator DMXRPT6 RN Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001. DMXRPT6 RU https://pubmed.ncbi.nlm.nih.gov/20420387 DMXSMF9 DI DMXSMF9 DMXSMF9 DN IMP-701 DMXSMF9 TI TTNVXAW DMXSMF9 TN Lymphocyte activation gene 3 protein (LAG3) DMXSMF9 RN IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5. DMXSMF9 RU https://pubmed.ncbi.nlm.nih.gov/17394654 DMXST9F DI DMXST9F DMXST9F DN DS-1205 DMXST9F TI TTZPY6J DMXST9F TN Tyrosine-protein kinase UFO (AXL) DMXST9F MA Inhibitor DMXST9F RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXST9F RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMXTKYR DI DMXTKYR DMXTKYR DN SB-1578 DMXTKYR TI TTRMX3V DMXTKYR TN Janus kinase 2 (JAK-2) DMXTKYR MA Inhibitor DMXTKYR RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DMXTKYR RU https://pubmed.ncbi.nlm.nih.gov/24818516 DMXTOCE DI DMXTOCE DMXTOCE DN XmAb13676 DMXTOCE TI TTUE541 DMXTOCE TN Leukocyte surface antigen Leu-16 (CD20) DMXTOCE RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXTOCE RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMXTYWJ DI DMXTYWJ DMXTYWJ DN Neovastat DMXTYWJ TI TT6X50U DMXTYWJ TN Matrix metalloproteinase-9 (MMP-9) DMXTYWJ MA Inhibitor DMXTYWJ RN Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. DMXTYWJ RU https://pubmed.ncbi.nlm.nih.gov/11740820 DMXTYWJ DI DMXTYWJ DMXTYWJ DN Neovastat DMXTYWJ TI TTXZ0KQ DMXTYWJ TN Matrix metalloproteinase-12 (MMP-12) DMXTYWJ MA Inhibitor DMXTYWJ RN Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. DMXTYWJ RU https://pubmed.ncbi.nlm.nih.gov/11740820 DMXTYWJ DI DMXTYWJ DMXTYWJ DN Neovastat DMXTYWJ TI TTLM12X DMXTYWJ TN Matrix metalloproteinase-2 (MMP-2) DMXTYWJ MA Inhibitor DMXTYWJ RN Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol. 2001 Dec;28(6):620-5. DMXTYWJ RU https://pubmed.ncbi.nlm.nih.gov/11740820 DMXU2GS DI DMXU2GS DMXU2GS DN SBS-1000 DMXU2GS TI TTZOPHG DMXU2GS TN Insulin (INS) DMXU2GS MA Modulator DMXU2GS RN Synergistic antihyperglycemic effects between plant-derived oleanolic acid and insulin in streptozotocin-induced diabetic rats. Ren Fail. 2010;32(7):832-9. DMXU2GS RU https://pubmed.ncbi.nlm.nih.gov/20662697 DMXU5FK DI DMXU5FK DMXU5FK DN BMS-986189 DMXU5FK TI TT8ZLTI DMXU5FK TN Programmed cell death 1 ligand 1 (PD-L1) DMXU5FK MA Inhibitor DMXU5FK RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMXU5FK RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMXUJ1P DI DMXUJ1P DMXUJ1P DN IBI188 DMXUJ1P TI TT28S46 DMXUJ1P TN Leukocyte surface antigen CD47 (CD47) DMXUJ1P MA Blocker DMXUJ1P RN Clinical pipeline report, company report or official report of Innovent Biologics. DMXUJ1P RU https://www.innoventbio.com/ScienceAndProducts/Pipeline/ProductRAndD DMXUT3Z DI DMXUT3Z DMXUT3Z DN CC-8490 DMXUT3Z TI TTZAYWL DMXUT3Z TN Estrogen receptor (ESR) DMXUT3Z MA Modulator DMXUT3Z RN Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res. 2004 Dec 15;64(24):9115-23. DMXUT3Z RU https://pubmed.ncbi.nlm.nih.gov/15604281 DMXW07J DI DMXW07J DMXW07J DN EDP-239 DMXW07J TI TTCJ2X8 DMXW07J TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMXW07J MA Modulator DMXW07J RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXW07J RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXYCZV DI DMXYCZV DMXYCZV DN AMG 256 DMXYCZV TI TTZO9B0 DMXYCZV TN Interleukin 21 receptor (IL21R) DMXYCZV MA Agonist DMXYCZV RN Clinical pipeline report, company report or official report of Amgen. DMXYCZV RU https://www.amgenpipeline.com/ DMXYN1H DI DMXYN1H DMXYN1H DN KAR5585 DMXYN1H TI TTZSJHV DMXYN1H TN Tryptophan 5-hydroxylase 1 (TPH1) DMXYN1H RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMXYN1H RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMXZ1A8 DI DMXZ1A8 DMXZ1A8 DN HMPL-523 DMXZ1A8 TI TTOU65C DMXZ1A8 TN Tyrosine-protein kinase SYK (SYK) DMXZ1A8 MA Inhibitor DMXZ1A8 RN Clinical pipeline report, company report or official report of Hutchison MediPharma. DMXZ1A8 RU https://www.hutch-med.com/pipeline-and-products/our-pipeline/ DMXZ6A0 DI DMXZ6A0 DMXZ6A0 DN DP-4088 DMXZ6A0 TI TT6L509 DMXZ6A0 TN Coagulation factor IIa (F2) DMXZ6A0 MA Inhibitor DMXZ6A0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMXZ6A0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMXZOI0 DI DMXZOI0 DMXZOI0 DN P11187 DMXZOI0 TI TTB8FUC DMXZOI0 TN Free fatty acid receptor 1 (GPR40) DMXZOI0 MA Modulator DMXZOI0 RN Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137. DMXZOI0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147718/ DMY0DPM DI DMY0DPM DMY0DPM DN ARC-1905 DMY0DPM TI TTKANGO DMY0DPM TN Complement C5 (CO5) DMY0DPM RN ClinicalTrials.gov (NCT00950638) A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration. U.S. National Institutes of Health. DMY0DPM RU https://clinicaltrials.gov/ct2/show/NCT00950638 DMY0HU6 DI DMY0HU6 DMY0HU6 DN ETC-1922159 DMY0HU6 TI TTNFBTO DMY0HU6 TN Protein-serine O-palmitoleoyltransferase porcupine (PORCN) DMY0HU6 MA Inhibitor DMY0HU6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY0HU6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY0QL7 DI DMY0QL7 DMY0QL7 DN Iomab-ACT DMY0QL7 TI TTUS45N DMY0QL7 TN Leukocyte common antigen (PTPRC) DMY0QL7 MA Inhibitor DMY0QL7 RN Clinical pipeline report, company report or official report of Actinium Pharmaceuticals. DMY0QL7 RU https://www.actiniumpharma.com/product-pipeline/iomab-b DMY1AFS DI DMY1AFS DMY1AFS DN LY294002 DMY1AFS TI TTHBTOP DMY1AFS TN PI3-kinase gamma (PIK3CG) DMY1AFS MA Inhibitor DMY1AFS RN Clinical pipeline report, company report or official report of Genentech (2009). DMY1AFS RU http://www.gene.com/gene/pipeline/status/ DMY1DFK DI DMY1DFK DMY1DFK DN ITASETRON DMY1DFK TI TTNXLKE DMY1DFK TN 5-HT 3 receptor (5HT3R) DMY1DFK MA Modulator DMY1DFK RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMY1DFK RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMY218P DI DMY218P DMY218P DN CART-19 autologous T-cells DMY218P TI TTW640A DMY218P TN B-lymphocyte surface antigen B4 (CD19) DMY218P MA CAR-T-Cell-Therapy DMY218P RN ClinicalTrials.gov (NCT02476734) FDG-PET/CT Imaging as Early Predictor of DP DMY218P RU https://clinicaltrials.gov/ct2/show/NCT02476734 DMY2GDQ DI DMY2GDQ DMY2GDQ DN P-PSMA-101 DMY2GDQ TI TTZ3P4W DMY2GDQ TN B-cell maturation protein (TNFRSF17) DMY2GDQ RN Clinical pipeline report, company report or official report of Poseida Therapeutics. DMY2GDQ RU https://poseida.com/science/pipeline/#cart-therapies DMY2MO4 DI DMY2MO4 DMY2MO4 DN Anti-meso-CAR T cells DMY2MO4 TI TT4RXME DMY2MO4 TN Mesothelin (MSLN) DMY2MO4 MA CAR-T-Cell-Therapy DMY2MO4 RN ClinicalTrials.gov (NCT02580747) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso DMY2MO4 RU https://clinicaltrials.gov/ct2/show/NCT02580747 DMY3NWK DI DMY3NWK DMY3NWK DN CART22 cells expressing anti-CD22 scFv TCRz:41BB DMY3NWK TI TTM6QSK DMY3NWK TN B-cell receptor CD22 (CD22) DMY3NWK MA CAR-T-Cell-Therapy DMY3NWK RN ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL DMY3NWK RU https://clinicaltrials.gov/ct2/show/NCT02650414 DMY4B6J DI DMY4B6J DMY4B6J DN BI-847325 DMY4B6J TI TTROQ37 DMY4B6J TN MAPK/ERK kinase kinase (MAP3K) DMY4B6J MA Modulator DMY4B6J RN doi: 10.1158/1535-7163.TARG-13-B281 DMY4B6J RU http://mct.aacrjournals.org/content/12/11_Supplement/B281.short DMY4B6J DI DMY4B6J DMY4B6J DN BI-847325 DMY4B6J TI TT5LS6T DMY4B6J TN Aurora kinase B (AURKB) DMY4B6J MA Modulator DMY4B6J RN doi: 10.1158/1535-7163.TARG-13-B281 DMY4B6J RU http://mct.aacrjournals.org/content/12/11_Supplement/B281.short DMY4WVK DI DMY4WVK DMY4WVK DN AG-024322 DMY4WVK TI TT7HF4W DMY4WVK TN Cyclin-dependent kinase 2 (CDK2) DMY4WVK MA Inhibitor DMY4WVK RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMY4WVK RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMY4WVK DI DMY4WVK DMY4WVK DN AG-024322 DMY4WVK TI TT0PG8F DMY4WVK TN Cyclin-dependent kinase 4 (CDK4) DMY4WVK MA Inhibitor DMY4WVK RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMY4WVK RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMY4WVK DI DMY4WVK DMY4WVK DN AG-024322 DMY4WVK TI TTH6V3D DMY4WVK TN Cyclin-dependent kinase 1 (CDK1) DMY4WVK MA Inhibitor DMY4WVK RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMY4WVK RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMY5IM2 DI DMY5IM2 DMY5IM2 DN ARL-67085 DMY5IM2 TI TTZ1DT0 DMY5IM2 TN P2Y purinoceptor 12 (P2RY12) DMY5IM2 MA Agonist DMY5IM2 RN Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206. DMY5IM2 RU https://pubmed.ncbi.nlm.nih.gov/10578132 DMY5V4U DI DMY5V4U DMY5V4U DN CM-CS1 T-cell DMY5V4U TI TTLRN4A DMY5V4U TN NKG2 D activating NK receptor (KLRK1) DMY5V4U MA CAR-T-Cell-Therapy DMY5V4U RN ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands DMY5V4U RU https://clinicaltrials.gov/ct2/show/NCT02203825 DMY61GX DI DMY61GX DMY61GX DN FGLL DMY61GX TI TTUBJQ3 DMY61GX TN Neural cell adhesion molecule (NCAM) DMY61GX MA Modulator DMY61GX RN An NCAM mimetic, FGL, alters hippocampal cellular morphometry in young adult (4 month-old) rats. Neurochem Res. 2013 Jun;38(6):1208-18. DMY61GX RU https://pubmed.ncbi.nlm.nih.gov/23076631 DMY6QFH DI DMY6QFH DMY6QFH DN DFP-11207 DMY6QFH TI TTU6BFZ DMY6QFH TN Candida Thymidylate synthase (Candi TMP1) DMY6QFH MA Inhibitor DMY6QFH RN National Cancer Institute Drug Dictionary (drug id 762603). DMY6QFH RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=762603 DMY6V5T DI DMY6V5T DMY6V5T DN ICasp9M28z T cell DMY6V5T TI TT4RXME DMY6V5T TN Mesothelin (MSLN) DMY6V5T MA CAR-T-Cell-Therapy DMY6V5T RN ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin DMY6V5T RU https://clinicaltrials.gov/ct2/show/NCT02414269 DMY7CW1 DI DMY7CW1 DMY7CW1 DN JNJ-74699157 DMY7CW1 TI TT3LH46 DMY7CW1 TN KRAS G12C mutant (KRAS G12C) DMY7CW1 MA Inhibitor DMY7CW1 RN KRAS: From undruggable to a druggable Cancer Target. Cancer Treat Rev. 2020 Sep;89:102070. DMY7CW1 RU https://pubmed.ncbi.nlm.nih.gov/32711246 DMY84TW DI DMY84TW DMY84TW DN CVT-6883 DMY84TW TI TTNE7KG DMY84TW TN Adenosine A2b receptor (ADORA2B) DMY84TW MA Modulator DMY84TW RN GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse. J Pharmacol Exp Ther. 2012 Dec;343(3):587-95. DMY84TW RU https://pubmed.ncbi.nlm.nih.gov/22923737 DMY8D5O DI DMY8D5O DMY8D5O DN RTI-336 DMY8D5O TI TTVBI8W DMY8D5O TN Dopamine transporter (DAT) DMY8D5O MA Modulator DMY8D5O RN Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.AAPS J.2006 Mar 24;8(1):E196-203. DMY8D5O RU https://www.ncbi.nlm.nih.gov/pubmed/16584128 DMY8W3S DI DMY8W3S DMY8W3S DN LY3484356 DMY8W3S TI TTZAYWL DMY8W3S TN Estrogen receptor (ESR) DMY8W3S MA Degrader DMY8W3S RN ClinicalTrials.gov (NCT04647487) A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2). U.S. National Institutes of Health. DMY8W3S RU https://clinicaltrials.gov/ct2/show/NCT04647487 DMY93SW DI DMY93SW DMY93SW DN XL550 DMY93SW TI TT26PHO DMY93SW TN Mineralocorticoid receptor (MR) DMY93SW MA Antagonist DMY93SW RN Clinical pipeline report, company report or official report of Exelixis (2011). DMY93SW RU http://www.exelixis.com/pipeline DMY95MZ DI DMY95MZ DMY95MZ DN DSP-0565 DMY95MZ TI TT5HONZ DMY95MZ TN Calcium channel unspecific (CaC) DMY95MZ MA Modulator DMY95MZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035668) DMY95MZ RU http://adisinsight.springer.com/drugs/800035668 DMY9L4C DI DMY9L4C DMY9L4C DN BXCL702 DMY9L4C TI TT3C1VN DMY9L4C TN Enzyme unspecific (Enz) DMY9L4C MA Inhibitor DMY9L4C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY9L4C RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMY9LG1 DI DMY9LG1 DMY9LG1 DN PAN-90806 DMY9LG1 TI TT9HKJA DMY9LG1 TN Vascular endothelial growth factor (VEGF) DMY9LG1 MA Inhibitor DMY9LG1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMY9LG1 RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMY9XWB DI DMY9XWB DMY9XWB DN PMI-005 DMY9XWB TI TTF8CQI DMY9XWB TN Tumor necrosis factor (TNF) DMY9XWB MA Inhibitor DMY9XWB RN US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases. DMY9XWB RU https://www.google.com.ar/patents/US20080269123 DMY9ZAS DI DMY9ZAS DMY9ZAS DN EUK-189 DMY9ZAS TI TTPS279 DMY9ZAS TN Catalase (CAT) DMY9ZAS MA Modulator DMY9ZAS RN Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90. DMY9ZAS RU https://pubmed.ncbi.nlm.nih.gov/18569084 DMY9ZAS DI DMY9ZAS DMY9ZAS DN EUK-189 DMY9ZAS TI TT6RVLG DMY9ZAS TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMY9ZAS MA Modulator DMY9ZAS RN Evaluation of EUK-189, a synthetic superoxide dismutase/catalase mimetic as a radiation countermeasure. Immunopharmacol Immunotoxicol. 2008;30(2):271-90. DMY9ZAS RU https://pubmed.ncbi.nlm.nih.gov/18569084 DMYAIUB DI DMYAIUB DMYAIUB DN Valortim DMYAIUB TI TT3YGCD DMYAIUB TN Bacterial Protective antigen (Bact pagA) DMYAIUB RN Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers. Clin Vaccine Immunol. 2011 December; 18(12): 2136-2142. DMYAIUB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232684/ DMYBELW DI DMYBELW DMYBELW DN REGN1193 DMYBELW TI TT9O6WS DMYBELW TN Glucagon receptor (GCGR) DMYBELW MA Blocker DMYBELW RN A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20(2):283-291. DMYBELW RU https://pubmed.ncbi.nlm.nih.gov/28755409 DMYBHER DI DMYBHER DMYBHER DN KPL-716 DMYBHER TI TT1RJXK DMYBHER TN Interleukin-31 (IL31) DMYBHER MA Inhibitor DMYBHER RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYBHER RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DMYBHIR DI DMYBHIR DMYBHIR DN IBI-20089 DMYBHIR TI TTYRL6O DMYBHIR TN Glucocorticoid receptor (NR3C1) DMYBHIR MA Agonist DMYBHIR RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYBHIR RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYBX4N DI DMYBX4N DMYBX4N DN AZD1390 DMYBX4N TI TTKBM7V DMYBX4N TN ATM serine/threonine kinase (ATM) DMYBX4N MA Inhibitor DMYBX4N RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYBX4N RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYCMNR DI DMYCMNR DMYCMNR DN CAR-T Cells targeting HER2 DMYCMNR TI TT6EO5L DMYCMNR TN Erbb2 tyrosine kinase receptor (HER2) DMYCMNR MA CAR-T-Cell-Therapy DMYCMNR RN ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. DMYCMNR RU https://clinicaltrials.gov/ct2/show/NCT03267173 DMYD31U DI DMYD31U DMYD31U DN CD33-CAR-T Cell DMYD31U TI TTJVYO3 DMYD31U TN Myeloid cell surface antigen CD33 (CD33) DMYD31U MA CAR-T-Cell-Therapy DMYD31U RN ClinicalTrials.gov (NCT03126864) Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia DMYD31U RU https://clinicaltrials.gov/ct2/show/NCT03126864 DMYD37G DI DMYD37G DMYD37G DN CV8102 DMYD37G TI TTVB0O3 DMYD37G TN Retinoic acid-inducible gene-1 (RIG-1) DMYD37G MA Agonist DMYD37G RN Clinical pipeline report, company report or official report of CureVac. DMYD37G RU https://www.curevac.com/en/pipeline/ DMYD37G DI DMYD37G DMYD37G DN CV8102 DMYD37G TI TTRJ1K4 DMYD37G TN Toll-like receptor 7 (TLR7) DMYD37G MA Agonist DMYD37G RN Clinical pipeline report, company report or official report of CureVac. DMYD37G RU https://www.curevac.com/en/pipeline/ DMYD37G DI DMYD37G DMYD37G DN CV8102 DMYD37G TI TT8CWFK DMYD37G TN Toll-like receptor 8 (TLR8) DMYD37G MA Agonist DMYD37G RN Clinical pipeline report, company report or official report of CureVac. DMYD37G RU https://www.curevac.com/en/pipeline/ DMYDNQ2 DI DMYDNQ2 DMYDNQ2 DN CA102N DMYDNQ2 TI TTVKILB DMYDNQ2 TN Prostaglandin G/H synthase 2 (COX-2) DMYDNQ2 MA Inhibitor DMYDNQ2 RN National Cancer Institute Drug Dictionary (drug name CA102N). DMYDNQ2 RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nimesulide-hyaluronic-acid-conjugate-ca102n DMYDTJ6 DI DMYDTJ6 DMYDTJ6 DN CEP-11981 DMYDTJ6 TI TTUTJGQ DMYDTJ6 TN Vascular endothelial growth factor receptor 2 (KDR) DMYDTJ6 MA Inhibitor DMYDTJ6 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMYDTJ6 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMYDTJ6 DI DMYDTJ6 DMYDTJ6 DN CEP-11981 DMYDTJ6 TI TT9VGXW DMYDTJ6 TN Angiopoietin 1 receptor (TEK) DMYDTJ6 MA Modulator DMYDTJ6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842). DMYDTJ6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1842 DMYDTJ6 DI DMYDTJ6 DMYDTJ6 DN CEP-11981 DMYDTJ6 TI TT2Q6G1 DMYDTJ6 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMYDTJ6 MA Modulator DMYDTJ6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8189). DMYDTJ6 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8189 DMYEALO DI DMYEALO DMYEALO DN TMC-647055 DMYEALO TI TTMVBWH DMYEALO TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMYEALO MA Inhibitor DMYEALO RN WO patent application no. 2014,1522,75, Deuterium modified derivatives of the ns5b polymerase inhibitor tmc647055. DMYEALO RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140925&CC=WO&NR=2014152275A1&KC=A1 DMYERSD DI DMYERSD DMYERSD DN BPX-701 DMYERSD TI TT7AKW1 DMYERSD TN T-cell receptor (TCR) DMYERSD MA Immunomodulator DMYERSD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYERSD RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMYFB10 DI DMYFB10 DMYFB10 DN Abaperidone DMYFB10 TI TTJQOD7 DMYFB10 TN 5-HT 2A receptor (HTR2A) DMYFB10 MA Modulator DMYFB10 RN 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9. DMYFB10 RU https://www.ncbi.nlm.nih.gov/pubmed/9876110 DMYFB10 DI DMYFB10 DMYFB10 DN Abaperidone DMYFB10 TI TTEX248 DMYFB10 TN Dopamine D2 receptor (D2R) DMYFB10 MA Modulator DMYFB10 RN 7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics. 2. Pharmacological profile of 7-[3-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)-piperidin-1-yl]propoxy]-3-(hydroxymeth yl)chromen -4-one (abaperidone, FI-8602). J Med Chem. 1998 Dec 31;41(27):5402-9. DMYFB10 RU https://www.ncbi.nlm.nih.gov/pubmed/9876110 DMYFOJQ DI DMYFOJQ DMYFOJQ DN DT-200 DMYFOJQ TI TTS64P2 DMYFOJQ TN Androgen receptor (AR) DMYFOJQ MA Modulator DMYFOJQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYFOJQ RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMYFUOP DI DMYFUOP DMYFUOP DN TTP-547 DMYFUOP TI TTDLNGZ DMYFUOP TN Glucokinase (GCK) DMYFUOP MA Activator DMYFUOP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798). DMYFUOP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798 DMYFWQT DI DMYFWQT DMYFWQT DN CD19 CAR T-cells DMYFWQT TI TTW640A DMYFWQT TN B-lymphocyte surface antigen B4 (CD19) DMYFWQT MA CAR-T-Cell-Therapy DMYFWQT RN ClinicalTrials.gov (NCT03298828) CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma DMYFWQT RU https://clinicaltrials.gov/ct2/show/NCT03298828 DMYFZLA DI DMYFZLA DMYFZLA DN AMG 420 DMYFZLA TI TTZ3P4W DMYFZLA TN B-cell maturation protein (TNFRSF17) DMYFZLA MA Inhibitor DMYFZLA RN Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 Mar 10;38(8):775-783. DMYFZLA RU https://pubmed.ncbi.nlm.nih.gov/31895611 DMYG3PZ DI DMYG3PZ DMYG3PZ DN IDX-189 DMYG3PZ TI TTMVBWH DMYG3PZ TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMYG3PZ MA Inhibitor DMYG3PZ RN Clinical pipeline report, company report or official report of Idenix (2011). DMYG3PZ RU http://www.idenix.com/ DMYG704 DI DMYG704 DMYG704 DN TAK-137 DMYG704 TI TTAN6JD DMYG704 TN Glutamate receptor AMPA (GRIA) DMYG704 MA Modulator DMYG704 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMYG704 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMYHEUA DI DMYHEUA DMYHEUA DN ASN007 DMYHEUA TI TT1MG9E DMYHEUA TN Extracellular signal-regulated kinase 1 (ERK1) DMYHEUA MA Inhibitor DMYHEUA RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYHEUA RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYHIAR DI DMYHIAR DMYHIAR DN AdRTVP-1 DMYHIAR TI TTEQF1O DMYHIAR TN Glioma pathogenesis-related protein 1 (GLIPR1) DMYHIAR MA Modulator DMYHIAR RN Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancer. Cancer Gene Ther. 2006 Jul;13(7):658-63. DMYHIAR RU https://pubmed.ncbi.nlm.nih.gov/16485011 DMYHNV3 DI DMYHNV3 DMYHNV3 DN BLY719 DMYHNV3 TI TTEUNMR DMYHNV3 TN PI3-kinase alpha (PIK3CA) DMYHNV3 MA Inhibitor DMYHNV3 RN In vitro anticancer activity of PI3K alpha selective inhibitor BYL719 in head and neck cancer. Anticancer Res. 2015 Jan;35(1):175-82. DMYHNV3 RU https://pubmed.ncbi.nlm.nih.gov/25550549 DMYHU24 DI DMYHU24 DMYHU24 DN DSP-3905 DMYHU24 TI TT4G2JS DMYHU24 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMYHU24 MA Inhibitor DMYHU24 RN Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357. DMYHU24 RU https://pubmed.ncbi.nlm.nih.gov/30728472 DMYIBFM DI DMYIBFM DMYIBFM DN BMS-936561 DMYIBFM TI TTNCIE0 DMYIBFM TN CD70 antigen (CD27-L) DMYIBFM MA Modulator DMYIBFM RN Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106. DMYIBFM RU https://pubmed.ncbi.nlm.nih.gov/25869904 DMYIPKJ DI DMYIPKJ DMYIPKJ DN AT13148 DMYIPKJ TI TTMQO60 DMYIPKJ TN Rho-associated protein kinase (ROCK) DMYIPKJ MA Modulator DMYIPKJ RN Company report (Astex) DMYIPKJ RU http://www.astx.com/pipeline/products/clinical DMYIXQZ DI DMYIXQZ DMYIXQZ DN LP-108 DMYIXQZ TI TTJGNVC DMYIXQZ TN Apoptosis regulator Bcl-2 (BCL-2) DMYIXQZ RN National Cancer Institute Drug Dictionary (drug name LP-108). DMYIXQZ RU https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bcl-2-inhibitor-lp-108 DMYIZFW DI DMYIZFW DMYIZFW DN Anti-CD123 CAR-T cells DMYIZFW TI TTENHJ0 DMYIZFW TN Interleukin 3 receptor alpha (IL3RA) DMYIZFW MA CAR-T-Cell-Therapy DMYIZFW RN ClinicalTrials.gov (NCT03121625) CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies DMYIZFW RU https://clinicaltrials.gov/ct2/show/NCT03121625 DMYJCUP DI DMYJCUP DMYJCUP DN JNJ-64417184 DMYJCUP TI TT6275O DMYJCUP TN HRSV RNA-directed RNA polymerase L (HRSV L) DMYJCUP MA Inhibitor DMYJCUP RN Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. DMYJCUP RU https://pubmed.ncbi.nlm.nih.gov/30974127 DMYK52O DI DMYK52O DMYK52O DN LHC165 DMYK52O TI TTRJ1K4 DMYK52O TN Toll-like receptor 7 (TLR7) DMYK52O MA Agonist DMYK52O RN Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238. DMYK52O RU https://pubmed.ncbi.nlm.nih.gov/32203790 DMYKPXJ DI DMYKPXJ DMYKPXJ DN 9cUAB-30 DMYKPXJ TI TTH029C DMYKPXJ TN Retinoic acid receptor RXR-gamma (RXRG) DMYKPXJ MA Modulator DMYKPXJ RN In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64. DMYKPXJ RU https://pubmed.ncbi.nlm.nih.gov/17446266 DMYLFQR DI DMYLFQR DMYLFQR DN BMS-986120 DMYLFQR TI TT3I4WV DMYLFQR TN Prostate apoptosis response-4 (PAWR) DMYLFQR MA Antagonist DMYLFQR RN PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol. 2018 Feb;38(2):448-456. DMYLFQR RU https://pubmed.ncbi.nlm.nih.gov/29269513 DMYNSRH DI DMYNSRH DMYNSRH DN NGM313 DMYNSRH TI TTARBVH DMYNSRH TN Beta-klotho (KLB) DMYNSRH MA Modulator DMYNSRH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYNSRH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYNSRH DI DMYNSRH DMYNSRH DN NGM313 DMYNSRH TI TTRLW2X DMYNSRH TN Fibroblast growth factor receptor 1 (FGFR1) DMYNSRH MA Modulator DMYNSRH RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYNSRH RU http://phrma-docs.phrma.org/files/dmfile/mid-diabetes-drug-list.pdf DMYP9WR DI DMYP9WR DMYP9WR DN PF-06940434 DMYP9WR TI TT7B3HE DMYP9WR TN Integrin alpha-V/beta-8 (ITGAV/B8) DMYP9WR MA Antagonist DMYP9WR RN ClinicalTrials.gov (NCT04152018) Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.. U.S. National Institutes of Health. DMYP9WR RU https://clinicaltrials.gov/ct2/show/NCT04152018 DMYPU8V DI DMYPU8V DMYPU8V DN BAY 1238097 DMYPU8V TI TTE4BSY DMYPU8V TN Bromodomain and extraterminal domain protein (BET) DMYPU8V MA Inhibitor DMYPU8V RN Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017 Sep;178(6):936-948. DMYPU8V RU https://pubmed.ncbi.nlm.nih.gov/28653353 DMYPWHD DI DMYPWHD DMYPWHD DN NLG919 DMYPWHD TI TTV8N19 DMYPWHD TN Immune checkpoint (ICH) DMYPWHD MA Modulator DMYPWHD RN Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies. Nat Rev Drug Discov. 2014 Dec;13(12):879. DMYPWHD RU https://pubmed.ncbi.nlm.nih.gov/25435209 DMYQFCN DI DMYQFCN DMYQFCN DN Anti-CD19-CAR T cells DMYQFCN TI TTW640A DMYQFCN TN B-lymphocyte surface antigen B4 (CD19) DMYQFCN MA CAR-T-Cell-Therapy DMYQFCN RN ClinicalTrials.gov (NCT02659943) T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies DMYQFCN RU https://clinicaltrials.gov/ct2/show/NCT02659943 DMYQUIP DI DMYQUIP DMYQUIP DN PAC1 DMYQUIP TI TTPF2QI DMYQUIP TN Caspase-3 (CASP3) DMYQUIP MA Activator DMYQUIP RN Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol. 2006 Oct;2(10):543-50. DMYQUIP RU https://pubmed.ncbi.nlm.nih.gov/16936720 DMYR1K8 DI DMYR1K8 DMYR1K8 DN S-17092-1 DMYR1K8 TI TTNGKET DMYR1K8 TN Prolyl endopeptidase (PREP) DMYR1K8 MA Inhibitor DMYR1K8 RN Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem. 2003 Mar;84(5):919-29. DMYR1K8 RU https://pubmed.ncbi.nlm.nih.gov/12603817 DMYR3IE DI DMYR3IE DMYR3IE DN JES-9501 DMYR3IE TI TTEB0GD DMYR3IE TN Cholinesterase (BCHE) DMYR3IE MA Modulator DMYR3IE RN Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol. 2001 Feb 16;413(2-3):221-5. DMYR3IE RU https://pubmed.ncbi.nlm.nih.gov/11226396 DMYR7XP DI DMYR7XP DMYR7XP DN PF-4455242 DMYR7XP TI TTQW87Y DMYR7XP TN Opioid receptor kappa (OPRK1) DMYR7XP MA Modulator DMYR7XP RN Design and discovery of a selective small molecule opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). J Med Chem. 2011 Aug 25;54(16):5868-77. DMYR7XP RU https://pubmed.ncbi.nlm.nih.gov/21744827 DMYRPBI DI DMYRPBI DMYRPBI DN SR-4554 DMYRPBI TI TT5XVD6 DMYRPBI TN Intracellular nitroreductase (INR) DMYRPBI MA Modulator DMYRPBI RN A phase I study of SR-4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res. 2003 Nov 1;9(14):5101-12. DMYRPBI RU https://pubmed.ncbi.nlm.nih.gov/14613987 DMYRPC8 DI DMYRPC8 DMYRPC8 DN RVSVIN HIV-1 gag vaccine DMYRPC8 TI TTFGZB6 DMYRPC8 TN Human immunodeficiency virus GAG protein (HIV gag) DMYRPC8 RN Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011 Nov;204 Suppl 3:S1075-81. DMYRPC8 RU https://pubmed.ncbi.nlm.nih.gov/21987744 DMYS13R DI DMYS13R DMYS13R DN XL999 DMYS13R TI TTUTJGQ DMYS13R TN Vascular endothelial growth factor receptor 2 (KDR) DMYS13R MA Inhibitor DMYS13R RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Mar;29(2):153-73. DMYS13R RU https://pubmed.ncbi.nlm.nih.gov/17440629 DMYSJTR DI DMYSJTR DMYSJTR DN MM-302 DMYSJTR TI TT6EO5L DMYSJTR TN Erbb2 tyrosine kinase receptor (HER2) DMYSJTR MA Modulator DMYSJTR RN Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24. DMYSJTR RU https://pubmed.ncbi.nlm.nih.gov/25918676 DMYSQHT DI DMYSQHT DMYSQHT DN XL-041 DMYSQHT TI TTM1EQF DMYSQHT TN Oxysterols receptor LXR (NR1H) DMYSQHT MA Modulator DMYSQHT RN Emerging small molecule drugs. Handb Exp Pharmacol. 2015;224:617-30. DMYSQHT RU https://pubmed.ncbi.nlm.nih.gov/25523004 DMYTIP4 DI DMYTIP4 DMYTIP4 DN Aleplasinin DMYTIP4 TI TT5QA2I DMYTIP4 TN Plasminogen activator inhibitor (PAI) DMYTIP4 MA Inhibitor DMYTIP4 RN CN patent application no. 102046168, Pai-1 expression and activity inhibitors for the treatment of ocular disorders. DMYTIP4 RU http://www.google.com/patents/CN102046168A?cl=en DMYTJG7 DI DMYTJG7 DMYTJG7 DN AG-270 DMYTJG7 TI TTSMPXQ DMYTJG7 TN S-adenosylmethionine synthase type-2 (MAT2A) DMYTJG7 MA Inhibitor DMYTJG7 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYTJG7 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYVBU6 DI DMYVBU6 DMYVBU6 DN MEDI0562 DMYVBU6 TI TTL31H0 DMYVBU6 TN OX40L receptor (CD134) DMYVBU6 MA Agonist DMYVBU6 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMYVBU6 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMYVDXW DI DMYVDXW DMYVDXW DN 11C-AZD-2184 DMYVDXW TI TTE4KHA DMYVDXW TN Amyloid beta A4 protein (APP) DMYVDXW MA Binder DMYVDXW RN Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593. DMYVDXW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590405/ DMYWDT4 DI DMYWDT4 DMYWDT4 DN GNKG-168 DMYWDT4 TI TTSHG0T DMYWDT4 TN Toll-like receptor 9 (TLR9) DMYWDT4 MA Modulator DMYWDT4 RN National Cancer Institute Drug Dictionary (drug id 662816). DMYWDT4 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=662816 DMYX4NP DI DMYX4NP DMYX4NP DN RG7203 DMYX4NP TI TTJW4LU DMYX4NP TN Phosphodiesterase 10A (PDE10) DMYX4NP MA Inhibitor DMYX4NP RN Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013 DMYX4NP RU http://www.nature.com/scibx/journal/v6/n41/pdf/scibx.2013.1153.pdf?WT.ec_id=SCIBX-20131024 DMYXDB9 DI DMYXDB9 DMYXDB9 DN NN-8828 DMYXDB9 TI TT9QEJ6 DMYXDB9 TN Interleukin-21 (IL21) DMYXDB9 RN Handbook of Therapeutic Antibodies. 2014. 1. Page(995). DMYXDB9 RU https://books.google.com.hk/books?id=svHsBQAAQBAJ&pg=PA995&lpg=PA995&dq=NN-8828++++++ANTI&source=bl&ots=OSgek3Ucgf&sig=8iYcf4GKsCAvCCC1QHsKqxZK3YQ&hl=zh-CN&sa=X&ved=0CEwQ6AEwBmoVChMIyrS7qtXGyAIVA0COCh20lgxt#v=onepage&q=NN-8828%20%20%20%20%20%20ANTI&f=false DMYXQBF DI DMYXQBF DMYXQBF DN CEP-37251 DMYXQBF TI TT9E8HR DMYXQBF TN Osteoclast differentiation factor (ODF) DMYXQBF MA Inhibitor DMYXQBF RN This week in therapeutics Cancer. SciBX 3(40); doi:10.1038/scibx.2010.1202. Oct. 14, 2010 DMYXQBF RU http://www.nature.com/scibx/journal/v3/n40/pdf/scibx.2010.1202.pdf DMZ0D3V DI DMZ0D3V DMZ0D3V DN GRC-6211 DMZ0D3V TI TTMI6F5 DMZ0D3V TN Transient receptor potential cation channel V1 (TRPV1) DMZ0D3V MA Antagonist DMZ0D3V RN GRC-6211, a new oral specific TRPV1 antagonist, decreases bladder overactivity and noxious bladder input in cystitis animal models. J Urol. 2009 Jan;181(1):379-86. DMZ0D3V RU https://pubmed.ncbi.nlm.nih.gov/19010489 DMZ0D3V DI DMZ0D3V DMZ0D3V DN GRC-6211 DMZ0D3V TI TT0IHXV DMZ0D3V TN DNA topoisomerase II (TOP2) DMZ0D3V MA Inhibitor DMZ0D3V RN Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. DMZ0D3V RU https://pubmed.ncbi.nlm.nih.gov/2847647 DMZ13WQ DI DMZ13WQ DMZ13WQ DN BCMA-CD19 cCAR DMZ13WQ TI TTW640A DMZ13WQ TN B-lymphocyte surface antigen B4 (CD19) DMZ13WQ RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMZ13WQ RU https://icellgene.com/our-pipeline.html DMZ13WQ DI DMZ13WQ DMZ13WQ DN BCMA-CD19 cCAR DMZ13WQ TI TTZ3P4W DMZ13WQ TN B-cell maturation protein (TNFRSF17) DMZ13WQ RN Clinical pipeline report, company report or official report of iCell Gene Therapeutics. DMZ13WQ RU https://icellgene.com/our-pipeline.html DMZ1V0E DI DMZ1V0E DMZ1V0E DN BIIB 022 DMZ1V0E TI TTHRID2 DMZ1V0E TN Insulin-like growth factor I receptor (IGF1R) DMZ1V0E MA Antagonist DMZ1V0E RN A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25. DMZ1V0E RU https://pubmed.ncbi.nlm.nih.gov/24458261 DMZ1XR5 DI DMZ1XR5 DMZ1XR5 DN SAR-114137 DMZ1XR5 TI TTUMQVO DMZ1XR5 TN Cathepsin S (CTSS) DMZ1XR5 MA Inhibitor DMZ1XR5 RN From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48. DMZ1XR5 RU https://pubmed.ncbi.nlm.nih.gov/23201054 DMZ1XR5 DI DMZ1XR5 DMZ1XR5 DN SAR-114137 DMZ1XR5 TI TTDZN01 DMZ1XR5 TN Cathepsin K (CTSK) DMZ1XR5 MA Inhibitor DMZ1XR5 RN From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48. DMZ1XR5 RU https://pubmed.ncbi.nlm.nih.gov/23201054 DMZ2D0G DI DMZ2D0G DMZ2D0G DN Anti-CD45 mabs DMZ2D0G TI TTUS45N DMZ2D0G TN Leukocyte common antigen (PTPRC) DMZ2D0G RN CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul;91(7):886-94. DMZ2D0G RU https://pubmed.ncbi.nlm.nih.gov/16818275 DMZ2G69 DI DMZ2G69 DMZ2G69 DN Navicixizumab DMZ2G69 TI TTOHSBA DMZ2G69 TN Vascular endothelial growth factor A (VEGFA) DMZ2G69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ2G69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZ2G69 DI DMZ2G69 DMZ2G69 DN Navicixizumab DMZ2G69 TI TTV23LH DMZ2G69 TN Delta-like protein 4 (DLL4) DMZ2G69 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ2G69 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZ39T6 DI DMZ39T6 DMZ39T6 DN AVID200 DMZ39T6 TI TTO3HT7 DMZ39T6 TN Transforming growth factor beta (TGFB) DMZ39T6 MA Inhibitor DMZ39T6 RN TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826. DMZ39T6 RU https://pubmed.ncbi.nlm.nih.gov/31211692 DMZ4I03 DI DMZ4I03 DMZ4I03 DN CART-meso-19 T cells DMZ4I03 TI TTW640A DMZ4I03 TN B-lymphocyte surface antigen B4 (CD19) DMZ4I03 MA CAR-T-Cell-Therapy(Dual specific) DMZ4I03 RN ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer DMZ4I03 RU https://clinicaltrials.gov/ct2/show/NCT02465983 DMZ4I03 DI DMZ4I03 DMZ4I03 DN CART-meso-19 T cells DMZ4I03 TI TT4RXME DMZ4I03 TN Mesothelin (MSLN) DMZ4I03 MA CAR-T-Cell-Therapy(Dual specific) DMZ4I03 RN ClinicalTrials.gov (NCT02465983) Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer DMZ4I03 RU https://clinicaltrials.gov/ct2/show/NCT02465983 DMZ4WMT DI DMZ4WMT DMZ4WMT DN BMS-986104 DMZ4WMT TI TT9JZCK DMZ4WMT TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMZ4WMT MA Modulator DMZ4WMT RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ4WMT RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DMZ51EX DI DMZ51EX DMZ51EX DN BCL201 DMZ51EX TI TTJGNVC DMZ51EX TN Apoptosis regulator Bcl-2 (BCL-2) DMZ51EX MA Inhibitor DMZ51EX RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ51EX RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ5A6D DI DMZ5A6D DMZ5A6D DN GSK2398852 DMZ5A6D TI TTB7VAT DMZ5A6D TN Serum amyloid P-component (APCS) DMZ5A6D RN ClinicalTrials.gov (NCT01777243) A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis. U.S. National Institutes of Health. DMZ5A6D RU https://clinicaltrials.gov/ct2/show/NCT01777243 DMZ5YMX DI DMZ5YMX DMZ5YMX DN 18F-FEDAA-1106 DMZ5YMX TI TTPTXIN DMZ5YMX TN Translocator protein (TSPO) DMZ5YMX MA Modulator DMZ5YMX RN Role of peripheral benzodiazepine receptors in mitochondrial, cellular, and cardiac damage induced by oxidative stress and ischemia-reperfusion. J Pharmacol Exp Ther. 2003 Sep;306(3):828-37. DMZ5YMX RU https://pubmed.ncbi.nlm.nih.gov/12928523 DMZ6042 DI DMZ6042 DMZ6042 DN ZYOG1 DMZ6042 TI TTVIMDE DMZ6042 TN Glucagon-like peptide 1 receptor (GLP1R) DMZ6042 MA Agonist DMZ6042 RN 2011 Pipeline of Zydus Cadila Group. DMZ6042 RU http://www.zyduscadila.com/ DMZ60X4 DI DMZ60X4 DMZ60X4 DN TNO155 DMZ60X4 TI TT7WUAV DMZ60X4 TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMZ60X4 MA Inhibitor DMZ60X4 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ60X4 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ72BD DI DMZ72BD DMZ72BD DN NP-G2-044 DMZ72BD TI TTTRS9B DMZ72BD TN Fascin (FSCN1) DMZ72BD MA Inhibitor DMZ72BD RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ72BD RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ763A DI DMZ763A DMZ763A DN Autologous T Cells Expressing MET scFv CAR DMZ763A TI TTNDSF4 DMZ763A TN Proto-oncogene c-Met (MET) DMZ763A MA CAR-T-Cell-Therapy DMZ763A RN ClinicalTrials.gov (NCT03060356) Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET) DMZ763A RU https://clinicaltrials.gov/ct2/show/NCT03060356 DMZ8QRI DI DMZ8QRI DMZ8QRI DN PF-04995274 DMZ8QRI TI TT07C3Y DMZ8QRI TN 5-HT 4 receptor (HTR4) DMZ8QRI MA Agonist DMZ8QRI RN Pharmacokinetics, safety and tolerability of PF04995274: A 5HT4 partial agonist being developed for the treatment of Alzheimer's disease. Alzheimer's and Dementia. DMZ8QRI RU http://www.alzheimersanddementia.com/article/S1552-5260(11)02414-9/abstract DMZ8WAQ DI DMZ8WAQ DMZ8WAQ DN Retroviral vector-transduced autologous T cells to express CD22-specific CARs DMZ8WAQ TI TTM6QSK DMZ8WAQ TN B-cell receptor CD22 (CD22) DMZ8WAQ MA CAR-T-Cell-Therapy DMZ8WAQ RN ClinicalTrials.gov (NCT02721407) Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients DMZ8WAQ RU https://clinicaltrials.gov/ct2/show/NCT02721407 DMZ9EMO DI DMZ9EMO DMZ9EMO DN TST001 DMZ9EMO TI TT6PKBX DMZ9EMO TN Claudin-18 (CLDN18) DMZ9EMO RN Clinical pipeline report, company report or official report of Transcenta. DMZ9EMO RU http://www.transcenta.com/pipeline DMZ9NVP DI DMZ9NVP DMZ9NVP DN M8891 DMZ9NVP TI TTZL0OI DMZ9NVP TN Methionine aminopeptidase 2 (METAP2) DMZ9NVP MA Inhibitor DMZ9NVP RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZ9NVP RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZ9YWG DI DMZ9YWG DMZ9YWG DN SB 11285 DMZ9YWG TI TTT402Y DMZ9YWG TN Stimulator of interferon genes protein (TMEM173) DMZ9YWG MA Agonist DMZ9YWG RN Clinical pipeline report, company report or official report of F-star Therapeutics. DMZ9YWG RU https://www.f-star.com/pipeline/sb-11285/ DMZC9XU DI DMZC9XU DMZC9XU DN GSK-1360707 DMZC9XU TI TT3ROYC DMZC9XU TN Serotonin transporter (SERT) DMZC9XU MA Inhibitor DMZC9XU RN Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. DMZC9XU RU https://pubmed.ncbi.nlm.nih.gov/23685546 DMZC9XU DI DMZC9XU DMZC9XU DN GSK-1360707 DMZC9XU TI TTAWNKZ DMZC9XU TN Norepinephrine transporter (NET) DMZC9XU MA Inhibitor DMZC9XU RN Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. DMZC9XU RU https://pubmed.ncbi.nlm.nih.gov/23685546 DMZC9XU DI DMZC9XU DMZC9XU DN GSK-1360707 DMZC9XU TI TTVBI8W DMZC9XU TN Dopamine transporter (DAT) DMZC9XU MA Inhibitor DMZC9XU RN Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7. DMZC9XU RU https://pubmed.ncbi.nlm.nih.gov/23685546 DMZCBMS DI DMZCBMS DMZCBMS DN Iboctadekin + Rituximab DMZCBMS TI TTRICUF DMZCBMS TN Interleukin-18 (IL18) DMZCBMS MA Modulator DMZCBMS RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMZCBMS RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMZCBMS DI DMZCBMS DMZCBMS DN Iboctadekin + Rituximab DMZCBMS TI TTUE541 DMZCBMS TN Leukocyte surface antigen Leu-16 (CD20) DMZCBMS RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMZCBMS RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMZCBMS DI DMZCBMS DMZCBMS DN Iboctadekin + Rituximab DMZCBMS TI TTN9VTF DMZCBMS TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMZCBMS MA Blocker DMZCBMS RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMZCBMS RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMZDLHV DI DMZDLHV DMZDLHV DN BCMA nanobody CAR-T cells DMZDLHV TI TTZ3P4W DMZDLHV TN B-cell maturation protein (TNFRSF17) DMZDLHV MA CAR-T-Cell-Therapy DMZDLHV RN ClinicalTrials.gov (NCT03664661) BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma DMZDLHV RU https://clinicaltrials.gov/ct2/show/NCT03664661 DMZG9U0 DI DMZG9U0 DMZG9U0 DN TeloB-Vax DMZG9U0 TI TTUJFD0 DMZG9U0 TN Telomerase reverse transcriptase (TERT) DMZG9U0 MA Modulator DMZG9U0 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMZG9U0 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMZI4UX DI DMZI4UX DMZI4UX DN ATLCAR.CD30 cells DMZI4UX TI TT2GM5R DMZI4UX TN Lymphocyte activation antigen CD30 (TNFRSF8) DMZI4UX MA CAR-T-Cell-Therapy DMZI4UX RN ClinicalTrials.gov (NCT03602157) Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and NHL DMZI4UX RU https://clinicaltrials.gov/ct2/show/NCT03602157 DMZIK8R DI DMZIK8R DMZIK8R DN TXA709 DMZIK8R TI TT4W1VJ DMZIK8R TN Bacterial Celldivision protein FtsZ (Bact ftsZ) DMZIK8R MA Inhibitor DMZIK8R RN Clinical pipeline report, company report or official report of TAXIS Pharmaceuticals. DMZIK8R RU https://www.taxispharma.com/research-development/our-pipeline/ DMZJH23 DI DMZJH23 DMZJH23 DN REP8839 DMZJH23 TI TTOJ46K DMZJH23 TN Streptococcus Methionyl-tRNA synthetase (Stre-coc metG) DMZJH23 MA Inhibitor DMZJH23 RN Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother. 2005 Oct;49(10):4247-52. DMZJH23 RU https://pubmed.ncbi.nlm.nih.gov/16189105 DMZJNHM DI DMZJNHM DMZJNHM DN SYNB1891 DMZJNHM TI TTT402Y DMZJNHM TN Stimulator of interferon genes protein (TMEM173) DMZJNHM MA Agonist DMZJNHM RN Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739. DMZJNHM RU https://pubmed.ncbi.nlm.nih.gov/32483165 DMZK1GW DI DMZK1GW DMZK1GW DN OG987SC DMZK1GW TI TTVIMDE DMZK1GW TN Glucagon-like peptide 1 receptor (GLP1R) DMZK1GW MA Modulator DMZK1GW RN Clinical pipeline report, company report or official report of Novo Nordisk A/S. DMZK1GW RU http://www.novonordisk.com/bin/getPDF.1866957.pdf DMZK7N8 DI DMZK7N8 DMZK7N8 DN Keratinocyte growth factor DMZK7N8 TI TTFY134 DMZK7N8 TN Keratinocyte growth factor (FGF7) DMZK7N8 MA Modulator DMZK7N8 RN Keratinocyte growth factor.Cell Biol Int.1995 May;19(5):399-411. DMZK7N8 RU https://www.ncbi.nlm.nih.gov/pubmed/7640656 DMZLCTD DI DMZLCTD DMZLCTD DN AV-203 DMZLCTD TI TTDC8N2 DMZLCTD TN Erbb3 tyrosine kinase receptor (Erbb-3) DMZLCTD RN Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models. Clin Cancer Res. 2015 Mar 1;21(5):1106-14. DMZLCTD RU https://pubmed.ncbi.nlm.nih.gov/25542901 DMZLIWX DI DMZLIWX DMZLIWX DN LY3475070 DMZLIWX TI TTK0O6Y DMZLIWX TN Ecto-5'-nucleotidase (CD73) DMZLIWX MA Inhibitor DMZLIWX RN CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. Front Immunol. 2020 Apr 15;11:508. DMZLIWX RU https://pubmed.ncbi.nlm.nih.gov/32351498 DMZM0T8 DI DMZM0T8 DMZM0T8 DN ABBV-838 DMZM0T8 TI TT7ILZ1 DMZM0T8 TN SLAM family member 7 SLAMF7 (CS1) DMZM0T8 MA Inhibitor DMZM0T8 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZM0T8 RU http://phrma-docs.phrma.org/files/dmfile/MID_Immuno-Oncology-2017_Drug-List1.pdf DMZMAOW DI DMZMAOW DMZMAOW DN BI 765063 DMZMAOW TI TTBRJS9 DMZMAOW TN Inhibitory receptor SHPS-1 (SIRPA) DMZMAOW MA Antagonist DMZMAOW RN Clinical pipeline report, company report or official report of OSE Immunotherapeutics. DMZMAOW RU https://ose-immuno.com/en/ose-product/ose-172/ DMZMSBI DI DMZMSBI DMZMSBI DN KO-947 DMZMSBI TI TTKPV6O DMZMSBI TN Ephrin type-B receptor 2 (EPHB2) DMZMSBI MA Inhibitor DMZMSBI RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZMSBI RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZN35T DI DMZN35T DMZN35T DN EGFRt/19-28z/4-1BBL CAR T cells DMZN35T TI TTW640A DMZN35T TN B-lymphocyte surface antigen B4 (CD19) DMZN35T MA CAR-T-Cell-Therapy DMZN35T RN ClinicalTrials.gov (NCT03085173) A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies DMZN35T RU https://clinicaltrials.gov/ct2/show/NCT03085173 DMZN5QX DI DMZN5QX DMZN5QX DN MGD014 DMZN5QX TI TTEC2T3 DMZN5QX TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DMZN5QX MA Inhibitor DMZN5QX RN Clinical pipeline report, company report or official report of MacroGenics. DMZN5QX RU https://www.macrogenics.com/mgd014/ DMZN5QX DI DMZN5QX DMZN5QX DN MGD014 DMZN5QX TI TTUN7MC DMZN5QX TN T-cell surface glycoprotein CD3 (CD3) DMZN5QX MA Inhibitor DMZN5QX RN Clinical pipeline report, company report or official report of MacroGenics. DMZN5QX RU https://www.macrogenics.com/mgd014/ DMZNTHJ DI DMZNTHJ DMZNTHJ DN AVE-8112 DMZNTHJ TI TTSKMI8 DMZNTHJ TN Phosphodiesterase 4D (PDE4D) DMZNTHJ MA Inhibitor DMZNTHJ RN Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33. DMZNTHJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/ DMZNTHJ DI DMZNTHJ DMZNTHJ DN AVE-8112 DMZNTHJ TI TTVIAT9 DMZNTHJ TN Phosphodiesterase 4B (PDE4B) DMZNTHJ MA Inhibitor DMZNTHJ RN Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33. DMZNTHJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/ DMZNTHJ DI DMZNTHJ DMZNTHJ DN AVE-8112 DMZNTHJ TI TTZ97H5 DMZNTHJ TN Phosphodiesterase 4A (PDE4A) DMZNTHJ MA Inhibitor DMZNTHJ RN Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33. DMZNTHJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899489/ DMZOAT3 DI DMZOAT3 DMZOAT3 DN FT-1101 DMZOAT3 TI TTE4BSY DMZOAT3 TN Bromodomain and extraterminal domain protein (BET) DMZOAT3 MA Inhibitor DMZOAT3 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZOAT3 RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZP671 DI DMZP671 DMZP671 DN SUVN 911 DMZP671 TI TTL1ATN DMZP671 TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMZP671 MA Antagonist DMZP671 RN Discovery and Development of 3-(6-Chloropyridine-3-yloxymethyl)-2-azabicyclo[3.1.0]hexane Hydrochloride (SUVN-911): A Novel, Potent, Selective, and Orally Active Neuronal Nicotinic Acetylcholine alpha42 Receptor Antagonist for the Treatment of Depression. J Med Chem. 2020 Mar 26;63(6):2833-2853. DMZP671 RU https://pubmed.ncbi.nlm.nih.gov/32026697 DMZQ2DK DI DMZQ2DK DMZQ2DK DN AMG 986 DMZQ2DK TI TTJ8E43 DMZQ2DK TN Apelin receptor (APLNR) DMZQ2DK MA Agonist DMZQ2DK RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZQ2DK RU http://phrma-docs.phrma.org/files/dmfile/2018_Heart-Disease-and-Stroke_MID-Drug-List.pdf DMZQEDY DI DMZQEDY DMZQEDY DN AZD-2551 DMZQEDY TI TTZBFA0 DMZQEDY TN Protease unspecific (PRO) DMZQEDY MA Inhibitor DMZQEDY RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854) DMZQEDY RU http://adisinsight.springer.com/drugs/800029854 DMZQP7N DI DMZQP7N DMZQP7N DN ZD7114 DMZQP7N TI TTMXGCW DMZQP7N TN Adrenergic receptor beta-3 (ADRB3) DMZQP7N MA Agonist DMZQP7N RN Urinary tract toxicity in rats following administration of beta 3-adrenoceptor agonists. Toxicol Pathol. 1999 Mar-Apr;27(2):165-70. DMZQP7N RU https://pubmed.ncbi.nlm.nih.gov/10207980 DMZS1D2 DI DMZS1D2 DMZS1D2 DN BMS-852927 DMZS1D2 TI TTM1EQF DMZS1D2 TN Oxysterols receptor LXR (NR1H) DMZS1D2 MA Modulator DMZS1D2 RN Liver X receptors in lipid metabolism: opportunities for drug discovery. Nat Rev Drug Discov. 2014 Jun;13(6):433-44. DMZS1D2 RU https://pubmed.ncbi.nlm.nih.gov/24833295 DMZS350 DI DMZS350 DMZS350 DN Donor-derived CD19/22 bispecific CAR-T cells DMZS350 TI TTM6QSK DMZS350 TN B-cell receptor CD22 (CD22) DMZS350 MA CAR-T-Cell-Therapy(Dual specific) DMZS350 RN ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia DMZS350 RU https://clinicaltrials.gov/ct2/show/NCT03463928 DMZS350 DI DMZS350 DMZS350 DN Donor-derived CD19/22 bispecific CAR-T cells DMZS350 TI TTW640A DMZS350 TN B-lymphocyte surface antigen B4 (CD19) DMZS350 MA CAR-T-Cell-Therapy(Dual specific) DMZS350 RN ClinicalTrials.gov (NCT03463928) A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia DMZS350 RU https://clinicaltrials.gov/ct2/show/NCT03463928 DMZSD3T DI DMZSD3T DMZSD3T DN Patient-derived CD19- and CD22 specific CAR DMZSD3T TI TTM6QSK DMZSD3T TN B-cell receptor CD22 (CD22) DMZSD3T MA CAR-T-Cell-Therapy(Dual specific) DMZSD3T RN ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma DMZSD3T RU https://clinicaltrials.gov/ct2/show/NCT03330691 DMZSD3T DI DMZSD3T DMZSD3T DN Patient-derived CD19- and CD22 specific CAR DMZSD3T TI TTW640A DMZSD3T TN B-lymphocyte surface antigen B4 (CD19) DMZSD3T MA CAR-T-Cell-Therapy(Dual specific) DMZSD3T RN ClinicalTrials.gov (NCT03330691) A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma DMZSD3T RU https://clinicaltrials.gov/ct2/show/NCT03330691 DMZT89C DI DMZT89C DMZT89C DN DNL151 DMZT89C TI TTK0FEA DMZT89C TN Leucine-rich repeat kinase 2 (LRRK2) DMZT89C MA Inhibitor DMZT89C RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZT89C RU http://phrma-docs.phrma.org/files/dmfile/MID_Neurological-Disorders-Drug-List_2018.pdf DMZTMEJ DI DMZTMEJ DMZTMEJ DN AG-270 DMZTMEJ TI TTSMPXQ DMZTMEJ TN S-adenosylmethionine synthase type-2 (MAT2A) DMZTMEJ MA Inhibitor DMZTMEJ RN Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem. 2021 Apr 22;64(8):4430-4449. DMZTMEJ RU https://pubmed.ncbi.nlm.nih.gov/33829783 DMZU2G1 DI DMZU2G1 DMZU2G1 DN LMP-1/LMP-2 CTLs DMZU2G1 TI TTBK351 DMZU2G1 TN Epstein-Barr virus Latent membrane protein 2 (EBV LMP2) DMZU2G1 MA Modulator DMZU2G1 RN In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42. DMZU2G1 RU https://pubmed.ncbi.nlm.nih.gov/16753867 DMZU2G1 DI DMZU2G1 DMZU2G1 DN LMP-1/LMP-2 CTLs DMZU2G1 TI TT0BI4Q DMZU2G1 TN Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) DMZU2G1 MA Modulator DMZU2G1 RN In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leuk Lymphoma. 2006 May;47(5):837-42. DMZU2G1 RU https://pubmed.ncbi.nlm.nih.gov/16753867 DMZUA5C DI DMZUA5C DMZUA5C DN MK-6302 DMZUA5C TI TTC70AJ DMZUA5C TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMZUA5C MA Modulator DMZUA5C RN Merck ditches biogeneric. Nat Biotechnol. 2010 Jul;28(7):636. DMZUA5C RU https://pubmed.ncbi.nlm.nih.gov/20622817 DMZUM67 DI DMZUM67 DMZUM67 DN M9241 DMZUM67 TI TTG68FB DMZUM67 TN Interleukine 12 (IL-12) DMZUM67 MA Replacement DMZUM67 RN Clinical pipeline report, company report or official report of EMD Serono. DMZUM67 RU https://medical.emdserono.com/content/healthcare/biopharma/usmi/en_US/home/immuno-oncology/m9241--nhs-il12--.html DMZVFOQ DI DMZVFOQ DMZVFOQ DN GS-5829 DMZVFOQ TI TTE4BSY DMZVFOQ TN Bromodomain and extraterminal domain protein (BET) DMZVFOQ MA Inhibitor DMZVFOQ RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMZVFOQ RU http://phrma-docs.phrma.org/files/dmfile/2018-Cancer-Drug-List.pdf DMZWFKQ DI DMZWFKQ DMZWFKQ DN OPC-14117 DMZWFKQ TI TTAD7UL DMZWFKQ TN Superoxide anion (SPA) DMZWFKQ MA Modulator DMZWFKQ RN Evaluation of superoxide scavenging activity of OPC-14117 by electron spin resonance technique. Free Radic Res Commun. 1991;15(4):223-30. DMZWFKQ RU https://pubmed.ncbi.nlm.nih.gov/1667773 DMZXDBN DI DMZXDBN DMZXDBN DN HER2-CAR T Cells DMZXDBN TI TT6EO5L DMZXDBN TN Erbb2 tyrosine kinase receptor (HER2) DMZXDBN MA CAR-T-Cell-Therapy DMZXDBN RN ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases DMZXDBN RU https://clinicaltrials.gov/ct2/show/NCT03696030 DMZXG7Q DI DMZXG7Q DMZXG7Q DN HPP971 DMZXG7Q TI TTA6ZN2 DMZXG7Q TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMZXG7Q MA Activator DMZXG7Q RN Clinical pipeline report, company report or official report of vTv Therapeutics. DMZXG7Q RU https://vtvtherapeutics.com/pipeline/nrf2-bach1-program/ DMZYCWT DI DMZYCWT DMZYCWT DN BCI-632 DMZYCWT TI TTXJ47W DMZYCWT TN Metabotropic glutamate receptor 2 (mGluR2) DMZYCWT MA Antagonist DMZYCWT RN Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87. DMZYCWT RU https://pubmed.ncbi.nlm.nih.gov/15317467 DMZYCWT DI DMZYCWT DMZYCWT DN BCI-632 DMZYCWT TI TT8A9EF DMZYCWT TN Metabotropic glutamate receptor 3 (mGluR3) DMZYCWT MA Modulator DMZYCWT RN Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists. J Med Chem. 2004 Aug 26;47(18):4570-87. DMZYCWT RU https://pubmed.ncbi.nlm.nih.gov/15317467 DM0RX5E DI DM0RX5E DM0RX5E DN CAR-GPC3 T cells DM0RX5E TI TTJTSX4 DM0RX5E TN Glypican-3 (GPC3) DM0RX5E MA CAR-T-Cell-Therapy DM0RX5E RN ClinicalTrials.gov (NCT03146234) CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma DM0RX5E RU https://clinicaltrials.gov/ct2/show/NCT03146234 DM21Y8J DI DM21Y8J DM21Y8J DN isatin sulfonamide 34 DM21Y8J TI TTM7Y45 DM21Y8J TN Caspase-7 (CASP7) DM21Y8J MA Inhibitor DM21Y8J RN Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26. DM21Y8J RU https://pubmed.ncbi.nlm.nih.gov/11384246 DM21Y8J DI DM21Y8J DM21Y8J DN isatin sulfonamide 34 DM21Y8J TI TTB6T7O DM21Y8J TN Caspase-9 (CASP9) DM21Y8J MA Inhibitor DM21Y8J RN Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26. DM21Y8J RU https://pubmed.ncbi.nlm.nih.gov/11384246 DM2N653 DI DM2N653 DM2N653 DN example 98 (WO2011020806) DM2N653 TI TT69DB8 DM2N653 TN Beta-site APP-cleaving enzyme 2 (BACE2) DM2N653 MA Inhibitor DM2N653 RN BACE2 as a new diabetes target: a patent review (2010 - 2012). Expert Opin Ther Pat. 2013 May;23(5):649-63. DM2N653 RU https://pubmed.ncbi.nlm.nih.gov/23506624 DM2NZ6K DI DM2NZ6K DM2NZ6K DN KGP94 DM2NZ6K TI TT36ETB DM2NZ6K TN Cathepsin L (CTSL) DM2NZ6K MA Inhibitor DM2NZ6K RN Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. DM2NZ6K RU https://pubmed.ncbi.nlm.nih.gov/20933415 DM2V6R7 DI DM2V6R7 DM2V6R7 DN CD19-CAR T Cells DM2V6R7 TI TTW640A DM2V6R7 TN B-lymphocyte surface antigen B4 (CD19) DM2V6R7 MA CAR-T-Cell-Therapy DM2V6R7 RN ClinicalTrials.gov (NCT03423706) Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation DM2V6R7 RU https://clinicaltrials.gov/ct2/show/NCT03423706 DM3ADQW DI DM3ADQW DM3ADQW DN NIA-114 DM3ADQW TI TTWNV8U DM3ADQW TN Nicotinic acid receptor (HCAR2) DM3ADQW MA Agonist DM3ADQW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3ADQW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3ADQW DI DM3ADQW DM3ADQW DN NIA-114 DM3ADQW TI TT8WFXV DM3ADQW TN Hydroxycarboxylic acid receptor 3 (HCAR3) DM3ADQW MA Agonist DM3ADQW RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DM3ADQW RU http://phrma-docs.phrma.org/files/dmfile/medicines-in-development-drug-list-autoimmune-diseases.pdf DM3M9OY DI DM3M9OY DM3M9OY DN Anti-CD19/20-CAR vector-transduced T cells DM3M9OY TI TTUE541 DM3M9OY TN Leukocyte surface antigen Leu-16 (CD20) DM3M9OY MA CAR-T-Cell-Therapy(Dual specific) DM3M9OY RN ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 DM3M9OY RU https://clinicaltrials.gov/ct2/show/NCT03097770 DM3M9OY DI DM3M9OY DM3M9OY DN Anti-CD19/20-CAR vector-transduced T cells DM3M9OY TI TTW640A DM3M9OY TN B-lymphocyte surface antigen B4 (CD19) DM3M9OY MA CAR-T-Cell-Therapy(Dual specific) DM3M9OY RN ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 DM3M9OY RU https://clinicaltrials.gov/ct2/show/NCT03097770 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTT2ZAR DM4XAU7 TN Prostaglandin F2-alpha receptor (PTGFR) DM4XAU7 MA Agonist DM4XAU7 RN Identification by site-directed mutagenesis of amino acids contributing to ligand-binding specificity or signal transduction properties of the human FP prostanoid receptor. Biochem J. 2003 Apr 15;371(Pt 2):443-9. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/12519077 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTQDMX5 DM4XAU7 TN Prostaglandin D2 receptor 2 (PTGDR2) DM4XAU7 MA Agonist DM4XAU7 RN Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/12721327 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TT2O84V DM4XAU7 TN Thromboxane A2 receptor (TBXA2R) DM4XAU7 MA Agonist DM4XAU7 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTG1QMU DM4XAU7 TN Prostaglandin E2 receptor EP1 (PTGER1) DM4XAU7 MA Agonist DM4XAU7 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTPNGDE DM4XAU7 TN Prostaglandin E2 receptor EP3 (PTGER3) DM4XAU7 MA Agonist DM4XAU7 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TT1ZAVI DM4XAU7 TN Prostaglandin E2 receptor EP2 (PTGER2) DM4XAU7 MA Agonist DM4XAU7 RN Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/10462542 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TT79WV3 DM4XAU7 TN Prostaglandin E2 receptor EP4 (PTGER4) DM4XAU7 MA Agonist DM4XAU7 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM4XAU7 DI DM4XAU7 DM4XAU7 DN PGF2alpha DM4XAU7 TI TTNVEIR DM4XAU7 TN Prostaglandin D2 receptor (PTGDR) DM4XAU7 MA Agonist DM4XAU7 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM4XAU7 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM531SA DI DM531SA DM531SA DN bimatoprost (free acid form) DM531SA TI TTT2ZAR DM531SA TN Prostaglandin F2-alpha receptor (PTGFR) DM531SA MA Agonist DM531SA RN Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds. Br J Pharmacol. 2000 Aug;130(8):1933-43. DM531SA RU https://pubmed.ncbi.nlm.nih.gov/10952685 DM5I2HL DI DM5I2HL DM5I2HL DN GSK269962A DM5I2HL TI TTGWKQJ DM5I2HL TN Rho-associated protein kinase 2 (ROCK2) DM5I2HL MA Inhibitor DM5I2HL RN Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. DM5I2HL RU https://pubmed.ncbi.nlm.nih.gov/17018693 DM5I2HL DI DM5I2HL DM5I2HL DN GSK269962A DM5I2HL TI TTZN7RP DM5I2HL TN Rho-associated protein kinase 1 (ROCK1) DM5I2HL MA Inhibitor DM5I2HL RN Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. 2007 Jan;320(1):89-98. DM5I2HL RU https://pubmed.ncbi.nlm.nih.gov/17018693 DM5UWH3 DI DM5UWH3 DM5UWH3 DN PMID22911925C2 DM5UWH3 TI TT8JRS7 DM5UWH3 TN Beta-secretase (BACE) DM5UWH3 MA Inhibitor DM5UWH3 RN Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived beta-secretase inhibitors. J Pharmacol Exp Ther. 2012 Nov;343(2):460-7. DM5UWH3 RU https://pubmed.ncbi.nlm.nih.gov/22911925 DM6NVPT DI DM6NVPT DM6NVPT DN Anti-CD19 Chimeric Antigen Receptor T Cells DM6NVPT TI TTW640A DM6NVPT TN B-lymphocyte surface antigen B4 (CD19) DM6NVPT MA CAR-T-Cell-Therapy DM6NVPT RN ClinicalTrials.gov (NCT03624686) Production of Clinical-grade Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory B-cell Malignancies DM6NVPT RU https://clinicaltrials.gov/ct2/show/NCT03624686 DM6ZHTV DI DM6ZHTV DM6ZHTV DN CAR-CLD18 T cell DM6ZHTV TI TT6PKBX DM6ZHTV TN Claudin-18 (CLDN18) DM6ZHTV MA CAR-T-Cell-Therapy DM6ZHTV RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DM6ZHTV RU https://clinicaltrials.gov/ct2/show/NCT03302403 DM7W6YN DI DM7W6YN DM7W6YN DN GR148672X DM7W6YN TI TTMF541 DM7W6YN TN Liver carboxylesterase (CES1) DM7W6YN MA Inhibitor DM7W6YN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592). DM7W6YN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592 DM87BTM DI DM87BTM DM87BTM DN GD2-targeted CAR-T cells DM87BTM TI TT80ARU DM87BTM TN Ganglioside GD2 (GD2) DM87BTM MA CAR-T-Cell-Therapy DM87BTM RN ClinicalTrials.gov (NCT02919046) Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children DM87BTM RU https://clinicaltrials.gov/ct2/show/NCT02919046 DM8VTF2 DI DM8VTF2 DM8VTF2 DN CD19-UCART DM8VTF2 TI TTW640A DM8VTF2 TN B-lymphocyte surface antigen B4 (CD19) DM8VTF2 MA CAR-T-Cell-Therapy DM8VTF2 RN ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART DM8VTF2 RU https://clinicaltrials.gov/ct2/show/NCT03229876 DMAK1ME DI DMAK1ME DMAK1ME DN CAR-T cells targeting CD56 DMAK1ME TI TTVXPHT DMAK1ME TN Neural cell adhesion molecule 1 (NCAM1) DMAK1ME MA CAR-T-Cell-Therapy DMAK1ME RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMAK1ME RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMAPV6J DI DMAPV6J DMAPV6J DN MK-0249 DMAPV6J TI TT9JNIC DMAPV6J TN Histamine H3 receptor (H3R) DMAPV6J MA Agonist DMAPV6J RN Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists. J Med Chem. 2008 Aug 14;51(15):4780-9. DMAPV6J RU https://pubmed.ncbi.nlm.nih.gov/18598020 DMBDT3V DI DMBDT3V DMBDT3V DN CAR-GPC3 T cell DMBDT3V TI TTJTSX4 DMBDT3V TN Glypican-3 (GPC3) DMBDT3V MA CAR-T-Cell-Therapy DMBDT3V RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DMBDT3V RU https://clinicaltrials.gov/ct2/show/NCT03302403 DMCEPKM DI DMCEPKM DMCEPKM DN BCMA-CART DMCEPKM TI TTZ3P4W DMCEPKM TN B-cell maturation protein (TNFRSF17) DMCEPKM MA CAR-T-Cell-Therapy DMCEPKM RN ClinicalTrials.gov (NCT03492268) Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma DMCEPKM RU https://clinicaltrials.gov/ct2/show/NCT03492268 DMCM5GK DI DMCM5GK DMCM5GK DN TAK-070 DMCM5GK TI TT8JRS7 DMCM5GK TN Beta-secretase (BACE) DMCM5GK MA Inhibitor DMCM5GK RN A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010 Aug 18;30(33):11157-66. DMCM5GK RU https://pubmed.ncbi.nlm.nih.gov/20720123 DMCV5ND DI DMCV5ND DMCV5ND DN GSK-264220A DMCV5ND TI TTHSZXO DMCV5ND TN Endothelial lipase (LIPG) DMCV5ND MA Inhibitor DMCV5ND RN Discovery of potent, selective sulfonylfuran urea endothelial lipase inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):27-30. DMCV5ND RU https://pubmed.ncbi.nlm.nih.gov/19058966 DMDU6GN DI DMDU6GN DMDU6GN DN JNJ-479655 DMDU6GN TI TT473XN DMDU6GN TN P2X purinoceptor 7 (P2RX7) DMDU6GN MA Antagonist DMDU6GN RN Pharmacological characterization of a novel centrally permeable P2X7 receptor antagonist: JNJ-47965567. Br J Pharmacol. 2013 Oct;170(3):624-40. DMDU6GN RU https://pubmed.ncbi.nlm.nih.gov/23889535 DMF936G DI DMF936G DMF936G DN CD19CART DMF936G TI TTW640A DMF936G TN B-lymphocyte surface antigen B4 (CD19) DMF936G MA CAR-T-Cell-Therapy DMF936G RN ClinicalTrials.gov (NCT02813837) Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies DMF936G RU https://clinicaltrials.gov/ct2/show/NCT02813837 DMGANIC DI DMGANIC DMGANIC DN tamatinib DMGANIC TI TTOU65C DMGANIC TN Tyrosine-protein kinase SYK (SYK) DMGANIC MA Inhibitor DMGANIC RN Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1944-9. DMGANIC RU https://pubmed.ncbi.nlm.nih.gov/19254842 DMGANIC DI DMGANIC DMGANIC DN tamatinib DMGANIC TI TT4DXQT DMGANIC TN Proto-oncogene c-Ret (RET) DMGANIC MA Inhibitor DMGANIC RN Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing. Birth Defects Res A Clin Mol Teratol. 2009 Feb;85(2):130-6. DMGANIC RU https://pubmed.ncbi.nlm.nih.gov/19107952 DMGPTFL DI DMGPTFL DMGPTFL DN AZ-4217 DMGPTFL TI TT8JRS7 DMGPTFL TN Beta-secretase (BACE) DMGPTFL MA Inhibitor DMGPTFL RN AZ-4217: a high potency BACE inhibitor displaying acute central efficacy in different in vivo models and reduced amyloid deposition in Tg2576 mice. J Neurosci. 2013 Jun 12;33(24):10075-84. DMGPTFL RU https://pubmed.ncbi.nlm.nih.gov/23761903 DMGW10M DI DMGW10M DMGW10M DN CAR-T cells targeting BCMA DMGW10M TI TTZ3P4W DMGW10M TN B-cell maturation protein (TNFRSF17) DMGW10M MA CAR-T-Cell-Therapy DMGW10M RN ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma DMGW10M RU https://clinicaltrials.gov/ct2/show/NCT03473496 DMH5C37 DI DMH5C37 DMH5C37 DN CAR-T cells targeting CD38 DMH5C37 TI TTPURFN DMH5C37 TN Cyclic ADP-ribose hydrolase 1 (CD38) DMH5C37 MA CAR-T-Cell-Therapy DMH5C37 RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMH5C37 RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMHBQYU DI DMHBQYU DMHBQYU DN CAR-T cells targeting CD138 DMHBQYU TI TTYDSVG DMHBQYU TN Syndecan-1 (SDC1) DMHBQYU MA CAR-T-Cell-Therapy DMHBQYU RN ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma DMHBQYU RU https://clinicaltrials.gov/ct2/show/NCT03473496 DMHPME3 DI DMHPME3 DMHPME3 DN PMID18163548C4 DMHPME3 TI TTGY7WI DMHPME3 TN Urokinase-type plasminogen activator (PLAU) DMHPME3 MA Inhibitor DMHPME3 RN Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6. DMHPME3 RU https://pubmed.ncbi.nlm.nih.gov/18163548 DMJGFLD DI DMJGFLD DMJGFLD DN PMID15026062C41 DMJGFLD TI TTLUQ8E DMJGFLD TN Hormone sensitive lipase (LIPE) DMJGFLD MA Inhibitor DMJGFLD RN Carbazates as potent inhibitors of hormone-sensitive lipase. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1741-4. DMJGFLD RU https://pubmed.ncbi.nlm.nih.gov/15026062 DMLF2UY DI DMLF2UY DMLF2UY DN CAR-BCMA T cell DMLF2UY TI TTZ3P4W DMLF2UY TN B-cell maturation protein (TNFRSF17) DMLF2UY MA CAR-T-Cell-Therapy DMLF2UY RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DMLF2UY RU https://clinicaltrials.gov/ct2/show/NCT03302403 DMLPAFG DI DMLPAFG DMLPAFG DN CD19-targeted CAR-T cells DMLPAFG TI TTW640A DMLPAFG TN B-lymphocyte surface antigen B4 (CD19) DMLPAFG MA CAR-T-Cell-Therapy DMLPAFG RN ClinicalTrials.gov (NCT03564977) CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation DMLPAFG RU https://clinicaltrials.gov/ct2/show/NCT03564977 DMN2EI1 DI DMN2EI1 DMN2EI1 DN bis-triazole derivative 10 DMN2EI1 TI TTP86E2 DMN2EI1 TN Plasminogen (PLG) DMN2EI1 MA Inhibitor DMN2EI1 RN A new strategy for the development of highly potent and selective plasmin inhibitors. J Med Chem. 2012 Feb 9;55(3):1171-80. DMN2EI1 RU https://pubmed.ncbi.nlm.nih.gov/22276953 DMN2I3P DI DMN2I3P DMN2I3P DN alpha-ketothiazole analogue 36 DMN2I3P TI TTDM4ZU DMN2I3P TN Factor XI messenger RNA (F11 mRNA) DMN2I3P MA Inhibitor DMN2I3P RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMN2I3P RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMO0892 DI DMO0892 DMO0892 DN PF-4708671 DMO0892 TI TTG0U4H DMO0892 TN Ribosomal protein S6 kinase beta-1 (S6K1) DMO0892 MA Inhibitor DMO0892 RN Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1). Biochem J. 2010 Oct 15;431(2):245-55. DMO0892 RU https://pubmed.ncbi.nlm.nih.gov/20704563 DMO1IHL DI DMO1IHL DMO1IHL DN PMID17935984C1 DMO1IHL TI TTHY57M DMO1IHL TN Matrix metalloproteinase-13 (MMP-13) DMO1IHL MA Inhibitor DMO1IHL RN Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34. DMO1IHL RU https://pubmed.ncbi.nlm.nih.gov/17935984 DMOI0TN DI DMOI0TN DMOI0TN DN VU0364739 DMOI0TN TI TTRLMKF DMOI0TN TN Phospholipase D2 (PLD2) DMOI0TN MA Inhibitor DMOI0TN RN Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J Med Chem. 2010 Sep 23;53(18):6706-19. DMOI0TN RU https://pubmed.ncbi.nlm.nih.gov/20735042 DMR1NYF DI DMR1NYF DMR1NYF DN KH064 DMR1NYF TI TTO8QRU DMR1NYF TN Group IIA phospholipase A2 (GIIA sPLA2) DMR1NYF MA Inhibitor DMR1NYF RN D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5. DMR1NYF RU https://pubmed.ncbi.nlm.nih.gov/12616631 DMS87UT DI DMS87UT DMS87UT DN CD19-targeted CAR-T cells DMS87UT TI TTW640A DMS87UT TN B-lymphocyte surface antigen B4 (CD19) DMS87UT MA CAR-T-Cell-Therapy DMS87UT RN ClinicalTrials.gov (NCT02728882) Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma DMS87UT RU https://clinicaltrials.gov/ct2/show/NCT02728882 DMSRK2A DI DMSRK2A DMSRK2A DN UK-356202 DMSRK2A TI TTGY7WI DMSRK2A TN Urokinase-type plasminogen activator (PLAU) DMSRK2A MA Inhibitor DMSRK2A RN Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. DMSRK2A RU https://pubmed.ncbi.nlm.nih.gov/15149680 DMUEQ6C DI DMUEQ6C DMUEQ6C DN CART-meso cells DMUEQ6C TI TT4RXME DMUEQ6C TN Mesothelin (MSLN) DMUEQ6C MA CAR-T-Cell-Therapy DMUEQ6C RN ClinicalTrials.gov (NCT03638193) Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer DMUEQ6C RU https://clinicaltrials.gov/ct2/show/NCT03638193 DMV6RMB DI DMV6RMB DMV6RMB DN EPCAM-targeted CAR-T cells DMV6RMB TI TTZ8WH4 DMV6RMB TN Tumor-associated calcium signal transducer 1 (EPCAM) DMV6RMB MA CAR-T-Cell-Therapy DMV6RMB RN ClinicalTrials.gov (NCT02725125) Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer DMV6RMB RU https://clinicaltrials.gov/ct2/show/NCT02725125 DMW15TC DI DMW15TC DMW15TC DN methyl 5-[(4-tert-butylbenzoyl)amino]-2H-1,2,4-triazole-3-carboxylate DMW15TC TI TTRJSMV DMW15TC TN Factor XII messenger RNA (FA12 mRNA) DMW15TC MA Inhibitor DMW15TC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2361). DMW15TC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2361 DMWA5XP DI DMWA5XP DMWA5XP DN KU-60019 DMWA5XP TI TTKBM7V DMWA5XP TN ATM serine/threonine kinase (ATM) DMWA5XP MA Inhibitor DMWA5XP RN Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902. DMWA5XP RU https://pubmed.ncbi.nlm.nih.gov/19808981 DMWXGRQ DI DMWXGRQ DMWXGRQ DN BCMA-UCART DMWXGRQ TI TTZ3P4W DMWXGRQ TN B-cell maturation protein (TNFRSF17) DMWXGRQ MA CAR-T-Cell-Therapy DMWXGRQ RN ClinicalTrials.gov (NCT03752541) Efficacy and Safety Evaluation of BCMA-UCART DMWXGRQ RU https://clinicaltrials.gov/ct2/show/NCT03752541 DMX1IZ9 DI DMX1IZ9 DMX1IZ9 DN PMID23981898C11d DMX1IZ9 TI TT8JRS7 DMX1IZ9 TN Beta-secretase (BACE) DMX1IZ9 MA Inhibitor DMX1IZ9 RN Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective beta-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid beta-peptides. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5300-6. DMX1IZ9 RU https://pubmed.ncbi.nlm.nih.gov/23981898 DMX1ZQV DI DMX1ZQV DMX1ZQV DN (S)-DRF-1042 DMX1ZQV TI TTGTQHC DMX1ZQV TN DNA topoisomerase I (TOP1) DMX1ZQV MA Inhibitor DMX1ZQV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMX1ZQV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMXE0F2 DI DMXE0F2 DMXE0F2 DN PMID10498202C1 DMXE0F2 TI TTPT2QI DMXE0F2 TN Cathepsin D (CTSD) DMXE0F2 MA Inhibitor DMXE0F2 RN Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6. DMXE0F2 RU https://pubmed.ncbi.nlm.nih.gov/10498202 DMXFI90 DI DMXFI90 DMXFI90 DN oxazine 89 DMXFI90 TI TT8JRS7 DMXFI90 TN Beta-secretase (BACE) DMXFI90 MA Inhibitor DMXFI90 RN beta-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem. 2013 May 23;56(10):3980-95. DMXFI90 RU https://pubmed.ncbi.nlm.nih.gov/23590342 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT8SJGB DMXM19W TN Cyclic nucleotide-gated channel alpha-2 (CNGA2) DMXM19W MA Blocker (channel blocker) DMXM19W RN State-dependent block of CNG channels by dequalinium. J Gen Physiol. 2004 Mar;123(3):295-304. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/14981138 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TTHIQMC DMXM19W TN Cyclic nucleotide-gated channel alpha-1 (CNGA1) DMXM19W MA Blocker (channel blocker) DMXM19W RN Dequalinium: a novel, high-affinity blocker of CNGA1 channels. J Gen Physiol. 2003 Jan;121(1):37-47. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/12508052 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT9R6BE DMXM19W TN Calcium-activated potassium channel KCa2.1 (KCNN1) DMXM19W MA Blocker (channel blocker) DMXM19W RN Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/10696100 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT9JH25 DMXM19W TN Calcium-activated potassium channel KCa2.3 (KCNN3) DMXM19W MA Blocker (channel blocker) DMXM19W RN Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/11369031 DMXM19W DI DMXM19W DMXM19W DN dequalinium DMXM19W TI TT2T5M0 DMXM19W TN Calcium-activated potassium channel KCa2.2 (KCNN2) DMXM19W MA Blocker (channel blocker) DMXM19W RN Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol. 2000 Jul 28;401(1):1-7. DMXM19W RU https://pubmed.ncbi.nlm.nih.gov/10915830 DMXU2D1 DI DMXU2D1 DMXU2D1 DN CAR-CD19 T cell DMXU2D1 TI TTW640A DMXU2D1 TN B-lymphocyte surface antigen B4 (CD19) DMXU2D1 MA CAR-T-Cell-Therapy DMXU2D1 RN ClinicalTrials.gov (NCT03302403) Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors DMXU2D1 RU https://clinicaltrials.gov/ct2/show/NCT03302403 DMZO6CV DI DMZO6CV DMZO6CV DN tiratricol DMZO6CV TI TTTSEPU DMZO6CV TN Thyroid hormone receptor alpha (THRA) DMZO6CV MA Agonist DMZO6CV RN Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34. DMZO6CV RU https://pubmed.ncbi.nlm.nih.gov/2158622 DMZO6CV DI DMZO6CV DMZO6CV DN tiratricol DMZO6CV TI TTGER3L DMZO6CV TN Thyroid hormone receptor beta (THRB) DMZO6CV MA Agonist DMZO6CV RN Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34. DMZO6CV RU https://pubmed.ncbi.nlm.nih.gov/2158622 DM01DG4 DI DM01DG4 DM01DG4 DN Isoxazoline derivative 4 DM01DG4 TI TTDP1UC DM01DG4 TN Fatty acid amide hydrolase (FAAH) DM01DG4 MA Inhibitor DM01DG4 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM01DG4 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM01FD3 DI DM01FD3 DM01FD3 DN Isoxazole-based bicyclic compound 19 DM01FD3 TI TTE4BSY DM01FD3 TN Bromodomain and extraterminal domain protein (BET) DM01FD3 MA Inhibitor DM01FD3 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM01FD3 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM01GEB DI DM01GEB DM01GEB DN Pyrrolidinyl urea derivative 6 DM01GEB TI TTTDVOJ DM01GEB TN Tropomyosin-related kinase A (TrkA) DM01GEB MA Inhibitor DM01GEB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM01GEB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM01GVE DI DM01GVE DM01GVE DN PMID26651364-Compound-5a DM01GVE TI TTTCRU2 DM01GVE TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM01GVE MA Antagonist DM01GVE RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM01GVE RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM01IWV DI DM01IWV DM01IWV DN PMID26651364-Compound-109 DM01IWV TI TTTCRU2 DM01IWV TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM01IWV MA Antagonist DM01IWV RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM01IWV RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM01RXU DI DM01RXU DM01RXU DN Imidazo bicyclic iminium derivative 1 DM01RXU TI TTJOMH6 DM01RXU TN Zinc finger protein GLI1 (Gli1) DM01RXU MA Inhibitor DM01RXU RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM01RXU RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM02D1B DI DM02D1B DM02D1B DN PMID25666693-Compound-29 DM02D1B TI TTMI6F5 DM02D1B TN Transient receptor potential cation channel V1 (TRPV1) DM02D1B MA Antagonist DM02D1B RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM02D1B RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM02J8N DI DM02J8N DM02J8N DN Spiroimidazolone derivative 3 DM02J8N TI TT9O6WS DM02J8N TN Glucagon receptor (GCGR) DM02J8N MA Antagonist DM02J8N RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM02J8N RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM02O5V DI DM02O5V DM02O5V DN PMID25666693-Compound-113 DM02O5V TI TTMI6F5 DM02O5V TN Transient receptor potential cation channel V1 (TRPV1) DM02O5V MA Antagonist DM02O5V RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM02O5V RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM02RQ4 DI DM02RQ4 DM02RQ4 DN N-acylpiperidine ether derivative 2 DM02RQ4 TI TTTDVOJ DM02RQ4 TN Tropomyosin-related kinase A (TrkA) DM02RQ4 MA Inhibitor DM02RQ4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM02RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TTCY4SB DM02V5Q TN Aurora kinase (AURK) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TTIDAPM DM02V5Q TN ERK activator kinase 1 (MEK1) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TTTU902 DM02V5Q TN Checkpoint kinase-1 (CHK1) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02V5Q DI DM02V5Q DM02V5Q DN Diamidothiazole derivative 1 DM02V5Q TI TT7HF4W DM02V5Q TN Cyclin-dependent kinase 2 (CDK2) DM02V5Q MA Inhibitor DM02V5Q RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM02V5Q RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM02ZM4 DI DM02ZM4 DM02ZM4 DN Urea and carbamate bioisostere derivative 5 DM02ZM4 TI TTL7C8Q DM02ZM4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM02ZM4 MA Inhibitor DM02ZM4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM02ZM4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM031RU DI DM031RU DM031RU DN Resorcinol compound 7 DM031RU TI TTULVH8 DM031RU TN Tyrosinase (TYR) DM031RU MA Inhibitor DM031RU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM031RU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM031YW DI DM031YW DM031YW DN Quinoxaline derivative 2 DM031YW TI TTSXVID DM031YW TN Nuclear factor NF-kappa-B (NFKB) DM031YW MA Inhibitor DM031YW RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM031YW RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM03UK2 DI DM03UK2 DM03UK2 DN PMID25482888-Compound-6 DM03UK2 TI TTDIGC1 DM03UK2 TN Dipeptidyl peptidase 4 (DPP-4) DM03UK2 MA Inhibitor DM03UK2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM03UK2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM048C1 DI DM048C1 DM048C1 DN PMID25747044-Compound-miRNA DM048C1 TI TTLUW5B DM048C1 TN Laminin receptor 37/67kDa (LRP/LR) DM048C1 MA Inhibitor DM048C1 RN Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease.Expert Opin Ther Pat. 2015 May;25(5):567-82. DM048C1 RU https://www.ncbi.nlm.nih.gov/pubmed/25747044 DM04ZJ2 DI DM04ZJ2 DM04ZJ2 DN Alkyl mannoside derivative 5 DM04ZJ2 TI TTTCRU2 DM04ZJ2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM04ZJ2 MA Antagonist DM04ZJ2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM04ZJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM05D48 DI DM05D48 DM05D48 DN PMID25666693-Compound-77 DM05D48 TI TTMI6F5 DM05D48 TN Transient receptor potential cation channel V1 (TRPV1) DM05D48 MA Antagonist DM05D48 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM05D48 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM05S2X DI DM05S2X DM05S2X DN Pyrazole and benzimidazole derivative 1 DM05S2X TI TTRZQE3 DM05S2X TN Glycogen synthase kinase-3 alpha (GSK-3A) DM05S2X MA Inhibitor DM05S2X RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM05S2X RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM05V8Q DI DM05V8Q DM05V8Q DN 4-aryl quinol derivative 3 DM05V8Q TI TTR7UJ3 DM05V8Q TN Cytoplasmic thioredoxin reductase (TXNRD1) DM05V8Q MA Inhibitor DM05V8Q RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM05V8Q RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM05VO6 DI DM05VO6 DM05VO6 DN Thiazolidine derivative 1 DM05VO6 TI TTULVH8 DM05VO6 TN Tyrosinase (TYR) DM05VO6 MA Inhibitor DM05VO6 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM05VO6 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM05WXD DI DM05WXD DM05WXD DN 2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD TI TTXNCBV DM05WXD TN Tryptophan 2,3-dioxygenase (TDO) DM05WXD MA Inhibitor DM05WXD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM05WXD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM05WXD DI DM05WXD DM05WXD DN 2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD TI TTALN9W DM05WXD TN Indoleamine 2,3-dioxygenase 2 (IDO2) DM05WXD MA Inhibitor DM05WXD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM05WXD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM05WXD DI DM05WXD DM05WXD DN 2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD TI TTZJYKH DM05WXD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM05WXD MA Inhibitor DM05WXD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM05WXD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM067UC DI DM067UC DM067UC DN Piperazine carbamate/urea derivative 7 DM067UC TI TT9JNIC DM067UC TN Histamine H3 receptor (H3R) DM067UC MA Ligand DM067UC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM067UC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM06IWA DI DM06IWA DM06IWA DN PMID25666693-Compound-161 DM06IWA TI TTMI6F5 DM06IWA TN Transient receptor potential cation channel V1 (TRPV1) DM06IWA MA Antagonist DM06IWA RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM06IWA RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM06LDV DI DM06LDV DM06LDV DN PMID25656651-Compound-28a DM06LDV TI TT3PJMV DM06LDV TN Tyrosine-protein kinase ABL1 (ABL) DM06LDV MA Inhibitor DM06LDV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM06LDV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM06MJH DI DM06MJH DM06MJH DN Diaryl amine derivative 1 DM06MJH TI TT1LVF2 DM06MJH TN Cyclin-dependent kinase 9 (CDK9) DM06MJH MA Inhibitor DM06MJH RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06MJH RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM06MJH DI DM06MJH DM06MJH DN Diaryl amine derivative 1 DM06MJH TI TT7HF4W DM06MJH TN Cyclin-dependent kinase 2 (CDK2) DM06MJH MA Inhibitor DM06MJH RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06MJH RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM06PX4 DI DM06PX4 DM06PX4 DN PMID30074415-Compound-19 DM06PX4 TI TTUNARX DM06PX4 TN Carbonic anhydrase (CA) DM06PX4 MA Inhibitor DM06PX4 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM06PX4 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM06U3J DI DM06U3J DM06U3J DN Alkyl sulfone derivative 1 DM06U3J TI TT1LVF2 DM06U3J TN Cyclin-dependent kinase 9 (CDK9) DM06U3J MA Inhibitor DM06U3J RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06U3J RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM06U3J DI DM06U3J DM06U3J DN Alkyl sulfone derivative 1 DM06U3J TI TT7HF4W DM06U3J TN Cyclin-dependent kinase 2 (CDK2) DM06U3J MA Inhibitor DM06U3J RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM06U3J RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM07C1I DI DM07C1I DM07C1I DN Phthalazine ketone derivative 2 DM07C1I TI TTVDSZ0 DM07C1I TN Poly [ADP-ribose] polymerase 1 (PARP1) DM07C1I MA Inhibitor DM07C1I RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM07C1I RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM07DC6 DI DM07DC6 DM07DC6 DN PMID26004420-Compound-US20140142115B DM07DC6 TI TTJ13ST DM07DC6 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM07DC6 MA Inhibitor DM07DC6 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM07DC6 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM07GEK DI DM07GEK DM07GEK DN Pyrazolo[1,5-a]pyrimidine derivative 10 DM07GEK TI TT6OEDT DM07GEK TN Cannabinoid receptor 1 (CB1) DM07GEK MA Antagonist DM07GEK RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM07GEK RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM07U5R DI DM07U5R DM07U5R DN PMID29053063-Compound-15 DM07U5R TI TTRQ6UD DM07U5R TN Diacylglycerol lipase alpha (DAGLA) DM07U5R MA Inhibitor DM07U5R RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM07U5R RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM07U5R DI DM07U5R DM07U5R DN PMID29053063-Compound-15 DM07U5R TI TTDP1UC DM07U5R TN Fatty acid amide hydrolase (FAAH) DM07U5R MA Inhibitor DM07U5R RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM07U5R RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM07U5R DI DM07U5R DM07U5R DN PMID29053063-Compound-15 DM07U5R TI TTZ963I DM07U5R TN Monoglyceride lipase (MAGL) DM07U5R MA Inhibitor DM07U5R RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM07U5R RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM08CBJ DI DM08CBJ DM08CBJ DN PMID30107136-Compound-Example51 DM08CBJ TI TT23XQV DM08CBJ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM08CBJ MA Inhibitor DM08CBJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM08CBJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM08OV7 DI DM08OV7 DM08OV7 DN PMID29671355-Compound-72b DM08OV7 TI TTTQGH8 DM08OV7 TN Histone deacetylase 4 (HDAC4) DM08OV7 MA Inhibitor DM08OV7 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM08OV7 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM09FOQ DI DM09FOQ DM09FOQ DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 4 DM09FOQ TI TTV8CRH DM09FOQ TN Lysine-specific demethylase 4C (KDM4C) DM09FOQ MA Inhibitor DM09FOQ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM09FOQ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM09LY3 DI DM09LY3 DM09LY3 DN Cycloalkyl acid derivative 2 DM09LY3 TI TTA592U DM09LY3 TN Urate anion exchanger 1 (URAT1) DM09LY3 MA Inhibitor DM09LY3 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM09LY3 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM0B578 DI DM0B578 DM0B578 DN PMID25666693-Compound-61 DM0B578 TI TTMI6F5 DM0B578 TN Transient receptor potential cation channel V1 (TRPV1) DM0B578 MA Antagonist DM0B578 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0B578 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0B9SP DI DM0B9SP DM0B9SP DN Aryl urea derivative 1 DM0B9SP TI TTDP1UC DM0B9SP TN Fatty acid amide hydrolase (FAAH) DM0B9SP MA Inhibitor DM0B9SP RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM0B9SP RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM0BRNU DI DM0BRNU DM0BRNU DN Polyhydroxy benzamide derivative 2 DM0BRNU TI TTULVH8 DM0BRNU TN Tyrosinase (TYR) DM0BRNU MA Inhibitor DM0BRNU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM0BRNU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM0BTH8 DI DM0BTH8 DM0BTH8 DN Metal complex derivative 2 DM0BTH8 TI TTR7UJ3 DM0BTH8 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM0BTH8 MA Inhibitor DM0BTH8 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM0BTH8 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM0C1ZO DI DM0C1ZO DM0C1ZO DN Aryl cyclopropylamine derivative 4 DM0C1ZO TI TTNR0UQ DM0C1ZO TN Lysine-specific histone demethylase 1 (LSD) DM0C1ZO MA Inhibitor DM0C1ZO RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM0C1ZO RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM0C48S DI DM0C48S DM0C48S DN Azetidinyl-piperazine derivative 2 DM0C48S TI TTZ963I DM0C48S TN Monoglyceride lipase (MAGL) DM0C48S MA Inhibitor DM0C48S RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM0C48S RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM0C9YL DI DM0C9YL DM0C9YL DN PMID25656651-Compound-15a DM0C9YL TI TTS7G69 DM0C9YL TN Fusion protein Bcr-Abl (Bcr-Abl) DM0C9YL MA Inhibitor DM0C9YL RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0C9YL RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0CEJM DI DM0CEJM DM0CEJM DN Antibodie derivative 8 DM0CEJM TI TTOHSBA DM0CEJM TN Vascular endothelial growth factor A (VEGFA) DM0CEJM MA Disrupter DM0CEJM RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM0CEJM RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM0D3HU DI DM0D3HU DM0D3HU DN Dihydrothieno [2,3-e]indazole derivative 2 DM0D3HU TI TTRPDBG DM0D3HU TN Inhibitor of nuclear factor kappa-B kinase (IKK) DM0D3HU MA Inhibitor DM0D3HU RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM0D3HU RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM0DAR1 DI DM0DAR1 DM0DAR1 DN PMID29324067-Compound-25 DM0DAR1 TI TT3WG5C DM0DAR1 TN Monoamine oxidase type A (MAO-A) DM0DAR1 MA Inhibitor DM0DAR1 RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM0DAR1 RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM0DYAU DI DM0DYAU DM0DYAU DN 3-(6-allyloxy-2-naphthyl)-1-(4-piperidylmethyl)pyrazolo[3,4-d]pyrimidin-4-amine DM0DYAU TI TT42OGM DM0DYAU TN Hematopoietic cell kinase (HCK) DM0DYAU MA Inhibitor DM0DYAU RN Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037. DM0DYAU RU http://www.freepatentsonline.com/US9765037.html DM0E38G DI DM0E38G DM0E38G DN Flavonoid derivative 6 DM0E38G TI TTV8CRH DM0E38G TN Lysine-specific demethylase 4C (KDM4C) DM0E38G MA Inhibitor DM0E38G RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM0E38G RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM0E8YF DI DM0E8YF DM0E8YF DN Azole benzene derivative 1 DM0E8YF TI TT7RJY8 DM0E8YF TN Xanthine dehydrogenase/oxidase (XDH) DM0E8YF MA Inhibitor DM0E8YF RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM0E8YF RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM0EBS8 DI DM0EBS8 DM0EBS8 DN Carbamoyl oxime derivative 1 DM0EBS8 TI TTGX13H DM0EBS8 TN Fatty-acid amide hydrolase 1 (FAAH1) DM0EBS8 MA Inhibitor DM0EBS8 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM0EBS8 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM0ECWR DI DM0ECWR DM0ECWR DN Octahydro-pyrrolo[3,4-c]-pyrrole derivative 1 DM0ECWR TI TTSCIM2 DM0ECWR TN Extracellular lysophospholipase D (E-NPP2) DM0ECWR MA Inhibitor DM0ECWR RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM0ECWR RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM0ENF3 DI DM0ENF3 DM0ENF3 DN Oxindole derivative 3 DM0ENF3 TI TT6AXLY DM0ENF3 TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DM0ENF3 MA Inhibitor DM0ENF3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM0ENF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM0ENF3 DI DM0ENF3 DM0ENF3 DN Oxindole derivative 3 DM0ENF3 TI TTK0FEA DM0ENF3 TN Leucine-rich repeat kinase 2 (LRRK2) DM0ENF3 MA Inhibitor DM0ENF3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM0ENF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM0EYON DI DM0EYON DM0EYON DN PMID25666693-Compound-148 DM0EYON TI TTMI6F5 DM0EYON TN Transient receptor potential cation channel V1 (TRPV1) DM0EYON MA Antagonist DM0EYON RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0EYON RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0F6VU DI DM0F6VU DM0F6VU DN PMID27607364-Compound-162 DM0F6VU TI TTPTXIN DM0F6VU TN Translocator protein (TSPO) DM0F6VU MA Ligand DM0F6VU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM0F6VU RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM0FPMV DI DM0FPMV DM0FPMV DN Pyrazolo[1,5-a]pyrimidine derivative 1 DM0FPMV TI TT6OEDT DM0FPMV TN Cannabinoid receptor 1 (CB1) DM0FPMV MA Antagonist DM0FPMV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0FPMV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0FSPQ DI DM0FSPQ DM0FSPQ DN Aryl mannoside derivative 17 DM0FSPQ TI TTTCRU2 DM0FSPQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0FSPQ MA Antagonist DM0FSPQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0FSPQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0G8XP DI DM0G8XP DM0G8XP DN Beta-phe compound 3 DM0G8XP TI TTDIGC1 DM0G8XP TN Dipeptidyl peptidase 4 (DPP-4) DM0G8XP MA Inhibitor DM0G8XP RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM0G8XP RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM0GCTY DI DM0GCTY DM0GCTY DN Piperidine derivative 6 DM0GCTY TI TT9NXW4 DM0GCTY TN Sigma intracellular receptor 2 (TMEM97) DM0GCTY MA Ligand DM0GCTY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0GCTY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0GCTY DI DM0GCTY DM0GCTY DN Piperidine derivative 6 DM0GCTY TI TT5TPI6 DM0GCTY TN Opioid receptor sigma 1 (OPRS1) DM0GCTY MA Ligand DM0GCTY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0GCTY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0GOCZ DI DM0GOCZ DM0GOCZ DN US9340511, 2 DM0GOCZ TI TT9ISBX DM0GOCZ TN HIF-prolyl hydroxylase 2 (HPH-2) DM0GOCZ MA Inhibitor DM0GOCZ RN Process for making isoquinoline compounds. US9708269. DM0GOCZ RU http://www.freepatentsonline.com/US9708269.html DM0GTUH DI DM0GTUH DM0GTUH DN Six-membered heterocyclic benzamide derivative 5 DM0GTUH TI TTTDVOJ DM0GTUH TN Tropomyosin-related kinase A (TrkA) DM0GTUH MA Inhibitor DM0GTUH RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM0GTUH RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM0HIQU DI DM0HIQU DM0HIQU DN 1,2-diamino cyclopentane-based derivative 23 DM0HIQU TI TT9N02I DM0HIQU TN Orexin receptor type 2 (HCRTR2) DM0HIQU MA Antagonist DM0HIQU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM0HIQU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM0HIQU DI DM0HIQU DM0HIQU DN 1,2-diamino cyclopentane-based derivative 23 DM0HIQU TI TT60Q8D DM0HIQU TN Orexin receptor type 1 (HCRTR1) DM0HIQU MA Antagonist DM0HIQU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM0HIQU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM0HOJW DI DM0HOJW DM0HOJW DN Aryl urea derivative 4 DM0HOJW TI TTDP1UC DM0HOJW TN Fatty acid amide hydrolase (FAAH) DM0HOJW MA Inhibitor DM0HOJW RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM0HOJW RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM0HU5O DI DM0HU5O DM0HU5O DN Pyrrolo[2,3-d]pyrimidine derivative 9 DM0HU5O TI TTH6V3D DM0HU5O TN Cyclin-dependent kinase 1 (CDK1) DM0HU5O MA Inhibitor DM0HU5O RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0HU5O RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0HU5O DI DM0HU5O DM0HU5O DN Pyrrolo[2,3-d]pyrimidine derivative 9 DM0HU5O TI TT7HF4W DM0HU5O TN Cyclin-dependent kinase 2 (CDK2) DM0HU5O MA Inhibitor DM0HU5O RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0HU5O RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0HU5O DI DM0HU5O DM0HU5O DN Pyrrolo[2,3-d]pyrimidine derivative 9 DM0HU5O TI TT0PG8F DM0HU5O TN Cyclin-dependent kinase 4 (CDK4) DM0HU5O MA Inhibitor DM0HU5O RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0HU5O RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0I72B DI DM0I72B DM0I72B DN PMID25666693-Compound-44 DM0I72B TI TTMI6F5 DM0I72B TN Transient receptor potential cation channel V1 (TRPV1) DM0I72B MA Antagonist DM0I72B RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0I72B RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0IJYQ DI DM0IJYQ DM0IJYQ DN Azetidinyl-piperidine derivative 1 DM0IJYQ TI TTZ963I DM0IJYQ TN Monoglyceride lipase (MAGL) DM0IJYQ MA Inhibitor DM0IJYQ RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM0IJYQ RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM0IRPO DI DM0IRPO DM0IRPO DN Carbamide derivative 23 DM0IRPO TI TTOHSBA DM0IRPO TN Vascular endothelial growth factor A (VEGFA) DM0IRPO MA Inhibitor DM0IRPO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM0IRPO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM0IZW8 DI DM0IZW8 DM0IZW8 DN Cyclopropyl-spiro piperidine derivative 3 DM0IZW8 TI TT4G2JS DM0IZW8 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM0IZW8 MA Blocker DM0IZW8 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM0IZW8 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM0J2TE DI DM0J2TE DM0J2TE DN Piperidinyl triazole derivative 3 DM0J2TE TI TTTJZ4M DM0J2TE TN Prolylcarboxypeptidase (PRCP) DM0J2TE MA Inhibitor DM0J2TE RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM0J2TE RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM0JSOZ DI DM0JSOZ DM0JSOZ DN PMID26924192-Compound-32 DM0JSOZ TI TTRA6BO DM0JSOZ TN Bromodomain-containing protein 4 (BRD4) DM0JSOZ MA Inhibitor DM0JSOZ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM0JSOZ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM0JSOZ DI DM0JSOZ DM0JSOZ DN PMID26924192-Compound-32 DM0JSOZ TI TTU6FSC DM0JSOZ TN Extracellular signal-regulated kinase 5 (ERK5) DM0JSOZ MA Inhibitor DM0JSOZ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM0JSOZ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM0JYWT DI DM0JYWT DM0JYWT DN Tricyclic pyrrolidine derivative 4 DM0JYWT TI TTWJBZ5 DM0JYWT TN 5-HT 2C receptor (HTR2C) DM0JYWT MA Agonist DM0JYWT RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM0JYWT RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM0K4XE DI DM0K4XE DM0K4XE DN PMID25399762-Compound-Figure1-Chukrasone B DM0K4XE TI TT3WG5C DM0K4XE TN Monoamine oxidase type A (MAO-A) DM0K4XE MA Inhibitor DM0K4XE RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM0K4XE RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM0K5Q1 DI DM0K5Q1 DM0K5Q1 DN Peptide analog 15 DM0K5Q1 TI TTSJMN8 DM0K5Q1 TN Immunoproteasome complex (IP) DM0K5Q1 MA Inhibitor DM0K5Q1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0K5Q1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0K62M DI DM0K62M DM0K62M DN Cyclic hydroxamate derivative 1 DM0K62M TI TTZJYKH DM0K62M TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM0K62M MA Inhibitor DM0K62M RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM0K62M RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM0KPQ9 DI DM0KPQ9 DM0KPQ9 DN PMID28394193-Compound-51 DM0KPQ9 TI TT9MZCQ DM0KPQ9 TN Enhancer of zeste homolog 2 (EZH2) DM0KPQ9 MA Inhibitor DM0KPQ9 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM0KPQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM0KR8E DI DM0KR8E DM0KR8E DN PMID27841045-Compound-136 DM0KR8E TI TT7RJY8 DM0KR8E TN Xanthine dehydrogenase/oxidase (XDH) DM0KR8E MA Inhibitor DM0KR8E RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM0KR8E RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM0L68P DI DM0L68P DM0L68P DN PMID27215781-Compound-37 DM0L68P TI TTMSFAW DM0L68P TN Cannabinoid receptor 2 (CB2) DM0L68P RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM0L68P RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM0L68P DI DM0L68P DM0L68P DN PMID27215781-Compound-37 DM0L68P TI TT6OEDT DM0L68P TN Cannabinoid receptor 1 (CB1) DM0L68P RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM0L68P RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM0LB21 DI DM0LB21 DM0LB21 DN PMID27977313-Compound-39 DM0LB21 TI TTR7UJ3 DM0LB21 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM0LB21 MA Inhibitor DM0LB21 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM0LB21 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM0LGTY DI DM0LGTY DM0LGTY DN PMID27998201-Compound-6 DM0LGTY TI TT36ETB DM0LGTY TN Cathepsin L (CTSL) DM0LGTY MA Inhibitor DM0LGTY RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM0LGTY RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM0LGTY DI DM0LGTY DM0LGTY DN PMID27998201-Compound-6 DM0LGTY TI TTUMQVO DM0LGTY TN Cathepsin S (CTSS) DM0LGTY MA Inhibitor DM0LGTY RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM0LGTY RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TTOUSTQ DM0LXT2 TN Proteasome beta-9 (PS beta-9) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TT8EPLT DM0LXT2 TN Proteasome beta-1 (PS beta-1) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TT68GPI DM0LXT2 TN Proteasome beta-5 (PS beta-5) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0LXT2 DI DM0LXT2 DM0LXT2 DN PMID29865878-Compound-51 DM0LXT2 TI TTEAD9J DM0LXT2 TN Proteasome beta-8 (PS beta-8) DM0LXT2 MA Inhibitor DM0LXT2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM0LXT2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM0MEXT DI DM0MEXT DM0MEXT DN PMID25666693-Compound-46 DM0MEXT TI TTMI6F5 DM0MEXT TN Transient receptor potential cation channel V1 (TRPV1) DM0MEXT MA Antagonist DM0MEXT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0MEXT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0MLI9 DI DM0MLI9 DM0MLI9 DN Quinoline derivative 19 DM0MLI9 TI TTSCO7R DM0MLI9 TN NAD-dependent deacetylase sirtuin (SIRT) DM0MLI9 MA Inhibitor DM0MLI9 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM0MLI9 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM0NEVC DI DM0NEVC DM0NEVC DN Indole-based analog 2 DM0NEVC TI TTU1E82 DM0NEVC TN Apoptosis regulator Bcl-xL (BCL-xL) DM0NEVC MA Inhibitor DM0NEVC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM0NEVC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM0NEVC DI DM0NEVC DM0NEVC DN Indole-based analog 2 DM0NEVC TI TTJGNVC DM0NEVC TN Apoptosis regulator Bcl-2 (BCL-2) DM0NEVC MA Inhibitor DM0NEVC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM0NEVC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM0NEVC DI DM0NEVC DM0NEVC DN Indole-based analog 2 DM0NEVC TI TTL53M6 DM0NEVC TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM0NEVC MA Inhibitor DM0NEVC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM0NEVC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM0NIB5 DI DM0NIB5 DM0NIB5 DN US9359293, TM DM0NIB5 TI TTLKF5M DM0NIB5 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DM0NIB5 MA Inhibitor DM0NIB5 RN Methods of treatment using modulators of SIRT2. US9359293. DM0NIB5 RU http://www.freepatentsonline.com/US9359293.html DM0NJFZ DI DM0NJFZ DM0NJFZ DN Aminocyclopentenone compound 6 DM0NJFZ TI TTRA6BO DM0NJFZ TN Bromodomain-containing protein 4 (BRD4) DM0NJFZ MA Inhibitor DM0NJFZ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM0NJFZ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM0NM1Y DI DM0NM1Y DM0NM1Y DN PMID26666989-Compound-Figure9left01 DM0NM1Y TI TT8BUGW DM0NM1Y TN Glycogen phosphorylase (PYG) DM0NM1Y MA Inhibitor DM0NM1Y RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM0NM1Y RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM0NYK3 DI DM0NYK3 DM0NYK3 DN PMID27321640-Compound-58 DM0NYK3 TI TTJW4LU DM0NYK3 TN Phosphodiesterase 10A (PDE10) DM0NYK3 MA Inhibitor DM0NYK3 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM0NYK3 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM0NYK3 DI DM0NYK3 DM0NYK3 DN PMID27321640-Compound-58 DM0NYK3 TI TTJGW1Z DM0NYK3 TN Phosphodiesterase 2A (PDE2A) DM0NYK3 MA Inhibitor DM0NYK3 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM0NYK3 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM0O18N DI DM0O18N DM0O18N DN PMID28766366-Compound-Scheme9EHT5372 DM0O18N TI TTYGQ8A DM0O18N TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM0O18N MA Inhibitor DM0O18N RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM0O18N RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM0O18N DI DM0O18N DM0O18N DN PMID28766366-Compound-Scheme9EHT5372 DM0O18N TI TTSBVFO DM0O18N TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM0O18N MA Inhibitor DM0O18N RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM0O18N RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM0O4WR DI DM0O4WR DM0O4WR DN Pyrazolo[1,5-a]pyrimidine derivative 11 DM0O4WR TI TT6OEDT DM0O4WR TN Cannabinoid receptor 1 (CB1) DM0O4WR MA Antagonist DM0O4WR RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0O4WR RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0O8WS DI DM0O8WS DM0O8WS DN US8987457, 198 DM0O8WS TI TTCGOIN DM0O8WS TN PIM-3 protein kinase (PIM3) DM0O8WS MA Inhibitor DM0O8WS RN Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457. DM0O8WS RU http://www.freepatentsonline.com/US8987457.html DM0OBAW DI DM0OBAW DM0OBAW DN PMID25470667-Compound-PF-04620110 DM0OBAW TI TTF8P9I DM0OBAW TN Diacylglycerol acyltransferase 1 (DGAT1) DM0OBAW MA Inhibitor DM0OBAW RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM0OBAW RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM0OMAL DI DM0OMAL DM0OMAL DN N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 DM0OMAL TI TTT7PJU DM0OMAL TN Janus kinase 3 (JAK-3) DM0OMAL MA Inhibitor DM0OMAL RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM0OMAL RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM0OMAL DI DM0OMAL DM0OMAL DN N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 DM0OMAL TI TT6DM01 DM0OMAL TN Janus kinase 1 (JAK-1) DM0OMAL MA Inhibitor DM0OMAL RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM0OMAL RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM0OMAL DI DM0OMAL DM0OMAL DN N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 DM0OMAL TI TTRMX3V DM0OMAL TN Janus kinase 2 (JAK-2) DM0OMAL MA Inhibitor DM0OMAL RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM0OMAL RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM0OMBW DI DM0OMBW DM0OMBW DN Cyclopropane 1-carboxylic acid derivative 6 DM0OMBW TI TTIY56R DM0OMBW TN Kynurenine 3-hydroxylase (KMO) DM0OMBW MA Inhibitor DM0OMBW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM0OMBW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM0ON7S DI DM0ON7S DM0ON7S DN Macrolactam derivative 1 DM0ON7S TI TTKFVXR DM0ON7S TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM0ON7S MA Inhibitor DM0ON7S RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM0ON7S RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM0OY5D DI DM0OY5D DM0OY5D DN PMID25666693-Compound-102 DM0OY5D TI TTMI6F5 DM0OY5D TN Transient receptor potential cation channel V1 (TRPV1) DM0OY5D MA Antagonist DM0OY5D RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM0OY5D RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM0OYCX DI DM0OYCX DM0OYCX DN Bicyclic heteroaryl amide derivative 3 DM0OYCX TI TT473XN DM0OYCX TN P2X purinoceptor 7 (P2RX7) DM0OYCX MA Antagonist DM0OYCX RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM0OYCX RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM0P2U3 DI DM0P2U3 DM0P2U3 DN AKOS003197197 DM0P2U3 TI TTLQUZS DM0P2U3 TN Cystathionine gamma-lyase (CTH) DM0P2U3 MA Inhibitor DM0P2U3 RN Cystathionine--lyase (CSE) inhibitors. US9725426. DM0P2U3 RU http://www.freepatentsonline.com/US9725426.html DM0P4F3 DI DM0P4F3 DM0P4F3 DN PMID25656651-Compound-37a DM0P4F3 TI TTIV39N DM0P4F3 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DM0P4F3 MA Inhibitor DM0P4F3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0P4F3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0P4F3 DI DM0P4F3 DM0P4F3 DN PMID25656651-Compound-37a DM0P4F3 TI TTS7G69 DM0P4F3 TN Fusion protein Bcr-Abl (Bcr-Abl) DM0P4F3 MA Inhibitor DM0P4F3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0P4F3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0P4TA DI DM0P4TA DM0P4TA DN PMID26004420-Compound-US20140309213B DM0P4TA TI TTJ13ST DM0P4TA TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM0P4TA MA Inhibitor DM0P4TA RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM0P4TA RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM0PBJT DI DM0PBJT DM0PBJT DN Phenoxypiperidine derivative 1 DM0PBJT TI TT9JNIC DM0PBJT TN Histamine H3 receptor (H3R) DM0PBJT RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM0PBJT RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM0Q37R DI DM0Q37R DM0Q37R DN PMID25991433-Compound-H1 DM0Q37R TI TT0K6EO DM0Q37R TN Stress-activated protein kinase JNK1 (JNK1) DM0Q37R MA Inhibitor DM0Q37R RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM0Q37R RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM0Q3HF DI DM0Q3HF DM0Q3HF DN Thiazole carboxamide derivative 11 DM0Q3HF TI TTCZOF2 DM0Q3HF TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM0Q3HF MA Inhibitor DM0Q3HF RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM0Q3HF RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM0Q9VY DI DM0Q9VY DM0Q9VY DN Triazolo-pyridine derivative 1 DM0Q9VY TI TT6DM01 DM0Q9VY TN Janus kinase 1 (JAK-1) DM0Q9VY MA Inhibitor DM0Q9VY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM0Q9VY RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM0Q9VY DI DM0Q9VY DM0Q9VY DN Triazolo-pyridine derivative 1 DM0Q9VY TI TTRMX3V DM0Q9VY TN Janus kinase 2 (JAK-2) DM0Q9VY MA Inhibitor DM0Q9VY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM0Q9VY RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM0QHLK DI DM0QHLK DM0QHLK DN PMID28270010-Compound-Figure24-b DM0QHLK TI TTXABCW DM0QHLK TN NT-3 growth factor receptor (TrkC) DM0QHLK MA Inhibitor DM0QHLK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM0QHLK RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM0QHLK DI DM0QHLK DM0QHLK DN PMID28270010-Compound-Figure24-b DM0QHLK TI TTTDVOJ DM0QHLK TN Tropomyosin-related kinase A (TrkA) DM0QHLK MA Inhibitor DM0QHLK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM0QHLK RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM0QHLK DI DM0QHLK DM0QHLK DN PMID28270010-Compound-Figure24-b DM0QHLK TI TTKN7QR DM0QHLK TN BDNF/NT-3 growth factors receptor (TrkB) DM0QHLK MA Inhibitor DM0QHLK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM0QHLK RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM0R5Y8 DI DM0R5Y8 DM0R5Y8 DN PMID27109571-Compound-21 DM0R5Y8 TI TTNT2S6 DM0R5Y8 TN Fatty acid-binding protein 5 (FABP5) DM0R5Y8 MA Inhibitor DM0R5Y8 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM0R5Y8 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM0R5Y8 DI DM0R5Y8 DM0R5Y8 DN PMID27109571-Compound-21 DM0R5Y8 TI TTHWMFZ DM0R5Y8 TN Fatty acid-binding protein 4 (FABP4) DM0R5Y8 MA Inhibitor DM0R5Y8 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM0R5Y8 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM0R653 DI DM0R653 DM0R653 DN Phenylpropylamine derivative 4 DM0R653 TI TT5TPI6 DM0R653 TN Opioid receptor sigma 1 (OPRS1) DM0R653 MA Ligand DM0R653 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0R653 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0RAC6 DI DM0RAC6 DM0RAC6 DN Benzo[d]oxazole derivative 4 DM0RAC6 TI TTA6ZN2 DM0RAC6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM0RAC6 MA Inhibitor DM0RAC6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM0RAC6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM0RAPC DI DM0RAPC DM0RAPC DN US10030004, Compound 19 DM0RAPC TI TTPKHTZ DM0RAPC TN Activin receptor type IB (ACVR1B) DM0RAPC MA Inhibitor DM0RAPC RN Compounds and methods of use. US10030004. DM0RAPC RU http://www.freepatentsonline.com/US10030004.html DM0RC1Z DI DM0RC1Z DM0RC1Z DN Pyrrole derivative 1 DM0RC1Z TI TT6OEDT DM0RC1Z TN Cannabinoid receptor 1 (CB1) DM0RC1Z MA Antagonist DM0RC1Z RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0RC1Z RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0RI7F DI DM0RI7F DM0RI7F DN Palbociclib/ribociclib analog 1 DM0RI7F TI TT7HF4W DM0RI7F TN Cyclin-dependent kinase 2 (CDK2) DM0RI7F MA Inhibitor DM0RI7F RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0RI7F RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0RI7F DI DM0RI7F DM0RI7F DN Palbociclib/ribociclib analog 1 DM0RI7F TI TT0PG8F DM0RI7F TN Cyclin-dependent kinase 4 (CDK4) DM0RI7F MA Inhibitor DM0RI7F RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM0RI7F RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM0S2UK DI DM0S2UK DM0S2UK DN US9422240, 1-286 DM0S2UK TI TT9ISBX DM0S2UK TN HIF-prolyl hydroxylase 2 (HPH-2) DM0S2UK MA Inhibitor DM0S2UK RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DM0S2UK RU http://www.freepatentsonline.com/US9422240.html DM0SOKJ DI DM0SOKJ DM0SOKJ DN Imidazole benzamide derivative 1 DM0SOKJ TI TTYLQ8V DM0SOKJ TN Prostaglandin E synthase (PTGES) DM0SOKJ MA Inhibitor DM0SOKJ RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM0SOKJ RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM0SY7Q DI DM0SY7Q DM0SY7Q DN PMID29649907-Compound-30 DM0SY7Q TI TTS4UGC DM0SY7Q TN Farnesoid X-activated receptor (FXR) DM0SY7Q MA Agonist DM0SY7Q RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM0SY7Q RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM0TKP2 DI DM0TKP2 DM0TKP2 DN Benzene sulfonamide derivative 7 DM0TKP2 TI TTIY56R DM0TKP2 TN Kynurenine 3-hydroxylase (KMO) DM0TKP2 MA Inhibitor DM0TKP2 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM0TKP2 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM0TURE DI DM0TURE DM0TURE DN Indandione derivative 3 DM0TURE TI TTV1C0Z DM0TURE TN Neuropeptide S receptor (NPSR) DM0TURE MA Antagonist DM0TURE RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM0TURE RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM0U7P9 DI DM0U7P9 DM0U7P9 DN Mannoside derivative 13 DM0U7P9 TI TTTCRU2 DM0U7P9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0U7P9 MA Antagonist DM0U7P9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0U7P9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0UWNY DI DM0UWNY DM0UWNY DN Benzamide derivative 2 DM0UWNY TI TT9NXW4 DM0UWNY TN Sigma intracellular receptor 2 (TMEM97) DM0UWNY MA Ligand DM0UWNY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM0UWNY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TT5ZKDI DM0VBMI TN Histone deacetylase 6 (HDAC6) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTT6LFV DM0VBMI TN Histone deacetylase 8 (HDAC8) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTTQGH8 DM0VBMI TN Histone deacetylase 4 (HDAC4) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TT6R7JZ DM0VBMI TN Histone deacetylase 1 (HDAC1) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTYHPU6 DM0VBMI TN Histone deacetylase 10 (HDAC10) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTMUEK1 DM0VBMI TN Histone deacetylase 7 (HDAC7) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TTSHTOI DM0VBMI TN Histone deacetylase 2 (HDAC2) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VBMI DI DM0VBMI DM0VBMI DN PMID29671355-Compound-56 DM0VBMI TI TT4YWTO DM0VBMI TN Histone deacetylase 3 (HDAC3) DM0VBMI MA Inhibitor DM0VBMI RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM0VBMI RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM0VEBI DI DM0VEBI DM0VEBI DN 6,6-fused nitrogenous heterocyclic compound 1 DM0VEBI TI TT3PJMV DM0VEBI TN Tyrosine-protein kinase ABL1 (ABL) DM0VEBI MA Inhibitor DM0VEBI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM0VEBI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM0VOY9 DI DM0VOY9 DM0VOY9 DN Pyridotriazolopyrimidine derivative 2 DM0VOY9 TI TT6OEDT DM0VOY9 TN Cannabinoid receptor 1 (CB1) DM0VOY9 MA Antagonist DM0VOY9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM0VOY9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM0VR23 DI DM0VR23 DM0VR23 DN Biphenyl mannoside derivative 4 DM0VR23 TI TTTCRU2 DM0VR23 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0VR23 MA Antagonist DM0VR23 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0VR23 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0W5UA DI DM0W5UA DM0W5UA DN PMID25482888-Compound-18 DM0W5UA TI TTDIGC1 DM0W5UA TN Dipeptidyl peptidase 4 (DPP-4) DM0W5UA MA Inhibitor DM0W5UA RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM0W5UA RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM0WBM3 DI DM0WBM3 DM0WBM3 DN 3-(phenoxymethyl) benzylamine derivative 6 DM0WBM3 TI TTULVH8 DM0WBM3 TN Tyrosinase (TYR) DM0WBM3 MA Inhibitor DM0WBM3 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM0WBM3 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM0XA3D DI DM0XA3D DM0XA3D DN PMID29338548-Compound-18 DM0XA3D TI TTHJTF7 DM0XA3D TN Glycine transporter GlyT-1 (SLC6A9) DM0XA3D MA Inhibitor DM0XA3D RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM0XA3D RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM0XVQY DI DM0XVQY DM0XVQY DN Quinazolinone derivative 2 DM0XVQY TI TTL7C8Q DM0XVQY TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM0XVQY MA Inhibitor DM0XVQY RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM0XVQY RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM0Y4X8 DI DM0Y4X8 DM0Y4X8 DN Imidazo bicyclic iminium derivative 7 DM0Y4X8 TI TT8J1S3 DM0Y4X8 TN Smoothened homolog (SMO) DM0Y4X8 MA Inhibitor DM0Y4X8 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM0Y4X8 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM0Y5NU DI DM0Y5NU DM0Y5NU DN PMID27539678-Compound-9 DM0Y5NU TI TTOHFIY DM0Y5NU TN Sphingosine kinase 1 (SPHK1) DM0Y5NU MA Inhibitor DM0Y5NU RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DM0Y5NU RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DM0YD3Z DI DM0YD3Z DM0YD3Z DN US8598172, 1 DM0YD3Z TI TT976FS DM0YD3Z TN Polo-like kinase 2 (PLK2) DM0YD3Z MA Inhibitor DM0YD3Z RN Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors. US8598172. DM0YD3Z RU http://www.freepatentsonline.com/US8598172.html DM0YTGS DI DM0YTGS DM0YTGS DN Cyclopropyl-spiro piperidine derivative 1 DM0YTGS TI TT4G2JS DM0YTGS TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM0YTGS MA Blocker DM0YTGS RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM0YTGS RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM0YUBR DI DM0YUBR DM0YUBR DN Aryl mannoside derivative 18 DM0YUBR TI TTTCRU2 DM0YUBR TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM0YUBR MA Antagonist DM0YUBR RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM0YUBR RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0ZDL3 DI DM0ZDL3 DM0ZDL3 DN US9475795, 80 DM0ZDL3 TI TTB9CIL DM0ZDL3 TN Prokineticin receptor-1 (PROKR1) DM0ZDL3 MA Inhibitor DM0ZDL3 RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795. DM0ZDL3 RU http://www.freepatentsonline.com/US9475795.html DM0ZJX7 DI DM0ZJX7 DM0ZJX7 DN N-(phenylpyrazolyl)benzamide derivative 1 DM0ZJX7 TI TTTDVOJ DM0ZJX7 TN Tropomyosin-related kinase A (TrkA) DM0ZJX7 MA Inhibitor DM0ZJX7 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM0ZJX7 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM0ZRI9 DI DM0ZRI9 DM0ZRI9 DN PMID29130358-Compound-Figure16(9c) DM0ZRI9 TI TTHY57M DM0ZRI9 TN Matrix metalloproteinase-13 (MMP-13) DM0ZRI9 MA Inhibitor DM0ZRI9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM0ZRI9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM0ZRI9 DI DM0ZRI9 DM0ZRI9 DN PMID29130358-Compound-Figure16(9c) DM0ZRI9 TI TTLM12X DM0ZRI9 TN Matrix metalloproteinase-2 (MMP-2) DM0ZRI9 MA Inhibitor DM0ZRI9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM0ZRI9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM106SU DI DM106SU DM106SU DN N-oxalyl-D-tyrosine derivative 6 DM106SU TI TTWAQBO DM106SU TN Lysine-specific demethylase 4E (KDM4E) DM106SU MA Inhibitor DM106SU RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM106SU RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM10CGB DI DM10CGB DM10CGB DN Fused heterocyclic compound 5 DM10CGB TI TT7RJY8 DM10CGB TN Xanthine dehydrogenase/oxidase (XDH) DM10CGB MA Inhibitor DM10CGB RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM10CGB RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM10UX4 DI DM10UX4 DM10UX4 DN 1,2-diamino cyclopentane-based derivative 13 DM10UX4 TI TT9N02I DM10UX4 TN Orexin receptor type 2 (HCRTR2) DM10UX4 MA Antagonist DM10UX4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM10UX4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM10UX4 DI DM10UX4 DM10UX4 DN 1,2-diamino cyclopentane-based derivative 13 DM10UX4 TI TT60Q8D DM10UX4 TN Orexin receptor type 1 (HCRTR1) DM10UX4 MA Antagonist DM10UX4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM10UX4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM12QO7 DI DM12QO7 DM12QO7 DN PMID25435285-Compound-10 DM12QO7 TI TTXJ47W DM12QO7 TN Metabotropic glutamate receptor 2 (mGluR2) DM12QO7 MA Antagonist DM12QO7 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM12QO7 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM12VO9 DI DM12VO9 DM12VO9 DN Peptide analog 40 DM12VO9 TI TTSJMN8 DM12VO9 TN Immunoproteasome complex (IP) DM12VO9 MA Inhibitor DM12VO9 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM12VO9 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM12X0P DI DM12X0P DM12X0P DN PMID27967267-Compound-43 DM12X0P TI TT1RS9F DM12X0P TN Acetylcholinesterase (AChE) DM12X0P MA Inhibitor DM12X0P RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM12X0P RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM13K8R DI DM13K8R DM13K8R DN N-oxalyl-D-tyrosine derivative 7 DM13K8R TI TTWAQBO DM13K8R TN Lysine-specific demethylase 4E (KDM4E) DM13K8R MA Inhibitor DM13K8R RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM13K8R RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM14029 DI DM14029 DM14029 DN Quinoline carboxamide derivative 5 DM14029 TI TTPTXIN DM14029 TN Translocator protein (TSPO) DM14029 MA Ligand DM14029 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM14029 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM142HI DI DM142HI DM142HI DN Imidazo triazine derivative 3 DM142HI TI TTJGW1Z DM142HI TN Phosphodiesterase 2A (PDE2A) DM142HI MA Inhibitor DM142HI RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM142HI RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM143OK DI DM143OK DM143OK DN 1,2-diamino cyclopentane-based derivative 3 DM143OK TI TT9N02I DM143OK TN Orexin receptor type 2 (HCRTR2) DM143OK MA Antagonist DM143OK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM143OK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM143OK DI DM143OK DM143OK DN 1,2-diamino cyclopentane-based derivative 3 DM143OK TI TT60Q8D DM143OK TN Orexin receptor type 1 (HCRTR1) DM143OK MA Antagonist DM143OK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM143OK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM146TA DI DM146TA DM146TA DN Aryl carboxamide derivative 2 DM146TA TI TT4G2JS DM146TA TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM146TA MA Inhibitor DM146TA RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM146TA RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM146TA DI DM146TA DM146TA DN Aryl carboxamide derivative 2 DM146TA TI TTZOVE0 DM146TA TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM146TA MA Inhibitor DM146TA RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM146TA RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM146TA DI DM146TA DM146TA DN Aryl carboxamide derivative 2 DM146TA TI TTAXZ0K DM146TA TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DM146TA MA Inhibitor DM146TA RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM146TA RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM149WN DI DM149WN DM149WN DN Carboxamide derivative 5 DM149WN TI TTG5QB7 DM149WN TN Calpain-2 (CAPN2) DM149WN MA Inhibitor DM149WN RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM149WN RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM14KHX DI DM14KHX DM14KHX DN Imidazole derivative 1 DM14KHX TI TT6OEDT DM14KHX TN Cannabinoid receptor 1 (CB1) DM14KHX MA Antagonist DM14KHX RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM14KHX RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM15AFI DI DM15AFI DM15AFI DN Six-membered heterocyclic benzamide derivative 7 DM15AFI TI TTTDVOJ DM15AFI TN Tropomyosin-related kinase A (TrkA) DM15AFI MA Inhibitor DM15AFI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM15AFI RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM15OKA DI DM15OKA DM15OKA DN PMID28621580-Compound-WO2013112959C68 DM15OKA TI TTOHSBA DM15OKA TN Vascular endothelial growth factor A (VEGFA) DM15OKA MA Inhibitor DM15OKA RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM15OKA RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM15TMH DI DM15TMH DM15TMH DN Peptidomimetic analog 7 DM15TMH TI TTUX68I DM15TMH TN Hypoxia-inducible factor 1 (HIF-1) DM15TMH MA Inhibitor DM15TMH RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM15TMH RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM16ANH DI DM16ANH DM16ANH DN PMID26651364-Compound-10b DM16ANH TI TTTCRU2 DM16ANH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM16ANH MA Antagonist DM16ANH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM16ANH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM16E95 DI DM16E95 DM16E95 DN PMID28092474-Compound-33i DM16E95 TI TT6R7JZ DM16E95 TN Histone deacetylase 1 (HDAC1) DM16E95 MA Inhibitor DM16E95 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM16E95 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM16E95 DI DM16E95 DM16E95 DN PMID28092474-Compound-33i DM16E95 TI TT5ZKDI DM16E95 TN Histone deacetylase 6 (HDAC6) DM16E95 MA Inhibitor DM16E95 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM16E95 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM16M4A DI DM16M4A DM16M4A DN Dihydropyridine compound 1 DM16M4A TI TT4DXQT DM16M4A TN Proto-oncogene c-Ret (RET) DM16M4A MA Inhibitor DM16M4A RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM16M4A RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM16URY DI DM16URY DM16URY DN PMID28270021-Compound-WO2015042088Example11 DM16URY TI TTTDVOJ DM16URY TN Tropomyosin-related kinase A (TrkA) DM16URY MA Inhibitor DM16URY RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM16URY RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM17D30 DI DM17D30 DM17D30 DN 3-phenyl propanoic derivative 2 DM17D30 TI TTA6ZN2 DM17D30 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM17D30 MA Inhibitor DM17D30 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM17D30 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM17D30 DI DM17D30 DM17D30 DN 3-phenyl propanoic derivative 2 DM17D30 TI TTHQJI6 DM17D30 TN Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE) DM17D30 MA Modulator DM17D30 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM17D30 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM17FKL DI DM17FKL DM17FKL DN PMID25416646-Compound-Figure5-C DM17FKL TI TT2JWF6 DM17FKL TN Peroxisome proliferator-activated receptor delta (PPARD) DM17FKL MA Agonist DM17FKL RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM17FKL RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM17FKL DI DM17FKL DM17FKL DN PMID25416646-Compound-Figure5-C DM17FKL TI TTZMAO3 DM17FKL TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM17FKL MA Agonist DM17FKL RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM17FKL RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM17KL2 DI DM17KL2 DM17KL2 DN PMID27454349-Compound-95 DM17KL2 TI TTK59TV DM17KL2 TN Vitamin D3 receptor (VDR) DM17KL2 MA Agonist DM17KL2 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DM17KL2 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DM17P3F DI DM17P3F DM17P3F DN PMID25991433-Compound-J3 DM17P3F TI TTHS0U8 DM17P3F TN Stress-activated protein kinase JNK2 (JNK2) DM17P3F MA Inhibitor DM17P3F RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM17P3F RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM17P3F DI DM17P3F DM17P3F DN PMID25991433-Compound-J3 DM17P3F TI TT0K6EO DM17P3F TN Stress-activated protein kinase JNK1 (JNK1) DM17P3F MA Inhibitor DM17P3F RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM17P3F RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM17P3F DI DM17P3F DM17P3F DN PMID25991433-Compound-J3 DM17P3F TI TT056SO DM17P3F TN Stress-activated protein kinase JNK3 (JNK3) DM17P3F MA Inhibitor DM17P3F RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM17P3F RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM17YHP DI DM17YHP DM17YHP DN US9132129, Cpd047 DM17YHP TI TTH9LDP DM17YHP TN PC4 and SFRS1-interacting protein (PSIP1) DM17YHP MA Inhibitor DM17YHP RN Antiviral compounds. US9132129. DM17YHP RU http://www.freepatentsonline.com/US9132129.html DM189D7 DI DM189D7 DM189D7 DN Lazabemide analog 1 DM189D7 TI TTGP7BY DM189D7 TN Monoamine oxidase type B (MAO-B) DM189D7 MA Inhibitor DM189D7 RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM189D7 RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM18DY6 DI DM18DY6 DM18DY6 DN PMID28092474-Compound-33g DM18DY6 TI TT5ZKDI DM18DY6 TN Histone deacetylase 6 (HDAC6) DM18DY6 MA Inhibitor DM18DY6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM18DY6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM18DY6 DI DM18DY6 DM18DY6 DN PMID28092474-Compound-33g DM18DY6 TI TT6R7JZ DM18DY6 TN Histone deacetylase 1 (HDAC1) DM18DY6 MA Inhibitor DM18DY6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM18DY6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM18FP4 DI DM18FP4 DM18FP4 DN PMID25399762-Compound-Table 5-O-methyl-M30 DM18FP4 TI TT3WG5C DM18FP4 TN Monoamine oxidase type A (MAO-A) DM18FP4 MA Inhibitor DM18FP4 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM18FP4 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM18LO7 DI DM18LO7 DM18LO7 DN PMID28074661-Compound-US20100022547C83 DM18LO7 TI TTL7C8Q DM18LO7 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM18LO7 MA Inhibitor DM18LO7 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM18LO7 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM18P4N DI DM18P4N DM18P4N DN Imidazo triazine derivative 5 DM18P4N TI TTJGW1Z DM18P4N TN Phosphodiesterase 2A (PDE2A) DM18P4N MA Inhibitor DM18P4N RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM18P4N RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM18PRU DI DM18PRU DM18PRU DN PMID28074661-Compound-US20120264760C82 DM18PRU TI TTL7C8Q DM18PRU TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM18PRU MA Inhibitor DM18PRU RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM18PRU RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM18UA5 DI DM18UA5 DM18UA5 DN PMID27744724-Compound-21 DM18UA5 TI TTL53M6 DM18UA5 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM18UA5 MA Inhibitor DM18UA5 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM18UA5 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM18UA5 DI DM18UA5 DM18UA5 DN PMID27744724-Compound-21 DM18UA5 TI TTU1E82 DM18UA5 TN Apoptosis regulator Bcl-xL (BCL-xL) DM18UA5 MA Inhibitor DM18UA5 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM18UA5 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM18UA5 DI DM18UA5 DM18UA5 DN PMID27744724-Compound-21 DM18UA5 TI TTJGNVC DM18UA5 TN Apoptosis regulator Bcl-2 (BCL-2) DM18UA5 MA Inhibitor DM18UA5 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM18UA5 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM198BY DI DM198BY DM198BY DN Palmarumycin derivative 3 DM198BY TI TTR7UJ3 DM198BY TN Cytoplasmic thioredoxin reductase (TXNRD1) DM198BY MA Inhibitor DM198BY RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM198BY RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM19BQ6 DI DM19BQ6 DM19BQ6 DN PMID28048944-Compound-20 DM19BQ6 TI TTZN7RP DM19BQ6 TN Rho-associated protein kinase 1 (ROCK1) DM19BQ6 MA Inhibitor DM19BQ6 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM19BQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM19GAY DI DM19GAY DM19GAY DN STK696827 DM19GAY TI TT1NFO3 DM19GAY TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DM19GAY MA Inhibitor DM19GAY RN Targeting NAD biosynthesis in bacterial pathogens. US8785499. DM19GAY RU http://www.freepatentsonline.com/US8785499.html DM1A0GT DI DM1A0GT DM1A0GT DN PMID25666693-Compound-65 DM1A0GT TI TTMI6F5 DM1A0GT TN Transient receptor potential cation channel V1 (TRPV1) DM1A0GT MA Antagonist DM1A0GT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1A0GT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1A0VB DI DM1A0VB DM1A0VB DN Pyrrole six-membered heteroaryl ring derivative 1 DM1A0VB TI TTRMX3V DM1A0VB TN Janus kinase 2 (JAK-2) DM1A0VB MA Inhibitor DM1A0VB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM1A0VB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM1A0VB DI DM1A0VB DM1A0VB DN Pyrrole six-membered heteroaryl ring derivative 1 DM1A0VB TI TTT7PJU DM1A0VB TN Janus kinase 3 (JAK-3) DM1A0VB MA Inhibitor DM1A0VB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM1A0VB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM1A0VB DI DM1A0VB DM1A0VB DN Pyrrole six-membered heteroaryl ring derivative 1 DM1A0VB TI TT6DM01 DM1A0VB TN Janus kinase 1 (JAK-1) DM1A0VB MA Inhibitor DM1A0VB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM1A0VB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM1A0WU DI DM1A0WU DM1A0WU DN Cyclohexane carboxamide derivative 2 DM1A0WU TI TTTJZ4M DM1A0WU TN Prolylcarboxypeptidase (PRCP) DM1A0WU MA Inhibitor DM1A0WU RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM1A0WU RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM1AGSD DI DM1AGSD DM1AGSD DN Tetrazole derivative 1 DM1AGSD TI TT473XN DM1AGSD TN P2X purinoceptor 7 (P2RX7) DM1AGSD MA Antagonist DM1AGSD RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM1AGSD RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM1B74D DI DM1B74D DM1B74D DN Oxazolo[3,4-a]pyrazine derivative 4 DM1B74D TI TTV1C0Z DM1B74D TN Neuropeptide S receptor (NPSR) DM1B74D MA Antagonist DM1B74D RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM1B74D RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM1BIY4 DI DM1BIY4 DM1BIY4 DN Phenylmethanesulfonamide derivative 1 DM1BIY4 TI TTJOW1I DM1BIY4 TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DM1BIY4 MA Inhibitor DM1BIY4 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM1BIY4 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM1BN74 DI DM1BN74 DM1BN74 DN PMID28048944-Compound-3 DM1BN74 TI TTZN7RP DM1BN74 TN Rho-associated protein kinase 1 (ROCK1) DM1BN74 MA Inhibitor DM1BN74 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM1BN74 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM1BN74 DI DM1BN74 DM1BN74 DN PMID28048944-Compound-3 DM1BN74 TI TTGWKQJ DM1BN74 TN Rho-associated protein kinase 2 (ROCK2) DM1BN74 MA Inhibitor DM1BN74 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM1BN74 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM1C8MA DI DM1C8MA DM1C8MA DN Thieno[3,2-c]pyridine-7-carboxamide derivative 1 DM1C8MA TI TTCZOF2 DM1C8MA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM1C8MA MA Inhibitor DM1C8MA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM1C8MA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TTT7PJU DM1CM7S TN Janus kinase 3 (JAK-3) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TTRMX3V DM1CM7S TN Janus kinase 2 (JAK-2) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TTBYWP2 DM1CM7S TN TYK2 tyrosine kinase (TYK2) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CM7S DI DM1CM7S DM1CM7S DN PMID27774824-Compound-Figure6Example12 DM1CM7S TI TT6DM01 DM1CM7S TN Janus kinase 1 (JAK-1) DM1CM7S MA Inhibitor DM1CM7S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1CM7S RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1CNRH DI DM1CNRH DM1CNRH DN Indole-based analog 12 DM1CNRH TI TTMBO1Z DM1CNRH TN Cyclin-dependent kinase (CDK) DM1CNRH MA Inhibitor DM1CNRH RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM1CNRH RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM1CWU7 DI DM1CWU7 DM1CWU7 DN Heteroaryl-carboxamide derivative 11 DM1CWU7 TI TT5L2VC DM1CWU7 TN Kallikrein-related peptidase (KLK) DM1CWU7 MA Inhibitor DM1CWU7 RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DM1CWU7 RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DM1D2AS DI DM1D2AS DM1D2AS DN Pyrimidine derivative 28 DM1D2AS TI TT0K1SC DM1D2AS TN 5-HT 2B receptor (HTR2B) DM1D2AS MA Antagonist DM1D2AS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1D2AS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1D2AS DI DM1D2AS DM1D2AS DN Pyrimidine derivative 28 DM1D2AS TI TTWJBZ5 DM1D2AS TN 5-HT 2C receptor (HTR2C) DM1D2AS MA Antagonist DM1D2AS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1D2AS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1D2AS DI DM1D2AS DM1D2AS DN Pyrimidine derivative 28 DM1D2AS TI TTJQOD7 DM1D2AS TN 5-HT 2A receptor (HTR2A) DM1D2AS MA Antagonist DM1D2AS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1D2AS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1D7CE DI DM1D7CE DM1D7CE DN Peptide analog 51 DM1D7CE TI TTDIGC1 DM1D7CE TN Dipeptidyl peptidase 4 (DPP-4) DM1D7CE MA Inhibitor DM1D7CE RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM1D7CE RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM1DN6V DI DM1DN6V DM1DN6V DN PMID28092474-Compound-33h DM1DN6V TI TT5ZKDI DM1DN6V TN Histone deacetylase 6 (HDAC6) DM1DN6V MA Inhibitor DM1DN6V RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM1DN6V RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM1DN6V DI DM1DN6V DM1DN6V DN PMID28092474-Compound-33h DM1DN6V TI TT6R7JZ DM1DN6V TN Histone deacetylase 1 (HDAC1) DM1DN6V MA Inhibitor DM1DN6V RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM1DN6V RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM1DN94 DI DM1DN94 DM1DN94 DN Carboxamide derivative 11 DM1DN94 TI TTG5QB7 DM1DN94 TN Calpain-2 (CAPN2) DM1DN94 MA Inhibitor DM1DN94 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM1DN94 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM1DXME DI DM1DXME DM1DXME DN Benzimidazole derivative 17 DM1DXME TI TTYLQ8V DM1DXME TN Prostaglandin E synthase (PTGES) DM1DXME MA Inhibitor DM1DXME RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM1DXME RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM1EU06 DI DM1EU06 DM1EU06 DN PMID25980951-Compound-45 DM1EU06 TI TTR7B60 DM1EU06 TN X-linked inhibitor of apoptosis protein (XIAP) DM1EU06 MA Antagonist DM1EU06 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM1EU06 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM1FTV6 DI DM1FTV6 DM1FTV6 DN PMID25666693-Compound-153 DM1FTV6 TI TTMI6F5 DM1FTV6 TN Transient receptor potential cation channel V1 (TRPV1) DM1FTV6 MA Antagonist DM1FTV6 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1FTV6 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1FUOY DI DM1FUOY DM1FUOY DN amidepsines DM1FUOY TI TTF8P9I DM1FUOY TN Diacylglycerol acyltransferase 1 (DGAT1) DM1FUOY MA Inhibitor DM1FUOY RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM1FUOY RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM1G2J5 DI DM1G2J5 DM1G2J5 DN Peptide analog 64 DM1G2J5 TI TTPLTSQ DM1G2J5 TN Neutrophil elastase (NE) DM1G2J5 MA Inhibitor DM1G2J5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM1G2J5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM1G6AE DI DM1G6AE DM1G6AE DN PMID25666693-Compound-15 DM1G6AE TI TTMI6F5 DM1G6AE TN Transient receptor potential cation channel V1 (TRPV1) DM1G6AE MA Antagonist DM1G6AE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1G6AE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1G7KI DI DM1G7KI DM1G7KI DN Aryl urea derivative 3 DM1G7KI TI TTDP1UC DM1G7KI TN Fatty acid amide hydrolase (FAAH) DM1G7KI MA Inhibitor DM1G7KI RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM1G7KI RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM1G8SM DI DM1G8SM DM1G8SM DN Isoxazole-based bicyclic compound 11 DM1G8SM TI TTE4BSY DM1G8SM TN Bromodomain and extraterminal domain protein (BET) DM1G8SM MA Inhibitor DM1G8SM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM1G8SM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM1GYZQ DI DM1GYZQ DM1GYZQ DN Pyrrolo[2,3-d]pyrimidine derivative 16 DM1GYZQ TI TTGM6VW DM1GYZQ TN Tyrosine-protein kinase BTK (ATK) DM1GYZQ MA Inhibitor DM1GYZQ RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM1GYZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM1HAGJ DI DM1HAGJ DM1HAGJ DN PMID26815044-Compound-122 DM1HAGJ TI TTULVH8 DM1HAGJ TN Tyrosinase (TYR) DM1HAGJ MA Inhibitor DM1HAGJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM1HAGJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM1HI8Q DI DM1HI8Q DM1HI8Q DN Hydrazide derivative 4 DM1HI8Q TI TTK0FEA DM1HI8Q TN Leucine-rich repeat kinase 2 (LRRK2) DM1HI8Q MA Inhibitor DM1HI8Q RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM1HI8Q RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM1HIEZ DI DM1HIEZ DM1HIEZ DN PMID26394986-Compound-43 DM1HIEZ TI TTH8FZW DM1HIEZ TN Signal transducer and activator of transcription 3 (STAT3) DM1HIEZ MA Inhibitor DM1HIEZ RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM1HIEZ RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM1HPY7 DI DM1HPY7 DM1HPY7 DN PMID27841036-Compound-XI DM1HPY7 TI TTEBCY8 DM1HPY7 TN Poly [ADP-ribose] polymerase (PARP) DM1HPY7 MA Inhibitor DM1HPY7 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM1HPY7 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM1HYW4 DI DM1HYW4 DM1HYW4 DN Phenylsulfonyl derivative 4 DM1HYW4 TI TT9JNIC DM1HYW4 TN Histamine H3 receptor (H3R) DM1HYW4 MA Inhibitor DM1HYW4 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM1HYW4 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM1I7Z6 DI DM1I7Z6 DM1I7Z6 DN Pyrimidinone derivative 1 DM1I7Z6 TI TTCZOF2 DM1I7Z6 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM1I7Z6 MA Inhibitor DM1I7Z6 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM1I7Z6 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM1I9JC DI DM1I9JC DM1I9JC DN PMID28454500-Compound-60 DM1I9JC TI TTA6ZN2 DM1I9JC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM1I9JC MA Inhibitor DM1I9JC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1I9JC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1I9JC DI DM1I9JC DM1I9JC DN PMID28454500-Compound-60 DM1I9JC TI TTGIZLN DM1I9JC TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DM1I9JC MA Modulator DM1I9JC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1I9JC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1J2V8 DI DM1J2V8 DM1J2V8 DN PMID27539678-Compound-13 DM1J2V8 TI TTOHFIY DM1J2V8 TN Sphingosine kinase 1 (SPHK1) DM1J2V8 MA Inhibitor DM1J2V8 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DM1J2V8 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DM1J3LE DI DM1J3LE DM1J3LE DN PMID25980951-Compound-16 DM1J3LE TI TTQ5LRD DM1J3LE TN Cellular inhibitor of apoptosis 1 (BIRC2) DM1J3LE MA Antagonist DM1J3LE RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM1J3LE RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM1JAFV DI DM1JAFV DM1JAFV DN PMID25522065-Compound-35 DM1JAFV TI TTX4RTB DM1JAFV TN Melanin-concentrating hormone receptor 1 (MCHR1) DM1JAFV MA Antagonist DM1JAFV RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM1JAFV RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TTDZN01 DM1JOZN TN Cathepsin K (CTSK) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TT36ETB DM1JOZN TN Cathepsin L (CTSL) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TTF2LRI DM1JOZN TN Cathepsin B (CTSB) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JOZN DI DM1JOZN DM1JOZN DN PMID27998201-Compound-9 DM1JOZN TI TTUMQVO DM1JOZN TN Cathepsin S (CTSS) DM1JOZN MA Inhibitor DM1JOZN RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1JOZN RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1JXKY DI DM1JXKY DM1JXKY DN Imidazo isoindole derivative 1 DM1JXKY TI TTZJYKH DM1JXKY TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM1JXKY MA Inhibitor DM1JXKY RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM1JXKY RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM1JYNW DI DM1JYNW DM1JYNW DN Imidazo[1,2-b]pyridazine derivative 2 DM1JYNW TI TTTDVOJ DM1JYNW TN Tropomyosin-related kinase A (TrkA) DM1JYNW MA Inhibitor DM1JYNW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM1JYNW RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM1JYNW DI DM1JYNW DM1JYNW DN Imidazo[1,2-b]pyridazine derivative 2 DM1JYNW TI TTSZ6Y3 DM1JYNW TN Proto-oncogene c-Ros (ROS1) DM1JYNW MA Inhibitor DM1JYNW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM1JYNW RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM1K5HS DI DM1K5HS DM1K5HS DN US8592431, 185 DM1K5HS TI TTLJKZ0 DM1K5HS TN Acetyl-CoA transporter (SLC33A1) DM1K5HS MA Inhibitor DM1K5HS RN Fused ring compound and use thereof. US8592431. DM1K5HS RU http://www.freepatentsonline.com/US8592431.html DM1K5T0 DI DM1K5T0 DM1K5T0 DN US9156852, 83 DM1K5T0 TI TTI1FPZ DM1K5T0 TN Epithelial discoidin domain receptor 1 (DDR1) DM1K5T0 MA Inhibitor DM1K5T0 RN Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852. DM1K5T0 RU http://www.freepatentsonline.com/US9156852.html DM1KBSV DI DM1KBSV DM1KBSV DN Macrocycle derivative 13 DM1KBSV TI TTKN7QR DM1KBSV TN BDNF/NT-3 growth factors receptor (TrkB) DM1KBSV MA Inhibitor DM1KBSV RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM1KBSV RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM1KHGY DI DM1KHGY DM1KHGY DN Triazolo-pyrazinone derivative 1 DM1KHGY TI TT473XN DM1KHGY TN P2X purinoceptor 7 (P2RX7) DM1KHGY MA Antagonist DM1KHGY RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM1KHGY RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM1KJAQ DI DM1KJAQ DM1KJAQ DN PMID27841036-Compound-38 DM1KJAQ TI TTEBCY8 DM1KJAQ TN Poly [ADP-ribose] polymerase (PARP) DM1KJAQ MA Inhibitor DM1KJAQ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM1KJAQ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM1KT4I DI DM1KT4I DM1KT4I DN Hexahydro naphthalene derivative 3 DM1KT4I TI TTPADOQ DM1KT4I TN HMG-CoA reductase (HMGCR) DM1KT4I MA Inhibitor DM1KT4I RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM1KT4I RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM1KVTZ DI DM1KVTZ DM1KVTZ DN Bicarboxylic and tricarboxylic ethynyl derivative 3 DM1KVTZ TI TTHS256 DM1KVTZ TN Metabotropic glutamate receptor 5 (mGluR5) DM1KVTZ MA Modulator DM1KVTZ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM1KVTZ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM1L3ZA DI DM1L3ZA DM1L3ZA DN Thiadiazolidindione derivative 1 DM1L3ZA TI TTRZQE3 DM1L3ZA TN Glycogen synthase kinase-3 alpha (GSK-3A) DM1L3ZA MA Inhibitor DM1L3ZA RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM1L3ZA RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM1LIRP DI DM1LIRP DM1LIRP DN PMID26651364-Compound-112 DM1LIRP TI TTTCRU2 DM1LIRP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1LIRP MA Antagonist DM1LIRP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1LIRP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1LPKH DI DM1LPKH DM1LPKH DN Oxazolo[3,4-a]pyrazine derivative 3 DM1LPKH TI TTV1C0Z DM1LPKH TN Neuropeptide S receptor (NPSR) DM1LPKH MA Antagonist DM1LPKH RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM1LPKH RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM1M3WF DI DM1M3WF DM1M3WF DN PMID26651364-Compound-8a DM1M3WF TI TTTCRU2 DM1M3WF TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1M3WF MA Antagonist DM1M3WF RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1M3WF RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1MQ7J DI DM1MQ7J DM1MQ7J DN US8710232, 8 DM1MQ7J TI TT4UJX5 DM1MQ7J TN Carboxypeptidase B1 (CPB1) DM1MQ7J MA Inhibitor DM1MQ7J RN Imidazole derivatives used as TAFIa inhibitors. US8710232. DM1MQ7J RU http://www.freepatentsonline.com/US8710232.html DM1MVQD DI DM1MVQD DM1MVQD DN PMID27376512-Compound-MTC-422 DM1MVQD TI TTJUALD DM1MVQD TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DM1MVQD MA Inhibitor DM1MVQD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM1MVQD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM1MVQD DI DM1MVQD DM1MVQD DN PMID27376512-Compound-MTC-422 DM1MVQD TI TT6VZ78 DM1MVQD TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM1MVQD MA Inhibitor DM1MVQD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM1MVQD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM1MVQD DI DM1MVQD DM1MVQD DN PMID27376512-Compound-MTC-422 DM1MVQD TI TT6S2FE DM1MVQD TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM1MVQD MA Inhibitor DM1MVQD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM1MVQD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM1MZ70 DI DM1MZ70 DM1MZ70 DN PMID25666693-Compound-82 DM1MZ70 TI TTMI6F5 DM1MZ70 TN Transient receptor potential cation channel V1 (TRPV1) DM1MZ70 MA Antagonist DM1MZ70 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM1MZ70 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM1N5UH DI DM1N5UH DM1N5UH DN PMID25522065-Compound-22 DM1N5UH TI TTX4RTB DM1N5UH TN Melanin-concentrating hormone receptor 1 (MCHR1) DM1N5UH MA Antagonist DM1N5UH RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM1N5UH RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM1N74R DI DM1N74R DM1N74R DN US8586571, 6 DM1N74R TI TT0C8BY DM1N74R TN Plasma retinol-binding protein (RBP4) DM1N74R MA Inhibitor DM1N74R RN Heterocyclic compound. US8586571. DM1N74R RU http://www.freepatentsonline.com/US8586571.html DM1NJ3U DI DM1NJ3U DM1NJ3U DN PMID29338548-Compound-49 DM1NJ3U TI TTHJTF7 DM1NJ3U TN Glycine transporter GlyT-1 (SLC6A9) DM1NJ3U MA Inhibitor DM1NJ3U RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM1NJ3U RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM1NMR6 DI DM1NMR6 DM1NMR6 DN Peptide analog 29 DM1NMR6 TI TTSJMN8 DM1NMR6 TN Immunoproteasome complex (IP) DM1NMR6 MA Inhibitor DM1NMR6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM1NMR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM1PU37 DI DM1PU37 DM1PU37 DN BDBM50173330 DM1PU37 TI TTTCXO0 DM1PU37 TN G protein-coupled receptor kinase 5 (GRK5) DM1PU37 MA Inhibitor DM1PU37 RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DM1PU37 RU http://www.freepatentsonline.com/US10023564.html DM1Q7AL DI DM1Q7AL DM1Q7AL DN Biaryl mannoside derivative 9 DM1Q7AL TI TTTCRU2 DM1Q7AL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1Q7AL MA Antagonist DM1Q7AL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1Q7AL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1QH8Z DI DM1QH8Z DM1QH8Z DN Five-membered heteroaromatic compound 2 DM1QH8Z TI TTZJYKH DM1QH8Z TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM1QH8Z MA Inhibitor DM1QH8Z RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM1QH8Z RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM1QHV0 DI DM1QHV0 DM1QHV0 DN PMID28870136-Compound-45 DM1QHV0 TI TTK0O6Y DM1QHV0 TN Ecto-5'-nucleotidase (CD73) DM1QHV0 MA Inhibitor DM1QHV0 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM1QHV0 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM1QUN0 DI DM1QUN0 DM1QUN0 DN PMID28074661-Compound-US20158969342C84 DM1QUN0 TI TTL7C8Q DM1QUN0 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM1QUN0 MA Inhibitor DM1QUN0 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM1QUN0 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM1R0FJ DI DM1R0FJ DM1R0FJ DN Dihydrodiazepinocarbazolone derivative 2 DM1R0FJ TI TTEBCY8 DM1R0FJ TN Poly [ADP-ribose] polymerase (PARP) DM1R0FJ MA Inhibitor DM1R0FJ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM1R0FJ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM1R205 DI DM1R205 DM1R205 DN Triazolo-pyridine derivative 5 DM1R205 TI TTJW4LU DM1R205 TN Phosphodiesterase 10A (PDE10) DM1R205 MA Inhibitor DM1R205 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM1R205 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM1R205 DI DM1R205 DM1R205 DN Triazolo-pyridine derivative 5 DM1R205 TI TTJGW1Z DM1R205 TN Phosphodiesterase 2A (PDE2A) DM1R205 MA Inhibitor DM1R205 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM1R205 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM1R6GA DI DM1R6GA DM1R6GA DN PMID27019002-Compound-28 DM1R6GA TI TTNR0UQ DM1R6GA TN Lysine-specific histone demethylase 1 (LSD) DM1R6GA MA Inhibitor DM1R6GA RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM1R6GA RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM1RN89 DI DM1RN89 DM1RN89 DN PMID28051882-Compound-XIV DM1RN89 TI TT9NXW4 DM1RN89 TN Sigma intracellular receptor 2 (TMEM97) DM1RN89 MA Ligand DM1RN89 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM1RN89 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM1RN89 DI DM1RN89 DM1RN89 DN PMID28051882-Compound-XIV DM1RN89 TI TT5TPI6 DM1RN89 TN Opioid receptor sigma 1 (OPRS1) DM1RN89 MA Ligand DM1RN89 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM1RN89 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTSHTOI DM1RPL4 TN Histone deacetylase 2 (HDAC2) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TT4YWTO DM1RPL4 TN Histone deacetylase 3 (HDAC3) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TT5ZKDI DM1RPL4 TN Histone deacetylase 6 (HDAC6) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TT6R7JZ DM1RPL4 TN Histone deacetylase 1 (HDAC1) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTTQGH8 DM1RPL4 TN Histone deacetylase 4 (HDAC4) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTMUEK1 DM1RPL4 TN Histone deacetylase 7 (HDAC7) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTUELN5 DM1RPL4 TN Histone deacetylase 5 (HDAC5) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RPL4 DI DM1RPL4 DM1RPL4 DN PMID29671355-Compound-67 DM1RPL4 TI TTT6LFV DM1RPL4 TN Histone deacetylase 8 (HDAC8) DM1RPL4 MA Inhibitor DM1RPL4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM1RPL4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM1RQIU DI DM1RQIU DM1RQIU DN Aminobenzoxazole analog 1 DM1RQIU TI TT473XN DM1RQIU TN P2X purinoceptor 7 (P2RX7) DM1RQIU MA Antagonist DM1RQIU RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM1RQIU RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM1RS4X DI DM1RS4X DM1RS4X DN PMID28454500-Compound-92 DM1RS4X TI TTA6ZN2 DM1RS4X TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM1RS4X MA Inhibitor DM1RS4X RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1RS4X RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1SH5R DI DM1SH5R DM1SH5R DN Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R TI TTDZN01 DM1SH5R TN Cathepsin K (CTSK) DM1SH5R MA Inhibitor DM1SH5R RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1SH5R RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1SH5R DI DM1SH5R DM1SH5R DN Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R TI TTUMQVO DM1SH5R TN Cathepsin S (CTSS) DM1SH5R MA Inhibitor DM1SH5R RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM1SH5R RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM1STAD DI DM1STAD DM1STAD DN L-piperazino-3-phenyl-indane derivative 1 DM1STAD TI TTWFZ1N DM1STAD TN Dopamine receptor (DR) DM1STAD MA Antagonist DM1STAD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1STAD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1STAD DI DM1STAD DM1STAD DN L-piperazino-3-phenyl-indane derivative 1 DM1STAD TI TTJQOD7 DM1STAD TN 5-HT 2A receptor (HTR2A) DM1STAD MA Antagonist DM1STAD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1STAD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1STAD DI DM1STAD DM1STAD DN L-piperazino-3-phenyl-indane derivative 1 DM1STAD TI TTEX248 DM1STAD TN Dopamine D2 receptor (D2R) DM1STAD MA Antagonist DM1STAD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM1STAD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM1SWYU DI DM1SWYU DM1SWYU DN PMID29334795-Compound-28 DM1SWYU TI TT9JNIC DM1SWYU TN Histamine H3 receptor (H3R) DM1SWYU RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM1SWYU RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM1TCBQ DI DM1TCBQ DM1TCBQ DN PMID30107136-Compound-Example47 DM1TCBQ TI TT23XQV DM1TCBQ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM1TCBQ MA Inhibitor DM1TCBQ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM1TCBQ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM1TV6F DI DM1TV6F DM1TV6F DN Aryl mannoside derivative 1 DM1TV6F TI TTTCRU2 DM1TV6F TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1TV6F MA Antagonist DM1TV6F RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1TV6F RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1U6H2 DI DM1U6H2 DM1U6H2 DN PMID29865878-Compound-64 DM1U6H2 TI TTEAD9J DM1U6H2 TN Proteasome beta-8 (PS beta-8) DM1U6H2 MA Inhibitor DM1U6H2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM1U6H2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM1VHYX DI DM1VHYX DM1VHYX DN PMID25991433-Compound-E4 DM1VHYX TI TT0K6EO DM1VHYX TN Stress-activated protein kinase JNK1 (JNK1) DM1VHYX MA Inhibitor DM1VHYX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM1VHYX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM1VOPH DI DM1VOPH DM1VOPH DN PMID27774824-Compound-Figure8Example99 DM1VOPH TI TTRMX3V DM1VOPH TN Janus kinase 2 (JAK-2) DM1VOPH MA Inhibitor DM1VOPH RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1VOPH RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1VPLU DI DM1VPLU DM1VPLU DN US10150740, Example 9 DM1VPLU TI TTQFZWR DM1VPLU TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DM1VPLU MA Inhibitor DM1VPLU RN 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740. DM1VPLU RU http://www.freepatentsonline.com/US10150740.html DM1VYZ9 DI DM1VYZ9 DM1VYZ9 DN Biphenyl 1,2-diamine derivative 1 DM1VYZ9 TI TTZJYKH DM1VYZ9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM1VYZ9 MA Modulator DM1VYZ9 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM1VYZ9 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM1W02D DI DM1W02D DM1W02D DN Tricyclic heterocycle derivative 2 DM1W02D TI TTRMX3V DM1W02D TN Janus kinase 2 (JAK-2) DM1W02D MA Inhibitor DM1W02D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1W02D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1W02D DI DM1W02D DM1W02D DN Tricyclic heterocycle derivative 2 DM1W02D TI TTT7PJU DM1W02D TN Janus kinase 3 (JAK-3) DM1W02D MA Inhibitor DM1W02D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM1W02D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM1XUVB DI DM1XUVB DM1XUVB DN Piperazine derivative 8 DM1XUVB TI TTSCIM2 DM1XUVB TN Extracellular lysophospholipase D (E-NPP2) DM1XUVB RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM1XUVB RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM1Y8OM DI DM1Y8OM DM1Y8OM DN Biaryl mannoside derivative 13 DM1Y8OM TI TTTCRU2 DM1Y8OM TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM1Y8OM MA Antagonist DM1Y8OM RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM1Y8OM RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM1ZFC9 DI DM1ZFC9 DM1ZFC9 DN PMID28454500-Compound-11 DM1ZFC9 TI TTA6ZN2 DM1ZFC9 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM1ZFC9 MA Activator DM1ZFC9 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1ZFC9 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1ZFC9 DI DM1ZFC9 DM1ZFC9 DN PMID28454500-Compound-11 DM1ZFC9 TI TT3Z6Y9 DM1ZFC9 TN Cysteines of Keap1 (KEAP1 Cysteines) DM1ZFC9 MA Modulator DM1ZFC9 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM1ZFC9 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM1ZIPN DI DM1ZIPN DM1ZIPN DN Cyclic octapeptide derivative 1 DM1ZIPN TI TTUX68I DM1ZIPN TN Hypoxia-inducible factor 1 (HIF-1) DM1ZIPN MA Inhibitor DM1ZIPN RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM1ZIPN RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM1ZK7E DI DM1ZK7E DM1ZK7E DN Ketoheterocycle derivative 1 DM1ZK7E TI TTDP1UC DM1ZK7E TN Fatty acid amide hydrolase (FAAH) DM1ZK7E MA Inhibitor DM1ZK7E RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM1ZK7E RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM1ZSEI DI DM1ZSEI DM1ZSEI DN PMID26560530-Compound-15 DM1ZSEI TI TT2F4OL DM1ZSEI TN Tissue transglutaminase (TG2) DM1ZSEI MA Inhibitor DM1ZSEI RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM1ZSEI RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM20YBJ DI DM20YBJ DM20YBJ DN Indoline derivative 3 DM20YBJ TI TT5OU0D DM20YBJ TN PRKR-like endoplasmic reticulum kinase (PERK) DM20YBJ MA Inhibitor DM20YBJ RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM20YBJ RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM2135Y DI DM2135Y DM2135Y DN PMID25991433-Compound-L1 DM2135Y TI TTQBR95 DM2135Y TN Stress-activated protein kinase 2a (p38 alpha) DM2135Y MA Inhibitor DM2135Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2135Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2135Y DI DM2135Y DM2135Y DN PMID25991433-Compound-L1 DM2135Y TI TT3ZIJL DM2135Y TN JNK-interacting protein peptide (pepJIP) DM2135Y MA Inhibitor DM2135Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2135Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2135Y DI DM2135Y DM2135Y DN PMID25991433-Compound-L1 DM2135Y TI TT0K6EO DM2135Y TN Stress-activated protein kinase JNK1 (JNK1) DM2135Y MA Inhibitor DM2135Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2135Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM214WA DI DM214WA DM214WA DN PMID27744724-Compound-19 DM214WA TI TTL53M6 DM214WA TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM214WA MA Inhibitor DM214WA RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM214WA RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM21J83 DI DM21J83 DM21J83 DN Tetra-hydro-oxazolopyridine derivative 4 DM21J83 TI TTHS256 DM21J83 TN Metabotropic glutamate receptor 5 (mGluR5) DM21J83 MA Modulator DM21J83 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM21J83 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM21QCE DI DM21QCE DM21QCE DN PMID29473428-Compound-16 DM21QCE TI TTZJYKH DM21QCE TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM21QCE RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM21QCE RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM21S5G DI DM21S5G DM21S5G DN Piperidinyl pyrazole derivative 2 DM21S5G TI TTTJZ4M DM21S5G TN Prolylcarboxypeptidase (PRCP) DM21S5G MA Inhibitor DM21S5G RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM21S5G RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM231WS DI DM231WS DM231WS DN P-coumaric acid derivative 1 DM231WS TI TTULVH8 DM231WS TN Tyrosinase (TYR) DM231WS MA Inhibitor DM231WS RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM231WS RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM23NEX DI DM23NEX DM23NEX DN PMID25399762-Compound-Figure1-Aphanamixoid A DM23NEX TI TT3WG5C DM23NEX TN Monoamine oxidase type A (MAO-A) DM23NEX MA Inhibitor DM23NEX RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM23NEX RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM23XQL DI DM23XQL DM23XQL DN Di-substituted piperidine derivative 2 DM23XQL TI TTEB0GD DM23XQL TN Cholinesterase (BCHE) DM23XQL MA Inhibitor DM23XQL RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM23XQL RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM23XQL DI DM23XQL DM23XQL DN Di-substituted piperidine derivative 2 DM23XQL TI TT1RS9F DM23XQL TN Acetylcholinesterase (AChE) DM23XQL MA Inhibitor DM23XQL RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM23XQL RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM249KU DI DM249KU DM249KU DN Benzodihydroisofuran derivative 1 DM249KU TI TTTJZ4M DM249KU TN Prolylcarboxypeptidase (PRCP) DM249KU MA Inhibitor DM249KU RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM249KU RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM24FSP DI DM24FSP DM24FSP DN PMID27109571-Compound-30 DM24FSP TI TTNT2S6 DM24FSP TN Fatty acid-binding protein 5 (FABP5) DM24FSP MA Inhibitor DM24FSP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM24FSP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM24FSP DI DM24FSP DM24FSP DN PMID27109571-Compound-30 DM24FSP TI TTHWMFZ DM24FSP TN Fatty acid-binding protein 4 (FABP4) DM24FSP MA Inhibitor DM24FSP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM24FSP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM24NZG DI DM24NZG DM24NZG DN Benzothiazepine analog 3 DM24NZG TI TTPTXIN DM24NZG TN Translocator protein (TSPO) DM24NZG MA Ligand DM24NZG RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM24NZG RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM251GL DI DM251GL DM251GL DN Aryl mannoside derivative 10 DM251GL TI TTTCRU2 DM251GL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM251GL MA Antagonist DM251GL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM251GL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM25BNZ DI DM25BNZ DM25BNZ DN PMID27998201-Compound-24 DM25BNZ TI TTF2LRI DM25BNZ TN Cathepsin B (CTSB) DM25BNZ MA Inhibitor DM25BNZ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM25BNZ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM25IMA DI DM25IMA DM25IMA DN Fused heterocyclic compound 9 DM25IMA TI TT7RJY8 DM25IMA TN Xanthine dehydrogenase/oxidase (XDH) DM25IMA MA Inhibitor DM25IMA RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM25IMA RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM25M8D DI DM25M8D DM25M8D DN Pyridine-carboximide derivative 1 DM25M8D TI TTF8P9I DM25M8D TN Diacylglycerol acyltransferase 1 (DGAT1) DM25M8D MA Inhibitor DM25M8D RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM25M8D RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM25PMQ DI DM25PMQ DM25PMQ DN PMID28394193-Compound-38 DM25PMQ TI TT9MZCQ DM25PMQ TN Enhancer of zeste homolog 2 (EZH2) DM25PMQ MA Inhibitor DM25PMQ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM25PMQ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM25WGP DI DM25WGP DM25WGP DN PMID26815044-Compound-124 DM25WGP TI TTULVH8 DM25WGP TN Tyrosinase (TYR) DM25WGP MA Inhibitor DM25WGP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM25WGP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM25ZY4 DI DM25ZY4 DM25ZY4 DN Benzothiazepine analog 7 DM25ZY4 TI TTPTXIN DM25ZY4 TN Translocator protein (TSPO) DM25ZY4 MA Ligand DM25ZY4 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM25ZY4 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM26IRH DI DM26IRH DM26IRH DN PMID29649907-Compound-41 DM26IRH TI TTS4UGC DM26IRH TN Farnesoid X-activated receptor (FXR) DM26IRH MA Agonist DM26IRH RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM26IRH RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM26NQE DI DM26NQE DM26NQE DN PMID25666693-Compound-90 DM26NQE TI TTMI6F5 DM26NQE TN Transient receptor potential cation channel V1 (TRPV1) DM26NQE MA Antagonist DM26NQE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM26NQE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM26WNY DI DM26WNY DM26WNY DN PMID28870136-Compound-63 DM26WNY TI TTK0O6Y DM26WNY TN Ecto-5'-nucleotidase (CD73) DM26WNY MA Inhibitor DM26WNY RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM26WNY RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM27154 DI DM27154 DM27154 DN PMID25666693-Compound-152 DM27154 TI TTMI6F5 DM27154 TN Transient receptor potential cation channel V1 (TRPV1) DM27154 MA Antagonist DM27154 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM27154 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM27DQP DI DM27DQP DM27DQP DN PMID25726713-Compound-46 DM27DQP TI TT8J1S3 DM27DQP TN Smoothened homolog (SMO) DM27DQP MA Inhibitor DM27DQP RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM27DQP RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM27SFD DI DM27SFD DM27SFD DN US10034861, Example 164 DM27SFD TI TT3ZS42 DM27SFD TN Phosphodiesterase 1B (PDE1B) DM27SFD MA Inhibitor DM27SFD RN 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861. DM27SFD RU http://www.freepatentsonline.com/US10034861.html DM27U1F DI DM27U1F DM27U1F DN PMID25435285-Compound-22 DM27U1F TI TT8A9EF DM27U1F TN Metabotropic glutamate receptor 3 (mGluR3) DM27U1F MA Antagonist DM27U1F RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM27U1F RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM27U1F DI DM27U1F DM27U1F DN PMID25435285-Compound-22 DM27U1F TI TTXJ47W DM27U1F TN Metabotropic glutamate receptor 2 (mGluR2) DM27U1F MA Antagonist DM27U1F RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM27U1F RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM28E0A DI DM28E0A DM28E0A DN Oxazolo[3,4-a]pyrazine derivative 2 DM28E0A TI TTV1C0Z DM28E0A TN Neuropeptide S receptor (NPSR) DM28E0A MA Antagonist DM28E0A RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM28E0A RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM28NK0 DI DM28NK0 DM28NK0 DN Peptide analog 62 DM28NK0 TI TTQAJF1 DM28NK0 TN Cathepsin G (CTSG) DM28NK0 MA Inhibitor DM28NK0 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM28NK0 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM28NK0 DI DM28NK0 DM28NK0 DN Peptide analog 62 DM28NK0 TI TTPLTSQ DM28NK0 TN Neutrophil elastase (NE) DM28NK0 MA Inhibitor DM28NK0 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM28NK0 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM28XHN DI DM28XHN DM28XHN DN US10035778, Example 1 DM28XHN TI TTIF29E DM28XHN TN Integrin beta-8 (ITGB8) DM28XHN MA Inhibitor DM28XHN RN Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778. DM28XHN RU http://www.freepatentsonline.com/US10035778.html DM29KS1 DI DM29KS1 DM29KS1 DN US8592431, 181 DM29KS1 TI TTLJKZ0 DM29KS1 TN Acetyl-CoA transporter (SLC33A1) DM29KS1 MA Inhibitor DM29KS1 RN Fused ring compound and use thereof. US8592431. DM29KS1 RU http://www.freepatentsonline.com/US8592431.html DM2A75P DI DM2A75P DM2A75P DN PMID28454500-Compound-96 DM2A75P TI TTA6ZN2 DM2A75P TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM2A75P MA Inhibitor DM2A75P RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM2A75P RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM2ANJ7 DI DM2ANJ7 DM2ANJ7 DN PMID26666989-Compound-Figure9middle02 DM2ANJ7 TI TT8BUGW DM2ANJ7 TN Glycogen phosphorylase (PYG) DM2ANJ7 MA Inhibitor DM2ANJ7 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM2ANJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM2AVEG DI DM2AVEG DM2AVEG DN PMID27841045-Compound-130 DM2AVEG TI TT7RJY8 DM2AVEG TN Xanthine dehydrogenase/oxidase (XDH) DM2AVEG MA Inhibitor DM2AVEG RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM2AVEG RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM2BLJ6 DI DM2BLJ6 DM2BLJ6 DN Central azetidine derivative 2 DM2BLJ6 TI TTHS256 DM2BLJ6 TN Metabotropic glutamate receptor 5 (mGluR5) DM2BLJ6 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM2BLJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM2BM1L DI DM2BM1L DM2BM1L DN Heteroaryl-substituted urea derivative 1 DM2BM1L TI TTDP1UC DM2BM1L TN Fatty acid amide hydrolase (FAAH) DM2BM1L MA Inhibitor DM2BM1L RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM2BM1L RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM2BTCU DI DM2BTCU DM2BTCU DN PMID25666693-Compound-158 DM2BTCU TI TTMI6F5 DM2BTCU TN Transient receptor potential cation channel V1 (TRPV1) DM2BTCU MA Antagonist DM2BTCU RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2BTCU RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2BZI0 DI DM2BZI0 DM2BZI0 DN Cyclic cyanoethypypazole derivative 1 DM2BZI0 TI TTRMX3V DM2BZI0 TN Janus kinase 2 (JAK-2) DM2BZI0 MA Inhibitor DM2BZI0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2BZI0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2BZI0 DI DM2BZI0 DM2BZI0 DN Cyclic cyanoethypypazole derivative 1 DM2BZI0 TI TT6DM01 DM2BZI0 TN Janus kinase 1 (JAK-1) DM2BZI0 MA Inhibitor DM2BZI0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2BZI0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2C58A DI DM2C58A DM2C58A DN PMID25666693-Compound-60 DM2C58A TI TTMI6F5 DM2C58A TN Transient receptor potential cation channel V1 (TRPV1) DM2C58A MA Antagonist DM2C58A RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2C58A RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2C6ZF DI DM2C6ZF DM2C6ZF DN PMID29671355-Compound-16 DM2C6ZF TI TT5ZKDI DM2C6ZF TN Histone deacetylase 6 (HDAC6) DM2C6ZF MA Inhibitor DM2C6ZF RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2C6ZF RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TT0PG8F DM2CT4G TN Cyclin-dependent kinase 4 (CDK4) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TTO0FDJ DM2CT4G TN Cyclin-dependent kinase 6 (CDK6) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TT8J1S3 DM2CT4G TN Smoothened homolog (SMO) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2CT4G DI DM2CT4G DM2CT4G DN PMID25726713-Compound-49 DM2CT4G TI TTCJG29 DM2CT4G TN Serine/threonine-protein kinase mTOR (mTOR) DM2CT4G MA Inhibitor DM2CT4G RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM2CT4G RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM2D4WQ DI DM2D4WQ DM2D4WQ DN Tetrazolyl urea derivative 1 DM2D4WQ TI TTDP1UC DM2D4WQ TN Fatty acid amide hydrolase (FAAH) DM2D4WQ MA Inhibitor DM2D4WQ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM2D4WQ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM2DEOA DI DM2DEOA DM2DEOA DN US10100051, Compound 11 DM2DEOA TI TT9ISBX DM2DEOA TN HIF-prolyl hydroxylase 2 (HPH-2) DM2DEOA MA Inhibitor DM2DEOA RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DM2DEOA RU http://www.freepatentsonline.com/US10100051.html DM2DK1E DI DM2DK1E DM2DK1E DN Pyrazole derivative 4 DM2DK1E TI TT6OEDT DM2DK1E TN Cannabinoid receptor 1 (CB1) DM2DK1E MA Antagonist DM2DK1E RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2DK1E RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2DL4I DI DM2DL4I DM2DL4I DN Imidazo[1,2-b]pyridazine derivative 4 DM2DL4I TI TTTDVOJ DM2DL4I TN Tropomyosin-related kinase A (TrkA) DM2DL4I MA Inhibitor DM2DL4I RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2DL4I RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2DT6L DI DM2DT6L DM2DT6L DN BB 0223767 DM2DT6L TI TTOJ9QL DM2DT6L TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM2DT6L MA Inhibitor DM2DT6L RN IRE-1 inhibitors. US8614253. DM2DT6L RU http://www.freepatentsonline.com/US8614253.html DM2DU7R DI DM2DU7R DM2DU7R DN US20160326143, 50 DM2DU7R TI TTW7OTG DM2DU7R TN Leukotriene C4 synthase (LTC4S) DM2DU7R MA Inhibitor DM2DU7R RN Compounds and uses. US9657001. DM2DU7R RU http://www.freepatentsonline.com/US9657001.html DM2DYMS DI DM2DYMS DM2DYMS DN Diphenyl purine derivative 1 DM2DYMS TI TT6OEDT DM2DYMS TN Cannabinoid receptor 1 (CB1) DM2DYMS MA Antagonist DM2DYMS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2DYMS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2E6M7 DI DM2E6M7 DM2E6M7 DN PMID26394986-Compound-42 DM2E6M7 TI TTH8FZW DM2E6M7 TN Signal transducer and activator of transcription 3 (STAT3) DM2E6M7 MA Inhibitor DM2E6M7 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM2E6M7 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM2E7DJ DI DM2E7DJ DM2E7DJ DN Pyrrolo[2,3-d]pyrimidine derivative 20 DM2E7DJ TI TTGM6VW DM2E7DJ TN Tyrosine-protein kinase BTK (ATK) DM2E7DJ MA Inhibitor DM2E7DJ RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM2E7DJ RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM2EDOM DI DM2EDOM DM2EDOM DN Azaindole derivative 3 DM2EDOM TI TT7RJY8 DM2EDOM TN Xanthine dehydrogenase/oxidase (XDH) DM2EDOM MA Inhibitor DM2EDOM RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM2EDOM RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM2EVJR DI DM2EVJR DM2EVJR DN Pyrrolo-pyridinone derivative 4 DM2EVJR TI TT4DXQT DM2EVJR TN Proto-oncogene c-Ret (RET) DM2EVJR MA Inhibitor DM2EVJR RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM2EVJR RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM2F0CQ DI DM2F0CQ DM2F0CQ DN PMID29671355-Compound-59 DM2F0CQ TI TT4YWTO DM2F0CQ TN Histone deacetylase 3 (HDAC3) DM2F0CQ MA Inhibitor DM2F0CQ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2F0CQ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2F0CQ DI DM2F0CQ DM2F0CQ DN PMID29671355-Compound-59 DM2F0CQ TI TTSHTOI DM2F0CQ TN Histone deacetylase 2 (HDAC2) DM2F0CQ MA Inhibitor DM2F0CQ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2F0CQ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2F0CQ DI DM2F0CQ DM2F0CQ DN PMID29671355-Compound-59 DM2F0CQ TI TT6R7JZ DM2F0CQ TN Histone deacetylase 1 (HDAC1) DM2F0CQ MA Inhibitor DM2F0CQ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM2F0CQ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM2F1T0 DI DM2F1T0 DM2F1T0 DN PMID25435179-Compound-WO2012106509CAY10602 DM2F1T0 TI TTUF2HO DM2F1T0 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM2F1T0 MA Inhibitor DM2F1T0 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM2F1T0 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM2FDCT DI DM2FDCT DM2FDCT DN PMID26004420-Compound-WO2014150132C DM2FDCT TI TTJ13ST DM2FDCT TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM2FDCT MA Inhibitor DM2FDCT RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM2FDCT RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM2FPHZ DI DM2FPHZ DM2FPHZ DN PMID28394193-Compound-55 DM2FPHZ TI TTJW2UQ DM2FPHZ TN EZH2 Y641N mutant (EZH2 Y641N) DM2FPHZ MA Inhibitor DM2FPHZ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2FPHZ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2FPHZ DI DM2FPHZ DM2FPHZ DN PMID28394193-Compound-55 DM2FPHZ TI TT9MZCQ DM2FPHZ TN Enhancer of zeste homolog 2 (EZH2) DM2FPHZ MA Inhibitor DM2FPHZ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2FPHZ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2FUIB DI DM2FUIB DM2FUIB DN Acyl piperidine derivative 2 DM2FUIB TI TT2F4OL DM2FUIB TN Tissue transglutaminase (TG2) DM2FUIB MA Inhibitor DM2FUIB RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2FUIB RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2FZPE DI DM2FZPE DM2FZPE DN Piperidinyl triazole derivative 2 DM2FZPE TI TTTJZ4M DM2FZPE TN Prolylcarboxypeptidase (PRCP) DM2FZPE MA Inhibitor DM2FZPE RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM2FZPE RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTJQOD7 DM2G3VE TN 5-HT 2A receptor (HTR2A) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTJS8PY DM2G3VE TN 5-HT 6 receptor (HTR6) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTO9X1H DM2G3VE TN 5-HT 7 receptor (HTR7) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTEX248 DM2G3VE TN Dopamine D2 receptor (D2R) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G3VE DI DM2G3VE DM2G3VE DN PMID30124346-Compound-34TABLE4 DM2G3VE TI TTSQIFT DM2G3VE TN 5-HT 1A receptor (HTR1A) DM2G3VE MA Ligand DM2G3VE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM2G3VE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM2G83R DI DM2G83R DM2G83R DN Benzimidazole and imadazopyridine carboximidamide compound 1 DM2G83R TI TTZJYKH DM2G83R TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM2G83R MA Inhibitor DM2G83R RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM2G83R RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM2G8DN DI DM2G8DN DM2G8DN DN PMID30074415-Compound-GS3 DM2G8DN TI TT2LVK8 DM2G8DN TN Carbonic anhydrase IX (CA-IX) DM2G8DN MA Inhibitor DM2G8DN RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM2G8DN RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM2GDXH DI DM2GDXH DM2GDXH DN PMID27744724-Compound-29 DM2GDXH TI TTL53M6 DM2GDXH TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM2GDXH MA Inhibitor DM2GDXH RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM2GDXH RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM2GL47 DI DM2GL47 DM2GL47 DN Isoflavone derivative 5 DM2GL47 TI TTJOMH6 DM2GL47 TN Zinc finger protein GLI1 (Gli1) DM2GL47 MA Inhibitor DM2GL47 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2GL47 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM2GL47 DI DM2GL47 DM2GL47 DN Isoflavone derivative 5 DM2GL47 TI TT8J1S3 DM2GL47 TN Smoothened homolog (SMO) DM2GL47 MA Inhibitor DM2GL47 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2GL47 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM2GON6 DI DM2GON6 DM2GON6 DN PMID26815044-Compound-117 DM2GON6 TI TTULVH8 DM2GON6 TN Tyrosinase (TYR) DM2GON6 MA Inhibitor DM2GON6 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2GON6 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2GPLQ DI DM2GPLQ DM2GPLQ DN Urea and carbamate bioisostere derivative 7 DM2GPLQ TI TTL7C8Q DM2GPLQ TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM2GPLQ MA Inhibitor DM2GPLQ RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM2GPLQ RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM2GR5Q DI DM2GR5Q DM2GR5Q DN Pyridinone compound 1 DM2GR5Q TI TTZCRP3 DM2GR5Q TN ERK activator kinase (MEK) DM2GR5Q MA Inhibitor DM2GR5Q RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM2GR5Q RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM2GZ5Y DI DM2GZ5Y DM2GZ5Y DN Biphenyl mannoside derivative 18 DM2GZ5Y TI TTTCRU2 DM2GZ5Y TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2GZ5Y MA Antagonist DM2GZ5Y RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2GZ5Y RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2H95E DI DM2H95E DM2H95E DN Thiazole carboxamide derivative 5 DM2H95E TI TTCZOF2 DM2H95E TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM2H95E MA Inhibitor DM2H95E RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM2H95E RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM2HG9U DI DM2HG9U DM2HG9U DN PMID25468267-Compound-49 DM2HG9U TI TT0RGE9 DM2HG9U TN Lysine-specific demethylase 4 (KDM4) DM2HG9U MA Inhibitor DM2HG9U RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM2HG9U RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM2HLGC DI DM2HLGC DM2HLGC DN DZ9 DM2HLGC TI TT1NFO3 DM2HLGC TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DM2HLGC MA Inhibitor DM2HLGC RN Targeting NAD biosynthesis in bacterial pathogens. US8785499. DM2HLGC RU http://www.freepatentsonline.com/US8785499.html DM2HO1S DI DM2HO1S DM2HO1S DN Pyrazole derivative 20 DM2HO1S TI TT6OEDT DM2HO1S TN Cannabinoid receptor 1 (CB1) DM2HO1S MA Antagonist DM2HO1S RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2HO1S RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2I1QZ DI DM2I1QZ DM2I1QZ DN PMID26651364-Compound-126b DM2I1QZ TI TTTCRU2 DM2I1QZ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2I1QZ MA Antagonist DM2I1QZ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2I1QZ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2I9HY DI DM2I9HY DM2I9HY DN PMID28394193-Compound-52 DM2I9HY TI TT9MZCQ DM2I9HY TN Enhancer of zeste homolog 2 (EZH2) DM2I9HY MA Inhibitor DM2I9HY RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2I9HY RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2IBX9 DI DM2IBX9 DM2IBX9 DN Di-substituted piperidine derivative 3 DM2IBX9 TI TTEB0GD DM2IBX9 TN Cholinesterase (BCHE) DM2IBX9 MA Inhibitor DM2IBX9 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM2IBX9 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM2IKDL DI DM2IKDL DM2IKDL DN Resorcinol compound 24 DM2IKDL TI TTULVH8 DM2IKDL TN Tyrosinase (TYR) DM2IKDL MA Inhibitor DM2IKDL RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2IKDL RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2ISDH DI DM2ISDH DM2ISDH DN PMID25991433-Compound-A7 DM2ISDH TI TTHS0U8 DM2ISDH TN Stress-activated protein kinase JNK2 (JNK2) DM2ISDH MA Inhibitor DM2ISDH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2ISDH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2ISDH DI DM2ISDH DM2ISDH DN PMID25991433-Compound-A7 DM2ISDH TI TT0K6EO DM2ISDH TN Stress-activated protein kinase JNK1 (JNK1) DM2ISDH MA Inhibitor DM2ISDH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2ISDH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2J8IS DI DM2J8IS DM2J8IS DN US8772478, 1 DM2J8IS TI TTQICM2 DM2J8IS TN ADAM metallopeptidase 33 (ADAM33) DM2J8IS MA Inhibitor DM2J8IS RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DM2J8IS RU http://www.freepatentsonline.com/US8772478.html DM2JF0T DI DM2JF0T DM2JF0T DN PMID28092474-Compound-32t DM2JF0T TI TT6R7JZ DM2JF0T TN Histone deacetylase 1 (HDAC1) DM2JF0T MA Inhibitor DM2JF0T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM2JF0T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM2JF0T DI DM2JF0T DM2JF0T DN PMID28092474-Compound-32t DM2JF0T TI TT5ZKDI DM2JF0T TN Histone deacetylase 6 (HDAC6) DM2JF0T MA Inhibitor DM2JF0T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM2JF0T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM2K54D DI DM2K54D DM2K54D DN PMID27967267-Compound-stenine DM2K54D TI TT1RS9F DM2K54D TN Acetylcholinesterase (AChE) DM2K54D MA Inhibitor DM2K54D RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM2K54D RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM2K6YU DI DM2K6YU DM2K6YU DN US8546370, 11 DM2K6YU TI TTUMHT8 DM2K6YU TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DM2K6YU MA Inhibitor DM2K6YU RN Compounds and compositions as kinase inhibitors. US8546370. DM2K6YU RU http://www.freepatentsonline.com/US8546370.html DM2KTAB DI DM2KTAB DM2KTAB DN PMID25666693-Compound-160 DM2KTAB TI TTMI6F5 DM2KTAB TN Transient receptor potential cation channel V1 (TRPV1) DM2KTAB MA Antagonist DM2KTAB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2KTAB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2KVDH DI DM2KVDH DM2KVDH DN PMID28394193-Compound-27 DM2KVDH TI TT9MZCQ DM2KVDH TN Enhancer of zeste homolog 2 (EZH2) DM2KVDH MA Inhibitor DM2KVDH RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2KVDH RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2KVMT DI DM2KVMT DM2KVMT DN Heterocycle-containing compound 2 DM2KVMT TI TT9O6WS DM2KVMT TN Glucagon receptor (GCGR) DM2KVMT MA Antagonist DM2KVMT RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM2KVMT RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM2L7ES DI DM2L7ES DM2L7ES DN PMID29338548-Compound-41 DM2L7ES TI TTHJTF7 DM2L7ES TN Glycine transporter GlyT-1 (SLC6A9) DM2L7ES MA Inhibitor DM2L7ES RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM2L7ES RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM2L83Y DI DM2L83Y DM2L83Y DN AGGGWZCOULSEER-PYUWXLGESA-N DM2L83Y TI TT5U49F DM2L83Y TN PRKACA messenger RNA (PRKACA mRNA) DM2L83Y MA Inhibitor DM2L83Y RN Purine derivatives. US8846696. DM2L83Y RU http://www.freepatentsonline.com/US8846696.html DM2L9KI DI DM2L9KI DM2L9KI DN Peptide analog 20 DM2L9KI TI TTSJMN8 DM2L9KI TN Immunoproteasome complex (IP) DM2L9KI MA Inhibitor DM2L9KI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM2L9KI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM2LQXY DI DM2LQXY DM2LQXY DN Ketoheterocycle derivative 4 DM2LQXY TI TTDP1UC DM2LQXY TN Fatty acid amide hydrolase (FAAH) DM2LQXY MA Inhibitor DM2LQXY RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM2LQXY RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM2MPN0 DI DM2MPN0 DM2MPN0 DN N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 2 DM2MPN0 TI TT6OEDT DM2MPN0 TN Cannabinoid receptor 1 (CB1) DM2MPN0 MA Antagonist DM2MPN0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2MPN0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2MQD0 DI DM2MQD0 DM2MQD0 DN SB19065 DM2MQD0 TI TT42OGM DM2MQD0 TN Hematopoietic cell kinase (HCK) DM2MQD0 MA Inhibitor DM2MQD0 RN Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same. US9062066. DM2MQD0 RU http://www.freepatentsonline.com/US9062066.html DM2MYL9 DI DM2MYL9 DM2MYL9 DN Isoindoline derivative 3 DM2MYL9 TI TTQ6VDM DM2MYL9 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM2MYL9 MA Ligand DM2MYL9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM2MYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM2MYL9 DI DM2MYL9 DM2MYL9 DN Isoindoline derivative 3 DM2MYL9 TI TT5TPI6 DM2MYL9 TN Opioid receptor sigma 1 (OPRS1) DM2MYL9 MA Ligand DM2MYL9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM2MYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM2MYL9 DI DM2MYL9 DM2MYL9 DN Isoindoline derivative 3 DM2MYL9 TI TT9NXW4 DM2MYL9 TN Sigma intracellular receptor 2 (TMEM97) DM2MYL9 MA Ligand DM2MYL9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM2MYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM2NS5T DI DM2NS5T DM2NS5T DN PMID28394193-Compound-39 DM2NS5T TI TT9MZCQ DM2NS5T TN Enhancer of zeste homolog 2 (EZH2) DM2NS5T MA Inhibitor DM2NS5T RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM2NS5T RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM2NVLZ DI DM2NVLZ DM2NVLZ DN PMID25514969-Compound-8 DM2NVLZ TI TT4EB85 DM2NVLZ TN Cholesterol 24-hydroxylase (CYP46A1) DM2NVLZ MA Inhibitor DM2NVLZ RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DM2NVLZ RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DM2OM4Z DI DM2OM4Z DM2OM4Z DN PMID28454500-Compound-35 DM2OM4Z TI TTA6ZN2 DM2OM4Z TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM2OM4Z MA Activator DM2OM4Z RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM2OM4Z RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM2OM4Z DI DM2OM4Z DM2OM4Z DN PMID28454500-Compound-35 DM2OM4Z TI TT3Z6Y9 DM2OM4Z TN Cysteines of Keap1 (KEAP1 Cysteines) DM2OM4Z MA Modulator DM2OM4Z RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM2OM4Z RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM2OTJS DI DM2OTJS DM2OTJS DN Dipeptide analog 1 DM2OTJS TI TTOUSTQ DM2OTJS TN Proteasome beta-9 (PS beta-9) DM2OTJS MA Inhibitor DM2OTJS RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM2OTJS RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM2OTJS DI DM2OTJS DM2OTJS DN Dipeptide analog 1 DM2OTJS TI TTEAD9J DM2OTJS TN Proteasome beta-8 (PS beta-8) DM2OTJS MA Inhibitor DM2OTJS RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM2OTJS RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM2OXW3 DI DM2OXW3 DM2OXW3 DN Peptide analog 69 DM2OXW3 TI TTPLTSQ DM2OXW3 TN Neutrophil elastase (NE) DM2OXW3 MA Inhibitor DM2OXW3 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM2OXW3 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM2P05S DI DM2P05S DM2P05S DN PMID29053063-Compound-5 DM2P05S TI TTZ963I DM2P05S TN Monoglyceride lipase (MAGL) DM2P05S MA Inhibitor DM2P05S RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM2P05S RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM2P509 DI DM2P509 DM2P509 DN N-oxalyl-D-tyrosine derivative 1 DM2P509 TI TTWAQBO DM2P509 TN Lysine-specific demethylase 4E (KDM4E) DM2P509 MA Inhibitor DM2P509 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM2P509 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM2P5J9 DI DM2P5J9 DM2P5J9 DN PMID27321640-Compound-75 DM2P5J9 TI TTJGW1Z DM2P5J9 TN Phosphodiesterase 2A (PDE2A) DM2P5J9 MA Inhibitor DM2P5J9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM2P5J9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM2PUBI DI DM2PUBI DM2PUBI DN PMID26099857-Compound-WO2011037610Formula(I) DM2PUBI TI TTKVTQO DM2PUBI TN Prostaglandin transporter (SLC21A2) DM2PUBI MA Inhibitor DM2PUBI RN Treatment of obesity and pulmonary arterial hypertension with inhibitors of the prostaglandin transporter: evaluation of patent WO2014/204895A1.Expert Opin Ther Pat. 2015;25(9):1069-77. DM2PUBI RU https://www.ncbi.nlm.nih.gov/pubmed/26099857 DM2QCBF DI DM2QCBF DM2QCBF DN Heterocyclic derivative 2 DM2QCBF TI TTHS256 DM2QCBF TN Metabotropic glutamate receptor 5 (mGluR5) DM2QCBF MA Modulator DM2QCBF RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM2QCBF RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM2QNMC DI DM2QNMC DM2QNMC DN Bidentate ligands of Markush derivative 2 DM2QNMC TI TTK0FEA DM2QNMC TN Leucine-rich repeat kinase 2 (LRRK2) DM2QNMC MA Inhibitor DM2QNMC RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM2QNMC RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM2QNMC DI DM2QNMC DM2QNMC DN Bidentate ligands of Markush derivative 2 DM2QNMC TI TTVOE6D DM2QNMC TN Mitogen-activated protein kinase (MAPK) DM2QNMC MA Inhibitor DM2QNMC RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM2QNMC RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM2QRIW DI DM2QRIW DM2QRIW DN PMID29130358-Compound-Figure17(13) DM2QRIW TI TT6X50U DM2QRIW TN Matrix metalloproteinase-9 (MMP-9) DM2QRIW MA Inhibitor DM2QRIW RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM2QRIW RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM2QVHY DI DM2QVHY DM2QVHY DN Fused heterocyclic compound 3 DM2QVHY TI TT7RJY8 DM2QVHY TN Xanthine dehydrogenase/oxidase (XDH) DM2QVHY MA Inhibitor DM2QVHY RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM2QVHY RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM2QWXF DI DM2QWXF DM2QWXF DN PMID26560530-Compound-32 DM2QWXF TI TT2F4OL DM2QWXF TN Tissue transglutaminase (TG2) DM2QWXF MA Inhibitor DM2QWXF RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2QWXF RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2QXVW DI DM2QXVW DM2QXVW DN Furopyridine derivative 1 DM2QXVW TI TT6OEDT DM2QXVW TN Cannabinoid receptor 1 (CB1) DM2QXVW MA Antagonist DM2QXVW RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2QXVW RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2R468 DI DM2R468 DM2R468 DN Piperazine carbamate/urea derivative 3 DM2R468 TI TT9JNIC DM2R468 TN Histamine H3 receptor (H3R) DM2R468 MA Ligand DM2R468 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM2R468 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM2RE91 DI DM2RE91 DM2RE91 DN US9586945, 1 DM2RE91 TI TTYJRN5 DM2RE91 TN N-acetylglucosaminyltransferase I (NAGAT1) DM2RE91 MA Inhibitor DM2RE91 RN Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945. DM2RE91 RU http://www.freepatentsonline.com/US9586945.html DM2RPYB DI DM2RPYB DM2RPYB DN Resorcinol compound 32 DM2RPYB TI TTULVH8 DM2RPYB TN Tyrosinase (TYR) DM2RPYB MA Inhibitor DM2RPYB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2RPYB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2RZL8 DI DM2RZL8 DM2RZL8 DN Sulfonamide derivative 9 DM2RZL8 TI TT2F4OL DM2RZL8 TN Tissue transglutaminase (TG2) DM2RZL8 MA Inhibitor DM2RZL8 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2RZL8 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2SUCK DI DM2SUCK DM2SUCK DN Isoxazole-based bicyclic compound 17 DM2SUCK TI TTE4BSY DM2SUCK TN Bromodomain and extraterminal domain protein (BET) DM2SUCK MA Inhibitor DM2SUCK RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM2SUCK RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM2SZ0B DI DM2SZ0B DM2SZ0B DN PMID26651364-Compound-7e DM2SZ0B TI TTTCRU2 DM2SZ0B TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2SZ0B MA Antagonist DM2SZ0B RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2SZ0B RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2TDXW DI DM2TDXW DM2TDXW DN Carbamide derivative 15 DM2TDXW TI TTOHSBA DM2TDXW TN Vascular endothelial growth factor A (VEGFA) DM2TDXW MA Inhibitor DM2TDXW RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM2TDXW RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM2TF64 DI DM2TF64 DM2TF64 DN Aminopyrimidine derivative 10 DM2TF64 TI TTH5TC2 DM2TF64 TN NF-kappa-B-activating kinase (TBK1) DM2TF64 MA Inhibitor DM2TF64 RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM2TF64 RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM2TNH4 DI DM2TNH4 DM2TNH4 DN PMID27599163-Compound-77 DM2TNH4 TI TTPTXIN DM2TNH4 TN Translocator protein (TSPO) DM2TNH4 MA Ligand DM2TNH4 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM2TNH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM2U1QH DI DM2U1QH DM2U1QH DN Diazepinone derivative 5 DM2U1QH TI TTHS256 DM2U1QH TN Metabotropic glutamate receptor 5 (mGluR5) DM2U1QH MA Modulator DM2U1QH RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM2U1QH RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM2UDV8 DI DM2UDV8 DM2UDV8 DN Azetidinyl-piperidine derivative 3 DM2UDV8 TI TTZ963I DM2UDV8 TN Monoglyceride lipase (MAGL) DM2UDV8 MA Inhibitor DM2UDV8 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM2UDV8 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM2UGK3 DI DM2UGK3 DM2UGK3 DN Azetidine-1-carboxamide derivative 3 DM2UGK3 TI TT6OEDT DM2UGK3 TN Cannabinoid receptor 1 (CB1) DM2UGK3 MA Antagonist DM2UGK3 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM2UGK3 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM2ULB8 DI DM2ULB8 DM2ULB8 DN US9187437, 38 DM2ULB8 TI TTDYP7I DM2ULB8 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM2ULB8 MA Inhibitor DM2ULB8 RN Substituted oxadiazole compounds. US9187437. DM2ULB8 RU http://www.freepatentsonline.com/US9187437.html DM2URPE DI DM2URPE DM2URPE DN Cyclohexyl carbamate derivative 7 DM2URPE TI TTULVH8 DM2URPE TN Tyrosinase (TYR) DM2URPE MA Inhibitor DM2URPE RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2URPE RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2UWSX DI DM2UWSX DM2UWSX DN Amidine compound 2 DM2UWSX TI TTQR74A DM2UWSX TN Proteinase activated receptor 2 (PAR2) DM2UWSX MA Antagonist DM2UWSX RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM2UWSX RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM2V31C DI DM2V31C DM2V31C DN Ampicidin analog 1 DM2V31C TI TTBH0VX DM2V31C TN Histone deacetylase (HDAC) DM2V31C MA Inhibitor DM2V31C RN Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30. DM2V31C RU https://www.ncbi.nlm.nih.gov/pubmed/26566576 DM2VHJ7 DI DM2VHJ7 DM2VHJ7 DN PMID26666989-Compound-Figure12bottommiddle02 DM2VHJ7 TI TT8BUGW DM2VHJ7 TN Glycogen phosphorylase (PYG) DM2VHJ7 MA Inhibitor DM2VHJ7 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM2VHJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TTT7PJU DM2VQ4P TN Janus kinase 3 (JAK-3) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TTBYWP2 DM2VQ4P TN TYK2 tyrosine kinase (TYK2) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TTRMX3V DM2VQ4P TN Janus kinase 2 (JAK-2) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VQ4P DI DM2VQ4P DM2VQ4P DN Pyrazolopyridine derivative 3 DM2VQ4P TI TT6DM01 DM2VQ4P TN Janus kinase 1 (JAK-1) DM2VQ4P MA Inhibitor DM2VQ4P RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2VQ4P RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2VZG6 DI DM2VZG6 DM2VZG6 DN PMID25435285-Compound-51 DM2VZG6 TI TTXJ47W DM2VZG6 TN Metabotropic glutamate receptor 2 (mGluR2) DM2VZG6 MA Antagonist DM2VZG6 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM2VZG6 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM2W7JE DI DM2W7JE DM2W7JE DN Aryl mannoside derivative 13 DM2W7JE TI TTTCRU2 DM2W7JE TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2W7JE MA Antagonist DM2W7JE RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2W7JE RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2W9AP DI DM2W9AP DM2W9AP DN PMID25482888-Compound-21 DM2W9AP TI TTDIGC1 DM2W9AP TN Dipeptidyl peptidase 4 (DPP-4) DM2W9AP MA Inhibitor DM2W9AP RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM2W9AP RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM2WDXV DI DM2WDXV DM2WDXV DN Thiazole derivative 1 DM2WDXV TI TTULVH8 DM2WDXV TN Tyrosinase (TYR) DM2WDXV MA Inhibitor DM2WDXV RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM2WDXV RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM2WJKR DI DM2WJKR DM2WJKR DN PMID25666693-Compound-134 DM2WJKR TI TTMI6F5 DM2WJKR TN Transient receptor potential cation channel V1 (TRPV1) DM2WJKR MA Antagonist DM2WJKR RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2WJKR RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2WMGO DI DM2WMGO DM2WMGO DN Antibodie derivative 4 DM2WMGO TI TTOHSBA DM2WMGO TN Vascular endothelial growth factor A (VEGFA) DM2WMGO MA Inhibitor DM2WMGO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM2WMGO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM2X4R0 DI DM2X4R0 DM2X4R0 DN PMID26560530-Compound-54 DM2X4R0 TI TT2F4OL DM2X4R0 TN Tissue transglutaminase (TG2) DM2X4R0 MA Inhibitor DM2X4R0 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM2X4R0 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM2XGNY DI DM2XGNY DM2XGNY DN Piperazine derivative 4 DM2XGNY TI TTJQOD7 DM2XGNY TN 5-HT 2A receptor (HTR2A) DM2XGNY MA Antagonist DM2XGNY RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM2XGNY RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM2XKTB DI DM2XKTB DM2XKTB DN PMID28270021-Compound-WO2013161919Example85-117 DM2XKTB TI TTTDVOJ DM2XKTB TN Tropomyosin-related kinase A (TrkA) DM2XKTB MA Inhibitor DM2XKTB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM2XKTB RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM2Y64W DI DM2Y64W DM2Y64W DN PMID26004420-Compound-WO2012058116C DM2Y64W TI TTJ13ST DM2Y64W TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM2Y64W MA Inhibitor DM2Y64W RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM2Y64W RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM2YAPJ DI DM2YAPJ DM2YAPJ DN PMID28270010-Compound-Figure5-1 DM2YAPJ TI TTTDVOJ DM2YAPJ TN Tropomyosin-related kinase A (TrkA) DM2YAPJ MA Inhibitor DM2YAPJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2YAPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2YAPJ DI DM2YAPJ DM2YAPJ DN PMID28270010-Compound-Figure5-1 DM2YAPJ TI TTXABCW DM2YAPJ TN NT-3 growth factor receptor (TrkC) DM2YAPJ MA Inhibitor DM2YAPJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2YAPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2YAPJ DI DM2YAPJ DM2YAPJ DN PMID28270010-Compound-Figure5-1 DM2YAPJ TI TTKN7QR DM2YAPJ TN BDNF/NT-3 growth factors receptor (TrkB) DM2YAPJ MA Inhibitor DM2YAPJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM2YAPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM2YPLF DI DM2YPLF DM2YPLF DN PMID27774822-Compound-Figure2Example1-1right DM2YPLF TI TTT7PJU DM2YPLF TN Janus kinase 3 (JAK-3) DM2YPLF MA Inhibitor DM2YPLF RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2YPLF RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2YPLF DI DM2YPLF DM2YPLF DN PMID27774822-Compound-Figure2Example1-1right DM2YPLF TI TTRMX3V DM2YPLF TN Janus kinase 2 (JAK-2) DM2YPLF MA Inhibitor DM2YPLF RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM2YPLF RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM2YVGH DI DM2YVGH DM2YVGH DN Biaryl mannoside derivative 23 DM2YVGH TI TTTCRU2 DM2YVGH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM2YVGH MA Antagonist DM2YVGH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM2YVGH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM2Z43I DI DM2Z43I DM2Z43I DN US9073931, E1 DM2Z43I TI TTECBXN DM2Z43I TN Oxysterols receptor LXR-alpha (NR1H3) DM2Z43I MA Inhibitor DM2Z43I RN Liver X receptor modulators. US9073931. DM2Z43I RU http://www.freepatentsonline.com/US9073931.html DM2ZCTW DI DM2ZCTW DM2ZCTW DN PMID25991433-Compound-E5 DM2ZCTW TI TT0K6EO DM2ZCTW TN Stress-activated protein kinase JNK1 (JNK1) DM2ZCTW MA Inhibitor DM2ZCTW RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM2ZCTW RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM2ZR8M DI DM2ZR8M DM2ZR8M DN PMID25666693-Compound-98 DM2ZR8M TI TTMI6F5 DM2ZR8M TN Transient receptor potential cation channel V1 (TRPV1) DM2ZR8M MA Antagonist DM2ZR8M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2ZR8M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2ZUVH DI DM2ZUVH DM2ZUVH DN PMID25399762-Compound-Table1-C18 DM2ZUVH TI TTGP7BY DM2ZUVH TN Monoamine oxidase type B (MAO-B) DM2ZUVH MA Inhibitor DM2ZUVH RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM2ZUVH RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM2ZVXD DI DM2ZVXD DM2ZVXD DN PMID25666693-Compound-83 DM2ZVXD TI TTMI6F5 DM2ZVXD TN Transient receptor potential cation channel V1 (TRPV1) DM2ZVXD MA Antagonist DM2ZVXD RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM2ZVXD RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM2ZWSM DI DM2ZWSM DM2ZWSM DN Cyclopropyl-spiro piperidine derivative 4 DM2ZWSM TI TT4G2JS DM2ZWSM TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM2ZWSM MA Blocker DM2ZWSM RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM2ZWSM RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM2ZYVL DI DM2ZYVL DM2ZYVL DN Isoflavone derivative 6 DM2ZYVL TI TTJOMH6 DM2ZYVL TN Zinc finger protein GLI1 (Gli1) DM2ZYVL MA Inhibitor DM2ZYVL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2ZYVL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM2ZYVL DI DM2ZYVL DM2ZYVL DN Isoflavone derivative 6 DM2ZYVL TI TT8J1S3 DM2ZYVL TN Smoothened homolog (SMO) DM2ZYVL MA Inhibitor DM2ZYVL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DM2ZYVL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DM305UL DI DM305UL DM305UL DN N-(pyridin-2-yl)pyridine methylsulfone derivative 1 DM305UL TI TT7HF4W DM305UL TN Cyclin-dependent kinase 2 (CDK2) DM305UL MA Inhibitor DM305UL RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM305UL RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM305UL DI DM305UL DM305UL DN N-(pyridin-2-yl)pyridine methylsulfone derivative 1 DM305UL TI TT1LVF2 DM305UL TN Cyclin-dependent kinase 9 (CDK9) DM305UL MA Inhibitor DM305UL RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM305UL RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TTT7PJU DM30Y8M TN Janus kinase 3 (JAK-3) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TTBYWP2 DM30Y8M TN TYK2 tyrosine kinase (TYK2) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TTRMX3V DM30Y8M TN Janus kinase 2 (JAK-2) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM30Y8M DI DM30Y8M DM30Y8M DN Pyrrolo[2,3-d]pyrimidine derivative 7 DM30Y8M TI TT6DM01 DM30Y8M TN Janus kinase 1 (JAK-1) DM30Y8M MA Inhibitor DM30Y8M RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM30Y8M RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM310ES DI DM310ES DM310ES DN N-(naphthylamino)-benzoate derivative 1 DM310ES TI TT5ZWB6 DM310ES TN Dihydrodiol dehydrogenase type I (AKR1C3) DM310ES MA Inhibitor; Antagonist; Blocker DM310ES RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM310ES RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM316FB DI DM316FB DM316FB DN US9434725, 315 DM316FB TI TTCGOIN DM316FB TN PIM-3 protein kinase (PIM3) DM316FB MA Inhibitor DM316FB RN 5-azaindazole compounds and methods of use. US9434725. DM316FB RU http://www.freepatentsonline.com/US9434725.html DM31BMP DI DM31BMP DM31BMP DN Metal complex derivative 3 DM31BMP TI TTR7UJ3 DM31BMP TN Cytoplasmic thioredoxin reductase (TXNRD1) DM31BMP MA Inhibitor DM31BMP RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM31BMP RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM32N7D DI DM32N7D DM32N7D DN Pyrimidopyridazinone derivative 1 DM32N7D TI TTRMX3V DM32N7D TN Janus kinase 2 (JAK-2) DM32N7D MA Inhibitor DM32N7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM32N7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM32N7D DI DM32N7D DM32N7D DN Pyrimidopyridazinone derivative 1 DM32N7D TI TTOU65C DM32N7D TN Tyrosine-protein kinase SYK (SYK) DM32N7D MA Inhibitor DM32N7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM32N7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TTRA6BO DM346EU TN Bromodomain-containing protein 4 (BRD4) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TTHE657 DM346EU TN Bromodomain-containing protein 3 (BRD3) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TTDP48B DM346EU TN Bromodomain-containing protein 2 (BRD2) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM346EU DI DM346EU DM346EU DN PMID26924192-Compound-104 DM346EU TI TT7CPI5 DM346EU TN Bromodomain testis-specific protein (BRDT) DM346EU MA Inhibitor DM346EU RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM346EU RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM34KXF DI DM34KXF DM34KXF DN US8921389, 1 DM34KXF TI TT9ISBX DM34KXF TN HIF-prolyl hydroxylase 2 (HPH-2) DM34KXF MA Inhibitor DM34KXF RN Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170. DM34KXF RU http://www.freepatentsonline.com/US9695170.html DM34MCP DI DM34MCP DM34MCP DN Triazolo[4,3-b]pyridazine derivative 1 DM34MCP TI TTSCO7R DM34MCP TN NAD-dependent deacetylase sirtuin (SIRT) DM34MCP MA Inhibitor DM34MCP RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM34MCP RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM34NZ8 DI DM34NZ8 DM34NZ8 DN Imatinib and nilotinib derivative 2 DM34NZ8 TI TTUNARX DM34NZ8 TN Carbonic anhydrase (CA) DM34NZ8 MA Inhibitor DM34NZ8 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM34NZ8 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM34ZCG DI DM34ZCG DM34ZCG DN Imidazo cyclohexylamine derivative 1 DM34ZCG TI TTDIGC1 DM34ZCG TN Dipeptidyl peptidase 4 (DPP-4) DM34ZCG MA Inhibitor DM34ZCG RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM34ZCG RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM361J8 DI DM361J8 DM361J8 DN Fused heterocyclic compound 2 DM361J8 TI TT7RJY8 DM361J8 TN Xanthine dehydrogenase/oxidase (XDH) DM361J8 MA Inhibitor DM361J8 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM361J8 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM36P7T DI DM36P7T DM36P7T DN PMID28627961-Compound-22 DM36P7T TI TTYLQ8V DM36P7T TN Prostaglandin E synthase (PTGES) DM36P7T MA Inhibitor DM36P7T RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM36P7T RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM36QM5 DI DM36QM5 DM36QM5 DN Azole derivative 5 DM36QM5 TI TTDP1UC DM36QM5 TN Fatty acid amide hydrolase (FAAH) DM36QM5 MA Inhibitor DM36QM5 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM36QM5 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM36R21 DI DM36R21 DM36R21 DN US8481733, 95 DM36R21 TI TTIET93 DM36R21 TN Activated CDC42 kinase 1 (ACK-1) DM36R21 MA Inhibitor DM36R21 RN Substituted imidazopyr- and imidazotri-azines. US8481733. DM36R21 RU http://www.freepatentsonline.com/US8481733.html DM37FDV DI DM37FDV DM37FDV DN PMID25684022-Compound-WO2010127754 DM37FDV TI TTCZOF2 DM37FDV TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM37FDV MA Inhibitor DM37FDV RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM37FDV RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM37GMQ DI DM37GMQ DM37GMQ DN PMID26004420-Compound-WO2010129379A DM37GMQ TI TTJ13ST DM37GMQ TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM37GMQ MA Inhibitor DM37GMQ RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM37GMQ RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM37MCN DI DM37MCN DM37MCN DN Epoxysuccinate derivative 5 DM37MCN TI TTG5QB7 DM37MCN TN Calpain-2 (CAPN2) DM37MCN MA Inhibitor DM37MCN RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM37MCN RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TTQBR95 DM37VIQ TN Stress-activated protein kinase 2a (p38 alpha) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TT0K6EO DM37VIQ TN Stress-activated protein kinase JNK1 (JNK1) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TTHS0U8 DM37VIQ TN Stress-activated protein kinase JNK2 (JNK2) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM37VIQ DI DM37VIQ DM37VIQ DN PMID25991433-Compound-F2 DM37VIQ TI TT056SO DM37VIQ TN Stress-activated protein kinase JNK3 (JNK3) DM37VIQ MA Inhibitor DM37VIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM37VIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM389YD DI DM389YD DM389YD DN Diazepinone derivative 4 DM389YD TI TTHS256 DM389YD TN Metabotropic glutamate receptor 5 (mGluR5) DM389YD MA Modulator DM389YD RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM389YD RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM394WH DI DM394WH DM394WH DN PMID29671355-Compound-70 DM394WH TI TTTQGH8 DM394WH TN Histone deacetylase 4 (HDAC4) DM394WH MA Inhibitor DM394WH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM394WH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM39FDV DI DM39FDV DM39FDV DN PMID30107136-Compound-Example53 DM39FDV TI TT23XQV DM39FDV TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM39FDV MA Inhibitor DM39FDV RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM39FDV RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM39H1F DI DM39H1F DM39H1F DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 3 DM39H1F TI TTPTXIN DM39H1F TN Translocator protein (TSPO) DM39H1F MA Ligand DM39H1F RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM39H1F RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM39HCU DI DM39HCU DM39HCU DN PMID29649907-Compound-33 DM39HCU TI TTS4UGC DM39HCU TN Farnesoid X-activated receptor (FXR) DM39HCU MA Agonist DM39HCU RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM39HCU RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM39NBT DI DM39NBT DM39NBT DN PMID25991433-Compound-A10 DM39NBT TI TTHS0U8 DM39NBT TN Stress-activated protein kinase JNK2 (JNK2) DM39NBT MA Inhibitor DM39NBT RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM39NBT RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM39NBT DI DM39NBT DM39NBT DN PMID25991433-Compound-A10 DM39NBT TI TT0K6EO DM39NBT TN Stress-activated protein kinase JNK1 (JNK1) DM39NBT MA Inhibitor DM39NBT RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM39NBT RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM39QU8 DI DM39QU8 DM39QU8 DN PMID28870136-Compound-60 DM39QU8 TI TTK0O6Y DM39QU8 TN Ecto-5'-nucleotidase (CD73) DM39QU8 MA Inhibitor DM39QU8 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM39QU8 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM3AUZS DI DM3AUZS DM3AUZS DN PMID27109571-Compound-44 DM3AUZS TI TTMY6L1 DM3AUZS TN Fatty acid-binding protein (FABP) DM3AUZS MA Inhibitor DM3AUZS RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM3AUZS RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM3AY9K DI DM3AY9K DM3AY9K DN PMID30107136-Compound-Example58 DM3AY9K TI TT23XQV DM3AY9K TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM3AY9K MA Inhibitor DM3AY9K RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM3AY9K RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM3B5RS DI DM3B5RS DM3B5RS DN Carbazole-3-carboxamide analog 1 DM3B5RS TI TTMSFAW DM3B5RS TN Cannabinoid receptor 2 (CB2) DM3B5RS MA Agonist DM3B5RS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM3B5RS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM3B5RS DI DM3B5RS DM3B5RS DN Carbazole-3-carboxamide analog 1 DM3B5RS TI TT6OEDT DM3B5RS TN Cannabinoid receptor 1 (CB1) DM3B5RS MA Agonist DM3B5RS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM3B5RS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM3BA1L DI DM3BA1L DM3BA1L DN PMID28766366-Compound-Scheme12-2 DM3BA1L TI TTSBVFO DM3BA1L TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM3BA1L MA Inhibitor DM3BA1L RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM3BA1L RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TT0PG8F DM3BDFV TN Cyclin-dependent kinase 4 (CDK4) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TTO0FDJ DM3BDFV TN Cyclin-dependent kinase 6 (CDK6) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TT8J1S3 DM3BDFV TN Smoothened homolog (SMO) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDFV DI DM3BDFV DM3BDFV DN PMID25726713-Compound-50 DM3BDFV TI TTCJG29 DM3BDFV TN Serine/threonine-protein kinase mTOR (mTOR) DM3BDFV MA Inhibitor DM3BDFV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BDFV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3BDHN DI DM3BDHN DM3BDHN DN US10081632, Compound 25 DM3BDHN TI TT3KYWB DM3BDHN TN Ribosomal protein S6 kinase alpha-6 (RSK6) DM3BDHN MA Inhibitor DM3BDHN RN Substituted tetrahydropyrido[3,2:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors. US9771366. DM3BDHN RU http://www.freepatentsonline.com/US9771366.html DM3BGEN DI DM3BGEN DM3BGEN DN Benzazepine derivative 3 DM3BGEN TI TTWJBZ5 DM3BGEN TN 5-HT 2C receptor (HTR2C) DM3BGEN MA Agonist DM3BGEN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM3BGEN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM3BOZP DI DM3BOZP DM3BOZP DN PMID25726713-Compound-16 DM3BOZP TI TT8J1S3 DM3BOZP TN Smoothened homolog (SMO) DM3BOZP MA Inhibitor DM3BOZP RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3BOZP RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3CF91 DI DM3CF91 DM3CF91 DN Carbamate derivative 11 DM3CF91 TI TTZ963I DM3CF91 TN Monoglyceride lipase (MAGL) DM3CF91 MA Inhibitor DM3CF91 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM3CF91 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM3CPJQ DI DM3CPJQ DM3CPJQ DN PMID27967267-Compound-neotuberostemonine DM3CPJQ TI TT1RS9F DM3CPJQ TN Acetylcholinesterase (AChE) DM3CPJQ MA Inhibitor DM3CPJQ RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM3CPJQ RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM3CVWU DI DM3CVWU DM3CVWU DN Aryl pyrimidine derivative 1 DM3CVWU TI TT1LVF2 DM3CVWU TN Cyclin-dependent kinase 9 (CDK9) DM3CVWU MA Inhibitor DM3CVWU RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM3CVWU RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TTT7PJU DM3D1L6 TN Janus kinase 3 (JAK-3) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TTBYWP2 DM3D1L6 TN TYK2 tyrosine kinase (TYK2) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TTRMX3V DM3D1L6 TN Janus kinase 2 (JAK-2) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D1L6 DI DM3D1L6 DM3D1L6 DN Pyrrolo[2,3-d]pyrimidine derivative 6 DM3D1L6 TI TT6DM01 DM3D1L6 TN Janus kinase 1 (JAK-1) DM3D1L6 MA Inhibitor DM3D1L6 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3D1L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3D4RI DI DM3D4RI DM3D4RI DN PMID25666693-Compound-14 DM3D4RI TI TTMI6F5 DM3D4RI TN Transient receptor potential cation channel V1 (TRPV1) DM3D4RI MA Antagonist DM3D4RI RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM3D4RI RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM3DIW9 DI DM3DIW9 DM3DIW9 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 2 DM3DIW9 TI TTJW4LU DM3DIW9 TN Phosphodiesterase 10A (PDE10) DM3DIW9 MA Inhibitor DM3DIW9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM3DIW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM3DIW9 DI DM3DIW9 DM3DIW9 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 2 DM3DIW9 TI TTJGW1Z DM3DIW9 TN Phosphodiesterase 2A (PDE2A) DM3DIW9 MA Inhibitor DM3DIW9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM3DIW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM3E5V6 DI DM3E5V6 DM3E5V6 DN Indomethacin analog 1 DM3E5V6 TI TT5ZWB6 DM3E5V6 TN Dihydrodiol dehydrogenase type I (AKR1C3) DM3E5V6 MA Inhibitor; Antagonist; Blocker DM3E5V6 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM3E5V6 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM3E75P DI DM3E75P DM3E75P DN Aromatic bicyclic compound 4 DM3E75P TI TTRMX3V DM3E75P TN Janus kinase 2 (JAK-2) DM3E75P MA Inhibitor DM3E75P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM3E75P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM3E75P DI DM3E75P DM3E75P DN Aromatic bicyclic compound 4 DM3E75P TI TT6PKBN DM3E75P TN Proto-oncogene c-Src (SRC) DM3E75P MA Inhibitor DM3E75P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM3E75P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM3EAHB DI DM3EAHB DM3EAHB DN Spiroimidazolone derivative 2 DM3EAHB TI TT9O6WS DM3EAHB TN Glucagon receptor (GCGR) DM3EAHB MA Antagonist DM3EAHB RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM3EAHB RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM3EHSN DI DM3EHSN DM3EHSN DN 4-Carboxamido-isoindolinone derivative 2 DM3EHSN TI TTVDSZ0 DM3EHSN TN Poly [ADP-ribose] polymerase 1 (PARP1) DM3EHSN MA Inhibitor DM3EHSN RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM3EHSN RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM3F4KS DI DM3F4KS DM3F4KS DN Pyridinone carboxamide derivative 1 DM3F4KS TI TTCZOF2 DM3F4KS TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM3F4KS MA Inhibitor DM3F4KS RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM3F4KS RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM3FAIS DI DM3FAIS DM3FAIS DN PMID27841036-Compound-V DM3FAIS TI TTEBCY8 DM3FAIS TN Poly [ADP-ribose] polymerase (PARP) DM3FAIS MA Inhibitor DM3FAIS RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM3FAIS RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM3FY85 DI DM3FY85 DM3FY85 DN PMID27774822-Compound-Figure6Example3 DM3FY85 TI TTT7PJU DM3FY85 TN Janus kinase 3 (JAK-3) DM3FY85 MA Inhibitor DM3FY85 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3FY85 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3G21F DI DM3G21F DM3G21F DN PMID27828716-Compound-15 DM3G21F TI TTRZQE3 DM3G21F TN Glycogen synthase kinase-3 alpha (GSK-3A) DM3G21F MA Inhibitor DM3G21F RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM3G21F RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM3G6YV DI DM3G6YV DM3G6YV DN PMID27019002-Compound-45 DM3G6YV TI TTNR0UQ DM3G6YV TN Lysine-specific histone demethylase 1 (LSD) DM3G6YV MA Inhibitor DM3G6YV RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM3G6YV RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM3GU7K DI DM3GU7K DM3GU7K DN Pyridic ketone derivative 1 DM3GU7K TI TTTW2NY DM3GU7K TN ERK activator kinase 2 (MEK2) DM3GU7K MA Inhibitor DM3GU7K RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM3GU7K RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM3GU7K DI DM3GU7K DM3GU7K DN Pyridic ketone derivative 1 DM3GU7K TI TTIDAPM DM3GU7K TN ERK activator kinase 1 (MEK1) DM3GU7K MA Inhibitor DM3GU7K RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM3GU7K RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM3GYPD DI DM3GYPD DM3GYPD DN Pyrimidine derivative 16 DM3GYPD TI TTNR0UQ DM3GYPD TN Lysine-specific histone demethylase 1 (LSD) DM3GYPD MA Inhibitor DM3GYPD RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM3GYPD RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTMUEK1 DM3H78D TN Histone deacetylase 7 (HDAC7) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT8M4E1 DM3H78D TN Histone deacetylase 9 (HDAC9) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTT6LFV DM3H78D TN Histone deacetylase 8 (HDAC8) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTTQGH8 DM3H78D TN Histone deacetylase 4 (HDAC4) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTUELN5 DM3H78D TN Histone deacetylase 5 (HDAC5) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT5ZKDI DM3H78D TN Histone deacetylase 6 (HDAC6) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TTSHTOI DM3H78D TN Histone deacetylase 2 (HDAC2) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT4YWTO DM3H78D TN Histone deacetylase 3 (HDAC3) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3H78D DI DM3H78D DM3H78D DN PMID29671355-Compound-31 DM3H78D TI TT6R7JZ DM3H78D TN Histone deacetylase 1 (HDAC1) DM3H78D MA Inhibitor DM3H78D RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM3H78D RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM3HR7F DI DM3HR7F DM3HR7F DN PMID28454500-Compound-9 DM3HR7F TI TTA6ZN2 DM3HR7F TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM3HR7F MA Activator DM3HR7F RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM3HR7F RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM3HR7F DI DM3HR7F DM3HR7F DN PMID28454500-Compound-9 DM3HR7F TI TT3Z6Y9 DM3HR7F TN Cysteines of Keap1 (KEAP1 Cysteines) DM3HR7F MA Modulator DM3HR7F RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM3HR7F RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM3HVCZ DI DM3HVCZ DM3HVCZ DN Tetra-hydro-pyrazolopyrazine derivative 1 DM3HVCZ TI TTHS256 DM3HVCZ TN Metabotropic glutamate receptor 5 (mGluR5) DM3HVCZ MA Modulator DM3HVCZ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM3HVCZ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM3I6OF DI DM3I6OF DM3I6OF DN PMID25522065-Compound-2 DM3I6OF TI TTX4RTB DM3I6OF TN Melanin-concentrating hormone receptor 1 (MCHR1) DM3I6OF MA Antagonist DM3I6OF RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM3I6OF RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM3I90D DI DM3I90D DM3I90D DN PMID25666693-Compound-20 DM3I90D TI TTMI6F5 DM3I90D TN Transient receptor potential cation channel V1 (TRPV1) DM3I90D MA Antagonist DM3I90D RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM3I90D RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM3IV7K DI DM3IV7K DM3IV7K DN Isoxazole-based bicyclic compound 8 DM3IV7K TI TTE4BSY DM3IV7K TN Bromodomain and extraterminal domain protein (BET) DM3IV7K MA Inhibitor DM3IV7K RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3IV7K RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3IXYL DI DM3IXYL DM3IXYL DN Quinoline carboxamide derivative 8 DM3IXYL TI TTPTXIN DM3IXYL TN Translocator protein (TSPO) DM3IXYL MA Ligand DM3IXYL RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM3IXYL RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM3IZ0H DI DM3IZ0H DM3IZ0H DN PMID25684022-Compound-WO2011137219 35(1-11) DM3IZ0H TI TTCZOF2 DM3IZ0H TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM3IZ0H MA Inhibitor DM3IZ0H RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM3IZ0H RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM3K25J DI DM3K25J DM3K25J DN Benzoheterocyclic compound 1 DM3K25J TI TTZCRP3 DM3K25J TN ERK activator kinase (MEK) DM3K25J MA Inhibitor DM3K25J RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM3K25J RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM3K7IM DI DM3K7IM DM3K7IM DN Piperazine urea derivative 4 DM3K7IM TI TTQR74A DM3K7IM TN Proteinase activated receptor 2 (PAR2) DM3K7IM MA Antagonist DM3K7IM RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM3K7IM RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM3KSV9 DI DM3KSV9 DM3KSV9 DN PMID25666693-Compound-51 DM3KSV9 TI TTMI6F5 DM3KSV9 TN Transient receptor potential cation channel V1 (TRPV1) DM3KSV9 MA Antagonist DM3KSV9 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM3KSV9 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM3KW2A DI DM3KW2A DM3KW2A DN Ketoheterocycle derivative 2 DM3KW2A TI TTDP1UC DM3KW2A TN Fatty acid amide hydrolase (FAAH) DM3KW2A MA Inhibitor DM3KW2A RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM3KW2A RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM3KWFQ DI DM3KWFQ DM3KWFQ DN PMID25991433-Compound-C1 DM3KWFQ TI TTHS0U8 DM3KWFQ TN Stress-activated protein kinase JNK2 (JNK2) DM3KWFQ MA Inhibitor DM3KWFQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3KWFQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3LCIM DI DM3LCIM DM3LCIM DN PMID26651364-Compound-7b DM3LCIM TI TTTCRU2 DM3LCIM TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM3LCIM MA Antagonist DM3LCIM RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM3LCIM RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM3LKTE DI DM3LKTE DM3LKTE DN Piperazinyl norbenzomorphane compound 1 DM3LKTE TI TT9NXW4 DM3LKTE TN Sigma intracellular receptor 2 (TMEM97) DM3LKTE MA Ligand DM3LKTE RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM3LKTE RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM3LNQG DI DM3LNQG DM3LNQG DN Aminoazetidine derivative 7 DM3LNQG TI TT6OEDT DM3LNQG TN Cannabinoid receptor 1 (CB1) DM3LNQG MA Antagonist DM3LNQG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM3LNQG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM3LWUR DI DM3LWUR DM3LWUR DN PMID25991433-Compound-L3 DM3LWUR TI TT3ZIJL DM3LWUR TN JNK-interacting protein peptide (pepJIP) DM3LWUR MA Inhibitor DM3LWUR RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3LWUR RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3LWUR DI DM3LWUR DM3LWUR DN PMID25991433-Compound-L3 DM3LWUR TI TTVOE6D DM3LWUR TN Mitogen-activated protein kinase (MAPK) DM3LWUR MA Inhibitor DM3LWUR RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3LWUR RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3LWUR DI DM3LWUR DM3LWUR DN PMID25991433-Compound-L3 DM3LWUR TI TTQBR95 DM3LWUR TN Stress-activated protein kinase 2a (p38 alpha) DM3LWUR MA Inhibitor DM3LWUR RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM3LWUR RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM3M169 DI DM3M169 DM3M169 DN Cyclopropane 1-carboxylic acid derivative 10 DM3M169 TI TTIY56R DM3M169 TN Kynurenine 3-hydroxylase (KMO) DM3M169 MA Inhibitor DM3M169 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM3M169 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM3M1NB DI DM3M1NB DM3M1NB DN PMID26004420-Compound-US20140031349B DM3M1NB TI TTJ13ST DM3M1NB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM3M1NB MA Inhibitor DM3M1NB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM3M1NB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM3M6SE DI DM3M6SE DM3M6SE DN PMID27774822-Compound-Figure10CompoundA DM3M6SE TI TTJSQEF DM3M6SE TN Tyrosine-protein kinase (PTK) DM3M6SE MA Inhibitor DM3M6SE RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3M6SE RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3MRD9 DI DM3MRD9 DM3MRD9 DN BDBM50061608 DM3MRD9 TI TTCGOIN DM3MRD9 TN PIM-3 protein kinase (PIM3) DM3MRD9 MA Inhibitor DM3MRD9 RN Azole compounds as PIM inhibitors. US9321756. DM3MRD9 RU http://www.freepatentsonline.com/US9321756.html DM3MVW1 DI DM3MVW1 DM3MVW1 DN PMID28350212-Compound-23 DM3MVW1 TI TTZS04O DM3MVW1 TN Gamma-secretase subunit APH-1A/1B (APH-1) DM3MVW1 MA Inhibitor DM3MVW1 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DM3MVW1 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DM3NE8J DI DM3NE8J DM3NE8J DN US9206139, 4 DM3NE8J TI TTYG6BU DM3NE8J TN Aggrecanase-1 (ADAMTS4) DM3NE8J MA Inhibitor DM3NE8J RN Aggrecanase inhibitors. US9206139. DM3NE8J RU http://www.freepatentsonline.com/US9206139.html DM3NPOU DI DM3NPOU DM3NPOU DN PMID30074415-Compound-21 DM3NPOU TI TTUNARX DM3NPOU TN Carbonic anhydrase (CA) DM3NPOU MA Inhibitor DM3NPOU RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM3NPOU RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM3NXP8 DI DM3NXP8 DM3NXP8 DN PMID26924192-Compound-57 DM3NXP8 TI TTE4BSY DM3NXP8 TN Bromodomain and extraterminal domain protein (BET) DM3NXP8 MA Inhibitor DM3NXP8 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3NXP8 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3O7UG DI DM3O7UG DM3O7UG DN Heteroaryl-azepine derivative 6 DM3O7UG TI TTWJBZ5 DM3O7UG TN 5-HT 2C receptor (HTR2C) DM3O7UG MA Agonist DM3O7UG RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM3O7UG RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM3OB4T DI DM3OB4T DM3OB4T DN SCHEMBL16322760 DM3OB4T TI TT78309 DM3OB4T TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DM3OB4T MA Inhibitor DM3OB4T RN Substituted benzylpyrazoles. US9765058. DM3OB4T RU http://www.freepatentsonline.com/US9765058.html DM3OCXI DI DM3OCXI DM3OCXI DN Di-substituted piperidine derivative 1 DM3OCXI TI TTEB0GD DM3OCXI TN Cholinesterase (BCHE) DM3OCXI MA Inhibitor DM3OCXI RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM3OCXI RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM3OPBR DI DM3OPBR DM3OPBR DN ZNFTXQFGUIKQQE-UHFFFAOYSA-N DM3OPBR TI TTDYP7I DM3OPBR TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM3OPBR MA Inhibitor DM3OPBR RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DM3OPBR RU http://www.freepatentsonline.com/US9150519.html DM3OZ0F DI DM3OZ0F DM3OZ0F DN Salicylic acid derivative 5 DM3OZ0F TI TTH8FZW DM3OZ0F TN Signal transducer and activator of transcription 3 (STAT3) DM3OZ0F MA Inhibitor DM3OZ0F RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM3OZ0F RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM3PEUN DI DM3PEUN DM3PEUN DN Dihydropyrido pyrazinone compound 3 DM3PEUN TI TTIYVQP DM3PEUN TN Polo-like kinase 1 (PLK1) DM3PEUN MA Inhibitor DM3PEUN RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3PEUN RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3PF60 DI DM3PF60 DM3PF60 DN Monoamine derivative 5 DM3PF60 TI TTULVH8 DM3PF60 TN Tyrosinase (TYR) DM3PF60 MA Inhibitor DM3PF60 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM3PF60 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM3PU57 DI DM3PU57 DM3PU57 DN US8940736, 23 DM3PU57 TI TTR93NU DM3PU57 TN Casein kinase II alpha prime (CSNK2A2) DM3PU57 MA Inhibitor DM3PU57 RN Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736. DM3PU57 RU http://www.freepatentsonline.com/US8940736.html DM3Q1FT DI DM3Q1FT DM3Q1FT DN PMID28766366-Compound-Scheme27LeucettamineB DM3Q1FT TI TTSBVFO DM3Q1FT TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM3Q1FT MA Inhibitor DM3Q1FT RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM3Q1FT RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM3Q9OX DI DM3Q9OX DM3Q9OX DN Deuterated 3-cyanoquinoline derivative 1 DM3Q9OX TI TTS7G69 DM3Q9OX TN Fusion protein Bcr-Abl (Bcr-Abl) DM3Q9OX MA Inhibitor DM3Q9OX RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM3Q9OX RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM3Q9OX DI DM3Q9OX DM3Q9OX DN Deuterated 3-cyanoquinoline derivative 1 DM3Q9OX TI TT6PKBN DM3Q9OX TN Proto-oncogene c-Src (SRC) DM3Q9OX MA Inhibitor DM3Q9OX RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM3Q9OX RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM3QIF4 DI DM3QIF4 DM3QIF4 DN US9181182, 40 DM3QIF4 TI TTDYP7I DM3QIF4 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM3QIF4 MA Inhibitor DM3QIF4 RN S1P receptors modulators. US9181182. DM3QIF4 RU http://www.freepatentsonline.com/US9181182.html DM3QMA0 DI DM3QMA0 DM3QMA0 DN Bicyclic heteroaryl carboxamide analog 3 DM3QMA0 TI TTHS256 DM3QMA0 TN Metabotropic glutamate receptor 5 (mGluR5) DM3QMA0 MA Modulator DM3QMA0 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM3QMA0 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM3QO5R DI DM3QO5R DM3QO5R DN PMID26004420-Compound-WO2014015495D DM3QO5R TI TTJ13ST DM3QO5R TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM3QO5R MA Inhibitor DM3QO5R RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM3QO5R RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM3QU80 DI DM3QU80 DM3QU80 DN PMID25726713-Compound-29 DM3QU80 TI TT8J1S3 DM3QU80 TN Smoothened homolog (SMO) DM3QU80 MA Inhibitor DM3QU80 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM3QU80 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM3QX0R DI DM3QX0R DM3QX0R DN PMID30124346-Compound-60TABLE5 DM3QX0R TI TTVIREA DM3QX0R TN Adrenergic receptor (ADR) DM3QX0R MA Ligand DM3QX0R RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM3QX0R RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM3QX0R DI DM3QX0R DM3QX0R DN PMID30124346-Compound-60TABLE5 DM3QX0R TI TTEX248 DM3QX0R TN Dopamine D2 receptor (D2R) DM3QX0R MA Ligand DM3QX0R RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM3QX0R RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM3QX0R DI DM3QX0R DM3QX0R DN PMID30124346-Compound-60TABLE5 DM3QX0R TI TTSQIFT DM3QX0R TN 5-HT 1A receptor (HTR1A) DM3QX0R MA Ligand DM3QX0R RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM3QX0R RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM3R7BT DI DM3R7BT DM3R7BT DN US9127005, P2B DM3R7BT TI TT3T17P DM3R7BT TN Phospholipase D1 (PLD1) DM3R7BT MA Inhibitor DM3R7BT RN Isoform selective phospholipase D inhibitors. US9127005. DM3R7BT RU http://www.freepatentsonline.com/US9127005.html DM3R9PL DI DM3R9PL DM3R9PL DN Pyrazole derivative 1 DM3R9PL TI TT6OEDT DM3R9PL TN Cannabinoid receptor 1 (CB1) DM3R9PL MA Antagonist DM3R9PL RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM3R9PL RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM3RAU4 DI DM3RAU4 DM3RAU4 DN Pyrazine carboxamide derivative 1 DM3RAU4 TI TTF8P9I DM3RAU4 TN Diacylglycerol acyltransferase 1 (DGAT1) DM3RAU4 MA Inhibitor DM3RAU4 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM3RAU4 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM3REN5 DI DM3REN5 DM3REN5 DN Pyrimido-indole derivative 2 DM3REN5 TI TTE4BSY DM3REN5 TN Bromodomain and extraterminal domain protein (BET) DM3REN5 MA Inhibitor DM3REN5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3REN5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3RK0S DI DM3RK0S DM3RK0S DN Cycloalkyl nitrile pyrazole carboxamide derivative 1 DM3RK0S TI TTRMX3V DM3RK0S TN Janus kinase 2 (JAK-2) DM3RK0S MA Inhibitor DM3RK0S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3RK0S RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3RK0S DI DM3RK0S DM3RK0S DN Cycloalkyl nitrile pyrazole carboxamide derivative 1 DM3RK0S TI TT6DM01 DM3RK0S TN Janus kinase 1 (JAK-1) DM3RK0S MA Inhibitor DM3RK0S RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM3RK0S RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM3S0LI DI DM3S0LI DM3S0LI DN Azaindazole derivative 1 DM3S0LI TI TTK0FEA DM3S0LI TN Leucine-rich repeat kinase 2 (LRRK2) DM3S0LI MA Inhibitor DM3S0LI RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3S0LI RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3SQUD DI DM3SQUD DM3SQUD DN Urea and carbamate bioisostere derivative 15 DM3SQUD TI TTL7C8Q DM3SQUD TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM3SQUD MA Inhibitor DM3SQUD RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM3SQUD RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM3T840 DI DM3T840 DM3T840 DN Isoxazole-based bicyclic compound 7 DM3T840 TI TTE4BSY DM3T840 TN Bromodomain and extraterminal domain protein (BET) DM3T840 MA Inhibitor DM3T840 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM3T840 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM3TVI6 DI DM3TVI6 DM3TVI6 DN Quinazolinedione derivative 2 DM3TVI6 TI TTVDSZ0 DM3TVI6 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM3TVI6 MA Inhibitor DM3TVI6 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM3TVI6 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM3U58I DI DM3U58I DM3U58I DN Oxindole derivative 4 DM3U58I TI TT6AXLY DM3U58I TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DM3U58I MA Inhibitor DM3U58I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3U58I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3U58I DI DM3U58I DM3U58I DN Oxindole derivative 4 DM3U58I TI TTK0FEA DM3U58I TN Leucine-rich repeat kinase 2 (LRRK2) DM3U58I MA Inhibitor DM3U58I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3U58I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3U79M DI DM3U79M DM3U79M DN Hydrazide derivative 3 DM3U79M TI TTK0FEA DM3U79M TN Leucine-rich repeat kinase 2 (LRRK2) DM3U79M MA Inhibitor DM3U79M RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM3U79M RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM3U7RN DI DM3U7RN DM3U7RN DN PMID27376512-Compound-PG-11048 DM3U7RN TI TTBH0VX DM3U7RN TN Histone deacetylase (HDAC) DM3U7RN MA Inhibitor DM3U7RN RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM3U7RN RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM3U7RN DI DM3U7RN DM3U7RN DN PMID27376512-Compound-PG-11048 DM3U7RN TI TTHVCUP DM3U7RN TN DNA [cytosine-5]-methyltransferase (DNMT) DM3U7RN MA Inhibitor DM3U7RN RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM3U7RN RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM3UBG2 DI DM3UBG2 DM3UBG2 DN Pyrazolo[1,5-a]pyrimidine derivative 5 DM3UBG2 TI TT6OEDT DM3UBG2 TN Cannabinoid receptor 1 (CB1) DM3UBG2 MA Antagonist DM3UBG2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM3UBG2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM3VA8P DI DM3VA8P DM3VA8P DN Pyrrolidine derivative 13 DM3VA8P TI TT4TFGN DM3VA8P TN Vasopressin V1a receptor (V1AR) DM3VA8P MA Antagonist DM3VA8P RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DM3VA8P RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DM3VA8P DI DM3VA8P DM3VA8P DN Pyrrolidine derivative 13 DM3VA8P TI TTSCIUP DM3VA8P TN Oxytocin receptor (OTR) DM3VA8P MA Antagonist DM3VA8P RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DM3VA8P RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DM3VB6G DI DM3VB6G DM3VB6G DN 3-phenyl pyrazole derivative 1 DM3VB6G TI TTJQOD7 DM3VB6G TN 5-HT 2A receptor (HTR2A) DM3VB6G MA Antagonist DM3VB6G RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM3VB6G RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM3VL64 DI DM3VL64 DM3VL64 DN PMID29334795-Compound-23 DM3VL64 TI TT9JNIC DM3VL64 TN Histamine H3 receptor (H3R) DM3VL64 MA Inverse agonist DM3VL64 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM3VL64 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM3VL82 DI DM3VL82 DM3VL82 DN Pyrrolidinyl urea derivative 13 DM3VL82 TI TTTDVOJ DM3VL82 TN Tropomyosin-related kinase A (TrkA) DM3VL82 MA Inhibitor DM3VL82 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM3VL82 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM3VNK0 DI DM3VNK0 DM3VNK0 DN BDBM50080563 DM3VNK0 TI TTDYP7I DM3VNK0 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM3VNK0 MA Inhibitor DM3VNK0 RN Pyridin-4-yl derivatives. US9617250. DM3VNK0 RU http://www.freepatentsonline.com/US9617250.html DM3VQ1Y DI DM3VQ1Y DM3VQ1Y DN PMID29865878-Compound-57 DM3VQ1Y TI TTEAD9J DM3VQ1Y TN Proteasome beta-8 (PS beta-8) DM3VQ1Y MA Inhibitor DM3VQ1Y RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM3VQ1Y RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM3W5SM DI DM3W5SM DM3W5SM DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 1 DM3W5SM TI TTXJ47W DM3W5SM TN Metabotropic glutamate receptor 2 (mGluR2) DM3W5SM MA Antagonist DM3W5SM RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM3W5SM RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM3WHL2 DI DM3WHL2 DM3WHL2 DN Azetidinyl-piperazine derivative 3 DM3WHL2 TI TTZ963I DM3WHL2 TN Monoglyceride lipase (MAGL) DM3WHL2 MA Inhibitor DM3WHL2 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM3WHL2 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM3WQNY DI DM3WQNY DM3WQNY DN 4-Hydroxybenzoicacid DM3WQNY TI TTGP7BY DM3WQNY TN Monoamine oxidase type B (MAO-B) DM3WQNY MA Inhibitor DM3WQNY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM3WQNY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM3X4PJ DI DM3X4PJ DM3X4PJ DN Cyclopropylamine derivative 7 DM3X4PJ TI TTNR0UQ DM3X4PJ TN Lysine-specific histone demethylase 1 (LSD) DM3X4PJ MA Inhibitor DM3X4PJ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM3X4PJ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM3XWMO DI DM3XWMO DM3XWMO DN US8598210, Table XV, 4 DM3XWMO TI TT9ISBX DM3XWMO TN HIF-prolyl hydroxylase 2 (HPH-2) DM3XWMO MA Inhibitor DM3XWMO RN Prolyl hydroxylase inhibitors and methods of use. US8598210. DM3XWMO RU http://www.freepatentsonline.com/US8598210.html DM3YMHP DI DM3YMHP DM3YMHP DN Imidazo pyridine derivative 4 DM3YMHP TI TTV1C0Z DM3YMHP TN Neuropeptide S receptor (NPSR) DM3YMHP MA Antagonist DM3YMHP RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM3YMHP RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM3YPX1 DI DM3YPX1 DM3YPX1 DN Indoline derivative 21 DM3YPX1 TI TTOHSBA DM3YPX1 TN Vascular endothelial growth factor A (VEGFA) DM3YPX1 MA Inhibitor DM3YPX1 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM3YPX1 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM3Z5UQ DI DM3Z5UQ DM3Z5UQ DN Benzo[d]oxazol-2(3H)-one derivative 3 DM3Z5UQ TI TT9JNIC DM3Z5UQ TN Histamine H3 receptor (H3R) DM3Z5UQ MA Inhibitor DM3Z5UQ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM3Z5UQ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM3Z5UQ DI DM3Z5UQ DM3Z5UQ DN Benzo[d]oxazol-2(3H)-one derivative 3 DM3Z5UQ TI TTEX248 DM3Z5UQ TN Dopamine D2 receptor (D2R) DM3Z5UQ MA Ligand DM3Z5UQ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM3Z5UQ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM3ZF95 DI DM3ZF95 DM3ZF95 DN 1,2-diamino cyclopentane-based derivative 10 DM3ZF95 TI TT9N02I DM3ZF95 TN Orexin receptor type 2 (HCRTR2) DM3ZF95 MA Antagonist DM3ZF95 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM3ZF95 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM3ZF95 DI DM3ZF95 DM3ZF95 DN 1,2-diamino cyclopentane-based derivative 10 DM3ZF95 TI TT60Q8D DM3ZF95 TN Orexin receptor type 1 (HCRTR1) DM3ZF95 MA Antagonist DM3ZF95 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM3ZF95 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM3ZGBH DI DM3ZGBH DM3ZGBH DN Coumaricacid DM3ZGBH TI TTGP7BY DM3ZGBH TN Monoamine oxidase type B (MAO-B) DM3ZGBH MA Inhibitor DM3ZGBH RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM3ZGBH RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM40FVN DI DM40FVN DM40FVN DN PMID25684022-Compound-US20130053382 36(3-5) DM40FVN TI TTCZOF2 DM40FVN TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM40FVN MA Inhibitor DM40FVN RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM40FVN RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM40KU8 DI DM40KU8 DM40KU8 DN US10023583, Example 8 DM40KU8 TI TTY2KP7 DM40KU8 TN Leucyl-cysteinyl aminopeptidase (LNPEP) DM40KU8 MA Inhibitor DM40KU8 RN Bicyclic pyridine compound. US10023583. DM40KU8 RU http://www.freepatentsonline.com/US10023583.html DM40LIN DI DM40LIN DM40LIN DN PMID27321640-Compound-76 DM40LIN TI TTJGW1Z DM40LIN TN Phosphodiesterase 2A (PDE2A) DM40LIN MA Inhibitor DM40LIN RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM40LIN RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM410Z6 DI DM410Z6 DM410Z6 DN PMID25522065-Compound-11 DM410Z6 TI TTX4RTB DM410Z6 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM410Z6 MA Antagonist DM410Z6 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM410Z6 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM417XY DI DM417XY DM417XY DN Aryl alkanolamine derivative 1 DM417XY TI TT5TPI6 DM417XY TN Opioid receptor sigma 1 (OPRS1) DM417XY MA Antagonist DM417XY RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM417XY RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM4192V DI DM4192V DM4192V DN Pyrimidine derivative 34 DM4192V TI TTPLTSQ DM4192V TN Neutrophil elastase (NE) DM4192V MA Inhibitor DM4192V RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM4192V RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM4198Z DI DM4198Z DM4198Z DN Benzofurans derivative 1 DM4198Z TI TTA592U DM4198Z TN Urate anion exchanger 1 (URAT1) DM4198Z MA Inhibitor DM4198Z RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM4198Z RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM41B5O DI DM41B5O DM41B5O DN PMID27321640-Compound-59 DM41B5O TI TTJW4LU DM41B5O TN Phosphodiesterase 10A (PDE10) DM41B5O MA Inhibitor DM41B5O RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM41B5O RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM41B5O DI DM41B5O DM41B5O DN PMID27321640-Compound-59 DM41B5O TI TTJGW1Z DM41B5O TN Phosphodiesterase 2A (PDE2A) DM41B5O MA Inhibitor DM41B5O RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM41B5O RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM41ZW9 DI DM41ZW9 DM41ZW9 DN Ruxolitinib derivative 1 DM41ZW9 TI TTJSQEF DM41ZW9 TN Tyrosine-protein kinase (PTK) DM41ZW9 MA Inhibitor DM41ZW9 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM41ZW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM42BU9 DI DM42BU9 DM42BU9 DN Benzoic acid linked peptide analog 3 DM42BU9 TI TTULVH8 DM42BU9 TN Tyrosinase (TYR) DM42BU9 MA Inhibitor DM42BU9 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM42BU9 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM42EST DI DM42EST DM42EST DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 DM42EST TI TTJGW1Z DM42EST TN Phosphodiesterase 2A (PDE2A) DM42EST MA Inhibitor DM42EST RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM42EST RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM42EST DI DM42EST DM42EST DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 8 DM42EST TI TTJW4LU DM42EST TN Phosphodiesterase 10A (PDE10) DM42EST MA Inhibitor DM42EST RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM42EST RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM42OYU DI DM42OYU DM42OYU DN PMID28870136-Compound-50 DM42OYU TI TTK0O6Y DM42OYU TN Ecto-5'-nucleotidase (CD73) DM42OYU MA Inhibitor DM42OYU RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM42OYU RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM42VUQ DI DM42VUQ DM42VUQ DN PMID27019002-Compound-42a DM42VUQ TI TTNR0UQ DM42VUQ TN Lysine-specific histone demethylase 1 (LSD) DM42VUQ MA Inhibitor DM42VUQ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM42VUQ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM42XWO DI DM42XWO DM42XWO DN US10053465, 8 DM42XWO TI TTIEMFN DM42XWO TN TYRO3 tyrosine kinase receptor (TYRO3) DM42XWO MA Inhibitor DM42XWO RN Pyrrolopyrimidine derivatives as TAM inhibitors. US10053465. DM42XWO RU http://www.freepatentsonline.com/US10053465.html DM435GR DI DM435GR DM435GR DN PMID27109571-Compound-25 DM435GR TI TTNT2S6 DM435GR TN Fatty acid-binding protein 5 (FABP5) DM435GR MA Inhibitor DM435GR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM435GR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM435GR DI DM435GR DM435GR DN PMID27109571-Compound-25 DM435GR TI TTHWMFZ DM435GR TN Fatty acid-binding protein 4 (FABP4) DM435GR MA Inhibitor DM435GR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM435GR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM437ZC DI DM437ZC DM437ZC DN PMID28270021-Compound-WO2010077680 103 DM437ZC TI TTTDVOJ DM437ZC TN Tropomyosin-related kinase A (TrkA) DM437ZC MA Antagonist DM437ZC RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM437ZC RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM43APD DI DM43APD DM43APD DN Aromatic ring compound 3 DM43APD TI TT9O6WS DM43APD TN Glucagon receptor (GCGR) DM43APD MA Antagonist DM43APD RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM43APD RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM43EKN DI DM43EKN DM43EKN DN 3-(phenoxymethyl) benzylamine derivative 3 DM43EKN TI TTULVH8 DM43EKN TN Tyrosinase (TYR) DM43EKN MA Inhibitor DM43EKN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM43EKN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM43YA0 DI DM43YA0 DM43YA0 DN 4-Carboxamido-isoindolinone derivative 3 DM43YA0 TI TTVDSZ0 DM43YA0 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM43YA0 MA Inhibitor DM43YA0 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM43YA0 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM43Z1G DI DM43Z1G DM43Z1G DN PMID26394986-Compound-22 DM43Z1G TI TTH8FZW DM43Z1G TN Signal transducer and activator of transcription 3 (STAT3) DM43Z1G MA Inhibitor DM43Z1G RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM43Z1G RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM45COR DI DM45COR DM45COR DN Chalcone derivative 4 DM45COR TI TTA6ZN2 DM45COR TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM45COR MA Activator DM45COR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM45COR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM45COR DI DM45COR DM45COR DN Chalcone derivative 4 DM45COR TI TT3Z6Y9 DM45COR TN Cysteines of Keap1 (KEAP1 Cysteines) DM45COR MA Modulator DM45COR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM45COR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM45JMT DI DM45JMT DM45JMT DN Peptide analog 61 DM45JMT TI TTQAJF1 DM45JMT TN Cathepsin G (CTSG) DM45JMT MA Inhibitor DM45JMT RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM45JMT RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM45JMT DI DM45JMT DM45JMT DN Peptide analog 61 DM45JMT TI TTPLTSQ DM45JMT TN Neutrophil elastase (NE) DM45JMT MA Inhibitor DM45JMT RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM45JMT RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM45QW1 DI DM45QW1 DM45QW1 DN PMID29865878-Compound-56 DM45QW1 TI TTSJMN8 DM45QW1 TN Immunoproteasome complex (IP) DM45QW1 MA Inhibitor DM45QW1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM45QW1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM460D1 DI DM460D1 DM460D1 DN PMID27336223-Compound-8 DM460D1 TI TTISP28 DM460D1 TN Retinoic acid receptor beta (RARB) DM460D1 MA Agonist DM460D1 RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM460D1 RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM462XZ DI DM462XZ DM462XZ DN PMID29865878-Compound-45 DM462XZ TI TTSJMN8 DM462XZ TN Immunoproteasome complex (IP) DM462XZ MA Inhibitor DM462XZ RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM462XZ RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM46NRV DI DM46NRV DM46NRV DN Biphenyl mannoside derivative 7 DM46NRV TI TTTCRU2 DM46NRV TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM46NRV MA Antagonist DM46NRV RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM46NRV RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM46UPM DI DM46UPM DM46UPM DN BDBM50363780 DM46UPM TI TTLKF5M DM46UPM TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DM46UPM MA Inhibitor DM46UPM RN Aroyl thiourea derivatives. US9365508. DM46UPM RU http://www.freepatentsonline.com/US9365508.html DM4765M DI DM4765M DM4765M DN Curcumin analog 1 DM4765M TI TTH8FZW DM4765M TN Signal transducer and activator of transcription 3 (STAT3) DM4765M MA Inhibitor DM4765M RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4765M RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM4765M DI DM4765M DM4765M DN Curcumin analog 1 DM4765M TI TTRMX3V DM4765M TN Janus kinase 2 (JAK-2) DM4765M MA Inhibitor DM4765M RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4765M RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM47FNS DI DM47FNS DM47FNS DN PMID28270021-Compound-WO2010077680 811 DM47FNS TI TTTDVOJ DM47FNS TN Tropomyosin-related kinase A (TrkA) DM47FNS MA Antagonist DM47FNS RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM47FNS RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM47KWB DI DM47KWB DM47KWB DN Benzo[d]oxazol-2(3H)-one derivative 2 DM47KWB TI TT9JNIC DM47KWB TN Histamine H3 receptor (H3R) DM47KWB MA Inhibitor DM47KWB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM47KWB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM47KWB DI DM47KWB DM47KWB DN Benzo[d]oxazol-2(3H)-one derivative 2 DM47KWB TI TTEX248 DM47KWB TN Dopamine D2 receptor (D2R) DM47KWB MA Ligand DM47KWB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM47KWB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM47L9Q DI DM47L9Q DM47L9Q DN Mycophenolic acid/nucleotide derivative 12 DM47L9Q TI TTL7C8Q DM47L9Q TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM47L9Q MA Inhibitor DM47L9Q RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM47L9Q RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM47M2U DI DM47M2U DM47M2U DN PMID29865878-Compound-52 DM47M2U TI TTSJMN8 DM47M2U TN Immunoproteasome complex (IP) DM47M2U MA Inhibitor DM47M2U RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM47M2U RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM47V3I DI DM47V3I DM47V3I DN Aryl oxyanilide derivative 2 DM47V3I TI TTPTXIN DM47V3I TN Translocator protein (TSPO) DM47V3I MA Ligand DM47V3I RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM47V3I RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM48PIO DI DM48PIO DM48PIO DN Azetidine urea derivative 3 DM48PIO TI TTDP1UC DM48PIO TN Fatty acid amide hydrolase (FAAH) DM48PIO MA Inhibitor DM48PIO RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM48PIO RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM48YKE DI DM48YKE DM48YKE DN PMID25772215-Compound-EP2149552diaminopyrimidines DM48YKE TI TT1ZAVI DM48YKE TN Prostaglandin E2 receptor EP2 (PTGER2) DM48YKE MA Antagonist DM48YKE RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM48YKE RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM49FU0 DI DM49FU0 DM49FU0 DN Epoxysuccinate derivative 9 DM49FU0 TI TTG5QB7 DM49FU0 TN Calpain-2 (CAPN2) DM49FU0 MA Inhibitor DM49FU0 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM49FU0 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM49V8G DI DM49V8G DM49V8G DN PMID26651364-Compound-9c DM49V8G TI TTTCRU2 DM49V8G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM49V8G MA Antagonist DM49V8G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM49V8G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM49YTU DI DM49YTU DM49YTU DN PMID29671355-Compound-74 DM49YTU TI TT5ZKDI DM49YTU TN Histone deacetylase 6 (HDAC6) DM49YTU MA Inhibitor DM49YTU RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM49YTU RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM49YTU DI DM49YTU DM49YTU DN PMID29671355-Compound-74 DM49YTU TI TTSHTOI DM49YTU TN Histone deacetylase 2 (HDAC2) DM49YTU MA Inhibitor DM49YTU RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM49YTU RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM4AFHY DI DM4AFHY DM4AFHY DN PMID26161698-Compound-25 DM4AFHY TI TT7HF4W DM4AFHY TN Cyclin-dependent kinase 2 (CDK2) DM4AFHY MA Inhibitor DM4AFHY RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM4AFHY RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM4AFHY DI DM4AFHY DM4AFHY DN PMID26161698-Compound-25 DM4AFHY TI TT1LVF2 DM4AFHY TN Cyclin-dependent kinase 9 (CDK9) DM4AFHY MA Inhibitor DM4AFHY RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM4AFHY RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM4AM1E DI DM4AM1E DM4AM1E DN Aromatic hydrazine carboxyimidoamide derivative 5 DM4AM1E TI TTULVH8 DM4AM1E TN Tyrosinase (TYR) DM4AM1E MA Inhibitor DM4AM1E RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM4AM1E RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM4AOIR DI DM4AOIR DM4AOIR DN PMID29473428-Compound-41 DM4AOIR TI TTZJYKH DM4AOIR TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM4AOIR MA Antagonist DM4AOIR RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM4AOIR RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM4C5QY DI DM4C5QY DM4C5QY DN Biaryl mannoside derivative 14 DM4C5QY TI TTTCRU2 DM4C5QY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4C5QY MA Antagonist DM4C5QY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4C5QY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4CN9K DI DM4CN9K DM4CN9K DN PMID30107136-Compound-Example13 DM4CN9K TI TT23XQV DM4CN9K TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM4CN9K MA Inhibitor DM4CN9K RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM4CN9K RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM4CSBD DI DM4CSBD DM4CSBD DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD TI TTJW4LU DM4CSBD TN Phosphodiesterase 10A (PDE10) DM4CSBD MA Inhibitor DM4CSBD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM4CSBD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM4CSBD DI DM4CSBD DM4CSBD DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD TI TTQ6VDM DM4CSBD TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM4CSBD MA Inhibitor DM4CSBD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM4CSBD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM4CSBD DI DM4CSBD DM4CSBD DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2 DM4CSBD TI TTJGW1Z DM4CSBD TN Phosphodiesterase 2A (PDE2A) DM4CSBD MA Inhibitor DM4CSBD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM4CSBD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM4D1WK DI DM4D1WK DM4D1WK DN PMID30107136-Compound-Example49 DM4D1WK TI TT23XQV DM4D1WK TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM4D1WK MA Inhibitor DM4D1WK RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM4D1WK RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM4D75L DI DM4D75L DM4D75L DN PMID27019002-Compound-50 DM4D75L TI TTNR0UQ DM4D75L TN Lysine-specific histone demethylase 1 (LSD) DM4D75L MA Inhibitor DM4D75L RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM4D75L RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM4DJA7 DI DM4DJA7 DM4DJA7 DN QCPOIDRINIAUKU-SRBBEKPSSA-N DM4DJA7 TI TTXHWA7 DM4DJA7 TN Ubiquitin-activating enzyme E1 (UBAE1) DM4DJA7 MA Inhibitor DM4DJA7 RN Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389. DM4DJA7 RU http://www.freepatentsonline.com/US10202389.html DM4DOUB DI DM4DOUB DM4DOUB DN PMID28460551-Compound-2 DM4DOUB TI TTI7421 DM4DOUB TN Platelet-derived growth factor receptor beta (PDGFRB) DM4DOUB MA Inhibitor DM4DOUB RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DM4DOUB RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DM4EFRL DI DM4EFRL DM4EFRL DN PMID27977313-Compound-48 DM4EFRL TI TTR7UJ3 DM4EFRL TN Cytoplasmic thioredoxin reductase (TXNRD1) DM4EFRL MA Inhibitor DM4EFRL RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM4EFRL RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM4EUFL DI DM4EUFL DM4EUFL DN Fused aromatic compound 1 DM4EUFL TI TTZMAO3 DM4EUFL TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM4EUFL MA Agonist DM4EUFL RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM4EUFL RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM4FD7C DI DM4FD7C DM4FD7C DN PMID28870136-Compound-46 DM4FD7C TI TTK0O6Y DM4FD7C TN Ecto-5'-nucleotidase (CD73) DM4FD7C MA Inhibitor DM4FD7C RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM4FD7C RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM4FHTG DI DM4FHTG DM4FHTG DN Benzoxazinone derivative 2 DM4FHTG TI TT5L2VC DM4FHTG TN Kallikrein-related peptidase (KLK) DM4FHTG MA Inhibitor DM4FHTG RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DM4FHTG RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DM4FHTG DI DM4FHTG DM4FHTG DN Benzoxazinone derivative 2 DM4FHTG TI TT4319X DM4FHTG TN Kallikrein-4 (KLK4) DM4FHTG MA Inhibitor DM4FHTG RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DM4FHTG RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DM4G3OC DI DM4G3OC DM4G3OC DN US8669361, 102 DM4G3OC TI TTCGOIN DM4G3OC TN PIM-3 protein kinase (PIM3) DM4G3OC MA Inhibitor DM4G3OC RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US9573943. DM4G3OC RU http://www.freepatentsonline.com/US9573943.html DM4GF58 DI DM4GF58 DM4GF58 DN Pyrazolo[3,4-d]pyrimidine derivative 7 DM4GF58 TI TT4DXQT DM4GF58 TN Proto-oncogene c-Ret (RET) DM4GF58 MA Inhibitor DM4GF58 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM4GF58 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM4GQJH DI DM4GQJH DM4GQJH DN PMID25553724-Compound-EP20132578214 2 DM4GQJH TI TTSXVID DM4GQJH TN Nuclear factor NF-kappa-B (NFKB) DM4GQJH MA Inhibitor DM4GQJH RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM4GQJH RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM4GR2C DI DM4GR2C DM4GR2C DN 1,3,4-oxadiazole derivative 4 DM4GR2C TI TT23XQV DM4GR2C TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM4GR2C MA Inhibitor DM4GR2C RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM4GR2C RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM4GUZO DI DM4GUZO DM4GUZO DN PMID25666693-Compound-50 DM4GUZO TI TTMI6F5 DM4GUZO TN Transient receptor potential cation channel V1 (TRPV1) DM4GUZO MA Antagonist DM4GUZO RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM4GUZO RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM4GZBI DI DM4GZBI DM4GZBI DN Indolizine derivative 1 DM4GZBI TI TTN9T81 DM4GZBI TN Arachidonate 15-lipoxygenase (15-LOX) DM4GZBI MA Inhibitor DM4GZBI RN Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225. DM4GZBI RU https://www.ncbi.nlm.nih.gov/pubmed/27718763 DM4GZBI DI DM4GZBI DM4GZBI DN Indolizine derivative 1 DM4GZBI TI TTDNFMT DM4GZBI TN Platelet-activating factor acetylhydrolase (PLA2G7) DM4GZBI MA Inhibitor DM4GZBI RN Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225. DM4GZBI RU https://www.ncbi.nlm.nih.gov/pubmed/27718763 DM4HBWU DI DM4HBWU DM4HBWU DN Tricyclic indole compound 1 DM4HBWU TI TTPTXIN DM4HBWU TN Translocator protein (TSPO) DM4HBWU MA Ligand DM4HBWU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM4HBWU RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM4I75L DI DM4I75L DM4I75L DN Monoamine derivative 3 DM4I75L TI TTULVH8 DM4I75L TN Tyrosinase (TYR) DM4I75L MA Inhibitor DM4I75L RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM4I75L RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM4I829 DI DM4I829 DM4I829 DN BDBM50080408 DM4I829 TI TTI1FPZ DM4I829 TN Epithelial discoidin domain receptor 1 (DDR1) DM4I829 MA Inhibitor DM4I829 RN Quinazolinedione derivative. US9567304. DM4I829 RU http://www.freepatentsonline.com/US9567304.html DM4ILAK DI DM4ILAK DM4ILAK DN PMID30280939-Compound-WO2015035128 DM4ILAK TI TTOK0LR DM4ILAK TN Toll-like receptor (TLR) DM4ILAK MA Agonist DM4ILAK RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM4ILAK RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM4IS6Q DI DM4IS6Q DM4IS6Q DN PMID27109571-Compound-32 DM4IS6Q TI TTMY6L1 DM4IS6Q TN Fatty acid-binding protein (FABP) DM4IS6Q MA Inhibitor DM4IS6Q RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM4IS6Q RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM4ISCQ DI DM4ISCQ DM4ISCQ DN Carbamide derivative 3 DM4ISCQ TI TTF8P9I DM4ISCQ TN Diacylglycerol acyltransferase 1 (DGAT1) DM4ISCQ MA Inhibitor DM4ISCQ RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM4ISCQ RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM4IZUH DI DM4IZUH DM4IZUH DN PMID27551786-Compound-138 DM4IZUH TI TT26PHO DM4IZUH TN Mineralocorticoid receptor (MR) DM4IZUH MA Antagonist DM4IZUH RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DM4IZUH RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DM4J2SM DI DM4J2SM DM4J2SM DN PMID25399762-Compound-Table 7-Veratraldehyde DM4J2SM TI TTGP7BY DM4J2SM TN Monoamine oxidase type B (MAO-B) DM4J2SM MA Inhibitor DM4J2SM RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4J2SM RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4JDHO DI DM4JDHO DM4JDHO DN Aminopiperidine derivative 2 DM4JDHO TI TTDIGC1 DM4JDHO TN Dipeptidyl peptidase 4 (DPP-4) DM4JDHO MA Inhibitor DM4JDHO RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM4JDHO RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM4JNLQ DI DM4JNLQ DM4JNLQ DN Indoline derivative 20 DM4JNLQ TI TTOHSBA DM4JNLQ TN Vascular endothelial growth factor A (VEGFA) DM4JNLQ MA Inhibitor DM4JNLQ RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM4JNLQ RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM4JZ2T DI DM4JZ2T DM4JZ2T DN Piperazine derivative 2 DM4JZ2T TI TT6OEDT DM4JZ2T TN Cannabinoid receptor 1 (CB1) DM4JZ2T MA Antagonist DM4JZ2T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM4JZ2T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM4K3AU DI DM4K3AU DM4K3AU DN PMID25435285-Compound-44 DM4K3AU TI TTXJ47W DM4K3AU TN Metabotropic glutamate receptor 2 (mGluR2) DM4K3AU MA Antagonist DM4K3AU RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM4K3AU RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTT7PJU DM4KBZQ TN Janus kinase 3 (JAK-3) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TT6DM01 DM4KBZQ TN Janus kinase 1 (JAK-1) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTBYWP2 DM4KBZQ TN TYK2 tyrosine kinase (TYK2) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTKAWRQ DM4KBZQ TN JAK-STAT signaling pathway (JAK-STAT pathway) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KBZQ DI DM4KBZQ DM4KBZQ DN Imidazo[4,5-c]pyridine derivative 1 DM4KBZQ TI TTJSQEF DM4KBZQ TN Tyrosine-protein kinase (PTK) DM4KBZQ MA Inhibitor DM4KBZQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM4KBZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM4KWVF DI DM4KWVF DM4KWVF DN PMID28594589-Compound-TABLE3C14 DM4KWVF TI TTZCRP3 DM4KWVF TN ERK activator kinase (MEK) DM4KWVF MA Inhibitor DM4KWVF RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM4KWVF RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM4LF0X DI DM4LF0X DM4LF0X DN PMID26651364-Compound-6e DM4LF0X TI TTTCRU2 DM4LF0X TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4LF0X MA Antagonist DM4LF0X RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4LF0X RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4M2TU DI DM4M2TU DM4M2TU DN PMID26004420-Compound-US20140336177D DM4M2TU TI TTJ13ST DM4M2TU TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM4M2TU MA Inhibitor DM4M2TU RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM4M2TU RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM4MA2X DI DM4MA2X DM4MA2X DN PMID26666989-Compound-Figure9middle01 DM4MA2X TI TT8BUGW DM4MA2X TN Glycogen phosphorylase (PYG) DM4MA2X MA Inhibitor DM4MA2X RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM4MA2X RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM4MAHK DI DM4MAHK DM4MAHK DN Salicylic acid derivative 4 DM4MAHK TI TTH8FZW DM4MAHK TN Signal transducer and activator of transcription 3 (STAT3) DM4MAHK MA Inhibitor DM4MAHK RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4MAHK RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM4MJ3U DI DM4MJ3U DM4MJ3U DN US9493447, 1001 DM4MJ3U TI TTIS4OW DM4MJ3U TN Phosphodiesterase 8 (PDE8) DM4MJ3U MA Inhibitor DM4MJ3U RN Optically active PDE10 inhibitor. US9493447. DM4MJ3U RU http://www.freepatentsonline.com/US9493447.html DM4MRP9 DI DM4MRP9 DM4MRP9 DN US8987457, 117 DM4MRP9 TI TTCGOIN DM4MRP9 TN PIM-3 protein kinase (PIM3) DM4MRP9 MA Inhibitor DM4MRP9 RN Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457. DM4MRP9 RU http://www.freepatentsonline.com/US8987457.html DM4MZ29 DI DM4MZ29 DM4MZ29 DN PMID26924192-Compound-21 DM4MZ29 TI TTRA6BO DM4MZ29 TN Bromodomain-containing protein 4 (BRD4) DM4MZ29 MA Inhibitor DM4MZ29 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM4MZ29 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM4NVTB DI DM4NVTB DM4NVTB DN PMID28394193-Compound-50 DM4NVTB TI TT9MZCQ DM4NVTB TN Enhancer of zeste homolog 2 (EZH2) DM4NVTB MA Inhibitor DM4NVTB RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4NVTB RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4NXBK DI DM4NXBK DM4NXBK DN PMID25684022-Compound-WO2011137219 38(5-7) DM4NXBK TI TTCZOF2 DM4NXBK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM4NXBK MA Inhibitor DM4NXBK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM4NXBK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM4O3DW DI DM4O3DW DM4O3DW DN 3,4-Dihydroxybenzaldehyde DM4O3DW TI TTGP7BY DM4O3DW TN Monoamine oxidase type B (MAO-B) DM4O3DW MA Inhibitor DM4O3DW RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4O3DW RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4O9T3 DI DM4O9T3 DM4O9T3 DN Flavonoid derivative 8 DM4O9T3 TI TTZMAO3 DM4O9T3 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM4O9T3 MA Agonist DM4O9T3 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM4O9T3 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM4O9T3 DI DM4O9T3 DM4O9T3 DN Flavonoid derivative 8 DM4O9T3 TI TTJ584C DM4O9T3 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM4O9T3 MA Agonist DM4O9T3 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM4O9T3 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM4OGKH DI DM4OGKH DM4OGKH DN Salicylic acid derivative 3 DM4OGKH TI TTH8FZW DM4OGKH TN Signal transducer and activator of transcription 3 (STAT3) DM4OGKH MA Inhibitor DM4OGKH RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM4OGKH RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM4OHB5 DI DM4OHB5 DM4OHB5 DN US9181182, 47 DM4OHB5 TI TTDYP7I DM4OHB5 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM4OHB5 MA Inhibitor DM4OHB5 RN S1P receptors modulators. US9181182. DM4OHB5 RU http://www.freepatentsonline.com/US9181182.html DM4P9HL DI DM4P9HL DM4P9HL DN Cyclopropane 1-carboxylic acid derivative 8 DM4P9HL TI TTIY56R DM4P9HL TN Kynurenine 3-hydroxylase (KMO) DM4P9HL MA Inhibitor DM4P9HL RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM4P9HL RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM4Q5SW DI DM4Q5SW DM4Q5SW DN PMID29338548-Compound-33 DM4Q5SW TI TTHJTF7 DM4Q5SW TN Glycine transporter GlyT-1 (SLC6A9) DM4Q5SW MA Inhibitor DM4Q5SW RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM4Q5SW RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM4Q6XZ DI DM4Q6XZ DM4Q6XZ DN PMID27376512-Compound-Table1Example5 DM4Q6XZ TI TT6S2FE DM4Q6XZ TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM4Q6XZ MA Inhibitor DM4Q6XZ RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM4Q6XZ RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM4QA6X DI DM4QA6X DM4QA6X DN PMID27788040-Compound-6a DM4QA6X TI TTV1C0Z DM4QA6X TN Neuropeptide S receptor (NPSR) DM4QA6X MA Antagonist DM4QA6X RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM4QA6X RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM4QUY0 DI DM4QUY0 DM4QUY0 DN Mannoside derivative 12 DM4QUY0 TI TTTCRU2 DM4QUY0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4QUY0 MA Antagonist DM4QUY0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4QUY0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4QVD0 DI DM4QVD0 DM4QVD0 DN Piperidinyl triazole derivative 5 DM4QVD0 TI TTTJZ4M DM4QVD0 TN Prolylcarboxypeptidase (PRCP) DM4QVD0 MA Inhibitor DM4QVD0 RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM4QVD0 RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM4QYIJ DI DM4QYIJ DM4QYIJ DN PMID25666693-Compound-84 DM4QYIJ TI TTMI6F5 DM4QYIJ TN Transient receptor potential cation channel V1 (TRPV1) DM4QYIJ MA Antagonist DM4QYIJ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM4QYIJ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM4R1MK DI DM4R1MK DM4R1MK DN Isoquinoline derivative 3 DM4R1MK TI TTMSFAW DM4R1MK TN Cannabinoid receptor 2 (CB2) DM4R1MK RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM4R1MK RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM4R7OQ DI DM4R7OQ DM4R7OQ DN Spirocyclic diamine urea derivative 1 DM4R7OQ TI TTDP1UC DM4R7OQ TN Fatty acid amide hydrolase (FAAH) DM4R7OQ MA Inhibitor DM4R7OQ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM4R7OQ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM4RTMO DI DM4RTMO DM4RTMO DN Cyclopropane 1-carboxylic acid derivative 7 DM4RTMO TI TTIY56R DM4RTMO TN Kynurenine 3-hydroxylase (KMO) DM4RTMO MA Inhibitor DM4RTMO RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM4RTMO RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM4S2U5 DI DM4S2U5 DM4S2U5 DN Aryl mannoside derivative 2 DM4S2U5 TI TTTCRU2 DM4S2U5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4S2U5 MA Antagonist DM4S2U5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4S2U5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4S5DF DI DM4S5DF DM4S5DF DN US8975409, Comparative compound B DM4S5DF TI TTVSMOH DM4S5DF TN Sphingosine-1-phosphate receptor 2 (S1PR2) DM4S5DF MA Inhibitor DM4S5DF RN Phenyl derivative. US8975409. DM4S5DF RU http://www.freepatentsonline.com/US8975409.html DM4S5ME DI DM4S5ME DM4S5ME DN PMID27109571-Compound-18 DM4S5ME TI TTNT2S6 DM4S5ME TN Fatty acid-binding protein 5 (FABP5) DM4S5ME MA Inhibitor DM4S5ME RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM4S5ME RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM4S5ME DI DM4S5ME DM4S5ME DN PMID27109571-Compound-18 DM4S5ME TI TTHWMFZ DM4S5ME TN Fatty acid-binding protein 4 (FABP4) DM4S5ME MA Inhibitor DM4S5ME RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM4S5ME RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM4S5PB DI DM4S5PB DM4S5PB DN PMID26651364-Compound-47 DM4S5PB TI TTTCRU2 DM4S5PB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4S5PB MA Antagonist DM4S5PB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4S5PB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4TOGU DI DM4TOGU DM4TOGU DN Benzanilide compound 1 DM4TOGU TI TTUX68I DM4TOGU TN Hypoxia-inducible factor 1 (HIF-1) DM4TOGU MA Inhibitor DM4TOGU RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM4TOGU RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM4U63E DI DM4U63E DM4U63E DN Five membered heterocyclic benzamide derivative 2 DM4U63E TI TTTDVOJ DM4U63E TN Tropomyosin-related kinase A (TrkA) DM4U63E MA Inhibitor DM4U63E RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM4U63E RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM4UM03 DI DM4UM03 DM4UM03 DN PMID25399762-Compound-Table 6-10 DM4UM03 TI TTGP7BY DM4UM03 TN Monoamine oxidase type B (MAO-B) DM4UM03 MA Inhibitor DM4UM03 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4UM03 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4UM03 DI DM4UM03 DM4UM03 DN PMID25399762-Compound-Table 6-10 DM4UM03 TI TTNR0UQ DM4UM03 TN Lysine-specific histone demethylase 1 (LSD) DM4UM03 MA Inhibitor DM4UM03 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM4UM03 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4V3AY DI DM4V3AY DM4V3AY DN PMID28766366-Compound-Scheme12-3 DM4V3AY TI TTSBVFO DM4V3AY TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM4V3AY MA Inhibitor DM4V3AY RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM4V3AY RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM4V3Y5 DI DM4V3Y5 DM4V3Y5 DN Benzamide derivative 11 DM4V3Y5 TI TT9NXW4 DM4V3Y5 TN Sigma intracellular receptor 2 (TMEM97) DM4V3Y5 MA Ligand DM4V3Y5 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM4V3Y5 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM4V3Y5 DI DM4V3Y5 DM4V3Y5 DN Benzamide derivative 11 DM4V3Y5 TI TT5TPI6 DM4V3Y5 TN Opioid receptor sigma 1 (OPRS1) DM4V3Y5 MA Ligand DM4V3Y5 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM4V3Y5 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM4VAQ3 DI DM4VAQ3 DM4VAQ3 DN PMID25666693-Compound-71 DM4VAQ3 TI TTMI6F5 DM4VAQ3 TN Transient receptor potential cation channel V1 (TRPV1) DM4VAQ3 MA Antagonist DM4VAQ3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM4VAQ3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM4VNWX DI DM4VNWX DM4VNWX DN Hexahydro quinoline derivative 1 DM4VNWX TI TTZJYKH DM4VNWX TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM4VNWX MA Inhibitor DM4VNWX RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM4VNWX RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM4VXY1 DI DM4VXY1 DM4VXY1 DN Benzo(b)carbazol-11-one compound 1 DM4VXY1 TI TT4DXQT DM4VXY1 TN Proto-oncogene c-Ret (RET) DM4VXY1 MA Inhibitor DM4VXY1 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM4VXY1 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM4W0BX DI DM4W0BX DM4W0BX DN PMID26651364-Compound-128 DM4W0BX TI TTTCRU2 DM4W0BX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4W0BX MA Antagonist DM4W0BX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4W0BX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4W72V DI DM4W72V DM4W72V DN PMID27724045-Compound-17 DM4W72V TI TT473XN DM4W72V TN P2X purinoceptor 7 (P2RX7) DM4W72V MA Antagonist DM4W72V RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM4W72V RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM4XAGS DI DM4XAGS DM4XAGS DN Pyridine-2,4-dicarboxylic acid analog 3 DM4XAGS TI TTWAQBO DM4XAGS TN Lysine-specific demethylase 4E (KDM4E) DM4XAGS MA Inhibitor DM4XAGS RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM4XAGS RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM4XJST DI DM4XJST DM4XJST DN PMID25726713-Compound-38 DM4XJST TI TT8J1S3 DM4XJST TN Smoothened homolog (SMO) DM4XJST MA Inhibitor DM4XJST RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM4XJST RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM4Y3US DI DM4Y3US DM4Y3US DN PMID28394193-Compound-57 DM4Y3US TI TTJW2UQ DM4Y3US TN EZH2 Y641N mutant (EZH2 Y641N) DM4Y3US MA Inhibitor DM4Y3US RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4Y3US RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4Y3US DI DM4Y3US DM4Y3US DN PMID28394193-Compound-57 DM4Y3US TI TT9MZCQ DM4Y3US TN Enhancer of zeste homolog 2 (EZH2) DM4Y3US MA Inhibitor DM4Y3US RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4Y3US RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4YE8W DI DM4YE8W DM4YE8W DN PMID25553724-Compound-WO2011127048 34 DM4YE8W TI TTSXVID DM4YE8W TN Nuclear factor NF-kappa-B (NFKB) DM4YE8W MA Modulator DM4YE8W RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM4YE8W RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM4Z2KY DI DM4Z2KY DM4Z2KY DN PMID30280939-Compound-WO2013148427 DM4Z2KY TI TTOK0LR DM4Z2KY TN Toll-like receptor (TLR) DM4Z2KY MA Agonist DM4Z2KY RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM4Z2KY RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM4Z72S DI DM4Z72S DM4Z72S DN Fused triazoloamino-phenyl analog 1 DM4Z72S TI TT473XN DM4Z72S TN P2X purinoceptor 7 (P2RX7) DM4Z72S MA Antagonist DM4Z72S RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM4Z72S RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM4ZAE8 DI DM4ZAE8 DM4ZAE8 DN PMID28394193-Compound-19 DM4ZAE8 TI TT9MZCQ DM4ZAE8 TN Enhancer of zeste homolog 2 (EZH2) DM4ZAE8 MA Inhibitor DM4ZAE8 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM4ZAE8 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM4ZG0Q DI DM4ZG0Q DM4ZG0Q DN PMID26651364-Compound-121 DM4ZG0Q TI TTTCRU2 DM4ZG0Q TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM4ZG0Q MA Antagonist DM4ZG0Q RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM4ZG0Q RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM4ZO21 DI DM4ZO21 DM4ZO21 DN PMID28092474-Compound-32p DM4ZO21 TI TT6R7JZ DM4ZO21 TN Histone deacetylase 1 (HDAC1) DM4ZO21 MA Inhibitor DM4ZO21 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM4ZO21 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM4ZO21 DI DM4ZO21 DM4ZO21 DN PMID28092474-Compound-32p DM4ZO21 TI TT5ZKDI DM4ZO21 TN Histone deacetylase 6 (HDAC6) DM4ZO21 MA Inhibitor DM4ZO21 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM4ZO21 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM4ZUDY DI DM4ZUDY DM4ZUDY DN Benzimidazole derivative 2 DM4ZUDY TI TT6OEDT DM4ZUDY TN Cannabinoid receptor 1 (CB1) DM4ZUDY MA Antagonist DM4ZUDY RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM4ZUDY RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM50E4Y DI DM50E4Y DM50E4Y DN Aminoazetidine derivative 4 DM50E4Y TI TT6OEDT DM50E4Y TN Cannabinoid receptor 1 (CB1) DM50E4Y MA Antagonist DM50E4Y RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM50E4Y RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM51JP6 DI DM51JP6 DM51JP6 DN PMID28092474-Compound-33c DM51JP6 TI TT6R7JZ DM51JP6 TN Histone deacetylase 1 (HDAC1) DM51JP6 MA Inhibitor DM51JP6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM51JP6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM51JP6 DI DM51JP6 DM51JP6 DN PMID28092474-Compound-33c DM51JP6 TI TT5ZKDI DM51JP6 TN Histone deacetylase 6 (HDAC6) DM51JP6 MA Inhibitor DM51JP6 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM51JP6 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM51MFS DI DM51MFS DM51MFS DN Pyrimidine derivative 25 DM51MFS TI TT0K1SC DM51MFS TN 5-HT 2B receptor (HTR2B) DM51MFS MA Antagonist DM51MFS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM51MFS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM51MFS DI DM51MFS DM51MFS DN Pyrimidine derivative 25 DM51MFS TI TTWJBZ5 DM51MFS TN 5-HT 2C receptor (HTR2C) DM51MFS MA Antagonist DM51MFS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM51MFS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM51MFS DI DM51MFS DM51MFS DN Pyrimidine derivative 25 DM51MFS TI TTJQOD7 DM51MFS TN 5-HT 2A receptor (HTR2A) DM51MFS MA Antagonist DM51MFS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM51MFS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM52683 DI DM52683 DM52683 DN Tetrazole acetic acid derivative 1 DM52683 TI TTA592U DM52683 TN Urate anion exchanger 1 (URAT1) DM52683 MA Inhibitor DM52683 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM52683 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM52IQF DI DM52IQF DM52IQF DN BDBM50177012 DM52IQF TI TTECBXN DM52IQF TN Oxysterols receptor LXR-alpha (NR1H3) DM52IQF MA Inhibitor DM52IQF RN Piperazine derivatives as liver X receptor modulators. US10144715. DM52IQF RU http://www.freepatentsonline.com/US10144715.html DM52MIK DI DM52MIK DM52MIK DN PMID26560530-Compound-14 DM52MIK TI TT2F4OL DM52MIK TN Tissue transglutaminase (TG2) DM52MIK MA Inhibitor DM52MIK RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM52MIK RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM52MKV DI DM52MKV DM52MKV DN PMID30273516-Compound-1 DM52MKV TI TTCW0KX DM52MKV TN Glutaminase (GLS) DM52MKV MA Inhibitor DM52MKV RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM52MKV RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM536FO DI DM536FO DM536FO DN US8703720, Reference Compound 2 DM536FO TI TTO3NYT DM536FO TN Galectin-1 (LGALS1) DM536FO MA Inhibitor DM536FO RN Galactoside inhibitors of galectins. US8703720. DM536FO RU http://www.freepatentsonline.com/US8703720.html DM536JN DI DM536JN DM536JN DN PMID25991433-Compound-Eb DM536JN TI TT0K6EO DM536JN TN Stress-activated protein kinase JNK1 (JNK1) DM536JN MA Inhibitor DM536JN RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM536JN RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM53JXE DI DM53JXE DM53JXE DN Indomethacin analog 3 DM53JXE TI TT5ZWB6 DM53JXE TN Dihydrodiol dehydrogenase type I (AKR1C3) DM53JXE MA Inhibitor; Antagonist; Blocker DM53JXE RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM53JXE RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM53LGD DI DM53LGD DM53LGD DN Pyrimido-indole derivative 3 DM53LGD TI TTE4BSY DM53LGD TN Bromodomain and extraterminal domain protein (BET) DM53LGD MA Inhibitor DM53LGD RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM53LGD RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM53O9Y DI DM53O9Y DM53O9Y DN Pyrimidinyl compound 4 DM53O9Y TI TTH5TC2 DM53O9Y TN NF-kappa-B-activating kinase (TBK1) DM53O9Y MA Inhibitor DM53O9Y RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM53O9Y RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM53PBG DI DM53PBG DM53PBG DN PMID25666693-Compound-5 DM53PBG TI TTMI6F5 DM53PBG TN Transient receptor potential cation channel V1 (TRPV1) DM53PBG MA Antagonist DM53PBG RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM53PBG RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM53Z4I DI DM53Z4I DM53Z4I DN US9040714, 7 DM53Z4I TI TTOJ9QL DM53Z4I TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM53Z4I MA Inhibitor DM53Z4I RN IRE-1 inhibitors. US9040714. DM53Z4I RU http://www.freepatentsonline.com/US9040714.html DM53ZPE DI DM53ZPE DM53ZPE DN Ethynyl compound 5 DM53ZPE TI TTHS256 DM53ZPE TN Metabotropic glutamate receptor 5 (mGluR5) DM53ZPE MA Modulator DM53ZPE RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM53ZPE RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM541QW DI DM541QW DM541QW DN N-(benzimidazolylcarbonyl)-piperidine derivative 1 DM541QW TI TT5ZWB6 DM541QW TN Dihydrodiol dehydrogenase type I (AKR1C3) DM541QW MA Inhibitor DM541QW RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM541QW RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM54DXT DI DM54DXT DM54DXT DN PMID25522065-Compound-3 DM54DXT TI TTX4RTB DM54DXT TN Melanin-concentrating hormone receptor 1 (MCHR1) DM54DXT MA Antagonist DM54DXT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM54DXT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM54EFD DI DM54EFD DM54EFD DN Terpyridineplatinum(II) complexe 3 DM54EFD TI TTEP6RV DM54EFD TN Glutathione reductase (GR) DM54EFD MA Inhibitor DM54EFD RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM54EFD RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM54EFD DI DM54EFD DM54EFD DN Terpyridineplatinum(II) complexe 3 DM54EFD TI TTR7UJ3 DM54EFD TN Cytoplasmic thioredoxin reductase (TXNRD1) DM54EFD MA Inhibitor DM54EFD RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM54EFD RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM54EV2 DI DM54EV2 DM54EV2 DN Bicyclic heteroaryl benzamide derivative 3 DM54EV2 TI TTTDVOJ DM54EV2 TN Tropomyosin-related kinase A (TrkA) DM54EV2 MA Inhibitor DM54EV2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM54EV2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM54V1R DI DM54V1R DM54V1R DN Aryl urea derivative 5 DM54V1R TI TTDP1UC DM54V1R TN Fatty acid amide hydrolase (FAAH) DM54V1R MA Inhibitor DM54V1R RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM54V1R RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM568TX DI DM568TX DM568TX DN N-alkylamide derivative 2 DM568TX TI TTHS256 DM568TX TN Metabotropic glutamate receptor 5 (mGluR5) DM568TX MA Modulator DM568TX RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM568TX RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM56I8H DI DM56I8H DM56I8H DN Quinoline derivative 7 DM56I8H TI TTXJ47W DM56I8H TN Metabotropic glutamate receptor 2 (mGluR2) DM56I8H MA Antagonist DM56I8H RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM56I8H RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM56T1P DI DM56T1P DM56T1P DN Heterocyclic derivative 26 DM56T1P TI TTIXKA4 DM56T1P TN Ribosomal protein S6 kinase alpha-1 (RSK1) DM56T1P MA Inhibitor DM56T1P RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DM56T1P RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DM571JP DI DM571JP DM571JP DN PMID29473428-Compound-15 DM571JP TI TTZJYKH DM571JP TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM571JP MA Inhibitor DM571JP RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM571JP RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM57N3Y DI DM57N3Y DM57N3Y DN PMID29671355-Compound-57 DM57N3Y TI TT4YWTO DM57N3Y TN Histone deacetylase 3 (HDAC3) DM57N3Y MA Inhibitor DM57N3Y RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM57N3Y RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM57N3Y DI DM57N3Y DM57N3Y DN PMID29671355-Compound-57 DM57N3Y TI TT6R7JZ DM57N3Y TN Histone deacetylase 1 (HDAC1) DM57N3Y MA Inhibitor DM57N3Y RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM57N3Y RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM57W29 DI DM57W29 DM57W29 DN Pyrrolo[2,3-d]pyrimidine derivative 30 DM57W29 TI TTGM6VW DM57W29 TN Tyrosine-protein kinase BTK (ATK) DM57W29 MA Inhibitor DM57W29 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM57W29 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM584EP DI DM584EP DM584EP DN PMID27607364-Compound-60 DM584EP TI TTPTXIN DM584EP TN Translocator protein (TSPO) DM584EP MA Ligand DM584EP RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM584EP RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM58QW1 DI DM58QW1 DM58QW1 DN PMID25666693-Compound-40 DM58QW1 TI TTMI6F5 DM58QW1 TN Transient receptor potential cation channel V1 (TRPV1) DM58QW1 MA Antagonist DM58QW1 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM58QW1 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM58UO9 DI DM58UO9 DM58UO9 DN PMID25991433-Compound-L2 DM58UO9 TI TTQBR95 DM58UO9 TN Stress-activated protein kinase 2a (p38 alpha) DM58UO9 MA Inhibitor DM58UO9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM58UO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM58UO9 DI DM58UO9 DM58UO9 DN PMID25991433-Compound-L2 DM58UO9 TI TT3ZIJL DM58UO9 TN JNK-interacting protein peptide (pepJIP) DM58UO9 MA Inhibitor DM58UO9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM58UO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM58UO9 DI DM58UO9 DM58UO9 DN PMID25991433-Compound-L2 DM58UO9 TI TTVOE6D DM58UO9 TN Mitogen-activated protein kinase (MAPK) DM58UO9 MA Inhibitor DM58UO9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM58UO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM58X6N DI DM58X6N DM58X6N DN 3-(phenoxymethyl) benzylamine derivative 4 DM58X6N TI TTULVH8 DM58X6N TN Tyrosinase (TYR) DM58X6N MA Inhibitor DM58X6N RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM58X6N RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM58Z4M DI DM58Z4M DM58Z4M DN PMID25666693-Compound-32 DM58Z4M TI TTMI6F5 DM58Z4M TN Transient receptor potential cation channel V1 (TRPV1) DM58Z4M MA Antagonist DM58Z4M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM58Z4M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM59INV DI DM59INV DM59INV DN PMID26004420-Compound-WO2014126944A DM59INV TI TTJ13ST DM59INV TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM59INV MA Inhibitor DM59INV RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM59INV RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM5A4TP DI DM5A4TP DM5A4TP DN Spiroimidazolone derivative 7 DM5A4TP TI TT9O6WS DM5A4TP TN Glucagon receptor (GCGR) DM5A4TP MA Antagonist DM5A4TP RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM5A4TP RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM5A62X DI DM5A62X DM5A62X DN Spiroimidazolone derivative 5 DM5A62X TI TT9O6WS DM5A62X TN Glucagon receptor (GCGR) DM5A62X MA Antagonist DM5A62X RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM5A62X RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM5A8F3 DI DM5A8F3 DM5A8F3 DN Pyrazole derivative 16 DM5A8F3 TI TT6OEDT DM5A8F3 TN Cannabinoid receptor 1 (CB1) DM5A8F3 MA Antagonist DM5A8F3 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5A8F3 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5ATIV DI DM5ATIV DM5ATIV DN PMID25553724-Compound-WO2011127048 31 DM5ATIV TI TTSXVID DM5ATIV TN Nuclear factor NF-kappa-B (NFKB) DM5ATIV MA Modulator DM5ATIV RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM5ATIV RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM5AUL0 DI DM5AUL0 DM5AUL0 DN Thiadiazolidindione derivative 2 DM5AUL0 TI TTRZQE3 DM5AUL0 TN Glycogen synthase kinase-3 alpha (GSK-3A) DM5AUL0 MA Inhibitor DM5AUL0 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM5AUL0 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM5AXHF DI DM5AXHF DM5AXHF DN Macrolactam derivative 4 DM5AXHF TI TTKFVXR DM5AXHF TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM5AXHF MA Inhibitor DM5AXHF RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM5AXHF RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM5B0F3 DI DM5B0F3 DM5B0F3 DN Diaminopyridine analog 5 DM5B0F3 TI TTKFVXR DM5B0F3 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM5B0F3 MA Inhibitor DM5B0F3 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM5B0F3 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM5B92W DI DM5B92W DM5B92W DN Tricyclic indole compound 3 DM5B92W TI TTPTXIN DM5B92W TN Translocator protein (TSPO) DM5B92W MA Ligand DM5B92W RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM5B92W RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM5BCGD DI DM5BCGD DM5BCGD DN Cyclopropylamine derivative 5 DM5BCGD TI TTNR0UQ DM5BCGD TN Lysine-specific histone demethylase 1 (LSD) DM5BCGD MA Inhibitor DM5BCGD RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM5BCGD RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM5BF6H DI DM5BF6H DM5BF6H DN Heteroaryl-azepine derivative 11 DM5BF6H TI TTWJBZ5 DM5BF6H TN 5-HT 2C receptor (HTR2C) DM5BF6H MA Agonist DM5BF6H RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5BF6H RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5BFJO DI DM5BFJO DM5BFJO DN CS-W011402 DM5BFJO TI TT6A59G DM5BFJO TN Phosphodiesterase 4C (PDE4C) DM5BFJO MA Inhibitor DM5BFJO RN Imidazopyridazine compounds. US9598421. DM5BFJO RU http://www.freepatentsonline.com/US9598421.html DM5BG6L DI DM5BG6L DM5BG6L DN PMID28766366-Compound-Scheme12-4 DM5BG6L TI TTSBVFO DM5BG6L TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM5BG6L MA Inhibitor DM5BG6L RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM5BG6L RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM5BVCS DI DM5BVCS DM5BVCS DN Galantamine analog 1 DM5BVCS TI TT1RS9F DM5BVCS TN Acetylcholinesterase (AChE) DM5BVCS MA Inhibitor DM5BVCS RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM5BVCS RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TT1RS9F DM5CKVF TN Acetylcholinesterase (AChE) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TTGP7BY DM5CKVF TN Monoamine oxidase type B (MAO-B) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TT3WG5C DM5CKVF TN Monoamine oxidase type A (MAO-A) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CKVF DI DM5CKVF DM5CKVF DN Tetra-hydro-isoquinoline derivative 2 DM5CKVF TI TTEB0GD DM5CKVF TN Cholinesterase (BCHE) DM5CKVF MA Inhibitor DM5CKVF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5CKVF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5CULA DI DM5CULA DM5CULA DN US8609715, A-1 DM5CULA TI TTXL0GC DM5CULA TN Enteropeptidase (TMPRSS15) DM5CULA MA Inhibitor DM5CULA RN Heteroarylcarboxylic acid ester derivative. US8609715. DM5CULA RU http://www.freepatentsonline.com/US8609715.html DM5CUSJ DI DM5CUSJ DM5CUSJ DN Sulfonamide derivative 15 DM5CUSJ TI TTZS04O DM5CUSJ TN Gamma-secretase subunit APH-1A/1B (APH-1) DM5CUSJ MA Inhibitor DM5CUSJ RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DM5CUSJ RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DM5CXQT DI DM5CXQT DM5CXQT DN Isoxazole-based bicyclic compound 1 DM5CXQT TI TTE4BSY DM5CXQT TN Bromodomain and extraterminal domain protein (BET) DM5CXQT MA Inhibitor DM5CXQT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM5CXQT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM5CY86 DI DM5CY86 DM5CY86 DN PMID25666693-Compound-151 DM5CY86 TI TTMI6F5 DM5CY86 TN Transient receptor potential cation channel V1 (TRPV1) DM5CY86 MA Antagonist DM5CY86 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM5CY86 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM5DC9A DI DM5DC9A DM5DC9A DN Oxazolo[3,4-a]pyrazine derivative 6 DM5DC9A TI TTV1C0Z DM5DC9A TN Neuropeptide S receptor (NPSR) DM5DC9A MA Antagonist DM5DC9A RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM5DC9A RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM5E1KS DI DM5E1KS DM5E1KS DN Pyrazolo[1,5-a]pyrimidine derivative 6 DM5E1KS TI TT6OEDT DM5E1KS TN Cannabinoid receptor 1 (CB1) DM5E1KS MA Antagonist DM5E1KS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5E1KS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5E1ZJ DI DM5E1ZJ DM5E1ZJ DN Pyrazole derivative 77 DM5E1ZJ TI TTXJ47W DM5E1ZJ TN Metabotropic glutamate receptor 2 (mGluR2) DM5E1ZJ MA Antagonist DM5E1ZJ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM5E1ZJ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM5E2B3 DI DM5E2B3 DM5E2B3 DN PMID25726713-Compound-42 DM5E2B3 TI TT8J1S3 DM5E2B3 TN Smoothened homolog (SMO) DM5E2B3 MA Inhibitor DM5E2B3 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM5E2B3 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM5E9RH DI DM5E9RH DM5E9RH DN US9340574, 7 DM5E9RH TI TTWMKXP DM5E9RH TN Protein-tyrosine phosphatase eta (HPTP) DM5E9RH MA Inhibitor DM5E9RH RN Inhibitors of protein tyrosine phosphatases. US9340574. DM5E9RH RU http://www.freepatentsonline.com/US9340574.html DM5ECH2 DI DM5ECH2 DM5ECH2 DN PMID25656651-Compound-11a DM5ECH2 TI TTS7G69 DM5ECH2 TN Fusion protein Bcr-Abl (Bcr-Abl) DM5ECH2 MA Inhibitor DM5ECH2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM5ECH2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM5EGBY DI DM5EGBY DM5EGBY DN Aryl piperazine derivative 10 DM5EGBY TI TTWJBZ5 DM5EGBY TN 5-HT 2C receptor (HTR2C) DM5EGBY MA Agonist DM5EGBY RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5EGBY RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5EHK2 DI DM5EHK2 DM5EHK2 DN PMID25656651-Compound-16b DM5EHK2 TI TTS7G69 DM5EHK2 TN Fusion protein Bcr-Abl (Bcr-Abl) DM5EHK2 MA Inhibitor DM5EHK2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM5EHK2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM5F1LR DI DM5F1LR DM5F1LR DN Imidazopyridazine derivative 6 DM5F1LR TI TTQR74A DM5F1LR TN Proteinase activated receptor 2 (PAR2) DM5F1LR MA Antagonist DM5F1LR RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM5F1LR RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM5F8J1 DI DM5F8J1 DM5F8J1 DN Indol-5-ol derivative 1 DM5F8J1 TI TT3PJMV DM5F8J1 TN Tyrosine-protein kinase ABL1 (ABL) DM5F8J1 MA Inhibitor DM5F8J1 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM5F8J1 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM5FVH0 DI DM5FVH0 DM5FVH0 DN 1,2-diamino cyclopentane-based derivative 29 DM5FVH0 TI TT9N02I DM5FVH0 TN Orexin receptor type 2 (HCRTR2) DM5FVH0 MA Antagonist DM5FVH0 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5FVH0 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5FVH0 DI DM5FVH0 DM5FVH0 DN 1,2-diamino cyclopentane-based derivative 29 DM5FVH0 TI TT60Q8D DM5FVH0 TN Orexin receptor type 1 (HCRTR1) DM5FVH0 MA Antagonist DM5FVH0 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5FVH0 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5G3CN DI DM5G3CN DM5G3CN DN Poly-substituted azoles statin lactone derivative 2 DM5G3CN TI TTPADOQ DM5G3CN TN HMG-CoA reductase (HMGCR) DM5G3CN MA Inhibitor DM5G3CN RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM5G3CN RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM5G67X DI DM5G67X DM5G67X DN Pyrrolo-pyridinone derivative 2 DM5G67X TI TT4DXQT DM5G67X TN Proto-oncogene c-Ret (RET) DM5G67X MA Inhibitor DM5G67X RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM5G67X RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM5GCUR DI DM5GCUR DM5GCUR DN N-acylpiperidine ether derivative 1 DM5GCUR TI TTTDVOJ DM5GCUR TN Tropomyosin-related kinase A (TrkA) DM5GCUR MA Inhibitor DM5GCUR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM5GCUR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM5GEBH DI DM5GEBH DM5GEBH DN Carboxamide derivative 1 DM5GEBH TI TT6OEDT DM5GEBH TN Cannabinoid receptor 1 (CB1) DM5GEBH MA Antagonist DM5GEBH RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5GEBH RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5GHJA DI DM5GHJA DM5GHJA DN PMID26651364-Compound-114 DM5GHJA TI TTTCRU2 DM5GHJA TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5GHJA MA Antagonist DM5GHJA RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5GHJA RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5GKS6 DI DM5GKS6 DM5GKS6 DN 3-phenyl propanoic derivative 3 DM5GKS6 TI TTA6ZN2 DM5GKS6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5GKS6 MA Inhibitor DM5GKS6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5GKS6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5GKS6 DI DM5GKS6 DM5GKS6 DN 3-phenyl propanoic derivative 3 DM5GKS6 TI TTGIZLN DM5GKS6 TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DM5GKS6 MA Modulator DM5GKS6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5GKS6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5GZNS DI DM5GZNS DM5GZNS DN Urea and carbamate bioisostere derivative 4 DM5GZNS TI TTL7C8Q DM5GZNS TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5GZNS MA Inhibitor DM5GZNS RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM5GZNS RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM5H3R8 DI DM5H3R8 DM5H3R8 DN PhyllanthoidA DM5H3R8 TI TT3WG5C DM5H3R8 TN Monoamine oxidase type A (MAO-A) DM5H3R8 MA Inhibitor DM5H3R8 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM5H3R8 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM5H3YA DI DM5H3YA DM5H3YA DN PMID25522065-Compound-32 DM5H3YA TI TTX4RTB DM5H3YA TN Melanin-concentrating hormone receptor 1 (MCHR1) DM5H3YA MA Antagonist DM5H3YA RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM5H3YA RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM5HUCR DI DM5HUCR DM5HUCR DN PMID27019002-Compound-44 DM5HUCR TI TTNR0UQ DM5HUCR TN Lysine-specific histone demethylase 1 (LSD) DM5HUCR MA Inhibitor DM5HUCR RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM5HUCR RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM5I1QV DI DM5I1QV DM5I1QV DN PMID29671355-Compound-47a DM5I1QV TI TTTQGH8 DM5I1QV TN Histone deacetylase 4 (HDAC4) DM5I1QV MA Inhibitor DM5I1QV RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5I1QV RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5I4CA DI DM5I4CA DM5I4CA DN Fused aryl carbocycle derivative 3 DM5I4CA TI TT9NXW4 DM5I4CA TN Sigma intracellular receptor 2 (TMEM97) DM5I4CA MA Ligand DM5I4CA RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM5I4CA RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM5IFBV DI DM5IFBV DM5IFBV DN PMID29757691-Compound-8a DM5IFBV TI TTEB0GD DM5IFBV TN Cholinesterase (BCHE) DM5IFBV MA Inhibitor DM5IFBV RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5IFBV RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5IFBV DI DM5IFBV DM5IFBV DN PMID29757691-Compound-8a DM5IFBV TI TT1RS9F DM5IFBV TN Acetylcholinesterase (AChE) DM5IFBV MA Inhibitor DM5IFBV RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM5IFBV RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM5IH2O DI DM5IH2O DM5IH2O DN Benzodihydroisofuran derivative 4 DM5IH2O TI TTTJZ4M DM5IH2O TN Prolylcarboxypeptidase (PRCP) DM5IH2O MA Inhibitor DM5IH2O RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DM5IH2O RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DM5IWX2 DI DM5IWX2 DM5IWX2 DN 4-aryl quinol derivative 4 DM5IWX2 TI TTR7UJ3 DM5IWX2 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5IWX2 MA Inhibitor DM5IWX2 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5IWX2 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5IZKD DI DM5IZKD DM5IZKD DN PMID28627961-Compound-32 DM5IZKD TI TTYLQ8V DM5IZKD TN Prostaglandin E synthase (PTGES) DM5IZKD MA Inhibitor DM5IZKD RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM5IZKD RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM5J09E DI DM5J09E DM5J09E DN Imidazo[1,2-b]pyridazine acetamide derivative 4 DM5J09E TI TTPTXIN DM5J09E TN Translocator protein (TSPO) DM5J09E MA Ligand DM5J09E RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM5J09E RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM5JSI3 DI DM5JSI3 DM5JSI3 DN PMID27977313-Compound-19 DM5JSI3 TI TTR7UJ3 DM5JSI3 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5JSI3 MA Inhibitor DM5JSI3 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5JSI3 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5JUR2 DI DM5JUR2 DM5JUR2 DN Indole-based analog 5 DM5JUR2 TI TTPTXIN DM5JUR2 TN Translocator protein (TSPO) DM5JUR2 MA Ligand DM5JUR2 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM5JUR2 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM5K3DF DI DM5K3DF DM5K3DF DN PMID30280939-Compound-WO2015091734 DM5K3DF TI TTOK0LR DM5K3DF TN Toll-like receptor (TLR) DM5K3DF MA Agonist DM5K3DF RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM5K3DF RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM5K4YF DI DM5K4YF DM5K4YF DN PMID27376512-Compound-PG-11047 DM5K4YF TI TTBH0VX DM5K4YF TN Histone deacetylase (HDAC) DM5K4YF MA Inhibitor DM5K4YF RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM5K4YF RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM5K4YF DI DM5K4YF DM5K4YF DN PMID27376512-Compound-PG-11047 DM5K4YF TI TTHVCUP DM5K4YF TN DNA [cytosine-5]-methyltransferase (DNMT) DM5K4YF MA Inhibitor DM5K4YF RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM5K4YF RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM5K6MG DI DM5K6MG DM5K6MG DN PMID29671355-Compound-26 DM5K6MG TI TT6R7JZ DM5K6MG TN Histone deacetylase 1 (HDAC1) DM5K6MG MA Inhibitor DM5K6MG RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5K6MG RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5K6MG DI DM5K6MG DM5K6MG DN PMID29671355-Compound-26 DM5K6MG TI TT5ZKDI DM5K6MG TN Histone deacetylase 6 (HDAC6) DM5K6MG MA Inhibitor DM5K6MG RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5K6MG RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5KARO DI DM5KARO DM5KARO DN PMID27599163-Compound-52 DM5KARO TI TTPTXIN DM5KARO TN Translocator protein (TSPO) DM5KARO MA Ligand DM5KARO RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DM5KARO RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DM5KEVG DI DM5KEVG DM5KEVG DN Peptide analog 4 DM5KEVG TI TT23XQV DM5KEVG TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM5KEVG MA Inhibitor DM5KEVG RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM5KEVG RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM5KTDY DI DM5KTDY DM5KTDY DN Beta-naphthylacetic acids derivative 1 DM5KTDY TI TT5ZWB6 DM5KTDY TN Dihydrodiol dehydrogenase type I (AKR1C3) DM5KTDY MA Inhibitor; Antagonist; Blocker DM5KTDY RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DM5KTDY RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DM5LK6O DI DM5LK6O DM5LK6O DN US10023583, Example 24 DM5LK6O TI TTY2KP7 DM5LK6O TN Leucyl-cysteinyl aminopeptidase (LNPEP) DM5LK6O MA Inhibitor DM5LK6O RN Bicyclic pyridine compound. US10023583. DM5LK6O RU http://www.freepatentsonline.com/US10023583.html DM5LOST DI DM5LOST DM5LOST DN PMID27454349-Compound-100 DM5LOST TI TTK59TV DM5LOST TN Vitamin D3 receptor (VDR) DM5LOST MA Agonist DM5LOST RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DM5LOST RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DM5LQJW DI DM5LQJW DM5LQJW DN 1,2-diamino cyclopentane-based derivative 27 DM5LQJW TI TT9N02I DM5LQJW TN Orexin receptor type 2 (HCRTR2) DM5LQJW MA Antagonist DM5LQJW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5LQJW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5LQJW DI DM5LQJW DM5LQJW DN 1,2-diamino cyclopentane-based derivative 27 DM5LQJW TI TT60Q8D DM5LQJW TN Orexin receptor type 1 (HCRTR1) DM5LQJW MA Antagonist DM5LQJW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5LQJW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TTTQGH8 DM5LYKR TN Histone deacetylase 4 (HDAC4) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TT8M4E1 DM5LYKR TN Histone deacetylase 9 (HDAC9) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TTMUEK1 DM5LYKR TN Histone deacetylase 7 (HDAC7) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5LYKR DI DM5LYKR DM5LYKR DN PMID29671355-Compound-45a DM5LYKR TI TTUELN5 DM5LYKR TN Histone deacetylase 5 (HDAC5) DM5LYKR MA Inhibitor DM5LYKR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM5LYKR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM5MIEC DI DM5MIEC DM5MIEC DN Aryl mannoside derivative 6 DM5MIEC TI TTTCRU2 DM5MIEC TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5MIEC MA Antagonist DM5MIEC RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5MIEC RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5MLQU DI DM5MLQU DM5MLQU DN Pyrimidine derivative 23 DM5MLQU TI TTWJBZ5 DM5MLQU TN 5-HT 2C receptor (HTR2C) DM5MLQU MA Antagonist DM5MLQU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5MLQU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5MLQU DI DM5MLQU DM5MLQU DN Pyrimidine derivative 23 DM5MLQU TI TT0K1SC DM5MLQU TN 5-HT 2B receptor (HTR2B) DM5MLQU MA Antagonist DM5MLQU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5MLQU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5MLQU DI DM5MLQU DM5MLQU DN Pyrimidine derivative 23 DM5MLQU TI TTJQOD7 DM5MLQU TN 5-HT 2A receptor (HTR2A) DM5MLQU MA Antagonist DM5MLQU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM5MLQU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM5MT4R DI DM5MT4R DM5MT4R DN Bicyclic heteroaryl benzamide derivative 2 DM5MT4R TI TTTDVOJ DM5MT4R TN Tropomyosin-related kinase A (TrkA) DM5MT4R MA Inhibitor DM5MT4R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM5MT4R RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TTJQOD7 DM5MUNG TN 5-HT 2A receptor (HTR2A) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TTNGILX DM5MUNG TN Adrenergic receptor alpha-1A (ADRA1A) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TT34BHT DM5MUNG TN Adrenergic receptor alpha-1D (ADRA1D) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MUNG DI DM5MUNG DM5MUNG DN PMID30124346-Compound-LDT8 DM5MUNG TI TTSQIFT DM5MUNG TN 5-HT 1A receptor (HTR1A) DM5MUNG MA Antagonist DM5MUNG RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM5MUNG RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM5MVLG DI DM5MVLG DM5MVLG DN Tetra-hydro-carboline derivative 1 DM5MVLG TI TTSCIM2 DM5MVLG TN Extracellular lysophospholipase D (E-NPP2) DM5MVLG MA Inhibitor DM5MVLG RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM5MVLG RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM5MXFK DI DM5MXFK DM5MXFK DN PMID29473428-Compound-11 DM5MXFK TI TTZJYKH DM5MXFK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5MXFK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM5MXFK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM5N8YJ DI DM5N8YJ DM5N8YJ DN PMID30273516-Compound-40 DM5N8YJ TI TTCW0KX DM5N8YJ TN Glutaminase (GLS) DM5N8YJ MA Inhibitor DM5N8YJ RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM5N8YJ RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM5N9M4 DI DM5N9M4 DM5N9M4 DN PMID26004420-Compound-WO2013062900A DM5N9M4 TI TTJ13ST DM5N9M4 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM5N9M4 MA Inhibitor DM5N9M4 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM5N9M4 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM5NEQ2 DI DM5NEQ2 DM5NEQ2 DN Imidazo[1,2-a]pyridine derivative 1 DM5NEQ2 TI TTHS256 DM5NEQ2 TN Metabotropic glutamate receptor 5 (mGluR5) DM5NEQ2 MA Modulator DM5NEQ2 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM5NEQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM5NJDK DI DM5NJDK DM5NJDK DN PMID28454500-Compound-49 DM5NJDK TI TTA6ZN2 DM5NJDK TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5NJDK MA Activator DM5NJDK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5NJDK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5NJDK DI DM5NJDK DM5NJDK DN PMID28454500-Compound-49 DM5NJDK TI TT3Z6Y9 DM5NJDK TN Cysteines of Keap1 (KEAP1 Cysteines) DM5NJDK MA Modulator DM5NJDK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5NJDK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5NKXO DI DM5NKXO DM5NKXO DN Pyrrolidine derivative 5 DM5NKXO TI TTHS256 DM5NKXO TN Metabotropic glutamate receptor 5 (mGluR5) DM5NKXO RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM5NKXO RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM5O8K0 DI DM5O8K0 DM5O8K0 DN 2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 TI TTALN9W DM5O8K0 TN Indoleamine 2,3-dioxygenase 2 (IDO2) DM5O8K0 MA Inhibitor DM5O8K0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM5O8K0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM5O8K0 DI DM5O8K0 DM5O8K0 DN 2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 TI TTZJYKH DM5O8K0 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5O8K0 MA Inhibitor DM5O8K0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM5O8K0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM5O8K0 DI DM5O8K0 DM5O8K0 DN 2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 TI TTXNCBV DM5O8K0 TN Tryptophan 2,3-dioxygenase (TDO) DM5O8K0 MA Inhibitor DM5O8K0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM5O8K0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM5OCM7 DI DM5OCM7 DM5OCM7 DN Piperazine urea derivative 2 DM5OCM7 TI TTGX13H DM5OCM7 TN Fatty-acid amide hydrolase 1 (FAAH1) DM5OCM7 MA Inhibitor DM5OCM7 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM5OCM7 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM5OEQZ DI DM5OEQZ DM5OEQZ DN Macrocycle derivative 2 DM5OEQZ TI TT5YPJF DM5OEQZ TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DM5OEQZ MA Inhibitor DM5OEQZ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM5OEQZ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM5OEQZ DI DM5OEQZ DM5OEQZ DN Macrocycle derivative 2 DM5OEQZ TI TT23XQV DM5OEQZ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM5OEQZ MA Inhibitor DM5OEQZ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM5OEQZ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM5OH8D DI DM5OH8D DM5OH8D DN Pyrazolopyridine derivative 6 DM5OH8D TI TTRMX3V DM5OH8D TN Janus kinase 2 (JAK-2) DM5OH8D MA Inhibitor DM5OH8D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM5OH8D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM5OH8D DI DM5OH8D DM5OH8D DN Pyrazolopyridine derivative 6 DM5OH8D TI TTT7PJU DM5OH8D TN Janus kinase 3 (JAK-3) DM5OH8D MA Inhibitor DM5OH8D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM5OH8D RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM5OQBR DI DM5OQBR DM5OQBR DN PMID27551786-Compound-106 DM5OQBR TI TT26PHO DM5OQBR TN Mineralocorticoid receptor (MR) DM5OQBR MA Antagonist DM5OQBR RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DM5OQBR RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DM5OXUK DI DM5OXUK DM5OXUK DN PMID27109571-Compound-34 DM5OXUK TI TTMY6L1 DM5OXUK TN Fatty acid-binding protein (FABP) DM5OXUK MA Inhibitor DM5OXUK RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM5OXUK RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM5OZPV DI DM5OZPV DM5OZPV DN Aminopyrimidine derivative 5 DM5OZPV TI TTBYWP2 DM5OZPV TN TYK2 tyrosine kinase (TYK2) DM5OZPV MA Inhibitor DM5OZPV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM5OZPV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM5P04R DI DM5P04R DM5P04R DN Thiazole carboxamide derivative 9 DM5P04R TI TTCZOF2 DM5P04R TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM5P04R MA Inhibitor DM5P04R RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM5P04R RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM5PS6K DI DM5PS6K DM5PS6K DN Methyl-piperidine compound 1 DM5PS6K TI TTYLQ8V DM5PS6K TN Prostaglandin E synthase (PTGES) DM5PS6K MA Inhibitor DM5PS6K RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM5PS6K RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM5Q4T2 DI DM5Q4T2 DM5Q4T2 DN Biphenyl mannoside derivative 26 DM5Q4T2 TI TTTCRU2 DM5Q4T2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5Q4T2 MA Antagonist DM5Q4T2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5Q4T2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5Q93Y DI DM5Q93Y DM5Q93Y DN XHPNYYOUZWOWNT-PYUWXLGESA-N DM5Q93Y TI TT5U49F DM5Q93Y TN PRKACA messenger RNA (PRKACA mRNA) DM5Q93Y MA Inhibitor DM5Q93Y RN Purine derivatives. US8846696. DM5Q93Y RU http://www.freepatentsonline.com/US8846696.html DM5Q962 DI DM5Q962 DM5Q962 DN PMID28454500-Compound-94 DM5Q962 TI TTA6ZN2 DM5Q962 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5Q962 MA Inhibitor DM5Q962 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5Q962 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5QAKR DI DM5QAKR DM5QAKR DN Hydroxyqunoline analog 5 DM5QAKR TI TTWAQBO DM5QAKR TN Lysine-specific demethylase 4E (KDM4E) DM5QAKR MA Inhibitor DM5QAKR RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM5QAKR RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM5QH4C DI DM5QH4C DM5QH4C DN PMID27998201-Compound-1 DM5QH4C TI TT36ETB DM5QH4C TN Cathepsin L (CTSL) DM5QH4C MA Inhibitor DM5QH4C RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM5QH4C RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM5RBFC DI DM5RBFC DM5RBFC DN PMID27607364-Compound-10 DM5RBFC TI TTPTXIN DM5RBFC TN Translocator protein (TSPO) DM5RBFC MA Ligand DM5RBFC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM5RBFC RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM5RCBV DI DM5RCBV DM5RCBV DN PMID28048944-Compound-6 DM5RCBV TI TTZN7RP DM5RCBV TN Rho-associated protein kinase 1 (ROCK1) DM5RCBV MA Inhibitor DM5RCBV RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM5RCBV RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM5RCBV DI DM5RCBV DM5RCBV DN PMID28048944-Compound-6 DM5RCBV TI TTGWKQJ DM5RCBV TN Rho-associated protein kinase 2 (ROCK2) DM5RCBV MA Inhibitor DM5RCBV RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM5RCBV RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM5RCW8 DI DM5RCW8 DM5RCW8 DN Pyrrolo[1,2-c]pyrazole derivative 1 DM5RCW8 TI TTZJYKH DM5RCW8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5RCW8 MA Inhibitor DM5RCW8 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM5RCW8 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM5RX9D DI DM5RX9D DM5RX9D DN PMID27376512-Compound-Table1Example30 DM5RX9D TI TT6S2FE DM5RX9D TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM5RX9D MA Inhibitor DM5RX9D RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM5RX9D RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM5RZWG DI DM5RZWG DM5RZWG DN PMID28454500-Compound-36 DM5RZWG TI TTA6ZN2 DM5RZWG TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM5RZWG MA Activator DM5RZWG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5RZWG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5RZWG DI DM5RZWG DM5RZWG DN PMID28454500-Compound-36 DM5RZWG TI TT3Z6Y9 DM5RZWG TN Cysteines of Keap1 (KEAP1 Cysteines) DM5RZWG MA Modulator DM5RZWG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM5RZWG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM5S3L0 DI DM5S3L0 DM5S3L0 DN Pyrazole derivative 13 DM5S3L0 TI TT6OEDT DM5S3L0 TN Cannabinoid receptor 1 (CB1) DM5S3L0 MA Antagonist DM5S3L0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM5S3L0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTBJR4L DM5SD9E TN Cyclin-dependent kinase 8 (CDK8) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTL4Q97 DM5SD9E TN Cyclin-dependent kinase 5 (CDK5) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TT1LVF2 DM5SD9E TN Cyclin-dependent kinase 9 (CDK9) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTH6V3D DM5SD9E TN Cyclin-dependent kinase 1 (CDK1) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SD9E DI DM5SD9E DM5SD9E DN Tricyclic benzimidazole derivative 1 DM5SD9E TI TTQYF7G DM5SD9E TN Cyclin-dependent kinase 7 (CDK7) DM5SD9E MA Inhibitor DM5SD9E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM5SD9E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM5SX8T DI DM5SX8T DM5SX8T DN Uracil derivative 1 DM5SX8T TI TTPLTSQ DM5SX8T TN Neutrophil elastase (NE) DM5SX8T MA Inhibitor DM5SX8T RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM5SX8T RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM5T29W DI DM5T29W DM5T29W DN Biaryl mannoside derivative 12 DM5T29W TI TTTCRU2 DM5T29W TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM5T29W MA Antagonist DM5T29W RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM5T29W RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM5TIFH DI DM5TIFH DM5TIFH DN N-substituted pyrazole derivative 3 DM5TIFH TI TTXJ47W DM5TIFH TN Metabotropic glutamate receptor 2 (mGluR2) DM5TIFH MA Antagonist DM5TIFH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM5TIFH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM5TILQ DI DM5TILQ DM5TILQ DN Triazole gold complexe 3 DM5TILQ TI TTR7UJ3 DM5TILQ TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5TILQ MA Inhibitor DM5TILQ RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5TILQ RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5U36G DI DM5U36G DM5U36G DN Sterol derivative 1 DM5U36G TI TTPADOQ DM5U36G TN HMG-CoA reductase (HMGCR) DM5U36G MA Inhibitor DM5U36G RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM5U36G RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM5U8WT DI DM5U8WT DM5U8WT DN PMID25991433-Compound-L DM5U8WT TI TTVOE6D DM5U8WT TN Mitogen-activated protein kinase (MAPK) DM5U8WT MA Inhibitor DM5U8WT RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM5U8WT RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM5UBMJ DI DM5UBMJ DM5UBMJ DN PMID30273516-Compound-41 DM5UBMJ TI TTCW0KX DM5UBMJ TN Glutaminase (GLS) DM5UBMJ MA Inhibitor DM5UBMJ RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM5UBMJ RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM5UI73 DI DM5UI73 DM5UI73 DN Tihotungstate derivative 1 DM5UI73 TI TTSXVID DM5UI73 TN Nuclear factor NF-kappa-B (NFKB) DM5UI73 MA Inhibitor DM5UI73 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM5UI73 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM5UM8I DI DM5UM8I DM5UM8I DN EEA DM5UM8I TI TTXLEG7 DM5UM8I TN Matrix metalloproteinase-10 (MMP-10) DM5UM8I MA Inhibitor DM5UM8I RN Pseudodipeptides as MMP inhibitors. US8691753. DM5UM8I RU http://www.freepatentsonline.com/US8691753.html DM5UPGZ DI DM5UPGZ DM5UPGZ DN Dihydroisoquinoline carboxamide analog 1 DM5UPGZ TI TT473XN DM5UPGZ TN P2X purinoceptor 7 (P2RX7) DM5UPGZ MA Antagonist DM5UPGZ RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM5UPGZ RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM5UQK6 DI DM5UQK6 DM5UQK6 DN Thiazole derivative 4 DM5UQK6 TI TTTDVOJ DM5UQK6 TN Tropomyosin-related kinase A (TrkA) DM5UQK6 MA Inhibitor DM5UQK6 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM5UQK6 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM5UX7B DI DM5UX7B DM5UX7B DN Mycophenolic acid/nucleotide derivative 3 DM5UX7B TI TTL7C8Q DM5UX7B TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5UX7B MA Inhibitor DM5UX7B RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM5UX7B RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM5V2D9 DI DM5V2D9 DM5V2D9 DN Carbamide derivative 4 DM5V2D9 TI TTL7C8Q DM5V2D9 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM5V2D9 MA Inhibitor DM5V2D9 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM5V2D9 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM5VCQP DI DM5VCQP DM5VCQP DN Quinoline and quinazoline derivative 4 DM5VCQP TI TTOHSBA DM5VCQP TN Vascular endothelial growth factor A (VEGFA) DM5VCQP MA Inhibitor DM5VCQP RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM5VCQP RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM5VRXW DI DM5VRXW DM5VRXW DN Aminopyrimidine derivative 9 DM5VRXW TI TTH5TC2 DM5VRXW TN NF-kappa-B-activating kinase (TBK1) DM5VRXW MA Inhibitor DM5VRXW RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM5VRXW RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM5W0A2 DI DM5W0A2 DM5W0A2 DN US8481586, 5 DM5W0A2 TI TTCGOIN DM5W0A2 TN PIM-3 protein kinase (PIM3) DM5W0A2 MA Inhibitor DM5W0A2 RN Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586. DM5W0A2 RU http://www.freepatentsonline.com/US8481586.html DM5WA29 DI DM5WA29 DM5WA29 DN Pyrrolidine derivative 2 DM5WA29 TI TTHS256 DM5WA29 TN Metabotropic glutamate receptor 5 (mGluR5) DM5WA29 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM5WA29 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM5WAGC DI DM5WAGC DM5WAGC DN Binuclear gold(I) compound 2 DM5WAGC TI TTR7UJ3 DM5WAGC TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5WAGC MA Inhibitor DM5WAGC RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5WAGC RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5WIX3 DI DM5WIX3 DM5WIX3 DN PMID25980951-Compound-29 DM5WIX3 TI TTR7B60 DM5WIX3 TN X-linked inhibitor of apoptosis protein (XIAP) DM5WIX3 MA Antagonist DM5WIX3 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM5WIX3 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM5WMO9 DI DM5WMO9 DM5WMO9 DN Carboxamide derivative 10 DM5WMO9 TI TTG5QB7 DM5WMO9 TN Calpain-2 (CAPN2) DM5WMO9 MA Inhibitor DM5WMO9 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM5WMO9 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM5WN0U DI DM5WN0U DM5WN0U DN Binuclear gold(I) compound 1 DM5WN0U TI TTR7UJ3 DM5WN0U TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5WN0U MA Inhibitor DM5WN0U RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM5WN0U RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM5WQP3 DI DM5WQP3 DM5WQP3 DN P-coumaric acid derivative 4 DM5WQP3 TI TTULVH8 DM5WQP3 TN Tyrosinase (TYR) DM5WQP3 MA Inhibitor DM5WQP3 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM5WQP3 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM5X160 DI DM5X160 DM5X160 DN Imidazopyridazine derivative 7 DM5X160 TI TTQR74A DM5X160 TN Proteinase activated receptor 2 (PAR2) DM5X160 MA Antagonist DM5X160 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM5X160 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM5X92S DI DM5X92S DM5X92S DN Amidopyrazole derivative 1 DM5X92S TI TTKFVXR DM5X92S TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM5X92S MA Inhibitor DM5X92S RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM5X92S RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM5Y13R DI DM5Y13R DM5Y13R DN Dihydropyrimidinone derivative 2 DM5Y13R TI TTPLTSQ DM5Y13R TN Neutrophil elastase (NE) DM5Y13R MA Inhibitor DM5Y13R RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM5Y13R RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM5Y1DC DI DM5Y1DC DM5Y1DC DN 1,2-diamino cyclopentane-based derivative 21 DM5Y1DC TI TT9N02I DM5Y1DC TN Orexin receptor type 2 (HCRTR2) DM5Y1DC MA Antagonist DM5Y1DC RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5Y1DC RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5Y1DC DI DM5Y1DC DM5Y1DC DN 1,2-diamino cyclopentane-based derivative 21 DM5Y1DC TI TT60Q8D DM5Y1DC TN Orexin receptor type 1 (HCRTR1) DM5Y1DC MA Antagonist DM5Y1DC RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM5Y1DC RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM5YD1K DI DM5YD1K DM5YD1K DN PMID25991433-Compound-A5 DM5YD1K TI TTHS0U8 DM5YD1K TN Stress-activated protein kinase JNK2 (JNK2) DM5YD1K MA Inhibitor DM5YD1K RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM5YD1K RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM5YD1K DI DM5YD1K DM5YD1K DN PMID25991433-Compound-A5 DM5YD1K TI TT0K6EO DM5YD1K TN Stress-activated protein kinase JNK1 (JNK1) DM5YD1K MA Inhibitor DM5YD1K RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM5YD1K RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM5YD4W DI DM5YD4W DM5YD4W DN Heteroaromatic ring derivative 2 DM5YD4W TI TTSCIM2 DM5YD4W TN Extracellular lysophospholipase D (E-NPP2) DM5YD4W MA Inhibitor DM5YD4W RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM5YD4W RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM5YMQH DI DM5YMQH DM5YMQH DN PMID25522065-Compound-39 DM5YMQH TI TTX4RTB DM5YMQH TN Melanin-concentrating hormone receptor 1 (MCHR1) DM5YMQH MA Antagonist DM5YMQH RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM5YMQH RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM5YNTM DI DM5YNTM DM5YNTM DN Benzamide derivative 19 DM5YNTM TI TTF8P9I DM5YNTM TN Diacylglycerol acyltransferase 1 (DGAT1) DM5YNTM MA Inhibitor DM5YNTM RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM5YNTM RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM5YSTU DI DM5YSTU DM5YSTU DN Tetra-hydro-naphthyridine derivative 1 DM5YSTU TI TTDP1UC DM5YSTU TN Fatty acid amide hydrolase (FAAH) DM5YSTU MA Inhibitor DM5YSTU RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM5YSTU RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM5ZELW DI DM5ZELW DM5ZELW DN PMID25666693-Compound-81 DM5ZELW TI TTMI6F5 DM5ZELW TN Transient receptor potential cation channel V1 (TRPV1) DM5ZELW MA Antagonist DM5ZELW RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM5ZELW RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM5ZGK3 DI DM5ZGK3 DM5ZGK3 DN US8829193, 3 DM5ZGK3 TI TTCGOIN DM5ZGK3 TN PIM-3 protein kinase (PIM3) DM5ZGK3 MA Inhibitor DM5ZGK3 RN PIM kinase inhibitors and methods of their use. US8829193. DM5ZGK3 RU http://www.freepatentsonline.com/US8829193.html DM5ZGNK DI DM5ZGNK DM5ZGNK DN Benzodiazepine derivative 2 DM5ZGNK TI TTJGW1Z DM5ZGNK TN Phosphodiesterase 2A (PDE2A) DM5ZGNK MA Inhibitor DM5ZGNK RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM5ZGNK RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM5ZKR2 DI DM5ZKR2 DM5ZKR2 DN Benzoic acid derivative 1 DM5ZKR2 TI TTA592U DM5ZKR2 TN Urate anion exchanger 1 (URAT1) DM5ZKR2 MA Inhibitor DM5ZKR2 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM5ZKR2 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM5ZQKS DI DM5ZQKS DM5ZQKS DN Triazolo-pyridine derivative 4 DM5ZQKS TI TTJW4LU DM5ZQKS TN Phosphodiesterase 10A (PDE10) DM5ZQKS MA Inhibitor DM5ZQKS RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM5ZQKS RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM5ZQKS DI DM5ZQKS DM5ZQKS DN Triazolo-pyridine derivative 4 DM5ZQKS TI TTJGW1Z DM5ZQKS TN Phosphodiesterase 2A (PDE2A) DM5ZQKS MA Inhibitor DM5ZQKS RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM5ZQKS RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM614F8 DI DM614F8 DM614F8 DN Isoxazole-based bicyclic compound 16 DM614F8 TI TTE4BSY DM614F8 TN Bromodomain and extraterminal domain protein (BET) DM614F8 MA Inhibitor DM614F8 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM614F8 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM61NOP DI DM61NOP DM61NOP DN PMID26882240-Compound-6 DM61NOP TI TTUX68I DM61NOP TN Hypoxia-inducible factor 1 (HIF-1) DM61NOP MA Inhibitor DM61NOP RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM61NOP RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM61SR0 DI DM61SR0 DM61SR0 DN PMID27539678-Compound-10 DM61SR0 TI TTOHFIY DM61SR0 TN Sphingosine kinase 1 (SPHK1) DM61SR0 MA Inhibitor DM61SR0 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DM61SR0 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DM628MP DI DM628MP DM628MP DN PMID28394193-Compound-32 DM628MP TI TT9MZCQ DM628MP TN Enhancer of zeste homolog 2 (EZH2) DM628MP MA Inhibitor DM628MP RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM628MP RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM6293C DI DM6293C DM6293C DN AC1MOZOL DM6293C TI TT3ZS42 DM6293C TN Phosphodiesterase 1B (PDE1B) DM6293C MA Inhibitor DM6293C RN Inhibitors of phosphodiesterase 11 (PDE11). US9173884. DM6293C RU http://www.freepatentsonline.com/US9173884.html DM62A1H DI DM62A1H DM62A1H DN PMID26004420-Compound-WO2010129379B DM62A1H TI TTJ13ST DM62A1H TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM62A1H MA Inhibitor DM62A1H RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM62A1H RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM62K40 DI DM62K40 DM62K40 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 DM62K40 TI TTJGW1Z DM62K40 TN Phosphodiesterase 2A (PDE2A) DM62K40 MA Inhibitor DM62K40 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM62K40 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM62K40 DI DM62K40 DM62K40 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 3 DM62K40 TI TTJW4LU DM62K40 TN Phosphodiesterase 10A (PDE10) DM62K40 MA Inhibitor DM62K40 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM62K40 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM62XNE DI DM62XNE DM62XNE DN PMID25991433-Compound-E3 DM62XNE TI TT0K6EO DM62XNE TN Stress-activated protein kinase JNK1 (JNK1) DM62XNE MA Inhibitor DM62XNE RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM62XNE RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM63128 DI DM63128 DM63128 DN Phenylsulfonyl derivative 2 DM63128 TI TT9JNIC DM63128 TN Histamine H3 receptor (H3R) DM63128 MA Inhibitor DM63128 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM63128 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM637IC DI DM637IC DM637IC DN PMID25980951-Compound-14 DM637IC TI TTR7B60 DM637IC TN X-linked inhibitor of apoptosis protein (XIAP) DM637IC MA Antagonist DM637IC RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM637IC RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM63NX5 DI DM63NX5 DM63NX5 DN 1,3-dihydroxy phenyl derivative 2 DM63NX5 TI TT23XQV DM63NX5 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM63NX5 MA Inhibitor DM63NX5 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM63NX5 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM63UM8 DI DM63UM8 DM63UM8 DN PMID25666693-Compound-19 DM63UM8 TI TTMI6F5 DM63UM8 TN Transient receptor potential cation channel V1 (TRPV1) DM63UM8 MA Antagonist DM63UM8 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM63UM8 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM63XHT DI DM63XHT DM63XHT DN Aryl piperazine derivative 16 DM63XHT TI TTWT5K7 DM63XHT TN 5-HT 1 receptor (5HT1R) DM63XHT MA Agonist DM63XHT RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM63XHT RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM63XHT DI DM63XHT DM63XHT DN Aryl piperazine derivative 16 DM63XHT TI TTSQIFT DM63XHT TN 5-HT 1A receptor (HTR1A) DM63XHT MA Agonist DM63XHT RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM63XHT RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM64QNL DI DM64QNL DM64QNL DN PMID28074661-Compound-WO2009018344C79 DM64QNL TI TTL7C8Q DM64QNL TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM64QNL MA Inhibitor DM64QNL RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM64QNL RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM64R2K DI DM64R2K DM64R2K DN Resorcinol compound 18 DM64R2K TI TTULVH8 DM64R2K TN Tyrosinase (TYR) DM64R2K MA Inhibitor DM64R2K RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM64R2K RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM654Z0 DI DM654Z0 DM654Z0 DN Imidazo[1,2-b]pyridazine acetamide derivative 1 DM654Z0 TI TTPTXIN DM654Z0 TN Translocator protein (TSPO) DM654Z0 MA Ligand DM654Z0 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM654Z0 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM658HJ DI DM658HJ DM658HJ DN PMID28394193-Compound-36 DM658HJ TI TT9MZCQ DM658HJ TN Enhancer of zeste homolog 2 (EZH2) DM658HJ MA Inhibitor DM658HJ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM658HJ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM65NBS DI DM65NBS DM65NBS DN Sulfonylated piperazine derivative 5 DM65NBS TI TT6OEDT DM65NBS TN Cannabinoid receptor 1 (CB1) DM65NBS MA Antagonist DM65NBS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM65NBS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM673GR DI DM673GR DM673GR DN N-oxalyl-D-tyrosine derivative 5 DM673GR TI TTWAQBO DM673GR TN Lysine-specific demethylase 4E (KDM4E) DM673GR MA Inhibitor DM673GR RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM673GR RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM675SX DI DM675SX DM675SX DN PMID27841045-Compound-155 DM675SX TI TT7RJY8 DM675SX TN Xanthine dehydrogenase/oxidase (XDH) DM675SX MA Inhibitor DM675SX RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM675SX RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM67DEG DI DM67DEG DM67DEG DN PMID25666693-Compound-49 DM67DEG TI TTMI6F5 DM67DEG TN Transient receptor potential cation channel V1 (TRPV1) DM67DEG MA Antagonist DM67DEG RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM67DEG RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM67NBI DI DM67NBI DM67NBI DN PMID27977313-Compound-28 DM67NBI TI TTR7UJ3 DM67NBI TN Cytoplasmic thioredoxin reductase (TXNRD1) DM67NBI MA Inhibitor DM67NBI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM67NBI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM67RMX DI DM67RMX DM67RMX DN PMID27998201-Compound-19 DM67RMX TI TT36ETB DM67RMX TN Cathepsin L (CTSL) DM67RMX MA Inhibitor DM67RMX RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM67RMX RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM67VNW DI DM67VNW DM67VNW DN PMID27376512-Compound-miR-155-5p DM67VNW TI TT6S2FE DM67VNW TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM67VNW MA Inhibitor DM67VNW RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM67VNW RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM67WM4 DI DM67WM4 DM67WM4 DN PMID25726713-Compound-15 DM67WM4 TI TT8J1S3 DM67WM4 TN Smoothened homolog (SMO) DM67WM4 MA Inhibitor DM67WM4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM67WM4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM67XSL DI DM67XSL DM67XSL DN PMID28870136-Compound-38 DM67XSL TI TTK0O6Y DM67XSL TN Ecto-5'-nucleotidase (CD73) DM67XSL MA Inhibitor DM67XSL RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM67XSL RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM6803W DI DM6803W DM6803W DN Biphenyl carboxamidopropanoic acid derivative 1 DM6803W TI TT9O6WS DM6803W TN Glucagon receptor (GCGR) DM6803W MA Antagonist DM6803W RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM6803W RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM683R7 DI DM683R7 DM683R7 DN 1,2,4-oxadiazole derivative 5 DM683R7 TI TT23XQV DM683R7 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM683R7 MA Inhibitor DM683R7 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM683R7 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM684IK DI DM684IK DM684IK DN PMID25656651-Compound-37c DM684IK TI TTIV39N DM684IK TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DM684IK MA Inhibitor DM684IK RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM684IK RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM684IK DI DM684IK DM684IK DN PMID25656651-Compound-37c DM684IK TI TTS7G69 DM684IK TN Fusion protein Bcr-Abl (Bcr-Abl) DM684IK MA Inhibitor DM684IK RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM684IK RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM68B1R DI DM68B1R DM68B1R DN PMID28117607-Compound-6 DM68B1R TI TTK0FEA DM68B1R TN Leucine-rich repeat kinase 2 (LRRK2) DM68B1R MA Inhibitor DM68B1R RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM68B1R RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM68KPS DI DM68KPS DM68KPS DN PMID27967267-Compound-42 DM68KPS TI TT1RS9F DM68KPS TN Acetylcholinesterase (AChE) DM68KPS MA Inhibitor DM68KPS RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM68KPS RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM68M0G DI DM68M0G DM68M0G DN Peptide analog 6 DM68M0G TI TT23XQV DM68M0G TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM68M0G MA Inhibitor DM68M0G RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM68M0G RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM69A05 DI DM69A05 DM69A05 DN PMID29324067-Compound-40 DM69A05 TI TTGP7BY DM69A05 TN Monoamine oxidase type B (MAO-B) DM69A05 MA Inhibitor DM69A05 RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM69A05 RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM69HL5 DI DM69HL5 DM69HL5 DN Bicyclic heteroaryl amide derivative 2 DM69HL5 TI TT473XN DM69HL5 TN P2X purinoceptor 7 (P2RX7) DM69HL5 MA Antagonist DM69HL5 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM69HL5 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM69Y7R DI DM69Y7R DM69Y7R DN PMID29338548-Compound-39 DM69Y7R TI TTHJTF7 DM69Y7R TN Glycine transporter GlyT-1 (SLC6A9) DM69Y7R MA Inhibitor DM69Y7R RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM69Y7R RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM6A8TS DI DM6A8TS DM6A8TS DN PMID25726713-Compound-64 DM6A8TS TI TT8J1S3 DM6A8TS TN Smoothened homolog (SMO) DM6A8TS MA Inhibitor DM6A8TS RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM6A8TS RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM6A8XJ DI DM6A8XJ DM6A8XJ DN US9586945, 5 DM6A8XJ TI TTYJRN5 DM6A8XJ TN N-acetylglucosaminyltransferase I (NAGAT1) DM6A8XJ MA Inhibitor DM6A8XJ RN Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945. DM6A8XJ RU http://www.freepatentsonline.com/US9586945.html DM6A9UR DI DM6A9UR DM6A9UR DN Flavonoid derivative 7 DM6A9UR TI TTL4Q97 DM6A9UR TN Cyclin-dependent kinase 5 (CDK5) DM6A9UR MA Inhibitor DM6A9UR RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM6A9UR RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM6BJEW DI DM6BJEW DM6BJEW DN Urea and carbamate bioisostere derivative 13 DM6BJEW TI TTL7C8Q DM6BJEW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM6BJEW MA Inhibitor DM6BJEW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM6BJEW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM6BKQ8 DI DM6BKQ8 DM6BKQ8 DN PMID29338548-Compound-38 DM6BKQ8 TI TTHJTF7 DM6BKQ8 TN Glycine transporter GlyT-1 (SLC6A9) DM6BKQ8 MA Inhibitor DM6BKQ8 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM6BKQ8 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM6BQFA DI DM6BQFA DM6BQFA DN PMID28454500-Compound-8 DM6BQFA TI TTA6ZN2 DM6BQFA TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM6BQFA MA Activator DM6BQFA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6BQFA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6BQFA DI DM6BQFA DM6BQFA DN PMID28454500-Compound-8 DM6BQFA TI TT3Z6Y9 DM6BQFA TN Cysteines of Keap1 (KEAP1 Cysteines) DM6BQFA MA Modulator DM6BQFA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6BQFA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6BTMX DI DM6BTMX DM6BTMX DN Pyrrolo[2,3-d]pyrimidine derivative 33 DM6BTMX TI TTGM6VW DM6BTMX TN Tyrosine-protein kinase BTK (ATK) DM6BTMX MA Inhibitor DM6BTMX RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM6BTMX RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM6C45G DI DM6C45G DM6C45G DN PMID26609882-Compound-83 DM6C45G TI TTWJBZ5 DM6C45G TN 5-HT 2C receptor (HTR2C) DM6C45G MA Agonist DM6C45G RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM6C45G RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM6C5DR DI DM6C5DR DM6C5DR DN Piperidine derivative 4 DM6C5DR TI TT5TPI6 DM6C5DR TN Opioid receptor sigma 1 (OPRS1) DM6C5DR MA Ligand DM6C5DR RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM6C5DR RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM6CK7J DI DM6CK7J DM6CK7J DN Aryl cyclopropylamine derivative 5 DM6CK7J TI TTNR0UQ DM6CK7J TN Lysine-specific histone demethylase 1 (LSD) DM6CK7J MA Inhibitor DM6CK7J RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6CK7J RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6D1XR DI DM6D1XR DM6D1XR DN Pyrido[3,2-d]pyrimidine derivative 3 DM6D1XR TI TTTDVOJ DM6D1XR TN Tropomyosin-related kinase A (TrkA) DM6D1XR MA Inhibitor DM6D1XR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6D1XR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6DFAK DI DM6DFAK DM6DFAK DN PMID25666693-Compound-63 DM6DFAK TI TTMI6F5 DM6DFAK TN Transient receptor potential cation channel V1 (TRPV1) DM6DFAK MA Antagonist DM6DFAK RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6DFAK RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6DFTX DI DM6DFTX DM6DFTX DN BDBM50434164 DM6DFTX TI TTOYT5L DM6DFTX TN Dipeptidyl-peptidase 7 (DPP7) DM6DFTX MA Inhibitor DM6DFTX RN FAP inhibitors. US9346814. DM6DFTX RU http://www.freepatentsonline.com/US9346814.html DM6DJZ7 DI DM6DJZ7 DM6DJZ7 DN PMID28092474-Compound-33o DM6DJZ7 TI TT5ZKDI DM6DJZ7 TN Histone deacetylase 6 (HDAC6) DM6DJZ7 MA Inhibitor DM6DJZ7 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6DJZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6DJZ7 DI DM6DJZ7 DM6DJZ7 DN PMID28092474-Compound-33o DM6DJZ7 TI TT6R7JZ DM6DJZ7 TN Histone deacetylase 1 (HDAC1) DM6DJZ7 MA Inhibitor DM6DJZ7 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6DJZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6E1N4 DI DM6E1N4 DM6E1N4 DN Quinoline and quinazoline derivative 10 DM6E1N4 TI TTOHSBA DM6E1N4 TN Vascular endothelial growth factor A (VEGFA) DM6E1N4 MA Inhibitor DM6E1N4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM6E1N4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM6E50A DI DM6E50A DM6E50A DN PMID27336223-Compound-5 DM6E50A TI TTW38KT DM6E50A TN Retinoic acid receptor alpha (RARA) DM6E50A MA Agonist DM6E50A RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM6E50A RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM6E9L4 DI DM6E9L4 DM6E9L4 DN Cyclopropylamine derivative 3 DM6E9L4 TI TTNR0UQ DM6E9L4 TN Lysine-specific histone demethylase 1 (LSD) DM6E9L4 MA Inhibitor DM6E9L4 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6E9L4 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6EFIN DI DM6EFIN DM6EFIN DN PMID26815044-Compound-125 DM6EFIN TI TTULVH8 DM6EFIN TN Tyrosinase (TYR) DM6EFIN MA Inhibitor DM6EFIN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6EFIN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6EJ93 DI DM6EJ93 DM6EJ93 DN PMID29671355-Compound-39 DM6EJ93 TI TT6R7JZ DM6EJ93 TN Histone deacetylase 1 (HDAC1) DM6EJ93 MA Inhibitor DM6EJ93 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM6EJ93 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM6EJ93 DI DM6EJ93 DM6EJ93 DN PMID29671355-Compound-39 DM6EJ93 TI TT5ZKDI DM6EJ93 TN Histone deacetylase 6 (HDAC6) DM6EJ93 MA Inhibitor DM6EJ93 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM6EJ93 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM6EKIV DI DM6EKIV DM6EKIV DN PMID30107136-Compound-Example16 DM6EKIV TI TTNBFWK DM6EKIV TN Programmed cell death protein 1 (PD-1) DM6EKIV MA Inhibitor DM6EKIV RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6EKIV RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6EMYB DI DM6EMYB DM6EMYB DN US8937193-compound-6b DM6EMYB TI TTGT9C7 DM6EMYB TN Bcl-2-related protein A1 (BCL2A1) DM6EMYB MA Inhibitor DM6EMYB RN Apogossypolone derivatives as anticancer agents. US8937193. DM6EMYB RU http://www.freepatentsonline.com/US8937193.html DM6EN54 DI DM6EN54 DM6EN54 DN PMID25470667-Compound-AZD3988 DM6EN54 TI TTF8P9I DM6EN54 TN Diacylglycerol acyltransferase 1 (DGAT1) DM6EN54 MA Inhibitor DM6EN54 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM6EN54 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM6EQVT DI DM6EQVT DM6EQVT DN US9682983, 1 DM6EQVT TI TTPKHTZ DM6EQVT TN Activin receptor type IB (ACVR1B) DM6EQVT MA Inhibitor DM6EQVT RN BMP inhibitors and methods of use thereof. US9682983. DM6EQVT RU http://www.freepatentsonline.com/US9682983.html DM6EY5Z DI DM6EY5Z DM6EY5Z DN Heterocycle-containing compound 5 DM6EY5Z TI TT9O6WS DM6EY5Z TN Glucagon receptor (GCGR) DM6EY5Z MA Antagonist DM6EY5Z RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM6EY5Z RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM6F7M2 DI DM6F7M2 DM6F7M2 DN US9623028, Compound 101 DM6F7M2 TI TTV298Y DM6F7M2 TN Calmodulin-dependent kinase II (CAMKK2) DM6F7M2 MA Inhibitor DM6F7M2 RN Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028. DM6F7M2 RU http://www.freepatentsonline.com/US9623028.html DM6FCS9 DI DM6FCS9 DM6FCS9 DN PMID25991433-Compound-P5 DM6FCS9 TI TT056SO DM6FCS9 TN Stress-activated protein kinase JNK3 (JNK3) DM6FCS9 MA Inhibitor DM6FCS9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM6FCS9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM6FCS9 DI DM6FCS9 DM6FCS9 DN PMID25991433-Compound-P5 DM6FCS9 TI TTHS0U8 DM6FCS9 TN Stress-activated protein kinase JNK2 (JNK2) DM6FCS9 MA Inhibitor DM6FCS9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM6FCS9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM6FCS9 DI DM6FCS9 DM6FCS9 DN PMID25991433-Compound-P5 DM6FCS9 TI TT0K6EO DM6FCS9 TN Stress-activated protein kinase JNK1 (JNK1) DM6FCS9 MA Inhibitor DM6FCS9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM6FCS9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM6FQ8L DI DM6FQ8L DM6FQ8L DN Aryl carboxamide derivative 3 DM6FQ8L TI TTZOVE0 DM6FQ8L TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM6FQ8L MA Inhibitor DM6FQ8L RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DM6FQ8L RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DM6G2WJ DI DM6G2WJ DM6G2WJ DN PMID26560530-Compound-5 DM6G2WJ TI TT2F4OL DM6G2WJ TN Tissue transglutaminase (TG2) DM6G2WJ MA Inhibitor DM6G2WJ RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM6G2WJ RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM6GFYR DI DM6GFYR DM6GFYR DN PMID26651364-Compound-50 DM6GFYR TI TTTCRU2 DM6GFYR TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6GFYR MA Antagonist DM6GFYR RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6GFYR RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6GSCV DI DM6GSCV DM6GSCV DN Quinoline derivative 10 DM6GSCV TI TT473XN DM6GSCV TN P2X purinoceptor 7 (P2RX7) DM6GSCV MA Antagonist DM6GSCV RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM6GSCV RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM6GTDM DI DM6GTDM DM6GTDM DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 DM6GTDM TI TT6OEDT DM6GTDM TN Cannabinoid receptor 1 (CB1) DM6GTDM MA Agonist DM6GTDM RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM6GTDM RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM6GTDM DI DM6GTDM DM6GTDM DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 2 DM6GTDM TI TTMSFAW DM6GTDM TN Cannabinoid receptor 2 (CB2) DM6GTDM MA Agonist DM6GTDM RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM6GTDM RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM6GZW4 DI DM6GZW4 DM6GZW4 DN Carboxamide derivative 6 DM6GZW4 TI TTG5QB7 DM6GZW4 TN Calpain-2 (CAPN2) DM6GZW4 MA Inhibitor DM6GZW4 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM6GZW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM6HI34 DI DM6HI34 DM6HI34 DN Carboxamide derivative 8 DM6HI34 TI TTG5QB7 DM6HI34 TN Calpain-2 (CAPN2) DM6HI34 MA Inhibitor DM6HI34 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM6HI34 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM6HOES DI DM6HOES DM6HOES DN PMID28870136-Compound-54 DM6HOES TI TTK0O6Y DM6HOES TN Ecto-5'-nucleotidase (CD73) DM6HOES MA Inhibitor DM6HOES RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DM6HOES RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DM6HTU0 DI DM6HTU0 DM6HTU0 DN PMID26651364-Compound-9b DM6HTU0 TI TTTCRU2 DM6HTU0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6HTU0 MA Antagonist DM6HTU0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6HTU0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6HWBK DI DM6HWBK DM6HWBK DN PMID27109571-Compound-12 DM6HWBK TI TTNT2S6 DM6HWBK TN Fatty acid-binding protein 5 (FABP5) DM6HWBK MA Inhibitor DM6HWBK RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM6HWBK RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM6HWBK DI DM6HWBK DM6HWBK DN PMID27109571-Compound-12 DM6HWBK TI TTHWMFZ DM6HWBK TN Fatty acid-binding protein 4 (FABP4) DM6HWBK MA Inhibitor DM6HWBK RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM6HWBK RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM6HWN3 DI DM6HWN3 DM6HWN3 DN Heterocyclic derivative 6 DM6HWN3 TI TTCZOF2 DM6HWN3 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM6HWN3 MA Inhibitor DM6HWN3 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM6HWN3 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM6I49E DI DM6I49E DM6I49E DN PMID25666693-Compound-42 DM6I49E TI TTMI6F5 DM6I49E TN Transient receptor potential cation channel V1 (TRPV1) DM6I49E MA Antagonist DM6I49E RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6I49E RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6IJRG DI DM6IJRG DM6IJRG DN Pyrrolo[2,3-d]pyrimidine derivative 29 DM6IJRG TI TTGM6VW DM6IJRG TN Tyrosine-protein kinase BTK (ATK) DM6IJRG MA Inhibitor DM6IJRG RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM6IJRG RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM6IQWE DI DM6IQWE DM6IQWE DN Peptide analog 57 DM6IQWE TI TTQAJF1 DM6IQWE TN Cathepsin G (CTSG) DM6IQWE MA Inhibitor DM6IQWE RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM6IQWE RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM6IQWE DI DM6IQWE DM6IQWE DN Peptide analog 57 DM6IQWE TI TTPLTSQ DM6IQWE TN Neutrophil elastase (NE) DM6IQWE MA Inhibitor DM6IQWE RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM6IQWE RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM6IRJL DI DM6IRJL DM6IRJL DN Heterocycle-containing compound 4 DM6IRJL TI TT9O6WS DM6IRJL TN Glucagon receptor (GCGR) DM6IRJL MA Antagonist DM6IRJL RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM6IRJL RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM6IYAT DI DM6IYAT DM6IYAT DN PMID28270010-Compound-Figure21-b DM6IYAT TI TTPMQSO DM6IYAT TN ALK tyrosine kinase receptor (ALK) DM6IYAT MA Inhibitor DM6IYAT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM6IYAT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM6IYAT DI DM6IYAT DM6IYAT DN PMID28270010-Compound-Figure21-b DM6IYAT TI TTSZ6Y3 DM6IYAT TN Proto-oncogene c-Ros (ROS1) DM6IYAT MA Inhibitor DM6IYAT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM6IYAT RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM6J0Z8 DI DM6J0Z8 DM6J0Z8 DN PMID29338548-Compound-15 DM6J0Z8 TI TTHJTF7 DM6J0Z8 TN Glycine transporter GlyT-1 (SLC6A9) DM6J0Z8 MA Inhibitor DM6J0Z8 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM6J0Z8 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM6JR3X DI DM6JR3X DM6JR3X DN Indoline derivative 11 DM6JR3X TI TT5OU0D DM6JR3X TN PRKR-like endoplasmic reticulum kinase (PERK) DM6JR3X MA Inhibitor DM6JR3X RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM6JR3X RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM6JRCW DI DM6JRCW DM6JRCW DN PMID28092474-Compound-34 DM6JRCW TI TTBH0VX DM6JRCW TN Histone deacetylase (HDAC) DM6JRCW MA Inhibitor DM6JRCW RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6JRCW RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TT8EPLT DM6JV1W TN Proteasome beta-1 (PS beta-1) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TT68GPI DM6JV1W TN Proteasome beta-5 (PS beta-5) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TTOUSTQ DM6JV1W TN Proteasome beta-9 (PS beta-9) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JV1W DI DM6JV1W DM6JV1W DN PMID29865878-Compound-53 DM6JV1W TI TTEAD9J DM6JV1W TN Proteasome beta-8 (PS beta-8) DM6JV1W MA Inhibitor DM6JV1W RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM6JV1W RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM6JVR5 DI DM6JVR5 DM6JVR5 DN PMID26161698-Compound-18 DM6JVR5 TI TTRSMW9 DM6JVR5 TN Glycogen synthase kinase-3 beta (GSK-3B) DM6JVR5 MA Inhibitor DM6JVR5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM6JVR5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM6JVR5 DI DM6JVR5 DM6JVR5 DN PMID26161698-Compound-18 DM6JVR5 TI TTL4Q97 DM6JVR5 TN Cyclin-dependent kinase 5 (CDK5) DM6JVR5 MA Inhibitor DM6JVR5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM6JVR5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM6K29H DI DM6K29H DM6K29H DN Aryl mannoside derivative 19 DM6K29H TI TTTCRU2 DM6K29H TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6K29H MA Antagonist DM6K29H RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6K29H RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6K59I DI DM6K59I DM6K59I DN Cyclopropane 1-carboxylic acid derivative 3 DM6K59I TI TTIY56R DM6K59I TN Kynurenine 3-hydroxylase (KMO) DM6K59I MA Inhibitor DM6K59I RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM6K59I RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM6KGUB DI DM6KGUB DM6KGUB DN Bipyrazole derivative 1 DM6KGUB TI TT6DM01 DM6KGUB TN Janus kinase 1 (JAK-1) DM6KGUB MA Inhibitor DM6KGUB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM6KGUB RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM6KJLG DI DM6KJLG DM6KJLG DN Trepenoid derivative 1 DM6KJLG TI TTA6ZN2 DM6KJLG TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM6KJLG MA Activator DM6KJLG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6KJLG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6KJLG DI DM6KJLG DM6KJLG DN Trepenoid derivative 1 DM6KJLG TI TT3Z6Y9 DM6KJLG TN Cysteines of Keap1 (KEAP1 Cysteines) DM6KJLG MA Modulator DM6KJLG RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6KJLG RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6KPYL DI DM6KPYL DM6KPYL DN STK296197 DM6KPYL TI TT3RMNA DM6KPYL TN Chymotrypsin-C (CLCR) DM6KPYL MA Inhibitor DM6KPYL RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DM6KPYL RU http://www.freepatentsonline.com/US9695194.html DM6KROX DI DM6KROX DM6KROX DN Pyrazole derivative 35 DM6KROX TI TT6OEDT DM6KROX TN Cannabinoid receptor 1 (CB1) DM6KROX MA Antagonist DM6KROX RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM6KROX RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM6KXOQ DI DM6KXOQ DM6KXOQ DN PMID28270021-Compound-WO2015042088Example4 DM6KXOQ TI TTKN7QR DM6KXOQ TN BDNF/NT-3 growth factors receptor (TrkB) DM6KXOQ MA Inhibitor DM6KXOQ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6KXOQ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6KXOQ DI DM6KXOQ DM6KXOQ DN PMID28270021-Compound-WO2015042088Example4 DM6KXOQ TI TTXABCW DM6KXOQ TN NT-3 growth factor receptor (TrkC) DM6KXOQ MA Inhibitor DM6KXOQ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6KXOQ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6KXOQ DI DM6KXOQ DM6KXOQ DN PMID28270021-Compound-WO2015042088Example4 DM6KXOQ TI TTTDVOJ DM6KXOQ TN Tropomyosin-related kinase A (TrkA) DM6KXOQ MA Inhibitor DM6KXOQ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6KXOQ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6LR42 DI DM6LR42 DM6LR42 DN PMID25399762-Compound-Table 6-13 DM6LR42 TI TTGP7BY DM6LR42 TN Monoamine oxidase type B (MAO-B) DM6LR42 MA Inhibitor DM6LR42 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM6LR42 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM6LR42 DI DM6LR42 DM6LR42 DN PMID25399762-Compound-Table 6-13 DM6LR42 TI TTNR0UQ DM6LR42 TN Lysine-specific histone demethylase 1 (LSD) DM6LR42 MA Inhibitor DM6LR42 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM6LR42 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM6LXHS DI DM6LXHS DM6LXHS DN PMID26651364-Compound-117a DM6LXHS TI TTTCRU2 DM6LXHS TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6LXHS MA Antagonist DM6LXHS RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6LXHS RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6MCBU DI DM6MCBU DM6MCBU DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 4 DM6MCBU TI TTV1C0Z DM6MCBU TN Neuropeptide S receptor (NPSR) DM6MCBU MA Antagonist DM6MCBU RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DM6MCBU RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DM6N8T3 DI DM6N8T3 DM6N8T3 DN Pyridine derivative 4 DM6N8T3 TI TTOHSBA DM6N8T3 TN Vascular endothelial growth factor A (VEGFA) DM6N8T3 MA Inhibitor DM6N8T3 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM6N8T3 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM6NJV7 DI DM6NJV7 DM6NJV7 DN Heterocyclic derivative 16 DM6NJV7 TI TTCZOF2 DM6NJV7 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM6NJV7 MA Inhibitor DM6NJV7 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM6NJV7 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM6NR9Y DI DM6NR9Y DM6NR9Y DN Diarylamine and arylheteroarylamine pyrazole derivative 2 DM6NR9Y TI TTJQOD7 DM6NR9Y TN 5-HT 2A receptor (HTR2A) DM6NR9Y MA Agonist DM6NR9Y RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM6NR9Y RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM6O2Q9 DI DM6O2Q9 DM6O2Q9 DN Pyrimido[4,5-d] pyrimidines and pyrido[4,3-d] pyrimidine derivative 1 DM6O2Q9 TI TTG0U4H DM6O2Q9 TN Ribosomal protein S6 kinase beta-1 (S6K1) DM6O2Q9 MA Inhibitor DM6O2Q9 RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DM6O2Q9 RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DM6O78C DI DM6O78C DM6O78C DN PMID29649907-Compound-26 DM6O78C TI TTS4UGC DM6O78C TN Farnesoid X-activated receptor (FXR) DM6O78C MA Agonist DM6O78C RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM6O78C RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM6OCSJ DI DM6OCSJ DM6OCSJ DN PMID27774824-Compound-Figure8Example22 DM6OCSJ TI TTRMX3V DM6OCSJ TN Janus kinase 2 (JAK-2) DM6OCSJ MA Inhibitor DM6OCSJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM6OCSJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM6ODU7 DI DM6ODU7 DM6ODU7 DN PMID25666693-Compound-124 DM6ODU7 TI TTMI6F5 DM6ODU7 TN Transient receptor potential cation channel V1 (TRPV1) DM6ODU7 MA Antagonist DM6ODU7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6ODU7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6OEHK DI DM6OEHK DM6OEHK DN PMID25980951-Compound-22 DM6OEHK TI TTR7B60 DM6OEHK TN X-linked inhibitor of apoptosis protein (XIAP) DM6OEHK MA Antagonist DM6OEHK RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM6OEHK RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM6OEHK DI DM6OEHK DM6OEHK DN PMID25980951-Compound-22 DM6OEHK TI TTQ5LRD DM6OEHK TN Cellular inhibitor of apoptosis 1 (BIRC2) DM6OEHK MA Antagonist DM6OEHK RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM6OEHK RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM6OG2Y DI DM6OG2Y DM6OG2Y DN N-phenyl-pyridine-2-carboxamide derivative 2 DM6OG2Y TI TT23XQV DM6OG2Y TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM6OG2Y MA Inhibitor DM6OG2Y RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6OG2Y RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6ON31 DI DM6ON31 DM6ON31 DN Disulfide compound 2 DM6ON31 TI TTR7UJ3 DM6ON31 TN Cytoplasmic thioredoxin reductase (TXNRD1) DM6ON31 MA Inhibitor DM6ON31 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM6ON31 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM6OQKM DI DM6OQKM DM6OQKM DN PMID26651364-Compound-113 DM6OQKM TI TTTCRU2 DM6OQKM TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6OQKM MA Antagonist DM6OQKM RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6OQKM RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6ORB9 DI DM6ORB9 DM6ORB9 DN PMID25726713-Compound-14 DM6ORB9 TI TT8J1S3 DM6ORB9 TN Smoothened homolog (SMO) DM6ORB9 MA Inhibitor DM6ORB9 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM6ORB9 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM6PDEH DI DM6PDEH DM6PDEH DN PMID29757691-Compound-8d DM6PDEH TI TT1RS9F DM6PDEH TN Acetylcholinesterase (AChE) DM6PDEH MA Inhibitor DM6PDEH RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM6PDEH RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM6PDEH DI DM6PDEH DM6PDEH DN PMID29757691-Compound-8d DM6PDEH TI TTEB0GD DM6PDEH TN Cholinesterase (BCHE) DM6PDEH MA Inhibitor DM6PDEH RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM6PDEH RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM6PMZC DI DM6PMZC DM6PMZC DN Benzenamine derivative 1 DM6PMZC TI TTNR0UQ DM6PMZC TN Lysine-specific histone demethylase 1 (LSD) DM6PMZC MA Inhibitor DM6PMZC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6PMZC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6PTOX DI DM6PTOX DM6PTOX DN Benzyl phenyl ether derivative 1 DM6PTOX TI TT23XQV DM6PTOX TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM6PTOX MA Inhibitor DM6PTOX RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6PTOX RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6QBV2 DI DM6QBV2 DM6QBV2 DN Polyhydroxy benzamide derivative 4 DM6QBV2 TI TTULVH8 DM6QBV2 TN Tyrosinase (TYR) DM6QBV2 MA Inhibitor DM6QBV2 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6QBV2 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6QHGV DI DM6QHGV DM6QHGV DN PMID25666693-Compound-128 DM6QHGV TI TTMI6F5 DM6QHGV TN Transient receptor potential cation channel V1 (TRPV1) DM6QHGV MA Antagonist DM6QHGV RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6QHGV RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6QHO0 DI DM6QHO0 DM6QHO0 DN Tihoacetate derivative 1 DM6QHO0 TI TTA592U DM6QHO0 TN Urate anion exchanger 1 (URAT1) DM6QHO0 MA Inhibitor DM6QHO0 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM6QHO0 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM6QSND DI DM6QSND DM6QSND DN Tricyclic isoxazoloquinazoline derivative 1 DM6QSND TI TT5OU0D DM6QSND TN PRKR-like endoplasmic reticulum kinase (PERK) DM6QSND MA Inhibitor DM6QSND RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM6QSND RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM6R1YP DI DM6R1YP DM6R1YP DN US9682983, 33 DM6R1YP TI TTPKHTZ DM6R1YP TN Activin receptor type IB (ACVR1B) DM6R1YP MA Inhibitor DM6R1YP RN BMP inhibitors and methods of use thereof. US9682983. DM6R1YP RU http://www.freepatentsonline.com/US9682983.html DM6R34M DI DM6R34M DM6R34M DN N-{4 DM6R34M TI TTCGOIN DM6R34M TN PIM-3 protein kinase (PIM3) DM6R34M MA Inhibitor DM6R34M RN Kinase inhibitors and methods of their use. US8592455. DM6R34M RU http://www.freepatentsonline.com/US8592455.html DM6RGOY DI DM6RGOY DM6RGOY DN Dihydropyridine compound 2 DM6RGOY TI TT4DXQT DM6RGOY TN Proto-oncogene c-Ret (RET) DM6RGOY MA Inhibitor DM6RGOY RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM6RGOY RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM6RLTV DI DM6RLTV DM6RLTV DN Dipeptide analog 3 DM6RLTV TI TT2F4OL DM6RLTV TN Tissue transglutaminase (TG2) DM6RLTV MA Inhibitor DM6RLTV RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM6RLTV RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM6RLVB DI DM6RLVB DM6RLVB DN Hydrazide derivative 5 DM6RLVB TI TTK0FEA DM6RLVB TN Leucine-rich repeat kinase 2 (LRRK2) DM6RLVB MA Inhibitor DM6RLVB RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM6RLVB RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM6RQKH DI DM6RQKH DM6RQKH DN PMID25666693-Compound-89 DM6RQKH TI TTMI6F5 DM6RQKH TN Transient receptor potential cation channel V1 (TRPV1) DM6RQKH MA Antagonist DM6RQKH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6RQKH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6SL9D DI DM6SL9D DM6SL9D DN PMID25666693-Compound-16 DM6SL9D TI TTMI6F5 DM6SL9D TN Transient receptor potential cation channel V1 (TRPV1) DM6SL9D MA Antagonist DM6SL9D RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM6SL9D RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM6SPTJ DI DM6SPTJ DM6SPTJ DN Bidentate pyrazolopyrimidine acetamide analog 2 DM6SPTJ TI TTPTXIN DM6SPTJ TN Translocator protein (TSPO) DM6SPTJ MA Ligand DM6SPTJ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM6SPTJ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM6T2FM DI DM6T2FM DM6T2FM DN PMID28394193-Compound-14 DM6T2FM TI TT9MZCQ DM6T2FM TN Enhancer of zeste homolog 2 (EZH2) DM6T2FM MA Inhibitor DM6T2FM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM6T2FM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM6T2FM DI DM6T2FM DM6T2FM DN PMID28394193-Compound-14 DM6T2FM TI TTJBYRU DM6T2FM TN EZH2 Y641F mutant (EZH2 Y641F) DM6T2FM MA Inhibitor DM6T2FM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM6T2FM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM6TB4Z DI DM6TB4Z DM6TB4Z DN Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z TI TTKFVXR DM6TB4Z TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM6TB4Z MA Inhibitor DM6TB4Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM6TB4Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM6TB4Z DI DM6TB4Z DM6TB4Z DN Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z TI TTXAJWN DM6TB4Z TN IL-1 receptor-associated kinase 1 (IRAK1) DM6TB4Z MA Inhibitor DM6TB4Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM6TB4Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM6TGUR DI DM6TGUR DM6TGUR DN PMID25656651-Compound-31b DM6TGUR TI TTIV39N DM6TGUR TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DM6TGUR MA Inhibitor DM6TGUR RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM6TGUR RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM6TJU0 DI DM6TJU0 DM6TJU0 DN PMID28270021-Compound-WO2010077680 803 DM6TJU0 TI TTTDVOJ DM6TJU0 TN Tropomyosin-related kinase A (TrkA) DM6TJU0 MA Antagonist DM6TJU0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6TJU0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6TMXL DI DM6TMXL DM6TMXL DN N-containing heterocyclic derivative 1 DM6TMXL TI TTJOW1I DM6TMXL TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DM6TMXL MA Inhibitor DM6TMXL RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM6TMXL RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM6TXF4 DI DM6TXF4 DM6TXF4 DN Biphenyl carboxylic acid derivative 2 DM6TXF4 TI TTL53M6 DM6TXF4 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM6TXF4 MA Inhibitor DM6TXF4 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM6TXF4 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM6TYM0 DI DM6TYM0 DM6TYM0 DN N-(arylalkyl)-1H-indole-2-sulfonic acid amide derivative 1 DM6TYM0 TI TT6OEDT DM6TYM0 TN Cannabinoid receptor 1 (CB1) DM6TYM0 MA Antagonist DM6TYM0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM6TYM0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM6U3ZR DI DM6U3ZR DM6U3ZR DN US8481586, 40 DM6U3ZR TI TTCGOIN DM6U3ZR TN PIM-3 protein kinase (PIM3) DM6U3ZR MA Inhibitor DM6U3ZR RN Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586. DM6U3ZR RU http://www.freepatentsonline.com/US8481586.html DM6UTAQ DI DM6UTAQ DM6UTAQ DN PMID27744724-Compound-5 DM6UTAQ TI TTL53M6 DM6UTAQ TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM6UTAQ MA Inhibitor DM6UTAQ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM6UTAQ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM6UXZK DI DM6UXZK DM6UXZK DN US9522888, 575 DM6UXZK TI TTDYP7I DM6UXZK TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM6UXZK MA Inhibitor DM6UXZK RN Substituted bicyclic compounds. US9522888. DM6UXZK RU http://www.freepatentsonline.com/US9522888.html DM6V13W DI DM6V13W DM6V13W DN PMID27336223-Compound-9 DM6V13W TI TT1Q3IE DM6V13W TN Retinoic acid receptor gamma (RARG) DM6V13W MA Agonist DM6V13W RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM6V13W RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM6VAS2 DI DM6VAS2 DM6VAS2 DN PMID28270021-Compound-WO2010077680 481 DM6VAS2 TI TTTDVOJ DM6VAS2 TN Tropomyosin-related kinase A (TrkA) DM6VAS2 MA Antagonist DM6VAS2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM6VAS2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM6VER5 DI DM6VER5 DM6VER5 DN PMID26651364-Compound-124 DM6VER5 TI TTTCRU2 DM6VER5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6VER5 MA Antagonist DM6VER5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6VER5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6VP5K DI DM6VP5K DM6VP5K DN PMID30280939-Compound-WO2005070959 DM6VP5K TI TTOK0LR DM6VP5K TN Toll-like receptor (TLR) DM6VP5K MA Immune response agent DM6VP5K RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM6VP5K RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM6VPIR DI DM6VPIR DM6VPIR DN Cyclohexyl carbamate derivative 2 DM6VPIR TI TTULVH8 DM6VPIR TN Tyrosinase (TYR) DM6VPIR MA Inhibitor DM6VPIR RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6VPIR RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6W0TM DI DM6W0TM DM6W0TM DN Benzamide derivative 5 DM6W0TM TI TTA6ZN2 DM6W0TM TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM6W0TM MA Inhibitor DM6W0TM RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM6W0TM RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM6WTR2 DI DM6WTR2 DM6WTR2 DN Thiazole carboxamide derivative 22 DM6WTR2 TI TTCZOF2 DM6WTR2 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM6WTR2 MA Inhibitor DM6WTR2 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM6WTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM6X2CO DI DM6X2CO DM6X2CO DN PMID28092474-Compound-34b DM6X2CO TI TT5ZKDI DM6X2CO TN Histone deacetylase 6 (HDAC6) DM6X2CO MA Inhibitor DM6X2CO RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6X2CO RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6X2CO DI DM6X2CO DM6X2CO DN PMID28092474-Compound-34b DM6X2CO TI TT6R7JZ DM6X2CO TN Histone deacetylase 1 (HDAC1) DM6X2CO MA Inhibitor DM6X2CO RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM6X2CO RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM6XFA5 DI DM6XFA5 DM6XFA5 DN Resorcinol compound 14 DM6XFA5 TI TTULVH8 DM6XFA5 TN Tyrosinase (TYR) DM6XFA5 MA Inhibitor DM6XFA5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM6XFA5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM6XRDH DI DM6XRDH DM6XRDH DN Benzazepine derivative 5 DM6XRDH TI TTWJBZ5 DM6XRDH TN 5-HT 2C receptor (HTR2C) DM6XRDH MA Agonist DM6XRDH RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM6XRDH RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM6XWL9 DI DM6XWL9 DM6XWL9 DN PMID30107136-Compound-Example59 DM6XWL9 TI TT23XQV DM6XWL9 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM6XWL9 MA Inhibitor DM6XWL9 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM6XWL9 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM6XYFB DI DM6XYFB DM6XYFB DN PMID29053063-Compound-7e DM6XYFB TI TTZ963I DM6XYFB TN Monoglyceride lipase (MAGL) DM6XYFB MA Inhibitor DM6XYFB RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM6XYFB RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM6Y27J DI DM6Y27J DM6Y27J DN Pyrazole derivative 76 DM6Y27J TI TTXJ47W DM6Y27J TN Metabotropic glutamate receptor 2 (mGluR2) DM6Y27J MA Antagonist DM6Y27J RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM6Y27J RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM6YBTR DI DM6YBTR DM6YBTR DN Tacrine-coumarin hybrid derivative 1 DM6YBTR TI TT3WG5C DM6YBTR TN Monoamine oxidase type A (MAO-A) DM6YBTR RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM6YBTR RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM6YBTR DI DM6YBTR DM6YBTR DN Tacrine-coumarin hybrid derivative 1 DM6YBTR TI TTGP7BY DM6YBTR TN Monoamine oxidase type B (MAO-B) DM6YBTR RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DM6YBTR RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DM6YGLT DI DM6YGLT DM6YGLT DN PMID26924192-Compound-56 DM6YGLT TI TTE4BSY DM6YGLT TN Bromodomain and extraterminal domain protein (BET) DM6YGLT MA Inhibitor DM6YGLT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM6YGLT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM6YLMB DI DM6YLMB DM6YLMB DN PMID28270010-Compound-Figure16-b-2 DM6YLMB TI TTTDVOJ DM6YLMB TN Tropomyosin-related kinase A (TrkA) DM6YLMB MA Inhibitor DM6YLMB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM6YLMB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM6YQO3 DI DM6YQO3 DM6YQO3 DN BK3 DM6YQO3 TI TT42OGM DM6YQO3 TN Hematopoietic cell kinase (HCK) DM6YQO3 MA Inhibitor DM6YQO3 RN Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037. DM6YQO3 RU http://www.freepatentsonline.com/US9765037.html DM6YV3O DI DM6YV3O DM6YV3O DN N-(2-phenylcyclopropyl) amino acid derivative 2 DM6YV3O TI TT32XQJ DM6YV3O TN Monoamine oxidase (MAO) DM6YV3O MA Inhibitor DM6YV3O RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6YV3O RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6YV3O DI DM6YV3O DM6YV3O DN N-(2-phenylcyclopropyl) amino acid derivative 2 DM6YV3O TI TTNR0UQ DM6YV3O TN Lysine-specific histone demethylase 1 (LSD) DM6YV3O MA Inhibitor DM6YV3O RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM6YV3O RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM6Z01B DI DM6Z01B DM6Z01B DN US9434725, 285 DM6Z01B TI TTCGOIN DM6Z01B TN PIM-3 protein kinase (PIM3) DM6Z01B MA Inhibitor DM6Z01B RN 5-azaindazole compounds and methods of use. US9434725. DM6Z01B RU http://www.freepatentsonline.com/US9434725.html DM6ZRV4 DI DM6ZRV4 DM6ZRV4 DN PMID26651364-Compound-118 DM6ZRV4 TI TTTCRU2 DM6ZRV4 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM6ZRV4 MA Antagonist DM6ZRV4 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM6ZRV4 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM6ZYMC DI DM6ZYMC DM6ZYMC DN Oxindole derivative 2 DM6ZYMC TI TTK0FEA DM6ZYMC TN Leucine-rich repeat kinase 2 (LRRK2) DM6ZYMC MA Inhibitor DM6ZYMC RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM6ZYMC RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM70CTE DI DM70CTE DM70CTE DN PMID27376512-Compound-MTC-434 DM70CTE TI TTHVCUP DM70CTE TN DNA [cytosine-5]-methyltransferase (DNMT) DM70CTE MA Inhibitor DM70CTE RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM70CTE RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM70QPF DI DM70QPF DM70QPF DN Pyrazole derivative 74 DM70QPF TI TTJQOD7 DM70QPF TN 5-HT 2A receptor (HTR2A) DM70QPF MA Antagonist DM70QPF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM70QPF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM712Y0 DI DM712Y0 DM712Y0 DN Benzo[d]oxazole derivative 3 DM712Y0 TI TTA6ZN2 DM712Y0 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM712Y0 MA Inhibitor DM712Y0 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM712Y0 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM715E8 DI DM715E8 DM715E8 DN Biphenyl carboxamidopropanoic acid derivative 4 DM715E8 TI TT9O6WS DM715E8 TN Glucagon receptor (GCGR) DM715E8 MA Antagonist DM715E8 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM715E8 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM71LVY DI DM71LVY DM71LVY DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 3 DM71LVY TI TTXJ47W DM71LVY TN Metabotropic glutamate receptor 2 (mGluR2) DM71LVY MA Antagonist DM71LVY RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM71LVY RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM71R3T DI DM71R3T DM71R3T DN Resorcinol compound 27 DM71R3T TI TTULVH8 DM71R3T TN Tyrosinase (TYR) DM71R3T MA Inhibitor DM71R3T RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM71R3T RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM71UYI DI DM71UYI DM71UYI DN Pyridotriazolopyrimidine derivative 1 DM71UYI TI TT6OEDT DM71UYI TN Cannabinoid receptor 1 (CB1) DM71UYI MA Antagonist DM71UYI RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM71UYI RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM72MDA DI DM72MDA DM72MDA DN Tetra-hydro-oxazolopyridine derivative 1 DM72MDA TI TTGP7BY DM72MDA TN Monoamine oxidase type B (MAO-B) DM72MDA MA Modulator DM72MDA RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM72MDA RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM72MDA DI DM72MDA DM72MDA DN Tetra-hydro-oxazolopyridine derivative 1 DM72MDA TI TTHS256 DM72MDA TN Metabotropic glutamate receptor 5 (mGluR5) DM72MDA MA Modulator DM72MDA RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM72MDA RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM72T58 DI DM72T58 DM72T58 DN Pyrimidinyl pyrazolamine derivative 1 DM72T58 TI TTS7G69 DM72T58 TN Fusion protein Bcr-Abl (Bcr-Abl) DM72T58 MA Inhibitor DM72T58 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM72T58 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM72TBJ DI DM72TBJ DM72TBJ DN PMID27019002-Compound-43c DM72TBJ TI TTNR0UQ DM72TBJ TN Lysine-specific histone demethylase 1 (LSD) DM72TBJ MA Inhibitor DM72TBJ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM72TBJ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM73CA5 DI DM73CA5 DM73CA5 DN PMID28394193-Compound-37 DM73CA5 TI TT9MZCQ DM73CA5 TN Enhancer of zeste homolog 2 (EZH2) DM73CA5 MA Inhibitor DM73CA5 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM73CA5 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM73ESA DI DM73ESA DM73ESA DN Imidazo[1,2-b]pyridazine acetamide derivative 6 DM73ESA TI TTPTXIN DM73ESA TN Translocator protein (TSPO) DM73ESA MA Ligand DM73ESA RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM73ESA RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM73GNJ DI DM73GNJ DM73GNJ DN Thiazolidine derivative 2 DM73GNJ TI TTULVH8 DM73GNJ TN Tyrosinase (TYR) DM73GNJ MA Inhibitor DM73GNJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM73GNJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTJGNVC DM73S2C TN Apoptosis regulator Bcl-2 (BCL-2) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTU1E82 DM73S2C TN Apoptosis regulator Bcl-xL (BCL-xL) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTQ79W8 DM73S2C TN Apoptosis regulator Bcl-W (BCL-W) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM73S2C DI DM73S2C DM73S2C DN PMID27744724-Compound-18 DM73S2C TI TTL53M6 DM73S2C TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM73S2C MA Inhibitor DM73S2C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM73S2C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM745TN DI DM745TN DM745TN DN Aminocyclopentenone compound 4 DM745TN TI TTRA6BO DM745TN TN Bromodomain-containing protein 4 (BRD4) DM745TN MA Inhibitor DM745TN RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM745TN RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM74GUB DI DM74GUB DM74GUB DN PMID26560530-Compound-31 DM74GUB TI TT2F4OL DM74GUB TN Tissue transglutaminase (TG2) DM74GUB MA Inhibitor DM74GUB RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM74GUB RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM74NBY DI DM74NBY DM74NBY DN PMID25666693-Compound-129 DM74NBY TI TTMI6F5 DM74NBY TN Transient receptor potential cation channel V1 (TRPV1) DM74NBY MA Antagonist DM74NBY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM74NBY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM74OGS DI DM74OGS DM74OGS DN PMID25666693-Compound-159 DM74OGS TI TTMI6F5 DM74OGS TN Transient receptor potential cation channel V1 (TRPV1) DM74OGS MA Antagonist DM74OGS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM74OGS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM74T5L DI DM74T5L DM74T5L DN Oligooxopiperazine derivative 1 DM74T5L TI TTUX68I DM74T5L TN Hypoxia-inducible factor 1 (HIF-1) DM74T5L MA Inhibitor DM74T5L RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM74T5L RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM74UP5 DI DM74UP5 DM74UP5 DN Mycophenolic acid/nucleotide derivative 5 DM74UP5 TI TTL7C8Q DM74UP5 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM74UP5 MA Inhibitor DM74UP5 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM74UP5 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM74WSJ DI DM74WSJ DM74WSJ DN PMID25435285-Compound-45 DM74WSJ TI TTXJ47W DM74WSJ TN Metabotropic glutamate receptor 2 (mGluR2) DM74WSJ MA Antagonist DM74WSJ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM74WSJ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM759MJ DI DM759MJ DM759MJ DN PMID25399762-Compound-Table 7-Vanillyl alcohol DM759MJ TI TTGP7BY DM759MJ TN Monoamine oxidase type B (MAO-B) DM759MJ MA Inhibitor DM759MJ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM759MJ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM75J4T DI DM75J4T DM75J4T DN Piperazine carbamate/urea derivative 4 DM75J4T TI TT9JNIC DM75J4T TN Histamine H3 receptor (H3R) DM75J4T MA Ligand DM75J4T RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM75J4T RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM75QVW DI DM75QVW DM75QVW DN PMID28074661-Compound-US20120264760C80 DM75QVW TI TTL7C8Q DM75QVW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM75QVW MA Inhibitor DM75QVW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM75QVW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM76HXA DI DM76HXA DM76HXA DN Azole derivative 1 DM76HXA TI TTDP1UC DM76HXA TN Fatty acid amide hydrolase (FAAH) DM76HXA MA Inhibitor DM76HXA RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM76HXA RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM76Q10 DI DM76Q10 DM76Q10 DN Crystalline anhydrous toluene derivative 1 DM76Q10 TI TTZMAO3 DM76Q10 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM76Q10 MA Agonist DM76Q10 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM76Q10 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM76WBP DI DM76WBP DM76WBP DN PMID26651364-Compound-11c DM76WBP TI TTTCRU2 DM76WBP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM76WBP MA Antagonist DM76WBP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM76WBP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM76XH4 DI DM76XH4 DM76XH4 DN Azepan-4-one derivative 1 DM76XH4 TI TTZC0KV DM76XH4 TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DM76XH4 MA Inhibitor DM76XH4 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM76XH4 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM786OD DI DM786OD DM786OD DN Beta-phe compound 2 DM786OD TI TTDIGC1 DM786OD TN Dipeptidyl peptidase 4 (DPP-4) DM786OD MA Inhibitor DM786OD RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM786OD RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM78IN5 DI DM78IN5 DM78IN5 DN PMID30259754-Compound-Px-102 DM78IN5 TI TTS4UGC DM78IN5 TN Farnesoid X-activated receptor (FXR) DM78IN5 MA Agonist DM78IN5 RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DM78IN5 RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DM78NOU DI DM78NOU DM78NOU DN Cyclic peptide derivative 1 DM78NOU TI TTGP7BY DM78NOU TN Monoamine oxidase type B (MAO-B) DM78NOU MA Inhibitor DM78NOU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM78NOU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM78NOU DI DM78NOU DM78NOU DN Cyclic peptide derivative 1 DM78NOU TI TT3WG5C DM78NOU TN Monoamine oxidase type A (MAO-A) DM78NOU MA Inhibitor DM78NOU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM78NOU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM78NOU DI DM78NOU DM78NOU DN Cyclic peptide derivative 1 DM78NOU TI TTNR0UQ DM78NOU TN Lysine-specific histone demethylase 1 (LSD) DM78NOU MA Inhibitor DM78NOU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM78NOU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7960M DI DM7960M DM7960M DN PMID25399762-Compound-Table1-C14 DM7960M TI TTGP7BY DM7960M TN Monoamine oxidase type B (MAO-B) DM7960M MA Inhibitor DM7960M RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM7960M RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM79BFU DI DM79BFU DM79BFU DN PMID25435179-Compound-WO2012149608USYDS1 DM79BFU TI TTSCO7R DM79BFU TN NAD-dependent deacetylase sirtuin (SIRT) DM79BFU MA Inhibitor DM79BFU RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM79BFU RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM79KEX DI DM79KEX DM79KEX DN Triazolo-benzodiazepine derivative 1 DM79KEX TI TT9JNIC DM79KEX TN Histamine H3 receptor (H3R) DM79KEX MA Ligand DM79KEX RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM79KEX RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM79WI1 DI DM79WI1 DM79WI1 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 1 DM79WI1 TI TTULVH8 DM79WI1 TN Tyrosinase (TYR) DM79WI1 MA Inhibitor DM79WI1 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM79WI1 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM7AHQE DI DM7AHQE DM7AHQE DN US9216972, 61 DM7AHQE TI TTDYP7I DM7AHQE TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM7AHQE MA Inhibitor DM7AHQE RN Tricyclic heterocyclic compounds. US9216972. DM7AHQE RU http://www.freepatentsonline.com/US9216972.html DM7ATLP DI DM7ATLP DM7ATLP DN PMID28627961-Compound-44 DM7ATLP TI TTYLQ8V DM7ATLP TN Prostaglandin E synthase (PTGES) DM7ATLP MA Inhibitor DM7ATLP RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM7ATLP RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM7AXSM DI DM7AXSM DM7AXSM DN Apogossypolone DM7AXSM TI TTGT9C7 DM7AXSM TN Bcl-2-related protein A1 (BCL2A1) DM7AXSM MA Inhibitor DM7AXSM RN Apogossypolone derivatives as anticancer agents. US8937193. DM7AXSM RU http://www.freepatentsonline.com/US8937193.html DM7B2XG DI DM7B2XG DM7B2XG DN Pyrimidine derivative 14 DM7B2XG TI TTUTJGQ DM7B2XG TN Vascular endothelial growth factor receptor 2 (KDR) DM7B2XG MA Inhibitor DM7B2XG RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM7B2XG RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM7B81V DI DM7B81V DM7B81V DN 4-(thiazol-5-yl)-pyrimidine derivative 1 DM7B81V TI TT7HF4W DM7B81V TN Cyclin-dependent kinase 2 (CDK2) DM7B81V MA Inhibitor DM7B81V RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM7B81V RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM7B81V DI DM7B81V DM7B81V DN 4-(thiazol-5-yl)-pyrimidine derivative 1 DM7B81V TI TT1LVF2 DM7B81V TN Cyclin-dependent kinase 9 (CDK9) DM7B81V MA Inhibitor DM7B81V RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM7B81V RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM7BRIT DI DM7BRIT DM7BRIT DN Aryl piperazine derivative 8 DM7BRIT TI TTWJBZ5 DM7BRIT TN 5-HT 2C receptor (HTR2C) DM7BRIT MA Agonist DM7BRIT RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM7BRIT RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM7BRPI DI DM7BRPI DM7BRPI DN PMID29473428-Compound-34 DM7BRPI TI TTZJYKH DM7BRPI TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7BRPI MA Inhibitor DM7BRPI RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7BRPI RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7C0R8 DI DM7C0R8 DM7C0R8 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 5 DM7C0R8 TI TTXJ47W DM7C0R8 TN Metabotropic glutamate receptor 2 (mGluR2) DM7C0R8 MA Antagonist DM7C0R8 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM7C0R8 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM7CMV6 DI DM7CMV6 DM7CMV6 DN Pyrazole derivative 40 DM7CMV6 TI TT6OEDT DM7CMV6 TN Cannabinoid receptor 1 (CB1) DM7CMV6 MA Antagonist DM7CMV6 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7CMV6 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7CWZ4 DI DM7CWZ4 DM7CWZ4 DN PMID27967267-Compound-36 DM7CWZ4 TI TT1RS9F DM7CWZ4 TN Acetylcholinesterase (AChE) DM7CWZ4 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM7CWZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM7D0CT DI DM7D0CT DM7D0CT DN PMID25828189-Compound-21 DM7D0CT TI TT9O6WS DM7D0CT TN Glucagon receptor (GCGR) DM7D0CT MA Antagonist DM7D0CT RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM7D0CT RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM7D12Y DI DM7D12Y DM7D12Y DN PMID25514969-Compound-Figure3 DM7D12Y TI TT4EB85 DM7D12Y TN Cholesterol 24-hydroxylase (CYP46A1) DM7D12Y MA Inhibitor DM7D12Y RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DM7D12Y RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DM7DF6Z DI DM7DF6Z DM7DF6Z DN Pyrrolidinyl urea derivative 1 DM7DF6Z TI TTDP1UC DM7DF6Z TN Fatty acid amide hydrolase (FAAH) DM7DF6Z MA Inhibitor DM7DF6Z RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM7DF6Z RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM7DG0M DI DM7DG0M DM7DG0M DN PMID30280939-Compound-WO2008009652 DM7DG0M TI TTOK0LR DM7DG0M TN Toll-like receptor (TLR) DM7DG0M MA Agonist DM7DG0M RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DM7DG0M RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DM7DTYS DI DM7DTYS DM7DTYS DN Pyrazole derivative 29 DM7DTYS TI TT6OEDT DM7DTYS TN Cannabinoid receptor 1 (CB1) DM7DTYS MA Antagonist DM7DTYS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7DTYS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7DU9P DI DM7DU9P DM7DU9P DN Pyrrolo[1,2-f]triazine derivative 2 DM7DU9P TI TTDIGC1 DM7DU9P TN Dipeptidyl peptidase 4 (DPP-4) DM7DU9P MA Inhibitor DM7DU9P RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM7DU9P RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM7E9HA DI DM7E9HA DM7E9HA DN PMID29649907-Compound-32 DM7E9HA TI TTS4UGC DM7E9HA TN Farnesoid X-activated receptor (FXR) DM7E9HA MA Agonist DM7E9HA RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM7E9HA RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM7EKZ6 DI DM7EKZ6 DM7EKZ6 DN PMID25772215-Compound-US02014179750M1 DM7EKZ6 TI TT1ZAVI DM7EKZ6 TN Prostaglandin E2 receptor EP2 (PTGER2) DM7EKZ6 MA Antagonist DM7EKZ6 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM7EKZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM7EOG4 DI DM7EOG4 DM7EOG4 DN Acrylamide compound 2 DM7EOG4 TI TT9JNIC DM7EOG4 TN Histamine H3 receptor (H3R) DM7EOG4 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM7EOG4 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM7EW5U DI DM7EW5U DM7EW5U DN PMID29473428-Compound-10 DM7EW5U TI TTZJYKH DM7EW5U TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7EW5U RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7EW5U RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7EXNI DI DM7EXNI DM7EXNI DN PMID27841045-Compound-157 DM7EXNI TI TT7RJY8 DM7EXNI TN Xanthine dehydrogenase/oxidase (XDH) DM7EXNI MA Inhibitor DM7EXNI RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM7EXNI RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM7F9V4 DI DM7F9V4 DM7F9V4 DN Pyrazole derivative 17 DM7F9V4 TI TT6OEDT DM7F9V4 TN Cannabinoid receptor 1 (CB1) DM7F9V4 MA Antagonist DM7F9V4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7F9V4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7G51M DI DM7G51M DM7G51M DN PMID25435285-Compound-49 DM7G51M TI TTXJ47W DM7G51M TN Metabotropic glutamate receptor 2 (mGluR2) DM7G51M MA Antagonist DM7G51M RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM7G51M RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM7GH4Y DI DM7GH4Y DM7GH4Y DN PMID28092474-Compound-33a DM7GH4Y TI TT5ZKDI DM7GH4Y TN Histone deacetylase 6 (HDAC6) DM7GH4Y MA Inhibitor DM7GH4Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM7GH4Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM7GH4Y DI DM7GH4Y DM7GH4Y DN PMID28092474-Compound-33a DM7GH4Y TI TT6R7JZ DM7GH4Y TN Histone deacetylase 1 (HDAC1) DM7GH4Y MA Inhibitor DM7GH4Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM7GH4Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM7HD0T DI DM7HD0T DM7HD0T DN Quinoline derivative 15 DM7HD0T TI TTRZQE3 DM7HD0T TN Glycogen synthase kinase-3 alpha (GSK-3A) DM7HD0T MA Inhibitor DM7HD0T RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM7HD0T RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM7I8ZV DI DM7I8ZV DM7I8ZV DN 1,2-diamino cyclopentane-based derivative 9 DM7I8ZV TI TT9N02I DM7I8ZV TN Orexin receptor type 2 (HCRTR2) DM7I8ZV MA Antagonist DM7I8ZV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7I8ZV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7I8ZV DI DM7I8ZV DM7I8ZV DN 1,2-diamino cyclopentane-based derivative 9 DM7I8ZV TI TT60Q8D DM7I8ZV TN Orexin receptor type 1 (HCRTR1) DM7I8ZV MA Antagonist DM7I8ZV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7I8ZV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7IB8L DI DM7IB8L DM7IB8L DN PMID27551786-Compound-IV DM7IB8L TI TT26PHO DM7IB8L TN Mineralocorticoid receptor (MR) DM7IB8L MA Antagonist DM7IB8L RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DM7IB8L RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DM7INA1 DI DM7INA1 DM7INA1 DN Central azetidine derivative 1 DM7INA1 TI TTHS256 DM7INA1 TN Metabotropic glutamate receptor 5 (mGluR5) DM7INA1 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM7INA1 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM7IPWB DI DM7IPWB DM7IPWB DN Pyrrolo[2,3-b]pyridine derivative 2 DM7IPWB TI TTTDVOJ DM7IPWB TN Tropomyosin-related kinase A (TrkA) DM7IPWB MA Inhibitor DM7IPWB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM7IPWB RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM7IYRM DI DM7IYRM DM7IYRM DN PMID27215781-Compound-32 DM7IYRM TI TTMSFAW DM7IYRM TN Cannabinoid receptor 2 (CB2) DM7IYRM RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7IYRM RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM7JARB DI DM7JARB DM7JARB DN Acrylamide compound 3 DM7JARB TI TT9JNIC DM7JARB TN Histamine H3 receptor (H3R) DM7JARB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM7JARB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM7JASU DI DM7JASU DM7JASU DN PMID27019002-Compound-17 DM7JASU TI TT32XQJ DM7JASU TN Monoamine oxidase (MAO) DM7JASU MA Inhibitor DM7JASU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM7JASU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7JASU DI DM7JASU DM7JASU DN PMID27019002-Compound-17 DM7JASU TI TTNR0UQ DM7JASU TN Lysine-specific histone demethylase 1 (LSD) DM7JASU MA Inhibitor DM7JASU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM7JASU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7JCM6 DI DM7JCM6 DM7JCM6 DN Pyridine derivative 14 DM7JCM6 TI TTHS256 DM7JCM6 TN Metabotropic glutamate receptor 5 (mGluR5) DM7JCM6 MA Modulator DM7JCM6 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM7JCM6 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM7JIF0 DI DM7JIF0 DM7JIF0 DN PMID27967267-Compound-3 DM7JIF0 TI TT1RS9F DM7JIF0 TN Acetylcholinesterase (AChE) DM7JIF0 MA Inhibitor DM7JIF0 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM7JIF0 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM7JX8U DI DM7JX8U DM7JX8U DN 1,2-diamino cyclopentane-based derivative 8 DM7JX8U TI TT9N02I DM7JX8U TN Orexin receptor type 2 (HCRTR2) DM7JX8U MA Antagonist DM7JX8U RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7JX8U RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7JX8U DI DM7JX8U DM7JX8U DN 1,2-diamino cyclopentane-based derivative 8 DM7JX8U TI TT60Q8D DM7JX8U TN Orexin receptor type 1 (HCRTR1) DM7JX8U MA Antagonist DM7JX8U RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7JX8U RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7K256 DI DM7K256 DM7K256 DN Ac-YVAD-FMK DM7K256 TI TTCQIBE DM7K256 TN Caspase-1 (CASP1) DM7K256 MA Inhibitor DM7K256 RN Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59. DM7K256 RU https://www.ncbi.nlm.nih.gov/pubmed/28885866 DM7K3A0 DI DM7K3A0 DM7K3A0 DN PMID30074415-Compound-12 DM7K3A0 TI TT2LVK8 DM7K3A0 TN Carbonic anhydrase IX (CA-IX) DM7K3A0 MA Inhibitor DM7K3A0 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DM7K3A0 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DM7KNXH DI DM7KNXH DM7KNXH DN Triazole derivative 2 DM7KNXH TI TT473XN DM7KNXH TN P2X purinoceptor 7 (P2RX7) DM7KNXH MA Antagonist DM7KNXH RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM7KNXH RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM7L6WS DI DM7L6WS DM7L6WS DN PMID26666989-Compound-Figure9left02 DM7L6WS TI TT8BUGW DM7L6WS TN Glycogen phosphorylase (PYG) DM7L6WS MA Inhibitor DM7L6WS RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM7L6WS RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM7L8T5 DI DM7L8T5 DM7L8T5 DN Biphenyl mannoside derivative 17 DM7L8T5 TI TTTCRU2 DM7L8T5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM7L8T5 MA Antagonist DM7L8T5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM7L8T5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM7LFNG DI DM7LFNG DM7LFNG DN Pyrazole derivative 12 DM7LFNG TI TT6OEDT DM7LFNG TN Cannabinoid receptor 1 (CB1) DM7LFNG MA Antagonist DM7LFNG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM7LFNG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM7MNE2 DI DM7MNE2 DM7MNE2 DN US10092575, Example 158 DM7MNE2 TI TT3ZS42 DM7MNE2 TN Phosphodiesterase 1B (PDE1B) DM7MNE2 MA Inhibitor DM7MNE2 RN Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575. DM7MNE2 RU http://www.freepatentsonline.com/US10092575.html DM7NTO9 DI DM7NTO9 DM7NTO9 DN Tri-substituted purine derivative 1 DM7NTO9 TI TTH8FZW DM7NTO9 TN Signal transducer and activator of transcription 3 (STAT3) DM7NTO9 MA Inhibitor DM7NTO9 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM7NTO9 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM7NUT2 DI DM7NUT2 DM7NUT2 DN PMID25399762-Compound-Figure3-Lycojaponicumin C DM7NUT2 TI TT3WG5C DM7NUT2 TN Monoamine oxidase type A (MAO-A) DM7NUT2 MA Inhibitor DM7NUT2 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM7NUT2 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM7O0MD DI DM7O0MD DM7O0MD DN Azepan-4-one derivative 2 DM7O0MD TI TTZC0KV DM7O0MD TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DM7O0MD MA Inhibitor DM7O0MD RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM7O0MD RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM7OA9E DI DM7OA9E DM7OA9E DN Aryl pyrimidine derivative 8 DM7OA9E TI TTIY56R DM7OA9E TN Kynurenine 3-hydroxylase (KMO) DM7OA9E MA Inhibitor DM7OA9E RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM7OA9E RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM7OBVT DI DM7OBVT DM7OBVT DN Isoxazole-based bicyclic compound 13 DM7OBVT TI TTE4BSY DM7OBVT TN Bromodomain and extraterminal domain protein (BET) DM7OBVT MA Inhibitor DM7OBVT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM7OBVT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM7OGWH DI DM7OGWH DM7OGWH DN PMID28766366-Compound-Scheme25-2 DM7OGWH TI TTYGQ8A DM7OGWH TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM7OGWH MA Inhibitor DM7OGWH RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7OGWH RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7OGWH DI DM7OGWH DM7OGWH DN PMID28766366-Compound-Scheme25-2 DM7OGWH TI TTSBVFO DM7OGWH TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM7OGWH MA Inhibitor DM7OGWH RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7OGWH RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7OS5E DI DM7OS5E DM7OS5E DN PMID27376512-Compound-MTC-433 DM7OS5E TI TT6S2FE DM7OS5E TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM7OS5E MA Inhibitor DM7OS5E RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM7OS5E RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM7PSB1 DI DM7PSB1 DM7PSB1 DN Urea and carbamate bioisostere derivative 18 DM7PSB1 TI TTL7C8Q DM7PSB1 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM7PSB1 MA Inhibitor DM7PSB1 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM7PSB1 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM7QIMN DI DM7QIMN DM7QIMN DN PMID25776143-Compound-7 DM7QIMN TI TT4TFGN DM7QIMN TN Vasopressin V1a receptor (V1AR) DM7QIMN MA Antagonist DM7QIMN RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DM7QIMN RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DM7QLX8 DI DM7QLX8 DM7QLX8 DN PMID28270010-Compound-Figure17-2 DM7QLX8 TI TTTDVOJ DM7QLX8 TN Tropomyosin-related kinase A (TrkA) DM7QLX8 MA Inhibitor DM7QLX8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM7QLX8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM7R2X0 DI DM7R2X0 DM7R2X0 DN PMID25656651-Compound-20a DM7R2X0 TI TTS7G69 DM7R2X0 TN Fusion protein Bcr-Abl (Bcr-Abl) DM7R2X0 MA Inhibitor DM7R2X0 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM7R2X0 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM7RG5I DI DM7RG5I DM7RG5I DN 1,2-diamino cyclopentane-based derivative 2 DM7RG5I TI TT9N02I DM7RG5I TN Orexin receptor type 2 (HCRTR2) DM7RG5I MA Antagonist DM7RG5I RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7RG5I RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7RG5I DI DM7RG5I DM7RG5I DN 1,2-diamino cyclopentane-based derivative 2 DM7RG5I TI TT60Q8D DM7RG5I TN Orexin receptor type 1 (HCRTR1) DM7RG5I MA Antagonist DM7RG5I RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM7RG5I RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM7RPKM DI DM7RPKM DM7RPKM DN PMID28766366-Compound-Scheme9EHT9851 DM7RPKM TI TTYGQ8A DM7RPKM TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM7RPKM MA Inhibitor DM7RPKM RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7RPKM RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7RPKM DI DM7RPKM DM7RPKM DN PMID28766366-Compound-Scheme9EHT9851 DM7RPKM TI TTSBVFO DM7RPKM TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM7RPKM MA Inhibitor DM7RPKM RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM7RPKM RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM7RQ2G DI DM7RQ2G DM7RQ2G DN Quinoline and quinazoline derivative 5 DM7RQ2G TI TTOHSBA DM7RQ2G TN Vascular endothelial growth factor A (VEGFA) DM7RQ2G MA Inhibitor DM7RQ2G RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM7RQ2G RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM7RTQP DI DM7RTQP DM7RTQP DN BDBM50173323 DM7RTQP TI TTTCXO0 DM7RTQP TN G protein-coupled receptor kinase 5 (GRK5) DM7RTQP MA Inhibitor DM7RTQP RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DM7RTQP RU http://www.freepatentsonline.com/US10023564.html DM7SIVA DI DM7SIVA DM7SIVA DN PMID28454500-Compound-13 DM7SIVA TI TTA6ZN2 DM7SIVA TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM7SIVA MA Activator DM7SIVA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM7SIVA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM7SIVA DI DM7SIVA DM7SIVA DN PMID28454500-Compound-13 DM7SIVA TI TT3Z6Y9 DM7SIVA TN Cysteines of Keap1 (KEAP1 Cysteines) DM7SIVA MA Modulator DM7SIVA RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM7SIVA RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM7SK5Q DI DM7SK5Q DM7SK5Q DN Five-and-six-membered heterocyclic compound 1 DM7SK5Q TI TTRMX3V DM7SK5Q TN Janus kinase 2 (JAK-2) DM7SK5Q MA Inhibitor DM7SK5Q RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM7SK5Q RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM7SK5Q DI DM7SK5Q DM7SK5Q DN Five-and-six-membered heterocyclic compound 1 DM7SK5Q TI TTT7PJU DM7SK5Q TN Janus kinase 3 (JAK-3) DM7SK5Q MA Inhibitor DM7SK5Q RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM7SK5Q RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM7SK5Q DI DM7SK5Q DM7SK5Q DN Five-and-six-membered heterocyclic compound 1 DM7SK5Q TI TT6DM01 DM7SK5Q TN Janus kinase 1 (JAK-1) DM7SK5Q MA Inhibitor DM7SK5Q RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM7SK5Q RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM7SOZN DI DM7SOZN DM7SOZN DN Chromene derivative 1 DM7SOZN TI TTWJBZ5 DM7SOZN TN 5-HT 2C receptor (HTR2C) DM7SOZN MA Agonist DM7SOZN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM7SOZN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM7SQKD DI DM7SQKD DM7SQKD DN US9682991, 7 DM7SQKD TI TTCGOIN DM7SQKD TN PIM-3 protein kinase (PIM3) DM7SQKD MA Inhibitor DM7SQKD RN Tricyclic compounds for use as kinase inhibitors. US9682991. DM7SQKD RU http://www.freepatentsonline.com/US9682991.html DM7SUFJ DI DM7SUFJ DM7SUFJ DN Hydroxy amidine derivative 2 DM7SUFJ TI TTZJYKH DM7SUFJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7SUFJ MA Inhibitor DM7SUFJ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7SUFJ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7T962 DI DM7T962 DM7T962 DN PMID25666693-Compound-28 DM7T962 TI TTMI6F5 DM7T962 TN Transient receptor potential cation channel V1 (TRPV1) DM7T962 MA Antagonist DM7T962 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM7T962 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM7TASJ DI DM7TASJ DM7TASJ DN BDBM50363773 DM7TASJ TI TTLKF5M DM7TASJ TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DM7TASJ MA Inhibitor DM7TASJ RN Aroyl thiourea derivatives. US9365508. DM7TASJ RU http://www.freepatentsonline.com/US9365508.html DM7TLDW DI DM7TLDW DM7TLDW DN PMID27967267-Compound-neostenine DM7TLDW TI TT1RS9F DM7TLDW TN Acetylcholinesterase (AChE) DM7TLDW MA Inhibitor DM7TLDW RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM7TLDW RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM7TPBF DI DM7TPBF DM7TPBF DN PMID29757691-Compound-7 DM7TPBF TI TT1RS9F DM7TPBF TN Acetylcholinesterase (AChE) DM7TPBF MA Inhibitor DM7TPBF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM7TPBF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM7TPBF DI DM7TPBF DM7TPBF DN PMID29757691-Compound-7 DM7TPBF TI TTEB0GD DM7TPBF TN Cholinesterase (BCHE) DM7TPBF MA Inhibitor DM7TPBF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DM7TPBF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DM7TW5Z DI DM7TW5Z DM7TW5Z DN 4-aryl quinol derivative 2 DM7TW5Z TI TTR7UJ3 DM7TW5Z TN Cytoplasmic thioredoxin reductase (TXNRD1) DM7TW5Z MA Inhibitor DM7TW5Z RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM7TW5Z RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM7U20W DI DM7U20W DM7U20W DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 9 DM7U20W TI TTULVH8 DM7U20W TN Tyrosinase (TYR) DM7U20W MA Inhibitor DM7U20W RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM7U20W RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM7U8WD DI DM7U8WD DM7U8WD DN Peptide analog 47 DM7U8WD TI TTDIGC1 DM7U8WD TN Dipeptidyl peptidase 4 (DPP-4) DM7U8WD MA Inhibitor DM7U8WD RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM7U8WD RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM7UAKH DI DM7UAKH DM7UAKH DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 DM7UAKH TI TTJW4LU DM7UAKH TN Phosphodiesterase 10A (PDE10) DM7UAKH MA Inhibitor DM7UAKH RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM7UAKH RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM7UAKH DI DM7UAKH DM7UAKH DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 5 DM7UAKH TI TTJGW1Z DM7UAKH TN Phosphodiesterase 2A (PDE2A) DM7UAKH MA Inhibitor DM7UAKH RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM7UAKH RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM7UDIM DI DM7UDIM DM7UDIM DN PMID28394193-Compound-47 DM7UDIM TI TT9MZCQ DM7UDIM TN Enhancer of zeste homolog 2 (EZH2) DM7UDIM MA Inhibitor DM7UDIM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM7UDIM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM7UEJT DI DM7UEJT DM7UEJT DN Benzamide derivative 7 DM7UEJT TI TT9NXW4 DM7UEJT TN Sigma intracellular receptor 2 (TMEM97) DM7UEJT MA Ligand DM7UEJT RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM7UEJT RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM7UEJT DI DM7UEJT DM7UEJT DN Benzamide derivative 7 DM7UEJT TI TT5TPI6 DM7UEJT TN Opioid receptor sigma 1 (OPRS1) DM7UEJT MA Ligand DM7UEJT RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM7UEJT RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM7UK5E DI DM7UK5E DM7UK5E DN KadcoccitoneA DM7UK5E TI TT3WG5C DM7UK5E TN Monoamine oxidase type A (MAO-A) DM7UK5E MA Inhibitor DM7UK5E RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM7UK5E RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM7ULWD DI DM7ULWD DM7ULWD DN PMID28350212-Compound-36 DM7ULWD TI TTZS04O DM7ULWD TN Gamma-secretase subunit APH-1A/1B (APH-1) DM7ULWD MA Inhibitor DM7ULWD RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DM7ULWD RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DM7UMW2 DI DM7UMW2 DM7UMW2 DN Imidazoleisoindoles derivative 1 DM7UMW2 TI TTZJYKH DM7UMW2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7UMW2 MA Inhibitor DM7UMW2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM7UMW2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM7USO9 DI DM7USO9 DM7USO9 DN PMID27215781-Compound-30 DM7USO9 TI TTMSFAW DM7USO9 TN Cannabinoid receptor 2 (CB2) DM7USO9 MA Agonist DM7USO9 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7USO9 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM7V6E0 DI DM7V6E0 DM7V6E0 DN PMID25684022-Compound-US20120277229 41(1.3) DM7V6E0 TI TTCZOF2 DM7V6E0 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM7V6E0 MA Inhibitor DM7V6E0 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM7V6E0 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM7VP8M DI DM7VP8M DM7VP8M DN Heterocyclic derivative 4 DM7VP8M TI TTCZOF2 DM7VP8M TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM7VP8M MA Inhibitor DM7VP8M RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM7VP8M RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM7WOD9 DI DM7WOD9 DM7WOD9 DN Piperazinyl methyl quinazolinone derivative 1 DM7WOD9 TI TT9NXW4 DM7WOD9 TN Sigma intracellular receptor 2 (TMEM97) DM7WOD9 MA Ligand DM7WOD9 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM7WOD9 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM7WXJ9 DI DM7WXJ9 DM7WXJ9 DN PMID29130358-Compound-Figure18(14) DM7WXJ9 TI TTHY57M DM7WXJ9 TN Matrix metalloproteinase-13 (MMP-13) DM7WXJ9 MA Inhibitor DM7WXJ9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM7WXJ9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM7WXJ9 DI DM7WXJ9 DM7WXJ9 DN PMID29130358-Compound-Figure18(14) DM7WXJ9 TI TTLM12X DM7WXJ9 TN Matrix metalloproteinase-2 (MMP-2) DM7WXJ9 MA Inhibitor DM7WXJ9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM7WXJ9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM7X62M DI DM7X62M DM7X62M DN Peptide analog 58 DM7X62M TI TTQAJF1 DM7X62M TN Cathepsin G (CTSG) DM7X62M MA Inhibitor DM7X62M RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM7X62M RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM7X62M DI DM7X62M DM7X62M DN Peptide analog 58 DM7X62M TI TTPLTSQ DM7X62M TN Neutrophil elastase (NE) DM7X62M MA Inhibitor DM7X62M RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DM7X62M RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DM7X6HR DI DM7X6HR DM7X6HR DN PMID25522065-Compound-17 DM7X6HR TI TTX4RTB DM7X6HR TN Melanin-concentrating hormone receptor 1 (MCHR1) DM7X6HR MA Antagonist DM7X6HR RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM7X6HR RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM7XQ18 DI DM7XQ18 DM7XQ18 DN Benzothiazepine analog 12 DM7XQ18 TI TTRA6BO DM7XQ18 TN Bromodomain-containing protein 4 (BRD4) DM7XQ18 MA Inhibitor DM7XQ18 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM7XQ18 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM7XQUT DI DM7XQUT DM7XQUT DN PMID25656651-Compound-46 DM7XQUT TI TT3PJMV DM7XQUT TN Tyrosine-protein kinase ABL1 (ABL) DM7XQUT MA Inhibitor DM7XQUT RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM7XQUT RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM7XS9G DI DM7XS9G DM7XS9G DN N-oxalyl-D-tyrosine derivative 3 DM7XS9G TI TTWAQBO DM7XS9G TN Lysine-specific demethylase 4E (KDM4E) DM7XS9G MA Inhibitor DM7XS9G RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM7XS9G RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM7XSHK DI DM7XSHK DM7XSHK DN Pyrazolopyrimidine derivative 4 DM7XSHK TI TTHS256 DM7XSHK TN Metabotropic glutamate receptor 5 (mGluR5) DM7XSHK MA Modulator DM7XSHK RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM7XSHK RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM7XYRA DI DM7XYRA DM7XYRA DN Eptastatin derivative 1 DM7XYRA TI TTPADOQ DM7XYRA TN HMG-CoA reductase (HMGCR) DM7XYRA MA Inhibitor DM7XYRA RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM7XYRA RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM7Y2RL DI DM7Y2RL DM7Y2RL DN Oxazole derivative 1 DM7Y2RL TI TTN7R6K DM7Y2RL TN Signal transducer and activator of transcription 1 (STAT1) DM7Y2RL MA Inhibitor DM7Y2RL RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM7Y2RL RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM7Y2RL DI DM7Y2RL DM7Y2RL DN Oxazole derivative 1 DM7Y2RL TI TTH8FZW DM7Y2RL TN Signal transducer and activator of transcription 3 (STAT3) DM7Y2RL MA Inhibitor DM7Y2RL RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM7Y2RL RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM7YA9Z DI DM7YA9Z DM7YA9Z DN Pyrimidine derivative 17 DM7YA9Z TI TTNR0UQ DM7YA9Z TN Lysine-specific histone demethylase 1 (LSD) DM7YA9Z MA Inhibitor DM7YA9Z RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM7YA9Z RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM7YFBT DI DM7YFBT DM7YFBT DN Quinoline carboxamide derivative 9 DM7YFBT TI TTPTXIN DM7YFBT TN Translocator protein (TSPO) DM7YFBT MA Ligand DM7YFBT RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM7YFBT RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM7YJ4L DI DM7YJ4L DM7YJ4L DN PMID25435179-Compound-WO2013059587(VI, 2nd set) DM7YJ4L TI TTSCO7R DM7YJ4L TN NAD-dependent deacetylase sirtuin (SIRT) DM7YJ4L MA Inhibitor DM7YJ4L RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DM7YJ4L RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TTSHTOI DM7YQJK TN Histone deacetylase 2 (HDAC2) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TTYHPU6 DM7YQJK TN Histone deacetylase 10 (HDAC10) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TT4YWTO DM7YQJK TN Histone deacetylase 3 (HDAC3) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TT6R7JZ DM7YQJK TN Histone deacetylase 1 (HDAC1) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YQJK DI DM7YQJK DM7YQJK DN PMID29671355-Compound-8 DM7YQJK TI TT5ZKDI DM7YQJK TN Histone deacetylase 6 (HDAC6) DM7YQJK MA Inhibitor DM7YQJK RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM7YQJK RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM7YVQL DI DM7YVQL DM7YVQL DN Tricyclic phytocannabinoid derivative 2 DM7YVQL TI TTMSFAW DM7YVQL TN Cannabinoid receptor 2 (CB2) DM7YVQL RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7YVQL RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM7YVQL DI DM7YVQL DM7YVQL DN Tricyclic phytocannabinoid derivative 2 DM7YVQL TI TT6OEDT DM7YVQL TN Cannabinoid receptor 1 (CB1) DM7YVQL RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM7YVQL RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM804T5 DI DM804T5 DM804T5 DN US9694002, 59 DM804T5 TI TTANOZH DM804T5 TN SCN1A messenger RNA (SCN1A mRNA) DM804T5 MA Inhibitor DM804T5 RN Substituted benzamides and methods of use thereof. US9694002. DM804T5 RU http://www.freepatentsonline.com/US9694002.html DM805ZN DI DM805ZN DM805ZN DN PMID28092474-Compound-32u DM805ZN TI TT6R7JZ DM805ZN TN Histone deacetylase 1 (HDAC1) DM805ZN MA Inhibitor DM805ZN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM805ZN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM805ZN DI DM805ZN DM805ZN DN PMID28092474-Compound-32u DM805ZN TI TT5ZKDI DM805ZN TN Histone deacetylase 6 (HDAC6) DM805ZN MA Inhibitor DM805ZN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM805ZN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM809AX DI DM809AX DM809AX DN PMID25684022-Compound-WO2004087707 DM809AX TI TTCZOF2 DM809AX TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM809AX MA Inhibitor DM809AX RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM809AX RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM809YH DI DM809YH DM809YH DN Resorcinol compound 6 DM809YH TI TTULVH8 DM809YH TN Tyrosinase (TYR) DM809YH MA Inhibitor DM809YH RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM809YH RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT4YWTO DM80A3V TN Histone deacetylase 3 (HDAC3) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT5ZKDI DM80A3V TN Histone deacetylase 6 (HDAC6) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TTT6LFV DM80A3V TN Histone deacetylase 8 (HDAC8) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TTSHTOI DM80A3V TN Histone deacetylase 2 (HDAC2) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT6R7JZ DM80A3V TN Histone deacetylase 1 (HDAC1) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TTYHPU6 DM80A3V TN Histone deacetylase 10 (HDAC10) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80A3V DI DM80A3V DM80A3V DN PMID29671355-Compound-44 DM80A3V TI TT8K17W DM80A3V TN Histone deacetylase 11 (HDAC11) DM80A3V MA Inhibitor DM80A3V RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM80A3V RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM80E3F DI DM80E3F DM80E3F DN PMID25666693-Compound-74 DM80E3F TI TTMI6F5 DM80E3F TN Transient receptor potential cation channel V1 (TRPV1) DM80E3F MA Antagonist DM80E3F RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM80E3F RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM80PI1 DI DM80PI1 DM80PI1 DN PMID26651364-Compound-126c DM80PI1 TI TTTCRU2 DM80PI1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM80PI1 MA Antagonist DM80PI1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM80PI1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM80TDC DI DM80TDC DM80TDC DN Benzamide derivative 6 DM80TDC TI TTA6ZN2 DM80TDC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM80TDC MA Inhibitor DM80TDC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM80TDC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM80XRM DI DM80XRM DM80XRM DN Piperidine derivative 3 DM80XRM TI TTQR74A DM80XRM TN Proteinase activated receptor 2 (PAR2) DM80XRM MA Antagonist DM80XRM RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM80XRM RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM81A50 DI DM81A50 DM81A50 DN PMID27967267-Compound-48 DM81A50 TI TT1RS9F DM81A50 TN Acetylcholinesterase (AChE) DM81A50 MA Reactivator DM81A50 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM81A50 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM81MV6 DI DM81MV6 DM81MV6 DN US9567304, Compound F-54 DM81MV6 TI TTI1FPZ DM81MV6 TN Epithelial discoidin domain receptor 1 (DDR1) DM81MV6 MA Inhibitor DM81MV6 RN Quinazolinedione derivative. US9567304. DM81MV6 RU http://www.freepatentsonline.com/US9567304.html DM81RIY DI DM81RIY DM81RIY DN Biphenyl mannoside derivative 30 DM81RIY TI TTTCRU2 DM81RIY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM81RIY MA Antagonist DM81RIY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM81RIY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM81SYN DI DM81SYN DM81SYN DN Cannabinoid quinone derivative 1 DM81SYN TI TTZMAO3 DM81SYN TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM81SYN MA Ligand DM81SYN RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM81SYN RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM826JW DI DM826JW DM826JW DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 DM826JW TI TTJGW1Z DM826JW TN Phosphodiesterase 2A (PDE2A) DM826JW MA Inhibitor DM826JW RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM826JW RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM826JW DI DM826JW DM826JW DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 DM826JW TI TTJW4LU DM826JW TN Phosphodiesterase 10A (PDE10) DM826JW MA Inhibitor DM826JW RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM826JW RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM82BAM DI DM82BAM DM82BAM DN PMID25666693-Compound-56 DM82BAM TI TTMI6F5 DM82BAM TN Transient receptor potential cation channel V1 (TRPV1) DM82BAM MA Antagonist DM82BAM RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM82BAM RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM839NQ DI DM839NQ DM839NQ DN PMID29338548-Compound-34 DM839NQ TI TTHJTF7 DM839NQ TN Glycine transporter GlyT-1 (SLC6A9) DM839NQ MA Inhibitor DM839NQ RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM839NQ RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM83LTH DI DM83LTH DM83LTH DN Biphenyl mannoside derivative 13 DM83LTH TI TTTCRU2 DM83LTH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM83LTH MA Antagonist DM83LTH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM83LTH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM83LWC DI DM83LWC DM83LWC DN PMID29338548-Compound-25 DM83LWC TI TTHJTF7 DM83LWC TN Glycine transporter GlyT-1 (SLC6A9) DM83LWC MA Inhibitor DM83LWC RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM83LWC RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM83P6H DI DM83P6H DM83P6H DN PMID28454500-Compound-37 DM83P6H TI TTA6ZN2 DM83P6H TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM83P6H MA Activator DM83P6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM83P6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM83P6H DI DM83P6H DM83P6H DN PMID28454500-Compound-37 DM83P6H TI TT3Z6Y9 DM83P6H TN Cysteines of Keap1 (KEAP1 Cysteines) DM83P6H MA Modulator DM83P6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM83P6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM847I2 DI DM847I2 DM847I2 DN Imidazolyl urea derivative 1 DM847I2 TI TTDP1UC DM847I2 TN Fatty acid amide hydrolase (FAAH) DM847I2 MA Inhibitor DM847I2 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM847I2 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM84HG2 DI DM84HG2 DM84HG2 DN 3-(phenoxymethyl) benzylamine derivative 5 DM84HG2 TI TTULVH8 DM84HG2 TN Tyrosinase (TYR) DM84HG2 MA Inhibitor DM84HG2 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM84HG2 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM84RES DI DM84RES DM84RES DN PMID27215781-Compound-1 DM84RES TI TT6OEDT DM84RES TN Cannabinoid receptor 1 (CB1) DM84RES MA Agonist DM84RES RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM84RES RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM84U7F DI DM84U7F DM84U7F DN PMID25522065-Compound-4 DM84U7F TI TTX4RTB DM84U7F TN Melanin-concentrating hormone receptor 1 (MCHR1) DM84U7F MA Antagonist DM84U7F RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM84U7F RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM853Y7 DI DM853Y7 DM853Y7 DN PMID25666693-Compound-31 DM853Y7 TI TTMI6F5 DM853Y7 TN Transient receptor potential cation channel V1 (TRPV1) DM853Y7 MA Antagonist DM853Y7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM853Y7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM859ZQ DI DM859ZQ DM859ZQ DN Palmarumycin derivative 1 DM859ZQ TI TTR7UJ3 DM859ZQ TN Cytoplasmic thioredoxin reductase (TXNRD1) DM859ZQ MA Inhibitor DM859ZQ RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM859ZQ RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM85ETX DI DM85ETX DM85ETX DN PMID29130358-Compound-Figure15(7) DM85ETX TI TTXPTJE DM85ETX TN Gelatinase (GEL) DM85ETX MA Inhibitor DM85ETX RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DM85ETX RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DM85VQR DI DM85VQR DM85VQR DN Dihydrothieno [2,3-e]indazole derivative 3 DM85VQR TI TTRPDBG DM85VQR TN Inhibitor of nuclear factor kappa-B kinase (IKK) DM85VQR MA Inhibitor DM85VQR RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM85VQR RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM85XKT DI DM85XKT DM85XKT DN PMID28074661-Compound-US20120264760C87 DM85XKT TI TTL7C8Q DM85XKT TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM85XKT MA Inhibitor DM85XKT RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM85XKT RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM86BDS DI DM86BDS DM86BDS DN T8361 DM86BDS TI TTOJ9QL DM86BDS TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM86BDS MA Inhibitor DM86BDS RN IRE-1 inhibitors. US8614253. DM86BDS RU http://www.freepatentsonline.com/US8614253.html DM86E2P DI DM86E2P DM86E2P DN Carboxylic acid derivative 1 DM86E2P TI TTYLQ8V DM86E2P TN Prostaglandin E synthase (PTGES) DM86E2P MA Inhibitor DM86E2P RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DM86E2P RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DM86HU3 DI DM86HU3 DM86HU3 DN Thiazoline derivative 1 DM86HU3 TI TTULVH8 DM86HU3 TN Tyrosinase (TYR) DM86HU3 MA Inhibitor DM86HU3 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM86HU3 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM86M7D DI DM86M7D DM86M7D DN PMID27774822-Compound-Figure2Example1-1left DM86M7D TI TTT7PJU DM86M7D TN Janus kinase 3 (JAK-3) DM86M7D MA Inhibitor DM86M7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM86M7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM86M7D DI DM86M7D DM86M7D DN PMID27774822-Compound-Figure2Example1-1left DM86M7D TI TTRMX3V DM86M7D TN Janus kinase 2 (JAK-2) DM86M7D MA Inhibitor DM86M7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DM86M7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DM875RE DI DM875RE DM875RE DN Pyrrole derivative 6 DM875RE TI TT6OEDT DM875RE TN Cannabinoid receptor 1 (CB1) DM875RE MA Antagonist DM875RE RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM875RE RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM87DOX DI DM87DOX DM87DOX DN Ethinyl-pyrazole derivative 3 DM87DOX TI TTXJ47W DM87DOX TN Metabotropic glutamate receptor 2 (mGluR2) DM87DOX MA Antagonist DM87DOX RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM87DOX RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM87HTO DI DM87HTO DM87HTO DN PMID25666693-Compound-68 DM87HTO TI TTMI6F5 DM87HTO TN Transient receptor potential cation channel V1 (TRPV1) DM87HTO MA Antagonist DM87HTO RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM87HTO RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM89GKE DI DM89GKE DM89GKE DN Pyrazolo[3,4-d]pyrimidine derivative 8 DM89GKE TI TT4DXQT DM89GKE TN Proto-oncogene c-Ret (RET) DM89GKE MA Inhibitor DM89GKE RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DM89GKE RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TTH6V3D DM89LF0 TN Cyclin-dependent kinase 1 (CDK1) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT0PG8F DM89LF0 TN Cyclin-dependent kinase 4 (CDK4) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT7HF4W DM89LF0 TN Cyclin-dependent kinase 2 (CDK2) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT056SO DM89LF0 TN Stress-activated protein kinase JNK3 (JNK3) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TTHS0U8 DM89LF0 TN Stress-activated protein kinase JNK2 (JNK2) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TT0K6EO DM89LF0 TN Stress-activated protein kinase JNK1 (JNK1) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LF0 DI DM89LF0 DM89LF0 DN PMID25991433-Compound-A1 DM89LF0 TI TTQBR95 DM89LF0 TN Stress-activated protein kinase 2a (p38 alpha) DM89LF0 MA Inhibitor DM89LF0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM89LF0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM89LKQ DI DM89LKQ DM89LKQ DN US9617250, Example 1 Example 204 of D1 DM89LKQ TI TTDYP7I DM89LKQ TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM89LKQ MA Inhibitor DM89LKQ RN Pyridin-4-yl derivatives. US9617250. DM89LKQ RU http://www.freepatentsonline.com/US9617250.html DM89VQT DI DM89VQT DM89VQT DN PMID26651364-Compound-7d DM89VQT TI TTTCRU2 DM89VQT TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM89VQT MA Antagonist DM89VQT RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM89VQT RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM8A4B5 DI DM8A4B5 DM8A4B5 DN PMID25666693-Compound-9 DM8A4B5 TI TTMI6F5 DM8A4B5 TN Transient receptor potential cation channel V1 (TRPV1) DM8A4B5 MA Antagonist DM8A4B5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM8A4B5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM8AG0Z DI DM8AG0Z DM8AG0Z DN Quinoline carboxamide derivative 7 DM8AG0Z TI TTPTXIN DM8AG0Z TN Translocator protein (TSPO) DM8AG0Z MA Ligand DM8AG0Z RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM8AG0Z RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM8B13I DI DM8B13I DM8B13I DN Peptide analog 5 DM8B13I TI TT23XQV DM8B13I TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM8B13I MA Inhibitor DM8B13I RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM8B13I RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM8B1Q4 DI DM8B1Q4 DM8B1Q4 DN US8889672, 252-036-001 DM8B1Q4 TI TTUWGRA DM8B1Q4 TN Protein kinase C zeta (PRKCZ) DM8B1Q4 MA Inhibitor DM8B1Q4 RN Compounds, formulations, and methods of protein kinase C inhibition. US8889672. DM8B1Q4 RU http://www.freepatentsonline.com/US8889672.html DM8D3FG DI DM8D3FG DM8D3FG DN Beta-phe compound 1 DM8D3FG TI TTDIGC1 DM8D3FG TN Dipeptidyl peptidase 4 (DPP-4) DM8D3FG MA Inhibitor DM8D3FG RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM8D3FG RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM8DHRN DI DM8DHRN DM8DHRN DN Indoline derivative 14 DM8DHRN TI TTOHSBA DM8DHRN TN Vascular endothelial growth factor A (VEGFA) DM8DHRN MA Inhibitor DM8DHRN RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM8DHRN RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM8DHZ4 DI DM8DHZ4 DM8DHZ4 DN Thiazole carboxamide derivative 26 DM8DHZ4 TI TTCZOF2 DM8DHZ4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM8DHZ4 MA Inhibitor DM8DHZ4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM8DHZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM8DZA6 DI DM8DZA6 DM8DZA6 DN PMID25666693-Compound-103 DM8DZA6 TI TTMI6F5 DM8DZA6 TN Transient receptor potential cation channel V1 (TRPV1) DM8DZA6 MA Antagonist DM8DZA6 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM8DZA6 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM8E702 DI DM8E702 DM8E702 DN PMID28074661-Compound-US20100022547C87 DM8E702 TI TTL7C8Q DM8E702 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM8E702 MA Inhibitor DM8E702 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM8E702 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM8EB57 DI DM8EB57 DM8EB57 DN Imidazopyridine derivative 1 DM8EB57 TI TTPTXIN DM8EB57 TN Translocator protein (TSPO) DM8EB57 MA Ligand DM8EB57 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM8EB57 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM8EQPJ DI DM8EQPJ DM8EQPJ DN Resorcinol compound 21 DM8EQPJ TI TTULVH8 DM8EQPJ TN Tyrosinase (TYR) DM8EQPJ MA Inhibitor DM8EQPJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM8EQPJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM8EY2G DI DM8EY2G DM8EY2G DN Quinoxaline derivative 5 DM8EY2G TI TTSXVID DM8EY2G TN Nuclear factor NF-kappa-B (NFKB) DM8EY2G MA Inhibitor DM8EY2G RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM8EY2G RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM8F4QP DI DM8F4QP DM8F4QP DN 4-(2-cyclohexylethoxy) aniline derivative 2 DM8F4QP TI TTA6ZN2 DM8F4QP TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM8F4QP MA Inhibitor DM8F4QP RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM8F4QP RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM8FAW3 DI DM8FAW3 DM8FAW3 DN Aryl pyrimidine derivative 7 DM8FAW3 TI TTIY56R DM8FAW3 TN Kynurenine 3-hydroxylase (KMO) DM8FAW3 MA Inhibitor DM8FAW3 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM8FAW3 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM8FGZB DI DM8FGZB DM8FGZB DN Peptide analog 26 DM8FGZB TI TTSJMN8 DM8FGZB TN Immunoproteasome complex (IP) DM8FGZB MA Inhibitor DM8FGZB RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM8FGZB RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM8FQJB DI DM8FQJB DM8FQJB DN PMID26004420-Compound-U2014S0288042A DM8FQJB TI TTJ13ST DM8FQJB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM8FQJB MA Inhibitor DM8FQJB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM8FQJB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM8GCVO DI DM8GCVO DM8GCVO DN Imidazole derivative 2 DM8GCVO TI TT6OEDT DM8GCVO TN Cannabinoid receptor 1 (CB1) DM8GCVO MA Antagonist DM8GCVO RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM8GCVO RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM8GJA7 DI DM8GJA7 DM8GJA7 DN N-(arylamino)sulfonamide derivative 1 DM8GJA7 TI TTZCRP3 DM8GJA7 TN ERK activator kinase (MEK) DM8GJA7 MA Inhibitor DM8GJA7 RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DM8GJA7 RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DM8GOH3 DI DM8GOH3 DM8GOH3 DN PMID27744724-Compound-26 DM8GOH3 TI TTU1E82 DM8GOH3 TN Apoptosis regulator Bcl-xL (BCL-xL) DM8GOH3 MA Inhibitor DM8GOH3 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM8GOH3 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM8GOH3 DI DM8GOH3 DM8GOH3 DN PMID27744724-Compound-26 DM8GOH3 TI TTL53M6 DM8GOH3 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM8GOH3 MA Inhibitor DM8GOH3 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DM8GOH3 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DM8GW54 DI DM8GW54 DM8GW54 DN US9241942, 32-12 DM8GW54 TI TTOJ9QL DM8GW54 TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DM8GW54 MA Inhibitor DM8GW54 RN IRE-1 inhibitors. US9493435. DM8GW54 RU http://www.freepatentsonline.com/US9493435.html DM8GYCD DI DM8GYCD DM8GYCD DN PMID27109571-Compound-7 DM8GYCD TI TTHWMFZ DM8GYCD TN Fatty acid-binding protein 4 (FABP4) DM8GYCD MA Inhibitor DM8GYCD RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DM8GYCD RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DM8HAJ3 DI DM8HAJ3 DM8HAJ3 DN PMID26651364-Compound-6a DM8HAJ3 TI TTTCRU2 DM8HAJ3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM8HAJ3 MA Antagonist DM8HAJ3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM8HAJ3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM8HDQT DI DM8HDQT DM8HDQT DN Aromatic hydrazine carboxyimidoamide derivative 6 DM8HDQT TI TTULVH8 DM8HDQT TN Tyrosinase (TYR) DM8HDQT MA Inhibitor DM8HDQT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM8HDQT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM8I051 DI DM8I051 DM8I051 DN Mannoside derivative 11 DM8I051 TI TTTCRU2 DM8I051 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM8I051 MA Antagonist DM8I051 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM8I051 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM8IL6Y DI DM8IL6Y DM8IL6Y DN PMID25772215-Compound-US02014179750TG8-15 DM8IL6Y TI TT1ZAVI DM8IL6Y TN Prostaglandin E2 receptor EP2 (PTGER2) DM8IL6Y MA Antagonist DM8IL6Y RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM8IL6Y RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM8IU1G DI DM8IU1G DM8IU1G DN Piperazine carbamic compound 3 DM8IU1G TI TTZ963I DM8IU1G TN Monoglyceride lipase (MAGL) DM8IU1G MA Inhibitor DM8IU1G RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8IU1G RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8JIDR DI DM8JIDR DM8JIDR DN PMID25482888-Compound-12 DM8JIDR TI TTDIGC1 DM8JIDR TN Dipeptidyl peptidase 4 (DPP-4) DM8JIDR MA Inhibitor DM8JIDR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DM8JIDR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DM8JK2D DI DM8JK2D DM8JK2D DN PMID29338548-Compound-30 DM8JK2D TI TTHJTF7 DM8JK2D TN Glycine transporter GlyT-1 (SLC6A9) DM8JK2D MA Inhibitor DM8JK2D RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DM8JK2D RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DM8K6IS DI DM8K6IS DM8K6IS DN Pyrimidine derivative 4 DM8K6IS TI TTUTJGQ DM8K6IS TN Vascular endothelial growth factor receptor 2 (KDR) DM8K6IS MA Inhibitor DM8K6IS RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM8K6IS RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM8KAIY DI DM8KAIY DM8KAIY DN PMID30107136-Compound-Example44 DM8KAIY TI TT23XQV DM8KAIY TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM8KAIY MA Inhibitor DM8KAIY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM8KAIY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM8KBHX DI DM8KBHX DM8KBHX DN Pyridine derivative 12 DM8KBHX TI TTHS256 DM8KBHX TN Metabotropic glutamate receptor 5 (mGluR5) DM8KBHX MA Modulator DM8KBHX RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM8KBHX RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM8KF15 DI DM8KF15 DM8KF15 DN PMID26666989-Compound-Figure9middle08 DM8KF15 TI TT8BUGW DM8KF15 TN Glycogen phosphorylase (PYG) DM8KF15 MA Inhibitor DM8KF15 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DM8KF15 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DM8KWQ9 DI DM8KWQ9 DM8KWQ9 DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 2 DM8KWQ9 TI TTJGW1Z DM8KWQ9 TN Phosphodiesterase 2A (PDE2A) DM8KWQ9 MA Inhibitor DM8KWQ9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM8KWQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM8L0MN DI DM8L0MN DM8L0MN DN 3-acylidene-2-oxoindole derivative 1 DM8L0MN TI TT2F4OL DM8L0MN TN Tissue transglutaminase (TG2) DM8L0MN MA Inhibitor DM8L0MN RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM8L0MN RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM8L3KM DI DM8L3KM DM8L3KM DN Aromatic bicyclic compound 6 DM8L3KM TI TTRMX3V DM8L3KM TN Janus kinase 2 (JAK-2) DM8L3KM MA Inhibitor DM8L3KM RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8L3KM RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8L3KM DI DM8L3KM DM8L3KM DN Aromatic bicyclic compound 6 DM8L3KM TI TT6PKBN DM8L3KM TN Proto-oncogene c-Src (SRC) DM8L3KM MA Inhibitor DM8L3KM RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8L3KM RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8L5JR DI DM8L5JR DM8L5JR DN PMID25684022-Compound-WO2008107444 DM8L5JR TI TTCZOF2 DM8L5JR TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM8L5JR MA Inhibitor DM8L5JR RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM8L5JR RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM8LFGS DI DM8LFGS DM8LFGS DN Triazole propanedioic acid derivative 1 DM8LFGS TI TTA592U DM8LFGS TN Urate anion exchanger 1 (URAT1) DM8LFGS MA Inhibitor DM8LFGS RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DM8LFGS RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DM8LNXQ DI DM8LNXQ DM8LNXQ DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 2 DM8LNXQ TI TTPTXIN DM8LNXQ TN Translocator protein (TSPO) DM8LNXQ MA Ligand DM8LNXQ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM8LNXQ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM8LZ60 DI DM8LZ60 DM8LZ60 DN PMID25726713-Compound-13 DM8LZ60 TI TT8J1S3 DM8LZ60 TN Smoothened homolog (SMO) DM8LZ60 MA Inhibitor DM8LZ60 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM8LZ60 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM8MZR6 DI DM8MZR6 DM8MZR6 DN Piperazine derivative 3 DM8MZR6 TI TTJQOD7 DM8MZR6 TN 5-HT 2A receptor (HTR2A) DM8MZR6 MA Antagonist DM8MZR6 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM8MZR6 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM8N10A DI DM8N10A DM8N10A DN PMID29334795-Compound-22 DM8N10A TI TT9JNIC DM8N10A TN Histamine H3 receptor (H3R) DM8N10A MA Agonis; Inverse agonist DM8N10A RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM8N10A RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM8NBJV DI DM8NBJV DM8NBJV DN PMID30273516-Compound-37 DM8NBJV TI TTCW0KX DM8NBJV TN Glutaminase (GLS) DM8NBJV MA Inhibitor DM8NBJV RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DM8NBJV RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DM8NBM0 DI DM8NBM0 DM8NBM0 DN Pyridine derivative 6 DM8NBM0 TI TTOHSBA DM8NBM0 TN Vascular endothelial growth factor A (VEGFA) DM8NBM0 MA Inhibitor DM8NBM0 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM8NBM0 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM8NE12 DI DM8NE12 DM8NE12 DN US8921389, 123 DM8NE12 TI TT9ISBX DM8NE12 TN HIF-prolyl hydroxylase 2 (HPH-2) DM8NE12 MA Inhibitor DM8NE12 RN Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase. US8921389. DM8NE12 RU http://www.freepatentsonline.com/US8921389.html DM8NHQS DI DM8NHQS DM8NHQS DN PMID28092474-Compound-32e DM8NHQS TI TT6R7JZ DM8NHQS TN Histone deacetylase 1 (HDAC1) DM8NHQS MA Inhibitor DM8NHQS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM8NHQS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM8NHQS DI DM8NHQS DM8NHQS DN PMID28092474-Compound-32e DM8NHQS TI TT5ZKDI DM8NHQS TN Histone deacetylase 6 (HDAC6) DM8NHQS MA Inhibitor DM8NHQS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DM8NHQS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DM8OLYQ DI DM8OLYQ DM8OLYQ DN PMID26609882-Compound-35 DM8OLYQ TI TTJQOD7 DM8OLYQ TN 5-HT 2A receptor (HTR2A) DM8OLYQ MA Antagonist DM8OLYQ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM8OLYQ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM8ONCL DI DM8ONCL DM8ONCL DN Carbamide derivative 25 DM8ONCL TI TTDP1UC DM8ONCL TN Fatty acid amide hydrolase (FAAH) DM8ONCL MA Inhibitor DM8ONCL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8ONCL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8ONCL DI DM8ONCL DM8ONCL DN Carbamide derivative 25 DM8ONCL TI TTZ963I DM8ONCL TN Monoglyceride lipase (MAGL) DM8ONCL MA Inhibitor DM8ONCL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8ONCL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8OYI4 DI DM8OYI4 DM8OYI4 DN Platinum IV complexe 1 DM8OYI4 TI TTLRFIH DM8OYI4 TN Signal transducer and activator of transcription 5 (STAT5) DM8OYI4 MA Inhibitor DM8OYI4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8OYI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8OYI4 DI DM8OYI4 DM8OYI4 DN Platinum IV complexe 1 DM8OYI4 TI TTN7R6K DM8OYI4 TN Signal transducer and activator of transcription 1 (STAT1) DM8OYI4 MA Inhibitor DM8OYI4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8OYI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8OYI4 DI DM8OYI4 DM8OYI4 DN Platinum IV complexe 1 DM8OYI4 TI TTH8FZW DM8OYI4 TN Signal transducer and activator of transcription 3 (STAT3) DM8OYI4 MA Inhibitor DM8OYI4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM8OYI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM8PET6 DI DM8PET6 DM8PET6 DN PMID28447479-Compound-21 DM8PET6 TI TTSCIM2 DM8PET6 TN Extracellular lysophospholipase D (E-NPP2) DM8PET6 MA Inhibitor DM8PET6 RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM8PET6 RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM8PHBG DI DM8PHBG DM8PHBG DN Heterocycle-containing compound 1 DM8PHBG TI TT9O6WS DM8PHBG TN Glucagon receptor (GCGR) DM8PHBG MA Antagonist DM8PHBG RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DM8PHBG RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DM8PJ3F DI DM8PJ3F DM8PJ3F DN PMID28394193-Compound-22 DM8PJ3F TI TT9MZCQ DM8PJ3F TN Enhancer of zeste homolog 2 (EZH2) DM8PJ3F MA Inhibitor DM8PJ3F RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DM8PJ3F RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DM8POGS DI DM8POGS DM8POGS DN PMID25656651-Compound-10 DM8POGS TI TTS7G69 DM8POGS TN Fusion protein Bcr-Abl (Bcr-Abl) DM8POGS MA Inhibitor DM8POGS RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM8POGS RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM8PVN3 DI DM8PVN3 DM8PVN3 DN Cyclopropane 1-carboxylic acid derivative 4 DM8PVN3 TI TTIY56R DM8PVN3 TN Kynurenine 3-hydroxylase (KMO) DM8PVN3 MA Inhibitor DM8PVN3 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DM8PVN3 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DM8PZ46 DI DM8PZ46 DM8PZ46 DN PMID29473428-Compound-76 DM8PZ46 TI TTXNCBV DM8PZ46 TN Tryptophan 2,3-dioxygenase (TDO) DM8PZ46 MA Inhibitor DM8PZ46 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM8PZ46 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM8PZ46 DI DM8PZ46 DM8PZ46 DN PMID29473428-Compound-76 DM8PZ46 TI TTZJYKH DM8PZ46 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM8PZ46 MA Inhibitor DM8PZ46 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM8PZ46 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM8Q19H DI DM8Q19H DM8Q19H DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 4 DM8Q19H TI TTVDSZ0 DM8Q19H TN Poly [ADP-ribose] polymerase 1 (PARP1) DM8Q19H MA Inhibitor DM8Q19H RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM8Q19H RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTDZN01 DM8QZNC TN Cathepsin K (CTSK) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TT36ETB DM8QZNC TN Cathepsin L (CTSL) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTF2LRI DM8QZNC TN Cathepsin B (CTSB) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTUMQVO DM8QZNC TN Cathepsin S (CTSS) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTJOKD1 DM8QZNC TN Cathepsin F (CTSF) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8QZNC DI DM8QZNC DM8QZNC DN PMID27998201-Compound-12 DM8QZNC TI TTSD9T1 DM8QZNC TN Cathepsin V (CTSV) DM8QZNC MA Inhibitor DM8QZNC RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DM8QZNC RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DM8RAK0 DI DM8RAK0 DM8RAK0 DN PMID29053063-Compound-4 DM8RAK0 TI TTZ963I DM8RAK0 TN Monoglyceride lipase (MAGL) DM8RAK0 MA Inhibitor DM8RAK0 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DM8RAK0 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DM8RJTQ DI DM8RJTQ DM8RJTQ DN PMID26004420-Compound-U2014S0288042C DM8RJTQ TI TTJ13ST DM8RJTQ TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM8RJTQ MA Inhibitor DM8RJTQ RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM8RJTQ RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM8S7NQ DI DM8S7NQ DM8S7NQ DN Dihydropyrido pyrazinone compound 1 DM8S7NQ TI TTE4BSY DM8S7NQ TN Bromodomain and extraterminal domain protein (BET) DM8S7NQ MA Inhibitor DM8S7NQ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM8S7NQ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM8STUQ DI DM8STUQ DM8STUQ DN Amidine oxime derivative 1 DM8STUQ TI TT1RS9F DM8STUQ TN Acetylcholinesterase (AChE) DM8STUQ MA Reactivator DM8STUQ RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DM8STUQ RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DM8SWHO DI DM8SWHO DM8SWHO DN PMID26815044-Compound-115 DM8SWHO TI TTULVH8 DM8SWHO TN Tyrosinase (TYR) DM8SWHO MA Inhibitor DM8SWHO RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM8SWHO RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM8SZKU DI DM8SZKU DM8SZKU DN Pyrrolidinyl urea derivative 4 DM8SZKU TI TTTDVOJ DM8SZKU TN Tropomyosin-related kinase A (TrkA) DM8SZKU MA Inhibitor DM8SZKU RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM8SZKU RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM8T2LV DI DM8T2LV DM8T2LV DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 2 DM8T2LV TI TT6OEDT DM8T2LV TN Cannabinoid receptor 1 (CB1) DM8T2LV MA Antagonist DM8T2LV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM8T2LV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM8TQS4 DI DM8TQS4 DM8TQS4 DN Carboxamide derivative 7 DM8TQS4 TI TTG5QB7 DM8TQS4 TN Calpain-2 (CAPN2) DM8TQS4 MA Inhibitor DM8TQS4 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DM8TQS4 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DM8UI4Z DI DM8UI4Z DM8UI4Z DN PMID26560530-Compound-16 DM8UI4Z TI TT2F4OL DM8UI4Z TN Tissue transglutaminase (TG2) DM8UI4Z MA Inhibitor DM8UI4Z RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM8UI4Z RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM8UMQH DI DM8UMQH DM8UMQH DN PMID29671355-Compound-14 DM8UMQH TI TT5ZKDI DM8UMQH TN Histone deacetylase 6 (HDAC6) DM8UMQH MA Inhibitor DM8UMQH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM8UMQH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM8UOKE DI DM8UOKE DM8UOKE DN US9096594, 3 DM8UOKE TI TTFQEMX DM8UOKE TN Casein kinase I alpha (CSNK1A1) DM8UOKE MA Inhibitor DM8UOKE RN Kinase inhibitors and methods of use thereof. US9096594. DM8UOKE RU http://www.freepatentsonline.com/US9096594.html DM8UOY6 DI DM8UOY6 DM8UOY6 DN MHHFJYABEVJNEG-UHFFFAOYSA-N DM8UOY6 TI TTDYP7I DM8UOY6 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM8UOY6 MA Inhibitor DM8UOY6 RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DM8UOY6 RU http://www.freepatentsonline.com/US9150519.html DM8UPO3 DI DM8UPO3 DM8UPO3 DN PMID26161698-Compound-44 DM8UPO3 TI TTMBO1Z DM8UPO3 TN Cyclin-dependent kinase (CDK) DM8UPO3 MA Inhibitor DM8UPO3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM8UPO3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM8UPO3 DI DM8UPO3 DM8UPO3 DN PMID26161698-Compound-44 DM8UPO3 TI TTSMTDI DM8UPO3 TN CDC7-related kinase (CDC7) DM8UPO3 MA Inhibitor DM8UPO3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DM8UPO3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DM8UXZ3 DI DM8UXZ3 DM8UXZ3 DN Benzenamine derivative 3 DM8UXZ3 TI TTNR0UQ DM8UXZ3 TN Lysine-specific histone demethylase 1 (LSD) DM8UXZ3 MA Inhibitor DM8UXZ3 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM8UXZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM8V7QH DI DM8V7QH DM8V7QH DN PMID27828716-Compound-19 DM8V7QH TI TTRZQE3 DM8V7QH TN Glycogen synthase kinase-3 alpha (GSK-3A) DM8V7QH MA Inhibitor DM8V7QH RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM8V7QH RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM8VBU2 DI DM8VBU2 DM8VBU2 DN PMID29473428-Compound-80 DM8VBU2 TI TTZJYKH DM8VBU2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM8VBU2 MA Inhibitor DM8VBU2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM8VBU2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM8VG4Q DI DM8VG4Q DM8VG4Q DN PMID29671355-Compound-71b DM8VG4Q TI TTTQGH8 DM8VG4Q TN Histone deacetylase 4 (HDAC4) DM8VG4Q MA Inhibitor DM8VG4Q RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM8VG4Q RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM8VIM4 DI DM8VIM4 DM8VIM4 DN Tricyclic isoxazoloquinazoline derivative 4 DM8VIM4 TI TTP7EGM DM8VIM4 TN Dual specificity protein kinase TTK (MPS1) DM8VIM4 MA Inhibitor DM8VIM4 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM8VIM4 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM8VIM4 DI DM8VIM4 DM8VIM4 DN Tricyclic isoxazoloquinazoline derivative 4 DM8VIM4 TI TT5OU0D DM8VIM4 TN PRKR-like endoplasmic reticulum kinase (PERK) DM8VIM4 MA Inhibitor DM8VIM4 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DM8VIM4 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DM8VYMA DI DM8VYMA DM8VYMA DN Pyrrolo-pyrrolone derivative 2 DM8VYMA TI TTRA6BO DM8VYMA TN Bromodomain-containing protein 4 (BRD4) DM8VYMA MA Inhibitor DM8VYMA RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM8VYMA RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM8WH97 DI DM8WH97 DM8WH97 DN Quinazolinone derivative 4 DM8WH97 TI TTE4BSY DM8WH97 TN Bromodomain and extraterminal domain protein (BET) DM8WH97 MA Inhibitor DM8WH97 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM8WH97 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM8WKYT DI DM8WKYT DM8WKYT DN PMID29649907-Compound-37 DM8WKYT TI TTS4UGC DM8WKYT TN Farnesoid X-activated receptor (FXR) DM8WKYT MA Agonist DM8WKYT RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DM8WKYT RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DM8WP3D DI DM8WP3D DM8WP3D DN PMID26560530-Compound-27 DM8WP3D TI TT2F4OL DM8WP3D TN Tissue transglutaminase (TG2) DM8WP3D MA Inhibitor DM8WP3D RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM8WP3D RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM8X5GP DI DM8X5GP DM8X5GP DN 7-azaindole derivative 6 DM8X5GP TI TT056SO DM8X5GP TN Stress-activated protein kinase JNK3 (JNK3) DM8X5GP MA Inhibitor DM8X5GP RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM8X5GP RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM8XESD DI DM8XESD DM8XESD DN PMID25980951-Compound-42 DM8XESD TI TTR7B60 DM8XESD TN X-linked inhibitor of apoptosis protein (XIAP) DM8XESD MA Antagonist DM8XESD RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM8XESD RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM8XESD DI DM8XESD DM8XESD DN PMID25980951-Compound-42 DM8XESD TI TTQ5LRD DM8XESD TN Cellular inhibitor of apoptosis 1 (BIRC2) DM8XESD MA Antagonist DM8XESD RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM8XESD RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM8XJTH DI DM8XJTH DM8XJTH DN SPHINX scaffold, 3 DM8XJTH TI TTU3WV6 DM8XJTH TN SRSF protein kinase 1 (SRPK1) DM8XJTH MA Inhibitor DM8XJTH RN Piperazine derivatives for treating disorders. US9695160. DM8XJTH RU http://www.freepatentsonline.com/US9695160.html DM8YR1V DI DM8YR1V DM8YR1V DN PMID25991433-Compound-E2 DM8YR1V TI TT0K6EO DM8YR1V TN Stress-activated protein kinase JNK1 (JNK1) DM8YR1V MA Inhibitor DM8YR1V RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DM8YR1V RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DM8ZRXE DI DM8ZRXE DM8ZRXE DN Bicyclo-heptan-2-amine derivative 3 DM8ZRXE TI TT9NXW4 DM8ZRXE TN Sigma intracellular receptor 2 (TMEM97) DM8ZRXE MA Ligand DM8ZRXE RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM8ZRXE RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM8ZXBS DI DM8ZXBS DM8ZXBS DN Thiazole derivative 2 DM8ZXBS TI TTA6ZN2 DM8ZXBS TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM8ZXBS MA Inhibitor DM8ZXBS RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM8ZXBS RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM904T7 DI DM904T7 DM904T7 DN Peptide analog 24 DM904T7 TI TTSJMN8 DM904T7 TN Immunoproteasome complex (IP) DM904T7 MA Inhibitor DM904T7 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM904T7 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM90WKN DI DM90WKN DM90WKN DN Pyrimidine derivative 26 DM90WKN TI TT0K1SC DM90WKN TN 5-HT 2B receptor (HTR2B) DM90WKN MA Antagonist DM90WKN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM90WKN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM90WKN DI DM90WKN DM90WKN DN Pyrimidine derivative 26 DM90WKN TI TTWJBZ5 DM90WKN TN 5-HT 2C receptor (HTR2C) DM90WKN MA Antagonist DM90WKN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM90WKN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM90WKN DI DM90WKN DM90WKN DN Pyrimidine derivative 26 DM90WKN TI TTJQOD7 DM90WKN TN 5-HT 2A receptor (HTR2A) DM90WKN MA Antagonist DM90WKN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DM90WKN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DM913KS DI DM913KS DM913KS DN Piperazinyl methyl quinazolinone derivative 2 DM913KS TI TT9NXW4 DM913KS TN Sigma intracellular receptor 2 (TMEM97) DM913KS MA Ligand DM913KS RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM913KS RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM91Z8B DI DM91Z8B DM91Z8B DN 1,2,4-triazole derivative 2 DM91Z8B TI TT6OEDT DM91Z8B TN Cannabinoid receptor 1 (CB1) DM91Z8B MA Antagonist DM91Z8B RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM91Z8B RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM92F1C DI DM92F1C DM92F1C DN PMID25435285-Compound-47 DM92F1C TI TTXJ47W DM92F1C TN Metabotropic glutamate receptor 2 (mGluR2) DM92F1C MA Antagonist DM92F1C RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM92F1C RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM92HZG DI DM92HZG DM92HZG DN PMID25522065-Compound-13 DM92HZG TI TTX4RTB DM92HZG TN Melanin-concentrating hormone receptor 1 (MCHR1) DM92HZG MA Antagonist DM92HZG RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM92HZG RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM92OT0 DI DM92OT0 DM92OT0 DN PMID26560530-Compound-3 DM92OT0 TI TT2F4OL DM92OT0 TN Tissue transglutaminase (TG2) DM92OT0 MA Inhibitor DM92OT0 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM92OT0 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM92SWJ DI DM92SWJ DM92SWJ DN Purin-6-one derivative 1 DM92SWJ TI TTJGW1Z DM92SWJ TN Phosphodiesterase 2A (PDE2A) DM92SWJ MA Inhibitor DM92SWJ RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM92SWJ RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM9358G DI DM9358G DM9358G DN PMID25666693-Compound-123 DM9358G TI TTMI6F5 DM9358G TN Transient receptor potential cation channel V1 (TRPV1) DM9358G MA Antagonist DM9358G RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM9358G RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM93VEB DI DM93VEB DM93VEB DN Biphenyl mannoside derivative 6 DM93VEB TI TTTCRU2 DM93VEB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM93VEB MA Antagonist DM93VEB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM93VEB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM94MT3 DI DM94MT3 DM94MT3 DN PMID28074661-Compound-US20100022547C82 DM94MT3 TI TTL7C8Q DM94MT3 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM94MT3 MA Inhibitor DM94MT3 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM94MT3 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM94NZF DI DM94NZF DM94NZF DN Tricyclic phytocannabinoid derivative 1 DM94NZF TI TT6OEDT DM94NZF TN Cannabinoid receptor 1 (CB1) DM94NZF RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM94NZF RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM94NZF DI DM94NZF DM94NZF DN Tricyclic phytocannabinoid derivative 1 DM94NZF TI TTMSFAW DM94NZF TN Cannabinoid receptor 2 (CB2) DM94NZF RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM94NZF RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM94TKW DI DM94TKW DM94TKW DN Binuclear gold(I) compound 3 DM94TKW TI TTR7UJ3 DM94TKW TN Cytoplasmic thioredoxin reductase (TXNRD1) DM94TKW MA Inhibitor DM94TKW RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM94TKW RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM951HL DI DM951HL DM951HL DN Carbamide derivative 5 DM951HL TI TTL7C8Q DM951HL TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM951HL MA Inhibitor DM951HL RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM951HL RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM953EV DI DM953EV DM953EV DN Peptide analog 9 DM953EV TI TTSJMN8 DM953EV TN Immunoproteasome complex (IP) DM953EV MA Inhibitor DM953EV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM953EV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM954C8 DI DM954C8 DM954C8 DN PMID27019002-Compound-28a DM954C8 TI TTNR0UQ DM954C8 TN Lysine-specific histone demethylase 1 (LSD) DM954C8 MA Inhibitor DM954C8 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM954C8 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM95FIN DI DM95FIN DM95FIN DN PMID30107136-Compound-Example42 DM95FIN TI TT23XQV DM95FIN TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM95FIN MA Inhibitor DM95FIN RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM95FIN RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM95YLX DI DM95YLX DM95YLX DN US10071110, Compound cCDV DM95YLX TI TT5DOVB DM95YLX TN Cytomegalovirus Protease (CMV UL80) DM95YLX MA Inhibitor DM95YLX RN Phosphonate compounds. US10071110. DM95YLX RU http://www.freepatentsonline.com/US10071110.html DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TT8EPLT DM96KXE TN Proteasome beta-1 (PS beta-1) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TTOUSTQ DM96KXE TN Proteasome beta-9 (PS beta-9) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TT49BVC DM96KXE TN Proteasome beta-2 (PS beta-2) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TTEAD9J DM96KXE TN Proteasome beta-8 (PS beta-8) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM96KXE DI DM96KXE DM96KXE DN Peptide analog 41 DM96KXE TI TT68GPI DM96KXE TN Proteasome beta-5 (PS beta-5) DM96KXE MA Inhibitor DM96KXE RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM96KXE RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM97BIQ DI DM97BIQ DM97BIQ DN Biphenyl mannoside derivative 15 DM97BIQ TI TTTCRU2 DM97BIQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM97BIQ MA Antagonist DM97BIQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM97BIQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM982GD DI DM982GD DM982GD DN Indoline derivative 13 DM982GD TI TTOHSBA DM982GD TN Vascular endothelial growth factor A (VEGFA) DM982GD MA Inhibitor DM982GD RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM982GD RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM983CY DI DM983CY DM983CY DN Pyrrolo[2,3-d]pyrimidine derivative 11 DM983CY TI TTRMX3V DM983CY TN Janus kinase 2 (JAK-2) DM983CY MA Inhibitor DM983CY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM983CY RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM983CY DI DM983CY DM983CY DN Pyrrolo[2,3-d]pyrimidine derivative 11 DM983CY TI TT6DM01 DM983CY TN Janus kinase 1 (JAK-1) DM983CY MA Inhibitor DM983CY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM983CY RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM987MK DI DM987MK DM987MK DN Thiazole carboxamide derivative 18 DM987MK TI TTCZOF2 DM987MK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM987MK MA Inhibitor DM987MK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM987MK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM9A8L5 DI DM9A8L5 DM9A8L5 DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 1 DM9A8L5 TI TT6OEDT DM9A8L5 TN Cannabinoid receptor 1 (CB1) DM9A8L5 MA Antagonist DM9A8L5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM9A8L5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM9A8PN DI DM9A8PN DM9A8PN DN PMID26077642-Compound-Figure3G DM9A8PN TI TTZC0KV DM9A8PN TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DM9A8PN MA Inhibitor DM9A8PN RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM9A8PN RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM9ADSN DI DM9ADSN DM9ADSN DN PMID28270021-Compound-WO2016054807Example82 DM9ADSN TI TTTDVOJ DM9ADSN TN Tropomyosin-related kinase A (TrkA) DM9ADSN MA Inhibitor DM9ADSN RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DM9ADSN RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DM9AGBT DI DM9AGBT DM9AGBT DN Indoline derivative 16 DM9AGBT TI TTOHSBA DM9AGBT TN Vascular endothelial growth factor A (VEGFA) DM9AGBT MA Inhibitor DM9AGBT RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM9AGBT RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM9AJVK DI DM9AJVK DM9AJVK DN PMID26004420-Compound-WO2012058134C DM9AJVK TI TTJ13ST DM9AJVK TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DM9AJVK MA Inhibitor DM9AJVK RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DM9AJVK RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DM9BYJ0 DI DM9BYJ0 DM9BYJ0 DN Methyl 2-amino-4-phenylthiophene-3-carboxylate DM9BYJ0 TI TTUWGRA DM9BYJ0 TN Protein kinase C zeta (PRKCZ) DM9BYJ0 MA Inhibitor DM9BYJ0 RN Compounds, formulations, and methods of protein kinase C inhibition. US8889672. DM9BYJ0 RU http://www.freepatentsonline.com/US8889672.html DM9C4XH DI DM9C4XH DM9C4XH DN PMID27537201-Compound-Figure11 DM9C4XH TI TTPADOQ DM9C4XH TN HMG-CoA reductase (HMGCR) DM9C4XH MA Inhibitor DM9C4XH RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DM9C4XH RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DM9C5Z8 DI DM9C5Z8 DM9C5Z8 DN Selenium compound 1 DM9C5Z8 TI TTZHPB8 DM9C5Z8 TN Lysine-specific demethylase 4A (KDM4A) DM9C5Z8 MA Inhibitor DM9C5Z8 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DM9C5Z8 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DM9DC3U DI DM9DC3U DM9DC3U DN Fused heterocyclic compound 6 DM9DC3U TI TT7RJY8 DM9DC3U TN Xanthine dehydrogenase/oxidase (XDH) DM9DC3U MA Inhibitor DM9DC3U RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DM9DC3U RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TTEX248 DM9DJGU TN Dopamine D2 receptor (D2R) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TTSQIFT DM9DJGU TN 5-HT 1A receptor (HTR1A) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TTJQOD7 DM9DJGU TN 5-HT 2A receptor (HTR2A) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DJGU DI DM9DJGU DM9DJGU DN Aryl piperazine derivative 1 DM9DJGU TI TT4C8EA DM9DJGU TN Dopamine D3 receptor (D3R) DM9DJGU MA Ligand DM9DJGU RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DM9DJGU RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DM9DL1E DI DM9DL1E DM9DL1E DN PMID30107136-Compound-Example54 DM9DL1E TI TT23XQV DM9DL1E TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM9DL1E MA Inhibitor DM9DL1E RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM9DL1E RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM9E0ZD DI DM9E0ZD DM9E0ZD DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 DM9E0ZD TI TTJGW1Z DM9E0ZD TN Phosphodiesterase 2A (PDE2A) DM9E0ZD MA Inhibitor DM9E0ZD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM9E0ZD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM9E0ZD DI DM9E0ZD DM9E0ZD DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 5 DM9E0ZD TI TTJW4LU DM9E0ZD TN Phosphodiesterase 10A (PDE10) DM9E0ZD MA Inhibitor DM9E0ZD RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DM9E0ZD RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DM9EGVN DI DM9EGVN DM9EGVN DN Amidine compound 4 DM9EGVN TI TTQR74A DM9EGVN TN Proteinase activated receptor 2 (PAR2) DM9EGVN MA Antagonist DM9EGVN RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM9EGVN RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM9ESPR DI DM9ESPR DM9ESPR DN A1-10436 DM9ESPR TI TT0C8BY DM9ESPR TN Plasma retinol-binding protein (RBP4) DM9ESPR MA Inhibitor DM9ESPR RN Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215. DM9ESPR RU http://www.freepatentsonline.com/US8853215.html DM9FIKD DI DM9FIKD DM9FIKD DN PMID26651364-Compound-9e DM9FIKD TI TTTCRU2 DM9FIKD TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9FIKD MA Antagonist DM9FIKD RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9FIKD RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9FJXS DI DM9FJXS DM9FJXS DN Peptide analog 53 DM9FJXS TI TT2F4OL DM9FJXS TN Tissue transglutaminase (TG2) DM9FJXS MA Inhibitor DM9FJXS RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM9FJXS RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM9FL81 DI DM9FL81 DM9FL81 DN Peptide analog 38 DM9FL81 TI TT49BVC DM9FL81 TN Proteasome beta-2 (PS beta-2) DM9FL81 MA Inhibitor DM9FL81 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM9FL81 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM9FL81 DI DM9FL81 DM9FL81 DN Peptide analog 38 DM9FL81 TI TT68GPI DM9FL81 TN Proteasome beta-5 (PS beta-5) DM9FL81 MA Inhibitor DM9FL81 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM9FL81 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM9FL81 DI DM9FL81 DM9FL81 DN Peptide analog 38 DM9FL81 TI TTPNACM DM9FL81 TN Proteasome beta-10 (PS beta-10) DM9FL81 MA Inhibitor DM9FL81 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DM9FL81 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DM9FPK1 DI DM9FPK1 DM9FPK1 DN Benzothiazepine analog 1 DM9FPK1 TI TTPTXIN DM9FPK1 TN Translocator protein (TSPO) DM9FPK1 MA Ligand DM9FPK1 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM9FPK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM9FRN6 DI DM9FRN6 DM9FRN6 DN 2-hydroxybenzamide derivative 2 DM9FRN6 TI TTA6ZN2 DM9FRN6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9FRN6 MA Activator DM9FRN6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9FRN6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9FRN6 DI DM9FRN6 DM9FRN6 DN 2-hydroxybenzamide derivative 2 DM9FRN6 TI TT3Z6Y9 DM9FRN6 TN Cysteines of Keap1 (KEAP1 Cysteines) DM9FRN6 MA Modulator DM9FRN6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9FRN6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9FRV7 DI DM9FRV7 DM9FRV7 DN Imidazopyridine derivative 2 DM9FRV7 TI TTPTXIN DM9FRV7 TN Translocator protein (TSPO) DM9FRV7 MA Ligand DM9FRV7 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM9FRV7 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM9FXE7 DI DM9FXE7 DM9FXE7 DN Quinoline derivative 12 DM9FXE7 TI TT473XN DM9FXE7 TN P2X purinoceptor 7 (P2RX7) DM9FXE7 MA Antagonist DM9FXE7 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM9FXE7 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM9FXE7 DI DM9FXE7 DM9FXE7 DN Quinoline derivative 12 DM9FXE7 TI TTQ6VDM DM9FXE7 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM9FXE7 MA Antagonist DM9FXE7 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DM9FXE7 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DM9GLQB DI DM9GLQB DM9GLQB DN BDBM50444058 DM9GLQB TI TTIEMFN DM9GLQB TN TYRO3 tyrosine kinase receptor (TYRO3) DM9GLQB MA Inhibitor DM9GLQB RN Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309. DM9GLQB RU http://www.freepatentsonline.com/US9649309.html DM9GPKR DI DM9GPKR DM9GPKR DN 3-Hydroxy-2-butanone DM9GPKR TI TTGP7BY DM9GPKR TN Monoamine oxidase type B (MAO-B) DM9GPKR MA Inhibitor DM9GPKR RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9GPKR RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9GX0F DI DM9GX0F DM9GX0F DN PMID30185082-Compound-53 DM9GX0F TI TT9NXW4 DM9GX0F TN Sigma intracellular receptor 2 (TMEM97) DM9GX0F MA Ligand DM9GX0F RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM9GX0F RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM9H0Q3 DI DM9H0Q3 DM9H0Q3 DN Biphenyl mannoside derivative 29 DM9H0Q3 TI TTTCRU2 DM9H0Q3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9H0Q3 MA Antagonist DM9H0Q3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9H0Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9H3LI DI DM9H3LI DM9H3LI DN PMID29334795-Compound-61 DM9H3LI TI TT9JNIC DM9H3LI TN Histamine H3 receptor (H3R) DM9H3LI RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9H3LI RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9H3LI DI DM9H3LI DM9H3LI DN PMID29334795-Compound-61 DM9H3LI TI TTTIBOJ DM9H3LI TN Histamine H1 receptor (H1R) DM9H3LI RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9H3LI RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9H3LI DI DM9H3LI DM9H3LI DN PMID29334795-Compound-61 DM9H3LI TI TT3ROYC DM9H3LI TN Serotonin transporter (SERT) DM9H3LI RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9H3LI RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9HMB4 DI DM9HMB4 DM9HMB4 DN PMID30107136-Compound-Example2 DM9HMB4 TI TT8ZLTI DM9HMB4 TN Programmed cell death 1 ligand 1 (PD-L1) DM9HMB4 MA Inhibitor DM9HMB4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DM9HMB4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DM9HOM6 DI DM9HOM6 DM9HOM6 DN PMID25666693-Compound-11 DM9HOM6 TI TTMI6F5 DM9HOM6 TN Transient receptor potential cation channel V1 (TRPV1) DM9HOM6 MA Antagonist DM9HOM6 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM9HOM6 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM9HQXC DI DM9HQXC DM9HQXC DN US9434727, 63 DM9HQXC TI TT0C8BY DM9HQXC TN Plasma retinol-binding protein (RBP4) DM9HQXC MA Inhibitor DM9HQXC RN Substituted 4-phenylpiperidines, their preparation and use. US9434727. DM9HQXC RU http://www.freepatentsonline.com/US9434727.html DM9HRZJ DI DM9HRZJ DM9HRZJ DN PMID26924192-Compound-106 DM9HRZJ TI TTDP48B DM9HRZJ TN Bromodomain-containing protein 2 (BRD2) DM9HRZJ MA Inhibitor DM9HRZJ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM9HRZJ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM9HZ03 DI DM9HZ03 DM9HZ03 DN US9650366, 2 DM9HZ03 TI TTXEZJ4 DM9HZ03 TN Tyrosine-protein kinase EIF2AK2 (p68) DM9HZ03 MA Inhibitor DM9HZ03 RN Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366. DM9HZ03 RU http://www.freepatentsonline.com/US9650366.html DM9I4EV DI DM9I4EV DM9I4EV DN PMID25772215-Compound-US02014179750TG7-74 DM9I4EV TI TT1ZAVI DM9I4EV TN Prostaglandin E2 receptor EP2 (PTGER2) DM9I4EV MA Antagonist DM9I4EV RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DM9I4EV RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DM9IL5Q DI DM9IL5Q DM9IL5Q DN Heteroaromatic ring derivative 4 DM9IL5Q TI TTSCIM2 DM9IL5Q TN Extracellular lysophospholipase D (E-NPP2) DM9IL5Q MA Inhibitor DM9IL5Q RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DM9IL5Q RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DM9IPDU DI DM9IPDU DM9IPDU DN Heteroaryl-carboxamide derivative 6 DM9IPDU TI TTCZOF2 DM9IPDU TN Pyruvate dehydrogenase kinase 1 (PDHK1) DM9IPDU MA Inhibitor DM9IPDU RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DM9IPDU RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DM9J57W DI DM9J57W DM9J57W DN PMID26651364-Compound-6d DM9J57W TI TTTCRU2 DM9J57W TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9J57W MA Antagonist DM9J57W RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9J57W RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9JCL2 DI DM9JCL2 DM9JCL2 DN US9670220, 33 DM9JCL2 TI TTDYP7I DM9JCL2 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM9JCL2 MA Inhibitor DM9JCL2 RN Fused heterocyclic derivatives as S1P modulators. US9670220. DM9JCL2 RU http://www.freepatentsonline.com/US9670220.html DM9JHYL DI DM9JHYL DM9JHYL DN Pyrazole derivative 79 DM9JHYL TI TTXJ47W DM9JHYL TN Metabotropic glutamate receptor 2 (mGluR2) DM9JHYL MA Antagonist DM9JHYL RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM9JHYL RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM9K5BZ DI DM9K5BZ DM9K5BZ DN PMID27841036-Compound-XVII DM9K5BZ TI TTEBCY8 DM9K5BZ TN Poly [ADP-ribose] polymerase (PARP) DM9K5BZ MA Inhibitor DM9K5BZ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM9K5BZ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM9K5CI DI DM9K5CI DM9K5CI DN Pyrrolo-pyridine derivative 1 DM9K5CI TI TTK0FEA DM9K5CI TN Leucine-rich repeat kinase 2 (LRRK2) DM9K5CI MA Inhibitor DM9K5CI RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DM9K5CI RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DM9K7P0 DI DM9K7P0 DM9K7P0 DN Tricyclic compound 3 DM9K7P0 TI TT6DM01 DM9K7P0 TN Janus kinase 1 (JAK-1) DM9K7P0 MA Inhibitor DM9K7P0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DM9K7P0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DM9KAF1 DI DM9KAF1 DM9KAF1 DN PMID25553724-Compound-US2012810604610 DM9KAF1 TI TTSXVID DM9KAF1 TN Nuclear factor NF-kappa-B (NFKB) DM9KAF1 MA Inhibitor DM9KAF1 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM9KAF1 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM9KOYX DI DM9KOYX DM9KOYX DN Pyridine-amide derivative 1 DM9KOYX TI TTF8P9I DM9KOYX TN Diacylglycerol acyltransferase 1 (DGAT1) DM9KOYX MA Inhibitor DM9KOYX RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DM9KOYX RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DM9KSVI DI DM9KSVI DM9KSVI DN US8940736, 7 DM9KSVI TI TTR93NU DM9KSVI TN Casein kinase II alpha prime (CSNK2A2) DM9KSVI MA Inhibitor DM9KSVI RN Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736. DM9KSVI RU http://www.freepatentsonline.com/US8940736.html DM9KTRA DI DM9KTRA DM9KTRA DN PMID25399762-Compound-Figure3-Fluevirosine A DM9KTRA TI TT3WG5C DM9KTRA TN Monoamine oxidase type A (MAO-A) DM9KTRA MA Inhibitor DM9KTRA RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9KTRA RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9KVOD DI DM9KVOD DM9KVOD DN PMID29473428-Compound-4 DM9KVOD TI TTZJYKH DM9KVOD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM9KVOD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DM9KVOD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DM9L2VR DI DM9L2VR DM9L2VR DN PMID28454500-Compound-95 DM9L2VR TI TTA6ZN2 DM9L2VR TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9L2VR MA Inhibitor DM9L2VR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9L2VR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9L5KO DI DM9L5KO DM9L5KO DN 4-Hydroxy-2,5-dimethyl-3(2H)-furanone DM9L5KO TI TTGP7BY DM9L5KO TN Monoamine oxidase type B (MAO-B) DM9L5KO MA Inhibitor DM9L5KO RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9L5KO RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9LMNB DI DM9LMNB DM9LMNB DN PMID29671355-Compound-19 DM9LMNB TI TT6R7JZ DM9LMNB TN Histone deacetylase 1 (HDAC1) DM9LMNB MA Inhibitor DM9LMNB RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM9LMNB RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM9LMNB DI DM9LMNB DM9LMNB DN PMID29671355-Compound-19 DM9LMNB TI TT5ZKDI DM9LMNB TN Histone deacetylase 6 (HDAC6) DM9LMNB MA Inhibitor DM9LMNB RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DM9LMNB RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DM9LQCH DI DM9LQCH DM9LQCH DN Heteroaryl-pyrazole derivative 1 DM9LQCH TI TTXJ47W DM9LQCH TN Metabotropic glutamate receptor 2 (mGluR2) DM9LQCH MA Antagonist DM9LQCH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DM9LQCH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DM9LZJ5 DI DM9LZJ5 DM9LZJ5 DN PMID25666693-Compound-73 DM9LZJ5 TI TTMI6F5 DM9LZJ5 TN Transient receptor potential cation channel V1 (TRPV1) DM9LZJ5 MA Antagonist DM9LZJ5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DM9LZJ5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DM9MFDH DI DM9MFDH DM9MFDH DN Carbamate derivative 4 DM9MFDH TI TTGX13H DM9MFDH TN Fatty-acid amide hydrolase 1 (FAAH1) DM9MFDH MA Inhibitor DM9MFDH RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DM9MFDH RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DM9MFUN DI DM9MFUN DM9MFUN DN PMID25726713-Compound-17 DM9MFUN TI TTW6JVU DM9MFUN TN Smoothened D473H mutant (SMO D473H) DM9MFUN MA Antagonist DM9MFUN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM9MFUN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM9MFUN DI DM9MFUN DM9MFUN DN PMID25726713-Compound-17 DM9MFUN TI TT8J1S3 DM9MFUN TN Smoothened homolog (SMO) DM9MFUN MA Antagonist DM9MFUN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DM9MFUN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DM9MLQ6 DI DM9MLQ6 DM9MLQ6 DN PMID25522065-Compound-24 DM9MLQ6 TI TTX4RTB DM9MLQ6 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM9MLQ6 MA Antagonist DM9MLQ6 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DM9MLQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DM9NE5T DI DM9NE5T DM9NE5T DN Heteroaryl-cyclopropylamine derivative 2 DM9NE5T TI TTNR0UQ DM9NE5T TN Lysine-specific histone demethylase 1 (LSD) DM9NE5T MA Inhibitor DM9NE5T RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DM9NE5T RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DM9NEFG DI DM9NEFG DM9NEFG DN PMID27607364-Compound-65 DM9NEFG TI TTPTXIN DM9NEFG TN Translocator protein (TSPO) DM9NEFG MA Ligand DM9NEFG RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DM9NEFG RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DM9NGDI DI DM9NGDI DM9NGDI DN PMID25553724-Compound-US20130237529 36 DM9NGDI TI TTBP3XA DM9NGDI TN Polyubiquitin-C (UBC) DM9NGDI MA Inhibitor DM9NGDI RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DM9NGDI RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DM9NMHS DI DM9NMHS DM9NMHS DN Fused benzoheterocycle amide derivative 2 DM9NMHS TI TTKFVXR DM9NMHS TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM9NMHS MA Inhibitor DM9NMHS RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DM9NMHS RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DM9NOP3 DI DM9NOP3 DM9NOP3 DN Phenylsulfonyl derivative 1 DM9NOP3 TI TT9JNIC DM9NOP3 TN Histamine H3 receptor (H3R) DM9NOP3 MA Inhibitor DM9NOP3 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DM9NOP3 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DM9NWXM DI DM9NWXM DM9NWXM DN PMID26924192-Compound-33 DM9NWXM TI TTRA6BO DM9NWXM TN Bromodomain-containing protein 4 (BRD4) DM9NWXM MA Inhibitor DM9NWXM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM9NWXM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM9NWXM DI DM9NWXM DM9NWXM DN PMID26924192-Compound-33 DM9NWXM TI TTU6FSC DM9NWXM TN Extracellular signal-regulated kinase 5 (ERK5) DM9NWXM MA Inhibitor DM9NWXM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DM9NWXM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DM9O56W DI DM9O56W DM9O56W DN Carbamide derivative 10 DM9O56W TI TTL7C8Q DM9O56W TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM9O56W MA Inhibitor DM9O56W RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DM9O56W RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DM9OHAN DI DM9OHAN DM9OHAN DN PMID25416646-Compound-Figure5-A DM9OHAN TI TTZMAO3 DM9OHAN TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM9OHAN MA Agonist DM9OHAN RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM9OHAN RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM9OHAN DI DM9OHAN DM9OHAN DN PMID25416646-Compound-Figure5-A DM9OHAN TI TTJ584C DM9OHAN TN Peroxisome proliferator-activated receptor alpha (PPARA) DM9OHAN MA Agonist DM9OHAN RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM9OHAN RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM9OXAB DI DM9OXAB DM9OXAB DN Pyrazolo[1,5-a]pyrimidine derivative 27 DM9OXAB TI TTTDVOJ DM9OXAB TN Tropomyosin-related kinase A (TrkA) DM9OXAB MA Inhibitor DM9OXAB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DM9OXAB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DM9PHIK DI DM9PHIK DM9PHIK DN 1,2-diamino cyclopentane-based derivative 20 DM9PHIK TI TT9N02I DM9PHIK TN Orexin receptor type 2 (HCRTR2) DM9PHIK MA Antagonist DM9PHIK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM9PHIK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM9PHIK DI DM9PHIK DM9PHIK DN 1,2-diamino cyclopentane-based derivative 20 DM9PHIK TI TT60Q8D DM9PHIK TN Orexin receptor type 1 (HCRTR1) DM9PHIK MA Antagonist DM9PHIK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DM9PHIK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DM9PKU2 DI DM9PKU2 DM9PKU2 DN Benzamide derivative 10 DM9PKU2 TI TT9NXW4 DM9PKU2 TN Sigma intracellular receptor 2 (TMEM97) DM9PKU2 MA Ligand DM9PKU2 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM9PKU2 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM9PKU2 DI DM9PKU2 DM9PKU2 DN Benzamide derivative 10 DM9PKU2 TI TT5TPI6 DM9PKU2 TN Opioid receptor sigma 1 (OPRS1) DM9PKU2 MA Ligand DM9PKU2 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DM9PKU2 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DM9PL3F DI DM9PL3F DM9PL3F DN Benzimidazole derivative 4 DM9PL3F TI TTULVH8 DM9PL3F TN Tyrosinase (TYR) DM9PL3F MA Inhibitor DM9PL3F RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM9PL3F RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM9PNTF DI DM9PNTF DM9PNTF DN Pyrazole derivative 54 DM9PNTF TI TT6OEDT DM9PNTF TN Cannabinoid receptor 1 (CB1) DM9PNTF MA Antagonist DM9PNTF RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DM9PNTF RU https://pubmed.ncbi.nlm.nih.gov/26161824 DM9PSI3 DI DM9PSI3 DM9PSI3 DN Quinoline and quinazoline derivative 2 DM9PSI3 TI TTOHSBA DM9PSI3 TN Vascular endothelial growth factor A (VEGFA) DM9PSI3 MA Inhibitor DM9PSI3 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DM9PSI3 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DM9Q0EC DI DM9Q0EC DM9Q0EC DN AC1LJNG0 DM9Q0EC TI TT1NFO3 DM9Q0EC TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DM9Q0EC MA Inhibitor DM9Q0EC RN Targeting NAD biosynthesis in bacterial pathogens. US8785499. DM9Q0EC RU http://www.freepatentsonline.com/US8785499.html DM9Q0JS DI DM9Q0JS DM9Q0JS DN Peptidomimetic analog 4 DM9Q0JS TI TTH8FZW DM9Q0JS TN Signal transducer and activator of transcription 3 (STAT3) DM9Q0JS MA Inhibitor DM9Q0JS RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM9Q0JS RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM9QB2S DI DM9QB2S DM9QB2S DN Triazole derivative 1 DM9QB2S TI TT2F4OL DM9QB2S TN Tissue transglutaminase (TG2) DM9QB2S MA Inhibitor DM9QB2S RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DM9QB2S RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DM9QCTJ DI DM9QCTJ DM9QCTJ DN US10065972, Example 560 DM9QCTJ TI TTT3IXG DM9QCTJ TN Kynurenine oxoglutarate transaminase II (AADAT) DM9QCTJ MA Inhibitor DM9QCTJ RN Bicyclic or tricyclic heterocyclic compound. US10065972. DM9QCTJ RU http://www.freepatentsonline.com/US10065972.html DM9QEIV DI DM9QEIV DM9QEIV DN PMID27376512-Compound-asCEBP-2HPE DM9QEIV TI TT6S2FE DM9QEIV TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM9QEIV MA Inhibitor DM9QEIV RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9QEIV RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9QM6I DI DM9QM6I DM9QM6I DN PMID27336223-Compound-7 DM9QM6I TI TTISP28 DM9QM6I TN Retinoic acid receptor beta (RARB) DM9QM6I MA Agonist DM9QM6I RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DM9QM6I RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DM9RIF4 DI DM9RIF4 DM9RIF4 DN US9132129, Cpd002 DM9RIF4 TI TTH9LDP DM9RIF4 TN PC4 and SFRS1-interacting protein (PSIP1) DM9RIF4 MA Inhibitor DM9RIF4 RN Antiviral compounds. US9132129. DM9RIF4 RU http://www.freepatentsonline.com/US9132129.html DM9RSDX DI DM9RSDX DM9RSDX DN PMID27376512-Compound-MTC-423 DM9RSDX TI TTJUALD DM9RSDX TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DM9RSDX MA Inhibitor DM9RSDX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9RSDX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9RSDX DI DM9RSDX DM9RSDX DN PMID27376512-Compound-MTC-423 DM9RSDX TI TT6VZ78 DM9RSDX TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM9RSDX MA Inhibitor DM9RSDX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9RSDX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9RSDX DI DM9RSDX DM9RSDX DN PMID27376512-Compound-MTC-423 DM9RSDX TI TT6S2FE DM9RSDX TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DM9RSDX MA Inhibitor DM9RSDX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DM9RSDX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DM9RZSH DI DM9RZSH DM9RZSH DN PMID25980951-Compound-4 DM9RZSH TI TTR7B60 DM9RZSH TN X-linked inhibitor of apoptosis protein (XIAP) DM9RZSH MA Antagonist DM9RZSH RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM9RZSH RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM9RZSH DI DM9RZSH DM9RZSH DN PMID25980951-Compound-4 DM9RZSH TI TTQ5LRD DM9RZSH TN Cellular inhibitor of apoptosis 1 (BIRC2) DM9RZSH MA Antagonist DM9RZSH RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DM9RZSH RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DM9S07A DI DM9S07A DM9S07A DN Pyrrolo[2,3-d]pyrimidine derivative 21 DM9S07A TI TTGM6VW DM9S07A TN Tyrosine-protein kinase BTK (ATK) DM9S07A MA Inhibitor DM9S07A RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DM9S07A RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DM9S2UP DI DM9S2UP DM9S2UP DN PMID27977313-Compound-44 DM9S2UP TI TTR7UJ3 DM9S2UP TN Cytoplasmic thioredoxin reductase (TXNRD1) DM9S2UP MA Inhibitor DM9S2UP RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DM9S2UP RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DM9SXYH DI DM9SXYH DM9SXYH DN Imidazopyridazine derivative 5 DM9SXYH TI TTQR74A DM9SXYH TN Proteinase activated receptor 2 (PAR2) DM9SXYH MA Antagonist DM9SXYH RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DM9SXYH RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DM9TJR5 DI DM9TJR5 DM9TJR5 DN PMID26651364-Compound-5e DM9TJR5 TI TTTCRU2 DM9TJR5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9TJR5 MA Antagonist DM9TJR5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9TJR5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9TVWJ DI DM9TVWJ DM9TVWJ DN PMID28454500-Compound-40 DM9TVWJ TI TTA6ZN2 DM9TVWJ TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DM9TVWJ MA Activator DM9TVWJ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9TVWJ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9TVWJ DI DM9TVWJ DM9TVWJ DN PMID28454500-Compound-40 DM9TVWJ TI TT3Z6Y9 DM9TVWJ TN Cysteines of Keap1 (KEAP1 Cysteines) DM9TVWJ MA Modulator DM9TVWJ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DM9TVWJ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DM9TW5O DI DM9TW5O DM9TW5O DN Pyrimidinyl compound 2 DM9TW5O TI TTH5TC2 DM9TW5O TN NF-kappa-B-activating kinase (TBK1) DM9TW5O MA Inhibitor DM9TW5O RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DM9TW5O RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DM9U4OZ DI DM9U4OZ DM9U4OZ DN Gold-complexed thiosaccharide derivative 2 DM9U4OZ TI TTH8FZW DM9U4OZ TN Signal transducer and activator of transcription 3 (STAT3) DM9U4OZ MA Inhibitor DM9U4OZ RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM9U4OZ RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM9V13U DI DM9V13U DM9V13U DN PMID26560362-Compound-90 DM9V13U TI TTN9T81 DM9V13U TN Arachidonate 15-lipoxygenase (15-LOX) DM9V13U MA Inhibitor DM9V13U RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DM9V13U RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DM9VMJ3 DI DM9VMJ3 DM9VMJ3 DN PMID27841036-Compound-24 DM9VMJ3 TI TTEBCY8 DM9VMJ3 TN Poly [ADP-ribose] polymerase (PARP) DM9VMJ3 MA Inhibitor DM9VMJ3 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DM9VMJ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DM9VXY7 DI DM9VXY7 DM9VXY7 DN PMID27828716-Compound-16 DM9VXY7 TI TTRZQE3 DM9VXY7 TN Glycogen synthase kinase-3 alpha (GSK-3A) DM9VXY7 MA Inhibitor DM9VXY7 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DM9VXY7 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DM9W1FO DI DM9W1FO DM9W1FO DN Beta-cyclodextrin conjugate derivative 2 DM9W1FO TI TTTCRU2 DM9W1FO TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9W1FO MA Antagonist DM9W1FO RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9W1FO RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9WMJ1 DI DM9WMJ1 DM9WMJ1 DN Ethylvanillin DM9WMJ1 TI TTGP7BY DM9WMJ1 TN Monoamine oxidase type B (MAO-B) DM9WMJ1 MA Inhibitor DM9WMJ1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM9WMJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM9WUH5 DI DM9WUH5 DM9WUH5 DN Bicyclo-heptan-2-amine derivative 2 DM9WUH5 TI TT9NXW4 DM9WUH5 TN Sigma intracellular receptor 2 (TMEM97) DM9WUH5 MA Ligand DM9WUH5 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM9WUH5 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM9XBL4 DI DM9XBL4 DM9XBL4 DN Tricyclic heterocycle derivative 4 DM9XBL4 TI TTVSYP9 DM9XBL4 TN Ubiquitin carboxyl-terminal hydrolase 14 (USP14) DM9XBL4 MA Inhibitor DM9XBL4 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DM9XBL4 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DM9XQBG DI DM9XQBG DM9XQBG DN Quinoline carboxamide derivative 2 DM9XQBG TI TTH8FZW DM9XQBG TN Signal transducer and activator of transcription 3 (STAT3) DM9XQBG MA Inhibitor DM9XQBG RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DM9XQBG RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DM9XRYU DI DM9XRYU DM9XRYU DN PMID25656651-Compound-16a DM9XRYU TI TTS7G69 DM9XRYU TN Fusion protein Bcr-Abl (Bcr-Abl) DM9XRYU MA Inhibitor DM9XRYU RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DM9XRYU RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DM9XUYM DI DM9XUYM DM9XUYM DN 2,2-dimethylbenzopyran derivative 2 DM9XUYM TI TTUX68I DM9XUYM TN Hypoxia-inducible factor 1 (HIF-1) DM9XUYM MA Inhibitor DM9XUYM RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DM9XUYM RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DM9Y4ZV DI DM9Y4ZV DM9Y4ZV DN Piperazine derivative 7 DM9Y4ZV TI TT9NXW4 DM9Y4ZV TN Sigma intracellular receptor 2 (TMEM97) DM9Y4ZV MA Ligand DM9Y4ZV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM9Y4ZV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM9Y4ZV DI DM9Y4ZV DM9Y4ZV DN Piperazine derivative 7 DM9Y4ZV TI TT5TPI6 DM9Y4ZV TN Opioid receptor sigma 1 (OPRS1) DM9Y4ZV MA Ligand DM9Y4ZV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DM9Y4ZV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DM9YD0Q DI DM9YD0Q DM9YD0Q DN Diazepinone derivative 1 DM9YD0Q TI TTHS256 DM9YD0Q TN Metabotropic glutamate receptor 5 (mGluR5) DM9YD0Q MA Modulator DM9YD0Q RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DM9YD0Q RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DM9YI3K DI DM9YI3K DM9YI3K DN US8598210, Table XV, 1 DM9YI3K TI TT9ISBX DM9YI3K TN HIF-prolyl hydroxylase 2 (HPH-2) DM9YI3K MA Inhibitor DM9YI3K RN Prolyl hydroxylase inhibitors and methods of use. US8598210. DM9YI3K RU http://www.freepatentsonline.com/US8598210.html DM9YJWU DI DM9YJWU DM9YJWU DN 3-(phenoxymethyl) benzylamine derivative 1 DM9YJWU TI TTULVH8 DM9YJWU TN Tyrosinase (TYR) DM9YJWU MA Inhibitor DM9YJWU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DM9YJWU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DM9YS40 DI DM9YS40 DM9YS40 DN Aryl mannoside derivative 7 DM9YS40 TI TTTCRU2 DM9YS40 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DM9YS40 MA Antagonist DM9YS40 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DM9YS40 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM9ZF3P DI DM9ZF3P DM9ZF3P DN PMID27215781-Compound-28 DM9ZF3P TI TTMSFAW DM9ZF3P TN Cannabinoid receptor 2 (CB2) DM9ZF3P MA Agonist DM9ZF3P RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DM9ZF3P RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DM9ZXOP DI DM9ZXOP DM9ZXOP DN PMID28048944-Compound-2 DM9ZXOP TI TTZN7RP DM9ZXOP TN Rho-associated protein kinase 1 (ROCK1) DM9ZXOP MA Inhibitor DM9ZXOP RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM9ZXOP RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DM9ZXOP DI DM9ZXOP DM9ZXOP DN PMID28048944-Compound-2 DM9ZXOP TI TTGWKQJ DM9ZXOP TN Rho-associated protein kinase 2 (ROCK2) DM9ZXOP MA Inhibitor DM9ZXOP RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DM9ZXOP RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMA02ED DI DMA02ED DMA02ED DN PMID26666989-Compound-Figure9middle07 DMA02ED TI TT8BUGW DMA02ED TN Glycogen phosphorylase (PYG) DMA02ED MA Inhibitor DMA02ED RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMA02ED RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMA04P6 DI DMA04P6 DMA04P6 DN PMID28270021-Compound-WO2014152663 701 DMA04P6 TI TTTDVOJ DMA04P6 TN Tropomyosin-related kinase A (TrkA) DMA04P6 MA Inhibitor DMA04P6 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMA04P6 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMA0RI8 DI DMA0RI8 DMA0RI8 DN PMID29649907-Compound-INT767 DMA0RI8 TI TTS4UGC DMA0RI8 TN Farnesoid X-activated receptor (FXR) DMA0RI8 MA Agonist DMA0RI8 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMA0RI8 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMA0RI8 DI DMA0RI8 DMA0RI8 DN PMID29649907-Compound-INT767 DMA0RI8 TI TTSDVTR DMA0RI8 TN G-protein coupled bile acid receptor 1 (GPBAR1) DMA0RI8 MA Agonist DMA0RI8 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMA0RI8 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMA0V4F DI DMA0V4F DMA0V4F DN Imidazopyridine derivative 6 DMA0V4F TI TTYLQ8V DMA0V4F TN Prostaglandin E synthase (PTGES) DMA0V4F MA Inhibitor DMA0V4F RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMA0V4F RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMA1FRM DI DMA1FRM DMA1FRM DN PMID28460551-Compound-3 DMA1FRM TI TTFJ8Q1 DMA1FRM TN Protein kinase C alpha (PRKCA) DMA1FRM MA Inhibitor DMA1FRM RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMA1FRM RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMA1OEF DI DMA1OEF DMA1OEF DN Phthalazine derivative 3 DMA1OEF TI TTVDSZ0 DMA1OEF TN Poly [ADP-ribose] polymerase 1 (PARP1) DMA1OEF MA Inhibitor DMA1OEF RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMA1OEF RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMA1RP9 DI DMA1RP9 DMA1RP9 DN PMID28350212-Compound-16 DMA1RP9 TI TTZS04O DMA1RP9 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMA1RP9 MA Inhibitor DMA1RP9 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMA1RP9 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMA1RVN DI DMA1RVN DMA1RVN DN Ac-YVAD-cmk DMA1RVN TI TTCQIBE DMA1RVN TN Caspase-1 (CASP1) DMA1RVN MA Inhibitor DMA1RVN RN Caspase inhibitors: a review of recently patented compounds (2013-2015).Expert Opin Ther Pat. 2018 Jan;28(1):47-59. DMA1RVN RU https://www.ncbi.nlm.nih.gov/pubmed/28885866 DMA1S6Q DI DMA1S6Q DMA1S6Q DN Dihydropyrimidinone derivative 3 DMA1S6Q TI TTJOW1I DMA1S6Q TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMA1S6Q MA Inhibitor DMA1S6Q RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMA1S6Q RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMA25XH DI DMA25XH DMA25XH DN Dihydropyrimidinone derivative 1 DMA25XH TI TTPLTSQ DMA25XH TN Neutrophil elastase (NE) DMA25XH MA Inhibitor DMA25XH RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMA25XH RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMA2IMQ DI DMA2IMQ DMA2IMQ DN PMID25623274-Compound-WO2014132220C1 DMA2IMQ TI TTI2WET DMA2IMQ TN Platelet-derived growth factor receptor (PDGFR) DMA2IMQ MA Inhibitor DMA2IMQ RN Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9. DMA2IMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25623274 DMA2JGU DI DMA2JGU DMA2JGU DN Azaindole derivative 7 DMA2JGU TI TT7RJY8 DMA2JGU TN Xanthine dehydrogenase/oxidase (XDH) DMA2JGU MA Inhibitor DMA2JGU RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMA2JGU RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMA32GJ DI DMA32GJ DMA32GJ DN Sulfonamide derivative 10 DMA32GJ TI TTA592U DMA32GJ TN Urate anion exchanger 1 (URAT1) DMA32GJ MA Inhibitor DMA32GJ RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMA32GJ RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMA360M DI DMA360M DMA360M DN PMID28092474-Compound-33f DMA360M TI TT5ZKDI DMA360M TN Histone deacetylase 6 (HDAC6) DMA360M MA Inhibitor DMA360M RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMA360M RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMA360M DI DMA360M DMA360M DN PMID28092474-Compound-33f DMA360M TI TT6R7JZ DMA360M TN Histone deacetylase 1 (HDAC1) DMA360M MA Inhibitor DMA360M RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMA360M RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMA3BCU DI DMA3BCU DMA3BCU DN Benzazepine derivative 1 DMA3BCU TI TTWJBZ5 DMA3BCU TN 5-HT 2C receptor (HTR2C) DMA3BCU MA Agonist DMA3BCU RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMA3BCU RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMA3OI4 DI DMA3OI4 DMA3OI4 DN US9359293, TA DMA3OI4 TI TTLKF5M DMA3OI4 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMA3OI4 MA Inhibitor DMA3OI4 RN Methods of treatment using modulators of SIRT2. US9359293. DMA3OI4 RU http://www.freepatentsonline.com/US9359293.html DMA3PE7 DI DMA3PE7 DMA3PE7 DN Ethinyl-pyrazole derivative 2 DMA3PE7 TI TTXJ47W DMA3PE7 TN Metabotropic glutamate receptor 2 (mGluR2) DMA3PE7 MA Antagonist DMA3PE7 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMA3PE7 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMA423P DI DMA423P DMA423P DN PMID28766366-Compound-Scheme15-3 DMA423P TI TTSBVFO DMA423P TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMA423P MA Inhibitor DMA423P RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMA423P RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMA42SB DI DMA42SB DMA42SB DN 1,2,4-oxadiazole derivative 2 DMA42SB TI TTNBFWK DMA42SB TN Programmed cell death protein 1 (PD-1) DMA42SB MA Inhibitor DMA42SB RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMA42SB RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMA430E DI DMA430E DMA430E DN Azetidine-benzoxazin-3(4H)-one derivative 3 DMA430E TI TTZ963I DMA430E TN Monoglyceride lipase (MAGL) DMA430E MA Inhibitor DMA430E RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMA430E RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMA59QF DI DMA59QF DMA59QF DN PMID26666989-Compound-Figure11topright DMA59QF TI TT8BUGW DMA59QF TN Glycogen phosphorylase (PYG) DMA59QF MA Inhibitor DMA59QF RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMA59QF RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMA6BCH DI DMA6BCH DMA6BCH DN Indandione derivative 1 DMA6BCH TI TTV1C0Z DMA6BCH TN Neuropeptide S receptor (NPSR) DMA6BCH MA Antagonist DMA6BCH RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMA6BCH RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMA6H4W DI DMA6H4W DMA6H4W DN PMID29649907-Compound-9 DMA6H4W TI TTS4UGC DMA6H4W TN Farnesoid X-activated receptor (FXR) DMA6H4W MA Agonist DMA6H4W RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMA6H4W RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMA749P DI DMA749P DMA749P DN 3-phenyl isoquinolin-1(2H) derivative 2 DMA749P TI TTVDSZ0 DMA749P TN Poly [ADP-ribose] polymerase 1 (PARP1) DMA749P MA Inhibitor DMA749P RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMA749P RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMA78MD DI DMA78MD DMA78MD DN Isoflavone derivative 9 DMA78MD TI TTJOMH6 DMA78MD TN Zinc finger protein GLI1 (Gli1) DMA78MD MA Inhibitor DMA78MD RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMA78MD RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMA78MD DI DMA78MD DMA78MD DN Isoflavone derivative 9 DMA78MD TI TT8J1S3 DMA78MD TN Smoothened homolog (SMO) DMA78MD MA Inhibitor DMA78MD RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMA78MD RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMA7D3K DI DMA7D3K DMA7D3K DN PMID26651364-Compound-108 DMA7D3K TI TTTCRU2 DMA7D3K TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMA7D3K MA Antagonist DMA7D3K RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMA7D3K RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMA7DI6 DI DMA7DI6 DMA7DI6 DN Imidazo bicyclic iminium derivative 2 DMA7DI6 TI TTJOMH6 DMA7DI6 TN Zinc finger protein GLI1 (Gli1) DMA7DI6 MA Inhibitor DMA7DI6 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMA7DI6 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMA7H63 DI DMA7H63 DMA7H63 DN PMID27551786-Compound-I DMA7H63 TI TT26PHO DMA7H63 TN Mineralocorticoid receptor (MR) DMA7H63 MA Antagonist DMA7H63 RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DMA7H63 RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DMA7H9T DI DMA7H9T DMA7H9T DN PMID28394193-Compound-12 DMA7H9T TI TT9MZCQ DMA7H9T TN Enhancer of zeste homolog 2 (EZH2) DMA7H9T MA Inhibitor DMA7H9T RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMA7H9T RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMA7H9T DI DMA7H9T DMA7H9T DN PMID28394193-Compound-12 DMA7H9T TI TTJBYRU DMA7H9T TN EZH2 Y641F mutant (EZH2 Y641F) DMA7H9T MA Inhibitor DMA7H9T RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMA7H9T RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMA7JB6 DI DMA7JB6 DMA7JB6 DN BDBM50054344 DMA7JB6 TI TT369M5 DMA7JB6 TN Protein-tyrosine phosphatase SHP-1 (PTPN6) DMA7JB6 MA Inhibitor DMA7JB6 RN Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). US9522881. DMA7JB6 RU http://www.freepatentsonline.com/US9522881.html DMA7OEF DI DMA7OEF DMA7OEF DN PMID28447479-Compound-10 DMA7OEF TI TTSCIM2 DMA7OEF TN Extracellular lysophospholipase D (E-NPP2) DMA7OEF MA Inhibitor DMA7OEF RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMA7OEF RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMA83QK DI DMA83QK DMA83QK DN Triazole derivative 5 DMA83QK TI TTSCIUP DMA83QK TN Oxytocin receptor (OTR) DMA83QK MA Antagonist DMA83QK RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMA83QK RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMA85UD DI DMA85UD DMA85UD DN N-(pyridinepyrroylylcarbonyl)-piperidine derivative 1 DMA85UD TI TT5ZWB6 DMA85UD TN Dihydrodiol dehydrogenase type I (AKR1C3) DMA85UD MA Inhibitor DMA85UD RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMA85UD RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMA89WQ DI DMA89WQ DMA89WQ DN Cyclopropylamine derivative 8 DMA89WQ TI TTNR0UQ DMA89WQ TN Lysine-specific histone demethylase 1 (LSD) DMA89WQ MA Inhibitor DMA89WQ RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMA89WQ RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMA8BLZ DI DMA8BLZ DMA8BLZ DN MyriberineA DMA8BLZ TI TT3WG5C DMA8BLZ TN Monoamine oxidase type A (MAO-A) DMA8BLZ MA Inhibitor DMA8BLZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMA8BLZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMA8G6B DI DMA8G6B DMA8G6B DN PMID25522065-Compound-5 DMA8G6B TI TTX4RTB DMA8G6B TN Melanin-concentrating hormone receptor 1 (MCHR1) DMA8G6B MA Antagonist DMA8G6B RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMA8G6B RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMA8JGP DI DMA8JGP DMA8JGP DN PMID26560530-Compound-12 DMA8JGP TI TT2F4OL DMA8JGP TN Tissue transglutaminase (TG2) DMA8JGP MA Inhibitor DMA8JGP RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMA8JGP RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMA91FM DI DMA91FM DMA91FM DN YYDJCLCSBYCSCO-UHFFFAOYSA-N DMA91FM TI TTDYP7I DMA91FM TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMA91FM MA Inhibitor DMA91FM RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DMA91FM RU http://www.freepatentsonline.com/US9150519.html DMA91IJ DI DMA91IJ DMA91IJ DN Heterocyclic-carboxamide derivative 1 DMA91IJ TI TTCZOF2 DMA91IJ TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMA91IJ MA Inhibitor DMA91IJ RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMA91IJ RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMA91X2 DI DMA91X2 DMA91X2 DN PMID28447479-Compound-14 DMA91X2 TI TTSCIM2 DMA91X2 TN Extracellular lysophospholipase D (E-NPP2) DMA91X2 MA Inhibitor DMA91X2 RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMA91X2 RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMA9B0V DI DMA9B0V DMA9B0V DN Aryl azepine derivative 1 DMA9B0V TI TT9NXW4 DMA9B0V TN Sigma intracellular receptor 2 (TMEM97) DMA9B0V MA Ligand DMA9B0V RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMA9B0V RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMA9PM4 DI DMA9PM4 DMA9PM4 DN Pyrrolo[2,3-d]pyrimidine derivative 31 DMA9PM4 TI TTGM6VW DMA9PM4 TN Tyrosine-protein kinase BTK (ATK) DMA9PM4 MA Inhibitor DMA9PM4 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMA9PM4 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMA9YDK DI DMA9YDK DMA9YDK DN PMID25666693-Compound-114 DMA9YDK TI TTMI6F5 DMA9YDK TN Transient receptor potential cation channel V1 (TRPV1) DMA9YDK MA Antagonist DMA9YDK RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMA9YDK RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMAB2EN DI DMAB2EN DMAB2EN DN Pyrazole derivative 75 DMAB2EN TI TTJQOD7 DMAB2EN TN 5-HT 2A receptor (HTR2A) DMAB2EN MA Antagonist DMAB2EN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMAB2EN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMAB3YG DI DMAB3YG DMAB3YG DN Pyrazoline derivative 11 DMAB3YG TI TT6OEDT DMAB3YG TN Cannabinoid receptor 1 (CB1) DMAB3YG MA Antagonist DMAB3YG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMAB3YG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMAB8QF DI DMAB8QF DMAB8QF DN 1,3,4-thiadiazole derivative 1 DMAB8QF TI TT23XQV DMAB8QF TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMAB8QF MA Inhibitor DMAB8QF RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMAB8QF RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMAB987 DI DMAB987 DMAB987 DN PMID28048944-Compound-5 DMAB987 TI TTZN7RP DMAB987 TN Rho-associated protein kinase 1 (ROCK1) DMAB987 MA Inhibitor DMAB987 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMAB987 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMAB987 DI DMAB987 DMAB987 DN PMID28048944-Compound-5 DMAB987 TI TTGWKQJ DMAB987 TN Rho-associated protein kinase 2 (ROCK2) DMAB987 MA Inhibitor DMAB987 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMAB987 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMACWQY DI DMACWQY DMACWQY DN PMID25991433-Compound-G4 DMACWQY TI TT0K6EO DMACWQY TN Stress-activated protein kinase JNK1 (JNK1) DMACWQY MA Inhibitor DMACWQY RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMACWQY RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMAD3VL DI DMAD3VL DMAD3VL DN US9695118, 8 DMAD3VL TI TTI1FPZ DMAD3VL TN Epithelial discoidin domain receptor 1 (DDR1) DMAD3VL MA Inhibitor DMAD3VL RN Benzamide derivative. US9695118. DMAD3VL RU http://www.freepatentsonline.com/US9695118.html DMADMWB DI DMADMWB DMADMWB DN PMID28092474-Compound-32m DMADMWB TI TT6R7JZ DMADMWB TN Histone deacetylase 1 (HDAC1) DMADMWB MA Inhibitor DMADMWB RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMADMWB RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMADMWB DI DMADMWB DMADMWB DN PMID28092474-Compound-32m DMADMWB TI TT5ZKDI DMADMWB TN Histone deacetylase 6 (HDAC6) DMADMWB MA Inhibitor DMADMWB RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMADMWB RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMAE6CK DI DMAE6CK DMAE6CK DN US20160326143, 28 DMAE6CK TI TTW7OTG DMAE6CK TN Leukotriene C4 synthase (LTC4S) DMAE6CK MA Inhibitor DMAE6CK RN COMPOUNDS AND USES. US20160326143. DMAE6CK RU http://www.freepatentsonline.com/US20160326143.html DMAEBJ4 DI DMAEBJ4 DMAEBJ4 DN Benzamide derivative 15 DMAEBJ4 TI TTYLQ8V DMAEBJ4 TN Prostaglandin E synthase (PTGES) DMAEBJ4 MA Inhibitor DMAEBJ4 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMAEBJ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMAEHCP DI DMAEHCP DMAEHCP DN US8791257, 38 DMAEHCP TI TTR93NU DMAEHCP TN Casein kinase II alpha prime (CSNK2A2) DMAEHCP MA Inhibitor DMAEHCP RN Substituted pyrrolotriazines as protein kinase inhibitors. US8791257. DMAEHCP RU http://www.freepatentsonline.com/US8791257.html DMAEPD4 DI DMAEPD4 DMAEPD4 DN PMID29671355-Compound-15 DMAEPD4 TI TT5ZKDI DMAEPD4 TN Histone deacetylase 6 (HDAC6) DMAEPD4 MA Inhibitor DMAEPD4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMAEPD4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMAEQ0I DI DMAEQ0I DMAEQ0I DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 2 DMAEQ0I TI TTULVH8 DMAEQ0I TN Tyrosinase (TYR) DMAEQ0I MA Inhibitor DMAEQ0I RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMAEQ0I RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMAEYNT DI DMAEYNT DMAEYNT DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 DMAEYNT TI TTJW4LU DMAEYNT TN Phosphodiesterase 10A (PDE10) DMAEYNT MA Inhibitor DMAEYNT RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMAEYNT RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMAEYNT DI DMAEYNT DMAEYNT DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 3 DMAEYNT TI TTJGW1Z DMAEYNT TN Phosphodiesterase 2A (PDE2A) DMAEYNT MA Inhibitor DMAEYNT RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMAEYNT RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMAEZB1 DI DMAEZB1 DMAEZB1 DN PMID25514969-Compound-9 DMAEZB1 TI TT4EB85 DMAEZB1 TN Cholesterol 24-hydroxylase (CYP46A1) DMAEZB1 MA Inhibitor DMAEZB1 RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMAEZB1 RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMAFE5R DI DMAFE5R DMAFE5R DN Thiazolopyridine derivative 1 DMAFE5R TI TTBYWP2 DMAFE5R TN TYK2 tyrosine kinase (TYK2) DMAFE5R MA Inhibitor DMAFE5R RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAFE5R RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAFZLP DI DMAFZLP DMAFZLP DN PMID25991433-Compound-P3 DMAFZLP TI TTVOE6D DMAFZLP TN Mitogen-activated protein kinase (MAPK) DMAFZLP MA Inhibitor DMAFZLP RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMAFZLP RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMAGKNJ DI DMAGKNJ DMAGKNJ DN PMID27774824-Compound-Figure12Example1 DMAGKNJ TI TTGM6VW DMAGKNJ TN Tyrosine-protein kinase BTK (ATK) DMAGKNJ MA Inhibitor DMAGKNJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMAGKNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMAGKNJ DI DMAGKNJ DMAGKNJ DN PMID27774824-Compound-Figure12Example1 DMAGKNJ TI TTT7PJU DMAGKNJ TN Janus kinase 3 (JAK-3) DMAGKNJ MA Inhibitor DMAGKNJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMAGKNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMAGNEH DI DMAGNEH DMAGNEH DN US8987457, 15 DMAGNEH TI TTCGOIN DMAGNEH TN PIM-3 protein kinase (PIM3) DMAGNEH MA Inhibitor DMAGNEH RN Ring-substituted N-pyridinyl amides as kinase inhibitors. US8987457. DMAGNEH RU http://www.freepatentsonline.com/US8987457.html DMAGVHX DI DMAGVHX DMAGVHX DN PMID28454500-Compound-3 DMAGVHX TI TTA6ZN2 DMAGVHX TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAGVHX MA Activator DMAGVHX RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAGVHX RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAGVHX DI DMAGVHX DMAGVHX DN PMID28454500-Compound-3 DMAGVHX TI TT3Z6Y9 DMAGVHX TN Cysteines of Keap1 (KEAP1 Cysteines) DMAGVHX MA Modulator DMAGVHX RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAGVHX RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAH1EP DI DMAH1EP DMAH1EP DN Dihydroxyfumaric acid derivative 1 DMAH1EP TI TTULVH8 DMAH1EP TN Tyrosinase (TYR) DMAH1EP MA Inhibitor DMAH1EP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMAH1EP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMAH1G7 DI DMAH1G7 DMAH1G7 DN PMID25468267-Compound-52 DMAH1G7 TI TT0RGE9 DMAH1G7 TN Lysine-specific demethylase 4 (KDM4) DMAH1G7 MA Inhibitor DMAH1G7 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMAH1G7 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMAH435 DI DMAH435 DMAH435 DN Quinazoline derivative 11 DMAH435 TI TTQR74A DMAH435 TN Proteinase activated receptor 2 (PAR2) DMAH435 MA Antagonist DMAH435 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMAH435 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMAH4P8 DI DMAH4P8 DMAH4P8 DN Quinoline derivative 13 DMAH4P8 TI TT473XN DMAH4P8 TN P2X purinoceptor 7 (P2RX7) DMAH4P8 MA Antagonist DMAH4P8 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMAH4P8 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMAH4P8 DI DMAH4P8 DMAH4P8 DN Quinoline derivative 13 DMAH4P8 TI TTQ6VDM DMAH4P8 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMAH4P8 MA Antagonist DMAH4P8 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMAH4P8 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMAH982 DI DMAH982 DMAH982 DN PMID29671355-Compound-47c DMAH982 TI TTTQGH8 DMAH982 TN Histone deacetylase 4 (HDAC4) DMAH982 MA Inhibitor DMAH982 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMAH982 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TTT7PJU DMAHFXV TN Janus kinase 3 (JAK-3) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TTRMX3V DMAHFXV TN Janus kinase 2 (JAK-2) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TT6DM01 DMAHFXV TN Janus kinase 1 (JAK-1) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAHFXV DI DMAHFXV DMAHFXV DN PMID27774822-Compound-Figure11Example5 DMAHFXV TI TTBYWP2 DMAHFXV TN TYK2 tyrosine kinase (TYK2) DMAHFXV MA Inhibitor DMAHFXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAHFXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAI19Z DI DMAI19Z DMAI19Z DN PMID25468267-Compound-56 DMAI19Z TI TTV8CRH DMAI19Z TN Lysine-specific demethylase 4C (KDM4C) DMAI19Z MA Inhibitor DMAI19Z RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMAI19Z RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMAI95U DI DMAI95U DMAI95U DN PMID25656651-Compound-5 DMAI95U TI TTS7G69 DMAI95U TN Fusion protein Bcr-Abl (Bcr-Abl) DMAI95U MA Inhibitor DMAI95U RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAI95U RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAIGJP DI DMAIGJP DMAIGJP DN PMID28454500-Compound-32 DMAIGJP TI TTA6ZN2 DMAIGJP TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAIGJP MA Activator DMAIGJP RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAIGJP RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAIGJP DI DMAIGJP DMAIGJP DN PMID28454500-Compound-32 DMAIGJP TI TT3Z6Y9 DMAIGJP TN Cysteines of Keap1 (KEAP1 Cysteines) DMAIGJP MA Modulator DMAIGJP RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAIGJP RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAIJHC DI DMAIJHC DMAIJHC DN Benzamide derivative 8 DMAIJHC TI TT9NXW4 DMAIJHC TN Sigma intracellular receptor 2 (TMEM97) DMAIJHC MA Ligand DMAIJHC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMAIJHC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMAIJHC DI DMAIJHC DMAIJHC DN Benzamide derivative 8 DMAIJHC TI TT5TPI6 DMAIJHC TN Opioid receptor sigma 1 (OPRS1) DMAIJHC MA Ligand DMAIJHC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMAIJHC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMAIKJV DI DMAIKJV DMAIKJV DN PMID25991433-Compound-Q2 DMAIKJV TI TTVOE6D DMAIKJV TN Mitogen-activated protein kinase (MAPK) DMAIKJV MA Inhibitor DMAIKJV RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMAIKJV RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMAIRL2 DI DMAIRL2 DMAIRL2 DN PMID28270010-Compound-Figure16-b-1 DMAIRL2 TI TTTDVOJ DMAIRL2 TN Tropomyosin-related kinase A (TrkA) DMAIRL2 MA Inhibitor DMAIRL2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMAIRL2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMAITK3 DI DMAITK3 DMAITK3 DN Biaryl mannoside derivative 3 DMAITK3 TI TTTCRU2 DMAITK3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMAITK3 MA Antagonist DMAITK3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMAITK3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMAIVEN DI DMAIVEN DMAIVEN DN PMID25656651-Compound-18 DMAIVEN TI TTS7G69 DMAIVEN TN Fusion protein Bcr-Abl (Bcr-Abl) DMAIVEN MA Inhibitor DMAIVEN RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAIVEN RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAJ74C DI DMAJ74C DMAJ74C DN Bicyclic pyrimidine derivative 1 DMAJ74C TI TTJOW1I DMAJ74C TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMAJ74C MA Inhibitor DMAJ74C RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMAJ74C RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMAJFDT DI DMAJFDT DMAJFDT DN Hydroxyqunoline analog 1 DMAJFDT TI TTWAQBO DMAJFDT TN Lysine-specific demethylase 4E (KDM4E) DMAJFDT MA Inhibitor DMAJFDT RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMAJFDT RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMAJLM1 DI DMAJLM1 DMAJLM1 DN Peptide analog 65 DMAJLM1 TI TTPLTSQ DMAJLM1 TN Neutrophil elastase (NE) DMAJLM1 MA Inhibitor DMAJLM1 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMAJLM1 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMAJRP1 DI DMAJRP1 DMAJRP1 DN PMID27841045-Compound-145 DMAJRP1 TI TT7RJY8 DMAJRP1 TN Xanthine dehydrogenase/oxidase (XDH) DMAJRP1 MA Inhibitor DMAJRP1 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMAJRP1 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMALDZ6 DI DMALDZ6 DMALDZ6 DN Fused heterocyclic compound 10 DMALDZ6 TI TT7RJY8 DMALDZ6 TN Xanthine dehydrogenase/oxidase (XDH) DMALDZ6 MA Inhibitor DMALDZ6 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMALDZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMALF06 DI DMALF06 DMALF06 DN Aromatic bicyclic compound 5 DMALF06 TI TT6PKBN DMALF06 TN Proto-oncogene c-Src (SRC) DMALF06 MA Inhibitor DMALF06 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMALF06 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMALF06 DI DMALF06 DMALF06 DN Aromatic bicyclic compound 5 DMALF06 TI TTRMX3V DMALF06 TN Janus kinase 2 (JAK-2) DMALF06 MA Inhibitor DMALF06 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMALF06 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMALOEW DI DMALOEW DMALOEW DN PMID29649907-Compound-25 DMALOEW TI TTS4UGC DMALOEW TN Farnesoid X-activated receptor (FXR) DMALOEW MA Agonist DMALOEW RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMALOEW RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMALXYR DI DMALXYR DMALXYR DN PMID29671355-Compound-13 DMALXYR TI TT6R7JZ DMALXYR TN Histone deacetylase 1 (HDAC1) DMALXYR MA Inhibitor DMALXYR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMALXYR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMALXYR DI DMALXYR DMALXYR DN PMID29671355-Compound-13 DMALXYR TI TT5ZKDI DMALXYR TN Histone deacetylase 6 (HDAC6) DMALXYR MA Inhibitor DMALXYR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMALXYR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMALXYR DI DMALXYR DMALXYR DN PMID29671355-Compound-13 DMALXYR TI TTT6LFV DMALXYR TN Histone deacetylase 8 (HDAC8) DMALXYR MA Inhibitor DMALXYR RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMALXYR RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMAM0US DI DMAM0US DMAM0US DN PMID29338548-Compound-37 DMAM0US TI TTHJTF7 DMAM0US TN Glycine transporter GlyT-1 (SLC6A9) DMAM0US MA Inhibitor DMAM0US RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMAM0US RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMAM50X DI DMAM50X DMAM50X DN Piperidinone derivative 1 DMAM50X TI TT473XN DMAM50X TN P2X purinoceptor 7 (P2RX7) DMAM50X MA Antagonist DMAM50X RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMAM50X RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMAM51Z DI DMAM51Z DMAM51Z DN US8536181, C35 DMAM51Z TI TT9ISBX DMAM51Z TN HIF-prolyl hydroxylase 2 (HPH-2) DMAM51Z MA Inhibitor DMAM51Z RN Prolyl hydroxylase inhibitors. US8536181. DMAM51Z RU http://www.freepatentsonline.com/US8536181.html DMAM6YC DI DMAM6YC DMAM6YC DN Indole-based analog 10 DMAM6YC TI TTPTXIN DMAM6YC TN Translocator protein (TSPO) DMAM6YC MA Ligand DMAM6YC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMAM6YC RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMAM7Y2 DI DMAM7Y2 DMAM7Y2 DN Tetra-hydro-pyrazolopyrazine derivative 5 DMAM7Y2 TI TTHS256 DMAM7Y2 TN Metabotropic glutamate receptor 5 (mGluR5) DMAM7Y2 MA Modulator DMAM7Y2 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMAM7Y2 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMAMRPW DI DMAMRPW DMAMRPW DN PMID25522065-Compound-9 DMAMRPW TI TTX4RTB DMAMRPW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMAMRPW MA Antagonist DMAMRPW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMAMRPW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMAN3BT DI DMAN3BT DMAN3BT DN PMID25522065-Compound-16 DMAN3BT TI TTX4RTB DMAN3BT TN Melanin-concentrating hormone receptor 1 (MCHR1) DMAN3BT MA Antagonist DMAN3BT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMAN3BT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMAN71J DI DMAN71J DMAN71J DN PMID27967267-Compound-7 DMAN71J TI TT1RS9F DMAN71J TN Acetylcholinesterase (AChE) DMAN71J MA Inhibitor DMAN71J RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMAN71J RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMAN7CG DI DMAN7CG DMAN7CG DN PMID27454349-Compound-91 DMAN7CG TI TTK59TV DMAN7CG TN Vitamin D3 receptor (VDR) DMAN7CG MA Agonist DMAN7CG RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMAN7CG RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMANFK8 DI DMANFK8 DMANFK8 DN US9024044, 4 DMANFK8 TI TTXL0GC DMANFK8 TN Enteropeptidase (TMPRSS15) DMANFK8 MA Inhibitor DMANFK8 RN Heteroarylcarboxylic acid ester derivative. US9655879. DMANFK8 RU http://www.freepatentsonline.com/US9655879.html DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TT7MRDV DMAOF0W TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TT8FYO9 DMAOF0W TN Platelet-derived growth factor receptor alpha (PDGFRA) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TTX41N9 DMAOF0W TN Tyrosine-protein kinase Kit (KIT) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAOF0W DI DMAOF0W DMAOF0W DN Pyridine derivative 20 DMAOF0W TI TT4DXQT DMAOF0W TN Proto-oncogene c-Ret (RET) DMAOF0W MA Inhibitor DMAOF0W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMAOF0W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMAP1DN DI DMAP1DN DMAP1DN DN US10087167, Compound 4001 DMAP1DN TI TTQFZWR DMAP1DN TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMAP1DN MA Inhibitor DMAP1DN RN Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167. DMAP1DN RU http://www.freepatentsonline.com/US10087167.html DMAP6YS DI DMAP6YS DMAP6YS DN Urea and carbamate bioisostere derivative 11 DMAP6YS TI TTL7C8Q DMAP6YS TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMAP6YS MA Inhibitor DMAP6YS RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMAP6YS RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMAPGBF DI DMAPGBF DMAPGBF DN US8592431, 457 DMAPGBF TI TTLJKZ0 DMAPGBF TN Acetyl-CoA transporter (SLC33A1) DMAPGBF MA Inhibitor DMAPGBF RN Fused ring compound and use thereof. US8592431. DMAPGBF RU http://www.freepatentsonline.com/US8592431.html DMAPMG2 DI DMAPMG2 DMAPMG2 DN PMID28870136-Compound-37 DMAPMG2 TI TTK0O6Y DMAPMG2 TN Ecto-5'-nucleotidase (CD73) DMAPMG2 MA Inhibitor DMAPMG2 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMAPMG2 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMAQBJP DI DMAQBJP DMAQBJP DN Fused aryl carbocycle derivative 2 DMAQBJP TI TT9NXW4 DMAQBJP TN Sigma intracellular receptor 2 (TMEM97) DMAQBJP MA Ligand DMAQBJP RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMAQBJP RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMAQHI5 DI DMAQHI5 DMAQHI5 DN PMID25684022-Compound-WO2011137219 36(3-5) DMAQHI5 TI TTCZOF2 DMAQHI5 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMAQHI5 MA Inhibitor DMAQHI5 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMAQHI5 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMAR2OX DI DMAR2OX DMAR2OX DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 1 DMAR2OX TI TTVDSZ0 DMAR2OX TN Poly [ADP-ribose] polymerase 1 (PARP1) DMAR2OX MA Inhibitor DMAR2OX RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMAR2OX RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMARHJ9 DI DMARHJ9 DMARHJ9 DN N-(indolylcarbonyl)-piperidine derivative 1 DMARHJ9 TI TT5ZWB6 DMARHJ9 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMARHJ9 MA Inhibitor DMARHJ9 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMARHJ9 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMARLZ6 DI DMARLZ6 DMARLZ6 DN Imidazo[1,2-b]pyridazine acetamide derivative 3 DMARLZ6 TI TTPTXIN DMARLZ6 TN Translocator protein (TSPO) DMARLZ6 MA Ligand DMARLZ6 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMARLZ6 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMARU0E DI DMARU0E DMARU0E DN Macrocycle derivative 9 DMARU0E TI TT23XQV DMARU0E TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMARU0E MA Inhibitor DMARU0E RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMARU0E RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMARU0E DI DMARU0E DMARU0E DN Macrocycle derivative 9 DMARU0E TI TT5YPJF DMARU0E TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMARU0E MA Inhibitor DMARU0E RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMARU0E RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMAS01P DI DMAS01P DMAS01P DN N-acylpiperidine ether derivative 6 DMAS01P TI TTTDVOJ DMAS01P TN Tropomyosin-related kinase A (TrkA) DMAS01P MA Inhibitor DMAS01P RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMAS01P RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMASGR1 DI DMASGR1 DMASGR1 DN Pyrimidine derivative 13 DMASGR1 TI TTUTJGQ DMASGR1 TN Vascular endothelial growth factor receptor 2 (KDR) DMASGR1 MA Inhibitor DMASGR1 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMASGR1 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMASV8I DI DMASV8I DMASV8I DN PMID28394193-Compound-43 DMASV8I TI TT9MZCQ DMASV8I TN Enhancer of zeste homolog 2 (EZH2) DMASV8I MA Inhibitor DMASV8I RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMASV8I RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMASXR5 DI DMASXR5 DMASXR5 DN Indoline derivative 2 DMASXR5 TI TT5OU0D DMASXR5 TN PRKR-like endoplasmic reticulum kinase (PERK) DMASXR5 MA Inhibitor DMASXR5 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMASXR5 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMAT9NE DI DMAT9NE DMAT9NE DN Mycophenolic acid/nucleotide derivative 2 DMAT9NE TI TTL7C8Q DMAT9NE TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMAT9NE MA Inhibitor DMAT9NE RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMAT9NE RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMATBZW DI DMATBZW DMATBZW DN Benzene sulfonamide derivative 16 DMATBZW TI TTA592U DMATBZW TN Urate anion exchanger 1 (URAT1) DMATBZW MA Inhibitor DMATBZW RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMATBZW RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMATU1X DI DMATU1X DMATU1X DN Benzene sulfonamide derivative 8 DMATU1X TI TTUX68I DMATU1X TN Hypoxia-inducible factor 1 (HIF-1) DMATU1X MA Inhibitor DMATU1X RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMATU1X RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMAUFS7 DI DMAUFS7 DMAUFS7 DN PMID30107136-Compound-Example14 DMAUFS7 TI TT23XQV DMAUFS7 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMAUFS7 MA Inhibitor DMAUFS7 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMAUFS7 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMAUO6C DI DMAUO6C DMAUO6C DN PMID25522065-Compound-42 DMAUO6C TI TTX4RTB DMAUO6C TN Melanin-concentrating hormone receptor 1 (MCHR1) DMAUO6C MA Antagonist DMAUO6C RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMAUO6C RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMAV4XY DI DMAV4XY DMAV4XY DN PMID25666693-Compound-87 DMAV4XY TI TTMI6F5 DMAV4XY TN Transient receptor potential cation channel V1 (TRPV1) DMAV4XY MA Antagonist DMAV4XY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMAV4XY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMAV8LM DI DMAV8LM DMAV8LM DN N-phenyl-pyrimidin-4-amine derivative 1 DMAV8LM TI TT7HF4W DMAV8LM TN Cyclin-dependent kinase 2 (CDK2) DMAV8LM MA Inhibitor DMAV8LM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMAV8LM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMAV8LM DI DMAV8LM DMAV8LM DN N-phenyl-pyrimidin-4-amine derivative 1 DMAV8LM TI TT1LVF2 DMAV8LM TN Cyclin-dependent kinase 9 (CDK9) DMAV8LM MA Inhibitor DMAV8LM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMAV8LM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TTT7PJU DMAW6KU TN Janus kinase 3 (JAK-3) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TTBYWP2 DMAW6KU TN TYK2 tyrosine kinase (TYK2) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TTRMX3V DMAW6KU TN Janus kinase 2 (JAK-2) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAW6KU DI DMAW6KU DMAW6KU DN Pyrrolo[2,3-d]pyrimidine derivative 8 DMAW6KU TI TT6DM01 DMAW6KU TN Janus kinase 1 (JAK-1) DMAW6KU MA Inhibitor DMAW6KU RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMAW6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TTRA6BO DMAWLGI TN Bromodomain-containing protein 4 (BRD4) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TTHE657 DMAWLGI TN Bromodomain-containing protein 3 (BRD3) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TTDP48B DMAWLGI TN Bromodomain-containing protein 2 (BRD2) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWLGI DI DMAWLGI DMAWLGI DN PMID26924192-Compound-105 DMAWLGI TI TT7CPI5 DMAWLGI TN Bromodomain testis-specific protein (BRDT) DMAWLGI MA Inhibitor DMAWLGI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWLGI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAWY4L DI DMAWY4L DMAWY4L DN Tetra-hydro-quinoline derivative 3 DMAWY4L TI TTE4BSY DMAWY4L TN Bromodomain and extraterminal domain protein (BET) DMAWY4L MA Inhibitor DMAWY4L RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAWY4L RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAXDV5 DI DMAXDV5 DMAXDV5 DN Benzothiazepine analog 8 DMAXDV5 TI TTPTXIN DMAXDV5 TN Translocator protein (TSPO) DMAXDV5 MA Ligand DMAXDV5 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMAXDV5 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMAXKPC DI DMAXKPC DMAXKPC DN Monoaryl-1,2-diamine derivative 3 DMAXKPC TI TTZJYKH DMAXKPC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMAXKPC MA Modulator DMAXKPC RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMAXKPC RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMAXS57 DI DMAXS57 DMAXS57 DN PMID28117607-Compound-20 DMAXS57 TI TTK0FEA DMAXS57 TN Leucine-rich repeat kinase 2 (LRRK2) DMAXS57 MA Inhibitor DMAXS57 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMAXS57 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMAXWPS DI DMAXWPS DMAXWPS DN PMID26651364-Compound-9a DMAXWPS TI TTTCRU2 DMAXWPS TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMAXWPS MA Antagonist DMAXWPS RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMAXWPS RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMAY4G1 DI DMAY4G1 DMAY4G1 DN 7-azaindole derivative 9 DMAY4G1 TI TTEBCY8 DMAY4G1 TN Poly [ADP-ribose] polymerase (PARP) DMAY4G1 MA Inhibitor DMAY4G1 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMAY4G1 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMAYHNI DI DMAYHNI DMAYHNI DN Aminocyclopentenone compound 2 DMAYHNI TI TTRA6BO DMAYHNI TN Bromodomain-containing protein 4 (BRD4) DMAYHNI MA Inhibitor DMAYHNI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAYHNI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAYINQ DI DMAYINQ DMAYINQ DN PMID25656651-Compound-11c DMAYINQ TI TTS7G69 DMAYINQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMAYINQ MA Inhibitor DMAYINQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAYINQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAYKZ9 DI DMAYKZ9 DMAYKZ9 DN Isoxazole-based bicyclic compound 10 DMAYKZ9 TI TTE4BSY DMAYKZ9 TN Bromodomain and extraterminal domain protein (BET) DMAYKZ9 MA Inhibitor DMAYKZ9 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMAYKZ9 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMAYSNQ DI DMAYSNQ DMAYSNQ DN PMID25656651-Compound-25 DMAYSNQ TI TTS7G69 DMAYSNQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMAYSNQ MA Inhibitor DMAYSNQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMAYSNQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMAYT2E DI DMAYT2E DMAYT2E DN PMID29473428-Compound-48 DMAYT2E TI TTZJYKH DMAYT2E TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMAYT2E MA Inhibitor DMAYT2E RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMAYT2E RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMAZ6DI DI DMAZ6DI DMAZ6DI DN Monoamine derivative 2 DMAZ6DI TI TTULVH8 DMAZ6DI TN Tyrosinase (TYR) DMAZ6DI MA Inhibitor DMAZ6DI RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMAZ6DI RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMAZI3D DI DMAZI3D DMAZI3D DN Pyrazolo[1,5-a]pyrimidine derivative 15 DMAZI3D TI TTTDVOJ DMAZI3D TN Tropomyosin-related kinase A (TrkA) DMAZI3D MA Inhibitor DMAZI3D RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMAZI3D RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMAZIY6 DI DMAZIY6 DMAZIY6 DN PMID26651364-Compound-5f DMAZIY6 TI TTTCRU2 DMAZIY6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMAZIY6 MA Antagonist DMAZIY6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMAZIY6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMAZOH4 DI DMAZOH4 DMAZOH4 DN Diterpenoid derivative 1 DMAZOH4 TI TTA6ZN2 DMAZOH4 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMAZOH4 MA Activator DMAZOH4 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAZOH4 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAZOH4 DI DMAZOH4 DMAZOH4 DN Diterpenoid derivative 1 DMAZOH4 TI TT3Z6Y9 DMAZOH4 TN Cysteines of Keap1 (KEAP1 Cysteines) DMAZOH4 MA Modulator DMAZOH4 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMAZOH4 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMAZVHJ DI DMAZVHJ DMAZVHJ DN PMID27998201-Compound-17 DMAZVHJ TI TT36ETB DMAZVHJ TN Cathepsin L (CTSL) DMAZVHJ MA Inhibitor DMAZVHJ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMAZVHJ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMAZVHJ DI DMAZVHJ DMAZVHJ DN PMID27998201-Compound-17 DMAZVHJ TI TTF2LRI DMAZVHJ TN Cathepsin B (CTSB) DMAZVHJ MA Inhibitor DMAZVHJ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMAZVHJ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMAZVHJ DI DMAZVHJ DMAZVHJ DN PMID27998201-Compound-17 DMAZVHJ TI TTUMQVO DMAZVHJ TN Cathepsin S (CTSS) DMAZVHJ MA Inhibitor DMAZVHJ RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMAZVHJ RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMB018S DI DMB018S DMB018S DN PMID27744724-Compound-28 DMB018S TI TTL53M6 DMB018S TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMB018S MA Inhibitor DMB018S RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMB018S RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMB08D3 DI DMB08D3 DMB08D3 DN Bidentate ligands of Markush derivative 1 DMB08D3 TI TTK0FEA DMB08D3 TN Leucine-rich repeat kinase 2 (LRRK2) DMB08D3 MA Inhibitor DMB08D3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMB08D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMB08D3 DI DMB08D3 DMB08D3 DN Bidentate ligands of Markush derivative 1 DMB08D3 TI TTVOE6D DMB08D3 TN Mitogen-activated protein kinase (MAPK) DMB08D3 MA Inhibitor DMB08D3 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMB08D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMB0D1H DI DMB0D1H DMB0D1H DN Six-membered heterocyclic benzamide derivative 4 DMB0D1H TI TTTDVOJ DMB0D1H TN Tropomyosin-related kinase A (TrkA) DMB0D1H MA Inhibitor DMB0D1H RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMB0D1H RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMB0DS5 DI DMB0DS5 DMB0DS5 DN PMID25726713-Compound-21 DMB0DS5 TI TT8J1S3 DMB0DS5 TN Smoothened homolog (SMO) DMB0DS5 MA Inhibitor DMB0DS5 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMB0DS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMB0NVQ DI DMB0NVQ DMB0NVQ DN Steroid derivative 1 DMB0NVQ TI TTUX68I DMB0NVQ TN Hypoxia-inducible factor 1 (HIF-1) DMB0NVQ MA Inhibitor DMB0NVQ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMB0NVQ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMB0S52 DI DMB0S52 DMB0S52 DN PMID27019002-Compound-7 DMB0S52 TI TTNR0UQ DMB0S52 TN Lysine-specific histone demethylase 1 (LSD) DMB0S52 MA Inhibitor DMB0S52 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMB0S52 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMB18V5 DI DMB18V5 DMB18V5 DN PMID27774824-Compound-Figure6Example6 DMB18V5 TI TT6DM01 DMB18V5 TN Janus kinase 1 (JAK-1) DMB18V5 MA Inhibitor DMB18V5 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMB18V5 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMB18V5 DI DMB18V5 DMB18V5 DN PMID27774824-Compound-Figure6Example6 DMB18V5 TI TTRMX3V DMB18V5 TN Janus kinase 2 (JAK-2) DMB18V5 MA Inhibitor DMB18V5 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMB18V5 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMB1EAW DI DMB1EAW DMB1EAW DN 6,6-fused nitrogenous heterocyclic compound 2 DMB1EAW TI TT3PJMV DMB1EAW TN Tyrosine-protein kinase ABL1 (ABL) DMB1EAW MA Inhibitor DMB1EAW RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMB1EAW RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMB1JG2 DI DMB1JG2 DMB1JG2 DN 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivative 1 DMB1JG2 TI TTOHSBA DMB1JG2 TN Vascular endothelial growth factor A (VEGFA) DMB1JG2 MA Inhibitor DMB1JG2 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMB1JG2 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMB1L32 DI DMB1L32 DMB1L32 DN Benzimidazole carboxamide derivative 1 DMB1L32 TI TTVDSZ0 DMB1L32 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMB1L32 MA Inhibitor DMB1L32 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB1L32 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB1T6S DI DMB1T6S DMB1T6S DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 2 DMB1T6S TI TTXJ47W DMB1T6S TN Metabotropic glutamate receptor 2 (mGluR2) DMB1T6S MA Antagonist DMB1T6S RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMB1T6S RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMB1WQZ DI DMB1WQZ DMB1WQZ DN 7-azaindole derivative 7 DMB1WQZ TI TT056SO DMB1WQZ TN Stress-activated protein kinase JNK3 (JNK3) DMB1WQZ MA Inhibitor DMB1WQZ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMB1WQZ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMB2INX DI DMB2INX DMB2INX DN Geminally-substituted cyanoethylpypazolo pyridone derivative 2 DMB2INX TI TTRMX3V DMB2INX TN Janus kinase 2 (JAK-2) DMB2INX MA Inhibitor DMB2INX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMB2INX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMB2INX DI DMB2INX DMB2INX DN Geminally-substituted cyanoethylpypazolo pyridone derivative 2 DMB2INX TI TT6DM01 DMB2INX TN Janus kinase 1 (JAK-1) DMB2INX MA Inhibitor DMB2INX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMB2INX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMB2MH3 DI DMB2MH3 DMB2MH3 DN PMID26924192-Compound-51 DMB2MH3 TI TTE4BSY DMB2MH3 TN Bromodomain and extraterminal domain protein (BET) DMB2MH3 MA Inhibitor DMB2MH3 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMB2MH3 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMB2MIT DI DMB2MIT DMB2MIT DN PMID25980951-Compound-15 DMB2MIT TI TTR7B60 DMB2MIT TN X-linked inhibitor of apoptosis protein (XIAP) DMB2MIT MA Antagonist DMB2MIT RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMB2MIT RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMB2RKC DI DMB2RKC DMB2RKC DN Cyclopropylamine derivative 6 DMB2RKC TI TTNR0UQ DMB2RKC TN Lysine-specific histone demethylase 1 (LSD) DMB2RKC MA Inhibitor DMB2RKC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMB2RKC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMB2RML DI DMB2RML DMB2RML DN PMID25666693-Compound-107 DMB2RML TI TTMI6F5 DMB2RML TN Transient receptor potential cation channel V1 (TRPV1) DMB2RML MA Antagonist DMB2RML RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMB2RML RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMB3806 DI DMB3806 DMB3806 DN 3-substituted-1,2,4-oxadiazole derivative 2 DMB3806 TI TT23XQV DMB3806 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMB3806 MA Inhibitor DMB3806 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMB3806 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMB3DMR DI DMB3DMR DMB3DMR DN PMID25482888-Compound-56 DMB3DMR TI TTDIGC1 DMB3DMR TN Dipeptidyl peptidase 4 (DPP-4) DMB3DMR MA Inhibitor DMB3DMR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMB3DMR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMB3IZT DI DMB3IZT DMB3IZT DN PMID25980951-Compound-5 DMB3IZT TI TTR7B60 DMB3IZT TN X-linked inhibitor of apoptosis protein (XIAP) DMB3IZT MA Antagonist DMB3IZT RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMB3IZT RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMB3IZT DI DMB3IZT DMB3IZT DN PMID25980951-Compound-5 DMB3IZT TI TTQ5LRD DMB3IZT TN Cellular inhibitor of apoptosis 1 (BIRC2) DMB3IZT MA Antagonist DMB3IZT RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMB3IZT RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMB40HC DI DMB40HC DMB40HC DN 3-phenyl isoquinolin-1(2H) derivative 1 DMB40HC TI TTQ4V96 DMB40HC TN Poly [ADP-ribose] polymerase 2 (PARP2) DMB40HC MA Inhibitor DMB40HC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB40HC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB40HC DI DMB40HC DMB40HC DN 3-phenyl isoquinolin-1(2H) derivative 1 DMB40HC TI TTD8MEH DMB40HC TN Poly [ADP-ribose] polymerase 3 (PARP3) DMB40HC MA Inhibitor DMB40HC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB40HC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB40HC DI DMB40HC DMB40HC DN 3-phenyl isoquinolin-1(2H) derivative 1 DMB40HC TI TTVDSZ0 DMB40HC TN Poly [ADP-ribose] polymerase 1 (PARP1) DMB40HC MA Inhibitor DMB40HC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMB40HC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMB4JS7 DI DMB4JS7 DMB4JS7 DN US9206139, 5 DMB4JS7 TI TTYG6BU DMB4JS7 TN Aggrecanase-1 (ADAMTS4) DMB4JS7 MA Inhibitor DMB4JS7 RN Aggrecanase inhibitors. US9206139. DMB4JS7 RU http://www.freepatentsonline.com/US9206139.html DMB4LNI DI DMB4LNI DMB4LNI DN Peptide analog 36 DMB4LNI TI TT49BVC DMB4LNI TN Proteasome beta-2 (PS beta-2) DMB4LNI MA Inhibitor DMB4LNI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMB4LNI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMB4LNI DI DMB4LNI DMB4LNI DN Peptide analog 36 DMB4LNI TI TTPNACM DMB4LNI TN Proteasome beta-10 (PS beta-10) DMB4LNI MA Inhibitor DMB4LNI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMB4LNI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMB4LNI DI DMB4LNI DMB4LNI DN Peptide analog 36 DMB4LNI TI TT68GPI DMB4LNI TN Proteasome beta-5 (PS beta-5) DMB4LNI MA Inhibitor DMB4LNI RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMB4LNI RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMB4MJ0 DI DMB4MJ0 DMB4MJ0 DN US9353089, 327 DMB4MJ0 TI TTXMNHO DMB4MJ0 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMB4MJ0 MA Inhibitor DMB4MJ0 RN Compositions and methods for the treatment of malaria. US9353089. DMB4MJ0 RU http://www.freepatentsonline.com/US9353089.html DMB4SH8 DI DMB4SH8 DMB4SH8 DN PMID26666989-Compound-Figure9middle10 DMB4SH8 TI TT8BUGW DMB4SH8 TN Glycogen phosphorylase (PYG) DMB4SH8 MA Inhibitor DMB4SH8 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMB4SH8 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMB56LS DI DMB56LS DMB56LS DN PMID25666693-Compound-80 DMB56LS TI TTMI6F5 DMB56LS TN Transient receptor potential cation channel V1 (TRPV1) DMB56LS MA Antagonist DMB56LS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMB56LS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMB5F8Q DI DMB5F8Q DMB5F8Q DN Isoquinoline derivative 4 DMB5F8Q TI TTMQO60 DMB5F8Q TN Rho-associated protein kinase (ROCK) DMB5F8Q MA Inhibitor DMB5F8Q RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMB5F8Q RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMB5KLD DI DMB5KLD DMB5KLD DN Benzothiazepine analog 6 DMB5KLD TI TTPTXIN DMB5KLD TN Translocator protein (TSPO) DMB5KLD MA Ligand DMB5KLD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMB5KLD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMB5UF7 DI DMB5UF7 DMB5UF7 DN Pyrimido-indole derivative 1 DMB5UF7 TI TTE4BSY DMB5UF7 TN Bromodomain and extraterminal domain protein (BET) DMB5UF7 MA Inhibitor DMB5UF7 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMB5UF7 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMB5XDM DI DMB5XDM DMB5XDM DN Bicyclic heteroaryl carboxamide analog 1 DMB5XDM TI TTHS256 DMB5XDM TN Metabotropic glutamate receptor 5 (mGluR5) DMB5XDM MA Modulator DMB5XDM RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMB5XDM RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMB65TO DI DMB65TO DMB65TO DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 DMB65TO TI TT6OEDT DMB65TO TN Cannabinoid receptor 1 (CB1) DMB65TO RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMB65TO RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMB65TO DI DMB65TO DMB65TO DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 2 DMB65TO TI TTMSFAW DMB65TO TN Cannabinoid receptor 2 (CB2) DMB65TO RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMB65TO RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMB65Z4 DI DMB65Z4 DMB65Z4 DN Purine derivative 1 DMB65Z4 TI TT6OEDT DMB65Z4 TN Cannabinoid receptor 1 (CB1) DMB65Z4 MA Antagonist DMB65Z4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMB65Z4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMB6EFV DI DMB6EFV DMB6EFV DN Pyrazolo[1,5-a]pyrimidine derivative 14 DMB6EFV TI TTTDVOJ DMB6EFV TN Tropomyosin-related kinase A (TrkA) DMB6EFV MA Inhibitor DMB6EFV RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMB6EFV RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMB6KS9 DI DMB6KS9 DMB6KS9 DN PMID29130358-Compound-Figure14(5) DMB6KS9 TI TTXPTJE DMB6KS9 TN Gelatinase (GEL) DMB6KS9 MA Inhibitor DMB6KS9 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMB6KS9 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMB6M3Y DI DMB6M3Y DMB6M3Y DN 3-benzyloxyphenyloxoacetic acid derivative 1 DMB6M3Y TI TTA592U DMB6M3Y TN Urate anion exchanger 1 (URAT1) DMB6M3Y MA Inhibitor DMB6M3Y RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMB6M3Y RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMB74LZ DI DMB74LZ DMB74LZ DN Benzonaphthyridine derivative 2 DMB74LZ TI TTCZOF2 DMB74LZ TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMB74LZ MA Inhibitor DMB74LZ RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMB74LZ RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMB79QJ DI DMB79QJ DMB79QJ DN Salicylic acid derivative 1 DMB79QJ TI TTH8FZW DMB79QJ TN Signal transducer and activator of transcription 3 (STAT3) DMB79QJ MA Inhibitor DMB79QJ RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMB79QJ RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMB7WNP DI DMB7WNP DMB7WNP DN PMID28394193-Compound-34 DMB7WNP TI TT9MZCQ DMB7WNP TN Enhancer of zeste homolog 2 (EZH2) DMB7WNP MA Inhibitor DMB7WNP RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMB7WNP RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMB8673 DI DMB8673 DMB8673 DN Indirubin derivative 1 DMB8673 TI TTLRFIH DMB8673 TN Signal transducer and activator of transcription 5 (STAT5) DMB8673 MA Inhibitor DMB8673 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMB8673 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMB87WZ DI DMB87WZ DMB87WZ DN PMID25772215-Compound-US02014179750TG7-112-2 DMB87WZ TI TT1ZAVI DMB87WZ TN Prostaglandin E2 receptor EP2 (PTGER2) DMB87WZ MA Antagonist DMB87WZ RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMB87WZ RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMB8AJP DI DMB8AJP DMB8AJP DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 2 DMB8AJP TI TTJW4LU DMB8AJP TN Phosphodiesterase 10A (PDE10) DMB8AJP MA Inhibitor DMB8AJP RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMB8AJP RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMB8AJP DI DMB8AJP DMB8AJP DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 2 DMB8AJP TI TTJGW1Z DMB8AJP TN Phosphodiesterase 2A (PDE2A) DMB8AJP MA Inhibitor DMB8AJP RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMB8AJP RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMB8GHJ DI DMB8GHJ DMB8GHJ DN PMID29334795-Compound-58 DMB8GHJ TI TT9JNIC DMB8GHJ TN Histamine H3 receptor (H3R) DMB8GHJ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMB8GHJ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TTH6V3D DMB8MNU TN Cyclin-dependent kinase 1 (CDK1) DMB8MNU MA Inhibitor DMB8MNU RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMB8MNU RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TTRSMW9 DMB8MNU TN Glycogen synthase kinase-3 beta (GSK-3B) DMB8MNU MA Inhibitor DMB8MNU RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMB8MNU RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TT4TQBX DMB8MNU TN Extracellular signal-regulated kinase 2 (ERK2) DMB8MNU MA Inhibitor DMB8MNU RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMB8MNU RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMB8MNU DI DMB8MNU DMB8MNU DN CHIR-99021 DMB8MNU TI TTRZQE3 DMB8MNU TN Glycogen synthase kinase-3 alpha (GSK-3A) DMB8MNU MA Inhibitor DMB8MNU RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMB8MNU RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMB92RA DI DMB92RA DMB92RA DN PMID26161698-Compound-17 DMB92RA TI TTMYWL7 DMB92RA TN Cyclin-dependent kinase 3 (CDK3) DMB92RA MA Inhibitor DMB92RA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMB92RA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMB92RA DI DMB92RA DMB92RA DN PMID26161698-Compound-17 DMB92RA TI TT0PG8F DMB92RA TN Cyclin-dependent kinase 4 (CDK4) DMB92RA MA Inhibitor DMB92RA RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMB92RA RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMB93QU DI DMB93QU DMB93QU DN PMID25522065-Compound-28 DMB93QU TI TTX4RTB DMB93QU TN Melanin-concentrating hormone receptor 1 (MCHR1) DMB93QU MA Antagonist DMB93QU RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMB93QU RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMB9DEO DI DMB9DEO DMB9DEO DN Cyclohexyl carbamate derivative 8 DMB9DEO TI TTULVH8 DMB9DEO TN Tyrosinase (TYR) DMB9DEO MA Inhibitor DMB9DEO RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMB9DEO RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMB9VEH DI DMB9VEH DMB9VEH DN Benzene sulfonamide derivative 1 DMB9VEH TI TTIY56R DMB9VEH TN Kynurenine 3-hydroxylase (KMO) DMB9VEH MA Inhibitor DMB9VEH RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMB9VEH RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBA2S3 DI DMBA2S3 DMBA2S3 DN PMID29649907-Compound-44 DMBA2S3 TI TTS4UGC DMBA2S3 TN Farnesoid X-activated receptor (FXR) DMBA2S3 MA Antagonist DMBA2S3 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMBA2S3 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMBAHYO DI DMBAHYO DMBAHYO DN Pyrimidine derivative 6 DMBAHYO TI TTOHSBA DMBAHYO TN Vascular endothelial growth factor A (VEGFA) DMBAHYO MA Inhibitor DMBAHYO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBAHYO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBANT7 DI DMBANT7 DMBANT7 DN Cyclic sulfonamide derivative 3 DMBANT7 TI TT8J1S3 DMBANT7 TN Smoothened homolog (SMO) DMBANT7 MA Inhibitor DMBANT7 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMBANT7 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMBC48K DI DMBC48K DMBC48K DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 5 DMBC48K TI TTULVH8 DMBC48K TN Tyrosinase (TYR) DMBC48K MA Inhibitor DMBC48K RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMBC48K RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMBC9UK DI DMBC9UK DMBC9UK DN 1,2-diamino cyclopentane-based derivative 17 DMBC9UK TI TT9N02I DMBC9UK TN Orexin receptor type 2 (HCRTR2) DMBC9UK MA Antagonist DMBC9UK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBC9UK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBC9UK DI DMBC9UK DMBC9UK DN 1,2-diamino cyclopentane-based derivative 17 DMBC9UK TI TT60Q8D DMBC9UK TN Orexin receptor type 1 (HCRTR1) DMBC9UK MA Antagonist DMBC9UK RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBC9UK RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBCFJU DI DMBCFJU DMBCFJU DN Peptide analog 56 DMBCFJU TI TTQAJF1 DMBCFJU TN Cathepsin G (CTSG) DMBCFJU MA Inhibitor DMBCFJU RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMBCFJU RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMBCFJU DI DMBCFJU DMBCFJU DN Peptide analog 56 DMBCFJU TI TTPLTSQ DMBCFJU TN Neutrophil elastase (NE) DMBCFJU MA Inhibitor DMBCFJU RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMBCFJU RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMBD4K9 DI DMBD4K9 DMBD4K9 DN PMID25980951-Compound-36 DMBD4K9 TI TTR7B60 DMBD4K9 TN X-linked inhibitor of apoptosis protein (XIAP) DMBD4K9 MA Antagonist DMBD4K9 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMBD4K9 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMBD4K9 DI DMBD4K9 DMBD4K9 DN PMID25980951-Compound-36 DMBD4K9 TI TTQ5LRD DMBD4K9 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMBD4K9 MA Antagonist DMBD4K9 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMBD4K9 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMBD706 DI DMBD706 DMBD706 DN PMID25656651-Compound-34b DMBD706 TI TT3PJMV DMBD706 TN Tyrosine-protein kinase ABL1 (ABL) DMBD706 MA Inhibitor DMBD706 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMBD706 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMBD95S DI DMBD95S DMBD95S DN US10059720, Example 80 DMBD95S TI TTY2KP7 DMBD95S TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMBD95S MA Inhibitor DMBD95S RN Pyridine derivative. US10059720. DMBD95S RU http://www.freepatentsonline.com/US10059720.html DMBD9S5 DI DMBD9S5 DMBD9S5 DN PMID25666693-Compound-4 DMBD9S5 TI TTMI6F5 DMBD9S5 TN Transient receptor potential cation channel V1 (TRPV1) DMBD9S5 MA Antagonist DMBD9S5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMBD9S5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMBE0R2 DI DMBE0R2 DMBE0R2 DN PMID25399762-Compound-Table1-C22 DMBE0R2 TI TTGP7BY DMBE0R2 TN Monoamine oxidase type B (MAO-B) DMBE0R2 MA Inhibitor DMBE0R2 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMBE0R2 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMBETU6 DI DMBETU6 DMBETU6 DN PMID27109571-Compound-17 DMBETU6 TI TTNT2S6 DMBETU6 TN Fatty acid-binding protein 5 (FABP5) DMBETU6 MA Inhibitor DMBETU6 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMBETU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMBETU6 DI DMBETU6 DMBETU6 DN PMID27109571-Compound-17 DMBETU6 TI TTHWMFZ DMBETU6 TN Fatty acid-binding protein 4 (FABP4) DMBETU6 MA Inhibitor DMBETU6 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMBETU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMBEYD1 DI DMBEYD1 DMBEYD1 DN Aryl pyrimidine derivative 9 DMBEYD1 TI TTIY56R DMBEYD1 TN Kynurenine 3-hydroxylase (KMO) DMBEYD1 MA Inhibitor DMBEYD1 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBEYD1 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBEZUY DI DMBEZUY DMBEZUY DN Pyrimidine derivative 10 DMBEZUY TI TTOHSBA DMBEZUY TN Vascular endothelial growth factor A (VEGFA) DMBEZUY MA Inhibitor DMBEZUY RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBEZUY RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBF1C0 DI DMBF1C0 DMBF1C0 DN US9006244, E1 DMBF1C0 TI TTECBXN DMBF1C0 TN Oxysterols receptor LXR-alpha (NR1H3) DMBF1C0 MA Inhibitor DMBF1C0 RN Liver X receptor modulators. US9006244. DMBF1C0 RU http://www.freepatentsonline.com/US9006244.html DMBF1OG DI DMBF1OG DMBF1OG DN PMID25726713-Compound-59 DMBF1OG TI TT8J1S3 DMBF1OG TN Smoothened homolog (SMO) DMBF1OG MA Inhibitor DMBF1OG RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMBF1OG RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMBF3ZE DI DMBF3ZE DMBF3ZE DN PMID30273516-Compound-39 DMBF3ZE TI TTCW0KX DMBF3ZE TN Glutaminase (GLS) DMBF3ZE MA Inhibitor DMBF3ZE RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMBF3ZE RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMBFUTL DI DMBFUTL DMBFUTL DN PMID27376512-Compound-CROs DMBFUTL TI TTHVCUP DMBFUTL TN DNA [cytosine-5]-methyltransferase (DNMT) DMBFUTL MA Inhibitor DMBFUTL RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMBFUTL RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMBGTNM DI DMBGTNM DMBGTNM DN Heteroaryl-carboxamide derivative 3 DMBGTNM TI TTCZOF2 DMBGTNM TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMBGTNM MA Inhibitor DMBGTNM RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMBGTNM RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMBH97R DI DMBH97R DMBH97R DN PMID25522065-Compound-46 DMBH97R TI TTX4RTB DMBH97R TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBH97R MA Antagonist DMBH97R RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMBH97R RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMBHIL2 DI DMBHIL2 DMBHIL2 DN Hydroxy amidine derivative 1 DMBHIL2 TI TTZJYKH DMBHIL2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBHIL2 MA Inhibitor DMBHIL2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMBHIL2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMBHJDR DI DMBHJDR DMBHJDR DN PMID27109571-Compound-39 DMBHJDR TI TTMY6L1 DMBHJDR TN Fatty acid-binding protein (FABP) DMBHJDR MA Inhibitor DMBHJDR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMBHJDR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMBHRUP DI DMBHRUP DMBHRUP DN PMID28270010-Compound-Figure16-a DMBHRUP TI TTTDVOJ DMBHRUP TN Tropomyosin-related kinase A (TrkA) DMBHRUP MA Inhibitor DMBHRUP RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMBHRUP RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMBHT2E DI DMBHT2E DMBHT2E DN PMID29649907-Compound-12 DMBHT2E TI TTS4UGC DMBHT2E TN Farnesoid X-activated receptor (FXR) DMBHT2E MA Agonist DMBHT2E RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMBHT2E RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMBIAQD DI DMBIAQD DMBIAQD DN US8829193, 2 DMBIAQD TI TTCGOIN DMBIAQD TN PIM-3 protein kinase (PIM3) DMBIAQD MA Inhibitor DMBIAQD RN PIM kinase inhibitors and methods of their use. US8829193. DMBIAQD RU http://www.freepatentsonline.com/US8829193.html DMBIK28 DI DMBIK28 DMBIK28 DN PMID30107136-Compound-Example8 DMBIK28 TI TT23XQV DMBIK28 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMBIK28 MA Inhibitor DMBIK28 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMBIK28 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMBINOJ DI DMBINOJ DMBINOJ DN PMID26651364-Compound-6b DMBINOJ TI TTTCRU2 DMBINOJ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMBINOJ MA Antagonist DMBINOJ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMBINOJ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMBINQ9 DI DMBINQ9 DMBINQ9 DN PMID26815044-Compound-31 DMBINQ9 TI TTULVH8 DMBINQ9 TN Tyrosinase (TYR) DMBINQ9 MA Inhibitor DMBINQ9 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMBINQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMBIQMS DI DMBIQMS DMBIQMS DN PMID25666693-Compound-118 DMBIQMS TI TTMI6F5 DMBIQMS TN Transient receptor potential cation channel V1 (TRPV1) DMBIQMS MA Antagonist DMBIQMS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMBIQMS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMBIRMA DI DMBIRMA DMBIRMA DN 2-pyrazinone derivative 5 DMBIRMA TI TTPLTSQ DMBIRMA TN Neutrophil elastase (NE) DMBIRMA MA Inhibitor DMBIRMA RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMBIRMA RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMBJH8N DI DMBJH8N DMBJH8N DN Heteroaryl-azepine derivative 8 DMBJH8N TI TTWJBZ5 DMBJH8N TN 5-HT 2C receptor (HTR2C) DMBJH8N MA Agonist DMBJH8N RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMBJH8N RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMBKIR0 DI DMBKIR0 DMBKIR0 DN Amide derivative 2 DMBKIR0 TI TTZJYKH DMBKIR0 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBKIR0 MA Inhibitor DMBKIR0 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMBKIR0 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMBKNDE DI DMBKNDE DMBKNDE DN PMID27539678-Compound-6 DMBKNDE TI TTOHFIY DMBKNDE TN Sphingosine kinase 1 (SPHK1) DMBKNDE MA Inhibitor DMBKNDE RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMBKNDE RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMBKRY7 DI DMBKRY7 DMBKRY7 DN PMID25656651-Compound-29b DMBKRY7 TI TTS7G69 DMBKRY7 TN Fusion protein Bcr-Abl (Bcr-Abl) DMBKRY7 MA Inhibitor DMBKRY7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMBKRY7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMBKSVH DI DMBKSVH DMBKSVH DN PMID28870136-Compound-64 DMBKSVH TI TTK0O6Y DMBKSVH TN Ecto-5'-nucleotidase (CD73) DMBKSVH MA Inhibitor DMBKSVH RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMBKSVH RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMBL5J9 DI DMBL5J9 DMBL5J9 DN PMID27977313-Compound-31 DMBL5J9 TI TTR7UJ3 DMBL5J9 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMBL5J9 MA Inhibitor DMBL5J9 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMBL5J9 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMBL86O DI DMBL86O DMBL86O DN Quinoline and quinazoline derivative 9 DMBL86O TI TTOHSBA DMBL86O TN Vascular endothelial growth factor A (VEGFA) DMBL86O MA Inhibitor DMBL86O RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBL86O RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBLSH1 DI DMBLSH1 DMBLSH1 DN Alkyl mannoside derivative 7 DMBLSH1 TI TTTCRU2 DMBLSH1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMBLSH1 MA Antagonist DMBLSH1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMBLSH1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMBMFPC DI DMBMFPC DMBMFPC DN Imidazo bicyclic iminium derivative 8 DMBMFPC TI TT8J1S3 DMBMFPC TN Smoothened homolog (SMO) DMBMFPC MA Inhibitor DMBMFPC RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMBMFPC RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMBMG1S DI DMBMG1S DMBMG1S DN Hydroxamate analog 2 DMBMG1S TI TT0RGE9 DMBMG1S TN Lysine-specific demethylase 4 (KDM4) DMBMG1S MA Inhibitor DMBMG1S RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMBMG1S RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMBMTUV DI DMBMTUV DMBMTUV DN PMID29473428-Compound-29 DMBMTUV TI TTZJYKH DMBMTUV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBMTUV MA Inhibitor DMBMTUV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMBMTUV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMBN3X4 DI DMBN3X4 DMBN3X4 DN PMID28766366-Compound-Scheme11 DMBN3X4 TI TTSBVFO DMBN3X4 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBN3X4 MA Inhibitor DMBN3X4 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBN3X4 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBN6KU DI DMBN6KU DMBN6KU DN PMID27336223-Compound-11 DMBN6KU TI TT1Q3IE DMBN6KU TN Retinoic acid receptor gamma (RARG) DMBN6KU MA Agonist DMBN6KU RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMBN6KU RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMBN6W2 DI DMBN6W2 DMBN6W2 DN US10035778, Example 12 DMBN6W2 TI TTIF29E DMBN6W2 TN Integrin beta-8 (ITGB8) DMBN6W2 MA Inhibitor DMBN6W2 RN Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778. DMBN6W2 RU http://www.freepatentsonline.com/US10035778.html DMBNAK9 DI DMBNAK9 DMBNAK9 DN PMID25522065-Compound-29 DMBNAK9 TI TTX4RTB DMBNAK9 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBNAK9 MA Antagonist DMBNAK9 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMBNAK9 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMBNHI7 DI DMBNHI7 DMBNHI7 DN PMID27967267-Compound-12 DMBNHI7 TI TT1RS9F DMBNHI7 TN Acetylcholinesterase (AChE) DMBNHI7 MA Inhibitor DMBNHI7 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMBNHI7 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMBOLSU DI DMBOLSU DMBOLSU DN 1,2-diamino cyclopentane-based derivative 33 DMBOLSU TI TT9N02I DMBOLSU TN Orexin receptor type 2 (HCRTR2) DMBOLSU MA Antagonist DMBOLSU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBOLSU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBOLSU DI DMBOLSU DMBOLSU DN 1,2-diamino cyclopentane-based derivative 33 DMBOLSU TI TT60Q8D DMBOLSU TN Orexin receptor type 1 (HCRTR1) DMBOLSU MA Antagonist DMBOLSU RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBOLSU RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBOX0K DI DMBOX0K DMBOX0K DN PMID27215781-Compound-2 DMBOX0K TI TT6OEDT DMBOX0K TN Cannabinoid receptor 1 (CB1) DMBOX0K MA Agonist DMBOX0K RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMBOX0K RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMBOX0K DI DMBOX0K DMBOX0K DN PMID27215781-Compound-2 DMBOX0K TI TTMSFAW DMBOX0K TN Cannabinoid receptor 2 (CB2) DMBOX0K MA Agonist DMBOX0K RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMBOX0K RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMBPT9Z DI DMBPT9Z DMBPT9Z DN PMID25468267-Compound-48 DMBPT9Z TI TT0RGE9 DMBPT9Z TN Lysine-specific demethylase 4 (KDM4) DMBPT9Z MA Inhibitor DMBPT9Z RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMBPT9Z RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMBQ0RN DI DMBQ0RN DMBQ0RN DN PMID28766366-Compound-Scheme14BINDY DMBQ0RN TI TT84OS6 DMBQ0RN TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMBQ0RN MA Inhibitor DMBQ0RN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ0RN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ0RN DI DMBQ0RN DMBQ0RN DN PMID28766366-Compound-Scheme14BINDY DMBQ0RN TI TTYGQ8A DMBQ0RN TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMBQ0RN MA Inhibitor DMBQ0RN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ0RN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ0RN DI DMBQ0RN DMBQ0RN DN PMID28766366-Compound-Scheme14BINDY DMBQ0RN TI TTSBVFO DMBQ0RN TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBQ0RN MA Inhibitor DMBQ0RN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ0RN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ21J DI DMBQ21J DMBQ21J DN PMID28766366-Compound-Scheme18 DMBQ21J TI TTSBVFO DMBQ21J TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBQ21J MA Inhibitor DMBQ21J RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBQ21J RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBQ981 DI DMBQ981 DMBQ981 DN PMID27551786-Compound-III DMBQ981 TI TT26PHO DMBQ981 TN Mineralocorticoid receptor (MR) DMBQ981 MA Antagonist DMBQ981 RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DMBQ981 RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DMBQOW4 DI DMBQOW4 DMBQOW4 DN PMID29671355-Compound-12 DMBQOW4 TI TTTQGH8 DMBQOW4 TN Histone deacetylase 4 (HDAC4) DMBQOW4 MA Inhibitor DMBQOW4 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMBQOW4 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMBR2Y9 DI DMBR2Y9 DMBR2Y9 DN 1,5-diphenylpyrrolidin-2-one derivative 2 DMBR2Y9 TI TT6OEDT DMBR2Y9 TN Cannabinoid receptor 1 (CB1) DMBR2Y9 MA Antagonist DMBR2Y9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMBR2Y9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMBR72X DI DMBR72X DMBR72X DN PMID29053063-Compound-14 DMBR72X TI TTDP1UC DMBR72X TN Fatty acid amide hydrolase (FAAH) DMBR72X MA Inhibitor DMBR72X RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMBR72X RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMBR72X DI DMBR72X DMBR72X DN PMID29053063-Compound-14 DMBR72X TI TTZ963I DMBR72X TN Monoglyceride lipase (MAGL) DMBR72X MA Inhibitor DMBR72X RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMBR72X RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMBRQP1 DI DMBRQP1 DMBRQP1 DN PMID29757691-Compound-2a-i DMBRQP1 TI TT1RS9F DMBRQP1 TN Acetylcholinesterase (AChE) DMBRQP1 MA Inhibitor DMBRQP1 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMBRQP1 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMBRQP1 DI DMBRQP1 DMBRQP1 DN PMID29757691-Compound-2a-i DMBRQP1 TI TTEB0GD DMBRQP1 TN Cholinesterase (BCHE) DMBRQP1 MA Inhibitor DMBRQP1 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMBRQP1 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMBRX8D DI DMBRX8D DMBRX8D DN Quinoxaline derivative 6 DMBRX8D TI TTSXVID DMBRX8D TN Nuclear factor NF-kappa-B (NFKB) DMBRX8D MA Inhibitor DMBRX8D RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMBRX8D RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMBS2FT DI DMBS2FT DMBS2FT DN PMID25482888-Compound-13 DMBS2FT TI TTDIGC1 DMBS2FT TN Dipeptidyl peptidase 4 (DPP-4) DMBS2FT MA Inhibitor DMBS2FT RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMBS2FT RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMBS4LE DI DMBS4LE DMBS4LE DN PMID25991433-Compound-K2 DMBS4LE TI TT0K6EO DMBS4LE TN Stress-activated protein kinase JNK1 (JNK1) DMBS4LE MA Inhibitor DMBS4LE RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMBS4LE RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMBS50K DI DMBS50K DMBS50K DN US10149841, Compound 5 DMBS50K TI TT9ISBX DMBS50K TN HIF-prolyl hydroxylase 2 (HPH-2) DMBS50K MA Inhibitor DMBS50K RN Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841. DMBS50K RU http://www.freepatentsonline.com/US10149841.html DMBSOED DI DMBSOED DMBSOED DN PMID25435179-Compound-WO2012106509Tenovin-6 DMBSOED TI TTUF2HO DMBSOED TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMBSOED MA Inhibitor DMBSOED RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMBSOED RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMBSP1G DI DMBSP1G DMBSP1G DN PMID25399762-Compound-Figure3-Lycojaponicumin A DMBSP1G TI TT3WG5C DMBSP1G TN Monoamine oxidase type A (MAO-A) DMBSP1G MA Inhibitor DMBSP1G RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMBSP1G RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMBT4RJ DI DMBT4RJ DMBT4RJ DN 1,2,4-oxadiazole derivative 7 DMBT4RJ TI TT23XQV DMBT4RJ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMBT4RJ MA Inhibitor DMBT4RJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMBT4RJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMBTZ8I DI DMBTZ8I DMBTZ8I DN PMID28621580-Compound-WO2013036866C66 DMBTZ8I TI TTOHSBA DMBTZ8I TN Vascular endothelial growth factor A (VEGFA) DMBTZ8I MA Inhibitor DMBTZ8I RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMBTZ8I RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMBUJ39 DI DMBUJ39 DMBUJ39 DN PMID29671355-Compound-47b DMBUJ39 TI TTTQGH8 DMBUJ39 TN Histone deacetylase 4 (HDAC4) DMBUJ39 MA Inhibitor DMBUJ39 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMBUJ39 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMBUQDR DI DMBUQDR DMBUQDR DN N-acylpiperidine ether derivative 4 DMBUQDR TI TTTDVOJ DMBUQDR TN Tropomyosin-related kinase A (TrkA) DMBUQDR MA Inhibitor DMBUQDR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMBUQDR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMBURAZ DI DMBURAZ DMBURAZ DN IncarviatoneA DMBURAZ TI TT3WG5C DMBURAZ TN Monoamine oxidase type A (MAO-A) DMBURAZ MA Inhibitor DMBURAZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMBURAZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMBUZHO DI DMBUZHO DMBUZHO DN PMID26394986-Compound-13 DMBUZHO TI TTH8FZW DMBUZHO TN Signal transducer and activator of transcription 3 (STAT3) DMBUZHO MA Inhibitor DMBUZHO RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMBUZHO RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMBV5Z0 DI DMBV5Z0 DMBV5Z0 DN CRWCYVOHVXAEMF-LBPRGKRZSA-N DMBV5Z0 TI TTOYT5L DMBV5Z0 TN Dipeptidyl-peptidase 7 (DPP7) DMBV5Z0 MA Inhibitor DMBV5Z0 RN FAP inhibitors. US9346814. DMBV5Z0 RU http://www.freepatentsonline.com/US9346814.html DMBVDHK DI DMBVDHK DMBVDHK DN Isoxazoline derivative 3 DMBVDHK TI TTDP1UC DMBVDHK TN Fatty acid amide hydrolase (FAAH) DMBVDHK MA Inhibitor DMBVDHK RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMBVDHK RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMBVI7L DI DMBVI7L DMBVI7L DN PMID28394193-Compound-29 DMBVI7L TI TT9MZCQ DMBVI7L TN Enhancer of zeste homolog 2 (EZH2) DMBVI7L MA Inhibitor DMBVI7L RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMBVI7L RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMBVOZK DI DMBVOZK DMBVOZK DN PMID29649907-Compound-18 DMBVOZK TI TTS4UGC DMBVOZK TN Farnesoid X-activated receptor (FXR) DMBVOZK MA Agonist DMBVOZK RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMBVOZK RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMBW208 DI DMBW208 DMBW208 DN Pyrrolo-pyrrolone derivative 6 DMBW208 TI TTFRCTK DMBW208 TN CREB-binding protein (CREBBP) DMBW208 MA Inhibitor DMBW208 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMBW208 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMBW36Y DI DMBW36Y DMBW36Y DN PMID25666693-Compound-38 DMBW36Y TI TTMI6F5 DMBW36Y TN Transient receptor potential cation channel V1 (TRPV1) DMBW36Y MA Antagonist DMBW36Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMBW36Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMBWA0V DI DMBWA0V DMBWA0V DN PMID25522065-Compound-50 DMBWA0V TI TTX4RTB DMBWA0V TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBWA0V MA Antagonist DMBWA0V RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMBWA0V RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMBWAV7 DI DMBWAV7 DMBWAV7 DN PMID28766366-Compound-Scheme24-11H-pyrido[4,3-a]carbazole DMBWAV7 TI TTSBVFO DMBWAV7 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBWAV7 MA Inhibitor DMBWAV7 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMBWAV7 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMBWH3O DI DMBWH3O DMBWH3O DN Aryl methoxyacrylate derivative 1 DMBWH3O TI TTUX68I DMBWH3O TN Hypoxia-inducible factor 1 (HIF-1) DMBWH3O MA Inhibitor DMBWH3O RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMBWH3O RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMBWJK4 DI DMBWJK4 DMBWJK4 DN US10065972, Example 281 DMBWJK4 TI TTT3IXG DMBWJK4 TN Kynurenine oxoglutarate transaminase II (AADAT) DMBWJK4 MA Inhibitor DMBWJK4 RN Bicyclic or tricyclic heterocyclic compound. US10065972. DMBWJK4 RU http://www.freepatentsonline.com/US10065972.html DMBWLSA DI DMBWLSA DMBWLSA DN PMID27172114-Compound-30 DMBWLSA TI TTXNCBV DMBWLSA TN Tryptophan 2,3-dioxygenase (TDO) DMBWLSA MA Inhibitor DMBWLSA RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBWLSA RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBWLSA DI DMBWLSA DMBWLSA DN PMID27172114-Compound-30 DMBWLSA TI TTALN9W DMBWLSA TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMBWLSA MA Inhibitor DMBWLSA RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBWLSA RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBWLSA DI DMBWLSA DMBWLSA DN PMID27172114-Compound-30 DMBWLSA TI TTZJYKH DMBWLSA TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBWLSA MA Inhibitor DMBWLSA RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMBWLSA RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMBWQ8L DI DMBWQ8L DMBWQ8L DN Biphenyl mannoside derivative 25 DMBWQ8L TI TTTCRU2 DMBWQ8L TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMBWQ8L MA Antagonist DMBWQ8L RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMBWQ8L RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMBY65W DI DMBY65W DMBY65W DN 1,2-diamino cyclopentane-based derivative 15 DMBY65W TI TT9N02I DMBY65W TN Orexin receptor type 2 (HCRTR2) DMBY65W MA Antagonist DMBY65W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBY65W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBY65W DI DMBY65W DMBY65W DN 1,2-diamino cyclopentane-based derivative 15 DMBY65W TI TT60Q8D DMBY65W TN Orexin receptor type 1 (HCRTR1) DMBY65W MA Antagonist DMBY65W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMBY65W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMBYTSI DI DMBYTSI DMBYTSI DN PMID26609882-Compound-34 DMBYTSI TI TTJQOD7 DMBYTSI TN 5-HT 2A receptor (HTR2A) DMBYTSI MA Antagonist DMBYTSI RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMBYTSI RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMBYWJI DI DMBYWJI DMBYWJI DN Pyrazole derivative 66 DMBYWJI TI TTH8FZW DMBYWJI TN Signal transducer and activator of transcription 3 (STAT3) DMBYWJI MA Inhibitor DMBYWJI RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMBYWJI RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT7MRDV DMBZMYT TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT8FYO9 DMBZMYT TN Platelet-derived growth factor receptor alpha (PDGFRA) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTX41N9 DMBZMYT TN Tyrosine-protein kinase Kit (KIT) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTI7421 DMBZMYT TN Platelet-derived growth factor receptor beta (PDGFRB) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT4DXQT DMBZMYT TN Proto-oncogene c-Ret (RET) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTGJCWZ DMBZMYT TN Fms-like tyrosine kinase 3 (FLT-3) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TTUTJGQ DMBZMYT TN Vascular endothelial growth factor receptor 2 (KDR) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMBZMYT DI DMBZMYT DMBZMYT DN Pyridine derivative 18 DMBZMYT TI TT6PKBN DMBZMYT TN Proto-oncogene c-Src (SRC) DMBZMYT MA Inhibitor DMBZMYT RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMBZMYT RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMC075A DI DMC075A DMC075A DN PMID30107136-Compound-Example45 DMC075A TI TT23XQV DMC075A TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMC075A MA Inhibitor DMC075A RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMC075A RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMC0PUI DI DMC0PUI DMC0PUI DN US9340511, 7 DMC0PUI TI TT9ISBX DMC0PUI TN HIF-prolyl hydroxylase 2 (HPH-2) DMC0PUI MA Inhibitor DMC0PUI RN Process for making isoquinoline compounds. US9708269. DMC0PUI RU http://www.freepatentsonline.com/US9708269.html DMC1QDB DI DMC1QDB DMC1QDB DN PMID25666693-Compound-121 DMC1QDB TI TTMI6F5 DMC1QDB TN Transient receptor potential cation channel V1 (TRPV1) DMC1QDB MA Antagonist DMC1QDB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMC1QDB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMC1Y2T DI DMC1Y2T DMC1Y2T DN PMID25980951-Compound-31 DMC1Y2T TI TTR7B60 DMC1Y2T TN X-linked inhibitor of apoptosis protein (XIAP) DMC1Y2T MA Antagonist DMC1Y2T RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMC1Y2T RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMC1YR5 DI DMC1YR5 DMC1YR5 DN US9493490, C DMC1YR5 TI TTAZ3MN DMC1YR5 TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMC1YR5 MA Inhibitor DMC1YR5 RN Boron-containing small molecules. US9493490. DMC1YR5 RU http://www.freepatentsonline.com/US9493490.html DMC1ZIX DI DMC1ZIX DMC1ZIX DN Hexahydro azepinone derivative 1 DMC1ZIX TI TTMQO60 DMC1ZIX TN Rho-associated protein kinase (ROCK) DMC1ZIX MA Inhibitor DMC1ZIX RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMC1ZIX RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMC24OL DI DMC24OL DMC24OL DN PMID28394193-Compound-28 DMC24OL TI TT9MZCQ DMC24OL TN Enhancer of zeste homolog 2 (EZH2) DMC24OL MA Inhibitor DMC24OL RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMC24OL RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMC26MT DI DMC26MT DMC26MT DN 1,2-diamino cyclopentane-based derivative 24 DMC26MT TI TT9N02I DMC26MT TN Orexin receptor type 2 (HCRTR2) DMC26MT MA Antagonist DMC26MT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMC26MT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMC26MT DI DMC26MT DMC26MT DN 1,2-diamino cyclopentane-based derivative 24 DMC26MT TI TT60Q8D DMC26MT TN Orexin receptor type 1 (HCRTR1) DMC26MT MA Antagonist DMC26MT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMC26MT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMC27TO DI DMC27TO DMC27TO DN Mycophenolic acid/nucleotide derivative 7 DMC27TO TI TTL7C8Q DMC27TO TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMC27TO MA Inhibitor DMC27TO RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMC27TO RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMC28VB DI DMC28VB DMC28VB DN PMID26815044-Compound-118 DMC28VB TI TTULVH8 DMC28VB TN Tyrosinase (TYR) DMC28VB MA Inhibitor DMC28VB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMC28VB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMC2O0Q DI DMC2O0Q DMC2O0Q DN PMID25828189-Compound-22 DMC2O0Q TI TT9O6WS DMC2O0Q TN Glucagon receptor (GCGR) DMC2O0Q MA Antagonist DMC2O0Q RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMC2O0Q RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMC2T4H DI DMC2T4H DMC2T4H DN Diphenyl purine derivative 5 DMC2T4H TI TT6OEDT DMC2T4H TN Cannabinoid receptor 1 (CB1) DMC2T4H MA Antagonist DMC2T4H RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMC2T4H RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMC3DT7 DI DMC3DT7 DMC3DT7 DN PMID25666693-Compound-30 DMC3DT7 TI TTMI6F5 DMC3DT7 TN Transient receptor potential cation channel V1 (TRPV1) DMC3DT7 MA Antagonist DMC3DT7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMC3DT7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMC3E8M DI DMC3E8M DMC3E8M DN Pyrimidine derivative 3 DMC3E8M TI TTCZOF2 DMC3E8M TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMC3E8M MA Inhibitor DMC3E8M RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMC3E8M RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMC3IN2 DI DMC3IN2 DMC3IN2 DN Dihydrodiazepinocarbazolone derivative 1 DMC3IN2 TI TTVDSZ0 DMC3IN2 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMC3IN2 MA Inhibitor DMC3IN2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMC3IN2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMC3IN2 DI DMC3IN2 DMC3IN2 DN Dihydrodiazepinocarbazolone derivative 1 DMC3IN2 TI TTQ4V96 DMC3IN2 TN Poly [ADP-ribose] polymerase 2 (PARP2) DMC3IN2 MA Inhibitor DMC3IN2 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMC3IN2 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMC3KTB DI DMC3KTB DMC3KTB DN 4-aryl quinol derivative 7 DMC3KTB TI TTR7UJ3 DMC3KTB TN Cytoplasmic thioredoxin reductase (TXNRD1) DMC3KTB MA Inhibitor DMC3KTB RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMC3KTB RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMC3NHJ DI DMC3NHJ DMC3NHJ DN PMID25980951-Compound-18 DMC3NHJ TI TTQ5LRD DMC3NHJ TN Cellular inhibitor of apoptosis 1 (BIRC2) DMC3NHJ MA Antagonist DMC3NHJ RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMC3NHJ RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMC3Q9O DI DMC3Q9O DMC3Q9O DN US9656955, Example 540 DMC3Q9O TI TTYJRN5 DMC3Q9O TN N-acetylglucosaminyltransferase I (NAGAT1) DMC3Q9O MA Inhibitor DMC3Q9O RN Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955. DMC3Q9O RU http://www.freepatentsonline.com/US9656955.html DMC3TJI DI DMC3TJI DMC3TJI DN Carbamide derivative 22 DMC3TJI TI TTOHSBA DMC3TJI TN Vascular endothelial growth factor A (VEGFA) DMC3TJI MA Inhibitor DMC3TJI RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMC3TJI RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMC41MA DI DMC41MA DMC41MA DN PMID27336223-Compound-14 DMC41MA TI TT1Q3IE DMC41MA TN Retinoic acid receptor gamma (RARG) DMC41MA MA Agonist DMC41MA RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMC41MA RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMC41TK DI DMC41TK DMC41TK DN Dihydropyridine compound 5 DMC41TK TI TT4DXQT DMC41TK TN Proto-oncogene c-Ret (RET) DMC41TK MA Inhibitor DMC41TK RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMC41TK RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMC48AX DI DMC48AX DMC48AX DN Peptide analog 46 DMC48AX TI TTDIGC1 DMC48AX TN Dipeptidyl peptidase 4 (DPP-4) DMC48AX MA Inhibitor DMC48AX RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMC48AX RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMC49SV DI DMC49SV DMC49SV DN Imidazo pyridine derivative 2 DMC49SV TI TTDIGC1 DMC49SV TN Dipeptidyl peptidase 4 (DPP-4) DMC49SV MA Inhibitor DMC49SV RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMC49SV RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMC4TQL DI DMC4TQL DMC4TQL DN PMID28092474-Compound-32 DMC4TQL TI TTBH0VX DMC4TQL TN Histone deacetylase (HDAC) DMC4TQL MA Inhibitor DMC4TQL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMC4TQL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMC50F3 DI DMC50F3 DMC50F3 DN PMID25772215-Compound-US02014179750M2 DMC50F3 TI TT1ZAVI DMC50F3 TN Prostaglandin E2 receptor EP2 (PTGER2) DMC50F3 MA Antagonist DMC50F3 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMC50F3 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMC52VP DI DMC52VP DMC52VP DN PMID27109571-Compound-22 DMC52VP TI TTHWMFZ DMC52VP TN Fatty acid-binding protein 4 (FABP4) DMC52VP MA Inhibitor DMC52VP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMC52VP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMC52VP DI DMC52VP DMC52VP DN PMID27109571-Compound-22 DMC52VP TI TTNT2S6 DMC52VP TN Fatty acid-binding protein 5 (FABP5) DMC52VP MA Inhibitor DMC52VP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMC52VP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMC5F3H DI DMC5F3H DMC5F3H DN Isoquinoline sulfonyl derivative 1 DMC5F3H TI TTMQO60 DMC5F3H TN Rho-associated protein kinase (ROCK) DMC5F3H MA Inhibitor DMC5F3H RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMC5F3H RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMC5G76 DI DMC5G76 DMC5G76 DN Oxazolo[3,4-a]pyrazine derivative 5 DMC5G76 TI TTV1C0Z DMC5G76 TN Neuropeptide S receptor (NPSR) DMC5G76 MA Antagonist DMC5G76 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMC5G76 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMC5G8P DI DMC5G8P DMC5G8P DN Phenoxypiperidine derivative 2 DMC5G8P TI TT9JNIC DMC5G8P TN Histamine H3 receptor (H3R) DMC5G8P RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMC5G8P RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMC5NR0 DI DMC5NR0 DMC5NR0 DN PMID28394193-Compound-20 DMC5NR0 TI TT9MZCQ DMC5NR0 TN Enhancer of zeste homolog 2 (EZH2) DMC5NR0 MA Inhibitor DMC5NR0 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMC5NR0 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMC5W1Y DI DMC5W1Y DMC5W1Y DN PMID25666693-Compound-6 DMC5W1Y TI TTMI6F5 DMC5W1Y TN Transient receptor potential cation channel V1 (TRPV1) DMC5W1Y MA Antagonist DMC5W1Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMC5W1Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMC64XQ DI DMC64XQ DMC64XQ DN PMID29130358-Compound-SB-3CT DMC64XQ TI TTLM12X DMC64XQ TN Matrix metalloproteinase-2 (MMP-2) DMC64XQ MA Inhibitor DMC64XQ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMC64XQ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMC64XQ DI DMC64XQ DMC64XQ DN PMID29130358-Compound-SB-3CT DMC64XQ TI TT6X50U DMC64XQ TN Matrix metalloproteinase-9 (MMP-9) DMC64XQ MA Inhibitor DMC64XQ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMC64XQ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMC67G4 DI DMC67G4 DMC67G4 DN US8669361, 103 DMC67G4 TI TTCGOIN DMC67G4 TN PIM-3 protein kinase (PIM3) DMC67G4 MA Inhibitor DMC67G4 RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361. DMC67G4 RU http://www.freepatentsonline.com/US8669361.html DMC6AF2 DI DMC6AF2 DMC6AF2 DN PMID27019002-Compound-21a DMC6AF2 TI TTNR0UQ DMC6AF2 TN Lysine-specific histone demethylase 1 (LSD) DMC6AF2 MA Inhibitor DMC6AF2 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMC6AF2 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMC6HPV DI DMC6HPV DMC6HPV DN PMID25435285-Compound-46 DMC6HPV TI TTXJ47W DMC6HPV TN Metabotropic glutamate receptor 2 (mGluR2) DMC6HPV MA Antagonist DMC6HPV RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMC6HPV RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMC6S0W DI DMC6S0W DMC6S0W DN PMID25514969-Compound-Figure2-2 DMC6S0W TI TT4EB85 DMC6S0W TN Cholesterol 24-hydroxylase (CYP46A1) DMC6S0W MA Inhibitor DMC6S0W RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMC6S0W RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMC7AXQ DI DMC7AXQ DMC7AXQ DN PMID26560530-Compound-2 DMC7AXQ TI TT2F4OL DMC7AXQ TN Tissue transglutaminase (TG2) DMC7AXQ MA Inhibitor DMC7AXQ RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMC7AXQ RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMC7PTY DI DMC7PTY DMC7PTY DN SCHEMBL17766424 DMC7PTY TI TT78309 DMC7PTY TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DMC7PTY MA Inhibitor DMC7PTY RN Substituted benzylpyrazoles. US9765058. DMC7PTY RU http://www.freepatentsonline.com/US9765058.html DMC7UHT DI DMC7UHT DMC7UHT DN Bidentate pyrazolopyrimidine acetamide analog 3 DMC7UHT TI TTPTXIN DMC7UHT TN Translocator protein (TSPO) DMC7UHT MA Ligand DMC7UHT RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMC7UHT RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMC812I DI DMC812I DMC812I DN US9434727, 153 DMC812I TI TT0C8BY DMC812I TN Plasma retinol-binding protein (RBP4) DMC812I MA Inhibitor DMC812I RN Substituted 4-phenylpiperidines, their preparation and use. US9434727. DMC812I RU http://www.freepatentsonline.com/US9434727.html DMC82UR DI DMC82UR DMC82UR DN PMID25482888-Compound-14 DMC82UR TI TTDIGC1 DMC82UR TN Dipeptidyl peptidase 4 (DPP-4) DMC82UR MA Inhibitor DMC82UR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMC82UR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMC8935 DI DMC8935 DMC8935 DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 TI TTJW4LU DMC8935 TN Phosphodiesterase 10A (PDE10) DMC8935 MA Inhibitor DMC8935 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMC8935 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMC8935 DI DMC8935 DMC8935 DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 TI TTQ6VDM DMC8935 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMC8935 MA Inhibitor DMC8935 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMC8935 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMC8935 DI DMC8935 DMC8935 DN Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMC8935 TI TTJGW1Z DMC8935 TN Phosphodiesterase 2A (PDE2A) DMC8935 MA Inhibitor DMC8935 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMC8935 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMC8OVU DI DMC8OVU DMC8OVU DN Biphenyl mannoside derivative 23 DMC8OVU TI TTTCRU2 DMC8OVU TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMC8OVU MA Antagonist DMC8OVU RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMC8OVU RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMC95N7 DI DMC95N7 DMC95N7 DN PMID29334795-Compound-67 DMC95N7 TI TT9JNIC DMC95N7 TN Histamine H3 receptor (H3R) DMC95N7 MA Inhibitor DMC95N7 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMC95N7 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMC95N7 DI DMC95N7 DMC95N7 DN PMID29334795-Compound-67 DMC95N7 TI TTEX248 DMC95N7 TN Dopamine D2 receptor (D2R) DMC95N7 MA Ligand DMC95N7 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMC95N7 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMC9TGM DI DMC9TGM DMC9TGM DN Pyrrolo[2,3-d]pyrimidine derivative 19 DMC9TGM TI TTGM6VW DMC9TGM TN Tyrosine-protein kinase BTK (ATK) DMC9TGM MA Inhibitor DMC9TGM RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMC9TGM RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMCAD64 DI DMCAD64 DMCAD64 DN Carbamide derivative 13 DMCAD64 TI TTZJYKH DMCAD64 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCAD64 MA Inhibitor DMCAD64 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCAD64 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCAS85 DI DMCAS85 DMCAS85 DN Quinoline carboxamide derivative 3 DMCAS85 TI TTH8FZW DMCAS85 TN Signal transducer and activator of transcription 3 (STAT3) DMCAS85 MA Inhibitor DMCAS85 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMCAS85 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMCAVF0 DI DMCAVF0 DMCAVF0 DN Pyrazolo[1,5-a]pyrimidine derivative 4 DMCAVF0 TI TT6OEDT DMCAVF0 TN Cannabinoid receptor 1 (CB1) DMCAVF0 MA Antagonist DMCAVF0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCAVF0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMCB0D6 DI DMCB0D6 DMCB0D6 DN PMID29473428-Compound-14 DMCB0D6 TI TTZJYKH DMCB0D6 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCB0D6 MA Inhibitor DMCB0D6 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCB0D6 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCBPI4 DI DMCBPI4 DMCBPI4 DN 1,2-diamino cyclopentane-based derivative 19 DMCBPI4 TI TT9N02I DMCBPI4 TN Orexin receptor type 2 (HCRTR2) DMCBPI4 MA Antagonist DMCBPI4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCBPI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCBPI4 DI DMCBPI4 DMCBPI4 DN 1,2-diamino cyclopentane-based derivative 19 DMCBPI4 TI TT60Q8D DMCBPI4 TN Orexin receptor type 1 (HCRTR1) DMCBPI4 MA Antagonist DMCBPI4 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCBPI4 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCD0MS DI DMCD0MS DMCD0MS DN Heterocyclic derivative 3 DMCD0MS TI TTHS256 DMCD0MS TN Metabotropic glutamate receptor 5 (mGluR5) DMCD0MS MA Modulator DMCD0MS RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMCD0MS RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMCD19T DI DMCD19T DMCD19T DN PMID27774822-Compound-Figure6Example2 DMCD19T TI TTT7PJU DMCD19T TN Janus kinase 3 (JAK-3) DMCD19T MA Inhibitor DMCD19T RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCD19T RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTRMX3V DMCDFLQ TN Janus kinase 2 (JAK-2) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TT6DM01 DMCDFLQ TN Janus kinase 1 (JAK-1) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTBYWP2 DMCDFLQ TN TYK2 tyrosine kinase (TYK2) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TT3C80U DMCDFLQ TN T-cell-specific kinase (ITK) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTNDSC3 DMCDFLQ TN B lymphocyte kinase (BLK) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TT1ZV49 DMCDFLQ TN Tyrosine-protein kinase Tec (PSCTK4) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTGM6VW DMCDFLQ TN Tyrosine-protein kinase BTK (ATK) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDFLQ DI DMCDFLQ DMCDFLQ DN Pyrazolo[4,3-c]pyridine derivative 2 DMCDFLQ TI TTT7PJU DMCDFLQ TN Janus kinase 3 (JAK-3) DMCDFLQ MA Inhibitor DMCDFLQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCDFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCDHZT DI DMCDHZT DMCDHZT DN PMID25553724-Compound-US2011803494010 DMCDHZT TI TTSXVID DMCDHZT TN Nuclear factor NF-kappa-B (NFKB) DMCDHZT MA Inhibitor DMCDHZT RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMCDHZT RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMCE3J0 DI DMCE3J0 DMCE3J0 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 6 DMCE3J0 TI TTXJ47W DMCE3J0 TN Metabotropic glutamate receptor 2 (mGluR2) DMCE3J0 MA Antagonist DMCE3J0 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMCE3J0 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMCE6MB DI DMCE6MB DMCE6MB DN PMID25666693-Compound-127 DMCE6MB TI TTMI6F5 DMCE6MB TN Transient receptor potential cation channel V1 (TRPV1) DMCE6MB MA Antagonist DMCE6MB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMCE6MB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMCEST4 DI DMCEST4 DMCEST4 DN PMID25656651-Compound-29a DMCEST4 TI TTS7G69 DMCEST4 TN Fusion protein Bcr-Abl (Bcr-Abl) DMCEST4 MA Inhibitor DMCEST4 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCEST4 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCF2G7 DI DMCF2G7 DMCF2G7 DN PMID25470667-Compound-roselipins DMCF2G7 TI TTRHEQ4 DMCF2G7 TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMCF2G7 MA Inhibitor DMCF2G7 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMCF2G7 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMCF6M8 DI DMCF6M8 DMCF6M8 DN Epoxysuccinate derivative 4 DMCF6M8 TI TTG5QB7 DMCF6M8 TN Calpain-2 (CAPN2) DMCF6M8 MA Inhibitor DMCF6M8 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMCF6M8 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMCFEAS DI DMCFEAS DMCFEAS DN Triazole derivative 4 DMCFEAS TI TTSCIUP DMCFEAS TN Oxytocin receptor (OTR) DMCFEAS MA Antagonist DMCFEAS RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMCFEAS RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMCFOXP DI DMCFOXP DMCFOXP DN PMID27744724-Compound-13 DMCFOXP TI TTL53M6 DMCFOXP TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMCFOXP MA Inhibitor DMCFOXP RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMCFOXP RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMCG6BE DI DMCG6BE DMCG6BE DN Piperazine carbamate/urea derivative 2 DMCG6BE TI TT9JNIC DMCG6BE TN Histamine H3 receptor (H3R) DMCG6BE MA Ligand DMCG6BE RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMCG6BE RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMCGUNB DI DMCGUNB DMCGUNB DN US9567304, Compound N-9 DMCGUNB TI TTI1FPZ DMCGUNB TN Epithelial discoidin domain receptor 1 (DDR1) DMCGUNB MA Inhibitor DMCGUNB RN Quinazolinedione derivative. US9567304. DMCGUNB RU http://www.freepatentsonline.com/US9567304.html DMCGX5S DI DMCGX5S DMCGX5S DN Benzazepine derivative 6 DMCGX5S TI TTWJBZ5 DMCGX5S TN 5-HT 2C receptor (HTR2C) DMCGX5S MA Agonist DMCGX5S RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMCGX5S RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMCH1DL DI DMCH1DL DMCH1DL DN Thiazole carboxamide derivative 15 DMCH1DL TI TTCZOF2 DMCH1DL TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMCH1DL MA Inhibitor DMCH1DL RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMCH1DL RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMCH1WX DI DMCH1WX DMCH1WX DN Benzothiazepine analog 5 DMCH1WX TI TTPTXIN DMCH1WX TN Translocator protein (TSPO) DMCH1WX MA Ligand DMCH1WX RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMCH1WX RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMCHLAN DI DMCHLAN DMCHLAN DN Resorcinol compound 28 DMCHLAN TI TTULVH8 DMCHLAN TN Tyrosinase (TYR) DMCHLAN MA Inhibitor DMCHLAN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMCHLAN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMCHWSF DI DMCHWSF DMCHWSF DN PMID25399762-Compound-Table 6-15 DMCHWSF TI TTGP7BY DMCHWSF TN Monoamine oxidase type B (MAO-B) DMCHWSF MA Inhibitor DMCHWSF RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCHWSF RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCHWSF DI DMCHWSF DMCHWSF DN PMID25399762-Compound-Table 6-15 DMCHWSF TI TTNR0UQ DMCHWSF TN Lysine-specific histone demethylase 1 (LSD) DMCHWSF MA Inhibitor DMCHWSF RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCHWSF RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCI6YH DI DMCI6YH DMCI6YH DN Monoaryl-1,2-diamine derivative 1 DMCI6YH TI TTZJYKH DMCI6YH TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCI6YH MA Inhibitor DMCI6YH RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCI6YH RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCIGJ1 DI DMCIGJ1 DMCIGJ1 DN PMID29671355-Compound-24 DMCIGJ1 TI TT6R7JZ DMCIGJ1 TN Histone deacetylase 1 (HDAC1) DMCIGJ1 MA Inhibitor DMCIGJ1 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCIGJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCIGJ1 DI DMCIGJ1 DMCIGJ1 DN PMID29671355-Compound-24 DMCIGJ1 TI TT5ZKDI DMCIGJ1 TN Histone deacetylase 6 (HDAC6) DMCIGJ1 MA Inhibitor DMCIGJ1 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCIGJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCIKR3 DI DMCIKR3 DMCIKR3 DN Quinolinyl pyrazinyl urea derivative 1 DMCIKR3 TI TTRZQE3 DMCIKR3 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMCIKR3 MA Inhibitor DMCIKR3 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMCIKR3 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMCIQ01 DI DMCIQ01 DMCIQ01 DN PMID25522065-Compound-40 DMCIQ01 TI TTX4RTB DMCIQ01 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMCIQ01 MA Antagonist DMCIQ01 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMCIQ01 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMCISHW DI DMCISHW DMCISHW DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 1 DMCISHW TI TTV1C0Z DMCISHW TN Neuropeptide S receptor (NPSR) DMCISHW MA Antagonist DMCISHW RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMCISHW RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMCIT5A DI DMCIT5A DMCIT5A DN PMID27019002-Compound-37b DMCIT5A TI TTNR0UQ DMCIT5A TN Lysine-specific histone demethylase 1 (LSD) DMCIT5A MA Inhibitor DMCIT5A RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMCIT5A RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMCIV32 DI DMCIV32 DMCIV32 DN Alkyl mannoside derivative 6 DMCIV32 TI TTTCRU2 DMCIV32 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCIV32 MA Antagonist DMCIV32 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCIV32 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCIXD4 DI DMCIXD4 DMCIXD4 DN Piperazine carbamate/urea derivative 1 DMCIXD4 TI TT9JNIC DMCIXD4 TN Histamine H3 receptor (H3R) DMCIXD4 MA Ligand DMCIXD4 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMCIXD4 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMCJ48G DI DMCJ48G DMCJ48G DN PMID27109571-Compound-36 DMCJ48G TI TTMY6L1 DMCJ48G TN Fatty acid-binding protein (FABP) DMCJ48G MA Inhibitor DMCJ48G RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMCJ48G RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMCJG8Z DI DMCJG8Z DMCJG8Z DN US9434727, 93 DMCJG8Z TI TT0C8BY DMCJG8Z TN Plasma retinol-binding protein (RBP4) DMCJG8Z MA Inhibitor DMCJG8Z RN Substituted 4-phenylpiperidines, their preparation and use. US10072016. DMCJG8Z RU http://www.freepatentsonline.com/US10072016.html DMCJH4F DI DMCJH4F DMCJH4F DN US8524917, 10 DMCJH4F TI TTDYP7I DMCJH4F TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMCJH4F MA Inhibitor DMCJH4F RN 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity. US8524917. DMCJH4F RU http://www.freepatentsonline.com/US8524917.html DMCJHK2 DI DMCJHK2 DMCJHK2 DN 3ts4 DMCJHK2 TI TTXLEG7 DMCJHK2 TN Matrix metalloproteinase-10 (MMP-10) DMCJHK2 MA Inhibitor DMCJHK2 RN Pseudodipeptides as MMP inhibitors. US8691753. DMCJHK2 RU http://www.freepatentsonline.com/US8691753.html DMCJO0R DI DMCJO0R DMCJO0R DN Resorcinol compound 9 DMCJO0R TI TTULVH8 DMCJO0R TN Tyrosinase (TYR) DMCJO0R MA Inhibitor DMCJO0R RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMCJO0R RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMCJR4N DI DMCJR4N DMCJR4N DN N-acylpiperidine ether derivative 7 DMCJR4N TI TTTDVOJ DMCJR4N TN Tropomyosin-related kinase A (TrkA) DMCJR4N MA Inhibitor DMCJR4N RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMCJR4N RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMCJTU1 DI DMCJTU1 DMCJTU1 DN PMID25416646-Compound-Figure5-H DMCJTU1 TI TTZMAO3 DMCJTU1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMCJTU1 MA Agonist DMCJTU1 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMCJTU1 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMCJTU1 DI DMCJTU1 DMCJTU1 DN PMID25416646-Compound-Figure5-H DMCJTU1 TI TTJ584C DMCJTU1 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMCJTU1 MA Agonist DMCJTU1 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMCJTU1 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMCJVLR DI DMCJVLR DMCJVLR DN Pyrazolopyridine derivative 2 DMCJVLR TI TTT7PJU DMCJVLR TN Janus kinase 3 (JAK-3) DMCJVLR MA Inhibitor DMCJVLR RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCJVLR RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCKAON DI DMCKAON DMCKAON DN PMID25656651-Compound-21a DMCKAON TI TTS7G69 DMCKAON TN Fusion protein Bcr-Abl (Bcr-Abl) DMCKAON MA Inhibitor DMCKAON RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCKAON RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCKAON DI DMCKAON DMCKAON DN PMID25656651-Compound-21a DMCKAON TI TTX41N9 DMCKAON TN Tyrosine-protein kinase Kit (KIT) DMCKAON MA Inhibitor DMCKAON RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCKAON RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCKAON DI DMCKAON DMCKAON DN PMID25656651-Compound-21a DMCKAON TI TTI7421 DMCKAON TN Platelet-derived growth factor receptor beta (PDGFRB) DMCKAON MA Inhibitor DMCKAON RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCKAON RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCKBGM DI DMCKBGM DMCKBGM DN Pyrimidinyl compound 5 DMCKBGM TI TTH5TC2 DMCKBGM TN NF-kappa-B-activating kinase (TBK1) DMCKBGM MA Inhibitor DMCKBGM RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMCKBGM RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMCKSJ8 DI DMCKSJ8 DMCKSJ8 DN Azaindole derivative 4 DMCKSJ8 TI TT7RJY8 DMCKSJ8 TN Xanthine dehydrogenase/oxidase (XDH) DMCKSJ8 MA Inhibitor DMCKSJ8 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMCKSJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMCL19N DI DMCL19N DMCL19N DN PMID27774822-Compound-Figure1Example20 DMCL19N TI TTT7PJU DMCL19N TN Janus kinase 3 (JAK-3) DMCL19N MA Inhibitor DMCL19N RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCL19N RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCL19N DI DMCL19N DMCL19N DN PMID27774822-Compound-Figure1Example20 DMCL19N TI TTRMX3V DMCL19N TN Janus kinase 2 (JAK-2) DMCL19N MA Inhibitor DMCL19N RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCL19N RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCL19N DI DMCL19N DMCL19N DN PMID27774822-Compound-Figure1Example20 DMCL19N TI TT6DM01 DMCL19N TN Janus kinase 1 (JAK-1) DMCL19N MA Inhibitor DMCL19N RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCL19N RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCLB5D DI DMCLB5D DMCLB5D DN Boswellia acid derivative 1 DMCLB5D TI TTYLQ8V DMCLB5D TN Prostaglandin E synthase (PTGES) DMCLB5D MA Inhibitor DMCLB5D RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMCLB5D RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMCLHX5 DI DMCLHX5 DMCLHX5 DN US9200020, Table 3 compound 8 DMCLHX5 TI TTBL49X DMCLHX5 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMCLHX5 MA Inhibitor DMCLHX5 RN 6-oxopurine phosphoribosyltransferase inhibitors. US9200020. DMCLHX5 RU http://www.freepatentsonline.com/US9200020.html DMCLJ0M DI DMCLJ0M DMCLJ0M DN PMID29473428-Compound-47 DMCLJ0M TI TTZJYKH DMCLJ0M TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCLJ0M MA Inhibitor DMCLJ0M RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCLJ0M RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCLKBY DI DMCLKBY DMCLKBY DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 3 DMCLKBY TI TTV8CRH DMCLKBY TN Lysine-specific demethylase 4C (KDM4C) DMCLKBY MA Inhibitor DMCLKBY RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCLKBY RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCLTY3 DI DMCLTY3 DMCLTY3 DN Biaryl mannoside derivative 29 DMCLTY3 TI TTTCRU2 DMCLTY3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCLTY3 MA Antagonist DMCLTY3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCLTY3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCLZWS DI DMCLZWS DMCLZWS DN Polyhydroxy benzamide derivative 3 DMCLZWS TI TTULVH8 DMCLZWS TN Tyrosinase (TYR) DMCLZWS MA Inhibitor DMCLZWS RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMCLZWS RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMCM3NW DI DMCM3NW DMCM3NW DN Mannoside derivative 6 DMCM3NW TI TTTCRU2 DMCM3NW TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCM3NW MA Antagonist DMCM3NW RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCM3NW RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCMKIL DI DMCMKIL DMCMKIL DN Hydroxyqunoline analog 3 DMCMKIL TI TTWAQBO DMCMKIL TN Lysine-specific demethylase 4E (KDM4E) DMCMKIL MA Inhibitor DMCMKIL RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCMKIL RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCNAM9 DI DMCNAM9 DMCNAM9 DN US8710232, 1 DMCNAM9 TI TT4UJX5 DMCNAM9 TN Carboxypeptidase B1 (CPB1) DMCNAM9 MA Inhibitor DMCNAM9 RN Imidazole derivatives used as TAFIa inhibitors. US8710232. DMCNAM9 RU http://www.freepatentsonline.com/US8710232.html DMCNF36 DI DMCNF36 DMCNF36 DN PMID29671355-Compound-73 DMCNF36 TI TT8M4E1 DMCNF36 TN Histone deacetylase 9 (HDAC9) DMCNF36 MA Inhibitor DMCNF36 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCNF36 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCNF36 DI DMCNF36 DMCNF36 DN PMID29671355-Compound-73 DMCNF36 TI TT5ZKDI DMCNF36 TN Histone deacetylase 6 (HDAC6) DMCNF36 MA Inhibitor DMCNF36 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCNF36 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCNF36 DI DMCNF36 DMCNF36 DN PMID29671355-Compound-73 DMCNF36 TI TT6R7JZ DMCNF36 TN Histone deacetylase 1 (HDAC1) DMCNF36 MA Inhibitor DMCNF36 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCNF36 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCNQAF DI DMCNQAF DMCNQAF DN 1,2-diamino cyclopentane-based derivative 18 DMCNQAF TI TT9N02I DMCNQAF TN Orexin receptor type 2 (HCRTR2) DMCNQAF MA Antagonist DMCNQAF RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCNQAF RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCNQAF DI DMCNQAF DMCNQAF DN 1,2-diamino cyclopentane-based derivative 18 DMCNQAF TI TT60Q8D DMCNQAF TN Orexin receptor type 1 (HCRTR1) DMCNQAF MA Antagonist DMCNQAF RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCNQAF RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCNS9T DI DMCNS9T DMCNS9T DN US8710232, 7 DMCNS9T TI TT4UJX5 DMCNS9T TN Carboxypeptidase B1 (CPB1) DMCNS9T MA Inhibitor DMCNS9T RN Imidazole derivatives used as TAFIa inhibitors. US8710232. DMCNS9T RU http://www.freepatentsonline.com/US8710232.html DMCNSZD DI DMCNSZD DMCNSZD DN PMID29473428-Compound-22 DMCNSZD TI TTZJYKH DMCNSZD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMCNSZD MA Inhibitor DMCNSZD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMCNSZD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMCNWPI DI DMCNWPI DMCNWPI DN Pyridine-2,4-dicarboxylic acid analog 2 DMCNWPI TI TTWAQBO DMCNWPI TN Lysine-specific demethylase 4E (KDM4E) DMCNWPI MA Inhibitor DMCNWPI RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCNWPI RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCO0ZS DI DMCO0ZS DMCO0ZS DN Benzotriazole derivative 1 DMCO0ZS TI TT2F4OL DMCO0ZS TN Tissue transglutaminase (TG2) DMCO0ZS MA Inhibitor DMCO0ZS RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMCO0ZS RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMCO8JD DI DMCO8JD DMCO8JD DN Sulfonylated piperazine derivative 1 DMCO8JD TI TT6OEDT DMCO8JD TN Cannabinoid receptor 1 (CB1) DMCO8JD MA Antagonist DMCO8JD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCO8JD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMCORT3 DI DMCORT3 DMCORT3 DN Indoline derivative 9 DMCORT3 TI TT5OU0D DMCORT3 TN PRKR-like endoplasmic reticulum kinase (PERK) DMCORT3 MA Inhibitor DMCORT3 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMCORT3 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMCP0WF DI DMCP0WF DMCP0WF DN PMID26004420-Compound-WO2013028474B DMCP0WF TI TTJ13ST DMCP0WF TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMCP0WF MA Inhibitor DMCP0WF RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMCP0WF RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMCP15K DI DMCP15K DMCP15K DN 1,2-diamino cyclopentane-based derivative 5 DMCP15K TI TT9N02I DMCP15K TN Orexin receptor type 2 (HCRTR2) DMCP15K MA Antagonist DMCP15K RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCP15K RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCP15K DI DMCP15K DMCP15K DN 1,2-diamino cyclopentane-based derivative 5 DMCP15K TI TT60Q8D DMCP15K TN Orexin receptor type 1 (HCRTR1) DMCP15K MA Antagonist DMCP15K RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMCP15K RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMCPV0D DI DMCPV0D DMCPV0D DN Thiazole-fused cycloalkyl carboxamide derivative 1 DMCPV0D TI TT473XN DMCPV0D TN P2X purinoceptor 7 (P2RX7) DMCPV0D MA Antagonist DMCPV0D RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMCPV0D RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMCPVRU DI DMCPVRU DMCPVRU DN Spiroimidazolone derivative 1 DMCPVRU TI TT9O6WS DMCPVRU TN Glucagon receptor (GCGR) DMCPVRU MA Antagonist DMCPVRU RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMCPVRU RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMCQB93 DI DMCQB93 DMCQB93 DN PMID27841045-Compound-132 DMCQB93 TI TT7RJY8 DMCQB93 TN Xanthine dehydrogenase/oxidase (XDH) DMCQB93 MA Inhibitor DMCQB93 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMCQB93 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMCQBZK DI DMCQBZK DMCQBZK DN Imidazo cyclohexylamine derivative 3 DMCQBZK TI TTDIGC1 DMCQBZK TN Dipeptidyl peptidase 4 (DPP-4) DMCQBZK MA Inhibitor DMCQBZK RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMCQBZK RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMCQLJY DI DMCQLJY DMCQLJY DN Benzene sulfonamide derivative 3 DMCQLJY TI TTIY56R DMCQLJY TN Kynurenine 3-hydroxylase (KMO) DMCQLJY MA Inhibitor DMCQLJY RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMCQLJY RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMCQN5M DI DMCQN5M DMCQN5M DN Pyrrolidine derivative 10 DMCQN5M TI TTSCIUP DMCQN5M TN Oxytocin receptor (OTR) DMCQN5M MA Antagonist DMCQN5M RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMCQN5M RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMCQP0B DI DMCQP0B DMCQP0B DN Flavonoid derivative 1 DMCQP0B TI TTH8FZW DMCQP0B TN Signal transducer and activator of transcription 3 (STAT3) DMCQP0B MA Inhibitor DMCQP0B RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMCQP0B RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMCRA2U DI DMCRA2U DMCRA2U DN PMID25656651-Compound-33a DMCRA2U TI TT3PJMV DMCRA2U TN Tyrosine-protein kinase ABL1 (ABL) DMCRA2U MA Inhibitor DMCRA2U RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMCRA2U RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMCRJO1 DI DMCRJO1 DMCRJO1 DN PMID26004420-Compound-US20140336177E DMCRJO1 TI TTJ13ST DMCRJO1 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMCRJO1 MA Inhibitor DMCRJO1 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMCRJO1 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMCRNWA DI DMCRNWA DMCRNWA DN PMID26651364-Compound-10c DMCRNWA TI TTTCRU2 DMCRNWA TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMCRNWA MA Antagonist DMCRNWA RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMCRNWA RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMCRVO5 DI DMCRVO5 DMCRVO5 DN Thiazole carboxamide derivative 29 DMCRVO5 TI TTCZOF2 DMCRVO5 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMCRVO5 MA Inhibitor DMCRVO5 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMCRVO5 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMCRWV3 DI DMCRWV3 DMCRWV3 DN PMID29671355-Compound-53 DMCRWV3 TI TTBH0VX DMCRWV3 TN Histone deacetylase (HDAC) DMCRWV3 MA Inhibitor DMCRWV3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMCRWV3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMCS08K DI DMCS08K DMCS08K DN Pyrazole derivative 22 DMCS08K TI TT6OEDT DMCS08K TN Cannabinoid receptor 1 (CB1) DMCS08K MA Antagonist DMCS08K RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCS08K RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMCSIYG DI DMCSIYG DMCSIYG DN Cyclopropane 1-carboxylic acid derivative 5 DMCSIYG TI TTIY56R DMCSIYG TN Kynurenine 3-hydroxylase (KMO) DMCSIYG MA Inhibitor DMCSIYG RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMCSIYG RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMCT6QW DI DMCT6QW DMCT6QW DN Pyrazolo[1,5-a]pyrimidine derivative 29 DMCT6QW TI TTF8P9I DMCT6QW TN Diacylglycerol acyltransferase 1 (DGAT1) DMCT6QW MA Inhibitor DMCT6QW RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMCT6QW RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMCTMB1 DI DMCTMB1 DMCTMB1 DN PMID27454349-Compound-93 DMCTMB1 TI TTK59TV DMCTMB1 TN Vitamin D3 receptor (VDR) DMCTMB1 MA Agonist DMCTMB1 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMCTMB1 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMCTQ9O DI DMCTQ9O DMCTQ9O DN Pyrazolopyridine derivative 7 DMCTQ9O TI TTT7PJU DMCTQ9O TN Janus kinase 3 (JAK-3) DMCTQ9O MA Inhibitor DMCTQ9O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCTQ9O RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCTQ9O DI DMCTQ9O DMCTQ9O DN Pyrazolopyridine derivative 7 DMCTQ9O TI TTRMX3V DMCTQ9O TN Janus kinase 2 (JAK-2) DMCTQ9O MA Inhibitor DMCTQ9O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMCTQ9O RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMCTWVY DI DMCTWVY DMCTWVY DN Pyrazolo[3,4-d]pyrimidine derivative 6 DMCTWVY TI TT4DXQT DMCTWVY TN Proto-oncogene c-Ret (RET) DMCTWVY MA Inhibitor DMCTWVY RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMCTWVY RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMCTXPQ DI DMCTXPQ DMCTXPQ DN PMID27774822-Compound-Figure10Example1 DMCTXPQ TI TTRMX3V DMCTXPQ TN Janus kinase 2 (JAK-2) DMCTXPQ MA Inhibitor DMCTXPQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCTXPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCTXPQ DI DMCTXPQ DMCTXPQ DN PMID27774822-Compound-Figure10Example1 DMCTXPQ TI TTT7PJU DMCTXPQ TN Janus kinase 3 (JAK-3) DMCTXPQ MA Inhibitor DMCTXPQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCTXPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCTXPQ DI DMCTXPQ DMCTXPQ DN PMID27774822-Compound-Figure10Example1 DMCTXPQ TI TTJSQEF DMCTXPQ TN Tyrosine-protein kinase (PTK) DMCTXPQ MA Inhibitor DMCTXPQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCTXPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCUAO9 DI DMCUAO9 DMCUAO9 DN PMID27977313-Compound-6 DMCUAO9 TI TTR7UJ3 DMCUAO9 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMCUAO9 MA Inhibitor DMCUAO9 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMCUAO9 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMCULI1 DI DMCULI1 DMCULI1 DN PMID25776143-Compound-3 DMCULI1 TI TT4TFGN DMCULI1 TN Vasopressin V1a receptor (V1AR) DMCULI1 MA Inhibitor DMCULI1 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMCULI1 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMCULK7 DI DMCULK7 DMCULK7 DN Lazabemide DMCULK7 TI TTGP7BY DMCULK7 TN Monoamine oxidase type B (MAO-B) DMCULK7 MA Inhibitor DMCULK7 RN The activity of MAO A and B in rat renal cells and tubules. Life Sci. 1998;62(8):727-37. DMCULK7 RU https://pubmed.ncbi.nlm.nih.gov/9489509 DMCULK7 DI DMCULK7 DMCULK7 DN Lazabemide DMCULK7 TI TT32XQJ DMCULK7 TN Monoamine oxidase (MAO) DMCULK7 MA Inhibitor DMCULK7 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMCULK7 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMCUMSV DI DMCUMSV DMCUMSV DN PMID25553724-Compound-US2012830453910 DMCUMSV TI TTSXVID DMCUMSV TN Nuclear factor NF-kappa-B (NFKB) DMCUMSV MA Inhibitor DMCUMSV RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMCUMSV RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMCUP4L DI DMCUP4L DMCUP4L DN Pyridine-2,4-dicarboxylic acid derivative 3 DMCUP4L TI TT0RGE9 DMCUP4L TN Lysine-specific demethylase 4 (KDM4) DMCUP4L MA Inhibitor DMCUP4L RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMCUP4L RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMCUQFG DI DMCUQFG DMCUQFG DN Pyrimidine derivative 32 DMCUQFG TI TTDIGC1 DMCUQFG TN Dipeptidyl peptidase 4 (DPP-4) DMCUQFG MA Inhibitor DMCUQFG RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMCUQFG RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMCUX42 DI DMCUX42 DMCUX42 DN PMID28067079-Compound-97 DMCUX42 TI TTHS256 DMCUX42 TN Metabotropic glutamate receptor 5 (mGluR5) DMCUX42 MA Modulator DMCUX42 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMCUX42 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMCVBPF DI DMCVBPF DMCVBPF DN N-naphtyl-N-benzylurea derivative 1 DMCVBPF TI TTRZQE3 DMCVBPF TN Glycogen synthase kinase-3 alpha (GSK-3A) DMCVBPF MA Inhibitor DMCVBPF RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMCVBPF RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMCWES7 DI DMCWES7 DMCWES7 DN Triazole gold complexe 1 DMCWES7 TI TTR7UJ3 DMCWES7 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMCWES7 MA Inhibitor DMCWES7 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMCWES7 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMCWFU1 DI DMCWFU1 DMCWFU1 DN Isoxazoles and isoxazoline derivative 5 DMCWFU1 TI TTIY56R DMCWFU1 TN Kynurenine 3-hydroxylase (KMO) DMCWFU1 MA Inhibitor DMCWFU1 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMCWFU1 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMCXDKS DI DMCXDKS DMCXDKS DN PMID25726713-Compound-34 DMCXDKS TI TT8J1S3 DMCXDKS TN Smoothened homolog (SMO) DMCXDKS MA Inhibitor DMCXDKS RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMCXDKS RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMCXELD DI DMCXELD DMCXELD DN PMID25666693-Compound-144 DMCXELD TI TTMI6F5 DMCXELD TN Transient receptor potential cation channel V1 (TRPV1) DMCXELD MA Antagonist DMCXELD RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMCXELD RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMCXHGW DI DMCXHGW DMCXHGW DN Imidazo pyridine derivative 1 DMCXHGW TI TTTDVOJ DMCXHGW TN Tropomyosin-related kinase A (TrkA) DMCXHGW MA Inhibitor DMCXHGW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMCXHGW RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMCY5M7 DI DMCY5M7 DMCY5M7 DN Benzimidazole derivative 14 DMCY5M7 TI TTYLQ8V DMCY5M7 TN Prostaglandin E synthase (PTGES) DMCY5M7 MA Inhibitor DMCY5M7 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMCY5M7 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMCYM8P DI DMCYM8P DMCYM8P DN US9073931, E3 DMCYM8P TI TTECBXN DMCYM8P TN Oxysterols receptor LXR-alpha (NR1H3) DMCYM8P MA Inhibitor DMCYM8P RN Liver X receptor modulators. US9073931. DMCYM8P RU http://www.freepatentsonline.com/US9073931.html DMCYOL7 DI DMCYOL7 DMCYOL7 DN Pyrrolo[2,3-b]pyridine derivative 3 DMCYOL7 TI TTTDVOJ DMCYOL7 TN Tropomyosin-related kinase A (TrkA) DMCYOL7 MA Inhibitor DMCYOL7 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMCYOL7 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMCZ3SH DI DMCZ3SH DMCZ3SH DN PMID29865878-Compound-38 DMCZ3SH TI TTSJMN8 DMCZ3SH TN Immunoproteasome complex (IP) DMCZ3SH MA Inhibitor DMCZ3SH RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMCZ3SH RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMCZ8UV DI DMCZ8UV DMCZ8UV DN Pyrrolo-pyridone derivative 2 DMCZ8UV TI TTRMX3V DMCZ8UV TN Janus kinase 2 (JAK-2) DMCZ8UV MA Inhibitor DMCZ8UV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCZ8UV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCZ8UV DI DMCZ8UV DMCZ8UV DN Pyrrolo-pyridone derivative 2 DMCZ8UV TI TT6DM01 DMCZ8UV TN Janus kinase 1 (JAK-1) DMCZ8UV MA Inhibitor DMCZ8UV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMCZ8UV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TT1RS9F DMCZA45 TN Acetylcholinesterase (AChE) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TTGP7BY DMCZA45 TN Monoamine oxidase type B (MAO-B) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TT3WG5C DMCZA45 TN Monoamine oxidase type A (MAO-A) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZA45 DI DMCZA45 DMCZA45 DN Tetra-hydro-isoquinoline derivative 3 DMCZA45 TI TTEB0GD DMCZA45 TN Cholinesterase (BCHE) DMCZA45 MA Inhibitor DMCZA45 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMCZA45 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMCZJ1W DI DMCZJ1W DMCZJ1W DN Pyrrolo[2,3-d]pyrimidine derivative 27 DMCZJ1W TI TTGM6VW DMCZJ1W TN Tyrosine-protein kinase BTK (ATK) DMCZJ1W MA Inhibitor DMCZJ1W RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMCZJ1W RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMCZORA DI DMCZORA DMCZORA DN Pyrazoline derivative 10 DMCZORA TI TT6OEDT DMCZORA TN Cannabinoid receptor 1 (CB1) DMCZORA MA Antagonist DMCZORA RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMCZORA RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMD03J5 DI DMD03J5 DMD03J5 DN Carbamide derivative 21 DMD03J5 TI TTOHSBA DMD03J5 TN Vascular endothelial growth factor A (VEGFA) DMD03J5 MA Inhibitor DMD03J5 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMD03J5 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMD0GN6 DI DMD0GN6 DMD0GN6 DN US10030004, Compound 33 DMD0GN6 TI TTPKHTZ DMD0GN6 TN Activin receptor type IB (ACVR1B) DMD0GN6 MA Inhibitor DMD0GN6 RN Compounds and methods of use. US10030004. DMD0GN6 RU http://www.freepatentsonline.com/US10030004.html DMD0HAT DI DMD0HAT DMD0HAT DN PMID27019002-Compound-13 DMD0HAT TI TTNR0UQ DMD0HAT TN Lysine-specific histone demethylase 1 (LSD) DMD0HAT MA Inhibitor DMD0HAT RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMD0HAT RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMD0T6S DI DMD0T6S DMD0T6S DN PMID27744724-Compound-20 DMD0T6S TI TTL53M6 DMD0T6S TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMD0T6S MA Inhibitor DMD0T6S RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMD0T6S RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMD0WIA DI DMD0WIA DMD0WIA DN PMID25666693-Compound-119 DMD0WIA TI TTMI6F5 DMD0WIA TN Transient receptor potential cation channel V1 (TRPV1) DMD0WIA MA Antagonist DMD0WIA RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMD0WIA RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMD0XIL DI DMD0XIL DMD0XIL DN Lactam derivative 3 DMD0XIL TI TTF8P9I DMD0XIL TN Diacylglycerol acyltransferase 1 (DGAT1) DMD0XIL MA Inhibitor DMD0XIL RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMD0XIL RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMD13OS DI DMD13OS DMD13OS DN PMID25666693-Compound-66 DMD13OS TI TTMI6F5 DMD13OS TN Transient receptor potential cation channel V1 (TRPV1) DMD13OS MA Antagonist DMD13OS RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMD13OS RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMD198F DI DMD198F DMD198F DN Cyanomethyl pypazole carboxamide derivative 1 DMD198F TI TTRMX3V DMD198F TN Janus kinase 2 (JAK-2) DMD198F MA Inhibitor DMD198F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD198F RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD198F DI DMD198F DMD198F DN Cyanomethyl pypazole carboxamide derivative 1 DMD198F TI TT6DM01 DMD198F TN Janus kinase 1 (JAK-1) DMD198F MA Inhibitor DMD198F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD198F RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD19QC DI DMD19QC DMD19QC DN Isoindoline derivative 1 DMD19QC TI TTQ6VDM DMD19QC TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMD19QC MA Ligand DMD19QC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD19QC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD19QC DI DMD19QC DMD19QC DN Isoindoline derivative 1 DMD19QC TI TT5TPI6 DMD19QC TN Opioid receptor sigma 1 (OPRS1) DMD19QC MA Ligand DMD19QC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD19QC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD19QC DI DMD19QC DMD19QC DN Isoindoline derivative 1 DMD19QC TI TT9NXW4 DMD19QC TN Sigma intracellular receptor 2 (TMEM97) DMD19QC MA Ligand DMD19QC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD19QC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TTL4Q97 DMD1G3Z TN Cyclin-dependent kinase 5 (CDK5) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TT1LVF2 DMD1G3Z TN Cyclin-dependent kinase 9 (CDK9) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TTH6V3D DMD1G3Z TN Cyclin-dependent kinase 1 (CDK1) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TTQYF7G DMD1G3Z TN Cyclin-dependent kinase 7 (CDK7) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1G3Z DI DMD1G3Z DMD1G3Z DN Roscovitine derivative 1 DMD1G3Z TI TT7HF4W DMD1G3Z TN Cyclin-dependent kinase 2 (CDK2) DMD1G3Z MA Inhibitor DMD1G3Z RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMD1G3Z RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMD1K7E DI DMD1K7E DMD1K7E DN Heterocyclic derivative 17 DMD1K7E TI TTCZOF2 DMD1K7E TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMD1K7E MA Inhibitor DMD1K7E RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMD1K7E RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TTOU65C DMD1RT0 TN Tyrosine-protein kinase SYK (SYK) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TTT7PJU DMD1RT0 TN Janus kinase 3 (JAK-3) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TT6DM01 DMD1RT0 TN Janus kinase 1 (JAK-1) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1RT0 DI DMD1RT0 DMD1RT0 DN Pyrimidopyridazinone derivative 2 DMD1RT0 TI TTRMX3V DMD1RT0 TN Janus kinase 2 (JAK-2) DMD1RT0 MA Inhibitor DMD1RT0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMD1RT0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMD1S92 DI DMD1S92 DMD1S92 DN Pyrrolo-pyrazine derivative 4 DMD1S92 TI TTOU65C DMD1S92 TN Tyrosine-protein kinase SYK (SYK) DMD1S92 MA Inhibitor DMD1S92 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD1S92 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD1S92 DI DMD1S92 DMD1S92 DN Pyrrolo-pyrazine derivative 4 DMD1S92 TI TTT7PJU DMD1S92 TN Janus kinase 3 (JAK-3) DMD1S92 MA Inhibitor DMD1S92 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD1S92 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD2BL3 DI DMD2BL3 DMD2BL3 DN Azaindole derivative 5 DMD2BL3 TI TT7RJY8 DMD2BL3 TN Xanthine dehydrogenase/oxidase (XDH) DMD2BL3 MA Inhibitor DMD2BL3 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMD2BL3 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMD2CX1 DI DMD2CX1 DMD2CX1 DN Piperazinyl norbenzomorphane compound 2 DMD2CX1 TI TT9NXW4 DMD2CX1 TN Sigma intracellular receptor 2 (TMEM97) DMD2CX1 MA Ligand DMD2CX1 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMD2CX1 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMD2KRW DI DMD2KRW DMD2KRW DN 2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW TI TTALN9W DMD2KRW TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMD2KRW MA Inhibitor DMD2KRW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD2KRW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD2KRW DI DMD2KRW DMD2KRW DN 2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW TI TTZJYKH DMD2KRW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMD2KRW MA Inhibitor DMD2KRW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD2KRW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD2KRW DI DMD2KRW DMD2KRW DN 2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW TI TTXNCBV DMD2KRW TN Tryptophan 2,3-dioxygenase (TDO) DMD2KRW MA Inhibitor DMD2KRW RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD2KRW RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD2R1H DI DMD2R1H DMD2R1H DN Phthalazine ketone derivative 1 DMD2R1H TI TTVDSZ0 DMD2R1H TN Poly [ADP-ribose] polymerase 1 (PARP1) DMD2R1H MA Inhibitor DMD2R1H RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMD2R1H RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMD3AHN DI DMD3AHN DMD3AHN DN PMID25726713-Compound-12 DMD3AHN TI TT8J1S3 DMD3AHN TN Smoothened homolog (SMO) DMD3AHN MA Inhibitor DMD3AHN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMD3AHN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMD3CB4 DI DMD3CB4 DMD3CB4 DN PMID25772215-Compound-WO2012177618M4 DMD3CB4 TI TT1ZAVI DMD3CB4 TN Prostaglandin E2 receptor EP2 (PTGER2) DMD3CB4 MA Antagonist DMD3CB4 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMD3CB4 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMD3LK1 DI DMD3LK1 DMD3LK1 DN Cycloalkyl nitrile pyrazolo pyridone derivative 1 DMD3LK1 TI TTRMX3V DMD3LK1 TN Janus kinase 2 (JAK-2) DMD3LK1 MA Inhibitor DMD3LK1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD3LK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD3LK1 DI DMD3LK1 DMD3LK1 DN Cycloalkyl nitrile pyrazolo pyridone derivative 1 DMD3LK1 TI TT6DM01 DMD3LK1 TN Janus kinase 1 (JAK-1) DMD3LK1 MA Inhibitor DMD3LK1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMD3LK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMD3T1Q DI DMD3T1Q DMD3T1Q DN PMID26609882-Compound-58 DMD3T1Q TI TTWJBZ5 DMD3T1Q TN 5-HT 2C receptor (HTR2C) DMD3T1Q MA Antagonist DMD3T1Q RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMD3T1Q RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMD3U96 DI DMD3U96 DMD3U96 DN PMID27788040-Compound-6b DMD3U96 TI TTV1C0Z DMD3U96 TN Neuropeptide S receptor (NPSR) DMD3U96 MA Antagonist DMD3U96 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMD3U96 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMD41UF DI DMD41UF DMD41UF DN PMID26004420-Compound-WO2012058116B DMD41UF TI TTJ13ST DMD41UF TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMD41UF MA Inhibitor DMD41UF RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMD41UF RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMD4CIU DI DMD4CIU DMD4CIU DN PMID27387065-Compound-6 DMD4CIU TI TTK25J1 DMD4CIU TN Adenosine A1 receptor (ADORA1) DMD4CIU MA Agonist DMD4CIU RN Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016).Expert Opin Ther Pat. 2016 Aug;26(8):947-56. DMD4CIU RU https://www.ncbi.nlm.nih.gov/pubmed/27387065 DMD4CU5 DI DMD4CU5 DMD4CU5 DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 DMD4CU5 TI TT6OEDT DMD4CU5 TN Cannabinoid receptor 1 (CB1) DMD4CU5 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMD4CU5 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMD4CU5 DI DMD4CU5 DMD4CU5 DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 2 DMD4CU5 TI TTMSFAW DMD4CU5 TN Cannabinoid receptor 2 (CB2) DMD4CU5 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMD4CU5 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMD4UMP DI DMD4UMP DMD4UMP DN Benzene sulfonamide derivative 6 DMD4UMP TI TTIY56R DMD4UMP TN Kynurenine 3-hydroxylase (KMO) DMD4UMP MA Inhibitor DMD4UMP RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD4UMP RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD51AV DI DMD51AV DMD51AV DN Sulfonamide derivative 6 DMD51AV TI TTZJYKH DMD51AV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMD51AV MA Inhibitor DMD51AV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMD51AV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMD51HM DI DMD51HM DMD51HM DN Pyrazole and thiophene derivative 2 DMD51HM TI TTRA6BO DMD51HM TN Bromodomain-containing protein 4 (BRD4) DMD51HM MA Inhibitor DMD51HM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMD51HM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMD59C2 DI DMD59C2 DMD59C2 DN PMID25991433-Compound-A11 DMD59C2 TI TTHS0U8 DMD59C2 TN Stress-activated protein kinase JNK2 (JNK2) DMD59C2 MA Inhibitor DMD59C2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD59C2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD59C2 DI DMD59C2 DMD59C2 DN PMID25991433-Compound-A11 DMD59C2 TI TT0K6EO DMD59C2 TN Stress-activated protein kinase JNK1 (JNK1) DMD59C2 MA Inhibitor DMD59C2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD59C2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD5QEL DI DMD5QEL DMD5QEL DN PMID28270021-Compound-WO2016054807Example1 DMD5QEL TI TTKN7QR DMD5QEL TN BDNF/NT-3 growth factors receptor (TrkB) DMD5QEL MA Inhibitor DMD5QEL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMD5QEL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMD5QEL DI DMD5QEL DMD5QEL DN PMID28270021-Compound-WO2016054807Example1 DMD5QEL TI TTXABCW DMD5QEL TN NT-3 growth factor receptor (TrkC) DMD5QEL MA Inhibitor DMD5QEL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMD5QEL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMD5QEL DI DMD5QEL DMD5QEL DN PMID28270021-Compound-WO2016054807Example1 DMD5QEL TI TTTDVOJ DMD5QEL TN Tropomyosin-related kinase A (TrkA) DMD5QEL MA Inhibitor DMD5QEL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMD5QEL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMD65GU DI DMD65GU DMD65GU DN PMID30107136-Compound-Example11 DMD65GU TI TT23XQV DMD65GU TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMD65GU MA Inhibitor DMD65GU RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMD65GU RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMD65GU DI DMD65GU DMD65GU DN PMID30107136-Compound-Example11 DMD65GU TI TT5YPJF DMD65GU TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMD65GU MA Inhibitor DMD65GU RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMD65GU RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMD6GNO DI DMD6GNO DMD6GNO DN Pyrimidine benzenesulfonamide derivative 1 DMD6GNO TI TTIY56R DMD6GNO TN Kynurenine 3-hydroxylase (KMO) DMD6GNO MA Inhibitor DMD6GNO RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMD6GNO RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMD6Y73 DI DMD6Y73 DMD6Y73 DN Carbamide derivative 24 DMD6Y73 TI TTDP1UC DMD6Y73 TN Fatty acid amide hydrolase (FAAH) DMD6Y73 MA Inhibitor DMD6Y73 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMD6Y73 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMD6Y73 DI DMD6Y73 DMD6Y73 DN Carbamide derivative 24 DMD6Y73 TI TTZ963I DMD6Y73 TN Monoglyceride lipase (MAGL) DMD6Y73 MA Inhibitor DMD6Y73 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMD6Y73 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMD7053 DI DMD7053 DMD7053 DN Biaryl mannoside derivative 7 DMD7053 TI TTTCRU2 DMD7053 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMD7053 MA Antagonist DMD7053 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMD7053 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMD7640 DI DMD7640 DMD7640 DN Benzamide derivative 18 DMD7640 TI TTYLQ8V DMD7640 TN Prostaglandin E synthase (PTGES) DMD7640 MA Inhibitor DMD7640 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMD7640 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMD7AU3 DI DMD7AU3 DMD7AU3 DN PMID28074661-Compound-US20120264760C83 DMD7AU3 TI TTL7C8Q DMD7AU3 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMD7AU3 MA Inhibitor DMD7AU3 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMD7AU3 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMD7OW0 DI DMD7OW0 DMD7OW0 DN Nitrogen/sulfur-substituted estrene derivative 1 DMD7OW0 TI TT5ZWB6 DMD7OW0 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMD7OW0 MA Inhibitor DMD7OW0 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMD7OW0 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMD7Z3H DI DMD7Z3H DMD7Z3H DN Benzylcinnamate DMD7Z3H TI TTGP7BY DMD7Z3H TN Monoamine oxidase type B (MAO-B) DMD7Z3H MA Inhibitor DMD7Z3H RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMD7Z3H RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMD803F DI DMD803F DMD803F DN US9216972, 132 DMD803F TI TTDYP7I DMD803F TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMD803F MA Inhibitor DMD803F RN Tricyclic heterocyclic compounds. US9216972. DMD803F RU http://www.freepatentsonline.com/US9216972.html DMD80Q6 DI DMD80Q6 DMD80Q6 DN PMID25399762-Compound-Table1-C13 DMD80Q6 TI TTGP7BY DMD80Q6 TN Monoamine oxidase type B (MAO-B) DMD80Q6 MA Inhibitor DMD80Q6 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMD80Q6 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMD8AKH DI DMD8AKH DMD8AKH DN Monoaryl-1,2-diamine derivative 4 DMD8AKH TI TTZJYKH DMD8AKH TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMD8AKH MA Modulator DMD8AKH RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMD8AKH RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMD8AX6 DI DMD8AX6 DMD8AX6 DN PMID25991433-Compound-P1 DMD8AX6 TI TTHS0U8 DMD8AX6 TN Stress-activated protein kinase JNK2 (JNK2) DMD8AX6 MA Inhibitor DMD8AX6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD8AX6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD8AX6 DI DMD8AX6 DMD8AX6 DN PMID25991433-Compound-P1 DMD8AX6 TI TT056SO DMD8AX6 TN Stress-activated protein kinase JNK3 (JNK3) DMD8AX6 MA Inhibitor DMD8AX6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD8AX6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD8AX6 DI DMD8AX6 DMD8AX6 DN PMID25991433-Compound-P1 DMD8AX6 TI TT0K6EO DMD8AX6 TN Stress-activated protein kinase JNK1 (JNK1) DMD8AX6 MA Inhibitor DMD8AX6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMD8AX6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMD8C9S DI DMD8C9S DMD8C9S DN Salicylic acid derivative 2 DMD8C9S TI TTH8FZW DMD8C9S TN Signal transducer and activator of transcription 3 (STAT3) DMD8C9S MA Inhibitor DMD8C9S RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMD8C9S RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMD8FS5 DI DMD8FS5 DMD8FS5 DN US10034861, Example 165 DMD8FS5 TI TT3ZS42 DMD8FS5 TN Phosphodiesterase 1B (PDE1B) DMD8FS5 MA Inhibitor DMD8FS5 RN 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861. DMD8FS5 RU http://www.freepatentsonline.com/US10034861.html DMD8N5O DI DMD8N5O DMD8N5O DN PMID28766366-Compound-Scheme22Middle DMD8N5O TI TTXZCO0 DMD8N5O TN Microtubule-associated protein tau phosphorylation (MAPT p) DMD8N5O MA Inhibitor DMD8N5O RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMD8N5O RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMD94MP DI DMD94MP DMD94MP DN Adamantyl derivative 1 DMD94MP TI TTMSFAW DMD94MP TN Cannabinoid receptor 2 (CB2) DMD94MP MA Agonist DMD94MP RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMD94MP RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMD965S DI DMD965S DMD965S DN Quinazoline derivative 15 DMD965S TI TTUTJGQ DMD965S TN Vascular endothelial growth factor receptor 2 (KDR) DMD965S MA Inhibitor DMD965S RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMD965S RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMD965S DI DMD965S DMD965S DN Quinazoline derivative 15 DMD965S TI TT4DXQT DMD965S TN Proto-oncogene c-Ret (RET) DMD965S MA Inhibitor DMD965S RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMD965S RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMD9PZQ DI DMD9PZQ DMD9PZQ DN Ethynyl compound 3 DMD9PZQ TI TTHS256 DMD9PZQ TN Metabotropic glutamate receptor 5 (mGluR5) DMD9PZQ MA Modulator DMD9PZQ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMD9PZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMD9QW2 DI DMD9QW2 DMD9QW2 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 1 DMD9QW2 TI TTJW4LU DMD9QW2 TN Phosphodiesterase 10A (PDE10) DMD9QW2 MA Inhibitor DMD9QW2 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMD9QW2 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMD9QW2 DI DMD9QW2 DMD9QW2 DN 1,2,4-triazole [4,3-a]quinoxaline derivative 1 DMD9QW2 TI TTJGW1Z DMD9QW2 TN Phosphodiesterase 2A (PDE2A) DMD9QW2 MA Inhibitor DMD9QW2 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMD9QW2 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMD9VC1 DI DMD9VC1 DMD9VC1 DN Benzimidazolone acetamide derivative 2 DMD9VC1 TI TTPTXIN DMD9VC1 TN Translocator protein (TSPO) DMD9VC1 MA Ligand DMD9VC1 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMD9VC1 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMD9W6H DI DMD9W6H DMD9W6H DN PMID28454500-Compound-10 DMD9W6H TI TTA6ZN2 DMD9W6H TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMD9W6H MA Activator DMD9W6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMD9W6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMD9W6H DI DMD9W6H DMD9W6H DN PMID28454500-Compound-10 DMD9W6H TI TT3Z6Y9 DMD9W6H TN Cysteines of Keap1 (KEAP1 Cysteines) DMD9W6H MA Modulator DMD9W6H RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMD9W6H RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMD9WRS DI DMD9WRS DMD9WRS DN PMID26815044-Compound-49 DMD9WRS TI TTULVH8 DMD9WRS TN Tyrosinase (TYR) DMD9WRS MA Inhibitor DMD9WRS RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMD9WRS RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMDA3PN DI DMDA3PN DMDA3PN DN PMID27828716-Compound-20 DMDA3PN TI TTRZQE3 DMDA3PN TN Glycogen synthase kinase-3 alpha (GSK-3A) DMDA3PN MA Inhibitor DMDA3PN RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMDA3PN RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMDB5FH DI DMDB5FH DMDB5FH DN Pyrazole derivative 27 DMDB5FH TI TT6OEDT DMDB5FH TN Cannabinoid receptor 1 (CB1) DMDB5FH MA Antagonist DMDB5FH RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDB5FH RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDBK6O DI DMDBK6O DMDBK6O DN Isochroman-4-ketone derivative 1 DMDBK6O TI TTEB0GD DMDBK6O TN Cholinesterase (BCHE) DMDBK6O MA Inhibitor DMDBK6O RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDBK6O RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDBK6O DI DMDBK6O DMDBK6O DN Isochroman-4-ketone derivative 1 DMDBK6O TI TT1RS9F DMDBK6O TN Acetylcholinesterase (AChE) DMDBK6O MA Inhibitor DMDBK6O RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDBK6O RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDCN43 DI DMDCN43 DMDCN43 DN PMID30107136-Compound-Example3 DMDCN43 TI TT23XQV DMDCN43 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMDCN43 MA Inhibitor DMDCN43 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMDCN43 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMDCZVI DI DMDCZVI DMDCZVI DN PMID25772215-Compound-WO2012177618M6 DMDCZVI TI TT1ZAVI DMDCZVI TN Prostaglandin E2 receptor EP2 (PTGER2) DMDCZVI MA Antagonist DMDCZVI RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMDCZVI RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMDEHYR DI DMDEHYR DMDEHYR DN PMID28454500-Compound-58 DMDEHYR TI TTA6ZN2 DMDEHYR TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMDEHYR MA Inhibitor DMDEHYR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMDEHYR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMDEHYR DI DMDEHYR DMDEHYR DN PMID28454500-Compound-58 DMDEHYR TI TTGIZLN DMDEHYR TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMDEHYR MA Modulator DMDEHYR RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMDEHYR RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMDELNU DI DMDELNU DMDELNU DN US9040714, 155 DMDELNU TI TTOJ9QL DMDELNU TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMDELNU MA Inhibitor DMDELNU RN IRE-1 inhibitors. US9040714. DMDELNU RU http://www.freepatentsonline.com/US9040714.html DMDETKY DI DMDETKY DMDETKY DN Pyrazole and thiophene derivative 4 DMDETKY TI TTRA6BO DMDETKY TN Bromodomain-containing protein 4 (BRD4) DMDETKY MA Inhibitor DMDETKY RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMDETKY RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMDFL6B DI DMDFL6B DMDFL6B DN Heteroaryl-azepine derivative 2 DMDFL6B TI TTWJBZ5 DMDFL6B TN 5-HT 2C receptor (HTR2C) DMDFL6B MA Agonist DMDFL6B RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMDFL6B RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMDFPIO DI DMDFPIO DMDFPIO DN PMID29130358-Compound-Figure13(4) DMDFPIO TI TTLM12X DMDFPIO TN Matrix metalloproteinase-2 (MMP-2) DMDFPIO MA Inhibitor DMDFPIO RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMDFPIO RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMDFPIO DI DMDFPIO DMDFPIO DN PMID29130358-Compound-Figure13(4) DMDFPIO TI TT6X50U DMDFPIO TN Matrix metalloproteinase-9 (MMP-9) DMDFPIO MA Inhibitor DMDFPIO RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMDFPIO RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMDFUBH DI DMDFUBH DMDFUBH DN Piperazine derivative 5 DMDFUBH TI TTQR74A DMDFUBH TN Proteinase activated receptor 2 (PAR2) DMDFUBH MA Antagonist DMDFUBH RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMDFUBH RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMDG5T9 DI DMDG5T9 DMDG5T9 DN Peptide analog 52 DMDG5T9 TI TT2F4OL DMDG5T9 TN Tissue transglutaminase (TG2) DMDG5T9 MA Inhibitor DMDG5T9 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMDG5T9 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMDGSKH DI DMDGSKH DMDGSKH DN Pyrazole derivative 5 DMDGSKH TI TT6OEDT DMDGSKH TN Cannabinoid receptor 1 (CB1) DMDGSKH MA Antagonist DMDGSKH RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDGSKH RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TTT7PJU DMDHGPN TN Janus kinase 3 (JAK-3) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TTRMX3V DMDHGPN TN Janus kinase 2 (JAK-2) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TT6DM01 DMDHGPN TN Janus kinase 1 (JAK-1) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHGPN DI DMDHGPN DMDHGPN DN Aminooxazole carboxamide derivative 1 DMDHGPN TI TTBYWP2 DMDHGPN TN TYK2 tyrosine kinase (TYK2) DMDHGPN MA Inhibitor DMDHGPN RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMDHGPN RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMDHJMU DI DMDHJMU DMDHJMU DN PMID25684022-Compound-US20130053382 35(1-11) DMDHJMU TI TTCZOF2 DMDHJMU TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMDHJMU MA Inhibitor DMDHJMU RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMDHJMU RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMDIYJ1 DI DMDIYJ1 DMDIYJ1 DN Biphenyl mannoside derivative 20 DMDIYJ1 TI TTTCRU2 DMDIYJ1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMDIYJ1 MA Antagonist DMDIYJ1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMDIYJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMDJ6O8 DI DMDJ6O8 DMDJ6O8 DN PMID29053063-Compound-7b DMDJ6O8 TI TTZ963I DMDJ6O8 TN Monoglyceride lipase (MAGL) DMDJ6O8 MA Inhibitor DMDJ6O8 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDJ6O8 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDJC96 DI DMDJC96 DMDJC96 DN N-oxalylglycine derivative 2 DMDJC96 TI TT0RGE9 DMDJC96 TN Lysine-specific demethylase 4 (KDM4) DMDJC96 MA Inhibitor DMDJC96 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMDJC96 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMDJFUX DI DMDJFUX DMDJFUX DN PMID29338548-Compound-13 DMDJFUX TI TTHJTF7 DMDJFUX TN Glycine transporter GlyT-1 (SLC6A9) DMDJFUX MA Inhibitor DMDJFUX RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMDJFUX RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMDJGPC DI DMDJGPC DMDJGPC DN PMID25656651-Compound-31c DMDJGPC TI TTIV39N DMDJGPC TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMDJGPC MA Inhibitor DMDJGPC RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMDJGPC RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMDJM1Y DI DMDJM1Y DMDJM1Y DN PMID27215781-Compound-29 DMDJM1Y TI TTMSFAW DMDJM1Y TN Cannabinoid receptor 2 (CB2) DMDJM1Y MA Agonist DMDJM1Y RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMDJM1Y RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TT6DM01 DMDK4RI TN Janus kinase 1 (JAK-1) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TTBYWP2 DMDK4RI TN TYK2 tyrosine kinase (TYK2) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TTRMX3V DMDK4RI TN Janus kinase 2 (JAK-2) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK4RI DI DMDK4RI DMDK4RI DN Benzimidazole derivative 7 DMDK4RI TI TTT7PJU DMDK4RI TN Janus kinase 3 (JAK-3) DMDK4RI MA Inhibitor DMDK4RI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDK4RI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDK7LQ DI DMDK7LQ DMDK7LQ DN Bicarboxylic and tricarboxylic ethynyl derivative 1 DMDK7LQ TI TTHS256 DMDK7LQ TN Metabotropic glutamate receptor 5 (mGluR5) DMDK7LQ MA Modulator DMDK7LQ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMDK7LQ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMDK98P DI DMDK98P DMDK98P DN US8598210, Table XV, 2 DMDK98P TI TT9ISBX DMDK98P TN HIF-prolyl hydroxylase 2 (HPH-2) DMDK98P MA Inhibitor DMDK98P RN Prolyl hydroxylase inhibitors and methods of use. US9598370. DMDK98P RU http://www.freepatentsonline.com/US9598370.html DMDKSJQ DI DMDKSJQ DMDKSJQ DN PMID30259754-Compound-WAY-362450 DMDKSJQ TI TTS4UGC DMDKSJQ TN Farnesoid X-activated receptor (FXR) DMDKSJQ MA Agonist DMDKSJQ RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DMDKSJQ RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DMDKT9X DI DMDKT9X DMDKT9X DN PMID29649907-Compound-1 DMDKT9X TI TTS4UGC DMDKT9X TN Farnesoid X-activated receptor (FXR) DMDKT9X MA Agonist DMDKT9X RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMDKT9X RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMDL3A5 DI DMDL3A5 DMDL3A5 DN Piperazine derivative 6 DMDL3A5 TI TT473XN DMDL3A5 TN P2X purinoceptor 7 (P2RX7) DMDL3A5 MA Antagonist DMDL3A5 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMDL3A5 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMDL6TG DI DMDL6TG DMDL6TG DN PMID25399762-Compound-Figure1-Sarcaboside B DMDL6TG TI TT3WG5C DMDL6TG TN Monoamine oxidase type A (MAO-A) DMDL6TG MA Inhibitor DMDL6TG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDL6TG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDLPB7 DI DMDLPB7 DMDLPB7 DN PMID25482888-Compound-52 DMDLPB7 TI TTDIGC1 DMDLPB7 TN Dipeptidyl peptidase 4 (DPP-4) DMDLPB7 MA Inhibitor DMDLPB7 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMDLPB7 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMDLS54 DI DMDLS54 DMDLS54 DN Poly-substituted azoles statin lactone derivative 1 DMDLS54 TI TTPADOQ DMDLS54 TN HMG-CoA reductase (HMGCR) DMDLS54 MA Inhibitor DMDLS54 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMDLS54 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMDLVXU DI DMDLVXU DMDLVXU DN PMID26666989-Compound-Figure12bottomright DMDLVXU TI TT8BUGW DMDLVXU TN Glycogen phosphorylase (PYG) DMDLVXU MA Inhibitor DMDLVXU RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMDLVXU RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMDLY38 DI DMDLY38 DMDLY38 DN Benzothiazole analog 3 DMDLY38 TI TTULVH8 DMDLY38 TN Tyrosinase (TYR) DMDLY38 MA Inhibitor DMDLY38 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMDLY38 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMDM806 DI DMDM806 DMDM806 DN Benzanilide compound 2 DMDM806 TI TTUX68I DMDM806 TN Hypoxia-inducible factor 1 (HIF-1) DMDM806 MA Inhibitor DMDM806 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMDM806 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMDMEHQ DI DMDMEHQ DMDMEHQ DN PMID27109571-Compound-29 DMDMEHQ TI TTNT2S6 DMDMEHQ TN Fatty acid-binding protein 5 (FABP5) DMDMEHQ MA Inhibitor DMDMEHQ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMDMEHQ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMDMEHQ DI DMDMEHQ DMDMEHQ DN PMID27109571-Compound-29 DMDMEHQ TI TTHWMFZ DMDMEHQ TN Fatty acid-binding protein 4 (FABP4) DMDMEHQ MA Inhibitor DMDMEHQ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMDMEHQ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMDMFJG DI DMDMFJG DMDMFJG DN PMID25666693-Compound-62 DMDMFJG TI TTMI6F5 DMDMFJG TN Transient receptor potential cation channel V1 (TRPV1) DMDMFJG MA Antagonist DMDMFJG RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMDMFJG RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMDMJYL DI DMDMJYL DMDMJYL DN PMID25684022-Compound-WO2008005457 DMDMJYL TI TTCZOF2 DMDMJYL TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMDMJYL MA Inhibitor DMDMJYL RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMDMJYL RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMDN4KP DI DMDN4KP DMDN4KP DN PMID29166791-Compound-AMPCP DMDN4KP TI TTK0O6Y DMDN4KP TN Ecto-5'-nucleotidase (CD73) DMDN4KP MA Inhibitor DMDN4KP RN Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.Expert Opin Ther Pat. 2018 Feb;28(2):167-171. DMDN4KP RU https://www.ncbi.nlm.nih.gov/pubmed/29166791 DMDN5Q4 DI DMDN5Q4 DMDN5Q4 DN PMID26924192-Compound-24 DMDN5Q4 TI TTRA6BO DMDN5Q4 TN Bromodomain-containing protein 4 (BRD4) DMDN5Q4 MA Inhibitor DMDN5Q4 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMDN5Q4 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMDN8P1 DI DMDN8P1 DMDN8P1 DN US8877733, 27 DMDN8P1 TI TTQFZWR DMDN8P1 TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMDN8P1 MA Inhibitor DMDN8P1 RN 1-substituted pyrimidine N-nucleoside analogs for antiviral treatment. US8877733. DMDN8P1 RU http://www.freepatentsonline.com/US8877733.html DMDOB20 DI DMDOB20 DMDOB20 DN Diaryl piperazine derivative 2 DMDOB20 TI TT6OEDT DMDOB20 TN Cannabinoid receptor 1 (CB1) DMDOB20 MA Antagonist DMDOB20 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDOB20 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDOCTB DI DMDOCTB DMDOCTB DN Benzamide derivative 1 DMDOCTB TI TT9NXW4 DMDOCTB TN Sigma intracellular receptor 2 (TMEM97) DMDOCTB MA Ligand DMDOCTB RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMDOCTB RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMDOEFC DI DMDOEFC DMDOEFC DN Ethynyl compound 6 DMDOEFC TI TTHS256 DMDOEFC TN Metabotropic glutamate receptor 5 (mGluR5) DMDOEFC MA Modulator DMDOEFC RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMDOEFC RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMDOQKY DI DMDOQKY DMDOQKY DN Heteroaryl-azepine derivative 1 DMDOQKY TI TTWJBZ5 DMDOQKY TN 5-HT 2C receptor (HTR2C) DMDOQKY MA Agonist DMDOQKY RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMDOQKY RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMDOVIZ DI DMDOVIZ DMDOVIZ DN PMID28447479-Compound-24 DMDOVIZ TI TTSCIM2 DMDOVIZ TN Extracellular lysophospholipase D (E-NPP2) DMDOVIZ RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMDOVIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMDP09N DI DMDP09N DMDP09N DN Urea and carbamate bioisostere derivative 14 DMDP09N TI TTL7C8Q DMDP09N TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMDP09N MA Inhibitor DMDP09N RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMDP09N RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMDP4GY DI DMDP4GY DMDP4GY DN Aminopyrimidine derivative 3 DMDP4GY TI TTS7G69 DMDP4GY TN Fusion protein Bcr-Abl (Bcr-Abl) DMDP4GY MA Inhibitor DMDP4GY RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMDP4GY RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMDP87V DI DMDP87V DMDP87V DN US8563594, 152 DMDP87V TI TTDYP7I DMDP87V TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMDP87V MA Inhibitor DMDP87V RN S1P3 receptor inhibitors for treating pain. US8563594. DMDP87V RU http://www.freepatentsonline.com/US8563594.html DMDP8J0 DI DMDP8J0 DMDP8J0 DN PMID26004420-Compound-US20140031349C DMDP8J0 TI TTJ13ST DMDP8J0 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMDP8J0 MA Inhibitor DMDP8J0 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMDP8J0 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMDPHT1 DI DMDPHT1 DMDPHT1 DN Azole benzene derivative 4 DMDPHT1 TI TT7RJY8 DMDPHT1 TN Xanthine dehydrogenase/oxidase (XDH) DMDPHT1 MA Inhibitor DMDPHT1 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMDPHT1 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMDQ6H7 DI DMDQ6H7 DMDQ6H7 DN PMID25553724-Compound-US2012820715110 DMDQ6H7 TI TTSXVID DMDQ6H7 TN Nuclear factor NF-kappa-B (NFKB) DMDQ6H7 MA Inhibitor DMDQ6H7 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMDQ6H7 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMDQLUP DI DMDQLUP DMDQLUP DN Imidazo[1,2-b]pyridazine derivative 7 DMDQLUP TI TTTDVOJ DMDQLUP TN Tropomyosin-related kinase A (TrkA) DMDQLUP MA Inhibitor DMDQLUP RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMDQLUP RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMDQMZT DI DMDQMZT DMDQMZT DN PMID27410995-Compound-Figure3c DMDQMZT TI TTG0U4H DMDQMZT TN Ribosomal protein S6 kinase beta-1 (S6K1) DMDQMZT MA Inhibitor DMDQMZT RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMDQMZT RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMDQNKW DI DMDQNKW DMDQNKW DN Pyrimidinone derivative 4 DMDQNKW TI TTPLTSQ DMDQNKW TN Neutrophil elastase (NE) DMDQNKW MA Inhibitor DMDQNKW RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMDQNKW RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMDQTA2 DI DMDQTA2 DMDQTA2 DN PMID26651364-Compound-5c DMDQTA2 TI TTTCRU2 DMDQTA2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMDQTA2 MA Antagonist DMDQTA2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMDQTA2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMDQYJ1 DI DMDQYJ1 DMDQYJ1 DN Hydroxamate analog 3 DMDQYJ1 TI TT0RGE9 DMDQYJ1 TN Lysine-specific demethylase 4 (KDM4) DMDQYJ1 MA Inhibitor DMDQYJ1 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMDQYJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMDRIZF DI DMDRIZF DMDRIZF DN Quinazolinone derivative 3 DMDRIZF TI TTE4BSY DMDRIZF TN Bromodomain and extraterminal domain protein (BET) DMDRIZF MA Inhibitor DMDRIZF RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMDRIZF RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMDRJ31 DI DMDRJ31 DMDRJ31 DN Antibodie derivative 9 DMDRJ31 TI TTOHSBA DMDRJ31 TN Vascular endothelial growth factor A (VEGFA) DMDRJ31 MA Stablizer DMDRJ31 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMDRJ31 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMDRJHO DI DMDRJHO DMDRJHO DN PMID29338548-Compound-48 DMDRJHO TI TTHJTF7 DMDRJHO TN Glycine transporter GlyT-1 (SLC6A9) DMDRJHO MA Inhibitor DMDRJHO RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMDRJHO RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMDRK68 DI DMDRK68 DMDRK68 DN PMID29053063-Compound-11d DMDRK68 TI TTDP1UC DMDRK68 TN Fatty acid amide hydrolase (FAAH) DMDRK68 MA Inhibitor DMDRK68 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDRK68 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDRK68 DI DMDRK68 DMDRK68 DN PMID29053063-Compound-11d DMDRK68 TI TTZ963I DMDRK68 TN Monoglyceride lipase (MAGL) DMDRK68 MA Inhibitor DMDRK68 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDRK68 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDRK68 DI DMDRK68 DMDRK68 DN PMID29053063-Compound-11d DMDRK68 TI TTSINOV DMDRK68 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMDRK68 MA Inhibitor DMDRK68 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDRK68 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDS2CU DI DMDS2CU DMDS2CU DN PMID26560530-Compound-23 DMDS2CU TI TT2F4OL DMDS2CU TN Tissue transglutaminase (TG2) DMDS2CU MA Inhibitor DMDS2CU RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMDS2CU RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMDSUGF DI DMDSUGF DMDSUGF DN Aniline derivative 1 DMDSUGF TI TT7HF4W DMDSUGF TN Cyclin-dependent kinase 2 (CDK2) DMDSUGF MA Inhibitor DMDSUGF RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMDSUGF RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMDSUGF DI DMDSUGF DMDSUGF DN Aniline derivative 1 DMDSUGF TI TTBH0VX DMDSUGF TN Histone deacetylase (HDAC) DMDSUGF MA Inhibitor DMDSUGF RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMDSUGF RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMDT5JI DI DMDT5JI DMDT5JI DN Phenylpyridine derivative 3 DMDT5JI TI TTQVOEI DMDT5JI TN Angiotensin II receptor type-2 (AGTR2) DMDT5JI MA Agonist DMDT5JI RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMDT5JI RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMDT5JI DI DMDT5JI DMDT5JI DN Phenylpyridine derivative 3 DMDT5JI TI TTZMAO3 DMDT5JI TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMDT5JI MA Agonist DMDT5JI RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMDT5JI RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMDTQCG DI DMDTQCG DMDTQCG DN Pyrazole derivative 31 DMDTQCG TI TT6OEDT DMDTQCG TN Cannabinoid receptor 1 (CB1) DMDTQCG MA Antagonist DMDTQCG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMDTQCG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMDTYJ9 DI DMDTYJ9 DMDTYJ9 DN BDBM50434165 DMDTYJ9 TI TTOYT5L DMDTYJ9 TN Dipeptidyl-peptidase 7 (DPP7) DMDTYJ9 MA Inhibitor DMDTYJ9 RN FAP inhibitors. US9346814. DMDTYJ9 RU http://www.freepatentsonline.com/US9346814.html DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TTEAD9J DMDU21R TN Proteasome beta-8 (PS beta-8) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TT68GPI DMDU21R TN Proteasome beta-5 (PS beta-5) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TTOUSTQ DMDU21R TN Proteasome beta-9 (PS beta-9) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TT8EPLT DMDU21R TN Proteasome beta-1 (PS beta-1) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TTPNACM DMDU21R TN Proteasome beta-10 (PS beta-10) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU21R DI DMDU21R DMDU21R DN Peptide analog 23 DMDU21R TI TT49BVC DMDU21R TN Proteasome beta-2 (PS beta-2) DMDU21R MA Inhibitor DMDU21R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMDU21R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMDU9XF DI DMDU9XF DMDU9XF DN Carbamide derivative 26 DMDU9XF TI TTDP1UC DMDU9XF TN Fatty acid amide hydrolase (FAAH) DMDU9XF MA Inhibitor DMDU9XF RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDU9XF RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDU9XF DI DMDU9XF DMDU9XF DN Carbamide derivative 26 DMDU9XF TI TTZ963I DMDU9XF TN Monoglyceride lipase (MAGL) DMDU9XF MA Inhibitor DMDU9XF RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMDU9XF RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMDUSN5 DI DMDUSN5 DMDUSN5 DN PMID28766366-Compound-Scheme8NCGC-00185981 DMDUSN5 TI TTSBVFO DMDUSN5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMDUSN5 MA Inhibitor DMDUSN5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMDUSN5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMDUXRT DI DMDUXRT DMDUXRT DN PMID26815044-Compound-116 DMDUXRT TI TTULVH8 DMDUXRT TN Tyrosinase (TYR) DMDUXRT MA Inhibitor DMDUXRT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMDUXRT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TT1RS9F DMDV0MP TN Acetylcholinesterase (AChE) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TTGP7BY DMDV0MP TN Monoamine oxidase type B (MAO-B) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TT3WG5C DMDV0MP TN Monoamine oxidase type A (MAO-A) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV0MP DI DMDV0MP DMDV0MP DN Tetra-hydro-isoquinoline derivative 4 DMDV0MP TI TTEB0GD DMDV0MP TN Cholinesterase (BCHE) DMDV0MP MA Inhibitor DMDV0MP RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMDV0MP RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMDV6EY DI DMDV6EY DMDV6EY DN Quinoline derivative 3 DMDV6EY TI TTXJ47W DMDV6EY TN Metabotropic glutamate receptor 2 (mGluR2) DMDV6EY MA Antagonist DMDV6EY RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMDV6EY RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMDWH8T DI DMDWH8T DMDWH8T DN PMID25666693-Compound-64 DMDWH8T TI TTMI6F5 DMDWH8T TN Transient receptor potential cation channel V1 (TRPV1) DMDWH8T MA Antagonist DMDWH8T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMDWH8T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMDWIPG DI DMDWIPG DMDWIPG DN PMID25399762-Compound-Table 6-9 DMDWIPG TI TTGP7BY DMDWIPG TN Monoamine oxidase type B (MAO-B) DMDWIPG MA Inhibitor DMDWIPG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDWIPG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDWIPG DI DMDWIPG DMDWIPG DN PMID25399762-Compound-Table 6-9 DMDWIPG TI TTNR0UQ DMDWIPG TN Lysine-specific histone demethylase 1 (LSD) DMDWIPG MA Inhibitor DMDWIPG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDWIPG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDWSIE DI DMDWSIE DMDWSIE DN PMID29649907-Compound-5 DMDWSIE TI TTS4UGC DMDWSIE TN Farnesoid X-activated receptor (FXR) DMDWSIE MA Agonist DMDWSIE RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMDWSIE RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMDX1MK DI DMDX1MK DMDX1MK DN PMID25399762-Compound-Figure1-Eryngiolide A DMDX1MK TI TT3WG5C DMDX1MK TN Monoamine oxidase type A (MAO-A) DMDX1MK MA Inhibitor DMDX1MK RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMDX1MK RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMDXIU9 DI DMDXIU9 DMDXIU9 DN PMID28766366-Compound-Scheme4Bottom DMDXIU9 TI TTYGQ8A DMDXIU9 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMDXIU9 MA Inhibitor DMDXIU9 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMDXIU9 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMDXIU9 DI DMDXIU9 DMDXIU9 DN PMID28766366-Compound-Scheme4Bottom DMDXIU9 TI TTSBVFO DMDXIU9 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMDXIU9 MA Inhibitor DMDXIU9 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMDXIU9 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMDXMH9 DI DMDXMH9 DMDXMH9 DN PMID27109571-Compound-3 DMDXMH9 TI TTMY6L1 DMDXMH9 TN Fatty acid-binding protein (FABP) DMDXMH9 MA Inhibitor DMDXMH9 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMDXMH9 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMDYKPC DI DMDYKPC DMDYKPC DN Lactam derivative 1 DMDYKPC TI TTF8P9I DMDYKPC TN Diacylglycerol acyltransferase 1 (DGAT1) DMDYKPC MA Inhibitor DMDYKPC RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMDYKPC RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMDYXKT DI DMDYXKT DMDYXKT DN 2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT TI TTALN9W DMDYXKT TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMDYXKT MA Inhibitor DMDYXKT RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMDYXKT RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMDYXKT DI DMDYXKT DMDYXKT DN 2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT TI TTZJYKH DMDYXKT TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMDYXKT MA Inhibitor DMDYXKT RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMDYXKT RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMDYXKT DI DMDYXKT DMDYXKT DN 2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT TI TTXNCBV DMDYXKT TN Tryptophan 2,3-dioxygenase (TDO) DMDYXKT MA Inhibitor DMDYXKT RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMDYXKT RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMDZ7QS DI DMDZ7QS DMDZ7QS DN Benzenamine derivative 2 DMDZ7QS TI TTNR0UQ DMDZ7QS TN Lysine-specific histone demethylase 1 (LSD) DMDZ7QS MA Inhibitor DMDZ7QS RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMDZ7QS RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMDZHAB DI DMDZHAB DMDZHAB DN PMID26004420-Compound-WO2013062900C DMDZHAB TI TTJ13ST DMDZHAB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMDZHAB MA Inhibitor DMDZHAB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMDZHAB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMDZKXC DI DMDZKXC DMDZKXC DN PMID27774824-Compound-Figure5Example13 DMDZKXC TI TTT7PJU DMDZKXC TN Janus kinase 3 (JAK-3) DMDZKXC MA Inhibitor DMDZKXC RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMDZKXC RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMDZT7Y DI DMDZT7Y DMDZT7Y DN PMID25684022-Compound-EP20041486488 DMDZT7Y TI TTCZOF2 DMDZT7Y TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMDZT7Y MA Inhibitor DMDZT7Y RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMDZT7Y RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DME0RJ2 DI DME0RJ2 DME0RJ2 DN PMID30259754-Compound-INT-767 DME0RJ2 TI TTS4UGC DME0RJ2 TN Farnesoid X-activated receptor (FXR) DME0RJ2 MA Agonist DME0RJ2 RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DME0RJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DME0TUJ DI DME0TUJ DME0TUJ DN PMID28270010-Compound-Figure17-3 DME0TUJ TI TTTDVOJ DME0TUJ TN Tropomyosin-related kinase A (TrkA) DME0TUJ MA Inhibitor DME0TUJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DME0TUJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DME0WSR DI DME0WSR DME0WSR DN Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR TI TTXABCW DME0WSR TN NT-3 growth factor receptor (TrkC) DME0WSR MA Inhibitor DME0WSR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DME0WSR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DME0WSR DI DME0WSR DME0WSR DN Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR TI TTTDVOJ DME0WSR TN Tropomyosin-related kinase A (TrkA) DME0WSR MA Inhibitor DME0WSR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DME0WSR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DME0WSR DI DME0WSR DME0WSR DN Pyrrolo[2,3-d]pyrimidine derivative 4 DME0WSR TI TTKN7QR DME0WSR TN BDNF/NT-3 growth factors receptor (TrkB) DME0WSR MA Inhibitor DME0WSR RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DME0WSR RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DME0XS4 DI DME0XS4 DME0XS4 DN PMID25514969-Compound-10 DME0XS4 TI TT4EB85 DME0XS4 TN Cholesterol 24-hydroxylase (CYP46A1) DME0XS4 MA Inhibitor DME0XS4 RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DME0XS4 RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DME1A80 DI DME1A80 DME1A80 DN US8921389, 210 DME1A80 TI TT9ISBX DME1A80 TN HIF-prolyl hydroxylase 2 (HPH-2) DME1A80 MA Inhibitor DME1A80 RN Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170. DME1A80 RU http://www.freepatentsonline.com/US9695170.html DME1B23 DI DME1B23 DME1B23 DN Sterol derivative 2 DME1B23 TI TTPADOQ DME1B23 TN HMG-CoA reductase (HMGCR) DME1B23 MA Inhibitor DME1B23 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DME1B23 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DME1Q3W DI DME1Q3W DME1Q3W DN Pyrrolo-pyridinone derivative 3 DME1Q3W TI TT4DXQT DME1Q3W TN Proto-oncogene c-Ret (RET) DME1Q3W MA Inhibitor DME1Q3W RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DME1Q3W RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DME1WHT DI DME1WHT DME1WHT DN PMID28092474-Compound-32h DME1WHT TI TT6R7JZ DME1WHT TN Histone deacetylase 1 (HDAC1) DME1WHT MA Inhibitor DME1WHT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DME1WHT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DME1WHT DI DME1WHT DME1WHT DN PMID28092474-Compound-32h DME1WHT TI TT5ZKDI DME1WHT TN Histone deacetylase 6 (HDAC6) DME1WHT MA Inhibitor DME1WHT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DME1WHT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DME24BI DI DME24BI DME24BI DN Quinazolines and azaquinazoline derivative 1 DME24BI TI TTZCRP3 DME24BI TN ERK activator kinase (MEK) DME24BI MA Inhibitor DME24BI RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DME24BI RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DME26SY DI DME26SY DME26SY DN Piperonal DME26SY TI TTGP7BY DME26SY TN Monoamine oxidase type B (MAO-B) DME26SY MA Inhibitor DME26SY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DME26SY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DME2AZG DI DME2AZG DME2AZG DN US10150740, Example 1 DME2AZG TI TTQFZWR DME2AZG TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DME2AZG MA Inhibitor DME2AZG RN 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740. DME2AZG RU http://www.freepatentsonline.com/US10150740.html DME2IHD DI DME2IHD DME2IHD DN PMID27841045-Compound-129 DME2IHD TI TT7RJY8 DME2IHD TN Xanthine dehydrogenase/oxidase (XDH) DME2IHD MA Inhibitor DME2IHD RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DME2IHD RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DME30O6 DI DME30O6 DME30O6 DN 4-(2-cyclohexylethoxy) aniline derivative 1 DME30O6 TI TTA6ZN2 DME30O6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DME30O6 MA Inhibitor DME30O6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DME30O6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DME3HLC DI DME3HLC DME3HLC DN PMID28870136-Compound-57 DME3HLC TI TTK0O6Y DME3HLC TN Ecto-5'-nucleotidase (CD73) DME3HLC MA Inhibitor DME3HLC RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DME3HLC RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DME3NTB DI DME3NTB DME3NTB DN PMID25666693-Compound-96 DME3NTB TI TTMI6F5 DME3NTB TN Transient receptor potential cation channel V1 (TRPV1) DME3NTB MA Antagonist DME3NTB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DME3NTB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TT6DM01 DME3TMS TN Janus kinase 1 (JAK-1) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TTRMX3V DME3TMS TN Janus kinase 2 (JAK-2) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TT3PJMV DME3TMS TN Tyrosine-protein kinase ABL1 (ABL) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TTBYWP2 DME3TMS TN TYK2 tyrosine kinase (TYK2) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3TMS DI DME3TMS DME3TMS DN PMID27774824-Compound-Figure9Example2up DME3TMS TI TTT7PJU DME3TMS TN Janus kinase 3 (JAK-3) DME3TMS MA Inhibitor DME3TMS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DME3TMS RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DME3YRI DI DME3YRI DME3YRI DN PMID28870136-Compound-67 DME3YRI TI TTK0O6Y DME3YRI TN Ecto-5'-nucleotidase (CD73) DME3YRI MA Inhibitor DME3YRI RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DME3YRI RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DME3ZJO DI DME3ZJO DME3ZJO DN PMID25980951-Compound-10 DME3ZJO TI TTR7B60 DME3ZJO TN X-linked inhibitor of apoptosis protein (XIAP) DME3ZJO MA Antagonist DME3ZJO RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DME3ZJO RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DME40TS DI DME40TS DME40TS DN PMID25470667-Compound-GO-CoA-Tat DME40TS TI TTSYOWR DME40TS TN Ghrelin O acyltransferase (GOAT) DME40TS MA Inhibitor DME40TS RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DME40TS RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DME4OGJ DI DME4OGJ DME4OGJ DN Resorcinol compound 20 DME4OGJ TI TTULVH8 DME4OGJ TN Tyrosinase (TYR) DME4OGJ MA Inhibitor DME4OGJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DME4OGJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DME57SJ DI DME57SJ DME57SJ DN P-toluenesulfonate derivative 1 DME57SJ TI TTZCRP3 DME57SJ TN ERK activator kinase (MEK) DME57SJ MA Inhibitor DME57SJ RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DME57SJ RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DME5WLD DI DME5WLD DME5WLD DN 2-pyrazinone derivative 3 DME5WLD TI TTPLTSQ DME5WLD TN Neutrophil elastase (NE) DME5WLD MA Inhibitor DME5WLD RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DME5WLD RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DME60LY DI DME60LY DME60LY DN PMID26924192-Compound-23 DME60LY TI TTRA6BO DME60LY TN Bromodomain-containing protein 4 (BRD4) DME60LY MA Inhibitor DME60LY RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DME60LY RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DME6FLN DI DME6FLN DME6FLN DN Phenylsulfonyl derivative 3 DME6FLN TI TT9JNIC DME6FLN TN Histamine H3 receptor (H3R) DME6FLN MA Inhibitor DME6FLN RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DME6FLN RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DME6FWY DI DME6FWY DME6FWY DN PMID28394193-Compound-44 DME6FWY TI TT9MZCQ DME6FWY TN Enhancer of zeste homolog 2 (EZH2) DME6FWY MA Inhibitor DME6FWY RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DME6FWY RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DME6H8Q DI DME6H8Q DME6H8Q DN PMID29649907-Compound-31 DME6H8Q TI TTS4UGC DME6H8Q TN Farnesoid X-activated receptor (FXR) DME6H8Q MA Agonist DME6H8Q RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DME6H8Q RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DME6P7T DI DME6P7T DME6P7T DN Quinolone derivative 1 DME6P7T TI TTL7C8Q DME6P7T TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DME6P7T MA Inhibitor DME6P7T RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DME6P7T RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DME72VA DI DME72VA DME72VA DN Macrolactam derivative 2 DME72VA TI TTKFVXR DME72VA TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DME72VA MA Inhibitor DME72VA RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DME72VA RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DME72ZH DI DME72ZH DME72ZH DN PMID28350212-Compound-12 DME72ZH TI TTZS04O DME72ZH TN Gamma-secretase subunit APH-1A/1B (APH-1) DME72ZH MA Inhibitor DME72ZH RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DME72ZH RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DME7M5R DI DME7M5R DME7M5R DN Imidazopyridine acetamide analog 6 DME7M5R TI TTPTXIN DME7M5R TN Translocator protein (TSPO) DME7M5R MA Ligand DME7M5R RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DME7M5R RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DME7UNT DI DME7UNT DME7UNT DN PMID26651364-Compound-8c DME7UNT TI TTTCRU2 DME7UNT TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DME7UNT MA Antagonist DME7UNT RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DME7UNT RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DME84S5 DI DME84S5 DME84S5 DN Tricyclic compound 7 DME84S5 TI TTGWKQJ DME84S5 TN Rho-associated protein kinase 2 (ROCK2) DME84S5 MA Inhibitor DME84S5 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DME84S5 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DME86DP DI DME86DP DME86DP DN Heteroaryl-azepine derivative 13 DME86DP TI TTWJBZ5 DME86DP TN 5-HT 2C receptor (HTR2C) DME86DP MA Agonist DME86DP RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DME86DP RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DME8CQA DI DME8CQA DME8CQA DN Isoxazole-based bicyclic compound 18 DME8CQA TI TTE4BSY DME8CQA TN Bromodomain and extraterminal domain protein (BET) DME8CQA MA Inhibitor DME8CQA RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DME8CQA RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DME8DQ0 DI DME8DQ0 DME8DQ0 DN Biaryl mannoside derivative 19 DME8DQ0 TI TTTCRU2 DME8DQ0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DME8DQ0 MA Antagonist DME8DQ0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DME8DQ0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DME8JTW DI DME8JTW DME8JTW DN Indazole derivative 1 DME8JTW TI TTCZOF2 DME8JTW TN Pyruvate dehydrogenase kinase 1 (PDHK1) DME8JTW MA Inhibitor DME8JTW RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DME8JTW RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DME8LUY DI DME8LUY DME8LUY DN PMID25666693-Compound-157 DME8LUY TI TTMI6F5 DME8LUY TN Transient receptor potential cation channel V1 (TRPV1) DME8LUY MA Antagonist DME8LUY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DME8LUY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DME8MN1 DI DME8MN1 DME8MN1 DN 1,2,4-triazole derivative 1 DME8MN1 TI TT6OEDT DME8MN1 TN Cannabinoid receptor 1 (CB1) DME8MN1 MA Antagonist DME8MN1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DME8MN1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DME8Q0F DI DME8Q0F DME8Q0F DN Pyrazole derivative 84 DME8Q0F TI TTDP1UC DME8Q0F TN Fatty acid amide hydrolase (FAAH) DME8Q0F MA Inhibitor DME8Q0F RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DME8Q0F RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DME8Q0F DI DME8Q0F DME8Q0F DN Pyrazole derivative 84 DME8Q0F TI TTZ963I DME8Q0F TN Monoglyceride lipase (MAGL) DME8Q0F MA Inhibitor DME8Q0F RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DME8Q0F RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DME9QCM DI DME9QCM DME9QCM DN PMID25726713-Compound-43 DME9QCM TI TT8J1S3 DME9QCM TN Smoothened homolog (SMO) DME9QCM MA Inhibitor DME9QCM RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DME9QCM RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEAO42 DI DMEAO42 DMEAO42 DN Carbamate derivative 8 DMEAO42 TI TTDP1UC DMEAO42 TN Fatty acid amide hydrolase (FAAH) DMEAO42 MA Inhibitor DMEAO42 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEAO42 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEARS2 DI DMEARS2 DMEARS2 DN US9200020, Table 3, Compound 1B DMEARS2 TI TTBL49X DMEARS2 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMEARS2 MA Inhibitor DMEARS2 RN 6-oxopurine phosphoribosyltransferase inhibitors. US9200020. DMEARS2 RU http://www.freepatentsonline.com/US9200020.html DMEASZY DI DMEASZY DMEASZY DN PMID28092474-Compound-32q DMEASZY TI TT6R7JZ DMEASZY TN Histone deacetylase 1 (HDAC1) DMEASZY MA Inhibitor DMEASZY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEASZY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEASZY DI DMEASZY DMEASZY DN PMID28092474-Compound-32q DMEASZY TI TT5ZKDI DMEASZY TN Histone deacetylase 6 (HDAC6) DMEASZY MA Inhibitor DMEASZY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEASZY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEAUJT DI DMEAUJT DMEAUJT DN US8901295, F609 DMEAUJT TI TTNAFOU DMEAUJT TN Rotamase D (PPID) DMEAUJT MA Inhibitor DMEAUJT RN Inhibitors of cyclophilins and uses thereof. US8901295. DMEAUJT RU http://www.freepatentsonline.com/US8901295.html DMEB59T DI DMEB59T DMEB59T DN US9714230, 12 DMEB59T TI TTIG67W DMEB59T TN Lysine-specific demethylase 5A (KDM5A) DMEB59T MA Inhibitor DMEB59T RN Histone demethylase inhibitors. US9714230. DMEB59T RU http://www.freepatentsonline.com/US9714230.html DMEBGZJ DI DMEBGZJ DMEBGZJ DN Tetra-hydro-naphthalene derivative 2 DMEBGZJ TI TTDP1UC DMEBGZJ TN Fatty acid amide hydrolase (FAAH) DMEBGZJ MA Inhibitor DMEBGZJ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEBGZJ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEC1TR DI DMEC1TR DMEC1TR DN PMID25828189-Compound-19 DMEC1TR TI TT9O6WS DMEC1TR TN Glucagon receptor (GCGR) DMEC1TR MA Antagonist DMEC1TR RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMEC1TR RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMECJDM DI DMECJDM DMECJDM DN Imidazolidine derivative 1 DMECJDM TI TT473XN DMECJDM TN P2X purinoceptor 7 (P2RX7) DMECJDM MA Antagonist DMECJDM RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMECJDM RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMECOY7 DI DMECOY7 DMECOY7 DN PMID25656651-Compound-38 DMECOY7 TI TTS7G69 DMECOY7 TN Fusion protein Bcr-Abl (Bcr-Abl) DMECOY7 MA Inhibitor DMECOY7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMECOY7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMECU90 DI DMECU90 DMECU90 DN PMID28906174-Compound-figure1g DMECU90 TI TT4TFGN DMECU90 TN Vasopressin V1a receptor (V1AR) DMECU90 MA Antagonist DMECU90 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMECU90 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMECU90 DI DMECU90 DMECU90 DN PMID28906174-Compound-figure1g DMECU90 TI TTSCIUP DMECU90 TN Oxytocin receptor (OTR) DMECU90 MA Antagonist DMECU90 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMECU90 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMECZVG DI DMECZVG DMECZVG DN Biphenyl mannoside derivative 16 DMECZVG TI TTTCRU2 DMECZVG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMECZVG MA Antagonist DMECZVG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMECZVG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMED71P DI DMED71P DMED71P DN PMID29865878-Compound-54 DMED71P TI TTSJMN8 DMED71P TN Immunoproteasome complex (IP) DMED71P MA Inhibitor DMED71P RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMED71P RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMEDFNC DI DMEDFNC DMEDFNC DN 2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC TI TTALN9W DMEDFNC TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMEDFNC MA Inhibitor DMEDFNC RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEDFNC RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEDFNC DI DMEDFNC DMEDFNC DN 2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC TI TTZJYKH DMEDFNC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMEDFNC MA Inhibitor DMEDFNC RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEDFNC RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEDFNC DI DMEDFNC DMEDFNC DN 2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC TI TTXNCBV DMEDFNC TN Tryptophan 2,3-dioxygenase (TDO) DMEDFNC MA Inhibitor DMEDFNC RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEDFNC RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEDNTJ DI DMEDNTJ DMEDNTJ DN Secondary and tertiary (hetero)arylamide derivative 1 DMEDNTJ TI TTGP7BY DMEDNTJ TN Monoamine oxidase type B (MAO-B) DMEDNTJ MA Inhibitor DMEDNTJ RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMEDNTJ RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMEDXW9 DI DMEDXW9 DMEDXW9 DN Pyrazole derivative 14 DMEDXW9 TI TT6OEDT DMEDXW9 TN Cannabinoid receptor 1 (CB1) DMEDXW9 MA Antagonist DMEDXW9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEDXW9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEFA20 DI DMEFA20 DMEFA20 DN PMID25726713-Compound-44 DMEFA20 TI TT8J1S3 DMEFA20 TN Smoothened homolog (SMO) DMEFA20 MA Inhibitor DMEFA20 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEFA20 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEFQND DI DMEFQND DMEFQND DN Maleimides derivative 3 DMEFQND TI TTRZQE3 DMEFQND TN Glycogen synthase kinase-3 alpha (GSK-3A) DMEFQND MA Inhibitor DMEFQND RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMEFQND RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMEG5YO DI DMEG5YO DMEG5YO DN Tetra-substituted urea derivative 1 DMEG5YO TI TTDP1UC DMEG5YO TN Fatty acid amide hydrolase (FAAH) DMEG5YO MA Inhibitor DMEG5YO RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEG5YO RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEG8CB DI DMEG8CB DMEG8CB DN PMID25666693-Compound-106 DMEG8CB TI TTMI6F5 DMEG8CB TN Transient receptor potential cation channel V1 (TRPV1) DMEG8CB MA Antagonist DMEG8CB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEG8CB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEGBHP DI DMEGBHP DMEGBHP DN PMID26394986-Compound-Figure17 DMEGBHP TI TTH8FZW DMEGBHP TN Signal transducer and activator of transcription 3 (STAT3) DMEGBHP MA Inhibitor DMEGBHP RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMEGBHP RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMEGJ73 DI DMEGJ73 DMEGJ73 DN PMID25435285-Compound-43 DMEGJ73 TI TTXJ47W DMEGJ73 TN Metabotropic glutamate receptor 2 (mGluR2) DMEGJ73 MA Antagonist DMEGJ73 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMEGJ73 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMEGK3Q DI DMEGK3Q DMEGK3Q DN Heterocyclic-fused piperazine derivative 1 DMEGK3Q TI TT473XN DMEGK3Q TN P2X purinoceptor 7 (P2RX7) DMEGK3Q MA Antagonist DMEGK3Q RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMEGK3Q RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMEGRMX DI DMEGRMX DMEGRMX DN PMID27454349-Compound-102 DMEGRMX TI TTK59TV DMEGRMX TN Vitamin D3 receptor (VDR) DMEGRMX MA Agonist DMEGRMX RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMEGRMX RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMEGS7U DI DMEGS7U DMEGS7U DN PMID25991433-Compound-P2 DMEGS7U TI TTVOE6D DMEGS7U TN Mitogen-activated protein kinase (MAPK) DMEGS7U MA Inhibitor DMEGS7U RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMEGS7U RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMEGS9U DI DMEGS9U DMEGS9U DN Pyrazoline derivative 5 DMEGS9U TI TT6OEDT DMEGS9U TN Cannabinoid receptor 1 (CB1) DMEGS9U MA Antagonist DMEGS9U RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEGS9U RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEGVD4 DI DMEGVD4 DMEGVD4 DN Six-membered heterocyclic benzamide derivative 3 DMEGVD4 TI TTTDVOJ DMEGVD4 TN Tropomyosin-related kinase A (TrkA) DMEGVD4 MA Inhibitor DMEGVD4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMEGVD4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMEH0RC DI DMEH0RC DMEH0RC DN N-phenyl-5-phenyl-pyrazolin-3-yl amide derivative 3 DMEH0RC TI TT6OEDT DMEH0RC TN Cannabinoid receptor 1 (CB1) DMEH0RC MA Antagonist DMEH0RC RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEH0RC RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEHIS4 DI DMEHIS4 DMEHIS4 DN PMID27774822-Compound-Figure2Example4-3 DMEHIS4 TI TTT7PJU DMEHIS4 TN Janus kinase 3 (JAK-3) DMEHIS4 MA Inhibitor DMEHIS4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMEHIS4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMEHMKY DI DMEHMKY DMEHMKY DN Mycophenolic acid/nucleotide derivative 4 DMEHMKY TI TTL7C8Q DMEHMKY TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMEHMKY MA Inhibitor DMEHMKY RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMEHMKY RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMEHSR7 DI DMEHSR7 DMEHSR7 DN US9187437, 8 DMEHSR7 TI TTDYP7I DMEHSR7 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMEHSR7 MA Inhibitor DMEHSR7 RN Substituted oxadiazole compounds. US9187437. DMEHSR7 RU http://www.freepatentsonline.com/US9187437.html DMEHYBJ DI DMEHYBJ DMEHYBJ DN Pyrrolo-pyrimidine derivative 2 DMEHYBJ TI TT4DXQT DMEHYBJ TN Proto-oncogene c-Ret (RET) DMEHYBJ MA Inhibitor DMEHYBJ RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMEHYBJ RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMEIA6Y DI DMEIA6Y DMEIA6Y DN PMID25684022-Compound-US20120277229 45(1.5) DMEIA6Y TI TTCZOF2 DMEIA6Y TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMEIA6Y MA Inhibitor DMEIA6Y RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMEIA6Y RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMEIDC0 DI DMEIDC0 DMEIDC0 DN Pyrrolo-pyrimidine derivative 11 DMEIDC0 TI TTK0FEA DMEIDC0 TN Leucine-rich repeat kinase 2 (LRRK2) DMEIDC0 MA Inhibitor DMEIDC0 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMEIDC0 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMEIG16 DI DMEIG16 DMEIG16 DN Tricyclic compound 4 DMEIG16 TI TTGWKQJ DMEIG16 TN Rho-associated protein kinase 2 (ROCK2) DMEIG16 MA Inhibitor DMEIG16 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMEIG16 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMEIH73 DI DMEIH73 DMEIH73 DN Quinazoline derivative 5 DMEIH73 TI TTPTXIN DMEIH73 TN Translocator protein (TSPO) DMEIH73 MA Ligand DMEIH73 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMEIH73 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMEIZ6Y DI DMEIZ6Y DMEIZ6Y DN PMID28092474-Compound-32f DMEIZ6Y TI TT6R7JZ DMEIZ6Y TN Histone deacetylase 1 (HDAC1) DMEIZ6Y MA Inhibitor DMEIZ6Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEIZ6Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEIZ6Y DI DMEIZ6Y DMEIZ6Y DN PMID28092474-Compound-32f DMEIZ6Y TI TT5ZKDI DMEIZ6Y TN Histone deacetylase 6 (HDAC6) DMEIZ6Y MA Inhibitor DMEIZ6Y RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEIZ6Y RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TTRA6BO DMEJ107 TN Bromodomain-containing protein 4 (BRD4) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TTHE657 DMEJ107 TN Bromodomain-containing protein 3 (BRD3) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TTDP48B DMEJ107 TN Bromodomain-containing protein 2 (BRD2) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ107 DI DMEJ107 DMEJ107 DN PMID26924192-Compound-102 DMEJ107 TI TT7CPI5 DMEJ107 TN Bromodomain testis-specific protein (BRDT) DMEJ107 MA Inhibitor DMEJ107 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEJ107 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEJ4LW DI DMEJ4LW DMEJ4LW DN PMID28074661-Compound-US20128202889C90 DMEJ4LW TI TTL7C8Q DMEJ4LW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMEJ4LW MA Inhibitor DMEJ4LW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMEJ4LW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMEJMPD DI DMEJMPD DMEJMPD DN PMID25656651-Compound-30b DMEJMPD TI TTS7G69 DMEJMPD TN Fusion protein Bcr-Abl (Bcr-Abl) DMEJMPD MA Inhibitor DMEJMPD RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMEJMPD RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMEJNUG DI DMEJNUG DMEJNUG DN PMID25399762-Compound-Table1-C5 DMEJNUG TI TTGP7BY DMEJNUG TN Monoamine oxidase type B (MAO-B) DMEJNUG MA Inhibitor DMEJNUG RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMEJNUG RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMEJOPL DI DMEJOPL DMEJOPL DN 2,2-bipyridyl derivative 5 DMEJOPL TI TT0RGE9 DMEJOPL TN Lysine-specific demethylase 4 (KDM4) DMEJOPL MA Inhibitor DMEJOPL RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMEJOPL RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TTNR0UQ DMEJR2F TN Lysine-specific histone demethylase 1 (LSD) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TT8VP2T DMEJR2F TN Lysine-specific histone demethylase 1B (KDM1B) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TTGP7BY DMEJR2F TN Monoamine oxidase type B (MAO-B) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEJR2F DI DMEJR2F DMEJR2F DN Tarnylcypromine derivative 2 DMEJR2F TI TT3WG5C DMEJR2F TN Monoamine oxidase type A (MAO-A) DMEJR2F MA Inhibitor DMEJR2F RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMEJR2F RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMEKBOG DI DMEKBOG DMEKBOG DN PMID26815044-Compound-64 DMEKBOG TI TTULVH8 DMEKBOG TN Tyrosinase (TYR) DMEKBOG MA Inhibitor DMEKBOG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMEKBOG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMEKO71 DI DMEKO71 DMEKO71 DN Tetra-hydro-quinoline derivative 2 DMEKO71 TI TTE4BSY DMEKO71 TN Bromodomain and extraterminal domain protein (BET) DMEKO71 MA Inhibitor DMEKO71 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEKO71 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMEL1WX DI DMEL1WX DMEL1WX DN PMID25666693-Compound-1 DMEL1WX TI TTMI6F5 DMEL1WX TN Transient receptor potential cation channel V1 (TRPV1) DMEL1WX MA Antagonist DMEL1WX RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEL1WX RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEL28G DI DMEL28G DMEL28G DN BDBM50177019 DMEL28G TI TTECBXN DMEL28G TN Oxysterols receptor LXR-alpha (NR1H3) DMEL28G MA Inhibitor DMEL28G RN Piperazine derivatives as liver X receptor modulators. US10144715. DMEL28G RU http://www.freepatentsonline.com/US10144715.html DMEL7XA DI DMEL7XA DMEL7XA DN PMID26924192-Compound-25 DMEL7XA TI TTRA6BO DMEL7XA TN Bromodomain-containing protein 4 (BRD4) DMEL7XA MA Inhibitor DMEL7XA RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMEL7XA RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMELA2F DI DMELA2F DMELA2F DN Pyrimidine derivative 21 DMELA2F TI TT8J1S3 DMELA2F TN Smoothened homolog (SMO) DMELA2F MA Inhibitor DMELA2F RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMELA2F RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEM2I8 DI DMEM2I8 DMEM2I8 DN PMID29865878-Compound-63 DMEM2I8 TI TTEAD9J DMEM2I8 TN Proteasome beta-8 (PS beta-8) DMEM2I8 MA Inhibitor DMEM2I8 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMEM2I8 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMEMBOW DI DMEMBOW DMEMBOW DN PMID25522065-Compound-31 DMEMBOW TI TTX4RTB DMEMBOW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMEMBOW MA Antagonist DMEMBOW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMEMBOW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMEMSB2 DI DMEMSB2 DMEMSB2 DN PMID25991433-Compound-Q1 DMEMSB2 TI TTR2TXZ DMEMSB2 TN Jun N terminal kinase (JNK) DMEMSB2 MA Inhibitor DMEMSB2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMEMSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMEMSB2 DI DMEMSB2 DMEMSB2 DN PMID25991433-Compound-Q1 DMEMSB2 TI TTVOE6D DMEMSB2 TN Mitogen-activated protein kinase (MAPK) DMEMSB2 MA Inhibitor DMEMSB2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMEMSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMEMT3I DI DMEMT3I DMEMT3I DN Resorcinol compound 12 DMEMT3I TI TTULVH8 DMEMT3I TN Tyrosinase (TYR) DMEMT3I MA Inhibitor DMEMT3I RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMEMT3I RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMEMYDZ DI DMEMYDZ DMEMYDZ DN 4-aryl quinol derivative 1 DMEMYDZ TI TTR7UJ3 DMEMYDZ TN Cytoplasmic thioredoxin reductase (TXNRD1) DMEMYDZ MA Inhibitor DMEMYDZ RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMEMYDZ RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMEN8RA DI DMEN8RA DMEN8RA DN PMID26651364-Compound-127 DMEN8RA TI TTTCRU2 DMEN8RA TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMEN8RA MA Antagonist DMEN8RA RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMEN8RA RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMENQ5O DI DMENQ5O DMENQ5O DN Quinoxaline derivative 1 DMENQ5O TI TTSXVID DMENQ5O TN Nuclear factor NF-kappa-B (NFKB) DMENQ5O MA Inhibitor DMENQ5O RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMENQ5O RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMENX90 DI DMENX90 DMENX90 DN PMID26077642-Compound-Figure3A DMENX90 TI TTVSYP9 DMENX90 TN Ubiquitin carboxyl-terminal hydrolase 14 (USP14) DMENX90 MA Inhibitor DMENX90 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMENX90 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMENX90 DI DMENX90 DMENX90 DN PMID26077642-Compound-Figure3A DMENX90 TI TTSX29Z DMENX90 TN Ubiquitin C-terminal hydrolase UCH37 (UCHL5) DMENX90 MA Inhibitor DMENX90 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMENX90 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMENYZ0 DI DMENYZ0 DMENYZ0 DN Imidazo bicyclic iminium derivative 3 DMENYZ0 TI TT8J1S3 DMENYZ0 TN Smoothened homolog (SMO) DMENYZ0 MA Inhibitor DMENYZ0 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMENYZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMENZPR DI DMENZPR DMENZPR DN Quinolinyl compound 1 DMENZPR TI TT9O6WS DMENZPR TN Glucagon receptor (GCGR) DMENZPR MA Antagonist DMENZPR RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMENZPR RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMEO9QB DI DMEO9QB DMEO9QB DN Phenylate derivative 1 DMEO9QB TI TT23XQV DMEO9QB TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMEO9QB MA Inhibitor DMEO9QB RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMEO9QB RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMEOHX2 DI DMEOHX2 DMEOHX2 DN PMID28394193-Compound-33 DMEOHX2 TI TT9MZCQ DMEOHX2 TN Enhancer of zeste homolog 2 (EZH2) DMEOHX2 MA Inhibitor DMEOHX2 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMEOHX2 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMEOKCB DI DMEOKCB DMEOKCB DN Thiazole carboxamide derivative 30 DMEOKCB TI TTCZOF2 DMEOKCB TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMEOKCB MA Inhibitor DMEOKCB RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMEOKCB RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMEOZKF DI DMEOZKF DMEOZKF DN PMID29757691-Compound-8b DMEOZKF TI TT1RS9F DMEOZKF TN Acetylcholinesterase (AChE) DMEOZKF MA Inhibitor DMEOZKF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEOZKF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEOZKF DI DMEOZKF DMEOZKF DN PMID29757691-Compound-8b DMEOZKF TI TTEB0GD DMEOZKF TN Cholinesterase (BCHE) DMEOZKF MA Inhibitor DMEOZKF RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEOZKF RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEP5MJ DI DMEP5MJ DMEP5MJ DN Imidazo bicyclic iminium derivative 6 DMEP5MJ TI TT8J1S3 DMEP5MJ TN Smoothened homolog (SMO) DMEP5MJ MA Inhibitor DMEP5MJ RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEP5MJ RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEP9O8 DI DMEP9O8 DMEP9O8 DN Aryl pyrimidine derivative 5 DMEP9O8 TI TTIY56R DMEP9O8 TN Kynurenine 3-hydroxylase (KMO) DMEP9O8 MA Inhibitor DMEP9O8 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMEP9O8 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMEPWGH DI DMEPWGH DMEPWGH DN PMID28092474-Compound-32z DMEPWGH TI TT6R7JZ DMEPWGH TN Histone deacetylase 1 (HDAC1) DMEPWGH MA Inhibitor DMEPWGH RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEPWGH RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEPWGH DI DMEPWGH DMEPWGH DN PMID28092474-Compound-32z DMEPWGH TI TT5ZKDI DMEPWGH TN Histone deacetylase 6 (HDAC6) DMEPWGH MA Inhibitor DMEPWGH RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMEPWGH RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMEPYGQ DI DMEPYGQ DMEPYGQ DN PMID25666693-Compound-70 DMEPYGQ TI TTMI6F5 DMEPYGQ TN Transient receptor potential cation channel V1 (TRPV1) DMEPYGQ MA Antagonist DMEPYGQ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEPYGQ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEQ3RD DI DMEQ3RD DMEQ3RD DN Tri-substituted benzene derivative 1 DMEQ3RD TI TTN9T81 DMEQ3RD TN Arachidonate 15-lipoxygenase (15-LOX) DMEQ3RD MA Inhibitor DMEQ3RD RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMEQ3RD RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMEQ9BN DI DMEQ9BN DMEQ9BN DN PMID25726713-Compound-33 DMEQ9BN TI TT8J1S3 DMEQ9BN TN Smoothened homolog (SMO) DMEQ9BN MA Inhibitor DMEQ9BN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEQ9BN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEQBTO DI DMEQBTO DMEQBTO DN Hydrazinoacetic acid DMEQBTO TI TTLQUZS DMEQBTO TN Cystathionine gamma-lyase (CTH) DMEQBTO MA Inhibitor DMEQBTO RN Cystathionine--lyase (CSE) inhibitors. US9725426. DMEQBTO RU http://www.freepatentsonline.com/US9725426.html DMEQFXZ DI DMEQFXZ DMEQFXZ DN Urea and carbamate bioisostere derivative 1 DMEQFXZ TI TTTB4UP DMEQFXZ TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMEQFXZ MA Inhibitor DMEQFXZ RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMEQFXZ RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMER2ZQ DI DMER2ZQ DMER2ZQ DN 2-hydroxybenzamide derivative 1 DMER2ZQ TI TTA6ZN2 DMER2ZQ TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMER2ZQ MA Activator DMER2ZQ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMER2ZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMER2ZQ DI DMER2ZQ DMER2ZQ DN 2-hydroxybenzamide derivative 1 DMER2ZQ TI TT3Z6Y9 DMER2ZQ TN Cysteines of Keap1 (KEAP1 Cysteines) DMER2ZQ MA Modulator DMER2ZQ RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMER2ZQ RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMER7QX DI DMER7QX DMER7QX DN JCXGHZCWAHCYGY-UHFFFAOYSA-N DMER7QX TI TTDYP7I DMER7QX TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMER7QX MA Inhibitor DMER7QX RN 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis. US9150519. DMER7QX RU http://www.freepatentsonline.com/US9150519.html DMERD39 DI DMERD39 DMERD39 DN PMID25666693-Compound-2 DMERD39 TI TTMI6F5 DMERD39 TN Transient receptor potential cation channel V1 (TRPV1) DMERD39 MA Antagonist DMERD39 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMERD39 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMERQ7V DI DMERQ7V DMERQ7V DN Diaryl piperazine derivative 1 DMERQ7V TI TT6OEDT DMERQ7V TN Cannabinoid receptor 1 (CB1) DMERQ7V MA Antagonist DMERQ7V RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMERQ7V RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMERWUQ DI DMERWUQ DMERWUQ DN US9586942, 16 DMERWUQ TI TTYJRN5 DMERWUQ TN N-acetylglucosaminyltransferase I (NAGAT1) DMERWUQ MA Inhibitor DMERWUQ RN Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942. DMERWUQ RU http://www.freepatentsonline.com/US9586942.html DMES0UY DI DMES0UY DMES0UY DN PMID29649907-Compound-21 DMES0UY TI TTS4UGC DMES0UY TN Farnesoid X-activated receptor (FXR) DMES0UY MA Agonist DMES0UY RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMES0UY RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMES41R DI DMES41R DMES41R DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 7 DMES41R TI TTULVH8 DMES41R TN Tyrosinase (TYR) DMES41R MA Inhibitor DMES41R RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMES41R RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMESAUL DI DMESAUL DMESAUL DN Thiazole derivative 5 DMESAUL TI TT473XN DMESAUL TN P2X purinoceptor 7 (P2RX7) DMESAUL MA Antagonist DMESAUL RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMESAUL RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMESKY1 DI DMESKY1 DMESKY1 DN Benzene sulfonamide derivative 12 DMESKY1 TI TT4G2JS DMESKY1 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMESKY1 MA Inhibitor DMESKY1 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMESKY1 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMESOA8 DI DMESOA8 DMESOA8 DN 1,2,4-oxadiazole derivative 1 DMESOA8 TI TTNBFWK DMESOA8 TN Programmed cell death protein 1 (PD-1) DMESOA8 MA Inhibitor DMESOA8 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMESOA8 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMETCI3 DI DMETCI3 DMETCI3 DN Pyrazole derivative 82 DMETCI3 TI TTZ963I DMETCI3 TN Monoglyceride lipase (MAGL) DMETCI3 MA Inhibitor DMETCI3 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMETCI3 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMETCI3 DI DMETCI3 DMETCI3 DN Pyrazole derivative 82 DMETCI3 TI TTDP1UC DMETCI3 TN Fatty acid amide hydrolase (FAAH) DMETCI3 MA Inhibitor DMETCI3 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMETCI3 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMETCI3 DI DMETCI3 DMETCI3 DN Pyrazole derivative 82 DMETCI3 TI TTSINOV DMETCI3 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMETCI3 MA Inhibitor DMETCI3 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMETCI3 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMETIKC DI DMETIKC DMETIKC DN Steroid derivative 3 DMETIKC TI TTUX68I DMETIKC TN Hypoxia-inducible factor 1 (HIF-1) DMETIKC MA Inhibitor DMETIKC RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMETIKC RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMETY0U DI DMETY0U DMETY0U DN US8524917, 11 DMETY0U TI TTDYP7I DMETY0U TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMETY0U MA Inhibitor DMETY0U RN S1P3 receptor inhibitors for treating pain. US8563594. DMETY0U RU http://www.freepatentsonline.com/US8563594.html DMEU12W DI DMEU12W DMEU12W DN NCGC00381656-01 DMEU12W TI TTIG67W DMEU12W TN Lysine-specific demethylase 5A (KDM5A) DMEU12W MA Inhibitor DMEU12W RN Histone demethylase inhibitors. US9738637. DMEU12W RU http://www.freepatentsonline.com/US9738637.html DMEU3J9 DI DMEU3J9 DMEU3J9 DN Furopyridine derivative 2 DMEU3J9 TI TT6OEDT DMEU3J9 TN Cannabinoid receptor 1 (CB1) DMEU3J9 MA Antagonist DMEU3J9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEU3J9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEU48I DI DMEU48I DMEU48I DN PMID25522065-Compound-51 DMEU48I TI TTX4RTB DMEU48I TN Melanin-concentrating hormone receptor 1 (MCHR1) DMEU48I MA Antagonist DMEU48I RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMEU48I RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMEU4Y1 DI DMEU4Y1 DMEU4Y1 DN PMID28394193-Compound-49 DMEU4Y1 TI TT9MZCQ DMEU4Y1 TN Enhancer of zeste homolog 2 (EZH2) DMEU4Y1 MA Inhibitor DMEU4Y1 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMEU4Y1 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMEU5ST DI DMEU5ST DMEU5ST DN US8598210, Table XV, 5 DMEU5ST TI TT9ISBX DMEU5ST TN HIF-prolyl hydroxylase 2 (HPH-2) DMEU5ST MA Inhibitor DMEU5ST RN Prolyl hydroxylase inhibitors and method of use. US8722895. DMEU5ST RU http://www.freepatentsonline.com/US8722895.html DMEUBDA DI DMEUBDA DMEUBDA DN PMID25980951-Compound-38 DMEUBDA TI TTR7B60 DMEUBDA TN X-linked inhibitor of apoptosis protein (XIAP) DMEUBDA MA Antagonist DMEUBDA RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMEUBDA RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMEUBDA DI DMEUBDA DMEUBDA DN PMID25980951-Compound-38 DMEUBDA TI TTQ5LRD DMEUBDA TN Cellular inhibitor of apoptosis 1 (BIRC2) DMEUBDA MA Antagonist DMEUBDA RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMEUBDA RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMEUC04 DI DMEUC04 DMEUC04 DN PMID29757691-Compound-2a DMEUC04 TI TT1RS9F DMEUC04 TN Acetylcholinesterase (AChE) DMEUC04 MA Inhibitor DMEUC04 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEUC04 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEUC04 DI DMEUC04 DMEUC04 DN PMID29757691-Compound-2a DMEUC04 TI TTEB0GD DMEUC04 TN Cholinesterase (BCHE) DMEUC04 MA Inhibitor DMEUC04 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMEUC04 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMEUHCD DI DMEUHCD DMEUHCD DN Aza-phenalene-3-ketone derivative 1 DMEUHCD TI TTEBCY8 DMEUHCD TN Poly [ADP-ribose] polymerase (PARP) DMEUHCD MA Inhibitor DMEUHCD RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMEUHCD RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMEUO8G DI DMEUO8G DMEUO8G DN 1,5-di-substituted pyridine derivative 1 DMEUO8G TI TT1LVF2 DMEUO8G TN Cyclin-dependent kinase 9 (CDK9) DMEUO8G MA Inhibitor DMEUO8G RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMEUO8G RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMEUO8G DI DMEUO8G DMEUO8G DN 1,5-di-substituted pyridine derivative 1 DMEUO8G TI TT7HF4W DMEUO8G TN Cyclin-dependent kinase 2 (CDK2) DMEUO8G MA Inhibitor DMEUO8G RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMEUO8G RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMEUSGR DI DMEUSGR DMEUSGR DN PMID26666989-Compound-Figure12topmiddile DMEUSGR TI TT8BUGW DMEUSGR TN Glycogen phosphorylase (PYG) DMEUSGR MA Inhibitor DMEUSGR RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMEUSGR RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMEUZM3 DI DMEUZM3 DMEUZM3 DN PMID29671355-Compound-52 DMEUZM3 TI TTTQGH8 DMEUZM3 TN Histone deacetylase 4 (HDAC4) DMEUZM3 MA Inhibitor DMEUZM3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMEUZM3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMEV9O3 DI DMEV9O3 DMEV9O3 DN Epoxysuccinate derivative 2 DMEV9O3 TI TTG5QB7 DMEV9O3 TN Calpain-2 (CAPN2) DMEV9O3 MA Inhibitor DMEV9O3 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMEV9O3 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMEVBZW DI DMEVBZW DMEVBZW DN AC1LFXA6 DMEVBZW TI TT25MVL DMEVBZW TN Serine protease hepsin (HPN) DMEVBZW MA Inhibitor DMEVBZW RN Hepsin inhibitors. US9182402. DMEVBZW RU http://www.freepatentsonline.com/US9182402.html DMEVGR6 DI DMEVGR6 DMEVGR6 DN US10149841, Compound 1 DMEVGR6 TI TT9ISBX DMEVGR6 TN HIF-prolyl hydroxylase 2 (HPH-2) DMEVGR6 MA Inhibitor DMEVGR6 RN Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841. DMEVGR6 RU http://www.freepatentsonline.com/US10149841.html DMEVL0S DI DMEVL0S DMEVL0S DN PMID25666693-Compound-48 DMEVL0S TI TTMI6F5 DMEVL0S TN Transient receptor potential cation channel V1 (TRPV1) DMEVL0S MA Antagonist DMEVL0S RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMEVL0S RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMEVMU9 DI DMEVMU9 DMEVMU9 DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 2 DMEVMU9 TI TTVDSZ0 DMEVMU9 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMEVMU9 MA Inhibitor DMEVMU9 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMEVMU9 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMEVXT0 DI DMEVXT0 DMEVXT0 DN Pyrrolo-pyrimidine derivative 1 DMEVXT0 TI TTK0FEA DMEVXT0 TN Leucine-rich repeat kinase 2 (LRRK2) DMEVXT0 MA Inhibitor DMEVXT0 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMEVXT0 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMEVZIK DI DMEVZIK DMEVZIK DN PMID29649907-Compound-29 DMEVZIK TI TTS4UGC DMEVZIK TN Farnesoid X-activated receptor (FXR) DMEVZIK MA Agonist DMEVZIK RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMEVZIK RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMEW0AT DI DMEW0AT DMEW0AT DN 1,2-diamino cyclopentane-based derivative 25 DMEW0AT TI TT9N02I DMEW0AT TN Orexin receptor type 2 (HCRTR2) DMEW0AT MA Antagonist DMEW0AT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMEW0AT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMEW0AT DI DMEW0AT DMEW0AT DN 1,2-diamino cyclopentane-based derivative 25 DMEW0AT TI TT60Q8D DMEW0AT TN Orexin receptor type 1 (HCRTR1) DMEW0AT MA Antagonist DMEW0AT RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMEW0AT RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMEW46T DI DMEW46T DMEW46T DN PMID27967267-Compound-15 DMEW46T TI TT1RS9F DMEW46T TN Acetylcholinesterase (AChE) DMEW46T MA Inhibitor DMEW46T RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMEW46T RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMEW5LD DI DMEW5LD DMEW5LD DN AC1M1SP5 DMEW5LD TI TTIS4OW DMEW5LD TN Phosphodiesterase 8 (PDE8) DMEW5LD MA Inhibitor DMEW5LD RN Inhibitors of phosphodiesterase 11 (PDE11). US9173884. DMEW5LD RU http://www.freepatentsonline.com/US9173884.html DMEWA7U DI DMEWA7U DMEWA7U DN Biaryl mannoside derivative 6 DMEWA7U TI TTTCRU2 DMEWA7U TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMEWA7U MA Antagonist DMEWA7U RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMEWA7U RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMEWAQ9 DI DMEWAQ9 DMEWAQ9 DN Piperazine urea derivative 1 DMEWAQ9 TI TTDP1UC DMEWAQ9 TN Fatty acid amide hydrolase (FAAH) DMEWAQ9 MA Inhibitor DMEWAQ9 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWAQ9 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEWPQ6 DI DMEWPQ6 DMEWPQ6 DN Carbamate derivative 2 DMEWPQ6 TI TTVKILB DMEWPQ6 TN Prostaglandin G/H synthase 2 (COX-2) DMEWPQ6 MA Inhibitor DMEWPQ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWPQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEWPQ6 DI DMEWPQ6 DMEWPQ6 DN Carbamate derivative 2 DMEWPQ6 TI TTGX13H DMEWPQ6 TN Fatty-acid amide hydrolase 1 (FAAH1) DMEWPQ6 MA Inhibitor DMEWPQ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWPQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEWPQ6 DI DMEWPQ6 DMEWPQ6 DN Carbamate derivative 2 DMEWPQ6 TI TT8NGED DMEWPQ6 TN Prostaglandin G/H synthase 1 (COX-1) DMEWPQ6 MA Inhibitor DMEWPQ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMEWPQ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMEX5VK DI DMEX5VK DMEX5VK DN Oxazolo[3,4-a]pyrazine derivative 7 DMEX5VK TI TTV1C0Z DMEX5VK TN Neuropeptide S receptor (NPSR) DMEX5VK MA Antagonist DMEX5VK RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMEX5VK RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMEX7PV DI DMEX7PV DMEX7PV DN Heterocyclic-substituted 3-alkyl azetidine derivative 2 DMEX7PV TI TT6OEDT DMEX7PV TN Cannabinoid receptor 1 (CB1) DMEX7PV MA Antagonist DMEX7PV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMEX7PV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMEXATH DI DMEXATH DMEXATH DN PMID27967267-Compound-47 DMEXATH TI TT1RS9F DMEXATH TN Acetylcholinesterase (AChE) DMEXATH MA Reactivator DMEXATH RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMEXATH RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMEXNOP DI DMEXNOP DMEXNOP DN PMID25726713-Compound-23 DMEXNOP TI TT8J1S3 DMEXNOP TN Smoothened homolog (SMO) DMEXNOP MA Inhibitor DMEXNOP RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMEXNOP RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMEXPAU DI DMEXPAU DMEXPAU DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 1 DMEXPAU TI TTMSFAW DMEXPAU TN Cannabinoid receptor 2 (CB2) DMEXPAU RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMEXPAU RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMEXT6J DI DMEXT6J DMEXT6J DN Dihydropyridine compound 6 DMEXT6J TI TT4DXQT DMEXT6J TN Proto-oncogene c-Ret (RET) DMEXT6J MA Inhibitor DMEXT6J RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMEXT6J RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMEXV6L DI DMEXV6L DMEXV6L DN PMID27454349-Compound-97 DMEXV6L TI TTK59TV DMEXV6L TN Vitamin D3 receptor (VDR) DMEXV6L MA Agonist DMEXV6L RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMEXV6L RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMEY6L8 DI DMEY6L8 DMEY6L8 DN Imidazopyridazine derivative 1 DMEY6L8 TI TT6DM01 DMEY6L8 TN Janus kinase 1 (JAK-1) DMEY6L8 MA Inhibitor DMEY6L8 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMEY6L8 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMEY6L8 DI DMEY6L8 DMEY6L8 DN Imidazopyridazine derivative 1 DMEY6L8 TI TTT7PJU DMEY6L8 TN Janus kinase 3 (JAK-3) DMEY6L8 MA Inhibitor DMEY6L8 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMEY6L8 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMEYLM2 DI DMEYLM2 DMEYLM2 DN PMID25482888-Compound-70 DMEYLM2 TI TTDIGC1 DMEYLM2 TN Dipeptidyl peptidase 4 (DPP-4) DMEYLM2 MA Inhibitor DMEYLM2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMEYLM2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMEYS3V DI DMEYS3V DMEYS3V DN Azaindazole derivative 2 DMEYS3V TI TTK0FEA DMEYS3V TN Leucine-rich repeat kinase 2 (LRRK2) DMEYS3V MA Inhibitor DMEYS3V RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMEYS3V RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMEZ3QV DI DMEZ3QV DMEZ3QV DN PMID25980951-Compound-39 DMEZ3QV TI TTR7B60 DMEZ3QV TN X-linked inhibitor of apoptosis protein (XIAP) DMEZ3QV MA Antagonist DMEZ3QV RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMEZ3QV RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMEZDQ4 DI DMEZDQ4 DMEZDQ4 DN Alkynyl-heteroaromatic ring compound 1 DMEZDQ4 TI TTIV39N DMEZDQ4 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMEZDQ4 MA Inhibitor DMEZDQ4 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMEZDQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMEZLBQ DI DMEZLBQ DMEZLBQ DN PMID26560530-Compound-4 DMEZLBQ TI TT2F4OL DMEZLBQ TN Tissue transglutaminase (TG2) DMEZLBQ MA Inhibitor DMEZLBQ RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMEZLBQ RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMEZQ29 DI DMEZQ29 DMEZQ29 DN Tricyclic indole compound 12 DMEZQ29 TI TTPTXIN DMEZQ29 TN Translocator protein (TSPO) DMEZQ29 MA Ligand DMEZQ29 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMEZQ29 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMEZUN7 DI DMEZUN7 DMEZUN7 DN Resorcinol compound 25 DMEZUN7 TI TTULVH8 DMEZUN7 TN Tyrosinase (TYR) DMEZUN7 MA Inhibitor DMEZUN7 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMEZUN7 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMF01AR DI DMF01AR DMF01AR DN Benzisoselenazolone difluorocytidine derivative 1 DMF01AR TI TTR7UJ3 DMF01AR TN Cytoplasmic thioredoxin reductase (TXNRD1) DMF01AR MA Inhibitor DMF01AR RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMF01AR RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMF05GL DI DMF05GL DMF05GL DN Quinazoline derivative 3 DMF05GL TI TTPTXIN DMF05GL TN Translocator protein (TSPO) DMF05GL MA Ligand DMF05GL RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMF05GL RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMF0DE2 DI DMF0DE2 DMF0DE2 DN Peptidomimetic analog 5 DMF0DE2 TI TTH8FZW DMF0DE2 TN Signal transducer and activator of transcription 3 (STAT3) DMF0DE2 MA Inhibitor DMF0DE2 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMF0DE2 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMF0DE2 DI DMF0DE2 DMF0DE2 DN Peptidomimetic analog 5 DMF0DE2 TI TTN7R6K DMF0DE2 TN Signal transducer and activator of transcription 1 (STAT1) DMF0DE2 MA Inhibitor DMF0DE2 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMF0DE2 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMF0L3E DI DMF0L3E DMF0L3E DN PMID26651364-Compound-9d DMF0L3E TI TTTCRU2 DMF0L3E TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF0L3E MA Antagonist DMF0L3E RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF0L3E RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TT0PG8F DMF0OW4 TN Cyclin-dependent kinase 4 (CDK4) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TTO0FDJ DMF0OW4 TN Cyclin-dependent kinase 6 (CDK6) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TT8J1S3 DMF0OW4 TN Smoothened homolog (SMO) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0OW4 DI DMF0OW4 DMF0OW4 DN PMID25726713-Compound-51 DMF0OW4 TI TTCJG29 DMF0OW4 TN Serine/threonine-protein kinase mTOR (mTOR) DMF0OW4 MA Inhibitor DMF0OW4 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMF0OW4 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMF0XI3 DI DMF0XI3 DMF0XI3 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 1 DMF0XI3 TI TTV8CRH DMF0XI3 TN Lysine-specific demethylase 4C (KDM4C) DMF0XI3 MA Inhibitor DMF0XI3 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMF0XI3 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMF1MV6 DI DMF1MV6 DMF1MV6 DN PMID26651364-Compound-9f DMF1MV6 TI TTTCRU2 DMF1MV6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF1MV6 MA Antagonist DMF1MV6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF1MV6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF1MZ4 DI DMF1MZ4 DMF1MZ4 DN Peptide analog 42 DMF1MZ4 TI TTSJMN8 DMF1MZ4 TN Immunoproteasome complex (IP) DMF1MZ4 MA Inhibitor DMF1MZ4 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMF1MZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMF1TR6 DI DMF1TR6 DMF1TR6 DN Peptide analog 18 DMF1TR6 TI TTSJMN8 DMF1TR6 TN Immunoproteasome complex (IP) DMF1TR6 MA Inhibitor DMF1TR6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMF1TR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMF1ZJ3 DI DMF1ZJ3 DMF1ZJ3 DN PMID28350212-Compound-30 DMF1ZJ3 TI TTZS04O DMF1ZJ3 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMF1ZJ3 MA Inhibitor DMF1ZJ3 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMF1ZJ3 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMF2ZNT DI DMF2ZNT DMF2ZNT DN PMID28092474-Compound-33k DMF2ZNT TI TT6R7JZ DMF2ZNT TN Histone deacetylase 1 (HDAC1) DMF2ZNT MA Inhibitor DMF2ZNT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMF2ZNT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMF2ZNT DI DMF2ZNT DMF2ZNT DN PMID28092474-Compound-33k DMF2ZNT TI TT5ZKDI DMF2ZNT TN Histone deacetylase 6 (HDAC6) DMF2ZNT MA Inhibitor DMF2ZNT RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMF2ZNT RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TT7MRDV DMF3907 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TT8FYO9 DMF3907 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TTX41N9 DMF3907 TN Tyrosine-protein kinase Kit (KIT) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3907 DI DMF3907 DMF3907 DN Pyridine derivative 21 DMF3907 TI TT4DXQT DMF3907 TN Proto-oncogene c-Ret (RET) DMF3907 MA Inhibitor DMF3907 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMF3907 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMF3LIX DI DMF3LIX DMF3LIX DN Peptide analog 1 DMF3LIX TI TT23XQV DMF3LIX TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMF3LIX MA Inhibitor DMF3LIX RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMF3LIX RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMF3NCO DI DMF3NCO DMF3NCO DN Phenylpyrrolidinone derivative 2 DMF3NCO TI TT5OU0D DMF3NCO TN PRKR-like endoplasmic reticulum kinase (PERK) DMF3NCO MA Inhibitor DMF3NCO RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMF3NCO RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TT84OS6 DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TTYGQ8A DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TTSBVFO DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF3X40 DI DMF3X40 DMF3X40 DN PMID28766366-Compound-Scheme21Right DMF3X40 TI TTV4EX0 DMF3X40 TN Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3) DMF3X40 MA Inhibitor DMF3X40 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMF3X40 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMF4YGC DI DMF4YGC DMF4YGC DN P-coumaric acid derivative 6 DMF4YGC TI TTULVH8 DMF4YGC TN Tyrosinase (TYR) DMF4YGC MA Inhibitor DMF4YGC RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMF4YGC RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMF5E6U DI DMF5E6U DMF5E6U DN Tricyclic compound 9 DMF5E6U TI TTAIQSN DMF5E6U TN Receptor-interacting protein 1 (RIPK1) DMF5E6U MA Inhibitor DMF5E6U RN Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256. DMF5E6U RU https://www.ncbi.nlm.nih.gov/pubmed/27568917 DMF5IWB DI DMF5IWB DMF5IWB DN PMID27774822-Compound-Figure7Example63 DMF5IWB TI TTRMX3V DMF5IWB TN Janus kinase 2 (JAK-2) DMF5IWB MA Inhibitor DMF5IWB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMF5IWB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMF5IWB DI DMF5IWB DMF5IWB DN PMID27774822-Compound-Figure7Example63 DMF5IWB TI TT6DM01 DMF5IWB TN Janus kinase 1 (JAK-1) DMF5IWB MA Inhibitor DMF5IWB RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMF5IWB RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMF5K9J DI DMF5K9J DMF5K9J DN PMID28870136-Compound-65 DMF5K9J TI TTK0O6Y DMF5K9J TN Ecto-5'-nucleotidase (CD73) DMF5K9J MA Inhibitor DMF5K9J RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMF5K9J RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMF5LNK DI DMF5LNK DMF5LNK DN PMID26666989-Compound-Figure12left DMF5LNK TI TT8BUGW DMF5LNK TN Glycogen phosphorylase (PYG) DMF5LNK MA Inhibitor DMF5LNK RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMF5LNK RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMF5ODZ DI DMF5ODZ DMF5ODZ DN PMID25666693-Compound-115 DMF5ODZ TI TTMI6F5 DMF5ODZ TN Transient receptor potential cation channel V1 (TRPV1) DMF5ODZ MA Antagonist DMF5ODZ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMF5ODZ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMF5TB4 DI DMF5TB4 DMF5TB4 DN Biaryl mannoside derivative 24 DMF5TB4 TI TTTCRU2 DMF5TB4 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF5TB4 MA Antagonist DMF5TB4 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF5TB4 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF5XU8 DI DMF5XU8 DMF5XU8 DN Aryl mannoside derivative 3 DMF5XU8 TI TTTCRU2 DMF5XU8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF5XU8 MA Antagonist DMF5XU8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF5XU8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF6B1I DI DMF6B1I DMF6B1I DN Benzodihydroisofuran derivative 3 DMF6B1I TI TTTJZ4M DMF6B1I TN Prolylcarboxypeptidase (PRCP) DMF6B1I MA Inhibitor DMF6B1I RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMF6B1I RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMF6DUT DI DMF6DUT DMF6DUT DN Pyrimidine derivative 7 DMF6DUT TI TTOHSBA DMF6DUT TN Vascular endothelial growth factor A (VEGFA) DMF6DUT MA Inhibitor DMF6DUT RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMF6DUT RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMF6N7Z DI DMF6N7Z DMF6N7Z DN Amidopyrazole derivative 4 DMF6N7Z TI TTKFVXR DMF6N7Z TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMF6N7Z MA Inhibitor DMF6N7Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMF6N7Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMF6W2Y DI DMF6W2Y DMF6W2Y DN 1,6-naphyridine-4-ketone fused heterocyclic derivative 1 DMF6W2Y TI TTOHSBA DMF6W2Y TN Vascular endothelial growth factor A (VEGFA) DMF6W2Y MA Inhibitor DMF6W2Y RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMF6W2Y RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMF6Z5I DI DMF6Z5I DMF6Z5I DN PMID26651364-Compound-5d DMF6Z5I TI TTTCRU2 DMF6Z5I TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMF6Z5I MA Antagonist DMF6Z5I RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMF6Z5I RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMF7MEB DI DMF7MEB DMF7MEB DN Pyridazinone derivative 1 DMF7MEB TI TT473XN DMF7MEB TN P2X purinoceptor 7 (P2RX7) DMF7MEB MA Antagonist DMF7MEB RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMF7MEB RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMF7NXJ DI DMF7NXJ DMF7NXJ DN Imidazopyridazine derivative 8 DMF7NXJ TI TTQR74A DMF7NXJ TN Proteinase activated receptor 2 (PAR2) DMF7NXJ MA Antagonist DMF7NXJ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMF7NXJ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMF89PY DI DMF89PY DMF89PY DN PMID25399762-Compound-Table1-C23 DMF89PY TI TTGP7BY DMF89PY TN Monoamine oxidase type B (MAO-B) DMF89PY MA Inhibitor DMF89PY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMF89PY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMF8MIB DI DMF8MIB DMF8MIB DN US8669361, 107 DMF8MIB TI TTCGOIN DMF8MIB TN PIM-3 protein kinase (PIM3) DMF8MIB MA Inhibitor DMF8MIB RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361. DMF8MIB RU http://www.freepatentsonline.com/US8669361.html DMF8V5J DI DMF8V5J DMF8V5J DN PMID25980951-Compound-7 DMF8V5J TI TTQ5LRD DMF8V5J TN Cellular inhibitor of apoptosis 1 (BIRC2) DMF8V5J MA Antagonist DMF8V5J RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMF8V5J RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMF8V5J DI DMF8V5J DMF8V5J DN PMID25980951-Compound-7 DMF8V5J TI TTR7B60 DMF8V5J TN X-linked inhibitor of apoptosis protein (XIAP) DMF8V5J MA Antagonist DMF8V5J RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMF8V5J RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMF9C4I DI DMF9C4I DMF9C4I DN PMID26161824-Compound-68 DMF9C4I TI TT6OEDT DMF9C4I TN Cannabinoid receptor 1 (CB1) DMF9C4I MA Antagonist DMF9C4I RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMF9C4I RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMF9J0Y DI DMF9J0Y DMF9J0Y DN PMID26394986-Compound-20 DMF9J0Y TI TTH8FZW DMF9J0Y TN Signal transducer and activator of transcription 3 (STAT3) DMF9J0Y MA Inhibitor DMF9J0Y RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMF9J0Y RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMF9LNO DI DMF9LNO DMF9LNO DN US8536181, A41 DMF9LNO TI TT9ISBX DMF9LNO TN HIF-prolyl hydroxylase 2 (HPH-2) DMF9LNO MA Inhibitor DMF9LNO RN Prolyl hydroxylase inhibitors. US8536181. DMF9LNO RU http://www.freepatentsonline.com/US8536181.html DMF9VMW DI DMF9VMW DMF9VMW DN Pyridine derivative 11 DMF9VMW TI TTOHSBA DMF9VMW TN Vascular endothelial growth factor A (VEGFA) DMF9VMW MA Inhibitor DMF9VMW RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMF9VMW RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMF9X6P DI DMF9X6P DMF9X6P DN PMID25399762-Compound-Table1-C12 DMF9X6P TI TTGP7BY DMF9X6P TN Monoamine oxidase type B (MAO-B) DMF9X6P MA Inhibitor DMF9X6P RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMF9X6P RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMFAGOZ DI DMFAGOZ DMFAGOZ DN PMID27774822-Compound-Figure10Compound12 DMFAGOZ TI TTRMX3V DMFAGOZ TN Janus kinase 2 (JAK-2) DMFAGOZ MA Inhibitor DMFAGOZ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFAGOZ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFAGOZ DI DMFAGOZ DMFAGOZ DN PMID27774822-Compound-Figure10Compound12 DMFAGOZ TI TTJNBQA DMFAGOZ TN Activin receptor-like kinase 2 (ALK-2) DMFAGOZ MA Inhibitor DMFAGOZ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFAGOZ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFALQN DI DMFALQN DMFALQN DN Pyridine derivative 3 DMFALQN TI TTOHSBA DMFALQN TN Vascular endothelial growth factor A (VEGFA) DMFALQN MA Inhibitor DMFALQN RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMFALQN RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMFAM8B DI DMFAM8B DMFAM8B DN Fused aryl carbocycle derivative 1 DMFAM8B TI TT9NXW4 DMFAM8B TN Sigma intracellular receptor 2 (TMEM97) DMFAM8B MA Ligand DMFAM8B RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMFAM8B RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMFARIK DI DMFARIK DMFARIK DN Pyrazole derivative 73 DMFARIK TI TTJQOD7 DMFARIK TN 5-HT 2A receptor (HTR2A) DMFARIK MA Antagonist DMFARIK RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMFARIK RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMFBHAC DI DMFBHAC DMFBHAC DN PMID25726713-Compound-30 DMFBHAC TI TT8J1S3 DMFBHAC TN Smoothened homolog (SMO) DMFBHAC MA Inhibitor DMFBHAC RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMFBHAC RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMFBPSX DI DMFBPSX DMFBPSX DN 1,2-diamino cyclopentane-based derivative 4 DMFBPSX TI TT9N02I DMFBPSX TN Orexin receptor type 2 (HCRTR2) DMFBPSX MA Antagonist DMFBPSX RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMFBPSX RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMFBPSX DI DMFBPSX DMFBPSX DN 1,2-diamino cyclopentane-based derivative 4 DMFBPSX TI TT60Q8D DMFBPSX TN Orexin receptor type 1 (HCRTR1) DMFBPSX MA Antagonist DMFBPSX RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMFBPSX RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMFBQHZ DI DMFBQHZ DMFBQHZ DN Peptide analog 25 DMFBQHZ TI TT68GPI DMFBQHZ TN Proteasome beta-5 (PS beta-5) DMFBQHZ MA Inhibitor DMFBQHZ RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMFBQHZ RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMFBQHZ DI DMFBQHZ DMFBQHZ DN Peptide analog 25 DMFBQHZ TI TTEAD9J DMFBQHZ TN Proteasome beta-8 (PS beta-8) DMFBQHZ MA Inhibitor DMFBQHZ RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMFBQHZ RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMFBRSL DI DMFBRSL DMFBRSL DN N-(2-phenylcyclopropyl) amino acid derivative 3 DMFBRSL TI TT3WG5C DMFBRSL TN Monoamine oxidase type A (MAO-A) DMFBRSL MA Inhibitor DMFBRSL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMFBRSL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMFBRSL DI DMFBRSL DMFBRSL DN N-(2-phenylcyclopropyl) amino acid derivative 3 DMFBRSL TI TTGP7BY DMFBRSL TN Monoamine oxidase type B (MAO-B) DMFBRSL MA Inhibitor DMFBRSL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMFBRSL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMFBRSL DI DMFBRSL DMFBRSL DN N-(2-phenylcyclopropyl) amino acid derivative 3 DMFBRSL TI TTNR0UQ DMFBRSL TN Lysine-specific histone demethylase 1 (LSD) DMFBRSL MA Inhibitor DMFBRSL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMFBRSL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMFCE51 DI DMFCE51 DMFCE51 DN PMID25553724-Compound-US2012832440110 DMFCE51 TI TTSXVID DMFCE51 TN Nuclear factor NF-kappa-B (NFKB) DMFCE51 MA Inhibitor DMFCE51 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMFCE51 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMFCIGE DI DMFCIGE DMFCIGE DN US9493490, E DMFCIGE TI TTAZ3MN DMFCIGE TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMFCIGE MA Inhibitor DMFCIGE RN Boron-containing small molecules. US9493490. DMFCIGE RU http://www.freepatentsonline.com/US9493490.html DMFD9UZ DI DMFD9UZ DMFD9UZ DN PMID29757691-Compound-4 DMFD9UZ TI TT3WG5C DMFD9UZ TN Monoamine oxidase type A (MAO-A) DMFD9UZ MA Inhibitor DMFD9UZ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFD9UZ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFD9UZ DI DMFD9UZ DMFD9UZ DN PMID29757691-Compound-4 DMFD9UZ TI TTGP7BY DMFD9UZ TN Monoamine oxidase type B (MAO-B) DMFD9UZ MA Inhibitor DMFD9UZ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFD9UZ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFD9UZ DI DMFD9UZ DMFD9UZ DN PMID29757691-Compound-4 DMFD9UZ TI TT1RS9F DMFD9UZ TN Acetylcholinesterase (AChE) DMFD9UZ MA Inhibitor DMFD9UZ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFD9UZ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFDERP DI DMFDERP DMFDERP DN PMID28870136-Compound-52 DMFDERP TI TTK0O6Y DMFDERP TN Ecto-5'-nucleotidase (CD73) DMFDERP MA Inhibitor DMFDERP RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMFDERP RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMFDLHN DI DMFDLHN DMFDLHN DN Pyrrolidinyl urea derivative 3 DMFDLHN TI TTTDVOJ DMFDLHN TN Tropomyosin-related kinase A (TrkA) DMFDLHN MA Inhibitor DMFDLHN RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMFDLHN RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTRMX3V DMFDRJT TN Janus kinase 2 (JAK-2) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTT7PJU DMFDRJT TN Janus kinase 3 (JAK-3) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TT6DM01 DMFDRJT TN Janus kinase 1 (JAK-1) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTBYWP2 DMFDRJT TN TYK2 tyrosine kinase (TYK2) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTKAWRQ DMFDRJT TN JAK-STAT signaling pathway (JAK-STAT pathway) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDRJT DI DMFDRJT DMFDRJT DN Imidazo[4,5-c]pyridine derivative 2 DMFDRJT TI TTJSQEF DMFDRJT TN Tyrosine-protein kinase (PTK) DMFDRJT MA Inhibitor DMFDRJT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMFDRJT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMFDURZ DI DMFDURZ DMFDURZ DN 3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ TI TTXABCW DMFDURZ TN NT-3 growth factor receptor (TrkC) DMFDURZ MA Inhibitor DMFDURZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFDURZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFDURZ DI DMFDURZ DMFDURZ DN 3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ TI TTKN7QR DMFDURZ TN BDNF/NT-3 growth factors receptor (TrkB) DMFDURZ MA Inhibitor DMFDURZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFDURZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFDURZ DI DMFDURZ DMFDURZ DN 3-amino-5-benzyl-substituted indazole derivative 1 DMFDURZ TI TTTDVOJ DMFDURZ TN Tropomyosin-related kinase A (TrkA) DMFDURZ MA Inhibitor DMFDURZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFDURZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFDXBJ DI DMFDXBJ DMFDXBJ DN Resorcinol compound 16 DMFDXBJ TI TTULVH8 DMFDXBJ TN Tyrosinase (TYR) DMFDXBJ MA Inhibitor DMFDXBJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFDXBJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFE4IY DI DMFE4IY DMFE4IY DN P-coumaric acid derivative 3 DMFE4IY TI TTULVH8 DMFE4IY TN Tyrosinase (TYR) DMFE4IY MA Inhibitor DMFE4IY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFE4IY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFEQD2 DI DMFEQD2 DMFEQD2 DN Mannoside derivative 2 DMFEQD2 TI TTTCRU2 DMFEQD2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMFEQD2 MA Antagonist DMFEQD2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMFEQD2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMFEUMZ DI DMFEUMZ DMFEUMZ DN US8481586, 15 DMFEUMZ TI TTCGOIN DMFEUMZ TN PIM-3 protein kinase (PIM3) DMFEUMZ MA Inhibitor DMFEUMZ RN Pyrrolo[2,3-a] carbazoles and use thereof as PIM kinase inhibitors. US8481586. DMFEUMZ RU http://www.freepatentsonline.com/US8481586.html DMFG2KT DI DMFG2KT DMFG2KT DN Peptide analog 68 DMFG2KT TI TTPLTSQ DMFG2KT TN Neutrophil elastase (NE) DMFG2KT MA Inhibitor DMFG2KT RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMFG2KT RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMFG7A8 DI DMFG7A8 DMFG7A8 DN Peptide analog 8 DMFG7A8 TI TTN7R6K DMFG7A8 TN Signal transducer and activator of transcription 1 (STAT1) DMFG7A8 MA Inhibitor DMFG7A8 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMFG7A8 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMFG9HP DI DMFG9HP DMFG9HP DN Hexahydro naphthalene derivative 2 DMFG9HP TI TTPADOQ DMFG9HP TN HMG-CoA reductase (HMGCR) DMFG9HP MA Inhibitor DMFG9HP RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMFG9HP RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMFGIPR DI DMFGIPR DMFGIPR DN US8703720, Reference Compound 1 DMFGIPR TI TTO3NYT DMFGIPR TN Galectin-1 (LGALS1) DMFGIPR MA Inhibitor DMFGIPR RN Galactoside inhibitors of galectins. US8703720. DMFGIPR RU http://www.freepatentsonline.com/US8703720.html DMFHC0O DI DMFHC0O DMFHC0O DN GypensapogeninA DMFHC0O TI TT3WG5C DMFHC0O TN Monoamine oxidase type A (MAO-A) DMFHC0O MA Inhibitor DMFHC0O RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMFHC0O RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMFHD05 DI DMFHD05 DMFHD05 DN Ketoheterocycle derivative 3 DMFHD05 TI TTDP1UC DMFHD05 TN Fatty acid amide hydrolase (FAAH) DMFHD05 MA Inhibitor DMFHD05 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMFHD05 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMFI2H6 DI DMFI2H6 DMFI2H6 DN Indole-based analog 9 DMFI2H6 TI TTPTXIN DMFI2H6 TN Translocator protein (TSPO) DMFI2H6 MA Ligand DMFI2H6 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMFI2H6 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMFIG8C DI DMFIG8C DMFIG8C DN Hydoxyamidine derivative 1 DMFIG8C TI TTZJYKH DMFIG8C TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMFIG8C MA Inhibitor DMFIG8C RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMFIG8C RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMFIP0D DI DMFIP0D DMFIP0D DN Imidazo[1,5-a]pyridine derivative 1 DMFIP0D TI TTZJYKH DMFIP0D TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMFIP0D MA Inhibitor DMFIP0D RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMFIP0D RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TTT7PJU DMFIXW4 TN Janus kinase 3 (JAK-3) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TTBYWP2 DMFIXW4 TN TYK2 tyrosine kinase (TYK2) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TTRMX3V DMFIXW4 TN Janus kinase 2 (JAK-2) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFIXW4 DI DMFIXW4 DMFIXW4 DN Tricyclic pyrrolopyridine compound 1 DMFIXW4 TI TT6DM01 DMFIXW4 TN Janus kinase 1 (JAK-1) DMFIXW4 MA Inhibitor DMFIXW4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMFIXW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMFJBZI DI DMFJBZI DMFJBZI DN Pyrrolo-pyrrolone derivative 4 DMFJBZI TI TTRA6BO DMFJBZI TN Bromodomain-containing protein 4 (BRD4) DMFJBZI MA Inhibitor DMFJBZI RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFJBZI RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFJD5L DI DMFJD5L DMFJD5L DN US8772478, 2 DMFJD5L TI TTQICM2 DMFJD5L TN ADAM metallopeptidase 33 (ADAM33) DMFJD5L MA Inhibitor DMFJD5L RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DMFJD5L RU http://www.freepatentsonline.com/US8772478.html DMFJG7P DI DMFJG7P DMFJG7P DN PMID27376512-Compound-Table1Example4 DMFJG7P TI TT6S2FE DMFJG7P TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMFJG7P MA Inhibitor DMFJG7P RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMFJG7P RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMFJTE9 DI DMFJTE9 DMFJTE9 DN Benzene sulfonamide derivative 15 DMFJTE9 TI TT4G2JS DMFJTE9 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMFJTE9 MA Blocker DMFJTE9 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMFJTE9 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMFK7EL DI DMFK7EL DMFK7EL DN Benzyl amine derivative 2 DMFK7EL TI TT5L2VC DMFK7EL TN Kallikrein-related peptidase (KLK) DMFK7EL MA Inhibitor DMFK7EL RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DMFK7EL RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DMFKGZ7 DI DMFKGZ7 DMFKGZ7 DN P-coumaric acid derivative 5 DMFKGZ7 TI TTULVH8 DMFKGZ7 TN Tyrosinase (TYR) DMFKGZ7 MA Inhibitor DMFKGZ7 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFKGZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFKN1O DI DMFKN1O DMFKN1O DN PMID25666693-Compound-142 DMFKN1O TI TTMI6F5 DMFKN1O TN Transient receptor potential cation channel V1 (TRPV1) DMFKN1O MA Antagonist DMFKN1O RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMFKN1O RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMFKS2P DI DMFKS2P DMFKS2P DN PMID27744724-Compound-10 DMFKS2P TI TTU1E82 DMFKS2P TN Apoptosis regulator Bcl-xL (BCL-xL) DMFKS2P MA Inhibitor DMFKS2P RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMFKS2P RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMFKS2P DI DMFKS2P DMFKS2P DN PMID27744724-Compound-10 DMFKS2P TI TTJGNVC DMFKS2P TN Apoptosis regulator Bcl-2 (BCL-2) DMFKS2P MA Inhibitor DMFKS2P RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMFKS2P RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMFKS2P DI DMFKS2P DMFKS2P DN PMID27744724-Compound-10 DMFKS2P TI TTL53M6 DMFKS2P TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMFKS2P MA Inhibitor DMFKS2P RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMFKS2P RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMFKTBM DI DMFKTBM DMFKTBM DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 2 DMFKTBM TI TTHS256 DMFKTBM TN Metabotropic glutamate receptor 5 (mGluR5) DMFKTBM MA Modulator DMFKTBM RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMFKTBM RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMFKTJL DI DMFKTJL DMFKTJL DN Aminopiperidine derivative 1 DMFKTJL TI TTDIGC1 DMFKTJL TN Dipeptidyl peptidase 4 (DPP-4) DMFKTJL MA Inhibitor DMFKTJL RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMFKTJL RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMFKX1M DI DMFKX1M DMFKX1M DN Benzoyl-piperidine derivative 2 DMFKX1M TI TTJQOD7 DMFKX1M TN 5-HT 2A receptor (HTR2A) DMFKX1M MA Antagonist DMFKX1M RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMFKX1M RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMFL38V DI DMFL38V DMFL38V DN PMID29649907-Compound-19 DMFL38V TI TTS4UGC DMFL38V TN Farnesoid X-activated receptor (FXR) DMFL38V MA Agonist DMFL38V RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMFL38V RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMFMJIN DI DMFMJIN DMFMJIN DN PMID29130358-Compound-Figure14(6) DMFMJIN TI TTXPTJE DMFMJIN TN Gelatinase (GEL) DMFMJIN MA Inhibitor DMFMJIN RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFMJIN RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFMZCW DI DMFMZCW DMFMZCW DN Terpyridineplatinum(II) complexe 1 DMFMZCW TI TTR7UJ3 DMFMZCW TN Cytoplasmic thioredoxin reductase (TXNRD1) DMFMZCW MA Inhibitor DMFMZCW RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMFMZCW RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMFN1AR DI DMFN1AR DMFN1AR DN PMID26924192-Compound-53 DMFN1AR TI TTE4BSY DMFN1AR TN Bromodomain and extraterminal domain protein (BET) DMFN1AR MA Inhibitor DMFN1AR RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFN1AR RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFNB1T DI DMFNB1T DMFNB1T DN PMID25666693-Compound-95 DMFNB1T TI TTMI6F5 DMFNB1T TN Transient receptor potential cation channel V1 (TRPV1) DMFNB1T MA Antagonist DMFNB1T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMFNB1T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMFNGUV DI DMFNGUV DMFNGUV DN Macrolactam derivative 3 DMFNGUV TI TTKFVXR DMFNGUV TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMFNGUV MA Inhibitor DMFNGUV RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMFNGUV RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMFNK0L DI DMFNK0L DMFNK0L DN Amidine compound 6 DMFNK0L TI TTQR74A DMFNK0L TN Proteinase activated receptor 2 (PAR2) DMFNK0L MA Antagonist DMFNK0L RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMFNK0L RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMFNU9D DI DMFNU9D DMFNU9D DN PMID28870136-Compound-61 DMFNU9D TI TTK0O6Y DMFNU9D TN Ecto-5'-nucleotidase (CD73) DMFNU9D MA Inhibitor DMFNU9D RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMFNU9D RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMFOBM9 DI DMFOBM9 DMFOBM9 DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 3 DMFOBM9 TI TTV1C0Z DMFOBM9 TN Neuropeptide S receptor (NPSR) DMFOBM9 MA Antagonist DMFOBM9 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMFOBM9 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMFOKRW DI DMFOKRW DMFOKRW DN Tacrine heterodimer derivative 1 DMFOKRW TI TT1RS9F DMFOKRW TN Acetylcholinesterase (AChE) DMFOKRW MA Inhibitor DMFOKRW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFOKRW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFOKRW DI DMFOKRW DMFOKRW DN Tacrine heterodimer derivative 1 DMFOKRW TI TTEB0GD DMFOKRW TN Cholinesterase (BCHE) DMFOKRW MA Inhibitor DMFOKRW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMFOKRW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMFORUW DI DMFORUW DMFORUW DN PMID28074661-Compound-WO2009018344C78 DMFORUW TI TTL7C8Q DMFORUW TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMFORUW MA Inhibitor DMFORUW RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMFORUW RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMFOVPT DI DMFOVPT DMFOVPT DN Bicyclic heteroaryl benzamide derivative 5 DMFOVPT TI TTTDVOJ DMFOVPT TN Tropomyosin-related kinase A (TrkA) DMFOVPT MA Inhibitor DMFOVPT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMFOVPT RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMFQERG DI DMFQERG DMFQERG DN US9340511, 5 DMFQERG TI TT9ISBX DMFQERG TN HIF-prolyl hydroxylase 2 (HPH-2) DMFQERG MA Inhibitor DMFQERG RN Process for making isoquinoline compounds. US9708269. DMFQERG RU http://www.freepatentsonline.com/US9708269.html DMFQSU8 DI DMFQSU8 DMFQSU8 DN Tricyclic indole compound 7 DMFQSU8 TI TTPTXIN DMFQSU8 TN Translocator protein (TSPO) DMFQSU8 MA Ligand DMFQSU8 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMFQSU8 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMFR23C DI DMFR23C DMFR23C DN 1,2,3-triazole derivative 2 DMFR23C TI TT6OEDT DMFR23C TN Cannabinoid receptor 1 (CB1) DMFR23C MA Antagonist DMFR23C RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMFR23C RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMFR4S0 DI DMFR4S0 DMFR4S0 DN Resorcinol compound 17 DMFR4S0 TI TTULVH8 DMFR4S0 TN Tyrosinase (TYR) DMFR4S0 MA Inhibitor DMFR4S0 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFR4S0 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFS2YL DI DMFS2YL DMFS2YL DN PMID25991433-Compound-F1 DMFS2YL TI TTVOE6D DMFS2YL TN Mitogen-activated protein kinase (MAPK) DMFS2YL MA Inhibitor DMFS2YL RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMFS2YL RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMFS7C3 DI DMFS7C3 DMFS7C3 DN Chalcone derivative 3 DMFS7C3 TI TTA6ZN2 DMFS7C3 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMFS7C3 MA Activator DMFS7C3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMFS7C3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMFS7C3 DI DMFS7C3 DMFS7C3 DN Chalcone derivative 3 DMFS7C3 TI TT3Z6Y9 DMFS7C3 TN Cysteines of Keap1 (KEAP1 Cysteines) DMFS7C3 MA Modulator DMFS7C3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMFS7C3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMFSB9Y DI DMFSB9Y DMFSB9Y DN PMID25991433-Compound-A6 DMFSB9Y TI TTHS0U8 DMFSB9Y TN Stress-activated protein kinase JNK2 (JNK2) DMFSB9Y MA Inhibitor DMFSB9Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMFSB9Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMFSB9Y DI DMFSB9Y DMFSB9Y DN PMID25991433-Compound-A6 DMFSB9Y TI TT0K6EO DMFSB9Y TN Stress-activated protein kinase JNK1 (JNK1) DMFSB9Y MA Inhibitor DMFSB9Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMFSB9Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMFSOQY DI DMFSOQY DMFSOQY DN US9156852, 38 DMFSOQY TI TTU98HG DMFSOQY TN Discoidin domain-containing receptor 2 (DDR2) DMFSOQY MA Inhibitor DMFSOQY RN Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852. DMFSOQY RU http://www.freepatentsonline.com/US9156852.html DMFT3RM DI DMFT3RM DMFT3RM DN PMID26609882-Compound-36 DMFT3RM TI TTJQOD7 DMFT3RM TN 5-HT 2A receptor (HTR2A) DMFT3RM MA Antagonist DMFT3RM RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMFT3RM RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMFTE3Y DI DMFTE3Y DMFTE3Y DN PMID26815044-Compound-123 DMFTE3Y TI TTULVH8 DMFTE3Y TN Tyrosinase (TYR) DMFTE3Y MA Inhibitor DMFTE3Y RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFTE3Y RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFTGZC DI DMFTGZC DMFTGZC DN PMID28350212-Compound-21 DMFTGZC TI TTZS04O DMFTGZC TN Gamma-secretase subunit APH-1A/1B (APH-1) DMFTGZC MA Inhibitor DMFTGZC RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMFTGZC RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMFTM8X DI DMFTM8X DMFTM8X DN PMID28870136-Compound-68 DMFTM8X TI TTK0O6Y DMFTM8X TN Ecto-5'-nucleotidase (CD73) DMFTM8X MA Inhibitor DMFTM8X RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMFTM8X RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMFTZBY DI DMFTZBY DMFTZBY DN P-coumaric acid derivative 2 DMFTZBY TI TTULVH8 DMFTZBY TN Tyrosinase (TYR) DMFTZBY MA Inhibitor DMFTZBY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMFTZBY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMFU6JR DI DMFU6JR DMFU6JR DN PMID26924192-Compound-52 DMFU6JR TI TTE4BSY DMFU6JR TN Bromodomain and extraterminal domain protein (BET) DMFU6JR MA Inhibitor DMFU6JR RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFU6JR RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFU6OD DI DMFU6OD DMFU6OD DN Quinazoline derivative 13 DMFU6OD TI TTQR74A DMFU6OD TN Proteinase activated receptor 2 (PAR2) DMFU6OD MA Antagonist DMFU6OD RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMFU6OD RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMFUEDL DI DMFUEDL DMFUEDL DN Heterocyclic derivative 18 DMFUEDL TI TTCZOF2 DMFUEDL TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMFUEDL MA Inhibitor DMFUEDL RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMFUEDL RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMFUNH4 DI DMFUNH4 DMFUNH4 DN Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 TI TTKFVXR DMFUNH4 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMFUNH4 MA Inhibitor DMFUNH4 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMFUNH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMFUNH4 DI DMFUNH4 DMFUNH4 DN Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 TI TTXAJWN DMFUNH4 TN IL-1 receptor-associated kinase 1 (IRAK1) DMFUNH4 MA Inhibitor DMFUNH4 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMFUNH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMFUSPR DI DMFUSPR DMFUSPR DN Pyrazolo[1,5-a]pyrimidine derivative 7 DMFUSPR TI TT6OEDT DMFUSPR TN Cannabinoid receptor 1 (CB1) DMFUSPR MA Antagonist DMFUSPR RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMFUSPR RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMFV36A DI DMFV36A DMFV36A DN Pyrazolo[1,5-a]pyrimidine derivative 19 DMFV36A TI TTTDVOJ DMFV36A TN Tropomyosin-related kinase A (TrkA) DMFV36A MA Inhibitor DMFV36A RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMFV36A RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMFV64B DI DMFV64B DMFV64B DN Pyrrole derivative 3 DMFV64B TI TT6OEDT DMFV64B TN Cannabinoid receptor 1 (CB1) DMFV64B MA Antagonist DMFV64B RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMFV64B RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMFWXPS DI DMFWXPS DMFWXPS DN PMID29130358-Compound-Figure10(2a) DMFWXPS TI TTMX39J DMFWXPS TN Matrix metalloproteinase-1 (MMP-1) DMFWXPS MA Inhibitor DMFWXPS RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFWXPS RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFWXPS DI DMFWXPS DMFWXPS DN PMID29130358-Compound-Figure10(2a) DMFWXPS TI TTLM12X DMFWXPS TN Matrix metalloproteinase-2 (MMP-2) DMFWXPS MA Inhibitor DMFWXPS RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFWXPS RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFWXPS DI DMFWXPS DMFWXPS DN PMID29130358-Compound-Figure10(2a) DMFWXPS TI TTUZ2L5 DMFWXPS TN Matrix metalloproteinase-3 (MMP-3) DMFWXPS MA Inhibitor DMFWXPS RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMFWXPS RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMFWYKE DI DMFWYKE DMFWYKE DN AC1LCOK0 DMFWYKE TI TT3RMNA DMFWYKE TN Chymotrypsin-C (CLCR) DMFWYKE MA Inhibitor DMFWYKE RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DMFWYKE RU http://www.freepatentsonline.com/US9695194.html DMFXC5L DI DMFXC5L DMFXC5L DN Benzodiazepine derivative 1 DMFXC5L TI TTPTXIN DMFXC5L TN Translocator protein (TSPO) DMFXC5L MA Ligand DMFXC5L RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMFXC5L RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMFXCPQ DI DMFXCPQ DMFXCPQ DN PMID29338548-Compound-17 DMFXCPQ TI TTHJTF7 DMFXCPQ TN Glycine transporter GlyT-1 (SLC6A9) DMFXCPQ MA Inhibitor DMFXCPQ RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMFXCPQ RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMFXK03 DI DMFXK03 DMFXK03 DN Aminocyclopentenone compound 3 DMFXK03 TI TTRA6BO DMFXK03 TN Bromodomain-containing protein 4 (BRD4) DMFXK03 MA Inhibitor DMFXK03 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMFXK03 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMFY78L DI DMFY78L DMFY78L DN Benzamide derivative 3 DMFY78L TI TT9NXW4 DMFY78L TN Sigma intracellular receptor 2 (TMEM97) DMFY78L MA Ligand DMFY78L RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMFY78L RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMFYKBJ DI DMFYKBJ DMFYKBJ DN 1,2,4-oxadiazole derivative 6 DMFYKBJ TI TT23XQV DMFYKBJ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMFYKBJ MA Inhibitor DMFYKBJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMFYKBJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMFZ3S4 DI DMFZ3S4 DMFZ3S4 DN PMID25666693-Compound-86 DMFZ3S4 TI TTMI6F5 DMFZ3S4 TN Transient receptor potential cation channel V1 (TRPV1) DMFZ3S4 MA Antagonist DMFZ3S4 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMFZ3S4 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMFZ9Q3 DI DMFZ9Q3 DMFZ9Q3 DN Pitavastatin derivative 1 DMFZ9Q3 TI TTPADOQ DMFZ9Q3 TN HMG-CoA reductase (HMGCR) DMFZ9Q3 MA Inhibitor DMFZ9Q3 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMFZ9Q3 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMFZM3X DI DMFZM3X DMFZM3X DN PMID26882240-Compound-3 DMFZM3X TI TTUX68I DMFZM3X TN Hypoxia-inducible factor 1 (HIF-1) DMFZM3X MA Inhibitor DMFZM3X RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMFZM3X RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMG0H73 DI DMG0H73 DMG0H73 DN Thiazole carboxamide derivative 12 DMG0H73 TI TTCZOF2 DMG0H73 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMG0H73 MA Inhibitor DMG0H73 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMG0H73 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMG0QZ1 DI DMG0QZ1 DMG0QZ1 DN US9522888, 618 DMG0QZ1 TI TTDYP7I DMG0QZ1 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMG0QZ1 MA Inhibitor DMG0QZ1 RN Substituted bicyclic compounds. US10166249. DMG0QZ1 RU http://www.freepatentsonline.com/US10166249.html DMG0ZSY DI DMG0ZSY DMG0ZSY DN Phenylate derivative 2 DMG0ZSY TI TT23XQV DMG0ZSY TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMG0ZSY MA Inhibitor DMG0ZSY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMG0ZSY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMG14E3 DI DMG14E3 DMG14E3 DN Heteroaryl-azepine derivative 3 DMG14E3 TI TTWJBZ5 DMG14E3 TN 5-HT 2C receptor (HTR2C) DMG14E3 MA Agonist DMG14E3 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMG14E3 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMG18XH DI DMG18XH DMG18XH DN US9132129, Cpd023 DMG18XH TI TTH9LDP DMG18XH TN PC4 and SFRS1-interacting protein (PSIP1) DMG18XH MA Inhibitor DMG18XH RN Antiviral compounds. US9132129. DMG18XH RU http://www.freepatentsonline.com/US9132129.html DMG1EKV DI DMG1EKV DMG1EKV DN PMID25399762-Compound-Figure2-Artoxanthochromane DMG1EKV TI TT3WG5C DMG1EKV TN Monoamine oxidase type A (MAO-A) DMG1EKV MA Inhibitor DMG1EKV RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMG1EKV RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TTT7PJU DMG1ESV TN Janus kinase 3 (JAK-3) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TTBYWP2 DMG1ESV TN TYK2 tyrosine kinase (TYK2) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TTRMX3V DMG1ESV TN Janus kinase 2 (JAK-2) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1ESV DI DMG1ESV DMG1ESV DN Tricyclic heterocycle derivative 5 DMG1ESV TI TT6DM01 DMG1ESV TN Janus kinase 1 (JAK-1) DMG1ESV MA Inhibitor DMG1ESV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMG1ESV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMG1RNL DI DMG1RNL DMG1RNL DN Pyrazolo[1,5-a]pyrimidine derivative 28 DMG1RNL TI TTF8P9I DMG1RNL TN Diacylglycerol acyltransferase 1 (DGAT1) DMG1RNL MA Inhibitor DMG1RNL RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMG1RNL RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMG1SYN DI DMG1SYN DMG1SYN DN PMID25666693-Compound-147 DMG1SYN TI TTMI6F5 DMG1SYN TN Transient receptor potential cation channel V1 (TRPV1) DMG1SYN MA Antagonist DMG1SYN RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMG1SYN RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMG1TIF DI DMG1TIF DMG1TIF DN Heteroaryl-azepine derivative 14 DMG1TIF TI TTWJBZ5 DMG1TIF TN 5-HT 2C receptor (HTR2C) DMG1TIF MA Agonist DMG1TIF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMG1TIF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMG2ES1 DI DMG2ES1 DMG2ES1 DN PMID25435285-Compound-39 DMG2ES1 TI TTXJ47W DMG2ES1 TN Metabotropic glutamate receptor 2 (mGluR2) DMG2ES1 MA Antagonist DMG2ES1 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMG2ES1 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMG2JEK DI DMG2JEK DMG2JEK DN PMID25468267-Compound-47 DMG2JEK TI TTV8CRH DMG2JEK TN Lysine-specific demethylase 4C (KDM4C) DMG2JEK MA Inhibitor DMG2JEK RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMG2JEK RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMG2PCZ DI DMG2PCZ DMG2PCZ DN PMID28067079-Compound-95 DMG2PCZ TI TTHS256 DMG2PCZ TN Metabotropic glutamate receptor 5 (mGluR5) DMG2PCZ MA Modulator DMG2PCZ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMG2PCZ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMG3T7E DI DMG3T7E DMG3T7E DN US8933095, 1 DMG3T7E TI TTT3IXG DMG3T7E TN Kynurenine oxoglutarate transaminase II (AADAT) DMG3T7E MA Inhibitor DMG3T7E RN KAT II inhibitors. US8933095. DMG3T7E RU http://www.freepatentsonline.com/US8933095.html DMG4EOP DI DMG4EOP DMG4EOP DN Peptide analog 34 DMG4EOP TI TT68GPI DMG4EOP TN Proteasome beta-5 (PS beta-5) DMG4EOP MA Inhibitor DMG4EOP RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMG4EOP RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMG4EOP DI DMG4EOP DMG4EOP DN Peptide analog 34 DMG4EOP TI TTEAD9J DMG4EOP TN Proteasome beta-8 (PS beta-8) DMG4EOP MA Inhibitor DMG4EOP RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMG4EOP RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMG4FYP DI DMG4FYP DMG4FYP DN Resorcinol compound 1 DMG4FYP TI TTULVH8 DMG4FYP TN Tyrosinase (TYR) DMG4FYP MA Inhibitor DMG4FYP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMG4FYP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMG4T13 DI DMG4T13 DMG4T13 DN US10030004, Compound 11a DMG4T13 TI TTPKHTZ DMG4T13 TN Activin receptor type IB (ACVR1B) DMG4T13 MA Inhibitor DMG4T13 RN Compounds and methods of use. US10030004. DMG4T13 RU http://www.freepatentsonline.com/US10030004.html DMG4WQB DI DMG4WQB DMG4WQB DN Biphenyl derivative 1 DMG4WQB TI TTZJYKH DMG4WQB TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMG4WQB MA Inhibitor DMG4WQB RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMG4WQB RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMG5CXB DI DMG5CXB DMG5CXB DN Pyrazolo[1,5-a]pyrimidine derivative 22 DMG5CXB TI TTTDVOJ DMG5CXB TN Tropomyosin-related kinase A (TrkA) DMG5CXB MA Inhibitor DMG5CXB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMG5CXB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMG5HI1 DI DMG5HI1 DMG5HI1 DN Piperidinyl triazole derivative 6 DMG5HI1 TI TTTJZ4M DMG5HI1 TN Prolylcarboxypeptidase (PRCP) DMG5HI1 MA Inhibitor DMG5HI1 RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMG5HI1 RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMG5I41 DI DMG5I41 DMG5I41 DN PMID25656651-Compound-34c DMG5I41 TI TT3PJMV DMG5I41 TN Tyrosine-protein kinase ABL1 (ABL) DMG5I41 MA Inhibitor DMG5I41 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMG5I41 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMG5J9Z DI DMG5J9Z DMG5J9Z DN PMID25522065-Compound-20 DMG5J9Z TI TTX4RTB DMG5J9Z TN Melanin-concentrating hormone receptor 1 (MCHR1) DMG5J9Z MA Antagonist DMG5J9Z RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMG5J9Z RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMG675B DI DMG675B DMG675B DN PMID29338548-Compound-36 DMG675B TI TTHJTF7 DMG675B TN Glycine transporter GlyT-1 (SLC6A9) DMG675B MA Inhibitor DMG675B RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMG675B RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMG6Q45 DI DMG6Q45 DMG6Q45 DN TDZD-8 DMG6Q45 TI TTRSMW9 DMG6Q45 TN Glycogen synthase kinase-3 beta (GSK-3B) DMG6Q45 MA Inhibitor DMG6Q45 RN Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6. DMG6Q45 RU https://pubmed.ncbi.nlm.nih.gov/23099099 DMG6Q45 DI DMG6Q45 DMG6Q45 DN TDZD-8 DMG6Q45 TI TTRZQE3 DMG6Q45 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMG6Q45 MA Inhibitor DMG6Q45 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMG6Q45 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMG6W3O DI DMG6W3O DMG6W3O DN Imidazo pyridine derivative 6 DMG6W3O TI TTV1C0Z DMG6W3O TN Neuropeptide S receptor (NPSR) DMG6W3O MA Antagonist DMG6W3O RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMG6W3O RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMG7VF1 DI DMG7VF1 DMG7VF1 DN PMID29865878-Compound-61 DMG7VF1 TI TTEAD9J DMG7VF1 TN Proteasome beta-8 (PS beta-8) DMG7VF1 MA Inhibitor DMG7VF1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMG7VF1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMG84D3 DI DMG84D3 DMG84D3 DN Chalcone derivative 2 DMG84D3 TI TTA6ZN2 DMG84D3 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMG84D3 MA Activator DMG84D3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMG84D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMG84D3 DI DMG84D3 DMG84D3 DN Chalcone derivative 2 DMG84D3 TI TT3Z6Y9 DMG84D3 TN Cysteines of Keap1 (KEAP1 Cysteines) DMG84D3 MA Modulator DMG84D3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMG84D3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMG8K1P DI DMG8K1P DMG8K1P DN PMID25980951-Compound-12 DMG8K1P TI TTR7B60 DMG8K1P TN X-linked inhibitor of apoptosis protein (XIAP) DMG8K1P MA Antagonist DMG8K1P RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMG8K1P RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMG8MCJ DI DMG8MCJ DMG8MCJ DN Diphenyl purine derivative 2 DMG8MCJ TI TT6OEDT DMG8MCJ TN Cannabinoid receptor 1 (CB1) DMG8MCJ MA Antagonist DMG8MCJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMG8MCJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMG8V31 DI DMG8V31 DMG8V31 DN Pyrazolopyrimidine derivative 6 DMG8V31 TI TTHS256 DMG8V31 TN Metabotropic glutamate receptor 5 (mGluR5) DMG8V31 MA Modulator DMG8V31 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMG8V31 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMG9CPH DI DMG9CPH DMG9CPH DN PMID25666693-Compound-35 DMG9CPH TI TTMI6F5 DMG9CPH TN Transient receptor potential cation channel V1 (TRPV1) DMG9CPH MA Antagonist DMG9CPH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMG9CPH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMG9FYH DI DMG9FYH DMG9FYH DN PMID25435285-Compound-20 DMG9FYH TI TTXJ47W DMG9FYH TN Metabotropic glutamate receptor 2 (mGluR2) DMG9FYH MA Antagonist DMG9FYH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMG9FYH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMG9FYH DI DMG9FYH DMG9FYH DN PMID25435285-Compound-20 DMG9FYH TI TT8A9EF DMG9FYH TN Metabotropic glutamate receptor 3 (mGluR3) DMG9FYH MA Antagonist DMG9FYH RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMG9FYH RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMG9O7D DI DMG9O7D DMG9O7D DN Bicarboxylic and tricarboxylic ethynyl derivative 2 DMG9O7D TI TTHS256 DMG9O7D TN Metabotropic glutamate receptor 5 (mGluR5) DMG9O7D MA Modulator DMG9O7D RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMG9O7D RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMGA0R6 DI DMGA0R6 DMGA0R6 DN Biphenyl mannoside derivative 19 DMGA0R6 TI TTTCRU2 DMGA0R6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGA0R6 MA Antagonist DMGA0R6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGA0R6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGA3U8 DI DMGA3U8 DMGA3U8 DN Peptide analog 45 DMGA3U8 TI TTDIGC1 DMGA3U8 TN Dipeptidyl peptidase 4 (DPP-4) DMGA3U8 MA Inhibitor DMGA3U8 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMGA3U8 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMGA3XL DI DMGA3XL DMGA3XL DN PMID28092474-Compound-32c DMGA3XL TI TT5ZKDI DMGA3XL TN Histone deacetylase 6 (HDAC6) DMGA3XL MA Inhibitor DMGA3XL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGA3XL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGA3XL DI DMGA3XL DMGA3XL DN PMID28092474-Compound-32c DMGA3XL TI TT6R7JZ DMGA3XL TN Histone deacetylase 1 (HDAC1) DMGA3XL MA Inhibitor DMGA3XL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGA3XL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGAQR5 DI DMGAQR5 DMGAQR5 DN PMID28766366-Compound-Scheme7WO2012/098070upper DMGAQR5 TI TTYGQ8A DMGAQR5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMGAQR5 MA Inhibitor DMGAQR5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGAQR5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGAQR5 DI DMGAQR5 DMGAQR5 DN PMID28766366-Compound-Scheme7WO2012/098070upper DMGAQR5 TI TTSBVFO DMGAQR5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMGAQR5 MA Inhibitor DMGAQR5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGAQR5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGATHZ DI DMGATHZ DMGATHZ DN Hydroxamate analog 1 DMGATHZ TI TTZHPB8 DMGATHZ TN Lysine-specific demethylase 4A (KDM4A) DMGATHZ MA Inhibitor DMGATHZ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGATHZ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGATHZ DI DMGATHZ DMGATHZ DN Hydroxamate analog 1 DMGATHZ TI TTV8CRH DMGATHZ TN Lysine-specific demethylase 4C (KDM4C) DMGATHZ MA Inhibitor DMGATHZ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGATHZ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGAW81 DI DMGAW81 DMGAW81 DN PMID28454500-Compound-41 DMGAW81 TI TTA6ZN2 DMGAW81 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMGAW81 MA Activator DMGAW81 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMGAW81 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMGAW81 DI DMGAW81 DMGAW81 DN PMID28454500-Compound-41 DMGAW81 TI TT3Z6Y9 DMGAW81 TN Cysteines of Keap1 (KEAP1 Cysteines) DMGAW81 MA Modulator DMGAW81 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMGAW81 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMGBFK3 DI DMGBFK3 DMGBFK3 DN PMID26651364-Compound-11b DMGBFK3 TI TTTCRU2 DMGBFK3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGBFK3 MA Antagonist DMGBFK3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGBFK3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGBR43 DI DMGBR43 DMGBR43 DN Pyridine derivative 15 DMGBR43 TI TTHS256 DMGBR43 TN Metabotropic glutamate receptor 5 (mGluR5) DMGBR43 MA Modulator DMGBR43 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMGBR43 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMGC7NW DI DMGC7NW DMGC7NW DN Peptide analog 63 DMGC7NW TI TTPLTSQ DMGC7NW TN Neutrophil elastase (NE) DMGC7NW MA Inhibitor DMGC7NW RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMGC7NW RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMGCE3Z DI DMGCE3Z DMGCE3Z DN PMID30280939-Compound-WO2015150568 DMGCE3Z TI TTOK0LR DMGCE3Z TN Toll-like receptor (TLR) DMGCE3Z MA Agonist DMGCE3Z RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMGCE3Z RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TTQV3NX DMGCHW9 TN RET V804M mutant (RET V804M) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT2RTDH DMGCHW9 TN RET V804L mutant (RET V804L) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TTB0IO2 DMGCHW9 TN RET Y791F mutant (RET Y791F) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TTY0WT7 DMGCHW9 TN RET G691S mutant (RET G691S) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT8BF4A DMGCHW9 TN RET S891A mutant (RET S891A) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT5XA6U DMGCHW9 TN RET M918T mutant (RET M918T) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCHW9 DI DMGCHW9 DMGCHW9 DN Benzo(b)carbazol-11-one compound 2 DMGCHW9 TI TT4DXQT DMGCHW9 TN Proto-oncogene c-Ret (RET) DMGCHW9 MA Inhibitor DMGCHW9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGCHW9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGCMF5 DI DMGCMF5 DMGCMF5 DN Pyridine-2,4-dicarboxylic acid derivative 2 DMGCMF5 TI TT0RGE9 DMGCMF5 TN Lysine-specific demethylase 4 (KDM4) DMGCMF5 MA Inhibitor DMGCMF5 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGCMF5 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGCUJB DI DMGCUJB DMGCUJB DN PMID26651364-Compound-7c DMGCUJB TI TTTCRU2 DMGCUJB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGCUJB MA Antagonist DMGCUJB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGCUJB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGDLPZ DI DMGDLPZ DMGDLPZ DN Resorcinol compound 11 DMGDLPZ TI TTULVH8 DMGDLPZ TN Tyrosinase (TYR) DMGDLPZ MA Inhibitor DMGDLPZ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGDLPZ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGDMWA DI DMGDMWA DMGDMWA DN Imidazo quinoline derivative 1 DMGDMWA TI TTCZOF2 DMGDMWA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMGDMWA MA Inhibitor DMGDMWA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMGDMWA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMGDQYW DI DMGDQYW DMGDQYW DN Resorcinol compound 2 DMGDQYW TI TTULVH8 DMGDQYW TN Tyrosinase (TYR) DMGDQYW MA Inhibitor DMGDQYW RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGDQYW RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGDZLP DI DMGDZLP DMGDZLP DN US10022354, Example 152 DMGDZLP TI TTIG67W DMGDZLP TN Lysine-specific demethylase 5A (KDM5A) DMGDZLP MA Inhibitor DMGDZLP RN IRE-1 inhibitors DMGDZLP RU http://www.freepatentsonline.com/US10022354.html DMGECO2 DI DMGECO2 DMGECO2 DN Quinazoline derivative 2 DMGECO2 TI TTPTXIN DMGECO2 TN Translocator protein (TSPO) DMGECO2 MA Ligand DMGECO2 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMGECO2 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMGEFIW DI DMGEFIW DMGEFIW DN Heteroaryl-carboxamide derivative 2 DMGEFIW TI TTCZOF2 DMGEFIW TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMGEFIW MA Inhibitor DMGEFIW RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMGEFIW RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMGEIZV DI DMGEIZV DMGEIZV DN Thiazole carboxamide derivative 28 DMGEIZV TI TTCZOF2 DMGEIZV TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMGEIZV MA Inhibitor DMGEIZV RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMGEIZV RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMGESCP DI DMGESCP DMGESCP DN Bicyclo-heptan-2-amine derivative 1 DMGESCP TI TT9NXW4 DMGESCP TN Sigma intracellular receptor 2 (TMEM97) DMGESCP MA Ligand DMGESCP RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMGESCP RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMGEWVP DI DMGEWVP DMGEWVP DN PMID29334795-Compound-25 DMGEWVP TI TT9JNIC DMGEWVP TN Histamine H3 receptor (H3R) DMGEWVP MA Inverse agonist DMGEWVP RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMGEWVP RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMGEYJW DI DMGEYJW DMGEYJW DN Pyridine and pyrimidine derivative 1 DMGEYJW TI TTSCIM2 DMGEYJW TN Extracellular lysophospholipase D (E-NPP2) DMGEYJW MA Inhibitor DMGEYJW RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMGEYJW RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMGEZT8 DI DMGEZT8 DMGEZT8 DN PMID28394193-Compound-30 DMGEZT8 TI TT9MZCQ DMGEZT8 TN Enhancer of zeste homolog 2 (EZH2) DMGEZT8 MA Inhibitor DMGEZT8 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMGEZT8 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMGF04T DI DMGF04T DMGF04T DN PMID27977313-Compound-46 DMGF04T TI TTR7UJ3 DMGF04T TN Cytoplasmic thioredoxin reductase (TXNRD1) DMGF04T MA Inhibitor DMGF04T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMGF04T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMGFAS6 DI DMGFAS6 DMGFAS6 DN Pyrazolo[3,4-d]pyrimidine derivative 4 DMGFAS6 TI TTJGW1Z DMGFAS6 TN Phosphodiesterase 2A (PDE2A) DMGFAS6 MA Inhibitor DMGFAS6 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMGFAS6 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMGFORB DI DMGFORB DMGFORB DN Mycophenolic acid/nucleotide derivative 6 DMGFORB TI TTL7C8Q DMGFORB TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMGFORB MA Inhibitor DMGFORB RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMGFORB RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMGH0LQ DI DMGH0LQ DMGH0LQ DN Pyrazoline derivative 3 DMGH0LQ TI TT6OEDT DMGH0LQ TN Cannabinoid receptor 1 (CB1) DMGH0LQ MA Antagonist DMGH0LQ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMGH0LQ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMGH9B3 DI DMGH9B3 DMGH9B3 DN US9580418, Example 8 DMGH9B3 TI TTCGOIN DMGH9B3 TN PIM-3 protein kinase (PIM3) DMGH9B3 MA Inhibitor DMGH9B3 RN Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418. DMGH9B3 RU http://www.freepatentsonline.com/US9580418.html DMGHR4D DI DMGHR4D DMGHR4D DN PMID25980951-Compound-13 DMGHR4D TI TTR7B60 DMGHR4D TN X-linked inhibitor of apoptosis protein (XIAP) DMGHR4D MA Antagonist DMGHR4D RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMGHR4D RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMGHSR9 DI DMGHSR9 DMGHSR9 DN PMID25776143-Compound-1 DMGHSR9 TI TT4TFGN DMGHSR9 TN Vasopressin V1a receptor (V1AR) DMGHSR9 MA Agonist DMGHSR9 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMGHSR9 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMGI5Z8 DI DMGI5Z8 DMGI5Z8 DN PMID27967267-Compound-14 DMGI5Z8 TI TT1RS9F DMGI5Z8 TN Acetylcholinesterase (AChE) DMGI5Z8 MA Inhibitor DMGI5Z8 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMGI5Z8 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMGIJZA DI DMGIJZA DMGIJZA DN US8546370, 17 DMGIJZA TI TTUMHT8 DMGIJZA TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DMGIJZA MA Inhibitor DMGIJZA RN Compounds and compositions as kinase inhibitors. US8546370. DMGIJZA RU http://www.freepatentsonline.com/US8546370.html DMGIPDH DI DMGIPDH DMGIPDH DN PMID26666989-Compound-Figure12bottommiddle01 DMGIPDH TI TT8BUGW DMGIPDH TN Glycogen phosphorylase (PYG) DMGIPDH MA Inhibitor DMGIPDH RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMGIPDH RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMGIV0M DI DMGIV0M DMGIV0M DN PMID25980951-Compound-19 DMGIV0M TI TTR7B60 DMGIV0M TN X-linked inhibitor of apoptosis protein (XIAP) DMGIV0M MA Antagonist DMGIV0M RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMGIV0M RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMGIV0M DI DMGIV0M DMGIV0M DN PMID25980951-Compound-19 DMGIV0M TI TTQ5LRD DMGIV0M TN Cellular inhibitor of apoptosis 1 (BIRC2) DMGIV0M MA Antagonist DMGIV0M RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMGIV0M RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMGIV3C DI DMGIV3C DMGIV3C DN PMID26651364-Compound-10d DMGIV3C TI TTTCRU2 DMGIV3C TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGIV3C MA Antagonist DMGIV3C RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGIV3C RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGK0FD DI DMGK0FD DMGK0FD DN Benzodihydroisofuran derivative 2 DMGK0FD TI TTTJZ4M DMGK0FD TN Prolylcarboxypeptidase (PRCP) DMGK0FD MA Inhibitor DMGK0FD RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMGK0FD RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMGKQXP DI DMGKQXP DMGKQXP DN Lycorine dimer salt derivative 1 DMGKQXP TI TT1RS9F DMGKQXP TN Acetylcholinesterase (AChE) DMGKQXP MA Inhibitor DMGKQXP RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMGKQXP RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMGLK92 DI DMGLK92 DMGLK92 DN Quinolinyl compound 2 DMGLK92 TI TT9O6WS DMGLK92 TN Glucagon receptor (GCGR) DMGLK92 MA Antagonist DMGLK92 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMGLK92 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMGM72Q DI DMGM72Q DMGM72Q DN A-substituted phenylpropionic acid derivative 1 DMGM72Q TI TTZMAO3 DMGM72Q TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMGM72Q MA Agonist DMGM72Q RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMGM72Q RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMGN9IX DI DMGN9IX DMGN9IX DN 3-(phenoxymethyl) benzylamine derivative 2 DMGN9IX TI TTULVH8 DMGN9IX TN Tyrosinase (TYR) DMGN9IX MA Inhibitor DMGN9IX RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGN9IX RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGNRZU DI DMGNRZU DMGNRZU DN PMID27376512-Compound-MTC-424 DMGNRZU TI TTJUALD DMGNRZU TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMGNRZU MA Inhibitor DMGNRZU RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMGNRZU RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMGNRZU DI DMGNRZU DMGNRZU DN PMID27376512-Compound-MTC-424 DMGNRZU TI TT6VZ78 DMGNRZU TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMGNRZU MA Inhibitor DMGNRZU RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMGNRZU RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMGNRZU DI DMGNRZU DMGNRZU DN PMID27376512-Compound-MTC-424 DMGNRZU TI TT6S2FE DMGNRZU TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMGNRZU MA Inhibitor DMGNRZU RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMGNRZU RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMGNW34 DI DMGNW34 DMGNW34 DN PMID29649907-Compound-20 DMGNW34 TI TTS4UGC DMGNW34 TN Farnesoid X-activated receptor (FXR) DMGNW34 MA Agonist DMGNW34 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMGNW34 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMGNWJD DI DMGNWJD DMGNWJD DN Fused heterocyclic compound 7 DMGNWJD TI TT7RJY8 DMGNWJD TN Xanthine dehydrogenase/oxidase (XDH) DMGNWJD MA Inhibitor DMGNWJD RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMGNWJD RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMGO1CB DI DMGO1CB DMGO1CB DN Indazole derivative 6 DMGO1CB TI TTRZQE3 DMGO1CB TN Glycogen synthase kinase-3 alpha (GSK-3A) DMGO1CB MA Inhibitor DMGO1CB RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMGO1CB RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMGO1PA DI DMGO1PA DMGO1PA DN PMID29334795-Compound-57 DMGO1PA TI TT9JNIC DMGO1PA TN Histamine H3 receptor (H3R) DMGO1PA RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMGO1PA RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMGO9WY DI DMGO9WY DMGO9WY DN Amidopyrazole derivative 2 DMGO9WY TI TTKFVXR DMGO9WY TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMGO9WY MA Inhibitor DMGO9WY RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMGO9WY RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMGONY4 DI DMGONY4 DMGONY4 DN Bicyclic heteroaryl benzamide derivative 9 DMGONY4 TI TTTDVOJ DMGONY4 TN Tropomyosin-related kinase A (TrkA) DMGONY4 MA Inhibitor DMGONY4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMGONY4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMGOSN2 DI DMGOSN2 DMGOSN2 DN Fluorinated compound 1 DMGOSN2 TI TT7HF4W DMGOSN2 TN Cyclin-dependent kinase 2 (CDK2) DMGOSN2 MA Inhibitor DMGOSN2 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMGOSN2 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMGP5AR DI DMGP5AR DMGP5AR DN Antibodie derivative 10 DMGP5AR TI TTUTJGQ DMGP5AR TN Vascular endothelial growth factor receptor 2 (KDR) DMGP5AR RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMGP5AR RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMGPCSR DI DMGPCSR DMGPCSR DN Pyridine-2,4-dicarboxylic acid analog 4 DMGPCSR TI TTWAQBO DMGPCSR TN Lysine-specific demethylase 4E (KDM4E) DMGPCSR MA Inhibitor DMGPCSR RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGPCSR RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGPDEF DI DMGPDEF DMGPDEF DN US9475795, 19 DMGPDEF TI TTB9CIL DMGPDEF TN Prokineticin receptor-1 (PROKR1) DMGPDEF MA Inhibitor DMGPDEF RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795. DMGPDEF RU http://www.freepatentsonline.com/US9475795.html DMGQ1PK DI DMGQ1PK DMGQ1PK DN Peptide analog 32 DMGQ1PK TI TTSJMN8 DMGQ1PK TN Immunoproteasome complex (IP) DMGQ1PK MA Inhibitor DMGQ1PK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMGQ1PK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMGQMCZ DI DMGQMCZ DMGQMCZ DN Hydroxyqunoline analog 4 DMGQMCZ TI TTWAQBO DMGQMCZ TN Lysine-specific demethylase 4E (KDM4E) DMGQMCZ MA Inhibitor DMGQMCZ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMGQMCZ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMGQWKH DI DMGQWKH DMGQWKH DN N-(benzimidazole/indole) benzoic acid derivative 1 DMGQWKH TI TT5ZWB6 DMGQWKH TN Dihydrodiol dehydrogenase type I (AKR1C3) DMGQWKH MA Inhibitor DMGQWKH RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMGQWKH RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMGR2JC DI DMGR2JC DMGR2JC DN PMID27109571-Compound-33 DMGR2JC TI TTMY6L1 DMGR2JC TN Fatty acid-binding protein (FABP) DMGR2JC MA Inhibitor DMGR2JC RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMGR2JC RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMGR6IJ DI DMGR6IJ DMGR6IJ DN Tihourea derivative 1 DMGR6IJ TI TTSXVID DMGR6IJ TN Nuclear factor NF-kappa-B (NFKB) DMGR6IJ MA Inhibitor DMGR6IJ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMGR6IJ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMGR6X1 DI DMGR6X1 DMGR6X1 DN Aromatic acetylene derivative 1 DMGR6X1 TI TT23XQV DMGR6X1 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMGR6X1 MA Inhibitor DMGR6X1 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMGR6X1 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMGRBAJ DI DMGRBAJ DMGRBAJ DN Cyclic compound 2 DMGRBAJ TI TTNBFWK DMGRBAJ TN Programmed cell death protein 1 (PD-1) DMGRBAJ MA Inhibitor DMGRBAJ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMGRBAJ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMGRD8B DI DMGRD8B DMGRD8B DN Benzimidazole derivative 11 DMGRD8B TI TTYLQ8V DMGRD8B TN Prostaglandin E synthase (PTGES) DMGRD8B MA Inhibitor DMGRD8B RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMGRD8B RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMGS2ET DI DMGS2ET DMGS2ET DN Pyrazoline derivative 1 DMGS2ET TI TT6OEDT DMGS2ET TN Cannabinoid receptor 1 (CB1) DMGS2ET MA Antagonist DMGS2ET RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMGS2ET RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMGSLHN DI DMGSLHN DMGSLHN DN Biaryl mannoside derivative 21 DMGSLHN TI TTTCRU2 DMGSLHN TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMGSLHN MA Antagonist DMGSLHN RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMGSLHN RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMGSUIV DI DMGSUIV DMGSUIV DN Pyridine derivative 2 DMGSUIV TI TTOHSBA DMGSUIV TN Vascular endothelial growth factor A (VEGFA) DMGSUIV MA Inhibitor DMGSUIV RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMGSUIV RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMGTBO3 DI DMGTBO3 DMGTBO3 DN US10179791, Compound 171 DMGTBO3 TI TTDYP7I DMGTBO3 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMGTBO3 MA Inhibitor DMGTBO3 RN Spiro-cyclic amine derivatives as S1P modulators. US10179791. DMGTBO3 RU http://www.freepatentsonline.com/US10179791.html DMGTIP6 DI DMGTIP6 DMGTIP6 DN US9682991, 23 DMGTIP6 TI TTCGOIN DMGTIP6 TN PIM-3 protein kinase (PIM3) DMGTIP6 MA Inhibitor DMGTIP6 RN Tricyclic compounds for use as kinase inhibitors. US9682991. DMGTIP6 RU http://www.freepatentsonline.com/US9682991.html DMGTSCP DI DMGTSCP DMGTSCP DN JWH-015 DMGTSCP TI TTMSFAW DMGTSCP TN Cannabinoid receptor 2 (CB2) DMGTSCP MA Agonist DMGTSCP RN Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81. DMGTSCP RU https://pubmed.ncbi.nlm.nih.gov/18524639 DMGTSXL DI DMGTSXL DMGTSXL DN PMID28092474-Compound-33e DMGTSXL TI TT5ZKDI DMGTSXL TN Histone deacetylase 6 (HDAC6) DMGTSXL MA Inhibitor DMGTSXL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGTSXL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGTSXL DI DMGTSXL DMGTSXL DN PMID28092474-Compound-33e DMGTSXL TI TT6R7JZ DMGTSXL TN Histone deacetylase 1 (HDAC1) DMGTSXL MA Inhibitor DMGTSXL RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGTSXL RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGU914 DI DMGU914 DMGU914 DN PMID26666989-Compound-Figure11Ala up DMGU914 TI TT8BUGW DMGU914 TN Glycogen phosphorylase (PYG) DMGU914 MA Inhibitor DMGU914 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMGU914 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMGV4PT DI DMGV4PT DMGV4PT DN PMID27109571-Compound-35 DMGV4PT TI TTMY6L1 DMGV4PT TN Fatty acid-binding protein (FABP) DMGV4PT MA Inhibitor DMGV4PT RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMGV4PT RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMGV8T9 DI DMGV8T9 DMGV8T9 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 3 DMGV8T9 TI TTULVH8 DMGV8T9 TN Tyrosinase (TYR) DMGV8T9 MA Inhibitor DMGV8T9 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMGV8T9 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMGVT5Y DI DMGVT5Y DMGVT5Y DN PMID28766366-Compound-Scheme25-3 DMGVT5Y TI TTYGQ8A DMGVT5Y TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMGVT5Y MA Inhibitor DMGVT5Y RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGVT5Y RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGVT5Y DI DMGVT5Y DMGVT5Y DN PMID28766366-Compound-Scheme25-3 DMGVT5Y TI TTSBVFO DMGVT5Y TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMGVT5Y MA Inhibitor DMGVT5Y RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMGVT5Y RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMGVU7M DI DMGVU7M DMGVU7M DN PMID25666693-Compound-85 DMGVU7M TI TTMI6F5 DMGVU7M TN Transient receptor potential cation channel V1 (TRPV1) DMGVU7M MA Antagonist DMGVU7M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMGVU7M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMGVXCL DI DMGVXCL DMGVXCL DN PMID26004420-Compound-WO2012058134B DMGVXCL TI TTJ13ST DMGVXCL TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMGVXCL MA Inhibitor DMGVXCL RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMGVXCL RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMGWQVT DI DMGWQVT DMGWQVT DN PMID26924192-Compound-55 DMGWQVT TI TTE4BSY DMGWQVT TN Bromodomain and extraterminal domain protein (BET) DMGWQVT MA Inhibitor DMGWQVT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMGWQVT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMGWYJR DI DMGWYJR DMGWYJR DN Imidazo[1,2-b]pyridazine acetamide derivative 5 DMGWYJR TI TTPTXIN DMGWYJR TN Translocator protein (TSPO) DMGWYJR MA Ligand DMGWYJR RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMGWYJR RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMGXI95 DI DMGXI95 DMGXI95 DN PMID27841036-Compound-33 DMGXI95 TI TTVDSZ0 DMGXI95 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMGXI95 MA Inhibitor DMGXI95 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMGXI95 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMGXOJK DI DMGXOJK DMGXOJK DN PMID25726713-Compound-37 DMGXOJK TI TT8J1S3 DMGXOJK TN Smoothened homolog (SMO) DMGXOJK MA Inhibitor DMGXOJK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMGXOJK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMGXUNA DI DMGXUNA DMGXUNA DN PMID29865878-Compound-40 DMGXUNA TI TTSJMN8 DMGXUNA TN Immunoproteasome complex (IP) DMGXUNA MA Inhibitor DMGXUNA RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMGXUNA RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMGY3OR DI DMGY3OR DMGY3OR DN Tricyclic pyrrolidine derivative 1 DMGY3OR TI TTWJBZ5 DMGY3OR TN 5-HT 2C receptor (HTR2C) DMGY3OR MA Agonist DMGY3OR RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMGY3OR RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMGY4WO DI DMGY4WO DMGY4WO DN Quinoline and quinazoline derivative 3 DMGY4WO TI TTOHSBA DMGY4WO TN Vascular endothelial growth factor A (VEGFA) DMGY4WO MA Inhibitor DMGY4WO RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMGY4WO RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMGYT81 DI DMGYT81 DMGYT81 DN Pyrrolo-pyrimidine derivative 6 DMGYT81 TI TT4DXQT DMGYT81 TN Proto-oncogene c-Ret (RET) DMGYT81 MA Inhibitor DMGYT81 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMGYT81 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMGYZQ2 DI DMGYZQ2 DMGYZQ2 DN 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 DMGYZQ2 TI TTQVOEI DMGYZQ2 TN Angiotensin II receptor type-2 (AGTR2) DMGYZQ2 MA Agonist DMGYZQ2 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMGYZQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMGYZQ2 DI DMGYZQ2 DMGYZQ2 DN 1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1 DMGYZQ2 TI TTZMAO3 DMGYZQ2 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMGYZQ2 MA Agonist DMGYZQ2 RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMGYZQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMGZ59Q DI DMGZ59Q DMGZ59Q DN Pyrazolo[1,5-a]pyrimidine derivative 26 DMGZ59Q TI TTTDVOJ DMGZ59Q TN Tropomyosin-related kinase A (TrkA) DMGZ59Q MA Inhibitor DMGZ59Q RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMGZ59Q RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMGZ61E DI DMGZ61E DMGZ61E DN PMID28092474-Compound-32a DMGZ61E TI TT6R7JZ DMGZ61E TN Histone deacetylase 1 (HDAC1) DMGZ61E MA Inhibitor DMGZ61E RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGZ61E RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGZ61E DI DMGZ61E DMGZ61E DN PMID28092474-Compound-32a DMGZ61E TI TT5ZKDI DMGZ61E TN Histone deacetylase 6 (HDAC6) DMGZ61E MA Inhibitor DMGZ61E RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMGZ61E RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMGZ9MW DI DMGZ9MW DMGZ9MW DN PMID28394193-Compound-13 DMGZ9MW TI TT9MZCQ DMGZ9MW TN Enhancer of zeste homolog 2 (EZH2) DMGZ9MW MA Inhibitor DMGZ9MW RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMGZ9MW RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMGZ9MW DI DMGZ9MW DMGZ9MW DN PMID28394193-Compound-13 DMGZ9MW TI TTJBYRU DMGZ9MW TN EZH2 Y641F mutant (EZH2 Y641F) DMGZ9MW MA Inhibitor DMGZ9MW RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMGZ9MW RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMGZER5 DI DMGZER5 DMGZER5 DN PMID25522065-Compound-14 DMGZER5 TI TTX4RTB DMGZER5 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMGZER5 MA Antagonist DMGZER5 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMGZER5 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMGZHRT DI DMGZHRT DMGZHRT DN Aryl carbamate analog 1 DMGZHRT TI TTUX68I DMGZHRT TN Hypoxia-inducible factor 1 (HIF-1) DMGZHRT MA Inhibitor DMGZHRT RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMGZHRT RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMGZUAY DI DMGZUAY DMGZUAY DN Pyrazole derivative 87 DMGZUAY TI TTSCIM2 DMGZUAY TN Extracellular lysophospholipase D (E-NPP2) DMGZUAY MA Inhibitor DMGZUAY RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMGZUAY RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMH02JL DI DMH02JL DMH02JL DN Quinoline derivative 11 DMH02JL TI TT473XN DMH02JL TN P2X purinoceptor 7 (P2RX7) DMH02JL MA Antagonist DMH02JL RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMH02JL RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMH02JL DI DMH02JL DMH02JL DN Quinoline derivative 11 DMH02JL TI TTQ6VDM DMH02JL TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMH02JL MA Antagonist DMH02JL RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMH02JL RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMH073T DI DMH073T DMH073T DN PMID25991433-Compound-O1 DMH073T TI TTR2TXZ DMH073T TN Jun N terminal kinase (JNK) DMH073T MA Inhibitor DMH073T RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMH073T RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMH0CQU DI DMH0CQU DMH0CQU DN PMID27454349-Compound-99 DMH0CQU TI TTK59TV DMH0CQU TN Vitamin D3 receptor (VDR) DMH0CQU MA Agonist DMH0CQU RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMH0CQU RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMH0LBI DI DMH0LBI DMH0LBI DN PMID26004420-Compound-WO2014126944B DMH0LBI TI TTJ13ST DMH0LBI TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH0LBI MA Inhibitor DMH0LBI RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH0LBI RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH1W89 DI DMH1W89 DMH1W89 DN Pyrazolo[1,5-a]pyridine derivative 1 DMH1W89 TI TTTDVOJ DMH1W89 TN Tropomyosin-related kinase A (TrkA) DMH1W89 MA Inhibitor DMH1W89 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMH1W89 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTKAWRQ DMH1W8F TN JAK-STAT signaling pathway (JAK-STAT pathway) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTJSQEF DMH1W8F TN Tyrosine-protein kinase (PTK) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTT7PJU DMH1W8F TN Janus kinase 3 (JAK-3) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTRMX3V DMH1W8F TN Janus kinase 2 (JAK-2) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TTBYWP2 DMH1W8F TN TYK2 tyrosine kinase (TYK2) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH1W8F DI DMH1W8F DMH1W8F DN PMID27774824-Compound-Figure11Example1up DMH1W8F TI TT6DM01 DMH1W8F TN Janus kinase 1 (JAK-1) DMH1W8F MA Inhibitor DMH1W8F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMH1W8F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMH249S DI DMH249S DMH249S DN PMID28074661-Compound-US20120264760C81 DMH249S TI TTL7C8Q DMH249S TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMH249S MA Inhibitor DMH249S RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMH249S RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMH26EO DI DMH26EO DMH26EO DN 1,3,4-oxadiazole derivative 2 DMH26EO TI TTNBFWK DMH26EO TN Programmed cell death protein 1 (PD-1) DMH26EO MA Inhibitor DMH26EO RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMH26EO RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMH2AYV DI DMH2AYV DMH2AYV DN Proline amide derivative 1 DMH2AYV TI TTTJZ4M DMH2AYV TN Prolylcarboxypeptidase (PRCP) DMH2AYV MA Inhibitor DMH2AYV RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMH2AYV RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMH2LFS DI DMH2LFS DMH2LFS DN Pyrazole derivative 23 DMH2LFS TI TT6OEDT DMH2LFS TN Cannabinoid receptor 1 (CB1) DMH2LFS MA Antagonist DMH2LFS RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMH2LFS RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMH3CK0 DI DMH3CK0 DMH3CK0 DN PMID25522065-Compound-37 DMH3CK0 TI TTX4RTB DMH3CK0 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMH3CK0 MA Antagonist DMH3CK0 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMH3CK0 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMH3FUR DI DMH3FUR DMH3FUR DN Phenylpropylamine derivative 3 DMH3FUR TI TT5TPI6 DMH3FUR TN Opioid receptor sigma 1 (OPRS1) DMH3FUR MA Ligand DMH3FUR RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMH3FUR RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMH3NOZ DI DMH3NOZ DMH3NOZ DN PMID25553724-Compound-WO2011127048 32 DMH3NOZ TI TTSXVID DMH3NOZ TN Nuclear factor NF-kappa-B (NFKB) DMH3NOZ MA Modulator DMH3NOZ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH3NOZ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH4DMY DI DMH4DMY DMH4DMY DN PMID25553724-Compound-US2011796857710 DMH4DMY TI TTSXVID DMH4DMY TN Nuclear factor NF-kappa-B (NFKB) DMH4DMY MA Inhibitor DMH4DMY RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH4DMY RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH4TY1 DI DMH4TY1 DMH4TY1 DN Tricyclic isoxazoloquinazoline derivative 2 DMH4TY1 TI TTP7EGM DMH4TY1 TN Dual specificity protein kinase TTK (MPS1) DMH4TY1 MA Inhibitor DMH4TY1 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMH4TY1 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMH4TY1 DI DMH4TY1 DMH4TY1 DN Tricyclic isoxazoloquinazoline derivative 2 DMH4TY1 TI TT5OU0D DMH4TY1 TN PRKR-like endoplasmic reticulum kinase (PERK) DMH4TY1 MA Inhibitor DMH4TY1 RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMH4TY1 RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMH57FG DI DMH57FG DMH57FG DN PMID30107136-Compound-Example48 DMH57FG TI TT23XQV DMH57FG TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMH57FG MA Inhibitor DMH57FG RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMH57FG RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMH5FEO DI DMH5FEO DMH5FEO DN A-substituted phenylpropionic acid derivative 2 DMH5FEO TI TTZMAO3 DMH5FEO TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMH5FEO MA Agonist DMH5FEO RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMH5FEO RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMH5N78 DI DMH5N78 DMH5N78 DN Spirocyclic diamine urea derivative 2 DMH5N78 TI TTDP1UC DMH5N78 TN Fatty acid amide hydrolase (FAAH) DMH5N78 MA Inhibitor DMH5N78 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMH5N78 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMH65CX DI DMH65CX DMH65CX DN N-quinolin-benzene sulphonamide derivative 2 DMH65CX TI TTSXVID DMH65CX TN Nuclear factor NF-kappa-B (NFKB) DMH65CX MA Inhibitor DMH65CX RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH65CX RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH7496 DI DMH7496 DMH7496 DN PMID25553724-Compound-WO2011127048 33 DMH7496 TI TTSXVID DMH7496 TN Nuclear factor NF-kappa-B (NFKB) DMH7496 MA Modulator DMH7496 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMH7496 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMH7DL5 DI DMH7DL5 DMH7DL5 DN US9422240, 1-298 DMH7DL5 TI TT9ISBX DMH7DL5 TN HIF-prolyl hydroxylase 2 (HPH-2) DMH7DL5 MA Inhibitor DMH7DL5 RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DMH7DL5 RU http://www.freepatentsonline.com/US9422240.html DMH7E38 DI DMH7E38 DMH7E38 DN PMID26004420-Compound-WO2013062892D DMH7E38 TI TTJ13ST DMH7E38 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH7E38 MA Inhibitor DMH7E38 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH7E38 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH7JKI DI DMH7JKI DMH7JKI DN PMID26004420-Compound-US20140275020E DMH7JKI TI TTJ13ST DMH7JKI TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH7JKI MA Inhibitor DMH7JKI RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH7JKI RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH7JVA DI DMH7JVA DMH7JVA DN US8470836, 2 DMH7JVA TI TTOYT5L DMH7JVA TN Dipeptidyl-peptidase 7 (DPP7) DMH7JVA MA Inhibitor DMH7JVA RN Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. DMH7JVA RU http://www.freepatentsonline.com/US8470836.html DMH7PGC DI DMH7PGC DMH7PGC DN Cyclopentane carboxamide derivative 1 DMH7PGC TI TTTJZ4M DMH7PGC TN Prolylcarboxypeptidase (PRCP) DMH7PGC MA Inhibitor DMH7PGC RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMH7PGC RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMH7PGU DI DMH7PGU DMH7PGU DN Pyrazole derivative 11 DMH7PGU TI TT6OEDT DMH7PGU TN Cannabinoid receptor 1 (CB1) DMH7PGU MA Antagonist DMH7PGU RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMH7PGU RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMH7T8C DI DMH7T8C DMH7T8C DN N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C TI TTNR0UQ DMH7T8C TN Lysine-specific histone demethylase 1 (LSD) DMH7T8C MA Inhibitor DMH7T8C RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH7T8C RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH7T8C DI DMH7T8C DMH7T8C DN N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C TI TTZHPB8 DMH7T8C TN Lysine-specific demethylase 4A (KDM4A) DMH7T8C MA Inhibitor DMH7T8C RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH7T8C RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH7T8C DI DMH7T8C DMH7T8C DN N-(2-phenylcyclopropyl) amino acid derivative 1 DMH7T8C TI TTGP7BY DMH7T8C TN Monoamine oxidase type B (MAO-B) DMH7T8C MA Inhibitor DMH7T8C RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH7T8C RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH7XL3 DI DMH7XL3 DMH7XL3 DN PMID26651364-Compound-5 DMH7XL3 TI TTTCRU2 DMH7XL3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMH7XL3 MA Antagonist DMH7XL3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMH7XL3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMH86F2 DI DMH86F2 DMH86F2 DN Quinazoline alkaloid derivative 1 DMH86F2 TI TT1RS9F DMH86F2 TN Acetylcholinesterase (AChE) DMH86F2 MA Inhibitor DMH86F2 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMH86F2 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMH86F2 DI DMH86F2 DMH86F2 DN Quinazoline alkaloid derivative 1 DMH86F2 TI TTEB0GD DMH86F2 TN Cholinesterase (BCHE) DMH86F2 MA Inhibitor DMH86F2 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMH86F2 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMH8E7S DI DMH8E7S DMH8E7S DN PMID26815044-Compound-30 DMH8E7S TI TTULVH8 DMH8E7S TN Tyrosinase (TYR) DMH8E7S MA Inhibitor DMH8E7S RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMH8E7S RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMH8GC6 DI DMH8GC6 DMH8GC6 DN PMID28350212-Compound-18 DMH8GC6 TI TTZS04O DMH8GC6 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMH8GC6 MA Inhibitor DMH8GC6 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMH8GC6 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMH8M1D DI DMH8M1D DMH8M1D DN PMID26004420-Compound-US20140309213A DMH8M1D TI TTJ13ST DMH8M1D TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMH8M1D MA Inhibitor DMH8M1D RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMH8M1D RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMH8Q4T DI DMH8Q4T DMH8Q4T DN Azole benzene derivative 3 DMH8Q4T TI TT7RJY8 DMH8Q4T TN Xanthine dehydrogenase/oxidase (XDH) DMH8Q4T MA Inhibitor DMH8Q4T RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMH8Q4T RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMH942E DI DMH942E DMH942E DN Azetidine urea derivative 1 DMH942E TI TTDP1UC DMH942E TN Fatty acid amide hydrolase (FAAH) DMH942E MA Inhibitor DMH942E RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMH942E RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMH9EQ1 DI DMH9EQ1 DMH9EQ1 DN Heteroaryl-cyclopropylamine derivative 3 DMH9EQ1 TI TTGP7BY DMH9EQ1 TN Monoamine oxidase type B (MAO-B) DMH9EQ1 MA Inhibitor DMH9EQ1 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH9EQ1 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH9EQ1 DI DMH9EQ1 DMH9EQ1 DN Heteroaryl-cyclopropylamine derivative 3 DMH9EQ1 TI TTNR0UQ DMH9EQ1 TN Lysine-specific histone demethylase 1 (LSD) DMH9EQ1 MA Inhibitor DMH9EQ1 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMH9EQ1 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMH9ION DI DMH9ION DMH9ION DN VFEDEOUBYBLDKN-AAFJCEBUSA-N DMH9ION TI TT5U49F DMH9ION TN PRKACA messenger RNA (PRKACA mRNA) DMH9ION MA Inhibitor DMH9ION RN Purine derivatives. US8846696. DMH9ION RU http://www.freepatentsonline.com/US8846696.html DMH9N2T DI DMH9N2T DMH9N2T DN Tacrine-indole hybrid derivative 2 DMH9N2T TI TT1RS9F DMH9N2T TN Acetylcholinesterase (AChE) DMH9N2T MA Inhibitor DMH9N2T RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMH9N2T RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMHA18O DI DMHA18O DMHA18O DN PMID26004420-Compound-WO2014015495C DMHA18O TI TTJ13ST DMHA18O TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMHA18O MA Inhibitor DMHA18O RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMHA18O RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMHAJCM DI DMHAJCM DMHAJCM DN Isothiazolone derivative 1 DMHAJCM TI TTN9T81 DMHAJCM TN Arachidonate 15-lipoxygenase (15-LOX) DMHAJCM MA Inhibitor DMHAJCM RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMHAJCM RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMHAOF1 DI DMHAOF1 DMHAOF1 DN PMID26924192-Compound-20 DMHAOF1 TI TTRA6BO DMHAOF1 TN Bromodomain-containing protein 4 (BRD4) DMHAOF1 MA Inhibitor DMHAOF1 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMHAOF1 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMHAVYS DI DMHAVYS DMHAVYS DN Y-9680 DMHAVYS TI TTUWGRA DMHAVYS TN Protein kinase C zeta (PRKCZ) DMHAVYS MA Inhibitor DMHAVYS RN Compounds, formulations, and methods of protein kinase C inhibition. US8889672. DMHAVYS RU http://www.freepatentsonline.com/US8889672.html DMHB5XG DI DMHB5XG DMHB5XG DN Carbamate derivative 5 DMHB5XG TI TTGX13H DMHB5XG TN Fatty-acid amide hydrolase 1 (FAAH1) DMHB5XG MA Inhibitor DMHB5XG RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMHB5XG RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMHBJFN DI DMHBJFN DMHBJFN DN 1,2,4-triazole derivative 4 DMHBJFN TI TT5TPI6 DMHBJFN TN Opioid receptor sigma 1 (OPRS1) DMHBJFN MA Inhibitor DMHBJFN RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMHBJFN RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMHBN5M DI DMHBN5M DMHBN5M DN PMID25666693-Compound-47 DMHBN5M TI TTMI6F5 DMHBN5M TN Transient receptor potential cation channel V1 (TRPV1) DMHBN5M MA Antagonist DMHBN5M RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHBN5M RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHBOK6 DI DMHBOK6 DMHBOK6 DN PMID29338548-Compound-47 DMHBOK6 TI TTHJTF7 DMHBOK6 TN Glycine transporter GlyT-1 (SLC6A9) DMHBOK6 MA Inhibitor DMHBOK6 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMHBOK6 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMHBWNS DI DMHBWNS DMHBWNS DN PMID25435285-Compound-15 DMHBWNS TI TTXJ47W DMHBWNS TN Metabotropic glutamate receptor 2 (mGluR2) DMHBWNS MA Antagonist DMHBWNS RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMHBWNS RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMHBWNS DI DMHBWNS DMHBWNS DN PMID25435285-Compound-15 DMHBWNS TI TT8A9EF DMHBWNS TN Metabotropic glutamate receptor 3 (mGluR3) DMHBWNS MA Antagonist DMHBWNS RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMHBWNS RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMHD51F DI DMHD51F DMHD51F DN Alkyl mannoside derivative 10 DMHD51F TI TTTCRU2 DMHD51F TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHD51F MA Antagonist DMHD51F RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHD51F RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHD8RK DI DMHD8RK DMHD8RK DN Mycophenolic acid/nucleotide derivative 10 DMHD8RK TI TTL7C8Q DMHD8RK TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMHD8RK MA Inhibitor DMHD8RK RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMHD8RK RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMHEAJQ DI DMHEAJQ DMHEAJQ DN Biaryl compound 1 DMHEAJQ TI TT23XQV DMHEAJQ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMHEAJQ MA Inhibitor DMHEAJQ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMHEAJQ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMHEAJQ DI DMHEAJQ DMHEAJQ DN Biaryl compound 1 DMHEAJQ TI TT5YPJF DMHEAJQ TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMHEAJQ MA Inhibitor DMHEAJQ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMHEAJQ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMHEPR3 DI DMHEPR3 DMHEPR3 DN PMID25666693-Compound-133 DMHEPR3 TI TTMI6F5 DMHEPR3 TN Transient receptor potential cation channel V1 (TRPV1) DMHEPR3 MA Antagonist DMHEPR3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHEPR3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHEQDT DI DMHEQDT DMHEQDT DN Benzimidazole derivative 16 DMHEQDT TI TTYLQ8V DMHEQDT TN Prostaglandin E synthase (PTGES) DMHEQDT MA Inhibitor DMHEQDT RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMHEQDT RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMHEX1Q DI DMHEX1Q DMHEX1Q DN 1,2-diamino cyclopentane-based derivative 16 DMHEX1Q TI TT9N02I DMHEX1Q TN Orexin receptor type 2 (HCRTR2) DMHEX1Q MA Antagonist DMHEX1Q RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHEX1Q RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHEX1Q DI DMHEX1Q DMHEX1Q DN 1,2-diamino cyclopentane-based derivative 16 DMHEX1Q TI TT60Q8D DMHEX1Q TN Orexin receptor type 1 (HCRTR1) DMHEX1Q MA Antagonist DMHEX1Q RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHEX1Q RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHF2OX DI DMHF2OX DMHF2OX DN US9409892, 19 DMHF2OX TI TT9ISBX DMHF2OX TN HIF-prolyl hydroxylase 2 (HPH-2) DMHF2OX MA Inhibitor DMHF2OX RN 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892. DMHF2OX RU http://www.freepatentsonline.com/US9409892.html DMHFQLC DI DMHFQLC DMHFQLC DN Heteroaryl-substituted urea derivative 2 DMHFQLC TI TTDP1UC DMHFQLC TN Fatty acid amide hydrolase (FAAH) DMHFQLC MA Inhibitor DMHFQLC RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMHFQLC RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMHG4WD DI DMHG4WD DMHG4WD DN PMID25991433-Compound-A8 DMHG4WD TI TTHS0U8 DMHG4WD TN Stress-activated protein kinase JNK2 (JNK2) DMHG4WD MA Inhibitor DMHG4WD RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMHG4WD RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMHG4WD DI DMHG4WD DMHG4WD DN PMID25991433-Compound-A8 DMHG4WD TI TT0K6EO DMHG4WD TN Stress-activated protein kinase JNK1 (JNK1) DMHG4WD MA Inhibitor DMHG4WD RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMHG4WD RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMHGE1T DI DMHGE1T DMHGE1T DN Dihydropyrrolopyrazole derivative 1 DMHGE1T TI TTDIGC1 DMHGE1T TN Dipeptidyl peptidase 4 (DPP-4) DMHGE1T MA Inhibitor DMHGE1T RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMHGE1T RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMHGPU1 DI DMHGPU1 DMHGPU1 DN Pyrrolo-pyrrolone derivative 3 DMHGPU1 TI TTRA6BO DMHGPU1 TN Bromodomain-containing protein 4 (BRD4) DMHGPU1 MA Inhibitor DMHGPU1 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMHGPU1 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMHGRTX DI DMHGRTX DMHGRTX DN Tri-substituted urea derivative 1 DMHGRTX TI TTTDVOJ DMHGRTX TN Tropomyosin-related kinase A (TrkA) DMHGRTX MA Inhibitor DMHGRTX RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMHGRTX RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMHI3O1 DI DMHI3O1 DMHI3O1 DN PMID25684022-Compound-WO2012135799 43(1.5) DMHI3O1 TI TTCZOF2 DMHI3O1 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHI3O1 MA Inhibitor DMHI3O1 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHI3O1 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHI4L6 DI DMHI4L6 DMHI4L6 DN PMID25522065-Compound-48 DMHI4L6 TI TTX4RTB DMHI4L6 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMHI4L6 MA Antagonist DMHI4L6 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMHI4L6 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMHI6RZ DI DMHI6RZ DMHI6RZ DN US8772478, 5 DMHI6RZ TI TTQICM2 DMHI6RZ TN ADAM metallopeptidase 33 (ADAM33) DMHI6RZ MA Inhibitor DMHI6RZ RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DMHI6RZ RU http://www.freepatentsonline.com/US8772478.html DMHIA26 DI DMHIA26 DMHIA26 DN PMID26651364-Compound-115 DMHIA26 TI TTTCRU2 DMHIA26 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHIA26 MA Antagonist DMHIA26 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHIA26 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHIAVW DI DMHIAVW DMHIAVW DN Isoquinoline sulfonyl derivative 3 DMHIAVW TI TTMQO60 DMHIAVW TN Rho-associated protein kinase (ROCK) DMHIAVW MA Inhibitor DMHIAVW RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMHIAVW RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TTHY57M DMHIBTZ TN Matrix metalloproteinase-13 (MMP-13) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TTMX39J DMHIBTZ TN Matrix metalloproteinase-1 (MMP-1) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TT6X50U DMHIBTZ TN Matrix metalloproteinase-9 (MMP-9) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIBTZ DI DMHIBTZ DMHIBTZ DN PMID29130358-Compound-Figure18(14a) DMHIBTZ TI TTLM12X DMHIBTZ TN Matrix metalloproteinase-2 (MMP-2) DMHIBTZ MA Inhibitor DMHIBTZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMHIBTZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMHIEBN DI DMHIEBN DMHIEBN DN 2-pyrazinone derivative 6 DMHIEBN TI TTPLTSQ DMHIEBN TN Neutrophil elastase (NE) DMHIEBN MA Inhibitor DMHIEBN RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMHIEBN RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMHIUWX DI DMHIUWX DMHIUWX DN PMID28766366-Compound-Scheme1WO2011135259 DMHIUWX TI TTSBVFO DMHIUWX TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMHIUWX MA Inhibitor DMHIUWX RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMHIUWX RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMHIV24 DI DMHIV24 DMHIV24 DN 1,2-diamino cyclopentane-based derivative 7 DMHIV24 TI TT9N02I DMHIV24 TN Orexin receptor type 2 (HCRTR2) DMHIV24 MA Antagonist DMHIV24 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHIV24 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHIV24 DI DMHIV24 DMHIV24 DN 1,2-diamino cyclopentane-based derivative 7 DMHIV24 TI TT60Q8D DMHIV24 TN Orexin receptor type 1 (HCRTR1) DMHIV24 MA Antagonist DMHIV24 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMHIV24 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMHIV2L DI DMHIV2L DMHIV2L DN PMID27841036-Compound-36 DMHIV2L TI TTEBCY8 DMHIV2L TN Poly [ADP-ribose] polymerase (PARP) DMHIV2L MA Inhibitor DMHIV2L RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMHIV2L RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMHJ98M DI DMHJ98M DMHJ98M DN Benzimidazole derivative 9 DMHJ98M TI TTQR74A DMHJ98M TN Proteinase activated receptor 2 (PAR2) DMHJ98M MA Antagonist DMHJ98M RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMHJ98M RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMHJBRO DI DMHJBRO DMHJBRO DN PMID27019002-Compound-42b DMHJBRO TI TTNR0UQ DMHJBRO TN Lysine-specific histone demethylase 1 (LSD) DMHJBRO MA Inhibitor DMHJBRO RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMHJBRO RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMHJDU6 DI DMHJDU6 DMHJDU6 DN Indazoletriazolephenyl derivative 1 DMHJDU6 TI TTKFVXR DMHJDU6 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMHJDU6 MA Inhibitor DMHJDU6 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMHJDU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMHJDU6 DI DMHJDU6 DMHJDU6 DN Indazoletriazolephenyl derivative 1 DMHJDU6 TI TTXAJWN DMHJDU6 TN IL-1 receptor-associated kinase 1 (IRAK1) DMHJDU6 MA Inhibitor DMHJDU6 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMHJDU6 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMHJOP7 DI DMHJOP7 DMHJOP7 DN PMID25666693-Compound-97 DMHJOP7 TI TTMI6F5 DMHJOP7 TN Transient receptor potential cation channel V1 (TRPV1) DMHJOP7 MA Antagonist DMHJOP7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHJOP7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHKRVL DI DMHKRVL DMHKRVL DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMHKRVL TI TTJGW1Z DMHKRVL TN Phosphodiesterase 2A (PDE2A) DMHKRVL MA Inhibitor DMHKRVL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMHKRVL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMHKRVL DI DMHKRVL DMHKRVL DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 1 DMHKRVL TI TTJW4LU DMHKRVL TN Phosphodiesterase 10A (PDE10) DMHKRVL MA Inhibitor DMHKRVL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMHKRVL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMHL7SW DI DMHL7SW DMHL7SW DN PMID29757691-Compound-8c DMHL7SW TI TTEB0GD DMHL7SW TN Cholinesterase (BCHE) DMHL7SW MA Inhibitor DMHL7SW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMHL7SW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMHL7SW DI DMHL7SW DMHL7SW DN PMID29757691-Compound-8c DMHL7SW TI TT1RS9F DMHL7SW TN Acetylcholinesterase (AChE) DMHL7SW MA Inhibitor DMHL7SW RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMHL7SW RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMHLA5V DI DMHLA5V DMHLA5V DN Steroidal carboxamide derivative 1 DMHLA5V TI TT9JNIC DMHLA5V TN Histamine H3 receptor (H3R) DMHLA5V RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHLA5V RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHLJA7 DI DMHLJA7 DMHLJA7 DN Quinazoline derivative 14 DMHLJA7 TI TT4DXQT DMHLJA7 TN Proto-oncogene c-Ret (RET) DMHLJA7 MA Inhibitor DMHLJA7 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMHLJA7 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMHLQ2T DI DMHLQ2T DMHLQ2T DN PMID25684022-Compound-US20130053382 38(5-7) DMHLQ2T TI TTCZOF2 DMHLQ2T TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHLQ2T MA Inhibitor DMHLQ2T RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHLQ2T RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHM8WJ DI DMHM8WJ DMHM8WJ DN Pyrrolidine derivative 3 DMHM8WJ TI TTHS256 DMHM8WJ TN Metabotropic glutamate receptor 5 (mGluR5) DMHM8WJ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMHM8WJ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMHMEFY DI DMHMEFY DMHMEFY DN PMID25666693-Compound-150 DMHMEFY TI TTMI6F5 DMHMEFY TN Transient receptor potential cation channel V1 (TRPV1) DMHMEFY MA Antagonist DMHMEFY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHMEFY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHMTF7 DI DMHMTF7 DMHMTF7 DN Heterocycle-containing compound 3 DMHMTF7 TI TT9O6WS DMHMTF7 TN Glucagon receptor (GCGR) DMHMTF7 MA Antagonist DMHMTF7 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMHMTF7 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMHN5KW DI DMHN5KW DMHN5KW DN Piperidine derivative 1 DMHN5KW TI TTTIBOJ DMHN5KW TN Histamine H1 receptor (H1R) DMHN5KW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHN5KW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHN5KW DI DMHN5KW DMHN5KW DN Piperidine derivative 1 DMHN5KW TI TT3ROYC DMHN5KW TN Serotonin transporter (SERT) DMHN5KW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHN5KW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHN5KW DI DMHN5KW DMHN5KW DN Piperidine derivative 1 DMHN5KW TI TT9JNIC DMHN5KW TN Histamine H3 receptor (H3R) DMHN5KW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMHN5KW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMHNPSO DI DMHNPSO DMHNPSO DN 1190312-92-5 DMHNPSO TI TTIG67W DMHNPSO TN Lysine-specific demethylase 5A (KDM5A) DMHNPSO MA Inhibitor DMHNPSO RN Histone demethylase inhibitors. US10174026. DMHNPSO RU http://www.freepatentsonline.com/US10174026.html DMHNYQU DI DMHNYQU DMHNYQU DN BDBM50011553 DMHNYQU TI TT6NI13 DMHNYQU TN MEK kinase kinase 4 (MAP4K4) DMHNYQU MA Inhibitor DMHNYQU RN Aminoquinazoline and pyridopyrimidine derivatives. US9592235. DMHNYQU RU http://www.freepatentsonline.com/US9592235.html DMHO3NB DI DMHO3NB DMHO3NB DN Pyrazolopyrimidine derivative 1 DMHO3NB TI TTHS256 DMHO3NB TN Metabotropic glutamate receptor 5 (mGluR5) DMHO3NB MA Modulator DMHO3NB RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMHO3NB RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMHOLQF DI DMHOLQF DMHOLQF DN Benzyl pyrrolyloxoacetamide derivative 2 DMHOLQF TI TTDP1UC DMHOLQF TN Fatty acid amide hydrolase (FAAH) DMHOLQF MA Inhibitor DMHOLQF RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMHOLQF RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMHOPE0 DI DMHOPE0 DMHOPE0 DN Biaryl mannoside derivative 18 DMHOPE0 TI TTTCRU2 DMHOPE0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHOPE0 MA Antagonist DMHOPE0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHOPE0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHP6J2 DI DMHP6J2 DMHP6J2 DN PMID25980951-Compound-37 DMHP6J2 TI TTR7B60 DMHP6J2 TN X-linked inhibitor of apoptosis protein (XIAP) DMHP6J2 MA Antagonist DMHP6J2 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMHP6J2 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMHP6J2 DI DMHP6J2 DMHP6J2 DN PMID25980951-Compound-37 DMHP6J2 TI TTQ5LRD DMHP6J2 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMHP6J2 MA Antagonist DMHP6J2 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMHP6J2 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMHP90Q DI DMHP90Q DMHP90Q DN PMID28870136-Compound-59 DMHP90Q TI TTK0O6Y DMHP90Q TN Ecto-5'-nucleotidase (CD73) DMHP90Q MA Inhibitor DMHP90Q RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMHP90Q RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMHPK31 DI DMHPK31 DMHPK31 DN PMID27788040-Compound-5 DMHPK31 TI TTV1C0Z DMHPK31 TN Neuropeptide S receptor (NPSR) DMHPK31 MA Antagonist DMHPK31 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMHPK31 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMHPQI2 DI DMHPQI2 DMHPQI2 DN SCHEMBL15198146 DMHPQI2 TI TTXHWA7 DMHPQI2 TN Ubiquitin-activating enzyme E1 (UBAE1) DMHPQI2 MA Inhibitor DMHPQI2 RN Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389. DMHPQI2 RU http://www.freepatentsonline.com/US10202389.html DMHPW3X DI DMHPW3X DMHPW3X DN PMID25666693-Compound-22 DMHPW3X TI TTMI6F5 DMHPW3X TN Transient receptor potential cation channel V1 (TRPV1) DMHPW3X MA Antagonist DMHPW3X RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHPW3X RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHQCEJ DI DMHQCEJ DMHQCEJ DN Thiazole carboxamide derivative 13 DMHQCEJ TI TTCZOF2 DMHQCEJ TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHQCEJ MA Inhibitor DMHQCEJ RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHQCEJ RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHQM8W DI DMHQM8W DMHQM8W DN PMID25666693-Compound-132 DMHQM8W TI TTMI6F5 DMHQM8W TN Transient receptor potential cation channel V1 (TRPV1) DMHQM8W MA Antagonist DMHQM8W RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHQM8W RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHR43K DI DMHR43K DMHR43K DN Tlouidine sulfonamide derivative 1 DMHR43K TI TTUX68I DMHR43K TN Hypoxia-inducible factor 1 (HIF-1) DMHR43K MA Inhibitor DMHR43K RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMHR43K RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMHREX9 DI DMHREX9 DMHREX9 DN PMID25666693-Compound-94 DMHREX9 TI TTMI6F5 DMHREX9 TN Transient receptor potential cation channel V1 (TRPV1) DMHREX9 MA Antagonist DMHREX9 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMHREX9 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMHRUIZ DI DMHRUIZ DMHRUIZ DN Pyrazolo[4,3-c]pyridine derivative 1 DMHRUIZ TI TTTDVOJ DMHRUIZ TN Tropomyosin-related kinase A (TrkA) DMHRUIZ MA Inhibitor DMHRUIZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMHRUIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMHRV8J DI DMHRV8J DMHRV8J DN Imidazo bicyclic iminium derivative 4 DMHRV8J TI TT8J1S3 DMHRV8J TN Smoothened homolog (SMO) DMHRV8J MA Inhibitor DMHRV8J RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMHRV8J RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMHRY63 DI DMHRY63 DMHRY63 DN Tricyclic indole compound 2 DMHRY63 TI TTPTXIN DMHRY63 TN Translocator protein (TSPO) DMHRY63 MA Ligand DMHRY63 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMHRY63 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMHS3ZW DI DMHS3ZW DMHS3ZW DN PMID25991433-Compound-G1 DMHS3ZW TI TT0K6EO DMHS3ZW TN Stress-activated protein kinase JNK1 (JNK1) DMHS3ZW MA Inhibitor DMHS3ZW RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMHS3ZW RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMHSDUR DI DMHSDUR DMHSDUR DN Pyridopyrimidinone derivative 3 DMHSDUR TI TTK0FEA DMHSDUR TN Leucine-rich repeat kinase 2 (LRRK2) DMHSDUR MA Inhibitor DMHSDUR RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMHSDUR RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMHSGPU DI DMHSGPU DMHSGPU DN PMID25522065-Compound-23 DMHSGPU TI TTX4RTB DMHSGPU TN Melanin-concentrating hormone receptor 1 (MCHR1) DMHSGPU MA Antagonist DMHSGPU RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMHSGPU RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMHSJ65 DI DMHSJ65 DMHSJ65 DN PMID28092474-Compound-32k DMHSJ65 TI TT6R7JZ DMHSJ65 TN Histone deacetylase 1 (HDAC1) DMHSJ65 MA Inhibitor DMHSJ65 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHSJ65 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHSJ65 DI DMHSJ65 DMHSJ65 DN PMID28092474-Compound-32k DMHSJ65 TI TT5ZKDI DMHSJ65 TN Histone deacetylase 6 (HDAC6) DMHSJ65 MA Inhibitor DMHSJ65 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHSJ65 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHSNA5 DI DMHSNA5 DMHSNA5 DN Aminoazetidine derivative 2 DMHSNA5 TI TT6OEDT DMHSNA5 TN Cannabinoid receptor 1 (CB1) DMHSNA5 MA Antagonist DMHSNA5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMHSNA5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMHT41B DI DMHT41B DMHT41B DN PMID25399762-Compound-Table1-C25 DMHT41B TI TTGP7BY DMHT41B TN Monoamine oxidase type B (MAO-B) DMHT41B MA Inhibitor DMHT41B RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMHT41B RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMHT4PF DI DMHT4PF DMHT4PF DN Peptide analog 28 DMHT4PF TI TT68GPI DMHT4PF TN Proteasome beta-5 (PS beta-5) DMHT4PF MA Inhibitor DMHT4PF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMHT4PF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMHT4PF DI DMHT4PF DMHT4PF DN Peptide analog 28 DMHT4PF TI TTEAD9J DMHT4PF TN Proteasome beta-8 (PS beta-8) DMHT4PF MA Inhibitor DMHT4PF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMHT4PF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMHTJ7N DI DMHTJ7N DMHTJ7N DN Sulfonamide derivative 18 DMHTJ7N TI TTZMAO3 DMHTJ7N TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMHTJ7N MA Agonist DMHTJ7N RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMHTJ7N RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTJS8PY DMHTJVA TN 5-HT 6 receptor (HTR6) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTO9X1H DMHTJVA TN 5-HT 7 receptor (HTR7) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTEX248 DMHTJVA TN Dopamine D2 receptor (D2R) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTJQOD7 DMHTJVA TN 5-HT 2A receptor (HTR2A) DMHTJVA MA Ligand DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTJVA DI DMHTJVA DMHTJVA DN PMID30124346-Compound-13TABLE4 DMHTJVA TI TTSQIFT DMHTJVA TN 5-HT 1A receptor (HTR1A) DMHTJVA MA Agonist DMHTJVA RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMHTJVA RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMHTS5G DI DMHTS5G DMHTS5G DN Fused heterocyclic compound 4 DMHTS5G TI TT7RJY8 DMHTS5G TN Xanthine dehydrogenase/oxidase (XDH) DMHTS5G MA Inhibitor DMHTS5G RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMHTS5G RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMHTV47 DI DMHTV47 DMHTV47 DN Pyrazolo[1,5-a]pyrimidine derivative 3 DMHTV47 TI TT6OEDT DMHTV47 TN Cannabinoid receptor 1 (CB1) DMHTV47 MA Antagonist DMHTV47 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMHTV47 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMHTVGM DI DMHTVGM DMHTVGM DN N-substituted pyrazole derivative 1 DMHTVGM TI TTXJ47W DMHTVGM TN Metabotropic glutamate receptor 2 (mGluR2) DMHTVGM MA Antagonist DMHTVGM RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMHTVGM RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMHUIXR DI DMHUIXR DMHUIXR DN Heteroaryl-carboxamide derivative 4 DMHUIXR TI TTCZOF2 DMHUIXR TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMHUIXR MA Inhibitor DMHUIXR RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMHUIXR RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMHV3ES DI DMHV3ES DMHV3ES DN PMID28092474-Compound-32v DMHV3ES TI TT5ZKDI DMHV3ES TN Histone deacetylase 6 (HDAC6) DMHV3ES MA Inhibitor DMHV3ES RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHV3ES RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHV3ES DI DMHV3ES DMHV3ES DN PMID28092474-Compound-32v DMHV3ES TI TT6R7JZ DMHV3ES TN Histone deacetylase 1 (HDAC1) DMHV3ES MA Inhibitor DMHV3ES RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMHV3ES RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMHV75N DI DMHV75N DMHV75N DN PMID28460551-Compound-1 DMHV75N TI TT8FYO9 DMHV75N TN Platelet-derived growth factor receptor alpha (PDGFRA) DMHV75N MA Inhibitor DMHV75N RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMHV75N RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMHVZ4M DI DMHVZ4M DMHVZ4M DN Methylsulfonylbenzamide derivative 2 DMHVZ4M TI TT4G2JS DMHVZ4M TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMHVZ4M MA Inhibitor DMHVZ4M RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMHVZ4M RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMHWNSD DI DMHWNSD DMHWNSD DN Pyrrolo[2,3-d]pyrimidine derivative 22 DMHWNSD TI TTGM6VW DMHWNSD TN Tyrosine-protein kinase BTK (ATK) DMHWNSD MA Inhibitor DMHWNSD RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMHWNSD RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMHWUEV DI DMHWUEV DMHWUEV DN PMID27539678-Compound-8 DMHWUEV TI TT3M2WO DMHWUEV TN Sphingosine kinase (SphK) DMHWUEV MA Inhibitor DMHWUEV RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMHWUEV RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMHWV67 DI DMHWV67 DMHWV67 DN PMID27321640-Compound-74 DMHWV67 TI TTJGW1Z DMHWV67 TN Phosphodiesterase 2A (PDE2A) DMHWV67 MA Inhibitor DMHWV67 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMHWV67 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMHX5VO DI DMHX5VO DMHX5VO DN Benzoimidazole derivative 2 DMHX5VO TI TTZCRP3 DMHX5VO TN ERK activator kinase (MEK) DMHX5VO MA Inhibitor DMHX5VO RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMHX5VO RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMHX8OF DI DMHX8OF DMHX8OF DN PMID27788040-Compound-6 DMHX8OF TI TTV1C0Z DMHX8OF TN Neuropeptide S receptor (NPSR) DMHX8OF MA Antagonist DMHX8OF RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMHX8OF RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMHXFCQ DI DMHXFCQ DMHXFCQ DN Benzothiazole analog 1 DMHXFCQ TI TTULVH8 DMHXFCQ TN Tyrosinase (TYR) DMHXFCQ MA Inhibitor DMHXFCQ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMHXFCQ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMHXFGU DI DMHXFGU DMHXFGU DN PMID26651364-Compound-48 DMHXFGU TI TTTCRU2 DMHXFGU TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMHXFGU MA Antagonist DMHXFGU RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMHXFGU RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMHXKFB DI DMHXKFB DMHXKFB DN 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1 DMHXKFB TI TT7HF4W DMHXKFB TN Cyclin-dependent kinase 2 (CDK2) DMHXKFB MA Inhibitor DMHXKFB RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMHXKFB RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMHXKFB DI DMHXKFB DMHXKFB DN 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivative 1 DMHXKFB TI TT1LVF2 DMHXKFB TN Cyclin-dependent kinase 9 (CDK9) DMHXKFB MA Inhibitor DMHXKFB RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMHXKFB RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMHXMB4 DI DMHXMB4 DMHXMB4 DN Piperidine derivative 2 DMHXMB4 TI TTQR74A DMHXMB4 TN Proteinase activated receptor 2 (PAR2) DMHXMB4 MA Antagonist DMHXMB4 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMHXMB4 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMHXT12 DI DMHXT12 DMHXT12 DN PMID26293650-Compound-34 DMHXT12 TI TTH5TC2 DMHXT12 TN NF-kappa-B-activating kinase (TBK1) DMHXT12 MA Inhibitor DMHXT12 RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMHXT12 RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMHXWZB DI DMHXWZB DMHXWZB DN Pyridine-carboximide derivative 2 DMHXWZB TI TTF8P9I DMHXWZB TN Diacylglycerol acyltransferase 1 (DGAT1) DMHXWZB MA Inhibitor DMHXWZB RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMHXWZB RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMHYDM7 DI DMHYDM7 DMHYDM7 DN PMID25656651-Compound-36b DMHYDM7 TI TTIV39N DMHYDM7 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMHYDM7 MA Inhibitor DMHYDM7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMHYDM7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMHYDM7 DI DMHYDM7 DMHYDM7 DN PMID25656651-Compound-36b DMHYDM7 TI TTS7G69 DMHYDM7 TN Fusion protein Bcr-Abl (Bcr-Abl) DMHYDM7 MA Inhibitor DMHYDM7 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMHYDM7 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMHYIAV DI DMHYIAV DMHYIAV DN 2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1 DMHYIAV TI TTA592U DMHYIAV TN Urate anion exchanger 1 (URAT1) DMHYIAV MA Inhibitor DMHYIAV RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMHYIAV RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMHZ8N1 DI DMHZ8N1 DMHZ8N1 DN PMID26560530-Compound-50 DMHZ8N1 TI TT2F4OL DMHZ8N1 TN Tissue transglutaminase (TG2) DMHZ8N1 MA Inhibitor DMHZ8N1 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMHZ8N1 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMHZJEA DI DMHZJEA DMHZJEA DN US8937193-compound-7 DMHZJEA TI TTGT9C7 DMHZJEA TN Bcl-2-related protein A1 (BCL2A1) DMHZJEA MA Inhibitor DMHZJEA RN Apogossypolone derivatives as anticancer agents. US8937193. DMHZJEA RU http://www.freepatentsonline.com/US8937193.html DMHZLSO DI DMHZLSO DMHZLSO DN Pyrido[2,3-d]pyrimidine derivative 1 DMHZLSO TI TT6OEDT DMHZLSO TN Cannabinoid receptor 1 (CB1) DMHZLSO MA Antagonist DMHZLSO RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMHZLSO RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMI04GC DI DMI04GC DMI04GC DN PMID29473428-Compound-17 DMI04GC TI TTZJYKH DMI04GC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMI04GC RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMI04GC RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMI0AW7 DI DMI0AW7 DMI0AW7 DN Pyrrolo[1,2-f]triazine derivative 1 DMI0AW7 TI TTDIGC1 DMI0AW7 TN Dipeptidyl peptidase 4 (DPP-4) DMI0AW7 MA Inhibitor DMI0AW7 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMI0AW7 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMI0J7D DI DMI0J7D DMI0J7D DN Pyrazolopyrimidine derivative 3 DMI0J7D TI TTHS256 DMI0J7D TN Metabotropic glutamate receptor 5 (mGluR5) DMI0J7D MA Modulator DMI0J7D RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMI0J7D RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMI0WHE DI DMI0WHE DMI0WHE DN PMID30185082-Compound-28 DMI0WHE TI TT9NXW4 DMI0WHE TN Sigma intracellular receptor 2 (TMEM97) DMI0WHE MA Ligand DMI0WHE RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMI0WHE RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMI0YWU DI DMI0YWU DMI0YWU DN PMID25666693-Compound-13 DMI0YWU TI TTMI6F5 DMI0YWU TN Transient receptor potential cation channel V1 (TRPV1) DMI0YWU MA Antagonist DMI0YWU RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMI0YWU RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMI1BKA DI DMI1BKA DMI1BKA DN Coumarin/resveratrol hybrid derivative 1 DMI1BKA TI TTGP7BY DMI1BKA TN Monoamine oxidase type B (MAO-B) DMI1BKA MA Inhibitor DMI1BKA RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMI1BKA RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMI1OWK DI DMI1OWK DMI1OWK DN Imidazopyridine and triazolopyridine compound 4 DMI1OWK TI TTHS256 DMI1OWK TN Metabotropic glutamate receptor 5 (mGluR5) DMI1OWK MA Modulator DMI1OWK RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMI1OWK RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMI1Z7D DI DMI1Z7D DMI1Z7D DN PMID25656651-Compound-19b DMI1Z7D TI TTS7G69 DMI1Z7D TN Fusion protein Bcr-Abl (Bcr-Abl) DMI1Z7D MA Inhibitor DMI1Z7D RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMI1Z7D RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMI1Z7D DI DMI1Z7D DMI1Z7D DN PMID25656651-Compound-19b DMI1Z7D TI TTIV39N DMI1Z7D TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMI1Z7D MA Inhibitor DMI1Z7D RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMI1Z7D RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMI2T1D DI DMI2T1D DMI2T1D DN Cyclohexyl-ethyl-substituted diaza and triaza-tricyclic compound 1 DMI2T1D TI TTZJYKH DMI2T1D TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMI2T1D MA Antagonist DMI2T1D RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMI2T1D RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMI30GA DI DMI30GA DMI30GA DN PMID26004420-Compound-WO2015017305D DMI30GA TI TTJ13ST DMI30GA TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMI30GA MA Inhibitor DMI30GA RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMI30GA RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMI31OD DI DMI31OD DMI31OD DN Benzothiazine-carboxamide compound 3 DMI31OD TI TTQR74A DMI31OD TN Proteinase activated receptor 2 (PAR2) DMI31OD MA Antagonist DMI31OD RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMI31OD RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMI3ELU DI DMI3ELU DMI3ELU DN PMID29649907-Compound-39 DMI3ELU TI TTS4UGC DMI3ELU TN Farnesoid X-activated receptor (FXR) DMI3ELU MA Agonist DMI3ELU RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMI3ELU RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMI3QLT DI DMI3QLT DMI3QLT DN PMID26815044-Compound-H DMI3QLT TI TTULVH8 DMI3QLT TN Tyrosinase (TYR) DMI3QLT MA Inhibitor DMI3QLT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMI3QLT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMI3X14 DI DMI3X14 DMI3X14 DN Thiazole carboxamide derivative 4 DMI3X14 TI TTCZOF2 DMI3X14 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMI3X14 MA Inhibitor DMI3X14 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMI3X14 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMI3XPJ DI DMI3XPJ DMI3XPJ DN Imidazopyridine derivative 7 DMI3XPJ TI TTYLQ8V DMI3XPJ TN Prostaglandin E synthase (PTGES) DMI3XPJ MA Inhibitor DMI3XPJ RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMI3XPJ RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMI3YO7 DI DMI3YO7 DMI3YO7 DN Iodophenyl-N-methyl-N-fluoroalkyl-3-isoquinoline carboxamide derivative 1 DMI3YO7 TI TTPTXIN DMI3YO7 TN Translocator protein (TSPO) DMI3YO7 MA Ligand DMI3YO7 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMI3YO7 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMI4KBC DI DMI4KBC DMI4KBC DN 2-PAM derivative 1 DMI4KBC TI TT1RS9F DMI4KBC TN Acetylcholinesterase (AChE) DMI4KBC MA Reactivator DMI4KBC RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMI4KBC RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMI4MJ2 DI DMI4MJ2 DMI4MJ2 DN Terpyridineplatinum(II) complexe 5 DMI4MJ2 TI TTR7UJ3 DMI4MJ2 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMI4MJ2 MA Inhibitor DMI4MJ2 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMI4MJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMI4US6 DI DMI4US6 DMI4US6 DN PMID28350212-Compound-19 DMI4US6 TI TTZS04O DMI4US6 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMI4US6 MA Inhibitor DMI4US6 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMI4US6 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMI4XBC DI DMI4XBC DMI4XBC DN Aryl azepine derivative 2 DMI4XBC TI TT9NXW4 DMI4XBC TN Sigma intracellular receptor 2 (TMEM97) DMI4XBC MA Ligand DMI4XBC RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMI4XBC RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMI5VZN DI DMI5VZN DMI5VZN DN 1,3,4-oxadiazole derivative 5 DMI5VZN TI TT23XQV DMI5VZN TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMI5VZN MA Inhibitor DMI5VZN RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMI5VZN RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMI61KF DI DMI61KF DMI61KF DN PMID27977313-Compound-47 DMI61KF TI TTR7UJ3 DMI61KF TN Cytoplasmic thioredoxin reductase (TXNRD1) DMI61KF MA Inhibitor DMI61KF RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMI61KF RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMI627Z DI DMI627Z DMI627Z DN Heteroaryl-carboxamide derivative 9 DMI627Z TI TTCZOF2 DMI627Z TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMI627Z MA Inhibitor DMI627Z RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMI627Z RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMI6VG9 DI DMI6VG9 DMI6VG9 DN Tetra-hydro-triazolopyrimidine derivative 2 DMI6VG9 TI TTPLTSQ DMI6VG9 TN Neutrophil elastase (NE) DMI6VG9 MA Inhibitor DMI6VG9 RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DMI6VG9 RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DMI732U DI DMI732U DMI732U DN Heteroaromatic ring derivative 1 DMI732U TI TTSCIM2 DMI732U TN Extracellular lysophospholipase D (E-NPP2) DMI732U MA Inhibitor DMI732U RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMI732U RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMI7KG4 DI DMI7KG4 DMI7KG4 DN Cyclic peptidomimetic derivative 3 DMI7KG4 TI TT23XQV DMI7KG4 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMI7KG4 MA Inhibitor DMI7KG4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMI7KG4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMI7W3K DI DMI7W3K DMI7W3K DN Imidazole derivative 10 DMI7W3K TI TTN9T81 DMI7W3K TN Arachidonate 15-lipoxygenase (15-LOX) DMI7W3K MA Inhibitor DMI7W3K RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMI7W3K RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMI8CB3 DI DMI8CB3 DMI8CB3 DN PMID25666693-Compound-25 DMI8CB3 TI TTMI6F5 DMI8CB3 TN Transient receptor potential cation channel V1 (TRPV1) DMI8CB3 MA Antagonist DMI8CB3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMI8CB3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMI8ZBK DI DMI8ZBK DMI8ZBK DN PMID28092474-Compound-33p DMI8ZBK TI TT5ZKDI DMI8ZBK TN Histone deacetylase 6 (HDAC6) DMI8ZBK MA Inhibitor DMI8ZBK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMI8ZBK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMI8ZBK DI DMI8ZBK DMI8ZBK DN PMID28092474-Compound-33p DMI8ZBK TI TT6R7JZ DMI8ZBK TN Histone deacetylase 1 (HDAC1) DMI8ZBK MA Inhibitor DMI8ZBK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMI8ZBK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMI93AX DI DMI93AX DMI93AX DN PMID25468267-Compound-54 DMI93AX TI TT0RGE9 DMI93AX TN Lysine-specific demethylase 4 (KDM4) DMI93AX MA Inhibitor DMI93AX RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMI93AX RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMIA3GH DI DMIA3GH DMIA3GH DN PMID27977313-Compound-18 DMIA3GH TI TTR7UJ3 DMIA3GH TN Cytoplasmic thioredoxin reductase (TXNRD1) DMIA3GH MA Inhibitor DMIA3GH RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMIA3GH RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMIAB94 DI DMIAB94 DMIAB94 DN Benzyl pyrrolyloxoacetamide derivative 1 DMIAB94 TI TTDP1UC DMIAB94 TN Fatty acid amide hydrolase (FAAH) DMIAB94 MA Inhibitor DMIAB94 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMIAB94 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMIAGPX DI DMIAGPX DMIAGPX DN US10022354, Example 5 DMIAGPX TI TTIG67W DMIAGPX TN Lysine-specific demethylase 5A (KDM5A) DMIAGPX MA Inhibitor DMIAGPX RN IRE-1 inhibitors DMIAGPX RU http://www.freepatentsonline.com/US10022354.html DMIAJMO DI DMIAJMO DMIAJMO DN Imidazopyridazine derivative 4 DMIAJMO TI TTQR74A DMIAJMO TN Proteinase activated receptor 2 (PAR2) DMIAJMO MA Antagonist DMIAJMO RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMIAJMO RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMIAV5M DI DMIAV5M DMIAV5M DN PMID25553724-Compound-US2011806744710 DMIAV5M TI TTSXVID DMIAV5M TN Nuclear factor NF-kappa-B (NFKB) DMIAV5M MA Inhibitor DMIAV5M RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMIAV5M RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMIBRE5 DI DMIBRE5 DMIBRE5 DN Quinazoline derivative 7 DMIBRE5 TI TTPTXIN DMIBRE5 TN Translocator protein (TSPO) DMIBRE5 MA Ligand DMIBRE5 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMIBRE5 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMIBZ2H DI DMIBZ2H DMIBZ2H DN PMID28394193-Compound-18 DMIBZ2H TI TT9MZCQ DMIBZ2H TN Enhancer of zeste homolog 2 (EZH2) DMIBZ2H MA Inhibitor DMIBZ2H RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMIBZ2H RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMIC86N DI DMIC86N DMIC86N DN Quinoline derivative 9 DMIC86N TI TTXJ47W DMIC86N TN Metabotropic glutamate receptor 2 (mGluR2) DMIC86N MA Antagonist DMIC86N RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMIC86N RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMICBFK DI DMICBFK DMICBFK DN PMID27977313-Compound-Figure6C DMICBFK TI TTR7UJ3 DMICBFK TN Cytoplasmic thioredoxin reductase (TXNRD1) DMICBFK MA Inhibitor DMICBFK RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMICBFK RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMICDV6 DI DMICDV6 DMICDV6 DN PMID29671355-Compound-72a DMICDV6 TI TTTQGH8 DMICDV6 TN Histone deacetylase 4 (HDAC4) DMICDV6 MA Inhibitor DMICDV6 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMICDV6 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMICZLS DI DMICZLS DMICZLS DN Pyridine derivative 16 DMICZLS TI TTHS256 DMICZLS TN Metabotropic glutamate receptor 5 (mGluR5) DMICZLS MA Modulator DMICZLS RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMICZLS RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMIDN6T DI DMIDN6T DMIDN6T DN Pyrazole derivative 6 DMIDN6T TI TT6OEDT DMIDN6T TN Cannabinoid receptor 1 (CB1) DMIDN6T MA Antagonist DMIDN6T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIDN6T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMIDUB4 DI DMIDUB4 DMIDUB4 DN Acyl piperidine derivative 3 DMIDUB4 TI TT2F4OL DMIDUB4 TN Tissue transglutaminase (TG2) DMIDUB4 MA Inhibitor DMIDUB4 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMIDUB4 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMIE0MR DI DMIE0MR DMIE0MR DN PMID25980951-Compound-21 DMIE0MR TI TTR7B60 DMIE0MR TN X-linked inhibitor of apoptosis protein (XIAP) DMIE0MR MA Antagonist DMIE0MR RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMIE0MR RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMIE0MR DI DMIE0MR DMIE0MR DN PMID25980951-Compound-21 DMIE0MR TI TTQ5LRD DMIE0MR TN Cellular inhibitor of apoptosis 1 (BIRC2) DMIE0MR MA Antagonist DMIE0MR RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMIE0MR RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMIE7U3 DI DMIE7U3 DMIE7U3 DN Mannoside derivative 1 DMIE7U3 TI TTTCRU2 DMIE7U3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMIE7U3 MA Antagonist DMIE7U3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMIE7U3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMIES9B DI DMIES9B DMIES9B DN Secondary and tertiary (hetero)arylamide derivative 2 DMIES9B TI TT3WG5C DMIES9B TN Monoamine oxidase type A (MAO-A) DMIES9B MA Inhibitor DMIES9B RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMIES9B RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMIEZ6L DI DMIEZ6L DMIEZ6L DN 1,3,4-oxadiazole derivative 6 DMIEZ6L TI TT23XQV DMIEZ6L TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMIEZ6L MA Inhibitor DMIEZ6L RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMIEZ6L RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMIF7KG DI DMIF7KG DMIF7KG DN PMID27977313-Compound-29 DMIF7KG TI TTR7UJ3 DMIF7KG TN Cytoplasmic thioredoxin reductase (TXNRD1) DMIF7KG MA Inhibitor DMIF7KG RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMIF7KG RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMIFH8T DI DMIFH8T DMIFH8T DN PMID25726713-Compound-32 DMIFH8T TI TT8J1S3 DMIFH8T TN Smoothened homolog (SMO) DMIFH8T MA Inhibitor DMIFH8T RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMIFH8T RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMIFTUN DI DMIFTUN DMIFTUN DN PMID27376512-Compound-Table1Example11 DMIFTUN TI TT6S2FE DMIFTUN TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMIFTUN MA Inhibitor DMIFTUN RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMIFTUN RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMIFV58 DI DMIFV58 DMIFV58 DN PMID26924192-Compound-31 DMIFV58 TI TTRA6BO DMIFV58 TN Bromodomain-containing protein 4 (BRD4) DMIFV58 MA Inhibitor DMIFV58 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMIFV58 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMIFVXE DI DMIFVXE DMIFVXE DN PMID25482888-Compound-16 DMIFVXE TI TTDIGC1 DMIFVXE TN Dipeptidyl peptidase 4 (DPP-4) DMIFVXE MA Inhibitor DMIFVXE RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMIFVXE RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMIFZLG DI DMIFZLG DMIFZLG DN Dihydropyridine compound 4 DMIFZLG TI TT4DXQT DMIFZLG TN Proto-oncogene c-Ret (RET) DMIFZLG MA Inhibitor DMIFZLG RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMIFZLG RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMIG0TQ DI DMIG0TQ DMIG0TQ DN Heteroaryl-pyrazole derivative 2 DMIG0TQ TI TTXJ47W DMIG0TQ TN Metabotropic glutamate receptor 2 (mGluR2) DMIG0TQ MA Antagonist DMIG0TQ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMIG0TQ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMIGS81 DI DMIGS81 DMIGS81 DN Indole-based analog 1 DMIGS81 TI TTL53M6 DMIGS81 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMIGS81 MA Inhibitor DMIGS81 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMIGS81 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMIH0F4 DI DMIH0F4 DMIH0F4 DN Pyrazolo[3,4-d]pyrimidine derivative 5 DMIH0F4 TI TT4DXQT DMIH0F4 TN Proto-oncogene c-Ret (RET) DMIH0F4 MA Inhibitor DMIH0F4 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMIH0F4 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMIHRG4 DI DMIHRG4 DMIHRG4 DN PMID25435179-Compound-WO2013059587(V, 1st set) DMIHRG4 TI TTSCO7R DMIHRG4 TN NAD-dependent deacetylase sirtuin (SIRT) DMIHRG4 MA Inhibitor DMIHRG4 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMIHRG4 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMIHRV9 DI DMIHRV9 DMIHRV9 DN Pyrrolidine derivative 11 DMIHRV9 TI TTSCIUP DMIHRV9 TN Oxytocin receptor (OTR) DMIHRV9 MA Antagonist DMIHRV9 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMIHRV9 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMIJGLB DI DMIJGLB DMIJGLB DN PMID27109571-Compound-19 DMIJGLB TI TTNT2S6 DMIJGLB TN Fatty acid-binding protein 5 (FABP5) DMIJGLB MA Inhibitor DMIJGLB RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMIJGLB RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMIJGLB DI DMIJGLB DMIJGLB DN PMID27109571-Compound-19 DMIJGLB TI TTHWMFZ DMIJGLB TN Fatty acid-binding protein 4 (FABP4) DMIJGLB MA Inhibitor DMIJGLB RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMIJGLB RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMIJQZV DI DMIJQZV DMIJQZV DN PMID28092474-Compound-33b DMIJQZV TI TT5ZKDI DMIJQZV TN Histone deacetylase 6 (HDAC6) DMIJQZV MA Inhibitor DMIJQZV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMIJQZV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMIJQZV DI DMIJQZV DMIJQZV DN PMID28092474-Compound-33b DMIJQZV TI TT6R7JZ DMIJQZV TN Histone deacetylase 1 (HDAC1) DMIJQZV MA Inhibitor DMIJQZV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMIJQZV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMIKAJC DI DMIKAJC DMIKAJC DN PMID27539678-Compound-11 DMIKAJC TI TTOHFIY DMIKAJC TN Sphingosine kinase 1 (SPHK1) DMIKAJC MA Inhibitor DMIKAJC RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMIKAJC RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMIKBV5 DI DMIKBV5 DMIKBV5 DN Isoxazoles and isoxazoline derivative 6 DMIKBV5 TI TTIY56R DMIKBV5 TN Kynurenine 3-hydroxylase (KMO) DMIKBV5 MA Inhibitor DMIKBV5 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMIKBV5 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMIKMBO DI DMIKMBO DMIKMBO DN Imidazopyridine acetamide analog 2 DMIKMBO TI TTPTXIN DMIKMBO TN Translocator protein (TSPO) DMIKMBO MA Ligand DMIKMBO RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMIKMBO RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMIKRCM DI DMIKRCM DMIKRCM DN PMID28074661-Compound-US20120264760C88 DMIKRCM TI TTL7C8Q DMIKRCM TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMIKRCM MA Inhibitor DMIKRCM RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMIKRCM RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMIKSVG DI DMIKSVG DMIKSVG DN Azetidine derivative 3 DMIKSVG TI TT6OEDT DMIKSVG TN Cannabinoid receptor 1 (CB1) DMIKSVG MA Antagonist DMIKSVG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIKSVG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMIKTVL DI DMIKTVL DMIKTVL DN PMID27841045-Compound-131 DMIKTVL TI TT7RJY8 DMIKTVL TN Xanthine dehydrogenase/oxidase (XDH) DMIKTVL MA Inhibitor DMIKTVL RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMIKTVL RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMIKUN9 DI DMIKUN9 DMIKUN9 DN Pyrazole and thiophene derivative 3 DMIKUN9 TI TTRA6BO DMIKUN9 TN Bromodomain-containing protein 4 (BRD4) DMIKUN9 MA Inhibitor DMIKUN9 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMIKUN9 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMIKZXD DI DMIKZXD DMIKZXD DN Mannoside derivative 9 DMIKZXD TI TTTCRU2 DMIKZXD TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMIKZXD MA Antagonist DMIKZXD RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMIKZXD RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMILUT8 DI DMILUT8 DMILUT8 DN PMID26394986-Compound-57 DMILUT8 TI TTLRFIH DMILUT8 TN Signal transducer and activator of transcription 5 (STAT5) DMILUT8 MA Inhibitor DMILUT8 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMILUT8 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMILY1P DI DMILY1P DMILY1P DN US9598431, 2 DMILY1P TI TTGB2LZ DMILY1P TN RAR-related orphan receptor-beta (RORB) DMILY1P MA Inhibitor DMILY1P RN Compounds useful for inhibiting ROR-gamma-t. US9598431. DMILY1P RU http://www.freepatentsonline.com/US9598431.html DMIM8UF DI DMIM8UF DMIM8UF DN PMID26004420-Compound-WO2013062900B DMIM8UF TI TTJ13ST DMIM8UF TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMIM8UF MA Inhibitor DMIM8UF RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMIM8UF RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMIM9EY DI DMIM9EY DMIM9EY DN Resorcinol compound 4 DMIM9EY TI TTULVH8 DMIM9EY TN Tyrosinase (TYR) DMIM9EY MA Inhibitor DMIM9EY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMIM9EY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMIMFND DI DMIMFND DMIMFND DN PMID27019002-Compound-43b DMIMFND TI TTNR0UQ DMIMFND TN Lysine-specific histone demethylase 1 (LSD) DMIMFND MA Inhibitor DMIMFND RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIMFND RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMINBJM DI DMINBJM DMINBJM DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 DMINBJM TI TTJGW1Z DMINBJM TN Phosphodiesterase 2A (PDE2A) DMINBJM MA Inhibitor DMINBJM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMINBJM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMINBJM DI DMINBJM DMINBJM DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 7 DMINBJM TI TTJW4LU DMINBJM TN Phosphodiesterase 10A (PDE10) DMINBJM MA Inhibitor DMINBJM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMINBJM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMINE6V DI DMINE6V DMINE6V DN 2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V TI TTALN9W DMINE6V TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMINE6V MA Inhibitor DMINE6V RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMINE6V RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMINE6V DI DMINE6V DMINE6V DN 2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V TI TTZJYKH DMINE6V TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMINE6V MA Inhibitor DMINE6V RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMINE6V RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMINE6V DI DMINE6V DMINE6V DN 2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V TI TTXNCBV DMINE6V TN Tryptophan 2,3-dioxygenase (TDO) DMINE6V MA Inhibitor DMINE6V RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMINE6V RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMINM8F DI DMINM8F DMINM8F DN Maleimides derivative 1 DMINM8F TI TTRZQE3 DMINM8F TN Glycogen synthase kinase-3 alpha (GSK-3A) DMINM8F MA Inhibitor DMINM8F RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMINM8F RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMINUDB DI DMINUDB DMINUDB DN PMID26651364-Compound-125 DMINUDB TI TTTCRU2 DMINUDB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMINUDB MA Antagonist DMINUDB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMINUDB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMINXMY DI DMINXMY DMINXMY DN CID 138805970 DMINXMY TI TT3KYWB DMINXMY TN Ribosomal protein S6 kinase alpha-6 (RSK6) DMINXMY MA Inhibitor DMINXMY RN Substituted tetrahydropyrido[3,2:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors. US9771366. DMINXMY RU http://www.freepatentsonline.com/US9771366.html DMIO8J3 DI DMIO8J3 DMIO8J3 DN PMID27019002-Compound-48 DMIO8J3 TI TTNR0UQ DMIO8J3 TN Lysine-specific histone demethylase 1 (LSD) DMIO8J3 MA Inhibitor DMIO8J3 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIO8J3 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMIO8J3 DI DMIO8J3 DMIO8J3 DN PMID27019002-Compound-48 DMIO8J3 TI TT8VP2T DMIO8J3 TN Lysine-specific histone demethylase 1B (KDM1B) DMIO8J3 MA Inhibitor DMIO8J3 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIO8J3 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMIOJD6 DI DMIOJD6 DMIOJD6 DN Pyrrolidine derivative 7 DMIOJD6 TI TT9O6WS DMIOJD6 TN Glucagon receptor (GCGR) DMIOJD6 MA Antagonist DMIOJD6 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMIOJD6 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMIPFO3 DI DMIPFO3 DMIPFO3 DN PMID25666693-Compound-69 DMIPFO3 TI TTMI6F5 DMIPFO3 TN Transient receptor potential cation channel V1 (TRPV1) DMIPFO3 MA Antagonist DMIPFO3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMIPFO3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMIPVYW DI DMIPVYW DMIPVYW DN Biphenyl derivative 4 DMIPVYW TI TT9JNIC DMIPVYW TN Histamine H3 receptor (H3R) DMIPVYW RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMIPVYW RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMIQ1PL DI DMIQ1PL DMIQ1PL DN Sulfonamide derivative 17 DMIQ1PL TI TT3M2WO DMIQ1PL TN Sphingosine kinase (SphK) DMIQ1PL MA Inhibitor DMIQ1PL RN Sulfonamide inhibitors: a patent review 2013-present.Expert Opin Ther Pat. 2018 Jul;28(7):541-549. DMIQ1PL RU https://www.ncbi.nlm.nih.gov/pubmed/29886770 DMIQ263 DI DMIQ263 DMIQ263 DN PMID29053063-Compound-7f DMIQ263 TI TTZ963I DMIQ263 TN Monoglyceride lipase (MAGL) DMIQ263 MA Inhibitor DMIQ263 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMIQ263 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMIQO8N DI DMIQO8N DMIQO8N DN US8791257, 4 DMIQO8N TI TTR93NU DMIQO8N TN Casein kinase II alpha prime (CSNK2A2) DMIQO8N MA Inhibitor DMIQO8N RN Substituted pyrrolotriazines as protein kinase inhibitors. US8791257. DMIQO8N RU http://www.freepatentsonline.com/US8791257.html DMIQOY7 DI DMIQOY7 DMIQOY7 DN Diaryl morpholine derivative 1 DMIQOY7 TI TT6OEDT DMIQOY7 TN Cannabinoid receptor 1 (CB1) DMIQOY7 MA Antagonist DMIQOY7 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIQOY7 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMIQSDW DI DMIQSDW DMIQSDW DN Pyrimidine derivative 27 DMIQSDW TI TT0K1SC DMIQSDW TN 5-HT 2B receptor (HTR2B) DMIQSDW MA Antagonist DMIQSDW RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMIQSDW RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMIQSDW DI DMIQSDW DMIQSDW DN Pyrimidine derivative 27 DMIQSDW TI TTWJBZ5 DMIQSDW TN 5-HT 2C receptor (HTR2C) DMIQSDW MA Antagonist DMIQSDW RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMIQSDW RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMIQSDW DI DMIQSDW DMIQSDW DN Pyrimidine derivative 27 DMIQSDW TI TTJQOD7 DMIQSDW TN 5-HT 2A receptor (HTR2A) DMIQSDW MA Antagonist DMIQSDW RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMIQSDW RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMIS4H0 DI DMIS4H0 DMIS4H0 DN PMID27376512-Compound-Figure3CM DMIS4H0 TI TTJUALD DMIS4H0 TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMIS4H0 MA Inhibitor DMIS4H0 RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMIS4H0 RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMIS97T DI DMIS97T DMIS97T DN Pyrazole derivative 2 DMIS97T TI TT6OEDT DMIS97T TN Cannabinoid receptor 1 (CB1) DMIS97T MA Antagonist DMIS97T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMIS97T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMISJDH DI DMISJDH DMISJDH DN PMID26666989-Compound-Figure9bottomright DMISJDH TI TT8BUGW DMISJDH TN Glycogen phosphorylase (PYG) DMISJDH MA Inhibitor DMISJDH RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMISJDH RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMIT0H3 DI DMIT0H3 DMIT0H3 DN US9434727, 120 DMIT0H3 TI TT0C8BY DMIT0H3 TN Plasma retinol-binding protein (RBP4) DMIT0H3 MA Inhibitor DMIT0H3 RN Substituted 4-phenylpiperidines, their preparation and use. US9434727. DMIT0H3 RU http://www.freepatentsonline.com/US9434727.html DMITK03 DI DMITK03 DMITK03 DN Pyrrolo-pyrimidine derivative 4 DMITK03 TI TT4DXQT DMITK03 TN Proto-oncogene c-Ret (RET) DMITK03 MA Inhibitor DMITK03 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMITK03 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMITLPW DI DMITLPW DMITLPW DN Biphenyl mannoside derivative 10 DMITLPW TI TTTCRU2 DMITLPW TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMITLPW MA Antagonist DMITLPW RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMITLPW RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMITNWZ DI DMITNWZ DMITNWZ DN PMID25399762-Compound-Table1-C20 DMITNWZ TI TTGP7BY DMITNWZ TN Monoamine oxidase type B (MAO-B) DMITNWZ MA Inhibitor DMITNWZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMITNWZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMITOY6 DI DMITOY6 DMITOY6 DN US10087167, Compound 3003 DMITOY6 TI TTQFZWR DMITOY6 TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMITOY6 MA Inhibitor DMITOY6 RN Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167. DMITOY6 RU http://www.freepatentsonline.com/US10087167.html DMITU83 DI DMITU83 DMITU83 DN PMID26560530-Compound-17 DMITU83 TI TT2F4OL DMITU83 TN Tissue transglutaminase (TG2) DMITU83 MA Inhibitor DMITU83 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMITU83 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMITVUY DI DMITVUY DMITVUY DN Pyridine derivative 8 DMITVUY TI TTOHSBA DMITVUY TN Vascular endothelial growth factor A (VEGFA) DMITVUY MA Inhibitor DMITVUY RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMITVUY RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMITX1G DI DMITX1G DMITX1G DN Citalopram derivative 1 DMITX1G TI TTTIBOJ DMITX1G TN Histamine H1 receptor (H1R) DMITX1G MA Inhibitor DMITX1G RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMITX1G RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMITX1G DI DMITX1G DMITX1G DN Citalopram derivative 1 DMITX1G TI TT3ROYC DMITX1G TN Serotonin transporter (SERT) DMITX1G MA Inhibitor DMITX1G RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMITX1G RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMIULVJ DI DMIULVJ DMIULVJ DN Xanthine derivative 1 DMIULVJ TI TTDIGC1 DMIULVJ TN Dipeptidyl peptidase 4 (DPP-4) DMIULVJ MA Inhibitor DMIULVJ RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMIULVJ RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMIUPSA DI DMIUPSA DMIUPSA DN 1,2,4-triazolo[1,5a]pyridine derivative 1 DMIUPSA TI TTON5IT DMIUPSA TN Focal adhesion kinase 1 (FAK) DMIUPSA MA Inhibitor DMIUPSA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMIUPSA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMIUPSA DI DMIUPSA DMIUPSA DN 1,2,4-triazolo[1,5a]pyridine derivative 1 DMIUPSA TI TTT7PJU DMIUPSA TN Janus kinase 3 (JAK-3) DMIUPSA MA Inhibitor DMIUPSA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMIUPSA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMIUPSA DI DMIUPSA DMIUPSA DN 1,2,4-triazolo[1,5a]pyridine derivative 1 DMIUPSA TI TTRMX3V DMIUPSA TN Janus kinase 2 (JAK-2) DMIUPSA MA Inhibitor DMIUPSA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMIUPSA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMIUTQW DI DMIUTQW DMIUTQW DN Isoindoline derivative 5 DMIUTQW TI TTQ6VDM DMIUTQW TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMIUTQW MA Ligand DMIUTQW RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMIUTQW RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMIUTQW DI DMIUTQW DMIUTQW DN Isoindoline derivative 5 DMIUTQW TI TT5TPI6 DMIUTQW TN Opioid receptor sigma 1 (OPRS1) DMIUTQW MA Ligand DMIUTQW RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMIUTQW RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMIUTQW DI DMIUTQW DMIUTQW DN Isoindoline derivative 5 DMIUTQW TI TT9NXW4 DMIUTQW TN Sigma intracellular receptor 2 (TMEM97) DMIUTQW MA Ligand DMIUTQW RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMIUTQW RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMIV92A DI DMIV92A DMIV92A DN PMID26004420-Compound-WO2013028474A DMIV92A TI TTJ13ST DMIV92A TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMIV92A MA Inhibitor DMIV92A RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMIV92A RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMIVJ2W DI DMIVJ2W DMIVJ2W DN PMID25468267-Compound-50 DMIVJ2W TI TT0RGE9 DMIVJ2W TN Lysine-specific demethylase 4 (KDM4) DMIVJ2W MA Inhibitor DMIVJ2W RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMIVJ2W RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMIVJMO DI DMIVJMO DMIVJMO DN PMID25435285-Compound-25 DMIVJMO TI TTXJ47W DMIVJMO TN Metabotropic glutamate receptor 2 (mGluR2) DMIVJMO MA Antagonist DMIVJMO RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMIVJMO RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMIVK7D DI DMIVK7D DMIVK7D DN N-methylmethanesulfonamide derivative 1 DMIVK7D TI TTT7PJU DMIVK7D TN Janus kinase 3 (JAK-3) DMIVK7D MA Inhibitor DMIVK7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMIVK7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMIVK7D DI DMIVK7D DMIVK7D DN N-methylmethanesulfonamide derivative 1 DMIVK7D TI TTBYWP2 DMIVK7D TN TYK2 tyrosine kinase (TYK2) DMIVK7D MA Inhibitor DMIVK7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMIVK7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMIVK7D DI DMIVK7D DMIVK7D DN N-methylmethanesulfonamide derivative 1 DMIVK7D TI TT6DM01 DMIVK7D TN Janus kinase 1 (JAK-1) DMIVK7D MA Inhibitor DMIVK7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMIVK7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMIWEZH DI DMIWEZH DMIWEZH DN PMID30273516-Compound-12 DMIWEZH TI TTCW0KX DMIWEZH TN Glutaminase (GLS) DMIWEZH MA Inhibitor DMIWEZH RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMIWEZH RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMIWQZ5 DI DMIWQZ5 DMIWQZ5 DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 2 DMIWQZ5 TI TTSXVID DMIWQZ5 TN Nuclear factor NF-kappa-B (NFKB) DMIWQZ5 MA Inhibitor DMIWQZ5 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMIWQZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMIWY93 DI DMIWY93 DMIWY93 DN Phthalazine ketone derivative 3 DMIWY93 TI TTVDSZ0 DMIWY93 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMIWY93 MA Inhibitor DMIWY93 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMIWY93 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMIX1K0 DI DMIX1K0 DMIX1K0 DN PMID25666693-Compound-130 DMIX1K0 TI TTMI6F5 DMIX1K0 TN Transient receptor potential cation channel V1 (TRPV1) DMIX1K0 MA Antagonist DMIX1K0 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMIX1K0 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMIX90M DI DMIX90M DMIX90M DN PMID27215781-Compound-11 DMIX90M TI TTMSFAW DMIX90M TN Cannabinoid receptor 2 (CB2) DMIX90M RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMIX90M RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMIXERP DI DMIXERP DMIXERP DN Benzimidazole and imidazopyridine derivative 1 DMIXERP TI TTCZOF2 DMIXERP TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMIXERP MA Inhibitor DMIXERP RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMIXERP RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMIXK7Y DI DMIXK7Y DMIXK7Y DN Pyridoindole derivative 2 DMIXK7Y TI TTS7G69 DMIXK7Y TN Fusion protein Bcr-Abl (Bcr-Abl) DMIXK7Y MA Inhibitor DMIXK7Y RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMIXK7Y RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMIXQRY DI DMIXQRY DMIXQRY DN PMID25468267-Compound-55 DMIXQRY TI TTV8CRH DMIXQRY TN Lysine-specific demethylase 4C (KDM4C) DMIXQRY MA Inhibitor DMIXQRY RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMIXQRY RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMIXV6G DI DMIXV6G DMIXV6G DN Biaryl mannoside derivative 17 DMIXV6G TI TTTCRU2 DMIXV6G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMIXV6G MA Antagonist DMIXV6G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMIXV6G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMIXVNQ DI DMIXVNQ DMIXVNQ DN PMID26004420-Compound-US20140142115A DMIXVNQ TI TTJ13ST DMIXVNQ TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMIXVNQ MA Inhibitor DMIXVNQ RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMIXVNQ RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMIY68N DI DMIY68N DMIY68N DN US8921389, 22 DMIY68N TI TT9ISBX DMIY68N TN HIF-prolyl hydroxylase 2 (HPH-2) DMIY68N MA Inhibitor DMIY68N RN Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase. US8921389. DMIY68N RU http://www.freepatentsonline.com/US8921389.html DMIYCFE DI DMIYCFE DMIYCFE DN PMID27336223-Compound-15 DMIYCFE TI TT1Q3IE DMIYCFE TN Retinoic acid receptor gamma (RARG) DMIYCFE MA Agonist DMIYCFE RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMIYCFE RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMIYD41 DI DMIYD41 DMIYD41 DN Urea and carbamate bioisostere derivative 9 DMIYD41 TI TTL7C8Q DMIYD41 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMIYD41 MA Inhibitor DMIYD41 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMIYD41 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TTH6V3D DMIYUAN TN Cyclin-dependent kinase 1 (CDK1) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TT0PG8F DMIYUAN TN Cyclin-dependent kinase 4 (CDK4) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TT7HF4W DMIYUAN TN Cyclin-dependent kinase 2 (CDK2) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYUAN DI DMIYUAN DMIYUAN DN Isoquinoline 1,3-dione derivative 1 DMIYUAN TI TTO0FDJ DMIYUAN TN Cyclin-dependent kinase 6 (CDK6) DMIYUAN MA Inhibitor DMIYUAN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMIYUAN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMIYVOC DI DMIYVOC DMIYVOC DN 4-Carboxamido-isoindolinone derivative 5 DMIYVOC TI TTVDSZ0 DMIYVOC TN Poly [ADP-ribose] polymerase 1 (PARP1) DMIYVOC MA Inhibitor DMIYVOC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMIYVOC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMIYXS8 DI DMIYXS8 DMIYXS8 DN Benzoxazepine analog 1 DMIYXS8 TI TTPTXIN DMIYXS8 TN Translocator protein (TSPO) DMIYXS8 MA Ligand DMIYXS8 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMIYXS8 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMIZ64O DI DMIZ64O DMIZ64O DN PMID25553724-Compound-US2011799419010 DMIZ64O TI TTSXVID DMIZ64O TN Nuclear factor NF-kappa-B (NFKB) DMIZ64O MA Inhibitor DMIZ64O RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMIZ64O RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMIZL8D DI DMIZL8D DMIZL8D DN PMID26936077-Compound-34 DMIZL8D TI TTQR74A DMIZL8D TN Proteinase activated receptor 2 (PAR2) DMIZL8D MA Antagonist DMIZL8D RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMIZL8D RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMIZTKS DI DMIZTKS DMIZTKS DN Pyrimidine derivative 18 DMIZTKS TI TTNR0UQ DMIZTKS TN Lysine-specific histone demethylase 1 (LSD) DMIZTKS MA Inhibitor DMIZTKS RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMIZTKS RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMIZWM6 DI DMIZWM6 DMIZWM6 DN US8669361, 105 DMIZWM6 TI TTCGOIN DMIZWM6 TN PIM-3 protein kinase (PIM3) DMIZWM6 MA Inhibitor DMIZWM6 RN Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use. US8669361. DMIZWM6 RU http://www.freepatentsonline.com/US8669361.html DMJ02N1 DI DMJ02N1 DMJ02N1 DN PMID28394193-Compound-31 DMJ02N1 TI TT9MZCQ DMJ02N1 TN Enhancer of zeste homolog 2 (EZH2) DMJ02N1 MA Inhibitor DMJ02N1 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMJ02N1 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMJ04RQ DI DMJ04RQ DMJ04RQ DN Tacrine-caffeic acid hybrid derivative 1 DMJ04RQ TI TT1RS9F DMJ04RQ TN Acetylcholinesterase (AChE) DMJ04RQ MA Inhibitor DMJ04RQ RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMJ04RQ RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMJ0QLB DI DMJ0QLB DMJ0QLB DN PMID27410995-Compound-Figure3k DMJ0QLB TI TT7M3PI DMJ0QLB TN Ribosomal protein S6 kinase (S6K) DMJ0QLB MA Activator DMJ0QLB RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJ0QLB RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJ0WVR DI DMJ0WVR DMJ0WVR DN Heterocyclic derivative 14 DMJ0WVR TI TTCZOF2 DMJ0WVR TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMJ0WVR MA Inhibitor DMJ0WVR RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMJ0WVR RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMJ1C0A DI DMJ1C0A DMJ1C0A DN PMID30107136-Compound-Example52 DMJ1C0A TI TT23XQV DMJ1C0A TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMJ1C0A MA Inhibitor DMJ1C0A RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMJ1C0A RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMJ1K4Y DI DMJ1K4Y DMJ1K4Y DN PMID27019002-Compound-31b DMJ1K4Y TI TTNR0UQ DMJ1K4Y TN Lysine-specific histone demethylase 1 (LSD) DMJ1K4Y MA Inhibitor DMJ1K4Y RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMJ1K4Y RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMJ1KFO DI DMJ1KFO DMJ1KFO DN PMID28454500-Compound-91 DMJ1KFO TI TTA6ZN2 DMJ1KFO TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMJ1KFO MA Inhibitor DMJ1KFO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMJ1KFO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMJ1O5R DI DMJ1O5R DMJ1O5R DN PMID29671355-Compound-37 DMJ1O5R TI TTT6LFV DMJ1O5R TN Histone deacetylase 8 (HDAC8) DMJ1O5R MA Inhibitor DMJ1O5R RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJ1O5R RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJ1X53 DI DMJ1X53 DMJ1X53 DN PMID25991433-Compound-A3 DMJ1X53 TI TTHS0U8 DMJ1X53 TN Stress-activated protein kinase JNK2 (JNK2) DMJ1X53 MA Inhibitor DMJ1X53 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMJ1X53 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMJ1X53 DI DMJ1X53 DMJ1X53 DN PMID25991433-Compound-A3 DMJ1X53 TI TT0K6EO DMJ1X53 TN Stress-activated protein kinase JNK1 (JNK1) DMJ1X53 MA Inhibitor DMJ1X53 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMJ1X53 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMJ1Z7U DI DMJ1Z7U DMJ1Z7U DN PMID26815044-Compound-48 DMJ1Z7U TI TTULVH8 DMJ1Z7U TN Tyrosinase (TYR) DMJ1Z7U MA Inhibitor DMJ1Z7U RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJ1Z7U RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJ23AL DI DMJ23AL DMJ23AL DN PMID28394193-Compound-11 DMJ23AL TI TTJBYRU DMJ23AL TN EZH2 Y641F mutant (EZH2 Y641F) DMJ23AL MA Inhibitor DMJ23AL RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMJ23AL RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMJ2CIY DI DMJ2CIY DMJ2CIY DN Benzimidazole and imadazopyridine carboximidamide compound 2 DMJ2CIY TI TTZJYKH DMJ2CIY TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ2CIY MA Inhibitor DMJ2CIY RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ2CIY RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ2CRO DI DMJ2CRO DMJ2CRO DN Indazole derivative 4 DMJ2CRO TI TTZJYKH DMJ2CRO TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ2CRO RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ2CRO RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ3201 DI DMJ3201 DMJ3201 DN PMID26651364-Compound-116 DMJ3201 TI TTTCRU2 DMJ3201 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJ3201 MA Antagonist DMJ3201 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJ3201 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJ37V2 DI DMJ37V2 DMJ37V2 DN Amidopyrazole derivative 5 DMJ37V2 TI TTKFVXR DMJ37V2 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMJ37V2 MA Inhibitor DMJ37V2 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMJ37V2 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMJ3AZ4 DI DMJ3AZ4 DMJ3AZ4 DN Benzimidazole derivative 15 DMJ3AZ4 TI TTYLQ8V DMJ3AZ4 TN Prostaglandin E synthase (PTGES) DMJ3AZ4 MA Inhibitor DMJ3AZ4 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMJ3AZ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMJ3GX6 DI DMJ3GX6 DMJ3GX6 DN PMID26666989-Compound-Figure9toprightR02 DMJ3GX6 TI TT8BUGW DMJ3GX6 TN Glycogen phosphorylase (PYG) DMJ3GX6 MA Inhibitor DMJ3GX6 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMJ3GX6 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMJ3YDT DI DMJ3YDT DMJ3YDT DN PMID25666693-Compound-23 DMJ3YDT TI TTMI6F5 DMJ3YDT TN Transient receptor potential cation channel V1 (TRPV1) DMJ3YDT MA Antagonist DMJ3YDT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJ3YDT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJ3ZAI DI DMJ3ZAI DMJ3ZAI DN Lactam derivative 4 DMJ3ZAI TI TTF8P9I DMJ3ZAI TN Diacylglycerol acyltransferase 1 (DGAT1) DMJ3ZAI MA Inhibitor DMJ3ZAI RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMJ3ZAI RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMJ3ZP2 DI DMJ3ZP2 DMJ3ZP2 DN Pyrrolidine derivative 6 DMJ3ZP2 TI TT9O6WS DMJ3ZP2 TN Glucagon receptor (GCGR) DMJ3ZP2 MA Antagonist DMJ3ZP2 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMJ3ZP2 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMJ41UI DI DMJ41UI DMJ41UI DN Indoline derivative 1 DMJ41UI TI TT1RS9F DMJ41UI TN Acetylcholinesterase (AChE) DMJ41UI MA Inhibitor DMJ41UI RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMJ41UI RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMJ41UI DI DMJ41UI DMJ41UI DN Indoline derivative 1 DMJ41UI TI TTEB0GD DMJ41UI TN Cholinesterase (BCHE) DMJ41UI MA Inhibitor DMJ41UI RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMJ41UI RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMJ4ACP DI DMJ4ACP DMJ4ACP DN 1,2-diamino cyclopentane-based derivative 6 DMJ4ACP TI TT9N02I DMJ4ACP TN Orexin receptor type 2 (HCRTR2) DMJ4ACP MA Antagonist DMJ4ACP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMJ4ACP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMJ4ACP DI DMJ4ACP DMJ4ACP DN 1,2-diamino cyclopentane-based derivative 6 DMJ4ACP TI TT60Q8D DMJ4ACP TN Orexin receptor type 1 (HCRTR1) DMJ4ACP MA Antagonist DMJ4ACP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMJ4ACP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMJ4DRI DI DMJ4DRI DMJ4DRI DN PMID25656651-Compound-15b DMJ4DRI TI TTS7G69 DMJ4DRI TN Fusion protein Bcr-Abl (Bcr-Abl) DMJ4DRI MA Inhibitor DMJ4DRI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMJ4DRI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMJ4QD5 DI DMJ4QD5 DMJ4QD5 DN Pyrimidine derivative 11 DMJ4QD5 TI TTOHSBA DMJ4QD5 TN Vascular endothelial growth factor A (VEGFA) DMJ4QD5 MA Inhibitor DMJ4QD5 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMJ4QD5 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMJ4TZX DI DMJ4TZX DMJ4TZX DN Biphenyl derivative 2 DMJ4TZX TI TTZJYKH DMJ4TZX TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ4TZX MA Inhibitor DMJ4TZX RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ4TZX RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ51VZ DI DMJ51VZ DMJ51VZ DN Benzothiazine-carboxamide compound 1 DMJ51VZ TI TTQR74A DMJ51VZ TN Proteinase activated receptor 2 (PAR2) DMJ51VZ MA Antagonist DMJ51VZ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMJ51VZ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMJ53DR DI DMJ53DR DMJ53DR DN US10035778, Example 16 DMJ53DR TI TTIF29E DMJ53DR TN Integrin beta-8 (ITGB8) DMJ53DR MA Inhibitor DMJ53DR RN Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists. US10035778. DMJ53DR RU http://www.freepatentsonline.com/US10035778.html DMJ5LGA DI DMJ5LGA DMJ5LGA DN PMID25435285-Compound-41 DMJ5LGA TI TTXJ47W DMJ5LGA TN Metabotropic glutamate receptor 2 (mGluR2) DMJ5LGA MA Antagonist DMJ5LGA RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMJ5LGA RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMJ5X46 DI DMJ5X46 DMJ5X46 DN Heterocyclic derivative 1 DMJ5X46 TI TTHS256 DMJ5X46 TN Metabotropic glutamate receptor 5 (mGluR5) DMJ5X46 MA Modulator DMJ5X46 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMJ5X46 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMJ6CI5 DI DMJ6CI5 DMJ6CI5 DN PMID27977313-Compound-Figure4b DMJ6CI5 TI TTR7UJ3 DMJ6CI5 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMJ6CI5 MA Inhibitor DMJ6CI5 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMJ6CI5 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMJ6GU9 DI DMJ6GU9 DMJ6GU9 DN US10059720, Example 82 DMJ6GU9 TI TTY2KP7 DMJ6GU9 TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMJ6GU9 MA Inhibitor DMJ6GU9 RN Pyridine derivative. US10059720. DMJ6GU9 RU http://www.freepatentsonline.com/US10059720.html DMJ6IE5 DI DMJ6IE5 DMJ6IE5 DN Pyrrolidinyl urea derivative 12 DMJ6IE5 TI TTTDVOJ DMJ6IE5 TN Tropomyosin-related kinase A (TrkA) DMJ6IE5 MA Inhibitor DMJ6IE5 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMJ6IE5 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMJ71Q0 DI DMJ71Q0 DMJ71Q0 DN Pyrimidine benzenesulfonamide derivative 3 DMJ71Q0 TI TTIY56R DMJ71Q0 TN Kynurenine 3-hydroxylase (KMO) DMJ71Q0 MA Inhibitor DMJ71Q0 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMJ71Q0 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMJ76RC DI DMJ76RC DMJ76RC DN US9580418, Example 11 DMJ76RC TI TTCGOIN DMJ76RC TN PIM-3 protein kinase (PIM3) DMJ76RC MA Inhibitor DMJ76RC RN Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors. US9580418. DMJ76RC RU http://www.freepatentsonline.com/US9580418.html DMJ7F1Q DI DMJ7F1Q DMJ7F1Q DN Piperazine derivative 1 DMJ7F1Q TI TT6OEDT DMJ7F1Q TN Cannabinoid receptor 1 (CB1) DMJ7F1Q MA Antagonist DMJ7F1Q RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJ7F1Q RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJ80IZ DI DMJ80IZ DMJ80IZ DN Piperazine carbamate/urea derivative 5 DMJ80IZ TI TT9JNIC DMJ80IZ TN Histamine H3 receptor (H3R) DMJ80IZ MA Ligand DMJ80IZ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMJ80IZ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMJ8BAS DI DMJ8BAS DMJ8BAS DN PMID27539678-Compound-4 DMJ8BAS TI TT3M2WO DMJ8BAS TN Sphingosine kinase (SphK) DMJ8BAS MA Inhibitor DMJ8BAS RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMJ8BAS RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMJ8MXZ DI DMJ8MXZ DMJ8MXZ DN PMID25726713-Compound-26 DMJ8MXZ TI TT8J1S3 DMJ8MXZ TN Smoothened homolog (SMO) DMJ8MXZ MA Inhibitor DMJ8MXZ RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJ8MXZ RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJ8QTX DI DMJ8QTX DMJ8QTX DN Peptide analog 67 DMJ8QTX TI TTPLTSQ DMJ8QTX TN Neutrophil elastase (NE) DMJ8QTX MA Inhibitor DMJ8QTX RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMJ8QTX RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMJ8X7A DI DMJ8X7A DMJ8X7A DN Aromatic hydrazine carboxyimidoamide derivative 1 DMJ8X7A TI TTULVH8 DMJ8X7A TN Tyrosinase (TYR) DMJ8X7A MA Inhibitor DMJ8X7A RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJ8X7A RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJ8YZK DI DMJ8YZK DMJ8YZK DN Monofluorine derivative 1 DMJ8YZK TI TTZJYKH DMJ8YZK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ8YZK MA Antagonist DMJ8YZK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ8YZK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJ91EM DI DMJ91EM DMJ91EM DN Peptide analog 17 DMJ91EM TI TT68GPI DMJ91EM TN Proteasome beta-5 (PS beta-5) DMJ91EM MA Inhibitor DMJ91EM RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJ91EM RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJ91EM DI DMJ91EM DMJ91EM DN Peptide analog 17 DMJ91EM TI TTEAD9J DMJ91EM TN Proteasome beta-8 (PS beta-8) DMJ91EM MA Inhibitor DMJ91EM RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJ91EM RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJ98VG DI DMJ98VG DMJ98VG DN 3-acylidene-2-oxoindole derivative 2 DMJ98VG TI TT2F4OL DMJ98VG TN Tissue transglutaminase (TG2) DMJ98VG MA Inhibitor DMJ98VG RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMJ98VG RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMJ9U0E DI DMJ9U0E DMJ9U0E DN Azetidine derivative 5 DMJ9U0E TI TTZJYKH DMJ9U0E TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ9U0E MA Inhibitor DMJ9U0E RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJ9U0E RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJA1XC DI DMJA1XC DMJA1XC DN PMID25772215-Compound-US02014179750M3 DMJA1XC TI TT1ZAVI DMJA1XC TN Prostaglandin E2 receptor EP2 (PTGER2) DMJA1XC MA Antagonist DMJA1XC RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMJA1XC RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMJADXV DI DMJADXV DMJADXV DN PMID27551786-Compound-II DMJADXV TI TT26PHO DMJADXV TN Mineralocorticoid receptor (MR) DMJADXV MA Antagonist DMJADXV RN Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1.Expert Opin Ther Pat. 2016 Sep 14:1-4. DMJADXV RU https://www.ncbi.nlm.nih.gov/pubmed/27551786 DMJAUWG DI DMJAUWG DMJAUWG DN PMID28048944-Compound-4 DMJAUWG TI TTZN7RP DMJAUWG TN Rho-associated protein kinase 1 (ROCK1) DMJAUWG MA Inhibitor DMJAUWG RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMJAUWG RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMJAUWG DI DMJAUWG DMJAUWG DN PMID28048944-Compound-4 DMJAUWG TI TTGWKQJ DMJAUWG TN Rho-associated protein kinase 2 (ROCK2) DMJAUWG MA Inhibitor DMJAUWG RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMJAUWG RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMJAWOI DI DMJAWOI DMJAWOI DN Tricyclic compound 2 DMJAWOI TI TTT7PJU DMJAWOI TN Janus kinase 3 (JAK-3) DMJAWOI MA Inhibitor DMJAWOI RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJAWOI RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TTT7PJU DMJAZ7D TN Janus kinase 3 (JAK-3) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TTBYWP2 DMJAZ7D TN TYK2 tyrosine kinase (TYK2) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TTRMX3V DMJAZ7D TN Janus kinase 2 (JAK-2) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJAZ7D DI DMJAZ7D DMJAZ7D DN Tricyclic compound 11 DMJAZ7D TI TT6DM01 DMJAZ7D TN Janus kinase 1 (JAK-1) DMJAZ7D MA Inhibitor DMJAZ7D RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJAZ7D RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJBGHL DI DMJBGHL DMJBGHL DN Azaindole derivative 6 DMJBGHL TI TT7RJY8 DMJBGHL TN Xanthine dehydrogenase/oxidase (XDH) DMJBGHL MA Inhibitor DMJBGHL RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMJBGHL RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMJBOL0 DI DMJBOL0 DMJBOL0 DN Benzoyl-piperidine derivative 1 DMJBOL0 TI TTJQOD7 DMJBOL0 TN 5-HT 2A receptor (HTR2A) DMJBOL0 MA Antagonist DMJBOL0 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMJBOL0 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMJBR86 DI DMJBR86 DMJBR86 DN Sulfonamide derivative 11 DMJBR86 TI TTA592U DMJBR86 TN Urate anion exchanger 1 (URAT1) DMJBR86 MA Inhibitor DMJBR86 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMJBR86 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMJBTZG DI DMJBTZG DMJBTZG DN Pyrrolo[2,3-b]pyridine derivative 4 DMJBTZG TI TTIV39N DMJBTZG TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMJBTZG MA Inhibitor DMJBTZG RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMJBTZG RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMJBY68 DI DMJBY68 DMJBY68 DN Aryl mannoside derivative 21 DMJBY68 TI TTTCRU2 DMJBY68 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJBY68 MA Antagonist DMJBY68 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJBY68 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJC4UZ DI DMJC4UZ DMJC4UZ DN Fused heterocyclic compound 11 DMJC4UZ TI TT7RJY8 DMJC4UZ TN Xanthine dehydrogenase/oxidase (XDH) DMJC4UZ MA Inhibitor DMJC4UZ RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMJC4UZ RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMJCAOD DI DMJCAOD DMJCAOD DN PMID27109571-Compound-37 DMJCAOD TI TTMY6L1 DMJCAOD TN Fatty acid-binding protein (FABP) DMJCAOD MA Inhibitor DMJCAOD RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMJCAOD RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMJCL53 DI DMJCL53 DMJCL53 DN PMID27109571-Compound-26 DMJCL53 TI TTHWMFZ DMJCL53 TN Fatty acid-binding protein 4 (FABP4) DMJCL53 MA Inhibitor DMJCL53 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMJCL53 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMJCL53 DI DMJCL53 DMJCL53 DN PMID27109571-Compound-26 DMJCL53 TI TTNT2S6 DMJCL53 TN Fatty acid-binding protein 5 (FABP5) DMJCL53 MA Inhibitor DMJCL53 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMJCL53 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMJCSL3 DI DMJCSL3 DMJCSL3 DN Imidazopyridine derivative 3 DMJCSL3 TI TTBYWP2 DMJCSL3 TN TYK2 tyrosine kinase (TYK2) DMJCSL3 MA Inhibitor DMJCSL3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMJCSL3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMJCVBM DI DMJCVBM DMJCVBM DN PMID25399762-Compound-Table1-C4 DMJCVBM TI TTGP7BY DMJCVBM TN Monoamine oxidase type B (MAO-B) DMJCVBM MA Inhibitor DMJCVBM RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMJCVBM RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMJCX8M DI DMJCX8M DMJCX8M DN Pyrazole derivative 15 DMJCX8M TI TT6OEDT DMJCX8M TN Cannabinoid receptor 1 (CB1) DMJCX8M MA Antagonist DMJCX8M RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJCX8M RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJD1S6 DI DMJD1S6 DMJD1S6 DN A1-10438 DMJD1S6 TI TT0C8BY DMJD1S6 TN Plasma retinol-binding protein (RBP4) DMJD1S6 MA Inhibitor DMJD1S6 RN Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215. DMJD1S6 RU http://www.freepatentsonline.com/US8853215.html DMJDC5T DI DMJDC5T DMJDC5T DN Benzothiazoline derivative 1 DMJDC5T TI TTULVH8 DMJDC5T TN Tyrosinase (TYR) DMJDC5T MA Inhibitor DMJDC5T RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJDC5T RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TTEAD9J DMJDFS1 TN Proteasome beta-8 (PS beta-8) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TT68GPI DMJDFS1 TN Proteasome beta-5 (PS beta-5) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TTOUSTQ DMJDFS1 TN Proteasome beta-9 (PS beta-9) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TT8EPLT DMJDFS1 TN Proteasome beta-1 (PS beta-1) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TTPNACM DMJDFS1 TN Proteasome beta-10 (PS beta-10) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDFS1 DI DMJDFS1 DMJDFS1 DN Peptide analog 21 DMJDFS1 TI TT49BVC DMJDFS1 TN Proteasome beta-2 (PS beta-2) DMJDFS1 MA Inhibitor DMJDFS1 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMJDFS1 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMJDG37 DI DMJDG37 DMJDG37 DN Ethynyl compound 2 DMJDG37 TI TTHS256 DMJDG37 TN Metabotropic glutamate receptor 5 (mGluR5) DMJDG37 MA Modulator DMJDG37 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMJDG37 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMJDTSN DI DMJDTSN DMJDTSN DN US9493490, L DMJDTSN TI TTAZ3MN DMJDTSN TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMJDTSN MA Inhibitor DMJDTSN RN Boron-containing small molecules. US9493490. DMJDTSN RU http://www.freepatentsonline.com/US9493490.html DMJEH0F DI DMJEH0F DMJEH0F DN PMID25666693-Compound-58 DMJEH0F TI TTMI6F5 DMJEH0F TN Transient receptor potential cation channel V1 (TRPV1) DMJEH0F MA Antagonist DMJEH0F RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJEH0F RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJETVH DI DMJETVH DMJETVH DN PMID25416646-Compound-Figure2-J DMJETVH TI TTZMAO3 DMJETVH TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJETVH MA Agonist DMJETVH RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMJETVH RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMJEV86 DI DMJEV86 DMJEV86 DN Pyrrolo-pyrimidine derivative 9 DMJEV86 TI TTK0FEA DMJEV86 TN Leucine-rich repeat kinase 2 (LRRK2) DMJEV86 MA Inhibitor DMJEV86 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMJEV86 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMJEX3D DI DMJEX3D DMJEX3D DN Heterocyclic-substituted 3-alkyl azetidine derivative 1 DMJEX3D TI TT6OEDT DMJEX3D TN Cannabinoid receptor 1 (CB1) DMJEX3D MA Antagonist DMJEX3D RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJEX3D RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJF6S0 DI DMJF6S0 DMJF6S0 DN Sphinx DMJF6S0 TI TTU3WV6 DMJF6S0 TN SRSF protein kinase 1 (SRPK1) DMJF6S0 MA Inhibitor DMJF6S0 RN Piperazine derivatives for treating disorders. US9695160. DMJF6S0 RU http://www.freepatentsonline.com/US9695160.html DMJFDNB DI DMJFDNB DMJFDNB DN Aryl mannoside derivative 22 DMJFDNB TI TTTCRU2 DMJFDNB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJFDNB MA Antagonist DMJFDNB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJFDNB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJFHVN DI DMJFHVN DMJFHVN DN Salicylic acid derivative 7 DMJFHVN TI TTH8FZW DMJFHVN TN Signal transducer and activator of transcription 3 (STAT3) DMJFHVN MA Inhibitor DMJFHVN RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMJFHVN RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMJFSOM DI DMJFSOM DMJFSOM DN PMID27336223-Compound-4 DMJFSOM TI TTW38KT DMJFSOM TN Retinoic acid receptor alpha (RARA) DMJFSOM MA Agonist DMJFSOM RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMJFSOM RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMJFYK1 DI DMJFYK1 DMJFYK1 DN Pyrrolo[2,3-d]pyrimidine derivative 2 DMJFYK1 TI TTIXKA4 DMJFYK1 TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMJFYK1 MA Inhibitor DMJFYK1 RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJFYK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJG1ZS DI DMJG1ZS DMJG1ZS DN Biaromatic compound 1 DMJG1ZS TI TTZMAO3 DMJG1ZS TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJG1ZS MA Agonist DMJG1ZS RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMJG1ZS RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMJG7M6 DI DMJG7M6 DMJG7M6 DN Azole benzene derivative 2 DMJG7M6 TI TT7RJY8 DMJG7M6 TN Xanthine dehydrogenase/oxidase (XDH) DMJG7M6 MA Inhibitor DMJG7M6 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMJG7M6 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMJIDLU DI DMJIDLU DMJIDLU DN Quinazoline derivative 4 DMJIDLU TI TTPTXIN DMJIDLU TN Translocator protein (TSPO) DMJIDLU MA Ligand DMJIDLU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMJIDLU RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMJIZPQ DI DMJIZPQ DMJIZPQ DN Resorcinol compound 19 DMJIZPQ TI TTULVH8 DMJIZPQ TN Tyrosinase (TYR) DMJIZPQ MA Inhibitor DMJIZPQ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMJIZPQ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMJIZWR DI DMJIZWR DMJIZWR DN PMID26004420-Compound-WO2014099633D DMJIZWR TI TTJ13ST DMJIZWR TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMJIZWR MA Inhibitor DMJIZWR RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMJIZWR RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMJK296 DI DMJK296 DMJK296 DN PMID25399762-Compound-Table1-C24 DMJK296 TI TTGP7BY DMJK296 TN Monoamine oxidase type B (MAO-B) DMJK296 MA Inhibitor DMJK296 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMJK296 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMJK98Z DI DMJK98Z DMJK98Z DN Pyrrolidine carboxamide derivative 1 DMJK98Z TI TTQHWNA DMJK98Z TN Hypoxia-inducible factor 1 alpha (HIF-1A) DMJK98Z MA Inhibitor DMJK98Z RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJK98Z RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJK98Z DI DMJK98Z DMJK98Z DN Pyrrolidine carboxamide derivative 1 DMJK98Z TI TTEMWSD DMJK98Z TN von Hippel-Lindau disease tumor suppressor (VHL) DMJK98Z MA Inhibitor DMJK98Z RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJK98Z RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJKFVU DI DMJKFVU DMJKFVU DN US8614253, 29-1 DMJKFVU TI TTOJ9QL DMJKFVU TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMJKFVU MA Inhibitor DMJKFVU RN IRE-1 inhibitors. US9241942. DMJKFVU RU http://www.freepatentsonline.com/US9241942.html DMJKOFB DI DMJKOFB DMJKOFB DN PMID25522065-Compound-44 DMJKOFB TI TTX4RTB DMJKOFB TN Melanin-concentrating hormone receptor 1 (MCHR1) DMJKOFB MA Antagonist DMJKOFB RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMJKOFB RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMJKS4X DI DMJKS4X DMJKS4X DN US10100051, Compound 1 DMJKS4X TI TT9ISBX DMJKS4X TN HIF-prolyl hydroxylase 2 (HPH-2) DMJKS4X MA Inhibitor DMJKS4X RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DMJKS4X RU http://www.freepatentsonline.com/US10100051.html DMJKTYW DI DMJKTYW DMJKTYW DN US10174026, Example 99 DMJKTYW TI TTIG67W DMJKTYW TN Lysine-specific demethylase 5A (KDM5A) DMJKTYW MA Inhibitor DMJKTYW RN Histone demethylase inhibitors. US10174026. DMJKTYW RU http://www.freepatentsonline.com/US10174026.html DMJL1MB DI DMJL1MB DMJL1MB DN 67S DMJL1MB TI TTECBXN DMJL1MB TN Oxysterols receptor LXR-alpha (NR1H3) DMJL1MB MA Inhibitor DMJL1MB RN Piperazine derivatives as liver X receptor modulators. US10144715. DMJL1MB RU http://www.freepatentsonline.com/US10144715.html DMJLFEN DI DMJLFEN DMJLFEN DN PMID25666693-Compound-138 DMJLFEN TI TTMI6F5 DMJLFEN TN Transient receptor potential cation channel V1 (TRPV1) DMJLFEN MA Antagonist DMJLFEN RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJLFEN RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJLU8R DI DMJLU8R DMJLU8R DN Pyrazolo[1,5-a]pyrimidine derivative 20 DMJLU8R TI TTTDVOJ DMJLU8R TN Tropomyosin-related kinase A (TrkA) DMJLU8R MA Inhibitor DMJLU8R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMJLU8R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMJMCKD DI DMJMCKD DMJMCKD DN PMID25522065-Compound-8 DMJMCKD TI TTX4RTB DMJMCKD TN Melanin-concentrating hormone receptor 1 (MCHR1) DMJMCKD MA Antagonist DMJMCKD RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMJMCKD RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMJMCNP DI DMJMCNP DMJMCNP DN 1,3,4-oxadiazole derivative 1 DMJMCNP TI TTNBFWK DMJMCNP TN Programmed cell death protein 1 (PD-1) DMJMCNP MA Inhibitor DMJMCNP RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMJMCNP RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMJMO72 DI DMJMO72 DMJMO72 DN PMID27215781-Compound-31 DMJMO72 TI TTMSFAW DMJMO72 TN Cannabinoid receptor 2 (CB2) DMJMO72 MA Agonist DMJMO72 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMJMO72 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMJMTNL DI DMJMTNL DMJMTNL DN PMID30124346-Compound-LDT66 DMJMTNL TI TTNGILX DMJMTNL TN Adrenergic receptor alpha-1A (ADRA1A) DMJMTNL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMJMTNL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMJMTNL DI DMJMTNL DMJMTNL DN PMID30124346-Compound-LDT66 DMJMTNL TI TTSQIFT DMJMTNL TN 5-HT 1A receptor (HTR1A) DMJMTNL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMJMTNL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMJMTNL DI DMJMTNL DMJMTNL DN PMID30124346-Compound-LDT66 DMJMTNL TI TT34BHT DMJMTNL TN Adrenergic receptor alpha-1D (ADRA1D) DMJMTNL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMJMTNL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMJMWDV DI DMJMWDV DMJMWDV DN Cyclic sulfonamide derivative 1 DMJMWDV TI TT8J1S3 DMJMWDV TN Smoothened homolog (SMO) DMJMWDV MA Inhibitor DMJMWDV RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJMWDV RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJN37O DI DMJN37O DMJN37O DN Antibodie derivative 7 DMJN37O TI TTOHSBA DMJN37O TN Vascular endothelial growth factor A (VEGFA) DMJN37O MA Binder DMJN37O RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMJN37O RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMJN5CI DI DMJN5CI DMJN5CI DN Spiroimidazolone derivative 6 DMJN5CI TI TT9O6WS DMJN5CI TN Glucagon receptor (GCGR) DMJN5CI MA Antagonist DMJN5CI RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMJN5CI RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMJN72E DI DMJN72E DMJN72E DN Triazolo-pyrimidinedione derivative 1 DMJN72E TI TTDIGC1 DMJN72E TN Dipeptidyl peptidase 4 (DPP-4) DMJN72E MA Inhibitor DMJN72E RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMJN72E RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMJNCD6 DI DMJNCD6 DMJNCD6 DN Tricyclic heterocycle derivative 3 DMJNCD6 TI TTZC0KV DMJNCD6 TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DMJNCD6 MA Inhibitor DMJNCD6 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMJNCD6 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMJNE4V DI DMJNE4V DMJNE4V DN Pyridine-2,4-dicarboxylic acid analog 1 DMJNE4V TI TTWAQBO DMJNE4V TN Lysine-specific demethylase 4E (KDM4E) DMJNE4V MA Inhibitor DMJNE4V RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMJNE4V RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMJNOB9 DI DMJNOB9 DMJNOB9 DN BDBM50080559 DMJNOB9 TI TTDYP7I DMJNOB9 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMJNOB9 MA Inhibitor DMJNOB9 RN Pyridin-4-yl derivatives. US9617250. DMJNOB9 RU http://www.freepatentsonline.com/US9617250.html DMJO3RW DI DMJO3RW DMJO3RW DN PMID28092474-Compound-32n DMJO3RW TI TT6R7JZ DMJO3RW TN Histone deacetylase 1 (HDAC1) DMJO3RW MA Inhibitor DMJO3RW RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMJO3RW RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMJO3RW DI DMJO3RW DMJO3RW DN PMID28092474-Compound-32n DMJO3RW TI TT5ZKDI DMJO3RW TN Histone deacetylase 6 (HDAC6) DMJO3RW MA Inhibitor DMJO3RW RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMJO3RW RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMJOBUZ DI DMJOBUZ DMJOBUZ DN PMID29473428-Compound-72 DMJOBUZ TI TTZJYKH DMJOBUZ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJOBUZ MA Inhibitor DMJOBUZ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJOBUZ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJOD8I DI DMJOD8I DMJOD8I DN PMID25980951-Compound-40 DMJOD8I TI TTR7B60 DMJOD8I TN X-linked inhibitor of apoptosis protein (XIAP) DMJOD8I MA Antagonist DMJOD8I RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMJOD8I RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMJOG3W DI DMJOG3W DMJOG3W DN PMID28766366-Compound-Scheme6Pyrrolo[2,3-d]pyrimidines DMJOG3W TI TTSBVFO DMJOG3W TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMJOG3W MA Inhibitor DMJOG3W RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMJOG3W RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMJON7D DI DMJON7D DMJON7D DN Triazole gold complexe 2 DMJON7D TI TTR7UJ3 DMJON7D TN Cytoplasmic thioredoxin reductase (TXNRD1) DMJON7D MA Inhibitor DMJON7D RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMJON7D RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMJOPEL DI DMJOPEL DMJOPEL DN PMID25482888-Compound-38 DMJOPEL TI TTDIGC1 DMJOPEL TN Dipeptidyl peptidase 4 (DPP-4) DMJOPEL MA Inhibitor DMJOPEL RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMJOPEL RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMJP0AG DI DMJP0AG DMJP0AG DN PMID28870136-Compound-40 DMJP0AG TI TTK0O6Y DMJP0AG TN Ecto-5'-nucleotidase (CD73) DMJP0AG MA Inhibitor DMJP0AG RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMJP0AG RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMJP0NB DI DMJP0NB DMJP0NB DN PMID25666693-Compound-143 DMJP0NB TI TTMI6F5 DMJP0NB TN Transient receptor potential cation channel V1 (TRPV1) DMJP0NB MA Antagonist DMJP0NB RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMJP0NB RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMJP16K DI DMJP16K DMJP16K DN Bicyclic pyrimidine derivative 2 DMJP16K TI TTDNFMT DMJP16K TN Platelet-activating factor acetylhydrolase (PLA2G7) DMJP16K MA Inhibitor DMJP16K RN Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Expert Opin Ther Pat. 2017 Feb;27(2):217-225. DMJP16K RU https://www.ncbi.nlm.nih.gov/pubmed/27718763 DMJP1IK DI DMJP1IK DMJP1IK DN Bicyclic hexapeptide derivative 2 DMJP1IK TI TT8J1S3 DMJP1IK TN Smoothened homolog (SMO) DMJP1IK MA Inhibitor DMJP1IK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJP1IK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJPQNH DI DMJPQNH DMJPQNH DN US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide DMJPQNH TI TT7ALZG DMJPQNH TN Integrin-linked protein kinase 1 (ILK) DMJPQNH MA Inhibitor DMJPQNH RN Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233. DMJPQNH RU http://www.freepatentsonline.com/US8754233.html DMJPW7C DI DMJPW7C DMJPW7C DN C06909 DMJPW7C TI TT5DOVB DMJPW7C TN Cytomegalovirus Protease (CMV UL80) DMJPW7C MA Inhibitor DMJPW7C RN Phosphonate compounds. US10071110. DMJPW7C RU http://www.freepatentsonline.com/US10071110.html DMJPYVS DI DMJPYVS DMJPYVS DN Steroid derivative 4 DMJPYVS TI TTUX68I DMJPYVS TN Hypoxia-inducible factor 1 (HIF-1) DMJPYVS MA Inhibitor DMJPYVS RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJPYVS RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJQBVH DI DMJQBVH DMJQBVH DN Thiazole carboxamide derivative 16 DMJQBVH TI TTCZOF2 DMJQBVH TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMJQBVH MA Inhibitor DMJQBVH RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMJQBVH RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMJQOAE DI DMJQOAE DMJQOAE DN US8975409, Example 9(3) DMJQOAE TI TTVSMOH DMJQOAE TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMJQOAE MA Inhibitor DMJQOAE RN Phenyl derivative. US8975409. DMJQOAE RU http://www.freepatentsonline.com/US8975409.html DMJRHS4 DI DMJRHS4 DMJRHS4 DN 2-pyrazinone derivative 4 DMJRHS4 TI TTPLTSQ DMJRHS4 TN Neutrophil elastase (NE) DMJRHS4 MA Inhibitor DMJRHS4 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMJRHS4 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMJRK9D DI DMJRK9D DMJRK9D DN 1313212-89-3 DMJRK9D TI TTNAFOU DMJRK9D TN Rotamase D (PPID) DMJRK9D MA Inhibitor DMJRK9D RN Inhibitors of cyclophilins and uses thereof. US8901295. DMJRK9D RU http://www.freepatentsonline.com/US8901295.html DMJRZLB DI DMJRZLB DMJRZLB DN PMID27410995-Compound-Figure3j DMJRZLB TI TT9ABMF DMJRZLB TN Serine/threonine-protein kinase Chk2 (RAD53) DMJRZLB MA Inhibitor DMJRZLB RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJRZLB RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJRZLB DI DMJRZLB DMJRZLB DN PMID27410995-Compound-Figure3j DMJRZLB TI TTUM2ZR DMJRZLB TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMJRZLB MA Inhibitor DMJRZLB RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMJRZLB RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMJS4RP DI DMJS4RP DMJS4RP DN PMID26882240-Compound-32 DMJS4RP TI TTUX68I DMJS4RP TN Hypoxia-inducible factor 1 (HIF-1) DMJS4RP MA Inhibitor DMJS4RP RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMJS4RP RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMJSH0F DI DMJSH0F DMJSH0F DN PMID30107136-Compound-Example43 DMJSH0F TI TT23XQV DMJSH0F TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMJSH0F MA Inhibitor DMJSH0F RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMJSH0F RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMJSIN8 DI DMJSIN8 DMJSIN8 DN Enzoxazolinone sulfonamide derivative 1 DMJSIN8 TI TT4G2JS DMJSIN8 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMJSIN8 MA Blocker DMJSIN8 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMJSIN8 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMJT1WG DI DMJT1WG DMJT1WG DN C-linked disaccharide biphenyl mannoside derivative 2 DMJT1WG TI TTTCRU2 DMJT1WG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMJT1WG MA Antagonist DMJT1WG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMJT1WG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMJTN91 DI DMJTN91 DMJTN91 DN Heteroaryl-carboxamide derivative 8 DMJTN91 TI TTCZOF2 DMJTN91 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMJTN91 MA Inhibitor DMJTN91 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMJTN91 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMJTO69 DI DMJTO69 DMJTO69 DN PMID25991433-Compound-B1 DMJTO69 TI TTVOE6D DMJTO69 TN Mitogen-activated protein kinase (MAPK) DMJTO69 MA Inhibitor DMJTO69 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMJTO69 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMJU0SO DI DMJU0SO DMJU0SO DN 4-(2-cyclohexylethoxy) aniline derivative 3 DMJU0SO TI TTA6ZN2 DMJU0SO TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMJU0SO MA Inhibitor DMJU0SO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMJU0SO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMJUHXB DI DMJUHXB DMJUHXB DN PMID25726713-Compound-22 DMJUHXB TI TT8J1S3 DMJUHXB TN Smoothened homolog (SMO) DMJUHXB MA Inhibitor DMJUHXB RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMJUHXB RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMJUL1A DI DMJUL1A DMJUL1A DN PMID27376512-Compound-asCEBP-2 DMJUL1A TI TT6S2FE DMJUL1A TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMJUL1A MA Inhibitor DMJUL1A RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMJUL1A RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMJUMC6 DI DMJUMC6 DMJUMC6 DN Pyrrole derivative 5 DMJUMC6 TI TT6OEDT DMJUMC6 TN Cannabinoid receptor 1 (CB1) DMJUMC6 MA Antagonist DMJUMC6 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMJUMC6 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMJURBM DI DMJURBM DMJURBM DN Indoline derivative 12 DMJURBM TI TTOHSBA DMJURBM TN Vascular endothelial growth factor A (VEGFA) DMJURBM MA Inhibitor DMJURBM RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMJURBM RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMJV1SY DI DMJV1SY DMJV1SY DN PMID29671355-Compound-55 DMJV1SY TI TT4YWTO DMJV1SY TN Histone deacetylase 3 (HDAC3) DMJV1SY MA Inhibitor DMJV1SY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJV1SY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJV1SY DI DMJV1SY DMJV1SY DN PMID29671355-Compound-55 DMJV1SY TI TTSHTOI DMJV1SY TN Histone deacetylase 2 (HDAC2) DMJV1SY MA Inhibitor DMJV1SY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJV1SY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJV1SY DI DMJV1SY DMJV1SY DN PMID29671355-Compound-55 DMJV1SY TI TT6R7JZ DMJV1SY TN Histone deacetylase 1 (HDAC1) DMJV1SY MA Inhibitor DMJV1SY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMJV1SY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMJWH4B DI DMJWH4B DMJWH4B DN Azaindazole amide derivative 1 DMJWH4B TI TTXABCW DMJWH4B TN NT-3 growth factor receptor (TrkC) DMJWH4B MA Inhibitor DMJWH4B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMJWH4B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMJWH4B DI DMJWH4B DMJWH4B DN Azaindazole amide derivative 1 DMJWH4B TI TTTDVOJ DMJWH4B TN Tropomyosin-related kinase A (TrkA) DMJWH4B MA Inhibitor DMJWH4B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMJWH4B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMJWH4B DI DMJWH4B DMJWH4B DN Azaindazole amide derivative 1 DMJWH4B TI TTKN7QR DMJWH4B TN BDNF/NT-3 growth factors receptor (TrkB) DMJWH4B MA Inhibitor DMJWH4B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMJWH4B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMJX6DV DI DMJX6DV DMJX6DV DN Aromatic ring compound 1 DMJX6DV TI TT9O6WS DMJX6DV TN Glucagon receptor (GCGR) DMJX6DV MA Antagonist DMJX6DV RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMJX6DV RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMJX8WY DI DMJX8WY DMJX8WY DN PMID26004420-Compound-WO2014150132B DMJX8WY TI TTJ13ST DMJX8WY TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMJX8WY MA Inhibitor DMJX8WY RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMJX8WY RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TTT7PJU DMJXNO1 TN Janus kinase 3 (JAK-3) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TTBYWP2 DMJXNO1 TN TYK2 tyrosine kinase (TYK2) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TTRMX3V DMJXNO1 TN Janus kinase 2 (JAK-2) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJXNO1 DI DMJXNO1 DMJXNO1 DN Bis-aminopyrimidine derivative 2 DMJXNO1 TI TT6DM01 DMJXNO1 TN Janus kinase 1 (JAK-1) DMJXNO1 MA Inhibitor DMJXNO1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMJXNO1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMJY0CD DI DMJY0CD DMJY0CD DN US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine DMJY0CD TI TT7ALZG DMJY0CD TN Integrin-linked protein kinase 1 (ILK) DMJY0CD MA Inhibitor DMJY0CD RN Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233. DMJY0CD RU http://www.freepatentsonline.com/US8754233.html DMJY8XI DI DMJY8XI DMJY8XI DN Azetidine urea derivative 2 DMJY8XI TI TTDP1UC DMJY8XI TN Fatty acid amide hydrolase (FAAH) DMJY8XI MA Inhibitor DMJY8XI RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMJY8XI RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMJYQLC DI DMJYQLC DMJYQLC DN PMID29338548-Compound-44 DMJYQLC TI TTHJTF7 DMJYQLC TN Glycine transporter GlyT-1 (SLC6A9) DMJYQLC MA Inhibitor DMJYQLC RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMJYQLC RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMJYUN2 DI DMJYUN2 DMJYUN2 DN PMID29473428-Compound-59 DMJYUN2 TI TTZJYKH DMJYUN2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJYUN2 MA Inhibitor DMJYUN2 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMJYUN2 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMJZ1IG DI DMJZ1IG DMJZ1IG DN Amidopyrazole derivative 6 DMJZ1IG TI TTKFVXR DMJZ1IG TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMJZ1IG MA Inhibitor DMJZ1IG RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMJZ1IG RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMJZGT8 DI DMJZGT8 DMJZGT8 DN Chalcone derivative 5 DMJZGT8 TI TT2F4OL DMJZGT8 TN Tissue transglutaminase (TG2) DMJZGT8 MA Inhibitor DMJZGT8 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMJZGT8 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMJZREU DI DMJZREU DMJZREU DN PMID28117607-Compound-7 DMJZREU TI TTK0FEA DMJZREU TN Leucine-rich repeat kinase 2 (LRRK2) DMJZREU MA Inhibitor DMJZREU RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMJZREU RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMJZSWF DI DMJZSWF DMJZSWF DN PMID28447479-Compound-26 DMJZSWF TI TTSCIM2 DMJZSWF TN Extracellular lysophospholipase D (E-NPP2) DMJZSWF MA Agonist DMJZSWF RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMJZSWF RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMK02LS DI DMK02LS DMK02LS DN US9353089, 330 DMK02LS TI TTXMNHO DMK02LS TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMK02LS MA Inhibitor DMK02LS RN Compositions and methods for the treatment of malaria. US9353089. DMK02LS RU http://www.freepatentsonline.com/US9353089.html DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TTOUSTQ DMK0GTV TN Proteasome beta-9 (PS beta-9) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TT68GPI DMK0GTV TN Proteasome beta-5 (PS beta-5) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TT8EPLT DMK0GTV TN Proteasome beta-1 (PS beta-1) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0GTV DI DMK0GTV DMK0GTV DN PMID29865878-Compound-49 DMK0GTV TI TTEAD9J DMK0GTV TN Proteasome beta-8 (PS beta-8) DMK0GTV MA Inhibitor DMK0GTV RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMK0GTV RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMK0RTV DI DMK0RTV DMK0RTV DN PMID28870136-Compound-56 DMK0RTV TI TTK0O6Y DMK0RTV TN Ecto-5'-nucleotidase (CD73) DMK0RTV MA Inhibitor DMK0RTV RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMK0RTV RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMK0S4I DI DMK0S4I DMK0S4I DN Tacrine-dihydropyridine hybrid derivative 1 DMK0S4I TI TT1RS9F DMK0S4I TN Acetylcholinesterase (AChE) DMK0S4I RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMK0S4I RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMK0SIM DI DMK0SIM DMK0SIM DN PMID27454349-Compound-94 DMK0SIM TI TTK59TV DMK0SIM TN Vitamin D3 receptor (VDR) DMK0SIM MA Agonist DMK0SIM RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMK0SIM RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMK0T9E DI DMK0T9E DMK0T9E DN SCHEMBL15295829 DMK0T9E TI TTVSMOH DMK0T9E TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMK0T9E MA Inhibitor DMK0T9E RN Sphingosine 1-phosphate receptor antagonists. US9663511. DMK0T9E RU http://www.freepatentsonline.com/US9663511.html DMK12OT DI DMK12OT DMK12OT DN Coumarin/resveratrol hybrid derivative 2 DMK12OT TI TTGP7BY DMK12OT TN Monoamine oxidase type B (MAO-B) DMK12OT MA Inhibitor DMK12OT RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMK12OT RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMK1QTH DI DMK1QTH DMK1QTH DN Tricyclic indole compound 10 DMK1QTH TI TTPTXIN DMK1QTH TN Translocator protein (TSPO) DMK1QTH MA Ligand DMK1QTH RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMK1QTH RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMK1UJV DI DMK1UJV DMK1UJV DN Aminopyrimidine derivative 1 DMK1UJV TI TTS7G69 DMK1UJV TN Fusion protein Bcr-Abl (Bcr-Abl) DMK1UJV MA Inhibitor DMK1UJV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMK1UJV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMK2FSY DI DMK2FSY DMK2FSY DN Pyrrolo-pyridinone derivative 5 DMK2FSY TI TT4G2JS DMK2FSY TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMK2FSY MA Inhibitor DMK2FSY RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMK2FSY RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMK2FSY DI DMK2FSY DMK2FSY DN Pyrrolo-pyridinone derivative 5 DMK2FSY TI TTAXZ0K DMK2FSY TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMK2FSY MA Inhibitor DMK2FSY RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMK2FSY RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMK2V6H DI DMK2V6H DMK2V6H DN Tricyclic pyrrolidine derivative 3 DMK2V6H TI TTWJBZ5 DMK2V6H TN 5-HT 2C receptor (HTR2C) DMK2V6H MA Agonist DMK2V6H RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMK2V6H RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMK31M6 DI DMK31M6 DMK31M6 DN Isothiocyanate derivative 1 DMK31M6 TI TT2F4OL DMK31M6 TN Tissue transglutaminase (TG2) DMK31M6 MA Inhibitor DMK31M6 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMK31M6 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMK39S5 DI DMK39S5 DMK39S5 DN PMID26560530-Compound-18 DMK39S5 TI TT2F4OL DMK39S5 TN Tissue transglutaminase (TG2) DMK39S5 MA Inhibitor DMK39S5 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMK39S5 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMK3GRZ DI DMK3GRZ DMK3GRZ DN PMID28270010-Compound-Figure5-2 DMK3GRZ TI TTTDVOJ DMK3GRZ TN Tropomyosin-related kinase A (TrkA) DMK3GRZ MA Inhibitor DMK3GRZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK3GRZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK3GRZ DI DMK3GRZ DMK3GRZ DN PMID28270010-Compound-Figure5-2 DMK3GRZ TI TTXABCW DMK3GRZ TN NT-3 growth factor receptor (TrkC) DMK3GRZ MA Inhibitor DMK3GRZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK3GRZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK3GRZ DI DMK3GRZ DMK3GRZ DN PMID28270010-Compound-Figure5-2 DMK3GRZ TI TTKN7QR DMK3GRZ TN BDNF/NT-3 growth factors receptor (TrkB) DMK3GRZ MA Inhibitor DMK3GRZ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK3GRZ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK3TMD DI DMK3TMD DMK3TMD DN PMID25656651-Compound-7 DMK3TMD TI TTS7G69 DMK3TMD TN Fusion protein Bcr-Abl (Bcr-Abl) DMK3TMD MA Inhibitor DMK3TMD RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMK3TMD RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMK3UJY DI DMK3UJY DMK3UJY DN Macrocycle derivative 5 DMK3UJY TI TT23XQV DMK3UJY TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMK3UJY MA Inhibitor DMK3UJY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMK3UJY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMK3UJY DI DMK3UJY DMK3UJY DN Macrocycle derivative 5 DMK3UJY TI TT5YPJF DMK3UJY TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMK3UJY MA Inhibitor DMK3UJY RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMK3UJY RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMK4LOH DI DMK4LOH DMK4LOH DN Pyrrolo[2,3-d]pyrimidine derivative 14 DMK4LOH TI TTGM6VW DMK4LOH TN Tyrosine-protein kinase BTK (ATK) DMK4LOH MA Inhibitor DMK4LOH RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMK4LOH RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMK4Y71 DI DMK4Y71 DMK4Y71 DN N-acylpyrrolidine ether derivative 2 DMK4Y71 TI TTTDVOJ DMK4Y71 TN Tropomyosin-related kinase A (TrkA) DMK4Y71 MA Inhibitor DMK4Y71 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMK4Y71 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMK5G7D DI DMK5G7D DMK5G7D DN Spirolaxine derivative 1 DMK5G7D TI TTZMAO3 DMK5G7D TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMK5G7D MA Agonist DMK5G7D RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMK5G7D RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMK5HAC DI DMK5HAC DMK5HAC DN Tarizine derivative 1 DMK5HAC TI TT4G2JS DMK5HAC TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMK5HAC MA Inhibitor DMK5HAC RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMK5HAC RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMK5M8Q DI DMK5M8Q DMK5M8Q DN Isoxazoline derivative 2 DMK5M8Q TI TTDP1UC DMK5M8Q TN Fatty acid amide hydrolase (FAAH) DMK5M8Q MA Inhibitor DMK5M8Q RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMK5M8Q RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMK5YJI DI DMK5YJI DMK5YJI DN Pyrido/pyrrolo-fused pyrimidine derivative 1 DMK5YJI TI TTSCIM2 DMK5YJI TN Extracellular lysophospholipase D (E-NPP2) DMK5YJI MA Inhibitor DMK5YJI RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMK5YJI RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMK6PFQ DI DMK6PFQ DMK6PFQ DN Aryl mannoside derivative 8 DMK6PFQ TI TTTCRU2 DMK6PFQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMK6PFQ MA Antagonist DMK6PFQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMK6PFQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMK6RFS DI DMK6RFS DMK6RFS DN Geminally-substituted cyanoethylpypazolo pyridone derivative 1 DMK6RFS TI TTRMX3V DMK6RFS TN Janus kinase 2 (JAK-2) DMK6RFS MA Inhibitor DMK6RFS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK6RFS RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK6RFS DI DMK6RFS DMK6RFS DN Geminally-substituted cyanoethylpypazolo pyridone derivative 1 DMK6RFS TI TT6DM01 DMK6RFS TN Janus kinase 1 (JAK-1) DMK6RFS MA Inhibitor DMK6RFS RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK6RFS RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK72JS DI DMK72JS DMK72JS DN PMID27788040-Compound-5c DMK72JS TI TTV1C0Z DMK72JS TN Neuropeptide S receptor (NPSR) DMK72JS MA Antagonist DMK72JS RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMK72JS RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMK75BT DI DMK75BT DMK75BT DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 1 DMK75BT TI TTSXVID DMK75BT TN Nuclear factor NF-kappa-B (NFKB) DMK75BT MA Inhibitor DMK75BT RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMK75BT RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMK7DJ2 DI DMK7DJ2 DMK7DJ2 DN Alkynyl-substituted pyrimidinyl-pyrrole derivative 1 DMK7DJ2 TI TT1RWNJ DMK7DJ2 TN Tyrosine-protein kinase Lyn (JTK8) DMK7DJ2 MA Inhibitor DMK7DJ2 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK7DJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK7DJ2 DI DMK7DJ2 DMK7DJ2 DN Alkynyl-substituted pyrimidinyl-pyrrole derivative 1 DMK7DJ2 TI TTRMX3V DMK7DJ2 TN Janus kinase 2 (JAK-2) DMK7DJ2 MA Inhibitor DMK7DJ2 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMK7DJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMK7DJR DI DMK7DJR DMK7DJR DN Carbamide derivative 11 DMK7DJR TI TTL7C8Q DMK7DJR TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMK7DJR MA Inhibitor DMK7DJR RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMK7DJR RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMK7F3A DI DMK7F3A DMK7F3A DN Pyrazolopyrimidine acetamide analog 2 DMK7F3A TI TTPTXIN DMK7F3A TN Translocator protein (TSPO) DMK7F3A MA Ligand DMK7F3A RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMK7F3A RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMK820T DI DMK820T DMK820T DN Pyrrolo-pyridinone derivative 1 DMK820T TI TT4DXQT DMK820T TN Proto-oncogene c-Ret (RET) DMK820T MA Inhibitor DMK820T RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMK820T RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMK8V7A DI DMK8V7A DMK8V7A DN Imidazo[1,2-b]pyridazine derivative 5 DMK8V7A TI TTTDVOJ DMK8V7A TN Tropomyosin-related kinase A (TrkA) DMK8V7A MA Inhibitor DMK8V7A RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMK8V7A RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMK90ED DI DMK90ED DMK90ED DN PMID25435179-Compound-WO2013059594(IV) DMK90ED TI TTSCO7R DMK90ED TN NAD-dependent deacetylase sirtuin (SIRT) DMK90ED MA Inhibitor DMK90ED RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMK90ED RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMK9DH7 DI DMK9DH7 DMK9DH7 DN PMID25980951-Compound-26 DMK9DH7 TI TTR7B60 DMK9DH7 TN X-linked inhibitor of apoptosis protein (XIAP) DMK9DH7 MA Antagonist DMK9DH7 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMK9DH7 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMK9FJG DI DMK9FJG DMK9FJG DN US9073931, E2 DMK9FJG TI TTECBXN DMK9FJG TN Oxysterols receptor LXR-alpha (NR1H3) DMK9FJG MA Inhibitor DMK9FJG RN Liver X receptor modulators. US9073931. DMK9FJG RU http://www.freepatentsonline.com/US9073931.html DMK9P7S DI DMK9P7S DMK9P7S DN Imidazole derivative 8 DMK9P7S TI TTTJZ4M DMK9P7S TN Prolylcarboxypeptidase (PRCP) DMK9P7S MA Inhibitor DMK9P7S RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMK9P7S RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMK9TJP DI DMK9TJP DMK9TJP DN PMID30273516-Compound-13 DMK9TJP TI TTCW0KX DMK9TJP TN Glutaminase (GLS) DMK9TJP MA Inhibitor DMK9TJP RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMK9TJP RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMK9XV8 DI DMK9XV8 DMK9XV8 DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 6 DMK9XV8 TI TTULVH8 DMK9XV8 TN Tyrosinase (TYR) DMK9XV8 MA Inhibitor DMK9XV8 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMK9XV8 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMKAFPC DI DMKAFPC DMKAFPC DN PMID29334795-Compound-62 DMKAFPC TI TT9JNIC DMKAFPC TN Histamine H3 receptor (H3R) DMKAFPC MA Inhibitor DMKAFPC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKAFPC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKAFPC DI DMKAFPC DMKAFPC DN PMID29334795-Compound-62 DMKAFPC TI TTEX248 DMKAFPC TN Dopamine D2 receptor (D2R) DMKAFPC MA Ligand DMKAFPC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKAFPC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKB7XV DI DMKB7XV DMKB7XV DN PMID25656651-Compound-28b DMKB7XV TI TT3PJMV DMKB7XV TN Tyrosine-protein kinase ABL1 (ABL) DMKB7XV MA Inhibitor DMKB7XV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKB7XV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKBZDP DI DMKBZDP DMKBZDP DN PMID27607364-Compound-4 DMKBZDP TI TTPTXIN DMKBZDP TN Translocator protein (TSPO) DMKBZDP MA Ligand DMKBZDP RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMKBZDP RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMKC6SA DI DMKC6SA DMKC6SA DN PMID26004420-Compound-WO2014085210C DMKC6SA TI TTJ13ST DMKC6SA TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMKC6SA MA Inhibitor DMKC6SA RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMKC6SA RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMKCARH DI DMKCARH DMKCARH DN PMID25666693-Compound-53 DMKCARH TI TTMI6F5 DMKCARH TN Transient receptor potential cation channel V1 (TRPV1) DMKCARH MA Antagonist DMKCARH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKCARH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKCJE1 DI DMKCJE1 DMKCJE1 DN Pyrazole derivative 69 DMKCJE1 TI TTJQOD7 DMKCJE1 TN 5-HT 2A receptor (HTR2A) DMKCJE1 MA Antagonist DMKCJE1 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMKCJE1 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMKCYSD DI DMKCYSD DMKCYSD DN Isoxazoles and isoxazoline derivative 2 DMKCYSD TI TTIY56R DMKCYSD TN Kynurenine 3-hydroxylase (KMO) DMKCYSD MA Inhibitor DMKCYSD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMKCYSD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMKD470 DI DMKD470 DMKD470 DN PMID30185082-Compound-64 DMKD470 TI TT5TPI6 DMKD470 TN Opioid receptor sigma 1 (OPRS1) DMKD470 MA Ligand DMKD470 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMKD470 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMKD470 DI DMKD470 DMKD470 DN PMID30185082-Compound-64 DMKD470 TI TT9NXW4 DMKD470 TN Sigma intracellular receptor 2 (TMEM97) DMKD470 MA Ligand DMKD470 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMKD470 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMKDBQG DI DMKDBQG DMKDBQG DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 13 DMKDBQG TI TTULVH8 DMKDBQG TN Tyrosinase (TYR) DMKDBQG MA Inhibitor DMKDBQG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMKDBQG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMKDTO4 DI DMKDTO4 DMKDTO4 DN Quinoline and quinazoline derivative 1 DMKDTO4 TI TTUTJGQ DMKDTO4 TN Vascular endothelial growth factor receptor 2 (KDR) DMKDTO4 MA Inhibitor DMKDTO4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMKDTO4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMKDX6W DI DMKDX6W DMKDX6W DN Pyrrolidine carboxamide derivative 2 DMKDX6W TI TTTJZ4M DMKDX6W TN Prolylcarboxypeptidase (PRCP) DMKDX6W MA Inhibitor DMKDX6W RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMKDX6W RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMKDZMQ DI DMKDZMQ DMKDZMQ DN 4-Hydroxybenzylalcohol DMKDZMQ TI TTGP7BY DMKDZMQ TN Monoamine oxidase type B (MAO-B) DMKDZMQ MA Inhibitor DMKDZMQ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMKDZMQ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMKE5PB DI DMKE5PB DMKE5PB DN Aromatic hydrazine carboxyimidoamide derivative 4 DMKE5PB TI TTULVH8 DMKE5PB TN Tyrosinase (TYR) DMKE5PB MA Inhibitor DMKE5PB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMKE5PB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMKE7YO DI DMKE7YO DMKE7YO DN Pyrazolo[1,5-a]pyrimidine derivative 25 DMKE7YO TI TTTDVOJ DMKE7YO TN Tropomyosin-related kinase A (TrkA) DMKE7YO MA Inhibitor DMKE7YO RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMKE7YO RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMKEOH8 DI DMKEOH8 DMKEOH8 DN 3-substituted-2-furancarboxylic acid hydrazide derivative 1 DMKEOH8 TI TT9O6WS DMKEOH8 TN Glucagon receptor (GCGR) DMKEOH8 MA Antagonist DMKEOH8 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMKEOH8 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMKES0G DI DMKES0G DMKES0G DN Biaryl mannoside derivative 11 DMKES0G TI TTTCRU2 DMKES0G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMKES0G MA Antagonist DMKES0G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMKES0G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMKEVDL DI DMKEVDL DMKEVDL DN BDBM50173327 DMKEVDL TI TTTCXO0 DMKEVDL TN G protein-coupled receptor kinase 5 (GRK5) DMKEVDL MA Inhibitor DMKEVDL RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DMKEVDL RU http://www.freepatentsonline.com/US10023564.html DMKEX51 DI DMKEX51 DMKEX51 DN US8933228, Ref 2 DMKEX51 TI TT42OGM DMKEX51 TN Hematopoietic cell kinase (HCK) DMKEX51 MA Inhibitor DMKEX51 RN 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors. US9724347. DMKEX51 RU http://www.freepatentsonline.com/US9724347.html DMKF26Z DI DMKF26Z DMKF26Z DN PMID26560530-Compound-13 DMKF26Z TI TT2F4OL DMKF26Z TN Tissue transglutaminase (TG2) DMKF26Z MA Inhibitor DMKF26Z RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMKF26Z RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMKF26Z DI DMKF26Z DMKF26Z DN PMID26560530-Compound-13 DMKF26Z TI TTXI2RA DMKF26Z TN Coagulation factor XIIIA (F13A1) DMKF26Z MA Inhibitor DMKF26Z RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMKF26Z RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMKF8HI DI DMKF8HI DMKF8HI DN Pyrrolo[3,2-c]pyridine derivative 1 DMKF8HI TI TTTDVOJ DMKF8HI TN Tropomyosin-related kinase A (TrkA) DMKF8HI MA Inhibitor DMKF8HI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMKF8HI RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMKFEO4 DI DMKFEO4 DMKFEO4 DN PMID28074661-Compound-US20120264760C86 DMKFEO4 TI TTL7C8Q DMKFEO4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMKFEO4 MA Inhibitor DMKFEO4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMKFEO4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMKFPJ7 DI DMKFPJ7 DMKFPJ7 DN Indomethacin analog 2 DMKFPJ7 TI TT5ZWB6 DMKFPJ7 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMKFPJ7 MA Inhibitor; Antagonist; Blocker DMKFPJ7 RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMKFPJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMKFV67 DI DMKFV67 DMKFV67 DN Aromatic bicyclic compound 2 DMKFV67 TI TT6PKBN DMKFV67 TN Proto-oncogene c-Src (SRC) DMKFV67 MA Inhibitor DMKFV67 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMKFV67 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMKFV67 DI DMKFV67 DMKFV67 DN Aromatic bicyclic compound 2 DMKFV67 TI TTRMX3V DMKFV67 TN Janus kinase 2 (JAK-2) DMKFV67 MA Inhibitor DMKFV67 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMKFV67 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMKFX2G DI DMKFX2G DMKFX2G DN PMID25435285-Compound-16 DMKFX2G TI TTXJ47W DMKFX2G TN Metabotropic glutamate receptor 2 (mGluR2) DMKFX2G MA Antagonist DMKFX2G RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMKFX2G RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMKFX2G DI DMKFX2G DMKFX2G DN PMID25435285-Compound-16 DMKFX2G TI TT8A9EF DMKFX2G TN Metabotropic glutamate receptor 3 (mGluR3) DMKFX2G MA Antagonist DMKFX2G RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMKFX2G RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMKGJ1S DI DMKGJ1S DMKGJ1S DN Tetra-hydro-pyrazolopyrazine derivative 3 DMKGJ1S TI TTHS256 DMKGJ1S TN Metabotropic glutamate receptor 5 (mGluR5) DMKGJ1S MA Modulator DMKGJ1S RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMKGJ1S RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMKHF39 DI DMKHF39 DMKHF39 DN 1,2,3-triazole derivative 1 DMKHF39 TI TT6OEDT DMKHF39 TN Cannabinoid receptor 1 (CB1) DMKHF39 MA Antagonist DMKHF39 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMKHF39 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMKHO8T DI DMKHO8T DMKHO8T DN PMID25666693-Compound-27 DMKHO8T TI TTMI6F5 DMKHO8T TN Transient receptor potential cation channel V1 (TRPV1) DMKHO8T MA Antagonist DMKHO8T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKHO8T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKHTE1 DI DMKHTE1 DMKHTE1 DN PMID29338548-Compound-19 DMKHTE1 TI TTHJTF7 DMKHTE1 TN Glycine transporter GlyT-1 (SLC6A9) DMKHTE1 MA Inhibitor DMKHTE1 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMKHTE1 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMKHWN9 DI DMKHWN9 DMKHWN9 DN Pyrrolo-pyrimidine derivative 3 DMKHWN9 TI TT4DXQT DMKHWN9 TN Proto-oncogene c-Ret (RET) DMKHWN9 MA Inhibitor DMKHWN9 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMKHWN9 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMKIS26 DI DMKIS26 DMKIS26 DN PMID29473428-Compound-54 DMKIS26 TI TTZJYKH DMKIS26 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMKIS26 MA Inhibitor DMKIS26 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMKIS26 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMKJ1HC DI DMKJ1HC DMKJ1HC DN PMID25684022-Compound-WO2008079988 DMKJ1HC TI TTCZOF2 DMKJ1HC TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMKJ1HC MA Inhibitor DMKJ1HC RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMKJ1HC RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMKJ27D DI DMKJ27D DMKJ27D DN Peptide analog 16 DMKJ27D TI TTSJMN8 DMKJ27D TN Immunoproteasome complex (IP) DMKJ27D MA Inhibitor DMKJ27D RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMKJ27D RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMKJ3PC DI DMKJ3PC DMKJ3PC DN Pyridazin-3(2H)-one derivative 1 DMKJ3PC TI TT9JNIC DMKJ3PC TN Histamine H3 receptor (H3R) DMKJ3PC MA Inverse agonist DMKJ3PC RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKJ3PC RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKJL5T DI DMKJL5T DMKJL5T DN Heteroaromatic ring derivative 3 DMKJL5T TI TTSCIM2 DMKJL5T TN Extracellular lysophospholipase D (E-NPP2) DMKJL5T MA Inhibitor DMKJL5T RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMKJL5T RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMKJN9G DI DMKJN9G DMKJN9G DN Quinolinyl pyrazinyl urea derivative 2 DMKJN9G TI TTRZQE3 DMKJN9G TN Glycogen synthase kinase-3 alpha (GSK-3A) DMKJN9G MA Inhibitor DMKJN9G RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMKJN9G RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TTNR0UQ DMKJOMC TN Lysine-specific histone demethylase 1 (LSD) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TT8VP2T DMKJOMC TN Lysine-specific histone demethylase 1B (KDM1B) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TTGP7BY DMKJOMC TN Monoamine oxidase type B (MAO-B) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKJOMC DI DMKJOMC DMKJOMC DN Tarnylcypromine derivative 3 DMKJOMC TI TT3WG5C DMKJOMC TN Monoamine oxidase type A (MAO-A) DMKJOMC MA Inhibitor DMKJOMC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMKJOMC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMKLCZF DI DMKLCZF DMKLCZF DN US9216972, 94 DMKLCZF TI TTDYP7I DMKLCZF TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMKLCZF MA Inhibitor DMKLCZF RN Tricyclic heterocyclic compounds. US9216972. DMKLCZF RU http://www.freepatentsonline.com/US9216972.html DMKLJ6O DI DMKLJ6O DMKLJ6O DN US8586571, 12 DMKLJ6O TI TT0C8BY DMKLJ6O TN Plasma retinol-binding protein (RBP4) DMKLJ6O MA Inhibitor DMKLJ6O RN Heterocyclic compound. US8586571. DMKLJ6O RU http://www.freepatentsonline.com/US8586571.html DMKLO2H DI DMKLO2H DMKLO2H DN Fused benzoheterocycle amide derivative 1 DMKLO2H TI TTKFVXR DMKLO2H TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMKLO2H MA Inhibitor DMKLO2H RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMKLO2H RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMKLVE4 DI DMKLVE4 DMKLVE4 DN US10059720, Example 84 DMKLVE4 TI TTY2KP7 DMKLVE4 TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMKLVE4 MA Inhibitor DMKLVE4 RN Pyridine derivative. US10059720. DMKLVE4 RU http://www.freepatentsonline.com/US10059720.html DMKLYCV DI DMKLYCV DMKLYCV DN US9127005, P0L DMKLYCV TI TT3T17P DMKLYCV TN Phospholipase D1 (PLD1) DMKLYCV MA Inhibitor DMKLYCV RN Isoform selective phospholipase D inhibitors. US9127005. DMKLYCV RU http://www.freepatentsonline.com/US9127005.html DMKM6BY DI DMKM6BY DMKM6BY DN Cyclopenta[d]pyrimidine derivative 1 DMKM6BY TI TTKN7QR DMKM6BY TN BDNF/NT-3 growth factors receptor (TrkB) DMKM6BY MA Inhibitor DMKM6BY RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMKM6BY RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMKM6BY DI DMKM6BY DMKM6BY DN Cyclopenta[d]pyrimidine derivative 1 DMKM6BY TI TTXABCW DMKM6BY TN NT-3 growth factor receptor (TrkC) DMKM6BY MA Inhibitor DMKM6BY RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMKM6BY RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMKM93Q DI DMKM93Q DMKM93Q DN US10150740, Example 4 DMKM93Q TI TTQFZWR DMKM93Q TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMKM93Q MA Inhibitor DMKM93Q RN 6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection. US10150740. DMKM93Q RU http://www.freepatentsonline.com/US10150740.html DMKMY4I DI DMKMY4I DMKMY4I DN PMID25656651-Compound-36d DMKMY4I TI TTIV39N DMKMY4I TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMKMY4I MA Inhibitor DMKMY4I RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKMY4I RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKMY4I DI DMKMY4I DMKMY4I DN PMID25656651-Compound-36d DMKMY4I TI TTS7G69 DMKMY4I TN Fusion protein Bcr-Abl (Bcr-Abl) DMKMY4I MA Inhibitor DMKMY4I RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKMY4I RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKN72Y DI DMKN72Y DMKN72Y DN PMID25666693-Compound-126 DMKN72Y TI TTMI6F5 DMKN72Y TN Transient receptor potential cation channel V1 (TRPV1) DMKN72Y MA Antagonist DMKN72Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKN72Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKNDMB DI DMKNDMB DMKNDMB DN US9024044, 3 DMKNDMB TI TTXL0GC DMKNDMB TN Enteropeptidase (TMPRSS15) DMKNDMB MA Inhibitor DMKNDMB RN Heteroarylcarboxylic acid ester derivative. US9024044. DMKNDMB RU http://www.freepatentsonline.com/US9024044.html DMKNITP DI DMKNITP DMKNITP DN Aminopyrimidine derivative 2 DMKNITP TI TTS7G69 DMKNITP TN Fusion protein Bcr-Abl (Bcr-Abl) DMKNITP MA Inhibitor DMKNITP RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMKNITP RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMKNU0Z DI DMKNU0Z DMKNU0Z DN PMID25666693-Compound-154 DMKNU0Z TI TTMI6F5 DMKNU0Z TN Transient receptor potential cation channel V1 (TRPV1) DMKNU0Z MA Antagonist DMKNU0Z RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKNU0Z RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKO4ZH DI DMKO4ZH DMKO4ZH DN PMID28270021-Compound-WO2014129431Example8-1 DMKO4ZH TI TTTDVOJ DMKO4ZH TN Tropomyosin-related kinase A (TrkA) DMKO4ZH MA Inhibitor DMKO4ZH RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMKO4ZH RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMKOSN5 DI DMKOSN5 DMKOSN5 DN PMID26161824-Compound-69 DMKOSN5 TI TT6OEDT DMKOSN5 TN Cannabinoid receptor 1 (CB1) DMKOSN5 MA Antagonist DMKOSN5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMKOSN5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMKP14O DI DMKP14O DMKP14O DN PMID30185082-Compound-54 DMKP14O TI TT9NXW4 DMKP14O TN Sigma intracellular receptor 2 (TMEM97) DMKP14O MA Ligand DMKP14O RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMKP14O RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMKP64Z DI DMKP64Z DMKP64Z DN PMID25399762-Compound-Figure3-Lycojaponicumin B DMKP64Z TI TT3WG5C DMKP64Z TN Monoamine oxidase type A (MAO-A) DMKP64Z MA Inhibitor DMKP64Z RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMKP64Z RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMKPAN3 DI DMKPAN3 DMKPAN3 DN Imidazo cyclohexylamine derivative 2 DMKPAN3 TI TTDIGC1 DMKPAN3 TN Dipeptidyl peptidase 4 (DPP-4) DMKPAN3 MA Inhibitor DMKPAN3 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMKPAN3 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMKPSIA DI DMKPSIA DMKPSIA DN Heterocyclic derivative 8 DMKPSIA TI TTCZOF2 DMKPSIA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMKPSIA MA Inhibitor DMKPSIA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMKPSIA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMKQ0GE DI DMKQ0GE DMKQ0GE DN SCHEMBL15198145 DMKQ0GE TI TTXHWA7 DMKQ0GE TN Ubiquitin-activating enzyme E1 (UBAE1) DMKQ0GE MA Inhibitor DMKQ0GE RN Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme. US10202389. DMKQ0GE RU http://www.freepatentsonline.com/US10202389.html DMKQFTY DI DMKQFTY DMKQFTY DN Pyridino tricyclic compound 1 DMKQFTY TI TTZJYKH DMKQFTY TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMKQFTY MA Inhibitor DMKQFTY RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMKQFTY RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMKR5ZO DI DMKR5ZO DMKR5ZO DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 DMKR5ZO TI TTJW4LU DMKR5ZO TN Phosphodiesterase 10A (PDE10) DMKR5ZO MA Inhibitor DMKR5ZO RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKR5ZO RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKR5ZO DI DMKR5ZO DMKR5ZO DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 4 DMKR5ZO TI TTJGW1Z DMKR5ZO TN Phosphodiesterase 2A (PDE2A) DMKR5ZO MA Inhibitor DMKR5ZO RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKR5ZO RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKREJ2 DI DMKREJ2 DMKREJ2 DN Benzazepine derivative 2 DMKREJ2 TI TTWJBZ5 DMKREJ2 TN 5-HT 2C receptor (HTR2C) DMKREJ2 MA Agonist DMKREJ2 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMKREJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMKRUAN DI DMKRUAN DMKRUAN DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 DMKRUAN TI TTJW4LU DMKRUAN TN Phosphodiesterase 10A (PDE10) DMKRUAN MA Inhibitor DMKRUAN RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKRUAN RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKRUAN DI DMKRUAN DMKRUAN DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 6 DMKRUAN TI TTJGW1Z DMKRUAN TN Phosphodiesterase 2A (PDE2A) DMKRUAN MA Inhibitor DMKRUAN RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKRUAN RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKRUPW DI DMKRUPW DMKRUPW DN PMID29473428-Compound-39 DMKRUPW TI TTZJYKH DMKRUPW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMKRUPW MA Antagonist DMKRUPW RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMKRUPW RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMKS7D9 DI DMKS7D9 DMKS7D9 DN US9656955, Example 652 DMKS7D9 TI TTYJRN5 DMKS7D9 TN N-acetylglucosaminyltransferase I (NAGAT1) DMKS7D9 MA Inhibitor DMKS7D9 RN Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955. DMKS7D9 RU http://www.freepatentsonline.com/US9656955.html DMKS7O3 DI DMKS7O3 DMKS7O3 DN Chlorobenzamide derivative 2 DMKS7O3 TI TT473XN DMKS7O3 TN P2X purinoceptor 7 (P2RX7) DMKS7O3 MA Antagonist DMKS7O3 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMKS7O3 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMKSNZG DI DMKSNZG DMKSNZG DN Isoxazole-based bicyclic compound 6 DMKSNZG TI TTE4BSY DMKSNZG TN Bromodomain and extraterminal domain protein (BET) DMKSNZG MA Inhibitor DMKSNZG RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMKSNZG RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMKT19M DI DMKT19M DMKT19M DN Diterpenoid derivative 2 DMKT19M TI TTA6ZN2 DMKT19M TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMKT19M MA Activator DMKT19M RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKT19M RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKT19M DI DMKT19M DMKT19M DN Diterpenoid derivative 2 DMKT19M TI TT3Z6Y9 DMKT19M TN Cysteines of Keap1 (KEAP1 Cysteines) DMKT19M MA Modulator DMKT19M RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKT19M RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKT7MD DI DMKT7MD DMKT7MD DN Bicyclic heteroaryl carboxamide analog 2 DMKT7MD TI TTHS256 DMKT7MD TN Metabotropic glutamate receptor 5 (mGluR5) DMKT7MD MA Modulator DMKT7MD RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMKT7MD RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMKTFJ2 DI DMKTFJ2 DMKTFJ2 DN Pyrazole and thiophene derivative 1 DMKTFJ2 TI TTRA6BO DMKTFJ2 TN Bromodomain-containing protein 4 (BRD4) DMKTFJ2 MA Inhibitor DMKTFJ2 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMKTFJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMKTJAH DI DMKTJAH DMKTJAH DN Mannoside derivative 8 DMKTJAH TI TTTCRU2 DMKTJAH TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMKTJAH MA Antagonist DMKTJAH RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMKTJAH RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMKTMCH DI DMKTMCH DMKTMCH DN AC1LDDOQ DMKTMCH TI TT3ZS42 DMKTMCH TN Phosphodiesterase 1B (PDE1B) DMKTMCH MA Inhibitor DMKTMCH RN Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575. DMKTMCH RU http://www.freepatentsonline.com/US10092575.html DMKTNBC DI DMKTNBC DMKTNBC DN Pyrazino[2,1-a]isoquinolin derivative 4 DMKTNBC TI TTA6ZN2 DMKTNBC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMKTNBC MA Activator DMKTNBC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKTNBC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKTNBC DI DMKTNBC DMKTNBC DN Pyrazino[2,1-a]isoquinolin derivative 4 DMKTNBC TI TT3Z6Y9 DMKTNBC TN Cysteines of Keap1 (KEAP1 Cysteines) DMKTNBC MA Modulator DMKTNBC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKTNBC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKTQX8 DI DMKTQX8 DMKTQX8 DN PMID27724045-Compound-29 DMKTQX8 TI TT473XN DMKTQX8 TN P2X purinoceptor 7 (P2RX7) DMKTQX8 MA Antagonist DMKTQX8 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMKTQX8 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMKU51G DI DMKU51G DMKU51G DN Thiazole derivative 3 DMKU51G TI TTA6ZN2 DMKU51G TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMKU51G MA Inhibitor DMKU51G RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMKU51G RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMKU6C3 DI DMKU6C3 DMKU6C3 DN PMID25666693-Compound-18 DMKU6C3 TI TTMI6F5 DMKU6C3 TN Transient receptor potential cation channel V1 (TRPV1) DMKU6C3 MA Antagonist DMKU6C3 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMKU6C3 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMKU7GD DI DMKU7GD DMKU7GD DN PMID27376512-Compound-Table1Example8 DMKU7GD TI TT6S2FE DMKU7GD TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMKU7GD MA Inhibitor DMKU7GD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMKU7GD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMKULV8 DI DMKULV8 DMKULV8 DN Quinoline derivative 17 DMKULV8 TI TTPADOQ DMKULV8 TN HMG-CoA reductase (HMGCR) DMKULV8 MA Inhibitor DMKULV8 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMKULV8 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMKUT6S DI DMKUT6S DMKUT6S DN Indazole amide derivative 1 DMKUT6S TI TTKFVXR DMKUT6S TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMKUT6S MA Inhibitor DMKUT6S RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMKUT6S RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMKVRTM DI DMKVRTM DMKVRTM DN PMID28394193-Compound-Figure5aVIII DMKVRTM TI TT9MZCQ DMKVRTM TN Enhancer of zeste homolog 2 (EZH2) DMKVRTM MA Inhibitor DMKVRTM RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMKVRTM RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMKWFVP DI DMKWFVP DMKWFVP DN PMID25991433-Compound-E1 DMKWFVP TI TT0K6EO DMKWFVP TN Stress-activated protein kinase JNK1 (JNK1) DMKWFVP MA Inhibitor DMKWFVP RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMKWFVP RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMKX5R8 DI DMKX5R8 DMKX5R8 DN PMID29130358-Compound-Figure16(9a) DMKX5R8 TI TTHY57M DMKX5R8 TN Matrix metalloproteinase-13 (MMP-13) DMKX5R8 MA Inhibitor DMKX5R8 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMKX5R8 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMKX5R8 DI DMKX5R8 DMKX5R8 DN PMID29130358-Compound-Figure16(9a) DMKX5R8 TI TTLM12X DMKX5R8 TN Matrix metalloproteinase-2 (MMP-2) DMKX5R8 MA Inhibitor DMKX5R8 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMKX5R8 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMKXD2V DI DMKXD2V DMKXD2V DN Benzo[d]oxazol-2(3H)-one derivative 1 DMKXD2V TI TT9JNIC DMKXD2V TN Histamine H3 receptor (H3R) DMKXD2V MA Inhibitor DMKXD2V RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKXD2V RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKXD2V DI DMKXD2V DMKXD2V DN Benzo[d]oxazol-2(3H)-one derivative 1 DMKXD2V TI TTEX248 DMKXD2V TN Dopamine D2 receptor (D2R) DMKXD2V MA Ligand DMKXD2V RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMKXD2V RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMKXRJ4 DI DMKXRJ4 DMKXRJ4 DN US8889696, 39 DMKXRJ4 TI TTUWGRA DMKXRJ4 TN Protein kinase C zeta (PRKCZ) DMKXRJ4 MA Inhibitor DMKXRJ4 RN Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696. DMKXRJ4 RU http://www.freepatentsonline.com/US8889696.html DMKXRYM DI DMKXRYM DMKXRYM DN 1,2,4-triazole [4,3-a]quinoxaline derivative 3 DMKXRYM TI TTJGW1Z DMKXRYM TN Phosphodiesterase 2A (PDE2A) DMKXRYM MA Inhibitor DMKXRYM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKXRYM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKXRYM DI DMKXRYM DMKXRYM DN 1,2,4-triazole [4,3-a]quinoxaline derivative 3 DMKXRYM TI TTJW4LU DMKXRYM TN Phosphodiesterase 10A (PDE10) DMKXRYM MA Inhibitor DMKXRYM RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMKXRYM RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMKXT7H DI DMKXT7H DMKXT7H DN Biaryl mannoside derivative 15 DMKXT7H TI TTTCRU2 DMKXT7H TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMKXT7H MA Antagonist DMKXT7H RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMKXT7H RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMKXZUA DI DMKXZUA DMKXZUA DN Tetra-substituted urea derivative 2 DMKXZUA TI TTDP1UC DMKXZUA TN Fatty acid amide hydrolase (FAAH) DMKXZUA MA Inhibitor DMKXZUA RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMKXZUA RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMKXZYC DI DMKXZYC DMKXZYC DN PMID28350212-Compound-22 DMKXZYC TI TTZS04O DMKXZYC TN Gamma-secretase subunit APH-1A/1B (APH-1) DMKXZYC MA Inhibitor DMKXZYC RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMKXZYC RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMKYNB0 DI DMKYNB0 DMKYNB0 DN US8703720, 15 DMKYNB0 TI TTO3NYT DMKYNB0 TN Galectin-1 (LGALS1) DMKYNB0 MA Inhibitor DMKYNB0 RN Galactoside inhibitors of galectins. US8703720. DMKYNB0 RU http://www.freepatentsonline.com/US8703720.html DMKYOLV DI DMKYOLV DMKYOLV DN Peptide analog 7 DMKYOLV TI TTH8FZW DMKYOLV TN Signal transducer and activator of transcription 3 (STAT3) DMKYOLV MA Inhibitor DMKYOLV RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMKYOLV RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMKYX7J DI DMKYX7J DMKYX7J DN Pyrazolodihydropyridine derivative 1 DMKYX7J TI TTRZQE3 DMKYX7J TN Glycogen synthase kinase-3 alpha (GSK-3A) DMKYX7J MA Inhibitor DMKYX7J RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMKYX7J RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMKZ6MD DI DMKZ6MD DMKZ6MD DN Quinazoline derivative 6 DMKZ6MD TI TTPTXIN DMKZ6MD TN Translocator protein (TSPO) DMKZ6MD MA Ligand DMKZ6MD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMKZ6MD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMKZC4V DI DMKZC4V DMKZC4V DN US9586945, 19a DMKZC4V TI TTYJRN5 DMKZC4V TN N-acetylglucosaminyltransferase I (NAGAT1) DMKZC4V MA Inhibitor DMKZC4V RN Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586945. DMKZC4V RU http://www.freepatentsonline.com/US9586945.html DMKZF8E DI DMKZF8E DMKZF8E DN PMID27215781-Compound-25 DMKZF8E TI TTMSFAW DMKZF8E TN Cannabinoid receptor 2 (CB2) DMKZF8E MA Agonist DMKZF8E RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMKZF8E RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMKZLCQ DI DMKZLCQ DMKZLCQ DN Bidentate pyrazolopyrimidine acetamide analog 4 DMKZLCQ TI TTPTXIN DMKZLCQ TN Translocator protein (TSPO) DMKZLCQ MA Ligand DMKZLCQ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMKZLCQ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMKZTVR DI DMKZTVR DMKZTVR DN PMID26666989-Compound-Figure9middle13 DMKZTVR TI TT8BUGW DMKZTVR TN Glycogen phosphorylase (PYG) DMKZTVR MA Inhibitor DMKZTVR RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMKZTVR RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMKZUO4 DI DMKZUO4 DMKZUO4 DN Piperazine carbamic compound 4 DMKZUO4 TI TTSINOV DMKZUO4 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMKZUO4 MA Inhibitor DMKZUO4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMKZUO4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMKZUO4 DI DMKZUO4 DMKZUO4 DN Piperazine carbamic compound 4 DMKZUO4 TI TTZ963I DMKZUO4 TN Monoglyceride lipase (MAGL) DMKZUO4 MA Inhibitor DMKZUO4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMKZUO4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DML1IXV DI DML1IXV DML1IXV DN Aryl oxyanilide derivative 1 DML1IXV TI TTPTXIN DML1IXV TN Translocator protein (TSPO) DML1IXV MA Ligand DML1IXV RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DML1IXV RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DML1U69 DI DML1U69 DML1U69 DN PMID25553724-Compound-WO2013082253 34 DML1U69 TI TTSXVID DML1U69 TN Nuclear factor NF-kappa-B (NFKB) DML1U69 MA Modulator DML1U69 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DML1U69 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DML25WY DI DML25WY DML25WY DN PMID27841045-Compound-137 DML25WY TI TT7RJY8 DML25WY TN Xanthine dehydrogenase/oxidase (XDH) DML25WY MA Inhibitor DML25WY RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DML25WY RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DML2B58 DI DML2B58 DML2B58 DN Alkyl mannoside derivative 3 DML2B58 TI TTTCRU2 DML2B58 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DML2B58 MA Antagonist DML2B58 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DML2B58 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DML2B7G DI DML2B7G DML2B7G DN Beta-cyclodextrin conjugate derivative 5 DML2B7G TI TTTCRU2 DML2B7G TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DML2B7G MA Antagonist DML2B7G RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DML2B7G RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DML2E8S DI DML2E8S DML2E8S DN Pyrimidinyl compound 6 DML2E8S TI TTH5TC2 DML2E8S TN NF-kappa-B-activating kinase (TBK1) DML2E8S MA Inhibitor DML2E8S RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DML2E8S RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DML2PWF DI DML2PWF DML2PWF DN Tricyclic isoxazoloquinazoline derivative 3 DML2PWF TI TTP7EGM DML2PWF TN Dual specificity protein kinase TTK (MPS1) DML2PWF MA Inhibitor DML2PWF RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DML2PWF RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DML2PWF DI DML2PWF DML2PWF DN Tricyclic isoxazoloquinazoline derivative 3 DML2PWF TI TT5OU0D DML2PWF TN PRKR-like endoplasmic reticulum kinase (PERK) DML2PWF MA Inhibitor DML2PWF RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DML2PWF RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DML2VUC DI DML2VUC DML2VUC DN PMID28350212-Compound-25 DML2VUC TI TTZS04O DML2VUC TN Gamma-secretase subunit APH-1A/1B (APH-1) DML2VUC MA Inhibitor DML2VUC RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DML2VUC RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DML32R8 DI DML32R8 DML32R8 DN VX-148 DML32R8 TI TTL7C8Q DML32R8 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DML32R8 MA Inhibitor DML32R8 RN Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. J Pharmacol Exp Ther. 2002 Sep;302(3):1272-7. DML32R8 RU https://pubmed.ncbi.nlm.nih.gov/12183689 DML3KHF DI DML3KHF DML3KHF DN PMID25666693-Compound-39 DML3KHF TI TTMI6F5 DML3KHF TN Transient receptor potential cation channel V1 (TRPV1) DML3KHF MA Antagonist DML3KHF RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DML3KHF RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DML3PE4 DI DML3PE4 DML3PE4 DN Benzimidazole derivative 10 DML3PE4 TI TTQR74A DML3PE4 TN Proteinase activated receptor 2 (PAR2) DML3PE4 MA Antagonist DML3PE4 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DML3PE4 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DML47KS DI DML47KS DML47KS DN PMID29865878-Compound-62 DML47KS TI TTEAD9J DML47KS TN Proteasome beta-8 (PS beta-8) DML47KS MA Inhibitor DML47KS RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML47KS RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML48NA DI DML48NA DML48NA DN PMID25435285-Compound-50 DML48NA TI TTXJ47W DML48NA TN Metabotropic glutamate receptor 2 (mGluR2) DML48NA MA Antagonist DML48NA RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DML48NA RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DML49UI DI DML49UI DML49UI DN PMID27109571-Compound-23 DML49UI TI TTNT2S6 DML49UI TN Fatty acid-binding protein 5 (FABP5) DML49UI MA Inhibitor DML49UI RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DML49UI RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DML49UI DI DML49UI DML49UI DN PMID27109571-Compound-23 DML49UI TI TTHWMFZ DML49UI TN Fatty acid-binding protein 4 (FABP4) DML49UI MA Inhibitor DML49UI RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DML49UI RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DML4AVX DI DML4AVX DML4AVX DN PMID27841045-Compound-156 DML4AVX TI TT7RJY8 DML4AVX TN Xanthine dehydrogenase/oxidase (XDH) DML4AVX MA Inhibitor DML4AVX RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DML4AVX RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DML4C6D DI DML4C6D DML4C6D DN PMID27977313-Compound-42 DML4C6D TI TTR7UJ3 DML4C6D TN Cytoplasmic thioredoxin reductase (TXNRD1) DML4C6D MA Inhibitor DML4C6D RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DML4C6D RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DML4OYQ DI DML4OYQ DML4OYQ DN Pyrimidinedione derivative 1 DML4OYQ TI TTDIGC1 DML4OYQ TN Dipeptidyl peptidase 4 (DPP-4) DML4OYQ MA Inhibitor DML4OYQ RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DML4OYQ RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DML4XJ2 DI DML4XJ2 DML4XJ2 DN Peptide analog 27 DML4XJ2 TI TT68GPI DML4XJ2 TN Proteasome beta-5 (PS beta-5) DML4XJ2 MA Inhibitor DML4XJ2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML4XJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML4XJ2 DI DML4XJ2 DML4XJ2 DN Peptide analog 27 DML4XJ2 TI TTEAD9J DML4XJ2 TN Proteasome beta-8 (PS beta-8) DML4XJ2 MA Inhibitor DML4XJ2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML4XJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML5G6D DI DML5G6D DML5G6D DN PMID29473428-Compound-71 DML5G6D TI TTZJYKH DML5G6D TN Indoleamine 2,3-dioxygenase 1 (IDO1) DML5G6D MA Inhibitor DML5G6D RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DML5G6D RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DML5I9K DI DML5I9K DML5I9K DN PMID26394986-Compound-50 DML5I9K TI TTH8FZW DML5I9K TN Signal transducer and activator of transcription 3 (STAT3) DML5I9K MA Inhibitor DML5I9K RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DML5I9K RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DML5KXB DI DML5KXB DML5KXB DN US20160326143, 3 DML5KXB TI TTW7OTG DML5KXB TN Leukotriene C4 synthase (LTC4S) DML5KXB MA Inhibitor DML5KXB RN COMPOUNDS AND USES. US20160326143. DML5KXB RU http://www.freepatentsonline.com/US20160326143.html DML5P6O DI DML5P6O DML5P6O DN Peptide analog 33 DML5P6O TI TT68GPI DML5P6O TN Proteasome beta-5 (PS beta-5) DML5P6O MA Inhibitor DML5P6O RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML5P6O RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML5P6O DI DML5P6O DML5P6O DN Peptide analog 33 DML5P6O TI TTEAD9J DML5P6O TN Proteasome beta-8 (PS beta-8) DML5P6O MA Inhibitor DML5P6O RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML5P6O RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML63B7 DI DML63B7 DML63B7 DN Aromatic hydrazine carboxyimidoamide derivative 3 DML63B7 TI TTULVH8 DML63B7 TN Tyrosinase (TYR) DML63B7 MA Inhibitor DML63B7 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DML63B7 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DML6PE0 DI DML6PE0 DML6PE0 DN PMID28394193-Compound-Figure3bII DML6PE0 TI TT9MZCQ DML6PE0 TN Enhancer of zeste homolog 2 (EZH2) DML6PE0 MA Inhibitor DML6PE0 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DML6PE0 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DML6V78 DI DML6V78 DML6V78 DN Pyrazolo-triazine derivative 2 DML6V78 TI TTQYF7G DML6V78 TN Cyclin-dependent kinase 7 (CDK7) DML6V78 MA Inhibitor DML6V78 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DML6V78 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DML6V78 DI DML6V78 DML6V78 DN Pyrazolo-triazine derivative 2 DML6V78 TI TT7HF4W DML6V78 TN Cyclin-dependent kinase 2 (CDK2) DML6V78 MA Inhibitor DML6V78 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DML6V78 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DML724H DI DML724H DML724H DN Tricyclic indole compound 11 DML724H TI TTPTXIN DML724H TN Translocator protein (TSPO) DML724H MA Ligand DML724H RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DML724H RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DML76MF DI DML76MF DML76MF DN PMID25666693-Compound-41 DML76MF TI TTMI6F5 DML76MF TN Transient receptor potential cation channel V1 (TRPV1) DML76MF MA Antagonist DML76MF RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DML76MF RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DML79XQ DI DML79XQ DML79XQ DN PMID28092474-Compound-32x DML79XQ TI TT6R7JZ DML79XQ TN Histone deacetylase 1 (HDAC1) DML79XQ MA Inhibitor DML79XQ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DML79XQ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DML79XQ DI DML79XQ DML79XQ DN PMID28092474-Compound-32x DML79XQ TI TT5ZKDI DML79XQ TN Histone deacetylase 6 (HDAC6) DML79XQ MA Inhibitor DML79XQ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DML79XQ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DML7ONU DI DML7ONU DML7ONU DN Resorcinol compound 29 DML7ONU TI TTULVH8 DML7ONU TN Tyrosinase (TYR) DML7ONU MA Inhibitor DML7ONU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DML7ONU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DML7SYH DI DML7SYH DML7SYH DN PMID25666693-Compound-131 DML7SYH TI TTMI6F5 DML7SYH TN Transient receptor potential cation channel V1 (TRPV1) DML7SYH MA Antagonist DML7SYH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DML7SYH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DML83KW DI DML83KW DML83KW DN Aminopyrimidine derivative 8 DML83KW TI TTH5TC2 DML83KW TN NF-kappa-B-activating kinase (TBK1) DML83KW MA Inhibitor DML83KW RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DML83KW RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TTGP7BY DML86IO TN Monoamine oxidase type B (MAO-B) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TT1RS9F DML86IO TN Acetylcholinesterase (AChE) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TT3WG5C DML86IO TN Monoamine oxidase type A (MAO-A) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML86IO DI DML86IO DML86IO DN Tetra-hydro-isoquinoline derivative 1 DML86IO TI TTEB0GD DML86IO TN Cholinesterase (BCHE) DML86IO MA Inhibitor DML86IO RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DML86IO RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DML8FUD DI DML8FUD DML8FUD DN PMID29130358-Compound-Figure15(8) DML8FUD TI TTXPTJE DML8FUD TN Gelatinase (GEL) DML8FUD MA Inhibitor DML8FUD RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DML8FUD RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DML8RVS DI DML8RVS DML8RVS DN 1-Benzyl-3-bromo-1H-pyrrole-2,5-dione DML8RVS TI TTWME23 DML8RVS TN Regulator of G-protein signaling 8 (RGS8) DML8RVS MA Inhibitor DML8RVS RN Small molecule inhibitors of RGS proteins. US8865750. DML8RVS RU http://www.freepatentsonline.com/US8865750.html DML8W16 DI DML8W16 DML8W16 DN Benzimidazole derivative 1 DML8W16 TI TT6OEDT DML8W16 TN Cannabinoid receptor 1 (CB1) DML8W16 MA Antagonist DML8W16 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DML8W16 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DML9C64 DI DML9C64 DML9C64 DN Peptide analog 11 DML9C64 TI TT68GPI DML9C64 TN Proteasome beta-5 (PS beta-5) DML9C64 MA Inhibitor DML9C64 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML9C64 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML9C64 DI DML9C64 DML9C64 DN Peptide analog 11 DML9C64 TI TTEAD9J DML9C64 TN Proteasome beta-8 (PS beta-8) DML9C64 MA Inhibitor DML9C64 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DML9C64 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DML9TF7 DI DML9TF7 DML9TF7 DN Benzene sulfonamide derivative 11 DML9TF7 TI TT4G2JS DML9TF7 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DML9TF7 MA Inhibitor DML9TF7 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DML9TF7 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMLAH39 DI DMLAH39 DMLAH39 DN PMID25435179-Compound-WO2012106509Salermide DMLAH39 TI TTUF2HO DMLAH39 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMLAH39 MA Inhibitor DMLAH39 RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMLAH39 RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMLAHC1 DI DMLAHC1 DMLAHC1 DN PMID29338548-Compound-40 DMLAHC1 TI TTHJTF7 DMLAHC1 TN Glycine transporter GlyT-1 (SLC6A9) DMLAHC1 MA Inhibitor DMLAHC1 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMLAHC1 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMLAS7K DI DMLAS7K DMLAS7K DN PMID25399762-Compound-Table 5-8 DMLAS7K TI TT3WG5C DMLAS7K TN Monoamine oxidase type A (MAO-A) DMLAS7K MA Inhibitor DMLAS7K RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMLAS7K RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMLAY8B DI DMLAY8B DMLAY8B DN PMID27376512-Compound-asCEBP-1HPE DMLAY8B TI TT6S2FE DMLAY8B TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMLAY8B MA Inhibitor DMLAY8B RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMLAY8B RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMLAYG7 DI DMLAYG7 DMLAYG7 DN 1,2,4,5-tetra-substituted imidazole derivative 1 DMLAYG7 TI TT6OEDT DMLAYG7 TN Cannabinoid receptor 1 (CB1) DMLAYG7 MA Antagonist DMLAYG7 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMLAYG7 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMLBA4D DI DMLBA4D DMLBA4D DN Thiazolidine dione crystalline derivative 1 DMLBA4D TI TTZMAO3 DMLBA4D TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMLBA4D MA Agonist DMLBA4D RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMLBA4D RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMLBEPW DI DMLBEPW DMLBEPW DN Salicylic acid derivative 6 DMLBEPW TI TTH8FZW DMLBEPW TN Signal transducer and activator of transcription 3 (STAT3) DMLBEPW MA Inhibitor DMLBEPW RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMLBEPW RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMLBK8V DI DMLBK8V DMLBK8V DN Thiazole carboxamide derivative 7 DMLBK8V TI TTCZOF2 DMLBK8V TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLBK8V MA Inhibitor DMLBK8V RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLBK8V RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLBN1T DI DMLBN1T DMLBN1T DN Diaryl amine derivative 3 DMLBN1T TI TT6R7JZ DMLBN1T TN Histone deacetylase 1 (HDAC1) DMLBN1T MA Inhibitor DMLBN1T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLBN1T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLBN1T DI DMLBN1T DMLBN1T DN Diaryl amine derivative 3 DMLBN1T TI TT5ZKDI DMLBN1T TN Histone deacetylase 6 (HDAC6) DMLBN1T MA Inhibitor DMLBN1T RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLBN1T RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLBQUS DI DMLBQUS DMLBQUS DN PMID29649907-Compound-13 DMLBQUS TI TTS4UGC DMLBQUS TN Farnesoid X-activated receptor (FXR) DMLBQUS MA Agonist DMLBQUS RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMLBQUS RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMLBR4F DI DMLBR4F DMLBR4F DN Tricyclic compound 1 DMLBR4F TI TTRMX3V DMLBR4F TN Janus kinase 2 (JAK-2) DMLBR4F MA Inhibitor DMLBR4F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMLBR4F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMLBR4F DI DMLBR4F DMLBR4F DN Tricyclic compound 1 DMLBR4F TI TTT7PJU DMLBR4F TN Janus kinase 3 (JAK-3) DMLBR4F MA Inhibitor DMLBR4F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMLBR4F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMLBR4F DI DMLBR4F DMLBR4F DN Tricyclic compound 1 DMLBR4F TI TT6DM01 DMLBR4F TN Janus kinase 1 (JAK-1) DMLBR4F MA Inhibitor DMLBR4F RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMLBR4F RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMLBZGO DI DMLBZGO DMLBZGO DN PMID26651364-Compound-45 DMLBZGO TI TTTCRU2 DMLBZGO TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMLBZGO MA Antagonist DMLBZGO RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMLBZGO RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMLC5WA DI DMLC5WA DMLC5WA DN Pyridine derivative 17 DMLC5WA TI TTHS256 DMLC5WA TN Metabotropic glutamate receptor 5 (mGluR5) DMLC5WA MA Modulator DMLC5WA RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLC5WA RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLCPWT DI DMLCPWT DMLCPWT DN PMID25726713-Compound-25 DMLCPWT TI TT8J1S3 DMLCPWT TN Smoothened homolog (SMO) DMLCPWT MA Inhibitor DMLCPWT RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMLCPWT RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMLD49W DI DMLD49W DMLD49W DN Cyclohexyl carbamate derivative 4 DMLD49W TI TTULVH8 DMLD49W TN Tyrosinase (TYR) DMLD49W MA Inhibitor DMLD49W RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMLD49W RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMLD7JU DI DMLD7JU DMLD7JU DN 1,3,5-triazine derivative 1 DMLD7JU TI TTMSFAW DMLD7JU TN Cannabinoid receptor 2 (CB2) DMLD7JU RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMLD7JU RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMLD8K3 DI DMLD8K3 DMLD8K3 DN PMID28394193-Compound-21 DMLD8K3 TI TT9MZCQ DMLD8K3 TN Enhancer of zeste homolog 2 (EZH2) DMLD8K3 MA Inhibitor DMLD8K3 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMLD8K3 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMLDFVN DI DMLDFVN DMLDFVN DN PMID29671355-Compound-50 DMLDFVN TI TTTQGH8 DMLDFVN TN Histone deacetylase 4 (HDAC4) DMLDFVN MA Inhibitor DMLDFVN RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLDFVN RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLDMO8 DI DMLDMO8 DMLDMO8 DN Ethynyl compound 4 DMLDMO8 TI TTHS256 DMLDMO8 TN Metabotropic glutamate receptor 5 (mGluR5) DMLDMO8 MA Modulator DMLDMO8 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLDMO8 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLDPGY DI DMLDPGY DMLDPGY DN PMID25416646-Compound-Figure2-N DMLDPGY TI TTZMAO3 DMLDPGY TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMLDPGY MA Agonist DMLDPGY RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMLDPGY RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMLDXOB DI DMLDXOB DMLDXOB DN Carbamide derivative 19 DMLDXOB TI TTOHSBA DMLDXOB TN Vascular endothelial growth factor A (VEGFA) DMLDXOB MA Inhibitor DMLDXOB RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMLDXOB RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMLE5BK DI DMLE5BK DMLE5BK DN PMID25666693-Compound-146 DMLE5BK TI TTMI6F5 DMLE5BK TN Transient receptor potential cation channel V1 (TRPV1) DMLE5BK MA Antagonist DMLE5BK RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLE5BK RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLEH4U DI DMLEH4U DMLEH4U DN 2-pyrazinone derivative 2 DMLEH4U TI TTPLTSQ DMLEH4U TN Neutrophil elastase (NE) DMLEH4U MA Inhibitor DMLEH4U RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMLEH4U RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMLET14 DI DMLET14 DMLET14 DN Benzene sulfonamide derivative 9 DMLET14 TI TT4G2JS DMLET14 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMLET14 MA Blocker DMLET14 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMLET14 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMLEWY6 DI DMLEWY6 DMLEWY6 DN PMID28870136-Compound-53 DMLEWY6 TI TTK0O6Y DMLEWY6 TN Ecto-5'-nucleotidase (CD73) DMLEWY6 MA Inhibitor DMLEWY6 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMLEWY6 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMLF53V DI DMLF53V DMLF53V DN Resorcinol compound 8 DMLF53V TI TTULVH8 DMLF53V TN Tyrosinase (TYR) DMLF53V MA Inhibitor DMLF53V RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMLF53V RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMLFY57 DI DMLFY57 DMLFY57 DN Pyrimidinone derivative 5 DMLFY57 TI TTSCIM2 DMLFY57 TN Extracellular lysophospholipase D (E-NPP2) DMLFY57 MA Inhibitor DMLFY57 RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMLFY57 RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMLGBR6 DI DMLGBR6 DMLGBR6 DN PMID29671355-Compound-68b DMLGBR6 TI TTTQGH8 DMLGBR6 TN Histone deacetylase 4 (HDAC4) DMLGBR6 MA Inhibitor DMLGBR6 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLGBR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLGBR6 DI DMLGBR6 DMLGBR6 DN PMID29671355-Compound-68b DMLGBR6 TI TTT6LFV DMLGBR6 TN Histone deacetylase 8 (HDAC8) DMLGBR6 MA Inhibitor DMLGBR6 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLGBR6 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLGD52 DI DMLGD52 DMLGD52 DN PMID25656651-Compound-40 DMLGD52 TI TTS7G69 DMLGD52 TN Fusion protein Bcr-Abl (Bcr-Abl) DMLGD52 MA Inhibitor DMLGD52 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMLGD52 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMLGKYI DI DMLGKYI DMLGKYI DN PMID30185082-Compound-56 DMLGKYI TI TT9NXW4 DMLGKYI TN Sigma intracellular receptor 2 (TMEM97) DMLGKYI MA Ligand DMLGKYI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMLGKYI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMLGNB2 DI DMLGNB2 DMLGNB2 DN Triazolo-pyrimidinedione derivative 2 DMLGNB2 TI TTDIGC1 DMLGNB2 TN Dipeptidyl peptidase 4 (DPP-4) DMLGNB2 MA Inhibitor DMLGNB2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMLGNB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMLGYXW DI DMLGYXW DMLGYXW DN PMID28627961-Compound-31 DMLGYXW TI TTYLQ8V DMLGYXW TN Prostaglandin E synthase (PTGES) DMLGYXW MA Inhibitor DMLGYXW RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMLGYXW RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMLGZPO DI DMLGZPO DMLGZPO DN PMID26560530-Compound-34 DMLGZPO TI TT2F4OL DMLGZPO TN Tissue transglutaminase (TG2) DMLGZPO MA Inhibitor DMLGZPO RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMLGZPO RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMLH45M DI DMLH45M DMLH45M DN Carbamate derivative 13 DMLH45M TI TTZ963I DMLH45M TN Monoglyceride lipase (MAGL) DMLH45M MA Inhibitor DMLH45M RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMLH45M RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMLH637 DI DMLH637 DMLH637 DN PMID26004420-Compound-WO2014015495B DMLH637 TI TTJ13ST DMLH637 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMLH637 MA Inhibitor DMLH637 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMLH637 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMLH9AQ DI DMLH9AQ DMLH9AQ DN Cyclopropane 1-carboxylic acid derivative 9 DMLH9AQ TI TTIY56R DMLH9AQ TN Kynurenine 3-hydroxylase (KMO) DMLH9AQ MA Inhibitor DMLH9AQ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMLH9AQ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMLHC5V DI DMLHC5V DMLHC5V DN PMID25991433-Compound-N3 DMLHC5V TI TT3ZIJL DMLHC5V TN JNK-interacting protein peptide (pepJIP) DMLHC5V MA Inhibitor DMLHC5V RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLHC5V RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLHC5V DI DMLHC5V DMLHC5V DN PMID25991433-Compound-N3 DMLHC5V TI TT0K6EO DMLHC5V TN Stress-activated protein kinase JNK1 (JNK1) DMLHC5V MA Inhibitor DMLHC5V RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLHC5V RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLHGC9 DI DMLHGC9 DMLHGC9 DN Indole carboxamide derivative 1 DMLHGC9 TI TT473XN DMLHGC9 TN P2X purinoceptor 7 (P2RX7) DMLHGC9 MA Antagonist DMLHGC9 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMLHGC9 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMLHJ1E DI DMLHJ1E DMLHJ1E DN PMID26651364-Compound-5b DMLHJ1E TI TTTCRU2 DMLHJ1E TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMLHJ1E MA Antagonist DMLHJ1E RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMLHJ1E RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMLI1YR DI DMLI1YR DMLI1YR DN PMID25666693-Compound-59 DMLI1YR TI TTMI6F5 DMLI1YR TN Transient receptor potential cation channel V1 (TRPV1) DMLI1YR MA Antagonist DMLI1YR RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLI1YR RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLI7TG DI DMLI7TG DMLI7TG DN PMID28394193-Compound-42 DMLI7TG TI TT9MZCQ DMLI7TG TN Enhancer of zeste homolog 2 (EZH2) DMLI7TG MA Inhibitor DMLI7TG RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMLI7TG RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMLIRGM DI DMLIRGM DMLIRGM DN Thiazole carboxamide derivative 2 DMLIRGM TI TTCZOF2 DMLIRGM TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLIRGM MA Inhibitor DMLIRGM RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLIRGM RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLIVT6 DI DMLIVT6 DMLIVT6 DN Peptide analog 19 DMLIVT6 TI TT68GPI DMLIVT6 TN Proteasome beta-5 (PS beta-5) DMLIVT6 MA Inhibitor DMLIVT6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMLIVT6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMLIVT6 DI DMLIVT6 DMLIVT6 DN Peptide analog 19 DMLIVT6 TI TTEAD9J DMLIVT6 TN Proteasome beta-8 (PS beta-8) DMLIVT6 MA Inhibitor DMLIVT6 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMLIVT6 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMLIW1X DI DMLIW1X DMLIW1X DN Quinoline derivative 8 DMLIW1X TI TTXJ47W DMLIW1X TN Metabotropic glutamate receptor 2 (mGluR2) DMLIW1X MA Antagonist DMLIW1X RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMLIW1X RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMLJ2HE DI DMLJ2HE DMLJ2HE DN Undecylenic acid derivative 1 DMLJ2HE TI TT1WBIJ DMLJ2HE TN Calpain-1 (CAPN1) DMLJ2HE RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMLJ2HE RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMLJH5T DI DMLJH5T DMLJH5T DN Boronic acid derivative 2 DMLJH5T TI TTDP1UC DMLJH5T TN Fatty acid amide hydrolase (FAAH) DMLJH5T MA Inhibitor DMLJH5T RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMLJH5T RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMLJU5P DI DMLJU5P DMLJU5P DN BDBM50080570 DMLJU5P TI TTDYP7I DMLJU5P TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMLJU5P MA Inhibitor DMLJU5P RN Pyridin-4-yl derivatives. US9617250. DMLJU5P RU http://www.freepatentsonline.com/US9617250.html DMLJV01 DI DMLJV01 DMLJV01 DN US10034861, Example 1 DMLJV01 TI TT3ZS42 DMLJV01 TN Phosphodiesterase 1B (PDE1B) DMLJV01 MA Inhibitor DMLJV01 RN 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors. US10034861. DMLJV01 RU http://www.freepatentsonline.com/US10034861.html DMLJYS1 DI DMLJYS1 DMLJYS1 DN Resorcinol compound 33 DMLJYS1 TI TTULVH8 DMLJYS1 TN Tyrosinase (TYR) DMLJYS1 MA Inhibitor DMLJYS1 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMLJYS1 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMLK29E DI DMLK29E DMLK29E DN 3-substituted-2-furancarboxylic acid hydrazide derivative 5 DMLK29E TI TT9O6WS DMLK29E TN Glucagon receptor (GCGR) DMLK29E MA Antagonist DMLK29E RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMLK29E RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMLKNWF DI DMLKNWF DMLKNWF DN Aryl piperazine derivative 9 DMLKNWF TI TTWJBZ5 DMLKNWF TN 5-HT 2C receptor (HTR2C) DMLKNWF MA Agonist DMLKNWF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMLKNWF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMLKNWF DI DMLKNWF DMLKNWF DN Aryl piperazine derivative 9 DMLKNWF TI TTJQOD7 DMLKNWF TN 5-HT 2A receptor (HTR2A) DMLKNWF MA Agonist DMLKNWF RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMLKNWF RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMLKP1O DI DMLKP1O DMLKP1O DN PMID28067079-Compound-98 DMLKP1O TI TTHS256 DMLKP1O TN Metabotropic glutamate receptor 5 (mGluR5) DMLKP1O MA Modulator DMLKP1O RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLKP1O RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLM6DT DI DMLM6DT DMLM6DT DN Pyrrolo-pyrazine derivative 3 DMLM6DT TI TTOU65C DMLM6DT TN Tyrosine-protein kinase SYK (SYK) DMLM6DT MA Inhibitor DMLM6DT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMLM6DT RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMLM6DT DI DMLM6DT DMLM6DT DN Pyrrolo-pyrazine derivative 3 DMLM6DT TI TTT7PJU DMLM6DT TN Janus kinase 3 (JAK-3) DMLM6DT MA Inhibitor DMLM6DT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMLM6DT RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMLMEPI DI DMLMEPI DMLMEPI DN PMID25666693-Compound-139 DMLMEPI TI TTMI6F5 DMLMEPI TN Transient receptor potential cation channel V1 (TRPV1) DMLMEPI MA Antagonist DMLMEPI RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLMEPI RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLMHR5 DI DMLMHR5 DMLMHR5 DN PMID29053063-Compound-11c DMLMHR5 TI TTZ963I DMLMHR5 TN Monoglyceride lipase (MAGL) DMLMHR5 MA Inhibitor DMLMHR5 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMLMHR5 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMLMHR5 DI DMLMHR5 DMLMHR5 DN PMID29053063-Compound-11c DMLMHR5 TI TTSINOV DMLMHR5 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMLMHR5 MA Inhibitor DMLMHR5 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMLMHR5 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMLMQD4 DI DMLMQD4 DMLMQD4 DN PMID26394986-Compound-21 DMLMQD4 TI TTH8FZW DMLMQD4 TN Signal transducer and activator of transcription 3 (STAT3) DMLMQD4 MA Inhibitor DMLMQD4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMLMQD4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMLMV1Y DI DMLMV1Y DMLMV1Y DN US10040779, Example 1 DMLMV1Y TI TTIG67W DMLMV1Y TN Lysine-specific demethylase 5A (KDM5A) DMLMV1Y MA Inhibitor DMLMV1Y RN Histone demethylase inhibitors. US10040779. DMLMV1Y RU http://www.freepatentsonline.com/US10040779.html DMLMV4O DI DMLMV4O DMLMV4O DN Boronic acid derivative 6 DMLMV4O TI TTDP1UC DMLMV4O TN Fatty acid amide hydrolase (FAAH) DMLMV4O MA Inhibitor DMLMV4O RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMLMV4O RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMLMXT6 DI DMLMXT6 DMLMXT6 DN Tetra-hydro-imidazo[1,5-d][1,4]oxazepin-3-yl derivative 4 DMLMXT6 TI TTXJ47W DMLMXT6 TN Metabotropic glutamate receptor 2 (mGluR2) DMLMXT6 MA Antagonist DMLMXT6 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMLMXT6 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMLNA8P DI DMLNA8P DMLNA8P DN PMID28051882-Compound-XI DMLNA8P TI TT9NXW4 DMLNA8P TN Sigma intracellular receptor 2 (TMEM97) DMLNA8P MA Ligand DMLNA8P RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMLNA8P RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMLOBAQ DI DMLOBAQ DMLOBAQ DN Ethinyl-pyrazole derivative 1 DMLOBAQ TI TTXJ47W DMLOBAQ TN Metabotropic glutamate receptor 2 (mGluR2) DMLOBAQ MA Antagonist DMLOBAQ RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMLOBAQ RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMLOIHD DI DMLOIHD DMLOIHD DN Aminoazetidine derivative 8 DMLOIHD TI TT6OEDT DMLOIHD TN Cannabinoid receptor 1 (CB1) DMLOIHD MA Antagonist DMLOIHD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMLOIHD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMLOVMP DI DMLOVMP DMLOVMP DN Biphenyl carboxamidopropanoic acid derivative 3 DMLOVMP TI TT9O6WS DMLOVMP TN Glucagon receptor (GCGR) DMLOVMP MA Antagonist DMLOVMP RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMLOVMP RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMLPMS7 DI DMLPMS7 DMLPMS7 DN Tricyclic compound 5 DMLPMS7 TI TTGWKQJ DMLPMS7 TN Rho-associated protein kinase 2 (ROCK2) DMLPMS7 MA Inhibitor DMLPMS7 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMLPMS7 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMLPO0K DI DMLPO0K DMLPO0K DN Pyrimidine derivative 19 DMLPO0K TI TT8J1S3 DMLPO0K TN Smoothened homolog (SMO) DMLPO0K MA Inhibitor DMLPO0K RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMLPO0K RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMLPOUR DI DMLPOUR DMLPOUR DN Carbamide derivative 16 DMLPOUR TI TTOHSBA DMLPOUR TN Vascular endothelial growth factor A (VEGFA) DMLPOUR MA Inhibitor DMLPOUR RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMLPOUR RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMLPQ7E DI DMLPQ7E DMLPQ7E DN Imidazole derivative 7 DMLPQ7E TI TT6OEDT DMLPQ7E TN Cannabinoid receptor 1 (CB1) DMLPQ7E MA Antagonist DMLPQ7E RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMLPQ7E RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMLPWK3 DI DMLPWK3 DMLPWK3 DN US9434727, 40 DMLPWK3 TI TT0C8BY DMLPWK3 TN Plasma retinol-binding protein (RBP4) DMLPWK3 MA Inhibitor DMLPWK3 RN Substituted 4-phenylpiperidines, their preparation and use. US9777010. DMLPWK3 RU http://www.freepatentsonline.com/US9777010.html DMLQ7PG DI DMLQ7PG DMLQ7PG DN Diazepinone derivative 2 DMLQ7PG TI TTHS256 DMLQ7PG TN Metabotropic glutamate receptor 5 (mGluR5) DMLQ7PG MA Modulator DMLQ7PG RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLQ7PG RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLQ8N1 DI DMLQ8N1 DMLQ8N1 DN AphanamgrandiolA DMLQ8N1 TI TT3WG5C DMLQ8N1 TN Monoamine oxidase type A (MAO-A) DMLQ8N1 MA Inhibitor DMLQ8N1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMLQ8N1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMLQCYV DI DMLQCYV DMLQCYV DN PMID28766366-Compound-Scheme13INDY DMLQCYV TI TTSBVFO DMLQCYV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMLQCYV MA Inhibitor DMLQCYV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMLQCYV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMLR03U DI DMLR03U DMLR03U DN PMID28092474-Compound-32y DMLR03U TI TT5ZKDI DMLR03U TN Histone deacetylase 6 (HDAC6) DMLR03U MA Inhibitor DMLR03U RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLR03U RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLR03U DI DMLR03U DMLR03U DN PMID28092474-Compound-32y DMLR03U TI TT6R7JZ DMLR03U TN Histone deacetylase 1 (HDAC1) DMLR03U MA Inhibitor DMLR03U RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLR03U RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLR8MS DI DMLR8MS DMLR8MS DN Isoxazoline derivative 1 DMLR8MS TI TTDP1UC DMLR8MS TN Fatty acid amide hydrolase (FAAH) DMLR8MS MA Inhibitor DMLR8MS RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMLR8MS RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMLRA3C DI DMLRA3C DMLRA3C DN Thiazole carboxamide derivative 3 DMLRA3C TI TTCZOF2 DMLRA3C TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLRA3C MA Inhibitor DMLRA3C RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLRA3C RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLRTFX DI DMLRTFX DMLRTFX DN Thiazole carboxamide derivative 25 DMLRTFX TI TTCZOF2 DMLRTFX TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMLRTFX MA Inhibitor DMLRTFX RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMLRTFX RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMLRY53 DI DMLRY53 DMLRY53 DN Tetra-azabenzo[e]azulene derivative 1 DMLRY53 TI TT4TFGN DMLRY53 TN Vasopressin V1a receptor (V1AR) DMLRY53 MA Inhibitor DMLRY53 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMLRY53 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMLS827 DI DMLS827 DMLS827 DN Pyrazolo[1,5-a]pyridine derivative 2 DMLS827 TI TTTDVOJ DMLS827 TN Tropomyosin-related kinase A (TrkA) DMLS827 MA Inhibitor DMLS827 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMLS827 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMLSK97 DI DMLSK97 DMLSK97 DN N-quinolin-benzene sulphonamide derivative 1 DMLSK97 TI TTSXVID DMLSK97 TN Nuclear factor NF-kappa-B (NFKB) DMLSK97 MA Inhibitor DMLSK97 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMLSK97 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMLSUH3 DI DMLSUH3 DMLSUH3 DN Isothiazolidine derivative 1 DMLSUH3 TI TT473XN DMLSUH3 TN P2X purinoceptor 7 (P2RX7) DMLSUH3 MA Antagonist DMLSUH3 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMLSUH3 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMLSWKR DI DMLSWKR DMLSWKR DN Phenylpurine acetamide analog 1 DMLSWKR TI TTPTXIN DMLSWKR TN Translocator protein (TSPO) DMLSWKR MA Ligand DMLSWKR RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMLSWKR RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMLT8PA DI DMLT8PA DMLT8PA DN PMID25991433-Compound-K1 DMLT8PA TI TT0K6EO DMLT8PA TN Stress-activated protein kinase JNK1 (JNK1) DMLT8PA MA Inhibitor DMLT8PA RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLT8PA RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLTKMS DI DMLTKMS DMLTKMS DN PMID28092474-Compound-32r DMLTKMS TI TT6R7JZ DMLTKMS TN Histone deacetylase 1 (HDAC1) DMLTKMS MA Inhibitor DMLTKMS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLTKMS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLTKMS DI DMLTKMS DMLTKMS DN PMID28092474-Compound-32r DMLTKMS TI TT5ZKDI DMLTKMS TN Histone deacetylase 6 (HDAC6) DMLTKMS MA Inhibitor DMLTKMS RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMLTKMS RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMLTR9E DI DMLTR9E DMLTR9E DN PMID25656651-Compound-23c DMLTR9E TI TTS7G69 DMLTR9E TN Fusion protein Bcr-Abl (Bcr-Abl) DMLTR9E MA Inhibitor DMLTR9E RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMLTR9E RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMLTZKX DI DMLTZKX DMLTZKX DN Dihydroisoxazole derivative 2 DMLTZKX TI TT2F4OL DMLTZKX TN Tissue transglutaminase (TG2) DMLTZKX MA Inhibitor DMLTZKX RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMLTZKX RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMLUFB2 DI DMLUFB2 DMLUFB2 DN PMID25656651-Compound-20b DMLUFB2 TI TTS7G69 DMLUFB2 TN Fusion protein Bcr-Abl (Bcr-Abl) DMLUFB2 MA Inhibitor DMLUFB2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMLUFB2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMLUPV1 DI DMLUPV1 DMLUPV1 DN Thieno[2,3-c]pyridine derivative 1 DMLUPV1 TI TTZJYKH DMLUPV1 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMLUPV1 MA Inhibitor DMLUPV1 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMLUPV1 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMLUWCD DI DMLUWCD DMLUWCD DN PMID25435179-Compound-WO2013059594(III) DMLUWCD TI TTSCO7R DMLUWCD TN NAD-dependent deacetylase sirtuin (SIRT) DMLUWCD MA Inhibitor DMLUWCD RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMLUWCD RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMLUYR0 DI DMLUYR0 DMLUYR0 DN Terpyridineplatinum(II) complexe 2 DMLUYR0 TI TTR7UJ3 DMLUYR0 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMLUYR0 MA Inhibitor DMLUYR0 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMLUYR0 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMLUZ3K DI DMLUZ3K DMLUZ3K DN Biphenyl mannoside derivative 24 DMLUZ3K TI TTTCRU2 DMLUZ3K TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMLUZ3K MA Antagonist DMLUZ3K RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMLUZ3K RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMLV6IY DI DMLV6IY DMLV6IY DN PMID26004420-Compound-WO2015017305F DMLV6IY TI TTJ13ST DMLV6IY TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMLV6IY MA Inhibitor DMLV6IY RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMLV6IY RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMLV9UR DI DMLV9UR DMLV9UR DN Bis-sulfonamide derivative 1 DMLV9UR TI TTR7UJ3 DMLV9UR TN Cytoplasmic thioredoxin reductase (TXNRD1) DMLV9UR MA Inhibitor DMLV9UR RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMLV9UR RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMLVSEK DI DMLVSEK DMLVSEK DN PMID30280939-Compound-WO200606195 DMLVSEK TI TTOK0LR DMLVSEK TN Toll-like receptor (TLR) DMLVSEK MA Agonist DMLVSEK RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMLVSEK RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMLVY7A DI DMLVY7A DMLVY7A DN Imidazo triazine derivative 1 DMLVY7A TI TTJGW1Z DMLVY7A TN Phosphodiesterase 2A (PDE2A) DMLVY7A MA Inhibitor DMLVY7A RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMLVY7A RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMLW7YO DI DMLW7YO DMLW7YO DN Tetra-hydro-oxazolopyridine derivative 6 DMLW7YO TI TTHS256 DMLW7YO TN Metabotropic glutamate receptor 5 (mGluR5) DMLW7YO MA Modulator DMLW7YO RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMLW7YO RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMLW95Y DI DMLW95Y DMLW95Y DN PMID25666693-Compound-54 DMLW95Y TI TTMI6F5 DMLW95Y TN Transient receptor potential cation channel V1 (TRPV1) DMLW95Y MA Antagonist DMLW95Y RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMLW95Y RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMLWIJ7 DI DMLWIJ7 DMLWIJ7 DN Selenium compound 2 DMLWIJ7 TI TTZHPB8 DMLWIJ7 TN Lysine-specific demethylase 4A (KDM4A) DMLWIJ7 MA Inhibitor DMLWIJ7 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMLWIJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMLWSNA DI DMLWSNA DMLWSNA DN PMID25991433-Compound-D2 DMLWSNA TI TTHS0U8 DMLWSNA TN Stress-activated protein kinase JNK2 (JNK2) DMLWSNA MA Inhibitor DMLWSNA RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLWSNA RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLWSNA DI DMLWSNA DMLWSNA DN PMID25991433-Compound-D2 DMLWSNA TI TT0K6EO DMLWSNA TN Stress-activated protein kinase JNK1 (JNK1) DMLWSNA MA Inhibitor DMLWSNA RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMLWSNA RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMLX183 DI DMLX183 DMLX183 DN Indirubin derivative 2 DMLX183 TI TTRZQE3 DMLX183 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMLX183 MA Inhibitor DMLX183 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMLX183 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMLX26R DI DMLX26R DMLX26R DN PMID28766366-Compound-Scheme27LeucettineL41 DMLX26R TI TTSBVFO DMLX26R TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMLX26R MA Inhibitor DMLX26R RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMLX26R RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMLXG43 DI DMLXG43 DMLXG43 DN US8569313, Inhibitor 19 DMLXG43 TI TTPRO7W DMLXG43 TN Suppressor of tumorigenicity 14 protein (ST14) DMLXG43 MA Inhibitor DMLXG43 RN Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313. DMLXG43 RU http://www.freepatentsonline.com/US8569313.html DMLXQET DI DMLXQET DMLXQET DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 DMLXQET TI TT6OEDT DMLXQET TN Cannabinoid receptor 1 (CB1) DMLXQET RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMLXQET RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMLXQET DI DMLXQET DMLXQET DN 2-cycloalkyl resorcinol cannabinoid ligand derivative 1 DMLXQET TI TTMSFAW DMLXQET TN Cannabinoid receptor 2 (CB2) DMLXQET RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMLXQET RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMLXSHW DI DMLXSHW DMLXSHW DN PMID29671355-Compound-28 DMLXSHW TI TT5ZKDI DMLXSHW TN Histone deacetylase 6 (HDAC6) DMLXSHW MA Inhibitor DMLXSHW RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLXSHW RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLXSHW DI DMLXSHW DMLXSHW DN PMID29671355-Compound-28 DMLXSHW TI TT6R7JZ DMLXSHW TN Histone deacetylase 1 (HDAC1) DMLXSHW MA Inhibitor DMLXSHW RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMLXSHW RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMLY3RE DI DMLY3RE DMLY3RE DN US8877733, 28 DMLY3RE TI TTQFZWR DMLY3RE TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMLY3RE MA Inhibitor DMLY3RE RN 1-substituted pyrimidine N-nucleoside analogs for antiviral treatment. US8877733. DMLY3RE RU http://www.freepatentsonline.com/US8877733.html DMLY7I3 DI DMLY7I3 DMLY7I3 DN PMID27607364-Compound-59 DMLY7I3 TI TTPTXIN DMLY7I3 TN Translocator protein (TSPO) DMLY7I3 MA Ligand DMLY7I3 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMLY7I3 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMLZ1UB DI DMLZ1UB DMLZ1UB DN Diarylamine and arylheteroarylamine pyrazole derivative 3 DMLZ1UB TI TTJQOD7 DMLZ1UB TN 5-HT 2A receptor (HTR2A) DMLZ1UB MA Agonist DMLZ1UB RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMLZ1UB RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMLZBRM DI DMLZBRM DMLZBRM DN US10179791, Compound 296 DMLZBRM TI TTDYP7I DMLZBRM TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMLZBRM MA Inhibitor DMLZBRM RN Spiro-cyclic amine derivatives as S1P modulators. US10179791. DMLZBRM RU http://www.freepatentsonline.com/US10179791.html DMLZDAK DI DMLZDAK DMLZDAK DN ZINC19658740 DMLZDAK TI TTB9CIL DMLZDAK TN Prokineticin receptor-1 (PROKR1) DMLZDAK MA Inhibitor DMLZDAK RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US10167273. DMLZDAK RU http://www.freepatentsonline.com/US10167273.html DMLZMIG DI DMLZMIG DMLZMIG DN Conjugated 3-(indolyl)-and 3-(azaindolyl)-4-arylmaleimide compound 1 DMLZMIG TI TTOHSBA DMLZMIG TN Vascular endothelial growth factor A (VEGFA) DMLZMIG MA Inhibitor DMLZMIG RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMLZMIG RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMLZRAI DI DMLZRAI DMLZRAI DN Quinoxaline derivative 3 DMLZRAI TI TTSXVID DMLZRAI TN Nuclear factor NF-kappa-B (NFKB) DMLZRAI MA Inhibitor DMLZRAI RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMLZRAI RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMLZV70 DI DMLZV70 DMLZV70 DN PMID28594589-Compound-TABLE3C1 DMLZV70 TI TTZCRP3 DMLZV70 TN ERK activator kinase (MEK) DMLZV70 MA Inhibitor DMLZV70 RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMLZV70 RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMM06K5 DI DMM06K5 DMM06K5 DN Tetra-hydro-pyrrolopyrimidinedione derivative 1 DMM06K5 TI TTPLTSQ DMM06K5 TN Neutrophil elastase (NE) DMM06K5 MA Inhibitor DMM06K5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMM06K5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMM0BVE DI DMM0BVE DMM0BVE DN PMID28447479-Compound-23 DMM0BVE TI TTSCIM2 DMM0BVE TN Extracellular lysophospholipase D (E-NPP2) DMM0BVE RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMM0BVE RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMM0R65 DI DMM0R65 DMM0R65 DN Cyclopropyl-spiro piperidine derivative 2 DMM0R65 TI TT4G2JS DMM0R65 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMM0R65 MA Blocker DMM0R65 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMM0R65 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMM1I8R DI DMM1I8R DMM1I8R DN Indazole derivative 5 DMM1I8R TI TTIV39N DMM1I8R TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMM1I8R MA Inhibitor DMM1I8R RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMM1I8R RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMM1I8R DI DMM1I8R DMM1I8R DN Indazole derivative 5 DMM1I8R TI TTZJTWA DMM1I8R TN ABL T315I mutant (ABL T315I) DMM1I8R MA Inhibitor DMM1I8R RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMM1I8R RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMM1LKF DI DMM1LKF DMM1LKF DN Bicyclic heteroaryl benzamide derivative 7 DMM1LKF TI TTTDVOJ DMM1LKF TN Tropomyosin-related kinase A (TrkA) DMM1LKF MA Inhibitor DMM1LKF RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMM1LKF RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMM2N4T DI DMM2N4T DMM2N4T DN 1607004-34-1 DMM2N4T TI TTYG6BU DMM2N4T TN Aggrecanase-1 (ADAMTS4) DMM2N4T MA Inhibitor DMM2N4T RN Aggrecanase inhibitors. US9206139. DMM2N4T RU http://www.freepatentsonline.com/US9206139.html DMM2RYG DI DMM2RYG DMM2RYG DN Pyrazole derivative 25 DMM2RYG TI TT6OEDT DMM2RYG TN Cannabinoid receptor 1 (CB1) DMM2RYG MA Antagonist DMM2RYG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMM2RYG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMM2WA4 DI DMM2WA4 DMM2WA4 DN Peptide analog 48 DMM2WA4 TI TTDIGC1 DMM2WA4 TN Dipeptidyl peptidase 4 (DPP-4) DMM2WA4 MA Inhibitor DMM2WA4 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMM2WA4 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMM30LJ DI DMM30LJ DMM30LJ DN PMID29334795-Compound-55 DMM30LJ TI TT9JNIC DMM30LJ TN Histamine H3 receptor (H3R) DMM30LJ RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMM30LJ RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMM3FJO DI DMM3FJO DMM3FJO DN PMID26815044-Compound-47 DMM3FJO TI TTULVH8 DMM3FJO TN Tyrosinase (TYR) DMM3FJO MA Inhibitor DMM3FJO RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMM3FJO RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMM3QEW DI DMM3QEW DMM3QEW DN PMID25553724-Compound-US2011000295210 DMM3QEW TI TTSXVID DMM3QEW TN Nuclear factor NF-kappa-B (NFKB) DMM3QEW MA Inhibitor DMM3QEW RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMM3QEW RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMM3SWV DI DMM3SWV DMM3SWV DN Biphenyl derivative 3 DMM3SWV TI TTZJYKH DMM3SWV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMM3SWV MA Inhibitor DMM3SWV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMM3SWV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMM3VA8 DI DMM3VA8 DMM3VA8 DN PMID27376512-Compound-Table1Example16 DMM3VA8 TI TT6S2FE DMM3VA8 TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMM3VA8 MA Inhibitor DMM3VA8 RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMM3VA8 RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMM45AC DI DMM45AC DMM45AC DN PMID25980951-Compound-20 DMM45AC TI TTR7B60 DMM45AC TN X-linked inhibitor of apoptosis protein (XIAP) DMM45AC MA Antagonist DMM45AC RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMM45AC RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMM45AC DI DMM45AC DMM45AC DN PMID25980951-Compound-20 DMM45AC TI TTQ5LRD DMM45AC TN Cellular inhibitor of apoptosis 1 (BIRC2) DMM45AC MA Antagonist DMM45AC RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMM45AC RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMM4GLH DI DMM4GLH DMM4GLH DN US8470836, 8 DMM4GLH TI TTOYT5L DMM4GLH TN Dipeptidyl-peptidase 7 (DPP7) DMM4GLH MA Inhibitor DMM4GLH RN Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. DMM4GLH RU http://www.freepatentsonline.com/US8470836.html DMM4TBH DI DMM4TBH DMM4TBH DN PMID29649907-Compound-2 DMM4TBH TI TTS4UGC DMM4TBH TN Farnesoid X-activated receptor (FXR) DMM4TBH MA Agonist DMM4TBH RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMM4TBH RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMM5BDS DI DMM5BDS DMM5BDS DN Isoquinoline sulfonamide derivative 1 DMM5BDS TI TTMQO60 DMM5BDS TN Rho-associated protein kinase (ROCK) DMM5BDS MA Inhibitor DMM5BDS RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMM5BDS RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMM5EI4 DI DMM5EI4 DMM5EI4 DN PMID25666693-Compound-93 DMM5EI4 TI TTMI6F5 DMM5EI4 TN Transient receptor potential cation channel V1 (TRPV1) DMM5EI4 MA Antagonist DMM5EI4 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMM5EI4 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMM5G7S DI DMM5G7S DMM5G7S DN PMID28350212-Compound-20 DMM5G7S TI TTZS04O DMM5G7S TN Gamma-secretase subunit APH-1A/1B (APH-1) DMM5G7S MA Inhibitor DMM5G7S RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMM5G7S RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMM6FOW DI DMM6FOW DMM6FOW DN PMID27744724-Compound-22 DMM6FOW TI TTL53M6 DMM6FOW TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMM6FOW MA Inhibitor DMM6FOW RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMM6FOW RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMM6WAB DI DMM6WAB DMM6WAB DN US10087167, Compound 3002 DMM6WAB TI TTQFZWR DMM6WAB TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMM6WAB MA Inhibitor DMM6WAB RN Benzofurans substituted with secondary benzamide as HCV inhibitors. US10087167. DMM6WAB RU http://www.freepatentsonline.com/US10087167.html DMM72LS DI DMM72LS DMM72LS DN Benzazepine derivative 4 DMM72LS TI TTWJBZ5 DMM72LS TN 5-HT 2C receptor (HTR2C) DMM72LS MA Agonist DMM72LS RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMM72LS RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMM73VG DI DMM73VG DMM73VG DN PMID29865878-Compound-59 DMM73VG TI TTEAD9J DMM73VG TN Proteasome beta-8 (PS beta-8) DMM73VG MA Inhibitor DMM73VG RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMM73VG RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMM78UR DI DMM78UR DMM78UR DN H3K7T DMM78UR TI TTSCO7R DMM78UR TN NAD-dependent deacetylase sirtuin (SIRT) DMM78UR MA Inhibitor DMM78UR RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMM78UR RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMM78VS DI DMM78VS DMM78VS DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 DMM78VS TI TT6OEDT DMM78VS TN Cannabinoid receptor 1 (CB1) DMM78VS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM78VS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM78VS DI DMM78VS DMM78VS DN N,N-methylenebis-2-phenylacetamide and benzenesulfonamide derivative 3 DMM78VS TI TTMSFAW DMM78VS TN Cannabinoid receptor 2 (CB2) DMM78VS RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM78VS RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM7N5E DI DMM7N5E DMM7N5E DN Benzothiazine-carboxamide compound 5 DMM7N5E TI TTQR74A DMM7N5E TN Proteinase activated receptor 2 (PAR2) DMM7N5E MA Antagonist DMM7N5E RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMM7N5E RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMM7OR3 DI DMM7OR3 DMM7OR3 DN Pyrazole derivative 19 DMM7OR3 TI TT6OEDT DMM7OR3 TN Cannabinoid receptor 1 (CB1) DMM7OR3 MA Antagonist DMM7OR3 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMM7OR3 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMM83WL DI DMM83WL DMM83WL DN PMID30280939-Compound-US20170128558 DMM83WL TI TTOK0LR DMM83WL TN Toll-like receptor (TLR) DMM83WL MA Agonist DMM83WL RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMM83WL RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMM8CL4 DI DMM8CL4 DMM8CL4 DN Pyrido[2,3-d]pyrimidine-2,4-diamine derivative 1 DMM8CL4 TI TTJGW1Z DMM8CL4 TN Phosphodiesterase 2A (PDE2A) DMM8CL4 MA Inhibitor DMM8CL4 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMM8CL4 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMM8IDC DI DMM8IDC DMM8IDC DN BDBM50061612 DMM8IDC TI TTCGOIN DMM8IDC TN PIM-3 protein kinase (PIM3) DMM8IDC MA Inhibitor DMM8IDC RN Azole compounds as PIM inhibitors. US9321756. DMM8IDC RU http://www.freepatentsonline.com/US9321756.html DMM8K7R DI DMM8K7R DMM8K7R DN Peptide analog 50 DMM8K7R TI TTDIGC1 DMM8K7R TN Dipeptidyl peptidase 4 (DPP-4) DMM8K7R MA Inhibitor DMM8K7R RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMM8K7R RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMM92KW DI DMM92KW DMM92KW DN Tetra-hydro-quinoline derivative 1 DMM92KW TI TTVDSZ0 DMM92KW TN Poly [ADP-ribose] polymerase 1 (PARP1) DMM92KW MA Inhibitor DMM92KW RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMM92KW RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMM9E1U DI DMM9E1U DMM9E1U DN PMID28074661-Compound-US20100022547C81 DMM9E1U TI TTL7C8Q DMM9E1U TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMM9E1U MA Inhibitor DMM9E1U RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMM9E1U RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMM9F8D DI DMM9F8D DMM9F8D DN Phytocannabinoid/aminoalkylindole derivative 1 DMM9F8D TI TTMSFAW DMM9F8D TN Cannabinoid receptor 2 (CB2) DMM9F8D RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM9F8D RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM9F8D DI DMM9F8D DMM9F8D DN Phytocannabinoid/aminoalkylindole derivative 1 DMM9F8D TI TT6OEDT DMM9F8D TN Cannabinoid receptor 1 (CB1) DMM9F8D RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMM9F8D RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMM9I1R DI DMM9I1R DMM9I1R DN 4-Carboxamido-isoindolinone derivative 1 DMM9I1R TI TTVDSZ0 DMM9I1R TN Poly [ADP-ribose] polymerase 1 (PARP1) DMM9I1R MA Inhibitor DMM9I1R RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMM9I1R RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMM9J34 DI DMM9J34 DMM9J34 DN Benzonaphthyridine derivative 1 DMM9J34 TI TTCZOF2 DMM9J34 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMM9J34 MA Inhibitor DMM9J34 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMM9J34 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMMAE3C DI DMMAE3C DMMAE3C DN PMID27998201-Compound-2 DMMAE3C TI TTF2LRI DMMAE3C TN Cathepsin B (CTSB) DMMAE3C MA Inhibitor DMMAE3C RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMMAE3C RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMMAF2S DI DMMAF2S DMMAF2S DN Dipeptide analog 2 DMMAF2S TI TT2F4OL DMMAF2S TN Tissue transglutaminase (TG2) DMMAF2S MA Inhibitor DMMAF2S RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMMAF2S RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMMAS3G DI DMMAS3G DMMAS3G DN Aromatic ring compound 2 DMMAS3G TI TT9O6WS DMMAS3G TN Glucagon receptor (GCGR) DMMAS3G MA Antagonist DMMAS3G RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMMAS3G RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMMB60X DI DMMB60X DMMB60X DN Biaryl mannoside derivative 2 DMMB60X TI TTTCRU2 DMMB60X TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMB60X MA Antagonist DMMB60X RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMB60X RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMB6XC DI DMMB6XC DMMB6XC DN PMID27019002-Compound-37a DMMB6XC TI TTNR0UQ DMMB6XC TN Lysine-specific histone demethylase 1 (LSD) DMMB6XC MA Inhibitor DMMB6XC RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMB6XC RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMBFQH DI DMMBFQH DMMBFQH DN Pyrimidine derivative 12 DMMBFQH TI TTUTJGQ DMMBFQH TN Vascular endothelial growth factor receptor 2 (KDR) DMMBFQH MA Inhibitor DMMBFQH RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMMBFQH RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMMBUGK DI DMMBUGK DMMBUGK DN 4-pyridone derivative 1 DMMBUGK TI TTPLTSQ DMMBUGK TN Neutrophil elastase (NE) DMMBUGK MA Inhibitor DMMBUGK RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMBUGK RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMC31N DI DMMC31N DMMC31N DN PMID27019002-Compound-21b DMMC31N TI TTNR0UQ DMMC31N TN Lysine-specific histone demethylase 1 (LSD) DMMC31N MA Inhibitor DMMC31N RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMC31N RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMC31N DI DMMC31N DMMC31N DN PMID27019002-Compound-21b DMMC31N TI TTZHPB8 DMMC31N TN Lysine-specific demethylase 4A (KDM4A) DMMC31N MA Inhibitor DMMC31N RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMC31N RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMC31R DI DMMC31R DMMC31R DN Aryl mannoside derivative 5 DMMC31R TI TTTCRU2 DMMC31R TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMC31R MA Antagonist DMMC31R RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMC31R RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMC3AG DI DMMC3AG DMMC3AG DN Tetra-hydro-quinoline derivative 4 DMMC3AG TI TTE4BSY DMMC3AG TN Bromodomain and extraterminal domain protein (BET) DMMC3AG MA Inhibitor DMMC3AG RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMMC3AG RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMMCDR7 DI DMMCDR7 DMMCDR7 DN Betais-sulfonylamino derivative 1 DMMCDR7 TI TTYLQ8V DMMCDR7 TN Prostaglandin E synthase (PTGES) DMMCDR7 MA Inhibitor DMMCDR7 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMMCDR7 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMMCHOW DI DMMCHOW DMMCHOW DN Pyrazole derivative 78 DMMCHOW TI TTXJ47W DMMCHOW TN Metabotropic glutamate receptor 2 (mGluR2) DMMCHOW MA Antagonist DMMCHOW RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMMCHOW RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMMCNVO DI DMMCNVO DMMCNVO DN US9694002, 129 DMMCNVO TI TTANOZH DMMCNVO TN SCN1A messenger RNA (SCN1A mRNA) DMMCNVO MA Inhibitor DMMCNVO RN Substituted benzamides and methods of use thereof. US9694002. DMMCNVO RU http://www.freepatentsonline.com/US9694002.html DMMCS9P DI DMMCS9P DMMCS9P DN Matairesinol derivative 1 DMMCS9P TI TTUX68I DMMCS9P TN Hypoxia-inducible factor 1 (HIF-1) DMMCS9P MA Inhibitor DMMCS9P RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMMCS9P RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMMCTAK DI DMMCTAK DMMCTAK DN Oxetane 3,3-dicarboxamide compound 2 DMMCTAK TI TTOHSBA DMMCTAK TN Vascular endothelial growth factor A (VEGFA) DMMCTAK MA Inhibitor DMMCTAK RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMMCTAK RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMMCWH9 DI DMMCWH9 DMMCWH9 DN Isoflavone derivative 1 DMMCWH9 TI TTJOMH6 DMMCWH9 TN Zinc finger protein GLI1 (Gli1) DMMCWH9 MA Inhibitor DMMCWH9 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMMCWH9 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMMCWH9 DI DMMCWH9 DMMCWH9 DN Isoflavone derivative 1 DMMCWH9 TI TT8J1S3 DMMCWH9 TN Smoothened homolog (SMO) DMMCWH9 MA Inhibitor DMMCWH9 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMMCWH9 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMMCYI5 DI DMMCYI5 DMMCYI5 DN 1,2,4,5-tetra-substituted imidazole derivative 2 DMMCYI5 TI TT6OEDT DMMCYI5 TN Cannabinoid receptor 1 (CB1) DMMCYI5 MA Antagonist DMMCYI5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMCYI5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMDJH8 DI DMMDJH8 DMMDJH8 DN PMID27539678-Compound-16 DMMDJH8 TI TTOHFIY DMMDJH8 TN Sphingosine kinase 1 (SPHK1) DMMDJH8 MA Inhibitor DMMDJH8 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMMDJH8 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMMDK6B DI DMMDK6B DMMDK6B DN PMID28454500-Compound-93 DMMDK6B TI TTA6ZN2 DMMDK6B TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMMDK6B MA Inhibitor DMMDK6B RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMMDK6B RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMMDYAV DI DMMDYAV DMMDYAV DN N-phenyl-pyridine-2-carboxamide derivative 1 DMMDYAV TI TT23XQV DMMDYAV TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMMDYAV MA Inhibitor DMMDYAV RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMMDYAV RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMMELYI DI DMMELYI DMMELYI DN 4-amino-3,5-di-substituted-thiazole derivative 1 DMMELYI TI TT7HF4W DMMELYI TN Cyclin-dependent kinase 2 (CDK2) DMMELYI MA Inhibitor DMMELYI RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMELYI RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMETW5 DI DMMETW5 DMMETW5 DN Epoxysuccinate derivative 3 DMMETW5 TI TTG5QB7 DMMETW5 TN Calpain-2 (CAPN2) DMMETW5 MA Inhibitor DMMETW5 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMMETW5 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMMF4XO DI DMMF4XO DMMF4XO DN PMID27607364-Compound-141 DMMF4XO TI TTPTXIN DMMF4XO TN Translocator protein (TSPO) DMMF4XO MA Ligand DMMF4XO RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMMF4XO RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMMF8A1 DI DMMF8A1 DMMF8A1 DN 2-(substituted ethynyl)quinoline derivative 3 DMMF8A1 TI TTHS256 DMMF8A1 TN Metabotropic glutamate receptor 5 (mGluR5) DMMF8A1 MA Antagonist DMMF8A1 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMMF8A1 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMMF9U6 DI DMMF9U6 DMMF9U6 DN Aryl pyrimidine derivative 6 DMMF9U6 TI TTIY56R DMMF9U6 TN Kynurenine 3-hydroxylase (KMO) DMMF9U6 MA Inhibitor DMMF9U6 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMMF9U6 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMMFBI3 DI DMMFBI3 DMMFBI3 DN Dihydropyrido phthalazinone derivative 3 DMMFBI3 TI TTEBCY8 DMMFBI3 TN Poly [ADP-ribose] polymerase (PARP) DMMFBI3 MA Inhibitor DMMFBI3 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMMFBI3 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMMFC0V DI DMMFC0V DMMFC0V DN US9409892, 136 DMMFC0V TI TT9ISBX DMMFC0V TN HIF-prolyl hydroxylase 2 (HPH-2) DMMFC0V MA Inhibitor DMMFC0V RN 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892. DMMFC0V RU http://www.freepatentsonline.com/US9409892.html DMMFCRU DI DMMFCRU DMMFCRU DN Imidazopyridine acetamide analog 5 DMMFCRU TI TTPTXIN DMMFCRU TN Translocator protein (TSPO) DMMFCRU MA Ligand DMMFCRU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMMFCRU RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMMFI5G DI DMMFI5G DMMFI5G DN Hypersulfated disaccharide compound 1 DMMFI5G TI TTPLTSQ DMMFI5G TN Neutrophil elastase (NE) DMMFI5G MA Inhibitor DMMFI5G RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMFI5G RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMFILA DI DMMFILA DMMFILA DN PMID25399762-Compound-Table1-C21 DMMFILA TI TTGP7BY DMMFILA TN Monoamine oxidase type B (MAO-B) DMMFILA MA Inhibitor DMMFILA RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMFILA RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMFK2Q DI DMMFK2Q DMMFK2Q DN PMID25726713-Compound-24 DMMFK2Q TI TT8J1S3 DMMFK2Q TN Smoothened homolog (SMO) DMMFK2Q MA Inhibitor DMMFK2Q RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMMFK2Q RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMMFZKC DI DMMFZKC DMMFZKC DN 2-alkyloxy-3-phenylethynyl-4a,5-dihydropyrido[2,3-b]pyrazine derivative 1 DMMFZKC TI TT2F4OL DMMFZKC TN Tissue transglutaminase (TG2) DMMFZKC MA Inhibitor DMMFZKC RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMMFZKC RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMMGBLC DI DMMGBLC DMMGBLC DN Phenylpurine acetamide analog 2 DMMGBLC TI TTPTXIN DMMGBLC TN Translocator protein (TSPO) DMMGBLC MA Ligand DMMGBLC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMMGBLC RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMMGLOA DI DMMGLOA DMMGLOA DN Pyrazole derivative 83 DMMGLOA TI TTDP1UC DMMGLOA TN Fatty acid amide hydrolase (FAAH) DMMGLOA MA Inhibitor DMMGLOA RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMGLOA RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMGLOA DI DMMGLOA DMMGLOA DN Pyrazole derivative 83 DMMGLOA TI TTZ963I DMMGLOA TN Monoglyceride lipase (MAGL) DMMGLOA MA Inhibitor DMMGLOA RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMGLOA RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMGQ7Z DI DMMGQ7Z DMMGQ7Z DN PMID26666870-Compound-16 DMMGQ7Z TI TTJOMH6 DMMGQ7Z TN Zinc finger protein GLI1 (Gli1) DMMGQ7Z MA Inhibitor DMMGQ7Z RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMMGQ7Z RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMMGWKE DI DMMGWKE DMMGWKE DN Pyrazole derivative 39 DMMGWKE TI TT6OEDT DMMGWKE TN Cannabinoid receptor 1 (CB1) DMMGWKE MA Antagonist DMMGWKE RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMGWKE RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMH27J DI DMMH27J DMMH27J DN Carbamate derivative 12 DMMH27J TI TTZ963I DMMH27J TN Monoglyceride lipase (MAGL) DMMH27J MA Inhibitor DMMH27J RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMH27J RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMHL2C DI DMMHL2C DMMHL2C DN PMID26560530-Compound-6 DMMHL2C TI TT2F4OL DMMHL2C TN Tissue transglutaminase (TG2) DMMHL2C MA Inhibitor DMMHL2C RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMMHL2C RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMMHLA9 DI DMMHLA9 DMMHLA9 DN PMID26004420-Compound-WO2013062892E DMMHLA9 TI TTJ13ST DMMHLA9 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMMHLA9 MA Inhibitor DMMHLA9 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMMHLA9 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMMI4KQ DI DMMI4KQ DMMI4KQ DN PMID27109571-Compound-11 DMMI4KQ TI TTHWMFZ DMMI4KQ TN Fatty acid-binding protein 4 (FABP4) DMMI4KQ MA Inhibitor DMMI4KQ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMMI4KQ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMMI7DY DI DMMI7DY DMMI7DY DN PMID28092474-Compound-34c DMMI7DY TI TT6R7JZ DMMI7DY TN Histone deacetylase 1 (HDAC1) DMMI7DY MA Inhibitor DMMI7DY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMMI7DY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMMI7DY DI DMMI7DY DMMI7DY DN PMID28092474-Compound-34c DMMI7DY TI TT5ZKDI DMMI7DY TN Histone deacetylase 6 (HDAC6) DMMI7DY MA Inhibitor DMMI7DY RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMMI7DY RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMMIKFU DI DMMIKFU DMMIKFU DN PMID29649907-Compound-15 DMMIKFU TI TTS4UGC DMMIKFU TN Farnesoid X-activated receptor (FXR) DMMIKFU MA Agonist DMMIKFU RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMMIKFU RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMMIOZ5 DI DMMIOZ5 DMMIOZ5 DN Pyrazole derivative 53 DMMIOZ5 TI TT6OEDT DMMIOZ5 TN Cannabinoid receptor 1 (CB1) DMMIOZ5 MA Antagonist DMMIOZ5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMIOZ5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMJ0YN DI DMMJ0YN DMMJ0YN DN Cyclopropylamine derivative 11 DMMJ0YN TI TT32XQJ DMMJ0YN TN Monoamine oxidase (MAO) DMMJ0YN MA Inhibitor DMMJ0YN RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMJ0YN RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMJ0YN DI DMMJ0YN DMMJ0YN DN Cyclopropylamine derivative 11 DMMJ0YN TI TTNR0UQ DMMJ0YN TN Lysine-specific histone demethylase 1 (LSD) DMMJ0YN MA Inhibitor DMMJ0YN RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMJ0YN RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMJ1FN DI DMMJ1FN DMMJ1FN DN Triazolo[4,3-b]pyridazine derivative 2 DMMJ1FN TI TTTDVOJ DMMJ1FN TN Tropomyosin-related kinase A (TrkA) DMMJ1FN MA Inhibitor DMMJ1FN RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMMJ1FN RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMMJ5SN DI DMMJ5SN DMMJ5SN DN PMID28766366-Compound-Scheme12-1 DMMJ5SN TI TTSBVFO DMMJ5SN TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMMJ5SN MA Inhibitor DMMJ5SN RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMMJ5SN RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMMJ81G DI DMMJ81G DMMJ81G DN Tricyclic compound 6 DMMJ81G TI TTGWKQJ DMMJ81G TN Rho-associated protein kinase 2 (ROCK2) DMMJ81G MA Inhibitor DMMJ81G RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMMJ81G RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMMJEWB DI DMMJEWB DMMJEWB DN Quinoline and quinazoline derivative 7 DMMJEWB TI TTOHSBA DMMJEWB TN Vascular endothelial growth factor A (VEGFA) DMMJEWB MA Inhibitor DMMJEWB RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMMJEWB RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMMJK0L DI DMMJK0L DMMJK0L DN PMID26815044-Compound-126 DMMJK0L TI TTULVH8 DMMJK0L TN Tyrosinase (TYR) DMMJK0L MA Inhibitor DMMJK0L RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMMJK0L RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMMJTUW DI DMMJTUW DMMJTUW DN Imatinib and nilotinib derivative 1 DMMJTUW TI TTUNARX DMMJTUW TN Carbonic anhydrase (CA) DMMJTUW MA Inhibitor DMMJTUW RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DMMJTUW RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DMMJVTW DI DMMJVTW DMMJVTW DN PMID27774822-Compound-Figure10Compound4 DMMJVTW TI TTJNBQA DMMJVTW TN Activin receptor-like kinase 2 (ALK-2) DMMJVTW MA Inhibitor DMMJVTW RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMMJVTW RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMMJVTW DI DMMJVTW DMMJVTW DN PMID27774822-Compound-Figure10Compound4 DMMJVTW TI TTRMX3V DMMJVTW TN Janus kinase 2 (JAK-2) DMMJVTW MA Inhibitor DMMJVTW RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMMJVTW RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMMKNP7 DI DMMKNP7 DMMKNP7 DN Thiazole carboxamide derivative 14 DMMKNP7 TI TTCZOF2 DMMKNP7 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMMKNP7 MA Inhibitor DMMKNP7 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMMKNP7 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMML258 DI DMML258 DMML258 DN US8846654, 251 DMML258 TI TTIS4OW DMML258 TN Phosphodiesterase 8 (PDE8) DMML258 MA Inhibitor DMML258 RN Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654. DMML258 RU http://www.freepatentsonline.com/US8846654.html DMML4PA DI DMML4PA DMML4PA DN PMID29130358-Compound-Figure17(12) DMML4PA TI TTXZ0KQ DMML4PA TN Matrix metalloproteinase-12 (MMP-12) DMML4PA MA Inhibitor DMML4PA RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMML4PA RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMML4PA DI DMML4PA DMML4PA DN PMID29130358-Compound-Figure17(12) DMML4PA TI TT6X50U DMML4PA TN Matrix metalloproteinase-9 (MMP-9) DMML4PA MA Inhibitor DMML4PA RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMML4PA RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMMLDUI DI DMMLDUI DMMLDUI DN Pyrazolo[1,5-a]pyrimidine derivative 12 DMMLDUI TI TT6OEDT DMMLDUI TN Cannabinoid receptor 1 (CB1) DMMLDUI MA Antagonist DMMLDUI RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMLDUI RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMLJ5E DI DMMLJ5E DMMLJ5E DN PMID25482888-Compound-50 DMMLJ5E TI TTDIGC1 DMMLJ5E TN Dipeptidyl peptidase 4 (DPP-4) DMMLJ5E MA Inhibitor DMMLJ5E RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMMLJ5E RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMMLQAS DI DMMLQAS DMMLQAS DN (-)-deprenyl DMMLQAS TI TT32XQJ DMMLQAS TN Monoamine oxidase (MAO) DMMLQAS MA Inhibitor DMMLQAS RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMLQAS RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMN8OY DI DMMN8OY DMMN8OY DN Amidine compound 5 DMMN8OY TI TTQR74A DMMN8OY TN Proteinase activated receptor 2 (PAR2) DMMN8OY MA Antagonist DMMN8OY RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMMN8OY RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMMNKFX DI DMMNKFX DMMNKFX DN Pyrrole derivative 2 DMMNKFX TI TT6OEDT DMMNKFX TN Cannabinoid receptor 1 (CB1) DMMNKFX MA Antagonist DMMNKFX RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMNKFX RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMNVZ5 DI DMMNVZ5 DMMNVZ5 DN 1,2,4-tri-substituted imidazoline derivative 1 DMMNVZ5 TI TT6OEDT DMMNVZ5 TN Cannabinoid receptor 1 (CB1) DMMNVZ5 MA Antagonist DMMNVZ5 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMNVZ5 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMNXA1 DI DMMNXA1 DMMNXA1 DN PMID26815044-Compound-121 DMMNXA1 TI TTULVH8 DMMNXA1 TN Tyrosinase (TYR) DMMNXA1 MA Inhibitor DMMNXA1 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMMNXA1 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMMNZ2U DI DMMNZ2U DMMNZ2U DN Alkyl mannoside derivative 11 DMMNZ2U TI TTTCRU2 DMMNZ2U TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMNZ2U MA Antagonist DMMNZ2U RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMNZ2U RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMO3F1 DI DMMO3F1 DMMO3F1 DN PMID25399762-Compound-Table1-C19 DMMO3F1 TI TTGP7BY DMMO3F1 TN Monoamine oxidase type B (MAO-B) DMMO3F1 MA Inhibitor DMMO3F1 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMO3F1 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMO6JY DI DMMO6JY DMMO6JY DN Thiazole carboxamide derivative 23 DMMO6JY TI TTCZOF2 DMMO6JY TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMMO6JY MA Inhibitor DMMO6JY RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMMO6JY RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMMOGL8 DI DMMOGL8 DMMOGL8 DN Gold-complexed thiosaccharide derivative 3 DMMOGL8 TI TTH8FZW DMMOGL8 TN Signal transducer and activator of transcription 3 (STAT3) DMMOGL8 MA Inhibitor DMMOGL8 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMMOGL8 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMMOSKZ DI DMMOSKZ DMMOSKZ DN Carbamate derivative 6 DMMOSKZ TI TTGX13H DMMOSKZ TN Fatty-acid amide hydrolase 1 (FAAH1) DMMOSKZ MA Inhibitor DMMOSKZ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMMOSKZ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMMOSVD DI DMMOSVD DMMOSVD DN Flavonoid derivative 4 DMMOSVD TI TTH8FZW DMMOSVD TN Signal transducer and activator of transcription 3 (STAT3) DMMOSVD MA Inhibitor DMMOSVD RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMMOSVD RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMMOTWK DI DMMOTWK DMMOTWK DN Biphenyl mannoside derivative 28 DMMOTWK TI TTTCRU2 DMMOTWK TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMOTWK MA Antagonist DMMOTWK RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMOTWK RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMOV67 DI DMMOV67 DMMOV67 DN PMID25522065-Compound-30 DMMOV67 TI TTX4RTB DMMOV67 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMMOV67 MA Antagonist DMMOV67 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMMOV67 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMMOVGU DI DMMOVGU DMMOVGU DN PMID27019002-Compound-43a DMMOVGU TI TTNR0UQ DMMOVGU TN Lysine-specific histone demethylase 1 (LSD) DMMOVGU MA Inhibitor DMMOVGU RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMOVGU RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMP09F DI DMMP09F DMMP09F DN PMID29649907-Compound-38 DMMP09F TI TTS4UGC DMMP09F TN Farnesoid X-activated receptor (FXR) DMMP09F MA Agonist DMMP09F RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMMP09F RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMMP2RT DI DMMP2RT DMMP2RT DN Benzothiazine-carboxamide compound 2 DMMP2RT TI TTQR74A DMMP2RT TN Proteinase activated receptor 2 (PAR2) DMMP2RT MA Antagonist DMMP2RT RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMMP2RT RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMMP7HX DI DMMP7HX DMMP7HX DN PMID25399762-Compound-Table1-C1 DMMP7HX TI TTGP7BY DMMP7HX TN Monoamine oxidase type B (MAO-B) DMMP7HX MA Inhibitor DMMP7HX RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMMP7HX RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMMP9N7 DI DMMP9N7 DMMP9N7 DN Peptidomimetic analog 1 DMMP9N7 TI TTH8FZW DMMP9N7 TN Signal transducer and activator of transcription 3 (STAT3) DMMP9N7 MA Inhibitor DMMP9N7 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMMP9N7 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMMPJ3E DI DMMPJ3E DMMPJ3E DN Biaryl mannoside derivative 31 DMMPJ3E TI TTTCRU2 DMMPJ3E TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMPJ3E MA Antagonist DMMPJ3E RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMPJ3E RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMQ0ZO DI DMMQ0ZO DMMQ0ZO DN Piperazine carbamic compound 2 DMMQ0ZO TI TTDP1UC DMMQ0ZO TN Fatty acid amide hydrolase (FAAH) DMMQ0ZO MA Inhibitor DMMQ0ZO RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMQ0ZO RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMQ0ZO DI DMMQ0ZO DMMQ0ZO DN Piperazine carbamic compound 2 DMMQ0ZO TI TTSINOV DMMQ0ZO TN Monoacylglycerol lipase ABHD6 (ABHD6) DMMQ0ZO MA Inhibitor DMMQ0ZO RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMQ0ZO RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMQ0ZO DI DMMQ0ZO DMMQ0ZO DN Piperazine carbamic compound 2 DMMQ0ZO TI TTZ963I DMMQ0ZO TN Monoglyceride lipase (MAGL) DMMQ0ZO MA Inhibitor DMMQ0ZO RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMQ0ZO RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMQ3UG DI DMMQ3UG DMMQ3UG DN PMID28394193-Compound-54 DMMQ3UG TI TT9MZCQ DMMQ3UG TN Enhancer of zeste homolog 2 (EZH2) DMMQ3UG MA Inhibitor DMMQ3UG RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMMQ3UG RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TTL4Q97 DMMQFCN TN Cyclin-dependent kinase 5 (CDK5) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TT1LVF2 DMMQFCN TN Cyclin-dependent kinase 9 (CDK9) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TTH6V3D DMMQFCN TN Cyclin-dependent kinase 1 (CDK1) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMQFCN DI DMMQFCN DMMQFCN DN 4-(thiazol-5-yl)-pyrimidine derivative 2 DMMQFCN TI TT7HF4W DMMQFCN TN Cyclin-dependent kinase 2 (CDK2) DMMQFCN MA Inhibitor DMMQFCN RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMQFCN RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMRT0Q DI DMMRT0Q DMMRT0Q DN PMID25435179-Compound-WO2012006391H3K9TSu DMMRT0Q TI TTSCO7R DMMRT0Q TN NAD-dependent deacetylase sirtuin (SIRT) DMMRT0Q MA Inhibitor DMMRT0Q RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMMRT0Q RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMMRTAL DI DMMRTAL DMMRTAL DN Pyrazole derivative 8 DMMRTAL TI TT6OEDT DMMRTAL TN Cannabinoid receptor 1 (CB1) DMMRTAL MA Antagonist DMMRTAL RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMRTAL RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMRTWG DI DMMRTWG DMMRTWG DN Biphenyl mannoside derivative 14 DMMRTWG TI TTTCRU2 DMMRTWG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMRTWG MA Antagonist DMMRTWG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMRTWG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMRUVT DI DMMRUVT DMMRUVT DN PMID25435179-Compound-EP20142759295NP-1 DMMRUVT TI TTSCO7R DMMRUVT TN NAD-dependent deacetylase sirtuin (SIRT) DMMRUVT MA Inhibitor DMMRUVT RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMMRUVT RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMMRXEQ DI DMMRXEQ DMMRXEQ DN Boronic acid derivative 1 DMMRXEQ TI TTDP1UC DMMRXEQ TN Fatty acid amide hydrolase (FAAH) DMMRXEQ MA Inhibitor DMMRXEQ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMMRXEQ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMMS4EI DI DMMS4EI DMMS4EI DN Benzyl phenyl ether derivative 2 DMMS4EI TI TT23XQV DMMS4EI TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMMS4EI MA Inhibitor DMMS4EI RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMMS4EI RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMMSHX4 DI DMMSHX4 DMMSHX4 DN US9623028, Compound 79 DMMSHX4 TI TTV298Y DMMSHX4 TN Calmodulin-dependent kinase II (CAMKK2) DMMSHX4 MA Inhibitor DMMSHX4 RN Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028. DMMSHX4 RU http://www.freepatentsonline.com/US9623028.html DMMSPX7 DI DMMSPX7 DMMSPX7 DN Azetidine-benzoxazin-3(4H)-one derivative 2 DMMSPX7 TI TTZ963I DMMSPX7 TN Monoglyceride lipase (MAGL) DMMSPX7 MA Inhibitor DMMSPX7 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMSPX7 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMSTNA DI DMMSTNA DMMSTNA DN Peptide analog 60 DMMSTNA TI TTQAJF1 DMMSTNA TN Cathepsin G (CTSG) DMMSTNA MA Inhibitor DMMSTNA RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMSTNA RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMSTNA DI DMMSTNA DMMSTNA DN Peptide analog 60 DMMSTNA TI TTPLTSQ DMMSTNA TN Neutrophil elastase (NE) DMMSTNA MA Inhibitor DMMSTNA RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMMSTNA RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMMSVW5 DI DMMSVW5 DMMSVW5 DN Oxindole derivative 1 DMMSVW5 TI TTJGW1Z DMMSVW5 TN Phosphodiesterase 2A (PDE2A) DMMSVW5 MA Inhibitor DMMSVW5 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMMSVW5 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMMT98V DI DMMT98V DMMT98V DN US9127005, P2C DMMT98V TI TT3T17P DMMT98V TN Phospholipase D1 (PLD1) DMMT98V MA Inhibitor DMMT98V RN Isoform selective phospholipase D inhibitors. US9127005. DMMT98V RU http://www.freepatentsonline.com/US9127005.html DMMTVN4 DI DMMTVN4 DMMTVN4 DN Resorcinol compound 30 DMMTVN4 TI TTULVH8 DMMTVN4 TN Tyrosinase (TYR) DMMTVN4 MA Inhibitor DMMTVN4 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMMTVN4 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMMU01R DI DMMU01R DMMU01R DN Heteroaryl-cyclopropylamine derivative 4 DMMU01R TI TTZHPB8 DMMU01R TN Lysine-specific demethylase 4A (KDM4A) DMMU01R MA Inhibitor DMMU01R RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMU01R RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMU01R DI DMMU01R DMMU01R DN Heteroaryl-cyclopropylamine derivative 4 DMMU01R TI TTNR0UQ DMMU01R TN Lysine-specific histone demethylase 1 (LSD) DMMU01R MA Inhibitor DMMU01R RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMMU01R RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMMV5A9 DI DMMV5A9 DMMV5A9 DN PMID26651364-Compound-49 DMMV5A9 TI TTTCRU2 DMMV5A9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMV5A9 MA Antagonist DMMV5A9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMV5A9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMV5KI DI DMMV5KI DMMV5KI DN PMID29473428-Compound-70 DMMV5KI TI TTZJYKH DMMV5KI TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMMV5KI MA Inhibitor DMMV5KI RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMMV5KI RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMMVETJ DI DMMVETJ DMMVETJ DN PMID25776143-Compound-4 DMMVETJ TI TT4TFGN DMMVETJ TN Vasopressin V1a receptor (V1AR) DMMVETJ MA Inhibitor DMMVETJ RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMMVETJ RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMMVG2O DI DMMVG2O DMMVG2O DN Pyrano[2,3-b]pyridine derivative 1 DMMVG2O TI TT6OEDT DMMVG2O TN Cannabinoid receptor 1 (CB1) DMMVG2O MA Antagonist DMMVG2O RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMMVG2O RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMMVHY4 DI DMMVHY4 DMMVHY4 DN Benzothiazine derivative 1 DMMVHY4 TI TTTN5QW DMMVHY4 TN Serine/threonine-protein kinase pim-1 (PIM1) DMMVHY4 MA Inhibitor DMMVHY4 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMVHY4 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMVHY4 DI DMMVHY4 DMMVHY4 DN Benzothiazine derivative 1 DMMVHY4 TI TT1LVF2 DMMVHY4 TN Cyclin-dependent kinase 9 (CDK9) DMMVHY4 MA Inhibitor DMMVHY4 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMMVHY4 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMMVPSY DI DMMVPSY DMMVPSY DN Tacrine-caffeic acid hybrid derivative 2 DMMVPSY TI TT1RS9F DMMVPSY TN Acetylcholinesterase (AChE) DMMVPSY MA Inhibitor DMMVPSY RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMMVPSY RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMMVQW8 DI DMMVQW8 DMMVQW8 DN PMID25470667-Compound-Figure4-1A DMMVQW8 TI TTF8P9I DMMVQW8 TN Diacylglycerol acyltransferase 1 (DGAT1) DMMVQW8 MA Inhibitor DMMVQW8 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMMVQW8 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMMVQW8 DI DMMVQW8 DMMVQW8 DN PMID25470667-Compound-Figure4-1A DMMVQW8 TI TTRHEQ4 DMMVQW8 TN Diacylglycerol O-acyltransferase 2 (DGAT2) DMMVQW8 MA Inhibitor DMMVQW8 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMMVQW8 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMMWK3E DI DMMWK3E DMMWK3E DN Azetidinyl-piperazine derivative 1 DMMWK3E TI TTZ963I DMMWK3E TN Monoglyceride lipase (MAGL) DMMWK3E MA Inhibitor DMMWK3E RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMMWK3E RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMMX0N5 DI DMMX0N5 DMMX0N5 DN Pyrrolo-pyrrolone derivative 5 DMMX0N5 TI TTRA6BO DMMX0N5 TN Bromodomain-containing protein 4 (BRD4) DMMX0N5 MA Inhibitor DMMX0N5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMMX0N5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMMX1ZE DI DMMX1ZE DMMX1ZE DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 DMMX1ZE TI TT6OEDT DMMX1ZE TN Cannabinoid receptor 1 (CB1) DMMX1ZE MA Agonist DMMX1ZE RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMMX1ZE RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMMX1ZE DI DMMX1ZE DMMX1ZE DN Cyano(dimethyl)methyl isoxazoles and [1,3,4]-thiadiazoles derivative 1 DMMX1ZE TI TTMSFAW DMMX1ZE TN Cannabinoid receptor 2 (CB2) DMMX1ZE MA Agonist DMMX1ZE RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMMX1ZE RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMMX5I6 DI DMMX5I6 DMMX5I6 DN PMID29130358-Compound-Figure9(1) DMMX5I6 TI TTXPTJE DMMX5I6 TN Gelatinase (GEL) DMMX5I6 MA Inhibitor DMMX5I6 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMMX5I6 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMMX6V4 DI DMMX6V4 DMMX6V4 DN Heteroaryl-carboxamide derivative 5 DMMX6V4 TI TTCZOF2 DMMX6V4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMMX6V4 MA Inhibitor DMMX6V4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMMX6V4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMMXNY8 DI DMMXNY8 DMMXNY8 DN Mannoside derivative 5 DMMXNY8 TI TTTCRU2 DMMXNY8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMXNY8 MA Antagonist DMMXNY8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMXNY8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMXQJU DI DMMXQJU DMMXQJU DN Bromo benzyl ether derivative 1 DMMXQJU TI TT23XQV DMMXQJU TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMMXQJU MA Inhibitor DMMXQJU RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMMXQJU RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMMYH82 DI DMMYH82 DMMYH82 DN PMID28074661-Compound-US20169447134C85 DMMYH82 TI TTL7C8Q DMMYH82 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMMYH82 MA Inhibitor DMMYH82 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMMYH82 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMMYW2L DI DMMYW2L DMMYW2L DN Pyrimidinyl compound 7 DMMYW2L TI TTH5TC2 DMMYW2L TN NF-kappa-B-activating kinase (TBK1) DMMYW2L MA Inhibitor DMMYW2L RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMMYW2L RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMMZ1WL DI DMMZ1WL DMMZ1WL DN PMID26651364-Compound-107 DMMZ1WL TI TTTCRU2 DMMZ1WL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMMZ1WL MA Antagonist DMMZ1WL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMMZ1WL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMMZ8LE DI DMMZ8LE DMMZ8LE DN Heteroaryl-azepine derivative 10 DMMZ8LE TI TTWJBZ5 DMMZ8LE TN 5-HT 2C receptor (HTR2C) DMMZ8LE MA Agonist DMMZ8LE RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMMZ8LE RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMMZGC8 DI DMMZGC8 DMMZGC8 DN PMID28766366-Compound-Scheme9EHT1610 DMMZGC8 TI TTYGQ8A DMMZGC8 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMMZGC8 MA Inhibitor DMMZGC8 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMMZGC8 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMMZGC8 DI DMMZGC8 DMMZGC8 DN PMID28766366-Compound-Scheme9EHT1610 DMMZGC8 TI TTSBVFO DMMZGC8 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMMZGC8 MA Inhibitor DMMZGC8 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMMZGC8 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMMZHB1 DI DMMZHB1 DMMZHB1 DN PMID25726713-Compound-57 DMMZHB1 TI TT8J1S3 DMMZHB1 TN Smoothened homolog (SMO) DMMZHB1 MA Inhibitor DMMZHB1 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMMZHB1 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMMZO8Y DI DMMZO8Y DMMZO8Y DN PMID25482888-Compound-37 DMMZO8Y TI TTDIGC1 DMMZO8Y TN Dipeptidyl peptidase 4 (DPP-4) DMMZO8Y MA Inhibitor DMMZO8Y RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMMZO8Y RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMN082G DI DMN082G DMN082G DN 6EP DMN082G TI TTIG67W DMN082G TN Lysine-specific demethylase 5A (KDM5A) DMN082G MA Inhibitor DMN082G RN Histone demethylase inhibitors. US9714230. DMN082G RU http://www.freepatentsonline.com/US9714230.html DMN0FCA DI DMN0FCA DMN0FCA DN PMID25666693-Compound-108 DMN0FCA TI TTMI6F5 DMN0FCA TN Transient receptor potential cation channel V1 (TRPV1) DMN0FCA MA Antagonist DMN0FCA RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMN0FCA RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMN0XJQ DI DMN0XJQ DMN0XJQ DN Isoflavone derivative 8 DMN0XJQ TI TTJOMH6 DMN0XJQ TN Zinc finger protein GLI1 (Gli1) DMN0XJQ MA Inhibitor DMN0XJQ RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMN0XJQ RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMN0XJQ DI DMN0XJQ DMN0XJQ DN Isoflavone derivative 8 DMN0XJQ TI TT8J1S3 DMN0XJQ TN Smoothened homolog (SMO) DMN0XJQ MA Inhibitor DMN0XJQ RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMN0XJQ RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMN13BI DI DMN13BI DMN13BI DN PMID25726713-Compound-31 DMN13BI TI TT8J1S3 DMN13BI TN Smoothened homolog (SMO) DMN13BI MA Inhibitor DMN13BI RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMN13BI RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMN1B3F DI DMN1B3F DMN1B3F DN PMID26004420-Compound-WO2014150132A DMN1B3F TI TTJ13ST DMN1B3F TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMN1B3F MA Inhibitor DMN1B3F RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMN1B3F RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMN1J09 DI DMN1J09 DMN1J09 DN Benzothiazole analog 5 DMN1J09 TI TTULVH8 DMN1J09 TN Tyrosinase (TYR) DMN1J09 MA Inhibitor DMN1J09 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMN1J09 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMN27QB DI DMN27QB DMN27QB DN PMID25991433-Compound-N1 DMN27QB TI TT0K6EO DMN27QB TN Stress-activated protein kinase JNK1 (JNK1) DMN27QB MA Inhibitor DMN27QB RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMN27QB RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMN27QB DI DMN27QB DMN27QB DN PMID25991433-Compound-N1 DMN27QB TI TTXKZ8Q DMN27QB TN JNK-interacting protein 1 peptide (pepJIP1) DMN27QB MA Inhibitor DMN27QB RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMN27QB RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMN2910 DI DMN2910 DMN2910 DN PMID28454500-Compound-34 DMN2910 TI TTA6ZN2 DMN2910 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMN2910 MA Activator DMN2910 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMN2910 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMN2910 DI DMN2910 DMN2910 DN PMID28454500-Compound-34 DMN2910 TI TT3Z6Y9 DMN2910 TN Cysteines of Keap1 (KEAP1 Cysteines) DMN2910 MA Modulator DMN2910 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMN2910 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMN2B87 DI DMN2B87 DMN2B87 DN 5-azolone derivative 1 DMN2B87 TI TTG5QB7 DMN2B87 TN Calpain-2 (CAPN2) DMN2B87 MA Inhibitor DMN2B87 RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMN2B87 RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMN2K10 DI DMN2K10 DMN2K10 DN PMID30107136-Compound-Example12 DMN2K10 TI TT23XQV DMN2K10 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMN2K10 MA Inhibitor DMN2K10 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN2K10 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN2K10 DI DMN2K10 DMN2K10 DN PMID30107136-Compound-Example12 DMN2K10 TI TT5YPJF DMN2K10 TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMN2K10 MA Inhibitor DMN2K10 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN2K10 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN2VZW DI DMN2VZW DMN2VZW DN Peptidomimetic analog 2 DMN2VZW TI TTH8FZW DMN2VZW TN Signal transducer and activator of transcription 3 (STAT3) DMN2VZW MA Inhibitor DMN2VZW RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMN2VZW RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMN37BI DI DMN37BI DMN37BI DN 4-PAM derivative 1 DMN37BI TI TT1RS9F DMN37BI TN Acetylcholinesterase (AChE) DMN37BI MA Reactivator DMN37BI RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMN37BI RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMN3WID DI DMN3WID DMN3WID DN Cyclohexane carboxamide derivative 1 DMN3WID TI TTTJZ4M DMN3WID TN Prolylcarboxypeptidase (PRCP) DMN3WID MA Inhibitor DMN3WID RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMN3WID RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMN3ZEF DI DMN3ZEF DMN3ZEF DN PMID28092474-Compound-32i DMN3ZEF TI TT6R7JZ DMN3ZEF TN Histone deacetylase 1 (HDAC1) DMN3ZEF MA Inhibitor DMN3ZEF RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMN3ZEF RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMN3ZEF DI DMN3ZEF DMN3ZEF DN PMID28092474-Compound-32i DMN3ZEF TI TT5ZKDI DMN3ZEF TN Histone deacetylase 6 (HDAC6) DMN3ZEF MA Inhibitor DMN3ZEF RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMN3ZEF RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMN42OT DI DMN42OT DMN42OT DN PMID25726713-Compound-11 DMN42OT TI TT8J1S3 DMN42OT TN Smoothened homolog (SMO) DMN42OT MA Inhibitor DMN42OT RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMN42OT RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMN43Q5 DI DMN43Q5 DMN43Q5 DN Peptide analog 70 DMN43Q5 TI TTQAJF1 DMN43Q5 TN Cathepsin G (CTSG) DMN43Q5 MA Inhibitor DMN43Q5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMN43Q5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMN43Q5 DI DMN43Q5 DMN43Q5 DN Peptide analog 70 DMN43Q5 TI TTPLTSQ DMN43Q5 TN Neutrophil elastase (NE) DMN43Q5 MA Inhibitor DMN43Q5 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMN43Q5 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMN4C2O DI DMN4C2O DMN4C2O DN PMID26815044-Compound-52 DMN4C2O TI TTULVH8 DMN4C2O TN Tyrosinase (TYR) DMN4C2O MA Inhibitor DMN4C2O RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMN4C2O RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMN4FRE DI DMN4FRE DMN4FRE DN US8772478, 3 DMN4FRE TI TTQICM2 DMN4FRE TN ADAM metallopeptidase 33 (ADAM33) DMN4FRE MA Inhibitor DMN4FRE RN Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics. US8772478. DMN4FRE RU http://www.freepatentsonline.com/US8772478.html DMN4SE5 DI DMN4SE5 DMN4SE5 DN Pyrrolo-pyrrolone derivative 1 DMN4SE5 TI TTRA6BO DMN4SE5 TN Bromodomain-containing protein 4 (BRD4) DMN4SE5 MA Inhibitor DMN4SE5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMN4SE5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMN4SE5 DI DMN4SE5 DMN4SE5 DN Pyrrolo-pyrrolone derivative 1 DMN4SE5 TI TTHE657 DMN4SE5 TN Bromodomain-containing protein 3 (BRD3) DMN4SE5 MA Inhibitor DMN4SE5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMN4SE5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMN4SE5 DI DMN4SE5 DMN4SE5 DN Pyrrolo-pyrrolone derivative 1 DMN4SE5 TI TTDP48B DMN4SE5 TN Bromodomain-containing protein 2 (BRD2) DMN4SE5 MA Inhibitor DMN4SE5 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMN4SE5 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMN51XF DI DMN51XF DMN51XF DN Ureido-phenyl-substituted triazine derivative 1 DMN51XF TI TTTDVOJ DMN51XF TN Tropomyosin-related kinase A (TrkA) DMN51XF MA Inhibitor DMN51XF RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMN51XF RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMN53R0 DI DMN53R0 DMN53R0 DN Pyrazole derivative 62 DMN53R0 TI TTH8FZW DMN53R0 TN Signal transducer and activator of transcription 3 (STAT3) DMN53R0 MA Inhibitor DMN53R0 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMN53R0 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMN580F DI DMN580F DMN580F DN Heterocyclic derivative 10 DMN580F TI TTCZOF2 DMN580F TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMN580F MA Inhibitor DMN580F RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMN580F RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMN5H3C DI DMN5H3C DMN5H3C DN PMID26815044-Compound-32 DMN5H3C TI TTULVH8 DMN5H3C TN Tyrosinase (TYR) DMN5H3C MA Inhibitor DMN5H3C RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMN5H3C RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMN5YUK DI DMN5YUK DMN5YUK DN Sulfonamide derivative 7 DMN5YUK TI TTZJYKH DMN5YUK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMN5YUK MA Inhibitor DMN5YUK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMN5YUK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMN64AK DI DMN64AK DMN64AK DN Pyrimidine derivative 22 DMN64AK TI TT8J1S3 DMN64AK TN Smoothened homolog (SMO) DMN64AK MA Inhibitor DMN64AK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMN64AK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMN692C DI DMN692C DMN692C DN PMID25666693-Compound-3 DMN692C TI TTMI6F5 DMN692C TN Transient receptor potential cation channel V1 (TRPV1) DMN692C MA Antagonist DMN692C RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMN692C RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMN6GTZ DI DMN6GTZ DMN6GTZ DN 4-Methoxybenzaldehyde DMN6GTZ TI TTGP7BY DMN6GTZ TN Monoamine oxidase type B (MAO-B) DMN6GTZ MA Inhibitor DMN6GTZ RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMN6GTZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMN6TG7 DI DMN6TG7 DMN6TG7 DN PMID26560530-Compound-8 DMN6TG7 TI TT2F4OL DMN6TG7 TN Tissue transglutaminase (TG2) DMN6TG7 MA Inhibitor DMN6TG7 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMN6TG7 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMN73KO DI DMN73KO DMN73KO DN PMID26666989-Compound-Figure9middle05 DMN73KO TI TT8BUGW DMN73KO TN Glycogen phosphorylase (PYG) DMN73KO MA Inhibitor DMN73KO RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMN73KO RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMN7I9C DI DMN7I9C DMN7I9C DN Macrocycle derivative 1 DMN7I9C TI TT23XQV DMN7I9C TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMN7I9C MA Inhibitor DMN7I9C RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN7I9C RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN7I9C DI DMN7I9C DMN7I9C DN Macrocycle derivative 1 DMN7I9C TI TT5YPJF DMN7I9C TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMN7I9C MA Inhibitor DMN7I9C RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMN7I9C RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMN97QF DI DMN97QF DMN97QF DN Peptide analog 14 DMN97QF TI TTOUSTQ DMN97QF TN Proteasome beta-9 (PS beta-9) DMN97QF MA Inhibitor DMN97QF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMN97QF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMN9KTJ DI DMN9KTJ DMN9KTJ DN Azole derivative 3 DMN9KTJ TI TTDP1UC DMN9KTJ TN Fatty acid amide hydrolase (FAAH) DMN9KTJ MA Inhibitor DMN9KTJ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMN9KTJ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMN9LDH DI DMN9LDH DMN9LDH DN PMID25666693-Compound-117 DMN9LDH TI TTMI6F5 DMN9LDH TN Transient receptor potential cation channel V1 (TRPV1) DMN9LDH MA Antagonist DMN9LDH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMN9LDH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMN9VQM DI DMN9VQM DMN9VQM DN Pyrimidine derivative 1 DMN9VQM TI TT4G2JS DMN9VQM TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMN9VQM MA Blocker DMN9VQM RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMN9VQM RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMN9VQM DI DMN9VQM DMN9VQM DN Pyrimidine derivative 1 DMN9VQM TI TTAXZ0K DMN9VQM TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMN9VQM MA Blocker DMN9VQM RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMN9VQM RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMNA941 DI DMNA941 DMNA941 DN Phthalazinone derivative 1 DMNA941 TI TTYLQ8V DMNA941 TN Prostaglandin E synthase (PTGES) DMNA941 MA Inhibitor DMNA941 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMNA941 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMNAJWQ DI DMNAJWQ DMNAJWQ DN Piperazine urea derivative 3 DMNAJWQ TI TTQR74A DMNAJWQ TN Proteinase activated receptor 2 (PAR2) DMNAJWQ MA Antagonist DMNAJWQ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMNAJWQ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMNATSQ DI DMNATSQ DMNATSQ DN PMID25666693-Compound-75 DMNATSQ TI TTMI6F5 DMNATSQ TN Transient receptor potential cation channel V1 (TRPV1) DMNATSQ MA Antagonist DMNATSQ RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNATSQ RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNBAZH DI DMNBAZH DMNBAZH DN Enol carbamate derivative 1 DMNBAZH TI TTDP1UC DMNBAZH TN Fatty acid amide hydrolase (FAAH) DMNBAZH MA Inhibitor DMNBAZH RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNBAZH RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNBCKI DI DMNBCKI DMNBCKI DN Pyrazole derivative 85 DMNBCKI TI TTZ963I DMNBCKI TN Monoglyceride lipase (MAGL) DMNBCKI MA Inhibitor DMNBCKI RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMNBCKI RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMNBT3K DI DMNBT3K DMNBT3K DN PMID29338548-Compound-28 DMNBT3K TI TTHJTF7 DMNBT3K TN Glycine transporter GlyT-1 (SLC6A9) DMNBT3K MA Inhibitor DMNBT3K RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMNBT3K RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMNBW8P DI DMNBW8P DMNBW8P DN Aryl carboxamide derivative 4 DMNBW8P TI TT4G2JS DMNBW8P TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMNBW8P MA Inhibitor DMNBW8P RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMNBW8P RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMNC0RX DI DMNC0RX DMNC0RX DN Aryl methoxyacrylate derivative 2 DMNC0RX TI TTUX68I DMNC0RX TN Hypoxia-inducible factor 1 (HIF-1) DMNC0RX MA Inhibitor DMNC0RX RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMNC0RX RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMNC5S0 DI DMNC5S0 DMNC5S0 DN Biaryl mannoside derivative 20 DMNC5S0 TI TTTCRU2 DMNC5S0 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMNC5S0 MA Antagonist DMNC5S0 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMNC5S0 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMNCHBL DI DMNCHBL DMNCHBL DN Isoflavone derivative 7 DMNCHBL TI TTJOMH6 DMNCHBL TN Zinc finger protein GLI1 (Gli1) DMNCHBL MA Inhibitor DMNCHBL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMNCHBL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMNCHBL DI DMNCHBL DMNCHBL DN Isoflavone derivative 7 DMNCHBL TI TT8J1S3 DMNCHBL TN Smoothened homolog (SMO) DMNCHBL MA Inhibitor DMNCHBL RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMNCHBL RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMND8R0 DI DMND8R0 DMND8R0 DN Benzoic acid linked peptide analog 1 DMND8R0 TI TTULVH8 DMND8R0 TN Tyrosinase (TYR) DMND8R0 MA Inhibitor DMND8R0 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMND8R0 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNDAT0 DI DMNDAT0 DMNDAT0 DN Benzothiazole analog 4 DMNDAT0 TI TTULVH8 DMNDAT0 TN Tyrosinase (TYR) DMNDAT0 MA Inhibitor DMNDAT0 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNDAT0 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNDF1Z DI DMNDF1Z DMNDF1Z DN PMID30185082-Compound-57 DMNDF1Z TI TT9NXW4 DMNDF1Z TN Sigma intracellular receptor 2 (TMEM97) DMNDF1Z MA Ligand DMNDF1Z RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMNDF1Z RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMNDF1Z DI DMNDF1Z DMNDF1Z DN PMID30185082-Compound-57 DMNDF1Z TI TT5TPI6 DMNDF1Z TN Opioid receptor sigma 1 (OPRS1) DMNDF1Z MA Ligand DMNDF1Z RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMNDF1Z RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMNDPEA DI DMNDPEA DMNDPEA DN Carbamate derivative 1 DMNDPEA TI TTDP1UC DMNDPEA TN Fatty acid amide hydrolase (FAAH) DMNDPEA MA Inhibitor DMNDPEA RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNDPEA RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNDVC9 DI DMNDVC9 DMNDVC9 DN PMID25991433-Compound-P6 DMNDVC9 TI TTHS0U8 DMNDVC9 TN Stress-activated protein kinase JNK2 (JNK2) DMNDVC9 MA Inhibitor DMNDVC9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMNDVC9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMNDVC9 DI DMNDVC9 DMNDVC9 DN PMID25991433-Compound-P6 DMNDVC9 TI TT0K6EO DMNDVC9 TN Stress-activated protein kinase JNK1 (JNK1) DMNDVC9 MA Inhibitor DMNDVC9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMNDVC9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMNDVC9 DI DMNDVC9 DMNDVC9 DN PMID25991433-Compound-P6 DMNDVC9 TI TT056SO DMNDVC9 TN Stress-activated protein kinase JNK3 (JNK3) DMNDVC9 MA Inhibitor DMNDVC9 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMNDVC9 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMNE9AX DI DMNE9AX DMNE9AX DN PMID29649907-Compound-10 DMNE9AX TI TTS4UGC DMNE9AX TN Farnesoid X-activated receptor (FXR) DMNE9AX MA Agonist DMNE9AX RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMNE9AX RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMNEBXL DI DMNEBXL DMNEBXL DN PMID25666693-Compound-116 DMNEBXL TI TTMI6F5 DMNEBXL TN Transient receptor potential cation channel V1 (TRPV1) DMNEBXL MA Antagonist DMNEBXL RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNEBXL RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNEGA0 DI DMNEGA0 DMNEGA0 DN PMID26394986-Compound-Figure16 DMNEGA0 TI TTH8FZW DMNEGA0 TN Signal transducer and activator of transcription 3 (STAT3) DMNEGA0 MA Inhibitor DMNEGA0 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMNEGA0 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMNEKOZ DI DMNEKOZ DMNEKOZ DN Dihydropyrimidinone derivative 4 DMNEKOZ TI TTJOW1I DMNEKOZ TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMNEKOZ MA Inhibitor DMNEKOZ RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMNEKOZ RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMNET19 DI DMNET19 DMNET19 DN Pyrimidine derivative 5 DMNET19 TI TTOHSBA DMNET19 TN Vascular endothelial growth factor A (VEGFA) DMNET19 MA Inhibitor DMNET19 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMNET19 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMNEY58 DI DMNEY58 DMNEY58 DN ML272 DMNEY58 TI TT3T17P DMNEY58 TN Phospholipase D1 (PLD1) DMNEY58 MA Inhibitor DMNEY58 RN Antiviral therapies with phospholipase D inhibitors. US9453017. DMNEY58 RU http://www.freepatentsonline.com/US9453017.html DMNG0WH DI DMNG0WH DMNG0WH DN Heterocyclic derivative 19 DMNG0WH TI TTCZOF2 DMNG0WH TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMNG0WH MA Inhibitor DMNG0WH RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMNG0WH RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMNGD2S DI DMNGD2S DMNGD2S DN PMID25666693-Compound-110 DMNGD2S TI TTMI6F5 DMNGD2S TN Transient receptor potential cation channel V1 (TRPV1) DMNGD2S MA Antagonist DMNGD2S RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNGD2S RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNGY8R DI DMNGY8R DMNGY8R DN Tacrine-phenothiazine hybrid derivative 1 DMNGY8R TI TT1RS9F DMNGY8R TN Acetylcholinesterase (AChE) DMNGY8R MA Inhibitor DMNGY8R RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMNGY8R RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMNH891 DI DMNH891 DMNH891 DN PMID27967267-Compound-51 DMNH891 TI TT1RS9F DMNH891 TN Acetylcholinesterase (AChE) DMNH891 MA Reactivator DMNH891 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMNH891 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMNH8GW DI DMNH8GW DMNH8GW DN 1,2-diamino cyclopentane-based derivative 1 DMNH8GW TI TT9N02I DMNH8GW TN Orexin receptor type 2 (HCRTR2) DMNH8GW MA Antagonist DMNH8GW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMNH8GW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMNH8GW DI DMNH8GW DMNH8GW DN 1,2-diamino cyclopentane-based derivative 1 DMNH8GW TI TT60Q8D DMNH8GW TN Orexin receptor type 1 (HCRTR1) DMNH8GW MA Antagonist DMNH8GW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMNH8GW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMNHCMY DI DMNHCMY DMNHCMY DN PMID28394193-Compound-23 DMNHCMY TI TT9MZCQ DMNHCMY TN Enhancer of zeste homolog 2 (EZH2) DMNHCMY MA Inhibitor DMNHCMY RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMNHCMY RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMNI03Z DI DMNI03Z DMNI03Z DN PMID25522065-Compound-49 DMNI03Z TI TTX4RTB DMNI03Z TN Melanin-concentrating hormone receptor 1 (MCHR1) DMNI03Z MA Antagonist DMNI03Z RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMNI03Z RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMNI0M1 DI DMNI0M1 DMNI0M1 DN Aminoazetidine derivative 1 DMNI0M1 TI TT6OEDT DMNI0M1 TN Cannabinoid receptor 1 (CB1) DMNI0M1 MA Antagonist DMNI0M1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMNI0M1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMNI0PH DI DMNI0PH DMNI0PH DN Isoxazole-based bicyclic compound 4 DMNI0PH TI TTE4BSY DMNI0PH TN Bromodomain and extraterminal domain protein (BET) DMNI0PH MA Inhibitor DMNI0PH RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMNI0PH RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMNIE4M DI DMNIE4M DMNIE4M DN AKOS020330656 DMNIE4M TI TTIG67W DMNIE4M TN Lysine-specific demethylase 5A (KDM5A) DMNIE4M MA Inhibitor DMNIE4M RN Histone demethylase inhibitors. US10179769. DMNIE4M RU http://www.freepatentsonline.com/US10179769.html DMNIER3 DI DMNIER3 DMNIER3 DN Pyrazolo[1,5-a]pyrimidine derivative 17 DMNIER3 TI TTTDVOJ DMNIER3 TN Tropomyosin-related kinase A (TrkA) DMNIER3 MA Inhibitor DMNIER3 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMNIER3 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMNIKTA DI DMNIKTA DMNIKTA DN PMID27539678-Compound-12 DMNIKTA TI TTOHFIY DMNIKTA TN Sphingosine kinase 1 (SPHK1) DMNIKTA MA Inhibitor DMNIKTA RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMNIKTA RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMNIPE6 DI DMNIPE6 DMNIPE6 DN Benzo[d]oxazole derivative 1 DMNIPE6 TI TTA6ZN2 DMNIPE6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMNIPE6 MA Inhibitor DMNIPE6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMNIPE6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMNISGE DI DMNISGE DMNISGE DN PMID25522065-Compound-36 DMNISGE TI TTX4RTB DMNISGE TN Melanin-concentrating hormone receptor 1 (MCHR1) DMNISGE MA Antagonist DMNISGE RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMNISGE RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMNIWVG DI DMNIWVG DMNIWVG DN N-(phenylamino)-benzoate derivative 1 DMNIWVG TI TT5ZWB6 DMNIWVG TN Dihydrodiol dehydrogenase type I (AKR1C3) DMNIWVG MA Inhibitor; Antagonist; Blocker DMNIWVG RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMNIWVG RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMNIZAR DI DMNIZAR DMNIZAR DN Benzoic acid linked peptide analog 5 DMNIZAR TI TTULVH8 DMNIZAR TN Tyrosinase (TYR) DMNIZAR MA Inhibitor DMNIZAR RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNIZAR RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNIZD7 DI DMNIZD7 DMNIZD7 DN PMID27774824-Compound-Figure12Example61 DMNIZD7 TI TTGM6VW DMNIZD7 TN Tyrosine-protein kinase BTK (ATK) DMNIZD7 MA Inhibitor DMNIZD7 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMNIZD7 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMNIZD7 DI DMNIZD7 DMNIZD7 DN PMID27774824-Compound-Figure12Example61 DMNIZD7 TI TTT7PJU DMNIZD7 TN Janus kinase 3 (JAK-3) DMNIZD7 MA Inhibitor DMNIZD7 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMNIZD7 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMNJ2R9 DI DMNJ2R9 DMNJ2R9 DN Isoquinoline derivative 5 DMNJ2R9 TI TTMQO60 DMNJ2R9 TN Rho-associated protein kinase (ROCK) DMNJ2R9 MA Inhibitor DMNJ2R9 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMNJ2R9 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMNJVR6 DI DMNJVR6 DMNJVR6 DN Heterocyclic-tetracyclic tetrahydrofuran derivative 1 DMNJVR6 TI TTYSN63 DMNJVR6 TN 5-HT 2 receptor (5HT2R) DMNJVR6 MA Antagonist DMNJVR6 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNJVR6 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMNK2DQ DI DMNK2DQ DMNK2DQ DN PMID25656651-Compound-15c DMNK2DQ TI TTS7G69 DMNK2DQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMNK2DQ MA Inhibitor DMNK2DQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMNK2DQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TT4YWTO DMNKABH TN Histone deacetylase 3 (HDAC3) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TTSHTOI DMNKABH TN Histone deacetylase 2 (HDAC2) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TT6R7JZ DMNKABH TN Histone deacetylase 1 (HDAC1) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKABH DI DMNKABH DMNKABH DN PMID29671355-Compound-11 DMNKABH TI TT5ZKDI DMNKABH TN Histone deacetylase 6 (HDAC6) DMNKABH MA Inhibitor DMNKABH RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMNKABH RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMNKH07 DI DMNKH07 DMNKH07 DN PMID27215781-Compound-13 DMNKH07 TI TTMSFAW DMNKH07 TN Cannabinoid receptor 2 (CB2) DMNKH07 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMNKH07 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMNKRSZ DI DMNKRSZ DMNKRSZ DN PMID28766366-Compound-Scheme24Paprotrain DMNKRSZ TI TTSBVFO DMNKRSZ TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMNKRSZ MA Inhibitor DMNKRSZ RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMNKRSZ RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMNKW1E DI DMNKW1E DMNKW1E DN PMID25666693-Compound-111 DMNKW1E TI TTMI6F5 DMNKW1E TN Transient receptor potential cation channel V1 (TRPV1) DMNKW1E MA Antagonist DMNKW1E RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNKW1E RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNKXJ2 DI DMNKXJ2 DMNKXJ2 DN PMID28870136-Compound-62 DMNKXJ2 TI TTK0O6Y DMNKXJ2 TN Ecto-5'-nucleotidase (CD73) DMNKXJ2 MA Inhibitor DMNKXJ2 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMNKXJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMNKYL9 DI DMNKYL9 DMNKYL9 DN Benzamide derivative 4 DMNKYL9 TI TT9NXW4 DMNKYL9 TN Sigma intracellular receptor 2 (TMEM97) DMNKYL9 MA Ligand DMNKYL9 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMNKYL9 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMNMU3R DI DMNMU3R DMNMU3R DN PMID25399762-Compound-Table1-C17 DMNMU3R TI TTGP7BY DMNMU3R TN Monoamine oxidase type B (MAO-B) DMNMU3R MA Inhibitor DMNMU3R RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMNMU3R RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMNO2BP DI DMNO2BP DMNO2BP DN Quinoline derivative 2 DMNO2BP TI TT0K1SC DMNO2BP TN 5-HT 2B receptor (HTR2B) DMNO2BP MA Antagonist DMNO2BP RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNO2BP RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMNO2BP DI DMNO2BP DMNO2BP DN Quinoline derivative 2 DMNO2BP TI TTWJBZ5 DMNO2BP TN 5-HT 2C receptor (HTR2C) DMNO2BP MA Agonist DMNO2BP RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNO2BP RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMNOAQB DI DMNOAQB DMNOAQB DN PMID28870136-Compound-44 DMNOAQB TI TTK0O6Y DMNOAQB TN Ecto-5'-nucleotidase (CD73) DMNOAQB MA Inhibitor DMNOAQB RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMNOAQB RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMNOD4A DI DMNOD4A DMNOD4A DN PMID25666693-Compound-101 DMNOD4A TI TTMI6F5 DMNOD4A TN Transient receptor potential cation channel V1 (TRPV1) DMNOD4A MA Antagonist DMNOD4A RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNOD4A RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNOJGW DI DMNOJGW DMNOJGW DN PMID26413912-Compound-84 DMNOJGW TI TTGX13H DMNOJGW TN Fatty-acid amide hydrolase 1 (FAAH1) DMNOJGW MA Inhibitor DMNOJGW RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNOJGW RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNOJGW DI DMNOJGW DMNOJGW DN PMID26413912-Compound-84 DMNOJGW TI TTDP1UC DMNOJGW TN Fatty acid amide hydrolase (FAAH) DMNOJGW MA Inhibitor DMNOJGW RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMNOJGW RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMNPBRG DI DMNPBRG DMNPBRG DN Antibodie derivative 3 DMNPBRG TI TTOHSBA DMNPBRG TN Vascular endothelial growth factor A (VEGFA) DMNPBRG RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMNPBRG RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMNPC0H DI DMNPC0H DMNPC0H DN PMID25468267-Compound-51 DMNPC0H TI TT0RGE9 DMNPC0H TN Lysine-specific demethylase 4 (KDM4) DMNPC0H MA Inhibitor DMNPC0H RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMNPC0H RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMNQF9S DI DMNQF9S DMNQF9S DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 4 DMNQF9S TI TTULVH8 DMNQF9S TN Tyrosinase (TYR) DMNQF9S MA Inhibitor DMNQF9S RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNQF9S RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNQLJU DI DMNQLJU DMNQLJU DN Azetidinyl-piperidine derivative 2 DMNQLJU TI TTZ963I DMNQLJU TN Monoglyceride lipase (MAGL) DMNQLJU MA Inhibitor DMNQLJU RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMNQLJU RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMNQUKP DI DMNQUKP DMNQUKP DN Alkyl mannoside derivative 2 DMNQUKP TI TTTCRU2 DMNQUKP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMNQUKP MA Antagonist DMNQUKP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMNQUKP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMNR6KL DI DMNR6KL DMNR6KL DN PMID27828716-Compound-18 DMNR6KL TI TTRZQE3 DMNR6KL TN Glycogen synthase kinase-3 alpha (GSK-3A) DMNR6KL MA Inhibitor DMNR6KL RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMNR6KL RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMNRG0P DI DMNRG0P DMNRG0P DN Purine derivative 2 DMNRG0P TI TT6OEDT DMNRG0P TN Cannabinoid receptor 1 (CB1) DMNRG0P MA Antagonist DMNRG0P RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMNRG0P RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMNROIP DI DMNROIP DMNROIP DN PMID25980951-Compound-41 DMNROIP TI TTR7B60 DMNROIP TN X-linked inhibitor of apoptosis protein (XIAP) DMNROIP MA Antagonist DMNROIP RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMNROIP RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMNROIP DI DMNROIP DMNROIP DN PMID25980951-Compound-41 DMNROIP TI TTQ5LRD DMNROIP TN Cellular inhibitor of apoptosis 1 (BIRC2) DMNROIP MA Antagonist DMNROIP RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMNROIP RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMNRU35 DI DMNRU35 DMNRU35 DN PMID27788040-Compound-6c DMNRU35 TI TTV1C0Z DMNRU35 TN Neuropeptide S receptor (NPSR) DMNRU35 MA Antagonist DMNRU35 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMNRU35 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMNSK7U DI DMNSK7U DMNSK7U DN Aryl mannoside derivative 9 DMNSK7U TI TTTCRU2 DMNSK7U TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMNSK7U MA Antagonist DMNSK7U RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMNSK7U RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMNTAYK DI DMNTAYK DMNTAYK DN PMID25416646-Compound-Figure2-K DMNTAYK TI TTZMAO3 DMNTAYK TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMNTAYK MA Agonist DMNTAYK RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMNTAYK RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMNTOZV DI DMNTOZV DMNTOZV DN 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide derivative 1 DMNTOZV TI TT6OEDT DMNTOZV TN Cannabinoid receptor 1 (CB1) DMNTOZV MA Antagonist DMNTOZV RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMNTOZV RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMNTQL5 DI DMNTQL5 DMNTQL5 DN PMID28270010-Compound-Figure24-a DMNTQL5 TI TTTDVOJ DMNTQL5 TN Tropomyosin-related kinase A (TrkA) DMNTQL5 MA Inhibitor DMNTQL5 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMNTQL5 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMNTQL5 DI DMNTQL5 DMNTQL5 DN PMID28270010-Compound-Figure24-a DMNTQL5 TI TT7MRDV DMNTQL5 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMNTQL5 MA Inhibitor DMNTQL5 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMNTQL5 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMNTRIZ DI DMNTRIZ DMNTRIZ DN PMID28092474-Compound-33j DMNTRIZ TI TT6R7JZ DMNTRIZ TN Histone deacetylase 1 (HDAC1) DMNTRIZ MA Inhibitor DMNTRIZ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMNTRIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMNTRIZ DI DMNTRIZ DMNTRIZ DN PMID28092474-Compound-33j DMNTRIZ TI TT5ZKDI DMNTRIZ TN Histone deacetylase 6 (HDAC6) DMNTRIZ MA Inhibitor DMNTRIZ RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMNTRIZ RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMNTVFH DI DMNTVFH DMNTVFH DN PMID25666693-Compound-7 DMNTVFH TI TTMI6F5 DMNTVFH TN Transient receptor potential cation channel V1 (TRPV1) DMNTVFH MA Antagonist DMNTVFH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMNTVFH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMNTZ93 DI DMNTZ93 DMNTZ93 DN Thiadiazolidindione derivative 3 DMNTZ93 TI TTRZQE3 DMNTZ93 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMNTZ93 MA Inhibitor DMNTZ93 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMNTZ93 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMNUA21 DI DMNUA21 DMNUA21 DN PMID28270021-Compound-WO2010077680 109 DMNUA21 TI TTTDVOJ DMNUA21 TN Tropomyosin-related kinase A (TrkA) DMNUA21 MA Antagonist DMNUA21 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMNUA21 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMNUR8E DI DMNUR8E DMNUR8E DN PMID28074661-Compound-US20100022547C88 DMNUR8E TI TTL7C8Q DMNUR8E TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMNUR8E MA Inhibitor DMNUR8E RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMNUR8E RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMNV0OA DI DMNV0OA DMNV0OA DN N-oxalyl-D-tyrosine derivative 8 DMNV0OA TI TTWAQBO DMNV0OA TN Lysine-specific demethylase 4E (KDM4E) DMNV0OA MA Inhibitor DMNV0OA RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMNV0OA RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMNW37Y DI DMNW37Y DMNW37Y DN PMID29338548-Compound-27 DMNW37Y TI TTHJTF7 DMNW37Y TN Glycine transporter GlyT-1 (SLC6A9) DMNW37Y MA Inhibitor DMNW37Y RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMNW37Y RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMNWCUJ DI DMNWCUJ DMNWCUJ DN PMID28394193-Compound-26 DMNWCUJ TI TT9MZCQ DMNWCUJ TN Enhancer of zeste homolog 2 (EZH2) DMNWCUJ MA Inhibitor DMNWCUJ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMNWCUJ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMNWRA0 DI DMNWRA0 DMNWRA0 DN PMID26666989-Compound-Figure9middle04 DMNWRA0 TI TT8BUGW DMNWRA0 TN Glycogen phosphorylase (PYG) DMNWRA0 MA Inhibitor DMNWRA0 RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMNWRA0 RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMNX5EU DI DMNX5EU DMNX5EU DN Benzoic acid linked peptide analog 4 DMNX5EU TI TTULVH8 DMNX5EU TN Tyrosinase (TYR) DMNX5EU MA Inhibitor DMNX5EU RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMNX5EU RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMNXAUZ DI DMNXAUZ DMNXAUZ DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 3 DMNXAUZ TI TTSXVID DMNXAUZ TN Nuclear factor NF-kappa-B (NFKB) DMNXAUZ MA Inhibitor DMNXAUZ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMNXAUZ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMNXBPQ DI DMNXBPQ DMNXBPQ DN Cyclopropane 1-carboxylic acid derivative 1 DMNXBPQ TI TTIY56R DMNXBPQ TN Kynurenine 3-hydroxylase (KMO) DMNXBPQ MA Inhibitor DMNXBPQ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMNXBPQ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMNXCZT DI DMNXCZT DMNXCZT DN Quinoline derivative 20 DMNXCZT TI TTSCO7R DMNXCZT TN NAD-dependent deacetylase sirtuin (SIRT) DMNXCZT MA Inhibitor DMNXCZT RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMNXCZT RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMNXJ8G DI DMNXJ8G DMNXJ8G DN Xanthine/amino piperidine compound 1 DMNXJ8G TI TTDIGC1 DMNXJ8G TN Dipeptidyl peptidase 4 (DPP-4) DMNXJ8G MA Inhibitor DMNXJ8G RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMNXJ8G RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMNXVY9 DI DMNXVY9 DMNXVY9 DN PMID25656651-Compound-36a DMNXVY9 TI TTIV39N DMNXVY9 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMNXVY9 MA Inhibitor DMNXVY9 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMNXVY9 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMNXVY9 DI DMNXVY9 DMNXVY9 DN PMID25656651-Compound-36a DMNXVY9 TI TTS7G69 DMNXVY9 TN Fusion protein Bcr-Abl (Bcr-Abl) DMNXVY9 MA Inhibitor DMNXVY9 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMNXVY9 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMNXYZP DI DMNXYZP DMNXYZP DN PMID27774822-Compound-Figure10Example19 DMNXYZP TI TTT7PJU DMNXYZP TN Janus kinase 3 (JAK-3) DMNXYZP MA Inhibitor DMNXYZP RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMNXYZP RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMNXYZP DI DMNXYZP DMNXYZP DN PMID27774822-Compound-Figure10Example19 DMNXYZP TI TTRMX3V DMNXYZP TN Janus kinase 2 (JAK-2) DMNXYZP MA Inhibitor DMNXYZP RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMNXYZP RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMNZD8T DI DMNZD8T DMNZD8T DN US9670220, 76 DMNZD8T TI TTDYP7I DMNZD8T TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMNZD8T MA Inhibitor DMNZD8T RN Fused heterocyclic derivatives as S1P modulators. US9670220. DMNZD8T RU http://www.freepatentsonline.com/US9670220.html DMNZO7V DI DMNZO7V DMNZO7V DN PMID29053063-Compound-7c DMNZO7V TI TTZ963I DMNZO7V TN Monoglyceride lipase (MAGL) DMNZO7V MA Inhibitor DMNZO7V RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMNZO7V RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMNZUHX DI DMNZUHX DMNZUHX DN Pyrazole derivative 67 DMNZUHX TI TTJQOD7 DMNZUHX TN 5-HT 2A receptor (HTR2A) DMNZUHX MA Antagonist DMNZUHX RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMNZUHX RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMO02EL DI DMO02EL DMO02EL DN PMID28270021-Compound-WO2014078408Example1 DMO02EL TI TTTDVOJ DMO02EL TN Tropomyosin-related kinase A (TrkA) DMO02EL MA Inhibitor DMO02EL RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMO02EL RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMO054V DI DMO054V DMO054V DN Pyrazolo[3,4-d]pyrimidine derivative 2 DMO054V TI TTJGW1Z DMO054V TN Phosphodiesterase 2A (PDE2A) DMO054V MA Inhibitor DMO054V RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMO054V RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMO0QME DI DMO0QME DMO0QME DN PMID27967267-Compound-27 DMO0QME TI TT1RS9F DMO0QME TN Acetylcholinesterase (AChE) DMO0QME RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMO0QME RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMO108N DI DMO108N DMO108N DN PMID29865878-Compound-58 DMO108N TI TTEAD9J DMO108N TN Proteasome beta-8 (PS beta-8) DMO108N MA Inhibitor DMO108N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMO108N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMO1920 DI DMO1920 DMO1920 DN 7-azaindole derivative 8 DMO1920 TI TTVDSZ0 DMO1920 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMO1920 MA Inhibitor DMO1920 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMO1920 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMO19Y6 DI DMO19Y6 DMO19Y6 DN Aryl mannoside derivative 4 DMO19Y6 TI TTTCRU2 DMO19Y6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMO19Y6 MA Antagonist DMO19Y6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMO19Y6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMO1I4W DI DMO1I4W DMO1I4W DN Pyrrolidinyl urea derivative 9 DMO1I4W TI TTTDVOJ DMO1I4W TN Tropomyosin-related kinase A (TrkA) DMO1I4W MA Inhibitor DMO1I4W RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMO1I4W RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMO1NAR DI DMO1NAR DMO1NAR DN PMID27828716-Compound-21 DMO1NAR TI TTRZQE3 DMO1NAR TN Glycogen synthase kinase-3 alpha (GSK-3A) DMO1NAR MA Inhibitor DMO1NAR RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMO1NAR RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMO1Y30 DI DMO1Y30 DMO1Y30 DN Heterocyclic-substituted 3-alkyl azetidine derivative 3 DMO1Y30 TI TT6OEDT DMO1Y30 TN Cannabinoid receptor 1 (CB1) DMO1Y30 MA Antagonist DMO1Y30 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMO1Y30 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TTT7PJU DMO1ZIG TN Janus kinase 3 (JAK-3) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TT6DM01 DMO1ZIG TN Janus kinase 1 (JAK-1) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TTRMX3V DMO1ZIG TN Janus kinase 2 (JAK-2) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO1ZIG DI DMO1ZIG DMO1ZIG DN Bis-aminopyrimidine derivative 4 DMO1ZIG TI TTBYWP2 DMO1ZIG TN TYK2 tyrosine kinase (TYK2) DMO1ZIG MA Inhibitor DMO1ZIG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMO1ZIG RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMO36RL DI DMO36RL DMO36RL DN PMID26560530-Compound-35 DMO36RL TI TT2F4OL DMO36RL TN Tissue transglutaminase (TG2) DMO36RL MA Inhibitor DMO36RL RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMO36RL RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMO3MJ7 DI DMO3MJ7 DMO3MJ7 DN Pyrazolo[1,5-a]pyrimidine derivative 2 DMO3MJ7 TI TT6OEDT DMO3MJ7 TN Cannabinoid receptor 1 (CB1) DMO3MJ7 MA Antagonist DMO3MJ7 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMO3MJ7 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMO3QDW DI DMO3QDW DMO3QDW DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 5 DMO3QDW TI TTV8CRH DMO3QDW TN Lysine-specific demethylase 4C (KDM4C) DMO3QDW MA Inhibitor DMO3QDW RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMO3QDW RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMO41ZB DI DMO41ZB DMO41ZB DN Imidazopyridine acetamide analog 1 DMO41ZB TI TTPTXIN DMO41ZB TN Translocator protein (TSPO) DMO41ZB MA Ligand DMO41ZB RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMO41ZB RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMO45G3 DI DMO45G3 DMO45G3 DN Heteroaryl-pyrazole derivative 3 DMO45G3 TI TTXJ47W DMO45G3 TN Metabotropic glutamate receptor 2 (mGluR2) DMO45G3 MA Antagonist DMO45G3 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMO45G3 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMO45VP DI DMO45VP DMO45VP DN PMID29649907-Compound-4 DMO45VP TI TTS4UGC DMO45VP TN Farnesoid X-activated receptor (FXR) DMO45VP MA Agonist DMO45VP RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMO45VP RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMO4JYK DI DMO4JYK DMO4JYK DN PMID29338548-Compound-45 DMO4JYK TI TTHJTF7 DMO4JYK TN Glycine transporter GlyT-1 (SLC6A9) DMO4JYK MA Inhibitor DMO4JYK RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMO4JYK RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMO4Q95 DI DMO4Q95 DMO4Q95 DN PMID28766366-Compound-Scheme2WO2012/098065bottom DMO4Q95 TI TTYGQ8A DMO4Q95 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMO4Q95 MA Inhibitor DMO4Q95 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO4Q95 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO4Q95 DI DMO4Q95 DMO4Q95 DN PMID28766366-Compound-Scheme2WO2012/098065bottom DMO4Q95 TI TTSBVFO DMO4Q95 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMO4Q95 MA Inhibitor DMO4Q95 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO4Q95 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO4YAB DI DMO4YAB DMO4YAB DN Acrylamide compound 1 DMO4YAB TI TT9JNIC DMO4YAB TN Histamine H3 receptor (H3R) DMO4YAB RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMO4YAB RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMO5479 DI DMO5479 DMO5479 DN PMID28394193-Compound-40 DMO5479 TI TT9MZCQ DMO5479 TN Enhancer of zeste homolog 2 (EZH2) DMO5479 MA Inhibitor DMO5479 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMO5479 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMO64LA DI DMO64LA DMO64LA DN Amide derivative 1 DMO64LA TI TT6OEDT DMO64LA TN Cannabinoid receptor 1 (CB1) DMO64LA MA Antagonist DMO64LA RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMO64LA RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMO6KZ5 DI DMO6KZ5 DMO6KZ5 DN PMID28766366-Compound-Scheme5 DMO6KZ5 TI TTYGQ8A DMO6KZ5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMO6KZ5 MA Inhibitor DMO6KZ5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO6KZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO6KZ5 DI DMO6KZ5 DMO6KZ5 DN PMID28766366-Compound-Scheme5 DMO6KZ5 TI TTSBVFO DMO6KZ5 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMO6KZ5 MA Inhibitor DMO6KZ5 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMO6KZ5 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMO6M1Q DI DMO6M1Q DMO6M1Q DN Pyrazole derivative 61 DMO6M1Q TI TTCZOF2 DMO6M1Q TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMO6M1Q MA Inhibitor DMO6M1Q RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMO6M1Q RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMO6NWD DI DMO6NWD DMO6NWD DN Carbamate derivative 3 DMO6NWD TI TTDP1UC DMO6NWD TN Fatty acid amide hydrolase (FAAH) DMO6NWD MA Inhibitor DMO6NWD RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMO6NWD RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMO7310 DI DMO7310 DMO7310 DN 1-phenyl-1,3,4-triazole derivative 2 DMO7310 TI TTA6ZN2 DMO7310 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMO7310 MA Inhibitor DMO7310 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMO7310 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMO7310 DI DMO7310 DMO7310 DN 1-phenyl-1,3,4-triazole derivative 2 DMO7310 TI TT956B0 DMO7310 TN Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) DMO7310 MA Modulator DMO7310 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMO7310 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMO74I9 DI DMO74I9 DMO74I9 DN PMID27599163-Compound-82 DMO74I9 TI TTPTXIN DMO74I9 TN Translocator protein (TSPO) DMO74I9 MA Ligand DMO74I9 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMO74I9 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMO7ZRW DI DMO7ZRW DMO7ZRW DN Sulfamoylamide derivative 1 DMO7ZRW TI TTZJYKH DMO7ZRW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMO7ZRW MA Inhibitor DMO7ZRW RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMO7ZRW RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMO8JE7 DI DMO8JE7 DMO8JE7 DN Fused heterocyclic compound 8 DMO8JE7 TI TT7RJY8 DMO8JE7 TN Xanthine dehydrogenase/oxidase (XDH) DMO8JE7 MA Inhibitor DMO8JE7 RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMO8JE7 RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMO8UKD DI DMO8UKD DMO8UKD DN Five-membered heteroaromatic compound 1 DMO8UKD TI TTZJYKH DMO8UKD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMO8UKD MA Inhibitor DMO8UKD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMO8UKD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMO913H DI DMO913H DMO913H DN PMID25482888-Compound-15 DMO913H TI TTDIGC1 DMO913H TN Dipeptidyl peptidase 4 (DPP-4) DMO913H MA Inhibitor DMO913H RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMO913H RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMO97LR DI DMO97LR DMO97LR DN PMID26815044-Compound-127 DMO97LR TI TTULVH8 DMO97LR TN Tyrosinase (TYR) DMO97LR MA Inhibitor DMO97LR RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMO97LR RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMO9Q8J DI DMO9Q8J DMO9Q8J DN Pyrrolo-pyrazine derivative 2 DMO9Q8J TI TTT7PJU DMO9Q8J TN Janus kinase 3 (JAK-3) DMO9Q8J MA Inhibitor DMO9Q8J RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMO9Q8J RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMO9RE8 DI DMO9RE8 DMO9RE8 DN Beta-cyclodextrin conjugate derivative 4 DMO9RE8 TI TTTCRU2 DMO9RE8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMO9RE8 MA Antagonist DMO9RE8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMO9RE8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOA8E4 DI DMOA8E4 DMOA8E4 DN Pyrazoline derivative 2 DMOA8E4 TI TT6OEDT DMOA8E4 TN Cannabinoid receptor 1 (CB1) DMOA8E4 MA Antagonist DMOA8E4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOA8E4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOASLQ DI DMOASLQ DMOASLQ DN PMID29473428-Compound-53 DMOASLQ TI TTZJYKH DMOASLQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOASLQ MA Inhibitor DMOASLQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMOASLQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMOAU09 DI DMOAU09 DMOAU09 DN PMID25991433-Compound-C2 DMOAU09 TI TTVOE6D DMOAU09 TN Mitogen-activated protein kinase (MAPK) DMOAU09 MA Inhibitor DMOAU09 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMOAU09 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMOAXKF DI DMOAXKF DMOAXKF DN Benzamide derivative 16 DMOAXKF TI TTYLQ8V DMOAXKF TN Prostaglandin E synthase (PTGES) DMOAXKF MA Inhibitor DMOAXKF RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMOAXKF RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMOAY3Q DI DMOAY3Q DMOAY3Q DN Isoquinoline carboxamide derivative 1 DMOAY3Q TI TTPTXIN DMOAY3Q TN Translocator protein (TSPO) DMOAY3Q MA Ligand DMOAY3Q RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMOAY3Q RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMOAYEV DI DMOAYEV DMOAYEV DN Heteroaryl-carboxamide derivative 7 DMOAYEV TI TTCZOF2 DMOAYEV TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOAYEV MA Inhibitor DMOAYEV RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOAYEV RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOB8LU DI DMOB8LU DMOB8LU DN PMID27998201-Compound-15 DMOB8LU TI TTDZN01 DMOB8LU TN Cathepsin K (CTSK) DMOB8LU MA Inhibitor DMOB8LU RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMOB8LU RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMOB8LU DI DMOB8LU DMOB8LU DN PMID27998201-Compound-15 DMOB8LU TI TTUMQVO DMOB8LU TN Cathepsin S (CTSS) DMOB8LU MA Inhibitor DMOB8LU RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMOB8LU RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMOBFAU DI DMOBFAU DMOBFAU DN Quinazoline derivative 1 DMOBFAU TI TTDIGC1 DMOBFAU TN Dipeptidyl peptidase 4 (DPP-4) DMOBFAU MA Inhibitor DMOBFAU RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMOBFAU RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMOCF4Y DI DMOCF4Y DMOCF4Y DN Cyclopropylamine derivative 4 DMOCF4Y TI TTNR0UQ DMOCF4Y TN Lysine-specific histone demethylase 1 (LSD) DMOCF4Y MA Inhibitor DMOCF4Y RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMOCF4Y RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMOD9BY DI DMOD9BY DMOD9BY DN PMID28766366-Compound-Scheme25-4 DMOD9BY TI TTYGQ8A DMOD9BY TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMOD9BY MA Inhibitor DMOD9BY RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMOD9BY RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMOD9BY DI DMOD9BY DMOD9BY DN PMID28766366-Compound-Scheme25-4 DMOD9BY TI TTSBVFO DMOD9BY TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMOD9BY MA Inhibitor DMOD9BY RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMOD9BY RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMODL3P DI DMODL3P DMODL3P DN PMID28627961-Compound-41 DMODL3P TI TTYLQ8V DMODL3P TN Prostaglandin E synthase (PTGES) DMODL3P MA Inhibitor DMODL3P RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMODL3P RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMODPFU DI DMODPFU DMODPFU DN PMID27599163-Compound-76 DMODPFU TI TTPTXIN DMODPFU TN Translocator protein (TSPO) DMODPFU MA Ligand DMODPFU RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMODPFU RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMODT8F DI DMODT8F DMODT8F DN PMID26924192-Compound-54 DMODT8F TI TTE4BSY DMODT8F TN Bromodomain and extraterminal domain protein (BET) DMODT8F MA Inhibitor DMODT8F RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMODT8F RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMODTSC DI DMODTSC DMODTSC DN Phthalazine derivative 2 DMODTSC TI TTEBCY8 DMODTSC TN Poly [ADP-ribose] polymerase (PARP) DMODTSC MA Inhibitor DMODTSC RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMODTSC RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMOE2FZ DI DMOE2FZ DMOE2FZ DN Pyrimidinyl compound 3 DMOE2FZ TI TTH5TC2 DMOE2FZ TN NF-kappa-B-activating kinase (TBK1) DMOE2FZ MA Inhibitor DMOE2FZ RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMOE2FZ RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMOE5N0 DI DMOE5N0 DMOE5N0 DN PMID25514969-Compound-12 DMOE5N0 TI TT4EB85 DMOE5N0 TN Cholesterol 24-hydroxylase (CYP46A1) DMOE5N0 MA Inhibitor DMOE5N0 RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMOE5N0 RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMOEFD3 DI DMOEFD3 DMOEFD3 DN Disulfiram analog 1 DMOEFD3 TI TTZHPB8 DMOEFD3 TN Lysine-specific demethylase 4A (KDM4A) DMOEFD3 MA Inhibitor DMOEFD3 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMOEFD3 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMOENP4 DI DMOENP4 DMOENP4 DN PMID27774822-Compound-Figure3CompoundI-165 DMOENP4 TI TTRMX3V DMOENP4 TN Janus kinase 2 (JAK-2) DMOENP4 MA Inhibitor DMOENP4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMOENP4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMOENP4 DI DMOENP4 DMOENP4 DN PMID27774822-Compound-Figure3CompoundI-165 DMOENP4 TI TTBYWP2 DMOENP4 TN TYK2 tyrosine kinase (TYK2) DMOENP4 MA Inhibitor DMOENP4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMOENP4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMOEYVT DI DMOEYVT DMOEYVT DN PMID27454349-Compound-92 DMOEYVT TI TTK59TV DMOEYVT TN Vitamin D3 receptor (VDR) DMOEYVT MA Agonist DMOEYVT RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMOEYVT RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMOFI09 DI DMOFI09 DMOFI09 DN Bicyclic heteroaryl amide derivative 1 DMOFI09 TI TT473XN DMOFI09 TN P2X purinoceptor 7 (P2RX7) DMOFI09 MA Antagonist DMOFI09 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMOFI09 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMOG72B DI DMOG72B DMOG72B DN Heteroaryl-azepine derivative 12 DMOG72B TI TTWJBZ5 DMOG72B TN 5-HT 2C receptor (HTR2C) DMOG72B MA Agonist DMOG72B RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOG72B RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOG8XT DI DMOG8XT DMOG8XT DN Aryl mannoside derivative 12 DMOG8XT TI TTTCRU2 DMOG8XT TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOG8XT MA Antagonist DMOG8XT RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOG8XT RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOGIAU DI DMOGIAU DMOGIAU DN PMID29130358-Compound-LonimacranthoideVII DMOGIAU TI TTLM12X DMOGIAU TN Matrix metalloproteinase-2 (MMP-2) DMOGIAU MA Inhibitor DMOGIAU RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMOGIAU RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMOGIAU DI DMOGIAU DMOGIAU DN PMID29130358-Compound-LonimacranthoideVII DMOGIAU TI TT6X50U DMOGIAU TN Matrix metalloproteinase-9 (MMP-9) DMOGIAU MA Inhibitor DMOGIAU RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMOGIAU RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMOGKSW DI DMOGKSW DMOGKSW DN PMID25656651-Compound-36c DMOGKSW TI TTIV39N DMOGKSW TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMOGKSW MA Inhibitor DMOGKSW RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMOGKSW RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMOGKSW DI DMOGKSW DMOGKSW DN PMID25656651-Compound-36c DMOGKSW TI TTS7G69 DMOGKSW TN Fusion protein Bcr-Abl (Bcr-Abl) DMOGKSW MA Inhibitor DMOGKSW RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMOGKSW RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMOGLBZ DI DMOGLBZ DMOGLBZ DN Macrocyclic peptide analog 2 DMOGLBZ TI TT23XQV DMOGLBZ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMOGLBZ MA Inhibitor DMOGLBZ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOGLBZ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOHBCN DI DMOHBCN DMOHBCN DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 12 DMOHBCN TI TTULVH8 DMOHBCN TN Tyrosinase (TYR) DMOHBCN MA Inhibitor DMOHBCN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMOHBCN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMOHERV DI DMOHERV DMOHERV DN Benzimidazole derivative 12 DMOHERV TI TTYLQ8V DMOHERV TN Prostaglandin E synthase (PTGES) DMOHERV MA Inhibitor DMOHERV RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMOHERV RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMOHITL DI DMOHITL DMOHITL DN Indoline derivative 19 DMOHITL TI TTOHSBA DMOHITL TN Vascular endothelial growth factor A (VEGFA) DMOHITL MA Inhibitor DMOHITL RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMOHITL RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMOIKB3 DI DMOIKB3 DMOIKB3 DN 5-Hydrazino-1H-tetrazole DMOIKB3 TI TTLQUZS DMOIKB3 TN Cystathionine gamma-lyase (CTH) DMOIKB3 MA Inhibitor DMOIKB3 RN Cystathionine--lyase (CSE) inhibitors. US9725426. DMOIKB3 RU http://www.freepatentsonline.com/US9725426.html DMOISDH DI DMOISDH DMOISDH DN PMID25666693-Compound-99 DMOISDH TI TTMI6F5 DMOISDH TN Transient receptor potential cation channel V1 (TRPV1) DMOISDH MA Antagonist DMOISDH RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMOISDH RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMOJ52P DI DMOJ52P DMOJ52P DN PMID26394986-Compound-44 DMOJ52P TI TTH8FZW DMOJ52P TN Signal transducer and activator of transcription 3 (STAT3) DMOJ52P MA Inhibitor DMOJ52P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMOJ52P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMOJ8P1 DI DMOJ8P1 DMOJ8P1 DN Pyrano[2,3-b]pyridine derivative 2 DMOJ8P1 TI TT6OEDT DMOJ8P1 TN Cannabinoid receptor 1 (CB1) DMOJ8P1 MA Antagonist DMOJ8P1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOJ8P1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOJ936 DI DMOJ936 DMOJ936 DN PMID26815044-Compound-114 DMOJ936 TI TTULVH8 DMOJ936 TN Tyrosinase (TYR) DMOJ936 MA Inhibitor DMOJ936 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMOJ936 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMOJAZ9 DI DMOJAZ9 DMOJAZ9 DN Sulfonylated piperazine derivative 3 DMOJAZ9 TI TT6OEDT DMOJAZ9 TN Cannabinoid receptor 1 (CB1) DMOJAZ9 MA Antagonist DMOJAZ9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOJAZ9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOJDQF DI DMOJDQF DMOJDQF DN Peptide analog 44 DMOJDQF TI TTDIGC1 DMOJDQF TN Dipeptidyl peptidase 4 (DPP-4) DMOJDQF MA Inhibitor DMOJDQF RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMOJDQF RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMOJTLU DI DMOJTLU DMOJTLU DN Pyrimidine derivative 31 DMOJTLU TI TTDIGC1 DMOJTLU TN Dipeptidyl peptidase 4 (DPP-4) DMOJTLU MA Inhibitor DMOJTLU RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMOJTLU RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMOJVK6 DI DMOJVK6 DMOJVK6 DN PMID26651364-Compound-105 DMOJVK6 TI TTTCRU2 DMOJVK6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOJVK6 MA Antagonist DMOJVK6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOJVK6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TT1LVF2 DMOK7CW TN Cyclin-dependent kinase 9 (CDK9) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TTH6V3D DMOK7CW TN Cyclin-dependent kinase 1 (CDK1) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TTL4Q97 DMOK7CW TN Cyclin-dependent kinase 5 (CDK5) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOK7CW DI DMOK7CW DMOK7CW DN Pyrazolo[1,5-a]-1,3,5-triazine derivative 1 DMOK7CW TI TT7HF4W DMOK7CW TN Cyclin-dependent kinase 2 (CDK2) DMOK7CW MA Inhibitor DMOK7CW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMOK7CW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMOKC41 DI DMOKC41 DMOKC41 DN Carbamate derivative 15 DMOKC41 TI TTZ963I DMOKC41 TN Monoglyceride lipase (MAGL) DMOKC41 MA Inhibitor DMOKC41 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMOKC41 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMOKG3Q DI DMOKG3Q DMOKG3Q DN US9181182, 34 DMOKG3Q TI TTDYP7I DMOKG3Q TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMOKG3Q MA Inhibitor DMOKG3Q RN S1P receptors modulators. US9181182. DMOKG3Q RU http://www.freepatentsonline.com/US9181182.html DMOKJEP DI DMOKJEP DMOKJEP DN Biphenyl mannoside derivative 3 DMOKJEP TI TTTCRU2 DMOKJEP TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOKJEP MA Antagonist DMOKJEP RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOKJEP RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOMGU5 DI DMOMGU5 DMOMGU5 DN Disulfiram analog 2 DMOMGU5 TI TTZHPB8 DMOMGU5 TN Lysine-specific demethylase 4A (KDM4A) DMOMGU5 MA Inhibitor DMOMGU5 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMOMGU5 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMOMTBE DI DMOMTBE DMOMTBE DN Macrocycle derivative 8 DMOMTBE TI TT23XQV DMOMTBE TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMOMTBE MA Inhibitor DMOMTBE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOMTBE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOMTBE DI DMOMTBE DMOMTBE DN Macrocycle derivative 8 DMOMTBE TI TT5YPJF DMOMTBE TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMOMTBE MA Inhibitor DMOMTBE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOMTBE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMON5RD DI DMON5RD DMON5RD DN Heteroaryl-azepine derivative 5 DMON5RD TI TTWJBZ5 DMON5RD TN 5-HT 2C receptor (HTR2C) DMON5RD MA Agonist DMON5RD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMON5RD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMONAZI DI DMONAZI DMONAZI DN PMID26651364-Compound-119 DMONAZI TI TTTCRU2 DMONAZI TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMONAZI MA Antagonist DMONAZI RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMONAZI RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMONCT1 DI DMONCT1 DMONCT1 DN Pyridoindole derivative 3 DMONCT1 TI TTS7G69 DMONCT1 TN Fusion protein Bcr-Abl (Bcr-Abl) DMONCT1 MA Inhibitor DMONCT1 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMONCT1 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMONDMG DI DMONDMG DMONDMG DN Benzothiazepine analog 9 DMONDMG TI TTPTXIN DMONDMG TN Translocator protein (TSPO) DMONDMG MA Ligand DMONDMG RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMONDMG RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMONEJ4 DI DMONEJ4 DMONEJ4 DN PMID28074661-Compound-US20100022547C86 DMONEJ4 TI TTL7C8Q DMONEJ4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMONEJ4 MA Inhibitor DMONEJ4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMONEJ4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMONJLT DI DMONJLT DMONJLT DN PMID25522065-Compound-45 DMONJLT TI TTX4RTB DMONJLT TN Melanin-concentrating hormone receptor 1 (MCHR1) DMONJLT MA Antagonist DMONJLT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMONJLT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMONQ4L DI DMONQ4L DMONQ4L DN Azetidine-1-carboxamide derivative 2 DMONQ4L TI TT6OEDT DMONQ4L TN Cannabinoid receptor 1 (CB1) DMONQ4L MA Antagonist DMONQ4L RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMONQ4L RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMONWYI DI DMONWYI DMONWYI DN PMID25468267-Compound-53 DMONWYI TI TT0RGE9 DMONWYI TN Lysine-specific demethylase 4 (KDM4) DMONWYI MA Inhibitor DMONWYI RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMONWYI RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMOPF9N DI DMOPF9N DMOPF9N DN Carbamate derivative 7 DMOPF9N TI TTDP1UC DMOPF9N TN Fatty acid amide hydrolase (FAAH) DMOPF9N MA Inhibitor DMOPF9N RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMOPF9N RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMOPNJ6 DI DMOPNJ6 DMOPNJ6 DN Azole derivative 2 DMOPNJ6 TI TTDP1UC DMOPNJ6 TN Fatty acid amide hydrolase (FAAH) DMOPNJ6 MA Inhibitor DMOPNJ6 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMOPNJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMOPR7A DI DMOPR7A DMOPR7A DN PMID26666989-Compound-Figure9middle03 DMOPR7A TI TT8BUGW DMOPR7A TN Glycogen phosphorylase (PYG) DMOPR7A MA Inhibitor DMOPR7A RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMOPR7A RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMOPUFM DI DMOPUFM DMOPUFM DN N-(benzimidazole/indole) benzoic acid derivative 2 DMOPUFM TI TT5ZWB6 DMOPUFM TN Dihydrodiol dehydrogenase type I (AKR1C3) DMOPUFM MA Inhibitor DMOPUFM RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMOPUFM RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMOQ726 DI DMOQ726 DMOQ726 DN Pyrimidine derivative 24 DMOQ726 TI TT0K1SC DMOQ726 TN 5-HT 2B receptor (HTR2B) DMOQ726 MA Antagonist DMOQ726 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOQ726 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOQ726 DI DMOQ726 DMOQ726 DN Pyrimidine derivative 24 DMOQ726 TI TTWJBZ5 DMOQ726 TN 5-HT 2C receptor (HTR2C) DMOQ726 MA Antagonist DMOQ726 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOQ726 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOQ726 DI DMOQ726 DMOQ726 DN Pyrimidine derivative 24 DMOQ726 TI TTJQOD7 DMOQ726 TN 5-HT 2A receptor (HTR2A) DMOQ726 MA Antagonist DMOQ726 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMOQ726 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMOQBN4 DI DMOQBN4 DMOQBN4 DN Macrocycle derivative 4 DMOQBN4 TI TT23XQV DMOQBN4 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMOQBN4 MA Inhibitor DMOQBN4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOQBN4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOQBN4 DI DMOQBN4 DMOQBN4 DN Macrocycle derivative 4 DMOQBN4 TI TT5YPJF DMOQBN4 TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMOQBN4 MA Inhibitor DMOQBN4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMOQBN4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMOQHA9 DI DMOQHA9 DMOQHA9 DN Aminoazetidine derivative 3 DMOQHA9 TI TT6OEDT DMOQHA9 TN Cannabinoid receptor 1 (CB1) DMOQHA9 MA Antagonist DMOQHA9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOQHA9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOQJMU DI DMOQJMU DMOQJMU DN Piperidinyl triazole derivative 4 DMOQJMU TI TTTJZ4M DMOQJMU TN Prolylcarboxypeptidase (PRCP) DMOQJMU MA Inhibitor DMOQJMU RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMOQJMU RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMOR9ZA DI DMOR9ZA DMOR9ZA DN Bis-indolylmaleimide derivative 1 DMOR9ZA TI TTCZOF2 DMOR9ZA TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOR9ZA MA Inhibitor DMOR9ZA RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOR9ZA RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMORBE3 DI DMORBE3 DMORBE3 DN Carbamide derivative 6 DMORBE3 TI TTL7C8Q DMORBE3 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMORBE3 MA Inhibitor DMORBE3 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMORBE3 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMORFPT DI DMORFPT DMORFPT DN Cyclohexyl carbamate derivative 1 DMORFPT TI TTULVH8 DMORFPT TN Tyrosinase (TYR) DMORFPT MA Inhibitor DMORFPT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMORFPT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMORK8H DI DMORK8H DMORK8H DN PMID25772215-Compound-US02014179750TG7-170 DMORK8H TI TT1ZAVI DMORK8H TN Prostaglandin E2 receptor EP2 (PTGER2) DMORK8H MA Antagonist DMORK8H RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMORK8H RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMORSH9 DI DMORSH9 DMORSH9 DN Thiazole carboxamide derivative 20 DMORSH9 TI TTCZOF2 DMORSH9 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMORSH9 MA Inhibitor DMORSH9 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMORSH9 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOS03R DI DMOS03R DMOS03R DN Biphenyl mannoside derivative 5 DMOS03R TI TTTCRU2 DMOS03R TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOS03R MA Antagonist DMOS03R RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOS03R RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOS7ZP DI DMOS7ZP DMOS7ZP DN PMID27724045-Compound-33 DMOS7ZP TI TT473XN DMOS7ZP TN P2X purinoceptor 7 (P2RX7) DMOS7ZP MA Antagonist DMOS7ZP RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMOS7ZP RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMOT1FQ DI DMOT1FQ DMOT1FQ DN Sterol derivative 3 DMOT1FQ TI TTPADOQ DMOT1FQ TN HMG-CoA reductase (HMGCR) DMOT1FQ MA Inhibitor DMOT1FQ RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMOT1FQ RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMOTG2Y DI DMOTG2Y DMOTG2Y DN Dihydropyrido pyrazinone compound 2 DMOTG2Y TI TTIYVQP DMOTG2Y TN Polo-like kinase 1 (PLK1) DMOTG2Y MA Inhibitor DMOTG2Y RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMOTG2Y RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMOTGEK DI DMOTGEK DMOTGEK DN Pyrido[4,3-d]pyrimidin-5(6H)-one derivative 1 DMOTGEK TI TTCZOF2 DMOTGEK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOTGEK MA Inhibitor DMOTGEK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOTGEK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOU84B DI DMOU84B DMOU84B DN Benzyl amine derivative 1 DMOU84B TI TT5L2VC DMOU84B TN Kallikrein-related peptidase (KLK) DMOU84B MA Inhibitor DMOU84B RN Serine protease inhibitors to treat inflammation: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Feb;28(2):93-110. DMOU84B RU https://www.ncbi.nlm.nih.gov/pubmed/29171765 DMOU8T3 DI DMOU8T3 DMOU8T3 DN Fused aryl carbocycle derivative 4 DMOU8T3 TI TT9NXW4 DMOU8T3 TN Sigma intracellular receptor 2 (TMEM97) DMOU8T3 MA Ligand DMOU8T3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMOU8T3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMOUT1F DI DMOUT1F DMOUT1F DN Mannoside derivative 7 DMOUT1F TI TTTCRU2 DMOUT1F TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMOUT1F MA Antagonist DMOUT1F RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMOUT1F RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMOV86T DI DMOV86T DMOV86T DN Terpyridineplatinum(II) complexe 4 DMOV86T TI TTEP6RV DMOV86T TN Glutathione reductase (GR) DMOV86T MA Inhibitor DMOV86T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMOV86T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMOV86T DI DMOV86T DMOV86T DN Terpyridineplatinum(II) complexe 4 DMOV86T TI TTR7UJ3 DMOV86T TN Cytoplasmic thioredoxin reductase (TXNRD1) DMOV86T MA Inhibitor DMOV86T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMOV86T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMOV9XA DI DMOV9XA DMOV9XA DN Azaindazole derivative 3 DMOV9XA TI TTK0FEA DMOV9XA TN Leucine-rich repeat kinase 2 (LRRK2) DMOV9XA MA Inhibitor DMOV9XA RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMOV9XA RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMOVEZF DI DMOVEZF DMOVEZF DN VAPBGCRAUJRZPO-UHFFFAOYSA-N DMOVEZF TI TTI1FPZ DMOVEZF TN Epithelial discoidin domain receptor 1 (DDR1) DMOVEZF MA Inhibitor DMOVEZF RN Benzamide derivative. US9695118. DMOVEZF RU http://www.freepatentsonline.com/US9695118.html DMOVJ35 DI DMOVJ35 DMOVJ35 DN Imidazo pyridine derivative 5 DMOVJ35 TI TTV1C0Z DMOVJ35 TN Neuropeptide S receptor (NPSR) DMOVJ35 MA Antagonist DMOVJ35 RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMOVJ35 RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMOVPWD DI DMOVPWD DMOVPWD DN PMID29473428-Compound-6 DMOVPWD TI TTZJYKH DMOVPWD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOVPWD RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMOVPWD RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMOW01E DI DMOW01E DMOW01E DN Azole derivative 4 DMOW01E TI TTDP1UC DMOW01E TN Fatty acid amide hydrolase (FAAH) DMOW01E MA Inhibitor DMOW01E RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMOW01E RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMOWFA5 DI DMOWFA5 DMOWFA5 DN Thieno[3,2-c]pyridine-7-carboxamide derivative 2 DMOWFA5 TI TTCZOF2 DMOWFA5 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMOWFA5 MA Inhibitor DMOWFA5 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMOWFA5 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMOWULJ DI DMOWULJ DMOWULJ DN PMID25991433-Compound-J6 DMOWULJ TI TTVOE6D DMOWULJ TN Mitogen-activated protein kinase (MAPK) DMOWULJ MA Inhibitor DMOWULJ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMOWULJ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMOX8E3 DI DMOX8E3 DMOX8E3 DN PMID26882240-Compound-7 DMOX8E3 TI TTUX68I DMOX8E3 TN Hypoxia-inducible factor 1 (HIF-1) DMOX8E3 MA Inhibitor DMOX8E3 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMOX8E3 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMOXHZJ DI DMOXHZJ DMOXHZJ DN Imidazole derivative 6 DMOXHZJ TI TT6OEDT DMOXHZJ TN Cannabinoid receptor 1 (CB1) DMOXHZJ MA Antagonist DMOXHZJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMOXHZJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMOXIZC DI DMOXIZC DMOXIZC DN Sulfonamide derivative 8 DMOXIZC TI TTZJYKH DMOXIZC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOXIZC MA Inhibitor DMOXIZC RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMOXIZC RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMOXJ7Q DI DMOXJ7Q DMOXJ7Q DN Phytocannabinoid/aminoalkylindole derivative 2 DMOXJ7Q TI TTMSFAW DMOXJ7Q TN Cannabinoid receptor 2 (CB2) DMOXJ7Q RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMOXJ7Q RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMOXJ7Q DI DMOXJ7Q DMOXJ7Q DN Phytocannabinoid/aminoalkylindole derivative 2 DMOXJ7Q TI TT6OEDT DMOXJ7Q TN Cannabinoid receptor 1 (CB1) DMOXJ7Q RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMOXJ7Q RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMOY5EK DI DMOY5EK DMOY5EK DN 2-(substituted ethynyl)quinoline derivative 1 DMOY5EK TI TTHS256 DMOY5EK TN Metabotropic glutamate receptor 5 (mGluR5) DMOY5EK MA Antagonist DMOY5EK RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMOY5EK RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMOYMWZ DI DMOYMWZ DMOYMWZ DN PMID28447479-Compound-11 DMOYMWZ TI TTSCIM2 DMOYMWZ TN Extracellular lysophospholipase D (E-NPP2) DMOYMWZ MA Inhibitor DMOYMWZ RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMOYMWZ RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMOZ4FS DI DMOZ4FS DMOZ4FS DN US8933095, 18 DMOZ4FS TI TTT3IXG DMOZ4FS TN Kynurenine oxoglutarate transaminase II (AADAT) DMOZ4FS MA Inhibitor DMOZ4FS RN KAT II inhibitors. US8598200. DMOZ4FS RU http://www.freepatentsonline.com/US8598200.html DMOZ84C DI DMOZ84C DMOZ84C DN US10077269, Example 6 DMOZ84C TI TT6A59G DMOZ84C TN Phosphodiesterase 4C (PDE4C) DMOZ84C MA Inhibitor DMOZ84C RN Imidazopyridazine compounds. US9598421. DMOZ84C RU http://www.freepatentsonline.com/US9598421.html DMOZHGU DI DMOZHGU DMOZHGU DN PMID28270021-Compound-WO2015042088Example12 DMOZHGU TI TTTDVOJ DMOZHGU TN Tropomyosin-related kinase A (TrkA) DMOZHGU MA Inhibitor DMOZHGU RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMOZHGU RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMOZKAH DI DMOZKAH DMOZKAH DN PMID27109571-Compound-5 DMOZKAH TI TTMY6L1 DMOZKAH TN Fatty acid-binding protein (FABP) DMOZKAH MA Inhibitor DMOZKAH RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMOZKAH RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMOZTUE DI DMOZTUE DMOZTUE DN Mycophenolic acid/nucleotide derivative 1 DMOZTUE TI TTL7C8Q DMOZTUE TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMOZTUE MA Inhibitor DMOZTUE RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMOZTUE RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMP04Z6 DI DMP04Z6 DMP04Z6 DN 879325-11-8 DMP04Z6 TI TTOJ9QL DMP04Z6 TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMP04Z6 MA Inhibitor DMP04Z6 RN IRE-1 inhibitors. US9040714. DMP04Z6 RU http://www.freepatentsonline.com/US9040714.html DMP0TBO DI DMP0TBO DMP0TBO DN US9006244, E2b DMP0TBO TI TTECBXN DMP0TBO TN Oxysterols receptor LXR-alpha (NR1H3) DMP0TBO MA Inhibitor DMP0TBO RN Liver X receptor modulators. US9006244. DMP0TBO RU http://www.freepatentsonline.com/US9006244.html DMP130R DI DMP130R DMP130R DN PMID26004420-Compound-WO2013039802B DMP130R TI TTJ13ST DMP130R TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMP130R MA Inhibitor DMP130R RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMP130R RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMP1MDV DI DMP1MDV DMP1MDV DN Pyrazino[2,1-a]isoquinolin derivative 1 DMP1MDV TI TTA6ZN2 DMP1MDV TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMP1MDV MA Activator DMP1MDV RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMP1MDV RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMP1MDV DI DMP1MDV DMP1MDV DN Pyrazino[2,1-a]isoquinolin derivative 1 DMP1MDV TI TT3Z6Y9 DMP1MDV TN Cysteines of Keap1 (KEAP1 Cysteines) DMP1MDV MA Modulator DMP1MDV RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMP1MDV RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMP1NKI DI DMP1NKI DMP1NKI DN Isoindoline derivative 4 DMP1NKI TI TTQ6VDM DMP1NKI TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMP1NKI MA Ligand DMP1NKI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMP1NKI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMP1NKI DI DMP1NKI DMP1NKI DN Isoindoline derivative 4 DMP1NKI TI TT5TPI6 DMP1NKI TN Opioid receptor sigma 1 (OPRS1) DMP1NKI MA Ligand DMP1NKI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMP1NKI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMP1NKI DI DMP1NKI DMP1NKI DN Isoindoline derivative 4 DMP1NKI TI TT9NXW4 DMP1NKI TN Sigma intracellular receptor 2 (TMEM97) DMP1NKI MA Ligand DMP1NKI RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMP1NKI RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMP1RV5 DI DMP1RV5 DMP1RV5 DN Picolinamido propanoic acid derivative 3 DMP1RV5 TI TT9O6WS DMP1RV5 TN Glucagon receptor (GCGR) DMP1RV5 MA Antagonist DMP1RV5 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMP1RV5 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMP29I0 DI DMP29I0 DMP29I0 DN Urea and carbamate bioisostere derivative 6 DMP29I0 TI TTL7C8Q DMP29I0 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMP29I0 MA Inhibitor DMP29I0 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMP29I0 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMP2AXV DI DMP2AXV DMP2AXV DN Imidazopyridine derivative 4 DMP2AXV TI TTT7PJU DMP2AXV TN Janus kinase 3 (JAK-3) DMP2AXV MA Inhibitor DMP2AXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMP2AXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMP2AXV DI DMP2AXV DMP2AXV DN Imidazopyridine derivative 4 DMP2AXV TI TTGM6VW DMP2AXV TN Tyrosine-protein kinase BTK (ATK) DMP2AXV MA Inhibitor DMP2AXV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMP2AXV RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMP2JF0 DI DMP2JF0 DMP2JF0 DN Macrocycle derivative 7 DMP2JF0 TI TT23XQV DMP2JF0 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMP2JF0 MA Inhibitor DMP2JF0 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMP2JF0 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMP2JF0 DI DMP2JF0 DMP2JF0 DN Macrocycle derivative 7 DMP2JF0 TI TT5YPJF DMP2JF0 TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMP2JF0 MA Inhibitor DMP2JF0 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMP2JF0 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMP2LDC DI DMP2LDC DMP2LDC DN Benzamide derivative 14 DMP2LDC TI TTYLQ8V DMP2LDC TN Prostaglandin E synthase (PTGES) DMP2LDC MA Inhibitor DMP2LDC RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMP2LDC RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMP2QDM DI DMP2QDM DMP2QDM DN Isosteric imidazolyl pyrimidine derivative 1 DMP2QDM TI TT6R7JZ DMP2QDM TN Histone deacetylase 1 (HDAC1) DMP2QDM MA Inhibitor DMP2QDM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP2QDM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP2QDM DI DMP2QDM DMP2QDM DN Isosteric imidazolyl pyrimidine derivative 1 DMP2QDM TI TT7HF4W DMP2QDM TN Cyclin-dependent kinase 2 (CDK2) DMP2QDM MA Inhibitor DMP2QDM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMP2QDM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMP3GRA DI DMP3GRA DMP3GRA DN Lactol derivative 2 DMP3GRA TI TTPADOQ DMP3GRA TN HMG-CoA reductase (HMGCR) DMP3GRA MA Inhibitor DMP3GRA RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMP3GRA RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMP3JF4 DI DMP3JF4 DMP3JF4 DN Diphenyl purine derivative 4 DMP3JF4 TI TT6OEDT DMP3JF4 TN Cannabinoid receptor 1 (CB1) DMP3JF4 MA Antagonist DMP3JF4 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMP3JF4 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TT8EPLT DMP3MXK TN Proteasome beta-1 (PS beta-1) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TTOUSTQ DMP3MXK TN Proteasome beta-9 (PS beta-9) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TT68GPI DMP3MXK TN Proteasome beta-5 (PS beta-5) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3MXK DI DMP3MXK DMP3MXK DN PMID29865878-Compound-46 DMP3MXK TI TTEAD9J DMP3MXK TN Proteasome beta-8 (PS beta-8) DMP3MXK MA Inhibitor DMP3MXK RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMP3MXK RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMP3RCH DI DMP3RCH DMP3RCH DN US8846654, 294 DMP3RCH TI TTIS4OW DMP3RCH TN Phosphodiesterase 8 (PDE8) DMP3RCH MA Inhibitor DMP3RCH RN Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654. DMP3RCH RU http://www.freepatentsonline.com/US8846654.html DMP4VYQ DI DMP4VYQ DMP4VYQ DN PMID25522065-Compound-19 DMP4VYQ TI TTX4RTB DMP4VYQ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMP4VYQ MA Antagonist DMP4VYQ RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMP4VYQ RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMP52HJ DI DMP52HJ DMP52HJ DN Biphenyl mannoside derivative 9 DMP52HJ TI TTTCRU2 DMP52HJ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMP52HJ MA Antagonist DMP52HJ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMP52HJ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMP580J DI DMP580J DMP580J DN PMID25656651-Compound-11b DMP580J TI TTS7G69 DMP580J TN Fusion protein Bcr-Abl (Bcr-Abl) DMP580J MA Inhibitor DMP580J RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMP580J RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMP59OX DI DMP59OX DMP59OX DN PMID27376512-Compound-Figure2aExample1 DMP59OX TI TTJUALD DMP59OX TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMP59OX MA Inhibitor DMP59OX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMP59OX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMP59OX DI DMP59OX DMP59OX DN PMID27376512-Compound-Figure2aExample1 DMP59OX TI TT3FDAV DMP59OX TN DNA [cytosine-5]-methyltransferase 3-like (DNMT3L) DMP59OX MA Inhibitor DMP59OX RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMP59OX RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMP5KEW DI DMP5KEW DMP5KEW DN PMID29649907-Compound-36 DMP5KEW TI TTS4UGC DMP5KEW TN Farnesoid X-activated receptor (FXR) DMP5KEW MA Agonist DMP5KEW RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMP5KEW RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMP5SA2 DI DMP5SA2 DMP5SA2 DN Peptide analog 49 DMP5SA2 TI TTDIGC1 DMP5SA2 TN Dipeptidyl peptidase 4 (DPP-4) DMP5SA2 MA Inhibitor DMP5SA2 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMP5SA2 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMP5Y19 DI DMP5Y19 DMP5Y19 DN PMID25399762-Compound-Figure3-Aspeverin DMP5Y19 TI TT3WG5C DMP5Y19 TN Monoamine oxidase type A (MAO-A) DMP5Y19 MA Inhibitor DMP5Y19 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMP5Y19 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMP65Z4 DI DMP65Z4 DMP65Z4 DN Tetra-hydro-oxazolopyridine derivative 2 DMP65Z4 TI TTGP7BY DMP65Z4 TN Monoamine oxidase type B (MAO-B) DMP65Z4 MA Modulator DMP65Z4 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMP65Z4 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMP65Z4 DI DMP65Z4 DMP65Z4 DN Tetra-hydro-oxazolopyridine derivative 2 DMP65Z4 TI TTHS256 DMP65Z4 TN Metabotropic glutamate receptor 5 (mGluR5) DMP65Z4 MA Modulator DMP65Z4 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMP65Z4 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMP6QEC DI DMP6QEC DMP6QEC DN Aryl mannoside derivative 16 DMP6QEC TI TTTCRU2 DMP6QEC TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMP6QEC MA Antagonist DMP6QEC RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMP6QEC RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMP6TUQ DI DMP6TUQ DMP6TUQ DN Pyridoindole derivative 1 DMP6TUQ TI TTS7G69 DMP6TUQ TN Fusion protein Bcr-Abl (Bcr-Abl) DMP6TUQ MA Inhibitor DMP6TUQ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMP6TUQ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMP6WCX DI DMP6WCX DMP6WCX DN PMID27019002-Compound-49 DMP6WCX TI TTNR0UQ DMP6WCX TN Lysine-specific histone demethylase 1 (LSD) DMP6WCX MA Inhibitor DMP6WCX RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMP6WCX RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMP7C5L DI DMP7C5L DMP7C5L DN PMID25726713-Compound-18 DMP7C5L TI TT8J1S3 DMP7C5L TN Smoothened homolog (SMO) DMP7C5L MA Antagonist DMP7C5L RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMP7C5L RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMP7DL6 DI DMP7DL6 DMP7DL6 DN PMID27376512-Compound-Figure3CN DMP7DL6 TI TTJUALD DMP7DL6 TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMP7DL6 MA Inhibitor DMP7DL6 RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMP7DL6 RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMP7S9E DI DMP7S9E DMP7S9E DN PMID29671355-Compound-27 DMP7S9E TI TT6R7JZ DMP7S9E TN Histone deacetylase 1 (HDAC1) DMP7S9E MA Inhibitor DMP7S9E RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMP7S9E RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMP7S9E DI DMP7S9E DMP7S9E DN PMID29671355-Compound-27 DMP7S9E TI TT5ZKDI DMP7S9E TN Histone deacetylase 6 (HDAC6) DMP7S9E MA Inhibitor DMP7S9E RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMP7S9E RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMP89E4 DI DMP89E4 DMP89E4 DN PMID25666693-Compound-145 DMP89E4 TI TTMI6F5 DMP89E4 TN Transient receptor potential cation channel V1 (TRPV1) DMP89E4 MA Antagonist DMP89E4 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMP89E4 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMP8I02 DI DMP8I02 DMP8I02 DN Pyrrolo-pyrazine derivative 1 DMP8I02 TI TTT7PJU DMP8I02 TN Janus kinase 3 (JAK-3) DMP8I02 MA Inhibitor DMP8I02 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMP8I02 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMP8RQ4 DI DMP8RQ4 DMP8RQ4 DN PMID26394986-Compound-10 DMP8RQ4 TI TTH8FZW DMP8RQ4 TN Signal transducer and activator of transcription 3 (STAT3) DMP8RQ4 MA Inhibitor DMP8RQ4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMP8RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMP8RQ4 DI DMP8RQ4 DMP8RQ4 DN PMID26394986-Compound-10 DMP8RQ4 TI TTLRFIH DMP8RQ4 TN Signal transducer and activator of transcription 5 (STAT5) DMP8RQ4 MA Inhibitor DMP8RQ4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMP8RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMP8RQ4 DI DMP8RQ4 DMP8RQ4 DN PMID26394986-Compound-10 DMP8RQ4 TI TTN7R6K DMP8RQ4 TN Signal transducer and activator of transcription 1 (STAT1) DMP8RQ4 MA Inhibitor DMP8RQ4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMP8RQ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMP9742 DI DMP9742 DMP9742 DN Biaryl mannoside derivative 16 DMP9742 TI TTTCRU2 DMP9742 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMP9742 MA Antagonist DMP9742 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMP9742 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMP98CL DI DMP98CL DMP98CL DN Carbamate derivative 10 DMP98CL TI TTDP1UC DMP98CL TN Fatty acid amide hydrolase (FAAH) DMP98CL MA Inhibitor DMP98CL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMP98CL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMP98CL DI DMP98CL DMP98CL DN Carbamate derivative 10 DMP98CL TI TTZ963I DMP98CL TN Monoglyceride lipase (MAGL) DMP98CL MA Inhibitor DMP98CL RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMP98CL RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMP9Z34 DI DMP9Z34 DMP9Z34 DN Sulfonamide-thiadiazole derivative 1 DMP9Z34 TI TT2LVK8 DMP9Z34 TN Carbonic anhydrase IX (CA-IX) DMP9Z34 MA Inhibitor DMP9Z34 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DMP9Z34 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DMPA26U DI DMPA26U DMPA26U DN Resorcinol compound 10 DMPA26U TI TTULVH8 DMPA26U TN Tyrosinase (TYR) DMPA26U MA Inhibitor DMPA26U RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMPA26U RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMPA3IX DI DMPA3IX DMPA3IX DN PMID26651364-Compound-110 DMPA3IX TI TTTCRU2 DMPA3IX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPA3IX MA Antagonist DMPA3IX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPA3IX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPA9OY DI DMPA9OY DMPA9OY DN PMID29671355-Compound-47d DMPA9OY TI TTTQGH8 DMPA9OY TN Histone deacetylase 4 (HDAC4) DMPA9OY MA Inhibitor DMPA9OY RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPA9OY RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPAE8N DI DMPAE8N DMPAE8N DN PMID26882240-Compound-1 DMPAE8N TI TTUX68I DMPAE8N TN Hypoxia-inducible factor 1 (HIF-1) DMPAE8N MA Inhibitor DMPAE8N RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMPAE8N RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMPAE8N DI DMPAE8N DMPAE8N DN PMID26882240-Compound-1 DMPAE8N TI TT9MZCQ DMPAE8N TN Enhancer of zeste homolog 2 (EZH2) DMPAE8N MA Inhibitor DMPAE8N RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMPAE8N RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMPAI5C DI DMPAI5C DMPAI5C DN Phenylpyrrolidinone derivative 1 DMPAI5C TI TT5OU0D DMPAI5C TN PRKR-like endoplasmic reticulum kinase (PERK) DMPAI5C MA Inhibitor DMPAI5C RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMPAI5C RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMPAQLZ DI DMPAQLZ DMPAQLZ DN PMID29130358-Compound-Figure16(9b) DMPAQLZ TI TTHY57M DMPAQLZ TN Matrix metalloproteinase-13 (MMP-13) DMPAQLZ MA Inhibitor DMPAQLZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMPAQLZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMPAQLZ DI DMPAQLZ DMPAQLZ DN PMID29130358-Compound-Figure16(9b) DMPAQLZ TI TTLM12X DMPAQLZ TN Matrix metalloproteinase-2 (MMP-2) DMPAQLZ MA Inhibitor DMPAQLZ RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMPAQLZ RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMPB4L6 DI DMPB4L6 DMPB4L6 DN Quinoline derivative 4 DMPB4L6 TI TTXJ47W DMPB4L6 TN Metabotropic glutamate receptor 2 (mGluR2) DMPB4L6 MA Antagonist DMPB4L6 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMPB4L6 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMPBMEU DI DMPBMEU DMPBMEU DN Fused aryl carbocycle derivative 8 DMPBMEU TI TT9NXW4 DMPBMEU TN Sigma intracellular receptor 2 (TMEM97) DMPBMEU MA Ligand DMPBMEU RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMPBMEU RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMPBNFM DI DMPBNFM DMPBNFM DN PMID28117607-Compound-5 DMPBNFM TI TTK0FEA DMPBNFM TN Leucine-rich repeat kinase 2 (LRRK2) DMPBNFM MA Inhibitor DMPBNFM RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMPBNFM RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMPCLZB DI DMPCLZB DMPCLZB DN Imidazo pyridine derivative 3 DMPCLZB TI TT0PG8F DMPCLZB TN Cyclin-dependent kinase 4 (CDK4) DMPCLZB MA Inhibitor DMPCLZB RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMPCLZB RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMPCYSW DI DMPCYSW DMPCYSW DN 2-(substituted ethynyl)quinoline derivative 2 DMPCYSW TI TTHS256 DMPCYSW TN Metabotropic glutamate receptor 5 (mGluR5) DMPCYSW MA Antagonist DMPCYSW RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMPCYSW RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMPDF9B DI DMPDF9B DMPDF9B DN US9006244, E2a DMPDF9B TI TTECBXN DMPDF9B TN Oxysterols receptor LXR-alpha (NR1H3) DMPDF9B MA Inhibitor DMPDF9B RN Liver X receptor modulators. US9006244. DMPDF9B RU http://www.freepatentsonline.com/US9006244.html DMPDTG0 DI DMPDTG0 DMPDTG0 DN Imidazo[1,2-b]pyridazine derivative 3 DMPDTG0 TI TTTDVOJ DMPDTG0 TN Tropomyosin-related kinase A (TrkA) DMPDTG0 MA Inhibitor DMPDTG0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMPDTG0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMPDTG0 DI DMPDTG0 DMPDTG0 DN Imidazo[1,2-b]pyridazine derivative 3 DMPDTG0 TI TTSZ6Y3 DMPDTG0 TN Proto-oncogene c-Ros (ROS1) DMPDTG0 MA Inhibitor DMPDTG0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMPDTG0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMPDTHQ DI DMPDTHQ DMPDTHQ DN PMID27537201-Compound-Figure13b DMPDTHQ TI TTPADOQ DMPDTHQ TN HMG-CoA reductase (HMGCR) DMPDTHQ MA Inhibitor DMPDTHQ RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMPDTHQ RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMPDX3L DI DMPDX3L DMPDX3L DN PMID25726713-Compound-58 DMPDX3L TI TT8J1S3 DMPDX3L TN Smoothened homolog (SMO) DMPDX3L MA Inhibitor DMPDX3L RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMPDX3L RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMPE7M8 DI DMPE7M8 DMPE7M8 DN PMID25666693-Compound-55 DMPE7M8 TI TTMI6F5 DMPE7M8 TN Transient receptor potential cation channel V1 (TRPV1) DMPE7M8 MA Antagonist DMPE7M8 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPE7M8 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPF2UG DI DMPF2UG DMPF2UG DN Mannoside derivative 3 DMPF2UG TI TTTCRU2 DMPF2UG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPF2UG MA Antagonist DMPF2UG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPF2UG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPF37N DI DMPF37N DMPF37N DN Biaryl mannoside derivative 10 DMPF37N TI TTTCRU2 DMPF37N TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPF37N MA Antagonist DMPF37N RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPF37N RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPF86L DI DMPF86L DMPF86L DN PMID26651364-Compound-6c DMPF86L TI TTTCRU2 DMPF86L TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPF86L MA Antagonist DMPF86L RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPF86L RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPFAST DI DMPFAST DMPFAST DN Five membered heterocyclic benzamide derivative 1 DMPFAST TI TTTDVOJ DMPFAST TN Tropomyosin-related kinase A (TrkA) DMPFAST MA Inhibitor DMPFAST RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMPFAST RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMPFLGO DI DMPFLGO DMPFLGO DN PMID25399762-Compound-Table1-C2 DMPFLGO TI TTGP7BY DMPFLGO TN Monoamine oxidase type B (MAO-B) DMPFLGO MA Inhibitor DMPFLGO RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMPFLGO RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMPFMSJ DI DMPFMSJ DMPFMSJ DN PMID25553724-Compound-WO2013082253 31 DMPFMSJ TI TTSXVID DMPFMSJ TN Nuclear factor NF-kappa-B (NFKB) DMPFMSJ MA Modulator DMPFMSJ RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMPFMSJ RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMPG3Y8 DI DMPG3Y8 DMPG3Y8 DN Antibodie derivative 11 DMPG3Y8 TI TTOHSBA DMPG3Y8 TN Vascular endothelial growth factor A (VEGFA) DMPG3Y8 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMPG3Y8 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMPG8MF DI DMPG8MF DMPG8MF DN PMID26293650-Compound-35 DMPG8MF TI TTH5TC2 DMPG8MF TN NF-kappa-B-activating kinase (TBK1) DMPG8MF MA Inhibitor DMPG8MF RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMPG8MF RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMPGMX2 DI DMPGMX2 DMPGMX2 DN Imidazole derivative 4 DMPGMX2 TI TT6OEDT DMPGMX2 TN Cannabinoid receptor 1 (CB1) DMPGMX2 MA Antagonist DMPGMX2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMPGMX2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMPGY0M DI DMPGY0M DMPGY0M DN US9024044, 1 DMPGY0M TI TTXL0GC DMPGY0M TN Enteropeptidase (TMPRSS15) DMPGY0M MA Inhibitor DMPGY0M RN Heteroarylcarboxylic acid ester derivative. US9227949. DMPGY0M RU http://www.freepatentsonline.com/US9227949.html DMPH05Y DI DMPH05Y DMPH05Y DN US9453017, 2 DMPH05Y TI TT3T17P DMPH05Y TN Phospholipase D1 (PLD1) DMPH05Y MA Inhibitor DMPH05Y RN Antiviral therapies with phospholipase D inhibitors. US9453017. DMPH05Y RU http://www.freepatentsonline.com/US9453017.html DMPH4JV DI DMPH4JV DMPH4JV DN PMID28766366-Compound-Scheme4Upper DMPH4JV TI TTYGQ8A DMPH4JV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMPH4JV MA Inhibitor DMPH4JV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPH4JV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPH4JV DI DMPH4JV DMPH4JV DN PMID28766366-Compound-Scheme4Upper DMPH4JV TI TTSBVFO DMPH4JV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMPH4JV MA Inhibitor DMPH4JV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPH4JV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPHCJ5 DI DMPHCJ5 DMPHCJ5 DN Polyhydroxy benzamide derivative 1 DMPHCJ5 TI TTULVH8 DMPHCJ5 TN Tyrosinase (TYR) DMPHCJ5 MA Inhibitor DMPHCJ5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMPHCJ5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMPHK87 DI DMPHK87 DMPHK87 DN Imidazopyridine acetamide analog 4 DMPHK87 TI TTPTXIN DMPHK87 TN Translocator protein (TSPO) DMPHK87 MA Ligand DMPHK87 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMPHK87 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMPHL3J DI DMPHL3J DMPHL3J DN Fused ring compound 1 DMPHL3J TI TTZMAO3 DMPHL3J TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMPHL3J MA Agonist DMPHL3J RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMPHL3J RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMPHMTR DI DMPHMTR DMPHMTR DN PMID27109571-Compound-6 DMPHMTR TI TTMY6L1 DMPHMTR TN Fatty acid-binding protein (FABP) DMPHMTR MA Inhibitor DMPHMTR RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMPHMTR RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMPHTC0 DI DMPHTC0 DMPHTC0 DN PMID27109571-Compound-24 DMPHTC0 TI TTNT2S6 DMPHTC0 TN Fatty acid-binding protein 5 (FABP5) DMPHTC0 MA Inhibitor DMPHTC0 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMPHTC0 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMPHTC0 DI DMPHTC0 DMPHTC0 DN PMID27109571-Compound-24 DMPHTC0 TI TTHWMFZ DMPHTC0 TN Fatty acid-binding protein 4 (FABP4) DMPHTC0 MA Inhibitor DMPHTC0 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMPHTC0 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMPI2S9 DI DMPI2S9 DMPI2S9 DN Purine derivative 3 DMPI2S9 TI TT6OEDT DMPI2S9 TN Cannabinoid receptor 1 (CB1) DMPI2S9 MA Antagonist DMPI2S9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMPI2S9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMPI86D DI DMPI86D DMPI86D DN PMID28270021-Compound-WO2016054807Example80 DMPI86D TI TTTDVOJ DMPI86D TN Tropomyosin-related kinase A (TrkA) DMPI86D MA Inhibitor DMPI86D RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMPI86D RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMPICE1 DI DMPICE1 DMPICE1 DN US8901295, F673 DMPICE1 TI TTNAFOU DMPICE1 TN Rotamase D (PPID) DMPICE1 MA Inhibitor DMPICE1 RN Inhibitors of cyclophilins and uses thereof. US8901295. DMPICE1 RU http://www.freepatentsonline.com/US8901295.html DMPIM9L DI DMPIM9L DMPIM9L DN PMID28870136-Compound-48 DMPIM9L TI TTK0O6Y DMPIM9L TN Ecto-5'-nucleotidase (CD73) DMPIM9L MA Inhibitor DMPIM9L RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMPIM9L RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMPIXAO DI DMPIXAO DMPIXAO DN PMID28394193-Compound-25 DMPIXAO TI TT9MZCQ DMPIXAO TN Enhancer of zeste homolog 2 (EZH2) DMPIXAO MA Inhibitor DMPIXAO RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMPIXAO RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMPJH6L DI DMPJH6L DMPJH6L DN PMID28350212-Compound-24 DMPJH6L TI TTZS04O DMPJH6L TN Gamma-secretase subunit APH-1A/1B (APH-1) DMPJH6L MA Inhibitor DMPJH6L RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMPJH6L RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTTQGH8 DMPJN0M TN Histone deacetylase 4 (HDAC4) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTYHPU6 DMPJN0M TN Histone deacetylase 10 (HDAC10) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT8M4E1 DMPJN0M TN Histone deacetylase 9 (HDAC9) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT4YWTO DMPJN0M TN Histone deacetylase 3 (HDAC3) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT8K17W DMPJN0M TN Histone deacetylase 11 (HDAC11) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTMUEK1 DMPJN0M TN Histone deacetylase 7 (HDAC7) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTSHTOI DMPJN0M TN Histone deacetylase 2 (HDAC2) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT6R7JZ DMPJN0M TN Histone deacetylase 1 (HDAC1) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TTT6LFV DMPJN0M TN Histone deacetylase 8 (HDAC8) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJN0M DI DMPJN0M DMPJN0M DN PMID29671355-Compound-21 DMPJN0M TI TT5ZKDI DMPJN0M TN Histone deacetylase 6 (HDAC6) DMPJN0M MA Inhibitor DMPJN0M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPJN0M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPJSB2 DI DMPJSB2 DMPJSB2 DN PMID28092474-Compound-33l DMPJSB2 TI TT5ZKDI DMPJSB2 TN Histone deacetylase 6 (HDAC6) DMPJSB2 MA Inhibitor DMPJSB2 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMPJSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMPJSB2 DI DMPJSB2 DMPJSB2 DN PMID28092474-Compound-33l DMPJSB2 TI TT6R7JZ DMPJSB2 TN Histone deacetylase 1 (HDAC1) DMPJSB2 MA Inhibitor DMPJSB2 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMPJSB2 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMPK7IU DI DMPK7IU DMPK7IU DN PMID28594589-Compound-TABLE3C12 DMPK7IU TI TTZCRP3 DMPK7IU TN ERK activator kinase (MEK) DMPK7IU MA Inhibitor DMPK7IU RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMPK7IU RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMPLAWQ DI DMPLAWQ DMPLAWQ DN Biaryl mannoside derivative 30 DMPLAWQ TI TTTCRU2 DMPLAWQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMPLAWQ MA Antagonist DMPLAWQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMPLAWQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMPLZSE DI DMPLZSE DMPLZSE DN Carbamate derivative 16 DMPLZSE TI TTZ963I DMPLZSE TN Monoglyceride lipase (MAGL) DMPLZSE MA Inhibitor DMPLZSE RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMPLZSE RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMPLZSE DI DMPLZSE DMPLZSE DN Carbamate derivative 16 DMPLZSE TI TTDP1UC DMPLZSE TN Fatty acid amide hydrolase (FAAH) DMPLZSE MA Inhibitor DMPLZSE RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMPLZSE RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMPM8VB DI DMPM8VB DMPM8VB DN US10053465, 12 DMPM8VB TI TTIEMFN DMPM8VB TN TYRO3 tyrosine kinase receptor (TYRO3) DMPM8VB MA Inhibitor DMPM8VB RN Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors. US9708333. DMPM8VB RU http://www.freepatentsonline.com/US9708333.html DMPMN92 DI DMPMN92 DMPMN92 DN Thiazole carboxamide derivative 17 DMPMN92 TI TTCZOF2 DMPMN92 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMPMN92 MA Inhibitor DMPMN92 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMPMN92 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMPNCOL DI DMPNCOL DMPNCOL DN US8933228, 3 DMPNCOL TI TT42OGM DMPNCOL TN Hematopoietic cell kinase (HCK) DMPNCOL MA Inhibitor DMPNCOL RN Respiratory formulations and compounds for use therein. US8933228. DMPNCOL RU http://www.freepatentsonline.com/US8933228.html DMPNG9C DI DMPNG9C DMPNG9C DN PMID28048944-Compound-21 DMPNG9C TI TTZN7RP DMPNG9C TN Rho-associated protein kinase 1 (ROCK1) DMPNG9C MA Inhibitor DMPNG9C RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMPNG9C RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMPNJ4X DI DMPNJ4X DMPNJ4X DN PMID26394986-Compound-56 DMPNJ4X TI TTLRFIH DMPNJ4X TN Signal transducer and activator of transcription 5 (STAT5) DMPNJ4X MA Inhibitor DMPNJ4X RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMPNJ4X RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMPOI27 DI DMPOI27 DMPOI27 DN PMID28270010-Compound-Figure17-1 DMPOI27 TI TTTDVOJ DMPOI27 TN Tropomyosin-related kinase A (TrkA) DMPOI27 MA Inhibitor DMPOI27 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMPOI27 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMPOR3G DI DMPOR3G DMPOR3G DN AC1LE05K DMPOR3G TI TTOJ9QL DMPOR3G TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMPOR3G MA Inhibitor DMPOR3G RN IRE-1 inhibitors. US9693992. DMPOR3G RU http://www.freepatentsonline.com/US9693992.html DMPOVZ6 DI DMPOVZ6 DMPOVZ6 DN BDBM50379214 DMPOVZ6 TI TTIET93 DMPOVZ6 TN Activated CDC42 kinase 1 (ACK-1) DMPOVZ6 MA Inhibitor DMPOVZ6 RN Kinase modulators for the treatment of cancer. US9416123. DMPOVZ6 RU http://www.freepatentsonline.com/US9416123.html DMPQ175 DI DMPQ175 DMPQ175 DN PMID25553724-Compound-WO2011152671 2 DMPQ175 TI TTSXVID DMPQ175 TN Nuclear factor NF-kappa-B (NFKB) DMPQ175 MA Inhibitor DMPQ175 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMPQ175 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMPQ2L9 DI DMPQ2L9 DMPQ2L9 DN 936563-93-8 DMPQ2L9 TI TTX6F0Q DMPQ2L9 TN Tyrosine-protein kinase CSK (CSK) DMPQ2L9 MA Inhibitor DMPQ2L9 RN Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors. US9278100. DMPQ2L9 RU http://www.freepatentsonline.com/US9278100.html DMPQF78 DI DMPQF78 DMPQF78 DN 2,2-bipyridyl derivative 3 DMPQF78 TI TT0RGE9 DMPQF78 TN Lysine-specific demethylase 4 (KDM4) DMPQF78 MA Inhibitor DMPQF78 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMPQF78 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMPQKXR DI DMPQKXR DMPQKXR DN PMID27788040-Compound-5b DMPQKXR TI TTV1C0Z DMPQKXR TN Neuropeptide S receptor (NPSR) DMPQKXR MA Antagonist DMPQKXR RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMPQKXR RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMPQX8R DI DMPQX8R DMPQX8R DN PMID29865878-Compound-60 DMPQX8R TI TTSJMN8 DMPQX8R TN Immunoproteasome complex (IP) DMPQX8R MA Inhibitor DMPQX8R RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMPQX8R RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMPR9GA DI DMPR9GA DMPR9GA DN PMID28394193-Compound-17 DMPR9GA TI TT9MZCQ DMPR9GA TN Enhancer of zeste homolog 2 (EZH2) DMPR9GA MA Inhibitor DMPR9GA RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMPR9GA RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMPRF1K DI DMPRF1K DMPRF1K DN Heteroaryl-carboxamide derivative 1 DMPRF1K TI TTCZOF2 DMPRF1K TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMPRF1K MA Inhibitor DMPRF1K RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMPRF1K RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMPRGLZ DI DMPRGLZ DMPRGLZ DN Triazole piperazine derivative 1 DMPRGLZ TI TTDIGC1 DMPRGLZ TN Dipeptidyl peptidase 4 (DPP-4) DMPRGLZ MA Inhibitor DMPRGLZ RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMPRGLZ RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMPRIS0 DI DMPRIS0 DMPRIS0 DN Bicyclo-heptan-2-amine derivative 4 DMPRIS0 TI TT9NXW4 DMPRIS0 TN Sigma intracellular receptor 2 (TMEM97) DMPRIS0 MA Ligand DMPRIS0 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMPRIS0 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMPSWXU DI DMPSWXU DMPSWXU DN PMID25980951-Compound-3 DMPSWXU TI TTR7B60 DMPSWXU TN X-linked inhibitor of apoptosis protein (XIAP) DMPSWXU MA Antagonist DMPSWXU RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMPSWXU RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMPSWXU DI DMPSWXU DMPSWXU DN PMID25980951-Compound-3 DMPSWXU TI TTQ5LRD DMPSWXU TN Cellular inhibitor of apoptosis 1 (BIRC2) DMPSWXU MA Antagonist DMPSWXU RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMPSWXU RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMPT2ZS DI DMPT2ZS DMPT2ZS DN US9108950, 1 DMPT2ZS TI TT42OGM DMPT2ZS TN Hematopoietic cell kinase (HCK) DMPT2ZS MA Inhibitor DMPT2ZS RN 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors. US9108950. DMPT2ZS RU http://www.freepatentsonline.com/US9108950.html DMPT3V9 DI DMPT3V9 DMPT3V9 DN PMID28048944-Compound-19 DMPT3V9 TI TTGWKQJ DMPT3V9 TN Rho-associated protein kinase 2 (ROCK2) DMPT3V9 MA Inhibitor DMPT3V9 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMPT3V9 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMPT3V9 DI DMPT3V9 DMPT3V9 DN PMID28048944-Compound-19 DMPT3V9 TI TTZN7RP DMPT3V9 TN Rho-associated protein kinase 1 (ROCK1) DMPT3V9 MA Inhibitor DMPT3V9 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMPT3V9 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMPTK0G DI DMPTK0G DMPTK0G DN Resorcinol compound 3 DMPTK0G TI TTULVH8 DMPTK0G TN Tyrosinase (TYR) DMPTK0G MA Inhibitor DMPTK0G RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMPTK0G RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMPTRQD DI DMPTRQD DMPTRQD DN 4,5,6,7-tetrahydrofuro[3,4-c]pyridine-1(3H)-one derivative 2 DMPTRQD TI TTV1C0Z DMPTRQD TN Neuropeptide S receptor (NPSR) DMPTRQD MA Antagonist DMPTRQD RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMPTRQD RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMPTZ69 DI DMPTZ69 DMPTZ69 DN Diazepinone derivative 3 DMPTZ69 TI TTHS256 DMPTZ69 TN Metabotropic glutamate receptor 5 (mGluR5) DMPTZ69 MA Modulator DMPTZ69 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMPTZ69 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMPU19H DI DMPU19H DMPU19H DN PMID25666693-Compound-149 DMPU19H TI TTMI6F5 DMPU19H TN Transient receptor potential cation channel V1 (TRPV1) DMPU19H MA Antagonist DMPU19H RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPU19H RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPUG2M DI DMPUG2M DMPUG2M DN Ethynyl compound 7 DMPUG2M TI TTHS256 DMPUG2M TN Metabotropic glutamate receptor 5 (mGluR5) DMPUG2M MA Modulator DMPUG2M RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMPUG2M RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMPUH4Z DI DMPUH4Z DMPUH4Z DN Diaminopyridine analog 4 DMPUH4Z TI TTKFVXR DMPUH4Z TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMPUH4Z MA Inhibitor DMPUH4Z RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMPUH4Z RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMPULIC DI DMPULIC DMPULIC DN 4-(2-cyclohexylethoxy) aniline derivative 4 DMPULIC TI TTA6ZN2 DMPULIC TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMPULIC MA Inhibitor DMPULIC RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMPULIC RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMPUXL3 DI DMPUXL3 DMPUXL3 DN Bipyridine derivative 1 DMPUXL3 TI TT1LVF2 DMPUXL3 TN Cyclin-dependent kinase 9 (CDK9) DMPUXL3 MA Inhibitor DMPUXL3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMPUXL3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTSHTOI DMPV0KZ TN Histone deacetylase 2 (HDAC2) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTYHPU6 DMPV0KZ TN Histone deacetylase 10 (HDAC10) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTTQGH8 DMPV0KZ TN Histone deacetylase 4 (HDAC4) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT8K17W DMPV0KZ TN Histone deacetylase 11 (HDAC11) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTMUEK1 DMPV0KZ TN Histone deacetylase 7 (HDAC7) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT8M4E1 DMPV0KZ TN Histone deacetylase 9 (HDAC9) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT4YWTO DMPV0KZ TN Histone deacetylase 3 (HDAC3) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTUELN5 DMPV0KZ TN Histone deacetylase 5 (HDAC5) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT6R7JZ DMPV0KZ TN Histone deacetylase 1 (HDAC1) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TTT6LFV DMPV0KZ TN Histone deacetylase 8 (HDAC8) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV0KZ DI DMPV0KZ DMPV0KZ DN PMID29671355-Compound-25 DMPV0KZ TI TT5ZKDI DMPV0KZ TN Histone deacetylase 6 (HDAC6) DMPV0KZ MA Inhibitor DMPV0KZ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMPV0KZ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMPV9L2 DI DMPV9L2 DMPV9L2 DN PMID25666693-Compound-67 DMPV9L2 TI TTMI6F5 DMPV9L2 TN Transient receptor potential cation channel V1 (TRPV1) DMPV9L2 MA Antagonist DMPV9L2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPV9L2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPVDSC DI DMPVDSC DMPVDSC DN Pyrazole derivative 38 DMPVDSC TI TT6OEDT DMPVDSC TN Cannabinoid receptor 1 (CB1) DMPVDSC MA Antagonist DMPVDSC RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMPVDSC RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMPVSG9 DI DMPVSG9 DMPVSG9 DN PMID29649907-Compound-3 DMPVSG9 TI TTS4UGC DMPVSG9 TN Farnesoid X-activated receptor (FXR) DMPVSG9 MA Agonist DMPVSG9 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMPVSG9 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMPVW2Q DI DMPVW2Q DMPVW2Q DN PMID30280939-Compound-US20179642901 DMPVW2Q TI TTOK0LR DMPVW2Q TN Toll-like receptor (TLR) DMPVW2Q MA Agonist DMPVW2Q RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMPVW2Q RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMPVZ6W DI DMPVZ6W DMPVZ6W DN PMID28766366-Compound-Scheme27LeucettineL41derivatives DMPVZ6W TI TTSBVFO DMPVZ6W TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMPVZ6W MA Inhibitor DMPVZ6W RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPVZ6W RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPW1GI DI DMPW1GI DMPW1GI DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 2 DMPW1GI TI TT9NXW4 DMPW1GI TN Sigma intracellular receptor 2 (TMEM97) DMPW1GI MA Ligand DMPW1GI RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMPW1GI RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMPW9ES DI DMPW9ES DMPW9ES DN Aminocyclopentenone compound 5 DMPW9ES TI TTRA6BO DMPW9ES TN Bromodomain-containing protein 4 (BRD4) DMPW9ES MA Inhibitor DMPW9ES RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMPW9ES RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMPWFJN DI DMPWFJN DMPWFJN DN Biphenyl carboxylic acid derivative 1 DMPWFJN TI TTL53M6 DMPWFJN TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMPWFJN MA Inhibitor DMPWFJN RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMPWFJN RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMPWKAH DI DMPWKAH DMPWKAH DN Bidentate pyrazolopyrimidine acetamide analog 1 DMPWKAH TI TTPTXIN DMPWKAH TN Translocator protein (TSPO) DMPWKAH MA Ligand DMPWKAH RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMPWKAH RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMPWS9N DI DMPWS9N DMPWS9N DN Peptidomimetic analog 3 DMPWS9N TI TTH8FZW DMPWS9N TN Signal transducer and activator of transcription 3 (STAT3) DMPWS9N MA Inhibitor DMPWS9N RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMPWS9N RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMPWYL8 DI DMPWYL8 DMPWYL8 DN PMID28350212-Compound-13 DMPWYL8 TI TTZS04O DMPWYL8 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMPWYL8 MA Inhibitor DMPWYL8 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMPWYL8 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMPXAGD DI DMPXAGD DMPXAGD DN Alkaloid derivative 4 DMPXAGD TI TTUX68I DMPXAGD TN Hypoxia-inducible factor 1 (HIF-1) DMPXAGD MA Inhibitor DMPXAGD RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMPXAGD RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMPXK1C DI DMPXK1C DMPXK1C DN Isoxazole-based bicyclic compound 15 DMPXK1C TI TTE4BSY DMPXK1C TN Bromodomain and extraterminal domain protein (BET) DMPXK1C MA Inhibitor DMPXK1C RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMPXK1C RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMPXVWE DI DMPXVWE DMPXVWE DN Urea and carbamate bioisostere derivative 3 DMPXVWE TI TTL7C8Q DMPXVWE TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMPXVWE MA Inhibitor DMPXVWE RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMPXVWE RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMPXZYN DI DMPXZYN DMPXZYN DN PMID29324067-Compound-38 DMPXZYN TI TTGP7BY DMPXZYN TN Monoamine oxidase type B (MAO-B) DMPXZYN MA Inhibitor DMPXZYN RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMPXZYN RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMPY1QC DI DMPY1QC DMPY1QC DN PMID25666693-Compound-136 DMPY1QC TI TTMI6F5 DMPY1QC TN Transient receptor potential cation channel V1 (TRPV1) DMPY1QC MA Antagonist DMPY1QC RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMPY1QC RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMPY8NU DI DMPY8NU DMPY8NU DN PMID25482888-Compound-69 DMPY8NU TI TTDIGC1 DMPY8NU TN Dipeptidyl peptidase 4 (DPP-4) DMPY8NU MA Inhibitor DMPY8NU RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMPY8NU RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMPYCIM DI DMPYCIM DMPYCIM DN PMID25991433-Compound-A9 DMPYCIM TI TTHS0U8 DMPYCIM TN Stress-activated protein kinase JNK2 (JNK2) DMPYCIM MA Inhibitor DMPYCIM RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMPYCIM RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMPYCIM DI DMPYCIM DMPYCIM DN PMID25991433-Compound-A9 DMPYCIM TI TT0K6EO DMPYCIM TN Stress-activated protein kinase JNK1 (JNK1) DMPYCIM MA Inhibitor DMPYCIM RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMPYCIM RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMPZ0U8 DI DMPZ0U8 DMPZ0U8 DN 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 2 DMPZ0U8 TI TTIXKA4 DMPZ0U8 TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMPZ0U8 MA Inhibitor DMPZ0U8 RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMPZ0U8 RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMPZ81S DI DMPZ81S DMPZ81S DN Oxazolo[3,4-a]pyrazine derivative 1 DMPZ81S TI TTV1C0Z DMPZ81S TN Neuropeptide S receptor (NPSR) DMPZ81S MA Antagonist DMPZ81S RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMPZ81S RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMPZECW DI DMPZECW DMPZECW DN 1,2-diamino cyclopentane-based derivative 11 DMPZECW TI TT60Q8D DMPZECW TN Orexin receptor type 1 (HCRTR1) DMPZECW MA Antagonist DMPZECW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMPZECW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMPZECW DI DMPZECW DMPZECW DN 1,2-diamino cyclopentane-based derivative 11 DMPZECW TI TT9N02I DMPZECW TN Orexin receptor type 2 (HCRTR2) DMPZECW MA Antagonist DMPZECW RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMPZECW RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMPZKQN DI DMPZKQN DMPZKQN DN Phenylpyrrolidinone derivative 3 DMPZKQN TI TT5OU0D DMPZKQN TN PRKR-like endoplasmic reticulum kinase (PERK) DMPZKQN MA Inhibitor DMPZKQN RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMPZKQN RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMPZS16 DI DMPZS16 DMPZS16 DN US9714230, 46 DMPZS16 TI TTIG67W DMPZS16 TN Lysine-specific demethylase 5A (KDM5A) DMPZS16 MA Inhibitor DMPZS16 RN Histone demethylase inhibitors. US9604961. DMPZS16 RU http://www.freepatentsonline.com/US9604961.html DMQ027F DI DMQ027F DMQ027F DN Tetra-hydro-pyrazolopyrazine derivative 2 DMQ027F TI TTHS256 DMQ027F TN Metabotropic glutamate receptor 5 (mGluR5) DMQ027F MA Modulator DMQ027F RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMQ027F RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMQ08BM DI DMQ08BM DMQ08BM DN Pyrazole derivative 60 DMQ08BM TI TT6OEDT DMQ08BM TN Cannabinoid receptor 1 (CB1) DMQ08BM MA Antagonist DMQ08BM RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMQ08BM RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMQ0RGB DI DMQ0RGB DMQ0RGB DN Steroid derivative 2 DMQ0RGB TI TTUX68I DMQ0RGB TN Hypoxia-inducible factor 1 (HIF-1) DMQ0RGB MA Inhibitor DMQ0RGB RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMQ0RGB RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMQ0VK4 DI DMQ0VK4 DMQ0VK4 DN Piperidine derivative 5 DMQ0VK4 TI TT9NXW4 DMQ0VK4 TN Sigma intracellular receptor 2 (TMEM97) DMQ0VK4 MA Ligand DMQ0VK4 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMQ0VK4 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMQ0VK4 DI DMQ0VK4 DMQ0VK4 DN Piperidine derivative 5 DMQ0VK4 TI TT5TPI6 DMQ0VK4 TN Opioid receptor sigma 1 (OPRS1) DMQ0VK4 MA Ligand DMQ0VK4 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMQ0VK4 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMQ0VK9 DI DMQ0VK9 DMQ0VK9 DN Sulfamic acid ester derivative 1 DMQ0VK9 TI TTZJYKH DMQ0VK9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQ0VK9 MA Inhibitor DMQ0VK9 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMQ0VK9 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMQ1FAH DI DMQ1FAH DMQ1FAH DN 2-piperidine thiazole derivative 1 DMQ1FAH TI TT3M2WO DMQ1FAH TN Sphingosine kinase (SphK) DMQ1FAH MA Inhibitor DMQ1FAH RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMQ1FAH RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMQ1LGV DI DMQ1LGV DMQ1LGV DN US9346821, B-42 DMQ1LGV TI TTXL0GC DMQ1LGV TN Enteropeptidase (TMPRSS15) DMQ1LGV MA Inhibitor DMQ1LGV RN Heterocyclic carboxylic acid ester derivative. US9346821. DMQ1LGV RU http://www.freepatentsonline.com/US9346821.html DMQ2MKT DI DMQ2MKT DMQ2MKT DN N-acylpiperidine ether derivative 5 DMQ2MKT TI TTTDVOJ DMQ2MKT TN Tropomyosin-related kinase A (TrkA) DMQ2MKT MA Inhibitor DMQ2MKT RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQ2MKT RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQ2U54 DI DMQ2U54 DMQ2U54 DN Pyrrolo-pyridazine derivative 1 DMQ2U54 TI TTK0FEA DMQ2U54 TN Leucine-rich repeat kinase 2 (LRRK2) DMQ2U54 MA Inhibitor DMQ2U54 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMQ2U54 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMQ2X6O DI DMQ2X6O DMQ2X6O DN Fused aryl carbocycle derivative 9 DMQ2X6O TI TT9NXW4 DMQ2X6O TN Sigma intracellular receptor 2 (TMEM97) DMQ2X6O MA Ligand DMQ2X6O RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMQ2X6O RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMQ3K5B DI DMQ3K5B DMQ3K5B DN Tacrine-indole hybrid derivative 1 DMQ3K5B TI TT1RS9F DMQ3K5B TN Acetylcholinesterase (AChE) DMQ3K5B MA Inhibitor DMQ3K5B RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQ3K5B RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQ3TGM DI DMQ3TGM DMQ3TGM DN Pyrazole derivative 80 DMQ3TGM TI TTZ963I DMQ3TGM TN Monoglyceride lipase (MAGL) DMQ3TGM MA Inhibitor DMQ3TGM RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMQ3TGM RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMQ3TGM DI DMQ3TGM DMQ3TGM DN Pyrazole derivative 80 DMQ3TGM TI TTDP1UC DMQ3TGM TN Fatty acid amide hydrolase (FAAH) DMQ3TGM MA Inhibitor DMQ3TGM RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMQ3TGM RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMQ3TGM DI DMQ3TGM DMQ3TGM DN Pyrazole derivative 80 DMQ3TGM TI TTSINOV DMQ3TGM TN Monoacylglycerol lipase ABHD6 (ABHD6) DMQ3TGM MA Inhibitor DMQ3TGM RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMQ3TGM RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMQ4TUE DI DMQ4TUE DMQ4TUE DN BDBM50061601 DMQ4TUE TI TTCGOIN DMQ4TUE TN PIM-3 protein kinase (PIM3) DMQ4TUE MA Inhibitor DMQ4TUE RN Azole compounds as PIM inhibitors. US9321756. DMQ4TUE RU http://www.freepatentsonline.com/US9321756.html DMQ4ULC DI DMQ4ULC DMQ4ULC DN N-acylpyrrolidine ether derivative 1 DMQ4ULC TI TTTDVOJ DMQ4ULC TN Tropomyosin-related kinase A (TrkA) DMQ4ULC MA Inhibitor DMQ4ULC RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQ4ULC RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQ5AIT DI DMQ5AIT DMQ5AIT DN PMID26004420-Compound-US20140275020D DMQ5AIT TI TTJ13ST DMQ5AIT TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMQ5AIT MA Inhibitor DMQ5AIT RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMQ5AIT RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMQ5AJ6 DI DMQ5AJ6 DMQ5AJ6 DN Selenium compound 3 DMQ5AJ6 TI TTZHPB8 DMQ5AJ6 TN Lysine-specific demethylase 4A (KDM4A) DMQ5AJ6 MA Inhibitor DMQ5AJ6 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMQ5AJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMQ5TYK DI DMQ5TYK DMQ5TYK DN Resorcinol compound 5 DMQ5TYK TI TTULVH8 DMQ5TYK TN Tyrosinase (TYR) DMQ5TYK MA Inhibitor DMQ5TYK RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQ5TYK RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQ5UEA DI DMQ5UEA DMQ5UEA DN PMID28766366-Compound-Scheme16DMAT DMQ5UEA TI TT84OS6 DMQ5UEA TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMQ5UEA MA Inhibitor DMQ5UEA RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQ5UEA RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQ5UEA DI DMQ5UEA DMQ5UEA DN PMID28766366-Compound-Scheme16DMAT DMQ5UEA TI TTSBVFO DMQ5UEA TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMQ5UEA MA Inhibitor DMQ5UEA RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQ5UEA RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQ6WEN DI DMQ6WEN DMQ6WEN DN PMID28048944-Compound-11 DMQ6WEN TI TTGWKQJ DMQ6WEN TN Rho-associated protein kinase 2 (ROCK2) DMQ6WEN MA Inhibitor DMQ6WEN RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMQ6WEN RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMQ704Z DI DMQ704Z DMQ704Z DN Quinazoline derivative 16 DMQ704Z TI TTUTJGQ DMQ704Z TN Vascular endothelial growth factor receptor 2 (KDR) DMQ704Z MA Inhibitor DMQ704Z RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMQ704Z RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMQ704Z DI DMQ704Z DMQ704Z DN Quinazoline derivative 16 DMQ704Z TI TT4DXQT DMQ704Z TN Proto-oncogene c-Ret (RET) DMQ704Z MA Inhibitor DMQ704Z RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMQ704Z RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMQ75BN DI DMQ75BN DMQ75BN DN Benzimidazole derivative 8 DMQ75BN TI TTQR74A DMQ75BN TN Proteinase activated receptor 2 (PAR2) DMQ75BN MA Antagonist DMQ75BN RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMQ75BN RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMQ7BV4 DI DMQ7BV4 DMQ7BV4 DN 7-azaindole derivative 3 DMQ7BV4 TI TTHS0U8 DMQ7BV4 TN Stress-activated protein kinase JNK2 (JNK2) DMQ7BV4 MA Inhibitor DMQ7BV4 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQ7BV4 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQ7BV4 DI DMQ7BV4 DMQ7BV4 DN 7-azaindole derivative 3 DMQ7BV4 TI TT0K6EO DMQ7BV4 TN Stress-activated protein kinase JNK1 (JNK1) DMQ7BV4 MA Inhibitor DMQ7BV4 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQ7BV4 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQ7BV4 DI DMQ7BV4 DMQ7BV4 DN 7-azaindole derivative 3 DMQ7BV4 TI TT056SO DMQ7BV4 TN Stress-activated protein kinase JNK3 (JNK3) DMQ7BV4 MA Inhibitor DMQ7BV4 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQ7BV4 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQ7ODW DI DMQ7ODW DMQ7ODW DN US10100051, Compound 10 DMQ7ODW TI TT9ISBX DMQ7ODW TN HIF-prolyl hydroxylase 2 (HPH-2) DMQ7ODW MA Inhibitor DMQ7ODW RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DMQ7ODW RU http://www.freepatentsonline.com/US10100051.html DMQ7Z5F DI DMQ7Z5F DMQ7Z5F DN PMID26004420-Compound-US20140142115C DMQ7Z5F TI TTJ13ST DMQ7Z5F TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMQ7Z5F MA Inhibitor DMQ7Z5F RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMQ7Z5F RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMQ83EV DI DMQ83EV DMQ83EV DN PMID27109571-Compound-40 DMQ83EV TI TTMY6L1 DMQ83EV TN Fatty acid-binding protein (FABP) DMQ83EV MA Inhibitor DMQ83EV RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMQ83EV RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMQ84KW DI DMQ84KW DMQ84KW DN Macrocycle derivative 6 DMQ84KW TI TT23XQV DMQ84KW TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMQ84KW MA Inhibitor DMQ84KW RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMQ84KW RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMQ84KW DI DMQ84KW DMQ84KW DN Macrocycle derivative 6 DMQ84KW TI TT5YPJF DMQ84KW TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMQ84KW MA Inhibitor DMQ84KW RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMQ84KW RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMQ8EYV DI DMQ8EYV DMQ8EYV DN PMID29473428-Compound-43 DMQ8EYV TI TTZJYKH DMQ8EYV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQ8EYV MA Inhibitor DMQ8EYV RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMQ8EYV RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMQ8X94 DI DMQ8X94 DMQ8X94 DN Boronic acid derivative 3 DMQ8X94 TI TTDP1UC DMQ8X94 TN Fatty acid amide hydrolase (FAAH) DMQ8X94 MA Inhibitor DMQ8X94 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMQ8X94 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMQ9ATN DI DMQ9ATN DMQ9ATN DN Quinoline carboxamide derivative 6 DMQ9ATN TI TTPTXIN DMQ9ATN TN Translocator protein (TSPO) DMQ9ATN MA Ligand DMQ9ATN RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMQ9ATN RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMQ9CBS DI DMQ9CBS DMQ9CBS DN PMID28270021-Compound-WO2010077680 495 DMQ9CBS TI TTTDVOJ DMQ9CBS TN Tropomyosin-related kinase A (TrkA) DMQ9CBS MA Antagonist DMQ9CBS RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQ9CBS RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQAC4K DI DMQAC4K DMQAC4K DN PMID27539678-Compound-7 DMQAC4K TI TTOHFIY DMQAC4K TN Sphingosine kinase 1 (SPHK1) DMQAC4K MA Inhibitor DMQAC4K RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMQAC4K RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMQARW2 DI DMQARW2 DMQARW2 DN SCHEMBL16365841 DMQARW2 TI TT78309 DMQARW2 TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DMQARW2 MA Inhibitor DMQARW2 RN Substituted benzylpyrazoles. US9765058. DMQARW2 RU http://www.freepatentsonline.com/US9765058.html DMQAV30 DI DMQAV30 DMQAV30 DN PMID29649907-Compound-14 DMQAV30 TI TTS4UGC DMQAV30 TN Farnesoid X-activated receptor (FXR) DMQAV30 MA Agonist DMQAV30 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMQAV30 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMQAZMC DI DMQAZMC DMQAZMC DN PMID28270021-Compound-WO2010077680 201 DMQAZMC TI TTTDVOJ DMQAZMC TN Tropomyosin-related kinase A (TrkA) DMQAZMC MA Antagonist DMQAZMC RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQAZMC RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQB03U DI DMQB03U DMQB03U DN PMID25514969-Compound-13 DMQB03U TI TT4EB85 DMQB03U TN Cholesterol 24-hydroxylase (CYP46A1) DMQB03U MA Inhibitor DMQB03U RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMQB03U RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMQB4DR DI DMQB4DR DMQB4DR DN Biphenyl mannoside derivative 2 DMQB4DR TI TTTCRU2 DMQB4DR TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQB4DR MA Antagonist DMQB4DR RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQB4DR RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQB4LE DI DMQB4LE DMQB4LE DN PMID25482888-Compound-11 DMQB4LE TI TTDIGC1 DMQB4LE TN Dipeptidyl peptidase 4 (DPP-4) DMQB4LE MA Inhibitor DMQB4LE RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMQB4LE RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMQBFI2 DI DMQBFI2 DMQBFI2 DN PMID25666693-Compound-26 DMQBFI2 TI TTMI6F5 DMQBFI2 TN Transient receptor potential cation channel V1 (TRPV1) DMQBFI2 MA Antagonist DMQBFI2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQBFI2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQBH81 DI DMQBH81 DMQBH81 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 DMQBH81 TI TTJW4LU DMQBH81 TN Phosphodiesterase 10A (PDE10) DMQBH81 MA Inhibitor DMQBH81 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQBH81 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQBH81 DI DMQBH81 DMQBH81 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 1 DMQBH81 TI TTJGW1Z DMQBH81 TN Phosphodiesterase 2A (PDE2A) DMQBH81 MA Inhibitor DMQBH81 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQBH81 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQD4X2 DI DMQD4X2 DMQD4X2 DN BK7 DMQD4X2 TI TT42OGM DMQD4X2 TN Hematopoietic cell kinase (HCK) DMQD4X2 MA Inhibitor DMQD4X2 RN Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US9765037. DMQD4X2 RU http://www.freepatentsonline.com/US9765037.html DMQD6IL DI DMQD6IL DMQD6IL DN Schiff base compound 1 DMQD6IL TI TTGP7BY DMQD6IL TN Monoamine oxidase type B (MAO-B) DMQD6IL RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMQD6IL RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMQD6IL DI DMQD6IL DMQD6IL DN Schiff base compound 1 DMQD6IL TI TT3WG5C DMQD6IL TN Monoamine oxidase type A (MAO-A) DMQD6IL RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMQD6IL RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMQDA3I DI DMQDA3I DMQDA3I DN Imidazopyridine acetamide analog 7 DMQDA3I TI TTPTXIN DMQDA3I TN Translocator protein (TSPO) DMQDA3I MA Ligand DMQDA3I RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMQDA3I RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMQDGZL DI DMQDGZL DMQDGZL DN PMID29649907-Compound-27 DMQDGZL TI TTS4UGC DMQDGZL TN Farnesoid X-activated receptor (FXR) DMQDGZL MA Agonist DMQDGZL RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMQDGZL RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMQDL43 DI DMQDL43 DMQDL43 DN Pyrrole derivative 4 DMQDL43 TI TT6OEDT DMQDL43 TN Cannabinoid receptor 1 (CB1) DMQDL43 MA Antagonist DMQDL43 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMQDL43 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMQDRUT DI DMQDRUT DMQDRUT DN PMID28394193-Compound-16 DMQDRUT TI TT9MZCQ DMQDRUT TN Enhancer of zeste homolog 2 (EZH2) DMQDRUT MA Inhibitor DMQDRUT RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMQDRUT RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMQEL1W DI DMQEL1W DMQEL1W DN US9266828, C DMQEL1W TI TTH9WF6 DMQEL1W TN Dibasic-processing enzyme (Furin) DMQEL1W MA Inhibitor DMQEL1W RN Inhibitors of Furin and other pro-protein convertases. US9266828. DMQEL1W RU http://www.freepatentsonline.com/US9266828.html DMQEYTJ DI DMQEYTJ DMQEYTJ DN Diamine derivative 2 DMQEYTJ TI TTULVH8 DMQEYTJ TN Tyrosinase (TYR) DMQEYTJ MA Inhibitor DMQEYTJ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQEYTJ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQF0RY DI DMQF0RY DMQF0RY DN N-oxalylglycine derivative 3 DMQF0RY TI TT0RGE9 DMQF0RY TN Lysine-specific demethylase 4 (KDM4) DMQF0RY MA Inhibitor DMQF0RY RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMQF0RY RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMQF1UM DI DMQF1UM DMQF1UM DN Egonol compound 1 DMQF1UM TI TTEB0GD DMQF1UM TN Cholinesterase (BCHE) DMQF1UM MA Inhibitor DMQF1UM RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQF1UM RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQF1UM DI DMQF1UM DMQF1UM DN Egonol compound 1 DMQF1UM TI TT1RS9F DMQF1UM TN Acetylcholinesterase (AChE) DMQF1UM MA Inhibitor DMQF1UM RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQF1UM RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQF2XN DI DMQF2XN DMQF2XN DN Biphenyl carboxamidopropanoic acid derivative 2 DMQF2XN TI TT9O6WS DMQF2XN TN Glucagon receptor (GCGR) DMQF2XN MA Antagonist DMQF2XN RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMQF2XN RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMQF62D DI DMQF62D DMQF62D DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 1 DMQF62D TI TTJGW1Z DMQF62D TN Phosphodiesterase 2A (PDE2A) DMQF62D MA Inhibitor DMQF62D RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQF62D RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQF90E DI DMQF90E DMQF90E DN Resorcinol compound 34 DMQF90E TI TTULVH8 DMQF90E TN Tyrosinase (TYR) DMQF90E MA Inhibitor DMQF90E RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQF90E RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQFDU8 DI DMQFDU8 DMQFDU8 DN PMID26651364-Compound-46 DMQFDU8 TI TTTCRU2 DMQFDU8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQFDU8 MA Antagonist DMQFDU8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQFDU8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQGA1I DI DMQGA1I DMQGA1I DN Tetra-hydro-oxazolopyridine derivative 5 DMQGA1I TI TTHS256 DMQGA1I TN Metabotropic glutamate receptor 5 (mGluR5) DMQGA1I MA Modulator DMQGA1I RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMQGA1I RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMQGFKY DI DMQGFKY DMQGFKY DN Biphenyl mannoside derivative 22 DMQGFKY TI TTTCRU2 DMQGFKY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQGFKY MA Antagonist DMQGFKY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQGFKY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQGI0R DI DMQGI0R DMQGI0R DN Pyrrolo[2,3-d]pyrimidine derivative 32 DMQGI0R TI TTGM6VW DMQGI0R TN Tyrosine-protein kinase BTK (ATK) DMQGI0R MA Inhibitor DMQGI0R RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMQGI0R RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMQGTJ5 DI DMQGTJ5 DMQGTJ5 DN PMID26815044-Compound-51 DMQGTJ5 TI TTULVH8 DMQGTJ5 TN Tyrosinase (TYR) DMQGTJ5 MA Inhibitor DMQGTJ5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMQGTJ5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMQGTYE DI DMQGTYE DMQGTYE DN PMID25666693-Compound-141 DMQGTYE TI TTMI6F5 DMQGTYE TN Transient receptor potential cation channel V1 (TRPV1) DMQGTYE MA Antagonist DMQGTYE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQGTYE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQGUMN DI DMQGUMN DMQGUMN DN PMID25991433-Compound-J1 DMQGUMN TI TTVOE6D DMQGUMN TN Mitogen-activated protein kinase (MAPK) DMQGUMN MA Inhibitor DMQGUMN RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQGUMN RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQGYWV DI DMQGYWV DMQGYWV DN Bicyclic heteroaryl benzamide derivative 6 DMQGYWV TI TTTDVOJ DMQGYWV TN Tropomyosin-related kinase A (TrkA) DMQGYWV MA Inhibitor DMQGYWV RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQGYWV RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQHAU1 DI DMQHAU1 DMQHAU1 DN N-arylmethyl-N-phenyl cyclic urea derivative 1 DMQHAU1 TI TTTDVOJ DMQHAU1 TN Tropomyosin-related kinase A (TrkA) DMQHAU1 MA Inhibitor DMQHAU1 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMQHAU1 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMQHCDZ DI DMQHCDZ DMQHCDZ DN Pyrazolo[3,4-c]pyridine derivative 1 DMQHCDZ TI TTSCIM2 DMQHCDZ TN Extracellular lysophospholipase D (E-NPP2) DMQHCDZ MA Inhibitor DMQHCDZ RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMQHCDZ RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMQHYMJ DI DMQHYMJ DMQHYMJ DN PMID27774824-Compound-Figure2Example4 DMQHYMJ TI TTRMX3V DMQHYMJ TN Janus kinase 2 (JAK-2) DMQHYMJ MA Inhibitor DMQHYMJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQHYMJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQHYMJ DI DMQHYMJ DMQHYMJ DN PMID27774824-Compound-Figure2Example4 DMQHYMJ TI TTT7PJU DMQHYMJ TN Janus kinase 3 (JAK-3) DMQHYMJ MA Inhibitor DMQHYMJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQHYMJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQHYMJ DI DMQHYMJ DMQHYMJ DN PMID27774824-Compound-Figure2Example4 DMQHYMJ TI TT6DM01 DMQHYMJ TN Janus kinase 1 (JAK-1) DMQHYMJ MA Inhibitor DMQHYMJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQHYMJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQI1YN DI DMQI1YN DMQI1YN DN PMID25666693-Compound-78 DMQI1YN TI TTMI6F5 DMQI1YN TN Transient receptor potential cation channel V1 (TRPV1) DMQI1YN MA Antagonist DMQI1YN RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQI1YN RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQIUD9 DI DMQIUD9 DMQIUD9 DN PMID28870136-Compound-58 DMQIUD9 TI TTK0O6Y DMQIUD9 TN Ecto-5'-nucleotidase (CD73) DMQIUD9 MA Inhibitor DMQIUD9 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMQIUD9 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMQIYM6 DI DMQIYM6 DMQIYM6 DN PMID27454349-Compound-101 DMQIYM6 TI TTK59TV DMQIYM6 TN Vitamin D3 receptor (VDR) DMQIYM6 MA Agonist DMQIYM6 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMQIYM6 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMQJ38W DI DMQJ38W DMQJ38W DN Poly-substituted miazine derivative 1 DMQJ38W TI TTPADOQ DMQJ38W TN HMG-CoA reductase (HMGCR) DMQJ38W MA Inhibitor DMQJ38W RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMQJ38W RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMQJ3TC DI DMQJ3TC DMQJ3TC DN PMID29671355-Compound-36 DMQJ3TC TI TTT6LFV DMQJ3TC TN Histone deacetylase 8 (HDAC8) DMQJ3TC MA Inhibitor DMQJ3TC RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMQJ3TC RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMQJ3TC DI DMQJ3TC DMQJ3TC DN PMID29671355-Compound-36 DMQJ3TC TI TT8K17W DMQJ3TC TN Histone deacetylase 11 (HDAC11) DMQJ3TC MA Inhibitor DMQJ3TC RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMQJ3TC RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMQJ5S8 DI DMQJ5S8 DMQJ5S8 DN BDBM50382283 DMQJ5S8 TI TTOYT5L DMQJ5S8 TN Dipeptidyl-peptidase 7 (DPP7) DMQJ5S8 MA Inhibitor DMQJ5S8 RN FAP inhibitors. US9346814. DMQJ5S8 RU http://www.freepatentsonline.com/US9346814.html DMQJF15 DI DMQJF15 DMQJF15 DN PMID28870136-Compound-36 DMQJF15 TI TTK0O6Y DMQJF15 TN Ecto-5'-nucleotidase (CD73) DMQJF15 MA Inhibitor DMQJF15 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMQJF15 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMQJF4P DI DMQJF4P DMQJF4P DN Beta-cyclodextrin conjugate derivative 3 DMQJF4P TI TTTCRU2 DMQJF4P TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQJF4P MA Antagonist DMQJF4P RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQJF4P RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQJK70 DI DMQJK70 DMQJK70 DN Tricyclic heterocycle derivative 6 DMQJK70 TI TTDIGC1 DMQJK70 TN Dipeptidyl peptidase 4 (DPP-4) DMQJK70 MA Inhibitor DMQJK70 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMQJK70 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMQJV3L DI DMQJV3L DMQJV3L DN PMID25399762-Compound-Table1-C7 DMQJV3L TI TTGP7BY DMQJV3L TN Monoamine oxidase type B (MAO-B) DMQJV3L MA Inhibitor DMQJV3L RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMQJV3L RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMQJW9R DI DMQJW9R DMQJW9R DN Heterocyclic derivative 12 DMQJW9R TI TTCZOF2 DMQJW9R TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMQJW9R MA Inhibitor DMQJW9R RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMQJW9R RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMQJZLI DI DMQJZLI DMQJZLI DN PMID25726713-Compound-19 DMQJZLI TI TT8J1S3 DMQJZLI TN Smoothened homolog (SMO) DMQJZLI MA Inhibitor DMQJZLI RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMQJZLI RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMQK4IX DI DMQK4IX DMQK4IX DN PMID28270021-Compound-WO2013009582Example76 DMQK4IX TI TTTDVOJ DMQK4IX TN Tropomyosin-related kinase A (TrkA) DMQK4IX MA Inhibitor DMQK4IX RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMQK4IX RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMQKLX0 DI DMQKLX0 DMQKLX0 DN PMID25991433-Compound-H3 DMQKLX0 TI TT0K6EO DMQKLX0 TN Stress-activated protein kinase JNK1 (JNK1) DMQKLX0 MA Inhibitor DMQKLX0 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQKLX0 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQKOMR DI DMQKOMR DMQKOMR DN Tarnylcypromine derivative 1 DMQKOMR TI TTNR0UQ DMQKOMR TN Lysine-specific histone demethylase 1 (LSD) DMQKOMR MA Inhibitor DMQKOMR RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQKOMR RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQL1TV DI DMQL1TV DMQL1TV DN Triazolo-pyridine derivative 3 DMQL1TV TI TTJW4LU DMQL1TV TN Phosphodiesterase 10A (PDE10) DMQL1TV MA Inhibitor DMQL1TV RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQL1TV RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQL1TV DI DMQL1TV DMQL1TV DN Triazolo-pyridine derivative 3 DMQL1TV TI TTJGW1Z DMQL1TV TN Phosphodiesterase 2A (PDE2A) DMQL1TV MA Inhibitor DMQL1TV RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQL1TV RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TT6DM01 DMQL34C TN Janus kinase 1 (JAK-1) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TTRMX3V DMQL34C TN Janus kinase 2 (JAK-2) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TTBYWP2 DMQL34C TN TYK2 tyrosine kinase (TYK2) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL34C DI DMQL34C DMQL34C DN Bis-aminopyrimidine derivative 1 DMQL34C TI TTT7PJU DMQL34C TN Janus kinase 3 (JAK-3) DMQL34C MA Inhibitor DMQL34C RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMQL34C RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMQL5B7 DI DMQL5B7 DMQL5B7 DN 7-azaindole derivative 1 DMQL5B7 TI TT0K6EO DMQL5B7 TN Stress-activated protein kinase JNK1 (JNK1) DMQL5B7 MA Inhibitor DMQL5B7 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQL5B7 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQL5B7 DI DMQL5B7 DMQL5B7 DN 7-azaindole derivative 1 DMQL5B7 TI TTHS0U8 DMQL5B7 TN Stress-activated protein kinase JNK2 (JNK2) DMQL5B7 MA Inhibitor DMQL5B7 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQL5B7 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQL5B7 DI DMQL5B7 DMQL5B7 DN 7-azaindole derivative 1 DMQL5B7 TI TT056SO DMQL5B7 TN Stress-activated protein kinase JNK3 (JNK3) DMQL5B7 MA Inhibitor DMQL5B7 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMQL5B7 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMQLBAJ DI DMQLBAJ DMQLBAJ DN PMID25522065-Compound-38 DMQLBAJ TI TTX4RTB DMQLBAJ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMQLBAJ MA Antagonist DMQLBAJ RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMQLBAJ RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMQLJU2 DI DMQLJU2 DMQLJU2 DN Imidazo[1,2-b]pyridazine acetamide derivative 7 DMQLJU2 TI TTPTXIN DMQLJU2 TN Translocator protein (TSPO) DMQLJU2 MA Ligand DMQLJU2 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMQLJU2 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMQLZUW DI DMQLZUW DMQLZUW DN Cyclohexane carboxamide derivative 3 DMQLZUW TI TTTJZ4M DMQLZUW TN Prolylcarboxypeptidase (PRCP) DMQLZUW MA Inhibitor DMQLZUW RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMQLZUW RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMQM6ZS DI DMQM6ZS DMQM6ZS DN Epoxysuccinate derivative 6 DMQM6ZS TI TTG5QB7 DMQM6ZS TN Calpain-2 (CAPN2) DMQM6ZS MA Inhibitor DMQM6ZS RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMQM6ZS RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMQMBY9 DI DMQMBY9 DMQMBY9 DN PMID26651364-Compound-7a DMQMBY9 TI TTTCRU2 DMQMBY9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQMBY9 MA Antagonist DMQMBY9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQMBY9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQNVUB DI DMQNVUB DMQNVUB DN PMID29338548-Compound-16 DMQNVUB TI TTHJTF7 DMQNVUB TN Glycine transporter GlyT-1 (SLC6A9) DMQNVUB MA Inhibitor DMQNVUB RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMQNVUB RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMQOAJP DI DMQOAJP DMQOAJP DN PMID27967267-Compound-39 DMQOAJP TI TT1RS9F DMQOAJP TN Acetylcholinesterase (AChE) DMQOAJP MA Inhibitor DMQOAJP RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQOAJP RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQOF53 DI DMQOF53 DMQOF53 DN PMID29334795-Compound-66 DMQOF53 TI TT9JNIC DMQOF53 TN Histamine H3 receptor (H3R) DMQOF53 MA Inhibitor DMQOF53 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMQOF53 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMQOF53 DI DMQOF53 DMQOF53 DN PMID29334795-Compound-66 DMQOF53 TI TTEX248 DMQOF53 TN Dopamine D2 receptor (D2R) DMQOF53 MA Ligand DMQOF53 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMQOF53 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMQOGHN DI DMQOGHN DMQOGHN DN Fluorinated donepezil derivative 1 DMQOGHN TI TT1RS9F DMQOGHN TN Acetylcholinesterase (AChE) DMQOGHN MA Inhibitor DMQOGHN RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQOGHN RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQOSH5 DI DMQOSH5 DMQOSH5 DN PMID25666693-Compound-112 DMQOSH5 TI TTMI6F5 DMQOSH5 TN Transient receptor potential cation channel V1 (TRPV1) DMQOSH5 MA Antagonist DMQOSH5 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQOSH5 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQOVKF DI DMQOVKF DMQOVKF DN PMID25482888-Compound-72 DMQOVKF TI TTDIGC1 DMQOVKF TN Dipeptidyl peptidase 4 (DPP-4) DMQOVKF MA Inhibitor DMQOVKF RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMQOVKF RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMQP3TD DI DMQP3TD DMQP3TD DN PMID25666693-Compound-10 DMQP3TD TI TTMI6F5 DMQP3TD TN Transient receptor potential cation channel V1 (TRPV1) DMQP3TD MA Antagonist DMQP3TD RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQP3TD RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQPIK4 DI DMQPIK4 DMQPIK4 DN PMID30107136-Compound-Example41 DMQPIK4 TI TT23XQV DMQPIK4 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMQPIK4 MA Inhibitor DMQPIK4 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMQPIK4 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMQPKCD DI DMQPKCD DMQPKCD DN PMID28454500-Compound-50 DMQPKCD TI TTA6ZN2 DMQPKCD TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMQPKCD MA Activator DMQPKCD RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQPKCD RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQPKCD DI DMQPKCD DMQPKCD DN PMID28454500-Compound-50 DMQPKCD TI TT3Z6Y9 DMQPKCD TN Cysteines of Keap1 (KEAP1 Cysteines) DMQPKCD MA Modulator DMQPKCD RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQPKCD RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQPOGC DI DMQPOGC DMQPOGC DN PMID25666693-Compound-52 DMQPOGC TI TTMI6F5 DMQPOGC TN Transient receptor potential cation channel V1 (TRPV1) DMQPOGC MA Antagonist DMQPOGC RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQPOGC RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQPTEJ DI DMQPTEJ DMQPTEJ DN Indanone and indandione derivative 1 DMQPTEJ TI TTV1C0Z DMQPTEJ TN Neuropeptide S receptor (NPSR) DMQPTEJ MA Antagonist DMQPTEJ RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMQPTEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMQPU7K DI DMQPU7K DMQPU7K DN PMID27019002-Compound-46 DMQPU7K TI TTNR0UQ DMQPU7K TN Lysine-specific histone demethylase 1 (LSD) DMQPU7K MA Inhibitor DMQPU7K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQPU7K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQPU7K DI DMQPU7K DMQPU7K DN PMID27019002-Compound-46 DMQPU7K TI TT8VP2T DMQPU7K TN Lysine-specific histone demethylase 1B (KDM1B) DMQPU7K MA Inhibitor DMQPU7K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQPU7K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQRECT DI DMQRECT DMQRECT DN Dihydroisoxazole derivative 1 DMQRECT TI TT2F4OL DMQRECT TN Tissue transglutaminase (TG2) DMQRECT MA Inhibitor DMQRECT RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMQRECT RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMQRFXT DI DMQRFXT DMQRFXT DN PMID25666693-Compound-57 DMQRFXT TI TTMI6F5 DMQRFXT TN Transient receptor potential cation channel V1 (TRPV1) DMQRFXT MA Antagonist DMQRFXT RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMQRFXT RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMQRFZK DI DMQRFZK DMQRFZK DN PMID28394193-Compound-56 DMQRFZK TI TTJW2UQ DMQRFZK TN EZH2 Y641N mutant (EZH2 Y641N) DMQRFZK MA Inhibitor DMQRFZK RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMQRFZK RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMQRFZK DI DMQRFZK DMQRFZK DN PMID28394193-Compound-56 DMQRFZK TI TT9MZCQ DMQRFZK TN Enhancer of zeste homolog 2 (EZH2) DMQRFZK MA Inhibitor DMQRFZK RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMQRFZK RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMQRO6G DI DMQRO6G DMQRO6G DN US8546370, 102 DMQRO6G TI TTUMHT8 DMQRO6G TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DMQRO6G MA Inhibitor DMQRO6G RN Compounds and compositions as kinase inhibitors. US8546370. DMQRO6G RU http://www.freepatentsonline.com/US8546370.html DMQS8CF DI DMQS8CF DMQS8CF DN Aryl mannoside derivative 15 DMQS8CF TI TTTCRU2 DMQS8CF TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQS8CF MA Antagonist DMQS8CF RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQS8CF RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMQSCHA DI DMQSCHA DMQSCHA DN Triazolo-benzodiazepine derivative 2 DMQSCHA TI TT9JNIC DMQSCHA TN Histamine H3 receptor (H3R) DMQSCHA MA Ligand DMQSCHA RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMQSCHA RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMQSTG9 DI DMQSTG9 DMQSTG9 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 DMQSTG9 TI TTJGW1Z DMQSTG9 TN Phosphodiesterase 2A (PDE2A) DMQSTG9 MA Inhibitor DMQSTG9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQSTG9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQSTG9 DI DMQSTG9 DMQSTG9 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 4 DMQSTG9 TI TTJW4LU DMQSTG9 TN Phosphodiesterase 10A (PDE10) DMQSTG9 MA Inhibitor DMQSTG9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMQSTG9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMQT7HV DI DMQT7HV DMQT7HV DN Benzenamine derivative 4 DMQT7HV TI TTNR0UQ DMQT7HV TN Lysine-specific histone demethylase 1 (LSD) DMQT7HV MA Inhibitor DMQT7HV RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMQT7HV RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMQTRFX DI DMQTRFX DMQTRFX DN PMID27967267-Compound-49 DMQTRFX TI TT1RS9F DMQTRFX TN Acetylcholinesterase (AChE) DMQTRFX MA Reactivator DMQTRFX RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMQTRFX RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMQTVPC DI DMQTVPC DMQTVPC DN Epoxysuccinate derivative 8 DMQTVPC TI TTG5QB7 DMQTVPC TN Calpain-2 (CAPN2) DMQTVPC MA Inhibitor DMQTVPC RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMQTVPC RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMQU10C DI DMQU10C DMQU10C DN PMID30185082-Compound-14 DMQU10C TI TT9NXW4 DMQU10C TN Sigma intracellular receptor 2 (TMEM97) DMQU10C MA Ligand DMQU10C RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMQU10C RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMQU9XP DI DMQU9XP DMQU9XP DN PMID27109571-Compound-20 DMQU9XP TI TTNT2S6 DMQU9XP TN Fatty acid-binding protein 5 (FABP5) DMQU9XP MA Inhibitor DMQU9XP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMQU9XP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMQU9XP DI DMQU9XP DMQU9XP DN PMID27109571-Compound-20 DMQU9XP TI TTHWMFZ DMQU9XP TN Fatty acid-binding protein 4 (FABP4) DMQU9XP MA Inhibitor DMQU9XP RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMQU9XP RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMQUE6D DI DMQUE6D DMQUE6D DN PMID29865878-Compound-43 DMQUE6D TI TT68GPI DMQUE6D TN Proteasome beta-5 (PS beta-5) DMQUE6D MA Inhibitor DMQUE6D RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMQUE6D RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMQUE6D DI DMQUE6D DMQUE6D DN PMID29865878-Compound-43 DMQUE6D TI TTEAD9J DMQUE6D TN Proteasome beta-8 (PS beta-8) DMQUE6D MA Inhibitor DMQUE6D RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMQUE6D RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMQUEDK DI DMQUEDK DMQUEDK DN Pyrimidine derivative 20 DMQUEDK TI TT8J1S3 DMQUEDK TN Smoothened homolog (SMO) DMQUEDK MA Inhibitor DMQUEDK RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMQUEDK RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMQURWZ DI DMQURWZ DMQURWZ DN Indole-based analog 14 DMQURWZ TI TTUM2ZR DMQURWZ TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMQURWZ MA Inhibitor DMQURWZ RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMQURWZ RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMQV6R0 DI DMQV6R0 DMQV6R0 DN PMID28766366-Compound-Scheme7WO2012/098070bottom DMQV6R0 TI TTYGQ8A DMQV6R0 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMQV6R0 MA Inhibitor DMQV6R0 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQV6R0 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQV6R0 DI DMQV6R0 DMQV6R0 DN PMID28766366-Compound-Scheme7WO2012/098070bottom DMQV6R0 TI TTSBVFO DMQV6R0 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMQV6R0 MA Inhibitor DMQV6R0 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMQV6R0 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMQVLP8 DI DMQVLP8 DMQVLP8 DN Pyrazolo[1,5-a]pyrimidine derivative 23 DMQVLP8 TI TTTDVOJ DMQVLP8 TN Tropomyosin-related kinase A (TrkA) DMQVLP8 MA Inhibitor DMQVLP8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMQVLP8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMQVMNJ DI DMQVMNJ DMQVMNJ DN 2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ TI TTALN9W DMQVMNJ TN Indoleamine 2,3-dioxygenase 2 (IDO2) DMQVMNJ MA Inhibitor DMQVMNJ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMQVMNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMQVMNJ DI DMQVMNJ DMQVMNJ DN 2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ TI TTZJYKH DMQVMNJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQVMNJ MA Inhibitor DMQVMNJ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMQVMNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMQVMNJ DI DMQVMNJ DMQVMNJ DN 2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ TI TTXNCBV DMQVMNJ TN Tryptophan 2,3-dioxygenase (TDO) DMQVMNJ MA Inhibitor DMQVMNJ RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMQVMNJ RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMQVYL0 DI DMQVYL0 DMQVYL0 DN Isoquinoline sulfonamide derivative 2 DMQVYL0 TI TTMQO60 DMQVYL0 TN Rho-associated protein kinase (ROCK) DMQVYL0 MA Inhibitor DMQVYL0 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMQVYL0 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMQVZ01 DI DMQVZ01 DMQVZ01 DN PMID26882240-Compound-14 DMQVZ01 TI TTUX68I DMQVZ01 TN Hypoxia-inducible factor 1 (HIF-1) DMQVZ01 MA Inhibitor DMQVZ01 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMQVZ01 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMQVZY5 DI DMQVZY5 DMQVZY5 DN Aminoarylpyridine derivative 1 DMQVZY5 TI TT1LVF2 DMQVZY5 TN Cyclin-dependent kinase 9 (CDK9) DMQVZY5 MA Inhibitor DMQVZY5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMQVZY5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMQW470 DI DMQW470 DMQW470 DN PMID28074661-Compound-US20100022547C80 DMQW470 TI TTL7C8Q DMQW470 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMQW470 MA Inhibitor DMQW470 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMQW470 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMQWJ12 DI DMQWJ12 DMQWJ12 DN Aryl urea derivative 2 DMQWJ12 TI TTDP1UC DMQWJ12 TN Fatty acid amide hydrolase (FAAH) DMQWJ12 MA Inhibitor DMQWJ12 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMQWJ12 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMQWODI DI DMQWODI DMQWODI DN N-substituted pyrazole derivative 2 DMQWODI TI TTXJ47W DMQWODI TN Metabotropic glutamate receptor 2 (mGluR2) DMQWODI MA Antagonist DMQWODI RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMQWODI RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMQWPSF DI DMQWPSF DMQWPSF DN PMID28454500-Compound-59 DMQWPSF TI TTA6ZN2 DMQWPSF TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMQWPSF MA Inhibitor DMQWPSF RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQWPSF RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQWPSF DI DMQWPSF DMQWPSF DN PMID28454500-Compound-59 DMQWPSF TI TTGIZLN DMQWPSF TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMQWPSF MA Modulator DMQWPSF RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMQWPSF RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMQX8SD DI DMQX8SD DMQX8SD DN 1,2-diamino cyclopentane-based derivative 32 DMQX8SD TI TT9N02I DMQX8SD TN Orexin receptor type 2 (HCRTR2) DMQX8SD MA Antagonist DMQX8SD RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMQX8SD RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMQX8SD DI DMQX8SD DMQX8SD DN 1,2-diamino cyclopentane-based derivative 32 DMQX8SD TI TT60Q8D DMQX8SD TN Orexin receptor type 1 (HCRTR1) DMQX8SD MA Antagonist DMQX8SD RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMQX8SD RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMQXCT1 DI DMQXCT1 DMQXCT1 DN Imidazo bicyclic iminium derivative 9 DMQXCT1 TI TT8J1S3 DMQXCT1 TN Smoothened homolog (SMO) DMQXCT1 MA Inhibitor DMQXCT1 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMQXCT1 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMQYKT2 DI DMQYKT2 DMQYKT2 DN Tetra-hydro-oxazolopyridine derivative 3 DMQYKT2 TI TTHS256 DMQYKT2 TN Metabotropic glutamate receptor 5 (mGluR5) DMQYKT2 MA Modulator DMQYKT2 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMQYKT2 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMQYWBR DI DMQYWBR DMQYWBR DN PMID26077642-Compound-Figure3H DMQYWBR TI TTZC0KV DMQYWBR TN Zinc finger-containing ubiquitin peptidase 1 (ZUP1) DMQYWBR MA Inhibitor DMQYWBR RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMQYWBR RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMQZJDF DI DMQZJDF DMQZJDF DN PMID26651364-Compound-106 DMQZJDF TI TTTCRU2 DMQZJDF TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMQZJDF MA Antagonist DMQZJDF RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMQZJDF RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMR0ANI DI DMR0ANI DMR0ANI DN Bis-sulfonamide derivative 2 DMR0ANI TI TTR7UJ3 DMR0ANI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMR0ANI MA Inhibitor DMR0ANI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMR0ANI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMR0E5W DI DMR0E5W DMR0E5W DN PMID26651364-Compound-123 DMR0E5W TI TTTCRU2 DMR0E5W TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMR0E5W MA Antagonist DMR0E5W RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMR0E5W RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMR0F4H DI DMR0F4H DMR0F4H DN ZINC959121 DMR0F4H TI TTU3WV6 DMR0F4H TN SRSF protein kinase 1 (SRPK1) DMR0F4H MA Inhibitor DMR0F4H RN Piperazine derivatives for treating disorders. US9695160. DMR0F4H RU http://www.freepatentsonline.com/US9695160.html DMR0JDW DI DMR0JDW DMR0JDW DN Ureido-phenyl-substituted triazine derivative 2 DMR0JDW TI TTTDVOJ DMR0JDW TN Tropomyosin-related kinase A (TrkA) DMR0JDW MA Inhibitor DMR0JDW RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMR0JDW RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMR0P1U DI DMR0P1U DMR0P1U DN PMID25399762-Compound-Table1-C15 DMR0P1U TI TTGP7BY DMR0P1U TN Monoamine oxidase type B (MAO-B) DMR0P1U MA Inhibitor DMR0P1U RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMR0P1U RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMR0PUA DI DMR0PUA DMR0PUA DN PMID28394193-Compound-10 DMR0PUA TI TTJBYRU DMR0PUA TN EZH2 Y641F mutant (EZH2 Y641F) DMR0PUA MA Inhibitor DMR0PUA RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMR0PUA RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMR0WM1 DI DMR0WM1 DMR0WM1 DN PMID25666693-Compound-125 DMR0WM1 TI TTMI6F5 DMR0WM1 TN Transient receptor potential cation channel V1 (TRPV1) DMR0WM1 MA Antagonist DMR0WM1 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMR0WM1 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMR0Y3K DI DMR0Y3K DMR0Y3K DN Isoquinoline derivative 1 DMR0Y3K TI TTMSFAW DMR0Y3K TN Cannabinoid receptor 2 (CB2) DMR0Y3K RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMR0Y3K RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMR0ZU6 DI DMR0ZU6 DMR0ZU6 DN Pyrrolo-pyrimidine derivative 10 DMR0ZU6 TI TTK0FEA DMR0ZU6 TN Leucine-rich repeat kinase 2 (LRRK2) DMR0ZU6 MA Inhibitor DMR0ZU6 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMR0ZU6 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMR1QP4 DI DMR1QP4 DMR1QP4 DN 1,2,4-triazole [1,5-a]pyrimidin-7-yl derivative 3 DMR1QP4 TI TTJGW1Z DMR1QP4 TN Phosphodiesterase 2A (PDE2A) DMR1QP4 MA Inhibitor DMR1QP4 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMR1QP4 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMR1YH9 DI DMR1YH9 DMR1YH9 DN PMID25553724-Compound-WO2013082253 33 DMR1YH9 TI TTSXVID DMR1YH9 TN Nuclear factor NF-kappa-B (NFKB) DMR1YH9 MA Modulator DMR1YH9 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMR1YH9 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMR1Z3I DI DMR1Z3I DMR1Z3I DN US9522888, 412 DMR1Z3I TI TTDYP7I DMR1Z3I TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMR1Z3I MA Inhibitor DMR1Z3I RN Substituted bicyclic compounds. US10166249. DMR1Z3I RU http://www.freepatentsonline.com/US10166249.html DMR2GW1 DI DMR2GW1 DMR2GW1 DN Indazolyl-thiadiazolamine derivative 1 DMR2GW1 TI TTGWKQJ DMR2GW1 TN Rho-associated protein kinase 2 (ROCK2) DMR2GW1 MA Inhibitor DMR2GW1 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMR2GW1 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMR2UGC DI DMR2UGC DMR2UGC DN BDBM50444062 DMR2UGC TI TTIEMFN DMR2UGC TN TYRO3 tyrosine kinase receptor (TYRO3) DMR2UGC MA Inhibitor DMR2UGC RN Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309. DMR2UGC RU http://www.freepatentsonline.com/US9649309.html DMR39ZY DI DMR39ZY DMR39ZY DN Chlorobenzamide derivative 1 DMR39ZY TI TT473XN DMR39ZY TN P2X purinoceptor 7 (P2RX7) DMR39ZY MA Antagonist DMR39ZY RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMR39ZY RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMR3AVK DI DMR3AVK DMR3AVK DN Dihydropyridine compound 3 DMR3AVK TI TT4DXQT DMR3AVK TN Proto-oncogene c-Ret (RET) DMR3AVK MA Inhibitor DMR3AVK RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMR3AVK RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMR3J9A DI DMR3J9A DMR3J9A DN PMID25684022-Compound-US20120277229 40(1.2) DMR3J9A TI TTCZOF2 DMR3J9A TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMR3J9A MA Inhibitor DMR3J9A RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMR3J9A RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMR3Z49 DI DMR3Z49 DMR3Z49 DN US9650366, 12 DMR3Z49 TI TTXEZJ4 DMR3Z49 TN Tyrosine-protein kinase EIF2AK2 (p68) DMR3Z49 MA Inhibitor DMR3Z49 RN Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366. DMR3Z49 RU http://www.freepatentsonline.com/US9650366.html DMR43JE DI DMR43JE DMR43JE DN PMID27841045-Compound-144 DMR43JE TI TT7RJY8 DMR43JE TN Xanthine dehydrogenase/oxidase (XDH) DMR43JE MA Inhibitor DMR43JE RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMR43JE RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMR4LPO DI DMR4LPO DMR4LPO DN Dihydrothieno [2,3-e]indazole derivative 4 DMR4LPO TI TTRPDBG DMR4LPO TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMR4LPO MA Inhibitor DMR4LPO RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMR4LPO RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMR4MSH DI DMR4MSH DMR4MSH DN PMID25684022-Compound-US20120277229 39(1.1) DMR4MSH TI TTCZOF2 DMR4MSH TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMR4MSH MA Inhibitor DMR4MSH RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMR4MSH RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMR4PQN DI DMR4PQN DMR4PQN DN Dihydropyrido phthalazinone derivative 2 DMR4PQN TI TTVDSZ0 DMR4PQN TN Poly [ADP-ribose] polymerase 1 (PARP1) DMR4PQN MA Inhibitor DMR4PQN RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMR4PQN RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMR58TX DI DMR58TX DMR58TX DN PMID28621580-Compound-WO2014079545C69 DMR58TX TI TTOHSBA DMR58TX TN Vascular endothelial growth factor A (VEGFA) DMR58TX MA Inhibitor DMR58TX RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMR58TX RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMR5O7T DI DMR5O7T DMR5O7T DN Pyrazolo[1,5-a]pyrimidine derivative 13 DMR5O7T TI TT6OEDT DMR5O7T TN Cannabinoid receptor 1 (CB1) DMR5O7T MA Antagonist DMR5O7T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMR5O7T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMR5V2A DI DMR5V2A DMR5V2A DN Benzo[d]oxazole derivative 2 DMR5V2A TI TTA6ZN2 DMR5V2A TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMR5V2A MA Inhibitor DMR5V2A RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMR5V2A RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMR63O2 DI DMR63O2 DMR63O2 DN PMID25666693-Compound-122 DMR63O2 TI TTMI6F5 DMR63O2 TN Transient receptor potential cation channel V1 (TRPV1) DMR63O2 MA Antagonist DMR63O2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMR63O2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMR648Z DI DMR648Z DMR648Z DN Aryl mannoside derivative 14 DMR648Z TI TTTCRU2 DMR648Z TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMR648Z MA Antagonist DMR648Z RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMR648Z RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMR6ODL DI DMR6ODL DMR6ODL DN US9475795, 89 DMR6ODL TI TTB9CIL DMR6ODL TN Prokineticin receptor-1 (PROKR1) DMR6ODL MA Inhibitor DMR6ODL RN Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases. US9475795. DMR6ODL RU http://www.freepatentsonline.com/US9475795.html DMR6P8T DI DMR6P8T DMR6P8T DN US9346821, B-13 DMR6P8T TI TTXL0GC DMR6P8T TN Enteropeptidase (TMPRSS15) DMR6P8T MA Inhibitor DMR6P8T RN Heterocyclic carboxylic acid ester derivative. US9346821. DMR6P8T RU http://www.freepatentsonline.com/US9346821.html DMR6QCE DI DMR6QCE DMR6QCE DN Pyrrolo-pyridone derivative 1 DMR6QCE TI TTRMX3V DMR6QCE TN Janus kinase 2 (JAK-2) DMR6QCE MA Inhibitor DMR6QCE RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMR6QCE RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMR6QCE DI DMR6QCE DMR6QCE DN Pyrrolo-pyridone derivative 1 DMR6QCE TI TT6DM01 DMR6QCE TN Janus kinase 1 (JAK-1) DMR6QCE MA Inhibitor DMR6QCE RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMR6QCE RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMR6VIG DI DMR6VIG DMR6VIG DN Pyrazole derivative 70 DMR6VIG TI TTJQOD7 DMR6VIG TN 5-HT 2A receptor (HTR2A) DMR6VIG MA Antagonist DMR6VIG RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMR6VIG RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMR6XF4 DI DMR6XF4 DMR6XF4 DN Benzothiazepine analog 10 DMR6XF4 TI TTRA6BO DMR6XF4 TN Bromodomain-containing protein 4 (BRD4) DMR6XF4 MA Inhibitor DMR6XF4 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMR6XF4 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMR6YAD DI DMR6YAD DMR6YAD DN N-alkyl-4-oxazolecar boxamide derivative 2 DMR6YAD TI TTDP1UC DMR6YAD TN Fatty acid amide hydrolase (FAAH) DMR6YAD MA Inhibitor DMR6YAD RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMR6YAD RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMR74ET DI DMR74ET DMR74ET DN Picolinamido propanoic acid derivative 2 DMR74ET TI TT9O6WS DMR74ET TN Glucagon receptor (GCGR) DMR74ET MA Antagonist DMR74ET RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMR74ET RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMR7A58 DI DMR7A58 DMR7A58 DN PMID25656651-Compound-26c DMR7A58 TI TTS7G69 DMR7A58 TN Fusion protein Bcr-Abl (Bcr-Abl) DMR7A58 MA Inhibitor DMR7A58 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMR7A58 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMR7MBY DI DMR7MBY DMR7MBY DN PMID27841045-Compound-143 DMR7MBY TI TT7RJY8 DMR7MBY TN Xanthine dehydrogenase/oxidase (XDH) DMR7MBY MA Inhibitor DMR7MBY RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMR7MBY RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMR7QKL DI DMR7QKL DMR7QKL DN 2,3-diamino-benzo[b]thiophene derivative 3 DMR7QKL TI TTXNCBV DMR7QKL TN Tryptophan 2,3-dioxygenase (TDO) DMR7QKL MA Inhibitor DMR7QKL RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMR7QKL RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMR7QKL DI DMR7QKL DMR7QKL DN 2,3-diamino-benzo[b]thiophene derivative 3 DMR7QKL TI TTZJYKH DMR7QKL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMR7QKL MA Inhibitor DMR7QKL RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMR7QKL RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMR7V9E DI DMR7V9E DMR7V9E DN PMID27828716-Compound-17 DMR7V9E TI TTRZQE3 DMR7V9E TN Glycogen synthase kinase-3 alpha (GSK-3A) DMR7V9E MA Inhibitor DMR7V9E RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMR7V9E RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMR8HSU DI DMR8HSU DMR8HSU DN PMID25726713-Compound-60 DMR8HSU TI TT8J1S3 DMR8HSU TN Smoothened homolog (SMO) DMR8HSU MA Inhibitor DMR8HSU RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMR8HSU RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMR8OVI DI DMR8OVI DMR8OVI DN PMID25726713-Compound-45 DMR8OVI TI TT8J1S3 DMR8OVI TN Smoothened homolog (SMO) DMR8OVI MA Inhibitor DMR8OVI RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMR8OVI RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMR9B2D DI DMR9B2D DMR9B2D DN PMID26004420-Compound-WO2012058116A DMR9B2D TI TTJ13ST DMR9B2D TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMR9B2D MA Inhibitor DMR9B2D RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMR9B2D RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMR9GLW DI DMR9GLW DMR9GLW DN PMID27215781-Compound-12 DMR9GLW TI TTMSFAW DMR9GLW TN Cannabinoid receptor 2 (CB2) DMR9GLW RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMR9GLW RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMR9IE5 DI DMR9IE5 DMR9IE5 DN EEC DMR9IE5 TI TTXLEG7 DMR9IE5 TN Matrix metalloproteinase-10 (MMP-10) DMR9IE5 MA Inhibitor DMR9IE5 RN Pseudodipeptides as MMP inhibitors. US8691753. DMR9IE5 RU http://www.freepatentsonline.com/US8691753.html DMRANS2 DI DMRANS2 DMRANS2 DN PMID28051882-Compound-Figure9 DMRANS2 TI TT9NXW4 DMRANS2 TN Sigma intracellular receptor 2 (TMEM97) DMRANS2 MA Ligand DMRANS2 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMRANS2 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMRAS8L DI DMRAS8L DMRAS8L DN Pyrazolopyrimidine acetamide analog 1 DMRAS8L TI TTPTXIN DMRAS8L TN Translocator protein (TSPO) DMRAS8L MA Ligand DMRAS8L RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMRAS8L RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMRAXD1 DI DMRAXD1 DMRAXD1 DN PMID26560530-Compound-7 DMRAXD1 TI TT2F4OL DMRAXD1 TN Tissue transglutaminase (TG2) DMRAXD1 MA Inhibitor DMRAXD1 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMRAXD1 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMRB7LI DI DMRB7LI DMRB7LI DN PMID30280939-Compound-WO2013119856 DMRB7LI TI TTOK0LR DMRB7LI TN Toll-like receptor (TLR) DMRB7LI MA Agonist DMRB7LI RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMRB7LI RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMRBFUA DI DMRBFUA DMRBFUA DN Z90308237 DMRBFUA TI TT3RMNA DMRBFUA TN Chymotrypsin-C (CLCR) DMRBFUA MA Inhibitor DMRBFUA RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DMRBFUA RU http://www.freepatentsonline.com/US9695194.html DMRBI5X DI DMRBI5X DMRBI5X DN Cyclohexyl azetidine derivative 1 DMRBI5X TI TT6DM01 DMRBI5X TN Janus kinase 1 (JAK-1) DMRBI5X MA Inhibitor DMRBI5X RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMRBI5X RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMRBYAV DI DMRBYAV DMRBYAV DN Diaryl amine derivative 2 DMRBYAV TI TT6R7JZ DMRBYAV TN Histone deacetylase 1 (HDAC1) DMRBYAV MA Inhibitor DMRBYAV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMRBYAV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMRBYAV DI DMRBYAV DMRBYAV DN Diaryl amine derivative 2 DMRBYAV TI TT5ZKDI DMRBYAV TN Histone deacetylase 6 (HDAC6) DMRBYAV MA Inhibitor DMRBYAV RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMRBYAV RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMRC4O7 DI DMRC4O7 DMRC4O7 DN US9598431, 3 DMRC4O7 TI TT1TYN7 DMRC4O7 TN Nuclear receptor ROR-alpha (RORA) DMRC4O7 MA Inhibitor DMRC4O7 RN Compounds useful for inhibiting ROR-gamma-t. US9598431. DMRC4O7 RU http://www.freepatentsonline.com/US9598431.html DMRCM1O DI DMRCM1O DMRCM1O DN PMID28447479-Compound-22 DMRCM1O TI TTSCIM2 DMRCM1O TN Extracellular lysophospholipase D (E-NPP2) DMRCM1O RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMRCM1O RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMRCPKV DI DMRCPKV DMRCPKV DN PMID25399762-Compound-Table1-C8 DMRCPKV TI TTGP7BY DMRCPKV TN Monoamine oxidase type B (MAO-B) DMRCPKV MA Inhibitor DMRCPKV RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMRCPKV RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMRD1XJ DI DMRD1XJ DMRD1XJ DN Tricyclic pyrrolidine derivative 2 DMRD1XJ TI TTWJBZ5 DMRD1XJ TN 5-HT 2C receptor (HTR2C) DMRD1XJ MA Agonist DMRD1XJ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMRD1XJ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMRDUS9 DI DMRDUS9 DMRDUS9 DN PMID26004420-Compound-WO2014015495A DMRDUS9 TI TTJ13ST DMRDUS9 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMRDUS9 MA Inhibitor DMRDUS9 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMRDUS9 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMRE2I3 DI DMRE2I3 DMRE2I3 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 1 DMRE2I3 TI TT1LVF2 DMRE2I3 TN Cyclin-dependent kinase 9 (CDK9) DMRE2I3 MA Inhibitor DMRE2I3 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRE2I3 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRE6GP DI DMRE6GP DMRE6GP DN PMID28092474-Compound-33 DMRE6GP TI TTBH0VX DMRE6GP TN Histone deacetylase (HDAC) DMRE6GP MA Inhibitor DMRE6GP RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMRE6GP RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMREZ9I DI DMREZ9I DMREZ9I DN PMID28270021-Compound-WO2016054807Example71 DMREZ9I TI TTTDVOJ DMREZ9I TN Tropomyosin-related kinase A (TrkA) DMREZ9I MA Inhibitor DMREZ9I RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMREZ9I RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMRF58Q DI DMRF58Q DMRF58Q DN Heteroaryl-cyclopropylamine derivative 1 DMRF58Q TI TTGP7BY DMRF58Q TN Monoamine oxidase type B (MAO-B) DMRF58Q MA Inhibitor DMRF58Q RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRF58Q RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRF58Q DI DMRF58Q DMRF58Q DN Heteroaryl-cyclopropylamine derivative 1 DMRF58Q TI TT3WG5C DMRF58Q TN Monoamine oxidase type A (MAO-A) DMRF58Q MA Inhibitor DMRF58Q RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRF58Q RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRF58Q DI DMRF58Q DMRF58Q DN Heteroaryl-cyclopropylamine derivative 1 DMRF58Q TI TTNR0UQ DMRF58Q TN Lysine-specific histone demethylase 1 (LSD) DMRF58Q MA Inhibitor DMRF58Q RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRF58Q RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRFEH4 DI DMRFEH4 DMRFEH4 DN Indoline derivative 15 DMRFEH4 TI TTOHSBA DMRFEH4 TN Vascular endothelial growth factor A (VEGFA) DMRFEH4 MA Inhibitor DMRFEH4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMRFEH4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMRFXMB DI DMRFXMB DMRFXMB DN 1,2-dihydroindazolo[4,3-bc][1,5]benzoxazepine derivative 1 DMRFXMB TI TTCZOF2 DMRFXMB TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMRFXMB MA Inhibitor DMRFXMB RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMRFXMB RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMRG1NL DI DMRG1NL DMRG1NL DN Atorvastatin lactole derivative 1 DMRG1NL TI TTPADOQ DMRG1NL TN HMG-CoA reductase (HMGCR) DMRG1NL MA Inhibitor DMRG1NL RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMRG1NL RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMRGOZ8 DI DMRGOZ8 DMRGOZ8 DN PMID25666693-Compound-92 DMRGOZ8 TI TTMI6F5 DMRGOZ8 TN Transient receptor potential cation channel V1 (TRPV1) DMRGOZ8 MA Antagonist DMRGOZ8 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMRGOZ8 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMRGV83 DI DMRGV83 DMRGV83 DN PMID29671355-Compound-22 DMRGV83 TI TT5ZKDI DMRGV83 TN Histone deacetylase 6 (HDAC6) DMRGV83 MA Inhibitor DMRGV83 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMRGV83 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMRGV83 DI DMRGV83 DMRGV83 DN PMID29671355-Compound-22 DMRGV83 TI TT6R7JZ DMRGV83 TN Histone deacetylase 1 (HDAC1) DMRGV83 MA Inhibitor DMRGV83 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMRGV83 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMRH2EJ DI DMRH2EJ DMRH2EJ DN Pyrazole derivative 34 DMRH2EJ TI TT6OEDT DMRH2EJ TN Cannabinoid receptor 1 (CB1) DMRH2EJ MA Antagonist DMRH2EJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMRH2EJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMRH7ZY DI DMRH7ZY DMRH7ZY DN PMID27967267-Compound-52 DMRH7ZY TI TT1RS9F DMRH7ZY TN Acetylcholinesterase (AChE) DMRH7ZY MA Reactivator DMRH7ZY RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMRH7ZY RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMRHAU4 DI DMRHAU4 DMRHAU4 DN Pyrido[3,2-d]pyrimidine derivative 2 DMRHAU4 TI TTTDVOJ DMRHAU4 TN Tropomyosin-related kinase A (TrkA) DMRHAU4 MA Inhibitor DMRHAU4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMRHAU4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMRHBLD DI DMRHBLD DMRHBLD DN Isoquinoline derivative 2 DMRHBLD TI TTMSFAW DMRHBLD TN Cannabinoid receptor 2 (CB2) DMRHBLD RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMRHBLD RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMRHNIL DI DMRHNIL DMRHNIL DN US8759338, 1 DMRHNIL TI TTCGOIN DMRHNIL TN PIM-3 protein kinase (PIM3) DMRHNIL MA Inhibitor DMRHNIL RN Heterocyclic kinase inhibitors. US8759338. DMRHNIL RU http://www.freepatentsonline.com/US8759338.html DMRHNOY DI DMRHNOY DMRHNOY DN PMID25399762-Compound-Figure1-Chukrasone A DMRHNOY TI TT3WG5C DMRHNOY TN Monoamine oxidase type A (MAO-A) DMRHNOY MA Inhibitor DMRHNOY RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMRHNOY RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMRHPN0 DI DMRHPN0 DMRHPN0 DN PMID29053063-Compound-17 DMRHPN0 TI TTZ963I DMRHPN0 TN Monoglyceride lipase (MAGL) DMRHPN0 MA Inhibitor DMRHPN0 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMRHPN0 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMRHQLF DI DMRHQLF DMRHQLF DN US10179791, Compound 176 DMRHQLF TI TTDYP7I DMRHQLF TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMRHQLF MA Inhibitor DMRHQLF RN Spiro-cyclic amine derivatives as S1P modulators. US10179791. DMRHQLF RU http://www.freepatentsonline.com/US10179791.html DMRHVWA DI DMRHVWA DMRHVWA DN N6-cyclopropyllydine derivative 1 DMRHVWA TI TTNR0UQ DMRHVWA TN Lysine-specific histone demethylase 1 (LSD) DMRHVWA MA Inhibitor DMRHVWA RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRHVWA RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRHZF3 DI DMRHZF3 DMRHZF3 DN PMID27774822-Compound-Figure8Example5 DMRHZF3 TI TTRMX3V DMRHZF3 TN Janus kinase 2 (JAK-2) DMRHZF3 MA Inhibitor DMRHZF3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMRHZF3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMRHZF3 DI DMRHZF3 DMRHZF3 DN PMID27774822-Compound-Figure8Example5 DMRHZF3 TI TTT7PJU DMRHZF3 TN Janus kinase 3 (JAK-3) DMRHZF3 MA Inhibitor DMRHZF3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMRHZF3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMRIEH3 DI DMRIEH3 DMRIEH3 DN PMID25399762-Compound-Figure1-Sarcaboside A DMRIEH3 TI TT3WG5C DMRIEH3 TN Monoamine oxidase type A (MAO-A) DMRIEH3 MA Inhibitor DMRIEH3 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMRIEH3 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMRIPVG DI DMRIPVG DMRIPVG DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 8 DMRIPVG TI TTULVH8 DMRIPVG TN Tyrosinase (TYR) DMRIPVG MA Inhibitor DMRIPVG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMRIPVG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMRIWKV DI DMRIWKV DMRIWKV DN PMID26161698-Compound-32 DMRIWKV TI TT1LVF2 DMRIWKV TN Cyclin-dependent kinase 9 (CDK9) DMRIWKV MA Inhibitor DMRIWKV RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRIWKV RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRJ1KY DI DMRJ1KY DMRJ1KY DN PMID25991433-Compound-G5 DMRJ1KY TI TT0K6EO DMRJ1KY TN Stress-activated protein kinase JNK1 (JNK1) DMRJ1KY MA Inhibitor DMRJ1KY RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMRJ1KY RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMRJ30G DI DMRJ30G DMRJ30G DN PMID25522065-Compound-10 DMRJ30G TI TTX4RTB DMRJ30G TN Melanin-concentrating hormone receptor 1 (MCHR1) DMRJ30G MA Antagonist DMRJ30G RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMRJ30G RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMRJKIQ DI DMRJKIQ DMRJKIQ DN Imidazoleisoindoles derivative 2 DMRJKIQ TI TTZJYKH DMRJKIQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMRJKIQ MA Inhibitor DMRJKIQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMRJKIQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMRK1W7 DI DMRK1W7 DMRK1W7 DN PMID25666693-Compound-17 DMRK1W7 TI TTMI6F5 DMRK1W7 TN Transient receptor potential cation channel V1 (TRPV1) DMRK1W7 MA Antagonist DMRK1W7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMRK1W7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMRK4AT DI DMRK4AT DMRK4AT DN Triazole derivative 7 DMRK4AT TI TTSCIUP DMRK4AT TN Oxytocin receptor (OTR) DMRK4AT MA Antagonist DMRK4AT RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMRK4AT RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMRK4IE DI DMRK4IE DMRK4IE DN Aryl piperazine derivative 15 DMRK4IE TI TTWT5K7 DMRK4IE TN 5-HT 1 receptor (5HT1R) DMRK4IE MA Agonist DMRK4IE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMRK4IE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMRK4IE DI DMRK4IE DMRK4IE DN Aryl piperazine derivative 15 DMRK4IE TI TTSQIFT DMRK4IE TN 5-HT 1A receptor (HTR1A) DMRK4IE MA Agonist DMRK4IE RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMRK4IE RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMRKIA1 DI DMRKIA1 DMRKIA1 DN PMID29338548-Compound-46 DMRKIA1 TI TTHJTF7 DMRKIA1 TN Glycine transporter GlyT-1 (SLC6A9) DMRKIA1 MA Inhibitor DMRKIA1 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMRKIA1 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMRKLTE DI DMRKLTE DMRKLTE DN PMID30107136-Compound-Example4 DMRKLTE TI TT23XQV DMRKLTE TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMRKLTE MA Inhibitor DMRKLTE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMRKLTE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMRKVP9 DI DMRKVP9 DMRKVP9 DN Pyrazolo[3,4-d]pyrimidine derivative 3 DMRKVP9 TI TTJGW1Z DMRKVP9 TN Phosphodiesterase 2A (PDE2A) DMRKVP9 MA Inhibitor DMRKVP9 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMRKVP9 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMRKWPQ DI DMRKWPQ DMRKWPQ DN PMID29473428-Compound-60 DMRKWPQ TI TTZJYKH DMRKWPQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMRKWPQ MA Inhibitor DMRKWPQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMRKWPQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMRL0WA DI DMRL0WA DMRL0WA DN US9340511, 6 DMRL0WA TI TT9ISBX DMRL0WA TN HIF-prolyl hydroxylase 2 (HPH-2) DMRL0WA MA Inhibitor DMRL0WA RN Process for making isoquinoline compounds. US9340511. DMRL0WA RU http://www.freepatentsonline.com/US9340511.html DMRLC4X DI DMRLC4X DMRLC4X DN Urea and carbamate bioisostere derivative 16 DMRLC4X TI TTL7C8Q DMRLC4X TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMRLC4X MA Inhibitor DMRLC4X RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMRLC4X RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMRLE65 DI DMRLE65 DMRLE65 DN C-linked disaccharide biphenyl mannoside derivative 4 DMRLE65 TI TTTCRU2 DMRLE65 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRLE65 MA Antagonist DMRLE65 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRLE65 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRLSKV DI DMRLSKV DMRLSKV DN PMID28766366-Compound-Scheme23MPPDerivatives DMRLSKV TI TTSBVFO DMRLSKV TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMRLSKV MA Inhibitor DMRLSKV RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMRLSKV RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMRLU8I DI DMRLU8I DMRLU8I DN PMID28627961-Compound-30 DMRLU8I TI TTYLQ8V DMRLU8I TN Prostaglandin E synthase (PTGES) DMRLU8I MA Inhibitor DMRLU8I RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMRLU8I RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMRLWP9 DI DMRLWP9 DMRLWP9 DN PMID27019002-Compound-47 DMRLWP9 TI TTNR0UQ DMRLWP9 TN Lysine-specific histone demethylase 1 (LSD) DMRLWP9 MA Inhibitor DMRLWP9 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRLWP9 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRLWP9 DI DMRLWP9 DMRLWP9 DN PMID27019002-Compound-47 DMRLWP9 TI TT8VP2T DMRLWP9 TN Lysine-specific histone demethylase 1B (KDM1B) DMRLWP9 MA Inhibitor DMRLWP9 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRLWP9 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRLWZI DI DMRLWZI DMRLWZI DN Palmarumycin derivative 2 DMRLWZI TI TTR7UJ3 DMRLWZI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMRLWZI MA Inhibitor DMRLWZI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMRLWZI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMRLZD2 DI DMRLZD2 DMRLZD2 DN PMID25772215-Compound-US02014179750TG6-129 DMRLZD2 TI TT1ZAVI DMRLZD2 TN Prostaglandin E2 receptor EP2 (PTGER2) DMRLZD2 MA Antagonist DMRLZD2 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMRLZD2 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMRM3E9 DI DMRM3E9 DMRM3E9 DN Biaryl mannoside derivative 25 DMRM3E9 TI TTTCRU2 DMRM3E9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRM3E9 MA Antagonist DMRM3E9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRM3E9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRM5I1 DI DMRM5I1 DMRM5I1 DN Dibenzo [c,f]-[2,7]naphthyridine derivative 1 DMRM5I1 TI TTCZOF2 DMRM5I1 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMRM5I1 MA Inhibitor DMRM5I1 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMRM5I1 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMRMED4 DI DMRMED4 DMRMED4 DN Azetidine-benzoxazin-3(4H)-one derivative 1 DMRMED4 TI TTZ963I DMRMED4 TN Monoglyceride lipase (MAGL) DMRMED4 MA Inhibitor DMRMED4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMRMED4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMRML9B DI DMRML9B DMRML9B DN Isoxazoles and isoxazoline derivative 1 DMRML9B TI TTIY56R DMRML9B TN Kynurenine 3-hydroxylase (KMO) DMRML9B MA Inhibitor DMRML9B RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMRML9B RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMRMTF6 DI DMRMTF6 DMRMTF6 DN Tetra-hydro-pyrazolopyrazine derivative 4 DMRMTF6 TI TTHS256 DMRMTF6 TN Metabotropic glutamate receptor 5 (mGluR5) DMRMTF6 MA Modulator DMRMTF6 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMRMTF6 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMRN2QI DI DMRN2QI DMRN2QI DN Pyrazolodiazepine derivative 1 DMRN2QI TI TT2F4OL DMRN2QI TN Tissue transglutaminase (TG2) DMRN2QI MA Inhibitor DMRN2QI RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMRN2QI RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMRN5F4 DI DMRN5F4 DMRN5F4 DN US8933095, 16 DMRN5F4 TI TTT3IXG DMRN5F4 TN Kynurenine oxoglutarate transaminase II (AADAT) DMRN5F4 MA Inhibitor DMRN5F4 RN KAT II inhibitors. US8933095. DMRN5F4 RU http://www.freepatentsonline.com/US8933095.html DMRNBP3 DI DMRNBP3 DMRNBP3 DN PMID27539678-Compound-3 DMRNBP3 TI TT3M2WO DMRNBP3 TN Sphingosine kinase (SphK) DMRNBP3 MA Inhibitor DMRNBP3 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMRNBP3 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMRPD8U DI DMRPD8U DMRPD8U DN US8524917, 60 DMRPD8U TI TTDYP7I DMRPD8U TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMRPD8U MA Inhibitor DMRPD8U RN 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity. US8524917. DMRPD8U RU http://www.freepatentsonline.com/US8524917.html DMRPJBF DI DMRPJBF DMRPJBF DN PMID30273516-Compound-38 DMRPJBF TI TTCW0KX DMRPJBF TN Glutaminase (GLS) DMRPJBF MA Inhibitor DMRPJBF RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMRPJBF RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMRPT5O DI DMRPT5O DMRPT5O DN Indazole amide derivative 2 DMRPT5O TI TTKFVXR DMRPT5O TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMRPT5O MA Inhibitor DMRPT5O RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMRPT5O RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMRQ1ZB DI DMRQ1ZB DMRQ1ZB DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 6 DMRQ1ZB TI TTV8CRH DMRQ1ZB TN Lysine-specific demethylase 4C (KDM4C) DMRQ1ZB MA Inhibitor DMRQ1ZB RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMRQ1ZB RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMRQ2G4 DI DMRQ2G4 DMRQ2G4 DN US9359293, TB DMRQ2G4 TI TTLKF5M DMRQ2G4 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMRQ2G4 MA Inhibitor DMRQ2G4 RN Methods of treatment using modulators of SIRT2. US9359293. DMRQ2G4 RU http://www.freepatentsonline.com/US9359293.html DMRQ74I DI DMRQ74I DMRQ74I DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 3 DMRQ74I TI TTVDSZ0 DMRQ74I TN Poly [ADP-ribose] polymerase 1 (PARP1) DMRQ74I MA Inhibitor DMRQ74I RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMRQ74I RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMRQHDF DI DMRQHDF DMRQHDF DN PMID27109571-Compound-38 DMRQHDF TI TTMY6L1 DMRQHDF TN Fatty acid-binding protein (FABP) DMRQHDF MA Inhibitor DMRQHDF RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMRQHDF RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMRS1WG DI DMRS1WG DMRS1WG DN Biaryl mannoside derivative 5 DMRS1WG TI TTTCRU2 DMRS1WG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRS1WG MA Antagonist DMRS1WG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRS1WG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRSCJ7 DI DMRSCJ7 DMRSCJ7 DN Piperazinyl norbenzomorphane compound 4 DMRSCJ7 TI TT9NXW4 DMRSCJ7 TN Sigma intracellular receptor 2 (TMEM97) DMRSCJ7 MA Ligand DMRSCJ7 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMRSCJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMRSP2M DI DMRSP2M DMRSP2M DN US8614253, 32-4 DMRSP2M TI TTOJ9QL DMRSP2M TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMRSP2M MA Inhibitor DMRSP2M RN IRE-1 inhibitors. US9493435. DMRSP2M RU http://www.freepatentsonline.com/US9493435.html DMRT7I8 DI DMRT7I8 DMRT7I8 DN Pyrazoline derivative 4 DMRT7I8 TI TT6OEDT DMRT7I8 TN Cannabinoid receptor 1 (CB1) DMRT7I8 MA Antagonist DMRT7I8 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMRT7I8 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMRTBKC DI DMRTBKC DMRTBKC DN PMID29338548-Compound-21 DMRTBKC TI TTHJTF7 DMRTBKC TN Glycine transporter GlyT-1 (SLC6A9) DMRTBKC MA Inhibitor DMRTBKC RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMRTBKC RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMRTDOA DI DMRTDOA DMRTDOA DN 2,2-bipyridyl derivative 1 DMRTDOA TI TT0RGE9 DMRTDOA TN Lysine-specific demethylase 4 (KDM4) DMRTDOA MA Inhibitor DMRTDOA RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMRTDOA RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMRTJSC DI DMRTJSC DMRTJSC DN Urea and carbamate bioisostere derivative 2 DMRTJSC TI TTL7C8Q DMRTJSC TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMRTJSC MA Inhibitor DMRTJSC RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMRTJSC RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMRTL63 DI DMRTL63 DMRTL63 DN US8536181, C17 DMRTL63 TI TT9ISBX DMRTL63 TN HIF-prolyl hydroxylase 2 (HPH-2) DMRTL63 MA Inhibitor DMRTL63 RN Methods for increasing the stabilization of hypoxia inducible factor-1 alpha. US8778412. DMRTL63 RU http://www.freepatentsonline.com/US8778412.html DMRTQ4I DI DMRTQ4I DMRTQ4I DN PMID29865878-Compound-44 DMRTQ4I TI TT68GPI DMRTQ4I TN Proteasome beta-5 (PS beta-5) DMRTQ4I MA Inhibitor DMRTQ4I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMRTQ4I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMRTQ4I DI DMRTQ4I DMRTQ4I DN PMID29865878-Compound-44 DMRTQ4I TI TTEAD9J DMRTQ4I TN Proteasome beta-8 (PS beta-8) DMRTQ4I MA Inhibitor DMRTQ4I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMRTQ4I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMRTZC4 DI DMRTZC4 DMRTZC4 DN PMID25772215-Compound-US02014179750TG7-76 DMRTZC4 TI TT1ZAVI DMRTZC4 TN Prostaglandin E2 receptor EP2 (PTGER2) DMRTZC4 MA Antagonist DMRTZC4 RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMRTZC4 RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMRTZE4 DI DMRTZE4 DMRTZE4 DN Antibodie derivative 5 DMRTZE4 TI TTOUZN5 DMRTZE4 TN Gremlin-1 (Gremlin-1) DMRTZE4 MA Inhibitor DMRTZE4 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMRTZE4 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMRU0BL DI DMRU0BL DMRU0BL DN PMID27215781-Compound-4 DMRU0BL TI TTMSFAW DMRU0BL TN Cannabinoid receptor 2 (CB2) DMRU0BL MA Agonist DMRU0BL RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMRU0BL RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMRUCK8 DI DMRUCK8 DMRUCK8 DN Golden phosphorous acetyletic compound 3 DMRUCK8 TI TTR7UJ3 DMRUCK8 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMRUCK8 MA Inhibitor DMRUCK8 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMRUCK8 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMRUTJZ DI DMRUTJZ DMRUTJZ DN US8846654, 11 DMRUTJZ TI TTIS4OW DMRUTJZ TN Phosphodiesterase 8 (PDE8) DMRUTJZ MA Inhibitor DMRUTJZ RN Therapeutic applications in the cardiovascular field of quinazolinedione derivatives. US8846654. DMRUTJZ RU http://www.freepatentsonline.com/US8846654.html DMRVE7Z DI DMRVE7Z DMRVE7Z DN PMID25553724-Compound-US20138552206 5 DMRVE7Z TI TTSXVID DMRVE7Z TN Nuclear factor NF-kappa-B (NFKB) DMRVE7Z MA Inhibitor DMRVE7Z RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMRVE7Z RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMRVIPL DI DMRVIPL DMRVIPL DN Aryl mannoside derivative 11 DMRVIPL TI TTTCRU2 DMRVIPL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMRVIPL MA Antagonist DMRVIPL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMRVIPL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMRVQ5Z DI DMRVQ5Z DMRVQ5Z DN US9598431, 1 DMRVQ5Z TI TTGB2LZ DMRVQ5Z TN RAR-related orphan receptor-beta (RORB) DMRVQ5Z MA Inhibitor DMRVQ5Z RN Compounds useful for inhibiting ROR-gamma-t. US9598431. DMRVQ5Z RU http://www.freepatentsonline.com/US9598431.html DMRWG2E DI DMRWG2E DMRWG2E DN Pyrrolo[2,3-d]pyrimidine derivative 10 DMRWG2E TI TTH6V3D DMRWG2E TN Cyclin-dependent kinase 1 (CDK1) DMRWG2E MA Inhibitor DMRWG2E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRWG2E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRWG2E DI DMRWG2E DMRWG2E DN Pyrrolo[2,3-d]pyrimidine derivative 10 DMRWG2E TI TT0PG8F DMRWG2E TN Cyclin-dependent kinase 4 (CDK4) DMRWG2E MA Inhibitor DMRWG2E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMRWG2E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMRWGHN DI DMRWGHN DMRWGHN DN PMID27019002-Compound-31a DMRWGHN TI TTNR0UQ DMRWGHN TN Lysine-specific histone demethylase 1 (LSD) DMRWGHN MA Inhibitor DMRWGHN RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRWGHN RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRWNAY DI DMRWNAY DMRWNAY DN Monoamine derivative 1 DMRWNAY TI TTULVH8 DMRWNAY TN Tyrosinase (TYR) DMRWNAY MA Inhibitor DMRWNAY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMRWNAY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMRX748 DI DMRX748 DMRX748 DN PMID27019002-Compound-20a DMRX748 TI TTNR0UQ DMRX748 TN Lysine-specific histone demethylase 1 (LSD) DMRX748 MA Inhibitor DMRX748 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRX748 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRX748 DI DMRX748 DMRX748 DN PMID27019002-Compound-20a DMRX748 TI TT32XQJ DMRX748 TN Monoamine oxidase (MAO) DMRX748 MA Inhibitor DMRX748 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMRX748 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMRXCYF DI DMRXCYF DMRXCYF DN US9586942, 3* DMRXCYF TI TTYJRN5 DMRXCYF TN N-acetylglucosaminyltransferase I (NAGAT1) DMRXCYF MA Inhibitor DMRXCYF RN Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942. DMRXCYF RU http://www.freepatentsonline.com/US9586942.html DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TT36ETB DMRXKJZ TN Cathepsin L (CTSL) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TTUMQVO DMRXKJZ TN Cathepsin S (CTSS) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TTG5QB7 DMRXKJZ TN Calpain-2 (CAPN2) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXKJZ DI DMRXKJZ DMRXKJZ DN PMID25399719-Compound-17 DMRXKJZ TI TTDZN01 DMRXKJZ TN Cathepsin K (CTSK) DMRXKJZ MA Inhibitor DMRXKJZ RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMRXKJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMRXMCH DI DMRXMCH DMRXMCH DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 10 DMRXMCH TI TTULVH8 DMRXMCH TN Tyrosinase (TYR) DMRXMCH MA Inhibitor DMRXMCH RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMRXMCH RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMRXN94 DI DMRXN94 DMRXN94 DN Aromatic bicyclic compound 3 DMRXN94 TI TTRMX3V DMRXN94 TN Janus kinase 2 (JAK-2) DMRXN94 MA Inhibitor DMRXN94 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMRXN94 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMRXN94 DI DMRXN94 DMRXN94 DN Aromatic bicyclic compound 3 DMRXN94 TI TT6PKBN DMRXN94 TN Proto-oncogene c-Src (SRC) DMRXN94 MA Inhibitor DMRXN94 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMRXN94 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMRY2HL DI DMRY2HL DMRY2HL DN Quinoline derivative 1 DMRY2HL TI TTPADOQ DMRY2HL TN HMG-CoA reductase (HMGCR) DMRY2HL MA Inhibitor DMRY2HL RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMRY2HL RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMRY7KV DI DMRY7KV DMRY7KV DN KRDULPYOVRWKMA-UHFFFAOYSA-N DMRY7KV TI TTIEMFN DMRY7KV TN TYRO3 tyrosine kinase receptor (TYRO3) DMRY7KV MA Inhibitor DMRY7KV RN Pyrrolopyrimidine derivatives as TAM inhibitors. US10053465. DMRY7KV RU http://www.freepatentsonline.com/US10053465.html DMRZELF DI DMRZELF DMRZELF DN Benzimidazolone acetamide derivative 1 DMRZELF TI TTPTXIN DMRZELF TN Translocator protein (TSPO) DMRZELF MA Ligand DMRZELF RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMRZELF RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMRZMH5 DI DMRZMH5 DMRZMH5 DN PMID25522065-Compound-21 DMRZMH5 TI TTX4RTB DMRZMH5 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMRZMH5 MA Antagonist DMRZMH5 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMRZMH5 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMS0169 DI DMS0169 DMS0169 DN Indole and benzimidazole derivative 1 DMS0169 TI TTN9T81 DMS0169 TN Arachidonate 15-lipoxygenase (15-LOX) DMS0169 RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMS0169 RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMS0EMU DI DMS0EMU DMS0EMU DN BDBM50444059 DMS0EMU TI TTIEMFN DMS0EMU TN TYRO3 tyrosine kinase receptor (TYRO3) DMS0EMU MA Inhibitor DMS0EMU RN Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity. US9649309. DMS0EMU RU http://www.freepatentsonline.com/US9649309.html DMS0P9E DI DMS0P9E DMS0P9E DN Five-membered heteroaromatic compound 3 DMS0P9E TI TTZJYKH DMS0P9E TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMS0P9E MA Inhibitor DMS0P9E RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMS0P9E RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMS103B DI DMS103B DMS103B DN PMID28092474-Compound-32s DMS103B TI TT6R7JZ DMS103B TN Histone deacetylase 1 (HDAC1) DMS103B MA Inhibitor DMS103B RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMS103B RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMS103B DI DMS103B DMS103B DN PMID28092474-Compound-32s DMS103B TI TT5ZKDI DMS103B TN Histone deacetylase 6 (HDAC6) DMS103B MA Inhibitor DMS103B RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMS103B RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMS1FKC DI DMS1FKC DMS1FKC DN PMID25522065-Compound-43 DMS1FKC TI TTX4RTB DMS1FKC TN Melanin-concentrating hormone receptor 1 (MCHR1) DMS1FKC MA Antagonist DMS1FKC RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMS1FKC RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMS1GJD DI DMS1GJD DMS1GJD DN Tetra-cyclic compound 1 DMS1GJD TI TTJSQEF DMS1GJD TN Tyrosine-protein kinase (PTK) DMS1GJD MA Inhibitor DMS1GJD RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMS1GJD RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMS1O0G DI DMS1O0G DMS1O0G DN 4-pyridone derivative 2 DMS1O0G TI TTPLTSQ DMS1O0G TN Neutrophil elastase (NE) DMS1O0G MA Inhibitor DMS1O0G RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMS1O0G RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMS1TOX DI DMS1TOX DMS1TOX DN Quinoline derivative 5 DMS1TOX TI TTXJ47W DMS1TOX TN Metabotropic glutamate receptor 2 (mGluR2) DMS1TOX MA Antagonist DMS1TOX RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMS1TOX RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMS3CDT DI DMS3CDT DMS3CDT DN Isoxazole-based bicyclic compound 14 DMS3CDT TI TTE4BSY DMS3CDT TN Bromodomain and extraterminal domain protein (BET) DMS3CDT MA Inhibitor DMS3CDT RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMS3CDT RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMS3PRT DI DMS3PRT DMS3PRT DN Quinoxaline derivative 4 DMS3PRT TI TTSXVID DMS3PRT TN Nuclear factor NF-kappa-B (NFKB) DMS3PRT MA Inhibitor DMS3PRT RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMS3PRT RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMS3ROL DI DMS3ROL DMS3ROL DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 DMS3ROL TI TTJW4LU DMS3ROL TN Phosphodiesterase 10A (PDE10) DMS3ROL MA Inhibitor DMS3ROL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMS3ROL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMS3ROL DI DMS3ROL DMS3ROL DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2 DMS3ROL TI TTJGW1Z DMS3ROL TN Phosphodiesterase 2A (PDE2A) DMS3ROL MA Inhibitor DMS3ROL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMS3ROL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMS3WEJ DI DMS3WEJ DMS3WEJ DN Heteroaryl-azepine derivative 15 DMS3WEJ TI TTWJBZ5 DMS3WEJ TN 5-HT 2C receptor (HTR2C) DMS3WEJ MA Agonist DMS3WEJ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMS3WEJ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMS3YPJ DI DMS3YPJ DMS3YPJ DN Tetra/penta-cyclic pyridophthalazinone derivative 1 DMS3YPJ TI TTEBCY8 DMS3YPJ TN Poly [ADP-ribose] polymerase (PARP) DMS3YPJ MA Inhibitor DMS3YPJ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMS3YPJ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMS415A DI DMS415A DMS415A DN US10149841, Compound 9 DMS415A TI TT9ISBX DMS415A TN HIF-prolyl hydroxylase 2 (HPH-2) DMS415A MA Inhibitor DMS415A RN Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841. DMS415A RU http://www.freepatentsonline.com/US10149841.html DMS42KH DI DMS42KH DMS42KH DN PMID30107136-Compound-Example7 DMS42KH TI TT23XQV DMS42KH TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMS42KH MA Inhibitor DMS42KH RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS42KH RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS4I6B DI DMS4I6B DMS4I6B DN Pyrrolo-benzo-diazine derivative 1 DMS4I6B TI TT4G2JS DMS4I6B TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMS4I6B MA Blocker DMS4I6B RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMS4I6B RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMS4RLZ DI DMS4RLZ DMS4RLZ DN PMID26882240-Compound-4 DMS4RLZ TI TTUX68I DMS4RLZ TN Hypoxia-inducible factor 1 (HIF-1) DMS4RLZ MA Inhibitor DMS4RLZ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMS4RLZ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMS527F DI DMS527F DMS527F DN Benzamide derivative 12 DMS527F TI TT473XN DMS527F TN P2X purinoceptor 7 (P2RX7) DMS527F MA Antagonist DMS527F RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMS527F RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMS5896 DI DMS5896 DMS5896 DN PMID25980951-Compound-44 DMS5896 TI TTIRY6K DMS5896 TN Cellular inhibitor of apoptosis 2 (BIRC3) DMS5896 MA Antagonist DMS5896 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMS5896 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMS5896 DI DMS5896 DMS5896 DN PMID25980951-Compound-44 DMS5896 TI TTQ5LRD DMS5896 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMS5896 MA Antagonist DMS5896 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMS5896 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMS5896 DI DMS5896 DMS5896 DN PMID25980951-Compound-44 DMS5896 TI TTR7B60 DMS5896 TN X-linked inhibitor of apoptosis protein (XIAP) DMS5896 MA Antagonist DMS5896 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMS5896 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMS5EHL DI DMS5EHL DMS5EHL DN 1-phenyl-1,3,4-triazole derivative 1 DMS5EHL TI TTA6ZN2 DMS5EHL TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMS5EHL MA Inhibitor DMS5EHL RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMS5EHL RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMS5EHL DI DMS5EHL DMS5EHL DN 1-phenyl-1,3,4-triazole derivative 1 DMS5EHL TI TT956B0 DMS5EHL TN Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) DMS5EHL MA Modulator DMS5EHL RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMS5EHL RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMS5UFX DI DMS5UFX DMS5UFX DN Biphenyl mannoside derivative 1 DMS5UFX TI TTTCRU2 DMS5UFX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMS5UFX MA Antagonist DMS5UFX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMS5UFX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMS65IT DI DMS65IT DMS65IT DN Macrocyclic peptide analog 1 DMS65IT TI TT23XQV DMS65IT TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMS65IT MA Inhibitor DMS65IT RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS65IT RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS68DP DI DMS68DP DMS68DP DN Cyclohexyl carbamate derivative 5 DMS68DP TI TTULVH8 DMS68DP TN Tyrosinase (TYR) DMS68DP MA Inhibitor DMS68DP RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMS68DP RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMS6EDU DI DMS6EDU DMS6EDU DN PMID26394986-Compound-53 DMS6EDU TI TTH8FZW DMS6EDU TN Signal transducer and activator of transcription 3 (STAT3) DMS6EDU MA Inhibitor DMS6EDU RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMS6EDU RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMS6HOG DI DMS6HOG DMS6HOG DN Heteroaryl-azepine derivative 7 DMS6HOG TI TTWJBZ5 DMS6HOG TN 5-HT 2C receptor (HTR2C) DMS6HOG MA Agonist DMS6HOG RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMS6HOG RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMS6UD2 DI DMS6UD2 DMS6UD2 DN PMID29649907-Compound-40 DMS6UD2 TI TTS4UGC DMS6UD2 TN Farnesoid X-activated receptor (FXR) DMS6UD2 MA Agonist DMS6UD2 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMS6UD2 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMS6XT4 DI DMS6XT4 DMS6XT4 DN Tricyclic indole compound 13 DMS6XT4 TI TTVDSZ0 DMS6XT4 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMS6XT4 MA Inhibitor DMS6XT4 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMS6XT4 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMS7RYP DI DMS7RYP DMS7RYP DN PMID25553724-Compound-US2012819831110 DMS7RYP TI TTSXVID DMS7RYP TN Nuclear factor NF-kappa-B (NFKB) DMS7RYP MA Inhibitor DMS7RYP RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMS7RYP RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMS7ZLK DI DMS7ZLK DMS7ZLK DN BDBM50158703 DMS7ZLK TI TTIG67W DMS7ZLK TN Lysine-specific demethylase 5A (KDM5A) DMS7ZLK MA Inhibitor DMS7ZLK RN Histone demethylase inhibitors. US9714230. DMS7ZLK RU http://www.freepatentsonline.com/US9714230.html DMS842X DI DMS842X DMS842X DN US9434725, 113 DMS842X TI TTCGOIN DMS842X TN PIM-3 protein kinase (PIM3) DMS842X MA Inhibitor DMS842X RN 5-azaindazole compounds and methods of use. US9434725. DMS842X RU http://www.freepatentsonline.com/US9434725.html DMS8GIU DI DMS8GIU DMS8GIU DN Imidazo bicyclic iminium derivative 5 DMS8GIU TI TT8J1S3 DMS8GIU TN Smoothened homolog (SMO) DMS8GIU MA Inhibitor DMS8GIU RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMS8GIU RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMS8KMB DI DMS8KMB DMS8KMB DN Indoline derivative 8 DMS8KMB TI TT5OU0D DMS8KMB TN PRKR-like endoplasmic reticulum kinase (PERK) DMS8KMB MA Inhibitor DMS8KMB RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMS8KMB RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMS8NFJ DI DMS8NFJ DMS8NFJ DN Piperidinyl pyrazole derivative 4 DMS8NFJ TI TTTJZ4M DMS8NFJ TN Prolylcarboxypeptidase (PRCP) DMS8NFJ MA Inhibitor DMS8NFJ RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMS8NFJ RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMS8OR3 DI DMS8OR3 DMS8OR3 DN Pyrimidine derivative 2 DMS8OR3 TI TTYLQ8V DMS8OR3 TN Prostaglandin E synthase (PTGES) DMS8OR3 MA Inhibitor DMS8OR3 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMS8OR3 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMS8OTG DI DMS8OTG DMS8OTG DN PMID28117607-Compound-21 DMS8OTG TI TTK0FEA DMS8OTG TN Leucine-rich repeat kinase 2 (LRRK2) DMS8OTG MA Inhibitor DMS8OTG RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMS8OTG RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMS8VYE DI DMS8VYE DMS8VYE DN Biaryl compound 2 DMS8VYE TI TT23XQV DMS8VYE TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMS8VYE MA Inhibitor DMS8VYE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS8VYE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS8VYE DI DMS8VYE DMS8VYE DN Biaryl compound 2 DMS8VYE TI TT5YPJF DMS8VYE TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMS8VYE MA Inhibitor DMS8VYE RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMS8VYE RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMS9KCF DI DMS9KCF DMS9KCF DN PMID26077642-Compound-Vif1 DMS9KCF TI TTXU3EQ DMS9KCF TN Herpesvirus ubiquitin-specific protease (HAUSP) DMS9KCF MA Inhibitor DMS9KCF RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMS9KCF RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMS9O6I DI DMS9O6I DMS9O6I DN Peptide analog 31 DMS9O6I TI TT68GPI DMS9O6I TN Proteasome beta-5 (PS beta-5) DMS9O6I MA Inhibitor DMS9O6I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMS9O6I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMS9O6I DI DMS9O6I DMS9O6I DN Peptide analog 31 DMS9O6I TI TTEAD9J DMS9O6I TN Proteasome beta-8 (PS beta-8) DMS9O6I MA Inhibitor DMS9O6I RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMS9O6I RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMS9Q3U DI DMS9Q3U DMS9Q3U DN PMID29334795-Compound-56 DMS9Q3U TI TT9JNIC DMS9Q3U TN Histamine H3 receptor (H3R) DMS9Q3U RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMS9Q3U RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMS9QA7 DI DMS9QA7 DMS9QA7 DN PMID27998201-Compound-22 DMS9QA7 TI TTF2LRI DMS9QA7 TN Cathepsin B (CTSB) DMS9QA7 MA Inhibitor DMS9QA7 RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMS9QA7 RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMS9W6O DI DMS9W6O DMS9W6O DN US9073936, 3 DMS9W6O TI TT3ZS42 DMS9W6O TN Phosphodiesterase 1B (PDE1B) DMS9W6O MA Inhibitor DMS9W6O RN Organic compounds. US9598426. DMS9W6O RU http://www.freepatentsonline.com/US9598426.html DMSA86Y DI DMSA86Y DMSA86Y DN US9365572, 5 DMSA86Y TI TTYXEPL DMSA86Y TN Ribosomal protein S6 kinase alpha-5 (RSK5) DMSA86Y MA Inhibitor DMSA86Y RN PI3K and/or mTOR inhibitor. US9365572. DMSA86Y RU http://www.freepatentsonline.com/US9365572.html DMSAD9B DI DMSAD9B DMSAD9B DN PMID29649907-Compound-42 DMSAD9B TI TTS4UGC DMSAD9B TN Farnesoid X-activated receptor (FXR) DMSAD9B MA Agonist DMSAD9B RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMSAD9B RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMSAO52 DI DMSAO52 DMSAO52 DN PMID29865878-Compound-41 DMSAO52 TI TTSJMN8 DMSAO52 TN Immunoproteasome complex (IP) DMSAO52 MA Inhibitor DMSAO52 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSAO52 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSB09X DI DMSB09X DMSB09X DN Oxetane 3,3-dicarboxamide compound 1 DMSB09X TI TTOHSBA DMSB09X TN Vascular endothelial growth factor A (VEGFA) DMSB09X MA Inhibitor DMSB09X RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMSB09X RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMSBRHJ DI DMSBRHJ DMSBRHJ DN US8759338, 2 DMSBRHJ TI TTCGOIN DMSBRHJ TN PIM-3 protein kinase (PIM3) DMSBRHJ MA Inhibitor DMSBRHJ RN Heterocyclic kinase inhibitors. US8759338. DMSBRHJ RU http://www.freepatentsonline.com/US8759338.html DMSC8B6 DI DMSC8B6 DMSC8B6 DN PMID25980951-Compound-17 DMSC8B6 TI TTQ5LRD DMSC8B6 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMSC8B6 MA Antagonist DMSC8B6 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMSC8B6 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMSC9MH DI DMSC9MH DMSC9MH DN PMID29649907-Compound-11 DMSC9MH TI TTS4UGC DMSC9MH TN Farnesoid X-activated receptor (FXR) DMSC9MH MA Agonist DMSC9MH RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMSC9MH RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMSCWZF DI DMSCWZF DMSCWZF DN PMID29865878-Compound-39 DMSCWZF TI TTSJMN8 DMSCWZF TN Immunoproteasome complex (IP) DMSCWZF MA Inhibitor DMSCWZF RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSCWZF RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSD04W DI DMSD04W DMSD04W DN Quinazolinedione derivative 1 DMSD04W TI TTVDSZ0 DMSD04W TN Poly [ADP-ribose] polymerase 1 (PARP1) DMSD04W MA Inhibitor DMSD04W RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMSD04W RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMSD2TN DI DMSD2TN DMSD2TN DN Cyclohexyl carbamate derivative 6 DMSD2TN TI TTULVH8 DMSD2TN TN Tyrosinase (TYR) DMSD2TN MA Inhibitor DMSD2TN RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSD2TN RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSD354 DI DMSD354 DMSD354 DN US9611221, Example 9 DMSD354 TI TTIG67W DMSD354 TN Lysine-specific demethylase 5A (KDM5A) DMSD354 MA Inhibitor DMSD354 RN Histone demethylase inhibitors. US9611221. DMSD354 RU http://www.freepatentsonline.com/US9611221.html DMSD4G0 DI DMSD4G0 DMSD4G0 DN N,N-bis(5-pyrazoyl)urea derivative 1 DMSD4G0 TI TTTDVOJ DMSD4G0 TN Tropomyosin-related kinase A (TrkA) DMSD4G0 MA Inhibitor DMSD4G0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSD4G0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSD647 DI DMSD647 DMSD647 DN PMID30273516-Compound-15 DMSD647 TI TTCW0KX DMSD647 TN Glutaminase (GLS) DMSD647 MA Inhibitor DMSD647 RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMSD647 RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMSDRA4 DI DMSDRA4 DMSDRA4 DN PMID25684022-Compound-WO2012135799 42(1.4) DMSDRA4 TI TTCZOF2 DMSDRA4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSDRA4 MA Inhibitor DMSDRA4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSDRA4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSDRNQ DI DMSDRNQ DMSDRNQ DN Aryl 1,2-diamine derivative 1 DMSDRNQ TI TTZJYKH DMSDRNQ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMSDRNQ MA Inhibitor DMSDRNQ RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMSDRNQ RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMSDVI1 DI DMSDVI1 DMSDVI1 DN Pyrazole derivative 36 DMSDVI1 TI TT6OEDT DMSDVI1 TN Cannabinoid receptor 1 (CB1) DMSDVI1 MA Antagonist DMSDVI1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMSDVI1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMSEIL0 DI DMSEIL0 DMSEIL0 DN PMID28350212-Compound-1 DMSEIL0 TI TTZS04O DMSEIL0 TN Gamma-secretase subunit APH-1A/1B (APH-1) DMSEIL0 MA Inhibitor DMSEIL0 RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMSEIL0 RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMSEKZG DI DMSEKZG DMSEKZG DN Peptide analog 71 DMSEKZG TI TTQR74A DMSEKZG TN Proteinase activated receptor 2 (PAR2) DMSEKZG MA Agonist DMSEKZG RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMSEKZG RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMSFL5B DI DMSFL5B DMSFL5B DN PMID28350212-Compound-15 DMSFL5B TI TTZS04O DMSFL5B TN Gamma-secretase subunit APH-1A/1B (APH-1) DMSFL5B MA Inhibitor DMSFL5B RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMSFL5B RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMSG71Z DI DMSG71Z DMSG71Z DN Quinoline derivative 18 DMSG71Z TI TTSCO7R DMSG71Z TN NAD-dependent deacetylase sirtuin (SIRT) DMSG71Z MA Inhibitor DMSG71Z RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMSG71Z RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMSGF8T DI DMSGF8T DMSGF8T DN Pyridine derivative 1 DMSGF8T TI TTZJYKH DMSGF8T TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMSGF8T MA Inhibitor DMSGF8T RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMSGF8T RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMSGO7D DI DMSGO7D DMSGO7D DN Aryl oxyanilide derivative 3 DMSGO7D TI TTPTXIN DMSGO7D TN Translocator protein (TSPO) DMSGO7D MA Ligand DMSGO7D RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMSGO7D RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMSGWTX DI DMSGWTX DMSGWTX DN PMID28092474-Compound-32j DMSGWTX TI TT6R7JZ DMSGWTX TN Histone deacetylase 1 (HDAC1) DMSGWTX MA Inhibitor DMSGWTX RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSGWTX RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSGWTX DI DMSGWTX DMSGWTX DN PMID28092474-Compound-32j DMSGWTX TI TT5ZKDI DMSGWTX TN Histone deacetylase 6 (HDAC6) DMSGWTX MA Inhibitor DMSGWTX RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSGWTX RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSHIT2 DI DMSHIT2 DMSHIT2 DN PMID27774822-Compound-Figure9Example15 DMSHIT2 TI TTBYWP2 DMSHIT2 TN TYK2 tyrosine kinase (TYK2) DMSHIT2 MA Inhibitor DMSHIT2 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSHIT2 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSI09Y DI DMSI09Y DMSI09Y DN US9707205, 40 DMSI09Y TI TTDYP7I DMSI09Y TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMSI09Y MA Inhibitor DMSI09Y RN S1P receptors modulators and their use thereof. US9707205. DMSI09Y RU http://www.freepatentsonline.com/US9707205.html DMSI7F2 DI DMSI7F2 DMSI7F2 DN PMID26560530-Compound-1 DMSI7F2 TI TT2F4OL DMSI7F2 TN Tissue transglutaminase (TG2) DMSI7F2 MA Inhibitor DMSI7F2 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMSI7F2 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TT7MRDV DMSIERF TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TT8FYO9 DMSIERF TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TTX41N9 DMSIERF TN Tyrosine-protein kinase Kit (KIT) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIERF DI DMSIERF DMSIERF DN Pyridine derivative 22 DMSIERF TI TT4DXQT DMSIERF TN Proto-oncogene c-Ret (RET) DMSIERF MA Inhibitor DMSIERF RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMSIERF RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMSIKM2 DI DMSIKM2 DMSIKM2 DN PMID25435285-Compound-38 DMSIKM2 TI TTXJ47W DMSIKM2 TN Metabotropic glutamate receptor 2 (mGluR2) DMSIKM2 MA Antagonist DMSIKM2 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMSIKM2 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TT0PG8F DMSIOUA TN Cyclin-dependent kinase 4 (CDK4) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TTO0FDJ DMSIOUA TN Cyclin-dependent kinase 6 (CDK6) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TT8J1S3 DMSIOUA TN Smoothened homolog (SMO) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIOUA DI DMSIOUA DMSIOUA DN PMID25726713-Compound-48 DMSIOUA TI TTCJG29 DMSIOUA TN Serine/threonine-protein kinase mTOR (mTOR) DMSIOUA MA Inhibitor DMSIOUA RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMSIOUA RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMSIRC2 DI DMSIRC2 DMSIRC2 DN Imidazo[1,2-b]pyridazine derivative 6 DMSIRC2 TI TTTDVOJ DMSIRC2 TN Tropomyosin-related kinase A (TrkA) DMSIRC2 MA Inhibitor DMSIRC2 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSIRC2 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSJ1C0 DI DMSJ1C0 DMSJ1C0 DN 2-piperidine thiazole derivative 2 DMSJ1C0 TI TT3M2WO DMSJ1C0 TN Sphingosine kinase (SphK) DMSJ1C0 MA Inhibitor DMSJ1C0 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMSJ1C0 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMSJHV3 DI DMSJHV3 DMSJHV3 DN Peptide analog 12 DMSJHV3 TI TTSJMN8 DMSJHV3 TN Immunoproteasome complex (IP) DMSJHV3 MA Inhibitor DMSJHV3 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSJHV3 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSJWZ3 DI DMSJWZ3 DMSJWZ3 DN Ruxolitinib derivative 2 DMSJWZ3 TI TT6DM01 DMSJWZ3 TN Janus kinase 1 (JAK-1) DMSJWZ3 MA Inhibitor DMSJWZ3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMSJWZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMSJWZ3 DI DMSJWZ3 DMSJWZ3 DN Ruxolitinib derivative 2 DMSJWZ3 TI TTT7PJU DMSJWZ3 TN Janus kinase 3 (JAK-3) DMSJWZ3 MA Inhibitor DMSJWZ3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMSJWZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMSJWZ3 DI DMSJWZ3 DMSJWZ3 DN Ruxolitinib derivative 2 DMSJWZ3 TI TTRMX3V DMSJWZ3 TN Janus kinase 2 (JAK-2) DMSJWZ3 MA Inhibitor DMSJWZ3 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMSJWZ3 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMSKCEH DI DMSKCEH DMSKCEH DN PMID25468267-Compound-46 DMSKCEH TI TTWAQBO DMSKCEH TN Lysine-specific demethylase 4E (KDM4E) DMSKCEH MA Inhibitor DMSKCEH RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMSKCEH RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMSKCEH DI DMSKCEH DMSKCEH DN PMID25468267-Compound-46 DMSKCEH TI TTZHPB8 DMSKCEH TN Lysine-specific demethylase 4A (KDM4A) DMSKCEH MA Inhibitor DMSKCEH RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMSKCEH RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMSKCEH DI DMSKCEH DMSKCEH DN PMID25468267-Compound-46 DMSKCEH TI TTV8CRH DMSKCEH TN Lysine-specific demethylase 4C (KDM4C) DMSKCEH MA Inhibitor DMSKCEH RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMSKCEH RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMSKE2O DI DMSKE2O DMSKE2O DN PMID28350212-Compound-35 DMSKE2O TI TTZS04O DMSKE2O TN Gamma-secretase subunit APH-1A/1B (APH-1) DMSKE2O MA Inhibitor DMSKE2O RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMSKE2O RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMSKWBE DI DMSKWBE DMSKWBE DN PMID25991433-Compound-C3 DMSKWBE TI TTVOE6D DMSKWBE TN Mitogen-activated protein kinase (MAPK) DMSKWBE MA Inhibitor DMSKWBE RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMSKWBE RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMSL3MB DI DMSL3MB DMSL3MB DN PMID25399762-Compound-Table 7-Vanillic acid DMSL3MB TI TTGP7BY DMSL3MB TN Monoamine oxidase type B (MAO-B) DMSL3MB MA Inhibitor DMSL3MB RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMSL3MB RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMSLBT3 DI DMSLBT3 DMSLBT3 DN US9346821, A-20 DMSLBT3 TI TTXL0GC DMSLBT3 TN Enteropeptidase (TMPRSS15) DMSLBT3 MA Inhibitor DMSLBT3 RN Heterocyclic carboxylic acid ester derivative. US9346821. DMSLBT3 RU http://www.freepatentsonline.com/US9346821.html DMSLJE8 DI DMSLJE8 DMSLJE8 DN Aminopyridine derivative 3 DMSLJE8 TI TT6AXLY DMSLJE8 TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DMSLJE8 MA Inhibitor DMSLJE8 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMSLJE8 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMSLJE8 DI DMSLJE8 DMSLJE8 DN Aminopyridine derivative 3 DMSLJE8 TI TTK0FEA DMSLJE8 TN Leucine-rich repeat kinase 2 (LRRK2) DMSLJE8 MA Inhibitor DMSLJE8 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMSLJE8 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMSLYVT DI DMSLYVT DMSLYVT DN Resorcinol compound 15 DMSLYVT TI TTULVH8 DMSLYVT TN Tyrosinase (TYR) DMSLYVT MA Inhibitor DMSLYVT RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSLYVT RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSM53I DI DMSM53I DMSM53I DN Pyrido[2,3-d]pyrimidine derivative 2 DMSM53I TI TT6OEDT DMSM53I TN Cannabinoid receptor 1 (CB1) DMSM53I MA Antagonist DMSM53I RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMSM53I RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMSMBCO DI DMSMBCO DMSMBCO DN Chalcone derivative 1 DMSMBCO TI TTA6ZN2 DMSMBCO TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMSMBCO MA Activator DMSMBCO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMSMBCO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMSMBCO DI DMSMBCO DMSMBCO DN Chalcone derivative 1 DMSMBCO TI TT3Z6Y9 DMSMBCO TN Cysteines of Keap1 (KEAP1 Cysteines) DMSMBCO MA Modulator DMSMBCO RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMSMBCO RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMSME2B DI DMSME2B DMSME2B DN PMID29130358-Compound-Figure11(3) DMSME2B TI TTLM12X DMSME2B TN Matrix metalloproteinase-2 (MMP-2) DMSME2B MA Inhibitor DMSME2B RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSME2B RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSME2B DI DMSME2B DMSME2B DN PMID29130358-Compound-Figure11(3) DMSME2B TI TTULVH8 DMSME2B TN Tyrosinase (TYR) DMSME2B MA Inhibitor DMSME2B RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSME2B RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSMXK3 DI DMSMXK3 DMSMXK3 DN Azaindole derivative 1 DMSMXK3 TI TT3PJMV DMSMXK3 TN Tyrosine-protein kinase ABL1 (ABL) DMSMXK3 MA Inhibitor DMSMXK3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSMXK3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSNMZ2 DI DMSNMZ2 DMSNMZ2 DN Biaryl mannoside derivative 28 DMSNMZ2 TI TTTCRU2 DMSNMZ2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSNMZ2 MA Antagonist DMSNMZ2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSNMZ2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSNQEJ DI DMSNQEJ DMSNQEJ DN Pyrrolo-pyridine derivative 3 DMSNQEJ TI TT6DM01 DMSNQEJ TN Janus kinase 1 (JAK-1) DMSNQEJ MA Inhibitor DMSNQEJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSNQEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSNQEJ DI DMSNQEJ DMSNQEJ DN Pyrrolo-pyridine derivative 3 DMSNQEJ TI TTRMX3V DMSNQEJ TN Janus kinase 2 (JAK-2) DMSNQEJ MA Inhibitor DMSNQEJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSNQEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSNQEJ DI DMSNQEJ DMSNQEJ DN Pyrrolo-pyridine derivative 3 DMSNQEJ TI TTT7PJU DMSNQEJ TN Janus kinase 3 (JAK-3) DMSNQEJ MA Inhibitor DMSNQEJ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMSNQEJ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMSNUVZ DI DMSNUVZ DMSNUVZ DN PMID25656651-Compound-19a DMSNUVZ TI TTS7G69 DMSNUVZ TN Fusion protein Bcr-Abl (Bcr-Abl) DMSNUVZ MA Inhibitor DMSNUVZ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSNUVZ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSNUVZ DI DMSNUVZ DMSNUVZ DN PMID25656651-Compound-19a DMSNUVZ TI TTIV39N DMSNUVZ TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMSNUVZ MA Inhibitor DMSNUVZ RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSNUVZ RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSNY3W DI DMSNY3W DMSNY3W DN Pyrazole derivative 71 DMSNY3W TI TTJQOD7 DMSNY3W TN 5-HT 2A receptor (HTR2A) DMSNY3W MA Antagonist DMSNY3W RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMSNY3W RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMSO2F8 DI DMSO2F8 DMSO2F8 DN PMID26651364-Compound-8d DMSO2F8 TI TTTCRU2 DMSO2F8 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSO2F8 MA Antagonist DMSO2F8 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSO2F8 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSOQG7 DI DMSOQG7 DMSOQG7 DN Peptide analog 35 DMSOQG7 TI TTSJMN8 DMSOQG7 TN Immunoproteasome complex (IP) DMSOQG7 MA Inhibitor DMSOQG7 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMSOQG7 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMSOT1R DI DMSOT1R DMSOT1R DN PMID28270010-Compound-Figure5-3 DMSOT1R TI TTTDVOJ DMSOT1R TN Tropomyosin-related kinase A (TrkA) DMSOT1R MA Inhibitor DMSOT1R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSOT1R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSOT1R DI DMSOT1R DMSOT1R DN PMID28270010-Compound-Figure5-3 DMSOT1R TI TTXABCW DMSOT1R TN NT-3 growth factor receptor (TrkC) DMSOT1R MA Inhibitor DMSOT1R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSOT1R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSOT1R DI DMSOT1R DMSOT1R DN PMID28270010-Compound-Figure5-3 DMSOT1R TI TTKN7QR DMSOT1R TN BDNF/NT-3 growth factors receptor (TrkB) DMSOT1R MA Inhibitor DMSOT1R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMSOT1R RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMSP5IA DI DMSP5IA DMSP5IA DN PMID28092474-Compound-32l DMSP5IA TI TT5ZKDI DMSP5IA TN Histone deacetylase 6 (HDAC6) DMSP5IA MA Inhibitor DMSP5IA RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSP5IA RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSP5IA DI DMSP5IA DMSP5IA DN PMID28092474-Compound-32l DMSP5IA TI TT6R7JZ DMSP5IA TN Histone deacetylase 1 (HDAC1) DMSP5IA MA Inhibitor DMSP5IA RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMSP5IA RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMSPCLD DI DMSPCLD DMSPCLD DN Resorcinol compound 31 DMSPCLD TI TTULVH8 DMSPCLD TN Tyrosinase (TYR) DMSPCLD MA Inhibitor DMSPCLD RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSPCLD RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSPG8Y DI DMSPG8Y DMSPG8Y DN PMID26004420-Compound-WO2014099633E DMSPG8Y TI TTJ13ST DMSPG8Y TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMSPG8Y MA Inhibitor DMSPG8Y RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMSPG8Y RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMSQ5J8 DI DMSQ5J8 DMSQ5J8 DN PMID25684022-Compound-WO2011137219 37(4-6) DMSQ5J8 TI TTCZOF2 DMSQ5J8 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSQ5J8 MA Inhibitor DMSQ5J8 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSQ5J8 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSQK50 DI DMSQK50 DMSQK50 DN Heterocyclic-carboxamide derivative 2 DMSQK50 TI TTCZOF2 DMSQK50 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSQK50 MA Inhibitor DMSQK50 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSQK50 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSQODK DI DMSQODK DMSQODK DN US8614253, 32-5 DMSQODK TI TTOJ9QL DMSQODK TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMSQODK MA Inhibitor DMSQODK RN IRE-1 inhibitors. US8614253. DMSQODK RU http://www.freepatentsonline.com/US8614253.html DMSR0X6 DI DMSR0X6 DMSR0X6 DN 1,3,4-oxadiazole derivative 3 DMSR0X6 TI TT23XQV DMSR0X6 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMSR0X6 MA Inhibitor DMSR0X6 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMSR0X6 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMSR218 DI DMSR218 DMSR218 DN PMID25666693-Compound-37 DMSR218 TI TTMI6F5 DMSR218 TN Transient receptor potential cation channel V1 (TRPV1) DMSR218 MA Antagonist DMSR218 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMSR218 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMSR5FO DI DMSR5FO DMSR5FO DN Pyrazolopyridines and imidazopyridine derivative 1 DMSR5FO TI TTCZOF2 DMSR5FO TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMSR5FO MA Inhibitor DMSR5FO RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMSR5FO RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMSR918 DI DMSR918 DMSR918 DN Benzothiazine-carboxamide compound 4 DMSR918 TI TTQR74A DMSR918 TN Proteinase activated receptor 2 (PAR2) DMSR918 MA Antagonist DMSR918 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMSR918 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMSRB8M DI DMSRB8M DMSRB8M DN Quinoline derivative 14 DMSRB8M TI TTRZQE3 DMSRB8M TN Glycogen synthase kinase-3 alpha (GSK-3A) DMSRB8M MA Inhibitor DMSRB8M RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMSRB8M RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMSRKON DI DMSRKON DMSRKON DN Aromatic ethylene derivative 1 DMSRKON TI TT23XQV DMSRKON TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMSRKON MA Inhibitor DMSRKON RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMSRKON RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMSRYIP DI DMSRYIP DMSRYIP DN PMID25435285-Compound-53 DMSRYIP TI TTXJ47W DMSRYIP TN Metabotropic glutamate receptor 2 (mGluR2) DMSRYIP MA Antagonist DMSRYIP RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMSRYIP RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMST6C2 DI DMST6C2 DMST6C2 DN PMID26560530-Compound-49 DMST6C2 TI TT2F4OL DMST6C2 TN Tissue transglutaminase (TG2) DMST6C2 MA Inhibitor DMST6C2 RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMST6C2 RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMST6IF DI DMST6IF DMST6IF DN US9422240, 1-297 DMST6IF TI TT9ISBX DMST6IF TN HIF-prolyl hydroxylase 2 (HPH-2) DMST6IF MA Inhibitor DMST6IF RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DMST6IF RU http://www.freepatentsonline.com/US9422240.html DMSTC9Z DI DMSTC9Z DMSTC9Z DN Dihydropyrido pyrimidine derivative 1 DMSTC9Z TI TTSCIM2 DMSTC9Z TN Extracellular lysophospholipase D (E-NPP2) DMSTC9Z MA Inhibitor DMSTC9Z RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMSTC9Z RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMSTD28 DI DMSTD28 DMSTD28 DN BDBM50173306 DMSTD28 TI TTAZ3MN DMSTD28 TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMSTD28 MA Inhibitor DMSTD28 RN G protein-coupled receptor kinase 2 inhibitors and methods for use of the same. US10023564. DMSTD28 RU http://www.freepatentsonline.com/US10023564.html DMSTKH6 DI DMSTKH6 DMSTKH6 DN PMID26651364-Compound-126a DMSTKH6 TI TTTCRU2 DMSTKH6 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSTKH6 MA Antagonist DMSTKH6 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSTKH6 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSU1PC DI DMSU1PC DMSU1PC DN Quinazolinone derivative 1 DMSU1PC TI TTL7C8Q DMSU1PC TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMSU1PC MA Inhibitor DMSU1PC RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMSU1PC RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMSU80N DI DMSU80N DMSU80N DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 1 DMSU80N TI TT9NXW4 DMSU80N TN Sigma intracellular receptor 2 (TMEM97) DMSU80N MA Ligand DMSU80N RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMSU80N RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMSUD5X DI DMSUD5X DMSUD5X DN Peptidomimetic analog 6 DMSUD5X TI TTQR74A DMSUD5X TN Proteinase activated receptor 2 (PAR2) DMSUD5X MA Agonist DMSUD5X RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMSUD5X RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMSV42L DI DMSV42L DMSV42L DN Imidazole derivative 9 DMSV42L TI TTTJZ4M DMSV42L TN Prolylcarboxypeptidase (PRCP) DMSV42L MA Inhibitor DMSV42L RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMSV42L RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMSVMUT DI DMSVMUT DMSVMUT DN Cyclic compound 1 DMSVMUT TI TTNBFWK DMSVMUT TN Programmed cell death protein 1 (PD-1) DMSVMUT MA Inhibitor DMSVMUT RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMSVMUT RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMSVQMO DI DMSVQMO DMSVQMO DN PMID25656651-Compound-31a DMSVQMO TI TTIV39N DMSVQMO TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMSVQMO MA Inhibitor DMSVQMO RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMSVQMO RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMSW0HB DI DMSW0HB DMSW0HB DN PMID26651364-Compound-5g DMSW0HB TI TTTCRU2 DMSW0HB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMSW0HB MA Antagonist DMSW0HB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMSW0HB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMSW3GB DI DMSW3GB DMSW3GB DN Resorcinol compound 22 DMSW3GB TI TTULVH8 DMSW3GB TN Tyrosinase (TYR) DMSW3GB MA Inhibitor DMSW3GB RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSW3GB RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSWI67 DI DMSWI67 DMSWI67 DN Polycyclic compound 1 DMSWI67 TI TTYLQ8V DMSWI67 TN Prostaglandin E synthase (PTGES) DMSWI67 MA Inhibitor DMSWI67 RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMSWI67 RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMSWJPO DI DMSWJPO DMSWJPO DN PMID29649907-Compound-35 DMSWJPO TI TTS4UGC DMSWJPO TN Farnesoid X-activated receptor (FXR) DMSWJPO MA Agonist DMSWJPO RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMSWJPO RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMSWM9Q DI DMSWM9Q DMSWM9Q DN PMID28870136-Compound-41 DMSWM9Q TI TTK0O6Y DMSWM9Q TN Ecto-5'-nucleotidase (CD73) DMSWM9Q MA Inhibitor DMSWM9Q RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMSWM9Q RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMSX09A DI DMSX09A DMSX09A DN PMID28766366-Compound-Scheme8NCGC-00010037 DMSX09A TI TTSBVFO DMSX09A TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMSX09A MA Inhibitor DMSX09A RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMSX09A RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMSX47Q DI DMSX47Q DMSX47Q DN Phenylpyrrolidinone derivative 4 DMSX47Q TI TT5OU0D DMSX47Q TN PRKR-like endoplasmic reticulum kinase (PERK) DMSX47Q MA Inhibitor DMSX47Q RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMSX47Q RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMSXB58 DI DMSXB58 DMSXB58 DN Cyclopropane 1-carboxylic acid derivative 2 DMSXB58 TI TTIY56R DMSXB58 TN Kynurenine 3-hydroxylase (KMO) DMSXB58 MA Inhibitor DMSXB58 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMSXB58 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMSXG78 DI DMSXG78 DMSXG78 DN US9217012, 10 DMSXG78 TI TT405FP DMSXG78 TN FAP-1 messenger RNA (PTPN13 mRNA) DMSXG78 MA Inhibitor DMSXG78 RN Inhibitors of protein tyrosine phosphatases. US9217012. DMSXG78 RU http://www.freepatentsonline.com/US9217012.html DMSXH8K DI DMSXH8K DMSXH8K DN Pyrrolo[2,3-d]pyrimidine derivative 18 DMSXH8K TI TTGM6VW DMSXH8K TN Tyrosine-protein kinase BTK (ATK) DMSXH8K MA Inhibitor DMSXH8K RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMSXH8K RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMSXJVY DI DMSXJVY DMSXJVY DN PMID27172114-Compound-49 DMSXJVY TI TTIY56R DMSXJVY TN Kynurenine 3-hydroxylase (KMO) DMSXJVY MA Inhibitor DMSXJVY RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMSXJVY RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMSXKP6 DI DMSXKP6 DMSXKP6 DN PMID29473428-Compound-52 DMSXKP6 TI TTZJYKH DMSXKP6 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMSXKP6 MA Inhibitor DMSXKP6 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMSXKP6 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMSYD3X DI DMSYD3X DMSYD3X DN US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine DMSYD3X TI TT7ALZG DMSYD3X TN Integrin-linked protein kinase 1 (ILK) DMSYD3X MA Inhibitor DMSYD3X RN Pyrazolylbenzothiazole derivatives and their use as therapeutic agents. US8754233. DMSYD3X RU http://www.freepatentsonline.com/US8754233.html DMSYD6Z DI DMSYD6Z DMSYD6Z DN Fused heterocyclic compound 12 DMSYD6Z TI TTA592U DMSYD6Z TN Urate anion exchanger 1 (URAT1) DMSYD6Z MA Inhibitor DMSYD6Z RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMSYD6Z RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMSYGHO DI DMSYGHO DMSYGHO DN PMID25399762-Compound-Figure1-Neonectrolide A DMSYGHO TI TT3WG5C DMSYGHO TN Monoamine oxidase type A (MAO-A) DMSYGHO MA Inhibitor DMSYGHO RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMSYGHO RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMSYRI3 DI DMSYRI3 DMSYRI3 DN US10174026, Example 2 DMSYRI3 TI TTIG67W DMSYRI3 TN Lysine-specific demethylase 5A (KDM5A) DMSYRI3 MA Inhibitor DMSYRI3 RN Histone demethylase inhibitors. US10174026. DMSYRI3 RU http://www.freepatentsonline.com/US10174026.html DMSYUHK DI DMSYUHK DMSYUHK DN US8889696, Staurosporine DMSYUHK TI TTCGOIN DMSYUHK TN PIM-3 protein kinase (PIM3) DMSYUHK MA Inhibitor DMSYUHK RN Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof. US8889696. DMSYUHK RU http://www.freepatentsonline.com/US8889696.html DMSYX4U DI DMSYX4U DMSYX4U DN Diamine derivative 3 DMSYX4U TI TTULVH8 DMSYX4U TN Tyrosinase (TYR) DMSYX4U MA Inhibitor DMSYX4U RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMSYX4U RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMSZ0GE DI DMSZ0GE DMSZ0GE DN PMID27977313-Compound-45 DMSZ0GE TI TTR7UJ3 DMSZ0GE TN Cytoplasmic thioredoxin reductase (TXNRD1) DMSZ0GE MA Inhibitor DMSZ0GE RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMSZ0GE RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMSZA9L DI DMSZA9L DMSZA9L DN PMID29130358-Compound-Figure17(11) DMSZA9L TI TTXZ0KQ DMSZA9L TN Matrix metalloproteinase-12 (MMP-12) DMSZA9L MA Inhibitor DMSZA9L RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSZA9L RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSZA9L DI DMSZA9L DMSZA9L DN PMID29130358-Compound-Figure17(11) DMSZA9L TI TT6X50U DMSZA9L TN Matrix metalloproteinase-9 (MMP-9) DMSZA9L MA Inhibitor DMSZA9L RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMSZA9L RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMSZLYD DI DMSZLYD DMSZLYD DN PMID27336223-Compound-13 DMSZLYD TI TT1Q3IE DMSZLYD TN Retinoic acid receptor gamma (RARG) DMSZLYD MA Agonist DMSZLYD RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMSZLYD RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMSZWAM DI DMSZWAM DMSZWAM DN PMID26394986-Compound-52 DMSZWAM TI TTH8FZW DMSZWAM TN Signal transducer and activator of transcription 3 (STAT3) DMSZWAM MA Inhibitor DMSZWAM RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMSZWAM RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMT0QLO DI DMT0QLO DMT0QLO DN PMID25726713-Compound-63 DMT0QLO TI TT8J1S3 DMT0QLO TN Smoothened homolog (SMO) DMT0QLO MA Inhibitor DMT0QLO RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMT0QLO RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMT1DJP DI DMT1DJP DMT1DJP DN Pyrazole derivative 30 DMT1DJP TI TT6OEDT DMT1DJP TN Cannabinoid receptor 1 (CB1) DMT1DJP MA Antagonist DMT1DJP RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMT1DJP RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMT1EH9 DI DMT1EH9 DMT1EH9 DN Gold-complexed thiosaccharide derivative 1 DMT1EH9 TI TTH8FZW DMT1EH9 TN Signal transducer and activator of transcription 3 (STAT3) DMT1EH9 MA Inhibitor DMT1EH9 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMT1EH9 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMT21JG DI DMT21JG DMT21JG DN Resorcinol compound 26 DMT21JG TI TTULVH8 DMT21JG TN Tyrosinase (TYR) DMT21JG MA Inhibitor DMT21JG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMT21JG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMT2B5A DI DMT2B5A DMT2B5A DN PMID28092474-Compound-32b DMT2B5A TI TT5ZKDI DMT2B5A TN Histone deacetylase 6 (HDAC6) DMT2B5A MA Inhibitor DMT2B5A RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMT2B5A RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMT2B5A DI DMT2B5A DMT2B5A DN PMID28092474-Compound-32b DMT2B5A TI TT6R7JZ DMT2B5A TN Histone deacetylase 1 (HDAC1) DMT2B5A MA Inhibitor DMT2B5A RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMT2B5A RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMT2D5H DI DMT2D5H DMT2D5H DN PMID29338548-Compound-26 DMT2D5H TI TTHJTF7 DMT2D5H TN Glycine transporter GlyT-1 (SLC6A9) DMT2D5H MA Inhibitor DMT2D5H RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMT2D5H RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMT2W97 DI DMT2W97 DMT2W97 DN PMID27744724-Compound-Fomula2 DMT2W97 TI TTL53M6 DMT2W97 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMT2W97 MA Inhibitor DMT2W97 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMT2W97 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMT2Z0I DI DMT2Z0I DMT2Z0I DN Hexahydro naphthalene derivative 1 DMT2Z0I TI TTPADOQ DMT2Z0I TN HMG-CoA reductase (HMGCR) DMT2Z0I MA Inhibitor DMT2Z0I RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMT2Z0I RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMT3AL5 DI DMT3AL5 DMT3AL5 DN PMID29338548-Compound-22 DMT3AL5 TI TTHJTF7 DMT3AL5 TN Glycine transporter GlyT-1 (SLC6A9) DMT3AL5 MA Inhibitor DMT3AL5 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMT3AL5 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMT46PS DI DMT46PS DMT46PS DN Isoxazole-based bicyclic compound 5 DMT46PS TI TTE4BSY DMT46PS TN Bromodomain and extraterminal domain protein (BET) DMT46PS MA Inhibitor DMT46PS RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMT46PS RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMT47DF DI DMT47DF DMT47DF DN US10092575, Example 141 DMT47DF TI TT3ZS42 DMT47DF TN Phosphodiesterase 1B (PDE1B) DMT47DF MA Inhibitor DMT47DF RN Therapeutic thiophene-, furan-, and pyridine-fused azolopyrimidin-5-(6h)-ones. US10105367. DMT47DF RU http://www.freepatentsonline.com/US10105367.html DMT4P7K DI DMT4P7K DMT4P7K DN PMID27336223-Compound-12 DMT4P7K TI TT1Q3IE DMT4P7K TN Retinoic acid receptor gamma (RARG) DMT4P7K MA Agonist DMT4P7K RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMT4P7K RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMT4ZP9 DI DMT4ZP9 DMT4ZP9 DN Pyrazolo[1,5-a]pyrimidine derivative 24 DMT4ZP9 TI TTTDVOJ DMT4ZP9 TN Tropomyosin-related kinase A (TrkA) DMT4ZP9 MA Inhibitor DMT4ZP9 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMT4ZP9 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMT57C4 DI DMT57C4 DMT57C4 DN Pyrazolo[3,4-d]pyrimidine derivative 1 DMT57C4 TI TTJGW1Z DMT57C4 TN Phosphodiesterase 2A (PDE2A) DMT57C4 MA Inhibitor DMT57C4 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMT57C4 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMT58QE DI DMT58QE DMT58QE DN Lactam derivative 2 DMT58QE TI TTF8P9I DMT58QE TN Diacylglycerol acyltransferase 1 (DGAT1) DMT58QE MA Inhibitor DMT58QE RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMT58QE RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMT5E7M DI DMT5E7M DMT5E7M DN Isoquinoline sulfonyl derivative 2 DMT5E7M TI TTMQO60 DMT5E7M TN Rho-associated protein kinase (ROCK) DMT5E7M MA Inhibitor DMT5E7M RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMT5E7M RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMT6CNM DI DMT6CNM DMT6CNM DN PMID26666989-Compound-Figure9middle11 DMT6CNM TI TT8BUGW DMT6CNM TN Glycogen phosphorylase (PYG) DMT6CNM MA Inhibitor DMT6CNM RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMT6CNM RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMT6EDP DI DMT6EDP DMT6EDP DN 1,2,4-oxadiazole derivative 4 DMT6EDP TI TT23XQV DMT6EDP TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMT6EDP MA Inhibitor DMT6EDP RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMT6EDP RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMT6HXB DI DMT6HXB DMT6HXB DN US9156852, 1 DMT6HXB TI TTU98HG DMT6HXB TN Discoidin domain-containing receptor 2 (DDR2) DMT6HXB MA Inhibitor DMT6HXB RN Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852. DMT6HXB RU http://www.freepatentsonline.com/US9156852.html DMT6O1N DI DMT6O1N DMT6O1N DN Pyrimidine-4(3H)-one derivative 1 DMT6O1N TI TTJOW1I DMT6O1N TN Mannoside acetylglucosaminyltransferase 2 (MGAT2) DMT6O1N MA Inhibitor DMT6O1N RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMT6O1N RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMT7GQ1 DI DMT7GQ1 DMT7GQ1 DN PMID26004420-Compound-WO2013039802A DMT7GQ1 TI TTJ13ST DMT7GQ1 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMT7GQ1 MA Inhibitor DMT7GQ1 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMT7GQ1 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMT7U1O DI DMT7U1O DMT7U1O DN PMID28460551-Compound-6 DMT7U1O TI TTWTSCV DMT7U1O TN RAC-alpha serine/threonine-protein kinase (AKT1) DMT7U1O MA Inhibitor DMT7U1O RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMT7U1O RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMT7U1O DI DMT7U1O DMT7U1O DN PMID28460551-Compound-6 DMT7U1O TI TT6PKBN DMT7U1O TN Proto-oncogene c-Src (SRC) DMT7U1O MA Inhibitor DMT7U1O RN Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761. DMT7U1O RU https://www.ncbi.nlm.nih.gov/pubmed/28460551 DMT7ZEL DI DMT7ZEL DMT7ZEL DN Flavonoid derivative 3 DMT7ZEL TI TTH8FZW DMT7ZEL TN Signal transducer and activator of transcription 3 (STAT3) DMT7ZEL MA Inhibitor DMT7ZEL RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMT7ZEL RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMT842O DI DMT842O DMT842O DN Isoxazole derivative 2 DMT842O TI TTRMX3V DMT842O TN Janus kinase 2 (JAK-2) DMT842O MA Inhibitor DMT842O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMT842O RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMT842O DI DMT842O DMT842O DN Isoxazole derivative 2 DMT842O TI TT6DM01 DMT842O TN Janus kinase 1 (JAK-1) DMT842O MA Inhibitor DMT842O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMT842O RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMT842O DI DMT842O DMT842O DN Isoxazole derivative 2 DMT842O TI TTT7PJU DMT842O TN Janus kinase 3 (JAK-3) DMT842O MA Inhibitor DMT842O RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMT842O RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMT85AH DI DMT85AH DMT85AH DN PMID27774824-Compound-Figure7Example10 DMT85AH TI TT6DM01 DMT85AH TN Janus kinase 1 (JAK-1) DMT85AH MA Inhibitor DMT85AH RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMT85AH RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMT85AH DI DMT85AH DMT85AH DN PMID27774824-Compound-Figure7Example10 DMT85AH TI TTRMX3V DMT85AH TN Janus kinase 2 (JAK-2) DMT85AH MA Inhibitor DMT85AH RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMT85AH RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMT8WVZ DI DMT8WVZ DMT8WVZ DN US10065972, Example 396 DMT8WVZ TI TTT3IXG DMT8WVZ TN Kynurenine oxoglutarate transaminase II (AADAT) DMT8WVZ MA Inhibitor DMT8WVZ RN Bicyclic or tricyclic heterocyclic compound. US10065972. DMT8WVZ RU http://www.freepatentsonline.com/US10065972.html DMT9EJL DI DMT9EJL DMT9EJL DN PMID25666693-Compound-88 DMT9EJL TI TTMI6F5 DMT9EJL TN Transient receptor potential cation channel V1 (TRPV1) DMT9EJL MA Antagonist DMT9EJL RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMT9EJL RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTA3D8 DI DMTA3D8 DMTA3D8 DN PMID29338548-Compound-23 DMTA3D8 TI TTHJTF7 DMTA3D8 TN Glycine transporter GlyT-1 (SLC6A9) DMTA3D8 MA Inhibitor DMTA3D8 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMTA3D8 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMTAZBC DI DMTAZBC DMTAZBC DN PMID27215781-Compound-34 DMTAZBC TI TTMSFAW DMTAZBC TN Cannabinoid receptor 2 (CB2) DMTAZBC RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMTAZBC RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMTB3KS DI DMTB3KS DMTB3KS DN Azetidine derivative 2 DMTB3KS TI TTZCRP3 DMTB3KS TN ERK activator kinase (MEK) DMTB3KS MA Inhibitor DMTB3KS RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMTB3KS RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMTBG39 DI DMTBG39 DMTBG39 DN Ethylaminopyrimidine derivative 1 DMTBG39 TI TTGX13H DMTBG39 TN Fatty-acid amide hydrolase 1 (FAAH1) DMTBG39 MA Inhibitor DMTBG39 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMTBG39 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMTBG39 DI DMTBG39 DMTBG39 DN Ethylaminopyrimidine derivative 1 DMTBG39 TI TTDP1UC DMTBG39 TN Fatty acid amide hydrolase (FAAH) DMTBG39 MA Inhibitor DMTBG39 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMTBG39 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMTBWC9 DI DMTBWC9 DMTBWC9 DN Bicyclic heteroaryl benzamide derivative 1 DMTBWC9 TI TTTDVOJ DMTBWC9 TN Tropomyosin-related kinase A (TrkA) DMTBWC9 MA Inhibitor DMTBWC9 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMTBWC9 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMTC129 DI DMTC129 DMTC129 DN Indolinone derivative 1 DMTC129 TI TTCZOF2 DMTC129 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMTC129 MA Inhibitor DMTC129 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMTC129 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMTCPNY DI DMTCPNY DMTCPNY DN PMID26004420-Compound-WO2013028474C DMTCPNY TI TTJ13ST DMTCPNY TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMTCPNY MA Inhibitor DMTCPNY RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMTCPNY RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMTCPSQ DI DMTCPSQ DMTCPSQ DN 2,2-dimethylbenzopyran derivative 3 DMTCPSQ TI TTUX68I DMTCPSQ TN Hypoxia-inducible factor 1 (HIF-1) DMTCPSQ MA Inhibitor DMTCPSQ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMTCPSQ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMTD0RK DI DMTD0RK DMTD0RK DN PMID26004420-Compound-WO2014085210B DMTD0RK TI TTJ13ST DMTD0RK TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMTD0RK MA Inhibitor DMTD0RK RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMTD0RK RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMTD1X8 DI DMTD1X8 DMTD1X8 DN PMID27109571-Compound-2 DMTD1X8 TI TTMY6L1 DMTD1X8 TN Fatty acid-binding protein (FABP) DMTD1X8 MA Inhibitor DMTD1X8 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTD1X8 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMTD3C1 DI DMTD3C1 DMTD3C1 DN Pyrazolo-triazine derivative 1 DMTD3C1 TI TTQYF7G DMTD3C1 TN Cyclin-dependent kinase 7 (CDK7) DMTD3C1 MA Inhibitor DMTD3C1 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTD3C1 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTDIA6 DI DMTDIA6 DMTDIA6 DN Phenylpropylamine derivative 2 DMTDIA6 TI TT5TPI6 DMTDIA6 TN Opioid receptor sigma 1 (OPRS1) DMTDIA6 MA Ligand DMTDIA6 RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMTDIA6 RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMTDPHY DI DMTDPHY DMTDPHY DN Biaryl mannoside derivative 27 DMTDPHY TI TTTCRU2 DMTDPHY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMTDPHY MA Antagonist DMTDPHY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMTDPHY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMTE0S3 DI DMTE0S3 DMTE0S3 DN Isoindoline derivative 2 DMTE0S3 TI TTQ6VDM DMTE0S3 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMTE0S3 MA Ligand DMTE0S3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMTE0S3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMTE0S3 DI DMTE0S3 DMTE0S3 DN Isoindoline derivative 2 DMTE0S3 TI TT5TPI6 DMTE0S3 TN Opioid receptor sigma 1 (OPRS1) DMTE0S3 MA Ligand DMTE0S3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMTE0S3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMTE0S3 DI DMTE0S3 DMTE0S3 DN Isoindoline derivative 2 DMTE0S3 TI TT9NXW4 DMTE0S3 TN Sigma intracellular receptor 2 (TMEM97) DMTE0S3 MA Ligand DMTE0S3 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMTE0S3 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMTE8QO DI DMTE8QO DMTE8QO DN US8592455, 90 DMTE8QO TI TTCGOIN DMTE8QO TN PIM-3 protein kinase (PIM3) DMTE8QO MA Inhibitor DMTE8QO RN Kinase inhibitors and methods of their use. US8592455. DMTE8QO RU http://www.freepatentsonline.com/US8592455.html DMTEJRB DI DMTEJRB DMTEJRB DN Phenylpropionic acid derivative 1 DMTEJRB TI TTZMAO3 DMTEJRB TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMTEJRB MA Agonist DMTEJRB RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMTEJRB RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMTEYQJ DI DMTEYQJ DMTEYQJ DN Indole-based analog 3 DMTEYQJ TI TTU1E82 DMTEYQJ TN Apoptosis regulator Bcl-xL (BCL-xL) DMTEYQJ MA Inhibitor DMTEYQJ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMTEYQJ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMTEYQJ DI DMTEYQJ DMTEYQJ DN Indole-based analog 3 DMTEYQJ TI TTL53M6 DMTEYQJ TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMTEYQJ MA Inhibitor DMTEYQJ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMTEYQJ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMTEYQJ DI DMTEYQJ DMTEYQJ DN Indole-based analog 3 DMTEYQJ TI TTJGNVC DMTEYQJ TN Apoptosis regulator Bcl-2 (BCL-2) DMTEYQJ MA Inhibitor DMTEYQJ RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMTEYQJ RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMTFG4J DI DMTFG4J DMTFG4J DN 1,2-diamino cyclopentane-based derivative 26 DMTFG4J TI TT9N02I DMTFG4J TN Orexin receptor type 2 (HCRTR2) DMTFG4J MA Antagonist DMTFG4J RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTFG4J RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTFG4J DI DMTFG4J DMTFG4J DN 1,2-diamino cyclopentane-based derivative 26 DMTFG4J TI TT60Q8D DMTFG4J TN Orexin receptor type 1 (HCRTR1) DMTFG4J MA Antagonist DMTFG4J RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTFG4J RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTFLVN DI DMTFLVN DMTFLVN DN PMID27977313-Compound-43 DMTFLVN TI TTR7UJ3 DMTFLVN TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTFLVN MA Inhibitor DMTFLVN RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTFLVN RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTFNGM DI DMTFNGM DMTFNGM DN Sulfonamide derivative 16 DMTFNGM TI TT5ZKDI DMTFNGM TN Histone deacetylase 6 (HDAC6) DMTFNGM MA Inhibitor DMTFNGM RN Sulfonamide inhibitors: a patent review 2013-present.Expert Opin Ther Pat. 2018 Jul;28(7):541-549. DMTFNGM RU https://www.ncbi.nlm.nih.gov/pubmed/29886770 DMTG6X9 DI DMTG6X9 DMTG6X9 DN 2-pyrazinone derivative 7 DMTG6X9 TI TTPLTSQ DMTG6X9 TN Neutrophil elastase (NE) DMTG6X9 MA Inhibitor DMTG6X9 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMTG6X9 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMTGEFW DI DMTGEFW DMTGEFW DN 4-Carboxamido-isoindolinone derivative 4 DMTGEFW TI TTVDSZ0 DMTGEFW TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTGEFW MA Inhibitor DMTGEFW RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMTGEFW RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMTGELI DI DMTGELI DMTGELI DN Pyrrolo[2,3-d]pyrimidine derivative 13 DMTGELI TI TTGM6VW DMTGELI TN Tyrosine-protein kinase BTK (ATK) DMTGELI MA Inhibitor DMTGELI RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMTGELI RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMTGIP7 DI DMTGIP7 DMTGIP7 DN Naphthyridine and isoquinoline derivative 1 DMTGIP7 TI TTH6V3D DMTGIP7 TN Cyclin-dependent kinase 1 (CDK1) DMTGIP7 MA Inhibitor DMTGIP7 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTGIP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTGIP7 DI DMTGIP7 DMTGIP7 DN Naphthyridine and isoquinoline derivative 1 DMTGIP7 TI TT7HF4W DMTGIP7 TN Cyclin-dependent kinase 2 (CDK2) DMTGIP7 MA Inhibitor DMTGIP7 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTGIP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTGIP7 DI DMTGIP7 DMTGIP7 DN Naphthyridine and isoquinoline derivative 1 DMTGIP7 TI TTL4Q97 DMTGIP7 TN Cyclin-dependent kinase 5 (CDK5) DMTGIP7 MA Inhibitor DMTGIP7 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTGIP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTHG87 DI DMTHG87 DMTHG87 DN Quinoline derivative 16 DMTHG87 TI TTPADOQ DMTHG87 TN HMG-CoA reductase (HMGCR) DMTHG87 MA Inhibitor DMTHG87 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMTHG87 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMTHKES DI DMTHKES DMTHKES DN Benzoic acid linked peptide analog 6 DMTHKES TI TTULVH8 DMTHKES TN Tyrosinase (TYR) DMTHKES MA Inhibitor DMTHKES RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMTHKES RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMTHS3L DI DMTHS3L DMTHS3L DN Amidopyrazole derivative 3 DMTHS3L TI TTKFVXR DMTHS3L TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMTHS3L MA Inhibitor DMTHS3L RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMTHS3L RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMTHXUC DI DMTHXUC DMTHXUC DN Phenylthioacetate derivative 1 DMTHXUC TI TTA592U DMTHXUC TN Urate anion exchanger 1 (URAT1) DMTHXUC MA Inhibitor DMTHXUC RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMTHXUC RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMTI5E3 DI DMTI5E3 DMTI5E3 DN PMID27977313-Compound-17 DMTI5E3 TI TTR7UJ3 DMTI5E3 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTI5E3 MA Inhibitor DMTI5E3 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTI5E3 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTIM1E DI DMTIM1E DMTIM1E DN PMID26161698-Compound-34 DMTIM1E TI TTQYF7G DMTIM1E TN Cyclin-dependent kinase 7 (CDK7) DMTIM1E MA Inhibitor DMTIM1E RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTIM1E RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTIQYD DI DMTIQYD DMTIQYD DN PMID27172114-Compound-47 DMTIQYD TI TTIY56R DMTIQYD TN Kynurenine 3-hydroxylase (KMO) DMTIQYD MA Inhibitor DMTIQYD RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMTIQYD RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMTJ0DP DI DMTJ0DP DMTJ0DP DN Imidazole derivative 11 DMTJ0DP TI TTN9T81 DMTJ0DP TN Arachidonate 15-lipoxygenase (15-LOX) DMTJ0DP MA Inhibitor DMTJ0DP RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMTJ0DP RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMTJ0LB DI DMTJ0LB DMTJ0LB DN PMID27724045-Compound-14 DMTJ0LB TI TT473XN DMTJ0LB TN P2X purinoceptor 7 (P2RX7) DMTJ0LB MA Antagonist DMTJ0LB RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMTJ0LB RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMTJ1G8 DI DMTJ1G8 DMTJ1G8 DN 2-cyclopropyl-4-substituted-phenoxy-quinoline derivative 1 DMTJ1G8 TI TTPADOQ DMTJ1G8 TN HMG-CoA reductase (HMGCR) DMTJ1G8 MA Inhibitor DMTJ1G8 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMTJ1G8 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMTJBCG DI DMTJBCG DMTJBCG DN Thiazole carboxamide derivative 21 DMTJBCG TI TTCZOF2 DMTJBCG TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMTJBCG MA Inhibitor DMTJBCG RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMTJBCG RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMTJEU5 DI DMTJEU5 DMTJEU5 DN PMID29130358-Compound-LonimacranthoideVI DMTJEU5 TI TTVKILB DMTJEU5 TN Prostaglandin G/H synthase 2 (COX-2) DMTJEU5 MA Inhibitor DMTJEU5 RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMTJEU5 RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMTJHAK DI DMTJHAK DMTJHAK DN PMID25435285-Compound-26 DMTJHAK TI TTXJ47W DMTJHAK TN Metabotropic glutamate receptor 2 (mGluR2) DMTJHAK MA Antagonist DMTJHAK RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMTJHAK RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMTJHC2 DI DMTJHC2 DMTJHC2 DN PMID27215781-Compound-27 DMTJHC2 TI TTMSFAW DMTJHC2 TN Cannabinoid receptor 2 (CB2) DMTJHC2 MA Agonist DMTJHC2 RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMTJHC2 RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMTJRCS DI DMTJRCS DMTJRCS DN PMID25980951-Compound-43 DMTJRCS TI TTIRY6K DMTJRCS TN Cellular inhibitor of apoptosis 2 (BIRC3) DMTJRCS MA Antagonist DMTJRCS RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMTJRCS RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMTJRCS DI DMTJRCS DMTJRCS DN PMID25980951-Compound-43 DMTJRCS TI TTR7B60 DMTJRCS TN X-linked inhibitor of apoptosis protein (XIAP) DMTJRCS MA Antagonist DMTJRCS RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMTJRCS RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMTJRCS DI DMTJRCS DMTJRCS DN PMID25980951-Compound-43 DMTJRCS TI TTQ5LRD DMTJRCS TN Cellular inhibitor of apoptosis 1 (BIRC2) DMTJRCS MA Antagonist DMTJRCS RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMTJRCS RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMTK9M6 DI DMTK9M6 DMTK9M6 DN PMID28454500-Compound-57 DMTK9M6 TI TTA6ZN2 DMTK9M6 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMTK9M6 MA Inhibitor DMTK9M6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTK9M6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTK9M6 DI DMTK9M6 DMTK9M6 DN PMID28454500-Compound-57 DMTK9M6 TI TTGIZLN DMTK9M6 TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMTK9M6 MA Modulator DMTK9M6 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTK9M6 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTKFX7 DI DMTKFX7 DMTKFX7 DN PMID27109571-Compound-8 DMTKFX7 TI TTHWMFZ DMTKFX7 TN Fatty acid-binding protein 4 (FABP4) DMTKFX7 MA Inhibitor DMTKFX7 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTKFX7 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMTKLEP DI DMTKLEP DMTKLEP DN PMID28092474-Compound-32g DMTKLEP TI TT5ZKDI DMTKLEP TN Histone deacetylase 6 (HDAC6) DMTKLEP MA Inhibitor DMTKLEP RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMTKLEP RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMTKLEP DI DMTKLEP DMTKLEP DN PMID28092474-Compound-32g DMTKLEP TI TT6R7JZ DMTKLEP TN Histone deacetylase 1 (HDAC1) DMTKLEP MA Inhibitor DMTKLEP RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMTKLEP RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMTL73W DI DMTL73W DMTL73W DN PMID25726713-Compound-27 DMTL73W TI TT8J1S3 DMTL73W TN Smoothened homolog (SMO) DMTL73W MA Inhibitor DMTL73W RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMTL73W RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMTLO1E DI DMTLO1E DMTLO1E DN Peptide analog 22 DMTLO1E TI TTSJMN8 DMTLO1E TN Immunoproteasome complex (IP) DMTLO1E MA Inhibitor DMTLO1E RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMTLO1E RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMTM82B DI DMTM82B DMTM82B DN Pyrazolo[4,3-h]quinazoline-3-carboxamide derivative 1 DMTM82B TI TTTDVOJ DMTM82B TN Tropomyosin-related kinase A (TrkA) DMTM82B MA Inhibitor DMTM82B RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMTM82B RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMTMFNK DI DMTMFNK DMTMFNK DN Vinyl sulfone derivative 1 DMTMFNK TI TTA6ZN2 DMTMFNK TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMTMFNK MA Activator DMTMFNK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTMFNK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTMFNK DI DMTMFNK DMTMFNK DN Vinyl sulfone derivative 1 DMTMFNK TI TT3Z6Y9 DMTMFNK TN Cysteines of Keap1 (KEAP1 Cysteines) DMTMFNK MA Modulator DMTMFNK RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMTMFNK RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMTMG02 DI DMTMG02 DMTMG02 DN US8569313, Inhibitor 15 DMTMG02 TI TTPRO7W DMTMG02 TN Suppressor of tumorigenicity 14 protein (ST14) DMTMG02 MA Inhibitor DMTMG02 RN Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313. DMTMG02 RU http://www.freepatentsonline.com/US8569313.html DMTMJ7S DI DMTMJ7S DMTMJ7S DN Azole derivative 6 DMTMJ7S TI TTF8P9I DMTMJ7S TN Diacylglycerol acyltransferase 1 (DGAT1) DMTMJ7S MA Inhibitor DMTMJ7S RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMTMJ7S RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMTMWKX DI DMTMWKX DMTMWKX DN Pyrrolo[2,3-d]pyrimidine derivative 23 DMTMWKX TI TTGM6VW DMTMWKX TN Tyrosine-protein kinase BTK (ATK) DMTMWKX MA Inhibitor DMTMWKX RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMTMWKX RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMTMYJ6 DI DMTMYJ6 DMTMYJ6 DN N-oxalyl-D-tyrosine derivative 9 DMTMYJ6 TI TTWAQBO DMTMYJ6 TN Lysine-specific demethylase 4E (KDM4E) DMTMYJ6 MA Inhibitor DMTMYJ6 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMTMYJ6 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMTN25V DI DMTN25V DMTN25V DN PMID25666693-Compound-43 DMTN25V TI TTMI6F5 DMTN25V TN Transient receptor potential cation channel V1 (TRPV1) DMTN25V MA Antagonist DMTN25V RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMTN25V RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTN79G DI DMTN79G DMTN79G DN PMID25435285-Compound-42 DMTN79G TI TTXJ47W DMTN79G TN Metabotropic glutamate receptor 2 (mGluR2) DMTN79G MA Antagonist DMTN79G RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMTN79G RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMTOA1Q DI DMTOA1Q DMTOA1Q DN PMID29334795-Compound-21 DMTOA1Q TI TT9JNIC DMTOA1Q TN Histamine H3 receptor (H3R) DMTOA1Q RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMTOA1Q RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMTOFGH DI DMTOFGH DMTOFGH DN PMID25656651-Compound-23b DMTOFGH TI TTS7G69 DMTOFGH TN Fusion protein Bcr-Abl (Bcr-Abl) DMTOFGH MA Inhibitor DMTOFGH RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMTOFGH RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMTOHNQ DI DMTOHNQ DMTOHNQ DN PMID29053063-Compound-7a DMTOHNQ TI TTZ963I DMTOHNQ TN Monoglyceride lipase (MAGL) DMTOHNQ MA Inhibitor DMTOHNQ RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMTOHNQ RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMTOJCG DI DMTOJCG DMTOJCG DN PMID26560530-Compound-46 DMTOJCG TI TT2F4OL DMTOJCG TN Tissue transglutaminase (TG2) DMTOJCG MA Inhibitor DMTOJCG RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMTOJCG RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMTP02Q DI DMTP02Q DMTP02Q DN PMID25684022-Compound-WO2009153313 DMTP02Q TI TTCZOF2 DMTP02Q TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMTP02Q MA Inhibitor DMTP02Q RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMTP02Q RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMTPBNY DI DMTPBNY DMTPBNY DN PMID26651364-Compound-10a DMTPBNY TI TTTCRU2 DMTPBNY TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMTPBNY MA Antagonist DMTPBNY RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMTPBNY RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMTPGRO DI DMTPGRO DMTPGRO DN Indoline derivative 10 DMTPGRO TI TT5OU0D DMTPGRO TN PRKR-like endoplasmic reticulum kinase (PERK) DMTPGRO MA Inhibitor DMTPGRO RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMTPGRO RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMTPJI8 DI DMTPJI8 DMTPJI8 DN PMID25522065-Compound-18 DMTPJI8 TI TTX4RTB DMTPJI8 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMTPJI8 MA Antagonist DMTPJI8 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMTPJI8 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMTQ26G DI DMTQ26G DMTQ26G DN PMID25666693-Compound-79 DMTQ26G TI TTMI6F5 DMTQ26G TN Transient receptor potential cation channel V1 (TRPV1) DMTQ26G MA Antagonist DMTQ26G RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMTQ26G RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTQBUD DI DMTQBUD DMTQBUD DN Pyrimidine derivative 30 DMTQBUD TI TTDIGC1 DMTQBUD TN Dipeptidyl peptidase 4 (DPP-4) DMTQBUD MA Inhibitor DMTQBUD RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMTQBUD RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMTQNYZ DI DMTQNYZ DMTQNYZ DN Pyrazolo[1,5-a]pyrimidine derivative 8 DMTQNYZ TI TT6OEDT DMTQNYZ TN Cannabinoid receptor 1 (CB1) DMTQNYZ MA Antagonist DMTQNYZ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMTQNYZ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMTQRVC DI DMTQRVC DMTQRVC DN PMID27376512-Compound-asCEBP-1 DMTQRVC TI TT6S2FE DMTQRVC TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMTQRVC MA Inhibitor DMTQRVC RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMTQRVC RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMTR6BX DI DMTR6BX DMTR6BX DN Biphenyl mannoside derivative 21 DMTR6BX TI TTTCRU2 DMTR6BX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMTR6BX MA Antagonist DMTR6BX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMTR6BX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMTROIQ DI DMTROIQ DMTROIQ DN PMID25991433-Compound-O2 DMTROIQ TI TTQBR95 DMTROIQ TN Stress-activated protein kinase 2a (p38 alpha) DMTROIQ MA Inhibitor DMTROIQ RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMTROIQ RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMTRPE6 DI DMTRPE6 DMTRPE6 DN Phenylpyridine derivative 2 DMTRPE6 TI TT1LVF2 DMTRPE6 TN Cyclin-dependent kinase 9 (CDK9) DMTRPE6 MA Inhibitor DMTRPE6 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTRPE6 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTRZI7 DI DMTRZI7 DMTRZI7 DN US9522888, 695 DMTRZI7 TI TTDYP7I DMTRZI7 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMTRZI7 MA Inhibitor DMTRZI7 RN Substituted bicyclic compounds. US9522888. DMTRZI7 RU http://www.freepatentsonline.com/US9522888.html DMTS8O9 DI DMTS8O9 DMTS8O9 DN Fluorophenyl-substituted heterocyclic amide analog 1 DMTS8O9 TI TT473XN DMTS8O9 TN P2X purinoceptor 7 (P2RX7) DMTS8O9 MA Antagonist DMTS8O9 RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMTS8O9 RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMTSPVF DI DMTSPVF DMTSPVF DN Epoxysuccinate derivative 7 DMTSPVF TI TTG5QB7 DMTSPVF TN Calpain-2 (CAPN2) DMTSPVF MA Inhibitor DMTSPVF RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMTSPVF RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMTSQXE DI DMTSQXE DMTSQXE DN PMID26394986-Compound-12 DMTSQXE TI TTH8FZW DMTSQXE TN Signal transducer and activator of transcription 3 (STAT3) DMTSQXE MA Inhibitor DMTSQXE RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMTSQXE RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMTSX7J DI DMTSX7J DMTSX7J DN Piperidinyl triazole derivative 1 DMTSX7J TI TTTJZ4M DMTSX7J TN Prolylcarboxypeptidase (PRCP) DMTSX7J MA Inhibitor DMTSX7J RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMTSX7J RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMTUA6E DI DMTUA6E DMTUA6E DN PMID25656651-Compound-42 DMTUA6E TI TT3PJMV DMTUA6E TN Tyrosine-protein kinase ABL1 (ABL) DMTUA6E MA Inhibitor DMTUA6E RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMTUA6E RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMTUA6E DI DMTUA6E DMTUA6E DN PMID25656651-Compound-42 DMTUA6E TI TTZJTWA DMTUA6E TN ABL T315I mutant (ABL T315I) DMTUA6E MA Inhibitor DMTUA6E RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMTUA6E RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMTUC9E DI DMTUC9E DMTUC9E DN PMID28870136-Compound-49 DMTUC9E TI TTK0O6Y DMTUC9E TN Ecto-5'-nucleotidase (CD73) DMTUC9E MA Inhibitor DMTUC9E RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMTUC9E RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMTUNW4 DI DMTUNW4 DMTUNW4 DN PMID27977313-Compound-5 DMTUNW4 TI TTR7UJ3 DMTUNW4 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTUNW4 MA Inhibitor DMTUNW4 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTUNW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTUQV0 DI DMTUQV0 DMTUQV0 DN PMID29334795-Compound-24 DMTUQV0 TI TT9JNIC DMTUQV0 TN Histamine H3 receptor (H3R) DMTUQV0 MA Inverse agonist DMTUQV0 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMTUQV0 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMTUS0Y DI DMTUS0Y DMTUS0Y DN Imidazopyridine and triazolopyridine compound 1 DMTUS0Y TI TTHS256 DMTUS0Y TN Metabotropic glutamate receptor 5 (mGluR5) DMTUS0Y MA Modulator DMTUS0Y RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMTUS0Y RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMTV5NU DI DMTV5NU DMTV5NU DN PMID27998201-Compound-11 DMTV5NU TI TTF2LRI DMTV5NU TN Cathepsin B (CTSB) DMTV5NU MA Inhibitor DMTV5NU RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMTV5NU RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMTVAJ0 DI DMTVAJ0 DMTVAJ0 DN Pyrazole derivative 63 DMTVAJ0 TI TTH8FZW DMTVAJ0 TN Signal transducer and activator of transcription 3 (STAT3) DMTVAJ0 MA Inhibitor DMTVAJ0 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMTVAJ0 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMTVAUP DI DMTVAUP DMTVAUP DN PMID25666693-Compound-156 DMTVAUP TI TTMI6F5 DMTVAUP TN Transient receptor potential cation channel V1 (TRPV1) DMTVAUP MA Antagonist DMTVAUP RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMTVAUP RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMTVZWM DI DMTVZWM DMTVZWM DN PMID26924192-Compound-50 DMTVZWM TI TTE4BSY DMTVZWM TN Bromodomain and extraterminal domain protein (BET) DMTVZWM MA Inhibitor DMTVZWM RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMTVZWM RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMTWAH3 DI DMTWAH3 DMTWAH3 DN Isoflavone derivative 2 DMTWAH3 TI TTJOMH6 DMTWAH3 TN Zinc finger protein GLI1 (Gli1) DMTWAH3 MA Inhibitor DMTWAH3 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMTWAH3 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMTWAH3 DI DMTWAH3 DMTWAH3 DN Isoflavone derivative 2 DMTWAH3 TI TT8J1S3 DMTWAH3 TN Smoothened homolog (SMO) DMTWAH3 MA Inhibitor DMTWAH3 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMTWAH3 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMTWAJX DI DMTWAJX DMTWAJX DN Flavonoid derivative 5 DMTWAJX TI TTH8FZW DMTWAJX TN Signal transducer and activator of transcription 3 (STAT3) DMTWAJX MA Inhibitor DMTWAJX RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMTWAJX RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMTWI1H DI DMTWI1H DMTWI1H DN BDBM50158803 DMTWI1H TI TTIG67W DMTWI1H TN Lysine-specific demethylase 5A (KDM5A) DMTWI1H MA Inhibitor DMTWI1H RN Histone demethylase inhibitors. US9617242. DMTWI1H RU http://www.freepatentsonline.com/US9617242.html DMTWIE2 DI DMTWIE2 DMTWIE2 DN BC11-28 DMTWIE2 TI TTIS4OW DMTWIE2 TN Phosphodiesterase 8 (PDE8) DMTWIE2 MA Inhibitor DMTWIE2 RN Inhibitors of phosphodiesterase 11 (PDE11). US9173884. DMTWIE2 RU http://www.freepatentsonline.com/US9173884.html DMTX1G4 DI DMTX1G4 DMTX1G4 DN Pyrrolo[2,3-d]pyrimidine derivative 3 DMTX1G4 TI TTTDVOJ DMTX1G4 TN Tropomyosin-related kinase A (TrkA) DMTX1G4 MA Inhibitor DMTX1G4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMTX1G4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMTX21L DI DMTX21L DMTX21L DN Sulfonamide derivative 1 DMTX21L TI TT6OEDT DMTX21L TN Cannabinoid receptor 1 (CB1) DMTX21L MA Antagonist DMTX21L RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMTX21L RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMTXDSG DI DMTXDSG DMTXDSG DN Succinamide derivative 1 DMTXDSG TI TTA592U DMTXDSG TN Urate anion exchanger 1 (URAT1) DMTXDSG MA Inhibitor DMTXDSG RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMTXDSG RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMTXGYS DI DMTXGYS DMTXGYS DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 1 DMTXGYS TI TTHS256 DMTXGYS TN Metabotropic glutamate receptor 5 (mGluR5) DMTXGYS MA Modulator DMTXGYS RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMTXGYS RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMTXZUF DI DMTXZUF DMTXZUF DN 2-(substituted ethynyl)quinoline derivative 4 DMTXZUF TI TTHS256 DMTXZUF TN Metabotropic glutamate receptor 5 (mGluR5) DMTXZUF MA Antagonist DMTXZUF RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMTXZUF RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMTYHCU DI DMTYHCU DMTYHCU DN PMID25435285-Compound-37 DMTYHCU TI TTXJ47W DMTYHCU TN Metabotropic glutamate receptor 2 (mGluR2) DMTYHCU MA Antagonist DMTYHCU RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMTYHCU RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMTYL68 DI DMTYL68 DMTYL68 DN Disulfide compound 1 DMTYL68 TI TTR7UJ3 DMTYL68 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMTYL68 MA Inhibitor DMTYL68 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMTYL68 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMTYN2D DI DMTYN2D DMTYN2D DN Pyrazolo[1,5-a]pyrimidine derivative 16 DMTYN2D TI TTTDVOJ DMTYN2D TN Tropomyosin-related kinase A (TrkA) DMTYN2D MA Inhibitor DMTYN2D RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMTYN2D RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMTYPBM DI DMTYPBM DMTYPBM DN 2,2-bipyridyl derivative 4 DMTYPBM TI TT0RGE9 DMTYPBM TN Lysine-specific demethylase 4 (KDM4) DMTYPBM MA Inhibitor DMTYPBM RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMTYPBM RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMTYQOF DI DMTYQOF DMTYQOF DN PMID25991433-Compound-B2 DMTYQOF TI TTVOE6D DMTYQOF TN Mitogen-activated protein kinase (MAPK) DMTYQOF MA Inhibitor DMTYQOF RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMTYQOF RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMTZ6K9 DI DMTZ6K9 DMTZ6K9 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 2 DMTZ6K9 TI TT7HF4W DMTZ6K9 TN Cyclin-dependent kinase 2 (CDK2) DMTZ6K9 MA Inhibitor DMTZ6K9 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTZ6K9 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTZ6K9 DI DMTZ6K9 DMTZ6K9 DN N-(pyridin-2-yl)pyrimidin-4-amine derivative 2 DMTZ6K9 TI TT1LVF2 DMTZ6K9 TN Cyclin-dependent kinase 9 (CDK9) DMTZ6K9 MA Inhibitor DMTZ6K9 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMTZ6K9 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMTZCLG DI DMTZCLG DMTZCLG DN Pyrazolopyridine derivative 5 DMTZCLG TI TTBYWP2 DMTZCLG TN TYK2 tyrosine kinase (TYK2) DMTZCLG MA Inhibitor DMTZCLG RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMTZCLG RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMTZDUV DI DMTZDUV DMTZDUV DN 1,2-diamino cyclopentane-based derivative 14 DMTZDUV TI TT9N02I DMTZDUV TN Orexin receptor type 2 (HCRTR2) DMTZDUV MA Antagonist DMTZDUV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTZDUV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTZDUV DI DMTZDUV DMTZDUV DN 1,2-diamino cyclopentane-based derivative 14 DMTZDUV TI TT60Q8D DMTZDUV TN Orexin receptor type 1 (HCRTR1) DMTZDUV MA Antagonist DMTZDUV RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMTZDUV RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMTZK6V DI DMTZK6V DMTZK6V DN Pyridopyrimidine derivative 1 DMTZK6V TI TTZCRP3 DMTZK6V TN ERK activator kinase (MEK) DMTZK6V MA Inhibitor DMTZK6V RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMTZK6V RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMTZNSM DI DMTZNSM DMTZNSM DN PMID27414413-Compound-Figure8right DMTZNSM TI TTA592U DMTZNSM TN Urate anion exchanger 1 (URAT1) DMTZNSM MA Inhibitor DMTZNSM RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMTZNSM RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMTZRCW DI DMTZRCW DMTZRCW DN Aryl carboxamide derivative 1 DMTZRCW TI TT4G2JS DMTZRCW TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMTZRCW MA Inhibitor DMTZRCW RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMTZRCW RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMTZRCW DI DMTZRCW DMTZRCW DN Aryl carboxamide derivative 1 DMTZRCW TI TTZOVE0 DMTZRCW TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMTZRCW MA Inhibitor DMTZRCW RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMTZRCW RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMTZRCW DI DMTZRCW DMTZRCW DN Aryl carboxamide derivative 1 DMTZRCW TI TTAXZ0K DMTZRCW TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMTZRCW MA Inhibitor DMTZRCW RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMTZRCW RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMTZRFP DI DMTZRFP DMTZRFP DN PMID25776143-Compound-2 DMTZRFP TI TT4TFGN DMTZRFP TN Vasopressin V1a receptor (V1AR) DMTZRFP MA Agonist DMTZRFP RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMTZRFP RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMTZVY3 DI DMTZVY3 DMTZVY3 DN PMID27109571-Compound-28 DMTZVY3 TI TTNT2S6 DMTZVY3 TN Fatty acid-binding protein 5 (FABP5) DMTZVY3 MA Inhibitor DMTZVY3 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTZVY3 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMTZVY3 DI DMTZVY3 DMTZVY3 DN PMID27109571-Compound-28 DMTZVY3 TI TTHWMFZ DMTZVY3 TN Fatty acid-binding protein 4 (FABP4) DMTZVY3 MA Inhibitor DMTZVY3 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMTZVY3 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMU04PM DI DMU04PM DMU04PM DN Carbamide derivative 14 DMU04PM TI TTOHSBA DMU04PM TN Vascular endothelial growth factor A (VEGFA) DMU04PM MA Inhibitor DMU04PM RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMU04PM RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMU07MO DI DMU07MO DMU07MO DN BDBM50158791 DMU07MO TI TTIG67W DMU07MO TN Lysine-specific demethylase 5A (KDM5A) DMU07MO MA Inhibitor DMU07MO RN Histone demethylase inhibitors. US9725441. DMU07MO RU http://www.freepatentsonline.com/US9725441.html DMU0S2W DI DMU0S2W DMU0S2W DN Phenylpropylamine derivative 5 DMU0S2W TI TT5TPI6 DMU0S2W TN Opioid receptor sigma 1 (OPRS1) DMU0S2W MA Ligand DMU0S2W RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMU0S2W RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMU0YST DI DMU0YST DMU0YST DN Biphenyl mannoside derivative 12 DMU0YST TI TTTCRU2 DMU0YST TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMU0YST MA Antagonist DMU0YST RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMU0YST RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMU15FW DI DMU15FW DMU15FW DN Triazole derivative 6 DMU15FW TI TTSCIUP DMU15FW TN Oxytocin receptor (OTR) DMU15FW MA Antagonist DMU15FW RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMU15FW RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMU18W6 DI DMU18W6 DMU18W6 DN PMID28870136-Compound-39 DMU18W6 TI TTK0O6Y DMU18W6 TN Ecto-5'-nucleotidase (CD73) DMU18W6 MA Inhibitor DMU18W6 RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMU18W6 RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMU1PEZ DI DMU1PEZ DMU1PEZ DN PMID25522065-Compound-6 DMU1PEZ TI TTX4RTB DMU1PEZ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMU1PEZ MA Antagonist DMU1PEZ RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMU1PEZ RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMU21PD DI DMU21PD DMU21PD DN US10023583, Example 13 DMU21PD TI TTY2KP7 DMU21PD TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMU21PD MA Inhibitor DMU21PD RN Bicyclic pyridine compound. US10023583. DMU21PD RU http://www.freepatentsonline.com/US10023583.html DMU26R7 DI DMU26R7 DMU26R7 DN US8609715, B-61 DMU26R7 TI TTXL0GC DMU26R7 TN Enteropeptidase (TMPRSS15) DMU26R7 MA Inhibitor DMU26R7 RN Heteroarylcarboxylic acid ester derivative. US8609715. DMU26R7 RU http://www.freepatentsonline.com/US8609715.html DMU2WGL DI DMU2WGL DMU2WGL DN N-alkyl-4-oxazolecar boxamide derivative 1 DMU2WGL TI TTDP1UC DMU2WGL TN Fatty acid amide hydrolase (FAAH) DMU2WGL MA Inhibitor DMU2WGL RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMU2WGL RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMU3APC DI DMU3APC DMU3APC DN Resorcinol compound 23 DMU3APC TI TTULVH8 DMU3APC TN Tyrosinase (TYR) DMU3APC MA Inhibitor DMU3APC RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMU3APC RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMU3MQB DI DMU3MQB DMU3MQB DN PMID28870136-Compound-51 DMU3MQB TI TTK0O6Y DMU3MQB TN Ecto-5'-nucleotidase (CD73) DMU3MQB MA Inhibitor DMU3MQB RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMU3MQB RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMU3PAR DI DMU3PAR DMU3PAR DN Imidazo[1,5-a]pyridine derivative 2 DMU3PAR TI TTZJYKH DMU3PAR TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMU3PAR MA Inhibitor DMU3PAR RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMU3PAR RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMU3XBH DI DMU3XBH DMU3XBH DN PMID25991433-Compound-G2 DMU3XBH TI TT0K6EO DMU3XBH TN Stress-activated protein kinase JNK1 (JNK1) DMU3XBH MA Inhibitor DMU3XBH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU3XBH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU4QYR DI DMU4QYR DMU4QYR DN PMID27998201-Compound-7 DMU4QYR TI TT36ETB DMU4QYR TN Cathepsin L (CTSL) DMU4QYR MA Inhibitor DMU4QYR RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMU4QYR RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMU4QYR DI DMU4QYR DMU4QYR DN PMID27998201-Compound-7 DMU4QYR TI TTUMQVO DMU4QYR TN Cathepsin S (CTSS) DMU4QYR MA Inhibitor DMU4QYR RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMU4QYR RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMU51T4 DI DMU51T4 DMU51T4 DN Pyrrolidinyl urea derivative 5 DMU51T4 TI TTTDVOJ DMU51T4 TN Tropomyosin-related kinase A (TrkA) DMU51T4 MA Inhibitor DMU51T4 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMU51T4 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMU59IJ DI DMU59IJ DMU59IJ DN Pyrazole derivative 32 DMU59IJ TI TT6OEDT DMU59IJ TN Cannabinoid receptor 1 (CB1) DMU59IJ MA Antagonist DMU59IJ RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMU59IJ RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TTPMQSO DMU5GKC TN ALK tyrosine kinase receptor (ALK) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TT4DXQT DMU5GKC TN Proto-oncogene c-Ret (RET) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TTSZ6Y3 DMU5GKC TN Proto-oncogene c-Ros (ROS1) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5GKC DI DMU5GKC DMU5GKC DN Carboxamide derivative 4 DMU5GKC TI TTGJCWZ DMU5GKC TN Fms-like tyrosine kinase 3 (FLT-3) DMU5GKC MA Inhibitor DMU5GKC RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMU5GKC RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMU5JC0 DI DMU5JC0 DMU5JC0 DN HouttuynoidA DMU5JC0 TI TT3WG5C DMU5JC0 TN Monoamine oxidase type A (MAO-A) DMU5JC0 MA Inhibitor DMU5JC0 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMU5JC0 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMU5KWC DI DMU5KWC DMU5KWC DN Indoline derivative 6 DMU5KWC TI TT5OU0D DMU5KWC TN PRKR-like endoplasmic reticulum kinase (PERK) DMU5KWC MA Inhibitor DMU5KWC RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMU5KWC RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMU61XP DI DMU61XP DMU61XP DN PMID29671355-Compound-69 DMU61XP TI TTBH0VX DMU61XP TN Histone deacetylase (HDAC) DMU61XP MA Inhibitor DMU61XP RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMU61XP RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMU65YX DI DMU65YX DMU65YX DN N-quinolin-benzene sulphonamide derivative 3 DMU65YX TI TTSXVID DMU65YX TN Nuclear factor NF-kappa-B (NFKB) DMU65YX MA Inhibitor DMU65YX RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMU65YX RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMU690T DI DMU690T DMU690T DN PMID27109571-Compound-31 DMU690T TI TTNT2S6 DMU690T TN Fatty acid-binding protein 5 (FABP5) DMU690T MA Inhibitor DMU690T RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMU690T RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMU690T DI DMU690T DMU690T DN PMID27109571-Compound-31 DMU690T TI TTHWMFZ DMU690T TN Fatty acid-binding protein 4 (FABP4) DMU690T MA Inhibitor DMU690T RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMU690T RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMU6LS4 DI DMU6LS4 DMU6LS4 DN Heterocyclic derivative 7 DMU6LS4 TI TTCZOF2 DMU6LS4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMU6LS4 MA Inhibitor DMU6LS4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMU6LS4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMU6ST7 DI DMU6ST7 DMU6ST7 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 2 DMU6ST7 TI TTJGW1Z DMU6ST7 TN Phosphodiesterase 2A (PDE2A) DMU6ST7 MA Inhibitor DMU6ST7 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMU6ST7 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMU75ZX DI DMU75ZX DMU75ZX DN PMID25991433-Compound-J5 DMU75ZX TI TT0K6EO DMU75ZX TN Stress-activated protein kinase JNK1 (JNK1) DMU75ZX MA Inhibitor DMU75ZX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU75ZX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU75ZX DI DMU75ZX DMU75ZX DN PMID25991433-Compound-J5 DMU75ZX TI TT056SO DMU75ZX TN Stress-activated protein kinase JNK3 (JNK3) DMU75ZX MA Inhibitor DMU75ZX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU75ZX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU75ZX DI DMU75ZX DMU75ZX DN PMID25991433-Compound-J5 DMU75ZX TI TTHS0U8 DMU75ZX TN Stress-activated protein kinase JNK2 (JNK2) DMU75ZX MA Inhibitor DMU75ZX RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMU75ZX RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMU7YC2 DI DMU7YC2 DMU7YC2 DN Antibodie derivative 2 DMU7YC2 TI TTOHSBA DMU7YC2 TN Vascular endothelial growth factor A (VEGFA) DMU7YC2 MA Binder DMU7YC2 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMU7YC2 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMU8CAD DI DMU8CAD DMU8CAD DN US10092575, Example 101 DMU8CAD TI TT3ZS42 DMU8CAD TN Phosphodiesterase 1B (PDE1B) DMU8CAD MA Inhibitor DMU8CAD RN Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds. US10092575. DMU8CAD RU http://www.freepatentsonline.com/US10092575.html DMU8ENF DI DMU8ENF DMU8ENF DN PMID28766366-Compound-Scheme15-2 DMU8ENF TI TTSBVFO DMU8ENF TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMU8ENF MA Inhibitor DMU8ENF RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMU8ENF RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMU8FC1 DI DMU8FC1 DMU8FC1 DN 1-phenyl-1,3,4-triazole derivative 3 DMU8FC1 TI TTA6ZN2 DMU8FC1 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMU8FC1 MA Inhibitor DMU8FC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMU8FC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMU8FC1 DI DMU8FC1 DMU8FC1 DN 1-phenyl-1,3,4-triazole derivative 3 DMU8FC1 TI TT956B0 DMU8FC1 TN Keap1-Nrf2[DLG] PPI (KEAP1-Nrf2 DLG) DMU8FC1 MA Modulator DMU8FC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMU8FC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMU8LPN DI DMU8LPN DMU8LPN DN Epoxysuccinate derivative 1 DMU8LPN TI TTG5QB7 DMU8LPN TN Calpain-2 (CAPN2) DMU8LPN MA Inhibitor DMU8LPN RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMU8LPN RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMU8OIL DI DMU8OIL DMU8OIL DN Acyl oxymethyl acrylamide ester derivative 2 DMU8OIL TI TTR7UJ3 DMU8OIL TN Cytoplasmic thioredoxin reductase (TXNRD1) DMU8OIL MA Inhibitor DMU8OIL RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMU8OIL RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMU8ZI3 DI DMU8ZI3 DMU8ZI3 DN PMID25656651-Compound-33b DMU8ZI3 TI TT3PJMV DMU8ZI3 TN Tyrosine-protein kinase ABL1 (ABL) DMU8ZI3 MA Inhibitor DMU8ZI3 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMU8ZI3 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMU9A7V DI DMU9A7V DMU9A7V DN Triazolo-phthalazine derivative 1 DMU9A7V TI TTJGW1Z DMU9A7V TN Phosphodiesterase 2A (PDE2A) DMU9A7V MA Inhibitor DMU9A7V RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMU9A7V RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMU9XMV DI DMU9XMV DMU9XMV DN 1,2,4-triazole derivative 3 DMU9XMV TI TT5TPI6 DMU9XMV TN Opioid receptor sigma 1 (OPRS1) DMU9XMV MA Inhibitor DMU9XMV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMU9XMV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMU9Y4B DI DMU9Y4B DMU9Y4B DN Aryl pyrimidine derivative 2 DMU9Y4B TI TTIY56R DMU9Y4B TN Kynurenine 3-hydroxylase (KMO) DMU9Y4B MA Inhibitor DMU9Y4B RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMU9Y4B RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMU9YPV DI DMU9YPV DMU9YPV DN US8741907-compound-3 DMU9YPV TI TTN34SQ DMU9YPV TN Phosphodiesterase 3B (PDE3B) DMU9YPV MA Inhibitor DMU9YPV RN Selective phosphodiesterase 9A inhibitors as medicaments for improving cognitive processes. US9067945. DMU9YPV RU http://www.freepatentsonline.com/US9067945.html DMUA740 DI DMUA740 DMUA740 DN Hydrazide derivative 1 DMUA740 TI TT6OEDT DMUA740 TN Cannabinoid receptor 1 (CB1) DMUA740 MA Antagonist DMUA740 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUA740 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUAC1T DI DMUAC1T DMUAC1T DN PMID29671355-Compound-71a DMUAC1T TI TTTQGH8 DMUAC1T TN Histone deacetylase 4 (HDAC4) DMUAC1T MA Inhibitor DMUAC1T RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUAC1T RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUASHT DI DMUASHT DMUASHT DN Aminoazetidine derivative 9 DMUASHT TI TT6OEDT DMUASHT TN Cannabinoid receptor 1 (CB1) DMUASHT MA Antagonist DMUASHT RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUASHT RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUB4QL DI DMUB4QL DMUB4QL DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 1 DMUB4QL TI TTJGW1Z DMUB4QL TN Phosphodiesterase 2A (PDE2A) DMUB4QL MA Inhibitor DMUB4QL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUB4QL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUB4QL DI DMUB4QL DMUB4QL DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 1 DMUB4QL TI TTJW4LU DMUB4QL TN Phosphodiesterase 10A (PDE10) DMUB4QL MA Inhibitor DMUB4QL RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUB4QL RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUB7RV DI DMUB7RV DMUB7RV DN Ring-fused compound 1 DMUB7RV TI TTA592U DMUB7RV TN Urate anion exchanger 1 (URAT1) DMUB7RV MA Inhibitor DMUB7RV RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMUB7RV RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMUBDYG DI DMUBDYG DMUBDYG DN Bicyclic heteroaryl benzamide derivative 4 DMUBDYG TI TTTDVOJ DMUBDYG TN Tropomyosin-related kinase A (TrkA) DMUBDYG MA Inhibitor DMUBDYG RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMUBDYG RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMUBG20 DI DMUBG20 DMUBG20 DN Benzoic acid linked peptide analog 2 DMUBG20 TI TTULVH8 DMUBG20 TN Tyrosinase (TYR) DMUBG20 MA Inhibitor DMUBG20 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMUBG20 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMUBM1Y DI DMUBM1Y DMUBM1Y DN PMID28447479-Compound-4 DMUBM1Y TI TTSCIM2 DMUBM1Y TN Extracellular lysophospholipase D (E-NPP2) DMUBM1Y MA Inhibitor DMUBM1Y RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMUBM1Y RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TT8K17W DMUBOEX TN Histone deacetylase 11 (HDAC11) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTSHTOI DMUBOEX TN Histone deacetylase 2 (HDAC2) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTTQGH8 DMUBOEX TN Histone deacetylase 4 (HDAC4) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TT6R7JZ DMUBOEX TN Histone deacetylase 1 (HDAC1) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTUELN5 DMUBOEX TN Histone deacetylase 5 (HDAC5) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TTT6LFV DMUBOEX TN Histone deacetylase 8 (HDAC8) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBOEX DI DMUBOEX DMUBOEX DN PMID29671355-Compound-23 DMUBOEX TI TT5ZKDI DMUBOEX TN Histone deacetylase 6 (HDAC6) DMUBOEX MA Inhibitor DMUBOEX RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUBOEX RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUBSFV DI DMUBSFV DMUBSFV DN PMID28350212-Compound-7 DMUBSFV TI TTZS04O DMUBSFV TN Gamma-secretase subunit APH-1A/1B (APH-1) DMUBSFV MA Inhibitor DMUBSFV RN Gamma secretase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2017 Jul;27(7):851-866. DMUBSFV RU https://www.ncbi.nlm.nih.gov/pubmed/28350212 DMUBZO3 DI DMUBZO3 DMUBZO3 DN PMID25553724-Compound-US20130116324 2 DMUBZO3 TI TTSXVID DMUBZO3 TN Nuclear factor NF-kappa-B (NFKB) DMUBZO3 MA Inhibitor DMUBZO3 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMUBZO3 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMUCIPE DI DMUCIPE DMUCIPE DN US9650366, 9 DMUCIPE TI TTXEZJ4 DMUCIPE TN Tyrosine-protein kinase EIF2AK2 (p68) DMUCIPE MA Inhibitor DMUCIPE RN Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors. US9650366. DMUCIPE RU http://www.freepatentsonline.com/US9650366.html DMUCW9Y DI DMUCW9Y DMUCW9Y DN Boronic acid derivative 5 DMUCW9Y TI TTDP1UC DMUCW9Y TN Fatty acid amide hydrolase (FAAH) DMUCW9Y MA Inhibitor DMUCW9Y RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMUCW9Y RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMUD7H8 DI DMUD7H8 DMUD7H8 DN Unii-I92MU0V408 DMUD7H8 TI TT42OGM DMUD7H8 TN Hematopoietic cell kinase (HCK) DMUD7H8 MA Inhibitor DMUD7H8 RN Respiratory formulations and compounds for use therein. US8933228. DMUD7H8 RU http://www.freepatentsonline.com/US8933228.html DMUD7IB DI DMUD7IB DMUD7IB DN PMID26004420-Compound-US20140031349D DMUD7IB TI TTJ13ST DMUD7IB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMUD7IB MA Inhibitor DMUD7IB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMUD7IB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMUDE89 DI DMUDE89 DMUDE89 DN US20160326143, 38 DMUDE89 TI TTW7OTG DMUDE89 TN Leukotriene C4 synthase (LTC4S) DMUDE89 MA Inhibitor DMUDE89 RN Compounds and uses. US9657001. DMUDE89 RU http://www.freepatentsonline.com/US9657001.html DMUDKE0 DI DMUDKE0 DMUDKE0 DN PMID29649907-Compound-34 DMUDKE0 TI TTS4UGC DMUDKE0 TN Farnesoid X-activated receptor (FXR) DMUDKE0 MA Agonist DMUDKE0 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMUDKE0 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMUE7R5 DI DMUE7R5 DMUE7R5 DN N-oxalyl-D-tyrosine derivative 4 DMUE7R5 TI TTWAQBO DMUE7R5 TN Lysine-specific demethylase 4E (KDM4E) DMUE7R5 MA Inhibitor DMUE7R5 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMUE7R5 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMUEI4N DI DMUEI4N DMUEI4N DN Tetra-azabenzo[e]azulene derivative 2 DMUEI4N TI TT4TFGN DMUEI4N TN Vasopressin V1a receptor (V1AR) DMUEI4N MA Inhibitor DMUEI4N RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMUEI4N RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMUF5AC DI DMUF5AC DMUF5AC DN Carbamide derivative 17 DMUF5AC TI TTOHSBA DMUF5AC TN Vascular endothelial growth factor A (VEGFA) DMUF5AC MA Inhibitor DMUF5AC RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMUF5AC RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMUF63N DI DMUF63N DMUF63N DN Pyridopyrimidinone derivative 2 DMUF63N TI TTK0FEA DMUF63N TN Leucine-rich repeat kinase 2 (LRRK2) DMUF63N MA Inhibitor DMUF63N RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMUF63N RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMUFSQ2 DI DMUFSQ2 DMUFSQ2 DN Imidazolidine-2,4-dione derivative 1 DMUFSQ2 TI TT6OEDT DMUFSQ2 TN Cannabinoid receptor 1 (CB1) DMUFSQ2 MA Antagonist DMUFSQ2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUFSQ2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUG69Q DI DMUG69Q DMUG69Q DN Diamine derivative 1 DMUG69Q TI TTULVH8 DMUG69Q TN Tyrosinase (TYR) DMUG69Q MA Inhibitor DMUG69Q RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMUG69Q RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMUG6YT DI DMUG6YT DMUG6YT DN Antibodie derivative 6 DMUG6YT TI TTUTJGQ DMUG6YT TN Vascular endothelial growth factor receptor 2 (KDR) DMUG6YT MA Binder DMUG6YT RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMUG6YT RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMUG7E9 DI DMUG7E9 DMUG7E9 DN C-linked disaccharide biphenyl mannoside derivative 5 DMUG7E9 TI TTTCRU2 DMUG7E9 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMUG7E9 MA Antagonist DMUG7E9 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMUG7E9 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMUG9X0 DI DMUG9X0 DMUG9X0 DN PMID27414413-Compound-Figure6right DMUG9X0 TI TTA592U DMUG9X0 TN Urate anion exchanger 1 (URAT1) DMUG9X0 MA Inhibitor DMUG9X0 RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMUG9X0 RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMUGC53 DI DMUGC53 DMUGC53 DN PMID29338548-Compound-29 DMUGC53 TI TTHJTF7 DMUGC53 TN Glycine transporter GlyT-1 (SLC6A9) DMUGC53 MA Inhibitor DMUGC53 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMUGC53 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMUGZNL DI DMUGZNL DMUGZNL DN Aminopyridine derivative 2 DMUGZNL TI TTK0FEA DMUGZNL TN Leucine-rich repeat kinase 2 (LRRK2) DMUGZNL MA Inhibitor DMUGZNL RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMUGZNL RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMUHEP8 DI DMUHEP8 DMUHEP8 DN PMID25726713-Compound-56 DMUHEP8 TI TT8J1S3 DMUHEP8 TN Smoothened homolog (SMO) DMUHEP8 MA Inhibitor DMUHEP8 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMUHEP8 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMUHFLQ DI DMUHFLQ DMUHFLQ DN N-oxalylglycine derivative 1 DMUHFLQ TI TT0RGE9 DMUHFLQ TN Lysine-specific demethylase 4 (KDM4) DMUHFLQ MA Inhibitor DMUHFLQ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMUHFLQ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMUHNS7 DI DMUHNS7 DMUHNS7 DN PMID29649907-Compound-24 DMUHNS7 TI TTS4UGC DMUHNS7 TN Farnesoid X-activated receptor (FXR) DMUHNS7 MA Agonist DMUHNS7 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMUHNS7 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMUHSAZ DI DMUHSAZ DMUHSAZ DN Unii-R228S06soh DMUHSAZ TI TTVSMOH DMUHSAZ TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMUHSAZ MA Inhibitor DMUHSAZ RN Sphingosine 1-phosphate receptor antagonists. US9663511. DMUHSAZ RU http://www.freepatentsonline.com/US9663511.html DMUI385 DI DMUI385 DMUI385 DN PMID28394193-Compound-Figure3bIII DMUI385 TI TT9MZCQ DMUI385 TN Enhancer of zeste homolog 2 (EZH2) DMUI385 MA Inhibitor DMUI385 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMUI385 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMUIK3W DI DMUIK3W DMUIK3W DN Pyrrolo-pyridone derivative 3 DMUIK3W TI TT6DM01 DMUIK3W TN Janus kinase 1 (JAK-1) DMUIK3W MA Inhibitor DMUIK3W RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUIK3W RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUIK3W DI DMUIK3W DMUIK3W DN Pyrrolo-pyridone derivative 3 DMUIK3W TI TTBYWP2 DMUIK3W TN TYK2 tyrosine kinase (TYK2) DMUIK3W MA Inhibitor DMUIK3W RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUIK3W RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUILMD DI DMUILMD DMUILMD DN C-linked disaccharide biphenyl mannoside derivative 6 DMUILMD TI TTTCRU2 DMUILMD TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMUILMD MA Antagonist DMUILMD RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMUILMD RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMUJ3XK DI DMUJ3XK DMUJ3XK DN Dihydrothieno [2,3-e]indazole derivative 1 DMUJ3XK TI TTRPDBG DMUJ3XK TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMUJ3XK MA Inhibitor DMUJ3XK RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMUJ3XK RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMUJFCK DI DMUJFCK DMUJFCK DN Benzoimidazole derivative 1 DMUJFCK TI TTZCRP3 DMUJFCK TN ERK activator kinase (MEK) DMUJFCK MA Inhibitor DMUJFCK RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMUJFCK RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMUKBGD DI DMUKBGD DMUKBGD DN Imidazopyridine derivative 5 DMUKBGD TI TTYLQ8V DMUKBGD TN Prostaglandin E synthase (PTGES) DMUKBGD MA Inhibitor DMUKBGD RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMUKBGD RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMUKFJ0 DI DMUKFJ0 DMUKFJ0 DN PMID25776143-Compound-8 DMUKFJ0 TI TT4TFGN DMUKFJ0 TN Vasopressin V1a receptor (V1AR) DMUKFJ0 MA Antagonist DMUKFJ0 RN Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jun;25(6):711-22. DMUKFJ0 RU https://www.ncbi.nlm.nih.gov/pubmed/25776143 DMUKIEJ DI DMUKIEJ DMUKIEJ DN PMID30280939-Compound-WO2013148426 DMUKIEJ TI TTOK0LR DMUKIEJ TN Toll-like receptor (TLR) DMUKIEJ MA Agonist DMUKIEJ RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMUKIEJ RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMUKNXF DI DMUKNXF DMUKNXF DN Benzothiazole analog 2 DMUKNXF TI TTULVH8 DMUKNXF TN Tyrosinase (TYR) DMUKNXF MA Inhibitor DMUKNXF RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMUKNXF RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMUKOGJ DI DMUKOGJ DMUKOGJ DN PMID27109571-Compound-13 DMUKOGJ TI TTNT2S6 DMUKOGJ TN Fatty acid-binding protein 5 (FABP5) DMUKOGJ MA Inhibitor DMUKOGJ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUKOGJ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMUKOGJ DI DMUKOGJ DMUKOGJ DN PMID27109571-Compound-13 DMUKOGJ TI TTHWMFZ DMUKOGJ TN Fatty acid-binding protein 4 (FABP4) DMUKOGJ MA Inhibitor DMUKOGJ RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUKOGJ RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMUL84D DI DMUL84D DMUL84D DN PMID26560530-Compound-33 DMUL84D TI TT2F4OL DMUL84D TN Tissue transglutaminase (TG2) DMUL84D MA Inhibitor DMUL84D RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMUL84D RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMULJOS DI DMULJOS DMULJOS DN Isoxazoles and isoxazoline derivative 3 DMULJOS TI TTIY56R DMULJOS TN Kynurenine 3-hydroxylase (KMO) DMULJOS MA Inhibitor DMULJOS RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMULJOS RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMULTAI DI DMULTAI DMULTAI DN Imidazo[1,2-b]pyridazine derivative 1 DMULTAI TI TTTDVOJ DMULTAI TN Tropomyosin-related kinase A (TrkA) DMULTAI MA Inhibitor DMULTAI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMULTAI RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMULTAI DI DMULTAI DMULTAI DN Imidazo[1,2-b]pyridazine derivative 1 DMULTAI TI TTSZ6Y3 DMULTAI TN Proto-oncogene c-Ros (ROS1) DMULTAI MA Inhibitor DMULTAI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMULTAI RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMUM3YW DI DMUM3YW DMUM3YW DN PMID25522065-Compound-25 DMUM3YW TI TTX4RTB DMUM3YW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMUM3YW MA Antagonist DMUM3YW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMUM3YW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMUM5L6 DI DMUM5L6 DMUM5L6 DN PMID27828716-Compound-BIO-acetoxime DMUM5L6 TI TTRZQE3 DMUM5L6 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMUM5L6 MA Inhibitor DMUM5L6 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMUM5L6 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMUMPZX DI DMUMPZX DMUMPZX DN Isoxazole derivative 1 DMUMPZX TI TTRMX3V DMUMPZX TN Janus kinase 2 (JAK-2) DMUMPZX MA Inhibitor DMUMPZX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUMPZX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUMPZX DI DMUMPZX DMUMPZX DN Isoxazole derivative 1 DMUMPZX TI TT6DM01 DMUMPZX TN Janus kinase 1 (JAK-1) DMUMPZX MA Inhibitor DMUMPZX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUMPZX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUMPZX DI DMUMPZX DMUMPZX DN Isoxazole derivative 1 DMUMPZX TI TTT7PJU DMUMPZX TN Janus kinase 3 (JAK-3) DMUMPZX MA Inhibitor DMUMPZX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMUMPZX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMUMYKX DI DMUMYKX DMUMYKX DN PMID25666693-Compound-24 DMUMYKX TI TTMI6F5 DMUMYKX TN Transient receptor potential cation channel V1 (TRPV1) DMUMYKX MA Antagonist DMUMYKX RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMUMYKX RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMUNFAT DI DMUNFAT DMUNFAT DN Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 DMUNFAT TI TT4G2JS DMUNFAT TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUNFAT MA Blocker DMUNFAT RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMUNFAT RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMUNFAT DI DMUNFAT DMUNFAT DN Dihydrobenzoxazine and tetrahydroquinoxaline sulfonamide derivative 1 DMUNFAT TI TTZOVE0 DMUNFAT TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMUNFAT MA Blocker DMUNFAT RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMUNFAT RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMUNLK8 DI DMUNLK8 DMUNLK8 DN Pyrazole derivative 33 DMUNLK8 TI TT6OEDT DMUNLK8 TN Cannabinoid receptor 1 (CB1) DMUNLK8 MA Antagonist DMUNLK8 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUNLK8 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUNME2 DI DMUNME2 DMUNME2 DN Methylbenzenesulfonamide derivative 1 DMUNME2 TI TTOHFIY DMUNME2 TN Sphingosine kinase 1 (SPHK1) DMUNME2 MA Inhibitor DMUNME2 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMUNME2 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TT6DM01 DMUNSYX TN Janus kinase 1 (JAK-1) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TTBYWP2 DMUNSYX TN TYK2 tyrosine kinase (TYK2) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TTRMX3V DMUNSYX TN Janus kinase 2 (JAK-2) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNSYX DI DMUNSYX DMUNSYX DN Bis-aminopyrimidine derivative 3 DMUNSYX TI TTT7PJU DMUNSYX TN Janus kinase 3 (JAK-3) DMUNSYX MA Inhibitor DMUNSYX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMUNSYX RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMUNXAR DI DMUNXAR DMUNXAR DN PMID29053063-Compound-7d DMUNXAR TI TTZ963I DMUNXAR TN Monoglyceride lipase (MAGL) DMUNXAR MA Inhibitor DMUNXAR RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMUNXAR RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMUO25Y DI DMUO25Y DMUO25Y DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 DMUO25Y TI TTJGW1Z DMUO25Y TN Phosphodiesterase 2A (PDE2A) DMUO25Y MA Inhibitor DMUO25Y RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUO25Y RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUO25Y DI DMUO25Y DMUO25Y DN Pyrido[1,2,4]triazolo[4,3-a]pyrazine derivative 2 DMUO25Y TI TTJW4LU DMUO25Y TN Phosphodiesterase 10A (PDE10) DMUO25Y MA Inhibitor DMUO25Y RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMUO25Y RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMUOI92 DI DMUOI92 DMUOI92 DN Heterocyclic derivative 11 DMUOI92 TI TTCZOF2 DMUOI92 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMUOI92 MA Inhibitor DMUOI92 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMUOI92 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMUOW3T DI DMUOW3T DMUOW3T DN Metal complex derivative 1 DMUOW3T TI TTR7UJ3 DMUOW3T TN Cytoplasmic thioredoxin reductase (TXNRD1) DMUOW3T MA Inhibitor DMUOW3T RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMUOW3T RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMUOZEJ DI DMUOZEJ DMUOZEJ DN Z223457004 DMUOZEJ TI TT3RMNA DMUOZEJ TN Chymotrypsin-C (CLCR) DMUOZEJ MA Inhibitor DMUOZEJ RN Benzoxazinone derivatives for treatment of skin diseases. US9695194. DMUOZEJ RU http://www.freepatentsonline.com/US9695194.html DMUP0WH DI DMUP0WH DMUP0WH DN Aryl alkanolamine derivative 2 DMUP0WH TI TT5TPI6 DMUP0WH TN Opioid receptor sigma 1 (OPRS1) DMUP0WH MA Antagonist DMUP0WH RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMUP0WH RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMUP4DX DI DMUP4DX DMUP4DX DN Picolinamido propanoic acid derivative 1 DMUP4DX TI TT9O6WS DMUP4DX TN Glucagon receptor (GCGR) DMUP4DX MA Antagonist DMUP4DX RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMUP4DX RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMUPL0W DI DMUPL0W DMUPL0W DN PMID25514969-Compound-11 DMUPL0W TI TT4EB85 DMUPL0W TN Cholesterol 24-hydroxylase (CYP46A1) DMUPL0W MA Inhibitor DMUPL0W RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMUPL0W RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMUPN01 DI DMUPN01 DMUPN01 DN AR-A014418 DMUPN01 TI TTRSMW9 DMUPN01 TN Glycogen synthase kinase-3 beta (GSK-3B) DMUPN01 MA Inhibitor DMUPN01 RN Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. DMUPN01 RU https://pubmed.ncbi.nlm.nih.gov/18929433 DMUPN01 DI DMUPN01 DMUPN01 DN AR-A014418 DMUPN01 TI TTRZQE3 DMUPN01 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMUPN01 RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMUPN01 RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMUPNHA DI DMUPNHA DMUPNHA DN Pyrazole derivative 21 DMUPNHA TI TT6OEDT DMUPNHA TN Cannabinoid receptor 1 (CB1) DMUPNHA MA Antagonist DMUPNHA RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUPNHA RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUPRX2 DI DMUPRX2 DMUPRX2 DN US8791257, 17 DMUPRX2 TI TTR93NU DMUPRX2 TN Casein kinase II alpha prime (CSNK2A2) DMUPRX2 MA Inhibitor DMUPRX2 RN Substituted pyrrolotriazines as protein kinase inhibitors. US8791257. DMUPRX2 RU http://www.freepatentsonline.com/US8791257.html DMUPT9A DI DMUPT9A DMUPT9A DN Amidine compound 1 DMUPT9A TI TTQR74A DMUPT9A TN Proteinase activated receptor 2 (PAR2) DMUPT9A MA Antagonist DMUPT9A RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMUPT9A RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMUQ04C DI DMUQ04C DMUQ04C DN PMID25684022-Compound-US20120277229 44(1.4) DMUQ04C TI TTCZOF2 DMUQ04C TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMUQ04C MA Inhibitor DMUQ04C RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMUQ04C RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMUQ9CF DI DMUQ9CF DMUQ9CF DN 1,6-diazanaphthalenes and pyrido[2,3-d] pyrimidine derivative 1 DMUQ9CF TI TTIXKA4 DMUQ9CF TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMUQ9CF MA Inhibitor DMUQ9CF RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMUQ9CF RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMUQI15 DI DMUQI15 DMUQI15 DN BDBM50363782 DMUQI15 TI TTLKF5M DMUQI15 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMUQI15 MA Inhibitor DMUQI15 RN Aroyl thiourea derivatives. US9365508. DMUQI15 RU http://www.freepatentsonline.com/US9365508.html DMUQSM1 DI DMUQSM1 DMUQSM1 DN PMID26651364-Compound-117b DMUQSM1 TI TTTCRU2 DMUQSM1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMUQSM1 MA Antagonist DMUQSM1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMUQSM1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMUR3FY DI DMUR3FY DMUR3FY DN PMID27109571-Compound-15 DMUR3FY TI TTNT2S6 DMUR3FY TN Fatty acid-binding protein 5 (FABP5) DMUR3FY MA Inhibitor DMUR3FY RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUR3FY RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMUR3FY DI DMUR3FY DMUR3FY DN PMID27109571-Compound-15 DMUR3FY TI TTHWMFZ DMUR3FY TN Fatty acid-binding protein 4 (FABP4) DMUR3FY MA Inhibitor DMUR3FY RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMUR3FY RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMURYO0 DI DMURYO0 DMURYO0 DN Tetra-hydro-naphthalene derivative 1 DMURYO0 TI TTDP1UC DMURYO0 TN Fatty acid amide hydrolase (FAAH) DMURYO0 MA Inhibitor DMURYO0 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMURYO0 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMURZHA DI DMURZHA DMURZHA DN PMID30273516-Compound-14 DMURZHA TI TTCW0KX DMURZHA TN Glutaminase (GLS) DMURZHA MA Inhibitor DMURZHA RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMURZHA RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMUS4Z0 DI DMUS4Z0 DMUS4Z0 DN Five membered heterocyclic benzamide derivative 3 DMUS4Z0 TI TTTDVOJ DMUS4Z0 TN Tropomyosin-related kinase A (TrkA) DMUS4Z0 MA Inhibitor DMUS4Z0 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMUS4Z0 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMUS7O3 DI DMUS7O3 DMUS7O3 DN 1,3-dihydroxy phenyl derivative 1 DMUS7O3 TI TT23XQV DMUS7O3 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMUS7O3 MA Inhibitor DMUS7O3 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMUS7O3 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMUTE5S DI DMUTE5S DMUTE5S DN Pyridyl compound 1 DMUTE5S TI TTA6ZN2 DMUTE5S TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMUTE5S MA Activator DMUTE5S RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUTE5S RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUTE5S DI DMUTE5S DMUTE5S DN Pyridyl compound 1 DMUTE5S TI TT3Z6Y9 DMUTE5S TN Cysteines of Keap1 (KEAP1 Cysteines) DMUTE5S MA Modulator DMUTE5S RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUTE5S RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUTF17 DI DMUTF17 DMUTF17 DN 1,2-diamino cyclopentane-based derivative 28 DMUTF17 TI TT9BPT3 DMUTF17 TN Orexin receptor (HCRTR) DMUTF17 MA Antagonist DMUTF17 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMUTF17 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMUTKNW DI DMUTKNW DMUTKNW DN Tacrine-indole hybrid derivative 3 DMUTKNW TI TT1RS9F DMUTKNW TN Acetylcholinesterase (AChE) DMUTKNW MA Inhibitor DMUTKNW RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMUTKNW RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMUVC25 DI DMUVC25 DMUVC25 DN US9493490, D DMUVC25 TI TTAZ3MN DMUVC25 TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMUVC25 MA Inhibitor DMUVC25 RN Boron-containing small molecules. US9493490. DMUVC25 RU http://www.freepatentsonline.com/US9493490.html DMUVPR8 DI DMUVPR8 DMUVPR8 DN Tri-substituted urea derivative 2 DMUVPR8 TI TTTDVOJ DMUVPR8 TN Tropomyosin-related kinase A (TrkA) DMUVPR8 MA Inhibitor DMUVPR8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMUVPR8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMUVYWE DI DMUVYWE DMUVYWE DN Maleimides derivative 2 DMUVYWE TI TTRZQE3 DMUVYWE TN Glycogen synthase kinase-3 alpha (GSK-3A) DMUVYWE RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMUVYWE RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMUWZD9 DI DMUWZD9 DMUWZD9 DN PMID28766366-Compound-Scheme8NCGC-00189310 DMUWZD9 TI TTSBVFO DMUWZD9 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMUWZD9 MA Inhibitor DMUWZD9 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMUWZD9 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMUX0SG DI DMUX0SG DMUX0SG DN PMID26004420-Compound-WO2012058134A DMUX0SG TI TTJ13ST DMUX0SG TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMUX0SG MA Inhibitor DMUX0SG RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMUX0SG RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMUXNKG DI DMUXNKG DMUXNKG DN Tetra-hydro-1H-1,2,6-triazaazulene derivative 1 DMUXNKG TI TT6OEDT DMUXNKG TN Cannabinoid receptor 1 (CB1) DMUXNKG MA Antagonist DMUXNKG RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMUXNKG RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMUXO47 DI DMUXO47 DMUXO47 DN PMID25666693-Compound-21 DMUXO47 TI TTMI6F5 DMUXO47 TN Transient receptor potential cation channel V1 (TRPV1) DMUXO47 MA Antagonist DMUXO47 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMUXO47 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMUXQST DI DMUXQST DMUXQST DN Pyrazinylpyridine derivative 1 DMUXQST TI TT1LVF2 DMUXQST TN Cyclin-dependent kinase 9 (CDK9) DMUXQST MA Inhibitor DMUXQST RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMUXQST RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMUY4LS DI DMUY4LS DMUY4LS DN PMID28454500-Compound-12 DMUY4LS TI TTA6ZN2 DMUY4LS TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMUY4LS MA Activator DMUY4LS RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUY4LS RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUY4LS DI DMUY4LS DMUY4LS DN PMID28454500-Compound-12 DMUY4LS TI TT3Z6Y9 DMUY4LS TN Cysteines of Keap1 (KEAP1 Cysteines) DMUY4LS MA Modulator DMUY4LS RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMUY4LS RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMUY53P DI DMUY53P DMUY53P DN PMID29671355-Compound-18 DMUY53P TI TT6R7JZ DMUY53P TN Histone deacetylase 1 (HDAC1) DMUY53P MA Inhibitor DMUY53P RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUY53P RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUY53P DI DMUY53P DMUY53P DN PMID29671355-Compound-18 DMUY53P TI TT5ZKDI DMUY53P TN Histone deacetylase 6 (HDAC6) DMUY53P MA Inhibitor DMUY53P RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMUY53P RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMUYVOP DI DMUYVOP DMUYVOP DN PMID25514969-Compound-Figure2-3 DMUYVOP TI TT4EB85 DMUYVOP TN Cholesterol 24-hydroxylase (CYP46A1) DMUYVOP MA Inhibitor DMUYVOP RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMUYVOP RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMUZ4L3 DI DMUZ4L3 DMUZ4L3 DN Tricyclic indole compound 4 DMUZ4L3 TI TTPTXIN DMUZ4L3 TN Translocator protein (TSPO) DMUZ4L3 MA Ligand DMUZ4L3 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMUZ4L3 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMUZ85A DI DMUZ85A DMUZ85A DN PMID30107136-Compound-Example60 DMUZ85A TI TT23XQV DMUZ85A TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMUZ85A MA Inhibitor DMUZ85A RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMUZ85A RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMUZQLR DI DMUZQLR DMUZQLR DN Benzene sulfonamide derivative 2 DMUZQLR TI TTIY56R DMUZQLR TN Kynurenine 3-hydroxylase (KMO) DMUZQLR MA Inhibitor DMUZQLR RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMUZQLR RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMUZR3X DI DMUZR3X DMUZR3X DN Heteroaryl-azepine derivative 9 DMUZR3X TI TTWJBZ5 DMUZR3X TN 5-HT 2C receptor (HTR2C) DMUZR3X MA Agonist DMUZR3X RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMUZR3X RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMV0EIA DI DMV0EIA DMV0EIA DN PMID25980951-Compound-28 DMV0EIA TI TTR7B60 DMV0EIA TN X-linked inhibitor of apoptosis protein (XIAP) DMV0EIA MA Antagonist DMV0EIA RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMV0EIA RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMV0QJ4 DI DMV0QJ4 DMV0QJ4 DN Amidine compound 3 DMV0QJ4 TI TTQR74A DMV0QJ4 TN Proteinase activated receptor 2 (PAR2) DMV0QJ4 MA Antagonist DMV0QJ4 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMV0QJ4 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMV0R2X DI DMV0R2X DMV0R2X DN PMID28870136-Compound-42 DMV0R2X TI TTK0O6Y DMV0R2X TN Ecto-5'-nucleotidase (CD73) DMV0R2X MA Inhibitor DMV0R2X RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMV0R2X RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMV15GM DI DMV15GM DMV15GM DN PMID30107136-Compound-Example50 DMV15GM TI TT23XQV DMV15GM TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMV15GM MA Inhibitor DMV15GM RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMV15GM RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMV172W DI DMV172W DMV172W DN Macrocyclic peptide analog 3 DMV172W TI TT23XQV DMV172W TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMV172W MA Inhibitor DMV172W RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMV172W RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMV1AGC DI DMV1AGC DMV1AGC DN PMID28394193-Compound-35 DMV1AGC TI TT9MZCQ DMV1AGC TN Enhancer of zeste homolog 2 (EZH2) DMV1AGC MA Inhibitor DMV1AGC RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMV1AGC RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMV1ER2 DI DMV1ER2 DMV1ER2 DN Imidazole derivative 3 DMV1ER2 TI TT6OEDT DMV1ER2 TN Cannabinoid receptor 1 (CB1) DMV1ER2 MA Antagonist DMV1ER2 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMV1ER2 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMV1OR0 DI DMV1OR0 DMV1OR0 DN US9694002, 495 DMV1OR0 TI TTANOZH DMV1OR0 TN SCN1A messenger RNA (SCN1A mRNA) DMV1OR0 MA Inhibitor DMV1OR0 RN Substituted benzamides and methods of use thereof. US9694002. DMV1OR0 RU http://www.freepatentsonline.com/US9694002.html DMV1QUX DI DMV1QUX DMV1QUX DN Alkyl mannoside derivative 9 DMV1QUX TI TTTCRU2 DMV1QUX TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMV1QUX MA Antagonist DMV1QUX RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMV1QUX RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMV1RQX DI DMV1RQX DMV1RQX DN Tricyclic compound 10 DMV1RQX TI TTAIQSN DMV1RQX TN Receptor-interacting protein 1 (RIPK1) DMV1RQX MA Inhibitor DMV1RQX RN Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256. DMV1RQX RU https://www.ncbi.nlm.nih.gov/pubmed/27568917 DMV1SCA DI DMV1SCA DMV1SCA DN Fluorinated donepezil derivative 2 DMV1SCA TI TT1RS9F DMV1SCA TN Acetylcholinesterase (AChE) DMV1SCA MA Inhibitor DMV1SCA RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMV1SCA RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMV1WND DI DMV1WND DMV1WND DN PMID27744724-Compound-4 DMV1WND TI TTL53M6 DMV1WND TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMV1WND MA Inhibitor DMV1WND RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV1WND RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV2D5M DI DMV2D5M DMV2D5M DN PMID29649907-Compound-8 DMV2D5M TI TTS4UGC DMV2D5M TN Farnesoid X-activated receptor (FXR) DMV2D5M MA Agonist DMV2D5M RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMV2D5M RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMV2D5M DI DMV2D5M DMV2D5M DN PMID29649907-Compound-8 DMV2D5M TI TTSDVTR DMV2D5M TN G-protein coupled bile acid receptor 1 (GPBAR1) DMV2D5M MA Agonist DMV2D5M RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMV2D5M RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMV2UQ5 DI DMV2UQ5 DMV2UQ5 DN Cyclic peptidomimetic derivative 1 DMV2UQ5 TI TT23XQV DMV2UQ5 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMV2UQ5 MA Inhibitor DMV2UQ5 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMV2UQ5 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMV2W9Z DI DMV2W9Z DMV2W9Z DN 1-hydroxyl-3,5-bis(4-hydroxylstyryl)benzene derivative 4 DMV2W9Z TI TTSXVID DMV2W9Z TN Nuclear factor NF-kappa-B (NFKB) DMV2W9Z MA Inhibitor DMV2W9Z RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMV2W9Z RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMV2Y84 DI DMV2Y84 DMV2Y84 DN Pyrimidine derivative 15 DMV2Y84 TI TTDCBX5 DMV2Y84 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMV2Y84 MA Inhibitor DMV2Y84 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMV2Y84 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMV30QO DI DMV30QO DMV30QO DN Thiazole carboxamide derivative 27 DMV30QO TI TTCZOF2 DMV30QO TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMV30QO MA Inhibitor DMV30QO RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMV30QO RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMV3H98 DI DMV3H98 DMV3H98 DN 7-azaindole derivative 5 DMV3H98 TI TTHS0U8 DMV3H98 TN Stress-activated protein kinase JNK2 (JNK2) DMV3H98 MA Inhibitor DMV3H98 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMV3H98 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMV3H98 DI DMV3H98 DMV3H98 DN 7-azaindole derivative 5 DMV3H98 TI TT0K6EO DMV3H98 TN Stress-activated protein kinase JNK1 (JNK1) DMV3H98 MA Inhibitor DMV3H98 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMV3H98 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMV3H98 DI DMV3H98 DMV3H98 DN 7-azaindole derivative 5 DMV3H98 TI TT056SO DMV3H98 TN Stress-activated protein kinase JNK3 (JNK3) DMV3H98 MA Inhibitor DMV3H98 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMV3H98 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMV3X64 DI DMV3X64 DMV3X64 DN PMID26004420-Compound-WO2010129379C DMV3X64 TI TTJ13ST DMV3X64 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMV3X64 MA Inhibitor DMV3X64 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMV3X64 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMV46DG DI DMV46DG DMV46DG DN PMID26815044-Compound-93 DMV46DG TI TTULVH8 DMV46DG TN Tyrosinase (TYR) DMV46DG MA Inhibitor DMV46DG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMV46DG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMV4AHL DI DMV4AHL DMV4AHL DN US9422240, 1-282 DMV4AHL TI TT9ISBX DMV4AHL TN HIF-prolyl hydroxylase 2 (HPH-2) DMV4AHL MA Inhibitor DMV4AHL RN Partially saturated nitrogen-containing heterocyclic compound. US9422240. DMV4AHL RU http://www.freepatentsonline.com/US9422240.html DMV4DQI DI DMV4DQI DMV4DQI DN Benzimidazole derivative 13 DMV4DQI TI TTYLQ8V DMV4DQI TN Prostaglandin E synthase (PTGES) DMV4DQI MA Inhibitor DMV4DQI RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMV4DQI RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMV4HQ5 DI DMV4HQ5 DMV4HQ5 DN PMID26004420-Compound-WO2015017305E DMV4HQ5 TI TTJ13ST DMV4HQ5 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMV4HQ5 MA Inhibitor DMV4HQ5 RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMV4HQ5 RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMV4I0K DI DMV4I0K DMV4I0K DN Cyclopropylamine derivative 12 DMV4I0K TI TT32XQJ DMV4I0K TN Monoamine oxidase (MAO) DMV4I0K MA Inhibitor DMV4I0K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMV4I0K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMV4I0K DI DMV4I0K DMV4I0K DN Cyclopropylamine derivative 12 DMV4I0K TI TTNR0UQ DMV4I0K TN Lysine-specific histone demethylase 1 (LSD) DMV4I0K MA Inhibitor DMV4I0K RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMV4I0K RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMV4OTD DI DMV4OTD DMV4OTD DN Benzothiazepine analog 4 DMV4OTD TI TTPTXIN DMV4OTD TN Translocator protein (TSPO) DMV4OTD MA Ligand DMV4OTD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMV4OTD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMV509A DI DMV509A DMV509A DN PMID25666693-Compound-105 DMV509A TI TTMI6F5 DMV509A TN Transient receptor potential cation channel V1 (TRPV1) DMV509A MA Antagonist DMV509A RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMV509A RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMV5XR7 DI DMV5XR7 DMV5XR7 DN 6-Phenylquinazolin-4-amine DMV5XR7 TI TT6NI13 DMV5XR7 TN MEK kinase kinase 4 (MAP4K4) DMV5XR7 MA Inhibitor DMV5XR7 RN Aminoquinazoline and pyridopyrimidine derivatives. US9592235. DMV5XR7 RU http://www.freepatentsonline.com/US9592235.html DMV6FL8 DI DMV6FL8 DMV6FL8 DN US8481733, 106 DMV6FL8 TI TTIET93 DMV6FL8 TN Activated CDC42 kinase 1 (ACK-1) DMV6FL8 MA Inhibitor DMV6FL8 RN Substituted imidazopyr- and imidazotri-azines. US8481733. DMV6FL8 RU http://www.freepatentsonline.com/US8481733.html DMV6GIC DI DMV6GIC DMV6GIC DN PMID26394986-Compound-51 DMV6GIC TI TTH8FZW DMV6GIC TN Signal transducer and activator of transcription 3 (STAT3) DMV6GIC MA Inhibitor DMV6GIC RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMV6GIC RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMV6H95 DI DMV6H95 DMV6H95 DN C-linked disaccharide biphenyl mannoside derivative 1 DMV6H95 TI TTTCRU2 DMV6H95 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMV6H95 MA Antagonist DMV6H95 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMV6H95 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMV6MLC DI DMV6MLC DMV6MLC DN PMID27744724-Compound-27 DMV6MLC TI TTU1E82 DMV6MLC TN Apoptosis regulator Bcl-xL (BCL-xL) DMV6MLC MA Inhibitor DMV6MLC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV6MLC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV6MLC DI DMV6MLC DMV6MLC DN PMID27744724-Compound-27 DMV6MLC TI TTL53M6 DMV6MLC TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMV6MLC MA Inhibitor DMV6MLC RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV6MLC RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV6U9Y DI DMV6U9Y DMV6U9Y DN Pyrimidine derivative 9 DMV6U9Y TI TTOHSBA DMV6U9Y TN Vascular endothelial growth factor A (VEGFA) DMV6U9Y MA Inhibitor DMV6U9Y RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMV6U9Y RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMV6YXJ DI DMV6YXJ DMV6YXJ DN Pyrrolidinyl urea derivative 10 DMV6YXJ TI TTTDVOJ DMV6YXJ TN Tropomyosin-related kinase A (TrkA) DMV6YXJ MA Inhibitor DMV6YXJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMV6YXJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMV7AX9 DI DMV7AX9 DMV7AX9 DN Indazole derivative 2 DMV7AX9 TI TTZJYKH DMV7AX9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMV7AX9 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMV7AX9 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMV7BF2 DI DMV7BF2 DMV7BF2 DN US10053465, 5 DMV7BF2 TI TTIEMFN DMV7BF2 TN TYRO3 tyrosine kinase receptor (TYRO3) DMV7BF2 MA Inhibitor DMV7BF2 RN Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors. US9708333. DMV7BF2 RU http://www.freepatentsonline.com/US9708333.html DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TT1LVF2 DMV7DFM TN Cyclin-dependent kinase 9 (CDK9) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TTH6V3D DMV7DFM TN Cyclin-dependent kinase 1 (CDK1) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TT7HF4W DMV7DFM TN Cyclin-dependent kinase 2 (CDK2) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7DFM DI DMV7DFM DMV7DFM DN Indole-based analog 13 DMV7DFM TI TT0PG8F DMV7DFM TN Cyclin-dependent kinase 4 (CDK4) DMV7DFM MA Inhibitor DMV7DFM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMV7DFM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMV7ISR DI DMV7ISR DMV7ISR DN PMID26004420-Compound-WO2013039802C DMV7ISR TI TTJ13ST DMV7ISR TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMV7ISR MA Inhibitor DMV7ISR RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMV7ISR RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMV7IX4 DI DMV7IX4 DMV7IX4 DN Fused thiophene derivative 1 DMV7IX4 TI TTC7A6G DMV7IX4 TN Leucine-rich repeat kinase 2 S935 phosphorylation (LRRK2 pS935) DMV7IX4 MA Inhibitor DMV7IX4 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMV7IX4 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMV7IX4 DI DMV7IX4 DMV7IX4 DN Fused thiophene derivative 1 DMV7IX4 TI TTK0FEA DMV7IX4 TN Leucine-rich repeat kinase 2 (LRRK2) DMV7IX4 MA Inhibitor DMV7IX4 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMV7IX4 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMV7P4N DI DMV7P4N DMV7P4N DN PMID27744724-Compound-6 DMV7P4N TI TTL53M6 DMV7P4N TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMV7P4N MA Inhibitor DMV7P4N RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMV7P4N RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMV7PNF DI DMV7PNF DMV7PNF DN PMID25684022-Compound-WO2006015124 DMV7PNF TI TTCZOF2 DMV7PNF TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMV7PNF MA Inhibitor DMV7PNF RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMV7PNF RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMV7SQH DI DMV7SQH DMV7SQH DN PMID25553724-Compound-US20138552206 4 DMV7SQH TI TTSXVID DMV7SQH TN Nuclear factor NF-kappa-B (NFKB) DMV7SQH MA Inhibitor DMV7SQH RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMV7SQH RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMV7TMB DI DMV7TMB DMV7TMB DN Benzimidazole derivative 6 DMV7TMB TI TTTDVOJ DMV7TMB TN Tropomyosin-related kinase A (TrkA) DMV7TMB MA Inhibitor DMV7TMB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMV7TMB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMV7TMB DI DMV7TMB DMV7TMB DN Benzimidazole derivative 6 DMV7TMB TI TTPMQSO DMV7TMB TN ALK tyrosine kinase receptor (ALK) DMV7TMB MA Inhibitor DMV7TMB RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMV7TMB RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMV9BQN DI DMV9BQN DMV9BQN DN PMID28092474-Compound-32o DMV9BQN TI TT6R7JZ DMV9BQN TN Histone deacetylase 1 (HDAC1) DMV9BQN MA Inhibitor DMV9BQN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMV9BQN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMV9BQN DI DMV9BQN DMV9BQN DN PMID28092474-Compound-32o DMV9BQN TI TT5ZKDI DMV9BQN TN Histone deacetylase 6 (HDAC6) DMV9BQN MA Inhibitor DMV9BQN RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMV9BQN RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMVA15O DI DMVA15O DMVA15O DN PMID29130358-Compound-Figure17(10) DMVA15O TI TTXZ0KQ DMVA15O TN Matrix metalloproteinase-12 (MMP-12) DMVA15O MA Inhibitor DMVA15O RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMVA15O RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMVA15O DI DMVA15O DMVA15O DN PMID29130358-Compound-Figure17(10) DMVA15O TI TT6X50U DMVA15O TN Matrix metalloproteinase-9 (MMP-9) DMVA15O MA Inhibitor DMVA15O RN Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46. DMVA15O RU https://www.ncbi.nlm.nih.gov/pubmed/29130358 DMVA7BC DI DMVA7BC DMVA7BC DN Tricyclic indole compound 9 DMVA7BC TI TTPTXIN DMVA7BC TN Translocator protein (TSPO) DMVA7BC MA Ligand DMVA7BC RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMVA7BC RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMVA8KL DI DMVA8KL DMVA8KL DN Isoxazole-based bicyclic compound 12 DMVA8KL TI TTE4BSY DMVA8KL TN Bromodomain and extraterminal domain protein (BET) DMVA8KL MA Inhibitor DMVA8KL RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMVA8KL RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMVA95G DI DMVA95G DMVA95G DN Pyrrolo-pyrimidine derivative 5 DMVA95G TI TT4DXQT DMVA95G TN Proto-oncogene c-Ret (RET) DMVA95G MA Inhibitor DMVA95G RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMVA95G RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMVABXI DI DMVABXI DMVABXI DN PMID25656651-Compound-21b DMVABXI TI TTS7G69 DMVABXI TN Fusion protein Bcr-Abl (Bcr-Abl) DMVABXI MA Inhibitor DMVABXI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVABXI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVABXI DI DMVABXI DMVABXI DN PMID25656651-Compound-21b DMVABXI TI TTX41N9 DMVABXI TN Tyrosine-protein kinase Kit (KIT) DMVABXI MA Inhibitor DMVABXI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVABXI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVABXI DI DMVABXI DMVABXI DN PMID25656651-Compound-21b DMVABXI TI TTI7421 DMVABXI TN Platelet-derived growth factor receptor beta (PDGFRB) DMVABXI MA Inhibitor DMVABXI RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVABXI RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVAKUI DI DMVAKUI DMVAKUI DN Golden phosphorous acetyletic compound 1 DMVAKUI TI TTEP6RV DMVAKUI TN Glutathione reductase (GR) DMVAKUI MA Inhibitor DMVAKUI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMVAKUI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMVAKUI DI DMVAKUI DMVAKUI DN Golden phosphorous acetyletic compound 1 DMVAKUI TI TTR7UJ3 DMVAKUI TN Cytoplasmic thioredoxin reductase (TXNRD1) DMVAKUI MA Inhibitor DMVAKUI RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMVAKUI RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMVARUE DI DMVARUE DMVARUE DN Resorcinol compound 13 DMVARUE TI TTULVH8 DMVARUE TN Tyrosinase (TYR) DMVARUE MA Inhibitor DMVARUE RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMVARUE RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMVASXW DI DMVASXW DMVASXW DN PMID25399762-Compound-Table1-C11 DMVASXW TI TTGP7BY DMVASXW TN Monoamine oxidase type B (MAO-B) DMVASXW MA Inhibitor DMVASXW RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMVASXW RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMVB42P DI DMVB42P DMVB42P DN US8975409, Example 13 DMVB42P TI TTVSMOH DMVB42P TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMVB42P MA Inhibitor DMVB42P RN Phenyl derivative. US8975409. DMVB42P RU http://www.freepatentsonline.com/US8975409.html DMVBAUC DI DMVBAUC DMVBAUC DN Bromo benzyl ether derivative 2 DMVBAUC TI TT23XQV DMVBAUC TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMVBAUC MA Inhibitor DMVBAUC RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMVBAUC RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMVBJKH DI DMVBJKH DMVBJKH DN PMID27537201-Compound-Figure15a DMVBJKH TI TTPADOQ DMVBJKH TN HMG-CoA reductase (HMGCR) DMVBJKH MA Inhibitor DMVBJKH RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMVBJKH RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMVBPGI DI DMVBPGI DMVBPGI DN Quinoline derivative 6 DMVBPGI TI TTXJ47W DMVBPGI TN Metabotropic glutamate receptor 2 (mGluR2) DMVBPGI MA Antagonist DMVBPGI RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMVBPGI RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMVBPML DI DMVBPML DMVBPML DN PMID28766366-Compound-Scheme9EHT3356 DMVBPML TI TTYGQ8A DMVBPML TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMVBPML MA Inhibitor DMVBPML RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVBPML RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVBPML DI DMVBPML DMVBPML DN PMID28766366-Compound-Scheme9EHT3356 DMVBPML TI TTSBVFO DMVBPML TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVBPML MA Inhibitor DMVBPML RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVBPML RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVBQJ1 DI DMVBQJ1 DMVBQJ1 DN Bicyclic heteroaryl benzamide derivative 8 DMVBQJ1 TI TTTDVOJ DMVBQJ1 TN Tropomyosin-related kinase A (TrkA) DMVBQJ1 MA Inhibitor DMVBQJ1 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVBQJ1 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVBZKF DI DMVBZKF DMVBZKF DN Tetra-hydro-naphthalene derivative 3 DMVBZKF TI TTDP1UC DMVBZKF TN Fatty acid amide hydrolase (FAAH) DMVBZKF MA Inhibitor DMVBZKF RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMVBZKF RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMVC51O DI DMVC51O DMVC51O DN Benzothiazepine analog 11 DMVC51O TI TTRA6BO DMVC51O TN Bromodomain-containing protein 4 (BRD4) DMVC51O MA Inhibitor DMVC51O RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMVC51O RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMVCBSK DI DMVCBSK DMVCBSK DN PMID28270021-Compound-WO2014078408Example26 DMVCBSK TI TTTDVOJ DMVCBSK TN Tropomyosin-related kinase A (TrkA) DMVCBSK MA Inhibitor DMVCBSK RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVCBSK RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVCKZT DI DMVCKZT DMVCKZT DN Phenylpropylamine derivative 1 DMVCKZT TI TT5TPI6 DMVCKZT TN Opioid receptor sigma 1 (OPRS1) DMVCKZT MA Ligand DMVCKZT RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMVCKZT RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMVCQKB DI DMVCQKB DMVCQKB DN PMID28870136-Compound-69 DMVCQKB TI TTK0O6Y DMVCQKB TN Ecto-5'-nucleotidase (CD73) DMVCQKB MA Inhibitor DMVCQKB RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMVCQKB RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMVCWXD DI DMVCWXD DMVCWXD DN US10022354, Example 151 DMVCWXD TI TTIG67W DMVCWXD TN Lysine-specific demethylase 5A (KDM5A) DMVCWXD MA Inhibitor DMVCWXD RN IRE-1 inhibitors DMVCWXD RU http://www.freepatentsonline.com/US10022354.html DMVD5TA DI DMVD5TA DMVD5TA DN Azachalcone derivative 1 DMVD5TA TI TT2F4OL DMVD5TA TN Tissue transglutaminase (TG2) DMVD5TA MA Inhibitor DMVD5TA RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMVD5TA RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMVDBHT DI DMVDBHT DMVDBHT DN PMID27724045-Compound-19 DMVDBHT TI TT473XN DMVDBHT TN P2X purinoceptor 7 (P2RX7) DMVDBHT MA Antagonist DMVDBHT RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMVDBHT RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMVDKXY DI DMVDKXY DMVDKXY DN PMID25666693-Compound-45 DMVDKXY TI TTMI6F5 DMVDKXY TN Transient receptor potential cation channel V1 (TRPV1) DMVDKXY MA Antagonist DMVDKXY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVDKXY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVEP6Y DI DMVEP6Y DMVEP6Y DN Pyrazolo[1,5-a]pyrimidine derivative 18 DMVEP6Y TI TTTDVOJ DMVEP6Y TN Tropomyosin-related kinase A (TrkA) DMVEP6Y MA Inhibitor DMVEP6Y RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMVEP6Y RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMVEQ2P DI DMVEQ2P DMVEQ2P DN PMID26560530-Compound-26 DMVEQ2P TI TT2F4OL DMVEQ2P TN Tissue transglutaminase (TG2) DMVEQ2P MA Inhibitor DMVEQ2P RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMVEQ2P RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMVF1BI DI DMVF1BI DMVF1BI DN Pyridine derivative 9 DMVF1BI TI TTOHSBA DMVF1BI TN Vascular endothelial growth factor A (VEGFA) DMVF1BI MA Inhibitor DMVF1BI RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMVF1BI RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMVF1D6 DI DMVF1D6 DMVF1D6 DN PMID25991433-Compound-P4 DMVF1D6 TI TT0K6EO DMVF1D6 TN Stress-activated protein kinase JNK1 (JNK1) DMVF1D6 MA Inhibitor DMVF1D6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVF1D6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVF1D6 DI DMVF1D6 DMVF1D6 DN PMID25991433-Compound-P4 DMVF1D6 TI TTHS0U8 DMVF1D6 TN Stress-activated protein kinase JNK2 (JNK2) DMVF1D6 MA Inhibitor DMVF1D6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVF1D6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVF1D6 DI DMVF1D6 DMVF1D6 DN PMID25991433-Compound-P4 DMVF1D6 TI TT056SO DMVF1D6 TN Stress-activated protein kinase JNK3 (JNK3) DMVF1D6 MA Inhibitor DMVF1D6 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVF1D6 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVF63N DI DMVF63N DMVF63N DN Biaryl mannoside derivative 4 DMVF63N TI TTTCRU2 DMVF63N TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMVF63N MA Antagonist DMVF63N RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMVF63N RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMVFBHD DI DMVFBHD DMVFBHD DN US9187437, 24 DMVFBHD TI TTDYP7I DMVFBHD TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMVFBHD MA Inhibitor DMVFBHD RN Substituted oxadiazole compounds. US9187437. DMVFBHD RU http://www.freepatentsonline.com/US9187437.html DMVFSJZ DI DMVFSJZ DMVFSJZ DN Benzamide derivative 9 DMVFSJZ TI TT9NXW4 DMVFSJZ TN Sigma intracellular receptor 2 (TMEM97) DMVFSJZ MA Ligand DMVFSJZ RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMVFSJZ RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMVFSJZ DI DMVFSJZ DMVFSJZ DN Benzamide derivative 9 DMVFSJZ TI TT5TPI6 DMVFSJZ TN Opioid receptor sigma 1 (OPRS1) DMVFSJZ MA Ligand DMVFSJZ RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMVFSJZ RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMVFTIL DI DMVFTIL DMVFTIL DN PMID26651364-Compound-122 DMVFTIL TI TTTCRU2 DMVFTIL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMVFTIL MA Antagonist DMVFTIL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMVFTIL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMVG275 DI DMVG275 DMVG275 DN PMID28766366-Compound-Scheme15-1 DMVG275 TI TTSBVFO DMVG275 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVG275 MA Inhibitor DMVG275 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVG275 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVG7A5 DI DMVG7A5 DMVG7A5 DN PMID27539678-Compound-17 DMVG7A5 TI TTOHFIY DMVG7A5 TN Sphingosine kinase 1 (SPHK1) DMVG7A5 MA Inhibitor DMVG7A5 RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMVG7A5 RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMVGQXK DI DMVGQXK DMVGQXK DN US9682991, 2 DMVGQXK TI TTCGOIN DMVGQXK TN PIM-3 protein kinase (PIM3) DMVGQXK MA Inhibitor DMVGQXK RN Tricyclic compounds for use as kinase inhibitors. US9682991. DMVGQXK RU http://www.freepatentsonline.com/US9682991.html DMVHL3W DI DMVHL3W DMVHL3W DN 1,2-diamino cyclopentane-based derivative 34 DMVHL3W TI TT9N02I DMVHL3W TN Orexin receptor type 2 (HCRTR2) DMVHL3W MA Antagonist DMVHL3W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVHL3W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVHL3W DI DMVHL3W DMVHL3W DN 1,2-diamino cyclopentane-based derivative 34 DMVHL3W TI TT60Q8D DMVHL3W TN Orexin receptor type 1 (HCRTR1) DMVHL3W MA Antagonist DMVHL3W RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVHL3W RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVHLQM DI DMVHLQM DMVHLQM DN Phenylpyridine derivative 1 DMVHLQM TI TT1LVF2 DMVHLQM TN Cyclin-dependent kinase 9 (CDK9) DMVHLQM MA Inhibitor DMVHLQM RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMVHLQM RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMVI83P DI DMVI83P DMVI83P DN US8614253, 29-19 DMVI83P TI TTOJ9QL DMVI83P TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMVI83P MA Inhibitor DMVI83P RN IRE-1 inhibitors. US9493435. DMVI83P RU http://www.freepatentsonline.com/US9493435.html DMVIFXR DI DMVIFXR DMVIFXR DN Boronic acid derivative 4 DMVIFXR TI TTDP1UC DMVIFXR TN Fatty acid amide hydrolase (FAAH) DMVIFXR MA Inhibitor DMVIFXR RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMVIFXR RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMVISYC DI DMVISYC DMVISYC DN Carboxamide derivative 9 DMVISYC TI TTG5QB7 DMVISYC TN Calpain-2 (CAPN2) DMVISYC MA Inhibitor DMVISYC RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMVISYC RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMVIY73 DI DMVIY73 DMVIY73 DN PMID28117607-Compound-4 DMVIY73 TI TTK0FEA DMVIY73 TN Leucine-rich repeat kinase 2 (LRRK2) DMVIY73 MA Inhibitor DMVIY73 RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMVIY73 RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMVIZTY DI DMVIZTY DMVIZTY DN Cyclohexyl carbamate derivative 3 DMVIZTY TI TTULVH8 DMVIZTY TN Tyrosinase (TYR) DMVIZTY MA Inhibitor DMVIZTY RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMVIZTY RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMVJDRI DI DMVJDRI DMVJDRI DN PMID28766366-Compound-Scheme2WO2012/098065upper DMVJDRI TI TTYGQ8A DMVJDRI TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMVJDRI MA Inhibitor DMVJDRI RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVJDRI RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVJDRI DI DMVJDRI DMVJDRI DN PMID28766366-Compound-Scheme2WO2012/098065upper DMVJDRI TI TTSBVFO DMVJDRI TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVJDRI MA Inhibitor DMVJDRI RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVJDRI RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVKCQU DI DMVKCQU DMVKCQU DN Pyrrolo[2,3-b]pyridine derivative 1 DMVKCQU TI TTTDVOJ DMVKCQU TN Tropomyosin-related kinase A (TrkA) DMVKCQU MA Inhibitor DMVKCQU RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVKCQU RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVKO9C DI DMVKO9C DMVKO9C DN PMID25522065-Compound-12 DMVKO9C TI TTX4RTB DMVKO9C TN Melanin-concentrating hormone receptor 1 (MCHR1) DMVKO9C MA Antagonist DMVKO9C RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMVKO9C RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMVKZU2 DI DMVKZU2 DMVKZU2 DN Quinazoline derivative 12 DMVKZU2 TI TTQR74A DMVKZU2 TN Proteinase activated receptor 2 (PAR2) DMVKZU2 MA Antagonist DMVKZU2 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMVKZU2 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMVL25C DI DMVL25C DMVL25C DN PMID25726713-Compound-39 DMVL25C TI TT8J1S3 DMVL25C TN Smoothened homolog (SMO) DMVL25C MA Inhibitor DMVL25C RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMVL25C RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMVL2G3 DI DMVL2G3 DMVL2G3 DN Pyridine derivative 10 DMVL2G3 TI TTOHSBA DMVL2G3 TN Vascular endothelial growth factor A (VEGFA) DMVL2G3 MA Inhibitor DMVL2G3 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMVL2G3 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMVL57U DI DMVL57U DMVL57U DN US9388139, 12 DMVL57U TI TTN34SQ DMVL57U TN Phosphodiesterase 3B (PDE3B) DMVL57U MA Inhibitor DMVL57U RN Derivatives of celeboxib, use thereof and preparation thereof. US9388139. DMVL57U RU http://www.freepatentsonline.com/US9388139.html DMVLP8H DI DMVLP8H DMVLP8H DN Peptide analog 55 DMVLP8H TI TTQAJF1 DMVLP8H TN Cathepsin G (CTSG) DMVLP8H MA Inhibitor DMVLP8H RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMVLP8H RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMVLP8H DI DMVLP8H DMVLP8H DN Peptide analog 55 DMVLP8H TI TTPLTSQ DMVLP8H TN Neutrophil elastase (NE) DMVLP8H MA Inhibitor DMVLP8H RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMVLP8H RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMVLQ2P DI DMVLQ2P DMVLQ2P DN Aromatic bicyclic compound 1 DMVLQ2P TI TTRMX3V DMVLQ2P TN Janus kinase 2 (JAK-2) DMVLQ2P MA Inhibitor DMVLQ2P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMVLQ2P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMVLQ2P DI DMVLQ2P DMVLQ2P DN Aromatic bicyclic compound 1 DMVLQ2P TI TT6PKBN DMVLQ2P TN Proto-oncogene c-Src (SRC) DMVLQ2P MA Inhibitor DMVLQ2P RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMVLQ2P RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMVLXRB DI DMVLXRB DMVLXRB DN PMID27019002-Compound-41 DMVLXRB TI TTNR0UQ DMVLXRB TN Lysine-specific histone demethylase 1 (LSD) DMVLXRB MA Inhibitor DMVLXRB RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMVLXRB RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMVM31E DI DMVM31E DMVM31E DN PMID27967267-Compound-28 DMVM31E TI TT1RS9F DMVM31E TN Acetylcholinesterase (AChE) DMVM31E RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMVM31E RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMVMD2O DI DMVMD2O DMVMD2O DN Imidazolidine-2,4-dione derivative 2 DMVMD2O TI TT6OEDT DMVMD2O TN Cannabinoid receptor 1 (CB1) DMVMD2O MA Antagonist DMVMD2O RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVMD2O RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVMNP1 DI DMVMNP1 DMVMNP1 DN US10166249, Example 695 DMVMNP1 TI TTDYP7I DMVMNP1 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMVMNP1 MA Inhibitor DMVMNP1 RN Substituted bicyclic compounds. US10166249. DMVMNP1 RU http://www.freepatentsonline.com/US10166249.html DMVMSQ2 DI DMVMSQ2 DMVMSQ2 DN PMID25656651-Compound-30a DMVMSQ2 TI TTS7G69 DMVMSQ2 TN Fusion protein Bcr-Abl (Bcr-Abl) DMVMSQ2 MA Inhibitor DMVMSQ2 RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMVMSQ2 RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMVMT26 DI DMVMT26 DMVMT26 DN PMID25399762-Compound-Table1-C9 DMVMT26 TI TTGP7BY DMVMT26 TN Monoamine oxidase type B (MAO-B) DMVMT26 MA Inhibitor DMVMT26 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMVMT26 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMVN5BD DI DMVN5BD DMVN5BD DN PMID27724045-Compound-15 DMVN5BD TI TT473XN DMVN5BD TN P2X purinoceptor 7 (P2RX7) DMVN5BD MA Antagonist DMVN5BD RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMVN5BD RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMVNY5I DI DMVNY5I DMVNY5I DN Pyrrolo-pyridine derivative 2 DMVNY5I TI TT6AXLY DMVNY5I TN Leucine-rich repeat kinase 2 G2019S mutant (LRRK2 G2019S) DMVNY5I MA Inhibitor DMVNY5I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMVNY5I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMVNY5I DI DMVNY5I DMVNY5I DN Pyrrolo-pyridine derivative 2 DMVNY5I TI TTK0FEA DMVNY5I TN Leucine-rich repeat kinase 2 (LRRK2) DMVNY5I MA Inhibitor DMVNY5I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMVNY5I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMVOEN7 DI DMVOEN7 DMVOEN7 DN Cyclic compound 3 DMVOEN7 TI TTNBFWK DMVOEN7 TN Programmed cell death protein 1 (PD-1) DMVOEN7 MA Inhibitor DMVOEN7 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMVOEN7 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMVOTKN DI DMVOTKN DMVOTKN DN Thiazole carboxamide derivative 8 DMVOTKN TI TTCZOF2 DMVOTKN TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMVOTKN MA Inhibitor DMVOTKN RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMVOTKN RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMVOWS5 DI DMVOWS5 DMVOWS5 DN PMID25991433-Compound-O3 DMVOWS5 TI TT0K6EO DMVOWS5 TN Stress-activated protein kinase JNK1 (JNK1) DMVOWS5 MA Inhibitor DMVOWS5 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVOWS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVOWS5 DI DMVOWS5 DMVOWS5 DN PMID25991433-Compound-O3 DMVOWS5 TI TT056SO DMVOWS5 TN Stress-activated protein kinase JNK3 (JNK3) DMVOWS5 MA Inhibitor DMVOWS5 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVOWS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVOWS5 DI DMVOWS5 DMVOWS5 DN PMID25991433-Compound-O3 DMVOWS5 TI TTHS0U8 DMVOWS5 TN Stress-activated protein kinase JNK2 (JNK2) DMVOWS5 MA Inhibitor DMVOWS5 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMVOWS5 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMVOYJ8 DI DMVOYJ8 DMVOYJ8 DN Pyrimidine derivative 29 DMVOYJ8 TI TT0K1SC DMVOYJ8 TN 5-HT 2B receptor (HTR2B) DMVOYJ8 MA Antagonist DMVOYJ8 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVOYJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVOYJ8 DI DMVOYJ8 DMVOYJ8 DN Pyrimidine derivative 29 DMVOYJ8 TI TTWJBZ5 DMVOYJ8 TN 5-HT 2C receptor (HTR2C) DMVOYJ8 MA Antagonist DMVOYJ8 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVOYJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVOYJ8 DI DMVOYJ8 DMVOYJ8 DN Pyrimidine derivative 29 DMVOYJ8 TI TTJQOD7 DMVOYJ8 TN 5-HT 2A receptor (HTR2A) DMVOYJ8 MA Antagonist DMVOYJ8 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVOYJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVP16K DI DMVP16K DMVP16K DN PMID30259754-Compound-pyrrole[2,3-d]azepines DMVP16K TI TTS4UGC DMVP16K TN Farnesoid X-activated receptor (FXR) DMVP16K MA Agonist DMVP16K RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DMVP16K RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DMVP7DL DI DMVP7DL DMVP7DL DN PMID29473428-Compound-58 DMVP7DL TI TTZJYKH DMVP7DL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMVP7DL MA Inhibitor DMVP7DL RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMVP7DL RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT8M4E1 DMVPMWJ TN Histone deacetylase 9 (HDAC9) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTUELN5 DMVPMWJ TN Histone deacetylase 5 (HDAC5) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTTQGH8 DMVPMWJ TN Histone deacetylase 4 (HDAC4) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTMUEK1 DMVPMWJ TN Histone deacetylase 7 (HDAC7) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTT6LFV DMVPMWJ TN Histone deacetylase 8 (HDAC8) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT4YWTO DMVPMWJ TN Histone deacetylase 3 (HDAC3) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTSHTOI DMVPMWJ TN Histone deacetylase 2 (HDAC2) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT6R7JZ DMVPMWJ TN Histone deacetylase 1 (HDAC1) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TTYHPU6 DMVPMWJ TN Histone deacetylase 10 (HDAC10) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT8K17W DMVPMWJ TN Histone deacetylase 11 (HDAC11) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPMWJ DI DMVPMWJ DMVPMWJ DN PMID29671355-Compound-43 DMVPMWJ TI TT5ZKDI DMVPMWJ TN Histone deacetylase 6 (HDAC6) DMVPMWJ MA Inhibitor DMVPMWJ RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMVPMWJ RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMVPR1D DI DMVPR1D DMVPR1D DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 11 DMVPR1D TI TTULVH8 DMVPR1D TN Tyrosinase (TYR) DMVPR1D MA Inhibitor DMVPR1D RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMVPR1D RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMVQ3IX DI DMVQ3IX DMVQ3IX DN US9453017, 1 DMVQ3IX TI TT3T17P DMVQ3IX TN Phospholipase D1 (PLD1) DMVQ3IX MA Inhibitor DMVQ3IX RN Antiviral therapies with phospholipase D inhibitors. US9453017. DMVQ3IX RU http://www.freepatentsonline.com/US9453017.html DMVQ4NS DI DMVQ4NS DMVQ4NS DN Pyrimidine benzenesulfonamide derivative 2 DMVQ4NS TI TTIY56R DMVQ4NS TN Kynurenine 3-hydroxylase (KMO) DMVQ4NS MA Inhibitor DMVQ4NS RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMVQ4NS RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMVQSYT DI DMVQSYT DMVQSYT DN PMID26004420-Compound-US20140031349A DMVQSYT TI TTJ13ST DMVQSYT TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMVQSYT MA Inhibitor DMVQSYT RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMVQSYT RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TTOUSTQ DMVQTR2 TN Proteasome beta-9 (PS beta-9) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TT8EPLT DMVQTR2 TN Proteasome beta-1 (PS beta-1) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TT68GPI DMVQTR2 TN Proteasome beta-5 (PS beta-5) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQTR2 DI DMVQTR2 DMVQTR2 DN PMID29865878-Compound-48 DMVQTR2 TI TTEAD9J DMVQTR2 TN Proteasome beta-8 (PS beta-8) DMVQTR2 MA Inhibitor DMVQTR2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVQTR2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVQU9T DI DMVQU9T DMVQU9T DN PMID25666693-Compound-140 DMVQU9T TI TTMI6F5 DMVQU9T TN Transient receptor potential cation channel V1 (TRPV1) DMVQU9T MA Antagonist DMVQU9T RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVQU9T RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVQXZJ DI DMVQXZJ DMVQXZJ DN Pyrazole-3-carboxamide derivative 1 DMVQXZJ TI TT0K1SC DMVQXZJ TN 5-HT 2B receptor (HTR2B) DMVQXZJ MA Antagonist DMVQXZJ RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVQXZJ RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVR04K DI DMVR04K DMVR04K DN Indandione derivative 2 DMVR04K TI TTV1C0Z DMVR04K TN Neuropeptide S receptor (NPSR) DMVR04K MA Antagonist DMVR04K RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMVR04K RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMVR9TJ DI DMVR9TJ DMVR9TJ DN PMID27841045-Compound-135 DMVR9TJ TI TT7RJY8 DMVR9TJ TN Xanthine dehydrogenase/oxidase (XDH) DMVR9TJ MA Inhibitor DMVR9TJ RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMVR9TJ RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMVREIM DI DMVREIM DMVREIM DN PMID25666693-Compound-120 DMVREIM TI TTMI6F5 DMVREIM TN Transient receptor potential cation channel V1 (TRPV1) DMVREIM MA Antagonist DMVREIM RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVREIM RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVRJZX DI DMVRJZX DMVRJZX DN PMID28870136-Compound-55 DMVRJZX TI TTK0O6Y DMVRJZX TN Ecto-5'-nucleotidase (CD73) DMVRJZX MA Inhibitor DMVRJZX RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMVRJZX RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMVRX7S DI DMVRX7S DMVRX7S DN Indole-based analog 11 DMVRX7S TI TTBH0VX DMVRX7S TN Histone deacetylase (HDAC) DMVRX7S MA Inhibitor DMVRX7S RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMVRX7S RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMVRX7S DI DMVRX7S DMVRX7S DN Indole-based analog 11 DMVRX7S TI TT7HF4W DMVRX7S TN Cyclin-dependent kinase 2 (CDK2) DMVRX7S MA Inhibitor DMVRX7S RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMVRX7S RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMVS1TU DI DMVS1TU DMVS1TU DN PMID26666989-Compound-Figure9topright01 DMVS1TU TI TT8BUGW DMVS1TU TN Glycogen phosphorylase (PYG) DMVS1TU MA Inhibitor DMVS1TU RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMVS1TU RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMVS7CJ DI DMVS7CJ DMVS7CJ DN PMID28270021-Compound-WO2013009582Example16 DMVS7CJ TI TTTDVOJ DMVS7CJ TN Tropomyosin-related kinase A (TrkA) DMVS7CJ MA Inhibitor DMVS7CJ RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMVS7CJ RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMVSFNE DI DMVSFNE DMVSFNE DN PMID25666693-Compound-12 DMVSFNE TI TTMI6F5 DMVSFNE TN Transient receptor potential cation channel V1 (TRPV1) DMVSFNE MA Antagonist DMVSFNE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMVSFNE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMVSW5N DI DMVSW5N DMVSW5N DN PMID25980951-Compound-6 DMVSW5N TI TTR7B60 DMVSW5N TN X-linked inhibitor of apoptosis protein (XIAP) DMVSW5N MA Antagonist DMVSW5N RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMVSW5N RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMVSW5N DI DMVSW5N DMVSW5N DN PMID25980951-Compound-6 DMVSW5N TI TTHZ8TA DMVSW5N TN Melanoma inhibitor of apoptosis protein (ML-IAP) DMVSW5N MA Antagonist DMVSW5N RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMVSW5N RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMVSW5N DI DMVSW5N DMVSW5N DN PMID25980951-Compound-6 DMVSW5N TI TTQ5LRD DMVSW5N TN Cellular inhibitor of apoptosis 1 (BIRC2) DMVSW5N MA Antagonist DMVSW5N RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMVSW5N RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMVSXUM DI DMVSXUM DMVSXUM DN Imidazole derivative 5 DMVSXUM TI TT6OEDT DMVSXUM TN Cannabinoid receptor 1 (CB1) DMVSXUM MA Antagonist DMVSXUM RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVSXUM RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVTARK DI DMVTARK DMVTARK DN Heteroaryl-carboxamide derivative 10 DMVTARK TI TTCZOF2 DMVTARK TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMVTARK MA Inhibitor DMVTARK RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMVTARK RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMVTPHY DI DMVTPHY DMVTPHY DN PMID27607364-Compound-63 DMVTPHY TI TTPTXIN DMVTPHY TN Translocator protein (TSPO) DMVTPHY MA Ligand DMVTPHY RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMVTPHY RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMVTZ6S DI DMVTZ6S DMVTZ6S DN Tetra-hydro-1H-1,2,6-triazaazulene derivative 2 DMVTZ6S TI TT6OEDT DMVTZ6S TN Cannabinoid receptor 1 (CB1) DMVTZ6S MA Antagonist DMVTZ6S RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVTZ6S RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVU9RG DI DMVU9RG DMVU9RG DN Fused heterocyclic compound 1 DMVU9RG TI TT7RJY8 DMVU9RG TN Xanthine dehydrogenase/oxidase (XDH) DMVU9RG MA Inhibitor DMVU9RG RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMVU9RG RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMVUJGI DI DMVUJGI DMVUJGI DN Azole derivative 7 DMVUJGI TI TTF8P9I DMVUJGI TN Diacylglycerol acyltransferase 1 (DGAT1) DMVUJGI MA Inhibitor DMVUJGI RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMVUJGI RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMVUNYD DI DMVUNYD DMVUNYD DN Quinoline carboxamide derivative 4 DMVUNYD TI TTPTXIN DMVUNYD TN Translocator protein (TSPO) DMVUNYD MA Ligand DMVUNYD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMVUNYD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMVUSF3 DI DMVUSF3 DMVUSF3 DN Pyrazolopyrimidine derivative 5 DMVUSF3 TI TTHS256 DMVUSF3 TN Metabotropic glutamate receptor 5 (mGluR5) DMVUSF3 MA Modulator DMVUSF3 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMVUSF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMVUWLK DI DMVUWLK DMVUWLK DN Indazole derivative 3 DMVUWLK TI TTXNCBV DMVUWLK TN Tryptophan 2,3-dioxygenase (TDO) DMVUWLK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMVUWLK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMVUWLK DI DMVUWLK DMVUWLK DN Indazole derivative 3 DMVUWLK TI TTZJYKH DMVUWLK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMVUWLK RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMVUWLK RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMVUWYB DI DMVUWYB DMVUWYB DN PMID27599163-Compound-79 DMVUWYB TI TTPTXIN DMVUWYB TN Translocator protein (TSPO) DMVUWYB MA Ligand DMVUWYB RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMVUWYB RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMVW25O DI DMVW25O DMVW25O DN Pyrimidine derivative 8 DMVW25O TI TTOHSBA DMVW25O TN Vascular endothelial growth factor A (VEGFA) DMVW25O MA Inhibitor DMVW25O RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMVW25O RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMVWF6I DI DMVWF6I DMVWF6I DN PMID25772215-Compound-EP20082149552C9 DMVWF6I TI TT1ZAVI DMVWF6I TN Prostaglandin E2 receptor EP2 (PTGER2) DMVWF6I MA Antagonist DMVWF6I RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMVWF6I RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMVX2D0 DI DMVX2D0 DMVX2D0 DN Pyrazole derivative 24 DMVX2D0 TI TT6OEDT DMVX2D0 TN Cannabinoid receptor 1 (CB1) DMVX2D0 MA Antagonist DMVX2D0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVX2D0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVX71N DI DMVX71N DMVX71N DN Peptide analog 37 DMVX71N TI TT68GPI DMVX71N TN Proteasome beta-5 (PS beta-5) DMVX71N MA Inhibitor DMVX71N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVX71N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVX71N DI DMVX71N DMVX71N DN Peptide analog 37 DMVX71N TI TT49BVC DMVX71N TN Proteasome beta-2 (PS beta-2) DMVX71N MA Inhibitor DMVX71N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVX71N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVX71N DI DMVX71N DMVX71N DN Peptide analog 37 DMVX71N TI TTPNACM DMVX71N TN Proteasome beta-10 (PS beta-10) DMVX71N MA Inhibitor DMVX71N RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMVX71N RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMVX7YB DI DMVX7YB DMVX7YB DN Imidazo[1,2-b]pyridazine acetamide derivative 2 DMVX7YB TI TTPTXIN DMVX7YB TN Translocator protein (TSPO) DMVX7YB MA Ligand DMVX7YB RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMVX7YB RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMVX7YT DI DMVX7YT DMVX7YT DN Pyrazole N-1 aryl and heteroaryl derivative 1 DMVX7YT TI TTKFVXR DMVX7YT TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMVX7YT MA Inhibitor DMVX7YT RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMVX7YT RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMVX9NK DI DMVX9NK DMVX9NK DN AC1LOJYQ DMVX9NK TI TTLKF5M DMVX9NK TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMVX9NK MA Inhibitor DMVX9NK RN Small molecule activators of NRF2 pathway. US9737525. DMVX9NK RU http://www.freepatentsonline.com/US9737525.html DMVXTIL DI DMVXTIL DMVXTIL DN PMID27998201-Compound-10 DMVXTIL TI TTDZN01 DMVXTIL TN Cathepsin K (CTSK) DMVXTIL MA Inhibitor DMVXTIL RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVXTIL RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVY0JT DI DMVY0JT DMVY0JT DN Pyrazole derivative 68 DMVY0JT TI TTJQOD7 DMVY0JT TN 5-HT 2A receptor (HTR2A) DMVY0JT MA Antagonist DMVY0JT RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMVY0JT RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMVY6B9 DI DMVY6B9 DMVY6B9 DN PMID27109571-Compound-14 DMVY6B9 TI TTNT2S6 DMVY6B9 TN Fatty acid-binding protein 5 (FABP5) DMVY6B9 MA Inhibitor DMVY6B9 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMVY6B9 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMVY6B9 DI DMVY6B9 DMVY6B9 DN PMID27109571-Compound-14 DMVY6B9 TI TTHWMFZ DMVY6B9 TN Fatty acid-binding protein 4 (FABP4) DMVY6B9 MA Inhibitor DMVY6B9 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMVY6B9 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMVY6PX DI DMVY6PX DMVY6PX DN PMID28766366-Compound-Scheme9EHT6840 DMVY6PX TI TTYGQ8A DMVY6PX TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMVY6PX MA Inhibitor DMVY6PX RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVY6PX RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVY6PX DI DMVY6PX DMVY6PX DN PMID28766366-Compound-Scheme9EHT6840 DMVY6PX TI TTSBVFO DMVY6PX TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMVY6PX MA Inhibitor DMVY6PX RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMVY6PX RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMVYG0U DI DMVYG0U DMVYG0U DN PMID28594589-Compound-TABLE3C2 DMVYG0U TI TTZCRP3 DMVYG0U TN ERK activator kinase (MEK) DMVYG0U MA Inhibitor DMVYG0U RN MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906. DMVYG0U RU https://www.ncbi.nlm.nih.gov/pubmed/28594589 DMVYO09 DI DMVYO09 DMVYO09 DN PMID27977313-Compound-27 DMVYO09 TI TTR7UJ3 DMVYO09 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMVYO09 MA Inhibitor DMVYO09 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMVYO09 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMVYP8K DI DMVYP8K DMVYP8K DN Phenylalanine derivative 1 DMVYP8K TI TT36ETB DMVYP8K TN Cathepsin L (CTSL) DMVYP8K MA Inhibitor DMVYP8K RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVYP8K RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVYP8K DI DMVYP8K DMVYP8K DN Phenylalanine derivative 1 DMVYP8K TI TTUMQVO DMVYP8K TN Cathepsin S (CTSS) DMVYP8K MA Inhibitor DMVYP8K RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVYP8K RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVYQXH DI DMVYQXH DMVYQXH DN US8470836, 6 DMVYQXH TI TTOYT5L DMVYQXH TN Dipeptidyl-peptidase 7 (DPP7) DMVYQXH MA Inhibitor DMVYQXH RN Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. DMVYQXH RU http://www.freepatentsonline.com/US8470836.html DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTDZN01 DMVZ0ND TN Cathepsin K (CTSK) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TT36ETB DMVZ0ND TN Cathepsin L (CTSL) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTF2LRI DMVZ0ND TN Cathepsin B (CTSB) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTUMQVO DMVZ0ND TN Cathepsin S (CTSS) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ0ND DI DMVZ0ND DMVZ0ND DN PMID27998201-Compound-5 DMVZ0ND TI TTJOKD1 DMVZ0ND TN Cathepsin F (CTSF) DMVZ0ND MA Inhibitor DMVZ0ND RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMVZ0ND RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMVZ5EP DI DMVZ5EP DMVZ5EP DN 1,2-diamino cyclopentane-based derivative 31 DMVZ5EP TI TT9N02I DMVZ5EP TN Orexin receptor type 2 (HCRTR2) DMVZ5EP MA Antagonist DMVZ5EP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVZ5EP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVZ5EP DI DMVZ5EP DMVZ5EP DN 1,2-diamino cyclopentane-based derivative 31 DMVZ5EP TI TT60Q8D DMVZ5EP TN Orexin receptor type 1 (HCRTR1) DMVZ5EP MA Antagonist DMVZ5EP RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMVZ5EP RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMVZ8KD DI DMVZ8KD DMVZ8KD DN Pyrazole derivative 18 DMVZ8KD TI TT6OEDT DMVZ8KD TN Cannabinoid receptor 1 (CB1) DMVZ8KD MA Antagonist DMVZ8KD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMVZ8KD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMVZA0U DI DMVZA0U DMVZA0U DN PMID30273516-Compound-22a DMVZA0U TI TTCW0KX DMVZA0U TN Glutaminase (GLS) DMVZA0U MA Inhibitor DMVZA0U RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMVZA0U RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMVZPIO DI DMVZPIO DMVZPIO DN PMID28447479-Compound-27 DMVZPIO TI TTSCIM2 DMVZPIO TN Extracellular lysophospholipase D (E-NPP2) DMVZPIO MA Agonist DMVZPIO RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMVZPIO RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMW039D DI DMW039D DMW039D DN Aminopyrimidine derivative 4 DMW039D TI TTS7G69 DMW039D TN Fusion protein Bcr-Abl (Bcr-Abl) DMW039D MA Inhibitor DMW039D RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMW039D RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMW0TM1 DI DMW0TM1 DMW0TM1 DN PMID27454349-Compound-96 DMW0TM1 TI TTK59TV DMW0TM1 TN Vitamin D3 receptor (VDR) DMW0TM1 MA Agonist DMW0TM1 RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMW0TM1 RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMW1PL7 DI DMW1PL7 DMW1PL7 DN NG7 DMW1PL7 TI TTI1FPZ DMW1PL7 TN Epithelial discoidin domain receptor 1 (DDR1) DMW1PL7 MA Inhibitor DMW1PL7 RN Fused 2-aminothiazole compounds. US8765747. DMW1PL7 RU http://www.freepatentsonline.com/US8765747.html DMW21U4 DI DMW21U4 DMW21U4 DN PMID28092474-Compound-32d DMW21U4 TI TT6R7JZ DMW21U4 TN Histone deacetylase 1 (HDAC1) DMW21U4 MA Inhibitor DMW21U4 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW21U4 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW21U4 DI DMW21U4 DMW21U4 DN PMID28092474-Compound-32d DMW21U4 TI TT5ZKDI DMW21U4 TN Histone deacetylase 6 (HDAC6) DMW21U4 MA Inhibitor DMW21U4 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW21U4 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW2C19 DI DMW2C19 DMW2C19 DN PMID25435285-Compound-40 DMW2C19 TI TTXJ47W DMW2C19 TN Metabotropic glutamate receptor 2 (mGluR2) DMW2C19 MA Antagonist DMW2C19 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMW2C19 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMW2JG8 DI DMW2JG8 DMW2JG8 DN Pyrrolidinyl urea derivative 8 DMW2JG8 TI TTTDVOJ DMW2JG8 TN Tropomyosin-related kinase A (TrkA) DMW2JG8 MA Inhibitor DMW2JG8 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMW2JG8 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMW2LD5 DI DMW2LD5 DMW2LD5 DN Nicotinyl hydroxamic acid derivative 1 DMW2LD5 TI TTULVH8 DMW2LD5 TN Tyrosinase (TYR) DMW2LD5 MA Inhibitor DMW2LD5 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMW2LD5 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTKAWRQ DMW2LZ0 TN JAK-STAT signaling pathway (JAK-STAT pathway) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTJSQEF DMW2LZ0 TN Tyrosine-protein kinase (PTK) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTT7PJU DMW2LZ0 TN Janus kinase 3 (JAK-3) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTBYWP2 DMW2LZ0 TN TYK2 tyrosine kinase (TYK2) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TTRMX3V DMW2LZ0 TN Janus kinase 2 (JAK-2) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2LZ0 DI DMW2LZ0 DMW2LZ0 DN Aminotriazolopyridine derivative 1 DMW2LZ0 TI TT6DM01 DMW2LZ0 TN Janus kinase 1 (JAK-1) DMW2LZ0 MA Inhibitor DMW2LZ0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMW2LZ0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMW2N5D DI DMW2N5D DMW2N5D DN PMID27109571-Compound-1 DMW2N5D TI TTMY6L1 DMW2N5D TN Fatty acid-binding protein (FABP) DMW2N5D MA Inhibitor DMW2N5D RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMW2N5D RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMW2S0J DI DMW2S0J DMW2S0J DN PMID30185082-Compound-63 DMW2S0J TI TT9NXW4 DMW2S0J TN Sigma intracellular receptor 2 (TMEM97) DMW2S0J MA Ligand DMW2S0J RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMW2S0J RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMW2ZRM DI DMW2ZRM DMW2ZRM DN PMID28270021-Compound-WO2016054807Example112 DMW2ZRM TI TTTDVOJ DMW2ZRM TN Tropomyosin-related kinase A (TrkA) DMW2ZRM MA Inhibitor DMW2ZRM RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMW2ZRM RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMW38MK DI DMW38MK DMW38MK DN PMID28092474-Compound-33d DMW38MK TI TT5ZKDI DMW38MK TN Histone deacetylase 6 (HDAC6) DMW38MK MA Inhibitor DMW38MK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW38MK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW38MK DI DMW38MK DMW38MK DN PMID28092474-Compound-33d DMW38MK TI TT6R7JZ DMW38MK TN Histone deacetylase 1 (HDAC1) DMW38MK MA Inhibitor DMW38MK RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMW38MK RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMW3EMH DI DMW3EMH DMW3EMH DN 7-azaindole derivative 4 DMW3EMH TI TT056SO DMW3EMH TN Stress-activated protein kinase JNK3 (JNK3) DMW3EMH MA Inhibitor DMW3EMH RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMW3EMH RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMW3JH0 DI DMW3JH0 DMW3JH0 DN Quinoline and quinazoline derivative 8 DMW3JH0 TI TTOHSBA DMW3JH0 TN Vascular endothelial growth factor A (VEGFA) DMW3JH0 MA Inhibitor DMW3JH0 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMW3JH0 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMW3JZV DI DMW3JZV DMW3JZV DN Isoxazoles and isoxazoline derivative 4 DMW3JZV TI TTIY56R DMW3JZV TN Kynurenine 3-hydroxylase (KMO) DMW3JZV MA Inhibitor DMW3JZV RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMW3JZV RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMW3PJV DI DMW3PJV DMW3PJV DN Pyrazole derivative 86 DMW3PJV TI TT5TPI6 DMW3PJV TN Opioid receptor sigma 1 (OPRS1) DMW3PJV MA Inhibitor DMW3PJV RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMW3PJV RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMW3X1I DI DMW3X1I DMW3X1I DN PMID27788040-Compound-5a DMW3X1I TI TTV1C0Z DMW3X1I TN Neuropeptide S receptor (NPSR) DMW3X1I MA Antagonist DMW3X1I RN Neuropeptide S receptor ligands: a patent review (2005-2016).Expert Opin Ther Pat. 2017 Mar;27(3):347-362. DMW3X1I RU https://www.ncbi.nlm.nih.gov/pubmed/27788040 DMW4B1U DI DMW4B1U DMW4B1U DN Carbamate derivative 9 DMW4B1U TI TTDP1UC DMW4B1U TN Fatty acid amide hydrolase (FAAH) DMW4B1U MA Inhibitor DMW4B1U RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMW4B1U RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMW4B1U DI DMW4B1U DMW4B1U DN Carbamate derivative 9 DMW4B1U TI TTZ963I DMW4B1U TN Monoglyceride lipase (MAGL) DMW4B1U MA Inhibitor DMW4B1U RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMW4B1U RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMW4J0P DI DMW4J0P DMW4J0P DN Chloroacetyl ester derivative 1 DMW4J0P TI TT2F4OL DMW4J0P TN Tissue transglutaminase (TG2) DMW4J0P MA Inhibitor DMW4J0P RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMW4J0P RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMW4JB0 DI DMW4JB0 DMW4JB0 DN Cycloalkyl nitrile pyrazolo pyridone derivative 2 DMW4JB0 TI TTRMX3V DMW4JB0 TN Janus kinase 2 (JAK-2) DMW4JB0 MA Inhibitor DMW4JB0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMW4JB0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMW4JB0 DI DMW4JB0 DMW4JB0 DN Cycloalkyl nitrile pyrazolo pyridone derivative 2 DMW4JB0 TI TT6DM01 DMW4JB0 TN Janus kinase 1 (JAK-1) DMW4JB0 MA Inhibitor DMW4JB0 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMW4JB0 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMW4NXV DI DMW4NXV DMW4NXV DN Benzene sulfonamide derivative 5 DMW4NXV TI TTIY56R DMW4NXV TN Kynurenine 3-hydroxylase (KMO) DMW4NXV MA Inhibitor DMW4NXV RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMW4NXV RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMW502M DI DMW502M DMW502M DN Peptide analog 66 DMW502M TI TTPLTSQ DMW502M TN Neutrophil elastase (NE) DMW502M MA Inhibitor DMW502M RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMW502M RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMW57UB DI DMW57UB DMW57UB DN Alkyl mannoside derivative 1 DMW57UB TI TTTCRU2 DMW57UB TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMW57UB MA Antagonist DMW57UB RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMW57UB RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMW59Q4 DI DMW59Q4 DMW59Q4 DN Thiazole carboxamide derivative 19 DMW59Q4 TI TTCZOF2 DMW59Q4 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMW59Q4 MA Inhibitor DMW59Q4 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMW59Q4 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMW5DC1 DI DMW5DC1 DMW5DC1 DN 1,2,3,4-tetrahydroisoquinoline derivative 1 DMW5DC1 TI TTA6ZN2 DMW5DC1 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMW5DC1 MA Inhibitor DMW5DC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW5DC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW5DC1 DI DMW5DC1 DMW5DC1 DN 1,2,3,4-tetrahydroisoquinoline derivative 1 DMW5DC1 TI TTGIZLN DMW5DC1 TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMW5DC1 MA Modulator DMW5DC1 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW5DC1 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW5GI3 DI DMW5GI3 DMW5GI3 DN Carbamide derivative 2 DMW5GI3 TI TTO9X1H DMW5GI3 TN 5-HT 7 receptor (HTR7) DMW5GI3 MA Inhibitor DMW5GI3 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMW5GI3 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMW5SD6 DI DMW5SD6 DMW5SD6 DN BDBM50011552 DMW5SD6 TI TT6NI13 DMW5SD6 TN MEK kinase kinase 4 (MAP4K4) DMW5SD6 MA Inhibitor DMW5SD6 RN Aminoquinazoline and pyridopyrimidine derivatives. US9592235. DMW5SD6 RU http://www.freepatentsonline.com/US9592235.html DMW5YJB DI DMW5YJB DMW5YJB DN Quinoline carboxamide derivative 1 DMW5YJB TI TTH8FZW DMW5YJB TN Signal transducer and activator of transcription 3 (STAT3) DMW5YJB MA Inhibitor DMW5YJB RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMW5YJB RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMW60HU DI DMW60HU DMW60HU DN PMID27109571-Compound-10 DMW60HU TI TTHWMFZ DMW60HU TN Fatty acid-binding protein 4 (FABP4) DMW60HU MA Inhibitor DMW60HU RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMW60HU RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMW62LX DI DMW62LX DMW62LX DN Thiazole carboxamide derivative 1 DMW62LX TI TTCZOF2 DMW62LX TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMW62LX MA Inhibitor DMW62LX RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMW62LX RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMW6R0H DI DMW6R0H DMW6R0H DN Isoquinolone derivative 1 DMW6R0H TI TT5ZWB6 DMW6R0H TN Dihydrodiol dehydrogenase type I (AKR1C3) DMW6R0H MA Inhibitor; Antagonist; Blocker DMW6R0H RN Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340. DMW6R0H RU https://www.ncbi.nlm.nih.gov/pubmed/28895472 DMW7981 DI DMW7981 DMW7981 DN PMID25666693-Compound-33 DMW7981 TI TTMI6F5 DMW7981 TN Transient receptor potential cation channel V1 (TRPV1) DMW7981 MA Antagonist DMW7981 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMW7981 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMW7HKS DI DMW7HKS DMW7HKS DN Aryl sulphoxide imine derivative 1 DMW7HKS TI TTZJYKH DMW7HKS TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMW7HKS MA Inhibitor DMW7HKS RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMW7HKS RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMW7T45 DI DMW7T45 DMW7T45 DN PMID29649907-Compound-23 DMW7T45 TI TTS4UGC DMW7T45 TN Farnesoid X-activated receptor (FXR) DMW7T45 MA Agonist DMW7T45 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMW7T45 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMW86YI DI DMW86YI DMW86YI DN 3-phenyl propanoic derivative 1 DMW86YI TI TTA6ZN2 DMW86YI TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMW86YI MA Inhibitor DMW86YI RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW86YI RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW86YI DI DMW86YI DMW86YI DN 3-phenyl propanoic derivative 1 DMW86YI TI TTHQJI6 DMW86YI TN Keap1-Nrf2[ETGE] PPI (KEAP1-Nrf2 ETGE) DMW86YI MA Modulator DMW86YI RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMW86YI RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMW8V4R DI DMW8V4R DMW8V4R DN PMID30185082-Compound-55 DMW8V4R TI TT9NXW4 DMW8V4R TN Sigma intracellular receptor 2 (TMEM97) DMW8V4R MA Ligand DMW8V4R RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMW8V4R RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMW8XD2 DI DMW8XD2 DMW8XD2 DN PMID25666693-Compound-72 DMW8XD2 TI TTMI6F5 DMW8XD2 TN Transient receptor potential cation channel V1 (TRPV1) DMW8XD2 MA Antagonist DMW8XD2 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMW8XD2 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMW94IQ DI DMW94IQ DMW94IQ DN Benzothiazine-carboxamide compound 6 DMW94IQ TI TTQR74A DMW94IQ TN Proteinase activated receptor 2 (PAR2) DMW94IQ MA Antagonist DMW94IQ RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMW94IQ RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMW98RI DI DMW98RI DMW98RI DN Aminopyrimidine derivative 7 DMW98RI TI TTH5TC2 DMW98RI TN NF-kappa-B-activating kinase (TBK1) DMW98RI MA Inhibitor DMW98RI RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMW98RI RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMW9P6U DI DMW9P6U DMW9P6U DN ZINC915379 DMW9P6U TI TTLKF5M DMW9P6U TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMW9P6U MA Inhibitor DMW9P6U RN Small molecule activators of NRF2 pathway. US9737525. DMW9P6U RU http://www.freepatentsonline.com/US9737525.html DMWA7RB DI DMWA7RB DMWA7RB DN Isoxazole-based bicyclic compound 9 DMWA7RB TI TTE4BSY DMWA7RB TN Bromodomain and extraterminal domain protein (BET) DMWA7RB MA Inhibitor DMWA7RB RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWA7RB RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWABOJ DI DMWABOJ DMWABOJ DN Imidazo [1,2-a]pyridine compound 1 DMWABOJ TI TTUX68I DMWABOJ TN Hypoxia-inducible factor 1 (HIF-1) DMWABOJ MA Inhibitor DMWABOJ RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMWABOJ RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMWAL5Q DI DMWAL5Q DMWAL5Q DN US9409892, 59 DMWAL5Q TI TT9ISBX DMWAL5Q TN HIF-prolyl hydroxylase 2 (HPH-2) DMWAL5Q MA Inhibitor DMWAL5Q RN 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892. DMWAL5Q RU http://www.freepatentsonline.com/US9409892.html DMWALOT DI DMWALOT DMWALOT DN PMID25522065-Compound-41 DMWALOT TI TTX4RTB DMWALOT TN Melanin-concentrating hormone receptor 1 (MCHR1) DMWALOT MA Antagonist DMWALOT RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMWALOT RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMWAU49 DI DMWAU49 DMWAU49 DN Cyclic sulfonamide derivative 4 DMWAU49 TI TT8J1S3 DMWAU49 TN Smoothened homolog (SMO) DMWAU49 MA Inhibitor DMWAU49 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMWAU49 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMWAYXP DI DMWAYXP DMWAYXP DN Piperidinyl pyrazole derivative 1 DMWAYXP TI TTTJZ4M DMWAYXP TN Prolylcarboxypeptidase (PRCP) DMWAYXP MA Inhibitor DMWAYXP RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMWAYXP RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMWB2YX DI DMWB2YX DMWB2YX DN 4-aryl quinol derivative 5 DMWB2YX TI TTR7UJ3 DMWB2YX TN Cytoplasmic thioredoxin reductase (TXNRD1) DMWB2YX MA Inhibitor DMWB2YX RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMWB2YX RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMWC1IY DI DMWC1IY DMWC1IY DN PMID26560530-Compound-47 DMWC1IY TI TT2F4OL DMWC1IY TN Tissue transglutaminase (TG2) DMWC1IY MA Inhibitor DMWC1IY RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMWC1IY RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMWC3P5 DI DMWC3P5 DMWC3P5 DN Lactol derivative 1 DMWC3P5 TI TTPADOQ DMWC3P5 TN HMG-CoA reductase (HMGCR) DMWC3P5 MA Inhibitor DMWC3P5 RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMWC3P5 RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMWCM2I DI DMWCM2I DMWCM2I DN PMID26560530-Compound-24 DMWCM2I TI TT2F4OL DMWCM2I TN Tissue transglutaminase (TG2) DMWCM2I MA Inhibitor DMWCM2I RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMWCM2I RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMWCT04 DI DMWCT04 DMWCT04 DN 3-substituted-1,2,4-oxadiazole derivative 1 DMWCT04 TI TT23XQV DMWCT04 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMWCT04 MA Inhibitor DMWCT04 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMWCT04 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMWD1FP DI DMWD1FP DMWD1FP DN PMID25772215-Compound-US02014179750TG6-10-1 DMWD1FP TI TT1ZAVI DMWD1FP TN Prostaglandin E2 receptor EP2 (PTGER2) DMWD1FP MA Antagonist DMWD1FP RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMWD1FP RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMWD20L DI DMWD20L DMWD20L DN Schiff base compound 2 DMWD20L TI TTGP7BY DMWD20L TN Monoamine oxidase type B (MAO-B) DMWD20L RN MAO inhibitors and their wider applications: a patent review.Expert Opin Ther Pat. 2018 Mar;28(3):211-226. DMWD20L RU https://www.ncbi.nlm.nih.gov/pubmed/29324067 DMWDGCH DI DMWDGCH DMWDGCH DN US10040779, Example 4 DMWDGCH TI TTIG67W DMWDGCH TN Lysine-specific demethylase 5A (KDM5A) DMWDGCH MA Inhibitor DMWDGCH RN Histone demethylase inhibitors. US10040779. DMWDGCH RU http://www.freepatentsonline.com/US10040779.html DMWE6NZ DI DMWE6NZ DMWE6NZ DN PMID27607364-Compound-61 DMWE6NZ TI TTPTXIN DMWE6NZ TN Translocator protein (TSPO) DMWE6NZ MA Ligand DMWE6NZ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMWE6NZ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMWEJ6U DI DMWEJ6U DMWEJ6U DN Dihydropyrido phthalazinone derivative 4 DMWEJ6U TI TTEBCY8 DMWEJ6U TN Poly [ADP-ribose] polymerase (PARP) DMWEJ6U MA Inhibitor DMWEJ6U RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMWEJ6U RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMWESZ1 DI DMWESZ1 DMWESZ1 DN US10100051, Compound 2 DMWESZ1 TI TT9ISBX DMWESZ1 TN HIF-prolyl hydroxylase 2 (HPH-2) DMWESZ1 MA Inhibitor DMWESZ1 RN Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof. US10100051. DMWESZ1 RU http://www.freepatentsonline.com/US10100051.html DMWF2VG DI DMWF2VG DMWF2VG DN Biaryl mannoside derivative 8 DMWF2VG TI TTTCRU2 DMWF2VG TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMWF2VG MA Antagonist DMWF2VG RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMWF2VG RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMWF4S7 DI DMWF4S7 DMWF4S7 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 4 DMWF4S7 TI TTJW4LU DMWF4S7 TN Phosphodiesterase 10A (PDE10) DMWF4S7 MA Inhibitor DMWF4S7 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMWF4S7 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMWF4S7 DI DMWF4S7 DMWF4S7 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 4 DMWF4S7 TI TTJGW1Z DMWF4S7 TN Phosphodiesterase 2A (PDE2A) DMWF4S7 MA Inhibitor DMWF4S7 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMWF4S7 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMWFHKR DI DMWFHKR DMWFHKR DN 4-oxadiazole derivative 1 DMWFHKR TI TTO9X1H DMWFHKR TN 5-HT 7 receptor (HTR7) DMWFHKR MA Inhibitor DMWFHKR RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMWFHKR RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMWFTCN DI DMWFTCN DMWFTCN DN Pyrazole derivative 72 DMWFTCN TI TTJQOD7 DMWFTCN TN 5-HT 2A receptor (HTR2A) DMWFTCN MA Antagonist DMWFTCN RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMWFTCN RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMWG95Z DI DMWG95Z DMWG95Z DN PMID25656651-Compound-26b DMWG95Z TI TTS7G69 DMWG95Z TN Fusion protein Bcr-Abl (Bcr-Abl) DMWG95Z MA Inhibitor DMWG95Z RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMWG95Z RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMWG98Z DI DMWG98Z DMWG98Z DN US9353089, 135 DMWG98Z TI TTXMNHO DMWG98Z TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMWG98Z MA Inhibitor DMWG98Z RN Compositions and methods for the treatment of malaria. US9353089. DMWG98Z RU http://www.freepatentsonline.com/US9353089.html DMWGAQU DI DMWGAQU DMWGAQU DN PMID25666693-Compound-34 DMWGAQU TI TTMI6F5 DMWGAQU TN Transient receptor potential cation channel V1 (TRPV1) DMWGAQU MA Antagonist DMWGAQU RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMWGAQU RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMWGIJS DI DMWGIJS DMWGIJS DN Mycophenolic acid/nucleotide derivative 8 DMWGIJS TI TTL7C8Q DMWGIJS TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMWGIJS MA Inhibitor DMWGIJS RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMWGIJS RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMWGIS7 DI DMWGIS7 DMWGIS7 DN PMID25666693-Compound-109 DMWGIS7 TI TTMI6F5 DMWGIS7 TN Transient receptor potential cation channel V1 (TRPV1) DMWGIS7 MA Antagonist DMWGIS7 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMWGIS7 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMWGV8N DI DMWGV8N DMWGV8N DN PMID28870136-Compound-43 DMWGV8N TI TTK0O6Y DMWGV8N TN Ecto-5'-nucleotidase (CD73) DMWGV8N MA Inhibitor DMWGV8N RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMWGV8N RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMWH3FP DI DMWH3FP DMWH3FP DN Cyclic peptidomimetic derivative 2 DMWH3FP TI TT23XQV DMWH3FP TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMWH3FP MA Inhibitor DMWH3FP RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMWH3FP RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMWHAKG DI DMWHAKG DMWHAKG DN PMID27977313-Compound-30 DMWHAKG TI TTR7UJ3 DMWHAKG TN Cytoplasmic thioredoxin reductase (TXNRD1) DMWHAKG MA Inhibitor DMWHAKG RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMWHAKG RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMWHCOE DI DMWHCOE DMWHCOE DN Thiazole carboxamide derivative 6 DMWHCOE TI TTCZOF2 DMWHCOE TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWHCOE MA Inhibitor DMWHCOE RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWHCOE RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWHN1O DI DMWHN1O DMWHN1O DN AKOS020330481 DMWHN1O TI TTIG67W DMWHN1O TN Lysine-specific demethylase 5A (KDM5A) DMWHN1O MA Inhibitor DMWHN1O RN Histone demethylase inhibitors. US9611221. DMWHN1O RU http://www.freepatentsonline.com/US9611221.html DMWI6V3 DI DMWI6V3 DMWI6V3 DN Peptide analog 13 DMWI6V3 TI TT68GPI DMWI6V3 TN Proteasome beta-5 (PS beta-5) DMWI6V3 MA Inhibitor DMWI6V3 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMWI6V3 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMWI6V3 DI DMWI6V3 DMWI6V3 DN Peptide analog 13 DMWI6V3 TI TTEAD9J DMWI6V3 TN Proteasome beta-8 (PS beta-8) DMWI6V3 MA Inhibitor DMWI6V3 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMWI6V3 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMWIMN9 DI DMWIMN9 DMWIMN9 DN PMID27977313-Compound-7 DMWIMN9 TI TTR7UJ3 DMWIMN9 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMWIMN9 MA Inhibitor DMWIMN9 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMWIMN9 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMWIYFQ DI DMWIYFQ DMWIYFQ DN Dihydropyrido phthalazinone derivative 1 DMWIYFQ TI TTVDSZ0 DMWIYFQ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMWIYFQ MA Inhibitor DMWIYFQ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMWIYFQ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMWJDEO DI DMWJDEO DMWJDEO DN Heterocyclic derivative 5 DMWJDEO TI TTCZOF2 DMWJDEO TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWJDEO MA Inhibitor DMWJDEO RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWJDEO RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWJRY7 DI DMWJRY7 DMWJRY7 DN PMID26882240-Compound-8 DMWJRY7 TI TTUX68I DMWJRY7 TN Hypoxia-inducible factor 1 (HIF-1) DMWJRY7 MA Inhibitor DMWJRY7 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMWJRY7 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMWJXRO DI DMWJXRO DMWJXRO DN PMID26666989-Compound-Figure11Ala down DMWJXRO TI TT8BUGW DMWJXRO TN Glycogen phosphorylase (PYG) DMWJXRO MA Inhibitor DMWJXRO RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMWJXRO RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMWJZU9 DI DMWJZU9 DMWJZU9 DN BDBM50158794 DMWJZU9 TI TTIG67W DMWJZU9 TN Lysine-specific demethylase 5A (KDM5A) DMWJZU9 MA Inhibitor DMWJZU9 RN Histone demethylase inhibitors. US10040779. DMWJZU9 RU http://www.freepatentsonline.com/US10040779.html DMWKDET DI DMWKDET DMWKDET DN US8829193, 1 DMWKDET TI TTCGOIN DMWKDET TN PIM-3 protein kinase (PIM3) DMWKDET MA Inhibitor DMWKDET RN PIM kinase inhibitors and methods of their use. US8829193. DMWKDET RU http://www.freepatentsonline.com/US8829193.html DMWKI89 DI DMWKI89 DMWKI89 DN Thiazole carboxamide derivative 10 DMWKI89 TI TTCZOF2 DMWKI89 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWKI89 MA Inhibitor DMWKI89 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWKI89 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWKSF3 DI DMWKSF3 DMWKSF3 DN Pyrrolidinyl urea derivative 11 DMWKSF3 TI TTTDVOJ DMWKSF3 TN Tropomyosin-related kinase A (TrkA) DMWKSF3 MA Inhibitor DMWKSF3 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMWKSF3 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMWKVZD DI DMWKVZD DMWKVZD DN PMID27537201-Compound-Figure17 DMWKVZD TI TTPADOQ DMWKVZD TN HMG-CoA reductase (HMGCR) DMWKVZD MA Inhibitor DMWKVZD RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMWKVZD RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMWKXN4 DI DMWKXN4 DMWKXN4 DN Carbamide derivative 7 DMWKXN4 TI TTL7C8Q DMWKXN4 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMWKXN4 MA Inhibitor DMWKXN4 RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMWKXN4 RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMWKYU4 DI DMWKYU4 DMWKYU4 DN PMID27744724-Compound-3 DMWKYU4 TI TTL53M6 DMWKYU4 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMWKYU4 MA Inhibitor DMWKYU4 RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMWKYU4 RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMWL5V0 DI DMWL5V0 DMWL5V0 DN Pyrimidine derivative 33 DMWL5V0 TI TTDIGC1 DMWL5V0 TN Dipeptidyl peptidase 4 (DPP-4) DMWL5V0 MA Inhibitor DMWL5V0 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMWL5V0 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMWLPEB DI DMWLPEB DMWLPEB DN Naphthalene derivative 1 DMWLPEB TI TTA6ZN2 DMWLPEB TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMWLPEB MA Inhibitor DMWLPEB RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMWLPEB RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMWLPEB DI DMWLPEB DMWLPEB DN Naphthalene derivative 1 DMWLPEB TI TTGIZLN DMWLPEB TN Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) DMWLPEB MA Modulator DMWLPEB RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMWLPEB RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMWM03O DI DMWM03O DMWM03O DN PMID27109571-Compound-9 DMWM03O TI TTHWMFZ DMWM03O TN Fatty acid-binding protein 4 (FABP4) DMWM03O MA Inhibitor DMWM03O RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMWM03O RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMWMPE2 DI DMWMPE2 DMWMPE2 DN PMID29338548-Compound-31 DMWMPE2 TI TTHJTF7 DMWMPE2 TN Glycine transporter GlyT-1 (SLC6A9) DMWMPE2 MA Inhibitor DMWMPE2 RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMWMPE2 RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMWMRKJ DI DMWMRKJ DMWMRKJ DN Isoxazole-based bicyclic compound 3 DMWMRKJ TI TTE4BSY DMWMRKJ TN Bromodomain and extraterminal domain protein (BET) DMWMRKJ MA Inhibitor DMWMRKJ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWMRKJ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWMV48 DI DMWMV48 DMWMV48 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 2 DMWMV48 TI TTV8CRH DMWMV48 TN Lysine-specific demethylase 4C (KDM4C) DMWMV48 MA Inhibitor DMWMV48 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMWMV48 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMWMZE4 DI DMWMZE4 DMWMZE4 DN PMID26394986-Compound-11 DMWMZE4 TI TTH8FZW DMWMZE4 TN Signal transducer and activator of transcription 3 (STAT3) DMWMZE4 MA Inhibitor DMWMZE4 RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMWMZE4 RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMWN17V DI DMWN17V DMWN17V DN Imidazopyrimidinone derivative 1 DMWN17V TI TTSCIM2 DMWN17V TN Extracellular lysophospholipase D (E-NPP2) DMWN17V MA Inhibitor DMWN17V RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMWN17V RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMWNKQ8 DI DMWNKQ8 DMWNKQ8 DN 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 1 DMWNKQ8 TI TTJGW1Z DMWNKQ8 TN Phosphodiesterase 2A (PDE2A) DMWNKQ8 MA Inhibitor DMWNKQ8 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMWNKQ8 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMWNR8I DI DMWNR8I DMWNR8I DN Urea and carbamate bioisostere derivative 10 DMWNR8I TI TTL7C8Q DMWNR8I TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMWNR8I MA Inhibitor DMWNR8I RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMWNR8I RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMWNZTI DI DMWNZTI DMWNZTI DN Pyrazolo[1,5-a]pyrimidine derivative 21 DMWNZTI TI TTTDVOJ DMWNZTI TN Tropomyosin-related kinase A (TrkA) DMWNZTI MA Inhibitor DMWNZTI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMWNZTI RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMWOBHM DI DMWOBHM DMWOBHM DN Heterocyclic derivative 13 DMWOBHM TI TTCZOF2 DMWOBHM TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWOBHM MA Inhibitor DMWOBHM RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWOBHM RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWOCP7 DI DMWOCP7 DMWOCP7 DN PMID26924192-Compound-103 DMWOCP7 TI TTRA6BO DMWOCP7 TN Bromodomain-containing protein 4 (BRD4) DMWOCP7 MA Inhibitor DMWOCP7 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWOCP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWOCP7 DI DMWOCP7 DMWOCP7 DN PMID26924192-Compound-103 DMWOCP7 TI TTHE657 DMWOCP7 TN Bromodomain-containing protein 3 (BRD3) DMWOCP7 MA Inhibitor DMWOCP7 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWOCP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWOCP7 DI DMWOCP7 DMWOCP7 DN PMID26924192-Compound-103 DMWOCP7 TI TTDP48B DMWOCP7 TN Bromodomain-containing protein 2 (BRD2) DMWOCP7 MA Inhibitor DMWOCP7 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWOCP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWOCP7 DI DMWOCP7 DMWOCP7 DN PMID26924192-Compound-103 DMWOCP7 TI TT7CPI5 DMWOCP7 TN Bromodomain testis-specific protein (BRDT) DMWOCP7 MA Inhibitor DMWOCP7 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWOCP7 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWOJLX DI DMWOJLX DMWOJLX DN Benzimidazole derivative 5 DMWOJLX TI TTT7PJU DMWOJLX TN Janus kinase 3 (JAK-3) DMWOJLX MA Inhibitor DMWOJLX RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMWOJLX RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMWOK1D DI DMWOK1D DMWOK1D DN Thiomorpholine derivative 2 DMWOK1D TI TTJGLZF DMWOK1D TN Dipeptidyl peptidase 8 (DPP-8) DMWOK1D MA Inhibitor DMWOK1D RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMWOK1D RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMWOK1D DI DMWOK1D DMWOK1D DN Thiomorpholine derivative 2 DMWOK1D TI TTDIGC1 DMWOK1D TN Dipeptidyl peptidase 4 (DPP-4) DMWOK1D MA Inhibitor DMWOK1D RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMWOK1D RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMWOK1D DI DMWOK1D DMWOK1D DN Thiomorpholine derivative 2 DMWOK1D TI TTNDUL7 DMWOK1D TN Dipeptidyl peptidase 9 (DPP-9) DMWOK1D MA Inhibitor DMWOK1D RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMWOK1D RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMWOR8B DI DMWOR8B DMWOR8B DN PMID25656651-Compound-34a DMWOR8B TI TT3PJMV DMWOR8B TN Tyrosine-protein kinase ABL1 (ABL) DMWOR8B MA Inhibitor DMWOR8B RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMWOR8B RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMWPXJ5 DI DMWPXJ5 DMWPXJ5 DN Pyrrolidine derivative 8 DMWPXJ5 TI TT9O6WS DMWPXJ5 TN Glucagon receptor (GCGR) DMWPXJ5 MA Antagonist DMWPXJ5 RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMWPXJ5 RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMWQ6FJ DI DMWQ6FJ DMWQ6FJ DN Biphenyl mannoside derivative 27 DMWQ6FJ TI TTTCRU2 DMWQ6FJ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMWQ6FJ MA Antagonist DMWQ6FJ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMWQ6FJ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMWRBSP DI DMWRBSP DMWRBSP DN 2,2-dimethylbenzopyran derivative 1 DMWRBSP TI TTUX68I DMWRBSP TN Hypoxia-inducible factor 1 (HIF-1) DMWRBSP MA Inhibitor DMWRBSP RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMWRBSP RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMWRGOX DI DMWRGOX DMWRGOX DN PMID29338548-Compound-24 DMWRGOX TI TTHJTF7 DMWRGOX TN Glycine transporter GlyT-1 (SLC6A9) DMWRGOX MA Inhibitor DMWRGOX RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMWRGOX RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TT8M4E1 DMWRS34 TN Histone deacetylase 9 (HDAC9) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TT4YWTO DMWRS34 TN Histone deacetylase 3 (HDAC3) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TTUELN5 DMWRS34 TN Histone deacetylase 5 (HDAC5) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TTSHTOI DMWRS34 TN Histone deacetylase 2 (HDAC2) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TTTQGH8 DMWRS34 TN Histone deacetylase 4 (HDAC4) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TT6R7JZ DMWRS34 TN Histone deacetylase 1 (HDAC1) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TTYHPU6 DMWRS34 TN Histone deacetylase 10 (HDAC10) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TT8K17W DMWRS34 TN Histone deacetylase 11 (HDAC11) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TTMUEK1 DMWRS34 TN Histone deacetylase 7 (HDAC7) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TT5ZKDI DMWRS34 TN Histone deacetylase 6 (HDAC6) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRS34 DI DMWRS34 DMWRS34 DN PMID29671355-Compound-62 DMWRS34 TI TTT6LFV DMWRS34 TN Histone deacetylase 8 (HDAC8) DMWRS34 MA Inhibitor DMWRS34 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMWRS34 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMWRXS8 DI DMWRXS8 DMWRXS8 DN US9024044, 2 DMWRXS8 TI TTXL0GC DMWRXS8 TN Enteropeptidase (TMPRSS15) DMWRXS8 MA Inhibitor DMWRXS8 RN Heteroarylcarboxylic acid ester derivative. US9655879. DMWRXS8 RU http://www.freepatentsonline.com/US9655879.html DMWSAL5 DI DMWSAL5 DMWSAL5 DN Aryl pyrimidine derivative 4 DMWSAL5 TI TTIY56R DMWSAL5 TN Kynurenine 3-hydroxylase (KMO) DMWSAL5 MA Inhibitor DMWSAL5 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMWSAL5 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMWSGV2 DI DMWSGV2 DMWSGV2 DN PMID25991433-Compound-B3 DMWSGV2 TI TTVOE6D DMWSGV2 TN Mitogen-activated protein kinase (MAPK) DMWSGV2 MA Inhibitor DMWSGV2 RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMWSGV2 RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMWSL5G DI DMWSL5G DMWSL5G DN PMID28447479-Compound-20 DMWSL5G TI TTSCIM2 DMWSL5G TN Extracellular lysophospholipase D (E-NPP2) DMWSL5G MA Inhibitor DMWSL5G RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMWSL5G RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMWSZMC DI DMWSZMC DMWSZMC DN N-oxalyl-D-tyrosine derivative 2 DMWSZMC TI TTWAQBO DMWSZMC TN Lysine-specific demethylase 4E (KDM4E) DMWSZMC MA Inhibitor DMWSZMC RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMWSZMC RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMWT437 DI DMWT437 DMWT437 DN Pyrazole derivative 81 DMWT437 TI TTZ963I DMWT437 TN Monoglyceride lipase (MAGL) DMWT437 MA Inhibitor DMWT437 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMWT437 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMWT437 DI DMWT437 DMWT437 DN Pyrazole derivative 81 DMWT437 TI TTDP1UC DMWT437 TN Fatty acid amide hydrolase (FAAH) DMWT437 MA Inhibitor DMWT437 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMWT437 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMWT437 DI DMWT437 DMWT437 DN Pyrazole derivative 81 DMWT437 TI TTSINOV DMWT437 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMWT437 MA Inhibitor DMWT437 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMWT437 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMWTCM8 DI DMWTCM8 DMWTCM8 DN Bicyclic hexapeptide derivative 1 DMWTCM8 TI TT8J1S3 DMWTCM8 TN Smoothened homolog (SMO) DMWTCM8 MA Inhibitor DMWTCM8 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMWTCM8 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMWTRUK DI DMWTRUK DMWTRUK DN PMID28766366-Compound-Scheme21Left DMWTRUK TI TT84OS6 DMWTRUK TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMWTRUK MA Inhibitor DMWTRUK RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMWTRUK RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMWTRUK DI DMWTRUK DMWTRUK DN PMID28766366-Compound-Scheme21Left DMWTRUK TI TTYGQ8A DMWTRUK TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DMWTRUK MA Inhibitor DMWTRUK RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMWTRUK RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMWTRUK DI DMWTRUK DMWTRUK DN PMID28766366-Compound-Scheme21Left DMWTRUK TI TTSBVFO DMWTRUK TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMWTRUK MA Inhibitor DMWTRUK RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMWTRUK RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMWTRUK DI DMWTRUK DMWTRUK DN PMID28766366-Compound-Scheme21Left DMWTRUK TI TTV4EX0 DMWTRUK TN Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3) DMWTRUK MA Inhibitor DMWTRUK RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMWTRUK RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMWTU8X DI DMWTU8X DMWTU8X DN Isoindole 1,3-dione analog 1 DMWTU8X TI TT473XN DMWTU8X TN P2X purinoceptor 7 (P2RX7) DMWTU8X MA Antagonist DMWTU8X RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMWTU8X RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMWU3O4 DI DMWU3O4 DMWU3O4 DN Pyrrolo[2,3-d]pyrimidine derivative 25 DMWU3O4 TI TTGM6VW DMWU3O4 TN Tyrosine-protein kinase BTK (ATK) DMWU3O4 MA Inhibitor DMWU3O4 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMWU3O4 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMWU8VM DI DMWU8VM DMWU8VM DN Imidazopyridine and triazolopyridine compound 3 DMWU8VM TI TTHS256 DMWU8VM TN Metabotropic glutamate receptor 5 (mGluR5) DMWU8VM MA Modulator DMWU8VM RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMWU8VM RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMWUAXM DI DMWUAXM DMWUAXM DN Beta-phenyl-alpha,beta-unsaturated carbonyl derivative 14 DMWUAXM TI TTULVH8 DMWUAXM TN Tyrosinase (TYR) DMWUAXM MA Inhibitor DMWUAXM RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMWUAXM RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMWUFKO DI DMWUFKO DMWUFKO DN Imidamide derivative 1 DMWUFKO TI TT3M2WO DMWUFKO TN Sphingosine kinase (SphK) DMWUFKO MA Inhibitor DMWUFKO RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMWUFKO RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMWUK9X DI DMWUK9X DMWUK9X DN PMID25772215-Compound-WO2012177618M5 DMWUK9X TI TT1ZAVI DMWUK9X TN Prostaglandin E2 receptor EP2 (PTGER2) DMWUK9X MA Antagonist DMWUK9X RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMWUK9X RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMWUNRV DI DMWUNRV DMWUNRV DN Aryl mannoside derivative 23 DMWUNRV TI TTTCRU2 DMWUNRV TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMWUNRV MA Antagonist DMWUNRV RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMWUNRV RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMWUYIB DI DMWUYIB DMWUYIB DN Oxime derivative 1 DMWUYIB TI TTEB0GD DMWUYIB TN Cholinesterase (BCHE) DMWUYIB MA Reactivator DMWUYIB RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMWUYIB RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMWV4YE DI DMWV4YE DMWV4YE DN PMID28627961-Compound-33 DMWV4YE TI TTYLQ8V DMWV4YE TN Prostaglandin E synthase (PTGES) DMWV4YE MA Inhibitor DMWV4YE RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMWV4YE RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMWV53X DI DMWV53X DMWV53X DN 1,2-diamino cyclopentane-based derivative 12 DMWV53X TI TT9N02I DMWV53X TN Orexin receptor type 2 (HCRTR2) DMWV53X MA Antagonist DMWV53X RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMWV53X RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMWV53X DI DMWV53X DMWV53X DN 1,2-diamino cyclopentane-based derivative 12 DMWV53X TI TT60Q8D DMWV53X TN Orexin receptor type 1 (HCRTR1) DMWV53X MA Antagonist DMWV53X RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMWV53X RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMWVQDA DI DMWVQDA DMWVQDA DN N-arylmethyl-N-phenyl cyclic urea derivative 2 DMWVQDA TI TTTDVOJ DMWVQDA TN Tropomyosin-related kinase A (TrkA) DMWVQDA MA Inhibitor DMWVQDA RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMWVQDA RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMWVR81 DI DMWVR81 DMWVR81 DN PMID25666693-Compound-36 DMWVR81 TI TTMI6F5 DMWVR81 TN Transient receptor potential cation channel V1 (TRPV1) DMWVR81 MA Antagonist DMWVR81 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMWVR81 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMWX0QK DI DMWX0QK DMWX0QK DN Alpha-substituted pirinixic acid and pirinixic acid ester derivative 1 DMWX0QK TI TTYLQ8V DMWX0QK TN Prostaglandin E synthase (PTGES) DMWX0QK MA Inhibitor DMWX0QK RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMWX0QK RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMWXEZD DI DMWXEZD DMWXEZD DN PMID27376512-Compound-MTC-427 DMWXEZD TI TTJUALD DMWXEZD TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMWXEZD MA Inhibitor DMWXEZD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMWXEZD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMWXEZD DI DMWXEZD DMWXEZD DN PMID27376512-Compound-MTC-427 DMWXEZD TI TT6VZ78 DMWXEZD TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMWXEZD MA Inhibitor DMWXEZD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMWXEZD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMWXEZD DI DMWXEZD DMWXEZD DN PMID27376512-Compound-MTC-427 DMWXEZD TI TT6S2FE DMWXEZD TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMWXEZD MA Inhibitor DMWXEZD RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMWXEZD RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMWXKRZ DI DMWXKRZ DMWXKRZ DN Ethynyl compound 1 DMWXKRZ TI TTHS256 DMWXKRZ TN Metabotropic glutamate receptor 5 (mGluR5) DMWXKRZ MA Modulator DMWXKRZ RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMWXKRZ RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMWXLK1 DI DMWXLK1 DMWXLK1 DN Bis-aminopyrimidine derivative 5 DMWXLK1 TI TTRMX3V DMWXLK1 TN Janus kinase 2 (JAK-2) DMWXLK1 MA Inhibitor DMWXLK1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMWXLK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMWXLK1 DI DMWXLK1 DMWXLK1 DN Bis-aminopyrimidine derivative 5 DMWXLK1 TI TTBYWP2 DMWXLK1 TN TYK2 tyrosine kinase (TYK2) DMWXLK1 MA Inhibitor DMWXLK1 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMWXLK1 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMWXNIJ DI DMWXNIJ DMWXNIJ DN PMID26924192-Compound-30 DMWXNIJ TI TTRA6BO DMWXNIJ TN Bromodomain-containing protein 4 (BRD4) DMWXNIJ MA Inhibitor DMWXNIJ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWXNIJ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWXNIJ DI DMWXNIJ DMWXNIJ DN PMID26924192-Compound-30 DMWXNIJ TI TTU6FSC DMWXNIJ TN Extracellular signal-regulated kinase 5 (ERK5) DMWXNIJ MA Inhibitor DMWXNIJ RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMWXNIJ RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMWXUS4 DI DMWXUS4 DMWXUS4 DN 2-pyrazinone derivative 1 DMWXUS4 TI TTPLTSQ DMWXUS4 TN Neutrophil elastase (NE) DMWXUS4 MA Inhibitor DMWXUS4 RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMWXUS4 RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMWXZBF DI DMWXZBF DMWXZBF DN Pyrrolo[2,3-b]pyridine carboxamide derivative 1 DMWXZBF TI TTS7G69 DMWXZBF TN Fusion protein Bcr-Abl (Bcr-Abl) DMWXZBF MA Inhibitor DMWXZBF RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMWXZBF RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMWY5XT DI DMWY5XT DMWY5XT DN PMID25399762-Compound-Table1-C10 DMWY5XT TI TTGP7BY DMWY5XT TN Monoamine oxidase type B (MAO-B) DMWY5XT MA Inhibitor DMWY5XT RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMWY5XT RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMWY9GM DI DMWY9GM DMWY9GM DN 1-Benzyl-3-p-tolyl-1H-pyrrole-2,5-dione DMWY9GM TI TTWME23 DMWY9GM TN Regulator of G-protein signaling 8 (RGS8) DMWY9GM MA Inhibitor DMWY9GM RN Small molecule inhibitors of RGS proteins. US8865750. DMWY9GM RU http://www.freepatentsonline.com/US8865750.html DMWYJF6 DI DMWYJF6 DMWYJF6 DN Complex heterocyclic compound 1 DMWYJF6 TI TTSCIM2 DMWYJF6 TN Extracellular lysophospholipase D (E-NPP2) DMWYJF6 MA Inhibitor DMWYJF6 RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMWYJF6 RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMWZ1PD DI DMWZ1PD DMWZ1PD DN PMID27537201-Compound-Figure13c DMWZ1PD TI TTPADOQ DMWZ1PD TN HMG-CoA reductase (HMGCR) DMWZ1PD MA Inhibitor DMWZ1PD RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMWZ1PD RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMWZARV DI DMWZARV DMWZARV DN Flavonoid derivative 2 DMWZARV TI TTH8FZW DMWZARV TN Signal transducer and activator of transcription 3 (STAT3) DMWZARV MA Inhibitor DMWZARV RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMWZARV RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMWZLK6 DI DMWZLK6 DMWZLK6 DN Indazoletriazolephenyl derivative 2 DMWZLK6 TI TTKFVXR DMWZLK6 TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMWZLK6 MA Inhibitor DMWZLK6 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMWZLK6 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMWZLK6 DI DMWZLK6 DMWZLK6 DN Indazoletriazolephenyl derivative 2 DMWZLK6 TI TTXAJWN DMWZLK6 TN IL-1 receptor-associated kinase 1 (IRAK1) DMWZLK6 MA Inhibitor DMWZLK6 RN Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DMWZLK6 RU https://www.ncbi.nlm.nih.gov/pubmed/27310003 DMWZNDO DI DMWZNDO DMWZNDO DN Heterocyclic derivative 15 DMWZNDO TI TTCZOF2 DMWZNDO TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMWZNDO MA Inhibitor DMWZNDO RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMWZNDO RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMWZOKP DI DMWZOKP DMWZOKP DN PMID27019002-Compound-21c DMWZOKP TI TTNR0UQ DMWZOKP TN Lysine-specific histone demethylase 1 (LSD) DMWZOKP MA Inhibitor DMWZOKP RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMWZOKP RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMWZOKP DI DMWZOKP DMWZOKP DN PMID27019002-Compound-21c DMWZOKP TI TTZHPB8 DMWZOKP TN Lysine-specific demethylase 4A (KDM4A) DMWZOKP MA Inhibitor DMWZOKP RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMWZOKP RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMX1ANB DI DMX1ANB DMX1ANB DN Pyrrolo[2,3-d]pyrimidine derivative 26 DMX1ANB TI TTGM6VW DMX1ANB TN Tyrosine-protein kinase BTK (ATK) DMX1ANB MA Inhibitor DMX1ANB RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMX1ANB RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMX1E6O DI DMX1E6O DMX1E6O DN PMID29865878-Compound-8 DMX1E6O TI TT68GPI DMX1E6O TN Proteasome beta-5 (PS beta-5) DMX1E6O MA Inhibitor DMX1E6O RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMX1E6O RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMX1E6O DI DMX1E6O DMX1E6O DN PMID29865878-Compound-8 DMX1E6O TI TTEAD9J DMX1E6O TN Proteasome beta-8 (PS beta-8) DMX1E6O MA Inhibitor DMX1E6O RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMX1E6O RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMX1OZF DI DMX1OZF DMX1OZF DN Alkyl mannoside derivative 12 DMX1OZF TI TTTCRU2 DMX1OZF TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMX1OZF MA Antagonist DMX1OZF RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMX1OZF RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMX2EFL DI DMX2EFL DMX2EFL DN Tetra-cyclic pyridophthalazinone derivative 1 DMX2EFL TI TTVDSZ0 DMX2EFL TN Poly [ADP-ribose] polymerase 1 (PARP1) DMX2EFL MA Inhibitor DMX2EFL RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMX2EFL RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMX2EFL DI DMX2EFL DMX2EFL DN Tetra-cyclic pyridophthalazinone derivative 1 DMX2EFL TI TTQ4V96 DMX2EFL TN Poly [ADP-ribose] polymerase 2 (PARP2) DMX2EFL MA Inhibitor DMX2EFL RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMX2EFL RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMX2NQW DI DMX2NQW DMX2NQW DN Pyrazole derivative 3 DMX2NQW TI TT6OEDT DMX2NQW TN Cannabinoid receptor 1 (CB1) DMX2NQW MA Antagonist DMX2NQW RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMX2NQW RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMX2V0W DI DMX2V0W DMX2V0W DN Piperidinyl pyrazole derivative 3 DMX2V0W TI TTTJZ4M DMX2V0W TN Prolylcarboxypeptidase (PRCP) DMX2V0W MA Inhibitor DMX2V0W RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMX2V0W RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMX31I2 DI DMX31I2 DMX31I2 DN PMID29865878-Compound-47 DMX31I2 TI TTSJMN8 DMX31I2 TN Immunoproteasome complex (IP) DMX31I2 MA Inhibitor DMX31I2 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMX31I2 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMX34PU DI DMX34PU DMX34PU DN Imidazotriazinone derivative 1 DMX34PU TI TTJGW1Z DMX34PU TN Phosphodiesterase 2A (PDE2A) DMX34PU MA Inhibitor DMX34PU RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMX34PU RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMX3A0O DI DMX3A0O DMX3A0O DN US8586571, 36 DMX3A0O TI TT0C8BY DMX3A0O TN Plasma retinol-binding protein (RBP4) DMX3A0O MA Inhibitor DMX3A0O RN Heterocyclic compound. US8586571. DMX3A0O RU http://www.freepatentsonline.com/US8586571.html DMX3MNT DI DMX3MNT DMX3MNT DN Azaindazole derivative 4 DMX3MNT TI TTK0FEA DMX3MNT TN Leucine-rich repeat kinase 2 (LRRK2) DMX3MNT MA Inhibitor DMX3MNT RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMX3MNT RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMX3TZ7 DI DMX3TZ7 DMX3TZ7 DN Hydroxyqunoline analog 2 DMX3TZ7 TI TTWAQBO DMX3TZ7 TN Lysine-specific demethylase 4E (KDM4E) DMX3TZ7 MA Inhibitor DMX3TZ7 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMX3TZ7 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMX3VCO DI DMX3VCO DMX3VCO DN 6,6-fused nitrogenous heterocyclic compound 3 DMX3VCO TI TT3PJMV DMX3VCO TN Tyrosine-protein kinase ABL1 (ABL) DMX3VCO MA Inhibitor DMX3VCO RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMX3VCO RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMX4ET5 DI DMX4ET5 DMX4ET5 DN GypensapogeninB DMX4ET5 TI TT3WG5C DMX4ET5 TN Monoamine oxidase type A (MAO-A) DMX4ET5 MA Inhibitor DMX4ET5 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMX4ET5 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMX4W2R DI DMX4W2R DMX4W2R DN PMID27215781-Compound-33 DMX4W2R TI TTMSFAW DMX4W2R TN Cannabinoid receptor 2 (CB2) DMX4W2R RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMX4W2R RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMX4WFP DI DMX4WFP DMX4WFP DN Triazolo-pyridine derivative 6 DMX4WFP TI TTJW4LU DMX4WFP TN Phosphodiesterase 10A (PDE10) DMX4WFP MA Inhibitor DMX4WFP RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMX4WFP RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMX4WFP DI DMX4WFP DMX4WFP DN Triazolo-pyridine derivative 6 DMX4WFP TI TTJGW1Z DMX4WFP TN Phosphodiesterase 2A (PDE2A) DMX4WFP MA Inhibitor DMX4WFP RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMX4WFP RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMX5FYZ DI DMX5FYZ DMX5FYZ DN Lactam derivative 5 DMX5FYZ TI TTF8P9I DMX5FYZ TN Diacylglycerol acyltransferase 1 (DGAT1) DMX5FYZ MA Inhibitor DMX5FYZ RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMX5FYZ RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMX5R9N DI DMX5R9N DMX5R9N DN PMID25482888-Compound-34 DMX5R9N TI TTDIGC1 DMX5R9N TN Dipeptidyl peptidase 4 (DPP-4) DMX5R9N MA Inhibitor DMX5R9N RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMX5R9N RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMX5YG9 DI DMX5YG9 DMX5YG9 DN Tricyclic indole compound 5 DMX5YG9 TI TTPTXIN DMX5YG9 TN Translocator protein (TSPO) DMX5YG9 MA Ligand DMX5YG9 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMX5YG9 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMX612V DI DMX612V DMX612V DN PMID26666989-Compound-Figure9middle12 DMX612V TI TT8BUGW DMX612V TN Glycogen phosphorylase (PYG) DMX612V MA Inhibitor DMX612V RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMX612V RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMX640D DI DMX640D DMX640D DN Indoline derivative 18 DMX640D TI TTOHSBA DMX640D TN Vascular endothelial growth factor A (VEGFA) DMX640D MA Inhibitor DMX640D RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMX640D RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMX6AKV DI DMX6AKV DMX6AKV DN Six-membered heterocyclic benzamide derivative 2 DMX6AKV TI TTTDVOJ DMX6AKV TN Tropomyosin-related kinase A (TrkA) DMX6AKV MA Inhibitor DMX6AKV RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMX6AKV RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMX6YGS DI DMX6YGS DMX6YGS DN Biaryl mannoside derivative 1 DMX6YGS TI TTTCRU2 DMX6YGS TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMX6YGS MA Antagonist DMX6YGS RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMX6YGS RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMX7KDR DI DMX7KDR DMX7KDR DN US8921389, 2 DMX7KDR TI TT9ISBX DMX7KDR TN HIF-prolyl hydroxylase 2 (HPH-2) DMX7KDR MA Inhibitor DMX7KDR RN Naphthyridine derivatives as inhibitors of Hypoxia inducible factor (HIF) hydroxylase. US9695170. DMX7KDR RU http://www.freepatentsonline.com/US9695170.html DMX7MHC DI DMX7MHC DMX7MHC DN PMID25991433-Compound-A2 DMX7MHC TI TTHS0U8 DMX7MHC TN Stress-activated protein kinase JNK2 (JNK2) DMX7MHC MA Inhibitor DMX7MHC RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMX7MHC RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMX7MHC DI DMX7MHC DMX7MHC DN PMID25991433-Compound-A2 DMX7MHC TI TT0K6EO DMX7MHC TN Stress-activated protein kinase JNK1 (JNK1) DMX7MHC MA Inhibitor DMX7MHC RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMX7MHC RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMX7RWV DI DMX7RWV DMX7RWV DN Pyrazolopyridine derivative 4 DMX7RWV TI TTRMX3V DMX7RWV TN Janus kinase 2 (JAK-2) DMX7RWV MA Inhibitor DMX7RWV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMX7RWV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMX7RWV DI DMX7RWV DMX7RWV DN Pyrazolopyridine derivative 4 DMX7RWV TI TTT7PJU DMX7RWV TN Janus kinase 3 (JAK-3) DMX7RWV MA Inhibitor DMX7RWV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMX7RWV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMX7RWV DI DMX7RWV DMX7RWV DN Pyrazolopyridine derivative 4 DMX7RWV TI TT6DM01 DMX7RWV TN Janus kinase 1 (JAK-1) DMX7RWV MA Inhibitor DMX7RWV RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMX7RWV RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMX7Y52 DI DMX7Y52 DMX7Y52 DN PMID26882240-Compound-2 DMX7Y52 TI TTUX68I DMX7Y52 TN Hypoxia-inducible factor 1 (HIF-1) DMX7Y52 MA Inhibitor DMX7Y52 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMX7Y52 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMX7YAL DI DMX7YAL DMX7YAL DN Cyclopropylamine derivative 9 DMX7YAL TI TT32XQJ DMX7YAL TN Monoamine oxidase (MAO) DMX7YAL MA Inhibitor DMX7YAL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMX7YAL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMX7YAL DI DMX7YAL DMX7YAL DN Cyclopropylamine derivative 9 DMX7YAL TI TTNR0UQ DMX7YAL TN Lysine-specific histone demethylase 1 (LSD) DMX7YAL MA Inhibitor DMX7YAL RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMX7YAL RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMX8NLB DI DMX8NLB DMX8NLB DN US8853215, 3 DMX8NLB TI TT0C8BY DMX8NLB TN Plasma retinol-binding protein (RBP4) DMX8NLB MA Inhibitor DMX8NLB RN Derivatives of N-acyl-N-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes. US8853215. DMX8NLB RU http://www.freepatentsonline.com/US8853215.html DMX8RGH DI DMX8RGH DMX8RGH DN Pyridine derivative 13 DMX8RGH TI TTHS256 DMX8RGH TN Metabotropic glutamate receptor 5 (mGluR5) DMX8RGH MA Modulator DMX8RGH RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMX8RGH RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMX92ZK DI DMX92ZK DMX92ZK DN Pyrazole derivative 26 DMX92ZK TI TT6OEDT DMX92ZK TN Cannabinoid receptor 1 (CB1) DMX92ZK MA Antagonist DMX92ZK RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMX92ZK RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMX93AI DI DMX93AI DMX93AI DN Thiadiazolyl carboxamide derivative 1 DMX93AI TI TTTDVOJ DMX93AI TN Tropomyosin-related kinase A (TrkA) DMX93AI MA Inhibitor DMX93AI RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMX93AI RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMX964E DI DMX964E DMX964E DN PMID26924192-Compound-22 DMX964E TI TTRA6BO DMX964E TN Bromodomain-containing protein 4 (BRD4) DMX964E MA Inhibitor DMX964E RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMX964E RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMX96FI DI DMX96FI DMX96FI DN PMID28621580-Compound-WO2015089220C70 DMX96FI TI TTOHSBA DMX96FI TN Vascular endothelial growth factor A (VEGFA) DMX96FI MA Inhibitor DMX96FI RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMX96FI RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMX98YV DI DMX98YV DMX98YV DN PMID25656651-Compound-37b DMX98YV TI TTIV39N DMX98YV TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMX98YV MA Inhibitor DMX98YV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMX98YV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMX98YV DI DMX98YV DMX98YV DN PMID25656651-Compound-37b DMX98YV TI TTS7G69 DMX98YV TN Fusion protein Bcr-Abl (Bcr-Abl) DMX98YV MA Inhibitor DMX98YV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMX98YV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMX9J1C DI DMX9J1C DMX9J1C DN Acyl piperidine derivative 1 DMX9J1C TI TTZJYKH DMX9J1C TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMX9J1C MA Inhibitor DMX9J1C RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMX9J1C RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMX9LGW DI DMX9LGW DMX9LGW DN PMID30074415-Compound-20 DMX9LGW TI TTUNARX DMX9LGW TN Carbonic anhydrase (CA) DMX9LGW MA Inhibitor DMX9LGW RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DMX9LGW RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DMXA70C DI DMXA70C DMXA70C DN PMID27744724-Compound-23 DMXA70C TI TTL53M6 DMXA70C TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMXA70C MA Inhibitor DMXA70C RN Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178. DMXA70C RU https://www.ncbi.nlm.nih.gov/pubmed/27744724 DMXAH9F DI DMXAH9F DMXAH9F DN PMID25980951-Compound-27 DMXAH9F TI TTIRY6K DMXAH9F TN Cellular inhibitor of apoptosis 2 (BIRC3) DMXAH9F MA Antagonist DMXAH9F RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMXAH9F RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMXAH9F DI DMXAH9F DMXAH9F DN PMID25980951-Compound-27 DMXAH9F TI TTR7B60 DMXAH9F TN X-linked inhibitor of apoptosis protein (XIAP) DMXAH9F MA Antagonist DMXAH9F RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMXAH9F RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMXAH9F DI DMXAH9F DMXAH9F DN PMID25980951-Compound-27 DMXAH9F TI TTQ5LRD DMXAH9F TN Cellular inhibitor of apoptosis 1 (BIRC2) DMXAH9F MA Antagonist DMXAH9F RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMXAH9F RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMXAKNH DI DMXAKNH DMXAKNH DN PMID25399762-Compound-Table1-C3 DMXAKNH TI TTGP7BY DMXAKNH TN Monoamine oxidase type B (MAO-B) DMXAKNH MA Inhibitor DMXAKNH RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMXAKNH RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMXALJE DI DMXALJE DMXALJE DN Pyrrolidine derivative 1 DMXALJE TI TTHS256 DMXALJE TN Metabotropic glutamate receptor 5 (mGluR5) DMXALJE RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMXALJE RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMXAS8P DI DMXAS8P DMXAS8P DN Tricyclic indole compound 6 DMXAS8P TI TTPTXIN DMXAS8P TN Translocator protein (TSPO) DMXAS8P MA Ligand DMXAS8P RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMXAS8P RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMXAURE DI DMXAURE DMXAURE DN Pyrazole derivative 64 DMXAURE TI TTH8FZW DMXAURE TN Signal transducer and activator of transcription 3 (STAT3) DMXAURE MA Inhibitor DMXAURE RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMXAURE RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMXAV42 DI DMXAV42 DMXAV42 DN PMID27774824-Compound-Figure9Example2down DMXAV42 TI TT3PJMV DMXAV42 TN Tyrosine-protein kinase ABL1 (ABL) DMXAV42 MA Inhibitor DMXAV42 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXAV42 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXAV42 DI DMXAV42 DMXAV42 DN PMID27774824-Compound-Figure9Example2down DMXAV42 TI TT6DM01 DMXAV42 TN Janus kinase 1 (JAK-1) DMXAV42 MA Inhibitor DMXAV42 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXAV42 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXAV42 DI DMXAV42 DMXAV42 DN PMID27774824-Compound-Figure9Example2down DMXAV42 TI TTRMX3V DMXAV42 TN Janus kinase 2 (JAK-2) DMXAV42 MA Inhibitor DMXAV42 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXAV42 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXAV42 DI DMXAV42 DMXAV42 DN PMID27774824-Compound-Figure9Example2down DMXAV42 TI TTBYWP2 DMXAV42 TN TYK2 tyrosine kinase (TYK2) DMXAV42 MA Inhibitor DMXAV42 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXAV42 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXAV42 DI DMXAV42 DMXAV42 DN PMID27774824-Compound-Figure9Example2down DMXAV42 TI TTZ04AF DMXAV42 TN EGFR T790M mutant (EGFR T790M) DMXAV42 MA Inhibitor DMXAV42 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXAV42 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXAV42 DI DMXAV42 DMXAV42 DN PMID27774824-Compound-Figure9Example2down DMXAV42 TI TTT7PJU DMXAV42 TN Janus kinase 3 (JAK-3) DMXAV42 MA Inhibitor DMXAV42 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXAV42 RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXAW2S DI DMXAW2S DMXAW2S DN Pyrazolo[1,5-a]pyrimidine derivative 9 DMXAW2S TI TT6OEDT DMXAW2S TN Cannabinoid receptor 1 (CB1) DMXAW2S MA Antagonist DMXAW2S RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMXAW2S RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMXBYHV DI DMXBYHV DMXBYHV DN Azaindole derivative 2 DMXBYHV TI TT3PJMV DMXBYHV TN Tyrosine-protein kinase ABL1 (ABL) DMXBYHV MA Inhibitor DMXBYHV RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMXBYHV RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMXC3UP DI DMXC3UP DMXC3UP DN PMID25435179-Compound-WO2014110399Splitomycin DMXC3UP TI TTSCO7R DMXC3UP TN NAD-dependent deacetylase sirtuin (SIRT) DMXC3UP MA Inhibitor DMXC3UP RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMXC3UP RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMXCSHE DI DMXCSHE DMXCSHE DN PMID25980951-Compound-30 DMXCSHE TI TTR7B60 DMXCSHE TN X-linked inhibitor of apoptosis protein (XIAP) DMXCSHE MA Antagonist DMXCSHE RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMXCSHE RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMXCUEG DI DMXCUEG DMXCUEG DN Benzene sulfonamide derivative 4 DMXCUEG TI TTIY56R DMXCUEG TN Kynurenine 3-hydroxylase (KMO) DMXCUEG MA Inhibitor DMXCUEG RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMXCUEG RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMXD8L1 DI DMXD8L1 DMXD8L1 DN PMID25435285-Compound-52 DMXD8L1 TI TTXJ47W DMXD8L1 TN Metabotropic glutamate receptor 2 (mGluR2) DMXD8L1 MA Antagonist DMXD8L1 RN Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present).Expert Opin Ther Pat. 2015 Jan;25(1):69-90. DMXD8L1 RU https://www.ncbi.nlm.nih.gov/pubmed/25435285 DMXDOGK DI DMXDOGK DMXDOGK DN PMID27774824-Compound-Figure3Example7 DMXDOGK TI TTT7PJU DMXDOGK TN Janus kinase 3 (JAK-3) DMXDOGK MA Inhibitor DMXDOGK RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXDOGK RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXDOGK DI DMXDOGK DMXDOGK DN PMID27774824-Compound-Figure3Example7 DMXDOGK TI TT3C80U DMXDOGK TN T-cell-specific kinase (ITK) DMXDOGK MA Inhibitor DMXDOGK RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMXDOGK RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMXDSYU DI DMXDSYU DMXDSYU DN Nitrogen mustard derivative 1 DMXDSYU TI TT7HF4W DMXDSYU TN Cyclin-dependent kinase 2 (CDK2) DMXDSYU MA Inhibitor DMXDSYU RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMXDSYU RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMXDSYU DI DMXDSYU DMXDSYU DN Nitrogen mustard derivative 1 DMXDSYU TI TTMYWL7 DMXDSYU TN Cyclin-dependent kinase 3 (CDK3) DMXDSYU MA Inhibitor DMXDSYU RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMXDSYU RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMXDSYU DI DMXDSYU DMXDSYU DN Nitrogen mustard derivative 1 DMXDSYU TI TT1LVF2 DMXDSYU TN Cyclin-dependent kinase 9 (CDK9) DMXDSYU MA Inhibitor DMXDSYU RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMXDSYU RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMXE5KM DI DMXE5KM DMXE5KM DN PMID25726713-Compound-47 DMXE5KM TI TT0PG8F DMXE5KM TN Cyclin-dependent kinase 4 (CDK4) DMXE5KM MA Inhibitor DMXE5KM RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMXE5KM RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMXE5KM DI DMXE5KM DMXE5KM DN PMID25726713-Compound-47 DMXE5KM TI TTO0FDJ DMXE5KM TN Cyclin-dependent kinase 6 (CDK6) DMXE5KM MA Inhibitor DMXE5KM RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMXE5KM RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMXE5KM DI DMXE5KM DMXE5KM DN PMID25726713-Compound-47 DMXE5KM TI TT8J1S3 DMXE5KM TN Smoothened homolog (SMO) DMXE5KM MA Inhibitor DMXE5KM RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMXE5KM RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMXE5KM DI DMXE5KM DMXE5KM DN PMID25726713-Compound-47 DMXE5KM TI TTCJG29 DMXE5KM TN Serine/threonine-protein kinase mTOR (mTOR) DMXE5KM MA Inhibitor DMXE5KM RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMXE5KM RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMXEFUD DI DMXEFUD DMXEFUD DN Azetidine derivative 1 DMXEFUD TI TT6OEDT DMXEFUD TN Cannabinoid receptor 1 (CB1) DMXEFUD MA Antagonist DMXEFUD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMXEFUD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMXEL56 DI DMXEL56 DMXEL56 DN Sulfonamide derivative 12 DMXEL56 TI TT2LVK8 DMXEL56 TN Carbonic anhydrase IX (CA-IX) DMXEL56 MA Inhibitor DMXEL56 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DMXEL56 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DMXETA8 DI DMXETA8 DMXETA8 DN PMID25980951-Compound-32 DMXETA8 TI TTR7B60 DMXETA8 TN X-linked inhibitor of apoptosis protein (XIAP) DMXETA8 MA Antagonist DMXETA8 RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMXETA8 RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMXEZWP DI DMXEZWP DMXEZWP DN PMID25623274-Compound-WO2014132220C2 DMXEZWP TI TTI2WET DMXEZWP TN Platelet-derived growth factor receptor (PDGFR) DMXEZWP MA Inhibitor DMXEZWP RN Evaluation of WO-2014132220, selective PDGFR inhibitors for the treatment of pulmonary arterial hypertension.Expert Opin Ther Pat. 2015 Apr;25(4):493-9. DMXEZWP RU https://www.ncbi.nlm.nih.gov/pubmed/25623274 DMXFB5Z DI DMXFB5Z DMXFB5Z DN US9200020, Table 3, Compound 2B DMXFB5Z TI TTBL49X DMXFB5Z TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMXFB5Z MA Inhibitor DMXFB5Z RN 6-oxopurine phosphoribosyltransferase inhibitors. US9200020. DMXFB5Z RU http://www.freepatentsonline.com/US9200020.html DMXFGTZ DI DMXFGTZ DMXFGTZ DN Thiazolidine derivative 3 DMXFGTZ TI TTULVH8 DMXFGTZ TN Tyrosinase (TYR) DMXFGTZ MA Inhibitor DMXFGTZ RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMXFGTZ RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMXFNOD DI DMXFNOD DMXFNOD DN Diarylamine and arylheteroarylamine pyrazole derivative 1 DMXFNOD TI TTJQOD7 DMXFNOD TN 5-HT 2A receptor (HTR2A) DMXFNOD MA Agonist DMXFNOD RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMXFNOD RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMXGF56 DI DMXGF56 DMXGF56 DN US9598431, 5 DMXGF56 TI TTGB2LZ DMXGF56 TN RAR-related orphan receptor-beta (RORB) DMXGF56 MA Inhibitor DMXGF56 RN Compounds useful for inhibiting ROR-gamma-t. US9598431. DMXGF56 RU http://www.freepatentsonline.com/US9598431.html DMXGLST DI DMXGLST DMXGLST DN Aromatic ring compound 4 DMXGLST TI TT9O6WS DMXGLST TN Glucagon receptor (GCGR) DMXGLST MA Antagonist DMXGLST RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMXGLST RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMXGNP8 DI DMXGNP8 DMXGNP8 DN Pyrrolo-pyridinone derivative 6 DMXGNP8 TI TT4G2JS DMXGNP8 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMXGNP8 MA Inhibitor DMXGNP8 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMXGNP8 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMXGNP8 DI DMXGNP8 DMXGNP8 DN Pyrrolo-pyridinone derivative 6 DMXGNP8 TI TTAXZ0K DMXGNP8 TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMXGNP8 MA Inhibitor DMXGNP8 RN Sodium channel blockers: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):279-90. DMXGNP8 RU https://www.ncbi.nlm.nih.gov/pubmed/25539043 DMXGT2A DI DMXGT2A DMXGT2A DN PMID27607364-Compound-62 DMXGT2A TI TTPTXIN DMXGT2A TN Translocator protein (TSPO) DMXGT2A MA Ligand DMXGT2A RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMXGT2A RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMXH1G3 DI DMXH1G3 DMXH1G3 DN PMID29671355-Compound-61 DMXH1G3 TI TT5ZKDI DMXH1G3 TN Histone deacetylase 6 (HDAC6) DMXH1G3 MA Inhibitor DMXH1G3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXH1G3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXH1G3 DI DMXH1G3 DMXH1G3 DN PMID29671355-Compound-61 DMXH1G3 TI TTTQGH8 DMXH1G3 TN Histone deacetylase 4 (HDAC4) DMXH1G3 MA Inhibitor DMXH1G3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXH1G3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXH1G3 DI DMXH1G3 DMXH1G3 DN PMID29671355-Compound-61 DMXH1G3 TI TTT6LFV DMXH1G3 TN Histone deacetylase 8 (HDAC8) DMXH1G3 MA Inhibitor DMXH1G3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXH1G3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXH1G3 DI DMXH1G3 DMXH1G3 DN PMID29671355-Compound-61 DMXH1G3 TI TT4YWTO DMXH1G3 TN Histone deacetylase 3 (HDAC3) DMXH1G3 MA Inhibitor DMXH1G3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXH1G3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXH1G3 DI DMXH1G3 DMXH1G3 DN PMID29671355-Compound-61 DMXH1G3 TI TTSHTOI DMXH1G3 TN Histone deacetylase 2 (HDAC2) DMXH1G3 MA Inhibitor DMXH1G3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXH1G3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXH1G3 DI DMXH1G3 DMXH1G3 DN PMID29671355-Compound-61 DMXH1G3 TI TT6R7JZ DMXH1G3 TN Histone deacetylase 1 (HDAC1) DMXH1G3 MA Inhibitor DMXH1G3 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXH1G3 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXH65Z DI DMXH65Z DMXH65Z DN Piperazine carbamic compound 5 DMXH65Z TI TTSINOV DMXH65Z TN Monoacylglycerol lipase ABHD6 (ABHD6) DMXH65Z MA Inhibitor DMXH65Z RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMXH65Z RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMXH65Z DI DMXH65Z DMXH65Z DN Piperazine carbamic compound 5 DMXH65Z TI TTZ963I DMXH65Z TN Monoglyceride lipase (MAGL) DMXH65Z MA Inhibitor DMXH65Z RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMXH65Z RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMXHN1V DI DMXHN1V DMXHN1V DN US8759338, 12 DMXHN1V TI TTCGOIN DMXHN1V TN PIM-3 protein kinase (PIM3) DMXHN1V MA Inhibitor DMXHN1V RN Heterocyclic kinase inhibitors. US8759338. DMXHN1V RU http://www.freepatentsonline.com/US8759338.html DMXI3O0 DI DMXI3O0 DMXI3O0 DN AC1LFGWU DMXI3O0 TI TTLKF5M DMXI3O0 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMXI3O0 MA Inhibitor DMXI3O0 RN Small molecule activators of NRF2 pathway. US9737525. DMXI3O0 RU http://www.freepatentsonline.com/US9737525.html DMXIG07 DI DMXIG07 DMXIG07 DN 1,3,4-thiadiazole derivative 2 DMXIG07 TI TT23XQV DMXIG07 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMXIG07 MA Inhibitor DMXIG07 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMXIG07 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMXIHPT DI DMXIHPT DMXIHPT DN Spiroimidazolone derivative 4 DMXIHPT TI TT9O6WS DMXIHPT TN Glucagon receptor (GCGR) DMXIHPT MA Antagonist DMXIHPT RN Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Jul;25(7):819-30. DMXIHPT RU https://www.ncbi.nlm.nih.gov/pubmed/25828189 DMXIO9A DI DMXIO9A DMXIO9A DN PMID29338548-Compound-14 DMXIO9A TI TTHJTF7 DMXIO9A TN Glycine transporter GlyT-1 (SLC6A9) DMXIO9A MA Inhibitor DMXIO9A RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMXIO9A RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMXJ837 DI DMXJ837 DMXJ837 DN 3-oxo-2,3-dihydro-1H-indazole-4-carboxamide derivative 5 DMXJ837 TI TTVDSZ0 DMXJ837 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMXJ837 MA Inhibitor DMXJ837 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMXJ837 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMXJT8R DI DMXJT8R DMXJT8R DN PMID25435179-Compound-US2012165330(I) DMXJT8R TI TTSCO7R DMXJT8R TN NAD-dependent deacetylase sirtuin (SIRT) DMXJT8R MA Inhibitor DMXJT8R RN Sirtuin modulators: an updated patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):5-15. DMXJT8R RU https://www.ncbi.nlm.nih.gov/pubmed/25435179 DMXJVW4 DI DMXJVW4 DMXJVW4 DN PMID27607364-Compound-58 DMXJVW4 TI TTPTXIN DMXJVW4 TN Translocator protein (TSPO) DMXJVW4 MA Ligand DMXJVW4 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMXJVW4 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMXK2GA DI DMXK2GA DMXK2GA DN PMID28394193-Compound-Figure3bI DMXK2GA TI TT9MZCQ DMXK2GA TN Enhancer of zeste homolog 2 (EZH2) DMXK2GA MA Inhibitor DMXK2GA RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMXK2GA RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMXK43O DI DMXK43O DMXK43O DN PMID25656651-Compound-27 DMXK43O TI TTS7G69 DMXK43O TN Fusion protein Bcr-Abl (Bcr-Abl) DMXK43O MA Inhibitor DMXK43O RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMXK43O RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMXK6LV DI DMXK6LV DMXK6LV DN PMID26936077-Compound-13 DMXK6LV TI TTQR74A DMXK6LV TN Proteinase activated receptor 2 (PAR2) DMXK6LV MA Antagonist DMXK6LV RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMXK6LV RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMXKUMJ DI DMXKUMJ DMXKUMJ DN Decyle nelycorine dibromo salt derivative 1 DMXKUMJ TI TT1RS9F DMXKUMJ TN Acetylcholinesterase (AChE) DMXKUMJ MA Inhibitor DMXKUMJ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMXKUMJ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMXKUMJ DI DMXKUMJ DMXKUMJ DN Decyle nelycorine dibromo salt derivative 1 DMXKUMJ TI TTEB0GD DMXKUMJ TN Cholinesterase (BCHE) DMXKUMJ MA Inhibitor DMXKUMJ RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMXKUMJ RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMXL2V9 DI DMXL2V9 DMXL2V9 DN Azetidine derivative 4 DMXL2V9 TI TT6OEDT DMXL2V9 TN Cannabinoid receptor 1 (CB1) DMXL2V9 MA Antagonist DMXL2V9 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMXL2V9 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMXL3A5 DI DMXL3A5 DMXL3A5 DN Flavopiridol analog 1 DMXL3A5 TI TT1LVF2 DMXL3A5 TN Cyclin-dependent kinase 9 (CDK9) DMXL3A5 MA Inhibitor DMXL3A5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMXL3A5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMXL3A5 DI DMXL3A5 DMXL3A5 DN Flavopiridol analog 1 DMXL3A5 TI TT7HF4W DMXL3A5 TN Cyclin-dependent kinase 2 (CDK2) DMXL3A5 MA Inhibitor DMXL3A5 RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMXL3A5 RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMXL96M DI DMXL96M DMXL96M DN PMID29671355-Compound-9 DMXL96M TI TT4YWTO DMXL96M TN Histone deacetylase 3 (HDAC3) DMXL96M MA Inhibitor DMXL96M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXL96M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXL96M DI DMXL96M DMXL96M DN PMID29671355-Compound-9 DMXL96M TI TTSHTOI DMXL96M TN Histone deacetylase 2 (HDAC2) DMXL96M MA Inhibitor DMXL96M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXL96M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXL96M DI DMXL96M DMXL96M DN PMID29671355-Compound-9 DMXL96M TI TT6R7JZ DMXL96M TN Histone deacetylase 1 (HDAC1) DMXL96M MA Inhibitor DMXL96M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXL96M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXL96M DI DMXL96M DMXL96M DN PMID29671355-Compound-9 DMXL96M TI TT5ZKDI DMXL96M TN Histone deacetylase 6 (HDAC6) DMXL96M MA Inhibitor DMXL96M RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXL96M RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXLJH4 DI DMXLJH4 DMXLJH4 DN Tricyclic heterocycle derivative 1 DMXLJH4 TI TTBYWP2 DMXLJH4 TN TYK2 tyrosine kinase (TYK2) DMXLJH4 MA Inhibitor DMXLJH4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMXLJH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMXLJH4 DI DMXLJH4 DMXLJH4 DN Tricyclic heterocycle derivative 1 DMXLJH4 TI TTT7PJU DMXLJH4 TN Janus kinase 3 (JAK-3) DMXLJH4 MA Inhibitor DMXLJH4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMXLJH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMXLJH4 DI DMXLJH4 DMXLJH4 DN Tricyclic heterocycle derivative 1 DMXLJH4 TI TTRMX3V DMXLJH4 TN Janus kinase 2 (JAK-2) DMXLJH4 MA Inhibitor DMXLJH4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMXLJH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMXLJH4 DI DMXLJH4 DMXLJH4 DN Tricyclic heterocycle derivative 1 DMXLJH4 TI TT6DM01 DMXLJH4 TN Janus kinase 1 (JAK-1) DMXLJH4 MA Inhibitor DMXLJH4 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMXLJH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMXM98J DI DMXM98J DMXM98J DN PMID25656651-Compound-26a DMXM98J TI TTS7G69 DMXM98J TN Fusion protein Bcr-Abl (Bcr-Abl) DMXM98J MA Inhibitor DMXM98J RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMXM98J RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMXMGSP DI DMXMGSP DMXMGSP DN Cycloalkyl acid derivative 1 DMXMGSP TI TTA592U DMXMGSP TN Urate anion exchanger 1 (URAT1) DMXMGSP MA Inhibitor DMXMGSP RN Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10. DMXMGSP RU https://www.ncbi.nlm.nih.gov/pubmed/27414413 DMXMP92 DI DMXMP92 DMXMP92 DN PMID28394193-Compound-15 DMXMP92 TI TT9MZCQ DMXMP92 TN Enhancer of zeste homolog 2 (EZH2) DMXMP92 MA Inhibitor DMXMP92 RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMXMP92 RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMXMRQP DI DMXMRQP DMXMRQP DN PMID28394193-Compound-53 DMXMRQP TI TT9MZCQ DMXMRQP TN Enhancer of zeste homolog 2 (EZH2) DMXMRQP MA Inhibitor DMXMRQP RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMXMRQP RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMXMTLP DI DMXMTLP DMXMTLP DN 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analog 3 DMXMTLP TI TTHS256 DMXMTLP TN Metabotropic glutamate receptor 5 (mGluR5) DMXMTLP MA Modulator DMXMTLP RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMXMTLP RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMXMV6N DI DMXMV6N DMXMV6N DN 3-phenyl acrylic acid derivative 1 DMXMV6N TI TTZMAO3 DMXMV6N TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMXMV6N MA Agonist DMXMV6N RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMXMV6N RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMXN361 DI DMXN361 DMXN361 DN Cyclopropylamine derivative 1 DMXN361 TI TTNR0UQ DMXN361 TN Lysine-specific histone demethylase 1 (LSD) DMXN361 MA Inhibitor DMXN361 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMXN361 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMXN4KB DI DMXN4KB DMXN4KB DN PMID25522065-Compound-27 DMXN4KB TI TTX4RTB DMXN4KB TN Melanin-concentrating hormone receptor 1 (MCHR1) DMXN4KB MA Antagonist DMXN4KB RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMXN4KB RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMXND26 DI DMXND26 DMXND26 DN Aryl pyrimidine derivative 3 DMXND26 TI TTIY56R DMXND26 TN Kynurenine 3-hydroxylase (KMO) DMXND26 MA Inhibitor DMXND26 RN Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32. DMXND26 RU https://www.ncbi.nlm.nih.gov/pubmed/27172114 DMXNLTR DI DMXNLTR DMXNLTR DN PMID25726713-Compound-62 DMXNLTR TI TT8J1S3 DMXNLTR TN Smoothened homolog (SMO) DMXNLTR MA Inhibitor DMXNLTR RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMXNLTR RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMXNVD4 DI DMXNVD4 DMXNVD4 DN Cyclopropylamine derivative 13 DMXNVD4 TI TT32XQJ DMXNVD4 TN Monoamine oxidase (MAO) DMXNVD4 MA Inhibitor DMXNVD4 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMXNVD4 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMXNVD4 DI DMXNVD4 DMXNVD4 DN Cyclopropylamine derivative 13 DMXNVD4 TI TTNR0UQ DMXNVD4 TN Lysine-specific histone demethylase 1 (LSD) DMXNVD4 MA Inhibitor DMXNVD4 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMXNVD4 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMXO8R5 DI DMXO8R5 DMXO8R5 DN Pyrrolidine derivative 12 DMXO8R5 TI TTSCIUP DMXO8R5 TN Oxytocin receptor (OTR) DMXO8R5 MA Antagonist DMXO8R5 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMXO8R5 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMXOKH3 DI DMXOKH3 DMXOKH3 DN Quinazolinone derivative 5 DMXOKH3 TI TTE4BSY DMXOKH3 TN Bromodomain and extraterminal domain protein (BET) DMXOKH3 MA Inhibitor DMXOKH3 RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMXOKH3 RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMXOPIJ DI DMXOPIJ DMXOPIJ DN Dipeptide analog 4 DMXOPIJ TI TT2F4OL DMXOPIJ TN Tissue transglutaminase (TG2) DMXOPIJ MA Inhibitor DMXOPIJ RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMXOPIJ RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMXP073 DI DMXP073 DMXP073 DN CQ7 DMXP073 TI TTV298Y DMXP073 TN Calmodulin-dependent kinase II (CAMKK2) DMXP073 MA Inhibitor DMXP073 RN Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof. US9623028. DMXP073 RU http://www.freepatentsonline.com/US9623028.html DMXP6W1 DI DMXP6W1 DMXP6W1 DN Pyridine derivative 5 DMXP6W1 TI TTOHSBA DMXP6W1 TN Vascular endothelial growth factor A (VEGFA) DMXP6W1 MA Inhibitor DMXP6W1 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMXP6W1 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMXPBL5 DI DMXPBL5 DMXPBL5 DN N-alkylamide derivative 1 DMXPBL5 TI TTHS256 DMXPBL5 TN Metabotropic glutamate receptor 5 (mGluR5) DMXPBL5 MA Modulator DMXPBL5 RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMXPBL5 RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMXPO6T DI DMXPO6T DMXPO6T DN PMID27841045-Compound-133 DMXPO6T TI TT7RJY8 DMXPO6T TN Xanthine dehydrogenase/oxidase (XDH) DMXPO6T MA Inhibitor DMXPO6T RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMXPO6T RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMXPQ24 DI DMXPQ24 DMXPQ24 DN Triazolo-pyridine derivative 2 DMXPQ24 TI TTJW4LU DMXPQ24 TN Phosphodiesterase 10A (PDE10) DMXPQ24 MA Inhibitor DMXPQ24 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMXPQ24 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMXPQ24 DI DMXPQ24 DMXPQ24 DN Triazolo-pyridine derivative 2 DMXPQ24 TI TTJGW1Z DMXPQ24 TN Phosphodiesterase 2A (PDE2A) DMXPQ24 MA Inhibitor DMXPQ24 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMXPQ24 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMXQE7C DI DMXQE7C DMXQE7C DN PMID28092474-Compound-34a DMXQE7C TI TT6R7JZ DMXQE7C TN Histone deacetylase 1 (HDAC1) DMXQE7C MA Inhibitor DMXQE7C RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMXQE7C RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMXQE7C DI DMXQE7C DMXQE7C DN PMID28092474-Compound-34a DMXQE7C TI TT5ZKDI DMXQE7C TN Histone deacetylase 6 (HDAC6) DMXQE7C MA Inhibitor DMXQE7C RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMXQE7C RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMXQTPJ DI DMXQTPJ DMXQTPJ DN Carbamide derivative 1 DMXQTPJ TI TTGX13H DMXQTPJ TN Fatty-acid amide hydrolase 1 (FAAH1) DMXQTPJ MA Inhibitor DMXQTPJ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMXQTPJ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMXQTPJ DI DMXQTPJ DMXQTPJ DN Carbamide derivative 1 DMXQTPJ TI TTDP1UC DMXQTPJ TN Fatty acid amide hydrolase (FAAH) DMXQTPJ MA Inhibitor DMXQTPJ RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMXQTPJ RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMXR5SZ DI DMXR5SZ DMXR5SZ DN US9216972, 67 DMXR5SZ TI TTDYP7I DMXR5SZ TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMXR5SZ MA Inhibitor DMXR5SZ RN Tricyclic heterocyclic compounds. US9216972. DMXR5SZ RU http://www.freepatentsonline.com/US9216972.html DMXRE1V DI DMXRE1V DMXRE1V DN Thiazoline derivative 2 DMXRE1V TI TTULVH8 DMXRE1V TN Tyrosinase (TYR) DMXRE1V MA Inhibitor DMXRE1V RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMXRE1V RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMXRHCJ DI DMXRHCJ DMXRHCJ DN PMID30280939-Compound-WO2009082440 DMXRHCJ TI TTOK0LR DMXRHCJ TN Toll-like receptor (TLR) DMXRHCJ MA Agonist DMXRHCJ RN Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847. DMXRHCJ RU https://www.ncbi.nlm.nih.gov/pubmed/30280939 DMXRI5J DI DMXRI5J DMXRI5J DN PMID25522065-Compound-47 DMXRI5J TI TTX4RTB DMXRI5J TN Melanin-concentrating hormone receptor 1 (MCHR1) DMXRI5J MA Antagonist DMXRI5J RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMXRI5J RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMXRJI2 DI DMXRJI2 DMXRJI2 DN Pyrrolo[2,3-d]pyrimidine derivative 28 DMXRJI2 TI TTGBPJE DMXRJI2 TN PI3-kinase delta (PIK3CD) DMXRJI2 MA Inhibitor DMXRJI2 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMXRJI2 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMXRJI2 DI DMXRJI2 DMXRJI2 DN Pyrrolo[2,3-d]pyrimidine derivative 28 DMXRJI2 TI TTGM6VW DMXRJI2 TN Tyrosine-protein kinase BTK (ATK) DMXRJI2 MA Inhibitor DMXRJI2 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMXRJI2 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMXRLI6 DI DMXRLI6 DMXRLI6 DN 1,2-diamino cyclopentane-based derivative 22 DMXRLI6 TI TT9N02I DMXRLI6 TN Orexin receptor type 2 (HCRTR2) DMXRLI6 MA Antagonist DMXRLI6 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMXRLI6 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMXRLI6 DI DMXRLI6 DMXRLI6 DN 1,2-diamino cyclopentane-based derivative 22 DMXRLI6 TI TT60Q8D DMXRLI6 TN Orexin receptor type 1 (HCRTR1) DMXRLI6 MA Antagonist DMXRLI6 RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMXRLI6 RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMXRTH4 DI DMXRTH4 DMXRTH4 DN PMID27109571-Compound-27 DMXRTH4 TI TTNT2S6 DMXRTH4 TN Fatty acid-binding protein 5 (FABP5) DMXRTH4 MA Inhibitor DMXRTH4 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMXRTH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMXRTH4 DI DMXRTH4 DMXRTH4 DN PMID27109571-Compound-27 DMXRTH4 TI TTHWMFZ DMXRTH4 TN Fatty acid-binding protein 4 (FABP4) DMXRTH4 MA Inhibitor DMXRTH4 RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMXRTH4 RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMXS46Y DI DMXS46Y DMXS46Y DN Indoline derivative 7 DMXS46Y TI TT5OU0D DMXS46Y TN PRKR-like endoplasmic reticulum kinase (PERK) DMXS46Y MA Inhibitor DMXS46Y RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMXS46Y RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMXS5WY DI DMXS5WY DMXS5WY DN PMID25666693-Compound-162 DMXS5WY TI TTMI6F5 DMXS5WY TN Transient receptor potential cation channel V1 (TRPV1) DMXS5WY MA Antagonist DMXS5WY RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMXS5WY RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMXSAN7 DI DMXSAN7 DMXSAN7 DN PMID25514969-Compound-Figure2-4 DMXSAN7 TI TT4EB85 DMXSAN7 TN Cholesterol 24-hydroxylase (CYP46A1) DMXSAN7 MA Inhibitor DMXSAN7 RN Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676).Expert Opin Ther Pat. 2015 Mar;25(3):373-7. DMXSAN7 RU https://www.ncbi.nlm.nih.gov/pubmed/25514969 DMXSFJ8 DI DMXSFJ8 DMXSFJ8 DN Indoline derivative 17 DMXSFJ8 TI TTOHSBA DMXSFJ8 TN Vascular endothelial growth factor A (VEGFA) DMXSFJ8 MA Inhibitor DMXSFJ8 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMXSFJ8 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMXSK8Y DI DMXSK8Y DMXSK8Y DN PMID25991433-Compound-D1 DMXSK8Y TI TTHS0U8 DMXSK8Y TN Stress-activated protein kinase JNK2 (JNK2) DMXSK8Y MA Inhibitor DMXSK8Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMXSK8Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMXSK8Y DI DMXSK8Y DMXSK8Y DN PMID25991433-Compound-D1 DMXSK8Y TI TT0K6EO DMXSK8Y TN Stress-activated protein kinase JNK1 (JNK1) DMXSK8Y MA Inhibitor DMXSK8Y RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMXSK8Y RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMXSPT9 DI DMXSPT9 DMXSPT9 DN PMID28092474-Compound-33m DMXSPT9 TI TT5ZKDI DMXSPT9 TN Histone deacetylase 6 (HDAC6) DMXSPT9 MA Inhibitor DMXSPT9 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMXSPT9 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMXSPT9 DI DMXSPT9 DMXSPT9 DN PMID28092474-Compound-33m DMXSPT9 TI TT6R7JZ DMXSPT9 TN Histone deacetylase 1 (HDAC1) DMXSPT9 MA Inhibitor DMXSPT9 RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMXSPT9 RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMXSRPH DI DMXSRPH DMXSRPH DN Macrocycle derivative 14 DMXSRPH TI TTBJR4L DMXSRPH TN Cyclin-dependent kinase 8 (CDK8) DMXSRPH MA Inhibitor DMXSRPH RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMXSRPH RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMXSZ5B DI DMXSZ5B DMXSZ5B DN Cyclic sulfonamide derivative 2 DMXSZ5B TI TT8J1S3 DMXSZ5B TN Smoothened homolog (SMO) DMXSZ5B MA Inhibitor DMXSZ5B RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMXSZ5B RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMXTCGM DI DMXTCGM DMXTCGM DN US8569313, Inhibitor 18 DMXTCGM TI TTPRO7W DMXTCGM TN Suppressor of tumorigenicity 14 protein (ST14) DMXTCGM MA Inhibitor DMXTCGM RN Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313. DMXTCGM RU http://www.freepatentsonline.com/US8569313.html DMXTL7V DI DMXTL7V DMXTL7V DN Tetra-hydro-carboline derivative 2 DMXTL7V TI TTSCIM2 DMXTL7V TN Extracellular lysophospholipase D (E-NPP2) DMXTL7V MA Inhibitor DMXTL7V RN Autotaxin inhibitors: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):815-829. DMXTL7V RU https://www.ncbi.nlm.nih.gov/pubmed/28447479 DMXTUE1 DI DMXTUE1 DMXTUE1 DN Acyl oxymethyl acrylamide ester derivative 1 DMXTUE1 TI TTEP6RV DMXTUE1 TN Glutathione reductase (GR) DMXTUE1 MA Inhibitor DMXTUE1 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMXTUE1 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMXTUE1 DI DMXTUE1 DMXTUE1 DN Acyl oxymethyl acrylamide ester derivative 1 DMXTUE1 TI TTR7UJ3 DMXTUE1 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMXTUE1 MA Inhibitor DMXTUE1 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMXTUE1 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMXU08A DI DMXU08A DMXU08A DN Pyrrolo[2,3-d]pyrimidine derivative 35 DMXU08A TI TTUM2ZR DMXU08A TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMXU08A MA Inhibitor DMXU08A RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMXU08A RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMXU3IE DI DMXU3IE DMXU3IE DN PMID25666693-Compound-91 DMXU3IE TI TTMI6F5 DMXU3IE TN Transient receptor potential cation channel V1 (TRPV1) DMXU3IE MA Antagonist DMXU3IE RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMXU3IE RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMXU71M DI DMXU71M DMXU71M DN Peptide analog 72 DMXU71M TI TTQR74A DMXU71M TN Proteinase activated receptor 2 (PAR2) DMXU71M MA Agonist DMXU71M RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMXU71M RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMXU8DI DI DMXU8DI DMXU8DI DN US9656955, Example 351 DMXU8DI TI TTYJRN5 DMXU8DI TN N-acetylglucosaminyltransferase I (NAGAT1) DMXU8DI MA Inhibitor DMXU8DI RN Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy. US9656955. DMXU8DI RU http://www.freepatentsonline.com/US9656955.html DMXUNZ1 DI DMXUNZ1 DMXUNZ1 DN Monoaryl-1,2-diamine derivative 2 DMXUNZ1 TI TTZJYKH DMXUNZ1 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMXUNZ1 MA Inhibitor DMXUNZ1 RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMXUNZ1 RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMXUVDH DI DMXUVDH DMXUVDH DN PMID29473428-Compound-50 DMXUVDH TI TTZJYKH DMXUVDH TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMXUVDH MA Inhibitor DMXUVDH RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMXUVDH RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMXV0CK DI DMXV0CK DMXV0CK DN PMID26560530-Compound-48 DMXV0CK TI TT2F4OL DMXV0CK TN Tissue transglutaminase (TG2) DMXV0CK MA Inhibitor DMXV0CK RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMXV0CK RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMXVCHZ DI DMXVCHZ DMXVCHZ DN PMID26161698-Compound-10 DMXVCHZ TI TTMBO1Z DMXVCHZ TN Cyclin-dependent kinase (CDK) DMXVCHZ MA Inhibitor DMXVCHZ RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMXVCHZ RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMXVNSR DI DMXVNSR DMXVNSR DN Tricyclic indole compound 14 DMXVNSR TI TTPTXIN DMXVNSR TN Translocator protein (TSPO) DMXVNSR MA Ligand DMXVNSR RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMXVNSR RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMXVOP3 DI DMXVOP3 DMXVOP3 DN Imidazopyridazine derivative 3 DMXVOP3 TI TTQR74A DMXVOP3 TN Proteinase activated receptor 2 (PAR2) DMXVOP3 MA Antagonist DMXVOP3 RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMXVOP3 RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMXW0PV DI DMXW0PV DMXW0PV DN Aromatic and heteroaryl compound 1 DMXW0PV TI TTUX68I DMXW0PV TN Hypoxia-inducible factor 1 (HIF-1) DMXW0PV MA Inhibitor DMXW0PV RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMXW0PV RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMXW108 DI DMXW108 DMXW108 DN PMID29649907-Compound-22 DMXW108 TI TTS4UGC DMXW108 TN Farnesoid X-activated receptor (FXR) DMXW108 MA Agonist DMXW108 RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMXW108 RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMXWE5R DI DMXWE5R DMXWE5R DN N-acylpiperidine ether derivative 3 DMXWE5R TI TTTDVOJ DMXWE5R TN Tropomyosin-related kinase A (TrkA) DMXWE5R MA Inhibitor DMXWE5R RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMXWE5R RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMXWOAG DI DMXWOAG DMXWOAG DN Mycophenolic acid/nucleotide derivative 11 DMXWOAG TI TTL7C8Q DMXWOAG TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMXWOAG MA Inhibitor DMXWOAG RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMXWOAG RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMXWVN2 DI DMXWVN2 DMXWVN2 DN Pyrrolo[2,3-d]pyrimidine derivative 17 DMXWVN2 TI TTGM6VW DMXWVN2 TN Tyrosine-protein kinase BTK (ATK) DMXWVN2 MA Inhibitor DMXWVN2 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMXWVN2 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMXY103 DI DMXY103 DMXY103 DN PMID29671355-Compound-42 DMXY103 TI TT6R7JZ DMXY103 TN Histone deacetylase 1 (HDAC1) DMXY103 MA Inhibitor DMXY103 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMXY103 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMXY3F0 DI DMXY3F0 DMXY3F0 DN Pyrido[1,2-a]indole-1.-carboxylic acid analog 7 DMXY3F0 TI TTV8CRH DMXY3F0 TN Lysine-specific demethylase 4C (KDM4C) DMXY3F0 MA Inhibitor DMXY3F0 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMXY3F0 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMXY4BE DI DMXY4BE DMXY4BE DN PMID25991433-Compound-N2 DMXY4BE TI TTVOE6D DMXY4BE TN Mitogen-activated protein kinase (MAPK) DMXY4BE MA Inhibitor DMXY4BE RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMXY4BE RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMXY4SP DI DMXY4SP DMXY4SP DN US8940736, 6 DMXY4SP TI TTR93NU DMXY4SP TN Casein kinase II alpha prime (CSNK2A2) DMXY4SP MA Inhibitor DMXY4SP RN Imidazotriazinecarbonitriles useful as kinase inhibitors. US8940736. DMXY4SP RU http://www.freepatentsonline.com/US8940736.html DMXYSO1 DI DMXYSO1 DMXYSO1 DN PMID25553724-Compound-WO2013082253 32 DMXYSO1 TI TTSXVID DMXYSO1 TN Nuclear factor NF-kappa-B (NFKB) DMXYSO1 MA Modulator DMXYSO1 RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMXYSO1 RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMXYT40 DI DMXYT40 DMXYT40 DN Pyridine derivative 19 DMXYT40 TI TT7MRDV DMXYT40 TN Macrophage colony-stimulating factor 1 receptor (CSF1R) DMXYT40 MA Inhibitor DMXYT40 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMXYT40 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMXYT40 DI DMXYT40 DMXYT40 DN Pyridine derivative 19 DMXYT40 TI TT8FYO9 DMXYT40 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMXYT40 MA Inhibitor DMXYT40 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMXYT40 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMXYT40 DI DMXYT40 DMXYT40 DN Pyridine derivative 19 DMXYT40 TI TTX41N9 DMXYT40 TN Tyrosine-protein kinase Kit (KIT) DMXYT40 MA Inhibitor DMXYT40 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMXYT40 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMXYT40 DI DMXYT40 DMXYT40 DN Pyridine derivative 19 DMXYT40 TI TT4DXQT DMXYT40 TN Proto-oncogene c-Ret (RET) DMXYT40 MA Inhibitor DMXYT40 RN RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99. DMXYT40 RU https://www.ncbi.nlm.nih.gov/pubmed/27646564 DMXYU3I DI DMXYU3I DMXYU3I DN Pyrazino[2,1-a]isoquinolin derivative 3 DMXYU3I TI TTA6ZN2 DMXYU3I TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMXYU3I MA Activator DMXYU3I RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMXYU3I RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMXYU3I DI DMXYU3I DMXYU3I DN Pyrazino[2,1-a]isoquinolin derivative 3 DMXYU3I TI TT3Z6Y9 DMXYU3I TN Cysteines of Keap1 (KEAP1 Cysteines) DMXYU3I MA Modulator DMXYU3I RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMXYU3I RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMXZ368 DI DMXZ368 DMXZ368 DN PMID28048944-Compound-7 DMXZ368 TI TTZN7RP DMXZ368 TN Rho-associated protein kinase 1 (ROCK1) DMXZ368 MA Inhibitor DMXZ368 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMXZ368 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMXZ368 DI DMXZ368 DMXZ368 DN PMID28048944-Compound-7 DMXZ368 TI TTGWKQJ DMXZ368 TN Rho-associated protein kinase 2 (ROCK2) DMXZ368 MA Inhibitor DMXZ368 RN Rho kinase inhibitors: a patent review (2014 - 2016).Expert Opin Ther Pat. 2017 Apr;27(4):507-515. DMXZ368 RU https://www.ncbi.nlm.nih.gov/pubmed/28048944 DMXZC8K DI DMXZC8K DMXZC8K DN Pyrazole derivative 59 DMXZC8K TI TT6OEDT DMXZC8K TN Cannabinoid receptor 1 (CB1) DMXZC8K MA Antagonist DMXZC8K RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMXZC8K RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMY01FU DI DMY01FU DMY01FU DN Benzoxazole derivative 1 DMY01FU TI TTDP1UC DMY01FU TN Fatty acid amide hydrolase (FAAH) DMY01FU MA Inhibitor DMY01FU RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMY01FU RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMY03RZ DI DMY03RZ DMY03RZ DN Pyrazolopyridine derivative 1 DMY03RZ TI TTT7PJU DMY03RZ TN Janus kinase 3 (JAK-3) DMY03RZ MA Inhibitor DMY03RZ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMY03RZ RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMY06VC DI DMY06VC DMY06VC DN Carbamide derivative 9 DMY06VC TI TTL7C8Q DMY06VC TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMY06VC MA Inhibitor DMY06VC RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMY06VC RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMY07NA DI DMY07NA DMY07NA DN PMID25522065-Compound-26 DMY07NA TI TTX4RTB DMY07NA TN Melanin-concentrating hormone receptor 1 (MCHR1) DMY07NA MA Antagonist DMY07NA RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMY07NA RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMY0HP1 DI DMY0HP1 DMY0HP1 DN PMID26651364-Compound-4 DMY0HP1 TI TTTCRU2 DMY0HP1 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMY0HP1 MA Antagonist DMY0HP1 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMY0HP1 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMY10T2 DI DMY10T2 DMY10T2 DN C-linked disaccharide biphenyl mannoside derivative 3 DMY10T2 TI TTTCRU2 DMY10T2 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMY10T2 MA Antagonist DMY10T2 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMY10T2 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMY2PTU DI DMY2PTU DMY2PTU DN PMID29865878-Compound-42 DMY2PTU TI TTSJMN8 DMY2PTU TN Immunoproteasome complex (IP) DMY2PTU MA Inhibitor DMY2PTU RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMY2PTU RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMY3140 DI DMY3140 DMY3140 DN PMID25470667-Compound-BAY744113 DMY3140 TI TTF8P9I DMY3140 TN Diacylglycerol acyltransferase 1 (DGAT1) DMY3140 MA Inhibitor DMY3140 RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMY3140 RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMY37VQ DI DMY37VQ DMY37VQ DN PMID30107136-Compound-Example1 DMY37VQ TI TT8ZLTI DMY37VQ TN Programmed cell death 1 ligand 1 (PD-L1) DMY37VQ MA Inhibitor DMY37VQ RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMY37VQ RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMY3Q58 DI DMY3Q58 DMY3Q58 DN PMID29671355-Compound-65a DMY3Q58 TI TT6R7JZ DMY3Q58 TN Histone deacetylase 1 (HDAC1) DMY3Q58 MA Inhibitor DMY3Q58 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMY3Q58 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMY3Q58 DI DMY3Q58 DMY3Q58 DN PMID29671355-Compound-65a DMY3Q58 TI TT5ZKDI DMY3Q58 TN Histone deacetylase 6 (HDAC6) DMY3Q58 MA Inhibitor DMY3Q58 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMY3Q58 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMY3U7N DI DMY3U7N DMY3U7N DN PMID27841045-Compound-134 DMY3U7N TI TT7RJY8 DMY3U7N TN Xanthine dehydrogenase/oxidase (XDH) DMY3U7N MA Inhibitor DMY3U7N RN An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345. DMY3U7N RU https://www.ncbi.nlm.nih.gov/pubmed/27841045 DMY3UKC DI DMY3UKC DMY3UKC DN PMID25399762-Compound-Table1-C6 DMY3UKC TI TTGP7BY DMY3UKC TN Monoamine oxidase type B (MAO-B) DMY3UKC MA Inhibitor DMY3UKC RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMY3UKC RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMY4AJ7 DI DMY4AJ7 DMY4AJ7 DN PMID25482888-Compound-17 DMY4AJ7 TI TTDIGC1 DMY4AJ7 TN Dipeptidyl peptidase 4 (DPP-4) DMY4AJ7 MA Inhibitor DMY4AJ7 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMY4AJ7 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMY4IAV DI DMY4IAV DMY4IAV DN PMID27109571-Compound-41 DMY4IAV TI TTMY6L1 DMY4IAV TN Fatty acid-binding protein (FABP) DMY4IAV MA Inhibitor DMY4IAV RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMY4IAV RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMY4LB7 DI DMY4LB7 DMY4LB7 DN Heterocyclic derivative 9 DMY4LB7 TI TTCZOF2 DMY4LB7 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMY4LB7 MA Inhibitor DMY4LB7 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMY4LB7 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMY52ZB DI DMY52ZB DMY52ZB DN PMID29865878-Compound-55 DMY52ZB TI TTOUSTQ DMY52ZB TN Proteasome beta-9 (PS beta-9) DMY52ZB MA Inhibitor DMY52ZB RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMY52ZB RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMY52ZB DI DMY52ZB DMY52ZB DN PMID29865878-Compound-55 DMY52ZB TI TT68GPI DMY52ZB TN Proteasome beta-5 (PS beta-5) DMY52ZB MA Inhibitor DMY52ZB RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMY52ZB RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMY52ZB DI DMY52ZB DMY52ZB DN PMID29865878-Compound-55 DMY52ZB TI TT8EPLT DMY52ZB TN Proteasome beta-1 (PS beta-1) DMY52ZB MA Inhibitor DMY52ZB RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMY52ZB RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMY52ZB DI DMY52ZB DMY52ZB DN PMID29865878-Compound-55 DMY52ZB TI TTEAD9J DMY52ZB TN Proteasome beta-8 (PS beta-8) DMY52ZB MA Inhibitor DMY52ZB RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMY52ZB RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMY5CFW DI DMY5CFW DMY5CFW DN Diphenyl purine derivative 3 DMY5CFW TI TT6OEDT DMY5CFW TN Cannabinoid receptor 1 (CB1) DMY5CFW MA Antagonist DMY5CFW RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMY5CFW RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMY5J23 DI DMY5J23 DMY5J23 DN Antibodie derivative 1 DMY5J23 TI TTOHSBA DMY5J23 TN Vascular endothelial growth factor A (VEGFA) DMY5J23 MA Blocker DMY5J23 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMY5J23 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMY5UB8 DI DMY5UB8 DMY5UB8 DN PMID27967267-Compound-13 DMY5UB8 TI TT1RS9F DMY5UB8 TN Acetylcholinesterase (AChE) DMY5UB8 MA Inhibitor DMY5UB8 RN Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015).Expert Opin Ther Pat. 2017 Apr;27(4):455-476. DMY5UB8 RU https://www.ncbi.nlm.nih.gov/pubmed/27967267 DMY6JAB DI DMY6JAB DMY6JAB DN PMID26004420-Compound-WO2014085210A DMY6JAB TI TTJ13ST DMY6JAB TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMY6JAB MA Inhibitor DMY6JAB RN Inhibitors of the renal outer medullary potassium channel: a patent review.Expert Opin Ther Pat. 2015;25(9):1035-51. DMY6JAB RU https://www.ncbi.nlm.nih.gov/pubmed/26004420 DMY7Z85 DI DMY7Z85 DMY7Z85 DN PMID25684022-Compound-US20130053382 37(4-6) DMY7Z85 TI TTCZOF2 DMY7Z85 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMY7Z85 MA Inhibitor DMY7Z85 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMY7Z85 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMY8FZA DI DMY8FZA DMY8FZA DN PMID26394986-Compound-54 DMY8FZA TI TTH8FZW DMY8FZA TN Signal transducer and activator of transcription 3 (STAT3) DMY8FZA MA Inhibitor DMY8FZA RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMY8FZA RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMY8NEL DI DMY8NEL DMY8NEL DN Aryl piperazine derivative 14 DMY8NEL TI TTWT5K7 DMY8NEL TN 5-HT 1 receptor (5HT1R) DMY8NEL MA Agonist DMY8NEL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMY8NEL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMY8NEL DI DMY8NEL DMY8NEL DN Aryl piperazine derivative 14 DMY8NEL TI TTSQIFT DMY8NEL TN 5-HT 1A receptor (HTR1A) DMY8NEL MA Agonist DMY8NEL RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMY8NEL RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMY8QIG DI DMY8QIG DMY8QIG DN Piperidine carboxamide derivative 1 DMY8QIG TI TTYLQ8V DMY8QIG TN Prostaglandin E synthase (PTGES) DMY8QIG MA Inhibitor DMY8QIG RN Microsomal prostaglandin E2 synthase-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Sep;27(9):1047-1059. DMY8QIG RU https://www.ncbi.nlm.nih.gov/pubmed/28627961 DMY8U6J DI DMY8U6J DMY8U6J DN US8592455, 3 DMY8U6J TI TTCGOIN DMY8U6J TN PIM-3 protein kinase (PIM3) DMY8U6J MA Inhibitor DMY8U6J RN Kinase inhibitors and methods of their use. US8592455. DMY8U6J RU http://www.freepatentsonline.com/US8592455.html DMY93WG DI DMY93WG DMY93WG DN Benzimidazole derivative 3 DMY93WG TI TTULVH8 DMY93WG TN Tyrosinase (TYR) DMY93WG MA Inhibitor DMY93WG RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMY93WG RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMY9R58 DI DMY9R58 DMY9R58 DN PMID26651364-Compound-111 DMY9R58 TI TTTCRU2 DMY9R58 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMY9R58 MA Antagonist DMY9R58 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMY9R58 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMY9SFE DI DMY9SFE DMY9SFE DN US8609715, A-26 DMY9SFE TI TTXL0GC DMY9SFE TN Enteropeptidase (TMPRSS15) DMY9SFE MA Inhibitor DMY9SFE RN Heteroarylcarboxylic acid ester derivative. US8609715. DMY9SFE RU http://www.freepatentsonline.com/US8609715.html DMY9WHZ DI DMY9WHZ DMY9WHZ DN PMID27841036-Compound-23 DMY9WHZ TI TTEBCY8 DMY9WHZ TN Poly [ADP-ribose] polymerase (PARP) DMY9WHZ MA Inhibitor DMY9WHZ RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMY9WHZ RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMYADJP DI DMYADJP DMYADJP DN Pyrrolidinyl urea derivative 7 DMYADJP TI TTTDVOJ DMYADJP TN Tropomyosin-related kinase A (TrkA) DMYADJP MA Inhibitor DMYADJP RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMYADJP RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMYATB5 DI DMYATB5 DMYATB5 DN PMID29671355-Compound-38a DMYATB5 TI TT6R7JZ DMYATB5 TN Histone deacetylase 1 (HDAC1) DMYATB5 MA Inhibitor DMYATB5 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMYATB5 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMYATB5 DI DMYATB5 DMYATB5 DN PMID29671355-Compound-38a DMYATB5 TI TT5ZKDI DMYATB5 TN Histone deacetylase 6 (HDAC6) DMYATB5 MA Inhibitor DMYATB5 RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMYATB5 RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMYAUVM DI DMYAUVM DMYAUVM DN Tricyclic indole compound 8 DMYAUVM TI TTPTXIN DMYAUVM TN Translocator protein (TSPO) DMYAUVM MA Ligand DMYAUVM RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMYAUVM RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMYCABN DI DMYCABN DMYCABN DN PMID25726713-Compound-35 DMYCABN TI TT8J1S3 DMYCABN TN Smoothened homolog (SMO) DMYCABN MA Inhibitor DMYCABN RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMYCABN RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMYCH0G DI DMYCH0G DMYCH0G DN ZINC584606052 DMYCH0G TI TT6A59G DMYCH0G TN Phosphodiesterase 4C (PDE4C) DMYCH0G MA Inhibitor DMYCH0G RN Imidazopyridazine compounds. US9598421. DMYCH0G RU http://www.freepatentsonline.com/US9598421.html DMYCLAM DI DMYCLAM DMYCLAM DN Imidazopyridine and triazolopyridine compound 2 DMYCLAM TI TTHS256 DMYCLAM TN Metabotropic glutamate receptor 5 (mGluR5) DMYCLAM MA Modulator DMYCLAM RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMYCLAM RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMYCQR4 DI DMYCQR4 DMYCQR4 DN PMID27599163-Compound-75 DMYCQR4 TI TTPTXIN DMYCQR4 TN Translocator protein (TSPO) DMYCQR4 MA Ligand DMYCQR4 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMYCQR4 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMYCT5B DI DMYCT5B DMYCT5B DN PMID25666693-Compound-104 DMYCT5B TI TTMI6F5 DMYCT5B TN Transient receptor potential cation channel V1 (TRPV1) DMYCT5B MA Antagonist DMYCT5B RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMYCT5B RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMYCVWZ DI DMYCVWZ DMYCVWZ DN PMID28394193-Compound-24 DMYCVWZ TI TT9MZCQ DMYCVWZ TN Enhancer of zeste homolog 2 (EZH2) DMYCVWZ MA Inhibitor DMYCVWZ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMYCVWZ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMYD5SQ DI DMYD5SQ DMYD5SQ DN Purine derivative 4 DMYD5SQ TI TTMBO1Z DMYD5SQ TN Cyclin-dependent kinase (CDK) DMYD5SQ MA Inhibitor DMYD5SQ RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMYD5SQ RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMYE1A7 DI DMYE1A7 DMYE1A7 DN Aminopyridine derivative 1 DMYE1A7 TI TTBYWP2 DMYE1A7 TN TYK2 tyrosine kinase (TYK2) DMYE1A7 MA Inhibitor DMYE1A7 RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMYE1A7 RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMYEDJI DI DMYEDJI DMYEDJI DN Tricyclic 5-quinolone derivative 1 DMYEDJI TI TTRZQE3 DMYEDJI TN Glycogen synthase kinase-3 alpha (GSK-3A) DMYEDJI MA Inhibitor DMYEDJI RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMYEDJI RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMYEFW1 DI DMYEFW1 DMYEFW1 DN Pyrazole derivative 28 DMYEFW1 TI TT6OEDT DMYEFW1 TN Cannabinoid receptor 1 (CB1) DMYEFW1 MA Antagonist DMYEFW1 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMYEFW1 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMYEJV0 DI DMYEJV0 DMYEJV0 DN Peptide analog 30 DMYEJV0 TI TTSJMN8 DMYEJV0 TN Immunoproteasome complex (IP) DMYEJV0 MA Inhibitor DMYEJV0 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMYEJV0 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMYF39U DI DMYF39U DMYF39U DN Epoxysuccinate derivative 10 DMYF39U TI TTG5QB7 DMYF39U TN Calpain-2 (CAPN2) DMYF39U MA Inhibitor DMYF39U RN An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31. DMYF39U RU https://www.ncbi.nlm.nih.gov/pubmed/25399719 DMYFK85 DI DMYFK85 DMYFK85 DN Six-membered heterocyclic benzamide derivative 1 DMYFK85 TI TTTDVOJ DMYFK85 TN Tropomyosin-related kinase A (TrkA) DMYFK85 MA Inhibitor DMYFK85 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMYFK85 RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMYFKP2 DI DMYFKP2 DMYFKP2 DN Monoamine derivative 4 DMYFKP2 TI TTULVH8 DMYFKP2 TN Tyrosinase (TYR) DMYFKP2 MA Inhibitor DMYFKP2 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMYFKP2 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMYFKR2 DI DMYFKR2 DMYFKR2 DN Isoflavone derivative 3 DMYFKR2 TI TTJOMH6 DMYFKR2 TN Zinc finger protein GLI1 (Gli1) DMYFKR2 MA Inhibitor DMYFKR2 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMYFKR2 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMYFKR2 DI DMYFKR2 DMYFKR2 DN Isoflavone derivative 3 DMYFKR2 TI TT8J1S3 DMYFKR2 TN Smoothened homolog (SMO) DMYFKR2 MA Inhibitor DMYFKR2 RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMYFKR2 RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMYFLT1 DI DMYFLT1 DMYFLT1 DN PMID30185082-Compound-27 DMYFLT1 TI TT9NXW4 DMYFLT1 TN Sigma intracellular receptor 2 (TMEM97) DMYFLT1 MA Ligand DMYFLT1 RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMYFLT1 RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMYFP95 DI DMYFP95 DMYFP95 DN Pyrrolidinyl urea derivative 2 DMYFP95 TI TTTDVOJ DMYFP95 TN Tropomyosin-related kinase A (TrkA) DMYFP95 MA Inhibitor DMYFP95 RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.Expert Opin Ther Pat. 2017 Jun;27(6):733-751. DMYFP95 RU https://www.ncbi.nlm.nih.gov/pubmed/28270010 DMYFSAD DI DMYFSAD DMYFSAD DN PMID30107136-Compound-Example46 DMYFSAD TI TT23XQV DMYFSAD TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMYFSAD MA Inhibitor DMYFSAD RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMYFSAD RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMYFUM6 DI DMYFUM6 DMYFUM6 DN Peptide analog 2 DMYFUM6 TI TT23XQV DMYFUM6 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMYFUM6 MA Inhibitor DMYFUM6 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMYFUM6 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMYFV3D DI DMYFV3D DMYFV3D DN PMID27977313-Compound-8 DMYFV3D TI TTR7UJ3 DMYFV3D TN Cytoplasmic thioredoxin reductase (TXNRD1) DMYFV3D MA Inhibitor DMYFV3D RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMYFV3D RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMYGB2O DI DMYGB2O DMYGB2O DN PMID25553724-Compound-US20130237529 35 DMYGB2O TI TTBP3XA DMYGB2O TN Polyubiquitin-C (UBC) DMYGB2O MA Inhibitor DMYGB2O RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMYGB2O RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMYGFTI DI DMYGFTI DMYGFTI DN Macrocycle derivative 3 DMYGFTI TI TT23XQV DMYGFTI TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMYGFTI MA Inhibitor DMYGFTI RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMYGFTI RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMYGFTI DI DMYGFTI DMYGFTI DN Macrocycle derivative 3 DMYGFTI TI TT5YPJF DMYGFTI TN CD80-PD-L1 interaction (CD80/PD-L1 PPI) DMYGFTI MA Inhibitor DMYGFTI RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMYGFTI RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMYGTU2 DI DMYGTU2 DMYGTU2 DN PMID25399762-Compound-Table 6-11 DMYGTU2 TI TTNR0UQ DMYGTU2 TN Lysine-specific histone demethylase 1 (LSD) DMYGTU2 MA Inhibitor DMYGTU2 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMYGTU2 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMYGTU2 DI DMYGTU2 DMYGTU2 DN PMID25399762-Compound-Table 6-11 DMYGTU2 TI TTGP7BY DMYGTU2 TN Monoamine oxidase type B (MAO-B) DMYGTU2 MA Inhibitor DMYGTU2 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMYGTU2 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMYH429 DI DMYH429 DMYH429 DN PMID25666693-Compound-76 DMYH429 TI TTMI6F5 DMYH429 TN Transient receptor potential cation channel V1 (TRPV1) DMYH429 MA Antagonist DMYH429 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMYH429 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMYH4AZ DI DMYH4AZ DMYH4AZ DN Piperazinyl methyl quinazolinone derivative 3 DMYH4AZ TI TT9NXW4 DMYH4AZ TN Sigma intracellular receptor 2 (TMEM97) DMYH4AZ MA Ligand DMYH4AZ RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMYH4AZ RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMYH4D1 DI DMYH4D1 DMYH4D1 DN Aromatic hydrazine carboxyimidoamide derivative 2 DMYH4D1 TI TTULVH8 DMYH4D1 TN Tyrosinase (TYR) DMYH4D1 MA Inhibitor DMYH4D1 RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMYH4D1 RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMYHQ0S DI DMYHQ0S DMYHQ0S DN PMID30107136-Compound-Example15 DMYHQ0S TI TTNBFWK DMYHQ0S TN Programmed cell death protein 1 (PD-1) DMYHQ0S MA Inhibitor DMYHQ0S RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMYHQ0S RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMYHRJD DI DMYHRJD DMYHRJD DN Aminocyclopentenone compound 1 DMYHRJD TI TTRA6BO DMYHRJD TN Bromodomain-containing protein 4 (BRD4) DMYHRJD MA Inhibitor DMYHRJD RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMYHRJD RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMYI1SX DI DMYI1SX DMYI1SX DN PMID26815044-Compound-50 DMYI1SX TI TTULVH8 DMYI1SX TN Tyrosinase (TYR) DMYI1SX MA Inhibitor DMYI1SX RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMYI1SX RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMYJ0I8 DI DMYJ0I8 DMYJ0I8 DN PMID25399762-Compound-Figure2-Spirooliganone B DMYJ0I8 TI TT3WG5C DMYJ0I8 TN Monoamine oxidase type A (MAO-A) DMYJ0I8 MA Inhibitor DMYJ0I8 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMYJ0I8 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMYJ15A DI DMYJ15A DMYJ15A DN Golden phosphorous acetyletic compound 2 DMYJ15A TI TTEP6RV DMYJ15A TN Glutathione reductase (GR) DMYJ15A MA Inhibitor DMYJ15A RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMYJ15A RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMYJ15A DI DMYJ15A DMYJ15A DN Golden phosphorous acetyletic compound 2 DMYJ15A TI TTR7UJ3 DMYJ15A TN Cytoplasmic thioredoxin reductase (TXNRD1) DMYJ15A MA Inhibitor DMYJ15A RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMYJ15A RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMYJF70 DI DMYJF70 DMYJF70 DN BDBM50158755 DMYJF70 TI TTIG67W DMYJF70 TN Lysine-specific demethylase 5A (KDM5A) DMYJF70 MA Inhibitor DMYJF70 RN Histone demethylase inhibitors. US10173996. DMYJF70 RU http://www.freepatentsonline.com/US10173996.html DMYJL2Z DI DMYJL2Z DMYJL2Z DN Spiroquinolone derivative 1 DMYJL2Z TI TTRZQE3 DMYJL2Z TN Glycogen synthase kinase-3 alpha (GSK-3A) DMYJL2Z MA Inhibitor DMYJL2Z RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMYJL2Z RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMYJOTP DI DMYJOTP DMYJOTP DN Peptide analog 39 DMYJOTP TI TT68GPI DMYJOTP TN Proteasome beta-5 (PS beta-5) DMYJOTP MA Inhibitor DMYJOTP RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMYJOTP RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMYJOTP DI DMYJOTP DMYJOTP DN Peptide analog 39 DMYJOTP TI TT49BVC DMYJOTP TN Proteasome beta-2 (PS beta-2) DMYJOTP MA Inhibitor DMYJOTP RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMYJOTP RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMYJOTP DI DMYJOTP DMYJOTP DN Peptide analog 39 DMYJOTP TI TT8EPLT DMYJOTP TN Proteasome beta-1 (PS beta-1) DMYJOTP MA Inhibitor DMYJOTP RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMYJOTP RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMYKHQ8 DI DMYKHQ8 DMYKHQ8 DN Pyrimidinyl compound 1 DMYKHQ8 TI TTH5TC2 DMYKHQ8 TN NF-kappa-B-activating kinase (TBK1) DMYKHQ8 MA Inhibitor DMYKHQ8 RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMYKHQ8 RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMYKOAM DI DMYKOAM DMYKOAM DN Peptide analog 10 DMYKOAM TI TTSJMN8 DMYKOAM TN Immunoproteasome complex (IP) DMYKOAM MA Inhibitor DMYKOAM RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMYKOAM RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMYKPHX DI DMYKPHX DMYKPHX DN PMID26666989-Compound-Figure9middle06 DMYKPHX TI TT8BUGW DMYKPHX TN Glycogen phosphorylase (PYG) DMYKPHX MA Inhibitor DMYKPHX RN Glycogen phosphorylase inhibitors: a patent review (2013 - 2015).Expert Opin Ther Pat. 2016;26(2):199-212. DMYKPHX RU https://www.ncbi.nlm.nih.gov/pubmed/26666989 DMYKU0T DI DMYKU0T DMYKU0T DN Pyrazole derivative 7 DMYKU0T TI TT6OEDT DMYKU0T TN Cannabinoid receptor 1 (CB1) DMYKU0T MA Antagonist DMYKU0T RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMYKU0T RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMYLQZ1 DI DMYLQZ1 DMYLQZ1 DN 2,2-bipyridyl derivative 2 DMYLQZ1 TI TT0RGE9 DMYLQZ1 TN Lysine-specific demethylase 4 (KDM4) DMYLQZ1 MA Inhibitor DMYLQZ1 RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMYLQZ1 RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMYLR2S DI DMYLR2S DMYLR2S DN Isoxazole-based bicyclic compound 2 DMYLR2S TI TTE4BSY DMYLR2S TN Bromodomain and extraterminal domain protein (BET) DMYLR2S MA Inhibitor DMYLR2S RN BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22. DMYLR2S RU https://www.ncbi.nlm.nih.gov/pubmed/26924192 DMYLVB3 DI DMYLVB3 DMYLVB3 DN Biaryl mannoside derivative 22 DMYLVB3 TI TTTCRU2 DMYLVB3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMYLVB3 MA Antagonist DMYLVB3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMYLVB3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMYLVTQ DI DMYLVTQ DMYLVTQ DN PMID28394193-Compound-41 DMYLVTQ TI TT9MZCQ DMYLVTQ TN Enhancer of zeste homolog 2 (EZH2) DMYLVTQ MA Inhibitor DMYLVTQ RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMYLVTQ RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMYM60P DI DMYM60P DMYM60P DN PMID25726713-Compound-28 DMYM60P TI TT8J1S3 DMYM60P TN Smoothened homolog (SMO) DMYM60P MA Inhibitor DMYM60P RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMYM60P RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMYMJIW DI DMYMJIW DMYMJIW DN PMID25522065-Compound-33 DMYMJIW TI TTX4RTB DMYMJIW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMYMJIW MA Antagonist DMYMJIW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMYMJIW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMYMJV3 DI DMYMJV3 DMYMJV3 DN Peptide analog 3 DMYMJV3 TI TT23XQV DMYMJV3 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMYMJV3 MA Inhibitor DMYMJV3 RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMYMJV3 RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMYMKZC DI DMYMKZC DMYMKZC DN PMID29649907-Compound-28 DMYMKZC TI TTS4UGC DMYMKZC TN Farnesoid X-activated receptor (FXR) DMYMKZC MA Agonist DMYMKZC RN Farnesoid X receptor modulators 2014-present: a patent review.Expert Opin Ther Pat. 2018 May;28(5):351-364. DMYMKZC RU https://www.ncbi.nlm.nih.gov/pubmed/29649907 DMYMPF9 DI DMYMPF9 DMYMPF9 DN Peptide analog 43 DMYMPF9 TI TTSJMN8 DMYMPF9 TN Immunoproteasome complex (IP) DMYMPF9 MA Inhibitor DMYMPF9 RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMYMPF9 RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMYMPNA DI DMYMPNA DMYMPNA DN PMID28394193-Compound-46 DMYMPNA TI TTJW2UQ DMYMPNA TN EZH2 Y641N mutant (EZH2 Y641N) DMYMPNA MA Inhibitor DMYMPNA RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMYMPNA RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMYMPNA DI DMYMPNA DMYMPNA DN PMID28394193-Compound-46 DMYMPNA TI TT9MZCQ DMYMPNA TN Enhancer of zeste homolog 2 (EZH2) DMYMPNA MA Inhibitor DMYMPNA RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMYMPNA RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMYMTSL DI DMYMTSL DMYMTSL DN PMID27215781-Compound-19 DMYMTSL TI TTMSFAW DMYMTSL TN Cannabinoid receptor 2 (CB2) DMYMTSL MA Agonist DMYMTSL RN Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.Expert Opin Ther Pat. 2016 Jul;26(7):843-56. DMYMTSL RU https://www.ncbi.nlm.nih.gov/pubmed/27215781 DMYO7VH DI DMYO7VH DMYO7VH DN PMID25416646-Compound-Figure5-E DMYO7VH TI TTQVOEI DMYO7VH TN Angiotensin II receptor type-2 (AGTR2) DMYO7VH MA Agonist DMYO7VH RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMYO7VH RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMYO7VH DI DMYO7VH DMYO7VH DN PMID25416646-Compound-Figure5-E DMYO7VH TI TTZMAO3 DMYO7VH TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMYO7VH MA Agonist DMYO7VH RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMYO7VH RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMYO9UD DI DMYO9UD DMYO9UD DN PMID25980951-Compound-33 DMYO9UD TI TTR7B60 DMYO9UD TN X-linked inhibitor of apoptosis protein (XIAP) DMYO9UD MA Antagonist DMYO9UD RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMYO9UD RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMYOSIA DI DMYOSIA DMYOSIA DN PMID27774824-Compound-Figure12Example10 DMYOSIA TI TTGM6VW DMYOSIA TN Tyrosine-protein kinase BTK (ATK) DMYOSIA MA Inhibitor DMYOSIA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMYOSIA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMYOSIA DI DMYOSIA DMYOSIA DN PMID27774824-Compound-Figure12Example10 DMYOSIA TI TTT7PJU DMYOSIA TN Janus kinase 3 (JAK-3) DMYOSIA MA Inhibitor DMYOSIA RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMYOSIA RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMYP5FK DI DMYP5FK DMYP5FK DN Cyclopentane carboxamide derivative 2 DMYP5FK TI TTTJZ4M DMYP5FK TN Prolylcarboxypeptidase (PRCP) DMYP5FK MA Inhibitor DMYP5FK RN Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.Expert Opin Ther Pat. 2017 Oct;27(10):1077-1088. DMYP5FK RU https://www.ncbi.nlm.nih.gov/pubmed/28699813 DMYPD4Z DI DMYPD4Z DMYPD4Z DN Aminoazetidine derivative 5 DMYPD4Z TI TT6OEDT DMYPD4Z TN Cannabinoid receptor 1 (CB1) DMYPD4Z MA Antagonist DMYPD4Z RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMYPD4Z RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMYPT2H DI DMYPT2H DMYPT2H DN PMID25980951-Compound-1 DMYPT2H TI TTR7B60 DMYPT2H TN X-linked inhibitor of apoptosis protein (XIAP) DMYPT2H MA Antagonist DMYPT2H RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMYPT2H RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMYPT2H DI DMYPT2H DMYPT2H DN PMID25980951-Compound-1 DMYPT2H TI TTIRY6K DMYPT2H TN Cellular inhibitor of apoptosis 2 (BIRC3) DMYPT2H MA Antagonist DMYPT2H RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMYPT2H RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMYPT2H DI DMYPT2H DMYPT2H DN PMID25980951-Compound-1 DMYPT2H TI TTQ5LRD DMYPT2H TN Cellular inhibitor of apoptosis 1 (BIRC2) DMYPT2H MA Antagonist DMYPT2H RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMYPT2H RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMYPT63 DI DMYPT63 DMYPT63 DN PMID25726713-Compound-36 DMYPT63 TI TT8J1S3 DMYPT63 TN Smoothened homolog (SMO) DMYPT63 MA Inhibitor DMYPT63 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMYPT63 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMYQHER DI DMYQHER DMYQHER DN Diterpene triepoxide derivative 1 DMYQHER TI TTLPJWH DMYQHER TN Thioredoxin reductase (PRDX5) DMYQHER RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMYQHER RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMYQTLK DI DMYQTLK DMYQTLK DN Mycophenolic acid/nucleotide derivative 9 DMYQTLK TI TTL7C8Q DMYQTLK TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMYQTLK MA Inhibitor DMYQTLK RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMYQTLK RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMYR10P DI DMYR10P DMYR10P DN US8470836, 5 DMYR10P TI TTOYT5L DMYR10P TN Dipeptidyl-peptidase 7 (DPP7) DMYR10P MA Inhibitor DMYR10P RN Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent. US8470836. DMYR10P RU http://www.freepatentsonline.com/US8470836.html DMYRG0Q DI DMYRG0Q DMYRG0Q DN PMID27109571-Compound-4 DMYRG0Q TI TTMY6L1 DMYRG0Q TN Fatty acid-binding protein (FABP) DMYRG0Q MA Inhibitor DMYRG0Q RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMYRG0Q RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMYRU7I DI DMYRU7I DMYRU7I DN Isoflavone derivative 4 DMYRU7I TI TTJOMH6 DMYRU7I TN Zinc finger protein GLI1 (Gli1) DMYRU7I MA Inhibitor DMYRU7I RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMYRU7I RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMYRU7I DI DMYRU7I DMYRU7I DN Isoflavone derivative 4 DMYRU7I TI TT8J1S3 DMYRU7I TN Smoothened homolog (SMO) DMYRU7I MA Inhibitor DMYRU7I RN Evaluation of WO2014207069 A1: Multitarget Hedgehog pathway inhibitors and uses thereof.Expert Opin Ther Pat. 2016;26(4):529-35. DMYRU7I RU https://www.ncbi.nlm.nih.gov/pubmed/26666870 DMYRV8I DI DMYRV8I DMYRV8I DN PMID27019002-Compound-20b DMYRV8I TI TTNR0UQ DMYRV8I TN Lysine-specific histone demethylase 1 (LSD) DMYRV8I MA Inhibitor DMYRV8I RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMYRV8I RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMYSH9J DI DMYSH9J DMYSH9J DN Benzamide derivative 13 DMYSH9J TI TT473XN DMYSH9J TN P2X purinoceptor 7 (P2RX7) DMYSH9J MA Antagonist DMYSH9J RN P2X7 receptor antagonists: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Mar;27(3):257-267. DMYSH9J RU https://www.ncbi.nlm.nih.gov/pubmed/27724045 DMYSI9J DI DMYSI9J DMYSI9J DN US10149841, Compound 19 DMYSI9J TI TT9ISBX DMYSI9J TN HIF-prolyl hydroxylase 2 (HPH-2) DMYSI9J MA Inhibitor DMYSI9J RN Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof. US10149841. DMYSI9J RU http://www.freepatentsonline.com/US10149841.html DMYSRPT DI DMYSRPT DMYSRPT DN Carbamate derivative 17 DMYSRPT TI TTDP1UC DMYSRPT TN Fatty acid amide hydrolase (FAAH) DMYSRPT MA Inhibitor DMYSRPT RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMYSRPT RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMYSRPT DI DMYSRPT DMYSRPT DN Carbamate derivative 17 DMYSRPT TI TTZ963I DMYSRPT TN Monoglyceride lipase (MAGL) DMYSRPT MA Inhibitor DMYSRPT RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMYSRPT RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMYSWG1 DI DMYSWG1 DMYSWG1 DN Carbamide derivative 20 DMYSWG1 TI TTOHSBA DMYSWG1 TN Vascular endothelial growth factor A (VEGFA) DMYSWG1 MA Inhibitor DMYSWG1 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMYSWG1 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMYT1QN DI DMYT1QN DMYT1QN DN Pyridine derivative 7 DMYT1QN TI TTOHSBA DMYT1QN TN Vascular endothelial growth factor A (VEGFA) DMYT1QN MA Inhibitor DMYT1QN RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMYT1QN RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMYTEAC DI DMYTEAC DMYTEAC DN PMID25399762-Compound-Table1-C16 DMYTEAC TI TTGP7BY DMYTEAC TN Monoamine oxidase type B (MAO-B) DMYTEAC MA Inhibitor DMYTEAC RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMYTEAC RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMYTLRJ DI DMYTLRJ DMYTLRJ DN Pyrazole derivative 65 DMYTLRJ TI TTH8FZW DMYTLRJ TN Signal transducer and activator of transcription 3 (STAT3) DMYTLRJ MA Inhibitor DMYTLRJ RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMYTLRJ RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMYTV49 DI DMYTV49 DMYTV49 DN Pyrrolo[2,3-d]pyrimidine derivative 12 DMYTV49 TI TTGM6VW DMYTV49 TN Tyrosine-protein kinase BTK (ATK) DMYTV49 MA Inhibitor DMYTV49 RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMYTV49 RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMYTZFP DI DMYTZFP DMYTZFP DN PMID25666693-Compound-100 DMYTZFP TI TTMI6F5 DMYTZFP TN Transient receptor potential cation channel V1 (TRPV1) DMYTZFP MA Antagonist DMYTZFP RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMYTZFP RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMYUDCE DI DMYUDCE DMYUDCE DN US9266828, B DMYUDCE TI TTH9WF6 DMYUDCE TN Dibasic-processing enzyme (Furin) DMYUDCE MA Inhibitor DMYUDCE RN Inhibitors of Furin and other pro-protein convertases. US9266828. DMYUDCE RU http://www.freepatentsonline.com/US9266828.html DMYUEA6 DI DMYUEA6 DMYUEA6 DN Pyrrolo[2,3-d]pyrimidine derivative 1 DMYUEA6 TI TTIXKA4 DMYUEA6 TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMYUEA6 MA Inhibitor DMYUEA6 RN Ribosomal S6 kinase (RSK) modulators: a patent review.Expert Opin Ther Pat. 2016 Sep;26(9):1061-78. DMYUEA6 RU https://www.ncbi.nlm.nih.gov/pubmed/27410995 DMYUL2X DI DMYUL2X DMYUL2X DN US9266828, E DMYUL2X TI TTH9WF6 DMYUL2X TN Dibasic-processing enzyme (Furin) DMYUL2X MA Inhibitor DMYUL2X RN Inhibitors of Furin and other pro-protein convertases. US9266828. DMYUL2X RU http://www.freepatentsonline.com/US9266828.html DMYUP6G DI DMYUP6G DMYUP6G DN PMID27336223-Compound-10 DMYUP6G TI TTISP28 DMYUP6G TN Retinoic acid receptor beta (RARB) DMYUP6G MA Agonist DMYUP6G RN Therapeutic use of selective synthetic ligands for retinoic acid receptors: a patent review.Expert Opin Ther Pat. 2016 Aug;26(8):957-71. DMYUP6G RU https://www.ncbi.nlm.nih.gov/pubmed/27336223 DMYVCTD DI DMYVCTD DMYVCTD DN Pyridotriazolopyrimidine derivative 3 DMYVCTD TI TT6OEDT DMYVCTD TN Cannabinoid receptor 1 (CB1) DMYVCTD MA Antagonist DMYVCTD RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMYVCTD RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMYVU36 DI DMYVU36 DMYVU36 DN PMID26651364-Compound-8b DMYVU36 TI TTTCRU2 DMYVU36 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMYVU36 MA Antagonist DMYVU36 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMYVU36 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMYWBRX DI DMYWBRX DMYWBRX DN PMID28870136-Compound-47 DMYWBRX TI TTK0O6Y DMYWBRX TN Ecto-5'-nucleotidase (CD73) DMYWBRX MA Inhibitor DMYWBRX RN Ectonucleotidase inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2017 Dec;27(12):1291-1304. DMYWBRX RU https://www.ncbi.nlm.nih.gov/pubmed/28870136 DMYX684 DI DMYX684 DMYX684 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 3 DMYX684 TI TTJW4LU DMYX684 TN Phosphodiesterase 10A (PDE10) DMYX684 MA Inhibitor DMYX684 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMYX684 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMYX684 DI DMYX684 DMYX684 DN Imidazo[5,1-c][1,2,4]benzotriazine derivative 3 DMYX684 TI TTJGW1Z DMYX684 TN Phosphodiesterase 2A (PDE2A) DMYX684 MA Inhibitor DMYX684 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMYX684 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMYXE4J DI DMYXE4J DMYXE4J DN PMID29671355-Compound-38b DMYXE4J TI TT6R7JZ DMYXE4J TN Histone deacetylase 1 (HDAC1) DMYXE4J MA Inhibitor DMYXE4J RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMYXE4J RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMYXE4J DI DMYXE4J DMYXE4J DN PMID29671355-Compound-38b DMYXE4J TI TT5ZKDI DMYXE4J TN Histone deacetylase 6 (HDAC6) DMYXE4J MA Inhibitor DMYXE4J RN HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17. DMYXE4J RU https://www.ncbi.nlm.nih.gov/pubmed/29671355 DMYXIS7 DI DMYXIS7 DMYXIS7 DN PMID26077642-Compound-Vif2 DMYXIS7 TI TTXU3EQ DMYXIS7 TN Herpesvirus ubiquitin-specific protease (HAUSP) DMYXIS7 MA Inhibitor DMYXIS7 RN Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208. DMYXIS7 RU https://www.ncbi.nlm.nih.gov/pubmed/26077642 DMYXK7I DI DMYXK7I DMYXK7I DN PMID25726713-Compound-61 DMYXK7I TI TT8J1S3 DMYXK7I TN Smoothened homolog (SMO) DMYXK7I MA Inhibitor DMYXK7I RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMYXK7I RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMYXKQ3 DI DMYXKQ3 DMYXKQ3 DN Pyrazino[2,1-a]isoquinolin derivative 2 DMYXKQ3 TI TTA6ZN2 DMYXKQ3 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMYXKQ3 MA Activator DMYXKQ3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMYXKQ3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMYXKQ3 DI DMYXKQ3 DMYXKQ3 DN Pyrazino[2,1-a]isoquinolin derivative 2 DMYXKQ3 TI TT3Z6Y9 DMYXKQ3 TN Cysteines of Keap1 (KEAP1 Cysteines) DMYXKQ3 MA Modulator DMYXKQ3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMYXKQ3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMYXLCJ DI DMYXLCJ DMYXLCJ DN Biaryl mannoside derivative 26 DMYXLCJ TI TTTCRU2 DMYXLCJ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMYXLCJ MA Antagonist DMYXLCJ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMYXLCJ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMYXQU3 DI DMYXQU3 DMYXQU3 DN PMID28454500-Compound-33 DMYXQU3 TI TTA6ZN2 DMYXQU3 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMYXQU3 MA Activator DMYXQU3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMYXQU3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMYXQU3 DI DMYXQU3 DMYXQU3 DN PMID28454500-Compound-33 DMYXQU3 TI TT3Z6Y9 DMYXQU3 TN Cysteines of Keap1 (KEAP1 Cysteines) DMYXQU3 MA Modulator DMYXQU3 RN Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. DMYXQU3 RU https://www.ncbi.nlm.nih.gov/pubmed/28454500 DMYZ2UA DI DMYZ2UA DMYZ2UA DN PMID25470667-Compound-K-604 DMYZ2UA TI TTK3C21 DMYZ2UA TN Acetoacetyl-CoA thiolase (ACAT1) DMYZ2UA MA Inhibitor DMYZ2UA RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMYZ2UA RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMYZ42W DI DMYZ42W DMYZ42W DN PMID27109571-Compound-43 DMYZ42W TI TTMY6L1 DMYZ42W TN Fatty acid-binding protein (FABP) DMYZ42W MA Inhibitor DMYZ42W RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMYZ42W RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMYZ6XQ DI DMYZ6XQ DMYZ6XQ DN PMID27774824-Compound-Figure3Example18 DMYZ6XQ TI TTT7PJU DMYZ6XQ TN Janus kinase 3 (JAK-3) DMYZ6XQ MA Inhibitor DMYZ6XQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMYZ6XQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMYZ6XQ DI DMYZ6XQ DMYZ6XQ DN PMID27774824-Compound-Figure3Example18 DMYZ6XQ TI TT6DM01 DMYZ6XQ TN Janus kinase 1 (JAK-1) DMYZ6XQ MA Inhibitor DMYZ6XQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMYZ6XQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMYZ6XQ DI DMYZ6XQ DMYZ6XQ DN PMID27774824-Compound-Figure3Example18 DMYZ6XQ TI TTRMX3V DMYZ6XQ TN Janus kinase 2 (JAK-2) DMYZ6XQ MA Inhibitor DMYZ6XQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMYZ6XQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMYZ6XQ DI DMYZ6XQ DMYZ6XQ DN PMID27774824-Compound-Figure3Example18 DMYZ6XQ TI TTBYWP2 DMYZ6XQ TN TYK2 tyrosine kinase (TYK2) DMYZ6XQ MA Inhibitor DMYZ6XQ RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMYZ6XQ RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMYZMX6 DI DMYZMX6 DMYZMX6 DN PMID25522065-Compound-7 DMYZMX6 TI TTX4RTB DMYZMX6 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMYZMX6 MA Antagonist DMYZMX6 RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMYZMX6 RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMYZVPD DI DMYZVPD DMYZVPD DN PMID25666693-Compound-135 DMYZVPD TI TTMI6F5 DMYZVPD TN Transient receptor potential cation channel V1 (TRPV1) DMYZVPD MA Antagonist DMYZVPD RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMYZVPD RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMZ02LA DI DMZ02LA DMZ02LA DN PMID27539678-Compound-14 DMZ02LA TI TTOHFIY DMZ02LA TN Sphingosine kinase 1 (SPHK1) DMZ02LA MA Inhibitor DMZ02LA RN Sphingosine kinase inhibitors: a review of patent literature (2006-2015).Expert Opin Ther Pat. 2016 Dec;26(12):1409-1416. DMZ02LA RU https://www.ncbi.nlm.nih.gov/pubmed/27539678 DMZ07RP DI DMZ07RP DMZ07RP DN PMID25399762-Compound-Table 6-12 DMZ07RP TI TTNR0UQ DMZ07RP TN Lysine-specific histone demethylase 1 (LSD) DMZ07RP MA Inhibitor DMZ07RP RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMZ07RP RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMZ07RP DI DMZ07RP DMZ07RP DN PMID25399762-Compound-Table 6-12 DMZ07RP TI TTGP7BY DMZ07RP TN Monoamine oxidase type B (MAO-B) DMZ07RP MA Inhibitor DMZ07RP RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMZ07RP RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMZ08LD DI DMZ08LD DMZ08LD DN Imidazopyridine acetamide analog 3 DMZ08LD TI TTPTXIN DMZ08LD TN Translocator protein (TSPO) DMZ08LD MA Ligand DMZ08LD RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMZ08LD RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMZ12V4 DI DMZ12V4 DMZ12V4 DN PMID26882240-Compound-15 DMZ12V4 TI TTUX68I DMZ12V4 TN Hypoxia-inducible factor 1 (HIF-1) DMZ12V4 MA Inhibitor DMZ12V4 RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMZ12V4 RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMZ1RMA DI DMZ1RMA DMZ1RMA DN US9156852, 105 DMZ1RMA TI TTU98HG DMZ1RMA TN Discoidin domain-containing receptor 2 (DDR2) DMZ1RMA MA Inhibitor DMZ1RMA RN Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases. US9156852. DMZ1RMA RU http://www.freepatentsonline.com/US9156852.html DMZ2ECB DI DMZ2ECB DMZ2ECB DN US8524917, 12 DMZ2ECB TI TTDYP7I DMZ2ECB TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMZ2ECB MA Inhibitor DMZ2ECB RN S1P3 receptor inhibitors for treating pain. US8563594. DMZ2ECB RU http://www.freepatentsonline.com/US8563594.html DMZ2HBL DI DMZ2HBL DMZ2HBL DN Pyrrolidine derivative 4 DMZ2HBL TI TTHS256 DMZ2HBL TN Metabotropic glutamate receptor 5 (mGluR5) DMZ2HBL RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMZ2HBL RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMZ2RV3 DI DMZ2RV3 DMZ2RV3 DN Aryl mannoside derivative 20 DMZ2RV3 TI TTTCRU2 DMZ2RV3 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZ2RV3 MA Antagonist DMZ2RV3 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZ2RV3 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZ2TB5 DI DMZ2TB5 DMZ2TB5 DN Quinoline and quinazoline derivative 6 DMZ2TB5 TI TTOHSBA DMZ2TB5 TN Vascular endothelial growth factor A (VEGFA) DMZ2TB5 MA Inhibitor DMZ2TB5 RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMZ2TB5 RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMZ37XI DI DMZ37XI DMZ37XI DN Carbamide derivative 18 DMZ37XI TI TTOHSBA DMZ37XI TN Vascular endothelial growth factor A (VEGFA) DMZ37XI MA Inhibitor DMZ37XI RN VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004. DMZ37XI RU https://www.ncbi.nlm.nih.gov/pubmed/28621580 DMZ3DS5 DI DMZ3DS5 DMZ3DS5 DN Aryl piperazine derivative 6 DMZ3DS5 TI TT4C8EA DMZ3DS5 TN Dopamine D3 receptor (D3R) DMZ3DS5 MA Ligand DMZ3DS5 RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMZ3DS5 RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMZ3DS5 DI DMZ3DS5 DMZ3DS5 DN Aryl piperazine derivative 6 DMZ3DS5 TI TTEX248 DMZ3DS5 TN Dopamine D2 receptor (D2R) DMZ3DS5 MA Ligand DMZ3DS5 RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMZ3DS5 RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMZ3DS5 DI DMZ3DS5 DMZ3DS5 DN Aryl piperazine derivative 6 DMZ3DS5 TI TTSQIFT DMZ3DS5 TN 5-HT 1A receptor (HTR1A) DMZ3DS5 MA Ligand DMZ3DS5 RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMZ3DS5 RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMZ3DS5 DI DMZ3DS5 DMZ3DS5 DN Aryl piperazine derivative 6 DMZ3DS5 TI TTJQOD7 DMZ3DS5 TN 5-HT 2A receptor (HTR2A) DMZ3DS5 MA Ligand DMZ3DS5 RN 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689. DMZ3DS5 RU https://www.ncbi.nlm.nih.gov/pubmed/30124346 DMZ3EHV DI DMZ3EHV DMZ3EHV DN PMID29338548-Compound-20 DMZ3EHV TI TTHJTF7 DMZ3EHV TN Glycine transporter GlyT-1 (SLC6A9) DMZ3EHV MA Inhibitor DMZ3EHV RN Glycine transporter-1 inhibitors: a patent review (2011-2016).Expert Opin Ther Pat. 2018 Mar;28(3):197-210. DMZ3EHV RU https://www.ncbi.nlm.nih.gov/pubmed/29338548 DMZ3FJO DI DMZ3FJO DMZ3FJO DN Carbamide derivative 8 DMZ3FJO TI TTL7C8Q DMZ3FJO TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMZ3FJO MA Inhibitor DMZ3FJO RN Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. DMZ3FJO RU https://www.ncbi.nlm.nih.gov/pubmed/28074661 DMZ3J78 DI DMZ3J78 DMZ3J78 DN Pyrazole derivative 57 DMZ3J78 TI TT6OEDT DMZ3J78 TN Cannabinoid receptor 1 (CB1) DMZ3J78 MA Antagonist DMZ3J78 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMZ3J78 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMZ3NSJ DI DMZ3NSJ DMZ3NSJ DN Benzothiazepine analog 2 DMZ3NSJ TI TTPTXIN DMZ3NSJ TN Translocator protein (TSPO) DMZ3NSJ MA Ligand DMZ3NSJ RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMZ3NSJ RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMZ3ORT DI DMZ3ORT DMZ3ORT DN Quinazoline derivative 10 DMZ3ORT TI TTQR74A DMZ3ORT TN Proteinase activated receptor 2 (PAR2) DMZ3ORT MA Antagonist DMZ3ORT RN Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83. DMZ3ORT RU https://www.ncbi.nlm.nih.gov/pubmed/26936077 DMZ43OM DI DMZ43OM DMZ43OM DN PMID26560530-Compound-25 DMZ43OM TI TT2F4OL DMZ43OM TN Tissue transglutaminase (TG2) DMZ43OM MA Inhibitor DMZ43OM RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMZ43OM RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMZ4B3W DI DMZ4B3W DMZ4B3W DN Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 DMZ4B3W TI TTF2LRI DMZ4B3W TN Cathepsin B (CTSB) DMZ4B3W MA Inhibitor DMZ4B3W RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMZ4B3W RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMZ4NJQ DI DMZ4NJQ DMZ4NJQ DN 1,2-diamino cyclopentane-based derivative 30 DMZ4NJQ TI TT9N02I DMZ4NJQ TN Orexin receptor type 2 (HCRTR2) DMZ4NJQ MA Antagonist DMZ4NJQ RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMZ4NJQ RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMZ4NJQ DI DMZ4NJQ DMZ4NJQ DN 1,2-diamino cyclopentane-based derivative 30 DMZ4NJQ TI TT60Q8D DMZ4NJQ TN Orexin receptor type 1 (HCRTR1) DMZ4NJQ MA Antagonist DMZ4NJQ RN Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).Expert Opin Ther Pat. 2016;26(3):409-15. DMZ4NJQ RU https://www.ncbi.nlm.nih.gov/pubmed/26593218 DMZ4PLC DI DMZ4PLC DMZ4PLC DN Pyrrolo[2,3-d]pyrimidine derivative 15 DMZ4PLC TI TTGM6VW DMZ4PLC TN Tyrosine-protein kinase BTK (ATK) DMZ4PLC MA Inhibitor DMZ4PLC RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMZ4PLC RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMZ5CDY DI DMZ5CDY DMZ5CDY DN PMID30259754-Compound-LY2562175 DMZ5CDY TI TTS4UGC DMZ5CDY TN Farnesoid X-activated receptor (FXR) DMZ5CDY MA Agonist DMZ5CDY RN FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782. DMZ5CDY RU https://www.ncbi.nlm.nih.gov/pubmed/30259754 DMZ5GIH DI DMZ5GIH DMZ5GIH DN Quinazolinedione derivative 3 DMZ5GIH TI TTVDSZ0 DMZ5GIH TN Poly [ADP-ribose] polymerase 1 (PARP1) DMZ5GIH MA Inhibitor DMZ5GIH RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMZ5GIH RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMZ5O3K DI DMZ5O3K DMZ5O3K DN PMID30273516-Compound-22b DMZ5O3K TI TTCW0KX DMZ5O3K TN Glutaminase (GLS) DMZ5O3K MA Inhibitor DMZ5O3K RN Glutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):823-835. DMZ5O3K RU https://www.ncbi.nlm.nih.gov/pubmed/30273516 DMZ5QC4 DI DMZ5QC4 DMZ5QC4 DN PMID27599163-Compound-81 DMZ5QC4 TI TTPTXIN DMZ5QC4 TN Translocator protein (TSPO) DMZ5QC4 MA Ligand DMZ5QC4 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMZ5QC4 RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMZ5UST DI DMZ5UST DMZ5UST DN PMID26560530-Compound-11 DMZ5UST TI TT2F4OL DMZ5UST TN Tissue transglutaminase (TG2) DMZ5UST MA Inhibitor DMZ5UST RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMZ5UST RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMZ5WN8 DI DMZ5WN8 DMZ5WN8 DN Cyclopropylamine derivative 10 DMZ5WN8 TI TT32XQJ DMZ5WN8 TN Monoamine oxidase (MAO) DMZ5WN8 MA Inhibitor DMZ5WN8 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMZ5WN8 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMZ5WN8 DI DMZ5WN8 DMZ5WN8 DN Cyclopropylamine derivative 10 DMZ5WN8 TI TTNR0UQ DMZ5WN8 TN Lysine-specific histone demethylase 1 (LSD) DMZ5WN8 MA Inhibitor DMZ5WN8 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMZ5WN8 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMZ61T8 DI DMZ61T8 DMZ61T8 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 DMZ61T8 TI TTJW4LU DMZ61T8 TN Phosphodiesterase 10A (PDE10) DMZ61T8 MA Inhibitor DMZ61T8 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMZ61T8 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMZ61T8 DI DMZ61T8 DMZ61T8 DN Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3 DMZ61T8 TI TTJGW1Z DMZ61T8 TN Phosphodiesterase 2A (PDE2A) DMZ61T8 MA Inhibitor DMZ61T8 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMZ61T8 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMZ6N2J DI DMZ6N2J DMZ6N2J DN PMID27537201-Compound-Figure15b DMZ6N2J TI TTPADOQ DMZ6N2J TN HMG-CoA reductase (HMGCR) DMZ6N2J MA Inhibitor DMZ6N2J RN HMG-CoA Reductase inhibitors: an updated review of patents of novel compounds and formulations (2011-2015).Expert Opin Ther Pat. 2016 Nov;26(11):1257-1272. DMZ6N2J RU https://www.ncbi.nlm.nih.gov/pubmed/27537201 DMZ6TSD DI DMZ6TSD DMZ6TSD DN Pyridopyrimidinone derivative 1 DMZ6TSD TI TTK0FEA DMZ6TSD TN Leucine-rich repeat kinase 2 (LRRK2) DMZ6TSD MA Inhibitor DMZ6TSD RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMZ6TSD RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMZ6YB0 DI DMZ6YB0 DMZ6YB0 DN Thiazole carboxamide derivative 24 DMZ6YB0 TI TTCZOF2 DMZ6YB0 TN Pyruvate dehydrogenase kinase 1 (PDHK1) DMZ6YB0 MA Inhibitor DMZ6YB0 RN PDK1 disruptors and modulators: a patent review.Expert Opin Ther Pat. 2015 May;25(5):513-37. DMZ6YB0 RU https://www.ncbi.nlm.nih.gov/pubmed/25684022 DMZ73D9 DI DMZ73D9 DMZ73D9 DN PMID25726713-Compound-10 DMZ73D9 TI TT8J1S3 DMZ73D9 TN Smoothened homolog (SMO) DMZ73D9 MA Inhibitor DMZ73D9 RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMZ73D9 RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMZ745J DI DMZ745J DMZ745J DN US9586942, 2 DMZ745J TI TTYJRN5 DMZ745J TN N-acetylglucosaminyltransferase I (NAGAT1) DMZ745J MA Inhibitor DMZ745J RN Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy. US9586942. DMZ745J RU http://www.freepatentsonline.com/US9586942.html DMZ7LAO DI DMZ7LAO DMZ7LAO DN PMID25666693-Compound-137 DMZ7LAO TI TTMI6F5 DMZ7LAO TN Transient receptor potential cation channel V1 (TRPV1) DMZ7LAO MA Antagonist DMZ7LAO RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMZ7LAO RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMZ83P1 DI DMZ83P1 DMZ83P1 DN Pyrimidinyl ethylenediamine derivative 1 DMZ83P1 TI TTGX13H DMZ83P1 TN Fatty-acid amide hydrolase 1 (FAAH1) DMZ83P1 MA Inhibitor DMZ83P1 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMZ83P1 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMZ83P1 DI DMZ83P1 DMZ83P1 DN Pyrimidinyl ethylenediamine derivative 1 DMZ83P1 TI TTDP1UC DMZ83P1 TN Fatty acid amide hydrolase (FAAH) DMZ83P1 MA Inhibitor DMZ83P1 RN Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).Expert Opin Ther Pat. 2015;25(11):1247-66. DMZ83P1 RU https://www.ncbi.nlm.nih.gov/pubmed/26413912 DMZ8BJX DI DMZ8BJX DMZ8BJX DN PMID29865878-Compound-50 DMZ8BJX TI TTSJMN8 DMZ8BJX TN Immunoproteasome complex (IP) DMZ8BJX MA Inhibitor DMZ8BJX RN A patent review of immunoproteasome inhibitors.Expert Opin Ther Pat. 2018 Jul;28(7):517-540. DMZ8BJX RU https://www.ncbi.nlm.nih.gov/pubmed/29865878 DMZ8S6X DI DMZ8S6X DMZ8S6X DN Curcumin analog 2 DMZ8S6X TI TTRMX3V DMZ8S6X TN Janus kinase 2 (JAK-2) DMZ8S6X MA Inhibitor DMZ8S6X RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMZ8S6X RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMZ8S6X DI DMZ8S6X DMZ8S6X DN Curcumin analog 2 DMZ8S6X TI TTH8FZW DMZ8S6X TN Signal transducer and activator of transcription 3 (STAT3) DMZ8S6X MA Inhibitor DMZ8S6X RN A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. DMZ8S6X RU https://www.ncbi.nlm.nih.gov/pubmed/26394986 DMZ96CG DI DMZ96CG DMZ96CG DN PMID25553724-Compound-US2011801300410 DMZ96CG TI TTSXVID DMZ96CG TN Nuclear factor NF-kappa-B (NFKB) DMZ96CG MA Inhibitor DMZ96CG RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMZ96CG RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMZ9BTN DI DMZ9BTN DMZ9BTN DN PMID25991433-Compound-H2 DMZ9BTN TI TT0K6EO DMZ9BTN TN Stress-activated protein kinase JNK1 (JNK1) DMZ9BTN MA Inhibitor DMZ9BTN RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMZ9BTN RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMZ9LSY DI DMZ9LSY DMZ9LSY DN PMID25980951-Compound-11 DMZ9LSY TI TTR7B60 DMZ9LSY TN X-linked inhibitor of apoptosis protein (XIAP) DMZ9LSY MA Antagonist DMZ9LSY RN Small molecule inhibitor of apoptosis proteins antagonists: a patent review.Expert Opin Ther Pat. 2015 Jul;25(7):755-74. DMZ9LSY RU https://www.ncbi.nlm.nih.gov/pubmed/25980951 DMZ9T8H DI DMZ9T8H DMZ9T8H DN PMID27019002-Compound-16 DMZ9T8H TI TTNR0UQ DMZ9T8H TN Lysine-specific histone demethylase 1 (LSD) DMZ9T8H MA Inhibitor DMZ9T8H RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMZ9T8H RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMZA3FL DI DMZA3FL DMZA3FL DN PMID29473428-Compound-33 DMZA3FL TI TTZJYKH DMZA3FL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMZA3FL MA Inhibitor DMZA3FL RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMZA3FL RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMZAE78 DI DMZAE78 DMZAE78 DN Sulfonamide-thiadiazole derivative 2 DMZAE78 TI TT2LVK8 DMZAE78 TN Carbonic anhydrase IX (CA-IX) DMZAE78 MA Inhibitor DMZAE78 RN Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008-2018).Expert Opin Ther Pat. 2018 Oct;28(10):729-740. DMZAE78 RU https://www.ncbi.nlm.nih.gov/pubmed/30074415 DMZAMNX DI DMZAMNX DMZAMNX DN Peptide analog 59 DMZAMNX TI TTQAJF1 DMZAMNX TN Cathepsin G (CTSG) DMZAMNX MA Inhibitor DMZAMNX RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMZAMNX RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMZAMNX DI DMZAMNX DMZAMNX DN Peptide analog 59 DMZAMNX TI TTPLTSQ DMZAMNX TN Neutrophil elastase (NE) DMZAMNX MA Inhibitor DMZAMNX RN Neutrophil elastase inhibitors: a patent review and potential applications for inflammatory lung diseases (2010 - 2014).Expert Opin Ther Pat. 2015;25(10):1145-58. DMZAMNX RU https://www.ncbi.nlm.nih.gov/pubmed/26118988 DMZB140 DI DMZB140 DMZB140 DN PMID25482888-Compound-71 DMZB140 TI TTDIGC1 DMZB140 TN Dipeptidyl peptidase 4 (DPP-4) DMZB140 MA Inhibitor DMZB140 RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMZB140 RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMZBHR9 DI DMZBHR9 DMZBHR9 DN PMID29757691-Compound-10 DMZBHR9 TI TTEB0GD DMZBHR9 TN Cholinesterase (BCHE) DMZBHR9 MA Inhibitor DMZBHR9 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMZBHR9 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMZBHR9 DI DMZBHR9 DMZBHR9 DN PMID29757691-Compound-10 DMZBHR9 TI TT1RS9F DMZBHR9 TN Acetylcholinesterase (AChE) DMZBHR9 MA Inhibitor DMZBHR9 RN A patent review of butyrylcholinesterase inhibitors and reactivators 2010-2017.Expert Opin Ther Pat. 2018 Jun;28(6):455-465. DMZBHR9 RU https://www.ncbi.nlm.nih.gov/pubmed/29757691 DMZBY73 DI DMZBY73 DMZBY73 DN Mannoside derivative 4 DMZBY73 TI TTTCRU2 DMZBY73 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZBY73 MA Antagonist DMZBY73 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZBY73 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZC58R DI DMZC58R DMZC58R DN PMID27599163-Compound-78 DMZC58R TI TTPTXIN DMZC58R TN Translocator protein (TSPO) DMZC58R MA Ligand DMZC58R RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010 - 2015; part 2).Expert Opin Ther Pat. 2016 Nov;26(11):1353-1366. DMZC58R RU https://www.ncbi.nlm.nih.gov/pubmed/27599163 DMZC6AI DI DMZC6AI DMZC6AI DN Polyhydroxy benzamide derivative 5 DMZC6AI TI TTULVH8 DMZC6AI TN Tyrosinase (TYR) DMZC6AI MA Inhibitor DMZC6AI RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMZC6AI RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMZCERW DI DMZCERW DMZCERW DN Pyrrole derivative 7 DMZCERW TI TT6DM01 DMZCERW TN Janus kinase 1 (JAK-1) DMZCERW MA Inhibitor DMZCERW RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMZCERW RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMZCERW DI DMZCERW DMZCERW DN Pyrrole derivative 7 DMZCERW TI TTBYWP2 DMZCERW TN TYK2 tyrosine kinase (TYK2) DMZCERW MA Inhibitor DMZCERW RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMZCERW RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMZCERW DI DMZCERW DMZCERW DN Pyrrole derivative 7 DMZCERW TI TTRMX3V DMZCERW TN Janus kinase 2 (JAK-2) DMZCERW MA Inhibitor DMZCERW RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. DMZCERW RU https://www.ncbi.nlm.nih.gov/pubmed/27774822 DMZCO6J DI DMZCO6J DMZCO6J DN PMID25553724-Compound-US2011788838110 DMZCO6J TI TTSXVID DMZCO6J TN Nuclear factor NF-kappa-B (NFKB) DMZCO6J MA Inhibitor DMZCO6J RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMZCO6J RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMZCWM5 DI DMZCWM5 DMZCWM5 DN Biphenyl mannoside derivative 8 DMZCWM5 TI TTTCRU2 DMZCWM5 TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZCWM5 MA Antagonist DMZCWM5 RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZCWM5 RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZD1L5 DI DMZD1L5 DMZD1L5 DN US9073936, 1 DMZD1L5 TI TT3ZS42 DMZD1L5 TN Phosphodiesterase 1B (PDE1B) DMZD1L5 MA Inhibitor DMZD1L5 RN Organic compounds. US9598426. DMZD1L5 RU http://www.freepatentsonline.com/US9598426.html DMZD6IJ DI DMZD6IJ DMZD6IJ DN BDBM108945 DMZD6IJ TI TTPKHTZ DMZD6IJ TN Activin receptor type IB (ACVR1B) DMZD6IJ MA Inhibitor DMZD6IJ RN BMP inhibitors and methods of use thereof. US9682983. DMZD6IJ RU http://www.freepatentsonline.com/US9682983.html DMZDIRQ DI DMZDIRQ DMZDIRQ DN PMID25522065-Compound-34 DMZDIRQ TI TTX4RTB DMZDIRQ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMZDIRQ MA Antagonist DMZDIRQ RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMZDIRQ RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMZDUNT DI DMZDUNT DMZDUNT DN 4-benzylidene-1-(cyclobutylo)piperidine derivative 1 DMZDUNT TI TT9JNIC DMZDUNT TN Histamine H3 receptor (H3R) DMZDUNT RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMZDUNT RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMZECH7 DI DMZECH7 DMZECH7 DN Aryl cyclopropylamine derivative 3 DMZECH7 TI TTNR0UQ DMZECH7 TN Lysine-specific histone demethylase 1 (LSD) DMZECH7 MA Inhibitor DMZECH7 RN LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80. DMZECH7 RU https://www.ncbi.nlm.nih.gov/pubmed/27019002 DMZEP5X DI DMZEP5X DMZEP5X DN Pyrazolopyrimidine derivative 2 DMZEP5X TI TTHS256 DMZEP5X TN Metabotropic glutamate receptor 5 (mGluR5) DMZEP5X MA Modulator DMZEP5X RN mGlu5 negative allosteric modulators: a patent review (2013 - 2016).Expert Opin Ther Pat. 2017 Jun;27(6):691-706. DMZEP5X RU https://www.ncbi.nlm.nih.gov/pubmed/28067079 DMZEPU3 DI DMZEPU3 DMZEPU3 DN Piperazine carbamate/urea derivative 6 DMZEPU3 TI TT9JNIC DMZEPU3 TN Histamine H3 receptor (H3R) DMZEPU3 MA Ligand DMZEPU3 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMZEPU3 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMZF0DK DI DMZF0DK DMZF0DK DN Aminopyrimidine derivative 6 DMZF0DK TI TTH5TC2 DMZF0DK TN NF-kappa-B-activating kinase (TBK1) DMZF0DK MA Inhibitor DMZF0DK RN TBK1 inhibitors: a review of patent literature (2011 - 2014).Expert Opin Ther Pat. 2015;25(12):1385-96. DMZF0DK RU https://www.ncbi.nlm.nih.gov/pubmed/26293650 DMZF3AQ DI DMZF3AQ DMZF3AQ DN US9695118, 4 DMZF3AQ TI TTI1FPZ DMZF3AQ TN Epithelial discoidin domain receptor 1 (DDR1) DMZF3AQ MA Inhibitor DMZF3AQ RN Benzamide derivative. US9695118. DMZF3AQ RU http://www.freepatentsonline.com/US9695118.html DMZF5XI DI DMZF5XI DMZF5XI DN Biphenyl mannoside derivative 11 DMZF5XI TI TTTCRU2 DMZF5XI TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZF5XI MA Antagonist DMZF5XI RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZF5XI RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZF9TM DI DMZF9TM DMZF9TM DN N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl-phenylcarbamate analog 3 DMZF9TM TI TT9NXW4 DMZF9TM TN Sigma intracellular receptor 2 (TMEM97) DMZF9TM MA Ligand DMZF9TM RN Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578. DMZF9TM RU https://www.ncbi.nlm.nih.gov/pubmed/28051882 DMZFG68 DI DMZFG68 DMZFG68 DN Imidazo triazine derivative 2 DMZFG68 TI TTJGW1Z DMZFG68 TN Phosphodiesterase 2A (PDE2A) DMZFG68 MA Inhibitor DMZFG68 RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMZFG68 RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMZFILT DI DMZFILT DMZFILT DN 1,2,4-triazolo[1,5a]pyridine derivative 2 DMZFILT TI TTRMX3V DMZFILT TN Janus kinase 2 (JAK-2) DMZFILT MA Inhibitor DMZFILT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMZFILT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMZFILT DI DMZFILT DMZFILT DN 1,2,4-triazolo[1,5a]pyridine derivative 2 DMZFILT TI TTPMQSO DMZFILT TN ALK tyrosine kinase receptor (ALK) DMZFILT MA Inhibitor DMZFILT RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMZFILT RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMZG1HO DI DMZG1HO DMZG1HO DN US9670220, 77 DMZG1HO TI TTDYP7I DMZG1HO TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMZG1HO MA Inhibitor DMZG1HO RN Fused heterocyclic derivatives as S1P modulators. US9670220. DMZG1HO RU http://www.freepatentsonline.com/US9670220.html DMZGI0R DI DMZGI0R DMZGI0R DN Palmarumycin derivative 4 DMZGI0R TI TTR7UJ3 DMZGI0R TN Cytoplasmic thioredoxin reductase (TXNRD1) DMZGI0R MA Inhibitor DMZGI0R RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMZGI0R RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMZGNWO DI DMZGNWO DMZGNWO DN PMID29473428-Compound-21 DMZGNWO TI TTZJYKH DMZGNWO TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMZGNWO MA Inhibitor DMZGNWO RN A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. DMZGNWO RU https://www.ncbi.nlm.nih.gov/pubmed/29473428 DMZH27I DI DMZH27I DMZH27I DN Pyrrolo-pyrimidine derivative 8 DMZH27I TI TTK0FEA DMZH27I TN Leucine-rich repeat kinase 2 (LRRK2) DMZH27I MA Inhibitor DMZH27I RN Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676. DMZH27I RU https://www.ncbi.nlm.nih.gov/pubmed/28117607 DMZH3MX DI DMZH3MX DMZH3MX DN US9073936, 2 DMZH3MX TI TT3ZS42 DMZH3MX TN Phosphodiesterase 1B (PDE1B) DMZH3MX MA Inhibitor DMZH3MX RN Organic compounds. US9598426. DMZH3MX RU http://www.freepatentsonline.com/US9598426.html DMZH8S9 DI DMZH8S9 DMZH8S9 DN Ampicidin analog 2 DMZH8S9 TI TTBH0VX DMZH8S9 TN Histone deacetylase (HDAC) DMZH8S9 MA Inhibitor DMZH8S9 RN Antiplasmodial drug targets: a patent review (2000 - 2013).Expert Opin Ther Pat. 2016;26(1):107-30. DMZH8S9 RU https://www.ncbi.nlm.nih.gov/pubmed/26566576 DMZHB9Y DI DMZHB9Y DMZHB9Y DN PMID25399762-Compound-Table 6-14 DMZHB9Y TI TTGP7BY DMZHB9Y TN Monoamine oxidase type B (MAO-B) DMZHB9Y MA Inhibitor DMZHB9Y RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMZHB9Y RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMZHB9Y DI DMZHB9Y DMZHB9Y DN PMID25399762-Compound-Table 6-14 DMZHB9Y TI TTNR0UQ DMZHB9Y TN Lysine-specific histone demethylase 1 (LSD) DMZHB9Y MA Inhibitor DMZHB9Y RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMZHB9Y RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMZHIM8 DI DMZHIM8 DMZHIM8 DN PMID27998201-Compound-13 DMZHIM8 TI TTF2LRI DMZHIM8 TN Cathepsin B (CTSB) DMZHIM8 MA Inhibitor DMZHIM8 RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMZHIM8 RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMZI25U DI DMZI25U DMZI25U DN PMID27109571-Compound-16 DMZI25U TI TTNT2S6 DMZI25U TN Fatty acid-binding protein 5 (FABP5) DMZI25U MA Inhibitor DMZI25U RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMZI25U RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMZI25U DI DMZI25U DMZI25U DN PMID27109571-Compound-16 DMZI25U TI TTHWMFZ DMZI25U TN Fatty acid-binding protein 4 (FABP4) DMZI25U MA Inhibitor DMZI25U RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMZI25U RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMZI8GK DI DMZI8GK DMZI8GK DN Tricyclic compound 8 DMZI8GK TI TTAIQSN DMZI8GK TN Receptor-interacting protein 1 (RIPK1) DMZI8GK MA Inhibitor DMZI8GK RN Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents.Expert Opin Ther Pat. 2016 Nov;26(11):1239-1256. DMZI8GK RU https://www.ncbi.nlm.nih.gov/pubmed/27568917 DMZIALN DI DMZIALN DMZIALN DN Olenolic acid acetate derivative 1 DMZIALN TI TTSXVID DMZIALN TN Nuclear factor NF-kappa-B (NFKB) DMZIALN MA Inhibitor DMZIALN RN Novel NF-B inhibitors: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):319-34. DMZIALN RU https://www.ncbi.nlm.nih.gov/pubmed/25553724 DMZIKN6 DI DMZIKN6 DMZIKN6 DN PMID27376512-Compound-Figure3CG DMZIKN6 TI TTJUALD DMZIKN6 TN DNA [cytosine-5]-methyltransferase 3A (DNMT3A) DMZIKN6 MA Inhibitor DMZIKN6 RN DNA methyltransferase inhibitors: an updated patent review (2012-2015).Expert Opin Ther Pat. 2016 Sep;26(9):1017-30. DMZIKN6 RU https://www.ncbi.nlm.nih.gov/pubmed/27376512 DMZIOW0 DI DMZIOW0 DMZIOW0 DN Pyrazole derivative 58 DMZIOW0 TI TT6OEDT DMZIOW0 TN Cannabinoid receptor 1 (CB1) DMZIOW0 MA Antagonist DMZIOW0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMZIOW0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMZISDR DI DMZISDR DMZISDR DN PMID26815044-Compound-I DMZISDR TI TTULVH8 DMZISDR TN Tyrosinase (TYR) DMZISDR MA Inhibitor DMZISDR RN Tyrosinase inhibitors: a patent review (2011-2015).Expert Opin Ther Pat. 2016;26(3):347-62. DMZISDR RU https://www.ncbi.nlm.nih.gov/pubmed/26815044 DMZJ5FN DI DMZJ5FN DMZJ5FN DN Pyrazole derivative 37 DMZJ5FN TI TT6OEDT DMZJ5FN TN Cannabinoid receptor 1 (CB1) DMZJ5FN MA Antagonist DMZJ5FN RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMZJ5FN RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMZJTSP DI DMZJTSP DMZJTSP DN US9409892, 148 DMZJTSP TI TT9ISBX DMZJTSP TN HIF-prolyl hydroxylase 2 (HPH-2) DMZJTSP MA Inhibitor DMZJTSP RN 4-hydroxy-isoquinoline compounds as HIF hydroxylase inhibitors. US9409892. DMZJTSP RU http://www.freepatentsonline.com/US9409892.html DMZJXPF DI DMZJXPF DMZJXPF DN PMID28394193-Compound-45 DMZJXPF TI TTJW2UQ DMZJXPF TN EZH2 Y641N mutant (EZH2 Y641N) DMZJXPF MA Inhibitor DMZJXPF RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMZJXPF RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMZJXPF DI DMZJXPF DMZJXPF DN PMID28394193-Compound-45 DMZJXPF TI TT9MZCQ DMZJXPF TN Enhancer of zeste homolog 2 (EZH2) DMZJXPF MA Inhibitor DMZJXPF RN EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. DMZJXPF RU https://www.ncbi.nlm.nih.gov/pubmed/28394193 DMZK0SY DI DMZK0SY DMZK0SY DN PMID27998201-Compound-8 DMZK0SY TI TTDZN01 DMZK0SY TN Cathepsin K (CTSK) DMZK0SY MA Inhibitor DMZK0SY RN Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656. DMZK0SY RU https://www.ncbi.nlm.nih.gov/pubmed/27998201 DMZK658 DI DMZK658 DMZK658 DN Pyrrolidine derivative 9 DMZK658 TI TTSCIUP DMZK658 TN Oxytocin receptor (OTR) DMZK658 MA Antagonist DMZK658 RN A patent review of oxytocin receptor antagonists 2013-2017.Expert Opin Ther Pat. 2017 Dec;27(12):1287-1290. DMZK658 RU https://www.ncbi.nlm.nih.gov/pubmed/28906174 DMZKGOX DI DMZKGOX DMZKGOX DN US9024044, 62 DMZKGOX TI TTXL0GC DMZKGOX TN Enteropeptidase (TMPRSS15) DMZKGOX MA Inhibitor DMZKGOX RN Heteroarylcarboxylic acid ester derivative. US9024044. DMZKGOX RU http://www.freepatentsonline.com/US9024044.html DMZKTHL DI DMZKTHL DMZKTHL DN Beta-cyclodextrin conjugate derivative 1 DMZKTHL TI TTTCRU2 DMZKTHL TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZKTHL MA Antagonist DMZKTHL RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZKTHL RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZKYMI DI DMZKYMI DMZKYMI DN PMID27454349-Compound-98 DMZKYMI TI TTK59TV DMZKYMI TN Vitamin D3 receptor (VDR) DMZKYMI MA Agonist DMZKYMI RN Vitamin D receptor 2016: novel ligands and structural insights.Expert Opin Ther Pat. 2016 Nov;26(11):1291-1306. DMZKYMI RU https://www.ncbi.nlm.nih.gov/pubmed/27454349 DMZL6AX DI DMZL6AX DMZL6AX DN Diaryl amine derivative 4 DMZL6AX TI TT4YWTO DMZL6AX TN Histone deacetylase 3 (HDAC3) DMZL6AX MA Inhibitor DMZL6AX RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMZL6AX RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMZL6AX DI DMZL6AX DMZL6AX DN Diaryl amine derivative 4 DMZL6AX TI TT5ZKDI DMZL6AX TN Histone deacetylase 6 (HDAC6) DMZL6AX MA Inhibitor DMZL6AX RN Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).Expert Opin Ther Pat. 2017 Mar;27(3):229-236. DMZL6AX RU https://www.ncbi.nlm.nih.gov/pubmed/28092474 DMZL6D8 DI DMZL6D8 DMZL6D8 DN Acrylamide compound 4 DMZL6D8 TI TT9JNIC DMZL6D8 TN Histamine H3 receptor (H3R) DMZL6D8 RN Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. DMZL6D8 RU https://www.ncbi.nlm.nih.gov/pubmed/29334795 DMZLB07 DI DMZLB07 DMZLB07 DN PMID25666693-Compound-155 DMZLB07 TI TTMI6F5 DMZLB07 TN Transient receptor potential cation channel V1 (TRPV1) DMZLB07 MA Antagonist DMZLB07 RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMZLB07 RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TTQYF7G DMZM6FW TN Cyclin-dependent kinase 7 (CDK7) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TTO0FDJ DMZM6FW TN Cyclin-dependent kinase 6 (CDK6) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TTMYWL7 DMZM6FW TN Cyclin-dependent kinase 3 (CDK3) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TT1LVF2 DMZM6FW TN Cyclin-dependent kinase 9 (CDK9) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TTH6V3D DMZM6FW TN Cyclin-dependent kinase 1 (CDK1) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TTBH0VX DMZM6FW TN Histone deacetylase (HDAC) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TT7HF4W DMZM6FW TN Cyclin-dependent kinase 2 (CDK2) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZM6FW DI DMZM6FW DMZM6FW DN Oxazolyl methylthiothiazole derivative 1 DMZM6FW TI TT0PG8F DMZM6FW TN Cyclin-dependent kinase 4 (CDK4) DMZM6FW MA Inhibitor DMZM6FW RN Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70. DMZM6FW RU https://www.ncbi.nlm.nih.gov/pubmed/26161698 DMZMQFW DI DMZMQFW DMZMQFW DN PMID25522065-Compound-15 DMZMQFW TI TTX4RTB DMZMQFW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMZMQFW MA Antagonist DMZMQFW RN Novel MCH1 receptor antagonists: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):193-207. DMZMQFW RU https://www.ncbi.nlm.nih.gov/pubmed/25522065 DMZNF59 DI DMZNF59 DMZNF59 DN US8536181, C14 DMZNF59 TI TT9ISBX DMZNF59 TN HIF-prolyl hydroxylase 2 (HPH-2) DMZNF59 MA Inhibitor DMZNF59 RN Prolyl hydroxylase inhibitors. US8536181. DMZNF59 RU http://www.freepatentsonline.com/US8536181.html DMZNM52 DI DMZNM52 DMZNM52 DN PMID27977313-Compound-32 DMZNM52 TI TTR7UJ3 DMZNM52 TN Cytoplasmic thioredoxin reductase (TXNRD1) DMZNM52 MA Inhibitor DMZNM52 RN Thioredoxin reductase inhibitors: a patent review.Expert Opin Ther Pat. 2017 May;27(5):547-556. DMZNM52 RU https://www.ncbi.nlm.nih.gov/pubmed/27977313 DMZOG9S DI DMZOG9S DMZOG9S DN PMID25726713-Compound-20 DMZOG9S TI TT8J1S3 DMZOG9S TN Smoothened homolog (SMO) DMZOG9S MA Inhibitor DMZOG9S RN Hedgehog inhibitors: a patent review (2013 - present).Expert Opin Ther Pat. 2015 May;25(5):549-65. DMZOG9S RU https://www.ncbi.nlm.nih.gov/pubmed/25726713 DMZOI3K DI DMZOI3K DMZOI3K DN PMID27109571-Compound-42 DMZOI3K TI TTMY6L1 DMZOI3K TN Fatty acid-binding protein (FABP) DMZOI3K MA Inhibitor DMZOI3K RN Fatty acid binding protein (FABP) inhibitors: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):767-76. DMZOI3K RU https://www.ncbi.nlm.nih.gov/pubmed/27109571 DMZORKY DI DMZORKY DMZORKY DN Imidazopyridazine derivative 2 DMZORKY TI TT6DM01 DMZORKY TN Janus kinase 1 (JAK-1) DMZORKY MA Inhibitor DMZORKY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMZORKY RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMZORKY DI DMZORKY DMZORKY DN Imidazopyridazine derivative 2 DMZORKY TI TTT7PJU DMZORKY TN Janus kinase 3 (JAK-3) DMZORKY MA Inhibitor DMZORKY RN Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. DMZORKY RU https://www.ncbi.nlm.nih.gov/pubmed/27774824 DMZP1JT DI DMZP1JT DMZP1JT DN Alkyl mannoside derivative 8 DMZP1JT TI TTTCRU2 DMZP1JT TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZP1JT MA Antagonist DMZP1JT RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZP1JT RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZP6KR DI DMZP6KR DMZP6KR DN Thiomorpholine derivative 1 DMZP6KR TI TTJGLZF DMZP6KR TN Dipeptidyl peptidase 8 (DPP-8) DMZP6KR MA Inhibitor DMZP6KR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMZP6KR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMZP6KR DI DMZP6KR DMZP6KR DN Thiomorpholine derivative 1 DMZP6KR TI TTDIGC1 DMZP6KR TN Dipeptidyl peptidase 4 (DPP-4) DMZP6KR MA Inhibitor DMZP6KR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMZP6KR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMZP6KR DI DMZP6KR DMZP6KR DN Thiomorpholine derivative 1 DMZP6KR TI TTNDUL7 DMZP6KR TN Dipeptidyl peptidase 9 (DPP-9) DMZP6KR MA Inhibitor DMZP6KR RN DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36. DMZP6KR RU https://www.ncbi.nlm.nih.gov/pubmed/25482888 DMZPHN5 DI DMZPHN5 DMZPHN5 DN Phthalazine derivative 1 DMZPHN5 TI TTEBCY8 DMZPHN5 TN Poly [ADP-ribose] polymerase (PARP) DMZPHN5 MA Inhibitor DMZPHN5 RN PARP inhibitors as antitumor agents: a patent update (2013-2015).Expert Opin Ther Pat. 2017 Mar;27(3):363-382. DMZPHN5 RU https://www.ncbi.nlm.nih.gov/pubmed/27841036 DMZQ6HC DI DMZQ6HC DMZQ6HC DN PMID25666693-Compound-8 DMZQ6HC TI TTMI6F5 DMZQ6HC TN Transient receptor potential cation channel V1 (TRPV1) DMZQ6HC MA Antagonist DMZQ6HC RN Transient receptor potential vanilloid type 1 antagonists: a patent review (2011 - 2014).Expert Opin Ther Pat. 2015 Mar;25(3):291-318. DMZQ6HC RU https://www.ncbi.nlm.nih.gov/pubmed/25666693 DMZQF9R DI DMZQF9R DMZQF9R DN Pyrrolo[2,3-d]pyrimidine derivative 24 DMZQF9R TI TTGKNB4 DMZQF9R TN Epidermal growth factor receptor (EGFR) DMZQF9R MA Inhibitor DMZQF9R RN Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. DMZQF9R RU https://www.ncbi.nlm.nih.gov/pubmed/28705083 DMZQIKL DI DMZQIKL DMZQIKL DN US8481733, 118 DMZQIKL TI TTIET93 DMZQIKL TN Activated CDC42 kinase 1 (ACK-1) DMZQIKL MA Inhibitor DMZQIKL RN Substituted imidazopyr- and imidazotri-azines. US8481733. DMZQIKL RU http://www.freepatentsonline.com/US8481733.html DMZR0TH DI DMZR0TH DMZR0TH DN Triazole derivative 3 DMZR0TH TI TTN9T81 DMZR0TH TN Arachidonate 15-lipoxygenase (15-LOX) DMZR0TH MA Inhibitor DMZR0TH RN 15-Lipoxygenase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):65-88. DMZR0TH RU https://www.ncbi.nlm.nih.gov/pubmed/26560362 DMZR10T DI DMZR10T DMZR10T DN US10023583, Example 5 DMZR10T TI TTY2KP7 DMZR10T TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMZR10T MA Inhibitor DMZR10T RN Bicyclic pyridine compound. US10023583. DMZR10T RU http://www.freepatentsonline.com/US10023583.html DMZR71O DI DMZR71O DMZR71O DN Alkyl mannoside derivative 4 DMZR71O TI TTTCRU2 DMZR71O TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZR71O MA Antagonist DMZR71O RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZR71O RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZRM2Q DI DMZRM2Q DMZRM2Q DN 7-azaindole derivative 2 DMZRM2Q TI TTHS0U8 DMZRM2Q TN Stress-activated protein kinase JNK2 (JNK2) DMZRM2Q MA Inhibitor DMZRM2Q RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMZRM2Q RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMZRM2Q DI DMZRM2Q DMZRM2Q DN 7-azaindole derivative 2 DMZRM2Q TI TT056SO DMZRM2Q TN Stress-activated protein kinase JNK3 (JNK3) DMZRM2Q MA Inhibitor DMZRM2Q RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMZRM2Q RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMZRM2Q DI DMZRM2Q DMZRM2Q DN 7-azaindole derivative 2 DMZRM2Q TI TT0K6EO DMZRM2Q TN Stress-activated protein kinase JNK1 (JNK1) DMZRM2Q MA Inhibitor DMZRM2Q RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMZRM2Q RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMZS0HT DI DMZS0HT DMZS0HT DN Carbamate derivative 14 DMZS0HT TI TTZ963I DMZS0HT TN Monoglyceride lipase (MAGL) DMZS0HT MA Inhibitor DMZS0HT RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMZS0HT RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMZSI15 DI DMZSI15 DMZSI15 DN PMID27607364-Compound-64 DMZSI15 TI TTPTXIN DMZSI15 TN Translocator protein (TSPO) DMZSI15 MA Ligand DMZSI15 RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMZSI15 RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMZSOCK DI DMZSOCK DMZSOCK DN PMID25991433-Compound-J2 DMZSOCK TI TTHS0U8 DMZSOCK TN Stress-activated protein kinase JNK2 (JNK2) DMZSOCK MA Inhibitor DMZSOCK RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMZSOCK RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMZSOCK DI DMZSOCK DMZSOCK DN PMID25991433-Compound-J2 DMZSOCK TI TT0K6EO DMZSOCK TN Stress-activated protein kinase JNK1 (JNK1) DMZSOCK MA Inhibitor DMZSOCK RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMZSOCK RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMZSOCK DI DMZSOCK DMZSOCK DN PMID25991433-Compound-J2 DMZSOCK TI TT056SO DMZSOCK TN Stress-activated protein kinase JNK3 (JNK3) DMZSOCK MA Inhibitor DMZSOCK RN c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. DMZSOCK RU https://www.ncbi.nlm.nih.gov/pubmed/25991433 DMZSTCQ DI DMZSTCQ DMZSTCQ DN Pyridine-2,4-dicarboxylic acid derivative 1 DMZSTCQ TI TT0RGE9 DMZSTCQ TN Lysine-specific demethylase 4 (KDM4) DMZSTCQ MA Inhibitor DMZSTCQ RN KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.Expert Opin Ther Pat. 2015 Feb;25(2):135-44. DMZSTCQ RU https://www.ncbi.nlm.nih.gov/pubmed/25468267 DMZSTLH DI DMZSTLH DMZSTLH DN Phenylpyrrolidinone derivative 5 DMZSTLH TI TT5OU0D DMZSTLH TN PRKR-like endoplasmic reticulum kinase (PERK) DMZSTLH MA Inhibitor DMZSTLH RN Protein kinase R(PKR)-like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2017 Jan;27(1):37-48. DMZSTLH RU https://www.ncbi.nlm.nih.gov/pubmed/27646439 DMZSYU4 DI DMZSYU4 DMZSYU4 DN Piperazine carbamic compound 1 DMZSYU4 TI TTDP1UC DMZSYU4 TN Fatty acid amide hydrolase (FAAH) DMZSYU4 MA Inhibitor DMZSYU4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMZSYU4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMZSYU4 DI DMZSYU4 DMZSYU4 DN Piperazine carbamic compound 1 DMZSYU4 TI TTZ963I DMZSYU4 TN Monoglyceride lipase (MAGL) DMZSYU4 MA Inhibitor DMZSYU4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMZSYU4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMZSYU4 DI DMZSYU4 DMZSYU4 DN Piperazine carbamic compound 1 DMZSYU4 TI TTSINOV DMZSYU4 TN Monoacylglycerol lipase ABHD6 (ABHD6) DMZSYU4 MA Inhibitor DMZSYU4 RN A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351. DMZSYU4 RU https://www.ncbi.nlm.nih.gov/pubmed/29053063 DMZTBEQ DI DMZTBEQ DMZTBEQ DN PMID26651364-Compound-120 DMZTBEQ TI TTTCRU2 DMZTBEQ TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZTBEQ MA Antagonist DMZTBEQ RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZTBEQ RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DMZTPUA DI DMZTPUA DMZTPUA DN Triptolidenol analog 1 DMZTPUA TI TTUX68I DMZTPUA TN Hypoxia-inducible factor 1 (HIF-1) DMZTPUA MA Inhibitor DMZTPUA RN Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2011-2015).Expert Opin Ther Pat. 2016;26(3):309-22. DMZTPUA RU https://www.ncbi.nlm.nih.gov/pubmed/26882240 DMZTQVF DI DMZTQVF DMZTQVF DN Quinoline carboxamide derivative 10 DMZTQVF TI TTPTXIN DMZTQVF TN Translocator protein (TSPO) DMZTQVF MA Ligand DMZTQVF RN Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1).Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. DMZTQVF RU https://www.ncbi.nlm.nih.gov/pubmed/27607364 DMZTS2O DI DMZTS2O DMZTS2O DN Imidazo triazine derivative 4 DMZTS2O TI TTJGW1Z DMZTS2O TN Phosphodiesterase 2A (PDE2A) DMZTS2O MA Inhibitor DMZTS2O RN Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46. DMZTS2O RU https://www.ncbi.nlm.nih.gov/pubmed/27321640 DMZU96C DI DMZU96C DMZU96C DN Six-membered heterocyclic benzamide derivative 6 DMZU96C TI TTTDVOJ DMZU96C TN Tropomyosin-related kinase A (TrkA) DMZU96C MA Inhibitor DMZU96C RN Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.Expert Opin Ther Pat. 2017 Jul;27(7):831-849. DMZU96C RU https://www.ncbi.nlm.nih.gov/pubmed/28270021 DMZUB3D DI DMZUB3D DMZUB3D DN PMID25656651-Compound-23a DMZUB3D TI TTS7G69 DMZUB3D TN Fusion protein Bcr-Abl (Bcr-Abl) DMZUB3D MA Inhibitor DMZUB3D RN Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. DMZUB3D RU https://www.ncbi.nlm.nih.gov/pubmed/25656651 DMZUNJ4 DI DMZUNJ4 DMZUNJ4 DN US8933095, 14 DMZUNJ4 TI TTT3IXG DMZUNJ4 TN Kynurenine oxoglutarate transaminase II (AADAT) DMZUNJ4 MA Inhibitor DMZUNJ4 RN KAT II inhibitors. US8598200. DMZUNJ4 RU http://www.freepatentsonline.com/US8598200.html DMZV6YT DI DMZV6YT DMZV6YT DN US8569313, Inhibitor 14 DMZV6YT TI TTPRO7W DMZV6YT TN Suppressor of tumorigenicity 14 protein (ST14) DMZV6YT MA Inhibitor DMZV6YT RN Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313. DMZV6YT RU http://www.freepatentsonline.com/US8569313.html DMZVB5U DI DMZVB5U DMZVB5U DN Peptide analog 54 DMZVB5U TI TT2F4OL DMZVB5U TN Tissue transglutaminase (TG2) DMZVB5U MA Inhibitor DMZVB5U RN Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. DMZVB5U RU https://www.ncbi.nlm.nih.gov/pubmed/26560530 DMZVLH2 DI DMZVLH2 DMZVLH2 DN Heteroaryl-azepine derivative 4 DMZVLH2 TI TTWJBZ5 DMZVLH2 TN 5-HT 2C receptor (HTR2C) DMZVLH2 MA Agonist DMZVLH2 RN Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106. DMZVLH2 RU https://www.ncbi.nlm.nih.gov/pubmed/26609882 DMZW2XP DI DMZW2XP DMZW2XP DN Sulfonylated piperazine derivative 4 DMZW2XP TI TT6OEDT DMZW2XP TN Cannabinoid receptor 1 (CB1) DMZW2XP MA Antagonist DMZW2XP RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMZW2XP RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMZX8Y0 DI DMZX8Y0 DMZX8Y0 DN Azetidine-1-carboxamide derivative 1 DMZX8Y0 TI TT6OEDT DMZX8Y0 TN Cannabinoid receptor 1 (CB1) DMZX8Y0 MA Antagonist DMZX8Y0 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMZX8Y0 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMZXC0D DI DMZXC0D DMZXC0D DN PMID30107136-Compound-Example57 DMZXC0D TI TT23XQV DMZXC0D TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMZXC0D MA Inhibitor DMZXC0D RN A patent review on PD-1/PD-L1 antagonists: small molecules, peptides, and macrocycles (2015-2018).Expert Opin Ther Pat. 2018 Sep;28(9):665-678. DMZXC0D RU https://www.ncbi.nlm.nih.gov/pubmed/30107136 DMZY3HC DI DMZY3HC DMZY3HC DN 1,5-diphenylpyrrolidin-2-one derivative 1 DMZY3HC TI TT6OEDT DMZY3HC TN Cannabinoid receptor 1 (CB1) DMZY3HC MA Antagonist DMZY3HC RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMZY3HC RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMZYJKG DI DMZYJKG DMZYJKG DN Piperazinyl norbenzomorphane compound 3 DMZYJKG TI TT9NXW4 DMZYJKG TN Sigma intracellular receptor 2 (TMEM97) DMZYJKG MA Ligand DMZYJKG RN The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663. DMZYJKG RU https://www.ncbi.nlm.nih.gov/pubmed/30185082 DMZYPV3 DI DMZYPV3 DMZYPV3 DN Sulfonylated piperazine derivative 2 DMZYPV3 TI TT6OEDT DMZYPV3 TN Cannabinoid receptor 1 (CB1) DMZYPV3 MA Antagonist DMZYPV3 RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMZYPV3 RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMZYRHN DI DMZYRHN DMZYRHN DN Mannoside derivative 10 DMZYRHN TI TTTCRU2 DMZYRHN TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMZYRHN MA Antagonist DMZYRHN RN Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Expert Opin Ther Pat. 2016;26(2):175-97. DMZYRHN RU https://www.ncbi.nlm.nih.gov/pubmed/26651364 DM0J92L DI DM0J92L DM0J92L DN Benactyzine DM0J92L TI TTH18TF DM0J92L TN Muscarinic acetylcholine receptor M5 (CHRM5) DM0J92L MA Antagonist DM0J92L RN The muscarinic antagonists aprophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor. Mol Pharmacol. 1987 Nov;32(5):678-85. DM0J92L RU https://pubmed.ncbi.nlm.nih.gov/3683366 DM2HN6Q DI DM2HN6Q DM2HN6Q DN Astemizole DM2HN6Q TI TTTIBOJ DM2HN6Q TN Histamine H1 receptor (H1R) DM2HN6Q MA Antagonist DM2HN6Q RN Histamine H1 receptor induces cytosolic calcium increase and aquaporin translocation in human salivary gland cells. J Pharmacol Exp Ther. 2009 Aug;330(2):403-12. DM2HN6Q RU https://pubmed.ncbi.nlm.nih.gov/19443731 DM3TON2 DI DM3TON2 DM3TON2 DN Temafloxacin DM3TON2 TI TTN6J5F DM3TON2 TN Bacterial DNA gyrase (Bact gyrase) DM3TON2 MA Modulator DM3TON2 RN Mechanisms and frequency of resistance to temafloxacin. Am J Med. 1991 Dec 30;91(6A):27S-30S. DM3TON2 RU https://pubmed.ncbi.nlm.nih.gov/1662892 DM4KLPT DI DM4KLPT DM4KLPT DN Terfenadine DM4KLPT TI TTTIBOJ DM4KLPT TN Histamine H1 receptor (H1R) DM4KLPT MA Antagonist DM4KLPT RN Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. Am J Physiol Cell Physiol. 2008 Aug;295(2):C499-513. DM4KLPT RU https://pubmed.ncbi.nlm.nih.gov/18508907 DM5QSKN DI DM5QSKN DM5QSKN DN INDOPROFEN DM5QSKN TI TTIV96N DM5QSKN TN Fatty acid-binding protein 1 (FABP1) DM5QSKN MA Inhibitor DM5QSKN RN Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64. DM5QSKN RU https://pubmed.ncbi.nlm.nih.gov/18533710 DM5QSKN DI DM5QSKN DM5QSKN DN INDOPROFEN DM5QSKN TI TT30C9G DM5QSKN TN C-X-C chemokine receptor type 2 (CXCR2) DM5QSKN MA Inhibitor DM5QSKN RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM5QSKN RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM5QSKN DI DM5QSKN DM5QSKN DN INDOPROFEN DM5QSKN TI TTMWT8Z DM5QSKN TN C-X-C chemokine receptor type 1 (CXCR1) DM5QSKN MA Inhibitor DM5QSKN RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM5QSKN RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM5QSKN DI DM5QSKN DM5QSKN DN INDOPROFEN DM5QSKN TI TTVKILB DM5QSKN TN Prostaglandin G/H synthase 2 (COX-2) DM5QSKN MA Inhibitor DM5QSKN RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM5QSKN RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM5QSKN DI DM5QSKN DM5QSKN DN INDOPROFEN DM5QSKN TI TT8NGED DM5QSKN TN Prostaglandin G/H synthase 1 (COX-1) DM5QSKN MA Inhibitor DM5QSKN RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM5QSKN RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM5ZOX8 DI DM5ZOX8 DM5ZOX8 DN Benoxaprofen DM5ZOX8 TI TTK3C21 DM5ZOX8 TN Acetoacetyl-CoA thiolase (ACAT1) DM5ZOX8 MA Inhibitor DM5ZOX8 RN Inhibition of lyso-PAF: acetyl-CoA acetyltransferase by salicylates and other compounds. Prostaglandins. 1988 Jun;35(6):939-44. DM5ZOX8 RU https://pubmed.ncbi.nlm.nih.gov/2903520 DM67PWD DI DM67PWD DM67PWD DN Etilefrine DM67PWD TI TTVIREA DM67PWD TN Adrenergic receptor (ADR) DM67PWD MA Modulator DM67PWD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM67PWD RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM746BZ DI DM746BZ DM746BZ DN Clioquinol DM746BZ TI TTUNARX DM746BZ TN Carbonic anhydrase (CA) DM746BZ MA Inhibitor DM746BZ RN Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. DM746BZ RU https://pubmed.ncbi.nlm.nih.gov/18501600 DM746BZ DI DM746BZ DM746BZ DN Clioquinol DM746BZ TI TTQW87Y DM746BZ TN Opioid receptor kappa (OPRK1) DM746BZ MA Inhibitor DM746BZ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM746BZ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM79GRO DI DM79GRO DM79GRO DN Metamizole DM79GRO TI TT8NGED DM79GRO TN Prostaglandin G/H synthase 1 (COX-1) DM79GRO MA Inhibitor DM79GRO RN Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. DM79GRO RU https://pubmed.ncbi.nlm.nih.gov/15035793 DM7APNJ DI DM7APNJ DM7APNJ DN Zomepirac DM7APNJ TI TTK0943 DM7APNJ TN Prostaglandin G/H synthase (COX) DM7APNJ MA Modulator DM7APNJ RN Effect of preischemia cyclooxygenase inhibition by zomepirac sodium on reflow, cerebral autoregulation, and EEG recovery in the cat after global ischemia. J Cereb Blood Flow Metab. 1986 Dec;6(6):691-702. DM7APNJ RU https://pubmed.ncbi.nlm.nih.gov/3098746 DM9AGWQ DI DM9AGWQ DM9AGWQ DN HEXESTROL DM9AGWQ TI TTZAYWL DM9AGWQ TN Estrogen receptor (ESR) DM9AGWQ MA Inhibitor DM9AGWQ RN Bone targeted drugs 2. synthesis of estrogens with hydroxyapatite affinity, Bioorg. Med. Chem. Lett. 6(9):1047-1050 (1996). DM9AGWQ RU http://www.sciencedirect.com/science/article/pii/0960894X96001655 DM9AGWQ DI DM9AGWQ DM9AGWQ DN HEXESTROL DM9AGWQ TI TTOM3J0 DM9AGWQ TN Estrogen receptor beta (ESR2) DM9AGWQ MA Inhibitor DM9AGWQ RN Bone targeted drugs 2. synthesis of estrogens with hydroxyapatite affinity, Bioorg. Med. Chem. Lett. 6(9):1047-1050 (1996). DM9AGWQ RU http://www.sciencedirect.com/science/article/pii/0960894X96001655 DMABRJL DI DMABRJL DMABRJL DN Ximelagatran DMABRJL TI TT6L509 DMABRJL TN Coagulation factor IIa (F2) DMABRJL MA Inhibitor DMABRJL RN Ximelagatran increases membrane fluidity and changes membrane lipid composition in primary human hepatocytes. Toxicol In Vitro. 2009 Oct;23(7):1305-10. DMABRJL RU https://pubmed.ncbi.nlm.nih.gov/19616086 DMACMLO DI DMACMLO DMACMLO DN LYSERGIC ACID DIETHYLAMIDE DMACMLO TI TTSQIFT DMACMLO TN 5-HT 1A receptor (HTR1A) DMACMLO MA Inhibitor DMACMLO RN Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J Med Chem. 1995 Mar 17;38(6):958-66. DMACMLO RU https://pubmed.ncbi.nlm.nih.gov/7699712 DMACMLO DI DMACMLO DMACMLO DN LYSERGIC ACID DIETHYLAMIDE DMACMLO TI TTJQOD7 DMACMLO TN 5-HT 2A receptor (HTR2A) DMACMLO MA Inhibitor DMACMLO RN C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74. DMACMLO RU https://pubmed.ncbi.nlm.nih.gov/16821786 DMBCK2S DI DMBCK2S DMBCK2S DN Sulfametopyrazine DMBCK2S TI TT4ILYC DMBCK2S TN Bacterial Dihydropteroate synthetase (Bact folP) DMBCK2S MA Inhibitor DMBCK2S RN Plasmodium falciparum dihydrofolate reductase Val-16 and Thr-108 mutation associated with in vivo resistance to antifolate drug: a case study. Indian J Malariol. 2001 Sep-Dec;38(3-4):76-83. DMBCK2S RU https://pubmed.ncbi.nlm.nih.gov/12125519 DMBQYO0 DI DMBQYO0 DMBQYO0 DN Casopitant DMBQYO0 TI TTZPO1L DMBQYO0 TN Substance-P receptor (TACR1) DMBQYO0 MA Antagonist DMBQYO0 RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMBQYO0 RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMCP2TS DI DMCP2TS DMCP2TS DN Nomifensine DMCP2TS TI TTEX248 DMCP2TS TN Dopamine D2 receptor (D2R) DMCP2TS MA Antagonist DMCP2TS RN Pharmacologically induced, subsecond dopamine transients in the caudate-putamen of the anesthetized rat. Synapse. 2007 Jan;61(1):37-9. DMCP2TS RU https://pubmed.ncbi.nlm.nih.gov/17068772 DMFR79T DI DMFR79T DMFR79T DN TBC 11251 (TBC) DMFR79T TI TTKRD0G DMFR79T TN Endothelin A receptor (EDNRA) DMFR79T MA Antagonist DMFR79T RN Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage:... Neurosurgery. 1998 Dec;43(6):1409-17; discussion 1417-8. DMFR79T RU https://pubmed.ncbi.nlm.nih.gov/9848855 DMGQF3R DI DMGQF3R DMGQF3R DN Remoxipride DMGQF3R TI TTEX248 DMGQF3R TN Dopamine D2 receptor (D2R) DMGQF3R MA Antagonist DMGQF3R RN Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002 Feb;47(1):27-38. DMGQF3R RU https://pubmed.ncbi.nlm.nih.gov/11873706 DMGTBC7 DI DMGTBC7 DMGTBC7 DN ISIS 2922 DMGTBC7 TI TTS92NQ DMGTBC7 TN Cytomegalovirus DNA polymerase messenger RNA (CMV DNA polymerase mRNA) DMGTBC7 RN US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections. DMGTBC7 RU http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true DMGVNJ7 DI DMGVNJ7 DMGVNJ7 DN Amineptine DMGVNJ7 TI TTVBI8W DMGVNJ7 TN Dopamine transporter (DAT) DMGVNJ7 MA Inhibitor DMGVNJ7 RN Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. J Med Assoc Thai. 1997 Sep;80(9):587-92. DMGVNJ7 RU https://pubmed.ncbi.nlm.nih.gov/9347672 DMH6NG5 DI DMH6NG5 DMH6NG5 DN Fendiline DMH6NG5 TI TT0K1SC DMH6NG5 TN 5-HT 2B receptor (HTR2B) DMH6NG5 MA Inhibitor DMH6NG5 RN Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86. DMH6NG5 RU https://pubmed.ncbi.nlm.nih.gov/20958049 DMJ7YDS DI DMJ7YDS DMJ7YDS DN Dexfenfluramine DMJ7YDS TI TT3ROYC DMJ7YDS TN Serotonin transporter (SERT) DMJ7YDS MA Inhibitor DMJ7YDS RN Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs. 2007;67(1):27-55. DMJ7YDS RU https://pubmed.ncbi.nlm.nih.gov/17209663 DMJMHNL DI DMJMHNL DMJMHNL DN Bethanidine DMJMHNL TI TTR6W5O DMJMHNL TN Adrenergic receptor beta-1 (ADRB1) DMJMHNL MA Antagonist DMJMHNL RN Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981 Aug;141(9):1125-7. DMJMHNL RU https://pubmed.ncbi.nlm.nih.gov/6114720 DMK0GHV DI DMK0GHV DMK0GHV DN Encainide DMK0GHV TI TTZOVE0 DMK0GHV TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMK0GHV MA Blocker DMK0GHV RN From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33. DMK0GHV RU https://pubmed.ncbi.nlm.nih.gov/8780326 DMKM5HB DI DMKM5HB DMKM5HB DN Sitaxsentan DMKM5HB TI TTKRD0G DMKM5HB TN Endothelin A receptor (EDNRA) DMKM5HB MA Antagonist DMKM5HB RN Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19. DMKM5HB RU https://pubmed.ncbi.nlm.nih.gov/17064221 DMMP65N DI DMMP65N DMMP65N DN Sertindole DMMP65N TI TTEX248 DMMP65N TN Dopamine D2 receptor (D2R) DMMP65N MA Antagonist DMMP65N RN Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with r... Psychopharmacology (Berl). 2009 Sep;206(1):39-49. DMMP65N RU https://pubmed.ncbi.nlm.nih.gov/19506838 DMNI3U2 DI DMNI3U2 DMNI3U2 DN ZIMELIDINE DMNI3U2 TI TT3ROYC DMNI3U2 TN Serotonin transporter (SERT) DMNI3U2 MA Inhibitor DMNI3U2 RN Nontricyclic antidepressant agents derived from cis- and trans-1-amino-4-aryltetralins. J Med Chem. 1984 Nov;27(11):1508-15. DMNI3U2 RU https://pubmed.ncbi.nlm.nih.gov/6492080 DMNSJFD DI DMNSJFD DMNSJFD DN Indoramin DMNSJFD TI TT34BHT DMNSJFD TN Adrenergic receptor alpha-1D (ADRA1D) DMNSJFD MA Inhibitor DMNSJFD RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMNSJFD RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMNSJFD DI DMNSJFD DMNSJFD DN Indoramin DMNSJFD TI TT2NUT5 DMNSJFD TN Adrenergic receptor alpha-2C (ADRA2C) DMNSJFD MA Inhibitor DMNSJFD RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMNSJFD RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMNSJFD DI DMNSJFD DMNSJFD DN Indoramin DMNSJFD TI TTWM4TY DMNSJFD TN Adrenergic receptor alpha-2B (ADRA2B) DMNSJFD MA Inhibitor DMNSJFD RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMNSJFD RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMPJKRL DI DMPJKRL DMPJKRL DN Bithionol DMPJKRL TI TTZAYWL DMPJKRL TN Estrogen receptor (ESR) DMPJKRL MA Inhibitor DMPJKRL RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMPJKRL RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMPJKRL DI DMPJKRL DMPJKRL DN Bithionol DMPJKRL TI TTG5QB7 DMPJKRL TN Calpain-2 (CAPN2) DMPJKRL MA Inhibitor DMPJKRL RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMPJKRL RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMPJKRL DI DMPJKRL DMPJKRL DN Bithionol DMPJKRL TI TTOM3J0 DMPJKRL TN Estrogen receptor beta (ESR2) DMPJKRL MA Inhibitor DMPJKRL RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMPJKRL RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMPJKRL DI DMPJKRL DMPJKRL DN Bithionol DMPJKRL TI TTL53M6 DMPJKRL TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMPJKRL MA Inhibitor DMPJKRL RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMPJKRL RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQ52JG DI DMQ52JG DMQ52JG DN Phenformin DMQ52JG TI TTLAFZV DMQ52JG TN AMP-activated protein kinase (AMPK) DMQ52JG MA Activator DMQ52JG RN Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59. DMQ52JG RU https://pubmed.ncbi.nlm.nih.gov/17995453 DMQ9RBV DI DMQ9RBV DMQ9RBV DN Aminopterin DMQ9RBV TI TT9SL3Q DMQ9RBV TN Polypeptide deformylase (PDF) DMQ9RBV MA Inhibitor DMQ9RBV RN Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. DMQ9RBV RU https://pubmed.ncbi.nlm.nih.gov/12494465 DMRQAM0 DI DMRQAM0 DMRQAM0 DN Phenacetin DMRQAM0 TI TT8NGED DMRQAM0 TN Prostaglandin G/H synthase 1 (COX-1) DMRQAM0 MA Inhibitor DMRQAM0 RN Direct toxicity of nonsteroidal antiinflammatory drugs for renal medullary cells. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5317-22. DMRQAM0 RU https://pubmed.ncbi.nlm.nih.gov/11320259 DMRQAM0 DI DMRQAM0 DMRQAM0 DN Phenacetin DMRQAM0 TI TTL7C8Q DMRQAM0 TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMRQAM0 MA Inhibitor DMRQAM0 RN A potent "fat base" nucleotide inhibitor of IMP dehydrogenase. Biochemistry. 1998 Aug 25;37(34):11949-52. DMRQAM0 RU https://pubmed.ncbi.nlm.nih.gov/9718319 DMRZ5D7 DI DMRZ5D7 DMRZ5D7 DN Droxicam DMRZ5D7 TI TTK0943 DMRZ5D7 TN Prostaglandin G/H synthase (COX) DMRZ5D7 MA Modulator DMRZ5D7 RN Pharmacokinetic profile of droxicam. Eur J Rheumatol Inflamm. 1991;11(4):10-4. DMRZ5D7 RU https://pubmed.ncbi.nlm.nih.gov/1365484 DMSO2T9 DI DMSO2T9 DMSO2T9 DN Ibuproxam DMSO2T9 TI TT2J34L DMSO2T9 TN Arachidonate 5-lipoxygenase (5-LOX) DMSO2T9 MA Inhibitor DMSO2T9 RN In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem. 1987 Nov;30(11):2121-6. DMSO2T9 RU https://pubmed.ncbi.nlm.nih.gov/3669019 DMSV2WZ DI DMSV2WZ DMSV2WZ DN Chlorotrianisene DMSV2WZ TI TTZAYWL DMSV2WZ TN Estrogen receptor (ESR) DMSV2WZ MA Binder DMSV2WZ RN Inactivation of the uterine estrogen receptor binding of estradiol during P-450 catalyzed metabolism of chlorotrianisene (TACE). Speculation that TACE antiestrogenic activity involves covalent binding to the estrogen receptor. FEBS Lett. 1990 Feb 12;261(1):59-62. DMSV2WZ RU https://pubmed.ncbi.nlm.nih.gov/2307235 DMTFK3O DI DMTFK3O DMTFK3O DN Phenylpropanolamine DMTFK3O TI TTG28O6 DMTFK3O TN Adrenergic receptor Alpha-1 (ADRA1) DMTFK3O MA Agonist DMTFK3O RN Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist. J Med Chem. 2004 Jun 3;47(12):3220-35. DMTFK3O RU https://pubmed.ncbi.nlm.nih.gov/15163201 DMV5KR3 DI DMV5KR3 DMV5KR3 DN Ebrotidine DMV5KR3 TI TTQHJ1K DMV5KR3 TN Histamine H2 receptor (H2R) DMV5KR3 MA Modulator DMV5KR3 RN Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46. DMV5KR3 RU https://pubmed.ncbi.nlm.nih.gov/9205740 DMVG9YN DI DMVG9YN DMVG9YN DN Fencamfamine DMVG9YN TI TTEX248 DMVG9YN TN Dopamine D2 receptor (D2R) DMVG9YN MA Agonist DMVG9YN RN Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study. Biochem Pharmacol. 1983 Aug 1;32(15):2329-31. DMVG9YN RU https://pubmed.ncbi.nlm.nih.gov/6136281 DMVMIK2 DI DMVMIK2 DMVMIK2 DN Roxithromycin DMVMIK2 TI TTUWYEA DMVMIK2 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMVMIK2 MA Inhibitor DMVMIK2 RN Molecular insights into 14-membered macrolides using the MM-PBSA method. J Chem Inf Model. 2009 Jun;49(6):1558-67. DMVMIK2 RU https://pubmed.ncbi.nlm.nih.gov/19469526 DMWIDJK DI DMWIDJK DMWIDJK DN FORMESTANE DMWIDJK TI TTSZLWK DMWIDJK TN Aromatase (CYP19A1) DMWIDJK MA Inhibitor DMWIDJK RN The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98. DMWIDJK RU https://pubmed.ncbi.nlm.nih.gov/20102168 DMXYA5K DI DMXYA5K DMXYA5K DN Agomelatine DMXYA5K TI TT0WAIE DMXYA5K TN Melatonin receptor type 1A (MTNR1A) DMXYA5K MA Agonist DMXYA5K RN Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8(11):954-68. DMXYA5K RU https://pubmed.ncbi.nlm.nih.gov/18673165 DMY9P37 DI DMY9P37 DMY9P37 DN Flupenthixol DMY9P37 TI TTEX248 DMY9P37 TN Dopamine D2 receptor (D2R) DMY9P37 MA Antagonist DMY9P37 RN A role for medial prefrontal dopaminergic innervation in instrumental conditioning. J Neurosci. 2009 May 20;29(20):6599-606. DMY9P37 RU https://pubmed.ncbi.nlm.nih.gov/19458230 DMYJ8Z3 DI DMYJ8Z3 DMYJ8Z3 DN Alprenolol DMYJ8Z3 TI TTR6W5O DMYJ8Z3 TN Adrenergic receptor beta-1 (ADRB1) DMYJ8Z3 MA Antagonist DMYJ8Z3 RN Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14555-60. DMYJ8Z3 RU https://pubmed.ncbi.nlm.nih.gov/18787115 DMEQ3IW DI DMEQ3IW DMEQ3IW DN (S)-amisulpride DMEQ3IW TI TTEX248 DMEQ3IW TN Dopamine D2 receptor (D2R) DMEQ3IW MA Antagonist DMEQ3IW RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMEQ3IW RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMPL2KM DI DMPL2KM DMPL2KM DN GW-501516 DMPL2KM TI TT2JWF6 DMPL2KM TN Peroxisome proliferator-activated receptor delta (PPARD) DMPL2KM MA Modulator DMPL2KM RN Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94. DMPL2KM RU https://www.ncbi.nlm.nih.gov/pubmed/22814748 DM05MCO DI DM05MCO DM05MCO DN Inaperisone DM05MCO TI TTJSZTB DM05MCO TN Nicotinic acetylcholine receptor (nAChR) DM05MCO MA Modulator DM05MCO RN Inhibitory effect of inaperisone hydrochloride (inaperisone), a new centrally acting muscle relaxant, on the micturition reflex. Eur J Pharmacol. 1992 Mar 31;213(3):409-15. DM05MCO RU https://pubmed.ncbi.nlm.nih.gov/1618281 DM1B8NU DI DM1B8NU DM1B8NU DN Isbogrel DM1B8NU TI TT2GVH5 DM1B8NU TN Isomerase unspecific (IsoM) DM1B8NU MA Modulator DM1B8NU RN Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995 Jul 1;79(1):95-107. DM1B8NU RU https://pubmed.ncbi.nlm.nih.gov/7495108 DM31OGZ DI DM31OGZ DM31OGZ DN MONTIRELIN TETRAHYDRATE DM31OGZ TI TT4J8MF DM31OGZ TN Thyrotropin-releasing hormone receptor (TRHR) DM31OGZ MA Modulator DM31OGZ RN Montirelin hydrate (NS-3), a TRH analog, improved the disturbance of consciousness caused by head concussion and pentobarbital in mice. Nihon Yakurigaku Zasshi. 1996 May;107(5):237-45. DM31OGZ RU https://pubmed.ncbi.nlm.nih.gov/8690305 DM3OUWC DI DM3OUWC DM3OUWC DN Domitroban DM3OUWC TI TT2O84V DM3OUWC TN Thromboxane A2 receptor (TBXA2R) DM3OUWC MA Antagonist DM3OUWC RN The effect of a novel thromboxane A2 (TXA2) receptor antagonist (S-1452) on the antigen-induced bronchoconstriction and airway hyperresponsiveness in guinea pigs. Prostaglandins Leukot Essent Fatty Acids. 1993 May;48(5):343-9. DM3OUWC RU https://pubmed.ncbi.nlm.nih.gov/7686675 DM4LSJ2 DI DM4LSJ2 DM4LSJ2 DN Satigrel DM4LSJ2 TI TTKNWZ4 DM4LSJ2 TN Thromboxane-A synthase (TBXAS1) DM4LSJ2 MA Modulator DM4LSJ2 RN Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33. DM4LSJ2 RU https://pubmed.ncbi.nlm.nih.gov/8799481 DM6E5VA DI DM6E5VA DM6E5VA DN Clinprost DM6E5VA TI TTOFYT1 DM6E5VA TN Prostacyclin receptor (PTGIR) DM6E5VA MA Modulator DM6E5VA RN Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8. DM6E5VA RU https://pubmed.ncbi.nlm.nih.gov/9374201 DM6PVWS DI DM6PVWS DM6PVWS DN Telenzepine DM6PVWS TI TTZ9SOR DM6PVWS TN Muscarinic acetylcholine receptor M1 (CHRM1) DM6PVWS MA Modulator DM6PVWS RN Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. Pulm Pharmacol. 1994 Apr;7(2):91-7. DM6PVWS RU https://pubmed.ncbi.nlm.nih.gov/8081076 DM6PVWS DI DM6PVWS DM6PVWS DN Telenzepine DM6PVWS TI TTOXS3C DM6PVWS TN Muscarinic acetylcholine receptor (CHRM) DM6PVWS MA Antagonist DM6PVWS RN The existence of stable enantiomers of telenzepine and their stereoselective interaction with muscarinic receptor subtypes. Mol Pharmacol. 1989 Apr;35(4):477-83. DM6PVWS RU https://pubmed.ncbi.nlm.nih.gov/2704371 DM7BN1A DI DM7BN1A DM7BN1A DN Bermoprofen DM7BN1A TI TTK0943 DM7BN1A TN Prostaglandin G/H synthase (COX) DM7BN1A MA Modulator DM7BN1A RN Prolongation of antipyretic action and reduction of gastric ulcerogenicity in the rat by controlled-release granules of bermoprofen, a new nonsteroidal anti-inflammatory drug. J Pharm Sci. 1991 Sep;80(9):876-80. DM7BN1A RU https://pubmed.ncbi.nlm.nih.gov/1800712 DM9ADLQ DI DM9ADLQ DM9ADLQ DN Monatepil maleate DM9ADLQ TI TT5HONZ DM9ADLQ TN Calcium channel unspecific (CaC) DM9ADLQ MA Modulator DM9ADLQ RN Antihypertensive, antiatherosclerotic, and plasma lipid-lowering effects of monatepil, a novel calcium antagonist with alpha 1-adrenoceptor-blocking activity in experimental animals. Am J Hypertens. 1994 Oct;7(10 Pt 2):131S-40S. DM9ADLQ RU https://pubmed.ncbi.nlm.nih.gov/7826563 DMBKNJT DI DMBKNJT DMBKNJT DN LEMINOPRAZOLE DMBKNJT TI TTLOKXP DMBKNJT TN Gastric H(+)/K(+) ATPase (Proton pump) DMBKNJT MA Modulator DMBKNJT RN Vasoinhibitory effect of leminoprazole, a H+,K(+)-ATPase inhibitor, on rat aortic rings. Gen Pharmacol. 1996 Jan;27(1):117-21. DMBKNJT RU https://www.ncbi.nlm.nih.gov/pubmed/8742507 DMC14HL DI DMC14HL DMC14HL DN Suriclone DMC14HL TI TTEX6LM DMC14HL TN GABA(A) receptor gamma-3 (GABRG3) DMC14HL MA Modulator DMC14HL RN The effect of cyclopyrrolones on GABAA receptor function is different from that of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):294-300. DMC14HL RU https://www.ncbi.nlm.nih.gov/pubmed/7824046 DMD8K3B DI DMD8K3B DMD8K3B DN PW-2101 DMD8K3B TI TTMXGCW DMD8K3B TN Adrenergic receptor beta-3 (ADRB3) DMD8K3B MA Antagonist DMD8K3B RN PW 2101 Penwest discontinued, USA (hypertension) Penwest non-approvable, USA (hypertension), R & D Focus Drug News. July 11, 2005 DMD8K3B RU http://business.highbeam.com/436989/article-1G1-133855652/pw-2101-penwest-discontinued-usa DMEQDHP DI DMEQDHP DMEQDHP DN Meluadrine DMEQDHP TI TT2CJVK DMEQDHP TN Adrenergic receptor beta-2 (ADRB2) DMEQDHP MA Modulator DMEQDHP RN Effects of meluadrine tartrate and ritodrine hydrochloride on oxytocin-induced uterine contraction, uterine arterial blood flow and maternal cardiovascular function in pregnant goats. Jpn J Pharmacol. 2002 Oct;90(2):107-13. DMEQDHP RU https://pubmed.ncbi.nlm.nih.gov/12419879 DMFGMD9 DI DMFGMD9 DMFGMD9 DN LUBELUZOLE DMFGMD9 TI TTRK8B9 DMFGMD9 TN Sodium channel unspecific (NaC) DMFGMD9 MA Inhibitor DMFGMD9 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DMFGMD9 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DMFGMD9 DI DMFGMD9 DMFGMD9 DN LUBELUZOLE DMFGMD9 TI TTZOVE0 DMFGMD9 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMFGMD9 MA Inhibitor DMFGMD9 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DMFGMD9 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DMFOEVQ DI DMFOEVQ DMFOEVQ DN Ecabapide DMFOEVQ TI TT2NUT5 DMFOEVQ TN Adrenergic receptor alpha-2C (ADRA2C) DMFOEVQ MA Modulator DMFOEVQ RN Identification of major biliary and urinary metabolites of ecabapide in rats. Xenobiotica. 1996 Sep;26(9):983-94. DMFOEVQ RU https://pubmed.ncbi.nlm.nih.gov/8893045 DMKQI7S DI DMKQI7S DMKQI7S DN EMITEFUR DMKQI7S TI TTU6BFZ DMKQI7S TN Candida Thymidylate synthase (Candi TMP1) DMKQI7S MA Inhibitor DMKQI7S RN Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. Jpn J Cancer Res. 1991 Apr;82(4):476-82. DMKQI7S RU https://pubmed.ncbi.nlm.nih.gov/1904428 DML1Y49 DI DML1Y49 DML1Y49 DN Epanolol DML1Y49 TI TTMXGCW DML1Y49 TN Adrenergic receptor beta-3 (ADRB3) DML1Y49 MA Modulator DML1Y49 RN Pharmacokinetics of epanolol after acute and chronic oral dosing in elderly patients with stable angina pectoris. Br J Clin Pharmacol. 1990 Mar;29(3):333-7. DML1Y49 RU https://pubmed.ncbi.nlm.nih.gov/1968755 DMNS4TK DI DMNS4TK DMNS4TK DN Levcromakalim DMNS4TK TI TT1VOHK DMNS4TK TN Potassium channel unspecific (KC) DMNS4TK MA Modulator DMNS4TK RN The potassium channel opener levcromakalim causes expansive remodelling of experimental vein grafts. J Vasc Surg. 2006 Jul;44(1):159-65. DMNS4TK RU https://www.ncbi.nlm.nih.gov/pubmed/16828441 DMP6BG4 DI DMP6BG4 DMP6BG4 DN Pirazolac DMP6BG4 TI TTK0943 DMP6BG4 TN Prostaglandin G/H synthase (COX) DMP6BG4 MA Modulator DMP6BG4 RN Differential dosing study of pirazolac, a new non-steroidal anti-inflammatory agent, in patients with rheumatoid arthritis. Curr Med Res Opin. 1985;9(8):542-7. DMP6BG4 RU https://pubmed.ncbi.nlm.nih.gov/3896664 DMTF9YV DI DMTF9YV DMTF9YV DN AE-0047 DMTF9YV TI TT5HONZ DMTF9YV TN Calcium channel unspecific (CaC) DMTF9YV MA Modulator DMTF9YV RN AE0047-mediated calcium channel blocking in vascular smooth muscles. Gen Pharmacol. 1997 Sep;29(3):337-43. DMTF9YV RU https://pubmed.ncbi.nlm.nih.gov/9378237 DMUH0KO DI DMUH0KO DMUH0KO DN Palonidipine hydrochloride DMUH0KO TI TT5HONZ DMUH0KO TN Calcium channel unspecific (CaC) DMUH0KO MA Modulator DMUH0KO RN Effect of palonidipine hydrochloride (TC-81), a novel calcium antagonist, on the canine coronary artery. Nihon Yakurigaku Zasshi. 1993 Jul;102(1):23-33. DMUH0KO RU https://pubmed.ncbi.nlm.nih.gov/8335285 DMXF0NS DI DMXF0NS DMXF0NS DN Norastemizole DMXF0NS TI TTTIBOJ DMXF0NS TN Histamine H1 receptor (H1R) DMXF0NS MA Modulator DMXF0NS RN Effect of tecastemizole on pulmonary and cutaneous allergic inflammatory responses. Clin Exp Allergy. 2007 Jun;37(6):909-17. DMXF0NS RU https://www.ncbi.nlm.nih.gov/pubmed/17517105 DMXZ4BK DI DMXZ4BK DMXZ4BK DN LAS-41001 DMXZ4BK TI TTOD7B3 DMXZ4BK TN Retinoic acid receptor (RAR) DMXZ4BK MA Modulator DMXZ4BK RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027956) DMXZ4BK RU http://adisinsight.springer.com/drugs/800027956 DMYBPJ1 DI DMYBPJ1 DMYBPJ1 DN Semotiadil DMYBPJ1 TI TT5HONZ DMYBPJ1 TN Calcium channel unspecific (CaC) DMYBPJ1 MA Blocker DMYBPJ1 RN Thyroid hypertrophic effect of semotiadil fumarate, a new calcium antagonist, in rats. J Toxicol Sci. 2000 May;25(2):121-30. DMYBPJ1 RU https://pubmed.ncbi.nlm.nih.gov/10845190 DM04ZUW DI DM04ZUW DM04ZUW DN Ponalrestat DM04ZUW TI TTN7Y4P DM04ZUW TN Sodium/glucose cotransporter 2 (SLC5A4) DM04ZUW MA Blocker DM04ZUW RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DM04ZUW RU http://www.isispharm.com/Pipeline/index.htm DM04ZUW DI DM04ZUW DM04ZUW DN Ponalrestat DM04ZUW TI TTFBNVI DM04ZUW TN Aldose reductase (AKR1B1) DM04ZUW MA Inhibitor DM04ZUW RN Ponalrestat, an aldose reductase inhibitor, inhibits cachexia syndrome induced by colon26 adenocarcinoma in mice. Anticancer Res. 1999 Sep-Oct;19(5B):4105-11. DM04ZUW RU https://pubmed.ncbi.nlm.nih.gov/10628361 DM09GSW DI DM09GSW DM09GSW DN Abafungin DM09GSW TI TTTSOUD DM09GSW TN Candida Cytochrome P450 51 (Candi ERG11) DM09GSW MA Inhibitor DM09GSW RN Upregulation of sterol C14-demethylase expression in Trypanosoma cruzi treated with sterol biosynthesis inhibitors. Mol Biochem Parasitol. 2005 Nov;144(1):68-75. DM09GSW RU https://pubmed.ncbi.nlm.nih.gov/16165233 DM0GMJ6 DI DM0GMJ6 DM0GMJ6 DN 2085-P DM0GMJ6 TI TTHI19T DM0GMJ6 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM0GMJ6 MA Modulator DM0GMJ6 RN US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. DM0GMJ6 RU http://www.google.com/patents/US20040023290 DM0HR5W DI DM0HR5W DM0HR5W DN BMS-181100 DM0HR5W TI TT5TPI6 DM0HR5W TN Opioid receptor sigma 1 (OPRS1) DM0HR5W MA Modulator DM0HR5W RN BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 1994 Feb;10(1):37-40. DM0HR5W RU https://www.ncbi.nlm.nih.gov/pubmed/7910021 DM0HR5W DI DM0HR5W DM0HR5W DN BMS-181100 DM0HR5W TI TTSQIFT DM0HR5W TN 5-HT 1A receptor (HTR1A) DM0HR5W MA Modulator DM0HR5W RN BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology. 1994 Feb;10(1):37-40. DM0HR5W RU https://www.ncbi.nlm.nih.gov/pubmed/7910021 DM0O2HP DI DM0O2HP DM0O2HP DN OLAMUFLOXACIN MESILATE DM0O2HP TI TTN6J5F DM0O2HP TN Bacterial DNA gyrase (Bact gyrase) DM0O2HP MA Modulator DM0O2HP RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM0O2HP RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM0T2QV DI DM0T2QV DM0T2QV DN Sitimagene ceradenovec DM0T2QV TI TTP3QRF DM0T2QV TN Thymidine kinase 1 (TK1) DM0T2QV MA Modulator DM0T2QV RN Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710. DM0T2QV RU https://pubmed.ncbi.nlm.nih.gov/21142657 DM0X36Y DI DM0X36Y DM0X36Y DN Ritanserin DM0X36Y TI TT0K1SC DM0X36Y TN 5-HT 2B receptor (HTR2B) DM0X36Y MA Antagonist DM0X36Y RN p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90. DM0X36Y RU https://pubmed.ncbi.nlm.nih.gov/9832390 DM0X36Y DI DM0X36Y DM0X36Y DN Ritanserin DM0X36Y TI TTJQOD7 DM0X36Y TN 5-HT 2A receptor (HTR2A) DM0X36Y MA Antagonist DM0X36Y RN Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7. DM0X36Y RU https://pubmed.ncbi.nlm.nih.gov/18644367 DM0X36Y DI DM0X36Y DM0X36Y DN Ritanserin DM0X36Y TI TTYSN63 DM0X36Y TN 5-HT 2 receptor (5HT2R) DM0X36Y MA Antagonist DM0X36Y RN Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7. DM0X36Y RU https://pubmed.ncbi.nlm.nih.gov/18644367 DM0X36Y DI DM0X36Y DM0X36Y DN Ritanserin DM0X36Y TI TT85JO3 DM0X36Y TN 5-HT receptor (5HTR) DM0X36Y MA Antagonist DM0X36Y RN Combined treatment of portal hypertension with ritanserin and propranolol in conscious and unrestrained cirrhotic rats. Hepatology. 1992 May;15(5):878-82. DM0X36Y RU https://pubmed.ncbi.nlm.nih.gov/1568730 DM0X36Y DI DM0X36Y DM0X36Y DN Ritanserin DM0X36Y TI TTWJBZ5 DM0X36Y TN 5-HT 2C receptor (HTR2C) DM0X36Y MA Antagonist DM0X36Y RN Characterization of contractile 5-hydroxytryptamine receptor subtypes in the in situ autoperfused kidney in the anaesthetized rat. Eur J Pharmacol. 2008 Sep 11;592(1-3):133-7. DM0X36Y RU https://pubmed.ncbi.nlm.nih.gov/18644367 DM0X36Y DI DM0X36Y DM0X36Y DN Ritanserin DM0X36Y TI TT4FDG6 DM0X36Y TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM0X36Y MA Blocker DM0X36Y RN N,N-dialkyl-dipeptidylamines as novel N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Mar 22;9(6):907-12. DM0X36Y RU https://pubmed.ncbi.nlm.nih.gov/10206559 DM159U2 DI DM159U2 DM159U2 DN Evernimicin DM159U2 TI TTUWYEA DM159U2 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM159U2 MA Modulator DM159U2 RN Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-n... Antimicrob Agents Chemother. 2000 May;44(5):1121-6. DM159U2 RU https://www.ncbi.nlm.nih.gov/pubmed/10770739 DM1AFPW DI DM1AFPW DM1AFPW DN KC-764 DM1AFPW TI TTK0943 DM1AFPW TN Prostaglandin G/H synthase (COX) DM1AFPW MA Modulator DM1AFPW RN Clinical and preclinical pharmacology of KC-764, a novel antiplatelet agent. Nihon Rinsho. 1992 Feb;50(2):379-84. DM1AFPW RU https://pubmed.ncbi.nlm.nih.gov/1613994 DM1FST8 DI DM1FST8 DM1FST8 DN Pazinaclone DM1FST8 TI TTEX6LM DM1FST8 TN GABA(A) receptor gamma-3 (GABRG3) DM1FST8 MA Modulator DM1FST8 RN The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs. 2005 May;14(5):601-18. DM1FST8 RU https://pubmed.ncbi.nlm.nih.gov/15926867 DM1RKWV DI DM1RKWV DM1RKWV DN ONO-3805 DM1RKWV TI TT2A0DR DM1RKWV TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM1RKWV MA Modulator DM1RKWV RN Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-redu... J Androl. 1994 Nov-Dec;15(6):521-7. DM1RKWV RU https://www.ncbi.nlm.nih.gov/pubmed/7721654 DM2KITF DI DM2KITF DM2KITF DN LY335979 DM2KITF TI TT3OT40 DM2KITF TN Multidrug resistance protein 1 (ABCB1) DM2KITF MA Modulator DM2KITF RN A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72. DM2KITF RU https://www.ncbi.nlm.nih.gov/pubmed/15161679 DM2KITF DI DM2KITF DM2KITF DN LY335979 DM2KITF TI TTJUXV6 DM2KITF TN Multidrug resistance protein 3 (ABCB4) DM2KITF MA Modulator DM2KITF RN A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxoru... Clin Cancer Res. 2004 May 15;10(10):3265-72. DM2KITF RU https://www.ncbi.nlm.nih.gov/pubmed/15161679 DM38CIV DI DM38CIV DM38CIV DN ELTANOLONE DM38CIV TI TT1MPAY DM38CIV TN GABA(A) receptor alpha-1 (GABRA1) DM38CIV MA Inhibitor DM38CIV RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DM38CIV RU https://pubmed.ncbi.nlm.nih.gov/15828844 DM38CIV DI DM38CIV DM38CIV DN ELTANOLONE DM38CIV TI TTZA1NY DM38CIV TN GABA(A) receptor beta-2 (GABRB2) DM38CIV MA Inhibitor DM38CIV RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DM38CIV RU https://pubmed.ncbi.nlm.nih.gov/15828844 DM38CIV DI DM38CIV DM38CIV DN ELTANOLONE DM38CIV TI TTNJYV2 DM38CIV TN Gamma-aminobutyric acid receptor (GAR) DM38CIV MA Inhibitor DM38CIV RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DM38CIV RU https://pubmed.ncbi.nlm.nih.gov/16854065 DM38CIV DI DM38CIV DM38CIV DN ELTANOLONE DM38CIV TI TT06RH5 DM38CIV TN GABA(A) receptor gamma-2 (GABRG2) DM38CIV MA Inhibitor DM38CIV RN Neurosteroid analogues. 10. The effect of methyl group substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic actions of (... J Med Chem. 2005 Apr 21;48(8):3051-9. DM38CIV RU https://pubmed.ncbi.nlm.nih.gov/15828844 DM3EZ68 DI DM3EZ68 DM3EZ68 DN Y-23684 DM3EZ68 TI TTEX6LM DM3EZ68 TN GABA(A) receptor gamma-3 (GABRG3) DM3EZ68 MA Modulator DM3EZ68 RN The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. Br J Pharmacol. 1994 Apr;111(4):1170-8. DM3EZ68 RU https://pubmed.ncbi.nlm.nih.gov/7913372 DM3FLIX DI DM3FLIX DM3FLIX DN Selfotel DM3FLIX TI TT9IK2Z DM3FLIX TN N-methyl-D-aspartate receptor (NMDAR) DM3FLIX MA Antagonist DM3FLIX RN Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. DM3FLIX RU https://pubmed.ncbi.nlm.nih.gov/12507405 DM3IJMN DI DM3IJMN DM3IJMN DN Seletracetam DM3IJMN TI TTT3P91 DM3IJMN TN Synaptic vesicle glycoprotein 2A (SV2A) DM3IJMN MA Binder DM3IJMN RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DM3IJMN RU https://pubmed.ncbi.nlm.nih.gov/17874969 DM3KC81 DI DM3KC81 DM3KC81 DN Sanfetrinem DM3KC81 TI TTJP4SM DM3KC81 TN Bacterial Penicillin binding protein (Bact PBP) DM3KC81 MA Modulator DM3KC81 RN Entry of Sanfetrinem into Human Polymorphonuclear Granulocytes and Its Cell-Associated Activity against Intracellular, Penicillin-Resistant Streptococcus pneumoniae DM3KC81 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105677 DM3OUT0 DI DM3OUT0 DM3OUT0 DN Etarotene DM3OUT0 TI TT4PTJ7 DM3OUT0 TN Ribonuclease P protein (RPP) DM3OUT0 MA Modulator DM3OUT0 RN Retinoids inhibit human epidermal keratinocyte RNase P activity. Biol Chem. 2003 Mar;384(3):457-62. DM3OUT0 RU https://pubmed.ncbi.nlm.nih.gov/12715896 DM3SE2N DI DM3SE2N DM3SE2N DN Avitriptan DM3SE2N TI TT6MSOK DM3SE2N TN 5-HT 1D receptor (HTR1D) DM3SE2N MA Agonist DM3SE2N RN Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan.Cephalalgia. 1998 Oct;18(8):546-51. DM3SE2N RU https://pubmed.ncbi.nlm.nih.gov/9827246 DM3SKAC DI DM3SKAC DM3SKAC DN Idraparinux DM3SKAC TI TTCIHJA DM3SKAC TN Coagulation factor Xa (F10) DM3SKAC MA Inhibitor DM3SKAC RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM3SKAC RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM47ZHW DI DM47ZHW DM47ZHW DN Bidisomide DM47ZHW TI TTRK8B9 DM47ZHW TN Sodium channel unspecific (NaC) DM47ZHW MA Modulator DM47ZHW RN Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics. Clin Pharmacol Ther. 1992 Apr;51(4):371-8. DM47ZHW RU https://pubmed.ncbi.nlm.nih.gov/1563207 DM4BV2W DI DM4BV2W DM4BV2W DN Asoprisnil DM4BV2W TI TTUV8G9 DM4BV2W TN Progesterone receptor (PGR) DM4BV2W MA Modulator DM4BV2W RN New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. DM4BV2W RU https://pubmed.ncbi.nlm.nih.gov/18616415 DM4HGMX DI DM4HGMX DM4HGMX DN CDP571 DM4HGMX TI TTF8CQI DM4HGMX TN Tumor necrosis factor (TNF) DM4HGMX MA Modulator DM4HGMX RN CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo... Aliment Pharmacol Ther. 2006 Mar 1;23(5):617-28. DM4HGMX RU https://www.ncbi.nlm.nih.gov/pubmed/16480401 DM4IM0G DI DM4IM0G DM4IM0G DN Pexelizumab DM4IM0G TI TTKANGO DM4IM0G TN Complement C5 (CO5) DM4IM0G RN Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients. Ann Thorac Surg. 2006 Aug;82(2):486-92. DM4IM0G RU https://pubmed.ncbi.nlm.nih.gov/16863750 DM51FVE DI DM51FVE DM51FVE DN Zamifenacin DM51FVE TI TTQ13Z5 DM51FVE TN Muscarinic acetylcholine receptor M3 (CHRM3) DM51FVE MA Antagonist DM51FVE RN Drug treatment options for irritable bowel syndrome: managing for success. Drugs Aging. 2001;18(3):201-11. DM51FVE RU https://pubmed.ncbi.nlm.nih.gov/11302287 DM5G9W0 DI DM5G9W0 DM5G9W0 DN Taranabant DM5G9W0 TI TT6OEDT DM5G9W0 TN Cannabinoid receptor 1 (CB1) DM5G9W0 MA Antagonist DM5G9W0 RN Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):133-44. DM5G9W0 RU https://pubmed.ncbi.nlm.nih.gov/19285266 DM5JUW0 DI DM5JUW0 DM5JUW0 DN EM-800 DM5JUW0 TI TTOM3J0 DM5JUW0 TN Estrogen receptor beta (ESR2) DM5JUW0 MA Antagonist DM5JUW0 RN EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 1998 Jan;139(1):111-8. DM5JUW0 RU https://pubmed.ncbi.nlm.nih.gov/9421405 DM5JUW0 DI DM5JUW0 DM5JUW0 DN EM-800 DM5JUW0 TI TTZAYWL DM5JUW0 TN Estrogen receptor (ESR) DM5JUW0 MA Antagonist DM5JUW0 RN EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology. 1998 Jan;139(1):111-8. DM5JUW0 RU https://pubmed.ncbi.nlm.nih.gov/9421405 DM6M8ZX DI DM6M8ZX DM6M8ZX DN Sunepitron DM6M8ZX TI TTBRKXS DM6M8ZX TN Adrenergic receptor alpha-1B (ADRA1B) DM6M8ZX MA Inhibitor DM6M8ZX RN An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35. DM6M8ZX RU https://pubmed.ncbi.nlm.nih.gov/16722631 DM6M8ZX DI DM6M8ZX DM6M8ZX DN Sunepitron DM6M8ZX TI TTSQIFT DM6M8ZX TN 5-HT 1A receptor (HTR1A) DM6M8ZX MA Inhibitor DM6M8ZX RN An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35. DM6M8ZX RU https://pubmed.ncbi.nlm.nih.gov/16722631 DM6M8ZX DI DM6M8ZX DM6M8ZX DN Sunepitron DM6M8ZX TI TTNGILX DM6M8ZX TN Adrenergic receptor alpha-1A (ADRA1A) DM6M8ZX MA Inhibitor DM6M8ZX RN An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35. DM6M8ZX RU https://pubmed.ncbi.nlm.nih.gov/16722631 DM6M8ZX DI DM6M8ZX DM6M8ZX DN Sunepitron DM6M8ZX TI TT34BHT DM6M8ZX TN Adrenergic receptor alpha-1D (ADRA1D) DM6M8ZX MA Inhibitor DM6M8ZX RN An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment o... J Med Chem. 2006 Jun 1;49(11):3116-35. DM6M8ZX RU https://pubmed.ncbi.nlm.nih.gov/16722631 DM753RT DI DM753RT DM753RT DN CVT-124 DM753RT TI TTK25J1 DM753RT TN Adenosine A1 receptor (ADORA1) DM753RT MA Antagonist DM753RT RN CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009. DM753RT RU http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-08-2007/0004700893&EDATE= DM7G8T0 DI DM7G8T0 DM7G8T0 DN Azithromycin/chloroquine DM7G8T0 TI TTUWYEA DM7G8T0 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM7G8T0 MA Binder DM7G8T0 RN Pfizer. Product Development Pipeline. March 31 2009. DM7G8T0 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM7RGFW DI DM7RGFW DM7RGFW DN Lamectacin DM7RGFW TI TTEX248 DM7RGFW TN Dopamine D2 receptor (D2R) DM7RGFW MA Antagonist DM7RGFW RN Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34. DM7RGFW RU https://pubmed.ncbi.nlm.nih.gov/17064222 DM7RNPJ DI DM7RNPJ DM7RNPJ DN Trenonacog alfa DM7RNPJ TI TTFEZ5Q DM7RNPJ TN Coagulation factor IX (F9) DM7RNPJ MA Modulator DM7RNPJ RN Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.Haemophilia.2012 Nov;18(6):881-7. DM7RNPJ RU https://www.ncbi.nlm.nih.gov/pubmed/22764744 DM7SA9J DI DM7SA9J DM7SA9J DN IR-103 DM7SA9J TI TTSHG0T DM7SA9J TN Toll-like receptor 9 (TLR9) DM7SA9J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759). DM7SA9J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759 DM86XJG DI DM86XJG DM86XJG DN MINALRESTAT DM86XJG TI TTFBNVI DM86XJG TN Aldose reductase (AKR1B1) DM86XJG MA Modulator DM86XJG RN Minalrestat, an aldose reductase inhibitor, corrects the impaired microvascular reactivity in diabetes. J Pharmacol Exp Ther. 2003 Mar;304(3):1236-42. DM86XJG RU https://www.ncbi.nlm.nih.gov/pubmed/12604701 DM8CEDR DI DM8CEDR DM8CEDR DN Laropiprant+niacin DM8CEDR TI TTNVEIR DM8CEDR TN Prostaglandin D2 receptor (PTGDR) DM8CEDR MA Antagonist DM8CEDR RN Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. DM8CEDR RU https://pubmed.ncbi.nlm.nih.gov/18537526 DM8DUZT DI DM8DUZT DM8DUZT DN Deramciclane DM8DUZT TI TTJQOD7 DM8DUZT TN 5-HT 2A receptor (HTR2A) DM8DUZT MA Modulator DM8DUZT RN Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl). 1998 Mar;136(2):99-104. DM8DUZT RU https://pubmed.ncbi.nlm.nih.gov/9551765 DM8DUZT DI DM8DUZT DM8DUZT DN Deramciclane DM8DUZT TI TTWJBZ5 DM8DUZT TN 5-HT 2C receptor (HTR2C) DM8DUZT MA Modulator DM8DUZT RN Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl). 1998 Mar;136(2):99-104. DM8DUZT RU https://pubmed.ncbi.nlm.nih.gov/9551765 DM8KSMX DI DM8KSMX DM8KSMX DN IMIRESTAT DM8KSMX TI TTFBNVI DM8KSMX TN Aldose reductase (AKR1B1) DM8KSMX MA Inhibitor DM8KSMX RN Spiro[fluoreneisothiazolidin]one dioxides: new aldose reductase and L-hexonate dehydrogenase inhibitors. J Med Chem. 1991 Nov;34(11):3229-34. DM8KSMX RU https://pubmed.ncbi.nlm.nih.gov/1956041 DM8M1X0 DI DM8M1X0 DM8M1X0 DN Ro-16-6028 DM8M1X0 TI TTPTXIN DM8M1X0 TN Translocator protein (TSPO) DM8M1X0 MA Modulator DM8M1X0 RN Bretazenil, a benzodiazepine receptor partial agonist, as an adjunct in the prophylactic treatment of OP poisoning. J Appl Toxicol. 2001 Dec;21 Suppl 1:S115-9. DM8M1X0 RU https://www.ncbi.nlm.nih.gov/pubmed/11920931 DM8OMI6 DI DM8OMI6 DM8OMI6 DN Lobucavir DM8OMI6 TI TT84ETX DM8OMI6 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM8OMI6 MA Modulator DM8OMI6 RN Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatit... Antiviral Res. 2000 Dec;48(3):197-203. DM8OMI6 RU https://www.ncbi.nlm.nih.gov/pubmed/11164506 DM8XO3B DI DM8XO3B DM8XO3B DN ARANOSE DM8XO3B TI TTUTN1I DM8XO3B TN Human Deoxyribonucleic acid (hDNA) DM8XO3B MA Binder DM8XO3B RN Alternative DNA loops regulate the arabinose operon in Escherichia coli. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5444-8. DM8XO3B RU https://pubmed.ncbi.nlm.nih.gov/3041410 DM9FJ7N DI DM9FJ7N DM9FJ7N DN Midafotel DM9FJ7N TI TT9IK2Z DM9FJ7N TN N-methyl-D-aspartate receptor (NMDAR) DM9FJ7N MA Modulator DM9FJ7N RN D-CPP-ene (SDZ EAA 494), a potent and competitive N-methyl-D-aspartate (NMDA) antagonist: effect on spontaneous activity and NMDA-induced depolarizations in the rat neocortical slice preparation, compared with other CPP derivatives and MK-801. Neurosci Lett. 1990 Jun 8;113(3):315-21. DM9FJ7N RU https://pubmed.ncbi.nlm.nih.gov/2166255 DM9T6MS DI DM9T6MS DM9T6MS DN Tecadenoson DM9T6MS TI TTK25J1 DM9T6MS TN Adenosine A1 receptor (ADORA1) DM9T6MS MA Agonist DM9T6MS RN CV Therapeutics. Company report from CV Therapeutics, Inc. CV Therapeutics. 2009. DM9T6MS RU http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-08-2007/0004700893&EDATE= DM9T6MS DI DM9T6MS DM9T6MS DN Tecadenoson DM9T6MS TI TTYVX59 DM9T6MS TN Protein kinase C (PRKC) DM9T6MS MA Binder DM9T6MS RN Protein kinase C as a molecular target for cancer prevention by selenocompounds. Nutr Cancer. 2001;40(1):55-63. DM9T6MS RU https://pubmed.ncbi.nlm.nih.gov/11799924 DMA4WY5 DI DMA4WY5 DMA4WY5 DN Taprostene DMA4WY5 TI TT9B4N3 DMA4WY5 TN Prostaglandin receptor (PTGR) DMA4WY5 MA Modulator DMA4WY5 RN Partial agonism of taprostene at prostanoid IP receptors in vascular preparations from guinea-pig, rat, and mouse. J Cardiovasc Pharmacol. 2004 Jun;43(6):795-807. DMA4WY5 RU https://pubmed.ncbi.nlm.nih.gov/15167273 DMAENDF DI DMAENDF DMAENDF DN Abetimus sodium DMAENDF TI TTUTN1I DMAENDF TN Human Deoxyribonucleic acid (hDNA) DMAENDF MA Inhibitor DMAENDF RN Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65. DMAENDF RU https://pubmed.ncbi.nlm.nih.gov/15757403 DMAINU1 DI DMAINU1 DMAINU1 DN RB-006 DMAINU1 TI TTFEZ5Q DMAINU1 TN Coagulation factor IX (F9) DMAINU1 MA Inhibitor DMAINU1 RN In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. Thromb Haemost. 2009 May;101(5):827-33. DMAINU1 RU https://pubmed.ncbi.nlm.nih.gov/19404534 DMAMFXC DI DMAMFXC DMAMFXC DN BCG65-E7 DMAMFXC TI TTD24Y0 DMAMFXC TN Toll-like receptor 3 (TLR3) DMAMFXC MA Agonist DMAMFXC RN Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia. Gynecol Oncol. 2010 Feb;116(2):208-12. DMAMFXC RU https://pubmed.ncbi.nlm.nih.gov/19555999 DMANMXZ DI DMANMXZ DMANMXZ DN CEFCANEL DALOXATE HYDROCHLORIDE DMANMXZ TI TTJP4SM DMANMXZ TN Bacterial Penicillin binding protein (Bact PBP) DMANMXZ MA Modulator DMANMXZ RN Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. J Antimicrob Chemother. 1994 Feb;33(2):281-8. DMANMXZ RU https://pubmed.ncbi.nlm.nih.gov/8182009 DMAZ28C DI DMAZ28C DMAZ28C DN Metazosin DMAZ28C TI TTG28O6 DMAZ28C TN Adrenergic receptor Alpha-1 (ADRA1) DMAZ28C MA Antagonist DMAZ28C RN Metazosin tablets (Kenosin) in the treatment of chronic congestive heart failure. Cas Lek Cesk. 1995 Sep 20;134(18):590-3. DMAZ28C RU https://pubmed.ncbi.nlm.nih.gov/7489576 DMB069L DI DMB069L DMB069L DN PUMAPRAZOLE DMB069L TI TTLOKXP DMB069L TN Gastric H(+)/K(+) ATPase (Proton pump) DMB069L MA Modulator DMB069L RN Effects of pumaprazole (BY841), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Heli... Aliment Pharmacol Ther. 1999 Jan;13(1):27-34. DMB069L RU https://www.ncbi.nlm.nih.gov/pubmed/9892876 DMBKN4P DI DMBKN4P DMBKN4P DN Riferminogene pecaplasmid DMBKN4P TI TTMY81X DMBKN4P TN Heparin-binding growth factor 1 (FGF1) DMBKN4P MA Modulator DMBKN4P RN Riferminogene pecaplasmide. Am J Cardiovasc Drugs. 2010;10(5):343-6. DMBKN4P RU https://pubmed.ncbi.nlm.nih.gov/20860417 DMBRYT8 DI DMBRYT8 DMBRYT8 DN XEMILOFIBAN DMBRYT8 TI TTJA1ZO DMBRYT8 TN ITGB3 messenger RNA (ITGB3 mRNA) DMBRYT8 MA Inhibitor DMBRYT8 RN Potent, orally active GPIIb/IIIa antagonists containing a nipecotic acid subunit. Structure-activity studies leading to the discovery of RWJ-53308. J Med Chem. 1999 Dec 16;42(25):5254-65. DMBRYT8 RU https://pubmed.ncbi.nlm.nih.gov/10602710 DMBRYT8 DI DMBRYT8 DMBRYT8 DN XEMILOFIBAN DMBRYT8 TI TT38RM1 DMBRYT8 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMBRYT8 MA Modulator DMBRYT8 RN Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. J Pharmacol Exp Ther. 2000 Nov;295(2):670-6. DMBRYT8 RU https://www.ncbi.nlm.nih.gov/pubmed/11046104 DMC40SD DI DMC40SD DMC40SD DN Darexaban maleate DMC40SD TI TTCIHJA DMC40SD TN Coagulation factor Xa (F10) DMC40SD MA Inhibitor DMC40SD RN The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol. 2013 Feb;75(2):440-9. DMC40SD RU https://pubmed.ncbi.nlm.nih.gov/22642721 DMCJLD1 DI DMCJLD1 DMCJLD1 DN SCH 727965 DMCJLD1 TI TT1LVF2 DMCJLD1 TN Cyclin-dependent kinase 9 (CDK9) DMCJLD1 MA Inhibitor DMCJLD1 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMCJLD1 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMCJLD1 DI DMCJLD1 DMCJLD1 DN SCH 727965 DMCJLD1 TI TT7HF4W DMCJLD1 TN Cyclin-dependent kinase 2 (CDK2) DMCJLD1 MA Inhibitor DMCJLD1 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMCJLD1 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMCJLD1 DI DMCJLD1 DMCJLD1 DN SCH 727965 DMCJLD1 TI TTH6V3D DMCJLD1 TN Cyclin-dependent kinase 1 (CDK1) DMCJLD1 MA Inhibitor DMCJLD1 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMCJLD1 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMCM239 DI DMCM239 DMCM239 DN Larotaxel DMCM239 TI TTML2WA DMCM239 TN Tubulin (TUB) DMCM239 MA Inhibitor DMCM239 RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMCM239 RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMCU1WO DI DMCU1WO DMCU1WO DN Eperezolid DMCU1WO TI TTUWYEA DMCU1WO TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMCU1WO MA Modulator DMCU1WO RN The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. DMCU1WO RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC164081 DMCV0BZ DI DMCV0BZ DMCV0BZ DN RhTPO DMCV0BZ TI TTIHYA4 DMCV0BZ TN Thrombopoietin receptor (MPL) DMCV0BZ MA Agonist DMCV0BZ RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMCV0BZ RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMDEL2W DI DMDEL2W DMDEL2W DN Iferanserin-Ventrus DMDEL2W TI TTJQOD7 DMDEL2W TN 5-HT 2A receptor (HTR2A) DMDEL2W MA Modulator DMDEL2W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 6). DMDEL2W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=6 DMDZBIQ DI DMDZBIQ DMDZBIQ DN PMI-001 DMDZBIQ TI TTVKILB DMDZBIQ TN Prostaglandin G/H synthase 2 (COX-2) DMDZBIQ MA Inhibitor DMDZBIQ RN Development of a botanical anti-arthritis drug, PMI-001. SBIR.STTR America's Seed Fund. DMDZBIQ RU https://www.sbir.gov/sbirsearch/detail/275638 DMDZBIQ DI DMDZBIQ DMDZBIQ DN PMI-001 DMDZBIQ TI TTF89GD DMDZBIQ TN Interleukin-2 (IL2) DMDZBIQ MA Inhibitor DMDZBIQ RN Development of a botanical anti-arthritis drug, PMI-001. SBIR.STTR America's Seed Fund. DMDZBIQ RU https://www.sbir.gov/sbirsearch/detail/275638 DME5QDP DI DME5QDP DME5QDP DN TIOSPIRONE DME5QDP TI TTBRKXS DME5QDP TN Adrenergic receptor alpha-1B (ADRA1B) DME5QDP MA Inhibitor DME5QDP RN 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8. DME5QDP RU https://pubmed.ncbi.nlm.nih.gov/8568801 DME5QDP DI DME5QDP DME5QDP DN TIOSPIRONE DME5QDP TI TT34BHT DME5QDP TN Adrenergic receptor alpha-1D (ADRA1D) DME5QDP MA Inhibitor DME5QDP RN 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8. DME5QDP RU https://pubmed.ncbi.nlm.nih.gov/8568801 DME5QDP DI DME5QDP DME5QDP DN TIOSPIRONE DME5QDP TI TTSQIFT DME5QDP TN 5-HT 1A receptor (HTR1A) DME5QDP MA Inhibitor DME5QDP RN Synthesis and biological activity of the putative metabolites of the atypical antipsychotic agent tiospirone. J Med Chem. 1991 Nov;34(11):3316-28. DME5QDP RU https://pubmed.ncbi.nlm.nih.gov/1683407 DME5QDP DI DME5QDP DME5QDP DN TIOSPIRONE DME5QDP TI TTJQOD7 DME5QDP TN 5-HT 2A receptor (HTR2A) DME5QDP MA Inhibitor DME5QDP RN 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8. DME5QDP RU https://pubmed.ncbi.nlm.nih.gov/8568801 DME5QDP DI DME5QDP DME5QDP DN TIOSPIRONE DME5QDP TI TTEX248 DME5QDP TN Dopamine D2 receptor (D2R) DME5QDP MA Inhibitor DME5QDP RN 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8. DME5QDP RU https://pubmed.ncbi.nlm.nih.gov/8568801 DME5QDP DI DME5QDP DME5QDP DN TIOSPIRONE DME5QDP TI TTNGILX DME5QDP TN Adrenergic receptor alpha-1A (ADRA1A) DME5QDP MA Inhibitor DME5QDP RN 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8. DME5QDP RU https://pubmed.ncbi.nlm.nih.gov/8568801 DME94QF DI DME94QF DME94QF DN Furnidipine DME94QF TI TTXHYV6 DME94QF TN Voltage-gated L-type calcium channel (L-CaC) DME94QF MA Modulator DME94QF RN Q-type Ca2+ channels are located closer to secretory sites than L-type channels: functional evidence in chromaffin cells. Pflugers Arch. 1998 Mar;435(4):472-8. DME94QF RU https://www.ncbi.nlm.nih.gov/pubmed/9446693 DMEDLXJ DI DMEDLXJ DMEDLXJ DN ORBOFIBAN DMEDLXJ TI TT38RM1 DMEDLXJ TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMEDLXJ MA Modulator DMEDLXJ RN Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26. DMEDLXJ RU https://www.ncbi.nlm.nih.gov/pubmed/11301411 DMEMF60 DI DMEMF60 DMEMF60 DN Delequamine hydrochloride DMEMF60 TI TT2NUT5 DMEMF60 TN Adrenergic receptor alpha-2C (ADRA2C) DMEMF60 MA Modulator DMEMF60 RN Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br J Pharmacol. 1996 May;118(1):63-72. DMEMF60 RU https://pubmed.ncbi.nlm.nih.gov/8733577 DMEMUQP DI DMEMUQP DMEMUQP DN CEFETECOL DMEMUQP TI TTJP4SM DMEMUQP TN Bacterial Penicillin binding protein (Bact PBP) DMEMUQP MA Modulator DMEMUQP RN Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1991 Jan;35(1):14-9. DMEMUQP RU https://pubmed.ncbi.nlm.nih.gov/2014969 DMFE3CT DI DMFE3CT DMFE3CT DN Alniditan DMFE3CT TI TT6MSOK DMFE3CT TN 5-HT 1D receptor (HTR1D) DMFE3CT MA Agonist DMFE3CT RN Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65. DMFE3CT RU https://pubmed.ncbi.nlm.nih.gov/9605573 DMFE3CT DI DMFE3CT DMFE3CT DN Alniditan DMFE3CT TI TTK8CXU DMFE3CT TN 5-HT 1B receptor (HTR1B) DMFE3CT MA Agonist DMFE3CT RN Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65. DMFE3CT RU https://pubmed.ncbi.nlm.nih.gov/9605573 DMFEN6T DI DMFEN6T DMFEN6T DN YM533 DMFEN6T TI TTOFYT1 DMFEN6T TN Prostacyclin receptor (PTGIR) DMFEN6T MA Modulator DMFEN6T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 345). DMFEN6T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345 DMFG4OM DI DMFG4OM DMFG4OM DN Avasimibe DMFG4OM TI TTMF541 DMFG4OM TN Liver carboxylesterase (CES1) DMFG4OM MA Inhibitor DMFG4OM RN New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology. 2002;97(2):59-66. DMFG4OM RU https://pubmed.ncbi.nlm.nih.gov/11978950 DMFJORV DI DMFJORV DMFJORV DN Verpasep caltespen DMFJORV TI TTVQGI2 DMFJORV TN Mycobacterium Heat shock protein 65 (MycB groL2) DMFJORV RN Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum. 2002 Apr;45(4):502-7. DMFJORV RU https://pubmed.ncbi.nlm.nih.gov/12006932 DMFNLDY DI DMFNLDY DMFNLDY DN P-1 DMFNLDY TI TTSXVID DMFNLDY TN Nuclear factor NF-kappa-B (NFKB) DMFNLDY MA Modulator DMFNLDY RN Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002291. DMFNLDY RU https://pubmed.ncbi.nlm.nih.gov/15495031 DMFZNLH DI DMFZNLH DMFZNLH DN BMS-204352 DMFZNLH TI TT1VOHK DMFZNLH TN Potassium channel unspecific (KC) DMFZNLH MA Modulator DMFZNLH RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMFZNLH RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMG6TS2 DI DMG6TS2 DMG6TS2 DN GW873140 DMG6TS2 TI TT2CEJG DMG6TS2 TN C-C chemokine receptor type 5 (CCR5) DMG6TS2 MA Binder DMG6TS2 RN In vitro and clinical investigation of the relationship between CCR5 receptor occupancy and anti-HIV activity of Aplaviroc. J Clin Pharmacol. 2008 Oct;48(10):1179-88. DMG6TS2 RU https://pubmed.ncbi.nlm.nih.gov/18676693 DMGOPMK DI DMGOPMK DMGOPMK DN Otamixaban DMGOPMK TI TTCIHJA DMGOPMK TN Coagulation factor Xa (F10) DMGOPMK MA Inhibitor DMGOPMK RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMGOPMK RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMGW07M DI DMGW07M DMGW07M DN Aloxistatin DMGW07M TI TTG5QB7 DMGW07M TN Calpain-2 (CAPN2) DMGW07M MA Inhibitor DMGW07M RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMGW07M RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMGW07M DI DMGW07M DMGW07M DN Aloxistatin DMGW07M TI TTQAJF1 DMGW07M TN Cathepsin G (CTSG) DMGW07M MA Inhibitor DMGW07M RN Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J Biol Chem. 2007 Jul 20;282(29):20836-46. DMGW07M RU https://pubmed.ncbi.nlm.nih.gov/17535802 DMGYKDN DI DMGYKDN DMGYKDN DN Hemoximer DMGYKDN TI TTQO71U DMGYKDN TN Hemoglobin (HB) DMGYKDN MA Antagonist DMGYKDN RN Effect of NaBH4 Concentration and Reaction Time on Physical Properties of Glutaraldehyde-Polymerized Hemoglobin. Biotechnology Progress. 05/2004; 20(3):946-52. DMGYKDN RU http://onlinelibrary.wiley.com/doi/10.1021/bp0499754/abstract DMHE804 DI DMHE804 DMHE804 DN LOTRAFIBAN DMHE804 TI TT38RM1 DMHE804 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMHE804 MA Modulator DMHE804 RN Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.Expert Opin Investig Drugs.2000 Nov;9(11):2673-87. DMHE804 RU https://www.ncbi.nlm.nih.gov/pubmed/11060829 DMHR1A7 DI DMHR1A7 DMHR1A7 DN LAMIFIBAN DMHR1A7 TI TT38RM1 DMHR1A7 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMHR1A7 MA Modulator DMHR1A7 RN Lamifiban. Drugs. 1999 Feb;57(2):215-21; discussion 222-3. DMHR1A7 RU https://www.ncbi.nlm.nih.gov/pubmed/10188762 DMHSLVO DI DMHSLVO DMHSLVO DN DA-7101 DMHSLVO TI TTHI19T DMHSLVO TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMHSLVO MA Inhibitor DMHSLVO RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMHSLVO RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMHSM7I DI DMHSM7I DMHSM7I DN Cilomilast DMHSM7I TI TTV5CGO DMHSM7I TN Phosphodiesterase 4 (PDE4) DMHSM7I MA Inhibitor DMHSM7I RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMHSM7I RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMHSM7I DI DMHSM7I DMHSM7I DN Cilomilast DMHSM7I TI TTZ97H5 DMHSM7I TN Phosphodiesterase 4A (PDE4A) DMHSM7I MA Inhibitor DMHSM7I RN Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. DMHSM7I RU https://pubmed.ncbi.nlm.nih.gov/19046132 DMI02PF DI DMI02PF DMI02PF DN PRINOMIDE TROMETHAMINE DMI02PF TI TTVKILB DMI02PF TN Prostaglandin G/H synthase 2 (COX-2) DMI02PF MA Inhibitor DMI02PF RN Dexketoprofene, selective cox-1 inhibitor nsaids, without gastrointestinal injury in rats. Acta Gastroenterol Latinoam. 2002 May;32(1):17-20. DMI02PF RU https://pubmed.ncbi.nlm.nih.gov/12136686 DMIEB8Y DI DMIEB8Y DMIEB8Y DN Bevasiranib DMIEB8Y TI TTOHSBA DMIEB8Y TN Vascular endothelial growth factor A (VEGFA) DMIEB8Y MA Modulator DMIEB8Y RN Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration DMIEB8Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661434 DMIHQZ8 DI DMIHQZ8 DMIHQZ8 DN Segard DMIHQZ8 TI TTF8CQI DMIHQZ8 TN Tumor necrosis factor (TNF) DMIHQZ8 RN Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med. 2001 Apr;29(4):765-9. DMIHQZ8 RU https://pubmed.ncbi.nlm.nih.gov/11373466 DMIK6C9 DI DMIK6C9 DMIK6C9 DN Zibotentan DMIK6C9 TI TTKRD0G DMIK6C9 TN Endothelin A receptor (EDNRA) DMIK6C9 MA Antagonist DMIK6C9 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMIK6C9 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMJ4KQS DI DMJ4KQS DMJ4KQS DN GW-406381 DMJ4KQS TI TTVKILB DMJ4KQS TN Prostaglandin G/H synthase 2 (COX-2) DMJ4KQS MA Inhibitor DMJ4KQS RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMJ4KQS RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMJ59A4 DI DMJ59A4 DMJ59A4 DN MOFEGILINE DMJ59A4 TI TTGP7BY DMJ59A4 TN Monoamine oxidase type B (MAO-B) DMJ59A4 MA Modulator DMJ59A4 RN Structural and mechanistic studies of mofegiline inhibition of recombinant human monoamine oxidase B. J Med Chem. 2008 Dec 25;51(24):8019-26. DMJ59A4 RU https://pubmed.ncbi.nlm.nih.gov/19053775 DMJL5TR DI DMJL5TR DMJL5TR DN NOLOMIROLE HYDROCHLORIDE DMJL5TR TI TT2NUT5 DMJL5TR TN Adrenergic receptor alpha-2C (ADRA2C) DMJL5TR MA Modulator DMJL5TR RN Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan;49(1):1-5. DMJL5TR RU https://pubmed.ncbi.nlm.nih.gov/14597145 DMJL5TR DI DMJL5TR DMJL5TR DN NOLOMIROLE HYDROCHLORIDE DMJL5TR TI TTEX248 DMJL5TR TN Dopamine D2 receptor (D2R) DMJL5TR MA Agonist DMJL5TR RN Effect of nolomirole on monocrotaline-induced heart failure. Pharmacol Res. 2004 Jan;49(1):1-5. DMJL5TR RU https://pubmed.ncbi.nlm.nih.gov/14597145 DMJOM31 DI DMJOM31 DMJOM31 DN ELGODIPINE HYDROCHLORIDE DMJOM31 TI TT5HONZ DMJOM31 TN Calcium channel unspecific (CaC) DMJOM31 MA Agonist DMJOM31 RN The calcium channel blocker amlodipine exerts its anti-proliferative action via p21(Waf1/Cip1) gene activation. FASEB J. 2004 Oct;18(13):1516-23. DMJOM31 RU https://pubmed.ncbi.nlm.nih.gov/15466360 DMJY9CW DI DMJY9CW DMJY9CW DN Lapaquistat acetate DMJY9CW TI TTFQEO5 DMJY9CW TN Squalene synthetase (FDFT1) DMJY9CW MA Inhibitor DMJY9CW RN Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous le... Br J Pharmacol. 2008 Jul;154(5):949-57. DMJY9CW RU https://pubmed.ncbi.nlm.nih.gov/18587443 DMKM543 DI DMKM543 DMKM543 DN Acecainide DMKM543 TI TT1VOHK DMKM543 TN Potassium channel unspecific (KC) DMKM543 MA Opener DMKM543 RN Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40. DMKM543 RU https://pubmed.ncbi.nlm.nih.gov/1693889 DMKM543 DI DMKM543 DMKM543 DN Acecainide DMKM543 TI TTZOVE0 DMKM543 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMKM543 MA Blocker DMKM543 RN Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12. DMKM543 RU https://pubmed.ncbi.nlm.nih.gov/9476974 DMKMTR7 DI DMKMTR7 DMKMTR7 DN LDI-200 DMKMTR7 TI TT2O4W9 DMKMTR7 TN Luteinizing hormone receptor (LHCGR) DMKMTR7 MA Modulator DMKMTR7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 254). DMKMTR7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254 DMKSFPE DI DMKSFPE DMKSFPE DN BMS 275291 DMKSFPE TI TTLM12X DMKSFPE TN Matrix metalloproteinase-2 (MMP-2) DMKSFPE MA Inhibitor DMKSFPE RN Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. DMKSFPE RU https://pubmed.ncbi.nlm.nih.gov/18224669 DMKSFPE DI DMKSFPE DMKSFPE DN BMS 275291 DMKSFPE TI TTMX39J DMKSFPE TN Matrix metalloproteinase-1 (MMP-1) DMKSFPE MA Inhibitor DMKSFPE RN Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. DMKSFPE RU https://pubmed.ncbi.nlm.nih.gov/18224669 DMKSFPE DI DMKSFPE DMKSFPE DN BMS 275291 DMKSFPE TI TTMTWOS DMKSFPE TN Matrix metalloproteinase-7 (MMP-7) DMKSFPE MA Inhibitor DMKSFPE RN Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer. 2008 Mar 1;112(5):1083-8. DMKSFPE RU https://pubmed.ncbi.nlm.nih.gov/18224669 DML1DGP DI DML1DGP DML1DGP DN FOROPAFANT DML1DGP TI TTQL5VC DML1DGP TN Platelet-activating factor receptor (PTAFR) DML1DGP MA Antagonist DML1DGP RN Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51. DML1DGP RU https://pubmed.ncbi.nlm.nih.gov/1656029 DML6EWH DI DML6EWH DML6EWH DN Posatirelin DML6EWH TI TT4J8MF DML6EWH TN Thyrotropin-releasing hormone receptor (TRHR) DML6EWH MA Modulator DML6EWH RN TRH analogs at Gedeon Richter Ltd.: highlights of experimental and clinical efficacy of posatirelin. Acta Pharm Hung. 2002;72(1):62-8. DML6EWH RU https://pubmed.ncbi.nlm.nih.gov/12426788 DMLXHZR DI DMLXHZR DMLXHZR DN BL-1832 DMLXHZR TI TTZPO1L DMLXHZR TN Substance-P receptor (TACR1) DMLXHZR MA Antagonist DMLXHZR RN WO patent application no. 2006,0132,05, Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation. DMLXHZR RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060209&CC=WO&NR=2006013205A1&KC=A1 DMM5ZX6 DI DMM5ZX6 DMM5ZX6 DN Epothilone B DMM5ZX6 TI TTML2WA DMM5ZX6 TN Tubulin (TUB) DMM5ZX6 MA Inhibitor DMM5ZX6 RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMM5ZX6 RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMMDY27 DI DMMDY27 DMMDY27 DN Nuleusin DMMDY27 TI TTF89GD DMMDY27 TN Interleukin-2 (IL2) DMMDY27 MA Agonist DMMDY27 RN Expression, purification and characterization of recombinant human interleukin-2-serum albumin (rhIL-2-HSA) fusion protein in Pichia pastoris. Protein Expr Purif. 2012 Jul;84(1):154-60. DMMDY27 RU https://pubmed.ncbi.nlm.nih.gov/22609631 DMMG47P DI DMMG47P DMMG47P DN SUN-09 DMMG47P TI TTDCVZW DMMG47P TN Gamma-aminobutyric acid B receptor (GABBR) DMMG47P MA Modulator DMMG47P RN The effects of the GABA agonist, baclofen, on sleep and breathing. Eur Respir J. 1995 Feb;8(2):230-4. DMMG47P RU https://www.ncbi.nlm.nih.gov/pubmed/7758556 DMMT1YQ DI DMMT1YQ DMMT1YQ DN Bropirimine DMMT1YQ TI TTV2CN0 DMMT1YQ TN Interferon receptor (IFNR) DMMT1YQ MA Modulator DMMT1YQ RN Comparison between circulating interferon and drug levels following administration of 2-amino-5-bromo-6-phenyl-4(3H)-pyrimidinone (ABPP) to different animal species. J Interferon Res. 1982;2(3):317-27. DMMT1YQ RU https://pubmed.ncbi.nlm.nih.gov/6182250 DMMT1YQ DI DMMT1YQ DMMT1YQ DN Bropirimine DMMT1YQ TI TTG9CFY DMMT1YQ TN Bacterial Dihydroneopterinaldolase (Bact folB) DMMT1YQ MA Inhibitor DMMT1YQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMT1YQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMZO8X DI DMMZO8X DMMZO8X DN Miproxifene DMMZO8X TI TTZAYWL DMMZO8X TN Estrogen receptor (ESR) DMMZO8X MA Modulator DMMZO8X RN Estrogen agonistic/antagonistic effects of miproxifene phosphate (TAT-59)Shibata J1, Toko T, Saito H, Lykkesfeldt AE, Fujioka A, Sato K, Hashimoto A, Wierzba K, Yamada Y.Author information1Hanno Research Center, Taiho Pharmaceutical Co., Ltd., 1-27 Misugidai, Hanno-City, Saitama, 357-8527, Japan.Erratum inCancer Chemother Pharmacol 2000;46(2):172. AbstractPURPOSE: We evaluated miproxifene phosphate (TAT-59) to elucidate its efficacy in antiestrogen therapy for breast cancer patients and to assess its tissue-selective estrogenic/antiestrogenic activity.METHODS: Using DP-TAT-59, a major and active metabolite of TAT-59, an in vitro cell growth inhibition test was performed. Antitumor activity was determined using TAT-59 against human tumor xenografts of the MCF-7 and the Br-10 cell lines andMCF-7-derived tamoxifen-resistant cell lines, R-27 and FST-1. The antitumor activity of DP-TAT-59 and DM-DP-TAT-59, major metabolites of TAT-59 found in human blood following a TAT-59 dose, was also examined after intravenous administration to experimental animals. The residual estrogenic activity of TAT-59, evaluated in terms of bone and lipid metabolism in ovariectomized rats, was then comparedwith that of tamoxifen.RESULTS: DP-TAT-59 significantly inhibited the proliferation of estrogen receptor-positive MCF-7 and T-47D tumor cells in the presence of 1 nM estradiol. TAT-59, given to mice bearing MCF-7 or Br-10 xenografts, at the dose level of 5 mg/kg, exerted a significant growth inhibitory effect that was stronger than that of tamoxifen. Moreover, R-27 and FST-1 tumors, which show a resistance to tamoxifen, responded strongly to TAT-59, suggesting that TAT-59 might be effective against tumors resistant to tamoxifen. The metabolites of TAT-59, DP-TAT-59 and DM-DP-TAT-59, showed similar antitumor activity. Both TAT-59 and tamoxifen suppressed the decrease in bone density and reduced the blood cholesterol levels in ovariectomized rats, suggesting that the estrogenic activity of TAT-59 is comparable to that of tamoxifen.CONCLUSIONS: On the basis of the above results, one may expect TAT-59 to become an effective drug in patients with tumors less sensitive to tamoxifen, while its estrogenic activity as determined by bone and lipid metabolism is similar to that of tamoxifen.PMID: 10663628 [PubMed - indexed for MEDLINE] ShareMeSH Terms, SubstancesMeSH TermsAnimalsAntineoplastic Agents, Hormonal/pharmacologyBreast Neoplasms/pathology*Cell Division/drug effectsDrug Screening Assays, AntitumorEstradiol/pharmacologyEstrogen Antagonists/pharmacology*FemaleHumansLipid MetabolismMiceMice, Inbred BALB CRatsRats, Sprague-DawleyReceptors, Estrogen/physiologyTamoxifen/analogs & derivatives*Tamoxifen/pharmacologyTransplantation, HeterologousTumor Cells, Cultured/drug effectsSubstancesAntineoplastic Agents, HormonalEstrogen AntagonistsReceptors, EstrogenTamoxifenTAT 59EstradiolLinkOut - more resourcesOther Literature SourcesAccess more work from the authors - ResearchGateMedicalBreast Cancer - MedlinePlus Health InformationMiscellaneousESTRADIOL - Hazardous Substances Data BankTAMOXIFEN - Hazardous Substances Data BankPubMed Commons home Cancer Chemother Pharmacol. 2000;45(2):133-41. DMMZO8X RU https://pubmed.ncbi.nlm.nih.gov/10663628 DMN1O7E DI DMN1O7E DMN1O7E DN FLUPAROXAN DMN1O7E TI TT2NUT5 DMN1O7E TN Adrenergic receptor alpha-2C (ADRA2C) DMN1O7E MA Modulator DMN1O7E RN The pharmacology of fluparoxan: a selective alpha 2-adrenoceptor antagonist. Br J Pharmacol. 1991 Apr;102(4):887-95. DMN1O7E RU https://pubmed.ncbi.nlm.nih.gov/1677298 DMN7TL8 DI DMN7TL8 DMN7TL8 DN Osutidine DMN7TL8 TI TTQHJ1K DMN7TL8 TN Histamine H2 receptor (H2R) DMN7TL8 MA Antagonist DMN7TL8 RN Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50. DMN7TL8 RU https://pubmed.ncbi.nlm.nih.gov/11215325 DMN9KJ2 DI DMN9KJ2 DMN9KJ2 DN Lenercept DMN9KJ2 TI TTZXH48 DMN9KJ2 TN TNF receptor (TNFR) DMN9KJ2 MA Modulator DMN9KJ2 RN Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controll... Crit Care Med. 2001 Mar;29(3):503-10. DMN9KJ2 RU https://www.ncbi.nlm.nih.gov/pubmed/11373411 DMNEM2C DI DMNEM2C DMNEM2C DN Anipamil DMNEM2C TI TT5HONZ DMNEM2C TN Calcium channel unspecific (CaC) DMNEM2C MA Modulator DMNEM2C RN Effects of the novel calcium channel blocker, anipamil, on the isolated rabbit heart. Comparison with verapamil and gallopamil. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):339-44. DMNEM2C RU https://pubmed.ncbi.nlm.nih.gov/1383837 DMNKZ61 DI DMNKZ61 DMNKZ61 DN Ablukast DMNKZ61 TI TTGKOY9 DMNKZ61 TN Leukotriene CysLT1 receptor (CYSLTR1) DMNKZ61 MA Modulator DMNKZ61 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMNKZ61 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMNQIKV DI DMNQIKV DMNQIKV DN DALTROBAN DMNQIKV TI TT2O84V DMNQIKV TN Thromboxane A2 receptor (TBXA2R) DMNQIKV MA Inhibitor DMNQIKV RN Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives. J Med Chem. 1992 Jun 12;35(12):2202-9. DMNQIKV RU https://pubmed.ncbi.nlm.nih.gov/1535377 DMNSE2I DI DMNSE2I DMNSE2I DN Galocitabine DMNSE2I TI TTU6BFZ DMNSE2I TN Candida Thymidylate synthase (Candi TMP1) DMNSE2I MA Inhibitor DMNSE2I RN The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul. 1996;36:143-63. DMNSE2I RU https://pubmed.ncbi.nlm.nih.gov/8869745 DMNTURD DI DMNTURD DMNTURD DN Ranagengliotucel-T DMNTURD TI TTI0KH6 DMNTURD TN TGF beta-2 messenger RNA (TGFB2 mRNA) DMNTURD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210) DMNTURD RU http://adisinsight.springer.com/drugs/800017210 DMNX0JH DI DMNX0JH DMNX0JH DN N-0861 DMNX0JH TI TTK25J1 DMNX0JH TN Adenosine A1 receptor (ADORA1) DMNX0JH MA Antagonist DMNX0JH RN N-0861 selectively antagonizes adenosine A1 receptors in vivo. Eur J Pharmacol. 1992 May 27;216(1):9-16. DMNX0JH RU https://pubmed.ncbi.nlm.nih.gov/1526257 DMO3AJS DI DMO3AJS DMO3AJS DN DG031 DMO3AJS TI TTDMBF5 DMO3AJS TN Arachidonate 5-lipoxygenase activating protein (FLAP) DMO3AJS MA Inhibitor DMO3AJS RN BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8. DMO3AJS RU https://pubmed.ncbi.nlm.nih.gov/17928652 DMO9XTJ DI DMO9XTJ DMO9XTJ DN Quinelorane DMO9XTJ TI TT4C8EA DMO9XTJ TN Dopamine D3 receptor (D3R) DMO9XTJ MA Modulator DMO9XTJ RN Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies.Pharmacol Biochem Behav.2008 Oct;90(4):686-90. DMO9XTJ RU https://www.ncbi.nlm.nih.gov/pubmed/18579193 DMOIP7R DI DMOIP7R DMOIP7R DN Flesinoxan DMOIP7R TI TTSQIFT DMOIP7R TN 5-HT 1A receptor (HTR1A) DMOIP7R MA Agonist DMOIP7R RN Effect of sustained administration of the 5-HT1A receptor agonist flesinoxan on rat 5-HT neurotransmission. Eur Neuropsychopharmacol. 1999 Sep;9(5):427-40. DMOIP7R RU https://pubmed.ncbi.nlm.nih.gov/10523050 DMOQIMS DI DMOQIMS DMOQIMS DN Bifeprunox DMOQIMS TI TTSQIFT DMOQIMS TN 5-HT 1A receptor (HTR1A) DMOQIMS MA Modulator DMOQIMS RN Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86. DMOQIMS RU https://www.ncbi.nlm.nih.gov/pubmed/21521422 DMOQIMS DI DMOQIMS DMOQIMS DN Bifeprunox DMOQIMS TI TTEX248 DMOQIMS TN Dopamine D2 receptor (D2R) DMOQIMS MA Modulator DMOQIMS RN Bifeprunox: a partial agonist at dopamine D2 and serotonin 1A receptors, influences nicotine-seeking behaviour in response to drug-associated stimuli in rats.Addict Biol.2012 Mar;17(2):274-86. DMOQIMS RU https://www.ncbi.nlm.nih.gov/pubmed/21521422 DMOU173 DI DMOU173 DMOU173 DN CP-945598 DMOU173 TI TT6OEDT DMOU173 TN Cannabinoid receptor 1 (CB1) DMOU173 MA Antagonist DMOU173 RN Pfizer. Product Development Pipeline. March 31 2009. DMOU173 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMOVJ60 DI DMOVJ60 DMOVJ60 DN RPAF-AH DMOVJ60 TI TTDNFMT DMOVJ60 TN Platelet-activating factor acetylhydrolase (PLA2G7) DMOVJ60 MA Modulator DMOVJ60 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006777) DMOVJ60 RU http://adisinsight.springer.com/drugs/800006777 DMPCY8K DI DMPCY8K DMPCY8K DN Milameline DMPCY8K TI TTOXS3C DMPCY8K TN Muscarinic acetylcholine receptor (CHRM) DMPCY8K MA Modulator DMPCY8K RN Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J Pharmacol Exp Ther. 1999 Nov;291(2):812-22. DMPCY8K RU https://pubmed.ncbi.nlm.nih.gov/10525104 DMPEHBJ DI DMPEHBJ DMPEHBJ DN OX-NLA DMPEHBJ TI TT7CXIM DMPEHBJ TN Histamine receptor (HR) DMPEHBJ MA Antagonist DMPEHBJ RN Clinical pipeline report, company report or official report of Orexo. DMPEHBJ RU http://www.orexo.com/Portfolio/OX-NLA/ DMPNTDL DI DMPNTDL DMPNTDL DN Seratrodast DMPNTDL TI TT2O84V DMPNTDL TN Thromboxane A2 receptor (TBXA2R) DMPNTDL MA Antagonist DMPNTDL RN Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002;1(1):11-7. DMPNTDL RU https://pubmed.ncbi.nlm.nih.gov/14720071 DMPQZ80 DI DMPQZ80 DMPQZ80 DN Acivicin DMPQZ80 TI TT5XOKS DMPQZ80 TN Leishmania Carbamoyl-phosphate synthase (Leishm CPS) DMPQZ80 MA Inhibitor DMPQZ80 RN Acivicin: a highly active potential chemotherapeutic agent against visceral leishmaniasis. Biochem Biophys Res Commun. 1990 Jul 31;170(2):426-32. DMPQZ80 RU https://pubmed.ncbi.nlm.nih.gov/2383250 DMPQZ80 DI DMPQZ80 DMPQZ80 DN Acivicin DMPQZ80 TI TTN12BZ DMPQZ80 TN CTP synthase (CTPS1) DMPQZ80 MA Inhibitor DMPQZ80 RN Synergistic effects with inhibitors of de novo pyrimidine synthesis, acivicin, and N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Sep;41(9 Pt 1):3419-23. DMPQZ80 RU https://pubmed.ncbi.nlm.nih.gov/7260907 DMPS14M DI DMPS14M DMPS14M DN Amibegron DMPS14M TI TTMXGCW DMPS14M TN Adrenergic receptor beta-3 (ADRB3) DMPS14M MA Agonist DMPS14M RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMPS14M RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMPTG39 DI DMPTG39 DMPTG39 DN Ataprost DMPTG39 TI TTOFYT1 DMPTG39 TN Prostacyclin receptor (PTGIR) DMPTG39 MA Modulator DMPTG39 RN Pharmacokinetics of intravenous ataprost alfadex, a new prostaglandin I2 analog in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1993 Aug;31(8):373-5. DMPTG39 RU https://pubmed.ncbi.nlm.nih.gov/8225681 DMPUED3 DI DMPUED3 DMPUED3 DN S-12968 DMPUED3 TI TT5HONZ DMPUED3 TN Calcium channel unspecific (CaC) DMPUED3 MA Blocker DMPUED3 RN (+)-S-12967 and (-)-S-12968: 1,4-dihydropyridine stereoisomers with calcium channel agonistic and antagonistic properties in rat resistance arteries. Br J Pharmacol. 1991 Jul;103(3):1703-8. DMPUED3 RU https://pubmed.ncbi.nlm.nih.gov/1933134 DMQN3JX DI DMQN3JX DMQN3JX DN Ocinaplon DMQN3JX TI TTEX6LM DMQN3JX TN GABA(A) receptor gamma-3 (GABRG3) DMQN3JX MA Modulator DMQN3JX RN Discriminative stimulus properties of GABAA receptor positive allosteric modulators TPA023, ocinaplon and NG2-73 in rats trained to discriminate chlordiazepoxide or zolpidem. Eur J Pharmacol. 2011 Oct 1;668(1-2):190-3. DMQN3JX RU https://pubmed.ncbi.nlm.nih.gov/21762686 DMQXJDM DI DMQXJDM DMQXJDM DN Piroximone DMQXJDM TI TTUST1O DMQXJDM TN Phosphodiesterase (PDE) DMQXJDM MA Inhibitor DMQXJDM RN Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14. DMQXJDM RU https://pubmed.ncbi.nlm.nih.gov/12959308 DMQZ6SE DI DMQZ6SE DMQZ6SE DN KW-2149 DMQZ6SE TI TTUTN1I DMQZ6SE TN Human Deoxyribonucleic acid (hDNA) DMQZ6SE MA Binder DMQZ6SE RN KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation. Biochem Pharmacol. 1998 Jun 1;55(11):1777-83. DMQZ6SE RU https://pubmed.ncbi.nlm.nih.gov/9714295 DMRA6H5 DI DMRA6H5 DMRA6H5 DN Broxaterol DMRA6H5 TI TT2CJVK DMRA6H5 TN Adrenergic receptor beta-2 (ADRB2) DMRA6H5 MA Modulator DMRA6H5 RN Broxaterol, a new beta 2-adrenoceptor agonist compared to salbutamol in asthmatics, oral and inhalation treatment. Respiration. 1989;55 Suppl 2:15-9. DMRA6H5 RU https://pubmed.ncbi.nlm.nih.gov/2572036 DMRBYH8 DI DMRBYH8 DMRBYH8 DN Sepimostat mesylate DMRBYH8 TI TTEMV5X DMRBYH8 TN Serine protease unspecific (SP) DMRBYH8 MA Modulator DMRBYH8 RN Effect of FUT-187, oral serine protease inhibitor, on inflammation in the gastric remnant. Gan To Kagaku Ryoho. 1996 Dec;23(14):1971-9. DMRBYH8 RU https://pubmed.ncbi.nlm.nih.gov/8978806 DMRQV8I DI DMRQV8I DMRQV8I DN Becatecarin DMRQV8I TI TTGTQHC DMRQV8I TN DNA topoisomerase I (TOP1) DMRQV8I MA Modulator DMRQV8I RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRQV8I RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMRXUY7 DI DMRXUY7 DMRXUY7 DN Idoxifene DMRXUY7 TI TTZAYWL DMRXUY7 TN Estrogen receptor (ESR) DMRXUY7 MA Modulator DMRXUY7 RN Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology. 1998 Dec;139(12):5224-34. DMRXUY7 RU https://pubmed.ncbi.nlm.nih.gov/9832463 DMRYC08 DI DMRYC08 DMRYC08 DN CGP71683A DMRYC08 TI TTY6EWA DMRYC08 TN Neuropeptide Y receptor type 5 (NPY5R) DMRYC08 MA Antagonist DMRYC08 RN Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402. DMRYC08 RU https://pubmed.ncbi.nlm.nih.gov/17382974 DMSC4K1 DI DMSC4K1 DMSC4K1 DN LY-544344 DMSC4K1 TI TTXJ47W DMSC4K1 TN Metabotropic glutamate receptor 2 (mGluR2) DMSC4K1 MA Agonist DMSC4K1 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMSC4K1 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMSC4K1 DI DMSC4K1 DMSC4K1 DN LY-544344 DMSC4K1 TI TT8A9EF DMSC4K1 TN Metabotropic glutamate receptor 3 (mGluR3) DMSC4K1 MA Agonist DMSC4K1 RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMSC4K1 RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMSPJX9 DI DMSPJX9 DMSPJX9 DN BEMESETRON DMSPJX9 TI TTR6K75 DMSPJX9 TN 5-HT 3B receptor (HTR3B) DMSPJX9 MA Inhibitor DMSPJX9 RN Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9. DMSPJX9 RU https://pubmed.ncbi.nlm.nih.gov/1732548 DMSPJX9 DI DMSPJX9 DMSPJX9 DN BEMESETRON DMSPJX9 TI TTPC4TU DMSPJX9 TN 5-HT 3A receptor (HTR3A) DMSPJX9 MA Inhibitor DMSPJX9 RN Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9. DMSPJX9 RU https://pubmed.ncbi.nlm.nih.gov/1732548 DMSPJX9 DI DMSPJX9 DMSPJX9 DN BEMESETRON DMSPJX9 TI TTJFY5U DMSPJX9 TN Adenosine A3 receptor (ADORA3) DMSPJX9 MA Inhibitor DMSPJX9 RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMSPJX9 RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMSRJY3 DI DMSRJY3 DMSRJY3 DN Saredutant DMSRJY3 TI TTYO0A3 DMSRJY3 TN Substance-K receptor (TACR2) DMSRJY3 MA Antagonist DMSRJY3 RN Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol. 2009 May 1;77(9):1522-30. DMSRJY3 RU https://pubmed.ncbi.nlm.nih.gov/19426690 DMSWLA3 DI DMSWLA3 DMSWLA3 DN Darapladib DMSWLA3 TI TT9V5JH DMSWLA3 TN Phospholipase A2 (PLA2G1B) DMSWLA3 MA Modulator DMSWLA3 RN Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs. 2009 Oct;12(10):648-55. DMSWLA3 RU https://www.ncbi.nlm.nih.gov/pubmed/19790016 DMT5O8I DI DMT5O8I DMT5O8I DN Axokine DMT5O8I TI TTY84UG DMT5O8I TN Acetyl-CoA carboxylase 2 (ACACB) DMT5O8I MA Inhibitor DMT5O8I RN Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21. DMT5O8I RU https://pubmed.ncbi.nlm.nih.gov/19199918 DMTCP8H DI DMTCP8H DMTCP8H DN Zanapezil DMTCP8H TI TT1RS9F DMTCP8H TN Acetylcholinesterase (AChE) DMTCP8H MA Inhibitor DMTCP8H RN Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats. Br J Pharmacol. 2005 Aug;145(8):1035-44. DMTCP8H RU https://pubmed.ncbi.nlm.nih.gov/15951830 DMTG18I DI DMTG18I DMTG18I DN Aleglitazar DMTG18I TI TTJ584C DMTG18I TN Peroxisome proliferator-activated receptor alpha (PPARA) DMTG18I MA Agonist DMTG18I RN Clinical pipeline report, company report or official report of Roche (2009). DMTG18I RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMTHMEI DI DMTHMEI DMTHMEI DN INS 316 DMTHMEI TI TTOZHQC DMTHMEI TN P2Y purinoceptor 2 (P2RY2) DMTHMEI MA Modulator DMTHMEI RN Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8. DMTHMEI RU https://pubmed.ncbi.nlm.nih.gov/11477729 DMTHMEI DI DMTHMEI DMTHMEI DN INS 316 DMTHMEI TI TT24DGP DMTHMEI TN P2Y purinoceptor 4 (P2RY4) DMTHMEI MA Agonist DMTHMEI RN ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31. DMTHMEI RU https://pubmed.ncbi.nlm.nih.gov/10779375 DMTHMEI DI DMTHMEI DMTHMEI DN INS 316 DMTHMEI TI TTYXPCO DMTHMEI TN P2Y purinoceptor 11 (P2RY11) DMTHMEI MA Agonist DMTHMEI RN Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling. Mol Pharmacol. 2003 Jun;63(6):1356-63. DMTHMEI RU https://pubmed.ncbi.nlm.nih.gov/12761346 DMTHMEI DI DMTHMEI DMTHMEI DN INS 316 DMTHMEI TI TTNVSKA DMTHMEI TN P2Y purinoceptor 6 (P2RY6) DMTHMEI MA Agonist DMTHMEI RN Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8. DMTHMEI RU https://pubmed.ncbi.nlm.nih.gov/8670200 DMUB0EC DI DMUB0EC DMUB0EC DN VELNACRINE DMUB0EC TI TT1RS9F DMUB0EC TN Acetylcholinesterase (AChE) DMUB0EC MA Inhibitor DMUB0EC RN Synthesis and biological activity of putative mono-hydroxylated metabolites of velnacrine, Bioorg. Med. Chem. Lett. 2(8):865-870 (1992). DMUB0EC RU http://www.sciencedirect.com/science/article/pii/S0960894X00805466 DMUM3CP DI DMUM3CP DMUM3CP DN 15(S)-hydroxyeicosatetraenoic acid (ophthalmic, dry eye), Alcon DMUM3CP TI TTHBUXE DMUM3CP TN Mucin (MUC) DMUM3CP MA Modulator DMUM3CP RN 15(S)-hydroxyeicosatetraenoic acid (15-HETE), a product of arachidonic acid peroxidation, is an active component of hemozoin toxicity to monocytes. Parassitologia. 1999 Sep;41(1-3):199-202. DMUM3CP RU https://pubmed.ncbi.nlm.nih.gov/10697856 DMUR3VP DI DMUR3VP DMUR3VP DN MDL-11939 DMUR3VP TI TTJQOD7 DMUR3VP TN 5-HT 2A receptor (HTR2A) DMUR3VP MA Inhibitor DMUR3VP RN Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10. DMUR3VP RU https://pubmed.ncbi.nlm.nih.gov/1479590 DMUYQH8 DI DMUYQH8 DMUYQH8 DN IRX-4310 DMUYQH8 TI TTOD7B3 DMUYQH8 TN Retinoic acid receptor (RAR) DMUYQH8 MA Antagonist DMUYQH8 RN An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. Br J Cancer. 2004 Aug 2;91(3):580-8. DMUYQH8 RU https://pubmed.ncbi.nlm.nih.gov/15266311 DMV2Y6L DI DMV2Y6L DMV2Y6L DN Alinidine DMV2Y6L TI TT1VOHK DMV2Y6L TN Potassium channel unspecific (KC) DMV2Y6L MA Blocker DMV2Y6L RN Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Naunyn Schmiedebergs Arch Pharmacol. 1984 Dec;328(2):210-3. DMV2Y6L RU https://pubmed.ncbi.nlm.nih.gov/6527706 DMV3PEA DI DMV3PEA DMV3PEA DN Almokalant DMV3PEA TI TT1VOHK DMV3PEA TN Potassium channel unspecific (KC) DMV3PEA MA Modulator DMV3PEA RN Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal reentrant tachycardia.Almokalant PSVT Study Group.J Cardiovasc Pharmacol.1995 Aug;26(2):198-206. DMV3PEA RU https://www.ncbi.nlm.nih.gov/pubmed/7475043 DMVB9XC DI DMVB9XC DMVB9XC DN Tanomastat DMVB9XC TI TTLM12X DMVB9XC TN Matrix metalloproteinase-2 (MMP-2) DMVB9XC MA Inhibitor DMVB9XC RN Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:44-6. DMVB9XC RU https://pubmed.ncbi.nlm.nih.gov/18336400 DMVL8PB DI DMVL8PB DMVL8PB DN IoGen DMVL8PB TI TTZAYWL DMVL8PB TN Estrogen receptor (ESR) DMVL8PB MA Modulator DMVL8PB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMVL8PB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMVRA8N DI DMVRA8N DMVRA8N DN Org-2766 DMVRA8N TI TTEDJN4 DMVRA8N TN Low-affinity nerve growth factor receptor (NGFR) DMVRA8N MA Modulator DMVRA8N RN Effects of the ACTH4-9 analog Org2766 on brain plasticity: modulation of excitatory neurotransmission. Psychoneuroendocrinology. 1992 Aug;17(4):315-25. DMVRA8N RU https://pubmed.ncbi.nlm.nih.gov/1332099 DMW9H7M DI DMW9H7M DMW9H7M DN Propiram fumarate DMW9H7M TI TTN4QDT DMW9H7M TN Opioid receptor (OPR) DMW9H7M MA Modulator DMW9H7M RN The relative analgesic efficacy of propiram fumarate, codeine, aspirin, and placebo in post-impaction dental pain. J Clin Pharmacol. 1984 Jan;24(1):35-42. DMW9H7M RU https://pubmed.ncbi.nlm.nih.gov/6368614 DMWB23S DI DMWB23S DMWB23S DN H1N1 influenza vaccine DMWB23S TI TT3J5ZI DMWB23S TN Cell mediated immunity response (CMIR) DMWB23S RN Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol. 2012 Dec 3;13:165. DMWB23S RU https://pubmed.ncbi.nlm.nih.gov/23206898 DMWMHU7 DI DMWMHU7 DMWMHU7 DN Dofequidar fumarate DMWMHU7 TI TTJUXV6 DMWMHU7 TN Multidrug resistance protein 3 (ABCB4) DMWMHU7 MA Modulator DMWMHU7 RN Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol. 1995;35(4):271-7. DMWMHU7 RU https://pubmed.ncbi.nlm.nih.gov/7828268 DMWNXES DI DMWNXES DMWNXES DN Thrombomodulin DMWNXES TI TTAPV67 DMWNXES TN Thrombomodulin (THBD) DMWNXES MA Modulator DMWNXES RN Thrombomodulin. Nihon Yakurigaku Zasshi. 2000 Nov;116(5):283-9. DMWNXES RU https://pubmed.ncbi.nlm.nih.gov/11215378 DMWPT8J DI DMWPT8J DMWPT8J DN Oxibendazole DMWPT8J TI TTORYTW DMWPT8J TN Polymerase unspecific (POL) DMWPT8J MA Inhibitor DMWPT8J RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMWPT8J RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMWUS8N DI DMWUS8N DMWUS8N DN Licarbazepine DMWUS8N TI TTRK8B9 DMWUS8N TN Sodium channel unspecific (NaC) DMWUS8N MA Blocker DMWUS8N RN Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34. DMWUS8N RU https://pubmed.ncbi.nlm.nih.gov/17064222 DMX2SHT DI DMX2SHT DMX2SHT DN Dianicline DMX2SHT TI TTL1ATN DMX2SHT TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMX2SHT MA Modulator DMX2SHT RN Dianicline, a novel 42 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.Nicotine Tob Res.2011 Jan;13(1):1-6. DMX2SHT RU https://www.ncbi.nlm.nih.gov/pubmed/21041839 DMX3IRE DI DMX3IRE DMX3IRE DN HBP-347 DMX3IRE TI TT78R5H DMX3IRE TN Heat shock protein 90 alpha (HSP90A) DMX3IRE MA Modulator DMX3IRE RN US patent application no. 2013,0023,420, Susceptibility to hsp90-inhibitors. DMX3IRE RU http://www.google.com/patents/US20130023420 DMXEU14 DI DMXEU14 DMXEU14 DN PF-1913539 DMXEU14 TI TTVBPDM DMXEU14 TN Metabotropic glutamate receptor 1 (mGluR1) DMXEU14 MA Antagonist DMXEU14 RN Pfizer. Product Development Pipeline. March 31 2009. DMXEU14 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMXEU14 DI DMXEU14 DMXEU14 DN PF-1913539 DMXEU14 TI TTNE7KG DMXEU14 TN Adenosine A2b receptor (ADORA2B) DMXEU14 MA Antagonist DMXEU14 RN Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75. DMXEU14 RU https://pubmed.ncbi.nlm.nih.gov/9920286 DMXEU14 DI DMXEU14 DMXEU14 DN PF-1913539 DMXEU14 TI TTM2AOE DMXEU14 TN Adenosine A2a receptor (ADORA2A) DMXEU14 MA Antagonist DMXEU14 RN Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003 Aug;43(2):190-4. DMXEU14 RU https://pubmed.ncbi.nlm.nih.gov/12838511 DMXHWK6 DI DMXHWK6 DMXHWK6 DN Neutralase DMXHWK6 TI TTR7GJO DMXHWK6 TN Heparanase (HPSE) DMXHWK6 MA Modulator DMXHWK6 RN Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost. 2006 Mar;4(3):560-5. DMXHWK6 RU https://pubmed.ncbi.nlm.nih.gov/16460439 DMXKWAL DI DMXKWAL DMXKWAL DN Deligoparin sodium DMXKWAL TI TT4QPUL DMXKWAL TN Antithrombin-III (ATIII) DMXKWAL MA Modulator DMXKWAL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). DMXKWAL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 DMXRU9M DI DMXRU9M DMXRU9M DN Valspodar DMXRU9M TI TT0JLSD DMXRU9M TN Multidrug resistance protein (MDR) DMXRU9M MA Modulator DMXRU9M RN Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15. Jpn J Cancer Res. 2001 Oct;92(10):1116-26. DMXRU9M RU https://pubmed.ncbi.nlm.nih.gov/11676863 DMXRU9M DI DMXRU9M DMXRU9M DN Valspodar DMXRU9M TI TTCIHJA DMXRU9M TN Coagulation factor Xa (F10) DMXRU9M MA Inhibitor DMXRU9M RN Non-hemostatic activity of coagulation factor Xa: potential implications for various diseases. Curr Opin Pharmacol. 2001 Apr;1(2):169-75. DMXRU9M RU https://pubmed.ncbi.nlm.nih.gov/11714092 DMXSTRM DI DMXSTRM DMXSTRM DN Pibutidine DMXSTRM TI TTQHJ1K DMXSTRM TN Histamine H2 receptor (H2R) DMXSTRM MA Modulator DMXSTRM RN Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82. DMXSTRM RU https://pubmed.ncbi.nlm.nih.gov/7476906 DMXT36M DI DMXT36M DMXT36M DN Mivazerol DMXT36M TI TTQ8AFT DMXT36M TN Adrenergic receptor Alpha-2 (ADRA2) DMXT36M MA Agonist DMXT36M RN Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia. 1999 Feb;54(2):146-65. DMXT36M RU https://pubmed.ncbi.nlm.nih.gov/10215710 DMXV28I DI DMXV28I DMXV28I DN RG-12915 DMXV28I TI TTNXLKE DMXV28I TN 5-HT 3 receptor (5HT3R) DMXV28I MA Antagonist DMXV28I RN Cataractogenesis in rats induced by in utero exposure to RG 12915, a 5-HT3 antagonist. Fundam Appl Toxicol. 1995 Sep;27(2):270-6. DMXV28I RU https://pubmed.ncbi.nlm.nih.gov/8529823 DMXW1Y3 DI DMXW1Y3 DMXW1Y3 DN SKF-96067 DMXW1Y3 TI TTLOKXP DMXW1Y3 TN Gastric H(+)/K(+) ATPase (Proton pump) DMXW1Y3 MA Modulator DMXW1Y3 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXW1Y3 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXWRGF DI DMXWRGF DMXWRGF DN L-759274 DMXWRGF TI TTZPO1L DMXWRGF TN Substance-P receptor (TACR1) DMXWRGF MA Antagonist DMXWRGF RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMXWRGF RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMYF1DN DI DMYF1DN DMYF1DN DN Terutroban sodium DMYF1DN TI TT2O84V DMYF1DN TN Thromboxane A2 receptor (TBXA2R) DMYF1DN MA Antagonist DMYF1DN RN Terutroban and endothelial TP receptors in atherogenesis. Med Sci (Paris). 2006 Apr;22(4):437-43. DMYF1DN RU https://pubmed.ncbi.nlm.nih.gov/16597416 DMYQT2V DI DMYQT2V DMYQT2V DN Sibenadet DMYQT2V TI TT2CJVK DMYQT2V TN Adrenergic receptor beta-2 (ADRB2) DMYQT2V MA Modulator DMYQT2V RN The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a... Respir Med. 2003 Jan;97 Suppl A:S23-33. DMYQT2V RU https://www.ncbi.nlm.nih.gov/pubmed/12564608 DMYQT2V DI DMYQT2V DMYQT2V DN Sibenadet DMYQT2V TI TTEX248 DMYQT2V TN Dopamine D2 receptor (D2R) DMYQT2V MA Modulator DMYQT2V RN The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a... Respir Med. 2003 Jan;97 Suppl A:S23-33. DMYQT2V RU https://www.ncbi.nlm.nih.gov/pubmed/12564608 DMYQZBT DI DMYQZBT DMYQZBT DN MR-889 DMYQZBT TI TTPLTSQ DMYQZBT TN Neutrophil elastase (NE) DMYQZBT MA Inhibitor DMYQZBT RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DMYQZBT RU https://pubmed.ncbi.nlm.nih.gov/12084007 DMZ38EN DI DMZ38EN DMZ38EN DN Dalvastatin DMZ38EN TI TTPADOQ DMZ38EN TN HMG-CoA reductase (HMGCR) DMZ38EN MA Inhibitor DMZ38EN RN RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent. Pharmacology. 1993;46(1):13-22. DMZ38EN RU https://pubmed.ncbi.nlm.nih.gov/8434028 DMZAL8C DI DMZAL8C DMZAL8C DN Motesanib DMZAL8C TI TTI2WET DMZAL8C TN Platelet-derived growth factor receptor (PDGFR) DMZAL8C MA Inhibitor DMZAL8C RN Clinical pipeline report, company report or official report of Amgen (2009). DMZAL8C RU http://www.amgen.com/science/pipe.jsp DMZAL8C DI DMZAL8C DMZAL8C DN Motesanib DMZAL8C TI TTUTJGQ DMZAL8C TN Vascular endothelial growth factor receptor 2 (KDR) DMZAL8C MA Inhibitor DMZAL8C RN Clinical pipeline report, company report or official report of Amgen (2009). DMZAL8C RU http://www.amgen.com/science/pipe.jsp DMZAL8C DI DMZAL8C DMZAL8C DN Motesanib DMZAL8C TI TTX41N9 DMZAL8C TN Tyrosine-protein kinase Kit (KIT) DMZAL8C MA Inhibitor DMZAL8C RN Clinical pipeline report, company report or official report of Amgen (2009). DMZAL8C RU http://www.amgen.com/science/pipe.jsp DMZIV6D DI DMZIV6D DMZIV6D DN Befloxatone DMZIV6D TI TT3WG5C DMZIV6D TN Monoamine oxidase type A (MAO-A) DMZIV6D MA Inhibitor DMZIV6D RN Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther. 1996 Apr;277(1):265-77. DMZIV6D RU https://pubmed.ncbi.nlm.nih.gov/8613929 DMZK70E DI DMZK70E DMZK70E DN BN 50730 DMZK70E TI TTQL5VC DMZK70E TN Platelet-activating factor receptor (PTAFR) DMZK70E MA Modulator DMZK70E RN Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2001 Jun;49(6):804-11. DMZK70E RU https://www.ncbi.nlm.nih.gov/pubmed/11385142 DMZMFX6 DI DMZMFX6 DMZMFX6 DN KU-1257 DMZMFX6 TI TTQHJ1K DMZMFX6 TN Histamine H2 receptor (H2R) DMZMFX6 MA Antagonist DMZMFX6 RN Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33. DMZMFX6 RU https://pubmed.ncbi.nlm.nih.gov/8096132 DMZU1TV DI DMZU1TV DMZU1TV DN SIBRAFIBAN DMZU1TV TI TT38RM1 DMZU1TV TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMZU1TV MA Modulator DMZU1TV RN Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. J Clin Pharmacol. 2000 May;40(5):488-95. DMZU1TV RU https://www.ncbi.nlm.nih.gov/pubmed/10806602 DM6R3WC DI DM6R3WC DM6R3WC DN BAY 86-6150 DM6R3WC TI TTF0EGX DM6R3WC TN Coagulation factor VII (F7) DM6R3WC MA Modulator DM6R3WC RN Bayer HealthCare and Maxygen Announce Hematology Agreement. U.S. Securities and Exchange Commission. July 2, 2008. DM6R3WC RU http://www.sec.gov/Archives/edgar/data/1068796/000095013408012286/f41954exv99w1.htm DMTR50E DI DMTR50E DMTR50E DN Ilepatril DMTR50E TI TT5TKPM DMTR50E TN Neutral endopeptidase (MME) DMTR50E MA Modulator DMTR50E RN Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9. DMTR50E RU https://pubmed.ncbi.nlm.nih.gov/18311667 DMTR50E DI DMTR50E DMTR50E DN Ilepatril DMTR50E TI TTL69WB DMTR50E TN Angiotensin-converting enzyme (ACE) DMTR50E MA Modulator DMTR50E RN Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension. Curr Opin Investig Drugs. 2008 Mar;9(3):301-9. DMTR50E RU https://pubmed.ncbi.nlm.nih.gov/18311667 DMMT4PB DI DMMT4PB DMMT4PB DN Osanetant DMMT4PB TI TTBPGLU DMMT4PB TN Neuromedin-K receptor (TACR3) DMMT4PB MA Antagonist DMMT4PB RN Pharmacological characterization of senktide-induced tail whips. Neuropharmacology. 2010 Jan;58(1):259-67. DMMT4PB RU https://pubmed.ncbi.nlm.nih.gov/19540857 DMLQVTJ DI DMLQVTJ DMLQVTJ DN Octopamine DMLQVTJ TI TTCIHJA DMLQVTJ TN Coagulation factor Xa (F10) DMLQVTJ MA Inhibitor DMLQVTJ RN Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost. 2009 Jul;7(7):1143-51. DMLQVTJ RU https://pubmed.ncbi.nlm.nih.gov/19422447 DM01MRZ DI DM01MRZ DM01MRZ DN Ro-24-4736 DM01MRZ TI TTQL5VC DM01MRZ TN Platelet-activating factor receptor (PTAFR) DM01MRZ MA Antagonist DM01MRZ RN Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736. J Pharmacol Exp Ther. 1991 Oct;259(1):78-85. DM01MRZ RU https://pubmed.ncbi.nlm.nih.gov/1656030 DM02ANM DI DM02ANM DM02ANM DN P-1075 DM02ANM TI TT1VOHK DM02ANM TN Potassium channel unspecific (KC) DM02ANM MA Opener DM02ANM RN The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery. J Cardiovasc Pharmacol. 2011 Jun;57(6):648-55. DM02ANM RU https://pubmed.ncbi.nlm.nih.gov/21346595 DM02DNQ DI DM02DNQ DM02DNQ DN APC-366 DM02DNQ TI TTM1TDX DM02DNQ TN Tryptase alpha/beta-1 (Tryptase) DM02DNQ MA Inhibitor DM02DNQ RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DM02DNQ RU https://pubmed.ncbi.nlm.nih.gov/10197050 DM03FHA DI DM03FHA DM03FHA DN LY293111 DM03FHA TI TTN53ZF DM03FHA TN Leukotriene B4 receptor 1 (LTB4R) DM03FHA MA Antagonist DM03FHA RN The Role of PPARgamma Receptors and Leukotriene B(4) Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer. PPAR Res. 2008;2008:827096. DM03FHA RU https://pubmed.ncbi.nlm.nih.gov/19190780 DM03I7V DI DM03I7V DM03I7V DN ERBULOZOLE DM03I7V TI TTML2WA DM03I7V TN Tubulin (TUB) DM03I7V MA Modulator DM03I7V RN Influence of the synthetic microtubule inhibitor erbulozole (P.I.N.N.) (R 55 104), a new tubulozole congener, and gamma irradiation on murine tumors in vivo. Eur J Cancer Clin Oncol. 1989 Oct;25(10):1499-504. DM03I7V RU https://pubmed.ncbi.nlm.nih.gov/2591442 DM03XVA DI DM03XVA DM03XVA DN CI-1018 DM03XVA TI TTZ97H5 DM03XVA TN Phosphodiesterase 4A (PDE4A) DM03XVA MA Inhibitor DM03XVA RN New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6. DM03XVA RU https://pubmed.ncbi.nlm.nih.gov/15149695 DM03XVA DI DM03XVA DM03XVA DN CI-1018 DM03XVA TI TTSKMI8 DM03XVA TN Phosphodiesterase 4D (PDE4D) DM03XVA MA Inhibitor DM03XVA RN New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6. DM03XVA RU https://pubmed.ncbi.nlm.nih.gov/15149695 DM03XVA DI DM03XVA DM03XVA DN CI-1018 DM03XVA TI TTVIAT9 DM03XVA TN Phosphodiesterase 4B (PDE4B) DM03XVA MA Inhibitor DM03XVA RN New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3303-6. DM03XVA RU https://pubmed.ncbi.nlm.nih.gov/15149695 DM04CIK DI DM04CIK DM04CIK DN AZT-P-DDI DM04CIK TI TT84ETX DM04CIK TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM04CIK MA Inhibitor DM04CIK RN Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro. Antiviral Res. 1996 Jun;31(1-2):115-20. DM04CIK RU https://pubmed.ncbi.nlm.nih.gov/8793015 DM05F1Z DI DM05F1Z DM05F1Z DN ENRASENTAN DM05F1Z TI TTKRD0G DM05F1Z TN Endothelin A receptor (EDNRA) DM05F1Z MA Modulator DM05F1Z RN Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16. DM05F1Z RU https://pubmed.ncbi.nlm.nih.gov/12595914 DM05F1Z DI DM05F1Z DM05F1Z DN ENRASENTAN DM05F1Z TI TT3ZTGU DM05F1Z TN Endothelin B receptor (EDNRB) DM05F1Z MA Modulator DM05F1Z RN Enrasentan, an antagonist of endothelin receptors. Cardiovasc Drug Rev. 2003 Spring;21(1):1-16. DM05F1Z RU https://pubmed.ncbi.nlm.nih.gov/12595914 DM06JTL DI DM06JTL DM06JTL DN Balicatib DM06JTL TI TTDZN01 DM06JTL TN Cathepsin K (CTSK) DM06JTL MA Inhibitor DM06JTL RN Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27. DM06JTL RU https://pubmed.ncbi.nlm.nih.gov/19046130 DM06SC9 DI DM06SC9 DM06SC9 DN FINROZOLE DM06SC9 TI TTSZLWK DM06SC9 TN Aromatase (CYP19A1) DM06SC9 MA Inhibitor DM06SC9 RN Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Br J Clin Pharmacol. 2001 Dec;52(6):702-4. DM06SC9 RU https://pubmed.ncbi.nlm.nih.gov/11736883 DM07VBW DI DM07VBW DM07VBW DN Glypromate DM07VBW TI TTGQUFK DM07VBW TN PI3K/AKT/mTOR pathway (PAm pathway) DM07VBW MA Modulator DM07VBW RN Dendritic spine dysgenesis in Rett syndrome. Front Neuroanat. 2014; 8: 97. DM07VBW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159975/ DM082ZW DI DM082ZW DM082ZW DN Prednisolone sodium metazoate DM082ZW TI TTP3UTW DM082ZW TN Steroid hormone receptor ERR (ESRR) DM082ZW MA Modulator DM082ZW RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM082ZW RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM08BIZ DI DM08BIZ DM08BIZ DN LY354740 DM08BIZ TI TT8A9EF DM08BIZ TN Metabotropic glutamate receptor 3 (mGluR3) DM08BIZ MA Agonist DM08BIZ RN Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA. ChemMedChem. 2009 Jul;4(7):1086-94. DM08BIZ RU https://pubmed.ncbi.nlm.nih.gov/19402024 DM08BIZ DI DM08BIZ DM08BIZ DN LY354740 DM08BIZ TI TTXJ47W DM08BIZ TN Metabotropic glutamate receptor 2 (mGluR2) DM08BIZ MA Agonist DM08BIZ RN Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6. DM08BIZ RU https://pubmed.ncbi.nlm.nih.gov/10884552 DM09CUO DI DM09CUO DM09CUO DN CTL-102-GDEPT DM09CUO TI TTFBNVI DM09CUO TN Aldose reductase (AKR1B1) DM09CUO MA Modulator DM09CUO RN Genes in the Service of Therapeutic Index: Progress for Virus-Directed Enzyme Prodrug Therapy. JCO May 1, 2004 vol. 22 no. 9 1535-1537c. DM09CUO RU http://jco.ascopubs.org/content/22/9/1535.full DM0B23J DI DM0B23J DM0B23J DN ELB-139 DM0B23J TI TTAN6JD DM0B23J TN Glutamate receptor AMPA (GRIA) DM0B23J MA Modulator DM0B23J RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DM0B23J RU https://pubmed.ncbi.nlm.nih.gov/16377242 DM0CF3B DI DM0CF3B DM0CF3B DN NPS 1776 DM0CF3B TI TTB6UM0 DM0CF3B TN Fatty aldehyde dehydrogenase (ALDH3A2) DM0CF3B MA Modulator DM0CF3B RN Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline. Epilepsy Res. 2006 June; 69(3): 273-294. DM0CF3B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562526/ DM0GKHX DI DM0GKHX DM0GKHX DN SLV319 DM0GKHX TI TT6OEDT DM0GKHX TN Cannabinoid receptor 1 (CB1) DM0GKHX MA Antagonist DM0GKHX RN JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6173-80. DM0GKHX RU https://pubmed.ncbi.nlm.nih.gov/22959249 DM0RXCK DI DM0RXCK DM0RXCK DN Emapunil DM0RXCK TI TTPTXIN DM0RXCK TN Translocator protein (TSPO) DM0RXCK MA Agonist DM0RXCK RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DM0RXCK RU https://pubmed.ncbi.nlm.nih.gov/18172433 DM0TDZI DI DM0TDZI DM0TDZI DN TAK-013 DM0TDZI TI TT8R70G DM0TDZI TN Gonadotropin-releasing hormone receptor (GNRHR) DM0TDZI MA Inhibitor DM0TDZI RN Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48. DM0TDZI RU https://pubmed.ncbi.nlm.nih.gov/18419112 DM0WG4U DI DM0WG4U DM0WG4U DN BRL-55834 DM0WG4U TI TT1VOHK DM0WG4U TN Potassium channel unspecific (KC) DM0WG4U MA Opener DM0WG4U RN Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats. Br J Pharmacol. 1993 Aug;109(4):1133-9. DM0WG4U RU https://pubmed.ncbi.nlm.nih.gov/8401925 DM0XF8J DI DM0XF8J DM0XF8J DN Elisartan potassium DM0XF8J TI TTGN1ZA DM0XF8J TN Angiotensin II receptor (AGTR) DM0XF8J MA Modulator DM0XF8J RN Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995 Apr 15;75(12):793-5. DM0XF8J RU https://pubmed.ncbi.nlm.nih.gov/7717281 DM10CBF DI DM10CBF DM10CBF DN GL-331 DM10CBF TI TT0IHXV DM10CBF TN DNA topoisomerase II (TOP2) DM10CBF MA Modulator DM10CBF RN GL331, a topoisomerase II inhibitor, induces radiosensitization of human glioma cells. Anticancer Res. 2006 May-Jun;26(3A):2149-56. DM10CBF RU https://pubmed.ncbi.nlm.nih.gov/16827158 DM10XWU DI DM10XWU DM10XWU DN Atipamezole DM10XWU TI TTQ8AFT DM10XWU TN Adrenergic receptor Alpha-2 (ADRA2) DM10XWU MA Antagonist DM10XWU RN Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance. Br J Pharmacol. 2008 Dec;155(8):1264-78. DM10XWU RU https://pubmed.ncbi.nlm.nih.gov/18806811 DM10ZJP DI DM10ZJP DM10ZJP DN Ronacaleret DM10ZJP TI TTBUYHA DM10ZJP TN Extracellular calcium-sensing receptor (CASR) DM10ZJP MA Antagonist DM10ZJP RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM10ZJP RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM15LAP DI DM15LAP DM15LAP DN Fonsartan DM15LAP TI TTQVOEI DM15LAP TN Angiotensin II receptor type-2 (AGTR2) DM15LAP MA Modulator DM15LAP RN Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43. DM15LAP RU https://pubmed.ncbi.nlm.nih.gov/9886894 DM17I8O DI DM17I8O DM17I8O DN CS-891B DM17I8O TI TT2A0DR DM17I8O TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM17I8O MA Inhibitor DM17I8O RN The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10(8):593-5. DM17I8O RU https://pubmed.ncbi.nlm.nih.gov/11125319 DM19Y0T DI DM19Y0T DM19Y0T DN SUPER-LEU-DOX DM19Y0T TI TT0IHXV DM19Y0T TN DNA topoisomerase II (TOP2) DM19Y0T MA Modulator DM19Y0T RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM19Y0T RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1AEVT DI DM1AEVT DM1AEVT DN CS-003 DM1AEVT TI TTYO0A3 DM1AEVT TN Substance-K receptor (TACR2) DM1AEVT MA Antagonist DM1AEVT RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM1AEVT RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM1AEVT DI DM1AEVT DM1AEVT DN CS-003 DM1AEVT TI TTZPO1L DM1AEVT TN Substance-P receptor (TACR1) DM1AEVT MA Antagonist DM1AEVT RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM1AEVT RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM1AEVT DI DM1AEVT DM1AEVT DN CS-003 DM1AEVT TI TTBPGLU DM1AEVT TN Neuromedin-K receptor (TACR3) DM1AEVT MA Antagonist DM1AEVT RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM1AEVT RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM1BQFY DI DM1BQFY DM1BQFY DN JTE-607 DM1BQFY TI TTXM6JN DM1BQFY TN Cytokine receptor unspecific (CRF) DM1BQFY MA Inhibitor DM1BQFY RN JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8. DM1BQFY RU https://pubmed.ncbi.nlm.nih.gov/10493164 DM1CDNS DI DM1CDNS DM1CDNS DN CJ-13610 DM1CDNS TI TT2J34L DM1CDNS TN Arachidonate 5-lipoxygenase (5-LOX) DM1CDNS MA Inhibitor DM1CDNS RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM1CDNS RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM1DHOT DI DM1DHOT DM1DHOT DN Esuprone DM1DHOT TI TT3WG5C DM1DHOT TN Monoamine oxidase type A (MAO-A) DM1DHOT MA Inhibitor DM1DHOT RN MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur J Clin Pharmacol. 1997;52(2):121-8. DM1DHOT RU https://pubmed.ncbi.nlm.nih.gov/9174681 DM1EOC3 DI DM1EOC3 DM1EOC3 DN Elzasonan hydrochloride DM1EOC3 TI TTK8CXU DM1EOC3 TN 5-HT 1B receptor (HTR1B) DM1EOC3 MA Modulator DM1EOC3 RN DOI: 10.1002/9781118541203.xen439 DM1EOC3 RU http://onlinelibrary.wiley.com/doi/10.1002/9781118541203.xen439/abstract DM1EOC3 DI DM1EOC3 DM1EOC3 DN Elzasonan hydrochloride DM1EOC3 TI TT6MSOK DM1EOC3 TN 5-HT 1D receptor (HTR1D) DM1EOC3 MA Modulator DM1EOC3 RN DOI: 10.1002/9781118541203.xen439 DM1EOC3 RU http://onlinelibrary.wiley.com/doi/10.1002/9781118541203.xen439/abstract DM1FIN9 DI DM1FIN9 DM1FIN9 DN GW-559090 DM1FIN9 TI TTHIZP9 DM1FIN9 TN Integrin alpha-5 (ITGA5) DM1FIN9 MA Antagonist DM1FIN9 RN Roles of integrin activation in eosinophil function and the eosinophilic inflammation of asthma. J Leukoc Biol. 2008 January; 83(1): 1-12. DM1FIN9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859217/ DM1J0YB DI DM1J0YB DM1J0YB DN SLX-2101 DM1J0YB TI TTJ0IQB DM1J0YB TN Phosphodiesterase 5A (PDE5A) DM1J0YB MA Inhibitor DM1J0YB RN Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64. DM1J0YB RU https://pubmed.ncbi.nlm.nih.gov/18491987 DM1JUS0 DI DM1JUS0 DM1JUS0 DN FK-224 DM1JUS0 TI TTZPO1L DM1JUS0 TN Substance-P receptor (TACR1) DM1JUS0 MA Modulator DM1JUS0 RN Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerv... J Pharmacol Exp Ther. 1992 Jul;262(1):403-8. DM1JUS0 RU https://www.ncbi.nlm.nih.gov/pubmed/1378097 DM1JUS0 DI DM1JUS0 DM1JUS0 DN FK-224 DM1JUS0 TI TTYO0A3 DM1JUS0 TN Substance-K receptor (TACR2) DM1JUS0 MA Modulator DM1JUS0 RN Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerv... J Pharmacol Exp Ther. 1992 Jul;262(1):403-8. DM1JUS0 RU https://www.ncbi.nlm.nih.gov/pubmed/1378097 DM1L5UX DI DM1L5UX DM1L5UX DN TAMOLARIZINE HYDROCHLORIDE DM1L5UX TI TT5HONZ DM1L5UX TN Calcium channel unspecific (CaC) DM1L5UX MA Blocker DM1L5UX RN Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist. Jpn J Pharmacol. 2000 Mar;82(3):265-8. DM1L5UX RU https://pubmed.ncbi.nlm.nih.gov/10887958 DM1LM7D DI DM1LM7D DM1LM7D DN Mannose phosphate DM1LM7D TI TTR9XHZ DM1LM7D TN Transforming growth factor beta 1 (TGFB1) DM1LM7D MA Modulator DM1LM7D RN The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF-beta1 pathway in human lung fibroblasts. Immunol Lett. 2015 Jun;165(2):90-101. DM1LM7D RU https://pubmed.ncbi.nlm.nih.gov/25929803 DM1LVRP DI DM1LVRP DM1LVRP DN IC-747 DM1LVRP TI TT48WR6 DM1LVRP TN Integrin alpha-L (ITGAL) DM1LVRP MA Antagonist DM1LVRP RN HECA-452+ T Cells Migrate Through Superficial Vascular Plexus but Not Through Deep Vascular Plexus Endothelium. Journal of Investigative Dermatology. 04/1997; 108(3):343-8. DM1LVRP RU http://www.nature.com/jid/journal/v121/n5/full/5602003a.html#tbl3 DM1OSUR DI DM1OSUR DM1OSUR DN CP-195543 DM1OSUR TI TTN53ZF DM1OSUR TN Leukotriene B4 receptor 1 (LTB4R) DM1OSUR MA Antagonist DM1OSUR RN The synthesis of CP-195543, an LTB4 antagonist for the treatment of inflammatory diseases. Curr Opin Drug Discov Devel. 1999 Nov;2(6):550-6. DM1OSUR RU https://pubmed.ncbi.nlm.nih.gov/19649826 DM1PJ0V DI DM1PJ0V DM1PJ0V DN HSR-609 DM1PJ0V TI TTTIBOJ DM1PJ0V TN Histamine H1 receptor (H1R) DM1PJ0V MA Antagonist DM1PJ0V RN Studies on the novel antiallergic agent HSR-609: its penetration into the central nervous system in mice and guinea pigs and its selectivity for the histamine H1-receptor. Jpn J Pharmacol. 1997 Apr;73(4):291-8. DM1PJ0V RU https://pubmed.ncbi.nlm.nih.gov/9165365 DM1QXPE DI DM1QXPE DM1QXPE DN ZELANDOPAM HYDROCHLORIDE DM1QXPE TI TTZFYLI DM1QXPE TN Dopamine D1 receptor (D1R) DM1QXPE MA Antagonist DM1QXPE RN Effect of zelandopam, a dopamine D1-like receptor agonist, in puromycin aminonucleoside nephrosis rats. Eur J Pharmacol. 2005 Mar 7;510(1-2):121-6. DM1QXPE RU https://pubmed.ncbi.nlm.nih.gov/15740732 DM1TDWI DI DM1TDWI DM1TDWI DN AZD2207 DM1TDWI TI TT6OEDT DM1TDWI TN Cannabinoid receptor 1 (CB1) DM1TDWI MA Antagonist DM1TDWI RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM1TDWI RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM1WGUT DI DM1WGUT DM1WGUT DN Epothilone D DM1WGUT TI TTYFKSZ DM1WGUT TN Tubulin beta (TUBB) DM1WGUT MA Inhibitor DM1WGUT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1WGUT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1YXPL DI DM1YXPL DM1YXPL DN Tomopenem DM1YXPL TI TTJP4SM DM1YXPL TN Bacterial Penicillin binding protein (Bact PBP) DM1YXPL MA Modulator DM1YXPL RN Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.Antimicrob Agents Chemother.2009 Mar;53(3):1238-41. DM1YXPL RU https://www.ncbi.nlm.nih.gov/pubmed/19104025 DM1Z74X DI DM1Z74X DM1Z74X DN Tacedinaline DM1Z74X TI TT6R7JZ DM1Z74X TN Histone deacetylase 1 (HDAC1) DM1Z74X MA Inhibitor DM1Z74X RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM1Z74X RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM2438J DI DM2438J DM2438J DN Z-335 DM2438J TI TT2O84V DM2438J TN Thromboxane A2 receptor (TBXA2R) DM2438J MA Antagonist DM2438J RN Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):782-90. DM2438J RU https://pubmed.ncbi.nlm.nih.gov/12092745 DM28AFU DI DM28AFU DM28AFU DN SCH-48461 DM28AFU TI TTNA5ZS DM28AFU TN Cholesterol absorption (Chole absorp) DM28AFU MA Modulator DM28AFU RN Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis. 1995 May;115(1):45-63. DM28AFU RU https://pubmed.ncbi.nlm.nih.gov/7669087 DM296V7 DI DM296V7 DM296V7 DN E-6080 DM296V7 TI TT2J34L DM296V7 TN Arachidonate 5-lipoxygenase (5-LOX) DM296V7 MA Inhibitor DM296V7 RN Effects of the new 5-lipoxygenase inhibitor E6080 on leukotriene release in vitro. Int Arch Allergy Immunol. 1992;97(4):267-73. DM296V7 RU https://pubmed.ncbi.nlm.nih.gov/1375926 DM29C6S DI DM29C6S DM29C6S DN JTP-2942 DM29C6S TI TT4J8MF DM29C6S TN Thyrotropin-releasing hormone receptor (TRHR) DM29C6S MA Modulator DM29C6S RN Effect of JTP-2942, a novel thyrotropin-releasing hormone analogue, on pentobarbital-induced anesthesia in rats. Eur J Pharmacol. 1995 Mar 24;276(1-2):177-82. DM29C6S RU https://pubmed.ncbi.nlm.nih.gov/7781687 DM2BDAW DI DM2BDAW DM2BDAW DN SK&F-S-106203 DM2BDAW TI TTTWGIX DM2BDAW TN Leukotriene receptor (LTR) DM2BDAW MA Modulator DM2BDAW RN Pharmacologic and pharmacokinetic profile of SK&F S-106203, a potent, orally active peptidoleukotriene receptor antagonist, in guinea-pig. Pulm Pharmacol. 1991;4(3):177-89. DM2BDAW RU https://pubmed.ncbi.nlm.nih.gov/1668219 DM2DK4A DI DM2DK4A DM2DK4A DN Mequitamium iodide DM2DK4A TI TTTIBOJ DM2DK4A TN Histamine H1 receptor (H1R) DM2DK4A MA Modulator DM2DK4A RN High-affinity binding of mequitamium iodide (LG 30435) to muscarinic and histamine H1 receptors. Eur J Pharmacol. 1990 Jul 17;182(3):413-20. DM2DK4A RU https://pubmed.ncbi.nlm.nih.gov/2226618 DM2FAH0 DI DM2FAH0 DM2FAH0 DN CBF-BS2 DM2FAH0 TI TTKN8W0 DM2FAH0 TN Glucose-6-phosphate dehydrogenase (G6PD) DM2FAH0 MA Modulator DM2FAH0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007279) DM2FAH0 RU http://adisinsight.springer.com/drugs/800007279 DM2G7IP DI DM2G7IP DM2G7IP DN E-4177 DM2G7IP TI TTGN1ZA DM2G7IP TN Angiotensin II receptor (AGTR) DM2G7IP MA Modulator DM2G7IP RN Prevention of renal damage by angiotensin II blockade, accompanied by increased renal hepatocyte growth factor in experimental hypertensive rats. Hypertension. 1999 Aug;34(2):279-84. DM2G7IP RU https://pubmed.ncbi.nlm.nih.gov/10454454 DM2I8NT DI DM2I8NT DM2I8NT DN Avosentan DM2I8NT TI TTKRD0G DM2I8NT TN Endothelin A receptor (EDNRA) DM2I8NT MA Antagonist DM2I8NT RN Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. DM2I8NT RU https://pubmed.ncbi.nlm.nih.gov/18764722 DM2KH9Y DI DM2KH9Y DM2KH9Y DN Talsaclidine fumarate DM2KH9Y TI TTZ9SOR DM2KH9Y TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2KH9Y MA Agonist DM2KH9Y RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DM2KH9Y RU https://pubmed.ncbi.nlm.nih.gov/19168056 DM2N0TO DI DM2N0TO DM2N0TO DN Physostigmine DM2N0TO TI TT1RS9F DM2N0TO TN Acetylcholinesterase (AChE) DM2N0TO MA Inhibitor DM2N0TO RN The effects of physostigmine on acetylcholinesterase activity of CSF plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharmacology. 1986 Oct;25(10):1167-77. DM2N0TO RU https://pubmed.ncbi.nlm.nih.gov/3785584 DM2NBXR DI DM2NBXR DM2NBXR DN BMY-21950 DM2NBXR TI TTPADOQ DM2NBXR TN HMG-CoA reductase (HMGCR) DM2NBXR MA Inhibitor DM2NBXR RN Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res. 1990 Jul;31(7):1271-82. DM2NBXR RU https://pubmed.ncbi.nlm.nih.gov/2401858 DM2NTJY DI DM2NTJY DM2NTJY DN R-68151 DM2NTJY TI TT2J34L DM2NTJY TN Arachidonate 5-lipoxygenase (5-LOX) DM2NTJY MA Inhibitor DM2NTJY RN Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. DM2NTJY RU https://pubmed.ncbi.nlm.nih.gov/10940813 DM2NTJY DI DM2NTJY DM2NTJY DN R-68151 DM2NTJY TI TTCIHJA DM2NTJY TN Coagulation factor Xa (F10) DM2NTJY MA Inhibitor DM2NTJY RN Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as a factor Xa inhibitor II. Substituent effect on biological activities. Chem Pharm Bull (Tokyo). 2002 Sep;50(9):1187-94. DM2NTJY RU https://pubmed.ncbi.nlm.nih.gov/12237534 DM2OWCV DI DM2OWCV DM2OWCV DN CGS-25462 DM2OWCV TI TT5TKPM DM2OWCV TN Neutral endopeptidase (MME) DM2OWCV MA Modulator DM2OWCV RN Quantitative analytical methods for the determination of a new hypertension drug, CGS 25462, and its metabolites (CGS 25659 and CGS 24592) in human plasma by high-performance liquid chromatography. JChromatogr B Biomed Sci Appl. 1998 Mar 20;706(2):287-94. DM2OWCV RU https://pubmed.ncbi.nlm.nih.gov/9551815 DM2Q5IS DI DM2Q5IS DM2Q5IS DN R-1438 DM2Q5IS TI TTDIGC1 DM2Q5IS TN Dipeptidyl peptidase 4 (DPP-4) DM2Q5IS MA Inhibitor DM2Q5IS RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DM2Q5IS RU https://pubmed.ncbi.nlm.nih.gov/19149538 DM2RH51 DI DM2RH51 DM2RH51 DN SCH-42495 DM2RH51 TI TT5TKPM DM2RH51 TN Neutral endopeptidase (MME) DM2RH51 MA Inhibitor DM2RH51 RN Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension. 1993 Jul;22(1):119-26. DM2RH51 RU https://pubmed.ncbi.nlm.nih.gov/8391513 DM2TDE7 DI DM2TDE7 DM2TDE7 DN NN8209 DM2TDE7 TI TTHXFA1 DM2TDE7 TN C5a anaphylatoxin chemotactic receptor (C5AR1) DM2TDE7 MA Modulator DM2TDE7 RN Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013 Apr 15;190(8):3839-47. DM2TDE7 RU https://pubmed.ncbi.nlm.nih.gov/23564578 DM2X6ME DI DM2X6ME DM2X6ME DN S-5751 DM2X6ME TI TTNVEIR DM2X6ME TN Prostaglandin D2 receptor (PTGDR) DM2X6ME MA Antagonist DM2X6ME RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DM2X6ME RU https://pubmed.ncbi.nlm.nih.gov/21948793 DM32IV4 DI DM32IV4 DM32IV4 DN RG7593 DM32IV4 TI TTM6QSK DM32IV4 TN B-cell receptor CD22 (CD22) DM32IV4 MA Modulator DM32IV4 RN Clinical pipeline report, company report or official report of Roche. DM32IV4 RU http://www.roche.com/irp3q12e-a.pdf DM32JL5 DI DM32JL5 DM32JL5 DN Linotroban DM32JL5 TI TT2O84V DM32JL5 TN Thromboxane A2 receptor (TBXA2R) DM32JL5 MA Antagonist DM32JL5 RN Effects of the novel thromboxane (TXA2) receptor antagonist linotroban on inulin and para-aminohippuric acid clearances in the conscious male and female rat. Arzneimittelforschung. 1997 Sep;47(9):1026-30. DM32JL5 RU https://pubmed.ncbi.nlm.nih.gov/9342416 DM32N5G DI DM32N5G DM32N5G DN VOROZOLE DM32N5G TI TTSZLWK DM32N5G TN Aromatase (CYP19A1) DM32N5G MA Inhibitor DM32N5G RN Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activ... J Med Chem. 2008 Jul 24;51(14):4226-38. DM32N5G RU https://pubmed.ncbi.nlm.nih.gov/18590272 DM35CQ4 DI DM35CQ4 DM35CQ4 DN JTS-653 DM35CQ4 TI TTMI6F5 DM35CQ4 TN Transient receptor potential cation channel V1 (TRPV1) DM35CQ4 MA Antagonist DM35CQ4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DM35CQ4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DM35KZG DI DM35KZG DM35KZG DN E-3040 DM35KZG TI TT2J34L DM35KZG TN Arachidonate 5-lipoxygenase (5-LOX) DM35KZG MA Inhibitor DM35KZG RN In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production. Eur J Pharmacol. 2001 Jun 22;422(1-3):209-16. DM35KZG RU https://pubmed.ncbi.nlm.nih.gov/11430933 DM39N7W DI DM39N7W DM39N7W DN CRx-401 DM39N7W TI TTVKILB DM39N7W TN Prostaglandin G/H synthase 2 (COX-2) DM39N7W MA Inhibitor DM39N7W RN ClinicalTrials.gov (NCT00506298) Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes. U.S. National Institutes of Health. DM39N7W RU https://clinicaltrials.gov/ct2/show/NCT00506298 DM39N7W DI DM39N7W DM39N7W DN CRx-401 DM39N7W TI TT8NGED DM39N7W TN Prostaglandin G/H synthase 1 (COX-1) DM39N7W MA Inhibitor DM39N7W RN ClinicalTrials.gov (NCT00506298) Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes. U.S. National Institutes of Health. DM39N7W RU https://clinicaltrials.gov/ct2/show/NCT00506298 DM3AVO1 DI DM3AVO1 DM3AVO1 DN DE-081 DM3AVO1 TI TTQL5VC DM3AVO1 TN Platelet-activating factor receptor (PTAFR) DM3AVO1 MA Modulator DM3AVO1 RN Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: a comparison of a microplate filtration system and a standard... J Pharmacol Toxicol Methods. 1996 Sep;36(1):53-62. DM3AVO1 RU https://pubmed.ncbi.nlm.nih.gov/8872920 DM3EAYN DI DM3EAYN DM3EAYN DN RESEQUINIL DM3EAYN TI TTEX6LM DM3EAYN TN GABA(A) receptor gamma-3 (GABRG3) DM3EAYN MA Agonist DM3EAYN RN WO patent application no. 2010,0024,51, Naphthyridin derivatives. DM3EAYN RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100107&CC=WO&NR=2010002451A1&KC=A1 DM3F5E0 DI DM3F5E0 DM3F5E0 DN TEI-6122 DM3F5E0 TI TT9B4N3 DM3F5E0 TN Prostaglandin receptor (PTGR) DM3F5E0 MA Modulator DM3F5E0 RN The effect of a synthetic 7-thiaprostaglandin E1 derivative, TEI-6122, on monocyte chemoattractant protein-1 induced chemotaxis in THP-1 cells.. Br J Pharmacol. 1995 October; 116(4): 2298-2302. DM3F5E0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1908987/ DM3HIQY DI DM3HIQY DM3HIQY DN Melanoma vaccine (ALVAC) DM3HIQY TI TT63M7Q DM3HIQY TN Melanoma-associated antigen 1 (MAGEA1) DM3HIQY RN Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. DM3HIQY RU https://pubmed.ncbi.nlm.nih.gov/20842062 DM3HIQY DI DM3HIQY DM3HIQY DN Melanoma vaccine (ALVAC) DM3HIQY TI TTE5ITK DM3HIQY TN Cancer/testis antigen 1 (NY-ESO-1) DM3HIQY RN Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. DM3HIQY RU https://pubmed.ncbi.nlm.nih.gov/20842062 DM3HIQY DI DM3HIQY DM3HIQY DN Melanoma vaccine (ALVAC) DM3HIQY TI TT8MK59 DM3HIQY TN Melanocytes lineage-specific antigen GP100 (PMEL) DM3HIQY RN Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. DM3HIQY RU https://pubmed.ncbi.nlm.nih.gov/20842062 DM3HIQY DI DM3HIQY DM3HIQY DN Melanoma vaccine (ALVAC) DM3HIQY TI TTWSKHD DM3HIQY TN Melanoma-associated antigen 3 (MAGEA3) DM3HIQY RN Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. DM3HIQY RU https://pubmed.ncbi.nlm.nih.gov/20842062 DM3HIQY DI DM3HIQY DM3HIQY DN Melanoma vaccine (ALVAC) DM3HIQY TI TT362RB DM3HIQY TN MART-1 melanoma antigen (MLANA) DM3HIQY RN Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. DM3HIQY RU https://pubmed.ncbi.nlm.nih.gov/20842062 DM3I0GS DI DM3I0GS DM3I0GS DN DG051 DM3I0GS TI TTXZEAJ DM3I0GS TN Leukotriene A-4 hydrolase (LTA4H) DM3I0GS MA Inhibitor DM3I0GS RN BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8. DM3I0GS RU https://pubmed.ncbi.nlm.nih.gov/17928652 DM3IRES DI DM3IRES DM3IRES DN Zilascorb (2H) DM3IRES TI TTLIZBJ DM3IRES TN Protein synthesis (hPRO synth) DM3IRES MA Modulator DM3IRES RN Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Anticancer Drugs. 1997 Mar;8(3):296-303. DM3IRES RU https://pubmed.ncbi.nlm.nih.gov/9095337 DM3ISKB DI DM3ISKB DM3ISKB DN PIRODAVIR DM3ISKB TI TT8R3VP DM3ISKB TN Rhinovirus Capsid protein (HRV VP) DM3ISKB MA Modulator DM3ISKB RN In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother. 2004 May;48(5):1766-72. DM3ISKB RU https://pubmed.ncbi.nlm.nih.gov/15105133 DM3M5TU DI DM3M5TU DM3M5TU DN T-588 DM3M5TU TI TTV8KWS DM3M5TU TN Vesicular acetylcholine transporter (SLC18A3) DM3M5TU MA Modulator DM3M5TU RN Involvement of noradrenaline transporters in S-nitrosocysteine-stimulated noradrenaline release from rat brain slices: existence of functional Na(+)-independent transporter activity. Neurochem Int. 2001 Apr;38(4):323-31. DM3M5TU RU https://pubmed.ncbi.nlm.nih.gov/11137627 DM3OJP0 DI DM3OJP0 DM3OJP0 DN CP-122288 DM3OJP0 TI TT6MSOK DM3OJP0 TN 5-HT 1D receptor (HTR1D) DM3OJP0 MA Agonist DM3OJP0 RN The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology. 1997 Jan;36(1):83-91. DM3OJP0 RU https://pubmed.ncbi.nlm.nih.gov/9144644 DM3PXLZ DI DM3PXLZ DM3PXLZ DN FO-152 DM3PXLZ TI TTU6BFZ DM3PXLZ TN Candida Thymidylate synthase (Candi TMP1) DM3PXLZ MA Modulator DM3PXLZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2642). DM3PXLZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2642 DM3R8TI DI DM3R8TI DM3R8TI DN Lifarizine DM3R8TI TI TT5HONZ DM3R8TI TN Calcium channel unspecific (CaC) DM3R8TI MA Blocker DM3R8TI RN The effect of lifarizine (RS-87476), a novel sodium and calcium channel modulator, on ischaemic dopamine depletion in the corpus striatum of the gerbil. Br J Pharmacol. 1993 May;109(1):175-7. DM3R8TI RU https://pubmed.ncbi.nlm.nih.gov/8388296 DM3R8TX DI DM3R8TX DM3R8TX DN ICI-D-8731 DM3R8TX TI TTGN1ZA DM3R8TX TN Angiotensin II receptor (AGTR) DM3R8TX MA Modulator DM3R8TX RN Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension. 1994 Jun;23(6 Pt 2):832-7. DM3R8TX RU https://pubmed.ncbi.nlm.nih.gov/8206613 DM3TU7D DI DM3TU7D DM3TU7D DN RG1578 DM3TU7D TI TTXJ47W DM3TU7D TN Metabotropic glutamate receptor 2 (mGluR2) DM3TU7D MA Modulator DM3TU7D RN Company report (Roche pipeline: 15 April 2014) DM3TU7D RU http://www.roche.com/irp1q14e-a.pdf DM3VFKM DI DM3VFKM DM3VFKM DN AZD4818 DM3VFKM TI TTC24WT DM3VFKM TN C-C chemokine receptor type 1 (CCR1) DM3VFKM MA Antagonist DM3VFKM RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM3VFKM RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM3VZ87 DI DM3VZ87 DM3VZ87 DN TCV-309 DM3VZ87 TI TTQL5VC DM3VZ87 TN Platelet-activating factor receptor (PTAFR) DM3VZ87 MA Modulator DM3VZ87 RN Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in r... Thromb Res. 1993 May 15;70(4):281-93. DM3VZ87 RU https://www.ncbi.nlm.nih.gov/pubmed/8332959 DM3YABD DI DM3YABD DM3YABD DN LANIQUIDAR DM3YABD TI TTJUXV6 DM3YABD TN Multidrug resistance protein 3 (ABCB4) DM3YABD MA Modulator DM3YABD RN Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9. DM3YABD RU https://pubmed.ncbi.nlm.nih.gov/19647170 DM40HTZ DI DM40HTZ DM40HTZ DN SKF-97426 DM40HTZ TI TTS4UGC DM40HTZ TN Farnesoid X-activated receptor (FXR) DM40HTZ MA Modulator DM40HTZ RN SK&F 97426-A a more potent bile acid sequestrant and hypocholesterolaemic agent than cholestyramine in the hamster. Atherosclerosis. 1993 Jun;101(1):51-60. DM40HTZ RU https://pubmed.ncbi.nlm.nih.gov/8216502 DM43JK0 DI DM43JK0 DM43JK0 DN BVT-115959 DM43JK0 TI TTM2AOE DM43JK0 TN Adenosine A2a receptor (ADORA2A) DM43JK0 MA Agonist DM43JK0 RN Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308. DM43JK0 RU https://pubmed.ncbi.nlm.nih.gov/21185259 DM457B1 DI DM457B1 DM457B1 DN FK-888 DM457B1 TI TTZPO1L DM457B1 TN Substance-P receptor (TACR1) DM457B1 MA Antagonist DM457B1 RN Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br J Pharmacol. 1992 Nov;107(3):785-9. DM457B1 RU https://pubmed.ncbi.nlm.nih.gov/1282073 DM46JIR DI DM46JIR DM46JIR DN ZD6416 DM46JIR TI TTG1QMU DM46JIR TN Prostaglandin E2 receptor EP1 (PTGER1) DM46JIR MA Antagonist DM46JIR RN The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25. DM46JIR RU https://pubmed.ncbi.nlm.nih.gov/12512025 DM48ECA DI DM48ECA DM48ECA DN DA-5018 DM48ECA TI TTMI6F5 DM48ECA TN Transient receptor potential cation channel V1 (TRPV1) DM48ECA MA Modulator DM48ECA RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM48ECA RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM48ELZ DI DM48ELZ DM48ELZ DN MK-386 DM48ELZ TI TTTU72V DM48ELZ TN Steroid 5-alpha-reductase 1 (SRD5A1) DM48ELZ MA Inhibitor DM48ELZ RN Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1. Bioorg Med Chem Lett. 2000 Feb 21;10(4):353-6. DM48ELZ RU https://pubmed.ncbi.nlm.nih.gov/10714498 DM497SK DI DM497SK DM497SK DN Agatolimod DM497SK TI TTSHG0T DM497SK TN Toll-like receptor 9 (TLR9) DM497SK MA Agonist DM497SK RN Pfizer. Product Development Pipeline. March 31 2009. DM497SK RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DM4B7CM DI DM4B7CM DM4B7CM DN AZD0328 DM4B7CM TI TTLA931 DM4B7CM TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM4B7CM MA Modulator DM4B7CM RN Ultra-low exposure to -7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in -7 receptor expression in rodents: implications for low dose clinical efficacy.Neuroscience.2011 Jul 14;186:76-87. DM4B7CM RU https://www.ncbi.nlm.nih.gov/pubmed/21550383 DM4FZWP DI DM4FZWP DM4FZWP DN UK-279,276 DM4FZWP TI TTIJWR7 DM4FZWP TN Integrin beta-2 (ITGB2) DM4FZWP MA Antagonist DM4FZWP RN Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs. 2007 Mar;12(1):97-112. DM4FZWP RU https://pubmed.ncbi.nlm.nih.gov/17355216 DM4GVZ9 DI DM4GVZ9 DM4GVZ9 DN RQ-00317076 DM4GVZ9 TI TTVKILB DM4GVZ9 TN Prostaglandin G/H synthase 2 (COX-2) DM4GVZ9 MA Inhibitor DM4GVZ9 RN Clinical pipeline report, company report or official report of raqualia. DM4GVZ9 RU http://www.raqualia.com/rq-cms/wp-content/uploads/2012/03/240313_Mid-Term-Business-Plan_final.pdf DM4K085 DI DM4K085 DM4K085 DN AZD-3778 DM4K085 TI TTQR8Z6 DM4K085 TN Chemokine receptor (CHR) DM4K085 MA Modulator DM4K085 RN New Drugs and Targets for Asthma and COPD. Trevor T. Hansel, Peter J. Barnes. 2010. Page(304). DM4K085 RU https://books.google.com.hk/books?id=aHipG471tVgC&pg=PT318&lpg=PT318&dq=%22AZD-3778%22&source=bl&ots=y_RqGG2ANK&sig=reQ4tfDvvdsUNpDF8vYyquoyO9Q&hl=zh-CN&sa=X&ved=0CD0Q6AEwBGoVChMI98D7zdG_yAIVSBiOCh0hpweg#v=onepage&q=%22AZD-3778%22&f=false DM4K3P9 DI DM4K3P9 DM4K3P9 DN Terflavoxate DM4K3P9 TI TTOXS3C DM4K3P9 TN Muscarinic acetylcholine receptor (CHRM) DM4K3P9 MA Modulator DM4K3P9 RN Effects of terflavoxate on stimulated contractions of urinary bladder in vitro. Arzneimittelforschung. 1993 Feb;43(2):122-8. DM4K3P9 RU https://pubmed.ncbi.nlm.nih.gov/8384453 DM4O7KA DI DM4O7KA DM4O7KA DN R-84760 DM4O7KA TI TTQW87Y DM4O7KA TN Opioid receptor kappa (OPRK1) DM4O7KA MA Agonist DM4O7KA RN Effects of R-84760, a selective kappa-opioid receptor agonist, on nociceptive reflex in isolated neonatal rat spinal cord. Eur J Pharmacol. 1998 Feb 19;343(2-3):171-7. DM4O7KA RU https://pubmed.ncbi.nlm.nih.gov/9570465 DM4RFT8 DI DM4RFT8 DM4RFT8 DN Amifloxacin DM4RFT8 TI TT0IHXV DM4RFT8 TN DNA topoisomerase II (TOP2) DM4RFT8 MA Inhibitor DM4RFT8 RN Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988 Aug;32(8):1182-6. DM4RFT8 RU https://pubmed.ncbi.nlm.nih.gov/2847647 DM4TE8R DI DM4TE8R DM4TE8R DN IX207-887 DM4TE8R TI TTPM6HI DM4TE8R TN Interleukin-1 alpha (IL1A) DM4TE8R MA Modulator DM4TE8R RN Inhibition of interleukin-1 release by IX 207-887. Agents Actions. 1990 Jun;30(3-4):350-62. DM4TE8R RU https://pubmed.ncbi.nlm.nih.gov/2386108 DM4WJDK DI DM4WJDK DM4WJDK DN IPENOXAZONE DM4WJDK TI TTAN6JD DM4WJDK TN Glutamate receptor AMPA (GRIA) DM4WJDK MA Modulator DM4WJDK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM4WJDK RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM4YA63 DI DM4YA63 DM4YA63 DN Ro-23-9424 DM4YA63 TI TTN6J5F DM4YA63 TN Bacterial DNA gyrase (Bact gyrase) DM4YA63 MA Modulator DM4YA63 RN Mode of action of the dual-action cephalosporin Ro 23-9424. Antimicrob Agents Chemother. 1989 Jul;33(7):1067-71. DM4YA63 RU https://www.ncbi.nlm.nih.gov/pubmed/2675755 DM4ZNKX DI DM4ZNKX DM4ZNKX DN PA-1806 DM4ZNKX TI TTJP4SM DM4ZNKX TN Bacterial Penicillin binding protein (Bact PBP) DM4ZNKX MA Modulator DM4ZNKX RN Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother. 1997 May;41(5):1010-6. DM4ZNKX RU https://www.ncbi.nlm.nih.gov/pubmed/9145861 DM4ZO01 DI DM4ZO01 DM4ZO01 DN DNK-333 DM4ZO01 TI TTZPO1L DM4ZO01 TN Substance-P receptor (TACR1) DM4ZO01 MA Modulator DM4ZO01 RN Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81. DM4ZO01 RU https://www.ncbi.nlm.nih.gov/pubmed/14738235 DM4ZO01 DI DM4ZO01 DM4ZO01 DN DNK-333 DM4ZO01 TI TTYO0A3 DM4ZO01 TN Substance-K receptor (TACR2) DM4ZO01 MA Modulator DM4ZO01 RN Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients. Eur Respir J. 2004 Jan;23(1):76-81. DM4ZO01 RU https://www.ncbi.nlm.nih.gov/pubmed/14738235 DM50PZH DI DM50PZH DM50PZH DN NP-619 DM50PZH TI TTS64P2 DM50PZH TN Androgen receptor (AR) DM50PZH MA Modulator DM50PZH RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028305) DM50PZH RU http://adisinsight.springer.com/drugs/800028305 DM51GZS DI DM51GZS DM51GZS DN HR325 DM51GZS TI TTLVP78 DM51GZS TN Dihydroorotate dehydrogenase (DHODH) DM51GZS MA Modulator DM51GZS RN In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scand J Immunol. 2002 Jul;56(1):35-42. DM51GZS RU https://www.ncbi.nlm.nih.gov/pubmed/12100469 DM51WJN DI DM51WJN DM51WJN DN S-16020-2 DM51WJN TI TTGTQHC DM51WJN TN DNA topoisomerase I (TOP1) DM51WJN MA Modulator DM51WJN RN Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain. Mol Pharmacol. 2000 Oct;58(4):709-18. DM51WJN RU https://www.ncbi.nlm.nih.gov/pubmed/10999940 DM524J3 DI DM524J3 DM524J3 DN FK-706 DM524J3 TI TTPLTSQ DM524J3 TN Neutrophil elastase (NE) DM524J3 MA Inhibitor DM524J3 RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DM524J3 RU https://pubmed.ncbi.nlm.nih.gov/12084007 DM54I8A DI DM54I8A DM54I8A DN L-696229 DM54I8A TI TT84ETX DM54I8A TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM54I8A MA Inhibitor DM54I8A RN L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro.. Antimicrob Agents Chemother. 1992 May; 36(5): 1019-1023. DM54I8A RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC188828/ DM54K2P DI DM54K2P DM54K2P DN BTS-67582 DM54K2P TI TTEF5MJ DM54K2P TN ATP-binding cassette transporter C9 (ABCC9) DM54K2P MA Modulator DM54K2P RN BTS-67582 (Knoll Pharmaceuticals Co). IDrugs. 1999 Apr;2(4):355-9. DM54K2P RU https://www.ncbi.nlm.nih.gov/pubmed/16158354 DM562BM DI DM562BM DM562BM DN E-5324 DM562BM TI TTMF541 DM562BM TN Liver carboxylesterase (CES1) DM562BM MA Modulator DM562BM RN Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbits. Atherosclerosis. 1994 Jun;107(2):187-201. DM562BM RU https://pubmed.ncbi.nlm.nih.gov/7980693 DM5DI1G DI DM5DI1G DM5DI1G DN CARZELESIN DM5DI1G TI TTUTN1I DM5DI1G TN Human Deoxyribonucleic acid (hDNA) DM5DI1G MA Binder DM5DI1G RN Sequence selectivity of DNA alkylation by adozelesin and carzelesin. Arch Pharm Res. 1998 Aug;21(4):385-90. DM5DI1G RU https://pubmed.ncbi.nlm.nih.gov/9875464 DM5E6MK DI DM5E6MK DM5E6MK DN J-104132 DM5E6MK TI TTKRD0G DM5E6MK TN Endothelin A receptor (EDNRA) DM5E6MK MA Modulator DM5E6MK RN Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther. 1999 Jun;289(3):1262-70. DM5E6MK RU https://pubmed.ncbi.nlm.nih.gov/10336515 DM5E6MK DI DM5E6MK DM5E6MK DN J-104132 DM5E6MK TI TT3ZTGU DM5E6MK TN Endothelin B receptor (EDNRB) DM5E6MK MA Modulator DM5E6MK RN Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist. J Pharmacol Exp Ther. 1999 Jun;289(3):1262-70. DM5E6MK RU https://pubmed.ncbi.nlm.nih.gov/10336515 DM5ENKG DI DM5ENKG DM5ENKG DN Lirequinil DM5ENKG TI TTPTXIN DM5ENKG TN Translocator protein (TSPO) DM5ENKG MA Agonist DM5ENKG RN Pharmacokinetics and pharmacodynamics of Ro 41-3696, a novel nonbenzodiazepine hypnotic. J Clin Pharmacol. 1995 Aug;35(8):821-9. DM5ENKG RU https://pubmed.ncbi.nlm.nih.gov/8522640 DM5JKCL DI DM5JKCL DM5JKCL DN GlycoPEGylated erythropoietin DM5JKCL TI TTAUX24 DM5JKCL TN Erythropoietin Receptor (EPOR) DM5JKCL MA Modulator DM5JKCL RN Design of Homogeneous, MonoPEGylated Erythropoietin Analogs With Preserved In Vitro Bioactivity. Exp Hematol. 2006 June; 34(6): 697-704. DM5JKCL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1634893/ DM5JZW2 DI DM5JZW2 DM5JZW2 DN Her-2-Bi-armed ATC DM5JZW2 TI TT6EO5L DM5JZW2 TN Erbb2 tyrosine kinase receptor (HER2) DM5JZW2 RN Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010 June; 12(3): 340-349. DM5JZW2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3785321/ DM5KJGB DI DM5KJGB DM5KJGB DN RG7160 DM5KJGB TI TTGKNB4 DM5KJGB TN Epidermal growth factor receptor (EGFR) DM5KJGB MA Modulator DM5KJGB RN GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38. DM5KJGB RU https://pubmed.ncbi.nlm.nih.gov/23209031 DM5NWPD DI DM5NWPD DM5NWPD DN R-568 DM5NWPD TI TTBUYHA DM5NWPD TN Extracellular calcium-sensing receptor (CASR) DM5NWPD MA Agonist DM5NWPD RN Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther. 1999 Jan;65(1):40-9. DM5NWPD RU https://pubmed.ncbi.nlm.nih.gov/9951429 DM5O6HM DI DM5O6HM DM5O6HM DN Testosterone glucoside DM5O6HM TI TTS64P2 DM5O6HM TN Androgen receptor (AR) DM5O6HM MA Agonist DM5O6HM RN Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26. DM5O6HM RU https://pubmed.ncbi.nlm.nih.gov/2912689 DM5OVGH DI DM5OVGH DM5OVGH DN NK-611 DM5OVGH TI TTGTQHC DM5OVGH TN DNA topoisomerase I (TOP1) DM5OVGH MA Inhibitor DM5OVGH RN DNA topoisomerase II poisons and inhibitors. Cancer Chemother Biol Response Modif. 1997;17:114-31. DM5OVGH RU https://pubmed.ncbi.nlm.nih.gov/9551211 DM5P1KQ DI DM5P1KQ DM5P1KQ DN RN6G DM5P1KQ TI TTE4KHA DM5P1KQ TN Amyloid beta A4 protein (APP) DM5P1KQ MA Inhibitor DM5P1KQ RN Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29. DM5P1KQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017905/ DM5QFT4 DI DM5QFT4 DM5QFT4 DN Declopramide DM5QFT4 TI TTEX248 DM5QFT4 TN Dopamine D2 receptor (D2R) DM5QFT4 MA Modulator DM5QFT4 RN Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice. Anticancer Drugs. 1999 Jan;10(1):79-88. DM5QFT4 RU https://pubmed.ncbi.nlm.nih.gov/10194550 DM5QFT4 DI DM5QFT4 DM5QFT4 DN Declopramide DM5QFT4 TI TTZ9SOR DM5QFT4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM5QFT4 MA Modulator DM5QFT4 RN Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice. Anticancer Drugs. 1999 Jan;10(1):79-88. DM5QFT4 RU https://pubmed.ncbi.nlm.nih.gov/10194550 DM5UCHW DI DM5UCHW DM5UCHW DN ZD-4953 DM5UCHW TI TT9B4N3 DM5UCHW TN Prostaglandin receptor (PTGR) DM5UCHW MA Modulator DM5UCHW RN WO patent application no. 2013,1675,82, Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease. DM5UCHW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131114&CC=WO&NR=2013167582A1&KC=A1 DM5WRJX DI DM5WRJX DM5WRJX DN GSK-677954 DM5WRJX TI TTZMAO3 DM5WRJX TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM5WRJX MA Agonist DM5WRJX RN Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. DM5WRJX RU https://pubmed.ncbi.nlm.nih.gov/18321154 DM5WRJX DI DM5WRJX DM5WRJX DN GSK-677954 DM5WRJX TI TT2JWF6 DM5WRJX TN Peroxisome proliferator-activated receptor delta (PPARD) DM5WRJX MA Agonist DM5WRJX RN Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. DM5WRJX RU https://pubmed.ncbi.nlm.nih.gov/18321154 DM5WRJX DI DM5WRJX DM5WRJX DN GSK-677954 DM5WRJX TI TTJ584C DM5WRJX TN Peroxisome proliferator-activated receptor alpha (PPARA) DM5WRJX MA Agonist DM5WRJX RN Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. DM5WRJX RU https://pubmed.ncbi.nlm.nih.gov/18321154 DM5WUK9 DI DM5WUK9 DM5WUK9 DN Icopezil maleate DM5WUK9 TI TT1RS9F DM5WUK9 TN Acetylcholinesterase (AChE) DM5WUK9 MA Inhibitor DM5WUK9 RN A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J Med Chem. 2004 Oct 21;47(22):5492-500. DM5WUK9 RU https://pubmed.ncbi.nlm.nih.gov/15481986 DM5YHJ2 DI DM5YHJ2 DM5YHJ2 DN KW-2170 DM5YHJ2 TI TT0IHXV DM5YHJ2 TN DNA topoisomerase II (TOP2) DM5YHJ2 MA Modulator DM5YHJ2 RN KW-2170 (Kyowa Hakko Kogyo). IDrugs. 2002 Oct;5(10):1000-3. DM5YHJ2 RU https://pubmed.ncbi.nlm.nih.gov/12800063 DM6032E DI DM6032E DM6032E DN Trombodipine DM6032E TI TT438XZ DM6032E TN Cyclin D1/E2F pathway (CCND1/E2F pathway) DM6032E MA Modulator DM6032E RN Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation. Br J Pharmacol. 2001 April; 132(7): 1597-1605. DM6032E RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572687/ DM63UA9 DI DM63UA9 DM63UA9 DN DU 125530 DM63UA9 TI TTSQIFT DM63UA9 TN 5-HT 1A receptor (HTR1A) DM63UA9 MA Antagonist DM63UA9 RN 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther. 2002 Jun;301(3):1144-50. DM63UA9 RU https://pubmed.ncbi.nlm.nih.gov/12023549 DM64CAS DI DM64CAS DM64CAS DN Didox DM64CAS TI TTX09M4 DM64CAS TN Ribonucleotide reductase (RIR) DM64CAS MA Inhibitor DM64CAS RN Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Cancer Biol Ther. 2002 Sep-Oct;1(5):539-45. DM64CAS RU https://pubmed.ncbi.nlm.nih.gov/12496485 DM65JCM DI DM65JCM DM65JCM DN Biricodar DM65JCM TI TT3OT40 DM65JCM TN Multidrug resistance protein 1 (ABCB1) DM65JCM MA Modulator DM65JCM RN ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health. DM65JCM RU https://clinicaltrials.gov/ct2/show/NCT00003847 DM6ANFC DI DM6ANFC DM6ANFC DN BCH-2687 DM6ANFC TI TTKWM86 DM6ANFC TN Opioid receptor mu (MOP) DM6ANFC MA Agonist DM6ANFC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009073) DM6ANFC RU http://adisinsight.springer.com/drugs/800009073 DM6BU7N DI DM6BU7N DM6BU7N DN Doramapimod DM6BU7N TI TT42OGM DM6BU7N TN Hematopoietic cell kinase (HCK) DM6BU7N MA Inhibitor DM6BU7N RN Respiratory formulations and compounds for use therein. US8933228. DM6BU7N RU http://www.freepatentsonline.com/US8933228.html DM6G0PN DI DM6G0PN DM6G0PN DN LTB 019 DM6G0PN TI TTN53ZF DM6G0PN TN Leukotriene B4 receptor 1 (LTB4R) DM6G0PN MA Antagonist DM6G0PN RN Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2008;21(2):409-17. DM6G0PN RU https://pubmed.ncbi.nlm.nih.gov/18063399 DM6HDO3 DI DM6HDO3 DM6HDO3 DN INOGATRAN DM6HDO3 TI TT6L509 DM6HDO3 TN Coagulation factor IIa (F2) DM6HDO3 MA Modulator DM6HDO3 RN Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis. J Pharmacol Exp Ther. 1996 Jun;277(3):1276-83. DM6HDO3 RU https://www.ncbi.nlm.nih.gov/pubmed/8667188 DM6IPWN DI DM6IPWN DM6IPWN DN AKP-020 DM6IPWN TI TTCBFJO DM6IPWN TN Insulin receptor (INSR) DM6IPWN MA Enhancer DM6IPWN RN Effect of vanadium on insulin and leptin in Zucker diabetic fatty rats. Mol Cell Biochem. 2001 Feb;218(1-2):93-6. DM6IPWN RU https://pubmed.ncbi.nlm.nih.gov/11330843 DM6NPUJ DI DM6NPUJ DM6NPUJ DN NLX-P101 DM6NPUJ TI TTURQ2G DM6NPUJ TN Glutamate decarboxylase (GLUL) DM6NPUJ MA Modulator DM6NPUJ RN NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs. 2010 Jul;11(7):813-22. DM6NPUJ RU https://pubmed.ncbi.nlm.nih.gov/20571977 DM6NTAS DI DM6NTAS DM6NTAS DN ERA-923 DM6NTAS TI TTZAYWL DM6NTAS TN Estrogen receptor (ESR) DM6NTAS MA Inhibitor DM6NTAS RN Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus. Endocr Relat Cancer. 2006 Sep;13(3):863-73. DM6NTAS RU https://pubmed.ncbi.nlm.nih.gov/16954435 DM6NTAS DI DM6NTAS DM6NTAS DN ERA-923 DM6NTAS TI TTOM3J0 DM6NTAS TN Estrogen receptor beta (ESR2) DM6NTAS MA Inhibitor DM6NTAS RN Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem. 2001 May 24;44(11):1654-7. DM6NTAS RU https://pubmed.ncbi.nlm.nih.gov/11356100 DM6OSPQ DI DM6OSPQ DM6OSPQ DN Rofleponide DM6OSPQ TI TTPNQAC DM6OSPQ TN Estrogen-related receptor-alpha (ESRRA) DM6OSPQ MA Modulator DM6OSPQ RN Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60. DM6OSPQ RU https://pubmed.ncbi.nlm.nih.gov/9076754 DM6TPCJ DI DM6TPCJ DM6TPCJ DN Panamesine DM6TPCJ TI TT5TPI6 DM6TPCJ TN Opioid receptor sigma 1 (OPRS1) DM6TPCJ MA Binder DM6TPCJ RN Efficacy and safety of the sigma receptor ligand EMD 57445 (panamesine) in patients with schizophrenia: an open clinical trial. Pharmacopsychiatry. 1999 Mar;32(2):68-72. DM6TPCJ RU https://pubmed.ncbi.nlm.nih.gov/10333165 DM6WSU2 DI DM6WSU2 DM6WSU2 DN Dermolastin DM6WSU2 TI TTPLTSQ DM6WSU2 TN Neutrophil elastase (NE) DM6WSU2 MA Inhibitor DM6WSU2 RN Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009. DM6WSU2 RU http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html DM6WSU2 DI DM6WSU2 DM6WSU2 DN Dermolastin DM6WSU2 TI TTQAJF1 DM6WSU2 TN Cathepsin G (CTSG) DM6WSU2 MA Inhibitor DM6WSU2 RN Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009. DM6WSU2 RU http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html DM6WSU2 DI DM6WSU2 DM6WSU2 DN Dermolastin DM6WSU2 TI TTJLNAW DM6WSU2 TN Tissue kallikrein (KLK2) DM6WSU2 MA Inhibitor DM6WSU2 RN Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009. DM6WSU2 RU http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html DM6WSU2 DI DM6WSU2 DM6WSU2 DN Dermolastin DM6WSU2 TI TT2WR1T DM6WSU2 TN Cationic trypsinogen (PRSS1) DM6WSU2 MA Inhibitor DM6WSU2 RN Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009. DM6WSU2 RU http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html DM6WSU2 DI DM6WSU2 DM6WSU2 DN Dermolastin DM6WSU2 TI TT6L509 DM6WSU2 TN Coagulation factor IIa (F2) DM6WSU2 MA Inhibitor DM6WSU2 RN Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009. DM6WSU2 RU http://www.prnewswire.co.uk/news-releases/arriva-prometic-recombinant-alpha-1-antitrypsin-raat-moves-into-the-clinic-for-dermatology-applications-154329065.html DM6XEQA DI DM6XEQA DM6XEQA DN PF-610355 DM6XEQA TI TT2CJVK DM6XEQA TN Adrenergic receptor beta-2 (ADRB2) DM6XEQA MA Agonist DM6XEQA RN Inhalation by design: novel ultra-long-acting beta(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010 Sep 23;53(18):6640-52. DM6XEQA RU https://pubmed.ncbi.nlm.nih.gov/20804199 DM6XJ9D DI DM6XJ9D DM6XJ9D DN SGS-111 DM6XJ9D TI TT9IK2Z DM6XJ9D TN N-methyl-D-aspartate receptor (NMDAR) DM6XJ9D MA Modulator DM6XJ9D RN Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends Pharmacol Sci. 2010 February; 31(2): 66. DM6XJ9D RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2815198/ DM71WGZ DI DM71WGZ DM71WGZ DN SLV-310 DM71WGZ TI TTEX248 DM71WGZ TN Dopamine D2 receptor (D2R) DM71WGZ MA Modulator DM71WGZ RN SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition. Bioorg Med Chem Lett. 2003 Feb 10;13(3):405-8. DM71WGZ RU https://www.ncbi.nlm.nih.gov/pubmed/12565939 DM73C4K DI DM73C4K DM73C4K DN Cryptophycin DM73C4K TI TTML2WA DM73C4K TN Tubulin (TUB) DM73C4K MA Inducer DM73C4K RN Single-walled tubulin ring polymers. Biopolymers. 2007 Aug 5-15;86(5-6):424-36. DM73C4K RU https://pubmed.ncbi.nlm.nih.gov/17480000 DM746L8 DI DM746L8 DM746L8 DN CE-1037 DM746L8 TI TTPLTSQ DM746L8 TN Neutrophil elastase (NE) DM746L8 MA Inhibitor DM746L8 RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DM746L8 RU https://pubmed.ncbi.nlm.nih.gov/12084007 DM75ZO0 DI DM75ZO0 DM75ZO0 DN SERAZAPINE HYDROCHLORIDE DM75ZO0 TI TTJQOD7 DM75ZO0 TN 5-HT 2A receptor (HTR2A) DM75ZO0 MA Antagonist DM75ZO0 RN Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. Biol Psychiatry. 1993 Jul 1-15;34(1-2):41-4. DM75ZO0 RU https://pubmed.ncbi.nlm.nih.gov/8104044 DM78623 DI DM78623 DM78623 DN AA-2379 DM78623 TI TTUST1O DM78623 TN Phosphodiesterase (PDE) DM78623 MA Inhibitor DM78623 RN Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55. DM78623 RU https://pubmed.ncbi.nlm.nih.gov/2556899 DM7IP8U DI DM7IP8U DM7IP8U DN KB-5492 DM7IP8U TI TT5TPI6 DM7IP8U TN Opioid receptor sigma 1 (OPRS1) DM7IP8U MA Antagonist DM7IP8U RN Sigma receptor-mediated effects of a new antiulcer agent, KB-5492, on experimental gastric mucosal lesions and gastric alkaline secretion in rats. J Pharmacol Exp Ther. 1994 May;269(2):799-805. DM7IP8U RU https://pubmed.ncbi.nlm.nih.gov/8182548 DM7JZ53 DI DM7JZ53 DM7JZ53 DN L-4-OXALYSINE DM7JZ53 TI TTNRF4L DM7JZ53 TN Histone synthesis (Histone synth) DM7JZ53 MA Modulator DM7JZ53 RN Immunostimulatory action of L-4-oxalysine counteracts immunosuppression induced by alpha-fetoprotein. Eur J Pharmacol. 1998 Jun 12;351(1):105-11. DM7JZ53 RU https://pubmed.ncbi.nlm.nih.gov/9698211 DM7LIDT DI DM7LIDT DM7LIDT DN CL-283796 DM7LIDT TI TTMF541 DM7LIDT TN Liver carboxylesterase (CES1) DM7LIDT MA Modulator DM7LIDT RN ACAT inhibitors CL 283,546 and CL 283,796 reduce LDL cholesterol without affecting cholesterol absorption in African green monkeys. J Lipid Res. 1995 Jun;36(6):1199-210. DM7LIDT RU https://pubmed.ncbi.nlm.nih.gov/7665998 DM7O0UR DI DM7O0UR DM7O0UR DN Idrapril DM7O0UR TI TTL69WB DM7O0UR TN Angiotensin-converting enzyme (ACE) DM7O0UR MA Inhibitor DM7O0UR RN Pharmacology of idrapril: a new class of angiotensin converting enzyme inhibitors. J Cardiovasc Pharmacol. 1992 Jul;20(1):139-46. DM7O0UR RU https://pubmed.ncbi.nlm.nih.gov/1383623 DM7OD3J DI DM7OD3J DM7OD3J DN RBx-2258 DM7OD3J TI TTNGILX DM7OD3J TN Adrenergic receptor alpha-1A (ADRA1A) DM7OD3J MA Antagonist DM7OD3J RN Drug Metabolism and Pharmacokinetics. Indian J Pharmacol. 2008 October; 40(Suppl 2): S91-S97. DM7OD3J RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086155/ DM7OE9F DI DM7OE9F DM7OE9F DN Atocalcitol DM7OE9F TI TTK59TV DM7OE9F TN Vitamin D3 receptor (VDR) DM7OE9F MA Agonist DM7OE9F RN Elocalcitol, a vitamin D3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. IDrugs. 2009 Jun;12(6):381-93. DM7OE9F RU https://pubmed.ncbi.nlm.nih.gov/19517319 DM7OHR6 DI DM7OHR6 DM7OHR6 DN YM-440 DM7OHR6 TI TTZMAO3 DM7OHR6 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM7OHR6 MA Inhibitor DM7OHR6 RN The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats. J Pharmacol Sci. 2006 Aug;101(4):311-7. DM7OHR6 RU https://pubmed.ncbi.nlm.nih.gov/16891767 DM7OVMH DI DM7OVMH DM7OVMH DN OPC-21268 DM7OVMH TI TT4TFGN DM7OVMH TN Vasopressin V1a receptor (V1AR) DM7OVMH MA Antagonist DM7OVMH RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DM7OVMH RU https://pubmed.ncbi.nlm.nih.gov/12436936 DM7OVMH DI DM7OVMH DM7OVMH DN OPC-21268 DM7OVMH TI TTPFZJ1 DM7OVMH TN Vasopressin V1 receptor (V1R) DM7OVMH MA Antagonist DM7OVMH RN Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900. DM7OVMH RU https://pubmed.ncbi.nlm.nih.gov/1337114 DM7OVMH DI DM7OVMH DM7OVMH DN OPC-21268 DM7OVMH TI TT2J34L DM7OVMH TN Arachidonate 5-lipoxygenase (5-LOX) DM7OVMH MA Inhibitor DM7OVMH RN Fuscoside: an anti-inflammatory marine natural product which selectively inhibits 5-lipoxygenase. Part II: Biochemical studies in the human neutrophil. J Pharmacol Exp Ther. 1992 Aug;262(2):874-82. DM7OVMH RU https://pubmed.ncbi.nlm.nih.gov/1323665 DM7S69Q DI DM7S69Q DM7S69Q DN TAK-218 DM7S69Q TI TTV0YFR DM7S69Q TN Lipid peroxidation (LPO) DM7S69Q MA Modulator DM7S69Q RN ESR study on the antioxidant activity of TAK-218 in biological model membranes. Chem Pharm Bull (Tokyo). 2000 Jun;48(6):784-92. DM7S69Q RU https://pubmed.ncbi.nlm.nih.gov/10866137 DM7TLF6 DI DM7TLF6 DM7TLF6 DN FK-739 DM7TLF6 TI TTGN1ZA DM7TLF6 TN Angiotensin II receptor (AGTR) DM7TLF6 MA Modulator DM7TLF6 RN The pharmacological characterization of FK 739, a new angiotensin II-receptor antagonist. Jpn J Pharmacol. 1993 Nov;63(3):335-43. DM7TLF6 RU https://pubmed.ncbi.nlm.nih.gov/8107326 DM7TM91 DI DM7TM91 DM7TM91 DN ELAROFIBAN DM7TM91 TI TT38RM1 DM7TM91 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM7TM91 MA Modulator DM7TM91 RN 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22. DM7TM91 RU https://pubmed.ncbi.nlm.nih.gov/11551763 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTMX39J DM7V9CT TN Matrix metalloproteinase-1 (MMP-1) DM7V9CT MA Inhibitor DM7V9CT RN Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/18782669 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTIQSC1 DM7V9CT TN Bacterial Lethal factor (Bact lef) DM7V9CT MA Inhibitor DM7V9CT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTYRF5E DM7V9CT TN Matrix metalloproteinase-21 (MMP-21) DM7V9CT MA Inhibitor DM7V9CT RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/16420030 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTJ4QE7 DM7V9CT TN Matrix metalloproteinase-14 (MMP-14) DM7V9CT MA Inhibitor DM7V9CT RN Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/18782669 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTGA1IV DM7V9CT TN Matrix metalloproteinase-8 (MMP-8) DM7V9CT MA Inhibitor DM7V9CT RN Hydroxamate inhibitors of human gelatinase B (92 kDa), Bioorg. Med. Chem. Lett. 5(4):349-352 (1995). DM7V9CT RU http://www.sciencedirect.com/science/article/pii/0960894X9500033P DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTLM12X DM7V9CT TN Matrix metalloproteinase-2 (MMP-2) DM7V9CT MA Inhibitor DM7V9CT RN Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/18782669 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTUZ2L5 DM7V9CT TN Matrix metalloproteinase-3 (MMP-3) DM7V9CT MA Inhibitor DM7V9CT RN Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/18782669 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TT6X50U DM7V9CT TN Matrix metalloproteinase-9 (MMP-9) DM7V9CT MA Inhibitor DM7V9CT RN Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/18782669 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTXZ0KQ DM7V9CT TN Matrix metalloproteinase-12 (MMP-12) DM7V9CT MA Inhibitor DM7V9CT RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/16420030 DM7V9CT DI DM7V9CT DM7V9CT DN GM6001 DM7V9CT TI TTHY57M DM7V9CT TN Matrix metalloproteinase-13 (MMP-13) DM7V9CT MA Inhibitor DM7V9CT RN Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia si... J Biol Chem. 2007 Sep 21;282(38):27781-91. DM7V9CT RU https://pubmed.ncbi.nlm.nih.gov/17623656 DM7VCDZ DI DM7VCDZ DM7VCDZ DN WY-47766 DM7VCDZ TI TTTK3BH DM7VCDZ TN Vacuolar-type proton ATPase (v-ATPase) DM7VCDZ MA Modulator DM7VCDZ RN A pharmacological assessment of the mammalian osteoclast vacuolar H(+)-ATPase. Bone Miner. 1994 Nov;27(2):159-66. DM7VCDZ RU https://pubmed.ncbi.nlm.nih.gov/7711523 DM7VSBH DI DM7VSBH DM7VSBH DN A-86719.1 DM7VSBH TI TTN6J5F DM7VSBH TN Bacterial DNA gyrase (Bact gyrase) DM7VSBH MA Modulator DM7VSBH RN Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyeloneph... J Antimicrob Chemother. 1996 Oct;38(4):641-53. DM7VSBH RU https://www.ncbi.nlm.nih.gov/pubmed/8937959 DM7WDAG DI DM7WDAG DM7WDAG DN YM-511 DM7WDAG TI TTSZLWK DM7WDAG TN Aromatase (CYP19A1) DM7WDAG MA Inhibitor DM7WDAG RN First dual aromatase-steroid sulfatase inhibitors. J Med Chem. 2003 Jul 17;46(15):3193-6. DM7WDAG RU https://pubmed.ncbi.nlm.nih.gov/12852749 DM7XC0U DI DM7XC0U DM7XC0U DN SIB-1553A DM7XC0U TI TTJSZTB DM7XC0U TN Nicotinic acetylcholine receptor (nAChR) DM7XC0U MA Agonist DM7XC0U RN The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 1998;62(17-18):1601-6. DM7XC0U RU https://pubmed.ncbi.nlm.nih.gov/9585143 DM7XC0U DI DM7XC0U DM7XC0U DN SIB-1553A DM7XC0U TI TTTVAFQ DM7XC0U TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DM7XC0U MA Agonist DM7XC0U RN SIB-1553A, (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride, a subtype-selective ligand for nicotinic acetylcholine receptors with putative cognitive-enhancing properties: effectson working and reference memory performances in aged rodents and nonhuman primates. J Pharmacol Exp Ther. 2001 Oct;299(1):297-306. DM7XC0U RU https://pubmed.ncbi.nlm.nih.gov/11561092 DM7XGJY DI DM7XGJY DM7XGJY DN T-506 DM7XGJY TI TTFH2RS DM7XGJY TN FK506-binding protein (FKBP) DM7XGJY MA Modulator DM7XGJY RN EP patent application no. 0831812, Methods and compositions for stimulating neurite growth. DM7XGJY RU https://www.google.com/patents/EP0831812A2?cl=en DM7ZI8A DI DM7ZI8A DM7ZI8A DN BM-17.0744 DM7ZI8A TI TTJ584C DM7ZI8A TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7ZI8A MA Activator DM7ZI8A RN Cardiac function and metabolism in Type 2 diabetic mice after treatment with BM 17.0744, a novel PPAR-alpha activator. Am J Physiol Heart Circ Physiol. 2002 Sep;283(3):H949-57. DM7ZI8A RU https://pubmed.ncbi.nlm.nih.gov/12181123 DM80UNM DI DM80UNM DM80UNM DN PD-134308 DM80UNM TI TTVFO0U DM80UNM TN Gastrin/cholecystokinin type B receptor (CCKBR) DM80UNM MA Modulator DM80UNM RN Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dop... Synapse. 1993 Feb;13(2):117-22. DM80UNM RU https://www.ncbi.nlm.nih.gov/pubmed/8446920 DM81XLA DI DM81XLA DM81XLA DN TV-4710 DM81XLA TI TTUTN1I DM81XLA TN Human Deoxyribonucleic acid (hDNA) DM81XLA MA Inhibitor DM81XLA RN Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65. DM81XLA RU https://pubmed.ncbi.nlm.nih.gov/15757403 DM845NM DI DM845NM DM845NM DN YM-992 DM845NM TI TTJQOD7 DM845NM TN 5-HT 2A receptor (HTR2A) DM845NM MA Inhibitor DM845NM RN Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. DM845NM RU https://pubmed.ncbi.nlm.nih.gov/17017959 DM845NM DI DM845NM DM845NM DN YM-992 DM845NM TI TT3ROYC DM845NM TN Serotonin transporter (SERT) DM845NM MA Inhibitor DM845NM RN Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. DM845NM RU https://pubmed.ncbi.nlm.nih.gov/17017959 DM89AV2 DI DM89AV2 DM89AV2 DN GSK2190915 DM89AV2 TI TTDMBF5 DM89AV2 TN Arachidonate 5-lipoxygenase activating protein (FLAP) DM89AV2 MA Inhibitor DM89AV2 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM89AV2 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM8A64W DI DM8A64W DM8A64W DN NP-118809 DM8A64W TI TTFK1JQ DM8A64W TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM8A64W MA Inhibitor DM8A64W RN Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. DM8A64W RU https://pubmed.ncbi.nlm.nih.gov/19815411 DM8BHL6 DI DM8BHL6 DM8BHL6 DN Naronapride DM8BHL6 TI TT07C3Y DM8BHL6 TN 5-HT 4 receptor (HTR4) DM8BHL6 MA Agonist DM8BHL6 RN Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67. DM8BHL6 RU https://pubmed.ncbi.nlm.nih.gov/22356640 DM8DT7U DI DM8DT7U DM8DT7U DN ABT-089 DM8DT7U TI TTL1ATN DM8DT7U TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DM8DT7U MA Modulator DM8DT7U RN Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.Biochem Pharmacol.2009 Oct 1;78(7):795-802. DM8DT7U RU https://www.ncbi.nlm.nih.gov/pubmed/19481067 DM8GZWC DI DM8GZWC DM8GZWC DN DS-4574 DM8GZWC TI TTGKOY9 DM8GZWC TN Leukotriene CysLT1 receptor (CYSLTR1) DM8GZWC MA Modulator DM8GZWC RN Inhibitory effect of DS-4574, a mast cell stabilizer with peptidoleukotriene receptor antagonism, on gastric acid secretion in rats. Eur J Pharmacol. 1994 Apr 1;255(1-3):229-34. DM8GZWC RU https://pubmed.ncbi.nlm.nih.gov/8026547 DM8GZWC DI DM8GZWC DM8GZWC DN DS-4574 DM8GZWC TI TT0PZR5 DM8GZWC TN Leukotriene CysLT2 receptor (CYSLTR2) DM8GZWC MA Modulator DM8GZWC RN Inhibitory effect of DS-4574, a mast cell stabilizer with peptidoleukotriene receptor antagonism, on gastric acid secretion in rats. Eur J Pharmacol. 1994 Apr 1;255(1-3):229-34. DM8GZWC RU https://pubmed.ncbi.nlm.nih.gov/8026547 DM8IB6K DI DM8IB6K DM8IB6K DN APC-2059 DM8IB6K TI TTM1TDX DM8IB6K TN Tryptase alpha/beta-1 (Tryptase) DM8IB6K MA Inhibitor DM8IB6K RN Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study. Aliment Pharmacol Ther. 2002 Mar;16(3):407-13. DM8IB6K RU https://pubmed.ncbi.nlm.nih.gov/11876693 DM8IL1U DI DM8IL1U DM8IL1U DN Gavestinel DM8IL1U TI TTZ8EM9 DM8IL1U TN Glycine receptor (GlyR) DM8IL1U MA Modulator DM8IL1U RN Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial.GAIN International Investigators.Lancet.2000 Jun 3;355(9219):1949-54. DM8IL1U RU https://www.ncbi.nlm.nih.gov/pubmed/10859040 DM8J2AV DI DM8J2AV DM8J2AV DN GSK159802 DM8J2AV TI TT2CJVK DM8J2AV TN Adrenergic receptor beta-2 (ADRB2) DM8J2AV MA Agonist DM8J2AV RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM8J2AV RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM8J30W DI DM8J30W DM8J30W DN GSK870086 DM8J30W TI TTYRL6O DM8J30W TN Glucocorticoid receptor (NR3C1) DM8J30W MA Modulator DM8J30W RN CN patent application no. 102388025, Pyrimidopyridazine derivatives useful as p38 mapk inhibitors. DM8J30W RU http://www.google.com/patents/CN102388025A?cl=en DM8L4Z0 DI DM8L4Z0 DM8L4Z0 DN Napsagatran DM8L4Z0 TI TT6L509 DM8L4Z0 TN Coagulation factor IIa (F2) DM8L4Z0 MA Inhibitor DM8L4Z0 RN Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J Pharmacol Exp Ther. 1996 Apr;277(1):71-8. DM8L4Z0 RU https://pubmed.ncbi.nlm.nih.gov/8613969 DM8NA4M DI DM8NA4M DM8NA4M DN AVT-02 UE DM8NA4M TI TTN7R6K DM8NA4M TN Signal transducer and activator of transcription 1 (STAT1) DM8NA4M MA Inhibitor DM8NA4M RN Avontec Announces Results of a Multiple Dose Clinical Phase I Study with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment in Male Healthy Volunteers. Avontec. 2008. DM8NA4M RU http://www.drugs.com/clinical_trials/avontec-announces-results-multiple-clinical-phase-study-candidate-avt-02-ue-ointment-after-topical-4866.html DM8OWID DI DM8OWID DM8OWID DN Telinavir DM8OWID TI TT5FNQT DM8OWID TN Human immunodeficiency virus Protease (HIV PR) DM8OWID MA Inhibitor DM8OWID RN Improvement of bioavailability of the HIV protease inhibitor SC-52151 in the beagle dog by coadministration of the CYP3A4 inhibitor, ketoconazole. Xenobiotica. 1997 May;27(5):489-97. DM8OWID RU https://pubmed.ncbi.nlm.nih.gov/9179989 DM8Q7XV DI DM8Q7XV DM8Q7XV DN Rolafagrel DM8Q7XV TI TTKNWZ4 DM8Q7XV TN Thromboxane-A synthase (TBXAS1) DM8Q7XV MA Inhibitor DM8Q7XV RN Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:707-10. DM8Q7XV RU https://pubmed.ncbi.nlm.nih.gov/1825400 DM8S173 DI DM8S173 DM8S173 DN TAK-201 DM8S173 TI TTYJQTF DM8S173 TN Immunoglobulin E (IgE) DM8S173 MA Modulator DM8S173 RN Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8. DM8S173 RU https://pubmed.ncbi.nlm.nih.gov/20426706 DM8U3R6 DI DM8U3R6 DM8U3R6 DN PROXODOLOL DM8U3R6 TI TTMXGCW DM8U3R6 TN Adrenergic receptor beta-3 (ADRB3) DM8U3R6 MA Modulator DM8U3R6 RN The efficacy of proxodolol, a new beta-adrenoblockader with alpha-adrenoblockader properties, in its single use in patients with stable stenocardia of effort. Eksp Klin Farmakol. 1994 May-Jun;57(3):47-50. DM8U3R6 RU https://pubmed.ncbi.nlm.nih.gov/7914121 DM8UC0K DI DM8UC0K DM8UC0K DN FANDOFLOXACIN HYDROCHLORIDE DM8UC0K TI TTN6J5F DM8UC0K TN Bacterial DNA gyrase (Bact gyrase) DM8UC0K MA Modulator DM8UC0K RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM8UC0K RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8W31H DI DM8W31H DM8W31H DN LG-1550 DM8W31H TI TTOD7B3 DM8W31H TN Retinoic acid receptor (RAR) DM8W31H MA Modulator DM8W31H RN US patent application no. 2005,0014,729, Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith. DM8W31H RU http://www.google.com/patents/US20050014729 DM8ZFS3 DI DM8ZFS3 DM8ZFS3 DN BY-1949 DM8ZFS3 TI TT5WKM8 DM8ZFS3 TN ATP phosphatase (ATPase) DM8ZFS3 MA Modulator DM8ZFS3 RN An activation of synaptosomal Na+,K(+)-ATPase by a novel dibenzoxazepine derivative (BY-1949) in the rat brain: its functional role in the neurotransmitter uptake systems. J Neurochem. 1992 Jan;58(1):362-8. DM8ZFS3 RU https://pubmed.ncbi.nlm.nih.gov/1345768 DM90SHY DI DM90SHY DM90SHY DN METIAPRIL DM90SHY TI TTL69WB DM90SHY TN Angiotensin-converting enzyme (ACE) DM90SHY MA Inhibitor DM90SHY RN The clinical efficacy of the first Russian angiotensin-converting enzyme inhibitor methiopril in patients with heart failure. Klin Med (Mosk). 1995;73(3):49-51. DM90SHY RU https://pubmed.ncbi.nlm.nih.gov/8577109 DM9BEDL DI DM9BEDL DM9BEDL DN S-8510 DM9BEDL TI TTPTXIN DM9BEDL TN Translocator protein (TSPO) DM9BEDL MA Agonist DM9BEDL RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM9BEDL RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM9BI3Y DI DM9BI3Y DM9BI3Y DN R7128 DM9BI3Y TI TTMVBWH DM9BI3Y TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM9BI3Y MA Inhibitor DM9BI3Y RN Clinical pipeline report, company report or official report of Roche (2009). DM9BI3Y RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DM9F650 DI DM9F650 DM9F650 DN ZANKIREN DM9F650 TI TTB2MXP DM9F650 TN Angiotensinogenase renin (REN) DM9F650 MA Inhibitor DM9F650 RN Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. J Med Chem. 2009 Jun 25;52(12):3689-702. DM9F650 RU https://pubmed.ncbi.nlm.nih.gov/19358611 DM9FQI0 DI DM9FQI0 DM9FQI0 DN Zolasartan DM9FQI0 TI TT8DBY3 DM9FQI0 TN Angiotensin II receptor type-1 (AGTR1) DM9FQI0 MA Agonist DM9FQI0 RN Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev. 2011 Nov-Dec;19(6):300-4. DM9FQI0 RU https://pubmed.ncbi.nlm.nih.gov/21983318 DM9HKOM DI DM9HKOM DM9HKOM DN NVP-DPP728 DM9HKOM TI TTDIGC1 DM9HKOM TN Dipeptidyl peptidase 4 (DPP-4) DM9HKOM MA Inhibitor DM9HKOM RN A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem. 2008 Aug;43(8):1603-11. DM9HKOM RU https://pubmed.ncbi.nlm.nih.gov/18207285 DM9J6BX DI DM9J6BX DM9J6BX DN LAS-37779 DM9J6BX TI TTZ97H5 DM9J6BX TN Phosphodiesterase 4A (PDE4A) DM9J6BX MA Inhibitor DM9J6BX RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894) DM9J6BX RU http://adisinsight.springer.com/drugs/800022894 DM9J6BX DI DM9J6BX DM9J6BX DN LAS-37779 DM9J6BX TI TTSKMI8 DM9J6BX TN Phosphodiesterase 4D (PDE4D) DM9J6BX MA Inhibitor DM9J6BX RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894) DM9J6BX RU http://adisinsight.springer.com/drugs/800022894 DM9J6BX DI DM9J6BX DM9J6BX DN LAS-37779 DM9J6BX TI TTVIAT9 DM9J6BX TN Phosphodiesterase 4B (PDE4B) DM9J6BX MA Inhibitor DM9J6BX RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022894) DM9J6BX RU http://adisinsight.springer.com/drugs/800022894 DM9JPUD DI DM9JPUD DM9JPUD DN Droloxifene DM9JPUD TI TTZAYWL DM9JPUD TN Estrogen receptor (ESR) DM9JPUD MA Modulator DM9JPUD RN Droloxifene, a new antiestrogen: its role in metastatic breast cancer. Breast Cancer Res Treat. 1994;31(1):83-94. DM9JPUD RU https://pubmed.ncbi.nlm.nih.gov/7981460 DM9K2IO DI DM9K2IO DM9K2IO DN Naxagolide DM9K2IO TI TTEX248 DM9K2IO TN Dopamine D2 receptor (D2R) DM9K2IO MA Modulator DM9K2IO RN Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol. 1994 Jul;112(3):873-80. DM9K2IO RU https://pubmed.ncbi.nlm.nih.gov/7921615 DM9KB8A DI DM9KB8A DM9KB8A DN SERGOLEXOLE MALEATE DM9KB8A TI TTJQOD7 DM9KB8A TN 5-HT 2A receptor (HTR2A) DM9KB8A MA Antagonist DM9KB8A RN 5-Hydroxytryptamine2 receptor antagonist activity of the acid metabolite (1-isopropyl dihydrolysergic acid) of the ergoline ester, sergolexole (LY281067). J Pharmacol Exp Ther. 1989 Dec;251(3):1006-11. DM9KB8A RU https://pubmed.ncbi.nlm.nih.gov/2600800 DM9MEAY DI DM9MEAY DM9MEAY DN Gonadimmune DM9MEAY TI TT8R70G DM9MEAY TN Gonadotropin-releasing hormone receptor (GNRHR) DM9MEAY MA Modulator DM9MEAY RN A novel retro-inverso gonadotropin-releasing hormone (GnRH) immunogen elicits antibodies that neutralize the activity of native GnRH. Endocrinology. 2003 Jul;144(7):3262-9. DM9MEAY RU https://pubmed.ncbi.nlm.nih.gov/12810583 DM9OPDE DI DM9OPDE DM9OPDE DN AZD2516 DM9OPDE TI TTHS256 DM9OPDE TN Metabotropic glutamate receptor 5 (mGluR5) DM9OPDE MA Antagonist DM9OPDE RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM9OPDE RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM9ORUL DI DM9ORUL DM9ORUL DN OPC-8490 DM9ORUL TI TTZCG4L DM9ORUL TN Phosphodiesterase 3 (PDE3) DM9ORUL MA Modulator DM9ORUL RN Mechanism of action of OPC-8490 in human ventricular myocardium. Circulation. 1996 Feb 15;93(4):817-25. DM9ORUL RU https://www.ncbi.nlm.nih.gov/pubmed/8641012 DM9P7Z2 DI DM9P7Z2 DM9P7Z2 DN CD-349 DM9P7Z2 TI TT5HONZ DM9P7Z2 TN Calcium channel unspecific (CaC) DM9P7Z2 MA Modulator DM9P7Z2 RN A new Ca-antagonist, CD-349, binding to the Ca-channel of rat myocardium and brain and hog coronary artery. Jpn J Pharmacol. 1988 Dec;48(4):453-62. DM9P7Z2 RU https://pubmed.ncbi.nlm.nih.gov/2854176 DM9S3R8 DI DM9S3R8 DM9S3R8 DN Davalintide DM9S3R8 TI TTAT87F DM9S3R8 TN Amylin receptor (IAPPR) DM9S3R8 MA Agonist DM9S3R8 RN Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Int J Obes (Lond). 2010 Feb;34(2):385-95. DM9S3R8 RU https://pubmed.ncbi.nlm.nih.gov/19935749 DM9SYUT DI DM9SYUT DM9SYUT DN PAMAPIMOD DM9SYUT TI TTQBR95 DM9SYUT TN Stress-activated protein kinase 2a (p38 alpha) DM9SYUT MA Inhibitor DM9SYUT RN Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem. 2010 Mar 25;53(6):2345-53. DM9SYUT RU https://pubmed.ncbi.nlm.nih.gov/19950901 DM9VHZC DI DM9VHZC DM9VHZC DN KRP-297 DM9VHZC TI TTZMAO3 DM9VHZC TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM9VHZC MA Modulator DM9VHZC RN KRP-297, MCC-555. Nihon Rinsho. 2001 Nov;59(11):2200-6. DM9VHZC RU https://pubmed.ncbi.nlm.nih.gov/11712408 DM9VHZC DI DM9VHZC DM9VHZC DN KRP-297 DM9VHZC TI TTJ584C DM9VHZC TN Peroxisome proliferator-activated receptor alpha (PPARA) DM9VHZC MA Modulator DM9VHZC RN KRP-297, MCC-555. Nihon Rinsho. 2001 Nov;59(11):2200-6. DM9VHZC RU https://pubmed.ncbi.nlm.nih.gov/11712408 DM9ZEGT DI DM9ZEGT DM9ZEGT DN MDX-070 DM9ZEGT TI TT9G4N0 DM9ZEGT TN Glutamate carboxypeptidase II (GCPII) DM9ZEGT RN Nanoparticles for Improving Cancer Diagnosis. Mater Sci Eng R Rep. 2013 March; 74(3): 35-69. DM9ZEGT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3779646/ DMA01BV DI DMA01BV DMA01BV DN S-18986 DMA01BV TI TTAN6JD DMA01BV TN Glutamate receptor AMPA (GRIA) DMA01BV MA Modulator DMA01BV RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMA01BV RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMA13WI DI DMA13WI DMA13WI DN Picumeterol DMA13WI TI TT2CJVK DMA13WI TN Adrenergic receptor beta-2 (ADRB2) DMA13WI MA Agonist DMA13WI RN Picumeterol: dissociation of improvement in lung function and reduction of airways hyperresponsiveness in asthmatics. Br J Clin Pharmacol. 1997 Feb;43(2):169-76. DMA13WI RU https://pubmed.ncbi.nlm.nih.gov/9131949 DMA4UCP DI DMA4UCP DMA4UCP DN BMY-30129 DMA4UCP TI TT9V5JH DMA4UCP TN Phospholipase A2 (PLA2G1B) DMA4UCP MA Inhibitor DMA4UCP RN Inhibitor of phospholipase A2 blocks eicosanoid and platelet activating factor biosynthesis and has topical anti-inflammatory activity. J Pharmacol Exp Ther. 1994 Nov;271(2):852-9. DMA4UCP RU https://pubmed.ncbi.nlm.nih.gov/7965805 DMA57O4 DI DMA57O4 DMA57O4 DN Ambasilide DMA57O4 TI TT1VOHK DMA57O4 TN Potassium channel unspecific (KC) DMA57O4 MA Blocker DMA57O4 RN Ambasilide prolongs the action potential and blocks multiple potassium currents in human atrium. J Cardiovasc Pharmacol. 1999 May;33(5):762-71. DMA57O4 RU https://pubmed.ncbi.nlm.nih.gov/10226864 DMA9Q2V DI DMA9Q2V DMA9Q2V DN AZD0837 DMA9Q2V TI TT6L509 DMA9Q2V TN Coagulation factor IIa (F2) DMA9Q2V MA Inhibitor DMA9Q2V RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMA9Q2V RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMAD1S5 DI DMAD1S5 DMAD1S5 DN UK-74505 DMAD1S5 TI TTQL5VC DMAD1S5 TN Platelet-activating factor receptor (PTAFR) DMAD1S5 MA Antagonist DMAD1S5 RN Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin. Br J Pharmacol. 1994 Oct;113(2):513-21. DMAD1S5 RU https://pubmed.ncbi.nlm.nih.gov/7834203 DMADPQX DI DMADPQX DMADPQX DN CI-930 DMADPQX TI TT06AWU DMADPQX TN Phosphodiesterase 3A (PDE3A) DMADPQX MA Inhibitor DMADPQX RN Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50. DMADPQX RU https://pubmed.ncbi.nlm.nih.gov/2536438 DMAGBM2 DI DMAGBM2 DMAGBM2 DN SCH-32615 DMAGBM2 TI TT5TKPM DMAGBM2 TN Neutral endopeptidase (MME) DMAGBM2 MA Inhibitor DMAGBM2 RN The antinociceptive effects of SCH-32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal, ventral medulla and amygdala. Brain Res. 1990 Jun 18;520(1-2):123-30. DMAGBM2 RU https://pubmed.ncbi.nlm.nih.gov/2207626 DMALIFO DI DMALIFO DMALIFO DN TS-033 DMALIFO TI TTLWPVF DMALIFO TN Sodium/glucose cotransporter 2 (SGLT2) DMALIFO MA Modulator DMALIFO RN Company report (Taisho) DMALIFO RU http://www.taisho.co.jp/en/company/release/2008/2008100201-e.pdf DMAM9BD DI DMAM9BD DMAM9BD DN SL65.0155 DMAM9BD TI TT07C3Y DMAM9BD TN 5-HT 4 receptor (HTR4) DMAM9BD MA Agonist DMAM9BD RN SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther. 2002 Aug;302(2):731-41. DMAM9BD RU https://pubmed.ncbi.nlm.nih.gov/12130738 DMAPRGQ DI DMAPRGQ DMAPRGQ DN R-1578 DMAPRGQ TI TT8A9EF DMAPRGQ TN Metabotropic glutamate receptor 3 (mGluR3) DMAPRGQ MA Antagonist DMAPRGQ RN Clinical pipeline report, company report or official report of Roche. DMAPRGQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMAPRGQ DI DMAPRGQ DMAPRGQ DN R-1578 DMAPRGQ TI TTXJ47W DMAPRGQ TN Metabotropic glutamate receptor 2 (mGluR2) DMAPRGQ MA Antagonist DMAPRGQ RN Clinical pipeline report, company report or official report of Roche. DMAPRGQ RU http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm DMAQ6DS DI DMAQ6DS DMAQ6DS DN BP-897 DMAQ6DS TI TT4C8EA DMAQ6DS TN Dopamine D3 receptor (D3R) DMAQ6DS MA Modulator DMAQ6DS RN BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction.CNS Drug Rev.2003 Summer;9(2):141-58. DMAQ6DS RU https://www.ncbi.nlm.nih.gov/pubmed/12847556 DMAQNBW DI DMAQNBW DMAQNBW DN AM103 DMAQNBW TI TTDMBF5 DMAQNBW TN Arachidonate 5-lipoxygenase activating protein (FLAP) DMAQNBW MA Inhibitor DMAQNBW RN AM103 Experimental Treatment for Respiratory Diseases. Amira Pharmaceuticals/GSK. 2009. DMAQNBW RU http://www.drugdevelopment-technology.com/projects/am103/ DMARQE0 DI DMARQE0 DMARQE0 DN Radafaxine DMARQE0 TI TTVBI8W DMARQE0 TN Dopamine transporter (DAT) DMARQE0 MA Inhibitor DMARQE0 RN Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34. DMARQE0 RU https://pubmed.ncbi.nlm.nih.gov/17064222 DMARQE0 DI DMARQE0 DMARQE0 DN Radafaxine DMARQE0 TI TTAWNKZ DMARQE0 TN Norepinephrine transporter (NET) DMARQE0 MA Inhibitor DMARQE0 RN Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34. DMARQE0 RU https://pubmed.ncbi.nlm.nih.gov/17064222 DMAVZ1F DI DMAVZ1F DMAVZ1F DN NPC-567 DMAVZ1F TI TTGY8IW DMAVZ1F TN B2 bradykinin receptor (BDKRB2) DMAVZ1F MA Inhibitor DMAVZ1F RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMAVZ1F RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMAXRBI DI DMAXRBI DMAXRBI DN GW876008 DMAXRBI TI TT7EFHR DMAXRBI TN Corticotropin-releasing factor receptor 1 (CRHR1) DMAXRBI MA Antagonist DMAXRBI RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMAXRBI RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMB0V5Y DI DMB0V5Y DMB0V5Y DN JTK-003 DMB0V5Y TI TT79JGK DMB0V5Y TN Mycobacterium RNA polymerase (MycB RNAP) DMB0V5Y MA Inhibitor DMB0V5Y RN Antiviral Therapy for Hepatitis C Virus: Beyond the Standard of Care. Viruses. 2010 April; 2(4): 826-866. DMB0V5Y RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185663/ DMB3W20 DI DMB3W20 DMB3W20 DN TA-6666 DMB3W20 TI TTDIGC1 DMB3W20 TN Dipeptidyl peptidase 4 (DPP-4) DMB3W20 MA Inhibitor DMB3W20 RN Dipeptidyl Peptidase-4 Inhibitors Clinical data and clinical implications. before print March 2, 2007. DMB3W20 RU http://care.diabetesjournals.org/content/30/6/1344.full DMB5TH3 DI DMB5TH3 DMB5TH3 DN AA-193 DMB5TH3 TI TTIF3GB DMB5TH3 TN Glucose transporter type 9 (GLUT9) DMB5TH3 MA Modulator DMB5TH3 RN Uricosurics inhibit urate transporter in rat renal brush border membrane vesicles. Eur J Pharmacol. 1990 Oct 23;187(3):303-12. DMB5TH3 RU https://pubmed.ncbi.nlm.nih.gov/2073918 DMB9QSJ DI DMB9QSJ DMB9QSJ DN CRx-191 DMB9QSJ TI TT93WF5 DMB9QSJ TN Interferon-gamma (IFNG) DMB9QSJ MA Inhibitor DMB9QSJ RN CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008. DMB9QSJ RU http://www.medicalnewstoday.com/articles/100566.php DMB9QSJ DI DMB9QSJ DMB9QSJ DN CRx-191 DMB9QSJ TI TTF8CQI DMB9QSJ TN Tumor necrosis factor (TNF) DMB9QSJ MA Inhibitor DMB9QSJ RN CombinatoRx Drug Candidate CRx-191 Demonstrates Positive Phase 2 Results In Psoriasis. CombinatoRx. 2008. DMB9QSJ RU http://www.medicalnewstoday.com/articles/100566.php DMBCYRG DI DMBCYRG DMBCYRG DN ELINAFIDE MESILATE DMBCYRG TI TT0IHXV DMBCYRG TN DNA topoisomerase II (TOP2) DMBCYRG MA Inhibitor DMBCYRG RN Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: intercalated ring flipping on the millisecond time scale. Biochemistry. 1999 Nov 16;38(46):15104-15. DMBCYRG RU https://pubmed.ncbi.nlm.nih.gov/10563793 DMBDPN2 DI DMBDPN2 DMBDPN2 DN PF-217830 DMBDPN2 TI TTEX248 DMBDPN2 TN Dopamine D2 receptor (D2R) DMBDPN2 MA Modulator DMBDPN2 RN Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents.Curr Med Chem.2014;21(4):437-57. DMBDPN2 RU https://www.ncbi.nlm.nih.gov/pubmed/24164194 DMBFYWU DI DMBFYWU DMBFYWU DN E-5531 DMBFYWU TI TTVQJLY DMBFYWU TN Lipopolysaccharide-binding protein (LBP) DMBFYWU MA Modulator DMBFYWU RN The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood. Vet Immunol Immunopathol. 2007 Apr 15;116(3-4):182-9. DMBFYWU RU https://pubmed.ncbi.nlm.nih.gov/17320193 DMBG6LP DI DMBG6LP DMBG6LP DN SGB-1534 DMBG6LP TI TT2NUT5 DMBG6LP TN Adrenergic receptor alpha-2C (ADRA2C) DMBG6LP MA Modulator DMBG6LP RN Potent alpha-adrenoceptor blocking action of SGB-1534, a new quinazoline antihypertensive agent in vitro experiments. Gen Pharmacol. 1986;17(2):143-9. DMBG6LP RU https://pubmed.ncbi.nlm.nih.gov/2870954 DMBIQL2 DI DMBIQL2 DMBIQL2 DN BISNAFIDE MESILATE DMBIQL2 TI TTUTN1I DMBIQL2 TN Human Deoxyribonucleic acid (hDNA) DMBIQL2 MA Inhibitor DMBIQL2 RN DNA sequence recognition by bispyrazinonaphthalimides antitumor agents. Biochemistry. 2003 Oct 14;42(40):11751-61. DMBIQL2 RU https://pubmed.ncbi.nlm.nih.gov/14529286 DMBJ8KG DI DMBJ8KG DMBJ8KG DN Urtoxazumab DMBJ8KG TI TTRV7FQ DMBJ8KG TN Enterobacteria Shiga-like toxin 2B (EntBac stxB2) DMBJ8KG RN Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother. 2010 Jan;54(1):239-43. DMBJ8KG RU https://pubmed.ncbi.nlm.nih.gov/19822704 DMBJLZG DI DMBJLZG DMBJLZG DN MK-852 DMBJLZG TI TT38RM1 DMBJLZG TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMBJLZG MA Modulator DMBJLZG RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBJLZG RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMBJQU6 DI DMBJQU6 DMBJQU6 DN CGP-49823 DMBJQU6 TI TTZPO1L DMBJQU6 TN Substance-P receptor (TACR1) DMBJQU6 MA Antagonist DMBJQU6 RN The potency of the novel tachykinin receptor antagonist CGP49823 at rat and gerbil motoneurones in vitro. Eur J Pharmacol. 1998 Jan 26;342(2-3):203-8. DMBJQU6 RU https://pubmed.ncbi.nlm.nih.gov/9548386 DMBO28J DI DMBO28J DMBO28J DN CI-976 DMBO28J TI TTMF541 DMBO28J TN Liver carboxylesterase (CES1) DMBO28J MA Inhibitor DMBO28J RN Acyl-coenzyme A:cholesterol-acyltransferase (ACAT) inhibitors modulate monocyte adhesion to aortic endothelial cells. Atherosclerosis. 1995 Jan 6;112(1):7-17. DMBO28J RU https://pubmed.ncbi.nlm.nih.gov/7772069 DMBQ87R DI DMBQ87R DMBQ87R DN TAK-044 DMBQ87R TI TTCV6O0 DMBQ87R TN Endothelin receptor (EDNR) DMBQ87R MA Modulator DMBQ87R RN Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol. 1995 Mar;114(5):949-54. DMBQ87R RU https://pubmed.ncbi.nlm.nih.gov/7780649 DMBQLS5 DI DMBQLS5 DMBQLS5 DN Angiozyme DMBQLS5 TI TT2Q6G1 DMBQLS5 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMBQLS5 MA Modulator DMBQLS5 RN An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.Cancer.2012 Sep 1;118(17):4098-104. DMBQLS5 RU https://www.ncbi.nlm.nih.gov/pubmed/22281842 DMBSHJ6 DI DMBSHJ6 DMBSHJ6 DN Zabiciprilat DMBSHJ6 TI TTL69WB DMBSHJ6 TN Angiotensin-converting enzyme (ACE) DMBSHJ6 MA Inhibitor DMBSHJ6 RN Enzyme immunoassays for a new angiotensin-converting enzyme inhibitor, zabicipril, and its active metabolite in human plasma: application to pharmacokinetic studies. Ther Drug Monit. 1993 Oct;15(5):448-54. DMBSHJ6 RU https://pubmed.ncbi.nlm.nih.gov/8249053 DMBSLZV DI DMBSLZV DMBSLZV DN Sulukast DMBSLZV TI TTGKOY9 DMBSLZV TN Leukotriene CysLT1 receptor (CYSLTR1) DMBSLZV MA Modulator DMBSLZV RN The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br J Pharmacol. 1989 Sep;98(1):259-67. DMBSLZV RU https://www.ncbi.nlm.nih.gov/pubmed/2553189 DMBSLZV DI DMBSLZV DMBSLZV DN Sulukast DMBSLZV TI TT0PZR5 DMBSLZV TN Leukotriene CysLT2 receptor (CYSLTR2) DMBSLZV MA Modulator DMBSLZV RN The pharmacological evaluation of LY 170680, a novel leukotriene D4 and E4 antagonist in the guinea-pig. Br J Pharmacol. 1989 Sep;98(1):259-67. DMBSLZV RU https://www.ncbi.nlm.nih.gov/pubmed/2553189 DMBSXPJ DI DMBSXPJ DMBSXPJ DN ZD-8321 DMBSXPJ TI TTPLTSQ DMBSXPJ TN Neutrophil elastase (NE) DMBSXPJ MA Inhibitor DMBSXPJ RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DMBSXPJ RU https://pubmed.ncbi.nlm.nih.gov/12084007 DMBTG8J DI DMBTG8J DMBTG8J DN AR-H047108 DMBTG8J TI TTLOKXP DMBTG8J TN Gastric H(+)/K(+) ATPase (Proton pump) DMBTG8J MA Modulator DMBTG8J RN Early stellate cell activation and veno-occlusive-disease (VOD)-like hepatotoxicity in dogs treated with AR-H047108, an imidazopyridine proton pump inhibitor.Toxicol Pathol.2008 Jul;36(5):727-37. DMBTG8J RU https://www.ncbi.nlm.nih.gov/pubmed/18648100 DMBU9O4 DI DMBU9O4 DMBU9O4 DN KRP-101 DMBU9O4 TI TTJ584C DMBU9O4 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMBU9O4 MA Agonist DMBU9O4 RN Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene. Biochem Pharmacol. 2009 Sep 1;78(5):523-30. DMBU9O4 RU https://pubmed.ncbi.nlm.nih.gov/19433068 DMBUH7E DI DMBUH7E DMBUH7E DN SM-10888 DMBUH7E TI TT1RS9F DMBUH7E TN Acetylcholinesterase (AChE) DMBUH7E MA Inhibitor DMBUH7E RN Pharmacological and biochemical assessment of SM-10888, a novel cholinesterase inhibitor. Jpn J Pharmacol. 1990 Jun;53(2):145-55. DMBUH7E RU https://pubmed.ncbi.nlm.nih.gov/2385001 DMBX6C7 DI DMBX6C7 DMBX6C7 DN KC706 DMBX6C7 TI TTYT93M DMBX6C7 TN MAP kinase p38 (MAPK12) DMBX6C7 MA Inhibitor DMBX6C7 RN KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126. DMBX6C7 RU http://circ.ahajournals.org/cgi/content/meeting_abstract/116/16_MeetingAbstracts/II_126-c DMBYQJH DI DMBYQJH DMBYQJH DN GSK256066 DMBYQJH TI TTZ97H5 DMBYQJH TN Phosphodiesterase 4A (PDE4A) DMBYQJH MA Inhibitor DMBYQJH RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMBYQJH RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMBZG2Y DI DMBZG2Y DMBZG2Y DN TA-5538 DMBZG2Y TI TTZPO1L DMBZG2Y TN Substance-P receptor (TACR1) DMBZG2Y MA Antagonist DMBZG2Y RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021639) DMBZG2Y RU http://adisinsight.springer.com/drugs/800021639 DMBZM0D DI DMBZM0D DMBZM0D DN SLV-305 DMBZM0D TI TT953CX DMBZM0D TN Motilin receptor (MLNR) DMBZM0D MA Modulator DMBZM0D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297). DMBZM0D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297 DMC0WNB DI DMC0WNB DMC0WNB DN Tetramethylpyrazine DMC0WNB TI TTJR60Z DMC0WNB TN Endothelin-1 (EDN1) DMC0WNB MA Modulator DMC0WNB RN Tetramethylpyrazine, a Chinese drug, blocks coronary vasoconstriction by endothelin-1 and decreases plasma endothelin-1 levels in experimental animals. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S313-6. DMC0WNB RU https://pubmed.ncbi.nlm.nih.gov/9595468 DMC28Y4 DI DMC28Y4 DMC28Y4 DN EAA-090 DMC28Y4 TI TT9IK2Z DMC28Y4 TN N-methyl-D-aspartate receptor (NMDAR) DMC28Y4 MA Antagonist DMC28Y4 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMC28Y4 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMC2WI7 DI DMC2WI7 DMC2WI7 DN AS-35 DMC2WI7 TI TTGKOY9 DMC2WI7 TN Leukotriene CysLT1 receptor (CYSLTR1) DMC2WI7 MA Modulator DMC2WI7 RN Inhibition of radiolabeled leukotriene-binding by AS-35 in guinea pig lung membrane fraction. Jpn J Pharmacol. 1992 Apr;58(4):357-64. DMC2WI7 RU https://www.ncbi.nlm.nih.gov/pubmed/1405033 DMC2WI7 DI DMC2WI7 DMC2WI7 DN AS-35 DMC2WI7 TI TT0PZR5 DMC2WI7 TN Leukotriene CysLT2 receptor (CYSLTR2) DMC2WI7 MA Modulator DMC2WI7 RN Inhibition of radiolabeled leukotriene-binding by AS-35 in guinea pig lung membrane fraction. Jpn J Pharmacol. 1992 Apr;58(4):357-64. DMC2WI7 RU https://www.ncbi.nlm.nih.gov/pubmed/1405033 DMC30N4 DI DMC30N4 DMC30N4 DN KCO-912 DMC30N4 TI TT1VOHK DMC30N4 TN Potassium channel unspecific (KC) DMC30N4 MA Agonist DMC30N4 RN KCO912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of card... Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):220-30. DMC30N4 RU https://pubmed.ncbi.nlm.nih.gov/11882918 DMC35T1 DI DMC35T1 DMC35T1 DN BN50727 DMC35T1 TI TTQL5VC DMC35T1 TN Platelet-activating factor receptor (PTAFR) DMC35T1 MA Modulator DMC35T1 RN Platelet-activating factor preferentially stimulates the phospholipase A2/cyclooxygenase cascade in the rabbit cornea. Curr Eye Res. 1995 Sep;14(9):769-75. DMC35T1 RU https://www.ncbi.nlm.nih.gov/pubmed/8529415 DMC57JU DI DMC57JU DMC57JU DN Saperconazole DMC57JU TI TT8YUAD DMC57JU TN P450-dependent ergosterol synthesis (PDE synth) DMC57JU MA Modulator DMC57JU RN Saperconazole: a selective inhibitor of the cytochrome P-450-dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes. Mycoses. 1990 Jul-Aug;33(7-8):335-52. DMC57JU RU https://pubmed.ncbi.nlm.nih.gov/2090934 DMC6H4Y DI DMC6H4Y DMC6H4Y DN ZIFROSILONE DMC6H4Y TI TT1RS9F DMC6H4Y TN Acetylcholinesterase (AChE) DMC6H4Y MA Inhibitor DMC6H4Y RN Acetylcholinesterase inhibition by zifrosilone: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1995 Jul;58(1):54-61. DMC6H4Y RU https://pubmed.ncbi.nlm.nih.gov/7628183 DMC87DR DI DMC87DR DMC87DR DN GLPG-0259 DMC87DR TI TT3UJ7Z DMC87DR TN MAPK-activated protein kinase 5 (MAPKAPK5) DMC87DR MA Inhibitor DMC87DR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2096). DMC87DR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2096 DMCAKPG DI DMCAKPG DMCAKPG DN MK-287 DMCAKPG TI TTQL5VC DMCAKPG TN Platelet-activating factor receptor (PTAFR) DMCAKPG MA Antagonist DMCAKPG RN MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor. J Lipid Mediat. 1993 Jun;7(2):115-34. DMCAKPG RU https://pubmed.ncbi.nlm.nih.gov/8400114 DMCEGN4 DI DMCEGN4 DMCEGN4 DN TTP-355 DMCEGN4 TI TTDLNGZ DMCEGN4 TN Glucokinase (GCK) DMCEGN4 MA Activator DMCEGN4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025266) DMCEGN4 RU http://adisinsight.springer.com/drugs/800025266 DMCEQKG DI DMCEQKG DMCEQKG DN SR-121787 DMCEQKG TI TT38RM1 DMCEQKG TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMCEQKG MA Modulator DMCEQKG RN Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist. J Pharmacol Exp Ther. 1998 Aug;286(2):670-5. DMCEQKG RU https://www.ncbi.nlm.nih.gov/pubmed/9694919 DMCINOE DI DMCINOE DMCINOE DN FK-011 DMCINOE TI TTGKOY9 DMCINOE TN Leukotriene CysLT1 receptor (CYSLTR1) DMCINOE MA Modulator DMCINOE RN Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). J Pharmacol Sci. 2003 Nov;93(3):347-55. DMCINOE RU https://pubmed.ncbi.nlm.nih.gov/14646253 DMCNEOZ DI DMCNEOZ DMCNEOZ DN DMP-543 DMCNEOZ TI TTQ29KF DMCNEOZ TN Voltage-gated potassium channel Kv7 (KCNQ) DMCNEOZ MA Modulator DMCNEOZ RN KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus.Pharmacol Res.2011 Oct;64(4):397-409. DMCNEOZ RU https://www.ncbi.nlm.nih.gov/pubmed/21740972 DMCQRS2 DI DMCQRS2 DMCQRS2 DN RG7414 DMCQRS2 TI TT7WD0H DMCQRS2 TN Epidermal growth factor-like protein 7 (EGFL7) DMCQRS2 MA Modulator DMCQRS2 RN Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 2013 September 3; 123(9): 3997-4009. DMCQRS2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3754254/ DMCRPKS DI DMCRPKS DMCRPKS DN CGRP DMCRPKS TI TTAFORY DMCRPKS TN Calcitonin gene-related peptide (CALC) DMCRPKS MA Modulator DMCRPKS RN Calcitonin gene-related peptide as inflammatory mediator.Pulm Pharmacol Ther.2003;16(3):121-30. DMCRPKS RU https://www.ncbi.nlm.nih.gov/pubmed/12749828 DMCS8FM DI DMCS8FM DMCS8FM DN SORAPRAZAN DMCS8FM TI TTLOKXP DMCS8FM TN Gastric H(+)/K(+) ATPase (Proton pump) DMCS8FM MA Modulator DMCS8FM RN Soraprazan: setting new standards in inhibition of gastric acid secretion.J Pharmacol Exp Ther.2007 Jun;321(3):866-74. DMCS8FM RU https://www.ncbi.nlm.nih.gov/pubmed/17369284 DMCX6MD DI DMCX6MD DMCX6MD DN AVE-8134 DMCX6MD TI TTJ584C DMCX6MD TN Peroxisome proliferator-activated receptor alpha (PPARA) DMCX6MD MA Agonist DMCX6MD RN The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin. 2009 Jul;30(7):935-46. DMCX6MD RU https://pubmed.ncbi.nlm.nih.gov/19503102 DMCXLIK DI DMCXLIK DMCXLIK DN GR-213487 DMCXLIK TI TTCYAXN DMCXLIK TN Chloride channel unspecific (ClC) DMCXLIK MA Modulator DMCXLIK RN EP patent application no. 1336602, Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases. DMCXLIK RU http://www.google.com/patents/EP1336602A1?cl=en DMCZ75T DI DMCZ75T DMCZ75T DN DRAFLAZINE DMCZ75T TI TT5BN70 DMCZ75T TN Nucleoside transporter (SLC) DMCZ75T MA Modulator DMCZ75T RN Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium. Br J Pharmacol. 1994 May;112(1):137-42. DMCZ75T RU https://pubmed.ncbi.nlm.nih.gov/8032635 DMCZI62 DI DMCZI62 DMCZI62 DN LORECLEZOLE DMCZI62 TI TTEX6LM DMCZI62 TN GABA(A) receptor gamma-3 (GABRG3) DMCZI62 MA Modulator DMCZI62 RN Direct activation of GABAA receptors by loreclezole, an anticonvulsant drug with selectivity for the beta-subunit. Neuropharmacology. 1996;35(12):1753-60. DMCZI62 RU https://pubmed.ncbi.nlm.nih.gov/9076754 DMCZIGQ DI DMCZIGQ DMCZIGQ DN YM-337 DMCZIGQ TI TT38RM1 DMCZIGQ TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMCZIGQ MA Modulator DMCZIGQ RN Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in hum... Br J Clin Pharmacol. 2003 Sep;56(3):321-6. DMCZIGQ RU https://www.ncbi.nlm.nih.gov/pubmed/12919181 DMCZKG0 DI DMCZKG0 DMCZKG0 DN BAY-Y-3118 DMCZKG0 TI TTN6J5F DMCZKG0 TN Bacterial DNA gyrase (Bact gyrase) DMCZKG0 MA Modulator DMCZKG0 RN Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. DMCZKG0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC284583 DMD16VS DI DMD16VS DMD16VS DN Loviride DMD16VS TI TT84ETX DMD16VS TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMD16VS MA Inhibitor DMD16VS RN Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine. J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. DMD16VS RU https://pubmed.ncbi.nlm.nih.gov/23687292 DMD308S DI DMD308S DMD308S DN Pyrazinoylguanidine DMD308S TI TTRK8B9 DMD308S TN Sodium channel unspecific (NaC) DMD308S MA Modulator DMD308S RN Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem. 2006 Jul 13;49(14):4098-115. DMD308S RU https://pubmed.ncbi.nlm.nih.gov/16821771 DMD39G4 DI DMD39G4 DMD39G4 DN Lintuzumab DMD39G4 TI TTJVYO3 DMD39G4 TN Myeloid cell surface antigen CD33 (CD33) DMD39G4 RN Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005 Jun 20;23(18):4110-6. DMD39G4 RU https://pubmed.ncbi.nlm.nih.gov/15961759 DMD3CUJ DI DMD3CUJ DMD3CUJ DN T-5224 DMD3CUJ TI TTN3GBV DMD3CUJ TN Transcription factor AP-1 (JUN) DMD3CUJ MA Inhibitor DMD3CUJ RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMD3CUJ RU http://www.centerwatch.com/ DMD8ZSW DI DMD8ZSW DMD8ZSW DN Rilotumumab DMD8ZSW TI TT4V2JM DMD8ZSW TN Hepatocyte growth factor (HGF) DMD8ZSW RN Clinical pipeline report, company report or official report of Amgen (2009). DMD8ZSW RU http://www.amgen.com/science/pipe.jsp DMDAS5B DI DMDAS5B DMDAS5B DN Enalkiren DMDAS5B TI TTB2MXP DMDAS5B TN Angiotensinogenase renin (REN) DMDAS5B MA Inhibitor DMDAS5B RN Comparative effects of three different potent renin inhibitors in primates. Hypertension. 1993 Jul;22(1):9-17. DMDAS5B RU https://pubmed.ncbi.nlm.nih.gov/8319997 DMDAUCR DI DMDAUCR DMDAUCR DN NGD 91-3 DMDAUCR TI TTEX6LM DMDAUCR TN GABA(A) receptor gamma-3 (GABRG3) DMDAUCR MA Agonist DMDAUCR RN Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr Drug Targets CNS Neurol Disord. 2003 Aug;2(4):213-32. DMDAUCR RU https://pubmed.ncbi.nlm.nih.gov/12871032 DMDHYM7 DI DMDHYM7 DMDHYM7 DN Torcetrapib DMDHYM7 TI TTFQAYR DMDHYM7 TN Cholesteryl ester transfer protein (CETP) DMDHYM7 MA Inhibitor DMDHYM7 RN Safety and tolerability of dalcetrapib. Am J Cardiol. 2009 Jul 1;104(1):82-91. DMDHYM7 RU https://pubmed.ncbi.nlm.nih.gov/19576325 DMDN3TV DI DMDN3TV DMDN3TV DN T611 DMDN3TV TI TT01UPE DMDN3TV TN Cytomegalovirus Replication (CMV replication) DMDN3TV MA Inhibitor DMDN3TV RN A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells. Cancer Cell. 2011 November 15; 20(5): 620-634. DMDN3TV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237683/ DMDOETQ DI DMDOETQ DMDOETQ DN R-873 DMDOETQ TI TTXEU7H DMDOETQ TN GPCR unspecific (GPCR) DMDOETQ MA Agonist DMDOETQ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020830) DMDOETQ RU http://adisinsight.springer.com/drugs/800020830 DMDOFE7 DI DMDOFE7 DMDOFE7 DN PSN357 DMDOFE7 TI TT31JXP DMDOFE7 TN Myophosphorylase (PYGM) DMDOFE7 MA Modulator DMDOFE7 RN PhRMA DMDOFE7 RU http://phrma.org/sites/default/files/pdf/2015-neurological-disorders_drug-list.pdf DMDQH5E DI DMDQH5E DMDQH5E DN Dabuzalgron DMDQH5E TI TT34BHT DMDQH5E TN Adrenergic receptor alpha-1D (ADRA1D) DMDQH5E MA Agonist DMDQH5E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3469). DMDQH5E RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3469 DMDQVY4 DI DMDQVY4 DMDQVY4 DN ABT-724 DMDQVY4 TI TTE0A2F DMDQVY4 TN Dopamine D4 receptor (D4R) DMDQVY4 MA Agonist DMDQVY4 RN Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763. DMDQVY4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC404118/ DMDVJKW DI DMDVJKW DMDVJKW DN TAK-637 DMDVJKW TI TTZPO1L DMDVJKW TN Substance-P receptor (TACR1) DMDVJKW MA Antagonist DMDVJKW RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMDVJKW RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMDXP3C DI DMDXP3C DMDXP3C DN YM-796 DMDXP3C TI TTZ9SOR DMDXP3C TN Muscarinic acetylcholine receptor M1 (CHRM1) DMDXP3C MA Modulator DMDXP3C RN YM796, a novel muscarinic agonist, improves the impairment of learning behavior in a rat model of chronic focal cerebral ischemia. Brain Res. 1995 Jan 9;669(1):107-14. DMDXP3C RU https://www.ncbi.nlm.nih.gov/pubmed/7712153 DMDZ7AY DI DMDZ7AY DMDZ7AY DN Suritozole DMDZ7AY TI TTEX6LM DMDZ7AY TN GABA(A) receptor gamma-3 (GABRG3) DMDZ7AY MA Modulator DMDZ7AY RN Chronic postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the GABAA receptor, and cognitive impairment in rats following traumatic brain injury. J Neurosurg. 1995 Nov;83(5):878-83. DMDZ7AY RU https://pubmed.ncbi.nlm.nih.gov/7472558 DME1JYP DI DME1JYP DME1JYP DN SL-25.1039 DME1JYP TI TT34BHT DME1JYP TN Adrenergic receptor alpha-1D (ADRA1D) DME1JYP MA Agonist DME1JYP RN Pharmaceutical co analysis sanofi aventis, 2006, Page(216). DME1JYP RU http://www.alacrastore.com/storecontent/Thomson-Reuters-Market-Research/PHARMACEUTICAL-CO-ANALYSIS-SANOFI-AVENTIS-ESPICOM-HEALTHCARE-INTELLIGENCE-50201119 DME4RSI DI DME4RSI DME4RSI DN Panomifene DME4RSI TI TTZAYWL DME4RSI TN Estrogen receptor (ESR) DME4RSI MA Modulator DME4RSI RN Species differences in metabolism of panomifene, an analogue of tamoxifen. Drug Metab Dispos. 1997 Dec;25(12):1370-8. DME4RSI RU https://pubmed.ncbi.nlm.nih.gov/9394026 DME5MGP DI DME5MGP DME5MGP DN RIPISARTAN DME5MGP TI TT8DBY3 DME5MGP TN Angiotensin II receptor type-1 (AGTR1) DME5MGP MA Antagonist DME5MGP RN In vitro pharmacological characterization of UP 269-6, a novel nonpeptide angiotensin II receptor antagonist. Fundam Clin Pharmacol. 1995;9(2):119-28. DME5MGP RU https://pubmed.ncbi.nlm.nih.gov/7628824 DME6OXB DI DME6OXB DME6OXB DN AKL-0707 DME6OXB TI TTG4R8V DME6OXB TN Growth hormone-releasing hormone receptor (GHRHR) DME6OXB MA Agonist DME6OXB RN A super-agonist of growth hormone-releasing hormone causes rapid improvement of nutritional status in patients with chronic kidney disease. Kidney Int. 2010 Mar;77(5):450-8. DME6OXB RU https://pubmed.ncbi.nlm.nih.gov/20016461 DME7OCX DI DME7OCX DME7OCX DN ENIPORIDE DME7OCX TI TTGSEFH DME7OCX TN Sodium/hydrogen exchanger 1 (SLC9A1) DME7OCX MA Inhibitor DME7OCX RN Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47. DME7OCX RU https://pubmed.ncbi.nlm.nih.gov/9733499 DME7OCX DI DME7OCX DME7OCX DN ENIPORIDE DME7OCX TI TTFZVPO DME7OCX TN Sodium/hydrogen exchanger 3 (SLC9A3) DME7OCX MA Inhibitor DME7OCX RN Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47. DME7OCX RU https://pubmed.ncbi.nlm.nih.gov/9733499 DME85Z9 DI DME85Z9 DME85Z9 DN TREFENTANIL HYDROCHLORIDE DME85Z9 TI TTKWM86 DME85Z9 TN Opioid receptor mu (MOP) DME85Z9 MA Agonist DME85Z9 RN Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther. 1994 Sep;56(3):261-71. DME85Z9 RU https://pubmed.ncbi.nlm.nih.gov/7924121 DME8KQW DI DME8KQW DME8KQW DN AZD-5423 DME8KQW TI TTYRL6O DME8KQW TN Glucocorticoid receptor (NR3C1) DME8KQW MA Agonist DME8KQW RN A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses. Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7. DME8KQW RU https://pubmed.ncbi.nlm.nih.gov/25473939 DME9V0I DI DME9V0I DME9V0I DN RNAPc2 DME9V0I TI TTF0EGX DME9V0I TN Coagulation factor VII (F7) DME9V0I MA Modulator DME9V0I RN rNAPc2 inhibits colorectal cancer in mice through tissue factor. Clin Cancer Res. 2009 Jan 1;15(1):208-16. DME9V0I RU https://pubmed.ncbi.nlm.nih.gov/19118048 DMEG240 DI DMEG240 DMEG240 DN A-437203 DMEG240 TI TT4C8EA DMEG240 TN Dopamine D3 receptor (D3R) DMEG240 MA Modulator DMEG240 RN Association of dopamine-related genetic loci to dopamine D3 receptor antagonist ABT-925 clinical response.Transl Psychiatry.2013 Apr 9;3:e245. DMEG240 RU https://www.ncbi.nlm.nih.gov/pubmed/23571810 DMEGMA2 DI DMEGMA2 DMEGMA2 DN ETH615 DMEGMA2 TI TT2J34L DMEGMA2 TN Arachidonate 5-lipoxygenase (5-LOX) DMEGMA2 MA Inhibitor DMEGMA2 RN Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. DMEGMA2 RU https://pubmed.ncbi.nlm.nih.gov/10940813 DMEH6LV DI DMEH6LV DMEH6LV DN Fontolizumab DMEH6LV TI TT93WF5 DMEH6LV TN Interferon-gamma (IFNG) DMEH6LV RN Emerging drugs to treat Crohn's disease. Expert Opin Emerg Drugs. 2007 Mar;12(1):49-59. DMEH6LV RU https://pubmed.ncbi.nlm.nih.gov/17355213 DMEI0LJ DI DMEI0LJ DMEI0LJ DN CDP-860 DMEI0LJ TI TTI7421 DMEI0LJ TN Platelet-derived growth factor receptor beta (PDGFRB) DMEI0LJ MA Modulator DMEI0LJ RN Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated w... J Clin Oncol. 2005 Feb 10;23(5):973-81. DMEI0LJ RU https://pubmed.ncbi.nlm.nih.gov/15466784 DMEJNM1 DI DMEJNM1 DMEJNM1 DN R-343 DMEJNM1 TI TTOU65C DMEJNM1 TN Tyrosine-protein kinase SYK (SYK) DMEJNM1 MA Inhibitor DMEJNM1 RN A novel Syk kinase inhibitor suitable for inhalation: R-343(. Expert Opin Ther Pat. 2009 Oct;19(10):1469-72. DMEJNM1 RU https://pubmed.ncbi.nlm.nih.gov/19552507 DMEK6J0 DI DMEK6J0 DMEK6J0 DN Bervastatin DMEK6J0 TI TTPADOQ DMEK6J0 TN HMG-CoA reductase (HMGCR) DMEK6J0 MA Inhibitor DMEK6J0 RN Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. Clin Cardiol. 2003 Jan;26(1):18-24. DMEK6J0 RU https://pubmed.ncbi.nlm.nih.gov/12539808 DMEKHX0 DI DMEKHX0 DMEKHX0 DN ALS 2-0426 DMEKHX0 TI TTDIGC1 DMEKHX0 TN Dipeptidyl peptidase 4 (DPP-4) DMEKHX0 MA Inhibitor DMEKHX0 RN Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews April 2012 vol. 64 no. 2 188-237. DMEKHX0 RU http://pharmrev.aspetjournals.org/content/64/2/188.full DMELXBQ DI DMELXBQ DMELXBQ DN PG-530742 DMELXBQ TI TTUZ2L5 DMELXBQ TN Matrix metalloproteinase-3 (MMP-3) DMELXBQ MA Inhibitor DMELXBQ RN Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. DMELXBQ RU https://pubmed.ncbi.nlm.nih.gov/16428338 DMEMKIS DI DMEMKIS DMEMKIS DN ISIS 2503 DMEMKIS TI TT28ZON DMEMKIS TN H-ras messenger RNA (HRAS mRNA) DMEMKIS RN A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res. 2003 Jan;9(1):115-23. DMEMKIS RU https://pubmed.ncbi.nlm.nih.gov/12538459 DMEO6A5 DI DMEO6A5 DMEO6A5 DN S-9977 DMEO6A5 TI TT1RS9F DMEO6A5 TN Acetylcholinesterase (AChE) DMEO6A5 MA Inhibitor DMEO6A5 RN Xanthine derivatives IBMX and S-9977-2 potentiate transmission at an Aplysia central cholinergic synapse. Brain Res. 1992 Jul 17;586(1):78-85. DMEO6A5 RU https://pubmed.ncbi.nlm.nih.gov/1380883 DMEO6PR DI DMEO6PR DMEO6PR DN Antide DMEO6PR TI TT8R70G DMEO6PR TN Gonadotropin-releasing hormone receptor (GNRHR) DMEO6PR MA Antagonist DMEO6PR RN Antide (Nal-Lys GnRH antagonist) suppression of pituitary-testicular function and sexual behavior in group-living rhesus monkeys. Physiol Behav. 1991 Aug;50(2):429-35. DMEO6PR RU https://pubmed.ncbi.nlm.nih.gov/1745690 DMEQ2N1 DI DMEQ2N1 DMEQ2N1 DN AZD8529 DMEQ2N1 TI TTVBPDM DMEQ2N1 TN Metabotropic glutamate receptor 1 (mGluR1) DMEQ2N1 MA Agonist DMEQ2N1 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMEQ2N1 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMEQL9U DI DMEQL9U DMEQL9U DN Benzydamine DMEQL9U TI TTK0943 DMEQL9U TN Prostaglandin G/H synthase (COX) DMEQL9U MA Inhibitor DMEQL9U RN Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. DMEQL9U RU https://pubmed.ncbi.nlm.nih.gov/18764726 DMEQLC4 DI DMEQLC4 DMEQLC4 DN DX-9065 DMEQLC4 TI TTCIHJA DMEQLC4 TN Coagulation factor Xa (F10) DMEQLC4 MA Inhibitor DMEQLC4 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMEQLC4 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMER3I9 DI DMER3I9 DMER3I9 DN S-9788 DMER3I9 TI TTO32GK DMER3I9 TN P-glycoprotein (P-GP) DMER3I9 MA Modulator DMER3I9 RN In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients. Cancer Chemother Pharmacol. 1995;36(3):195-203. DMER3I9 RU https://pubmed.ncbi.nlm.nih.gov/7781138 DMERM0K DI DMERM0K DMERM0K DN RS-8359 DMERM0K TI TT3WG5C DMERM0K TN Monoamine oxidase type A (MAO-A) DMERM0K MA Inhibitor DMERM0K RN Stereospecific oxidation of the (S)-enantiomer of RS-8359, a selective and reversible monoamine oxidase A (MAO-A) inhibitor, by aldehyde oxidase. Xenobiotica. 2005 Jun;35(6):561-73. DMERM0K RU https://pubmed.ncbi.nlm.nih.gov/16192108 DMEROU4 DI DMEROU4 DMEROU4 DN Tolafentrine DMEROU4 TI TTZCG4L DMEROU4 TN Phosphodiesterase 3 (PDE3) DMEROU4 MA Modulator DMEROU4 RN Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration DMEROU4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1291406 DMEV1H5 DI DMEV1H5 DMEV1H5 DN V-11294A DMEV1H5 TI TTVIAT9 DMEV1H5 TN Phosphodiesterase 4B (PDE4B) DMEV1H5 MA Inhibitor DMEV1H5 RN Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol. 2002 Nov;54(5):478-84. DMEV1H5 RU https://pubmed.ncbi.nlm.nih.gov/12445026 DMEV1H5 DI DMEV1H5 DMEV1H5 DN V-11294A DMEV1H5 TI TTSKMI8 DMEV1H5 TN Phosphodiesterase 4D (PDE4D) DMEV1H5 MA Inhibitor DMEV1H5 RN Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol. 2002 Nov;54(5):478-84. DMEV1H5 RU https://pubmed.ncbi.nlm.nih.gov/12445026 DMEV1H5 DI DMEV1H5 DMEV1H5 DN V-11294A DMEV1H5 TI TTZ97H5 DMEV1H5 TN Phosphodiesterase 4A (PDE4A) DMEV1H5 MA Inhibitor DMEV1H5 RN Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers. Br J Clin Pharmacol. 2002 Nov;54(5):478-84. DMEV1H5 RU https://pubmed.ncbi.nlm.nih.gov/12445026 DMF1IH5 DI DMF1IH5 DMF1IH5 DN Milveterol DMF1IH5 TI TT2CJVK DMF1IH5 TN Adrenergic receptor beta-2 (ADRB2) DMF1IH5 MA Agonist DMF1IH5 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMF1IH5 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMF1RTW DI DMF1RTW DMF1RTW DN Lurtotecan DMF1RTW TI TTGTQHC DMF1RTW TN DNA topoisomerase I (TOP1) DMF1RTW MA Inhibitor DMF1RTW RN Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer. 2004 Apr 1;100(7):1449-58. DMF1RTW RU https://pubmed.ncbi.nlm.nih.gov/15042679 DMF1VY4 DI DMF1VY4 DMF1VY4 DN Taprizosin DMF1VY4 TI TTNGILX DMF1VY4 TN Adrenergic receptor alpha-1A (ADRA1A) DMF1VY4 MA Antagonist DMF1VY4 RN Impact of physicochemical and structural properties on the pharmacokinetics of a series of alpha1L-adrenoceptor antagonists. Drug Metab Dispos. 2007 Aug;35(8):1435-45. DMF1VY4 RU https://pubmed.ncbi.nlm.nih.gov/17502340 DMF3E51 DI DMF3E51 DMF3E51 DN DANOFLOXACIN DMF3E51 TI TTN6J5F DMF3E51 TN Bacterial DNA gyrase (Bact gyrase) DMF3E51 MA Modulator DMF3E51 RN Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows. J Vet Pharmacol Ther. 1998 Jun;21(3):209-13. DMF3E51 RU https://www.ncbi.nlm.nih.gov/pubmed/9673962 DMF4MRD DI DMF4MRD DMF4MRD DN A-75925 DMF4MRD TI TT5FNQT DMF4MRD TN Human immunodeficiency virus Protease (HIV PR) DMF4MRD MA Inhibitor DMF4MRD RN Solvation studies of DMP323 and A76928 bound to HIV protease: analysis of water sites using grand canonical Monte Carlo simulations. Protein Sci. 1998 Mar;7(3):573-9. DMF4MRD RU https://pubmed.ncbi.nlm.nih.gov/9541388 DMF8B62 DI DMF8B62 DMF8B62 DN Linetastine DMF8B62 TI TT2J34L DMF8B62 TN Arachidonate 5-lipoxygenase (5-LOX) DMF8B62 MA Inhibitor DMF8B62 RN Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. DMF8B62 RU https://pubmed.ncbi.nlm.nih.gov/10940813 DMF8B62 DI DMF8B62 DMF8B62 DN Linetastine DMF8B62 TI TTYPXQF DMF8B62 TN Protein kinase C beta (PRKCB) DMF8B62 MA Inhibitor DMF8B62 RN Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8. DMF8B62 RU https://pubmed.ncbi.nlm.nih.gov/11992868 DMF8KH7 DI DMF8KH7 DMF8KH7 DN AM336 DMF8KH7 TI TT5HONZ DMF8KH7 TN Calcium channel unspecific (CaC) DMF8KH7 MA Modulator DMF8KH7 RN Intravenous injection of leconotide, an omega conotoxin: synergistic antihyperalgesic effects with morphine in a rat model of bone cancer pain.Pain Med.2011 Jun;12(6):923-41. DMF8KH7 RU https://www.ncbi.nlm.nih.gov/pubmed/21539704 DMF9Y57 DI DMF9Y57 DMF9Y57 DN Napitane mesilate DMF9Y57 TI TTAWNKZ DMF9Y57 TN Norepinephrine transporter (NET) DMF9Y57 MA Modulator DMF9Y57 RN Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant DMF9Y57 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2426812 DMFAG8W DI DMFAG8W DMFAG8W DN AZD1386 DMFAG8W TI TTMI6F5 DMFAG8W TN Transient receptor potential cation channel V1 (TRPV1) DMFAG8W MA Blocker DMFAG8W RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMFAG8W RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMFBNI6 DI DMFBNI6 DMFBNI6 DN Ceronapril DMFBNI6 TI TTL69WB DMFBNI6 TN Angiotensin-converting enzyme (ACE) DMFBNI6 MA Inhibitor DMFBNI6 RN Radioimmunoassay for ceronapril, a new angiotensin-converting enzyme inhibitor, and its application to a pharmacokinetic study in healthy male volunteers. Ther Drug Monit. 1992 Jun;14(3):209-19. DMFBNI6 RU https://pubmed.ncbi.nlm.nih.gov/1412607 DMFCOZL DI DMFCOZL DMFCOZL DN AVN 397 DMFCOZL TI TTJS8PY DMFCOZL TN 5-HT 6 receptor (HTR6) DMFCOZL MA Antagonist DMFCOZL RN Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91. DMFCOZL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346261/ DMFGJNW DI DMFGJNW DMFGJNW DN FK-664 DMFGJNW TI TTTWGIX DMFGJNW TN Leukotriene receptor (LTR) DMFGJNW MA Modulator DMFGJNW RN US patent application no. 7,175,854, Pharmaceutical preparation comprising an active dispersed on a matrix. DMFGJNW RU http://www.google.com/patents/US7175854 DMFN1WI DI DMFN1WI DMFN1WI DN BR3-Fc DMFN1WI TI TTWMIDN DMFN1WI TN B-cell-activating factor (TNFSF13B) DMFN1WI MA Inhibitor DMFN1WI RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMFN1WI RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMFN21T DI DMFN21T DMFN21T DN GV-196771 DMFN21T TI TTZ8EM9 DMFN21T TN Glycine receptor (GlyR) DMFN21T MA Modulator DMFN21T RN First time in human for GV196771: interspecies scaling applied on dose selection. J Clin Pharmacol. 1999 Jun;39(6):560-6. DMFN21T RU https://pubmed.ncbi.nlm.nih.gov/10354959 DMFWC3O DI DMFWC3O DMFWC3O DN Perillyl alcohol DMFWC3O TI TTW2R9X DMFWC3O TN GTPase NRas (NRAS) DMFWC3O MA Modulator DMFWC3O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823). DMFWC3O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2823 DMFYM61 DI DMFYM61 DMFYM61 DN VTP-201227 DMFYM61 TI TTOQ9GZ DMFYM61 TN Cytochrome P450 reductase (P450) DMFYM61 MA Inhibitor DMFYM61 RN VTP-201227. VietMedix. DMFYM61 RU http://vietmedix.com/Drug/drug-vtp-201227.5277.html DMG0I6L DI DMG0I6L DMG0I6L DN 97-139 DMG0I6L TI TTKRD0G DMG0I6L TN Endothelin A receptor (EDNRA) DMG0I6L MA Antagonist DMG0I6L RN S-0139 (Shionogi). Curr Opin Investig Drugs. 2002 Jul;3(7):1051-6. DMG0I6L RU https://pubmed.ncbi.nlm.nih.gov/12186266 DMG3HX2 DI DMG3HX2 DMG3HX2 DN CV-6504 DMG3HX2 TI TT2J34L DMG3HX2 TN Arachidonate 5-lipoxygenase (5-LOX) DMG3HX2 MA Inhibitor DMG3HX2 RN A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Ann Oncol. 2000 Sep;11(9):1165-70. DMG3HX2 RU https://pubmed.ncbi.nlm.nih.gov/11061613 DMG3R14 DI DMG3R14 DMG3R14 DN EP-2104R DMG3R14 TI TTWODQF DMG3R14 TN Fibrin (FG) DMG3R14 MA Modulator DMG3R14 RN EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus. J Am Chem Soc. 2008 May 7;130(18):6025-39. DMG3R14 RU https://pubmed.ncbi.nlm.nih.gov/18393503 DMG4RFO DI DMG4RFO DMG4RFO DN TAK-442 DMG4RFO TI TTCIHJA DMG4RFO TN Coagulation factor Xa (F10) DMG4RFO MA Inhibitor DMG4RFO RN Clinical pipeline report, company report or official report of Takeda (2009). DMG4RFO RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMG5VJF DI DMG5VJF DMG5VJF DN L-660771 DMG5VJF TI TTGKOY9 DMG5VJF TN Leukotriene CysLT1 receptor (CYSLTR1) DMG5VJF MA Modulator DMG5VJF RN Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can J Physiol Pharmacol. 1991 Dec;69(12):1847-54. DMG5VJF RU https://www.ncbi.nlm.nih.gov/pubmed/1666333 DMG62H1 DI DMG62H1 DMG62H1 DN CereCRIB DMG62H1 TI TTN4QDT DMG62H1 TN Opioid receptor (OPR) DMG62H1 MA Modulator DMG62H1 RN US patent application no. 5,874,099, Methods for making immunoisolatary implantable vehicles with a biocompatible jacket and a biocompatible matrix core. DMG62H1 RU http://www.google.co.ug/patents/US5874099 DMGD20T DI DMGD20T DMGD20T DN PEG-Infergen DMGD20T TI TT95SOA DMGD20T TN Interferon alpha (IFNA) DMGD20T MA Modulator DMGD20T RN Patent CN102245599 B. DMGD20T RU http://www.google.com/patents/CN102245599B?cl=en DMGD5QN DI DMGD5QN DMGD5QN DN Filaminast DMGD5QN TI TTVIAT9 DMGD5QN TN Phosphodiesterase 4B (PDE4B) DMGD5QN MA Inhibitor DMGD5QN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGD5QN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGDPSI DI DMGDPSI DMGDPSI DN AOD-9604 DMGDPSI TI TTKMAZ6 DMGDPSI TN Growth hormone receptor (GHR) DMGDPSI MA Agonist DMGDPSI RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMGDPSI RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMGE9OA DI DMGE9OA DMGE9OA DN LY-2523199 DMGE9OA TI TTN7BL9 DMGE9OA TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMGE9OA MA Inhibitor DMGE9OA RN Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease. before print June 15, 2014. DMGE9OA RU http://diabetes.diabetesjournals.org/content/63/7/2253.full DMGEBUQ DI DMGEBUQ DMGEBUQ DN NC-190 DMGEBUQ TI TT0IHXV DMGEBUQ TN DNA topoisomerase II (TOP2) DMGEBUQ MA Modulator DMGEBUQ RN The topoisomerase II-inhibitor NC-190 reduces the level of thymidine kinase mRNA in murine tumor cells. Res Commun Mol Pathol Pharmacol. 2002;111(1-4):77-87. DMGEBUQ RU https://pubmed.ncbi.nlm.nih.gov/14632316 DMGF35T DI DMGF35T DMGF35T DN Tisocalcitate DMGF35T TI TTK59TV DMGF35T TN Vitamin D3 receptor (VDR) DMGF35T MA Inhibitor DMGF35T RN The Rationale Behind Topical Vitamin D Analogs in the Treatment of Psoriasis: Where Does Topical Calcitriol Fit In . J Clin Aesthet Dermatol. 2010 August; 3(8): 46-53. DMGF35T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945865/ DMGFS51 DI DMGFS51 DMGFS51 DN T-1095 DMGFS51 TI TT2UE56 DMGFS51 TN Sodium/glucose cotransporter 1 (SGLT1) DMGFS51 MA Modulator DMGFS51 RN T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999 Sep;48(9):1794-800. DMGFS51 RU https://pubmed.ncbi.nlm.nih.gov/10480610 DMGJMQH DI DMGJMQH DMGJMQH DN Examorelin DMGJMQH TI TTG4R8V DMGJMQH TN Growth hormone-releasing hormone receptor (GHRHR) DMGJMQH MA Modulator DMGJMQH RN Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa. J Endocrinol Invest. 1997 May;20(5):257-63. DMGJMQH RU https://pubmed.ncbi.nlm.nih.gov/9258804 DMGL0Q2 DI DMGL0Q2 DMGL0Q2 DN AN-9 DMGL0Q2 TI TT6R7JZ DMGL0Q2 TN Histone deacetylase 1 (HDAC1) DMGL0Q2 MA Inhibitor DMGL0Q2 RN Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. DMGL0Q2 RU https://pubmed.ncbi.nlm.nih.gov/16955068 DMGM2HY DI DMGM2HY DMGM2HY DN DCDT-2980S DMGM2HY TI TTM6QSK DMGM2HY TN B-cell receptor CD22 (CD22) DMGM2HY RN Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma. Oncoimmunology. 2012 December 1; 1(9): 1469-1475. DMGM2HY RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525602/ DMGMBCW DI DMGMBCW DMGMBCW DN ABT-594 DMGMBCW TI TT5KPZR DMGMBCW TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMGMBCW MA Agonist DMGMBCW RN The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13. DMGMBCW RU https://pubmed.ncbi.nlm.nih.gov/10716232 DMGMBCW DI DMGMBCW DMGMBCW DN ABT-594 DMGMBCW TI TT4H1MQ DMGMBCW TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMGMBCW MA Agonist DMGMBCW RN The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport. 1999 Dec 16;10(18):3909-13. DMGMBCW RU https://pubmed.ncbi.nlm.nih.gov/10716232 DMGMBCW DI DMGMBCW DMGMBCW DN ABT-594 DMGMBCW TI TTJSZTB DMGMBCW TN Nicotinic acetylcholine receptor (nAChR) DMGMBCW MA Agonist DMGMBCW RN ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization. J Pharmacol Exp Ther. 1998 May;285(2):787-94. DMGMBCW RU https://pubmed.ncbi.nlm.nih.gov/9580627 DMGO2AV DI DMGO2AV DMGO2AV DN PTI-701 DMGO2AV TI TTN4QDT DMGO2AV TN Opioid receptor (OPR) DMGO2AV MA Modulator DMGO2AV RN Clinical pipeline report, company report or official report of Pain Therapeutics. DMGO2AV RU http://www.paintrials.com/ DMGPHTJ DI DMGPHTJ DMGPHTJ DN BMS-181168 DMGPHTJ TI TTH18TF DMGPHTJ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMGPHTJ MA Modulator DMGPHTJ RN Efficacy and safety of BMY 21,502 in Alzheimer disease. Ann Pharmacother. 1996 Dec;30(12):1376-80. DMGPHTJ RU https://pubmed.ncbi.nlm.nih.gov/8968446 DMGQJ2U DI DMGQJ2U DMGQJ2U DN LESOPITRON DIHYDROCHLORIDE DMGQJ2U TI TTSQIFT DMGQJ2U TN 5-HT 1A receptor (HTR1A) DMGQJ2U MA Agonist DMGQJ2U RN Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover. Br J Pharmacol. 1994 Oct;113(2):425-30. DMGQJ2U RU https://pubmed.ncbi.nlm.nih.gov/7530571 DMGR7Y3 DI DMGR7Y3 DMGR7Y3 DN Theradigm-HBV DMGR7Y3 TI TTZTEFH DMGR7Y3 TN Major histocompatibility complex (MHC) DMGR7Y3 MA Modulator DMGR7Y3 RN Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor. Hepatology. 1997 Oct;26(4):1027-34. DMGR7Y3 RU https://pubmed.ncbi.nlm.nih.gov/9328331 DMGVRQ2 DI DMGVRQ2 DMGVRQ2 DN R-18893 DMGVRQ2 TI TT84ETX DMGVRQ2 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMGVRQ2 MA Modulator DMGVRQ2 RN EP patent application no. 0767664, Combination therapy for hiv infection. DMGVRQ2 RU http://www.google.com/patents/EP0767664A2?cl=en DMGVYXB DI DMGVYXB DMGVYXB DN NB-506 DMGVYXB TI TTUTN1I DMGVYXB TN Human Deoxyribonucleic acid (hDNA) DMGVYXB MA Inhibitor DMGVYXB RN DNA binding properties of the indolocarbazole antitumor drug NB-506. Anticancer Drug Des. 2001 Apr-Jun;16(2-3):99-107. DMGVYXB RU https://pubmed.ncbi.nlm.nih.gov/11962518 DMGWFZJ DI DMGWFZJ DMGWFZJ DN BIBR-363 DMGWFZJ TI TTGN1ZA DMGWFZJ TN Angiotensin II receptor (AGTR) DMGWFZJ MA Modulator DMGWFZJ RN Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system. Br J Clin Pharmacol. 1999 October; 48(4): 594-604. DMGWFZJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2014379/ DMGYXA4 DI DMGYXA4 DMGYXA4 DN CS-722 DMGYXA4 TI TT3WG5C DMGYXA4 TN Monoamine oxidase type A (MAO-A) DMGYXA4 MA Inhibitor DMGYXA4 RN Mechanisms of spinal reflex depressant effects of CS-722, a newly synthesized centrally acting muscle relaxant, in spinal rats. Neuropharmacology. 1992 Sep;31(9):949-54. DMGYXA4 RU https://pubmed.ncbi.nlm.nih.gov/1436401 DMGZ3BF DI DMGZ3BF DMGZ3BF DN Lodenosine DMGZ3BF TI TT84ETX DMGZ3BF TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMGZ3BF MA Inhibitor DMGZ3BF RN 2 ,3 -Dialdehyde of ATP, ADP, and adenosine inhibit HIV-1 reverse transcriptase and HIV-1 replication. Curr HIV Res. 2014;12(5):347-58. DMGZ3BF RU https://pubmed.ncbi.nlm.nih.gov/25174839 DMGZ3DR DI DMGZ3DR DMGZ3DR DN NT-3 DMGZ3DR TI TTZHKV9 DMGZ3DR TN Neurotrophin-3 (NTF3) DMGZ3DR MA Modulator DMGZ3DR RN NT-3. Takeda/Regeneron/Amgen. IDrugs. 2001 Jul;4(7):820-4. DMGZ3DR RU https://pubmed.ncbi.nlm.nih.gov/15995939 DMGZV7U DI DMGZV7U DMGZV7U DN ISIS 14803 DMGZV7U TI TTXWCK2 DMGZV7U TN Hepatitis C virus Internal ribosome entry site messenger RNA (HCV IRES mRNA) DMGZV7U RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMGZV7U RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMH2QBM DI DMH2QBM DMH2QBM DN NSP-805 DMH2QBM TI TTZCG4L DMH2QBM TN Phosphodiesterase 3 (PDE3) DMH2QBM MA Modulator DMH2QBM RN [The effect of phosphodiesterase type 3 inhibitor on chorio-retinal blood flow in rabbits eyes].Nippon Ganka Gakkai Zasshi.2002 Oct;106(10):615-20. DMH2QBM RU https://www.ncbi.nlm.nih.gov/pubmed/12420371 DMH3DXY DI DMH3DXY DMH3DXY DN FK-453 DMH3DXY TI TTK25J1 DMH3DXY TN Adenosine A1 receptor (ADORA1) DMH3DXY MA Modulator DMH3DXY RN Cardiovascular and renal effects of blocking A1 adenosine receptors. J Cardiovasc Pharmacol. 1993 May;21(5):822-8. DMH3DXY RU https://www.ncbi.nlm.nih.gov/pubmed/7685455 DMH4U87 DI DMH4U87 DMH4U87 DN VX-366 DMH4U87 TI TTQO71U DMH4U87 TN Hemoglobin (HB) DMH4U87 MA Inhibitor DMH4U87 RN A combination of hydroxyurea and isobutyramide to induce fetal hemoglobin in transgenic mice is more hematotoxic than the individual agents. Blood Cells Mol Dis. 1999 Jun-Aug;25(3-4):255-69. DMH4U87 RU https://pubmed.ncbi.nlm.nih.gov/10575551 DMH5LKS DI DMH5LKS DMH5LKS DN CPA-926 DMH5LKS TI TTG3K2U DMH5LKS TN Lipoxygenase (ALOX) DMH5LKS MA Modulator DMH5LKS RN Esculetin (dihydroxycoumarin) inhibits the production of matrix metalloproteinases in cartilage explants, and oral administration of its prodrug, CPA-926, suppresses cartilage destruction in rabbit experimental osteoarthritis. J Rheumatol. 1999 Mar;26(3):654-62. DMH5LKS RU https://pubmed.ncbi.nlm.nih.gov/10090178 DMH6QAI DI DMH6QAI DMH6QAI DN FK778 DMH6QAI TI TTLVP78 DMH6QAI TN Dihydroorotate dehydrogenase (DHODH) DMH6QAI MA Modulator DMH6QAI RN Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation. 2003 Dec 15;76(11):1627-9. DMH6QAI RU https://www.ncbi.nlm.nih.gov/pubmed/14702537 DMH912O DI DMH912O DMH912O DN RO-48-6791 DMH912O TI TTEX6LM DMH912O TN GABA(A) receptor gamma-3 (GABRG3) DMH912O MA Modulator DMH912O RN Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997 Nov;44(5):477-86. DMH912O RU https://pubmed.ncbi.nlm.nih.gov/9384465 DMHA5ME DI DMHA5ME DMHA5ME DN AZD-9684 DMHA5ME TI TTP18AY DMHA5ME TN Carboxypeptidase B2 (CPB2) DMHA5ME MA Inhibitor DMHA5ME RN Clinical pipeline report, company report or official report of AstraZeneca. DMHA5ME RU http://www.astrazeneca.com.au/research/cardiovascular?itemId=396161 DMHA5ME DI DMHA5ME DMHA5ME DN AZD-9684 DMHA5ME TI TTLA931 DMHA5ME TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMHA5ME MA Antagonist DMHA5ME RN Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51. DMHA5ME RU https://pubmed.ncbi.nlm.nih.gov/11379686 DMHA5ME DI DMHA5ME DMHA5ME DN AZD-9684 DMHA5ME TI TT5KPZR DMHA5ME TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMHA5ME MA Antagonist DMHA5ME RN Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51. DMHA5ME RU https://pubmed.ncbi.nlm.nih.gov/11379686 DMHA5ME DI DMHA5ME DMHA5ME DN AZD-9684 DMHA5ME TI TTMT0HG DMHA5ME TN Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3) DMHA5ME MA Antagonist DMHA5ME RN Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology. 2001 Apr;94(4):643-51. DMHA5ME RU https://pubmed.ncbi.nlm.nih.gov/11379686 DMHAM2J DI DMHAM2J DMHAM2J DN Gantofiban DMHAM2J TI TT38RM1 DMHAM2J TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMHAM2J MA Modulator DMHAM2J RN Enantioseparation of gantofiban precursors on chiral stationary phases of the poly-(N-acryloyl amino acid derivative)-type. J Pharm Biomed Anal. 2002 Jan 15;27(3-4):627-37. DMHAM2J RU https://www.ncbi.nlm.nih.gov/pubmed/11755763 DMHCBQS DI DMHCBQS DMHCBQS DN ReN-1869 DMHCBQS TI TTTIBOJ DMHCBQS TN Histamine H1 receptor (H1R) DMHCBQS MA Antagonist DMHCBQS RN ReN 1869, a novel tricyclic antihistamine, is active against neurogenic pain and inflammation. Eur J Pharmacol. 2002 Jan 18;435(1):43-57. DMHCBQS RU https://pubmed.ncbi.nlm.nih.gov/11790377 DMHCLVQ DI DMHCLVQ DMHCLVQ DN Vitaxin DMHCLVQ TI TT69TQN DMHCLVQ TN Integrin alpha-V/beta-3 (ITGAV/B3) DMHCLVQ MA Modulator DMHCLVQ RN Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood. 2000 Jan 15;95(2):368-74. DMHCLVQ RU https://www.ncbi.nlm.nih.gov/pubmed/10627437 DMHCOFM DI DMHCOFM DMHCOFM DN Vasoflux DMHCOFM TI TT6L509 DMHCOFM TN Coagulation factor IIa (F2) DMHCOFM MA Inhibitor DMHCOFM RN Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation. 1999 Feb 9;99(5):682-9. DMHCOFM RU https://pubmed.ncbi.nlm.nih.gov/9950667 DMHDP9R DI DMHDP9R DMHDP9R DN PRS-211375 iv DMHDP9R TI TTMSFAW DMHDP9R TN Cannabinoid receptor 2 (CB2) DMHDP9R MA Agonist DMHDP9R RN Brain CB2 Receptors: Implications for Neuropsychiatric Disorders. Pharmaceuticals (Basel) 2010 August; 3(8): 2517-2553. DMHDP9R RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033937/ DMHEW40 DI DMHEW40 DMHEW40 DN E-2078 DMHEW40 TI TTQW87Y DMHEW40 TN Opioid receptor kappa (OPRK1) DMHEW40 MA Modulator DMHEW40 RN Systemic effects of E-2078, a stabilized dynorphin A(1-8) analog, in rhesus monkeys. Psychopharmacology (Berl). 1999 Apr;143(2):190-6. DMHEW40 RU https://pubmed.ncbi.nlm.nih.gov/10326782 DMHFOIX DI DMHFOIX DMHFOIX DN OxycoDex DMHFOIX TI TTN4QDT DMHFOIX TN Opioid receptor (OPR) DMHFOIX MA Modulator DMHFOIX RN Differential activation of the -opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model. Br J Pharmacol. 2013 Jan;168(2):375-88. DMHFOIX RU https://pubmed.ncbi.nlm.nih.gov/22889192 DMHFOIX DI DMHFOIX DMHFOIX DN OxycoDex DMHFOIX TI TT3ROYC DMHFOIX TN Serotonin transporter (SERT) DMHFOIX MA Inhibitor DMHFOIX RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMHFOIX RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMHFOIX DI DMHFOIX DMHFOIX DN OxycoDex DMHFOIX TI TT5TPI6 DMHFOIX TN Opioid receptor sigma 1 (OPRS1) DMHFOIX MA Modulator DMHFOIX RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMHFOIX RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMHFTD0 DI DMHFTD0 DMHFTD0 DN Y-700 DMHFTD0 TI TT7RJY8 DMHFTD0 TN Xanthine dehydrogenase/oxidase (XDH) DMHFTD0 MA Inhibitor DMHFTD0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHFTD0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHITR4 DI DMHITR4 DMHITR4 DN SOLPECAINOL HYDROCHLORIDE DMHITR4 TI TTRK8B9 DMHITR4 TN Sodium channel unspecific (NaC) DMHITR4 MA Modulator DMHITR4 RN US patent application no. 2002,0102,217, Diagnostic,therapeutic agents. DMHITR4 RU http://www.google.com.na/patents/US20020102217 DMHIUGT DI DMHIUGT DMHIUGT DN FK-352 DMHIUGT TI TTK25J1 DMHIUGT TN Adenosine A1 receptor (ADORA1) DMHIUGT MA Antagonist DMHIUGT RN Adenosine A1 receptor antagonist improves intradialytic hypotension. Kidney Int. 2006 Mar;69(5):877-83. DMHIUGT RU https://pubmed.ncbi.nlm.nih.gov/16395260 DMHJ3SN DI DMHJ3SN DMHJ3SN DN Cadrofloxacin DMHJ3SN TI TTN6J5F DMHJ3SN TN Bacterial DNA gyrase (Bact gyrase) DMHJ3SN MA Modulator DMHJ3SN RN Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug;40(8):1835-42. DMHJ3SN RU https://pubmed.ncbi.nlm.nih.gov/8843290 DMHK8IM DI DMHK8IM DMHK8IM DN CFC-222 DMHK8IM TI TTN6J5F DMHK8IM TN Bacterial DNA gyrase (Bact gyrase) DMHK8IM MA Modulator DMHK8IM RN Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on r... J Antimicrob Chemother. 2002 Oct;50(4):589-92. DMHK8IM RU https://www.ncbi.nlm.nih.gov/pubmed/12356806 DMHNZ31 DI DMHNZ31 DMHNZ31 DN TAK-802 DMHNZ31 TI TT1RS9F DMHNZ31 TN Acetylcholinesterase (AChE) DMHNZ31 MA Inhibitor DMHNZ31 RN Effects of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rats and guinea pigs. Eur J Pharmacol. 2004 Feb 6;485(1-3):299-305. DMHNZ31 RU https://pubmed.ncbi.nlm.nih.gov/14757154 DMHOMFK DI DMHOMFK DMHOMFK DN G-1128 DMHOMFK TI TT6B75U DMHOMFK TN ABL messenger RNA (ABL mRNA) DMHOMFK RN Pharmaceutical Design And Development: A Molecular Biology Approach, T V Ramabhadran, 2005. Page(219). DMHOMFK RU https://books.google.com.sg/books?id=wmPsNyVMLVsC&pg=PA219&lpg=PA219&dq=%E2%80%9CG-1128%E2%80%9D+antisense&source=bl&ots=_53NgYwdeA&sig=0CKK88IXybZco5YWV-7pU8EugPs&hl=zh-CN&sa=X&ved=0CCYQ6AEwAWoVChMI8cD98f--yAIVQQSOCh24qgAR DMHP6OY DI DMHP6OY DMHP6OY DN AZD2066 DMHP6OY TI TTHS256 DMHP6OY TN Metabotropic glutamate receptor 5 (mGluR5) DMHP6OY MA Antagonist DMHP6OY RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMHP6OY RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMHSUQ1 DI DMHSUQ1 DMHSUQ1 DN R-ketoprofen DMHSUQ1 TI TT30C9G DMHSUQ1 TN C-X-C chemokine receptor type 2 (CXCR2) DMHSUQ1 MA Inhibitor DMHSUQ1 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMHSUQ1 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMHSUQ1 DI DMHSUQ1 DMHSUQ1 DN R-ketoprofen DMHSUQ1 TI TTMWT8Z DMHSUQ1 TN C-X-C chemokine receptor type 1 (CXCR1) DMHSUQ1 MA Inhibitor DMHSUQ1 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMHSUQ1 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMHSUQ1 DI DMHSUQ1 DMHSUQ1 DN R-ketoprofen DMHSUQ1 TI TTVKILB DMHSUQ1 TN Prostaglandin G/H synthase 2 (COX-2) DMHSUQ1 MA Inhibitor DMHSUQ1 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMHSUQ1 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMHSUQ1 DI DMHSUQ1 DMHSUQ1 DN R-ketoprofen DMHSUQ1 TI TTCTE1G DMHSUQ1 TN Interleukin-8 (IL8) DMHSUQ1 MA Inhibitor DMHSUQ1 RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DMHSUQ1 RU https://pubmed.ncbi.nlm.nih.gov/19560921 DMHSUQ1 DI DMHSUQ1 DMHSUQ1 DN R-ketoprofen DMHSUQ1 TI TT8NGED DMHSUQ1 TN Prostaglandin G/H synthase 1 (COX-1) DMHSUQ1 MA Inhibitor DMHSUQ1 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMHSUQ1 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMHZ3DE DI DMHZ3DE DMHZ3DE DN AZD6765 DMHZ3DE TI TT9IK2Z DMHZ3DE TN N-methyl-D-aspartate receptor (NMDAR) DMHZ3DE MA Antagonist DMHZ3DE RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMHZ3DE RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMHZQ0T DI DMHZQ0T DMHZQ0T DN GSK2190914 DMHZQ0T TI TTDMBF5 DMHZQ0T TN Arachidonate 5-lipoxygenase activating protein (FLAP) DMHZQ0T MA Inhibitor DMHZQ0T RN FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs. 2009 Nov;10(11):1163-72. DMHZQ0T RU https://pubmed.ncbi.nlm.nih.gov/19876784 DMI0UJS DI DMI0UJS DMI0UJS DN JTP-4819 DMI0UJS TI TTNGKET DMI0UJS TN Prolyl endopeptidase (PREP) DMI0UJS MA Modulator DMI0UJS RN A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res. 1997 Feb;83(1-2):147-51. DMI0UJS RU https://pubmed.ncbi.nlm.nih.gov/9062674 DMI1SXB DI DMI1SXB DMI1SXB DN Rafabegron DMI1SXB TI TTMXGCW DMI1SXB TN Adrenergic receptor beta-3 (ADRB3) DMI1SXB MA Modulator DMI1SXB RN Lack of an effect of a novel beta3-adrenoceptor agonist, TAK-677, on energy metabolism in obese individuals: a double-blind, placebo-controlled ran... J Clin Endocrinol Metab. 2007 Feb;92(2):527-31. DMI1SXB RU https://pubmed.ncbi.nlm.nih.gov/17118998 DMI1XQ9 DI DMI1XQ9 DMI1XQ9 DN RG7697 DMI1XQ9 TI TTYMKBE DMI1XQ9 TN Gastric inhibitory polypeptide receptor (GIPR) DMI1XQ9 MA Modulator DMI1XQ9 RN Company report (Roche pipeline: 16 October 2014) DMI1XQ9 RU http://www.roche.com/dam/jcr:d7744c7f-f7de-46b5-b028-df69d7bc3a05/en/irp3q14e-a.pdf DMI2LFG DI DMI2LFG DMI2LFG DN BW-773U82 DMI2LFG TI TT0IHXV DMI2LFG TN DNA topoisomerase II (TOP2) DMI2LFG MA Modulator DMI2LFG RN Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols. Anticancer Drug Des. 1998 Oct;13(7):825-35. DMI2LFG RU https://pubmed.ncbi.nlm.nih.gov/9807165 DMI3T64 DI DMI3T64 DMI3T64 DN BP-2.94 DMI3T64 TI TT9JNIC DMI3T64 TN Histamine H3 receptor (H3R) DMI3T64 MA Modulator DMI3T64 RN Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology. 1996 Jul;15(1):31-5. DMI3T64 RU https://pubmed.ncbi.nlm.nih.gov/8797189 DMI5XKC DI DMI5XKC DMI5XKC DN DMP-961 DMI5XKC TI TT84ETX DMI5XKC TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI5XKC MA Inhibitor DMI5XKC RN Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 December; 1(4): 55-61. DMI5XKC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750457/ DMI8T41 DI DMI8T41 DMI8T41 DN Pumafentrine DMI8T41 TI TTZCG4L DMI8T41 TN Phosphodiesterase 3 (PDE3) DMI8T41 MA Modulator DMI8T41 RN The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.PLoS One.2013;8(2):e56867. DMI8T41 RU https://www.ncbi.nlm.nih.gov/pubmed/23468885 DMIAXCZ DI DMIAXCZ DMIAXCZ DN Alrestatin DMIAXCZ TI TTFBNVI DMIAXCZ TN Aldose reductase (AKR1B1) DMIAXCZ MA Inhibitor DMIAXCZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIAXCZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMICR39 DI DMICR39 DMICR39 DN XL784 DMICR39 TI TTMX39J DMICR39 TN Matrix metalloproteinase-1 (MMP-1) DMICR39 MA Inhibitor DMICR39 RN Agents in development for the treatment of diabetic nephropathy. Expert Opin Emerg Drugs. 2008 Sep;13(3):447-63. DMICR39 RU https://pubmed.ncbi.nlm.nih.gov/18764722 DMIDGZU DI DMIDGZU DMIDGZU DN Telbermin DMIDGZU TI TT2Q6G1 DMIDGZU TN Vascular endothelial growth factor receptor 1 (FLT-1) DMIDGZU MA Activator DMIDGZU RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMIDGZU RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMIEFH0 DI DMIEFH0 DMIEFH0 DN REC-15/3079 DMIEFH0 TI TTSQIFT DMIEFH0 TN 5-HT 1A receptor (HTR1A) DMIEFH0 MA Antagonist DMIEFH0 RN N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-nitrophenyl) cyclohexanecarboxamide: a novel pre- and postsynaptic 5-hydroxytryptamine(1A) receptor antagonist active on the lower urinary tract. JPharmacol Exp Ther. 2001 Dec;299(3):1027-37. DMIEFH0 RU https://pubmed.ncbi.nlm.nih.gov/11714892 DMIF4VJ DI DMIF4VJ DMIF4VJ DN SB-201993 DMIF4VJ TI TTN53ZF DMIF4VJ TN Leukotriene B4 receptor 1 (LTB4R) DMIF4VJ MA Inhibitor DMIF4VJ RN (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41. DMIF4VJ RU https://pubmed.ncbi.nlm.nih.gov/8809171 DMIG5W8 DI DMIG5W8 DMIG5W8 DN MCPP DMIG5W8 TI TTWJBZ5 DMIG5W8 TN 5-HT 2C receptor (HTR2C) DMIG5W8 MA Agonist DMIG5W8 RN mCPP-induced hyperactivity in 5-HT2C receptor mutant mice is mediated by activation of multiple 5-HT receptor subtypes. Neuropharmacology. 2004 Apr;46(5):663-71. DMIG5W8 RU https://pubmed.ncbi.nlm.nih.gov/14996544 DMIHSOG DI DMIHSOG DMIHSOG DN BRL-46470 DMIHSOG TI TTNXLKE DMIHSOG TN 5-HT 3 receptor (5HT3R) DMIHSOG MA Modulator DMIHSOG RN Evidence that the atypical 5-HT3 receptor ligand, [3H]-BRL46470, labels additional 5-HT3 binding sites compared to [3H]-granisetron. Br J Pharmacol. 1995 Sep;116(2):1781-8. DMIHSOG RU https://www.ncbi.nlm.nih.gov/pubmed/8528560 DMIJ6FX DI DMIJ6FX DMIJ6FX DN KRH-594 DMIJ6FX TI TT8DBY3 DMIJ6FX TN Angiotensin II receptor type-1 (AGTR1) DMIJ6FX MA Antagonist DMIJ6FX RN Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors. Fundam Clin Pharmacol. 2002 Aug;16(4):317-23. DMIJ6FX RU https://pubmed.ncbi.nlm.nih.gov/12570021 DMIJSB3 DI DMIJSB3 DMIJSB3 DN HMR-1426 DMIJSB3 TI TT63CB1 DMIJSB3 TN Food intake (FI) DMIJSB3 MA Modulator DMIJSB3 RN Analysis of the anorectic efficacy of HMR1426 in rodents and its effects on gastric emptying in rats. Int J Obes Relat Metab Disord. 2004 Feb;28(2):211-21. DMIJSB3 RU https://pubmed.ncbi.nlm.nih.gov/14663491 DMIKLRN DI DMIKLRN DMIKLRN DN ALPRENOXIME HYDROCHLORIDE DMIKLRN TI TTMXGCW DMIKLRN TN Adrenergic receptor beta-3 (ADRB3) DMIKLRN MA Modulator DMIKLRN RN Improved delivery through biological membranes. LVI. Pharmacological evaluation of alprenoxime--a new potential antiglaucoma agent. Pharm Res. 1991 Nov;8(11):1389-95. DMIKLRN RU https://pubmed.ncbi.nlm.nih.gov/1798675 DMIKUXN DI DMIKUXN DMIKUXN DN RSD-921 DMIKUXN TI TTRK8B9 DMIKUXN TN Sodium channel unspecific (NaC) DMIKUXN MA Modulator DMIKUXN RN Molecular analysis of the Na+ channel blocking actions of the novel class I anti-arrhythmic agent RSD 921. Br J Pharmacol. 1999 May;127(1):9-18. DMIKUXN RU https://pubmed.ncbi.nlm.nih.gov/10369450 DMILUHA DI DMILUHA DMILUHA DN IDEC-151 DMILUHA TI TTN2JFW DMILUHA TN T-cell surface glycoprotein CD4 (CD4) DMILUHA RN Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41. DMILUHA RU https://pubmed.ncbi.nlm.nih.gov/10734150 DMIN73Y DI DMIN73Y DMIN73Y DN Reglixane DMIN73Y TI TTZMAO3 DMIN73Y TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMIN73Y MA Modulator DMIN73Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMIN73Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMIN73Y DI DMIN73Y DMIN73Y DN Reglixane DMIN73Y TI TTJ584C DMIN73Y TN Peroxisome proliferator-activated receptor alpha (PPARA) DMIN73Y MA Modulator DMIN73Y RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMIN73Y RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMIP3EC DI DMIP3EC DMIP3EC DN DM-83 DMIP3EC TI TTCBFJO DMIP3EC TN Insulin receptor (INSR) DMIP3EC MA Stimulator DMIP3EC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMIP3EC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMIQRJW DI DMIQRJW DMIQRJW DN EMR-62203 DMIQRJW TI TTJ0IQB DMIQRJW TN Phosphodiesterase 5A (PDE5A) DMIQRJW MA Inhibitor DMIQRJW RN WO patent application no. 2006,0180,88, Use of a pde 5 inhibitor for treating and preventing hypopigmentary disorders. DMIQRJW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060223&CC=WO&NR=2006018088A1&KC=A1 DMIR4FB DI DMIR4FB DMIR4FB DN CEMADOTIN HYDROCHLORIDE DMIR4FB TI TTYFKSZ DMIR4FB TN Tubulin beta (TUBB) DMIR4FB MA Modulator DMIR4FB RN Suppression of microtubule dynamics by binding of cemadotin to tubulin: possible mechanism for its antitumor action. Biochemistry. 1998 Dec 15;37(50):17571-8. DMIR4FB RU https://pubmed.ncbi.nlm.nih.gov/9860873 DMIRSLV DI DMIRSLV DMIRSLV DN YM-17K DMIRSLV TI TTR8XOH DMIRSLV TN GPCR secretin protein unspecific (GPCRB) DMIRSLV MA Modulator DMIRSLV RN Antibiotics, Macrolides. Published Online: 18 OCT 2001. DMIRSLV RU http://onlinelibrary.wiley.com/doi/10.1002/0471238961.1301031811091819.a01.pub2/abstract DMIS7DW DI DMIS7DW DMIS7DW DN LY-307161 DMIS7DW TI TTVIMDE DMIS7DW TN Glucagon-like peptide 1 receptor (GLP1R) DMIS7DW MA Modulator DMIS7DW RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):565-97. DMIS7DW RU https://pubmed.ncbi.nlm.nih.gov/14571286 DMIUFS4 DI DMIUFS4 DMIUFS4 DN GI 181771 DMIUFS4 TI TTCG0AL DMIUFS4 TN Cholecystokinin receptor type A (CCKAR) DMIUFS4 MA Agonist DMIUFS4 RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506. DMIUFS4 RU https://pubmed.ncbi.nlm.nih.gov/12949633 DMIXUMZ DI DMIXUMZ DMIXUMZ DN DX-9065a DMIXUMZ TI TTCIHJA DMIXUMZ TN Coagulation factor Xa (F10) DMIXUMZ MA Inhibitor DMIXUMZ RN DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins. Thromb Haemost. 2003 Jan;89(1):112-21. DMIXUMZ RU https://pubmed.ncbi.nlm.nih.gov/12540961 DMIZ59O DI DMIZ59O DMIZ59O DN BIM-23268 DMIZ59O TI TTOMNR9 DMIZ59O TN Somatostatin receptor (SSTR) DMIZ59O MA Modulator DMIZ59O RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMIZ59O RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMIZXFJ DI DMIZXFJ DMIZXFJ DN ONO-4007 DMIZXFJ TI TTOK0LR DMIZXFJ TN Toll-like receptor (TLR) DMIZXFJ MA Modulator DMIZXFJ RN Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin Exp Immunol. 2006 August; 145(2): 346-356. DMIZXFJ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1809678/ DMJ0ZB6 DI DMJ0ZB6 DMJ0ZB6 DN GSK-732461 DMJ0ZB6 TI TTFGZB6 DMJ0ZB6 TN Human immunodeficiency virus GAG protein (HIV gag) DMJ0ZB6 RN Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013. DMJ0ZB6 RU http://i-base.info/htb/21502 DMJ0ZB6 DI DMJ0ZB6 DMJ0ZB6 DN GSK-732461 DMJ0ZB6 TI TT4NXYM DMJ0ZB6 TN Human immunodeficiency virus Negative factor (HIV nef) DMJ0ZB6 RN Preventive technologies, research toward a cure, and immune-based and gene therapies. HIV Treatment Bulletin. 30 June 2013. DMJ0ZB6 RU http://i-base.info/htb/21502 DMJ1ZTB DI DMJ1ZTB DMJ1ZTB DN JTT-811 DMJ1ZTB TI TTFBNVI DMJ1ZTB TN Aldose reductase (AKR1B1) DMJ1ZTB MA Inhibitor DMJ1ZTB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DMJ1ZTB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DMJ2ZFV DI DMJ2ZFV DMJ2ZFV DN EB-1053 DMJ2ZFV TI TTKOBY0 DMJ2ZFV TN Bone resorption factor (BRF) DMJ2ZFV MA Modulator DMJ2ZFV RN Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo. J Bone Miner Res. 1992 Aug;7(8):981-6. DMJ2ZFV RU https://pubmed.ncbi.nlm.nih.gov/1442212 DMJ3ZT8 DI DMJ3ZT8 DMJ3ZT8 DN Lexacalcitol DMJ3ZT8 TI TTK59TV DMJ3ZT8 TN Vitamin D3 receptor (VDR) DMJ3ZT8 MA Agonist DMJ3ZT8 RN The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: principal metabolites generated retain significant biological activity. Endocrinology. 1997 Dec;138(12):5485-96. DMJ3ZT8 RU https://pubmed.ncbi.nlm.nih.gov/9389535 DMJ4WR6 DI DMJ4WR6 DMJ4WR6 DN Darotropium DMJ4WR6 TI TTZ9SOR DMJ4WR6 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMJ4WR6 MA Agonist DMJ4WR6 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMJ4WR6 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMJ52FZ DI DMJ52FZ DMJ52FZ DN EPI-2010 DMJ52FZ TI TT92EIB DMJ52FZ TN ADORA1 messenger RNA (ADORA1 mRNA) DMJ52FZ RN RASONs: a novel antisense oligonucleotide therapeutic approach for asthma. Expert Opin Biol Ther. 2001 Nov;1(6):979-83. DMJ52FZ RU https://pubmed.ncbi.nlm.nih.gov/11728229 DMJ816F DI DMJ816F DMJ816F DN Sodelglitazar DMJ816F TI TTZMAO3 DMJ816F TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJ816F MA Agonist DMJ816F RN Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7. DMJ816F RU https://pubmed.ncbi.nlm.nih.gov/21592078 DMJ816F DI DMJ816F DMJ816F DN Sodelglitazar DMJ816F TI TTJ584C DMJ816F TN Peroxisome proliferator-activated receptor alpha (PPARA) DMJ816F MA Agonist DMJ816F RN Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7. DMJ816F RU https://pubmed.ncbi.nlm.nih.gov/21592078 DMJ816F DI DMJ816F DMJ816F DN Sodelglitazar DMJ816F TI TT2JWF6 DMJ816F TN Peroxisome proliferator-activated receptor delta (PPARD) DMJ816F MA Agonist DMJ816F RN Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7. DMJ816F RU https://pubmed.ncbi.nlm.nih.gov/21592078 DMJ8ZFR DI DMJ8ZFR DMJ8ZFR DN ADOZELESIN DMJ8ZFR TI TTUTN1I DMJ8ZFR TN Human Deoxyribonucleic acid (hDNA) DMJ8ZFR MA Binder DMJ8ZFR RN Mapping of DNA alkylation sites induced by adozelesin and bizelesin in human cells by ligation-mediated polymerase chain reaction. Biochemistry. 1994 May 17;33(19):6024-30. DMJ8ZFR RU https://pubmed.ncbi.nlm.nih.gov/8180230 DMJG7VP DI DMJG7VP DMJG7VP DN Tariquidar DMJG7VP TI TT3OT40 DMJG7VP TN Multidrug resistance protein 1 (ABCB1) DMJG7VP MA Modulator DMJG7VP RN Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Biochem Pharmacol.2008 Mar 15;75(6):1302-12. DMJG7VP RU https://www.ncbi.nlm.nih.gov/pubmed/18234154 DMJKN0B DI DMJKN0B DMJKN0B DN PIBROZELESIN HYDROCHLORIDE DMJKN0B TI TTUTN1I DMJKN0B TN Human Deoxyribonucleic acid (hDNA) DMJKN0B MA Binder DMJKN0B RN Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial. J Gastrointest Cancer. 2007;38(1):10-4. DMJKN0B RU https://pubmed.ncbi.nlm.nih.gov/19065716 DMJLEV7 DI DMJLEV7 DMJLEV7 DN FS-205-397 DMJLEV7 TI TTK0943 DMJLEV7 TN Prostaglandin G/H synthase (COX) DMJLEV7 MA Modulator DMJLEV7 RN FS 205-397: a new antipyretic analgesic with a paracetamol-like profile of activity but lack of acute hepatotoxicity in mice. Life Sci. 1988;43(11):905-12. DMJLEV7 RU https://pubmed.ncbi.nlm.nih.gov/3261827 DMJLNUD DI DMJLNUD DMJLNUD DN MILACAINIDE TARTRATE DMJLNUD TI TTKNWZ4 DMJLNUD TN Thromboxane-A synthase (TBXAS1) DMJLNUD MA Antagonist DMJLNUD RN Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83. DMJLNUD RU https://pubmed.ncbi.nlm.nih.gov/8930195 DMJM38Q DI DMJM38Q DMJM38Q DN INGN-234 DMJM38Q TI TT7SBF5 DMJM38Q TN Cellular tumor antigen p53 (TP53) DMJM38Q MA Suppressor DMJM38Q RN Prevent Oral Cancer With Mouthwash. Introgen Therapeutics. DMJM38Q RU http://www.medgadget.com/2005/11/prevent_oral_ca.html DMJNSML DI DMJNSML DMJNSML DN KW-7158 DMJNSML TI TT1VOHK DMJNSML TN Potassium channel unspecific (KC) DMJNSML MA Agonist DMJNSML RN KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide] enhances A-type K+... J Pharmacol Exp Ther. 2004 Jul;310(1):159-68. DMJNSML RU https://pubmed.ncbi.nlm.nih.gov/15010502 DMJRF5G DI DMJRF5G DMJRF5G DN FIDUXOSIN HYDROCHLORIDE DMJRF5G TI TT34BHT DMJRF5G TN Adrenergic receptor alpha-1D (ADRA1D) DMJRF5G MA Antagonist DMJRF5G RN Effect of fiduxosin, an antagonist selective for alpha(1A)- and alpha(1D)-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. J Pharmacol Exp Ther. 2002 Feb;300(2):487-94. DMJRF5G RU https://pubmed.ncbi.nlm.nih.gov/11805208 DMJSKUI DI DMJSKUI DMJSKUI DN Norcisapride DMJSKUI TI TT07C3Y DMJSKUI TN 5-HT 4 receptor (HTR4) DMJSKUI MA Inhibitor DMJSKUI RN mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83. DMJSKUI RU https://pubmed.ncbi.nlm.nih.gov/19700325 DMJSKUI DI DMJSKUI DMJSKUI DN Norcisapride DMJSKUI TI TTPC4TU DMJSKUI TN 5-HT 3A receptor (HTR3A) DMJSKUI MA Inhibitor DMJSKUI RN mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83. DMJSKUI RU https://pubmed.ncbi.nlm.nih.gov/19700325 DMJT8Q0 DI DMJT8Q0 DMJT8Q0 DN Dezinamide DMJT8Q0 TI TTNJYV2 DMJT8Q0 TN Gamma-aminobutyric acid receptor (GAR) DMJT8Q0 MA Modulator DMJT8Q0 RN Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia. 1995;36 Suppl 2:S105-14. DMJT8Q0 RU https://pubmed.ncbi.nlm.nih.gov/8784219 DMJTOP8 DI DMJTOP8 DMJTOP8 DN R-61837 DMJTOP8 TI TT2Y1AN DMJTOP8 TN Rhinovirus Protein 1 (HRV P1D) DMJTOP8 MA Modulator DMJTOP8 RN In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol. 1988;101(3-4):155-67. DMJTOP8 RU https://pubmed.ncbi.nlm.nih.gov/2845889 DMJYW80 DI DMJYW80 DMJYW80 DN SB-209670 DMJYW80 TI TTKRD0G DMJYW80 TN Endothelin A receptor (EDNRA) DMJYW80 MA Modulator DMJYW80 RN Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol. 1996 May;118(1):198-204. DMJYW80 RU https://pubmed.ncbi.nlm.nih.gov/8733596 DMJYW80 DI DMJYW80 DMJYW80 DN SB-209670 DMJYW80 TI TT3ZTGU DMJYW80 TN Endothelin B receptor (EDNRB) DMJYW80 MA Modulator DMJYW80 RN Effects of the endothelin receptor antagonist, SB 209670, on circulatory failure and organ injury in endotoxic shock in the anaesthetized rat. Br J Pharmacol. 1996 May;118(1):198-204. DMJYW80 RU https://pubmed.ncbi.nlm.nih.gov/8733596 DMK0PVC DI DMK0PVC DMK0PVC DN BOF-4272 DMK0PVC TI TT7RJY8 DMK0PVC TN Xanthine dehydrogenase/oxidase (XDH) DMK0PVC MA Inhibitor DMK0PVC RN Enantioselective uptake of BOF-4272, a xanthine oxidase inhibitor with a chiral sulfoxide, by isolated rat hepatocytes. Yakugaku Zasshi. 2001 Dec;121(12):989-94. DMK0PVC RU https://pubmed.ncbi.nlm.nih.gov/11766411 DMK5WLZ DI DMK5WLZ DMK5WLZ DN Nolpitantium besilate DMK5WLZ TI TTZPO1L DMK5WLZ TN Substance-P receptor (TACR1) DMK5WLZ MA Antagonist DMK5WLZ RN SR 140333, a novel, selective, and potent nonpeptide antagonist of the NK1 tachykinin receptor: characterization on the U373MG cell line. J Neurochem. 1994 Apr;62(4):1399-407. DMK5WLZ RU https://pubmed.ncbi.nlm.nih.gov/7510780 DMKC0J5 DI DMKC0J5 DMKC0J5 DN GW-766994 DMKC0J5 TI TTRQJTC DMKC0J5 TN C-X-C chemokine receptor type 7 (ACKR3) DMKC0J5 MA Antagonist DMKC0J5 RN Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014 Apr;44(4):508-16. DMKC0J5 RU https://pubmed.ncbi.nlm.nih.gov/24286456 DMKEYSX DI DMKEYSX DMKEYSX DN MDL 101,731 DMKEYSX TI TTBWDI0 DMKEYSX TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMKEYSX MA Modulator DMKEYSX RN Tezacitabine Hoechst Marion Roussel.Curr Opin Investig Drugs.2000 Sep;1(1):135-40. DMKEYSX RU https://www.ncbi.nlm.nih.gov/pubmed/11249589 DMKF3TD DI DMKF3TD DMKF3TD DN Nafagrel DMKF3TD TI TT2GVH5 DMKF3TD TN Isomerase unspecific (IsoM) DMKF3TD MA Modulator DMKF3TD RN FMLP actions and its binding sites in isolated human coronary arteries. J Mol Cell Cardiol. 1997 Mar;29(3):881-94. DMKF3TD RU https://pubmed.ncbi.nlm.nih.gov/9152849 DMKFMYR DI DMKFMYR DMKFMYR DN CLOTURIN DMKFMYR TI TTUBNVO DMKFMYR TN DNA synthesis (DNA synth) DMKFMYR MA Modulator DMKFMYR RN Inhibition of biosynthetic processes in P388 and Ehrlich ascites cells by cloturin. Drugs Exp Clin Res. 1988;14(9):575-80. DMKFMYR RU https://pubmed.ncbi.nlm.nih.gov/3229320 DMKGXT2 DI DMKGXT2 DMKGXT2 DN DPI-3290 DMKGXT2 TI TT27RFC DMKGXT2 TN Opioid receptor delta (OPRD1) DMKGXT2 MA Agonist DMKGXT2 RN DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33. DMKGXT2 RU https://pubmed.ncbi.nlm.nih.gov/14534367 DMKGXT2 DI DMKGXT2 DMKGXT2 DN DPI-3290 DMKGXT2 TI TTKWM86 DMKGXT2 TN Opioid receptor mu (MOP) DMKGXT2 MA Agonist DMKGXT2 RN DPI-3290 [(+)-3-((alpha-R)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A mixed opioid agonist with potent antinociceptive activity and limited effects on respiratory function. J Pharmacol Exp Ther. 2003 Dec;307(3):1227-33. DMKGXT2 RU https://pubmed.ncbi.nlm.nih.gov/14534367 DMKSEIY DI DMKSEIY DMKSEIY DN L-158282 DMKSEIY TI TTQVOEI DMKSEIY TN Angiotensin II receptor type-2 (AGTR2) DMKSEIY MA Inhibitor DMKSEIY RN Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994). DMKSEIY RU http://www.sciencedirect.com/science/article/pii/S0960894X01811458 DMKSY2R DI DMKSY2R DMKSY2R DN Levosemotiadil DMKSY2R TI TTRK8B9 DMKSY2R TN Sodium channel unspecific (NaC) DMKSY2R MA Modulator DMKSY2R RN Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33. DMKSY2R RU https://pubmed.ncbi.nlm.nih.gov/10527493 DMKSY2R DI DMKSY2R DMKSY2R DN Levosemotiadil DMKSY2R TI TT5HONZ DMKSY2R TN Calcium channel unspecific (CaC) DMKSY2R MA Modulator DMKSY2R RN Binding study of semotiadil and levosemotiadil with alpha(1)-acid glycoprotein using high-performance frontal analysis. Anal Biochem. 1999 Oct 1;274(1):27-33. DMKSY2R RU https://pubmed.ncbi.nlm.nih.gov/10527493 DMKUVZO DI DMKUVZO DMKUVZO DN ICI-170809 DMKUVZO TI TTYSN63 DMKUVZO TN 5-HT 2 receptor (5HT2R) DMKUVZO MA Modulator DMKUVZO RN 5-HT2 receptor blockade by ICI 170,809 does not affect the inhibitory effect of the 5-HT1A receptor ligand gepirone on neuroleptic-induced catalepsy. Braz J Med Biol Res. 1994 Oct;27(10):2437-41. DMKUVZO RU https://pubmed.ncbi.nlm.nih.gov/7640635 DMKY2UE DI DMKY2UE DMKY2UE DN Ispronicline DMKY2UE TI TTL1ATN DMKY2UE TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMKY2UE MA Modulator DMKY2UE RN Ispronicline: a novel alpha4beta2 nicotinic acetylcholine receptor-selective agonist with cognition-enhancing and neuroprotective properties. J Mol Neurosci. 2006;30(1-2):19-20. DMKY2UE RU https://www.ncbi.nlm.nih.gov/pubmed/17192610 DML2IXO DI DML2IXO DML2IXO DN YM-114 DML2IXO TI TTPC4TU DML2IXO TN 5-HT 3A receptor (HTR3A) DML2IXO MA Antagonist DML2IXO RN Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14. DML2IXO RU https://pubmed.ncbi.nlm.nih.gov/8699628 DML3RSF DI DML3RSF DML3RSF DN AZD1236 DML3RSF TI TTXZ0KQ DML3RSF TN Matrix metalloproteinase-12 (MMP-12) DML3RSF MA Inhibitor DML3RSF RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DML3RSF RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DML6MVP DI DML6MVP DML6MVP DN FPL-64170 DML6MVP TI TT2J34L DML6MVP TN Arachidonate 5-lipoxygenase (5-LOX) DML6MVP MA Inhibitor DML6MVP RN Selective blockade of leukotriene production by a single dose of the FPL 64170XX 0.5% enema in active ulcerative colitis. Pharmacol Toxicol. 1995 Dec;77(6):371-6. DML6MVP RU https://pubmed.ncbi.nlm.nih.gov/8835361 DMLA4DU DI DMLA4DU DMLA4DU DN WC-3027 DMLA4DU TI TTYRL6O DMLA4DU TN Glucocorticoid receptor (NR3C1) DMLA4DU MA Agonist DMLA4DU RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021444) DMLA4DU RU http://adisinsight.springer.com/drugs/800021444 DMLC154 DI DMLC154 DMLC154 DN GW842470X DMLC154 TI TTV5CGO DMLC154 TN Phosphodiesterase 4 (PDE4) DMLC154 MA Inhibitor DMLC154 RN Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79. DMLC154 RU https://pubmed.ncbi.nlm.nih.gov/19216704 DMLCTBP DI DMLCTBP DMLCTBP DN VTX-2337 DMLCTBP TI TT8CWFK DMLCTBP TN Toll-like receptor 8 (TLR8) DMLCTBP MA Modulator DMLCTBP RN Clinical pipeline report, company report or official report of Array BioPharma (Drug: Motolimod / VTX2337). DMLCTBP RU http://www.arraybiopharma.com/product-pipeline/other-compounds/vtx-2337/ DMLCYX8 DI DMLCYX8 DMLCYX8 DN S-15261 DMLCYX8 TI TTZOPHG DMLCYX8 TN Insulin (INS) DMLCYX8 MA Modulator DMLCYX8 RN Beneficial insulin-sensitizing and vascular effects of S15261 in the insulin-resistant JCR:LA-cp rat. J Pharmacol Exp Ther. 2000 Nov;295(2):753-60. DMLCYX8 RU https://pubmed.ncbi.nlm.nih.gov/11046115 DMLFCNY DI DMLFCNY DMLFCNY DN GT-389255 DMLFCNY TI TT3GKN5 DMLFCNY TN Lipase unspecific (LIP) DMLFCNY MA Inhibitor DMLFCNY RN Obesity drugs in clinical development. Curr Opin Investig Drugs. 2006 Apr;7(4):312-8. DMLFCNY RU https://pubmed.ncbi.nlm.nih.gov/16625817 DMLFNMB DI DMLFNMB DMLFNMB DN ZD-2486 DMLFNMB TI TT38RM1 DMLFNMB TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMLFNMB MA Modulator DMLFNMB RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMLFNMB RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMLG7QB DI DMLG7QB DMLG7QB DN Mozenavir DMLG7QB TI TT5FNQT DMLG7QB TN Human immunodeficiency virus Protease (HIV PR) DMLG7QB MA Inhibitor DMLG7QB RN Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996 Apr;3(4):301-14. DMLG7QB RU https://pubmed.ncbi.nlm.nih.gov/8807858 DMLJEFH DI DMLJEFH DMLJEFH DN Relacatib DMLJEFH TI TTDZN01 DMLJEFH TN Cathepsin K (CTSK) DMLJEFH MA Inhibitor DMLJEFH RN The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. DMLJEFH RU https://pubmed.ncbi.nlm.nih.gov/18226527 DMLK5IM DI DMLK5IM DMLK5IM DN PNU-142633 DMLK5IM TI TT6MSOK DMLK5IM TN 5-HT 1D receptor (HTR1D) DMLK5IM MA Agonist DMLK5IM RN Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: pharmacological correlation with the 5-HT1B a... Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):220-7. DMLK5IM RU https://pubmed.ncbi.nlm.nih.gov/14673512 DMLK605 DI DMLK605 DMLK605 DN Semparatide DMLK605 TI TTEPJL5 DMLK605 TN Parathyroid hormone receptor (PTH2R) DMLK605 MA Modulator DMLK605 RN Quantitative cell membrane-based radioligand binding assays for parathyroid hormone receptors. J Pharmacol Toxicol Methods. 1999 Apr-Jun;41(2-3):83-90. DMLK605 RU https://pubmed.ncbi.nlm.nih.gov/10598679 DMLMT5O DI DMLMT5O DMLMT5O DN Gemopatrilat DMLMT5O TI TT5TKPM DMLMT5O TN Neutral endopeptidase (MME) DMLMT5O MA Modulator DMLMT5O RN Omapatrilat.Bristol-Myers Squibb.Curr Opin Investig Drugs.2001 Oct;2(10):1414-22. DMLMT5O RU https://www.ncbi.nlm.nih.gov/pubmed/11890357 DMLOGR3 DI DMLOGR3 DMLOGR3 DN Pro 542 DMLOGR3 TI TTBYP1X DMLOGR3 TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMLOGR3 MA Modulator DMLOGR3 RN Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother. 2004 Feb;48(2):423-9. DMLOGR3 RU https://www.ncbi.nlm.nih.gov/pubmed/14742190 DMLOKXI DI DMLOKXI DMLOKXI DN KW-5139 DMLOKXI TI TT953CX DMLOKXI TN Motilin receptor (MLNR) DMLOKXI MA Modulator DMLOKXI RN Stimulating action of KW-5139 (Leu13-motilin) on gastrointestinal motility in the rabbit. Br J Pharmacol. 1994 Jan;111(1):288-94. DMLOKXI RU https://pubmed.ncbi.nlm.nih.gov/8012708 DMLQWFA DI DMLQWFA DMLQWFA DN IS-159 DMLQWFA TI TTK8CXU DMLQWFA TN 5-HT 1B receptor (HTR1B) DMLQWFA MA Modulator DMLQWFA RN Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clin Pharmacol Ther. 2000 Aug;68(2):114-21. DMLQWFA RU https://www.ncbi.nlm.nih.gov/pubmed/10976542 DMLQWFA DI DMLQWFA DMLQWFA DN IS-159 DMLQWFA TI TT6MSOK DMLQWFA TN 5-HT 1D receptor (HTR1D) DMLQWFA MA Modulator DMLQWFA RN Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist. Clin Pharmacol Ther. 2000 Aug;68(2):114-21. DMLQWFA RU https://www.ncbi.nlm.nih.gov/pubmed/10976542 DMLWBYO DI DMLWBYO DMLWBYO DN Tienoxolol DMLWBYO TI TTMXGCW DMLWBYO TN Adrenergic receptor beta-3 (ADRB3) DMLWBYO MA Modulator DMLWBYO RN Effects of the beta-adrenoceptor antagonists atenolol and propranolol on human parotid and submandibular-sublingual salivary secretion. J Dent Res. 1994 Jan;73(1):5-10. DMLWBYO RU https://pubmed.ncbi.nlm.nih.gov/8294618 DMLZIT2 DI DMLZIT2 DMLZIT2 DN Dexniguldipine DMLZIT2 TI TTJUXV6 DMLZIT2 TN Multidrug resistance protein 3 (ABCB4) DMLZIT2 MA Modulator DMLZIT2 RN Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol. 1995 Mar 1;49(5):603-9. DMLZIT2 RU https://pubmed.ncbi.nlm.nih.gov/7887974 DMM02XV DI DMM02XV DMM02XV DN AD-5467 DMM02XV TI TTFBNVI DMM02XV TN Aldose reductase (AKR1B1) DMM02XV MA Inhibitor DMM02XV RN Studies on antidiabetic agents. IX. A new aldose reductase inhibitor, AD-5467, and related 1,4-benzoxazine and 1,4-benzothiazine derivatives: synthesis and biological activity. Chem Pharm Bull (Tokyo). 1990 May;38(5):1238-45. DMM02XV RU https://pubmed.ncbi.nlm.nih.gov/2118427 DMM1SLF DI DMM1SLF DMM1SLF DN KP-736 DMM1SLF TI TTJP4SM DMM1SLF TN Bacterial Penicillin binding protein (Bact PBP) DMM1SLF MA Modulator DMM1SLF RN In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother. 1991 Jan;35(1):104-10. DMM1SLF RU https://pubmed.ncbi.nlm.nih.gov/2014964 DMM5WQL DI DMM5WQL DMM5WQL DN Elvucitabine DMM5WQL TI TT84ETX DMM5WQL TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMM5WQL MA Modulator DMM5WQL RN Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects.Antimicrob Agents Chemother.2009 Feb;53(2):662-9. DMM5WQL RU https://www.ncbi.nlm.nih.gov/pubmed/19015343 DMM843E DI DMM843E DMM843E DN LOSOXANTRONE DMM843E TI TT0IHXV DMM843E TN DNA topoisomerase II (TOP2) DMM843E MA Modulator DMM843E RN A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone. J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35. DMM843E RU https://www.ncbi.nlm.nih.gov/pubmed/16859314 DMM8UNL DI DMM8UNL DMM8UNL DN JTV-506 DMM8UNL TI TT1VOHK DMM8UNL TN Potassium channel unspecific (KC) DMM8UNL MA Opener DMM8UNL RN Effects of the new potassium channel opener JTV-506 on coronary vessels in vitro and in vivo. Arzneimittelforschung. 1999 Mar;49(3):199-206. DMM8UNL RU https://pubmed.ncbi.nlm.nih.gov/10219462 DMMC6H7 DI DMMC6H7 DMMC6H7 DN Dopropidil DMMC6H7 TI TT5HONZ DMMC6H7 TN Calcium channel unspecific (CaC) DMMC6H7 MA Modulator DMMC6H7 RN Effects of bepridil and CERM 4205 (ORG 30701) on the relation between cardiac cycle length and QT duration in healthy volunteers. Am J Cardiol. 1990 Sep 1;66(5):636-41. DMMC6H7 RU https://pubmed.ncbi.nlm.nih.gov/2203243 DMMF9RS DI DMMF9RS DMMF9RS DN PSN-9301 DMMF9RS TI TTDIGC1 DMMF9RS TN Dipeptidyl peptidase 4 (DPP-4) DMMF9RS MA Inhibitor DMMF9RS RN Navigating the chemical space of dipeptidyl peptidase-4 inhibitors. Drug Des Devel Ther. 2015; 9: 4515-4549. DMMF9RS RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539085/ DMMIR1K DI DMMIR1K DMMIR1K DN GSK184072 DMMIR1K TI TTUF2HO DMMIR1K TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMMIR1K MA Activator DMMIR1K RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMMIR1K RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMMIR1K DI DMMIR1K DMMIR1K DN GSK184072 DMMIR1K TI TTTG60L DMMIR1K TN CAP-dependent endonuclease (CDE) DMMIR1K MA Inhibitor DMMIR1K RN Synthesis of natural flutimide and analogous fully substituted pyrazine-2,6-diones, endonuclease inhibitors of influenza virus. J Org Chem. 2001 Aug 10;66(16):5504-16. DMMIR1K RU https://pubmed.ncbi.nlm.nih.gov/11485475 DMMJDYI DI DMMJDYI DMMJDYI DN BMY-30123 DMMJDYI TI TTOD7B3 DMMJDYI TN Retinoic acid receptor (RAR) DMMJDYI MA Modulator DMMJDYI RN The pharmacology of a novel topical retinoid, BMY 30123: comparison with tretinoin. J Pharm Pharmacol. 1992 May;44(5):379-86. DMMJDYI RU https://pubmed.ncbi.nlm.nih.gov/1359051 DMMKFUP DI DMMKFUP DMMKFUP DN Adatanserin DMMKFUP TI TTSQIFT DMMKFUP TN 5-HT 1A receptor (HTR1A) DMMKFUP MA Agonist DMMKFUP RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMMKFUP RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMMKFUP DI DMMKFUP DMMKFUP DN Adatanserin DMMKFUP TI TTJQOD7 DMMKFUP TN 5-HT 2A receptor (HTR2A) DMMKFUP MA Antagonist DMMKFUP RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMMKFUP RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMMKHGN DI DMMKHGN DMMKHGN DN MP-435 DMMKHGN TI TTKANGO DMMKHGN TN Complement C5 (CO5) DMMKHGN MA Antagonist DMMKHGN RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027730) DMMKHGN RU http://adisinsight.springer.com/drugs/800027730 DMML2PX DI DMML2PX DMML2PX DN EML-336 DMML2PX TI TTCBFJO DMML2PX TN Insulin receptor (INSR) DMML2PX MA Modulator DMML2PX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMML2PX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMML5WB DI DMML5WB DMML5WB DN AR-D-111421 DMML5WB TI TTZC9FV DMML5WB TN Vasoactive intestinal polypeptide receptor (VIPR) DMML5WB MA Modulator DMML5WB RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013264) DMML5WB RU http://adisinsight.springer.com/drugs/800013264 DMMNUZC DI DMMNUZC DMMNUZC DN MK-912 DMMNUZC TI TT2NUT5 DMMNUZC TN Adrenergic receptor alpha-2C (ADRA2C) DMMNUZC MA Antagonist DMMNUZC RN Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol. 2000 Apr;278(4):H1075-83. DMMNUZC RU https://pubmed.ncbi.nlm.nih.gov/10749700 DMMQ4GC DI DMMQ4GC DMMQ4GC DN Sipatrigine DMMQ4GC TI TT7RGTM DMMQ4GC TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMMQ4GC MA Inhibitor DMMQ4GC RN Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995). DMMQ4GC RU http://www.sciencedirect.com/science/article/pii/0960894X95003927 DMMQ4GC DI DMMQ4GC DMMQ4GC DN Sipatrigine DMMQ4GC TI TTAXZ0K DMMQ4GC TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMMQ4GC MA Inhibitor DMMQ4GC RN Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. J Med Chem. 2002 Aug 15;45(17):3755-64. DMMQ4GC RU https://pubmed.ncbi.nlm.nih.gov/12166948 DMMQ4GC DI DMMQ4GC DMMQ4GC DN Sipatrigine DMMQ4GC TI TTRK8B9 DMMQ4GC TN Sodium channel unspecific (NaC) DMMQ4GC MA Inhibitor DMMQ4GC RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DMMQ4GC RU https://pubmed.ncbi.nlm.nih.gov/11170622 DMMQ4GC DI DMMQ4GC DMMQ4GC DN Sipatrigine DMMQ4GC TI TT84DRB DMMQ4GC TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMMQ4GC MA Inhibitor DMMQ4GC RN Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707. DMMQ4GC RU https://pubmed.ncbi.nlm.nih.gov/19341281 DMMQ4GC DI DMMQ4GC DMMQ4GC DN Sipatrigine DMMQ4GC TI TTZOVE0 DMMQ4GC TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMMQ4GC MA Inhibitor DMMQ4GC RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DMMQ4GC RU https://pubmed.ncbi.nlm.nih.gov/11170622 DMMQ4GC DI DMMQ4GC DMMQ4GC DN Sipatrigine DMMQ4GC TI TT4G2JS DMMQ4GC TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMMQ4GC MA Inhibitor DMMQ4GC RN Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707. DMMQ4GC RU https://pubmed.ncbi.nlm.nih.gov/19341281 DMMQ4GC DI DMMQ4GC DMMQ4GC DN Sipatrigine DMMQ4GC TI TT90XZ8 DMMQ4GC TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMMQ4GC MA Inhibitor DMMQ4GC RN Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707. DMMQ4GC RU https://pubmed.ncbi.nlm.nih.gov/19341281 DMMSFK0 DI DMMSFK0 DMMSFK0 DN Fabesetron DMMSFK0 TI TT07C3Y DMMSFK0 TN 5-HT 4 receptor (HTR4) DMMSFK0 MA Modulator DMMSFK0 RN Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993 May;265(2):752-8. DMMSFK0 RU https://www.ncbi.nlm.nih.gov/pubmed/8496821 DMMSFK0 DI DMMSFK0 DMMSFK0 DN Fabesetron DMMSFK0 TI TTNXLKE DMMSFK0 TN 5-HT 3 receptor (5HT3R) DMMSFK0 MA Modulator DMMSFK0 RN Pharmacological characterization of FK1052, a dihydropyridoindole derivative, as a new serotonin 3 and 4 dual receptor antagonist. J Pharmacol Exp Ther. 1993 May;265(2):752-8. DMMSFK0 RU https://www.ncbi.nlm.nih.gov/pubmed/8496821 DMMSZ1A DI DMMSZ1A DMMSZ1A DN S-2474 DMMSZ1A TI TTVKILB DMMSZ1A TN Prostaglandin G/H synthase 2 (COX-2) DMMSZ1A MA Inhibitor DMMSZ1A RN Effects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell death. Br J Pharmacol. 2001 Oct;134(3):673-81. DMMSZ1A RU https://pubmed.ncbi.nlm.nih.gov/11588123 DMMUE8P DI DMMUE8P DMMUE8P DN TEBUFELONE DMMUE8P TI TT8NGED DMMUE8P TN Prostaglandin G/H synthase 1 (COX-1) DMMUE8P MA Inhibitor DMMUE8P RN New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37. DMMUE8P RU https://pubmed.ncbi.nlm.nih.gov/9544212 DMMUE8P DI DMMUE8P DMMUE8P DN TEBUFELONE DMMUE8P TI TTVKILB DMMUE8P TN Prostaglandin G/H synthase 2 (COX-2) DMMUE8P MA Inhibitor DMMUE8P RN New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37. DMMUE8P RU https://pubmed.ncbi.nlm.nih.gov/9544212 DMMUE8P DI DMMUE8P DMMUE8P DN TEBUFELONE DMMUE8P TI TT2J34L DMMUE8P TN Arachidonate 5-lipoxygenase (5-LOX) DMMUE8P MA Inhibitor DMMUE8P RN New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37. DMMUE8P RU https://pubmed.ncbi.nlm.nih.gov/9544212 DMMUE8P DI DMMUE8P DMMUE8P DN TEBUFELONE DMMUE8P TI TTSJ6Q4 DMMUE8P TN LOX-5 messenger RNA (ALOX5 mRNA) DMMUE8P MA Inhibitor DMMUE8P RN New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflam... J Med Chem. 1998 Aug 27;41(18):3515-29. DMMUE8P RU https://pubmed.ncbi.nlm.nih.gov/9719605 DMMUS8X DI DMMUS8X DMMUS8X DN AMG 108 DMMUS8X TI TT51DEV DMMUS8X TN Interleukin 1 receptor type 2 (IL1R2) DMMUS8X MA Antagonist DMMUS8X RN Clinical pipeline report, company report or official report of Amgen (2009). DMMUS8X RU http://www.amgen.com/science/pipe.jsp DMMV6RK DI DMMV6RK DMMV6RK DN DDP-200 DMMV6RK TI TTH18TF DMMV6RK TN Muscarinic acetylcholine receptor M5 (CHRM5) DMMV6RK MA Modulator DMMV6RK RN CA patent application no. 753057, Sustained release oral dosage forms of an r-baclofen prodrug. DMMV6RK RU http://www.google.com/patents/CA2753057A1?cl=en DMMYNKH DI DMMYNKH DMMYNKH DN PD-348292 DMMYNKH TI TTCIHJA DMMYNKH TN Coagulation factor Xa (F10) DMMYNKH MA Inhibitor DMMYNKH RN Pfizer. Product Development Pipeline. March 31 2009. DMMYNKH RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMMZ2JT DI DMMZ2JT DMMZ2JT DN SINITRODIL DMMZ2JT TI TTJ0IQB DMMZ2JT TN Phosphodiesterase 5A (PDE5A) DMMZ2JT MA Modulator DMMZ2JT RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMMZ2JT RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMMZ4E9 DI DMMZ4E9 DMMZ4E9 DN Merbarone DMMZ4E9 TI TT0IHXV DMMZ4E9 TN DNA topoisomerase II (TOP2) DMMZ4E9 MA Modulator DMMZ4E9 RN The DNA topoisomerase II catalytic inhibitor merbarone is genotoxic and induces endoreduplication. Mutat Res. 2012 Oct-Nov;738-739:45-51. DMMZ4E9 RU https://pubmed.ncbi.nlm.nih.gov/22921906 DMMZQVS DI DMMZQVS DMMZQVS DN GYKI-16084 DMMZQVS TI TT2NUT5 DMMZQVS TN Adrenergic receptor alpha-2C (ADRA2C) DMMZQVS MA Antagonist DMMZQVS RN A novel approach to the treatment of benign prostatic hyperplasia. BJU Int. 2006 Jun;97(6):1252-5. DMMZQVS RU https://pubmed.ncbi.nlm.nih.gov/16686721 DMMZQVS DI DMMZQVS DMMZQVS DN GYKI-16084 DMMZQVS TI TT34BHT DMMZQVS TN Adrenergic receptor alpha-1D (ADRA1D) DMMZQVS MA Antagonist DMMZQVS RN A novel approach to the treatment of benign prostatic hyperplasia. BJU Int. 2006 Jun;97(6):1252-5. DMMZQVS RU https://pubmed.ncbi.nlm.nih.gov/16686721 DMN1YHP DI DMN1YHP DMN1YHP DN TAK-603 DMN1YHP TI TT93WF5 DMN1YHP TN Interferon-gamma (IFNG) DMN1YHP MA Modulator DMN1YHP RN T helper 1 inhibitor TAK-603 inhibits IFN-gamma and IL-12 production with no effect on IL-18: an observation in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis. 2004 Oct;21(3):204-11. DMN1YHP RU https://pubmed.ncbi.nlm.nih.gov/15554077 DMN4BIA DI DMN4BIA DMN4BIA DN KN-38-7271 DMN4BIA TI TTMSFAW DMN4BIA TN Cannabinoid receptor 2 (CB2) DMN4BIA MA Modulator DMN4BIA RN BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.CNS Drug Rev.2003 Winter;9(4):343-58. DMN4BIA RU https://www.ncbi.nlm.nih.gov/pubmed/14647528 DMN4BIA DI DMN4BIA DMN4BIA DN KN-38-7271 DMN4BIA TI TT6OEDT DMN4BIA TN Cannabinoid receptor 1 (CB1) DMN4BIA MA Modulator DMN4BIA RN BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.CNS Drug Rev.2003 Winter;9(4):343-58. DMN4BIA RU https://www.ncbi.nlm.nih.gov/pubmed/14647528 DMN4QSW DI DMN4QSW DMN4QSW DN CI-949 DMN4QSW TI TTN53ZF DMN4QSW TN Leukotriene B4 receptor 1 (LTB4R) DMN4QSW MA Modulator DMN4QSW RN Inhibition of histamine, leukotriene C4/D4, and thromboxane B2 release from human leukocytes and human chopped lung mast cells by the allergic mediator release inhibitor, CI-949. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 1):902-8. DMN4QSW RU https://pubmed.ncbi.nlm.nih.gov/1702129 DMN4RV0 DI DMN4RV0 DMN4RV0 DN PRX-00023 DMN4RV0 TI TTSQIFT DMN4RV0 TN 5-HT 1A receptor (HTR1A) DMN4RV0 MA Modulator DMN4RV0 RN PRX-00023, a selective serotonin 1A receptor agonist, reduces ultrasonic vocalizations in infant rats bred for high infantile anxiety.Pharmacol Biochem Behav.2009 Nov;94(1):8-15. DMN4RV0 RU https://www.ncbi.nlm.nih.gov/pubmed/19576924 DMN7BM3 DI DMN7BM3 DMN7BM3 DN SSR-182289 DMN7BM3 TI TT6L509 DMN7BM3 TN Coagulation factor IIa (F2) DMN7BM3 MA Inhibitor DMN7BM3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMN7BM3 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMNBUS7 DI DMNBUS7 DMNBUS7 DN Rozrolimupab DMNBUS7 TI TTLCKI8 DMNBUS7 TN Blood group Rh(D) polypeptide (RHD) DMNBUS7 RN Rozrolimupab, symphobodies against rhesus D, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura. Curr Opin Mol Ther. 2010 Dec;12(6):734-40. DMNBUS7 RU https://pubmed.ncbi.nlm.nih.gov/21154165 DMNEA78 DI DMNEA78 DMNEA78 DN ONO-4057 DMNEA78 TI TTVJX54 DMNEA78 TN Leukotriene B4 receptor 2 (LTB4R2) DMNEA78 MA Modulator DMNEA78 RN ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions. Prostaglandins. 1992 Oct;44(4):261-75. DMNEA78 RU https://pubmed.ncbi.nlm.nih.gov/1332129 DMNGQM0 DI DMNGQM0 DMNGQM0 DN Arm036 DMNGQM0 TI TTU5CIX DMNGQM0 TN Ryanodine receptor 1 (RYR1) DMNGQM0 MA Modulator DMNGQM0 RN The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726. DMNGQM0 RU http://circ.ahajournals.org/content/130/Suppl_2/A13726.abstract DMNJD9H DI DMNJD9H DMNJD9H DN CP-118 DMNJD9H TI TT7CXIM DMNJD9H TN Histamine receptor (HR) DMNJD9H MA Antagonist DMNJD9H RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025139) DMNJD9H RU http://adisinsight.springer.com/drugs/800025139 DMNOLHT DI DMNOLHT DMNOLHT DN Caracemide DMNOLHT TI TT1RS9F DMNOLHT TN Acetylcholinesterase (AChE) DMNOLHT MA Inhibitor DMNOLHT RN Biochemical pharmacology of N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea (caracemide; NSC-253272). Biochem Pharmacol. 1986 Aug 15;35(16):2781-7. DMNOLHT RU https://pubmed.ncbi.nlm.nih.gov/3527174 DMNP72I DI DMNP72I DMNP72I DN ABT-418 DMNP72I TI TT4H1MQ DMNP72I TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMNP72I MA Agonist DMNP72I RN (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization. J Pharmacol Exp Ther. 1994 Jul;270(1):319-28. DMNP72I RU https://pubmed.ncbi.nlm.nih.gov/7913497 DMNP72I DI DMNP72I DMNP72I DN ABT-418 DMNP72I TI TTJSZTB DMNP72I TN Nicotinic acetylcholine receptor (nAChR) DMNP72I MA Agonist DMNP72I RN Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. Psychopharmacology (Berl). 1999 May;144(2):175-82. DMNP72I RU https://pubmed.ncbi.nlm.nih.gov/10394999 DMNP72I DI DMNP72I DMNP72I DN ABT-418 DMNP72I TI TT5KPZR DMNP72I TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMNP72I MA Agonist DMNP72I RN Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44. DMNP72I RU https://pubmed.ncbi.nlm.nih.gov/10880717 DMNRGB7 DI DMNRGB7 DMNRGB7 DN Risotilide DMNRGB7 TI TT1VOHK DMNRGB7 TN Potassium channel unspecific (KC) DMNRGB7 MA Opener DMNRGB7 RN Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation. 1991 Jun;83(6):2067-75. DMNRGB7 RU https://pubmed.ncbi.nlm.nih.gov/1645624 DMNRQA9 DI DMNRQA9 DMNRQA9 DN INCB47986 DMNRQA9 TI TT6DM01 DMNRQA9 TN Janus kinase 1 (JAK-1) DMNRQA9 MA Inhibitor DMNRQA9 RN Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. DMNRQA9 RU https://pubmed.ncbi.nlm.nih.gov/24818516 DMNRW68 DI DMNRW68 DMNRW68 DN SU-14813 DMNRW68 TI TTUTJGQ DMNRW68 TN Vascular endothelial growth factor receptor 2 (KDR) DMNRW68 MA Inhibitor DMNRW68 RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMNRW68 RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMNU2MH DI DMNU2MH DMNU2MH DN Tandutinib DMNU2MH TI TTGJCWZ DMNU2MH TN Fms-like tyrosine kinase 3 (FLT-3) DMNU2MH MA Inhibitor DMNU2MH RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMNU2MH RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMO8PN9 DI DMO8PN9 DMO8PN9 DN OBERADILOL MONOETHYL MALEATE DMO8PN9 TI TTMXGCW DMO8PN9 TN Adrenergic receptor beta-3 (ADRB3) DMO8PN9 MA Modulator DMO8PN9 RN US patent application no. 9,062,094, Dipeptide-based prodrug linkers for aliphatic amine-containing drugs. DMO8PN9 RU http://www.google.com/patents/US9062094 DMO90RN DI DMO90RN DMO90RN DN Y-27152 DMO90RN TI TT1VOHK DMO90RN TN Potassium channel unspecific (KC) DMO90RN MA Opener DMO90RN RN Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. J Clin Pharmacol. 1996 May;36(5):439-51. DMO90RN RU https://pubmed.ncbi.nlm.nih.gov/8739023 DMO9HWU DI DMO9HWU DMO9HWU DN D-7193 DMO9HWU TI TTK0943 DMO9HWU TN Prostaglandin G/H synthase (COX) DMO9HWU MA Modulator DMO9HWU RN US patent application no. 6,673,908, Tumor necrosis factor receptor 2. DMO9HWU RU http://www.google.com/patents/US6673908 DMOB2K5 DI DMOB2K5 DMOB2K5 DN UTIBAPRIL DMOB2K5 TI TTL69WB DMOB2K5 TN Angiotensin-converting enzyme (ACE) DMOB2K5 MA Inhibitor DMOB2K5 RN Differential inhibition of plasma versus tissue ACE by utibapril: biochemical and functional evidence for inhibition of vascular ACE activity. J Cardiovasc Pharmacol. 1997 May;29(5):684-91. DMOB2K5 RU https://pubmed.ncbi.nlm.nih.gov/9213213 DMOCMXH DI DMOCMXH DMOCMXH DN FLOSATIDIL DMOCMXH TI TT5HONZ DMOCMXH TN Calcium channel unspecific (CaC) DMOCMXH MA Antagonist DMOCMXH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMOCMXH RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMODK2J DI DMODK2J DMODK2J DN BMS-193884 DMODK2J TI TTKRD0G DMODK2J TN Endothelin A receptor (EDNRA) DMODK2J MA Modulator DMODK2J RN Vasodilator effects of the endothelin ETA receptor selective antagonist BMS-193884 in healthy men DMODK2J RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884878 DMOG1LX DI DMOG1LX DMOG1LX DN IGN-101 DMOG1LX TI TTZ8WH4 DMOG1LX TN Tumor-associated calcium signal transducer 1 (EPCAM) DMOG1LX RN Drug evaluation: IGN-101--an anti-EpCAM murine antibody vaccine for cancer. Curr Opin Mol Ther. 2006 Aug;8(4):358-65. DMOG1LX RU https://pubmed.ncbi.nlm.nih.gov/16955700 DMOIL29 DI DMOIL29 DMOIL29 DN GW-275919 DMOIL29 TI TTS64P2 DMOIL29 TN Androgen receptor (AR) DMOIL29 MA Modulator DMOIL29 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010426) DMOIL29 RU http://adisinsight.springer.com/drugs/800010426 DMOITN2 DI DMOITN2 DMOITN2 DN KC-11458 DMOITN2 TI TT953CX DMOITN2 TN Motilin receptor (MLNR) DMOITN2 MA Modulator DMOITN2 RN Effect of the motilin agonist KC 11458 on gastric emptying in diabetic gastroparesis. Aliment Pharmacol Ther. 2004 Aug 1;20(3):333-8. DMOITN2 RU https://pubmed.ncbi.nlm.nih.gov/15274670 DMOP95G DI DMOP95G DMOP95G DN Bimoclomol DMOP95G TI TTHYBIX DMOP95G TN Heat shock protein 70 (HSP70) DMOP95G MA Modulator DMOP95G RN Bimoclomol elevates heat shock protein 70 and cytoprotects rat neonatal cardiomyocytes. Eur J Pharmacol. 2002 Jan 18;435(1):73-7. DMOP95G RU https://pubmed.ncbi.nlm.nih.gov/11790380 DMOS6CM DI DMOS6CM DMOS6CM DN VLTS-587 DMOS6CM TI TTF89GD DMOS6CM TN Interleukin-2 (IL2) DMOS6CM MA Modulator DMOS6CM RN CN patent application no. 101039956, Cell surface glycoprotein. DMOS6CM RU http://www.google.com/patents/CN101039956A?cl=en DMOTANY DI DMOTANY DMOTANY DN RS-130830 DMOTANY TI TTUZ2L5 DMOTANY TN Matrix metalloproteinase-3 (MMP-3) DMOTANY MA Inhibitor DMOTANY RN Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. DMOTANY RU https://pubmed.ncbi.nlm.nih.gov/15686921 DMOTANY DI DMOTANY DMOTANY DN RS-130830 DMOTANY TI TTLM12X DMOTANY TN Matrix metalloproteinase-2 (MMP-2) DMOTANY MA Inhibitor DMOTANY RN Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. DMOTANY RU https://pubmed.ncbi.nlm.nih.gov/15686921 DMOTANY DI DMOTANY DMOTANY DN RS-130830 DMOTANY TI TT6X50U DMOTANY TN Matrix metalloproteinase-9 (MMP-9) DMOTANY MA Inhibitor DMOTANY RN Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. DMOTANY RU https://pubmed.ncbi.nlm.nih.gov/15686921 DMOTANY DI DMOTANY DMOTANY DN RS-130830 DMOTANY TI TTHY57M DMOTANY TN Matrix metalloproteinase-13 (MMP-13) DMOTANY MA Inhibitor DMOTANY RN Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. DMOTANY RU https://pubmed.ncbi.nlm.nih.gov/15686921 DMOTANY DI DMOTANY DMOTANY DN RS-130830 DMOTANY TI TTMX39J DMOTANY TN Matrix metalloproteinase-1 (MMP-1) DMOTANY MA Inhibitor DMOTANY RN Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6. DMOTANY RU https://pubmed.ncbi.nlm.nih.gov/15686921 DMOWIGC DI DMOWIGC DMOWIGC DN DASANTAFIL DMOWIGC TI TTJ0IQB DMOWIGC TN Phosphodiesterase 5A (PDE5A) DMOWIGC MA Inhibitor DMOWIGC RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMOWIGC RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMOWLVF DI DMOWLVF DMOWLVF DN NGD-8243 DMOWLVF TI TTMI6F5 DMOWLVF TN Transient receptor potential cation channel V1 (TRPV1) DMOWLVF MA Blocker DMOWLVF RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMOWLVF RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMOXUEP DI DMOXUEP DMOXUEP DN SL-89.0591 DMOXUEP TI TT34BHT DMOXUEP TN Adrenergic receptor alpha-1D (ADRA1D) DMOXUEP MA Modulator DMOXUEP RN Effects of alpha1-adrenoceptor antagonists on agonist and tilt-induced changes in blood pressure: relationships to uroselectivity. Eur J Pharmacol. 1999 May 28;373(1):51-62. DMOXUEP RU https://pubmed.ncbi.nlm.nih.gov/10408251 DMOYMGV DI DMOYMGV DMOYMGV DN EVT-101 DMOYMGV TI TTN9D8E DMOYMGV TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMOYMGV MA Antagonist DMOYMGV RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMOYMGV RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMOZEN6 DI DMOZEN6 DMOZEN6 DN RJR-2403 DMOZEN6 TI TTJSZTB DMOZEN6 TN Nicotinic acetylcholine receptor (nAChR) DMOZEN6 MA Agonist DMOZEN6 RN The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30. DMOZEN6 RU https://pubmed.ncbi.nlm.nih.gov/11772288 DMOZUPB DI DMOZUPB DMOZUPB DN MK-944a DMOZUPB TI TT5FNQT DMOZUPB TN Human immunodeficiency virus Protease (HIV PR) DMOZUPB MA Inhibitor DMOZUPB RN Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitors. J Med Chem. 2000 Sep 7;43(18):3386-99. DMOZUPB RU https://pubmed.ncbi.nlm.nih.gov/10978186 DMP0ARJ DI DMP0ARJ DMP0ARJ DN Opaviraline DMP0ARJ TI TT84ETX DMP0ARJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMP0ARJ MA Modulator DMP0ARJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMP0ARJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMP1A4S DI DMP1A4S DMP1A4S DN TC-2696 DMP1A4S TI TTL1ATN DMP1A4S TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMP1A4S MA Modulator DMP1A4S RN alpha4beta2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats. Neuropharmacology. 2013 Aug;71:191-203. DMP1A4S RU https://pubmed.ncbi.nlm.nih.gov/23583932 DMP43IR DI DMP43IR DMP43IR DN Pranazepide DMP43IR TI TTCG0AL DMP43IR TN Cholecystokinin receptor type A (CCKAR) DMP43IR MA Inhibitor DMP43IR RN Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines, Bioorg. Med. Chem. Lett. 7(2):169-174 (1997). DMP43IR RU http://www.sciencedirect.com/science/article/pii/S0960894X96006099 DMP8CVD DI DMP8CVD DMP8CVD DN Milveterol+Fluticasone DMP8CVD TI TT2CJVK DMP8CVD TN Adrenergic receptor beta-2 (ADRB2) DMP8CVD MA Agonist DMP8CVD RN Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94. DMP8CVD RU https://pubmed.ncbi.nlm.nih.gov/19265487 DMP8SIV DI DMP8SIV DMP8SIV DN BMS-187745 DMP8SIV TI TTFQEO5 DMP8SIV TN Squalene synthetase (FDFT1) DMP8SIV MA Inhibitor DMP8SIV RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DMP8SIV RU https://pubmed.ncbi.nlm.nih.gov/19191557 DMP8TKA DI DMP8TKA DMP8TKA DN CY-208243 DMP8TKA TI TTZFYLI DMP8TKA TN Dopamine D1 receptor (D1R) DMP8TKA MA Agonist DMP8TKA RN The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset. Eur J Pharmacol. 1988 Nov 1;156(2):197-206. DMP8TKA RU https://pubmed.ncbi.nlm.nih.gov/2977118 DMP8TKA DI DMP8TKA DMP8TKA DN CY-208243 DMP8TKA TI TT0R12H DMP8TKA TN Neuron-specific vesicular protein calcyon (CALY) DMP8TKA MA Activator DMP8TKA RN Dopamine D1 receptor agonists induce penile erections in rats. Eur J Pharmacol. 2003 Jan 26;460(1):71-4. DMP8TKA RU https://pubmed.ncbi.nlm.nih.gov/12535862 DMPAEK5 DI DMPAEK5 DMPAEK5 DN SOU-001 DMPAEK5 TI TTBRKXS DMPAEK5 TN Adrenergic receptor alpha-1B (ADRA1B) DMPAEK5 MA Modulator DMPAEK5 RN Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83. DMPAEK5 RU https://pubmed.ncbi.nlm.nih.gov/15286734 DMPAEK5 DI DMPAEK5 DMPAEK5 DN SOU-001 DMPAEK5 TI TTNGILX DMPAEK5 TN Adrenergic receptor alpha-1A (ADRA1A) DMPAEK5 MA Modulator DMPAEK5 RN Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83. DMPAEK5 RU https://pubmed.ncbi.nlm.nih.gov/15286734 DMPAEK5 DI DMPAEK5 DMPAEK5 DN SOU-001 DMPAEK5 TI TT34BHT DMPAEK5 TN Adrenergic receptor alpha-1D (ADRA1D) DMPAEK5 MA Modulator DMPAEK5 RN Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673-83. DMPAEK5 RU https://pubmed.ncbi.nlm.nih.gov/15286734 DMPAH74 DI DMPAH74 DMPAH74 DN R-sibutramine metabolite DMPAH74 TI TTAWNKZ DMPAH74 TN Norepinephrine transporter (NET) DMPAH74 MA Modulator DMPAH74 RN Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56. DMPAH74 RU https://www.ncbi.nlm.nih.gov/pubmed/24821570 DMPAH74 DI DMPAH74 DMPAH74 DN R-sibutramine metabolite DMPAH74 TI TT3ROYC DMPAH74 TN Serotonin transporter (SERT) DMPAH74 MA Modulator DMPAH74 RN Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56. DMPAH74 RU https://www.ncbi.nlm.nih.gov/pubmed/24821570 DMPB36I DI DMPB36I DMPB36I DN Tesmilifene DMPB36I TI TT7CXIM DMPB36I TN Histamine receptor (HR) DMPB36I MA Modulator DMPB36I RN Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol. 2010 Aug;62(8):1084-8. DMPB36I RU https://pubmed.ncbi.nlm.nih.gov/20663044 DMPB80O DI DMPB80O DMPB80O DN RO-26-9228 DMPB80O TI TTK59TV DMPB80O TN Vitamin D3 receptor (VDR) DMPB80O MA Agonist DMPB80O RN Evidence for tissue- and cell-type selective activation of the vitamin D receptor by Ro-26-9228, a noncalcemic analog of vitamin D3. J Cell Biochem. 2003 Feb 1;88(2):267-73. DMPB80O RU https://pubmed.ncbi.nlm.nih.gov/12520525 DMPCRUT DI DMPCRUT DMPCRUT DN Teglicar DMPCRUT TI TTC8M31 DMPCRUT TN Carnitine acyltransferase (CRAT) DMPCRUT MA Inhibitor DMPCRUT RN Selective Reversible Inhibition of Liver Carnitine Palmitoyl-Transferase 1 by Teglicar Reduces Gluconeogenesis and Improves Glucose Homeostasis. Diabetes. 2011 February; 60(2): 644-651. DMPCRUT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3028366/ DMPD8O2 DI DMPD8O2 DMPD8O2 DN FK-960 DMPD8O2 TI TTOMNR9 DMPD8O2 TN Somatostatin receptor (SSTR) DMPD8O2 MA Modulator DMPD8O2 RN FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7. DMPD8O2 RU https://www.ncbi.nlm.nih.gov/pubmed/11172755 DMPE5XM DI DMPE5XM DMPE5XM DN WAY-123641 DMPE5XM TI TT9V5JH DMPE5XM TN Phospholipase A2 (PLA2G1B) DMPE5XM MA Inhibitor DMPE5XM RN Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J Pharmacol Exp Ther. 1994 Feb;268(2):888-96. DMPE5XM RU https://pubmed.ncbi.nlm.nih.gov/8114002 DMPFQLX DI DMPFQLX DMPFQLX DN ADL 10-0101 DMPFQLX TI TTQW87Y DMPFQLX TN Opioid receptor kappa (OPRK1) DMPFQLX MA Agonist DMPFQLX RN Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. Pain. 2003 Jan;101(1-2):89-95. DMPFQLX RU https://pubmed.ncbi.nlm.nih.gov/12507703 DMPIJE7 DI DMPIJE7 DMPIJE7 DN Becampanel DMPIJE7 TI TTAN6JD DMPIJE7 TN Glutamate receptor AMPA (GRIA) DMPIJE7 MA Antagonist DMPIJE7 RN Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22. DMPIJE7 RU https://pubmed.ncbi.nlm.nih.gov/17874969 DMPM58S DI DMPM58S DMPM58S DN Nuvanil DMPM58S TI TTMI6F5 DMPM58S TN Transient receptor potential cation channel V1 (TRPV1) DMPM58S MA Agonist DMPM58S RN TRPV1: ON THE ROAD TO PAIN RELIEF. Curr Mol Pharmacol. 2008 November; 1(3): 255-269. DMPM58S RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2802457/ DMPMKUF DI DMPMKUF DMPMKUF DN BAM-1110 DMPMKUF TI TTZFYLI DMPMKUF TN Dopamine D1 receptor (D1R) DMPMKUF MA Modulator DMPMKUF RN Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33. DMPMKUF RU https://www.ncbi.nlm.nih.gov/pubmed/9655864 DMPMKUF DI DMPMKUF DMPMKUF DN BAM-1110 DMPMKUF TI TTEX248 DMPMKUF TN Dopamine D2 receptor (D2R) DMPMKUF MA Modulator DMPMKUF RN Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinso... J Pharmacol Exp Ther. 1998 Jul;286(1):228-33. DMPMKUF RU https://www.ncbi.nlm.nih.gov/pubmed/9655864 DMPMR2I DI DMPMR2I DMPMR2I DN NP-50301 DMPMR2I TI TTZAYWL DMPMR2I TN Estrogen receptor (ESR) DMPMR2I MA Modulator DMPMR2I RN Therapeutic targets in dry eye syndrome. Drug News Perspect. 2008 Apr;21(3):166-76. DMPMR2I RU https://pubmed.ncbi.nlm.nih.gov/18560615 DMPQC18 DI DMPQC18 DMPQC18 DN RG7685 DMPQC18 TI TTVIMDE DMPQC18 TN Glucagon-like peptide 1 receptor (GLP1R) DMPQC18 MA Modulator DMPQC18 RN Company report (Roche pipeline: October 16, 2012) DMPQC18 RU http://www.roche.com/irp3q12e-a.pdf DMPQC18 DI DMPQC18 DMPQC18 DN RG7685 DMPQC18 TI TTYMKBE DMPQC18 TN Gastric inhibitory polypeptide receptor (GIPR) DMPQC18 MA Modulator DMPQC18 RN Company report (Roche pipeline: October 16, 2012) DMPQC18 RU http://www.roche.com/irp3q12e-a.pdf DMPQSE4 DI DMPQSE4 DMPQSE4 DN HCV-796 DMPQSE4 TI TTMVBWH DMPQSE4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMPQSE4 MA Inhibitor DMPQSE4 RN Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. DMPQSE4 RU https://pubmed.ncbi.nlm.nih.gov/18321145 DMPWSRA DI DMPWSRA DMPWSRA DN Tilmacoxib DMPWSRA TI TTVKILB DMPWSRA TN Prostaglandin G/H synthase 2 (COX-2) DMPWSRA MA Inhibitor DMPWSRA RN 4-(4-cycloalkyl/aryl-oxazol-5-yl)benzenesulfonamides as selective cyclooxygenase-2 inhibitors: enhancement of the selectivity by introduction of a ... J Med Chem. 2002 Mar 28;45(7):1511-7. DMPWSRA RU https://pubmed.ncbi.nlm.nih.gov/11906292 DMPZFDE DI DMPZFDE DMPZFDE DN CASTANOSPERMINE DMPZFDE TI TTQRL1H DMPZFDE TN Glucosidase unspecific (GAN) DMPZFDE MA Modulator DMPZFDE RN Castanospermine inhibits alpha-glucosidase activities and alters glycogen distribution in animals. Proc Natl Acad Sci U S A. 1985 Jan;82(1):93-7. DMPZFDE RU https://pubmed.ncbi.nlm.nih.gov/3881759 DMQ0T6L DI DMQ0T6L DMQ0T6L DN SC-45662 DMQ0T6L TI TT2J34L DMQ0T6L TN Arachidonate 5-lipoxygenase (5-LOX) DMQ0T6L MA Inhibitor DMQ0T6L RN The immunosuppressive properties of enisoprost and a 5-lipoxygenase inhibitor (SC-45662). Transplantation. 1991 Dec;52(6):1053-7. DMQ0T6L RU https://pubmed.ncbi.nlm.nih.gov/1750068 DMQ1LWU DI DMQ1LWU DMQ1LWU DN M-100240 DMQ1LWU TI TT5TKPM DMQ1LWU TN Neutral endopeptidase (MME) DMQ1LWU MA Modulator DMQ1LWU RN Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiot... J Cardiovasc Pharmacol. 1998 Mar;31(3):408-17. DMQ1LWU RU https://www.ncbi.nlm.nih.gov/pubmed/9514186 DMQ1LWU DI DMQ1LWU DMQ1LWU DN M-100240 DMQ1LWU TI TTL69WB DMQ1LWU TN Angiotensin-converting enzyme (ACE) DMQ1LWU MA Modulator DMQ1LWU RN Effects of MDL 100,240, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase on the vasopressor response to exogenous angiot... J Cardiovasc Pharmacol. 1998 Mar;31(3):408-17. DMQ1LWU RU https://www.ncbi.nlm.nih.gov/pubmed/9514186 DMQ2RDZ DI DMQ2RDZ DMQ2RDZ DN S-312-d DMQ2RDZ TI TT5HONZ DMQ2RDZ TN Calcium channel unspecific (CaC) DMQ2RDZ MA Blocker DMQ2RDZ RN Protective effects of a selective L-type voltage-sensitive calcium channel blocker, S-312-d, on neuronal cell death. Biochem Pharmacol. 2004 Mar 15;67(6):1153-65. DMQ2RDZ RU https://pubmed.ncbi.nlm.nih.gov/15006551 DMQ2ULV DI DMQ2ULV DMQ2ULV DN Imitrodast DMQ2ULV TI TTKNWZ4 DMQ2ULV TN Thromboxane-A synthase (TBXAS1) DMQ2ULV MA Inhibitor DMQ2ULV RN RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20. DMQ2ULV RU https://pubmed.ncbi.nlm.nih.gov/3175990 DMQ3O4C DI DMQ3O4C DMQ3O4C DN FK-633 DMQ3O4C TI TT38RM1 DMQ3O4C TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMQ3O4C MA Modulator DMQ3O4C RN Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. Eur J Cardiothorac Surg. 2004 Aug;26(2):289-93. DMQ3O4C RU https://www.ncbi.nlm.nih.gov/pubmed/15296885 DMQ4IKZ DI DMQ4IKZ DMQ4IKZ DN RHIZOXIN DMQ4IKZ TI TTML2WA DMQ4IKZ TN Tubulin (TUB) DMQ4IKZ MA Inhibitor DMQ4IKZ RN Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51. DMQ4IKZ RU https://pubmed.ncbi.nlm.nih.gov/16870433 DMQ4IKZ DI DMQ4IKZ DMQ4IKZ DN RHIZOXIN DMQ4IKZ TI TTYFKSZ DMQ4IKZ TN Tubulin beta (TUBB) DMQ4IKZ MA Inhibitor DMQ4IKZ RN Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4748-51. DMQ4IKZ RU https://pubmed.ncbi.nlm.nih.gov/16870433 DMQ6CYE DI DMQ6CYE DMQ6CYE DN BIWB-1 DMQ6CYE TI TTF89GD DMQ6CYE TN Interleukin-2 (IL2) DMQ6CYE RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMQ6CYE RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMQ7A35 DI DMQ7A35 DMQ7A35 DN Lu-35138 DMQ7A35 TI TTE0A2F DMQ7A35 TN Dopamine D4 receptor (D4R) DMQ7A35 MA Antagonist DMQ7A35 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237) DMQ7A35 RU http://adisinsight.springer.com/drugs/800014237 DMQ82T5 DI DMQ82T5 DMQ82T5 DN NS-220 DMQ82T5 TI TTJ584C DMQ82T5 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMQ82T5 MA Agonist DMQ82T5 RN Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6471-5. DMQ82T5 RU https://pubmed.ncbi.nlm.nih.gov/18976908 DMQ8P4U DI DMQ8P4U DMQ8P4U DN NS-49 DMQ8P4U TI TT34BHT DMQ8P4U TN Adrenergic receptor alpha-1D (ADRA1D) DMQ8P4U MA Modulator DMQ8P4U RN Pharmacokinetics of NS-49, a phenethylamine class alpha 1A-adrenoceptor agonist. 3rd communication: metabolism in rats, rabbits, dogs and monkeys, and effects on hepatic drug-metabolizing enzyme activities in rats after repeated administration. Arzneimittelforschung. 1999 Jul;49(7):612-7. DMQ8P4U RU https://pubmed.ncbi.nlm.nih.gov/10442210 DMQ92WF DI DMQ92WF DMQ92WF DN GW 468816 DMQ92WF TI TTZ8EM9 DMQ92WF TN Glycine receptor (GlyR) DMQ92WF MA Modulator DMQ92WF RN A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females.J Clin Psychopharmacol.2011 Oct;31(5):597-602. DMQ92WF RU https://www.ncbi.nlm.nih.gov/pubmed/21869693 DMQ9IO0 DI DMQ9IO0 DMQ9IO0 DN DuP-654 DMQ9IO0 TI TT2J34L DMQ9IO0 TN Arachidonate 5-lipoxygenase (5-LOX) DMQ9IO0 MA Inhibitor DMQ9IO0 RN The lipoxygenase inhibitor 2-phenylmethyl-1-naphthol (DuP 654) is a 12(S)-hydroxyeicosatetraenoic acid receptor antagonist in the human epidermal cell line SCL-II. Skin Pharmacol. 1993;6(2):148-51. DMQ9IO0 RU https://pubmed.ncbi.nlm.nih.gov/8394724 DMQD2LS DI DMQD2LS DMQD2LS DN CJC-1131 DMQD2LS TI TTVIMDE DMQD2LS TN Glucagon-like peptide 1 receptor (GLP1R) DMQD2LS MA Modulator DMQD2LS RN Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int J Clin Pharmacol Ther. 2008 Sep;46(9):443-52. DMQD2LS RU https://pubmed.ncbi.nlm.nih.gov/18793574 DMQM4OV DI DMQM4OV DMQM4OV DN OP-2507 DMQM4OV TI TTOFYT1 DMQM4OV TN Prostacyclin receptor (PTGIR) DMQM4OV MA Modulator DMQM4OV RN Effect of a prostaglandin I(2) analog on the expression of thrombomodulin in liver and spleen endothelial cells after an extensive hepatectomy. Surg Today. 2011 Feb;41(2):230-6. DMQM4OV RU https://pubmed.ncbi.nlm.nih.gov/21264759 DMQM54P DI DMQM54P DMQM54P DN ADL-5945 DMQM54P TI TTKWM86 DMQM54P TN Opioid receptor mu (MOP) DMQM54P MA Antagonist DMQM54P RN Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56. DMQM54P RU https://pubmed.ncbi.nlm.nih.gov/21663526 DMQMA17 DI DMQMA17 DMQMA17 DN SAVOXEPIN MESYLATE DMQMA17 TI TTEX248 DMQMA17 TN Dopamine D2 receptor (D2R) DMQMA17 MA Agonist DMQMA17 RN Savoxepine: striatal dopamine-D2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Eur J Clin Pharmacol. 1993;44(2):135-40. DMQMA17 RU https://pubmed.ncbi.nlm.nih.gov/8095895 DMQPXLF DI DMQPXLF DMQPXLF DN NPS-2143 DMQPXLF TI TTBUYHA DMQPXLF TN Extracellular calcium-sensing receptor (CASR) DMQPXLF MA Antagonist DMQPXLF RN Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52. DMQPXLF RU https://pubmed.ncbi.nlm.nih.gov/23628734 DMQRKH4 DI DMQRKH4 DMQRKH4 DN JTH-601 DMQRKH4 TI TT34BHT DMQRKH4 TN Adrenergic receptor alpha-1D (ADRA1D) DMQRKH4 MA Antagonist DMQRKH4 RN Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30. DMQRKH4 RU https://pubmed.ncbi.nlm.nih.gov/10771044 DMQRKH4 DI DMQRKH4 DMQRKH4 DN JTH-601 DMQRKH4 TI TT2NUT5 DMQRKH4 TN Adrenergic receptor alpha-2C (ADRA2C) DMQRKH4 MA Antagonist DMQRKH4 RN Effect of JTH-601, a novel alpha(1)-adrenoceptor antagonist, on prostate function in dogs. Eur J Pharmacol. 2000 Apr 7;394(1):123-30. DMQRKH4 RU https://pubmed.ncbi.nlm.nih.gov/10771044 DMQSNV8 DI DMQSNV8 DMQSNV8 DN TgAAV-CFTR DMQSNV8 TI TTCYAXN DMQSNV8 TN Chloride channel unspecific (ClC) DMQSNV8 MA Modulator DMQSNV8 RN Novel molecular approaches to cystic fibrosis gene therapy. Biochem J. 2005 April 1; 387(Pt 1): 1-15. DMQSNV8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1134927/ DMQV4C3 DI DMQV4C3 DMQV4C3 DN 4030W92 DMQV4C3 TI TTRK8B9 DMQV4C3 TN Sodium channel unspecific (NaC) DMQV4C3 MA Modulator DMQV4C3 RN Lack of effect of two oral sodium channel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesia model. Pharmacol Biochem Behav. 2004 Jun;78(2):349-55. DMQV4C3 RU https://pubmed.ncbi.nlm.nih.gov/15219777 DMQWA2R DI DMQWA2R DMQWA2R DN TY-11345 DMQWA2R TI TTLOKXP DMQWA2R TN Gastric H(+)/K(+) ATPase (Proton pump) DMQWA2R MA Modulator DMQWA2R RN Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals. Jpn J Pharmacol. 1993 Aug;62(4):363-71. DMQWA2R RU https://pubmed.ncbi.nlm.nih.gov/8230863 DMR0K85 DI DMR0K85 DMR0K85 DN RX-77368 DMR0K85 TI TT2Z39D DMR0K85 TN Thyrotropin-releasing hormone (TRH) DMR0K85 MA Modulator DMR0K85 RN Intracisternal urocortin inhibits vagally stimulated gastric motility in rats: role of CRF(2).Br J Pharmacol.2002 May;136(2):237-47. DMR0K85 RU https://www.ncbi.nlm.nih.gov/pubmed/12010772 DMR1OJM DI DMR1OJM DMR1OJM DN PSD-508 DMR1OJM TI TTK0943 DMR1OJM TN Prostaglandin G/H synthase (COX) DMR1OJM MA Inhibitor DMR1OJM RN CN patent application no. 104797935, A method for prognosis and treatment of cancer metastasis. DMR1OJM RU http://www.google.com/patents/CN104797935A?cl=en DMR2FPO DI DMR2FPO DMR2FPO DN FK-584 DMR2FPO TI TTH18TF DMR2FPO TN Muscarinic acetylcholine receptor M5 (CHRM5) DMR2FPO MA Modulator DMR2FPO RN US patent application no. 2005,0261,328, Pharmaceutical composition comprising beta-3-adrenoceptor-agonists and antimuscarinic agents. DMR2FPO RU http://www.google.com/patents/US20050261328 DMR2STB DI DMR2STB DMR2STB DN ISIS 2105 DMR2STB TI TTXQPKC DMR2STB TN Human papillomavirus E2 transactivator messenger RNA (HPV E2 mRNA) DMR2STB RN US patent application no. 5,665,580, Antisense oligonucleotide inhibition of papillomavirus transformed cells. DMR2STB RU http://www.patentbuddy.com/Patent/5665580?ft=true&sr=true DMR3Q82 DI DMR3Q82 DMR3Q82 DN Apricoxib DMR3Q82 TI TTVKILB DMR3Q82 TN Prostaglandin G/H synthase 2 (COX-2) DMR3Q82 MA Inhibitor DMR3Q82 RN Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. IDrugs. 2009 Nov;12(11):711-22. DMR3Q82 RU https://pubmed.ncbi.nlm.nih.gov/19844858 DMR569L DI DMR569L DMR569L DN BBR-3438 DMR569L TI TTUTN1I DMR569L TN Human Deoxyribonucleic acid (hDNA) DMR569L MA Binder DMR569L RN A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. Oncology. 2001;61(3):234-42. DMR569L RU https://pubmed.ncbi.nlm.nih.gov/11574780 DMRA3EZ DI DMRA3EZ DMRA3EZ DN MLN3897 DMRA3EZ TI TTC24WT DMRA3EZ TN C-C chemokine receptor type 1 (CCR1) DMRA3EZ MA Antagonist DMRA3EZ RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMRA3EZ RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMRB23N DI DMRB23N DMRB23N DN ETRX-101 DMRB23N TI TTGN1ZA DMRB23N TN Angiotensin II receptor (AGTR) DMRB23N MA Modulator DMRB23N RN WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides. DMRB23N RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100325&CC=WO&NR=2010033207A1&KC=A1 DMRDXYV DI DMRDXYV DMRDXYV DN Ultramorph DMRDXYV TI TTN4QDT DMRDXYV TN Opioid receptor (OPR) DMRDXYV MA Agonist DMRDXYV RN Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain. 2000 Feb;84(2-3):121-31. DMRDXYV RU https://pubmed.ncbi.nlm.nih.gov/10666516 DMRGC5B DI DMRGC5B DMRGC5B DN RPR-106541 DMRGC5B TI TTPNQAC DMRGC5B TN Estrogen-related receptor-alpha (ESRRA) DMRGC5B MA Agonist DMRGC5B RN Use of the steroid derivative RPR 106541 in combination with site-directed mutagenesis for enhanced cytochrome P-450 3A4 structure/function analysis. J Pharmacol Exp Ther. 1999 Aug;290(2):594-602. DMRGC5B RU https://pubmed.ncbi.nlm.nih.gov/10411567 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TT34BHT DMRHYAU TN Adrenergic receptor alpha-1D (ADRA1D) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TTSQIFT DMRHYAU TN 5-HT 1A receptor (HTR1A) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TTJQOD7 DMRHYAU TN 5-HT 2A receptor (HTR2A) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TTWM4TY DMRHYAU TN Adrenergic receptor alpha-2B (ADRA2B) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TTEX248 DMRHYAU TN Dopamine D2 receptor (D2R) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TTWG9A4 DMRHYAU TN Adrenergic receptor alpha-2A (ADRA2A) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TTBRKXS DMRHYAU TN Adrenergic receptor alpha-1B (ADRA1B) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TT4C8EA DMRHYAU TN Dopamine D3 receptor (D3R) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TTNGILX DMRHYAU TN Adrenergic receptor alpha-1A (ADRA1A) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHYAU DI DMRHYAU DMRHYAU DN MAZAPERTINE DMRHYAU TI TT2NUT5 DMRHYAU TN Adrenergic receptor alpha-2C (ADRA2C) DMRHYAU MA Inhibitor DMRHYAU RN A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2. DMRHYAU RU https://pubmed.ncbi.nlm.nih.gov/7909336 DMRHZBD DI DMRHZBD DMRHZBD DN INCB19602 DMRHZBD TI TTWNV8U DMRHZBD TN Nicotinic acid receptor (HCAR2) DMRHZBD MA Modulator DMRHZBD RN DOI: 10.1038/scibx.2010.313 DMRHZBD RU http://www.nature.com/scibx/journal/v3/n10/full/scibx.2010.313.html DMRKBIU DI DMRKBIU DMRKBIU DN BRL-32872A DMRKBIU TI TT5HONZ DMRKBIU TN Calcium channel unspecific (CaC) DMRKBIU MA Modulator DMRKBIU RN Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46. DMRKBIU RU https://www.ncbi.nlm.nih.gov/pubmed/8632331 DMRKBIU DI DMRKBIU DMRKBIU DN BRL-32872A DMRKBIU TI TT1VOHK DMRKBIU TN Potassium channel unspecific (KC) DMRKBIU MA Modulator DMRKBIU RN Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46. DMRKBIU RU https://www.ncbi.nlm.nih.gov/pubmed/8632331 DMRKE9G DI DMRKE9G DMRKE9G DN SRI-62-834 DMRKE9G TI TT8FYO9 DMRKE9G TN Platelet-derived growth factor receptor alpha (PDGFRA) DMRKE9G MA Inhibitor DMRKE9G RN Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3. Lipids. 1987 Nov;22(11):884-90. DMRKE9G RU https://pubmed.ncbi.nlm.nih.gov/2832680 DMRKE9G DI DMRKE9G DMRKE9G DN SRI-62-834 DMRKE9G TI TTI7421 DMRKE9G TN Platelet-derived growth factor receptor beta (PDGFRB) DMRKE9G MA Inhibitor DMRKE9G RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMRKE9G RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMRN7GC DI DMRN7GC DMRN7GC DN Manifaxine DMRN7GC TI TTAWNKZ DMRN7GC TN Norepinephrine transporter (NET) DMRN7GC MA Modulator DMRN7GC RN Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9. DMRN7GC RU https://pubmed.ncbi.nlm.nih.gov/16272960 DMRN7GC DI DMRN7GC DMRN7GC DN Manifaxine DMRN7GC TI TTVBI8W DMRN7GC TN Dopamine transporter (DAT) DMRN7GC MA Modulator DMRN7GC RN Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9. DMRN7GC RU https://pubmed.ncbi.nlm.nih.gov/16272960 DMRNJPY DI DMRNJPY DMRNJPY DN GSK835726 DMRNJPY TI TTTIBOJ DMRNJPY TN Histamine H1 receptor (H1R) DMRNJPY MA Antagonist DMRNJPY RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMRNJPY RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMRNJPY DI DMRNJPY DMRNJPY DN GSK835726 DMRNJPY TI TT9JNIC DMRNJPY TN Histamine H3 receptor (H3R) DMRNJPY MA Antagonist DMRNJPY RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMRNJPY RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMRODZS DI DMRODZS DMRODZS DN PV-707 DMRODZS TI TTDB5IS DMRODZS TN Receptor unspecific (Rec) DMRODZS MA Modulator DMRODZS RN EP patent application no. 1904089, Promotion of epithelial regeneration. DMRODZS RU http://www.google.com/patents/EP1904089A2?cl=en DMROKDM DI DMROKDM DMROKDM DN SR-90067 DMROKDM TI TTZAYWL DMROKDM TN Estrogen receptor (ESR) DMROKDM MA Agonist DMROKDM RN US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions. DMROKDM RU https://www.google.com.ar/patents/US20100278784 DMROSHN DI DMROSHN DMROSHN DN Velneperit DMROSHN TI TTY6EWA DMROSHN TN Neuropeptide Y receptor type 5 (NPY5R) DMROSHN MA Antagonist DMROSHN RN Clinical pipeline report, company report or official report of Shionogi (2011). DMROSHN RU http://www.shionogi.co.jp/index_e.html DMRPBJW DI DMRPBJW DMRPBJW DN IDX375 DMRPBJW TI TTMVBWH DMRPBJW TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMRPBJW MA Inhibitor DMRPBJW RN Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression. Indian J Psychiatry. 1997 Apr;39(2):147-53. DMRPBJW RU https://pubmed.ncbi.nlm.nih.gov/21584062 DMRPU10 DI DMRPU10 DMRPU10 DN BMS-488043 DMRPU10 TI TTBYP1X DMRPU10 TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMRPU10 MA Modulator DMRPU10 RN The investigations on HIV-1 gp120 bound with BMS-488043 by using docking and molecular dynamics simulations.J Mol Model.2013 Feb;19(2):905-17. DMRPU10 RU https://www.ncbi.nlm.nih.gov/pubmed/23086459 DMRPUEC DI DMRPUEC DMRPUEC DN EDONENTAN HYDRATE DMRPUEC TI TTKRD0G DMRPUEC TN Endothelin A receptor (EDNRA) DMRPUEC MA Antagonist DMRPUEC RN US patent application no. 9,062,094, Dipeptide-based prodrug linkers for aliphatic amine-containing drugs. DMRPUEC RU http://www.google.com/patents/US9062094 DMRSMW8 DI DMRSMW8 DMRSMW8 DN PAI-2 DMRSMW8 TI TTGY7WI DMRSMW8 TN Urokinase-type plasminogen activator (PLAU) DMRSMW8 MA Inhibitor DMRSMW8 RN Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41. DMRSMW8 RU https://pubmed.ncbi.nlm.nih.gov/10754515 DMRU1KT DI DMRU1KT DMRU1KT DN Fasidotril DMRU1KT TI TT5TKPM DMRU1KT TN Neutral endopeptidase (MME) DMRU1KT MA Modulator DMRU1KT RN Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans. Hypertension. 2000 May;35(5):1148-53. DMRU1KT RU https://www.ncbi.nlm.nih.gov/pubmed/10818079 DMRVH2S DI DMRVH2S DMRVH2S DN Brecanavir DMRVH2S TI TT5FNQT DMRVH2S TN Human immunodeficiency virus Protease (HIV PR) DMRVH2S MA Modulator DMRVH2S RN Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects.Antimicrob Agents Chemother.2007 Apr;51(4):1202-8. DMRVH2S RU https://www.ncbi.nlm.nih.gov/pubmed/17261626 DMRVJ1A DI DMRVJ1A DMRVJ1A DN Corus 1030 DMRVJ1A TI TT4G2JS DMRVJ1A TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMRVJ1A MA Modulator DMRVJ1A RN Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol. 2004 Jun;142(3):576-84. DMRVJ1A RU https://pubmed.ncbi.nlm.nih.gov/15148257 DMRVJ1A DI DMRVJ1A DMRVJ1A DN Corus 1030 DMRVJ1A TI TT90XZ8 DMRVJ1A TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMRVJ1A MA Modulator DMRVJ1A RN Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol. 2004 Jun;142(3):576-84. DMRVJ1A RU https://pubmed.ncbi.nlm.nih.gov/15148257 DMRWSKX DI DMRWSKX DMRWSKX DN Afegostat DMRWSKX TI TT1B5PU DMRWSKX TN Glucosylceramidase (GBA) DMRWSKX MA Inhibitor DMRWSKX RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DMRWSKX RU https://pubmed.ncbi.nlm.nih.gov/31477883 DMRXHAC DI DMRXHAC DMRXHAC DN Otenzepad DMRXHAC TI TTYEG6Q DMRXHAC TN Muscarinic acetylcholine receptor M2 (CHRM2) DMRXHAC MA Antagonist DMRXHAC RN Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S43-9. DMRXHAC RU https://pubmed.ncbi.nlm.nih.gov/11811358 DMRY9V8 DI DMRY9V8 DMRY9V8 DN AMESERGIDE DMRY9V8 TI TTJQOD7 DMRY9V8 TN 5-HT 2A receptor (HTR2A) DMRY9V8 MA Antagonist DMRY9V8 RN Effects of the serotonin antagonist amesergide on reproduction in female rats. Reprod Toxicol. 1993 Nov-Dec;7(6):607-12. DMRY9V8 RU https://pubmed.ncbi.nlm.nih.gov/8118111 DMRYK1C DI DMRYK1C DMRYK1C DN AVE-0847 DMRYK1C TI TTZMAO3 DMRYK1C TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMRYK1C MA Modulator DMRYK1C RN DOI: 10.1038/scibx.2012.669 DMRYK1C RU http://www.nature.com/scibx/journal/v5/n26/fig_tab/scibx.2012.669_T1.html DMRYK1C DI DMRYK1C DMRYK1C DN AVE-0847 DMRYK1C TI TTJ584C DMRYK1C TN Peroxisome proliferator-activated receptor alpha (PPARA) DMRYK1C MA Modulator DMRYK1C RN DOI: 10.1038/scibx.2012.669 DMRYK1C RU http://www.nature.com/scibx/journal/v5/n26/fig_tab/scibx.2012.669_T1.html DMRZI3C DI DMRZI3C DMRZI3C DN R-87366 DMRZI3C TI TT5FNQT DMRZI3C TN Human immunodeficiency virus Protease (HIV PR) DMRZI3C MA Inhibitor DMRZI3C RN In vitro and ex vivo anti-human immunodeficiency virus (HIV) activities of a new water-soluble HIV protease inhibitor, R-87366, containing (2S,3S)-3-amino-2-hydroxy-4-phenylbutanoic acid. Biol Pharm Bull. 1997 Feb;20(2):175-80. DMRZI3C RU https://pubmed.ncbi.nlm.nih.gov/9057982 DMS0LCZ DI DMS0LCZ DMS0LCZ DN ARX-201 DMS0LCZ TI TTT3YKH DMS0LCZ TN Somatotropin (GH1) DMS0LCZ MA Modulator DMS0LCZ RN Company report (Avarx) DMS0LCZ RU http://www.avarx.com/search/showOpportunityDetails?asset_id=1309 DMS2IC9 DI DMS2IC9 DMS2IC9 DN BMS-587101 DMS2IC9 TI TTIJWR7 DMS2IC9 TN Integrin beta-2 (ITGB2) DMS2IC9 MA Inhibitor DMS2IC9 RN Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non-7-yl-methyl]-3-thioph... J Med Chem. 2006 Nov 30;49(24):6946-9. DMS2IC9 RU https://pubmed.ncbi.nlm.nih.gov/17125246 DMS2IC9 DI DMS2IC9 DMS2IC9 DN BMS-587101 DMS2IC9 TI TT48WR6 DMS2IC9 TN Integrin alpha-L (ITGAL) DMS2IC9 MA Inhibitor DMS2IC9 RN Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-(... J Med Chem. 2010 May 13;53(9):3814-30. DMS2IC9 RU https://pubmed.ncbi.nlm.nih.gov/20405922 DMS3ECJ DI DMS3ECJ DMS3ECJ DN Camobucol DMS3ECJ TI TTF8CQI DMS3ECJ TN Tumor necrosis factor (TNF) DMS3ECJ MA Inhibitor DMS3ECJ RN AGIX-4207 [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetic acid], a novel ... J Pharmacol Exp Ther. 2005 May;313(2):492-501. DMS3ECJ RU https://pubmed.ncbi.nlm.nih.gov/15701708 DMS4BUK DI DMS4BUK DMS4BUK DN TG-1042 DMS4BUK TI TT93WF5 DMS4BUK TN Interferon-gamma (IFNG) DMS4BUK MA Modulator DMS4BUK RN Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas. Curr Opin Investig Drugs. 2007 Jun;8(6):493-8. DMS4BUK RU https://pubmed.ncbi.nlm.nih.gov/17621880 DMS56UD DI DMS56UD DMS56UD DN Indeglitazar DMS56UD TI TTJ584C DMS56UD TN Peroxisome proliferator-activated receptor alpha (PPARA) DMS56UD MA Agonist DMS56UD RN Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. DMS56UD RU https://pubmed.ncbi.nlm.nih.gov/19116277 DMS56UD DI DMS56UD DMS56UD DN Indeglitazar DMS56UD TI TTZMAO3 DMS56UD TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMS56UD MA Agonist DMS56UD RN Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. DMS56UD RU https://pubmed.ncbi.nlm.nih.gov/19116277 DMS56UD DI DMS56UD DMS56UD DN Indeglitazar DMS56UD TI TT2JWF6 DMS56UD TN Peroxisome proliferator-activated receptor delta (PPARD) DMS56UD MA Agonist DMS56UD RN Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. DMS56UD RU https://pubmed.ncbi.nlm.nih.gov/19116277 DMS5X94 DI DMS5X94 DMS5X94 DN Lintitript DMS5X94 TI TTCG0AL DMS5X94 TN Cholecystokinin receptor type A (CCKAR) DMS5X94 MA Antagonist DMS5X94 RN A cholecystokinin-1 receptor agonist (CCK-8) mediates increased permeability of brain barriers to leptin. Br J Pharmacol. 2008 Jul;154(5):1009-15. DMS5X94 RU https://pubmed.ncbi.nlm.nih.gov/18587446 DMS6NAK DI DMS6NAK DMS6NAK DN S-12363 DMS6NAK TI TTYFKSZ DMS6NAK TN Tubulin beta (TUBB) DMS6NAK MA Modulator DMS6NAK RN Microtubule assembly protects the region 28-38 of the beta- tubulin subunit. Article first published online: 4 FEB 2005. DMS6NAK RU http://onlinelibrary.wiley.com/doi/10.1002/cm.970220104/abstract DMS7TC5 DI DMS7TC5 DMS7TC5 DN Geldanamycin DMS7TC5 TI TT78R5H DMS7TC5 TN Heat shock protein 90 alpha (HSP90A) DMS7TC5 MA Inhibitor DMS7TC5 RN Heat shock protein 90 regulates the stability of MEKK3 in HEK293 cells. Cell Immunol. 2009;259(1):49-55. DMS7TC5 RU https://pubmed.ncbi.nlm.nih.gov/19560753 DMS87T9 DI DMS87T9 DMS87T9 DN FK-838 DMS87T9 TI TTK25J1 DMS87T9 TN Adenosine A1 receptor (ADORA1) DMS87T9 MA Modulator DMS87T9 RN An orally active adenosine A1 receptor antagonist, FK838, increases renal excretion and maintains glomerular filtration rate in furosemide-resistan... Br J Pharmacol. 2003 Aug;139(8):1383-8. DMS87T9 RU https://www.ncbi.nlm.nih.gov/pubmed/12922924 DMS8AHE DI DMS8AHE DMS8AHE DN SL-65.1498 DMS8AHE TI TTEX6LM DMS8AHE TN GABA(A) receptor gamma-3 (GABRG3) DMS8AHE MA Agonist DMS8AHE RN WO patent application no. 2005,0749,31, Pharmaceutical combinations comprising (s) -pantoprazole. DMS8AHE RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050818&CC=WO&NR=2005074931A1&KC=A1 DMS8JIU DI DMS8JIU DMS8JIU DN ADROGOLIDE HYDROCHLORIDE DMS8JIU TI TTZFYLI DMS8JIU TN Dopamine D1 receptor (D1R) DMS8JIU MA Agonist DMS8JIU RN Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data. CNS Drug Rev. 2001 Fall;7(3):305-16. DMS8JIU RU https://pubmed.ncbi.nlm.nih.gov/11607045 DMS95DX DI DMS95DX DMS95DX DN ZD-0947 DMS95DX TI TT1VOHK DMS95DX TN Potassium channel unspecific (KC) DMS95DX MA Opener DMS95DX RN Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol. 2002 Aug;168(2):837-42. DMS95DX RU https://pubmed.ncbi.nlm.nih.gov/12131377 DMSATO0 DI DMSATO0 DMSATO0 DN IO-21 DMSATO0 TI TT9GOIR DMSATO0 TN Streptococcus Diphtheria protein (Stre DIPP) DMSATO0 MA Modulator DMSATO0 RN Interplay between Longitudinal and Transverse Contrasts in Fe3O4 Nanoplates with (111) Exposed Surfaces. ACS Nano. 2014 August 26; 8(8): 7976-7985. DMSATO0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568839/ DMSF5VK DI DMSF5VK DMSF5VK DN Affitope AD-02 DMSF5VK TI TTE4KHA DMSF5VK TN Amyloid beta A4 protein (APP) DMSF5VK RN Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014 Mar;10(3):405-19. DMSF5VK RU https://pubmed.ncbi.nlm.nih.gov/24490853 DMSFL76 DI DMSFL76 DMSFL76 DN Labradimil DMSFL76 TI TTGY8IW DMSFL76 TN B2 bradykinin receptor (BDKRB2) DMSFL76 MA Agonist DMSFL76 RN Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med. 2009 May 13;7:33. DMSFL76 RU https://pubmed.ncbi.nlm.nih.gov/19439100 DMSGY5M DI DMSGY5M DMSGY5M DN 99mTc-ciprofloxacin DMSGY5M TI TTN6J5F DMSGY5M TN Bacterial DNA gyrase (Bact gyrase) DMSGY5M MA Inhibitor DMSGY5M RN Binding of ciprofloxacin labelled with technetium Tc 99m versus 99mTc-pertechnetate to a live and killed equine isolate of Escherichia coli. Can J Vet Res. 2005 October; 69(4): 272-277. DMSGY5M RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1250239/ DMSJYEX DI DMSJYEX DMSJYEX DN Nitecapone DMSJYEX TI TTKWFB8 DMSJYEX TN Catechol-O-methyl-transferase (COMT) DMSJYEX MA Modulator DMSJYEX RN Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol. 1990 Oct;13(5):436-47. DMSJYEX RU https://pubmed.ncbi.nlm.nih.gov/2272023 DMSLP2O DI DMSLP2O DMSLP2O DN SERM-3339 DMSLP2O TI TTZAYWL DMSLP2O TN Estrogen receptor (ESR) DMSLP2O MA Modulator DMSLP2O RN CN patent application no. 102406650, Sex steroid precursors alone or in combination with selective estrogen receptor modulator for prevention and treatment of vaginal dryness and sexual dysfunction in postmenop. DMSLP2O RU http://www.google.com/patents/CN102406650A?cl=en DMSOALX DI DMSOALX DMSOALX DN Repifermin DMSOALX TI TTNPEFX DMSOALX TN Fibroblast growth factor-10 (FGF10) DMSOALX MA Modulator DMSOALX RN Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003 Jun 1;17(11):1355-64. DMSOALX RU https://pubmed.ncbi.nlm.nih.gov/12786629 DMSQ794 DI DMSQ794 DMSQ794 DN PKI166 DMSQ794 TI TTGKNB4 DMSQ794 TN Epidermal growth factor receptor (EGFR) DMSQ794 MA Modulator DMSQ794 RN Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.J Pharmacol Exp Ther.2013 Jun;345(3):393-403. DMSQ794 RU https://www.ncbi.nlm.nih.gov/pubmed/23528611 DMSQRXW DI DMSQRXW DMSQRXW DN SQ-32709 DMSQRXW TI TTFQEO5 DMSQRXW TN Squalene synthetase (FDFT1) DMSQRXW MA Modulator DMSQRXW RN Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol. 1998 Dec;38(12):1116-21. DMSQRXW RU https://pubmed.ncbi.nlm.nih.gov/11301563 DMSTA5L DI DMSTA5L DMSTA5L DN DX-619 DMSTA5L TI TTN6J5F DMSTA5L TN Bacterial DNA gyrase (Bact gyrase) DMSTA5L MA Modulator DMSTA5L RN DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7. DMSTA5L RU https://pubmed.ncbi.nlm.nih.gov/16304172 DMSTA5L DI DMSTA5L DMSTA5L DN DX-619 DMSTA5L TI TTIXTO3 DMSTA5L TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMSTA5L MA Modulator DMSTA5L RN DX-619, a novel des-fluoro(6) quinolone manifesting low frequency of selection of resistant Staphylococcus aureus mutants: quinolone resistance beyond modification of type II topoisomerases. Antimicrob Agents Chemother. 2005 Dec;49(12):5051-7. DMSTA5L RU https://pubmed.ncbi.nlm.nih.gov/16304172 DMSV6KP DI DMSV6KP DMSV6KP DN GSK 679769 DMSV6KP TI TTZPO1L DMSV6KP TN Substance-P receptor (TACR1) DMSV6KP MA Antagonist DMSV6KP RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMSV6KP RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMSVQK2 DI DMSVQK2 DMSVQK2 DN ONO-4819 DMSVQK2 TI TT79WV3 DMSVQK2 TN Prostaglandin E2 receptor EP4 (PTGER4) DMSVQK2 MA Agonist DMSVQK2 RN Effect of a prostaglandin EP4 receptor agonist on early fixation of hydroxyapatite/titanium composite- and titanium-coated rough-surfaced implants ... J Biomed Mater Res A. 2010 Mar 1;92(3):1202-9. DMSVQK2 RU https://pubmed.ncbi.nlm.nih.gov/19322876 DMSWDKX DI DMSWDKX DMSWDKX DN KW-4490 DMSWDKX TI TTZ97H5 DMSWDKX TN Phosphodiesterase 4A (PDE4A) DMSWDKX MA Inhibitor DMSWDKX RN Pharmacokinetics and metabolism of KW-4490, a selective phosphodiesterase 4 inhibitor: difference in excretion of KW-4490 and acylglucuronide metabolites between rats and cynomolgus monkeys. Xenobiotica. 2008 May;38(5):511-26. DMSWDKX RU https://pubmed.ncbi.nlm.nih.gov/18421624 DMSWDKX DI DMSWDKX DMSWDKX DN KW-4490 DMSWDKX TI TTSKMI8 DMSWDKX TN Phosphodiesterase 4D (PDE4D) DMSWDKX MA Inhibitor DMSWDKX RN Pharmacokinetics and metabolism of KW-4490, a selective phosphodiesterase 4 inhibitor: difference in excretion of KW-4490 and acylglucuronide metabolites between rats and cynomolgus monkeys. Xenobiotica. 2008 May;38(5):511-26. DMSWDKX RU https://pubmed.ncbi.nlm.nih.gov/18421624 DMSWDKX DI DMSWDKX DMSWDKX DN KW-4490 DMSWDKX TI TTVIAT9 DMSWDKX TN Phosphodiesterase 4B (PDE4B) DMSWDKX MA Inhibitor DMSWDKX RN Pharmacokinetics and metabolism of KW-4490, a selective phosphodiesterase 4 inhibitor: difference in excretion of KW-4490 and acylglucuronide metabolites between rats and cynomolgus monkeys. Xenobiotica. 2008 May;38(5):511-26. DMSWDKX RU https://pubmed.ncbi.nlm.nih.gov/18421624 DMT0KB1 DI DMT0KB1 DMT0KB1 DN PSD-506 DMT0KB1 TI TTYEG6Q DMT0KB1 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMT0KB1 MA Modulator DMT0KB1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT0KB1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT0KB1 DI DMT0KB1 DMT0KB1 DN PSD-506 DMT0KB1 TI TTQ13Z5 DMT0KB1 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMT0KB1 MA Modulator DMT0KB1 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMT0KB1 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMT0O7H DI DMT0O7H DMT0O7H DN MK-886 DMT0O7H TI TT2J34L DMT0O7H TN Arachidonate 5-lipoxygenase (5-LOX) DMT0O7H MA Modulator DMT0O7H RN Inhibitory effects of MK-886 on arachidonic acid metabolism in human phagocytes. Br J Pharmacol. 1990 May;100(1):15-20. DMT0O7H RU https://www.ncbi.nlm.nih.gov/pubmed/2164857 DMT0QK8 DI DMT0QK8 DMT0QK8 DN TNP-470 DMT0QK8 TI TTZL0OI DMT0QK8 TN Methionine aminopeptidase 2 (METAP2) DMT0QK8 MA Inhibitor DMT0QK8 RN Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9. DMT0QK8 RU https://pubmed.ncbi.nlm.nih.gov/14633714 DMT13ZR DI DMT13ZR DMT13ZR DN L-365260 DMT13ZR TI TTVFO0U DMT13ZR TN Gastrin/cholecystokinin type B receptor (CCKBR) DMT13ZR MA Modulator DMT13ZR RN Pharmacological analysis of CCK(2) receptor ligands using COS-7 and SK-N-MC cells, expressing the human CCK(2) receptor. Regul Pept. 2002 Jan 15;103(1):29-37. DMT13ZR RU https://pubmed.ncbi.nlm.nih.gov/11738246 DMT1LQS DI DMT1LQS DMT1LQS DN GLENVASTATIN DMT1LQS TI TTPADOQ DMT1LQS TN HMG-CoA reductase (HMGCR) DMT1LQS MA Inhibitor DMT1LQS RN Bile acid derived HMG-CoA reductase inhibitors. Biochim Biophys Acta. 1994 Nov 29;1227(3):137-54. DMT1LQS RU https://pubmed.ncbi.nlm.nih.gov/7986821 DMT2WVP DI DMT2WVP DMT2WVP DN Dynorphin A DMT2WVP TI TTKWM86 DMT2WVP TN Opioid receptor mu (MOP) DMT2WVP MA Inhibitor DMT2WVP RN Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71. DMT2WVP RU https://pubmed.ncbi.nlm.nih.gov/18487043 DMT2WVP DI DMT2WVP DMT2WVP DN Dynorphin A DMT2WVP TI TT27RFC DMT2WVP TN Opioid receptor delta (OPRD1) DMT2WVP MA Inhibitor DMT2WVP RN Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7. DMT2WVP RU https://pubmed.ncbi.nlm.nih.gov/8096246 DMT2WVP DI DMT2WVP DMT2WVP DN Dynorphin A DMT2WVP TI TTQW87Y DMT2WVP TN Opioid receptor kappa (OPRK1) DMT2WVP MA Inhibitor DMT2WVP RN Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71. DMT2WVP RU https://pubmed.ncbi.nlm.nih.gov/18487043 DMT2Z1L DI DMT2Z1L DMT2Z1L DN FCE-22716 DMT2Z1L TI TTJQOD7 DMT2Z1L TN 5-HT 2A receptor (HTR2A) DMT2Z1L MA Antagonist DMT2Z1L RN Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology. 1989;38(2):78-92. DMT2Z1L RU https://pubmed.ncbi.nlm.nih.gov/2727050 DMT2Z1L DI DMT2Z1L DMT2Z1L DN FCE-22716 DMT2Z1L TI TT34BHT DMT2Z1L TN Adrenergic receptor alpha-1D (ADRA1D) DMT2Z1L MA Modulator DMT2Z1L RN Mechanism of the antihypertensive effect of FCE 22716, a new ergoline derivative, in the spontaneously hypertensive rat. Pharmacology. 1989;38(2):78-92. DMT2Z1L RU https://pubmed.ncbi.nlm.nih.gov/2727050 DMT4VSE DI DMT4VSE DMT4VSE DN BMS-181101 DMT4VSE TI TT6MSOK DMT4VSE TN 5-HT 1D receptor (HTR1D) DMT4VSE MA Antagonist DMT4VSE RN Sensitive triple-quadrupole mass spectrometric assay for the determination of BMS-181885, a 5-HT1 agonist, in human plasma following solid phase extraction. Biomed Chromatogr. 1999 Oct;13(6):425-30. DMT4VSE RU https://pubmed.ncbi.nlm.nih.gov/10477901 DMT5KBF DI DMT5KBF DMT5KBF DN ALNESPIRONE DMT5KBF TI TTSQIFT DMT5KBF TN 5-HT 1A receptor (HTR1A) DMT5KBF MA Agonist DMT5KBF RN Chronic alnespirone-induced desensitization of somatodendritic 5-HT1A autoreceptors in the rat dorsal raphe nucleus. Eur J Pharmacol. 1999 Jan 22;365(2-3):165-73. DMT5KBF RU https://pubmed.ncbi.nlm.nih.gov/9988099 DMT5ZK3 DI DMT5ZK3 DMT5ZK3 DN AZD3355 DMT5ZK3 TI TTDCVZW DMT5ZK3 TN Gamma-aminobutyric acid B receptor (GABBR) DMT5ZK3 MA Modulator DMT5ZK3 RN Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial.Gut.2013 Sep;62(9):1248-55. DMT5ZK3 RU https://www.ncbi.nlm.nih.gov/pubmed/22730470 DMT6IUR DI DMT6IUR DMT6IUR DN MIRFENTANIL HYDROCHLORIDE DMT6IUR TI TTKWM86 DMT6IUR TN Opioid receptor mu (MOP) DMT6IUR MA Agonist DMT6IUR RN Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J Pharmacol Exp Ther. 1991 Aug;258(2):502-10. DMT6IUR RU https://pubmed.ncbi.nlm.nih.gov/1650830 DMTAKNF DI DMTAKNF DMTAKNF DN Cipralisant DMTAKNF TI TT9JNIC DMTAKNF TN Histamine H3 receptor (H3R) DMTAKNF MA Binder DMTAKNF RN G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. J Pharmacol Exp Ther. 2005 Jul;314(1):271-81. DMTAKNF RU https://pubmed.ncbi.nlm.nih.gov/15821027 DMTC4VY DI DMTC4VY DMTC4VY DN SQ-30741 DMTC4VY TI TT2O84V DMTC4VY TN Thromboxane A2 receptor (TBXA2R) DMTC4VY MA Antagonist DMTC4VY RN Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed. J Appl Physiol (1985). 1991 Nov;71(5):2012-8. DMTC4VY RU https://pubmed.ncbi.nlm.nih.gov/1837015 DMTE14H DI DMTE14H DMTE14H DN DOV-216303 DMTE14H TI TTVBI8W DMTE14H TN Dopamine transporter (DAT) DMTE14H MA Inhibitor DMTE14H RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMTE14H RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMTE14H DI DMTE14H DMTE14H DN DOV-216303 DMTE14H TI TT3ROYC DMTE14H TN Serotonin transporter (SERT) DMTE14H MA Inhibitor DMTE14H RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMTE14H RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMTE14H DI DMTE14H DMTE14H DN DOV-216303 DMTE14H TI TTAWNKZ DMTE14H TN Norepinephrine transporter (NET) DMTE14H MA Inhibitor DMTE14H RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMTE14H RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMTE3UV DI DMTE3UV DMTE3UV DN BI 1467335 DMTE3UV TI TT7HC21 DMTE3UV TN Membrane copper amine oxidase (AOC3) DMTE3UV MA Inhibitor DMTE3UV RN Clinical pipeline report, company report or official report of Boehringer Ingelheim. DMTE3UV RU https://www.boehringer-ingelheim.us/press-release/boehringer-ingelheim-discontinues-development-bi-1467335-diabetic-retinopathy DMTEQ0G DI DMTEQ0G DMTEQ0G DN Brofaromine DMTEQ0G TI TT3WG5C DMTEQ0G TN Monoamine oxidase type A (MAO-A) DMTEQ0G MA Modulator DMTEQ0G RN Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors. J Neural Transm Suppl. 1989;28:5-20. DMTEQ0G RU https://pubmed.ncbi.nlm.nih.gov/2677242 DMTEW80 DI DMTEW80 DMTEW80 DN FK-906 DMTEW80 TI TTB2MXP DMTEW80 TN Angiotensinogenase renin (REN) DMTEW80 MA Inhibitor DMTEW80 RN Antihypertensive efficacy of FK906, a novel human renin inhibitor. Clin Ther. 1993 May-Jun;15(3):539-48. DMTEW80 RU https://pubmed.ncbi.nlm.nih.gov/8364945 DMTGBPW DI DMTGBPW DMTGBPW DN Pentisomide DMTGBPW TI TTRK8B9 DMTGBPW TN Sodium channel unspecific (NaC) DMTGBPW MA Modulator DMTGBPW RN Antiarrhythmic effect related to the plasma concentration of pentisomide in vivo and the antiarrhythmic-concentration relationship in vitro. Drugs Exp Clin Res. 1995;21(4):145-51. DMTGBPW RU https://pubmed.ncbi.nlm.nih.gov/8529527 DMTGFV6 DI DMTGFV6 DMTGFV6 DN PYY3-36 DMTGFV6 TI TTJ6WK9 DMTGFV6 TN Neuropeptide Y receptor type 2 (NPY2R) DMTGFV6 MA Agonist DMTGFV6 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMTGFV6 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMTJNRL DI DMTJNRL DMTJNRL DN SPD-473 DMTJNRL TI TTVBI8W DMTJNRL TN Dopamine transporter (DAT) DMTJNRL MA Inhibitor DMTJNRL RN Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31. DMTJNRL RU https://pubmed.ncbi.nlm.nih.gov/15542624 DMTJNRL DI DMTJNRL DMTJNRL DN SPD-473 DMTJNRL TI TT3ROYC DMTJNRL TN Serotonin transporter (SERT) DMTJNRL MA Inhibitor DMTJNRL RN Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31. DMTJNRL RU https://pubmed.ncbi.nlm.nih.gov/15542624 DMTJNRL DI DMTJNRL DMTJNRL DN SPD-473 DMTJNRL TI TTAWNKZ DMTJNRL TN Norepinephrine transporter (NET) DMTJNRL MA Inhibitor DMTJNRL RN Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31. DMTJNRL RU https://pubmed.ncbi.nlm.nih.gov/15542624 DMTNYSF DI DMTNYSF DMTNYSF DN Galarubicin DMTNYSF TI TT6X50U DMTNYSF TN Matrix metalloproteinase-9 (MMP-9) DMTNYSF MA Inhibitor DMTNYSF RN Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31. DMTNYSF RU https://pubmed.ncbi.nlm.nih.gov/16271263 DMTNYSF DI DMTNYSF DMTNYSF DN Galarubicin DMTNYSF TI TTLM12X DMTNYSF TN Matrix metalloproteinase-2 (MMP-2) DMTNYSF MA Inhibitor DMTNYSF RN Inhibitory effect of DA-125, a new anthracyclin analog antitumor agent, on the invasion of human fibrosarcoma cells by down-regulating the matrix m... Biochem Pharmacol. 2005 Dec 19;71(1-2):21-31. DMTNYSF RU https://pubmed.ncbi.nlm.nih.gov/16271263 DMTOCV7 DI DMTOCV7 DMTOCV7 DN Adaprolol maleate-SME DMTOCV7 TI TTMXGCW DMTOCV7 TN Adrenergic receptor beta-3 (ADRB3) DMTOCV7 MA Modulator DMTOCV7 RN Synthesis and pharmacological activity of adaprolol enantiomers: a new soft drug for treating glaucoma. J Ocul Pharmacol Ther. 1996 Summer;12(2):115-22. DMTOCV7 RU https://pubmed.ncbi.nlm.nih.gov/8773927 DMTQ3BS DI DMTQ3BS DMTQ3BS DN RP-64477 DMTQ3BS TI TTMF541 DMTQ3BS TN Liver carboxylesterase (CES1) DMTQ3BS MA Modulator DMTQ3BS RN RP 64477: a potent inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol. 1996 Feb 23;51(4):413-21. DMTQ3BS RU https://pubmed.ncbi.nlm.nih.gov/8619885 DMTRBU4 DI DMTRBU4 DMTRBU4 DN Frakefamide DMTRBU4 TI TTKWM86 DMTRBU4 TN Opioid receptor mu (MOP) DMTRBU4 MA Agonist DMTRBU4 RN A novel molecule (frakefamide) with peripheral opioid properties: the effects on resting ventilation compared with morphine and placebo. Anesth Analg. 2005 Mar;100(3):713-7, table of contents. DMTRBU4 RU https://pubmed.ncbi.nlm.nih.gov/15728057 DMTRMBL DI DMTRMBL DMTRMBL DN NBI-6024 DMTRMBL TI TTZOPHG DMTRMBL TN Insulin (INS) DMTRMBL MA Modulator DMTRMBL RN No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.Diabetes Care.2009 Nov;32(11):2036-40. DMTRMBL RU https://www.ncbi.nlm.nih.gov/pubmed/19690081 DMTS1X5 DI DMTS1X5 DMTS1X5 DN LY-2300559 DMTS1X5 TI TTXJ47W DMTS1X5 TN Metabotropic glutamate receptor 2 (mGluR2) DMTS1X5 MA Modulator DMTS1X5 RN Annual Reports in Medicinal Chemistry. Elsevier (ISBN: 9780123964922). 2012, p78 DMTS1X5 RU https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=LY-2300559++mGluR2&source=bl&ots=oPRCoyeFUF&sig=mBJoAwlOyt44UDkkH77x_aHKhbE&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIup7Nm-HwyAIVgRmmCh2Dpgc7#v=onepage&q=LY-2300559%20%20mGluR2&f=false DMTS1X5 DI DMTS1X5 DMTS1X5 DN LY-2300559 DMTS1X5 TI TTGKOY9 DMTS1X5 TN Leukotriene CysLT1 receptor (CYSLTR1) DMTS1X5 MA Modulator DMTS1X5 RN Annual Reports in Medicinal Chemistry. Elsevier (ISBN: 9780123964922). 2012, p78 DMTS1X5 RU https://books.google.com.hk/books?id=y7GH165YoOsC&pg=PA78&lpg=PA78&dq=LY-2300559++mGluR2&source=bl&ots=oPRCoyeFUF&sig=mBJoAwlOyt44UDkkH77x_aHKhbE&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIup7Nm-HwyAIVgRmmCh2Dpgc7#v=onepage&q=LY-2300559%20%20mGluR2&f=false DMTUHWM DI DMTUHWM DMTUHWM DN Esreboxetine DMTUHWM TI TTAWNKZ DMTUHWM TN Norepinephrine transporter (NET) DMTUHWM MA Blocker DMTUHWM RN Pfizer. Product Development Pipeline. March 31 2009. DMTUHWM RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMTUPZ2 DI DMTUPZ2 DMTUPZ2 DN Ezlopitant DMTUPZ2 TI TTZPO1L DMTUPZ2 TN Substance-P receptor (TACR1) DMTUPZ2 MA Antagonist DMTUPZ2 RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMTUPZ2 RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMTWLG8 DI DMTWLG8 DMTWLG8 DN MLN-977 DMTWLG8 TI TT2J34L DMTWLG8 TN Arachidonate 5-lipoxygenase (5-LOX) DMTWLG8 MA Inhibitor DMTWLG8 RN Inflammation, Cancer and Oxidative Lipoxygenase Activity are Intimately Linked. Cancers (Basel) 2014 September; 6(3): 1500-1521. DMTWLG8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190552/ DMTX97J DI DMTX97J DMTX97J DN MILFASARTAN DMTX97J TI TT8DBY3 DMTX97J TN Angiotensin II receptor type-1 (AGTR1) DMTX97J MA Antagonist DMTX97J RN Dual action molecules: bioassays of combined novel antioxidants and angiotensin II receptor antagonists. Eur J Pharmacol. 2012 Nov 15;695(1-3):96-103. DMTX97J RU https://pubmed.ncbi.nlm.nih.gov/22975712 DMTY5VE DI DMTY5VE DMTY5VE DN Lavoltidine DMTY5VE TI TTQHJ1K DMTY5VE TN Histamine H2 receptor (H2R) DMTY5VE MA Antagonist DMTY5VE RN New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16. DMTY5VE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895610/ DMTYHK4 DI DMTYHK4 DMTYHK4 DN FOSOPAMINE DMTYHK4 TI TTEX248 DMTYHK4 TN Dopamine D2 receptor (D2R) DMTYHK4 MA Modulator DMTYHK4 RN Development of dopaminergic drugs for the chronic treatment of congestive heart failure. J Auton Pharmacol. 1990;10 Suppl 1:s85-93. DMTYHK4 RU https://pubmed.ncbi.nlm.nih.gov/1983011 DMTZ7E4 DI DMTZ7E4 DMTZ7E4 DN SC-106 DMTZ7E4 TI TT9V5JH DMTZ7E4 TN Phospholipase A2 (PLA2G1B) DMTZ7E4 MA Inhibitor DMTZ7E4 RN US patent application no. 6,673,908, Tumor necrosis factor receptor 2. DMTZ7E4 RU http://www.google.com/patents/US6673908 DMTZBXQ DI DMTZBXQ DMTZBXQ DN GSK-159797 DMTZBXQ TI TT2CJVK DMTZBXQ TN Adrenergic receptor beta-2 (ADRB2) DMTZBXQ MA Agonist DMTZBXQ RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMTZBXQ RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMTZBXQ DI DMTZBXQ DMTZBXQ DN GSK-159797 DMTZBXQ TI TTDW3Z2 DMTZBXQ TN Telomerase messenger RNA (Telomerase mRNA) DMTZBXQ RN Combination therapy of 2-5A antisense against telomerase RNA and cisplatin for malignant gliomas. Int J Oncol. 2001 Jun;18(6):1287-92. DMTZBXQ RU https://pubmed.ncbi.nlm.nih.gov/11351264 DMU4N1O DI DMU4N1O DMU4N1O DN IGN-2098 DMU4N1O TI TTQHJ1K DMU4N1O TN Histamine H2 receptor (H2R) DMU4N1O MA Antagonist DMU4N1O RN Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80. DMU4N1O RU https://pubmed.ncbi.nlm.nih.gov/1354631 DMU596F DI DMU596F DMU596F DN NMI-870 DMU596F TI TTWG9A4 DMU596F TN Adrenergic receptor alpha-2A (ADRA2A) DMU596F MA Modulator DMU596F RN Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269. DMU596F RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008577/ DMU596F DI DMU596F DMU596F DN NMI-870 DMU596F TI TT2NUT5 DMU596F TN Adrenergic receptor alpha-2C (ADRA2C) DMU596F MA Modulator DMU596F RN Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269. DMU596F RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3008577/ DMU5PFD DI DMU5PFD DMU5PFD DN Org-7797 DMU5PFD TI TTRK8B9 DMU5PFD TN Sodium channel unspecific (NaC) DMU5PFD MA Modulator DMU5PFD RN Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs. J Cardiovasc Pharmacol. 1989 Aug;14(2):205-12. DMU5PFD RU https://pubmed.ncbi.nlm.nih.gov/2476592 DMU5RKC DI DMU5RKC DMU5RKC DN SL65.0472 DMU5RKC TI TTJQOD7 DMU5RKC TN 5-HT 2A receptor (HTR2A) DMU5RKC MA Modulator DMU5RKC RN Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist.Thromb Haemost.2001 Mar;85(3):521-8. DMU5RKC RU https://www.ncbi.nlm.nih.gov/pubmed/11307825 DMU872N DI DMU872N DMU872N DN E-4031 DMU872N TI TT1VOHK DMU872N TN Potassium channel unspecific (KC) DMU872N MA Modulator DMU872N RN Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.Br J Pharmacol.2012 Jan;165(2):467-78. DMU872N RU https://www.ncbi.nlm.nih.gov/pubmed/21718297 DMUC9OS DI DMUC9OS DMUC9OS DN GSK-644784 DMUC9OS TI TTVKILB DMUC9OS TN Prostaglandin G/H synthase 2 (COX-2) DMUC9OS MA Inhibitor DMUC9OS RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMUC9OS RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMUD0IN DI DMUD0IN DMUD0IN DN FOZIVUDINE TIDOXIL DMUD0IN TI TT84ETX DMUD0IN TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMUD0IN MA Inhibitor DMUD0IN RN Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. J Vet Intern Med. 2011 May-Jun;25(3):413-8. DMUD0IN RU https://pubmed.ncbi.nlm.nih.gov/21457319 DMUG5OB DI DMUG5OB DMUG5OB DN CETi-1 DMUG5OB TI TTFQAYR DMUG5OB TN Cholesteryl ester transfer protein (CETP) DMUG5OB RN CETi-1. AVANT. Curr Opin Investig Drugs. 2004 Mar;5(3):334-8. DMUG5OB RU https://pubmed.ncbi.nlm.nih.gov/15083601 DMUJ2X6 DI DMUJ2X6 DMUJ2X6 DN Tiqueside DMUJ2X6 TI TTNA5ZS DMUJ2X6 TN Cholesterol absorption (Chole absorp) DMUJ2X6 MA Modulator DMUJ2X6 RN Inhibiting cholesterol absorption with CP-88,818 (beta-tigogenin cellobioside; tiqueside): studies in normal and hyperlipidemic subjects. J Cardiovasc Pharmacol. 1997 Jul;30(1):55-60. DMUJ2X6 RU https://pubmed.ncbi.nlm.nih.gov/9268221 DMUMGCY DI DMUMGCY DMUMGCY DN HP-290 DMUMGCY TI TT1RS9F DMUMGCY TN Acetylcholinesterase (AChE) DMUMGCY MA Inhibitor DMUMGCY RN NXX-066 in patients with Alzheimer's disease: a bridging study. Life Sci. 1999;64(14):1215-21. DMUMGCY RU https://pubmed.ncbi.nlm.nih.gov/10210264 DMUPJW4 DI DMUPJW4 DMUPJW4 DN CDP840 DMUPJW4 TI TTVIAT9 DMUPJW4 TN Phosphodiesterase 4B (PDE4B) DMUPJW4 MA Inhibitor DMUPJW4 RN Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. DMUPJW4 RU https://pubmed.ncbi.nlm.nih.gov/16168647 DMUPJW4 DI DMUPJW4 DMUPJW4 DN CDP840 DMUPJW4 TI TTZ97H5 DMUPJW4 TN Phosphodiesterase 4A (PDE4A) DMUPJW4 MA Inhibitor DMUPJW4 RN Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. DMUPJW4 RU https://pubmed.ncbi.nlm.nih.gov/16168647 DMUPJW4 DI DMUPJW4 DMUPJW4 DN CDP840 DMUPJW4 TI TTSKMI8 DMUPJW4 TN Phosphodiesterase 4D (PDE4D) DMUPJW4 MA Inhibitor DMUPJW4 RN Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. DMUPJW4 RU https://pubmed.ncbi.nlm.nih.gov/16168647 DMUQ6IL DI DMUQ6IL DMUQ6IL DN AVE-1642 DMUQ6IL TI TTHRID2 DMUQ6IL TN Insulin-like growth factor I receptor (IGF1R) DMUQ6IL RN Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growthfactor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5445-56. DMUQ6IL RU https://pubmed.ncbi.nlm.nih.gov/19706799 DMUQN83 DI DMUQN83 DMUQN83 DN FL-386 DMUQN83 TI TTZPS91 DMUQN83 TN Dihydrothymine dehydrogenase (DPYD) DMUQN83 MA Modulator DMUQN83 RN Effects of FL-386 on faecal lipid excretion in humans. J Int Med Res. 1993 Sep-Oct;21(5):225-33. DMUQN83 RU https://pubmed.ncbi.nlm.nih.gov/8112480 DMURWPH DI DMURWPH DMURWPH DN ISIS 104838 DMURWPH TI TTC97NF DMURWPH TN TNFA messenger RNA (TNF mRNA) DMURWPH RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMURWPH RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMUW6QX DI DMUW6QX DMUW6QX DN E-6123 DMUW6QX TI TTQL5VC DMUW6QX TN Platelet-activating factor receptor (PTAFR) DMUW6QX MA Modulator DMUW6QX RN Inhibitory effects of a novel PAF antagonist E6123 on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensiti... Prostaglandins. 1991 Dec;42(6):541-55. DMUW6QX RU https://www.ncbi.nlm.nih.gov/pubmed/1801063 DMUXMGN DI DMUXMGN DMUXMGN DN 4991W93 DMUXMGN TI TTRK8B9 DMUXMGN TN Sodium channel unspecific (NaC) DMUXMGN MA Modulator DMUXMGN RN CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010 Oct;6(10):573-82. DMUXMGN RU https://pubmed.ncbi.nlm.nih.gov/20820195 DMUZNF0 DI DMUZNF0 DMUZNF0 DN Tridolgosir DMUZNF0 TI TT34DCN DMUZNF0 TN Golgi alpha-mannosidase II (MAN2A1) DMUZNF0 MA Inhibitor DMUZNF0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010383) DMUZNF0 RU http://adisinsight.springer.com/drugs/800010383 DMV1ES3 DI DMV1ES3 DMV1ES3 DN AZALANSTAT DMV1ES3 TI TTTSOUD DMV1ES3 TN Candida Cytochrome P450 51 (Candi ERG11) DMV1ES3 MA Modulator DMV1ES3 RN Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity. Biochem Pharmacol. 1995 Aug 8;50(4):529-44. DMV1ES3 RU https://www.ncbi.nlm.nih.gov/pubmed/7646560 DMV2DIW DI DMV2DIW DMV2DIW DN BAY 10-00394 DMV2DIW TI TT7HF4W DMV2DIW TN Cyclin-dependent kinase 2 (CDK2) DMV2DIW MA Inhibitor DMV2DIW RN National Cancer Institute Drug Dictionary (drug id 770319). DMV2DIW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=770319 DMV2DIW DI DMV2DIW DMV2DIW DN BAY 10-00394 DMV2DIW TI TT1LVF2 DMV2DIW TN Cyclin-dependent kinase 9 (CDK9) DMV2DIW MA Inhibitor DMV2DIW RN National Cancer Institute Drug Dictionary (drug id 770319). DMV2DIW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=770319 DMV2DIW DI DMV2DIW DMV2DIW DN BAY 10-00394 DMV2DIW TI TT0PG8F DMV2DIW TN Cyclin-dependent kinase 4 (CDK4) DMV2DIW MA Inhibitor DMV2DIW RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DMV2DIW RU https://pubmed.ncbi.nlm.nih.gov/21253554 DMV2DIW DI DMV2DIW DMV2DIW DN BAY 10-00394 DMV2DIW TI TTH6V3D DMV2DIW TN Cyclin-dependent kinase 1 (CDK1) DMV2DIW MA Inhibitor DMV2DIW RN National Cancer Institute Drug Dictionary (drug id 770319). DMV2DIW RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=770319 DMV2DY3 DI DMV2DY3 DMV2DY3 DN CARIPORIDE DMV2DY3 TI TTGSEFH DMV2DY3 TN Sodium/hydrogen exchanger 1 (SLC9A1) DMV2DY3 MA Inhibitor DMV2DY3 RN Synthesis and bioactivity of substituted indan-1-ylideneaminoguanidine derivatives. Eur J Med Chem. 2009 Sep;44(9):3771-6. DMV2DY3 RU https://pubmed.ncbi.nlm.nih.gov/19482383 DMV2DY3 DI DMV2DY3 DMV2DY3 DN CARIPORIDE DMV2DY3 TI TTFZVPO DMV2DY3 TN Sodium/hydrogen exchanger 3 (SLC9A3) DMV2DY3 MA Inhibitor DMV2DY3 RN Bicyclic acylguanidine Na+/H+ antiporter inhibitors. J Med Chem. 1998 Sep 10;41(19):3736-47. DMV2DY3 RU https://pubmed.ncbi.nlm.nih.gov/9733499 DMV3UN4 DI DMV3UN4 DMV3UN4 DN JTC-801 DMV3UN4 TI TTNT7K8 DMV3UN4 TN Nociceptin receptor (OPRL1) DMV3UN4 MA Antagonist DMV3UN4 RN Nociceptin receptor antagonist JTC-801 inhibits nitrous oxide-induced analgesia in mice. J Anesth. 2009;23(2):301-3. DMV3UN4 RU https://pubmed.ncbi.nlm.nih.gov/19444578 DMV3Y8R DI DMV3Y8R DMV3Y8R DN BRL-61063 DMV3Y8R TI TTK25J1 DMV3Y8R TN Adenosine A1 receptor (ADORA1) DMV3Y8R MA Inhibitor DMV3Y8R RN Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine. J Med Chem. 1994 Feb 18;37(4):476-85. DMV3Y8R RU https://pubmed.ncbi.nlm.nih.gov/8120866 DMV3Y8R DI DMV3Y8R DMV3Y8R DN BRL-61063 DMV3Y8R TI TTJ0IQB DMV3Y8R TN Phosphodiesterase 5A (PDE5A) DMV3Y8R MA Inhibitor DMV3Y8R RN Inhibition of cyclic nucleotide phosphodiesterase by derivatives of 1,3-bis(cyclopropylmethyl)xanthine. J Med Chem. 1994 Feb 18;37(4):476-85. DMV3Y8R RU https://pubmed.ncbi.nlm.nih.gov/8120866 DMV4FT2 DI DMV4FT2 DMV4FT2 DN SR-57227 DMV4FT2 TI TTNXLKE DMV4FT2 TN 5-HT 3 receptor (5HT3R) DMV4FT2 MA Modulator DMV4FT2 RN Antidepressant-like effects of SR 57227A, a 5-HT3 receptor agonist, in rodents. J Neural Transm Gen Sect. 1995;102(2):83-90. DMV4FT2 RU https://pubmed.ncbi.nlm.nih.gov/8748673 DMV5FN1 DI DMV5FN1 DMV5FN1 DN NKS-01 DMV5FN1 TI TTSZLWK DMV5FN1 TN Aromatase (CYP19A1) DMV5FN1 MA Inhibitor DMV5FN1 RN Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer. 1999 Jun;6(2):197-204. DMV5FN1 RU https://pubmed.ncbi.nlm.nih.gov/10731109 DMVBGIT DI DMVBGIT DMVBGIT DN BMS-180448 DMVBGIT TI TT1VOHK DMVBGIT TN Potassium channel unspecific (KC) DMVBGIT MA Agonist DMVBGIT RN The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):444-51. DMVBGIT RU https://pubmed.ncbi.nlm.nih.gov/8897447 DMVBL25 DI DMVBL25 DMVBL25 DN ZD-6169 DMVBL25 TI TT1VOHK DMVBL25 TN Potassium channel unspecific (KC) DMVBL25 MA Opener DMVBL25 RN Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol. 2002 Aug;168(2):837-42. DMVBL25 RU https://pubmed.ncbi.nlm.nih.gov/12131377 DMVEGW6 DI DMVEGW6 DMVEGW6 DN MK-499 DMVEGW6 TI TTQ6VDM DMVEGW6 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMVEGW6 MA Inhibitor DMVEGW6 RN Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett. 2003 May 19;13(10):1829-35. DMVEGW6 RU https://pubmed.ncbi.nlm.nih.gov/12729675 DMVF2R1 DI DMVF2R1 DMVF2R1 DN Minopafant DMVF2R1 TI TTQL5VC DMVF2R1 TN Platelet-activating factor receptor (PTAFR) DMVF2R1 MA Antagonist DMVF2R1 RN Formation of spherical micelles composed of the novel platelet activating factor receptor antagonist, E5880. Pharm Dev Technol. 2005;10(1):11-6. DMVF2R1 RU https://pubmed.ncbi.nlm.nih.gov/15776809 DMVFCX7 DI DMVFCX7 DMVFCX7 DN ZD-2138 DMVFCX7 TI TTSJ6Q4 DMVFCX7 TN LOX-5 messenger RNA (ALOX5 mRNA) DMVFCX7 MA Inhibitor DMVFCX7 RN Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines. Bioorg Med Chem. 2010 Jun 1;18(11):3910-24. DMVFCX7 RU https://pubmed.ncbi.nlm.nih.gov/20451397 DMVH3I7 DI DMVH3I7 DMVH3I7 DN NM-135 DMVH3I7 TI TTYRL6O DMVH3I7 TN Glucocorticoid receptor (NR3C1) DMVH3I7 MA Modulator DMVH3I7 RN Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model. Jpn J Pharmacol. 1998 Dec;78(4):505-9. DMVH3I7 RU https://pubmed.ncbi.nlm.nih.gov/9920209 DMVHT6F DI DMVHT6F DMVHT6F DN Rispenzepine DMVHT6F TI TTZ9SOR DMVHT6F TN Muscarinic acetylcholine receptor M1 (CHRM1) DMVHT6F MA Antagonist DMVHT6F RN Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. Am J Respir Crit Care Med. 1995 Sep;152(3):872-8. DMVHT6F RU https://pubmed.ncbi.nlm.nih.gov/7663798 DMVM4NE DI DMVM4NE DMVM4NE DN OPM-3023 DMVM4NE TI TTOV74C DMVM4NE TN Bone metabolism (Bone metab) DMVM4NE MA Inhibitor DMVM4NE RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030958) DMVM4NE RU http://adisinsight.springer.com/drugs/800030958 DMVO9WM DI DMVO9WM DMVO9WM DN DG041 DMVO9WM TI TTPNGDE DMVO9WM TN Prostaglandin E2 receptor EP3 (PTGER3) DMVO9WM MA Antagonist DMVO9WM RN BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8. DMVO9WM RU https://pubmed.ncbi.nlm.nih.gov/17928652 DMVP4YK DI DMVP4YK DMVP4YK DN CB1954 DMVP4YK TI TTJLP0R DMVP4YK TN Quinone reductase 2 (NQO2) DMVP4YK MA Inhibitor DMVP4YK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVP4YK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVRJ8D DI DMVRJ8D DMVRJ8D DN NS-2389 DMVRJ8D TI TT3ROYC DMVRJ8D TN Serotonin transporter (SERT) DMVRJ8D MA Modulator DMVRJ8D RN Clinical pipeline report, company report or official report of Neurosearch. DMVRJ8D RU http://neurosearch.com/Default.aspx DMVRJ8D DI DMVRJ8D DMVRJ8D DN NS-2389 DMVRJ8D TI TTAWNKZ DMVRJ8D TN Norepinephrine transporter (NET) DMVRJ8D MA Modulator DMVRJ8D RN Clinical pipeline report, company report or official report of Neurosearch. DMVRJ8D RU http://neurosearch.com/Default.aspx DMVRJ8D DI DMVRJ8D DMVRJ8D DN NS-2389 DMVRJ8D TI TTVBI8W DMVRJ8D TN Dopamine transporter (DAT) DMVRJ8D MA Modulator DMVRJ8D RN Clinical pipeline report, company report or official report of Neurosearch. DMVRJ8D RU http://neurosearch.com/Default.aspx DMVU4A5 DI DMVU4A5 DMVU4A5 DN CRD-5 DMVU4A5 TI TT7GN3U DMVU4A5 TN Apolipoprotein A-I (APOA1) DMVU4A5 MA Stimulator DMVU4A5 RN Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. DMVU4A5 RU https://pubmed.ncbi.nlm.nih.gov/18537526 DMVXTZG DI DMVXTZG DMVXTZG DN MK-591 DMVXTZG TI TT2J34L DMVXTZG TN Arachidonate 5-lipoxygenase (5-LOX) DMVXTZG MA Inhibitor DMVXTZG RN Antileukotriene therapy for asthma. Am J Health Syst Pharm. 1996 Dec 1;53(23):2821-30; quiz 2877-8. DMVXTZG RU https://pubmed.ncbi.nlm.nih.gov/8957342 DMVZSRG DI DMVZSRG DMVZSRG DN AZD6370 DMVZSRG TI TTDLNGZ DMVZSRG TN Glucokinase (GCK) DMVZSRG MA Activator DMVZSRG RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMVZSRG RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMW05DS DI DMW05DS DMW05DS DN TNP-351 DMW05DS TI TTYZVDJ DMW05DS TN Dihydrofolate reductase (DHFR) DMW05DS MA Inhibitor DMW05DS RN A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction. J Org Chem. 1996 Nov 1;61(22):7973-7974. DMW05DS RU https://pubmed.ncbi.nlm.nih.gov/11667765 DMW1FT0 DI DMW1FT0 DMW1FT0 DN ORG-9273 DMW1FT0 TI TTJSZTB DMW1FT0 TN Nicotinic acetylcholine receptor (nAChR) DMW1FT0 MA Modulator DMW1FT0 RN Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent. Anesth Analg. 1991 Jun;72(6):811-6. DMW1FT0 RU https://pubmed.ncbi.nlm.nih.gov/1674648 DMW59FE DI DMW59FE DMW59FE DN Mitonafide DMW59FE TI TT0IHXV DMW59FE TN DNA topoisomerase II (TOP2) DMW59FE MA Modulator DMW59FE RN Effect of mitonafide analogs on topoisomerase II of Leishmania chagasi. Antimicrob Agents Chemother. 1996 Mar;40(3):706-9. DMW59FE RU https://pubmed.ncbi.nlm.nih.gov/8851597 DMW7LQT DI DMW7LQT DMW7LQT DN TM30339 DMW7LQT TI TTW4N16 DMW7LQT TN Neuropeptide Y receptor type 4 (NPY4R) DMW7LQT MA Agonist DMW7LQT RN Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev. 2007 Oct;28(6):664-84. DMW7LQT RU https://pubmed.ncbi.nlm.nih.gov/17785427 DMW8NOH DI DMW8NOH DMW8NOH DN L-771688 DMW8NOH TI TTNGILX DMW8NOH TN Adrenergic receptor alpha-1A (ADRA1A) DMW8NOH MA Inhibitor DMW8NOH RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMW8NOH RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMW9MOK DI DMW9MOK DMW9MOK DN Lomeguatrib DMW9MOK TI TTX2N1T DMW9MOK TN Transferase unspecific (TF) DMW9MOK MA Inhibitor DMW9MOK RN O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas. Cell Death Dis. 2013 Oct 24;4:e876. DMW9MOK RU https://pubmed.ncbi.nlm.nih.gov/24157870 DMWA957 DI DMWA957 DMWA957 DN Avarofloxacin DMWA957 TI TTIXTO3 DMWA957 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMWA957 MA Modulator DMWA957 RN Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. DMWA957 RU https://pubmed.ncbi.nlm.nih.gov/21911562 DMWB7DO DI DMWB7DO DMWB7DO DN LY-223982 DMWB7DO TI TTN53ZF DMWB7DO TN Leukotriene B4 receptor 1 (LTB4R) DMWB7DO MA Modulator DMWB7DO RN Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982. J Pharmacol Exp Ther. 1992 Dec;263(3):1009-14. DMWB7DO RU https://pubmed.ncbi.nlm.nih.gov/1335049 DMWCAQD DI DMWCAQD DMWCAQD DN P1A DMWCAQD TI TTHI19T DMWCAQD TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMWCAQD MA Modulator DMWCAQD RN IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs. 2009 Aug;10(8):838-44. DMWCAQD RU https://pubmed.ncbi.nlm.nih.gov/19649928 DMWCLZ6 DI DMWCLZ6 DMWCLZ6 DN PALOSURAN DMWCLZ6 TI TTW5UDX DMWCLZ6 TN Urotensin II receptor (UTS2R) DMWCLZ6 MA Inhibitor DMWCLZ6 RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DMWCLZ6 RU https://pubmed.ncbi.nlm.nih.gov/20043680 DMWDCG7 DI DMWDCG7 DMWDCG7 DN AP-521 DMWDCG7 TI TTSQIFT DMWDCG7 TN 5-HT 1A receptor (HTR1A) DMWDCG7 MA Agonist DMWDCG7 RN The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats. J Pharmacol Sci. 2015 Jan;127(1):109-16. DMWDCG7 RU https://pubmed.ncbi.nlm.nih.gov/25704026 DMWE6V1 DI DMWE6V1 DMWE6V1 DN Putrescine DMWE6V1 TI TTBFROQ DMWE6V1 TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMWE6V1 MA Inhibitor DMWE6V1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWE6V1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWE6V1 DI DMWE6V1 DMWE6V1 DN Putrescine DMWE6V1 TI TTUMGNO DMWE6V1 TN Ornithine decarboxylase (ODC1) DMWE6V1 MA Inhibitor DMWE6V1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWE6V1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWF95G DI DMWF95G DMWF95G DN E-3620 DMWF95G TI TT07C3Y DMWF95G TN 5-HT 4 receptor (HTR4) DMWF95G MA Modulator DMWF95G RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWF95G RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWF95G DI DMWF95G DMWF95G DN E-3620 DMWF95G TI TTNXLKE DMWF95G TN 5-HT 3 receptor (5HT3R) DMWF95G MA Modulator DMWF95G RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMWF95G RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMWH4CY DI DMWH4CY DMWH4CY DN HE-2000 DMWH4CY TI TTS64P2 DMWH4CY TN Androgen receptor (AR) DMWH4CY MA Inhibitor DMWH4CY RN Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J Neurobiol. 2003 Nov;57(2):163-71. DMWH4CY RU https://pubmed.ncbi.nlm.nih.gov/14556282 DMWHQM3 DI DMWHQM3 DMWHQM3 DN CDP-850 DMWHQM3 TI TTE5VG0 DMWHQM3 TN P-selectin (SELP) DMWHQM3 RN WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection. DMWHQM3 RU http://www.google.com/patents/WO2001027621A2?cl=en DMWIA56 DI DMWIA56 DMWIA56 DN E-4021 DMWIA56 TI TTJ0IQB DMWIA56 TN Phosphodiesterase 5A (PDE5A) DMWIA56 MA Inhibitor DMWIA56 RN Potency and mechanism of action of E4021, a type 5 phosphodiesterase isozyme-selective inhibitor, on the photoreceptor phosphodiesterase depend on the state of activation of the enzyme. Mol Pharmacol. 1999 Mar;55(3):508-14. DMWIA56 RU https://pubmed.ncbi.nlm.nih.gov/10051534 DMWJ245 DI DMWJ245 DMWJ245 DN ATX-201 DMWJ245 TI TTML2WA DMWJ245 TN Tubulin (TUB) DMWJ245 MA Inhibitor DMWJ245 RN Clinical pipeline report, company report or official report of Kythera Biopharmaceuticals. DMWJ245 RU http://www.kythera.com/kythera-biopharmaceuticals-announces-discontinuation-of-actinic-keratosis-clinical-program/ DMWKJCB DI DMWKJCB DMWKJCB DN AP-5346 DMWKJCB TI TTUTN1I DMWKJCB TN Human Deoxyribonucleic acid (hDNA) DMWKJCB MA Inhibitor DMWKJCB RN Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2248-54. DMWKJCB RU https://pubmed.ncbi.nlm.nih.gov/16609041 DMWN09H DI DMWN09H DMWN09H DN Istaroxime DMWN09H TI TTQ38E9 DMWN09H TN Sodium/potassium-transporting ATPase (SPT ATPase) DMWN09H MA Inhibitor DMWN09H RN Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship. J Med Chem. 2008 Aug 14;51(15):4601-8. DMWN09H RU https://pubmed.ncbi.nlm.nih.gov/18637667 DMWOT92 DI DMWOT92 DMWOT92 DN ZOPOLRESTAT DMWOT92 TI TTFBNVI DMWOT92 TN Aldose reductase (AKR1B1) DMWOT92 MA Modulator DMWOT92 RN Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx. Pharmacology. 1997 Feb;54(2):76-83. DMWOT92 RU https://www.ncbi.nlm.nih.gov/pubmed/9088040 DMWROJ5 DI DMWROJ5 DMWROJ5 DN NCX-701 DMWROJ5 TI TTK0943 DMWROJ5 TN Prostaglandin G/H synthase (COX) DMWROJ5 MA Modulator DMWROJ5 RN Antinociceptive effects of NCX-701 (nitro-paracetamol) in neuropathic rats: enhancement of antinociception by co-administration with gabapentin. Br J Pharmacol. 2009 September; 158(2): 601-609. DMWROJ5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757700/ DMWRT4L DI DMWRT4L DMWRT4L DN YM-90K DMWRT4L TI TT0MYE2 DMWRT4L TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMWRT4L MA Inhibitor DMWRT4L RN 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. DMWRT4L RU https://pubmed.ncbi.nlm.nih.gov/10843235 DMWRT4L DI DMWRT4L DMWRT4L DN YM-90K DMWRT4L TI TTVPQTF DMWRT4L TN Glutamate receptor AMPA 1 (GRIA1) DMWRT4L MA Inhibitor DMWRT4L RN Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11. DMWRT4L RU https://pubmed.ncbi.nlm.nih.gov/15380209 DMWRT4L DI DMWRT4L DMWRT4L DN YM-90K DMWRT4L TI TTLD29N DMWRT4L TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMWRT4L MA Inhibitor DMWRT4L RN 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. DMWRT4L RU https://pubmed.ncbi.nlm.nih.gov/10843235 DMWRT4L DI DMWRT4L DMWRT4L DN YM-90K DMWRT4L TI TTKJEMQ DMWRT4L TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMWRT4L MA Inhibitor DMWRT4L RN 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. DMWRT4L RU https://pubmed.ncbi.nlm.nih.gov/10843235 DMWRT4L DI DMWRT4L DMWRT4L DN YM-90K DMWRT4L TI TTAN6JD DMWRT4L TN Glutamate receptor AMPA (GRIA) DMWRT4L MA Inhibitor DMWRT4L RN Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11. DMWRT4L RU https://pubmed.ncbi.nlm.nih.gov/15380209 DMWRT4L DI DMWRT4L DMWRT4L DN YM-90K DMWRT4L TI TTN9D8E DMWRT4L TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMWRT4L MA Inhibitor DMWRT4L RN 4,10-Dihydro-4-oxo-4H-imidazo[1,2-a]indeno[1,2-e]pyrazin-2-carboxylic acid derivatives: highly potent and selective AMPA receptors antagonists with... Bioorg Med Chem Lett. 2000 May 15;10(10):1133-7. DMWRT4L RU https://pubmed.ncbi.nlm.nih.gov/10843235 DMWS7C2 DI DMWS7C2 DMWS7C2 DN ONO-5334 DMWS7C2 TI TTDZN01 DMWS7C2 TN Cathepsin K (CTSK) DMWS7C2 MA Inhibitor DMWS7C2 RN New approach for osteoporosis treatment: cathepsin K inhibitor, ONO-5334. Clin Calcium. 2011 Jan;21(1):64-9. DMWS7C2 RU https://pubmed.ncbi.nlm.nih.gov/21187596 DMWTLQ4 DI DMWTLQ4 DMWTLQ4 DN SUN-1334H DMWTLQ4 TI TTTIBOJ DMWTLQ4 TN Histamine H1 receptor (H1R) DMWTLQ4 MA Antagonist DMWTLQ4 RN Preclinical efficacy and safety pharmacology of SUN-1334H, a potent orally active antihistamine agent. Drugs R D. 2008;9(2):93-112. DMWTLQ4 RU https://pubmed.ncbi.nlm.nih.gov/18298128 DMWVPEU DI DMWVPEU DMWVPEU DN Tallimustine DMWVPEU TI TTUTN1I DMWVPEU TN Human Deoxyribonucleic acid (hDNA) DMWVPEU MA Modulator DMWVPEU RN Sequence-specific DNA alkylation of novel tallimustine derivatives. Anticancer Drug Des. 1998 Apr;13(3):193-205. DMWVPEU RU https://www.ncbi.nlm.nih.gov/pubmed/9595033 DMWXOJN DI DMWXOJN DMWXOJN DN TT-62 DMWXOJN TI TTU6BFZ DMWXOJN TN Candida Thymidylate synthase (Candi TMP1) DMWXOJN MA Inhibitor DMWXOJN RN TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES. Future Oncology. AUGUST 1995. VOLUME 1, NUMBER 4. DMWXOJN RU http://www.oncologyknowledgebase.net/futureoncology/pdfs/Future_Oncology.Vol.1.No.4.pdf DMWYJHC DI DMWYJHC DMWYJHC DN PF-4480682 DMWYJHC TI TTGXH6N DMWYJHC TN GABA(A) receptor delta (GABRD) DMWYJHC MA Modulator DMWYJHC RN WO patent application no. 2014,1515,17, Methods of improving microvascular integrity. DMWYJHC RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140925&CC=WO&NR=2014151517A1&KC=A1 DMWYJHC DI DMWYJHC DMWYJHC DN PF-4480682 DMWYJHC TI TTBMV1G DMWYJHC TN GABA(A) receptor alpha-2 (GABRA2) DMWYJHC MA Modulator DMWYJHC RN WO patent application no. 2014,1515,17, Methods of improving microvascular integrity. DMWYJHC RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20140925&CC=WO&NR=2014151517A1&KC=A1 DMWZXF7 DI DMWZXF7 DMWZXF7 DN ORG-33628 DMWZXF7 TI TTHL6YX DMWZXF7 TN Progesterone (PG) DMWZXF7 MA Modulator DMWZXF7 RN ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens. Semin Reprod Med. 2005 Feb;23(1):101-11. DMWZXF7 RU https://pubmed.ncbi.nlm.nih.gov/15714394 DMX0Z51 DI DMX0Z51 DMX0Z51 DN Gallium maltolate DMX0Z51 TI TTBWDI0 DMX0Z51 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMX0Z51 MA Binder DMX0Z51 RN Gallium maltolate is a promising chemotherapeutic agent for the treatment of hepatocellular carcinoma. Anticancer Res. 2006 May-Jun;26(3A):1739-43. DMX0Z51 RU https://pubmed.ncbi.nlm.nih.gov/16827101 DMX32RC DI DMX32RC DMX32RC DN Transdur-sufentanil DMX32RC TI TTKWM86 DMX32RC TN Opioid receptor mu (MOP) DMX32RC MA Agonist DMX32RC RN [3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983 Feb 18;87(2-3):209-25. DMX32RC RU https://pubmed.ncbi.nlm.nih.gov/6132825 DMX4938 DI DMX4938 DMX4938 DN SDZ-LAP-977 DMX4938 TI TTJSQEF DMX4938 TN Tyrosine-protein kinase (PTK) DMX4938 MA Inhibitor DMX4938 RN Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications. Bioorg Med Chem. 2008 Aug 15;16(16):7552-60. DMX4938 RU https://pubmed.ncbi.nlm.nih.gov/18678497 DMX4ZWK DI DMX4ZWK DMX4ZWK DN REC-15-2739 DMX4ZWK TI TT34BHT DMX4ZWK TN Adrenergic receptor alpha-1D (ADRA1D) DMX4ZWK MA Modulator DMX4ZWK RN Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther. 1996 Jun;277(3):1237-46. DMX4ZWK RU https://pubmed.ncbi.nlm.nih.gov/8667184 DMX4ZWK DI DMX4ZWK DMX4ZWK DN REC-15-2739 DMX4ZWK TI TTNGILX DMX4ZWK TN Adrenergic receptor alpha-1A (ADRA1A) DMX4ZWK MA Inhibitor DMX4ZWK RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMX4ZWK RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMX56G4 DI DMX56G4 DMX56G4 DN A-5021 DMX56G4 TI TTF1HYB DMX56G4 TN Herpesvirus DNA polymerase (KSHV DNAP) DMX56G4 MA Modulator DMX56G4 RN Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus. Antimicrob Agents Chemother. 1998 Aug;42(8):2095-102. DMX56G4 RU https://pubmed.ncbi.nlm.nih.gov/9687413 DMX6GFR DI DMX6GFR DMX6GFR DN Omega interferon DMX6GFR TI TTSYFMA DMX6GFR TN Interferon alpha/beta receptor 1 (IFNAR1) DMX6GFR MA Modulator DMX6GFR RN Human interferon omega--a review. Mult Scler. 1995;1 Suppl 1:S44-7. DMX6GFR RU https://pubmed.ncbi.nlm.nih.gov/9345398 DMX6ZYE DI DMX6ZYE DMX6ZYE DN Tarazepide DMX6ZYE TI TTCG0AL DMX6ZYE TN Cholecystokinin receptor type A (CCKAR) DMX6ZYE MA Antagonist DMX6ZYE RN Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 2007 Dec;58 Suppl 6:65-80. DMX6ZYE RU https://pubmed.ncbi.nlm.nih.gov/18212401 DMX7DVH DI DMX7DVH DMX7DVH DN GSK163090 DMX7DVH TI TTSQIFT DMX7DVH TN 5-HT 1A receptor (HTR1A) DMX7DVH MA Antagonist DMX7DVH RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMX7DVH RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMX9KYW DI DMX9KYW DMX9KYW DN NTx-488 DMX9KYW TI TTJ2TSA DMX9KYW TN Prolactin (PRL) DMX9KYW MA Modulator DMX9KYW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028330) DMX9KYW RU http://adisinsight.springer.com/drugs/800028330 DMX9M53 DI DMX9M53 DMX9M53 DN KDS-2000 DMX9M53 TI TT6OEDT DMX9M53 TN Cannabinoid receptor 1 (CB1) DMX9M53 MA Agonist DMX9M53 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMX9M53 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMXFQS1 DI DMXFQS1 DMXFQS1 DN SB-756050 DMXFQS1 TI TTS4UGC DMXFQS1 TN Farnesoid X-activated receptor (FXR) DMXFQS1 MA Agonist DMXFQS1 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMXFQS1 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMXNK0J DI DMXNK0J DMXNK0J DN AVE1625 DMXNK0J TI TT6OEDT DMXNK0J TN Cannabinoid receptor 1 (CB1) DMXNK0J MA Antagonist DMXNK0J RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DMXNK0J RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DMXNQLU DI DMXNQLU DMXNQLU DN TM30338 DMXNQLU TI TTJ6WK9 DMXNQLU TN Neuropeptide Y receptor type 2 (NPY2R) DMXNQLU MA Modulator DMXNQLU RN Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108) DMXNQLU RU https://books.google.com.hk/books?id=lc4WdvCmD54C&pg=PA108&lpg=PA108&dq=obinepitide++agonist%27&source=bl&ots=8jUZzCOibY&sig=RbRzNpJyEKp_V0-bNYHEwcTnPL8&hl=zh-CN&sa=X#v=onepage&q=obinepitide%20%20agonist%27&f=false DMXNQLU DI DMXNQLU DMXNQLU DN TM30338 DMXNQLU TI TTW4N16 DMXNQLU TN Neuropeptide Y receptor type 4 (NPY4R) DMXNQLU MA Modulator DMXNQLU RN Anti-Obesity Drug Discovery and Development, Atta-ur- Rahman, page(108) DMXNQLU RU https://books.google.com.hk/books?id=lc4WdvCmD54C&pg=PA108&lpg=PA108&dq=obinepitide++agonist%27&source=bl&ots=8jUZzCOibY&sig=RbRzNpJyEKp_V0-bNYHEwcTnPL8&hl=zh-CN&sa=X#v=onepage&q=obinepitide%20%20agonist%27&f=false DMXO49B DI DMXO49B DMXO49B DN CE-326597 DMXO49B TI TTCG0AL DMXO49B TN Cholecystokinin receptor type A (CCKAR) DMXO49B MA Agonist DMXO49B RN Obesity Pharmacotherapy: Current Perspectives and Future Directions. Curr Cardiol Rev. 2013 February; 9(1): 33-54. DMXO49B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584306/ DMXO9BQ DI DMXO9BQ DMXO9BQ DN Daxalipram DMXO9BQ TI TTSKMI8 DMXO9BQ TN Phosphodiesterase 4D (PDE4D) DMXO9BQ MA Inhibitor DMXO9BQ RN Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci. 2014 May 27;8:129. DMXO9BQ RU https://pubmed.ncbi.nlm.nih.gov/24904269 DMXO9BQ DI DMXO9BQ DMXO9BQ DN Daxalipram DMXO9BQ TI TTVIAT9 DMXO9BQ TN Phosphodiesterase 4B (PDE4B) DMXO9BQ MA Inhibitor DMXO9BQ RN Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci. 2014 May 27;8:129. DMXO9BQ RU https://pubmed.ncbi.nlm.nih.gov/24904269 DMXO9BQ DI DMXO9BQ DMXO9BQ DN Daxalipram DMXO9BQ TI TTZ97H5 DMXO9BQ TN Phosphodiesterase 4A (PDE4A) DMXO9BQ MA Inhibitor DMXO9BQ RN Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J mice. Front Neurosci. 2014 May 27;8:129. DMXO9BQ RU https://pubmed.ncbi.nlm.nih.gov/24904269 DMXQCBU DI DMXQCBU DMXQCBU DN Valtorcitabine DMXQCBU TI TTT4SY6 DMXQCBU TN Hepatitis B virus Polymerase (HBV P) DMXQCBU MA Inhibitor DMXQCBU RN Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci. 2008 Mar;97(3):1109-34. DMXQCBU RU https://pubmed.ncbi.nlm.nih.gov/17696166 DMXZVPH DI DMXZVPH DMXZVPH DN SEGLITIDE DMXZVPH TI TTOMNR9 DMXZVPH TN Somatostatin receptor (SSTR) DMXZVPH MA Modulator DMXZVPH RN Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899. DMXZVPH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2175736/ DMY30G2 DI DMY30G2 DMY30G2 DN SILPERISONE HYDROCHLORIDE DMY30G2 TI TTRK8B9 DMY30G2 TN Sodium channel unspecific (NaC) DMY30G2 MA Modulator DMY30G2 RN Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage-gated sodium and calcium channels. J Pharmacol Exp Ther. 2005 Dec;315(3):1237-46. DMY30G2 RU https://pubmed.ncbi.nlm.nih.gov/16126840 DMY3M0J DI DMY3M0J DMY3M0J DN DAT-582 DMY3M0J TI TTNXLKE DMY3M0J TN 5-HT 3 receptor (5HT3R) DMY3M0J MA Antagonist DMY3M0J RN 5-HT3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370. Eur J Pharmacol. 1992 Jun 17;216(3):435-40. DMY3M0J RU https://pubmed.ncbi.nlm.nih.gov/1425931 DMY40KZ DI DMY40KZ DMY40KZ DN Tomeglovir DMY40KZ TI TTIU7X1 DMY40KZ TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMY40KZ MA Inhibitor DMY40KZ RN Focus on new drugs in development against human cytomegalovirus. Drugs. 2002;62(13):1853-8. DMY40KZ RU https://pubmed.ncbi.nlm.nih.gov/12215056 DMY8X6Q DI DMY8X6Q DMY8X6Q DN ICI-192605 DMY8X6Q TI TT2O84V DMY8X6Q TN Thromboxane A2 receptor (TBXA2R) DMY8X6Q MA Antagonist DMY8X6Q RN The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheumatol Int. 1991;11(4-5):163-8. DMY8X6Q RU https://pubmed.ncbi.nlm.nih.gov/1838424 DMYCLZR DI DMYCLZR DMYCLZR DN Norelin DMYCLZR TI TT0ID4A DMYCLZR TN Leutinizing-hormone-releasing hormone (GNRH1) DMYCLZR MA Inhibitor DMYCLZR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011623) DMYCLZR RU http://adisinsight.springer.com/drugs/800011623 DMYDWHN DI DMYDWHN DMYDWHN DN Romergoline DMYDWHN TI TTEX248 DMYDWHN TN Dopamine D2 receptor (D2R) DMYDWHN MA Modulator DMYDWHN RN CA patent application no. 648479, Implants for the treatment of dopamine associated states. DMYDWHN RU https://www.google.com.ar/patents/CA2648479A1?cl=en&hl=zh-CN DMYH2PU DI DMYH2PU DMYH2PU DN TIBENELAST DMYH2PU TI TTUST1O DMYH2PU TN Phosphodiesterase (PDE) DMYH2PU MA Inhibitor DMYH2PU RN Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7. DMYH2PU RU https://pubmed.ncbi.nlm.nih.gov/8382824 DMYJ1ZB DI DMYJ1ZB DMYJ1ZB DN HN-10200 DMYJ1ZB TI TTUST1O DMYJ1ZB TN Phosphodiesterase (PDE) DMYJ1ZB MA Inhibitor DMYJ1ZB RN HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65. DMYJ1ZB RU https://pubmed.ncbi.nlm.nih.gov/1382554 DMYJ28R DI DMYJ28R DMYJ28R DN Deriglidole DMYJ28R TI TT2NUT5 DMYJ28R TN Adrenergic receptor alpha-2C (ADRA2C) DMYJ28R MA Modulator DMYJ28R RN Mechanisms of the hypoglycemic effects of the alpha2-adrenoceptor antagonists SL84.0418 and deriglidole. Life Sci. 1998;62(9):839-52. DMYJ28R RU https://pubmed.ncbi.nlm.nih.gov/9496702 DMYJ28R DI DMYJ28R DMYJ28R DN Deriglidole DMYJ28R TI TT34BHT DMYJ28R TN Adrenergic receptor alpha-1D (ADRA1D) DMYJ28R MA Modulator DMYJ28R RN Mechanisms of the hypoglycemic effects of the alpha2-adrenoceptor antagonists SL84.0418 and deriglidole. Life Sci. 1998;62(9):839-52. DMYJ28R RU https://pubmed.ncbi.nlm.nih.gov/9496702 DMYJ9CF DI DMYJ9CF DMYJ9CF DN H-409/22 DMYJ9CF TI TTRK9JT DMYJ9CF TN Neuropeptide Y receptor type 1 (NPY1R) DMYJ9CF MA Antagonist DMYJ9CF RN In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25. DMYJ9CF RU https://pubmed.ncbi.nlm.nih.gov/11026655 DMYM8OG DI DMYM8OG DMYM8OG DN OPC-28326 DMYM8OG TI TT34BHT DMYM8OG TN Adrenergic receptor alpha-1D (ADRA1D) DMYM8OG MA Antagonist DMYM8OG RN Mechanisms of action of OPC-28326, a selective hindlimb vasodilator. J Pharmacol Exp Ther. 1999 Nov;291(2):604-11. DMYM8OG RU https://pubmed.ncbi.nlm.nih.gov/10525078 DMYM9JL DI DMYM9JL DMYM9JL DN PT-14 DMYM9JL TI TTD0CIQ DMYM9JL TN Melanocortin receptor 4 (MC4R) DMYM9JL MA Agonist DMYM9JL RN The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51. DMYM9JL RU https://pubmed.ncbi.nlm.nih.gov/24290566 DMYN6G0 DI DMYN6G0 DMYN6G0 DN TGP-580 DMYN6G0 TI TTGKIED DMYN6G0 TN Fibroblast growth factor-2 (FGF2) DMYN6G0 MA Modulator DMYN6G0 RN Expression of fibroblast growth factor-2 transcripts in the healing of acetic acid-induced gastric ulcers. APMIS. 1999 Aug;107(8):767-72. DMYN6G0 RU https://pubmed.ncbi.nlm.nih.gov/10515127 DMYOG98 DI DMYOG98 DMYOG98 DN 534U87 DMYOG98 TI TTRK8B9 DMYOG98 TN Sodium channel unspecific (NaC) DMYOG98 MA Modulator DMYOG98 RN The anticonvulsant BW534U87 depresses epileptiform activity in rat hippocampal slices by an adenosine-dependent mechanism and through inhibition of voltage-gated Na+ channels. Br J Pharmacol. 1999 Nov;128(5):1011-20. DMYOG98 RU https://pubmed.ncbi.nlm.nih.gov/10556938 DMYP3KI DI DMYP3KI DMYP3KI DN SINOMENINE DMYP3KI TI TTFQVUT DMYP3KI TN NADPH oxidase (NOX) DMYP3KI MA Modulator DMYP3KI RN Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J Neuroinflammation. 2007 Sep 19;4:23. DMYP3KI RU https://pubmed.ncbi.nlm.nih.gov/17880684 DMYR2U3 DI DMYR2U3 DMYR2U3 DN Lurosetron DMYR2U3 TI TTNXLKE DMYR2U3 TN 5-HT 3 receptor (5HT3R) DMYR2U3 MA Modulator DMYR2U3 RN US patent application no. 7,932,267, Use of α-glucosidase inhibitors to treat alphavirus infections. DMYR2U3 RU http://www.google.is/Patents/US7932267 DMYR5OX DI DMYR5OX DMYR5OX DN EREMOMYCIN DMYR5OX TI TTXT4D5 DMYR5OX TN Bacterial Cell membrane (Bact CM) DMYR5OX MA Modulator DMYR5OX RN Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics. J Med Chem. 2003 Mar 27;46(7):1204-9. DMYR5OX RU https://pubmed.ncbi.nlm.nih.gov/12646030 DMYSADI DI DMYSADI DMYSADI DN RBx10558 DMYSADI TI TTPADOQ DMYSADI TN HMG-CoA reductase (HMGCR) DMYSADI MA Inhibitor DMYSADI RN New Frontiers in the Treatment of Diabetic Dyslipidemia. Rev Diabet Stud. 2013 Summer-Fall; 10(2-3): 204-212. DMYSADI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063101/ DMZ1SEW DI DMZ1SEW DMZ1SEW DN KRN-2391 DMZ1SEW TI TTEF5MJ DMZ1SEW TN ATP-binding cassette transporter C9 (ABCC9) DMZ1SEW MA Modulator DMZ1SEW RN Effects of KRN2391 on ionic currents in rabbit femoral arterial myocytes DMZ1SEW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572643 DMZ2OBD DI DMZ2OBD DMZ2OBD DN GW-493838 DMZ2OBD TI TTK25J1 DMZ2OBD TN Adenosine A1 receptor (ADORA1) DMZ2OBD MA Modulator DMZ2OBD RN A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10. DMZ2OBD RU https://pubmed.ncbi.nlm.nih.gov/19012505 DMZ76EM DI DMZ76EM DMZ76EM DN CP-316,311 DMZ76EM TI TT7EFHR DMZ76EM TN Corticotropin-releasing factor receptor 1 (CRHR1) DMZ76EM MA Antagonist DMZ76EM RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMZ76EM RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMZ7WKN DI DMZ7WKN DMZ7WKN DN Adyvia DMZ7WKN TI TTHBTOP DMZ7WKN TN PI3-kinase gamma (PIK3CG) DMZ7WKN MA Modulator DMZ7WKN RN Insulinotropic agent ID-1101 (4-hydroxyisoleucine) activates insulin signaling in rat.Am J Physiol Endocrinol Metab.2004 Sep;287(3):E463-71. DMZ7WKN RU https://www.ncbi.nlm.nih.gov/pubmed/15082420 DMZ8VI0 DI DMZ8VI0 DMZ8VI0 DN SUN-C5174 DMZ8VI0 TI TTYSN63 DMZ8VI0 TN 5-HT 2 receptor (5HT2R) DMZ8VI0 MA Antagonist DMZ8VI0 RN Synthesis and serotonin 2 (5-HT2) receptor antagonist activity of 5-aminoalkyl-substituted pyrrolo[3,2-c]azepines and related compounds. Chem Pharm Bull (Tokyo). 2000 May;48(5):623-35. DMZ8VI0 RU https://pubmed.ncbi.nlm.nih.gov/10823697 DMZ98Y4 DI DMZ98Y4 DMZ98Y4 DN TRO-40303 DMZ98Y4 TI TTPTXIN DMZ98Y4 TN Translocator protein (TSPO) DMZ98Y4 MA Modulator DMZ98Y4 RN Translation of TRO40303 from myocardial infarction models to demonstration of safety and tolerance in a randomized Phase I trial. J Transl Med. 2014; 12: 38. DMZ98Y4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923730/ DMZA06U DI DMZA06U DMZA06U DN TOPIXANTRONE HYDROCHLORIDE DMZA06U TI TTUTN1I DMZA06U TN Human Deoxyribonucleic acid (hDNA) DMZA06U MA Inhibitor DMZA06U RN Clinical pipeline report, company report or official report of CTI BioPharma. DMZA06U RU http://www.ctibiopharma.com/pipeline/pixantrone/ DMZAISC DI DMZAISC DMZAISC DN Robalzotan DMZAISC TI TTSQIFT DMZAISC TN 5-HT 1A receptor (HTR1A) DMZAISC MA Antagonist DMZAISC RN Use of PET and the radioligand [carbonyl-(11)C]WAY-100635 in psychotropic drug development. Nucl Med Biol. 2000 Jul;27(5):515-21. DMZAISC RU https://pubmed.ncbi.nlm.nih.gov/10962260 DMZD023 DI DMZD023 DMZD023 DN GV-150013 DMZD023 TI TTVFO0U DMZD023 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMZD023 MA Antagonist DMZD023 RN The role of cholecystokinin (CCK), CCK-A or CCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp Clin Pharmacol. 1998 Oct;20(8):679-97. DMZD023 RU https://pubmed.ncbi.nlm.nih.gov/9922984 DMZEMG6 DI DMZEMG6 DMZEMG6 DN Atiratecan DMZEMG6 TI TTGTQHC DMZEMG6 TN DNA topoisomerase I (TOP1) DMZEMG6 MA Inhibitor DMZEMG6 RN Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30):3415-22. DMZEMG6 RU https://pubmed.ncbi.nlm.nih.gov/21975380 DMZEV63 DI DMZEV63 DMZEV63 DN Org-9731 DMZEV63 TI TTZCG4L DMZEV63 TN Phosphodiesterase 3 (PDE3) DMZEV63 MA Modulator DMZEV63 RN Effects of a novel cardiotonic agent, Org 9731, on force and aequorin light transients in intact ventricular myocardium of the dog: involvement of ... J Card Fail. 1995 Mar;1(2):143-53. DMZEV63 RU https://www.ncbi.nlm.nih.gov/pubmed/9420644 DMZFS69 DI DMZFS69 DMZFS69 DN ISIS 3521 DMZFS69 TI TTFJ8Q1 DMZFS69 TN Protein kinase C alpha (PRKCA) DMZFS69 MA Modulator DMZFS69 RN Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80. DMZFS69 RU https://www.ncbi.nlm.nih.gov/pubmed/16507327 DMZKBU9 DI DMZKBU9 DMZKBU9 DN EPC-K1 DMZKBU9 TI TT9V5JH DMZKBU9 TN Phospholipase A2 (PLA2G1B) DMZKBU9 MA Inhibitor DMZKBU9 RN Posttreatment with EPC-K1, an inhibitor of lipid peroxidation and of phospholipase A2 activity, reduces functional deficits after global ischemia in rats. Brain Res Bull. 1995;36(3):257-60. DMZKBU9 RU https://pubmed.ncbi.nlm.nih.gov/7697379 DMZLIUQ DI DMZLIUQ DMZLIUQ DN Cromafiban DMZLIUQ TI TT38RM1 DMZLIUQ TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMZLIUQ MA Modulator DMZLIUQ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMZLIUQ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMZMQDN DI DMZMQDN DMZMQDN DN NK-1001 DMZMQDN TI TTHYBIX DMZMQDN TN Heat shock protein 70 (HSP70) DMZMQDN MA Modulator DMZMQDN RN Novel therapeutic targets in the management of atrial fibrillation. Am J Cardiovasc Drugs. 2014 Dec;14(6):403-21. DMZMQDN RU https://pubmed.ncbi.nlm.nih.gov/25090973 DMZMQDN DI DMZMQDN DMZMQDN DN NK-1001 DMZMQDN TI TTMG98T DMZMQDN TN Heat shock protein 27 (HSP27) DMZMQDN MA Modulator DMZMQDN RN Novel therapeutic targets in the management of atrial fibrillation. Am J Cardiovasc Drugs. 2014 Dec;14(6):403-21. DMZMQDN RU https://pubmed.ncbi.nlm.nih.gov/25090973 DMZR6GI DI DMZR6GI DMZR6GI DN Sch-34826 DMZR6GI TI TT5TKPM DMZR6GI TN Neutral endopeptidase (MME) DMZR6GI MA Modulator DMZR6GI RN Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic. J Pharmacol Exp Ther. 1988 Jun;245(3):829-38. DMZR6GI RU https://pubmed.ncbi.nlm.nih.gov/3164388 DMZRW5E DI DMZRW5E DMZRW5E DN AGN211745 DMZRW5E TI TTPFN62 DMZRW5E TN VEGFR2 messenger RNA (VEGFR2 mRNA) DMZRW5E RN Teaming up to tackle RNAi delivery challenge. Nat Rev Drug Discov. 2009 Jul;8(7):525-6. DMZRW5E RU https://pubmed.ncbi.nlm.nih.gov/19568274 DMZS2M4 DI DMZS2M4 DMZS2M4 DN ADX-10061 DMZS2M4 TI TTZFYLI DMZS2M4 TN Dopamine D1 receptor (D1R) DMZS2M4 MA Antagonist DMZS2M4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001476) DMZS2M4 RU http://adisinsight.springer.com/drugs/800001476 DMZTL7H DI DMZTL7H DMZTL7H DN T487 DMZTL7H TI TT1UCIJ DMZTL7H TN C-X-C chemokine receptor type 3 (CXCR3) DMZTL7H MA Antagonist DMZTL7H RN Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71. DMZTL7H RU https://pubmed.ncbi.nlm.nih.gov/15761110 DMZXRF2 DI DMZXRF2 DMZXRF2 DN Eflucimibe DMZXRF2 TI TTMF541 DMZXRF2 TN Liver carboxylesterase (CES1) DMZXRF2 MA Inhibitor DMZXRF2 RN Prospects for drug therapy for hyperlipoproteinaemia. Diabete Metab. 1995 Apr;21(2):139-46. DMZXRF2 RU https://pubmed.ncbi.nlm.nih.gov/7621974 DMZYGW0 DI DMZYGW0 DMZYGW0 DN SM-10661 DMZYGW0 TI TTQL5VC DMZYGW0 TN Platelet-activating factor receptor (PTAFR) DMZYGW0 MA Antagonist DMZYGW0 RN Effect of the PAF-receptor antagonist SM-12502 on human platelets. Inflammation. 1996 Feb;20(1):71-85. DMZYGW0 RU https://pubmed.ncbi.nlm.nih.gov/8926050 DM17GMN DI DM17GMN DM17GMN DN EG-011 DM17GMN TI TTOM5H4 DM17GMN TN Vascular endothelial growth factor D (VEGFD) DM17GMN MA Modulator DM17GMN RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030807) DM17GMN RU http://adisinsight.springer.com/drugs/800030807 DM3P84V DI DM3P84V DM3P84V DN AVE-5883 DM3P84V TI TTZPO1L DM3P84V TN Substance-P receptor (TACR1) DM3P84V MA Modulator DM3P84V RN Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007 Mar 1;175(5):450-7. DM3P84V RU https://pubmed.ncbi.nlm.nih.gov/17170385 DM3P84V DI DM3P84V DM3P84V DN AVE-5883 DM3P84V TI TTYO0A3 DM3P84V TN Substance-K receptor (TACR2) DM3P84V MA Modulator DM3P84V RN Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma. Am J Respir Crit Care Med. 2007 Mar 1;175(5):450-7. DM3P84V RU https://pubmed.ncbi.nlm.nih.gov/17170385 DM7JMVR DI DM7JMVR DM7JMVR DN EG-016 DM7JMVR TI TTOM5H4 DM7JMVR TN Vascular endothelial growth factor D (VEGFD) DM7JMVR MA Modulator DM7JMVR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030807) DM7JMVR RU http://adisinsight.springer.com/drugs/800030807 DM7L8SG DI DM7L8SG DM7L8SG DN AZD8055 DM7L8SG TI TTCJG29 DM7L8SG TN Serine/threonine-protein kinase mTOR (mTOR) DM7L8SG MA Inhibitor DM7L8SG RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM7L8SG RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM7QGSX DI DM7QGSX DM7QGSX DN KW-2450 DM7QGSX TI TTHRID2 DM7QGSX TN Insulin-like growth factor I receptor (IGF1R) DM7QGSX MA Modulator DM7QGSX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7QGSX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7QGSX DI DM7QGSX DM7QGSX DN KW-2450 DM7QGSX TI TTCBFJO DM7QGSX TN Insulin receptor (INSR) DM7QGSX MA Modulator DM7QGSX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7QGSX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7R126 DI DM7R126 DM7R126 DN GS-9005 DM7R126 TI TT5FNQT DM7R126 TN Human immunodeficiency virus Protease (HIV PR) DM7R126 MA Inhibitor DM7R126 RN WO patent application no. 2003,0906,90, Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such. DM7R126 RU http://www.google.com/patents/WO2003090690A2?cl=pt DM8Q2ZR DI DM8Q2ZR DM8Q2ZR DN WX-UK1 DM8Q2ZR TI TTGY7WI DM8Q2ZR TN Urokinase-type plasminogen activator (PLAU) DM8Q2ZR MA Inhibitor DM8Q2ZR RN Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system. Int J Cancer. 2004 Jul 20;110(6):815-24. DM8Q2ZR RU https://pubmed.ncbi.nlm.nih.gov/15170662 DM9AOJT DI DM9AOJT DM9AOJT DN HuM-195-Bi-213 DM9AOJT TI TTJVYO3 DM9AOJT TN Myeloid cell surface antigen CD33 (CD33) DM9AOJT MA Inhibitor DM9AOJT RN Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010 Nov 1;16(21):5303-11. DM9AOJT RU https://pubmed.ncbi.nlm.nih.gov/20858843 DMAYLS3 DI DMAYLS3 DMAYLS3 DN IDX-320 DMAYLS3 TI TTRHUKY DMAYLS3 TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMAYLS3 MA Modulator DMAYLS3 RN Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.Antivir Ther.2012;17(4):633-42. DMAYLS3 RU https://www.ncbi.nlm.nih.gov/pubmed/22427481 DMB35UN DI DMB35UN DMB35UN DN FGF-21 DMB35UN TI TTQ916P DMB35UN TN Fibroblast growth factor-21 (FGF21) DMB35UN MA Agonist DMB35UN RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028644) DMB35UN RU http://adisinsight.springer.com/drugs/800028644 DMB8XJM DI DMB8XJM DMB8XJM DN AD-121 DMB8XJM TI TTPNQAC DMB8XJM TN Estrogen-related receptor-alpha (ESRRA) DMB8XJM MA Modulator DMB8XJM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DMB8XJM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DMCWRYS DI DMCWRYS DMCWRYS DN CYT-009-GhrQb DMCWRYS TI TTWDC17 DMCWRYS TN Growth hormone secretagogue receptor 1 (GHSR) DMCWRYS MA Antagonist DMCWRYS RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMCWRYS RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMEF9JW DI DMEF9JW DMEF9JW DN IM0-8400 DMEF9JW TI TTSHG0T DMEF9JW TN Toll-like receptor 9 (TLR9) DMEF9JW MA Antagonist DMEF9JW RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals. DMEF9JW RU http://www.iderapharma.com/pipeline DMEF9JW DI DMEF9JW DMEF9JW DN IM0-8400 DMEF9JW TI TT8CWFK DMEF9JW TN Toll-like receptor 8 (TLR8) DMEF9JW MA Antagonist DMEF9JW RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals. DMEF9JW RU http://www.iderapharma.com/pipeline DMEF9JW DI DMEF9JW DMEF9JW DN IM0-8400 DMEF9JW TI TTRJ1K4 DMEF9JW TN Toll-like receptor 7 (TLR7) DMEF9JW MA Antagonist DMEF9JW RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals. DMEF9JW RU http://www.iderapharma.com/pipeline DMGEDAY DI DMGEDAY DMGEDAY DN AVI-4065 DMGEDAY TI TT20AHC DMGEDAY TN Hepatitis C virus NS3 helicase messenger RNA (HCV NS3 mRNA) DMGEDAY RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMGEDAY RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMH40I3 DI DMH40I3 DMH40I3 DN CM-GLP-1 DMH40I3 TI TTVIMDE DMH40I3 TN Glucagon-like peptide 1 receptor (GLP1R) DMH40I3 MA Modulator DMH40I3 RN Reversal of diabetes in rats using GLP-1-expressing adult pancreatic duct-like precursor cells transformed from acinar to ductal cells. Stem Cells Dev. 2009 Sep;18(7):991-1002. DMH40I3 RU https://pubmed.ncbi.nlm.nih.gov/19125629 DMHXRZF DI DMHXRZF DMHXRZF DN UK-369003 DMHXRZF TI TTJ0IQB DMHXRZF TN Phosphodiesterase 5A (PDE5A) DMHXRZF MA Inhibitor DMHXRZF RN Pfizer. Product Development Pipeline. March 31 2009. DMHXRZF RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMIAZJ9 DI DMIAZJ9 DMIAZJ9 DN RhApo2L/TRAIL DMIAZJ9 TI TT5WLRX DMIAZJ9 TN TRAIL receptor 1 (TRAIL-R1) DMIAZJ9 MA Agonist DMIAZJ9 RN Clinical pipeline report, company report or official report of Amgen (2009). DMIAZJ9 RU http://www.amgen.com/science/pipe.jsp DMIAZJ9 DI DMIAZJ9 DMIAZJ9 DN RhApo2L/TRAIL DMIAZJ9 TI TTW20TU DMIAZJ9 TN TRAIL receptor 2 (TRAIL-R2) DMIAZJ9 MA Agonist DMIAZJ9 RN Clinical pipeline report, company report or official report of Amgen (2009). DMIAZJ9 RU http://www.amgen.com/science/pipe.jsp DMJTB4E DI DMJTB4E DMJTB4E DN CDP-484 DMJTB4E TI TTRYK0X DMJTB4E TN Interleukin-1 beta (IL1B) DMJTB4E MA Inhibitor DMJTB4E RN Biological targets for therapeutic interventions in COPD: clinical potential. Int J Chron Obstruct Pulmon Dis. 2006 September; 1(3): 321-334. DMJTB4E RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707155/ DMKFIBH DI DMKFIBH DMKFIBH DN CYT-007-TNFQb DMKFIBH TI TTF8CQI DMKFIBH TN Tumor necrosis factor (TNF) DMKFIBH MA Inhibitor DMKFIBH RN Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465. DMKFIBH RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269456/ DMMJC4Q DI DMMJC4Q DMMJC4Q DN KSB-303 DMMJC4Q TI TTY6DTE DMMJC4Q TN Carcinoembryonic antigen CEA (CD66e) DMMJC4Q RN Anticancer Antibodies. (2003) American Journal of Clinical Pathology, 119, 472-485. DMMJC4Q RU http://ajcp.ascpjournals.org/content/119/4/472.full.pdf DMMZ79C DI DMMZ79C DMMZ79C DN CER-227185 DMMZ79C TI TT3PTB6 DMMZ79C TN Translationally-controlled tumor protein (TPT1) DMMZ79C MA Inhibitor DMMZ79C RN Clinical pipeline report, company report or official report of Cerep. DMMZ79C RU http://www.cerep.fr/Cerep/Users/pages/News/PressReleases/2006/215.pdf DMNXCFZ DI DMNXCFZ DMNXCFZ DN NCX 950 DMNXCFZ TI TTMXGCW DMNXCFZ TN Adrenergic receptor beta-3 (ADRB3) DMNXCFZ MA Agonist DMNXCFZ RN A Nitric Oxide-Releasing Salbutamol Elicits Potent Relaxant and Anti-Inflammatory Activities. JPET July 2004 vol. 310 no. 1 367-375. DMNXCFZ RU http://jpet.aspetjournals.org/content/310/1/367.abstract DMO34NQ DI DMO34NQ DMO34NQ DN PD-151832 DMO34NQ TI TTZ9SOR DMO34NQ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMO34NQ MA Agonist DMO34NQ RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMO34NQ RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMR8XEN DI DMR8XEN DMR8XEN DN AME-527 DMR8XEN TI TTF8CQI DMR8XEN TN Tumor necrosis factor (TNF) DMR8XEN RN IND Filed for AME-527, Monoclonal Antibody That Is a Potential Treatment for Rheumatoid Arthritis. P&T Community. 2015. DMR8XEN RU http://ww.ptjournal.com/news/2003-11-26-000000/ind-filed-ame-527-monoclonal-antibody-potential-treatment-rheumatoid DMRQPOD DI DMRQPOD DMRQPOD DN R-803 DMRQPOD TI TTMVBWH DMRQPOD TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMRQPOD MA Modulator DMRQPOD RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMRQPOD RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXB20Y DI DMXB20Y DMXB20Y DN MDX-214 DMXB20Y TI TTGUJAO DMXB20Y TN Immunoglobulin alpha Fc receptor (FCAR) DMXB20Y RN A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of MDX-214, a novel immune-mediated mechanism agent targeting the epithelial growth factor receptor (EGFR), in patients with advanced solid tumors. Journal of Clinical Oncology, Vol 24, No 18S (June 20 Supplement), 2006: 2523. DMXB20Y RU http://meeting.ascopubs.org/cgi/content/short/24/18_suppl/2523 DMXB4T9 DI DMXB4T9 DMXB4T9 DN GS-9132 DMXB4T9 TI TTRHUKY DMXB4T9 TN Hepatitis C virus Serine protease NS4A (HCV NS4A) DMXB4T9 MA Modulator DMXB4T9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXB4T9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMYR7LO DI DMYR7LO DMYR7LO DN GPG DMYR7LO TI TTEC2T3 DMYR7LO TN Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env) DMYR7LO MA Inhibitor DMYR7LO RN GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20. DMYR7LO RU http://www.retrovirology.com/content/7/1/20 DM041IZ DI DM041IZ DM041IZ DN GED-aPC DM041IZ TI TTZUXYS DM041IZ TN Vitamin K-dependent protein C (PROC) DM041IZ MA Modulator DM041IZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2396). DM041IZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2396 DM0DLC1 DI DM0DLC1 DM0DLC1 DN A-75998 DM0DLC1 TI TT8R70G DM0DLC1 TN Gonadotropin-releasing hormone receptor (GNRHR) DM0DLC1 MA Antagonist DM0DLC1 RN Physicochemical properties of A-75998, an antagonist of luteinizing hormone releasing hormone. J Pharm Sci. 1995 Aug;84(8):953-8. DM0DLC1 RU https://pubmed.ncbi.nlm.nih.gov/7500280 DM0FSA9 DI DM0FSA9 DM0FSA9 DN YM-17E DM0FSA9 TI TTMF541 DM0FSA9 TN Liver carboxylesterase (CES1) DM0FSA9 MA Modulator DM0FSA9 RN Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Jpn J Pharmacol. 1997 Jan;73(1):41-50. DM0FSA9 RU https://pubmed.ncbi.nlm.nih.gov/9032133 DM0HZBU DI DM0HZBU DM0HZBU DN VP-025 DM0HZBU TI TTXM6JN DM0HZBU TN Cytokine receptor unspecific (CRF) DM0HZBU MA Modulator DM0HZBU RN List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Dis 2007;4:443-486. DM0HZBU RU http://www.karger.com/Article/PDF/107705 DM0ILRU DI DM0ILRU DM0ILRU DN RDEA-436 DM0ILRU TI TTIDAPM DM0ILRU TN ERK activator kinase 1 (MEK1) DM0ILRU MA Inhibitor DM0ILRU RN Clinical pipeline report, company report or official report of MedKoo Biosciences. DM0ILRU RU http://www.medkoo.com/Anticancer-trials/RDEA-436.htm DM0ILRU DI DM0ILRU DM0ILRU DN RDEA-436 DM0ILRU TI TTTW2NY DM0ILRU TN ERK activator kinase 2 (MEK2) DM0ILRU MA Inhibitor DM0ILRU RN Clinical pipeline report, company report or official report of MedKoo Biosciences. DM0ILRU RU http://www.medkoo.com/Anticancer-trials/RDEA-436.htm DM0JUAL DI DM0JUAL DM0JUAL DN ChelASE DM0JUAL TI TTLG1PD DM0JUAL TN Proliferating cell nuclear antigen (PCNA) DM0JUAL MA Inhibitor DM0JUAL RN Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy. Arch Ophthalmol. 2007 Sep;125(9):1161-7. DM0JUAL RU https://pubmed.ncbi.nlm.nih.gov/17846353 DM0LXBW DI DM0LXBW DM0LXBW DN RG-7256 DM0LXBW TI TTWCGQT DM0LXBW TN Serine/threonine-protein kinase B-raf (BRAF) DM0LXBW MA Inhibitor DM0LXBW RN First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. Target Oncol. 2016 Apr;11(2):149-56. DM0LXBW RU https://pubmed.ncbi.nlm.nih.gov/26310975 DM0PXGU DI DM0PXGU DM0PXGU DN LG-101280 DM0PXGU TI TTJ584C DM0PXGU TN Peroxisome proliferator-activated receptor alpha (PPARA) DM0PXGU MA Modulator DM0PXGU RN A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent... Mol Endocrinol. 2005 Jun;19(6):1593-605. DM0PXGU RU https://pubmed.ncbi.nlm.nih.gov/15831517 DM0UEKF DI DM0UEKF DM0UEKF DN BAY-Y-1015 DM0UEKF TI TTTWGIX DM0UEKF TN Leukotriene receptor (LTR) DM0UEKF MA Modulator DM0UEKF RN The effect of leukotriene synthesis inhibitors in models of acute and chronic inflammation. Arthritis Rheum. 1996 Mar;39(3):515-21. DM0UEKF RU https://pubmed.ncbi.nlm.nih.gov/8607901 DM0W2TA DI DM0W2TA DM0W2TA DN HGS-TR2J DM0W2TA TI TTW20TU DM0W2TA TN TRAIL receptor 2 (TRAIL-R2) DM0W2TA RN Enhancement of Glioma Radiation Therapy and Chemotherapy Response with Targeted Antibody Therapy Against Death Receptor 5. Int J Radiat Oncol Biol Phys. 2008 June 1; 71(2): 507-516. DM0W2TA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750837/ DM12VHC DI DM12VHC DM12VHC DN RG-7185 DM12VHC TI TTQDMX5 DM12VHC TN Prostaglandin D2 receptor 2 (PTGDR2) DM12VHC MA Antagonist DM12VHC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033115) DM12VHC RU http://adisinsight.springer.com/drugs/800033115 DM13GK8 DI DM13GK8 DM13GK8 DN GR-63799X DM13GK8 TI TTPNGDE DM13GK8 TN Prostaglandin E2 receptor EP3 (PTGER3) DM13GK8 MA Modulator DM13GK8 RN Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58. DM13GK8 RU https://pubmed.ncbi.nlm.nih.gov/10193764 DM13YN0 DI DM13YN0 DM13YN0 DN TAK-937 DM13YN0 TI TTMSFAW DM13YN0 TN Cannabinoid receptor 2 (CB2) DM13YN0 MA Modulator DM13YN0 RN Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res. 2012 Jan 9;1430:93-100. DM13YN0 RU https://pubmed.ncbi.nlm.nih.gov/22119394 DM13YN0 DI DM13YN0 DM13YN0 DN TAK-937 DM13YN0 TI TT6OEDT DM13YN0 TN Cannabinoid receptor 1 (CB1) DM13YN0 MA Modulator DM13YN0 RN Cerebroprotective effects of TAK-937, a cannabinoid receptor agonist, on ischemic brain damage in middle cerebral artery occluded rats and non-human primates. Brain Res. 2012 Jan 9;1430:93-100. DM13YN0 RU https://pubmed.ncbi.nlm.nih.gov/22119394 DM1C0K4 DI DM1C0K4 DM1C0K4 DN SDZ-GLC-756 DM1C0K4 TI TTZFYLI DM1C0K4 TN Dopamine D1 receptor (D1R) DM1C0K4 MA Modulator DM1C0K4 RN SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm. 1996;103(1-2):17-30. DM1C0K4 RU https://pubmed.ncbi.nlm.nih.gov/9026371 DM1C0K4 DI DM1C0K4 DM1C0K4 DN SDZ-GLC-756 DM1C0K4 TI TTEX248 DM1C0K4 TN Dopamine D2 receptor (D2R) DM1C0K4 MA Modulator DM1C0K4 RN SDZ GLC 756, a novel octahydrobenzo[g]quinoline derivative exerts opposing effects on dopamine D1 and D2 receptors. J Neural Transm. 1996;103(1-2):17-30. DM1C0K4 RU https://pubmed.ncbi.nlm.nih.gov/9026371 DM1C4IN DI DM1C4IN DM1C4IN DN CP-105696 DM1C4IN TI TTN53ZF DM1C4IN TN Leukotriene B4 receptor 1 (LTB4R) DM1C4IN MA Inhibitor DM1C4IN RN 3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997). DM1C4IN RU http://www.sciencedirect.com/science/article/pii/S0960894X97004149 DM1C4IN DI DM1C4IN DM1C4IN DN CP-105696 DM1C4IN TI TTVJX54 DM1C4IN TN Leukotriene B4 receptor 2 (LTB4R2) DM1C4IN MA Inhibitor DM1C4IN RN 3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997). DM1C4IN RU http://www.sciencedirect.com/science/article/pii/S0960894X97004149 DM1EB6H DI DM1EB6H DM1EB6H DN ZD-7349 DM1EB6H TI TTHIZP9 DM1EB6H TN Integrin alpha-5 (ITGA5) DM1EB6H MA Antagonist DM1EB6H RN Eosinophil adhesion to cholinergic nerves via ICAM-1 and VCAM-1 and associated eosinophil degranulation. Am J Physiol Lung Cell Mol Physiol. 2002 Jun;282(6):L1279-88. DM1EB6H RU https://pubmed.ncbi.nlm.nih.gov/12003784 DM1I7UO DI DM1I7UO DM1I7UO DN Cyclocreatine DM1I7UO TI TTU8W4S DM1I7UO TN Protein kinase (PK) DM1I7UO MA Inhibitor DM1I7UO RN Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta. 1989 Oct 19;998(3):317-20. DM1I7UO RU https://pubmed.ncbi.nlm.nih.gov/2804134 DM1JN6A DI DM1JN6A DM1JN6A DN Axovan-3 DM1JN6A TI TTY6EWA DM1JN6A TN Neuropeptide Y receptor type 5 (NPY5R) DM1JN6A MA Antagonist DM1JN6A RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM1JN6A RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM1QZKS DI DM1QZKS DM1QZKS DN NTC-801 DM1QZKS TI TT1VOHK DM1QZKS TN Potassium channel unspecific (KC) DM1QZKS MA Inhibitor DM1QZKS RN Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs. J Cardiovasc Pharmacol. 2014 May;63(5):421-7. DM1QZKS RU https://pubmed.ncbi.nlm.nih.gov/24805146 DM1R8Z7 DI DM1R8Z7 DM1R8Z7 DN S-33138 DM1R8Z7 TI TT4C8EA DM1R8Z7 TN Dopamine D3 receptor (D3R) DM1R8Z7 MA Antagonist DM1R8Z7 RN The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51. DM1R8Z7 RU https://pubmed.ncbi.nlm.nih.gov/20663270 DM1TYM4 DI DM1TYM4 DM1TYM4 DN AG-021541 DM1TYM4 TI TTMVBWH DM1TYM4 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM1TYM4 MA Inhibitor DM1TYM4 RN Emerging drugs for hepatitis C. Expert Opin Emerg Drugs. 2008 Mar;13(1):1-19. DM1TYM4 RU https://pubmed.ncbi.nlm.nih.gov/18321145 DM1XEUV DI DM1XEUV DM1XEUV DN SKF-97574 DM1XEUV TI TTLOKXP DM1XEUV TN Gastric H(+)/K(+) ATPase (Proton pump) DM1XEUV MA Modulator DM1XEUV RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM1XEUV RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM1Z42H DI DM1Z42H DM1Z42H DN SURADISTA DM1Z42H TI TTBID49 DM1Z42H TN C-X-C chemokine receptor type 4 (CXCR4) DM1Z42H MA Modulator DM1Z42H RN Suradista NSC 651016 inhibits the angiogenic activity of CXCL12-stromal cell-derived factor 1alpha. Clin Cancer Res. 2002 Dec;8(12):3955-60. DM1Z42H RU https://pubmed.ncbi.nlm.nih.gov/12473612 DM1ZVO3 DI DM1ZVO3 DM1ZVO3 DN AZD-9343 DM1ZVO3 TI TTDCVZW DM1ZVO3 TN Gamma-aminobutyric acid B receptor (GABBR) DM1ZVO3 MA Modulator DM1ZVO3 RN The GABA(B) receptor agonist AZD9343 inhibits transient lower oesophageal sphincter relaxations and acid reflux in healthy volunteers: a phase I study. Aliment Pharmacol Ther. 2009 Nov 1;30(9):937-46. DM1ZVO3 RU https://pubmed.ncbi.nlm.nih.gov/19650825 DM1ZYCA DI DM1ZYCA DM1ZYCA DN TALTOBULIN DM1ZYCA TI TTML2WA DM1ZYCA TN Tubulin (TUB) DM1ZYCA MA Inhibitor DM1ZYCA RN Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1535-8. DM1ZYCA RU https://pubmed.ncbi.nlm.nih.gov/20137930 DM23KBM DI DM23KBM DM23KBM DN MIV-701 DM23KBM TI TTDZN01 DM23KBM TN Cathepsin K (CTSK) DM23KBM MA Inhibitor DM23KBM RN Medivir designates MIV-710 a Candidate Drug (CD) for Osteoporosis and Osteoarthritis, 2009 DM23KBM RU http://www.medivir.se/v5/en/uptodate/pressrelease.cfm?releaseid=D575F7294C8454BE&year=2009 DM25DB4 DI DM25DB4 DM25DB4 DN TAK-591 DM25DB4 TI TTQVOEI DM25DB4 TN Angiotensin II receptor type-2 (AGTR2) DM25DB4 MA Antagonist DM25DB4 RN Clinical pipeline report, company report or official report of Takeda (2009). DM25DB4 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM25DB4 DI DM25DB4 DM25DB4 DN TAK-591 DM25DB4 TI TT8DBY3 DM25DB4 TN Angiotensin II receptor type-1 (AGTR1) DM25DB4 MA Antagonist DM25DB4 RN Clinical pipeline report, company report or official report of Takeda (2009). DM25DB4 RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DM296HE DI DM296HE DM296HE DN BW-1370U87 DM296HE TI TT3WG5C DM296HE TN Monoamine oxidase type A (MAO-A) DM296HE MA Inhibitor DM296HE RN Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor. Clin Neuropharmacol. 1993;16 Suppl 2:S25-33. DM296HE RU https://pubmed.ncbi.nlm.nih.gov/8313394 DM2AP64 DI DM2AP64 DM2AP64 DN GSK945237 DM2AP64 TI TTN6J5F DM2AP64 TN Bacterial DNA gyrase (Bact gyrase) DM2AP64 MA Modulator DM2AP64 RN Company report (gsk) DM2AP64 RU http://www.gsk-clinicalstudyregister.com/study/107895#ps DM2C0LN DI DM2C0LN DM2C0LN DN SB 249417 DM2C0LN TI TTFEZ5Q DM2C0LN TN Coagulation factor IX (F9) DM2C0LN RN Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin Pharmacol Ther. 2002 Apr;71(4):235-45. DM2C0LN RU https://pubmed.ncbi.nlm.nih.gov/11956506 DM2J5AO DI DM2J5AO DM2J5AO DN R-1518 DM2J5AO TI TTCAQMW DM2J5AO TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DM2J5AO MA Modulator DM2J5AO RN US patent application no. 2010,0092,479, Compositions and methods for treatment of viral diseases. DM2J5AO RU http://www.google.com/patents/US20100092479 DM2PUYI DI DM2PUYI DM2PUYI DN MN-246 DM2PUYI TI TTMXGCW DM2PUYI TN Adrenergic receptor beta-3 (ADRB3) DM2PUYI MA Agonist DM2PUYI RN CA patent application no. 630818, Pharmaceutical composition for prevention or treatment of neurogenic pain. DM2PUYI RU http://www.google.com/patents/CA2630818A1?cl=en DM2QHVW DI DM2QHVW DM2QHVW DN AZD6918 DM2QHVW TI TTTDVOJ DM2QHVW TN Tropomyosin-related kinase A (TrkA) DM2QHVW MA Inhibitor DM2QHVW RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM2QHVW RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM2QMKJ DI DM2QMKJ DM2QMKJ DN ALS-00T2-0501 DM2QMKJ TI TTF8CQI DM2QMKJ TN Tumor necrosis factor (TNF) DM2QMKJ MA Modulator DM2QMKJ RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM2QMKJ RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM2RF06 DI DM2RF06 DM2RF06 DN HCV-086 DM2RF06 TI TTMVBWH DM2RF06 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM2RF06 MA Inhibitor DM2RF06 RN Challenges and successes in developing new therapies for hepatitis C. Nature. 2005 Aug 18;436(7053):953-60. DM2RF06 RU https://pubmed.ncbi.nlm.nih.gov/16107835 DM2V5XP DI DM2V5XP DM2V5XP DN Emakalim DM2V5XP TI TT1VOHK DM2V5XP TN Potassium channel unspecific (KC) DM2V5XP MA Opener DM2V5XP RN Therapeutic potential of potassium channel activators in coronary heart disease. Eur Heart J. 1994 Aug;15 Suppl C:82-8. DM2V5XP RU https://pubmed.ncbi.nlm.nih.gov/7995277 DM2V7WH DI DM2V7WH DM2V7WH DN PF-251802 DM2V7WH TI TTYRL6O DM2V7WH TN Glucocorticoid receptor (NR3C1) DM2V7WH MA Agonist DM2V7WH RN Glucocorticoids Pharmacology: Past, Present and Future. Current Pharmaceutical Design. VOLUME 16, ISSUE 32, Page(3540-3553), DOI: 10.2174/138161210793797915. DM2V7WH RU http://www.eurekaselect.com/72976/article DM2WOPX DI DM2WOPX DM2WOPX DN U-78875 DM2WOPX TI TTNJYV2 DM2WOPX TN Gamma-aminobutyric acid receptor (GAR) DM2WOPX MA Inhibitor DM2WOPX RN Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. J Med Chem. 1999 Apr 8;42(7):1123-44. DM2WOPX RU https://pubmed.ncbi.nlm.nih.gov/10197957 DM2WOPX DI DM2WOPX DM2WOPX DN U-78875 DM2WOPX TI TT06RH5 DM2WOPX TN GABA(A) receptor gamma-2 (GABRG2) DM2WOPX MA Inhibitor DM2WOPX RN 3-Phenyl-substituted imidazo[1,5-alpha]quinoxalin-4-ones and imidazo[1,5-alpha]quinoxaline ureas that have high affinity at the GABAA/benzodiazepin... J Med Chem. 1996 Sep 13;39(19):3820-36. DM2WOPX RU https://pubmed.ncbi.nlm.nih.gov/8809170 DM2WOPX DI DM2WOPX DM2WOPX DN U-78875 DM2WOPX TI TTZA1NY DM2WOPX TN GABA(A) receptor beta-2 (GABRB2) DM2WOPX MA Inhibitor DM2WOPX RN High-affinity alpha-aminobutyric acid A/benzodiazepine ligands: synthesis and structure-activity relationship studies of a new series of tetracycli... J Med Chem. 1996 Nov 8;39(23):4654-66. DM2WOPX RU https://pubmed.ncbi.nlm.nih.gov/8917654 DM2WOPX DI DM2WOPX DM2WOPX DN U-78875 DM2WOPX TI TT1MPAY DM2WOPX TN GABA(A) receptor alpha-1 (GABRA1) DM2WOPX MA Inhibitor DM2WOPX RN Piperazine imidazo[1,5-a]quinoxaline ureas as high-affinity GABAA ligands of dual functionality. J Med Chem. 1999 Apr 8;42(7):1123-44. DM2WOPX RU https://pubmed.ncbi.nlm.nih.gov/10197957 DM37IH5 DI DM37IH5 DM37IH5 DN KN-203 DM37IH5 TI TTKWM86 DM37IH5 TN Opioid receptor mu (MOP) DM37IH5 MA Agonist DM37IH5 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026307) DM37IH5 RU http://adisinsight.springer.com/drugs/800026307 DM3G4JD DI DM3G4JD DM3G4JD DN CBD cannabis derivative DM3G4JD TI TT6OEDT DM3G4JD TN Cannabinoid receptor 1 (CB1) DM3G4JD MA Antagonist DM3G4JD RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM3G4JD RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM3GD7V DI DM3GD7V DM3GD7V DN WAY-100289 DM3GD7V TI TTNXLKE DM3GD7V TN 5-HT 3 receptor (5HT3R) DM3GD7V MA Modulator DM3GD7V RN The selective 5-HT3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology (Berl). 1995 Feb;117(3):318-32. DM3GD7V RU https://pubmed.ncbi.nlm.nih.gov/7770608 DM3HB06 DI DM3HB06 DM3HB06 DN AMG-517 DM3HB06 TI TTMI6F5 DM3HB06 TN Transient receptor potential cation channel V1 (TRPV1) DM3HB06 MA Blocker DM3HB06 RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DM3HB06 RU https://pubmed.ncbi.nlm.nih.gov/19481638 DM3HRQI DI DM3HRQI DM3HRQI DN BINOSPIRONE MESYLATE DM3HRQI TI TTSQIFT DM3HRQI TN 5-HT 1A receptor (HTR1A) DM3HRQI MA Antagonist DM3HRQI RN Quantifying the 5-HT1A agonist action of buspirone in man. Psychopharmacology (Berl). 2001 Nov;158(3):224-9. DM3HRQI RU https://pubmed.ncbi.nlm.nih.gov/11713611 DM3LKAR DI DM3LKAR DM3LKAR DN ER-35786 DM3LKAR TI TTJP4SM DM3LKAR TN Bacterial Penicillin binding protein (Bact PBP) DM3LKAR MA Inhibitor DM3LKAR RN In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother. 1997 Feb;41(2):298-307. DM3LKAR RU https://pubmed.ncbi.nlm.nih.gov/9021183 DM3O4ST DI DM3O4ST DM3O4ST DN SS1(dsFv)-PE38 DM3O4ST TI TT4RXME DM3O4ST TN Mesothelin (MSLN) DM3O4ST RN Mesothelin targeted cancer immunotherapy. Eur J Cancer. 2008 Jan;44(1):46-53. DM3O4ST RU https://pubmed.ncbi.nlm.nih.gov/17945478 DM3Q8UW DI DM3Q8UW DM3Q8UW DN CJC-1004 DM3Q8UW TI TT6L509 DM3Q8UW TN Coagulation factor IIa (F2) DM3Q8UW MA Inhibitor DM3Q8UW RN Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jun;25(5):387-408. DM3Q8UW RU https://pubmed.ncbi.nlm.nih.gov/12851663 DM3V5O2 DI DM3V5O2 DM3V5O2 DN RB-6145 DM3V5O2 TI TTUTN1I DM3V5O2 TN Human Deoxyribonucleic acid (hDNA) DM3V5O2 MA Binder DM3V5O2 RN Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069.. Br J Cancer. 1995 March; 71(3): 537-542. DM3V5O2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033631/ DM3Y6M7 DI DM3Y6M7 DM3Y6M7 DN XTL-2125 DM3Y6M7 TI TT79JGK DM3Y6M7 TN Mycobacterium RNA polymerase (MycB RNAP) DM3Y6M7 MA Modulator DM3Y6M7 RN DOI: 10.1111/j.1365-2036.2009.03927.x DM3Y6M7 RU http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.03927.x/full DM412S9 DI DM412S9 DM412S9 DN DMP-851 DM412S9 TI TT5FNQT DM412S9 TN Human immunodeficiency virus Protease (HIV PR) DM412S9 MA Inhibitor DM412S9 RN Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. Chem Biol. 1998 Oct;5(10):597-608. DM412S9 RU https://pubmed.ncbi.nlm.nih.gov/9818151 DM41RK2 DI DM41RK2 DM41RK2 DN LG100268 DM41RK2 TI TTW38KT DM41RK2 TN Retinoic acid receptor alpha (RARA) DM41RK2 MA Agonist DM41RK2 RN Placental steroidogenesis in rats is independent of signaling pathways induced by retinoic acids. Gen Comp Endocrinol. 2009 Sep 15;163(3):285-91. DM41RK2 RU https://pubmed.ncbi.nlm.nih.gov/19409899 DM471IG DI DM471IG DM471IG DN SR-33805 DM471IG TI TT5HONZ DM471IG TN Calcium channel unspecific (CaC) DM471IG MA Modulator DM471IG RN Effects of a new class of calcium antagonists, SR33557 (fantofarone) and SR33805, on neuronal voltage-activated Ca++ channels. J Pharmacol Exp Ther. 1994 Dec;271(3):1348-52. DM471IG RU https://pubmed.ncbi.nlm.nih.gov/7996445 DM47ELH DI DM47ELH DM47ELH DN Oncolysin M DM47ELH TI TTJVYO3 DM47ELH TN Myeloid cell surface antigen CD33 (CD33) DM47ELH MA Modulator DM47ELH RN US patent application no. 6,926,898, Albumin fusion proteins. DM47ELH RU http://www.google.com/patents/US6926898 DM4JPLM DI DM4JPLM DM4JPLM DN SYN-114 DM4JPLM TI TTJS8PY DM4JPLM TN 5-HT 6 receptor (HTR6) DM4JPLM MA Antagonist DM4JPLM RN Lewy bodies. Proc Natl Acad Sci U S A. 2006 February 7; 103(6): 1661-1668. DM4JPLM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413649/ DM4LNBQ DI DM4LNBQ DM4LNBQ DN Pyroxamide DM4LNBQ TI TT6R7JZ DM4LNBQ TN Histone deacetylase 1 (HDAC1) DM4LNBQ MA Inhibitor DM4LNBQ RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM4LNBQ RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM4MTPU DI DM4MTPU DM4MTPU DN NBI-42902 DM4MTPU TI TT8R70G DM4MTPU TN Gonadotropin-releasing hormone receptor (GNRHR) DM4MTPU MA Inhibitor DM4MTPU RN Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478-85. DM4MTPU RU https://pubmed.ncbi.nlm.nih.gov/19006286 DM4P5WO DI DM4P5WO DM4P5WO DN RS-8891 DM4P5WO TI TTB2MXP DM4P5WO TN Angiotensinogenase renin (REN) DM4P5WO MA Inhibitor DM4P5WO RN Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertension Research (2006) 29, 997-1005. doi:10.1291/hypres.29.997 DM4P5WO RU http://www.nature.com/hr/journal/v29/n12/full/hr2006137a.html DM4WJHY DI DM4WJHY DM4WJHY DN R-82913 DM4WJHY TI TT84ETX DM4WJHY TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4WJHY MA Modulator DM4WJHY RN A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Res. 1991 Oct;16(3):257-66. DM4WJHY RU https://www.ncbi.nlm.nih.gov/pubmed/1725247 DM4ZDVY DI DM4ZDVY DM4ZDVY DN Gem 92 DM4ZDVY TI TTFGZB6 DM4ZDVY TN Human immunodeficiency virus GAG protein (HIV gag) DM4ZDVY MA Modulator DM4ZDVY RN Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther. 1999 Aug;1(4):521-3. DM4ZDVY RU https://www.ncbi.nlm.nih.gov/pubmed/11713769 DM520D8 DI DM520D8 DM520D8 DN Gevotroline DM520D8 TI TT5TPI6 DM520D8 TN Opioid receptor sigma 1 (OPRS1) DM520D8 MA Modulator DM520D8 RN Sigma receptor ligands alter concentrations of corticosterone in plasma in the rat. Neuropharmacology. 1991 Jan;30(1):79-87. DM520D8 RU https://www.ncbi.nlm.nih.gov/pubmed/1675451 DM54W9A DI DM54W9A DM54W9A DN AC3056 DM54W9A TI TTC0BEN DM54W9A TN Oxidative stress (OS) DM54W9A MA Inhibitor DM54W9A RN The novel antioxidant, AC3056 (2,6-di-t-butyl-4-((dimethyl-4-methoxyphenylsilyl)methyloxy)phenol), reverses erectile dysfunction in diabetic rats and improves NO-mediated responses in penile tissue from diabetic men. J Sex Med. 2009 Feb;6(2):373-87. DM54W9A RU https://pubmed.ncbi.nlm.nih.gov/19040617 DM57HZW DI DM57HZW DM57HZW DN SB-332235 DM57HZW TI TT30C9G DM57HZW TN C-X-C chemokine receptor type 2 (CXCR2) DM57HZW MA Antagonist DM57HZW RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM57HZW RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM59WQ7 DI DM59WQ7 DM59WQ7 DN DuP-532 DM59WQ7 TI TTGN1ZA DM59WQ7 TN Angiotensin II receptor (AGTR) DM59WQ7 MA Modulator DM59WQ7 RN DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan. Clin Pharmacol Ther. 1997 Jan;61(1):59-69. DM59WQ7 RU https://pubmed.ncbi.nlm.nih.gov/9024174 DM5BG4P DI DM5BG4P DM5BG4P DN CDP-1050 DM5BG4P TI TTU5CIX DM5BG4P TN Ryanodine receptor 1 (RYR1) DM5BG4P MA Modulator DM5BG4P RN The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726. DM5BG4P RU http://circ.ahajournals.org/content/130/Suppl_2/A13726.abstract DM5D8JW DI DM5D8JW DM5D8JW DN D-1927 DM5D8JW TI TT1GHVO DM5D8JW TN Matrix metalloproteinase (MMP) DM5D8JW MA Modulator DM5D8JW RN Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5. DM5D8JW RU https://pubmed.ncbi.nlm.nih.gov/10096553 DM5FDX2 DI DM5FDX2 DM5FDX2 DN AVE-5997EF DM5FDX2 TI TT4C8EA DM5FDX2 TN Dopamine D3 receptor (D3R) DM5FDX2 MA Antagonist DM5FDX2 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM5FDX2 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM5FW8Y DI DM5FW8Y DM5FW8Y DN FR-158999 DM5FW8Y TI TT38RM1 DM5FW8Y TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM5FW8Y MA Antagonist DM5FW8Y RN QSAR study of the peptidic fibrinogen inhibitors FK633, FR158999 and related derivatives, using a novel and useful hydrophobic descriptor (logPmw). Bioorganic & Medicinal Chemistry Letters Volume 8, Issue 18, 22 September 1998, Pages 2483-2488. DM5FW8Y RU http://www.sciencedirect.com/science/article/pii/S0960894X98004053 DM5G43H DI DM5G43H DM5G43H DN Denibulin DM5G43H TI TTYFKSZ DM5G43H TN Tubulin beta (TUBB) DM5G43H MA Inhibitor DM5G43H RN An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971. DM5G43H RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667160/ DM5HAG0 DI DM5HAG0 DM5HAG0 DN DPC-681 DM5HAG0 TI TT5FNQT DM5HAG0 TN Human immunodeficiency virus Protease (HIV PR) DM5HAG0 MA Inhibitor DM5HAG0 RN DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8. DM5HAG0 RU https://pubmed.ncbi.nlm.nih.gov/11600351 DM5L9I2 DI DM5L9I2 DM5L9I2 DN APP-018 DM5L9I2 TI TT7GN3U DM5L9I2 TN Apolipoprotein A-I (APOA1) DM5L9I2 MA Modulator DM5L9I2 RN Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs. 2010 September; 11(9): 989-996. DM5L9I2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3074469/ DM5LRKC DI DM5LRKC DM5LRKC DN L-368899 DM5LRKC TI TTSCIUP DM5LRKC TN Oxytocin receptor (OTR) DM5LRKC MA Antagonist DM5LRKC RN Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs. Drug Metab Dispos. 1997 Oct;25(10):1113-8. DM5LRKC RU https://pubmed.ncbi.nlm.nih.gov/9321512 DM5PZ60 DI DM5PZ60 DM5PZ60 DN TAZOMELINE DM5PZ60 TI TTZ9SOR DM5PZ60 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM5PZ60 MA Agonist DM5PZ60 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM5PZ60 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM5R2MG DI DM5R2MG DM5R2MG DN PF-2393296 DM5R2MG TI TTGXH6N DM5R2MG TN GABA(A) receptor delta (GABRD) DM5R2MG MA Agonist DM5R2MG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 416). DM5R2MG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=416 DM5TJIY DI DM5TJIY DM5TJIY DN SLV-311 DM5TJIY TI TT953CX DM5TJIY TN Motilin receptor (MLNR) DM5TJIY MA Modulator DM5TJIY RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017412) DM5TJIY RU http://adisinsight.springer.com/drugs/800017412 DM5UYI7 DI DM5UYI7 DM5UYI7 DN OX 19 DM5UYI7 TI TTK8R02 DM5UYI7 TN Vasopressin V2 receptor (V2R) DM5UYI7 MA Agonist DM5UYI7 RN Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Biopolymers. 2006 Apr 5;81(5):321-38. DM5UYI7 RU https://pubmed.ncbi.nlm.nih.gov/16333859 DM62T1C DI DM62T1C DM62T1C DN GW-311616 DM62T1C TI TTPLTSQ DM62T1C TN Neutrophil elastase (NE) DM62T1C MA Inhibitor DM62T1C RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DM62T1C RU https://pubmed.ncbi.nlm.nih.gov/12084007 DM64FX9 DI DM64FX9 DM64FX9 DN JTK-853 DM64FX9 TI TTMVBWH DM64FX9 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM64FX9 MA Inhibitor DM64FX9 RN Preclinical Characterization of JTK-853, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Antimicrob Agents Chemother. 2012 August; 56(8): 4250-4256. DM64FX9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3421577/ DM65MUI DI DM65MUI DM65MUI DN AZD1175 DM65MUI TI TT6OEDT DM65MUI TN Cannabinoid receptor 1 (CB1) DM65MUI MA Antagonist DM65MUI RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM65MUI RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM68PYA DI DM68PYA DM68PYA DN PF-05236812 DM68PYA TI TTE4KHA DM68PYA TN Amyloid beta A4 protein (APP) DM68PYA MA Inhibitor DM68PYA RN Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18. DM68PYA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681567/ DM69OR8 DI DM69OR8 DM69OR8 DN FR167653 DM69OR8 TI TTPLTSQ DM69OR8 TN Neutrophil elastase (NE) DM69OR8 MA Inhibitor DM69OR8 RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DM69OR8 RU https://pubmed.ncbi.nlm.nih.gov/12084007 DM69OR8 DI DM69OR8 DM69OR8 DN FR167653 DM69OR8 TI TTQBR95 DM69OR8 TN Stress-activated protein kinase 2a (p38 alpha) DM69OR8 MA Inhibitor DM69OR8 RN Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003 Sep;48(9):2670-81. DM69OR8 RU https://pubmed.ncbi.nlm.nih.gov/13130488 DM6BIHE DI DM6BIHE DM6BIHE DN RWJ-56423 DM6BIHE TI TT2WR1T DM6BIHE TN Cationic trypsinogen (PRSS1) DM6BIHE MA Inhibitor DM6BIHE RN Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. J Med Chem. 2004 Feb 12;47(4):769-87. DM6BIHE RU https://pubmed.ncbi.nlm.nih.gov/14761180 DM6BO7R DI DM6BO7R DM6BO7R DN SUN-9221 DM6BO7R TI TTYSN63 DM6BO7R TN 5-HT 2 receptor (5HT2R) DM6BO7R MA Modulator DM6BO7R RN Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):246-56. DM6BO7R RU https://pubmed.ncbi.nlm.nih.gov/10071857 DM6BO7R DI DM6BO7R DM6BO7R DN SUN-9221 DM6BO7R TI TT34BHT DM6BO7R TN Adrenergic receptor alpha-1D (ADRA1D) DM6BO7R MA Modulator DM6BO7R RN Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Chem Pharm Bull (Tokyo). 1999 Feb;47(2):246-56. DM6BO7R RU https://pubmed.ncbi.nlm.nih.gov/10071857 DM6CLX9 DI DM6CLX9 DM6CLX9 DN SM-6586 DM6CLX9 TI TT5HONZ DM6CLX9 TN Calcium channel unspecific (CaC) DM6CLX9 MA Antagonist DM6CLX9 RN Calcium channel blocking properties of SM-6586 in rat heart and brain as assessed by radioligand binding assay. Jpn J Pharmacol. 1993 Oct;63(2):165-9. DM6CLX9 RU https://pubmed.ncbi.nlm.nih.gov/8283826 DM6E84O DI DM6E84O DM6E84O DN GSK568859 DM6E84O TI TTDNFMT DM6E84O TN Platelet-activating factor acetylhydrolase (PLA2G7) DM6E84O MA Modulator DM6E84O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1432). DM6E84O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1432 DM6LQGO DI DM6LQGO DM6LQGO DN Pafenolol DM6LQGO TI TTMXGCW DM6LQGO TN Adrenergic receptor beta-3 (ADRB3) DM6LQGO MA Modulator DM6LQGO RN Presystemic elimination of the beta-blocker pafenolol in the rat after oral and intraperitoneal administration and identification of a main metabolite in both rats and humans. Drug Metab Dispos. 1993May-Jun;21(3):435-40. DM6LQGO RU https://pubmed.ncbi.nlm.nih.gov/8100498 DM6LTRC DI DM6LTRC DM6LTRC DN KNI-764 DM6LTRC TI TT5FNQT DM6LTRC TN Human immunodeficiency virus Protease (HIV PR) DM6LTRC MA Modulator DM6LTRC RN JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8675-80. DM6LTRC RU https://www.ncbi.nlm.nih.gov/pubmed/10411934 DM6SON1 DI DM6SON1 DM6SON1 DN S-23906-1 DM6SON1 TI TTUTN1I DM6SON1 TN Human Deoxyribonucleic acid (hDNA) DM6SON1 MA Binder DM6SON1 RN Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis. Mol Pharmacol. 2001 Dec;60(6):1383-91. DM6SON1 RU https://pubmed.ncbi.nlm.nih.gov/11723246 DM6SUDC DI DM6SUDC DM6SUDC DN Totrombopag DM6SUDC TI TTIHYA4 DM6SUDC TN Thrombopoietin receptor (MPL) DM6SUDC MA Agonist DM6SUDC RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM6SUDC RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM6X9M8 DI DM6X9M8 DM6X9M8 DN SR-271425 DM6X9M8 TI TTUTN1I DM6X9M8 TN Human Deoxyribonucleic acid (hDNA) DM6X9M8 MA Binder DM6X9M8 RN A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. Am J Clin Oncol. 2009 Feb;32(1):9-14. DM6X9M8 RU https://pubmed.ncbi.nlm.nih.gov/19194116 DM704HO DI DM704HO DM704HO DN AC-253 DM704HO TI TTAT87F DM704HO TN Amylin receptor (IAPPR) DM704HO MA Antagonist DM704HO RN Biotechnology and Its Application in Pharmacy. Kulkarn. 2002. Page157. DM704HO RU https://books.google.com.hk/books?id=cw7bgQnWz9YC&pg=PA157&lpg=PA157&dq=AC-625+++Amylin+receptor&source=bl&ots=sLtM1OBea8&sig=MvdugRHN-VfgpBV2ac2K8BTY7d8&hl=zh-CN&sa=X&ved=0CCQQ6AEwAWoVChMIv7Wi4vS2yAIVDhuOCh3wKgMe#v=onepage&q=AC-625%20%20%20Amylin%20receptor&f=false DM70MJQ DI DM70MJQ DM70MJQ DN SDZ-CPI-975 DM70MJQ TI TTDL0NY DM70MJQ TN Carnitine O-palmitoyltransferase I (CPT1B) DM70MJQ MA Inhibitor DM70MJQ RN Hypoglycemic effects of a novel fatty acid oxidation inhibitor in rats and monkeys. Am J Physiol. 1998 Feb;274(2 Pt 2):R524-8. DM70MJQ RU https://pubmed.ncbi.nlm.nih.gov/9486313 DM71C6D DI DM71C6D DM71C6D DN Aphidicolin DM71C6D TI TTIU7X1 DM71C6D TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM71C6D MA Inhibitor DM71C6D RN Proteasome regulation of ULBP1 transcription. J Immunol. 2009 May 15;182(10):6600-9. DM71C6D RU https://pubmed.ncbi.nlm.nih.gov/19414815 DM74BK8 DI DM74BK8 DM74BK8 DN KT-362 DM74BK8 TI TT5HONZ DM74BK8 TN Calcium channel unspecific (CaC) DM74BK8 MA Modulator DM74BK8 RN Comparative cardiac effects of KT-362 and verapamil in isolated heart--correlation to calcium channel current depression. J Cardiovasc Pharmacol. 1991 Oct;18(4):594-604. DM74BK8 RU https://pubmed.ncbi.nlm.nih.gov/1724538 DM76GRQ DI DM76GRQ DM76GRQ DN Farampator DM76GRQ TI TTVPQTF DM76GRQ TN Glutamate receptor AMPA 1 (GRIA1) DM76GRQ MA Binder DM76GRQ RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM76GRQ RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM76O23 DI DM76O23 DM76O23 DN KW-6055 DM76O23 TI TTZJD1B DM76O23 TN Acetylcholine release (Ach rele) DM76O23 MA Modulator DM76O23 RN Effects of KW-6055, a novel benzylpyridine derivative, on central cholinergic systems. Nihon Yakurigaku Zasshi. 1992 Jun;99(6):435-43. DM76O23 RU https://pubmed.ncbi.nlm.nih.gov/1398340 DM79MI4 DI DM79MI4 DM79MI4 DN E-6087 DM79MI4 TI TTVKILB DM79MI4 TN Prostaglandin G/H synthase 2 (COX-2) DM79MI4 MA Inhibitor DM79MI4 RN Enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: Validation and pharmacokinetic application. Chirality. 2004 May 15;16(5):302-8. DM79MI4 RU https://pubmed.ncbi.nlm.nih.gov/15069660 DM7ACJ4 DI DM7ACJ4 DM7ACJ4 DN GSK1018921 DM7ACJ4 TI TTHJTF7 DM7ACJ4 TN Glycine transporter GlyT-1 (SLC6A9) DM7ACJ4 MA Blocker DM7ACJ4 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DM7ACJ4 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DM7HLFD DI DM7HLFD DM7HLFD DN Licofelone DM7HLFD TI TT2J34L DM7HLFD TN Arachidonate 5-lipoxygenase (5-LOX) DM7HLFD MA Inhibitor DM7HLFD RN Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors. Prostaglandins Leukot Essent Fatty Acids. 2008 Feb;78(2):99-108. DM7HLFD RU https://pubmed.ncbi.nlm.nih.gov/18280718 DM7JUCI DI DM7JUCI DM7JUCI DN ZD-2767 DM7JUCI TI TTUTN1I DM7JUCI TN Human Deoxyribonucleic acid (hDNA) DM7JUCI MA Binder DM7JUCI RN Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue. Br J Cancer. 2001 September; 85(5): 764-771. DM7JUCI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364118/ DM7KJTI DI DM7KJTI DM7KJTI DN PD-153035 DM7KJTI TI TTGKNB4 DM7KJTI TN Epidermal growth factor receptor (EGFR) DM7KJTI MA Modulator DM7KJTI RN EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.Diabetes.2009 Dec;58(12):2910-9. DM7KJTI RU https://www.ncbi.nlm.nih.gov/pubmed/19696185 DM7OR48 DI DM7OR48 DM7OR48 DN SAR-152954 DM7OR48 TI TT9JNIC DM7OR48 TN Histamine H3 receptor (H3R) DM7OR48 MA Antagonist DM7OR48 RN Clinical pipeline report, company report or official report of Sanofi. DM7OR48 RU https://ncats.nih.gov/files/SAR152954.pdf DM7WPI0 DI DM7WPI0 DM7WPI0 DN R-1487 DM7WPI0 TI TTQBR95 DM7WPI0 TN Stress-activated protein kinase 2a (p38 alpha) DM7WPI0 MA Inhibitor DM7WPI0 RN Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38alpha mitogen-activated protein kinase. J Med Chem. 2011 Apr 14;54(7):2255-65. DM7WPI0 RU https://pubmed.ncbi.nlm.nih.gov/21375264 DM7XQTM DI DM7XQTM DM7XQTM DN AZD-4407 DM7XQTM TI TT2J34L DM7XQTM TN Arachidonate 5-lipoxygenase (5-LOX) DM7XQTM MA Inhibitor DM7XQTM RN Palladium catalyzed aryl(alkyl)thiolation of unactivated arenes. Org Lett. 2014 Feb 7;16(3):848-51. DM7XQTM RU https://pubmed.ncbi.nlm.nih.gov/24437617 DM80P4U DI DM80P4U DM80P4U DN S-234462 DM80P4U TI TTY6EWA DM80P4U TN Neuropeptide Y receptor type 5 (NPY5R) DM80P4U MA Antagonist DM80P4U RN Clinical pipeline report, company report or official report of Shionogi (2011). DM80P4U RU http://www.shionogi.co.jp/index_e.html DM8139E DI DM8139E DM8139E DN ITAMELINE DM8139E TI TTZ9SOR DM8139E TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8139E MA Agonist DM8139E RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM8139E RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM82V1D DI DM82V1D DM82V1D DN ZD-0892 DM82V1D TI TTPLTSQ DM82V1D TN Neutrophil elastase (NE) DM82V1D MA Inhibitor DM82V1D RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DM82V1D RU https://pubmed.ncbi.nlm.nih.gov/12084007 DM85SYL DI DM85SYL DM85SYL DN Cetefloxacin DM85SYL TI TTN6J5F DM85SYL TN Bacterial DNA gyrase (Bact gyrase) DM85SYL MA Modulator DM85SYL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM85SYL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM8BIV4 DI DM8BIV4 DM8BIV4 DN SDZ-210-086 DM8BIV4 TI TTZ9SOR DM8BIV4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8BIV4 MA Agonist DM8BIV4 RN Influence of the cholinergic agonist SDZ 210-086 on sleep in healthy subjects. Neuropsychopharmacology. 1993 Nov;9(3):225-32. DM8BIV4 RU https://pubmed.ncbi.nlm.nih.gov/8280346 DM8C3G5 DI DM8C3G5 DM8C3G5 DN SDZ-NKT-343 DM8C3G5 TI TTZPO1L DM8C3G5 TN Substance-P receptor (TACR1) DM8C3G5 MA Antagonist DM8C3G5 RN The effects of SDZ NKT 343, a potent NK1 receptor antagonist, on cutaneous responses of primate spinothalamic tract neurones sensitized by intradermal capsaicin injection. Exp Brain Res. 1998 Aug;121(3):355-8. DM8C3G5 RU https://pubmed.ncbi.nlm.nih.gov/9746141 DM8GZAS DI DM8GZAS DM8GZAS DN ABT-299 DM8GZAS TI TTQL5VC DM8GZAS TN Platelet-activating factor receptor (PTAFR) DM8GZAS MA Antagonist DM8GZAS RN ABT-299, a novel PAF antagonist, attenuates multiple effects of endotoxemia in conscious rats. Shock. 1996 Aug;6(2):112-7. DM8GZAS RU https://pubmed.ncbi.nlm.nih.gov/8856845 DM8J9SF DI DM8J9SF DM8J9SF DN SCH-C DM8J9SF TI TTJIH8Q DM8J9SF TN CCR5 messenger RNA (CCR5 mRNA) DM8J9SF MA Antagonist DM8J9SF RN Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005 Dec;49(12):4911-9. DM8J9SF RU https://pubmed.ncbi.nlm.nih.gov/16304152 DM8J9SF DI DM8J9SF DM8J9SF DN SCH-C DM8J9SF TI TT2CEJG DM8J9SF TN C-C chemokine receptor type 5 (CCR5) DM8J9SF MA Binder DM8J9SF RN Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. DM8J9SF RU https://pubmed.ncbi.nlm.nih.gov/16182193 DM8KN2M DI DM8KN2M DM8KN2M DN ONO-2231 DM8KN2M TI TTEBCY8 DM8KN2M TN Poly [ADP-ribose] polymerase (PARP) DM8KN2M MA Modulator DM8KN2M RN Company report (ONO PHARMACEUTICAL) DM8KN2M RU https://www.ono.co.jp/eng/investor/pdf/fr/2006/fi0618.pdf DM8OYZB DI DM8OYZB DM8OYZB DN Imepitoin DM8OYZB TI TTPTXIN DM8OYZB TN Translocator protein (TSPO) DM8OYZB MA Agonist DM8OYZB RN The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs. 2014 Jan;28(1):29-43. DM8OYZB RU https://pubmed.ncbi.nlm.nih.gov/24357084 DM8PTUC DI DM8PTUC DM8PTUC DN INCB8696 DM8PTUC TI TTFZYTO DM8PTUC TN C-C chemokine receptor type 2 (CCR2) DM8PTUC MA Antagonist DM8PTUC RN Incyte. Product Development Pipeline. DM8PTUC RU http://www.incyte.com/drugs_product_pipeline.html DM8SCON DI DM8SCON DM8SCON DN AZD5904 DM8SCON TI TTVCZPI DM8SCON TN Myeloperoxidase (MPO) DM8SCON MA Inhibitor DM8SCON RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DM8SCON RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DM8SVHI DI DM8SVHI DM8SVHI DN WAY-181187 DM8SVHI TI TTJS8PY DM8SVHI TN 5-HT 6 receptor (HTR6) DM8SVHI MA Modulator DM8SVHI RN Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.Neuropsychopharmacology.2008 May;33(6):1323-35. DM8SVHI RU https://www.ncbi.nlm.nih.gov/pubmed/17625499 DM8XODL DI DM8XODL DM8XODL DN AGN-191743 DM8XODL TI TTQL5VC DM8XODL TN Platelet-activating factor receptor (PTAFR) DM8XODL MA Modulator DM8XODL RN US patent application no. 6,274,627, Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor. DM8XODL RU http://www.google.com/patents/US6274627 DM8Z5VH DI DM8Z5VH DM8Z5VH DN NN8210 DM8Z5VH TI TTHXFA1 DM8Z5VH TN C5a anaphylatoxin chemotactic receptor (C5AR1) DM8Z5VH MA Modulator DM8Z5VH RN Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol. 2013 Apr 15;190(8):3839-47. DM8Z5VH RU https://pubmed.ncbi.nlm.nih.gov/23564578 DM92BXN DI DM92BXN DM92BXN DN SB-435495 DM92BXN TI TT9V5JH DM92BXN TN Phospholipase A2 (PLA2G1B) DM92BXN MA Inhibitor DM92BXN RN The effect of lipoprotein-associated phospholipase A2 deficiency on pulmonary allergic responses in Aspergillus fumigatus sensitized mice. Respir Res. 2012 Nov 12;13:100. DM92BXN RU https://pubmed.ncbi.nlm.nih.gov/23140447 DM92E0W DI DM92E0W DM92E0W DN SCH-211803 DM92E0W TI TTYEG6Q DM92E0W TN Muscarinic acetylcholine receptor M2 (CHRM2) DM92E0W MA Inhibitor DM92E0W RN Improving the oral efficacy of CNS drug candidates: discovery of highly orally efficacious piperidinyl piperidine M2 muscarinic receptor antagonists. J Med Chem. 2002 Dec 5;45(25):5415-8. DM92E0W RU https://pubmed.ncbi.nlm.nih.gov/12459007 DM9450Z DI DM9450Z DM9450Z DN EVT-103 DM9450Z TI TTN9D8E DM9450Z TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM9450Z MA Antagonist DM9450Z RN Clinical pipeline report, company report or official report of Evotec. DM9450Z RU https://www.evotec.com/archive/en/Press-releases/2009/Evotec-starts-Phase-I-with-EVT-103-an-NR2B-selective-NMDA-receptor-antagonist/1956/1 DM94R8B DI DM94R8B DM94R8B DN RS-100975 DM94R8B TI TTNGILX DM94R8B TN Adrenergic receptor alpha-1A (ADRA1A) DM94R8B MA Antagonist DM94R8B RN In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. Br J Pharmacol. 1999 May;127(1):252-8. DM94R8B RU https://pubmed.ncbi.nlm.nih.gov/10369480 DM95NDT DI DM95NDT DM95NDT DN NN-2501 DM95NDT TI TT9O6WS DM95NDT TN Glucagon receptor (GCGR) DM95NDT MA Antagonist DM95NDT RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018428) DM95NDT RU http://adisinsight.springer.com/drugs/800018428 DM9C1LQ DI DM9C1LQ DM9C1LQ DN GR-79236 DM9C1LQ TI TTK25J1 DM9C1LQ TN Adenosine A1 receptor (ADORA1) DM9C1LQ MA Agonist DM9C1LQ RN Effect of the adenosine A1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia. 2003 May;23(4):287-92. DM9C1LQ RU https://pubmed.ncbi.nlm.nih.gov/12716347 DM9C6LN DI DM9C6LN DM9C6LN DN R-1479 DM9C6LN TI TT79JGK DM9C6LN TN Mycobacterium RNA polymerase (MycB RNAP) DM9C6LN MA Inhibitor DM9C6LN RN The novel nucleoside analog R1479 (4'-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cel... J Biol Chem. 2006 Feb 17;281(7):3793-9. DM9C6LN RU https://pubmed.ncbi.nlm.nih.gov/16316989 DM9F4LP DI DM9F4LP DM9F4LP DN BIM-26226 DM9F4LP TI TTC1MVT DM9F4LP TN Gastrin-releasing peptide receptor (GRPR) DM9F4LP MA Modulator DM9F4LP RN Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86. DM9F4LP RU https://pubmed.ncbi.nlm.nih.gov/9650851 DM9GSWY DI DM9GSWY DM9GSWY DN Anthrax vaccine DM9GSWY TI TT3YGCD DM9GSWY TN Bacterial Protective antigen (Bact pagA) DM9GSWY RN Annual Reports in Medicinal Chemistry. Annette M. Doherty. 2005. Page(214). DM9GSWY RU https://books.google.com.hk/books?id=TRA7aZ90tGsC&pg=PA214&lpg=PA214&dq=anthrax+vaccine,+DynPort/AVANT&source=bl&ots=WIkYd7mdbg&sig=8JNU9x-vtT17RRlxsG9FJ0_QZ2c&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI2b_539DEyAIVSBiOCh1eBAQb#v=onepage&q=anthrax%20vaccine%2C%20DynPort%2FAVANT&f=false DM9KLD3 DI DM9KLD3 DM9KLD3 DN AZD-6703 DM9KLD3 TI TTWELHI DM9KLD3 TN Stress-activated protein kinase (p38) DM9KLD3 MA Inhibitor DM9KLD3 RN The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38alpha MAP kinase inhibitor for the treatment of inflammatory diseases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3879-83. DM9KLD3 RU https://pubmed.ncbi.nlm.nih.gov/22608965 DM9KYVQ DI DM9KYVQ DM9KYVQ DN TG-1024 DM9KYVQ TI TTF89GD DM9KYVQ TN Interleukin-2 (IL2) DM9KYVQ MA Modulator DM9KYVQ RN Melanoma and Immunotherapy. Hematology/Oncology Clinics of North America Volume 23, Issue 3, June 2009, Pages 547-564. DM9KYVQ RU http://www.sciencedirect.com/science/article/pii/S0889858809000458 DM9LEGU DI DM9LEGU DM9LEGU DN LGD2941 DM9LEGU TI TTS64P2 DM9LEGU TN Androgen receptor (AR) DM9LEGU MA Modulator DM9LEGU RN Influence of testosterone and a novel SARM on gene expression in whole blood of Macaca fascicularis. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):167-73. DM9LEGU RU https://pubmed.ncbi.nlm.nih.gov/19429447 DM9LY4Q DI DM9LY4Q DM9LY4Q DN HuMV833 DM9LY4Q TI TTVJ1D8 DM9LY4Q TN Vascular endothelial growth factor receptor (VEGFR) DM9LY4Q RN Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93. DM9LY4Q RU https://pubmed.ncbi.nlm.nih.gov/12359857 DM9S51Q DI DM9S51Q DM9S51Q DN DU-6681 DM9S51Q TI TTJP4SM DM9S51Q TN Bacterial Penicillin binding protein (Bact PBP) DM9S51Q MA Modulator DM9S51Q RN Pharmacokinetics and Safety of Ascending Single Doses of DZ-2640, a New Oral Carbapenem Antibiotic, Administered to Healthy Japanese Subjects. Antimicrob Agents Chemother. 2000 March; 44(3): 578-582. DM9S51Q RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89729/ DM9WEP5 DI DM9WEP5 DM9WEP5 DN LJP-1082 DM9WEP5 TI TT2OUI9 DM9WEP5 TN Beta-2-glycoprotein 1 (APOH) DM9WEP5 MA Inhibitor DM9WEP5 RN Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb;10(1):53-65. DM9WEP5 RU https://pubmed.ncbi.nlm.nih.gov/15757403 DM9ZBO0 DI DM9ZBO0 DM9ZBO0 DN CI-972 DM9ZBO0 TI TTMCF1Y DM9ZBO0 TN Purine nucleoside phosphorylase (PNP) DM9ZBO0 MA Inhibitor DM9ZBO0 RN Inhibitors of human purine nucleoside phosphorylase. Synthesis of pyrrolo[3,2-d]pyrimidines, a new class of purine nucleoside phosphorylase inhibitors as potentially T-cell selective immunosuppressive agents. Description of 2,6-diamino-3,5-dihydro-7-(3-thienylmethyl)-4H-pyrrolo[3,2-d] pyrimidin-4-one. J Med Chem. 1992 May 1;35(9):1605-9. DM9ZBO0 RU https://pubmed.ncbi.nlm.nih.gov/1578487 DMA2RM3 DI DMA2RM3 DMA2RM3 DN ABT-518 DMA2RM3 TI TT1GHVO DMA2RM3 TN Matrix metalloproteinase (MMP) DMA2RM3 MA Inhibitor DMA2RM3 RN Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88. DMA2RM3 RU https://pubmed.ncbi.nlm.nih.gov/15039935 DMA3OWI DI DMA3OWI DMA3OWI DN AZD4769 DMA3OWI TI TTGKNB4 DMA3OWI TN Epidermal growth factor receptor (EGFR) DMA3OWI MA Inhibitor DMA3OWI RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMA3OWI RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMA3OWI DI DMA3OWI DMA3OWI DN AZD4769 DMA3OWI TI TTDMBF5 DMA3OWI TN Arachidonate 5-lipoxygenase activating protein (FLAP) DMA3OWI MA Inhibitor DMA3OWI RN 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72. DMA3OWI RU https://pubmed.ncbi.nlm.nih.gov/1538707 DMA412G DI DMA412G DMA412G DN Z-300 DMA412G TI TTQHJ1K DMA412G TN Histamine H2 receptor (H2R) DMA412G MA Antagonist DMA412G RN Effects of a new histamine H2-receptor antagonist, Z-300, on gastric secretion and gastro-duodenal lesions in rats: comparison with roxatidine. Jpn J Pharmacol. 1992 Jul;59(3):275-89. DMA412G RU https://pubmed.ncbi.nlm.nih.gov/1359178 DMA7DH0 DI DMA7DH0 DMA7DH0 DN DPC-168 DMA7DH0 TI TTD3XFU DMA7DH0 TN C-C chemokine receptor type 3 (CCR3) DMA7DH0 MA Antagonist DMA7DH0 RN CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2992-7. DMA7DH0 RU https://pubmed.ncbi.nlm.nih.gov/17418570 DMADKHB DI DMADKHB DMADKHB DN ABN-912 DMADKHB TI TTNAY0P DMADKHB TN Monocyte chemotactic and activating factor (CCL2) DMADKHB RN A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2387-92. DMADKHB RU https://pubmed.ncbi.nlm.nih.gov/16869001 DMAICVN DI DMAICVN DMAICVN DN SR-47063 DMAICVN TI TT1VOHK DMAICVN TN Potassium channel unspecific (KC) DMAICVN MA Opener DMAICVN RN Vasorelaxant effects of the potassium channel opener SR 47063 on the isolated human saphenous vein and rat aorta. Braz J Med Biol Res. 2000 Aug;33(8):961-6. DMAICVN RU https://pubmed.ncbi.nlm.nih.gov/10920439 DMAJDPN DI DMAJDPN DMAJDPN DN Ro-31-6930 DMAJDPN TI TT1VOHK DMAJDPN TN Potassium channel unspecific (KC) DMAJDPN MA Opener DMAJDPN RN Evaluation of the bronchodilator properties of Ro 31-6930, a novel potassium channel opener, in the guinea-pig. Br J Pharmacol. 1990 Jun;100(2):289-94. DMAJDPN RU https://pubmed.ncbi.nlm.nih.gov/2379034 DMALVX2 DI DMALVX2 DMALVX2 DN AMELTOLIDE DMALVX2 TI TTRK8B9 DMALVX2 TN Sodium channel unspecific (NaC) DMALVX2 MA Modulator DMALVX2 RN Synthesis and pharmacological evaluation of a major metabolite of ameltolide, a potent anticonvulsant. J Med Chem. 1991 Apr;34(4):1253-7. DMALVX2 RU https://pubmed.ncbi.nlm.nih.gov/2016702 DMAOZH3 DI DMAOZH3 DMAOZH3 DN DE-310 DMAOZH3 TI TTGTQHC DMAOZH3 TN DNA topoisomerase I (TOP1) DMAOZH3 MA Inhibitor DMAOZH3 RN DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors. Invest New Drugs. 2005 Aug;23(4):339-47. DMAOZH3 RU https://pubmed.ncbi.nlm.nih.gov/16012793 DMAPD6M DI DMAPD6M DMAPD6M DN PLD-147 DMAPD6M TI TTUTN1I DMAPD6M TN Human Deoxyribonucleic acid (hDNA) DMAPD6M MA Binder DMAPD6M RN The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Mol Cancer. 2010 Jun 15;9:147. DMAPD6M RU https://pubmed.ncbi.nlm.nih.gov/20550649 DMAR068 DI DMAR068 DMAR068 DN Discodermolide DMAR068 TI TTML2WA DMAR068 TN Tubulin (TUB) DMAR068 MA Modulator DMAR068 RN The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, andinhibits the growth of paclitaxel-resistant cells. Mol Pharmacol. 1997 Oct;52(4):613-22. DMAR068 RU https://pubmed.ncbi.nlm.nih.gov/9380024 DMATEL0 DI DMATEL0 DMATEL0 DN Vorsetuzumab mafodotin DMATEL0 TI TTNCIE0 DMATEL0 TN CD70 antigen (CD27-L) DMATEL0 RN National Cancer Institute Drug Dictionary (drug id 660730). DMATEL0 RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=660730 DMAU79Q DI DMAU79Q DMAU79Q DN IDEC-131 DMAU79Q TI TTIJP3Q DMAU79Q TN TNF related activation protein (CD40LG) DMAU79Q RN Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol. 2001 Jan;28(1):95-101. DMAU79Q RU https://pubmed.ncbi.nlm.nih.gov/11196549 DMB1OAR DI DMB1OAR DMB1OAR DN LY-73497 DMB1OAR TI TT84ETX DMB1OAR TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMB1OAR MA Inhibitor DMB1OAR RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMB1OAR RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMB24V7 DI DMB24V7 DMB24V7 DN D-1367 DMB24V7 TI TTK0943 DMB24V7 TN Prostaglandin G/H synthase (COX) DMB24V7 MA Modulator DMB24V7 RN US patent application no. 2007,0072,861, Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders. DMB24V7 RU http://www.google.com.ar/patents/US20070072861 DMB5HMS DI DMB5HMS DMB5HMS DN FK-973 DMB5HMS TI TTUTN1I DMB5HMS TN Human Deoxyribonucleic acid (hDNA) DMB5HMS MA Binder DMB5HMS RN Specific metabolic activation of FK973, a new antitumor antibiotic, in L1210 leukemia cells. Jpn J Pharmacol. 1990 Aug;53(4):463-72. DMB5HMS RU https://pubmed.ncbi.nlm.nih.gov/2214370 DMB5NOI DI DMB5NOI DMB5NOI DN MK-6592 DMB5NOI TI TTLYXIT DMB5NOI TN Aurora kinase C (AURKC) DMB5NOI MA Inhibitor DMB5NOI RN Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93. DMB5NOI RU https://pubmed.ncbi.nlm.nih.gov/19684075 DMB5TL9 DI DMB5TL9 DMB5TL9 DN Orazipone DMB5TL9 TI TTNSUK0 DMB5TL9 TN Protein thiol group (PTG) DMB5TL9 MA Modulator DMB5TL9 RN Antieosinophilic activity of orazipone. Mol Pharmacol. 2006 Jun;69(6):1861-70. DMB5TL9 RU https://pubmed.ncbi.nlm.nih.gov/16540599 DMB7EIN DI DMB7EIN DMB7EIN DN PF-915275 DMB7EIN TI TTN7BL9 DMB7EIN TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMB7EIN MA Inhibitor DMB7EIN RN N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3493-7. DMB7EIN RU https://pubmed.ncbi.nlm.nih.gov/19473839 DMB8T5U DI DMB8T5U DMB8T5U DN ONT-093 DMB8T5U TI TT3OT40 DMB8T5U TN Multidrug resistance protein 1 (ABCB1) DMB8T5U MA Inhibitor DMB8T5U RN A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. Invest New Drugs. 2005 Aug;23(4):311-5. DMB8T5U RU https://pubmed.ncbi.nlm.nih.gov/16012790 DMBCQFH DI DMBCQFH DMBCQFH DN SUN-8399 DMBCQFH TI TTSQIFT DMBCQFH TN 5-HT 1A receptor (HTR1A) DMBCQFH MA Agonist DMBCQFH RN Effects of SUN 8399, a potent and selective 5-HT1A agonist, on conflict behavior and ambulatory activity in mice: comparison with those of buspirone, tandospirone and diazepam. Jpn J Pharmacol. 1994 Apr;64(4):273-80. DMBCQFH RU https://pubmed.ncbi.nlm.nih.gov/8057528 DMBE5OF DI DMBE5OF DMBE5OF DN TAK165 DMBE5OF TI TTGKNB4 DMBE5OF TN Epidermal growth factor receptor (EGFR) DMBE5OF MA Inhibitor DMBE5OF RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMBE5OF RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMBE5OF DI DMBE5OF DMBE5OF DN TAK165 DMBE5OF TI TT6EO5L DMBE5OF TN Erbb2 tyrosine kinase receptor (HER2) DMBE5OF MA Inhibitor DMBE5OF RN A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. DMBE5OF RU https://pubmed.ncbi.nlm.nih.gov/17692029 DMBH5G3 DI DMBH5G3 DMBH5G3 DN KT2-962 DMBH5G3 TI TT2O84V DMBH5G3 TN Thromboxane A2 receptor (TBXA2R) DMBH5G3 MA Antagonist DMBH5G3 RN Azulene derivatives as TXA2/PGH2 receptor antagonists--II. Synthesis and biological activity of 6-mono- and 6-dihydroxylated-isopropylazulenes. Bioorg Med Chem. 1996 Apr;4(4):575-91. DMBH5G3 RU https://pubmed.ncbi.nlm.nih.gov/8735846 DMBIR5P DI DMBIR5P DMBIR5P DN L-697639 DMBIR5P TI TT84ETX DMBIR5P TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBIR5P MA Inhibitor DMBIR5P RN Human pharmacokinetics and tolerability of L-697,639, a non-nucleoside HIV-1 reverse transcriptase inhibitor. Int J Clin Pharmacol Res. 1994;14(2):45-50. DMBIR5P RU https://pubmed.ncbi.nlm.nih.gov/7530697 DMBQPA5 DI DMBQPA5 DMBQPA5 DN Vanoxerine DMBQPA5 TI TTVBI8W DMBQPA5 TN Dopamine transporter (DAT) DMBQPA5 MA Blocker DMBQPA5 RN Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs. 2006 Mar;11(1):91-8. DMBQPA5 RU https://pubmed.ncbi.nlm.nih.gov/16503828 DMBQZTO DI DMBQZTO DMBQZTO DN Rilmakalim DMBQZTO TI TT1VOHK DMBQZTO TN Potassium channel unspecific (KC) DMBQZTO MA Opener DMBQZTO RN Hypotonic stress increases efficacy of rilmakalim, but not pinacidil, to activate ATP-sensitive K(+) current in guinea pig ventricular myocytes. J Pharmacol Sci. 2004 Jun;95(2):189-95. DMBQZTO RU https://pubmed.ncbi.nlm.nih.gov/15215643 DMBXYKG DI DMBXYKG DMBXYKG DN GSK-1362885 DMBXYKG TI TT31JXP DMBXYKG TN Myophosphorylase (PYGM) DMBXYKG MA Modulator DMBXYKG RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMBXYKG RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMC2V5J DI DMC2V5J DMC2V5J DN Mirisetron maleate DMC2V5J TI TTNXLKE DMC2V5J TN 5-HT 3 receptor (5HT3R) DMC2V5J MA Modulator DMC2V5J RN The effects of 5-HT3 receptor antagonists on cognitive performance in aged monkeys. Neurobiol Aging. 1997 Jan-Feb;18(1):21-8. DMC2V5J RU https://pubmed.ncbi.nlm.nih.gov/8983029 DMC3DVB DI DMC3DVB DMC3DVB DN Figitumumab DMC3DVB TI TTHRID2 DMC3DVB TN Insulin-like growth factor I receptor (IGF1R) DMC3DVB MA Inhibitor DMC3DVB RN Pfizer. Product Development Pipeline. March 31 2009. DMC3DVB RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMC49KO DI DMC49KO DMC49KO DN SMART anti-E/P selectin DMC49KO TI TTE5VG0 DMC49KO TN P-selectin (SELP) DMC49KO MA Modulator DMC49KO RN HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res. 2002 Nov 15;91(10):907-14. DMC49KO RU https://pubmed.ncbi.nlm.nih.gov/12433835 DMC49KO DI DMC49KO DMC49KO DN SMART anti-E/P selectin DMC49KO TI TTAU4D6 DMC49KO TN E-selectin (SELE) DMC49KO MA Modulator DMC49KO RN HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res. 2002 Nov 15;91(10):907-14. DMC49KO RU https://pubmed.ncbi.nlm.nih.gov/12433835 DMC4RK7 DI DMC4RK7 DMC4RK7 DN MX-4509 DMC4RK7 TI TTZAYWL DMC4RK7 TN Estrogen receptor (ESR) DMC4RK7 MA Inhibitor DMC4RK7 RN Review of the effects of 17alpha-estradiol in humans: a less feminizing estrogen with neuroprotective potential. Article first published online: 9 FEB 2009. DMC4RK7 RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.20284/pdf DMC4RK7 DI DMC4RK7 DMC4RK7 DN MX-4509 DMC4RK7 TI TTS64P2 DMC4RK7 TN Androgen receptor (AR) DMC4RK7 MA Antagonist DMC4RK7 RN Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor. Biochem Pharmacol. 1998 May 1;55(9):1427-33. DMC4RK7 RU https://pubmed.ncbi.nlm.nih.gov/10076535 DMC7M3K DI DMC7M3K DMC7M3K DN 447C88 DMC7M3K TI TTMF541 DMC7M3K TN Liver carboxylesterase (CES1) DMC7M3K MA Modulator DMC7M3K RN The tolerability, pharmacokinetics and lack of effect on plasma cholesterol of 447C88, an AcylCoA: Cholesterol Acyl Transferase (ACAT) inhibitor with low bioavailability, in healthy volunteers. Eur JClin Pharmacol. 1995;49(3):243-9. DMC7M3K RU https://pubmed.ncbi.nlm.nih.gov/8666002 DMC94D2 DI DMC94D2 DMC94D2 DN U-104067F DMC94D2 TI TTV0YFR DMC94D2 TN Lipid peroxidation (LPO) DMC94D2 MA Modulator DMC94D2 RN Two novel pyrrolopyrimidine lipid peroxidation inhibitors U-101033E and U-104067F protect facial motor neurons following neonatal axotomy. Exp Neurol. 1996 Oct;141(2):304-9. DMC94D2 RU https://pubmed.ncbi.nlm.nih.gov/8812165 DMCA97F DI DMCA97F DMCA97F DN TD-2749 DMCA97F TI TT07C3Y DMCA97F TN 5-HT 4 receptor (HTR4) DMCA97F MA Agonist DMCA97F RN A Hybrid Structural Approach to Analyze Ligand Binding by the Serotonin Type 4 Receptor (5-HT4). Mol Cell Proteomics. 2013 May; 12(5): 1259-1271. DMCA97F RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3650337/ DMCAKMV DI DMCAKMV DMCAKMV DN AZD5985 DMCAKMV TI TTQDMX5 DMCAKMV TN Prostaglandin D2 receptor 2 (PTGDR2) DMCAKMV MA Antagonist DMCAKMV RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMCAKMV RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMCDK6S DI DMCDK6S DMCDK6S DN YM-976 DMCDK6S TI TTSKMI8 DMCDK6S TN Phosphodiesterase 4D (PDE4D) DMCDK6S MA Inhibitor DMCDK6S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMCDK6S RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMCDK6S DI DMCDK6S DMCDK6S DN YM-976 DMCDK6S TI TTVIAT9 DMCDK6S TN Phosphodiesterase 4B (PDE4B) DMCDK6S MA Inhibitor DMCDK6S RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMCDK6S RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMCDK6S DI DMCDK6S DMCDK6S DN YM-976 DMCDK6S TI TTZ97H5 DMCDK6S TN Phosphodiesterase 4A (PDE4A) DMCDK6S MA Inhibitor DMCDK6S RN Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. J Pharmacol Exp Ther. 2001 Apr;297(1):165-73. DMCDK6S RU https://pubmed.ncbi.nlm.nih.gov/11259541 DMCEM0L DI DMCEM0L DMCEM0L DN AG-331 DMCEM0L TI TTU6BFZ DMCEM0L TN Candida Thymidylate synthase (Candi TMP1) DMCEM0L MA Inhibitor DMCEM0L RN Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clin Cancer Res. 1996 Oct;2(10):1685-92. DMCEM0L RU https://pubmed.ncbi.nlm.nih.gov/9816117 DMCEOAJ DI DMCEOAJ DMCEOAJ DN Sabcomeline DMCEOAJ TI TTZ9SOR DMCEOAJ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMCEOAJ MA Agonist DMCEOAJ RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMCEOAJ RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMCF0XK DI DMCF0XK DMCF0XK DN IPI-493 DMCF0XK TI TT78R5H DMCF0XK TN Heat shock protein 90 alpha (HSP90A) DMCF0XK MA Inhibitor DMCF0XK RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMCF0XK RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMCFOSG DI DMCFOSG DMCFOSG DN TAK-810 DMCFOSG TI TT0ID4A DMCFOSG TN Leutinizing-hormone-releasing hormone (GNRH1) DMCFOSG MA Inhibitor DMCFOSG RN EP patent application no. 2018865, Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate. DMCFOSG RU http://www.google.es/patents/EP2018865A2?hl=es&cl=en DMCFYZM DI DMCFYZM DMCFYZM DN PF-3185043 DMCFYZM TI TTFQAYR DMCFYZM TN Cholesteryl ester transfer protein (CETP) DMCFYZM MA Inhibitor DMCFYZM RN Pfizer. Product Development Pipeline. March 31 2009. DMCFYZM RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMCJ1B2 DI DMCJ1B2 DMCJ1B2 DN MT-500 DMCJ1B2 TI TT0K1SC DMCJ1B2 TN 5-HT 2B receptor (HTR2B) DMCJ1B2 MA Antagonist DMCJ1B2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMCJ1B2 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMCK210 DI DMCK210 DMCK210 DN XR-9051 DMCK210 TI TTO32GK DMCK210 TN P-glycoprotein (P-GP) DMCK210 MA Inhibitor DMCK210 RN Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol. 2000 Sep;58(3):624-32. DMCK210 RU https://pubmed.ncbi.nlm.nih.gov/10953057 DMCK7LM DI DMCK7LM DMCK7LM DN DMP-728 DMCK7LM TI TT38RM1 DMCK7LM TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMCK7LM MA Modulator DMCK7LM RN Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation. 1994 Jan;89(1):3-12. DMCK7LM RU https://www.ncbi.nlm.nih.gov/pubmed/8281661 DMCMNKV DI DMCMNKV DMCMNKV DN MPC-9055 DMCMNKV TI TTFGZB6 DMCMNKV TN Human immunodeficiency virus GAG protein (HIV gag) DMCMNKV MA Inhibitor DMCMNKV RN New Small-Molecule Inhibitor Class Targeting Human Immunodeficiency Virus Type 1 Virion Maturation . Antimicrob Agents Chemother. 2009 December; 53(12): 5080-5087. DMCMNKV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786326/ DMCOKFY DI DMCOKFY DMCOKFY DN Beloxepin DMCOKFY TI TTYSN63 DMCOKFY TN 5-HT 2 receptor (5HT2R) DMCOKFY MA Modulator DMCOKFY RN WO patent application no. 2009,1055,07, Beloxepin, its enantiomers, and analogs thereof for the treatment of pain. DMCOKFY RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090827&CC=WO&NR=2009105507A2&KC=A2 DMCOMG5 DI DMCOMG5 DMCOMG5 DN AZD-1744 DMCOMG5 TI TTD3XFU DMCOMG5 TN C-C chemokine receptor type 3 (CCR3) DMCOMG5 MA Modulator DMCOMG5 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMCOMG5 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMCOMG5 DI DMCOMG5 DMCOMG5 DN AZD-1744 DMCOMG5 TI TTTIBOJ DMCOMG5 TN Histamine H1 receptor (H1R) DMCOMG5 MA Modulator DMCOMG5 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMCOMG5 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMCP2KH DI DMCP2KH DMCP2KH DN HE2100 DMCP2KH TI TTZAYWL DMCP2KH TN Estrogen receptor (ESR) DMCP2KH MA Inhibitor DMCP2KH RN Androstene-3,5-dienes as ER-beta selective SERMs. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8. DMCP2KH RU https://pubmed.ncbi.nlm.nih.gov/17890084 DMCP2KH DI DMCP2KH DMCP2KH DN HE2100 DMCP2KH TI TTOM3J0 DMCP2KH TN Estrogen receptor beta (ESR2) DMCP2KH MA Inhibitor DMCP2KH RN Androstene-3,5-dienes as ER-beta selective SERMs. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6295-8. DMCP2KH RU https://pubmed.ncbi.nlm.nih.gov/17890084 DMCQI25 DI DMCQI25 DMCQI25 DN SEP-226332 DMCQI25 TI TTNXLKE DMCQI25 TN 5-HT 3 receptor (5HT3R) DMCQI25 MA Antagonist DMCQI25 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020129) DMCQI25 RU http://adisinsight.springer.com/drugs/800020129 DMCS06R DI DMCS06R DMCS06R DN HSR-6071 DMCS06R TI TT4IN7L DMCS06R TN Histamine release (His rele) DMCS06R MA Modulator DMCS06R RN Inhibitory effect of HSR-6071, a new anti-allergic agent, on experimental asthma in rats and guinea-pigs. J Pharm Pharmacol. 1990 Apr;42(4):236-41. DMCS06R RU https://pubmed.ncbi.nlm.nih.gov/1974289 DMCV2KQ DI DMCV2KQ DMCV2KQ DN TP-9201 DMCV2KQ TI TT38RM1 DMCV2KQ TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMCV2KQ MA Modulator DMCV2KQ RN TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 1997 Sep;28(9):1789-96. DMCV2KQ RU https://pubmed.ncbi.nlm.nih.gov/9303027 DMCZ8SF DI DMCZ8SF DMCZ8SF DN EVT-301 DMCZ8SF TI TTGP7BY DMCZ8SF TN Monoamine oxidase type B (MAO-B) DMCZ8SF MA Inhibitor DMCZ8SF RN Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009 May;85(5):506-12. DMCZ8SF RU https://pubmed.ncbi.nlm.nih.gov/19129751 DMCZAJW DI DMCZAJW DMCZAJW DN Garnocestim DMCZAJW TI TTBID49 DMCZAJW TN C-X-C chemokine receptor type 4 (CXCR4) DMCZAJW MA Modulator DMCZAJW RN CN patent application no. 101094684, With the combination of chemokine activation progenitor cells/stem cells. DMCZAJW RU https://www.google.com.ar/patents/CN101094684A DMD42MN DI DMD42MN DMD42MN DN PF-3274167 DMD42MN TI TT4TFGN DMD42MN TN Vasopressin V1a receptor (V1AR) DMD42MN MA Inhibitor DMD42MN RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DMD42MN RU https://pubmed.ncbi.nlm.nih.gov/20550119 DMD42MN DI DMD42MN DMD42MN DN PF-3274167 DMD42MN TI TTSCIUP DMD42MN TN Oxytocin receptor (OTR) DMD42MN MA Inhibitor DMD42MN RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DMD42MN RU https://pubmed.ncbi.nlm.nih.gov/20550119 DMD83VY DI DMD83VY DMD83VY DN PF-05212372 DMD83VY TI TT9V5JH DMD83VY TN Phospholipase A2 (PLA2G1B) DMD83VY MA Inhibitor DMD83VY RN Phagedena due to leishmaniasis. Immunologic and experimental studies. Ann Dermatol Syphiligr (Paris). 1976;103(1):23-30. DMD83VY RU https://pubmed.ncbi.nlm.nih.gov/793505 DMD8QHV DI DMD8QHV DMD8QHV DN CCX-832 DMD8QHV TI TTE836A DMD8QHV TN C-C chemokine receptor type 8 (CCR8) DMD8QHV MA Antagonist DMD8QHV RN Increased Expression of Chemerin in Squamous Esophageal Cancer Myofibroblasts and Role in Recruitment of Mesenchymal Stromal Cells. PLoS One. 2014; 9(8): e104877. DMD8QHV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134237/ DMDAO8E DI DMDAO8E DMDAO8E DN DS-6930 DMDAO8E TI TTZMAO3 DMDAO8E TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMDAO8E MA Modulator DMDAO8E RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036558) DMDAO8E RU http://adisinsight.springer.com/drugs/800036558 DMDC4BA DI DMDC4BA DMDC4BA DN DV-7751A DMDC4BA TI TTN6J5F DMDC4BA TN Bacterial DNA gyrase (Bact gyrase) DMDC4BA MA Modulator DMDC4BA RN Antimicrobial activity of DV-7751a, a new fluoroquinolone. DMDC4BA RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC192237 DMDCOSP DI DMDCOSP DMDCOSP DN OPC-51803 DMDCOSP TI TTK8R02 DMDCOSP TN Vasopressin V2 receptor (V2R) DMDCOSP MA Agonist DMDCOSP RN Effects of OPC-51803, a novel, nonpeptide vasopressin V2-receptor agonist, on micturition frequency in Brattleboro and aged rats. J Pharmacol Sci. 2003 Dec;93(4):484-8. DMDCOSP RU https://pubmed.ncbi.nlm.nih.gov/14737021 DMDJ2O5 DI DMDJ2O5 DMDJ2O5 DN YM-75466 DMDJ2O5 TI TTCIHJA DMDJ2O5 TN Coagulation factor Xa (F10) DMDJ2O5 MA Inhibitor DMDJ2O5 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMDJ2O5 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMDK6HP DI DMDK6HP DMDK6HP DN DMP-802 DMDK6HP TI TTJA1ZO DMDK6HP TN ITGB3 messenger RNA (ITGB3 mRNA) DMDK6HP MA Inhibitor DMDK6HP RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DMDK6HP RU https://pubmed.ncbi.nlm.nih.gov/10999999 DMDOTW0 DI DMDOTW0 DMDOTW0 DN PF-477736 DMDOTW0 TI TTTU902 DMDOTW0 TN Checkpoint kinase-1 (CHK1) DMDOTW0 MA Inhibitor DMDOTW0 RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMDOTW0 RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMDPWCM DI DMDPWCM DMDPWCM DN RG-7236 DMDPWCM TI TTUMQVO DMDPWCM TN Cathepsin S (CTSS) DMDPWCM MA Inhibitor DMDPWCM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DMDPWCM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DMDRFZV DI DMDRFZV DMDRFZV DN CVS-1123 DMDRFZV TI TT6L509 DMDRFZV TN Coagulation factor IIa (F2) DMDRFZV MA Inhibitor DMDRFZV RN CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol. 1997 Feb;29(2):240-9. DMDRFZV RU https://pubmed.ncbi.nlm.nih.gov/9057074 DMDT5HZ DI DMDT5HZ DMDT5HZ DN Teloxantrone DMDT5HZ TI TT0IHXV DMDT5HZ TN DNA topoisomerase II (TOP2) DMDT5HZ MA Modulator DMDT5HZ RN Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical... J Natl Cancer Inst. 1994 Aug 17;86(16):1239-44. DMDT5HZ RU https://www.ncbi.nlm.nih.gov/pubmed/8040892 DMDTRJB DI DMDTRJB DMDTRJB DN UK-224671 DMDTRJB TI TTYO0A3 DMDTRJB TN Substance-K receptor (TACR2) DMDTRJB MA Antagonist DMDTRJB RN Pharmacokinetics and metabolism of a sulphamide NK2 antagonist in rat, dog and human. Xenobiotica. 2000 Jun;30(6):627-42. DMDTRJB RU https://pubmed.ncbi.nlm.nih.gov/10923864 DMDUM0Z DI DMDUM0Z DMDUM0Z DN LymphoRad-131 DMDUM0Z TI TTWMIDN DMDUM0Z TN B-cell-activating factor (TNFSF13B) DMDUM0Z MA Modulator DMDUM0Z RN Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo. PLoS One. 2012; 7(10): e47361. DMDUM0Z RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467252/ DMDUZ5W DI DMDUZ5W DMDUZ5W DN DACOPAFANT DMDUZ5W TI TTQL5VC DMDUZ5W TN Platelet-activating factor receptor (PTAFR) DMDUZ5W MA Antagonist DMDUZ5W RN RP 55778, a PAF receptor antagonist, prevents and reverses LPS-induced hemoconcentration and TNF release. J Lipid Mediat. 1989 Nov-Dec;1(6):349-60. DMDUZ5W RU https://pubmed.ncbi.nlm.nih.gov/2519903 DMDW64X DI DMDW64X DMDW64X DN FT-105 DMDW64X TI TTZOPHG DMDW64X TN Insulin (INS) DMDW64X MA Modulator DMDW64X RN Degludec insulin: A novel basal insulin. Indian J Endocrinol Metab. 2011 July; 15(Suppl1): S12-S16. DMDW64X RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152187/ DME5PXL DI DME5PXL DME5PXL DN DK-507k DME5PXL TI TTIXTO3 DME5PXL TN Staphylococcus Topoisomerase IV (Stap-coc parC) DME5PXL MA Modulator DME5PXL RN In Vitro and In Vivo Antibacterial Activities of DK-507k, a Novel Fluoroquinolone DME5PXL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC296186 DME98LV DI DME98LV DME98LV DN AC-162352 DME98LV TI TTJ6WK9 DME98LV TN Neuropeptide Y receptor type 2 (NPY2R) DME98LV MA Agonist DME98LV RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DME98LV RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMEADBG DI DMEADBG DMEADBG DN JTK-656 DMEADBG TI TT5FH9Y DMEADBG TN Human immunodeficiency virus Integrase (HIV IN) DMEADBG MA Inhibitor DMEADBG RN US patent application no. 8,497,270, Macrocyclic integrase inhibitors. DMEADBG RU http://www.google.com/patents/US8497270 DMEC6RD DI DMEC6RD DMEC6RD DN GSK1004723 DMEC6RD TI TT9JNIC DMEC6RD TN Histamine H3 receptor (H3R) DMEC6RD MA Antagonist DMEC6RD RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMEC6RD RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMEC6RD DI DMEC6RD DMEC6RD DN GSK1004723 DMEC6RD TI TTTIBOJ DMEC6RD TN Histamine H1 receptor (H1R) DMEC6RD MA Antagonist DMEC6RD RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMEC6RD RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMELNA8 DI DMELNA8 DMELNA8 DN TGN-1412 DMELNA8 TI TTQ13FT DMELNA8 TN T-cell-specific surface glycoprotein CD28 (CD28) DMELNA8 RN TGN1412: From Discovery to Disaster. J Young Pharm. 2010 Jul-Sep; 2(3): 332-336. DMELNA8 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964774/ DMERKWM DI DMERKWM DMERKWM DN MK-434 DMERKWM TI TT2A0DR DMERKWM TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMERKWM MA Inhibitor DMERKWM RN The effects of progesterone, 4,16-androstadien-3-one and MK-434 on the kinetics of pig testis microsomal testosterone-4-ene-5alpha-reductase activity. J Steroid Biochem Mol Biol. 1997 Mar;60(5-6):353-9. DMERKWM RU https://pubmed.ncbi.nlm.nih.gov/9219928 DMETAP8 DI DMETAP8 DMETAP8 DN R7232 DMETAP8 TI TTFQAYR DMETAP8 TN Cholesteryl ester transfer protein (CETP) DMETAP8 MA Inhibitor DMETAP8 RN Clinical pipeline report, company report or official report of Roche (2009). DMETAP8 RU http://www.roche.com/research_and_development/pipeline/roche_pharma_pipeline.htm DMEX12T DI DMEX12T DMEX12T DN FC EPO DMEX12T TI TTQG4NR DMEX12T TN Erythropoietin (EPO) DMEX12T MA Agonist DMEX12T RN Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing. Drug Test Anal. 2012 Nov;4(11):818-29. DMEX12T RU https://pubmed.ncbi.nlm.nih.gov/22764129 DMF05DL DI DMF05DL DMF05DL DN CGS-22652 DMF05DL TI TT2O84V DMF05DL TN Thromboxane A2 receptor (TBXA2R) DMF05DL MA Modulator DMF05DL RN Blood pressure effects of thromboxane A2 blockade in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993 Nov;20(11):679-87. DMF05DL RU https://www.ncbi.nlm.nih.gov/pubmed/8306513 DMF0O2H DI DMF0O2H DMF0O2H DN CGP-53437 DMF0O2H TI TT5FNQT DMF0O2H TN Human immunodeficiency virus Protease (HIV PR) DMF0O2H MA Inhibitor DMF0O2H RN CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother. 1993 Oct;37(10):2087-92. DMF0O2H RU https://pubmed.ncbi.nlm.nih.gov/8257128 DMF3A6H DI DMF3A6H DMF3A6H DN R-701 DMF3A6H TI TTXEU7H DMF3A6H TN GPCR unspecific (GPCR) DMF3A6H MA Antagonist DMF3A6H RN R 701 Roche discontinued, USA (overactive bladder), R & D Focus Drug News. February 23, 2004 DMF3A6H RU http://business.highbeam.com/436989/article-1G1-113440920/r-701-roche-discontinued-usa DMF4KPM DI DMF4KPM DMF4KPM DN PA-1050040 DMF4KPM TI TTFGZB6 DMF4KPM TN Human immunodeficiency virus GAG protein (HIV gag) DMF4KPM MA Inhibitor DMF4KPM RN US patent application no. 2015,0105,350, Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections. DMF4KPM RU http://www.google.com.ar/patents/US20150105350 DMFACQU DI DMFACQU DMFACQU DN IMS DMFACQU TI TTCAQMW DMFACQU TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DMFACQU MA Modulator DMFACQU RN The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury. Shock. 2009 Sep;32(3):258-62. DMFACQU RU https://pubmed.ncbi.nlm.nih.gov/19174745 DMFAZLU DI DMFAZLU DMFAZLU DN AZD6280 DMFAZLU TI TT37EDJ DMFAZLU TN GABA(A) receptor alpha-3 (GABRA3) DMFAZLU MA Modulator DMFAZLU RN AZD6280, a novel partial -aminobutyric acid A receptor modulator, demonstrates a pharmacodynamically selective effect profile in healthy male volunteers.J Clin Psychopharmacol.2015 Feb;35(1):22-33. DMFAZLU RU https://www.ncbi.nlm.nih.gov/pubmed/25493397 DMFC19E DI DMFC19E DMFC19E DN SC-52012 DMFC19E TI TT38RM1 DMFC19E TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMFC19E MA Modulator DMFC19E RN Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIa. Platelets. 1995;6(5):288-95. DMFC19E RU https://pubmed.ncbi.nlm.nih.gov/21043715 DMFCKJ1 DI DMFCKJ1 DMFCKJ1 DN AMG-221 DMFCKJ1 TI TTN7BL9 DMFCKJ1 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMFCKJ1 MA Inhibitor DMFCKJ1 RN Discovery of a potent, orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: identification of (S)-2-((1S,2S,4R)-b... J Med Chem. 2010 Jun 10;53(11):4481-7. DMFCKJ1 RU https://pubmed.ncbi.nlm.nih.gov/20465278 DMFES2K DI DMFES2K DMFES2K DN TA-5493 DMFES2K TI TTWELHI DMFES2K TN Stress-activated protein kinase (p38) DMFES2K MA Inhibitor DMFES2K RN US patent application no. 2008,0269,123, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases. DMFES2K RU http://www.google.com/patents/US20080269123 DMFGTMR DI DMFGTMR DMFGTMR DN Eptapirone DMFGTMR TI TTSQIFT DMFGTMR TN 5-HT 1A receptor (HTR1A) DMFGTMR MA Agonist DMFGTMR RN The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. J Psychopharmacol. 2005 Nov;19(6):609-13. DMFGTMR RU https://pubmed.ncbi.nlm.nih.gov/16272182 DMFKC7L DI DMFKC7L DMFKC7L DN PN-355 DMFKC7L TI TTJSQEF DMFKC7L TN Tyrosine-protein kinase (PTK) DMFKC7L MA Inhibitor DMFKC7L RN WO patent application no. 2005,0502,03, Biological materials and uses thereof. DMFKC7L RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050602&CC=WO&NR=2005050203A2&KC=A2 DMFLOT4 DI DMFLOT4 DMFLOT4 DN SDZ-WAG-994 DMFLOT4 TI TTK25J1 DMFLOT4 TN Adenosine A1 receptor (ADORA1) DMFLOT4 MA Agonist DMFLOT4 RN The cardiac effects of a novel A1-adenosine receptor agonist in guinea pig isolated heart. J Pharmacol Exp Ther. 1994 Dec;271(3):1371-82. DMFLOT4 RU https://pubmed.ncbi.nlm.nih.gov/7996449 DMFR3PD DI DMFR3PD DMFR3PD DN ANA-975 DMFR3PD TI TTRJ1K4 DMFR3PD TN Toll-like receptor 7 (TLR7) DMFR3PD MA Agonist DMFR3PD RN Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40. DMFR3PD RU https://pubmed.ncbi.nlm.nih.gov/18066870 DMFUCZQ DI DMFUCZQ DMFUCZQ DN Delucemine DMFUCZQ TI TT9IK2Z DMFUCZQ TN N-methyl-D-aspartate receptor (NMDAR) DMFUCZQ MA Modulator DMFUCZQ RN NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Ann N Y Acad Sci. 1999;890:450-7. DMFUCZQ RU https://pubmed.ncbi.nlm.nih.gov/10668449 DMFUTHB DI DMFUTHB DMFUTHB DN SL-90.0571 DMFUTHB TI TTRK8B9 DMFUTHB TN Sodium channel unspecific (NaC) DMFUTHB MA Modulator DMFUTHB RN WO patent application no. 19990639849, Novel sodium channel drugs and uses. DMFUTHB RU http://www.google.com/patents/WO1999063984A9?cl=en DMG068H DI DMG068H DMG068H DN KW-3635 DMG068H TI TT2O84V DMG068H TN Thromboxane A2 receptor (TBXA2R) DMG068H MA Antagonist DMG068H RN Antithrombotic effects of KW-3635, a thromboxane A2-receptor antagonist, in guinea pigs. Jpn J Pharmacol. 1994 Jun;65(2):93-8. DMG068H RU https://pubmed.ncbi.nlm.nih.gov/7967232 DMG2WAX DI DMG2WAX DMG2WAX DN Prostate cancer vaccine DMG2WAX TI TT8R70G DMG2WAX TN Gonadotropin-releasing hormone receptor (GNRHR) DMG2WAX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DMG2WAX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DMG72VK DI DMG72VK DMG72VK DN MLN0415 DMG72VK TI TTJ3E9X DMG72VK TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMG72VK MA Modulator DMG72VK RN Company report (Millennium) DMG72VK RU http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle_Print&ID=900341 DMG9U8D DI DMG9U8D DMG9U8D DN RG-7152 DMG9U8D TI TTGKOY9 DMG9U8D TN Leukotriene CysLT1 receptor (CYSLTR1) DMG9U8D MA Antagonist DMG9U8D RN Induction of peroxisomal enzymes by a tetrazole-substituted 2-quinolinylmethoxy leukotriene D4 antagonist. Fundam Appl Toxicol. 1994 Aug;23(2):298-303. DMG9U8D RU https://pubmed.ncbi.nlm.nih.gov/7982537 DMG9Y80 DI DMG9Y80 DMG9Y80 DN ABT-202 DMG9Y80 TI TTJSZTB DMG9Y80 TN Nicotinic acetylcholine receptor (nAChR) DMG9Y80 MA Modulator DMG9Y80 RN Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opin Investig Drugs. 2004 Jan;5(1):76-81. DMG9Y80 RU https://pubmed.ncbi.nlm.nih.gov/14983978 DMGAERX DI DMGAERX DMGAERX DN AIR-Epinephrine DMGAERX TI TTVIREA DMGAERX TN Adrenergic receptor (ADR) DMGAERX MA Agonist DMGAERX RN Prostaglandin synthesis inhibitors reverse alpha-adrenergic inhibition of acute insulin response to glucose. Am J Physiol. 1980 Dec;239(6):E490-500. DMGAERX RU https://pubmed.ncbi.nlm.nih.gov/6255805 DMGCUTI DI DMGCUTI DMGCUTI DN INOC-002 DMGCUTI TI TTW1KTD DMGCUTI TN Phosphoric monoester hydrolase (PMH) DMGCUTI MA Inhibitor DMGCUTI RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022435) DMGCUTI RU http://adisinsight.springer.com/drugs/800022435 DMGDSCK DI DMGDSCK DMGDSCK DN BAY-27-9955 DMGDSCK TI TT9O6WS DMGDSCK TN Glucagon receptor (GCGR) DMGDSCK MA Antagonist DMGDSCK RN Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia. 2001 Nov;44(11):2018-24. DMGDSCK RU https://pubmed.ncbi.nlm.nih.gov/11719833 DMGEWQ7 DI DMGEWQ7 DMGEWQ7 DN A-80987 DMGEWQ7 TI TT5FNQT DMGEWQ7 TN Human immunodeficiency virus Protease (HIV PR) DMGEWQ7 MA Inhibitor DMGEWQ7 RN Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1996 Jun;40(6):1491-7. DMGEWQ7 RU https://pubmed.ncbi.nlm.nih.gov/8726025 DMGFPIY DI DMGFPIY DMGFPIY DN UK-156406 DMGFPIY TI TT6L509 DMGFPIY TN Coagulation factor IIa (F2) DMGFPIY MA Inhibitor DMGFPIY RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMGFPIY RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMGHDTB DI DMGHDTB DMGHDTB DN SB 418790 DMGHDTB TI TTMXGCW DMGHDTB TN Adrenergic receptor beta-3 (ADRB3) DMGHDTB MA Agonist DMGHDTB RN News and Analysis. Nature Reviews Drug Discovery 1, 257-258 (April 2002). DMGHDTB RU http://www.nature.com/nrd/journal/v1/n4/fig_tab/nrd781_T1.html DMGLRK0 DI DMGLRK0 DMGLRK0 DN RG-7167 DMGLRK0 TI TTROQ37 DMGLRK0 TN MAPK/ERK kinase kinase (MAP3K) DMGLRK0 MA Inhibitor DMGLRK0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063). DMGLRK0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063 DMGP42Q DI DMGP42Q DMGP42Q DN JTT-651 DMGP42Q TI TTZHY6R DMGP42Q TN Glycogen phosphorylase muscle form (GP) DMGP42Q MA Inhibitor DMGP42Q RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026877) DMGP42Q RU http://adisinsight.springer.com/drugs/800026877 DMGUX5Y DI DMGUX5Y DMGUX5Y DN Lu-AA38466 DMGUX5Y TI TTM7WCE DMGUX5Y TN Ion channel unspecific (IC) DMGUX5Y MA Modulator DMGUX5Y RN Lundbeck is developing new and promising pharmaceuticals for the treatment of depression, anxiety and psychotic disorders and for new disease areas such as stroke and alcohol dependence. Pipeline report of Lundbeck in 2008. DMGUX5Y RU http://www.e-pages.dk/lundbeck/157/swf/20.swf DMGVEJ6 DI DMGVEJ6 DMGVEJ6 DN BTS-73947 DMGVEJ6 TI TTZFYLI DMGVEJ6 TN Dopamine D1 receptor (D1R) DMGVEJ6 MA Antagonist DMGVEJ6 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008043) DMGVEJ6 RU http://adisinsight.springer.com/drugs/800008043 DMGX08C DI DMGX08C DMGX08C DN ERB-196 DMGX08C TI TTOM3J0 DMGX08C TN Estrogen receptor beta (ESR2) DMGX08C MA Agonist DMGX08C RN WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med. 2006 Aug;34(8):2188-93. DMGX08C RU https://pubmed.ncbi.nlm.nih.gov/16755255 DMH0AMG DI DMH0AMG DMH0AMG DN Lu-AA44608 DMH0AMG TI TTKG67B DMH0AMG TN Neuropeptide Y receptor (NPYR) DMH0AMG MA Antagonist DMH0AMG RN CA patent application no. 690841, Synthetic bile acid composition, method, and preparation. DMH0AMG RU http://www.google.com/patents/CA2690841A1?cl=en DMH16ND DI DMH16ND DMH16ND DN TAK-100 DMH16ND TI TTDIGC1 DMH16ND TN Dipeptidyl peptidase 4 (DPP-4) DMH16ND MA Inhibitor DMH16ND RN Clinical pipeline report, company report or official report of Takeda (2009). DMH16ND RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMH1PQ0 DI DMH1PQ0 DMH1PQ0 DN CEP-2563 DMH1PQ0 TI TTXABCW DMH1PQ0 TN NT-3 growth factor receptor (TrkC) DMH1PQ0 MA Modulator DMH1PQ0 RN Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58. DMH1PQ0 RU https://pubmed.ncbi.nlm.nih.gov/15292715 DMH1PQ0 DI DMH1PQ0 DMH1PQ0 DN CEP-2563 DMH1PQ0 TI TTI7421 DMH1PQ0 TN Platelet-derived growth factor receptor beta (PDGFRB) DMH1PQ0 MA Inhibitor DMH1PQ0 RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMH1PQ0 RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMH1PQ0 DI DMH1PQ0 DMH1PQ0 DN CEP-2563 DMH1PQ0 TI TT8FYO9 DMH1PQ0 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMH1PQ0 MA Inhibitor DMH1PQ0 RN Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58. DMH1PQ0 RU https://pubmed.ncbi.nlm.nih.gov/15292715 DMH32LM DI DMH32LM DMH32LM DN HRC-302 DMH32LM TI TTQO71U DMH32LM TN Hemoglobin (HB) DMH32LM MA Modulator DMH32LM RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014790) DMH32LM RU http://adisinsight.springer.com/drugs/800014790 DMH4ANG DI DMH4ANG DMH4ANG DN HMN-214 DMH4ANG TI TTIYVQP DMH4ANG TN Polo-like kinase 1 (PLK1) DMH4ANG MA Inhibitor DMH4ANG RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMH4ANG RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMH5SA6 DI DMH5SA6 DMH5SA6 DN TR-14531 DMH5SA6 TI TTHIZP9 DMH5SA6 TN Integrin alpha-5 (ITGA5) DMH5SA6 MA Antagonist DMH5SA6 RN US patent application no. US2010278784 (A1), Methods and compositions for treating skin conditions. DMH5SA6 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20101104&CC=US&NR=2010278784A1&KC=A1 DMHEKIN DI DMHEKIN DMHEKIN DN LASINAVIR DMHEKIN TI TT5FNQT DMHEKIN TN Human immunodeficiency virus Protease (HIV PR) DMHEKIN MA Inhibitor DMHEKIN RN Quantitative determination of CGP 61755, a protease inhibitor, in plasma and urine by high-performance liquid chromatography and fluorescence detection. J Chromatogr B Biomed Sci Appl. 1997 Aug 15;696(1):123-30. DMHEKIN RU https://pubmed.ncbi.nlm.nih.gov/9300916 DMHJXL6 DI DMHJXL6 DMHJXL6 DN TT-235 DMHJXL6 TI TTSCIUP DMHJXL6 TN Oxytocin receptor (OTR) DMHJXL6 MA Antagonist DMHJXL6 RN In vivo activity of the potent oxytocin antagonist on uterine activity in the rat. In Vivo. 2004 Nov-Dec;18(6):763-6. DMHJXL6 RU https://pubmed.ncbi.nlm.nih.gov/15646817 DMHMST3 DI DMHMST3 DMHMST3 DN CCX915 DMHMST3 TI TTFZYTO DMHMST3 TN C-C chemokine receptor type 2 (CCR2) DMHMST3 MA Antagonist DMHMST3 RN Marketed and experimental medicines for the treatment of multiple sclerosis. The Association of the British Pharmaceutical Industry. 2009. DMHMST3 RU http://www.abpi.org.uk/publications/publication_details/targetMS/table.asp DMHMST3 DI DMHMST3 DMHMST3 DN CCX915 DMHMST3 TI TTEF5MJ DMHMST3 TN ATP-binding cassette transporter C9 (ABCC9) DMHMST3 MA Blocker DMHMST3 RN Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol. 2003 Feb 15;547(Pt 1):159-68. DMHMST3 RU https://pubmed.ncbi.nlm.nih.gov/12562963 DMHPV1D DI DMHPV1D DMHPV1D DN R-1065 DMHPV1D TI TTWJBZ5 DMHPV1D TN 5-HT 2C receptor (HTR2C) DMHPV1D MA Agonist DMHPV1D RN Antiaversive effects of 5HT2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol. 1998 Aug;8(3):161-8. DMHPV1D RU https://pubmed.ncbi.nlm.nih.gov/9716307 DMHRYX6 DI DMHRYX6 DMHRYX6 DN SLV-323 DMHRYX6 TI TTZPO1L DMHRYX6 TN Substance-P receptor (TACR1) DMHRYX6 MA Modulator DMHRYX6 RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMHRYX6 RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMHT84I DI DMHT84I DMHT84I DN A-216546 DMHT84I TI TTKRD0G DMHT84I TN Endothelin A receptor (EDNRA) DMHT84I MA Antagonist DMHT84I RN Pharmacology of A-216546: a highly selective antagonist for endothelin ET(A) receptor. Eur J Pharmacol. 1999 Feb 5;366(2-3):189-201. DMHT84I RU https://pubmed.ncbi.nlm.nih.gov/10082200 DMHTG38 DI DMHTG38 DMHTG38 DN XL844 DMHTG38 TI TT9ABMF DMHTG38 TN Serine/threonine-protein kinase Chk2 (RAD53) DMHTG38 MA Modulator DMHTG38 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHTG38 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHTG38 DI DMHTG38 DMHTG38 DN XL844 DMHTG38 TI TTTU902 DMHTG38 TN Checkpoint kinase-1 (CHK1) DMHTG38 MA Modulator DMHTG38 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMHTG38 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMHV3IW DI DMHV3IW DMHV3IW DN AZD-6714 DMHV3IW TI TTDLNGZ DMHV3IW TN Glucokinase (GCK) DMHV3IW MA Stimulator DMHV3IW RN Glucokinase (GCK). SciBX 2(37); doi:10.1038/scibx.2009.1408. Sep. 24 2009 DMHV3IW RU http://www.nature.com/scibx/journal/v2/n37/full/scibx.2009.1408.html DMHZN42 DI DMHZN42 DMHZN42 DN AR-H049020 DMHZN42 TI TTJ584C DMHZN42 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMHZN42 MA Agonist DMHZN42 RN CN patent application no. 100577175, Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators. DMHZN42 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050119&CC=CN&NR=1568190A&KC=A DMI0Q8Y DI DMI0Q8Y DMI0Q8Y DN TOP-53 DMI0Q8Y TI TT0IHXV DMI0Q8Y TN DNA topoisomerase II (TOP2) DMI0Q8Y MA Modulator DMI0Q8Y RN DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action. Biochemistry. 2001 Jan 23;40(3):712-8. DMI0Q8Y RU https://pubmed.ncbi.nlm.nih.gov/11170388 DMI3K2D DI DMI3K2D DMI3K2D DN SSR-162369 DMI3K2D TI TTDIGC1 DMI3K2D TN Dipeptidyl peptidase 4 (DPP-4) DMI3K2D MA Inhibitor DMI3K2D RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMI3K2D RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMI52NT DI DMI52NT DMI52NT DN TAFA-93 DMI52NT TI TTCJG29 DMI52NT TN Serine/threonine-protein kinase mTOR (mTOR) DMI52NT MA Inhibitor DMI52NT RN EP patent application no. 2275103, Mtor inhibitors in the treatment of endocrine tumors. DMI52NT RU http://www.google.com/patents/EP2275103A2?cl=en DMI5EPB DI DMI5EPB DMI5EPB DN DUP-734 DMI5EPB TI TTJQOD7 DMI5EPB TN 5-HT 2A receptor (HTR2A) DMI5EPB MA Modulator DMI5EPB RN Piperidinyltetralin sigma ligands. J Med Chem. 1994 Feb 4;37(3):364-70. DMI5EPB RU https://www.ncbi.nlm.nih.gov/pubmed/7905926 DMI5EPB DI DMI5EPB DMI5EPB DN DUP-734 DMI5EPB TI TT5TPI6 DMI5EPB TN Opioid receptor sigma 1 (OPRS1) DMI5EPB MA Modulator DMI5EPB RN Piperidinyltetralin sigma ligands. J Med Chem. 1994 Feb 4;37(3):364-70. DMI5EPB RU https://www.ncbi.nlm.nih.gov/pubmed/7905926 DMI6KQM DI DMI6KQM DMI6KQM DN GSK1059615 DMI6KQM TI TTHBTOP DMI6KQM TN PI3-kinase gamma (PIK3CG) DMI6KQM MA Inhibitor DMI6KQM RN Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug;8(8):627-44. DMI6KQM RU https://pubmed.ncbi.nlm.nih.gov/19644473 DMI7Z1Y DI DMI7Z1Y DMI7Z1Y DN JTT-553 DMI7Z1Y TI TTF8P9I DMI7Z1Y TN Diacylglycerol acyltransferase 1 (DGAT1) DMI7Z1Y MA Inhibitor DMI7Z1Y RN JTT-553, a novel Acyl CoA:diacylglycerol acyltransferase (DGAT) 1 inhibitor, improves glucose metabolism in diet-induced obesity and genetic T2DM mice. J Pharmacol Sci. 2015 Sep;129(1):51-8. DMI7Z1Y RU https://pubmed.ncbi.nlm.nih.gov/26354408 DMI9NZ3 DI DMI9NZ3 DMI9NZ3 DN E2101 DMI9NZ3 TI TTSQIFT DMI9NZ3 TN 5-HT 1A receptor (HTR1A) DMI9NZ3 MA Modulator DMI9NZ3 RN In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos. 2002 Jul;30(7):805-13. DMI9NZ3 RU https://pubmed.ncbi.nlm.nih.gov/12065439 DMIB3AT DI DMIB3AT DMIB3AT DN AVE-9940 DMIB3AT TI TTWELHI DMIB3AT TN Stress-activated protein kinase (p38) DMIB3AT MA Inhibitor DMIB3AT RN US patent application no. 2008,0119,498, Therapeutic agent for pruritus comprising p38 map kinase inhibitor as the active ingredient. DMIB3AT RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=1&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080522&CC=US&NR=2008119498A1&KC=A1 DMIBFAV DI DMIBFAV DMIBFAV DN SB-267268 DMIBFAV TI TT69TQN DMIBFAV TN Integrin alpha-V/beta-3 (ITGAV/B3) DMIBFAV MA Modulator DMIBFAV RN SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5. DMIBFAV RU https://pubmed.ncbi.nlm.nih.gov/16565398 DMIBFAV DI DMIBFAV DMIBFAV DN SB-267268 DMIBFAV TI TTPRDH7 DMIBFAV TN Integrin alpha-V/beta-5 (ITGAV/B5) DMIBFAV MA Modulator DMIBFAV RN SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1600-5. DMIBFAV RU https://pubmed.ncbi.nlm.nih.gov/16565398 DMICLMR DI DMICLMR DMICLMR DN KP106 DMICLMR TI TTVBI8W DMICLMR TN Dopamine transporter (DAT) DMICLMR MA Agonist DMICLMR RN Treating Attention-Deficit/Hyperactivity Disorder in Adults: Focus on Once-Daily Medications. Prim Care Companion CNS Disord 2011. DMICLMR RU http://www.psychiatrist.com/PCC/article/Pages/2011/v13n06/11r01168.aspx DMIJB68 DI DMIJB68 DMIJB68 DN AC-625 DMIJB68 TI TTAT87F DMIJB68 TN Amylin receptor (IAPPR) DMIJB68 MA Modulator DMIJB68 RN Biotechnology and Its Application in Pharmacy. Kulkarn. 2002. Page157. DMIJB68 RU https://books.google.com.hk/books?id=cw7bgQnWz9YC&pg=PA157&lpg=PA157&dq=AC-625+++Amylin+receptor&source=bl&ots=sLtM1OBea8&sig=MvdugRHN-VfgpBV2ac2K8BTY7d8&hl=zh-CN&sa=X&ved=0CCQQ6AEwAWoVChMIv7Wi4vS2yAIVDhuOCh3wKgMe#v=onepage&q=AC-625%20%20%20Amylin%20receptor&f=false DMIKQ40 DI DMIKQ40 DMIKQ40 DN AMG 076 DMIKQ40 TI TTX4RTB DMIKQ40 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMIKQ40 MA Antagonist DMIKQ40 RN Stereoselective synthesis of a MCHr1 antagonist. J Org Chem. 2007 Dec 7;72(25):9648-55. DMIKQ40 RU https://pubmed.ncbi.nlm.nih.gov/17997573 DMIM9N1 DI DMIM9N1 DMIM9N1 DN AZD-1080 DMIM9N1 TI TTRSMW9 DMIM9N1 TN Glycogen synthase kinase-3 beta (GSK-3B) DMIM9N1 MA Modulator DMIM9N1 RN AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans.J Neurochem.2013 May;125(3):446-56. DMIM9N1 RU https://www.ncbi.nlm.nih.gov/pubmed/23410232 DMINF80 DI DMINF80 DMINF80 DN AS-601811 DMINF80 TI TTTU72V DMINF80 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMINF80 MA Inhibitor DMINF80 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013228) DMINF80 RU http://adisinsight.springer.com/drugs/800013228 DMITYCN DI DMITYCN DMITYCN DN PF-3557156 DMITYCN TI TTWIEY9 DMITYCN TN Phosphodiesterase 7B (PDE7B) DMITYCN MA Modulator DMITYCN RN Company report (Pfizer pipeline: October 28, 2008) DMITYCN RU https://www.pfizer.com/files/investors/presentations/acr_102808_v2.pdf DMITYCN DI DMITYCN DMITYCN DN PF-3557156 DMITYCN TI TT1BC3A DMITYCN TN Phosphodiesterase 7A (PDE7A) DMITYCN MA Modulator DMITYCN RN Company report (Pfizer pipeline: October 28, 2008) DMITYCN RU https://www.pfizer.com/files/investors/presentations/acr_102808_v2.pdf DMIVRWS DI DMIVRWS DMIVRWS DN SC-57666 DMIVRWS TI TTVKILB DMIVRWS TN Prostaglandin G/H synthase 2 (COX-2) DMIVRWS MA Inhibitor DMIVRWS RN New cyclooxygenase-2/5-lipoxygenase inhibitors. 2. 7-tert-butyl-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflamm... J Med Chem. 1998 Mar 26;41(7):1124-37. DMIVRWS RU https://pubmed.ncbi.nlm.nih.gov/9544212 DMIX9O0 DI DMIX9O0 DMIX9O0 DN BRL-44154 DMIX9O0 TI TTJP4SM DMIX9O0 TN Bacterial Penicillin binding protein (Bact PBP) DMIX9O0 MA Modulator DMIX9O0 RN Can beta-lactams be re-engineered to beat MRSA . Clinical Microbiology and Infection Volume 12, Issue Supplement s2, pages 11-16, April 2006. DMIX9O0 RU http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2006.01403.x/full DMIYEZG DI DMIYEZG DMIYEZG DN AZD8566 DMIYEZG TI TT2CEJG DMIYEZG TN C-C chemokine receptor type 5 (CCR5) DMIYEZG MA Antagonist DMIYEZG RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMIYEZG RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMIZ7Q4 DI DMIZ7Q4 DMIZ7Q4 DN SAR101099 DMIZ7Q4 TI TTW5UDX DMIZ7Q4 TN Urotensin II receptor (UTS2R) DMIZ7Q4 MA Antagonist DMIZ7Q4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 365). DMIZ7Q4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=365 DMJ2ZVW DI DMJ2ZVW DMJ2ZVW DN R-944 DMJ2ZVW TI TT5FNQT DMJ2ZVW TN Human immunodeficiency virus Protease (HIV PR) DMJ2ZVW MA Inhibitor DMJ2ZVW RN CN patent application no. 101115713, Hiv protease inhibitors. DMJ2ZVW RU http://www.google.com/patents/CN101115713A?cl=en DMJ5UYL DI DMJ5UYL DMJ5UYL DN Chpmpc DMJ5UYL TI TTIU7X1 DMJ5UYL TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMJ5UYL MA Modulator DMJ5UYL RN Conversion of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine to cidofovir by an intracellular cyclic CMP phosphodiesterase.. Antimicrob Agents Chemother. 1997 March; 41(3): 641-646. DMJ5UYL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC163765/ DMJ9R4A DI DMJ9R4A DMJ9R4A DN ZK 304709 DMJ9R4A TI TT7HF4W DMJ9R4A TN Cyclin-dependent kinase 2 (CDK2) DMJ9R4A MA Inhibitor DMJ9R4A RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMJ9R4A RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMJ9R4A DI DMJ9R4A DMJ9R4A DN ZK 304709 DMJ9R4A TI TTQYF7G DMJ9R4A TN Cyclin-dependent kinase 7 (CDK7) DMJ9R4A MA Inhibitor DMJ9R4A RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMJ9R4A RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMJ9R4A DI DMJ9R4A DMJ9R4A DN ZK 304709 DMJ9R4A TI TTH6V3D DMJ9R4A TN Cyclin-dependent kinase 1 (CDK1) DMJ9R4A MA Inhibitor DMJ9R4A RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMJ9R4A RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMJ9R4A DI DMJ9R4A DMJ9R4A DN ZK 304709 DMJ9R4A TI TT1LVF2 DMJ9R4A TN Cyclin-dependent kinase 9 (CDK9) DMJ9R4A MA Inhibitor DMJ9R4A RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMJ9R4A RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMJ9R4A DI DMJ9R4A DMJ9R4A DN ZK 304709 DMJ9R4A TI TT0PG8F DMJ9R4A TN Cyclin-dependent kinase 4 (CDK4) DMJ9R4A MA Inhibitor DMJ9R4A RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMJ9R4A RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMJDYBX DI DMJDYBX DMJDYBX DN Artilide DMJDYBX TI TTRK8B9 DMJDYBX TN Sodium channel unspecific (NaC) DMJDYBX MA Modulator DMJDYBX RN Potassium channel blockers as antiarrhythmic drugs. Drug Development Research Volume 33, Issue 3, pages 235-249, November 1994. DMJDYBX RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430330307/abstract DMJFWB7 DI DMJFWB7 DMJFWB7 DN SLV-313 DMJFWB7 TI TTSQIFT DMJFWB7 TN 5-HT 1A receptor (HTR1A) DMJFWB7 MA Modulator DMJFWB7 RN Synthesis and dual D2 and 5-HT1A receptor binding affinities of 7-piperazinyl and 7-piperidinyl-3,4-dihydroquinazolin-2(1H)-ones. Med Chem. 2014;10(5):484-96. DMJFWB7 RU https://www.ncbi.nlm.nih.gov/pubmed/24024527 DMJFWB7 DI DMJFWB7 DMJFWB7 DN SLV-313 DMJFWB7 TI TTEX248 DMJFWB7 TN Dopamine D2 receptor (D2R) DMJFWB7 MA Modulator DMJFWB7 RN Synthesis and dual D2 and 5-HT1A receptor binding affinities of 7-piperazinyl and 7-piperidinyl-3,4-dihydroquinazolin-2(1H)-ones. Med Chem. 2014;10(5):484-96. DMJFWB7 RU https://www.ncbi.nlm.nih.gov/pubmed/24024527 DMJTIUP DI DMJTIUP DMJTIUP DN ABJ-879 DMJTIUP TI TTML2WA DMJTIUP TN Tubulin (TUB) DMJTIUP MA Modulator DMJTIUP RN Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol. 2007 Jul;18 Suppl 5:v9-15. DMJTIUP RU https://pubmed.ncbi.nlm.nih.gov/17656562 DMJVZ9O DI DMJVZ9O DMJVZ9O DN Cefdaloxime pentexil tosilate DMJVZ9O TI TTJP4SM DMJVZ9O TN Bacterial Penicillin binding protein (Bact PBP) DMJVZ9O MA Modulator DMJVZ9O RN Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter. 2006 Mar;19(1):39-44. DMJVZ9O RU https://pubmed.ncbi.nlm.nih.gov/16688290 DMJWLBU DI DMJWLBU DMJWLBU DN BL-1827 DMJWLBU TI TTN4QDT DMJWLBU TN Opioid receptor (OPR) DMJWLBU MA Agonist DMJWLBU RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013581) DMJWLBU RU http://adisinsight.springer.com/drugs/800013581 DMJWR1I DI DMJWR1I DMJWR1I DN E-3030 DMJWR1I TI TTZMAO3 DMJWR1I TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMJWR1I MA Modulator DMJWR1I RN Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8. DMJWR1I RU https://www.ncbi.nlm.nih.gov/pubmed/18776709 DMJWR1I DI DMJWR1I DMJWR1I DN E-3030 DMJWR1I TI TTJ584C DMJWR1I TN Peroxisome proliferator-activated receptor alpha (PPARA) DMJWR1I MA Modulator DMJWR1I RN Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.J Pharmacol Sci.2008 Sep;108(1):40-8. DMJWR1I RU https://www.ncbi.nlm.nih.gov/pubmed/18776709 DMK25FU DI DMK25FU DMK25FU DN R547 DMK25FU TI TT0PG8F DMK25FU TN Cyclin-dependent kinase 4 (CDK4) DMK25FU MA Inhibitor DMK25FU RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMK25FU RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMK25FU DI DMK25FU DMK25FU DN R547 DMK25FU TI TTH6V3D DMK25FU TN Cyclin-dependent kinase 1 (CDK1) DMK25FU MA Inhibitor DMK25FU RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMK25FU RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMK25FU DI DMK25FU DMK25FU DN R547 DMK25FU TI TTQYF7G DMK25FU TN Cyclin-dependent kinase 7 (CDK7) DMK25FU MA Inhibitor DMK25FU RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMK25FU RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMK25FU DI DMK25FU DMK25FU DN R547 DMK25FU TI TT7HF4W DMK25FU TN Cyclin-dependent kinase 2 (CDK2) DMK25FU MA Inhibitor DMK25FU RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMK25FU RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMK40VO DI DMK40VO DMK40VO DN SCH-351591 DMK40VO TI TTVIAT9 DMK40VO TN Phosphodiesterase 4B (PDE4B) DMK40VO MA Inhibitor DMK40VO RN Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3. DMK40VO RU https://pubmed.ncbi.nlm.nih.gov/12039576 DMK40VO DI DMK40VO DMK40VO DN SCH-351591 DMK40VO TI TTZ97H5 DMK40VO TN Phosphodiesterase 4A (PDE4A) DMK40VO MA Inhibitor DMK40VO RN Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3. DMK40VO RU https://pubmed.ncbi.nlm.nih.gov/12039576 DMK40VO DI DMK40VO DMK40VO DN SCH-351591 DMK40VO TI TTSKMI8 DMK40VO TN Phosphodiesterase 4D (PDE4D) DMK40VO MA Inhibitor DMK40VO RN Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 17;12(12):1621-3. DMK40VO RU https://pubmed.ncbi.nlm.nih.gov/12039576 DMK4XT8 DI DMK4XT8 DMK4XT8 DN SR 144190 DMK4XT8 TI TTYO0A3 DMK4XT8 TN Substance-K receptor (TACR2) DMK4XT8 MA Antagonist DMK4XT8 RN Pharmacologic evaluation of neurokinin-2 receptor antagonists in the guinea pig respiratory tract. Am J Vet Res. 2004 Jul;65(7):984-91. DMK4XT8 RU https://pubmed.ncbi.nlm.nih.gov/15281659 DMK5I07 DI DMK5I07 DMK5I07 DN Banoxantrone DMK5I07 TI TT0IHXV DMK5I07 TN DNA topoisomerase II (TOP2) DMK5I07 MA Modulator DMK5I07 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMK5I07 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMK5VB2 DI DMK5VB2 DMK5VB2 DN Nerisopam DMK5VB2 TI TTSQIFT DMK5VB2 TN 5-HT 1A receptor (HTR1A) DMK5VB2 MA Agonist DMK5VB2 RN Simultaneous determination of nerisopam, a novel anxiolytic agent showing polymorphic metabolism, and its N-acetyl metabolite from human plasma by a validated high performance liquid chromatographic method. J Chromatogr B Biomed Appl. 1996 Mar 29;678(1):63-72. DMK5VB2 RU https://pubmed.ncbi.nlm.nih.gov/8861657 DMK91WR DI DMK91WR DMK91WR DN MP-136 DMK91WR TI TTJ584C DMK91WR TN Peroxisome proliferator-activated receptor alpha (PPARA) DMK91WR MA Agonist DMK91WR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593). DMK91WR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593 DMK93VQ DI DMK93VQ DMK93VQ DN CEREBROCRAST DMK93VQ TI TT5HONZ DMK93VQ TN Calcium channel unspecific (CaC) DMK93VQ MA Inhibitor DMK93VQ RN The dihydropyridine analogue cerebrocrast blocks both T-type and L-type calcium currents. Can J Physiol Pharmacol. 2009 Nov;87(11):923-32. DMK93VQ RU https://pubmed.ncbi.nlm.nih.gov/19935900 DMKA612 DI DMKA612 DMKA612 DN HMR-3562 DMKA612 TI TTUWYEA DMKA612 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMKA612 MA Modulator DMKA612 RN Structure-activity relationships for six ketolide antibiotics. Curr Microbiol. 2001 Mar;42(3):203-10. DMKA612 RU https://pubmed.ncbi.nlm.nih.gov/11270656 DMKEHGT DI DMKEHGT DMKEHGT DN SPP-676 DMKEHGT TI TTB2MXP DMKEHGT TN Angiotensinogenase renin (REN) DMKEHGT MA Inhibitor DMKEHGT RN New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. DMKEHGT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/ DMKF9U3 DI DMKF9U3 DMKF9U3 DN AZD8075 DMKF9U3 TI TTQDMX5 DMKF9U3 TN Prostaglandin D2 receptor 2 (PTGDR2) DMKF9U3 MA Antagonist DMKF9U3 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMKF9U3 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMKFXTD DI DMKFXTD DMKFXTD DN BMS-191095 DMKFXTD TI TTEF5MJ DMKFXTD TN ATP-binding cassette transporter C9 (ABCC9) DMKFXTD MA Modulator DMKFXTD RN The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats.J Cereb Blood Flow Metab.2007 Feb;27(2):348-55. DMKFXTD RU https://www.ncbi.nlm.nih.gov/pubmed/16736040 DMKGL2I DI DMKGL2I DMKGL2I DN SPI-256 DMKGL2I TI TT5FNQT DMKGL2I TN Human immunodeficiency virus Protease (HIV PR) DMKGL2I MA Inhibitor DMKGL2I RN Current and Novel Inhibitors of HIV Protease. Viruses. 2009 December; 1(3): 1209-1239. DMKGL2I RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185513/ DMKHEQL DI DMKHEQL DMKHEQL DN Mofarotene DMKHEQL TI TT8WZ3Q DMKHEQL TN Mitochondrial gene transcription (MGT) DMKHEQL MA Modulator DMKHEQL RN Down-regulation of mitochondrial gene expression by the anti-tumor arotinoid mofarotene (Ro 40-8757). Int J Cancer. 1994 Sep 15;58(6):891-7. DMKHEQL RU https://pubmed.ncbi.nlm.nih.gov/7927884 DMKJ3IA DI DMKJ3IA DMKJ3IA DN BAY-73-7977 DMKJ3IA TI TT9O6WS DMKJ3IA TN Glucagon receptor (GCGR) DMKJ3IA MA Antagonist DMKJ3IA RN WO patent application no. 2012,0351,39, Prodrugs comprising an exendin linker conjugate. DMKJ3IA RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120322&CC=WO&NR=2012035139A1&KC=A1 DMKLCRI DI DMKLCRI DMKLCRI DN ARC-183 DMKLCRI TI TT6L509 DMKLCRI TN Coagulation factor IIa (F2) DMKLCRI RN A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. J Thromb Haemost. 2012 May;10(5):870-80. DMKLCRI RU https://pubmed.ncbi.nlm.nih.gov/22385910 DMKLPMW DI DMKLPMW DMKLPMW DN RG-7166 DMKLPMW TI TT3ROYC DMKLPMW TN Serotonin transporter (SERT) DMKLPMW MA Inhibitor DMKLPMW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598) DMKLPMW RU http://adisinsight.springer.com/drugs/800031598 DMKLPMW DI DMKLPMW DMKLPMW DN RG-7166 DMKLPMW TI TTVBI8W DMKLPMW TN Dopamine transporter (DAT) DMKLPMW MA Inhibitor DMKLPMW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598) DMKLPMW RU http://adisinsight.springer.com/drugs/800031598 DMKLPMW DI DMKLPMW DMKLPMW DN RG-7166 DMKLPMW TI TTAWNKZ DMKLPMW TN Norepinephrine transporter (NET) DMKLPMW MA Inhibitor DMKLPMW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598) DMKLPMW RU http://adisinsight.springer.com/drugs/800031598 DMKMIQ6 DI DMKMIQ6 DMKMIQ6 DN LY-315902 DMKMIQ6 TI TTVIMDE DMKMIQ6 TN Glucagon-like peptide 1 receptor (GLP1R) DMKMIQ6 MA Modulator DMKMIQ6 RN Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. Regul Pept. 2002 Jun 15;106(1-3):89-95. DMKMIQ6 RU https://pubmed.ncbi.nlm.nih.gov/12047915 DMKRG0I DI DMKRG0I DMKRG0I DN VNA-932 DMKRG0I TI TTK8R02 DMKRG0I TN Vasopressin V2 receptor (V2R) DMKRG0I MA Agonist DMKRG0I RN Biased Agonist Pharmacochaperones of the AVP V2 Receptor May Treat Congenital Nephrogenic Diabetes Insipidus. J Am Soc Nephrol. 2009 October; 20(10): 2190-2203. DMKRG0I RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2754097/ DMKRVUN DI DMKRVUN DMKRVUN DN ONO-4817 DMKRVUN TI TT1GHVO DMKRVUN TN Matrix metalloproteinase (MMP) DMKRVUN MA Inhibitor DMKRVUN RN ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6. DMKRVUN RU https://pubmed.ncbi.nlm.nih.gov/10858013 DMKSFL0 DI DMKSFL0 DMKSFL0 DN SB-242235 DMKSFL0 TI TT9AZWY DMKSFL0 TN HSPB1 messenger RNA (HSPB1 mRNA) DMKSFL0 MA Inhibitor DMKSFL0 RN Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7. DMKSFL0 RU https://pubmed.ncbi.nlm.nih.gov/18602262 DMKSFL0 DI DMKSFL0 DMKSFL0 DN SB-242235 DMKSFL0 TI TTQBR95 DMKSFL0 TN Stress-activated protein kinase 2a (p38 alpha) DMKSFL0 MA Inhibitor DMKSFL0 RN Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4433-7. DMKSFL0 RU https://pubmed.ncbi.nlm.nih.gov/18602262 DMKWTPX DI DMKWTPX DMKWTPX DN FLM-5011 DMKWTPX TI TTG3K2U DMKWTPX TN Lipoxygenase (ALOX) DMKWTPX MA Modulator DMKWTPX RN Lipoxygenase inhibitor FLM 5011, an effective protectant of myocardial microvessels against ischemia-reperfusion injury. Exp Toxicol Pathol. 2000 Mar;52(1):27-36. DMKWTPX RU https://pubmed.ncbi.nlm.nih.gov/10779150 DMKXDOI DI DMKXDOI DMKXDOI DN AS602868 DMKXDOI TI TTSXVID DMKXDOI TN Nuclear factor NF-kappa-B (NFKB) DMKXDOI MA Inhibitor DMKXDOI RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMKXDOI RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMKXDOI DI DMKXDOI DMKXDOI DN AS602868 DMKXDOI TI TT3WG5C DMKXDOI TN Monoamine oxidase type A (MAO-A) DMKXDOI MA Inhibitor DMKXDOI RN Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80. DMKXDOI RU https://pubmed.ncbi.nlm.nih.gov/11169165 DMKXDOI DI DMKXDOI DMKXDOI DN AS602868 DMKXDOI TI TTGP7BY DMKXDOI TN Monoamine oxidase type B (MAO-B) DMKXDOI MA Inhibitor DMKXDOI RN Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80. DMKXDOI RU https://pubmed.ncbi.nlm.nih.gov/11169165 DML1AUZ DI DML1AUZ DML1AUZ DN ADL-7445 DML1AUZ TI TTKWM86 DML1AUZ TN Opioid receptor mu (MOP) DML1AUZ MA Antagonist DML1AUZ RN Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011 Aug;20(8):1047-56. DML1AUZ RU https://pubmed.ncbi.nlm.nih.gov/21663526 DML4M5K DI DML4M5K DML4M5K DN T-0632 DML4M5K TI TTCG0AL DML4M5K TN Cholecystokinin receptor type A (CCKAR) DML4M5K MA Antagonist DML4M5K RN Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12. DML4M5K RU https://pubmed.ncbi.nlm.nih.gov/9074944 DML51D0 DI DML51D0 DML51D0 DN UCL-2000; butabindide DML51D0 TI TTCG0AL DML51D0 TN Cholecystokinin receptor type A (CCKAR) DML51D0 MA Agonist DML51D0 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DML51D0 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DML51D0 DI DML51D0 DML51D0 DN UCL-2000; butabindide DML51D0 TI TTQ7R2V DML51D0 TN Tripeptidyl-peptidase II (TPP2) DML51D0 MA Inhibitor DML51D0 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DML51D0 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DML6A8X DI DML6A8X DML6A8X DN S-18327 DML6A8X TI TTEX248 DML6A8X TN Dopamine D2 receptor (D2R) DML6A8X MA Modulator DML6A8X RN S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile. J Pharmacol Exp Ther. 2000 Jan;292(1):38-53. DML6A8X RU https://pubmed.ncbi.nlm.nih.gov/10604930 DML73BR DI DML73BR DML73BR DN U-96988 DML73BR TI TT5FNQT DML73BR TN Human immunodeficiency virus Protease (HIV PR) DML73BR MA Inhibitor DML73BR RN Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem. 1994 Sep 30;37(20):3200-4. DML73BR RU https://pubmed.ncbi.nlm.nih.gov/7932546 DML7KCO DI DML7KCO DML7KCO DN SR-146131 DML7KCO TI TTCG0AL DML7KCO TN Cholecystokinin receptor type A (CCKAR) DML7KCO MA Agonist DML7KCO RN SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. J Pharmacol Exp Ther. 1999 May;289(2):742-51. DML7KCO RU https://pubmed.ncbi.nlm.nih.gov/10215648 DML7M3S DI DML7M3S DML7M3S DN R-1068 DML7M3S TI TTXEU7H DML7M3S TN GPCR unspecific (GPCR) DML7M3S MA Modulator DML7M3S RN R 1068 Roche discontinued, Europe (emesis). R & D Focus Drug New. February 16, 2004 DML7M3S RU http://business.highbeam.com/436989/article-1G1-113216640/r-1068-roche-discontinued-europe DML7Q56 DI DML7Q56 DML7Q56 DN ONO-1714 DML7Q56 TI TTF10I9 DML7Q56 TN Nitric-oxide synthase inducible (NOS2) DML7Q56 MA Modulator DML7Q56 RN ONO-1714, a new inducible nitric oxide synthase inhibitor, attenuates diaphragmatic dysfunction associated with cerulein-induced pancreatitis in rats. Crit Care Med. 2001 Jun;29(6):1215-21. DML7Q56 RU https://www.ncbi.nlm.nih.gov/pubmed/11395607 DML86MJ DI DML86MJ DML86MJ DN Lu-AA47070 DML86MJ TI TTM2AOE DML86MJ TN Adenosine A2a receptor (ADORA2A) DML86MJ MA Antagonist DML86MJ RN The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacol Biochem Behav. 2012 Jan;100(3):498-505. DML86MJ RU https://pubmed.ncbi.nlm.nih.gov/22037410 DMLD2R0 DI DMLD2R0 DMLD2R0 DN YM-750 DMLD2R0 TI TTMF541 DMLD2R0 TN Liver carboxylesterase (CES1) DMLD2R0 MA Inhibitor DMLD2R0 RN Effects of an anti-oxidative ACAT inhibitor on apoptosis/necrosis and cholesterol accumulation under oxidative stress in THP-1 cell-derived foam ce... Life Sci. 2008 Jan 2;82(1-2):79-84. DMLD2R0 RU https://pubmed.ncbi.nlm.nih.gov/18037448 DMLFMSY DI DMLFMSY DMLFMSY DN V85546 DMLFMSY TI TTXZ0KQ DMLFMSY TN Matrix metalloproteinase-12 (MMP-12) DMLFMSY MA Inhibitor DMLFMSY RN Clinical pipeline report, company report or official report of Vernalis. DMLFMSY RU http://www.vernalis.com/partnering/out-licensing/v158866-1 DMLH28J DI DMLH28J DMLH28J DN REGN 3051 DMLH28J TI TT85VHW DMLH28J TN MERS-CoV spike glycoprotein (S) DMLH28J MA Inhibitor DMLH28J RN Pre- And Postexposure Efficacy of Fully Human Antibodies Against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112. DMLH28J RU https://pubmed.ncbi.nlm.nih.gov/26124093 DMLHE5A DI DMLHE5A DMLHE5A DN L-692429 DMLHE5A TI TTG4R8V DMLHE5A TN Growth hormone-releasing hormone receptor (GHRHR) DMLHE5A MA Modulator DMLHE5A RN Nonpeptide and peptide growth hormone secretagogues act both as ghrelin receptor agonist and as positive or negative allosteric modulators of ghrel... Mol Endocrinol. 2005 Sep;19(9):2400-11. DMLHE5A RU https://pubmed.ncbi.nlm.nih.gov/15905359 DMLO2QY DI DMLO2QY DMLO2QY DN Z-321 DMLO2QY TI TTNGKET DMLO2QY TN Prolyl endopeptidase (PREP) DMLO2QY MA Modulator DMLO2QY RN Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices. Behav Brain Res. 1997 Feb;83(1-2):213-6. DMLO2QY RU https://pubmed.ncbi.nlm.nih.gov/9062687 DMLQD6F DI DMLQD6F DMLQD6F DN RIG-200 DMLQD6F TI TTLBYH1 DMLQD6F TN Guanylate cyclase soluble beta-1 (GUCY1B1) DMLQD6F MA Modulator DMLQD6F RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMLQD6F RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMLRF7U DI DMLRF7U DMLRF7U DN F-11105 DMLRF7U TI TTK0943 DMLRF7U TN Prostaglandin G/H synthase (COX) DMLRF7U MA Inhibitor DMLRF7U RN US patent application no. 6,673,908, Tumor necrosis factor receptor 2. DMLRF7U RU http://www.google.com/patents/US6673908 DMM7Q3L DI DMM7Q3L DMM7Q3L DN GSK2849466 DMM7Q3L TI TTS64P2 DMM7Q3L TN Androgen receptor (AR) DMM7Q3L MA Modulator DMM7Q3L RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036899) DMM7Q3L RU http://adisinsight.springer.com/drugs/800036899 DMMAFQP DI DMMAFQP DMMAFQP DN Besonprodil DMMAFQP TI TTN9D8E DMMAFQP TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMMAFQP MA Antagonist DMMAFQP RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMMAFQP RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMMD6LR DI DMMD6LR DMMD6LR DN KR-30450 DMMD6LR TI TT1VOHK DMMD6LR TN Potassium channel unspecific (KC) DMMD6LR MA Opener DMMD6LR RN Cardioprotective effects of KR-30450, a novel K+(ATP) opener, and its major metabolite KR-30818 on isolated rat hearts. Jpn J Pharmacol. 1998 Jan;76(1):65-73. DMMD6LR RU https://pubmed.ncbi.nlm.nih.gov/9517406 DMMEAZ2 DI DMMEAZ2 DMMEAZ2 DN RU-58841 DMMEAZ2 TI TTKPW01 DMMEAZ2 TN Androgen receptor messenger RNA (AR mRNA) DMMEAZ2 MA Inhibitor DMMEAZ2 RN Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4. DMMEAZ2 RU https://pubmed.ncbi.nlm.nih.gov/18921992 DMMEC1W DI DMMEC1W DMMEC1W DN CCD-3693 DMMEC1W TI TTEX6LM DMMEC1W TN GABA(A) receptor gamma-3 (GABRG3) DMMEC1W MA Modulator DMMEC1W RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMEC1W RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMF0OP DI DMMF0OP DMMF0OP DN RO-4987655 DMMF0OP TI TTROQ37 DMMF0OP TN MAPK/ERK kinase kinase (MAP3K) DMMF0OP MA Modulator DMMF0OP RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DMMF0OP RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DMMG6W5 DI DMMG6W5 DMMG6W5 DN F-50040 DMMG6W5 TI TT362RB DMMG6W5 TN MART-1 melanoma antigen (MLANA) DMMG6W5 MA Modulator DMMG6W5 RN Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8. DMMG6W5 RU https://pubmed.ncbi.nlm.nih.gov/11851331 DMMG6W5 DI DMMG6W5 DMMG6W5 DN F-50040 DMMG6W5 TI TTY7ZHS DMMG6W5 TN Toll-like receptor 2 (TLR2) DMMG6W5 MA Modulator DMMG6W5 RN Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8. DMMG6W5 RU https://pubmed.ncbi.nlm.nih.gov/11851331 DMMK42O DI DMMK42O DMMK42O DN Roquinimex DMMK42O TI TTF89GD DMMK42O TN Interleukin-2 (IL2) DMMK42O MA Modulator DMMK42O RN The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors. Leuk Res. 1996 Jan;20(1):57-63. DMMK42O RU https://pubmed.ncbi.nlm.nih.gov/8632678 DMMLESX DI DMMLESX DMMLESX DN ND1251 DMMLESX TI TTZSJIV DMMLESX TN Sphingomyelin phosphodiesterase 4 (SMPD4) DMMLESX MA Inhibitor DMMLESX RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMMLESX RU http://www.centerwatch.com/ DMMLESX DI DMMLESX DMMLESX DN ND1251 DMMLESX TI TTNT7K8 DMMLESX TN Nociceptin receptor (OPRL1) DMMLESX MA Agonist DMMLESX RN The nociceptin receptor as a potential target in drug design. Drug News Perspect. 2001 Aug;14(6):335-45. DMMLESX RU https://pubmed.ncbi.nlm.nih.gov/12813596 DMMPBZF DI DMMPBZF DMMPBZF DN AVE-3247 DMMPBZF TI TTCIHJA DMMPBZF TN Coagulation factor Xa (F10) DMMPBZF MA Inhibitor DMMPBZF RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMMPBZF RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMMSWJ3 DI DMMSWJ3 DMMSWJ3 DN U-93385 DMMSWJ3 TI TTSQIFT DMMSWJ3 TN 5-HT 1A receptor (HTR1A) DMMSWJ3 MA Agonist DMMSWJ3 RN Tolerance development to the vagal-mediated bradycardia produced by 5-HT1A receptor agonists. J Pharmacol Exp Ther. 1994 Nov;271(2):776-81. DMMSWJ3 RU https://pubmed.ncbi.nlm.nih.gov/7965796 DMMT7BC DI DMMT7BC DMMT7BC DN NIP-520 DMMT7BC TI TTZCG4L DMMT7BC TN Phosphodiesterase 3 (PDE3) DMMT7BC MA Modulator DMMT7BC RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMMT7BC RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMMU1W3 DI DMMU1W3 DMMU1W3 DN PF-3526299 DMMU1W3 TI TTOU65C DMMU1W3 TN Tyrosine-protein kinase SYK (SYK) DMMU1W3 MA Inhibitor DMMU1W3 RN Pipeline report of RIGEL Pharmaceuticals. DMMU1W3 RU http://www.rigel.com/index.php/pipeline/ DMMVG34 DI DMMVG34 DMMVG34 DN MPC-0920 DMMVG34 TI TT6L509 DMMVG34 TN Coagulation factor IIa (F2) DMMVG34 MA Inhibitor DMMVG34 RN Clinical pipeline report, company report or official report of MYRIAD GENETICS, INC. DMMVG34 RU http://investor.myriad.com/secfiling.cfm?filingid=1193125-08-186392&cik= DMMWCU3 DI DMMWCU3 DMMWCU3 DN Licostinel DMMWCU3 TI TT6L509 DMMWCU3 TN Coagulation factor IIa (F2) DMMWCU3 MA Inhibitor DMMWCU3 RN Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. DMMWCU3 RU https://pubmed.ncbi.nlm.nih.gov/12507405 DMMYI9U DI DMMYI9U DMMYI9U DN Org-21465 DMMYI9U TI TTEX6LM DMMYI9U TN GABA(A) receptor gamma-3 (GABRG3) DMMYI9U MA Modulator DMMYI9U RN Computer-controlled infusion of ORG 21465, a water soluble steroid i.v. anaesthetic agent, into human volunteers. Br J Anaesth. 1997 Oct;79(4):433-9. DMMYI9U RU https://pubmed.ncbi.nlm.nih.gov/9389258 DMN02XD DI DMN02XD DMN02XD DN TAK-029 DMN02XD TI TT38RM1 DMN02XD TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMN02XD MA Modulator DMN02XD RN Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study. Artif Organs. 1998 Apr;22(4):348-52. DMN02XD RU https://www.ncbi.nlm.nih.gov/pubmed/9555968 DMN2XR7 DI DMN2XR7 DMN2XR7 DN BCX-1470 DMN2XR7 TI TT6L509 DMN2XR7 TN Coagulation factor IIa (F2) DMN2XR7 MA Inhibitor DMN2XR7 RN Recent Developments in Low Molecular Weight Complement Inhibitors. Mol Immunol. 2009 December; 47(2-3): 185-195. DMN2XR7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788007/ DMN8R2U DI DMN8R2U DMN8R2U DN APD668 DMN8R2U TI TT7QNVC DMN8R2U TN Glucose-dependent insulinotropic receptor (GPR119) DMN8R2U MA Agonist DMN8R2U RN Announces Initiation of Phase 1 Clinical Trial of Arena Type 2 Diabetes Drug Candidate in Collaboration With Ortho-McNeil. Arena Pharmaceuticals, Inc. FEBRUARY 07, 2006. DMN8R2U RU http://www.prnewswire.com/news-releases/arena-pharmaceuticals-inc-announces-initiation-of-phase-1-clinical-trial-of-arena-type-2-diabetes-drug-candidate-in-collaboration-with-ortho-mcneil-55232422.html DMN9KXU DI DMN9KXU DMN9KXU DN DU-29894 DMN9KXU TI TTSQIFT DMN9KXU TN 5-HT 1A receptor (HTR1A) DMN9KXU MA Modulator DMN9KXU RN A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol. 1995 Jan;39(1):7-14. DMN9KXU RU https://pubmed.ncbi.nlm.nih.gov/7756102 DMN9KXU DI DMN9KXU DMN9KXU DN DU-29894 DMN9KXU TI TTEX248 DMN9KXU TN Dopamine D2 receptor (D2R) DMN9KXU MA Modulator DMN9KXU RN A comparison of the neuro-endocrinological and temperature effects of DU 29894, flesinoxan, sulpiride and haloperidol in normal volunteers. Br J Clin Pharmacol. 1995 Jan;39(1):7-14. DMN9KXU RU https://pubmed.ncbi.nlm.nih.gov/7756102 DMNAJGK DI DMNAJGK DMNAJGK DN MK-0963 DMNAJGK TI TT2A0DR DMNAJGK TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DMNAJGK MA Inhibitor DMNAJGK RN Pharmacodynamics of MK-0963, a new 5 alpha-reductase inhibitor: effects on serum androgen concentrations. Clin Pharmacol Ther. 1994 Jan;55(1):50-4. DMNAJGK RU https://pubmed.ncbi.nlm.nih.gov/8299317 DMNC1A3 DI DMNC1A3 DMNC1A3 DN HOE-065 DMNC1A3 TI TTZJD1B DMNC1A3 TN Acetylcholine release (Ach rele) DMNC1A3 MA Modulator DMNC1A3 RN Effects of the novel compound, Hoe 065, upon impaired learning and memory in rodents. Eur J Pharmacol. 1989 Nov 14;171(1):79-85. DMNC1A3 RU https://pubmed.ncbi.nlm.nih.gov/2612569 DMNFWR1 DI DMNFWR1 DMNFWR1 DN Gedocarnil DMNFWR1 TI TTNJYV2 DMNFWR1 TN Gamma-aminobutyric acid receptor (GAR) DMNFWR1 MA Modulator DMNFWR1 RN US patent application no. US20040102438 A1. DMNFWR1 RU https://www.google.com.ar/patents/US20040102438 DMNH8XU DI DMNH8XU DMNH8XU DN SB 235699 DMNH8XU TI TTQBR95 DMNH8XU TN Stress-activated protein kinase 2a (p38 alpha) DMNH8XU MA Inhibitor DMNH8XU RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMNH8XU RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMNH8XU DI DMNH8XU DMNH8XU DN SB 235699 DMNH8XU TI TT73U6C DMNH8XU TN Stress-activated protein kinase 2b (p38 beta) DMNH8XU MA Inhibitor DMNH8XU RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMNH8XU RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMNH8XU DI DMNH8XU DMNH8XU DN SB 235699 DMNH8XU TI TTYT93M DMNH8XU TN MAP kinase p38 (MAPK12) DMNH8XU MA Inhibitor DMNH8XU RN Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J Med Chem. 2003 Dec 18;46(26):5651-62. DMNH8XU RU https://pubmed.ncbi.nlm.nih.gov/14667219 DMNL9DS DI DMNL9DS DMNL9DS DN NSD-644 DMNL9DS TI TTVBI8W DMNL9DS TN Dopamine transporter (DAT) DMNL9DS MA Activator DMNL9DS RN NSD-644: Phase I started.NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark, GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. DMNL9DS RU http://www.biocentury.com/weekinreview/clinicalstatus/2007-12-10/nsd-644-phase-i-started-199006 DMNL9DS DI DMNL9DS DMNL9DS DN NSD-644 DMNL9DS TI TT3ROYC DMNL9DS TN Serotonin transporter (SERT) DMNL9DS MA Activator DMNL9DS RN NSD-644: Phase I started.NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark, GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K. DMNL9DS RU http://www.biocentury.com/weekinreview/clinicalstatus/2007-12-10/nsd-644-phase-i-started-199006 DMNL9DS DI DMNL9DS DMNL9DS DN NSD-644 DMNL9DS TI TTAWNKZ DMNL9DS TN Norepinephrine transporter (NET) DMNL9DS MA Activator DMNL9DS RN Clinical pipeline report, company report or official report of Neurosearch. DMNL9DS RU http://www.neurosearch.dk/Admin/Public/Download.aspx?file=Files%2FFiler%2FPdf%2FFonds.08-08_-_selskabsmeddelelser_i_2007_-_uk.pdf DMNLAU7 DI DMNLAU7 DMNLAU7 DN PF-4629991 DMNLAU7 TI TT9JZCK DMNLAU7 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMNLAU7 MA Agonist DMNLAU7 RN US patent application no. 2010,0158,905, Combination therapy of arthritis with tranilast. DMNLAU7 RU https://www.google.com/patents/US20100158905 DMNOZAI DI DMNOZAI DMNOZAI DN ALX-0646 DMNOZAI TI TT6MSOK DMNOZAI TN 5-HT 1D receptor (HTR1D) DMNOZAI MA Agonist DMNOZAI RN Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75. DMNOZAI RU http://www.thejournalofheadacheandpain.com/content/pdf/1129-2377-14-S1-P75.pdf DMNPJL3 DI DMNPJL3 DMNPJL3 DN LY-444711 DMNPJL3 TI TTWDC17 DMNPJL3 TN Growth hormone secretagogue receptor 1 (GHSR) DMNPJL3 MA Agonist DMNPJL3 RN Synthesis and biological evaluation of an orally active ghrelin agonist that stimulates food consumption and adiposity in rats. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5873-6. DMNPJL3 RU https://pubmed.ncbi.nlm.nih.gov/15501059 DMO075K DI DMO075K DMO075K DN CEFTRAZONAL BOPENTIL DMO075K TI TTJP4SM DMO075K TN Bacterial Penicillin binding protein (Bact PBP) DMO075K MA Inhibitor DMO075K RN Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):946-9. DMO075K RU https://pubmed.ncbi.nlm.nih.gov/1486894 DMO4S6T DI DMO4S6T DMO4S6T DN PF-03814735 DMO4S6T TI TTPS3C0 DMO4S6T TN Aurora kinase A (AURKA) DMO4S6T MA Inhibitor DMO4S6T RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMO4S6T RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMO4S6T DI DMO4S6T DMO4S6T DN PF-03814735 DMO4S6T TI TT5LS6T DMO4S6T TN Aurora kinase B (AURKB) DMO4S6T MA Inhibitor DMO4S6T RN Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66. DMO4S6T RU https://pubmed.ncbi.nlm.nih.gov/19568282 DMO7920 DI DMO7920 DMO7920 DN AM-831 DMO7920 TI TTJQOD7 DMO7920 TN 5-HT 2A receptor (HTR2A) DMO7920 MA Agonist DMO7920 RN Clinical pipeline report, company report or official report of Avarx. DMO7920 RU http://www.avarx.com/AvaRx/SubDomains/Company44/Listings/bucket496701808487035926/Public.Listing.display.html DMO7920 DI DMO7920 DMO7920 DN AM-831 DMO7920 TI TTEX248 DMO7920 TN Dopamine D2 receptor (D2R) DMO7920 MA Agonist DMO7920 RN Clinical pipeline report, company report or official report of Avarx. DMO7920 RU http://www.avarx.com/AvaRx/SubDomains/Company44/Listings/bucket496701808487035926/Public.Listing.display.html DMO7920 DI DMO7920 DMO7920 DN AM-831 DMO7920 TI TTH18TF DMO7920 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMO7920 MA Agonist DMO7920 RN Clinical pipeline report, company report or official report of Avarx. DMO7920 RU http://www.avarx.com/AvaRx/SubDomains/Company44/Listings/bucket496701808487035926/Public.Listing.display.html DMOCBQW DI DMOCBQW DMOCBQW DN CD-581 DMOCBQW TI TT2J34L DMOCBQW TN Arachidonate 5-lipoxygenase (5-LOX) DMOCBQW MA Inhibitor DMOCBQW RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMOCBQW RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMOHEYU DI DMOHEYU DMOHEYU DN TS-032 DMOHEYU TI TTXJ47W DMOHEYU TN Metabotropic glutamate receptor 2 (mGluR2) DMOHEYU MA Agonist DMOHEYU RN Metabotropic glutamate receptor subtype 2/3 (mGluR2/3); serotonin receptor (5-HT2A receptor). SciBX 1(6); doi:10.1038/scibx.2008.145. March 6 2008 DMOHEYU RU http://www.nature.com/scibx/journal/v1/n6/full/scibx.2008.145.html DMOI037 DI DMOI037 DMOI037 DN RG-4934 DMOI037 TI TTG0MT6 DMOI037 TN Interleukin-17 (IL17) DMOI037 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032677) DMOI037 RU http://adisinsight.springer.com/drugs/800032677 DMOMVW9 DI DMOMVW9 DMOMVW9 DN NPC-15669 DMOMVW9 TI TTJAY96 DMOMVW9 TN Polymorphonuclear neutrophil adhesion (PMNA) DMOMVW9 MA Modulator DMOMVW9 RN NPC 15669-modulated human polymorphonuclear neutrophil functional responsiveness: effects on receptor-coupled signal transduction. Br J Pharmacol. 1995 Apr;114(8):1694-702. DMOMVW9 RU https://pubmed.ncbi.nlm.nih.gov/7599938 DMOPM7L DI DMOPM7L DMOPM7L DN DRF 10945 DMOPM7L TI TTJ584C DMOPM7L TN Peroxisome proliferator-activated receptor alpha (PPARA) DMOPM7L MA Agonist DMOPM7L RN Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 2010 September; 6(5): 657-691. DMOPM7L RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246744/ DMOQZIW DI DMOQZIW DMOQZIW DN PF-3052334 DMOQZIW TI TTPADOQ DMOQZIW TN HMG-CoA reductase (HMGCR) DMOQZIW MA Inhibitor DMOQZIW RN Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylca... J Med Chem. 2008 Jan 10;51(1):31-45. DMOQZIW RU https://pubmed.ncbi.nlm.nih.gov/18072721 DMOULQ4 DI DMOULQ4 DMOULQ4 DN CGP-37849 DMOULQ4 TI TT9IK2Z DMOULQ4 TN N-methyl-D-aspartate receptor (NMDAR) DMOULQ4 MA Modulator DMOULQ4 RN The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol. 1990 Jul;342(1):61-6. DMOULQ4 RU https://pubmed.ncbi.nlm.nih.gov/1976233 DMOVLDT DI DMOVLDT DMOVLDT DN SB-247853 DMOVLDT TI TTWJBZ5 DMOVLDT TN 5-HT 2C receptor (HTR2C) DMOVLDT MA Agonist DMOVLDT RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016366) DMOVLDT RU http://adisinsight.springer.com/drugs/800016366 DMOVZDY DI DMOVZDY DMOVZDY DN RO-16-8714 DMOVZDY TI TTMXGCW DMOVZDY TN Adrenergic receptor beta-3 (ADRB3) DMOVZDY MA Modulator DMOVZDY RN The novel thermogenic beta-adrenergic agonist Ro 16-8714 increases the interscapular brown-fat beta-receptor-adenylate cyclase and the uncoupling-protein mRNA level in obese (fa/fa) Zucker rats. Biochem J. 1989 Aug 1;261(3):721-4. DMOVZDY RU https://pubmed.ncbi.nlm.nih.gov/2572217 DMOX8AD DI DMOX8AD DMOX8AD DN RO-48-8684 DMOX8AD TI TTEX6LM DMOX8AD TN GABA(A) receptor gamma-3 (GABRG3) DMOX8AD MA Modulator DMOX8AD RN Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol. 1997 Nov;44(5):487-93. DMOX8AD RU https://pubmed.ncbi.nlm.nih.gov/9384466 DMP0DLW DI DMP0DLW DMP0DLW DN SL-25.1188 DMP0DLW TI TTGP7BY DMP0DLW TN Monoamine oxidase type B (MAO-B) DMP0DLW MA Inhibitor DMP0DLW RN [(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse. 2010 Jan;64(1):61-9. DMP0DLW RU https://pubmed.ncbi.nlm.nih.gov/19728365 DMP0YNU DI DMP0YNU DMP0YNU DN RO7040547 DMP0YNU TI TTG0MT6 DMP0YNU TN Interleukin-17 (IL17) DMP0YNU MA Inhibitor DMP0YNU RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DMP0YNU RU https://pubmed.ncbi.nlm.nih.gov/31175342 DMP0YNU DI DMP0YNU DMP0YNU DN RO7040547 DMP0YNU TI TT0GVCH DMP0YNU TN Interleukin-13 (IL13) DMP0YNU MA Inhibitor DMP0YNU RN Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608. DMP0YNU RU https://pubmed.ncbi.nlm.nih.gov/31175342 DMP19KT DI DMP19KT DMP19KT DN MBI 1121 DMP19KT TI TTK025N DMP19KT TN Human papillomavirus E1 region messenger RNA (HPV E1 mRNA) DMP19KT RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMP19KT RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMP8MBW DI DMP8MBW DMP8MBW DN IGANIDIPINE HYDROCHLORIDE DMP8MBW TI TT5HONZ DMP8MBW TN Calcium channel unspecific (CaC) DMP8MBW MA Blocker DMP8MBW RN Improving effects of topical administration of iganidipine, a new calcium channel blocker, on the impaired visual evoked potential after endothelin-1 injection into the vitreous body of rabbits. CurrEye Res. 2000 Feb;20(2):101-8. DMP8MBW RU https://pubmed.ncbi.nlm.nih.gov/10617910 DMPC9K3 DI DMPC9K3 DMPC9K3 DN F-1394 DMPC9K3 TI TTMF541 DMPC9K3 TN Liver carboxylesterase (CES1) DMPC9K3 MA Modulator DMPC9K3 RN ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits. J Lipid Res. 2001 Apr;42(4):480-8. DMPC9K3 RU https://pubmed.ncbi.nlm.nih.gov/11290819 DMPCYV6 DI DMPCYV6 DMPCYV6 DN ABT-107 DMPCYV6 TI TTLA931 DMPCYV6 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMPCYV6 MA Modulator DMPCYV6 RN In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107. J Pharmacol Exp Ther. 2010 Sep 1;334(3):863-74. DMPCYV6 RU https://pubmed.ncbi.nlm.nih.gov/20504915 DMPDJC8 DI DMPDJC8 DMPDJC8 DN Opterone DMPDJC8 TI TTS64P2 DMPDJC8 TN Androgen receptor (AR) DMPDJC8 MA Inhibitor DMPDJC8 RN Evidence for a role of testosterone-androgen receptor interactions in mediating masculine sexual behavior in male rats. Endocrinology. 1989 Feb;124(2):618-26. DMPDJC8 RU https://pubmed.ncbi.nlm.nih.gov/2912689 DMPWG2K DI DMPWG2K DMPWG2K DN PNU-142721 DMPWG2K TI TT84ETX DMPWG2K TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMPWG2K MA Inhibitor DMPWG2K RN Activation of the human nuclear xenobiotic receptor PXR by the reverse transcriptase-targeted anti-HIV drug PNU-142721. Protein Sci. 2011 Oct;20(10):1713-9. DMPWG2K RU https://pubmed.ncbi.nlm.nih.gov/21805522 DMQ2VYT DI DMQ2VYT DMQ2VYT DN AZD-4750 DMQ2VYT TI TTQR8Z6 DMQ2VYT TN Chemokine receptor (CHR) DMQ2VYT MA Modulator DMQ2VYT RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018778) DMQ2VYT RU http://adisinsight.springer.com/drugs/800018778 DMQ4HUA DI DMQ4HUA DMQ4HUA DN CAB-2 DMQ4HUA TI TTA0P7K DMQ4HUA TN Complement factor B (CFB) DMQ4HUA MA Inhibitor DMQ4HUA RN A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation. Xenotransplantation. 2002 Mar;9(2):125-34. DMQ4HUA RU https://pubmed.ncbi.nlm.nih.gov/11897005 DMQA5JW DI DMQA5JW DMQA5JW DN MLN-2201 DMQA5JW TI TTIJWR7 DMQA5JW TN Integrin beta-2 (ITGB2) DMQA5JW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010178) DMQA5JW RU http://adisinsight.springer.com/drugs/800010178 DMQBURK DI DMQBURK DMQBURK DN Ordopidine DMQBURK TI TTEX248 DMQBURK TN Dopamine D2 receptor (D2R) DMQBURK MA Modulator DMQBURK RN The dopaminergic stabilizers pridopidine and ordopidine enhance cortico-striatal Arc gene expression. J Neural Transm. 2014 Nov;121(11):1337-47. DMQBURK RU https://pubmed.ncbi.nlm.nih.gov/24817271 DMQDNU1 DI DMQDNU1 DMQDNU1 DN ZD-4927 DMQDNU1 TI TTCIHJA DMQDNU1 TN Coagulation factor Xa (F10) DMQDNU1 MA Inhibitor DMQDNU1 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMQDNU1 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMQH8L2 DI DMQH8L2 DMQH8L2 DN EMD-503982 DMQH8L2 TI TTCIHJA DMQH8L2 TN Coagulation factor Xa (F10) DMQH8L2 MA Inhibitor DMQH8L2 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMQH8L2 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMQI2F4 DI DMQI2F4 DMQI2F4 DN BEPH DMQI2F4 TI TT0DBAO DMQI2F4 TN Polyamine unspecific (PLA) DMQI2F4 MA Modulator DMQI2F4 RN Antitumor activity of a novel synthetic polyamine analogue, N,N'-bis-[3-(ethylamino)-propyl]-1-7-heptane diamine: potentiation by polyamine oxidase inhibitors. Anticancer Res. 1990 Sep-Oct;10(5A):1281-7. DMQI2F4 RU https://pubmed.ncbi.nlm.nih.gov/2241104 DMQIWZL DI DMQIWZL DMQIWZL DN Candoxatrilat DMQIWZL TI TT5TKPM DMQIWZL TN Neutral endopeptidase (MME) DMQIWZL MA Inhibitor DMQIWZL RN Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992 Mar;10(3):271-7. DMQIWZL RU https://pubmed.ncbi.nlm.nih.gov/1315825 DMQIXD2 DI DMQIXD2 DMQIXD2 DN IMC-1C11 DMQIXD2 TI TTUTJGQ DMQIXD2 TN Vascular endothelial growth factor receptor 2 (KDR) DMQIXD2 RN Technology evaluation: IMC-1C11, ImClone Systems. Curr Opin Mol Ther. 2001 Aug;3(4):418-24. DMQIXD2 RU https://pubmed.ncbi.nlm.nih.gov/11525567 DMQK53O DI DMQK53O DMQK53O DN DS-7250 DMQK53O TI TTF8P9I DMQK53O TN Diacylglycerol acyltransferase 1 (DGAT1) DMQK53O MA Modulator DMQK53O RN Clinical pipeline report, company report or official report of Daiichi Sankyo. DMQK53O RU http://www.daiichisankyo.com/rd/pipeline/pdf/20130513_Pipeline_EN1.pdf DMQKH07 DI DMQKH07 DMQKH07 DN XM-323 DMQKH07 TI TT5FNQT DMQKH07 TN Human immunodeficiency virus Protease (HIV PR) DMQKH07 MA Inhibitor DMQKH07 RN In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother. 1993 Dec;37(12):2606-11. DMQKH07 RU https://pubmed.ncbi.nlm.nih.gov/8109924 DMQKRWO DI DMQKRWO DMQKRWO DN CERM-11956 DMQKRWO TI TT5HONZ DMQKRWO TN Calcium channel unspecific (CaC) DMQKRWO MA Antagonist DMQKRWO RN The anti-ischaemic activity of the novel compound, CERM 11956, compared with that of bepridil and nifedipine in isolated guinea-pig hearts. Eur J Pharmacol. 1988 May 10;149(3):195-203. DMQKRWO RU https://pubmed.ncbi.nlm.nih.gov/3261692 DMQNX02 DI DMQNX02 DMQNX02 DN GYKI-12743 DMQNX02 TI TT2NUT5 DMQNX02 TN Adrenergic receptor alpha-2C (ADRA2C) DMQNX02 MA Modulator DMQNX02 RN GYKI-12743 a new postsynaptic vascular alpha-adrenoceptor antagonist. Acta Physiol Hung. 1991;77(3-4):257-67. DMQNX02 RU https://pubmed.ncbi.nlm.nih.gov/1684485 DMQOW8H DI DMQOW8H DMQOW8H DN HO-221 DMQOW8H TI TTGPJ0U DMQOW8H TN DNA polymerase alpha catalytic p180 (POLA1) DMQOW8H MA Modulator DMQOW8H RN Effect of novel benzoylphenylurea derivatives on DNA polymerase alpha activity using the synthesome-based in vitro model system. Invest New Drugs. 2003 Nov;21(4):421-8. DMQOW8H RU https://www.ncbi.nlm.nih.gov/pubmed/14586209 DMQSGOD DI DMQSGOD DMQSGOD DN SMP-028 DMQSGOD TI TTTWGIX DMQSGOD TN Leukotriene receptor (LTR) DMQSGOD MA Modulator DMQSGOD RN Effect of SMP-028 on steroidogenesis in rats; mechanism of toxicological events on endocrine organs of rats. Toxicol In Vitro. 2014 Apr;28(3):397-402. DMQSGOD RU https://pubmed.ncbi.nlm.nih.gov/24362046 DMQVLZH DI DMQVLZH DMQVLZH DN T-62 DMQVLZH TI TTM2AOE DMQVLZH TN Adenosine A2a receptor (ADORA2A) DMQVLZH MA Antagonist DMQVLZH RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMQVLZH RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMQYWAH DI DMQYWAH DMQYWAH DN HRT DMQYWAH TI TTZAYWL DMQYWAH TN Estrogen receptor (ESR) DMQYWAH MA Agonist DMQYWAH RN US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions. DMQYWAH RU https://www.google.com.ar/patents/US20100278784 DMQZCET DI DMQZCET DMQZCET DN AZD-6553 DMQZCET TI TTPLTSQ DMQZCET TN Neutrophil elastase (NE) DMQZCET MA Inhibitor DMQZCET RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032703) DMQZCET RU http://adisinsight.springer.com/drugs/800032703 DMR2EUV DI DMR2EUV DMR2EUV DN V-102862 DMR2EUV TI TT84DRB DMR2EUV TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMR2EUV MA Inhibitor DMR2EUV RN 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52. DMR2EUV RU https://pubmed.ncbi.nlm.nih.gov/14998340 DMR2EUV DI DMR2EUV DMR2EUV DN V-102862 DMR2EUV TI TT4G2JS DMR2EUV TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMR2EUV MA Inhibitor DMR2EUV RN Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40. DMR2EUV RU https://pubmed.ncbi.nlm.nih.gov/20709552 DMR6INY DI DMR6INY DMR6INY DN DPC 423 DMR6INY TI TTCIHJA DMR6INY TN Coagulation factor Xa (F10) DMR6INY MA Inhibitor DMR6INY RN The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49. DMR6INY RU https://pubmed.ncbi.nlm.nih.gov/11899249 DMR6QMJ DI DMR6QMJ DMR6QMJ DN RC-8800 DMR6QMJ TI TTTHCPF DMR6QMJ TN Cholesterol 24-monooxygenase (CYP46A1) DMR6QMJ MA Inhibitor DMR6QMJ RN Clinical pipeline report, company report or official report of Boston Millennia Partners. DMR6QMJ RU http://www.bostonmillenniapartners.com/OurPortfolio/Default.asp?PortfolioCompanyID=68 DMR7WYX DI DMR7WYX DMR7WYX DN BLX-883 DMR7WYX TI TTSYFMA DMR7WYX TN Interferon alpha/beta receptor 1 (IFNAR1) DMR7WYX MA Modulator DMR7WYX RN Patent CN103536906 A. DMR7WYX RU http://www.google.com/patents/CN103536906A?cl=en DMR9JA8 DI DMR9JA8 DMR9JA8 DN SSR-146977 DMR9JA8 TI TTBPGLU DMR9JA8 TN Neuromedin-K receptor (TACR3) DMR9JA8 MA Antagonist DMR9JA8 RN Biochemical and pharmacological activities of SSR 146977, a new potent nonpeptide tachykinin NK3 receptor antagonist. Can J Physiol Pharmacol. 2002 May;80(5):482-8. DMR9JA8 RU https://pubmed.ncbi.nlm.nih.gov/12056557 DMRD8HK DI DMRD8HK DMRD8HK DN TAK-683 DMRD8HK TI TT3KBZY DMRD8HK TN G-protein coupled receptor 54 (KISS1R) DMRD8HK MA Agonist DMRD8HK RN Clinical pipeline report, company report or official report of Takeda (2009). DMRD8HK RU http://www.takeda.com/pdf/usr/default/10_1_34992_2.pdf DMRD8HK DI DMRD8HK DMRD8HK DN TAK-683 DMRD8HK TI TTN53ZF DMRD8HK TN Leukotriene B4 receptor 1 (LTB4R) DMRD8HK MA Antagonist DMRD8HK RN A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000 Aug 7;192(3):421-32. DMRD8HK RU https://pubmed.ncbi.nlm.nih.gov/10934230 DMRHF97 DI DMRHF97 DMRHF97 DN R1204 DMRHF97 TI TTXEU7H DMRHF97 TN GPCR unspecific (GPCR) DMRHF97 MA Modulator DMRHF97 RN Clinical pipeline report, company report or official report of Roche. DMRHF97 RU http://www.roche.com/pages/downloads/investor/pdf/praesentations/irp2702ch.pdf DMRIK2Y DI DMRIK2Y DMRIK2Y DN MC-02,479 DMRIK2Y TI TTJP4SM DMRIK2Y TN Bacterial Penicillin binding protein (Bact PBP) DMRIK2Y MA Inhibitor DMRIK2Y RN RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal be... Antimicrob Agents Chemother. 2003 Feb;47(2):658-64. DMRIK2Y RU https://pubmed.ncbi.nlm.nih.gov/12543674 DMRLHNW DI DMRLHNW DMRLHNW DN Aprosulate sodium DMRLHNW TI TTZBFA0 DMRLHNW TN Protease unspecific (PRO) DMRLHNW MA Modulator DMRLHNW RN Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model. Pol J Pharmacol. 1996 May-Jun;48(3):317-22. DMRLHNW RU https://pubmed.ncbi.nlm.nih.gov/9112669 DMRNI6K DI DMRNI6K DMRNI6K DN GR-127607 DMRNI6K TI TTSQIFT DMRNI6K TN 5-HT 1A receptor (HTR1A) DMRNI6K MA Agonist DMRNI6K RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003531) DMRNI6K RU http://adisinsight.springer.com/drugs/800003531 DMRQFIE DI DMRQFIE DMRQFIE DN ANQ-9040 DMRQFIE TI TTJSZTB DMRQFIE TN Nicotinic acetylcholine receptor (nAChR) DMRQFIE MA Modulator DMRQFIE RN Patent US20030087306 A1. DMRQFIE RU http://www.google.com/patents/US20030087306 DMRQVI9 DI DMRQVI9 DMRQVI9 DN GW-473178 DMRQVI9 TI TT6L509 DMRQVI9 TN Coagulation factor IIa (F2) DMRQVI9 MA Inhibitor DMRQVI9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015039) DMRQVI9 RU http://adisinsight.springer.com/drugs/800015039 DMRSEZD DI DMRSEZD DMRSEZD DN AE-3763 DMRSEZD TI TTPLTSQ DMRSEZD TN Neutrophil elastase (NE) DMRSEZD MA Inhibitor DMRSEZD RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DMRSEZD RU https://pubmed.ncbi.nlm.nih.gov/12084007 DMRSJ49 DI DMRSJ49 DMRSJ49 DN IL-18BP DMRSJ49 TI TTRICUF DMRSJ49 TN Interleukin-18 (IL18) DMRSJ49 MA Binder DMRSJ49 RN Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. DMRSJ49 RU https://pubmed.ncbi.nlm.nih.gov/18321156 DMRTPY6 DI DMRTPY6 DMRTPY6 DN GSK729327 DMRTPY6 TI TTAN6JD DMRTPY6 TN Glutamate receptor AMPA (GRIA) DMRTPY6 MA Modulator DMRTPY6 RN Clinical pipeline report, company report or official report of GlaxoSmithKline (2009). DMRTPY6 RU http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-feb09.pdf DMRXB8F DI DMRXB8F DMRXB8F DN S-1746 DMRXB8F TI TT9IK2Z DMRXB8F TN N-methyl-D-aspartate receptor (NMDAR) DMRXB8F MA Antagonist DMRXB8F RN 1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77. DMRXB8F RU https://pubmed.ncbi.nlm.nih.gov/16453316 DMRXB8F DI DMRXB8F DMRXB8F DN S-1746 DMRXB8F TI TTAN6JD DMRXB8F TN Glutamate receptor AMPA (GRIA) DMRXB8F MA Antagonist DMRXB8F RN 1,026 experimental treatments in acute stroke. Ann Neurol. 2006 Mar;59(3):467-77. DMRXB8F RU https://pubmed.ncbi.nlm.nih.gov/16453316 DMS19VG DI DMS19VG DMS19VG DN DPC-684 DMS19VG TI TT5FNQT DMS19VG TN Human immunodeficiency virus Protease (HIV PR) DMS19VG MA Inhibitor DMS19VG RN DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants. Antimicrob Agents Chemother. 2001 Nov;45(11):3021-8. DMS19VG RU https://pubmed.ncbi.nlm.nih.gov/11600351 DMS4IBW DI DMS4IBW DMS4IBW DN DS-1442 DMS4IBW TI TTFQAYR DMS4IBW TN Cholesteryl ester transfer protein (CETP) DMS4IBW MA Modulator DMS4IBW RN Ds-1442b is a Novel, Potent Cetp Inhibitor That Reduces Atherosclerosis by Hdl Elevation and Non-hdl Reduction. Circulation. 2012; 126: A11806. DMS4IBW RU http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11806 DMS5C06 DI DMS5C06 DMS5C06 DN ALTU-237 DMS5C06 TI TTMDQIJ DMS5C06 TN Oxalate absorption (Oxalate absor) DMS5C06 MA Modulator DMS5C06 RN Hyperoxaluria: a gut-kidney axis. Kidney Int. 2011 Dec;80(11):1146-58. DMS5C06 RU https://pubmed.ncbi.nlm.nih.gov/21866092 DMS7M0U DI DMS7M0U DMS7M0U DN PF-514273 DMS7M0U TI TT6OEDT DMS7M0U TN Cannabinoid receptor 1 (CB1) DMS7M0U MA Modulator DMS7M0U RN Effects of the novel cannabinoid CB1 receptor antagonist PF 514273 on the acquisition and expression of ethanol conditioned place preference. Alcohol. 2014 Aug;48(5):427-31. DMS7M0U RU https://pubmed.ncbi.nlm.nih.gov/24954022 DMSB0J8 DI DMSB0J8 DMSB0J8 DN L-734217 DMSB0J8 TI TT38RM1 DMSB0J8 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMSB0J8 MA Modulator DMSB0J8 RN Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73. DMSB0J8 RU https://www.ncbi.nlm.nih.gov/pubmed/8764336 DMSB7WV DI DMSB7WV DMSB7WV DN CL-277082 DMSB7WV TI TTMF541 DMSB7WV TN Liver carboxylesterase (CES1) DMSB7WV MA Modulator DMSB7WV RN CL 277,082: a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J Lipid Res. 1989 May;30(5):681-90. DMSB7WV RU https://pubmed.ncbi.nlm.nih.gov/2760542 DMSE3WP DI DMSE3WP DMSE3WP DN PF-06260414 DMSE3WP TI TTS64P2 DMSE3WP TN Androgen receptor (AR) DMSE3WP MA Modulator DMSE3WP RN Phase I clinical trail of PF-06260414 for treating cachexia. Pfizer Inc. DMSE3WP RU http://www.biocentury.com/products/pf-06260414 DMSFA7L DI DMSFA7L DMSFA7L DN FCE-28161 DMSFA7L TI TTML2WA DMSFA7L TN Tubulin (TUB) DMSFA7L MA Modulator DMSFA7L RN CN patent application no. 101065129, A combination of n-(3-metoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic agent for the treatment of cancer. DMSFA7L RU http://www.google.com/patents/CN101065129B?cl=en DMSFV9T DI DMSFV9T DMSFV9T DN TRM-115 DMSFV9T TI TTQHJ1K DMSFV9T TN Histamine H2 receptor (H2R) DMSFV9T MA Antagonist DMSFV9T RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002138) DMSFV9T RU http://adisinsight.springer.com/drugs/800002138 DMSGUY9 DI DMSGUY9 DMSGUY9 DN Goxalapladib DMSGUY9 TI TTDNFMT DMSGUY9 TN Platelet-activating factor acetylhydrolase (PLA2G7) DMSGUY9 MA Modulator DMSGUY9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020582) DMSGUY9 RU http://adisinsight.springer.com/drugs/800020582 DMSHYAP DI DMSHYAP DMSHYAP DN RUS 3108 DMSHYAP TI TT5UM29 DMSHYAP TN Perlecan (HSPG) DMSHYAP MA Modulator DMSHYAP RN A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan. EuroIntervention. 2010 May;6(1):134-40. DMSHYAP RU https://pubmed.ncbi.nlm.nih.gov/20542809 DMSL0Y5 DI DMSL0Y5 DMSL0Y5 DN LOR-2501 DMSL0Y5 TI TTWP0NS DMSL0Y5 TN RRM1 messenger RNA (RRM1 mRNA) DMSL0Y5 RN Non-covalent complexes of folic acid and oleic acid conjugated polyethylenimine: An efficient vehicle for antisense oligonucleotide delivery. Colloids Surf B Biointerfaces. 2015 Jul 26;135:274-282. DMSL0Y5 RU https://pubmed.ncbi.nlm.nih.gov/26263216 DMSOBW2 DI DMSOBW2 DMSOBW2 DN SSR-125180 DMSOBW2 TI TTCG0AL DMSOBW2 TN Cholecystokinin receptor type A (CCKAR) DMSOBW2 MA Agonist DMSOBW2 RN US patent application no. 8,748,419, Antagonists. DMSOBW2 RU http://www.google.com.ar/Patents/US8748419 DMSOH09 DI DMSOH09 DMSOH09 DN Ebalzotan DMSOH09 TI TTSQIFT DMSOH09 TN 5-HT 1A receptor (HTR1A) DMSOH09 MA Agonist DMSOH09 RN The pharmacological profile of (R)-3,4-dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a selective 5-hydroxytryptamine(1A) receptor agonist. J Pharmacol Exp Ther. 2001 Dec;299(3):883-93. DMSOH09 RU https://pubmed.ncbi.nlm.nih.gov/11714872 DMSOHR6 DI DMSOHR6 DMSOHR6 DN DPC-082 DMSOHR6 TI TT84ETX DMSOHR6 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSOHR6 MA Inhibitor DMSOHR6 RN Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999 Dec;43(12):2893-7. DMSOHR6 RU https://pubmed.ncbi.nlm.nih.gov/10582878 DMSPBJ9 DI DMSPBJ9 DMSPBJ9 DN Symakalim DMSPBJ9 TI TT1VOHK DMSPBJ9 TN Potassium channel unspecific (KC) DMSPBJ9 MA Agonist DMSPBJ9 RN Synthesis and antihypertensive activity of 4-(diazabicyclo[4.1.0]-heptenyloxy)benzopyran derivatives and their analogues. Chem Pharm Bull (Tokyo). 1998 Apr;46(4):602-9. DMSPBJ9 RU https://pubmed.ncbi.nlm.nih.gov/9579035 DMSPW3N DI DMSPW3N DMSPW3N DN ACH-2928 DMSPW3N TI TTCJ2X8 DMSPW3N TN Hepatitis C virus Non-structural 5A (HCV NS5A) DMSPW3N MA Modulator DMSPW3N RN Company report (Achillion) DMSPW3N RU http://ir.achillion.com/releasedetail.cfm?releaseid=629849 DMSRD5U DI DMSRD5U DMSRD5U DN LBY-135 DMSRD5U TI TTW20TU DMSRD5U TN TRAIL receptor 2 (TRAIL-R2) DMSRD5U RN Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44. DMSRD5U RU https://pubmed.ncbi.nlm.nih.gov/23589214 DMSTN6W DI DMSTN6W DMSTN6W DN CA9-ADC DMSTN6W TI TT2LVK8 DMSTN6W TN Carbonic anhydrase IX (CA-IX) DMSTN6W RN Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9. DMSTN6W RU https://pubmed.ncbi.nlm.nih.gov/22147747 DMSUV3B DI DMSUV3B DMSUV3B DN RG-7432 DMSUV3B TI TTMVBWH DMSUV3B TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMSUV3B MA Inhibitor DMSUV3B RN Chutes and Ladders in Hepatitis C Nucleoside Drug Development. Antiviral Res. 2014 February; 102: 119-147. DMSUV3B RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3910353/ DMSZJ5H DI DMSZJ5H DMSZJ5H DN Wetimicin DMSZJ5H TI TTOVFH2 DMSZJ5H TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMSZJ5H MA Inhibitor DMSZJ5H RN Cross susceptibility of ototoxicity about aminoglycoside antibiotics. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1997 Jan;11(1):9-10. DMSZJ5H RU https://pubmed.ncbi.nlm.nih.gov/9644172 DMT5VXF DI DMT5VXF DMT5VXF DN Revatropate DMT5VXF TI TTQ13Z5 DMT5VXF TN Muscarinic acetylcholine receptor M3 (CHRM3) DMT5VXF MA Modulator DMT5VXF RN Discovery & development of selective M3 antagonists for clinical use.Life Sci.1997;60(13-14):1053-60. DMT5VXF RU https://www.ncbi.nlm.nih.gov/pubmed/9121347 DMT8IGE DI DMT8IGE DMT8IGE DN NP-252 DMT8IGE TI TT5HONZ DMT8IGE TN Calcium channel unspecific (CaC) DMT8IGE MA Blocker DMT8IGE RN Pharmacological characteristics of NP-252, a new dihydropyridine slow Ca2+ channel blocker, in isolated rabbit vascular smooth muscle and guinea pig myocardium: vascular selectivity. Eur J Pharmacol.1991 Oct 22;203(3):337-44. DMT8IGE RU https://pubmed.ncbi.nlm.nih.gov/1773820 DMT8V9G DI DMT8V9G DMT8V9G DN R1295 DMT8V9G TI TT7ZMI1 DMT8V9G TN Integrin alpha-4/beta-7 (ITGA4/B7) DMT8V9G MA Modulator DMT8V9G RN Vedolizumab: an 47 integrin inhibitor for inflammatory bowel diseases.Ann Pharmacother.2014 Dec;48(12):1629-35. DMT8V9G RU https://www.ncbi.nlm.nih.gov/pubmed/25186623 DMTC4LP DI DMTC4LP DMTC4LP DN Tidembersat DMTC4LP TI TT6MSOK DMTC4LP TN 5-HT 1D receptor (HTR1D) DMTC4LP MA Antagonist DMTC4LP RN Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-HT1B and 5-HT1D receptors. . The Journal of Headache and Pain 201314(Suppl 1):P75. DMTC4LP RU http://www.thejournalofheadacheandpain.com/content/pdf/1129-2377-14-S1-P75.pdf DMTG9EZ DI DMTG9EZ DMTG9EZ DN AWD-140-190 DMTG9EZ TI TTRK8B9 DMTG9EZ TN Sodium channel unspecific (NaC) DMTG9EZ MA Modulator DMTG9EZ RN Effects of AWD 140-190 on stimulus-induced field potentials and on different patterns of epileptiform activity induced by low calcium or low magnesium in rat entorhinal cortex hippocampal slices. Epilepsy Res. 1997 Dec;29(1):59-69. DMTG9EZ RU https://pubmed.ncbi.nlm.nih.gov/9416460 DMTGCSX DI DMTGCSX DMTGCSX DN SIM-916 DMTGCSX TI TTSXVID DMTGCSX TN Nuclear factor NF-kappa-B (NFKB) DMTGCSX MA Modulator DMTGCSX RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMTGCSX RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMTK3DR DI DMTK3DR DMTK3DR DN R-82150 DMTK3DR TI TT84ETX DMTK3DR TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMTK3DR MA Modulator DMTK3DR RN Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4,5,1-jk]-[1,4]-benzodiazepin... J Biol Chem. 1991 Aug 5;266(22):14232-6. DMTK3DR RU https://www.ncbi.nlm.nih.gov/pubmed/1713579 DMTM0UI DI DMTM0UI DMTM0UI DN CP-66948 DMTM0UI TI TTQHJ1K DMTM0UI TN Histamine H2 receptor (H2R) DMTM0UI MA Antagonist DMTM0UI RN CP-66,948: an antisecretory histamine H2-receptor antagonist with mucosal protective properties. Dig Dis Sci. 1991 Dec;36(12):1721-8. DMTM0UI RU https://pubmed.ncbi.nlm.nih.gov/1748041 DMTOH03 DI DMTOH03 DMTOH03 DN SDZ-NVI-085 DMTOH03 TI TTNGILX DMTOH03 TN Adrenergic receptor alpha-1A (ADRA1A) DMTOH03 MA Antagonist DMTOH03 RN SDZ NVI 085, an alpha 1A-adrenoceptor agonist with 5-HT2A receptor antagonist properties. Eur J Pharmacol. 1996 Feb 15;297(1-2):83-6. DMTOH03 RU https://pubmed.ncbi.nlm.nih.gov/8851170 DMTVC3W DI DMTVC3W DMTVC3W DN U-103017 DMTVC3W TI TT5FNQT DMTVC3W TN Human immunodeficiency virus Protease (HIV PR) DMTVC3W MA Inhibitor DMTVC3W RN Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. J Med Chem. 1995 Dec 22;38(26):4968-71. DMTVC3W RU https://pubmed.ncbi.nlm.nih.gov/8544171 DMTYWE9 DI DMTYWE9 DMTYWE9 DN ABT-080 DMTYWE9 TI TTTWGIX DMTYWE9 TN Leukotriene receptor (LTR) DMTYWE9 MA Modulator DMTYWE9 RN An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol. 2010 February; 10(1): 60-66. DMTYWE9 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838730/ DMU1YON DI DMU1YON DMU1YON DN Berupipam DMU1YON TI TTZFYLI DMU1YON TN Dopamine D1 receptor (D1R) DMU1YON MA Antagonist DMU1YON RN Characterization of benzazepine UDP-glucuronosyl-transferases in laboratory animals and man. Xenobiotica. 1995 Jun;25(6):611-22. DMU1YON RU https://pubmed.ncbi.nlm.nih.gov/7483661 DMU3TQJ DI DMU3TQJ DMU3TQJ DN SDZ-62-434 DMU3TQJ TI TTQL5VC DMU3TQJ TN Platelet-activating factor receptor (PTAFR) DMU3TQJ MA Antagonist DMU3TQJ RN In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434. Br J Cancer. 1993 May;67(5):989-95. DMU3TQJ RU https://pubmed.ncbi.nlm.nih.gov/8388233 DMU93JL DI DMU93JL DMU93JL DN R 80122 DMU93JL TI TTZCG4L DMU93JL TN Phosphodiesterase 3 (PDE3) DMU93JL MA Modulator DMU93JL RN Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14. DMU93JL RU https://pubmed.ncbi.nlm.nih.gov/1328613 DMUANK9 DI DMUANK9 DMUANK9 DN GR-328713 DMUANK9 TI TTUS1RD DMUANK9 TN Microsomal triglyceride transfer protein (MTTP) DMUANK9 MA Modulator DMUANK9 RN Patent CN101237870 B. DMUANK9 RU http://www.google.com/patents/CN101237870B?cl=en DMUCQPB DI DMUCQPB DMUCQPB DN AZD-3342 DMUCQPB TI TTZBFA0 DMUCQPB TN Protease unspecific (PRO) DMUCQPB MA Modulator DMUCQPB RN New Drugs and Targets for Asthma and COPD. Trevor T. Hansel, Peter J. Barnes. 2010. Page(227). DMUCQPB RU https://books.google.com.hk/books?id=aHipG471tVgC&pg=PT241&lpg=PT241&dq=%22AZD-3342%22++Protease&source=bl&ots=y_RqGK1AQK&sig=_sZUylCbhLctfTNcybYmrZ3Mbvo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIuJj-gOPAyAIVChmOCh0K3Amt#v=onepage&q=%22AZD-3342%22%20%20Protease&f=false DMUD6IK DI DMUD6IK DMUD6IK DN BXL-746 DMUD6IK TI TTK59TV DMUD6IK TN Vitamin D3 receptor (VDR) DMUD6IK MA Stimulator DMUD6IK RN Inter-species differences in sensitivity to the calcemic activity of the novel 1,25-dihydroxyvitamin D3 analog BXL746. Regul Toxicol Pharmacol. 2008 Dec;52(3):332-41. DMUD6IK RU https://pubmed.ncbi.nlm.nih.gov/18854204 DMUDLFM DI DMUDLFM DMUDLFM DN ZD-1611 DMUDLFM TI TTKRD0G DMUDLFM TN Endothelin A receptor (EDNRA) DMUDLFM MA Antagonist DMUDLFM RN Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1999 Sep;290(3):1085-91. DMUDLFM RU https://pubmed.ncbi.nlm.nih.gov/10454481 DMUKNQ5 DI DMUKNQ5 DMUKNQ5 DN AZD8330 DMUKNQ5 TI TTROQ37 DMUKNQ5 TN MAPK/ERK kinase kinase (MAP3K) DMUKNQ5 MA Modulator DMUKNQ5 RN MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. DMUKNQ5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626705/ DMUMAHC DI DMUMAHC DMUMAHC DN DUP 697 DMUMAHC TI TTVKILB DMUMAHC TN Prostaglandin G/H synthase 2 (COX-2) DMUMAHC MA Inhibitor DMUMAHC RN Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90. DMUMAHC RU https://pubmed.ncbi.nlm.nih.gov/18220987 DMUMSFR DI DMUMSFR DMUMSFR DN ME-3277 DMUMSFR TI TT38RM1 DMUMSFR TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMUMSFR MA Modulator DMUMSFR RN ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. J Cereb Blood Flow Metab. 2000 Jun;20(6):988-97. DMUMSFR RU https://pubmed.ncbi.nlm.nih.gov/10894182 DMUNYR7 DI DMUNYR7 DMUNYR7 DN JTK-109 DMUNYR7 TI TTMVBWH DMUNYR7 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMUNYR7 MA Inhibitor DMUNYR7 RN Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem. 2006 Jul 27;49(15):4721-36. DMUNYR7 RU https://pubmed.ncbi.nlm.nih.gov/16854079 DMUO3T2 DI DMUO3T2 DMUO3T2 DN AMG 317 DMUO3T2 TI TTDWHC3 DMUO3T2 TN Interleukin 4 receptor alpha (IL4R) DMUO3T2 MA Antagonist DMUO3T2 RN Clinical pipeline report, company report or official report of Amgen (2009). DMUO3T2 RU http://www.amgen.com/science/pipe.jsp DMUPEJK DI DMUPEJK DMUPEJK DN D-4418 DMUPEJK TI TTZ97H5 DMUPEJK TN Phosphodiesterase 4A (PDE4A) DMUPEJK MA Inhibitor DMUPEJK RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking. Br J Pharmacol. 2008 Oct;155(3):288-90. DMUPEJK RU https://pubmed.ncbi.nlm.nih.gov/18660832 DMUPEJK DI DMUPEJK DMUPEJK DN D-4418 DMUPEJK TI TTSKMI8 DMUPEJK TN Phosphodiesterase 4D (PDE4D) DMUPEJK MA Inhibitor DMUPEJK RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking. Br J Pharmacol. 2008 Oct;155(3):288-90. DMUPEJK RU https://pubmed.ncbi.nlm.nih.gov/18660832 DMUPEJK DI DMUPEJK DMUPEJK DN D-4418 DMUPEJK TI TTVIAT9 DMUPEJK TN Phosphodiesterase 4B (PDE4B) DMUPEJK MA Inhibitor DMUPEJK RN Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking. Br J Pharmacol. 2008 Oct;155(3):288-90. DMUPEJK RU https://pubmed.ncbi.nlm.nih.gov/18660832 DMUPOIG DI DMUPOIG DMUPOIG DN HT-1067 DMUPOIG TI TTGP7BY DMUPOIG TN Monoamine oxidase type B (MAO-B) DMUPOIG MA Inhibitor DMUPOIG RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034020) DMUPOIG RU http://adisinsight.springer.com/drugs/800034020 DMUR6OV DI DMUR6OV DMUR6OV DN RG-7356 DMUR6OV TI TTG8DNU DMUR6OV TN Hyaluronic acid receptor (LYVE1) DMUR6OV RN Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies. MAbs. 2014 Mar-Apr;6(2):567-75. DMUR6OV RU https://pubmed.ncbi.nlm.nih.gov/24492295 DMURVE8 DI DMURVE8 DMURVE8 DN Elacridar DMURVE8 TI TT3OT40 DMURVE8 TN Multidrug resistance protein 1 (ABCB1) DMURVE8 MA Inhibitor DMURVE8 RN 2-[(3-Methoxyphenylethyl)phenoxy]-based ABCB1 inhibitors: effect of different basic side-chains on their biological properties. J Med Chem. 2008 Dec 11;51(23):7602-13. DMURVE8 RU https://pubmed.ncbi.nlm.nih.gov/19053888 DMUSKY0 DI DMUSKY0 DMUSKY0 DN ONO-4127 DMUSKY0 TI TTNVEIR DMUSKY0 TN Prostaglandin D2 receptor (PTGDR) DMUSKY0 MA Antagonist DMUSKY0 RN Sleep-wake regulation by prostaglandin D2 and adenosine. Brain Nerve. 2012 Jun;64(6):621-8. DMUSKY0 RU https://pubmed.ncbi.nlm.nih.gov/22647469 DMV7M1H DI DMV7M1H DMV7M1H DN SB-273005 DMV7M1H TI TT69TQN DMV7M1H TN Integrin alpha-V/beta-3 (ITGAV/B3) DMV7M1H MA Modulator DMV7M1H RN Disease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthri... Arthritis Rheum. 2001 Jan;44(1):128-37. DMV7M1H RU https://www.ncbi.nlm.nih.gov/pubmed/11212150 DMVBKLO DI DMVBKLO DMVBKLO DN ALBIFYLLINE DMVBKLO TI TTUST1O DMVBKLO TN Phosphodiesterase (PDE) DMVBKLO MA Inhibitor DMVBKLO RN Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53. DMVBKLO RU https://pubmed.ncbi.nlm.nih.gov/7843225 DMVDLT4 DI DMVDLT4 DMVDLT4 DN CS-4771 DMVDLT4 TI TTISGCA DMVDLT4 TN Toll-like receptor 4 (TLR4) DMVDLT4 MA Modulator DMVDLT4 RN Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013 DMVDLT4 RU http://www.nature.com/scibx/journal/v6/n19/full/scibx.2013.453.html DMVE4P3 DI DMVE4P3 DMVE4P3 DN AZD1704 DMVE4P3 TI TT6OEDT DMVE4P3 TN Cannabinoid receptor 1 (CB1) DMVE4P3 MA Antagonist DMVE4P3 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMVE4P3 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMVFGWM DI DMVFGWM DMVFGWM DN PD-131112 DMVFGWM TI TTN6J5F DMVFGWM TN Bacterial DNA gyrase (Bact gyrase) DMVFGWM MA Modulator DMVFGWM RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMVFGWM RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMVID8E DI DMVID8E DMVID8E DN Ramorelix DMVID8E TI TT8R70G DMVID8E TN Gonadotropin-releasing hormone receptor (GNRHR) DMVID8E MA Antagonist DMVID8E RN Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol. 1993;119(8):457-62. DMVID8E RU https://pubmed.ncbi.nlm.nih.gov/8509436 DMVL5RC DI DMVL5RC DMVL5RC DN FK-041 DMVL5RC TI TTJP4SM DMVL5RC TN Bacterial Penicillin binding protein (Bact PBP) DMVL5RC MA Inhibitor DMVL5RC RN In vitro antibacterial activity of FK041, a new orally active cephalosporin. J Antibiot (Tokyo). 1999 Jul;52(7):649-59. DMVL5RC RU https://pubmed.ncbi.nlm.nih.gov/10513845 DMVS8IE DI DMVS8IE DMVS8IE DN EMD-53998 DMVS8IE TI TT06AWU DMVS8IE TN Phosphodiesterase 3A (PDE3A) DMVS8IE MA Inhibitor DMVS8IE RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMVS8IE RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMVYG5X DI DMVYG5X DMVYG5X DN LY-929 DMVYG5X TI TTZMAO3 DMVYG5X TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMVYG5X MA Agonist DMVYG5X RN CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection. DMVYG5X RU http://www.google.com.ar/patents/CN1882326A?cl=en DMVYG5X DI DMVYG5X DMVYG5X DN LY-929 DMVYG5X TI TTJ584C DMVYG5X TN Peroxisome proliferator-activated receptor alpha (PPARA) DMVYG5X MA Agonist DMVYG5X RN CN patent application no. 1882326, Ppar agonists for the treatment of hcv infection. DMVYG5X RU http://www.google.com.ar/patents/CN1882326A?cl=en DMW08TD DI DMW08TD DMW08TD DN REGN 3048 DMW08TD TI TT85VHW DMW08TD TN MERS-CoV spike glycoprotein (S) DMW08TD MA Inhibitor DMW08TD RN Pre- And Postexposure Efficacy of Fully Human Antibodies Against Spike Protein in a Novel Humanized Mouse Model of MERS-CoV Infection. Proc Natl Acad Sci U S A. 2015 Jul 14;112(28):8738-43. doi: 10.1073/pnas.1510830112. DMW08TD RU https://pubmed.ncbi.nlm.nih.gov/26124093 DMW4G68 DI DMW4G68 DMW4G68 DN RG-201 DMW4G68 TI TT1D5X3 DMW4G68 TN Pneumocystis jirovecii DNA topoisomerase 2 (PJ top2) DMW4G68 MA Modulator DMW4G68 RN US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. DMW4G68 RU http://www.google.com/patents/US20040023290 DMW6IUB DI DMW6IUB DMW6IUB DN AZD-8309 DMW6IUB TI TTQR8Z6 DMW6IUB TN Chemokine receptor (CHR) DMW6IUB MA Modulator DMW6IUB RN CXCR2: From Bench to Bedside. Front Immunol. 2012; 3: 263. DMW6IUB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3426767/ DMW87YE DI DMW87YE DMW87YE DN RG7458 DMW87YE TI TTC1PS3 DMW87YE TN Ovarian carcinoma antigen CA125 (MUC16) DMW87YE RN Phase I clinical trail of RG7458 for treating Ovarian cancer. Genentech Inc. DMW87YE RU http://www.biocentury.com/products/rg7458 DMW9LHG DI DMW9LHG DMW9LHG DN ES-285 DMW9LHG TI TTFNDGV DMW9LHG TN Transforming protein RhoA (RHOA) DMW9LHG MA Inhibitor DMW9LHG RN Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Eur J Pharmacol. 2008 Apr 28;584(2-3):237-45. DMW9LHG RU https://pubmed.ncbi.nlm.nih.gov/18343365 DMWD39E DI DMWD39E DMWD39E DN Tr-14035 DMWD39E TI TT7ZMI1 DMWD39E TN Integrin alpha-4/beta-7 (ITGA4/B7) DMWD39E MA Modulator DMWD39E RN Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89. DMWD39E RU https://www.ncbi.nlm.nih.gov/pubmed/16019958 DMWD39E DI DMWD39E DMWD39E DN Tr-14035 DMWD39E TI TT6S84X DMWD39E TN Integrin alpha-4/beta-1 (ITGA4/B1) DMWD39E MA Modulator DMWD39E RN Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89. DMWD39E RU https://www.ncbi.nlm.nih.gov/pubmed/16019958 DMWDE8K DI DMWDE8K DMWDE8K DN NOStentin DMWDE8K TI TTF10I9 DMWDE8K TN Nitric-oxide synthase inducible (NOS2) DMWDE8K MA Modulator DMWDE8K RN Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H584-9. DMWDE8K RU https://pubmed.ncbi.nlm.nih.gov/16172153 DMWJZAP DI DMWJZAP DMWJZAP DN GW-250495 DMWJZAP TI TTPNQAC DMWJZAP TN Estrogen-related receptor-alpha (ESRRA) DMWJZAP MA Agonist DMWJZAP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DMWJZAP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DMWKYV7 DI DMWKYV7 DMWKYV7 DN AZD-5099 DMWKYV7 TI TTN6J5F DMWKYV7 TN Bacterial DNA gyrase (Bact gyrase) DMWKYV7 MA Modulator DMWKYV7 RN Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099). J Med Chem. 2014 Jul 24;57(14):6060-82. DMWKYV7 RU https://pubmed.ncbi.nlm.nih.gov/24959892 DMWQKEN DI DMWQKEN DMWQKEN DN SPP-1148 DMWQKEN TI TTB2MXP DMWQKEN TN Angiotensinogenase renin (REN) DMWQKEN MA Inhibitor DMWQKEN RN New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. DMWQKEN RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412646/ DMWRQG7 DI DMWRQG7 DMWRQG7 DN Eltenac DMWRQG7 TI TTK0943 DMWRQG7 TN Prostaglandin G/H synthase (COX) DMWRQG7 MA Modulator DMWRQG7 RN Effect of eltenac in horses with induced endotoxaemia. Equine Vet J Suppl. 2000 Jun;(32):26-31. DMWRQG7 RU https://pubmed.ncbi.nlm.nih.gov/11202378 DMWVBGD DI DMWVBGD DMWVBGD DN CR-2093 DMWVBGD TI TTVFO0U DMWVBGD TN Gastrin/cholecystokinin type B receptor (CCKBR) DMWVBGD MA Modulator DMWVBGD RN Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591-7. DMWVBGD RU https://pubmed.ncbi.nlm.nih.gov/7858292 DMWVFDH DI DMWVFDH DMWVFDH DN ABT-279 DMWVFDH TI TTDIGC1 DMWVFDH TN Dipeptidyl peptidase 4 (DPP-4) DMWVFDH MA Inhibitor DMWVFDH RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMWVFDH RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMWY2F6 DI DMWY2F6 DMWY2F6 DN GR-253035 DMWY2F6 TI TTVKILB DMWY2F6 TN Prostaglandin G/H synthase 2 (COX-2) DMWY2F6 MA Modulator DMWY2F6 RN Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice. Gut. 2005 May; 54(5): 608-616. DMWY2F6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1774510/ DMWY2NT DI DMWY2NT DMWY2NT DN CY-1787 DMWY2NT TI TTE5VG0 DMWY2NT TN P-selectin (SELP) DMWY2NT MA Modulator DMWY2NT RN Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33. DMWY2NT RU https://pubmed.ncbi.nlm.nih.gov/8605793 DMX59E8 DI DMX59E8 DMX59E8 DN S-18326 DMX59E8 TI TT6L509 DMX59E8 TN Coagulation factor IIa (F2) DMX59E8 MA Inhibitor DMX59E8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMX59E8 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMX63W1 DI DMX63W1 DMX63W1 DN AZD-7140 DMX63W1 TI TTQR8Z6 DMX63W1 TN Chemokine receptor (CHR) DMX63W1 MA Antagonist DMX63W1 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017126) DMX63W1 RU http://adisinsight.springer.com/drugs/800017126 DMX7PNY DI DMX7PNY DMX7PNY DN SB-234551 DMX7PNY TI TTKRD0G DMX7PNY TN Endothelin A receptor (EDNRA) DMX7PNY MA Antagonist DMX7PNY RN Effects of the novel selective endothelin ET(A) receptor antagonist, SB 234551, on the cardiovascular responses to endotoxaemia in conscious rats. Br J Pharmacol. 2001 Aug;133(8):1371-7. DMX7PNY RU https://pubmed.ncbi.nlm.nih.gov/11498524 DMXD93K DI DMXD93K DMXD93K DN ARRY-614 DMXD93K TI TTWELHI DMXD93K TN Stress-activated protein kinase (p38) DMXD93K MA Modulator DMXD93K RN Cmpany report (Arraybiopharma) DMXD93K RU http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-614/ DMXD93K DI DMXD93K DMXD93K DN ARRY-614 DMXD93K TI TT9VGXW DMXD93K TN Angiopoietin 1 receptor (TEK) DMXD93K MA Modulator DMXD93K RN Cmpany report (Arraybiopharma) DMXD93K RU http://www.arraybiopharma.com/product-pipeline/other-compounds/arry-614/ DMXDLUH DI DMXDLUH DMXDLUH DN NGD-4715 DMXDLUH TI TTX4RTB DMXDLUH TN Melanin-concentrating hormone receptor 1 (MCHR1) DMXDLUH MA Antagonist DMXDLUH RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMXDLUH RU http://www.centerwatch.com/ DMXI5YW DI DMXI5YW DMXI5YW DN NP-61 DMXI5YW TI TT1RS9F DMXI5YW TN Acetylcholinesterase (AChE) DMXI5YW MA Inhibitor DMXI5YW RN Potent beta-amyloid modulators. Neurodegener Dis. 2008;5(3-4):153-6. DMXI5YW RU https://pubmed.ncbi.nlm.nih.gov/18322376 DMXJ54Z DI DMXJ54Z DMXJ54Z DN DW-908e DMXJ54Z TI TTHIZP9 DMXJ54Z TN Integrin alpha-5 (ITGA5) DMXJ54Z MA Antagonist DMXJ54Z RN WO patent application no. 2008,1439,28, Methods and compositions for treating skin conditions. DMXJ54Z RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20081127&CC=WO&NR=2008143928A1&KC=A1 DMXJAFC DI DMXJAFC DMXJAFC DN RG7602 DMXJAFC TI TTTU902 DMXJAFC TN Checkpoint kinase-1 (CHK1) DMXJAFC MA Modulator DMXJAFC RN National Cancer Institute Drug Dictionary (drug id 701310). DMXJAFC RU http://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=701310 DMXJO5F DI DMXJO5F DMXJO5F DN NZ-107 DMXJO5F TI TTTWGIX DMXJO5F TN Leukotriene receptor (LTR) DMXJO5F MA Modulator DMXJO5F RN Effects of NZ-107 on tracheal responses to adenosine in the guinea pig. Jpn J Pharmacol. 1991 May;56(1):79-84. DMXJO5F RU https://pubmed.ncbi.nlm.nih.gov/1880989 DMXK8FQ DI DMXK8FQ DMXK8FQ DN VP004 DMXK8FQ TI TTQW87Y DMXK8FQ TN Opioid receptor kappa (OPRK1) DMXK8FQ RN WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders. DMXK8FQ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070614&CC=WO&NR=2007067714A2&KC=A2 DMXK8FQ DI DMXK8FQ DMXK8FQ DN VP004 DMXK8FQ TI TT27RFC DMXK8FQ TN Opioid receptor delta (OPRD1) DMXK8FQ RN WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders. DMXK8FQ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070614&CC=WO&NR=2007067714A2&KC=A2 DMXK8FQ DI DMXK8FQ DMXK8FQ DN VP004 DMXK8FQ TI TTKWM86 DMXK8FQ TN Opioid receptor mu (MOP) DMXK8FQ RN WO patent application no. 2007,0677,14, Treatment of sequelae of psychiatric disorders. DMXK8FQ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070614&CC=WO&NR=2007067714A2&KC=A2 DMXKB8V DI DMXKB8V DMXKB8V DN CS-526 DMXKB8V TI TTLOKXP DMXKB8V TN Gastric H(+)/K(+) ATPase (Proton pump) DMXKB8V MA Modulator DMXKB8V RN Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]... J Pharmacol Exp Ther. 2007 Oct;323(1):308-17. DMXKB8V RU https://pubmed.ncbi.nlm.nih.gov/17630360 DMXMQAT DI DMXMQAT DMXMQAT DN RG-7273 DMXMQAT TI TTJW1GN DMXMQAT TN ATP-binding cassette transporter A1 (ABCA1) DMXMQAT MA Inducer DMXMQAT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 756). DMXMQAT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=756 DMXN9Z5 DI DMXN9Z5 DMXN9Z5 DN UR-7198 DMXN9Z5 TI TT8DBY3 DMXN9Z5 TN Angiotensin II receptor type-1 (AGTR1) DMXN9Z5 MA Antagonist DMXN9Z5 RN Pharmacologic profile of UR-7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. J Cardiovasc Pharmacol. 2000 Mar;35(3):383-9. DMXN9Z5 RU https://pubmed.ncbi.nlm.nih.gov/10710122 DMXRHDL DI DMXRHDL DMXRHDL DN RG7418 DMXRHDL TI TTKSND3 DMXRHDL TN Lectin-like oxidized LDL receptor (OLR1) DMXRHDL MA Modulator DMXRHDL RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMXRHDL RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMXUH6W DI DMXUH6W DMXUH6W DN JTV-803 DMXUH6W TI TTCIHJA DMXUH6W TN Coagulation factor Xa (F10) DMXUH6W MA Inhibitor DMXUH6W RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMXUH6W RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMXY43L DI DMXY43L DMXY43L DN CTP-354 DMXY43L TI TTEX6LM DMXY43L TN GABA(A) receptor gamma-3 (GABRG3) DMXY43L MA Modulator DMXY43L RN Clinical pipeline report, company report or official report of Concert Pharmaceuticals. DMXY43L RU http://www.concertpharma.com/news/documents/CTP-354_ACNP_Liu_final.pdf DMY3FES DI DMY3FES DMY3FES DN SW-33377 DMY3FES TI TTUTN1I DMY3FES TN Human Deoxyribonucleic acid (hDNA) DMY3FES MA Binder DMY3FES RN Effects of SW 33377, SW 68210 and SW 71425 thioxanthones on in vitro colony formation of freshly explanted human tumor cells. Invest New Drugs. 1998-1999;16(3):221-5. DMY3FES RU https://pubmed.ncbi.nlm.nih.gov/10360601 DMY8KO4 DI DMY8KO4 DMY8KO4 DN CGP-48369 DMY8KO4 TI TTGN1ZA DMY8KO4 TN Angiotensin II receptor (AGTR) DMY8KO4 MA Modulator DMY8KO4 RN Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994 May;89(5):2212-8. DMY8KO4 RU https://pubmed.ncbi.nlm.nih.gov/8181147 DMYCPF9 DI DMYCPF9 DMYCPF9 DN CB-182804 DMYCPF9 TI TTXT4D5 DMYCPF9 TN Bacterial Cell membrane (Bact CM) DMYCPF9 MA Inhibitor DMYCPF9 RN Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City. Microb Drug Resist. 2012 Apr;18(2):132-6. DMYCPF9 RU https://pubmed.ncbi.nlm.nih.gov/22196342 DMYK8OG DI DMYK8OG DMYK8OG DN BB-2983 DMYK8OG TI TT1GHVO DMYK8OG TN Matrix metalloproteinase (MMP) DMYK8OG MA Modulator DMYK8OG RN Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9. DMYK8OG RU https://pubmed.ncbi.nlm.nih.gov/14743149 DMYPFLR DI DMYPFLR DMYPFLR DN Clomet DMYPFLR TI TTUTN1I DMYPFLR TN Human Deoxyribonucleic acid (hDNA) DMYPFLR MA Inhibitor DMYPFLR RN The comet assay: a sensitive genotoxicity test for the detection of DNA damage and repair. Methods Mol Biol. 2006;314:275-86. DMYPFLR RU https://pubmed.ncbi.nlm.nih.gov/16673888 DMYSBN3 DI DMYSBN3 DMYSBN3 DN AZD-9272 DMYSBN3 TI TTVBPDM DMYSBN3 TN Metabotropic glutamate receptor 1 (mGluR1) DMYSBN3 MA Modulator DMYSBN3 RN Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. DMYSBN3 RU https://pubmed.ncbi.nlm.nih.gov/17355217 DMYTAJW DI DMYTAJW DMYTAJW DN SB-281832 DMYTAJW TI TTWELHI DMYTAJW TN Stress-activated protein kinase (p38) DMYTAJW MA Inhibitor DMYTAJW RN p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. J Pharmacol Exp Ther. 2003 Dec;307(3):932-8. DMYTAJW RU https://pubmed.ncbi.nlm.nih.gov/14561851 DMZ0YU7 DI DMZ0YU7 DMZ0YU7 DN CP-800569 DMZ0YU7 TI TTFQAYR DMZ0YU7 TN Cholesteryl ester transfer protein (CETP) DMZ0YU7 MA Inhibitor DMZ0YU7 RN Pfizer. Product Development Pipeline. March 31 2009. DMZ0YU7 RU http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf DMZ5RA7 DI DMZ5RA7 DMZ5RA7 DN TRK-851 DMZ5RA7 TI TT27RFC DMZ5RA7 TN Opioid receptor delta (OPRD1) DMZ5RA7 MA Antagonist DMZ5RA7 RN Design and synthesis of a metabolically stable and potent antitussive agent, a novel delta opioid receptor antagonist, TRK-851. Bioorg Med Chem. 2008 Sep 1;16(17):7956-67. DMZ5RA7 RU https://pubmed.ncbi.nlm.nih.gov/18701308 DMZ9WLO DI DMZ9WLO DMZ9WLO DN NGD-94-4 DMZ9WLO TI TTE0A2F DMZ9WLO TN Dopamine D4 receptor (D4R) DMZ9WLO MA Modulator DMZ9WLO RN I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9. DMZ9WLO RU https://pubmed.ncbi.nlm.nih.gov/9262370 DMZFEY1 DI DMZFEY1 DMZFEY1 DN JTK-652 DMZFEY1 TI TTMVBWH DMZFEY1 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMZFEY1 MA Inhibitor DMZFEY1 RN Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. Antivir Ther. 2010;15(5):765-73. DMZFEY1 RU https://pubmed.ncbi.nlm.nih.gov/20710058 DMZHOYM DI DMZHOYM DMZHOYM DN SDZ-PCO-400 DMZHOYM TI TT1VOHK DMZHOYM TN Potassium channel unspecific (KC) DMZHOYM MA Opener DMZHOYM RN Effects of a potassium channel opener (SDZ PCO 400) on guinea-pig and human pulmonary airways. Br J Pharmacol. 1992 Jun;106(2):423-9. DMZHOYM RU https://pubmed.ncbi.nlm.nih.gov/1382782 DMZKTU5 DI DMZKTU5 DMZKTU5 DN Org-31710 DMZKTU5 TI TTUV8G9 DMZKTU5 TN Progesterone receptor (PGR) DMZKTU5 MA Modulator DMZKTU5 RN Progesterone receptor antagonists Org 31710 and RU 486 increase apoptosis in human periovulatory granulosa cells. Fertil Steril. 2001 Dec;76(6):1225-31. DMZKTU5 RU https://pubmed.ncbi.nlm.nih.gov/11730755 DMZN6F3 DI DMZN6F3 DMZN6F3 DN Odapipam DMZN6F3 TI TTZFYLI DMZN6F3 TN Dopamine D1 receptor (D1R) DMZN6F3 MA Antagonist DMZN6F3 RN PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse. 1999 May;32(2):93-109. DMZN6F3 RU https://pubmed.ncbi.nlm.nih.gov/10231129 DMZYA9E DI DMZYA9E DMZYA9E DN ICI-D-6888 DMZYA9E TI TTGN1ZA DMZYA9E TN Angiotensin II receptor (AGTR) DMZYA9E MA Modulator DMZYA9E RN WO patent application no. 1995,0216,09, Treatment of normotensive glaucoma with angiotensin ii antagonists. DMZYA9E RU http://www.google.com.au/patents/WO1995021609A1 DMZYRI3 DI DMZYRI3 DMZYRI3 DN S-3536 DMZYRI3 TI TT1GHVO DMZYRI3 TN Matrix metalloproteinase (MMP) DMZYRI3 MA Inhibitor DMZYRI3 RN CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83. DMZYRI3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694827/ DMZYVFH DI DMZYVFH DMZYVFH DN DF-1111301 DMZYVFH TI TTQL5VC DMZYVFH TN Platelet-activating factor receptor (PTAFR) DMZYVFH MA Antagonist DMZYVFH RN US patent application no. 2007,0196,421, Soft tissue implants and drug combination compositions, and use thereof. DMZYVFH RU http://www.google.is/patents/US20070196421 DMZYVPB DI DMZYVPB DMZYVPB DN ABX-MA1 DMZYVPB TI TTD26RC DMZYVPB TN Cell adhesion molecule (CADM) DMZYVPB RN Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res. 2002 Sep 1;62(17):5106-14. DMZYVPB RU https://pubmed.ncbi.nlm.nih.gov/12208768 DMHXVN1 DI DMHXVN1 DMHXVN1 DN DFD-11 DMHXVN1 TI TT1GHVO DMHXVN1 TN Matrix metalloproteinase (MMP) DMHXVN1 MA Inhibitor DMHXVN1 RN Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) DMHXVN1 RU http://phrma-docs.phrma.org/files/dmfile/MID_Skin_Diseases_2018_9_FINAL.pdf DM3V8JN DI DM3V8JN DM3V8JN DN Anti-CD19 CAR T cells DM3V8JN TI TTW640A DM3V8JN TN B-lymphocyte surface antigen B4 (CD19) DM3V8JN MA CAR-T-Cell-Therapy DM3V8JN RN ClinicalTrials.gov (NCT02277522) CD19 Redirected Autologous T Cells for Hodgkin Lymphoma DM3V8JN RU https://clinicaltrials.gov/ct2/show/NCT02277522 DMA85ND DI DMA85ND DMA85ND DN ET-1 DMA85ND TI TT3ZTGU DMA85ND TN Endothelin B receptor (EDNRB) DMA85ND MA Inhibitor DMA85ND RN IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996). DMA85ND RU http://www.sciencedirect.com/science/article/pii/0960894X96004210 DMA85ND DI DMA85ND DMA85ND DN ET-1 DMA85ND TI TTKRD0G DMA85ND TN Endothelin A receptor (EDNRA) DMA85ND MA Inhibitor DMA85ND RN 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6. DMA85ND RU https://pubmed.ncbi.nlm.nih.gov/19916528 DMC7EQT DI DMC7EQT DMC7EQT DN AAB-002 DMC7EQT TI TTE4KHA DMC7EQT TN Amyloid beta A4 protein (APP) DMC7EQT MA Modulator DMC7EQT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMC7EQT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMFRA38 DI DMFRA38 DMFRA38 DN CART19 cells DMFRA38 TI TTW640A DMFRA38 TN B-lymphocyte surface antigen B4 (CD19) DMFRA38 MA CAR-T-Cell-Therapy DMFRA38 RN ClinicalTrials.gov (NCT02624258) Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma DMFRA38 RU https://clinicaltrials.gov/ct2/show/NCT02624258 DMYZ3O9 DI DMYZ3O9 DMYZ3O9 DN Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes DMYZ3O9 TI TTENHJ0 DMYZ3O9 TN Interleukin 3 receptor alpha (IL3RA) DMYZ3O9 MA CAR-T-Cell-Therapy DMYZ3O9 RN ClinicalTrials.gov (NCT02623582) CD123 Redirected Autologous T Cells for AML DMYZ3O9 RU https://clinicaltrials.gov/ct2/show/NCT02623582 DM04UGQ DI DM04UGQ DM04UGQ DN GSK366 DM04UGQ TI TTIY56R DM04UGQ TN Kynurenine 3-hydroxylase (KMO) DM04UGQ MA Inhibitor DM04UGQ RN Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017 Jun 12;8:15827. DM04UGQ RU https://pubmed.ncbi.nlm.nih.gov/28604669 DM065ZH DI DM065ZH DM065ZH DN CCT-018159 DM065ZH TI TT78R5H DM065ZH TN Heat shock protein 90 alpha (HSP90A) DM065ZH MA Inhibitor DM065ZH RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DM065ZH RU https://pubmed.ncbi.nlm.nih.gov/18855578 DM06BUL DI DM06BUL DM06BUL DN TPT-43 DM06BUL TI TTAN6JD DM06BUL TN Glutamate receptor AMPA (GRIA) DM06BUL MA Modulator DM06BUL RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DM06BUL RU https://pubmed.ncbi.nlm.nih.gov/16377242 DM07EU4 DI DM07EU4 DM07EU4 DN Organon-3 DM07EU4 TI TTHJTF7 DM07EU4 TN Glycine transporter GlyT-1 (SLC6A9) DM07EU4 MA Blocker DM07EU4 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM07EU4 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM0BHL8 DI DM0BHL8 DM0BHL8 DN CLIK-148 DM0BHL8 TI TT36ETB DM0BHL8 TN Cathepsin L (CTSL) DM0BHL8 MA Inhibitor DM0BHL8 RN Structure-based development of specific inhibitors for individual cathepsins and their medical applications. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):29-39. DM0BHL8 RU https://pubmed.ncbi.nlm.nih.gov/21321479 DM0KM6F DI DM0KM6F DM0KM6F DN AUNP-12 DM0KM6F TI TTNBFWK DM0KM6F TN Programmed cell death protein 1 (PD-1) DM0KM6F MA Inhibitor DM0KM6F RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM0KM6F RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM0NPIO DI DM0NPIO DM0NPIO DN SSYA10-001 DM0NPIO TI TTY732E DM0NPIO TN MERS-CoV helicase (Hel) DM0NPIO MA Inhibitor DM0NPIO RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM0NPIO RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM0NPIO DI DM0NPIO DM0NPIO DN SSYA10-001 DM0NPIO TI TTQKWR5 DM0NPIO TN SARS-CoV helicase (Hel) DM0NPIO MA Inhibitor DM0NPIO RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM0NPIO RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM0PJU9 DI DM0PJU9 DM0PJU9 DN BN-GU-005-DHP DM0PJU9 TI TTZAYWL DM0PJU9 TN Estrogen receptor (ESR) DM0PJU9 MA Modulator DM0PJU9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897) DM0PJU9 RU http://adisinsight.springer.com/drugs/800023897 DM0ULO2 DI DM0ULO2 DM0ULO2 DN CF602 DM0ULO2 TI TTJFY5U DM0ULO2 TN Adenosine A3 receptor (ADORA3) DM0ULO2 MA Agonist DM0ULO2 RN 2011 Pipeline of Can-Fite BioPharm. DM0ULO2 RU http://www.canfite.com/pipeline.html DM0URLP DI DM0URLP DM0URLP DN Lopinavir + ritonavir + interferon alpha DM0URLP TI TT1D53B DM0URLP TN COVID-19 3C-like protease (3CLpro) DM0URLP MA Inhibitor DM0URLP RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DM0URLP RU https://pubmed.ncbi.nlm.nih.gov/32205870 DM0YOXQ DI DM0YOXQ DM0YOXQ DN SB-431542 DM0YOXQ TI TTP4520 DM0YOXQ TN TGF-beta receptor type I (TGFBR1) DM0YOXQ MA Inhibitor DM0YOXQ RN Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9. DM0YOXQ RU https://pubmed.ncbi.nlm.nih.gov/19914068 DM13YRT DI DM13YRT DM13YRT DN AEOL-10150 DM13YRT TI TT6RVLG DM13YRT TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DM13YRT MA Modulator DM13YRT RN AEOL-10150 (Aeolus). Curr Opin Investig Drugs. 2006 Jan;7(1):70-80. DM13YRT RU https://pubmed.ncbi.nlm.nih.gov/16425674 DM16W8F DI DM16W8F DM16W8F DN Phenylisoserine derivatives SK80 DM16W8F TI TTPZG3C DM16W8F TN SARS-CoV 3C-like protease (3CLpro) DM16W8F MA Inhibitor DM16W8F RN Synthesis and Evaluation of Phenylisoserine Derivatives for the SARS-CoV 3CL Protease Inhibitor. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2746-2751. DM16W8F RU https://pubmed.ncbi.nlm.nih.gov/28454669 DM1982I DI DM1982I DM1982I DN LDN-57444 DM1982I TI TTX9IFP DM1982I TN Ubiquitin thioesterase L1 (UCHL1) DM1982I MA Inhibitor DM1982I RN Inhibition of UCH-L1 Deubiquitinating Activity with Two Forms of LDN-57444 Has Anti-Invasive Effects in Metastatic Carcinoma Cells. Int J Mol Sci. 2019 Jul 31;20(15):3733. DM1982I RU https://pubmed.ncbi.nlm.nih.gov/31370144 DM19R28 DI DM19R28 DM19R28 DN ADC-01 DM19R28 TI TTXU3EQ DM19R28 TN Herpesvirus ubiquitin-specific protease (HAUSP) DM19R28 MA Inhibitor DM19R28 RN Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel). 2020 Jun 15;12(6):1579. DM19R28 RU https://pubmed.ncbi.nlm.nih.gov/32549302 DM19T2V DI DM19T2V DM19T2V DN GRL001 DM19T2V TI TT1D53B DM19T2V TN COVID-19 3C-like protease (3CLpro) DM19T2V MA Inhibitor DM19T2V RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM19T2V RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM1A2UI DI DM1A2UI DM1A2UI DN PGX-200097 DM1A2UI TI TTKWFB8 DM1A2UI TN Catechol-O-methyl-transferase (COMT) DM1A2UI MA Inhibitor DM1A2UI RN Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23. DM1A2UI RU https://pubmed.ncbi.nlm.nih.gov/20655178 DM1A2UI DI DM1A2UI DM1A2UI DN PGX-200097 DM1A2UI TI TTEX248 DM1A2UI TN Dopamine D2 receptor (D2R) DM1A2UI MA Inhibitor DM1A2UI RN Schizophrenia, "just the facts" 5. Treatment and prevention. Past, present, and future. Schizophr Res. 2010 Sep;122(1-3):1-23. DM1A2UI RU https://pubmed.ncbi.nlm.nih.gov/20655178 DM1H45U DI DM1H45U DM1H45U DN A-366 DM1H45U TI TTS6RZT DM1H45U TN Histone-lysine N-methyltransferase EHMT2 (EHMT2) DM1H45U MA Inhibitor DM1H45U RN Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9. DM1H45U RU https://pubmed.ncbi.nlm.nih.gov/24900801 DM1H45U DI DM1H45U DM1H45U DN A-366 DM1H45U TI TTOFXD7 DM1H45U TN Euchromatic histone-lysine N-methyltransferase 1 (EHMT1) DM1H45U MA Inhibitor DM1H45U RN Discovery and development of potent and selective inhibitors of histone methyltransferase g9a. ACS Med Chem Lett. 2014 Jan 2;5(2):205-9. DM1H45U RU https://pubmed.ncbi.nlm.nih.gov/24900801 DM1H8D6 DI DM1H8D6 DM1H8D6 DN CNX-011-67 DM1H8D6 TI TTB8FUC DM1H8D6 TN Free fatty acid receptor 1 (GPR40) DM1H8D6 MA Inhibitor DM1H8D6 RN CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol. 2014 Mar 25;15:19. DM1H8D6 RU https://pubmed.ncbi.nlm.nih.gov/24666736 DM1KTOC DI DM1KTOC DM1KTOC DN TGX-6B4 DM1KTOC TI TTVB0Q9 DM1KTOC TN Platelet glycoprotein Ib alpha (CD42b) DM1KTOC RN Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol. 2000 May;20(5):1347-53. DM1KTOC RU https://pubmed.ncbi.nlm.nih.gov/10807753 DM1MGBX DI DM1MGBX DM1MGBX DN Alpha-Helical lipopeptides IIS DM1MGBX TI TT85VHW DM1MGBX TN MERS-CoV spike glycoprotein (S) DM1MGBX MA Inhibitor DM1MGBX RN De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745. DM1MGBX RU https://pubmed.ncbi.nlm.nih.gov/30192544 DM1MQON DI DM1MQON DM1MQON DN ANAVEX 1-41 DM1MQON TI TT5TPI6 DM1MQON TN Opioid receptor sigma 1 (OPRS1) DM1MQON MA Agonist DM1MQON RN 2011 Pipeline of Anavex. DM1MQON RU http://anavex.com/pipeline.html DM1O2C3 DI DM1O2C3 DM1O2C3 DN 227Th-labelled HER2-TTC DM1O2C3 TI TT6EO5L DM1O2C3 TN Erbb2 tyrosine kinase receptor (HER2) DM1O2C3 RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DM1O2C3 RU https://pubmed.ncbi.nlm.nih.gov/32728208 DM1R3VC DI DM1R3VC DM1R3VC DN 2-Amino-4-[3-hydroxyphenyl]-4-hydroxybutanoic acid DM1R3VC TI TTWQM3J DM1R3VC TN Kynureninase (KYNU) DM1R3VC MA Inhibitor DM1R3VC RN 2-Amino-4-[3'-hydroxyphenyl]-4-hydroxybutanoic acid; a potent inhibitor of rat and recombinant human kynureninase. Bioorg Med Chem Lett. 2002 Feb 11;12(3):361-3. DM1R3VC RU https://pubmed.ncbi.nlm.nih.gov/11814797 DM1RZVI DI DM1RZVI DM1RZVI DN ICA-69673 DM1RZVI TI TTIVDM3 DM1RZVI TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DM1RZVI MA Modulator DM1RZVI RN Voltage-gated Potassium Channels as Therapeutic Drug Targets DM1RZVI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790170 DM1RZVI DI DM1RZVI DM1RZVI DN ICA-69673 DM1RZVI TI TTPXI3S DM1RZVI TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DM1RZVI MA Modulator DM1RZVI RN Voltage-gated Potassium Channels as Therapeutic Drug Targets DM1RZVI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790170 DM1S5UO DI DM1S5UO DM1S5UO DN GSK4112 DM1S5UO TI TTAD1O8 DM1S5UO TN V-erbA-related protein 1 (NR1D1) DM1S5UO MA Agonist DM1S5UO RN Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol. 2011 Feb 18;6(2):131-4. DM1S5UO RU https://pubmed.ncbi.nlm.nih.gov/21043485 DM1XYGF DI DM1XYGF DM1XYGF DN MAX-10129 DM1XYGF TI TT23XQV DM1XYGF TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM1XYGF MA Inhibitor DM1XYGF RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM1XYGF RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM21I35 DI DM21I35 DM21I35 DN ADC-03 DM21I35 TI TTXU3EQ DM21I35 TN Herpesvirus ubiquitin-specific protease (HAUSP) DM21I35 MA Inhibitor DM21I35 RN Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel). 2020 Jun 15;12(6):1579. DM21I35 RU https://pubmed.ncbi.nlm.nih.gov/32549302 DM25N8B DI DM25N8B DM25N8B DN GI-264879A DM25N8B TI TTRK9JT DM25N8B TN Neuropeptide Y receptor type 1 (NPY1R) DM25N8B MA Antagonist DM25N8B RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM25N8B RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM29BW1 DI DM29BW1 DM29BW1 DN SD1003 DM29BW1 TI TT36ETB DM29BW1 TN Cathepsin L (CTSL) DM29BW1 MA Inhibitor DM29BW1 RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DM29BW1 RU https://pubmed.ncbi.nlm.nih.gov/31477883 DM29BW1 DI DM29BW1 DM29BW1 DN SD1003 DM29BW1 TI TTF2LRI DM29BW1 TN Cathepsin B (CTSB) DM29BW1 MA Inhibitor DM29BW1 RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DM29BW1 RU https://pubmed.ncbi.nlm.nih.gov/31477883 DM29M4R DI DM29M4R DM29M4R DN F24F2 DM29M4R TI TTM0O8B DM29M4R TN Bacillus poly-gamma-d-glutamic acid (Bacillus PGA) DM29M4R RN Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007 Jan;75(1):152-63. DM29M4R RU https://pubmed.ncbi.nlm.nih.gov/17060470 DM2GEHA DI DM2GEHA DM2GEHA DN F26G3 DM2GEHA TI TTM0O8B DM2GEHA TN Bacillus poly-gamma-d-glutamic acid (Bacillus PGA) DM2GEHA RN Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007 Jan;75(1):152-63. DM2GEHA RU https://pubmed.ncbi.nlm.nih.gov/17060470 DM2JOXF DI DM2JOXF DM2JOXF DN BIIR-777 DM2JOXF TI TTAN6JD DM2JOXF TN Glutamate receptor AMPA (GRIA) DM2JOXF MA Modulator DM2JOXF RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM2JOXF RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM2K51E DI DM2K51E DM2K51E DN EP-01492 DM2K51E TI TTWDC17 DM2K51E TN Growth hormone secretagogue receptor 1 (GHSR) DM2K51E MA Antagonist DM2K51E RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM2K51E RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM2N637 DI DM2N637 DM2N637 DN LY-25582 DM2N637 TI TT27RFC DM2N637 TN Opioid receptor delta (OPRD1) DM2N637 MA Inhibitor DM2N637 RN Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90. DM2N637 RU https://pubmed.ncbi.nlm.nih.gov/9599247 DM2N637 DI DM2N637 DM2N637 DN LY-25582 DM2N637 TI TTQW87Y DM2N637 TN Opioid receptor kappa (OPRK1) DM2N637 MA Inhibitor DM2N637 RN Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90. DM2N637 RU https://pubmed.ncbi.nlm.nih.gov/9599247 DM2N637 DI DM2N637 DM2N637 DN LY-25582 DM2N637 TI TTKWM86 DM2N637 TN Opioid receptor mu (MOP) DM2N637 MA Antagonist DM2N637 RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DM2N637 RU https://pubmed.ncbi.nlm.nih.gov/17980586 DM2TESM DI DM2TESM DM2TESM DN EPZ028862 DM2TESM TI TTKLJYX DM2TESM TN Histone-lysine N-methyltransferase SMYD3 (SMYD3) DM2TESM MA Inhibitor DM2TESM RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DM2TESM RU https://pubmed.ncbi.nlm.nih.gov/33469207 DM2U16Z DI DM2U16Z DM2U16Z DN ANAVEX 1007 DM2U16Z TI TT9NXW4 DM2U16Z TN Sigma intracellular receptor 2 (TMEM97) DM2U16Z MA Agonist DM2U16Z RN 2011 Pipeline of Anavex. DM2U16Z RU http://anavex.com/pipeline.html DM2U16Z DI DM2U16Z DM2U16Z DN ANAVEX 1007 DM2U16Z TI TT5TPI6 DM2U16Z TN Opioid receptor sigma 1 (OPRS1) DM2U16Z MA Agonist DM2U16Z RN 2011 Pipeline of Anavex. DM2U16Z RU http://anavex.com/pipeline.html DM2WKDN DI DM2WKDN DM2WKDN DN ADX-2 series DM2WKDN TI TT9IK2Z DM2WKDN TN N-methyl-D-aspartate receptor (NMDAR) DM2WKDN MA Antagonist DM2WKDN RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM2WKDN RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM32NMB DI DM32NMB DM32NMB DN S-Phenyl-L-cysteine sulfoxide DM32NMB TI TTLQ3OP DM32NMB TN Pseudomonas Kynureninase (Pseudo kynU) DM32NMB MA Inhibitor DM32NMB RN Chemical Inhibition of Kynureninase Reduces Pseudomonas aeruginosa Quorum Sensing and Virulence Factor Expression. ACS Chem Biol. 2016 Apr 15;11(4):1106-17. DM32NMB RU https://pubmed.ncbi.nlm.nih.gov/26785289 DM32XJS DI DM32XJS DM32XJS DN M64 DM32XJS TI TT7L1ZX DM32XJS TN Pseudomonas Multiple virulence factor regulator MvfR (Pseudo MvfR) DM32XJS MA Inhibitor DM32XJS RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DM32XJS RU https://pubmed.ncbi.nlm.nih.gov/28337021 DM34FEA DI DM34FEA DM34FEA DN ATA2431 DM34FEA TI TTM6QSK DM34FEA TN B-cell receptor CD22 (CD22) DM34FEA RN Clinical pipeline report, company report or official report of Atara Biotherapeutics. DM34FEA RU https://www.atarabio.com/pipeline/ DM34FEA DI DM34FEA DM34FEA DN ATA2431 DM34FEA TI TTW640A DM34FEA TN B-lymphocyte surface antigen B4 (CD19) DM34FEA RN Clinical pipeline report, company report or official report of Atara Biotherapeutics. DM34FEA RU https://www.atarabio.com/pipeline/ DM34FEA DI DM34FEA DM34FEA DN ATA2431 DM34FEA TI TTUE541 DM34FEA TN Leukocyte surface antigen Leu-16 (CD20) DM34FEA RN Clinical pipeline report, company report or official report of Atara Biotherapeutics. DM34FEA RU https://www.atarabio.com/pipeline/ DM39C47 DI DM39C47 DM39C47 DN N-Octyl-beta-valienamine DM39C47 TI TT1B5PU DM39C47 TN Glucosylceramidase (GBA) DM39C47 MA Inhibitor DM39C47 RN Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002 Jun;10(6):1967-72. DM39C47 RU https://pubmed.ncbi.nlm.nih.gov/11937356 DM3AIQO DI DM3AIQO DM3AIQO DN RX-01-423 DM3AIQO TI TTUWYEA DM3AIQO TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM3AIQO MA Modulator DM3AIQO RN DOI: 10.1038/nrd2202 DM3AIQO RU http://www.nature.com/nrd/journal/v6/n1/full/nrd2202.html DM3EUBA DI DM3EUBA DM3EUBA DN BC-1215 DM3EUBA TI TTUX14L DM3EUBA TN F-box only protein 3 (FBXO3) DM3EUBA MA Antagonist DM3EUBA RN Targeting F box protein Fbxo3 to control cytokine-driven inflammation. J Immunol. 2013 Nov 15;191(10):5247-55. DM3EUBA RU https://pubmed.ncbi.nlm.nih.gov/24123678 DM3G0OP DI DM3G0OP DM3G0OP DN CAR-T cells targeting CD34 DM3G0OP TI TTZAVYN DM3G0OP TN Hematopoietic progenitor cell antigen CD34 (CD34) DM3G0OP MA CAR-T-Cell-Therapy DM3G0OP RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DM3G0OP RU https://clinicaltrials.gov/ct2/show/NCT03473457 DM3NP4I DI DM3NP4I DM3NP4I DN Huntingtin gene antisense DM3NP4I TI TTIWZ0O DM3NP4I TN Huntingtin messenger RNA (HTT mRNA) DM3NP4I RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM3NP4I RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM3PMAZ DI DM3PMAZ DM3PMAZ DN GW-3333 DM3PMAZ TI TTDU0HP DM3PMAZ TN Bacterial Cystathionine gamma-synthase (Bact metB) DM3PMAZ MA Inhibitor DM3PMAZ RN Crystal structures of cystathionine gamma-synthase inhibitor complexes rationalize the increased affinity of a novel inhibitor. J Mol Biol. 2001 Aug 24;311(4):789-801. DM3PMAZ RU https://pubmed.ncbi.nlm.nih.gov/11518531 DM3PMAZ DI DM3PMAZ DM3PMAZ DN GW-3333 DM3PMAZ TI TT6AZXG DM3PMAZ TN TNF alpha converting enzyme (ADAM17) DM3PMAZ MA Inhibitor DM3PMAZ RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM3PMAZ RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM3U2S5 DI DM3U2S5 DM3U2S5 DN PF-04859989 DM3U2S5 TI TTT3IXG DM3U2S5 TN Kynurenine oxoglutarate transaminase II (AADAT) DM3U2S5 MA Inhibitor DM3U2S5 RN Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations. Brain Res Bull. 2019 Mar;146:185-191. DM3U2S5 RU https://pubmed.ncbi.nlm.nih.gov/30639278 DM3WHB2 DI DM3WHB2 DM3WHB2 DN BST-1005 DM3WHB2 TI TTNS7H3 DM3WHB2 TN Laminin gamma-2 subunit (LAMC2) DM3WHB2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019225) DM3WHB2 RU http://adisinsight.springer.com/drugs/800019225 DM3WVM4 DI DM3WVM4 DM3WVM4 DN Alpha-Helical lipopeptides LLS DM3WVM4 TI TT85VHW DM3WVM4 TN MERS-CoV spike glycoprotein (S) DM3WVM4 MA Inhibitor DM3WVM4 RN De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745. DM3WVM4 RU https://pubmed.ncbi.nlm.nih.gov/30192544 DM3X4JL DI DM3X4JL DM3X4JL DN SMITB14 DM3X4JL TI TT3V4L8 DM3X4JL TN Mycobacterial lipoarabinomannan (MycB LAM) DM3X4JL MA Inhibitor DM3X4JL RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DM3X4JL RU https://pubmed.ncbi.nlm.nih.gov/28337021 DM3ZE5A DI DM3ZE5A DM3ZE5A DN RO-26-2853 DM3ZE5A TI TTLM12X DM3ZE5A TN Matrix metalloproteinase-2 (MMP-2) DM3ZE5A MA Inhibitor DM3ZE5A RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DM3ZE5A RU https://pubmed.ncbi.nlm.nih.gov/17604499 DM46QXZ DI DM46QXZ DM46QXZ DN Organon-2 DM46QXZ TI TTHJTF7 DM46QXZ TN Glycine transporter GlyT-1 (SLC6A9) DM46QXZ MA Blocker DM46QXZ RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM46QXZ RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM4BDGW DI DM4BDGW DM4BDGW DN TH301 DM4BDGW TI TT5MLZR DM4BDGW TN Cryptochrome circadian clock 1 (CRY1) DM4BDGW MA Modulator DM4BDGW RN Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307. DM4BDGW RU https://pubmed.ncbi.nlm.nih.gov/33589815 DM4BDGW DI DM4BDGW DM4BDGW DN TH301 DM4BDGW TI TTAO58M DM4BDGW TN Cryptochrome-2 (CRY2) DM4BDGW MA Modulator DM4BDGW RN Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307. DM4BDGW RU https://pubmed.ncbi.nlm.nih.gov/33589815 DM4BZEJ DI DM4BZEJ DM4BZEJ DN BMS-986118 DM4BZEJ TI TTB8FUC DM4BZEJ TN Free fatty acid receptor 1 (GPR40) DM4BZEJ MA Agonist DM4BZEJ RN Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists. J Med Chem. 2018 Feb 8;61(3):681-694. DM4BZEJ RU https://pubmed.ncbi.nlm.nih.gov/29316397 DM4NURZ DI DM4NURZ DM4NURZ DN 2E9IgA1 DM4NURZ TI TTTB3L1 DM4NURZ TN Alpha-crystallin (CRYA) DM4NURZ MA Inhibitor DM4NURZ RN A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 2011 Mar 1;186(5):3113-9. DM4NURZ RU https://pubmed.ncbi.nlm.nih.gov/21257971 DM4V8ZD DI DM4V8ZD DM4V8ZD DN S32504 DM4V8ZD TI TT4C8EA DM4V8ZD TN Dopamine D3 receptor (D3R) DM4V8ZD MA Modulator DM4V8ZD RN S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity ... J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. DM4V8ZD RU https://pubmed.ncbi.nlm.nih.gov/14978195 DM4V8ZD DI DM4V8ZD DM4V8ZD DN S32504 DM4V8ZD TI TTEX248 DM4V8ZD TN Dopamine D2 receptor (D2R) DM4V8ZD MA Modulator DM4V8ZD RN S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity ... J Pharmacol Exp Ther. 2004 Jun;309(3):921-35. DM4V8ZD RU https://pubmed.ncbi.nlm.nih.gov/14978195 DM4XZU2 DI DM4XZU2 DM4XZU2 DN ATL-1101 DM4XZU2 TI TTQFBMY DM4XZU2 TN IGF1R messenger RNA (IGF1R mRNA) DM4XZU2 RN Clinical pipeline report, company report or official report of Antisense Therapeutics. DM4XZU2 RU http://www.antisense.com.au/product-pipeline/atl1101-for-prostate-cancer/ DM503DN DI DM503DN DM503DN DN 1954U89 DM503DN TI TTYZVDJ DM503DN TN Dihydrofolate reductase (DHFR) DM503DN MA Modulator DM503DN RN The pharmacokinetics of 1954U89, 1,3-diamino-7-(1-ethylpropyl)-8-methyl-7H-pyrrolo-(3,2-f)quinazoline, in dogs and rats after intravenous and oral administration. Biopharm Drug Dispos. 1997 Jul;18(5):433-42. DM503DN RU https://pubmed.ncbi.nlm.nih.gov/9210981 DM53JW0 DI DM53JW0 DM53JW0 DN CB1 antagonist, Bayer DM53JW0 TI TT6OEDT DM53JW0 TN Cannabinoid receptor 1 (CB1) DM53JW0 MA Antagonist DM53JW0 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM53JW0 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM57GL1 DI DM57GL1 DM57GL1 DN 4-(4-fluoropyrazol-1-yl)-1,2-oxazol-5-amine DM57GL1 TI TTXNCBV DM57GL1 TN Tryptophan 2,3-dioxygenase (TDO) DM57GL1 MA Inhibitor DM57GL1 RN Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. DM57GL1 RU https://pubmed.ncbi.nlm.nih.gov/30760888 DM5AMFV DI DM5AMFV DM5AMFV DN MS012 DM5AMFV TI TTS6RZT DM5AMFV TN Histone-lysine N-methyltransferase EHMT2 (EHMT2) DM5AMFV MA Inhibitor DM5AMFV RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DM5AMFV RU https://pubmed.ncbi.nlm.nih.gov/33469207 DM5AOI3 DI DM5AOI3 DM5AOI3 DN GSK2643943A DM5AOI3 TI TT07QDI DM5AOI3 TN Ubiquitin carboxyl-terminal hydrolase 20 (USP20) DM5AOI3 MA Inhibitor DM5AOI3 RN Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78. DM5AOI3 RU https://pubmed.ncbi.nlm.nih.gov/28959952 DM5CBNY DI DM5CBNY DM5CBNY DN BIX-01294 DM5CBNY TI TTS6RZT DM5CBNY TN Histone-lysine N-methyltransferase EHMT2 (EHMT2) DM5CBNY MA Inhibitor DM5CBNY RN Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81. DM5CBNY RU https://pubmed.ncbi.nlm.nih.gov/17289593 DM5CBNY DI DM5CBNY DM5CBNY DN BIX-01294 DM5CBNY TI TTOFXD7 DM5CBNY TN Euchromatic histone-lysine N-methyltransferase 1 (EHMT1) DM5CBNY MA Inhibitor DM5CBNY RN Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007 Feb 9;25(3):473-81. DM5CBNY RU https://pubmed.ncbi.nlm.nih.gov/17289593 DM5CVBM DI DM5CVBM DM5CVBM DN 3-Oxo-C12-(2-amino-cyclohexanone) DM5CVBM TI TTOMVUW DM5CVBM TN Pseudomonas Transcriptional activator protein LasR (Pseudo LasR) DM5CVBM MA Agonist DM5CVBM RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DM5CVBM RU https://pubmed.ncbi.nlm.nih.gov/28337021 DM5H2W9 DI DM5H2W9 DM5H2W9 DN Dioscin DM5H2W9 TI TT1UCIJ DM5H2W9 TN C-X-C chemokine receptor type 3 (CXCR3) DM5H2W9 MA Antagonist DM5H2W9 RN Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol Divers. 2005;9(1-3):123-9. DM5H2W9 RU https://pubmed.ncbi.nlm.nih.gov/15789559 DM5IMAU DI DM5IMAU DM5IMAU DN MAb173 DM5IMAU TI TTBID49 DM5IMAU TN C-X-C chemokine receptor type 4 (CXCR4) DM5IMAU MA Antagonist DM5IMAU RN Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120). Virology. 2000 Mar 15;268(2):329-44. DM5IMAU RU https://pubmed.ncbi.nlm.nih.gov/10704341 DM5IUN8 DI DM5IUN8 DM5IUN8 DN 12B9m DM5IUN8 TI TTPCG5T DM5IUN8 TN Hepcidin (HAMP) DM5IUN8 MA Inhibitor DM5IUN8 RN Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 2010 Dec;12(4):646-57. DM5IUN8 RU https://pubmed.ncbi.nlm.nih.gov/20737261 DM5K17C DI DM5K17C DM5K17C DN EPL-1410 DM5K17C TI TTXNCBV DM5K17C TN Tryptophan 2,3-dioxygenase (TDO) DM5K17C MA Inhibitor DM5K17C RN Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. DM5K17C RU https://pubmed.ncbi.nlm.nih.gov/30760888 DM5K17C DI DM5K17C DM5K17C DN EPL-1410 DM5K17C TI TTZJYKH DM5K17C TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5K17C MA Inhibitor DM5K17C RN Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. DM5K17C RU https://pubmed.ncbi.nlm.nih.gov/30760888 DM5KE4R DI DM5KE4R DM5KE4R DN SNAP-7941 DM5KE4R TI TTX4RTB DM5KE4R TN Melanin-concentrating hormone receptor 1 (MCHR1) DM5KE4R MA Antagonist DM5KE4R RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM5KE4R RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM61TDB DI DM61TDB DM61TDB DN ARI-809 DM61TDB TI TTFBNVI DM61TDB TN Aldose reductase (AKR1B1) DM61TDB MA Inhibitor DM61TDB RN A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes. 2006 Oct;55(10):2757-62. DM61TDB RU https://pubmed.ncbi.nlm.nih.gov/17003340 DM648KQ DI DM648KQ DM648KQ DN ALN-FLU01 DM648KQ TI TTM27B5 DM648KQ TN Influenza NA messenger RNA (Influenza NA mRNA) DM648KQ RN Respiratory viral diseases: access to RNA interference therapy. Drug Discov Today Ther Strateg. 2007; 4(4): 273-276. DM648KQ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597863/ DM65UZ2 DI DM65UZ2 DM65UZ2 DN NTU281 DM65UZ2 TI TT2F4OL DM65UZ2 TN Tissue transglutaminase (TG2) DM65UZ2 MA Inhibitor DM65UZ2 RN Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855. DM65UZ2 RU https://pubmed.ncbi.nlm.nih.gov/29218009 DM682UV DI DM682UV DM682UV DN PD-158771 DM682UV TI TTSQIFT DM682UV TN 5-HT 1A receptor (HTR1A) DM682UV MA Antagonist DM682UV RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM682UV RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM682UV DI DM682UV DM682UV DN PD-158771 DM682UV TI TT4C8EA DM682UV TN Dopamine D3 receptor (D3R) DM682UV MA Antagonist DM682UV RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM682UV RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM682UV DI DM682UV DM682UV DN PD-158771 DM682UV TI TTEX248 DM682UV TN Dopamine D2 receptor (D2R) DM682UV MA Antagonist DM682UV RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM682UV RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM69UZG DI DM69UZG DM69UZG DN HPP-851 DM69UZG TI TTN7BL9 DM69UZG TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM69UZG MA Inhibitor DM69UZG RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027759) DM69UZG RU http://adisinsight.springer.com/drugs/800027759 DM6BGJ9 DI DM6BGJ9 DM6BGJ9 DN BFF-122 DM6BGJ9 TI TTT3IXG DM6BGJ9 TN Kynurenine oxoglutarate transaminase II (AADAT) DM6BGJ9 MA Inhibitor DM6BGJ9 RN Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. DM6BGJ9 RU https://pubmed.ncbi.nlm.nih.gov/30760888 DM6GSI1 DI DM6GSI1 DM6GSI1 DN HBX19818 DM6GSI1 TI TTXU3EQ DM6GSI1 TN Herpesvirus ubiquitin-specific protease (HAUSP) DM6GSI1 MA Inhibitor DM6GSI1 RN Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug;8(8):2286-95. DM6GSI1 RU https://pubmed.ncbi.nlm.nih.gov/19671755 DM6HADZ DI DM6HADZ DM6HADZ DN CL-314698 DM6HADZ TI TTMXGCW DM6HADZ TN Adrenergic receptor beta-3 (ADRB3) DM6HADZ MA Agonist DM6HADZ RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM6HADZ RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM6RFLE DI DM6RFLE DM6RFLE DN ML364 DM6RFLE TI TTUEQ1W DM6RFLE TN Ubiquitin carboxyl-terminal hydrolase 2 (USP2) DM6RFLE MA Inhibitor DM6RFLE RN The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer. Cell Death Differ. 2020 Sep;27(9):2710-2725. DM6RFLE RU https://pubmed.ncbi.nlm.nih.gov/32327714 DM6W9YM DI DM6W9YM DM6W9YM DN TP-023 DM6W9YM TI TTAN6JD DM6W9YM TN Glutamate receptor AMPA (GRIA) DM6W9YM MA Modulator DM6W9YM RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DM6W9YM RU https://pubmed.ncbi.nlm.nih.gov/16377242 DM6WC1Q DI DM6WC1Q DM6WC1Q DN HR2P peptide DM6WC1Q TI TTJ4EIV DM6WC1Q TN MERS-CoV spike glycoprotein S2 subunit (S S2) DM6WC1Q MA Inhibitor DM6WC1Q RN Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067. DM6WC1Q RU https://pubmed.ncbi.nlm.nih.gov/24473083 DM6X0PZ DI DM6X0PZ DM6X0PZ DN SB222200 DM6X0PZ TI TTBPGLU DM6X0PZ TN Neuromedin-K receptor (TACR3) DM6X0PZ MA Antagonist DM6X0PZ RN Evidence for mediation of nociception by injection of the NK-3 receptor agonist, senktide, into the dorsal periaqueductal gray of rats. Psychopharmacology (Berl). 2009 May;204(1):13-24. DM6X0PZ RU https://pubmed.ncbi.nlm.nih.gov/19093101 DM7DNOG DI DM7DNOG DM7DNOG DN SK-7041 DM7DNOG TI TT6R7JZ DM7DNOG TN Histone deacetylase 1 (HDAC1) DM7DNOG MA Inhibitor DM7DNOG RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM7DNOG RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM7E324 DI DM7E324 DM7E324 DN SAND-5 DM7E324 TI TTKANGO DM7E324 TN Complement C5 (CO5) DM7E324 MA Inhibitor DM7E324 RN Progress and Trends in Complement Therapeutics. Adv Exp Med Biol. 2013; 734: 1-22. DM7E324 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526805/ DM7HUVB DI DM7HUVB DM7HUVB DN m337 DM7HUVB TI TTZ3COY DM7HUVB TN COVID-19 spike glycoprotein (S) DM7HUVB MA Inhibitor DM7HUVB RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM7HUVB RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM7JH0K DI DM7JH0K DM7JH0K DN RG70099 DM7JH0K TI TTXNCBV DM7JH0K TN Tryptophan 2,3-dioxygenase (TDO) DM7JH0K MA Inhibitor DM7JH0K RN Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. DM7JH0K RU https://pubmed.ncbi.nlm.nih.gov/30760888 DM7JH0K DI DM7JH0K DM7JH0K DN RG70099 DM7JH0K TI TTZJYKH DM7JH0K TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7JH0K MA Inhibitor DM7JH0K RN Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. DM7JH0K RU https://pubmed.ncbi.nlm.nih.gov/30760888 DM7MDZE DI DM7MDZE DM7MDZE DN SR1078 DM7MDZE TI TTGV6LY DM7MDZE TN Nuclear receptor ROR-gamma (RORG) DM7MDZE MA Agonist DM7MDZE RN Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORalpha and ROR. ACS Chem Biol. 2010 Nov 19;5(11):1029-34. DM7MDZE RU https://pubmed.ncbi.nlm.nih.gov/20735016 DM7MDZE DI DM7MDZE DM7MDZE DN SR1078 DM7MDZE TI TT1TYN7 DM7MDZE TN Nuclear receptor ROR-alpha (RORA) DM7MDZE MA Agonist DM7MDZE RN Identification of SR1078, a synthetic agonist for the orphan nuclear receptors RORalpha and ROR. ACS Chem Biol. 2010 Nov 19;5(11):1029-34. DM7MDZE RU https://pubmed.ncbi.nlm.nih.gov/20735016 DM7NS1L DI DM7NS1L DM7NS1L DN Savirin DM7NS1L TI TTWPX3M DM7NS1L TN Staphylococcus Accessory gene regulator protein A (Stap-coc agrA) DM7NS1L MA Inhibitor DM7NS1L RN Selective chemical inhibition of agr quorum sensing in Staphylococcus aureus promotes host defense with minimal impact on resistance. PLoS Pathog. 2014 Jun 12;10(6):e1004174. DM7NS1L RU https://pubmed.ncbi.nlm.nih.gov/24945495 DM7PBJC DI DM7PBJC DM7PBJC DN GC813 DM7PBJC TI TTWOH4Q DM7PBJC TN MERS-CoV 3C-like proteinase (3CLpro) DM7PBJC MA Inhibitor DM7PBJC RN Structure-guided Design of Potent and Permeable Inhibitors of MERS Coronavirus 3CL Protease That Utilize a Piperidine Moiety as a Novel Design Element Eur J Med Chem. 2018 Apr 25;150:334-346. DM7PBJC RU https://pubmed.ncbi.nlm.nih.gov/29544147 DM7Q1PF DI DM7Q1PF DM7Q1PF DN MEDI-543 DM7Q1PF TI TTRJB2G DM7Q1PF TN Ephrin type-A receptor 2 (EPHA2) DM7Q1PF RN Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther. 2010 Dec 15;10(12):1306-14. DM7Q1PF RU https://pubmed.ncbi.nlm.nih.gov/20948320 DM7R3B6 DI DM7R3B6 DM7R3B6 DN Nobiletin DM7R3B6 TI TTGV6LY DM7R3B6 TN Nuclear receptor ROR-gamma (RORG) DM7R3B6 MA Agonist DM7R3B6 RN The Small Molecule Nobiletin Targets the Molecular Oscillator to Enhance Circadian Rhythms and Protect against Metabolic Syndrome. Cell Metab. 2016 Apr 12;23(4):610-21. DM7R3B6 RU https://pubmed.ncbi.nlm.nih.gov/27076076 DM7RHOC DI DM7RHOC DM7RHOC DN 5N,6S-(N'-butyliminomethylidene)-6-thio-1-deoxygalactonojirimycin DM7RHOC TI TTNGJPH DM7RHOC TN Beta-galactosidase (GLB1) DM7RHOC MA Inhibitor DM7RHOC RN A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther. 2013 Mar;21(3):526-32. DM7RHOC RU https://pubmed.ncbi.nlm.nih.gov/23337983 DM7RMG9 DI DM7RMG9 DM7RMG9 DN Thioguanine DM7RMG9 TI TTYJOLE DM7RMG9 TN MERS-CoV papain-like proteinase (PL-PRO) DM7RMG9 MA Inhibitor DM7RMG9 RN Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16. DM7RMG9 RU https://pubmed.ncbi.nlm.nih.gov/25542975 DM7RMG9 DI DM7RMG9 DM7RMG9 DN Thioguanine DM7RMG9 TI TTRGHB2 DM7RMG9 TN SARS-CoV papain-like proteinase (PL-PRO) DM7RMG9 MA Inhibitor DM7RMG9 RN Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16. DM7RMG9 RU https://pubmed.ncbi.nlm.nih.gov/25542975 DM7UGY9 DI DM7UGY9 DM7UGY9 DN MC-3002 DM7UGY9 TI TTZMAO3 DM7UGY9 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM7UGY9 MA Modulator DM7UGY9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7UGY9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7UGY9 DI DM7UGY9 DM7UGY9 DN MC-3002 DM7UGY9 TI TTJ584C DM7UGY9 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM7UGY9 MA Modulator DM7UGY9 RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DM7UGY9 RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DM7UJ1I DI DM7UJ1I DM7UJ1I DN FX-107 DM7UJ1I TI TTWODQF DM7UJ1I TN Fibrin (FG) DM7UJ1I MA Inhibitor DM7UJ1I RN FX-06, a fibrin-derived Bbeta15-42 peptide for the potential treatment of reperfusion injury following myocardial infarction. Curr Opin Investig Drugs. 2009 Sep;10(9):997-1003. DM7UJ1I RU https://pubmed.ncbi.nlm.nih.gov/19705343 DM7X4SV DI DM7X4SV DM7X4SV DN HR2P-M2 peptide DM7X4SV TI TTJ4EIV DM7X4SV TN MERS-CoV spike glycoprotein S2 subunit (S S2) DM7X4SV MA Inhibitor DM7X4SV RN Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067. DM7X4SV RU https://pubmed.ncbi.nlm.nih.gov/24473083 DM7XPDB DI DM7XPDB DM7XPDB DN LY-2463665 DM7XPDB TI TTDIGC1 DM7XPDB TN Dipeptidyl peptidase 4 (DPP-4) DM7XPDB MA Inhibitor DM7XPDB RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DM7XPDB RU https://pubmed.ncbi.nlm.nih.gov/19149538 DM7Y4GT DI DM7Y4GT DM7Y4GT DN T-226293 DM7Y4GT TI TTTK0NH DM7Y4GT TN Delta(24)-sterol reductase (DHCR24) DM7Y4GT MA Inhibitor DM7Y4GT RN Antilipemic drug-induced skin manifestations. Hautarzt. 1995 Feb;46(2):76-80. DM7Y4GT RU https://pubmed.ncbi.nlm.nih.gov/7706076 DM7Y4GT DI DM7Y4GT DM7Y4GT DN T-226293 DM7Y4GT TI TTX4RTB DM7Y4GT TN Melanin-concentrating hormone receptor 1 (MCHR1) DM7Y4GT MA Antagonist DM7Y4GT RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DM7Y4GT RU https://pubmed.ncbi.nlm.nih.gov/16083333 DM82Y75 DI DM82Y75 DM82Y75 DN PIRINIXIC ACID DM82Y75 TI TTJ584C DM82Y75 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM82Y75 MA Inhibitor DM82Y75 RN O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3185-90. DM82Y75 RU https://pubmed.ncbi.nlm.nih.gov/12951090 DM83DSA DI DM83DSA DM83DSA DN NOX-F37 DM83DSA TI TT4TFGN DM83DSA TN Vasopressin V1a receptor (V1AR) DM83DSA MA Antagonist DM83DSA RN Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95. DM83DSA RU https://pubmed.ncbi.nlm.nih.gov/17355215 DM84EOW DI DM84EOW DM84EOW DN SSR-103800 DM84EOW TI TTHJTF7 DM84EOW TN Glycine transporter GlyT-1 (SLC6A9) DM84EOW MA Blocker DM84EOW RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM84EOW RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM86YBK DI DM86YBK DM86YBK DN K11777 DM86YBK TI TTS586L DM86YBK TN HUMAN cathepsin L (CTSL) DM86YBK MA Blocker DM86YBK RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM86YBK RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM89DQP DI DM89DQP DM89DQP DN Chlamydocin DM89DQP TI TT6R7JZ DM89DQP TN Histone deacetylase 1 (HDAC1) DM89DQP MA Inhibitor DM89DQP RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM89DQP RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM89VIO DI DM89VIO DM89VIO DN RS2-1G9 DM89VIO TI TTM2AGN DM89VIO TN 3-oxo-dodecanoyl-homoserine lactone (C12) DM89VIO MA Inhibitor DM89VIO RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DM89VIO RU https://pubmed.ncbi.nlm.nih.gov/28337021 DM8AR0E DI DM8AR0E DM8AR0E DN Cruentaren DM8AR0E TI TTL2PXZ DM8AR0E TN Vacuolar-type proton ATPase catalytic A (v-ATPase-A) DM8AR0E MA Inhibitor DM8AR0E RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DM8AR0E RU https://pubmed.ncbi.nlm.nih.gov/19463273 DM8DYJQ DI DM8DYJQ DM8DYJQ DN SHP656 DM8DYJQ TI TT5MLZR DM8DYJQ TN Cryptochrome circadian clock 1 (CRY1) DM8DYJQ MA Modulator DM8DYJQ RN Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307. DM8DYJQ RU https://pubmed.ncbi.nlm.nih.gov/33589815 DM8DYJQ DI DM8DYJQ DM8DYJQ DN SHP656 DM8DYJQ TI TTAO58M DM8DYJQ TN Cryptochrome-2 (CRY2) DM8DYJQ MA Modulator DM8DYJQ RN Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307. DM8DYJQ RU https://pubmed.ncbi.nlm.nih.gov/33589815 DM8OAZ6 DI DM8OAZ6 DM8OAZ6 DN JT08 DM8OAZ6 TI TTIW59R DM8OAZ6 TN C-X-C chemokine receptor type 5 (CXCR5) DM8OAZ6 MA Inhibitor DM8OAZ6 RN Clinical pipeline report, company report or official report of Jyant Technologies. DM8OAZ6 RU http://jyanttech.com/index.php?/pipeline DM8P9ST DI DM8P9ST DM8P9ST DN PF-4800567 DM8P9ST TI TTA8PLI DM8P9ST TN Casein kinase I epsilon (CSNK1E) DM8P9ST MA Inhibitor DM8P9ST RN Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9. DM8P9ST RU https://pubmed.ncbi.nlm.nih.gov/19458106 DM8P9ST DI DM8P9ST DM8P9ST DN PF-4800567 DM8P9ST TI TTH30UI DM8P9ST TN Casein kinase I delta (CSNK1D) DM8P9ST MA Inhibitor DM8P9ST RN Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period. J Pharmacol Exp Ther. 2009 Aug;330(2):430-9. DM8P9ST RU https://pubmed.ncbi.nlm.nih.gov/19458106 DM8SKU1 DI DM8SKU1 DM8SKU1 DN SR9009 DM8SKU1 TI TTAD1O8 DM8SKU1 TN V-erbA-related protein 1 (NR1D1) DM8SKU1 MA Agonist DM8SKU1 RN Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018 Jan 18;553(7688):351-355. DM8SKU1 RU https://pubmed.ncbi.nlm.nih.gov/29320480 DM8T6H7 DI DM8T6H7 DM8T6H7 DN ALN-HTT DM8T6H7 TI TTIWZ0O DM8T6H7 TN Huntingtin messenger RNA (HTT mRNA) DM8T6H7 RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011). DM8T6H7 RU http://www.alnylam.com/Programs-and-Pipeline/index.php DM8TAI9 DI DM8TAI9 DM8TAI9 DN BMS-986202 DM8TAI9 TI TTQ6S1K DM8TAI9 TN Lysophosphatidic acid receptor 1 (LPAR1) DM8TAI9 MA Antagonist DM8TAI9 RN Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700. DM8TAI9 RU https://pubmed.ncbi.nlm.nih.gov/21159750 DM8UKL0 DI DM8UKL0 DM8UKL0 DN EPZ031686 DM8UKL0 TI TTKLJYX DM8UKL0 TN Histone-lysine N-methyltransferase SMYD3 (SMYD3) DM8UKL0 MA Inhibitor DM8UKL0 RN Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Expert Opin Ther Targets. 2017 Feb;21(2):145-157. DM8UKL0 RU https://pubmed.ncbi.nlm.nih.gov/28019723 DM8WDAL DI DM8WDAL DM8WDAL DN BN-OD-026 DM8WDAL TI TTZAYWL DM8WDAL TN Estrogen receptor (ESR) DM8WDAL MA Modulator DM8WDAL RN Clinical pipeline report, company report or official report of Bionovo. DM8WDAL RU http://bionovo.com/investors/pr/MjAxMTEyMDgwODAw DM8WTAZ DI DM8WTAZ DM8WTAZ DN Debio1453 DM8WTAZ TI TT9142J DM8WTAZ TN Neisseria gonorrhoeae Enoyl-[acyl-carrier-protein] reductase (Neisseria fabI) DM8WTAZ MA Inhibitor DM8WTAZ RN Clinical pipeline report, company report or official report of Debiopharm. DM8WTAZ RU https://www.debiopharm.com/drug-development/pipeline/debio-1453/ DM8XHJG DI DM8XHJG DM8XHJG DN A-893 DM8XHJG TI TT7YJFO DM8XHJG TN SET and MYND domain-containing protein 2 (SMYD2) DM8XHJG MA Inhibitor DM8XHJG RN Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2. ACS Med Chem Lett. 2015 Apr 29;6(6):695-700. DM8XHJG RU https://pubmed.ncbi.nlm.nih.gov/26101576 DM8YSW7 DI DM8YSW7 DM8YSW7 DN DX-2802 DM8YSW7 TI TT6X50U DM8YSW7 TN Matrix metalloproteinase-9 (MMP-9) DM8YSW7 RN Clinical pipeline report, company report or official report of DeepDyve. DM8YSW7 RU https://www.deepdyve.com/lp/elsevier/490-mmp-9-as-a-stromal-target-in-cancer-pzh95qPjis DM8YUJT DI DM8YUJT DM8YUJT DN CWHM-12 DM8YUJT TI TTIQSVM DM8YUJT TN Integrin alpha-V/beta-6 (ITGAV/B6) DM8YUJT MA Inhibitor DM8YUJT RN Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec;19(12):1617-24. DM8YUJT RU https://pubmed.ncbi.nlm.nih.gov/24216753 DM92VRP DI DM92VRP DM92VRP DN Batimastat DM92VRP TI TTUZ2L5 DM92VRP TN Matrix metalloproteinase-3 (MMP-3) DM92VRP MA Modulator DM92VRP RN Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8. DM92VRP RU https://www.ncbi.nlm.nih.gov/pubmed/8062271 DM94ZOI DI DM94ZOI DM94ZOI DN PMID21925774-compound-5e DM94ZOI TI TTQKWR5 DM94ZOI TN SARS-CoV helicase (Hel) DM94ZOI MA Inhibitor DM94ZOI RN 2,6-Bis-arylmethyloxy-5-hydroxychromones With Antiviral Activity Against Both Hepatitis C Virus (HCV) and SARS-associated Coronavirus (SCV) Eur J Med Chem. 2011 Nov;46(11):5698-704. DM94ZOI RU https://pubmed.ncbi.nlm.nih.gov/21925774 DM95VQ6 DI DM95VQ6 DM95VQ6 DN vialinin A DM95VQ6 TI TTGYTMA DM95VQ6 TN Isopeptidase T (USP5) DM95VQ6 MA Inhibitor DM95VQ6 RN Vialinin A is a ubiquitin-specific peptidase inhibitor. Bioorg Med Chem Lett. 2013 Aug 1;23(15):4328-31. DM95VQ6 RU https://pubmed.ncbi.nlm.nih.gov/23791076 DM96IUW DI DM96IUW DM96IUW DN SR3335 DM96IUW TI TT1TYN7 DM96IUW TN Nuclear receptor ROR-alpha (RORA) DM96IUW MA Agonist DM96IUW RN Identification of SR3335 (ML-176): a synthetic RORalpha selective inverse agonist. ACS Chem Biol. 2011 Mar 18;6(3):218-22. DM96IUW RU https://pubmed.ncbi.nlm.nih.gov/21090593 DM97RV4 DI DM97RV4 DM97RV4 DN GYKI-47261 DM97RV4 TI TTAN6JD DM97RV4 TN Glutamate receptor AMPA (GRIA) DM97RV4 MA Antagonist DM97RV4 RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DM97RV4 RU https://pubmed.ncbi.nlm.nih.gov/18991661 DM9HG6S DI DM9HG6S DM9HG6S DN CAR-T cells targeting CD117 DM9HG6S TI TTX41N9 DM9HG6S TN Tyrosine-protein kinase Kit (KIT) DM9HG6S MA CAR-T-Cell-Therapy DM9HG6S RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DM9HG6S RU https://clinicaltrials.gov/ct2/show/NCT03473457 DM9JZ21 DI DM9JZ21 DM9JZ21 DN Scriptaid DM9JZ21 TI TT6R7JZ DM9JZ21 TN Histone deacetylase 1 (HDAC1) DM9JZ21 MA Inhibitor DM9JZ21 RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM9JZ21 RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM9LS0R DI DM9LS0R DM9LS0R DN PMID31955138-compound-16 DM9LS0R TI TTY732E DM9LS0R TN MERS-CoV helicase (Hel) DM9LS0R MA Inhibitor DM9LS0R RN Design, synthesis and molecular docking of novel triazole derivatives as potential CoV helicase inhibitors. Acta Pharm. 2020 Jun 1;70(2):145-159. DM9LS0R RU https://pubmed.ncbi.nlm.nih.gov/31955138 DM9SY8E DI DM9SY8E DM9SY8E DN PT630 DM9SY8E TI TTDIGC1 DM9SY8E TN Dipeptidyl peptidase 4 (DPP-4) DM9SY8E MA Inhibitor DM9SY8E RN Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25. DM9SY8E RU https://pubmed.ncbi.nlm.nih.gov/19920354 DM9SY8E DI DM9SY8E DM9SY8E DN PT630 DM9SY8E TI TTGPQ0F DM9SY8E TN Prolyl endopeptidase FAP (FAP) DM9SY8E MA Inhibitor DM9SY8E RN Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25. DM9SY8E RU https://pubmed.ncbi.nlm.nih.gov/19920354 DM9TQDE DI DM9TQDE DM9TQDE DN 111In-hEGF DM9TQDE TI TTGKNB4 DM9TQDE TN Epidermal growth factor receptor (EGFR) DM9TQDE MA Modulator DM9TQDE RN A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11. DM9TQDE RU https://pubmed.ncbi.nlm.nih.gov/10809207 DM9Y05C DI DM9Y05C DM9Y05C DN S-(2-Aminophenyl)-L-cysteine S,S-dioxide DM9Y05C TI TTWQM3J DM9Y05C TN Kynureninase (KYNU) DM9Y05C MA Inhibitor DM9Y05C RN Structure, mechanism, and substrate specificity of kynureninase. Biochim Biophys Acta. 2011 Nov;1814(11):1481-8. DM9Y05C RU https://pubmed.ncbi.nlm.nih.gov/21167323 DMA1BLC DI DMA1BLC DMA1BLC DN CAR-T cells targeting Mucl DMA1BLC TI TTBHFYQ DMA1BLC TN Mucin-1 (MUC1) DMA1BLC MA CAR-T-Cell-Therapy DMA1BLC RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMA1BLC RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMA1MK5 DI DMA1MK5 DMA1MK5 DN CYC-800 DMA1MK5 TI TTIYVQP DMA1MK5 TN Polo-like kinase 1 (PLK1) DMA1MK5 MA Inhibitor DMA1MK5 RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMA1MK5 RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMA2K7C DI DMA2K7C DMA2K7C DN Donitriptan DMA2K7C TI TTK8CXU DMA2K7C TN 5-HT 1B receptor (HTR1B) DMA2K7C MA Modulator DMA2K7C RN Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.Br J Pharmacol.2006 Sep;149(1):82-91. DMA2K7C RU https://www.ncbi.nlm.nih.gov/pubmed/16880765 DMA2K7C DI DMA2K7C DMA2K7C DN Donitriptan DMA2K7C TI TT6MSOK DMA2K7C TN 5-HT 1D receptor (HTR1D) DMA2K7C MA Modulator DMA2K7C RN Donitriptan, but not sumatriptan, inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors.Br J Pharmacol.2006 Sep;149(1):82-91. DMA2K7C RU https://www.ncbi.nlm.nih.gov/pubmed/16880765 DMA5T3J DI DMA5T3J DMA5T3J DN Pepticlere DMA5T3J TI TTE4KHA DMA5T3J TN Amyloid beta A4 protein (APP) DMA5T3J MA Inhibitor DMA5T3J RN Preclinical trail of Pepticlere (DP-74) for treating Alzheimer's disease. ProteoTech Inc. DMA5T3J RU http://www.biocentury.com/products/pepticlere DMAJWLD DI DMAJWLD DMAJWLD DN 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)-6-chloroindolin-2-one DMAJWLD TI TTLPC70 DMAJWLD TN Lysosomal alpha-glucosidase (GAA) DMAJWLD MA Inhibitor DMAJWLD RN 5-(4-(4-Acetylphenyl)piperazin-1-ylsulfonyl)indolin-2-one Analogs as Inhibitors of Acid alpha-Glucosidase for Potential Chaperone Treatment of Pompe Disease or Intervention for Diabetes Mellitus Type 2. N.A.. N.A. DMAJWLD RU https://pubmed.ncbi.nlm.nih.gov/23905200 DMAK6H3 DI DMAK6H3 DMAK6H3 DN A-74498 DMAK6H3 TI TTCG0AL DMAK6H3 TN Cholecystokinin receptor type A (CCKAR) DMAK6H3 MA Agonist DMAK6H3 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMAK6H3 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMAM4FE DI DMAM4FE DMAM4FE DN 2-Ethoxypropanoic acid DMAM4FE TI TT5MLZR DMAM4FE TN Cryptochrome circadian clock 1 (CRY1) DMAM4FE MA Inhibitor DMAM4FE RN The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life Sci. 2018 May 1;200:49-55. DMAM4FE RU https://pubmed.ncbi.nlm.nih.gov/29534992 DMAM4FE DI DMAM4FE DMAM4FE DN 2-Ethoxypropanoic acid DMAM4FE TI TTAO58M DMAM4FE TN Cryptochrome-2 (CRY2) DMAM4FE MA Inhibitor DMAM4FE RN The cryptochrome inhibitor KS15 enhances E-box-mediated transcription by disrupting the feedback action of a circadian transcription-repressor complex. Life Sci. 2018 May 1;200:49-55. DMAM4FE RU https://pubmed.ncbi.nlm.nih.gov/29534992 DMAPO0T DI DMAPO0T DMAPO0T DN Ciglitazone DMAPO0T TI TTZMAO3 DMAPO0T TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMAPO0T MA Agonist DMAPO0T RN New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. DMAPO0T RU https://pubmed.ncbi.nlm.nih.gov/18616415 DMATQB7 DI DMATQB7 DMATQB7 DN Alpha-Helical lipopeptides FFS DMATQB7 TI TT85VHW DMATQB7 TN MERS-CoV spike glycoprotein (S) DMATQB7 MA Inhibitor DMATQB7 RN De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745. DMATQB7 RU https://pubmed.ncbi.nlm.nih.gov/30192544 DMATUKO DI DMATUKO DMATUKO DN CP-114271 DMATUKO TI TTMXGCW DMATUKO TN Adrenergic receptor beta-3 (ADRB3) DMATUKO MA Agonist DMATUKO RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMATUKO RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMAUILH DI DMAUILH DMAUILH DN DecRVKRCMK DMAUILH TI TTH9WF6 DMAUILH TN Dibasic-processing enzyme (Furin) DMAUILH MA Inhibitor DMAUILH RN Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage. Viruses. 2019 Oct 31;11(11):1011. DMAUILH RU https://pubmed.ncbi.nlm.nih.gov/31683742 DMAVQ2X DI DMAVQ2X DMAVQ2X DN F26G4 DMAVQ2X TI TTM0O8B DMAVQ2X TN Bacillus poly-gamma-d-glutamic acid (Bacillus PGA) DMAVQ2X RN Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule. Infect Immun. 2007 Jan;75(1):152-63. DMAVQ2X RU https://pubmed.ncbi.nlm.nih.gov/17060470 DMAX2EW DI DMAX2EW DMAX2EW DN FAS1 DMAX2EW TI TT7AOUD DMAX2EW TN Fatty acid synthase (FASN) DMAX2EW MA Inhibitor DMAX2EW RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DMAX2EW RU https://pubmed.ncbi.nlm.nih.gov/19463273 DMAZROV DI DMAZROV DMAZROV DN GSK2807 DMAZROV TI TTKLJYX DMAZROV TN Histone-lysine N-methyltransferase SMYD3 (SMYD3) DMAZROV MA Inhibitor DMAZROV RN Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets. Structure. 2016 May 3;24(5):774-781. DMAZROV RU https://pubmed.ncbi.nlm.nih.gov/27066749 DMB1ET0 DI DMB1ET0 DMB1ET0 DN Cutamesine DMB1ET0 TI TT5TPI6 DMB1ET0 TN Opioid receptor sigma 1 (OPRS1) DMB1ET0 MA Agonist DMB1ET0 RN Effect of SA4503, a novel sigma1 receptor agonist, against glutamate neurotoxicity in cultured rat retinal neurons. Eur J Pharmacol. 1998 Jan 19;342(1):105-11. DMB1ET0 RU https://pubmed.ncbi.nlm.nih.gov/9544798 DMB4FWX DI DMB4FWX DMB4FWX DN CS-00028 DMB4FWX TI TTBH0VX DMB4FWX TN Histone deacetylase (HDAC) DMB4FWX MA Antagonist DMB4FWX RN US patent application no. 2009,0162,329, Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure. DMB4FWX RU https://www.google.com/patents/US20090162329 DMB7WEY DI DMB7WEY DMB7WEY DN TV-1390 DMB7WEY TI TT4TZ8J DMB7WEY TN Interferon-beta (IFNB1) DMB7WEY MA Modulator DMB7WEY RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032947) DMB7WEY RU http://adisinsight.springer.com/drugs/800032947 DMB9IPR DI DMB9IPR DMB9IPR DN RS-504393 DMB9IPR TI TTFZYTO DMB9IPR TN C-C chemokine receptor type 2 (CCR2) DMB9IPR MA Antagonist DMB9IPR RN Beneficial or detrimental effects of carotenoids contained in food: cell culture models. Mini Rev Med Chem. 2007 Nov;7(11):1120-8. DMB9IPR RU https://pubmed.ncbi.nlm.nih.gov/18045215 DMB9IPR DI DMB9IPR DMB9IPR DN RS-504393 DMB9IPR TI TTNAY0P DMB9IPR TN Monocyte chemotactic and activating factor (CCL2) DMB9IPR MA Inhibitor DMB9IPR RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DMB9IPR RU https://pubmed.ncbi.nlm.nih.gov/18045214 DMB9Z4C DI DMB9Z4C DMB9Z4C DN PD-160170 DMB9Z4C TI TTRK9JT DMB9Z4C TN Neuropeptide Y receptor type 1 (NPY1R) DMB9Z4C MA Antagonist DMB9Z4C RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMB9Z4C RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMBI1H2 DI DMBI1H2 DMBI1H2 DN AD-529 DMBI1H2 TI TT9IK2Z DMBI1H2 TN N-methyl-D-aspartate receptor (NMDAR) DMBI1H2 MA Antagonist DMBI1H2 RN WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors. DMBI1H2 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2 DMBINP0 DI DMBINP0 DMBINP0 DN ER-319711-15 DMBINP0 TI TTDIGC1 DMBINP0 TN Dipeptidyl peptidase 4 (DPP-4) DMBINP0 MA Inhibitor DMBINP0 RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMBINP0 RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMBPTDC DI DMBPTDC DMBPTDC DN BN-CB-045 DMBPTDC TI TTZAYWL DMBPTDC TN Estrogen receptor (ESR) DMBPTDC MA Modulator DMBPTDC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897) DMBPTDC RU http://adisinsight.springer.com/drugs/800023897 DMBQGZ9 DI DMBQGZ9 DMBQGZ9 DN INOC-005 DMBQGZ9 TI TT0PG8F DMBQGZ9 TN Cyclin-dependent kinase 4 (CDK4) DMBQGZ9 MA Inhibitor DMBQGZ9 RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DMBQGZ9 RU https://pubmed.ncbi.nlm.nih.gov/21253554 DMBQGZ9 DI DMBQGZ9 DMBQGZ9 DN INOC-005 DMBQGZ9 TI TTO0FDJ DMBQGZ9 TN Cyclin-dependent kinase 6 (CDK6) DMBQGZ9 MA Inhibitor DMBQGZ9 RN What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15. DMBQGZ9 RU https://pubmed.ncbi.nlm.nih.gov/19357322 DMBQGZ9 DI DMBQGZ9 DMBQGZ9 DN INOC-005 DMBQGZ9 TI TT7HF4W DMBQGZ9 TN Cyclin-dependent kinase 2 (CDK2) DMBQGZ9 MA Inhibitor DMBQGZ9 RN What are next generation innovative therapeutic targets. J Pharmacol Exp Ther. 2009 Jul;330(1):304-15. DMBQGZ9 RU https://pubmed.ncbi.nlm.nih.gov/19357322 DMBT2RJ DI DMBT2RJ DMBT2RJ DN MC-2001 DMBT2RJ TI TTGJCWZ DMBT2RJ TN Fms-like tyrosine kinase 3 (FLT-3) DMBT2RJ MA Inhibitor DMBT2RJ RN Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003 Oct;17(10):1961-6. DMBT2RJ RU https://pubmed.ncbi.nlm.nih.gov/14513045 DMBT2RJ DI DMBT2RJ DMBT2RJ DN MC-2001 DMBT2RJ TI TT3PJMV DMBT2RJ TN Tyrosine-protein kinase ABL1 (ABL) DMBT2RJ MA Inhibitor DMBT2RJ RN Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003 Oct;17(10):1961-6. DMBT2RJ RU https://pubmed.ncbi.nlm.nih.gov/14513045 DMBZVYG DI DMBZVYG DMBZVYG DN FOXO4-DRI DMBZVYG TI TTKW9CI DMBZVYG TN FOXO4-P53 interaction (FOXO4-P53 PPI) DMBZVYG MA Antagonist DMBZVYG RN FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020 Jan 20;12(2):1272-1284. DMBZVYG RU https://pubmed.ncbi.nlm.nih.gov/31959736 DMC1WAJ DI DMC1WAJ DMC1WAJ DN SPI-376 DMC1WAJ TI TTE0A2F DMC1WAJ TN Dopamine D4 receptor (D4R) DMC1WAJ MA Binder DMC1WAJ RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMC1WAJ RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMC3NSK DI DMC3NSK DMC3NSK DN MUT-056399 DMC3NSK TI TTZBRVL DMC3NSK TN Staphylococcus Enoyl ACP reductase (Stap-coc fabI) DMC3NSK MA Modulator DMC3NSK RN The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7. DMC3NSK RU https://pubmed.ncbi.nlm.nih.gov/21825292 DMC3NSK DI DMC3NSK DMC3NSK DN MUT-056399 DMC3NSK TI TTFKXOM DMC3NSK TN Bacterial NADH-dependent enoyl-ACP reductase (Bact fabI) DMC3NSK MA Modulator DMC3NSK RN The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob Agents Chemother. 2011 Oct;55(10):4692-7. DMC3NSK RU https://pubmed.ncbi.nlm.nih.gov/21825292 DMC4IUQ DI DMC4IUQ DMC4IUQ DN 5-(N,N-hexamethylene)-amiloride DMC4IUQ TI TT8R70G DMC4IUQ TN Gonadotropin-releasing hormone receptor (GNRHR) DMC4IUQ MA Modulator (allosteric modulator) DMC4IUQ RN Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol Pharmacol. 2008 Jun;73(6):1808-15. DMC4IUQ RU https://pubmed.ncbi.nlm.nih.gov/18344315 DMC4IUQ DI DMC4IUQ DMC4IUQ DN 5-(N,N-hexamethylene)-amiloride DMC4IUQ TI TT2NUT5 DMC4IUQ TN Adrenergic receptor alpha-2C (ADRA2C) DMC4IUQ MA Modulator (allosteric modulator) DMC4IUQ RN Characterization of the allosteric interactions between antagonists and amiloride analogues at the human alpha2A-adrenergic receptor. Mol Pharmacol. 1998 May;53(5):916-25. DMC4IUQ RU https://pubmed.ncbi.nlm.nih.gov/9584219 DMCDTIG DI DMCDTIG DMCDTIG DN 680C91 DMCDTIG TI TTXNCBV DMCDTIG TN Tryptophan 2,3-dioxygenase (TDO) DMCDTIG MA Inhibitor DMCDTIG RN Effects of IDO1 and TDO2 inhibition on cognitive deficits and anxiety following LPS-induced neuroinflammation. Acta Neuropsychiatr. 2020 Feb;32(1):43-53. DMCDTIG RU https://pubmed.ncbi.nlm.nih.gov/31753057 DMCGFY6 DI DMCGFY6 DMCGFY6 DN KOS-1815 DMCGFY6 TI TTCJUR4 DMCGFY6 TN Exportin-1 (XPO1) DMCGFY6 MA Inhibitor DMCGFY6 RN Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73. DMCGFY6 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108511/ DMCI371 DI DMCI371 DMCI371 DN SK-7068 DMCI371 TI TT6R7JZ DMCI371 TN Histone deacetylase 1 (HDAC1) DMCI371 MA Inhibitor DMCI371 RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMCI371 RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMCJMOS DI DMCJMOS DMCJMOS DN ALN-PCS DMCJMOS TI TTNIZ2B DMCJMOS TN PCSK9 messenger RNA (PCSK9 mRNA) DMCJMOS RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011). DMCJMOS RU http://www.alnylam.com/Programs-and-Pipeline/index.php DMCMS7V DI DMCMS7V DMCMS7V DN Org-24461 DMCMS7V TI TTHJTF7 DMCMS7V TN Glycine transporter GlyT-1 (SLC6A9) DMCMS7V MA Blocker DMCMS7V RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMCMS7V RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMCNBHY DI DMCNBHY DMCNBHY DN JNJ-42905343 DMCNBHY TI TTJQFBG DMCNBHY TN HIF-prolyl hydroxylase (HPH) DMCNBHY MA Inhibitor DMCNBHY RN Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88. DMCNBHY RU https://pubmed.ncbi.nlm.nih.gov/25988595 DMCPQJ9 DI DMCPQJ9 DMCPQJ9 DN BN-AA-003-NY DMCPQJ9 TI TTZAYWL DMCPQJ9 TN Estrogen receptor (ESR) DMCPQJ9 MA Modulator DMCPQJ9 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897) DMCPQJ9 RU http://adisinsight.springer.com/drugs/800023897 DMCVXBE DI DMCVXBE DMCVXBE DN E-64D DMCVXBE TI TTS586L DMCVXBE TN HUMAN cathepsin L (CTSL) DMCVXBE MA Blocker DMCVXBE RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMCVXBE RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMCZW4Q DI DMCZW4Q DMCZW4Q DN Mteron-F1 DMCZW4Q TI TTNDSF4 DMCZW4Q TN Proto-oncogene c-Met (MET) DMCZW4Q MA Stimulator DMCZW4Q RN Emerging drugs for chemotherapy-induced mucositis. Expert Opin Emerg Drugs. 2008 Sep;13(3):511-22. DMCZW4Q RU https://pubmed.ncbi.nlm.nih.gov/18764726 DMD0GB4 DI DMD0GB4 DMD0GB4 DN PD-165167 DMD0GB4 TI TTE0A2F DMD0GB4 TN Dopamine D4 receptor (D4R) DMD0GB4 MA Antagonist DMD0GB4 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMD0GB4 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMD0T1U DI DMD0T1U DMD0T1U DN Depudecin DMD0T1U TI TT6R7JZ DMD0T1U TN Histone deacetylase 1 (HDAC1) DMD0T1U MA Inhibitor DMD0T1U RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMD0T1U RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMD1E4J DI DMD1E4J DMD1E4J DN UNC0379 DMD1E4J TI TTGC95K DMD1E4J TN SET domain containing 8 (KMT5A) DMD1E4J MA Inhibitor DMD1E4J RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMD1E4J RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMD8JIC DI DMD8JIC DMD8JIC DN P22077 DMD8JIC TI TTXU3EQ DMD8JIC TN Herpesvirus ubiquitin-specific protease (HAUSP) DMD8JIC MA Inhibitor DMD8JIC RN P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6. Aging (Albany NY). 2020 Jun 9;12(11):10969-10982. DMD8JIC RU https://pubmed.ncbi.nlm.nih.gov/32516131 DMD8TNK DI DMD8TNK DMD8TNK DN XL475 DMD8TNK TI TTSDVTR DMD8TNK TN G-protein coupled bile acid receptor 1 (GPBAR1) DMD8TNK MA Agonist DMD8TNK RN Clinical pipeline report, company report or official report of Exelixis (2011). DMD8TNK RU http://www.exelixis.com/pipeline DMDE7OR DI DMDE7OR DMDE7OR DN NA-808 DMDE7OR TI TTZVMA7 DMDE7OR TN Serine palmitoyltransferase (SPTC) DMDE7OR MA Modulator DMDE7OR RN Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. DMDE7OR RU https://www.ncbi.nlm.nih.gov/pubmed/15950434 DMDEJBQ DI DMDEJBQ DMDEJBQ DN MS2177 DMDEJBQ TI TTGC95K DMDEJBQ TN SET domain containing 8 (KMT5A) DMDEJBQ MA Inhibitor DMDEJBQ RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMDEJBQ RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMDMQIE DI DMDMQIE DMDMQIE DN THAPSIGARGIN DMDMQIE TI TTZVSJ2 DMDMQIE TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMDMQIE MA Inhibitor DMDMQIE RN Elucidation of the topography of the thapsigargin binding site in the sarco-endoplasmic calcium ATPase. Bioorg Med Chem. 2010 Aug 1;18(15):5634-46. DMDMQIE RU https://pubmed.ncbi.nlm.nih.gov/20615710 DMDO6NZ DI DMDO6NZ DMDO6NZ DN EPZ033294 DMDO6NZ TI TT7YJFO DMDO6NZ TN SET and MYND domain-containing protein 2 (SMYD2) DMDO6NZ MA Inhibitor DMDO6NZ RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMDO6NZ RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMDRQIA DI DMDRQIA DMDRQIA DN ZBzl-YAA5911 DMDRQIA TI TTZXI0P DMDRQIA TN Enterococcus fsrC (Ente-cocc fsrC) DMDRQIA MA Antagonist DMDRQIA RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DMDRQIA RU https://pubmed.ncbi.nlm.nih.gov/28337021 DMDSJO8 DI DMDSJO8 DMDSJO8 DN TMC-353121 DMDSJO8 TI TT57ID8 DMDSJO8 TN Respiratory syncytial virus protein F (RSV F) DMDSJO8 MA Inhibitor DMDSJO8 RN Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87. DMDSJO8 RU https://pubmed.ncbi.nlm.nih.gov/19562644 DMDSR1X DI DMDSR1X DMDSR1X DN PD-157695 DMDSR1X TI TTEX248 DMDSR1X TN Dopamine D2 receptor (D2R) DMDSR1X MA Antagonist DMDSR1X RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMDSR1X RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMDSR1X DI DMDSR1X DMDSR1X DN PD-157695 DMDSR1X TI TT4C8EA DMDSR1X TN Dopamine D3 receptor (D3R) DMDSR1X MA Antagonist DMDSR1X RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMDSR1X RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMDSR1X DI DMDSR1X DMDSR1X DN PD-157695 DMDSR1X TI TT38ECI DMDSR1X TN Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) DMDSR1X MA Inhibitor DMDSR1X RN Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: synthesis and biochemical and crystallographic studies. J Med Chem. 2001 Apr 26;44(9):1364-71. DMDSR1X RU https://pubmed.ncbi.nlm.nih.gov/11311059 DMDSR1X DI DMDSR1X DMDSR1X DN PD-157695 DMDSR1X TI TT30C9G DMDSR1X TN C-X-C chemokine receptor type 2 (CXCR2) DMDSR1X MA Antagonist DMDSR1X RN Interleukin-8 receptor antagonists in pulmonary diseases. Curr Opin Pharmacol. 2001 Jun;1(3):242-7. DMDSR1X RU https://pubmed.ncbi.nlm.nih.gov/11712746 DMDSX58 DI DMDSX58 DMDSX58 DN BVT-A DMDSX58 TI TTKMAZ6 DMDSX58 TN Growth hormone receptor (GHR) DMDSX58 MA Antagonist DMDSX58 RN Emerging drugs for acromegaly. Expert Opin Emerg Drugs. 2008 Jun;13(2):273-93. DMDSX58 RU https://pubmed.ncbi.nlm.nih.gov/18537521 DMDUKMR DI DMDUKMR DMDUKMR DN CAT4001 DMDUKMR TI TTA6ZN2 DMDUKMR TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMDUKMR MA Activator DMDUKMR RN Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. DMDUKMR RU https://pubmed.ncbi.nlm.nih.gov/30610225 DMDVZQ8 DI DMDVZQ8 DMDVZQ8 DN UPF-648 DMDVZQ8 TI TTIY56R DMDVZQ8 TN Kynurenine 3-hydroxylase (KMO) DMDVZQ8 MA Inhibitor DMDVZQ8 RN Structural basis of kynurenine 3-monooxygenase inhibition. Nature. 2013 Apr 18;496(7445):382-5. DMDVZQ8 RU https://pubmed.ncbi.nlm.nih.gov/23575632 DME8AL0 DI DME8AL0 DME8AL0 DN TZP-301 DME8AL0 TI TTWDC17 DME8AL0 TN Growth hormone secretagogue receptor 1 (GHSR) DME8AL0 MA Antagonist DME8AL0 RN Clinical pipeline report, company report or official report of Tranzyme Pharma (2011). DME8AL0 RU http://www.tranzyme.com/products DMECV6L DI DMECV6L DMECV6L DN A-425619 DMECV6L TI TTMI6F5 DMECV6L TN Transient receptor potential cation channel V1 (TRPV1) DMECV6L MA Blocker DMECV6L RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMECV6L RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMEHO9G DI DMEHO9G DMEHO9G DN NC043 DMEHO9G TI TTQ9EDI DMEHO9G TN Ubiquitin carboxyl-terminal hydrolase 30 (USP30) DMEHO9G MA Inhibitor DMEHO9G RN A small natural molecule promotes mitochondrial fusion through inhibition of the deubiquitinase USP30. Cell Res. 2014 Apr;24(4):482-96. DMEHO9G RU https://pubmed.ncbi.nlm.nih.gov/24513856 DMEJYV4 DI DMEJYV4 DMEJYV4 DN (S)-4-(Ethylsulfonyl)benzoylalanine DMEJYV4 TI TTT3IXG DMEJYV4 TN Kynurenine oxoglutarate transaminase II (AADAT) DMEJYV4 MA Inhibitor DMEJYV4 RN Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009 Mar 3;159(1):196-203. DMEJYV4 RU https://pubmed.ncbi.nlm.nih.gov/19138730 DMEK78T DI DMEK78T DMEK78T DN MNLP-18 DMEK78T TI TTZ7HX8 DMEK78T TN Glycoside hydrolase (GlyH) DMEK78T MA Inhibitor DMEK78T RN viral infection therapy, MNLpharma MNLpharma partnering opportunity, Worldwide, R & D Focus Drug News, May 29, 2006 DMEK78T RU http://business.highbeam.com/436989/article-1G1-146237368/viral-infection-therapy-mnlpharma-mnlpharma-partnering DMEKMV0 DI DMEKMV0 DMEKMV0 DN 9-(Ethoxyimino)-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile DMEKMV0 TI TT1J07C DMEKMV0 TN Ubiquitin isopeptidase Y (USP8) DMEKMV0 MA Inhibitor DMEKMV0 RN Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem. 2010 Apr 6;5(4):552-8. DMEKMV0 RU https://pubmed.ncbi.nlm.nih.gov/20186914 DMELFBU DI DMELFBU DMELFBU DN SCY-641 DMELFBU TI TTATDGJ DMELFBU TN Calcium signal-modulating cyclophilin ligand (CAML) DMELFBU MA Inhibitor DMELFBU RN 2011 Pipeline of SCYNEXIS. DMELFBU RU http://www.scynexis.com/pipeline/ DMELPJM DI DMELPJM DMELPJM DN EDD7H9 DMELPJM TI TTDYP7I DMELPJM TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMELPJM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 277). DMELPJM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=277 DMEOVDQ DI DMEOVDQ DMEOVDQ DN PD-170292 DMEOVDQ TI TTCG0AL DMEOVDQ TN Cholecystokinin receptor type A (CCKAR) DMEOVDQ MA Agonist DMEOVDQ RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMEOVDQ RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMEOVDQ DI DMEOVDQ DMEOVDQ DN PD-170292 DMEOVDQ TI TTVFO0U DMEOVDQ TN Gastrin/cholecystokinin type B receptor (CCKBR) DMEOVDQ MA Agonist DMEOVDQ RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMEOVDQ RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMERKYO DI DMERKYO DMERKYO DN EP-2167 DMERKYO TI TTV5YEH DMERKYO TN Transferrin (TF) DMERKYO MA Inducer DMERKYO RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017941) DMERKYO RU http://adisinsight.springer.com/drugs/800017941 DMERWUC DI DMERWUC DMERWUC DN Organon DMERWUC TI TTHJTF7 DMERWUC TN Glycine transporter GlyT-1 (SLC6A9) DMERWUC MA Blocker DMERWUC RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMERWUC RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMEWFOL DI DMEWFOL DMEWFOL DN ADX-71943 DMEWFOL TI TTDCVZW DMEWFOL TN Gamma-aminobutyric acid B receptor (GABBR) DMEWFOL MA Modulator DMEWFOL RN Evaluation of peripheral versus central effects of GABA(B) receptor activation using a novel, positive allosteric modulator of the GABA(B) receptor ADX71943, a pharmacological tool compound with a fully peripheral activity profile. Br J Pharmacol. 2014 Nov;171(21):4941-54. DMEWFOL RU https://pubmed.ncbi.nlm.nih.gov/24923436 DMEXLU5 DI DMEXLU5 DMEXLU5 DN ON-01135 DMEXLU5 TI TTH6V3D DMEXLU5 TN Cyclin-dependent kinase 1 (CDK1) DMEXLU5 MA Inhibitor DMEXLU5 RN Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013; 3(3): 323-338. DMEXLU5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3696538/ DMF3YQZ DI DMF3YQZ DMF3YQZ DN Ro-27-3225 DMF3YQZ TI TTD0CIQ DMF3YQZ TN Melanocortin receptor 4 (MC4R) DMF3YQZ MA Agonist DMF3YQZ RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMF3YQZ RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMF53Z7 DI DMF53Z7 DMF53Z7 DN FR167356 DMF53Z7 TI TTTK3BH DMF53Z7 TN Vacuolar-type proton ATPase (v-ATPase) DMF53Z7 MA Inhibitor DMF53Z7 RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMF53Z7 RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMFBMXD DI DMFBMXD DMFBMXD DN LAS-101057 DMFBMXD TI TTNE7KG DMFBMXD TN Adenosine A2b receptor (ADORA2B) DMFBMXD MA Antagonist DMFBMXD RN Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A2B Adenosine Receptor Antagonist. ACS Med Chem Lett. 2010 Dec 20;2(3):213-8. DMFBMXD RU https://pubmed.ncbi.nlm.nih.gov/24900298 DMFJ0ZA DI DMFJ0ZA DMFJ0ZA DN GSK-326416 DMFJ0ZA TI TT953CX DMFJ0ZA TN Motilin receptor (MLNR) DMFJ0ZA MA Agonist DMFJ0ZA RN Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26. DMFJ0ZA RU https://pubmed.ncbi.nlm.nih.gov/17979603 DMFLIC0 DI DMFLIC0 DMFLIC0 DN KOS-1803 DMFLIC0 TI TTYFKSZ DMFLIC0 TN Tubulin beta (TUBB) DMFLIC0 MA Inhibitor DMFLIC0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMFLIC0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMFNLE6 DI DMFNLE6 DMFNLE6 DN BN-DF-037 DMFNLE6 TI TTZAYWL DMFNLE6 TN Estrogen receptor (ESR) DMFNLE6 MA Modulator DMFNLE6 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897) DMFNLE6 RU http://adisinsight.springer.com/drugs/800023897 DMFNS7U DI DMFNS7U DMFNS7U DN PMID26048809-compound2 DMFNS7U TI TTOA6YT DMFNS7U TN MERS-CoV RNA-directed RNA polymerase (RdRp) DMFNS7U MA Inhibitor DMFNS7U RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMFNS7U RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMFP316 DI DMFP316 DMFP316 DN A-196 DMFP316 TI TTJGV7F DMFP316 TN Histone-lysine N-methyltransferase KMT5B (KMT5B) DMFP316 MA Inhibitor DMFP316 RN The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017 Mar;13(3):317-324. DMFP316 RU https://pubmed.ncbi.nlm.nih.gov/28114273 DMFP316 DI DMFP316 DMFP316 DN A-196 DMFP316 TI TT7H3YM DMFP316 TN Histone-lysine N-methyltransferase KMT5C (KMT5C) DMFP316 MA Inhibitor DMFP316 RN The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity. Nat Chem Biol. 2017 Mar;13(3):317-324. DMFP316 RU https://pubmed.ncbi.nlm.nih.gov/28114273 DMFQI38 DI DMFQI38 DMFQI38 DN GG-8573 DMFQI38 TI TTCG0AL DMFQI38 TN Cholecystokinin receptor type A (CCKAR) DMFQI38 MA Agonist DMFQI38 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMFQI38 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMFQI38 DI DMFQI38 DMFQI38 DN GG-8573 DMFQI38 TI TTVFO0U DMFQI38 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMFQI38 MA Antagonist DMFQI38 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMFQI38 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMFW0H9 DI DMFW0H9 DMFW0H9 DN GCR-1087 DMFW0H9 TI TTMXGCW DMFW0H9 TN Adrenergic receptor beta-3 (ADRB3) DMFW0H9 MA Agonist DMFW0H9 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMFW0H9 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMFXJDL DI DMFXJDL DMFXJDL DN SB 242784 DMFXJDL TI TTTK3BH DMFXJDL TN Vacuolar-type proton ATPase (v-ATPase) DMFXJDL MA Inhibitor DMFXJDL RN SB 242784, a selective inhibitor of the osteoclastic V-H+ATPase, inhibits arterial calcification in the rat. Circ Res. 2002 Sep 20;91(6):547-52. DMFXJDL RU https://pubmed.ncbi.nlm.nih.gov/12242274 DMG4DHX DI DMG4DHX DMG4DHX DN ED-1812 DMG4DHX TI TT9IK2Z DMG4DHX TN N-methyl-D-aspartate receptor (NMDAR) DMG4DHX MA Antagonist DMG4DHX RN WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors. DMG4DHX RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2 DMG5YRP DI DMG5YRP DMG5YRP DN MERS-five-helix bundle DMG5YRP TI TT85VHW DMG5YRP TN MERS-CoV spike glycoprotein (S) DMG5YRP MA Inhibitor DMG5YRP RN Identification of a Novel Inhibitor against Middle East Respiratory Syndrome Coronavirus. Viruses. 2017 Sep 14;9(9). pii: E255. DMG5YRP RU https://pubmed.ncbi.nlm.nih.gov/28906430 DMGIR3F DI DMGIR3F DMGIR3F DN P5091 DMGIR3F TI TTXU3EQ DMGIR3F TN Herpesvirus ubiquitin-specific protease (HAUSP) DMGIR3F MA Inhibitor DMGIR3F RN USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochem Pharmacol. 2017 May 1;131:29-39. DMGIR3F RU https://pubmed.ncbi.nlm.nih.gov/28216017 DMGJL16 DI DMGJL16 DMGJL16 DN LE-300 DMGJL16 TI TTS2PH3 DMGJL16 TN Dopamine D5 receptor (D5R) DMGJL16 MA Antagonist DMGJL16 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMGJL16 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMGXVRZ DI DMGXVRZ DMGXVRZ DN Salicylihalamide A DMGXVRZ TI TTTK3BH DMGXVRZ TN Vacuolar-type proton ATPase (v-ATPase) DMGXVRZ MA Inhibitor DMGXVRZ RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DMGXVRZ RU https://pubmed.ncbi.nlm.nih.gov/11259534 DMH0I9N DI DMH0I9N DMH0I9N DN YW327.6S2 DMH0I9N TI TTZPY6J DMH0I9N TN Tyrosine-protein kinase UFO (AXL) DMH0I9N RN AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153. DMH0I9N RU https://pubmed.ncbi.nlm.nih.gov/31684958 DMH1FRY DI DMH1FRY DMH1FRY DN RWJ-416457 DMH1FRY TI TTGP7BY DMH1FRY TN Monoamine oxidase type B (MAO-B) DMH1FRY MA Inhibitor DMH1FRY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DMH1FRY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DMH1WNI DI DMH1WNI DMH1WNI DN SGN-19A DMH1WNI TI TTW640A DMH1WNI TN B-lymphocyte surface antigen B4 (CD19) DMH1WNI RN 2011 Pipeline of Seattle Genetics. DMH1WNI RU http://www.seagen.com/product_pipeline.php DMH7BT9 DI DMH7BT9 DMH7BT9 DN CAR-T cells targeting CD33 DMH7BT9 TI TTJVYO3 DMH7BT9 TN Myeloid cell surface antigen CD33 (CD33) DMH7BT9 MA CAR-T-Cell-Therapy DMH7BT9 RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMH7BT9 RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMHAI0M DI DMHAI0M DMHAI0M DN CNSB-004 DMHAI0M TI TT4FDG6 DMHAI0M TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMHAI0M MA Modulator DMHAI0M RN CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med. 2010 Feb;11(2):262-73. DMHAI0M RU https://pubmed.ncbi.nlm.nih.gov/20002322 DMHAONP DI DMHAONP DMHAONP DN SHP-627 DMHAONP TI TTO3HT7 DMHAONP TN Transforming growth factor beta (TGFB) DMHAONP MA Inhibitor DMHAONP RN Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855. DMHAONP RU https://pubmed.ncbi.nlm.nih.gov/29218009 DMHAWBR DI DMHAWBR DMHAWBR DN BMS-192548 DMHAWBR TI TTJ6WK9 DMHAWBR TN Neuropeptide Y receptor type 2 (NPY2R) DMHAWBR MA Antagonist DMHAWBR RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMHAWBR RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMHBWOP DI DMHBWOP DMHBWOP DN JT07 DMHBWOP TI TTRQJTC DMHBWOP TN C-X-C chemokine receptor type 7 (ACKR3) DMHBWOP MA Inhibitor DMHBWOP RN Clinical pipeline report, company report or official report of Jyant Technologies. DMHBWOP RU http://jyanttech.com/index.php?/pipeline DMHBWOP DI DMHBWOP DMHBWOP DN JT07 DMHBWOP TI TT1UCIJ DMHBWOP TN C-X-C chemokine receptor type 3 (CXCR3) DMHBWOP MA Inhibitor DMHBWOP RN Clinical pipeline report, company report or official report of Jyant Technologies. DMHBWOP RU http://jyanttech.com/index.php?/pipeline DMHD3R8 DI DMHD3R8 DMHD3R8 DN D-4476 DMHD3R8 TI TTH30UI DMHD3R8 TN Casein kinase I delta (CSNK1D) DMHD3R8 MA Inhibitor DMHD3R8 RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMHD3R8 RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMHD3R8 DI DMHD3R8 DMHD3R8 DN D-4476 DMHD3R8 TI TTFQEMX DMHD3R8 TN Casein kinase I alpha (CSNK1A1) DMHD3R8 MA Inhibitor DMHD3R8 RN Discovery of N6-phenyl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamine derivatives as novel CK1 inhibitors using common-feature pharmacophore model based virtual screening and hit-to-lead optimization. Eur J Med Chem. 2012 Oct;56:30-8. DMHD3R8 RU https://pubmed.ncbi.nlm.nih.gov/22944772 DMHIS6Z DI DMHIS6Z DMHIS6Z DN Apilimod DMHIS6Z TI TT0S3MP DMHIS6Z TN HUMAN phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) DMHIS6Z MA Inhibitor DMHIS6Z RN A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. April 17, 2020. DMHIS6Z RU https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1 DMHJLPS DI DMHJLPS DMHJLPS DN M-carboxycinnamic acid bishydroxamide DMHJLPS TI TT6R7JZ DMHJLPS TN Histone deacetylase 1 (HDAC1) DMHJLPS MA Inhibitor DMHJLPS RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMHJLPS RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMHQUM2 DI DMHQUM2 DMHQUM2 DN Org-23366 DMHQUM2 TI TTJQOD7 DMHQUM2 TN 5-HT 2A receptor (HTR2A) DMHQUM2 MA Antagonist DMHQUM2 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMHQUM2 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMHQUM2 DI DMHQUM2 DMHQUM2 DN Org-23366 DMHQUM2 TI TTEX248 DMHQUM2 TN Dopamine D2 receptor (D2R) DMHQUM2 MA Antagonist DMHQUM2 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMHQUM2 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMHQUM2 DI DMHQUM2 DMHQUM2 DN Org-23366 DMHQUM2 TI TTH18TF DMHQUM2 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHQUM2 MA Antagonist DMHQUM2 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMHQUM2 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMHU742 DI DMHU742 DMHU742 DN EPZ032597 DMHU742 TI TT7YJFO DMHU742 TN SET and MYND domain-containing protein 2 (SMYD2) DMHU742 MA Inhibitor DMHU742 RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMHU742 RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMHUD27 DI DMHUD27 DMHUD27 DN GW-594884A DMHUD27 TI TTY6EWA DMHUD27 TN Neuropeptide Y receptor type 5 (NPY5R) DMHUD27 MA Antagonist DMHUD27 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMHUD27 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMHX1LA DI DMHX1LA DMHX1LA DN KL001 DMHX1LA TI TT5MLZR DMHX1LA TN Cryptochrome circadian clock 1 (CRY1) DMHX1LA MA Activator DMHX1LA RN Identification of small molecule activators of cryptochrome. Science. 2012 Aug 31;337(6098):1094-7. DMHX1LA RU https://pubmed.ncbi.nlm.nih.gov/22798407 DMHX1LA DI DMHX1LA DMHX1LA DN KL001 DMHX1LA TI TTAO58M DMHX1LA TN Cryptochrome-2 (CRY2) DMHX1LA MA Activator DMHX1LA RN Identification of small molecule activators of cryptochrome. Science. 2012 Aug 31;337(6098):1094-7. DMHX1LA RU https://pubmed.ncbi.nlm.nih.gov/22798407 DMI3E0Y DI DMI3E0Y DMI3E0Y DN MK6-83 DMI3E0Y TI TT9XBVO DMI3E0Y TN Mucolipin-1 (TRPML1) DMI3E0Y MA Agonist DMI3E0Y RN ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Res. 2020 Oct;182:104922. DMI3E0Y RU https://pubmed.ncbi.nlm.nih.gov/32858116 DMIGH6W DI DMIGH6W DMIGH6W DN PHENSERINE TARTRATE DMIGH6W TI TT1RS9F DMIGH6W TN Acetylcholinesterase (AChE) DMIGH6W MA Inhibitor DMIGH6W RN An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul;2(3):281-90. DMIGH6W RU https://pubmed.ncbi.nlm.nih.gov/15974893 DMINSA5 DI DMINSA5 DMINSA5 DN XL-499 DMINSA5 TI TTGBPJE DMINSA5 TN PI3-kinase delta (PIK3CD) DMINSA5 MA Inhibitor DMINSA5 RN Clinical pipeline report, company report or official report of Exelixis. DMINSA5 RU http://www.exelixis.com/pipeline/xl499 DMIQXEP DI DMIQXEP DMIQXEP DN KD-3020 DMIQXEP TI TT2JWF6 DMIQXEP TN Peroxisome proliferator-activated receptor delta (PPARD) DMIQXEP MA Agonist DMIQXEP RN Emerging drugs for non-alcoholic fatty liver disease. Expert Opin Emerg Drugs. 2008 Mar;13(1):145-58. DMIQXEP RU https://pubmed.ncbi.nlm.nih.gov/18321154 DMIS1G7 DI DMIS1G7 DMIS1G7 DN 2-(1H-indole-3,-carbonyl)-thiazole-4-carboxylic acid methyl ester DMIS1G7 TI TT037IE DMIS1G7 TN Aryl hydrocarbon receptor (AHR) DMIS1G7 MA Agonist DMIS1G7 RN 1'H-Indole-3'-Carbonyl-Thiazole-4-Carboxylic Acid Methyl Ester Blocked Human Glioma Cell Invasion via Aryl Hydrocarbon Receptor's Regulation of Cytoskeletal Contraction. Biomed Res Int. 2020 Oct 3;2020:2616930. DMIS1G7 RU https://pubmed.ncbi.nlm.nih.gov/33083460 DMIUZEX DI DMIUZEX DMIUZEX DN (R)-PFI-2 DMIUZEX TI TTJ0FSU DMIUZEX TN Histone-lysine N-methyltransferase SETD7 (SETD7) DMIUZEX MA Inhibitor DMIUZEX RN (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12853-8. DMIUZEX RU https://pubmed.ncbi.nlm.nih.gov/25136132 DMIYSD4 DI DMIYSD4 DMIYSD4 DN IDDB-41331 DMIYSD4 TI TTTM6W8 DMIYSD4 TN Melanin-concentrating hormone receptor (MCHR) DMIYSD4 MA Antagonist DMIYSD4 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMIYSD4 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMIZCOE DI DMIZCOE DMIZCOE DN Piperlongumine DMIZCOE TI TTWO3SH DMIZCOE TN Glutathione S-transferase omega-1 (GSTO-1) DMIZCOE MA Inhibitor DMIZCOE RN Activity-based protein profiling reveals GSTO1 as the covalent target of piperlongumine and a promising target for combination therapy for cancer. Chem Commun (Camb). 2019 Apr 9;55(30):4407-4410. DMIZCOE RU https://pubmed.ncbi.nlm.nih.gov/30916079 DMJ0A2R DI DMJ0A2R DMJ0A2R DN IU1 DMJ0A2R TI TTVSYP9 DMJ0A2R TN Ubiquitin carboxyl-terminal hydrolase 14 (USP14) DMJ0A2R MA Inhibitor DMJ0A2R RN Neurotoxic mechanisms by which the USP14 inhibitor IU1 depletes ubiquitinated proteins and Tau in rat cerebral cortical neurons: Relevance to Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1157-1170. DMJ0A2R RU https://pubmed.ncbi.nlm.nih.gov/28372990 DMJ6P9U DI DMJ6P9U DMJ6P9U DN T-226296 DMJ6P9U TI TTW0CMT DMJ6P9U TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMJ6P9U MA Blocker DMJ6P9U RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMJ6P9U RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMJ6P9U DI DMJ6P9U DMJ6P9U DN T-226296 DMJ6P9U TI TTX4RTB DMJ6P9U TN Melanin-concentrating hormone receptor 1 (MCHR1) DMJ6P9U MA Antagonist DMJ6P9U RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMJ6P9U RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMJDT5O DI DMJDT5O DMJDT5O DN VIS513 DMJDT5O TI TTMYZNX DMJDT5O TN Dengue virus Envelope (DENV E) DMJDT5O MA Inhibitor DMJDT5O RN Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein. PLoS Negl Trop Dis. 2018 Feb 9;12(2):e0006209. DMJDT5O RU https://pubmed.ncbi.nlm.nih.gov/29425203 DMJEKQM DI DMJEKQM DMJEKQM DN EP-128504 DMJEKQM TI TTPNE41 DMJEKQM TN CI Man-6-P receptor (IGF2R) DMJEKQM MA Modulator DMJEKQM RN The discovery and mechanism of action of novel tumor-selective and apoptosis-inducing 3,5-diaryl-1,2,4-oxadiazole series using a chemical genetics approach. Mol Cancer Ther. 2005 May;4(5):761-71. DMJEKQM RU https://pubmed.ncbi.nlm.nih.gov/15897240 DMJGQD2 DI DMJGQD2 DMJGQD2 DN RMG-40083 DMJGQD2 TI TTLA931 DMJGQD2 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMJGQD2 MA Antagonist DMJGQD2 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMJGQD2 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMJHWYP DI DMJHWYP DMJHWYP DN Spautin 1 DMJHWYP TI TTVJIO2 DMJHWYP TN Ubiquitin carboxyl-terminal hydrolase 13 (USP13) DMJHWYP MA Inhibitor DMJHWYP RN Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin. J Cell Mol Med. 2020 Apr;24(7):4324-4340. DMJHWYP RU https://pubmed.ncbi.nlm.nih.gov/32129945 DMJHWYP DI DMJHWYP DMJHWYP DN Spautin 1 DMJHWYP TI TT5IH09 DMJHWYP TN Ubiquitin carboxyl-terminal hydrolase 10 (USP10) DMJHWYP MA Inhibitor DMJHWYP RN Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin. J Cell Mol Med. 2020 Apr;24(7):4324-4340. DMJHWYP RU https://pubmed.ncbi.nlm.nih.gov/32129945 DMJKQFT DI DMJKQFT DMJKQFT DN Dec-RVKR-CMK DMJKQFT TI TTUD6MS DMJKQFT TN HUMAN dibasic-processing enzyme (Furin) DMJKQFT MA Blocker DMJKQFT RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMJKQFT RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMJTYH3 DI DMJTYH3 DMJTYH3 DN ATA3219 DMJTYH3 TI TTW640A DMJTYH3 TN B-lymphocyte surface antigen B4 (CD19) DMJTYH3 RN Clinical pipeline report, company report or official report of Atara Biotherapeutics. DMJTYH3 RU https://www.atarabio.com/pipeline/ DMJUQ6E DI DMJUQ6E DMJUQ6E DN CB7993113 DMJUQ6E TI TT037IE DMJUQ6E TN Aryl hydrocarbon receptor (AHR) DMJUQ6E MA Antagonist DMJUQ6E RN In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo. Mol Pharmacol. 2014 Nov;86(5):593-608. DMJUQ6E RU https://pubmed.ncbi.nlm.nih.gov/25159092 DMJXZIS DI DMJXZIS DMJXZIS DN LH846 DMJXZIS TI TT7OGZP DMJXZIS TN Casein kinase 1 (CK1) DMJXZIS MA Inhibitor DMJXZIS RN A small molecule modulates circadian rhythms through phosphorylation of the period protein. Angew Chem Int Ed Engl. 2011 Nov 4;50(45):10608-11. DMJXZIS RU https://pubmed.ncbi.nlm.nih.gov/21954091 DMK230A DI DMK230A DMK230A DN CS-3030 DMK230A TI TTCIHJA DMK230A TN Coagulation factor Xa (F10) DMK230A MA Inhibitor DMK230A RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMK230A RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMK3SAF DI DMK3SAF DMK3SAF DN BI-D1870 DMK3SAF TI TT0ZW9O DMK3SAF TN Ribosomal protein S6 kinase alpha-2 (RSK2) DMK3SAF MA Inhibitor DMK3SAF RN BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38. DMK3SAF RU https://pubmed.ncbi.nlm.nih.gov/17040210 DMK3SAF DI DMK3SAF DMK3SAF DN BI-D1870 DMK3SAF TI TTIXKA4 DMK3SAF TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMK3SAF MA Inhibitor DMK3SAF RN BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38. DMK3SAF RU https://pubmed.ncbi.nlm.nih.gov/17040210 DMK3SAF DI DMK3SAF DMK3SAF DN BI-D1870 DMK3SAF TI TTUM2ZR DMK3SAF TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMK3SAF MA Inhibitor DMK3SAF RN BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38. DMK3SAF RU https://pubmed.ncbi.nlm.nih.gov/17040210 DMK3SAF DI DMK3SAF DMK3SAF DN BI-D1870 DMK3SAF TI TT3KYWB DMK3SAF TN Ribosomal protein S6 kinase alpha-6 (RSK6) DMK3SAF MA Inhibitor DMK3SAF RN BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J. 2007 Jan 1;401(1):29-38. DMK3SAF RU https://pubmed.ncbi.nlm.nih.gov/17040210 DMK3TXY DI DMK3TXY DMK3TXY DN L-742791 DMK3TXY TI TTMXGCW DMK3TXY TN Adrenergic receptor beta-3 (ADRB3) DMK3TXY MA Agonist DMK3TXY RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMK3TXY RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMK8UD0 DI DMK8UD0 DMK8UD0 DN NKP-46 DMK8UD0 TI TTBWDI0 DMK8UD0 TN Ribonucleoside-diphosphate reductase M2 (RRM2) DMK8UD0 RN Phase I and pharmacokinetic study of the oral tris-(8-quinolinolato)gallium(III) complex (FFC11, KP46) in patients with solid tumors - a study of the CESAR Central European Society for Anticancer Drug Research - EWIV. J Clin Oncol (Meeting Abstracts) June 2005 vol. 23 no. 16_suppl 3205. DMK8UD0 RU http://meeting.ascopubs.org/cgi/content/short/23/16_suppl/3205 DMKE5QH DI DMKE5QH DMKE5QH DN WZB-117 DMKE5QH TI TT79TKF DMKE5QH TN HepG2 glucose transporter (SLC2A1) DMKE5QH MA Inhibitor DMKE5QH RN Quercetin inhibits glucose transport by binding to an exofacial site on GLUT1. Biochimie. 2018 Aug;151:107-114. DMKE5QH RU https://pubmed.ncbi.nlm.nih.gov/29857184 DMKFAG3 DI DMKFAG3 DMKFAG3 DN CB-01-16 DMKFAG3 TI TTN4QDT DMKFAG3 TN Opioid receptor (OPR) DMKFAG3 MA Antagonist DMKFAG3 RN Clinical pipeline report, company report or official report of Cosmo. DMKFAG3 RU http://www.cosmopharmaceuticals.com/activities/pipeline/cb-01-16.aspx DMKQ20J DI DMKQ20J DMKQ20J DN AZ505 DMKQ20J TI TT7YJFO DMKQ20J TN SET and MYND domain-containing protein 2 (SMYD2) DMKQ20J MA Inhibitor DMKQ20J RN Structural basis of substrate methylation and inhibition of SMYD2. Structure. 2011 Sep 7;19(9):1262-73. DMKQ20J RU https://pubmed.ncbi.nlm.nih.gov/21782458 DMKUPW0 DI DMKUPW0 DMKUPW0 DN ABX-0401 DMKUPW0 TI TTF8CQI DMKUPW0 TN Tumor necrosis factor (TNF) DMKUPW0 MA Inhibitor DMKUPW0 RN US patent application no. 8007,790, Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases. DMKUPW0 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20081030&CC=US&NR=2008269123A1&KC=A1 DMKVW25 DI DMKVW25 DMKVW25 DN Cu-anti-hAXL DMKVW25 TI TTZPY6J DMKVW25 TN Tyrosine-protein kinase UFO (AXL) DMKVW25 RN MicroPET/CT Imaging of AXL Downregulation by HSP90 Inhibition in Triple-Negative Breast Cancer. Contrast Media Mol Imaging. 2017 May 14;2017:1686525. DMKVW25 RU https://pubmed.ncbi.nlm.nih.gov/29097911 DMKZCBE DI DMKZCBE DMKZCBE DN CX-1501 DMKZCBE TI TTAN6JD DMKZCBE TN Glutamate receptor AMPA (GRIA) DMKZCBE MA Modulator DMKZCBE RN Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007 May;8(5):583-602. DMKZCBE RU https://pubmed.ncbi.nlm.nih.gov/17504103 DML5SO1 DI DML5SO1 DML5SO1 DN A-366833 DML5SO1 TI TTL1ATN DML5SO1 TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DML5SO1 MA Modulator DML5SO1 RN Antinociceptive activity of alpha4beta2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory pain. Eur J Pharmacol. 2011 Oct 1;668(1-2):155-62. DML5SO1 RU https://pubmed.ncbi.nlm.nih.gov/21756895 DMLAF6C DI DMLAF6C DMLAF6C DN SD1002 DMLAF6C TI TT36ETB DMLAF6C TN Cathepsin L (CTSL) DMLAF6C MA Inhibitor DMLAF6C RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DMLAF6C RU https://pubmed.ncbi.nlm.nih.gov/31477883 DMLAF6C DI DMLAF6C DMLAF6C DN SD1002 DMLAF6C TI TTF2LRI DMLAF6C TN Cathepsin B (CTSB) DMLAF6C MA Inhibitor DMLAF6C RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DMLAF6C RU https://pubmed.ncbi.nlm.nih.gov/31477883 DMLG682 DI DMLG682 DMLG682 DN SCH-1359113 DMLG682 TI TT8JRS7 DMLG682 TN Beta-secretase (BACE) DMLG682 MA Inhibitor DMLG682 RN ACS Meeting News: Using chemistry tools to refine an Alzheimer's drug candidate. C&EN. April 5, 2010. Volume 88, Number 14 p.14. DMLG682 RU https://pubs.acs.org/cen/coverstory/88/8814cover1.html DMLK2D0 DI DMLK2D0 DMLK2D0 DN MC-3001 DMLK2D0 TI TTJ584C DMLK2D0 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMLK2D0 MA Agonist DMLK2D0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021175) DMLK2D0 RU http://adisinsight.springer.com/drugs/800021175 DMLMRGH DI DMLMRGH DMLMRGH DN Saliphenylhalamide DMLMRGH TI TTF1QVM DMLMRGH TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMLMRGH MA Inhibitor DMLMRGH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DMLMRGH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DMLNRCI DI DMLNRCI DMLNRCI DN FSA2 DMLNRCI TI TT7AOUD DMLNRCI TN Fatty acid synthase (FASN) DMLNRCI MA Inhibitor DMLNRCI RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DMLNRCI RU https://pubmed.ncbi.nlm.nih.gov/19463273 DMLNYGX DI DMLNYGX DMLNYGX DN NN-818 DMLNYGX TI TTE4KHA DMLNYGX TN Amyloid beta A4 protein (APP) DMLNYGX MA Modulator DMLNYGX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMLNYGX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMLVADH DI DMLVADH DMLVADH DN 212Pb-labelled aCD37 DMLVADH TI TTFCW29 DMLVADH TN Leukocyte antigen CD37 (CD37) DMLVADH RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DMLVADH RU https://pubmed.ncbi.nlm.nih.gov/32728208 DMLXMCB DI DMLXMCB DMLXMCB DN COR-D DMLXMCB TI TT1MG9E DMLXMCB TN Extracellular signal-regulated kinase 1 (ERK1) DMLXMCB MA Activator DMLXMCB RN Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26. DMLXMCB RU https://pubmed.ncbi.nlm.nih.gov/22965801 DMLXMCB DI DMLXMCB DMLXMCB DN COR-D DMLXMCB TI TT0K6EO DMLXMCB TN Stress-activated protein kinase JNK1 (JNK1) DMLXMCB MA Activator DMLXMCB RN Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26. DMLXMCB RU https://pubmed.ncbi.nlm.nih.gov/22965801 DMLXMCB DI DMLXMCB DMLXMCB DN COR-D DMLXMCB TI TT4TQBX DMLXMCB TN Extracellular signal-regulated kinase 2 (ERK2) DMLXMCB MA Activator DMLXMCB RN Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26. DMLXMCB RU https://pubmed.ncbi.nlm.nih.gov/22965801 DMLXMCB DI DMLXMCB DMLXMCB DN COR-D DMLXMCB TI TTHS0U8 DMLXMCB TN Stress-activated protein kinase JNK2 (JNK2) DMLXMCB MA Activator DMLXMCB RN Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26. DMLXMCB RU https://pubmed.ncbi.nlm.nih.gov/22965801 DMLZ5TQ DI DMLZ5TQ DMLZ5TQ DN Hexamethylene amiloride DMLZ5TQ TI TTL3H2W DMLZ5TQ TN SARS-CoV envelope small membrane protein (E) DMLZ5TQ MA Inhibitor DMLZ5TQ RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMLZ5TQ RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMM149N DI DMM149N DMM149N DN PHA-568487 DMM149N TI TTLA931 DMM149N TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMM149N MA Agonist DMM149N RN Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett. 2010 Aug;4(3):162-72. DMM149N RU https://pubmed.ncbi.nlm.nih.gov/20642449 DMM1O0P DI DMM1O0P DMM1O0P DN BNC-102 DMM1O0P TI TTTSGRH DMM1O0P TN Leucine-rich repeat-containing GPCR 5 (LGR5) DMM1O0P MA Inhibitor DMM1O0P RN Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661. DMM1O0P RU https://pubmed.ncbi.nlm.nih.gov/28860586 DMM1O0P DI DMM1O0P DMM1O0P DN BNC-102 DMM1O0P TI TTY6C71 DMM1O0P TN G-protein coupled receptor 48 (LGR4) DMM1O0P MA Inhibitor DMM1O0P RN Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017 Sep 1;16(9):661. DMM1O0P RU https://pubmed.ncbi.nlm.nih.gov/28860586 DMMA2ZW DI DMMA2ZW DMMA2ZW DN SPH-1285 DMMA2ZW TI TT1RS9F DMMA2ZW TN Acetylcholinesterase (AChE) DMMA2ZW MA Inhibitor DMMA2ZW RN Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001 Feb 1;49(3):289-99. DMMA2ZW RU https://pubmed.ncbi.nlm.nih.gov/11230880 DMMBIHO DI DMMBIHO DMMBIHO DN ONO-1301 DMMBIHO TI TTKNWZ4 DMMBIHO TN Thromboxane-A synthase (TBXAS1) DMMBIHO MA Agonist DMMBIHO RN A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, ONO-1301, protects myocardium from ischemia/reperfusion injury. Eur J Pharmacol. 2012 Jan 15;674(2-3):352-8. DMMBIHO RU https://pubmed.ncbi.nlm.nih.gov/22094066 DMMD8VY DI DMMD8VY DMMD8VY DN AR-R-1589 DMMD8VY TI TTCG0AL DMMD8VY TN Cholecystokinin receptor type A (CCKAR) DMMD8VY MA Agonist DMMD8VY RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMMD8VY RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMMEH12 DI DMMEH12 DMMEH12 DN L-006235-1 DMMEH12 TI TTUMQVO DMMEH12 TN Cathepsin S (CTSS) DMMEH12 MA Inhibitor DMMEH12 RN Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43. DMMEH12 RU https://pubmed.ncbi.nlm.nih.gov/16302795 DMMEH12 DI DMMEH12 DMMEH12 DN L-006235-1 DMMEH12 TI TT36ETB DMMEH12 TN Cathepsin L (CTSL) DMMEH12 MA Inhibitor DMMEH12 RN Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43. DMMEH12 RU https://pubmed.ncbi.nlm.nih.gov/16302795 DMMEH12 DI DMMEH12 DMMEH12 DN L-006235-1 DMMEH12 TI TTF2LRI DMMEH12 TN Cathepsin B (CTSB) DMMEH12 MA Inhibitor DMMEH12 RN Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43. DMMEH12 RU https://pubmed.ncbi.nlm.nih.gov/16302795 DMMEH12 DI DMMEH12 DMMEH12 DN L-006235-1 DMMEH12 TI TTDZN01 DMMEH12 TN Cathepsin K (CTSK) DMMEH12 MA Inhibitor DMMEH12 RN Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional se... J Med Chem. 2005 Dec 1;48(24):7535-43. DMMEH12 RU https://pubmed.ncbi.nlm.nih.gov/16302795 DMMI2EY DI DMMI2EY DMMI2EY DN DS-1558 DMMI2EY TI TTB8FUC DMMI2EY TN Free fatty acid receptor 1 (GPR40) DMMI2EY MA Agonist DMMI2EY RN Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist. ACS Med Chem Lett. 2015 Jan 13;6(3):266-70. DMMI2EY RU https://pubmed.ncbi.nlm.nih.gov/25815144 DMMRY0Z DI DMMRY0Z DMMRY0Z DN NPS-2390 DMMRY0Z TI TTVBPDM DMMRY0Z TN Metabotropic glutamate receptor 1 (mGluR1) DMMRY0Z MA Inhibitor DMMRY0Z RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DMMRY0Z RU https://pubmed.ncbi.nlm.nih.gov/18173231 DMMRY0Z DI DMMRY0Z DMMRY0Z DN NPS-2390 DMMRY0Z TI TTBUYHA DMMRY0Z TN Extracellular calcium-sensing receptor (CASR) DMMRY0Z MA Modulator DMMRY0Z RN The Extracellular Calcium-Sensing Receptor (CASR) Regulates Gonadotropins-Induced Meiotic Maturation of Porcine Oocytes.Biol Reprod.2015 Dec;93(6):131. DMMRY0Z RU https://www.ncbi.nlm.nih.gov/pubmed/26490840 DMMUVAF DI DMMUVAF DMMUVAF DN IRX-4 DMMUVAF TI TT9G4N0 DMMUVAF TN Glutamate carboxypeptidase II (GCPII) DMMUVAF MA Immunomodulator (Immunostimulant) DMMUVAF RN Irx4 identifies a chamber-specific cell population that contributes to ventricular myocardium development. Dev Dyn. 2014 Mar;243(3):381-92. DMMUVAF RU https://pubmed.ncbi.nlm.nih.gov/24123507 DMMUYC2 DI DMMUYC2 DMMUYC2 DN YM-344031 DMMUYC2 TI TTD3XFU DMMUYC2 TN C-C chemokine receptor type 3 (CCR3) DMMUYC2 MA Antagonist DMMUYC2 RN Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. DMMUYC2 RU https://pubmed.ncbi.nlm.nih.gov/19046132 DMMVS07 DI DMMVS07 DMMVS07 DN RWJ-51204 DMMVS07 TI TTEX6LM DMMVS07 TN GABA(A) receptor gamma-3 (GABRG3) DMMVS07 MA Modulator DMMVS07 RN 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90. DMMVS07 RU https://pubmed.ncbi.nlm.nih.gov/12388665 DMMWQTI DI DMMWQTI DMMWQTI DN Peptide P21S10 DMMWQTI TI TT85VHW DMMWQTI TN MERS-CoV spike glycoprotein (S) DMMWQTI MA Inhibitor DMMWQTI RN Discovery of Hydrocarbon-Stapled Short -Helical Peptides as Promising Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Fusion Inhibitors. J Med Chem. 2018 Mar 8;61(5):2018-2026. DMMWQTI RU https://pubmed.ncbi.nlm.nih.gov/29442512 DMMXR3L DI DMMXR3L DMMXR3L DN PMX205 DMMXR3L TI TTHXFA1 DMMXR3L TN C5a anaphylatoxin chemotactic receptor (C5AR1) DMMXR3L MA Antagonist DMMXR3L RN Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. Sci Rep. 2018 May 25;8(1):8101. DMMXR3L RU https://pubmed.ncbi.nlm.nih.gov/29802264 DMN0GTR DI DMN0GTR DMN0GTR DN COR100140 DMN0GTR TI TT2AST1 DMN0GTR TN Macrophage migration inhibitory factor (MIF) DMN0GTR MA Inhibitor DMN0GTR RN Cortical Pty Ltd Presents MIF Antagonist Data at World Congress on Inflammation. Cortical Pty Ltd. 2005. DMN0GTR RU http://www.cortical.com.au/downloads/20050901_mediarelease_MIF_Antagonist_Data.pdf DMNA9KW DI DMNA9KW DMNA9KW DN CCT251545 DMNA9KW TI TTBJR4L DMNA9KW TN Cyclin-dependent kinase 8 (CDK8) DMNA9KW MA Inhibitor DMNA9KW RN Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377. DMNA9KW RU https://pubmed.ncbi.nlm.nih.gov/29545548 DMNAT5V DI DMNAT5V DMNAT5V DN GW-2592X DMNAT5V TI TTDZN01 DMNAT5V TN Cathepsin K (CTSK) DMNAT5V MA Inhibitor DMNAT5V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350). DMNAT5V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350 DMNF9P5 DI DMNF9P5 DMNF9P5 DN HR1P peptide DMNF9P5 TI TTJ4EIV DMNF9P5 TN MERS-CoV spike glycoprotein S2 subunit (S S2) DMNF9P5 MA Inhibitor DMNF9P5 RN Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067. DMNF9P5 RU https://pubmed.ncbi.nlm.nih.gov/24473083 DMNG84V DI DMNG84V DMNG84V DN ZK-thiazolidinone DMNG84V TI TTIYVQP DMNG84V TN Polo-like kinase 1 (PLK1) DMNG84V MA Inhibitor DMNG84V RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMNG84V RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMNIM96 DI DMNIM96 DMNIM96 DN P-BCMA-ALL01 DMNIM96 TI TTZ3P4W DMNIM96 TN B-cell maturation protein (TNFRSF17) DMNIM96 RN Clinical pipeline report, company report or official report of Poseida Therapeutics. DMNIM96 RU https://poseida.com/science/pipeline/ DMNIWF5 DI DMNIWF5 DMNIWF5 DN Lopinavir DMNIWF5 TI TTWOH4Q DMNIWF5 TN MERS-CoV 3C-like proteinase (3CLpro) DMNIWF5 MA Inhibitor DMNIWF5 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMNIWF5 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMNIWF5 DI DMNIWF5 DMNIWF5 DN Lopinavir DMNIWF5 TI TTPZG3C DMNIWF5 TN SARS-CoV 3C-like protease (3CLpro) DMNIWF5 MA Inhibitor DMNIWF5 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMNIWF5 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMNO20J DI DMNO20J DMNO20J DN mAb926 DMNO20J TI TTTCRU2 DMNO20J TN Bacterial Fimbrin D-mannose adhesin (Bact FimH) DMNO20J MA Inhibitor DMNO20J RN FimH as a scaffold for regulated molecular recognition. J Biol Eng. 2021 Jan 12;15(1):3. DMNO20J RU https://pubmed.ncbi.nlm.nih.gov/33436006 DMNOE1M DI DMNOE1M DMNOE1M DN LLY-507 DMNOE1M TI TT7YJFO DMNOE1M TN SET and MYND domain-containing protein 2 (SMYD2) DMNOE1M MA Inhibitor DMNOE1M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2714). DMNOE1M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2714 DMNU3SI DI DMNU3SI DMNU3SI DN GSK180 DMNU3SI TI TTIY56R DMNU3SI TN Kynurenine 3-hydroxylase (KMO) DMNU3SI MA Inhibitor DMNU3SI RN Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401. DMNU3SI RU https://pubmed.ncbi.nlm.nih.gov/30760888 DMNZA4L DI DMNZA4L DMNZA4L DN Griffithsin DMNZA4L TI TTTL19V DMNZA4L TN SARS-CoV spike glycoprotein (S) DMNZA4L MA Blocker DMNZA4L RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMNZA4L RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMNZG8T DI DMNZG8T DMNZG8T DN PF-821385 DMNZG8T TI TTBYP1X DMNZG8T TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMNZG8T MA Inhibitor DMNZG8T RN Increased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution. PLoS Pathog. 2013 February; 9(2): e1003184. DMNZG8T RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585149/ DMO15TX DI DMO15TX DMO15TX DN BSF-78438 DMO15TX TI TTZFYLI DMO15TX TN Dopamine D1 receptor (D1R) DMO15TX MA Binder DMO15TX RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMO15TX RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMO2UKI DI DMO2UKI DMO2UKI DN SP-MET-1 DMO2UKI TI TTPR5SX DMO2UKI TN S100 calcium-binding protein A4 (S100A4) DMO2UKI MA Antagonist DMO2UKI RN Lost in migration. Nat Biotechnol. 2010 Mar;28(3):214-29. DMO2UKI RU https://pubmed.ncbi.nlm.nih.gov/20212481 DMO5EXL DI DMO5EXL DMO5EXL DN NVP-2 DMO5EXL TI TT1LVF2 DMO5EXL TN Cyclin-dependent kinase 9 (CDK9) DMO5EXL MA Inhibitor DMO5EXL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1981). DMO5EXL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1981 DMO5MUY DI DMO5MUY DMO5MUY DN NSC-207895 DMO5MUY TI TT9OUDQ DMO5MUY TN p53-binding protein Mdm4 (MDM4) DMO5MUY MA Inhibitor DMO5MUY RN Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12. DMO5MUY RU https://pubmed.ncbi.nlm.nih.gov/24382383 DMOERXK DI DMOERXK DMOERXK DN L-751250 DMOERXK TI TTH6V3D DMOERXK TN Cyclin-dependent kinase 1 (CDK1) DMOERXK MA Binder DMOERXK RN Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76. DMOERXK RU https://pubmed.ncbi.nlm.nih.gov/14988404 DMOERXK DI DMOERXK DMOERXK DN L-751250 DMOERXK TI TTL4Q97 DMOERXK TN Cyclin-dependent kinase 5 (CDK5) DMOERXK MA Inhibitor DMOERXK RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMOERXK RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMOERXK DI DMOERXK DMOERXK DN L-751250 DMOERXK TI TT7HF4W DMOERXK TN Cyclin-dependent kinase 2 (CDK2) DMOERXK MA Inhibitor DMOERXK RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMOERXK RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMOERXK DI DMOERXK DMOERXK DN L-751250 DMOERXK TI TTMXGCW DMOERXK TN Adrenergic receptor beta-3 (ADRB3) DMOERXK MA Agonist DMOERXK RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMOERXK RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMOGRWB DI DMOGRWB DMOGRWB DN NPS-1034 DMOGRWB TI TTNDSF4 DMOGRWB TN Proto-oncogene c-Met (MET) DMOGRWB MA Inhibitor DMOGRWB RN NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. Invest New Drugs. 2014 Jun;32(3):389-99. DMOGRWB RU https://pubmed.ncbi.nlm.nih.gov/24173966 DMOHPX4 DI DMOHPX4 DMOHPX4 DN PMID25197057-Compound6e DMOHPX4 TI TTEN986 DMOHPX4 TN Staphylococcus Sortase A (Stap-coc srtA) DMOHPX4 MA Inhibitor DMOHPX4 RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DMOHPX4 RU https://pubmed.ncbi.nlm.nih.gov/28337021 DMOIWVC DI DMOIWVC DMOIWVC DN U-99363E DMOIWVC TI TTE0A2F DMOIWVC TN Dopamine D4 receptor (D4R) DMOIWVC MA Binder DMOIWVC RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMOIWVC RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMONGIR DI DMONGIR DMONGIR DN Tosyl-l-arginine methyl ester DMONGIR TI TTBKFDV DMONGIR TN Cell division cycle protein 20 homolog (CDC20) DMONGIR MA Inhibitor DMONGIR RN Targeting Cdc20 as a novel cancer therapeutic strategy. Pharmacol Ther. 2015 Jul;151:141-51. DMONGIR RU https://pubmed.ncbi.nlm.nih.gov/25850036 DMOQ63E DI DMOQ63E DMOQ63E DN Rottlerin DMOQ63E TI TTYVX59 DMOQ63E TN Protein kinase C (PRKC) DMOQ63E MA Inhibitor DMOQ63E RN Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42. DMOQ63E RU https://pubmed.ncbi.nlm.nih.gov/18991661 DMOW07D DI DMOW07D DMOW07D DN BAP-15 DMOW07D TI TTVSYP9 DMOW07D TN Ubiquitin carboxyl-terminal hydrolase 14 (USP14) DMOW07D MA Inhibitor DMOW07D RN The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948. DMOW07D RU https://pubmed.ncbi.nlm.nih.gov/31666925 DMOW07D DI DMOW07D DMOW07D DN BAP-15 DMOW07D TI TTGYTMA DMOW07D TN Isopeptidase T (USP5) DMOW07D MA Inhibitor DMOW07D RN The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948. DMOW07D RU https://pubmed.ncbi.nlm.nih.gov/31666925 DMOY15R DI DMOY15R DMOY15R DN VT-111 DMOY15R TI TTEMV5X DMOY15R TN Serine protease unspecific (SP) DMOY15R MA Inhibitor DMOY15R RN New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21. DMOY15R RU https://pubmed.ncbi.nlm.nih.gov/19265486 DMP9EJ7 DI DMP9EJ7 DMP9EJ7 DN CM-2236 DMP9EJ7 TI TTNGILX DMP9EJ7 TN Adrenergic receptor alpha-1A (ADRA1A) DMP9EJ7 MA Agonist DMP9EJ7 RN CN patent application no. 104151292, Indole derivative or a pharmaceutically acceptable salt thereof. DMP9EJ7 RU http://www.google.com/patents/CN104151292A?cl=en DMP9EJ7 DI DMP9EJ7 DMP9EJ7 DN CM-2236 DMP9EJ7 TI TTSQIFT DMP9EJ7 TN 5-HT 1A receptor (HTR1A) DMP9EJ7 MA Agonist DMP9EJ7 RN CN patent application no. 104151292, Indole derivative or a pharmaceutically acceptable salt thereof. DMP9EJ7 RU http://www.google.com/patents/CN104151292A?cl=en DMPC29W DI DMPC29W DMPC29W DN PMID27240464-compound-3f DMPC29W TI TTWOH4Q DMPC29W TN MERS-CoV 3C-like proteinase (3CLpro) DMPC29W MA Inhibitor DMPC29W RN Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. DMPC29W RU https://pubmed.ncbi.nlm.nih.gov/27240464 DMPC29W DI DMPC29W DMPC29W DN PMID27240464-compound-3f DMPC29W TI TTPZG3C DMPC29W TN SARS-CoV 3C-like protease (3CLpro) DMPC29W MA Inhibitor DMPC29W RN Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors. Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. DMPC29W RU https://pubmed.ncbi.nlm.nih.gov/27240464 DMPLZ7E DI DMPLZ7E DMPLZ7E DN HC-Toxin DMPLZ7E TI TT6R7JZ DMPLZ7E TN Histone deacetylase 1 (HDAC1) DMPLZ7E MA Inhibitor DMPLZ7E RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMPLZ7E RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMPUBK8 DI DMPUBK8 DMPUBK8 DN BIO-306 DMPUBK8 TI TT27RFC DMPUBK8 TN Opioid receptor delta (OPRD1) DMPUBK8 MA Agonist DMPUBK8 RN Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007 Sep;12(3):367-88. DMPUBK8 RU https://pubmed.ncbi.nlm.nih.gov/17874967 DMPUSM5 DI DMPUSM5 DMPUSM5 DN Otamixaban DMPUSM5 TI TTK9LUQ DMPUSM5 TN HUAMN serine protease factor Xa (SERPINA5) DMPUSM5 MA Inhibitor DMPUSM5 RN A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020 May 1;10.1111/bph.15094. DMPUSM5 RU https://pubmed.ncbi.nlm.nih.gov/32358833 DMPWUFT DI DMPWUFT DMPWUFT DN PMID28216367-compound-6d DMPWUFT TI TTWOH4Q DMPWUFT TN MERS-CoV 3C-like proteinase (3CLpro) DMPWUFT MA Inhibitor DMPWUFT RN Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017 May;141:101-106. DMPWUFT RU https://pubmed.ncbi.nlm.nih.gov/28216367 DMPWUFT DI DMPWUFT DMPWUFT DN PMID28216367-compound-6d DMPWUFT TI TTPZG3C DMPWUFT TN SARS-CoV 3C-like protease (3CLpro) DMPWUFT MA Inhibitor DMPWUFT RN Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors. Antiviral Res. 2017 May;141:101-106. DMPWUFT RU https://pubmed.ncbi.nlm.nih.gov/28216367 DMQ0NU1 DI DMQ0NU1 DMQ0NU1 DN ABI-013 DMQ0NU1 TI TTML2WA DMQ0NU1 TN Tubulin (TUB) DMQ0NU1 RN Cardiovascular and CNS safety profile of ABI-013, a novel nanoparticle albumin-bound (nab) analog of docetaxel. Cancer Research. 01/2011; 70(8 Supplement):2617-2617. DMQ0NU1 RU http://cancerres.aacrjournals.org/content/70/8_Supplement/2617.short DMQ3BXV DI DMQ3BXV DMQ3BXV DN IDDBCP-150101 DMQ3BXV TI TTD0CIQ DMQ3BXV TN Melanocortin receptor 4 (MC4R) DMQ3BXV MA Agonist DMQ3BXV RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMQ3BXV RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMQFUCD DI DMQFUCD DMQFUCD DN PMID26868298-compound-N3 DMQFUCD TI TTNHMO8 DMQFUCD TN COVID-19 papain-like proteinase (PL-PRO) DMQFUCD MA Inhibitor DMQFUCD RN Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. DMQFUCD RU https://pubmed.ncbi.nlm.nih.gov/32272481 DMQFUCD DI DMQFUCD DMQFUCD DN PMID26868298-compound-N3 DMQFUCD TI TTWOH4Q DMQFUCD TN MERS-CoV 3C-like proteinase (3CLpro) DMQFUCD MA Inhibitor DMQFUCD RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMQFUCD RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMQFUCD DI DMQFUCD DMQFUCD DN PMID26868298-compound-N3 DMQFUCD TI TTPZG3C DMQFUCD TN SARS-CoV 3C-like protease (3CLpro) DMQFUCD MA Inhibitor DMQFUCD RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMQFUCD RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMQG2EY DI DMQG2EY DMQG2EY DN Virstatin DMQG2EY TI TTVFR2S DMQG2EY TN Vibrio TCP pilus virulence regulatory protein (Vibrio tcpN) DMQG2EY MA Inhibitor DMQG2EY RN Virstatin inhibits dimerization of the transcriptional activator ToxT. Proc Natl Acad Sci U S A. 2007 Feb 13;104(7):2372-7. DMQG2EY RU https://pubmed.ncbi.nlm.nih.gov/17283330 DMQG39T DI DMQG39T DMQG39T DN BMS-695735 DMQG39T TI TTHRID2 DMQG39T TN Insulin-like growth factor I receptor (IGF1R) DMQG39T MA Inhibitor DMQG39T RN Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900. DMQG39T RU https://pubmed.ncbi.nlm.nih.gov/18763755 DMQG39T DI DMQG39T DMQG39T DN BMS-695735 DMQG39T TI TTRLW2X DMQG39T TN Fibroblast growth factor receptor 1 (FGFR1) DMQG39T MA Inhibitor DMQG39T RN Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900. DMQG39T RU https://pubmed.ncbi.nlm.nih.gov/18763755 DMQGRC8 DI DMQGRC8 DMQGRC8 DN CPH-102 DMQGRC8 TI TTVDSZ0 DMQGRC8 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMQGRC8 MA Inhibitor DMQGRC8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMQGRC8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMQRZ4T DI DMQRZ4T DMQRZ4T DN NSC632839 DMQRZ4T TI TTX9IFP DMQRZ4T TN Ubiquitin thioesterase L1 (UCHL1) DMQRZ4T MA Inhibitor DMQRZ4T RN Ubiquitin C-Terminal Hydrolase L1 regulates autophagy by inhibiting autophagosome formation through its deubiquitinating enzyme activity. Biochem Biophys Res Commun. 2018 Mar 4;497(2):726-733. DMQRZ4T RU https://pubmed.ncbi.nlm.nih.gov/29462615 DMQSJ20 DI DMQSJ20 DMQSJ20 DN CF502 DMQSJ20 TI TTJFY5U DMQSJ20 TN Adenosine A3 receptor (ADORA3) DMQSJ20 MA Agonist DMQSJ20 RN 2011 Pipeline of Can-Fite BioPharm. DMQSJ20 RU http://www.canfite.com/pipeline.html DMQTR4I DI DMQTR4I DMQTR4I DN SSR-504734 DMQTR4I TI TTHJTF7 DMQTR4I TN Glycine transporter GlyT-1 (SLC6A9) DMQTR4I MA Blocker DMQTR4I RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMQTR4I RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMR1CLY DI DMR1CLY DMR1CLY DN GC376 DMR1CLY TI TT1D53B DMR1CLY TN COVID-19 3C-like protease (3CLpro) DMR1CLY MA Inhibitor DMR1CLY RN Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581 DMR1CLY RU https://www.biorxiv.org/content/10.1101/2020.04.20.051581v1 DMR1CLY DI DMR1CLY DMR1CLY DN GC376 DMR1CLY TI TTWOH4Q DMR1CLY TN MERS-CoV 3C-like proteinase (3CLpro) DMR1CLY MA Inhibitor DMR1CLY RN Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016 Mar 30;12(3):e1005531. DMR1CLY RU https://pubmed.ncbi.nlm.nih.gov/27027316 DMR1CLY DI DMR1CLY DMR1CLY DN GC376 DMR1CLY TI TTPZG3C DMR1CLY TN SARS-CoV 3C-like protease (3CLpro) DMR1CLY MA Inhibitor DMR1CLY RN Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor. PLoS Pathog. 2016 Mar 30;12(3):e1005531. DMR1CLY RU https://pubmed.ncbi.nlm.nih.gov/27027316 DMR3XDH DI DMR3XDH DMR3XDH DN VCB102 DMR3XDH TI TT3Z6Y9 DMR3XDH TN Cysteines of Keap1 (KEAP1 Cysteines) DMR3XDH MA Inactivator DMR3XDH RN NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904. DMR3XDH RU https://pubmed.ncbi.nlm.nih.gov/32545924 DMRCMEK DI DMRCMEK DMRCMEK DN BMS-PCSK9 DMRCMEK TI TTNIZ2B DMRCMEK TN PCSK9 messenger RNA (PCSK9 mRNA) DMRCMEK RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). DMRCMEK RU http://www.isispharm.com/index.htm DMRDQPT DI DMRDQPT DMRDQPT DN 2-D08 DMRDQPT TI TTW30FR DMRDQPT TN Small ubiquitin-related modifier (SUMO) DMRDQPT MA Inhibitor DMRDQPT RN Inhibiting SUMO1-mediated SUMOylation induces autophagy-mediated cancer cell death and reduces tumour cell invasion via RAC1. J Cell Sci. 2019 Oct 22;132(20):jcs234120. DMRDQPT RU https://pubmed.ncbi.nlm.nih.gov/31578236 DMRE52S DI DMRE52S DMRE52S DN HL-004 DMRE52S TI TTMF541 DMRE52S TN Liver carboxylesterase (CES1) DMRE52S MA Modulator DMRE52S RN ACAT inhibitor HL-004 accelerates the regression of hypercholesterolemia in stroke-prone spontaneously hypertensive rats (SHRSP): stimulation of bile acid production by HL-004. Atherosclerosis. 1997 Aug;133(1):97-104. DMRE52S RU https://pubmed.ncbi.nlm.nih.gov/9258412 DMRGZQA DI DMRGZQA DMRGZQA DN TZP-202 DMRGZQA TI TT953CX DMRGZQA TN Motilin receptor (MLNR) DMRGZQA MA Antagonist DMRGZQA RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023009) DMRGZQA RU http://adisinsight.springer.com/drugs/800023009 DMRIMZL DI DMRIMZL DMRIMZL DN IDX136 DMRIMZL TI TTIU7X1 DMRIMZL TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMRIMZL MA Inhibitor DMRIMZL RN Therapy with amineptine, a dopamine reuptake inhibitor, in patients with major depression. Indian J Psychiatry. 1997 Apr;39(2):147-53. DMRIMZL RU https://pubmed.ncbi.nlm.nih.gov/21584062 DMRJ9P4 DI DMRJ9P4 DMRJ9P4 DN INT-767 DMRJ9P4 TI TTS4UGC DMRJ9P4 TN Farnesoid X-activated receptor (FXR) DMRJ9P4 MA Agonist DMRJ9P4 RN FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137. DMRJ9P4 RU https://pubmed.ncbi.nlm.nih.gov/29089371 DMRJ9P4 DI DMRJ9P4 DMRJ9P4 DN INT-767 DMRJ9P4 TI TTSDVTR DMRJ9P4 TN G-protein coupled bile acid receptor 1 (GPBAR1) DMRJ9P4 MA Agonist DMRJ9P4 RN FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity. J Am Soc Nephrol. 2018 Jan;29(1):118-137. DMRJ9P4 RU https://pubmed.ncbi.nlm.nih.gov/29089371 DMRPX4W DI DMRPX4W DMRPX4W DN ASP8497 DMRPX4W TI TTDIGC1 DMRPX4W TN Dipeptidyl peptidase 4 (DPP-4) DMRPX4W MA Inhibitor DMRPX4W RN Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. DMRPX4W RU https://pubmed.ncbi.nlm.nih.gov/19149538 DMRT3FK DI DMRT3FK DMRT3FK DN RO5461111 DMRT3FK TI TTUMQVO DMRT3FK TN Cathepsin S (CTSS) DMRT3FK MA Inhibitor DMRT3FK RN Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. Ann Rheum Dis. 2015 Feb;74(2):452-63. DMRT3FK RU https://pubmed.ncbi.nlm.nih.gov/24300027 DMRZBM7 DI DMRZBM7 DMRZBM7 DN RANBEZOLID HYDROCHLORIDE DMRZBM7 TI TTUWYEA DMRZBM7 TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMRZBM7 MA Modulator DMRZBM7 RN Mode of Action of Ranbezolid against Staphylococci and Structural Modeling Studies of Its Interaction with Ribosomes . Antimicrob Agents Chemother. 2009 April; 53(4): 1427-1433. DMRZBM7 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663096/ DMS5LPF DI DMS5LPF DMS5LPF DN Viquidacin DMS5LPF TI TTN6J5F DMS5LPF TN Bacterial DNA gyrase (Bact gyrase) DMS5LPF MA Modulator DMS5LPF RN Selenophene-containing inhibitors of type IIA bacterial topoisomerases.J Med Chem.2011 May 12;54(9):3418-25. DMS5LPF RU https://www.ncbi.nlm.nih.gov/pubmed/21443219 DMS6KT8 DI DMS6KT8 DMS6KT8 DN MERS-4 DMS6KT8 TI TTZ3COY DMS6KT8 TN COVID-19 spike glycoprotein (S) DMS6KT8 MA Inhibitor DMS6KT8 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMS6KT8 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMSJ2I6 DI DMSJ2I6 DMSJ2I6 DN Beta-aminopropionitrile DMSJ2I6 TI TTFSUHX DMSJ2I6 TN Lysyl oxidase homolog 2 (LOXL2) DMSJ2I6 MA Inhibitor DMSJ2I6 RN Wnt signaling and Loxl2 promote aggressive osteosarcoma. Cell Res. 2020 Oct;30(10):885-901. DMSJ2I6 RU https://pubmed.ncbi.nlm.nih.gov/32686768 DMSK5N3 DI DMSK5N3 DMSK5N3 DN SR8278 DMSK5N3 TI TTAD1O8 DMSK5N3 TN V-erbA-related protein 1 (NR1D1) DMSK5N3 MA Antagonist DMSK5N3 RN Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. ACS Chem Biol. 2011 Feb 18;6(2):131-4. DMSK5N3 RU https://pubmed.ncbi.nlm.nih.gov/21043485 DMSNX4O DI DMSNX4O DMSNX4O DN SoRI-9409 DMSNX4O TI TT27RFC DMSNX4O TN Opioid receptor delta (OPRD1) DMSNX4O MA Antagonist DMSNX4O RN In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. J Pharmacol Exp Ther. 2001 May;297(2):597-605. DMSNX4O RU https://pubmed.ncbi.nlm.nih.gov/11303048 DMSO8IE DI DMSO8IE DMSO8IE DN A-841720 DMSO8IE TI TTVBPDM DMSO8IE TN Metabotropic glutamate receptor 1 (mGluR1) DMSO8IE MA Antagonist DMSO8IE RN Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition. Behav Pharmacol. 2007 Jul;18(4):273-81. DMSO8IE RU https://pubmed.ncbi.nlm.nih.gov/17551319 DMSR96X DI DMSR96X DMSR96X DN HR2P-M1 peptide DMSR96X TI TTJ4EIV DMSR96X TN MERS-CoV spike glycoprotein S2 subunit (S S2) DMSR96X MA Inhibitor DMSR96X RN Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067. DMSR96X RU https://pubmed.ncbi.nlm.nih.gov/24473083 DMSW07R DI DMSW07R DMSW07R DN GLPG-0492 DMSW07R TI TTS64P2 DMSW07R TN Androgen receptor (AR) DMSW07R MA Modulator DMSW07R RN GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Pharmacol Res. 2013 Jun;72:9-24. DMSW07R RU https://pubmed.ncbi.nlm.nih.gov/23523664 DMSXOPE DI DMSXOPE DMSXOPE DN JNJ-26070109 DMSXOPE TI TTVFO0U DMSXOPE TN Gastrin/cholecystokinin type B receptor (CCKBR) DMSXOPE MA Antagonist DMSXOPE RN The cholecystokinin CCK2 receptor antagonist, JNJ-26070109, inhibits gastric acid secretion and prevents omeprazole-induced acid rebound in the rat. Br J Pharmacol. 2012 Jul;166(5):1684-93. DMSXOPE RU https://pubmed.ncbi.nlm.nih.gov/22300007 DMSZNQE DI DMSZNQE DMSZNQE DN CAR-T cells targeting CD123 DMSZNQE TI TTENHJ0 DMSZNQE TN Interleukin 3 receptor alpha (IL3RA) DMSZNQE MA CAR-T-Cell-Therapy DMSZNQE RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMSZNQE RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMT06MI DI DMT06MI DMT06MI DN UCART-CLL1 DMT06MI TI TT70N8V DMT06MI TN Myeloid inhibitory C-type lectin-like receptor (CD371) DMT06MI RN Off-the-shelf' allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185-199. DMT06MI RU https://pubmed.ncbi.nlm.nih.gov/31900462 DMT2C78 DI DMT2C78 DMT2C78 DN Brensocatib DMT2C78 TI TTQ9J6R DMT2C78 TN HUMAN dipeptidyl peptidase 1 (CTSC) DMT2C78 MA Inhibitor DMT2C78 RN Brensocatib (Formerly INS1007) to be Studied in Patients with Severe COVID-19 in Investigator-Initiated Trial. Apr 23, 2020. DMT2C78 RU https://www.biospace.com/article/releases/brensocatib-formerly-ins1007-to-be-studied-in-patients-with-severe-covid-19-in-investigator-initiated-trial/ DMT8SFV DI DMT8SFV DMT8SFV DN 1-methyl-L-tryptophan DMT8SFV TI TTZJYKH DMT8SFV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMT8SFV MA Inhibitor DMT8SFV RN Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31. DMT8SFV RU https://pubmed.ncbi.nlm.nih.gov/24099220 DMTDG7L DI DMTDG7L DMTDG7L DN Z-VAD-fmk DMTDG7L TI TTZY5KP DMTDG7L TN Caspase (CASP) DMTDG7L MA Inhibitor DMTDG7L RN Clinical pipeline report, company report or official report of InvivoGen. DMTDG7L RU https://www.invivogen.com/z-vad-fmk DMTEJV1 DI DMTEJV1 DMTEJV1 DN BAY 60-6583 DMTEJV1 TI TTK25J1 DMTEJV1 TN Adenosine A1 receptor (ADORA1) DMTEJV1 MA Agonist DMTEJV1 RN Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71. DMTEJV1 RU https://pubmed.ncbi.nlm.nih.gov/17632123 DMTEJV1 DI DMTEJV1 DMTEJV1 DN BAY 60-6583 DMTEJV1 TI TTNE7KG DMTEJV1 TN Adenosine A2b receptor (ADORA2B) DMTEJV1 MA Agonist DMTEJV1 RN Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation. 2007 Mar 27;115(12):1581-90. DMTEJV1 RU https://pubmed.ncbi.nlm.nih.gov/17353435 DMTEJV1 DI DMTEJV1 DMTEJV1 DN BAY 60-6583 DMTEJV1 TI TTJFY5U DMTEJV1 TN Adenosine A3 receptor (ADORA3) DMTEJV1 MA Agonist DMTEJV1 RN Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007 Sep;43(3):262-71. DMTEJV1 RU https://pubmed.ncbi.nlm.nih.gov/17632123 DMTG730 DI DMTG730 DMTG730 DN PD-157533 DMTG730 TI TT4C8EA DMTG730 TN Dopamine D3 receptor (D3R) DMTG730 MA Antagonist DMTG730 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMTG730 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMTGI64 DI DMTGI64 DMTGI64 DN JD-5037 DMTGI64 TI TT6OEDT DMTGI64 TN Cannabinoid receptor 1 (CB1) DMTGI64 MA Agonist DMTGI64 RN 2011 Pipeline of Jenrin Discovery. DMTGI64 RU http://www.jenrindiscovery.com/pipeline.html DMTHLB8 DI DMTHLB8 DMTHLB8 DN FA-613 DMTHLB8 TI TT3UY29 DMTHLB8 TN HUMAN dihydroorotate dehydrogenase (DHODH) DMTHLB8 MA Inhibitor DMTHLB8 RN Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response. J Gen Virol. 2017 May;98(5):946-954. DMTHLB8 RU https://pubmed.ncbi.nlm.nih.gov/28555543 DMTJBP9 DI DMTJBP9 DMTJBP9 DN PF-670462 DMTJBP9 TI TTH30UI DMTJBP9 TN Casein kinase I delta (CSNK1D) DMTJBP9 MA Inhibitor DMTJBP9 RN Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218. DMTJBP9 RU https://pubmed.ncbi.nlm.nih.gov/29317454 DMTJBP9 DI DMTJBP9 DMTJBP9 DN PF-670462 DMTJBP9 TI TTA8PLI DMTJBP9 TN Casein kinase I epsilon (CSNK1E) DMTJBP9 MA Inhibitor DMTJBP9 RN Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. Blood. 2018 Mar 15;131(11):1206-1218. DMTJBP9 RU https://pubmed.ncbi.nlm.nih.gov/29317454 DMTJRLU DI DMTJRLU DMTJRLU DN GNTI DMTJRLU TI TTQW87Y DMTJRLU TN Opioid receptor kappa (OPRK1) DMTJRLU MA Antagonist DMTJRLU RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMTJRLU RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMTJRLU DI DMTJRLU DMTJRLU DN GNTI DMTJRLU TI TTKWM86 DMTJRLU TN Opioid receptor mu (MOP) DMTJRLU MA Antagonist DMTJRLU RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMTJRLU RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMTM1LK DI DMTM1LK DMTM1LK DN YM-355179 DMTM1LK TI TTD3XFU DMTM1LK TN C-C chemokine receptor type 3 (CCR3) DMTM1LK MA Antagonist DMTM1LK RN Emerging drugs for asthma. Expert Opin Emerg Drugs. 2008 Dec;13(4):643-53. DMTM1LK RU https://pubmed.ncbi.nlm.nih.gov/19046132 DMTQ2UD DI DMTQ2UD DMTQ2UD DN N-Octyl-4-epi-beta-valienamine DMTQ2UD TI TTNGJPH DMTQ2UD TN Beta-galactosidase (GLB1) DMTQ2UD MA Inhibitor DMTQ2UD RN Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives. Bioorg Med Chem. 2002 Jun;10(6):1967-72. DMTQ2UD RU https://pubmed.ncbi.nlm.nih.gov/11937356 DMTQXS7 DI DMTQXS7 DMTQXS7 DN Mercaptopurine DMTQXS7 TI TTYJOLE DMTQXS7 TN MERS-CoV papain-like proteinase (PL-PRO) DMTQXS7 MA Inhibitor DMTQXS7 RN Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16. DMTQXS7 RU https://pubmed.ncbi.nlm.nih.gov/25542975 DMTQXS7 DI DMTQXS7 DMTQXS7 DN Mercaptopurine DMTQXS7 TI TTRGHB2 DMTQXS7 TN SARS-CoV papain-like proteinase (PL-PRO) DMTQXS7 MA Inhibitor DMTQXS7 RN Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015 Mar;115:9-16. DMTQXS7 RU https://pubmed.ncbi.nlm.nih.gov/25542975 DMU86XT DI DMU86XT DMU86XT DN YM-201636 DMU86XT TI TTA4M1N DMU86XT TN Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3) DMU86XT MA Inhibitor DMU86XT RN PIKfyve negatively regulates exocytosis in neurosecretory cells. J Biol Chem. 2008 Feb 1;283(5):2804-13. DMU86XT RU https://pubmed.ncbi.nlm.nih.gov/18039667 DMUAPNF DI DMUAPNF DMUAPNF DN humanin DMUAPNF TI TTOJ1NF DMUAPNF TN FMLP-related receptor I (FPR2) DMUAPNF MA Agonist DMUAPNF RN N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004 Nov 5;324(1):255-61. DMUAPNF RU https://pubmed.ncbi.nlm.nih.gov/15465011 DMUAPNF DI DMUAPNF DMUAPNF DN humanin DMUAPNF TI TT16TM5 DMUAPNF TN N-formyl peptide receptor 3 (FPR3) DMUAPNF MA Agonist DMUAPNF RN N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem Biophys Res Commun. 2004 Nov 5;324(1):255-61. DMUAPNF RU https://pubmed.ncbi.nlm.nih.gov/15465011 DMUFIO9 DI DMUFIO9 DMUFIO9 DN M102 DMUFIO9 TI TTA6ZN2 DMUFIO9 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMUFIO9 MA Activator DMUFIO9 RN Clinical pipeline report, company report or official report of Aclipse Therapeutics. DMUFIO9 RU https://aclipsetherapeutics.com/therapeutics/m102/ DMUFP05 DI DMUFP05 DMUFP05 DN F-15063 DMUFP05 TI TT4C8EA DMUFP05 TN Dopamine D3 receptor (D3R) DMUFP05 MA Modulator DMUFP05 RN F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.Naunyn Schmiedebergs Arch Pharmacol.2007 Jun;375(4):241-50. DMUFP05 RU https://www.ncbi.nlm.nih.gov/pubmed/17453175 DMUFP05 DI DMUFP05 DMUFP05 DN F-15063 DMUFP05 TI TTEX248 DMUFP05 TN Dopamine D2 receptor (D2R) DMUFP05 MA Modulator DMUFP05 RN F15063, a potential antipsychotic with dopamine D(2)/D(3) antagonist, 5-HT(1A) agonist and D(4) partial agonist properties: (IV) duration of brain D2-like receptor occupancy and antipsychotic-like activity versus plasma concentration in mice.Naunyn Schmiedebergs Arch Pharmacol.2007 Jun;375(4):241-50. DMUFP05 RU https://www.ncbi.nlm.nih.gov/pubmed/17453175 DMUH012 DI DMUH012 DMUH012 DN PMID26911565-peptide-P9 DMUH012 TI TTTL19V DMUH012 TN SARS-CoV spike glycoprotein (S) DMUH012 MA Inhibitor DMUH012 RN A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016 Feb 25;6:22008. DMUH012 RU https://pubmed.ncbi.nlm.nih.gov/26911565 DMUH012 DI DMUH012 DMUH012 DN PMID26911565-peptide-P9 DMUH012 TI TT85VHW DMUH012 TN MERS-CoV spike glycoprotein (S) DMUH012 MA Inhibitor DMUH012 RN A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep. 2016 Feb 25;6:22008. DMUH012 RU https://pubmed.ncbi.nlm.nih.gov/26911565 DMUHVEA DI DMUHVEA DMUHVEA DN FPL-14294 DMUHVEA TI TTCG0AL DMUHVEA TN Cholecystokinin receptor type A (CCKAR) DMUHVEA MA Agonist DMUHVEA RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMUHVEA RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMUKVYL DI DMUKVYL DMUKVYL DN EPZ0330456 DMUKVYL TI TTKLJYX DMUKVYL TN Histone-lysine N-methyltransferase SMYD3 (SMYD3) DMUKVYL MA Inhibitor DMUKVYL RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMUKVYL RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMUO6XC DI DMUO6XC DMUO6XC DN VCB101 DMUO6XC TI TT3Z6Y9 DMUO6XC TN Cysteines of Keap1 (KEAP1 Cysteines) DMUO6XC MA Inactivator DMUO6XC RN NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules. 2020 Jun 14;10(6):904. DMUO6XC RU https://pubmed.ncbi.nlm.nih.gov/32545924 DMUWRIF DI DMUWRIF DMUWRIF DN DAP-81 DMUWRIF TI TTIYVQP DMUWRIF TN Polo-like kinase 1 (PLK1) DMUWRIF MA Inhibitor DMUWRIF RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMUWRIF RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMV0RFU DI DMV0RFU DMV0RFU DN CKI-7 DMV0RFU TI TT7OGZP DMV0RFU TN Casein kinase 1 (CK1) DMV0RFU MA Inhibitor DMV0RFU RN Crystal structures of two aminoglycoside kinases bound with a eukaryotic protein kinase inhibitor. PLoS One. 2011 May 9;6(5):e19589. DMV0RFU RU https://pubmed.ncbi.nlm.nih.gov/21573013 DMV1A25 DI DMV1A25 DMV1A25 DN LpxC-1 DMV1A25 TI TT0OFWN DMV1A25 TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DMV1A25 MA Inhibitor DMV1A25 RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DMV1A25 RU https://pubmed.ncbi.nlm.nih.gov/28337021 DMV2F84 DI DMV2F84 DMV2F84 DN ML209 DMV2F84 TI TTGV6LY DMV2F84 TN Nuclear receptor ROR-gamma (RORG) DMV2F84 MA Agonist DMV2F84 RN ROR nuclear receptors: structures, related diseases, and drug discovery. Acta Pharmacol Sin. 2015 Jan;36(1):71-87. DMV2F84 RU https://pubmed.ncbi.nlm.nih.gov/25500868 DMV5KSA DI DMV5KSA DMV5KSA DN IMX-942 DMV5KSA TI TTOT2RY DMV5KSA TN Sequestosome-1 p62 (SQSTM1) DMV5KSA MA Regulator (upregulator) DMV5KSA RN Clinical pipeline report, company report or official report of SARomics Biostructures. DMV5KSA RU http://www.saromics.com/news/news/News2010.html DMV8APG DI DMV8APG DMV8APG DN Cytolin DMV8APG TI TT48WR6 DMV8APG TN Integrin alpha-L (ITGAL) DMV8APG RN Cytokine-induced phagocyte adhesion to human mesangial cells: role of CD11/CD18 integrins and ICAM-1. Am J Physiol. 1991 Dec;261(6 Pt 2):F1071-9. DMV8APG RU https://pubmed.ncbi.nlm.nih.gov/1721495 DMVB0P3 DI DMVB0P3 DMVB0P3 DN PMID30784880-compound-6-5 DMVB0P3 TI TTPZG3C DMVB0P3 TN SARS-CoV 3C-like protease (3CLpro) DMVB0P3 MA Inhibitor DMVB0P3 RN Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives. Eur J Med Chem. 2019 Apr 1;167:472-484. DMVB0P3 RU https://pubmed.ncbi.nlm.nih.gov/30784880 DMVB1PD DI DMVB1PD DMVB1PD DN GRL-001 DMVB1PD TI TTWOH4Q DMVB1PD TN MERS-CoV 3C-like proteinase (3CLpro) DMVB1PD MA Inhibitor DMVB1PD RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMVB1PD RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMVB1PD DI DMVB1PD DMVB1PD DN GRL-001 DMVB1PD TI TTPZG3C DMVB1PD TN SARS-CoV 3C-like protease (3CLpro) DMVB1PD MA Inhibitor DMVB1PD RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMVB1PD RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMVESTF DI DMVESTF DMVESTF DN BAY-38-1315 DMVESTF TI TTFQAYR DMVESTF TN Cholesteryl ester transfer protein (CETP) DMVESTF MA Inhibitor DMVESTF RN Chromanol derivatives--a novel class of CETP inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):488-91. DMVESTF RU https://pubmed.ncbi.nlm.nih.gov/21084191 DMVGIB4 DI DMVGIB4 DMVGIB4 DN MERS-27 DMVGIB4 TI TTZ3COY DMVGIB4 TN COVID-19 spike glycoprotein (S) DMVGIB4 MA Inhibitor DMVGIB4 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMVGIB4 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMVMY4X DI DMVMY4X DMVMY4X DN BN-AO-014 DMVMY4X TI TTZAYWL DMVMY4X TN Estrogen receptor (ESR) DMVMY4X MA Modulator DMVMY4X RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023897) DMVMY4X RU http://adisinsight.springer.com/drugs/800023897 DMVN3FU DI DMVN3FU DMVN3FU DN CA-074Me DMVN3FU TI TTF2LRI DMVN3FU TN Cathepsin B (CTSB) DMVN3FU MA Inhibitor DMVN3FU RN CA-074Me inhibits Cathepsin-B and alleviates fibrosis after myocardial infarction. Panminerva Med. 2019 Sep 24. DMVN3FU RU https://pubmed.ncbi.nlm.nih.gov/31577087 DMVSKQF DI DMVSKQF DMVSKQF DN Alpha-Helical lipopeptides IIK DMVSKQF TI TT85VHW DMVSKQF TN MERS-CoV spike glycoprotein (S) DMVSKQF MA Inhibitor DMVSKQF RN De Novo Design of -Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery. J Med Chem. 2018 Oct 11;61(19):8734-8745. DMVSKQF RU https://pubmed.ncbi.nlm.nih.gov/30192544 DMW3TGI DI DMW3TGI DMW3TGI DN PCI-45292 DMW3TGI TI TTGM6VW DMW3TGI TN Tyrosine-protein kinase BTK (ATK) DMW3TGI MA Inhibitor DMW3TGI RN Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 October 10; 122(15): 2539-2549. DMW3TGI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795457/ DMW7XEU DI DMW7XEU DMW7XEU DN ALN-TMP DMW7XEU TI TTNIUKC DMW7XEU TN TMPRSS6 messenger RNA (TMPRSS6 mRNA) DMW7XEU MA Inhibitor DMW7XEU RN Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 Jun;16(6):400-423. DMW7XEU RU https://pubmed.ncbi.nlm.nih.gov/28154410 DMW87JR DI DMW87JR DMW87JR DN U-99194A DMW87JR TI TT4C8EA DMW87JR TN Dopamine D3 receptor (D3R) DMW87JR MA Binder DMW87JR RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMW87JR RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMWAR1T DI DMWAR1T DMWAR1T DN Ro 61-8048 DMWAR1T TI TTIY56R DMWAR1T TN Kynurenine 3-hydroxylase (KMO) DMWAR1T MA Inhibitor DMWAR1T RN Modification of kynurenine pathway via inhibition of kynurenine hydroxylase attenuates surgical brain injury complications in a male rat model. J Neurosci Res. 2020 Jan;98(1):155-167. DMWAR1T RU https://pubmed.ncbi.nlm.nih.gov/31257634 DMWBCTA DI DMWBCTA DMWBCTA DN SIS-3 DMWBCTA TI TTHQZV7 DMWBCTA TN Mothers against decapentaplegic homolog 3 (SMAD3) DMWBCTA MA Inhibitor DMWBCTA RN Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006 Feb;69(2):597-607. DMWBCTA RU https://pubmed.ncbi.nlm.nih.gov/16288083 DMWCBG8 DI DMWCBG8 DMWCBG8 DN SR2211 DMWCBG8 TI TTGV6LY DMWCBG8 TN Nuclear receptor ROR-gamma (RORG) DMWCBG8 MA Agonist DMWCBG8 RN Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307. DMWCBG8 RU https://pubmed.ncbi.nlm.nih.gov/33589815 DMWH19X DI DMWH19X DMWH19X DN BAY 598 DMWH19X TI TT7YJFO DMWH19X TN SET and MYND domain-containing protein 2 (SMYD2) DMWH19X MA Inhibitor DMWH19X RN Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2. J Med Chem. 2016 May 26;59(10):4578-600. DMWH19X RU https://pubmed.ncbi.nlm.nih.gov/27075367 DMWMBIV DI DMWMBIV DMWMBIV DN CRA1000 DMWMBIV TI TT7EFHR DMWMBIV TN Corticotropin-releasing factor receptor 1 (CRHR1) DMWMBIV MA Antagonist DMWMBIV RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DMWMBIV RU https://pubmed.ncbi.nlm.nih.gov/17109611 DMWQ3TH DI DMWQ3TH DMWQ3TH DN S-33084 DMWQ3TH TI TT4C8EA DMWQ3TH TN Dopamine D3 receptor (D3R) DMWQ3TH MA Modulator DMWQ3TH RN S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther. 2000 Jun;293(3):1063-73. DMWQ3TH RU https://pubmed.ncbi.nlm.nih.gov/10869411 DMWQIJX DI DMWQIJX DMWQIJX DN Celastrol DMWQIJX TI TTRYK0X DMWQIJX TN Interleukin-1 beta (IL1B) DMWQIJX MA Suppressor DMWQIJX RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMWQIJX RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMWQIJX DI DMWQIJX DMWQIJX DN Celastrol DMWQIJX TI TTF8CQI DMWQIJX TN Tumor necrosis factor (TNF) DMWQIJX MA Suppressor DMWQIJX RN Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52. DMWQIJX RU https://pubmed.ncbi.nlm.nih.gov/17604499 DMWZCIF DI DMWZCIF DMWZCIF DN TTA-A8 DMWZCIF TI TTZPWGN DMWZCIF TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMWZCIF MA Antagonist DMWZCIF RN Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett. 2010 Aug 24;1(9):504-9. DMWZCIF RU https://pubmed.ncbi.nlm.nih.gov/24900239 DMX23CZ DI DMX23CZ DMX23CZ DN Z-Phe-Ala-diazomethylketone DMX23CZ TI TT36ETB DMX23CZ TN Cathepsin L (CTSL) DMX23CZ MA Inhibitor DMX23CZ RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DMX23CZ RU https://pubmed.ncbi.nlm.nih.gov/31477883 DMX23CZ DI DMX23CZ DMX23CZ DN Z-Phe-Ala-diazomethylketone DMX23CZ TI TTF2LRI DMX23CZ TN Cathepsin B (CTSB) DMX23CZ MA Inhibitor DMX23CZ RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DMX23CZ RU https://pubmed.ncbi.nlm.nih.gov/31477883 DMX7Q3H DI DMX7Q3H DMX7Q3H DN Nemorubicin DMX7Q3H TI TT0IHXV DMX7Q3H TN DNA topoisomerase II (TOP2) DMX7Q3H MA Modulator DMX7Q3H RN The interaction of nemorubicin metabolite PNU-159682 with DNA fragments d(CGTACG)(2), d(CGATCG)(2) and d(CGCGCG)(2) shows a strong but reversible binding to G:C base pairs. Bioorg Med Chem. 2012 Dec 15;20(24):6979-88. DMX7Q3H RU https://pubmed.ncbi.nlm.nih.gov/23154079 DMX9AGF DI DMX9AGF DMX9AGF DN GRL0617 DMX9AGF TI TTNHMO8 DMX9AGF TN COVID-19 papain-like proteinase (PL-PRO) DMX9AGF MA Inhibitor DMX9AGF RN Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B. 2021 Jan;11(1):237-245. DMX9AGF RU https://pubmed.ncbi.nlm.nih.gov/32895623 DMXB95R DI DMXB95R DMXB95R DN IC261 DMXB95R TI TTFQEMX DMXB95R TN Casein kinase I alpha (CSNK1A1) DMXB95R MA Inhibitor DMXB95R RN Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60. DMXB95R RU https://pubmed.ncbi.nlm.nih.gov/10749871 DMXB95R DI DMXB95R DMXB95R DN IC261 DMXB95R TI TTH30UI DMXB95R TN Casein kinase I delta (CSNK1D) DMXB95R MA Inhibitor DMXB95R RN Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60. DMXB95R RU https://pubmed.ncbi.nlm.nih.gov/10749871 DMXB95R DI DMXB95R DMXB95R DN IC261 DMXB95R TI TTA8PLI DMXB95R TN Casein kinase I epsilon (CSNK1E) DMXB95R MA Inhibitor DMXB95R RN Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem. 2000 Jun 30;275(26):20052-60. DMXB95R RU https://pubmed.ncbi.nlm.nih.gov/10749871 DMXCKL9 DI DMXCKL9 DMXCKL9 DN PMID30940566-compound-6 DMXCKL9 TI TTYJOLE DMXCKL9 TN MERS-CoV papain-like proteinase (PL-PRO) DMXCKL9 MA Inhibitor DMXCKL9 RN Identification and Design of Novel Small Molecule Inhibitors Against MERS-CoV Papain-Like Protease via High-Throughput Screening and Molecular Modeling Bioorg Med Chem. 2019 May 15;27(10):1981-1989. DMXCKL9 RU https://pubmed.ncbi.nlm.nih.gov/30940566 DMXE6ML DI DMXE6ML DMXE6ML DN FX-007 DMXE6ML TI TTTDVOJ DMXE6ML TN Tropomyosin-related kinase A (TrkA) DMXE6ML MA Inhibitor DMXE6ML RN Preclinical trail of FX007 for treating osteoarthritis. Flexion Therapeutics Inc. DMXE6ML RU http://www.biocentury.com/products/fx007 DMXFC3W DI DMXFC3W DMXFC3W DN 4SC-202 DMXFC3W TI TT6R7JZ DMXFC3W TN Histone deacetylase 1 (HDAC1) DMXFC3W MA Inhibitor DMXFC3W RN 2011 Pipeline of 4SC AG. DMXFC3W RU http://www.pharmaceutical-market-research.com/publications/pharmaceutical_companies/4sc_ag_product_pipeline_review.html DMXG0O1 DI DMXG0O1 DMXG0O1 DN NCGC607 DMXG0O1 TI TT1B5PU DMXG0O1 TN Glucosylceramidase (GBA) DMXG0O1 MA Inhibitor DMXG0O1 RN A New Glucocerebrosidase Chaperone Reduces alpha-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. J Neurosci. 2016 Jul 13;36(28):7441-52. DMXG0O1 RU https://pubmed.ncbi.nlm.nih.gov/27413154 DMXJO20 DI DMXJO20 DMXJO20 DN Indol-3-carbinol DMXJO20 TI TT27K59 DMXJO20 TN Platelet activating factor (PAF) DMXJO20 MA Inhibitor DMXJO20 RN Pinusolide from the leaves of Biota orientalis as potent platelet activating factor antagonist. Planta Med. 1999 Feb;65(1):39-42. DMXJO20 RU https://pubmed.ncbi.nlm.nih.gov/10083843 DMXJO20 DI DMXJO20 DMXJO20 DN Indol-3-carbinol DMXJO20 TI TTUTN1I DMXJO20 TN Human Deoxyribonucleic acid (hDNA) DMXJO20 MA Binder DMXJO20 RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DMXJO20 RU https://pubmed.ncbi.nlm.nih.gov/19463273 DMXKN6R DI DMXKN6R DMXKN6R DN CLIK-181 DMXKN6R TI TT36ETB DMXKN6R TN Cathepsin L (CTSL) DMXKN6R MA Inhibitor DMXKN6R RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DMXKN6R RU https://pubmed.ncbi.nlm.nih.gov/31477883 DMXM2BZ DI DMXM2BZ DMXM2BZ DN Rycals DMXM2BZ TI TT5HONZ DMXM2BZ TN Calcium channel unspecific (CaC) DMXM2BZ MA Modulator DMXM2BZ RN Fixing ryanodine receptor Ca2+ leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. Drug Discov Today Dis Mech. 2010 SUMMER; 7(2): e151-e157. DMXM2BZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2989530/ DMXN2ZQ DI DMXN2ZQ DMXN2ZQ DN IMO-2134 DMXN2ZQ TI TTSHG0T DMXN2ZQ TN Toll-like receptor 9 (TLR9) DMXN2ZQ MA Agonist DMXN2ZQ RN Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011). DMXN2ZQ RU http://www.iderapharma.com/ DMXN4UC DI DMXN4UC DMXN4UC DN SBX-101 DMXN4UC TI TTQALFH DMXN4UC TN Bacterial Beta-glucuronidase (Bact uidA) DMXN4UC MA Inhibitor DMXN4UC RN Microbiome therapeutics go small molecule. Nat Rev Drug Discov. 2019 Jul;18(8):569-572. DMXN4UC RU https://pubmed.ncbi.nlm.nih.gov/31367062 DMXO6YH DI DMXO6YH DMXO6YH DN PJ34 DMXO6YH TI TTVDSZ0 DMXO6YH TN Poly [ADP-ribose] polymerase 1 (PARP1) DMXO6YH MA Inhibitor DMXO6YH RN Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001 Jan;7(1):108-13. DMXO6YH RU https://pubmed.ncbi.nlm.nih.gov/11135624 DMXQVBT DI DMXQVBT DMXQVBT DN ATA3271 DMXQVBT TI TT4RXME DMXQVBT TN Mesothelin (MSLN) DMXQVBT RN Clinical pipeline report, company report or official report of Atara Biotherapeutics. DMXQVBT RU https://www.atarabio.com/pipeline/ DMXR287 DI DMXR287 DMXR287 DN FR-79620 DMXR287 TI TTY6EWA DMXR287 TN Neuropeptide Y receptor type 5 (NPY5R) DMXR287 MA Antagonist DMXR287 RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMXR287 RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMXUCSN DI DMXUCSN DMXUCSN DN NPY5RA-972 DMXUCSN TI TTY6EWA DMXUCSN TN Neuropeptide Y receptor type 5 (NPY5R) DMXUCSN MA Antagonist DMXUCSN RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMXUCSN RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMXVHOQ DI DMXVHOQ DMXVHOQ DN GNE684 DMXVHOQ TI TTAIQSN DMXVHOQ TN Receptor-interacting protein 1 (RIPK1) DMXVHOQ MA Inhibitor DMXVHOQ RN Impaired RIPK1 ubiquitination sensitizes mice to TNF toxicity and inflammatory cell death. Cell Death Differ. 2021 Mar;28(3):985-1000. DMXVHOQ RU https://pubmed.ncbi.nlm.nih.gov/32999468 DMXY81K DI DMXY81K DMXY81K DN KOS-2484 DMXY81K TI TT78R5H DMXY81K TN Heat shock protein 90 alpha (HSP90A) DMXY81K MA Inhibitor DMXY81K RN US patent application no. 2014,0079,636, Targeted therapeutics. DMXY81K RU http://www.google.com.na/patents/US20140079636 DMXYDMP DI DMXYDMP DMXYDMP DN LM10 DMXYDMP TI TTXNCBV DMXYDMP TN Tryptophan 2,3-dioxygenase (TDO) DMXYDMP MA Inhibitor DMXYDMP RN The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO). Immunol Lett. 2020 Jan;217:25-30. DMXYDMP RU https://pubmed.ncbi.nlm.nih.gov/31726186 DMXZ08K DI DMXZ08K DMXZ08K DN SSYA10-001 DMXZ08K TI TTQKWR5 DMXZ08K TN SARS-CoV helicase (Hel) DMXZ08K MA Inhibitor DMXZ08K RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMXZ08K RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMY7R3X DI DMY7R3X DMY7R3X DN AZD-1678 DMY7R3X TI TT7HQD0 DMY7R3X TN C-C chemokine receptor type 4 (CCR4) DMY7R3X MA Antagonist DMY7R3X RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030818) DMY7R3X RU http://adisinsight.springer.com/drugs/800030818 DMY8GDA DI DMY8GDA DMY8GDA DN Trimidox DMY8GDA TI TTCIHJA DMY8GDA TN Coagulation factor Xa (F10) DMY8GDA MA Inhibitor DMY8GDA RN Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search. J Mol Graph Model. 2003 Nov;22(2):105-14. DMY8GDA RU https://pubmed.ncbi.nlm.nih.gov/12932781 DMY8GDA DI DMY8GDA DMY8GDA DN Trimidox DMY8GDA TI TTX09M4 DMY8GDA TN Ribonucleotide reductase (RIR) DMY8GDA MA Inhibitor DMY8GDA RN Suppression of retrovirus-induced immunodeficiency disease (murine AIDS) by trimidox and didox: novel ribonucleotide reductase inhibitors with less bone marrow toxicity than hydroxyurea. Antiviral Res. 2002 Nov;56(2):167-81. DMY8GDA RU https://pubmed.ncbi.nlm.nih.gov/12367722 DMY8QP5 DI DMY8QP5 DMY8QP5 DN TFM735 DMY8QP5 TI TTA6ZN2 DMY8QP5 TN Nuclear factor erythroid 2-related factor 2 (Nrf2) DMY8QP5 MA Activator DMY8QP5 RN The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur J Pharmacol. 2017 May 5;802:76-84. DMY8QP5 RU https://pubmed.ncbi.nlm.nih.gov/28246026 DMY91A3 DI DMY91A3 DMY91A3 DN ML323 DMY91A3 TI TTG9MT5 DMY91A3 TN Deubiquitinating enzyme 1 (USP1) DMY91A3 MA Inhibitor DMY91A3 RN Synthesis and structure-activity relationship studies of N-benzyl-2-phenylpyrimidin-4-amine derivatives as potent USP1/UAF1 deubiquitinase inhibitors with anticancer activity against nonsmall cell lung cancer. J Med Chem. 2014 Oct 9;57(19):8099-110. DMY91A3 RU https://pubmed.ncbi.nlm.nih.gov/25229643 DMY9DA3 DI DMY9DA3 DMY9DA3 DN SLV-332 DMY9DA3 TI TTYO0A3 DMY9DA3 TN Substance-K receptor (TACR2) DMY9DA3 MA Antagonist DMY9DA3 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMY9DA3 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMY9F1M DI DMY9F1M DMY9F1M DN C30 DMY9F1M TI TTOMVUW DMY9F1M TN Pseudomonas Transcriptional activator protein LasR (Pseudo LasR) DMY9F1M MA Inhibitor DMY9F1M RN Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat Rev Drug Discov. 2017 Jul;16(7):457-471. DMY9F1M RU https://pubmed.ncbi.nlm.nih.gov/28337021 DMYEFKH DI DMYEFKH DMYEFKH DN MCP-1 DMYEFKH TI TTFZYTO DMYEFKH TN C-C chemokine receptor type 2 (CCR2) DMYEFKH MA Antagonist DMYEFKH RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMYEFKH RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMYEFKH DI DMYEFKH DMYEFKH DN MCP-1 DMYEFKH TI TTNAY0P DMYEFKH TN Monocyte chemotactic and activating factor (CCL2) DMYEFKH MA Inhibitor DMYEFKH RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMYEFKH RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMYFVZ3 DI DMYFVZ3 DMYFVZ3 DN FAP5-DM1 DMYFVZ3 TI TTGPQ0F DMYFVZ3 TN Prolyl endopeptidase FAP (FAP) DMYFVZ3 RN Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008 Jul 15;14(14):4584-92. DMYFVZ3 RU https://pubmed.ncbi.nlm.nih.gov/18628473 DMYGITU DI DMYGITU DMYGITU DN CHDI-340246 DMYGITU TI TTIY56R DMYGITU TN Kynurenine 3-hydroxylase (KMO) DMYGITU MA Inhibitor DMYGITU RN The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease. Exp Neurol. 2016 Aug;282:99-118. DMYGITU RU https://pubmed.ncbi.nlm.nih.gov/27163548 DMYH3VR DI DMYH3VR DMYH3VR DN DP-3975 DMYH3VR TI TTZPY6J DMYH3VR TN Tyrosine-protein kinase UFO (AXL) DMYH3VR MA Inhibitor DMYH3VR RN AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153. DMYH3VR RU https://pubmed.ncbi.nlm.nih.gov/31684958 DMYIK5D DI DMYIK5D DMYIK5D DN AEZS-123 DMYIK5D TI TTWDC17 DMYIK5D TN Growth hormone secretagogue receptor 1 (GHSR) DMYIK5D MA Antagonist DMYIK5D RN 2011 Pipeline of Aeterna Zentaris. DMYIK5D RU http://www.aezsinc.com/en/index.php DMYK8MV DI DMYK8MV DMYK8MV DN Melanotetan II DMYK8MV TI TTD0CIQ DMYK8MV TN Melanocortin receptor 4 (MC4R) DMYK8MV MA Agonist DMYK8MV RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMYK8MV RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMYK8MV DI DMYK8MV DMYK8MV DN Melanotetan II DMYK8MV TI TTNI91K DMYK8MV TN Melanocortin receptor 3 (MC3R) DMYK8MV MA Agonist DMYK8MV RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMYK8MV RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMYNCWK DI DMYNCWK DMYNCWK DN PMID28624700-compound-3-31 DMYNCWK TI TTPZG3C DMYNCWK TN SARS-CoV 3C-like protease (3CLpro) DMYNCWK MA Inhibitor DMYNCWK RN Discovery of Unsymmetrical Aromatic Disulfides as Novel Inhibitors of SARS-CoV Main Protease: Chemical Synthesis, Biological Evaluation, Molecular Docking and 3D-QSAR Study Eur J Med Chem. 2017 Sep 8;137:450-461. DMYNCWK RU https://pubmed.ncbi.nlm.nih.gov/28624700 DMYOR5T DI DMYOR5T DMYOR5T DN CAR-T cells targeting CD133 DMYOR5T TI TTXMZ81 DMYOR5T TN Prominin-1 (PROM1) DMYOR5T MA CAR-T-Cell-Therapy DMYOR5T RN ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia DMYOR5T RU https://clinicaltrials.gov/ct2/show/NCT03473457 DMYZQKC DI DMYZQKC DMYZQKC DN SPHINX31 DMYZQKC TI TTU3WV6 DMYZQKC TN SRSF protein kinase 1 (SRPK1) DMYZQKC MA Inhibitor DMYZQKC RN Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018 May;17(5):353-377. DMYZQKC RU https://pubmed.ncbi.nlm.nih.gov/29545548 DMZ3YP6 DI DMZ3YP6 DMZ3YP6 DN EGFR/IGFR tandem adnectin DMZ3YP6 TI TTHRID2 DMZ3YP6 TN Insulin-like growth factor I receptor (IGF1R) DMZ3YP6 MA Inhibitor DMZ3YP6 RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMZ3YP6 RU http://news.bms.com/press-release/rd-news/bristol-myers-squibb-announces-collaboration-evaluate-opdivo-nivolumab-combina DMZ3YP6 DI DMZ3YP6 DMZ3YP6 DN EGFR/IGFR tandem adnectin DMZ3YP6 TI TTGKNB4 DMZ3YP6 TN Epidermal growth factor receptor (EGFR) DMZ3YP6 MA Inhibitor DMZ3YP6 RN Clinical pipeline report, company report or official report of Bristol-Myers Squibb. DMZ3YP6 RU http://news.bms.com/press-release/rd-news/bristol-myers-squibb-announces-collaboration-evaluate-opdivo-nivolumab-combina DMZ4HMP DI DMZ4HMP DMZ4HMP DN A-71378 DMZ4HMP TI TTCG0AL DMZ4HMP TN Cholecystokinin receptor type A (CCKAR) DMZ4HMP MA Agonist DMZ4HMP RN Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. DMZ4HMP RU https://pubmed.ncbi.nlm.nih.gov/16083333 DMZ9BO8 DI DMZ9BO8 DMZ9BO8 DN SR9011 DMZ9BO8 TI TTAD1O8 DMZ9BO8 TN V-erbA-related protein 1 (NR1D1) DMZ9BO8 MA Agonist DMZ9BO8 RN Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature. 2018 Jan 18;553(7688):351-355. DMZ9BO8 RU https://pubmed.ncbi.nlm.nih.gov/29320480 DMZC91G DI DMZC91G DMZC91G DN GL21.T DMZC91G TI TTZPY6J DMZC91G TN Tyrosine-protein kinase UFO (AXL) DMZC91G RN AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019 Nov 4;18(1):153. DMZC91G RU https://pubmed.ncbi.nlm.nih.gov/31684958 DMZCW3J DI DMZCW3J DMZCW3J DN KP3 DMZCW3J TI TTHDS05 DMZCW3J TN Klebsiella Fimbrial subunit type 3 (Klebsiella mrkA) DMZCW3J MA Inhibitor DMZCW3J RN Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA. PLoS One. 2017 Jan 20;12(1):e0170529. DMZCW3J RU https://pubmed.ncbi.nlm.nih.gov/28107434 DMZHAVG DI DMZHAVG DMZHAVG DN VPM-4-001 DMZHAVG TI TTF89GD DMZHAVG TN Interleukin-2 (IL2) DMZHAVG RN BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5. DMZHAVG RU https://pubmed.ncbi.nlm.nih.gov/20191431 DMZHAVG DI DMZHAVG DMZHAVG DN VPM-4-001 DMZHAVG TI TT93WF5 DMZHAVG TN Interferon-gamma (IFNG) DMZHAVG RN BioPartnering North America--Programs from Pharma in Europe and the Middle East. IDrugs. 2010 Mar;13(3):162-5. DMZHAVG RU https://pubmed.ncbi.nlm.nih.gov/20191431 DMZJVR5 DI DMZJVR5 DMZJVR5 DN ATI-17000 DMZJVR5 TI TTNT7K8 DMZJVR5 TN Nociceptin receptor (OPRL1) DMZJVR5 MA Antagonist DMZJVR5 RN Nocistatin and nociceptin given centrally induce opioid-mediated gastric mucosal protection. Peptides. 2008 Dec;29(12):2257-65. DMZJVR5 RU https://pubmed.ncbi.nlm.nih.gov/18930088 DMZJVR5 DI DMZJVR5 DMZJVR5 DN ATI-17000 DMZJVR5 TI TTPC4TU DMZJVR5 TN 5-HT 3A receptor (HTR3A) DMZJVR5 MA Antagonist DMZJVR5 RN Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. DMZJVR5 RU https://pubmed.ncbi.nlm.nih.gov/16634703 DMZJWON DI DMZJWON DMZJWON DN PMID31244113-compound-2c DMZJWON TI TTOA6YT DMZJWON TN MERS-CoV RNA-directed RNA polymerase (RdRp) DMZJWON MA Inhibitor DMZJWON RN Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362. DMZJWON RU https://pubmed.ncbi.nlm.nih.gov/31244113 DMZJWON DI DMZJWON DMZJWON DN PMID31244113-compound-2c DMZJWON TI TTKXI53 DMZJWON TN SARS-CoV RNA-directed RNA polymerase (RdRp) DMZJWON MA Inhibitor DMZJWON RN Design, Synthesis, and Anti-RNA Virus Activity of 6'-Fluorinated-Aristeromycin Analogues. J Med Chem. 2019 Jul 11;62(13):6346-6362. DMZJWON RU https://pubmed.ncbi.nlm.nih.gov/31244113 DMZKY56 DI DMZKY56 DMZKY56 DN VX-166 DMZKY56 TI TTZY5KP DMZKY56 TN Caspase (CASP) DMZKY56 MA Inhibitor DMZKY56 RN VX-166: a novel potent small molecule caspase inhibitor as a potential therapy for sepsis. Crit Care. 2009;13(5):R146. DMZKY56 RU https://pubmed.ncbi.nlm.nih.gov/19740426 DMZMYU5 DI DMZMYU5 DMZMYU5 DN PMID26868298-compound-5705213 DMZMYU5 TI TTS586L DMZMYU5 TN HUMAN cathepsin L (CTSL) DMZMYU5 MA Blocker DMZMYU5 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMZMYU5 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMZOUX4 DI DMZOUX4 DMZOUX4 DN Romazarit DMZOUX4 TI TTJ584C DMZOUX4 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMZOUX4 MA Modulator DMZOUX4 RN Fibrates as therapy for osteoarthritis and rheumatoid arthritis A systematic review. Ther Adv Musculoskelet Dis. 2013 February; 5(1): 33-44. DMZOUX4 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3582306/ DMZV9JX DI DMZV9JX DMZV9JX DN SR1555 DMZV9JX TI TTGV6LY DMZV9JX TN Nuclear receptor ROR-gamma (RORG) DMZV9JX MA Agonist DMZV9JX RN Circadian rhythm as a therapeutic target. Nat Rev Drug Discov. 2021 Apr;20(4):287-307. DMZV9JX RU https://pubmed.ncbi.nlm.nih.gov/33589815 DM0195G DI DM0195G DM0195G DN ICI-198615 DM0195G TI TTTWGIX DM0195G TN Leukotriene receptor (LTR) DM0195G MA Modulator DM0195G RN In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther. 1987 Nov;243(2):548-56. DM0195G RU https://pubmed.ncbi.nlm.nih.gov/2824751 DM0195G DI DM0195G DM0195G DN ICI-198615 DM0195G TI TTGKOY9 DM0195G TN Leukotriene CysLT1 receptor (CYSLTR1) DM0195G MA Antagonist DM0195G RN Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol. 1992 Oct 6;44(7):1411-5. DM0195G RU https://pubmed.ncbi.nlm.nih.gov/1329767 DM0195G DI DM0195G DM0195G DN ICI-198615 DM0195G TI TT0PZR5 DM0195G TN Leukotriene CysLT2 receptor (CYSLTR2) DM0195G MA Antagonist DM0195G RN Heterogeneity of binding sites for ICI 198,615 in human lung parenchyma. Biochem Pharmacol. 1992 Oct 6;44(7):1411-5. DM0195G RU https://pubmed.ncbi.nlm.nih.gov/1329767 DM019Y7 DI DM019Y7 DM019Y7 DN BIBN-140 DM019Y7 TI TTYEG6Q DM019Y7 TN Muscarinic acetylcholine receptor M2 (CHRM2) DM019Y7 MA Modulator DM019Y7 RN Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology. Life Sci. 1993;52(5-6):497-503. DM019Y7 RU https://pubmed.ncbi.nlm.nih.gov/8441330 DM01HLX DI DM01HLX DM01HLX DN GR-127935 DM01HLX TI TTK8CXU DM01HLX TN 5-HT 1B receptor (HTR1B) DM01HLX MA Modulator DM01HLX RN GR127935: a potent and selective 5-HT1D receptor antagonist.Behav Brain Res.1996;73(1-2):157-61. DM01HLX RU https://www.ncbi.nlm.nih.gov/pubmed/8788495 DM01HLX DI DM01HLX DM01HLX DN GR-127935 DM01HLX TI TT6MSOK DM01HLX TN 5-HT 1D receptor (HTR1D) DM01HLX MA Modulator DM01HLX RN GR127935: a potent and selective 5-HT1D receptor antagonist.Behav Brain Res.1996;73(1-2):157-61. DM01HLX RU https://www.ncbi.nlm.nih.gov/pubmed/8788495 DM037SB DI DM037SB DM037SB DN Sch-207758 DM037SB TI TT7WZIJ DM037SB TN CAAX farnesyltransferase beta (FNTB) DM037SB MA Inhibitor DM037SB RN Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase. J Med Chem. 2002 Aug 29;45(18):3854-64. DM037SB RU https://pubmed.ncbi.nlm.nih.gov/12190309 DM03LZB DI DM03LZB DM03LZB DN CNS-1307 DM03LZB TI TT5TPI6 DM03LZB TN Opioid receptor sigma 1 (OPRS1) DM03LZB MA Modulator DM03LZB RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DM03LZB RU https://pubmed.ncbi.nlm.nih.gov/24648790 DM0582D DI DM0582D DM0582D DN FR-123826 DM0582D TI TTVKILB DM0582D TN Prostaglandin G/H synthase 2 (COX-2) DM0582D MA Inhibitor DM0582D RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007983) DM0582D RU http://adisinsight.springer.com/drugs/800007983 DM05IQU DI DM05IQU DM05IQU DN S-14506 DM05IQU TI TTSQIFT DM05IQU TN 5-HT 1A receptor (HTR1A) DM05IQU MA Modulator DM05IQU RN S 14506: novel receptor coupling at 5-HT(1A) receptors. Neuropharmacology. 2001 Mar;40(3):334-44. DM05IQU RU https://www.ncbi.nlm.nih.gov/pubmed/11166326 DM07S4N DI DM07S4N DM07S4N DN LAS-30538 DM07S4N TI TT5HONZ DM07S4N TN Calcium channel unspecific (CaC) DM07S4N MA Modulator DM07S4N RN The calcium channel blocker LAS 30538, unlike nifedipine, verapamil, diltiazem or flunarizine, potently inhibits insulin secretion in-vivo in rats and dogs. J Pharm Pharmacol. 1992 Oct;44(10):851-5. DM07S4N RU https://pubmed.ncbi.nlm.nih.gov/1360513 DM07ZSC DI DM07ZSC DM07ZSC DN Ro-25-6833 DM07ZSC TI TTXT4D5 DM07ZSC TN Bacterial Cell membrane (Bact CM) DM07ZSC MA Modulator DM07ZSC RN Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. J Pharm Sci. 1998 Apr;87(4):496-500. DM07ZSC RU https://pubmed.ncbi.nlm.nih.gov/9548904 DM083JB DI DM083JB DM083JB DN SQ-33351 DM083JB TI TT5HONZ DM083JB TN Calcium channel unspecific (CaC) DM083JB MA Modulator DM083JB RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002577) DM083JB RU http://adisinsight.springer.com/drugs/800002577 DM08BUV DI DM08BUV DM08BUV DN RDEA-427 DM08BUV TI TT84ETX DM08BUV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM08BUV MA Inhibitor DM08BUV RN CN patent application no. 103360398, Triazolopyrimidine hiv-1 retrovirus inhibitor and its preparation method and application thereof. DM08BUV RU http://www.google.com/patents/CN103360398A?cl=en DM08XS2 DI DM08XS2 DM08XS2 DN ERIC-1 DM08XS2 TI TTUBJQ3 DM08XS2 TN Neural cell adhesion molecule (NCAM) DM08XS2 MA Antagonist DM08XS2 RN Monoclonal antibody UJ13A recognizes the neural cell adhesion molecule (NCAM). Int J Cancer. 1989 Dec 15;44(6):1062-8. DM08XS2 RU https://pubmed.ncbi.nlm.nih.gov/2558078 DM098BL DI DM098BL DM098BL DN BIBS-39 DM098BL TI TTGN1ZA DM098BL TN Angiotensin II receptor (AGTR) DM098BL MA Modulator DM098BL RN Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol. 1992 Jul 21;218(1):35-41. DM098BL RU https://pubmed.ncbi.nlm.nih.gov/1397034 DM09QLY DI DM09QLY DM09QLY DN RP-66055 DM09QLY TI TTRK8B9 DM09QLY TN Sodium channel unspecific (NaC) DM09QLY MA Modulator DM09QLY RN Synthesis, anticonvulsant and neuroprotective activities of RP 66055, a riluzole derivative. Bioorg Med Chem. 1994 Aug;2(8):793-8. DM09QLY RU https://pubmed.ncbi.nlm.nih.gov/7894973 DM0BEM3 DI DM0BEM3 DM0BEM3 DN RP-68303 DM0BEM3 TI TTJQOD7 DM0BEM3 TN 5-HT 2A receptor (HTR2A) DM0BEM3 MA Inhibitor DM0BEM3 RN New indole derivatives as potent and selective serotonin uptake inhibitors. J Med Chem. 1993 Apr 30;36(9):1194-202. DM0BEM3 RU https://pubmed.ncbi.nlm.nih.gov/8487257 DM0BYU2 DI DM0BYU2 DM0BYU2 DN NNC-252504 DM0BYU2 TI TT9O6WS DM0BYU2 TN Glucagon receptor (GCGR) DM0BYU2 MA Antagonist DM0BYU2 RN A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose production in the conscious dog. J Pharmacol Exp Ther. 2007 May;321(2):743-52. DM0BYU2 RU https://pubmed.ncbi.nlm.nih.gov/17308040 DM0CWJZ DI DM0CWJZ DM0CWJZ DN VUF-8929 DM0CWJZ TI TT5HONZ DM0CWJZ TN Calcium channel unspecific (CaC) DM0CWJZ MA Modulator DM0CWJZ RN In vitro and in vivo characterization of a calcium modulator of the diphenylalkylamine type with selective coronary dilatory properties. Arzneimittelforschung. 1997 Nov;47(11):1211-8. DM0CWJZ RU https://pubmed.ncbi.nlm.nih.gov/9428976 DM0DO4S DI DM0DO4S DM0DO4S DN Bivatuzumab mertansine DM0DO4S TI TTWFBT7 DM0DO4S TN Extracellular matrix receptor III (CD44) DM0DO4S RN A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72. DM0DO4S RU https://pubmed.ncbi.nlm.nih.gov/17062682 DM0IKB4 DI DM0IKB4 DM0IKB4 DN GLY-515n DM0IKB4 TI TTQG4NR DM0IKB4 TN Erythropoietin (EPO) DM0IKB4 MA Modulator DM0IKB4 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027536) DM0IKB4 RU http://adisinsight.springer.com/drugs/800027536 DM0JDCS DI DM0JDCS DM0JDCS DN DBO-83 DM0JDCS TI TTJSZTB DM0JDCS TN Nicotinic acetylcholine receptor (nAChR) DM0JDCS MA Agonist DM0JDCS RN The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30. DM0JDCS RU https://pubmed.ncbi.nlm.nih.gov/11772288 DM0K4DZ DI DM0K4DZ DM0K4DZ DN BMS-182657 DM0K4DZ TI TT5TKPM DM0K4DZ TN Neutral endopeptidase (MME) DM0K4DZ MA Modulator DM0K4DZ RN Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52. DM0K4DZ RU https://pubmed.ncbi.nlm.nih.gov/7473162 DM0K4DZ DI DM0K4DZ DM0K4DZ DN BMS-182657 DM0K4DZ TI TTL69WB DM0K4DZ TN Angiotensin-converting enzyme (ACE) DM0K4DZ MA Modulator DM0K4DZ RN Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther. 1995 Nov;275(2):745-52. DM0K4DZ RU https://pubmed.ncbi.nlm.nih.gov/7473162 DM0MXWC DI DM0MXWC DM0MXWC DN KA-398 DM0MXWC TI TTTIBOJ DM0MXWC TN Histamine H1 receptor (H1R) DM0MXWC MA Modulator DM0MXWC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 262). DM0MXWC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=262 DM0NJMG DI DM0NJMG DM0NJMG DN Ciprokiren DM0NJMG TI TTB2MXP DM0NJMG TN Angiotensinogenase renin (REN) DM0NJMG MA Inhibitor DM0NJMG RN Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension. 1994 Aug;24(2):163-9. DM0NJMG RU https://pubmed.ncbi.nlm.nih.gov/8039839 DM0NY6K DI DM0NY6K DM0NY6K DN A 77636 DM0NY6K TI TTZFYLI DM0NY6K TN Dopamine D1 receptor (D1R) DM0NY6K MA Modulator DM0NY6K RN Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology (Berl). 1999 Feb;142(1):51-60. DM0NY6K RU https://www.ncbi.nlm.nih.gov/pubmed/10102782 DM0P8CE DI DM0P8CE DM0P8CE DN BX-044 DM0P8CE TI TT5QA2I DM0P8CE TN Plasminogen activator inhibitor (PAI) DM0P8CE MA Inhibitor DM0P8CE RN Characterization of a small molecule PAI-1 inhibitor, ZK4044. Thromb Res. 2005;115(4):341-50. DM0P8CE RU https://pubmed.ncbi.nlm.nih.gov/15668194 DM0PSCF DI DM0PSCF DM0PSCF DN Ro 20-1724 DM0PSCF TI TTV5CGO DM0PSCF TN Phosphodiesterase 4 (PDE4) DM0PSCF MA Inhibitor DM0PSCF RN Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Invest Dermatol. 1993 May;100(5):681-4. DM0PSCF RU https://pubmed.ncbi.nlm.nih.gov/8388009 DM0PSCF DI DM0PSCF DM0PSCF DN Ro 20-1724 DM0PSCF TI TTLZS4Q DM0PSCF TN M-phase inducer phosphatase 1 (MPIP1) DM0PSCF MA Inhibitor DM0PSCF RN Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000 Sep;106(6):753-61. DM0PSCF RU https://pubmed.ncbi.nlm.nih.gov/10995786 DM0RZEO DI DM0RZEO DM0RZEO DN Ro-48-8724 DM0RZEO TI TTHI19T DM0RZEO TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM0RZEO MA Modulator DM0RZEO RN Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724). Diagn Microbiol Infect Dis. 1998 Oct;32(2):85-94. DM0RZEO RU https://pubmed.ncbi.nlm.nih.gov/9823530 DM0SCDB DI DM0SCDB DM0SCDB DN TIAPAFANT DM0SCDB TI TTQL5VC DM0SCDB TN Platelet-activating factor receptor (PTAFR) DM0SCDB MA Antagonist DM0SCDB RN PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover. Eur J Pharmacol. 1995 Aug 15;290(3):183-8. DM0SCDB RU https://pubmed.ncbi.nlm.nih.gov/7589212 DM0TBQK DI DM0TBQK DM0TBQK DN ZM-230487 DM0TBQK TI TT2J34L DM0TBQK TN Arachidonate 5-lipoxygenase (5-LOX) DM0TBQK MA Inhibitor DM0TBQK RN Pharmacological nature of nicotine-induced contraction in the rat basilar artery: involvement of arachidonic acid metabolites. Eur J Pharmacol. 2007 Dec 22;577(1-3):109-14. DM0TBQK RU https://pubmed.ncbi.nlm.nih.gov/17765890 DM0TELR DI DM0TELR DM0TELR DN TAK-779 DM0TELR TI TT2CEJG DM0TELR TN C-C chemokine receptor type 5 (CCR5) DM0TELR MA Antagonist DM0TELR RN Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. Int Immunopharmacol. 2007 Dec 5;7(12):1528-34. DM0TELR RU https://pubmed.ncbi.nlm.nih.gov/17920529 DM0TV9L DI DM0TV9L DM0TV9L DN LY467711 DM0TV9L TI TTHS256 DM0TV9L TN Metabotropic glutamate receptor 5 (mGluR5) DM0TV9L MA Antagonist DM0TV9L RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DM0TV9L RU https://pubmed.ncbi.nlm.nih.gov/16377242 DM0X147 DI DM0X147 DM0X147 DN CY-1748 DM0X147 TI TTD26RC DM0X147 TN Cell adhesion molecule (CADM) DM0X147 MA Modulator DM0X147 RN US patent application no. 6,492,332, Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation. DM0X147 RU https://www.google.com/patents/US6492332 DM0XU4P DI DM0XU4P DM0XU4P DN ICI-181037 DM0XU4P TI TT1VOHK DM0XU4P TN Potassium channel unspecific (KC) DM0XU4P MA Opener DM0XU4P RN ICI 181,037: a novel eukalemic diuretic with antiarrhythmic activity. Jpn J Pharmacol. 1991 Nov;57(3):263-77. DM0XU4P RU https://pubmed.ncbi.nlm.nih.gov/1813657 DM0YFZ6 DI DM0YFZ6 DM0YFZ6 DN D-43787 DM0YFZ6 TI TTATDGJ DM0YFZ6 TN Calcium signal-modulating cyclophilin ligand (CAML) DM0YFZ6 MA Binder DM0YFZ6 RN Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787. J Pharmacol Exp Ther. 2002 May;301(2):738-46. DM0YFZ6 RU https://pubmed.ncbi.nlm.nih.gov/11961080 DM0YHKB DI DM0YHKB DM0YHKB DN Acteoside DM0YHKB TI TTFJ8Q1 DM0YHKB TN Protein kinase C alpha (PRKCA) DM0YHKB MA Inhibitor DM0YHKB RN Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2. DM0YHKB RU https://pubmed.ncbi.nlm.nih.gov/9834166 DM0YXRQ DI DM0YXRQ DM0YXRQ DN PD-128483 DM0YXRQ TI TTEX248 DM0YXRQ TN Dopamine D2 receptor (D2R) DM0YXRQ MA Inhibitor DM0YXRQ RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DM0YXRQ RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DM0Z7PK DI DM0Z7PK DM0Z7PK DN UC-38 DM0Z7PK TI TT84ETX DM0Z7PK TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM0Z7PK MA Modulator DM0Z7PK RN Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther. 1996 Jan;276(1):298-305. DM0Z7PK RU https://pubmed.ncbi.nlm.nih.gov/8558446 DM12EYR DI DM12EYR DM12EYR DN R348 DM12EYR TI TTT7PJU DM12EYR TN Janus kinase 3 (JAK-3) DM12EYR MA Inhibitor DM12EYR RN Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. DM12EYR RU https://pubmed.ncbi.nlm.nih.gov/19249988 DM149HL DI DM149HL DM149HL DN EPD-clofarabine DM149HL TI TTUBNVO DM149HL TN DNA synthesis (DNA synth) DM149HL MA Inhibitor DM149HL RN 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. DM149HL RU https://pubmed.ncbi.nlm.nih.gov/15756752 DM160FM DI DM160FM DM160FM DN Darodipine DM160FM TI TT5HONZ DM160FM TN Calcium channel unspecific (CaC) DM160FM MA Modulator DM160FM RN Effect of cromakalim on contractions in rabbit isolated renal artery in the presence and absence of extracellular Ca2+. Br J Pharmacol. 1989 Dec;98(4):1303-11. DM160FM RU https://pubmed.ncbi.nlm.nih.gov/2575415 DM16S98 DI DM16S98 DM16S98 DN IGE-026 DM16S98 TI TTYJQTF DM16S98 TN Immunoglobulin E (IgE) DM16S98 MA Inhibitor DM16S98 RN IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5. DM16S98 RU https://pubmed.ncbi.nlm.nih.gov/10224354 DM17NYA DI DM17NYA DM17NYA DN CYC-103 DM17NYA TI TTO0FDJ DM17NYA TN Cyclin-dependent kinase 6 (CDK6) DM17NYA MA Inhibitor DM17NYA RN WO patent application no. 2007,0898,78, Sutures and anti-scarring agents. DM17NYA RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20070809&CC=WO&NR=2007089878A2&KC=A2 DM17NYA DI DM17NYA DM17NYA DN CYC-103 DM17NYA TI TT0PG8F DM17NYA TN Cyclin-dependent kinase 4 (CDK4) DM17NYA MA Inhibitor DM17NYA RN Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. DM17NYA RU https://pubmed.ncbi.nlm.nih.gov/21253554 DM17S85 DI DM17S85 DM17S85 DN L-757464 DM17S85 TI TTNGILX DM17S85 TN Adrenergic receptor alpha-1A (ADRA1A) DM17S85 MA Antagonist DM17S85 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010051) DM17S85 RU http://adisinsight.springer.com/drugs/800010051 DM17WNG DI DM17WNG DM17WNG DN RWJ-37868 DM17WNG TI TT5HONZ DM17WNG TN Calcium channel unspecific (CaC) DM17WNG MA Modulator DM17WNG RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008896) DM17WNG RU http://adisinsight.springer.com/drugs/800008896 DM185DR DI DM185DR DM185DR DN MEN-10207 DM185DR TI TTYO0A3 DM185DR TN Substance-K receptor (TACR2) DM185DR MA Modulator DM185DR RN Role of D-tryptophan for affinity of MEN 10207 tachykinin antagonist at NK2 receptors. Peptides. 1991 Sep-Oct;12(5):1015-8. DM185DR RU https://pubmed.ncbi.nlm.nih.gov/1666180 DM193WR DI DM193WR DM193WR DN ZT-386 DM193WR TI TT2O84V DM193WR TN Thromboxane A2 receptor (TBXA2R) DM193WR MA Modulator DM193WR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004057) DM193WR RU http://adisinsight.springer.com/drugs/800004057 DM197D0 DI DM197D0 DM197D0 DN TAR-1 DM197D0 TI TT7SBF5 DM197D0 TN Cellular tumor antigen p53 (TP53) DM197D0 RN Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 2013; 10: 86. DM197D0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751525/ DM19OGY DI DM19OGY DM19OGY DN NS-2979 DM19OGY TI TTPTXIN DM19OGY TN Translocator protein (TSPO) DM19OGY MA Modulator DM19OGY RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013494) DM19OGY RU http://adisinsight.springer.com/drugs/800013494 DM1AQVE DI DM1AQVE DM1AQVE DN DPI-201-106 DM1AQVE TI TTRK8B9 DM1AQVE TN Sodium channel unspecific (NaC) DM1AQVE MA Modulator DM1AQVE RN Interaction between DPI 201-106 enantiomers at the cardiac sodium channel. Mol Pharmacol. 1990 Jan;37(1):17-24. DM1AQVE RU https://pubmed.ncbi.nlm.nih.gov/2153906 DM1AQVE DI DM1AQVE DM1AQVE DN DPI-201-106 DM1AQVE TI TT2CJVK DM1AQVE TN Adrenergic receptor beta-2 (ADRB2) DM1AQVE MA Inhibitor DM1AQVE RN Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5. DM1AQVE RU https://pubmed.ncbi.nlm.nih.gov/18829308 DM1AXZ6 DI DM1AXZ6 DM1AXZ6 DN PXS-2076 DM1AXZ6 TI TTMSFAW DM1AXZ6 TN Cannabinoid receptor 2 (CB2) DM1AXZ6 MA Agonist DM1AXZ6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DM1AXZ6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DM1BDHY DI DM1BDHY DM1BDHY DN A-68552 DM1BDHY TI TTKAPQ1 DM1BDHY TN Cholecystokinin receptor (CCKR) DM1BDHY MA Modulator DM1BDHY RN CN patent application no. 102481276, Chemosensory receptor ligand-based therapies. DM1BDHY RU http://www.google.com/patents/CN102481276A?cl=en DM1C4IG DI DM1C4IG DM1C4IG DN ICA-1 DM1C4IG TI TTWJTHX DM1C4IG TN Protein kinase C iota (PRKCI) DM1C4IG MA Inhibitor DM1C4IG RN A novel PKC- inhibitor abrogates cell proliferation and induces apoptosis in neuroblastoma. Int J Biochem Cell Biol. 2011 May;43(5):784-94. DM1C4IG RU https://pubmed.ncbi.nlm.nih.gov/21315177 DM1CG0J DI DM1CG0J DM1CG0J DN GGTI-298 DM1CG0J TI TTX20QP DM1CG0J TN Geranylgeranyl transferase I (GGTase-I) DM1CG0J MA Inhibitor DM1CG0J RN The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem. 1997 Oct 24;272(43):27224-9. DM1CG0J RU https://pubmed.ncbi.nlm.nih.gov/9341167 DM1E7H3 DI DM1E7H3 DM1E7H3 DN CS-204 DM1E7H3 TI TTZMAO3 DM1E7H3 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM1E7H3 MA Agonist DM1E7H3 RN Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137. DM1E7H3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430035/ DM1E7H3 DI DM1E7H3 DM1E7H3 DN CS-204 DM1E7H3 TI TT2JWF6 DM1E7H3 TN Peroxisome proliferator-activated receptor delta (PPARD) DM1E7H3 MA Agonist DM1E7H3 RN Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137. DM1E7H3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430035/ DM1E7H3 DI DM1E7H3 DM1E7H3 DN CS-204 DM1E7H3 TI TTJ584C DM1E7H3 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM1E7H3 MA Agonist DM1E7H3 RN Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. PPAR Res. 2008; 2008: 679137. DM1E7H3 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430035/ DM1GKTS DI DM1GKTS DM1GKTS DN SR-26831 DM1GKTS TI TTPLTSQ DM1GKTS TN Neutrophil elastase (NE) DM1GKTS MA Modulator DM1GKTS RN Biochemical and pharmacological activities of SR 26831, a potent and selective elastase inhibitor. J Pharmacol Exp Ther. 1992 Feb;260(2):809-16. DM1GKTS RU https://pubmed.ncbi.nlm.nih.gov/1738126 DM1GLIN DI DM1GLIN DM1GLIN DN A-81988 DM1GLIN TI TTGN1ZA DM1GLIN TN Angiotensin II receptor (AGTR) DM1GLIN MA Modulator DM1GLIN RN [3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994 Mar 15;267(1):49-54. DM1GLIN RU https://pubmed.ncbi.nlm.nih.gov/8206129 DM1GLIN DI DM1GLIN DM1GLIN DN A-81988 DM1GLIN TI TT8DBY3 DM1GLIN TN Angiotensin II receptor type-1 (AGTR1) DM1GLIN MA Antagonist DM1GLIN RN [3H]A-81988, a potent, selective, competitive antagonist radioligand for angiotensin AT1 receptors. Eur J Pharmacol. 1994 Mar 15;267(1):49-54. DM1GLIN RU https://pubmed.ncbi.nlm.nih.gov/8206129 DM1IO9X DI DM1IO9X DM1IO9X DN B-956 DM1IO9X TI TT7WZIJ DM1IO9X TN CAAX farnesyltransferase beta (FNTB) DM1IO9X MA Modulator DM1IO9X RN Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res. 1995 Nov 15;55(22):5310-4. DM1IO9X RU https://pubmed.ncbi.nlm.nih.gov/7585593 DM1KBAY DI DM1KBAY DM1KBAY DN A-93178 DM1KBAY TI TTDMBF5 DM1KBAY TN Arachidonate 5-lipoxygenase activating protein (FLAP) DM1KBAY MA Modulator DM1KBAY RN Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis. Adv Exp Med Biol. 1997;433:91-4. DM1KBAY RU https://pubmed.ncbi.nlm.nih.gov/9561111 DM1LGKP DI DM1LGKP DM1LGKP DN Mevastatin DM1LGKP TI TTPADOQ DM1LGKP TN HMG-CoA reductase (HMGCR) DM1LGKP MA Antagonist DM1LGKP RN Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos. 2002 Dec;30(12):1400-5. DM1LGKP RU https://pubmed.ncbi.nlm.nih.gov/12433810 DM1MBG9 DI DM1MBG9 DM1MBG9 DN CR-3124 DM1MBG9 TI TTNXLKE DM1MBG9 TN 5-HT 3 receptor (5HT3R) DM1MBG9 MA Modulator DM1MBG9 RN Physicochemical and biopharmaceutical characterization of endo-2-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-1H-benz[e]isoindol-1-one (CR312... J Pharm Sci. 2006 Dec;95(12):2706-21. DM1MBG9 RU https://www.ncbi.nlm.nih.gov/pubmed/16924684 DM1MQ6Z DI DM1MQ6Z DM1MQ6Z DN SC-102 DM1MQ6Z TI TTQBR95 DM1MQ6Z TN Stress-activated protein kinase 2a (p38 alpha) DM1MQ6Z MA Inhibitor DM1MQ6Z RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM1MQ6Z RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM1SLJ9 DI DM1SLJ9 DM1SLJ9 DN AD-5075 DM1SLJ9 TI TTZMAO3 DM1SLJ9 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM1SLJ9 MA Modulator DM1SLJ9 RN Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95. DM1SLJ9 RU https://pubmed.ncbi.nlm.nih.gov/8828476 DM1SLJ9 DI DM1SLJ9 DM1SLJ9 DN AD-5075 DM1SLJ9 TI TTT2SVW DM1SLJ9 TN PPAR-gamma messenger RNA (PPARG mRNA) DM1SLJ9 MA Agonist DM1SLJ9 RN Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95. DM1SLJ9 RU https://pubmed.ncbi.nlm.nih.gov/8828476 DM1SVQX DI DM1SVQX DM1SVQX DN BE-16627B DM1SVQX TI TT1GHVO DM1SVQX TN Matrix metalloproteinase (MMP) DM1SVQX MA Modulator DM1SVQX RN Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int J Cancer. 1999 Aug 27;82(5):743-7. DM1SVQX RU https://pubmed.ncbi.nlm.nih.gov/10417774 DM1SWOY DI DM1SWOY DM1SWOY DN MANUMYCIN A DM1SWOY TI TTXQKM3 DM1SWOY TN Farnesyl protein transferase (Ftase) DM1SWOY MA Inhibitor DM1SWOY RN A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 5;13(9):1523-6. DM1SWOY RU https://pubmed.ncbi.nlm.nih.gov/12699746 DM1SWOY DI DM1SWOY DM1SWOY DN MANUMYCIN A DM1SWOY TI TT7WZIJ DM1SWOY TN CAAX farnesyltransferase beta (FNTB) DM1SWOY MA Inhibitor DM1SWOY RN A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorg Med Chem Lett. 2003 May 5;13(9):1523-6. DM1SWOY RU https://pubmed.ncbi.nlm.nih.gov/12699746 DM1SXG9 DI DM1SXG9 DM1SXG9 DN NNC-90-0270 DM1SXG9 TI TTJSZTB DM1SXG9 TN Nicotinic acetylcholine receptor (nAChR) DM1SXG9 MA Agonist DM1SXG9 RN Nicotinic agonists, antagonists, and modulators from natural sources. Cell Mol Neurobiol. 2005 Jun;25(3-4):513-52. DM1SXG9 RU https://pubmed.ncbi.nlm.nih.gov/16075378 DM1TG3C DI DM1TG3C DM1TG3C DN Oxamflatin DM1TG3C TI TT6R7JZ DM1TG3C TN Histone deacetylase 1 (HDAC1) DM1TG3C MA Inhibitor DM1TG3C RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM1TG3C RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM1U0TB DI DM1U0TB DM1U0TB DN RPR 200765A DM1U0TB TI TTVKILB DM1U0TB TN Prostaglandin G/H synthase 2 (COX-2) DM1U0TB MA Inhibitor DM1U0TB RN The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy. Bioorg Med Chem. 2001 Feb;9(2):537-54. DM1U0TB RU https://pubmed.ncbi.nlm.nih.gov/11249145 DM1VZ2I DI DM1VZ2I DM1VZ2I DN CGS-32359 DM1VZ2I TI TTKANGO DM1VZ2I TN Complement C5 (CO5) DM1VZ2I MA Inhibitor DM1VZ2I RN Anticomplement therapy. Biologics. 2008 December; 2(4): 671-685. DM1VZ2I RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727911/ DM1XBKC DI DM1XBKC DM1XBKC DN L-731735 DM1XBKC TI TTXQKM3 DM1XBKC TN Farnesyl protein transferase (Ftase) DM1XBKC MA Inhibitor DM1XBKC RN N-Arylalkyl pseudopeptide inhibitors of farnesyltransferase. J Med Chem. 1998 Jul 2;41(14):2651-6. DM1XBKC RU https://pubmed.ncbi.nlm.nih.gov/9651171 DM1XBKC DI DM1XBKC DM1XBKC DN L-731735 DM1XBKC TI TT7WZIJ DM1XBKC TN CAAX farnesyltransferase beta (FNTB) DM1XBKC MA Inhibitor DM1XBKC RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DM1XBKC RU https://pubmed.ncbi.nlm.nih.gov/9301658 DM1XYJU DI DM1XYJU DM1XYJU DN RES-701-1 DM1XYJU TI TT3ZTGU DM1XYJU TN Endothelin B receptor (EDNRB) DM1XYJU MA Inhibitor DM1XYJU RN RES-701-1/endothelin-1 hybrid peptide having a potent binding activity for type B receptor, Bioorg. Med. Chem. Lett. 7(13):1715-1720 (1997). DM1XYJU RU http://www.sciencedirect.com/science/article/pii/S0960894X97002965 DM1Y75C DI DM1Y75C DM1Y75C DN BMS-181184 DM1Y75C TI TTXT4D5 DM1Y75C TN Bacterial Cell membrane (Bact CM) DM1Y75C MA Modulator DM1Y75C RN Antifungal Activity of the Pradimicin Derivative BMS 181184 in the Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob Agents Chemother. 1998 September; 42(9): 2399-2404. DM1Y75C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105840/ DM21Y75 DI DM21Y75 DM21Y75 DN RPR-101821 DM21Y75 TI TTFQEO5 DM21Y75 TN Squalene synthetase (FDFT1) DM21Y75 MA Modulator DM21Y75 RN RPR 101821, a new potent cholesterol-lowering agent: inhibition of squalene synthase and 7-dehydrocholesterol reductase. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):233-40. DM21Y75 RU https://pubmed.ncbi.nlm.nih.gov/8717165 DM23OHW DI DM23OHW DM23OHW DN F-12682 DM23OHW TI TTK8CXU DM23OHW TN 5-HT 1B receptor (HTR1B) DM23OHW MA Antagonist DM23OHW RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010898) DM23OHW RU http://adisinsight.springer.com/drugs/800010898 DM23YPS DI DM23YPS DM23YPS DN UK-51656 DM23YPS TI TT5HONZ DM23YPS TN Calcium channel unspecific (CaC) DM23YPS MA Modulator DM23YPS RN Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists. J Med Chem. 1990 Feb;33(2):585-91. DM23YPS RU https://pubmed.ncbi.nlm.nih.gov/2153819 DM23ZHN DI DM23ZHN DM23ZHN DN PNU156804 DM23ZHN TI TTT7PJU DM23ZHN TN Janus kinase 3 (JAK-3) DM23ZHN MA Inhibitor DM23ZHN RN Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15;99(2):680-9. DM23ZHN RU https://pubmed.ncbi.nlm.nih.gov/11781254 DM25MUA DI DM25MUA DM25MUA DN SC-56525 DM25MUA TI TTB2MXP DM25MUA TN Angiotensinogenase renin (REN) DM25MUA MA Inhibitor DM25MUA RN Effects of SC-56525, a potent, orally active renin inhibitor, in salt-depleted and renal hypertensive dogs. Hypertension. 1995 Jul;26(1):95-100. DM25MUA RU https://pubmed.ncbi.nlm.nih.gov/7607739 DM2CBTU DI DM2CBTU DM2CBTU DN SDZ-64-412 DM2CBTU TI TTQL5VC DM2CBTU TN Platelet-activating factor receptor (PTAFR) DM2CBTU MA Inhibitor DM2CBTU RN Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists. J Med Chem. 1993 Oct 15;36(21):3098-102. DM2CBTU RU https://pubmed.ncbi.nlm.nih.gov/8230095 DM2EKX5 DI DM2EKX5 DM2EKX5 DN Antalarmin DM2EKX5 TI TT7EFHR DM2EKX5 TN Corticotropin-releasing factor receptor 1 (CRHR1) DM2EKX5 MA Antagonist DM2EKX5 RN Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sci. 1999;65(4):PL53-8. DM2EKX5 RU https://pubmed.ncbi.nlm.nih.gov/10421433 DM2F4GT DI DM2F4GT DM2F4GT DN L-694247 DM2F4GT TI TT6MSOK DM2F4GT TN 5-HT 1D receptor (HTR1D) DM2F4GT MA Agonist DM2F4GT RN L-694,247: a potent 5-HT1D receptor agonist. Br J Pharmacol. 1993 Nov;110(3):1196-200. DM2F4GT RU https://pubmed.ncbi.nlm.nih.gov/8298808 DM2FNPO DI DM2FNPO DM2FNPO DN FR-901451 DM2FNPO TI TTPLTSQ DM2FNPO TN Neutrophil elastase (NE) DM2FNPO MA Inhibitor DM2FNPO RN Resisting degradation by human elastase: commonality of design features shared by 'canonical' plant and bacterial macrocyclic protease inhibitor sc... Bioorg Med Chem. 2007 Jul 1;15(13):4618-28. DM2FNPO RU https://pubmed.ncbi.nlm.nih.gov/17470393 DM2GV78 DI DM2GV78 DM2GV78 DN RP-66784 DM2GV78 TI TT1VOHK DM2GV78 TN Potassium channel unspecific (KC) DM2GV78 MA Opener DM2GV78 RN Syntheses and biological activities of potent potassium channel openers derived from (+/-)-2-oxo-1-pyridin-3-yl-cyclohexanecarbothioic acid methylamide: new potassium channel openers. J Med Chem. 1993 May 28;36(11):1604-12. DM2GV78 RU https://pubmed.ncbi.nlm.nih.gov/8496928 DM2L0VF DI DM2L0VF DM2L0VF DN KRH-2731 DM2L0VF TI TTBID49 DM2L0VF TN C-X-C chemokine receptor type 4 (CXCR4) DM2L0VF MA Binder DM2L0VF RN Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94. DM2L0VF RU https://pubmed.ncbi.nlm.nih.gov/16182193 DM2LFYD DI DM2LFYD DM2LFYD DN KB-5246 DM2LFYD TI TTN6J5F DM2LFYD TN Bacterial DNA gyrase (Bact gyrase) DM2LFYD MA Modulator DM2LFYD RN Activity of KB-5246 against outer membrane mutants of Escherichia coli and Salmonella typhimurium.. Antimicrob Agents Chemother. 1990 July; 34(7): 1323-1325. DM2LFYD RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC175974/ DM2MU98 DI DM2MU98 DM2MU98 DN NS-377 DM2MU98 TI TTAN6JD DM2MU98 TN Glutamate receptor AMPA (GRIA) DM2MU98 MA Antagonist DM2MU98 RN In vivo and in vitro evaluation of AMPA receptor antagonists in rat hippocampal neurones and cultured mouse cortical neurones. Eur J Pharmacol. 1998 Jul 24;353(2-3):159-67. DM2MU98 RU https://pubmed.ncbi.nlm.nih.gov/9726646 DM2N76V DI DM2N76V DM2N76V DN YP-008 DM2N76V TI TT9B4N3 DM2N76V TN Prostaglandin receptor (PTGR) DM2N76V MA Inhibitor DM2N76V RN CA patent application no. 841416, Method of selecting therapeutic indications. DM2N76V RU http://www.google.com/patents/CA2841416A1?cl=en DM2NHLW DI DM2NHLW DM2NHLW DN EPTALOPROST DM2NHLW TI TTOFYT1 DM2NHLW TN Prostacyclin receptor (PTGIR) DM2NHLW MA Modulator DM2NHLW RN Bioactivation of eptaloprost in animals and man. Prostaglandins. 1993 Aug;46(2):177-89. DM2NHLW RU https://pubmed.ncbi.nlm.nih.gov/7692471 DM2O8SF DI DM2O8SF DM2O8SF DN SC-53116 DM2O8SF TI TT07C3Y DM2O8SF TN 5-HT 4 receptor (HTR4) DM2O8SF MA Modulator DM2O8SF RN Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3073-5. DM2O8SF RU https://www.ncbi.nlm.nih.gov/pubmed/15149647 DM2OFBT DI DM2OFBT DM2OFBT DN Talisomycin DM2OFBT TI TTUTN1I DM2OFBT TN Human Deoxyribonucleic acid (hDNA) DM2OFBT MA Breaker DM2OFBT RN Bleomycin and talisomycin sequence-specific strand scission of DNA: a mechanism of double-strand cleavage. Cancer Res. 1982 Jul;42(7):2779-85. DM2OFBT RU https://pubmed.ncbi.nlm.nih.gov/6177398 DM2PVMZ DI DM2PVMZ DM2PVMZ DN E-0722 DM2PVMZ TI TTFBNVI DM2PVMZ TN Aldose reductase (AKR1B1) DM2PVMZ MA Modulator DM2PVMZ RN Aldose reductase inhibitors and prevention of galactose cataracts in rats. Invest Ophthalmol Vis Sci. 1989 Jul;30(7):1623-32. DM2PVMZ RU https://pubmed.ncbi.nlm.nih.gov/2545646 DM2TF9P DI DM2TF9P DM2TF9P DN BMY-40062 DM2TF9P TI TTN6J5F DM2TF9P TN Bacterial DNA gyrase (Bact gyrase) DM2TF9P MA Modulator DM2TF9P RN Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular accumulation of 11 fluoroquinolones. Antimicrob Agents Chemother. 1992 Dec;36(12):2622-7. DM2TF9P RU https://www.ncbi.nlm.nih.gov/pubmed/1336340 DM2VRK7 DI DM2VRK7 DM2VRK7 DN ONO-8711 DM2VRK7 TI TTG1QMU DM2VRK7 TN Prostaglandin E2 receptor EP1 (PTGER1) DM2VRK7 MA Antagonist DM2VRK7 RN Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4. DM2VRK7 RU https://pubmed.ncbi.nlm.nih.gov/11751431 DM2X5R6 DI DM2X5R6 DM2X5R6 DN TERIKALANT DM2X5R6 TI TT1VOHK DM2X5R6 TN Potassium channel unspecific (KC) DM2X5R6 MA Modulator DM2X5R6 RN Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. J Mol Cell Cardiol. 1998 Sep;30(9):1817-25. DM2X5R6 RU https://www.ncbi.nlm.nih.gov/pubmed/9769237 DM2XTB9 DI DM2XTB9 DM2XTB9 DN WAY-132983 DM2XTB9 TI TTZ9SOR DM2XTB9 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM2XTB9 MA Agonist DM2XTB9 RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DM2XTB9 RU https://pubmed.ncbi.nlm.nih.gov/19168056 DM314CZ DI DM314CZ DM314CZ DN REV-598 DM314CZ TI TT85JO3 DM314CZ TN 5-HT receptor (5HTR) DM314CZ MA Inhibitor DM314CZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819) DM314CZ RU http://adisinsight.springer.com/drugs/800016819 DM314CZ DI DM314CZ DM314CZ DN REV-598 DM314CZ TI TT7CXIM DM314CZ TN Histamine receptor (HR) DM314CZ MA Inhibitor DM314CZ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016819) DM314CZ RU http://adisinsight.springer.com/drugs/800016819 DM31CV2 DI DM31CV2 DM31CV2 DN NAFAZATROM DM31CV2 TI TT2J34L DM31CV2 TN Arachidonate 5-lipoxygenase (5-LOX) DM31CV2 MA Inhibitor DM31CV2 RN Design, synthesis, and 5-lipoxygenase-inhibiting properties of 1-thio-substituted butadienes. J Med Chem. 1990 Apr;33(4):1163-70. DM31CV2 RU https://pubmed.ncbi.nlm.nih.gov/2319562 DM31VE4 DI DM31VE4 DM31VE4 DN Sorbinil DM31VE4 TI TTFBNVI DM31VE4 TN Aldose reductase (AKR1B1) DM31VE4 MA Inhibitor DM31VE4 RN A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes. 1983 Oct;32(10):938-42. DM31VE4 RU https://pubmed.ncbi.nlm.nih.gov/6225686 DM31WQC DI DM31WQC DM31WQC DN Maxy-10 DM31WQC TI TT4TZ8J DM31WQC TN Interferon-beta (IFNB1) DM31WQC MA Modulator DM31WQC RN US patent application no. 8,669,257, Phenazine derivatives and uses thereof as potassium channel modulators. DM31WQC RU https://www.google.com/patents/US8669257 DM35ABD DI DM35ABD DM35ABD DN MEN-10627 DM35ABD TI TTYO0A3 DM35ABD TN Substance-K receptor (TACR2) DM35ABD MA Modulator DM35ABD RN MEN 10,627, a novel polycyclic peptide antagonist of tachykinin NK2 receptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1489-500. DM35ABD RU https://pubmed.ncbi.nlm.nih.gov/7996462 DM35LJC DI DM35LJC DM35LJC DN Anpirtoline DM35LJC TI TTK8CXU DM35LJC TN 5-HT 1B receptor (HTR1B) DM35LJC MA Modulator DM35LJC RN Effects of anpirtoline on regional serotonin synthesis in the rat brain: an autoradiographic study. Nucl Med Biol. 2006 Apr;33(3):325-32. DM35LJC RU https://pubmed.ncbi.nlm.nih.gov/16631081 DM35LJC DI DM35LJC DM35LJC DN Anpirtoline DM35LJC TI TTSQIFT DM35LJC TN 5-HT 1A receptor (HTR1A) DM35LJC MA Modulator DM35LJC RN Effects of anpirtoline on regional serotonin synthesis in the rat brain: an autoradiographic study. Nucl Med Biol. 2006 Apr;33(3):325-32. DM35LJC RU https://pubmed.ncbi.nlm.nih.gov/16631081 DM35RTJ DI DM35RTJ DM35RTJ DN NPC-16377 DM35RTJ TI TT5TPI6 DM35RTJ TN Opioid receptor sigma 1 (OPRS1) DM35RTJ MA Modulator DM35RTJ RN Effects of the selective sigma receptor ligand, 6-[6-(4-hydroxypiperidinyl)hexyloxy]-3-methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther. 1993 Aug;266(2):473-82. DM35RTJ RU https://pubmed.ncbi.nlm.nih.gov/8355185 DM36JFP DI DM36JFP DM36JFP DN R-59494 DM36JFP TI TTRK8B9 DM36JFP TN Sodium channel unspecific (NaC) DM36JFP MA Modulator DM36JFP RN Veratridine activates a silent sodium channel in rat isolated aorta. Eur J Pharmacol. 1992 Aug 25;219(2):253-9. DM36JFP RU https://pubmed.ncbi.nlm.nih.gov/1330608 DM3786U DI DM3786U DM3786U DN F-12509A DM3786U TI TTOHFIY DM3786U TN Sphingosine kinase 1 (SPHK1) DM3786U MA Inhibitor DM3786U RN F-12509A, a new sphingosine kinase inhibitor, produced by a discomycete. J Antibiot (Tokyo). 2000 May;53(5):459-66. DM3786U RU https://pubmed.ncbi.nlm.nih.gov/10908108 DM37DOC DI DM37DOC DM37DOC DN UP-275-22 DM37DOC TI TT8DBY3 DM37DOC TN Angiotensin II receptor type-1 (AGTR1) DM37DOC MA Modulator DM37DOC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34). DM37DOC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34 DM37OS4 DI DM37OS4 DM37OS4 DN FR-173657 DM37OS4 TI TTGY8IW DM37OS4 TN B2 bradykinin receptor (BDKRB2) DM37OS4 MA Inhibitor DM37OS4 RN Novel small molecule bradykinin B2 receptor antagonists. J Med Chem. 2009 Jul 23;52(14):4370-9. DM37OS4 RU https://pubmed.ncbi.nlm.nih.gov/19552431 DM385D9 DI DM385D9 DM385D9 DN Tomelukast DM385D9 TI TTGKOY9 DM385D9 TN Leukotriene CysLT1 receptor (CYSLTR1) DM385D9 MA Modulator DM385D9 RN Effects of chronic treatment with the leukotriene D4 antagonist compound LY171883 on Fischer 344 rats and rhesus monkeys. Fundam Appl Toxicol. 1990 Jan;14(1):123-30. DM385D9 RU https://www.ncbi.nlm.nih.gov/pubmed/2307311 DM39PQI DI DM39PQI DM39PQI DN CGS-9896 DM39PQI TI TTNJYV2 DM39PQI TN Gamma-aminobutyric acid receptor (GAR) DM39PQI MA Inhibitor DM39PQI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DM39PQI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DM39PQI DI DM39PQI DM39PQI DN CGS-9896 DM39PQI TI TT06RH5 DM39PQI TN GABA(A) receptor gamma-2 (GABRG2) DM39PQI MA Inhibitor DM39PQI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DM39PQI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DM39PQI DI DM39PQI DM39PQI DN CGS-9896 DM39PQI TI TTZA1NY DM39PQI TN GABA(A) receptor beta-2 (GABRB2) DM39PQI MA Inhibitor DM39PQI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DM39PQI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DM39PQI DI DM39PQI DM39PQI DN CGS-9896 DM39PQI TI TT1MPAY DM39PQI TN GABA(A) receptor alpha-1 (GABRA1) DM39PQI MA Inhibitor DM39PQI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DM39PQI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DM39SEK DI DM39SEK DM39SEK DN BE-22179 DM39SEK TI TT0IHXV DM39SEK TN DNA topoisomerase II (TOP2) DM39SEK MA Modulator DM39SEK RN A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity. J Antibiot (Tokyo). 1994 Feb;47(2):129-35. DM39SEK RU https://pubmed.ncbi.nlm.nih.gov/8150706 DM3BHN1 DI DM3BHN1 DM3BHN1 DN Etomoxir DM3BHN1 TI TTDL0NY DM3BHN1 TN Carnitine O-palmitoyltransferase I (CPT1B) DM3BHN1 MA Modulator DM3BHN1 RN Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988 Dec;63(6):1036-43. DM3BHN1 RU https://pubmed.ncbi.nlm.nih.gov/3197271 DM3D0WA DI DM3D0WA DM3D0WA DN Amidox DM3D0WA TI TTX09M4 DM3D0WA TN Ribonucleotide reductase (RIR) DM3D0WA MA Inhibitor DM3D0WA RN Metabolism of the new ribonucleotide reductase inhibitor amidox in the isolated perfused rat liver. Anticancer Res. 2000 Sep- Oct;20(5B):3521-6. DM3D0WA RU https://pubmed.ncbi.nlm.nih.gov/11131656 DM3G5IB DI DM3G5IB DM3G5IB DN Sch-40338 DM3G5IB TI TTQL5VC DM3G5IB TN Platelet-activating factor receptor (PTAFR) DM3G5IB MA Modulator DM3G5IB RN Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Bioorg Med Chem. 1999 Jul;7(7):1413-23. DM3G5IB RU https://www.ncbi.nlm.nih.gov/pubmed/10465415 DM3H90W DI DM3H90W DM3H90W DN KC-11404 DM3H90W TI TT2J34L DM3H90W TN Arachidonate 5-lipoxygenase (5-LOX) DM3H90W MA Modulator DM3H90W RN Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J Med Chem. 1995 Feb 17;38(4):669-85. DM3H90W RU https://pubmed.ncbi.nlm.nih.gov/7861415 DM3H90W DI DM3H90W DM3H90W DN KC-11404 DM3H90W TI TTQL5VC DM3H90W TN Platelet-activating factor receptor (PTAFR) DM3H90W MA Modulator DM3H90W RN Synthesis, structure-activity relationships, and pharmacological evaluation of pyrrolo[3,2,1-ij]quinoline derivatives: potent histamine and platelet activating factor antagonism and 5-lipoxygenase inhibitory properties. Potential therapeutic application in asthma. J Med Chem. 1995 Feb 17;38(4):669-85. DM3H90W RU https://pubmed.ncbi.nlm.nih.gov/7861415 DM3H921 DI DM3H921 DM3H921 DN RO-25-6981 DM3H921 TI TTN9D8E DM3H921 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM3H921 MA Antagonist DM3H921 RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DM3H921 RU https://pubmed.ncbi.nlm.nih.gov/15757410 DM3IYMF DI DM3IYMF DM3IYMF DN A-79296 DM3IYMF TI TT84ETX DM3IYMF TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3IYMF MA Modulator DM3IYMF RN US patent application no. 5,830,759, Unique associated kaposi's sarcoma virus sequences and uses thereof. DM3IYMF RU http://www.google.com/patents/US5830759 DM3JQCF DI DM3JQCF DM3JQCF DN SB-223245 DM3JQCF TI TTJA1ZO DM3JQCF TN ITGB3 messenger RNA (ITGB3 mRNA) DM3JQCF MA Inhibitor DM3JQCF RN Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6. DM3JQCF RU https://pubmed.ncbi.nlm.nih.gov/9873697 DM3JQCF DI DM3JQCF DM3JQCF DN SB-223245 DM3JQCF TI TTT1R2L DM3JQCF TN Integrin alpha-V (ITGAV) DM3JQCF MA Inhibitor DM3JQCF RN Discovery of an imidazopyridine-containing 1,4-benzodiazepine nonpeptide vitronectin receptor (alpha v beta 3) antagonist with efficacy in a resten... Bioorg Med Chem Lett. 1998 Nov 17;8(22):3171-6. DM3JQCF RU https://pubmed.ncbi.nlm.nih.gov/9873697 DM3JY2N DI DM3JY2N DM3JY2N DN NBI-37582 DM3JY2N TI TT7EFHR DM3JY2N TN Corticotropin-releasing factor receptor 1 (CRHR1) DM3JY2N MA Antagonist DM3JY2N RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DM3JY2N RU http://www.centerwatch.com/ DM3KN2Q DI DM3KN2Q DM3KN2Q DN GI-270384X DM3KN2Q TI TTCT6F7 DM3KN2Q TN Intercellular adhesion molecule ICAM-1 (ICAM1) DM3KN2Q MA Modulator DM3KN2Q RN Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96. DM3KN2Q RU https://pubmed.ncbi.nlm.nih.gov/19126181 DM3KN2Q DI DM3KN2Q DM3KN2Q DN GI-270384X DM3KN2Q TI TTAU4D6 DM3KN2Q TN E-selectin (SELE) DM3KN2Q MA Modulator DM3KN2Q RN Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96. DM3KN2Q RU https://pubmed.ncbi.nlm.nih.gov/19126181 DM3L0T1 DI DM3L0T1 DM3L0T1 DN DW-1350 DM3L0T1 TI TTN53ZF DM3L0T1 TN Leukotriene B4 receptor 1 (LTB4R) DM3L0T1 MA Modulator DM3L0T1 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026850) DM3L0T1 RU http://adisinsight.springer.com/drugs/800026850 DM3LJK5 DI DM3LJK5 DM3LJK5 DN DAA-1097 DM3LJK5 TI TTPTXIN DM3LJK5 TN Translocator protein (TSPO) DM3LJK5 MA Agonist DM3LJK5 RN Neuropharmacological profile of peripheral benzodiazepine receptor agonists, DAA1097 and DAA1106. Life Sci. 1999;64(16):1455-64. DM3LJK5 RU https://pubmed.ncbi.nlm.nih.gov/10321725 DM3M16Q DI DM3M16Q DM3M16Q DN SB-277011 DM3M16Q TI TT4C8EA DM3M16Q TN Dopamine D3 receptor (D3R) DM3M16Q MA Antagonist DM3M16Q RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM3M16Q RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM3O4BG DI DM3O4BG DM3O4BG DN BQ-518 DM3O4BG TI TTKRD0G DM3O4BG TN Endothelin A receptor (EDNRA) DM3O4BG MA Modulator DM3O4BG RN Structure-activity relationships of cyclic pentapeptide endothelin A receptor antagonists. J Med Chem. 1995 Oct 13;38(21):4309-24. DM3O4BG RU https://pubmed.ncbi.nlm.nih.gov/7473559 DM3TP8X DI DM3TP8X DM3TP8X DN BCH-2763 DM3TP8X TI TT6L509 DM3TP8X TN Coagulation factor IIa (F2) DM3TP8X MA Inhibitor DM3TP8X RN BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 1998 Feb;79(2):431-8. DM3TP8X RU https://pubmed.ncbi.nlm.nih.gov/9493603 DM3VWZF DI DM3VWZF DM3VWZF DN Org-34092 DM3VWZF TI TT6L509 DM3VWZF TN Coagulation factor IIa (F2) DM3VWZF MA Inhibitor DM3VWZF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DM3VWZF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DM3WFB5 DI DM3WFB5 DM3WFB5 DN AZD3409 DM3WFB5 TI TTXQKM3 DM3WFB5 TN Farnesyl protein transferase (Ftase) DM3WFB5 MA Inhibitor DM3WFB5 RN AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib. Breast Cancer Res Treat. 2007 May;102(3):275-82. DM3WFB5 RU https://pubmed.ncbi.nlm.nih.gov/17004112 DM3WKO5 DI DM3WKO5 DM3WKO5 DN AG490 DM3WKO5 TI TTRMX3V DM3WKO5 TN Janus kinase 2 (JAK-2) DM3WKO5 MA Inhibitor DM3WKO5 RN Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem. 2004 Aug 13;279(33):34547-52. DM3WKO5 RU https://pubmed.ncbi.nlm.nih.gov/15159394 DM3WKO5 DI DM3WKO5 DM3WKO5 DN AG490 DM3WKO5 TI TTT7PJU DM3WKO5 TN Janus kinase 3 (JAK-3) DM3WKO5 MA Inhibitor DM3WKO5 RN Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84. DM3WKO5 RU https://pubmed.ncbi.nlm.nih.gov/16978033 DM3YG5P DI DM3YG5P DM3YG5P DN GYKI-52466 DM3YG5P TI TTVPQTF DM3YG5P TN Glutamate receptor AMPA 1 (GRIA1) DM3YG5P MA Inhibitor DM3YG5P RN New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70. DM3YG5P RU https://pubmed.ncbi.nlm.nih.gov/16216501 DM3YG5P DI DM3YG5P DM3YG5P DN GYKI-52466 DM3YG5P TI TTAN6JD DM3YG5P TN Glutamate receptor AMPA (GRIA) DM3YG5P MA Inhibitor DM3YG5P RN New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70. DM3YG5P RU https://pubmed.ncbi.nlm.nih.gov/16216501 DM40ORU DI DM40ORU DM40ORU DN BAY-44-3428 DM40ORU TI TTM1TDX DM40ORU TN Tryptase alpha/beta-1 (Tryptase) DM40ORU MA Inhibitor DM40ORU RN Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire DM40ORU RU http://www.thefreelibrary.com/Axys+Pharmaceuticals+Announces+Bayer+AG's+Decision+to+Discontinue...-a062275428 DM42XHS DI DM42XHS DM42XHS DN GT-2016 DM42XHS TI TT9JNIC DM42XHS TN Histamine H3 receptor (H3R) DM42XHS MA Inhibitor DM42XHS RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DM42XHS RU https://pubmed.ncbi.nlm.nih.gov/9871722 DM46YHG DI DM46YHG DM46YHG DN R-102444 DM46YHG TI TTJQOD7 DM46YHG TN 5-HT 2A receptor (HTR2A) DM46YHG MA Modulator DM46YHG RN Effects of R-102444 and its active metabolite R-96544, selective 5-HT2A receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT2A receptors in the development of experimental pancreatitis.Eur J Pharmacol.2005 Oct 3;521(1-3):156-63. DM46YHG RU https://www.ncbi.nlm.nih.gov/pubmed/16183055 DM47MKE DI DM47MKE DM47MKE DN L-703014 DM47MKE TI TT38RM1 DM47MKE TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM47MKE MA Modulator DM47MKE RN Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. Pharm Res. 1994 Mar;11(3):426-31. DM47MKE RU https://www.ncbi.nlm.nih.gov/pubmed/8008711 DM47WS2 DI DM47WS2 DM47WS2 DN MF-8615 DM47WS2 TI TT1RS9F DM47WS2 TN Acetylcholinesterase (AChE) DM47WS2 MA Inhibitor DM47WS2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006922) DM47WS2 RU http://adisinsight.springer.com/drugs/800006922 DM48HVI DI DM48HVI DM48HVI DN JTT-551 DM48HVI TI TTMS7KP DM48HVI TN Protein-tyrosine phosphatase 1B (PTP1B) DM48HVI MA Inhibitor DM48HVI RN Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice. J Diabetes Res. 2014;2014:680348. DM48HVI RU https://pubmed.ncbi.nlm.nih.gov/24987707 DM48MCL DI DM48MCL DM48MCL DN SDZ-PSD-958 DM48MCL TI TTZFYLI DM48MCL TN Dopamine D1 receptor (D1R) DM48MCL MA Modulator DM48MCL RN SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity. J Neural Transm. 1996;103(3):261-76. DM48MCL RU https://pubmed.ncbi.nlm.nih.gov/8739838 DM4A92X DI DM4A92X DM4A92X DN MRL-953 DM4A92X TI TT51DEV DM4A92X TN Interleukin 1 receptor type 2 (IL1R2) DM4A92X MA Agonist DM4A92X RN SDZ MRL 953, a lipid A analog as selective cytokine inducer. Prog Clin Biol Res. 1995;392:549-65. DM4A92X RU https://pubmed.ncbi.nlm.nih.gov/8524963 DM4B1VF DI DM4B1VF DM4B1VF DN NP-7557 DM4B1VF TI TT1RS9F DM4B1VF TN Acetylcholinesterase (AChE) DM4B1VF MA Inhibitor DM4B1VF RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017551) DM4B1VF RU http://adisinsight.springer.com/drugs/800017551 DM4BPFV DI DM4BPFV DM4BPFV DN Doxorubicin-CEA conjugate DM4BPFV TI TTUTN1I DM4BPFV TN Human Deoxyribonucleic acid (hDNA) DM4BPFV MA Modulator DM4BPFV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4BPFV RU https://www.fda.gov/ DM4BPFV DI DM4BPFV DM4BPFV DN Doxorubicin-CEA conjugate DM4BPFV TI TT0IHXV DM4BPFV TN DNA topoisomerase II (TOP2) DM4BPFV MA Modulator DM4BPFV RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM4BPFV RU https://www.fda.gov/ DM4CNM9 DI DM4CNM9 DM4CNM9 DN SNF-9007 DM4CNM9 TI TTVFO0U DM4CNM9 TN Gastrin/cholecystokinin type B receptor (CCKBR) DM4CNM9 MA Inhibitor DM4CNM9 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM4CNM9 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM4CNM9 DI DM4CNM9 DM4CNM9 DN SNF-9007 DM4CNM9 TI TTKWM86 DM4CNM9 TN Opioid receptor mu (MOP) DM4CNM9 MA Inhibitor DM4CNM9 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM4CNM9 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM4CNM9 DI DM4CNM9 DM4CNM9 DN SNF-9007 DM4CNM9 TI TTCG0AL DM4CNM9 TN Cholecystokinin receptor type A (CCKAR) DM4CNM9 MA Inhibitor DM4CNM9 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM4CNM9 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM4CNM9 DI DM4CNM9 DM4CNM9 DN SNF-9007 DM4CNM9 TI TT27RFC DM4CNM9 TN Opioid receptor delta (OPRD1) DM4CNM9 MA Inhibitor DM4CNM9 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM4CNM9 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM4CVEG DI DM4CVEG DM4CVEG DN ONO-8815Ly DM4CVEG TI TT1ZAVI DM4CVEG TN Prostaglandin E2 receptor EP2 (PTGER2) DM4CVEG MA Agonist DM4CVEG RN Prostaglandin E2 receptor type 2-selective agonist prevents the degeneration of articular cartilage in rabbit knees with traumatic instability. Arthritis Res Ther. 2011;13(5):R146. DM4CVEG RU https://pubmed.ncbi.nlm.nih.gov/21914215 DM4ESAP DI DM4ESAP DM4ESAP DN Selenotifen DM4ESAP TI TTTIBOJ DM4ESAP TN Histamine H1 receptor (H1R) DM4ESAP MA Modulator DM4ESAP RN Effect of BN 52256 and other mediator antagonists on ouabain-induced cardiac arrhythmia in a model of anaphylaxis in guinea-pigs. Pharmacol Res. 1992 Feb-Mar;25(2):173-80. DM4ESAP RU https://pubmed.ncbi.nlm.nih.gov/1635894 DM4FNWO DI DM4FNWO DM4FNWO DN RC-01 DM4FNWO TI TT0OFWN DM4FNWO TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DM4FNWO MA Inhibitor DM4FNWO RN The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020 May;18(5):275-285. DM4FNWO RU https://pubmed.ncbi.nlm.nih.gov/31745331 DM4G0D5 DI DM4G0D5 DM4G0D5 DN MEDI-542 DM4G0D5 TI TTG84D3 DM4G0D5 TN Ephrin type-A receptor 4 (EPHA4) DM4G0D5 RN Product Pipeline Review of MedImmune, LLC in 2012. DM4G0D5 RU http://www.researchandmarkets.com/reports/2245301/medimmune_llc_product_pipeline_review_2012.pdf DM4GEUF DI DM4GEUF DM4GEUF DN BCX-25 DM4GEUF TI TTX2N1T DM4GEUF TN Transferase unspecific (TF) DM4GEUF MA Modulator DM4GEUF RN CN patent application no. 1096855, Composition produced by treatment and induction of nitrogen mono oxide synthase expressed matter, and use thereof. DM4GEUF RU http://www.google.com/patents/CN1096855C?cl=en DM4HA9C DI DM4HA9C DM4HA9C DN HydrocoDex DM4HA9C TI TT3ROYC DM4HA9C TN Serotonin transporter (SERT) DM4HA9C MA Modulator DM4HA9C RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DM4HA9C RU https://pubmed.ncbi.nlm.nih.gov/24648790 DM4HA9C DI DM4HA9C DM4HA9C DN HydrocoDex DM4HA9C TI TT5TPI6 DM4HA9C TN Opioid receptor sigma 1 (OPRS1) DM4HA9C MA Modulator DM4HA9C RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DM4HA9C RU https://pubmed.ncbi.nlm.nih.gov/24648790 DM4HRXI DI DM4HRXI DM4HRXI DN A-78773 DM4HRXI TI TT2J34L DM4HRXI TN Arachidonate 5-lipoxygenase (5-LOX) DM4HRXI MA Inhibitor DM4HRXI RN (+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-3... J Med Chem. 1998 May 21;41(11):1970-9. DM4HRXI RU https://pubmed.ncbi.nlm.nih.gov/9599246 DM4HYWR DI DM4HYWR DM4HYWR DN CP-96345 DM4HYWR TI TTZPO1L DM4HYWR TN Substance-P receptor (TACR1) DM4HYWR MA Inhibitor DM4HYWR RN 2-Aryl-1-azabicyclo[2.2.2]octanes as novel nonpeptide substance P antagonists, Bioorg. Med. Chem. Lett. 4(6):839-842 (1994). DM4HYWR RU http://www.sciencedirect.com/science/article/pii/S0960894X01808593 DM4JBQD DI DM4JBQD DM4JBQD DN DPC-333 DM4JBQD TI TT6AZXG DM4JBQD TN TNF alpha converting enzyme (ADAM17) DM4JBQD MA Inhibitor DM4JBQD RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DM4JBQD RU https://pubmed.ncbi.nlm.nih.gov/16634702 DM4JZPT DI DM4JZPT DM4JZPT DN Squalestatin 1 DM4JZPT TI TTFQEO5 DM4JZPT TN Squalene synthetase (FDFT1) DM4JZPT MA Modulator DM4JZPT RN Squalestatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem. 1992 Jun 15;267(17):11705-8. DM4JZPT RU https://pubmed.ncbi.nlm.nih.gov/1601846 DM4JZPT DI DM4JZPT DM4JZPT DN Squalestatin 1 DM4JZPT TI TTWTSCV DM4JZPT TN RAC-alpha serine/threonine-protein kinase (AKT1) DM4JZPT MA Inhibitor DM4JZPT RN Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008 Sep;4(9):538-47. DM4JZPT RU https://pubmed.ncbi.nlm.nih.gov/18641634 DM4KOTA DI DM4KOTA DM4KOTA DN UR-8328 DM4KOTA TI TT1VOHK DM4KOTA TN Potassium channel unspecific (KC) DM4KOTA MA Opener DM4KOTA RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005293) DM4KOTA RU http://adisinsight.springer.com/drugs/800005293 DM4LGPT DI DM4LGPT DM4LGPT DN SKF-81297 DM4LGPT TI TTZFYLI DM4LGPT TN Dopamine D1 receptor (D1R) DM4LGPT MA Modulator DM4LGPT RN Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys. J Pharmacol Exp Ther. 1993 Nov;267(2):765-75. DM4LGPT RU https://pubmed.ncbi.nlm.nih.gov/7902432 DM4OT0S DI DM4OT0S DM4OT0S DN BU-4601A DM4OT0S TI TT2J34L DM4OT0S TN Arachidonate 5-lipoxygenase (5-LOX) DM4OT0S MA Inhibitor DM4OT0S RN 5-Hydroxyanthranilic acid derivatives as potent 5-lipoxygenase inhibitors. J Antibiot (Tokyo). 1993 May;46(5):705-11. DM4OT0S RU https://pubmed.ncbi.nlm.nih.gov/8514624 DM4QHNG DI DM4QHNG DM4QHNG DN KRI-1314 DM4QHNG TI TTB2MXP DM4QHNG TN Angiotensinogenase renin (REN) DM4QHNG MA Inhibitor DM4QHNG RN KRI-1314: an orally effective inhibitor of human renin. Jpn J Pharmacol. 1993 Sep;63(1):109-19. DM4QHNG RU https://pubmed.ncbi.nlm.nih.gov/8271523 DM4RKDU DI DM4RKDU DM4RKDU DN GK-128 DM4RKDU TI TTNXLKE DM4RKDU TN 5-HT 3 receptor (5HT3R) DM4RKDU MA Modulator DM4RKDU RN Effect of a novel 5-hydroxytryptamine3 (5-HT3) receptor antagonist, GK-128, on 5-HT3 receptors mediating contractions and relaxations in guinea-pig distal colon. Gen Pharmacol. 1997 Sep;29(3):353-9. DM4RKDU RU https://pubmed.ncbi.nlm.nih.gov/9378239 DM4SVIR DI DM4SVIR DM4SVIR DN Sulotroban DM4SVIR TI TT2O84V DM4SVIR TN Thromboxane A2 receptor (TBXA2R) DM4SVIR MA Modulator DM4SVIR RN The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation. Prostaglandins. 1988 Dec;36(6):751-60. DM4SVIR RU https://pubmed.ncbi.nlm.nih.gov/2469101 DM4TGY0 DI DM4TGY0 DM4TGY0 DN CGP-60474 DM4TGY0 TI TTH6V3D DM4TGY0 TN Cyclin-dependent kinase 1 (CDK1) DM4TGY0 MA Inhibitor DM4TGY0 RN Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. J Med Chem. 2005 Mar 24;48(6):1886-900. DM4TGY0 RU https://pubmed.ncbi.nlm.nih.gov/15771433 DM4U72A DI DM4U72A DM4U72A DN CGS-26393 DM4U72A TI TT5TKPM DM4U72A TN Neutral endopeptidase (MME) DM4U72A MA Modulator DM4U72A RN Oral administration of an inhibitor of endothelin-converting enzyme attenuates cerebral vasospasm following experimental subarachnoid haemorrhage in rabbits. Clin Sci (Lond). 2002 Aug;103 Suppl 48:414S-417S. DM4U72A RU https://pubmed.ncbi.nlm.nih.gov/12193135 DM4U7XB DI DM4U7XB DM4U7XB DN NIK-616 DM4U7XB TI TTZ97H5 DM4U7XB TN Phosphodiesterase 4A (PDE4A) DM4U7XB MA Inhibitor DM4U7XB RN Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO). 2004 DM4U7XB RU http://adisinsight.springer.com/drugs/800020194 DM4U7XB DI DM4U7XB DM4U7XB DN NIK-616 DM4U7XB TI TTVIAT9 DM4U7XB TN Phosphodiesterase 4B (PDE4B) DM4U7XB MA Inhibitor DM4U7XB RN Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO). 2004 DM4U7XB RU http://adisinsight.springer.com/drugs/800020194 DM4U7XB DI DM4U7XB DM4U7XB DN NIK-616 DM4U7XB TI TTSKMI8 DM4U7XB TN Phosphodiesterase 4D (PDE4D) DM4U7XB MA Inhibitor DM4U7XB RN Preclinical trials in Chronic obstructive pulmonary disease in Japan (PO). 2004 DM4U7XB RU http://adisinsight.springer.com/drugs/800020194 DM4UN9A DI DM4UN9A DM4UN9A DN ABT-839 DM4UN9A TI TTXQKM3 DM4UN9A TN Farnesyl protein transferase (Ftase) DM4UN9A MA Inhibitor DM4UN9A RN Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1359-62. DM4UN9A RU https://pubmed.ncbi.nlm.nih.gov/12657282 DM4UN9A DI DM4UN9A DM4UN9A DN ABT-839 DM4UN9A TI TT7WZIJ DM4UN9A TN CAAX farnesyltransferase beta (FNTB) DM4UN9A MA Inhibitor DM4UN9A RN Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8. DM4UN9A RU https://pubmed.ncbi.nlm.nih.gov/15582430 DM4UP7R DI DM4UP7R DM4UP7R DN L-745631 DM4UP7R TI TTX20QP DM4UP7R TN Geranylgeranyl transferase I (GGTase-I) DM4UP7R MA Inhibitor DM4UP7R RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DM4UP7R RU https://pubmed.ncbi.nlm.nih.gov/9301658 DM4UP7R DI DM4UP7R DM4UP7R DN L-745631 DM4UP7R TI TT7WZIJ DM4UP7R TN CAAX farnesyltransferase beta (FNTB) DM4UP7R MA Inhibitor DM4UP7R RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DM4UP7R RU https://pubmed.ncbi.nlm.nih.gov/9301658 DM4UP7R DI DM4UP7R DM4UP7R DN L-745631 DM4UP7R TI TTXQKM3 DM4UP7R TN Farnesyl protein transferase (Ftase) DM4UP7R MA Inhibitor DM4UP7R RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DM4UP7R RU https://pubmed.ncbi.nlm.nih.gov/9301658 DM4UTXV DI DM4UTXV DM4UTXV DN AVE0675 DM4UTXV TI TTSHG0T DM4UTXV TN Toll-like receptor 9 (TLR9) DM4UTXV MA Agonist DM4UTXV RN Pharma & Vaccines. Product Development Pipeline. April 29 2009. DM4UTXV RU http://en.sanofi-aventis.com/binaries/RD_Phase_III_EN_tcm28-24007.pdf DM4VCJI DI DM4VCJI DM4VCJI DN Rovelizumab DM4VCJI TI TTD26RC DM4VCJI TN Cell adhesion molecule (CADM) DM4VCJI RN Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6. DM4VCJI RU https://pubmed.ncbi.nlm.nih.gov/16100700 DM4VY8S DI DM4VY8S DM4VY8S DN Ro-43-8857 DM4VY8S TI TTJA1ZO DM4VY8S TN ITGB3 messenger RNA (ITGB3 mRNA) DM4VY8S MA Inhibitor DM4VY8S RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DM4VY8S RU https://pubmed.ncbi.nlm.nih.gov/10999999 DM4W3MU DI DM4W3MU DM4W3MU DN CGS-18102A DM4W3MU TI TTSQIFT DM4W3MU TN 5-HT 1A receptor (HTR1A) DM4W3MU MA Modulator DM4W3MU RN Quantitative determination of CGS 18102A, a new anxiolytic, in human plasma using capillary gas chromatography/mass spectrometry. Biomed Chromatogr. 1992 Sep-Oct;6(5):244-7. DM4W3MU RU https://pubmed.ncbi.nlm.nih.gov/1361157 DM4WT7Z DI DM4WT7Z DM4WT7Z DN A-62176 DM4WT7Z TI TT4NVEM DM4WT7Z TN DNA topoisomerase II beta (TOP2B) DM4WT7Z MA Inhibitor DM4WT7Z RN Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8. DM4WT7Z RU https://pubmed.ncbi.nlm.nih.gov/9784102 DM4WT7Z DI DM4WT7Z DM4WT7Z DN A-62176 DM4WT7Z TI TT0IHXV DM4WT7Z TN DNA topoisomerase II (TOP2) DM4WT7Z MA Inhibitor DM4WT7Z RN Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model. J Med Chem. 1998 Oct 22;41(22):4273-8. DM4WT7Z RU https://pubmed.ncbi.nlm.nih.gov/9784102 DM4WUEP DI DM4WUEP DM4WUEP DN U-54494A DM4WUEP TI TTRK8B9 DM4WUEP TN Sodium channel unspecific (NaC) DM4WUEP MA Modulator DM4WUEP RN U-54494A: a unique anticonvulsant related to kappa opioid agonists. J Pharmacol Exp Ther. 1987 Nov;243(2):542-7. DM4WUEP RU https://pubmed.ncbi.nlm.nih.gov/2824750 DM4YJ2W DI DM4YJ2W DM4YJ2W DN Isomazole DM4YJ2W TI TTUST1O DM4YJ2W TN Phosphodiesterase (PDE) DM4YJ2W MA Inhibitor DM4YJ2W RN Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97. DM4YJ2W RU https://pubmed.ncbi.nlm.nih.gov/1720839 DM4YQDX DI DM4YQDX DM4YQDX DN TJN-220 DM4YQDX TI TTLWS2O DM4YQDX TN Calcitonin receptor (CALCR) DM4YQDX MA Modulator DM4YQDX RN Evaluation of the long-lasting antihypertensive action of 7-O-ethylfangchinoline. Jpn J Pharmacol. 1994 Sep;66(1):35-46. DM4YQDX RU https://pubmed.ncbi.nlm.nih.gov/7861666 DM50HB8 DI DM50HB8 DM50HB8 DN AN-10 DM50HB8 TI TTQO71U DM50HB8 TN Hemoglobin (HB) DM50HB8 MA Modulator DM50HB8 RN Genes for Development, Cell Growth and Infectious Diseases, Gabriel Gachelin, 1995. Page(215). DM50HB8 RU https://books.google.com.hk/books?id=pFFFUsab0P4C&pg=PA215&lpg=PA215&dq=%22AN-10%22+Hemoglobin&source=bl&ots=qL5psDKJAZ&sig=fpeRIeD9GtukNkelArzs80kTSAo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI-cbDu7DDyAIVzQmOCh3V2QwO#v=onepage&q=%22AN-10%22%20Hemoglobin&f=false DM5107E DI DM5107E DM5107E DN BIBS-222 DM5107E TI TTGN1ZA DM5107E TN Angiotensin II receptor (AGTR) DM5107E MA Modulator DM5107E RN Characterization of BIBS 39 and BIBS 222: two new nonpeptide angiotensin II receptor antagonists. Eur J Pharmacol. 1992 Jul 21;218(1):35-41. DM5107E RU https://pubmed.ncbi.nlm.nih.gov/1397034 DM51NI0 DI DM51NI0 DM51NI0 DN AK-295 DM51NI0 TI TTG5QB7 DM51NI0 TN Calpain-2 (CAPN2) DM51NI0 MA Inhibitor DM51NI0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336). DM51NI0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2336 DM51XDU DI DM51XDU DM51XDU DN CR-2991 DM51XDU TI TT34BHT DM51XDU TN Adrenergic receptor alpha-1D (ADRA1D) DM51XDU MA Antagonist DM51XDU RN WO patent application no. 2006,1244,90, Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia. DM51XDU RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20061123&CC=WO&NR=2006124490A2&KC=A2 DM543VY DI DM543VY DM543VY DN MOL-218 DM543VY TI TTSXVID DM543VY TN Nuclear factor NF-kappa-B (NFKB) DM543VY MA Inhibitor DM543VY RN NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br J Pharmacol. 2005 May;145(2):246-54. DM543VY RU https://pubmed.ncbi.nlm.nih.gov/15765103 DM54V0X DI DM54V0X DM54V0X DN Tamoxifen methyl iodide DM54V0X TI TTZAYWL DM54V0X TN Estrogen receptor (ESR) DM54V0X MA Inhibitor DM54V0X RN Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. DM54V0X RU https://pubmed.ncbi.nlm.nih.gov/20621492 DM56VPY DI DM56VPY DM56VPY DN L-687414 DM56VPY TI TTKJEMQ DM56VPY TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM56VPY MA Inhibitor DM56VPY RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DM56VPY RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DM56VPY DI DM56VPY DM56VPY DN L-687414 DM56VPY TI TTN9D8E DM56VPY TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM56VPY MA Inhibitor DM56VPY RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DM56VPY RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DM56VPY DI DM56VPY DM56VPY DN L-687414 DM56VPY TI TTLD29N DM56VPY TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM56VPY MA Inhibitor DM56VPY RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DM56VPY RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DM56WD3 DI DM56WD3 DM56WD3 DN Bertosamil DM56WD3 TI TTQ6VDM DM56WD3 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM56WD3 MA Modulator DM56WD3 RN Bertosamil blocks HERG potassium channels in their open and inactivated states. Br J Pharmacol. 2002 Sep;137(2):221-8. DM56WD3 RU https://pubmed.ncbi.nlm.nih.gov/12208779 DM579WS DI DM579WS DM579WS DN PSI-661 DM579WS TI TTMVBWH DM579WS TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM579WS MA Modulator DM579WS RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM579WS RU https://www.fda.gov/ DM57S3D DI DM57S3D DM57S3D DN MEN-10690 DM57S3D TI TT84ETX DM57S3D TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM57S3D MA Modulator DM57S3D RN US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. DM57S3D RU http://www.google.com/patents/US20040023290 DM57YO8 DI DM57YO8 DM57YO8 DN Protosufloxacin DM57YO8 TI TTN6J5F DM57YO8 TN Bacterial DNA gyrase (Bact gyrase) DM57YO8 MA Modulator DM57YO8 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM57YO8 RU https://www.fda.gov/ DM58PKG DI DM58PKG DM58PKG DN SB-213698 DM58PKG TI TTKWM86 DM58PKG TN Opioid receptor mu (MOP) DM58PKG MA Inhibitor DM58PKG RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DM58PKG RU https://pubmed.ncbi.nlm.nih.gov/19362480 DM58PKG DI DM58PKG DM58PKG DN SB-213698 DM58PKG TI TTQW87Y DM58PKG TN Opioid receptor kappa (OPRK1) DM58PKG MA Inhibitor DM58PKG RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DM58PKG RU https://pubmed.ncbi.nlm.nih.gov/19362480 DM58PKG DI DM58PKG DM58PKG DN SB-213698 DM58PKG TI TT27RFC DM58PKG TN Opioid receptor delta (OPRD1) DM58PKG MA Inhibitor DM58PKG RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DM58PKG RU https://pubmed.ncbi.nlm.nih.gov/19362480 DM592WE DI DM592WE DM592WE DN ALP-242 DM592WE TI TTZBFA0 DM592WE TN Protease unspecific (PRO) DM592WE MA Modulator DM592WE RN Oxidation resistant muteins of antileukoproteinase as potential therapeutic agents. Agents Actions Suppl. 1993;42:111-21. DM592WE RU https://pubmed.ncbi.nlm.nih.gov/8356918 DM5A3GX DI DM5A3GX DM5A3GX DN HRC-201 DM5A3GX TI TTQO71U DM5A3GX TN Hemoglobin (HB) DM5A3GX MA Enhancer DM5A3GX RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DM5A3GX RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DM5B72D DI DM5B72D DM5B72D DN AP22408 DM5B72D TI TT6PKBN DM5B72D TN Proto-oncogene c-Src (SRC) DM5B72D MA Inhibitor DM5B72D RN Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity. Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9373-8. DM5B72D RU https://pubmed.ncbi.nlm.nih.gov/10944210 DM5EKPM DI DM5EKPM DM5EKPM DN B-581 DM5EKPM TI TTV8ETH DM5EKPM TN Protein prenyl transferase (PPTF) DM5EKPM MA Inhibitor DM5EKPM RN Spectroscopic study of fluorescent peptides for prenyl transferase assays. J Pharm Biomed Anal. 2005 Mar 9;37(3):417-22. DM5EKPM RU https://pubmed.ncbi.nlm.nih.gov/15740898 DM5ESZU DI DM5ESZU DM5ESZU DN CGP-25454A DM5ESZU TI TTEX248 DM5ESZU TN Dopamine D2 receptor (D2R) DM5ESZU MA Modulator DM5ESZU RN CGP 25454A, a novel and selective presynaptic dopamine autoreceptor antagonist. Naunyn Schmiedebergs Arch Pharmacol. 1994 Sep;350(3):230-8. DM5ESZU RU https://pubmed.ncbi.nlm.nih.gov/7824038 DM5FEBQ DI DM5FEBQ DM5FEBQ DN CD-832 DM5FEBQ TI TT5HONZ DM5FEBQ TN Calcium channel unspecific (CaC) DM5FEBQ MA Modulator DM5FEBQ RN Effects of CD-832, a new calcium antagonist, on intracranial pressure in anesthetized dogs. Life Sci. 1998;62(19):PL283-8. DM5FEBQ RU https://pubmed.ncbi.nlm.nih.gov/9585114 DM5HMZW DI DM5HMZW DM5HMZW DN Hementin DM5HMZW TI TT6L509 DM5HMZW TN Coagulation factor IIa (F2) DM5HMZW MA Inhibitor DM5HMZW RN Hementin: anticoagulant protease from the salivary gland of the leech Haementeria ghilianii. J Lab Clin Med. 1984 Jan;103(1):44-58. DM5HMZW RU https://pubmed.ncbi.nlm.nih.gov/6361187 DM5IDAQ DI DM5IDAQ DM5IDAQ DN AC-187 DM5IDAQ TI TTAT87F DM5IDAQ TN Amylin receptor (IAPPR) DM5IDAQ MA Modulator DM5IDAQ RN Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons. J Neurosci. 2004 Jun 16;24(24):5579-84. DM5IDAQ RU https://pubmed.ncbi.nlm.nih.gov/15201330 DM5IFU9 DI DM5IFU9 DM5IFU9 DN NMI-1182 DM5IFU9 TI TTK0943 DM5IFU9 TN Prostaglandin G/H synthase (COX) DM5IFU9 MA Inhibitor DM5IFU9 RN NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology. 2005;12(5-6):521-34. DM5IFU9 RU https://pubmed.ncbi.nlm.nih.gov/16259719 DM5ITJF DI DM5ITJF DM5ITJF DN EC-154 DM5ITJF TI TT78R5H DM5ITJF TN Heat shock protein 90 alpha (HSP90A) DM5ITJF MA Inhibitor DM5ITJF RN WO patent application no. 2013,1734,36, Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status. DM5ITJF RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131121&CC=WO&NR=2013173436A1&KC=A1 DM5JDH1 DI DM5JDH1 DM5JDH1 DN SB-236049 DM5JDH1 TI TTHI19T DM5JDH1 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM5JDH1 MA Inhibitor DM5JDH1 RN Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases. Antimicrob Agents Chemother. 2002 Jun;46(6):1880-6. DM5JDH1 RU https://pubmed.ncbi.nlm.nih.gov/12019104 DM5KSCI DI DM5KSCI DM5KSCI DN ZD-7155 DM5KSCI TI TTGN1ZA DM5KSCI TN Angiotensin II receptor (AGTR) DM5KSCI MA Modulator DM5KSCI RN Comparative cardiovascular effects of the angiotensin II type 1 receptor antagonists ZD 7155 and losartan in the rat. J Pharm Pharmacol. 1996 Aug;48(8):829-33. DM5KSCI RU https://pubmed.ncbi.nlm.nih.gov/8887734 DM5MVF9 DI DM5MVF9 DM5MVF9 DN 6-nitroquipazine DM5MVF9 TI TT3ROYC DM5MVF9 TN Serotonin transporter (SERT) DM5MVF9 MA Inhibitor DM5MVF9 RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 5: 2'-Substituted 6-nitroquipazines. Bioorg Med Chem. 2007 May 15;15(10):3499-504. DM5MVF9 RU https://pubmed.ncbi.nlm.nih.gov/17376695 DM5PG6C DI DM5PG6C DM5PG6C DN BMS-182874 DM5PG6C TI TTKRD0G DM5PG6C TN Endothelin A receptor (EDNRA) DM5PG6C MA Inhibitor DM5PG6C RN Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET... J Med Chem. 2000 Aug 10;43(16):3111-7. DM5PG6C RU https://pubmed.ncbi.nlm.nih.gov/10956219 DM5SBUJ DI DM5SBUJ DM5SBUJ DN Sipoglitazar DM5SBUJ TI TTZMAO3 DM5SBUJ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM5SBUJ MA Modulator DM5SBUJ RN Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. DM5SBUJ RU https://pubmed.ncbi.nlm.nih.gov/24062180 DM5SBUJ DI DM5SBUJ DM5SBUJ DN Sipoglitazar DM5SBUJ TI TTJ584C DM5SBUJ TN Peroxisome proliferator-activated receptor alpha (PPARA) DM5SBUJ MA Modulator DM5SBUJ RN Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16. DM5SBUJ RU https://pubmed.ncbi.nlm.nih.gov/24062180 DM5VFR0 DI DM5VFR0 DM5VFR0 DN DHP-218 DM5VFR0 TI TT5HONZ DM5VFR0 TN Calcium channel unspecific (CaC) DM5VFR0 MA Modulator DM5VFR0 RN Effect of DHP-218, a novel dihydropyridine phosphonate, on atrioventricular nodal conductivity compared with its vascular effect in dogs. J Cardiovasc Pharmacol. 1987 Sep;10(3):274-9. DM5VFR0 RU https://pubmed.ncbi.nlm.nih.gov/2444774 DM5ZNSQ DI DM5ZNSQ DM5ZNSQ DN TP-20 DM5ZNSQ TI TT6ATLX DM5ZNSQ TN Complement factor I (CFI) DM5ZNSQ MA Inhibitor DM5ZNSQ RN Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol. 1999 Apr 15;162(8):4952-9. DM5ZNSQ RU https://pubmed.ncbi.nlm.nih.gov/10202042 DM5ZPQJ DI DM5ZPQJ DM5ZPQJ DN SB-206284A DM5ZPQJ TI TT5HONZ DM5ZPQJ TN Calcium channel unspecific (CaC) DM5ZPQJ MA Modulator DM5ZPQJ RN The effects of SB 206284A, a novel neuronal calcium-channel antagonist, in models of cerebral ischemia. J Cereb Blood Flow Metab. 1997 Apr;17(4):421-9. DM5ZPQJ RU https://pubmed.ncbi.nlm.nih.gov/9143224 DM61AV4 DI DM61AV4 DM61AV4 DN ADX415 DM61AV4 TI TTQ8AFT DM61AV4 TN Adrenergic receptor Alpha-2 (ADRA2) DM61AV4 MA Antagonist DM61AV4 RN Clinical pipeline report, company report or official report of Shionogi (2011). DM61AV4 RU http://www.shionogi.co.jp/index_e.html DM61BWZ DI DM61BWZ DM61BWZ DN Diaspirin crosslinked hemoglobin DM61BWZ TI TTQO71U DM61BWZ TN Hemoglobin (HB) DM61BWZ MA Modulator DM61BWZ RN Diaspirin cross-linked hemoglobin infusion did not influence base deficit and lactic acid levels in two clinical trials of traumatic hemorrhagic shock patient resuscitation. J Trauma. 2010 May;68(5):1158-71. DM61BWZ RU https://pubmed.ncbi.nlm.nih.gov/20145575 DM61NFD DI DM61NFD DM61NFD DN PD-157667 DM61NFD TI TT4FDG6 DM61NFD TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM61NFD MA Inhibitor DM61NFD RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DM61NFD RU https://pubmed.ncbi.nlm.nih.gov/10476885 DM61RGQ DI DM61RGQ DM61RGQ DN RDEA-640 DM61RGQ TI TT84ETX DM61RGQ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM61RGQ MA Inhibitor DM61RGQ RN WO patent application no. 2008,0165,22, Novel hiv reverse transcriptase inhibitors. DM61RGQ RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20080207&CC=WO&NR=2008016522A2&KC=A2 DM625LN DI DM625LN DM625LN DN AG-041R DM625LN TI TTVFO0U DM625LN TN Gastrin/cholecystokinin type B receptor (CCKBR) DM625LN MA Modulator DM625LN RN AG-041R, a gastrin/CCK-B antagonist, stimulates chondrocyte proliferation and metabolism in vitro. Biochem Biophys Res Commun. 2001 May 25;283(5):1118-23. DM625LN RU https://pubmed.ncbi.nlm.nih.gov/11355888 DM63O4F DI DM63O4F DM63O4F DN PURPUROGALLIN DM63O4F TI TT2IYXF DM63O4F TN L-selectin (SELL) DM63O4F MA Inhibitor DM63O4F RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DM63O4F RU https://pubmed.ncbi.nlm.nih.gov/17302397 DM63O4F DI DM63O4F DM63O4F DN PURPUROGALLIN DM63O4F TI TTE5VG0 DM63O4F TN P-selectin (SELP) DM63O4F MA Inhibitor DM63O4F RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DM63O4F RU https://pubmed.ncbi.nlm.nih.gov/17302397 DM63O4F DI DM63O4F DM63O4F DN PURPUROGALLIN DM63O4F TI TTRE6AX DM63O4F TN Bcl-x messenger RNA (BCL2L1 mRNA) DM63O4F MA Inhibitor DM63O4F RN Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003 Sep 25;46(20):4259-64. DM63O4F RU https://pubmed.ncbi.nlm.nih.gov/13678404 DM63OD7 DI DM63OD7 DM63OD7 DN Pifithrin-alpha DM63OD7 TI TT7SBF5 DM63OD7 TN Cellular tumor antigen p53 (TP53) DM63OD7 MA Inhibitor DM63OD7 RN An evaluation of the ability of pifithrin-alpha and -beta to inhibit p53 function in two wild-type p53 human tumor cell lines. Mol Cancer Ther. 2005 Sep;4(9):1369-77. DM63OD7 RU https://pubmed.ncbi.nlm.nih.gov/16170029 DM64YJW DI DM64YJW DM64YJW DN Amitivir DM64YJW TI TTIU7X1 DM64YJW TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM64YJW MA Modulator DM64YJW RN Approaches and strategies for the treatment of influenza virus infections. Antivir Chem Chemother. 1999 Jul;10(4):155-85. DM64YJW RU https://pubmed.ncbi.nlm.nih.gov/10480736 DM679IY DI DM679IY DM679IY DN LZ-8 DM679IY TI TTISGCA DM679IY TN Toll-like receptor 4 (TLR4) DM679IY MA Modulator DM679IY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DM679IY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DM67VDK DI DM67VDK DM67VDK DN DPC-A78277 DM67VDK TI TT84ETX DM67VDK TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM67VDK MA Inhibitor DM67VDK RN The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Dispos. 2004 Dec;32(12):1359-69. DM67VDK RU https://pubmed.ncbi.nlm.nih.gov/15333515 DM69EHF DI DM69EHF DM69EHF DN BAY-793 DM69EHF TI TT5FNQT DM69EHF TN Human immunodeficiency virus Protease (HIV PR) DM69EHF MA Modulator DM69EHF RN HIV protease inhibitor HOE/BAY 793, structure-activity relationships in a series of C2-symmetric diols. Bioorg Med Chem. 1995 May;3(5):559-71. DM69EHF RU https://pubmed.ncbi.nlm.nih.gov/7648204 DM69YWS DI DM69YWS DM69YWS DN CGP-40215A DM69YWS TI TTBFROQ DM69YWS TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DM69YWS MA Modulator DM69YWS RN Antileishmanial effect of a potent S-adenosylmethionine decarboxylase inhibitor: CGP 40215A. Pharmacol Res. 1996 Jan;33(1):67-70. DM69YWS RU https://pubmed.ncbi.nlm.nih.gov/8817649 DM6ASLF DI DM6ASLF DM6ASLF DN SR-80027A DM6ASLF TI TT6L509 DM6ASLF TN Coagulation factor IIa (F2) DM6ASLF MA Inhibitor DM6ASLF RN Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood. 1994 Oct 15;84(8):2571-7. DM6ASLF RU https://pubmed.ncbi.nlm.nih.gov/7919374 DM6C7WJ DI DM6C7WJ DM6C7WJ DN UR-8308 DM6C7WJ TI TT1VOHK DM6C7WJ TN Potassium channel unspecific (KC) DM6C7WJ MA Opener DM6C7WJ RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005294) DM6C7WJ RU http://adisinsight.springer.com/drugs/800005294 DM6CSRU DI DM6CSRU DM6CSRU DN A-131701 DM6CSRU TI TTNGILX DM6CSRU TN Adrenergic receptor alpha-1A (ADRA1A) DM6CSRU MA Inhibitor DM6CSRU RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DM6CSRU RU https://pubmed.ncbi.nlm.nih.gov/15664832 DM6EJVF DI DM6EJVF DM6EJVF DN Droxinavir hydrochloride DM6EJVF TI TT5FNQT DM6EJVF TN Human immunodeficiency virus Protease (HIV PR) DM6EJVF MA Modulator DM6EJVF RN A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob Agents Chemother. 1997 Mar;41(3):515-22. DM6EJVF RU https://pubmed.ncbi.nlm.nih.gov/9055985 DM6ETM8 DI DM6ETM8 DM6ETM8 DN BB-2275 DM6ETM8 TI TTZXH48 DM6ETM8 TN TNF receptor (TNFR) DM6ETM8 MA Modulator DM6ETM8 RN Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA sy... J Clin Invest. 1996 Jun 15;97(12):2833-41. DM6ETM8 RU https://www.ncbi.nlm.nih.gov/pubmed/8675695 DM6F8L5 DI DM6F8L5 DM6F8L5 DN Clinafloxacin DM6F8L5 TI TTN6J5F DM6F8L5 TN Bacterial DNA gyrase (Bact gyrase) DM6F8L5 MA Modulator DM6F8L5 RN DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998 Nov;42(11):2810-6. DM6F8L5 RU https://pubmed.ncbi.nlm.nih.gov/9797208 DM6HBQJ DI DM6HBQJ DM6HBQJ DN Patamostat DM6HBQJ TI TT2WR1T DM6HBQJ TN Cationic trypsinogen (PRSS1) DM6HBQJ MA Modulator DM6HBQJ RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DM6HBQJ RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DM6HJX7 DI DM6HJX7 DM6HJX7 DN RP-66364 DM6HJX7 TI TTN53ZF DM6HJX7 TN Leukotriene B4 receptor 1 (LTB4R) DM6HJX7 MA Modulator DM6HJX7 RN WO patent application no. 1997,0297,75, Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist. DM6HJX7 RU http://www.google.com/patents/WO1997029775A1?cl=en DM6HJX7 DI DM6HJX7 DM6HJX7 DN RP-66364 DM6HJX7 TI TTK0943 DM6HJX7 TN Prostaglandin G/H synthase (COX) DM6HJX7 MA Modulator DM6HJX7 RN WO patent application no. 1997,0297,75, Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist. DM6HJX7 RU http://www.google.com/patents/WO1997029775A1?cl=en DM6HZU1 DI DM6HZU1 DM6HZU1 DN GI-197111 DM6HZU1 TI TT2A0DR DM6HZU1 TN Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A) DM6HZU1 MA Modulator DM6HZU1 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008867) DM6HZU1 RU http://adisinsight.springer.com/drugs/800008867 DM6IGRL DI DM6IGRL DM6IGRL DN DARGLITAZONE DM6IGRL TI TTZMAO3 DM6IGRL TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM6IGRL MA Agonist DM6IGRL RN The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse. J Cereb Blood Flow Metab. 2010 February; 30(2): 352-360. DM6IGRL RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949120/ DM6IY4M DI DM6IY4M DM6IY4M DN Epiroprim DM6IY4M TI TTV8DM2 DM6IY4M TN Bacterial Dihydrofolate reductase (Bact DHFR) DM6IY4M MA Modulator DM6IY4M RN In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium ... Int J Antimicrob Agents. 1999 Aug;12(4):319-23. DM6IY4M RU https://www.ncbi.nlm.nih.gov/pubmed/10493608 DM6JNV3 DI DM6JNV3 DM6JNV3 DN Genevx DM6JNV3 TI TTVJ1D8 DM6JNV3 TN Vascular endothelial growth factor receptor (VEGFR) DM6JNV3 MA Modulator DM6JNV3 RN Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury. Circulation. 2005; 112: 2477-2486. DM6JNV3 RU http://circ.ahajournals.org/content/112/16/2477.figures-only?sid=d5a20876-08aa-4d32-9f57-765c26558bd6 DM6JO30 DI DM6JO30 DM6JO30 DN Rogletimide DM6JO30 TI TTSZLWK DM6JO30 TN Aromatase (CYP19A1) DM6JO30 MA Inhibitor DM6JO30 RN Analogues of 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione as selective inhibitors of aromatase: derivatives with variable 1-alkyl and 3-alkyl substitu... J Med Chem. 1987 Sep;30(9):1550-4. DM6JO30 RU https://pubmed.ncbi.nlm.nih.gov/3625703 DM6KRJW DI DM6KRJW DM6KRJW DN BEA-005 DM6KRJW TI TT84ETX DM6KRJW TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6KRJW MA Modulator DM6KRJW RN Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2). J Virol. 2000 October; 74(20): 9771-9775. DM6KRJW RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC112413/ DM6LP0R DI DM6LP0R DM6LP0R DN Dianicline+rimonabant DM6LP0R TI TTEX248 DM6LP0R TN Dopamine D2 receptor (D2R) DM6LP0R MA Antagonist DM6LP0R RN Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem. 2003 Nov;87(3):631-41. DM6LP0R RU https://pubmed.ncbi.nlm.nih.gov/14535946 DM6LP0R DI DM6LP0R DM6LP0R DN Dianicline+rimonabant DM6LP0R TI TT4C8EA DM6LP0R TN Dopamine D3 receptor (D3R) DM6LP0R MA Antagonist DM6LP0R RN Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem. 2003 Nov;87(3):631-41. DM6LP0R RU https://pubmed.ncbi.nlm.nih.gov/14535946 DM6LP0R DI DM6LP0R DM6LP0R DN Dianicline+rimonabant DM6LP0R TI TTJSZTB DM6LP0R TN Nicotinic acetylcholine receptor (nAChR) DM6LP0R MA Agonist DM6LP0R RN Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs. 2009 Mar;14(1):23-32. DM6LP0R RU https://pubmed.ncbi.nlm.nih.gov/19278367 DM6LP0R DI DM6LP0R DM6LP0R DN Dianicline+rimonabant DM6LP0R TI TT6OEDT DM6LP0R TN Cannabinoid receptor 1 (CB1) DM6LP0R MA Agonist DM6LP0R RN Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs. 2009 Mar;14(1):23-32. DM6LP0R RU https://pubmed.ncbi.nlm.nih.gov/19278367 DM6M9GC DI DM6M9GC DM6M9GC DN ZD-3638 DM6M9GC TI TTJQOD7 DM6M9GC TN 5-HT 2A receptor (HTR2A) DM6M9GC MA Binder DM6M9GC RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM6M9GC RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM6M9GC DI DM6M9GC DM6M9GC DN ZD-3638 DM6M9GC TI TTS2PH3 DM6M9GC TN Dopamine D5 receptor (D5R) DM6M9GC MA Binder DM6M9GC RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM6M9GC RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM6M9GC DI DM6M9GC DM6M9GC DN ZD-3638 DM6M9GC TI TTEX248 DM6M9GC TN Dopamine D2 receptor (D2R) DM6M9GC MA Binder DM6M9GC RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM6M9GC RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM6MEX4 DI DM6MEX4 DM6MEX4 DN CGS-12066B DM6MEX4 TI TTK8CXU DM6MEX4 TN 5-HT 1B receptor (HTR1B) DM6MEX4 MA Modulator DM6MEX4 RN Biochemical and pharmacological characterization of CGS 12066B, a selective serotonin-1B agonist. Eur J Pharmacol. 1987 Apr 7;136(1):1-9. DM6MEX4 RU https://www.ncbi.nlm.nih.gov/pubmed/3496228 DM6MSKT DI DM6MSKT DM6MSKT DN SIB-1765F DM6MSKT TI TTJSZTB DM6MSKT TN Nicotinic acetylcholine receptor (nAChR) DM6MSKT MA Agonist DM6MSKT RN Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats. J Pharmacol Exp Ther. 1997 Jan;280(1):393-401. DM6MSKT RU https://pubmed.ncbi.nlm.nih.gov/8996220 DM6OIJ1 DI DM6OIJ1 DM6OIJ1 DN Flosulide DM6OIJ1 TI TTVKILB DM6OIJ1 TN Prostaglandin G/H synthase 2 (COX-2) DM6OIJ1 MA Modulator DM6OIJ1 RN Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney Int. 1999 Nov;56(5):1770-8. DM6OIJ1 RU https://pubmed.ncbi.nlm.nih.gov/10571785 DM6PFVD DI DM6PFVD DM6PFVD DN FR-901277 DM6PFVD TI TTPLTSQ DM6PFVD TN Neutrophil elastase (NE) DM6PFVD MA Inhibitor DM6PFVD RN Resisting degradation by human elastase: commonality of design features shared by 'canonical' plant and bacterial macrocyclic protease inhibitor sc... Bioorg Med Chem. 2007 Jul 1;15(13):4618-28. DM6PFVD RU https://pubmed.ncbi.nlm.nih.gov/17470393 DM6Q05K DI DM6Q05K DM6Q05K DN Dotarizine DM6Q05K TI TTYSN63 DM6Q05K TN 5-HT 2 receptor (5HT2R) DM6Q05K MA Modulator DM6Q05K RN Vasostabilizing effect of Dotarizine (Ca(2+)-channel blocker) on cerebrovascular reactivity in rabbits. Neurol Res. 2000 Mar;22(2):229-32. DM6Q05K RU https://pubmed.ncbi.nlm.nih.gov/10763515 DM6QT9P DI DM6QT9P DM6QT9P DN BIBB-515 DM6QT9P TI TT7O8ZA DM6QT9P TN Lanosterol synthase (LSS) DM6QT9P MA Modulator DM6QT9P RN Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75. DM6QT9P RU https://pubmed.ncbi.nlm.nih.gov/9101437 DM6RVXU DI DM6RVXU DM6RVXU DN SK-951 DM6RVXU TI TT07C3Y DM6RVXU TN 5-HT 4 receptor (HTR4) DM6RVXU MA Agonist DM6RVXU RN Identification of SK-951, a novel benzofuran derivative, as an agonist to 5-HT4 receptors. Jpn J Pharmacol. 1999 Feb;79(2):203-12. DM6RVXU RU https://pubmed.ncbi.nlm.nih.gov/10202856 DM6SW2R DI DM6SW2R DM6SW2R DN SQ-26332 DM6SW2R TI TT5TKPM DM6SW2R TN Neutral endopeptidase (MME) DM6SW2R MA Inhibitor DM6SW2R RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DM6SW2R RU https://pubmed.ncbi.nlm.nih.gov/16220969 DM6SW2R DI DM6SW2R DM6SW2R DN SQ-26332 DM6SW2R TI TTL69WB DM6SW2R TN Angiotensin-converting enzyme (ACE) DM6SW2R MA Inhibitor DM6SW2R RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DM6SW2R RU https://pubmed.ncbi.nlm.nih.gov/16220969 DM6TXKR DI DM6TXKR DM6TXKR DN JTP-4761 DM6TXKR TI TTB2MXP DM6TXKR TN Angiotensinogenase renin (REN) DM6TXKR MA Inhibitor DM6TXKR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005981) DM6TXKR RU http://adisinsight.springer.com/drugs/800005981 DM6UYN1 DI DM6UYN1 DM6UYN1 DN MEN-10979 DM6UYN1 TI TT84ETX DM6UYN1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6UYN1 MA Modulator DM6UYN1 RN New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase. Antiviral Res. 1996 May;30(2-3):109-24. DM6UYN1 RU https://pubmed.ncbi.nlm.nih.gov/8783803 DM6WQ8F DI DM6WQ8F DM6WQ8F DN BE-13793C DM6WQ8F TI TTGTQHC DM6WQ8F TN DNA topoisomerase I (TOP1) DM6WQ8F MA Modulator DM6WQ8F RN DOI: 10.1002/3527601783.ch20 DM6WQ8F RU http://onlinelibrary.wiley.com/doi/10.1002/3527601783.ch20/pdf DM6X430 DI DM6X430 DM6X430 DN SJA-6017 DM6X430 TI TTG5QB7 DM6X430 TN Calpain-2 (CAPN2) DM6X430 MA Inhibitor DM6X430 RN Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6911-23. DM6X430 RU https://pubmed.ncbi.nlm.nih.gov/18571418 DM6X4IT DI DM6X4IT DM6X4IT DN MDL-28133A DM6X4IT TI TTYSN63 DM6X4IT TN 5-HT 2 receptor (5HT2R) DM6X4IT MA Modulator DM6X4IT RN Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs. J Cardiovasc Pharmacol. 1994 Nov;24(5):761-72. DM6X4IT RU https://pubmed.ncbi.nlm.nih.gov/7532754 DM6Y49D DI DM6Y49D DM6Y49D DN L-NIL DM6Y49D TI TTF10I9 DM6Y49D TN Nitric-oxide synthase inducible (NOS2) DM6Y49D MA Inhibitor DM6Y49D RN Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43. DM6Y49D RU https://pubmed.ncbi.nlm.nih.gov/18024030 DM6Y49D DI DM6Y49D DM6Y49D DN L-NIL DM6Y49D TI TTZUFI5 DM6Y49D TN Nitric-oxide synthase brain (NOS1) DM6Y49D MA Inhibitor DM6Y49D RN Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43. DM6Y49D RU https://pubmed.ncbi.nlm.nih.gov/18024030 DM6Y49D DI DM6Y49D DM6Y49D DN L-NIL DM6Y49D TI TTCM4B3 DM6Y49D TN Nitric-oxide synthase endothelial (NOS3) DM6Y49D MA Inhibitor DM6Y49D RN Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43. DM6Y49D RU https://pubmed.ncbi.nlm.nih.gov/18024030 DM70HZD DI DM70HZD DM70HZD DN Zonampanel DM70HZD TI TTVPQTF DM70HZD TN Glutamate receptor AMPA 1 (GRIA1) DM70HZD MA Inhibitor DM70HZD RN Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11. DM70HZD RU https://pubmed.ncbi.nlm.nih.gov/15380209 DM70HZD DI DM70HZD DM70HZD DN Zonampanel DM70HZD TI TTAN6JD DM70HZD TN Glutamate receptor AMPA (GRIA) DM70HZD MA Inhibitor DM70HZD RN Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11. DM70HZD RU https://pubmed.ncbi.nlm.nih.gov/15380209 DM70TKB DI DM70TKB DM70TKB DN zoxazolamine DM70TKB TI TT2T5M0 DM70TKB TN Calcium-activated potassium channel KCa2.2 (KCNN2) DM70TKB MA Activator DM70TKB RN Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. J Pharmacol Exp Ther. 2001 Mar;296(3):683-9. DM70TKB RU https://pubmed.ncbi.nlm.nih.gov/11181893 DM72MQP DI DM72MQP DM72MQP DN MF-5137 DM72MQP TI TTN6J5F DM72MQP TN Bacterial DNA gyrase (Bact gyrase) DM72MQP MA Modulator DM72MQP RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM72MQP RU https://www.fda.gov/ DM73EPK DI DM73EPK DM73EPK DN Vapaliximab DM73EPK TI TT7HC21 DM73EPK TN Membrane copper amine oxidase (AOC3) DM73EPK RN Clinical pipeline report, company report or official report of Huginonline. DM73EPK RU http://reports.huginonline.com/845929/98523.pdf DM759KX DI DM759KX DM759KX DN S-14080 DM759KX TI TTK0943 DM759KX TN Prostaglandin G/H synthase (COX) DM759KX MA Modulator DM759KX RN US patent application no. 7,022,689, 5-amidino-n-(2-aminophenethyl)-n-hydroxy-benzenesulffonamide derivative, medical composition containing the same, pharmaceutical use thereof and intermediate therefor. DM759KX RU http://www.google.com/patents/US7022689 DM75DZ1 DI DM75DZ1 DM75DZ1 DN NS-1546 DM75DZ1 TI TT1VOHK DM75DZ1 TN Potassium channel unspecific (KC) DM75DZ1 MA Opener DM75DZ1 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006187) DM75DZ1 RU http://adisinsight.springer.com/drugs/800006187 DM75KBM DI DM75KBM DM75KBM DN CB-1267 DM75KBM TI TTK59TV DM75KBM TN Vitamin D3 receptor (VDR) DM75KBM MA Modulator DM75KBM RN Novel 20-epi-vitamin D3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate. 1999 Aug 1;40(3):141-9. DM75KBM RU https://pubmed.ncbi.nlm.nih.gov/10398275 DM784QJ DI DM784QJ DM784QJ DN Hirufaxin DM784QJ TI TTCIHJA DM784QJ TN Coagulation factor Xa (F10) DM784QJ MA Inhibitor DM784QJ RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DM784QJ RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM78P4X DI DM78P4X DM78P4X DN NOX-200 DM78P4X TI TT5U0XA DM78P4X TN Solute carrier family 36 member 2 (SLC36A2) DM78P4X MA Inhibitor DM78P4X RN Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2). Biochim Biophys Acta. 2011 Jan;1808(1):260-70. DM78P4X RU https://pubmed.ncbi.nlm.nih.gov/20691150 DM78P4X DI DM78P4X DM78P4X DN NOX-200 DM78P4X TI TTB6H2S DM78P4X TN Amino acid transporter ATB0+ (SLC6A14) DM78P4X MA Inhibitor DM78P4X RN Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J. 2008 Sep 15;414(3):343-55. DM78P4X RU https://pubmed.ncbi.nlm.nih.gov/18522536 DM79E6W DI DM79E6W DM79E6W DN Saviprazole DM79E6W TI TTLOKXP DM79E6W TN Gastric H(+)/K(+) ATPase (Proton pump) DM79E6W MA Modulator DM79E6W RN Gastric acid inhibitory profile of saviprazole (HOE 731) compared to omeprazole. Pharmacology. 1991;43(6):293-303. DM79E6W RU https://pubmed.ncbi.nlm.nih.gov/1664524 DM7AUF2 DI DM7AUF2 DM7AUF2 DN Ro-48-5545 DM7AUF2 TI TTHI19T DM7AUF2 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM7AUF2 MA Inhibitor DM7AUF2 RN Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother. 1997 Sep;40(3):335-43. DM7AUF2 RU https://pubmed.ncbi.nlm.nih.gov/9338484 DM7B2WH DI DM7B2WH DM7B2WH DN Ro-23-7777 DM7B2WH TI TTN6J5F DM7B2WH TN Bacterial DNA gyrase (Bact gyrase) DM7B2WH MA Modulator DM7B2WH RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7B2WH RU https://www.fda.gov/ DM7CY0T DI DM7CY0T DM7CY0T DN RHb1.1 DM7CY0T TI TTQO71U DM7CY0T TN Hemoglobin (HB) DM7CY0T MA Modulator DM7CY0T RN Effects of recombinant-hemoglobin solutions rHb2.0 and rHb1.1 on blood pressure, intestinal blood flow, and gut oxygenation in a rat model of hemorrhagic shock. J Lab Clin Med. 2005 Jan;145(1):21-32. DM7CY0T RU https://pubmed.ncbi.nlm.nih.gov/15668658 DM7F94W DI DM7F94W DM7F94W DN UR-12670 DM7F94W TI TT27K59 DM7F94W TN Platelet activating factor (PAF) DM7F94W MA Inhibitor DM7F94W RN Long-term protective effect of UR-12670 after warm renal ischemia in uninephrectomized rats. Kidney Int. 1999 Nov;56(5):1798-808. DM7F94W RU https://pubmed.ncbi.nlm.nih.gov/10571788 DM7FI3S DI DM7FI3S DM7FI3S DN A-72055 DM7FI3S TI TTOXS3C DM7FI3S TN Muscarinic acetylcholine receptor (CHRM) DM7FI3S MA Modulator DM7FI3S RN US patent application no. 2011,0020,423, Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation. DM7FI3S RU http://www.google.com.ar/patents/US20110020423 DM7FTCV DI DM7FTCV DM7FTCV DN D-22888 DM7FTCV TI TTZ97H5 DM7FTCV TN Phosphodiesterase 4A (PDE4A) DM7FTCV MA Inhibitor DM7FTCV RN Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther. 1998 Feb;11(1):13-21. DM7FTCV RU https://pubmed.ncbi.nlm.nih.gov/9802959 DM7FTCV DI DM7FTCV DM7FTCV DN D-22888 DM7FTCV TI TTSKMI8 DM7FTCV TN Phosphodiesterase 4D (PDE4D) DM7FTCV MA Modulator DM7FTCV RN Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther. 1998 Feb;11(1):13-21. DM7FTCV RU https://pubmed.ncbi.nlm.nih.gov/9802959 DM7FTCV DI DM7FTCV DM7FTCV DN D-22888 DM7FTCV TI TTVIAT9 DM7FTCV TN Phosphodiesterase 4B (PDE4B) DM7FTCV MA Modulator DM7FTCV RN Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm Pharmacol Ther. 1998 Feb;11(1):13-21. DM7FTCV RU https://pubmed.ncbi.nlm.nih.gov/9802959 DM7GH5Z DI DM7GH5Z DM7GH5Z DN BB-1101 DM7GH5Z TI TTMX39J DM7GH5Z TN Matrix metalloproteinase-1 (MMP-1) DM7GH5Z MA Inhibitor DM7GH5Z RN Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8. DM7GH5Z RU https://pubmed.ncbi.nlm.nih.gov/9873367 DM7GH5Z DI DM7GH5Z DM7GH5Z DN BB-1101 DM7GH5Z TI TTLM12X DM7GH5Z TN Matrix metalloproteinase-2 (MMP-2) DM7GH5Z MA Inhibitor DM7GH5Z RN Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8. DM7GH5Z RU https://pubmed.ncbi.nlm.nih.gov/9873367 DM7GH5Z DI DM7GH5Z DM7GH5Z DN BB-1101 DM7GH5Z TI TTUZ2L5 DM7GH5Z TN Matrix metalloproteinase-3 (MMP-3) DM7GH5Z MA Inhibitor DM7GH5Z RN Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8. DM7GH5Z RU https://pubmed.ncbi.nlm.nih.gov/9873367 DM7GH5Z DI DM7GH5Z DM7GH5Z DN BB-1101 DM7GH5Z TI TTGA1IV DM7GH5Z TN Matrix metalloproteinase-8 (MMP-8) DM7GH5Z MA Inhibitor DM7GH5Z RN New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. J Med Chem. 1999 Nov 18;42(23):4890-908. DM7GH5Z RU https://pubmed.ncbi.nlm.nih.gov/10579851 DM7HAE9 DI DM7HAE9 DM7HAE9 DN Ralitoline DM7HAE9 TI TTRK8B9 DM7HAE9 TN Sodium channel unspecific (NaC) DM7HAE9 MA Modulator DM7HAE9 RN Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Naunyn Schmiedebergs Arch Pharmacol. 1992 Oct;346(4):442-52. DM7HAE9 RU https://pubmed.ncbi.nlm.nih.gov/1331817 DM7I6VO DI DM7I6VO DM7I6VO DN SC-241 DM7I6VO TI TTIY658 DM7I6VO TN Corticotropin-releasing factor receptor 2 (CRHR2) DM7I6VO MA Modulator DM7I6VO RN US patent application no. 2015,0094,310, Crhr1 antagonists for use in the treatment of patients having crh overactivity. DM7I6VO RU http://www.google.com.ar/patents/US20150094310 DM7IXH3 DI DM7IXH3 DM7IXH3 DN MINAMESTANE DM7IXH3 TI TTSZLWK DM7IXH3 TN Aromatase (CYP19A1) DM7IXH3 MA Inhibitor DM7IXH3 RN High-performance liquid chromatographic determination of FCE 24928, a new aromatase inhibitor, in human plasma. J Chromatogr A. 1994 Feb 4;660(1-2):293-8. DM7IXH3 RU https://pubmed.ncbi.nlm.nih.gov/8148992 DM7J6QH DI DM7J6QH DM7J6QH DN L-768277 DM7J6QH TI TTVKILB DM7J6QH TN Prostaglandin G/H synthase 2 (COX-2) DM7J6QH MA Modulator DM7J6QH RN Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766,112. Bioorganic & Medicinal Chemistry Letters Volume 7, Issue 1, 7 January 1997, Pages 53-56. DM7J6QH RU http://www.sciencedirect.com/science/article/pii/S0960894X96005811 DM7J8IO DI DM7J8IO DM7J8IO DN IPH-3201 DM7J8IO TI TTRJ1K4 DM7J8IO TN Toll-like receptor 7 (TLR7) DM7J8IO MA Modulator DM7J8IO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757). DM7J8IO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757 DM7JT3D DI DM7JT3D DM7JT3D DN Fluoratec DM7JT3D TI TTVBI8W DM7JT3D TN Dopamine transporter (DAT) DM7JT3D MA Modulator DM7JT3D RN Technepine: a high-affinity 99m-technetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse. 1996 Mar;22(3):239-46. DM7JT3D RU https://pubmed.ncbi.nlm.nih.gov/9132992 DM7LAXF DI DM7LAXF DM7LAXF DN AP-227 DM7LAXF TI TTOFYT1 DM7LAXF TN Prostacyclin receptor (PTGIR) DM7LAXF MA Inhibitor DM7LAXF RN Molecular design of novel PGI2 agonists without PG skeleton, Bioorg. Med. Chem. Lett. 5(10):1071-1076 (1995). DM7LAXF RU http://www.sciencedirect.com/science/article/pii/0960894X9500168S DM7LZFQ DI DM7LZFQ DM7LZFQ DN BAY-17-1998 DM7LZFQ TI TTM1TDX DM7LZFQ TN Tryptase alpha/beta-1 (Tryptase) DM7LZFQ MA Modulator DM7LZFQ RN Bayer AG to Develop Arris Asthma Compound; Arris to Receive Milestone Payment. 1996 Business Wire DM7LZFQ RU http://www.thefreelibrary.com/Axys+Pharmaceuticals+Announces+Bayer+AG's+Decision+to+Discontinue...-a062275428 DM7QPYK DI DM7QPYK DM7QPYK DN SKF-106760 DM7QPYK TI TT38RM1 DM7QPYK TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM7QPYK MA Modulator DM7QPYK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM7QPYK RU https://www.fda.gov/ DM7ROS1 DI DM7ROS1 DM7ROS1 DN Efegatran DM7ROS1 TI TT6L509 DM7ROS1 TN Coagulation factor IIa (F2) DM7ROS1 MA Inhibitor DM7ROS1 RN Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204. DM7ROS1 RU https://pubmed.ncbi.nlm.nih.gov/11441979 DM7T2FO DI DM7T2FO DM7T2FO DN Naltiazem hydrochloride DM7T2FO TI TT5HONZ DM7T2FO TN Calcium channel unspecific (CaC) DM7T2FO MA Blocker DM7T2FO RN Assessment of hyperglycemia after calcium channel blocker overdoses involving diltiazem or verapamil. Crit Care Med. 2007 Sep;35(9):2071-5. DM7T2FO RU https://pubmed.ncbi.nlm.nih.gov/17855820 DM7TQYF DI DM7TQYF DM7TQYF DN Y-20024 DM7TQYF TI TTEX248 DM7TQYF TN Dopamine D2 receptor (D2R) DM7TQYF MA Agonist DM7TQYF RN Neuroleptic properties of Y-20024, a new benzofurancarboxamide derivative. Nihon Yakurigaku Zasshi. 1989 Nov;94(5):269-80. DM7TQYF RU https://pubmed.ncbi.nlm.nih.gov/2575566 DM7VGOC DI DM7VGOC DM7VGOC DN Ym60828 DM7VGOC TI TTCIHJA DM7VGOC TN Coagulation factor Xa (F10) DM7VGOC MA Inhibitor DM7VGOC RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DM7VGOC RU https://pubmed.ncbi.nlm.nih.gov/11804648 DM7WGXS DI DM7WGXS DM7WGXS DN FR-76830 DM7WGXS TI TT5WKM8 DM7WGXS TN ATP phosphatase (ATPase) DM7WGXS MA Modulator DM7WGXS RN On the mode of cardioprotection produced by a new bradycardic agent, FR 76830, during ischaemia and after reperfusion in the isolated perfused rat heart: a 31P-NMR study. Cardiovasc Res. 1990 Dec;24(12):1008-12. DM7WGXS RU https://pubmed.ncbi.nlm.nih.gov/2151429 DM7YORJ DI DM7YORJ DM7YORJ DN DuP-630 DM7YORJ TI TTOQ9GZ DM7YORJ TN Cytochrome P450 reductase (P450) DM7YORJ MA Modulator DM7YORJ RN CN patent application no. 1096855, Composition produced by treatment and induction of nitrogen mono oxide synthase expressed matter, and use thereof. DM7YORJ RU http://www.google.com/patents/CN1096855C?cl=en DM7YRFE DI DM7YRFE DM7YRFE DN BB-3644 DM7YRFE TI TTMTWOS DM7YRFE TN Matrix metalloproteinase-7 (MMP-7) DM7YRFE MA Inhibitor DM7YRFE RN Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. DM7YRFE RU https://pubmed.ncbi.nlm.nih.gov/16498445 DM7YRFE DI DM7YRFE DM7YRFE DN BB-3644 DM7YRFE TI TTLM12X DM7YRFE TN Matrix metalloproteinase-2 (MMP-2) DM7YRFE MA Inhibitor DM7YRFE RN Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. DM7YRFE RU https://pubmed.ncbi.nlm.nih.gov/16498445 DM7YRFE DI DM7YRFE DM7YRFE DN BB-3644 DM7YRFE TI TTMX39J DM7YRFE TN Matrix metalloproteinase-1 (MMP-1) DM7YRFE MA Inhibitor DM7YRFE RN Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer. 2006 Mar;6(3):227-39. DM7YRFE RU https://pubmed.ncbi.nlm.nih.gov/16498445 DM7ZOLE DI DM7ZOLE DM7ZOLE DN SR-31742A DM7ZOLE TI TT5TPI6 DM7ZOLE TN Opioid receptor sigma 1 (OPRS1) DM7ZOLE MA Binder DM7ZOLE RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM7ZOLE RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM81DJV DI DM81DJV DM81DJV DN Zindoxifene DM81DJV TI TTZAYWL DM81DJV TN Estrogen receptor (ESR) DM81DJV MA Modulator DM81DJV RN Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study.. Br J Cancer. 1990 March; 61(3): 451-453. DM81DJV RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971274/ DM84KOY DI DM84KOY DM84KOY DN CT-1746 DM84KOY TI TT6X50U DM84KOY TN Matrix metalloproteinase-9 (MMP-9) DM84KOY MA Modulator DM84KOY RN Conversion of highly malignant colon cancer from an aggressive to a controlled disease by oral administration of a metalloproteinase inhibitor. Clin Exp Metastasis. 1997 Mar;15(2):184-95. DM84KOY RU https://pubmed.ncbi.nlm.nih.gov/9062395 DM84RHP DI DM84RHP DM84RHP DN PTX-008313 DM84RHP TI TTQAOZR DM84RHP TN Bacterial Chorismate synthase (Bact aroC) DM84RHP MA Inhibitor DM84RHP RN US patent application no. 2009,0048,155, Methods for preventing and treating tissue injury and sepsis associated with yersinia pestis infection. DM84RHP RU http://www.google.com/patents/US20090048155 DM872CU DI DM872CU DM872CU DN DuP-983 DM872CU TI TTOQ9GZ DM872CU TN Cytochrome P450 reductase (P450) DM872CU MA Modulator DM872CU RN CN patent application no. 1096855, Composition produced by treatment and induction of nitrogen mono oxide synthase expressed matter, and use thereof. DM872CU RU http://www.google.com/patents/CN1096855C?cl=en DM874YU DI DM874YU DM874YU DN SC-58125 DM874YU TI TTVKILB DM874YU TN Prostaglandin G/H synthase 2 (COX-2) DM874YU MA Inhibitor DM874YU RN Identification and optimisation of a novel series of pyrimidine based cyclooxygenase-2 (COX-2) inhibitors. Utilisation of a biotransformation appro... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4509-14. DM874YU RU https://pubmed.ncbi.nlm.nih.gov/19523822 DM87ZWP DI DM87ZWP DM87ZWP DN DU-1777 DM87ZWP TI TTL69WB DM87ZWP TN Angiotensin-converting enzyme (ACE) DM87ZWP MA Inhibitor DM87ZWP RN Antihypertensive properties of a new long-acting angiotensin converting enzyme inhibitor in renin-dependent and independent hypertensive models. Arzneimittelforschung. 1995 Aug;45(8):853-8. DM87ZWP RU https://pubmed.ncbi.nlm.nih.gov/7575746 DM89BA1 DI DM89BA1 DM89BA1 DN WS-75624B DM89BA1 TI TT1BGDH DM89BA1 TN Endothelin-converting enzyme (ECE) DM89BA1 MA Modulator DM89BA1 RN WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. II. Structure elucidation of WS75624 A and B. J Antibiot (Tokyo). 1995 Oct;48(10):1073-5. DM89BA1 RU https://pubmed.ncbi.nlm.nih.gov/7490209 DM89BGE DI DM89BGE DM89BGE DN A-80263 DM89BGE TI TT2J34L DM89BGE TN Arachidonate 5-lipoxygenase (5-LOX) DM89BGE MA Inhibitor DM89BGE RN CA patent application no. 445634, Acne treatment comprising lipoxygenase inhibitors. DM89BGE RU http://www.google.com/patents/CA2445634A1?cl=en DM89RT7 DI DM89RT7 DM89RT7 DN PTX-007011 DM89RT7 TI TT4YO0Z DM89RT7 TN Phosphopantetheine adenylyltransferase (PPAT) DM89RT7 MA Inhibitor DM89RT7 RN NME DIGEST. Drug News & Perspect 2002, 15(8):519, ISSN 0214-0934. DM89RT7 RU https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=3&p_RefId=695454&p_IsPs=N DM89TXB DI DM89TXB DM89TXB DN JTV-605 DM89TXB TI TTK8R02 DM89TXB TN Vasopressin V2 receptor (V2R) DM89TXB MA Antagonist DM89TXB RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DM89TXB RU https://pubmed.ncbi.nlm.nih.gov/12436936 DM89TXB DI DM89TXB DM89TXB DN JTV-605 DM89TXB TI TT4TFGN DM89TXB TN Vasopressin V1a receptor (V1AR) DM89TXB MA Antagonist DM89TXB RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DM89TXB RU https://pubmed.ncbi.nlm.nih.gov/12436936 DM8AGOE DI DM8AGOE DM8AGOE DN BABIM DM8AGOE TI TTM1TDX DM8AGOE TN Tryptase alpha/beta-1 (Tryptase) DM8AGOE MA Inhibitor DM8AGOE RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DM8AGOE RU https://pubmed.ncbi.nlm.nih.gov/10197050 DM8B1DH DI DM8B1DH DM8B1DH DN RU-46556 DM8B1DH TI TTUV8G9 DM8B1DH TN Progesterone receptor (PGR) DM8B1DH MA Modulator DM8B1DH RN New analogues of mifepristone with more dissociated antiprogesterone activities. J Steroid Biochem. 1989;34(1-6):413-7. DM8B1DH RU https://pubmed.ncbi.nlm.nih.gov/2560520 DM8B9YT DI DM8B9YT DM8B9YT DN Ro-31-4724 DM8B9YT TI TTMX39J DM8B9YT TN Matrix metalloproteinase-1 (MMP-1) DM8B9YT MA Inhibitor DM8B9YT RN Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase. J Med Chem. 2004 May 20;47(11):2761-7. DM8B9YT RU https://pubmed.ncbi.nlm.nih.gov/15139754 DM8BSF3 DI DM8BSF3 DM8BSF3 DN HuMax-TAC DM8BSF3 TI TT10Y9E DM8BSF3 TN Interleukin 2 receptor alpha (IL2RA) DM8BSF3 RN Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines. Med Res Rev. 2012 Mar;32(2):254-93. DM8BSF3 RU https://pubmed.ncbi.nlm.nih.gov/20544978 DM8EVK5 DI DM8EVK5 DM8EVK5 DN Wortmannin DM8EVK5 TI TTHBTOP DM8EVK5 TN PI3-kinase gamma (PIK3CG) DM8EVK5 MA Inhibitor DM8EVK5 RN Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002 Aug 15;62(16):4671-7. DM8EVK5 RU https://pubmed.ncbi.nlm.nih.gov/12183424 DM8EVK5 DI DM8EVK5 DM8EVK5 DN Wortmannin DM8EVK5 TI TTGBPJE DM8EVK5 TN PI3-kinase delta (PIK3CD) DM8EVK5 MA Inhibitor DM8EVK5 RN Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9. DM8EVK5 RU https://pubmed.ncbi.nlm.nih.gov/12927784 DM8FB6E DI DM8FB6E DM8FB6E DN Navuridine DM8FB6E TI TT84ETX DM8FB6E TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM8FB6E MA Inhibitor DM8FB6E RN Synthesis and anti-human immunodeficiency virus (HIV-1) activity of 3'-deoxy-3'-(triazol-1-yl)thymidines and 2',3'-dideoxy-3'-(triazol-1-yl)uridines and inhibition of reverse transcriptase by their 5'-triphosphates. Chem Pharm Bull (Tokyo). 1990 Sep;38(9):2597-601. DM8FB6E RU https://pubmed.ncbi.nlm.nih.gov/1704819 DM8GHT2 DI DM8GHT2 DM8GHT2 DN DBO-11 DM8GHT2 TI TTKWM86 DM8GHT2 TN Opioid receptor mu (MOP) DM8GHT2 MA Agonist DM8GHT2 RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DM8GHT2 RU https://pubmed.ncbi.nlm.nih.gov/15757410 DM8I5UF DI DM8I5UF DM8I5UF DN B-5354a DM8I5UF TI TTOHFIY DM8I5UF TN Sphingosine kinase 1 (SPHK1) DM8I5UF MA Inhibitor DM8I5UF RN Characterization of B-5354c, a new sphingosine kinase inhibitor, produced by a marine bacterium. J Antibiot (Tokyo). 2000 Aug;53(8):759-64. DM8I5UF RU https://pubmed.ncbi.nlm.nih.gov/11079797 DM8MWFZ DI DM8MWFZ DM8MWFZ DN SKF-104351 DM8MWFZ TI TT2J34L DM8MWFZ TN Arachidonate 5-lipoxygenase (5-LOX) DM8MWFZ MA Modulator DM8MWFZ RN WO patent application no. 2006,1317,37, Method and composition for treating inflammatory disorders. DM8MWFZ RU http://www.google.com/patents/WO2006131737A2?cl=en DM8MZWR DI DM8MZWR DM8MZWR DN SRSS-021 DM8MZWR TI TTNXLKE DM8MZWR TN 5-HT 3 receptor (5HT3R) DM8MZWR MA Antagonist DM8MZWR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019090) DM8MZWR RU http://adisinsight.springer.com/drugs/800019090 DM8NVZQ DI DM8NVZQ DM8NVZQ DN CR-1795 DM8NVZQ TI TTCG0AL DM8NVZQ TN Cholecystokinin receptor type A (CCKAR) DM8NVZQ MA Inhibitor DM8NVZQ RN Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists, Bioorg. Med. Chem. Lett. 3(5):861-866 (1993). DM8NVZQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00806812 DM8P05S DI DM8P05S DM8P05S DN PS-388023 DM8P05S TI TT69TQN DM8P05S TN Integrin alpha-V/beta-3 (ITGAV/B3) DM8P05S MA Modulator DM8P05S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8P05S RU https://www.fda.gov/ DM8P05S DI DM8P05S DM8P05S DN PS-388023 DM8P05S TI TTPRDH7 DM8P05S TN Integrin alpha-V/beta-5 (ITGAV/B5) DM8P05S MA Modulator DM8P05S RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM8P05S RU https://www.fda.gov/ DM8R3N0 DI DM8R3N0 DM8R3N0 DN BMY-44621 DM8R3N0 TI TT2WR1T DM8R3N0 TN Cationic trypsinogen (PRSS1) DM8R3N0 MA Inhibitor DM8R3N0 RN Design and synthesis of conformationally constrained arginal thrombin inhibitors, Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997). DM8R3N0 RU http://www.sciencedirect.com/science/article/pii/S0960894X97004034 DM8RHST DI DM8RHST DM8RHST DN QAP-642 DM8RHST TI TTD3XFU DM8RHST TN C-C chemokine receptor type 3 (CCR3) DM8RHST MA Antagonist DM8RHST RN New Drugs and Targets for Asthma and COPD. T.T. Hansel, P.J. Barnes. 2010. Page 158. DM8RHST RU https://books.google.com.hk/books?id=-Zg7AQAAQBAJ&pg=PT172&lpg=PT172&dq=QAP-642++CCR3&source=bl&ots=mTJNnzpSCz&sig=TbtUMK5VhyKIqvrzRk-gWt9mjqk&hl=zh-CN&sa=X&ved=0CCEQ6AEwAWoVChMIjYeezrbGyAIVChuOCh1s3QSC#v=onepage&q=QAP-642%20%20CCR3&f=false DM8RIA6 DI DM8RIA6 DM8RIA6 DN RGH-1756 DM8RIA6 TI TT4C8EA DM8RIA6 TN Dopamine D3 receptor (D3R) DM8RIA6 MA Antagonist DM8RIA6 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DM8RIA6 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DM8S593 DI DM8S593 DM8S593 DN Thioperamide DM8S593 TI TT9JNIC DM8S593 TN Histamine H3 receptor (H3R) DM8S593 MA Antagonist DM8S593 RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM8S593 RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM8S593 DI DM8S593 DM8S593 DN Thioperamide DM8S593 TI TTXJ178 DM8S593 TN Histamine H4 receptor (H4R) DM8S593 MA Antagonist DM8S593 RN Role of histamine in short- and long-term effects of methamphetamine on the developing mouse brain. J Neurochem. 2008 Nov;107(4):976-86. DM8S593 RU https://pubmed.ncbi.nlm.nih.gov/18786166 DM8TLY3 DI DM8TLY3 DM8TLY3 DN CGS-27830 DM8TLY3 TI TT7RGTM DM8TLY3 TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DM8TLY3 MA Inhibitor DM8TLY3 RN CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993). DM8TLY3 RU http://www.sciencedirect.com/science/article/pii/S0960894X01810258 DM8TLY3 DI DM8TLY3 DM8TLY3 DN CGS-27830 DM8TLY3 TI TTZIFHC DM8TLY3 TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DM8TLY3 MA Inhibitor DM8TLY3 RN CGS 27830, a potent nonpeptide endothelin receptor antagonist, Bioorg. Med. Chem. Lett. 3(10):2099-2104 (1993). DM8TLY3 RU http://www.sciencedirect.com/science/article/pii/S0960894X01810258 DM8TQC9 DI DM8TQC9 DM8TQC9 DN Clentiazem DM8TQC9 TI TT5HONZ DM8TQC9 TN Calcium channel unspecific (CaC) DM8TQC9 MA Modulator DM8TQC9 RN Coronary and cardiac sensitivity to the vasoselective benzothiazepine-like calcium antagonist, clentiazem, in experimental heart failure. Cardiovasc Drugs Ther. 1997 Mar;11(1):71-9. DM8TQC9 RU https://www.ncbi.nlm.nih.gov/pubmed/9140681 DM8UDSF DI DM8UDSF DM8UDSF DN SC-50560 DM8UDSF TI TTQVOEI DM8UDSF TN Angiotensin II receptor type-2 (AGTR2) DM8UDSF MA Inhibitor DM8UDSF RN N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993). DM8UDSF RU http://www.sciencedirect.com/science/article/pii/S0960894X00802863 DM8V0YA DI DM8V0YA DM8V0YA DN ZM-224832 DM8V0YA TI TT5HONZ DM8V0YA TN Calcium channel unspecific (CaC) DM8V0YA MA Modulator DM8V0YA RN Diuretic and antihypertensive activity of ZENECA ZM224,832: a novel eukalemic diuretic with calcium channel blocking activity. Pharmacology. 1994 Mar;48(3):167-75. DM8V0YA RU https://pubmed.ncbi.nlm.nih.gov/8153144 DM8VMJ3 DI DM8VMJ3 DM8VMJ3 DN KT-95 DM8VMJ3 TI TTQW87Y DM8VMJ3 TN Opioid receptor kappa (OPRK1) DM8VMJ3 MA Modulator DM8VMJ3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). DM8VMJ3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 DM8WTGA DI DM8WTGA DM8WTGA DN SB-269970 DM8WTGA TI TTO9X1H DM8WTGA TN 5-HT 7 receptor (HTR7) DM8WTGA MA Modulator DM8WTGA RN [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17. DM8WTGA RU https://pubmed.ncbi.nlm.nih.gov/10807680 DM8XBKG DI DM8XBKG DM8XBKG DN R-1554 DM8XBKG TI TTXEU7H DM8XBKG TN GPCR unspecific (GPCR) DM8XBKG MA Antagonist DM8XBKG RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018539) DM8XBKG RU http://adisinsight.springer.com/drugs/800018539 DM8ZDU2 DI DM8ZDU2 DM8ZDU2 DN MDL-28161 DM8ZDU2 TI TTJQOD7 DM8ZDU2 TN 5-HT 2A receptor (HTR2A) DM8ZDU2 MA Inhibitor DM8ZDU2 RN Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10. DM8ZDU2 RU https://pubmed.ncbi.nlm.nih.gov/1479590 DM904B6 DI DM904B6 DM904B6 DN Lorglumide DM904B6 TI TTCG0AL DM904B6 TN Cholecystokinin receptor type A (CCKAR) DM904B6 MA Antagonist DM904B6 RN Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety. Hokkaido Igaku Zasshi. 1998 Sep;73(5):463-73. DM904B6 RU https://pubmed.ncbi.nlm.nih.gov/9846276 DM904UQ DI DM904UQ DM904UQ DN H-216/44 DM904UQ TI TTMXGCW DM904UQ TN Adrenergic receptor beta-3 (ADRB3) DM904UQ MA Modulator DM904UQ RN Binding of the beta-blockers timolol and H 216/44 to ocular melanin. Exp Eye Res. 1988 Oct;47(4):565-77. DM904UQ RU https://pubmed.ncbi.nlm.nih.gov/2903066 DM91IPH DI DM91IPH DM91IPH DN ZD-3980 DM91IPH TI TTS64P2 DM91IPH TN Androgen receptor (AR) DM91IPH MA Modulator DM91IPH RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009538) DM91IPH RU http://adisinsight.springer.com/drugs/800009538 DM92VUF DI DM92VUF DM92VUF DN PD-123319 DM92VUF TI TTQVOEI DM92VUF TN Angiotensin II receptor type-2 (AGTR2) DM92VUF MA Inhibitor DM92VUF RN Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 sub... J Med Chem. 1991 Nov;34(11):3248-60. DM92VUF RU https://pubmed.ncbi.nlm.nih.gov/1956044 DM94WIO DI DM94WIO DM94WIO DN CGS-30440 DM94WIO TI TT5TKPM DM94WIO TN Neutral endopeptidase (MME) DM94WIO MA Modulator DM94WIO RN Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther. 1998 Mar;284(3):974-82. DM94WIO RU https://pubmed.ncbi.nlm.nih.gov/9495857 DM94WIO DI DM94WIO DM94WIO DN CGS-30440 DM94WIO TI TTL69WB DM94WIO TN Angiotensin-converting enzyme (ACE) DM94WIO MA Modulator DM94WIO RN Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther. 1998 Mar;284(3):974-82. DM94WIO RU https://pubmed.ncbi.nlm.nih.gov/9495857 DM956N7 DI DM956N7 DM956N7 DN CEP-751 DM956N7 TI TT4DXQT DM956N7 TN Proto-oncogene c-Ret (RET) DM956N7 MA Inhibitor DM956N7 RN CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003 Sep 1;63(17):5559-63. DM956N7 RU https://pubmed.ncbi.nlm.nih.gov/14500395 DM95QG2 DI DM95QG2 DM95QG2 DN Org-20781 DM95QG2 TI TT1VOHK DM95QG2 TN Potassium channel unspecific (KC) DM95QG2 MA Opener DM95QG2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003350) DM95QG2 RU http://adisinsight.springer.com/drugs/800003350 DM960I8 DI DM960I8 DM960I8 DN WIN-64821 DM960I8 TI TTZPO1L DM960I8 TN Substance-P receptor (TACR1) DM960I8 MA Antagonist DM960I8 RN WIN 64821, a novel neurokinin antagonist produced by an Aspergillus sp. II. Biological activity. J Antibiot (Tokyo). 1994 Apr;47(4):399-410. DM960I8 RU https://pubmed.ncbi.nlm.nih.gov/7515038 DM965P4 DI DM965P4 DM965P4 DN XL-541 DM965P4 TI TT9JZCK DM965P4 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM965P4 MA Antagonist DM965P4 RN Discovery of a novel class of potent and orally bioavailable sphingosine 1-phosphate receptor 1 antagonists. J Med Chem. 2012 Feb 9;55(3):1368-81. DM965P4 RU https://pubmed.ncbi.nlm.nih.gov/22214363 DM96KF7 DI DM96KF7 DM96KF7 DN GR-94839 DM96KF7 TI TTQW87Y DM96KF7 TN Opioid receptor kappa (OPRK1) DM96KF7 MA Modulator DM96KF7 RN GR94839, a kappa-opioid agonist with limited access to the central nervous system, has antinociceptive activity. Br J Pharmacol. 1992 Aug;106(4):783-9. DM96KF7 RU https://pubmed.ncbi.nlm.nih.gov/1327387 DM96WKA DI DM96WKA DM96WKA DN Midaglizole DM96WKA TI TT2NUT5 DM96WKA TN Adrenergic receptor alpha-2C (ADRA2C) DM96WKA MA Modulator DM96WKA RN Studies of midaglizole (DG-5128). A new type of oral hypoglycemic drug in healthy subjects. Diabetes. 1987 Feb;36(2):216-20. DM96WKA RU https://pubmed.ncbi.nlm.nih.gov/3542646 DM97ULM DI DM97ULM DM97ULM DN YM-022 DM97ULM TI TTVFO0U DM97ULM TN Gastrin/cholecystokinin type B receptor (CCKBR) DM97ULM MA Antagonist DM97ULM RN YM022, a potent and selective gastrin/CCK-B receptor antagonist, inhibits peptone meal-induced gastric acid secretion in Heidenhain pouch dogs. Dig Dis Sci. 1997 Apr;42(4):707-14. DM97ULM RU https://pubmed.ncbi.nlm.nih.gov/9125636 DM98K76 DI DM98K76 DM98K76 DN Siguazodan DM98K76 TI TTZCG4L DM98K76 TN Phosphodiesterase 3 (PDE3) DM98K76 MA Modulator DM98K76 RN Cyclic-AMP-dependent proliferation of a human osteoblast cell line (HOS cells) induced by hydroxyapatite: effect of exogenous nitric oxide. Acta Biomed. 2008 Aug;79(2):110-6. DM98K76 RU https://www.ncbi.nlm.nih.gov/pubmed/18788505 DM98POQ DI DM98POQ DM98POQ DN LY-367385 DM98POQ TI TTVBPDM DM98POQ TN Metabotropic glutamate receptor 1 (mGluR1) DM98POQ MA Agonist DM98POQ RN Anticonvulsant actions of LY 367385 ((+)-2-methyl-4-carboxyphenylglycine) and AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid). Eur J Pharmacol. 1999 Feb 26;368(1):17-24. DM98POQ RU https://pubmed.ncbi.nlm.nih.gov/10096765 DM9DJFS DI DM9DJFS DM9DJFS DN SQ-28603 DM9DJFS TI TT5TKPM DM9DJFS TN Neutral endopeptidase (MME) DM9DJFS MA Modulator DM9DJFS RN Evaluation of SQ 28,603, an inhibitor of neutral endopeptidase, in conscious monkeys. Can J Physiol Pharmacol. 1991 Oct;69(10):1609-17. DM9DJFS RU https://pubmed.ncbi.nlm.nih.gov/1663819 DM9F7R0 DI DM9F7R0 DM9F7R0 DN SBP-002 DM9F7R0 TI TT0E5SK DM9F7R0 TN Interleukin 6 receptor (IL6R) DM9F7R0 MA Modulator DM9F7R0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DM9F7R0 RU https://www.fda.gov/ DM9F81Z DI DM9F81Z DM9F81Z DN NS-257 DM9F81Z TI TTAN6JD DM9F81Z TN Glutamate receptor AMPA (GRIA) DM9F81Z MA Antagonist DM9F81Z RN Characterization of the binding of [3H]NS 257, a novel competitive AMPA receptor antagonist, to rat brain membranes and brain sections. J Neurochem. 1995 Sep;65(3):1264-73. DM9F81Z RU https://pubmed.ncbi.nlm.nih.gov/7543932 DM9FT5E DI DM9FT5E DM9FT5E DN UD-CG-212 DM9FT5E TI TTZCG4L DM9FT5E TN Phosphodiesterase 3 (PDE3) DM9FT5E MA Modulator DM9FT5E RN Phosphodiesterase inhibition in ventricular cardiomyocytes from guinea-pig hearts. Br J Pharmacol. 1992 Sep;107(1):127-33. DM9FT5E RU https://www.ncbi.nlm.nih.gov/pubmed/1384905 DM9GOT6 DI DM9GOT6 DM9GOT6 DN MGBG DM9GOT6 TI TTBFROQ DM9GOT6 TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DM9GOT6 MA Inhibitor DM9GOT6 RN A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours. Br J Cancer. 2000 Sep;83(5):594-601. DM9GOT6 RU https://pubmed.ncbi.nlm.nih.gov/10944598 DM9HFV7 DI DM9HFV7 DM9HFV7 DN SPD-756 DM9HFV7 TI TT84ETX DM9HFV7 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9HFV7 MA Inhibitor DM9HFV7 RN Single dose pharmacokinetics of SPD-756 in healthy adult volunteers, P F Smith, Poster Exhibition: The XIV International AIDS Conference: Abstract no. WePeB6050. DM9HFV7 RU https://www.aids2014.org/Abstracts/A1704.aspx DM9HZ8D DI DM9HZ8D DM9HZ8D DN AR-C-89855 DM9HZ8D TI TT2CJVK DM9HZ8D TN Adrenergic receptor beta-2 (ADRB2) DM9HZ8D MA Agonist DM9HZ8D RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013263) DM9HZ8D RU http://adisinsight.springer.com/drugs/800013263 DM9IQR6 DI DM9IQR6 DM9IQR6 DN BK-218 DM9IQR6 TI TTJP4SM DM9IQR6 TN Bacterial Penicillin binding protein (Bact PBP) DM9IQR6 MA Inhibitor DM9IQR6 RN In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimicrob Agents Chemother. 1990 Feb;34(2):349-54. DM9IQR6 RU https://pubmed.ncbi.nlm.nih.gov/2109582 DM9JE7Y DI DM9JE7Y DM9JE7Y DN L-159689 DM9JE7Y TI TT8DBY3 DM9JE7Y TN Angiotensin II receptor type-1 (AGTR1) DM9JE7Y MA Inhibitor DM9JE7Y RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DM9JE7Y RU https://pubmed.ncbi.nlm.nih.gov/16220969 DM9JE7Y DI DM9JE7Y DM9JE7Y DN L-159689 DM9JE7Y TI TTQVOEI DM9JE7Y TN Angiotensin II receptor type-2 (AGTR2) DM9JE7Y MA Inhibitor DM9JE7Y RN The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists, Bioorg. Med. Chem. Lett. 6(8):923-928 (1996). DM9JE7Y RU http://www.sciencedirect.com/science/article/pii/0960894X96001163 DM9KNFZ DI DM9KNFZ DM9KNFZ DN A-70276 DM9KNFZ TI TTCG0AL DM9KNFZ TN Cholecystokinin receptor type A (CCKAR) DM9KNFZ MA Modulator DM9KNFZ RN Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors. J Med Chem. 1991 Dec;34(12):3350-9. DM9KNFZ RU https://pubmed.ncbi.nlm.nih.gov/1766000 DM9L50N DI DM9L50N DM9L50N DN RPR-104632 DM9L50N TI TTN9D8E DM9L50N TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM9L50N MA Inhibitor DM9L50N RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DM9L50N RU https://pubmed.ncbi.nlm.nih.gov/10882363 DM9L50N DI DM9L50N DM9L50N DN RPR-104632 DM9L50N TI TTKJEMQ DM9L50N TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM9L50N MA Inhibitor DM9L50N RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DM9L50N RU https://pubmed.ncbi.nlm.nih.gov/10882363 DM9L50N DI DM9L50N DM9L50N DN RPR-104632 DM9L50N TI TTLD29N DM9L50N TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM9L50N MA Inhibitor DM9L50N RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DM9L50N RU https://pubmed.ncbi.nlm.nih.gov/10882363 DM9P4ZN DI DM9P4ZN DM9P4ZN DN EXP-6803 DM9P4ZN TI TTGN1ZA DM9P4ZN TN Angiotensin II receptor (AGTR) DM9P4ZN MA Modulator DM9P4ZN RN Nonpeptide angiotensin II receptor antagonists. IV. EXP6155 and EXP6803. Hypertension. 1989 May;13(5):489-97. DM9P4ZN RU https://pubmed.ncbi.nlm.nih.gov/2656519 DM9S1EA DI DM9S1EA DM9S1EA DN Pepstatin DM9S1EA TI TTXMNHO DM9S1EA TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM9S1EA MA Inhibitor DM9S1EA RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DM9S1EA RU https://pubmed.ncbi.nlm.nih.gov/17339102 DM9S1EA DI DM9S1EA DM9S1EA DN Pepstatin DM9S1EA TI TTJNPTK DM9S1EA TN Plasmodium Cysteine protease falcipain (Malaria CPF) DM9S1EA MA Inhibitor DM9S1EA RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DM9S1EA RU https://pubmed.ncbi.nlm.nih.gov/17339102 DM9S1EA DI DM9S1EA DM9S1EA DN Pepstatin DM9S1EA TI TT7EASG DM9S1EA TN Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) DM9S1EA MA Inhibitor DM9S1EA RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DM9S1EA RU https://pubmed.ncbi.nlm.nih.gov/18298458 DM9S1EA DI DM9S1EA DM9S1EA DN Pepstatin DM9S1EA TI TTH9VL3 DM9S1EA TN Plasmodium Plasmepsin 1 (Malaria PLA1) DM9S1EA MA Inhibitor DM9S1EA RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DM9S1EA RU https://pubmed.ncbi.nlm.nih.gov/17339102 DM9V6AU DI DM9V6AU DM9V6AU DN FR-129169 DM9V6AU TI TTMF541 DM9V6AU TN Liver carboxylesterase (CES1) DM9V6AU MA Modulator DM9V6AU RN Plasma cholesterol reducing effect of FR129169, a novel acyl-CoA:cholesterol acyltransferase inhibitor, in the rat. Jpn J Pharmacol. 1996 Jan;70(1):35-41. DM9V6AU RU https://pubmed.ncbi.nlm.nih.gov/8822087 DM9VDZP DI DM9VDZP DM9VDZP DN CGP-53353 DM9VDZP TI TTGKNB4 DM9VDZP TN Epidermal growth factor receptor (EGFR) DM9VDZP MA Inhibitor DM9VDZP RN Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27. DM9VDZP RU https://pubmed.ncbi.nlm.nih.gov/8151612 DM9X1DZ DI DM9X1DZ DM9X1DZ DN BIMG80 DM9X1DZ TI TTZFYLI DM9X1DZ TN Dopamine D1 receptor (D1R) DM9X1DZ MA Modulator DM9X1DZ RN BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90. DM9X1DZ RU https://pubmed.ncbi.nlm.nih.gov/9202309 DM9X1DZ DI DM9X1DZ DM9X1DZ DN BIMG80 DM9X1DZ TI TTE0A2F DM9X1DZ TN Dopamine D4 receptor (D4R) DM9X1DZ MA Modulator DM9X1DZ RN BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90. DM9X1DZ RU https://pubmed.ncbi.nlm.nih.gov/9202309 DM9X1DZ DI DM9X1DZ DM9X1DZ DN BIMG80 DM9X1DZ TI TTEX248 DM9X1DZ TN Dopamine D2 receptor (D2R) DM9X1DZ MA Modulator DM9X1DZ RN BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90. DM9X1DZ RU https://pubmed.ncbi.nlm.nih.gov/9202309 DM9X24J DI DM9X24J DM9X24J DN A-70826 DM9X24J TI TTN6J5F DM9X24J TN Bacterial DNA gyrase (Bact gyrase) DM9X24J MA Modulator DM9X24J RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001978) DM9X24J RU http://adisinsight.springer.com/drugs/800001978 DM9X2D0 DI DM9X2D0 DM9X2D0 DN Calphostin C DM9X2D0 TI TTYVX59 DM9X2D0 TN Protein kinase C (PRKC) DM9X2D0 MA Inhibitor DM9X2D0 RN Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. DM9X2D0 RU https://pubmed.ncbi.nlm.nih.gov/10982151 DM9YOMX DI DM9YOMX DM9YOMX DN OT-4003 DM9YOMX TI TTGKOY9 DM9YOMX TN Leukotriene CysLT1 receptor (CYSLTR1) DM9YOMX MA Modulator DM9YOMX RN Discovery of OT4003, a novel, potent, and orally active cys-LT1 receptor antagonist. Bioorg Med Chem. 1997 Feb;5(2):415-27. DM9YOMX RU https://pubmed.ncbi.nlm.nih.gov/9061206 DMA0DKI DI DMA0DKI DMA0DKI DN CDE-6960 DMA0DKI TI TTBZ7OD DMA0DKI TN Protein kinase C epsilon (PRKCE) DMA0DKI MA Inhibitor DMA0DKI RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002) DMA0DKI RU http://adisinsight.springer.com/drugs/800025002 DMA0DKI DI DMA0DKI DMA0DKI DN CDE-6960 DMA0DKI TI TT8QL1J DMA0DKI TN Protein kinase C theta (PRKCQ) DMA0DKI MA Inhibitor DMA0DKI RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025002) DMA0DKI RU http://adisinsight.springer.com/drugs/800025002 DMA13OD DI DMA13OD DMA13OD DN XR-510 DMA13OD TI TT8DBY3 DMA13OD TN Angiotensin II receptor type-1 (AGTR1) DMA13OD MA Modulator DMA13OD RN Pharmacology of XR510, a potent orally active nonpeptide angiotensin II AT1 receptor antagonist with high affinity for the AT2 receptor subtype. J Cardiovasc Pharmacol. 1995 Sep;26(3):354-62. DMA13OD RU https://pubmed.ncbi.nlm.nih.gov/8583775 DMA187T DI DMA187T DMA187T DN R zileuton DMA187T TI TT2J34L DMA187T TN Arachidonate 5-lipoxygenase (5-LOX) DMA187T MA Inhibitor DMA187T RN Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60. DMA187T RU https://pubmed.ncbi.nlm.nih.gov/14570767 DMA1NJW DI DMA1NJW DMA1NJW DN L-733060 DMA1NJW TI TTZPO1L DMA1NJW TN Substance-P receptor (TACR1) DMA1NJW MA Inhibitor DMA1NJW RN 3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997). DMA1NJW RU http://www.sciencedirect.com/science/article/pii/S0960894X97101184 DMA4DNX DI DMA4DNX DMA4DNX DN CL-387626 DMA4DNX TI TT57ID8 DMA4DNX TN Respiratory syncytial virus protein F (RSV F) DMA4DNX MA Inhibitor DMA4DNX RN Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses. 2013 January; 5(1): 211-225. DMA4DNX RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564118/ DMA6RL2 DI DMA6RL2 DMA6RL2 DN GT-16-239 DMA6RL2 TI TTPADOQ DMA6RL2 TN HMG-CoA reductase (HMGCR) DMA6RL2 MA Modulator DMA6RL2 RN Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS). Atherosclerosis. 1998 Oct;140(2):315-24. DMA6RL2 RU https://pubmed.ncbi.nlm.nih.gov/9862274 DMA7EFM DI DMA7EFM DMA7EFM DN Human chorionic gonadotropin DMA7EFM TI TT2O4W9 DMA7EFM TN Luteinizing hormone receptor (LHCGR) DMA7EFM MA Inhibitor DMA7EFM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 254). DMA7EFM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254 DMA7FX1 DI DMA7FX1 DMA7FX1 DN GR-199114X DMA7FX1 TI TTVFO0U DMA7FX1 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMA7FX1 MA Modulator DMA7FX1 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009210) DMA7FX1 RU http://adisinsight.springer.com/drugs/800009210 DMA93D8 DI DMA93D8 DMA93D8 DN AC-260584 DMA93D8 TI TTZ9SOR DMA93D8 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMA93D8 MA Agonist DMA93D8 RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMA93D8 RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMA971L DI DMA971L DMA971L DN Reveromycin A DMA971L TI TT6KYJ5 DMA971L TN Bacterial Isoleucyl-tRNA synthetase (Bact ileS) DMA971L MA Inhibitor DMA971L RN Chemical modification of reveromycin A and its biological activities. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3363-6. DMA971L RU https://pubmed.ncbi.nlm.nih.gov/12419362 DMA971L DI DMA971L DMA971L DN Reveromycin A DMA971L TI TTYD3AN DMA971L TN Isoleucyl-tRNA synthetase (IARS) DMA971L MA Inhibitor DMA971L RN Synthesis and biological activities of reveromycin A and spirofungin A derivatives. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3756-60. DMA971L RU https://pubmed.ncbi.nlm.nih.gov/18519164 DMABY43 DI DMABY43 DMABY43 DN AZD-5106 DMABY43 TI TTYO0A3 DMABY43 TN Substance-K receptor (TACR2) DMABY43 MA Antagonist DMABY43 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015341) DMABY43 RU http://adisinsight.springer.com/drugs/800015341 DMACBIW DI DMACBIW DMACBIW DN WIN-55212-2 DMACBIW TI TT6OEDT DMACBIW TN Cannabinoid receptor 1 (CB1) DMACBIW MA Inhibitor DMACBIW RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMACBIW RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMACBIW DI DMACBIW DMACBIW DN WIN-55212-2 DMACBIW TI TTMSFAW DMACBIW TN Cannabinoid receptor 2 (CB2) DMACBIW MA Inhibitor DMACBIW RN Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. 2008 Mar;43(3):513-39. DMACBIW RU https://pubmed.ncbi.nlm.nih.gov/17582659 DMADYF7 DI DMADYF7 DMADYF7 DN CGX-1160 DMADYF7 TI TTTUMEP DMADYF7 TN Neurotensin receptor type 1 (NTSR1) DMADYF7 MA Agonist DMADYF7 RN Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem. 2008 Aug;8(6):603-17. DMADYF7 RU https://pubmed.ncbi.nlm.nih.gov/18690825 DMAE43P DI DMAE43P DMAE43P DN DSP-7238 DMAE43P TI TTDIGC1 DMAE43P TN Dipeptidyl peptidase 4 (DPP-4) DMAE43P MA Inhibitor DMAE43P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DMAE43P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DMAEDQG DI DMAEDQG DMAEDQG DN EMODIN DMAEDQG TI TTER6YH DMAEDQG TN Casein kinase II alpha (CSNK2A1) DMAEDQG MA Inhibitor DMAEDQG RN Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. DMAEDQG RU https://pubmed.ncbi.nlm.nih.gov/19414254 DMAET6F DI DMAET6F DMAET6F DN SB 203580 DMAET6F TI TTQBR95 DMAET6F TN Stress-activated protein kinase 2a (p38 alpha) DMAET6F MA Inhibitor DMAET6F RN The p38 mitogen-activated protein kinase pathway plays a critical role in thrombin-induced endothelial chemokine production and leukocyte recruitment. Blood. 2001 Aug 1;98(3):667-73. DMAET6F RU https://pubmed.ncbi.nlm.nih.gov/11468165 DMAET6F DI DMAET6F DMAET6F DN SB 203580 DMAET6F TI TTVKILB DMAET6F TN Prostaglandin G/H synthase 2 (COX-2) DMAET6F MA Inhibitor DMAET6F RN Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000 May;47(2-3):185-201. DMAET6F RU https://pubmed.ncbi.nlm.nih.gov/10878289 DMAET6F DI DMAET6F DMAET6F DN SB 203580 DMAET6F TI TTWOTEA DMAET6F TN Interleukin 1 receptor type 1 (IL1R1) DMAET6F MA Antagonist DMAET6F RN IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol. 2001 Jun;187(3):294-303. DMAET6F RU https://pubmed.ncbi.nlm.nih.gov/11319753 DMAG86C DI DMAG86C DMAG86C DN WY-28342 DMAG86C TI TTK0943 DMAG86C TN Prostaglandin G/H synthase (COX) DMAG86C MA Modulator DMAG86C RN Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81. DMAG86C RU https://pubmed.ncbi.nlm.nih.gov/7739006 DMAG86C DI DMAG86C DMAG86C DN WY-28342 DMAG86C TI TT2J34L DMAG86C TN Arachidonate 5-lipoxygenase (5-LOX) DMAG86C MA Modulator DMAG86C RN Synthesis and antiinflammatory activity of certain 5,6,7,8-tetrahydroquinolines and related compounds. J Med Chem. 1995 Apr 28;38(9):1473-81. DMAG86C RU https://pubmed.ncbi.nlm.nih.gov/7739006 DMAGUY0 DI DMAGUY0 DMAGUY0 DN Omapatrilat DMAGUY0 TI TT5TKPM DMAGUY0 TN Neutral endopeptidase (MME) DMAGUY0 MA Modulator DMAGUY0 RN Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5. DMAGUY0 RU https://pubmed.ncbi.nlm.nih.gov/11254898 DMAGUY0 DI DMAGUY0 DMAGUY0 DN Omapatrilat DMAGUY0 TI TTL69WB DMAGUY0 TN Angiotensin-converting enzyme (ACE) DMAGUY0 MA Modulator DMAGUY0 RN Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr;155(2):291-5. DMAGUY0 RU https://pubmed.ncbi.nlm.nih.gov/11254898 DMAH3Z9 DI DMAH3Z9 DMAH3Z9 DN BTS-79018 DMAH3Z9 TI TT4C8EA DMAH3Z9 TN Dopamine D3 receptor (D3R) DMAH3Z9 MA Binder DMAH3Z9 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMAH3Z9 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMAH3Z9 DI DMAH3Z9 DMAH3Z9 DN BTS-79018 DMAH3Z9 TI TTSQIFT DMAH3Z9 TN 5-HT 1A receptor (HTR1A) DMAH3Z9 MA Binder DMAH3Z9 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMAH3Z9 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMAHNF6 DI DMAHNF6 DMAHNF6 DN GR-95168 DMAHNF6 TI TTIU7X1 DMAHNF6 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMAHNF6 MA Modulator DMAHNF6 RN US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. DMAHNF6 RU http://www.google.com/patents/US20040023290 DMAIH90 DI DMAIH90 DMAIH90 DN NPC-18166 DMAIH90 TI TTYSN63 DMAIH90 TN 5-HT 2 receptor (5HT2R) DMAIH90 MA Modulator DMAIH90 RN WO patent application no. 2004,0825,84, 5ht2c receptor antagonists in the treatment of schizophrenia. DMAIH90 RU http://www.google.nl/patents/WO2004082584A2?cl=en DMAIJSX DI DMAIJSX DMAIJSX DN L-701324 DMAIJSX TI TTKJEMQ DMAIJSX TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMAIJSX MA Inhibitor DMAIJSX RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMAIJSX RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMAIJSX DI DMAIJSX DMAIJSX DN L-701324 DMAIJSX TI TTN9D8E DMAIJSX TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMAIJSX MA Inhibitor DMAIJSX RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMAIJSX RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMAIJSX DI DMAIJSX DMAIJSX DN L-701324 DMAIJSX TI TTLD29N DMAIJSX TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMAIJSX MA Inhibitor DMAIJSX RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMAIJSX RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMAIJT6 DI DMAIJT6 DMAIJT6 DN RPR-114334 DMAIJT6 TI TTXQKM3 DMAIJT6 TN Farnesyl protein transferase (Ftase) DMAIJT6 MA Inhibitor DMAIJT6 RN Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7. DMAIJT6 RU https://pubmed.ncbi.nlm.nih.gov/9191950 DMAIJT6 DI DMAIJT6 DMAIJT6 DN RPR-114334 DMAIJT6 TI TT7WZIJ DMAIJT6 TN CAAX farnesyltransferase beta (FNTB) DMAIJT6 MA Inhibitor DMAIJT6 RN Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7. DMAIJT6 RU https://pubmed.ncbi.nlm.nih.gov/9191950 DMAITRL DI DMAITRL DMAITRL DN MKC-1313 DMAITRL TI TTBH0VX DMAITRL TN Histone deacetylase (HDAC) DMAITRL MA Inhibitor DMAITRL RN ENTREMED TO ACQUIRE MIIKANA THERAPEUTICS. U.S. Securities and Exchange Commission. December 22, 2005. DMAITRL RU http://www.sec.gov/Archives/edgar/data/895051/000095013305005669/w15948exv99w1.htm DMAJ9ZD DI DMAJ9ZD DMAJ9ZD DN Phosphonate DMAJ9ZD TI TT1UZQH DMAJ9ZD TN Phospholipase C (PLC) DMAJ9ZD MA Inhibitor DMAJ9ZD RN Inhibition of phosphatidylinositol-specific phospholipase C by phosphonate substrate analogues. Biochim Biophys Acta. 1990 Feb 23;1042(3):410-2. DMAJ9ZD RU https://pubmed.ncbi.nlm.nih.gov/2106349 DMAK3V7 DI DMAK3V7 DMAK3V7 DN DIO-901 DMAK3V7 TI TT9O6WS DMAK3V7 TN Glucagon receptor (GCGR) DMAK3V7 MA Agonist DMAK3V7 RN Effects of low-dose and high-dose glucagon on glucose production and gluconeogenesis in humans. Metabolism. 2000 Jan;49(1):39-46. DMAK3V7 RU https://pubmed.ncbi.nlm.nih.gov/10647062 DMAKXN3 DI DMAKXN3 DMAKXN3 DN BAY-50-9062 DMAKXN3 TI TTVC5K6 DMAKXN3 TN Estradiol 17 beta-dehydrogenase (17-beta-HSD) DMAKXN3 MA Inhibitor DMAKXN3 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015540) DMAKXN3 RU http://adisinsight.springer.com/drugs/800015540 DMALPDW DI DMALPDW DMALPDW DN ABS-205 DMALPDW TI TTD26RC DMALPDW TN Cell adhesion molecule (CADM) DMALPDW MA Modulator DMALPDW RN Drug Discovery and Development for Alzheimer's Disease, 2000. Page(21). DMALPDW RU https://books.google.com.hk/books?id=mB0SXrpofmwC&pg=PA184&lpg=PA184&dq=%22ABS-205%22++Cell+adhesion&source=bl&ots=UtcoGEnNKZ&sig=1dVQ1oxHOCcy90TN5liCl__WXno&hl=zh-CN&sa=X&ved=0CCsQ6AEwAmoVChMIhIOO3Me_yAIVAsKOCh2rAgWU#v=onepage&q=%22ABS-205%22%20%20Cell%20adhesion&f=false DMALV1W DI DMALV1W DMALV1W DN AG-1350 DMALV1W TI TT5FNQT DMALV1W TN Human immunodeficiency virus Protease (HIV PR) DMALV1W MA Inhibitor DMALV1W RN Ly316340: A potent HIV-1 protease inhibitor containing a high affinity octahydrothienopyridine hydroxyethylamine isostere. Bioorganic & Medicinal Chemistry Letters Volume 5, Issue 23, 7 December 1995, Pages 2885-2890. DMALV1W RU http://www.sciencedirect.com/science/article/pii/0960894X9500506O DMAM3OH DI DMAM3OH DMAM3OH DN SUN-E3001 DMAM3OH TI TT6F7GZ DMAM3OH TN Parathyroid hormone (PTH) DMAM3OH MA Modulator DMAM3OH RN Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003 Mar;18(3):539-43. DMAM3OH RU https://www.ncbi.nlm.nih.gov/pubmed/12619939 DMAOHXY DI DMAOHXY DMAOHXY DN PD166285 DMAOHXY TI TT6PKBN DMAOHXY TN Proto-oncogene c-Src (SRC) DMAOHXY MA Inhibitor DMAOHXY RN Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35. DMAOHXY RU https://pubmed.ncbi.nlm.nih.gov/10638483 DMASENP DI DMASENP DMASENP DN TULOPAFANT DMASENP TI TTQL5VC DMASENP TN Platelet-activating factor receptor (PTAFR) DMASENP MA Antagonist DMASENP RN Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. J Lipid Mediat. 1993 May;7(1):79-84. DMASENP RU https://pubmed.ncbi.nlm.nih.gov/8395256 DMAT657 DI DMAT657 DMAT657 DN SDZ-62-826 DMAT657 TI TT6MP2Z DMAT657 TN GMCSFR-alpha (CSF2RA) DMAT657 MA Modulator DMAT657 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DMAT657 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DMAU0FP DI DMAU0FP DMAU0FP DN E-2070 DMAU0FP TI TTRK8B9 DMAU0FP TN Sodium channel unspecific (NaC) DMAU0FP MA Blocker DMAU0FP RN Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108. DMAU0FP RU https://pubmed.ncbi.nlm.nih.gov/15757406 DMAU5WL DI DMAU5WL DMAU5WL DN BILD-733 DMAU5WL TI TTMJX4U DMAU5WL TN Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1) DMAU5WL MA Inhibitor DMAU5WL RN Resistance of herpes simplex virus type 1 to peptidomimetic ribonucleotide reductase inhibitors: selection and characterization of mutant isolates. J Virol. 1996 Feb;70(2):787-93. DMAU5WL RU https://pubmed.ncbi.nlm.nih.gov/8551616 DMAUG0L DI DMAUG0L DMAUG0L DN L-739749 DMAUG0L TI TT7WZIJ DMAUG0L TN CAAX farnesyltransferase beta (FNTB) DMAUG0L MA Inhibitor DMAUG0L RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DMAUG0L RU https://pubmed.ncbi.nlm.nih.gov/9301658 DMAV2FM DI DMAV2FM DMAV2FM DN QX-314 DMAV2FM TI TTN9VTF DMAV2FM TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMAV2FM MA Blocker DMAV2FM RN Voltage-gated sodium channel blockers for the treatment of chronic pain. Curr Top Med Chem. 2009;9(4):362-76. DMAV2FM RU https://pubmed.ncbi.nlm.nih.gov/19442207 DMAVD4Q DI DMAVD4Q DMAVD4Q DN MPI-461359 DMAVD4Q TI TTFGZB6 DMAVD4Q TN Human immunodeficiency virus GAG protein (HIV gag) DMAVD4Q MA Inhibitor DMAVD4Q RN Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology. 2012 Aug 6;9:63. DMAVD4Q RU https://pubmed.ncbi.nlm.nih.gov/22867298 DMAVZEJ DI DMAVZEJ DMAVZEJ DN PD156707 DMAVZEJ TI TTKRD0G DMAVZEJ TN Endothelin A receptor (EDNRA) DMAVZEJ MA Antagonist DMAVZEJ RN Discovery and development of an endothelin A receptor-selective antagonist PD 156707. Pharm Biotechnol. 1998;11:81-112. DMAVZEJ RU https://pubmed.ncbi.nlm.nih.gov/9760677 DMAZB1R DI DMAZB1R DMAZB1R DN CCR5Qb DMAZB1R TI TT2CEJG DMAZB1R TN C-C chemokine receptor type 5 (CCR5) DMAZB1R RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021743) DMAZB1R RU http://adisinsight.springer.com/drugs/800021743 DMAZVUB DI DMAZVUB DMAZVUB DN ER-34122 DMAZVUB TI TT2J34L DMAZVUB TN Arachidonate 5-lipoxygenase (5-LOX) DMAZVUB MA Modulator DMAZVUB RN Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci. 2002 Jan;91(1):258-66. DMAZVUB RU https://pubmed.ncbi.nlm.nih.gov/11782915 DMB0IQT DI DMB0IQT DMB0IQT DN Org-34116 DMB0IQT TI TTYRL6O DMB0IQT TN Glucocorticoid receptor (NR3C1) DMB0IQT MA Antagonist DMB0IQT RN Blockade of glucocorticoid receptors with ORG 34116 does not normalize stress-induced symptoms in male tree shrews. Eur J Pharmacol. 2002 Dec 20;457(2-3):207-16. DMB0IQT RU https://pubmed.ncbi.nlm.nih.gov/12464368 DMB26LO DI DMB26LO DMB26LO DN SC-51316 DMB26LO TI TTGN1ZA DMB26LO TN Angiotensin II receptor (AGTR) DMB26LO MA Modulator DMB26LO RN In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316. J Pharmacol Exp Ther. 1992 Jun;261(3):1037-43. DMB26LO RU https://pubmed.ncbi.nlm.nih.gov/1602371 DMB3ZTI DI DMB3ZTI DMB3ZTI DN L-709780 DMB3ZTI TI TTJA1ZO DMB3ZTI TN ITGB3 messenger RNA (ITGB3 mRNA) DMB3ZTI MA Inhibitor DMB3ZTI RN Non-peptide fibrinogen receptor antagonists. 3. design and discovery of a centrally constrained inhibitorc, Bioorg. Med. Chem. Lett. 4(15):1835-1840 (1994). DMB3ZTI RU http://www.sciencedirect.com/science/article/pii/S0960894X01803802 DMB6T7K DI DMB6T7K DMB6T7K DN Siramesine DMB6T7K TI TTNGILX DMB6T7K TN Adrenergic receptor alpha-1A (ADRA1A) DMB6T7K MA Inhibitor DMB6T7K RN Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem. 1995 May 26;38(11):1998-2008. DMB6T7K RU https://pubmed.ncbi.nlm.nih.gov/7783131 DMB6T7K DI DMB6T7K DMB6T7K DN Siramesine DMB6T7K TI TT34BHT DMB6T7K TN Adrenergic receptor alpha-1D (ADRA1D) DMB6T7K MA Inhibitor DMB6T7K RN Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem. 1995 May 26;38(11):1998-2008. DMB6T7K RU https://pubmed.ncbi.nlm.nih.gov/7783131 DMB6T7K DI DMB6T7K DMB6T7K DN Siramesine DMB6T7K TI TTBRKXS DMB6T7K TN Adrenergic receptor alpha-1B (ADRA1B) DMB6T7K MA Inhibitor DMB6T7K RN Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles. J Med Chem. 1995 May 26;38(11):1998-2008. DMB6T7K RU https://pubmed.ncbi.nlm.nih.gov/7783131 DMB74CM DI DMB74CM DMB74CM DN DIAVERIDINE DMB74CM TI TTV8DM2 DMB74CM TN Bacterial Dihydrofolate reductase (Bact DHFR) DMB74CM MA Modulator DMB74CM RN Acute and sub-chronic toxicity study of diaveridine in Wistar rats.Regul Toxicol Pharmacol.2015 Oct;73(1):232-40. DMB74CM RU https://www.ncbi.nlm.nih.gov/pubmed/26209270 DMBA4DK DI DMBA4DK DMBA4DK DN APC-6336 DMBA4DK TI TT3C1VN DMBA4DK TN Enzyme unspecific (Enz) DMBA4DK MA Inhibitor DMBA4DK RN CN patent application no. 103263414, Application of 2,2'-(1,4-phenylene)di(benzimidazole-5-carboxylic acid) in preparation of antitumor drug. DMBA4DK RU http://www.google.com/patents/CN103263414A?cl=en DMBC12X DI DMBC12X DMBC12X DN BRL-42715 DMBC12X TI TTHI19T DMBC12X TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMBC12X MA Inhibitor DMBC12X RN In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother. 1989 Sep;33(9):1580-7. DMBC12X RU https://pubmed.ncbi.nlm.nih.gov/2817854 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TTWG9A4 DMBC3DG TN Adrenergic receptor alpha-2A (ADRA2A) DMBC3DG MA Inhibitor DMBC3DG RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TTSQIFT DMBC3DG TN 5-HT 1A receptor (HTR1A) DMBC3DG MA Inhibitor DMBC3DG RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TTJQOD7 DMBC3DG TN 5-HT 2A receptor (HTR2A) DMBC3DG MA Inhibitor DMBC3DG RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TTEX248 DMBC3DG TN Dopamine D2 receptor (D2R) DMBC3DG MA Inhibitor DMBC3DG RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TTWM4TY DMBC3DG TN Adrenergic receptor alpha-2B (ADRA2B) DMBC3DG MA Inhibitor DMBC3DG RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TT3ROYC DMBC3DG TN Serotonin transporter (SERT) DMBC3DG MA Inhibitor DMBC3DG RN Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT upt... J Med Chem. 1997 Mar 28;40(7):1049-62. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/9089327 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TTE0A2F DMBC3DG TN Dopamine D4 receptor (D4R) DMBC3DG MA Inhibitor DMBC3DG RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMBC3DG DI DMBC3DG DMBC3DG DN A-80426 DMBC3DG TI TT2NUT5 DMBC3DG TN Adrenergic receptor alpha-2C (ADRA2C) DMBC3DG MA Inhibitor DMBC3DG RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMBC3DG RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMBCANZ DI DMBCANZ DMBCANZ DN SB-237376 DMBCANZ TI TT5HONZ DMBCANZ TN Calcium channel unspecific (CaC) DMBCANZ MA Modulator DMBCANZ RN Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21. DMBCANZ RU https://pubmed.ncbi.nlm.nih.gov/12605020 DMBCANZ DI DMBCANZ DMBCANZ DN SB-237376 DMBCANZ TI TT1VOHK DMBCANZ TN Potassium channel unspecific (KC) DMBCANZ MA Modulator DMBCANZ RN Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21. DMBCANZ RU https://pubmed.ncbi.nlm.nih.gov/12605020 DMBCIPO DI DMBCIPO DMBCIPO DN RGH-2721 DMBCIPO TI TT85JO3 DMBCIPO TN 5-HT receptor (5HTR) DMBCIPO MA Modulator DMBCIPO RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004008) DMBCIPO RU http://adisinsight.springer.com/drugs/800004008 DMBDCL4 DI DMBDCL4 DMBDCL4 DN ONO-8130 DMBDCL4 TI TTG1QMU DMBDCL4 TN Prostaglandin E2 receptor EP1 (PTGER1) DMBDCL4 MA Modulator DMBDCL4 RN ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81. DMBDCL4 RU https://pubmed.ncbi.nlm.nih.gov/21396778 DMBEIFL DI DMBEIFL DMBEIFL DN A-74273 DMBEIFL TI TTB2MXP DMBEIFL TN Angiotensinogenase renin (REN) DMBEIFL MA Inhibitor DMBEIFL RN The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metab Dispos. 1994 Nov-Dec;22(6):880-8. DMBEIFL RU https://pubmed.ncbi.nlm.nih.gov/7895605 DMBEUN6 DI DMBEUN6 DMBEUN6 DN SRI-3072 DMBEUN6 TI TT3C1VN DMBEUN6 TN Enzyme unspecific (Enz) DMBEUN6 MA Inhibitor DMBEUN6 RN 2-Alkoxycarbonylaminopyridines: inhibitors of Mycobacterium tuberculosis FtsZ. J Antimicrob Chemother. 2002 Jul;50(1):111-4. DMBEUN6 RU https://pubmed.ncbi.nlm.nih.gov/12096015 DMBFCHW DI DMBFCHW DMBFCHW DN M-40401 DMBFCHW TI TT6RVLG DMBFCHW TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMBFCHW MA Modulator DMBFCHW RN Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion. Br J Pharmacol. 2001 Jan;132(1):19-29. DMBFCHW RU https://pubmed.ncbi.nlm.nih.gov/11156557 DMBHYIJ DI DMBHYIJ DMBHYIJ DN CI-992 DMBHYIJ TI TTPT2QI DMBHYIJ TN Cathepsin D (CTSD) DMBHYIJ MA Inhibitor DMBHYIJ RN Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72. DMBHYIJ RU https://pubmed.ncbi.nlm.nih.gov/1635057 DMBIDQX DI DMBIDQX DMBIDQX DN MDL-43291 DMBIDQX TI TTGKOY9 DMBIDQX TN Leukotriene CysLT1 receptor (CYSLTR1) DMBIDQX MA Modulator DMBIDQX RN Conformationally restricted leukotriene receptor antagonists: [(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]ace tic acids. Pharmacology. 1990;40(5):271-6. DMBIDQX RU https://www.ncbi.nlm.nih.gov/pubmed/2177202 DMBIDQX DI DMBIDQX DMBIDQX DN MDL-43291 DMBIDQX TI TT0PZR5 DMBIDQX TN Leukotriene CysLT2 receptor (CYSLTR2) DMBIDQX MA Modulator DMBIDQX RN Conformationally restricted leukotriene receptor antagonists: [(octahydro-2-oxo-7-tetradecylidene-2H-1-benzopyran-8-yl)thio]ace tic acids. Pharmacology. 1990;40(5):271-6. DMBIDQX RU https://www.ncbi.nlm.nih.gov/pubmed/2177202 DMBJAUC DI DMBJAUC DMBJAUC DN D-26344 DMBJAUC TI TT8R70G DMBJAUC TN Gonadotropin-releasing hormone receptor (GNRHR) DMBJAUC MA Inhibitor DMBJAUC RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003256) DMBJAUC RU http://adisinsight.springer.com/drugs/800003256 DMBJERO DI DMBJERO DMBJERO DN BCX-140 DMBJERO TI TT50QJ3 DMBJERO TN Influenza Neuraminidase (Influ NA) DMBJERO MA Inhibitor DMBJERO RN CN patent application no. 104447481, Benzoic acid thiourea anti-influenza virus compounds as well as preparation method and use thereof. DMBJERO RU http://www.google.com/patents/CN104447481A?cl=en DMBKZ4R DI DMBKZ4R DMBKZ4R DN IGN-311 DMBKZ4R TI TTV75BJ DMBKZ4R TN Carbohydrate antigen Lewis-Y (Lewis-Y) DMBKZ4R RN IGN-311. Igeneon. Curr Opin Investig Drugs. 2005 Dec;6(12):1272-9. DMBKZ4R RU https://pubmed.ncbi.nlm.nih.gov/16370394 DMBMAPH DI DMBMAPH DMBMAPH DN GPI-3000 DMBMAPH TI TT9IK2Z DMBMAPH TN N-methyl-D-aspartate receptor (NMDAR) DMBMAPH MA Modulator DMBMAPH RN Treatment with the competitive NMDA antagonist GPI 3000 does not improve outcome after cardiac arrest in dogs. Stroke. 1998 Apr;29(4):824-9. DMBMAPH RU https://pubmed.ncbi.nlm.nih.gov/9550518 DMBMOI6 DI DMBMOI6 DMBMOI6 DN WF-2421 DMBMOI6 TI TTFBNVI DMBMOI6 TN Aldose reductase (AKR1B1) DMBMOI6 MA Modulator DMBMOI6 RN WF-2421, a new aldose reductase inhibitor produced from a fungus, Humicola grisea. J Antibiot (Tokyo). 1991 Feb;44(2):130-5. DMBMOI6 RU https://pubmed.ncbi.nlm.nih.gov/1901310 DMBNWM1 DI DMBNWM1 DMBNWM1 DN Cilofungin DMBNWM1 TI TTZMS1L DMBNWM1 TN Fungal Papulacandin B resistance protein 1 (Fung FKS1) DMBNWM1 MA Inhibitor DMBNWM1 RN Cryptococcus neoformans resistance to echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. Antimicrob Agents Chemother. 2005 Jul;49(7):2851-6. DMBNWM1 RU https://pubmed.ncbi.nlm.nih.gov/15980360 DMBOFSQ DI DMBOFSQ DMBOFSQ DN FR-149581 DMBOFSQ TI TTGN1ZA DMBOFSQ TN Angiotensin II receptor (AGTR) DMBOFSQ MA Antagonist DMBOFSQ RN US patent application no. 2003,0087,306, Methods for identifying novel multimeric agents that modulate receptors. DMBOFSQ RU http://www.google.com/patents/US20030087306 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TT6X50U DMBPNKT TN Matrix metalloproteinase-9 (MMP-9) DMBPNKT MA Inhibitor DMBPNKT RN Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50. DMBPNKT RU https://pubmed.ncbi.nlm.nih.gov/11585439 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TTGA1IV DMBPNKT TN Matrix metalloproteinase-8 (MMP-8) DMBPNKT MA Inhibitor DMBPNKT RN Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50. DMBPNKT RU https://pubmed.ncbi.nlm.nih.gov/11585439 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TTUZ2L5 DMBPNKT TN Matrix metalloproteinase-3 (MMP-3) DMBPNKT MA Inhibitor DMBPNKT RN Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997). DMBPNKT RU http://www.sciencedirect.com/science/article/pii/S0960894X97001820 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TTLM12X DMBPNKT TN Matrix metalloproteinase-2 (MMP-2) DMBPNKT MA Inhibitor DMBPNKT RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DMBPNKT RU https://pubmed.ncbi.nlm.nih.gov/12877590 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TTMTWOS DMBPNKT TN Matrix metalloproteinase-7 (MMP-7) DMBPNKT MA Inhibitor DMBPNKT RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DMBPNKT RU https://pubmed.ncbi.nlm.nih.gov/12877590 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TTXSU2Y DMBPNKT TN Aggrecanase (ADAMTS5) DMBPNKT MA Inhibitor DMBPNKT RN Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50. DMBPNKT RU https://pubmed.ncbi.nlm.nih.gov/11585439 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TTMX39J DMBPNKT TN Matrix metalloproteinase-1 (MMP-1) DMBPNKT MA Inhibitor DMBPNKT RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DMBPNKT RU https://pubmed.ncbi.nlm.nih.gov/12877590 DMBPNKT DI DMBPNKT DMBPNKT DN SC-44463 DMBPNKT TI TTYG6BU DMBPNKT TN Aggrecanase-1 (ADAMTS4) DMBPNKT MA Inhibitor DMBPNKT RN Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivati... J Med Chem. 2001 Oct 11;44(21):3347-50. DMBPNKT RU https://pubmed.ncbi.nlm.nih.gov/11585439 DMBR48G DI DMBR48G DMBR48G DN BI-L-357 DMBR48G TI TT2J34L DMBR48G TN Arachidonate 5-lipoxygenase (5-LOX) DMBR48G MA Inhibitor DMBR48G RN A prodrug of a 2,6-disubstituted 4-(2-arylethenyl)phenol is a selective and orally active 5-lipoxygenase inhibitor. J Pharmacol Exp Ther. 1993 May;265(2):483-9. DMBR48G RU https://pubmed.ncbi.nlm.nih.gov/8388452 DMBU24I DI DMBU24I DMBU24I DN R-1437 DMBU24I TI TTXEU7H DMBU24I TN GPCR unspecific (GPCR) DMBU24I MA Antagonist DMBU24I RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017122) DMBU24I RU http://adisinsight.springer.com/drugs/800017122 DMBXDQG DI DMBXDQG DMBXDQG DN RWJ-22108 DMBXDQG TI TT5HONZ DMBXDQG TN Calcium channel unspecific (CaC) DMBXDQG MA Modulator DMBXDQG RN Design and discovery of RWJ 22108--a novel bronchoselective calcium channel blocker. Drug Des Discov. 1998 May;15(3):135-48. DMBXDQG RU https://pubmed.ncbi.nlm.nih.gov/9689497 DMBY6CQ DI DMBY6CQ DMBY6CQ DN SDZ-87-469 DMBY6CQ TI TTE14XG DMBY6CQ TN Squalene monooxygenase (SQLE) DMBY6CQ MA Modulator DMBY6CQ RN Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81. DMBY6CQ RU https://pubmed.ncbi.nlm.nih.gov/1416865 DMBY7AZ DI DMBY7AZ DMBY7AZ DN ACEA-1011 DMBY7AZ TI TT9IK2Z DMBY7AZ TN N-methyl-D-aspartate receptor (NMDAR) DMBY7AZ MA Modulator DMBY7AZ RN NMDA receptor antagonists, MK-801 and ACEA-1011, prevent the development of tonic pain following subcutaneous formalin. Brain Res. 1993 Jul 2;615(2):331-4. DMBY7AZ RU https://pubmed.ncbi.nlm.nih.gov/8364741 DMBZ7SF DI DMBZ7SF DMBZ7SF DN SIM-6080 DMBZ7SF TI TT5HONZ DMBZ7SF TN Calcium channel unspecific (CaC) DMBZ7SF MA Blocker DMBZ7SF RN Determination of the calcium antagonist SIM6080 and its N- and O-demethylated metabolites in plasma, urine and tissues by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996 Feb 9;676(1):77-85. DMBZ7SF RU https://pubmed.ncbi.nlm.nih.gov/8852047 DMC0JN8 DI DMC0JN8 DMC0JN8 DN GYKI-53655 DMC0JN8 TI TTVPQTF DMC0JN8 TN Glutamate receptor AMPA 1 (GRIA1) DMC0JN8 MA Inhibitor DMC0JN8 RN Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6. DMC0JN8 RU https://pubmed.ncbi.nlm.nih.gov/8558499 DMC0JN8 DI DMC0JN8 DMC0JN8 DN GYKI-53655 DMC0JN8 TI TTAN6JD DMC0JN8 TN Glutamate receptor AMPA (GRIA) DMC0JN8 MA Inhibitor DMC0JN8 RN Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6. DMC0JN8 RU https://pubmed.ncbi.nlm.nih.gov/8558499 DMC1A42 DI DMC1A42 DMC1A42 DN SUN-11031 DMC1A42 TI TTWDC17 DMC1A42 TN Growth hormone secretagogue receptor 1 (GHSR) DMC1A42 MA Agonist DMC1A42 RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DMC1A42 RU https://pubmed.ncbi.nlm.nih.gov/16634704 DMC295V DI DMC295V DMC295V DN KC-11425 DMC295V TI TTQL5VC DMC295V TN Platelet-activating factor receptor (PTAFR) DMC295V MA Antagonist DMC295V RN WO patent application no. 2002,01223,5, 1,4-dihydropyridines as bradykinin antagonists. DMC295V RU https://www.google.com/patents/WO2002012235A1?cl=en&hl=zh-CN DMC295V DI DMC295V DMC295V DN KC-11425 DMC295V TI TT2J34L DMC295V TN Arachidonate 5-lipoxygenase (5-LOX) DMC295V MA Antagonist DMC295V RN WO patent application no. 2002,01223,5, 1,4-dihydropyridines as bradykinin antagonists. DMC295V RU https://www.google.com/patents/WO2002012235A1?cl=en&hl=zh-CN DMC38FO DI DMC38FO DMC38FO DN ZARDAVERINE DMC38FO TI TTZCG4L DMC38FO TN Phosphodiesterase 3 (PDE3) DMC38FO MA Modulator DMC38FO RN Zardaverine: a cyclic AMP specific PDE III/IV inhibitor.Agents Actions Suppl.1991;34:379-402. DMC38FO RU https://www.ncbi.nlm.nih.gov/pubmed/1665311 DMC3MH5 DI DMC3MH5 DMC3MH5 DN A-75729 DMC3MH5 TI TTR8XOH DMC3MH5 TN GPCR secretin protein unspecific (GPCRB) DMC3MH5 MA Modulator DMC3MH5 RN Olfaction. Leffingwell Reports, Vol. 2 (No. 1). May, 2002. DMC3MH5 RU http://www.leffingwell.com/download/Olfaction5.pdf DMC5O3X DI DMC5O3X DMC5O3X DN FRG-8701 DMC5O3X TI TTQHJ1K DMC5O3X TN Histamine H2 receptor (H2R) DMC5O3X MA Modulator DMC5O3X RN Effects of FRG-8701 on gastric acid secretion, gastric mucosal lesions by necrotizing agents and experimental gastric or duodenal ulcer in rats. Jpn J Pharmacol. 1990 Nov;54(3):277-85. DMC5O3X RU https://pubmed.ncbi.nlm.nih.gov/1982548 DMC8J6F DI DMC8J6F DMC8J6F DN Methylthioadenosine DMC8J6F TI TTDBX7N DMC8J6F TN S-methyl-5'-thioadenosine phosphorylase (MTAP) DMC8J6F MA Inhibitor DMC8J6F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMC8J6F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMC8J6F DI DMC8J6F DMC8J6F DN Methylthioadenosine DMC8J6F TI TTJFY5U DMC8J6F TN Adenosine A3 receptor (ADORA3) DMC8J6F MA Inhibitor DMC8J6F RN Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55. DMC8J6F RU https://pubmed.ncbi.nlm.nih.gov/15084123 DMC8J6F DI DMC8J6F DMC8J6F DN Methylthioadenosine DMC8J6F TI TTM2AOE DMC8J6F TN Adenosine A2a receptor (ADORA2A) DMC8J6F MA Inhibitor DMC8J6F RN Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55. DMC8J6F RU https://pubmed.ncbi.nlm.nih.gov/15084123 DMC8J6F DI DMC8J6F DMC8J6F DN Methylthioadenosine DMC8J6F TI TTNE7KG DMC8J6F TN Adenosine A2b receptor (ADORA2B) DMC8J6F MA Inhibitor DMC8J6F RN Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55. DMC8J6F RU https://pubmed.ncbi.nlm.nih.gov/15084123 DMC8J6F DI DMC8J6F DMC8J6F DN Methylthioadenosine DMC8J6F TI TTK25J1 DMC8J6F TN Adenosine A1 receptor (ADORA1) DMC8J6F MA Inhibitor DMC8J6F RN Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55. DMC8J6F RU https://pubmed.ncbi.nlm.nih.gov/15084123 DMCAZPR DI DMCAZPR DMCAZPR DN FR-113680 DMCAZPR TI TTZPO1L DMCAZPR TN Substance-P receptor (TACR1) DMCAZPR MA Inhibitor DMCAZPR RN FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity. Br J Pharmacol. 1992 May;106(1):123-6. DMCAZPR RU https://pubmed.ncbi.nlm.nih.gov/1380378 DMCDMWJ DI DMCDMWJ DMCDMWJ DN DC-015 DMCDMWJ TI TTG28O6 DMCDMWJ TN Adrenergic receptor Alpha-1 (ADRA1) DMCDMWJ MA Antagonist DMCDMWJ RN Antihypertensive and Hypolipidemic Effects of DC-015, a Novel, Potent and Specific alpha(1)-Adrenoceptor Antagonist: Comparison with Prazosin in Spontaneously Hypertensive Rats. J Biomed Sci. 1996 Apr;3(2):108-116. DMCDMWJ RU https://pubmed.ncbi.nlm.nih.gov/11725091 DMCFGS6 DI DMCFGS6 DMCFGS6 DN TCV-295 DMCFGS6 TI TT1VOHK DMCFGS6 TN Potassium channel unspecific (KC) DMCFGS6 MA Opener DMCFGS6 RN Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs. J Cardiovasc Pharmacol. 1994 Dec;24(6):929-36. DMCFGS6 RU https://pubmed.ncbi.nlm.nih.gov/7898076 DMCHFIT DI DMCHFIT DMCHFIT DN HMR-3787 DMCHFIT TI TTUWYEA DMCHFIT TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DMCHFIT MA Modulator DMCHFIT RN Structure-activity relationships for six ketolide antibiotics. Curr Microbiol. 2001 Mar;42(3):203-10. DMCHFIT RU https://pubmed.ncbi.nlm.nih.gov/11270656 DMCHLJ4 DI DMCHLJ4 DMCHLJ4 DN NS-004 DMCHLJ4 TI TT1VOHK DMCHLJ4 TN Potassium channel unspecific (KC) DMCHLJ4 MA Opener DMCHLJ4 RN Effects of K+ channel inhibitors and antagonists on NS-004 evoked relaxations in guinea-pig isolated trachea. Fundam Clin Pharmacol. 1997;11(1):78-82. DMCHLJ4 RU https://pubmed.ncbi.nlm.nih.gov/9182080 DMCIXYR DI DMCIXYR DMCIXYR DN CP-331 DMCIXYR TI TTQHJ1K DMCIXYR TN Histamine H2 receptor (H2R) DMCIXYR MA Modulator DMCIXYR RN Conjugation of chlorin p(6) to histamine enhances its cellular uptake and phototoxicity in oral cancer cells. Cancer Chemother Pharmacol. 2011 Aug;68(2):359-69. DMCIXYR RU https://pubmed.ncbi.nlm.nih.gov/20978762 DMCJ7N1 DI DMCJ7N1 DMCJ7N1 DN CI-996 DMCJ7N1 TI TTGN1ZA DMCJ7N1 TN Angiotensin II receptor (AGTR) DMCJ7N1 MA Modulator DMCJ7N1 RN Pharmacologic characterization of CI-996, a new angiotensin receptor antagonist. J Pharmacol Exp Ther. 1995 Mar;272(3):963-9. DMCJ7N1 RU https://pubmed.ncbi.nlm.nih.gov/7891350 DMCNE2G DI DMCNE2G DMCNE2G DN PX-867 DMCNE2G TI TTHBTOP DMCNE2G TN PI3-kinase gamma (PIK3CG) DMCNE2G MA Modulator DMCNE2G RN Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death. J Pharmacol Exp Ther. 2013 Dec;347(3):669-80. DMCNE2G RU https://pubmed.ncbi.nlm.nih.gov/24068833 DMCPDBS DI DMCPDBS DMCPDBS DN SLV-307 DMCPDBS TI TTSQIFT DMCPDBS TN 5-HT 1A receptor (HTR1A) DMCPDBS MA Antagonist DMCPDBS RN Development and validation of a capillary electrophoresis method for the enantiomeric purity determination of SLV307, a basic potential antipsychotic compound. Electrophoresis. 2004 Aug;25(16):2854-9. DMCPDBS RU https://pubmed.ncbi.nlm.nih.gov/15352019 DMCPDBS DI DMCPDBS DMCPDBS DN SLV-307 DMCPDBS TI TTEX248 DMCPDBS TN Dopamine D2 receptor (D2R) DMCPDBS MA Antagonist DMCPDBS RN Development and validation of a capillary electrophoresis method for the enantiomeric purity determination of SLV307, a basic potential antipsychotic compound. Electrophoresis. 2004 Aug;25(16):2854-9. DMCPDBS RU https://pubmed.ncbi.nlm.nih.gov/15352019 DMCQHG4 DI DMCQHG4 DMCQHG4 DN FR-183998 DMCQHG4 TI TT70SZ3 DMCQHG4 TN Sodium/hydrogen exchanger (SLC) DMCQHG4 MA Modulator DMCQHG4 RN Protective effect of FR183998, a Na+/H+ exchanger inhibitor, and its inhibition of iNOS induction in hepatic ischemia-reperfusion injury in rats. Shock. 2008 Sep;30(3):311-7. DMCQHG4 RU https://pubmed.ncbi.nlm.nih.gov/18277953 DMCRQTH DI DMCRQTH DMCRQTH DN L-371257 DMCRQTH TI TT4TFGN DMCRQTH TN Vasopressin V1a receptor (V1AR) DMCRQTH MA Inhibitor DMCRQTH RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DMCRQTH RU https://pubmed.ncbi.nlm.nih.gov/20550119 DMCRQTH DI DMCRQTH DMCRQTH DN L-371257 DMCRQTH TI TTSCIUP DMCRQTH TN Oxytocin receptor (OTR) DMCRQTH MA Inhibitor DMCRQTH RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DMCRQTH RU https://pubmed.ncbi.nlm.nih.gov/20550119 DMCT1IX DI DMCT1IX DMCT1IX DN ZD-7944 DMCT1IX TI TTYO0A3 DMCT1IX TN Substance-K receptor (TACR2) DMCT1IX MA Modulator DMCT1IX RN Discovery of novel, orally active dual NK1/NK2 antagonists. Bioorg Med Chem Lett. 2001 Oct 22;11(20):2769-73. DMCT1IX RU https://pubmed.ncbi.nlm.nih.gov/11591520 DMCVY4U DI DMCVY4U DMCVY4U DN L-689560 DMCVY4U TI TT9IK2Z DMCVY4U TN N-methyl-D-aspartate receptor (NMDAR) DMCVY4U MA Modulator DMCVY4U RN Characterization of the binding of [3H]L-689,560, an antagonist for the glycine site on the N-methyl-D-aspartate receptor, to rat brain membranes. Mol Pharmacol. 1992 May;41(5):923-30. DMCVY4U RU https://pubmed.ncbi.nlm.nih.gov/1375318 DMCVY4U DI DMCVY4U DMCVY4U DN L-689560 DMCVY4U TI TTLD29N DMCVY4U TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMCVY4U MA Antagonist DMCVY4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMCVY4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMCVY4U DI DMCVY4U DMCVY4U DN L-689560 DMCVY4U TI TT5POTG DMCVY4U TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMCVY4U MA Antagonist DMCVY4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMCVY4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMCVY4U DI DMCVY4U DMCVY4U DN L-689560 DMCVY4U TI TTKJEMQ DMCVY4U TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMCVY4U MA Antagonist DMCVY4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMCVY4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMCVY4U DI DMCVY4U DMCVY4U DN L-689560 DMCVY4U TI TT1M8OW DMCVY4U TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMCVY4U MA Antagonist DMCVY4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMCVY4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMCVY4U DI DMCVY4U DMCVY4U DN L-689560 DMCVY4U TI TTN9D8E DMCVY4U TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMCVY4U MA Antagonist DMCVY4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMCVY4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMCW5DJ DI DMCW5DJ DMCW5DJ DN ABS-301 DMCW5DJ TI TT1RS9F DMCW5DJ TN Acetylcholinesterase (AChE) DMCW5DJ MA Modulator DMCW5DJ RN Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. J Med Chem. 1997 Oct 24;40(22):3516-23. DMCW5DJ RU https://pubmed.ncbi.nlm.nih.gov/9357518 DMCWNVB DI DMCWNVB DMCWNVB DN ACEA-1031 DMCWNVB TI TT9IK2Z DMCWNVB TN N-methyl-D-aspartate receptor (NMDAR) DMCWNVB MA Modulator DMCWNVB RN In vitro pharmacology of ACEA-1021 and ACEA-1031: systemically active quinoxalinediones with high affinity and selectivity for N-methyl-D-aspartate receptor glycine sites. Mol Pharmacol. 1995 Mar;47(3):568-81. DMCWNVB RU https://pubmed.ncbi.nlm.nih.gov/7700254 DMCYZL3 DI DMCYZL3 DMCYZL3 DN GS-9148 DMCYZL3 TI TT84ETX DMCYZL3 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMCYZL3 MA Inhibitor DMCYZL3 RN Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother. 2009 Jan;53(1):150-6. DMCYZL3 RU https://pubmed.ncbi.nlm.nih.gov/19001108 DMCZDE9 DI DMCZDE9 DMCZDE9 DN SB-219994 DMCZDE9 TI TTZMAO3 DMCZDE9 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMCZDE9 MA Agonist DMCZDE9 RN PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J. 2004 Jul;24(1):18-23. DMCZDE9 RU https://pubmed.ncbi.nlm.nih.gov/15293600 DMD01GK DI DMD01GK DMD01GK DN NPC-17923 DMD01GK TI TTD26RC DMD01GK TN Cell adhesion molecule (CADM) DMD01GK MA Modulator DMD01GK RN Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin. Eur J Pharmacol. 1993 Mar 2;232(2-3):169-72. DMD01GK RU https://pubmed.ncbi.nlm.nih.gov/8467855 DMD0FNH DI DMD0FNH DMD0FNH DN KC-399 DMD0FNH TI TT1VOHK DMD0FNH TN Potassium channel unspecific (KC) DMD0FNH MA Opener DMD0FNH RN Action of KC-399, a newly synthesized potassium channel opener, on mechanical activity and 86Rb efflux in rat aorta. J Cardiovasc Pharmacol. 1994 Feb;23(2):220-6. DMD0FNH RU https://pubmed.ncbi.nlm.nih.gov/7511750 DMD3CA5 DI DMD3CA5 DMD3CA5 DN UCL-1390 DMD3CA5 TI TT9JNIC DMD3CA5 TN Histamine H3 receptor (H3R) DMD3CA5 MA Antagonist DMD3CA5 RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DMD3CA5 RU https://pubmed.ncbi.nlm.nih.gov/16634704 DMD4BFY DI DMD4BFY DMD4BFY DN Spermine DMD4BFY TI TTKJEMQ DMD4BFY TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMD4BFY MA Inhibitor DMD4BFY RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DMD4BFY RU https://pubmed.ncbi.nlm.nih.gov/20361801 DMD4BFY DI DMD4BFY DMD4BFY DN Spermine DMD4BFY TI TTUNARX DMD4BFY TN Carbonic anhydrase (CA) DMD4BFY MA Inhibitor DMD4BFY RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD4BFY RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4BFY DI DMD4BFY DMD4BFY DN Spermine DMD4BFY TI TTZHA0O DMD4BFY TN Carbonic anhydrase IV (CA-IV) DMD4BFY MA Inhibitor DMD4BFY RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD4BFY RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4BFY DI DMD4BFY DMD4BFY DN Spermine DMD4BFY TI TTLD29N DMD4BFY TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMD4BFY MA Inhibitor DMD4BFY RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DMD4BFY RU https://pubmed.ncbi.nlm.nih.gov/20361801 DMD4BFY DI DMD4BFY DMD4BFY DN Spermine DMD4BFY TI TT2LVK8 DMD4BFY TN Carbonic anhydrase IX (CA-IX) DMD4BFY MA Inhibitor DMD4BFY RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD4BFY RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4BFY DI DMD4BFY DMD4BFY DN Spermine DMD4BFY TI TTCFSPE DMD4BFY TN Carbonic anhydrase VI (CA-VI) DMD4BFY MA Inhibitor DMD4BFY RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD4BFY RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4BFY DI DMD4BFY DMD4BFY DN Spermine DMD4BFY TI TTEYTKG DMD4BFY TN Carbonic anhydrase XIV (CA-XIV) DMD4BFY MA Inhibitor DMD4BFY RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMD4BFY RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMD4GQ8 DI DMD4GQ8 DMD4GQ8 DN E-2011 DMD4GQ8 TI TT3WG5C DMD4GQ8 TN Monoamine oxidase type A (MAO-A) DMD4GQ8 MA Modulator DMD4GQ8 RN Species differences and mechanism of the epimerization of a new MAO-A inhibitor. Xenobiotica. 1998 Mar;28(3):269-80. DMD4GQ8 RU https://pubmed.ncbi.nlm.nih.gov/9574815 DMD5WK4 DI DMD5WK4 DMD5WK4 DN Gpi-1046 DMD5WK4 TI TTMW94E DMD5WK4 TN FK506-binding protein 1A (FKBP1A) DMD5WK4 MA Inhibitor DMD5WK4 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMD5WK4 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMD6L82 DI DMD6L82 DMD6L82 DN PD136450 DMD6L82 TI TTVFO0U DMD6L82 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMD6L82 MA Antagonist DMD6L82 RN Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gut. 1994 Feb;35(2):270-4. DMD6L82 RU https://pubmed.ncbi.nlm.nih.gov/8307482 DMD6SXO DI DMD6SXO DMD6SXO DN ISIS-1082 DMD6SXO TI TT84ETX DMD6SXO TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMD6SXO MA Modulator DMD6SXO RN Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats. Toxicology. 1997 Jan 15;116(1-3):77-88. DMD6SXO RU https://pubmed.ncbi.nlm.nih.gov/9020509 DMD82LM DI DMD82LM DMD82LM DN AMT-030 DMD82LM TI TTF5NVW DMD82LM TN Alanine glyoxylate aminotransferase (AGXT) DMD82LM MA Modulator DMD82LM RN Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011 Dec 22;365(25):2357-65. DMD82LM RU https://pubmed.ncbi.nlm.nih.gov/22149959 DMD8ZM1 DI DMD8ZM1 DMD8ZM1 DN AWD-23-111 DMD8ZM1 TI TT1VOHK DMD8ZM1 TN Potassium channel unspecific (KC) DMD8ZM1 MA Opener DMD8ZM1 RN The new antiarrhythmic substance AWD 23-111 inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Pharmazie. 1999 Jan;54(1):61-8. DMD8ZM1 RU https://pubmed.ncbi.nlm.nih.gov/9987799 DMDAMBW DI DMDAMBW DMDAMBW DN AMPEROZIDE DMDAMBW TI TTJQOD7 DMDAMBW TN 5-HT 2A receptor (HTR2A) DMDAMBW MA Modulator DMDAMBW RN Action of the 5-HT2A antagonist amperozide on alcohol-induced poikilothermia in rats. Pharmacol Biochem Behav. 1998 Jan;59(1):91-5. DMDAMBW RU https://www.ncbi.nlm.nih.gov/pubmed/9443541 DMDBICR DI DMDBICR DMDBICR DN ICM-3 DMDBICR TI TTD26RC DMDBICR TN Cell adhesion molecule (CADM) DMDBICR RN Anti-tumor activity of an ICAM-3 antibody (ICM3) Against human leukemic xenograft tumors in nude mice. Volume 28, Issue 7, Supplement 1, 1 July 2000, Pages 59-60. DMDBICR RU http://www.sciencedirect.com/science/article/pii/S0301472X00002745 DMDC2E8 DI DMDC2E8 DMDC2E8 DN Recainam DMDC2E8 TI TTRK8B9 DMDC2E8 TN Sodium channel unspecific (NaC) DMDC2E8 MA Modulator DMDC2E8 RN Effects of renal function on recainam pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1995 May;57(5):492-8. DMDC2E8 RU https://pubmed.ncbi.nlm.nih.gov/7768071 DMDEPKM DI DMDEPKM DMDEPKM DN CP-471358 DMDEPKM TI TT1GHVO DMDEPKM TN Matrix metalloproteinase (MMP) DMDEPKM MA Inhibitor DMDEPKM RN A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42. DMDEPKM RU https://pubmed.ncbi.nlm.nih.gov/15592721 DMDH0AM DI DMDH0AM DMDH0AM DN CEP-431 DMDH0AM TI TTZBFA0 DMDH0AM TN Protease unspecific (PRO) DMDH0AM MA Inhibitor DMDH0AM RN US patent application no. 7,935,815, Imidazoyl pyridine compounds and salts thereof. DMDH0AM RU http://www.google.com/patents/US7935815 DMDHLUC DI DMDHLUC DMDHLUC DN LU-29252 DMDHLUC TI TT5TPI6 DMDHLUC TN Opioid receptor sigma 1 (OPRS1) DMDHLUC MA Modulator DMDHLUC RN Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems. Eur J Pharmacol. 1999 Mar 5;368(2-3):183-96. DMDHLUC RU https://pubmed.ncbi.nlm.nih.gov/10193654 DMDIYFH DI DMDIYFH DMDIYFH DN PRE-084 DMDIYFH TI TT5TPI6 DMDIYFH TN Opioid receptor sigma 1 (OPRS1) DMDIYFH MA Modulator DMDIYFH RN Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice. Pharmacol Rep. 2009 Nov-Dec;61(6):1179-83. DMDIYFH RU https://pubmed.ncbi.nlm.nih.gov/20081254 DMDJT7U DI DMDJT7U DMDJT7U DN NSC-661755 DMDJT7U TI TT12ABZ DMDJT7U TN Arachidonate 12-lipoxygenase (12-LOX) DMDJT7U MA Inhibitor DMDJT7U RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DMDJT7U RU https://pubmed.ncbi.nlm.nih.gov/17826100 DMDJT7U DI DMDJT7U DMDJT7U DN NSC-661755 DMDJT7U TI TTN9T81 DMDJT7U TN Arachidonate 15-lipoxygenase (15-LOX) DMDJT7U MA Inhibitor DMDJT7U RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DMDJT7U RU https://pubmed.ncbi.nlm.nih.gov/17826100 DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TT57MT2 DMDLN9E TN PKC-epsilon messenger RNA (PRKCE mRNA) DMDLN9E MA Inhibitor DMDLN9E RN Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995). DMDLN9E RU http://www.sciencedirect.com/science/article/pii/0960894X9500352T DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTER6YH DMDLN9E TN Casein kinase II alpha (CSNK2A1) DMDLN9E MA Inhibitor DMDLN9E RN Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27. DMDLN9E RU https://pubmed.ncbi.nlm.nih.gov/8978850 DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTBSN0L DMDLN9E TN PKC-zeta messenger RNA (PRKCZ mRNA) DMDLN9E MA Inhibitor DMDLN9E RN Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995). DMDLN9E RU http://www.sciencedirect.com/science/article/pii/0960894X9500352T DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TT7A1BO DMDLN9E TN PKC-delta messenger RNA (PRKCD mRNA) DMDLN9E MA Inhibitor DMDLN9E RN Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995). DMDLN9E RU http://www.sciencedirect.com/science/article/pii/0960894X9500352T DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTYVI76 DMDLN9E TN Fungal Protein kinase A (Fung ypkA) DMDLN9E MA Inhibitor DMDLN9E RN Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address; DMDLN9E RU https://pubmed.ncbi.nlm.nih.gov/16134928 DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTW4Y2M DMDLN9E TN cAMP protein kinase type II-beta (PRKAR2B) DMDLN9E MA Inhibitor DMDLN9E RN Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address; DMDLN9E RU https://pubmed.ncbi.nlm.nih.gov/16134928 DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTRFOXJ DMDLN9E TN Protein kinase C gamma (PRKCG) DMDLN9E MA Inhibitor DMDLN9E RN Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995). DMDLN9E RU http://www.sciencedirect.com/science/article/pii/0960894X9500352T DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTONI0R DMDLN9E TN PKC-eta messenger RNA (PRKCH mRNA) DMDLN9E MA Inhibitor DMDLN9E RN Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995). DMDLN9E RU http://www.sciencedirect.com/science/article/pii/0960894X9500352T DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TT5U49F DMDLN9E TN PRKACA messenger RNA (PRKACA mRNA) DMDLN9E MA Inhibitor DMDLN9E RN Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address; DMDLN9E RU https://pubmed.ncbi.nlm.nih.gov/16134928 DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTFJ8Q1 DMDLN9E TN Protein kinase C alpha (PRKCA) DMDLN9E MA Inhibitor DMDLN9E RN Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995). DMDLN9E RU http://www.sciencedirect.com/science/article/pii/0960894X9500352T DMDLN9E DI DMDLN9E DMDLN9E DN BALANOL DMDLN9E TI TTYPXQF DMDLN9E TN Protein kinase C beta (PRKCB) DMDLN9E MA Inhibitor DMDLN9E RN Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995). DMDLN9E RU http://www.sciencedirect.com/science/article/pii/0960894X9500352T DMDLW64 DI DMDLW64 DMDLW64 DN RP-67580 DMDLW64 TI TTZPO1L DMDLW64 TN Substance-P receptor (TACR1) DMDLW64 MA Antagonist DMDLW64 RN Effects of RP 67580, a tachykinin NK1 receptor antagonist, on a primary afferent-evoked response of ventral roots in the neonatal rat spinal cord. Br J Pharmacol. 1994 Dec;113(4):1141-6. DMDLW64 RU https://pubmed.ncbi.nlm.nih.gov/7534180 DMDOQCV DI DMDOQCV DMDOQCV DN ABANOQUIL DMDOQCV TI TTNGILX DMDOQCV TN Adrenergic receptor alpha-1A (ADRA1A) DMDOQCV MA Inhibitor DMDOQCV RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMDOQCV RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMDOQCV DI DMDOQCV DMDOQCV DN ABANOQUIL DMDOQCV TI TT34BHT DMDOQCV TN Adrenergic receptor alpha-1D (ADRA1D) DMDOQCV MA Inhibitor DMDOQCV RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMDOQCV RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMDOQCV DI DMDOQCV DMDOQCV DN ABANOQUIL DMDOQCV TI TTBRKXS DMDOQCV TN Adrenergic receptor alpha-1B (ADRA1B) DMDOQCV MA Inhibitor DMDOQCV RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMDOQCV RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMDPJ8M DI DMDPJ8M DMDPJ8M DN BMY-20844 DMDPJ8M TI TT06AWU DMDPJ8M TN Phosphodiesterase 3A (PDE3A) DMDPJ8M MA Inhibitor DMDPJ8M RN Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96. DMDPJ8M RU https://pubmed.ncbi.nlm.nih.gov/1321911 DMDPUK6 DI DMDPUK6 DMDPUK6 DN ABX-PTH DMDPUK6 TI TT6F7GZ DMDPUK6 TN Parathyroid hormone (PTH) DMDPUK6 RN Focus on parathyroid carcinoma. International Journal of Surgery Volume 9, Issue 1, 2011, Pages 13-19. DMDPUK6 RU http://www.sciencedirect.com/science/article/pii/S1743919110004437 DMDQBAL DI DMDQBAL DMDQBAL DN CP-293019 DMDQBAL TI TTSQIFT DMDQBAL TN 5-HT 1A receptor (HTR1A) DMDQBAL MA Inhibitor DMDQBAL RN Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist. Bioorg Med Chem Lett. 1998 Apr 7;8(7):725-30. DMDQBAL RU https://pubmed.ncbi.nlm.nih.gov/9871530 DMDQGFR DI DMDQGFR DMDQGFR DN S-1389 DMDQGFR TI TT1VOHK DMDQGFR TN Potassium channel unspecific (KC) DMDQGFR MA Opener DMDQGFR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000214) DMDQGFR RU http://adisinsight.springer.com/drugs/800000214 DMDTA36 DI DMDTA36 DMDTA36 DN A-252444.0 DMDTA36 TI TTCT6F7 DMDTA36 TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMDTA36 MA Antagonist DMDTA36 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012566) DMDTA36 RU http://adisinsight.springer.com/drugs/800012566 DMDVAI5 DI DMDVAI5 DMDVAI5 DN Florifenine DMDVAI5 TI TTK0943 DMDVAI5 TN Prostaglandin G/H synthase (COX) DMDVAI5 MA Modulator DMDVAI5 RN A study of the novel anti-inflammatory agent florifenine topical anti-inflammatory activity and influence on arachidonic acid metabolism and neutrophil functions. Naunyn Schmiedebergs Arch Pharmacol.1995 Mar;351(3):298-304. DMDVAI5 RU https://pubmed.ncbi.nlm.nih.gov/7609784 DMDXLG2 DI DMDXLG2 DMDXLG2 DN YM-099 DMDXLG2 TI TT1VOHK DMDXLG2 TN Potassium channel unspecific (KC) DMDXLG2 MA Opener DMDXLG2 RN Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta. Arch Int Pharmacodyn Ther. 1994 May-Jun;327(3):330-43. DMDXLG2 RU https://pubmed.ncbi.nlm.nih.gov/7848015 DME07ML DI DME07ML DME07ML DN D-21775 DME07ML TI TT8R70G DME07ML TN Gonadotropin-releasing hormone receptor (GNRHR) DME07ML MA Modulator DME07ML RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DME07ML RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DME20VP DI DME20VP DME20VP DN BMS-433771 DME20VP TI TT8DSFC DME20VP TN Hydroxyphenylpyruvate dioxygenase (HPD) DME20VP MA Inhibitor DME20VP RN Emerging drugs for respiratory syncytial virus infection. Expert Opin Emerg Drugs. 2009 Jun;14(2):207-17. DME20VP RU https://pubmed.ncbi.nlm.nih.gov/19453286 DME694O DI DME694O DME694O DN Fananserin DME694O TI TTJQOD7 DME694O TN 5-HT 2A receptor (HTR2A) DME694O MA Antagonist DME694O RN Autoradiographic studies of RP 62203, a potent 5-HT2 receptor antagonist. Pharmacological characterization of [3H]RP 62203 binding in the rat brain. Eur J Pharmacol. 1993 Mar 16;233(1):37-45. DME694O RU https://pubmed.ncbi.nlm.nih.gov/8472747 DME6OFU DI DME6OFU DME6OFU DN B-428 DME6OFU TI TTGY7WI DME6OFU TN Urokinase-type plasminogen activator (PLAU) DME6OFU MA Inhibitor DME6OFU RN Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol. 2000;477:331-41. DME6OFU RU https://pubmed.ncbi.nlm.nih.gov/10849761 DME9Q3V DI DME9Q3V DME9Q3V DN Sch-45752 DME9Q3V TI TTUST1O DME9Q3V TN Phosphodiesterase (PDE) DME9Q3V MA Inhibitor DME9Q3V RN SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13. DME9Q3V RU https://pubmed.ncbi.nlm.nih.gov/8385657 DME9Q3V DI DME9Q3V DME9Q3V DN Sch-45752 DME9Q3V TI TTL53M6 DME9Q3V TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DME9Q3V MA Inhibitor DME9Q3V RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DME9Q3V RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMEDLHG DI DMEDLHG DMEDLHG DN BMS-182193 DMEDLHG TI TT5FNQT DMEDLHG TN Human immunodeficiency virus Protease (HIV PR) DMEDLHG MA Modulator DMEDLHG RN Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother. 1995 Feb;39(2):374-9. DMEDLHG RU https://pubmed.ncbi.nlm.nih.gov/7726501 DMEH50J DI DMEH50J DMEH50J DN NE-033 DMEH50J TI TT5TPI6 DMEH50J TN Opioid receptor sigma 1 (OPRS1) DMEH50J MA Modulator DMEH50J RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004064) DMEH50J RU http://adisinsight.springer.com/drugs/800004064 DMEH9OY DI DMEH9OY DMEH9OY DN ACEA-1328 DMEH9OY TI TT9IK2Z DMEH9OY TN N-methyl-D-aspartate receptor (NMDAR) DMEH9OY MA Antagonist DMEH9OY RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DMEH9OY RU https://pubmed.ncbi.nlm.nih.gov/15757410 DMEHAI2 DI DMEHAI2 DMEHAI2 DN YM-26734 DMEHAI2 TI TT9V5JH DMEHAI2 TN Phospholipase A2 (PLA2G1B) DMEHAI2 MA Modulator DMEHAI2 RN Simplified YM-26734 Inhibitors of Secreted Phospholipase A2 Group IIA DMEHAI2 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2578825 DMEIR7F DI DMEIR7F DMEIR7F DN UP-116-77 DMEIR7F TI TT2O84V DMEIR7F TN Thromboxane A2 receptor (TBXA2R) DMEIR7F MA Modulator DMEIR7F RN Synthesis and structure-activity relationships of novel benzimidazole and imidazo[4,5-b]pyridine acid derivatives as thromboxane A2 receptor antagonists. J Med Chem. 1993 Apr 30;36(9):1175-87. DMEIR7F RU https://pubmed.ncbi.nlm.nih.gov/8487256 DMEIW7K DI DMEIW7K DMEIW7K DN CMI-206 DMEIW7K TI TT2J34L DMEIW7K TN Arachidonate 5-lipoxygenase (5-LOX) DMEIW7K MA Modulator DMEIW7K RN DOI: 10.1016/0960-894X(95)00088-B DMEIW7K RU http://www.sciencedirect.com/science/article/pii/0960894X9500088B DMEIW7K DI DMEIW7K DMEIW7K DN CMI-206 DMEIW7K TI TTQL5VC DMEIW7K TN Platelet-activating factor receptor (PTAFR) DMEIW7K MA Modulator DMEIW7K RN DOI: 10.1016/0960-894X(95)00088-B DMEIW7K RU http://www.sciencedirect.com/science/article/pii/0960894X9500088B DMEJBQY DI DMEJBQY DMEJBQY DN CP-903397 DMEJBQY TI TTEX248 DMEJBQY TN Dopamine D2 receptor (D2R) DMEJBQY MA Modulator DMEJBQY RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025558) DMEJBQY RU http://adisinsight.springer.com/drugs/800025558 DMEJU1L DI DMEJU1L DMEJU1L DN Ipsapirone DMEJU1L TI TTSQIFT DMEJU1L TN 5-HT 1A receptor (HTR1A) DMEJU1L MA Agonist DMEJU1L RN Chronic voluntary ethanol intake hypersensitizes 5-HT(1A) autoreceptors in C57BL/6J mice. J Neurochem. 2008 Dec;107(6):1660-70. DMEJU1L RU https://pubmed.ncbi.nlm.nih.gov/19094059 DMEN6YO DI DMEN6YO DMEN6YO DN Sameridine DMEN6YO TI TTKWM86 DMEN6YO TN Opioid receptor mu (MOP) DMEN6YO MA Modulator DMEN6YO RN The effects on resting ventilation of intravenous infusions of morphine or sameridine, a novel molecule with both local anesthetic and opioid properties. Anesth Analg. 1999 Jan;88(1):160-5. DMEN6YO RU https://pubmed.ncbi.nlm.nih.gov/9895085 DMEO7YD DI DMEO7YD DMEO7YD DN RWJ-46458 DMEO7YD TI TTGN1ZA DMEO7YD TN Angiotensin II receptor (AGTR) DMEO7YD MA Modulator DMEO7YD RN WO patent application no. 1996,0402,58, Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure. DMEO7YD RU http://www.google.com/patents/WO1996040258A2?cl=en DMEP9B6 DI DMEP9B6 DMEP9B6 DN BW-1003C87 DMEP9B6 TI TTRK8B9 DMEP9B6 TN Sodium channel unspecific (NaC) DMEP9B6 MA Modulator DMEP9B6 RN The pyrimidine-derivative, BW1003C87, protects CA1 and striatal neurons following transient severe forebrain ischaemia in rats. A microdialysis and histological study. Neuroscience. 1993 Sep;56(1):93-9. DMEP9B6 RU https://pubmed.ncbi.nlm.nih.gov/7901808 DMES0OT DI DMES0OT DMES0OT DN NS-1619 DMES0OT TI TT1AQ50 DMES0OT TN Charybdotoxin receptor beta-4 (BKbeta4) DMES0OT MA Modulator DMES0OT RN BK channel activation by NS-1619 is partially mediated by intracellular Ca2+ release in smooth muscle cells of porcine coronary artery DMES0OT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1572625 DMESWV1 DI DMESWV1 DMESWV1 DN OX-23 DMESWV1 TI TTN4QDT DMESWV1 TN Opioid receptor (OPR) DMESWV1 RN CA patent application no. 212323, Method for improving gastrointestinal motility. DMESWV1 RU http://www.google.com/patents/CA1212323A1?cl=en DMETDFM DI DMETDFM DMETDFM DN SR 120819A DMETDFM TI TTRK9JT DMETDFM TN Neuropeptide Y receptor type 1 (NPY1R) DMETDFM MA Antagonist DMETDFM RN SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6. DMETDFM RU https://pubmed.ncbi.nlm.nih.gov/7720871 DMEVIP9 DI DMEVIP9 DMEVIP9 DN GM-7050 DMEVIP9 TI TTD26RC DMEVIP9 TN Cell adhesion molecule (CADM) DMEVIP9 MA Modulator DMEVIP9 RN US patent application no. 6,673,908, Tumor necrosis factor receptor 2. DMEVIP9 RU http://www.google.com/patents/US6673908 DMEVSZO DI DMEVSZO DMEVSZO DN XR-5082 DMEVSZO TI TT5QA2I DMEVSZO TN Plasminogen activator inhibitor (PAI) DMEVSZO MA Inhibitor DMEVSZO RN Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost. 1996 May;75(5):808-15. DMEVSZO RU https://pubmed.ncbi.nlm.nih.gov/8725728 DMEWLZ7 DI DMEWLZ7 DMEWLZ7 DN SCH-54470 DMEWLZ7 TI TTL69WB DMEWLZ7 TN Angiotensin-converting enzyme (ACE) DMEWLZ7 MA Inhibitor DMEWLZ7 RN Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20. DMEWLZ7 RU https://pubmed.ncbi.nlm.nih.gov/19899765 DMEWLZ7 DI DMEWLZ7 DMEWLZ7 DN SCH-54470 DMEWLZ7 TI TTQ9RYT DMEWLZ7 TN Endothelin-converting enzyme 1 (ECE1) DMEWLZ7 MA Inhibitor DMEWLZ7 RN Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20. DMEWLZ7 RU https://pubmed.ncbi.nlm.nih.gov/19899765 DMEWLZ7 DI DMEWLZ7 DMEWLZ7 DN SCH-54470 DMEWLZ7 TI TT5TKPM DMEWLZ7 TN Neutral endopeptidase (MME) DMEWLZ7 MA Inhibitor DMEWLZ7 RN Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20. DMEWLZ7 RU https://pubmed.ncbi.nlm.nih.gov/19899765 DMEYNB0 DI DMEYNB0 DMEYNB0 DN MEN-11149 DMEYNB0 TI TTZPO1L DMEYNB0 TN Substance-P receptor (TACR1) DMEYNB0 MA Antagonist DMEYNB0 RN Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist. Eur J Pharmacol. 1998 Jan 12;341(2-3):201-9. DMEYNB0 RU https://pubmed.ncbi.nlm.nih.gov/9543241 DMEZ5P2 DI DMEZ5P2 DMEZ5P2 DN HRC-101 DMEZ5P2 TI TTQO71U DMEZ5P2 TN Hemoglobin (HB) DMEZ5P2 MA Modulator DMEZ5P2 RN The novel hemoglobin-based oxygen carrier HRC 101 improves survival in murine sickle cell disease. Anesthesiology. 2007 Aug;107(2):281-7. DMEZ5P2 RU https://pubmed.ncbi.nlm.nih.gov/17667573 DMF0QMD DI DMF0QMD DMF0QMD DN SM 11044 DMF0QMD TI TTMXGCW DMF0QMD TN Adrenergic receptor beta-3 (ADRB3) DMF0QMD MA Agonist DMF0QMD RN Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34. DMF0QMD RU https://pubmed.ncbi.nlm.nih.gov/8696421 DMF1CDK DI DMF1CDK DMF1CDK DN FPL-55712 DMF1CDK TI TTGKOY9 DMF1CDK TN Leukotriene CysLT1 receptor (CYSLTR1) DMF1CDK MA Modulator DMF1CDK RN Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat. Br J Pharmacol. 1991 Apr;102(4):865-70. DMF1CDK RU https://pubmed.ncbi.nlm.nih.gov/1855116 DMF1CDK DI DMF1CDK DMF1CDK DN FPL-55712 DMF1CDK TI TT0PZR5 DMF1CDK TN Leukotriene CysLT2 receptor (CYSLTR2) DMF1CDK MA Modulator DMF1CDK RN Effect of the leukotriene receptor antagonists FPL 55712, LY 163443, and MK-571 on the elimination of cysteinyl leukotrienes in the rat. Br J Pharmacol. 1991 Apr;102(4):865-70. DMF1CDK RU https://pubmed.ncbi.nlm.nih.gov/1855116 DMF27BS DI DMF27BS DMF27BS DN MMV00/0053 DMF27BS TI TTVTX4N DMF27BS TN Bacterial Fatty acid synthetase I (Bact inhA) DMF27BS MA Inhibitor DMF27BS RN SAR and pharmacophore models for the rhodanine inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase. IUBMB Life. 2010 Mar;62(3):204-13. DMF27BS RU https://pubmed.ncbi.nlm.nih.gov/20131353 DMF2ME4 DI DMF2ME4 DMF2ME4 DN AG-3296 DMF2ME4 TI TT1GHVO DMF2ME4 TN Matrix metalloproteinase (MMP) DMF2ME4 MA Modulator DMF2ME4 RN US patent application no. 6,858,598, Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia. DMF2ME4 RU https://www.google.com.ar/patents/US6858598 DMF2XMA DI DMF2XMA DMF2XMA DN NSD-721 DMF2XMA TI TTEX6LM DMF2XMA TN GABA(A) receptor gamma-3 (GABRG3) DMF2XMA MA Modulator DMF2XMA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMF2XMA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMF6OY8 DI DMF6OY8 DMF6OY8 DN BW-A502U DMF6OY8 TI TTUTN1I DMF6OY8 TN Human Deoxyribonucleic acid (hDNA) DMF6OY8 MA Binder DMF6OY8 RN Pharmacokinetics and disposition in the rat of a DNA intercalator 502U83. Drug Metab Dispos. 1993 Jan-Feb;21(1):62-70. DMF6OY8 RU https://pubmed.ncbi.nlm.nih.gov/8095228 DMF710M DI DMF710M DMF710M DN S-33516 DMF710M TI TTVKILB DMF710M TN Prostaglandin G/H synthase 2 (COX-2) DMF710M MA Inhibitor DMF710M RN S 33516 Servier preclinical data. R & D Focus Drug News. July 12, 1999. DMF710M RU http://business.highbeam.com/436989/article-1G1-56540224/s-33516-servier-preclinical-data DMF8TCI DI DMF8TCI DMF8TCI DN CZ-112 DMF8TCI TI TTGTQHC DMF8TCI TN DNA topoisomerase I (TOP1) DMF8TCI MA Inhibitor DMF8TCI RN Pharmacology of camptothecin esters. Ann N Y Acad Sci. 2000;922:216-23. DMF8TCI RU https://pubmed.ncbi.nlm.nih.gov/11193897 DMF9XU4 DI DMF9XU4 DMF9XU4 DN LM-1376 DMF9XU4 TI TTGKOY9 DMF9XU4 TN Leukotriene CysLT1 receptor (CYSLTR1) DMF9XU4 MA Modulator DMF9XU4 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMF9XU4 RU https://www.fda.gov/ DMFA26E DI DMFA26E DMFA26E DN NGD-93-1 DMFA26E TI TTEX248 DMFA26E TN Dopamine D2 receptor (D2R) DMFA26E MA Modulator DMFA26E RN Dopamine D4 receptors in human postmortem brain tissue of normal and schizophrenic subjects. An [3]NGD-94-1 study. Schizophrenia Research Volume 29, Issues 1-2, January 1998, Pages 93. DMFA26E RU http://www.sciencedirect.com/science/article/pii/S0920996497885337 DMFA27N DI DMFA27N DMFA27N DN PD142893 DMFA27N TI TT3ZTGU DMFA27N TN Endothelin B receptor (EDNRB) DMFA27N MA Antagonist DMFA27N RN Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13. DMFA27N RU https://pubmed.ncbi.nlm.nih.gov/12147606 DMFA27N DI DMFA27N DMFA27N DN PD142893 DMFA27N TI TTKRD0G DMFA27N TN Endothelin A receptor (EDNRA) DMFA27N MA Antagonist DMFA27N RN Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13. DMFA27N RU https://pubmed.ncbi.nlm.nih.gov/12147606 DMFCMPS DI DMFCMPS DMFCMPS DN Daidzin DMFCMPS TI TTFLN4T DMFCMPS TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMFCMPS MA Inhibitor DMFCMPS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFCMPS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFE3CD DI DMFE3CD DMFE3CD DN AZD-9935 DMFE3CD TI TTVJ1D8 DMFE3CD TN Vascular endothelial growth factor receptor (VEGFR) DMFE3CD MA Antagonist DMFE3CD RN WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use. DMFE3CD RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090507&CC=WO&NR=2009058267A2&KC=A2 DMFE3CD DI DMFE3CD DMFE3CD DN AZD-9935 DMFE3CD TI TTGKNB4 DMFE3CD TN Epidermal growth factor receptor (EGFR) DMFE3CD MA Antagonist DMFE3CD RN WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use. DMFE3CD RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090507&CC=WO&NR=2009058267A2&KC=A2 DMFEMTG DI DMFEMTG DMFEMTG DN Lecimibide DMFEMTG TI TTMF541 DMFEMTG TN Liver carboxylesterase (CES1) DMFEMTG MA Modulator DMFEMTG RN Effect of the acyl-CoA:cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin Pharmacol Ther. 1994 Jul;56(1):65-74. DMFEMTG RU https://pubmed.ncbi.nlm.nih.gov/8033496 DMFHR2O DI DMFHR2O DMFHR2O DN XR-1853 DMFHR2O TI TT5QA2I DMFHR2O TN Plasminogen activator inhibitor (PAI) DMFHR2O MA Modulator DMFHR2O RN Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost. 2002 Jul;88(1):137-43. DMFHR2O RU https://pubmed.ncbi.nlm.nih.gov/12152654 DMFI0GW DI DMFI0GW DMFI0GW DN Sonepiprazole DMFI0GW TI TTE0A2F DMFI0GW TN Dopamine D4 receptor (D4R) DMFI0GW MA Binder DMFI0GW RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMFI0GW RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMFIR0S DI DMFIR0S DMFIR0S DN LY-255283 DMFIR0S TI TTN53ZF DMFIR0S TN Leukotriene B4 receptor 1 (LTB4R) DMFIR0S MA Inhibitor DMFIR0S RN o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3978-81. DMFIR0S RU https://pubmed.ncbi.nlm.nih.gov/7902871 DMFIR0S DI DMFIR0S DMFIR0S DN LY-255283 DMFIR0S TI TTVJX54 DMFIR0S TN Leukotriene B4 receptor 2 (LTB4R2) DMFIR0S MA Inhibitor DMFIR0S RN o-phenylphenols: potent and orally active leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3978-81. DMFIR0S RU https://pubmed.ncbi.nlm.nih.gov/7902871 DMFJ0KC DI DMFJ0KC DMFJ0KC DN RS-2135 DMFJ0KC TI TTRK8B9 DMFJ0KC TN Sodium channel unspecific (NaC) DMFJ0KC MA Modulator DMFJ0KC RN Electrophysiologic effects of RS-2135, a new antiarrhythmic compound, on canine Purkinje fibers. J Cardiovasc Pharmacol. 1992 Dec;20(6):955-60. DMFJ0KC RU https://pubmed.ncbi.nlm.nih.gov/1282599 DMFJ3UW DI DMFJ3UW DMFJ3UW DN DBO-17 DMFJ3UW TI TTKWM86 DMFJ3UW TN Opioid receptor mu (MOP) DMFJ3UW MA Agonist DMFJ3UW RN Emerging analgesics in cancer pain management. Expert Opin Emerg Drugs. 2005 Feb;10(1):151-71. DMFJ3UW RU https://pubmed.ncbi.nlm.nih.gov/15757410 DMFJ4VT DI DMFJ4VT DMFJ4VT DN CS-207 DMFJ4VT TI TTJ584C DMFJ4VT TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFJ4VT MA Agonist DMFJ4VT RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026848) DMFJ4VT RU http://adisinsight.springer.com/drugs/800026848 DMFJPYV DI DMFJPYV DMFJPYV DN LSI-518P DMFJPYV TI TT7GN3U DMFJPYV TN Apolipoprotein A-I (APOA1) DMFJPYV MA Modulator DMFJPYV RN Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J Clin Endocrinol Metab. 2011 May;96(5):1246-57. DMFJPYV RU https://pubmed.ncbi.nlm.nih.gov/21389140 DMFLPU5 DI DMFLPU5 DMFLPU5 DN SRSC-355 DMFLPU5 TI TTRK8B9 DMFLPU5 TN Sodium channel unspecific (NaC) DMFLPU5 MA Modulator DMFLPU5 RN WO patent application no. 2013,0439,25, Sodium channel blockers reduce glucagon secretion. DMFLPU5 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130328&CC=WO&NR=2013043925A1&KC=A1 DMFRCM2 DI DMFRCM2 DMFRCM2 DN Ro-19-8022 DMFRCM2 TI TTEX6LM DMFRCM2 TN GABA(A) receptor gamma-3 (GABRG3) DMFRCM2 MA Modulator DMFRCM2 RN Partial agonist of benzodiazepine receptors Ro 19-8022 elicits withdrawal symptoms after short-term administration in immature rats. Physiol Res. 2012;61(3):319-23. DMFRCM2 RU https://www.ncbi.nlm.nih.gov/pubmed/22816377 DMFRW0G DI DMFRW0G DMFRW0G DN CEP-5214 DMFRW0G TI TTUTJGQ DMFRW0G TN Vascular endothelial growth factor receptor 2 (KDR) DMFRW0G MA Antagonist DMFRW0G RN Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood. 2006 Aug 15;108(4):1243-50. DMFRW0G RU https://pubmed.ncbi.nlm.nih.gov/16621967 DMFV47R DI DMFV47R DMFV47R DN ZD-9720 DMFV47R TI TT7O8ZA DMFV47R TN Lanosterol synthase (LSS) DMFV47R MA Modulator DMFV47R RN Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9. DMFV47R RU https://pubmed.ncbi.nlm.nih.gov/11421484 DMFVB7Z DI DMFVB7Z DMFVB7Z DN HuMax-HepC DMFVB7Z TI TTDBG95 DMFVB7Z TN Hepatitis C virus Envelope glycoprotein E2 (HCV NS1) DMFVB7Z RN Clinical pipeline report, company report or official report of Genmab. DMFVB7Z RU http://www.genmab.com/docs/products/humax-hepc-fact-sheet.pdf DMFVYID DI DMFVYID DMFVYID DN LY-353433 DMFVYID TI TT07C3Y DMFVYID TN 5-HT 4 receptor (HTR4) DMFVYID MA Antagonist DMFVYID RN LY353433, a potent, orally effective, long-acting 5-HT(4) receptor antagonist: comparison to cisapride and RS23597-190. J Pharmacol Exp Ther. 1996 Apr;277(1):97-104. DMFVYID RU https://pubmed.ncbi.nlm.nih.gov/8613972 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TT9WJ8U DMFZ1YW TN Protein kinase C delta (PRKCD) DMFZ1YW MA Inhibitor DMFZ1YW RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMFZ1YW RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TTBZ7OD DMFZ1YW TN Protein kinase C epsilon (PRKCE) DMFZ1YW MA Inhibitor DMFZ1YW RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMFZ1YW RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TT8QL1J DMFZ1YW TN Protein kinase C theta (PRKCQ) DMFZ1YW MA Inhibitor DMFZ1YW RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMFZ1YW RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TTUWGRA DMFZ1YW TN Protein kinase C zeta (PRKCZ) DMFZ1YW MA Inhibitor DMFZ1YW RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMFZ1YW RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TTYPXQF DMFZ1YW TN Protein kinase C beta (PRKCB) DMFZ1YW MA Inhibitor DMFZ1YW RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMFZ1YW RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TTFJ8Q1 DMFZ1YW TN Protein kinase C alpha (PRKCA) DMFZ1YW MA Inhibitor DMFZ1YW RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMFZ1YW RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TTRSMW9 DMFZ1YW TN Glycogen synthase kinase-3 beta (GSK-3B) DMFZ1YW MA Inhibitor DMFZ1YW RN Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. DMFZ1YW RU https://pubmed.ncbi.nlm.nih.gov/20138512 DMFZ1YW DI DMFZ1YW DMFZ1YW DN RO-320432 DMFZ1YW TI TTRFOXJ DMFZ1YW TN Protein kinase C gamma (PRKCG) DMFZ1YW MA Inhibitor DMFZ1YW RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMFZ1YW RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMFZM09 DI DMFZM09 DMFZM09 DN CGS-26303 DMFZM09 TI TT5TKPM DMFZM09 TN Neutral endopeptidase (MME) DMFZM09 MA Inhibitor DMFZM09 RN Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11, Bioorg. Med. Chem. Lett. 7(8):1059-1064 (1997). DMFZM09 RU http://www.sciencedirect.com/science/article/pii/S0960894X97001595 DMFZNUA DI DMFZNUA DMFZNUA DN SCR-44001 DMFZNUA TI TTCJG29 DMFZNUA TN Serine/threonine-protein kinase mTOR (mTOR) DMFZNUA MA Inhibitor DMFZNUA RN Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010 Sep 24;5(9):e12965. DMFZNUA RU https://pubmed.ncbi.nlm.nih.gov/20885974 DMFZNUA DI DMFZNUA DMFZNUA DN SCR-44001 DMFZNUA TI TTHBTOP DMFZNUA TN PI3-kinase gamma (PIK3CG) DMFZNUA MA Inhibitor DMFZNUA RN Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice. PLoS One. 2010 Sep 24;5(9):e12965. DMFZNUA RU https://pubmed.ncbi.nlm.nih.gov/20885974 DMFZO4Y DI DMFZO4Y DMFZO4Y DN EMBELIN DMFZO4Y TI TTK3WBU DMFZO4Y TN XIAP messenger RNA (XIAP mRNA) DMFZO4Y MA Inhibitor DMFZO4Y RN Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40. DMFZO4Y RU https://pubmed.ncbi.nlm.nih.gov/15115387 DMG024B DI DMG024B DMG024B DN Y-931 DMG024B TI TTEX248 DMG024B TN Dopamine D2 receptor (D2R) DMG024B MA Binder DMG024B RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMG024B RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMG1FQW DI DMG1FQW DMG1FQW DN IDRA-21 DMG1FQW TI TTAN6JD DMG1FQW TN Glutamate receptor AMPA (GRIA) DMG1FQW MA Modulator DMG1FQW RN IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13. DMG1FQW RU https://pubmed.ncbi.nlm.nih.gov/15111017 DMG1FQW DI DMG1FQW DMG1FQW DN IDRA-21 DMG1FQW TI TT9IK2Z DMG1FQW TN N-methyl-D-aspartate receptor (NMDAR) DMG1FQW MA Modulator DMG1FQW RN IDRA-21, a positive AMPA receptor modulator, inhibits synaptic and extrasynaptic NMDA receptor mediated events in cultured cerebellar granule cells. Neuropharmacology. 2004 Jun;46(8):1105-13. DMG1FQW RU https://pubmed.ncbi.nlm.nih.gov/15111017 DMG1MPD DI DMG1MPD DMG1MPD DN TH-9229 DMG1MPD TI TTX4QDJ DMG1MPD TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMG1MPD MA Modulator DMG1MPD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159) DMG1MPD RU http://adisinsight.springer.com/drugs/800008159 DMG1MPD DI DMG1MPD DMG1MPD DN TH-9229 DMG1MPD TI TT7RGTM DMG1MPD TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMG1MPD MA Modulator DMG1MPD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159) DMG1MPD RU http://adisinsight.springer.com/drugs/800008159 DMG1MPD DI DMG1MPD DMG1MPD DN TH-9229 DMG1MPD TI TTZIFHC DMG1MPD TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMG1MPD MA Modulator DMG1MPD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159) DMG1MPD RU http://adisinsight.springer.com/drugs/800008159 DMG1MPD DI DMG1MPD DMG1MPD DN TH-9229 DMG1MPD TI TTYRP0M DMG1MPD TN Voltage-gated calcium channel alpha Cav2.3 (CACNA1E) DMG1MPD MA Modulator DMG1MPD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159) DMG1MPD RU http://adisinsight.springer.com/drugs/800008159 DMG1MPD DI DMG1MPD DMG1MPD DN TH-9229 DMG1MPD TI TT4FDG6 DMG1MPD TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMG1MPD MA Modulator DMG1MPD RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008159) DMG1MPD RU http://adisinsight.springer.com/drugs/800008159 DMG2SQM DI DMG2SQM DMG2SQM DN SYN-1134 DMG2SQM TI TT3NKIB DMG2SQM TN Pancreatic elastase 1 (CELA1) DMG2SQM MA Inhibitor DMG2SQM RN EP patent application no. 1292314, Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans. DMG2SQM RU http://www.google.com/patents/EP1292314A2?cl=en DMG58FX DI DMG58FX DMG58FX DN WAY-100635 DMG58FX TI TTSQIFT DMG58FX TN 5-HT 1A receptor (HTR1A) DMG58FX MA Antagonist DMG58FX RN Pharmacological characterization of recombinant human 5-hydroxytryptamine1A receptors using a novel antagonist radioligand, [3H]WAY-100635. Life Sci. 1997;60(9):653-65. DMG58FX RU https://pubmed.ncbi.nlm.nih.gov/9048968 DMG5A1Z DI DMG5A1Z DMG5A1Z DN GW-660511 DMG5A1Z TI TT5TKPM DMG5A1Z TN Neutral endopeptidase (MME) DMG5A1Z MA Modulator DMG5A1Z RN The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol. 2000 Feb;129(4):671-80. DMG5A1Z RU https://pubmed.ncbi.nlm.nih.gov/10683191 DMG5A1Z DI DMG5A1Z DMG5A1Z DN GW-660511 DMG5A1Z TI TTL69WB DMG5A1Z TN Angiotensin-converting enzyme (ACE) DMG5A1Z MA Modulator DMG5A1Z RN The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol. 2000 Feb;129(4):671-80. DMG5A1Z RU https://pubmed.ncbi.nlm.nih.gov/10683191 DMG79NT DI DMG79NT DMG79NT DN LY-274614 DMG79NT TI TT9IK2Z DMG79NT TN N-methyl-D-aspartate receptor (NMDAR) DMG79NT MA Modulator DMG79NT RN The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 1994 Jan;56(1):69-75. DMG79NT RU https://pubmed.ncbi.nlm.nih.gov/7512709 DMG7B61 DI DMG7B61 DMG7B61 DN JTP-2724 DMG7B61 TI TTB2MXP DMG7B61 TN Angiotensinogenase renin (REN) DMG7B61 MA Inhibitor DMG7B61 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010026) DMG7B61 RU http://adisinsight.springer.com/drugs/800010026 DMG8YE9 DI DMG8YE9 DMG8YE9 DN LY288513 DMG8YE9 TI TTVFO0U DMG8YE9 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMG8YE9 MA Antagonist DMG8YE9 RN Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety. Hokkaido Igaku Zasshi. 1998 Sep;73(5):463-73. DMG8YE9 RU https://pubmed.ncbi.nlm.nih.gov/9846276 DMG90YW DI DMG90YW DMG90YW DN Siratiazem DMG90YW TI TT5HONZ DMG90YW TN Calcium channel unspecific (CaC) DMG90YW MA Modulator DMG90YW RN Comparison of the effects of diltiazem and its analogue siratiazem on contractility in arteries, ileum and cardiac muscle. J Auton Pharmacol. 1995 Apr;15(2):107-13. DMG90YW RU https://pubmed.ncbi.nlm.nih.gov/7615573 DMG9R8E DI DMG9R8E DMG9R8E DN EM-2487 DMG9R8E TI TTT3ZC9 DMG9R8E TN Human immunodeficiency virus Tat protein (HIV tat) DMG9R8E MA Inhibitor DMG9R8E RN EM2487, a novel anti-HIV-1 antibiotic, produced by Streptomyces sp. Mer-2487: taxonomy, fermentation, biological properties, isolation and structure elucidation. J Antibiot (Tokyo). 1999 Nov;52(11):971-82. DMG9R8E RU https://pubmed.ncbi.nlm.nih.gov/10656569 DMGAKD8 DI DMGAKD8 DMGAKD8 DN HIMBACINE DMGAKD8 TI TTZ9SOR DMGAKD8 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMGAKD8 MA Inhibitor DMGAKD8 RN Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70. DMGAKD8 RU https://pubmed.ncbi.nlm.nih.gov/15225708 DMGAKD8 DI DMGAKD8 DMGAKD8 DN HIMBACINE DMGAKD8 TI TTYEG6Q DMGAKD8 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMGAKD8 MA Inhibitor DMGAKD8 RN Himbacine analogs as muscarinic receptor antagonists--effects of tether and heterocyclic variations. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3967-70. DMGAKD8 RU https://pubmed.ncbi.nlm.nih.gov/15225708 DMGAPH1 DI DMGAPH1 DMGAPH1 DN Befiperide DMGAPH1 TI TTWT5K7 DMGAPH1 TN 5-HT 1 receptor (5HT1R) DMGAPH1 MA Modulator DMGAPH1 RN Behavioral Pharmacology of 5-ht. Paul Bevan, Paul Bevan Duphar, Alexander R. Cools. 2013. Figure(15.2). DMGAPH1 RU https://books.google.com.hk/books?id=oJIFi5E-YI0C&pg=PT294&lpg=PT294&dq=befiperide+++5HT&source=bl&ots=MsOmWqq_Lp&sig=XqN92Fe4GBpDtwToXK7DG-tUXVk&hl=zh-CN&sa=X&ved=0CBwQ6AEwAGoVChMIq4aV3uy8yAIVDsWOCh0H6AMC#v=onepage&q=befiperide%20%20%205HT&f=false DMGBT63 DI DMGBT63 DMGBT63 DN AM-66 DMGBT63 TI TTRK8B9 DMGBT63 TN Sodium channel unspecific (NaC) DMGBT63 MA Blocker DMGBT63 RN CA patent application no. 849505, Sodium channel blockers reduce glucagon secretion. DMGBT63 RU http://www.google.com/patents/CA2849505A1?cl=en DMGBT9Z DI DMGBT9Z DMGBT9Z DN ALS-769 DMGBT9Z TI TTZY5KP DMGBT9Z TN Caspase (CASP) DMGBT9Z MA Inducer DMGBT9Z RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025089) DMGBT9Z RU http://adisinsight.springer.com/drugs/800025089 DMGCI6E DI DMGCI6E DMGCI6E DN Tipredane DMGCI6E TI TTTWGIX DMGCI6E TN Leukotriene receptor (LTR) DMGCI6E MA Modulator DMGCI6E RN New drugs for asthma. Nat Rev Drug Discov. 2004 Oct;3(10):831-44. DMGCI6E RU https://pubmed.ncbi.nlm.nih.gov/15459674 DMGCYPE DI DMGCYPE DMGCYPE DN Sch-57790 DMGCYPE TI TTYEG6Q DMGCYPE TN Muscarinic acetylcholine receptor M2 (CHRM2) DMGCYPE MA Antagonist DMGCYPE RN SCH 57790: a novel M2 receptor selective antagonist. Life Sci. 1999;64(6-7):535-9. DMGCYPE RU https://pubmed.ncbi.nlm.nih.gov/10069520 DMGDC36 DI DMGDC36 DMGDC36 DN PNU-282987 DMGDC36 TI TTLA931 DMGDC36 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMGDC36 MA Antagonist DMGDC36 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMGDC36 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMGDC36 DI DMGDC36 DMGDC36 DN PNU-282987 DMGDC36 TI TTC97NF DMGDC36 TN TNFA messenger RNA (TNF mRNA) DMGDC36 RN Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis. J Pharmacol Exp Ther. 2003 Jan;304(1):411-24. DMGDC36 RU https://pubmed.ncbi.nlm.nih.gov/12490618 DMGDTLX DI DMGDTLX DMGDTLX DN BL-1872 DMGDTLX TI TTMI6F5 DMGDTLX TN Transient receptor potential cation channel V1 (TRPV1) DMGDTLX MA Modulator DMGDTLX RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMGDTLX RU https://www.fda.gov/ DMGEFX7 DI DMGEFX7 DMGEFX7 DN CEE-03-320 DMGEFX7 TI TTZFYLI DMGEFX7 TN Dopamine D1 receptor (D1R) DMGEFX7 MA Modulator DMGEFX7 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007189) DMGEFX7 RU http://adisinsight.springer.com/drugs/800007189 DMGEHZ9 DI DMGEHZ9 DMGEHZ9 DN NNC-09-0026 DMGEHZ9 TI TT5HONZ DMGEHZ9 TN Calcium channel unspecific (CaC) DMGEHZ9 MA Modulator DMGEHZ9 RN Pharmacological profile of a novel neuronal calcium channel blocker includes reduced cerebral damage and neurological deficits in rat focal ischemia. Pharmacol Biochem Behav. 1994 May;48(1):77-85. DMGEHZ9 RU https://pubmed.ncbi.nlm.nih.gov/8029306 DMGEWUS DI DMGEWUS DMGEWUS DN PSN821 DMGEWUS TI TT7QNVC DMGEWUS TN Glucose-dependent insulinotropic receptor (GPR119) DMGEWUS MA Agonist DMGEWUS RN Clinical pipeline report, company report or official report of Astellas Pharma (2011). DMGEWUS RU http://www.astellas.com/en/ DMGH3QD DI DMGH3QD DMGH3QD DN F-14413 DMGH3QD TI TT2NUT5 DMGH3QD TN Adrenergic receptor alpha-2C (ADRA2C) DMGH3QD MA Antagonist DMGH3QD RN Activation of noradrenergic transmission by alpha2-adrenoceptor antagonists counteracts deafferentation-induced neuronal death and cell proliferation in the adult mouse olfactory bulb. Exp Neurol. 2005 Aug;194(2):444-56. DMGH3QD RU https://pubmed.ncbi.nlm.nih.gov/16022870 DMGH3T5 DI DMGH3T5 DMGH3T5 DN Zaprinast DMGH3T5 TI TTHQENC DMGH3T5 TN Phosphodiesterase 1 (PDE1) DMGH3T5 MA Inhibitor DMGH3T5 RN The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62. DMGH3T5 RU https://pubmed.ncbi.nlm.nih.gov/15887951 DMGH3T5 DI DMGH3T5 DMGH3T5 DN Zaprinast DMGH3T5 TI TTSKMI8 DMGH3T5 TN Phosphodiesterase 4D (PDE4D) DMGH3T5 MA Inhibitor DMGH3T5 RN 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors. J Med Chem. 2005 Feb 24;48(4):1237-43. DMGH3T5 RU https://pubmed.ncbi.nlm.nih.gov/15715490 DMGH3T5 DI DMGH3T5 DMGH3T5 DN Zaprinast DMGH3T5 TI TTJ0IQB DMGH3T5 TN Phosphodiesterase 5A (PDE5A) DMGH3T5 MA Inhibitor DMGH3T5 RN 4-(3-Chloro-4-methoxybenzyl)aminophthalazines: synthesis and inhibitory activity toward phosphodiesterase 5. J Med Chem. 2000 Jun 29;43(13):2523-9. DMGH3T5 RU https://pubmed.ncbi.nlm.nih.gov/10891111 DMGIZHX DI DMGIZHX DMGIZHX DN Co-60549 DMGIZHX TI TTGXH6N DMGIZHX TN GABA(A) receptor delta (GABRD) DMGIZHX MA Modulator DMGIZHX RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007012) DMGIZHX RU http://adisinsight.springer.com/drugs/800007012 DMGJNQW DI DMGJNQW DMGJNQW DN WY-48989 DMGJNQW TI TTZBFA0 DMGJNQW TN Protease unspecific (PRO) DMGJNQW MA Modulator DMGJNQW RN Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989. Agents Actions. 1991 Sep;34(1-2):223-5. DMGJNQW RU https://pubmed.ncbi.nlm.nih.gov/1665295 DMGKVPH DI DMGKVPH DMGKVPH DN PD-0204318 DMGKVPH TI TT4FDG6 DMGKVPH TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMGKVPH MA Antagonist DMGKVPH RN US patent application no. 2012,0172,429, Permanently charged sodium and calcium channel blockers as anti- inflammatory agents. DMGKVPH RU http://www.google.com/Patents/US20120172429 DMGM3VP DI DMGM3VP DMGM3VP DN GE-20372A DMGM3VP TI TT5FNQT DMGM3VP TN Human immunodeficiency virus Protease (HIV PR) DMGM3VP MA Inhibitor DMGM3VP RN US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases. DMGM3VP RU http://www.google.com/patents/US20080161324 DMGMS2D DI DMGMS2D DMGMS2D DN CDP-845 DMGMS2D TI TTLM12X DMGMS2D TN Matrix metalloproteinase-2 (MMP-2) DMGMS2D MA Modulator DMGMS2D RN Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29. DMGMS2D RU https://pubmed.ncbi.nlm.nih.gov/10566004 DMGMS2D DI DMGMS2D DMGMS2D DN CDP-845 DMGMS2D TI TT6X50U DMGMS2D TN Matrix metalloproteinase-9 (MMP-9) DMGMS2D MA Modulator DMGMS2D RN Clinical potential of matrix metalloprotease inhibitors. Drugs R D. 1999 Feb;1(2):117-29. DMGMS2D RU https://pubmed.ncbi.nlm.nih.gov/10566004 DMGNUXC DI DMGNUXC DMGNUXC DN DMP-757 DMGNUXC TI TTJA1ZO DMGNUXC TN ITGB3 messenger RNA (ITGB3 mRNA) DMGNUXC MA Inhibitor DMGNUXC RN Synthesis and antiplatelet activity of DMP 757 analogs, Bioorg. Med. Chem. Lett. 5(18):2097-2100 (1995). DMGNUXC RU http://www.sciencedirect.com/science/article/pii/0960894X9500351S DMGNZUX DI DMGNZUX DMGNZUX DN SB-201146 DMGNZUX TI TTN53ZF DMGNZUX TN Leukotriene B4 receptor 1 (LTB4R) DMGNZUX MA Inhibitor DMGNZUX RN (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist w... J Med Chem. 1996 Sep 13;39(19):3837-41. DMGNZUX RU https://pubmed.ncbi.nlm.nih.gov/8809171 DMGQ9WP DI DMGQ9WP DMGQ9WP DN CDE-5110 DMGQ9WP TI TTGWKQJ DMGQ9WP TN Rho-associated protein kinase 2 (ROCK2) DMGQ9WP MA Inhibitor DMGQ9WP RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025959) DMGQ9WP RU http://adisinsight.springer.com/drugs/800025959 DMGQ9WP DI DMGQ9WP DMGQ9WP DN CDE-5110 DMGQ9WP TI TTZN7RP DMGQ9WP TN Rho-associated protein kinase 1 (ROCK1) DMGQ9WP MA Inhibitor DMGQ9WP RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025959) DMGQ9WP RU http://adisinsight.springer.com/drugs/800025959 DMGSN1V DI DMGSN1V DMGSN1V DN GW-275175 DMGSN1V TI TTZHSBO DMGSN1V TN Cytomegalovirus Terminase (CMV TRM) DMGSN1V MA Inhibitor DMGSN1V RN Progress in Drug Research, 2012. Page(106). DMGSN1V RU https://books.google.com.hk/books?id=MoEECAAAQBAJ&pg=PA106&lpg=PA106&dq=%22GW-275175%22++terminase&source=bl&ots=f4vjuv3udg&sig=PDAZfA0gFYZn-7A4DEHDiG2ffEY&hl=zh-CN&sa=X&ved=0CBwQ6AEwAGoVChMIg9Tgov_AyAIVFAmOCh1lPgeT#v=onepage&q=%22GW-275175%22%20%20terminase&f=false DMGUA9Y DI DMGUA9Y DMGUA9Y DN SAN-61 DMGUA9Y TI TTRSMW9 DMGUA9Y TN Glycogen synthase kinase-3 beta (GSK-3B) DMGUA9Y MA Inhibitor DMGUA9Y RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029796) DMGUA9Y RU http://adisinsight.springer.com/drugs/800029796 DMGUMWP DI DMGUMWP DMGUMWP DN U-80816 DMGUMWP TI TTOXS3C DMGUMWP TN Muscarinic acetylcholine receptor (CHRM) DMGUMWP MA Modulator DMGUMWP RN U-80816: A novel partial muscarinic agonist. Drug Development Research Volume 24, Issue 1, pages 53-66, 1991. DMGUMWP RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430240105/abstract DMGVIZY DI DMGVIZY DMGVIZY DN NPC-17731 DMGVIZY TI TTGY8IW DMGVIZY TN B2 bradykinin receptor (BDKRB2) DMGVIZY MA Antagonist DMGVIZY RN Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice. Br J Pharmacol. 1996 Feb;117(3):552-558. DMGVIZY RU https://pubmed.ncbi.nlm.nih.gov/8821548 DMGX0E1 DI DMGX0E1 DMGX0E1 DN BRL 26830A DMGX0E1 TI TTMXGCW DMGX0E1 TN Adrenergic receptor beta-3 (ADRB3) DMGX0E1 MA Agonist DMGX0E1 RN Anti-obesity and anti-diabetic actions of a beta 3-adrenoceptor agonist, BRL 26830A, in yellow KK mice. Endocrinol Jpn. 1991 Aug;38(4):397-403. DMGX0E1 RU https://pubmed.ncbi.nlm.nih.gov/1687027 DMGX3MK DI DMGX3MK DMGX3MK DN L-655240 DMGX3MK TI TTYLQ8V DMGX3MK TN Prostaglandin E synthase (PTGES) DMGX3MK MA Inhibitor DMGX3MK RN Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3352-5. DMGX3MK RU https://pubmed.ncbi.nlm.nih.gov/15953724 DMGX5Q0 DI DMGX5Q0 DMGX5Q0 DN Gepirone DMGX5Q0 TI TTSQIFT DMGX5Q0 TN 5-HT 1A receptor (HTR1A) DMGX5Q0 MA Agonist DMGX5Q0 RN Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. DMGX5Q0 RU https://pubmed.ncbi.nlm.nih.gov/18172433 DMGY51F DI DMGY51F DMGY51F DN ReN-1826 DMGY51F TI TTIM2WO DMGY51F TN Neurotrophin-4 (NTF4) DMGY51F MA Inhibitor DMGY51F RN Pulmonary distribution, regulation, and functional role of Trk receptors in a murine model of asthma. J Allergy Clin Immunol. 2006 Sep;118(3):597-605. DMGY51F RU https://pubmed.ncbi.nlm.nih.gov/16950277 DMGY51F DI DMGY51F DMGY51F DN ReN-1826 DMGY51F TI TTZHKV9 DMGY51F TN Neurotrophin-3 (NTF3) DMGY51F MA Inhibitor DMGY51F RN Pulmonary distribution, regulation, and functional role of Trk receptors in a murine model of asthma. J Allergy Clin Immunol. 2006 Sep;118(3):597-605. DMGY51F RU https://pubmed.ncbi.nlm.nih.gov/16950277 DMH1YL8 DI DMH1YL8 DMH1YL8 DN NPI-1999 DMH1YL8 TI TTEMV5X DMH1YL8 TN Serine protease unspecific (SP) DMH1YL8 MA Inhibitor DMH1YL8 RN US patent application no. 2005,0096,323, Diketopiperazine derivatives to inhibit thrombin. DMH1YL8 RU http://www.google.com/patents/US20050096323 DMH21JG DI DMH21JG DMH21JG DN LY-293284 DMH21JG TI TTSQIFT DMH21JG TN 5-HT 1A receptor (HTR1A) DMH21JG MA Agonist DMH21JG RN Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity. J Pharmacol Exp Ther. 1994 Sep;270(3):1270-81. DMH21JG RU https://pubmed.ncbi.nlm.nih.gov/7523657 DMH3RPO DI DMH3RPO DMH3RPO DN PT-630 DMH3RPO TI TTDIGC1 DMH3RPO TN Dipeptidyl peptidase 4 (DPP-4) DMH3RPO MA Modulator DMH3RPO RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMH3RPO RU https://www.fda.gov/ DMH6K7N DI DMH6K7N DMH6K7N DN IRL-2500 DMH6K7N TI TT3ZTGU DMH6K7N TN Endothelin B receptor (EDNRB) DMH6K7N MA Inhibitor DMH6K7N RN IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996). DMH6K7N RU http://www.sciencedirect.com/science/article/pii/0960894X96004210 DMH6LCD DI DMH6LCD DMH6LCD DN A-81282 DMH6LCD TI TTGN1ZA DMH6LCD TN Angiotensin II receptor (AGTR) DMH6LCD MA Modulator DMH6LCD RN Pharmacological characterization of Abbott-81282, a novel, non-peptide angiotensin-II antagonist selective for type-1 receptors. Life Sci. 1993;53(11):929-37. DMH6LCD RU https://pubmed.ncbi.nlm.nih.gov/8366760 DMH78J6 DI DMH78J6 DMH78J6 DN AS-602305 DMH78J6 TI TTSCIUP DMH78J6 TN Oxytocin receptor (OTR) DMH78J6 MA Antagonist DMH78J6 RN Clinical pipeline report, company report or official report of darkpharma. DMH78J6 RU http://www.darkpharma.nl/uploads/7/3/2/8/7328594/journal.pmed.0050022.pdf DMH7YD4 DI DMH7YD4 DMH7YD4 DN Bexlosteride DMH7YD4 TI TTTU72V DMH7YD4 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMH7YD4 MA Inhibitor DMH7YD4 RN Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1. Bioorg Med Chem Lett. 2000 Feb 21;10(4):353-6. DMH7YD4 RU https://pubmed.ncbi.nlm.nih.gov/10714498 DMHG70W DI DMHG70W DMHG70W DN VE-16084 DMHG70W TI TTCQIBE DMHG70W TN Caspase-1 (CASP1) DMHG70W MA Inhibitor DMHG70W RN Interleukin-1 beta converting enzyme inhibition blocks progression of type II collagen-induced arthritis in mice. Cytokine. 1996 May;8(5):377-86. DMHG70W RU https://pubmed.ncbi.nlm.nih.gov/8726666 DMHJAD4 DI DMHJAD4 DMHJAD4 DN Daniplestim DMHJAD4 TI TTENHJ0 DMHJAD4 TN Interleukin 3 receptor alpha (IL3RA) DMHJAD4 MA Agonist DMHJAD4 RN The combined administration of daniplestim and Mpl ligand augments the hematopoietic reconstitution observed with single cytokine administration in a nonhuman primate model of myelosuppression. Stem Cells. 1998;16 Suppl 2:143-54. DMHJAD4 RU https://pubmed.ncbi.nlm.nih.gov/11012186 DMHLUFN DI DMHLUFN DMHLUFN DN BVT-24834 DMHLUFN TI TTMY6L1 DMHLUFN TN Fatty acid-binding protein (FABP) DMHLUFN MA Inhibitor DMHLUFN RN Fragment-Based Drug Discovery: A Practical Approach. Edward Zartler, Michael Shapiro, 2008. Page(84). DMHLUFN RU https://books.google.com.hk/books?id=9F9lZr6efAYC&pg=PA84&lpg=PA84&dq=%22BVT-1960%22++Fatty+acid&source=bl&ots=7Gqa3Stpb2&sig=jhrU7gjl54K0_vD7DwfrRUCfLpQ&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMI0MaW3PzFyAIVFZCOCh1D2QNI#v=onepage&q=%22BVT-1960%22%20%20Fatty%20acid&f=false DMHM0EU DI DMHM0EU DMHM0EU DN GR-233548 DMHM0EU TI TT38RM1 DMHM0EU TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMHM0EU MA Modulator DMHM0EU RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHM0EU RU https://www.fda.gov/ DMHNZ1P DI DMHNZ1P DMHNZ1P DN D-9120 DMHNZ1P TI TT1GHVO DMHNZ1P TN Matrix metalloproteinase (MMP) DMHNZ1P MA Inhibitor DMHNZ1P RN WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation. DMHNZ1P RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20061102&CC=WO&NR=2006113993A1&KC=A1 DMHO5AG DI DMHO5AG DMHO5AG DN RP-70676 DMHO5AG TI TTMF541 DMHO5AG TN Liver carboxylesterase (CES1) DMHO5AG MA Modulator DMHO5AG RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002876) DMHO5AG RU http://adisinsight.springer.com/drugs/800002876 DMHP9WV DI DMHP9WV DMHP9WV DN HOMOEPIBATIDINE DMHP9WV TI TT4H1MQ DMHP9WV TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMHP9WV MA Inhibitor DMHP9WV RN Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7. DMHP9WV RU https://pubmed.ncbi.nlm.nih.gov/16934977 DMHP9WV DI DMHP9WV DMHP9WV DN HOMOEPIBATIDINE DMHP9WV TI TT5KPZR DMHP9WV TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMHP9WV MA Inhibitor DMHP9WV RN Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7. DMHP9WV RU https://pubmed.ncbi.nlm.nih.gov/16934977 DMHP9WV DI DMHP9WV DMHP9WV DN HOMOEPIBATIDINE DMHP9WV TI TTTVAFQ DMHP9WV TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMHP9WV MA Inhibitor DMHP9WV RN Epibatidine isomers and analogues: structure-activity relationships. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5493-7. DMHP9WV RU https://pubmed.ncbi.nlm.nih.gov/16934977 DMHQ5ZE DI DMHQ5ZE DMHQ5ZE DN RN-1005 DMHQ5ZE TI TTVZ87F DMHQ5ZE TN Wnt protein (WNT) DMHQ5ZE MA Modulator DMHQ5ZE RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033803) DMHQ5ZE RU http://adisinsight.springer.com/drugs/800033803 DMHQSF8 DI DMHQSF8 DMHQSF8 DN PD-146176 DMHQSF8 TI TT2J34L DMHQSF8 TN Arachidonate 5-lipoxygenase (5-LOX) DMHQSF8 MA Modulator DMHQSF8 RN A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit.Atherosclerosis.1998 Feb;136(2):203-16. DMHQSF8 RU https://www.ncbi.nlm.nih.gov/pubmed/9543090 DMHS5DX DI DMHS5DX DMHS5DX DN TEI-6522 DMHS5DX TI TTMF541 DMHS5DX TN Liver carboxylesterase (CES1) DMHS5DX MA Modulator DMHS5DX RN Potent inhibitors of acyl-CoA:cholesterol acyltransferase. Structure-activity relationships of novel N-(4-oxochroman-8-yl)amides. J Med Chem. 1995 Aug 4;38(16):3174-86. DMHS5DX RU https://pubmed.ncbi.nlm.nih.gov/7636880 DMHU1E8 DI DMHU1E8 DMHU1E8 DN AR177 DMHU1E8 TI TT5FH9Y DMHU1E8 TN Human immunodeficiency virus Integrase (HIV IN) DMHU1E8 MA Inhibitor DMHU1E8 RN Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6. DMHU1E8 RU https://pubmed.ncbi.nlm.nih.gov/11502522 DMHUJCI DI DMHUJCI DMHUJCI DN MDL-105519 DMHUJCI TI TTLD29N DMHUJCI TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMHUJCI MA Inhibitor DMHUJCI RN CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018. DMHUJCI RU https://pubmed.ncbi.nlm.nih.gov/15715469 DMHUJCI DI DMHUJCI DMHUJCI DN MDL-105519 DMHUJCI TI TTN9D8E DMHUJCI TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMHUJCI MA Inhibitor DMHUJCI RN CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018. DMHUJCI RU https://pubmed.ncbi.nlm.nih.gov/15715469 DMHUJCI DI DMHUJCI DMHUJCI DN MDL-105519 DMHUJCI TI TTKJEMQ DMHUJCI TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMHUJCI MA Inhibitor DMHUJCI RN CoMFA, synthesis, and pharmacological evaluation of (E)-3-(2-carboxy-2-arylvinyl)-4,6-dichloro-1H-indole-2-carboxylic acids: 3-[2-(3-aminophenyl)-2... J Med Chem. 2005 Feb 24;48(4):995-1018. DMHUJCI RU https://pubmed.ncbi.nlm.nih.gov/15715469 DMHV43M DI DMHV43M DMHV43M DN FR-145237 DMHV43M TI TTMF541 DMHV43M TN Liver carboxylesterase (CES1) DMHV43M MA Modulator DMHV43M RN Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wall. Biochim Biophys Acta. 1995 Dec 7;1259(3):254-60. DMHV43M RU https://pubmed.ncbi.nlm.nih.gov/8541332 DMHV5OD DI DMHV5OD DMHV5OD DN MF268 DMHV5OD TI TT1RS9F DMHV5OD TN Acetylcholinesterase (AChE) DMHV5OD MA Inhibitor DMHV5OD RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHV5OD RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHX6IC DI DMHX6IC DMHX6IC DN ME-3221 DMHX6IC TI TTGN1ZA DMHX6IC TN Angiotensin II receptor (AGTR) DMHX6IC MA Modulator DMHX6IC RN Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1996 Mar;23(3):229-35. DMHX6IC RU https://pubmed.ncbi.nlm.nih.gov/8934613 DMHXJV2 DI DMHXJV2 DMHXJV2 DN SM-16 DMHXJV2 TI TTP4520 DMHXJV2 TN TGF-beta receptor type I (TGFBR1) DMHXJV2 MA Inhibitor DMHXJV2 RN TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26. DMHXJV2 RU https://pubmed.ncbi.nlm.nih.gov/17135447 DMHXRN8 DI DMHXRN8 DMHXRN8 DN GNI-104 DMHXRN8 TI TTXAKVF DMHXRN8 TN Hepatitis C virus Envelope glycoprotein (HCV Env) DMHXRN8 RN WO patent application no. 2009,1433,45, Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders. DMHXRN8 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20091126&CC=WO&NR=2009143345A2&KC=A2 DMHYQ8K DI DMHYQ8K DMHYQ8K DN Nerve growth factor DMHYQ8K TI TTDN3LF DMHYQ8K TN Nerve growth factor (NGF) DMHYQ8K MA Modulator DMHYQ8K RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMHYQ8K RU https://www.fda.gov/ DMI0CYV DI DMI0CYV DMI0CYV DN RG-8803 DMI0CYV TI TTGKIED DMI0CYV TN Fibroblast growth factor-2 (FGF2) DMI0CYV MA Inhibitor DMI0CYV RN US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions. DMI0CYV RU https://www.google.com.ar/patents/US20100278784 DMI0CYV DI DMI0CYV DMI0CYV DN RG-8803 DMI0CYV TI TTVJ1D8 DMI0CYV TN Vascular endothelial growth factor receptor (VEGFR) DMI0CYV MA Inhibitor DMI0CYV RN US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions. DMI0CYV RU https://www.google.com.ar/patents/US20100278784 DMI0QZ3 DI DMI0QZ3 DMI0QZ3 DN SC-51146 DMI0QZ3 TI TTN53ZF DMI0QZ3 TN Leukotriene B4 receptor 1 (LTB4R) DMI0QZ3 MA Inhibitor DMI0QZ3 RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DMI0QZ3 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DMI0TD8 DI DMI0TD8 DMI0TD8 DN CI-986 DMI0TD8 TI TT2J34L DMI0TD8 TN Arachidonate 5-lipoxygenase (5-LOX) DMI0TD8 MA Modulator DMI0TD8 RN Role of leukotrienes on coronary vasoconstriction in isolated hearts of arthritic rats: effect of in vivo treatment with CI-986, a dual inhibitor of cyclooxygenase and lipoxygenase. Pharmacology. 2000 Jan;60(1):41-6. DMI0TD8 RU https://pubmed.ncbi.nlm.nih.gov/10629442 DMI0WHC DI DMI0WHC DMI0WHC DN PS-519 DMI0WHC TI TTU7ZMG DMI0WHC TN Proteasome (PS) DMI0WHC MA Modulator DMI0WHC RN Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in... Neurotox Res. 2003;5(7):505-14. DMI0WHC RU https://www.ncbi.nlm.nih.gov/pubmed/14715434 DMI1WNF DI DMI1WNF DMI1WNF DN SL-18.1616 DMI1WNF TI TT0WAIE DMI1WNF TN Melatonin receptor type 1A (MTNR1A) DMI1WNF MA Agonist DMI1WNF RN US patent application no. 2005,016,4987, Melatonin combination therapy for improving sleep quality. DMI1WNF RU http://www.google.com/patents/US20050164987 DMI1Y92 DI DMI1Y92 DMI1Y92 DN FUSIDIENOL DMI1Y92 TI TT7WZIJ DMI1Y92 TN CAAX farnesyltransferase beta (FNTB) DMI1Y92 MA Inhibitor DMI1Y92 RN Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J Med Chem. 2002 Mar 28;45(7):1460-5. DMI1Y92 RU https://pubmed.ncbi.nlm.nih.gov/11906287 DMI2N9H DI DMI2N9H DMI2N9H DN Pranidipine DMI2N9H TI TT5HONZ DMI2N9H TN Calcium channel unspecific (CaC) DMI2N9H MA Modulator DMI2N9H RN Pranidipine, a new 1,4-dihydropyridine calcium channel blocker, enhances cyclic GMP-independent nitric oxide-induced relaxation of the rat aorta. Mol Cell Biochem. 1998 Jan;178(1-2):335-43. DMI2N9H RU https://pubmed.ncbi.nlm.nih.gov/9546618 DMI46T3 DI DMI46T3 DMI46T3 DN NS-696 DMI46T3 TI TT5HONZ DMI46T3 TN Calcium channel unspecific (CaC) DMI46T3 MA Modulator DMI46T3 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005355) DMI46T3 RU http://adisinsight.springer.com/drugs/800005355 DMI79JN DI DMI79JN DMI79JN DN SKF-96365 DMI79JN TI TT5HONZ DMI79JN TN Calcium channel unspecific (CaC) DMI79JN MA Modulator DMI79JN RN The transient receptor potential channel antagonist SKF96365 is a potent blocker of low-voltage-activated T-type calcium channels. Br J Pharmacol. 2010 Jul;160(6):1464-75. DMI79JN RU https://pubmed.ncbi.nlm.nih.gov/20590636 DMI94L1 DI DMI94L1 DMI94L1 DN REV-5901 DMI94L1 TI TT2J34L DMI94L1 TN Arachidonate 5-lipoxygenase (5-LOX) DMI94L1 MA Inhibitor DMI94L1 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMI94L1 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMIBCZ5 DI DMIBCZ5 DMIBCZ5 DN R-1315 DMIBCZ5 TI TTXEU7H DMIBCZ5 TN GPCR unspecific (GPCR) DMIBCZ5 MA Modulator DMIBCZ5 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017252) DMIBCZ5 RU http://adisinsight.springer.com/drugs/800017252 DMIC460 DI DMIC460 DMIC460 DN Edaglitazone DMIC460 TI TTZMAO3 DMIC460 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMIC460 MA Modulator DMIC460 RN A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats. Redox Rep. 2002;7(5):343-6. DMIC460 RU https://pubmed.ncbi.nlm.nih.gov/12688526 DMIDFLV DI DMIDFLV DMIDFLV DN Cetamolol DMIDFLV TI TTR6W5O DMIDFLV TN Adrenergic receptor beta-1 (ADRB1) DMIDFLV MA Modulator DMIDFLV RN Comparison of the beta-adrenoceptor affinity and selectivity of cetamolol, atenolol, betaxolol, and ICI-118,551. J Cardiovasc Pharmacol. 1988 Aug;12(2):208-17. DMIDFLV RU https://pubmed.ncbi.nlm.nih.gov/2459552 DMIDK36 DI DMIDK36 DMIDK36 DN LY-243062 DMIDK36 TI TTEX248 DMIDK36 TN Dopamine D2 receptor (D2R) DMIDK36 MA Modulator DMIDK36 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005079) DMIDK36 RU http://adisinsight.springer.com/drugs/800005079 DMIE039 DI DMIE039 DMIE039 DN SC-47643 DMIE039 TI TTD0652 DMIE039 TN Proteinase activated receptor 4 (F2RL3) DMIE039 MA Inhibitor DMIE039 RN Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41. DMIE039 RU https://pubmed.ncbi.nlm.nih.gov/7837237 DMIE039 DI DMIE039 DMIE039 DN SC-47643 DMIE039 TI TTJA1ZO DMIE039 TN ITGB3 messenger RNA (ITGB3 mRNA) DMIE039 MA Inhibitor DMIE039 RN Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation. J Med Chem. 1995 Jan 6;38(1):34-41. DMIE039 RU https://pubmed.ncbi.nlm.nih.gov/7837237 DMIFDPL DI DMIFDPL DMIFDPL DN AS-8112 DMIFDPL TI TTPC4TU DMIFDPL TN 5-HT 3A receptor (HTR3A) DMIFDPL MA Antagonist DMIFDPL RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMIFDPL RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMIFDPL DI DMIFDPL DMIFDPL DN AS-8112 DMIFDPL TI TT4C8EA DMIFDPL TN Dopamine D3 receptor (D3R) DMIFDPL MA Antagonist DMIFDPL RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMIFDPL RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMIGXQF DI DMIGXQF DMIGXQF DN FK-355 DMIGXQF TI TTZPO1L DMIGXQF TN Substance-P receptor (TACR1) DMIGXQF MA Antagonist DMIGXQF RN FK 224, a novel cyclopeptide substance P antagonist with NK1 and NK2 receptor selectivity. J Pharmacol Exp Ther. 1992 Jul;262(1):398-402. DMIGXQF RU https://pubmed.ncbi.nlm.nih.gov/1378096 DMIJCH1 DI DMIJCH1 DMIJCH1 DN GR-218231 DMIJCH1 TI TT4C8EA DMIJCH1 TN Dopamine D3 receptor (D3R) DMIJCH1 MA Inhibitor DMIJCH1 RN Design, synthesis, and binding affinities of potential positron emission tomography (PET) ligands with optimal lipophilicity for brain imaging of t... Bioorg Med Chem. 2009 Jan 15;17(2):758-66. DMIJCH1 RU https://pubmed.ncbi.nlm.nih.gov/19081257 DMIK72F DI DMIK72F DMIK72F DN XR-5118 DMIK72F TI TTTO43N DMIK72F TN Endothelial plasminogen activator inhibitor (SERPINE1) DMIK72F MA Inhibitor DMIK72F RN Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization. J Med Chem. 2004 Jul 1;47(14):3491-4. DMIK72F RU https://pubmed.ncbi.nlm.nih.gov/15214776 DMIMJ8Z DI DMIMJ8Z DMIMJ8Z DN SKF 38393 DMIMJ8Z TI TTZFYLI DMIMJ8Z TN Dopamine D1 receptor (D1R) DMIMJ8Z MA Modulator DMIMJ8Z RN The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus. Neuroscience. 1999;94(4):1063-70. DMIMJ8Z RU https://pubmed.ncbi.nlm.nih.gov/10625048 DMINSRW DI DMINSRW DMINSRW DN NZ-1002 DMINSRW TI TT3C1VN DMINSRW TN Enzyme unspecific (Enz) DMINSRW MA Modulator DMINSRW RN Expression of a cytokinin synthesis gene from Agrobacterium tumefaciens T-DNA in basket willow (Salix viminalis). Physiologia Plantarum Volume 88, Issue 3, pages 439-445, July 1993. DMINSRW RU http://onlinelibrary.wiley.com/doi/10.1111/j.1399-3054.1993.tb01357.x/abstract?userIsAuthenticated=false&deniedAccessCustomisedMessage= DMINUWH DI DMINUWH DMINUWH DN NS398 DMINUWH TI TTVKILB DMINUWH TN Prostaglandin G/H synthase 2 (COX-2) DMINUWH MA Inhibitor DMINUWH RN New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202. DMINUWH RU https://pubmed.ncbi.nlm.nih.gov/18616415 DMIP8NB DI DMIP8NB DMIP8NB DN EK-399 DMIP8NB TI TTN4QDT DMIP8NB TN Opioid receptor (OPR) DMIP8NB MA Modulator DMIP8NB RN Evaluation of the discriminative stimulus effect of an enkephalin analog, EK-399, in the rat. Nihon Yakurigaku Zasshi. 1991 Jun;97(6):361-9. DMIP8NB RU https://pubmed.ncbi.nlm.nih.gov/1651892 DMIQB9E DI DMIQB9E DMIQB9E DN FR-171113 DMIQB9E TI TTL935N DMIQB9E TN Proteinase activated receptor 1 (F2R) DMIQB9E MA Modulator DMIQB9E RN In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol. 1999 Nov 19;384(2-3):197-202. DMIQB9E RU https://pubmed.ncbi.nlm.nih.gov/10611442 DMITV4F DI DMITV4F DMITV4F DN BBB-022 DMITV4F TI TTUST1O DMITV4F TN Phosphodiesterase (PDE) DMITV4F MA Inhibitor DMITV4F RN Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400. DMITV4F RU https://pubmed.ncbi.nlm.nih.gov/11740200 DMIWC64 DI DMIWC64 DMIWC64 DN AZM-134 DMIWC64 TI TTVIMDE DMIWC64 TN Glucagon-like peptide 1 receptor (GLP1R) DMIWC64 MA Modulator DMIWC64 RN US patent application no. 2011,0171,312, Modified therapeutic peptides, methods of their preparation and use. DMIWC64 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110714&CC=US&NR=2011171312A1&KC=A1 DMIWUFC DI DMIWUFC DMIWUFC DN CGP-52411 DMIWUFC TI TTGKNB4 DMIWUFC TN Epidermal growth factor receptor (EGFR) DMIWUFC MA Inhibitor DMIWUFC RN Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34. DMIWUFC RU https://pubmed.ncbi.nlm.nih.gov/8741214 DMIY51U DI DMIY51U DMIY51U DN M-241247 DMIY51U TI TTZ8EM9 DMIY51U TN Glycine receptor (GlyR) DMIY51U MA Antagonist DMIY51U RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415) DMIY51U RU http://adisinsight.springer.com/drugs/800003415 DMIY51U DI DMIY51U DMIY51U DN M-241247 DMIY51U TI TT9IK2Z DMIY51U TN N-methyl-D-aspartate receptor (NMDAR) DMIY51U MA Antagonist DMIY51U RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003415) DMIY51U RU http://adisinsight.springer.com/drugs/800003415 DMIYMS2 DI DMIYMS2 DMIYMS2 DN LF-984 DMIYMS2 TI TTP4520 DMIYMS2 TN TGF-beta receptor type I (TGFBR1) DMIYMS2 MA Inhibitor DMIYMS2 RN US patent application no. 2013,0028,978, Compositions and methods for wound treatment. DMIYMS2 RU https://www.google.com.ar/patents/US20130028978 DMIYPLU DI DMIYPLU DMIYPLU DN BVT-142 DMIYPLU TI TTZMAO3 DMIYPLU TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMIYPLU MA Agonist DMIYPLU RN A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30. DMIYPLU RU https://pubmed.ncbi.nlm.nih.gov/15258145 DMIYPLU DI DMIYPLU DMIYPLU DN BVT-142 DMIYPLU TI TTJ584C DMIYPLU TN Peroxisome proliferator-activated receptor alpha (PPARA) DMIYPLU MA Agonist DMIYPLU RN A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J Biol Chem. 2004 Sep 24;279(39):41124-30. DMIYPLU RU https://pubmed.ncbi.nlm.nih.gov/15258145 DMIYTPE DI DMIYTPE DMIYTPE DN Apolipoprotein E DMIYTPE TI TTKS9CB DMIYTPE TN Apolipoprotein E (APOE) DMIYTPE MA Modulator DMIYTPE RN Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem. 1994 Mar;54(3):299-308. DMIYTPE RU https://pubmed.ncbi.nlm.nih.gov/8200910 DMIZMJD DI DMIZMJD DMIZMJD DN CP-663427 DMIZMJD TI TT7WZIJ DMIZMJD TN CAAX farnesyltransferase beta (FNTB) DMIZMJD MA Inhibitor DMIZMJD RN WO patent application no. 2011,0881,26, Treatment of viral infection with prenyltransferase inhibitors. DMIZMJD RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110721&CC=WO&NR=2011088126A2&KC=A2 DMJ0A5U DI DMJ0A5U DMJ0A5U DN EFIPLADIB DMJ0A5U TI TTT1JVS DMJ0A5U TN Cytosolic phospholipase A2 (GIVA cPLA2) DMJ0A5U MA Inhibitor DMJ0A5U RN Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71. DMJ0A5U RU https://pubmed.ncbi.nlm.nih.gov/19178292 DMJ2P1Q DI DMJ2P1Q DMJ2P1Q DN CI-1002 DMJ2P1Q TI TT1RS9F DMJ2P1Q TN Acetylcholinesterase (AChE) DMJ2P1Q MA Modulator DMJ2P1Q RN PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist. Mol Neurobiol. 1994 Aug-Dec;9(1-3):93-106. DMJ2P1Q RU https://pubmed.ncbi.nlm.nih.gov/7888109 DMJ325M DI DMJ325M DMJ325M DN CGP-53716 DMJ325M TI TTI2WET DMJ325M TN Platelet-derived growth factor receptor (PDGFR) DMJ325M MA Modulator DMJ325M RN Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716. J Pharmacol Exp Ther. 1997 Oct;283(1):402-10. DMJ325M RU https://pubmed.ncbi.nlm.nih.gov/9336349 DMJ35RC DI DMJ35RC DMJ35RC DN FH-510 DMJ35RC TI TT5TPI6 DMJ35RC TN Opioid receptor sigma 1 (OPRS1) DMJ35RC MA Modulator DMJ35RC RN FH-510, a potent and selective ligand for rat brain sigma recognition sites. Eur J Pharmacol. 1993 Jul 6;238(1):89-92. DMJ35RC RU https://pubmed.ncbi.nlm.nih.gov/8104803 DMJ37IX DI DMJ37IX DMJ37IX DN L-775606 DMJ37IX TI TTK8CXU DMJ37IX TN 5-HT 1B receptor (HTR1B) DMJ37IX MA Inhibitor DMJ37IX RN Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1997 Oct 24;40(22):3501-3. DMJ37IX RU https://pubmed.ncbi.nlm.nih.gov/9357515 DMJ37IX DI DMJ37IX DMJ37IX DN L-775606 DMJ37IX TI TT6MSOK DMJ37IX TN 5-HT 1D receptor (HTR1D) DMJ37IX MA Inhibitor DMJ37IX RN Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16. DMJ37IX RU https://pubmed.ncbi.nlm.nih.gov/18507369 DMJ3MAZ DI DMJ3MAZ DMJ3MAZ DN F-992 DMJ3MAZ TI TTYCILE DMJ3MAZ TN Vasopressin receptor (VR) DMJ3MAZ MA Agonist DMJ3MAZ RN A site of tyrosine phosphorylation in the C terminus of the epidermal growth factor receptor is required to activate phospholipase C.. Mol Cell Biol. 1992 January; 12(1): 128-135. DMJ3MAZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC364076/ DMJ3ZUN DI DMJ3ZUN DMJ3ZUN DN Irindalone DMJ3ZUN TI TT3ROYC DMJ3ZUN TN Serotonin transporter (SERT) DMJ3ZUN MA Inhibitor DMJ3ZUN RN Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity. J Med Chem. 1988 Dec;31(12):2247-56. DMJ3ZUN RU https://pubmed.ncbi.nlm.nih.gov/2903929 DMJ4FGZ DI DMJ4FGZ DMJ4FGZ DN CGS-26529 DMJ4FGZ TI TT2J34L DMJ4FGZ TN Arachidonate 5-lipoxygenase (5-LOX) DMJ4FGZ MA Inhibitor DMJ4FGZ RN CGS 26529: the biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action. Inflamm Res. 1995 Aug;44 Suppl 2:S147-8. DMJ4FGZ RU https://pubmed.ncbi.nlm.nih.gov/8548371 DMJ4PNR DI DMJ4PNR DMJ4PNR DN GT-2203 DMJ4PNR TI TT9JNIC DMJ4PNR TN Histamine H3 receptor (H3R) DMJ4PNR MA Agonist DMJ4PNR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DMJ4PNR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DMJ54E9 DI DMJ54E9 DMJ54E9 DN LY-221068 DMJ54E9 TI TT2J34L DMJ54E9 TN Arachidonate 5-lipoxygenase (5-LOX) DMJ54E9 MA Inhibitor DMJ54E9 RN Anti-inflammatory effects of LY221068 and LY269415. Agents Actions. 1991 Sep;34(1-2):100-2. DMJ54E9 RU https://pubmed.ncbi.nlm.nih.gov/1793009 DMJ5STO DI DMJ5STO DMJ5STO DN PD-159913 DMJ5STO TI TT9IK2Z DMJ5STO TN N-methyl-D-aspartate receptor (NMDAR) DMJ5STO MA Modulator DMJ5STO RN WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors. DMJ5STO RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2 DMJ63GW DI DMJ63GW DMJ63GW DN RPR-113829 DMJ63GW TI TT7WZIJ DMJ63GW TN CAAX farnesyltransferase beta (FNTB) DMJ63GW MA Inhibitor DMJ63GW RN Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7. DMJ63GW RU https://pubmed.ncbi.nlm.nih.gov/9191950 DMJ63GW DI DMJ63GW DMJ63GW DN RPR-113829 DMJ63GW TI TTXQKM3 DMJ63GW TN Farnesyl protein transferase (Ftase) DMJ63GW MA Inhibitor DMJ63GW RN Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase. J Med Chem. 1997 Jun 6;40(12):1763-7. DMJ63GW RU https://pubmed.ncbi.nlm.nih.gov/9191950 DMJ6BEO DI DMJ6BEO DMJ6BEO DN AHR-16462B DMJ6BEO TI TT5HONZ DMJ6BEO TN Calcium channel unspecific (CaC) DMJ6BEO MA Modulator DMJ6BEO RN A pharmacological and biochemical examination of AHR-16462B, a novel calcium antagonist coronary vasodilator/antihypertensive. Drug Development Research. 01/1991; 22(3):259-271. DMJ6BEO RU http://www.researchgate.net/publication/240125183_A_pharmacological_and_biochemical_examination_of_AHR-16462B_a_novel_calcium_antagonist_coronary_vasodilatorantihypertensive DMJ9RLX DI DMJ9RLX DMJ9RLX DN SL-91.0893 DMJ9RLX TI TT34BHT DMJ9RLX TN Adrenergic receptor alpha-1D (ADRA1D) DMJ9RLX MA Modulator DMJ9RLX RN Tissue Selectivity of in vivo alpha1-Adrenoceptor Biding of KMD-3213 in Rats. Eur Urol 1999;36(suppl 1):113-117. DMJ9RLX RU https://www.karger.com/Article/Pdf/52331 DMJACXN DI DMJACXN DMJACXN DN HRC-102 DMJACXN TI TTQO71U DMJACXN TN Hemoglobin (HB) DMJACXN MA Modulator DMJACXN RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMJACXN RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMJAGKY DI DMJAGKY DMJAGKY DN CBR-2092 DMJAGKY TI TTN6J5F DMJAGKY TN Bacterial DNA gyrase (Bact gyrase) DMJAGKY MA Modulator DMJAGKY RN In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Antimicrob Agents Chemother.2008 Jul;52(7):2313-23. DMJAGKY RU https://www.ncbi.nlm.nih.gov/pubmed/18443108 DMJAGKY DI DMJAGKY DMJAGKY DN CBR-2092 DMJAGKY TI TTIXTO3 DMJAGKY TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMJAGKY MA Modulator DMJAGKY RN In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.Antimicrob Agents Chemother.2008 Jul;52(7):2313-23. DMJAGKY RU https://www.ncbi.nlm.nih.gov/pubmed/18443108 DMJBGI1 DI DMJBGI1 DMJBGI1 DN CL-184005 DMJBGI1 TI TTQL5VC DMJBGI1 TN Platelet-activating factor receptor (PTAFR) DMJBGI1 MA Modulator DMJBGI1 RN Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis. Antimicrob Agents Chemother. 1992 Sep;36(9):1971-7. DMJBGI1 RU https://www.ncbi.nlm.nih.gov/pubmed/1416889 DMJC82N DI DMJC82N DMJC82N DN UR-8225 DMJC82N TI TT1VOHK DMJC82N TN Potassium channel unspecific (KC) DMJC82N MA Opener DMJC82N RN Effects of the novel potassium channel opener, UR-8225, on contractile responses in rat isolated smooth muscle. Br J Pharmacol. 1993 Nov;110(3):1165-71. DMJC82N RU https://pubmed.ncbi.nlm.nih.gov/8298804 DMJD15H DI DMJD15H DMJD15H DN SB-208651 DMJD15H TI TT38RM1 DMJD15H TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMJD15H MA Modulator DMJD15H RN Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Bioorg Med Chem. 1994 Sep;2(9):897-908. DMJD15H RU https://www.ncbi.nlm.nih.gov/pubmed/7712125 DMJDMTK DI DMJDMTK DMJDMTK DN BU-4514N DMJDMTK TI TTEDJN4 DMJDMTK TN Low-affinity nerve growth factor receptor (NGFR) DMJDMTK MA Modulator DMJDMTK RN A new neuritogenetic compound BU-4514N produced by Microtetraspora sp. J Antibiot (Tokyo). 1993 Jun;46(6):875-83. DMJDMTK RU https://pubmed.ncbi.nlm.nih.gov/8344867 DMJEZOP DI DMJEZOP DMJEZOP DN ZD-7717 DMJEZOP TI TT2J34L DMJEZOP TN Arachidonate 5-lipoxygenase (5-LOX) DMJEZOP MA Modulator DMJEZOP RN CA patent application no. 445634, Acne treatment comprising lipoxygenase inhibitors. DMJEZOP RU http://www.google.hr/patents/CA2445634A1?cl=en&hl=hr DMJFY2I DI DMJFY2I DMJFY2I DN AD 198 DMJFY2I TI TT9WJ8U DMJFY2I TN Protein kinase C delta (PRKCD) DMJFY2I MA Activator DMJFY2I RN Novel extranuclear-targeted anthracyclines override the antiapoptotic functions of Bcl-2 and target protein kinase C pathways to induce apoptosis. Mol Cancer Ther. 2002 May;1(7):469-81. DMJFY2I RU https://pubmed.ncbi.nlm.nih.gov/12479265 DMJGCYO DI DMJGCYO DMJGCYO DN DuP-129 DMJGCYO TI TTMF541 DMJGCYO TN Liver carboxylesterase (CES1) DMJGCYO MA Inhibitor DMJGCYO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592). DMJGCYO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592 DMJH7IX DI DMJH7IX DMJH7IX DN AZD-0275 DMJH7IX TI TTQR8Z6 DMJH7IX TN Chemokine receptor (CHR) DMJH7IX MA Antagonist DMJH7IX RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019127) DMJH7IX RU http://adisinsight.springer.com/drugs/800019127 DMJLRC7 DI DMJLRC7 DMJLRC7 DN XR-3005 DMJLRC7 TI TT7WZIJ DMJLRC7 TN CAAX farnesyltransferase beta (FNTB) DMJLRC7 MA Modulator DMJLRC7 RN US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent. DMJLRC7 RU http://www.google.com/patents/US20050227929 DMJLV03 DI DMJLV03 DMJLV03 DN Vapiprost DMJLV03 TI TT2O84V DMJLV03 TN Thromboxane A2 receptor (TBXA2R) DMJLV03 MA Modulator DMJLV03 RN Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.. Br J Pharmacol. 1992 July; 106(3): 533-538. DMJLV03 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907568/ DMJN7MY DI DMJN7MY DMJN7MY DN ED-110 DMJN7MY TI TTGTQHC DMJN7MY TN DNA topoisomerase I (TOP1) DMJN7MY MA Modulator DMJN7MY RN ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Jpn J Cancer Res. 1993 May;84(5):574-81. DMJN7MY RU https://www.ncbi.nlm.nih.gov/pubmed/8320174 DMJQ3WR DI DMJQ3WR DMJQ3WR DN C-AFG DMJQ3WR TI TT84ETX DMJQ3WR TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJQ3WR MA Modulator DMJQ3WR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003394) DMJQ3WR RU http://adisinsight.springer.com/drugs/800003394 DMJQA0D DI DMJQA0D DMJQA0D DN Ro-24-0238 DMJQA0D TI TTQL5VC DMJQA0D TN Platelet-activating factor receptor (PTAFR) DMJQA0D MA Inhibitor DMJQA0D RN Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. J Med Chem. 1989 Aug;32(8):1820-35. DMJQA0D RU https://pubmed.ncbi.nlm.nih.gov/2754709 DMJS9YB DI DMJS9YB DMJS9YB DN FR-62765 DMJS9YB TI TTFBNVI DMJS9YB TN Aldose reductase (AKR1B1) DMJS9YB MA Modulator DMJS9YB RN Studies on WF-3681, a novel aldose reductase inhibitor. IV. Effect of FR-62765, a derivative of WF-3681, on the diabetic neuropathy in rats. J Antibiot (Tokyo). 1991 Apr;44(4):441-4. DMJS9YB RU https://pubmed.ncbi.nlm.nih.gov/1903376 DMJTR0U DI DMJTR0U DMJTR0U DN Milacemide DMJTR0U TI TTGP7BY DMJTR0U TN Monoamine oxidase type B (MAO-B) DMJTR0U MA Modulator DMJTR0U RN Milacemide, the selective substrate and enzyme-activated specific inhibitor of monoamine oxidase B, increases dopamine but not serotonin in caudate nucleus of rhesus monkey. Neurochem Int. 1990;17(2):325-9. DMJTR0U RU https://pubmed.ncbi.nlm.nih.gov/20504633 DMJU39N DI DMJU39N DMJU39N DN Endovion DMJU39N TI TTCYAXN DMJU39N TN Chloride channel unspecific (ClC) DMJU39N MA Antagonist DMJU39N RN Inhibition of the endogenous volume-regulated anion channel (VRAC) in HEK293 cells by acidic di-aryl-ureas. J Membr Biol. 2003 Nov 15;196(2):83-94. DMJU39N RU https://pubmed.ncbi.nlm.nih.gov/14724745 DMJUW8H DI DMJUW8H DMJUW8H DN Dazoxiben DMJUW8H TI TTKNWZ4 DMJUW8H TN Thromboxane-A synthase (TBXAS1) DMJUW8H MA Inhibitor DMJUW8H RN Metabolic protection of the reperfused canine endocardium by the thromboxane synthetase inhibitor, dazoxiben. Prostaglandins Leukot Essent Fatty Acids. 1988 Jul;33(1):13-22. DMJUW8H RU https://pubmed.ncbi.nlm.nih.gov/3054935 DMJVTQN DI DMJVTQN DMJVTQN DN NB-598 DMJVTQN TI TTE14XG DMJVTQN TN Squalene monooxygenase (SQLE) DMJVTQN MA Inhibitor DMJVTQN RN Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50. DMJVTQN RU https://pubmed.ncbi.nlm.nih.gov/12467639 DMJX1IB DI DMJX1IB DMJX1IB DN Fedotozine DMJX1IB TI TTQW87Y DMJX1IB TN Opioid receptor kappa (OPRK1) DMJX1IB MA Agonist DMJX1IB RN Irritable bowel syndrome neuropharmacology. A review of approved and investigational compounds. J Clin Gastroenterol. 2002 Jul;35(1 Suppl):S58-67. DMJX1IB RU https://pubmed.ncbi.nlm.nih.gov/12184141 DMJXEV7 DI DMJXEV7 DMJXEV7 DN ERTIPROTAFIB DMJXEV7 TI TTELIN2 DMJXEV7 TN PTPN1 messenger RNA (PTPN1 mRNA) DMJXEV7 MA Inhibitor DMJXEV7 RN 2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60. DMJXEV7 RU https://pubmed.ncbi.nlm.nih.gov/17728130 DMJYIVA DI DMJYIVA DMJYIVA DN ZK-91296 DMJYIVA TI TTEX6LM DMJYIVA TN GABA(A) receptor gamma-3 (GABRG3) DMJYIVA MA Modulator DMJYIVA RN Enhancement of gamma-aminobutyric acid binding by the anxiolytic beta-carbolines ZK 93423 and ZK 91296. J Neurochem. 1987 May;48(5):1355-8. DMJYIVA RU https://www.ncbi.nlm.nih.gov/pubmed/2881979 DMJZ48W DI DMJZ48W DMJZ48W DN AHR-16303B DMJZ48W TI TT5HONZ DMJZ48W TN Calcium channel unspecific (CaC) DMJZ48W MA Modulator DMJZ48W RN AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53. DMJZ48W RU https://pubmed.ncbi.nlm.nih.gov/1708055 DMJZ48W DI DMJZ48W DMJZ48W DN AHR-16303B DMJZ48W TI TTYSN63 DMJZ48W TN 5-HT 2 receptor (5HT2R) DMJZ48W MA Modulator DMJZ48W RN AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels. J Cardiovasc Pharmacol. 1991 Jan;17(1):41-53. DMJZ48W RU https://pubmed.ncbi.nlm.nih.gov/1708055 DMJZH7N DI DMJZH7N DMJZH7N DN ZK-118182 DMJZH7N TI TTNVEIR DMJZH7N TN Prostaglandin D2 receptor (PTGDR) DMJZH7N MA Modulator DMJZH7N RN Characterization of prostanoid receptors mediating inhibition of histamine release from anti-IgE-activated rat peritoneal mast cells. Br J Pharmacol. 2000 Feb;129(3):589-97. DMJZH7N RU https://pubmed.ncbi.nlm.nih.gov/10711359 DMK1UJM DI DMK1UJM DMK1UJM DN YP-004 DMK1UJM TI TTDB5IS DMK1UJM TN Receptor unspecific (Rec) DMK1UJM MA Inhibitor DMK1UJM RN CA patent application no. 815512, Method for increasing the efficiency of double-strand break-induced mutagenesis. DMK1UJM RU http://www.google.com/patents/CA2815512A1?cl=en DMK1VHF DI DMK1VHF DMK1VHF DN Hu Dreg 55 DMK1VHF TI TT2IYXF DMK1VHF TN L-selectin (SELL) DMK1VHF RN Clinical pipeline report, company report or official report of glycomimetics. DMK1VHF RU http://www.glycomimetics.com/programs-pipeline/gmi-1271/ DMK2QW0 DI DMK2QW0 DMK2QW0 DN L-374,087 DMK2QW0 TI TT6L509 DMK2QW0 TN Coagulation factor IIa (F2) DMK2QW0 MA Inhibitor DMK2QW0 RN Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21. DMK2QW0 RU https://pubmed.ncbi.nlm.nih.gov/12714830 DMK7BV9 DI DMK7BV9 DMK7BV9 DN NNC-22-0031 DMK7BV9 TI TTZFYLI DMK7BV9 TN Dopamine D1 receptor (D1R) DMK7BV9 MA Modulator DMK7BV9 RN NNC-19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile. Psychopharmacology (Berl). 1997 Jan;129(2):168-78. DMK7BV9 RU https://pubmed.ncbi.nlm.nih.gov/9040123 DMK7BV9 DI DMK7BV9 DMK7BV9 DN NNC-22-0031 DMK7BV9 TI TTEX248 DMK7BV9 TN Dopamine D2 receptor (D2R) DMK7BV9 MA Modulator DMK7BV9 RN NNC-19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile. Psychopharmacology (Berl). 1997 Jan;129(2):168-78. DMK7BV9 RU https://pubmed.ncbi.nlm.nih.gov/9040123 DMKAGLV DI DMKAGLV DMKAGLV DN GR-131663 DMKAGLV TI TT0WAIE DMKAGLV TN Melatonin receptor type 1A (MTNR1A) DMKAGLV MA Modulator DMKAGLV RN Novel non-indolic melatonin receptor agonists differentially entrain endogenous melatonin rhythm and increase its amplitude. Eur J Pharmacol. 1999 Oct 15;382(3):157-66. DMKAGLV RU https://pubmed.ncbi.nlm.nih.gov/10556666 DMKBILF DI DMKBILF DMKBILF DN UK-78282 DMKBILF TI TTY3UE6 DMKBILF TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMKBILF MA Inhibitor DMKBILF RN Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56. DMKBILF RU https://pubmed.ncbi.nlm.nih.gov/11312924 DMKCXBJ DI DMKCXBJ DMKCXBJ DN SDZ-MTH-958 DMKCXBJ TI TTEMV5X DMKCXBJ TN Serine protease unspecific (SP) DMKCXBJ MA Modulator DMKCXBJ RN Thrombin inhibition in an ex vivo model of porcine heart xenograft hyperacute rejection. Transplantation. 1996 Mar 27;61(6):862-8. DMKCXBJ RU https://pubmed.ncbi.nlm.nih.gov/8623150 DMKDS1C DI DMKDS1C DMKDS1C DN Rimcazole DMKDS1C TI TT5TPI6 DMKDS1C TN Opioid receptor sigma 1 (OPRS1) DMKDS1C MA Antagonist DMKDS1C RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMKDS1C RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMKFQC7 DI DMKFQC7 DMKFQC7 DN RG-14893 DMKFQC7 TI TTN53ZF DMKFQC7 TN Leukotriene B4 receptor 1 (LTB4R) DMKFQC7 MA Modulator DMKFQC7 RN Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain. J Med Chem. 1996 Sep 13;39(19):3756-68. DMKFQC7 RU https://pubmed.ncbi.nlm.nih.gov/8809164 DMKFYDE DI DMKFYDE DMKFYDE DN ZK-119010 DMKFYDE TI TTOM3J0 DMKFYDE TN Estrogen receptor beta (ESR2) DMKFYDE MA Inhibitor DMKFYDE RN 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors. J Med Chem. 1991 Jul;34(7):2145-52. DMKFYDE RU https://pubmed.ncbi.nlm.nih.gov/2066987 DMKFYDE DI DMKFYDE DMKFYDE DN ZK-119010 DMKFYDE TI TTZAYWL DMKFYDE TN Estrogen receptor (ESR) DMKFYDE MA Inhibitor DMKFYDE RN 2-Phenylindole-linked [2-(aminoalkyl)pyridine]dichloroplatinum(II): complexes with a selective action on estrogen receptor positive mammary tumors. J Med Chem. 1991 Jul;34(7):2145-52. DMKFYDE RU https://pubmed.ncbi.nlm.nih.gov/2066987 DMKITQN DI DMKITQN DMKITQN DN BM-13677 DMKITQN TI TT3C1VN DMKITQN TN Enzyme unspecific (Enz) DMKITQN MA Modulator DMKITQN RN Progress in medicinal chemistry, 1994. Page(448). DMKITQN RU https://books.google.com.hk/books?id=5_7mxy2G9a0C&pg=PA448&lpg=PA448&dq=%22BM-13677%22+enzyme&source=bl&ots=UzcIa2xi2D&sig=dx8ohd8OK-bXYWQUJ32VCTQc48A&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIn6Gx-cG_yAIVTyOOCh1w6Qe_#v=onepage&q=%22BM-13677%22%20enzyme&f=false DMKL482 DI DMKL482 DMKL482 DN A-364 DMKL482 TI TT3C1VN DMKL482 TN Enzyme unspecific (Enz) DMKL482 MA Inhibitor DMKL482 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015550) DMKL482 RU http://adisinsight.springer.com/drugs/800015550 DMKNJM7 DI DMKNJM7 DMKNJM7 DN DV-7028 DMKNJM7 TI TTJQOD7 DMKNJM7 TN 5-HT 2A receptor (HTR2A) DMKNJM7 MA Agonist DMKNJM7 RN Vascular and cardiac effects of DV-7028, a selective, 5-HT2-receptor antagonist in rats. J Cardiovasc Pharmacol. 1998 Aug;32(2):266-73. DMKNJM7 RU https://pubmed.ncbi.nlm.nih.gov/9700989 DMKNS10 DI DMKNS10 DMKNS10 DN BIPHALIN DMKNS10 TI TTKWM86 DMKNS10 TN Opioid receptor mu (MOP) DMKNS10 MA Inhibitor DMKNS10 RN Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501. DMKNS10 RU https://pubmed.ncbi.nlm.nih.gov/20617791 DMKNS10 DI DMKNS10 DMKNS10 DN BIPHALIN DMKNS10 TI TT27RFC DMKNS10 TN Opioid receptor delta (OPRD1) DMKNS10 MA Inhibitor DMKNS10 RN The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43. DMKNS10 RU https://pubmed.ncbi.nlm.nih.gov/19762245 DMKQV9A DI DMKQV9A DMKQV9A DN RS 86 DMKQV9A TI TTH18TF DMKQV9A TN Muscarinic acetylcholine receptor M5 (CHRM5) DMKQV9A MA Agonist DMKQV9A RN The pharmacological assessment of RS 86 (2-ethyl-8-methyl-2,8-diazaspiro-[4,5]-decan-1,3-dion hydrobromide). A potent, specific muscarinic acetylcholine receptor agonist. Eur J Pharmacol. 1986 Jun 5;125(1):45-62. DMKQV9A RU https://pubmed.ncbi.nlm.nih.gov/3732391 DMKRBL2 DI DMKRBL2 DMKRBL2 DN Bisbenzimide DMKRBL2 TI TTUTN1I DMKRBL2 TN Human Deoxyribonucleic acid (hDNA) DMKRBL2 MA Binder (minor groove binder) DMKRBL2 RN Sequence-dependent effects in drug-DNA interaction: the crystal structure of Hoechst 33258 bound to the d(CGCAAATTTGCG)2 duplex. Nucleic Acids Res. 1994 May 11;22(9):1607-12. DMKRBL2 RU https://pubmed.ncbi.nlm.nih.gov/7515488 DMKS1W0 DI DMKS1W0 DMKS1W0 DN MEN-10880 DMKS1W0 TI TT84ETX DMKS1W0 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMKS1W0 MA Modulator DMKS1W0 RN US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. DMKS1W0 RU http://www.google.com/patents/US20040023290 DMKS4Z9 DI DMKS4Z9 DMKS4Z9 DN IL1aQb DMKS4Z9 TI TTPM6HI DMKS4Z9 TN Interleukin-1 alpha (IL1A) DMKS4Z9 RN Cytos Biotechnology AG - Product Pipeline Review - 2013. Global Markets Direct. Dec 2013. DMKS4Z9 RU http://www.researchmoz.us/cytos-biotechnology-ag-product-pipeline-review-2013-report.html DMKSPYI DI DMKSPYI DMKSPYI DN TJN-598 DMKSPYI TI TTVIAT9 DMKSPYI TN Phosphodiesterase 4B (PDE4B) DMKSPYI MA Inhibitor DMKSPYI RN Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin Exp Nephrol. 2011 Feb;15(1):14-24. DMKSPYI RU https://pubmed.ncbi.nlm.nih.gov/20820840 DMKSPYI DI DMKSPYI DMKSPYI DN TJN-598 DMKSPYI TI TTSKMI8 DMKSPYI TN Phosphodiesterase 4D (PDE4D) DMKSPYI MA Inhibitor DMKSPYI RN Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin Exp Nephrol. 2011 Feb;15(1):14-24. DMKSPYI RU https://pubmed.ncbi.nlm.nih.gov/20820840 DMKSPYI DI DMKSPYI DMKSPYI DN TJN-598 DMKSPYI TI TTZ97H5 DMKSPYI TN Phosphodiesterase 4A (PDE4A) DMKSPYI MA Inhibitor DMKSPYI RN Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats. Clin Exp Nephrol. 2011 Feb;15(1):14-24. DMKSPYI RU https://pubmed.ncbi.nlm.nih.gov/20820840 DMKU469 DI DMKU469 DMKU469 DN DMP-963 DMKU469 TI TT84ETX DMKU469 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMKU469 MA Inhibitor DMKU469 RN Effect of drug substance particle size on the characteristics of granulation manufactured in a high-shear mixer. AAPS PharmSciTech. 2000 December; 1(4): 55-61. DMKU469 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750457/ DMKUETX DI DMKUETX DMKUETX DN CGS 8515 DMKUETX TI TT2J34L DMKUETX TN Arachidonate 5-lipoxygenase (5-LOX) DMKUETX MA Inhibitor DMKUETX RN Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models. Biochim Biophys Acta. 1988 Apr 15;959(3):332-42. DMKUETX RU https://pubmed.ncbi.nlm.nih.gov/2833314 DMKWJ59 DI DMKWJ59 DMKWJ59 DN SC-52150 DMKWJ59 TI TTNXLKE DMKWJ59 TN 5-HT 3 receptor (5HT3R) DMKWJ59 MA Modulator DMKWJ59 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001830) DMKWJ59 RU http://adisinsight.springer.com/drugs/800001830 DMKZ3PW DI DMKZ3PW DMKZ3PW DN BMS-186318 DMKZ3PW TI TT5FNQT DMKZ3PW TN Human immunodeficiency virus Protease (HIV PR) DMKZ3PW MA Modulator DMKZ3PW RN Determination of BMS-186318 in dog, rat and monkey plasma by liquid chromatography-ionspray mass spectrometry. J Pharm Biomed Anal. 1995 Dec;14(1-2):43-8. DMKZ3PW RU https://pubmed.ncbi.nlm.nih.gov/8833965 DMKZNTY DI DMKZNTY DMKZNTY DN A-71623 DMKZNTY TI TTCG0AL DMKZNTY TN Cholecystokinin receptor type A (CCKAR) DMKZNTY MA Modulator DMKZNTY RN Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol. 1991 Mar;39(3):346-51. DMKZNTY RU https://pubmed.ncbi.nlm.nih.gov/1706470 DML0B97 DI DML0B97 DML0B97 DN HOE-694 DML0B97 TI TTGSEFH DML0B97 TN Sodium/hydrogen exchanger 1 (SLC9A1) DML0B97 MA Inhibitor DML0B97 RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DML0B97 RU https://pubmed.ncbi.nlm.nih.gov/9207943 DML0B97 DI DML0B97 DML0B97 DN HOE-694 DML0B97 TI TTFZVPO DML0B97 TN Sodium/hydrogen exchanger 3 (SLC9A3) DML0B97 MA Inhibitor DML0B97 RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DML0B97 RU https://pubmed.ncbi.nlm.nih.gov/9207943 DML0DBV DI DML0DBV DML0DBV DN ABT-737 DML0DBV TI TTJGNVC DML0DBV TN Apoptosis regulator Bcl-2 (BCL-2) DML0DBV MA Inhibitor DML0DBV RN Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem. 2007 Feb 22;50(4):641-62. DML0DBV RU https://pubmed.ncbi.nlm.nih.gov/17256834 DML3NEU DI DML3NEU DML3NEU DN RO-319790 DML3NEU TI TTMX39J DML3NEU TN Matrix metalloproteinase-1 (MMP-1) DML3NEU MA Inhibitor DML3NEU RN The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8. DML3NEU RU https://pubmed.ncbi.nlm.nih.gov/9871728 DML3NEU DI DML3NEU DML3NEU DN RO-319790 DML3NEU TI TT6X50U DML3NEU TN Matrix metalloproteinase-9 (MMP-9) DML3NEU MA Inhibitor DML3NEU RN The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8. DML3NEU RU https://pubmed.ncbi.nlm.nih.gov/9871728 DML3NEU DI DML3NEU DML3NEU DN RO-319790 DML3NEU TI TTUZ2L5 DML3NEU TN Matrix metalloproteinase-3 (MMP-3) DML3NEU MA Inhibitor DML3NEU RN The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8. DML3NEU RU https://pubmed.ncbi.nlm.nih.gov/9871728 DMLA3P1 DI DMLA3P1 DMLA3P1 DN EUK-207 DMLA3P1 TI TT6RVLG DMLA3P1 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMLA3P1 MA Modulator DMLA3P1 RN A synthetic superoxide dismutase/catalase mimetic EUK-207 mitigates radiation dermatitis and promotes wound healing in irradiated rat skin. J Invest Dermatol. 2013 Apr;133(4):1088-96. DMLA3P1 RU https://pubmed.ncbi.nlm.nih.gov/23190879 DMLAIZG DI DMLAIZG DMLAIZG DN R-7025 DMLAIZG TI TT95SOA DMLAIZG TN Interferon alpha (IFNA) DMLAIZG MA Modulator DMLAIZG RN WO patent application no. 2013,0667,53, Compositions useful for the treatment of viral diseases. DMLAIZG RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20130510&CC=WO&NR=2013066753A1&KC=A1 DMLAVES DI DMLAVES DMLAVES DN Y-29794 DMLAVES TI TTNGKET DMLAVES TN Prolyl endopeptidase (PREP) DMLAVES MA Inhibitor DMLAVES RN Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38. DMLAVES RU https://pubmed.ncbi.nlm.nih.gov/20058865 DMLBS83 DI DMLBS83 DMLBS83 DN DMPDDF DMLBS83 TI TTU6BFZ DMLBS83 TN Candida Thymidylate synthase (Candi TMP1) DMLBS83 MA Inhibitor DMLBS83 RN Folate analogues. 32. Synthesis and biological evaluation of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid and related compounds. J Med Chem. 1989 Jun;32(6):1284-9. DMLBS83 RU https://pubmed.ncbi.nlm.nih.gov/2542557 DMLCSRF DI DMLCSRF DMLCSRF DN AZM-131 DMLCSRF TI TTXMY0J DMLCSRF TN Pancreatic triacylglycerol lipase (PNLIP) DMLCSRF MA Modulator DMLCSRF RN US patent application no. 7217,697, Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor. DMLCSRF RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20040909&CC=US&NR=2004176308A1&KC=A1 DMLENQ7 DI DMLENQ7 DMLENQ7 DN L-659989 DMLENQ7 TI TTQL5VC DMLENQ7 TN Platelet-activating factor receptor (PTAFR) DMLENQ7 MA Inhibitor DMLENQ7 RN Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,... J Med Chem. 1992 Sep 18;35(19):3474-82. DMLENQ7 RU https://pubmed.ncbi.nlm.nih.gov/1404229 DMLEVNC DI DMLEVNC DMLEVNC DN PD-135666 DMLEVNC TI TTVFO0U DMLEVNC TN Gastrin/cholecystokinin type B receptor (CCKBR) DMLEVNC MA Inhibitor DMLEVNC RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMLEVNC RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMLEVNC DI DMLEVNC DMLEVNC DN PD-135666 DMLEVNC TI TTCG0AL DMLEVNC TN Cholecystokinin receptor type A (CCKAR) DMLEVNC MA Inhibitor DMLEVNC RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMLEVNC RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMLG426 DI DMLG426 DMLG426 DN FR-208419 DMLG426 TI TTVFO0U DMLG426 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMLG426 MA Modulator DMLG426 RN Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419. Chem Pharm Bull (Tokyo). 2000 Jan;48(1):1-15. DMLG426 RU https://pubmed.ncbi.nlm.nih.gov/10705468 DMLG426 DI DMLG426 DMLG426 DN FR-208419 DMLG426 TI TTCG0AL DMLG426 TN Cholecystokinin receptor type A (CCKAR) DMLG426 MA Modulator DMLG426 RN Dual CCK-A and CCK-B receptor antagonists (II). Preparation and structure activity relationships of 5-alkyl-9-methyl-1,4-benzodiazepines and discovery of FR208419. Chem Pharm Bull (Tokyo). 2000 Jan;48(1):1-15. DMLG426 RU https://pubmed.ncbi.nlm.nih.gov/10705468 DMLIM7B DI DMLIM7B DMLIM7B DN GINKOLIDE B DMLIM7B TI TTF45NW DMLIM7B TN Strychnine-binding glycine receptor (GLRA1) DMLIM7B MA Inhibitor DMLIM7B RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMLIM7B RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMLIM7B DI DMLIM7B DMLIM7B DN GINKOLIDE B DMLIM7B TI TTZ8EM9 DMLIM7B TN Glycine receptor (GlyR) DMLIM7B MA Inhibitor DMLIM7B RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMLIM7B RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMLKQUR DI DMLKQUR DMLKQUR DN Palinavir DMLKQUR TI TT5FNQT DMLKQUR TN Human immunodeficiency virus Protease (HIV PR) DMLKQUR MA Modulator DMLKQUR RN Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1997 May;41(5):965-71. DMLKQUR RU https://pubmed.ncbi.nlm.nih.gov/9145853 DMLMISK DI DMLMISK DMLMISK DN PNU-96391A DMLMISK TI TT4C8EA DMLMISK TN Dopamine D3 receptor (D3R) DMLMISK MA Modulator DMLMISK RN The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects. Neuropsychopharmacology. 2015 Jan;40(2):472-9. DMLMISK RU https://pubmed.ncbi.nlm.nih.gov/25248987 DMLMISK DI DMLMISK DMLMISK DN PNU-96391A DMLMISK TI TTEX248 DMLMISK TN Dopamine D2 receptor (D2R) DMLMISK MA Modulator DMLMISK RN The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [(11)C]raclopride PET study in healthy human subjects. Neuropsychopharmacology. 2015 Jan;40(2):472-9. DMLMISK RU https://pubmed.ncbi.nlm.nih.gov/25248987 DMLN0Y5 DI DMLN0Y5 DMLN0Y5 DN Alvameline DMLN0Y5 TI TTQ13Z5 DMLN0Y5 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMLN0Y5 MA Modulator DMLN0Y5 RN In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40. DMLN0Y5 RU https://pubmed.ncbi.nlm.nih.gov/9683000 DMLN0Y5 DI DMLN0Y5 DMLN0Y5 DN Alvameline DMLN0Y5 TI TTZ9SOR DMLN0Y5 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMLN0Y5 MA Modulator DMLN0Y5 RN In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40. DMLN0Y5 RU https://pubmed.ncbi.nlm.nih.gov/9683000 DMLN0Y5 DI DMLN0Y5 DMLN0Y5 DN Alvameline DMLN0Y5 TI TTYEG6Q DMLN0Y5 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMLN0Y5 MA Modulator DMLN0Y5 RN In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40. DMLN0Y5 RU https://pubmed.ncbi.nlm.nih.gov/9683000 DMLQ71Y DI DMLQ71Y DMLQ71Y DN GR-159897 DMLQ71Y TI TTYO0A3 DMLQ71Y TN Substance-K receptor (TACR2) DMLQ71Y MA Modulator DMLQ71Y RN GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors. Eur J Pharmacol. 1995 Jan 16;272(2-3):241-8. DMLQ71Y RU https://pubmed.ncbi.nlm.nih.gov/7713168 DMLRBN1 DI DMLRBN1 DMLRBN1 DN L-698544 DMLRBN1 TI TTAN6JD DMLRBN1 TN Glutamate receptor AMPA (GRIA) DMLRBN1 MA Antagonist DMLRBN1 RN 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408. DMLRBN1 RU https://pubmed.ncbi.nlm.nih.gov/8230130 DMLRBN1 DI DMLRBN1 DMLRBN1 DN L-698544 DMLRBN1 TI TT9IK2Z DMLRBN1 TN N-methyl-D-aspartate receptor (NMDAR) DMLRBN1 MA Modulator DMLRBN1 RN 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory amino acid antagonists acting at glycine-site NMDA and (RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. J Med Chem. 1993 Oct 29;36(22):3397-408. DMLRBN1 RU https://pubmed.ncbi.nlm.nih.gov/8230130 DMLRBN1 DI DMLRBN1 DMLRBN1 DN L-698544 DMLRBN1 TI TTN9D8E DMLRBN1 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMLRBN1 MA Inhibitor DMLRBN1 RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMLRBN1 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMLRBN1 DI DMLRBN1 DMLRBN1 DN L-698544 DMLRBN1 TI TTKJEMQ DMLRBN1 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMLRBN1 MA Inhibitor DMLRBN1 RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMLRBN1 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMLRBN1 DI DMLRBN1 DMLRBN1 DN L-698544 DMLRBN1 TI TTLD29N DMLRBN1 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMLRBN1 MA Inhibitor DMLRBN1 RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMLRBN1 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMLTYFI DI DMLTYFI DMLTYFI DN NNC-26-0762 DMLTYFI TI TTG4R8V DMLTYFI TN Growth hormone-releasing hormone receptor (GHRHR) DMLTYFI MA Agonist DMLTYFI RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010046) DMLTYFI RU http://adisinsight.springer.com/drugs/800010046 DMLWQOP DI DMLWQOP DMLWQOP DN VR-147 DMLWQOP TI TT6MSOK DMLWQOP TN 5-HT 1D receptor (HTR1D) DMLWQOP MA Modulator DMLWQOP RN US patent application no. 2010,0112,050, Dosage form for insertion into the mouth. DMLWQOP RU http://www.google.com/patents/US20100112050 DMLWQOP DI DMLWQOP DMLWQOP DN VR-147 DMLWQOP TI TTK8CXU DMLWQOP TN 5-HT 1B receptor (HTR1B) DMLWQOP MA Modulator DMLWQOP RN US patent application no. 2010,0112,050, Dosage form for insertion into the mouth. DMLWQOP RU http://www.google.com/patents/US20100112050 DMLY2TN DI DMLY2TN DMLY2TN DN PPACK DMLY2TN TI TT6L509 DMLY2TN TN Coagulation factor IIa (F2) DMLY2TN MA Inhibitor DMLY2TN RN Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204. DMLY2TN RU https://pubmed.ncbi.nlm.nih.gov/11441979 DMM0ZIJ DI DMM0ZIJ DMM0ZIJ DN Belaperidone DMM0ZIJ TI TTE0A2F DMM0ZIJ TN Dopamine D4 receptor (D4R) DMM0ZIJ MA Antagonist DMM0ZIJ RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMM0ZIJ RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMM20PI DI DMM20PI DMM20PI DN LY-317644 DMM20PI TI TTFJ8Q1 DMM20PI TN Protein kinase C alpha (PRKCA) DMM20PI MA Inhibitor DMM20PI RN Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995). DMM20PI RU http://www.sciencedirect.com/science/article/pii/0960894X95003503 DMM20PI DI DMM20PI DMM20PI DN LY-317644 DMM20PI TI TTYPXQF DMM20PI TN Protein kinase C beta (PRKCB) DMM20PI MA Inhibitor DMM20PI RN Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995). DMM20PI RU http://www.sciencedirect.com/science/article/pii/0960894X95003503 DMM20PI DI DMM20PI DMM20PI DN LY-317644 DMM20PI TI TTUWGRA DMM20PI TN Protein kinase C zeta (PRKCZ) DMM20PI MA Inhibitor DMM20PI RN Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995). DMM20PI RU http://www.sciencedirect.com/science/article/pii/0960894X95003503 DMM20PI DI DMM20PI DMM20PI DN LY-317644 DMM20PI TI TTRFOXJ DMM20PI TN Protein kinase C gamma (PRKCG) DMM20PI MA Inhibitor DMM20PI RN Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995). DMM20PI RU http://www.sciencedirect.com/science/article/pii/0960894X95003503 DMM20PI DI DMM20PI DMM20PI DN LY-317644 DMM20PI TI TT9WJ8U DMM20PI TN Protein kinase C delta (PRKCD) DMM20PI MA Inhibitor DMM20PI RN Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995). DMM20PI RU http://www.sciencedirect.com/science/article/pii/0960894X95003503 DMM20PI DI DMM20PI DMM20PI DN LY-317644 DMM20PI TI TTBZ7OD DMM20PI TN Protein kinase C epsilon (PRKCE) DMM20PI MA Inhibitor DMM20PI RN Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995). DMM20PI RU http://www.sciencedirect.com/science/article/pii/0960894X95003503 DMM20PI DI DMM20PI DMM20PI DN LY-317644 DMM20PI TI TT8QL1J DMM20PI TN Protein kinase C theta (PRKCQ) DMM20PI MA Inhibitor DMM20PI RN Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995). DMM20PI RU http://www.sciencedirect.com/science/article/pii/0960894X95003503 DMM3UK5 DI DMM3UK5 DMM3UK5 DN 50-235 DMM3UK5 TI TTKRD0G DMM3UK5 TN Endothelin A receptor (EDNRA) DMM3UK5 MA Modulator DMM3UK5 RN Structure-activity relationships of an endothelin ETA receptor antagonist, 50-235, and its derivatives. Eur J Pharmacol. 1993 Oct 15;247(2):219-21. DMM3UK5 RU https://pubmed.ncbi.nlm.nih.gov/8282010 DMM7S3V DI DMM7S3V DMM7S3V DN KB-5359 DMM7S3V TI TTQWUPT DMM7S3V TN Thyroid hormone receptor (THR) DMM7S3V MA Modulator DMM7S3V RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMM7S3V RU https://www.fda.gov/ DMM8F0V DI DMM8F0V DMM8F0V DN SKF-107260 DMM8F0V TI TTJA1ZO DMM8F0V TN ITGB3 messenger RNA (ITGB3 mRNA) DMM8F0V MA Inhibitor DMM8F0V RN Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993). DMM8F0V RU http://www.sciencedirect.com/science/article/pii/S0960894X00803108 DMMA92L DI DMMA92L DMMA92L DN Org-30035 DMMA92L TI TTN4QDT DMMA92L TN Opioid receptor (OPR) DMMA92L MA Modulator DMMA92L RN WO patent application no. 2010,0332,07, Polymer conjugates of therapeutic peptides. DMMA92L RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100325&CC=WO&NR=2010033207A1&KC=A1 DMMBTU6 DI DMMBTU6 DMMBTU6 DN BMS-210285 DMMBTU6 TI TTMXGCW DMMBTU6 TN Adrenergic receptor beta-3 (ADRB3) DMMBTU6 MA Agonist DMMBTU6 RN CA patent application no. 509835, Nitrogen-containing heterocyclic derivatives, medicinal compositions containing the same and medicinal use thereof. DMMBTU6 RU https://www.google.com.ar/patents/CA2509835A1?cl=en DMMCI4H DI DMMCI4H DMMCI4H DN HELENALIN DMMCI4H TI TTSXVID DMMCI4H TN Nuclear factor NF-kappa-B (NFKB) DMMCI4H MA Inhibitor DMMCI4H RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DMMCI4H RU https://pubmed.ncbi.nlm.nih.gov/15537359 DMMCI4H DI DMMCI4H DMMCI4H DN HELENALIN DMMCI4H TI TT8DBY3 DMMCI4H TN Angiotensin II receptor type-1 (AGTR1) DMMCI4H MA Inhibitor DMMCI4H RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMMCI4H RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMMDO3X DI DMMDO3X DMMDO3X DN CVS-995 DMMDO3X TI TT6L509 DMMDO3X TN Coagulation factor IIa (F2) DMMDO3X MA Inhibitor DMMDO3X RN Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an alpha-keto-amide transition-state mimetic. Protein Sci. 1996 Mar;5(3):422-33. DMMDO3X RU https://pubmed.ncbi.nlm.nih.gov/8868478 DMMDQ5T DI DMMDQ5T DMMDQ5T DN ZK-93426 DMMDQ5T TI TTEX6LM DMMDQ5T TN GABA(A) receptor gamma-3 (GABRG3) DMMDQ5T MA Modulator DMMDQ5T RN Actions of the beta-carboline ZK 93426 in an animal test of anxiety and the holeboard: interactions with Ro 15-1788. J Neural Transm. 1986;65(2):103-14. DMMDQ5T RU https://www.ncbi.nlm.nih.gov/pubmed/3009709 DMMG1K3 DI DMMG1K3 DMMG1K3 DN MDL-201112 DMMG1K3 TI TTF8CQI DMMG1K3 TN Tumor necrosis factor (TNF) DMMG1K3 MA Inhibitor DMMG1K3 RN Effect of the carbocyclic nucleoside analogue MDL 201,112 on inhibition of interferon-gamma-induced priming of Lewis (LEW/N) rat macrophages for enhanced respiratory burst and MHC class II Ia+ antigen expression. J Leukoc Biol. 1994 Aug;56(2):133-44. DMMG1K3 RU https://pubmed.ncbi.nlm.nih.gov/8071590 DMMGYXR DI DMMGYXR DMMGYXR DN Dizocilpine DMMGYXR TI TTLD29N DMMGYXR TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMMGYXR MA Inhibitor DMMGYXR RN Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9. DMMGYXR RU https://pubmed.ncbi.nlm.nih.gov/7608913 DMMGYXR DI DMMGYXR DMMGYXR DN Dizocilpine DMMGYXR TI TTJFY5U DMMGYXR TN Adenosine A3 receptor (ADORA3) DMMGYXR MA Inhibitor DMMGYXR RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMMGYXR RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMMGYXR DI DMMGYXR DMMGYXR DN Dizocilpine DMMGYXR TI TTN9D8E DMMGYXR TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMMGYXR MA Inhibitor DMMGYXR RN Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9. DMMGYXR RU https://pubmed.ncbi.nlm.nih.gov/7608913 DMMGYXR DI DMMGYXR DMMGYXR DN Dizocilpine DMMGYXR TI TTKJEMQ DMMGYXR TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMMGYXR MA Inhibitor DMMGYXR RN Synthesis and evaluation of 6,11-ethanohexahydrobenzo[b]quinolizidines: a new class of noncompetitive N-methyl-D-aspartate antagonists. J Med Chem. 1995 Jun 23;38(13):2483-9. DMMGYXR RU https://pubmed.ncbi.nlm.nih.gov/7608913 DMMKOCL DI DMMKOCL DMMKOCL DN AMT-050 DMMKOCL TI TT7GN3U DMMKOCL TN Apolipoprotein A-I (APOA1) DMMKOCL MA Modulator DMMKOCL RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026835) DMMKOCL RU http://adisinsight.springer.com/drugs/800026835 DMML3J4 DI DMML3J4 DMML3J4 DN NAN-190 DMML3J4 TI TTSQIFT DMML3J4 TN 5-HT 1A receptor (HTR1A) DMML3J4 MA Antagonist DMML3J4 RN Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol Biochem Behav. 1997 Oct;58(2):593-603. DMML3J4 RU https://pubmed.ncbi.nlm.nih.gov/9300624 DMMLDG8 DI DMMLDG8 DMMLDG8 DN Anatumomab mafenatox DMMLDG8 TI TT70MLA DMMLDG8 TN Oncotrophoblast glycoprotein 5T4 (TPBG) DMMLDG8 RN A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74. DMMLDG8 RU https://pubmed.ncbi.nlm.nih.gov/17285137 DMMLXRG DI DMMLXRG DMMLXRG DN ON-09300 DMMLXRG TI TTVKILB DMMLXRG TN Prostaglandin G/H synthase 2 (COX-2) DMMLXRG MA Modulator DMMLXRG RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMMLXRG RU https://www.fda.gov/ DMMNI5K DI DMMNI5K DMMNI5K DN BIBU-251 DMMNI5K TI TT38RM1 DMMNI5K TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMMNI5K MA Modulator DMMNI5K RN CN patent application no. 101312747, Anticoagulant antithrombotic dual inhibitors comprising a biotin label. DMMNI5K RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20081126&CC=CN&NR=101312747A&KC=A DMMOAN0 DI DMMOAN0 DMMOAN0 DN NNC-13-8119 DMMOAN0 TI TTPTXIN DMMOAN0 TN Translocator protein (TSPO) DMMOAN0 MA Modulator DMMOAN0 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004060) DMMOAN0 RU http://adisinsight.springer.com/drugs/800004060 DMMOBHW DI DMMOBHW DMMOBHW DN FR-128998 DMMOBHW TI TTQL5VC DMMOBHW TN Platelet-activating factor receptor (PTAFR) DMMOBHW MA Modulator DMMOBHW RN Effect of FR128998, a novel PAF receptor antagonist, on endotoxin-induced disseminated intravascular coagulation. Eur J Pharmacol. 1994 Jun 13;258(3):239-46. DMMOBHW RU https://pubmed.ncbi.nlm.nih.gov/8088357 DMMOS8G DI DMMOS8G DMMOS8G DN WAY-123223 DMMOS8G TI TT1VOHK DMMOS8G TN Potassium channel unspecific (KC) DMMOS8G MA Opener DMMOS8G RN Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives. J Med Chem. 1991 Nov;34(11):3212-28. DMMOS8G RU https://pubmed.ncbi.nlm.nih.gov/1956040 DMMPSY2 DI DMMPSY2 DMMPSY2 DN SRI 63-441 DMMPSY2 TI TT27K59 DMMPSY2 TN Platelet activating factor (PAF) DMMPSY2 MA Inhibitor DMMPSY2 RN Pharmacologic modulation of experimental postischemic hepatic function. Ann Surg. 1989 Feb;209(2):200-10. DMMPSY2 RU https://pubmed.ncbi.nlm.nih.gov/2916864 DMMRLPF DI DMMRLPF DMMRLPF DN LX-2932 DMMRLPF TI TT618Q2 DMMRLPF TN Sphingosine-1-phosphate lyase 1 (SGPL1) DMMRLPF MA Inhibitor DMMRLPF RN Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J Med Chem. 2010 Dec 23;53(24):8650-62. DMMRLPF RU https://pubmed.ncbi.nlm.nih.gov/21090716 DMMRWKP DI DMMRWKP DMMRWKP DN SQ-33800 DMMRWKP TI TTB2MXP DMMRWKP TN Angiotensinogenase renin (REN) DMMRWKP MA Inhibitor DMMRWKP RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002406) DMMRWKP RU http://adisinsight.springer.com/drugs/800002406 DMMTZXV DI DMMTZXV DMMTZXV DN AKP-320 DMMTZXV TI TTZMAO3 DMMTZXV TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMMTZXV MA Modulator DMMTZXV RN Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato) oxovanadium(IV) in ZDF rats. Canadian Journal of Physiology and Pharmacology. 12/2003; 81(11):1049-55. DMMTZXV RU http://www.researchgate.net/publication/8922382_Chronic_glucose-lowering_effects_of_rosiglitazone_and_bis(ethylmaltolato)_oxovanadium(IV)_in_ZDF_rats DMMXG2I DI DMMXG2I DMMXG2I DN Heparin-EGF-like factor DMMXG2I TI TTGKNB4 DMMXG2I TN Epidermal growth factor receptor (EGFR) DMMXG2I MA Modulator DMMXG2I RN The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608. DMMXG2I RU https://pubmed.ncbi.nlm.nih.gov/7844173 DMMYUWT DI DMMYUWT DMMYUWT DN GSK-923295 DMMYUWT TI TTZD5QR DMMYUWT TN Centromeric protein E (CENPE) DMMYUWT MA Inhibitor DMMYUWT RN Cytokinetics Announces Non-Clinical Trial Data Presented at 2007 AACR Annual Meeting. Cytokinetics, Incorporated. 2007. DMMYUWT RU http://www.newsrx.com/newsletters/Blood-Weekly/2007-05-10/80510200710BW.html DMMZ9DY DI DMMZ9DY DMMZ9DY DN BN-80245 DMMZ9DY TI TTGTQHC DMMZ9DY TN DNA topoisomerase I (TOP1) DMMZ9DY MA Inhibitor DMMZ9DY RN BN 80245: An E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorganic & Medicinal Chemistry Letters Volume 7, Issue 17, 9 September 1997, Pages2235-2238. DMMZ9DY RU http://www.sciencedirect.com/science/article/pii/S0960894X97003983 DMMZJY3 DI DMMZJY3 DMMZJY3 DN CGS-17867A DMMZJY3 TI TT06RH5 DMMZJY3 TN GABA(A) receptor gamma-2 (GABRG2) DMMZJY3 MA Inhibitor DMMZJY3 RN 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4. DMMZJY3 RU https://pubmed.ncbi.nlm.nih.gov/15177449 DMMZJY3 DI DMMZJY3 DMMZJY3 DN CGS-17867A DMMZJY3 TI TTBMV1G DMMZJY3 TN GABA(A) receptor alpha-2 (GABRA2) DMMZJY3 MA Inhibitor DMMZJY3 RN 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4. DMMZJY3 RU https://pubmed.ncbi.nlm.nih.gov/15177449 DMMZJY3 DI DMMZJY3 DMMZJY3 DN CGS-17867A DMMZJY3 TI TTNJYV2 DMMZJY3 TN Gamma-aminobutyric acid receptor (GAR) DMMZJY3 MA Inhibitor DMMZJY3 RN 2,5-Dihydropyrazolo[4,3-c]pyridin-3-ones: functionally selective benzodiazepine binding site ligands on the GABAA receptor. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3441-4. DMMZJY3 RU https://pubmed.ncbi.nlm.nih.gov/15177449 DMMZNSC DI DMMZNSC DMMZNSC DN AM-92016 DMMZNSC TI TTLD29N DMMZNSC TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMMZNSC MA Inhibitor DMMZNSC RN Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem. 2008 Sep 25;51(18):5506-21. DMMZNSC RU https://pubmed.ncbi.nlm.nih.gov/18800760 DMN1A70 DI DMN1A70 DMN1A70 DN PD-117596 DMN1A70 TI TTN6J5F DMN1A70 TN Bacterial DNA gyrase (Bact gyrase) DMN1A70 MA Modulator DMN1A70 RN In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):245-58. DMN1A70 RU https://www.ncbi.nlm.nih.gov/pubmed/1889177 DMN4E5H DI DMN4E5H DMN4E5H DN Fradafiban DMN4E5H TI TT38RM1 DMN4E5H TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMN4E5H MA Modulator DMN4E5H RN Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997Aug 19;96(4):1130-8. DMN4E5H RU https://pubmed.ncbi.nlm.nih.gov/9286940 DMN5IY7 DI DMN5IY7 DMN5IY7 DN SDZ-ICM-567 DMN5IY7 TI TTNXLKE DMN5IY7 TN 5-HT 3 receptor (5HT3R) DMN5IY7 MA Antagonist DMN5IY7 RN Microdialysis sampling to determine the pharmacokinetics of unbound SDZ ICM 567 in blood and brain in awake, freely-moving rats. Pharm Res. 1995 Feb;12(2):291-4. DMN5IY7 RU https://pubmed.ncbi.nlm.nih.gov/7784347 DMN8FAG DI DMN8FAG DMN8FAG DN BP4.879a DMN8FAG TI TT4C8EA DMN8FAG TN Dopamine D3 receptor (D3R) DMN8FAG MA Antagonist DMN8FAG RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMN8FAG RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMN8FAG DI DMN8FAG DMN8FAG DN BP4.879a DMN8FAG TI TTPC4TU DMN8FAG TN 5-HT 3A receptor (HTR3A) DMN8FAG MA Antagonist DMN8FAG RN Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J Neurochem. 1993 Feb;60(2):730-7. DMN8FAG RU https://pubmed.ncbi.nlm.nih.gov/8419547 DMN8FAG DI DMN8FAG DMN8FAG DN BP4.879a DMN8FAG TI TTNXLKE DMN8FAG TN 5-HT 3 receptor (5HT3R) DMN8FAG MA Antagonist DMN8FAG RN 5-HT(3A) receptor subunit is required for 5-HT3 antagonist-induced reductions in alcohol drinking. Neuropsychopharmacology. 2004 Oct;29(10):1807-13. DMN8FAG RU https://pubmed.ncbi.nlm.nih.gov/15162158 DMN8TH1 DI DMN8TH1 DMN8TH1 DN GR-144053 DMN8TH1 TI TT38RM1 DMN8TH1 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMN8TH1 MA Modulator DMN8TH1 RN GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in ... Br J Pharmacol. 1997 Nov;122(6):1099-104. DMN8TH1 RU https://www.ncbi.nlm.nih.gov/pubmed/9480031 DMN91EK DI DMN91EK DMN91EK DN SK&F-104856 DMN91EK TI TT34BHT DMN91EK TN Adrenergic receptor alpha-1D (ADRA1D) DMN91EK MA Inhibitor DMN91EK RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMN91EK RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMN91EK DI DMN91EK DMN91EK DN SK&F-104856 DMN91EK TI TTNGILX DMN91EK TN Adrenergic receptor alpha-1A (ADRA1A) DMN91EK MA Inhibitor DMN91EK RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMN91EK RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMN91EK DI DMN91EK DMN91EK DN SK&F-104856 DMN91EK TI TTBRKXS DMN91EK TN Adrenergic receptor alpha-1B (ADRA1B) DMN91EK MA Inhibitor DMN91EK RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMN91EK RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMNACIV DI DMNACIV DMNACIV DN FR-194738 DMNACIV TI TTE14XG DMNACIV TN Squalene monooxygenase (SQLE) DMNACIV MA Modulator DMNACIV RN Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett. 2004 Feb 9;14(3):633-7. DMNACIV RU https://pubmed.ncbi.nlm.nih.gov/14741258 DMNAFG1 DI DMNAFG1 DMNAFG1 DN Olomoucine DMNAFG1 TI TTH6V3D DMNAFG1 TN Cyclin-dependent kinase 1 (CDK1) DMNAFG1 MA Binder DMNAFG1 RN Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cell Mol Life Sci. 2005 Aug;62(15):1763-71. DMNAFG1 RU https://pubmed.ncbi.nlm.nih.gov/16003486 DMNAFG1 DI DMNAFG1 DMNAFG1 DN Olomoucine DMNAFG1 TI TT7HF4W DMNAFG1 TN Cyclin-dependent kinase 2 (CDK2) DMNAFG1 MA Inhibitor DMNAFG1 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMNAFG1 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMNAFG1 DI DMNAFG1 DMNAFG1 DN Olomoucine DMNAFG1 TI TTL4Q97 DMNAFG1 TN Cyclin-dependent kinase 5 (CDK5) DMNAFG1 MA Inhibitor DMNAFG1 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMNAFG1 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMNCGOP DI DMNCGOP DMNCGOP DN A-74932 DMNCGOP TI TT0IHXV DMNCGOP TN DNA topoisomerase II (TOP2) DMNCGOP MA Modulator DMNCGOP RN Use of catalytic topoisomerase II inhibitors to probe mechanisms of chemical-induced clastogenicity in Chinese hamster V79 cells. Environ Mol Mutagen. 2000;35(1):13-21. DMNCGOP RU https://www.ncbi.nlm.nih.gov/pubmed/10692223 DMNE4TS DI DMNE4TS DMNE4TS DN SNAP-6201 DMNE4TS TI TTNGILX DMNE4TS TN Adrenergic receptor alpha-1A (ADRA1A) DMNE4TS MA Inhibitor DMNE4TS RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMNE4TS RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMNH9A6 DI DMNH9A6 DMNH9A6 DN BCH-150 DMNH9A6 TI TTKWM86 DMNH9A6 TN Opioid receptor mu (MOP) DMNH9A6 MA Modulator DMNH9A6 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003724) DMNH9A6 RU http://adisinsight.springer.com/drugs/800003724 DMNJ7LY DI DMNJ7LY DMNJ7LY DN SB 203186 DMNJ7LY TI TT07C3Y DMNJ7LY TN 5-HT 4 receptor (HTR4) DMNJ7LY MA Antagonist DMNJ7LY RN 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58. DMNJ7LY RU https://pubmed.ncbi.nlm.nih.gov/11874527 DMNJXRG DI DMNJXRG DMNJXRG DN CEB-925 DMNJXRG TI TTMF541 DMNJXRG TN Liver carboxylesterase (CES1) DMNJXRG MA Inhibitor DMNJXRG RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010079) DMNJXRG RU http://adisinsight.springer.com/drugs/800010079 DMNK2I0 DI DMNK2I0 DMNK2I0 DN PRS-639058 DMNK2I0 TI TTMSFAW DMNK2I0 TN Cannabinoid receptor 2 (CB2) DMNK2I0 MA Agonist DMNK2I0 RN Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009 April; 60(1): 255-266. DMNK2I0 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549801/ DMNL1VM DI DMNL1VM DMNL1VM DN NPS-846 DMNL1VM TI TTDXZ24 DMNL1VM TN Glutamate receptor ionotropic (GRI) DMNL1VM MA Modulator DMNL1VM RN Neuroprotective effects of NPS 846, a novel N-methyl-D-aspartate receptor antagonist, after closed head trauma in rats. J Neurosurg. 1998 Jun;88(6):1066-74. DMNL1VM RU https://pubmed.ncbi.nlm.nih.gov/9609302 DMNRJA0 DI DMNRJA0 DMNRJA0 DN GR-133347 DMNRJA0 TI TT0WAIE DMNRJA0 TN Melatonin receptor type 1A (MTNR1A) DMNRJA0 MA Modulator DMNRJA0 RN US patent application no. 5,151,446, Substituted 2-amidotetralins as melatonin agonists and antagonists. DMNRJA0 RU http://www.google.com/patents/US5151446 DMNRUGA DI DMNRUGA DMNRUGA DN FR-121196 DMNRUGA TI TTAE1BR DMNRUGA TN Somatostatin receptor type 4 (SSTR4) DMNRUGA MA Modulator DMNRUGA RN Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34. DMNRUGA RU https://pubmed.ncbi.nlm.nih.gov/7901036 DMNRUGA DI DMNRUGA DMNRUGA DN FR-121196 DMNRUGA TI TTZ6T9E DMNRUGA TN Somatostatin receptor type 2 (SSTR2) DMNRUGA MA Modulator DMNRUGA RN Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34. DMNRUGA RU https://pubmed.ncbi.nlm.nih.gov/7901036 DMNRUGA DI DMNRUGA DMNRUGA DN FR-121196 DMNRUGA TI TTJX3UE DMNRUGA TN Somatostatin receptor type 3 (SSTR3) DMNRUGA MA Modulator DMNRUGA RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMNRUGA RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMNRUGA DI DMNRUGA DMNRUGA DN FR-121196 DMNRUGA TI TT2BC4G DMNRUGA TN Somatostatin receptor type 5 (SSTR5) DMNRUGA MA Modulator DMNRUGA RN Role of somatostatin in the augmentation of hippocampal long-term potentiation by FR121196, a putative cognitive enhancer. Eur J Pharmacol. 1993 Sep 7;241(1):27-34. DMNRUGA RU https://pubmed.ncbi.nlm.nih.gov/7901036 DMNRUGA DI DMNRUGA DMNRUGA DN FR-121196 DMNRUGA TI TTIND6G DMNRUGA TN Somatostatin receptor type 1 (SSTR1) DMNRUGA MA Modulator DMNRUGA RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMNRUGA RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMNSDM1 DI DMNSDM1 DMNSDM1 DN DMP-696 DMNSDM1 TI TT7EFHR DMNSDM1 TN Corticotropin-releasing factor receptor 1 (CRHR1) DMNSDM1 MA Inhibitor DMNSDM1 RN In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. J Med Chem. 2009 Jul 23;52(14):4161-72. DMNSDM1 RU https://pubmed.ncbi.nlm.nih.gov/19552436 DMNSH0V DI DMNSH0V DMNSH0V DN L-741604 DMNSH0V TI TT6MSOK DMNSH0V TN 5-HT 1D receptor (HTR1D) DMNSH0V MA Inhibitor DMNSH0V RN 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1999 Feb 25;42(4):691-705. DMNSH0V RU https://pubmed.ncbi.nlm.nih.gov/10052976 DMNTGXQ DI DMNTGXQ DMNTGXQ DN SL-910102 DMNTGXQ TI TTGN1ZA DMNTGXQ TN Angiotensin II receptor (AGTR) DMNTGXQ MA Modulator DMNTGXQ RN A radioreceptor assay for the analysis of AT1-receptor antagonists. Correlation with complementary LC data reveals a potential contribution of active metabolites. J Pharm Biomed Anal. 1998 May;17(1):111-24. DMNTGXQ RU https://pubmed.ncbi.nlm.nih.gov/9608433 DMNTIWC DI DMNTIWC DMNTIWC DN MEN-11467 DMNTIWC TI TTZPO1L DMNTIWC TN Substance-P receptor (TACR1) DMNTIWC MA Antagonist DMNTIWC RN Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol. 2001 Jan;132(1):189-96. DMNTIWC RU https://pubmed.ncbi.nlm.nih.gov/11156577 DMNUKB4 DI DMNUKB4 DMNUKB4 DN PD-85639 DMNUKB4 TI TTRK8B9 DMNUKB4 TN Sodium channel unspecific (NaC) DMNUKB4 MA Inhibitor DMNUKB4 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DMNUKB4 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DMNUKB4 DI DMNUKB4 DMNUKB4 DN PD-85639 DMNUKB4 TI TTAXZ0K DMNUKB4 TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMNUKB4 MA Inhibitor DMNUKB4 RN Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74. DMNUKB4 RU https://pubmed.ncbi.nlm.nih.gov/8295214 DMNUKB4 DI DMNUKB4 DMNUKB4 DN PD-85639 DMNUKB4 TI TTZOVE0 DMNUKB4 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMNUKB4 MA Inhibitor DMNUKB4 RN Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37. DMNUKB4 RU https://pubmed.ncbi.nlm.nih.gov/11170622 DMNUMDG DI DMNUMDG DMNUMDG DN BW A4C DMNUMDG TI TT2J34L DMNUMDG TN Arachidonate 5-lipoxygenase (5-LOX) DMNUMDG MA Inhibitor DMNUMDG RN Reactive oxygen species and lipoxygenases regulate the oncogenicity of NPM-ALK-positive anaplastic large cell lymphomas. Oncogene. 2009 Jul 23;28(29):2690-6. DMNUMDG RU https://pubmed.ncbi.nlm.nih.gov/19503098 DMNUMDG DI DMNUMDG DMNUMDG DN BW A4C DMNUMDG TI TTSJ6Q4 DMNUMDG TN LOX-5 messenger RNA (ALOX5 mRNA) DMNUMDG MA Inhibitor DMNUMDG RN Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem. 2008 Sep 11;51(17):5449-53. DMNUMDG RU https://pubmed.ncbi.nlm.nih.gov/18710209 DMNX93E DI DMNX93E DMNX93E DN SM-19712 DMNX93E TI TT1BGDH DMNX93E TN Endothelin-converting enzyme (ECE) DMNX93E MA Inhibitor DMNX93E RN Protective effect of SM-19712, a novel and potent endothelin converting enzyme inhibitor, on ischemic acute renal failure in rats. Jpn J Pharmacol. 2000 Sep;84(1):16-24. DMNX93E RU https://pubmed.ncbi.nlm.nih.gov/11043448 DMNXKR2 DI DMNXKR2 DMNXKR2 DN LG-2293 DMNXKR2 TI TTS64P2 DMNXKR2 TN Androgen receptor (AR) DMNXKR2 MA Modulator DMNXKR2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006840) DMNXKR2 RU http://adisinsight.springer.com/drugs/800006840 DMNYKOT DI DMNYKOT DMNYKOT DN Zatebradine DMNYKOT TI TTW0CMT DMNYKOT TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMNYKOT MA Modulator DMNYKOT RN DOI: 10.1161/01.CIR.94.3.562 DMNYKOT RU http://circ.ahajournals.org/content/94/3/562.abstract DMNYLEU DI DMNYLEU DMNYLEU DN MSC-204 DMNYLEU TI TT84ETX DMNYLEU TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMNYLEU MA Modulator DMNYLEU RN WO patent application no. 2004,0290,42, Pyrazole derivatives as reverse transcriptase inhibitors. DMNYLEU RU http://www.google.com/patents/WO2004029042A1?cl=en DMNZ1LR DI DMNZ1LR DMNZ1LR DN KF-15766 DMNZ1LR TI TT7CXIM DMNZ1LR TN Histamine receptor (HR) DMNZ1LR MA Modulator DMNZ1LR RN Mutational analysis of the antagonist-binding site of the histamine H(1) receptor. J Biol Chem. 1999 Oct 15;274(42):29994-30000. DMNZ1LR RU https://pubmed.ncbi.nlm.nih.gov/10514483 DMNZ356 DI DMNZ356 DMNZ356 DN MX-781 DMNZ356 TI TTOD7B3 DMNZ356 TN Retinoic acid receptor (RAR) DMNZ356 MA Modulator DMNZ356 RN The retinoid antagonist MX781 induces clusterin expression in prostate cancer cells via heat shock factor-1 and activator protein-1 transcription factors. Cancer Res. 2004 Aug 15;64(16):5905-12. DMNZ356 RU https://pubmed.ncbi.nlm.nih.gov/15313936 DMO06JV DI DMO06JV DMO06JV DN Mitoflaxone DMO06JV TI TT3SZBT DMO06JV TN von Willebrand factor (VWF) DMO06JV MA Inhibitor DMO06JV RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DMO06JV RU https://pubmed.ncbi.nlm.nih.gov/11804648 DMO1URE DI DMO1URE DMO1URE DN SC-236 DMO1URE TI TTVKILB DMO1URE TN Prostaglandin G/H synthase 2 (COX-2) DMO1URE MA Inhibitor DMO1URE RN Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther. 2004 Apr;3(4):417-24. DMO1URE RU https://pubmed.ncbi.nlm.nih.gov/15078985 DMO26E7 DI DMO26E7 DMO26E7 DN DMP-811 DMO26E7 TI TTGN1ZA DMO26E7 TN Angiotensin II receptor (AGTR) DMO26E7 MA Modulator DMO26E7 RN Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzee. Drug Metab Dispos. 1995 Oct;23(10):1104-9. DMO26E7 RU https://pubmed.ncbi.nlm.nih.gov/8654199 DMO2S6T DI DMO2S6T DMO2S6T DN MOXIFETIN HYDROGEN MALEATE DMO2S6T TI TT3ROYC DMO2S6T TN Serotonin transporter (SERT) DMO2S6T RN Moxidectin causes adult worm mortality of human lymphatic filarial parasite Brugia malayi in rodent models. Folia Parasitol (Praha). 2014 Dec;61(6):561-70. DMO2S6T RU https://pubmed.ncbi.nlm.nih.gov/25651699 DMO3486 DI DMO3486 DMO3486 DN COSALANE DMO3486 TI TTC24WT DMO3486 TN C-C chemokine receptor type 1 (CCR1) DMO3486 MA Inhibitor DMO3486 RN Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds. Bioorg Med Chem Lett. 2001 Jan 8;11(1):59-62. DMO3486 RU https://pubmed.ncbi.nlm.nih.gov/11140734 DMO3FYI DI DMO3FYI DMO3FYI DN RP-73163 DMO3FYI TI TTMF541 DMO3FYI TN Liver carboxylesterase (CES1) DMO3FYI MA Modulator DMO3FYI RN Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol. Biochem Pharmacol. 1996 Oct 25;52(8):1177-86. DMO3FYI RU https://pubmed.ncbi.nlm.nih.gov/8937424 DMO3XBP DI DMO3XBP DMO3XBP DN Divaplon DMO3XBP TI TT1MPAY DMO3XBP TN GABA(A) receptor alpha-1 (GABRA1) DMO3XBP MA Inhibitor DMO3XBP RN (Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics. J Med Chem. 1988 Jun;31(6):1220-6. DMO3XBP RU https://pubmed.ncbi.nlm.nih.gov/2897468 DMO3XBP DI DMO3XBP DMO3XBP DN Divaplon DMO3XBP TI TTNJYV2 DMO3XBP TN Gamma-aminobutyric acid receptor (GAR) DMO3XBP MA Inhibitor DMO3XBP RN (Imidazo[1,2-a]pyrimidin-2-yl)phenylmethanones and related compounds as potential nonsedative anxiolytics. J Med Chem. 1988 Jun;31(6):1220-6. DMO3XBP RU https://pubmed.ncbi.nlm.nih.gov/2897468 DMO4WB8 DI DMO4WB8 DMO4WB8 DN SIB-1663 DMO4WB8 TI TTJSZTB DMO4WB8 TN Nicotinic acetylcholine receptor (nAChR) DMO4WB8 MA Agonist DMO4WB8 RN The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin Investig Drugs. 2001 Oct;10(10):1819-30. DMO4WB8 RU https://pubmed.ncbi.nlm.nih.gov/11772288 DMO69X8 DI DMO69X8 DMO69X8 DN L-738167 DMO69X8 TI TTJA1ZO DMO69X8 TN ITGB3 messenger RNA (ITGB3 mRNA) DMO69X8 MA Inhibitor DMO69X8 RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DMO69X8 RU https://pubmed.ncbi.nlm.nih.gov/10999999 DMO6BA0 DI DMO6BA0 DMO6BA0 DN 3-DEAZAADENOSINE DMO6BA0 TI TTANY71 DMO6BA0 TN AdoHcy hydrolase (SAHase) DMO6BA0 MA Modulator DMO6BA0 RN Anti-HIV-1 activity of 3-deaza-adenosine analogs. Inhibition of S-adenosylhomocysteine hydrolase and nucleotide congeners. Eur J Biochem. 2003 Sep;270(17):3507-17. DMO6BA0 RU https://pubmed.ncbi.nlm.nih.gov/12919315 DMO7C09 DI DMO7C09 DMO7C09 DN BMS-182566 DMO7C09 TI TT7WZIJ DMO7C09 TN CAAX farnesyltransferase beta (FNTB) DMO7C09 MA Modulator DMO7C09 RN US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent. DMO7C09 RU http://www.google.com/patents/US20050227929 DMO7GWC DI DMO7GWC DMO7GWC DN L-702958 DMO7GWC TI TTQ6VDM DMO7GWC TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMO7GWC MA Modulator DMO7GWC RN Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel.Biochem Pharmacol.2009 May 15;77(10):1602-11. DMO7GWC RU https://www.ncbi.nlm.nih.gov/pubmed/19426697 DMO9HM7 DI DMO9HM7 DMO9HM7 DN L-698532 DMO9HM7 TI TTLD29N DMO9HM7 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMO9HM7 MA Inhibitor DMO9HM7 RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMO9HM7 RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMO9HM7 DI DMO9HM7 DMO9HM7 DN L-698532 DMO9HM7 TI TTN9D8E DMO9HM7 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMO9HM7 MA Inhibitor DMO9HM7 RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMO9HM7 RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMO9HM7 DI DMO9HM7 DMO9HM7 DN L-698532 DMO9HM7 TI TTKJEMQ DMO9HM7 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMO9HM7 MA Inhibitor DMO9HM7 RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMO9HM7 RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMO9UCK DI DMO9UCK DMO9UCK DN SU5614 DMO9UCK TI TTGJCWZ DMO9UCK TN Fms-like tyrosine kinase 3 (FLT-3) DMO9UCK MA Inhibitor DMO9UCK RN FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res. 2009 Apr 1;69(7):3032-41. DMO9UCK RU https://pubmed.ncbi.nlm.nih.gov/19318574 DMOALVR DI DMOALVR DMOALVR DN GSK-2485852 DMOALVR TI TTMVBWH DMOALVR TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMOALVR MA Inhibitor DMOALVR RN In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2013 Nov;57(11):5216-24. DMOALVR RU https://pubmed.ncbi.nlm.nih.gov/23939896 DMOAURL DI DMOAURL DMOAURL DN GDC-0834 DMOAURL TI TTGM6VW DMOAURL TN Tyrosine-protein kinase BTK (ATK) DMOAURL MA Inhibitor DMOAURL RN Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther. 2011 Jul;338(1):154-63. DMOAURL RU https://pubmed.ncbi.nlm.nih.gov/21521773 DMODQW0 DI DMODQW0 DMODQW0 DN INXC-ICAM1 DMODQW0 TI TTA1L39 DMODQW0 TN ICAM1 messenger RNA (ICAM1 mRNA) DMODQW0 RN ISIS 2302. INXC ICAM1, Oligo-TCS. Drugs R D. 1999 Jan;1(1):85-6. DMODQW0 RU https://pubmed.ncbi.nlm.nih.gov/10565996 DMOEYX2 DI DMOEYX2 DMOEYX2 DN FR-152558 DMOEYX2 TI TT1RS9F DMOEYX2 TN Acetylcholinesterase (AChE) DMOEYX2 MA Inhibitor DMOEYX2 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006757) DMOEYX2 RU http://adisinsight.springer.com/drugs/800006757 DMOGQ2L DI DMOGQ2L DMOGQ2L DN T-686 DMOGQ2L TI TT5QA2I DMOGQ2L TN Plasminogen activator inhibitor (PAI) DMOGQ2L MA Inhibitor DMOGQ2L RN T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats. Eur J Pharmacol. 1997 Jul 9;330(2-3):151-6. DMOGQ2L RU https://pubmed.ncbi.nlm.nih.gov/9253948 DMOIWFM DI DMOIWFM DMOIWFM DN AM-577 DMOIWFM TI TTMSFAW DMOIWFM TN Cannabinoid receptor 2 (CB2) DMOIWFM MA Agonist DMOIWFM RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018288) DMOIWFM RU http://adisinsight.springer.com/drugs/800018288 DMOJM08 DI DMOJM08 DMOJM08 DN Steroid hormone conjugates DMOJM08 TI TTPNQAC DMOJM08 TN Estrogen-related receptor-alpha (ESRRA) DMOJM08 MA Modulator DMOJM08 RN The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf). 1998 Oct;49(4):421-32. DMOJM08 RU https://pubmed.ncbi.nlm.nih.gov/9876338 DMOJP9E DI DMOJP9E DMOJP9E DN ANX-201 DMOJP9E TI TT84ETX DMOJP9E TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMOJP9E MA Modulator DMOJP9E RN DOI: 10.1038/scibx.2008.591 DMOJP9E RU http://www.nature.com/scibx/journal/v1/n25/full/scibx.2008.591.html DMOJTZV DI DMOJTZV DMOJTZV DN AJ-3941 DMOJTZV TI TT5HONZ DMOJTZV TN Calcium channel unspecific (CaC) DMOJTZV MA Modulator DMOJTZV RN Prevention by the new Ca2+ channel antagonist, AJ-3941, of loss of endothelium-dependent relaxation after subarachnoid hemorrhage in rats. Eur J Pharmacol. 1996 Nov 21;315(3):297-303. DMOJTZV RU https://pubmed.ncbi.nlm.nih.gov/8982668 DMOKZ2V DI DMOKZ2V DMOKZ2V DN L-373890 DMOKZ2V TI TT6L509 DMOKZ2V TN Coagulation factor IIa (F2) DMOKZ2V MA Inhibitor DMOKZ2V RN L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett. 1998 Apr 7;8(7):817-22. DMOKZ2V RU https://pubmed.ncbi.nlm.nih.gov/9871547 DMONQYZ DI DMONQYZ DMONQYZ DN Gliotoxin DMONQYZ TI TTSXVID DMONQYZ TN Nuclear factor NF-kappa-B (NFKB) DMONQYZ MA Inhibitor DMONQYZ RN Gliotoxin inhibits neointimal hyperplasia after vascular injury in rats. J Vasc Res. 2009;46(4):278-89. DMONQYZ RU https://pubmed.ncbi.nlm.nih.gov/19033690 DMOQIWH DI DMOQIWH DMOQIWH DN L-745337 DMOQIWH TI TTVKILB DMOQIWH TN Prostaglandin G/H synthase 2 (COX-2) DMOQIWH MA Modulator DMOQIWH RN Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect ... J Pharmacol Exp Ther. 1995 Sep;274(3):1531-7. DMOQIWH RU https://www.ncbi.nlm.nih.gov/pubmed/7562530 DMOS9NZ DI DMOS9NZ DMOS9NZ DN PF-03882845 DMOS9NZ TI TT26PHO DMOS9NZ TN Mineralocorticoid receptor (MR) DMOS9NZ MA Modulator DMOS9NZ RN Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g] indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.J Med Chem.2010 Aug 26;53(16):5979-6002. DMOS9NZ RU https://www.ncbi.nlm.nih.gov/pubmed/20672822 DMOTY3G DI DMOTY3G DMOTY3G DN L-657925 DMOTY3G TI TT2O84V DMOTY3G TN Thromboxane A2 receptor (TBXA2R) DMOTY3G MA Inhibitor DMOTY3G RN Novel synthesis and biochemical properties of an [125I]-labeled photoaffinity probe for thromboxane A2/prostaglandin H2 receptors. J Med Chem. 1991 Apr;34(4):1511-4. DMOTY3G RU https://pubmed.ncbi.nlm.nih.gov/1826745 DMOY8UA DI DMOY8UA DMOY8UA DN GR-175737 DMOY8UA TI TT9JNIC DMOY8UA TN Histamine H3 receptor (H3R) DMOY8UA MA Inhibitor DMOY8UA RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DMOY8UA RU https://pubmed.ncbi.nlm.nih.gov/9871722 DMOZQHX DI DMOZQHX DMOZQHX DN BVT-3498 DMOZQHX TI TTN7BL9 DMOZQHX TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMOZQHX MA Inhibitor DMOZQHX RN Current and future drug targets in weight management. Pharm Res. 2011 Aug;28(8):1792-818. DMOZQHX RU https://pubmed.ncbi.nlm.nih.gov/21181547 DMP26BW DI DMP26BW DMP26BW DN MX-7065 DMP26BW TI TTESBNC DMP26BW TN M-phase inducer phosphatase 3 (MPIP3) DMP26BW MA Inhibitor DMP26BW RN Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11). DMP26BW RU https://books.google.com.hk/books?id=RmrLBQAAQBAJ&pg=PA11&lpg=PA11&dq=%22MX-7214%22+++Cdc25&source=bl&ots=un9o85IdEu&sig=UeS1s5P6-6iLhA8n-4L8xMrnpuo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIxIXHkOHFyAIVRASOCh2thghY#v=onepage&q=%22MX-7214%22%20%20%20Cdc25&f=false DMP26BW DI DMP26BW DMP26BW DN MX-7065 DMP26BW TI TTLZS4Q DMP26BW TN M-phase inducer phosphatase 1 (MPIP1) DMP26BW MA Inhibitor DMP26BW RN Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11). DMP26BW RU https://books.google.com.hk/books?id=RmrLBQAAQBAJ&pg=PA11&lpg=PA11&dq=%22MX-7214%22+++Cdc25&source=bl&ots=un9o85IdEu&sig=UeS1s5P6-6iLhA8n-4L8xMrnpuo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIxIXHkOHFyAIVRASOCh2thghY#v=onepage&q=%22MX-7214%22%20%20%20Cdc25&f=false DMP26BW DI DMP26BW DMP26BW DN MX-7065 DMP26BW TI TTR0SWN DMP26BW TN M-phase inducer phosphatase 2 (MPIP2) DMP26BW MA Inhibitor DMP26BW RN Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11). DMP26BW RU https://books.google.com.hk/books?id=RmrLBQAAQBAJ&pg=PA11&lpg=PA11&dq=%22MX-7214%22+++Cdc25&source=bl&ots=un9o85IdEu&sig=UeS1s5P6-6iLhA8n-4L8xMrnpuo&hl=zh-CN&sa=X&ved=0CBoQ6AEwAGoVChMIxIXHkOHFyAIVRASOCh2thghY#v=onepage&q=%22MX-7214%22%20%20%20Cdc25&f=false DMP3QAZ DI DMP3QAZ DMP3QAZ DN CNS-1237 DMP3QAZ TI TT1AQ50 DMP3QAZ TN Charybdotoxin receptor beta-4 (BKbeta4) DMP3QAZ MA Modulator DMP3QAZ RN Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31. DMP3QAZ RU https://pubmed.ncbi.nlm.nih.gov/9286613 DMP3X6Q DI DMP3X6Q DMP3X6Q DN Dacetuzumab DMP3X6Q TI TTIJP3Q DMP3X6Q TN TNF related activation protein (CD40LG) DMP3X6Q MA Modulator DMP3X6Q RN A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia.Leuk Lymphoma.2010 Feb;51(2):228-35. DMP3X6Q RU https://www.ncbi.nlm.nih.gov/pubmed/20038235 DMP4J7T DI DMP4J7T DMP4J7T DN NE-100 DMP4J7T TI TT5TPI6 DMP4J7T TN Opioid receptor sigma 1 (OPRS1) DMP4J7T MA Antagonist DMP4J7T RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMP4J7T RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMP9GFZ DI DMP9GFZ DMP9GFZ DN DAU-6285 DMP9GFZ TI TT07C3Y DMP9GFZ TN 5-HT 4 receptor (HTR4) DMP9GFZ MA Modulator DMP9GFZ RN The novel 5-HT4 receptor antagonist DAU 6285 antagonizes 5-hydroxytryptamine-induced tachycardia in pigs. Eur J Pharmacol. 1993 Mar 23;233(2-3):295-7. DMP9GFZ RU https://www.ncbi.nlm.nih.gov/pubmed/8467876 DMPA8WO DI DMPA8WO DMPA8WO DN NU1025 DMPA8WO TI TTVDSZ0 DMPA8WO TN Poly [ADP-ribose] polymerase 1 (PARP1) DMPA8WO MA Inhibitor DMPA8WO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPA8WO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPBCLA DI DMPBCLA DMPBCLA DN CY-9652 DMPBCLA TI TT6S84X DMPBCLA TN Integrin alpha-4/beta-1 (ITGA4/B1) DMPBCLA MA Antagonist DMPBCLA RN US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions. DMPBCLA RU https://www.google.com.ar/patents/US20100278784 DMPCFRN DI DMPCFRN DMPCFRN DN AZD-1134 DMPCFRN TI TTK8CXU DMPCFRN TN 5-HT 1B receptor (HTR1B) DMPCFRN MA Antagonist DMPCFRN RN N-methyl-3H3AZ10419369 binding to the 5-HT1B receptor: in vitro characterization and in vivo receptor occupancy. J Pharmacol Exp Ther. 2009 Jul;330(1):342-51. DMPCFRN RU https://pubmed.ncbi.nlm.nih.gov/19401496 DMPEB0Z DI DMPEB0Z DMPEB0Z DN AA-861 DMPEB0Z TI TT2J34L DMPEB0Z TN Arachidonate 5-lipoxygenase (5-LOX) DMPEB0Z MA Inhibitor DMPEB0Z RN Platelets stimulate airway smooth muscle cell proliferation through mechanisms involving 5-lipoxygenase and reactive oxygen species. Platelets. 2008 Nov;19(7):528-36. DMPEB0Z RU https://pubmed.ncbi.nlm.nih.gov/18979365 DMPEJ4O DI DMPEJ4O DMPEJ4O DN A-204176 DMPEJ4O TI TTNGILX DMPEJ4O TN Adrenergic receptor alpha-1A (ADRA1A) DMPEJ4O MA Agonist DMPEJ4O RN Pharmacological properties of A-204176, a novel and selective alpha1A adrenergic agonist, in in vitro and in vivo models of urethral function. Life Sci. 2001 Nov 30;70(2):181-97. DMPEJ4O RU https://pubmed.ncbi.nlm.nih.gov/11787943 DMPFLS5 DI DMPFLS5 DMPFLS5 DN ABT-100 DMPFLS5 TI TT7WZIJ DMPFLS5 TN CAAX farnesyltransferase beta (FNTB) DMPFLS5 MA Inhibitor DMPFLS5 RN Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. J Heart Lung Transplant. 2005 Sep;24(9):1403-9. DMPFLS5 RU https://pubmed.ncbi.nlm.nih.gov/16143263 DMPG703 DI DMPG703 DMPG703 DN NSL-036 DMPG703 TI TTU593I DMPG703 TN Neurokinin receptor (NKR) DMPG703 MA Antagonist DMPG703 RN US patent application no. 2008,0039,404, Bifunctional analgesic compounds for opioid receptor agonists and neurokinin-1 receptor antagonists. DMPG703 RU http://www.google.com/patents/US20080039404 DMPHUBO DI DMPHUBO DMPHUBO DN PLD-177 DMPHUBO TI TTPNQAC DMPHUBO TN Estrogen-related receptor-alpha (ESRRA) DMPHUBO MA Modulator DMPHUBO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DMPHUBO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DMPL0C9 DI DMPL0C9 DMPL0C9 DN C-202 DMPL0C9 TI TTNJYV2 DMPL0C9 TN Gamma-aminobutyric acid receptor (GAR) DMPL0C9 MA Modulator DMPL0C9 RN Capreomycin Binds across the Ribosomal Subunit Interface Using tlyA-Encoded 2 O-Methylations in 16S and 23S rRNAs. Molecular Cell Volume 23, Issue 2, 21 July 2006, Pages 173-182. DMPL0C9 RU http://www.sciencedirect.com/science/article/pii/S1097276506004333 DMPL1OV DI DMPL1OV DMPL1OV DN A-69024 DMPL1OV TI TTZFYLI DMPL1OV TN Dopamine D1 receptor (D1R) DMPL1OV MA Modulator DMPL1OV RN (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nucl Med Biol. 2002 Apr;29(3):295-302. DMPL1OV RU https://pubmed.ncbi.nlm.nih.gov/11929698 DMPLYHU DI DMPLYHU DMPLYHU DN GW-974 DMPLYHU TI TT6EO5L DMPLYHU TN Erbb2 tyrosine kinase receptor (HER2) DMPLYHU MA Inhibitor DMPLYHU RN WO patent application no. 2005,0443,02, Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer. DMPLYHU RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050519&CC=WO&NR=2005044302A1&KC=A1 DMPMW03 DI DMPMW03 DMPMW03 DN AQ-RA-741 DMPMW03 TI TTYEG6Q DMPMW03 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMPMW03 MA Modulator DMPMW03 RN Pharmacological profile of selective muscarinic receptor antagonists on guinea-pig ileal smooth muscle. Eur J Pharmacol. 1994 Mar 3;253(3):275-81. DMPMW03 RU https://pubmed.ncbi.nlm.nih.gov/8200421 DMPNHF0 DI DMPNHF0 DMPNHF0 DN Ro-43-5054 DMPNHF0 TI TTJA1ZO DMPNHF0 TN ITGB3 messenger RNA (ITGB3 mRNA) DMPNHF0 MA Inhibitor DMPNHF0 RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DMPNHF0 RU https://pubmed.ncbi.nlm.nih.gov/10999999 DMPNMAR DI DMPNMAR DMPNMAR DN LY525327 DMPNMAR TI TTHS256 DMPNMAR TN Metabotropic glutamate receptor 5 (mGluR5) DMPNMAR MA Antagonist DMPNMAR RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMPNMAR RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMPODL9 DI DMPODL9 DMPODL9 DN GP-683 DMPODL9 TI TTL732K DMPODL9 TN Adenosine kinase (ADK) DMPODL9 MA Inhibitor DMPODL9 RN The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth Analg. 1997 Sep;85(3):675-80. DMPODL9 RU https://pubmed.ncbi.nlm.nih.gov/9296430 DMPQIUH DI DMPQIUH DMPQIUH DN S-34109 DMPQIUH TI TTN6J5F DMPQIUH TN Bacterial DNA gyrase (Bact gyrase) DMPQIUH MA Modulator DMPQIUH RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007670) DMPQIUH RU http://adisinsight.springer.com/drugs/800007670 DMPRNQL DI DMPRNQL DMPRNQL DN BQ610 DMPRNQL TI TTKRD0G DMPRNQL TN Endothelin A receptor (EDNRA) DMPRNQL MA Antagonist DMPRNQL RN Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13. DMPRNQL RU https://pubmed.ncbi.nlm.nih.gov/12147606 DMPSZR0 DI DMPSZR0 DMPSZR0 DN GS-2992 DMPSZR0 TI TT5FNQT DMPSZR0 TN Human immunodeficiency virus Protease (HIV PR) DMPSZR0 MA Modulator DMPSZR0 RN US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases. DMPSZR0 RU http://www.google.com/patents/US20080161324 DMPT74G DI DMPT74G DMPT74G DN NS-638 DMPT74G TI TT5HONZ DMPT74G TN Calcium channel unspecific (CaC) DMPT74G MA Modulator DMPT74G RN Pharmacological profile and anti-ischemic properties of the Ca(2+)-channel blocker NS-638. Neurol Res. 1995 Oct;17(5):353-60. DMPT74G RU https://pubmed.ncbi.nlm.nih.gov/8584126 DMPUG18 DI DMPUG18 DMPUG18 DN BAY-39-9624 DMPUG18 TI TTUV8G9 DMPUG18 TN Progesterone receptor (PGR) DMPUG18 MA Agonist DMPUG18 RN Bayer is seeking an exclusive licensee for its end-of-Phase I progestinagonist Bay 39-9624. Thepharmaletter. 29-04-2002. DMPUG18 RU http://www.thepharmaletter.com/article/bayer-offers-license-opportunity DMPUVFH DI DMPUVFH DMPUVFH DN SDZ 216-525 DMPUVFH TI TTSQIFT DMPUVFH TN 5-HT 1A receptor (HTR1A) DMPUVFH MA Antagonist DMPUVFH RN Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol Biochem Behav. 1997 Oct;58(2):593-603. DMPUVFH RU https://pubmed.ncbi.nlm.nih.gov/9300624 DMPWBNU DI DMPWBNU DMPWBNU DN L-755507 DMPWBNU TI TTR6W5O DMPWBNU TN Adrenergic receptor beta-1 (ADRB1) DMPWBNU MA Inhibitor DMPWBNU RN (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66. DMPWBNU RU https://pubmed.ncbi.nlm.nih.gov/11311069 DMPWBNU DI DMPWBNU DMPWBNU DN L-755507 DMPWBNU TI TTEAID7 DMPWBNU TN Trypanosoma Cruzipain (Trypano CYSP) DMPWBNU MA Inhibitor DMPWBNU RN Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51. DMPWBNU RU https://pubmed.ncbi.nlm.nih.gov/19908840 DMPWBNU DI DMPWBNU DMPWBNU DN L-755507 DMPWBNU TI TT2CJVK DMPWBNU TN Adrenergic receptor beta-2 (ADRB2) DMPWBNU MA Inhibitor DMPWBNU RN (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66. DMPWBNU RU https://pubmed.ncbi.nlm.nih.gov/11311069 DMPWZCI DI DMPWZCI DMPWZCI DN CVT-1 DMPWZCI TI TTTRNQW DMPWZCI TN Bile-salt-activated lipase (CEL) DMPWZCI MA Modulator DMPWZCI RN Lack of effect of cholesterol esterase inhibitor CVT-1 on cholesterol absorption and LDL cholesterol in humans. Cardiovasc Drugs Ther. 1999 Sep;13(5):449-54. DMPWZCI RU https://pubmed.ncbi.nlm.nih.gov/10547226 DMPX37E DI DMPX37E DMPX37E DN A-75169 DMPX37E TI TT2NUT5 DMPX37E TN Adrenergic receptor alpha-2C (ADRA2C) DMPX37E MA Modulator DMPX37E RN A-75169 HCI: Pharmacological profile and ocular pharmacology studies of a new alpha-2 antagonist. Drug Development Research Volume 28, Issue 1, pages 56-64, January 1993. DMPX37E RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430280107/abstract DMPXLG2 DI DMPXLG2 DMPXLG2 DN YP-009 DMPXLG2 TI TT9B4N3 DMPXLG2 TN Prostaglandin receptor (PTGR) DMPXLG2 MA Agonist DMPXLG2 RN YP 009 York Pharma pc preclinical, UK(cancer), R & D Focus Drug News, November 12, 2007 DMPXLG2 RU http://business.highbeam.com/436989/article-1G1-171156623/yp-009-york-pharma-pc-preclinical-uk DMPZ1EC DI DMPZ1EC DMPZ1EC DN NNC 05-2045 DMPZ1EC TI TTV9MQG DMPZ1EC TN Gamma-aminobutyric acid uptake (GABAU) DMPZ1EC MA Inhibitor DMPZ1EC RN GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology. 2000 Sep;39(12):2399-407. DMPZ1EC RU https://pubmed.ncbi.nlm.nih.gov/10974324 DMPZ7AO DI DMPZ7AO DMPZ7AO DN LY-290154 DMPZ7AO TI TTGKOY9 DMPZ7AO TN Leukotriene CysLT1 receptor (CYSLTR1) DMPZ7AO MA Modulator DMPZ7AO RN DOI: 10.1021/op060036x DMPZ7AO RU http://pubs.acs.org/doi/abs/10.1021/op060036x DMPZ7AO DI DMPZ7AO DMPZ7AO DN LY-290154 DMPZ7AO TI TT0PZR5 DMPZ7AO TN Leukotriene CysLT2 receptor (CYSLTR2) DMPZ7AO MA Modulator DMPZ7AO RN DOI: 10.1021/op060036x DMPZ7AO RU http://pubs.acs.org/doi/abs/10.1021/op060036x DMPZLKC DI DMPZLKC DMPZLKC DN SDZ-249482 DMPZLKC TI TT5HONZ DMPZLKC TN Calcium channel unspecific (CaC) DMPZLKC MA Modulator DMPZLKC RN Physiology and Pharmacology of the Vanilloid Receptor. Curr Neuropharmacol. 2006 January; 4(1): 1-15. DMPZLKC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2430674/ DMQ0IOF DI DMQ0IOF DMQ0IOF DN ICI-169369 DMQ0IOF TI TTJQOD7 DMQ0IOF TN 5-HT 2A receptor (HTR2A) DMQ0IOF MA Modulator DMQ0IOF RN Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.Drugs Today (Barc).2010 Mar;46(3):183-93. DMQ0IOF RU https://www.ncbi.nlm.nih.gov/pubmed/20467592 DMQ0IOF DI DMQ0IOF DMQ0IOF DN ICI-169369 DMQ0IOF TI TTWJBZ5 DMQ0IOF TN 5-HT 2C receptor (HTR2C) DMQ0IOF MA Modulator DMQ0IOF RN Serotonin 5-HT(2A) receptor antagonists in the treatment of insomnia: present status and future prospects.Drugs Today (Barc).2010 Mar;46(3):183-93. DMQ0IOF RU https://www.ncbi.nlm.nih.gov/pubmed/20467592 DMQ4LDB DI DMQ4LDB DMQ4LDB DN L-158809 DMQ4LDB TI TT8DBY3 DMQ4LDB TN Angiotensin II receptor type-1 (AGTR1) DMQ4LDB MA Antagonist DMQ4LDB RN Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand. Mol Pharmacol. 1992 Dec;42(6):1077-82. DMQ4LDB RU https://pubmed.ncbi.nlm.nih.gov/1480133 DMQ4LDB DI DMQ4LDB DMQ4LDB DN L-158809 DMQ4LDB TI TTQVOEI DMQ4LDB TN Angiotensin II receptor type-2 (AGTR2) DMQ4LDB MA Inhibitor DMQ4LDB RN Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994). DMQ4LDB RU http://www.sciencedirect.com/science/article/pii/S0960894X01811458 DMQ4X7Y DI DMQ4X7Y DMQ4X7Y DN 443C81 DMQ4X7Y TI TTKWM86 DMQ4X7Y TN Opioid receptor mu (MOP) DMQ4X7Y MA Modulator DMQ4X7Y RN Inhibition of cholinergic neurotransmission in human airways by opioids. J Appl Physiol (1985). 1992 Mar;72(3):1096-100. DMQ4X7Y RU https://pubmed.ncbi.nlm.nih.gov/1314798 DMQ52JR DI DMQ52JR DMQ52JR DN ARC239 DMQ52JR TI TT2NUT5 DMQ52JR TN Adrenergic receptor alpha-2C (ADRA2C) DMQ52JR MA Antagonist DMQ52JR RN Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. DMQ52JR RU https://pubmed.ncbi.nlm.nih.gov/11481271 DMQ6K8J DI DMQ6K8J DMQ6K8J DN Z-6568 DMQ6K8J TI TT5HONZ DMQ6K8J TN Calcium channel unspecific (CaC) DMQ6K8J MA Modulator DMQ6K8J RN Determination of the dihydropyridine aryloxypropanolamine Z6568 and its acidic metabolites in plasma, urine and tissues by solid phase extraction and liquid chromatography/negative-ion mass spectrometry. J Mass Spectrom. 1996 Sep;31(9):994-1002. DMQ6K8J RU https://pubmed.ncbi.nlm.nih.gov/8831152 DMQ8S4L DI DMQ8S4L DMQ8S4L DN S-18616 DMQ8S4L TI TTWG9A4 DMQ8S4L TN Adrenergic receptor alpha-2A (ADRA2A) DMQ8S4L MA Modulator DMQ8S4L RN S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther. 2000 Dec;295(3):1206-22. DMQ8S4L RU https://pubmed.ncbi.nlm.nih.gov/11082458 DMQA4JU DI DMQA4JU DMQA4JU DN Berlafenone DMQA4JU TI TTRK8B9 DMQA4JU TN Sodium channel unspecific (NaC) DMQA4JU MA Modulator DMQA4JU RN WO patent application no. 19990639849, Novel sodium channel drugs and uses. DMQA4JU RU http://www.google.com/patents/WO1999063984A9?cl=en DMQALR5 DI DMQALR5 DMQALR5 DN Almorexant DMQALR5 TI TT60Q8D DMQALR5 TN Orexin receptor type 1 (HCRTR1) DMQALR5 MA Antagonist DMQALR5 RN Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31. DMQALR5 RU https://pubmed.ncbi.nlm.nih.gov/19542319 DMQB8TW DI DMQB8TW DMQB8TW DN Mimosine DMQB8TW TI TTO8YH2 DMQB8TW TN Plasmodium Serine hydroxymethyltransferase (Malaria SHMT) DMQB8TW MA Inhibitor DMQB8TW RN Mimosine targets serine hydroxymethyltransferase. J Biol Chem. 1996 Feb 2;271(5):2548-56. DMQB8TW RU https://pubmed.ncbi.nlm.nih.gov/8576220 DMQBULC DI DMQBULC DMQBULC DN CV 6209 DMQBULC TI TTQL5VC DMQBULC TN Platelet-activating factor receptor (PTAFR) DMQBULC MA Modulator DMQBULC RN CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther. 1987 Jul;242(1):263-8. DMQBULC RU https://www.ncbi.nlm.nih.gov/pubmed/3612533 DMQCNWD DI DMQCNWD DMQCNWD DN PD-155080 DMQCNWD TI TTKRD0G DMQCNWD TN Endothelin A receptor (EDNRA) DMQCNWD MA Modulator DMQCNWD RN Potency of PD155080, an orally active ETA receptor antagonist, determined for human endothelin receptors. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S362-4. DMQCNWD RU https://www.ncbi.nlm.nih.gov/pubmed/8587415 DMQDWMJ DI DMQDWMJ DMQDWMJ DN S-20928 DMQDWMJ TI TT0WAIE DMQDWMJ TN Melatonin receptor type 1A (MTNR1A) DMQDWMJ MA Modulator DMQDWMJ RN Effects of two melatonin analogues, S-20098 and S-20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res. 1998 Oct;25(3):172-6. DMQDWMJ RU https://pubmed.ncbi.nlm.nih.gov/9745986 DMQESM7 DI DMQESM7 DMQESM7 DN Cordil DMQESM7 TI TTQ38E9 DMQESM7 TN Sodium/potassium-transporting ATPase (SPT ATPase) DMQESM7 MA Modulator DMQESM7 RN WO patent application no. 1995,0085,58, Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds. DMQESM7 RU http://www.google.com/patents/WO1995008558A1?cl=en DMQFSAB DI DMQFSAB DMQFSAB DN UK-290795 DMQFSAB TI TTYO0A3 DMQFSAB TN Substance-K receptor (TACR2) DMQFSAB MA Antagonist DMQFSAB RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017162) DMQFSAB RU http://adisinsight.springer.com/drugs/800017162 DMQG3CK DI DMQG3CK DMQG3CK DN SR-11237 DMQG3CK TI TTH029C DMQG3CK TN Retinoic acid receptor RXR-gamma (RXRG) DMQG3CK MA Modulator DMQG3CK RN Silicon analogues of the RXR-selective retinoid agonist SR11237 (BMS649): chemistry and biology. ChemMedChem. 2009 Jul;4(7):1143-52. DMQG3CK RU https://pubmed.ncbi.nlm.nih.gov/19496083 DMQINWF DI DMQINWF DMQINWF DN HT-90B DMQINWF TI TTSQIFT DMQINWF TN 5-HT 1A receptor (HTR1A) DMQINWF MA Modulator DMQINWF RN Pharmacological profile of (-)HT-90B, a novel 5-HT1A receptor agonist/5-HT2 receptor antagonist. Prog Neuropsychopharmacol Biol Psychiatry. 1995 Nov;19(7):1201-16. DMQINWF RU https://pubmed.ncbi.nlm.nih.gov/8787043 DMQIYZR DI DMQIYZR DMQIYZR DN TER-16998 DMQIYZR TI TTCBFJO DMQIYZR TN Insulin receptor (INSR) DMQIYZR MA Activator DMQIYZR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMQIYZR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMQKEHA DI DMQKEHA DMQKEHA DN E-2050 DMQKEHA TI TT5HONZ DMQKEHA TN Calcium channel unspecific (CaC) DMQKEHA MA Modulator DMQKEHA RN Solubility of E2050 at various pH: a case in which apparent solubility is affected by the amount of excess solid. J Pharm Sci. 2002 Jun;91(6):1445-55. DMQKEHA RU https://www.ncbi.nlm.nih.gov/pubmed/12115844 DMQM3P4 DI DMQM3P4 DMQM3P4 DN BW755C DMQM3P4 TI TT2J34L DMQM3P4 TN Arachidonate 5-lipoxygenase (5-LOX) DMQM3P4 MA Inhibitor DMQM3P4 RN Anti-inflammatory activity of Acanthus ilicifolius. J Ethnopharmacol. 2008 Oct 30;120(1):7-12. DMQM3P4 RU https://pubmed.ncbi.nlm.nih.gov/18703126 DMQNFZE DI DMQNFZE DMQNFZE DN Ad5-AC6 DMQNFZE TI TT2QM9D DMQNFZE TN Adenylate cyclase (ADCY) DMQNFZE MA Modulator DMQNFZE RN Unanticipated Signaling Events Associated with Cardiac Adenylyl Cyclase Gene Transfer. J Mol Cell Cardiol. 2011 May; 50(5): 751-758. DMQNFZE RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3095111/ DMQRHMT DI DMQRHMT DMQRHMT DN PD-29361 DMQRHMT TI TT4FDG6 DMQRHMT TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMQRHMT MA Inhibitor DMQRHMT RN Synthesis and structure-activity relationship of substituted 1,2,3,4-tetrahydroisoquinolines as N-type calcium channel blockers. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2415-8. DMQRHMT RU https://pubmed.ncbi.nlm.nih.gov/9873552 DMQRSMD DI DMQRSMD DMQRSMD DN Trequinsin DMQRSMD TI TTJ0IQB DMQRSMD TN Phosphodiesterase 5A (PDE5A) DMQRSMD MA Inhibitor DMQRSMD RN Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J Med Chem. 1989 Jul;32(7):1450-7. DMQRSMD RU https://pubmed.ncbi.nlm.nih.gov/2544722 DMQSMB1 DI DMQSMB1 DMQSMB1 DN GS-9160 DMQSMB1 TI TT5FH9Y DMQSMB1 TN Human immunodeficiency virus Integrase (HIV IN) DMQSMB1 MA Inhibitor DMQSMB1 RN Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 2009 Mar;53(3):1194-203. DMQSMB1 RU https://pubmed.ncbi.nlm.nih.gov/19104010 DMQU8AR DI DMQU8AR DMQU8AR DN Org-20599 DMQU8AR TI TTGXH6N DMQU8AR TN GABA(A) receptor delta (GABRD) DMQU8AR MA Modulator DMQU8AR RN The anaesthetic action and modulation of GABAA receptor activity by the novel water-soluble aminosteroid Org 20599. Neuropharmacology. 1996;35(9-10):1209-22. DMQU8AR RU https://pubmed.ncbi.nlm.nih.gov/9014136 DMQU8B1 DI DMQU8B1 DMQU8B1 DN WB-4101 DMQU8B1 TI TTBRKXS DMQU8B1 TN Adrenergic receptor alpha-1B (ADRA1B) DMQU8B1 MA Inhibitor DMQU8B1 RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMQU8B1 RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMQU8B1 DI DMQU8B1 DMQU8B1 DN WB-4101 DMQU8B1 TI TTWG9A4 DMQU8B1 TN Adrenergic receptor alpha-2A (ADRA2A) DMQU8B1 MA Inhibitor DMQU8B1 RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMQU8B1 RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMQU8B1 DI DMQU8B1 DMQU8B1 DN WB-4101 DMQU8B1 TI TTSQIFT DMQU8B1 TN 5-HT 1A receptor (HTR1A) DMQU8B1 MA Inhibitor DMQU8B1 RN Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem. 1993 Oct 15;36(21):3161-5. DMQU8B1 RU https://pubmed.ncbi.nlm.nih.gov/8230102 DMQU8B1 DI DMQU8B1 DMQU8B1 DN WB-4101 DMQU8B1 TI TT2NUT5 DMQU8B1 TN Adrenergic receptor alpha-2C (ADRA2C) DMQU8B1 MA Inhibitor DMQU8B1 RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMQU8B1 RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMQU8B1 DI DMQU8B1 DMQU8B1 DN WB-4101 DMQU8B1 TI TTWM4TY DMQU8B1 TN Adrenergic receptor alpha-2B (ADRA2B) DMQU8B1 MA Inhibitor DMQU8B1 RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMQU8B1 RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMQU8B1 DI DMQU8B1 DMQU8B1 DN WB-4101 DMQU8B1 TI TTNGILX DMQU8B1 TN Adrenergic receptor alpha-1A (ADRA1A) DMQU8B1 MA Inhibitor DMQU8B1 RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMQU8B1 RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMQU8B1 DI DMQU8B1 DMQU8B1 DN WB-4101 DMQU8B1 TI TT34BHT DMQU8B1 TN Adrenergic receptor alpha-1D (ADRA1D) DMQU8B1 MA Inhibitor DMQU8B1 RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMQU8B1 RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMQUF9I DI DMQUF9I DMQUF9I DN SR-58894A DMQUF9I TI TTMXGCW DMQUF9I TN Adrenergic receptor beta-3 (ADRB3) DMQUF9I MA Modulator DMQUF9I RN Pharmacological characterization of beta-adrenoceptor subtypes mediating relaxation in porcine isolated ureteral smooth muscle. J Urol. 2004 Sep;172(3):1155-9. DMQUF9I RU https://pubmed.ncbi.nlm.nih.gov/15311061 DMQUSG9 DI DMQUSG9 DMQUSG9 DN Zenarestat DMQUSG9 TI TTFBNVI DMQUSG9 TN Aldose reductase (AKR1B1) DMQUSG9 MA Inhibitor DMQUSG9 RN The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats. Life Sci. 2001 Feb 9;68(12):1439-48. DMQUSG9 RU https://pubmed.ncbi.nlm.nih.gov/11388695 DMQUX28 DI DMQUX28 DMQUX28 DN AZD5672 DMQUX28 TI TT2CEJG DMQUX28 TN C-C chemokine receptor type 5 (CCR5) DMQUX28 MA Antagonist DMQUX28 RN Clinical pipeline report, company report or official report of AstraZeneca (2009). DMQUX28 RU http://www.astrazeneca.com/_mshost3690701/content/resources/media/investors/AZN-Q2-2009/AZN-Q2-2009-Pipeline.pdf DMQW6B0 DI DMQW6B0 DMQW6B0 DN SB-219825 DMQW6B0 TI TT27RFC DMQW6B0 TN Opioid receptor delta (OPRD1) DMQW6B0 MA Modulator DMQW6B0 RN Mutation W284L of the human delta opioid receptor reveals agonist specific receptor conformations for G protein activation. Life Sci. 2001 Apr 6;68(19-20):2233-42. DMQW6B0 RU https://pubmed.ncbi.nlm.nih.gov/11358332 DMQXPJB DI DMQXPJB DMQXPJB DN Ki-1769 DMQXPJB TI TT1VOHK DMQXPJB TN Potassium channel unspecific (KC) DMQXPJB MA Opener DMQXPJB RN Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery. Eur J Pharmacol. 1993 Sep 14;241(2-3):177-81. DMQXPJB RU https://pubmed.ncbi.nlm.nih.gov/8243553 DMQZ2JA DI DMQZ2JA DMQZ2JA DN RP-58802B DMQZ2JA TI TT2CJVK DMQZ2JA TN Adrenergic receptor beta-2 (ADRB2) DMQZ2JA MA Modulator DMQZ2JA RN RP 58802B, a long-acting beta 2-adrenoceptor agonist: assessment of antiasthma activity in the guinea-pig in vivo. Pulm Pharmacol. 1992 Sep;5(3):203-12. DMQZ2JA RU https://pubmed.ncbi.nlm.nih.gov/1280178 DMQZW6D DI DMQZW6D DMQZW6D DN L-709049 DMQZW6D TI TTCQIBE DMQZW6D TN Caspase-1 (CASP1) DMQZW6D MA Inhibitor DMQZW6D RN Succinic acid amides as P2-P3 replacements for inhibitors of interleukin-1beta converting enzyme (ICE or caspase 1). Bioorg Med Chem Lett. 2010 Sep 1;20(17):5184-90. DMQZW6D RU https://pubmed.ncbi.nlm.nih.gov/20656488 DMR01WE DI DMR01WE DMR01WE DN BILD-1351 DMR01WE TI TTMJX4U DMR01WE TN Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1) DMR01WE MA Inhibitor DMR01WE RN The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture. Antiviral Res. 1998 Jul;39(1):35-46. DMR01WE RU https://pubmed.ncbi.nlm.nih.gov/9754948 DMR1NMD DI DMR1NMD DMR1NMD DN Nimesulide DMR1NMD TI TTVKILB DMR1NMD TN Prostaglandin G/H synthase 2 (COX-2) DMR1NMD MA Inhibitor DMR1NMD RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DMR1NMD RU https://pubmed.ncbi.nlm.nih.gov/11752352 DMR1NMD DI DMR1NMD DMR1NMD DN Nimesulide DMR1NMD TI TTSZDQU DMR1NMD TN Lactotransferrin (LTF) DMR1NMD MA Inhibitor DMR1NMD RN Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. DMR1NMD RU https://pubmed.ncbi.nlm.nih.gov/11752352 DMR1NMD DI DMR1NMD DMR1NMD DN Nimesulide DMR1NMD TI TTA5MS9 DMR1NMD TN TNF related apoptosis inducing ligand (TNFSF10) DMR1NMD MA Modulator DMR1NMD RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMR1NMD RU https://www.fda.gov/ DMR1X2U DI DMR1X2U DMR1X2U DN F-0401 DMR1X2U TI TT27K59 DMR1X2U TN Platelet activating factor (PAF) DMR1X2U MA Inhibitor DMR1X2U RN Protective effects of a novel calcium antagonist with platelet-activating factor-antagonistic action, F-0401, against ischemic brain damage. Arch Int Pharmacodyn Ther. 1994 May-Jun;327(3):266-78. DMR1X2U RU https://pubmed.ncbi.nlm.nih.gov/7848011 DMR2TZK DI DMR2TZK DMR2TZK DN GR-82334 DMR2TZK TI TTZPO1L DMR2TZK TN Substance-P receptor (TACR1) DMR2TZK MA Antagonist DMR2TZK RN Effect of the NK-1 receptor antagonist GR 82,334 on reflexly-induced bladder contractions. Life Sci. 1992;51(26):PL277-80. DMR2TZK RU https://pubmed.ncbi.nlm.nih.gov/1335533 DMR3S9B DI DMR3S9B DMR3S9B DN Tyloxapol DMR3S9B TI TTSXVID DMR3S9B TN Nuclear factor NF-kappa-B (NFKB) DMR3S9B MA Inhibitor DMR3S9B RN Study of influence of additives of tyloxapol on the chromatographic characteristics of the model compounds: the comparative characterization of micellar mobile phases of tyloxapol and Triton X-100. Biomed Chromatogr. 2009 Jul;23(7):700-6. DMR3S9B RU https://pubmed.ncbi.nlm.nih.gov/19309752 DMR3ZWA DI DMR3ZWA DMR3ZWA DN FCE-25876 DMR3ZWA TI TTWT5K7 DMR3ZWA TN 5-HT 1 receptor (5HT1R) DMR3ZWA MA Modulator DMR3ZWA RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001389) DMR3ZWA RU http://adisinsight.springer.com/drugs/800001389 DMR80AL DI DMR80AL DMR80AL DN Datelliptium chloride DMR80AL TI TT0IHXV DMR80AL TN DNA topoisomerase II (TOP2) DMR80AL MA Modulator DMR80AL RN Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302. DMR80AL RU https://pubmed.ncbi.nlm.nih.gov/20732126 DMR80AL DI DMR80AL DMR80AL DN Datelliptium chloride DMR80AL TI TTGTQHC DMR80AL TN DNA topoisomerase I (TOP1) DMR80AL MA Modulator DMR80AL RN Toxicity of the antitumoral drug datelliptium in hepatic cells: Use of models in vitro for the prediction of toxicity in vivo. Toxicol In Vitro. 1992 Jul;6(4):295-302. DMR80AL RU https://pubmed.ncbi.nlm.nih.gov/20732126 DMR861Q DI DMR861Q DMR861Q DN E-5110 DMR861Q TI TTK0943 DMR861Q TN Prostaglandin G/H synthase (COX) DMR861Q MA Modulator DMR861Q RN Effect of E-5110, a novel non-steroidal anti-inflammatory drug, on trimethadione metabolism as an indicator of hepatic drug-oxidizing capacity in beagle dog. Xenobiotica. 1994 Mar;24(3):215-20. DMR861Q RU https://pubmed.ncbi.nlm.nih.gov/8009884 DMR87MO DI DMR87MO DMR87MO DN PIROXANTRONE DMR87MO TI TTGTQHC DMR87MO TN DNA topoisomerase I (TOP1) DMR87MO MA Modulator DMR87MO RN The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotec... J Inorg Biochem. 1999 Nov-Dec;77(3-4):257-9. DMR87MO RU https://www.ncbi.nlm.nih.gov/pubmed/10643663 DMRADBU DI DMRADBU DMRADBU DN SK&F-104078 DMRADBU TI TTBRKXS DMRADBU TN Adrenergic receptor alpha-1B (ADRA1B) DMRADBU MA Inhibitor DMRADBU RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMRADBU RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMRADBU DI DMRADBU DMRADBU DN SK&F-104078 DMRADBU TI TTWG9A4 DMRADBU TN Adrenergic receptor alpha-2A (ADRA2A) DMRADBU MA Inhibitor DMRADBU RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMRADBU RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMRADBU DI DMRADBU DMRADBU DN SK&F-104078 DMRADBU TI TTWM4TY DMRADBU TN Adrenergic receptor alpha-2B (ADRA2B) DMRADBU MA Inhibitor DMRADBU RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMRADBU RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMRADBU DI DMRADBU DMRADBU DN SK&F-104078 DMRADBU TI TTNGILX DMRADBU TN Adrenergic receptor alpha-1A (ADRA1A) DMRADBU MA Inhibitor DMRADBU RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMRADBU RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMRADBU DI DMRADBU DMRADBU DN SK&F-104078 DMRADBU TI TT2NUT5 DMRADBU TN Adrenergic receptor alpha-2C (ADRA2C) DMRADBU MA Inhibitor DMRADBU RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J Med Chem. 1995 Sep 1;38(18):3415-44. DMRADBU RU https://pubmed.ncbi.nlm.nih.gov/7658428 DMRADBU DI DMRADBU DMRADBU DN SK&F-104078 DMRADBU TI TT34BHT DMRADBU TN Adrenergic receptor alpha-1D (ADRA1D) DMRADBU MA Inhibitor DMRADBU RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMRADBU RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMRBGI6 DI DMRBGI6 DMRBGI6 DN Torbafylline DMRBGI6 TI TTZ97H5 DMRBGI6 TN Phosphodiesterase 4A (PDE4A) DMRBGI6 MA Inhibitor DMRBGI6 RN Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):152-63. DMRBGI6 RU https://pubmed.ncbi.nlm.nih.gov/24973766 DMRBGI6 DI DMRBGI6 DMRBGI6 DN Torbafylline DMRBGI6 TI TTSKMI8 DMRBGI6 TN Phosphodiesterase 4D (PDE4D) DMRBGI6 MA Modulator DMRBGI6 RN Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):152-63. DMRBGI6 RU https://pubmed.ncbi.nlm.nih.gov/24973766 DMRBGI6 DI DMRBGI6 DMRBGI6 DN Torbafylline DMRBGI6 TI TTVIAT9 DMRBGI6 TN Phosphodiesterase 4B (PDE4B) DMRBGI6 MA Modulator DMRBGI6 RN Phosphodiesterase (PDE) inhibitor torbafylline (HWA 448) attenuates burn-induced rat skeletal muscle proteolysis through the PDE4/cAMP/EPAC/PI3K/Akt pathway. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):152-63. DMRBGI6 RU https://pubmed.ncbi.nlm.nih.gov/24973766 DMRBXEA DI DMRBXEA DMRBXEA DN U-75875 DMRBXEA TI TT5FNQT DMRBXEA TN Human immunodeficiency virus Protease (HIV PR) DMRBXEA MA Modulator DMRBXEA RN Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob Agents Chemother. 1994 Jun;38(6):1277-83. DMRBXEA RU https://pubmed.ncbi.nlm.nih.gov/7522427 DMRCH1M DI DMRCH1M DMRCH1M DN MOR-102 DMRCH1M TI TTCT6F7 DMRCH1M TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMRCH1M RN Efficacy of the fully human monoclonal antibody MOR102 (#5) against intercellular adhesion molecule 1 in the psoriasis-severe combined immunodeficient mouse model. Br J Dermatol. 2005 Oct;153(4):758-66. DMRCH1M RU https://pubmed.ncbi.nlm.nih.gov/16181457 DMRFYOS DI DMRFYOS DMRFYOS DN RG-13022 DMRFYOS TI TT8FYO9 DMRFYOS TN Platelet-derived growth factor receptor alpha (PDGFRA) DMRFYOS MA Inhibitor DMRFYOS RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMRFYOS RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMRFYOS DI DMRFYOS DMRFYOS DN RG-13022 DMRFYOS TI TTI7421 DMRFYOS TN Platelet-derived growth factor receptor beta (PDGFRB) DMRFYOS MA Inhibitor DMRFYOS RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMRFYOS RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMRHCEG DI DMRHCEG DMRHCEG DN BMY-7378 DMRHCEG TI TT34BHT DMRHCEG TN Adrenergic receptor alpha-1D (ADRA1D) DMRHCEG MA Inhibitor DMRHCEG RN Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9. DMRHCEG RU https://pubmed.ncbi.nlm.nih.gov/15828846 DMRHCEG DI DMRHCEG DMRHCEG DN BMY-7378 DMRHCEG TI TTNGILX DMRHCEG TN Adrenergic receptor alpha-1A (ADRA1A) DMRHCEG MA Inhibitor DMRHCEG RN Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9. DMRHCEG RU https://pubmed.ncbi.nlm.nih.gov/15828846 DMRHCEG DI DMRHCEG DMRHCEG DN BMY-7378 DMRHCEG TI TTSQIFT DMRHCEG TN 5-HT 1A receptor (HTR1A) DMRHCEG MA Inhibitor DMRHCEG RN 8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as busp... J Med Chem. 1996 Mar 1;39(5):1125-9. DMRHCEG RU https://pubmed.ncbi.nlm.nih.gov/8676348 DMRHCEG DI DMRHCEG DMRHCEG DN BMY-7378 DMRHCEG TI TTBRKXS DMRHCEG TN Adrenergic receptor alpha-1B (ADRA1B) DMRHCEG MA Inhibitor DMRHCEG RN Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9. DMRHCEG RU https://pubmed.ncbi.nlm.nih.gov/15828846 DMRHEWX DI DMRHEWX DMRHEWX DN A-76202M DMRHEWX TI TTXWASR DMRHEWX TN Intestinal maltase-glucoamylase (MGAM) DMRHEWX MA Modulator DMRHEWX RN Synthesis and biological activity of 4',8-dihydroxyisoflavon-7-yl D-hexopyranosides. Carbohydr Res. 2001 Oct 15;335(4):283-9. DMRHEWX RU https://pubmed.ncbi.nlm.nih.gov/11595222 DMRHSG4 DI DMRHSG4 DMRHSG4 DN ACEA-1416 DMRHSG4 TI TT9IK2Z DMRHSG4 TN N-methyl-D-aspartate receptor (NMDAR) DMRHSG4 MA Modulator DMRHSG4 RN Tolerance develops to the antinociceptive and motor impairing effects of ACEA-1416, a NMDA receptor antagonist, in the formalin and rotarod test in mice. Pharmacol Res. 1998 Apr;37(4):295-302. DMRHSG4 RU https://pubmed.ncbi.nlm.nih.gov/9634646 DMRI7YB DI DMRI7YB DMRI7YB DN AG-1284 DMRI7YB TI TT5FNQT DMRI7YB TN Human immunodeficiency virus Protease (HIV PR) DMRI7YB MA Modulator DMRI7YB RN Exploring the energy landscapes of molecular recognition by a genetic algorithm: analysis of the requirements for robust docking of HIV-1 protease and FKBP-12 complexes. Proteins. 1996 Jul;25(3):342-53. DMRI7YB RU https://pubmed.ncbi.nlm.nih.gov/8844869 DMRLXC3 DI DMRLXC3 DMRLXC3 DN CGP-70726 DMRLXC3 TI TT5FNQT DMRLXC3 TN Human immunodeficiency virus Protease (HIV PR) DMRLXC3 MA Modulator DMRLXC3 RN Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Release. 2000 Aug 10;68(2):291-8. DMRLXC3 RU https://pubmed.ncbi.nlm.nih.gov/10925137 DMRM7H0 DI DMRM7H0 DMRM7H0 DN SK&F-95601 DMRM7H0 TI TTLOKXP DMRM7H0 TN Gastric H(+)/K(+) ATPase (Proton pump) DMRM7H0 MA Modulator DMRM7H0 RN 2-[[(4-Amino-2-pyridyl)methyl]sulfinyl]benzimidazole H+/K+-ATPase inhibitors.The relationship between pyridine basicity, stability, and activity.J Med Chem.1989 Aug;32(8):1970-7. DMRM7H0 RU https://www.ncbi.nlm.nih.gov/pubmed/2547073 DMRNB7V DI DMRNB7V DMRNB7V DN CRA-028129 DMRNB7V TI TTUMQVO DMRNB7V TN Cathepsin S (CTSS) DMRNB7V MA Inhibitor DMRNB7V RN Phase I clinical trial for cathepsin S inhibitor for psoriasis begins. Celera Genomics. 2005. DMRNB7V RU http://www.newsrx.com/newsletters/FDA-Law-Weekly/2005-10-20/10172005333500FL.html DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TTWM4TY DMROJEN TN Adrenergic receptor alpha-2B (ADRA2B) DMROJEN MA Inhibitor DMROJEN RN Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/10522703 DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TTNGILX DMROJEN TN Adrenergic receptor alpha-1A (ADRA1A) DMROJEN MA Inhibitor DMROJEN RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TT2NUT5 DMROJEN TN Adrenergic receptor alpha-2C (ADRA2C) DMROJEN MA Inhibitor DMROJEN RN Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/10522703 DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TT7RGTM DMROJEN TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMROJEN MA Inhibitor DMROJEN RN Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine. J Med Chem. 1995 May 12;38(10):1579-81. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/7752182 DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TT34BHT DMROJEN TN Adrenergic receptor alpha-1D (ADRA1D) DMROJEN MA Inhibitor DMROJEN RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TTZIFHC DMROJEN TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMROJEN MA Inhibitor DMROJEN RN Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/10522703 DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TTBRKXS DMROJEN TN Adrenergic receptor alpha-1B (ADRA1B) DMROJEN MA Inhibitor DMROJEN RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMROJEN DI DMROJEN DMROJEN DN SNAP-5089 DMROJEN TI TTWG9A4 DMROJEN TN Adrenergic receptor alpha-2A (ADRA2A) DMROJEN MA Inhibitor DMROJEN RN Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8. DMROJEN RU https://pubmed.ncbi.nlm.nih.gov/10522703 DMRP7BX DI DMRP7BX DMRP7BX DN ES-1005 DMRP7BX TI TTB2MXP DMRP7BX TN Angiotensinogenase renin (REN) DMRP7BX MA Inhibitor DMRP7BX RN The effect of the renin inhibitor ES-1005 on the expression of the kidney renin gene in sodium-depleted marmosets. J Hypertens. 1990 Dec;8(12):1143-6. DMRP7BX RU https://pubmed.ncbi.nlm.nih.gov/1962804 DMRPE3D DI DMRPE3D DMRPE3D DN GR-65630 DMRPE3D TI TTNXLKE DMRPE3D TN 5-HT 3 receptor (5HT3R) DMRPE3D MA Modulator DMRPE3D RN Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol. 1989 Jan 10;159(2):157-64. DMRPE3D RU https://pubmed.ncbi.nlm.nih.gov/2707305 DMRQOXG DI DMRQOXG DMRQOXG DN Etrabamine DMRQOXG TI TTEX248 DMRQOXG TN Dopamine D2 receptor (D2R) DMRQOXG MA Modulator DMRQOXG RN WO patent application no. 2009,0568,11, Medicaments. DMRQOXG RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090507&CC=WO&NR=2009056811A2&KC=A2 DMRQZWN DI DMRQZWN DMRQZWN DN RWJ-25730 DMRQZWN TI TTSQIFT DMRQZWN TN 5-HT 1A receptor (HTR1A) DMRQZWN MA Modulator DMRQZWN RN Piperazinylalkyl heterocycles as potential antipsychotic agents. J Med Chem. 1995 Oct 13;38(21):4198-210. DMRQZWN RU https://www.ncbi.nlm.nih.gov/pubmed/7473547 DMRQZWN DI DMRQZWN DMRQZWN DN RWJ-25730 DMRQZWN TI TTEX248 DMRQZWN TN Dopamine D2 receptor (D2R) DMRQZWN MA Modulator DMRQZWN RN Piperazinylalkyl heterocycles as potential antipsychotic agents. J Med Chem. 1995 Oct 13;38(21):4198-210. DMRQZWN RU https://www.ncbi.nlm.nih.gov/pubmed/7473547 DMRSOBG DI DMRSOBG DMRSOBG DN Mdl 101,146 DMRSOBG TI TTPLTSQ DMRSOBG TN Neutrophil elastase (NE) DMRSOBG MA Inhibitor DMRSOBG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRSOBG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRSOBG DI DMRSOBG DMRSOBG DN Mdl 101,146 DMRSOBG TI TT3NKIB DMRSOBG TN Pancreatic elastase 1 (CELA1) DMRSOBG MA Inhibitor DMRSOBG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRSOBG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRT69H DI DMRT69H DMRT69H DN PNU-177864 DMRT69H TI TT4C8EA DMRT69H TN Dopamine D3 receptor (D3R) DMRT69H MA Antagonist DMRT69H RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMRT69H RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMRT6FV DI DMRT6FV DMRT6FV DN Ro-46-2005 DMRT6FV TI TTCV6O0 DMRT6FV TN Endothelin receptor (EDNR) DMRT6FV MA Modulator DMRT6FV RN In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993 Nov 15;334(2):210-4. DMRT6FV RU https://pubmed.ncbi.nlm.nih.gov/8224248 DMRV48P DI DMRV48P DMRV48P DN WIN-63759 DMRV48P TI TT3NKIB DMRV48P TN Pancreatic elastase 1 (CELA1) DMRV48P MA Modulator DMRV48P RN Biological activity of WIN 63759, an orally bioavailable inhibitor of human neutrophil elastase. Drug Development Research Volume 34, Issue 3, pages 306-316, March 1995. DMRV48P RU http://onlinelibrary.wiley.com/doi/10.1002/ddr.430340308/abstract DMRV4UL DI DMRV4UL DMRV4UL DN BILA-2157BS DMRV4UL TI TTB2MXP DMRV4UL TN Angiotensinogenase renin (REN) DMRV4UL MA Inhibitor DMRV4UL RN Comparative studies on differential inhibition of the renin - angiotensin system in the anesthetized guinea pig. Can J Physiol Pharmacol. 1995 Oct;73(10):1512-8. DMRV4UL RU https://pubmed.ncbi.nlm.nih.gov/8748944 DMRVXEQ DI DMRVXEQ DMRVXEQ DN L-741671 DMRVXEQ TI TTZPO1L DMRVXEQ TN Substance-P receptor (TACR1) DMRVXEQ MA Inhibitor DMRVXEQ RN N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists. J Med Chem. 1996 Jul 19;39(15):2907-14. DMRVXEQ RU https://pubmed.ncbi.nlm.nih.gov/8709125 DMRVZMX DI DMRVZMX DMRVZMX DN IPH-4201 DMRVZMX TI TTBFHXC DMRVZMX TN Feto-acinar pancreatic protein (FAPP) DMRVZMX RN Clinical pipeline report, company report or official report of Gimv. DMRVZMX RU http://www.gimv.com/nl/media-en-nieuws/persberichten/innate-pharma-announces-the-entry-into-pre-clinical-validation-of-iph-4201-a-new-monoclonal-antibody-targeting-pancreatic-cancer-745404 DMRWDX5 DI DMRWDX5 DMRWDX5 DN A-134974 DMRWDX5 TI TTL732K DMRWDX5 TN Adenosine kinase (ADK) DMRWDX5 MA Inhibitor DMRWDX5 RN Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J Pharmacol Exp Ther. 2001Feb;296(2):501-9. DMRWDX5 RU https://pubmed.ncbi.nlm.nih.gov/11160637 DMRXB74 DI DMRXB74 DMRXB74 DN ARISTEROMYCIN DMRXB74 TI TTE2KUJ DMRXB74 TN Adenosylhomocysteinase (AHCY) DMRXB74 MA Inhibitor DMRXB74 RN Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. Bioorg Med Chem. 2008 Apr 1;16(7):3809-15. DMRXB74 RU https://pubmed.ncbi.nlm.nih.gov/18295495 DMRXB74 DI DMRXB74 DMRXB74 DN ARISTEROMYCIN DMRXB74 TI TTM2AOE DMRXB74 TN Adenosine A2a receptor (ADORA2A) DMRXB74 MA Inhibitor DMRXB74 RN Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem. 2000 Jun 1;43(11):2196-203. DMRXB74 RU https://pubmed.ncbi.nlm.nih.gov/10841798 DMRXB74 DI DMRXB74 DMRXB74 DN ARISTEROMYCIN DMRXB74 TI TTK25J1 DMRXB74 TN Adenosine A1 receptor (ADORA1) DMRXB74 MA Inhibitor DMRXB74 RN Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem. 2000 Jun 1;43(11):2196-203. DMRXB74 RU https://pubmed.ncbi.nlm.nih.gov/10841798 DMRXWCO DI DMRXWCO DMRXWCO DN BIBX-79 DMRXWCO TI TT7O8ZA DMRXWCO TN Lanosterol synthase (LSS) DMRXWCO MA Modulator DMRXWCO RN Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58. DMRXWCO RU https://pubmed.ncbi.nlm.nih.gov/8820110 DMRYJ40 DI DMRYJ40 DMRYJ40 DN AL-0671 DMRYJ40 TI TT1VOHK DMRYJ40 TN Potassium channel unspecific (KC) DMRYJ40 MA Opener DMRYJ40 RN A possible mechanism of action of a new potassium channel opener, AL0671, on lipid metabolism in obese Zucker rats. J Pharmacol Exp Ther. 1994 Dec;271(3):1666-71. DMRYJ40 RU https://pubmed.ncbi.nlm.nih.gov/7996482 DMRYQBE DI DMRYQBE DMRYQBE DN AS-1406 DMRYQBE TI TTRBUYN DMRYQBE TN Ribonuclease (RNase) DMRYQBE MA Modulator DMRYQBE RN WO patent application no. 2005,0657,17, Liquid formulations of antibody conjugates. DMRYQBE RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20050721&CC=WO&NR=2005065717A2&KC=A2 DMRZCH4 DI DMRZCH4 DMRZCH4 DN Org-9935 DMRZCH4 TI TTZCG4L DMRZCH4 TN Phosphodiesterase 3 (PDE3) DMRZCH4 MA Modulator DMRZCH4 RN The phosphodiesterase 3 inhibitor ORG 9935 inhibits oocyte maturation in the naturally selected dominant follicle in rhesus macaques.Contraception.2008 Apr;77(4):303-7. DMRZCH4 RU https://www.ncbi.nlm.nih.gov/pubmed/18342656 DMS0QEP DI DMS0QEP DMS0QEP DN SB 206553 DMS0QEP TI TT0K1SC DMS0QEP TN 5-HT 2B receptor (HTR2B) DMS0QEP MA Antagonist DMS0QEP RN Strain-dependent effects of diazepam and the 5-HT2B/2C receptor antagonist SB 206553 in spontaneously hypertensive and Lewis rats tested in the elevated plus-maze. Braz J Med Biol Res. 2001 May;34(5):675-82. DMS0QEP RU https://pubmed.ncbi.nlm.nih.gov/11323756 DMS1XK5 DI DMS1XK5 DMS1XK5 DN PD-158473 DMS1XK5 TI TT9IK2Z DMS1XK5 TN N-methyl-D-aspartate receptor (NMDAR) DMS1XK5 MA Modulator DMS1XK5 RN Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters. J Pharm Sci. 2002 Dec;91(12):2579-87. DMS1XK5 RU https://pubmed.ncbi.nlm.nih.gov/12434401 DMS23JX DI DMS23JX DMS23JX DN CP-0597 DMS23JX TI TTGY8IW DMS23JX TN B2 bradykinin receptor (BDKRB2) DMS23JX MA Antagonist DMS23JX RN CP-0597, a selective bradykinin B2 receptor antagonist, inhibits brain injury in a rat model of reversible middle cerebral artery occlusion. Stroke. 1997 Jul;28(7):1430-6. DMS23JX RU https://pubmed.ncbi.nlm.nih.gov/9227696 DMS2FB3 DI DMS2FB3 DMS2FB3 DN ATLIPROFEN METHYL ESTER DMS2FB3 TI TT8NGED DMS2FB3 TN Prostaglandin G/H synthase 1 (COX-1) DMS2FB3 MA Modulator DMS2FB3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS2FB3 RU https://www.fda.gov/ DMS2FB3 DI DMS2FB3 DMS2FB3 DN ATLIPROFEN METHYL ESTER DMS2FB3 TI TTVKILB DMS2FB3 TN Prostaglandin G/H synthase 2 (COX-2) DMS2FB3 MA Modulator DMS2FB3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS2FB3 RU https://www.fda.gov/ DMS2KEG DI DMS2KEG DMS2KEG DN KW-3433 DMS2KEG TI TTGN1ZA DMS2KEG TN Angiotensin II receptor (AGTR) DMS2KEG MA Modulator DMS2KEG RN Effects of various antihypertensive drugs on the function of osteoblast. Biol Pharm Bull. 2001 Jun;24(6):628-33. DMS2KEG RU https://pubmed.ncbi.nlm.nih.gov/11411549 DMS2M58 DI DMS2M58 DMS2M58 DN SKF-96231 DMS2M58 TI TTJ0IQB DMS2M58 TN Phosphodiesterase 5A (PDE5A) DMS2M58 MA Inhibitor DMS2M58 RN Analogue-based Drug Discovery II. Janos Fischer,C. Robin Ganellin. Page(150). DMS2M58 RU https://books.google.com.hk/books?id=h2Kd8ci4Ln8C&pg=PA150&lpg=PA150&dq=SKF-96231++++++++++++++PDE+5&source=bl&ots=yRj1Q8yHYq&sig=60AYTs3Vk3T_KDV-F7MHenbl4T4&hl=zh-CN&sa=X&ved=0CB8Q6AEwAGoVChMIhvKspOq5yAIVCXKOCh3MhAmi#v=onepage&q=SKF-96231%20%20%20%20%20%20%20%20%20%20%20%20%20%20PDE%205&f=false DMS3R15 DI DMS3R15 DMS3R15 DN A-74283 DMS3R15 TI TTSQIFT DMS3R15 TN 5-HT 1A receptor (HTR1A) DMS3R15 MA Agonist DMS3R15 RN Cardiovascular activity of A-74283, a 5-hydroxytryptamine 1A agent, in the spontaneously hypertensive rat. Pharmacology. 1998 Jan;56(1):17-29. DMS3R15 RU https://pubmed.ncbi.nlm.nih.gov/9467184 DMS4320 DI DMS4320 DMS4320 DN BRL 37344 DMS4320 TI TTMXGCW DMS4320 TN Adrenergic receptor beta-3 (ADRB3) DMS4320 MA Agonist DMS4320 RN Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34. DMS4320 RU https://pubmed.ncbi.nlm.nih.gov/8696421 DMS4FG0 DI DMS4FG0 DMS4FG0 DN Promegapoietin DMS4FG0 TI TTIHYA4 DMS4FG0 TN Thrombopoietin receptor (MPL) DMS4FG0 MA Modulator DMS4FG0 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMS4FG0 RU https://www.fda.gov/ DMS5CZ4 DI DMS5CZ4 DMS5CZ4 DN METRIFUDIL DMS5CZ4 TI TTJFY5U DMS5CZ4 TN Adenosine A3 receptor (ADORA3) DMS5CZ4 MA Inhibitor DMS5CZ4 RN (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists. J Med Chem. 2005 Mar 24;48(6):1745-58. DMS5CZ4 RU https://pubmed.ncbi.nlm.nih.gov/15771421 DMS5CZ4 DI DMS5CZ4 DMS5CZ4 DN METRIFUDIL DMS5CZ4 TI TTM2AOE DMS5CZ4 TN Adenosine A2a receptor (ADORA2A) DMS5CZ4 MA Inhibitor DMS5CZ4 RN N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem. 1999 Sep 9;42(18):3463-77. DMS5CZ4 RU https://pubmed.ncbi.nlm.nih.gov/10479279 DMS5CZ4 DI DMS5CZ4 DMS5CZ4 DN METRIFUDIL DMS5CZ4 TI TTK25J1 DMS5CZ4 TN Adenosine A1 receptor (ADORA1) DMS5CZ4 MA Inhibitor DMS5CZ4 RN N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J Med Chem. 1999 Sep 9;42(18):3463-77. DMS5CZ4 RU https://pubmed.ncbi.nlm.nih.gov/10479279 DMS7INR DI DMS7INR DMS7INR DN AZD-0902 DMS7INR TI TTM7WCE DMS7INR TN Ion channel unspecific (IC) DMS7INR MA Antagonist DMS7INR RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019129) DMS7INR RU http://adisinsight.springer.com/drugs/800019129 DMS7UPZ DI DMS7UPZ DMS7UPZ DN AG-2024 DMS7UPZ TI TT1GHVO DMS7UPZ TN Matrix metalloproteinase (MMP) DMS7UPZ MA Modulator DMS7UPZ RN US patent application no. 6,858,598, Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia. DMS7UPZ RU https://www.google.com.ar/patents/US6858598 DMS9EJ5 DI DMS9EJ5 DMS9EJ5 DN SR-58878 DMS9EJ5 TI TTMXGCW DMS9EJ5 TN Adrenergic receptor beta-3 (ADRB3) DMS9EJ5 MA Modulator DMS9EJ5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 30). DMS9EJ5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30 DMSBUET DI DMSBUET DMSBUET DN SB220025 DMSBUET TI TTQBR95 DMSBUET TN Stress-activated protein kinase 2a (p38 alpha) DMSBUET MA Inhibitor DMSBUET RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSBUET RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSBUET DI DMSBUET DMSBUET DN SB220025 DMSBUET TI TT4TQBX DMSBUET TN Extracellular signal-regulated kinase 2 (ERK2) DMSBUET MA Inhibitor DMSBUET RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSBUET RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSKAGP DI DMSKAGP DMSKAGP DN Omniferon DMSKAGP TI TTV2CN0 DMSKAGP TN Interferon receptor (IFNR) DMSKAGP MA Modulator DMSKAGP RN US patent application no. 2004,0229,936, Treatment of hepatitis c virus infection with sesquiterpene lactones. DMSKAGP RU http://www.google.co.ve/patents/US20040229936 DMSKHGQ DI DMSKHGQ DMSKHGQ DN SC-53228 DMSKHGQ TI TTN53ZF DMSKHGQ TN Leukotriene B4 receptor 1 (LTB4R) DMSKHGQ MA Inhibitor DMSKHGQ RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DMSKHGQ RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DMSNOH3 DI DMSNOH3 DMSNOH3 DN PF-04620110 DMSNOH3 TI TTF8P9I DMSNOH3 TN Diacylglycerol acyltransferase 1 (DGAT1) DMSNOH3 MA Inhibitor DMSNOH3 RN Clinical pipeline report, company report or official report of Pfizer (2011). DMSNOH3 RU http://www.pfizer.com/home/ DMSOT07 DI DMSOT07 DMSOT07 DN CP-83101 DMSOT07 TI TTPADOQ DMSOT07 TN HMG-CoA reductase (HMGCR) DMSOT07 MA Inhibitor DMSOT07 RN Efficacy, tissue distribution and biliary excretion of methyl (3R*,5S*)-(E)-3,5-dihydroxy-9,9-diphenyl-6,8-nonadienoate (CP-83101), a hepatoselective inhibitor of HMG-CoA reductase activity in the rat. Biochem Pharmacol. 1990 Sep 15;40(6):1281-93. DMSOT07 RU https://pubmed.ncbi.nlm.nih.gov/2403382 DMSPWMF DI DMSPWMF DMSPWMF DN Niguldipine DMSPWMF TI TTBRKXS DMSPWMF TN Adrenergic receptor alpha-1B (ADRA1B) DMSPWMF MA Inhibitor DMSPWMF RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMSPWMF RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMSPWMF DI DMSPWMF DMSPWMF DN Niguldipine DMSPWMF TI TTZIFHC DMSPWMF TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMSPWMF MA Inhibitor DMSPWMF RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMSPWMF RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMSPWMF DI DMSPWMF DMSPWMF DN Niguldipine DMSPWMF TI TT34BHT DMSPWMF TN Adrenergic receptor alpha-1D (ADRA1D) DMSPWMF MA Inhibitor DMSPWMF RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMSPWMF RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMSPWMF DI DMSPWMF DMSPWMF DN Niguldipine DMSPWMF TI TTNGILX DMSPWMF TN Adrenergic receptor alpha-1A (ADRA1A) DMSPWMF MA Inhibitor DMSPWMF RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMSPWMF RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMSRDGE DI DMSRDGE DMSRDGE DN TH-0318 DMSRDGE TI TTVIMDE DMSRDGE TN Glucagon-like peptide 1 receptor (GLP1R) DMSRDGE MA Modulator DMSRDGE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMSRDGE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMSVMF2 DI DMSVMF2 DMSVMF2 DN Girisopam DMSVMF2 TI TTEX6LM DMSVMF2 TN GABA(A) receptor gamma-3 (GABRG3) DMSVMF2 MA Modulator DMSVMF2 RN [(3)H]-girisopam, a novel selective benzodiazepine for the 2, 3-benzodiazepine binding site. Brain Res Brain Res Protoc. 1999 Jul;4(2):230-5. DMSVMF2 RU https://www.ncbi.nlm.nih.gov/pubmed/10446419 DMSWFMQ DI DMSWFMQ DMSWFMQ DN RU-33965 DMSWFMQ TI TTEX6LM DMSWFMQ TN GABA(A) receptor gamma-3 (GABRG3) DMSWFMQ MA Modulator DMSWFMQ RN Discriminative stimulus properties of RU 33965, a benzodiazepine receptor weak partial inverse agonist. Pharmacol Biochem Behav. 1992 Oct;43(2):583-8. DMSWFMQ RU https://pubmed.ncbi.nlm.nih.gov/1359581 DMSYLIF DI DMSYLIF DMSYLIF DN Fosfluridine tidoxil DMSYLIF TI TTU6BFZ DMSYLIF TN Candida Thymidylate synthase (Candi TMP1) DMSYLIF MA Inhibitor DMSYLIF RN Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):733-9. DMSYLIF RU https://pubmed.ncbi.nlm.nih.gov/18600533 DMSZH0I DI DMSZH0I DMSZH0I DN GW-3600 DMSZH0I TI TTSKMI8 DMSZH0I TN Phosphodiesterase 4D (PDE4D) DMSZH0I MA Inhibitor DMSZH0I RN Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate. Biochemistry. 1998 May 12;37(19):6894-904. DMSZH0I RU https://pubmed.ncbi.nlm.nih.gov/9578576 DMSZH0I DI DMSZH0I DMSZH0I DN GW-3600 DMSZH0I TI TTVIAT9 DMSZH0I TN Phosphodiesterase 4B (PDE4B) DMSZH0I MA Inhibitor DMSZH0I RN Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate. Biochemistry. 1998 May 12;37(19):6894-904. DMSZH0I RU https://pubmed.ncbi.nlm.nih.gov/9578576 DMSZH0I DI DMSZH0I DMSZH0I DN GW-3600 DMSZH0I TI TTZ97H5 DMSZH0I TN Phosphodiesterase 4A (PDE4A) DMSZH0I MA Inhibitor DMSZH0I RN Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate. Biochemistry. 1998 May 12;37(19):6894-904. DMSZH0I RU https://pubmed.ncbi.nlm.nih.gov/9578576 DMSZJUM DI DMSZJUM DMSZJUM DN SDZ-ISQ-844 DMSZJUM TI TTZCG4L DMSZJUM TN Phosphodiesterase 3 (PDE3) DMSZJUM MA Modulator DMSZJUM RN [Effects of SDZ ISQ 844, a cyclic nucleotide phosphodiesterase isozyme type III/IV inhibitor, on the release of histamine from human peripheral leukocytes].Arerugi.1997 May;46(5):426-32. DMSZJUM RU https://www.ncbi.nlm.nih.gov/pubmed/9232912 DMT10C2 DI DMT10C2 DMT10C2 DN AG1295 DMT10C2 TI TTGJCWZ DMT10C2 TN Fms-like tyrosine kinase 3 (FLT-3) DMT10C2 MA Inhibitor DMT10C2 RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMT10C2 RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMT10C2 DI DMT10C2 DMT10C2 DN AG1295 DMT10C2 TI TTI7421 DMT10C2 TN Platelet-derived growth factor receptor beta (PDGFRB) DMT10C2 MA Inhibitor DMT10C2 RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMT10C2 RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMT10C2 DI DMT10C2 DMT10C2 DN AG1295 DMT10C2 TI TTUTJGQ DMT10C2 TN Vascular endothelial growth factor receptor 2 (KDR) DMT10C2 MA Inhibitor DMT10C2 RN Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase i... Bioorg Med Chem. 2009 Oct 15;17(20):7324-36. DMT10C2 RU https://pubmed.ncbi.nlm.nih.gov/19748785 DMT10C2 DI DMT10C2 DMT10C2 DN AG1295 DMT10C2 TI TT8FYO9 DMT10C2 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMT10C2 MA Inhibitor DMT10C2 RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMT10C2 RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMT1DNS DI DMT1DNS DMT1DNS DN L-695902 DMT1DNS TI TTKJEMQ DMT1DNS TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMT1DNS MA Inhibitor DMT1DNS RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMT1DNS RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMT1DNS DI DMT1DNS DMT1DNS DN L-695902 DMT1DNS TI TTN9D8E DMT1DNS TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMT1DNS MA Inhibitor DMT1DNS RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMT1DNS RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMT1DNS DI DMT1DNS DMT1DNS DN L-695902 DMT1DNS TI TTLD29N DMT1DNS TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMT1DNS MA Inhibitor DMT1DNS RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMT1DNS RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMT1RH6 DI DMT1RH6 DMT1RH6 DN GMC-283 DMT1RH6 TI TTS2PH3 DMT1RH6 TN Dopamine D5 receptor (D5R) DMT1RH6 MA Antagonist DMT1RH6 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMT1RH6 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMT1RH6 DI DMT1RH6 DMT1RH6 DN GMC-283 DMT1RH6 TI TTJQOD7 DMT1RH6 TN 5-HT 2A receptor (HTR2A) DMT1RH6 MA Antagonist DMT1RH6 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMT1RH6 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMT1RH6 DI DMT1RH6 DMT1RH6 DN GMC-283 DMT1RH6 TI TTEX248 DMT1RH6 TN Dopamine D2 receptor (D2R) DMT1RH6 MA Antagonist DMT1RH6 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMT1RH6 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMT3B4G DI DMT3B4G DMT3B4G DN MEDI-500 DMT3B4G TI TTBMAOZ DMT3B4G TN Regulatory protein unspecific (RGP) DMT3B4G MA Modulator DMT3B4G RN T10B9 (MEDI-500) mediated immunosuppression: studies on the mechanism of action. Clin Transplant. 1996 Dec;10(6 Pt 2):607-13. DMT3B4G RU https://pubmed.ncbi.nlm.nih.gov/8996751 DMT43AI DI DMT43AI DMT43AI DN SIB-1508Y DMT43AI TI TTL1ATN DMT43AI TN Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) DMT43AI MA Modulator DMT43AI RN Nicotinic Receptors in Neurodegeneration DMT43AI RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3648781 DMT4P89 DI DMT4P89 DMT4P89 DN Actinonin DMT4P89 TI TTICO5G DMT4P89 TN Staphylococcus Peptide deformylase (Stap-coc def) DMT4P89 MA Inhibitor DMT4P89 RN Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry. 2000 Feb 15;39(6):1256-62. DMT4P89 RU https://pubmed.ncbi.nlm.nih.gov/10684604 DMT584A DI DMT584A DMT584A DN ALN-VEG01 DMT584A TI TT3LJ9K DMT584A TN VEGF messenger RNA (VEGF mRNA) DMT584A RN Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. DMT584A RU http://investors.alnylam.com/releasedetail.cfm?ReleaseID=446269 DMT5DH0 DI DMT5DH0 DMT5DH0 DN RS-66252 DMT5DH0 TI TT8DBY3 DMT5DH0 TN Angiotensin II receptor type-1 (AGTR1) DMT5DH0 MA Modulator DMT5DH0 RN Virtual Screening in Drug Discovery, Juan Alvarez Brian Shoichet. Page(218). DMT5DH0 RU https://books.google.com.hk/books?id=Yj9HgUgq_uwC&pg=PA218&lpg=PA218&dq=RS-66252++++angiotensin+II&source=bl&ots=ohMTzwCVx9&sig=wzHmoRk4h2AhEdyLvkPdYcfjhPk&hl=zh-CN&sa=X&ved=0CB8Q6AEwAGoVChMIzrnc9469yAIVEAmOCh0byQrL DMT5LX0 DI DMT5LX0 DMT5LX0 DN SQ-33600 DMT5LX0 TI TTPADOQ DMT5LX0 TN HMG-CoA reductase (HMGCR) DMT5LX0 MA Inhibitor DMT5LX0 RN Determination of SQ 33,600, a phosphinic acid containing HMG CoA reductase inhibitor, in human serum by high-performance liquid chromatography combined with ionspray mass spectrometry. Biol Mass Spectrom. 1992 Apr;21(4):189-94. DMT5LX0 RU https://pubmed.ncbi.nlm.nih.gov/1567915 DMT5ZFG DI DMT5ZFG DMT5ZFG DN A-79175 DMT5ZFG TI TT2J34L DMT5ZFG TN Arachidonate 5-lipoxygenase (5-LOX) DMT5ZFG MA Inhibitor DMT5ZFG RN The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. DMT5ZFG RU https://pubmed.ncbi.nlm.nih.gov/9435164 DMT6J1E DI DMT6J1E DMT6J1E DN GI-248573 DMT6J1E TI TTCG0AL DMT6J1E TN Cholecystokinin receptor type A (CCKAR) DMT6J1E MA Modulator DMT6J1E RN US patent application no. 8,748,419, Antagonists. DMT6J1E RU http://www.google.com.ar/Patents/US8748419 DMT6R8I DI DMT6R8I DMT6R8I DN FR-229934 DMT6R8I TI TTJ0IQB DMT6R8I TN Phosphodiesterase 5A (PDE5A) DMT6R8I MA Inhibitor DMT6R8I RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014897) DMT6R8I RU http://adisinsight.springer.com/drugs/800014897 DMT6S9B DI DMT6S9B DMT6S9B DN GS-522 DMT6S9B TI TT6L509 DMT6S9B TN Coagulation factor IIa (F2) DMT6S9B MA Inhibitor DMT6S9B RN A novel oligodeoxynucleotide inhibitor of thrombin. I. In vitro metabolic stability in plasma and serum. Pharm Res. 1995 Dec;12(12):1937-42. DMT6S9B RU https://pubmed.ncbi.nlm.nih.gov/8786969 DMT7O9V DI DMT7O9V DMT7O9V DN SQ-34919 DMT7O9V TI TTFQEO5 DMT7O9V TN Squalene synthetase (FDFT1) DMT7O9V MA Inhibitor DMT7O9V RN Inhibition of farnesyl protein transferase by new farnesyl phosphonate derivatives of phenylalanine, Bioorg. Med. Chem. Lett. 6(12):1291-1296 (1996). DMT7O9V RU http://www.sciencedirect.com/science/article/pii/0960894X96002387 DMT819N DI DMT819N DMT819N DN Pegorgotein DMT819N TI TT6RVLG DMT819N TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMT819N MA Modulator DMT819N RN Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury. Adv Exp Med Biol. 1994;366:389-400. DMT819N RU https://pubmed.ncbi.nlm.nih.gov/7771267 DMT83V6 DI DMT83V6 DMT83V6 DN PNQX DMT83V6 TI TTAN6JD DMT83V6 TN Glutamate receptor AMPA (GRIA) DMT83V6 MA Antagonist DMT83V6 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005697) DMT83V6 RU http://adisinsight.springer.com/drugs/800005697 DMT9QB5 DI DMT9QB5 DMT9QB5 DN MIV-170 DMT9QB5 TI TT84ETX DMT9QB5 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMT9QB5 MA Inhibitor DMT9QB5 RN Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochem Pharmacol. 2010 Oct 15;80(8):1133-40. DMT9QB5 RU https://pubmed.ncbi.nlm.nih.gov/20599774 DMTA7O8 DI DMTA7O8 DMTA7O8 DN BMS-185857 DMTA7O8 TI TT7WZIJ DMTA7O8 TN CAAX farnesyltransferase beta (FNTB) DMTA7O8 MA Modulator DMTA7O8 RN US patent application no. 2005,0227,929, Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent. DMTA7O8 RU http://www.google.com/patents/US20050227929 DMTBWU1 DI DMTBWU1 DMTBWU1 DN Seridopidine DMTBWU1 TI TTVBI8W DMTBWU1 TN Dopamine transporter (DAT) DMTBWU1 MA Modulator DMTBWU1 RN Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses. Psychopharmacology (Berl). 2015 Sep;232(18):3443-53. DMTBWU1 RU https://pubmed.ncbi.nlm.nih.gov/26159455 DMTDLHG DI DMTDLHG DMTDLHG DN SORETOLIDE DMTDLHG TI TTVPQTF DMTDLHG TN Glutamate receptor AMPA 1 (GRIA1) DMTDLHG MA Modulator DMTDLHG RN Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24. DMTDLHG RU https://pubmed.ncbi.nlm.nih.gov/23480152 DMTEY8W DI DMTEY8W DMTEY8W DN E-6276 DMTEY8W TI TT5TPI6 DMTEY8W TN Opioid receptor sigma 1 (OPRS1) DMTEY8W MA Binder DMTEY8W RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMTEY8W RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMTF6D9 DI DMTF6D9 DMTF6D9 DN A-76895 DMTF6D9 TI TTRK8B9 DMTF6D9 TN Sodium channel unspecific (NaC) DMTF6D9 MA Modulator DMTF6D9 RN CA patent application no. 849505, Sodium channel blockers reduce glucagon secretion. DMTF6D9 RU http://www.google.com/patents/CA2849505A1?cl=en DMTGCA6 DI DMTGCA6 DMTGCA6 DN HuCD40L DMTGCA6 TI TTN6Y9A DMTGCA6 TN CD40L receptor (CD40) DMTGCA6 MA Binder DMTGCA6 RN Recombinant human CD40 ligand inhibits simian immunodeficiency virus replication: a role for interleukin- 16. J Med Primatol. 1999 Aug-Oct;28(4-5):190-4. DMTGCA6 RU https://pubmed.ncbi.nlm.nih.gov/10593485 DMTGH8N DI DMTGH8N DMTGH8N DN GR-89696 DMTGH8N TI TTQW87Y DMTGH8N TN Opioid receptor kappa (OPRK1) DMTGH8N MA Modulator DMTGH8N RN [(11)C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers. Nucl Med Biol. 2002 Jan;29(1):47-53. DMTGH8N RU https://pubmed.ncbi.nlm.nih.gov/11786275 DMTGIUV DI DMTGIUV DMTGIUV DN SPR-210 DMTGIUV TI TTFBNVI DMTGIUV TN Aldose reductase (AKR1B1) DMTGIUV MA Inhibitor DMTGIUV RN Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats. Jpn J Pharmacol. 1994 Feb;64(2):115-24. DMTGIUV RU https://pubmed.ncbi.nlm.nih.gov/8028228 DMTH52F DI DMTH52F DMTH52F DN 21-AMINOEPOTHILONE B DMTH52F TI TTML2WA DMTH52F TN Tubulin (TUB) DMTH52F MA Inhibitor DMTH52F RN Tubulin-Interactive Natural Products as Anticancer Agents. Correction in: J Nat Prod. 2011 May 27; 74(5): 1352. DMTH52F RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2765517/ DMTI10C DI DMTI10C DMTI10C DN CEP-427 DMTI10C TI TTEDJN4 DMTI10C TN Low-affinity nerve growth factor receptor (NGFR) DMTI10C MA Modulator DMTI10C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMTI10C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMTIW6K DI DMTIW6K DMTIW6K DN Ro-31-8830 DMTIW6K TI TTYVX59 DMTIW6K TN Protein kinase C (PRKC) DMTIW6K MA Inhibitor DMTIW6K RN Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor. Agents Actions. 1992 Sep;37(1-2):85-9. DMTIW6K RU https://pubmed.ncbi.nlm.nih.gov/1456183 DMTKCNJ DI DMTKCNJ DMTKCNJ DN L-648051 DMTKCNJ TI TTGKOY9 DMTKCNJ TN Leukotriene CysLT1 receptor (CYSLTR1) DMTKCNJ MA Modulator DMTKCNJ RN Effects of a leukotriene D4 receptor antagonist, L-648,051, and a dual inhibitor lypoxygenase and cyclooxygenase, BW-755C, on digoxin-induced arrhy... Arch Int Pharmacodyn Ther. 1993 Jan-Feb;321:72-80. DMTKCNJ RU https://www.ncbi.nlm.nih.gov/pubmed/8391788 DMTKJDS DI DMTKJDS DMTKJDS DN BN-50726 DMTKJDS TI TTQL5VC DMTKJDS TN Platelet-activating factor receptor (PTAFR) DMTKJDS MA Antagonist DMTKJDS RN Effects of the PAF antagonists BN50726 and BN50739 on arrhythmogenesis and extent of necrosis during myocardial ischaemia/reperfusion in rabbits. Br J Pharmacol. 1992 Nov;107(3):705-9. DMTKJDS RU https://pubmed.ncbi.nlm.nih.gov/1472967 DMTMS3L DI DMTMS3L DMTMS3L DN Barucainide DMTMS3L TI TT05DLS DMTMS3L TN E3 ubiquitin-protein ligase COP1 (RFWD2) DMTMS3L MA Modulator DMTMS3L RN Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60. DMTMS3L RU https://pubmed.ncbi.nlm.nih.gov/2330863 DMTMZJ4 DI DMTMZJ4 DMTMZJ4 DN U-90042 DMTMZJ4 TI TTNJYV2 DMTMZJ4 TN Gamma-aminobutyric acid receptor (GAR) DMTMZJ4 MA Modulator DMTMZJ4 RN U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes. J Pharmacol Exp Ther. 1995 Nov;275(2):761-7. DMTMZJ4 RU https://pubmed.ncbi.nlm.nih.gov/7473164 DMTNB6G DI DMTNB6G DMTNB6G DN TNFQb therapeutic vaccines DMTNB6G TI TTF8CQI DMTNB6G TN Tumor necrosis factor (TNF) DMTNB6G RN Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial. PLoS One. 2014; 9(12): e113465. DMTNB6G RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269456/ DMTPDX7 DI DMTPDX7 DMTPDX7 DN CR-3834 DMTPDX7 TI TT8DBY3 DMTPDX7 TN Angiotensin II receptor type-1 (AGTR1) DMTPDX7 MA Antagonist DMTPDX7 RN Pharmacokinetic study of a new angiotensin-AT1 antagonist by HPLC. J Pharm Biomed Anal. 2008 Sep 29;48(2):422-7. DMTPDX7 RU https://pubmed.ncbi.nlm.nih.gov/18514458 DMTS6HB DI DMTS6HB DMTS6HB DN ON-579 DMTS6HB TI TT2O84V DMTS6HB TN Thromboxane A2 receptor (TBXA2R) DMTS6HB MA Modulator DMTS6HB RN The effect of a TXA2 receptor antagonist ON-579 on experimental allergic reactions. Prostaglandins Leukot Essent Fatty Acids. 1995 Aug;53(2):123-33. DMTS6HB RU https://pubmed.ncbi.nlm.nih.gov/7480074 DMTWXE3 DI DMTWXE3 DMTWXE3 DN NPS-1392 DMTWXE3 TI TT9IK2Z DMTWXE3 TN N-methyl-D-aspartate receptor (NMDAR) DMTWXE3 MA Antagonist DMTWXE3 RN Synthesis, biological activity, and absolute stereochemical assignment of NPS 1392: a potent and stereoselective NMDA receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1915-20. DMTWXE3 RU https://pubmed.ncbi.nlm.nih.gov/10450953 DMTXPSB DI DMTXPSB DMTXPSB DN DB-200 DMTXPSB TI TTDL0NY DMTXPSB TN Carnitine O-palmitoyltransferase I (CPT1B) DMTXPSB MA Inhibitor DMTXPSB RN Comparison of the effects of carnitine palmitoyltransferase-1 and -2 inhibitors on rat heart hypertrophy. Cardioscience. 1994 Sep;5(3):193-7. DMTXPSB RU https://pubmed.ncbi.nlm.nih.gov/7827256 DMTY7PE DI DMTY7PE DMTY7PE DN WAY-126227 DMTY7PE TI TTGN1ZA DMTY7PE TN Angiotensin II receptor (AGTR) DMTY7PE MA Modulator DMTY7PE RN WO patent application no. 1996,0402,58, Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure. DMTY7PE RU http://www.google.com/patents/WO1996040258A2?cl=en DMTYCJ6 DI DMTYCJ6 DMTYCJ6 DN BW B70C DMTYCJ6 TI TT2J34L DMTYCJ6 TN Arachidonate 5-lipoxygenase (5-LOX) DMTYCJ6 MA Inhibitor DMTYCJ6 RN Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99. DMTYCJ6 RU https://pubmed.ncbi.nlm.nih.gov/1793063 DMTYO3P DI DMTYO3P DMTYO3P DN U-92032 DMTYO3P TI TTQZFTH DMTYO3P TN Voltage-gated calcium channel alpha Cav3.3 (CACNA1I) DMTYO3P MA Inhibitor DMTYO3P RN Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6. DMTYO3P RU https://pubmed.ncbi.nlm.nih.gov/10978184 DMTYO3P DI DMTYO3P DMTYO3P DN U-92032 DMTYO3P TI TTRK8B9 DMTYO3P TN Sodium channel unspecific (NaC) DMTYO3P MA Inhibitor DMTYO3P RN Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6. DMTYO3P RU https://pubmed.ncbi.nlm.nih.gov/10978184 DMTYO3P DI DMTYO3P DMTYO3P DN U-92032 DMTYO3P TI TTZPWGN DMTYO3P TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMTYO3P MA Inhibitor DMTYO3P RN Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6. DMTYO3P RU https://pubmed.ncbi.nlm.nih.gov/10978184 DMTYO3P DI DMTYO3P DMTYO3P DN U-92032 DMTYO3P TI TTAXZ0K DMTYO3P TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMTYO3P MA Inhibitor DMTYO3P RN Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6. DMTYO3P RU https://pubmed.ncbi.nlm.nih.gov/10978184 DMU1TRQ DI DMU1TRQ DMU1TRQ DN BN50739 DMU1TRQ TI TTQL5VC DMU1TRQ TN Platelet-activating factor receptor (PTAFR) DMU1TRQ MA Modulator DMU1TRQ RN Effect of the platelet-activating factor antagonist BN 50739 and its diluents on mitochondrial respiration and membrane lipids during and following... J Neurochem. 1994 May;62(5):1929-38. DMU1TRQ RU https://www.ncbi.nlm.nih.gov/pubmed/8158141 DMU24HR DI DMU24HR DMU24HR DN LY-292728 DMU24HR TI TTVJX54 DMU24HR TN Leukotriene B4 receptor 2 (LTB4R2) DMU24HR MA Inhibitor DMU24HR RN Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4. DMU24HR RU https://pubmed.ncbi.nlm.nih.gov/8254628 DMU24HR DI DMU24HR DMU24HR DN LY-292728 DMU24HR TI TTN53ZF DMU24HR TN Leukotriene B4 receptor 1 (LTB4R) DMU24HR MA Inhibitor DMU24HR RN Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4. DMU24HR RU https://pubmed.ncbi.nlm.nih.gov/8254628 DMU2F6Q DI DMU2F6Q DMU2F6Q DN ZD-6003 DMU2F6Q TI TTC70AJ DMU2F6Q TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMU2F6Q MA Modulator DMU2F6Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMU2F6Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMU2ZVY DI DMU2ZVY DMU2ZVY DN SR12813 DMU2ZVY TI TTPADOQ DMU2ZVY TN HMG-CoA reductase (HMGCR) DMU2ZVY MA Modulator DMU2ZVY RN The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A r... J Biol Chem. 1996 Jun 14;271(24):14376-82. DMU2ZVY RU https://www.ncbi.nlm.nih.gov/pubmed/8662919 DMU3BDY DI DMU3BDY DMU3BDY DN TAN-1496 DMU3BDY TI TTGTQHC DMU3BDY TN DNA topoisomerase I (TOP1) DMU3BDY MA Modulator DMU3BDY RN TAN-1496 A, C and E, diketopiperazine antibiotics with inhibitory activity against mammalian DNA topoisomerase I. J Antibiot (Tokyo). 1994 Nov;47(11):1202-18. DMU3BDY RU https://pubmed.ncbi.nlm.nih.gov/8002382 DMU3D1K DI DMU3D1K DMU3D1K DN NTE-122 DMU3D1K TI TTMF541 DMU3D1K TN Liver carboxylesterase (CES1) DMU3D1K MA Inhibitor DMU3D1K RN Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits. Jpn J Pharmacol. 1998 Nov;78(3):355-64. DMU3D1K RU https://pubmed.ncbi.nlm.nih.gov/9869270 DMU5TGC DI DMU5TGC DMU5TGC DN JSM-10292 DMU5TGC TI TTGY8IW DMU5TGC TN B2 bradykinin receptor (BDKRB2) DMU5TGC MA Antagonist DMU5TGC RN Binding characteristics of [3H]-JSM10292: a new cell membrane-permeant non-peptide bradykinin B2 receptor antagonist. Br J Pharmacol. 2012 Oct;167(4):839-53. DMU5TGC RU https://pubmed.ncbi.nlm.nih.gov/22646218 DMU5TZD DI DMU5TZD DMU5TZD DN Co-152791 DMU5TZD TI TTEX6LM DMU5TZD TN GABA(A) receptor gamma-3 (GABRG3) DMU5TZD MA Modulator DMU5TZD RN Substituted 3beta-phenylethynyl derivatives of 3alpha-hydroxy-5alpha-pregnan-20-one: remarkably potent neuroactive steroid modulators of gamma-aminobutyric acidA receptors. J Pharmacol Exp Ther. 1998Oct;287(1):198-207. DMU5TZD RU https://pubmed.ncbi.nlm.nih.gov/9765338 DMU6L4I DI DMU6L4I DMU6L4I DN AZD-7545 DMU6L4I TI TTJGCKM DMU6L4I TN Pyruvate dehydrogenase kinase 2 (PDHK2) DMU6L4I MA Inhibitor DMU6L4I RN Recognition of the inner lipoyl-bearing domain of dihydrolipoyl transacetylase and of the blood glucose-lowering compound AZD7545 by pyruvate dehyd... Biochemistry. 2007 Jul 24;46(29):8592-602. DMU6L4I RU https://pubmed.ncbi.nlm.nih.gov/17602666 DMU73F0 DI DMU73F0 DMU73F0 DN Bifemelane DMU73F0 TI TT3WG5C DMU73F0 TN Monoamine oxidase type A (MAO-A) DMU73F0 MA Modulator DMU73F0 RN 4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase. J Neurochem. 1988 Jan;50(1):243-7. DMU73F0 RU https://pubmed.ncbi.nlm.nih.gov/3335842 DMU9JAH DI DMU9JAH DMU9JAH DN Ro-46-5934 DMU9JAH TI TT1RS9F DMU9JAH TN Acetylcholinesterase (AChE) DMU9JAH MA Inhibitor DMU9JAH RN A novel acetylcholinesterase inhibitor, Ro 46-5934, which interacts with muscarinic M2 receptors. Biochem Soc Trans. 1994 Aug;22(3):755-8. DMU9JAH RU https://pubmed.ncbi.nlm.nih.gov/7821679 DMUCP8K DI DMUCP8K DMUCP8K DN RPK-739 DMUCP8K TI TTNYZG2 DMUCP8K TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMUCP8K MA Modulator DMUCP8K RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUCP8K RU https://www.fda.gov/ DMUDE1T DI DMUDE1T DMUDE1T DN RWJ-63556 DMUDE1T TI TT2J34L DMUDE1T TN Arachidonate 5-lipoxygenase (5-LOX) DMUDE1T MA Modulator DMUDE1T RN Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101. DMUDE1T RU https://pubmed.ncbi.nlm.nih.gov/9262379 DMUDE1T DI DMUDE1T DMUDE1T DN RWJ-63556 DMUDE1T TI TTVKILB DMUDE1T TN Prostaglandin G/H synthase 2 (COX-2) DMUDE1T MA Modulator DMUDE1T RN Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J Pharmacol Exp Ther. 1997 Aug;282(2):1094-101. DMUDE1T RU https://pubmed.ncbi.nlm.nih.gov/9262379 DMUEB4P DI DMUEB4P DMUEB4P DN LY-210073 DMUEB4P TI TTN53ZF DMUEB4P TN Leukotriene B4 receptor 1 (LTB4R) DMUEB4P MA Modulator DMUEB4P RN Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists. J Med Chem. 1993 Jun 11;36(12):1726-34. DMUEB4P RU https://pubmed.ncbi.nlm.nih.gov/8389876 DMUG82P DI DMUG82P DMUG82P DN GW-278884 DMUG82P TI TT3C1VN DMUG82P TN Enzyme unspecific (Enz) DMUG82P MA Modulator DMUG82P RN WO patent application no. 2010,1112,71, Orally bioavailable lipid-based constructs. DMUG82P RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100930&CC=WO&NR=2010111271A1&KC=A1 DMUGC2X DI DMUGC2X DMUGC2X DN Org-10490 DMUGC2X TI TTZFYLI DMUGC2X TN Dopamine D1 receptor (D1R) DMUGC2X MA Modulator DMUGC2X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUGC2X RU https://www.fda.gov/ DMUGC2X DI DMUGC2X DMUGC2X DN Org-10490 DMUGC2X TI TTEX248 DMUGC2X TN Dopamine D2 receptor (D2R) DMUGC2X MA Modulator DMUGC2X RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMUGC2X RU https://www.fda.gov/ DMUGPDB DI DMUGPDB DMUGPDB DN SRSS-023 DMUGPDB TI TTWT5K7 DMUGPDB TN 5-HT 1 receptor (5HT1R) DMUGPDB MA Agonist DMUGPDB RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019089) DMUGPDB RU http://adisinsight.springer.com/drugs/800019089 DMUGZMO DI DMUGZMO DMUGZMO DN RWJ-49815 DMUGZMO TI TTY6EWA DMUGZMO TN Neuropeptide Y receptor type 5 (NPY5R) DMUGZMO MA Antagonist DMUGZMO RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DMUGZMO RU https://pubmed.ncbi.nlm.nih.gov/16634704 DMUGZMO DI DMUGZMO DMUGZMO DN RWJ-49815 DMUGZMO TI TTJVCG0 DMUGZMO TN Bacterial Sporulation kinase A (Bact kinA) DMUGZMO MA Inhibitor DMUGZMO RN Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem. 2002 Apr;10(4):855-67. DMUGZMO RU https://pubmed.ncbi.nlm.nih.gov/11836091 DMUHBSI DI DMUHBSI DMUHBSI DN Tridegin DMUHBSI TI TTAXGIP DMUHBSI TN Coagulation factor XIII (F13B) DMUHBSI MA Modulator DMUHBSI RN Tridegin, a new peptidic inhibitor of factor XIIIa, from the blood-sucking leech Haementeria ghilianii. Biochem J. 1997 Jun 15;324 ( Pt 3):797-805. DMUHBSI RU https://www.ncbi.nlm.nih.gov/pubmed/9210403 DMUHG0F DI DMUHG0F DMUHG0F DN LY-117018 DMUHG0F TI TTOM3J0 DMUHG0F TN Estrogen receptor beta (ESR2) DMUHG0F MA Inhibitor DMUHG0F RN Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J Med Chem. 1990 Dec;33(12):3222-9. DMUHG0F RU https://pubmed.ncbi.nlm.nih.gov/2258908 DMUHG0F DI DMUHG0F DMUHG0F DN LY-117018 DMUHG0F TI TTZAYWL DMUHG0F TN Estrogen receptor (ESR) DMUHG0F MA Inhibitor DMUHG0F RN Structure-activity relationship of antiestrogens. Phenolic analogues of 2,3-diaryl-2H-1-benzopyrans. J Med Chem. 1990 Dec;33(12):3222-9. DMUHG0F RU https://pubmed.ncbi.nlm.nih.gov/2258908 DMUI81C DI DMUI81C DMUI81C DN AR-709 DMUI81C TI TTV8DM2 DMUI81C TN Bacterial Dihydrofolate reductase (Bact DHFR) DMUI81C MA Modulator DMUI81C RN Activity of the Diaminopyrimidine AR-709 against Recently Collected Multidrug-Resistant Isolates of Invasive Streptococcus pneumoniae from North America DMUI81C RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2258536 DMUID46 DI DMUID46 DMUID46 DN A-87049 DMUID46 TI TTFQEO5 DMUID46 TN Squalene synthetase (FDFT1) DMUID46 MA Inhibitor DMUID46 RN (1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent ... J Med Chem. 1997 Jul 4;40(14):2123-5. DMUID46 RU https://pubmed.ncbi.nlm.nih.gov/9216829 DMUIGM3 DI DMUIGM3 DMUIGM3 DN M-216765 DMUIGM3 TI TTSLI08 DMUIGM3 TN Adenosine receptor (ADOR) DMUIGM3 MA Modulator DMUIGM3 RN US patent application no. 2010,0009,934, Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders. DMUIGM3 RU http://www.google.com/patents/US20100009934 DMUJ94B DI DMUJ94B DMUJ94B DN A-68930 DMUJ94B TI TTZFYLI DMUJ94B TN Dopamine D1 receptor (D1R) DMUJ94B MA Modulator DMUJ94B RN Comparison of the D1-dopamine agonists SKF-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: behavioral effects and induction of c-fos-like immunoreactivity. J Pharmacol Exp Ther. 1992 Aug;262(2):855-65. DMUJ94B RU https://pubmed.ncbi.nlm.nih.gov/1354257 DMUJ94B DI DMUJ94B DMUJ94B DN A-68930 DMUJ94B TI TTEX248 DMUJ94B TN Dopamine D2 receptor (D2R) DMUJ94B MA Inhibitor DMUJ94B RN (1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50. DMUJ94B RU https://pubmed.ncbi.nlm.nih.gov/1977907 DMUK9L4 DI DMUK9L4 DMUK9L4 DN CI-1021 DMUK9L4 TI TTZPO1L DMUK9L4 TN Substance-P receptor (TACR1) DMUK9L4 MA Antagonist DMUK9L4 RN Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther. 2002 Nov;303(2):730-5. DMUK9L4 RU https://pubmed.ncbi.nlm.nih.gov/12388658 DMUL4VX DI DMUL4VX DMUL4VX DN SCH-44342 DMUL4VX TI TTXQKM3 DMUL4VX TN Farnesyl protein transferase (Ftase) DMUL4VX MA Inhibitor DMUL4VX RN Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships. J Med Chem. 1999 Jun 17;42(12):2125-35. DMUL4VX RU https://pubmed.ncbi.nlm.nih.gov/10377218 DMUL4VX DI DMUL4VX DMUL4VX DN SCH-44342 DMUL4VX TI TT7WZIJ DMUL4VX TN CAAX farnesyltransferase beta (FNTB) DMUL4VX MA Inhibitor DMUL4VX RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DMUL4VX RU https://pubmed.ncbi.nlm.nih.gov/9301658 DMUOPBF DI DMUOPBF DMUOPBF DN BILD-1263 DMUOPBF TI TTMJX4U DMUOPBF TN Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1) DMUOPBF MA Inhibitor DMUOPBF RN Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease. Antimicrob Agents Chemother. 1996 May;40(5):1078-84. DMUOPBF RU https://pubmed.ncbi.nlm.nih.gov/8723444 DMUPKYO DI DMUPKYO DMUPKYO DN CGS-13080 DMUPKYO TI TTKNWZ4 DMUPKYO TN Thromboxane-A synthase (TBXAS1) DMUPKYO MA Inhibitor DMUPKYO RN Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors. J Med Chem. 1985 Feb;28(2):164-70. DMUPKYO RU https://pubmed.ncbi.nlm.nih.gov/3918169 DMUR1FK DI DMUR1FK DMUR1FK DN Ecalcidene DMUR1FK TI TTK59TV DMUR1FK TN Vitamin D3 receptor (VDR) DMUR1FK MA Modulator DMUR1FK RN Degradation chemistry of a Vitamin D analogue (ecalcidene) investigated by HPLC-MS, HPLC-NMR and chemical derivatization. J Pharm Biomed Anal. 2006 Mar 3;40(4):850-63. DMUR1FK RU https://pubmed.ncbi.nlm.nih.gov/16242878 DMUY4FD DI DMUY4FD DMUY4FD DN RP-69698 DMUY4FD TI TTN53ZF DMUY4FD TN Leukotriene B4 receptor 1 (LTB4R) DMUY4FD MA Modulator DMUY4FD RN omega-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists. J Med Chem. 1992 Nov 13;35(23):4315-24. DMUY4FD RU https://pubmed.ncbi.nlm.nih.gov/1333012 DMV0QI1 DI DMV0QI1 DMV0QI1 DN E-5842 DMV0QI1 TI TT5TPI6 DMV0QI1 TN Opioid receptor sigma 1 (OPRS1) DMV0QI1 MA Binder DMV0QI1 RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMV0QI1 RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMV1J0P DI DMV1J0P DMV1J0P DN CI-999 DMV1J0P TI TTMF541 DMV1J0P TN Liver carboxylesterase (CES1) DMV1J0P MA Inhibitor DMV1J0P RN Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates. Bioorg Med Chem Lett. 1998 Feb 3;8(3):289-94. DMV1J0P RU https://pubmed.ncbi.nlm.nih.gov/9871672 DMV3B5Y DI DMV3B5Y DMV3B5Y DN BMS-189664 DMV3B5Y TI TT6L509 DMV3B5Y TN Coagulation factor IIa (F2) DMV3B5Y MA Inhibitor DMV3B5Y RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMV3B5Y RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMV5K0I DI DMV5K0I DMV5K0I DN BDF-9148 DMV5K0I TI TTRK8B9 DMV5K0I TN Sodium channel unspecific (NaC) DMV5K0I MA Modulator DMV5K0I RN The relaxing effect of BDF 9148 on the KCl-contracted aorta isolated from normo- and hyper-tensive rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Feb;357(2):126-32. DMV5K0I RU https://pubmed.ncbi.nlm.nih.gov/9521485 DMV785R DI DMV785R DMV785R DN L-696418 DMV785R TI TTUZ2L5 DMV785R TN Matrix metalloproteinase-3 (MMP-3) DMV785R MA Inhibitor DMV785R RN Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995). DMV785R RU http://www.sciencedirect.com/science/article/pii/0960894X95000799 DMV785R DI DMV785R DMV785R DN L-696418 DMV785R TI TTLM12X DMV785R TN Matrix metalloproteinase-2 (MMP-2) DMV785R MA Inhibitor DMV785R RN Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995). DMV785R RU http://www.sciencedirect.com/science/article/pii/0960894X95000799 DMV785R DI DMV785R DMV785R DN L-696418 DMV785R TI TTMX39J DMV785R TN Matrix metalloproteinase-1 (MMP-1) DMV785R MA Inhibitor DMV785R RN Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995). DMV785R RU http://www.sciencedirect.com/science/article/pii/0960894X95000799 DMV7JC6 DI DMV7JC6 DMV7JC6 DN GS-3435 DMV7JC6 TI TT50QJ3 DMV7JC6 TN Influenza Neuraminidase (Influ NA) DMV7JC6 MA Modulator DMV7JC6 RN US patent application no. 2010,0081,713, Compositions and methods for treating viral infections. DMV7JC6 RU http://www.google.com/patents/US20100081713 DMV8GUE DI DMV8GUE DMV8GUE DN UR-12460 DMV8GUE TI TTQL5VC DMV8GUE TN Platelet-activating factor receptor (PTAFR) DMV8GUE MA Modulator DMV8GUE RN Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis. Br J Pharmacol. 1995 Feb;114(4):895-901. DMV8GUE RU https://pubmed.ncbi.nlm.nih.gov/7539698 DMVAM18 DI DMVAM18 DMVAM18 DN Gene therapy, IFN-alpha DMVAM18 TI TT95SOA DMVAM18 TN Interferon alpha (IFNA) DMVAM18 MA Modulator DMVAM18 RN 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9. DMVAM18 RU https://pubmed.ncbi.nlm.nih.gov/18246607 DMVB0C3 DI DMVB0C3 DMVB0C3 DN Ro-25-4094 DMVB0C3 TI TTN53ZF DMVB0C3 TN Leukotriene B4 receptor 1 (LTB4R) DMVB0C3 MA Modulator DMVB0C3 RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005401) DMVB0C3 RU http://adisinsight.springer.com/drugs/800005401 DMVBNTP DI DMVBNTP DMVBNTP DN SB-209247 DMVBNTP TI TTN53ZF DMVBNTP TN Leukotriene B4 receptor 1 (LTB4R) DMVBNTP MA Antagonist DMVBNTP RN Formation and protein binding of the acyl glucuronide of a leukotriene B4 antagonist (SB-209247): relation to species differences in hepatotoxicity. Drug Metab Dispos. 2005 Feb;33(2):271-81. DMVBNTP RU https://pubmed.ncbi.nlm.nih.gov/15523047 DMVEXID DI DMVEXID DMVEXID DN PD-153103 DMVEXID TI TT5FNQT DMVEXID TN Human immunodeficiency virus Protease (HIV PR) DMVEXID MA Modulator DMVEXID RN US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases. DMVEXID RU http://www.google.com/patents/US20080161324 DMVGK24 DI DMVGK24 DMVGK24 DN SC-58451 DMVGK24 TI TTVKILB DMVGK24 TN Prostaglandin G/H synthase 2 (COX-2) DMVGK24 MA Inhibitor DMVGK24 RN Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors, Bioorg. Med. Chem. Lett. 6(22):2677-2682 (1996). DMVGK24 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600501X DMVGK24 DI DMVGK24 DMVGK24 DN SC-58451 DMVGK24 TI TT8NGED DMVGK24 TN Prostaglandin G/H synthase 1 (COX-1) DMVGK24 MA Inhibitor DMVGK24 RN Novel 1,2-diarylcyclobutenes: Selective and orally active cox-2 inhibitors, Bioorg. Med. Chem. Lett. 6(22):2677-2682 (1996). DMVGK24 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600501X DMVHTQI DI DMVHTQI DMVHTQI DN CDE-5498 DMVHTQI TI TTPLQO0 DMVHTQI TN Voltage-gated potassium channel Kv4.3 (KCND3) DMVHTQI MA Antagonist DMVHTQI RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020444) DMVHTQI RU http://adisinsight.springer.com/drugs/800020444 DMVK78Q DI DMVK78Q DMVK78Q DN Bepafant DMVK78Q TI TTQL5VC DMVK78Q TN Platelet-activating factor receptor (PTAFR) DMVK78Q MA Antagonist DMVK78Q RN Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther. 1990 Dec;255(3):962-8. DMVK78Q RU https://pubmed.ncbi.nlm.nih.gov/2262914 DMVO0LU DI DMVO0LU DMVO0LU DN 131I-81C6 DMVO0LU TI TTUCPMY DMVO0LU TN Tenascin (TNC) DMVO0LU RN Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502. DMVO0LU RU https://pubmed.ncbi.nlm.nih.gov/9796983 DMVP4E5 DI DMVP4E5 DMVP4E5 DN AZD6482 DMVP4E5 TI TTTHBCA DMVP4E5 TN PI3-kinase beta (PIK3CB) DMVP4E5 MA Modulator DMVP4E5 RN Human target validation of phosphoinositide 3-kinase (PI3K)beta: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kbeta inhibitor. J Thromb Haemost. 2012 Oct;10(10):2127-36. DMVP4E5 RU https://pubmed.ncbi.nlm.nih.gov/22906130 DMVPG1N DI DMVPG1N DMVPG1N DN OX-30 DMVPG1N TI TTUS45N DMVPG1N TN Leukocyte common antigen (PTPRC) DMVPG1N RN CD45 / PTPRC Antibody, Biotin conjugate (OX-30). DMVPG1N RU http://www.thermofisher.com/order/genome-database/details/antibody/MA5-17376.html DMVS6BN DI DMVS6BN DMVS6BN DN AGN-193080 DMVS6BN TI TTBRKXS DMVS6BN TN Adrenergic receptor alpha-1B (ADRA1B) DMVS6BN MA Inhibitor DMVS6BN RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMVS6BN RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMVS6BN DI DMVS6BN DMVS6BN DN AGN-193080 DMVS6BN TI TT34BHT DMVS6BN TN Adrenergic receptor alpha-1D (ADRA1D) DMVS6BN MA Inhibitor DMVS6BN RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMVS6BN RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMVS6BN DI DMVS6BN DMVS6BN DN AGN-193080 DMVS6BN TI TTNGILX DMVS6BN TN Adrenergic receptor alpha-1A (ADRA1A) DMVS6BN MA Inhibitor DMVS6BN RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMVS6BN RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMVUL4P DI DMVUL4P DMVUL4P DN CLX-0301 DMVUL4P TI TTJSQEF DMVUL4P TN Tyrosine-protein kinase (PTK) DMVUL4P MA Inhibitor DMVUL4P RN CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3. DMVUL4P RU https://pubmed.ncbi.nlm.nih.gov/11569941 DMVW3I9 DI DMVW3I9 DMVW3I9 DN RU 24969 DMVW3I9 TI TTWT5K7 DMVW3I9 TN 5-HT 1 receptor (5HT1R) DMVW3I9 MA Agonist DMVW3I9 RN Effect of chronic treatment with 5-HT1 agonist (8-OH-DPAT and RU 24969) and antagonist (isapirone) drugs on the behavioural responses of mice to 5-HT1 and 5-HT2 agonists. Br J Pharmacol. 1986 Oct;89(2):377-84. DMVW3I9 RU https://pubmed.ncbi.nlm.nih.gov/2946344 DMVWRU9 DI DMVWRU9 DMVWRU9 DN ZD-4190 DMVWRU9 TI TTVJ1D8 DMVWRU9 TN Vascular endothelial growth factor receptor (VEGFR) DMVWRU9 MA Modulator DMVWRU9 RN ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000 Feb 15;60(4):970-5. DMVWRU9 RU https://pubmed.ncbi.nlm.nih.gov/10706112 DMVWZN1 DI DMVWZN1 DMVWZN1 DN F-200 DMVWZN1 TI TTH4QIS DMVWZN1 TN Integrin alpha-5/beta-1 (ITGA5/B1) DMVWZN1 MA Inhibitor DMVWZN1 RN US patent application no. 8,541,413, Sustained release eye drop formulations. DMVWZN1 RU http://www.google.com/patents/US8541413 DMVXKMF DI DMVXKMF DMVXKMF DN L-732138 DMVXKMF TI TTZPO1L DMVXKMF TN Substance-P receptor (TACR1) DMVXKMF MA Inhibitor DMVXKMF RN The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43. DMVXKMF RU https://pubmed.ncbi.nlm.nih.gov/19762245 DMVXKMF DI DMVXKMF DMVXKMF DN L-732138 DMVXKMF TI TTYO0A3 DMVXKMF TN Substance-K receptor (TACR2) DMVXKMF MA Inhibitor DMVXKMF RN Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501. DMVXKMF RU https://pubmed.ncbi.nlm.nih.gov/20617791 DMVZSAM DI DMVZSAM DMVZSAM DN KRP-105 DMVZSAM TI TTJ584C DMVZSAM TN Peroxisome proliferator-activated receptor alpha (PPARA) DMVZSAM MA Agonist DMVZSAM RN Discovery of cyclic amine-substituted benzoic acids as PPARalpha agonists. Bioorg Med Chem Lett. 2012 Jan 1;22(1):334-8. DMVZSAM RU https://pubmed.ncbi.nlm.nih.gov/22133631 DMW210B DI DMW210B DMW210B DN Emopamil DMW210B TI TT5HONZ DMW210B TN Calcium channel unspecific (CaC) DMW210B MA Modulator DMW210B RN Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54. DMW210B RU https://pubmed.ncbi.nlm.nih.gov/8882635 DMW210B DI DMW210B DMW210B DN Emopamil DMW210B TI TTYSN63 DMW210B TN 5-HT 2 receptor (5HT2R) DMW210B MA Modulator DMW210B RN Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats. Br J Pharmacol. 1996 Mar;117(6):1348-54. DMW210B RU https://pubmed.ncbi.nlm.nih.gov/8882635 DMW2K1L DI DMW2K1L DMW2K1L DN LAS-31180 DMW2K1L TI TT06AWU DMW2K1L TN Phosphodiesterase 3A (PDE3A) DMW2K1L MA Modulator DMW2K1L RN Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6. DMW2K1L RU https://pubmed.ncbi.nlm.nih.gov/11148864 DMW39DV DI DMW39DV DMW39DV DN INCB3344 DMW39DV TI TTFZYTO DMW39DV TN C-C chemokine receptor type 2 (CCR2) DMW39DV MA Antagonist DMW39DV RN Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile. Bioorg Med Chem Lett. 2011 May 1;21(9):2626-30. DMW39DV RU https://pubmed.ncbi.nlm.nih.gov/21315584 DMW4UTB DI DMW4UTB DMW4UTB DN RhuCD40L DMW4UTB TI TTN6Y9A DMW4UTB TN CD40L receptor (CD40) DMW4UTB MA Binder DMW4UTB RN Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 2001 Oct 15;61(20):7556-62. DMW4UTB RU https://pubmed.ncbi.nlm.nih.gov/11606394 DMW5RNZ DI DMW5RNZ DMW5RNZ DN AMR-103 DMW5RNZ TI TTEX248 DMW5RNZ TN Dopamine D2 receptor (D2R) DMW5RNZ MA Agonist DMW5RNZ RN ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl). 2005 Dec;183(2):144-53. DMW5RNZ RU https://pubmed.ncbi.nlm.nih.gov/16220333 DMW68CE DI DMW68CE DMW68CE DN Oral insulin DMW68CE TI TTZOPHG DMW68CE TN Insulin (INS) DMW68CE MA Modulator DMW68CE RN ClinicalTrials.gov (NCT01120912) Safety and Efficacy of Single Administration of Oshadi Oral Insulin in Type I Diabetes Patients. U.S. National Institutes of Health. DMW68CE RU https://clinicaltrials.gov/ct2/show/NCT01120912 DMW9H4A DI DMW9H4A DMW9H4A DN SCH 50911 DMW9H4A TI TTDCVZW DMW9H4A TN Gamma-aminobutyric acid B receptor (GABBR) DMW9H4A MA Antagonist DMW9H4A RN Activation of nigral dopamine neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm. 1999;106(5-6):383-94. DMW9H4A RU https://pubmed.ncbi.nlm.nih.gov/10443545 DMWAKC8 DI DMWAKC8 DMWAKC8 DN BB-1433 DMWAKC8 TI TT1GHVO DMWAKC8 TN Matrix metalloproteinase (MMP) DMWAKC8 MA Inhibitor DMWAKC8 RN Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing. Inflamm Res. 1997 Jun;46(6):211-5. DMWAKC8 RU https://pubmed.ncbi.nlm.nih.gov/9243304 DMWCR1Z DI DMWCR1Z DMWCR1Z DN SU-740 DMWCR1Z TI TTH18TF DMWCR1Z TN Muscarinic acetylcholine receptor M5 (CHRM5) DMWCR1Z MA Modulator DMWCR1Z RN SU-840, a novel synthetic flavonoid derivative of sophoradin, with potent gastroprotective and ulcer healing activity. Journal of physiology and pharmacology. 49:1 1998 Mar pg 83-98 DMWCR1Z RU http://www.unboundmedicine.com/medline/citation/9594413/SU_840_a_novel_synthetic_flavonoid_derivative_of_sophoradin_with_potent_gastroprotective_and_ulcer_healing_activity_ DMWD1RC DI DMWD1RC DMWD1RC DN PBI-1101 DMWD1RC TI TT3NKIB DMWD1RC TN Pancreatic elastase 1 (CELA1) DMWD1RC MA Inhibitor DMWD1RC RN CN patent application no. 1813706, Use of elastic protease inhibitor for preparing medicine for protecting cerebral hemorrhage. DMWD1RC RU http://www.google.com/patents/CN1813706A?cl=en DMWDRI0 DI DMWDRI0 DMWDRI0 DN BMS-180560 DMWDRI0 TI TTGN1ZA DMWDRI0 TN Angiotensin II receptor (AGTR) DMWDRI0 MA Modulator DMWDRI0 RN BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br J Pharmacol. 1994 Sep;113(1):179-89. DMWDRI0 RU https://pubmed.ncbi.nlm.nih.gov/7812609 DMWFI4A DI DMWFI4A DMWFI4A DN CP-67015 DMWFI4A TI TTN6J5F DMWFI4A TN Bacterial DNA gyrase (Bact gyrase) DMWFI4A MA Modulator DMWFI4A RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. DMWFI4A RU https://www.fda.gov/ DMWI094 DI DMWI094 DMWI094 DN YM-43611 DMWI094 TI TT4C8EA DMWI094 TN Dopamine D3 receptor (D3R) DMWI094 MA Modulator DMWI094 RN Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 1997 Jul;17(1):27-33. DMWI094 RU https://www.ncbi.nlm.nih.gov/pubmed/9194047 DMWI094 DI DMWI094 DMWI094 DN YM-43611 DMWI094 TI TTE0A2F DMWI094 TN Dopamine D4 receptor (D4R) DMWI094 MA Modulator DMWI094 RN Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 1997 Jul;17(1):27-33. DMWI094 RU https://www.ncbi.nlm.nih.gov/pubmed/9194047 DMWIAUK DI DMWIAUK DMWIAUK DN ReN-1820 DMWIAUK TI TTEDJN4 DMWIAUK TN Low-affinity nerve growth factor receptor (NGFR) DMWIAUK MA Inhibitor DMWIAUK RN Phosphorylation of Extracellular Signal-Regulated Kinases (pERK1/2) in Bladder Afferent Pathways with Cyclophosphamide (CYP)-Induced Cystitis. Neuroscience. 2009 November 10; 163(4): 1353-1362. DMWIAUK RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2760658/ DMWL4MI DI DMWL4MI DMWL4MI DN SSR-69071 DMWL4MI TI TT3NKIB DMWL4MI TN Pancreatic elastase 1 (CELA1) DMWL4MI MA Inhibitor DMWL4MI RN Pivotal role for alpha1-antichymotrypsin in skin repair. J Biol Chem. 2011 Aug 19;286(33):28889-901. DMWL4MI RU https://pubmed.ncbi.nlm.nih.gov/21693707 DMWNMYS DI DMWNMYS DMWNMYS DN ALB-127158(a) DMWNMYS TI TTX4RTB DMWNMYS TN Melanin-concentrating hormone receptor 1 (MCHR1) DMWNMYS MA Antagonist DMWNMYS RN Clinical pipeline report, company report or official report of Albany Molecular Research (2011). DMWNMYS RU http://www.amriglobal.com/ DMWO107 DI DMWO107 DMWO107 DN SC-51895 DMWO107 TI TTQVOEI DMWO107 TN Angiotensin II receptor type-2 (AGTR2) DMWO107 MA Inhibitor DMWO107 RN N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993). DMWO107 RU http://www.sciencedirect.com/science/article/pii/S0960894X00802863 DMWQ38G DI DMWQ38G DMWQ38G DN ZM-241385 DMWQ38G TI TTK25J1 DMWQ38G TN Adenosine A1 receptor (ADORA1) DMWQ38G MA Inhibitor DMWQ38G RN 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52. DMWQ38G RU https://pubmed.ncbi.nlm.nih.gov/19743865 DMWQ38G DI DMWQ38G DMWQ38G DN ZM-241385 DMWQ38G TI TTNE7KG DMWQ38G TN Adenosine A2b receptor (ADORA2B) DMWQ38G MA Inhibitor DMWQ38G RN Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors. Bioorg Med Chem. 2010 Mar 15;18(6):2081-2088. DMWQ38G RU https://pubmed.ncbi.nlm.nih.gov/20202853 DMWQ38G DI DMWQ38G DMWQ38G DN ZM-241385 DMWQ38G TI TTM2AOE DMWQ38G TN Adenosine A2a receptor (ADORA2A) DMWQ38G MA Inhibitor DMWQ38G RN 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52. DMWQ38G RU https://pubmed.ncbi.nlm.nih.gov/19743865 DMWRSXK DI DMWRSXK DMWRSXK DN Epocarbazolin-A DMWRSXK TI TT2J34L DMWRSXK TN Arachidonate 5-lipoxygenase (5-LOX) DMWRSXK MA Inhibitor DMWRSXK RN Epocarbazolins A and B, novel 5-lipoxygenase inhibitors. Taxonomy, fermentation, isolation, structures and biological activities. J Antibiot (Tokyo). 1993 Jan;46(1):25-33. DMWRSXK RU https://pubmed.ncbi.nlm.nih.gov/8436556 DMWTFO3 DI DMWTFO3 DMWTFO3 DN IMAZODAN DMWTFO3 TI TTJ0IQB DMWTFO3 TN Phosphodiesterase 5A (PDE5A) DMWTFO3 MA Inhibitor DMWTFO3 RN Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of conges... J Med Chem. 1984 Sep;27(9):1099-101. DMWTFO3 RU https://pubmed.ncbi.nlm.nih.gov/6471063 DMWTFO3 DI DMWTFO3 DMWTFO3 DN IMAZODAN DMWTFO3 TI TTJGW1Z DMWTFO3 TN Phosphodiesterase 2A (PDE2A) DMWTFO3 MA Inhibitor DMWTFO3 RN Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of conges... J Med Chem. 1984 Sep;27(9):1099-101. DMWTFO3 RU https://pubmed.ncbi.nlm.nih.gov/6471063 DMWTFO3 DI DMWTFO3 DMWTFO3 DN IMAZODAN DMWTFO3 TI TT06AWU DMWTFO3 TN Phosphodiesterase 3A (PDE3A) DMWTFO3 MA Inhibitor DMWTFO3 RN 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8. DMWTFO3 RU https://pubmed.ncbi.nlm.nih.gov/1311763 DMWUOA8 DI DMWUOA8 DMWUOA8 DN PSI-6130 DMWUOA8 TI TTMVBWH DMWUOA8 TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMWUOA8 MA Inhibitor DMWUOA8 RN An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem. 2009 Sep 4;74(17):6819-24. DMWUOA8 RU https://pubmed.ncbi.nlm.nih.gov/19642660 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TTO0FDJ DMWYP86 TN Cyclin-dependent kinase 6 (CDK6) DMWYP86 MA Inhibitor DMWYP86 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TT0PG8F DMWYP86 TN Cyclin-dependent kinase 4 (CDK4) DMWYP86 MA Inhibitor DMWYP86 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TT7HF4W DMWYP86 TN Cyclin-dependent kinase 2 (CDK2) DMWYP86 MA Inhibitor DMWYP86 RN Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/11101352 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TTAMQ62 DMWYP86 TN Cyclin A2 (CCNA2) DMWYP86 MA Inhibitor DMWYP86 RN Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/11101352 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TTRLW2X DMWYP86 TN Fibroblast growth factor receptor 1 (FGFR1) DMWYP86 MA Inhibitor DMWYP86 RN Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/11101352 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TTCEJ4F DMWYP86 TN G1/S-specific cyclin-E1 (CCNE1) DMWYP86 MA Inhibitor DMWYP86 RN Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/11101352 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TT1KX2S DMWYP86 TN FGFR4 messenger RNA (FGFR4 mRNA) DMWYP86 MA Inhibitor DMWYP86 RN Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/11101352 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TTST7KB DMWYP86 TN Fibroblast growth factor receptor 3 (FGFR3) DMWYP86 MA Inhibitor DMWYP86 RN Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/11101352 DMWYP86 DI DMWYP86 DMWYP86 DN PD-0183812 DMWYP86 TI TTGJVQM DMWYP86 TN Fibroblast growth factor receptor 2 (FGFR2) DMWYP86 MA Inhibitor DMWYP86 RN Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16. DMWYP86 RU https://pubmed.ncbi.nlm.nih.gov/11101352 DMX0N9P DI DMX0N9P DMX0N9P DN Ginkgolide B (GKB) DMX0N9P TI TTPTXIN DMX0N9P TN Translocator protein (TSPO) DMX0N9P MA Suppressor DMX0N9P RN Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells. Anticancer Res. 2000 Sep-Oct;20(5A):2835-47. DMX0N9P RU https://pubmed.ncbi.nlm.nih.gov/11062691 DMX0PTO DI DMX0PTO DMX0PTO DN XR-368 DMX0PTO TI TTNJYV2 DMX0PTO TN Gamma-aminobutyric acid receptor (GAR) DMX0PTO MA Modulator DMX0PTO RN Regulation of neuronal and recombinant GABA(A) receptor ion channels by xenovulene A, a natural product isolated from Acremonium strictum. J Pharmacol Exp Ther. 1997 Aug;282(2):513-20. DMX0PTO RU https://pubmed.ncbi.nlm.nih.gov/9262310 DMX4E75 DI DMX4E75 DMX4E75 DN RP-66153 DMX4E75 TI TTN53ZF DMX4E75 TN Leukotriene B4 receptor 1 (LTB4R) DMX4E75 MA Modulator DMX4E75 RN Omega-[(omega-arylalkyl)thienyl]alkanoic acids: from specific LTA4 hydrolase inhibitors to LTB4 receptor antagonists. J Med Chem. 1992 Aug 21;35(17):3170-9. DMX4E75 RU https://pubmed.ncbi.nlm.nih.gov/1324316 DMX4KIT DI DMX4KIT DMX4KIT DN Draculin DMX4KIT TI TTCIHJA DMX4KIT TN Coagulation factor Xa (F10) DMX4KIT MA Modulator DMX4KIT RN Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochim Biophys Acta. 1998 Oct 23;1425(2):291-9. DMX4KIT RU https://pubmed.ncbi.nlm.nih.gov/9795244 DMX4KIT DI DMX4KIT DMX4KIT DN Draculin DMX4KIT TI TTFEZ5Q DMX4KIT TN Coagulation factor IX (F9) DMX4KIT MA Modulator DMX4KIT RN Expression of biological activity of draculin, the anticoagulant factor from vampire bat saliva, is strictly dependent on the appropriate glycosylation of the native molecule. Biochim Biophys Acta. 1998 Oct 23;1425(2):291-9. DMX4KIT RU https://pubmed.ncbi.nlm.nih.gov/9795244 DMX5K4C DI DMX5K4C DMX5K4C DN 7-methoxytacrine DMX5K4C TI TT1RS9F DMX5K4C TN Acetylcholinesterase (AChE) DMX5K4C MA Inhibitor DMX5K4C RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMX5K4C RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMX5SN8 DI DMX5SN8 DMX5SN8 DN Du-123015 DMX5SN8 TI TTSQIFT DMX5SN8 TN 5-HT 1A receptor (HTR1A) DMX5SN8 MA Modulator DMX5SN8 RN Neither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT1A agonist in rat models of ischaemic stroke. BMC Neuroscience 2009, 10:82. DMX5SN8 RU http://www.biomedcentral.com/1471-2202/10/82 DMX6DNZ DI DMX6DNZ DMX6DNZ DN NMI-150 DMX6DNZ TI TTVKILB DMX6DNZ TN Prostaglandin G/H synthase 2 (COX-2) DMX6DNZ MA Inhibitor DMX6DNZ RN Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res. 2011 Autumn; 10(4): 655-683. DMX6DNZ RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813081/ DMXB8SE DI DMXB8SE DMXB8SE DN F-3796 DMXB8SE TI TT1RS9F DMXB8SE TN Acetylcholinesterase (AChE) DMXB8SE MA Inhibitor DMXB8SE RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004498) DMXB8SE RU http://adisinsight.springer.com/drugs/800004498 DMXBJCY DI DMXBJCY DMXBJCY DN Sch-40120 DMXBJCY TI TT2J34L DMXBJCY TN Arachidonate 5-lipoxygenase (5-LOX) DMXBJCY MA Modulator DMXBJCY RN Actions of a 5-lipoxygenase inhibitor, Sch 40120, on acute inflammatory responses. J Pharmacol Exp Ther. 1992 Aug;262(2):721-8. DMXBJCY RU https://pubmed.ncbi.nlm.nih.gov/1386887 DMXERCA DI DMXERCA DMXERCA DN MS-377 DMXERCA TI TT5TPI6 DMXERCA TN Opioid receptor sigma 1 (OPRS1) DMXERCA MA Antagonist DMXERCA RN The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. DMXERCA RU https://pubmed.ncbi.nlm.nih.gov/17667958 DMXFZWJ DI DMXFZWJ DMXFZWJ DN BW 373U86 DMXFZWJ TI TT27RFC DMXFZWJ TN Opioid receptor delta (OPRD1) DMXFZWJ MA Agonist DMXFZWJ RN BW373U86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol. 2001 Aug;33(8):1455-65. DMXFZWJ RU https://pubmed.ncbi.nlm.nih.gov/11448134 DMXH3A2 DI DMXH3A2 DMXH3A2 DN Benafentrine dimaleate DMXH3A2 TI TTZCG4L DMXH3A2 TN Phosphodiesterase 3 (PDE3) DMXH3A2 MA Modulator DMXH3A2 RN Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways. Jpn J Pharmacol. 1995 Feb;67(2):149-56. DMXH3A2 RU https://pubmed.ncbi.nlm.nih.gov/7542355 DMXHN6U DI DMXHN6U DMXHN6U DN D-5410 DMXHN6U TI TT1GHVO DMXHN6U TN Matrix metalloproteinase (MMP) DMXHN6U MA Modulator DMXHN6U RN US patent application no. US20080187572 A1. DMXHN6U RU https://www.google.com.ar/patents/US20080187572 DMXHW91 DI DMXHW91 DMXHW91 DN SDZ-SER-082 DMXHW91 TI TTWJBZ5 DMXHW91 TN 5-HT 2C receptor (HTR2C) DMXHW91 MA Modulator DMXHW91 RN Effect of the activation of central 5-HT2C receptors by the 5-HT2C agonist mCPP on blood pressure and heart rate in rats. Brain Res. 2005 Apr 8;1040(1-2):64-72. DMXHW91 RU https://www.ncbi.nlm.nih.gov/pubmed/15804427 DMXI185 DI DMXI185 DMXI185 DN Anti-IFN gamma DMXI185 TI TTG043C DMXI185 TN Tumor necrosis factor receptor type I (TNF-R1) DMXI185 RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DMXI185 RU https://pubmed.ncbi.nlm.nih.gov/15507622 DMXI39O DI DMXI39O DMXI39O DN XR-3054 DMXI39O TI TT7WZIJ DMXI39O TN CAAX farnesyltransferase beta (FNTB) DMXI39O MA Inhibitor DMXI39O RN XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase. Eur J Cancer. 1999 Jun;35(6):1014-9. DMXI39O RU https://pubmed.ncbi.nlm.nih.gov/10533487 DMXIH3Q DI DMXIH3Q DMXIH3Q DN BIBW-22 DMXIH3Q TI TTHQENC DMXIH3Q TN Phosphodiesterase 1 (PDE1) DMXIH3Q MA Inhibitor DMXIH3Q RN BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells. Mol Pharmacol. 1996 Sep;50(3):482-92. DMXIH3Q RU https://pubmed.ncbi.nlm.nih.gov/8794885 DMXK4CI DI DMXK4CI DMXK4CI DN Albupoietin DMXK4CI TI TTAUX24 DMXK4CI TN Erythropoietin Receptor (EPOR) DMXK4CI MA Modulator DMXK4CI RN Clinical pipeline report, company report or official report of cogenesys. DMXK4CI RU http://cogenesys.com/Collaboration.asp DMXKMRV DI DMXKMRV DMXKMRV DN NS-649 DMXKMRV TI TT5HONZ DMXKMRV TN Calcium channel unspecific (CaC) DMXKMRV MA Modulator DMXKMRV RN Effects of Ca2+ and Na+ channel inhibitors in vitro and in global cerebral ischaemia in vivo. Eur J Pharmacol. 1997 Aug 6;332(2):121-31. DMXKMRV RU https://pubmed.ncbi.nlm.nih.gov/9286613 DMXKZDU DI DMXKZDU DMXKZDU DN Antova DMXKZDU TI TTIJP3Q DMXKZDU TN TNF related activation protein (CD40LG) DMXKZDU MA Modulator DMXKZDU RN CD40 and Autoimmunity: The Dark Side of a Great Activator DMXKZDU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753170 DMXLB02 DI DMXLB02 DMXLB02 DN ACEA-2085 DMXLB02 TI TTAN6JD DMXLB02 TN Glutamate receptor AMPA (GRIA) DMXLB02 MA Antagonist DMXLB02 RN Interaction among NMDA receptor-, NMDA glycine site- and AMPA receptor antagonists in spinally mediated analgesia. Can J Anaesth. 2000 Jul;47(7):693-8. DMXLB02 RU https://pubmed.ncbi.nlm.nih.gov/10930211 DMXLCB6 DI DMXLCB6 DMXLCB6 DN MCI-826 DMXLCB6 TI TTGKOY9 DMXLCB6 TN Leukotriene CysLT1 receptor (CYSLTR1) DMXLCB6 MA Antagonist DMXLCB6 RN Leukotriene receptors in the skin of rats differ from those of mouse skin or rat stomach strip. Eur J Pharmacol. 1992 Oct 20;221(2-3):333-42. DMXLCB6 RU https://pubmed.ncbi.nlm.nih.gov/1330627 DMXLJBA DI DMXLJBA DMXLJBA DN AP-23588 DMXLJBA TI TTJSQEF DMXLJBA TN Tyrosine-protein kinase (PTK) DMXLJBA MA Inhibitor DMXLJBA RN Foye's Principles of Medicinal Chemistry, Thomas L. Lemke, David A. Williams. 2008. Page(950). DMXLJBA RU https://books.google.com.hk/books?id=R0W1ErpsQpkC&pg=PA950&lpg=PA950&dq=%22AP-23588%22++Protein+tyrosine+kinase&source=bl&ots=oCPoj5ZYqs&sig=4H-SJKuzkNOCopt3dSUJP3i2EEA&hl=zh-CN&sa=X&ved=0CCEQ6AEwAWoVChMIv4zt6NC_yAIVEHCOCh3qywXw#v=onepage&q=%22AP-23588%22%20%20Protein%20tyrosine%20kinase&f=false DMXM3B4 DI DMXM3B4 DMXM3B4 DN TEI-9874 DMXM3B4 TI TTYJQTF DMXM3B4 TN Immunoglobulin E (IgE) DMXM3B4 MA Modulator DMXM3B4 RN Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95. DMXM3B4 RU https://pubmed.ncbi.nlm.nih.gov/10958896 DMXMP3D DI DMXMP3D DMXMP3D DN Ro-48-1220 DMXMP3D TI TTHI19T DMXMP3D TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMXMP3D MA Modulator DMXMP3D RN Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam beta-lactamase inhibitor. Clin Microbiol Infect. 1995 Feb;1(2):86-100. DMXMP3D RU https://pubmed.ncbi.nlm.nih.gov/11866735 DMXR3V1 DI DMXR3V1 DMXR3V1 DN DNP-004089 DMXR3V1 TI TT8JRS7 DMXR3V1 TN Beta-secretase (BACE) DMXR3V1 MA Inhibitor DMXR3V1 RN US patent application no. 8,269,019, Inhibitors. DMXR3V1 RU http://www.google.co.in/patents/US8269019?cl=pt-PT DMXRJQV DI DMXRJQV DMXRJQV DN Luzindole DMXRJQV TI TT0WAIE DMXRJQV TN Melatonin receptor type 1A (MTNR1A) DMXRJQV MA Modulator DMXRJQV RN Luzindole (N-0774): a novel melatonin receptor antagonist. J Pharmacol Exp Ther. 1988 Sep;246(3):902-10. DMXRJQV RU https://pubmed.ncbi.nlm.nih.gov/2843633 DMXRQS6 DI DMXRQS6 DMXRQS6 DN AMG-8562 DMXRQS6 TI TTMI6F5 DMXRQS6 TN Transient receptor potential cation channel V1 (TRPV1) DMXRQS6 MA Blocker DMXRQS6 RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMXRQS6 RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMXRTFM DI DMXRTFM DMXRTFM DN Ber-H2/saporin DMXRTFM TI TT2GM5R DMXRTFM TN Lymphocyte activation antigen CD30 (TNFRSF8) DMXRTFM RN Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma. Blood. 1995 Apr15;85(8):2139-46. DMXRTFM RU https://pubmed.ncbi.nlm.nih.gov/7718885 DMXRU72 DI DMXRU72 DMXRU72 DN SEP-227900 DMXRU72 TI TT7Y3EJ DMXRU72 TN D-amino acid oxidase (DAO) DMXRU72 MA Inhibitor DMXRU72 RN The Therapeutic Potential of D-Amino Acid Oxidase (DAAO) Inhibitors. Open Med Chem J. 2010; 4: 3-9. DMXRU72 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905773/ DMXT2SL DI DMXT2SL DMXT2SL DN KRG-3332 DMXT2SL TI TTNGILX DMXT2SL TN Adrenergic receptor alpha-1A (ADRA1A) DMXT2SL MA Antagonist DMXT2SL RN The beta-adrenoceptor. Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 3):S146-53. DMXT2SL RU https://pubmed.ncbi.nlm.nih.gov/9817738 DMXVP13 DI DMXVP13 DMXVP13 DN GI-129471 DMXVP13 TI TT1GHVO DMXVP13 TN Matrix metalloproteinase (MMP) DMXVP13 MA Modulator DMXVP13 RN Stimulation of matrix metalloproteinase-9 expression in human fibrosarcoma cells by synthetic matrix metalloproteinase inhibitors. Exp Cell Res. 2002 Apr 15;275(1):110-21. DMXVP13 RU https://pubmed.ncbi.nlm.nih.gov/11925109 DMXW67H DI DMXW67H DMXW67H DN MX-6120 DMXW67H TI TTKRD0G DMXW67H TN Endothelin A receptor (EDNRA) DMXW67H MA Antagonist DMXW67H RN Endothelin receptor antagonists in heart failure: current status and future directions. Drugs. 2004;64(10):1029-40. DMXW67H RU https://pubmed.ncbi.nlm.nih.gov/15139784 DMXWG6Z DI DMXWG6Z DMXWG6Z DN A-798 DMXWG6Z TI TTX4RTB DMXWG6Z TN Melanin-concentrating hormone receptor 1 (MCHR1) DMXWG6Z MA Antagonist DMXWG6Z RN Disruption of the melanin-concentrating hormone receptor 1 (MCH1R) affects thyroid function. Endocrinology. 2012 Dec;153(12):6145-54. DMXWG6Z RU https://pubmed.ncbi.nlm.nih.gov/23024261 DMXWL0N DI DMXWL0N DMXWL0N DN FR-133605 DMXWL0N TI TTF8CQI DMXWL0N TN Tumor necrosis factor (TNF) DMXWL0N MA Modulator DMXWL0N RN Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol. 1996 Oct;23(10):1778-83. DMXWL0N RU https://pubmed.ncbi.nlm.nih.gov/8895158 DMXWL0N DI DMXWL0N DMXWL0N DN FR-133605 DMXWL0N TI TT51DEV DMXWL0N TN Interleukin 1 receptor type 2 (IL1R2) DMXWL0N MA Modulator DMXWL0N RN Effect of FR133605, a novel cytokine suppressive agent, on bone and cartilage destruction in adjuvant arthritic rats. J Rheumatol. 1996 Oct;23(10):1778-83. DMXWL0N RU https://pubmed.ncbi.nlm.nih.gov/8895158 DMXY5AV DI DMXY5AV DMXY5AV DN AH-9700 DMXY5AV TI TT5TPI6 DMXY5AV TN Opioid receptor sigma 1 (OPRS1) DMXY5AV MA Modulator DMXY5AV RN Pharmacological actions of AH-9700 on micturition reflex in anesthetized rats. Eur J Pharmacol. 2001 Jan 26;412(2):171-9. DMXY5AV RU https://pubmed.ncbi.nlm.nih.gov/11165228 DMXYDJR DI DMXYDJR DMXYDJR DN LXR-015-2 DMXYDJR TI TTC8M31 DMXYDJR TN Carnitine acyltransferase (CRAT) DMXYDJR MA Inhibitor DMXYDJR RN EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury. Brain Res. 2006 Nov 6;1118(1):168-75. DMXYDJR RU https://pubmed.ncbi.nlm.nih.gov/17026968 DMXZNB2 DI DMXZNB2 DMXZNB2 DN KNI-102 DMXZNB2 TI TT5FNQT DMXZNB2 TN Human immunodeficiency virus Protease (HIV PR) DMXZNB2 MA Modulator DMXZNB2 RN KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. Chem Pharm Bull (Tokyo). 1991 Nov;39(11):3088-90. DMXZNB2 RU https://pubmed.ncbi.nlm.nih.gov/1799953 DMY0V6J DI DMY0V6J DMY0V6J DN VG-106 DMY0V6J TI TTXM6JN DMY0V6J TN Cytokine receptor unspecific (CRF) DMY0V6J MA Modulator DMY0V6J RN WO patent application no. 2011,0955,45, Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same. DMY0V6J RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110811&CC=WO&NR=2011095545A1&KC=A1 DMY1KE8 DI DMY1KE8 DMY1KE8 DN SDZ-224-015 DMY1KE8 TI TTCQIBE DMY1KE8 TN Caspase-1 (CASP1) DMY1KE8 MA Modulator DMY1KE8 RN Reduction of inflammation and pyrexia in the rat by oral administration of SDZ 224-015, an inhibitor of the interleukin-1 beta converting enzyme. Br J Pharmacol. 1995 Jun;115(4):601-6. DMY1KE8 RU https://pubmed.ncbi.nlm.nih.gov/7582478 DMY1LRI DI DMY1LRI DMY1LRI DN FR-172357 DMY1LRI TI TTGY8IW DMY1LRI TN B2 bradykinin receptor (BDKRB2) DMY1LRI MA Antagonist DMY1LRI RN Characterization of FR 172357, a new non-peptide bradykinin B(2) receptor antagonist, in human, pig and rabbit preparations. Eur J Pharmacol. 1999 Dec 10;386(1):25-31. DMY1LRI RU https://pubmed.ncbi.nlm.nih.gov/10611460 DMY1TLZ DI DMY1TLZ DMY1TLZ DN Baicalin DMY1TLZ TI TTNGKET DMY1TLZ TN Prolyl endopeptidase (PREP) DMY1TLZ MA Inhibitor DMY1TLZ RN Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38. DMY1TLZ RU https://pubmed.ncbi.nlm.nih.gov/20058865 DMY2IB8 DI DMY2IB8 DMY2IB8 DN FR-115427 DMY2IB8 TI TT9IK2Z DMY2IB8 TN N-methyl-D-aspartate receptor (NMDAR) DMY2IB8 MA Modulator DMY2IB8 RN Non-competitive NMDA antagonists, FR115427 and MK801, enhance neuronal survival in primary culture. Neurosci Lett. 1995 Feb 9;185(2):107-10. DMY2IB8 RU https://pubmed.ncbi.nlm.nih.gov/7746498 DMY3BMC DI DMY3BMC DMY3BMC DN IPH-3102 DMY3BMC TI TTD24Y0 DMY3BMC TN Toll-like receptor 3 (TLR3) DMY3BMC MA Agonist DMY3BMC RN Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716. DMY3BMC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429574/ DMY3LXH DI DMY3LXH DMY3LXH DN Org-37684 DMY3LXH TI TTWJBZ5 DMY3LXH TN 5-HT 2C receptor (HTR2C) DMY3LXH MA Agonist DMY3LXH RN Role of 5-hT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):441-9. DMY3LXH RU https://pubmed.ncbi.nlm.nih.gov/11999893 DMY71LJ DI DMY71LJ DMY71LJ DN LY53857 DMY71LJ TI TTWJBZ5 DMY71LJ TN 5-HT 2C receptor (HTR2C) DMY71LJ MA Antagonist DMY71LJ RN The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticostero... J Pharmacol Exp Ther. 2007 May;321(2):485-91. DMY71LJ RU https://pubmed.ncbi.nlm.nih.gov/17289838 DMY71LJ DI DMY71LJ DMY71LJ DN LY53857 DMY71LJ TI TT0K1SC DMY71LJ TN 5-HT 2B receptor (HTR2B) DMY71LJ MA Antagonist DMY71LJ RN p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90. DMY71LJ RU https://pubmed.ncbi.nlm.nih.gov/9832390 DMY71LJ DI DMY71LJ DMY71LJ DN LY53857 DMY71LJ TI TTJQOD7 DMY71LJ TN 5-HT 2A receptor (HTR2A) DMY71LJ MA Antagonist DMY71LJ RN The 5-hydroxytryptamine2A receptor is involved in (+)-norfenfluramine-induced arterial contraction and blood pressure increase in deoxycorticostero... J Pharmacol Exp Ther. 2007 May;321(2):485-91. DMY71LJ RU https://pubmed.ncbi.nlm.nih.gov/17289838 DMY7KHW DI DMY7KHW DMY7KHW DN SC-49992 DMY7KHW TI TT38RM1 DMY7KHW TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMY7KHW MA Modulator DMY7KHW RN SC-49992--a potent and specific inhibitor of platelet aggregation. Thromb Res. 1994 Jun 1;74(5):523-35. DMY7KHW RU https://www.ncbi.nlm.nih.gov/pubmed/8085253 DMY7ZRA DI DMY7ZRA DMY7ZRA DN BMS-605339 DMY7ZRA TI TTWXB3E DMY7ZRA TN Hepatitis C virus NS3 helicase (HCV NS3) DMY7ZRA MA Inhibitor DMY7ZRA RN Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem.2014 Mar 13;57(5):1708-29. DMY7ZRA RU https://pubmed.ncbi.nlm.nih.gov/24555570 DMY9NG1 DI DMY9NG1 DMY9NG1 DN WEB-2347 DMY9NG1 TI TTQL5VC DMY9NG1 TN Platelet-activating factor receptor (PTAFR) DMY9NG1 MA Modulator DMY9NG1 RN WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs. J Lipid Mediat. 1991 Jul-Aug;4(1):39-44. DMY9NG1 RU https://pubmed.ncbi.nlm.nih.gov/1893086 DMY9UEZ DI DMY9UEZ DMY9UEZ DN UC-84 DMY9UEZ TI TT84ETX DMY9UEZ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMY9UEZ MA Modulator DMY9UEZ RN Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 1998 Oct 13;37(41):14394-403. DMY9UEZ RU https://pubmed.ncbi.nlm.nih.gov/9772165 DMYAMP5 DI DMYAMP5 DMYAMP5 DN EHT-1864 DMYAMP5 TI TT2M9CG DMYAMP5 TN Ras-related C3 botulinum toxin substrate 1 (RAC1) DMYAMP5 MA Inhibitor DMYAMP5 RN Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J Biol Chem. 2007 Dec 7;282(49):35666-78. DMYAMP5 RU https://pubmed.ncbi.nlm.nih.gov/17932039 DMYB5RV DI DMYB5RV DMYB5RV DN L-163017 DMYB5RV TI TTGN1ZA DMYB5RV TN Angiotensin II receptor (AGTR) DMYB5RV MA Modulator DMYB5RV RN In vivo pharmacology of an angiotensin AT1 receptor antagonist with balanced affinity for AT2 receptors. Eur J Pharmacol. 1995 Dec 29;294(2-3):439-50. DMYB5RV RU https://pubmed.ncbi.nlm.nih.gov/8750704 DMYBR9D DI DMYBR9D DMYBR9D DN BIBP 3226 DMYBR9D TI TTRK9JT DMYBR9D TN Neuropeptide Y receptor type 1 (NPY1R) DMYBR9D MA Antagonist DMYBR9D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305). DMYBR9D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=305 DMYCPFU DI DMYCPFU DMYCPFU DN IQM-95333 DMYCPFU TI TTVFO0U DMYCPFU TN Gastrin/cholecystokinin type B receptor (CCKBR) DMYCPFU MA Inhibitor DMYCPFU RN Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7. DMYCPFU RU https://pubmed.ncbi.nlm.nih.gov/9341915 DMYCPFU DI DMYCPFU DMYCPFU DN IQM-95333 DMYCPFU TI TTCG0AL DMYCPFU TN Cholecystokinin receptor type A (CCKAR) DMYCPFU MA Inhibitor DMYCPFU RN Synthesis and stereochemical structure-activity relationships of 1,3-dioxoperhydropyrido[1,2-c]pyrimidine derivatives: potent and selective cholecy... J Med Chem. 1997 Oct 10;40(21):3402-7. DMYCPFU RU https://pubmed.ncbi.nlm.nih.gov/9341915 DMYD04O DI DMYD04O DMYD04O DN APF-580 DMYD04O TI TTN4QDT DMYD04O TN Opioid receptor (OPR) DMYD04O MA Modulator DMYD04O RN WO patent application no. 2010,0094,51, Long-acting injectable analgesic formulations for animals. DMYD04O RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20100121&CC=WO&NR=2010009451A2&KC=A2 DMYFE23 DI DMYFE23 DMYFE23 DN SB-206343 DMYFE23 TI TT5FNQT DMYFE23 TN Human immunodeficiency virus Protease (HIV PR) DMYFE23 MA Modulator DMYFE23 RN Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere. J Med Chem. 1994 Sep 16;37(19):3100-7. DMYFE23 RU https://pubmed.ncbi.nlm.nih.gov/7932533 DMYGJCL DI DMYGJCL DMYGJCL DN LB30057 DMYGJCL TI TT6L509 DMYGJCL TN Coagulation factor IIa (F2) DMYGJCL MA Inhibitor DMYGJCL RN Antithrombotic activity of LB30057, a newly synthesized direct thrombin inhibitor. Thromb Haemost. 2003 Jan;89(1):104-11. DMYGJCL RU https://pubmed.ncbi.nlm.nih.gov/12540960 DMYIPLH DI DMYIPLH DMYIPLH DN AMG-548 DMYIPLH TI TTWELHI DMYIPLH TN Stress-activated protein kinase (p38) DMYIPLH MA Inhibitor DMYIPLH RN p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel. 2005 Jul;8(4):421-30. DMYIPLH RU https://pubmed.ncbi.nlm.nih.gov/16022178 DMYJMV9 DI DMYJMV9 DMYJMV9 DN ABT-702 DMYJMV9 TI TTL732K DMYJMV9 TN Adenosine kinase (ADK) DMYJMV9 MA Inhibitor DMYJMV9 RN ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93(2-3):78-88. DMYJMV9 RU https://pubmed.ncbi.nlm.nih.gov/23770229 DMYK31O DI DMYK31O DMYK31O DN MDL-28170 DMYK31O TI TTG5QB7 DMYK31O TN Calpain-2 (CAPN2) DMYK31O MA Inhibitor DMYK31O RN Synthesis of a small library of diketopiperazines as potential inhibitors of calpain. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3034-8. DMYK31O RU https://pubmed.ncbi.nlm.nih.gov/15896956 DMYML2N DI DMYML2N DMYML2N DN CL-186659 DMYML2N TI TTHI19T DMYML2N TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMYML2N MA Modulator DMYML2N RN US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes. DMYML2N RU http://www.google.com/patents/US20040023290 DMYN3WG DI DMYN3WG DMYN3WG DN ICI-164384 DMYN3WG TI TTZAYWL DMYN3WG TN Estrogen receptor (ESR) DMYN3WG MA Inhibitor DMYN3WG RN Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem. 1991 May;34(5):1624-30. DMYN3WG RU https://pubmed.ncbi.nlm.nih.gov/2033587 DMYN3WG DI DMYN3WG DMYN3WG DN ICI-164384 DMYN3WG TI TTOM3J0 DMYN3WG TN Estrogen receptor beta (ESR2) DMYN3WG MA Inhibitor DMYN3WG RN Synthesis and biological activity of new halo-steroidal antiestrogens. J Med Chem. 1991 May;34(5):1624-30. DMYN3WG RU https://pubmed.ncbi.nlm.nih.gov/2033587 DMYPRS9 DI DMYPRS9 DMYPRS9 DN CLX-0900 DMYPRS9 TI TTCBFJO DMYPRS9 TN Insulin receptor (INSR) DMYPRS9 MA Modulator DMYPRS9 RN CLX-0901 (Calyx Therapeutics). Curr Opin Investig Drugs. 2001 May;2(5):650-3. DMYPRS9 RU https://pubmed.ncbi.nlm.nih.gov/11569941 DMYSEBK DI DMYSEBK DMYSEBK DN L-162234 DMYSEBK TI TTQVOEI DMYSEBK TN Angiotensin II receptor type-2 (AGTR2) DMYSEBK MA Inhibitor DMYSEBK RN Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity. J Med Chem. 2000 May 18;43(10):1993-2006. DMYSEBK RU https://pubmed.ncbi.nlm.nih.gov/10821712 DMYSTAD DI DMYSTAD DMYSTAD DN ER-37328 DMYSTAD TI TT0IHXV DMYSTAD TN DNA topoisomerase II (TOP2) DMYSTAD MA Inhibitor DMYSTAD RN Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor. Mol Cancer Ther. 2002 Jan;1(3):169-75. DMYSTAD RU https://pubmed.ncbi.nlm.nih.gov/12467211 DMYTI3J DI DMYTI3J DMYTI3J DN R-56865 DMYTI3J TI TTZIFHC DMYTI3J TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMYTI3J MA Inhibitor DMYTI3J RN Novel calcium antagonists with both calcium overload inhibition and antioxidant activity. 1. 2-(3, 5-di-tert-butyl-4-hydroxyphenyl)-3-(aminopropyl)... J Med Chem. 1998 Oct 22;41(22):4309-16. DMYTI3J RU https://pubmed.ncbi.nlm.nih.gov/9784106 DMYV9M1 DI DMYV9M1 DMYV9M1 DN NS-1608 DMYV9M1 TI TT1VOHK DMYV9M1 TN Potassium channel unspecific (KC) DMYV9M1 MA Opener DMYV9M1 RN Modulation of the Ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+. Neuropharmacology. 1996;35(7):903-14. DMYV9M1 RU https://pubmed.ncbi.nlm.nih.gov/8938721 DMYWI04 DI DMYWI04 DMYWI04 DN BMS-181885 DMYWI04 TI TT6MSOK DMYWI04 TN 5-HT 1D receptor (HTR1D) DMYWI04 MA Agonist DMYWI04 RN Sensitive triple-quadrupole mass spectrometric assay for the determination of BMS-181885, a 5-HT1 agonist, in human plasma following solid phase extraction. Biomed Chromatogr. 1999 Oct;13(6):425-30. DMYWI04 RU https://pubmed.ncbi.nlm.nih.gov/10477901 DMYXD6A DI DMYXD6A DMYXD6A DN RWJ-58259 DMYXD6A TI TTL935N DMYXD6A TN Proteinase activated receptor 1 (F2R) DMYXD6A MA Modulator DMYXD6A RN RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev. 2003 Winter;21(4):313-26. DMYXD6A RU https://pubmed.ncbi.nlm.nih.gov/14647534 DMYZPJU DI DMYZPJU DMYZPJU DN L-733560 DMYZPJU TI TT0SFXH DMYZPJU TN Fungal 1,3-beta-glucan synthase (Fung GSC2) DMYZPJU MA Modulator DMYZPJU RN Discovery of Novel Antifungal (1,3)--d-Glucan Synthase Inhibitors DMYZPJU RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89685 DMZ1JKX DI DMZ1JKX DMZ1JKX DN E-4080 DMZ1JKX TI TT1VOHK DMZ1JKX TN Potassium channel unspecific (KC) DMZ1JKX MA Opener DMZ1JKX RN Ionic currents involved in vasodilating actions of E4080, a newly synthesized bradycardia-inducing agent, in dispersed smooth muscle cells of the rabbit portal vein. J Pharmacol Exp Ther. 1991 Dec;259(3):1396-403. DMZ1JKX RU https://pubmed.ncbi.nlm.nih.gov/1762086 DMZ3QHF DI DMZ3QHF DMZ3QHF DN CB-102930 DMZ3QHF TI TTBZHDM DMZ3QHF TN Fungal Isoleucyl t-RNA synthetase (Fung ILS1) DMZ3QHF MA Inhibitor DMZ3QHF RN Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob Agents Chemother. 2005 December; 49(12): 4821-4833. DMZ3QHF RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1315952/ DMZ402C DI DMZ402C DMZ402C DN L-768673 DMZ402C TI TT846HF DMZ402C TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMZ402C MA Inhibitor DMZ402C RN Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(... J Med Chem. 1997 Nov 21;40(24):3865-8. DMZ402C RU https://pubmed.ncbi.nlm.nih.gov/9397166 DMZ52P6 DI DMZ52P6 DMZ52P6 DN ABS-212 DMZ52P6 TI TTTUMEP DMZ52P6 TN Neurotensin receptor type 1 (NTSR1) DMZ52P6 MA Agonist DMZ52P6 RN Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic. J Med Chem. 2010 Jun 24;53(12):4623-32. DMZ52P6 RU https://pubmed.ncbi.nlm.nih.gov/20481538 DMZ5N2I DI DMZ5N2I DMZ5N2I DN CNS-1531 DMZ5N2I TI TT9IK2Z DMZ5N2I TN N-methyl-D-aspartate receptor (NMDAR) DMZ5N2I MA Modulator DMZ5N2I RN WO patent application no. 2009,0164,86, Use of nmda receptor antagonists for treatment of urologic tumors. DMZ5N2I RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20090205&CC=WO&NR=2009016486A2&KC=A2 DMZ5NQP DI DMZ5NQP DMZ5NQP DN A-11259 DMZ5NQP TI TT3C1VN DMZ5NQP TN Enzyme unspecific (Enz) DMZ5NQP MA Inhibitor DMZ5NQP RN The Identification of Nanomolar 1,4-benzoquinone Inhibitors of Shikimate Kinase. Aspergillus & Aspergillosis Website. 2002. DMZ5NQP RU http://www.aspergillus.org.uk/content/identification-nanomolar-14-benzoquinone-inhibitors-shikimate-kinase DMZ8HW7 DI DMZ8HW7 DMZ8HW7 DN PF-572778 DMZ8HW7 TI TTIY658 DMZ8HW7 TN Corticotropin-releasing factor receptor 2 (CRHR2) DMZ8HW7 MA Modulator DMZ8HW7 RN WO patent application no. 2013,1603,15, Genetic predictors of response to treatment with crhr1 antagonists. DMZ8HW7 RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131031&CC=WO&NR=2013160315A2&KC=A2 DMZ8OMT DI DMZ8OMT DMZ8OMT DN DACTIMICIN DMZ8OMT TI TTOVFH2 DMZ8OMT TN Bacterial 30S ribosomal RNA (Bact 30S rRNA) DMZ8OMT MA Inhibitor DMZ8OMT RN Aminoglycosides: Activity and Resistance. Antimicrob Agents Chemother. 1999 April; 43(4): 727-737. DMZ8OMT RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89199/ DMZ8SXP DI DMZ8SXP DMZ8SXP DN SR-27950 DMZ8SXP TI TTCG0AL DMZ8SXP TN Cholecystokinin receptor type A (CCKAR) DMZ8SXP MA Modulator DMZ8SXP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 76). DMZ8SXP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=76 DMZ90OV DI DMZ90OV DMZ90OV DN AZD-6942 DMZ90OV TI TTFZYTO DMZ90OV TN C-C chemokine receptor type 2 (CCR2) DMZ90OV MA Antagonist DMZ90OV RN Patent EP2727944 A1. DMZ90OV RU http://www.google.com/patents/EP2727944A1?cl=en DMZA5Q4 DI DMZA5Q4 DMZA5Q4 DN EP-2060 DMZA5Q4 TI TTZBFA0 DMZA5Q4 TN Protease unspecific (PRO) DMZA5Q4 MA Inducer DMZA5Q4 RN Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem. 2009 May;9(4):437-56. DMZA5Q4 RU https://pubmed.ncbi.nlm.nih.gov/19442043 DMZBNHC DI DMZBNHC DMZBNHC DN JTT-608 DMZBNHC TI TTUST1O DMZBNHC TN Phosphodiesterase (PDE) DMZBNHC MA Inhibitor DMZBNHC RN JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9. DMZBNHC RU https://pubmed.ncbi.nlm.nih.gov/10082270 DMZBQ4I DI DMZBQ4I DMZBQ4I DN SQ-33961 DMZBQ4I TI TT2O84V DMZBQ4I TN Thromboxane A2 receptor (TBXA2R) DMZBQ4I MA Modulator DMZBQ4I RN Conformationally-restricted analogs of TXA2 antagonist SQ 33,961: Receptor binding conformation of the carboxyl sidechain. Bioorganic & Medicinal Chemistry Letters Volume 1, Issue 9, 1991, Pages 465-470. DMZBQ4I RU http://www.sciencedirect.com/science/article/pii/S0960894X01811070 DMZE0SJ DI DMZE0SJ DMZE0SJ DN CEP-4186 DMZE0SJ TI TTK59TV DMZE0SJ TN Vitamin D3 receptor (VDR) DMZE0SJ MA Modulator DMZE0SJ RN Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol. 1998 Sep;13(3):421-8. DMZE0SJ RU https://pubmed.ncbi.nlm.nih.gov/9683773 DMZF9CY DI DMZF9CY DMZF9CY DN GE-68 DMZF9CY TI TTRK8B9 DMZF9CY TN Sodium channel unspecific (NaC) DMZF9CY MA Modulator DMZF9CY RN Electrophysiological properties of the propafenone-analogue GE 68 (1-[3-(phenylethyl)-2-benzofuryl]-2-(propylamino)-ethanol) in isolated preparations and ventricular myocytes of guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1997 Feb;355(2):230-8. DMZF9CY RU https://pubmed.ncbi.nlm.nih.gov/9050017 DMZFTLK DI DMZFTLK DMZFTLK DN BMY-22089 DMZFTLK TI TTPADOQ DMZFTLK TN HMG-CoA reductase (HMGCR) DMZFTLK MA Inhibitor DMZFTLK RN Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J Lipid Res. 1990 Jul;31(7):1271-82. DMZFTLK RU https://pubmed.ncbi.nlm.nih.gov/2401858 DMZGFM6 DI DMZGFM6 DMZGFM6 DN BAY-Z-4305 DMZGFM6 TI TT84ETX DMZGFM6 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMZGFM6 MA Inhibitor DMZGFM6 RN US patent application no. 2008,0161,324, Compositions and methods for treatment of viral diseases. DMZGFM6 RU http://www.google.com/patents/US20080161324 DMZHS9U DI DMZHS9U DMZHS9U DN RS-93522 DMZHS9U TI TT5HONZ DMZHS9U TN Calcium channel unspecific (CaC) DMZHS9U MA Blocker DMZHS9U RN Intranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist. Pharm Res. 1991 Jan;8(1):134-5. DMZHS9U RU https://pubmed.ncbi.nlm.nih.gov/2014202 DMZKIE0 DI DMZKIE0 DMZKIE0 DN Tolerimab DMZKIE0 TI TTHGXBU DMZKIE0 TN T-lymphocyte activation antigen CD86 (FUN1) DMZKIE0 RN US patent application no. 2004,0171,123, Albumin fusion proteins. DMZKIE0 RU https://www.google.com/patents/US20040171123 DMZKIE0 DI DMZKIE0 DMZKIE0 DN Tolerimab DMZKIE0 TI TTFZDNP DMZKIE0 TN Activation B7-1 antigen (CD80) DMZKIE0 RN US patent application no. 2004,0171,123, Albumin fusion proteins. DMZKIE0 RU https://www.google.com/patents/US20040171123 DMZLKCF DI DMZLKCF DMZLKCF DN SB-282241 DMZLKCF TI TTFZYTO DMZLKCF TN C-C chemokine receptor type 2 (CCR2) DMZLKCF MA Antagonist DMZLKCF RN Patent EP2727944 A1. DMZLKCF RU http://www.google.com/patents/EP2727944A1?cl=en DMZM70X DI DMZM70X DMZM70X DN CGP-35348 DMZM70X TI TTDCVZW DMZM70X TN Gamma-aminobutyric acid B receptor (GABBR) DMZM70X MA Modulator DMZM70X RN The selective GABAB antagonist CGP-35348 blocks spike-wave bursts in the cholesterol synthesis rat absence epilepsy model. Brain Res. 1996 Aug 12;729(2):147-50. DMZM70X RU https://www.ncbi.nlm.nih.gov/pubmed/8876982 DMZMUG2 DI DMZMUG2 DMZMUG2 DN BILD-1357 DMZMUG2 TI TTMJX4U DMZMUG2 TN Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1) DMZMUG2 MA Inhibitor DMZMUG2 RN Peptidomimetic inhibitors of herpes simplex virus ribonucleotide reductase with improved in vivo antiviral activity. J Med Chem. 1996 Oct 11;39(21):4173-80. DMZMUG2 RU https://pubmed.ncbi.nlm.nih.gov/8863795 DMZNM2K DI DMZNM2K DMZNM2K DN PNU-109291 DMZNM2K TI TT6MSOK DMZNM2K TN 5-HT 1D receptor (HTR1D) DMZNM2K MA Agonist DMZNM2K RN Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn. Br J Pharmacol. 2012 Mar;165(6):1956-65. DMZNM2K RU https://pubmed.ncbi.nlm.nih.gov/21950560 DMZNWAV DI DMZNWAV DMZNWAV DN Miltirone DMZNWAV TI TTPTXIN DMZNWAV TN Translocator protein (TSPO) DMZNWAV MA Modulator DMZNWAV RN Miltirone, a central benzodiazepine receptor partial agonist from a Chinese medicinal herb Salvia miltiorrhiza. Neurosci Lett. 1991 Jun 24;127(2):237-41. DMZNWAV RU https://pubmed.ncbi.nlm.nih.gov/1652718 DMZOCHT DI DMZOCHT DMZOCHT DN DuP 714 DMZOCHT TI TT6L509 DMZOCHT TN Coagulation factor IIa (F2) DMZOCHT MA Inhibitor DMZOCHT RN Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001 Jul;7(3):195-204. DMZOCHT RU https://pubmed.ncbi.nlm.nih.gov/11441979 DMZQJVN DI DMZQJVN DMZQJVN DN R-85355 DMZQJVN TI TT2J34L DMZQJVN TN Arachidonate 5-lipoxygenase (5-LOX) DMZQJVN MA Inhibitor DMZQJVN RN Topical R-85355, a potent and selective 5-lipoxygenase inhibitor, fails to improve psoriasis. Skin Pharmacol. 1996;9(5):307-11. DMZQJVN RU https://pubmed.ncbi.nlm.nih.gov/8990505 DMZSQU8 DI DMZSQU8 DMZSQU8 DN Ro-60-0175 DMZSQU8 TI TTJQOD7 DMZSQU8 TN 5-HT 2A receptor (HTR2A) DMZSQU8 MA Inhibitor DMZSQU8 RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DMZSQU8 RU https://pubmed.ncbi.nlm.nih.gov/18035544 DMZSQU8 DI DMZSQU8 DMZSQU8 DN Ro-60-0175 DMZSQU8 TI TT0K1SC DMZSQU8 TN 5-HT 2B receptor (HTR2B) DMZSQU8 MA Inhibitor DMZSQU8 RN Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. DMZSQU8 RU https://pubmed.ncbi.nlm.nih.gov/16257207 DMZSQU8 DI DMZSQU8 DMZSQU8 DN Ro-60-0175 DMZSQU8 TI TTWJBZ5 DMZSQU8 TN 5-HT 2C receptor (HTR2C) DMZSQU8 MA Inhibitor DMZSQU8 RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DMZSQU8 RU https://pubmed.ncbi.nlm.nih.gov/18035544 DMZTPCX DI DMZTPCX DMZTPCX DN BIBN-99 DMZTPCX TI TTYEG6Q DMZTPCX TN Muscarinic acetylcholine receptor M2 (CHRM2) DMZTPCX MA Modulator DMZTPCX RN Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur J Pharmacol. 1993 Sep 21;242(1):23-30. DMZTPCX RU https://pubmed.ncbi.nlm.nih.gov/8223934 DMZWU8V DI DMZWU8V DMZWU8V DN E-2040 DMZWU8V TI TTYSN63 DMZWU8V TN 5-HT 2 receptor (5HT2R) DMZWU8V MA Modulator DMZWU8V RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009126) DMZWU8V RU http://adisinsight.springer.com/drugs/800009126 DMZWU8V DI DMZWU8V DMZWU8V DN E-2040 DMZWU8V TI TT4C8EA DMZWU8V TN Dopamine D3 receptor (D3R) DMZWU8V MA Modulator DMZWU8V RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009126) DMZWU8V RU http://adisinsight.springer.com/drugs/800009126 DMZWU8V DI DMZWU8V DMZWU8V DN E-2040 DMZWU8V TI TTEX248 DMZWU8V TN Dopamine D2 receptor (D2R) DMZWU8V MA Modulator DMZWU8V RN Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009126) DMZWU8V RU http://adisinsight.springer.com/drugs/800009126 DMZXA0W DI DMZXA0W DMZXA0W DN Garenoxacin DMZXA0W TI TT0IHXV DMZXA0W TN DNA topoisomerase II (TOP2) DMZXA0W MA Inhibitor DMZXA0W RN The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues. J Antimicrob Chemother. 2001 Aug;48(2):195-201. DMZXA0W RU https://pubmed.ncbi.nlm.nih.gov/11481288 DMZY0SF DI DMZY0SF DMZY0SF DN CNS-5788 DMZY0SF TI TT9IK2Z DMZY0SF TN N-methyl-D-aspartate receptor (NMDAR) DMZY0SF MA Antagonist DMZY0SF RN Identification and characterization of a potential ischemia-selective N-methyl-D-aspartate (NMDA) receptor ion-channel blocker, CNS 5788. Bioorg Med Chem Lett. 2001 Feb 26;11(4):501-4. DMZY0SF RU https://pubmed.ncbi.nlm.nih.gov/11229757 DM012TN DI DM012TN DM012TN DN N-(4-Ethoxybutyl)-2-oxohexadecanamide DM012TN TI TTT1JVS DM012TN TN Cytosolic phospholipase A2 (GIVA cPLA2) DM012TN MA Inhibitor DM012TN RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DM012TN RU https://pubmed.ncbi.nlm.nih.gov/18993078 DM014WS DI DM014WS DM014WS DN EHNA DM014WS TI TTJGW1Z DM014WS TN Phosphodiesterase 2A (PDE2A) DM014WS MA Inhibitor DM014WS RN Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 1996 Feb;8(2):97-110. DM014WS RU https://pubmed.ncbi.nlm.nih.gov/8730511 DM014WS DI DM014WS DM014WS DN EHNA DM014WS TI TTLP57V DM014WS TN Adenosine deaminase (ADA) DM014WS MA Inhibitor DM014WS RN Tight-binding inhibitors--IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol. 1977 Mar 1;26(5):359-67. DM014WS RU https://pubmed.ncbi.nlm.nih.gov/849330 DM0163O DI DM0163O DM0163O DN [3H]nelivaptan DM0163O TI TTL9MHW DM0163O TN Vasopressin V1b receptor (V1BR) DM0163O MA Antagonist DM0163O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 367). DM0163O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=367 DM0164B DI DM0164B DM0164B DN NSC-686549 DM0164B TI TTGECUM DM0164B TN Cot oncogene messenger RNA (MAP3K8 mRNA) DM0164B MA Inhibitor DM0164B RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DM0164B RU https://pubmed.ncbi.nlm.nih.gov/18077363 DM0164B DI DM0164B DM0164B DN NSC-686549 DM0164B TI TTROQ37 DM0164B TN MAPK/ERK kinase kinase (MAP3K) DM0164B MA Inhibitor DM0164B RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DM0164B RU https://pubmed.ncbi.nlm.nih.gov/18077363 DM019LA DI DM019LA DM019LA DN ISIS 111119 DM019LA TI TTOM97J DM019LA TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DM019LA RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DM019LA RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DM01BKR DI DM01BKR DM01BKR DN 3-(Octahydro-quinolizin-3-yl)-phenol DM01BKR TI TTEX248 DM01BKR TN Dopamine D2 receptor (D2R) DM01BKR MA Inhibitor DM01BKR RN Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22. DM01BKR RU https://pubmed.ncbi.nlm.nih.gov/1968512 DM01MW7 DI DM01MW7 DM01MW7 DN EPALRESTATE DM01MW7 TI TTFBNVI DM01MW7 TN Aldose reductase (AKR1B1) DM01MW7 MA Inhibitor DM01MW7 RN Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5. DM01MW7 RU https://pubmed.ncbi.nlm.nih.gov/18298080 DM01RZX DI DM01RZX DM01RZX DN QNZ 46 DM01RZX TI TT5POTG DM01RZX TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DM01RZX MA Modulator (allosteric modulator) DM01RZX RN Structural and mechanistic determinants of a novel site for noncompetitive inhibition of GluN2D-containing NMDA receptors. J Neurosci. 2011 Mar 9;31(10):3650-61. DM01RZX RU https://pubmed.ncbi.nlm.nih.gov/21389220 DM01UDZ DI DM01UDZ DM01UDZ DN ISIS 134603 DM01UDZ TI TTKW4ML DM01UDZ TN Caspase 6 messenger RNA (CASP6 mRNA) DM01UDZ RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DM01UDZ RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DM01WBD DI DM01WBD DM01WBD DN 3-acetyl-7-hydroxy-2H-chromen-2-one DM01WBD TI TT6804T DM01WBD TN MIF messenger RNA (MIF mRNA) DM01WBD MA Inhibitor DM01WBD RN Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24. DM01WBD RU https://pubmed.ncbi.nlm.nih.gov/19090668 DM01WOF DI DM01WOF DM01WOF DN Salvinorin B fluoromethyl ether DM01WOF TI TTQW87Y DM01WOF TN Opioid receptor kappa (OPRK1) DM01WOF MA Inhibitor DM01WOF RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DM01WOF RU https://pubmed.ncbi.nlm.nih.gov/17981041 DM01Y37 DI DM01Y37 DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide DM01Y37 TI TTSHTOI DM01Y37 TN Histone deacetylase 2 (HDAC2) DM01Y37 MA Inhibitor DM01Y37 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM01Y37 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM01Y37 DI DM01Y37 DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide DM01Y37 TI TTYHPU6 DM01Y37 TN Histone deacetylase 10 (HDAC10) DM01Y37 MA Inhibitor DM01Y37 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM01Y37 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM01Y37 DI DM01Y37 DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide DM01Y37 TI TT6R7JZ DM01Y37 TN Histone deacetylase 1 (HDAC1) DM01Y37 MA Inhibitor DM01Y37 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM01Y37 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM01Y37 DI DM01Y37 DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide DM01Y37 TI TT5ZKDI DM01Y37 TN Histone deacetylase 6 (HDAC6) DM01Y37 MA Inhibitor DM01Y37 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM01Y37 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM01Y37 DI DM01Y37 DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide DM01Y37 TI TTTQGH8 DM01Y37 TN Histone deacetylase 4 (HDAC4) DM01Y37 MA Inhibitor DM01Y37 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM01Y37 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM01Y37 DI DM01Y37 DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide DM01Y37 TI TTBH0VX DM01Y37 TN Histone deacetylase (HDAC) DM01Y37 MA Inhibitor DM01Y37 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM01Y37 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM01Y37 DI DM01Y37 DM01Y37 DN N-(6-Mercapto-hexyl)-benzamide DM01Y37 TI TTT6LFV DM01Y37 TN Histone deacetylase 8 (HDAC8) DM01Y37 MA Inhibitor DM01Y37 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM01Y37 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0214E DI DM0214E DM0214E DN NSC-401077 DM0214E TI TTHVCUP DM0214E TN DNA [cytosine-5]-methyltransferase (DNMT) DM0214E MA Inhibitor DM0214E RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM0214E RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM0214E DI DM0214E DM0214E DN NSC-401077 DM0214E TI TT6VZ78 DM0214E TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM0214E MA Inhibitor DM0214E RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM0214E RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM02FGH DI DM02FGH DM02FGH DN UK-356618 DM02FGH TI TT6X50U DM02FGH TN Matrix metalloproteinase-9 (MMP-9) DM02FGH MA Inhibitor DM02FGH RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DM02FGH RU https://pubmed.ncbi.nlm.nih.gov/12877590 DM02FGH DI DM02FGH DM02FGH DN UK-356618 DM02FGH TI TTUZ2L5 DM02FGH TN Matrix metalloproteinase-3 (MMP-3) DM02FGH MA Inhibitor DM02FGH RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DM02FGH RU https://pubmed.ncbi.nlm.nih.gov/12877590 DM02FGH DI DM02FGH DM02FGH DN UK-356618 DM02FGH TI TTLM12X DM02FGH TN Matrix metalloproteinase-2 (MMP-2) DM02FGH MA Inhibitor DM02FGH RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DM02FGH RU https://pubmed.ncbi.nlm.nih.gov/12877590 DM02FGH DI DM02FGH DM02FGH DN UK-356618 DM02FGH TI TTHY57M DM02FGH TN Matrix metalloproteinase-13 (MMP-13) DM02FGH MA Inhibitor DM02FGH RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DM02FGH RU https://pubmed.ncbi.nlm.nih.gov/12877590 DM02FGH DI DM02FGH DM02FGH DN UK-356618 DM02FGH TI TTJ4QE7 DM02FGH TN Matrix metalloproteinase-14 (MMP-14) DM02FGH MA Inhibitor DM02FGH RN A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers. J Med Chem. 2003 Jul 31;46(16):3514-25. DM02FGH RU https://pubmed.ncbi.nlm.nih.gov/12877590 DM02PAW DI DM02PAW DM02PAW DN Phenethylcarbamic Acid Biphenyl-3-yl Ester DM02PAW TI TTDP1UC DM02PAW TN Fatty acid amide hydrolase (FAAH) DM02PAW MA Inhibitor DM02PAW RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DM02PAW RU https://pubmed.ncbi.nlm.nih.gov/18507372 DM02Q8N DI DM02Q8N DM02Q8N DN 4-Benzo[b]thiophen-4-yl-1H-imidazole DM02Q8N TI TTWM4TY DM02Q8N TN Adrenergic receptor alpha-2B (ADRA2B) DM02Q8N MA Inhibitor DM02Q8N RN alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8. DM02Q8N RU https://pubmed.ncbi.nlm.nih.gov/10715142 DM02Q8N DI DM02Q8N DM02Q8N DN 4-Benzo[b]thiophen-4-yl-1H-imidazole DM02Q8N TI TTNGILX DM02Q8N TN Adrenergic receptor alpha-1A (ADRA1A) DM02Q8N MA Inhibitor DM02Q8N RN alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8. DM02Q8N RU https://pubmed.ncbi.nlm.nih.gov/10715142 DM02Q8N DI DM02Q8N DM02Q8N DN 4-Benzo[b]thiophen-4-yl-1H-imidazole DM02Q8N TI TT34BHT DM02Q8N TN Adrenergic receptor alpha-1D (ADRA1D) DM02Q8N MA Inhibitor DM02Q8N RN alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8. DM02Q8N RU https://pubmed.ncbi.nlm.nih.gov/10715142 DM02Q8N DI DM02Q8N DM02Q8N DN 4-Benzo[b]thiophen-4-yl-1H-imidazole DM02Q8N TI TTBRKXS DM02Q8N TN Adrenergic receptor alpha-1B (ADRA1B) DM02Q8N MA Inhibitor DM02Q8N RN alpha(2) Adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-Imidazo)-1,3-dimethyl-6,7-dihydrothianaphthene [corrected] as a ... J Med Chem. 2000 Mar 9;43(5):765-8. DM02Q8N RU https://pubmed.ncbi.nlm.nih.gov/10715142 DM02Q8N DI DM02Q8N DM02Q8N DN 4-Benzo[b]thiophen-4-yl-1H-imidazole DM02Q8N TI TTWG9A4 DM02Q8N TN Adrenergic receptor alpha-2A (ADRA2A) DM02Q8N MA Inhibitor DM02Q8N RN Alpha(2) adrenoceptor agonists as potential analgesic agents. 2. Discovery of 4-(4-imidazo)-1,3-dimethyl-6,7-dihydro-thianaphthene as a high-affini... J Med Chem. 2000 Apr 6;43(7):1423-6. DM02Q8N RU https://pubmed.ncbi.nlm.nih.gov/10753480 DM02YSE DI DM02YSE DM02YSE DN PMID20947351C16 DM02YSE TI TT5ZKDI DM02YSE TN Histone deacetylase 6 (HDAC6) DM02YSE MA Inhibitor DM02YSE RN Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70. DM02YSE RU https://pubmed.ncbi.nlm.nih.gov/20947351 DM032YM DI DM032YM DM032YM DN 2-pentenal DM032YM TI TTELV3W DM032YM TN Transformation-sensitive protein p120 (TRPA1) DM032YM MA Activator DM032YM RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DM032YM RU https://pubmed.ncbi.nlm.nih.gov/20356305 DM03526 DI DM03526 DM03526 DN PD-144550 DM03526 TI TTU8P3M DM03526 TN Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2) DM03526 MA Inhibitor DM03526 RN Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994). DM03526 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808556 DM03526 DI DM03526 DM03526 DN PD-144550 DM03526 TI TTFK1JQ DM03526 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM03526 MA Inhibitor DM03526 RN Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994). DM03526 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808556 DM03526 DI DM03526 DM03526 DN PD-144550 DM03526 TI TTN7T29 DM03526 TN Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3) DM03526 MA Inhibitor DM03526 RN Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994). DM03526 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808556 DM03BQD DI DM03BQD DM03BQD DN 4-(benzylideneamino)benzenesulfonamide DM03BQD TI TTANPDJ DM03BQD TN Carbonic anhydrase II (CA-II) DM03BQD MA Inhibitor DM03BQD RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DM03BQD RU https://pubmed.ncbi.nlm.nih.gov/19796939 DM03BQD DI DM03BQD DM03BQD DN 4-(benzylideneamino)benzenesulfonamide DM03BQD TI TTVKILB DM03BQD TN Prostaglandin G/H synthase 2 (COX-2) DM03BQD MA Inhibitor DM03BQD RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DM03BQD RU https://pubmed.ncbi.nlm.nih.gov/18063374 DM03E28 DI DM03E28 DM03E28 DN ARD-412 DM03E28 TI TT27RFC DM03E28 TN Opioid receptor delta (OPRD1) DM03E28 MA Agonist DM03E28 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DM03E28 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DM03N5V DI DM03N5V DM03N5V DN (R)PK-11195 DM03N5V TI TTPTXIN DM03N5V TN Translocator protein (TSPO) DM03N5V MA Inhibitor DM03N5V RN [18F]FMDAA1106 and [18F]FEDAA1106: two positron-emitter labeled ligands for peripheral benzodiazepine receptor (PBR). Bioorg Med Chem Lett. 2003 Jan 20;13(2):201-4. DM03N5V RU https://pubmed.ncbi.nlm.nih.gov/12482423 DM03NUV DI DM03NUV DM03NUV DN CDDO DM03NUV TI TTF10I9 DM03NUV TN Nitric-oxide synthase inducible (NOS2) DM03NUV MA Inhibitor DM03NUV RN Studies on the reactivity of CDDO, a promising new chemopreventive and chemotherapeutic agent: implications for a molecular mechanism of action. Bioorg Med Chem Lett. 2005 May 2;15(9):2215-9. DM03NUV RU https://pubmed.ncbi.nlm.nih.gov/15837296 DM03RIT DI DM03RIT DM03RIT DN Rp-5-OMe-UDPalphaB DM03RIT TI TTNVSKA DM03RIT TN P2Y purinoceptor 6 (P2RY6) DM03RIT MA Agonist DM03RIT RN 5-OMe-uridine-5'-O-(alpha-boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y(6) receptor protects against death-receptor mediated glial apoptosis. Neurosci Lett. 2014 Aug 22;578:80-4. DM03RIT RU https://pubmed.ncbi.nlm.nih.gov/24970757 DM03ROH DI DM03ROH DM03ROH DN 3-bromo-1-(4-hexylphenyl)propan-1-one DM03ROH TI TTGER3L DM03ROH TN Thyroid hormone receptor beta (THRB) DM03ROH MA Inhibitor DM03ROH RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM03ROH RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM03ROH DI DM03ROH DM03ROH DN 3-bromo-1-(4-hexylphenyl)propan-1-one DM03ROH TI TTTSEPU DM03ROH TN Thyroid hormone receptor alpha (THRA) DM03ROH MA Inhibitor DM03ROH RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM03ROH RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM03VXN DI DM03VXN DM03VXN DN N-(4-methylthiazol-2-yl)-2-phenylacetamide DM03VXN TI TTSJ6Q4 DM03VXN TN LOX-5 messenger RNA (ALOX5 mRNA) DM03VXN MA Inhibitor DM03VXN RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DM03VXN RU https://pubmed.ncbi.nlm.nih.gov/17461565 DM03X7D DI DM03X7D DM03X7D DN EISAI-1 DM03X7D TI TTTUMEP DM03X7D TN Neurotensin receptor type 1 (NTSR1) DM03X7D MA Agonist DM03X7D RN Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 2003 Aug;64(2):421-9. DM03X7D RU https://pubmed.ncbi.nlm.nih.gov/12869647 DM03XYF DI DM03XYF DM03XYF DN 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide DM03XYF TI TTTQGH8 DM03XYF TN Histone deacetylase 4 (HDAC4) DM03XYF MA Inhibitor DM03XYF RN Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38. DM03XYF RU https://pubmed.ncbi.nlm.nih.gov/17929798 DM03XYF DI DM03XYF DM03XYF DN 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide DM03XYF TI TT5ZKDI DM03XYF TN Histone deacetylase 6 (HDAC6) DM03XYF MA Inhibitor DM03XYF RN Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38. DM03XYF RU https://pubmed.ncbi.nlm.nih.gov/17929798 DM03XYF DI DM03XYF DM03XYF DN 7-mercapto-N-(4-phenylthiazol-2-yl)heptanamide DM03XYF TI TT6R7JZ DM03XYF TN Histone deacetylase 1 (HDAC1) DM03XYF MA Inhibitor DM03XYF RN Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38. DM03XYF RU https://pubmed.ncbi.nlm.nih.gov/17929798 DM043N8 DI DM043N8 DM043N8 DN 1-(2,5-dimethoxyphenyl)propan-2-amine DM043N8 TI TT6MSOK DM043N8 TN 5-HT 1D receptor (HTR1D) DM043N8 MA Inhibitor DM043N8 RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM043N8 RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM043N8 DI DM043N8 DM043N8 DN 1-(2,5-dimethoxyphenyl)propan-2-amine DM043N8 TI TTSQIFT DM043N8 TN 5-HT 1A receptor (HTR1A) DM043N8 MA Inhibitor DM043N8 RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM043N8 RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM043N8 DI DM043N8 DM043N8 DN 1-(2,5-dimethoxyphenyl)propan-2-amine DM043N8 TI TTJQOD7 DM043N8 TN 5-HT 2A receptor (HTR2A) DM043N8 MA Inhibitor DM043N8 RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DM043N8 RU https://pubmed.ncbi.nlm.nih.gov/18296055 DM047DQ DI DM047DQ DM047DQ DN BCEAB DM047DQ TI TT8VUE0 DM047DQ TN Chymase (CYM) DM047DQ MA Inhibitor DM047DQ RN Development of a chymase inhibitor: pharmacological characterization of a chymase inhibitor in inflamed tissue remodeling and fibrosis. Jpn J Pharmacol. 2002 Nov;90(3):206-9. DM047DQ RU https://pubmed.ncbi.nlm.nih.gov/12499572 DM048OG DI DM048OG DM048OG DN D-420720 DM048OG TI TTDIGC1 DM048OG TN Dipeptidyl peptidase 4 (DPP-4) DM048OG MA Inhibitor DM048OG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DM048OG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DM049QO DI DM049QO DM049QO DN 4-Morpholin-2-yl-benzene-1,2-diol DM049QO TI TTNGILX DM049QO TN Adrenergic receptor alpha-1A (ADRA1A) DM049QO MA Inhibitor DM049QO RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DM049QO RU https://pubmed.ncbi.nlm.nih.gov/1313109 DM049QO DI DM049QO DM049QO DN 4-Morpholin-2-yl-benzene-1,2-diol DM049QO TI TTBRKXS DM049QO TN Adrenergic receptor alpha-1B (ADRA1B) DM049QO MA Inhibitor DM049QO RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DM049QO RU https://pubmed.ncbi.nlm.nih.gov/1313109 DM049QO DI DM049QO DM049QO DN 4-Morpholin-2-yl-benzene-1,2-diol DM049QO TI TT34BHT DM049QO TN Adrenergic receptor alpha-1D (ADRA1D) DM049QO MA Inhibitor DM049QO RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DM049QO RU https://pubmed.ncbi.nlm.nih.gov/1313109 DM04BHI DI DM04BHI DM04BHI DN (S)-PIA DM04BHI TI TTNE7KG DM04BHI TN Adenosine A2b receptor (ADORA2B) DM04BHI MA Agonist DM04BHI RN Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13. DM04BHI RU https://pubmed.ncbi.nlm.nih.gov/10496952 DM04BHI DI DM04BHI DM04BHI DN (S)-PIA DM04BHI TI TTK25J1 DM04BHI TN Adenosine A1 receptor (ADORA1) DM04BHI MA Agonist DM04BHI RN A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. J Biol Chem. 1994 Jan 28;269(4):2373-6. DM04BHI RU https://pubmed.ncbi.nlm.nih.gov/8300561 DM04BHI DI DM04BHI DM04BHI DN (S)-PIA DM04BHI TI TTJFY5U DM04BHI TN Adenosine A3 receptor (ADORA3) DM04BHI MA Agonist DM04BHI RN [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. DM04BHI RU https://pubmed.ncbi.nlm.nih.gov/10779381 DM04C9V DI DM04C9V DM04C9V DN PKF-241-466 DM04C9V TI TT6AZXG DM04C9V TN TNF alpha converting enzyme (ADAM17) DM04C9V MA Inhibitor DM04C9V RN Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59. DM04C9V RU https://pubmed.ncbi.nlm.nih.gov/19095454 DM04C9V DI DM04C9V DM04C9V DN PKF-241-466 DM04C9V TI TTF8CQI DM04C9V TN Tumor necrosis factor (TNF) DM04C9V MA Inhibitor DM04C9V RN Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93. DM04C9V RU https://pubmed.ncbi.nlm.nih.gov/12014967 DM04CUL DI DM04CUL DM04CUL DN ISIS 25082 DM04CUL TI TT8H9GB DM04CUL TN MEK2 messenger RNA (MEK2 mRNA) DM04CUL RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DM04CUL RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DM04HUC DI DM04HUC DM04HUC DN VU0152100 DM04HUC TI TTOXS3C DM04HUC TN Muscarinic acetylcholine receptor (CHRM) DM04HUC MA Modulator (allosteric modulator) DM04HUC RN Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther. 2008 Dec;327(3):941-53. DM04HUC RU https://pubmed.ncbi.nlm.nih.gov/18772318 DM04KS1 DI DM04KS1 DM04KS1 DN 1,3-ditolylguanidine DM04KS1 TI TT9NXW4 DM04KS1 TN Sigma intracellular receptor 2 (TMEM97) DM04KS1 MA Agonist DM04KS1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2553). DM04KS1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2553 DM04KS1 DI DM04KS1 DM04KS1 DN 1,3-ditolylguanidine DM04KS1 TI TT5TPI6 DM04KS1 TN Opioid receptor sigma 1 (OPRS1) DM04KS1 MA Agonist DM04KS1 RN Sigma1 and sigma2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse. 2006 May;59(6):350-8. DM04KS1 RU https://pubmed.ncbi.nlm.nih.gov/16463398 DM04KS1 DI DM04KS1 DM04KS1 DN 1,3-ditolylguanidine DM04KS1 TI TTLD29N DM04KS1 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM04KS1 MA Inhibitor DM04KS1 RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM04KS1 RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM04KS1 DI DM04KS1 DM04KS1 DN 1,3-ditolylguanidine DM04KS1 TI TTN9D8E DM04KS1 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM04KS1 MA Inhibitor DM04KS1 RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM04KS1 RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM04KS1 DI DM04KS1 DM04KS1 DN 1,3-ditolylguanidine DM04KS1 TI TTKJEMQ DM04KS1 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM04KS1 MA Inhibitor DM04KS1 RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM04KS1 RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM04MK7 DI DM04MK7 DM04MK7 DN 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine DM04MK7 TI TTIQUX7 DM04MK7 TN Steroid 11-beta-hydroxylase (CYP11B1) DM04MK7 MA Inhibitor DM04MK7 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM04MK7 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM04MK7 DI DM04MK7 DM04MK7 DN 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine DM04MK7 TI TTRA5BZ DM04MK7 TN Steroid 17-alpha-monooxygenase (S17AH) DM04MK7 MA Inhibitor DM04MK7 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM04MK7 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM04MK7 DI DM04MK7 DM04MK7 DN 4-[(3'-Hydroxybiphenyl-4-yl)methyl]pyridine DM04MK7 TI TTSZLWK DM04MK7 TN Aromatase (CYP19A1) DM04MK7 MA Inhibitor DM04MK7 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM04MK7 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM04N7I DI DM04N7I DM04N7I DN 3,5-dihydroxybenzoic acid DM04N7I TI TTVK4ZO DM04N7I TN G protein coupled receptor 81 (HCAR1) DM04N7I MA Agonist DM04N7I RN 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes. J Pharmacol Exp Ther. 2012 Jun;341(3):794-801. DM04N7I RU https://pubmed.ncbi.nlm.nih.gov/22434674 DM04OFE DI DM04OFE DM04OFE DN 4-Chloro-6-nitro-2-piperazin-1-yl-quinoline DM04OFE TI TT3ROYC DM04OFE TN Serotonin transporter (SERT) DM04OFE MA Inhibitor DM04OFE RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DM04OFE RU https://pubmed.ncbi.nlm.nih.gov/11859009 DM04QWX DI DM04QWX DM04QWX DN 9-Cyclobutyl-9H-adenine DM04QWX TI TTM2AOE DM04QWX TN Adenosine A2a receptor (ADORA2A) DM04QWX MA Inhibitor DM04QWX RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM04QWX RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM04QWX DI DM04QWX DM04QWX DN 9-Cyclobutyl-9H-adenine DM04QWX TI TTNE7KG DM04QWX TN Adenosine A2b receptor (ADORA2B) DM04QWX MA Inhibitor DM04QWX RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM04QWX RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM04QWX DI DM04QWX DM04QWX DN 9-Cyclobutyl-9H-adenine DM04QWX TI TTK25J1 DM04QWX TN Adenosine A1 receptor (ADORA1) DM04QWX MA Inhibitor DM04QWX RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM04QWX RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM04S2P DI DM04S2P DM04S2P DN Grandisine F DM04S2P TI TT27RFC DM04S2P TN Opioid receptor delta (OPRD1) DM04S2P MA Inhibitor DM04S2P RN Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9. DM04S2P RU https://pubmed.ncbi.nlm.nih.gov/16989522 DM04SWY DI DM04SWY DM04SWY DN 1-Phenyl-propane-1,2-dione DM04SWY TI TTMF541 DM04SWY TN Liver carboxylesterase (CES1) DM04SWY MA Inhibitor DM04SWY RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DM04SWY RU https://pubmed.ncbi.nlm.nih.gov/15828829 DM04WVH DI DM04WVH DM04WVH DN 5-Carbazol-9-yl-pentanoic acid DM04WVH TI TTNT2S6 DM04WVH TN Fatty acid-binding protein 5 (FABP5) DM04WVH MA Inhibitor DM04WVH RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DM04WVH RU https://pubmed.ncbi.nlm.nih.gov/15357969 DM04WVH DI DM04WVH DM04WVH DN 5-Carbazol-9-yl-pentanoic acid DM04WVH TI TTHWMFZ DM04WVH TN Fatty acid-binding protein 4 (FABP4) DM04WVH MA Inhibitor DM04WVH RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DM04WVH RU https://pubmed.ncbi.nlm.nih.gov/15357969 DM051PI DI DM051PI DM051PI DN FR-180204 DM051PI TI TT4TQBX DM051PI TN Extracellular signal-regulated kinase 2 (ERK2) DM051PI MA Inhibitor DM051PI RN Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. Bioorg Med Chem Lett. 2006 Jan 1;16(1):55-8. DM051PI RU https://pubmed.ncbi.nlm.nih.gov/16242327 DM052M3 DI DM052M3 DM052M3 DN ISIS 9606 DM052M3 TI TT2MI95 DM052M3 TN PKC-alpha messenger RNA (PRKCA mRNA) DM052M3 RN US patent application no. 6,300,320, Modulation of c-jun using inhibitors of protein kinase C. DM052M3 RU http://www.patentbuddy.com/Patent/6300320?ft=true&sr=true DM054NF DI DM054NF DM054NF DN N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide DM054NF TI TTILUKB DM054NF TN IRAK4 messenger RNA (IRAK4 mRNA) DM054NF MA Inhibitor DM054NF RN Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5. DM054NF RU https://pubmed.ncbi.nlm.nih.gov/16563752 DM054SL DI DM054SL DM054SL DN ISIS 9984 DM054SL TI TT1PL7M DM054SL TN E-selectin messenger RNA (SELE mRNA) DM054SL RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DM054SL RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DM0564K DI DM0564K DM0564K DN 4-hydroxyphenylpyruvic acid DM0564K TI TT6L509 DM0564K TN Coagulation factor IIa (F2) DM0564K MA Inhibitor DM0564K RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0564K RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0564K DI DM0564K DM0564K DN 4-hydroxyphenylpyruvic acid DM0564K TI TT2AST1 DM0564K TN Macrophage migration inhibitory factor (MIF) DM0564K MA Inhibitor DM0564K RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0564K RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0574W DI DM0574W DM0574W DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Phe11]SRIF DM0574W TI TTIND6G DM0574W TN Somatostatin receptor type 1 (SSTR1) DM0574W MA Inhibitor DM0574W RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM0574W RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM057MP DI DM057MP DM057MP DN [Ncy(SO,methyl)4]acyline DM057MP TI TT8R70G DM057MP TN Gonadotropin-releasing hormone receptor (GNRHR) DM057MP MA Inhibitor DM057MP RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM057MP RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM05AYE DI DM05AYE DM05AYE DN alloswitch-1 DM05AYE TI TTHS256 DM05AYE TN Metabotropic glutamate receptor 5 (mGluR5) DM05AYE MA Modulator (allosteric modulator) DM05AYE RN An allosteric modulator to control endogenous G protein-coupled receptors with light. Nat Chem Biol. 2014 Oct;10(10):813-5. DM05AYE RU https://pubmed.ncbi.nlm.nih.gov/25173999 DM05DOF DI DM05DOF DM05DOF DN PS-725074 DM05DOF TI TTXMNHO DM05DOF TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM05DOF MA Inhibitor DM05DOF RN Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20. DM05DOF RU https://pubmed.ncbi.nlm.nih.gov/9873534 DM05HBC DI DM05HBC DM05HBC DN 2-(4-hexyl-2-methoxyphenoxy)pyrimidine DM05HBC TI TTVTX4N DM05HBC TN Bacterial Fatty acid synthetase I (Bact inhA) DM05HBC MA Inhibitor DM05HBC RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DM05HBC RU https://pubmed.ncbi.nlm.nih.gov/18457948 DM05L3S DI DM05L3S DM05L3S DN Morpholino(1'H-phenothiazin-1'-yl)methanone DM05L3S TI TTEB0GD DM05L3S TN Cholinesterase (BCHE) DM05L3S MA Inhibitor DM05L3S RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM05L3S RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM05M9X DI DM05M9X DM05M9X DN CD2665 DM05M9X TI TT1Q3IE DM05M9X TN Retinoic acid receptor gamma (RARG) DM05M9X MA Antagonist DM05M9X RN Induction of apoptosis by retinoids and retinoic acid receptor gamma-selective compounds in mouse thymocytes through a novel apoptosis pathway. Mol Pharmacol. 1997 Jun;51(6):972-82. DM05M9X RU https://pubmed.ncbi.nlm.nih.gov/9187263 DM05O7J DI DM05O7J DM05O7J DN N5-(1-iminopropyl)-L-ornithine DM05O7J TI TTF10I9 DM05O7J TN Nitric-oxide synthase inducible (NOS2) DM05O7J MA Inhibitor DM05O7J RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM05O7J RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM05O7J DI DM05O7J DM05O7J DN N5-(1-iminopropyl)-L-ornithine DM05O7J TI TTZUFI5 DM05O7J TN Nitric-oxide synthase brain (NOS1) DM05O7J MA Inhibitor DM05O7J RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM05O7J RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM05O7J DI DM05O7J DM05O7J DN N5-(1-iminopropyl)-L-ornithine DM05O7J TI TTCM4B3 DM05O7J TN Nitric-oxide synthase endothelial (NOS3) DM05O7J MA Inhibitor DM05O7J RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM05O7J RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM05OJD DI DM05OJD DM05OJD DN 2-(1-adamantyl) piperidine DM05OJD TI TTXT3PU DM05OJD TN Influenza M2 protein (Influ M) DM05OJD MA Inhibitor DM05OJD RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DM05OJD RU https://pubmed.ncbi.nlm.nih.gov/17139286 DM05OMF DI DM05OMF DM05OMF DN 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione DM05OMF TI TTLM12X DM05OMF TN Matrix metalloproteinase-2 (MMP-2) DM05OMF MA Inhibitor DM05OMF RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DM05OMF RU https://pubmed.ncbi.nlm.nih.gov/11327602 DM05OMF DI DM05OMF DM05OMF DN 5-(4-Phenoxy-phenyl)-pyrimidine-2,4,6-trione DM05OMF TI TT6X50U DM05OMF TN Matrix metalloproteinase-9 (MMP-9) DM05OMF MA Inhibitor DM05OMF RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DM05OMF RU https://pubmed.ncbi.nlm.nih.gov/11327602 DM063XM DI DM063XM DM063XM DN ISIS 113131 DM063XM TI TT53XHB DM063XM TN CD86 messenger RNA (CD86 mRNA) DM063XM RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DM063XM RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DM067NL DI DM067NL DM067NL DN Benzo[1,3]dioxol-5-ylmethyl-quinazolin-4-yl-amine DM067NL TI TTJ0IQB DM067NL TN Phosphodiesterase 5A (PDE5A) DM067NL MA Inhibitor DM067NL RN Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37(13):2106-11. DM067NL RU https://pubmed.ncbi.nlm.nih.gov/8027992 DM068CY DI DM068CY DM068CY DN EUPATORIOPICRIN DM068CY TI TTICX3S DM068CY TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DM068CY MA Inhibitor DM068CY RN Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5605-9. DM068CY RU https://pubmed.ncbi.nlm.nih.gov/16945528 DM06AQZ DI DM06AQZ DM06AQZ DN Ethyl 2-cyano-2-(quinoxalin-2(1H)-ylidene)acetate DM06AQZ TI TTHY57M DM06AQZ TN Matrix metalloproteinase-13 (MMP-13) DM06AQZ MA Inhibitor DM06AQZ RN High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. DM06AQZ RU https://pubmed.ncbi.nlm.nih.gov/18358729 DM06AV8 DI DM06AV8 DM06AV8 DN 4-Pyridin-3-yl-5-quinolin-4-yl-thiazol-2-ylamine DM06AV8 TI TTP4520 DM06AV8 TN TGF-beta receptor type I (TGFBR1) DM06AV8 MA Inhibitor DM06AV8 RN Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506. DM06AV8 RU https://pubmed.ncbi.nlm.nih.gov/15317461 DM06BGV DI DM06BGV DM06BGV DN RU79256 DM06BGV TI TT6PKBN DM06BGV TN Proto-oncogene c-Src (SRC) DM06BGV MA Inhibitor DM06BGV RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM06BGV RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM06DI1 DI DM06DI1 DM06DI1 DN TCI15 DM06DI1 TI TTMSB0A DM06DI1 TN Integrin alpha-2/beta-1 (ITGA2/B1) DM06DI1 MA Inhibitor DM06DI1 RN Small-molecule inhibitors of integrin alpha2beta1 that prevent pathological thrombus formation via an allosteric mechanism. Proc Natl Acad Sci U S A. 2009 Jan 20;106(3):719-24. DM06DI1 RU https://pubmed.ncbi.nlm.nih.gov/19141632 DM06NUM DI DM06NUM DM06NUM DN (S)-2-amino-1-(4-methylthiophenyl)-propane DM06NUM TI TT3WG5C DM06NUM TN Monoamine oxidase type A (MAO-A) DM06NUM MA Inhibitor DM06NUM RN Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206. DM06NUM RU https://pubmed.ncbi.nlm.nih.gov/17521909 DM06OLY DI DM06OLY DM06OLY DN Cyclohexylcarbamic acidbiphenyl-3-yl ester DM06OLY TI TTDP1UC DM06OLY TN Fatty acid amide hydrolase (FAAH) DM06OLY MA Inhibitor DM06OLY RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DM06OLY RU https://pubmed.ncbi.nlm.nih.gov/18507372 DM06Q2V DI DM06Q2V DM06Q2V DN [des-His1,Tyr5,Glu9,D-Phe10]glucagon-NH2 DM06Q2V TI TT9O6WS DM06Q2V TN Glucagon receptor (GCGR) DM06Q2V MA Inhibitor DM06Q2V RN Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55. DM06Q2V RU https://pubmed.ncbi.nlm.nih.gov/8691441 DM06S5Z DI DM06S5Z DM06S5Z DN N-(2-methoxybenzyl)cinnamamidine DM06S5Z TI TTN9D8E DM06S5Z TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM06S5Z MA Inhibitor DM06S5Z RN Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41. DM06S5Z RU https://pubmed.ncbi.nlm.nih.gov/16213709 DM06S5Z DI DM06S5Z DM06S5Z DN N-(2-methoxybenzyl)cinnamamidine DM06S5Z TI TTKJEMQ DM06S5Z TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM06S5Z MA Inhibitor DM06S5Z RN Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41. DM06S5Z RU https://pubmed.ncbi.nlm.nih.gov/16213709 DM06S5Z DI DM06S5Z DM06S5Z DN N-(2-methoxybenzyl)cinnamamidine DM06S5Z TI TTLD29N DM06S5Z TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM06S5Z MA Inhibitor DM06S5Z RN Indole-2-carboxamidines as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5439-41. DM06S5Z RU https://pubmed.ncbi.nlm.nih.gov/16213709 DM06S9X DI DM06S9X DM06S9X DN [125I]SCH23982 DM06S9X TI TTZFYLI DM06S9X TN Dopamine D1 receptor (D1R) DM06S9X MA Antagonist DM06S9X RN Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature. 1990 Sep 6;347(6288):72-6. DM06S9X RU https://pubmed.ncbi.nlm.nih.gov/2144334 DM06S9X DI DM06S9X DM06S9X DN [125I]SCH23982 DM06S9X TI TTS2PH3 DM06S9X TN Dopamine D5 receptor (D5R) DM06S9X MA Antagonist DM06S9X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 218). DM06S9X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=218 DM06TZN DI DM06TZN DM06TZN DN 2-methyl-9H-carbazole DM06TZN TI TTBGTCW DM06TZN TN Kinesin spindle messenger RNA (KIF11 mRNA) DM06TZN MA Inhibitor DM06TZN RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM06TZN RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM06V1Q DI DM06V1Q DM06V1Q DN PMID21536438C36j DM06V1Q TI TT7QNVC DM06V1Q TN Glucose-dependent insulinotropic receptor (GPR119) DM06V1Q MA Agonist DM06V1Q RN Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3290-6. DM06V1Q RU https://pubmed.ncbi.nlm.nih.gov/21536438 DM06VGY DI DM06VGY DM06VGY DN Dmt-Pro-Emp-Phe-NH2 DM06VGY TI TTQW87Y DM06VGY TN Opioid receptor kappa (OPRK1) DM06VGY MA Inhibitor DM06VGY RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM06VGY RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM06VGY DI DM06VGY DM06VGY DN Dmt-Pro-Emp-Phe-NH2 DM06VGY TI TT27RFC DM06VGY TN Opioid receptor delta (OPRD1) DM06VGY MA Inhibitor DM06VGY RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM06VGY RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM06VGY DI DM06VGY DM06VGY DN Dmt-Pro-Emp-Phe-NH2 DM06VGY TI TTKWM86 DM06VGY TN Opioid receptor mu (MOP) DM06VGY MA Inhibitor DM06VGY RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM06VGY RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM0748C DI DM0748C DM0748C DN Meta-Tyrosine DM0748C TI TTUHP71 DM0748C TN Tyrosine 3-monooxygenase (TH) DM0748C MA Inhibitor DM0748C RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0748C RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0749Z DI DM0749Z DM0749Z DN IODOPRIDE DM0749Z TI TTEX248 DM0749Z TN Dopamine D2 receptor (D2R) DM0749Z MA Inhibitor DM0749Z RN Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8. DM0749Z RU https://pubmed.ncbi.nlm.nih.gov/8093734 DM07FBL DI DM07FBL DM07FBL DN TAS-203 DM07FBL TI TTSKMI8 DM07FBL TN Phosphodiesterase 4D (PDE4D) DM07FBL MA Inhibitor DM07FBL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DM07FBL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DM07FBL DI DM07FBL DM07FBL DN TAS-203 DM07FBL TI TTVIAT9 DM07FBL TN Phosphodiesterase 4B (PDE4B) DM07FBL MA Inhibitor DM07FBL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DM07FBL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DM07FBL DI DM07FBL DM07FBL DN TAS-203 DM07FBL TI TTZ97H5 DM07FBL TN Phosphodiesterase 4A (PDE4A) DM07FBL MA Inhibitor DM07FBL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DM07FBL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DM07HYA DI DM07HYA DM07HYA DN 5,6-dinitroacenaphthoquinone DM07HYA TI TTEB0GD DM07HYA TN Cholinesterase (BCHE) DM07HYA MA Inhibitor DM07HYA RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DM07HYA RU https://pubmed.ncbi.nlm.nih.gov/17941623 DM07HYA DI DM07HYA DM07HYA DN 5,6-dinitroacenaphthoquinone DM07HYA TI TT1RS9F DM07HYA TN Acetylcholinesterase (AChE) DM07HYA MA Inhibitor DM07HYA RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DM07HYA RU https://pubmed.ncbi.nlm.nih.gov/17941623 DM07HYA DI DM07HYA DM07HYA DN 5,6-dinitroacenaphthoquinone DM07HYA TI TTMF541 DM07HYA TN Liver carboxylesterase (CES1) DM07HYA MA Inhibitor DM07HYA RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DM07HYA RU https://pubmed.ncbi.nlm.nih.gov/17941623 DM07NT9 DI DM07NT9 DM07NT9 DN 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol DM07NT9 TI TTZAYWL DM07NT9 TN Estrogen receptor (ESR) DM07NT9 MA Inhibitor DM07NT9 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM07NT9 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM07NT9 DI DM07NT9 DM07NT9 DN 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol DM07NT9 TI TTOM3J0 DM07NT9 TN Estrogen receptor beta (ESR2) DM07NT9 MA Inhibitor DM07NT9 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM07NT9 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM07P5E DI DM07P5E DM07P5E DN 5-(2-phenethylpiperazin-1-yl)-1H-indazole DM07P5E TI TTXV4FI DM07P5E TN Albendazole monooxygenase (CYP3A4) DM07P5E MA Inhibitor DM07P5E RN 2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression, Bioorg. Med. Chem. Lett. 20(13):3941-3945 (2010). DM07P5E RU http://www.sciencedirect.com/science/article/pii/S0960894X10006372 DM07QD3 DI DM07QD3 DM07QD3 DN 7-bromoindirubin-3-oxime DM07QD3 TI TT9RTBL DM07QD3 TN Aurora B messenger RNA (AURKB mRNA) DM07QD3 MA Inhibitor DM07QD3 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM07QD3 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM07QD3 DI DM07QD3 DM07QD3 DN 7-bromoindirubin-3-oxime DM07QD3 TI TTLYXIT DM07QD3 TN Aurora kinase C (AURKC) DM07QD3 MA Inhibitor DM07QD3 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM07QD3 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM07TVS DI DM07TVS DM07TVS DN PMID17929793C23i DM07TVS TI TTVBPDM DM07TVS TN Metabotropic glutamate receptor 1 (mGluR1) DM07TVS MA Modulator (allosteric modulator) DM07TVS RN Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3. DM07TVS RU https://pubmed.ncbi.nlm.nih.gov/17929793 DM07VRS DI DM07VRS DM07VRS DN CV-1808 DM07VRS TI TTNE7KG DM07VRS TN Adenosine A2b receptor (ADORA2B) DM07VRS MA Agonist DM07VRS RN Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol. 1997 Jun;121(3):353-60. DM07VRS RU https://pubmed.ncbi.nlm.nih.gov/9179373 DM07XBG DI DM07XBG DM07XBG DN JWH-268 DM07XBG TI TTMSFAW DM07XBG TN Cannabinoid receptor 2 (CB2) DM07XBG MA Inhibitor DM07XBG RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DM07XBG RU https://pubmed.ncbi.nlm.nih.gov/19143566 DM07XBG DI DM07XBG DM07XBG DN JWH-268 DM07XBG TI TT6OEDT DM07XBG TN Cannabinoid receptor 1 (CB1) DM07XBG MA Inhibitor DM07XBG RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DM07XBG RU https://pubmed.ncbi.nlm.nih.gov/19143566 DM081G2 DI DM081G2 DM081G2 DN 9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide DM081G2 TI TTEB0GD DM081G2 TN Cholinesterase (BCHE) DM081G2 MA Inhibitor DM081G2 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DM081G2 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DM081G2 DI DM081G2 DM081G2 DN 9-O-[2-(Phenylol-1-yloxy)hexyl]berberine bromide DM081G2 TI TT1RS9F DM081G2 TN Acetylcholinesterase (AChE) DM081G2 MA Inhibitor DM081G2 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DM081G2 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DM086VJ DI DM086VJ DM086VJ DN N-(4,4-Diphenyl-butyl)-nicotinamide DM086VJ TI TT7WVHI DM086VJ TN Soluble epoxide hydrolase (EPHX2) DM086VJ MA Inhibitor DM086VJ RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DM086VJ RU https://pubmed.ncbi.nlm.nih.gov/19746975 DM0872E DI DM0872E DM0872E DN 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane DM0872E TI TTVBI8W DM0872E TN Dopamine transporter (DAT) DM0872E MA Inhibitor DM0872E RN 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7. DM0872E RU https://pubmed.ncbi.nlm.nih.gov/11078197 DM0872E DI DM0872E DM0872E DN 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane DM0872E TI TTAWNKZ DM0872E TN Norepinephrine transporter (NET) DM0872E MA Inhibitor DM0872E RN 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7. DM0872E RU https://pubmed.ncbi.nlm.nih.gov/11078197 DM0872E DI DM0872E DM0872E DN 3-p-Tolyl-8-aza-bicyclo[3.2.1]octane DM0872E TI TT3ROYC DM0872E TN Serotonin transporter (SERT) DM0872E MA Inhibitor DM0872E RN 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7. DM0872E RU https://pubmed.ncbi.nlm.nih.gov/11078197 DM08963 DI DM08963 DM08963 DN 4-(1-Imidazol-1-yl-vinyl)-benzonitrile DM08963 TI TTSZLWK DM08963 TN Aromatase (CYP19A1) DM08963 MA Inhibitor DM08963 RN Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem. 1993 May 14;36(10):1393-400. DM08963 RU https://pubmed.ncbi.nlm.nih.gov/8496907 DM08CG7 DI DM08CG7 DM08CG7 DN 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine DM08CG7 TI TTS2PH3 DM08CG7 TN Dopamine D5 receptor (D5R) DM08CG7 MA Inhibitor DM08CG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DM08CG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DM08CG7 DI DM08CG7 DM08CG7 DN 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine DM08CG7 TI TTE0A2F DM08CG7 TN Dopamine D4 receptor (D4R) DM08CG7 MA Inhibitor DM08CG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DM08CG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DM08CG7 DI DM08CG7 DM08CG7 DN 4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine DM08CG7 TI TTZFYLI DM08CG7 TN Dopamine D1 receptor (D1R) DM08CG7 MA Inhibitor DM08CG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DM08CG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DM08GRF DI DM08GRF DM08GRF DN 3-(2-Diethylamino-acetamino)-rutaecarpine DM08GRF TI TTEB0GD DM08GRF TN Cholinesterase (BCHE) DM08GRF MA Inhibitor DM08GRF RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DM08GRF RU https://pubmed.ncbi.nlm.nih.gov/20079560 DM08GRF DI DM08GRF DM08GRF DN 3-(2-Diethylamino-acetamino)-rutaecarpine DM08GRF TI TT1RS9F DM08GRF TN Acetylcholinesterase (AChE) DM08GRF MA Inhibitor DM08GRF RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DM08GRF RU https://pubmed.ncbi.nlm.nih.gov/20079560 DM08SVH DI DM08SVH DM08SVH DN MEL57A DM08SVH TI TTNB6UQ DM08SVH TN Hyperpolarization cyclic nucleotide-gated channel 1 (HCN1) DM08SVH MA Blocker (channel blocker) DM08SVH RN Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue. Br J Pharmacol. 2012 May;166(2):602-16. DM08SVH RU https://pubmed.ncbi.nlm.nih.gov/22091830 DM08UQF DI DM08UQF DM08UQF DN (3-Hydroxy-2-methyl-phenyl)-trimethyl-ammonium DM08UQF TI TT1RS9F DM08UQF TN Acetylcholinesterase (AChE) DM08UQF MA Inhibitor DM08UQF RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DM08UQF RU https://pubmed.ncbi.nlm.nih.gov/8978837 DM08V9W DI DM08V9W DM08V9W DN 3-Nitro-9H-beta-carboline DM08V9W TI TTNJYV2 DM08V9W TN Gamma-aminobutyric acid receptor (GAR) DM08V9W MA Inhibitor DM08V9W RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DM08V9W RU https://pubmed.ncbi.nlm.nih.gov/2842507 DM08V9W DI DM08V9W DM08V9W DN 3-Nitro-9H-beta-carboline DM08V9W TI TT1MPAY DM08V9W TN GABA(A) receptor alpha-1 (GABRA1) DM08V9W MA Inhibitor DM08V9W RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DM08V9W RU https://pubmed.ncbi.nlm.nih.gov/2842507 DM08VHZ DI DM08VHZ DM08VHZ DN Indirubin-5-sulfonate DM08VHZ TI TTZHY6R DM08VHZ TN Glycogen phosphorylase muscle form (GP) DM08VHZ MA Inhibitor DM08VHZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM08VHZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM08VHZ DI DM08VHZ DM08VHZ DN Indirubin-5-sulfonate DM08VHZ TI TT9PCE0 DM08VHZ TN Plasmodium CDK PfPK5 (Malaria PfPK5) DM08VHZ MA Inhibitor DM08VHZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM08VHZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM08VHZ DI DM08VHZ DM08VHZ DN Indirubin-5-sulfonate DM08VHZ TI TTL4Q97 DM08VHZ TN Cyclin-dependent kinase 5 (CDK5) DM08VHZ MA Inhibitor DM08VHZ RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DM08VHZ RU https://pubmed.ncbi.nlm.nih.gov/12237154 DM08VHZ DI DM08VHZ DM08VHZ DN Indirubin-5-sulfonate DM08VHZ TI TT7HF4W DM08VHZ TN Cyclin-dependent kinase 2 (CDK2) DM08VHZ MA Inhibitor DM08VHZ RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DM08VHZ RU https://pubmed.ncbi.nlm.nih.gov/12237154 DM08VHZ DI DM08VHZ DM08VHZ DN Indirubin-5-sulfonate DM08VHZ TI TTH6V3D DM08VHZ TN Cyclin-dependent kinase 1 (CDK1) DM08VHZ MA Binder DM08VHZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM08VHZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM08W6U DI DM08W6U DM08W6U DN Naphthalen-2-yl 10H-phenothiazine-10-carboxylate DM08W6U TI TTEB0GD DM08W6U TN Cholinesterase (BCHE) DM08W6U MA Inhibitor DM08W6U RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DM08W6U RU https://pubmed.ncbi.nlm.nih.gov/18570368 DM08WPL DI DM08WPL DM08WPL DN CODEINONE DM08WPL TI TTKWM86 DM08WPL TN Opioid receptor mu (MOP) DM08WPL MA Inhibitor DM08WPL RN Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32. DM08WPL RU https://pubmed.ncbi.nlm.nih.gov/17616524 DM093GO DI DM093GO DM093GO DN N-((1H-indol-2-yl)methyl)(phenyl)methanamine DM093GO TI TT3WG5C DM093GO TN Monoamine oxidase type A (MAO-A) DM093GO MA Inhibitor DM093GO RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DM093GO RU https://pubmed.ncbi.nlm.nih.gov/18951803 DM096SC DI DM096SC DM096SC DN Phorbol 12-myristate DM096SC TI TTBZ7OD DM096SC TN Protein kinase C epsilon (PRKCE) DM096SC MA Activator DM096SC RN Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8. DM096SC RU https://pubmed.ncbi.nlm.nih.gov/11490365 DM096SI DI DM096SI DM096SI DN Methyl Phosphinic Acid DM096SI TI TT1RS9F DM096SI TN Acetylcholinesterase (AChE) DM096SI MA Inhibitor DM096SI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM096SI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM096SI DI DM096SI DM096SI DN Methyl Phosphinic Acid DM096SI TI TTEB0GD DM096SI TN Cholinesterase (BCHE) DM096SI MA Inhibitor DM096SI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM096SI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM09BJ4 DI DM09BJ4 DM09BJ4 DN AC-8632 DM09BJ4 TI TTY84UG DM09BJ4 TN Acetyl-CoA carboxylase 2 (ACACB) DM09BJ4 MA Inhibitor DM09BJ4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264). DM09BJ4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264 DM09BJ4 DI DM09BJ4 DM09BJ4 DN AC-8632 DM09BJ4 TI TTYAWV0 DM09BJ4 TN Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) DM09BJ4 MA Inhibitor DM09BJ4 RN Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science. 2000 Jun 30;288(5475):2379-81. DM09BJ4 RU https://pubmed.ncbi.nlm.nih.gov/10875926 DM09IEK DI DM09IEK DM09IEK DN PMID19191557C35 DM09IEK TI TTFQEO5 DM09IEK TN Squalene synthetase (FDFT1) DM09IEK MA Inhibitor DM09IEK RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DM09IEK RU https://pubmed.ncbi.nlm.nih.gov/19191557 DM09LY4 DI DM09LY4 DM09LY4 DN 3,3-Dimethyl-dihydro-furan-2-one DM09LY4 TI TTNJYV2 DM09LY4 TN Gamma-aminobutyric acid receptor (GAR) DM09LY4 MA Inhibitor DM09LY4 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM09LY4 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM09MY1 DI DM09MY1 DM09MY1 DN Phosphonotyrosine DM09MY1 TI TT6PKBN DM09MY1 TN Proto-oncogene c-Src (SRC) DM09MY1 MA Inhibitor DM09MY1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM09MY1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM09MY1 DI DM09MY1 DM09MY1 DN Phosphonotyrosine DM09MY1 TI TTX41N9 DM09MY1 TN Tyrosine-protein kinase Kit (KIT) DM09MY1 MA Inhibitor DM09MY1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM09MY1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM09NGV DI DM09NGV DM09NGV DN Ribavirin-TP DM09NGV TI TTWXB3E DM09NGV TN Hepatitis C virus NS3 helicase (HCV NS3) DM09NGV MA Inhibitor DM09NGV RN ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim Pol. 2000;47(1):173-80. DM09NGV RU https://pubmed.ncbi.nlm.nih.gov/10961691 DM09T76 DI DM09T76 DM09T76 DN physalaemin DM09T76 TI TTZPO1L DM09T76 TN Substance-P receptor (TACR1) DM09T76 MA Agonist DM09T76 RN The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7. DM09T76 RU https://pubmed.ncbi.nlm.nih.gov/8702757 DM09UFT DI DM09UFT DM09UFT DN NCT-400 DM09UFT TI TTKWM86 DM09UFT TN Opioid receptor mu (MOP) DM09UFT MA Modulator DM09UFT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DM09UFT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DM09UIS DI DM09UIS DM09UIS DN SB-202235 DM09UIS TI TT2J34L DM09UIS TN Arachidonate 5-lipoxygenase (5-LOX) DM09UIS MA Modulator DM09UIS RN Pharmacological characterization of SB 202235, a potent and selective 5-lipoxygenase inhibitor: effects in models of allergic asthma. J Pharmacol Exp Ther. 1995 Jun;273(3):1147-55. DM09UIS RU https://www.ncbi.nlm.nih.gov/pubmed/7791085 DM09Y72 DI DM09Y72 DM09Y72 DN 5-Bromo-8-imidazol-1-ylmethyl-chromen-4-one DM09Y72 TI TTSZLWK DM09Y72 TN Aromatase (CYP19A1) DM09Y72 MA Inhibitor DM09Y72 RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DM09Y72 RU https://pubmed.ncbi.nlm.nih.gov/11262078 DM09YI7 DI DM09YI7 DM09YI7 DN DBT-1339 DM09YI7 TI TTE4KHA DM09YI7 TN Amyloid beta A4 protein (APP) DM09YI7 MA Inhibitor DM09YI7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM09YI7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM09Z35 DI DM09Z35 DM09Z35 DN bilobalide DM09Z35 TI TTR6K75 DM09Z35 TN 5-HT 3B receptor (HTR3B) DM09Z35 MA Blocker (channel blocker) DM09Z35 RN Ginkgolide B and bilobalide block the pore of the 5-HT eceptor at a location that overlaps the picrotoxin binding site. Neuropharmacology. 2011 Feb-Mar;60(2-3):488-95. DM09Z35 RU https://pubmed.ncbi.nlm.nih.gov/21059362 DM09Z35 DI DM09Z35 DM09Z35 DN bilobalide DM09Z35 TI TTPC4TU DM09Z35 TN 5-HT 3A receptor (HTR3A) DM09Z35 MA Blocker (channel blocker) DM09Z35 RN Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol. 2011 Jul;80(1):183-90. DM09Z35 RU https://pubmed.ncbi.nlm.nih.gov/21505038 DM09Z35 DI DM09Z35 DM09Z35 DN bilobalide DM09Z35 TI TTZ8EM9 DM09Z35 TN Glycine receptor (GlyR) DM09Z35 MA Antagonist DM09Z35 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 427). DM09Z35 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=427 DM0A1YI DI DM0A1YI DM0A1YI DN 1na DM0A1YI TI TTE5VG0 DM0A1YI TN P-selectin (SELP) DM0A1YI MA Inhibitor DM0A1YI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0A1YI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0A1YI DI DM0A1YI DM0A1YI DN 1na DM0A1YI TI TTAU4D6 DM0A1YI TN E-selectin (SELE) DM0A1YI MA Inhibitor DM0A1YI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0A1YI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0A2MG DI DM0A2MG DM0A2MG DN L-761000 DM0A2MG TI TTVKILB DM0A2MG TN Prostaglandin G/H synthase 2 (COX-2) DM0A2MG MA Inhibitor DM0A2MG RN From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 6(6):725-730 (1996). DM0A2MG RU http://www.sciencedirect.com/science/article/pii/0960894X9600100X DM0A2UF DI DM0A2UF DM0A2UF DN HS-173 DM0A2UF TI TTHBTOP DM0A2UF TN PI3-kinase gamma (PIK3CG) DM0A2UF MA Inhibitor DM0A2UF RN Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis. J Med Chem. 2011 Apr 14;54(7):2455-66. DM0A2UF RU https://pubmed.ncbi.nlm.nih.gov/21388141 DM0A3DB DI DM0A3DB DM0A3DB DN 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine DM0A3DB TI TTVBPDM DM0A3DB TN Metabotropic glutamate receptor 1 (mGluR1) DM0A3DB MA Inhibitor DM0A3DB RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DM0A3DB RU https://pubmed.ncbi.nlm.nih.gov/19854049 DM0A3DB DI DM0A3DB DM0A3DB DN 6-bromo-N-(3-chlorophenyl)quinazolin-4-amine DM0A3DB TI TTHS256 DM0A3DB TN Metabotropic glutamate receptor 5 (mGluR5) DM0A3DB MA Inhibitor DM0A3DB RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DM0A3DB RU https://pubmed.ncbi.nlm.nih.gov/19854049 DM0A54V DI DM0A54V DM0A54V DN D-65476 DM0A54V TI TT8FYO9 DM0A54V TN Platelet-derived growth factor receptor alpha (PDGFRA) DM0A54V MA Inhibitor DM0A54V RN Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem. 2002 Feb 28;45(5):1002-18. DM0A54V RU https://pubmed.ncbi.nlm.nih.gov/11855980 DM0AC3S DI DM0AC3S DM0AC3S DN ISIS 16123 DM0AC3S TI TTHMYB1 DM0AC3S TN E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA) DM0AC3S RN US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression. DM0AC3S RU http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true DM0AC84 DI DM0AC84 DM0AC84 DN Ro01-6128 DM0AC84 TI TTVBPDM DM0AC84 TN Metabotropic glutamate receptor 1 (mGluR1) DM0AC84 MA Modulator (allosteric modulator) DM0AC84 RN Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7. DM0AC84 RU https://pubmed.ncbi.nlm.nih.gov/11606768 DM0ACKJ DI DM0ACKJ DM0ACKJ DN RO-145974 DM0ACKJ TI TT06RH5 DM0ACKJ TN GABA(A) receptor gamma-2 (GABRG2) DM0ACKJ MA Inhibitor DM0ACKJ RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM0ACKJ RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM0ACKJ DI DM0ACKJ DM0ACKJ DN RO-145974 DM0ACKJ TI TTNJYV2 DM0ACKJ TN Gamma-aminobutyric acid receptor (GAR) DM0ACKJ MA Inhibitor DM0ACKJ RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM0ACKJ RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM0ACKJ DI DM0ACKJ DM0ACKJ DN RO-145974 DM0ACKJ TI TTZA1NY DM0ACKJ TN GABA(A) receptor beta-2 (GABRB2) DM0ACKJ MA Inhibitor DM0ACKJ RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM0ACKJ RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM0ACKJ DI DM0ACKJ DM0ACKJ DN RO-145974 DM0ACKJ TI TT1MPAY DM0ACKJ TN GABA(A) receptor alpha-1 (GABRA1) DM0ACKJ MA Inhibitor DM0ACKJ RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM0ACKJ RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM0ACL9 DI DM0ACL9 DM0ACL9 DN Coformycin DM0ACL9 TI TTKZ09F DM0ACL9 TN Adenosine monophosphate deaminase (AMPD) DM0ACL9 MA Inhibitor DM0ACL9 RN Mechanisms of cell death induced by 2-chloroadenosine in leukemic B-cells. Biochem Pharmacol. 2008 Apr 1;75(7):1451-60. DM0ACL9 RU https://pubmed.ncbi.nlm.nih.gov/18242582 DM0AFY7 DI DM0AFY7 DM0AFY7 DN Glyphosate DM0AFY7 TI TTVL895 DM0AFY7 TN Plasmodium Enopyruvyl shikimate phosphate synthase (Malaria ESPS) DM0AFY7 MA Inhibitor DM0AFY7 RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DM0AFY7 RU https://pubmed.ncbi.nlm.nih.gov/11768328 DM0AFY7 DI DM0AFY7 DM0AFY7 DN Glyphosate DM0AFY7 TI TTB30PF DM0AFY7 TN Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA) DM0AFY7 MA Inhibitor DM0AFY7 RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DM0AFY7 RU https://pubmed.ncbi.nlm.nih.gov/17339102 DM0AIOW DI DM0AIOW DM0AIOW DN 5-methyl nicotinic acid DM0AIOW TI TTWNV8U DM0AIOW TN Nicotinic acid receptor (HCAR2) DM0AIOW MA Agonist DM0AIOW RN Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. DM0AIOW RU https://pubmed.ncbi.nlm.nih.gov/12522134 DM0ARKB DI DM0ARKB DM0ARKB DN 1-(1,2-diphenylethyl)piperazine DM0ARKB TI TTAWNKZ DM0ARKB TN Norepinephrine transporter (NET) DM0ARKB MA Inhibitor DM0ARKB RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM0ARKB RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM0ARKB DI DM0ARKB DM0ARKB DN 1-(1,2-diphenylethyl)piperazine DM0ARKB TI TT3ROYC DM0ARKB TN Serotonin transporter (SERT) DM0ARKB MA Inhibitor DM0ARKB RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM0ARKB RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM0ARP8 DI DM0ARP8 DM0ARP8 DN N-(4'-chloro-4-biphenylyl)methanesulfonamide DM0ARP8 TI TTBGTCW DM0ARP8 TN Kinesin spindle messenger RNA (KIF11 mRNA) DM0ARP8 MA Inhibitor DM0ARP8 RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DM0ARP8 RU https://pubmed.ncbi.nlm.nih.gov/17725339 DM0AZLE DI DM0AZLE DM0AZLE DN WY-46016 DM0AZLE TI TTGKOY9 DM0AZLE TN Leukotriene CysLT1 receptor (CYSLTR1) DM0AZLE MA Modulator DM0AZLE RN N-[(arylmethoxy)phenyl] carboxylic acids, hydroxamic acids, tetrazoles, and sulfonyl carboxamides.Potent orally active leukotriene D4 antagonists of novel structure.J Med Chem.1990 Jan;33(1):240-5. DM0AZLE RU https://www.ncbi.nlm.nih.gov/pubmed/2104935 DM0B4RD DI DM0B4RD DM0B4RD DN ISIS 6739 DM0B4RD TI TTBLG3H DM0B4RD TN P120 messenger RNA (NOP2 mRNA) DM0B4RD RN US patent application no. 5,814,619, Oligonucleotide inhibition of P120. DM0B4RD RU http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true DM0B54M DI DM0B54M DM0B54M DN [3H](S)-zacopride DM0B54M TI TTPC4TU DM0B54M TN 5-HT 3A receptor (HTR3A) DM0B54M MA Antagonist DM0B54M RN Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J Neurol Sci. 1996 Dec;144(1-2):119-27. DM0B54M RU https://pubmed.ncbi.nlm.nih.gov/8994113 DM0B7NO DI DM0B7NO DM0B7NO DN Isoarnebin 4 DM0B7NO TI TTNHMO8 DM0B7NO TN COVID-19 papain-like proteinase (PL-PRO) DM0B7NO MA Inhibitor DM0B7NO RN Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. DM0B7NO RU https://pubmed.ncbi.nlm.nih.gov/32272481 DM0B9V5 DI DM0B9V5 DM0B9V5 DN ISIS 113909 DM0B9V5 TI TTIX0ZU DM0B9V5 TN MEKK2 messenger RNA (MAP3K2 mRNA) DM0B9V5 RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DM0B9V5 RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DM0BAX4 DI DM0BAX4 DM0BAX4 DN ISIS 188755 DM0BAX4 TI TTLRVIA DM0BAX4 TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DM0BAX4 RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DM0BAX4 RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DM0BEZS DI DM0BEZS DM0BEZS DN Quinapril analogue DM0BEZS TI TTGY8IW DM0BEZS TN B2 bradykinin receptor (BDKRB2) DM0BEZS MA Inhibitor DM0BEZS RN Ace inhibitors as a template for the design of bradykinin B2 receptor antagonists, Bioorg. Med. Chem. Lett. 5(4):367-370 (1995). DM0BEZS RU http://www.sciencedirect.com/science/article/pii/0960894X9500037T DM0BGNE DI DM0BGNE DM0BGNE DN H-Dmt-Tic-NH-(CH2)6-NH-Phe-H DM0BGNE TI TTKWM86 DM0BGNE TN Opioid receptor mu (MOP) DM0BGNE MA Inhibitor DM0BGNE RN New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. DM0BGNE RU https://pubmed.ncbi.nlm.nih.gov/16183273 DM0BGNE DI DM0BGNE DM0BGNE DN H-Dmt-Tic-NH-(CH2)6-NH-Phe-H DM0BGNE TI TT27RFC DM0BGNE TN Opioid receptor delta (OPRD1) DM0BGNE MA Inhibitor DM0BGNE RN New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. DM0BGNE RU https://pubmed.ncbi.nlm.nih.gov/16183273 DM0BHCJ DI DM0BHCJ DM0BHCJ DN Pyrrolidin-3-yl-acetic acid DM0BHCJ TI TT1MPAY DM0BHCJ TN GABA(A) receptor alpha-1 (GABRA1) DM0BHCJ MA Inhibitor DM0BHCJ RN Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985 May;28(5):653-60. DM0BHCJ RU https://pubmed.ncbi.nlm.nih.gov/2985785 DM0BHCJ DI DM0BHCJ DM0BHCJ DN Pyrrolidin-3-yl-acetic acid DM0BHCJ TI TTNJYV2 DM0BHCJ TN Gamma-aminobutyric acid receptor (GAR) DM0BHCJ MA Inhibitor DM0BHCJ RN Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985 May;28(5):653-60. DM0BHCJ RU https://pubmed.ncbi.nlm.nih.gov/2985785 DM0BHKM DI DM0BHKM DM0BHKM DN 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine DM0BHKM TI TTK25J1 DM0BHKM TN Adenosine A1 receptor (ADORA1) DM0BHKM MA Inhibitor DM0BHKM RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DM0BHKM RU https://pubmed.ncbi.nlm.nih.gov/18407496 DM0BHKM DI DM0BHKM DM0BHKM DN 2-ethyl-4-(furan-2-yl)thieno[3,2-d]pyrimidine DM0BHKM TI TTM2AOE DM0BHKM TN Adenosine A2a receptor (ADORA2A) DM0BHKM MA Inhibitor DM0BHKM RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DM0BHKM RU https://pubmed.ncbi.nlm.nih.gov/18407496 DM0BNYU DI DM0BNYU DM0BNYU DN NV-31 DM0BNYU TI TTZ8EM9 DM0BNYU TN Glycine receptor (GlyR) DM0BNYU RN Subunit-specific potentiation of recombinant glycine receptors by NV-31, a bilobalide-derived compound. Neurosci Lett. 2008 Apr 18;435(2):147-51. DM0BNYU RU https://pubmed.ncbi.nlm.nih.gov/18329806 DM0BPCT DI DM0BPCT DM0BPCT DN N-omega-allyl-L-arginine DM0BPCT TI TTF10I9 DM0BPCT TN Nitric-oxide synthase inducible (NOS2) DM0BPCT MA Inhibitor DM0BPCT RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM0BPCT RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM0BPCT DI DM0BPCT DM0BPCT DN N-omega-allyl-L-arginine DM0BPCT TI TTZUFI5 DM0BPCT TN Nitric-oxide synthase brain (NOS1) DM0BPCT MA Inhibitor DM0BPCT RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM0BPCT RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM0BPCT DI DM0BPCT DM0BPCT DN N-omega-allyl-L-arginine DM0BPCT TI TTCM4B3 DM0BPCT TN Nitric-oxide synthase endothelial (NOS3) DM0BPCT MA Inhibitor DM0BPCT RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM0BPCT RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM0BQYX DI DM0BQYX DM0BQYX DN 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol DM0BQYX TI TT27RFC DM0BQYX TN Opioid receptor delta (OPRD1) DM0BQYX MA Inhibitor DM0BQYX RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM0BQYX RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM0BQYX DI DM0BQYX DM0BQYX DN 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol DM0BQYX TI TTQW87Y DM0BQYX TN Opioid receptor kappa (OPRK1) DM0BQYX MA Inhibitor DM0BQYX RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM0BQYX RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM0BQYX DI DM0BQYX DM0BQYX DN 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol DM0BQYX TI TTNT7K8 DM0BQYX TN Nociceptin receptor (OPRL1) DM0BQYX MA Inhibitor DM0BQYX RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM0BQYX RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM0BQYX DI DM0BQYX DM0BQYX DN 1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol DM0BQYX TI TTKWM86 DM0BQYX TN Opioid receptor mu (MOP) DM0BQYX MA Inhibitor DM0BQYX RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM0BQYX RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM0BV9I DI DM0BV9I DM0BV9I DN AcGlu-Dif-Glu-Cha-Cys DM0BV9I TI TTWXB3E DM0BV9I TN Hepatitis C virus NS3 helicase (HCV NS3) DM0BV9I MA Inhibitor DM0BV9I RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DM0BV9I RU https://pubmed.ncbi.nlm.nih.gov/11206459 DM0BVJN DI DM0BVJN DM0BVJN DN APG-201 DM0BVJN TI TTDWHC3 DM0BVJN TN Interleukin 4 receptor alpha (IL4R) DM0BVJN MA Antagonist DM0BVJN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697). DM0BVJN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697 DM0C1FX DI DM0C1FX DM0C1FX DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DM0C1FX TI TTMSFAW DM0C1FX TN Cannabinoid receptor 2 (CB2) DM0C1FX MA Inhibitor DM0C1FX RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM0C1FX RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM0C1FX DI DM0C1FX DM0C1FX DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DM0C1FX TI TT6OEDT DM0C1FX TN Cannabinoid receptor 1 (CB1) DM0C1FX MA Inhibitor DM0C1FX RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM0C1FX RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM0C3SF DI DM0C3SF DM0C3SF DN LP-44 DM0C3SF TI TTJQOD7 DM0C3SF TN 5-HT 2A receptor (HTR2A) DM0C3SF MA Agonist DM0C3SF RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM0C3SF RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM0C3SF DI DM0C3SF DM0C3SF DN LP-44 DM0C3SF TI TTSQIFT DM0C3SF TN 5-HT 1A receptor (HTR1A) DM0C3SF MA Agonist DM0C3SF RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM0C3SF RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM0C3SF DI DM0C3SF DM0C3SF DN LP-44 DM0C3SF TI TTEX248 DM0C3SF TN Dopamine D2 receptor (D2R) DM0C3SF MA Agonist DM0C3SF RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM0C3SF RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM0C3SF DI DM0C3SF DM0C3SF DN LP-44 DM0C3SF TI TTO9X1H DM0C3SF TN 5-HT 7 receptor (HTR7) DM0C3SF MA Agonist DM0C3SF RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM0C3SF RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM0C4GP DI DM0C4GP DM0C4GP DN Alpha-methylcubebin DM0C4GP TI TTXV4FI DM0C4GP TN Albendazole monooxygenase (CYP3A4) DM0C4GP MA Inhibitor DM0C4GP RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DM0C4GP RU https://pubmed.ncbi.nlm.nih.gov/15679319 DM0C4QD DI DM0C4QD DM0C4QD DN ADS-103293 DM0C4QD TI TTX4RTB DM0C4QD TN Melanin-concentrating hormone receptor 1 (MCHR1) DM0C4QD MA Inhibitor DM0C4QD RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DM0C4QD RU https://pubmed.ncbi.nlm.nih.gov/17178222 DM0C5O3 DI DM0C5O3 DM0C5O3 DN 2-(Biphenyl-2-yloxy)-N,N-dimethylethanamine DM0C5O3 TI TTO9X1H DM0C5O3 TN 5-HT 7 receptor (HTR7) DM0C5O3 MA Inhibitor DM0C5O3 RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DM0C5O3 RU https://pubmed.ncbi.nlm.nih.gov/20138771 DM0C8BW DI DM0C8BW DM0C8BW DN 2,6-diphenyl-8-ethyl-1-deazapurine DM0C8BW TI TTJFY5U DM0C8BW TN Adenosine A3 receptor (ADORA3) DM0C8BW MA Inhibitor DM0C8BW RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM0C8BW RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM0C8BW DI DM0C8BW DM0C8BW DN 2,6-diphenyl-8-ethyl-1-deazapurine DM0C8BW TI TTK25J1 DM0C8BW TN Adenosine A1 receptor (ADORA1) DM0C8BW MA Inhibitor DM0C8BW RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM0C8BW RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM0C8BW DI DM0C8BW DM0C8BW DN 2,6-diphenyl-8-ethyl-1-deazapurine DM0C8BW TI TTM2AOE DM0C8BW TN Adenosine A2a receptor (ADORA2A) DM0C8BW MA Inhibitor DM0C8BW RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM0C8BW RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM0C8N3 DI DM0C8N3 DM0C8N3 DN NNC 711 DM0C8N3 TI TTV9MQG DM0C8N3 TN Gamma-aminobutyric acid uptake (GABAU) DM0C8N3 MA Inhibitor DM0C8N3 RN Effects of NNC 711, a GABA uptake inhibitor, on pentylenetetrazol-induced seizures in developing and adult rats. Naunyn Schmiedebergs Arch Pharmacol. 1998 Sep;358(3):334-41. DM0C8N3 RU https://pubmed.ncbi.nlm.nih.gov/9774221 DM0CAKS DI DM0CAKS DM0CAKS DN MRS2496 DM0CAKS TI TTA93TL DM0CAKS TN P2Y purinoceptor 1 (P2RY1) DM0CAKS MA Antagonist DM0CAKS RN Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol. 2004 Nov 15;68(10):1995-2002. DM0CAKS RU https://pubmed.ncbi.nlm.nih.gov/15476670 DM0CDRP DI DM0CDRP DM0CDRP DN 2-(4-fluorophenylsulfonamido)-1-naphthoic acid DM0CDRP TI TTZL0OI DM0CDRP TN Methionine aminopeptidase 2 (METAP2) DM0CDRP MA Inhibitor DM0CDRP RN Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. DM0CDRP RU https://pubmed.ncbi.nlm.nih.gov/16632353 DM0CEY3 DI DM0CEY3 DM0CEY3 DN Lefaxin DM0CEY3 TI TTCIHJA DM0CEY3 TN Coagulation factor Xa (F10) DM0CEY3 MA Inhibitor DM0CEY3 RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DM0CEY3 RU https://pubmed.ncbi.nlm.nih.gov/11804648 DM0CI4L DI DM0CI4L DM0CI4L DN N-[3H]methylhistamine DM0CI4L TI TTXJ178 DM0CI4L TN Histamine H4 receptor (H4R) DM0CI4L MA Agonist DM0CI4L RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DM0CI4L RU https://pubmed.ncbi.nlm.nih.gov/11179434 DM0CI4L DI DM0CI4L DM0CI4L DN N-[3H]methylhistamine DM0CI4L TI TT9JNIC DM0CI4L TN Histamine H3 receptor (H3R) DM0CI4L MA Agonist DM0CI4L RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DM0CI4L RU https://pubmed.ncbi.nlm.nih.gov/11179434 DM0CP36 DI DM0CP36 DM0CP36 DN NalBzOH DM0CP36 TI TTQW87Y DM0CP36 TN Opioid receptor kappa (OPRK1) DM0CP36 MA Inhibitor DM0CP36 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM0CP36 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM0CP36 DI DM0CP36 DM0CP36 DN NalBzOH DM0CP36 TI TTKWM86 DM0CP36 TN Opioid receptor mu (MOP) DM0CP36 MA Inhibitor DM0CP36 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM0CP36 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM0CQIP DI DM0CQIP DM0CQIP DN Duocarmycin DM0CQIP TI TTOVXHF DM0CQIP TN Human Deoxyribonucleic acid minor groove (hDNA min) DM0CQIP MA Breaker DM0CQIP RN Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215. DM0CQIP RU https://pubmed.ncbi.nlm.nih.gov/10576292 DM0CS3V DI DM0CS3V DM0CS3V DN MRS2365 DM0CS3V TI TTA93TL DM0CS3V TN P2Y purinoceptor 1 (P2RY1) DM0CS3V MA Agonist DM0CS3V RN Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational con... J Pharmacol Exp Ther. 2004 Dec;311(3):1038-43. DM0CS3V RU https://pubmed.ncbi.nlm.nih.gov/15345752 DM0CSH8 DI DM0CSH8 DM0CSH8 DN 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole DM0CSH8 TI TTTU902 DM0CSH8 TN Checkpoint kinase-1 (CHK1) DM0CSH8 MA Inhibitor DM0CSH8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0CSH8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0CSH8 DI DM0CSH8 DM0CSH8 DN 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole DM0CSH8 TI TTRLW2X DM0CSH8 TN Fibroblast growth factor receptor 1 (FGFR1) DM0CSH8 MA Inhibitor DM0CSH8 RN Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9. DM0CSH8 RU https://pubmed.ncbi.nlm.nih.gov/16603352 DM0CSH8 DI DM0CSH8 DM0CSH8 DN 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole DM0CSH8 TI TTI7421 DM0CSH8 TN Platelet-derived growth factor receptor beta (PDGFRB) DM0CSH8 MA Inhibitor DM0CSH8 RN Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9. DM0CSH8 RU https://pubmed.ncbi.nlm.nih.gov/16603352 DM0CSH8 DI DM0CSH8 DM0CSH8 DN 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole DM0CSH8 TI TT1VAUK DM0CSH8 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM0CSH8 MA Inhibitor DM0CSH8 RN Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9. DM0CSH8 RU https://pubmed.ncbi.nlm.nih.gov/16603352 DM0CSH8 DI DM0CSH8 DM0CSH8 DN 2-(1H-indazol-3-yl)-1H-benzo[d]imidazole DM0CSH8 TI TTUTJGQ DM0CSH8 TN Vascular endothelial growth factor receptor 2 (KDR) DM0CSH8 MA Inhibitor DM0CSH8 RN Design and structure-activity relationship of 3-benzimidazol-2-yl-1H-indazoles as inhibitors of receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3595-9. DM0CSH8 RU https://pubmed.ncbi.nlm.nih.gov/16603352 DM0CTG7 DI DM0CTG7 DM0CTG7 DN N,N'-Bis-(4-ethyl-phenyl)-guanidine DM0CTG7 TI TTKJEMQ DM0CTG7 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM0CTG7 MA Inhibitor DM0CTG7 RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM0CTG7 RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM0CTG7 DI DM0CTG7 DM0CTG7 DN N,N'-Bis-(4-ethyl-phenyl)-guanidine DM0CTG7 TI TTN9D8E DM0CTG7 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM0CTG7 MA Inhibitor DM0CTG7 RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM0CTG7 RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM0CTG7 DI DM0CTG7 DM0CTG7 DN N,N'-Bis-(4-ethyl-phenyl)-guanidine DM0CTG7 TI TTLD29N DM0CTG7 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM0CTG7 MA Inhibitor DM0CTG7 RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM0CTG7 RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM0CVTI DI DM0CVTI DM0CVTI DN 6-Hydroxy-5,7-dimethyl-beta-carboline DM0CVTI TI TTJFY5U DM0CVTI TN Adenosine A3 receptor (ADORA3) DM0CVTI MA Inhibitor DM0CVTI RN Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30. DM0CVTI RU https://pubmed.ncbi.nlm.nih.gov/18262425 DM0CWHT DI DM0CWHT DM0CWHT DN 2-(2-Amino-phenyl)-6-methyl-chromen-4-one DM0CWHT TI TTNJYV2 DM0CWHT TN Gamma-aminobutyric acid receptor (GAR) DM0CWHT MA Inhibitor DM0CWHT RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DM0CWHT RU https://pubmed.ncbi.nlm.nih.gov/12213060 DM0CWPX DI DM0CWPX DM0CWPX DN N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide DM0CWPX TI TTILUKB DM0CWPX TN IRAK4 messenger RNA (IRAK4 mRNA) DM0CWPX MA Inhibitor DM0CWPX RN Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5. DM0CWPX RU https://pubmed.ncbi.nlm.nih.gov/16563752 DM0CZ1F DI DM0CZ1F DM0CZ1F DN 6-Benzyl-2-cyclohexylsulfanyl-3H-pyrimidin-4-one DM0CZ1F TI TT84ETX DM0CZ1F TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM0CZ1F MA Inhibitor DM0CZ1F RN Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J Med Chem. 1995 Aug 18;38(17):3258-63. DM0CZ1F RU https://pubmed.ncbi.nlm.nih.gov/7650679 DM0D1Z5 DI DM0D1Z5 DM0D1Z5 DN Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 DM0D1Z5 TI TTCG0AL DM0D1Z5 TN Cholecystokinin receptor type A (CCKAR) DM0D1Z5 MA Inhibitor DM0D1Z5 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM0D1Z5 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM0D1Z5 DI DM0D1Z5 DM0D1Z5 DN Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 DM0D1Z5 TI TT27RFC DM0D1Z5 TN Opioid receptor delta (OPRD1) DM0D1Z5 MA Inhibitor DM0D1Z5 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM0D1Z5 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM0D1Z5 DI DM0D1Z5 DM0D1Z5 DN Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 DM0D1Z5 TI TTKWM86 DM0D1Z5 TN Opioid receptor mu (MOP) DM0D1Z5 MA Inhibitor DM0D1Z5 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM0D1Z5 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM0D1Z5 DI DM0D1Z5 DM0D1Z5 DN Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 DM0D1Z5 TI TTVFO0U DM0D1Z5 TN Gastrin/cholecystokinin type B receptor (CCKBR) DM0D1Z5 MA Inhibitor DM0D1Z5 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM0D1Z5 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM0D6JN DI DM0D6JN DM0D6JN DN 1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene DM0D6JN TI TTE4KHA DM0D6JN TN Amyloid beta A4 protein (APP) DM0D6JN MA Inhibitor DM0D6JN RN Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. DM0D6JN RU https://pubmed.ncbi.nlm.nih.gov/16640346 DM0D7LA DI DM0D7LA DM0D7LA DN BROMODEOXYURIDINE DM0D7LA TI TT5B8AX DM0D7LA TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DM0D7LA MA Inhibitor DM0D7LA RN Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial ac... Bioorg Med Chem. 2008 Jun 1;16(11):6075-85. DM0D7LA RU https://pubmed.ncbi.nlm.nih.gov/18467107 DM0DFNJ DI DM0DFNJ DM0DFNJ DN Nicotinaldehyde O-4-butoxyphenylcarbamoyl oxime DM0DFNJ TI TTDP1UC DM0DFNJ TN Fatty acid amide hydrolase (FAAH) DM0DFNJ MA Inhibitor DM0DFNJ RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM0DFNJ RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM0DG1K DI DM0DG1K DM0DG1K DN ISIS 29246 DM0DG1K TI TTYMGWX DM0DG1K TN PDK-1 messenger RNA (PDK-1 mRNA) DM0DG1K RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DM0DG1K RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DM0DH98 DI DM0DH98 DM0DH98 DN 1-phenyl-1-(piperidin-2-yl)propan-2-one DM0DH98 TI TTVBI8W DM0DH98 TN Dopamine transporter (DAT) DM0DH98 MA Inhibitor DM0DH98 RN Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. DM0DH98 RU https://pubmed.ncbi.nlm.nih.gov/17228864 DM0DKQN DI DM0DKQN DM0DKQN DN GSK-2210875 DM0DKQN TI TTHS256 DM0DKQN TN Metabotropic glutamate receptor 5 (mGluR5) DM0DKQN MA Antagonist DM0DKQN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). DM0DKQN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 DM0DM6X DI DM0DM6X DM0DM6X DN Endothelin-3 DM0DM6X TI TT3ZTGU DM0DM6X TN Endothelin B receptor (EDNRB) DM0DM6X MA Inhibitor DM0DM6X RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DM0DM6X RU https://pubmed.ncbi.nlm.nih.gov/18983139 DM0DMNS DI DM0DMNS DM0DMNS DN U-44069 DM0DMNS TI TT2O84V DM0DMNS TN Thromboxane A2 receptor (TBXA2R) DM0DMNS MA Inhibitor DM0DMNS RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DM0DMNS RU https://pubmed.ncbi.nlm.nih.gov/18983139 DM0DNSV DI DM0DNSV DM0DNSV DN PMID21295468C47 DM0DNSV TI TTHS256 DM0DNSV TN Metabotropic glutamate receptor 5 (mGluR5) DM0DNSV MA Modulator (allosteric modulator) DM0DNSV RN Discovery of novel positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Bioorg Med Chem Lett. 2011 Mar 1;21(5):1402-6. DM0DNSV RU https://pubmed.ncbi.nlm.nih.gov/21295468 DM0DRHP DI DM0DRHP DM0DRHP DN N-hydroxy-9H-xanthene-9-carboxamide DM0DRHP TI TTBH0VX DM0DRHP TN Histone deacetylase (HDAC) DM0DRHP MA Inhibitor DM0DRHP RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM0DRHP RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM0DRHP DI DM0DRHP DM0DRHP DN N-hydroxy-9H-xanthene-9-carboxamide DM0DRHP TI TTTQGH8 DM0DRHP TN Histone deacetylase 4 (HDAC4) DM0DRHP MA Inhibitor DM0DRHP RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM0DRHP RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM0DRO8 DI DM0DRO8 DM0DRO8 DN LUF-5437 DM0DRO8 TI TTM2AOE DM0DRO8 TN Adenosine A2a receptor (ADORA2A) DM0DRO8 MA Inhibitor DM0DRO8 RN Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62. DM0DRO8 RU https://pubmed.ncbi.nlm.nih.gov/11262085 DM0DWSR DI DM0DWSR DM0DWSR DN bradyzide DM0DWSR TI TTGY8IW DM0DWSR TN B2 bradykinin receptor (BDKRB2) DM0DWSR MA Antagonist DM0DWSR RN Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol. 2000 Jan;129(1):77-86. DM0DWSR RU https://pubmed.ncbi.nlm.nih.gov/10694205 DM0DZ9J DI DM0DZ9J DM0DZ9J DN N-(furan-2-ylmethyl)-estrone-16-methyl carboxamide DM0DZ9J TI TTIWB6L DM0DZ9J TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM0DZ9J MA Inhibitor DM0DZ9J RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM0DZ9J RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM0DZFX DI DM0DZFX DM0DZFX DN 4-(4-benzenesulfonylphenyl)piperazine DM0DZFX TI TTJS8PY DM0DZFX TN 5-HT 6 receptor (HTR6) DM0DZFX MA Inhibitor DM0DZFX RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DM0DZFX RU https://pubmed.ncbi.nlm.nih.gov/16913710 DM0E1SH DI DM0E1SH DM0E1SH DN ISIS 112021 DM0E1SH TI TTPJ9XK DM0E1SH TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DM0E1SH RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DM0E1SH RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DM0E1Y9 DI DM0E1Y9 DM0E1Y9 DN 5-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM0E1Y9 TI TT06AWU DM0E1Y9 TN Phosphodiesterase 3A (PDE3A) DM0E1Y9 MA Inhibitor DM0E1Y9 RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DM0E1Y9 RU https://pubmed.ncbi.nlm.nih.gov/1654430 DM0E2SM DI DM0E2SM DM0E2SM DN SC-52073 DM0E2SM TI TTN53ZF DM0E2SM TN Leukotriene B4 receptor 1 (LTB4R) DM0E2SM MA Inhibitor DM0E2SM RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DM0E2SM RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DM0E4OW DI DM0E4OW DM0E4OW DN PD-118057 DM0E4OW TI TTQ6VDM DM0E4OW TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM0E4OW MA Activator DM0E4OW RN Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity. Mol Pharmacol. 2005 Sep;68(3):876-84. DM0E4OW RU https://pubmed.ncbi.nlm.nih.gov/15976038 DM0E5FH DI DM0E5FH DM0E5FH DN 1,2-Bis-(4-chloro-phenyl)-ethane-1,2-dione DM0E5FH TI TTMF541 DM0E5FH TN Liver carboxylesterase (CES1) DM0E5FH MA Inhibitor DM0E5FH RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DM0E5FH RU https://pubmed.ncbi.nlm.nih.gov/15828829 DM0E5G9 DI DM0E5G9 DM0E5G9 DN Pseudocolumbamine trifluoroacetate DM0E5G9 TI TT1RS9F DM0E5G9 TN Acetylcholinesterase (AChE) DM0E5G9 MA Inhibitor DM0E5G9 RN Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation. J Nat Prod. 2010 Oct 22;73(10):1632-5. DM0E5G9 RU https://pubmed.ncbi.nlm.nih.gov/20828184 DM0E95B DI DM0E95B DM0E95B DN MERIOLIN 8 DM0E95B TI TT7HF4W DM0E95B TN Cyclin-dependent kinase 2 (CDK2) DM0E95B MA Inhibitor DM0E95B RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM0E95B RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM0E95B DI DM0E95B DM0E95B DN MERIOLIN 8 DM0E95B TI TTAMQ62 DM0E95B TN Cyclin A2 (CCNA2) DM0E95B MA Inhibitor DM0E95B RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM0E95B RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM0E95B DI DM0E95B DM0E95B DN MERIOLIN 8 DM0E95B TI TT1LVF2 DM0E95B TN Cyclin-dependent kinase 9 (CDK9) DM0E95B MA Inhibitor DM0E95B RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM0E95B RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM0E9BR DI DM0E9BR DM0E9BR DN Staurosporine DM0E9BR TI TTJ3E9X DM0E9BR TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM0E9BR MA Inhibitor DM0E9BR RN UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65. DM0E9BR RU https://pubmed.ncbi.nlm.nih.gov/8667426 DM0E9BR DI DM0E9BR DM0E9BR DN Staurosporine DM0E9BR TI TTYVX59 DM0E9BR TN Protein kinase C (PRKC) DM0E9BR MA Inhibitor DM0E9BR RN Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. DM0E9BR RU https://pubmed.ncbi.nlm.nih.gov/10982151 DM0E9O1 DI DM0E9O1 DM0E9O1 DN 5-ethyl-2-(phenylsulfonamido)benzoic acid DM0E9O1 TI TTZL0OI DM0E9O1 TN Methionine aminopeptidase 2 (METAP2) DM0E9O1 MA Inhibitor DM0E9O1 RN Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. DM0E9O1 RU https://pubmed.ncbi.nlm.nih.gov/16632353 DM0EBAF DI DM0EBAF DM0EBAF DN dysiherbaine DM0EBAF TI TTO6LI7 DM0EBAF TN Glutamate receptor ionotropic kainate 5 (GRIK5) DM0EBAF MA Agonist DM0EBAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454). DM0EBAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454 DM0EBAF DI DM0EBAF DM0EBAF DN dysiherbaine DM0EBAF TI TT0K5RG DM0EBAF TN Glutamate receptor ionotropic kainate 2 (GRIK2) DM0EBAF MA Agonist DM0EBAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451). DM0EBAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451 DM0EBAF DI DM0EBAF DM0EBAF DN dysiherbaine DM0EBAF TI TT0MYE2 DM0EBAF TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM0EBAF MA Agonist DM0EBAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM0EBAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM0EBAF DI DM0EBAF DM0EBAF DN dysiherbaine DM0EBAF TI TTNP6O2 DM0EBAF TN Glutamate receptor ionotropic kainate 3 (GluK3) DM0EBAF MA Agonist DM0EBAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452). DM0EBAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=452 DM0EBAF DI DM0EBAF DM0EBAF DN dysiherbaine DM0EBAF TI TTQV6BO DM0EBAF TN Glutamate receptor ionotropic kainate 4 (GluK4) DM0EBAF MA Agonist DM0EBAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453). DM0EBAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453 DM0EBWR DI DM0EBWR DM0EBWR DN 5-{8(Z),11(Z)-pentadecadienyl}resorcinol DM0EBWR TI TTULVH8 DM0EBWR TN Tyrosinase (TYR) DM0EBWR MA Inhibitor DM0EBWR RN Tyrosinase inhibitors from Anacardium occidentale fruits. J Nat Prod. 1994 Apr;57(4):545-51. DM0EBWR RU https://pubmed.ncbi.nlm.nih.gov/8021657 DM0ECUK DI DM0ECUK DM0ECUK DN LORNEIC ACID A DM0ECUK TI TTJ0IQB DM0ECUK TN Phosphodiesterase 5A (PDE5A) DM0ECUK MA Inhibitor DM0ECUK RN Lorneic acids, trialkyl-substituted aromatic acids from a marine-derived actinomycete. J Nat Prod. 2009 Nov;72(11):2046-8. DM0ECUK RU https://pubmed.ncbi.nlm.nih.gov/19856955 DM0EFHM DI DM0EFHM DM0EFHM DN ISIS 110067 DM0EFHM TI TTK1V5Q DM0EFHM TN Nucleolin messenger RNA (NCL mRNA) DM0EFHM RN US patent application no. 6,165,786, Antisense modulation of nucleolin expression. DM0EFHM RU http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true DM0EKO5 DI DM0EKO5 DM0EKO5 DN Boldenone DM0EKO5 TI TTS64P2 DM0EKO5 TN Androgen receptor (AR) DM0EKO5 MA Agonist DM0EKO5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0EKO5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0EP51 DI DM0EP51 DM0EP51 DN TAMARIXETIN DM0EP51 TI TTI84H7 DM0EP51 TN Cytochrome P450 1B1 (CYP1B1) DM0EP51 MA Inhibitor DM0EP51 RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM0EP51 RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM0EPJT DI DM0EPJT DM0EPJT DN 11BETA,13-DIHYDRO-10-EPI-8-DEOXYCUMAM-BRIN B DM0EPJT TI TTSZLWK DM0EPJT TN Aromatase (CYP19A1) DM0EPJT MA Inhibitor DM0EPJT RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM0EPJT RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM0EQTM DI DM0EQTM DM0EQTM DN (S)-EF-1520 DM0EQTM TI TTPRKM0 DM0EQTM TN GABA transporter GAT-1 (SLC6A1) DM0EQTM MA Inhibitor DM0EQTM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929). DM0EQTM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929 DM0EQTM DI DM0EQTM DM0EQTM DN (S)-EF-1520 DM0EQTM TI TTQBMPI DM0EQTM TN Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) DM0EQTM MA Inhibitor DM0EQTM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 932). DM0EQTM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=932 DM0EZSR DI DM0EZSR DM0EZSR DN 1-(2-methoxyphenyl)-4-pentylpiperazine DM0EZSR TI TTSQIFT DM0EZSR TN 5-HT 1A receptor (HTR1A) DM0EZSR MA Inhibitor DM0EZSR RN Identification of a red-emitting fluorescent ligand for in vitro visualization of human serotonin 5-HT(1A) receptors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6628-32. DM0EZSR RU https://pubmed.ncbi.nlm.nih.gov/20888762 DM0F3SR DI DM0F3SR DM0F3SR DN 12-(3-n-Hexylureido)dodec-8(Z)-enoic acid DM0F3SR TI TT7WVHI DM0F3SR TN Soluble epoxide hydrolase (EPHX2) DM0F3SR MA Inhibitor DM0F3SR RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM0F3SR RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM0FA6B DI DM0FA6B DM0FA6B DN Nle-Pro-Glu DM0FA6B TI TTN9D8E DM0FA6B TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM0FA6B MA Inhibitor DM0FA6B RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM0FA6B RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM0FA6B DI DM0FA6B DM0FA6B DN Nle-Pro-Glu DM0FA6B TI TTKJEMQ DM0FA6B TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM0FA6B MA Inhibitor DM0FA6B RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM0FA6B RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM0FA6B DI DM0FA6B DM0FA6B DN Nle-Pro-Glu DM0FA6B TI TTLD29N DM0FA6B TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM0FA6B MA Inhibitor DM0FA6B RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM0FA6B RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM0FKV9 DI DM0FKV9 DM0FKV9 DN PSB-0788 DM0FKV9 TI TTK25J1 DM0FKV9 TN Adenosine A1 receptor (ADORA1) DM0FKV9 MA Inhibitor DM0FKV9 RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DM0FKV9 RU https://pubmed.ncbi.nlm.nih.gov/19569717 DM0FKV9 DI DM0FKV9 DM0FKV9 DN PSB-0788 DM0FKV9 TI TTM2AOE DM0FKV9 TN Adenosine A2a receptor (ADORA2A) DM0FKV9 MA Inhibitor DM0FKV9 RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DM0FKV9 RU https://pubmed.ncbi.nlm.nih.gov/19569717 DM0FKV9 DI DM0FKV9 DM0FKV9 DN PSB-0788 DM0FKV9 TI TTNE7KG DM0FKV9 TN Adenosine A2b receptor (ADORA2B) DM0FKV9 MA Inhibitor DM0FKV9 RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DM0FKV9 RU https://pubmed.ncbi.nlm.nih.gov/19569717 DM0FNUX DI DM0FNUX DM0FNUX DN 9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide DM0FNUX TI TT1RS9F DM0FNUX TN Acetylcholinesterase (AChE) DM0FNUX MA Inhibitor DM0FNUX RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DM0FNUX RU https://pubmed.ncbi.nlm.nih.gov/20056426 DM0FNUX DI DM0FNUX DM0FNUX DN 9-O-[3-(Phenylol-1-yloxy)propyl]berberine bromide DM0FNUX TI TTEB0GD DM0FNUX TN Cholinesterase (BCHE) DM0FNUX MA Inhibitor DM0FNUX RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DM0FNUX RU https://pubmed.ncbi.nlm.nih.gov/20056426 DM0FROP DI DM0FROP DM0FROP DN Nafoxidine DM0FROP TI TTOM3J0 DM0FROP TN Estrogen receptor beta (ESR2) DM0FROP MA Inhibitor DM0FROP RN Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthal... J Med Chem. 1998 Jul 30;41(16):2928-31. DM0FROP RU https://pubmed.ncbi.nlm.nih.gov/9685230 DM0FROP DI DM0FROP DM0FROP DN Nafoxidine DM0FROP TI TTZAYWL DM0FROP TN Estrogen receptor (ESR) DM0FROP MA Inhibitor DM0FROP RN Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthal... J Med Chem. 1998 Jul 30;41(16):2928-31. DM0FROP RU https://pubmed.ncbi.nlm.nih.gov/9685230 DM0FWNJ DI DM0FWNJ DM0FWNJ DN 9-hydroxyoctadecadienoic acid DM0FWNJ TI TTNBW4F DM0FWNJ TN G2 accumulation protein (GPR132) DM0FWNJ MA Agonist DM0FWNJ RN Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J Biol Chem. 2005 Dec 9;280(49):40676-83. DM0FWNJ RU https://pubmed.ncbi.nlm.nih.gov/16236715 DM0FWNJ DI DM0FWNJ DM0FWNJ DN 9-hydroxyoctadecadienoic acid DM0FWNJ TI TTZMAO3 DM0FWNJ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM0FWNJ MA Inhibitor DM0FWNJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0FWNJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0G2IR DI DM0G2IR DM0G2IR DN Trisnorsqualene cyclopropylamine DM0G2IR TI TTE14XG DM0G2IR TN Squalene monooxygenase (SQLE) DM0G2IR MA Inhibitor DM0G2IR RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DM0G2IR RU https://pubmed.ncbi.nlm.nih.gov/11520216 DM0G2N5 DI DM0G2N5 DM0G2N5 DN 5-Methyl-3,4-diphenyl-isoxazole DM0G2N5 TI TT8NGED DM0G2N5 TN Prostaglandin G/H synthase 1 (COX-1) DM0G2N5 MA Inhibitor DM0G2N5 RN Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90. DM0G2N5 RU https://pubmed.ncbi.nlm.nih.gov/15369392 DM0G2N5 DI DM0G2N5 DM0G2N5 DN 5-Methyl-3,4-diphenyl-isoxazole DM0G2N5 TI TTVKILB DM0G2N5 TN Prostaglandin G/H synthase 2 (COX-2) DM0G2N5 MA Inhibitor DM0G2N5 RN Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90. DM0G2N5 RU https://pubmed.ncbi.nlm.nih.gov/15369392 DM0G42B DI DM0G42B DM0G42B DN PMID18477808CB DM0G42B TI TTB8FUC DM0G42B TN Free fatty acid receptor 1 (GPR40) DM0G42B MA Agonist DM0G42B RN Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes. 2008 Aug;57(8):2211-9. DM0G42B RU https://pubmed.ncbi.nlm.nih.gov/18477808 DM0G4HP DI DM0G4HP DM0G4HP DN FR190997 DM0G4HP TI TTGY8IW DM0G4HP TN B2 bradykinin receptor (BDKRB2) DM0G4HP MA Agonist DM0G4HP RN Nonpeptide mimic of bradykinin with long-acting properties at the bradykinin B2 receptor. Mol Pharmacol. 1997 Jul;52(1):16-20. DM0G4HP RU https://pubmed.ncbi.nlm.nih.gov/9224807 DM0GCEK DI DM0GCEK DM0GCEK DN 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine DM0GCEK TI TTM2AOE DM0GCEK TN Adenosine A2a receptor (ADORA2A) DM0GCEK MA Inhibitor DM0GCEK RN Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7. DM0GCEK RU https://pubmed.ncbi.nlm.nih.gov/16971117 DM0GCEK DI DM0GCEK DM0GCEK DN 4-(ethylthio)-6-phenyl-1,3,5-triazin-2-amine DM0GCEK TI TTK25J1 DM0GCEK TN Adenosine A1 receptor (ADORA1) DM0GCEK MA Inhibitor DM0GCEK RN Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7. DM0GCEK RU https://pubmed.ncbi.nlm.nih.gov/16971117 DM0GJVS DI DM0GJVS DM0GJVS DN SPONGIADIOXIN A DM0GJVS TI TTN9T81 DM0GJVS TN Arachidonate 15-lipoxygenase (15-LOX) DM0GJVS MA Inhibitor DM0GJVS RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DM0GJVS RU https://pubmed.ncbi.nlm.nih.gov/15267244 DM0GJZM DI DM0GJZM DM0GJZM DN 3-aminoacetamido-4'-methylfuro[3,2-g]coumarin DM0GJZM TI TT3WG5C DM0GJZM TN Monoamine oxidase type A (MAO-A) DM0GJZM MA Inhibitor DM0GJZM RN A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56. DM0GJZM RU https://pubmed.ncbi.nlm.nih.gov/16451079 DM0GKMA DI DM0GKMA DM0GKMA DN [125I]SQ-29548 DM0GKMA TI TT2O84V DM0GKMA TN Thromboxane A2 receptor (TBXA2R) DM0GKMA MA Antagonist DM0GKMA RN Characterization of [5,6-3H]SQ 29,548 as a high affinity radioligand, binding to thromboxane A2/prostaglandin H2-receptors in human platelets. J Pharmacol Exp Ther. 1988 Jun;245(3):786-92. DM0GKMA RU https://pubmed.ncbi.nlm.nih.gov/2968449 DM0GLYB DI DM0GLYB DM0GLYB DN MCP-203 DM0GLYB TI TT27RFC DM0GLYB TN Opioid receptor delta (OPRD1) DM0GLYB MA Agonist DM0GLYB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DM0GLYB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DM0GO7U DI DM0GO7U DM0GO7U DN D[Cha4,Lys8]VP DM0GO7U TI TT4TFGN DM0GO7U TN Vasopressin V1a receptor (V1AR) DM0GO7U MA Inhibitor DM0GO7U RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM0GO7U RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM0GO7U DI DM0GO7U DM0GO7U DN D[Cha4,Lys8]VP DM0GO7U TI TTSCIUP DM0GO7U TN Oxytocin receptor (OTR) DM0GO7U MA Inhibitor DM0GO7U RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM0GO7U RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM0GO7U DI DM0GO7U DM0GO7U DN D[Cha4,Lys8]VP DM0GO7U TI TTL9MHW DM0GO7U TN Vasopressin V1b receptor (V1BR) DM0GO7U MA Inhibitor DM0GO7U RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM0GO7U RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM0GO7U DI DM0GO7U DM0GO7U DN D[Cha4,Lys8]VP DM0GO7U TI TTK8R02 DM0GO7U TN Vasopressin V2 receptor (V2R) DM0GO7U MA Inhibitor DM0GO7U RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM0GO7U RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM0GOPV DI DM0GOPV DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide DM0GOPV TI TTYHPU6 DM0GOPV TN Histone deacetylase 10 (HDAC10) DM0GOPV MA Inhibitor DM0GOPV RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DM0GOPV RU https://pubmed.ncbi.nlm.nih.gov/15808449 DM0GOPV DI DM0GOPV DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide DM0GOPV TI TTSHTOI DM0GOPV TN Histone deacetylase 2 (HDAC2) DM0GOPV MA Inhibitor DM0GOPV RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DM0GOPV RU https://pubmed.ncbi.nlm.nih.gov/15808449 DM0GOPV DI DM0GOPV DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide DM0GOPV TI TTBH0VX DM0GOPV TN Histone deacetylase (HDAC) DM0GOPV MA Inhibitor DM0GOPV RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DM0GOPV RU https://pubmed.ncbi.nlm.nih.gov/15808449 DM0GOPV DI DM0GOPV DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide DM0GOPV TI TTTQGH8 DM0GOPV TN Histone deacetylase 4 (HDAC4) DM0GOPV MA Inhibitor DM0GOPV RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DM0GOPV RU https://pubmed.ncbi.nlm.nih.gov/15808449 DM0GOPV DI DM0GOPV DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide DM0GOPV TI TT6R7JZ DM0GOPV TN Histone deacetylase 1 (HDAC1) DM0GOPV MA Inhibitor DM0GOPV RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DM0GOPV RU https://pubmed.ncbi.nlm.nih.gov/15808449 DM0GOPV DI DM0GOPV DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide DM0GOPV TI TT5ZKDI DM0GOPV TN Histone deacetylase 6 (HDAC6) DM0GOPV MA Inhibitor DM0GOPV RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DM0GOPV RU https://pubmed.ncbi.nlm.nih.gov/15808449 DM0GOPV DI DM0GOPV DM0GOPV DN N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide DM0GOPV TI TTT6LFV DM0GOPV TN Histone deacetylase 8 (HDAC8) DM0GOPV MA Inhibitor DM0GOPV RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DM0GOPV RU https://pubmed.ncbi.nlm.nih.gov/15808449 DM0GQJ2 DI DM0GQJ2 DM0GQJ2 DN Di-Stearoyl-3-Sn-Phosphatidylcholine DM0GQJ2 TI TTU5A6Q DM0GQJ2 TN Adenine nucleotide translocator 1 (SLC25A4) DM0GQJ2 MA Inhibitor DM0GQJ2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0GQJ2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0GRMD DI DM0GRMD DM0GRMD DN 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane DM0GRMD TI TTEX248 DM0GRMD TN Dopamine D2 receptor (D2R) DM0GRMD MA Inhibitor DM0GRMD RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DM0GRMD RU https://pubmed.ncbi.nlm.nih.gov/20481570 DM0GRMD DI DM0GRMD DM0GRMD DN 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane DM0GRMD TI TTJQOD7 DM0GRMD TN 5-HT 2A receptor (HTR2A) DM0GRMD MA Inhibitor DM0GRMD RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DM0GRMD RU https://pubmed.ncbi.nlm.nih.gov/20481570 DM0GRMD DI DM0GRMD DM0GRMD DN 1,6-bis(4-(pyridin-2-yl)piperazin-1-yl)hexane DM0GRMD TI TTSQIFT DM0GRMD TN 5-HT 1A receptor (HTR1A) DM0GRMD MA Inhibitor DM0GRMD RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DM0GRMD RU https://pubmed.ncbi.nlm.nih.gov/20481570 DM0GSRL DI DM0GSRL DM0GSRL DN 6'-Iodononivamide DM0GSRL TI TTMI6F5 DM0GSRL TN Transient receptor potential cation channel V1 (TRPV1) DM0GSRL MA Inhibitor DM0GSRL RN Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin. Bioorg Med Chem. 2010 Nov 15;18(22):8092-105. DM0GSRL RU https://pubmed.ncbi.nlm.nih.gov/20937561 DM0GVZO DI DM0GVZO DM0GVZO DN ODN-1411 DM0GVZO TI TT8CWFK DM0GVZO TN Toll-like receptor 8 (TLR8) DM0GVZO MA Inhibitor DM0GVZO RN Oligodeoxynucleotide inhibition of Toll-like receptors 3, 7, 8, and 9 suppresses cytokine production in a human rheumatoid arthritis model. Eur J Immunol. 2016 Mar;46(3):772-81. DM0GVZO RU https://pubmed.ncbi.nlm.nih.gov/26593270 DM0GWAC DI DM0GWAC DM0GWAC DN NSC-625409 DM0GWAC TI TTSZLWK DM0GWAC TN Aromatase (CYP19A1) DM0GWAC MA Inhibitor DM0GWAC RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DM0GWAC RU https://pubmed.ncbi.nlm.nih.gov/19072235 DM0GXFB DI DM0GXFB DM0GXFB DN 3-(6-Methoxynaphthalen-2-yl)-4-methylpyridine DM0GXFB TI TTIQUX7 DM0GXFB TN Steroid 11-beta-hydroxylase (CYP11B1) DM0GXFB MA Inhibitor DM0GXFB RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DM0GXFB RU https://pubmed.ncbi.nlm.nih.gov/18672861 DM0H3NV DI DM0H3NV DM0H3NV DN [Mpa1, D-Tyr(Et)2, L-Tic7]OT DM0H3NV TI TTSCIUP DM0H3NV TN Oxytocin receptor (OTR) DM0H3NV MA Inhibitor DM0H3NV RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DM0H3NV RU https://pubmed.ncbi.nlm.nih.gov/17316912 DM0H7AV DI DM0H7AV DM0H7AV DN Chebulagic acid DM0H7AV TI TT2J34L DM0H7AV TN Arachidonate 5-lipoxygenase (5-LOX) DM0H7AV MA Inhibitor DM0H7AV RN Chebulagic acid, a COX-LOX dual inhibitor isolated from the fruits of Terminalia chebula Retz., induces apoptosis in COLO-205 cell line. J Ethnopharmacol. 2009 Jul 30;124(3):506-12. DM0H7AV RU https://pubmed.ncbi.nlm.nih.gov/19481594 DM0H8CK DI DM0H8CK DM0H8CK DN N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine DM0H8CK TI TTFZVPO DM0H8CK TN Sodium/hydrogen exchanger 3 (SLC9A3) DM0H8CK MA Inhibitor DM0H8CK RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DM0H8CK RU https://pubmed.ncbi.nlm.nih.gov/9207943 DM0H8CK DI DM0H8CK DM0H8CK DN N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine DM0H8CK TI TTGSEFH DM0H8CK TN Sodium/hydrogen exchanger 1 (SLC9A1) DM0H8CK MA Inhibitor DM0H8CK RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DM0H8CK RU https://pubmed.ncbi.nlm.nih.gov/9207943 DM0HCG6 DI DM0HCG6 DM0HCG6 DN 5-bromo orotate DM0HCG6 TI TT09NOX DM0HCG6 TN Plasmodium Dihydroorotase (Malaria dho) DM0HCG6 MA Inhibitor DM0HCG6 RN Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301. DM0HCG6 RU https://pubmed.ncbi.nlm.nih.gov/1348618 DM0HD3O DI DM0HD3O DM0HD3O DN RPR-101511 DM0HD3O TI TTI7421 DM0HD3O TN Platelet-derived growth factor receptor beta (PDGFRB) DM0HD3O MA Inhibitor DM0HD3O RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0HD3O RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0HD3O DI DM0HD3O DM0HD3O DN RPR-101511 DM0HD3O TI TT8FYO9 DM0HD3O TN Platelet-derived growth factor receptor alpha (PDGFRA) DM0HD3O MA Inhibitor DM0HD3O RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0HD3O RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0HJD4 DI DM0HJD4 DM0HJD4 DN tedisamil DM0HJD4 TI TTCVBT7 DM0HJD4 TN Voltage-gated potassium channel Kv1.7 (KCNA7) DM0HJD4 MA Blocker (channel blocker) DM0HJD4 RN Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7. J Biol Chem. 1998 Mar6;273(10):5851-7. DM0HJD4 RU https://pubmed.ncbi.nlm.nih.gov/9488722 DM0HK6L DI DM0HK6L DM0HK6L DN SB-258741 DM0HK6L TI TTO9X1H DM0HK6L TN 5-HT 7 receptor (HTR7) DM0HK6L MA Inhibitor DM0HK6L RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DM0HK6L RU https://pubmed.ncbi.nlm.nih.gov/12825922 DM0HNU3 DI DM0HNU3 DM0HNU3 DN 9H-carbazole-3-carbaldehyde DM0HNU3 TI TTBGTCW DM0HNU3 TN Kinesin spindle messenger RNA (KIF11 mRNA) DM0HNU3 MA Inhibitor DM0HNU3 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM0HNU3 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM0HO6C DI DM0HO6C DM0HO6C DN 5-Azidomethyl-3-pyrrol-1-yl-oxazolidin-2-one DM0HO6C TI TT3WG5C DM0HO6C TN Monoamine oxidase type A (MAO-A) DM0HO6C MA Inhibitor DM0HO6C RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DM0HO6C RU https://pubmed.ncbi.nlm.nih.gov/11881986 DM0HOEA DI DM0HOEA DM0HOEA DN streptonigrin DM0HOEA TI TTQHAXM DM0HOEA TN Peptidyl arginine deiminase type IV (PADI4) DM0HOEA MA Inhibitor DM0HOEA RN A fluopol-ABPP HTS assay to identify PAD inhibitors. Chem Commun (Camb). 2010 Oct 14;46(38):7175-7. DM0HOEA RU https://pubmed.ncbi.nlm.nih.gov/20740228 DM0HOEA DI DM0HOEA DM0HOEA DN streptonigrin DM0HOEA TI TTSCHFW DM0HOEA TN Peptidyl arginine deiminase type III (PADI3) DM0HOEA MA Inhibitor DM0HOEA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2878). DM0HOEA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2878 DM0HPWY DI DM0HPWY DM0HPWY DN biochanin A DM0HPWY TI TTPNQAC DM0HPWY TN Estrogen-related receptor-alpha (ESRRA) DM0HPWY MA Agonist DM0HPWY RN Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. DM0HPWY RU https://pubmed.ncbi.nlm.nih.gov/14638870 DM0HPWY DI DM0HPWY DM0HPWY DN biochanin A DM0HPWY TI TT9ZRHB DM0HPWY TN Estrogen-related receptor-gamma (ESRRG) DM0HPWY MA Agonist DM0HPWY RN Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. DM0HPWY RU https://pubmed.ncbi.nlm.nih.gov/14638870 DM0HPWY DI DM0HPWY DM0HPWY DN biochanin A DM0HPWY TI TTKF0XS DM0HPWY TN Estrogen-related receptor-beta (ESRRB) DM0HPWY MA Agonist DM0HPWY RN Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. DM0HPWY RU https://pubmed.ncbi.nlm.nih.gov/14638870 DM0HPWY DI DM0HPWY DM0HPWY DN biochanin A DM0HPWY TI TTSZLWK DM0HPWY TN Aromatase (CYP19A1) DM0HPWY MA Inhibitor DM0HPWY RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM0HPWY RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM0HPWY DI DM0HPWY DM0HPWY DN biochanin A DM0HPWY TI TTHPFTS DM0HPWY TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DM0HPWY MA Inhibitor DM0HPWY RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DM0HPWY RU https://pubmed.ncbi.nlm.nih.gov/16722653 DM0HPWY DI DM0HPWY DM0HPWY DN biochanin A DM0HPWY TI TT7AOUD DM0HPWY TN Fatty acid synthase (FASN) DM0HPWY MA Inhibitor DM0HPWY RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DM0HPWY RU https://pubmed.ncbi.nlm.nih.gov/16722653 DM0HQF6 DI DM0HQF6 DM0HQF6 DN Hydrohalisulfate 1 DM0HQF6 TI TTN9T81 DM0HQF6 TN Arachidonate 15-lipoxygenase (15-LOX) DM0HQF6 MA Inhibitor DM0HQF6 RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DM0HQF6 RU https://pubmed.ncbi.nlm.nih.gov/12608855 DM0HQF6 DI DM0HQF6 DM0HQF6 DN Hydrohalisulfate 1 DM0HQF6 TI TT58ZYW DM0HQF6 TN Mycobacterium Isocitrate lyase (MycB icl) DM0HQF6 MA Inhibitor DM0HQF6 RN Sesterterpene sulfates as isocitrate lyase inhibitors from tropical sponge Hippospongia sp. Bioorg Med Chem Lett. 2007 May 1;17(9):2483-6. DM0HQF6 RU https://pubmed.ncbi.nlm.nih.gov/17317180 DM0HS7L DI DM0HS7L DM0HS7L DN hexocyclium DM0HS7L TI TTZ9SOR DM0HS7L TN Muscarinic acetylcholine receptor M1 (CHRM1) DM0HS7L MA Modulator DM0HS7L RN Hexocyclium derivatives with a high selectivity for smooth muscle muscarinic receptors. Br J Pharmacol. 1990 May;100(1):150-2. DM0HS7L RU https://www.ncbi.nlm.nih.gov/pubmed/2372655 DM0HTXO DI DM0HTXO DM0HTXO DN AZD8542 DM0HTXO TI TT8J1S3 DM0HTXO TN Smoothened homolog (SMO) DM0HTXO MA Antagonist DM0HTXO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 239). DM0HTXO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=239 DM0HWB1 DI DM0HWB1 DM0HWB1 DN Glu20-Lys24][Gly8][GLP-1(7-37)-NH2 DM0HWB1 TI TTVIMDE DM0HWB1 TN Glucagon-like peptide 1 receptor (GLP1R) DM0HWB1 MA Inhibitor DM0HWB1 RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DM0HWB1 RU https://pubmed.ncbi.nlm.nih.gov/18412318 DM0HWRN DI DM0HWRN DM0HWRN DN ISIS 134583 DM0HWRN TI TTKW4ML DM0HWRN TN Caspase 6 messenger RNA (CASP6 mRNA) DM0HWRN RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DM0HWRN RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DM0HYDZ DI DM0HYDZ DM0HYDZ DN 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole DM0HYDZ TI TTE0A2F DM0HYDZ TN Dopamine D4 receptor (D4R) DM0HYDZ MA Inhibitor DM0HYDZ RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DM0HYDZ RU https://pubmed.ncbi.nlm.nih.gov/8642550 DM0HYDZ DI DM0HYDZ DM0HYDZ DN 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole DM0HYDZ TI TTEX248 DM0HYDZ TN Dopamine D2 receptor (D2R) DM0HYDZ MA Inhibitor DM0HYDZ RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DM0HYDZ RU https://pubmed.ncbi.nlm.nih.gov/8642550 DM0HYDZ DI DM0HYDZ DM0HYDZ DN 3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole DM0HYDZ TI TT4C8EA DM0HYDZ TN Dopamine D3 receptor (D3R) DM0HYDZ MA Inhibitor DM0HYDZ RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DM0HYDZ RU https://pubmed.ncbi.nlm.nih.gov/8642550 DM0I2RH DI DM0I2RH DM0I2RH DN 1-[4-(4-Iodophenoxy)phenyl]piperazine DM0I2RH TI TTXZEAJ DM0I2RH TN Leukotriene A-4 hydrolase (LTA4H) DM0I2RH MA Inhibitor DM0I2RH RN Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85. DM0I2RH RU https://pubmed.ncbi.nlm.nih.gov/19950900 DM0I6UT DI DM0I6UT DM0I6UT DN 3,4-Dihydro-1H-quinolin-(2E)-ylideneamine DM0I6UT TI TTZUFI5 DM0I6UT TN Nitric-oxide synthase brain (NOS1) DM0I6UT MA Inhibitor DM0I6UT RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DM0I6UT RU https://pubmed.ncbi.nlm.nih.gov/15808455 DM0I6UT DI DM0I6UT DM0I6UT DN 3,4-Dihydro-1H-quinolin-(2E)-ylideneamine DM0I6UT TI TTF10I9 DM0I6UT TN Nitric-oxide synthase inducible (NOS2) DM0I6UT MA Inhibitor DM0I6UT RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DM0I6UT RU https://pubmed.ncbi.nlm.nih.gov/15808455 DM0IJFZ DI DM0IJFZ DM0IJFZ DN C(his-D-phe-arg-trp-Ahp) DM0IJFZ TI TTD0CIQ DM0IJFZ TN Melanocortin receptor 4 (MC4R) DM0IJFZ MA Inhibitor DM0IJFZ RN Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6. DM0IJFZ RU https://pubmed.ncbi.nlm.nih.gov/16678415 DM0INZX DI DM0INZX DM0INZX DN 4-Fluoro-1,1':4',1''-terphenyl-3,3''-diol DM0INZX TI TTIWB6L DM0INZX TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM0INZX MA Inhibitor DM0INZX RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM0INZX RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM0IT5E DI DM0IT5E DM0IT5E DN 4-(2-(3-chlorophenoxy)phenyl)piperidine DM0IT5E TI TTAWNKZ DM0IT5E TN Norepinephrine transporter (NET) DM0IT5E MA Inhibitor DM0IT5E RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0IT5E RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0IT5E DI DM0IT5E DM0IT5E DN 4-(2-(3-chlorophenoxy)phenyl)piperidine DM0IT5E TI TTSQIFT DM0IT5E TN 5-HT 1A receptor (HTR1A) DM0IT5E MA Inhibitor DM0IT5E RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0IT5E RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0IT5E DI DM0IT5E DM0IT5E DN 4-(2-(3-chlorophenoxy)phenyl)piperidine DM0IT5E TI TT3ROYC DM0IT5E TN Serotonin transporter (SERT) DM0IT5E MA Inhibitor DM0IT5E RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0IT5E RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0IT5E DI DM0IT5E DM0IT5E DN 4-(2-(3-chlorophenoxy)phenyl)piperidine DM0IT5E TI TTVBI8W DM0IT5E TN Dopamine transporter (DAT) DM0IT5E MA Inhibitor DM0IT5E RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0IT5E RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0IYLS DI DM0IYLS DM0IYLS DN EtBut-RYYRIK-NH2 DM0IYLS TI TTNT7K8 DM0IYLS TN Nociceptin receptor (OPRL1) DM0IYLS MA Inhibitor DM0IYLS RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DM0IYLS RU https://pubmed.ncbi.nlm.nih.gov/18068993 DM0J38I DI DM0J38I DM0J38I DN MIP-1375 DM0J38I TI TT9G4N0 DM0J38I TN Glutamate carboxypeptidase II (GCPII) DM0J38I MA Inhibitor DM0J38I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DM0J38I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DM0J5KF DI DM0J5KF DM0J5KF DN Glycerol-2-Phosphate DM0J5KF TI TTNS6X4 DM0J5KF TN Bacterial Triosephosphate isomerase (Bact TPI) DM0J5KF MA Inhibitor DM0J5KF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0J5KF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0J8P6 DI DM0J8P6 DM0J8P6 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H DM0J8P6 TI TTKWM86 DM0J8P6 TN Opioid receptor mu (MOP) DM0J8P6 MA Inhibitor DM0J8P6 RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DM0J8P6 RU https://pubmed.ncbi.nlm.nih.gov/17201419 DM0J8P6 DI DM0J8P6 DM0J8P6 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H DM0J8P6 TI TT27RFC DM0J8P6 TN Opioid receptor delta (OPRD1) DM0J8P6 MA Inhibitor DM0J8P6 RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DM0J8P6 RU https://pubmed.ncbi.nlm.nih.gov/17201419 DM0J937 DI DM0J937 DM0J937 DN SCH-48375 DM0J937 TI TTMF541 DM0J937 TN Liver carboxylesterase (CES1) DM0J937 MA Inhibitor DM0J937 RN 2-Azetidinones as inhibitors of cholesterol absorption. J Med Chem. 1994 Jun 10;37(12):1733-6. DM0J937 RU https://pubmed.ncbi.nlm.nih.gov/8021912 DM0J9I5 DI DM0J9I5 DM0J9I5 DN Cyclopentyl(5-(pyridin-2-yl)oxazol-2-yl)methanone DM0J9I5 TI TTDP1UC DM0J9I5 TN Fatty acid amide hydrolase (FAAH) DM0J9I5 MA Inhibitor DM0J9I5 RN Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2007 Jul 12;50(14):3359-68. DM0J9I5 RU https://pubmed.ncbi.nlm.nih.gov/17559203 DM0JCN2 DI DM0JCN2 DM0JCN2 DN NCFP DM0JCN2 TI TTHS256 DM0JCN2 TN Metabotropic glutamate receptor 5 (mGluR5) DM0JCN2 MA Modulator (allosteric modulator) DM0JCN2 RN A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol. 2013 Apr;83(4):835-47. DM0JCN2 RU https://pubmed.ncbi.nlm.nih.gov/23348500 DM0JE4N DI DM0JE4N DM0JE4N DN AL12180 DM0JE4N TI TTT2ZAR DM0JE4N TN Prostaglandin F2-alpha receptor (PTGFR) DM0JE4N MA Agonist DM0JE4N RN Preclinical pharmacology of AL-12182, a new ocular hypotensive 11-oxa prostaglandin analog. J Ocul Pharmacol Ther. 2006 Oct;22(5):291-309. DM0JE4N RU https://pubmed.ncbi.nlm.nih.gov/17076623 DM0JE7H DI DM0JE7H DM0JE7H DN N-(3-(1H-indol-4-yloxy)propyl)cyclohexanamine DM0JE7H TI TTSQIFT DM0JE7H TN 5-HT 1A receptor (HTR1A) DM0JE7H MA Inhibitor DM0JE7H RN Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4. DM0JE7H RU https://pubmed.ncbi.nlm.nih.gov/17804228 DM0JEA6 DI DM0JEA6 DM0JEA6 DN 8-aminoguanosine DM0JEA6 TI TTMCF1Y DM0JEA6 TN Purine nucleoside phosphorylase (PNP) DM0JEA6 MA Inhibitor DM0JEA6 RN Differential metabolism of guanine nucleosides by human lymphoid cell lines. Proc Soc Exp Biol Med. 1985 Sep;179(4):427-31. DM0JEA6 RU https://pubmed.ncbi.nlm.nih.gov/3875100 DM0JEQ6 DI DM0JEQ6 DM0JEQ6 DN 18-Dimethylaminocoronaridine DM0JEQ6 TI TTTVAFQ DM0JEQ6 TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DM0JEQ6 MA Inhibitor DM0JEQ6 RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DM0JEQ6 RU https://pubmed.ncbi.nlm.nih.gov/12801235 DM0JHYF DI DM0JHYF DM0JHYF DN Grandisine D DM0JHYF TI TT27RFC DM0JHYF TN Opioid receptor delta (OPRD1) DM0JHYF MA Inhibitor DM0JHYF RN Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9. DM0JHYF RU https://pubmed.ncbi.nlm.nih.gov/16989522 DM0JI2L DI DM0JI2L DM0JI2L DN N-phenyl-2,3,4-trihydroxy-5-benzyl-benzamide DM0JI2L TI TTJGNVC DM0JI2L TN Apoptosis regulator Bcl-2 (BCL-2) DM0JI2L MA Inhibitor DM0JI2L RN Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. DM0JI2L RU https://pubmed.ncbi.nlm.nih.gov/17034116 DM0JNO2 DI DM0JNO2 DM0JNO2 DN N-hydroxy-6-oxo-6-phenylhexanamide DM0JNO2 TI TT6R7JZ DM0JNO2 TN Histone deacetylase 1 (HDAC1) DM0JNO2 MA Inhibitor DM0JNO2 RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DM0JNO2 RU https://pubmed.ncbi.nlm.nih.gov/19136179 DM0JW2V DI DM0JW2V DM0JW2V DN APETX2 DM0JW2V TI TTLGDIS DM0JW2V TN Acid-sensing ion channel 3 (ASIC3) DM0JW2V MA Blocker DM0JW2V RN Challenges in analgesic drug development. Clin Pharmacol Ther. 2009 Oct;86(4):447-50. DM0JW2V RU https://pubmed.ncbi.nlm.nih.gov/19675542 DM0JXBK DI DM0JXBK DM0JXBK DN DZNep DM0JXBK TI TTE2KUJ DM0JXBK TN Adenosylhomocysteinase (AHCY) DM0JXBK MA Inhibitor DM0JXBK RN 3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. Biochem Biophys Res Commun. 1986 Mar 13;135(2):688-94. DM0JXBK RU https://pubmed.ncbi.nlm.nih.gov/3457563 DM0K2T1 DI DM0K2T1 DM0K2T1 DN 1-(2-Furan-2-yl-ethyl)-3-thiazol-2-yl-thiourea DM0K2T1 TI TT84ETX DM0K2T1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM0K2T1 MA Inhibitor DM0K2T1 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM0K2T1 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM0K5JM DI DM0K5JM DM0K5JM DN 4,4'-thiodipyridine-3-sulfonamide DM0K5JM TI TTSYM0R DM0K5JM TN Carbonic anhydrase XII (CA-XII) DM0K5JM MA Inhibitor DM0K5JM RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM0K5JM RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM0K5JM DI DM0K5JM DM0K5JM DN 4,4'-thiodipyridine-3-sulfonamide DM0K5JM TI TTANPDJ DM0K5JM TN Carbonic anhydrase II (CA-II) DM0K5JM MA Inhibitor DM0K5JM RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM0K5JM RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM0K5JM DI DM0K5JM DM0K5JM DN 4,4'-thiodipyridine-3-sulfonamide DM0K5JM TI TTEYTKG DM0K5JM TN Carbonic anhydrase XIV (CA-XIV) DM0K5JM MA Inhibitor DM0K5JM RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM0K5JM RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM0K5JM DI DM0K5JM DM0K5JM DN 4,4'-thiodipyridine-3-sulfonamide DM0K5JM TI TT2LVK8 DM0K5JM TN Carbonic anhydrase IX (CA-IX) DM0K5JM MA Inhibitor DM0K5JM RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM0K5JM RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM0K5JM DI DM0K5JM DM0K5JM DN 4,4'-thiodipyridine-3-sulfonamide DM0K5JM TI TTHQPL7 DM0K5JM TN Carbonic anhydrase I (CA-I) DM0K5JM MA Inhibitor DM0K5JM RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM0K5JM RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM0K6QH DI DM0K6QH DM0K6QH DN Bis-Napthyl Beta-Ketophosphonic Acid DM0K6QH TI TTQAJF1 DM0K6QH TN Cathepsin G (CTSG) DM0K6QH MA Inhibitor DM0K6QH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0K6QH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0K75N DI DM0K75N DM0K75N DN LUF-6258 DM0K75N TI TTK25J1 DM0K75N TN Adenosine A1 receptor (ADORA1) DM0K75N MA Inhibitor DM0K75N RN Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem. 2010 Apr 22;53(8):3028-37. DM0K75N RU https://pubmed.ncbi.nlm.nih.gov/20345101 DM0K7U5 DI DM0K7U5 DM0K7U5 DN 5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid DM0K7U5 TI TT7WBSV DM0K7U5 TN Oxoeicosanoid receptor 1 (OXER1) DM0K7U5 MA Antagonist DM0K7U5 RN 5-Oxo-ETE receptor antagonists. J Med Chem. 2013 May 9;56(9):3725-32. DM0K7U5 RU https://pubmed.ncbi.nlm.nih.gov/23581530 DM0KDSA DI DM0KDSA DM0KDSA DN N-Cyclopentyl-1'H-phenothiazine-1'-carboxamide DM0KDSA TI TTEB0GD DM0KDSA TN Cholinesterase (BCHE) DM0KDSA MA Inhibitor DM0KDSA RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM0KDSA RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM0KDTG DI DM0KDTG DM0KDTG DN ARC-1028 DM0KDTG TI TTZC6DR DM0KDTG TN cGMP-dependent protein kinase (cGK) DM0KDTG MA Inhibitor DM0KDTG RN Structural analysis of ARC-type inhibitor (ARC-1034) binding to protein kinase A catalytic subunit and rational design of bisubstrate analogue inhi... J Med Chem. 2009 Jan 22;52(2):308-21. DM0KDTG RU https://pubmed.ncbi.nlm.nih.gov/19143565 DM0KFW2 DI DM0KFW2 DM0KFW2 DN H-Phe-Phe-NH2 DM0KFW2 TI TTZPO1L DM0KFW2 TN Substance-P receptor (TACR1) DM0KFW2 MA Inhibitor DM0KFW2 RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DM0KFW2 RU https://pubmed.ncbi.nlm.nih.gov/20178322 DM0KGHP DI DM0KGHP DM0KGHP DN [3H](-)devapamil DM0KGHP TI TT94HRF DM0KGHP TN Voltage-gated calcium channel alpha Cav1.1 (CACNA1S) DM0KGHP MA Inhibitor (gating inhibitor) DM0KGHP RN (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle. FEBS Lett. 1984 Oct 29;176(2):371-7. DM0KGHP RU https://pubmed.ncbi.nlm.nih.gov/6092142 DM0KGHP DI DM0KGHP DM0KGHP DN [3H](-)devapamil DM0KGHP TI TTZIFHC DM0KGHP TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DM0KGHP MA Inhibitor (gating inhibitor) DM0KGHP RN Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol Pharmacol. 1991 Nov;40(5):734-41. DM0KGHP RU https://pubmed.ncbi.nlm.nih.gov/1719369 DM0KGHP DI DM0KGHP DM0KGHP DN [3H](-)devapamil DM0KGHP TI TTXHYV6 DM0KGHP TN Voltage-gated L-type calcium channel (L-CaC) DM0KGHP MA Blocker DM0KGHP RN Role of apoptosis in the kidney after reperfusion. Orv Hetil. 2008 Feb 17;149(7):305-15. DM0KGHP RU https://pubmed.ncbi.nlm.nih.gov/18258561 DM0KMPN DI DM0KMPN DM0KMPN DN JBP-1 DM0KMPN TI TT7MRGU DM0KMPN TN Chymotrypsin (CTR) DM0KMPN MA Modulator DM0KMPN RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DM0KMPN RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DM0KMPN DI DM0KMPN DM0KMPN DN JBP-1 DM0KMPN TI TTHCF4J DM0KMPN TN Alpha-glucosidase (GLA) DM0KMPN MA Modulator DM0KMPN RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DM0KMPN RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DM0KMPN DI DM0KMPN DM0KMPN DN JBP-1 DM0KMPN TI TT2WR1T DM0KMPN TN Cationic trypsinogen (PRSS1) DM0KMPN MA Modulator DM0KMPN RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DM0KMPN RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DM0KSFN DI DM0KSFN DM0KSFN DN V-103 DM0KSFN TI TT2NUT5 DM0KSFN TN Adrenergic receptor alpha-2C (ADRA2C) DM0KSFN MA Modulator DM0KSFN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 27). DM0KSFN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=27 DM0KUMX DI DM0KUMX DM0KUMX DN 2-(4-methoxyphenyl)-4,5-dihydro-1H-imidazole DM0KUMX TI TT3WG5C DM0KUMX TN Monoamine oxidase type A (MAO-A) DM0KUMX MA Inhibitor DM0KUMX RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DM0KUMX RU https://pubmed.ncbi.nlm.nih.gov/19064321 DM0KXP1 DI DM0KXP1 DM0KXP1 DN (4-guanidino-benzyl)-carbamic acid benzyl ester DM0KXP1 TI TTGY7WI DM0KXP1 TN Urokinase-type plasminogen activator (PLAU) DM0KXP1 MA Inhibitor DM0KXP1 RN Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. J Med Chem. 2007 Dec 27;50(26):6638-46. DM0KXP1 RU https://pubmed.ncbi.nlm.nih.gov/18052026 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTE0A2F DM0L3GE TN Dopamine D4 receptor (D4R) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TT2NUT5 DM0L3GE TN Adrenergic receptor alpha-2C (ADRA2C) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTEX248 DM0L3GE TN Dopamine D2 receptor (D2R) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTO9X1H DM0L3GE TN 5-HT 7 receptor (HTR7) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TT3ROYC DM0L3GE TN Serotonin transporter (SERT) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTWM4TY DM0L3GE TN Adrenergic receptor alpha-2B (ADRA2B) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTNGILX DM0L3GE TN Adrenergic receptor alpha-1A (ADRA1A) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TT0K1SC DM0L3GE TN 5-HT 2B receptor (HTR2B) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTJQOD7 DM0L3GE TN 5-HT 2A receptor (HTR2A) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTJS8PY DM0L3GE TN 5-HT 6 receptor (HTR6) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTZFYLI DM0L3GE TN Dopamine D1 receptor (D1R) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TT6MSOK DM0L3GE TN 5-HT 1D receptor (HTR1D) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TT34BHT DM0L3GE TN Adrenergic receptor alpha-1D (ADRA1D) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TT4C8EA DM0L3GE TN Dopamine D3 receptor (D3R) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTKWM86 DM0L3GE TN Opioid receptor mu (MOP) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTS2PH3 DM0L3GE TN Dopamine D5 receptor (D5R) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTQHJ1K DM0L3GE TN Histamine H2 receptor (H2R) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTRUFDT DM0L3GE TN 5-HT 5A receptor (HTR5A) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTBRKXS DM0L3GE TN Adrenergic receptor alpha-1B (ADRA1B) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTR6W5O DM0L3GE TN Adrenergic receptor beta-1 (ADRB1) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTK8CXU DM0L3GE TN 5-HT 1B receptor (HTR1B) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTWJBZ5 DM0L3GE TN 5-HT 2C receptor (HTR2C) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L3GE DI DM0L3GE DM0L3GE DN (+/-)-nantenine DM0L3GE TI TTWG9A4 DM0L3GE TN Adrenergic receptor alpha-2A (ADRA2A) DM0L3GE MA Inhibitor DM0L3GE RN Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31. DM0L3GE RU https://pubmed.ncbi.nlm.nih.gov/19963380 DM0L6E1 DI DM0L6E1 DM0L6E1 DN Cycloleucine DM0L6E1 TI TTLD29N DM0L6E1 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM0L6E1 MA Inhibitor DM0L6E1 RN Effects of D-cycloserine and cycloleucine, ligands for the NMDA-associated strychnine-insensitive glycine site, on brain-stimulation reward and spontaneous locomotion. Pharmacol Biochem Behav. 1990 Aug;36(4):735-8. DM0L6E1 RU https://pubmed.ncbi.nlm.nih.gov/2170997 DM0L6ES DI DM0L6ES DM0L6ES DN (R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine DM0L6ES TI TT9JNIC DM0L6ES TN Histamine H3 receptor (H3R) DM0L6ES MA Inhibitor DM0L6ES RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DM0L6ES RU https://pubmed.ncbi.nlm.nih.gov/18077160 DM0LD3F DI DM0LD3F DM0LD3F DN JL-18 DM0LD3F TI TTE0A2F DM0LD3F TN Dopamine D4 receptor (D4R) DM0LD3F MA Inhibitor DM0LD3F RN (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist. J Med Chem. 1996 Jun 21;39(13):2435-7. DM0LD3F RU https://pubmed.ncbi.nlm.nih.gov/8691438 DM0LGWJ DI DM0LGWJ DM0LGWJ DN 13-n-Heptanamidotridec-8(Z)-enoic acid DM0LGWJ TI TT7WVHI DM0LGWJ TN Soluble epoxide hydrolase (EPHX2) DM0LGWJ MA Inhibitor DM0LGWJ RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM0LGWJ RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM0LKPE DI DM0LKPE DM0LKPE DN LXT-101 DM0LKPE TI TT8R70G DM0LKPE TN Gonadotropin-releasing hormone receptor (GNRHR) DM0LKPE MA Antagonist DM0LKPE RN In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats. Regul Pept. 2006 Sep 11;136(1-3):122-9. DM0LKPE RU https://pubmed.ncbi.nlm.nih.gov/16828893 DM0LMQH DI DM0LMQH DM0LMQH DN ISIS 122970 DM0LMQH TI TTJZNIG DM0LMQH TN MEKK3 messenger RNA (MAP3K3 mRNA) DM0LMQH RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DM0LMQH RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DM0LR7G DI DM0LR7G DM0LR7G DN FLUORO-NEPLANOCIN A DM0LR7G TI TTE2KUJ DM0LR7G TN Adenosylhomocysteinase (AHCY) DM0LR7G MA Inhibitor DM0LR7G RN Synthesis of 5'-substituted fluoro-neplanocin A analogues: importance of a hydrogen bonding donor at 5'-position for the inhibitory activity of S-a... Bioorg Med Chem Lett. 2004 Nov 15;14(22):5641-4. DM0LR7G RU https://pubmed.ncbi.nlm.nih.gov/15482939 DM0LTB2 DI DM0LTB2 DM0LTB2 DN PT-103 DM0LTB2 TI TT84ETX DM0LTB2 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM0LTB2 MA Inhibitor DM0LTB2 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM0LTB2 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM0LTNJ DI DM0LTNJ DM0LTNJ DN PD-135222 DM0LTNJ TI TTEX248 DM0LTNJ TN Dopamine D2 receptor (D2R) DM0LTNJ MA Inhibitor DM0LTNJ RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DM0LTNJ RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DM0LUOM DI DM0LUOM DM0LUOM DN ABIO 09-01 DM0LUOM TI TTFYL58 DM0LUOM TN CaM-kinase II (CAMK2) DM0LUOM MA Inhibitor DM0LUOM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1558). DM0LUOM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1558 DM0LW7G DI DM0LW7G DM0LW7G DN pregnenolone-16alpha-carbonitrile DM0LW7G TI TT7LCTF DM0LW7G TN Pregnane X receptor (NR1I2) DM0LW7G MA Agonist DM0LW7G RN An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998 Jan 9;92(1):73-82. DM0LW7G RU https://pubmed.ncbi.nlm.nih.gov/9489701 DM0LWAV DI DM0LWAV DM0LWAV DN 1,2-bis(3,4,5-trifluorophenyl)-2-hydroxyethanone DM0LWAV TI TTMF541 DM0LWAV TN Liver carboxylesterase (CES1) DM0LWAV MA Inhibitor DM0LWAV RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM0LWAV RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM0LWUV DI DM0LWUV DM0LWUV DN SC-51322 DM0LWUV TI TTG1QMU DM0LWUV TN Prostaglandin E2 receptor EP1 (PTGER1) DM0LWUV MA Modulator DM0LWUV RN Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest. 2007 Sep;117(9):2496-505. DM0LWUV RU https://www.ncbi.nlm.nih.gov/pubmed/17710229 DM0M59T DI DM0M59T DM0M59T DN BAY412272 DM0M59T TI TTWNFC2 DM0M59T TN Soluble guanylyl cyclase (GUCY2D) DM0M59T MA Activator DM0M59T RN NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001 Mar 8;410(6825):212-5. DM0M59T RU https://pubmed.ncbi.nlm.nih.gov/11242081 DM0M81E DI DM0M81E DM0M81E DN D609 DM0M81E TI TT6ERZB DM0M81E TN Bacterial Phosphatidylcholine-specificphospholipase C (Bact plcN) DM0M81E MA Inhibitor DM0M81E RN Function of the p55 tumor necrosis factor receptor "death domain" mediated by phosphatidylcholine-specific phospholipase C. J Exp Med. 1996 Aug 1;184(2):725-33. DM0M81E RU https://pubmed.ncbi.nlm.nih.gov/8760826 DM0M8G5 DI DM0M8G5 DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide DM0M8G5 TI TTT6LFV DM0M8G5 TN Histone deacetylase 8 (HDAC8) DM0M8G5 MA Inhibitor DM0M8G5 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM0M8G5 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0M8G5 DI DM0M8G5 DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide DM0M8G5 TI TTBH0VX DM0M8G5 TN Histone deacetylase (HDAC) DM0M8G5 MA Inhibitor DM0M8G5 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM0M8G5 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0M8G5 DI DM0M8G5 DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide DM0M8G5 TI TTTQGH8 DM0M8G5 TN Histone deacetylase 4 (HDAC4) DM0M8G5 MA Inhibitor DM0M8G5 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM0M8G5 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0M8G5 DI DM0M8G5 DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide DM0M8G5 TI TT5ZKDI DM0M8G5 TN Histone deacetylase 6 (HDAC6) DM0M8G5 MA Inhibitor DM0M8G5 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM0M8G5 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0M8G5 DI DM0M8G5 DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide DM0M8G5 TI TT6R7JZ DM0M8G5 TN Histone deacetylase 1 (HDAC1) DM0M8G5 MA Inhibitor DM0M8G5 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM0M8G5 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0M8G5 DI DM0M8G5 DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide DM0M8G5 TI TTYHPU6 DM0M8G5 TN Histone deacetylase 10 (HDAC10) DM0M8G5 MA Inhibitor DM0M8G5 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM0M8G5 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0M8G5 DI DM0M8G5 DM0M8G5 DN 4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide DM0M8G5 TI TTSHTOI DM0M8G5 TN Histone deacetylase 2 (HDAC2) DM0M8G5 MA Inhibitor DM0M8G5 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM0M8G5 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM0MAIW DI DM0MAIW DM0MAIW DN AS-1907417 DM0MAIW TI TT7QNVC DM0MAIW TN Glucose-dependent insulinotropic receptor (GPR119) DM0MAIW MA Agonist DM0MAIW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DM0MAIW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DM0MGFQ DI DM0MGFQ DM0MGFQ DN 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL DM0MGFQ TI TTOM3J0 DM0MGFQ TN Estrogen receptor beta (ESR2) DM0MGFQ MA Inhibitor DM0MGFQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0MGFQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0MGFQ DI DM0MGFQ DM0MGFQ DN 1-CHLORO-6-(4-HYDROXYPHENYL)-2-NAPHTHOL DM0MGFQ TI TTZAYWL DM0MGFQ TN Estrogen receptor (ESR) DM0MGFQ MA Inhibitor DM0MGFQ RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM0MGFQ RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM0MIGU DI DM0MIGU DM0MIGU DN 8-(2,5-dimethoxyphenyl)-9H-purine-2,6-diamine DM0MIGU TI TT9SL3Q DM0MIGU TN Polypeptide deformylase (PDF) DM0MIGU MA Inhibitor DM0MIGU RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DM0MIGU RU https://pubmed.ncbi.nlm.nih.gov/20117005 DM0MK6D DI DM0MK6D DM0MK6D DN BIS-IMIDE A DM0MK6D TI TTTU902 DM0MK6D TN Checkpoint kinase-1 (CHK1) DM0MK6D MA Inhibitor DM0MK6D RN Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3... Eur J Med Chem. 2008 Feb;43(2):282-92. DM0MK6D RU https://pubmed.ncbi.nlm.nih.gov/17502122 DM0MLU9 DI DM0MLU9 DM0MLU9 DN [3H]SNAP-7941 DM0MLU9 TI TTX4RTB DM0MLU9 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM0MLU9 MA Antagonist DM0MLU9 RN Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med. 2002 Aug;8(8):825-30. DM0MLU9 RU https://pubmed.ncbi.nlm.nih.gov/12118247 DM0MQHP DI DM0MQHP DM0MQHP DN 6-bromo-3-ethoxycarbonyl-4-quinolone DM0MQHP TI TT1MPAY DM0MQHP TN GABA(A) receptor alpha-1 (GABRA1) DM0MQHP MA Inhibitor DM0MQHP RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM0MQHP RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM0MQHP DI DM0MQHP DM0MQHP DN 6-bromo-3-ethoxycarbonyl-4-quinolone DM0MQHP TI TTZA1NY DM0MQHP TN GABA(A) receptor beta-2 (GABRB2) DM0MQHP MA Inhibitor DM0MQHP RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM0MQHP RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM0MQHP DI DM0MQHP DM0MQHP DN 6-bromo-3-ethoxycarbonyl-4-quinolone DM0MQHP TI TT06RH5 DM0MQHP TN GABA(A) receptor gamma-2 (GABRG2) DM0MQHP MA Inhibitor DM0MQHP RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM0MQHP RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM0MQHP DI DM0MQHP DM0MQHP DN 6-bromo-3-ethoxycarbonyl-4-quinolone DM0MQHP TI TTNJYV2 DM0MQHP TN Gamma-aminobutyric acid receptor (GAR) DM0MQHP MA Inhibitor DM0MQHP RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM0MQHP RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM0MQHP DI DM0MQHP DM0MQHP DN 6-bromo-3-ethoxycarbonyl-4-quinolone DM0MQHP TI TT37EDJ DM0MQHP TN GABA(A) receptor alpha-3 (GABRA3) DM0MQHP MA Inhibitor DM0MQHP RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM0MQHP RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TTCNGJ5 DM0MUKQ TN Candida Elongation factor 2 (Candi EFT2) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TT6HP1T DM0MUKQ TN Streptococcus Elongation factor G (Stre-coc fusA) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TT2F4OL DM0MUKQ TN Tissue transglutaminase (TG2) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TTYQ4AE DM0MUKQ TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TTG45NU DM0MUKQ TN Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TTO3MV6 DM0MUKQ TN Bacterial GTP-binding protein YihA (Bact engB) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TT4W1VJ DM0MUKQ TN Bacterial Celldivision protein FtsZ (Bact ftsZ) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MUKQ DI DM0MUKQ DM0MUKQ DN Guanosine-5'-Diphosphate DM0MUKQ TI TT958S6 DM0MUKQ TN Ras-related protein Rab-9A (RAB9A) DM0MUKQ MA Inhibitor DM0MUKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0MUKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0MWVU DI DM0MWVU DM0MWVU DN 4-(2-((dimethylamino)methyl)phenoxy)benzonitrile DM0MWVU TI TT3ROYC DM0MWVU TN Serotonin transporter (SERT) DM0MWVU MA Inhibitor DM0MWVU RN Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4018-21. DM0MWVU RU https://pubmed.ncbi.nlm.nih.gov/18571404 DM0N1DH DI DM0N1DH DM0N1DH DN PETCM DM0N1DH TI TTPF2QI DM0N1DH TN Caspase-3 (CASP3) DM0N1DH MA Activator DM0N1DH RN Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science. 2003 Jan 10;299(5604):223-6. DM0N1DH RU https://pubmed.ncbi.nlm.nih.gov/12522243 DM0N5J4 DI DM0N5J4 DM0N5J4 DN 2-Amino-6-(2-methoxy-phenylsulfanyl)-benzonitrile DM0N5J4 TI TT84ETX DM0N5J4 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM0N5J4 MA Inhibitor DM0N5J4 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM0N5J4 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM0N634 DI DM0N634 DM0N634 DN CITCO DM0N634 TI TTRANFM DM0N634 TN Orphan nuclear receptor NR1I3 (NR1I3) DM0N634 MA Agonist DM0N634 RN Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003 May 9;278(19):17277-83. DM0N634 RU https://pubmed.ncbi.nlm.nih.gov/12611900 DM0N68L DI DM0N68L DM0N68L DN 8-(3-Nitro-phenyl)-6-pyridin-4-ylmethyl-quinoline DM0N68L TI TTZ97H5 DM0N68L TN Phosphodiesterase 4A (PDE4A) DM0N68L MA Inhibitor DM0N68L RN Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3. DM0N68L RU https://pubmed.ncbi.nlm.nih.gov/11052785 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TTUNARX DM0N8ZM TN Carbonic anhydrase (CA) DM0N8ZM MA Inhibitor DM0N8ZM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TTZHA0O DM0N8ZM TN Carbonic anhydrase IV (CA-IV) DM0N8ZM MA Inhibitor DM0N8ZM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TTHQPL7 DM0N8ZM TN Carbonic anhydrase I (CA-I) DM0N8ZM MA Inhibitor DM0N8ZM RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/21067924 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TTCFSPE DM0N8ZM TN Carbonic anhydrase VI (CA-VI) DM0N8ZM MA Inhibitor DM0N8ZM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TT2LVK8 DM0N8ZM TN Carbonic anhydrase IX (CA-IX) DM0N8ZM MA Inhibitor DM0N8ZM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TTEYTKG DM0N8ZM TN Carbonic anhydrase XIV (CA-XIV) DM0N8ZM MA Inhibitor DM0N8ZM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TTANPDJ DM0N8ZM TN Carbonic anhydrase II (CA-II) DM0N8ZM MA Inhibitor DM0N8ZM RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/21067924 DM0N8ZM DI DM0N8ZM DM0N8ZM DN Coumarin DM0N8ZM TI TTSYM0R DM0N8ZM TN Carbonic anhydrase XII (CA-XII) DM0N8ZM MA Inhibitor DM0N8ZM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM0N8ZM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM0NBKR DI DM0NBKR DM0NBKR DN PGC GLP-1 DM0NBKR TI TTVIMDE DM0NBKR TN Glucagon-like peptide 1 receptor (GLP1R) DM0NBKR MA Modulator DM0NBKR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DM0NBKR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DM0NJAL DI DM0NJAL DM0NJAL DN N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine DM0NJAL TI TTGP7BY DM0NJAL TN Monoamine oxidase type B (MAO-B) DM0NJAL MA Inhibitor DM0NJAL RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DM0NJAL RU https://pubmed.ncbi.nlm.nih.gov/18951803 DM0NJAL DI DM0NJAL DM0NJAL DN N-Benzyl-N-(1H-indol-2-ylmethyl)-N-methylamine DM0NJAL TI TT3WG5C DM0NJAL TN Monoamine oxidase type A (MAO-A) DM0NJAL MA Inhibitor DM0NJAL RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DM0NJAL RU https://pubmed.ncbi.nlm.nih.gov/18951803 DM0NJYZ DI DM0NJYZ DM0NJYZ DN 2-acetylaminoquinazoline-4-carboxyanilide DM0NJYZ TI TTJFY5U DM0NJYZ TN Adenosine A3 receptor (ADORA3) DM0NJYZ MA Inhibitor DM0NJYZ RN Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606. DM0NJYZ RU https://pubmed.ncbi.nlm.nih.gov/18047262 DM0NQLI DI DM0NQLI DM0NQLI DN BPH-608 DM0NQLI TI TTIKWV4 DM0NQLI TN Geranyltranstransferase (FDPS) DM0NQLI MA Inhibitor DM0NQLI RN Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. DM0NQLI RU https://pubmed.ncbi.nlm.nih.gov/17535895 DM0NRJG DI DM0NRJG DM0NRJG DN 13-(3-n-Pentylureido)tridec-5(Z)-enoic acid DM0NRJG TI TT7WVHI DM0NRJG TN Soluble epoxide hydrolase (EPHX2) DM0NRJG MA Inhibitor DM0NRJG RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM0NRJG RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM0NTA3 DI DM0NTA3 DM0NTA3 DN (4-phenylpiperazin-1-yl)(p-tolyl)methanone DM0NTA3 TI TTVTX4N DM0NTA3 TN Bacterial Fatty acid synthetase I (Bact inhA) DM0NTA3 MA Inhibitor DM0NTA3 RN Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. DM0NTA3 RU https://pubmed.ncbi.nlm.nih.gov/17723305 DM0NTU5 DI DM0NTU5 DM0NTU5 DN C[L-Phe-D-pro-L-Phe-D-trp] DM0NTU5 TI TTQW87Y DM0NTU5 TN Opioid receptor kappa (OPRK1) DM0NTU5 MA Inhibitor DM0NTU5 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM0NTU5 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM0NTU5 DI DM0NTU5 DM0NTU5 DN C[L-Phe-D-pro-L-Phe-D-trp] DM0NTU5 TI TTKWM86 DM0NTU5 TN Opioid receptor mu (MOP) DM0NTU5 MA Inhibitor DM0NTU5 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM0NTU5 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM0O2ZB DI DM0O2ZB DM0O2ZB DN 3-(3-Dimethylamino-propyl)-1H-indol-4-ol DM0O2ZB TI TTWJBZ5 DM0O2ZB TN 5-HT 2C receptor (HTR2C) DM0O2ZB MA Inhibitor DM0O2ZB RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM0O2ZB RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM0O2ZB DI DM0O2ZB DM0O2ZB DN 3-(3-Dimethylamino-propyl)-1H-indol-4-ol DM0O2ZB TI TTJQOD7 DM0O2ZB TN 5-HT 2A receptor (HTR2A) DM0O2ZB MA Inhibitor DM0O2ZB RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM0O2ZB RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM0O2ZB DI DM0O2ZB DM0O2ZB DN 3-(3-Dimethylamino-propyl)-1H-indol-4-ol DM0O2ZB TI TT0K1SC DM0O2ZB TN 5-HT 2B receptor (HTR2B) DM0O2ZB MA Inhibitor DM0O2ZB RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM0O2ZB RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM0O4A2 DI DM0O4A2 DM0O4A2 DN ETHYL (1E)-2-PHENYL-N-(SULFOOXY)ETHANIMIDOTHIOATE DM0O4A2 TI TTA0OSE DM0O4A2 TN Lactase-phlorizin hydrolase (LCT) DM0O4A2 MA Inhibitor DM0O4A2 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0O4A2 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0O8KR DI DM0O8KR DM0O8KR DN E55888 DM0O8KR TI TTO9X1H DM0O8KR TN 5-HT 7 receptor (HTR7) DM0O8KR MA Agonist DM0O8KR RN 5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice. Pain. 2009 Feb;141(3):239-47. DM0O8KR RU https://pubmed.ncbi.nlm.nih.gov/19118950 DM0O8N6 DI DM0O8N6 DM0O8N6 DN Propionate DM0O8N6 TI TT6TMZU DM0O8N6 TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DM0O8N6 MA Inhibitor DM0O8N6 RN Molecular dynamics studies of alanine racemase: a structural model for drug design. Biopolymers. 2003 Oct;70(2):186-200. DM0O8N6 RU https://pubmed.ncbi.nlm.nih.gov/14517907 DM0O9VG DI DM0O9VG DM0O9VG DN RGD-039 DM0O9VG TI TT38RM1 DM0O9VG TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DM0O9VG MA Modulator DM0O9VG RN Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM). J Clin Pharmacol. 2000 Oct;40(10):1129-40. DM0O9VG RU https://pubmed.ncbi.nlm.nih.gov/11028252 DM0O9WM DI DM0O9WM DM0O9WM DN ISIS 32000 DM0O9WM TI TT9H4P3 DM0O9WM TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DM0O9WM RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DM0O9WM RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DM0OCLU DI DM0OCLU DM0OCLU DN N-(6-benzyl-1H-indazol-3-yl)butyramide DM0OCLU TI TTRSMW9 DM0OCLU TN Glycogen synthase kinase-3 beta (GSK-3B) DM0OCLU MA Inhibitor DM0OCLU RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DM0OCLU RU https://pubmed.ncbi.nlm.nih.gov/20167481 DM0OEGV DI DM0OEGV DM0OEGV DN NAPHTHYRIDINONE DM0OEGV TI TTMSFAW DM0OEGV TN Cannabinoid receptor 2 (CB2) DM0OEGV MA Inhibitor DM0OEGV RN Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):681-5. DM0OEGV RU https://pubmed.ncbi.nlm.nih.gov/16263284 DM0OEGV DI DM0OEGV DM0OEGV DN NAPHTHYRIDINONE DM0OEGV TI TT6OEDT DM0OEGV TN Cannabinoid receptor 1 (CB1) DM0OEGV MA Inhibitor DM0OEGV RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM0OEGV RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM0OEH3 DI DM0OEH3 DM0OEH3 DN PD-4048 DM0OEH3 TI TTJ6WK9 DM0OEH3 TN Neuropeptide Y receptor type 2 (NPY2R) DM0OEH3 MA Agonist DM0OEH3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 306). DM0OEH3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=306 DM0OEQJ DI DM0OEQJ DM0OEQJ DN (Z)-2'-des-methyl sulindac sulfide DM0OEQJ TI TTVKILB DM0OEQJ TN Prostaglandin G/H synthase 2 (COX-2) DM0OEQJ MA Inhibitor DM0OEQJ RN The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3271-4. DM0OEQJ RU https://pubmed.ncbi.nlm.nih.gov/19427206 DM0OEQJ DI DM0OEQJ DM0OEQJ DN (Z)-2'-des-methyl sulindac sulfide DM0OEQJ TI TT8NGED DM0OEQJ TN Prostaglandin G/H synthase 1 (COX-1) DM0OEQJ MA Inhibitor DM0OEQJ RN The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3271-4. DM0OEQJ RU https://pubmed.ncbi.nlm.nih.gov/19427206 DM0OF64 DI DM0OF64 DM0OF64 DN 3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol DM0OF64 TI TTGTQHC DM0OF64 TN DNA topoisomerase I (TOP1) DM0OF64 MA Inhibitor DM0OF64 RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DM0OF64 RU https://pubmed.ncbi.nlm.nih.gov/20392646 DM0OF64 DI DM0OF64 DM0OF64 DN 3-(4-phenyl-6-(thiophen-2-yl)pyridin-2-yl)-phenol DM0OF64 TI TT0IHXV DM0OF64 TN DNA topoisomerase II (TOP2) DM0OF64 MA Inhibitor DM0OF64 RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DM0OF64 RU https://pubmed.ncbi.nlm.nih.gov/20392646 DM0OFRQ DI DM0OFRQ DM0OFRQ DN 4-(2-(phenoxymethyl)phenyl)piperidine DM0OFRQ TI TTAWNKZ DM0OFRQ TN Norepinephrine transporter (NET) DM0OFRQ MA Inhibitor DM0OFRQ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0OFRQ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0OFRQ DI DM0OFRQ DM0OFRQ DN 4-(2-(phenoxymethyl)phenyl)piperidine DM0OFRQ TI TTVBI8W DM0OFRQ TN Dopamine transporter (DAT) DM0OFRQ MA Inhibitor DM0OFRQ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0OFRQ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0OFRQ DI DM0OFRQ DM0OFRQ DN 4-(2-(phenoxymethyl)phenyl)piperidine DM0OFRQ TI TT3ROYC DM0OFRQ TN Serotonin transporter (SERT) DM0OFRQ MA Inhibitor DM0OFRQ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0OFRQ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0OFT6 DI DM0OFT6 DM0OFT6 DN Monoisopropylphosphorylserine DM0OFT6 TI TT1RS9F DM0OFT6 TN Acetylcholinesterase (AChE) DM0OFT6 MA Inhibitor DM0OFT6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0OFT6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0OHL3 DI DM0OHL3 DM0OHL3 DN TG7-171 DM0OHL3 TI TT1ZAVI DM0OHL3 TN Prostaglandin E2 receptor EP2 (PTGER2) DM0OHL3 MA Antagonist DM0OHL3 RN Development of second generation EP2 antagonists with high selectivity. Eur J Med Chem. 2014 Jul 23;82:521-35. DM0OHL3 RU https://pubmed.ncbi.nlm.nih.gov/24937185 DM0OJZF DI DM0OJZF DM0OJZF DN 5-hexyl-2-(2-nitrophenoxy)phenol DM0OJZF TI TTVTX4N DM0OJZF TN Bacterial Fatty acid synthetase I (Bact inhA) DM0OJZF MA Inhibitor DM0OJZF RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DM0OJZF RU https://pubmed.ncbi.nlm.nih.gov/18457948 DM0OLYF DI DM0OLYF DM0OLYF DN SB-559457 DM0OLYF TI TTIHYA4 DM0OLYF TN Thrombopoietin receptor (MPL) DM0OLYF MA Agonist DM0OLYF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DM0OLYF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DM0OM9L DI DM0OM9L DM0OM9L DN SRIF-28 DM0OM9L TI TT2BC4G DM0OM9L TN Somatostatin receptor type 5 (SSTR5) DM0OM9L MA Inhibitor DM0OM9L RN Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97. DM0OM9L RU https://pubmed.ncbi.nlm.nih.gov/20666484 DM0OM9L DI DM0OM9L DM0OM9L DN SRIF-28 DM0OM9L TI TTJX3UE DM0OM9L TN Somatostatin receptor type 3 (SSTR3) DM0OM9L MA Inhibitor DM0OM9L RN Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97. DM0OM9L RU https://pubmed.ncbi.nlm.nih.gov/20666484 DM0OM9L DI DM0OM9L DM0OM9L DN SRIF-28 DM0OM9L TI TTIND6G DM0OM9L TN Somatostatin receptor type 1 (SSTR1) DM0OM9L MA Inhibitor DM0OM9L RN Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97. DM0OM9L RU https://pubmed.ncbi.nlm.nih.gov/20666484 DM0OM9L DI DM0OM9L DM0OM9L DN SRIF-28 DM0OM9L TI TTZ6T9E DM0OM9L TN Somatostatin receptor type 2 (SSTR2) DM0OM9L MA Inhibitor DM0OM9L RN Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97. DM0OM9L RU https://pubmed.ncbi.nlm.nih.gov/20666484 DM0OM9L DI DM0OM9L DM0OM9L DN SRIF-28 DM0OM9L TI TTAE1BR DM0OM9L TN Somatostatin receptor type 4 (SSTR4) DM0OM9L MA Inhibitor DM0OM9L RN Novel octreotide dicarba-analogues with high affinity and different selectivity for somatostatin receptors. J Med Chem. 2010 Aug 26;53(16):6188-97. DM0OM9L RU https://pubmed.ncbi.nlm.nih.gov/20666484 DM0OQTJ DI DM0OQTJ DM0OQTJ DN 5-Fluoro-3-thiophen-3-yl-quinoline DM0OQTJ TI TT8FYO9 DM0OQTJ TN Platelet-derived growth factor receptor alpha (PDGFRA) DM0OQTJ MA Inhibitor DM0OQTJ RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0OQTJ RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0OWTS DI DM0OWTS DM0OWTS DN MOLASSAMIDE DM0OWTS TI TT3NKIB DM0OWTS TN Pancreatic elastase 1 (CELA1) DM0OWTS MA Inhibitor DM0OWTS RN Molassamide, a depsipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J Nat Prod. 2010 Mar 26;73(3):459-62. DM0OWTS RU https://pubmed.ncbi.nlm.nih.gov/20020755 DM0P3R5 DI DM0P3R5 DM0P3R5 DN ISIS 119264 DM0P3R5 TI TTKS60G DM0P3R5 TN STXBP4 messenger RNA (STXBP4 mRNA) DM0P3R5 RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DM0P3R5 RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DM0P4V6 DI DM0P4V6 DM0P4V6 DN L-454560 DM0P4V6 TI TTSKMI8 DM0P4V6 TN Phosphodiesterase 4D (PDE4D) DM0P4V6 MA Inhibitor DM0P4V6 RN The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5. DM0P4V6 RU https://pubmed.ncbi.nlm.nih.gov/20709547 DM0P4V6 DI DM0P4V6 DM0P4V6 DN L-454560 DM0P4V6 TI TTZ97H5 DM0P4V6 TN Phosphodiesterase 4A (PDE4A) DM0P4V6 MA Inhibitor DM0P4V6 RN The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5. DM0P4V6 RU https://pubmed.ncbi.nlm.nih.gov/20709547 DM0P4V6 DI DM0P4V6 DM0P4V6 DN L-454560 DM0P4V6 TI TTVIAT9 DM0P4V6 TN Phosphodiesterase 4B (PDE4B) DM0P4V6 MA Inhibitor DM0P4V6 RN The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5502-5. DM0P4V6 RU https://pubmed.ncbi.nlm.nih.gov/20709547 DM0P59E DI DM0P59E DM0P59E DN MEBUDIPINE DM0P59E TI TTZIFHC DM0P59E TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DM0P59E MA Inhibitor DM0P59E RN Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58. DM0P59E RU https://pubmed.ncbi.nlm.nih.gov/20382537 DM0P59E DI DM0P59E DM0P59E DN MEBUDIPINE DM0P59E TI TT7RGTM DM0P59E TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DM0P59E MA Inhibitor DM0P59E RN Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels Ca V 1.3 and Ca V 1.2. Bioorg Med Chem. 2010 May 1;18(9):3147-58. DM0P59E RU https://pubmed.ncbi.nlm.nih.gov/20382537 DM0P5Z9 DI DM0P5Z9 DM0P5Z9 DN UCL1972 DM0P5Z9 TI TT9JNIC DM0P5Z9 TN Histamine H3 receptor (H3R) DM0P5Z9 MA Antagonist DM0P5Z9 RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM0P5Z9 RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM0P6A3 DI DM0P6A3 DM0P6A3 DN 2-(5-Mercapto-pentyl)-pentanedioic acid DM0P6A3 TI TT9G4N0 DM0P6A3 TN Glutamate carboxypeptidase II (GCPII) DM0P6A3 MA Inhibitor DM0P6A3 RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DM0P6A3 RU https://pubmed.ncbi.nlm.nih.gov/12723961 DM0PA6I DI DM0PA6I DM0PA6I DN 2-(cinnamyloxy)pyrido[2,3-d]pyrimidin-4(3H)-one DM0PA6I TI TTWNV8U DM0PA6I TN Nicotinic acid receptor (HCAR2) DM0PA6I MA Inhibitor DM0PA6I RN Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5426-30. DM0PA6I RU https://pubmed.ncbi.nlm.nih.gov/20724150 DM0PETL DI DM0PETL DM0PETL DN SB-525334 DM0PETL TI TTP4520 DM0PETL TN TGF-beta receptor type I (TGFBR1) DM0PETL MA Inhibitor DM0PETL RN Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4228-4232 (2010). DM0PETL RU http://www.sciencedirect.com/science/article/pii/S0960894X10006736 DM0PHEW DI DM0PHEW DM0PHEW DN Erythromycin salnacedin DM0PHEW TI TTUWYEA DM0PHEW TN Bacterial 50S ribosomal RNA (Bact 50S rRNA) DM0PHEW MA Modulator DM0PHEW RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM0PHEW RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM0PMKW DI DM0PMKW DM0PMKW DN OG-L002 DM0PMKW TI TTNR0UQ DM0PMKW TN Lysine-specific histone demethylase 1 (LSD) DM0PMKW MA Inhibitor DM0PMKW RN A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 2013 Feb 5;4(1):e00558-12. DM0PMKW RU https://pubmed.ncbi.nlm.nih.gov/23386436 DM0POH2 DI DM0POH2 DM0POH2 DN 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline DM0POH2 TI TTI7421 DM0POH2 TN Platelet-derived growth factor receptor beta (PDGFRB) DM0POH2 MA Inhibitor DM0POH2 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0POH2 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0POH2 DI DM0POH2 DM0POH2 DN 3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline DM0POH2 TI TT8FYO9 DM0POH2 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM0POH2 MA Inhibitor DM0POH2 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0POH2 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0PQ37 DI DM0PQ37 DM0PQ37 DN ICI 200,880 DM0PQ37 TI TTPLTSQ DM0PQ37 TN Neutrophil elastase (NE) DM0PQ37 MA Inhibitor DM0PQ37 RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DM0PQ37 RU https://pubmed.ncbi.nlm.nih.gov/12084007 DM0PQH1 DI DM0PQH1 DM0PQH1 DN 5'-S-ethyl-5'-thioadenosine DM0PQH1 TI TTE2KUJ DM0PQH1 TN Adenosylhomocysteinase (AHCY) DM0PQH1 MA Inhibitor DM0PQH1 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0PQH1 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0PT8R DI DM0PT8R DM0PT8R DN 2-N-(Isopropyl)amino-1-(4-methylthiophenyl)butane DM0PT8R TI TT3ROYC DM0PT8R TN Serotonin transporter (SERT) DM0PT8R MA Inhibitor DM0PT8R RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM0PT8R RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM0PV2Y DI DM0PV2Y DM0PV2Y DN Hippuristanol DM0PV2Y TI TTIGYVZ DM0PV2Y TN HUMAN eukaryotic initiation factor-4A (eIF4A) DM0PV2Y MA Inhibitor DM0PV2Y RN Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia. Biochem Pharmacol. 2011 Mar 15;81(6):713-22. DM0PV2Y RU https://pubmed.ncbi.nlm.nih.gov/21219881 DM0PVD9 DI DM0PVD9 DM0PVD9 DN AZD1332 DM0PVD9 TI TTXABCW DM0PVD9 TN NT-3 growth factor receptor (TrkC) DM0PVD9 MA Inhibitor DM0PVD9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1817). DM0PVD9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1817 DM0PVD9 DI DM0PVD9 DM0PVD9 DN AZD1332 DM0PVD9 TI TTKN7QR DM0PVD9 TN BDNF/NT-3 growth factors receptor (TrkB) DM0PVD9 MA Inhibitor DM0PVD9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818). DM0PVD9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1818 DM0Q46C DI DM0Q46C DM0Q46C DN 1-fluoro-5-phenyl-3-aza-bicyclo[3.1.0]hexane DM0Q46C TI TT3ROYC DM0Q46C TN Serotonin transporter (SERT) DM0Q46C MA Inhibitor DM0Q46C RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DM0Q46C RU https://pubmed.ncbi.nlm.nih.gov/18539031 DM0Q56N DI DM0Q56N DM0Q56N DN 7-(3-chlorophenyl)-2-methylquinoline DM0Q56N TI TTHS256 DM0Q56N TN Metabotropic glutamate receptor 5 (mGluR5) DM0Q56N MA Inhibitor DM0Q56N RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DM0Q56N RU https://pubmed.ncbi.nlm.nih.gov/17590335 DM0QGF3 DI DM0QGF3 DM0QGF3 DN MRS2279 DM0QGF3 TI TTA93TL DM0QGF3 TN P2Y purinoceptor 1 (P2RY1) DM0QGF3 MA Antagonist DM0QGF3 RN Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57. DM0QGF3 RU https://pubmed.ncbi.nlm.nih.gov/12391289 DM0QI8V DI DM0QI8V DM0QI8V DN 7-Fluoro-3-thiophen-3-yl-quinoline DM0QI8V TI TTI7421 DM0QI8V TN Platelet-derived growth factor receptor beta (PDGFRB) DM0QI8V MA Inhibitor DM0QI8V RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0QI8V RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0QI8V DI DM0QI8V DM0QI8V DN 7-Fluoro-3-thiophen-3-yl-quinoline DM0QI8V TI TT8FYO9 DM0QI8V TN Platelet-derived growth factor receptor alpha (PDGFRA) DM0QI8V MA Inhibitor DM0QI8V RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0QI8V RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0QJSO DI DM0QJSO DM0QJSO DN NILTUBACIN DM0QJSO TI TT5ZKDI DM0QJSO TN Histone deacetylase 6 (HDAC6) DM0QJSO MA Inhibitor DM0QJSO RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DM0QJSO RU https://pubmed.ncbi.nlm.nih.gov/20139990 DM0QJSO DI DM0QJSO DM0QJSO DN NILTUBACIN DM0QJSO TI TTT6LFV DM0QJSO TN Histone deacetylase 8 (HDAC8) DM0QJSO MA Inhibitor DM0QJSO RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DM0QJSO RU https://pubmed.ncbi.nlm.nih.gov/20139990 DM0QRJ3 DI DM0QRJ3 DM0QRJ3 DN 4-(4-((phenethylamino)methyl)phenoxy)benzamide DM0QRJ3 TI TTQW87Y DM0QRJ3 TN Opioid receptor kappa (OPRK1) DM0QRJ3 MA Inhibitor DM0QRJ3 RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DM0QRJ3 RU https://pubmed.ncbi.nlm.nih.gov/17720493 DM0QRJ3 DI DM0QRJ3 DM0QRJ3 DN 4-(4-((phenethylamino)methyl)phenoxy)benzamide DM0QRJ3 TI TT27RFC DM0QRJ3 TN Opioid receptor delta (OPRD1) DM0QRJ3 MA Inhibitor DM0QRJ3 RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DM0QRJ3 RU https://pubmed.ncbi.nlm.nih.gov/17720493 DM0QRJ3 DI DM0QRJ3 DM0QRJ3 DN 4-(4-((phenethylamino)methyl)phenoxy)benzamide DM0QRJ3 TI TTKWM86 DM0QRJ3 TN Opioid receptor mu (MOP) DM0QRJ3 MA Inhibitor DM0QRJ3 RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DM0QRJ3 RU https://pubmed.ncbi.nlm.nih.gov/17720493 DM0QY1V DI DM0QY1V DM0QY1V DN dioctanoylglycerol pyrophosphate DM0QY1V TI TTQ6S1K DM0QY1V TN Lysophosphatidic acid receptor 1 (LPAR1) DM0QY1V MA Antagonist DM0QY1V RN Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84. DM0QY1V RU https://pubmed.ncbi.nlm.nih.gov/11562440 DM0QY1V DI DM0QY1V DM0QY1V DN dioctanoylglycerol pyrophosphate DM0QY1V TI TTO897C DM0QY1V TN G protein coupled receptor 87 (GPR87) DM0QY1V MA Antagonist DM0QY1V RN The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2007 Nov 23;363(3):861-6. DM0QY1V RU https://pubmed.ncbi.nlm.nih.gov/17905198 DM0QY1V DI DM0QY1V DM0QY1V DN dioctanoylglycerol pyrophosphate DM0QY1V TI TTMFOU6 DM0QY1V TN P2Y purinoceptor 10 (P2RY10) DM0QY1V MA Antagonist DM0QY1V RN Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12. DM0QY1V RU https://pubmed.ncbi.nlm.nih.gov/18466763 DM0QY1V DI DM0QY1V DM0QY1V DN dioctanoylglycerol pyrophosphate DM0QY1V TI TTE2YJR DM0QY1V TN Lysophosphatidate-3 receptor (LPAR3) DM0QY1V MA Antagonist DM0QY1V RN Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84. DM0QY1V RU https://pubmed.ncbi.nlm.nih.gov/11562440 DM0QYLP DI DM0QYLP DM0QYLP DN HI-242 DM0QYLP TI TT84ETX DM0QYLP TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM0QYLP MA Inhibitor DM0QYLP RN Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90. DM0QYLP RU https://pubmed.ncbi.nlm.nih.gov/10636251 DM0QZ6I DI DM0QZ6I DM0QZ6I DN D-kynurenine DM0QZ6I TI TT8WFXV DM0QZ6I TN Hydroxycarboxylic acid receptor 3 (HCAR3) DM0QZ6I MA Agonist DM0QZ6I RN Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3930-4. DM0QZ6I RU https://pubmed.ncbi.nlm.nih.gov/19237584 DM0R5U6 DI DM0R5U6 DM0R5U6 DN 2-(3-(benzyloxy)phenyl)isoindoline-1,3-dione DM0R5U6 TI TTHS256 DM0R5U6 TN Metabotropic glutamate receptor 5 (mGluR5) DM0R5U6 MA Inhibitor DM0R5U6 RN Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. DM0R5U6 RU https://pubmed.ncbi.nlm.nih.gov/16439120 DM0R6MT DI DM0R6MT DM0R6MT DN O-tolyl 10H-phenothiazine-10-carboxylate DM0R6MT TI TTEB0GD DM0R6MT TN Cholinesterase (BCHE) DM0R6MT MA Inhibitor DM0R6MT RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DM0R6MT RU https://pubmed.ncbi.nlm.nih.gov/18570368 DM0RB53 DI DM0RB53 DM0RB53 DN 6,11-dihydrothiochromeno[4,3-b]indol-8-ol DM0RB53 TI TTS64P2 DM0RB53 TN Androgen receptor (AR) DM0RB53 MA Inhibitor DM0RB53 RN Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7. DM0RB53 RU https://pubmed.ncbi.nlm.nih.gov/16603353 DM0RC8M DI DM0RC8M DM0RC8M DN KETOCYCLAZOCINE DM0RC8M TI TTKWM86 DM0RC8M TN Opioid receptor mu (MOP) DM0RC8M MA Inhibitor DM0RC8M RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DM0RC8M RU https://pubmed.ncbi.nlm.nih.gov/19027293 DM0RC8M DI DM0RC8M DM0RC8M DN KETOCYCLAZOCINE DM0RC8M TI TTQW87Y DM0RC8M TN Opioid receptor kappa (OPRK1) DM0RC8M MA Inhibitor DM0RC8M RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DM0RC8M RU https://pubmed.ncbi.nlm.nih.gov/19027293 DM0RDC4 DI DM0RDC4 DM0RDC4 DN Sarafotoxin 6C DM0RDC4 TI TT3ZTGU DM0RDC4 TN Endothelin B receptor (EDNRB) DM0RDC4 MA Antagonist DM0RDC4 RN Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2704-13. DM0RDC4 RU https://pubmed.ncbi.nlm.nih.gov/12147606 DM0RFTJ DI DM0RFTJ DM0RFTJ DN CH-3697 DM0RFTJ TI TTVIAT9 DM0RFTJ TN Phosphodiesterase 4B (PDE4B) DM0RFTJ MA Modulator DM0RFTJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DM0RFTJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DM0RFTJ DI DM0RFTJ DM0RFTJ DN CH-3697 DM0RFTJ TI TTSKMI8 DM0RFTJ TN Phosphodiesterase 4D (PDE4D) DM0RFTJ MA Modulator DM0RFTJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DM0RFTJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DM0RFTJ DI DM0RFTJ DM0RFTJ DN CH-3697 DM0RFTJ TI TTZ97H5 DM0RFTJ TN Phosphodiesterase 4A (PDE4A) DM0RFTJ MA Inhibitor DM0RFTJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DM0RFTJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DM0RH3S DI DM0RH3S DM0RH3S DN CI-218872 DM0RH3S TI TTZA1NY DM0RH3S TN GABA(A) receptor beta-2 (GABRB2) DM0RH3S MA Inhibitor DM0RH3S RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DM0RH3S RU https://pubmed.ncbi.nlm.nih.gov/7799410 DM0RH3S DI DM0RH3S DM0RH3S DN CI-218872 DM0RH3S TI TT1MPAY DM0RH3S TN GABA(A) receptor alpha-1 (GABRA1) DM0RH3S MA Inhibitor DM0RH3S RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DM0RH3S RU https://pubmed.ncbi.nlm.nih.gov/7799410 DM0RH3S DI DM0RH3S DM0RH3S DN CI-218872 DM0RH3S TI TTNZPQ1 DM0RH3S TN GABA(A) receptor alpha-5 (GABRA5) DM0RH3S MA Inhibitor DM0RH3S RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM0RH3S RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM0RH3S DI DM0RH3S DM0RH3S DN CI-218872 DM0RH3S TI TT06RH5 DM0RH3S TN GABA(A) receptor gamma-2 (GABRG2) DM0RH3S MA Inhibitor DM0RH3S RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DM0RH3S RU https://pubmed.ncbi.nlm.nih.gov/7799410 DM0RH3S DI DM0RH3S DM0RH3S DN CI-218872 DM0RH3S TI TTBMV1G DM0RH3S TN GABA(A) receptor alpha-2 (GABRA2) DM0RH3S MA Inhibitor DM0RH3S RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM0RH3S RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM0RH3S DI DM0RH3S DM0RH3S DN CI-218872 DM0RH3S TI TTNJYV2 DM0RH3S TN Gamma-aminobutyric acid receptor (GAR) DM0RH3S MA Inhibitor DM0RH3S RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM0RH3S RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM0RH3S DI DM0RH3S DM0RH3S DN CI-218872 DM0RH3S TI TT37EDJ DM0RH3S TN GABA(A) receptor alpha-3 (GABRA3) DM0RH3S MA Inhibitor DM0RH3S RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM0RH3S RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM0RQGU DI DM0RQGU DM0RQGU DN N,N'-Bis-(4-hexyl-phenyl)-guanidine DM0RQGU TI TTLD29N DM0RQGU TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM0RQGU MA Inhibitor DM0RQGU RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM0RQGU RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM0RQGU DI DM0RQGU DM0RQGU DN N,N'-Bis-(4-hexyl-phenyl)-guanidine DM0RQGU TI TTN9D8E DM0RQGU TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM0RQGU MA Inhibitor DM0RQGU RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM0RQGU RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM0RQGU DI DM0RQGU DM0RQGU DN N,N'-Bis-(4-hexyl-phenyl)-guanidine DM0RQGU TI TTKJEMQ DM0RQGU TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM0RQGU MA Inhibitor DM0RQGU RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DM0RQGU RU https://pubmed.ncbi.nlm.nih.gov/9703475 DM0RUQ8 DI DM0RUQ8 DM0RUQ8 DN ANNULIN A DM0RUQ8 TI TTZJYKH DM0RUQ8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM0RUQ8 MA Inhibitor DM0RUQ8 RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DM0RUQ8 RU https://pubmed.ncbi.nlm.nih.gov/17067170 DM0RV9C DI DM0RV9C DM0RV9C DN PATULIN DM0RV9C TI TTWXB3E DM0RV9C TN Hepatitis C virus NS3 helicase (HCV NS3) DM0RV9C MA Inhibitor DM0RV9C RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DM0RV9C RU https://pubmed.ncbi.nlm.nih.gov/15633995 DM0RZDF DI DM0RZDF DM0RZDF DN MCP-204 DM0RZDF TI TT27RFC DM0RZDF TN Opioid receptor delta (OPRD1) DM0RZDF MA Agonist DM0RZDF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DM0RZDF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DM0S5PE DI DM0S5PE DM0S5PE DN ZYKLOPHIN DM0S5PE TI TTKWM86 DM0S5PE TN Opioid receptor mu (MOP) DM0S5PE MA Inhibitor DM0S5PE RN The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21. DM0S5PE RU https://pubmed.ncbi.nlm.nih.gov/19807094 DM0S5PE DI DM0S5PE DM0S5PE DN ZYKLOPHIN DM0S5PE TI TTQW87Y DM0S5PE TN Opioid receptor kappa (OPRK1) DM0S5PE MA Inhibitor DM0S5PE RN The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21. DM0S5PE RU https://pubmed.ncbi.nlm.nih.gov/19807094 DM0S71O DI DM0S71O DM0S71O DN N-{4-[2-(4-Methoxyphenyl)ethyl]phenyl}phthalimide DM0S71O TI TTECBXN DM0S71O TN Oxysterols receptor LXR-alpha (NR1H3) DM0S71O MA Inhibitor DM0S71O RN Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. DM0S71O RU https://pubmed.ncbi.nlm.nih.gov/19539483 DM0S82C DI DM0S82C DM0S82C DN (2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime DM0S82C TI TT7HF4W DM0S82C TN Cyclin-dependent kinase 2 (CDK2) DM0S82C MA Inhibitor DM0S82C RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM0S82C RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM0S82C DI DM0S82C DM0S82C DN (2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime DM0S82C TI TTCEJ4F DM0S82C TN G1/S-specific cyclin-E1 (CCNE1) DM0S82C MA Inhibitor DM0S82C RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM0S82C RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM0SCDR DI DM0SCDR DM0SCDR DN Piretanide DM0SCDR TI TTS087L DM0SCDR TN Solute carrier family 12 member 1 (SLC12A1) DM0SCDR MA Blocker DM0SCDR RN Peripheral and central antinociceptive action of Na+-K+-2Cl- cotransporter blockers on formalin-induced nociception in rats. Pain. 2005 Mar;114(1-2):231-8. DM0SCDR RU https://pubmed.ncbi.nlm.nih.gov/15733649 DM0SCK8 DI DM0SCK8 DM0SCK8 DN Glycyl-H 1152 DM0SCK8 TI TTGWKQJ DM0SCK8 TN Rho-associated protein kinase 2 (ROCK2) DM0SCK8 MA Inhibitor DM0SCK8 RN Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52. DM0SCK8 RU https://pubmed.ncbi.nlm.nih.gov/16213195 DM0SCK8 DI DM0SCK8 DM0SCK8 DN Glycyl-H 1152 DM0SCK8 TI TTLYXIT DM0SCK8 TN Aurora kinase C (AURKC) DM0SCK8 MA Inhibitor DM0SCK8 RN Development of specific Rho-kinase inhibitors and their clinical application. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):245-52. DM0SCK8 RU https://pubmed.ncbi.nlm.nih.gov/16213195 DM0SCW9 DI DM0SCW9 DM0SCW9 DN (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine DM0SCW9 TI TT6EO5L DM0SCW9 TN Erbb2 tyrosine kinase receptor (HER2) DM0SCW9 MA Inhibitor DM0SCW9 RN Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5. DM0SCW9 RU https://pubmed.ncbi.nlm.nih.gov/11378364 DM0SCW9 DI DM0SCW9 DM0SCW9 DN (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine DM0SCW9 TI TTR5TV4 DM0SCW9 TN ERBB2 messenger RNA (HER2 mRNA) DM0SCW9 MA Inhibitor DM0SCW9 RN Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5. DM0SCW9 RU https://pubmed.ncbi.nlm.nih.gov/11378364 DM0SEL5 DI DM0SEL5 DM0SEL5 DN 3-Pyridin-4-yl-quinolin-7-ol DM0SEL5 TI TT8FYO9 DM0SEL5 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM0SEL5 MA Inhibitor DM0SEL5 RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM0SEL5 RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM0SEL5 DI DM0SEL5 DM0SEL5 DN 3-Pyridin-4-yl-quinolin-7-ol DM0SEL5 TI TTI7421 DM0SEL5 TN Platelet-derived growth factor receptor beta (PDGFRB) DM0SEL5 MA Inhibitor DM0SEL5 RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM0SEL5 RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM0SEYN DI DM0SEYN DM0SEYN DN (S)-dimethylenastron DM0SEYN TI TTBGTCW DM0SEYN TN Kinesin spindle messenger RNA (KIF11 mRNA) DM0SEYN MA Inhibitor DM0SEYN RN Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. J Med Chem. 2010 Aug 12;53(15):5676-83. DM0SEYN RU https://pubmed.ncbi.nlm.nih.gov/20597485 DM0STFR DI DM0STFR DM0STFR DN ENHYDRIN DM0STFR TI TTSXVID DM0STFR TN Nuclear factor NF-kappa-B (NFKB) DM0STFR MA Inhibitor DM0STFR RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DM0STFR RU https://pubmed.ncbi.nlm.nih.gov/16570920 DM0T1NZ DI DM0T1NZ DM0T1NZ DN 4-Benzyloxybenzo[b]thiophene-2-carboxamidine DM0T1NZ TI TTFEZ5Q DM0T1NZ TN Coagulation factor IX (F9) DM0T1NZ MA Inhibitor DM0T1NZ RN Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72. DM0T1NZ RU https://pubmed.ncbi.nlm.nih.gov/20121198 DM0T2LQ DI DM0T2LQ DM0T2LQ DN FPT-038 DM0T2LQ TI TTCBFJO DM0T2LQ TN Insulin receptor (INSR) DM0T2LQ MA Modulator DM0T2LQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM0T2LQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM0T8ZU DI DM0T8ZU DM0T8ZU DN IPS-01003 DM0T8ZU TI TTGKNB4 DM0T8ZU TN Epidermal growth factor receptor (EGFR) DM0T8ZU MA Antagonist DM0T8ZU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM0T8ZU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM0THB9 DI DM0THB9 DM0THB9 DN [3H]N5-methylfolate DM0THB9 TI TTY8Z2E DM0THB9 TN Proton-coupled folate transporter (SLC46A1) DM0THB9 MA Modulator DM0THB9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DM0THB9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DM0TJ6R DI DM0TJ6R DM0TJ6R DN BPH-628 DM0TJ6R TI TTIKWV4 DM0TJ6R TN Geranyltranstransferase (FDPS) DM0TJ6R MA Inhibitor DM0TJ6R RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DM0TJ6R RU https://pubmed.ncbi.nlm.nih.gov/18800762 DM0TP2R DI DM0TP2R DM0TP2R DN Z-YVAD-CHO DM0TP2R TI TTCQIBE DM0TP2R TN Caspase-1 (CASP1) DM0TP2R MA Inhibitor DM0TP2R RN Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg Med Chem Lett. 2006 Feb;16(3):559-62. DM0TP2R RU https://pubmed.ncbi.nlm.nih.gov/16274992 DM0TRAZ DI DM0TRAZ DM0TRAZ DN [3H]WIN55212-2 DM0TRAZ TI TT6OEDT DM0TRAZ TN Cannabinoid receptor 1 (CB1) DM0TRAZ MA Agonist DM0TRAZ RN Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J Neurochem. 1998 Jan;70(1):366-73. DM0TRAZ RU https://pubmed.ncbi.nlm.nih.gov/9422383 DM0TRAZ DI DM0TRAZ DM0TRAZ DN [3H]WIN55212-2 DM0TRAZ TI TTMSFAW DM0TRAZ TN Cannabinoid receptor 2 (CB2) DM0TRAZ MA Agonist DM0TRAZ RN Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol. 1995 Aug;48(2):352-61. DM0TRAZ RU https://pubmed.ncbi.nlm.nih.gov/7651369 DM0TS21 DI DM0TS21 DM0TS21 DN N5-(1-iminopent-3-enyl)-L-ornithine DM0TS21 TI TTZUFI5 DM0TS21 TN Nitric-oxide synthase brain (NOS1) DM0TS21 MA Inhibitor DM0TS21 RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM0TS21 RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM0TUKZ DI DM0TUKZ DM0TUKZ DN (1-phenylcyclopentyl)methanamine DM0TUKZ TI TTDIGC1 DM0TUKZ TN Dipeptidyl peptidase 4 (DPP-4) DM0TUKZ MA Inhibitor DM0TUKZ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM0TUKZ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM0TVL5 DI DM0TVL5 DM0TVL5 DN 8-Propoxy-quinolin-2-ylamine DM0TVL5 TI TTX4RTB DM0TVL5 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM0TVL5 MA Inhibitor DM0TVL5 RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM0TVL5 RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM0U5N9 DI DM0U5N9 DM0U5N9 DN KNT-63 DM0U5N9 TI TTKWM86 DM0U5N9 TN Opioid receptor mu (MOP) DM0U5N9 MA Inhibitor DM0U5N9 RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DM0U5N9 RU https://pubmed.ncbi.nlm.nih.gov/19962305 DM0U5N9 DI DM0U5N9 DM0U5N9 DN KNT-63 DM0U5N9 TI TTQW87Y DM0U5N9 TN Opioid receptor kappa (OPRK1) DM0U5N9 MA Inhibitor DM0U5N9 RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DM0U5N9 RU https://pubmed.ncbi.nlm.nih.gov/19962305 DM0U7CK DI DM0U7CK DM0U7CK DN NSC-637992 DM0U7CK TI TTJLP0R DM0U7CK TN Quinone reductase 2 (NQO2) DM0U7CK MA Inhibitor DM0U7CK RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DM0U7CK RU https://pubmed.ncbi.nlm.nih.gov/20356739 DM0U8IV DI DM0U8IV DM0U8IV DN hyp 9 DM0U8IV TI TTRBT3W DM0U8IV TN Short transient receptor potential channel 6 (TRPC6) DM0U8IV MA Activator DM0U8IV RN Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore. Mol Pharmacol. 2010 Mar;77(3):368-77. DM0U8IV RU https://pubmed.ncbi.nlm.nih.gov/20008516 DM0UADK DI DM0UADK DM0UADK DN OCTOCLOTHEPIN DM0UADK TI TTWJBZ5 DM0UADK TN 5-HT 2C receptor (HTR2C) DM0UADK MA Inhibitor DM0UADK RN Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34. DM0UADK RU https://pubmed.ncbi.nlm.nih.gov/20857909 DM0UADK DI DM0UADK DM0UADK DN OCTOCLOTHEPIN DM0UADK TI TTTIBOJ DM0UADK TN Histamine H1 receptor (H1R) DM0UADK MA Inhibitor DM0UADK RN Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34. DM0UADK RU https://pubmed.ncbi.nlm.nih.gov/20857909 DM0UADK DI DM0UADK DM0UADK DN OCTOCLOTHEPIN DM0UADK TI TTBRKXS DM0UADK TN Adrenergic receptor alpha-1B (ADRA1B) DM0UADK MA Inhibitor DM0UADK RN Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34. DM0UADK RU https://pubmed.ncbi.nlm.nih.gov/20857909 DM0UADK DI DM0UADK DM0UADK DN OCTOCLOTHEPIN DM0UADK TI TT34BHT DM0UADK TN Adrenergic receptor alpha-1D (ADRA1D) DM0UADK MA Inhibitor DM0UADK RN Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34. DM0UADK RU https://pubmed.ncbi.nlm.nih.gov/20857909 DM0UADK DI DM0UADK DM0UADK DN OCTOCLOTHEPIN DM0UADK TI TTEX248 DM0UADK TN Dopamine D2 receptor (D2R) DM0UADK MA Inhibitor DM0UADK RN Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34. DM0UADK RU https://pubmed.ncbi.nlm.nih.gov/20857909 DM0UADK DI DM0UADK DM0UADK DN OCTOCLOTHEPIN DM0UADK TI TTNGILX DM0UADK TN Adrenergic receptor alpha-1A (ADRA1A) DM0UADK MA Inhibitor DM0UADK RN Exploring the neuroleptic substituent in octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for (1)-adre... J Med Chem. 2010 Oct 14;53(19):7021-34. DM0UADK RU https://pubmed.ncbi.nlm.nih.gov/20857909 DM0UADK DI DM0UADK DM0UADK DN OCTOCLOTHEPIN DM0UADK TI TTJS8PY DM0UADK TN 5-HT 6 receptor (HTR6) DM0UADK MA Inhibitor DM0UADK RN Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95. DM0UADK RU https://pubmed.ncbi.nlm.nih.gov/15771424 DM0UBI9 DI DM0UBI9 DM0UBI9 DN N,N-diethyl-2-(1H-indol-3-yl)ethanamine DM0UBI9 TI TTJS8PY DM0UBI9 TN 5-HT 6 receptor (HTR6) DM0UBI9 MA Inhibitor DM0UBI9 RN Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5832-5. DM0UBI9 RU https://pubmed.ncbi.nlm.nih.gov/16945532 DM0UE28 DI DM0UE28 DM0UE28 DN SL-3111 DM0UE28 TI TTKWM86 DM0UE28 TN Opioid receptor mu (MOP) DM0UE28 MA Inhibitor DM0UE28 RN Exploring the structure-activity relationships of [1-(4-tert-butyl-3'-hydroxy)benzhydryl-4-benzylpiperazine] (SL-3111), a high-affinity and selecti... J Med Chem. 1999 Dec 30;42(26):5359-68. DM0UE28 RU https://pubmed.ncbi.nlm.nih.gov/10639279 DM0ULZM DI DM0ULZM DM0ULZM DN C[RGDf-(3S)-Carboxymorpholine] DM0ULZM TI TTT1R2L DM0ULZM TN Integrin alpha-V (ITGAV) DM0ULZM MA Inhibitor DM0ULZM RN Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity. Bioorg Med Chem. 2009 Feb 15;17(4):1542-9. DM0ULZM RU https://pubmed.ncbi.nlm.nih.gov/19195898 DM0UMSF DI DM0UMSF DM0UMSF DN PMID30247903-Compound-General structure41 DM0UMSF TI TT23XQV DM0UMSF TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM0UMSF MA Inhibitor DM0UMSF RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM0UMSF RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM0UNM1 DI DM0UNM1 DM0UNM1 DN 2-methyl-6-(4-phenylpent-1-ynyl)pyridine DM0UNM1 TI TTHS256 DM0UNM1 TN Metabotropic glutamate receptor 5 (mGluR5) DM0UNM1 MA Inhibitor DM0UNM1 RN Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91. DM0UNM1 RU https://pubmed.ncbi.nlm.nih.gov/16837196 DM0UOF1 DI DM0UOF1 DM0UOF1 DN M3IBu6S DM0UOF1 TI TTQW87Y DM0UOF1 TN Opioid receptor kappa (OPRK1) DM0UOF1 MA Inhibitor DM0UOF1 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM0UOF1 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM0UOF1 DI DM0UOF1 DM0UOF1 DN M3IBu6S DM0UOF1 TI TTKWM86 DM0UOF1 TN Opioid receptor mu (MOP) DM0UOF1 MA Inhibitor DM0UOF1 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM0UOF1 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM0UOL3 DI DM0UOL3 DM0UOL3 DN ISIS 109111 DM0UOL3 TI TTQSMFG DM0UOL3 TN Talin messenger RNA (TLN1 mRNA) DM0UOL3 RN US patent application no. 6,372,492, Antisense modulation of talin expression. DM0UOL3 RU http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true DM0URFY DI DM0URFY DM0URFY DN 2,4-diisobutylamino-6-isopentylpyrimidine DM0URFY TI TTZAYWL DM0URFY TN Estrogen receptor (ESR) DM0URFY MA Inhibitor DM0URFY RN Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30. DM0URFY RU https://pubmed.ncbi.nlm.nih.gov/18785725 DM0URSE DI DM0URSE DM0URSE DN 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine DM0URSE TI TTVBI8W DM0URSE TN Dopamine transporter (DAT) DM0URSE MA Inhibitor DM0URSE RN Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12. DM0URSE RU https://pubmed.ncbi.nlm.nih.gov/3735309 DM0URSE DI DM0URSE DM0URSE DN 1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine DM0URSE TI TTAWNKZ DM0URSE TN Norepinephrine transporter (NET) DM0URSE MA Inhibitor DM0URSE RN Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12. DM0URSE RU https://pubmed.ncbi.nlm.nih.gov/3735309 DM0UXNF DI DM0UXNF DM0UXNF DN VE-821 DM0UXNF TI TT8ZYBQ DM0UXNF TN Serine/threonine-protein kinase ATR (FRP1) DM0UXNF MA Inhibitor DM0UXNF RN ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79. DM0UXNF RU https://pubmed.ncbi.nlm.nih.gov/25269479 DM0UZHL DI DM0UZHL DM0UZHL DN 1-(2-(benzyloxy)phenyl)piperazine DM0UZHL TI TTAWNKZ DM0UZHL TN Norepinephrine transporter (NET) DM0UZHL MA Inhibitor DM0UZHL RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0UZHL RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0UZHL DI DM0UZHL DM0UZHL DN 1-(2-(benzyloxy)phenyl)piperazine DM0UZHL TI TT3ROYC DM0UZHL TN Serotonin transporter (SERT) DM0UZHL MA Inhibitor DM0UZHL RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0UZHL RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0UZHL DI DM0UZHL DM0UZHL DN 1-(2-(benzyloxy)phenyl)piperazine DM0UZHL TI TTSQIFT DM0UZHL TN 5-HT 1A receptor (HTR1A) DM0UZHL MA Inhibitor DM0UZHL RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM0UZHL RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM0V1NH DI DM0V1NH DM0V1NH DN DEHYDROLEUCODIN DM0V1NH TI TTSZLWK DM0V1NH TN Aromatase (CYP19A1) DM0V1NH MA Inhibitor DM0V1NH RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM0V1NH RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM0V8MA DI DM0V8MA DM0V8MA DN 4-[4-(benzyloxy)piperidino]butyl-4-chlorobenzoate DM0V8MA TI TTEB0GD DM0V8MA TN Cholinesterase (BCHE) DM0V8MA MA Inhibitor DM0V8MA RN Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. DM0V8MA RU https://pubmed.ncbi.nlm.nih.gov/17681794 DM0V9HB DI DM0V9HB DM0V9HB DN (4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine DM0V9HB TI TTZUFI5 DM0V9HB TN Nitric-oxide synthase brain (NOS1) DM0V9HB MA Inhibitor DM0V9HB RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM0V9HB RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM0V9HB DI DM0V9HB DM0V9HB DN (4S,5R)-4,5-Dimethyl-oxazolidin-(2Z)-ylideneamine DM0V9HB TI TTF10I9 DM0V9HB TN Nitric-oxide synthase inducible (NOS2) DM0V9HB MA Inhibitor DM0V9HB RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM0V9HB RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM0VAUR DI DM0VAUR DM0VAUR DN ISIS 191761 DM0VAUR TI TT0GV3R DM0VAUR TN DGAT1 messenger RNA (DGAT1 mRNA) DM0VAUR RN US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression. DM0VAUR RU http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true DM0VBUL DI DM0VBUL DM0VBUL DN Aprophen DM0VBUL TI TTH18TF DM0VBUL TN Muscarinic acetylcholine receptor M5 (CHRM5) DM0VBUL MA Antagonist DM0VBUL RN The muscarinic antagonists aprophen and benactyzine are noncompetitive inhibitors of the nicotinic acetylcholine receptor. Mol Pharmacol. 1987 Nov;32(5):678-85. DM0VBUL RU https://pubmed.ncbi.nlm.nih.gov/3683366 DM0VC84 DI DM0VC84 DM0VC84 DN Her2- and PSA-targeted TGX-D1 DM0VC84 TI TTHBTOP DM0VC84 TN PI3-kinase gamma (PIK3CG) DM0VC84 MA Inhibitor DM0VC84 RN Development of a peptide-drug conjugate for prostate cancer therapy. Mol Pharm. 2011 Jun 6;8(3):901-12. DM0VC84 RU https://pubmed.ncbi.nlm.nih.gov/21510670 DM0VCWA DI DM0VCWA DM0VCWA DN Dmt-Pro-Phe-D-1-Nal-NH2 DM0VCWA TI TTKWM86 DM0VCWA TN Opioid receptor mu (MOP) DM0VCWA MA Inhibitor DM0VCWA RN Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20. DM0VCWA RU https://pubmed.ncbi.nlm.nih.gov/17266203 DM0VCWA DI DM0VCWA DM0VCWA DN Dmt-Pro-Phe-D-1-Nal-NH2 DM0VCWA TI TT27RFC DM0VCWA TN Opioid receptor delta (OPRD1) DM0VCWA MA Inhibitor DM0VCWA RN Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20. DM0VCWA RU https://pubmed.ncbi.nlm.nih.gov/17266203 DM0VGCX DI DM0VGCX DM0VGCX DN 5-butyl-methyl immidazole carboxylate 30 DM0VGCX TI TT8DBY3 DM0VGCX TN Angiotensin II receptor type-1 (AGTR1) DM0VGCX MA Antagonist DM0VGCX RN The discovery of new potent non-peptide Angiotensin II AT1 receptor blockers: a concise synthesis, molecular docking studies and biological evaluation of N-substituted 5-butylimidazole derivatives. Eur J Med Chem. 2012 Sep;55:358-74. DM0VGCX RU https://pubmed.ncbi.nlm.nih.gov/22889560 DM0VIH4 DI DM0VIH4 DM0VIH4 DN Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) DM0VIH4 TI TT5ZKDI DM0VIH4 TN Histone deacetylase 6 (HDAC6) DM0VIH4 MA Inhibitor DM0VIH4 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DM0VIH4 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DM0VIH4 DI DM0VIH4 DM0VIH4 DN Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) DM0VIH4 TI TT6R7JZ DM0VIH4 TN Histone deacetylase 1 (HDAC1) DM0VIH4 MA Inhibitor DM0VIH4 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DM0VIH4 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DM0VIH4 DI DM0VIH4 DM0VIH4 DN Cyclo(-L-Am7(S2Py)-L-A1in-L-Ala-D-Pro-) DM0VIH4 TI TTTQGH8 DM0VIH4 TN Histone deacetylase 4 (HDAC4) DM0VIH4 MA Inhibitor DM0VIH4 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DM0VIH4 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DM0VKA2 DI DM0VKA2 DM0VKA2 DN Bip-tyr-ala-pro-lys-thr(obzl)-gly DM0VKA2 TI TTVBI8W DM0VKA2 TN Dopamine transporter (DAT) DM0VKA2 MA Inhibitor DM0VKA2 RN Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. DM0VKA2 RU https://pubmed.ncbi.nlm.nih.gov/16821765 DM0VKFO DI DM0VKFO DM0VKFO DN C-(5-bromo-4,7-dimethoxyindan-1-yl)methylamine DM0VKFO TI TTJQOD7 DM0VKFO TN 5-HT 2A receptor (HTR2A) DM0VKFO MA Inhibitor DM0VKFO RN 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agoni... J Med Chem. 2006 Sep 21;49(19):5794-803. DM0VKFO RU https://pubmed.ncbi.nlm.nih.gov/16970404 DM0VL17 DI DM0VL17 DM0VL17 DN 3-(3,4-dihydronaphthalen-2-yl)pyridine DM0VL17 TI TTIQUX7 DM0VL17 TN Steroid 11-beta-hydroxylase (CYP11B1) DM0VL17 MA Inhibitor DM0VL17 RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DM0VL17 RU https://pubmed.ncbi.nlm.nih.gov/16570918 DM0VL17 DI DM0VL17 DM0VL17 DN 3-(3,4-dihydronaphthalen-2-yl)pyridine DM0VL17 TI TTSZLWK DM0VL17 TN Aromatase (CYP19A1) DM0VL17 MA Inhibitor DM0VL17 RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DM0VL17 RU https://pubmed.ncbi.nlm.nih.gov/16570918 DM0VMZ4 DI DM0VMZ4 DM0VMZ4 DN BMN-168 DM0VMZ4 TI TTGSVH2 DM0VMZ4 TN Phenylalanine hydroxylase (PAH) DM0VMZ4 MA Modulator DM0VMZ4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240). DM0VMZ4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240 DM0VOXN DI DM0VOXN DM0VOXN DN PMID21982499C14k DM0VOXN TI TTGJCWZ DM0VOXN TN Fms-like tyrosine kinase 3 (FLT-3) DM0VOXN MA Inhibitor DM0VOXN RN 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92. DM0VOXN RU https://pubmed.ncbi.nlm.nih.gov/21982499 DM0VOXN DI DM0VOXN DM0VOXN DN PMID21982499C14k DM0VOXN TI TT69J2Z DM0VOXN TN Serine/threonine-protein kinase pim-2 (PIM2) DM0VOXN MA Inhibitor DM0VOXN RN 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92. DM0VOXN RU https://pubmed.ncbi.nlm.nih.gov/21982499 DM0VOXN DI DM0VOXN DM0VOXN DN PMID21982499C14k DM0VOXN TI TT34L5N DM0VOXN TN Casein kinase I gamma-3 (CSNK1G3) DM0VOXN MA Inhibitor DM0VOXN RN 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92. DM0VOXN RU https://pubmed.ncbi.nlm.nih.gov/21982499 DM0VOXN DI DM0VOXN DM0VOXN DN PMID21982499C14k DM0VOXN TI TTTN5QW DM0VOXN TN Serine/threonine-protein kinase pim-1 (PIM1) DM0VOXN MA Inhibitor DM0VOXN RN 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92. DM0VOXN RU https://pubmed.ncbi.nlm.nih.gov/21982499 DM0VOXN DI DM0VOXN DM0VOXN DN PMID21982499C14k DM0VOXN TI TTCGOIN DM0VOXN TN PIM-3 protein kinase (PIM3) DM0VOXN MA Inhibitor DM0VOXN RN 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011 Nov 15;21(22):6687-92. DM0VOXN RU https://pubmed.ncbi.nlm.nih.gov/21982499 DM0VP79 DI DM0VP79 DM0VP79 DN C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 DM0VP79 TI TTNI91K DM0VP79 TN Melanocortin receptor 3 (MC3R) DM0VP79 MA Inhibitor DM0VP79 RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DM0VP79 RU https://pubmed.ncbi.nlm.nih.gov/18088090 DM0VP79 DI DM0VP79 DM0VP79 DN C[CO-(CH2)3-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 DM0VP79 TI TTEOSZT DM0VP79 TN Melanocortin receptor (MCR) DM0VP79 MA Inhibitor DM0VP79 RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DM0VP79 RU https://pubmed.ncbi.nlm.nih.gov/18088090 DM0VSPE DI DM0VSPE DM0VSPE DN KNI-10743 DM0VSPE TI TTXMNHO DM0VSPE TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM0VSPE MA Inhibitor DM0VSPE RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DM0VSPE RU https://pubmed.ncbi.nlm.nih.gov/20634066 DM0W2IS DI DM0W2IS DM0W2IS DN RS-25344 DM0W2IS TI TTVIAT9 DM0W2IS TN Phosphodiesterase 4B (PDE4B) DM0W2IS MA Inhibitor DM0W2IS RN Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40. DM0W2IS RU https://pubmed.ncbi.nlm.nih.gov/9720765 DM0W2IS DI DM0W2IS DM0W2IS DN RS-25344 DM0W2IS TI TTSKMI8 DM0W2IS TN Phosphodiesterase 4D (PDE4D) DM0W2IS MA Inhibitor DM0W2IS RN Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40. DM0W2IS RU https://pubmed.ncbi.nlm.nih.gov/9720765 DM0W2IS DI DM0W2IS DM0W2IS DN RS-25344 DM0W2IS TI TTZ97H5 DM0W2IS TN Phosphodiesterase 4A (PDE4A) DM0W2IS MA Inhibitor DM0W2IS RN Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40. DM0W2IS RU https://pubmed.ncbi.nlm.nih.gov/9720765 DM0W2IS DI DM0W2IS DM0W2IS DN RS-25344 DM0W2IS TI TT6A59G DM0W2IS TN Phosphodiesterase 4C (PDE4C) DM0W2IS MA Inhibitor DM0W2IS RN Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cell Signal. 1998 Jun;10(6):427-40. DM0W2IS RU https://pubmed.ncbi.nlm.nih.gov/9720765 DM0W2QB DI DM0W2QB DM0W2QB DN 2-Cyclopropylmethylenepropanal DM0W2QB TI TTB2MXP DM0W2QB TN Angiotensinogenase renin (REN) DM0W2QB MA Inhibitor DM0W2QB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM0W2QB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM0W47U DI DM0W47U DM0W47U DN ISIS 3303 DM0W47U TI TTSC4OM DM0W47U TN Influenza PB2 messenger RNA (Influ PB2 mRNA) DM0W47U RN US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides. DM0W47U RU http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true DM0W54R DI DM0W54R DM0W54R DN SNG-8033 DM0W54R TI TTZAYWL DM0W54R TN Estrogen receptor (ESR) DM0W54R MA Inhibitor DM0W54R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DM0W54R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DM0W64U DI DM0W64U DM0W64U DN Dihydropyridines DM0W64U TI TTXHYV6 DM0W64U TN Voltage-gated L-type calcium channel (L-CaC) DM0W64U MA Blocker DM0W64U RN Pharmacology of N-type Ca2+ channels distributed in cardiovascular system (Review). Int J Mol Med. 1999 May;3(5):455-66. DM0W64U RU https://pubmed.ncbi.nlm.nih.gov/10202175 DM0W6C9 DI DM0W6C9 DM0W6C9 DN PMID20809633C29b DM0W6C9 TI TTHS256 DM0W6C9 TN Metabotropic glutamate receptor 5 (mGluR5) DM0W6C9 MA Modulator (allosteric modulator) DM0W6C9 RN Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5. J Med Chem. 2010 Oct 14;53(19):7107-18. DM0W6C9 RU https://pubmed.ncbi.nlm.nih.gov/20809633 DM0WH1L DI DM0WH1L DM0WH1L DN ISIS 298697 DM0WH1L TI TTSN6QU DM0WH1L TN HIF1-alpha messenger RNA (HIF1A mRNA) DM0WH1L RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DM0WH1L RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DM0WKNI DI DM0WKNI DM0WKNI DN Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate DM0WKNI TI TT27RFC DM0WKNI TN Opioid receptor delta (OPRD1) DM0WKNI MA Inhibitor DM0WKNI RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DM0WKNI RU https://pubmed.ncbi.nlm.nih.gov/16392810 DM0WKNI DI DM0WKNI DM0WKNI DN Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate DM0WKNI TI TTQW87Y DM0WKNI TN Opioid receptor kappa (OPRK1) DM0WKNI MA Inhibitor DM0WKNI RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DM0WKNI RU https://pubmed.ncbi.nlm.nih.gov/16392810 DM0WKNI DI DM0WKNI DM0WKNI DN Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate DM0WKNI TI TTKWM86 DM0WKNI TN Opioid receptor mu (MOP) DM0WKNI MA Inhibitor DM0WKNI RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DM0WKNI RU https://pubmed.ncbi.nlm.nih.gov/16392810 DM0WMBC DI DM0WMBC DM0WMBC DN 2-Phenethyl-1,2-dihydro-indazol-3-one DM0WMBC TI TTVKILB DM0WMBC TN Prostaglandin G/H synthase 2 (COX-2) DM0WMBC MA Inhibitor DM0WMBC RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM0WMBC RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM0WMBC DI DM0WMBC DM0WMBC DN 2-Phenethyl-1,2-dihydro-indazol-3-one DM0WMBC TI TT2J34L DM0WMBC TN Arachidonate 5-lipoxygenase (5-LOX) DM0WMBC MA Inhibitor DM0WMBC RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM0WMBC RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM0WMBC DI DM0WMBC DM0WMBC DN 2-Phenethyl-1,2-dihydro-indazol-3-one DM0WMBC TI TT8NGED DM0WMBC TN Prostaglandin G/H synthase 1 (COX-1) DM0WMBC MA Inhibitor DM0WMBC RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM0WMBC RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM0WMKJ DI DM0WMKJ DM0WMKJ DN N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine DM0WMKJ TI TTM2AOE DM0WMKJ TN Adenosine A2a receptor (ADORA2A) DM0WMKJ MA Inhibitor DM0WMKJ RN N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47. DM0WMKJ RU https://pubmed.ncbi.nlm.nih.gov/18045744 DM0WMKJ DI DM0WMKJ DM0WMKJ DN N6-[(4-Amino)-phenyl]-9-benzyl-2-phenyladenine DM0WMKJ TI TTK25J1 DM0WMKJ TN Adenosine A1 receptor (ADORA1) DM0WMKJ MA Inhibitor DM0WMKJ RN N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47. DM0WMKJ RU https://pubmed.ncbi.nlm.nih.gov/18045744 DM0WNHQ DI DM0WNHQ DM0WNHQ DN SKF89976A DM0WNHQ TI TTPRKM0 DM0WNHQ TN GABA transporter GAT-1 (SLC6A1) DM0WNHQ MA Inhibitor DM0WNHQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929). DM0WNHQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929 DM0WOS6 DI DM0WOS6 DM0WOS6 DN BELFOSDIL DM0WOS6 TI TT5HONZ DM0WOS6 TN Calcium channel unspecific (CaC) DM0WOS6 MA Modulator DM0WOS6 RN Determination of belfosdil, a new calcium channel blocker, in human plasma by capillary gas chromatography with nitrogen-phosphorus detection. J Chromatogr. 1990 May 18;527(2):343-50. DM0WOS6 RU https://www.ncbi.nlm.nih.gov/pubmed/2387881 DM0WVTF DI DM0WVTF DM0WVTF DN 3-Methyl-4-phenylbut-3-en-2-one oxime DM0WVTF TI TTELV3W DM0WVTF TN Transformation-sensitive protein p120 (TRPA1) DM0WVTF MA Inhibitor DM0WVTF RN Oxime derivatives related to AP18: Agonists and antagonists of the TRPA1 receptor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):276-9. DM0WVTF RU https://pubmed.ncbi.nlm.nih.gov/19945872 DM0X5SY DI DM0X5SY DM0X5SY DN 4-(7-chloro-1-cyclopentyl-1H-indazol-3-yl)phenol DM0X5SY TI TTZAYWL DM0X5SY TN Estrogen receptor (ESR) DM0X5SY MA Inhibitor DM0X5SY RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DM0X5SY RU https://pubmed.ncbi.nlm.nih.gov/15588074 DM0X824 DI DM0X824 DM0X824 DN [125I]cetrorelix DM0X824 TI TT8R70G DM0X824 TN Gonadotropin-releasing hormone receptor (GNRHR) DM0X824 MA Antagonist DM0X824 RN Residues within transmembrane helices 2 and 5 of the human gonadotropin-releasing hormone receptor contribute to agonist and antagonist binding. Mol Endocrinol. 2000 Jul;14(7):1099-115. DM0X824 RU https://pubmed.ncbi.nlm.nih.gov/10894158 DM0XD6T DI DM0XD6T DM0XD6T DN 3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine DM0XD6T TI TTSZLWK DM0XD6T TN Aromatase (CYP19A1) DM0XD6T MA Inhibitor DM0XD6T RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM0XD6T RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM0XD6T DI DM0XD6T DM0XD6T DN 3-[4-Chloro-indan-(1E)-ylidenemethyl]-pyridine DM0XD6T TI TTIQUX7 DM0XD6T TN Steroid 11-beta-hydroxylase (CYP11B1) DM0XD6T MA Inhibitor DM0XD6T RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM0XD6T RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM0XDFG DI DM0XDFG DM0XDFG DN S-(4-Bromobenzyl)isothiourea hydrobromide DM0XDFG TI TTZJYKH DM0XDFG TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM0XDFG MA Inhibitor DM0XDFG RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DM0XDFG RU https://pubmed.ncbi.nlm.nih.gov/20688518 DM0XDG6 DI DM0XDG6 DM0XDG6 DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide DM0XDG6 TI TTVG215 DM0XDG6 TN Debrisoquine 4-hydroxylase (CYP2D6) DM0XDG6 MA Inhibitor DM0XDG6 RN Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702. DM0XDG6 RU https://pubmed.ncbi.nlm.nih.gov/19694468 DM0XDG6 DI DM0XDG6 DM0XDG6 DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide DM0XDG6 TI TTQ6VDM DM0XDG6 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM0XDG6 MA Inhibitor DM0XDG6 RN Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702. DM0XDG6 RU https://pubmed.ncbi.nlm.nih.gov/19694468 DM0XDG6 DI DM0XDG6 DM0XDG6 DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide DM0XDG6 TI TTKWM86 DM0XDG6 TN Opioid receptor mu (MOP) DM0XDG6 MA Inhibitor DM0XDG6 RN Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702. DM0XDG6 RU https://pubmed.ncbi.nlm.nih.gov/19694468 DM0XDG6 DI DM0XDG6 DM0XDG6 DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide DM0XDG6 TI TT27RFC DM0XDG6 TN Opioid receptor delta (OPRD1) DM0XDG6 MA Inhibitor DM0XDG6 RN Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702. DM0XDG6 RU https://pubmed.ncbi.nlm.nih.gov/19694468 DM0XDG6 DI DM0XDG6 DM0XDG6 DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide DM0XDG6 TI TTQW87Y DM0XDG6 TN Opioid receptor kappa (OPRK1) DM0XDG6 MA Inhibitor DM0XDG6 RN Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702. DM0XDG6 RU https://pubmed.ncbi.nlm.nih.gov/19694468 DM0XNMP DI DM0XNMP DM0XNMP DN 1-(1-(3-nitrophenyl)propylidene)thiosemicarbazide DM0XNMP TI TTEAID7 DM0XNMP TN Trypanosoma Cruzipain (Trypano CYSP) DM0XNMP MA Inhibitor DM0XNMP RN Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4405-9. DM0XNMP RU https://pubmed.ncbi.nlm.nih.gov/16781147 DM0XQZO DI DM0XQZO DM0XQZO DN PMID22795084C1 DM0XQZO TI TTL4XSQ DM0XQZO TN Protein arginine methyltransferase 3 (PRMT3) DM0XQZO MA Inhibitor DM0XQZO RN An allosteric inhibitor of protein arginine methyltransferase 3. Structure. 2012 Aug 8;20(8):1425-35. DM0XQZO RU https://pubmed.ncbi.nlm.nih.gov/22795084 DM0XT69 DI DM0XT69 DM0XT69 DN orexin-B DM0XT69 TI TT60Q8D DM0XT69 TN Orexin receptor type 1 (HCRTR1) DM0XT69 MA Agonist DM0XT69 RN Agonist ligand discrimination by the two orexin receptors depends on the expression system. Neurosci Lett. 2011 Apr 20;494(1):57-60. DM0XT69 RU https://pubmed.ncbi.nlm.nih.gov/21362456 DM0XT69 DI DM0XT69 DM0XT69 DN orexin-B DM0XT69 TI TT9N02I DM0XT69 TN Orexin receptor type 2 (HCRTR2) DM0XT69 MA Agonist DM0XT69 RN The signalling profile of recombinant human orexin-2 receptor. Cell Signal. 2008 Sep;20(9):1651-61. DM0XT69 RU https://pubmed.ncbi.nlm.nih.gov/18599270 DM0XU3C DI DM0XU3C DM0XU3C DN PMID7966163C6d DM0XU3C TI TTFQEO5 DM0XU3C TN Squalene synthetase (FDFT1) DM0XU3C MA Inhibitor DM0XU3C RN Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51. DM0XU3C RU https://pubmed.ncbi.nlm.nih.gov/7966163 DM0XUPK DI DM0XUPK DM0XUPK DN [125I]SB-236636 DM0XUPK TI TTT2SVW DM0XUPK TN PPAR-gamma messenger RNA (PPARG mRNA) DM0XUPK MA Agonist DM0XUPK RN Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998 Feb;284(2):751-9. DM0XUPK RU https://pubmed.ncbi.nlm.nih.gov/9454824 DM0Y2P1 DI DM0Y2P1 DM0Y2P1 DN 2-(1H-benzo[d]imidazol-2-yl)quinoxaline DM0Y2P1 TI TTM2AOE DM0Y2P1 TN Adenosine A2a receptor (ADORA2A) DM0Y2P1 MA Inhibitor DM0Y2P1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DM0Y2P1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DM0Y2P1 DI DM0Y2P1 DM0Y2P1 DN 2-(1H-benzo[d]imidazol-2-yl)quinoxaline DM0Y2P1 TI TTK25J1 DM0Y2P1 TN Adenosine A1 receptor (ADORA1) DM0Y2P1 MA Inhibitor DM0Y2P1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DM0Y2P1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DM0Y2P1 DI DM0Y2P1 DM0Y2P1 DN 2-(1H-benzo[d]imidazol-2-yl)quinoxaline DM0Y2P1 TI TTJFY5U DM0Y2P1 TN Adenosine A3 receptor (ADORA3) DM0Y2P1 MA Inhibitor DM0Y2P1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DM0Y2P1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DM0Y2SC DI DM0Y2SC DM0Y2SC DN [3H]strychnine DM0Y2SC TI TTZ8EM9 DM0Y2SC TN Glycine receptor (GlyR) DM0Y2SC MA Antagonist DM0Y2SC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 425). DM0Y2SC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=425 DM0Y2SC DI DM0Y2SC DM0Y2SC DN [3H]strychnine DM0Y2SC TI TTF45NW DM0Y2SC TN Strychnine-binding glycine receptor (GLRA1) DM0Y2SC MA Inhibitor DM0Y2SC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM0Y2SC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM0Y52J DI DM0Y52J DM0Y52J DN 8-Methoxy-1,4-dimethylquinolin-2(1H)-one DM0Y52J TI TTJLP0R DM0Y52J TN Quinone reductase 2 (NQO2) DM0Y52J MA Inhibitor DM0Y52J RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DM0Y52J RU https://pubmed.ncbi.nlm.nih.gov/19265439 DM0Y8OW DI DM0Y8OW DM0Y8OW DN N,N-dimethylarginine DM0Y8OW TI TTF10I9 DM0Y8OW TN Nitric-oxide synthase inducible (NOS2) DM0Y8OW MA Inhibitor DM0Y8OW RN Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med. 2007;45(12):1683-7. DM0Y8OW RU https://pubmed.ncbi.nlm.nih.gov/17937610 DM0Y8OW DI DM0Y8OW DM0Y8OW DN N,N-dimethylarginine DM0Y8OW TI TTCM4B3 DM0Y8OW TN Nitric-oxide synthase endothelial (NOS3) DM0Y8OW MA Inhibitor DM0Y8OW RN Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med. 2007;45(12):1683-7. DM0Y8OW RU https://pubmed.ncbi.nlm.nih.gov/17937610 DM0YEGM DI DM0YEGM DM0YEGM DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzamide DM0YEGM TI TT3ROYC DM0YEGM TN Serotonin transporter (SERT) DM0YEGM MA Inhibitor DM0YEGM RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM0YEGM RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM0YELX DI DM0YELX DM0YELX DN (R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine DM0YELX TI TTJQOD7 DM0YELX TN 5-HT 2A receptor (HTR2A) DM0YELX MA Inhibitor DM0YELX RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DM0YELX RU https://pubmed.ncbi.nlm.nih.gov/20570529 DM0YELX DI DM0YELX DM0YELX DN (R,S)-1-(6-fluoro-1H-indol-1-yl)propan-2-amine DM0YELX TI TTWJBZ5 DM0YELX TN 5-HT 2C receptor (HTR2C) DM0YELX MA Inhibitor DM0YELX RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DM0YELX RU https://pubmed.ncbi.nlm.nih.gov/20570529 DM0YJHS DI DM0YJHS DM0YJHS DN [3H]LSD DM0YJHS TI TTO9X1H DM0YJHS TN 5-HT 7 receptor (HTR7) DM0YJHS MA Agonist DM0YJHS RN Human serotonin 5-HT7 receptor: cloning and pharmacological characterisation of two receptor variants. FEBS Lett. 1997 Aug 25;413(3):489-94. DM0YJHS RU https://pubmed.ncbi.nlm.nih.gov/9303561 DM0YJHS DI DM0YJHS DM0YJHS DN [3H]LSD DM0YJHS TI TT0K1SC DM0YJHS TN 5-HT 2B receptor (HTR2B) DM0YJHS MA Agonist DM0YJHS RN Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling. Life Sci. 2003 May 30;73(2):193-207. DM0YJHS RU https://pubmed.ncbi.nlm.nih.gov/12738034 DM0YJHS DI DM0YJHS DM0YJHS DN [3H]LSD DM0YJHS TI TTJS8PY DM0YJHS TN 5-HT 6 receptor (HTR6) DM0YJHS MA Agonist DM0YJHS RN Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27. DM0YJHS RU https://pubmed.ncbi.nlm.nih.gov/10327430 DM0YJHS DI DM0YJHS DM0YJHS DN [3H]LSD DM0YJHS TI TTWJBZ5 DM0YJHS TN 5-HT 2C receptor (HTR2C) DM0YJHS MA Agonist DM0YJHS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8). DM0YJHS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8 DM0YLPV DI DM0YLPV DM0YLPV DN C[YYAEGLEE]-NH2 DM0YLPV TI TT1VAUK DM0YLPV TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM0YLPV MA Inhibitor DM0YLPV RN Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem. 2010 Jun 10;53(11):4428-40. DM0YLPV RU https://pubmed.ncbi.nlm.nih.gov/20462213 DM0YOZJ DI DM0YOZJ DM0YOZJ DN 3-(6-Amino-purin-9-yl)-non-5-yn-2-ol DM0YOZJ TI TTLP57V DM0YOZJ TN Adenosine deaminase (ADA) DM0YOZJ MA Inhibitor DM0YOZJ RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DM0YOZJ RU https://pubmed.ncbi.nlm.nih.gov/11101360 DM0YQHM DI DM0YQHM DM0YQHM DN D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2 DM0YQHM TI TT2BC4G DM0YQHM TN Somatostatin receptor type 5 (SSTR5) DM0YQHM MA Inhibitor DM0YQHM RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DM0YQHM RU https://pubmed.ncbi.nlm.nih.gov/16220980 DM0YQHM DI DM0YQHM DM0YQHM DN D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Asp-NH2 DM0YQHM TI TTZ6T9E DM0YQHM TN Somatostatin receptor type 2 (SSTR2) DM0YQHM MA Inhibitor DM0YQHM RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DM0YQHM RU https://pubmed.ncbi.nlm.nih.gov/16220980 DM0YROF DI DM0YROF DM0YROF DN Ethylmorphine DM0YROF TI TTKWM86 DM0YROF TN Opioid receptor mu (MOP) DM0YROF MA Agonist DM0YROF RN Biotransformation and pharmacokinetics of ethylmorphine after a single oral dose. Br J Clin Pharmacol. 1995 Jun;39(6):611-20. DM0YROF RU https://pubmed.ncbi.nlm.nih.gov/7654478 DM0YS25 DI DM0YS25 DM0YS25 DN 3-Morpholin-4-ylmethyl-5H-phenanthridin-6-one DM0YS25 TI TTVDSZ0 DM0YS25 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM0YS25 MA Inhibitor DM0YS25 RN 4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5. DM0YS25 RU https://pubmed.ncbi.nlm.nih.gov/16098744 DM0YS36 DI DM0YS36 DM0YS36 DN 4-Methyl-pyrrolidin-(2Z)-ylideneamine DM0YS36 TI TTZUFI5 DM0YS36 TN Nitric-oxide synthase brain (NOS1) DM0YS36 MA Inhibitor DM0YS36 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM0YS36 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM0YS36 DI DM0YS36 DM0YS36 DN 4-Methyl-pyrrolidin-(2Z)-ylideneamine DM0YS36 TI TTF10I9 DM0YS36 TN Nitric-oxide synthase inducible (NOS2) DM0YS36 MA Inhibitor DM0YS36 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM0YS36 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM0YS36 DI DM0YS36 DM0YS36 DN 4-Methyl-pyrrolidin-(2Z)-ylideneamine DM0YS36 TI TTCM4B3 DM0YS36 TN Nitric-oxide synthase endothelial (NOS3) DM0YS36 MA Inhibitor DM0YS36 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM0YS36 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM0Z1HJ DI DM0Z1HJ DM0Z1HJ DN N-(3-Bromophenyl)-5-methoxybenzo[d]oxazol-2-amine DM0Z1HJ TI TT2J34L DM0Z1HJ TN Arachidonate 5-lipoxygenase (5-LOX) DM0Z1HJ MA Inhibitor DM0Z1HJ RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DM0Z1HJ RU https://pubmed.ncbi.nlm.nih.gov/20870413 DM0ZA7T DI DM0ZA7T DM0ZA7T DN 4-Methyl-5-piperidin-4-yl-isoxazol-3-ol DM0ZA7T TI TTNJYV2 DM0ZA7T TN Gamma-aminobutyric acid receptor (GAR) DM0ZA7T MA Inhibitor DM0ZA7T RN A novel class of potent 3-isoxazolol GABA(A) antagonists: design, synthesis, and pharmacology. J Med Chem. 2000 Dec 28;43(26):4930-3. DM0ZA7T RU https://pubmed.ncbi.nlm.nih.gov/11150163 DM0ZB89 DI DM0ZB89 DM0ZB89 DN 2-(5-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline DM0ZB89 TI TTJFY5U DM0ZB89 TN Adenosine A3 receptor (ADORA3) DM0ZB89 MA Inhibitor DM0ZB89 RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DM0ZB89 RU https://pubmed.ncbi.nlm.nih.gov/16366607 DM0ZHJQ DI DM0ZHJQ DM0ZHJQ DN 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline DM0ZHJQ TI TT8FYO9 DM0ZHJQ TN Platelet-derived growth factor receptor alpha (PDGFRA) DM0ZHJQ MA Inhibitor DM0ZHJQ RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0ZHJQ RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0ZHJQ DI DM0ZHJQ DM0ZHJQ DN 3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline DM0ZHJQ TI TTI7421 DM0ZHJQ TN Platelet-derived growth factor receptor beta (PDGFRB) DM0ZHJQ MA Inhibitor DM0ZHJQ RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM0ZHJQ RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM0ZRDV DI DM0ZRDV DM0ZRDV DN 3-(2,3-Dimethyl-phenyl)-1-propyl-piperidine DM0ZRDV TI TTEX248 DM0ZRDV TN Dopamine D2 receptor (D2R) DM0ZRDV MA Inhibitor DM0ZRDV RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DM0ZRDV RU https://pubmed.ncbi.nlm.nih.gov/9836610 DM0ZXBQ DI DM0ZXBQ DM0ZXBQ DN N-benzyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine DM0ZXBQ TI TT1RS9F DM0ZXBQ TN Acetylcholinesterase (AChE) DM0ZXBQ MA Inhibitor DM0ZXBQ RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DM0ZXBQ RU https://pubmed.ncbi.nlm.nih.gov/20472431 DM1043B DI DM1043B DM1043B DN 4-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one DM1043B TI TTSZLWK DM1043B TN Aromatase (CYP19A1) DM1043B MA Inhibitor DM1043B RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DM1043B RU https://pubmed.ncbi.nlm.nih.gov/19072235 DM105NU DI DM105NU DM105NU DN KNI-727 DM105NU TI TTXMNHO DM105NU TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM105NU MA Inhibitor DM105NU RN Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. Biochemistry. 2002 Feb 19;41(7):2273-80. DM105NU RU https://pubmed.ncbi.nlm.nih.gov/11841219 DM105YR DI DM105YR DM105YR DN Carboxylated glucosamine DM105YR TI TT6X50U DM105YR TN Matrix metalloproteinase-9 (MMP-9) DM105YR MA Inhibitor DM105YR RN Carboxy derivatized glucosamine is a potent inhibitor of matrix metalloproteinase-9 in HT1080 cells. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3105-10. DM105YR RU https://pubmed.ncbi.nlm.nih.gov/16616490 DM107RT DI DM107RT DM107RT DN H-Arg-Arg-Pro-Tyr-N-Me-Ile-Leu-OH DM107RT TI TTTUMEP DM107RT TN Neurotensin receptor type 1 (NTSR1) DM107RT MA Inhibitor DM107RT RN Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68. DM107RT RU https://pubmed.ncbi.nlm.nih.gov/18809332 DM109IL DI DM109IL DM109IL DN 5-Cl-5-deoxy-(+/-)-ENBA DM109IL TI TTK25J1 DM109IL TN Adenosine A1 receptor (ADORA1) DM109IL MA Agonist DM109IL RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DM109IL RU https://pubmed.ncbi.nlm.nih.gov/19317449 DM10A9S DI DM10A9S DM10A9S DN 6-Chloro-N-(2-morpholinoethyl)nicotinamide DM10A9S TI TT3WG5C DM10A9S TN Monoamine oxidase type A (MAO-A) DM10A9S MA Inhibitor DM10A9S RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM10A9S RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM10AUP DI DM10AUP DM10AUP DN Biphenyl-3-ylcarbamic acid cyclohexyl ester DM10AUP TI TTDP1UC DM10AUP TN Fatty acid amide hydrolase (FAAH) DM10AUP MA Inhibitor DM10AUP RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DM10AUP RU https://pubmed.ncbi.nlm.nih.gov/19583260 DM10BOC DI DM10BOC DM10BOC DN Cudratricusxanthone F DM10BOC TI TT50QJ3 DM10BOC TN Influenza Neuraminidase (Influ NA) DM10BOC MA Inhibitor DM10BOC RN Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. DM10BOC RU https://pubmed.ncbi.nlm.nih.gov/19285413 DM10D85 DI DM10D85 DM10D85 DN Edetic acid DM10D85 TI TT0VH8G DM10D85 TN Elegans Endoprotease bli-4 (Elegans bli-4) DM10D85 MA Inhibitor DM10D85 RN Removal of the glycosylphosphatidylinositol anchor from PrP(Sc) by cathepsin D does not reduce prion infectivity. Biochem J. 2006 Apr 15;395(2):443-8. DM10D85 RU https://pubmed.ncbi.nlm.nih.gov/16441239 DM10IQP DI DM10IQP DM10IQP DN PMID8709131C17 DM10IQP TI TTFQEO5 DM10IQP TN Squalene synthetase (FDFT1) DM10IQP MA Inhibitor DM10IQP RN Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9. DM10IQP RU https://pubmed.ncbi.nlm.nih.gov/8709131 DM10KIW DI DM10KIW DM10KIW DN PTHr pepducins DM10KIW TI TTEPJL5 DM10KIW TN Parathyroid hormone receptor (PTH2R) DM10KIW MA Modulator DM10KIW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332). DM10KIW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332 DM10MET DI DM10MET DM10MET DN S-(4-Fluorobenzyl)isothiourea hydrochloride DM10MET TI TTZJYKH DM10MET TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM10MET MA Inhibitor DM10MET RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DM10MET RU https://pubmed.ncbi.nlm.nih.gov/20688518 DM10U6S DI DM10U6S DM10U6S DN 4-cyclohexyl-6-propylpyrimidine-2-carbonitrile DM10U6S TI TTDZN01 DM10U6S TN Cathepsin K (CTSK) DM10U6S MA Inhibitor DM10U6S RN Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. DM10U6S RU https://pubmed.ncbi.nlm.nih.gov/20149657 DM10UHA DI DM10UHA DM10UHA DN BVB-808 DM10UHA TI TTRMX3V DM10UHA TN Janus kinase 2 (JAK-2) DM10UHA MA Inhibitor DM10UHA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). DM10UHA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048 DM10Z5W DI DM10Z5W DM10Z5W DN Il-8((3-73))K11R DM10Z5W TI TT30C9G DM10Z5W TN C-X-C chemokine receptor type 2 (CXCR2) DM10Z5W MA Agonist DM10Z5W RN Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem Biophys Res Commun. 2001 Aug 24;286(3):595-600. DM10Z5W RU https://pubmed.ncbi.nlm.nih.gov/11511101 DM10Z5W DI DM10Z5W DM10Z5W DN Il-8((3-73))K11R DM10Z5W TI TTMWT8Z DM10Z5W TN C-X-C chemokine receptor type 1 (CXCR1) DM10Z5W MA Agonist DM10Z5W RN Il-8((3-73))K11R is a high affinity agonist of the neutrophil CXCR1 and CXCR2. Biochem Biophys Res Commun. 2001 Aug 24;286(3):595-600. DM10Z5W RU https://pubmed.ncbi.nlm.nih.gov/11511101 DM123TU DI DM123TU DM123TU DN PMID22420767C42 DM123TU TI TTWNV8U DM123TU TN Nicotinic acid receptor (HCAR2) DM123TU MA Modulator (allosteric modulator) DM123TU RN Novel 3,6,7-substituted pyrazolopyrimidines as positive allosteric modulators for the hydroxycarboxylic acid receptor 2 (GPR109A). J Med Chem. 2012 Apr 12;55(7):3563-7. DM123TU RU https://pubmed.ncbi.nlm.nih.gov/22420767 DM124K5 DI DM124K5 DM124K5 DN A-317920 DM124K5 TI TT9JNIC DM124K5 TN Histamine H3 receptor (H3R) DM124K5 MA Antagonist DM124K5 RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM124K5 RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM12DVT DI DM12DVT DM12DVT DN 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline DM12DVT TI TTI7421 DM12DVT TN Platelet-derived growth factor receptor beta (PDGFRB) DM12DVT MA Inhibitor DM12DVT RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM12DVT RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM12DVT DI DM12DVT DM12DVT DN 6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline DM12DVT TI TT8FYO9 DM12DVT TN Platelet-derived growth factor receptor alpha (PDGFRA) DM12DVT MA Inhibitor DM12DVT RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM12DVT RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM12E76 DI DM12E76 DM12E76 DN ISIS 7853 DM12E76 TI TTAN5W2 DM12E76 TN Raf messenger RNA (Raf mRNA) DM12E76 RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DM12E76 RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DM12GHQ DI DM12GHQ DM12GHQ DN (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid DM12GHQ TI TTZMAO3 DM12GHQ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM12GHQ MA Inhibitor DM12GHQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM12GHQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM12NGE DI DM12NGE DM12NGE DN Thiophosphoric acid dec-9-enyl ester DM12NGE TI TTQ6S1K DM12NGE TN Lysophosphatidic acid receptor 1 (LPAR1) DM12NGE MA Inhibitor DM12NGE RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DM12NGE RU https://pubmed.ncbi.nlm.nih.gov/16033271 DM12Q9O DI DM12Q9O DM12Q9O DN (2S)-aminobutyryl-L-proline n-butylamide DM12Q9O TI TTQ7R2V DM12Q9O TN Tripeptidyl-peptidase II (TPP2) DM12Q9O MA Inhibitor DM12Q9O RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DM12Q9O RU https://pubmed.ncbi.nlm.nih.gov/16279793 DM12R4M DI DM12R4M DM12R4M DN 4-(Carbamolymethylthio)pyridine-3-sulfonamide DM12R4M TI TTSYM0R DM12R4M TN Carbonic anhydrase XII (CA-XII) DM12R4M MA Inhibitor DM12R4M RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM12R4M RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM12R4M DI DM12R4M DM12R4M DN 4-(Carbamolymethylthio)pyridine-3-sulfonamide DM12R4M TI TTANPDJ DM12R4M TN Carbonic anhydrase II (CA-II) DM12R4M MA Inhibitor DM12R4M RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM12R4M RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM12R4M DI DM12R4M DM12R4M DN 4-(Carbamolymethylthio)pyridine-3-sulfonamide DM12R4M TI TTEYTKG DM12R4M TN Carbonic anhydrase XIV (CA-XIV) DM12R4M MA Inhibitor DM12R4M RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM12R4M RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM12R4M DI DM12R4M DM12R4M DN 4-(Carbamolymethylthio)pyridine-3-sulfonamide DM12R4M TI TT2LVK8 DM12R4M TN Carbonic anhydrase IX (CA-IX) DM12R4M MA Inhibitor DM12R4M RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM12R4M RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM12R4M DI DM12R4M DM12R4M DN 4-(Carbamolymethylthio)pyridine-3-sulfonamide DM12R4M TI TTHQPL7 DM12R4M TN Carbonic anhydrase I (CA-I) DM12R4M MA Inhibitor DM12R4M RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM12R4M RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM12RH3 DI DM12RH3 DM12RH3 DN 3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol DM12RH3 TI TTK25J1 DM12RH3 TN Adenosine A1 receptor (ADORA1) DM12RH3 MA Inhibitor DM12RH3 RN 1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10. DM12RH3 RU https://pubmed.ncbi.nlm.nih.gov/16099648 DM12RH3 DI DM12RH3 DM12RH3 DN 3-Benzyl-7-methyl-[1,8]naphthyridine-4-thiol DM12RH3 TI TTM2AOE DM12RH3 TN Adenosine A2a receptor (ADORA2A) DM12RH3 MA Inhibitor DM12RH3 RN 1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10. DM12RH3 RU https://pubmed.ncbi.nlm.nih.gov/16099648 DM12SKU DI DM12SKU DM12SKU DN 3-Phenylquinoline-8-carboxamide DM12SKU TI TTVDSZ0 DM12SKU TN Poly [ADP-ribose] polymerase 1 (PARP1) DM12SKU MA Inhibitor DM12SKU RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DM12SKU RU https://pubmed.ncbi.nlm.nih.gov/19117416 DM12WYV DI DM12WYV DM12WYV DN 6-bromoindirubin-3-oxime DM12WYV TI TTRZQE3 DM12WYV TN Glycogen synthase kinase-3 alpha (GSK-3A) DM12WYV MA Inhibitor DM12WYV RN Stable generation of serum- and feeder-free embryonic stem cell-derived mice with full germline-competency by using a GSK3 specific inhibitor. Genesis. 2009 Jun;47(6):414-22. DM12WYV RU https://pubmed.ncbi.nlm.nih.gov/19391115 DM12WYV DI DM12WYV DM12WYV DN 6-bromoindirubin-3-oxime DM12WYV TI TT9RTBL DM12WYV TN Aurora B messenger RNA (AURKB mRNA) DM12WYV MA Inhibitor DM12WYV RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM12WYV RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM12WYV DI DM12WYV DM12WYV DN 6-bromoindirubin-3-oxime DM12WYV TI TTPS3C0 DM12WYV TN Aurora kinase A (AURKA) DM12WYV MA Inhibitor DM12WYV RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM12WYV RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM12WYV DI DM12WYV DM12WYV DN 6-bromoindirubin-3-oxime DM12WYV TI TTLYXIT DM12WYV TN Aurora kinase C (AURKC) DM12WYV MA Inhibitor DM12WYV RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM12WYV RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM12YH4 DI DM12YH4 DM12YH4 DN 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one DM12YH4 TI TTML2WA DM12YH4 TN Tubulin (TUB) DM12YH4 MA Inhibitor DM12YH4 RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DM12YH4 RU https://pubmed.ncbi.nlm.nih.gov/9301667 DM12YH4 DI DM12YH4 DM12YH4 DN 2-Naphthalen-2-yl-1H-[1,8]naphthyridin-4-one DM12YH4 TI TTYFKSZ DM12YH4 TN Tubulin beta (TUBB) DM12YH4 MA Inhibitor DM12YH4 RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DM12YH4 RU https://pubmed.ncbi.nlm.nih.gov/9301667 DM1325C DI DM1325C DM1325C DN 3-(3-Benzyl-6-methoxynaphthalen-2-yl)pyridine DM1325C TI TTIQUX7 DM1325C TN Steroid 11-beta-hydroxylase (CYP11B1) DM1325C MA Inhibitor DM1325C RN Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49. DM1325C RU https://pubmed.ncbi.nlm.nih.gov/18763754 DM134UV DI DM134UV DM134UV DN (R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile DM134UV TI TTAWNKZ DM134UV TN Norepinephrine transporter (NET) DM134UV MA Inhibitor DM134UV RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM134UV RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM134UV DI DM134UV DM134UV DN (R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile DM134UV TI TT3ROYC DM134UV TN Serotonin transporter (SERT) DM134UV MA Inhibitor DM134UV RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM134UV RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM1387P DI DM1387P DM1387P DN 1-Propyl-3-m-tolyl-piperidine hydrochloride DM1387P TI TTEX248 DM1387P TN Dopamine D2 receptor (D2R) DM1387P MA Inhibitor DM1387P RN New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8. DM1387P RU https://pubmed.ncbi.nlm.nih.gov/12502370 DM13D4E DI DM13D4E DM13D4E DN 1-[bis(4-bromophenyl)methyl]-3-phenylthiourea DM13D4E TI TT6OEDT DM13D4E TN Cannabinoid receptor 1 (CB1) DM13D4E MA Inhibitor DM13D4E RN 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90. DM13D4E RU https://pubmed.ncbi.nlm.nih.gov/16279809 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TT1ZAVI DM13FX4 TN Prostaglandin E2 receptor EP2 (PTGER2) DM13FX4 MA Agonist DM13FX4 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TTPNGDE DM13FX4 TN Prostaglandin E2 receptor EP3 (PTGER3) DM13FX4 MA Agonist DM13FX4 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TTOFYT1 DM13FX4 TN Prostacyclin receptor (PTGIR) DM13FX4 MA Agonist DM13FX4 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TTG1QMU DM13FX4 TN Prostaglandin E2 receptor EP1 (PTGER1) DM13FX4 MA Agonist DM13FX4 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TTQDMX5 DM13FX4 TN Prostaglandin D2 receptor 2 (PTGDR2) DM13FX4 MA Agonist DM13FX4 RN Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/12466225 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TTT2ZAR DM13FX4 TN Prostaglandin F2-alpha receptor (PTGFR) DM13FX4 MA Agonist DM13FX4 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TTNVEIR DM13FX4 TN Prostaglandin D2 receptor (PTGDR) DM13FX4 MA Agonist DM13FX4 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TT79WV3 DM13FX4 TN Prostaglandin E2 receptor EP4 (PTGER4) DM13FX4 MA Agonist DM13FX4 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM13FX4 DI DM13FX4 DM13FX4 DN U46619 DM13FX4 TI TT2O84V DM13FX4 TN Thromboxane A2 receptor (TBXA2R) DM13FX4 MA Agonist DM13FX4 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM13FX4 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM13HGN DI DM13HGN DM13HGN DN 1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene DM13HGN TI TTZ3S8C DM13HGN TN Presenilin 1 (PSEN1) DM13HGN MA Inhibitor DM13HGN RN Aryl sulfones: a new class of gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8. DM13HGN RU https://pubmed.ncbi.nlm.nih.gov/15863342 DM13HGN DI DM13HGN DM13HGN DN 1-Chloro-4-(1-phenyl-cyclohexanesulfonyl)-benzene DM13HGN TI TTWN3F4 DM13HGN TN Presenilin 2 (PSEN2) DM13HGN MA Inhibitor DM13HGN RN Aryl sulfones: a new class of gamma-secretase inhibitors. Bioorg Med Chem Lett. 2005 May 16;15(10):2685-8. DM13HGN RU https://pubmed.ncbi.nlm.nih.gov/15863342 DM13TUY DI DM13TUY DM13TUY DN MIV-710 DM13TUY TI TTDZN01 DM13TUY TN Cathepsin K (CTSK) DM13TUY MA Modulator DM13TUY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350). DM13TUY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350 DM145QS DI DM145QS DM145QS DN 1-(4-hydroxyphenyl)prop-2-en-1-one DM145QS TI TTT2LD9 DM145QS TN GABA transaminase (ABAT) DM145QS MA Inhibitor DM145QS RN Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5. DM145QS RU https://pubmed.ncbi.nlm.nih.gov/16290145 DM145QS DI DM145QS DM145QS DN 1-(4-hydroxyphenyl)prop-2-en-1-one DM145QS TI TTJUWVB DM145QS TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DM145QS MA Inhibitor DM145QS RN Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5. DM145QS RU https://pubmed.ncbi.nlm.nih.gov/16290145 DM149IX DI DM149IX DM149IX DN 5-(2-1H-indenyl)-1,3-benzodioxole DM149IX TI TT8NGED DM149IX TN Prostaglandin G/H synthase 1 (COX-1) DM149IX MA Inhibitor DM149IX RN 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18. DM149IX RU https://pubmed.ncbi.nlm.nih.gov/17604631 DM14C9V DI DM14C9V DM14C9V DN 4-(ethylamino)naphthalen-1-ol DM14C9V TI TTZJYKH DM14C9V TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM14C9V MA Inhibitor DM14C9V RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DM14C9V RU https://pubmed.ncbi.nlm.nih.gov/20055453 DM14DEL DI DM14DEL DM14DEL DN Ac-I[CV(2Igl)QDWGAHRC]T DM14DEL TI TTJGY7A DM14DEL TN Complement C3 (CO3) DM14DEL MA Inhibitor DM14DEL RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DM14DEL RU https://pubmed.ncbi.nlm.nih.gov/15634022 DM14HCY DI DM14HCY DM14HCY DN 2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol DM14HCY TI TTW0CMT DM14HCY TN Voltage-gated potassium channel Kv1.5 (KCNA5) DM14HCY MA Inhibitor DM14HCY RN Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. DM14HCY RU https://pubmed.ncbi.nlm.nih.gov/20304642 DM14I6C DI DM14I6C DM14I6C DN 4-(4-chloro-2-cyclohexylphenoxy)butanoic acid DM14I6C TI TTQDMX5 DM14I6C TN Prostaglandin D2 receptor 2 (PTGDR2) DM14I6C MA Inhibitor DM14I6C RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DM14I6C RU https://pubmed.ncbi.nlm.nih.gov/17531480 DM14L7O DI DM14L7O DM14L7O DN N-Isopropyl-1'H-phenothiazine-1'-carboxamide DM14L7O TI TTEB0GD DM14L7O TN Cholinesterase (BCHE) DM14L7O MA Inhibitor DM14L7O RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM14L7O RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM14OHR DI DM14OHR DM14OHR DN 7-vinyl-6H-chromeno[4,3-b]quinoline-3,9-diol DM14OHR TI TTPNQAC DM14OHR TN Estrogen-related receptor-alpha (ESRRA) DM14OHR MA Inhibitor DM14OHR RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DM14OHR RU https://pubmed.ncbi.nlm.nih.gov/17482813 DM14PLC DI DM14PLC DM14PLC DN ST-1025 DM14PLC TI TT9JNIC DM14PLC TN Histamine H3 receptor (H3R) DM14PLC MA Inhibitor DM14PLC RN Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5883-6. DM14PLC RU https://pubmed.ncbi.nlm.nih.gov/20727744 DM14VI3 DI DM14VI3 DM14VI3 DN 4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol DM14VI3 TI TTZAYWL DM14VI3 TN Estrogen receptor (ESR) DM14VI3 MA Inhibitor DM14VI3 RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM14VI3 RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM14VI3 DI DM14VI3 DM14VI3 DN 4,6,6,7-tetramethyl-6H-benzo[c]chromene-3,8-diol DM14VI3 TI TTOM3J0 DM14VI3 TN Estrogen receptor beta (ESR2) DM14VI3 MA Inhibitor DM14VI3 RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM14VI3 RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM14X29 DI DM14X29 DM14X29 DN diarylpropionitril DM14X29 TI TTOM3J0 DM14X29 TN Estrogen receptor beta (ESR2) DM14X29 MA Agonist DM14X29 RN Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem. 2001 Nov 22;44(24):4230-51. DM14X29 RU https://pubmed.ncbi.nlm.nih.gov/11708925 DM14XB7 DI DM14XB7 DM14XB7 DN PT-317 DM14XB7 TI TT84ETX DM14XB7 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM14XB7 MA Inhibitor DM14XB7 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM14XB7 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM153Y8 DI DM153Y8 DM153Y8 DN 1-Benzooxazol-2-yl-6-phenyl-hexan-1-one DM153Y8 TI TTDP1UC DM153Y8 TN Fatty acid amide hydrolase (FAAH) DM153Y8 MA Inhibitor DM153Y8 RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DM153Y8 RU https://pubmed.ncbi.nlm.nih.gov/15771430 DM154G2 DI DM154G2 DM154G2 DN H-Cpa-Gly-Gly-Phe-Met-OH DM154G2 TI TTKWM86 DM154G2 TN Opioid receptor mu (MOP) DM154G2 MA Inhibitor DM154G2 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM154G2 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM154G2 DI DM154G2 DM154G2 DN H-Cpa-Gly-Gly-Phe-Met-OH DM154G2 TI TT27RFC DM154G2 TN Opioid receptor delta (OPRD1) DM154G2 MA Inhibitor DM154G2 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM154G2 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM154G2 DI DM154G2 DM154G2 DN H-Cpa-Gly-Gly-Phe-Met-OH DM154G2 TI TTQW87Y DM154G2 TN Opioid receptor kappa (OPRK1) DM154G2 MA Inhibitor DM154G2 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM154G2 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM157LQ DI DM157LQ DM157LQ DN N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide DM157LQ TI TT1MPAY DM157LQ TN GABA(A) receptor alpha-1 (GABRA1) DM157LQ MA Inhibitor DM157LQ RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DM157LQ RU https://pubmed.ncbi.nlm.nih.gov/17335185 DM157LQ DI DM157LQ DM157LQ DN N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide DM157LQ TI TTZA1NY DM157LQ TN GABA(A) receptor beta-2 (GABRB2) DM157LQ MA Inhibitor DM157LQ RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DM157LQ RU https://pubmed.ncbi.nlm.nih.gov/17335185 DM157LQ DI DM157LQ DM157LQ DN N-butyl-2-(1H-indol-3-yl)-2-oxoacetamide DM157LQ TI TT06RH5 DM157LQ TN GABA(A) receptor gamma-2 (GABRG2) DM157LQ MA Inhibitor DM157LQ RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DM157LQ RU https://pubmed.ncbi.nlm.nih.gov/17335185 DM157OQ DI DM157OQ DM157OQ DN 5-Bromo-6-methoxy-9H-beta-carboline DM157OQ TI TTRPDBG DM157OQ TN Inhibitor of nuclear factor kappa-B kinase (IKK) DM157OQ MA Inhibitor DM157OQ RN Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22. DM157OQ RU https://pubmed.ncbi.nlm.nih.gov/12824047 DM157OQ DI DM157OQ DM157OQ DN 5-Bromo-6-methoxy-9H-beta-carboline DM157OQ TI TT1F8OQ DM157OQ TN IKKA messenger RNA (IKKA mRNA) DM157OQ MA Inhibitor DM157OQ RN Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22. DM157OQ RU https://pubmed.ncbi.nlm.nih.gov/12824047 DM157OQ DI DM157OQ DM157OQ DN 5-Bromo-6-methoxy-9H-beta-carboline DM157OQ TI TTJ3E9X DM157OQ TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM157OQ MA Inhibitor DM157OQ RN Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2419-22. DM157OQ RU https://pubmed.ncbi.nlm.nih.gov/12824047 DM157SO DI DM157SO DM157SO DN 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran DM157SO TI TTVBI8W DM157SO TN Dopamine transporter (DAT) DM157SO MA Inhibitor DM157SO RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM157SO RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM157SO DI DM157SO DM157SO DN 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran DM157SO TI TT3ROYC DM157SO TN Serotonin transporter (SERT) DM157SO MA Inhibitor DM157SO RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM157SO RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM157SO DI DM157SO DM157SO DN 2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran DM157SO TI TTAWNKZ DM157SO TN Norepinephrine transporter (NET) DM157SO MA Inhibitor DM157SO RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM157SO RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM15BA7 DI DM15BA7 DM15BA7 DN 2-(m-tolylethynyl)pyrimidine DM15BA7 TI TTHS256 DM15BA7 TN Metabotropic glutamate receptor 5 (mGluR5) DM15BA7 MA Inhibitor DM15BA7 RN Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a... J Med Chem. 2009 Jul 23;52(14):4103-6. DM15BA7 RU https://pubmed.ncbi.nlm.nih.gov/19537763 DM15CJZ DI DM15CJZ DM15CJZ DN UCL-2138 DM15CJZ TI TT9JNIC DM15CJZ TN Histamine H3 receptor (H3R) DM15CJZ MA Inhibitor DM15CJZ RN Fluorinated non-imidazole histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2172-5. DM15CJZ RU https://pubmed.ncbi.nlm.nih.gov/19286376 DM15KLR DI DM15KLR DM15KLR DN ARX-AHD DM15KLR TI TTGKNB4 DM15KLR TN Epidermal growth factor receptor (EGFR) DM15KLR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM15KLR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM15L2J DI DM15L2J DM15L2J DN BPH-830 DM15L2J TI TTFQEO5 DM15L2J TN Squalene synthetase (FDFT1) DM15L2J MA Inhibitor DM15L2J RN Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem. 2009 Jul 9;52(13):3869-80. DM15L2J RU https://pubmed.ncbi.nlm.nih.gov/19456099 DM15LE0 DI DM15LE0 DM15LE0 DN (+/-)-threo-N-Benzyl-3'-chloromethylphenidate DM15LE0 TI TTVBI8W DM15LE0 TN Dopamine transporter (DAT) DM15LE0 MA Inhibitor DM15LE0 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM15LE0 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM15LVG DI DM15LVG DM15LVG DN 8-(3-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one DM15LVG TI TTK3PY9 DM15LVG TN DNA-dependent protein kinase catalytic (PRKDC) DM15LVG MA Inhibitor DM15LVG RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DM15LVG RU https://pubmed.ncbi.nlm.nih.gov/16302822 DM15MQT DI DM15MQT DM15MQT DN N-Cyclohexyl-2-phenyl-acetamide DM15MQT TI TT7WVHI DM15MQT TN Soluble epoxide hydrolase (EPHX2) DM15MQT MA Inhibitor DM15MQT RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DM15MQT RU https://pubmed.ncbi.nlm.nih.gov/15887969 DM15P2G DI DM15P2G DM15P2G DN (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G TI TT23PYC DM15P2G TN Soluble guanylate cyclase (GCS) DM15P2G MA Activator DM15P2G RN Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res. 2002 Feb;14(1):8-14. DM15P2G RU https://pubmed.ncbi.nlm.nih.gov/11896472 DM15P2G DI DM15P2G DM15P2G DN (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol DM15P2G TI TTSN6QU DM15P2G TN HIF1-alpha messenger RNA (HIF1A mRNA) DM15P2G MA Inhibitor DM15P2G RN Synthesis of (aryloxyacetylamino)-isonicotinic/nicotinic acid analogues as potent hypoxia-inducible factor (HIF)-1alpha inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6305-10. DM15P2G RU https://pubmed.ncbi.nlm.nih.gov/17884495 DM15YL0 DI DM15YL0 DM15YL0 DN ML204 DM15YL0 TI TTX0H5W DM15YL0 TN Short transient receptor potential channel 4 (TRPC4) DM15YL0 MA Blocker (channel blocker) DM15YL0 RN Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem. 2011 Sep 23;286(38):33436-46. DM15YL0 RU https://pubmed.ncbi.nlm.nih.gov/21795696 DM15YL0 DI DM15YL0 DM15YL0 DN ML204 DM15YL0 TI TT32NQ1 DM15YL0 TN Short transient receptor potential channel 5 (TRPC5) DM15YL0 MA Blocker (channel blocker) DM15YL0 RN Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels. J Biol Chem. 2011 Sep 23;286(38):33436-46. DM15YL0 RU https://pubmed.ncbi.nlm.nih.gov/21795696 DM15YM7 DI DM15YM7 DM15YM7 DN 2-(4-chloro-2-cycloheptylphenoxy)acetic acid DM15YM7 TI TTQDMX5 DM15YM7 TN Prostaglandin D2 receptor 2 (PTGDR2) DM15YM7 MA Inhibitor DM15YM7 RN 7-Azaindole-3-acetic acid derivatives: potent and selective CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4794-8. DM15YM7 RU https://pubmed.ncbi.nlm.nih.gov/19592244 DM16G80 DI DM16G80 DM16G80 DN N-Hydroxy-4-isobutyl-benzamide DM16G80 TI TT2J34L DM16G80 TN Arachidonate 5-lipoxygenase (5-LOX) DM16G80 MA Inhibitor DM16G80 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DM16G80 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DM16GUV DI DM16GUV DM16GUV DN BRL 52537 hydrochloride DM16GUV TI TTQW87Y DM16GUV TN Opioid receptor kappa (OPRK1) DM16GUV MA Agonist DM16GUV RN Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg. 2003 Dec;97(6):1776-83. DM16GUV RU https://pubmed.ncbi.nlm.nih.gov/14633559 DM16JFS DI DM16JFS DM16JFS DN (R)-2-(biphenyl-4-sulfonylamino)-propionic acid DM16JFS TI TTYG6BU DM16JFS TN Aggrecanase-1 (ADAMTS4) DM16JFS MA Inhibitor DM16JFS RN Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):311-6. DM16JFS RU https://pubmed.ncbi.nlm.nih.gov/16275085 DM16KSA DI DM16KSA DM16KSA DN Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide DM16KSA TI TTED9LZ DM16KSA TN Neuroendocrine convertase 1 (PCSK1) DM16KSA MA Inhibitor DM16KSA RN Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem. 2010 Feb 11;53(3):1067-75. DM16KSA RU https://pubmed.ncbi.nlm.nih.gov/20038105 DM16KSA DI DM16KSA DM16KSA DN Phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide DM16KSA TI TT46F0P DM16KSA TN Neuroendocrine convertase 2 (PCSK2) DM16KSA MA Inhibitor DM16KSA RN Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics. J Med Chem. 2010 Feb 11;53(3):1067-75. DM16KSA RU https://pubmed.ncbi.nlm.nih.gov/20038105 DM16KZS DI DM16KZS DM16KZS DN 8-Cyclopentylmethoxy-quinolin-2-ylamine DM16KZS TI TTX4RTB DM16KZS TN Melanin-concentrating hormone receptor 1 (MCHR1) DM16KZS MA Inhibitor DM16KZS RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM16KZS RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM16N7Z DI DM16N7Z DM16N7Z DN (S)-pyrrolidin-2-yl(thiazolidin-3-yl)methanone DM16N7Z TI TTDIGC1 DM16N7Z TN Dipeptidyl peptidase 4 (DPP-4) DM16N7Z MA Inhibitor DM16N7Z RN [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2618-21. DM16N7Z RU https://pubmed.ncbi.nlm.nih.gov/17317162 DM16P3N DI DM16P3N DM16P3N DN 4-chloro-7-methyl-1H-indole-2,3-dione DM16P3N TI TTMF541 DM16P3N TN Liver carboxylesterase (CES1) DM16P3N MA Inhibitor DM16P3N RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM16P3N RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM16QTM DI DM16QTM DM16QTM DN CHALCONE DM16QTM TI TTGP7BY DM16QTM TN Monoamine oxidase type B (MAO-B) DM16QTM MA Inhibitor DM16QTM RN Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem. 2009 May 14;52(9):2818-24. DM16QTM RU https://pubmed.ncbi.nlm.nih.gov/19378991 DM16SVM DI DM16SVM DM16SVM DN Myxopyronin B DM16SVM TI TTS31JH DM16SVM TN Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) DM16SVM MA Inhibitor DM16SVM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM16SVM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM16U5F DI DM16U5F DM16U5F DN 1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole DM16U5F TI TTSZLWK DM16U5F TN Aromatase (CYP19A1) DM16U5F MA Inhibitor DM16U5F RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DM16U5F RU https://pubmed.ncbi.nlm.nih.gov/16220979 DM16U5F DI DM16U5F DM16U5F DN 1-(3-Methoxy-naphthalen-2-yl)-1H-imidazole DM16U5F TI TTIQUX7 DM16U5F TN Steroid 11-beta-hydroxylase (CYP11B1) DM16U5F MA Inhibitor DM16U5F RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DM16U5F RU https://pubmed.ncbi.nlm.nih.gov/16220979 DM170BV DI DM170BV DM170BV DN 1-(4-acetyloxazol-2-yl)-7-phenylheptan-1-one DM170BV TI TTDP1UC DM170BV TN Fatty acid amide hydrolase (FAAH) DM170BV MA Inhibitor DM170BV RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DM170BV RU https://pubmed.ncbi.nlm.nih.gov/18639454 DM170G5 DI DM170G5 DM170G5 DN AS1269574 DM170G5 TI TT7QNVC DM170G5 TN Glucose-dependent insulinotropic receptor (GPR119) DM170G5 MA Agonist DM170G5 RN Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem Biophys Res Commun. 2010 Sep 24;400(3):437-41. DM170G5 RU https://pubmed.ncbi.nlm.nih.gov/20804735 DM174HN DI DM174HN DM174HN DN 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine DM174HN TI TTQW87Y DM174HN TN Opioid receptor kappa (OPRK1) DM174HN MA Inhibitor DM174HN RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM174HN RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM174HN DI DM174HN DM174HN DN 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine DM174HN TI TT27RFC DM174HN TN Opioid receptor delta (OPRD1) DM174HN MA Inhibitor DM174HN RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM174HN RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM174HN DI DM174HN DM174HN DN 17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine DM174HN TI TTKWM86 DM174HN TN Opioid receptor mu (MOP) DM174HN MA Inhibitor DM174HN RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM174HN RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM17DY6 DI DM17DY6 DM17DY6 DN 13-(3-n-Pentylureido)tridec-8(E)-enoic acid DM17DY6 TI TT7WVHI DM17DY6 TN Soluble epoxide hydrolase (EPHX2) DM17DY6 MA Inhibitor DM17DY6 RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM17DY6 RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM17G39 DI DM17G39 DM17G39 DN ISIS 23452 DM17G39 TI TTAIWZN DM17G39 TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DM17G39 RN US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression. DM17G39 RU http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true DM17G82 DI DM17G82 DM17G82 DN N-Cyclohexyl-N'-Decylurea DM17G82 TI TT7WVHI DM17G82 TN Soluble epoxide hydrolase (EPHX2) DM17G82 MA Inhibitor DM17G82 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM17G82 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM17GIV DI DM17GIV DM17GIV DN GNF-PF-3645 DM17GIV TI TT1MPAY DM17GIV TN GABA(A) receptor alpha-1 (GABRA1) DM17GIV MA Inhibitor DM17GIV RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM17GIV RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM17GIV DI DM17GIV DM17GIV DN GNF-PF-3645 DM17GIV TI TT06RH5 DM17GIV TN GABA(A) receptor gamma-2 (GABRG2) DM17GIV MA Inhibitor DM17GIV RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM17GIV RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM17GIV DI DM17GIV DM17GIV DN GNF-PF-3645 DM17GIV TI TTNJYV2 DM17GIV TN Gamma-aminobutyric acid receptor (GAR) DM17GIV MA Inhibitor DM17GIV RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM17GIV RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM17GIV DI DM17GIV DM17GIV DN GNF-PF-3645 DM17GIV TI TTZA1NY DM17GIV TN GABA(A) receptor beta-2 (GABRB2) DM17GIV MA Inhibitor DM17GIV RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM17GIV RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM17JFO DI DM17JFO DM17JFO DN Tamarixetin 3-glucoside-7-sulfate DM17JFO TI TTFBNVI DM17JFO TN Aldose reductase (AKR1B1) DM17JFO MA Inhibitor DM17JFO RN Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5. DM17JFO RU https://pubmed.ncbi.nlm.nih.gov/8699190 DM17QG8 DI DM17QG8 DM17QG8 DN 4-(2-Hydroxyethoxy)-1-naphthol DM17QG8 TI TTZJYKH DM17QG8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM17QG8 MA Inhibitor DM17QG8 RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DM17QG8 RU https://pubmed.ncbi.nlm.nih.gov/20055453 DM17QMV DI DM17QMV DM17QMV DN H-mCpa-ala-Gly-Phe-leu-OH DM17QMV TI TTKWM86 DM17QMV TN Opioid receptor mu (MOP) DM17QMV MA Inhibitor DM17QMV RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM17QMV RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM17QMV DI DM17QMV DM17QMV DN H-mCpa-ala-Gly-Phe-leu-OH DM17QMV TI TT27RFC DM17QMV TN Opioid receptor delta (OPRD1) DM17QMV MA Inhibitor DM17QMV RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM17QMV RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM17SNR DI DM17SNR DM17SNR DN 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole DM17SNR TI TTE0A2F DM17SNR TN Dopamine D4 receptor (D4R) DM17SNR MA Inhibitor DM17SNR RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DM17SNR RU https://pubmed.ncbi.nlm.nih.gov/8642550 DM17SNR DI DM17SNR DM17SNR DN 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole DM17SNR TI TTEX248 DM17SNR TN Dopamine D2 receptor (D2R) DM17SNR MA Inhibitor DM17SNR RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DM17SNR RU https://pubmed.ncbi.nlm.nih.gov/8642550 DM17SNR DI DM17SNR DM17SNR DN 3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole DM17SNR TI TT4C8EA DM17SNR TN Dopamine D3 receptor (D3R) DM17SNR MA Inhibitor DM17SNR RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DM17SNR RU https://pubmed.ncbi.nlm.nih.gov/8642550 DM17TIX DI DM17TIX DM17TIX DN 1-Benzyl-1,2-dihydro-indazol-3-one DM17TIX TI TT2J34L DM17TIX TN Arachidonate 5-lipoxygenase (5-LOX) DM17TIX MA Inhibitor DM17TIX RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM17TIX RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM17TYR DI DM17TYR DM17TYR DN Everolimus DM17TYR TI TT7HQAF DM17TYR TN HUMAN mammalian target of rapamycin (mTOR) DM17TYR MA Inhibitor DM17TYR RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM17TYR RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM183RV DI DM183RV DM183RV DN GNF-PF-1399 DM183RV TI TTH8FZW DM183RV TN Signal transducer and activator of transcription 3 (STAT3) DM183RV MA Inhibitor DM183RV RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM183RV RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM1865H DI DM1865H DM1865H DN GSK-325971A DM1865H TI TTUV8G9 DM1865H TN Progesterone receptor (PGR) DM1865H MA Inhibitor DM1865H RN The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2340-3. DM1865H RU https://pubmed.ncbi.nlm.nih.gov/20202837 DM187UQ DI DM187UQ DM187UQ DN 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole DM187UQ TI TTGP7BY DM187UQ TN Monoamine oxidase type B (MAO-B) DM187UQ MA Inhibitor DM187UQ RN Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. DM187UQ RU https://pubmed.ncbi.nlm.nih.gov/20579890 DM187UQ DI DM187UQ DM187UQ DN 2-(2-cycloheptylidenehydrazinyl)-4-phenylthiazole DM187UQ TI TT3WG5C DM187UQ TN Monoamine oxidase type A (MAO-A) DM187UQ MA Inhibitor DM187UQ RN Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. DM187UQ RU https://pubmed.ncbi.nlm.nih.gov/20579890 DM18CUZ DI DM18CUZ DM18CUZ DN CORYNANTHEINE DM18CUZ TI TT34BHT DM18CUZ TN Adrenergic receptor alpha-1D (ADRA1D) DM18CUZ MA Inhibitor DM18CUZ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DM18CUZ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DM18CUZ DI DM18CUZ DM18CUZ DN CORYNANTHEINE DM18CUZ TI TTNGILX DM18CUZ TN Adrenergic receptor alpha-1A (ADRA1A) DM18CUZ MA Inhibitor DM18CUZ RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DM18CUZ RU https://pubmed.ncbi.nlm.nih.gov/15664832 DM18CUZ DI DM18CUZ DM18CUZ DN CORYNANTHEINE DM18CUZ TI TTZIFHC DM18CUZ TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DM18CUZ MA Inhibitor DM18CUZ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DM18CUZ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DM18CUZ DI DM18CUZ DM18CUZ DN CORYNANTHEINE DM18CUZ TI TTBRKXS DM18CUZ TN Adrenergic receptor alpha-1B (ADRA1B) DM18CUZ MA Inhibitor DM18CUZ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DM18CUZ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DM18CV3 DI DM18CV3 DM18CV3 DN TRACIZOLINE DM18CV3 TI TT2NUT5 DM18CV3 TN Adrenergic receptor alpha-2C (ADRA2C) DM18CV3 MA Inhibitor DM18CV3 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM18CV3 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM18CV3 DI DM18CV3 DM18CV3 DN TRACIZOLINE DM18CV3 TI TT3WG5C DM18CV3 TN Monoamine oxidase type A (MAO-A) DM18CV3 MA Inhibitor DM18CV3 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM18CV3 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM18CV3 DI DM18CV3 DM18CV3 DN TRACIZOLINE DM18CV3 TI TTWM4TY DM18CV3 TN Adrenergic receptor alpha-2B (ADRA2B) DM18CV3 MA Inhibitor DM18CV3 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM18CV3 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM18CV3 DI DM18CV3 DM18CV3 DN TRACIZOLINE DM18CV3 TI TTGP7BY DM18CV3 TN Monoamine oxidase type B (MAO-B) DM18CV3 MA Inhibitor DM18CV3 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM18CV3 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM18CV3 DI DM18CV3 DM18CV3 DN TRACIZOLINE DM18CV3 TI TTWG9A4 DM18CV3 TN Adrenergic receptor alpha-2A (ADRA2A) DM18CV3 MA Inhibitor DM18CV3 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM18CV3 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM18DB3 DI DM18DB3 DM18DB3 DN 1-(3-Fluorobenzyl)-1H-imidazole DM18DB3 TI TTIQUX7 DM18DB3 TN Steroid 11-beta-hydroxylase (CYP11B1) DM18DB3 MA Inhibitor DM18DB3 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM18DB3 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM18E9D DI DM18E9D DM18E9D DN (1R,2R)-1,2-diphenylethane-1,2-diamine DM18E9D TI TTDIGC1 DM18E9D TN Dipeptidyl peptidase 4 (DPP-4) DM18E9D MA Inhibitor DM18E9D RN In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9. DM18E9D RU https://pubmed.ncbi.nlm.nih.gov/16321524 DM18IKZ DI DM18IKZ DM18IKZ DN Soraphen A DM18IKZ TI TTY84UG DM18IKZ TN Acetyl-CoA carboxylase 2 (ACACB) DM18IKZ MA Inhibitor DM18IKZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM18IKZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM18MOH DI DM18MOH DM18MOH DN 3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide DM18MOH TI TT2LVK8 DM18MOH TN Carbonic anhydrase IX (CA-IX) DM18MOH MA Inhibitor DM18MOH RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DM18MOH RU https://pubmed.ncbi.nlm.nih.gov/19773173 DM18MOH DI DM18MOH DM18MOH DN 3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide DM18MOH TI TTANPDJ DM18MOH TN Carbonic anhydrase II (CA-II) DM18MOH MA Inhibitor DM18MOH RN Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32. DM18MOH RU https://pubmed.ncbi.nlm.nih.gov/19651511 DM18MOH DI DM18MOH DM18MOH DN 3-(4'-Hydroxyphenyl)diazenylbenzenesulfonamide DM18MOH TI TTSYM0R DM18MOH TN Carbonic anhydrase XII (CA-XII) DM18MOH MA Inhibitor DM18MOH RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DM18MOH RU https://pubmed.ncbi.nlm.nih.gov/19773173 DM18R6J DI DM18R6J DM18R6J DN (Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid DM18R6J TI TTXQKM3 DM18R6J TN Farnesyl protein transferase (Ftase) DM18R6J MA Inhibitor DM18R6J RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DM18R6J RU https://pubmed.ncbi.nlm.nih.gov/9301658 DM18R6J DI DM18R6J DM18R6J DN (Z)-2-Methyl-3-tetradecyl-but-2-enedioic acid DM18R6J TI TT7WZIJ DM18R6J TN CAAX farnesyltransferase beta (FNTB) DM18R6J MA Inhibitor DM18R6J RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DM18R6J RU https://pubmed.ncbi.nlm.nih.gov/9301658 DM18ZNJ DI DM18ZNJ DM18ZNJ DN [D-Ala2]Met-enkephalinamide DM18ZNJ TI TTKWM86 DM18ZNJ TN Opioid receptor mu (MOP) DM18ZNJ MA Inhibitor DM18ZNJ RN Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates a... J Med Chem. 1982 Dec;25(12):1423-7. DM18ZNJ RU https://pubmed.ncbi.nlm.nih.gov/7154002 DM190QW DI DM190QW DM190QW DN [3H]hemicholinium-3 DM190QW TI TTRV7W3 DM190QW TN High affinity choline transporter 1 (CHT) DM190QW MA Modulator DM190QW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 914). DM190QW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=914 DM196LK DI DM196LK DM196LK DN MI-219 DM196LK TI TT08GJW DM196LK TN Ubiquitin-protein ligase E3 Mdm2 (MDM2) DM196LK MA Inhibitor DM196LK RN MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26. DM196LK RU https://pubmed.ncbi.nlm.nih.gov/20818437 DM19D7G DI DM19D7G DM19D7G DN PMID22686657C(R)-26 DM19D7G TI TTUMQVO DM19D7G TN Cathepsin S (CTSS) DM19D7G MA Inhibitor DM19D7G RN Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F. J Med Chem. 2012 Jun 28;55(12):5982-6. DM19D7G RU https://pubmed.ncbi.nlm.nih.gov/22686657 DM19D7G DI DM19D7G DM19D7G DN PMID22686657C(R)-26 DM19D7G TI TTJOKD1 DM19D7G TN Cathepsin F (CTSF) DM19D7G MA Inhibitor DM19D7G RN Selective nitrile inhibitors to modulate the proteolytic synergism of cathepsins S and F. J Med Chem. 2012 Jun 28;55(12):5982-6. DM19D7G RU https://pubmed.ncbi.nlm.nih.gov/22686657 DM19FS3 DI DM19FS3 DM19FS3 DN Norzimelidine DM19FS3 TI TTJXYQ6 DM19FS3 TN Monoamine uptake (MA uptake) DM19FS3 MA Inhibitor DM19FS3 RN The antidepressant agents desipramine, fluoxetine, fluvoxamine and norzimelidine inhibit uptake of [3H]noradrenaline and [3H]5-hydroxytryptamine in slices of human and rat cortical brain tissue. Brain Res. 1983 Sep 19;275(1):99-104. DM19FS3 RU https://pubmed.ncbi.nlm.nih.gov/6226337 DM19I62 DI DM19I62 DM19I62 DN 7-Phloroethol DM19I62 TI TT8JRS7 DM19I62 TN Beta-secretase (BACE) DM19I62 MA Inhibitor DM19I62 RN Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5. DM19I62 RU https://pubmed.ncbi.nlm.nih.gov/20462757 DM19K2D DI DM19K2D DM19K2D DN ST-3050 DM19K2D TI TTYHPU6 DM19K2D TN Histone deacetylase 10 (HDAC10) DM19K2D MA Inhibitor DM19K2D RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DM19K2D RU https://pubmed.ncbi.nlm.nih.gov/19285395 DM19K2D DI DM19K2D DM19K2D DN ST-3050 DM19K2D TI TTT6LFV DM19K2D TN Histone deacetylase 8 (HDAC8) DM19K2D MA Inhibitor DM19K2D RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DM19K2D RU https://pubmed.ncbi.nlm.nih.gov/19285395 DM19K2D DI DM19K2D DM19K2D DN ST-3050 DM19K2D TI TTBH0VX DM19K2D TN Histone deacetylase (HDAC) DM19K2D MA Inhibitor DM19K2D RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DM19K2D RU https://pubmed.ncbi.nlm.nih.gov/19285395 DM19K2D DI DM19K2D DM19K2D DN ST-3050 DM19K2D TI TTTQGH8 DM19K2D TN Histone deacetylase 4 (HDAC4) DM19K2D MA Inhibitor DM19K2D RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DM19K2D RU https://pubmed.ncbi.nlm.nih.gov/19285395 DM19K2D DI DM19K2D DM19K2D DN ST-3050 DM19K2D TI TT6R7JZ DM19K2D TN Histone deacetylase 1 (HDAC1) DM19K2D MA Inhibitor DM19K2D RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DM19K2D RU https://pubmed.ncbi.nlm.nih.gov/19285395 DM19K2D DI DM19K2D DM19K2D DN ST-3050 DM19K2D TI TT5ZKDI DM19K2D TN Histone deacetylase 6 (HDAC6) DM19K2D MA Inhibitor DM19K2D RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DM19K2D RU https://pubmed.ncbi.nlm.nih.gov/19285395 DM19KY6 DI DM19KY6 DM19KY6 DN ADC-7828 DM19KY6 TI TTPLTSQ DM19KY6 TN Neutrophil elastase (NE) DM19KY6 MA Inhibitor DM19KY6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358). DM19KY6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358 DM19NAI DI DM19NAI DM19NAI DN Alpha-Sulfanylpropylphosphonic acid DM19NAI TI TTHI19T DM19NAI TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM19NAI MA Inhibitor DM19NAI RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DM19NAI RU https://pubmed.ncbi.nlm.nih.gov/20527888 DM19NMF DI DM19NMF DM19NMF DN Ac-WVTH[hArg]LAGLLS[hArg]SGGVVRKNFVPTDVGPFAF-NH2 DM19NMF TI TTVSFJW DM19NMF TN Calcitonin gene-related peptide 1 (CALCA) DM19NMF MA Inhibitor DM19NMF RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DM19NMF RU https://pubmed.ncbi.nlm.nih.gov/19053766 DM1A4BS DI DM1A4BS DM1A4BS DN 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole DM1A4BS TI TTNGILX DM1A4BS TN Adrenergic receptor alpha-1A (ADRA1A) DM1A4BS MA Inhibitor DM1A4BS RN 2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9. DM1A4BS RU https://pubmed.ncbi.nlm.nih.gov/15324890 DM1A4BS DI DM1A4BS DM1A4BS DN 2-(4-tert-Butyl-phenyl)-4,5-dihydro-1H-imidazole DM1A4BS TI TT6MSOK DM1A4BS TN 5-HT 1D receptor (HTR1D) DM1A4BS MA Inhibitor DM1A4BS RN 2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9. DM1A4BS RU https://pubmed.ncbi.nlm.nih.gov/15324890 DM1AD8T DI DM1AD8T DM1AD8T DN NSC-645833 DM1AD8T TI TTJLP0R DM1AD8T TN Quinone reductase 2 (NQO2) DM1AD8T MA Inhibitor DM1AD8T RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DM1AD8T RU https://pubmed.ncbi.nlm.nih.gov/20356739 DM1ADE5 DI DM1ADE5 DM1ADE5 DN N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine DM1ADE5 TI TTGP7BY DM1ADE5 TN Monoamine oxidase type B (MAO-B) DM1ADE5 MA Inhibitor DM1ADE5 RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM1ADE5 RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM1ADE5 DI DM1ADE5 DM1ADE5 DN N-(2-phenylethyl),N-(pyrrol-2-ylmethyl)amine DM1ADE5 TI TT3WG5C DM1ADE5 TN Monoamine oxidase type A (MAO-A) DM1ADE5 MA Inhibitor DM1ADE5 RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM1ADE5 RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM1AEK4 DI DM1AEK4 DM1AEK4 DN 2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine DM1AEK4 TI TT6MSOK DM1AEK4 TN 5-HT 1D receptor (HTR1D) DM1AEK4 MA Inhibitor DM1AEK4 RN 5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine. Bioorg Med Chem Lett. 2000 May 1;10(9):903-5. DM1AEK4 RU https://pubmed.ncbi.nlm.nih.gov/10853656 DM1AEK4 DI DM1AEK4 DM1AEK4 DN 2-(5-Thiophen-2-yl-1H-indol-3-yl)-ethylamine DM1AEK4 TI TTK8CXU DM1AEK4 TN 5-HT 1B receptor (HTR1B) DM1AEK4 MA Inhibitor DM1AEK4 RN 5-Thienyltryptamine derivatives as serotonin 5-HT1B/1D receptor agonists: potential treatments for migraine. Bioorg Med Chem Lett. 2000 May 1;10(9):903-5. DM1AEK4 RU https://pubmed.ncbi.nlm.nih.gov/10853656 DM1AHIW DI DM1AHIW DM1AHIW DN S-(N-Hydroxy-N-Iodophenylcarbamoyl)Glutathione DM1AHIW TI TTV9A7R DM1AHIW TN Lactoylglutathione lyase (GLO1) DM1AHIW MA Inhibitor DM1AHIW RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM1AHIW RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM1ALTR DI DM1ALTR DM1ALTR DN Tert-Butyl 5-(2-oxohexadecanamido)pentanoate DM1ALTR TI TTT1JVS DM1ALTR TN Cytosolic phospholipase A2 (GIVA cPLA2) DM1ALTR MA Inhibitor DM1ALTR RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DM1ALTR RU https://pubmed.ncbi.nlm.nih.gov/18993078 DM1ASK6 DI DM1ASK6 DM1ASK6 DN 2-(1-(aminomethyl)-3-ethylcyclopentyl)acetic acid DM1ASK6 TI TTFK1JQ DM1ASK6 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM1ASK6 MA Inhibitor DM1ASK6 RN Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5. DM1ASK6 RU https://pubmed.ncbi.nlm.nih.gov/19897364 DM1ATS3 DI DM1ATS3 DM1ATS3 DN 1-(oxazol-2-yl)octadec-9-en-1-one DM1ATS3 TI TTDP1UC DM1ATS3 TN Fatty acid amide hydrolase (FAAH) DM1ATS3 MA Inhibitor DM1ATS3 RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DM1ATS3 RU https://pubmed.ncbi.nlm.nih.gov/18630870 DM1AU8V DI DM1AU8V DM1AU8V DN Oxindole derivative DM1AU8V TI TTSFWA7 DM1AU8V TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DM1AU8V MA Inhibitor DM1AU8V RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DM1AU8V RU https://pubmed.ncbi.nlm.nih.gov/17339102 DM1AV5R DI DM1AV5R DM1AV5R DN DR2313 DM1AV5R TI TTVDSZ0 DM1AV5R TN Poly [ADP-ribose] polymerase 1 (PARP1) DM1AV5R MA Inhibitor DM1AV5R RN Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. DM1AV5R RU https://pubmed.ncbi.nlm.nih.gov/15864271 DM1AVCZ DI DM1AVCZ DM1AVCZ DN N-oleoyl-dopamine DM1AVCZ TI TTIQSC1 DM1AVCZ TN Bacterial Lethal factor (Bact lef) DM1AVCZ MA Inhibitor DM1AVCZ RN Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8. DM1AVCZ RU https://pubmed.ncbi.nlm.nih.gov/17574849 DM1AYVU DI DM1AYVU DM1AYVU DN Factor VIII-XTEN DM1AYVU TI TT1290U DM1AYVU TN Coagulation factor VIII (F8) DM1AYVU MA Modulator DM1AYVU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM1AYVU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM1B0PY DI DM1B0PY DM1B0PY DN CLP-635 DM1B0PY TI TTH6UZY DM1B0PY TN Solute carrier family 12 member 5 (SLC12A5) DM1B0PY MA Modulator DM1B0PY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 972). DM1B0PY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=972 DM1BALV DI DM1BALV DM1BALV DN 3-Bromo-2'-hydroxy-4-methoxychalcone DM1BALV TI TTVKILB DM1BALV TN Prostaglandin G/H synthase 2 (COX-2) DM1BALV MA Inhibitor DM1BALV RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DM1BALV RU https://pubmed.ncbi.nlm.nih.gov/19233646 DM1BDM8 DI DM1BDM8 DM1BDM8 DN Dihydrofolic Acid DM1BDM8 TI TT9SL3Q DM1BDM8 TN Polypeptide deformylase (PDF) DM1BDM8 MA Inhibitor DM1BDM8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1BDM8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1BGQN DI DM1BGQN DM1BGQN DN 1-Methyl-1,2-dihydro-indazol-3-one DM1BGQN TI TT2J34L DM1BGQN TN Arachidonate 5-lipoxygenase (5-LOX) DM1BGQN MA Inhibitor DM1BGQN RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM1BGQN RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM1BI65 DI DM1BI65 DM1BI65 DN 2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DM1BI65 TI TTCEJ4F DM1BI65 TN G1/S-specific cyclin-E1 (CCNE1) DM1BI65 MA Inhibitor DM1BI65 RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DM1BI65 RU https://pubmed.ncbi.nlm.nih.gov/17064068 DM1BI65 DI DM1BI65 DM1BI65 DN 2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DM1BI65 TI TT7HF4W DM1BI65 TN Cyclin-dependent kinase 2 (CDK2) DM1BI65 MA Inhibitor DM1BI65 RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DM1BI65 RU https://pubmed.ncbi.nlm.nih.gov/17064068 DM1BLCX DI DM1BLCX DM1BLCX DN HC3-1496 DM1BLCX TI TT8D13I DM1BLCX TN Complement factor D (CFD) DM1BLCX MA Modulator DM1BLCX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2842). DM1BLCX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2842 DM1BMT7 DI DM1BMT7 DM1BMT7 DN D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT DM1BMT7 TI TT4TFGN DM1BMT7 TN Vasopressin V1a receptor (V1AR) DM1BMT7 MA Inhibitor DM1BMT7 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM1BMT7 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM1BMT7 DI DM1BMT7 DM1BMT7 DN D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT DM1BMT7 TI TTSCIUP DM1BMT7 TN Oxytocin receptor (OTR) DM1BMT7 MA Inhibitor DM1BMT7 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM1BMT7 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM1BMT7 DI DM1BMT7 DM1BMT7 DN D(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr9-NH2]VT DM1BMT7 TI TTK8R02 DM1BMT7 TN Vasopressin V2 receptor (V2R) DM1BMT7 MA Inhibitor DM1BMT7 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM1BMT7 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM1BQY3 DI DM1BQY3 DM1BQY3 DN PMID21185185C21 DM1BQY3 TI TTWNV8U DM1BQY3 TN Nicotinic acid receptor (HCAR2) DM1BQY3 MA Agonist DM1BQY3 RN The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME properties. Bioorg Med Chem Lett. 2011 May 1;21(9):2721-4. DM1BQY3 RU https://pubmed.ncbi.nlm.nih.gov/21185185 DM1BU5P DI DM1BU5P DM1BU5P DN N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide DM1BU5P TI TTW0CMT DM1BU5P TN Voltage-gated potassium channel Kv1.5 (KCNA5) DM1BU5P MA Inhibitor DM1BU5P RN Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2823-7. DM1BU5P RU https://pubmed.ncbi.nlm.nih.gov/15125940 DM1BVW3 DI DM1BVW3 DM1BVW3 DN TGSC01AA(4) DM1BVW3 TI TTPTXIN DM1BVW3 TN Translocator protein (TSPO) DM1BVW3 MA Binder DM1BVW3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DM1BVW3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DM1C3NZ DI DM1C3NZ DM1C3NZ DN 4-(3-fluoro-2-phenoxyphenyl)piperidine DM1C3NZ TI TTAWNKZ DM1C3NZ TN Norepinephrine transporter (NET) DM1C3NZ MA Inhibitor DM1C3NZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM1C3NZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM1C3NZ DI DM1C3NZ DM1C3NZ DN 4-(3-fluoro-2-phenoxyphenyl)piperidine DM1C3NZ TI TTSQIFT DM1C3NZ TN 5-HT 1A receptor (HTR1A) DM1C3NZ MA Inhibitor DM1C3NZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM1C3NZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM1C3NZ DI DM1C3NZ DM1C3NZ DN 4-(3-fluoro-2-phenoxyphenyl)piperidine DM1C3NZ TI TT3ROYC DM1C3NZ TN Serotonin transporter (SERT) DM1C3NZ MA Inhibitor DM1C3NZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM1C3NZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM1C3NZ DI DM1C3NZ DM1C3NZ DN 4-(3-fluoro-2-phenoxyphenyl)piperidine DM1C3NZ TI TTVBI8W DM1C3NZ TN Dopamine transporter (DAT) DM1C3NZ MA Inhibitor DM1C3NZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM1C3NZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM1C40H DI DM1C40H DM1C40H DN N-(3,5-dimethoxyphenethyl)oleamide DM1C40H TI TT6OEDT DM1C40H TN Cannabinoid receptor 1 (CB1) DM1C40H MA Inhibitor DM1C40H RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM1C40H RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM1C5GZ DI DM1C5GZ DM1C5GZ DN Semorphone DM1C5GZ TI TTKWM86 DM1C5GZ TN Opioid receptor mu (MOP) DM1C5GZ MA Modulator DM1C5GZ RN Respiratory effects and tolerability of Mr 2264 Cl.A new opiate partial agonist in comparison with morphine and placebo.Eur J Clin Pharmacol.1994;46(4):301-4. DM1C5GZ RU https://www.ncbi.nlm.nih.gov/pubmed/7957512 DM1C5U6 DI DM1C5U6 DM1C5U6 DN 4-(2-Hydroxy-ethyl)-benzenesulfonamide DM1C5U6 TI TTSYM0R DM1C5U6 TN Carbonic anhydrase XII (CA-XII) DM1C5U6 MA Inhibitor DM1C5U6 RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DM1C5U6 RU https://pubmed.ncbi.nlm.nih.gov/15686894 DM1C5U6 DI DM1C5U6 DM1C5U6 DN 4-(2-Hydroxy-ethyl)-benzenesulfonamide DM1C5U6 TI TTANPDJ DM1C5U6 TN Carbonic anhydrase II (CA-II) DM1C5U6 MA Inhibitor DM1C5U6 RN Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503. DM1C5U6 RU https://pubmed.ncbi.nlm.nih.gov/20624682 DM1C5U6 DI DM1C5U6 DM1C5U6 DN 4-(2-Hydroxy-ethyl)-benzenesulfonamide DM1C5U6 TI TTEYTKG DM1C5U6 TN Carbonic anhydrase XIV (CA-XIV) DM1C5U6 MA Inhibitor DM1C5U6 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DM1C5U6 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DM1C5U6 DI DM1C5U6 DM1C5U6 DN 4-(2-Hydroxy-ethyl)-benzenesulfonamide DM1C5U6 TI TTCFSPE DM1C5U6 TN Carbonic anhydrase VI (CA-VI) DM1C5U6 MA Inhibitor DM1C5U6 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM1C5U6 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM1C5U6 DI DM1C5U6 DM1C5U6 DN 4-(2-Hydroxy-ethyl)-benzenesulfonamide DM1C5U6 TI TT2LVK8 DM1C5U6 TN Carbonic anhydrase IX (CA-IX) DM1C5U6 MA Inhibitor DM1C5U6 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM1C5U6 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM1C5U6 DI DM1C5U6 DM1C5U6 DN 4-(2-Hydroxy-ethyl)-benzenesulfonamide DM1C5U6 TI TTUNARX DM1C5U6 TN Carbonic anhydrase (CA) DM1C5U6 MA Inhibitor DM1C5U6 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM1C5U6 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM1C864 DI DM1C864 DM1C864 DN 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine DM1C864 TI TTJFY5U DM1C864 TN Adenosine A3 receptor (ADORA3) DM1C864 MA Inhibitor DM1C864 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM1C864 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM1C864 DI DM1C864 DM1C864 DN 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine DM1C864 TI TTK25J1 DM1C864 TN Adenosine A1 receptor (ADORA1) DM1C864 MA Inhibitor DM1C864 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM1C864 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM1C864 DI DM1C864 DM1C864 DN 2-(4-hydroxypent-1-yl)-N6-methoxyadenosine DM1C864 TI TTM2AOE DM1C864 TN Adenosine A2a receptor (ADORA2A) DM1C864 MA Inhibitor DM1C864 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM1C864 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM1C8FW DI DM1C8FW DM1C8FW DN Epitinib DM1C8FW TI TTGKNB4 DM1C8FW TN Epidermal growth factor receptor (EGFR) DM1C8FW MA Inhibitor DM1C8FW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM1C8FW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM1C90Y DI DM1C90Y DM1C90Y DN (3-Phenyl-propyl)-quinazolin-4-yl-amine DM1C90Y TI TT64EPS DM1C90Y TN Fungal Scytalone dehydratase (Fung SDH1) DM1C90Y MA Inhibitor DM1C90Y RN A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase, Bioorg. Med. Chem. Lett. 3(8):1605-1608 (1993). DM1C90Y RU http://www.sciencedirect.com/science/article/pii/S0960894X00800268 DM1C9W3 DI DM1C9W3 DM1C9W3 DN S-(N-methyl-N-hydroxycarbamoyl)glutathione DM1C9W3 TI TTV9A7R DM1C9W3 TN Lactoylglutathione lyase (GLO1) DM1C9W3 MA Inhibitor DM1C9W3 RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DM1C9W3 RU https://pubmed.ncbi.nlm.nih.gov/11052803 DM1CB5J DI DM1CB5J DM1CB5J DN 2-Benzyl-1,2-dihydro-indazol-3-one DM1CB5J TI TT8NGED DM1CB5J TN Prostaglandin G/H synthase 1 (COX-1) DM1CB5J MA Inhibitor DM1CB5J RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM1CB5J RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM1CB5J DI DM1CB5J DM1CB5J DN 2-Benzyl-1,2-dihydro-indazol-3-one DM1CB5J TI TT2J34L DM1CB5J TN Arachidonate 5-lipoxygenase (5-LOX) DM1CB5J MA Inhibitor DM1CB5J RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM1CB5J RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM1CB5J DI DM1CB5J DM1CB5J DN 2-Benzyl-1,2-dihydro-indazol-3-one DM1CB5J TI TTVKILB DM1CB5J TN Prostaglandin G/H synthase 2 (COX-2) DM1CB5J MA Inhibitor DM1CB5J RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM1CB5J RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM1CNU5 DI DM1CNU5 DM1CNU5 DN BN-81,644 DM1CNU5 TI TTJX3UE DM1CNU5 TN Somatostatin receptor type 3 (SSTR3) DM1CNU5 MA Agonist DM1CNU5 RN Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem. 2001 Aug 30;44(18):2990-3000. DM1CNU5 RU https://pubmed.ncbi.nlm.nih.gov/11520208 DM1CX9Y DI DM1CX9Y DM1CX9Y DN Butyl-indol-1-yl-pyridin-4-yl-amine DM1CX9Y TI TT2NUT5 DM1CX9Y TN Adrenergic receptor alpha-2C (ADRA2C) DM1CX9Y MA Inhibitor DM1CX9Y RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM1CX9Y RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM1CX9Y DI DM1CX9Y DM1CX9Y DN Butyl-indol-1-yl-pyridin-4-yl-amine DM1CX9Y TI TTWM4TY DM1CX9Y TN Adrenergic receptor alpha-2B (ADRA2B) DM1CX9Y MA Inhibitor DM1CX9Y RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM1CX9Y RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM1CX9Y DI DM1CX9Y DM1CX9Y DN Butyl-indol-1-yl-pyridin-4-yl-amine DM1CX9Y TI TTWG9A4 DM1CX9Y TN Adrenergic receptor alpha-2A (ADRA2A) DM1CX9Y MA Inhibitor DM1CX9Y RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM1CX9Y RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM1CYWB DI DM1CYWB DM1CYWB DN quin-C7 DM1CYWB TI TTOJ1NF DM1CYWB TN FMLP-related receptor I (FPR2) DM1CYWB MA Antagonist DM1CYWB RN Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1. Mol Pharmacol. 2007 Oct;72(4):976-83. DM1CYWB RU https://pubmed.ncbi.nlm.nih.gov/17652444 DM1D47I DI DM1D47I DM1D47I DN BU-E 47 DM1D47I TI TTTIBOJ DM1D47I TN Histamine H1 receptor (H1R) DM1D47I MA Antagonist DM1D47I RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DM1D47I RU https://pubmed.ncbi.nlm.nih.gov/12626648 DM1D5F0 DI DM1D5F0 DM1D5F0 DN HwFwLL-NH2 DM1D5F0 TI TTWDC17 DM1D5F0 TN Growth hormone secretagogue receptor 1 (GHSR) DM1D5F0 MA Inhibitor DM1D5F0 RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DM1D5F0 RU https://pubmed.ncbi.nlm.nih.gov/17371869 DM1D6CQ DI DM1D6CQ DM1D6CQ DN ICI-174864 DM1D6CQ TI TT27RFC DM1D6CQ TN Opioid receptor delta (OPRD1) DM1D6CQ MA Inhibitor DM1D6CQ RN Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor. J Med Chem. 2006 Sep 7;49(18):5597-609. DM1D6CQ RU https://pubmed.ncbi.nlm.nih.gov/16942033 DM1D7KY DI DM1D7KY DM1D7KY DN S-(-)-sulpiride DM1D7KY TI TTEX248 DM1D7KY TN Dopamine D2 receptor (D2R) DM1D7KY MA Antagonist DM1D7KY RN The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother. 2002 Jul;3(7):899-914. DM1D7KY RU https://pubmed.ncbi.nlm.nih.gov/12083990 DM1DCFP DI DM1DCFP DM1DCFP DN ISIS 150451 DM1DCFP TI TTP9K3Q DM1DCFP TN SOD1 messenger RNA (SOD1 mRNA) DM1DCFP RN US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. DM1DCFP RU http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true DM1DE3F DI DM1DE3F DM1DE3F DN Salvinorin B 2,2,2-trifluoroethoxymethyl ether DM1DE3F TI TTQW87Y DM1DE3F TN Opioid receptor kappa (OPRK1) DM1DE3F MA Inhibitor DM1DE3F RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DM1DE3F RU https://pubmed.ncbi.nlm.nih.gov/17981041 DM1DEYU DI DM1DEYU DM1DEYU DN JWH-133 DM1DEYU TI TTMSFAW DM1DEYU TN Cannabinoid receptor 2 (CB2) DM1DEYU MA Inhibitor DM1DEYU RN Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 ... J Med Chem. 2006 Oct 5;49(20):5947-57. DM1DEYU RU https://pubmed.ncbi.nlm.nih.gov/17004710 DM1DEYU DI DM1DEYU DM1DEYU DN JWH-133 DM1DEYU TI TT6OEDT DM1DEYU TN Cannabinoid receptor 1 (CB1) DM1DEYU MA Inhibitor DM1DEYU RN 1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. Bioorg Med Chem. 2010 Nov 15;18(22):7809-15. DM1DEYU RU https://pubmed.ncbi.nlm.nih.gov/20943404 DM1DH96 DI DM1DH96 DM1DH96 DN QUERCITRIN DM1DH96 TI TTFBNVI DM1DH96 TN Aldose reductase (AKR1B1) DM1DH96 MA Inhibitor DM1DH96 RN Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5. DM1DH96 RU https://pubmed.ncbi.nlm.nih.gov/18298080 DM1DJX2 DI DM1DJX2 DM1DJX2 DN (2S)-aminobutyryl-L-proline n-pentylamide DM1DJX2 TI TTQ7R2V DM1DJX2 TN Tripeptidyl-peptidase II (TPP2) DM1DJX2 MA Inhibitor DM1DJX2 RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DM1DJX2 RU https://pubmed.ncbi.nlm.nih.gov/16279793 DM1DKSV DI DM1DKSV DM1DKSV DN 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID DM1DKSV TI TT50QJ3 DM1DKSV TN Influenza Neuraminidase (Influ NA) DM1DKSV MA Inhibitor DM1DKSV RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM1DKSV RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM1DMR2 DI DM1DMR2 DM1DMR2 DN C[RGDf-(3R)-Carboxymorpholine] DM1DMR2 TI TTT1R2L DM1DMR2 TN Integrin alpha-V (ITGAV) DM1DMR2 MA Inhibitor DM1DMR2 RN Morpholine-based RGD-cyclopentapeptides as alphavbeta3/alphavbeta5 integrin ligands: role of configuration towards receptor binding affinity. Bioorg Med Chem. 2009 Feb 15;17(4):1542-9. DM1DMR2 RU https://pubmed.ncbi.nlm.nih.gov/19195898 DM1DNRP DI DM1DNRP DM1DNRP DN (S)-5-iodowillardiine DM1DNRP TI TT0MYE2 DM1DNRP TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM1DNRP MA Agonist DM1DNRP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM1DNRP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM1DQGJ DI DM1DQGJ DM1DQGJ DN 3-(2-Methyl-2-aza-bicyclo[3.3.1]non-5-yl)-phenol DM1DQGJ TI TTKWM86 DM1DQGJ TN Opioid receptor mu (MOP) DM1DQGJ MA Inhibitor DM1DQGJ RN Phenylmorphans and analogues: opioid receptor subtype selectivity and effect of conformation on activity. J Med Chem. 1992 May 1;35(9):1521-5. DM1DQGJ RU https://pubmed.ncbi.nlm.nih.gov/1315868 DM1DS3B DI DM1DS3B DM1DS3B DN 8-Bromo-9-methyl-9H-adenine DM1DS3B TI TTK25J1 DM1DS3B TN Adenosine A1 receptor (ADORA1) DM1DS3B MA Inhibitor DM1DS3B RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM1DS3B RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM1DS3B DI DM1DS3B DM1DS3B DN 8-Bromo-9-methyl-9H-adenine DM1DS3B TI TTM2AOE DM1DS3B TN Adenosine A2a receptor (ADORA2A) DM1DS3B MA Inhibitor DM1DS3B RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM1DS3B RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM1DS3B DI DM1DS3B DM1DS3B DN 8-Bromo-9-methyl-9H-adenine DM1DS3B TI TTNE7KG DM1DS3B TN Adenosine A2b receptor (ADORA2B) DM1DS3B MA Inhibitor DM1DS3B RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM1DS3B RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM1DWCP DI DM1DWCP DM1DWCP DN AcDif-Ile-Cha-Cys DM1DWCP TI TTWXB3E DM1DWCP TN Hepatitis C virus NS3 helicase (HCV NS3) DM1DWCP MA Inhibitor DM1DWCP RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DM1DWCP RU https://pubmed.ncbi.nlm.nih.gov/11206459 DM1DWRN DI DM1DWRN DM1DWRN DN A-119637 DM1DWRN TI TTBRKXS DM1DWRN TN Adrenergic receptor alpha-1B (ADRA1B) DM1DWRN MA Inhibitor DM1DWRN RN Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien. Bioorg Med Chem Lett. 2001 May 7;11(9):1119-21. DM1DWRN RU https://pubmed.ncbi.nlm.nih.gov/11354357 DM1DWRN DI DM1DWRN DM1DWRN DN A-119637 DM1DWRN TI TTNGILX DM1DWRN TN Adrenergic receptor alpha-1A (ADRA1A) DM1DWRN MA Inhibitor DM1DWRN RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DM1DWRN RU https://pubmed.ncbi.nlm.nih.gov/15664832 DM1DXHG DI DM1DXHG DM1DXHG DN [125I]SAP DM1DXHG TI TT2O84V DM1DXHG TN Thromboxane A2 receptor (TBXA2R) DM1DXHG MA Antagonist DM1DXHG RN 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):632-7. DM1DXHG RU https://pubmed.ncbi.nlm.nih.gov/1386885 DM1DYU4 DI DM1DYU4 DM1DYU4 DN 9-octadecynoic acid DM1DYU4 TI TTPADOQ DM1DYU4 TN HMG-CoA reductase (HMGCR) DM1DYU4 MA Inhibitor DM1DYU4 RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DM1DYU4 RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DM1DZEL DI DM1DZEL DM1DZEL DN N,N-dimethyl-2-(2'-methylbiphenyl-3-yl)ethanamine DM1DZEL TI TTO9X1H DM1DZEL TN 5-HT 7 receptor (HTR7) DM1DZEL MA Inhibitor DM1DZEL RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DM1DZEL RU https://pubmed.ncbi.nlm.nih.gov/20138771 DM1E5C4 DI DM1E5C4 DM1E5C4 DN D 2343 DM1E5C4 TI TT2CJVK DM1E5C4 TN Adrenergic receptor beta-2 (ADRB2) DM1E5C4 MA Agonist DM1E5C4 RN A new beta 2-adrenoceptor agonist--D 2343--with long duration. Inhalation comparison with terbutaline in asthmatics. Allergy. 1984 Aug;39(6):485-9. DM1E5C4 RU https://pubmed.ncbi.nlm.nih.gov/6437263 DM1E5QZ DI DM1E5QZ DM1E5QZ DN 3-ethoxycarbonyl-6-propyl-4-quinolone DM1E5QZ TI TT1MPAY DM1E5QZ TN GABA(A) receptor alpha-1 (GABRA1) DM1E5QZ MA Inhibitor DM1E5QZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1E5QZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1E5QZ DI DM1E5QZ DM1E5QZ DN 3-ethoxycarbonyl-6-propyl-4-quinolone DM1E5QZ TI TTNJYV2 DM1E5QZ TN Gamma-aminobutyric acid receptor (GAR) DM1E5QZ MA Inhibitor DM1E5QZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1E5QZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1E5QZ DI DM1E5QZ DM1E5QZ DN 3-ethoxycarbonyl-6-propyl-4-quinolone DM1E5QZ TI TT06RH5 DM1E5QZ TN GABA(A) receptor gamma-2 (GABRG2) DM1E5QZ MA Inhibitor DM1E5QZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1E5QZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1E5QZ DI DM1E5QZ DM1E5QZ DN 3-ethoxycarbonyl-6-propyl-4-quinolone DM1E5QZ TI TTZA1NY DM1E5QZ TN GABA(A) receptor beta-2 (GABRB2) DM1E5QZ MA Inhibitor DM1E5QZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1E5QZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1EANV DI DM1EANV DM1EANV DN 4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol DM1EANV TI TTZAYWL DM1EANV TN Estrogen receptor (ESR) DM1EANV MA Inhibitor DM1EANV RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM1EANV RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM1EANV DI DM1EANV DM1EANV DN 4-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,3-diol DM1EANV TI TTOM3J0 DM1EANV TN Estrogen receptor beta (ESR2) DM1EANV MA Inhibitor DM1EANV RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM1EANV RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM1EGC3 DI DM1EGC3 DM1EGC3 DN H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 DM1EGC3 TI TT2BC4G DM1EGC3 TN Somatostatin receptor type 5 (SSTR5) DM1EGC3 MA Inhibitor DM1EGC3 RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DM1EGC3 RU https://pubmed.ncbi.nlm.nih.gov/16220980 DM1EGC3 DI DM1EGC3 DM1EGC3 DN H-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 DM1EGC3 TI TTZ6T9E DM1EGC3 TN Somatostatin receptor type 2 (SSTR2) DM1EGC3 MA Inhibitor DM1EGC3 RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DM1EGC3 RU https://pubmed.ncbi.nlm.nih.gov/16220980 DM1EGP9 DI DM1EGP9 DM1EGP9 DN 2-Amino-6-(toluene-3-sulfonyl)-benzonitrile DM1EGP9 TI TT84ETX DM1EGP9 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1EGP9 MA Inhibitor DM1EGP9 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM1EGP9 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM1EHG5 DI DM1EHG5 DM1EHG5 DN XEN-D0104 DM1EHG5 TI TTW0CMT DM1EHG5 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DM1EHG5 MA Opener DM1EHG5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542). DM1EHG5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542 DM1EJ6W DI DM1EJ6W DM1EJ6W DN 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one DM1EJ6W TI TT8NGED DM1EJ6W TN Prostaglandin G/H synthase 1 (COX-1) DM1EJ6W MA Inhibitor DM1EJ6W RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM1EJ6W RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM1EJ6W DI DM1EJ6W DM1EJ6W DN 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one DM1EJ6W TI TT2J34L DM1EJ6W TN Arachidonate 5-lipoxygenase (5-LOX) DM1EJ6W MA Inhibitor DM1EJ6W RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM1EJ6W RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM1EJ6W DI DM1EJ6W DM1EJ6W DN 2-Naphthalen-2-ylmethyl-1,2-dihydro-indazol-3-one DM1EJ6W TI TTVKILB DM1EJ6W TN Prostaglandin G/H synthase 2 (COX-2) DM1EJ6W MA Inhibitor DM1EJ6W RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM1EJ6W RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM1EPLC DI DM1EPLC DM1EPLC DN ISIS 25075 DM1EPLC TI TT8H9GB DM1EPLC TN MEK2 messenger RNA (MEK2 mRNA) DM1EPLC RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DM1EPLC RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DM1EPZB DI DM1EPZB DM1EPZB DN [des-His1,Tyr5,Glu9,D-Ala10]glucagon-NH2 DM1EPZB TI TT9O6WS DM1EPZB TN Glucagon receptor (GCGR) DM1EPZB MA Inhibitor DM1EPZB RN Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55. DM1EPZB RU https://pubmed.ncbi.nlm.nih.gov/8691441 DM1ERJC DI DM1ERJC DM1ERJC DN 11-deoxy-PGE1 DM1ERJC TI TTPNGDE DM1ERJC TN Prostaglandin E2 receptor EP3 (PTGER3) DM1ERJC MA Agonist DM1ERJC RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM1ERJC RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM1ERJC DI DM1ERJC DM1ERJC DN 11-deoxy-PGE1 DM1ERJC TI TT79WV3 DM1ERJC TN Prostaglandin E2 receptor EP4 (PTGER4) DM1ERJC MA Agonist DM1ERJC RN Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br J Pharmacol. 2000 Aug;130(8):1919-26. DM1ERJC RU https://pubmed.ncbi.nlm.nih.gov/10952683 DM1ERJC DI DM1ERJC DM1ERJC DN 11-deoxy-PGE1 DM1ERJC TI TT1ZAVI DM1ERJC TN Prostaglandin E2 receptor EP2 (PTGER2) DM1ERJC MA Agonist DM1ERJC RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM1ERJC RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM1ESMZ DI DM1ESMZ DM1ESMZ DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 DM1ESMZ TI TT27RFC DM1ESMZ TN Opioid receptor delta (OPRD1) DM1ESMZ MA Inhibitor DM1ESMZ RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM1ESMZ RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM1ESMZ DI DM1ESMZ DM1ESMZ DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 DM1ESMZ TI TTZPO1L DM1ESMZ TN Substance-P receptor (TACR1) DM1ESMZ MA Inhibitor DM1ESMZ RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM1ESMZ RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM1ESMZ DI DM1ESMZ DM1ESMZ DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 DM1ESMZ TI TTKWM86 DM1ESMZ TN Opioid receptor mu (MOP) DM1ESMZ MA Inhibitor DM1ESMZ RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM1ESMZ RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TTEYTKG DM1ESVR TN Carbonic anhydrase XIV (CA-XIV) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TTCFSPE DM1ESVR TN Carbonic anhydrase VI (CA-VI) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TT2LVK8 DM1ESVR TN Carbonic anhydrase IX (CA-IX) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TTSYM0R DM1ESVR TN Carbonic anhydrase XII (CA-XII) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TTANPDJ DM1ESVR TN Carbonic anhydrase II (CA-II) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TTZHA0O DM1ESVR TN Carbonic anhydrase IV (CA-IV) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TTUNARX DM1ESVR TN Carbonic anhydrase (CA) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ESVR DI DM1ESVR DM1ESVR DN Decane-1,10-diyl disulfamate DM1ESVR TI TTHQPL7 DM1ESVR TN Carbonic anhydrase I (CA-I) DM1ESVR MA Inhibitor DM1ESVR RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM1ESVR RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM1ETX5 DI DM1ETX5 DM1ETX5 DN NSC-745794 DM1ETX5 TI TTQY2EJ DM1ETX5 TN TERT messenger RNA (TERT mRNA) DM1ETX5 MA Inhibitor DM1ETX5 RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DM1ETX5 RU https://pubmed.ncbi.nlm.nih.gov/19804981 DM1EZ3N DI DM1EZ3N DM1EZ3N DN Namn DM1EZ3N TI TTH29K0 DM1EZ3N TN Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC) DM1EZ3N MA Inhibitor DM1EZ3N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1EZ3N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1F2K0 DI DM1F2K0 DM1F2K0 DN Triazolopyridine DM1F2K0 TI TTQBR95 DM1F2K0 TN Stress-activated protein kinase 2a (p38 alpha) DM1F2K0 MA Inhibitor DM1F2K0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM1F2K0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM1F4TN DI DM1F4TN DM1F4TN DN 2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline DM1F4TN TI TTNJYV2 DM1F4TN TN Gamma-aminobutyric acid receptor (GAR) DM1F4TN MA Inhibitor DM1F4TN RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DM1F4TN RU https://pubmed.ncbi.nlm.nih.gov/8709114 DM1F4TN DI DM1F4TN DM1F4TN DN 2-Isoxazol-3-yl-3H-imidazo[4,5-c]quinoline DM1F4TN TI TT1MPAY DM1F4TN TN GABA(A) receptor alpha-1 (GABRA1) DM1F4TN MA Inhibitor DM1F4TN RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DM1F4TN RU https://pubmed.ncbi.nlm.nih.gov/8709114 DM1F53L DI DM1F53L DM1F53L DN Indol-1-yl-pyridin-4-yl-amine DM1F53L TI TT2NUT5 DM1F53L TN Adrenergic receptor alpha-2C (ADRA2C) DM1F53L MA Inhibitor DM1F53L RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM1F53L RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM1F53L DI DM1F53L DM1F53L DN Indol-1-yl-pyridin-4-yl-amine DM1F53L TI TTWG9A4 DM1F53L TN Adrenergic receptor alpha-2A (ADRA2A) DM1F53L MA Inhibitor DM1F53L RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM1F53L RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM1F53L DI DM1F53L DM1F53L DN Indol-1-yl-pyridin-4-yl-amine DM1F53L TI TTWM4TY DM1F53L TN Adrenergic receptor alpha-2B (ADRA2B) DM1F53L MA Inhibitor DM1F53L RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM1F53L RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM1F7I5 DI DM1F7I5 DM1F7I5 DN Cyclohexyl-(9-ethyl-9H-purin-6-yl)-amine DM1F7I5 TI TTK25J1 DM1F7I5 TN Adenosine A1 receptor (ADORA1) DM1F7I5 MA Inhibitor DM1F7I5 RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DM1F7I5 RU https://pubmed.ncbi.nlm.nih.gov/1895305 DM1FEVB DI DM1FEVB DM1FEVB DN MF-8623 DM1FEVB TI TTEB0GD DM1FEVB TN Cholinesterase (BCHE) DM1FEVB MA Inhibitor DM1FEVB RN A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17(3):159-65. DM1FEVB RU https://pubmed.ncbi.nlm.nih.gov/11900310 DM1FL5G DI DM1FL5G DM1FL5G DN 7-Phenoxy-heptanoic acid hydroxyamide DM1FL5G TI TT6R7JZ DM1FL5G TN Histone deacetylase 1 (HDAC1) DM1FL5G MA Inhibitor DM1FL5G RN A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. DM1FL5G RU https://pubmed.ncbi.nlm.nih.gov/14552787 DM1FL5G DI DM1FL5G DM1FL5G DN 7-Phenoxy-heptanoic acid hydroxyamide DM1FL5G TI TTSHTOI DM1FL5G TN Histone deacetylase 2 (HDAC2) DM1FL5G MA Inhibitor DM1FL5G RN A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. DM1FL5G RU https://pubmed.ncbi.nlm.nih.gov/14552787 DM1FOIZ DI DM1FOIZ DM1FOIZ DN 3-(2-Diethylamino-propionamino)-rutaecarpine DM1FOIZ TI TT1RS9F DM1FOIZ TN Acetylcholinesterase (AChE) DM1FOIZ MA Inhibitor DM1FOIZ RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DM1FOIZ RU https://pubmed.ncbi.nlm.nih.gov/20079560 DM1FOIZ DI DM1FOIZ DM1FOIZ DN 3-(2-Diethylamino-propionamino)-rutaecarpine DM1FOIZ TI TTEB0GD DM1FOIZ TN Cholinesterase (BCHE) DM1FOIZ MA Inhibitor DM1FOIZ RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DM1FOIZ RU https://pubmed.ncbi.nlm.nih.gov/20079560 DM1FOSP DI DM1FOSP DM1FOSP DN NCX-1047 DM1FOSP TI TTPNQAC DM1FOSP TN Estrogen-related receptor-alpha (ESRRA) DM1FOSP MA Modulator DM1FOSP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DM1FOSP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DM1FSZM DI DM1FSZM DM1FSZM DN 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline DM1FSZM TI TT8FYO9 DM1FSZM TN Platelet-derived growth factor receptor alpha (PDGFRA) DM1FSZM MA Inhibitor DM1FSZM RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM1FSZM RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM1FSZM DI DM1FSZM DM1FSZM DN 3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline DM1FSZM TI TTI7421 DM1FSZM TN Platelet-derived growth factor receptor beta (PDGFRB) DM1FSZM MA Inhibitor DM1FSZM RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM1FSZM RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM1FX7N DI DM1FX7N DM1FX7N DN ISIS 138616 DM1FX7N TI TTTEOPU DM1FX7N TN Helicase-moi messenger RNA (DICER1 mRNA) DM1FX7N RN US patent application no. 7,427,470, Antisense modulation of helicase-moi expression. DM1FX7N RU http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true DM1G4S9 DI DM1G4S9 DM1G4S9 DN Sodium Phosphate, Dibasic, Anhydrous DM1G4S9 TI TTZHA0O DM1G4S9 TN Carbonic anhydrase IV (CA-IV) DM1G4S9 MA Inhibitor DM1G4S9 RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7. DM1G4S9 RU https://pubmed.ncbi.nlm.nih.gov/15501037 DM1G7P9 DI DM1G7P9 DM1G7P9 DN 6-{[(CYCLOHEXYLAMINO)CARBONYL]AMINO}HEXANOIC ACID DM1G7P9 TI TT7WVHI DM1G7P9 TN Soluble epoxide hydrolase (EPHX2) DM1G7P9 MA Inhibitor DM1G7P9 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM1G7P9 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM1GBX8 DI DM1GBX8 DM1GBX8 DN (S)-2-amino-3-cyclohexylpropanoic acid DM1GBX8 TI TTFK1JQ DM1GBX8 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM1GBX8 MA Inhibitor DM1GBX8 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DM1GBX8 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DM1GCV3 DI DM1GCV3 DM1GCV3 DN (R)-2-(4-Benzylphenoxymethyl)pyrrolidine DM1GCV3 TI TTXZEAJ DM1GCV3 TN Leukotriene A-4 hydrolase (LTA4H) DM1GCV3 MA Inhibitor DM1GCV3 RN Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85. DM1GCV3 RU https://pubmed.ncbi.nlm.nih.gov/19950900 DM1GJX8 DI DM1GJX8 DM1GJX8 DN Xanthosine-5'-monophosphate disodium salt DM1GJX8 TI TTV7Y40 DM1GJX8 TN Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF) DM1GJX8 MA Inhibitor DM1GJX8 RN Structural diversity and plasticity associated with nucleotides targeting orotidine monophosphate decarboxylase. J Med Chem. 2008 Feb 14;51(3):432-8. DM1GJX8 RU https://pubmed.ncbi.nlm.nih.gov/18181562 DM1GRWY DI DM1GRWY DM1GRWY DN 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol DM1GRWY TI TT27RFC DM1GRWY TN Opioid receptor delta (OPRD1) DM1GRWY MA Inhibitor DM1GRWY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM1GRWY RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM1GRWY DI DM1GRWY DM1GRWY DN 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol DM1GRWY TI TTQW87Y DM1GRWY TN Opioid receptor kappa (OPRK1) DM1GRWY MA Inhibitor DM1GRWY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM1GRWY RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM1GRWY DI DM1GRWY DM1GRWY DN 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol DM1GRWY TI TTKWM86 DM1GRWY TN Opioid receptor mu (MOP) DM1GRWY MA Inhibitor DM1GRWY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM1GRWY RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM1GRWY DI DM1GRWY DM1GRWY DN 4-phenyl-1-(1-phenylhexyl)piperidin-4-ol DM1GRWY TI TTNT7K8 DM1GRWY TN Nociceptin receptor (OPRL1) DM1GRWY MA Inhibitor DM1GRWY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM1GRWY RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM1GTVW DI DM1GTVW DM1GTVW DN N-cyclobutyl-N-(piperidin-4-yl)-2-naphthamide DM1GTVW TI TT3ROYC DM1GTVW TN Serotonin transporter (SERT) DM1GTVW MA Inhibitor DM1GTVW RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DM1GTVW RU https://pubmed.ncbi.nlm.nih.gov/19740658 DM1GUTC DI DM1GUTC DM1GUTC DN MRS5151 DM1GUTC TI TTJFY5U DM1GUTC TN Adenosine A3 receptor (ADORA3) DM1GUTC MA Agonist DM1GUTC RN Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9. DM1GUTC RU https://pubmed.ncbi.nlm.nih.gov/18424135 DM1GUTC DI DM1GUTC DM1GUTC DN MRS5151 DM1GUTC TI TTK25J1 DM1GUTC TN Adenosine A1 receptor (ADORA1) DM1GUTC MA Agonist DM1GUTC RN Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9. DM1GUTC RU https://pubmed.ncbi.nlm.nih.gov/18424135 DM1GUTC DI DM1GUTC DM1GUTC DN MRS5151 DM1GUTC TI TTNE7KG DM1GUTC TN Adenosine A2b receptor (ADORA2B) DM1GUTC MA Agonist DM1GUTC RN Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. Bioorg Med Chem Lett. 2008 May 1;18(9):2813-9. DM1GUTC RU https://pubmed.ncbi.nlm.nih.gov/18424135 DM1GV7K DI DM1GV7K DM1GV7K DN Pomolic acid DM1GV7K TI TTELIN2 DM1GV7K TN PTPN1 messenger RNA (PTPN1 mRNA) DM1GV7K MA Inhibitor DM1GV7K RN Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8. DM1GV7K RU https://pubmed.ncbi.nlm.nih.gov/18798681 DM1GVE8 DI DM1GVE8 DM1GVE8 DN 3-(4-(4-hydroxyphenyl)phthalazin-1-ylamino)phenol DM1GVE8 TI TTXWASR DM1GVE8 TN Intestinal maltase-glucoamylase (MGAM) DM1GVE8 MA Inhibitor DM1GVE8 RN Discovery of novel alpha-glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure. Bioorg Med Chem. 2008 Jan 1;16(1):284-92. DM1GVE8 RU https://pubmed.ncbi.nlm.nih.gov/17920282 DM1H3FJ DI DM1H3FJ DM1H3FJ DN A 137491 DM1H3FJ TI TTQL5VC DM1H3FJ TN Platelet-activating factor receptor (PTAFR) DM1H3FJ MA Modulator DM1H3FJ RN The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. DM1H3FJ RU https://pubmed.ncbi.nlm.nih.gov/9435164 DM1H428 DI DM1H428 DM1H428 DN ISIS 114390 DM1H428 TI TT8OY02 DM1H428 TN ARA70 messenger RNA (NCOA4 mRNA) DM1H428 RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DM1H428 RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DM1H5DL DI DM1H5DL DM1H5DL DN VU0469650 DM1H5DL TI TTVBPDM DM1H5DL TN Metabotropic glutamate receptor 1 (mGluR1) DM1H5DL MA Modulator (allosteric modulator) DM1H5DL RN N-Acyl-N'-arylpiperazines as negative allosteric modulators of mGlu1: identification of VU0469650, a potent and selective tool compound with CNS exposure in rats. Bioorg Med Chem Lett. 2013 Jul 1;23(13):3713-8. DM1H5DL RU https://pubmed.ncbi.nlm.nih.gov/23727046 DM1H5TO DI DM1H5TO DM1H5TO DN KKHT-10613 DM1H5TO TI TT729IR DM1H5TO TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM1H5TO MA Inhibitor DM1H5TO RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DM1H5TO RU https://pubmed.ncbi.nlm.nih.gov/17035033 DM1H865 DI DM1H865 DM1H865 DN ZL-N-91 DM1H865 TI TTZ97H5 DM1H865 TN Phosphodiesterase 4A (PDE4A) DM1H865 MA Inhibitor DM1H865 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DM1H865 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DM1H865 DI DM1H865 DM1H865 DN ZL-N-91 DM1H865 TI TTVIAT9 DM1H865 TN Phosphodiesterase 4B (PDE4B) DM1H865 MA Modulator DM1H865 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DM1H865 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DM1H865 DI DM1H865 DM1H865 DN ZL-N-91 DM1H865 TI TTSKMI8 DM1H865 TN Phosphodiesterase 4D (PDE4D) DM1H865 MA Modulator DM1H865 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DM1H865 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DM1HABS DI DM1HABS DM1HABS DN 2-tolyl-6-phenyl-9H-purine DM1HABS TI TTJFY5U DM1HABS TN Adenosine A3 receptor (ADORA3) DM1HABS MA Inhibitor DM1HABS RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM1HABS RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM1HABS DI DM1HABS DM1HABS DN 2-tolyl-6-phenyl-9H-purine DM1HABS TI TTM2AOE DM1HABS TN Adenosine A2a receptor (ADORA2A) DM1HABS MA Inhibitor DM1HABS RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM1HABS RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM1HABS DI DM1HABS DM1HABS DN 2-tolyl-6-phenyl-9H-purine DM1HABS TI TTK25J1 DM1HABS TN Adenosine A1 receptor (ADORA1) DM1HABS MA Inhibitor DM1HABS RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM1HABS RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM1HAD0 DI DM1HAD0 DM1HAD0 DN S24773 DM1HAD0 TI TT0WAIE DM1HAD0 TN Melatonin receptor type 1A (MTNR1A) DM1HAD0 MA Agonist DM1HAD0 RN New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. DM1HAD0 RU https://pubmed.ncbi.nlm.nih.gov/12764576 DM1HAWR DI DM1HAWR DM1HAWR DN 6-(4-Methyl-piperazin-1-yl)-phenanthridine DM1HAWR TI TTPC4TU DM1HAWR TN 5-HT 3A receptor (HTR3A) DM1HAWR MA Inhibitor DM1HAWR RN Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75. DM1HAWR RU https://pubmed.ncbi.nlm.nih.gov/10229626 DM1HAWR DI DM1HAWR DM1HAWR DN 6-(4-Methyl-piperazin-1-yl)-phenanthridine DM1HAWR TI TTR6K75 DM1HAWR TN 5-HT 3B receptor (HTR3B) DM1HAWR MA Inhibitor DM1HAWR RN Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75. DM1HAWR RU https://pubmed.ncbi.nlm.nih.gov/10229626 DM1HBF5 DI DM1HBF5 DM1HBF5 DN BMS-812204 DM1HBF5 TI TT6OEDT DM1HBF5 TN Cannabinoid receptor 1 (CB1) DM1HBF5 MA Antagonist DM1HBF5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56). DM1HBF5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56 DM1HM3F DI DM1HM3F DM1HM3F DN 4-(piperazin-1-yl)-3-tosyl-1H-indazole DM1HM3F TI TTJS8PY DM1HM3F TN 5-HT 6 receptor (HTR6) DM1HM3F MA Inhibitor DM1HM3F RN 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46. DM1HM3F RU https://pubmed.ncbi.nlm.nih.gov/20932009 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TT57MT2 DM1HMJ5 TN PKC-epsilon messenger RNA (PRKCE mRNA) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TT7A1BO DM1HMJ5 TN PKC-delta messenger RNA (PRKCD mRNA) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TT9WJ8U DM1HMJ5 TN Protein kinase C delta (PRKCD) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TTONI0R DM1HMJ5 TN PKC-eta messenger RNA (PRKCH mRNA) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TTRFOXJ DM1HMJ5 TN Protein kinase C gamma (PRKCG) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TT1MS7X DM1HMJ5 TN PKC-theta messenger RNA (PRKCQ mRNA) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TTYPXQF DM1HMJ5 TN Protein kinase C beta (PRKCB) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMJ5 DI DM1HMJ5 DM1HMJ5 DN PROSTRATIN DM1HMJ5 TI TTFJ8Q1 DM1HMJ5 TN Protein kinase C alpha (PRKCA) DM1HMJ5 MA Inhibitor DM1HMJ5 RN A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86. DM1HMJ5 RU https://pubmed.ncbi.nlm.nih.gov/1597853 DM1HMWA DI DM1HMWA DM1HMWA DN 2'-Deoxyuridine DM1HMWA TI TTU6BFZ DM1HMWA TN Candida Thymidylate synthase (Candi TMP1) DM1HMWA MA Inhibitor DM1HMWA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1HMWA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1HMWA DI DM1HMWA DM1HMWA DN 2'-Deoxyuridine DM1HMWA TI TTP3QRF DM1HMWA TN Thymidine kinase 1 (TK1) DM1HMWA MA Inhibitor DM1HMWA RN Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes. J Med Chem. 1982 Jun;25(6):644-9. DM1HMWA RU https://pubmed.ncbi.nlm.nih.gov/7097717 DM1HQ3D DI DM1HQ3D DM1HQ3D DN [Sar1,Bpa2]AngII DM1HQ3D TI TT8DBY3 DM1HQ3D TN Angiotensin II receptor type-1 (AGTR1) DM1HQ3D MA Inhibitor DM1HQ3D RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DM1HQ3D RU https://pubmed.ncbi.nlm.nih.gov/20146480 DM1I0AN DI DM1I0AN DM1I0AN DN GSK575594A DM1I0AN TI TTNET8J DM1I0AN TN G-protein coupled receptor 55 (GPR55) DM1I0AN MA Agonist DM1I0AN RN Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46. DM1I0AN RU https://pubmed.ncbi.nlm.nih.gov/21233197 DM1I0TA DI DM1I0TA DM1I0TA DN 4-(methyl(octyl)amino)-N-(quinolin-3-yl)benzamide DM1I0TA TI TTMI6F5 DM1I0TA TN Transient receptor potential cation channel V1 (TRPV1) DM1I0TA MA Inhibitor DM1I0TA RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DM1I0TA RU https://pubmed.ncbi.nlm.nih.gov/18359227 DM1I25F DI DM1I25F DM1I25F DN 8-Pyridin-4-yl-9H-purine-2,6-diamine DM1I25F TI TT9SL3Q DM1I25F TN Polypeptide deformylase (PDF) DM1I25F MA Inhibitor DM1I25F RN Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneum... J Med Chem. 1997 Sep 12;40(19):3032-9. DM1I25F RU https://pubmed.ncbi.nlm.nih.gov/9301665 DM1I578 DI DM1I578 DM1I578 DN PMID9003518C3 DM1I578 TI TT7O8ZA DM1I578 TN Lanosterol synthase (LSS) DM1I578 MA Inhibitor DM1I578 RN Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9. DM1I578 RU https://pubmed.ncbi.nlm.nih.gov/9003518 DM1I6AY DI DM1I6AY DM1I6AY DN PMID18334293C15b DM1I6AY TI TTFYL58 DM1I6AY TN CaM-kinase II (CAMK2) DM1I6AY MA Inhibitor DM1I6AY RN Pyrimidine-based inhibitors of CaMKIIdelta. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2404-8. DM1I6AY RU https://pubmed.ncbi.nlm.nih.gov/18334293 DM1I6SO DI DM1I6SO DM1I6SO DN 2-(3,4,5-Trihydroxy-benzylidene)-malononitrile DM1I6SO TI TT860QF DM1I6SO TN LCK tyrosine protein kinase (LCK) DM1I6SO MA Inhibitor DM1I6SO RN Tyrphostins. 3. Structure-activity relationship studies of alpha-substituted benzylidenemalononitrile 5-S-aryltyrphostins. J Med Chem. 1993 Nov 12;36(23):3556-64. DM1I6SO RU https://pubmed.ncbi.nlm.nih.gov/7902440 DM1I8LU DI DM1I8LU DM1I8LU DN Coenzyme A DM1I8LU TI TTSEOPJ DM1I8LU TN Bacterial Pantothenate kinase (Bact coaA) DM1I8LU MA Inhibitor DM1I8LU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1I8LU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1I8LU DI DM1I8LU DM1I8LU DN Coenzyme A DM1I8LU TI TTPADOQ DM1I8LU TN HMG-CoA reductase (HMGCR) DM1I8LU MA Inhibitor DM1I8LU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1I8LU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1I8LU DI DM1I8LU DM1I8LU DN Coenzyme A DM1I8LU TI TT8HWCD DM1I8LU TN Staphylococcus DHNA-CoA synthase (Stap-coc menB) DM1I8LU MA Inhibitor DM1I8LU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1I8LU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1I8LU DI DM1I8LU DM1I8LU DN Coenzyme A DM1I8LU TI TT4YO0Z DM1I8LU TN Phosphopantetheine adenylyltransferase (PPAT) DM1I8LU MA Inhibitor DM1I8LU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1I8LU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1I8LU DI DM1I8LU DM1I8LU DN Coenzyme A DM1I8LU TI TTC8M31 DM1I8LU TN Carnitine acyltransferase (CRAT) DM1I8LU MA Inhibitor DM1I8LU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1I8LU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1I9LQ DI DM1I9LQ DM1I9LQ DN 2-(N-Pyrrolidinyl)-3'-nitropropiophenone DM1I9LQ TI TTVBI8W DM1I9LQ TN Dopamine transporter (DAT) DM1I9LQ MA Inhibitor DM1I9LQ RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM1I9LQ RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM1I9LQ DI DM1I9LQ DM1I9LQ DN 2-(N-Pyrrolidinyl)-3'-nitropropiophenone DM1I9LQ TI TTAWNKZ DM1I9LQ TN Norepinephrine transporter (NET) DM1I9LQ MA Inhibitor DM1I9LQ RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM1I9LQ RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM1IC54 DI DM1IC54 DM1IC54 DN ISIS 150464 DM1IC54 TI TTP9K3Q DM1IC54 TN SOD1 messenger RNA (SOD1 mRNA) DM1IC54 RN US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. DM1IC54 RU http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true DM1ICOW DI DM1ICOW DM1ICOW DN mab 224G11 DM1ICOW TI TTNDSF4 DM1ICOW TN Proto-oncogene c-Met (MET) DM1ICOW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM1ICOW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM1IGOD DI DM1IGOD DM1IGOD DN 5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid DM1IGOD TI TTE2KUJ DM1IGOD TN Adenosylhomocysteinase (AHCY) DM1IGOD MA Inhibitor DM1IGOD RN Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogues with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl u... Bioorg Med Chem. 2008 May 15;16(10):5424-33. DM1IGOD RU https://pubmed.ncbi.nlm.nih.gov/18457953 DM1IHCV DI DM1IHCV DM1IHCV DN 4-Amino-3-benzofuran-2-yl-butyric acid DM1IHCV TI TTDCVZW DM1IHCV TN Gamma-aminobutyric acid B receptor (GABBR) DM1IHCV MA Inhibitor DM1IHCV RN Synthesis and pharmacological evaluation of gamma-aminobutyric acid analogues. New ligand for GABAB sites. J Med Chem. 1987 Apr;30(4):743-6. DM1IHCV RU https://pubmed.ncbi.nlm.nih.gov/3031294 DM1IN35 DI DM1IN35 DM1IN35 DN AZ12216052 DM1IN35 TI TT0IFKL DM1IN35 TN Metabotropic glutamate receptor 8 (mGluR8) DM1IN35 MA Modulator (allosteric modulator) DM1IN35 RN Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav Brain Res. 2010 Oct 15;212(2):168-73. DM1IN35 RU https://pubmed.ncbi.nlm.nih.gov/20385173 DM1ISJU DI DM1ISJU DM1ISJU DN PMID12470711C3 DM1ISJU TI TTVBPDM DM1ISJU TN Metabotropic glutamate receptor 1 (mGluR1) DM1ISJU MA Modulator (allosteric modulator) DM1ISJU RN Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg Med Chem. 2003 Jan 17;11(2):171-83. DM1ISJU RU https://pubmed.ncbi.nlm.nih.gov/12470711 DM1ITJ5 DI DM1ITJ5 DM1ITJ5 DN Decyltrimethylammonium DM1ITJ5 TI TTT1MCF DM1ITJ5 TN Permeability pathway (NP pathway) DM1ITJ5 MA Inhibitor DM1ITJ5 RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DM1ITJ5 RU https://pubmed.ncbi.nlm.nih.gov/18298458 DM1IXOG DI DM1IXOG DM1IXOG DN Boc-D-Glu-Tyr(SO3H)-Nle-D-Nle-Trp-Nle-Asp-Phe-NH2 DM1IXOG TI TTCG0AL DM1IXOG TN Cholecystokinin receptor type A (CCKAR) DM1IXOG MA Inhibitor DM1IXOG RN Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90. DM1IXOG RU https://pubmed.ncbi.nlm.nih.gov/2724293 DM1IZA7 DI DM1IZA7 DM1IZA7 DN Benzimidazole DM1IZA7 TI TTSBVFO DM1IZA7 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM1IZA7 MA Inhibitor DM1IZA7 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DM1IZA7 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DM1J46S DI DM1J46S DM1J46S DN AMG-9090 DM1J46S TI TTELV3W DM1J46S TN Transformation-sensitive protein p120 (TRPA1) DM1J46S MA Inhibitor DM1J46S RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DM1J46S RU https://pubmed.ncbi.nlm.nih.gov/20356305 DM1J4MT DI DM1J4MT DM1J4MT DN 2-(3-Methyl-piperazin-1-yl)-6-nitro-quinoline DM1J4MT TI TT3ROYC DM1J4MT TN Serotonin transporter (SERT) DM1J4MT MA Inhibitor DM1J4MT RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DM1J4MT RU https://pubmed.ncbi.nlm.nih.gov/10915050 DM1JGDM DI DM1JGDM DM1JGDM DN Lpc-Ether DM1JGDM TI TT9V5JH DM1JGDM TN Phospholipase A2 (PLA2G1B) DM1JGDM MA Inhibitor DM1JGDM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1JGDM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1JIVR DI DM1JIVR DM1JIVR DN AL6528 DM1JIVR TI TTANPDJ DM1JIVR TN Carbonic anhydrase II (CA-II) DM1JIVR MA Inhibitor DM1JIVR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1JIVR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1JKWL DI DM1JKWL DM1JKWL DN 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide DM1JKWL TI TTHQPL7 DM1JKWL TN Carbonic anhydrase I (CA-I) DM1JKWL MA Inhibitor DM1JKWL RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DM1JKWL RU https://pubmed.ncbi.nlm.nih.gov/17276072 DM1JKWL DI DM1JKWL DM1JKWL DN 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide DM1JKWL TI TTANPDJ DM1JKWL TN Carbonic anhydrase II (CA-II) DM1JKWL MA Inhibitor DM1JKWL RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DM1JKWL RU https://pubmed.ncbi.nlm.nih.gov/17276072 DM1JKWL DI DM1JKWL DM1JKWL DN 2-(4-chlorobenzyloxyamino)-N-hydroxyacetamide DM1JKWL TI TT2LVK8 DM1JKWL TN Carbonic anhydrase IX (CA-IX) DM1JKWL MA Inhibitor DM1JKWL RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DM1JKWL RU https://pubmed.ncbi.nlm.nih.gov/17276072 DM1JL03 DI DM1JL03 DM1JL03 DN 4-(2-Phenylacetamidoethyl)benzenesulfonamide DM1JL03 TI TTANPDJ DM1JL03 TN Carbonic anhydrase II (CA-II) DM1JL03 MA Inhibitor DM1JL03 RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM1JL03 RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM1JL03 DI DM1JL03 DM1JL03 DN 4-(2-Phenylacetamidoethyl)benzenesulfonamide DM1JL03 TI TTUNARX DM1JL03 TN Carbonic anhydrase (CA) DM1JL03 MA Inhibitor DM1JL03 RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM1JL03 RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM1JL03 DI DM1JL03 DM1JL03 DN 4-(2-Phenylacetamidoethyl)benzenesulfonamide DM1JL03 TI TTHQPL7 DM1JL03 TN Carbonic anhydrase I (CA-I) DM1JL03 MA Inhibitor DM1JL03 RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM1JL03 RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM1JL5W DI DM1JL5W DM1JL5W DN D-Trp8-SRIF-14 DM1JL5W TI TTAE1BR DM1JL5W TN Somatostatin receptor type 4 (SSTR4) DM1JL5W MA Inhibitor DM1JL5W RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DM1JL5W RU https://pubmed.ncbi.nlm.nih.gov/15943475 DM1JLUV DI DM1JLUV DM1JLUV DN 10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one DM1JLUV TI TT84ETX DM1JLUV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1JLUV MA Inhibitor DM1JLUV RN Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97. DM1JLUV RU https://pubmed.ncbi.nlm.nih.gov/1375293 DM1JQPW DI DM1JQPW DM1JQPW DN 1-[(cyclohexylamino)ethyl]-1,1-bisphosphonicacid DM1JQPW TI TTIKWV4 DM1JQPW TN Geranyltranstransferase (FDPS) DM1JQPW MA Inhibitor DM1JQPW RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DM1JQPW RU https://pubmed.ncbi.nlm.nih.gov/18096393 DM1JRGI DI DM1JRGI DM1JRGI DN PMID18754614C10 DM1JRGI TI TTFQEO5 DM1JRGI TN Squalene synthetase (FDFT1) DM1JRGI MA Inhibitor DM1JRGI RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DM1JRGI RU https://pubmed.ncbi.nlm.nih.gov/18754614 DM1JU8F DI DM1JU8F DM1JU8F DN KYS-05040 DM1JU8F TI TT729IR DM1JU8F TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM1JU8F MA Inhibitor DM1JU8F RN 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84. DM1JU8F RU https://pubmed.ncbi.nlm.nih.gov/15177437 DM1JU8F DI DM1JU8F DM1JU8F DN KYS-05040 DM1JU8F TI TTZPWGN DM1JU8F TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DM1JU8F MA Inhibitor DM1JU8F RN 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84. DM1JU8F RU https://pubmed.ncbi.nlm.nih.gov/15177437 DM1JWGH DI DM1JWGH DM1JWGH DN Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS) DM1JWGH TI TTYVI76 DM1JWGH TN Fungal Protein kinase A (Fung ypkA) DM1JWGH MA Inhibitor DM1JWGH RN Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4. DM1JWGH RU https://pubmed.ncbi.nlm.nih.gov/12492305 DM1K0E2 DI DM1K0E2 DM1K0E2 DN 6-Acetyl-7-hydroxy-2H-chromen-2-one DM1K0E2 TI TT2LVK8 DM1K0E2 TN Carbonic anhydrase IX (CA-IX) DM1K0E2 MA Inhibitor DM1K0E2 RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DM1K0E2 RU https://pubmed.ncbi.nlm.nih.gov/21067924 DM1K0U5 DI DM1K0U5 DM1K0U5 DN 2-(2-Phenyl-1H-indol-3-yl)-N,N-dipropyl-acetamide DM1K0U5 TI TTPTXIN DM1K0U5 TN Translocator protein (TSPO) DM1K0U5 MA Inhibitor DM1K0U5 RN Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20. DM1K0U5 RU https://pubmed.ncbi.nlm.nih.gov/8411007 DM1K2A4 DI DM1K2A4 DM1K2A4 DN N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine DM1K2A4 TI TTK25J1 DM1K2A4 TN Adenosine A1 receptor (ADORA1) DM1K2A4 MA Inhibitor DM1K2A4 RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM1K2A4 RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM1K2A4 DI DM1K2A4 DM1K2A4 DN N*6*-Cyclohexyl-N*2*-ethyl-9H-purine-2,6-diamine DM1K2A4 TI TTJFY5U DM1K2A4 TN Adenosine A3 receptor (ADORA3) DM1K2A4 MA Inhibitor DM1K2A4 RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM1K2A4 RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM1K5E2 DI DM1K5E2 DM1K5E2 DN MRS1086 DM1K5E2 TI TTK25J1 DM1K5E2 TN Adenosine A1 receptor (ADORA1) DM1K5E2 MA Antagonist DM1K5E2 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM1K5E2 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM1K5E2 DI DM1K5E2 DM1K5E2 DN MRS1086 DM1K5E2 TI TTNE7KG DM1K5E2 TN Adenosine A2b receptor (ADORA2B) DM1K5E2 MA Antagonist DM1K5E2 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM1K5E2 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM1K64F DI DM1K64F DM1K64F DN N-CPM[D-Pro-10]Dyn A-(1-11) DM1K64F TI TTQW87Y DM1K64F TN Opioid receptor kappa (OPRK1) DM1K64F MA Inhibitor DM1K64F RN Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9. DM1K64F RU https://pubmed.ncbi.nlm.nih.gov/9276018 DM1K6DX DI DM1K6DX DM1K6DX DN ISIS 3304 DM1K6DX TI TT6HV2K DM1K6DX TN Influenza PB1 messenger RNA (Influ PB1 mRNA) DM1K6DX RN US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides. DM1K6DX RU http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true DM1KA9R DI DM1KA9R DM1KA9R DN N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine DM1KA9R TI TTK25J1 DM1KA9R TN Adenosine A1 receptor (ADORA1) DM1KA9R MA Inhibitor DM1KA9R RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM1KA9R RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM1KA9R DI DM1KA9R DM1KA9R DN N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine DM1KA9R TI TTJFY5U DM1KA9R TN Adenosine A3 receptor (ADORA3) DM1KA9R MA Inhibitor DM1KA9R RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM1KA9R RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM1KCHN DI DM1KCHN DM1KCHN DN LY256548 DM1KCHN TI TT9V5JH DM1KCHN TN Phospholipase A2 (PLA2G1B) DM1KCHN MA Binder DM1KCHN RN The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. DM1KCHN RU https://pubmed.ncbi.nlm.nih.gov/2508442 DM1KCUV DI DM1KCUV DM1KCUV DN 2-(3''-(benzotriazole-1''-yl)ethyloxy)adenosine DM1KCUV TI TTJFY5U DM1KCUV TN Adenosine A3 receptor (ADORA3) DM1KCUV MA Inhibitor DM1KCUV RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DM1KCUV RU https://pubmed.ncbi.nlm.nih.gov/17378544 DM1KDJV DI DM1KDJV DM1KDJV DN Ac-bhg-F-N-Y-Y-W DM1KDJV TI TT3ZTGU DM1KDJV TN Endothelin B receptor (EDNRB) DM1KDJV MA Inhibitor DM1KDJV RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DM1KDJV RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DM1KDJV DI DM1KDJV DM1KDJV DN Ac-bhg-F-N-Y-Y-W DM1KDJV TI TTKRD0G DM1KDJV TN Endothelin A receptor (EDNRA) DM1KDJV MA Inhibitor DM1KDJV RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DM1KDJV RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DM1KDWE DI DM1KDWE DM1KDWE DN Cbz-Ile-Pro-Ala-LeuVSMe DM1KDWE TI TTUMQVO DM1KDWE TN Cathepsin S (CTSS) DM1KDWE MA Inhibitor DM1KDWE RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DM1KDWE RU https://pubmed.ncbi.nlm.nih.gov/16686537 DM1KJAE DI DM1KJAE DM1KJAE DN Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE TI TTJX3UE DM1KJAE TN Somatostatin receptor type 3 (SSTR3) DM1KJAE MA Inhibitor DM1KJAE RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DM1KJAE RU https://pubmed.ncbi.nlm.nih.gov/15658865 DM1KJAE DI DM1KJAE DM1KJAE DN Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE TI TT2BC4G DM1KJAE TN Somatostatin receptor type 5 (SSTR5) DM1KJAE MA Inhibitor DM1KJAE RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DM1KJAE RU https://pubmed.ncbi.nlm.nih.gov/15658865 DM1KJAE DI DM1KJAE DM1KJAE DN Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE TI TTAE1BR DM1KJAE TN Somatostatin receptor type 4 (SSTR4) DM1KJAE MA Inhibitor DM1KJAE RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DM1KJAE RU https://pubmed.ncbi.nlm.nih.gov/15658865 DM1KJAE DI DM1KJAE DM1KJAE DN Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE TI TTZ6T9E DM1KJAE TN Somatostatin receptor type 2 (SSTR2) DM1KJAE MA Inhibitor DM1KJAE RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DM1KJAE RU https://pubmed.ncbi.nlm.nih.gov/15658865 DM1KJAE DI DM1KJAE DM1KJAE DN Des-AA1,2,5,12,13-[D-Trp8]SRIF DM1KJAE TI TTIND6G DM1KJAE TN Somatostatin receptor type 1 (SSTR1) DM1KJAE MA Inhibitor DM1KJAE RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DM1KJAE RU https://pubmed.ncbi.nlm.nih.gov/15658865 DM1KND6 DI DM1KND6 DM1KND6 DN 1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one DM1KND6 TI TT1MPAY DM1KND6 TN GABA(A) receptor alpha-1 (GABRA1) DM1KND6 MA Inhibitor DM1KND6 RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DM1KND6 RU https://pubmed.ncbi.nlm.nih.gov/2826782 DM1KND6 DI DM1KND6 DM1KND6 DN 1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one DM1KND6 TI TTNJYV2 DM1KND6 TN Gamma-aminobutyric acid receptor (GAR) DM1KND6 MA Inhibitor DM1KND6 RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DM1KND6 RU https://pubmed.ncbi.nlm.nih.gov/2826782 DM1KND6 DI DM1KND6 DM1KND6 DN 1,3-Diphenyl-1H-chromeno[4,3-c]pyrazol-4-one DM1KND6 TI TT06RH5 DM1KND6 TN GABA(A) receptor gamma-2 (GABRG2) DM1KND6 MA Inhibitor DM1KND6 RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DM1KND6 RU https://pubmed.ncbi.nlm.nih.gov/2826782 DM1KO7U DI DM1KO7U DM1KO7U DN 5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol DM1KO7U TI TTXZEAJ DM1KO7U TN Leukotriene A-4 hydrolase (LTA4H) DM1KO7U MA Inhibitor DM1KO7U RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM1KO7U RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM1KVPG DI DM1KVPG DM1KVPG DN N-(2-amino-5-(pyridin-4-yl)phenyl)benzamide DM1KVPG TI TTSHTOI DM1KVPG TN Histone deacetylase 2 (HDAC2) DM1KVPG MA Inhibitor DM1KVPG RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DM1KVPG RU https://pubmed.ncbi.nlm.nih.gov/20392638 DM1KW0L DI DM1KW0L DM1KW0L DN LY-392098 DM1KW0L TI TTAN6JD DM1KW0L TN Glutamate receptor AMPA (GRIA) DM1KW0L MA Modulator DM1KW0L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4251). DM1KW0L RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4251 DM1L3FM DI DM1L3FM DM1L3FM DN N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide DM1L3FM TI TTBH0VX DM1L3FM TN Histone deacetylase (HDAC) DM1L3FM MA Inhibitor DM1L3FM RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM1L3FM RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM1L3FM DI DM1L3FM DM1L3FM DN N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide DM1L3FM TI TT6R7JZ DM1L3FM TN Histone deacetylase 1 (HDAC1) DM1L3FM MA Inhibitor DM1L3FM RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM1L3FM RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM1L3US DI DM1L3US DM1L3US DN 2-(2,4-dichlorophenoxy)-5-methylphenol DM1L3US TI TTNX2CS DM1L3US TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM1L3US MA Inhibitor DM1L3US RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DM1L3US RU https://pubmed.ncbi.nlm.nih.gov/17567585 DM1L5IJ DI DM1L5IJ DM1L5IJ DN 3 beta-O-acetyloleanolic acid DM1L5IJ TI TT8NGED DM1L5IJ TN Prostaglandin G/H synthase 1 (COX-1) DM1L5IJ MA Inhibitor DM1L5IJ RN Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2. J Nat Prod. 2006 Jun;69(6):887-90. DM1L5IJ RU https://pubmed.ncbi.nlm.nih.gov/16792405 DM1L5IJ DI DM1L5IJ DM1L5IJ DN 3 beta-O-acetyloleanolic acid DM1L5IJ TI TTVKILB DM1L5IJ TN Prostaglandin G/H synthase 2 (COX-2) DM1L5IJ MA Inhibitor DM1L5IJ RN Nitrogen-containing phorbol esters from Croton ciliatoglandulifer and their effects on cyclooxygenases-1 and -2. J Nat Prod. 2006 Jun;69(6):887-90. DM1L5IJ RU https://pubmed.ncbi.nlm.nih.gov/16792405 DM1L7PN DI DM1L7PN DM1L7PN DN 2-Propyl-pentanoic acid 4-sulfamoyl-benzyl ester DM1L7PN TI TTZHA0O DM1L7PN TN Carbonic anhydrase IV (CA-IV) DM1L7PN MA Inhibitor DM1L7PN RN Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20. DM1L7PN RU https://pubmed.ncbi.nlm.nih.gov/11784136 DM1L89K DI DM1L89K DM1L89K DN N1,2-dibenzyl-N3-hydroxy-N1-phenethylmalonamide DM1L89K TI TTPHMWB DM1L89K TN Aminopeptidase N (ANPEP) DM1L89K MA Inhibitor DM1L89K RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DM1L89K RU https://pubmed.ncbi.nlm.nih.gov/17326615 DM1LG27 DI DM1LG27 DM1LG27 DN (E)-3-(2,3-dichlorophenylimino)indolin-2-one DM1LG27 TI TTOPAY7 DM1LG27 TN Galanin receptor (GAL-R) DM1LG27 MA Inhibitor DM1LG27 RN 3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists. J Med Chem. 2006 Jun 29;49(13):3757-8. DM1LG27 RU https://pubmed.ncbi.nlm.nih.gov/16789730 DM1LHD3 DI DM1LHD3 DM1LHD3 DN N-Phenyl-1'H-phenothiazine-1'-carboxamide DM1LHD3 TI TTEB0GD DM1LHD3 TN Cholinesterase (BCHE) DM1LHD3 MA Inhibitor DM1LHD3 RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM1LHD3 RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM1LK0C DI DM1LK0C DM1LK0C DN DSM1 DM1LK0C TI TT3PQ2Y DM1LK0C TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM1LK0C MA Inhibitor DM1LK0C RN Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010 Jun;10(3):226-39. DM1LK0C RU https://pubmed.ncbi.nlm.nih.gov/20334617 DM1LKEP DI DM1LKEP DM1LKEP DN N,N'-(1',2'-ethylene)-bis-(-)-nor-MEP DM1LKEP TI TTEB0GD DM1LKEP TN Cholinesterase (BCHE) DM1LKEP MA Inhibitor DM1LKEP RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DM1LKEP RU https://pubmed.ncbi.nlm.nih.gov/18333606 DM1LMFG DI DM1LMFG DM1LMFG DN FAUC213 DM1LMFG TI TTE0A2F DM1LMFG TN Dopamine D4 receptor (D4R) DM1LMFG MA Agonist DM1LMFG RN Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9. DM1LMFG RU https://pubmed.ncbi.nlm.nih.gov/15448188 DM1LW62 DI DM1LW62 DM1LW62 DN 6-methyl-4-(piperazin-1-yl)furo[2,3-d]pyrimidine DM1LW62 TI TTWJBZ5 DM1LW62 TN 5-HT 2C receptor (HTR2C) DM1LW62 MA Inhibitor DM1LW62 RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DM1LW62 RU https://pubmed.ncbi.nlm.nih.gov/19914063 DM1LWGI DI DM1LWGI DM1LWGI DN ISIS 1831 DM1LWGI TI TTSJ6Q4 DM1LWGI TN LOX-5 messenger RNA (ALOX5 mRNA) DM1LWGI RN US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism. DM1LWGI RU http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true DM1LWMU DI DM1LWMU DM1LWMU DN nahuoic acid A DM1LWMU TI TTGC95K DM1LWMU TN SET domain containing 8 (KMT5A) DM1LWMU MA Inhibitor DM1LWMU RN Nahuoic acid A produced by a Streptomyces sp. isolated from a marine sediment is a selective SAM-competitive inhibitor of the histone methyltransferase SETD8. Org Lett. 2013 Jan 18;15(2):414-7. DM1LWMU RU https://pubmed.ncbi.nlm.nih.gov/23272941 DM1LY0S DI DM1LY0S DM1LY0S DN 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid DM1LY0S TI TTELIN2 DM1LY0S TN PTPN1 messenger RNA (PTPN1 mRNA) DM1LY0S MA Inhibitor DM1LY0S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1LY0S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1M67Q DI DM1M67Q DM1M67Q DN 1-(4-nitrophenyl)-2-(phenylsulfonyl)ethanone DM1M67Q TI TTN7BL9 DM1M67Q TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM1M67Q MA Inhibitor DM1M67Q RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DM1M67Q RU https://pubmed.ncbi.nlm.nih.gov/17490884 DM1MAVU DI DM1MAVU DM1MAVU DN Ada-RYYRIK-NH2 DM1MAVU TI TTNT7K8 DM1MAVU TN Nociceptin receptor (OPRL1) DM1MAVU MA Inhibitor DM1MAVU RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DM1MAVU RU https://pubmed.ncbi.nlm.nih.gov/18068993 DM1MC06 DI DM1MC06 DM1MC06 DN 3,4-Benzo-7-acetonyloxy-8-methoxycoumarin DM1MC06 TI TTGP7BY DM1MC06 TN Monoamine oxidase type B (MAO-B) DM1MC06 MA Inhibitor DM1MC06 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DM1MC06 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DM1MC06 DI DM1MC06 DM1MC06 DN 3,4-Benzo-7-acetonyloxy-8-methoxycoumarin DM1MC06 TI TT3WG5C DM1MC06 TN Monoamine oxidase type A (MAO-A) DM1MC06 MA Inhibitor DM1MC06 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DM1MC06 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DM1MEY3 DI DM1MEY3 DM1MEY3 DN PMID19191557C3 DM1MEY3 TI TTFQEO5 DM1MEY3 TN Squalene synthetase (FDFT1) DM1MEY3 MA Inhibitor DM1MEY3 RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DM1MEY3 RU https://pubmed.ncbi.nlm.nih.gov/19191557 DM1MFTZ DI DM1MFTZ DM1MFTZ DN BETA-CCM DM1MFTZ TI TTZA1NY DM1MFTZ TN GABA(A) receptor beta-2 (GABRB2) DM1MFTZ MA Inhibitor DM1MFTZ RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DM1MFTZ RU https://pubmed.ncbi.nlm.nih.gov/7799410 DM1MFTZ DI DM1MFTZ DM1MFTZ DN BETA-CCM DM1MFTZ TI TTNJYV2 DM1MFTZ TN Gamma-aminobutyric acid receptor (GAR) DM1MFTZ MA Inhibitor DM1MFTZ RN Synthetic routes to 4-amino-3-carboxy-beta-carboline derivatives: incidental formation of novel furo[3,4-c]-beta-carbolin-2-ones displaying high af... J Med Chem. 1995 Jan 6;38(1):189-98. DM1MFTZ RU https://pubmed.ncbi.nlm.nih.gov/7837230 DM1MFTZ DI DM1MFTZ DM1MFTZ DN BETA-CCM DM1MFTZ TI TT06RH5 DM1MFTZ TN GABA(A) receptor gamma-2 (GABRG2) DM1MFTZ MA Inhibitor DM1MFTZ RN beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503. DM1MFTZ RU https://pubmed.ncbi.nlm.nih.gov/6300400 DM1MFTZ DI DM1MFTZ DM1MFTZ DN BETA-CCM DM1MFTZ TI TT1MPAY DM1MFTZ TN GABA(A) receptor alpha-1 (GABRA1) DM1MFTZ MA Inhibitor DM1MFTZ RN Synthetic routes to 4-amino-3-carboxy-beta-carboline derivatives: incidental formation of novel furo[3,4-c]-beta-carbolin-2-ones displaying high af... J Med Chem. 1995 Jan 6;38(1):189-98. DM1MFTZ RU https://pubmed.ncbi.nlm.nih.gov/7837230 DM1MGQ6 DI DM1MGQ6 DM1MGQ6 DN 2-methoxy-4-(m-tolyloxy)benzonitrile DM1MGQ6 TI TTKPW01 DM1MGQ6 TN Androgen receptor messenger RNA (AR mRNA) DM1MGQ6 MA Inhibitor DM1MGQ6 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM1MGQ6 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM1MGTX DI DM1MGTX DM1MGTX DN ETHOXYCLUSIN DM1MGTX TI TTXV4FI DM1MGTX TN Albendazole monooxygenase (CYP3A4) DM1MGTX MA Inhibitor DM1MGTX RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DM1MGTX RU https://pubmed.ncbi.nlm.nih.gov/15679319 DM1MIRJ DI DM1MIRJ DM1MIRJ DN R-84 DM1MIRJ TI TTUTJGQ DM1MIRJ TN Vascular endothelial growth factor receptor 2 (KDR) DM1MIRJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM1MIRJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM1MJCE DI DM1MJCE DM1MJCE DN 1-(7-Methoxy-naphthalen-2-yl)-piperazine DM1MJCE TI TTSQIFT DM1MJCE TN 5-HT 1A receptor (HTR1A) DM1MJCE MA Inhibitor DM1MJCE RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DM1MJCE RU https://pubmed.ncbi.nlm.nih.gov/9397179 DM1MJCE DI DM1MJCE DM1MJCE DN 1-(7-Methoxy-naphthalen-2-yl)-piperazine DM1MJCE TI TT6MSOK DM1MJCE TN 5-HT 1D receptor (HTR1D) DM1MJCE MA Inhibitor DM1MJCE RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DM1MJCE RU https://pubmed.ncbi.nlm.nih.gov/9397179 DM1MJCE DI DM1MJCE DM1MJCE DN 1-(7-Methoxy-naphthalen-2-yl)-piperazine DM1MJCE TI TTK8CXU DM1MJCE TN 5-HT 1B receptor (HTR1B) DM1MJCE MA Inhibitor DM1MJCE RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DM1MJCE RU https://pubmed.ncbi.nlm.nih.gov/9397179 DM1MOB9 DI DM1MOB9 DM1MOB9 DN 2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile DM1MOB9 TI TTM2AOE DM1MOB9 TN Adenosine A2a receptor (ADORA2A) DM1MOB9 MA Inhibitor DM1MOB9 RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DM1MOB9 RU https://pubmed.ncbi.nlm.nih.gov/18258439 DM1MOB9 DI DM1MOB9 DM1MOB9 DN 2-Amino-4,6-diphenyl-pyrimidin-5-carbonitrile DM1MOB9 TI TTK25J1 DM1MOB9 TN Adenosine A1 receptor (ADORA1) DM1MOB9 MA Inhibitor DM1MOB9 RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DM1MOB9 RU https://pubmed.ncbi.nlm.nih.gov/18258439 DM1MOG8 DI DM1MOG8 DM1MOG8 DN NPY-1 antagonist DM1MOG8 TI TTRK9JT DM1MOG8 TN Neuropeptide Y receptor type 1 (NPY1R) DM1MOG8 MA Antagonist DM1MOG8 RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM1MOG8 RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM1MP96 DI DM1MP96 DM1MP96 DN 4-(2-(Cyclohexylamino)ethyl)-1H-imidazole DM1MP96 TI TT9JNIC DM1MP96 TN Histamine H3 receptor (H3R) DM1MP96 MA Inhibitor DM1MP96 RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DM1MP96 RU https://pubmed.ncbi.nlm.nih.gov/20384344 DM1MPJ9 DI DM1MPJ9 DM1MPJ9 DN NSC-645812 DM1MPJ9 TI TTJLP0R DM1MPJ9 TN Quinone reductase 2 (NQO2) DM1MPJ9 MA Inhibitor DM1MPJ9 RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DM1MPJ9 RU https://pubmed.ncbi.nlm.nih.gov/20356739 DM1MRFW DI DM1MRFW DM1MRFW DN NSC-119911 DM1MRFW TI TTMQL3K DM1MRFW TN Lipopolysaccharide-associated protein 1 (HSPA8) DM1MRFW MA Inhibitor DM1MRFW RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM1MRFW RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM1MRFW DI DM1MRFW DM1MRFW DN NSC-119911 DM1MRFW TI TTHYBIX DM1MRFW TN Heat shock protein 70 (HSP70) DM1MRFW MA Inhibitor DM1MRFW RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM1MRFW RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM1MSAC DI DM1MSAC DM1MSAC DN 1-(2-iodoethyl)-1H-indole-2,3-dione DM1MSAC TI TTMF541 DM1MSAC TN Liver carboxylesterase (CES1) DM1MSAC MA Inhibitor DM1MSAC RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM1MSAC RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM1N08O DI DM1N08O DM1N08O DN 2-(4-methoxyphenyl)-N-(thiazol-2-yl)acetamide DM1N08O TI TTSJ6Q4 DM1N08O TN LOX-5 messenger RNA (ALOX5 mRNA) DM1N08O MA Inhibitor DM1N08O RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DM1N08O RU https://pubmed.ncbi.nlm.nih.gov/17461565 DM1N0ED DI DM1N0ED DM1N0ED DN CCK-33 DM1N0ED TI TTCG0AL DM1N0ED TN Cholecystokinin receptor type A (CCKAR) DM1N0ED MA Agonist DM1N0ED RN Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci U S A. 1980 Nov;77(11):6917-21. DM1N0ED RU https://pubmed.ncbi.nlm.nih.gov/6256771 DM1N0ED DI DM1N0ED DM1N0ED DN CCK-33 DM1N0ED TI TTVFO0U DM1N0ED TN Gastrin/cholecystokinin type B receptor (CCKBR) DM1N0ED MA Agonist DM1N0ED RN Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. J Biol Chem. 1993 Aug 25;268(24):18300-5. DM1N0ED RU https://pubmed.ncbi.nlm.nih.gov/8349705 DM1N46J DI DM1N46J DM1N46J DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DM1N46J TI TT6OEDT DM1N46J TN Cannabinoid receptor 1 (CB1) DM1N46J MA Inhibitor DM1N46J RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM1N46J RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM1N46J DI DM1N46J DM1N46J DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-((R)-1-HYDROXYETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DM1N46J TI TTMSFAW DM1N46J TN Cannabinoid receptor 2 (CB2) DM1N46J MA Inhibitor DM1N46J RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM1N46J RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM1N4LK DI DM1N4LK DM1N4LK DN 1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole DM1N4LK TI TTJS8PY DM1N4LK TN 5-HT 6 receptor (HTR6) DM1N4LK MA Inhibitor DM1N4LK RN Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4780-5. DM1N4LK RU https://pubmed.ncbi.nlm.nih.gov/16125933 DM1N73J DI DM1N73J DM1N73J DN N4-Butyl-2-cinnamamido-N1-hydroxysuccinamide DM1N73J TI TTPHMWB DM1N73J TN Aminopeptidase N (ANPEP) DM1N73J MA Inhibitor DM1N73J RN Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404. DM1N73J RU https://pubmed.ncbi.nlm.nih.gov/19782572 DM1N7AG DI DM1N7AG DM1N7AG DN N-(thiazol-2-yl)benzamide DM1N7AG TI TTSJ6Q4 DM1N7AG TN LOX-5 messenger RNA (ALOX5 mRNA) DM1N7AG MA Inhibitor DM1N7AG RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DM1N7AG RU https://pubmed.ncbi.nlm.nih.gov/17461565 DM1NAMK DI DM1NAMK DM1NAMK DN 5'-Deoxy-5'-dimethylsulfonioadenosine chloride DM1NAMK TI TTBFROQ DM1NAMK TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DM1NAMK MA Inhibitor DM1NAMK RN New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407. DM1NAMK RU https://pubmed.ncbi.nlm.nih.gov/19209891 DM1NHJ8 DI DM1NHJ8 DM1NHJ8 DN ISIS 112000 DM1NHJ8 TI TTPJ9XK DM1NHJ8 TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DM1NHJ8 RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DM1NHJ8 RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DM1NITL DI DM1NITL DM1NITL DN Tyr-Pro-L-(NMe)Phe-Pro-NH2 DM1NITL TI TT27RFC DM1NITL TN Opioid receptor delta (OPRD1) DM1NITL MA Inhibitor DM1NITL RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DM1NITL RU https://pubmed.ncbi.nlm.nih.gov/8384662 DM1NITL DI DM1NITL DM1NITL DN Tyr-Pro-L-(NMe)Phe-Pro-NH2 DM1NITL TI TTKWM86 DM1NITL TN Opioid receptor mu (MOP) DM1NITL MA Inhibitor DM1NITL RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DM1NITL RU https://pubmed.ncbi.nlm.nih.gov/8384662 DM1NJD7 DI DM1NJD7 DM1NJD7 DN ISIS 196103 DM1NJD7 TI TTJA1ZO DM1NJD7 TN ITGB3 messenger RNA (ITGB3 mRNA) DM1NJD7 RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DM1NJD7 RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DM1NK2M DI DM1NK2M DM1NK2M DN 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one DM1NK2M TI TTK25J1 DM1NK2M TN Adenosine A1 receptor (ADORA1) DM1NK2M MA Inhibitor DM1NK2M RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DM1NK2M RU https://pubmed.ncbi.nlm.nih.gov/17665891 DM1NL3Z DI DM1NL3Z DM1NL3Z DN FG-5893 DM1NL3Z TI TTSQIFT DM1NL3Z TN 5-HT 1A receptor (HTR1A) DM1NL3Z MA Agonist DM1NL3Z RN Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. DM1NL3Z RU https://pubmed.ncbi.nlm.nih.gov/9760039 DM1NM5F DI DM1NM5F DM1NM5F DN PTeB DM1NM5F TI TTHS256 DM1NM5F TN Metabotropic glutamate receptor 5 (mGluR5) DM1NM5F MA Modulator (allosteric modulator) DM1NM5F RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DM1NM5F RU https://pubmed.ncbi.nlm.nih.gov/15341479 DM1NT5G DI DM1NT5G DM1NT5G DN H-Tyr-NMe-D-Ala-Phe-Sar-NH2 DM1NT5G TI TT27RFC DM1NT5G TN Opioid receptor delta (OPRD1) DM1NT5G MA Inhibitor DM1NT5G RN Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4. DM1NT5G RU https://pubmed.ncbi.nlm.nih.gov/18370374 DM1NUO5 DI DM1NUO5 DM1NUO5 DN Heptyl-methyl-prop-2-ynyl-amine hydrochloride DM1NUO5 TI TTGP7BY DM1NUO5 TN Monoamine oxidase type B (MAO-B) DM1NUO5 MA Inhibitor DM1NUO5 RN Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13. DM1NUO5 RU https://pubmed.ncbi.nlm.nih.gov/1433183 DM1NVEI DI DM1NVEI DM1NVEI DN 4,4'-(ethane-1,2-diyl)dibenzene-1,3-diol DM1NVEI TI TTULVH8 DM1NVEI TN Tyrosinase (TYR) DM1NVEI MA Inhibitor DM1NVEI RN Molecular design of potent tyrosinase inhibitors having the bibenzyl skeleton. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5252-4. DM1NVEI RU https://pubmed.ncbi.nlm.nih.gov/18782667 DM1NXDA DI DM1NXDA DM1NXDA DN [125I]CGP42112 DM1NXDA TI TTQVOEI DM1NXDA TN Angiotensin II receptor type-2 (AGTR2) DM1NXDA MA Agonist DM1NXDA RN Radioiodinated CGP 42112A: a novel high affinity and highly selective ligand for the characterization of angiotensin AT2 receptors. Biochem Biophys Res Commun. 1991 Dec 31;181(3):1365-71. DM1NXDA RU https://pubmed.ncbi.nlm.nih.gov/1764088 DM1NXFL DI DM1NXFL DM1NXFL DN S-isopentyl 3-methylbutane-1-sulfinothioate DM1NXFL TI TT2SUAQ DM1NXFL TN Cysteine protease (CYP) DM1NXFL MA Inhibitor DM1NXFL RN Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3. DM1NXFL RU https://pubmed.ncbi.nlm.nih.gov/20692829 DM1O0JD DI DM1O0JD DM1O0JD DN 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine DM1O0JD TI TTWJBZ5 DM1O0JD TN 5-HT 2C receptor (HTR2C) DM1O0JD MA Inhibitor DM1O0JD RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM1O0JD RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM1O0JD DI DM1O0JD DM1O0JD DN 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine DM1O0JD TI TTJQOD7 DM1O0JD TN 5-HT 2A receptor (HTR2A) DM1O0JD MA Inhibitor DM1O0JD RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM1O0JD RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM1O0JD DI DM1O0JD DM1O0JD DN 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine DM1O0JD TI TTSQIFT DM1O0JD TN 5-HT 1A receptor (HTR1A) DM1O0JD MA Inhibitor DM1O0JD RN A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95. DM1O0JD RU https://pubmed.ncbi.nlm.nih.gov/12954071 DM1O0JD DI DM1O0JD DM1O0JD DN 2-(5-Methoxy-1H-indol-3-yl)-1-methyl-ethylamine DM1O0JD TI TT0K1SC DM1O0JD TN 5-HT 2B receptor (HTR2B) DM1O0JD MA Inhibitor DM1O0JD RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM1O0JD RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM1O6KQ DI DM1O6KQ DM1O6KQ DN 1-Propyl-3-o-tolyl-piperidine hydrochloride DM1O6KQ TI TTEX248 DM1O6KQ TN Dopamine D2 receptor (D2R) DM1O6KQ MA Inhibitor DM1O6KQ RN New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8. DM1O6KQ RU https://pubmed.ncbi.nlm.nih.gov/12502370 DM1OAW3 DI DM1OAW3 DM1OAW3 DN Cbz-Ile-Phe-Ala-LeuVSMe DM1OAW3 TI TTUMQVO DM1OAW3 TN Cathepsin S (CTSS) DM1OAW3 MA Inhibitor DM1OAW3 RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DM1OAW3 RU https://pubmed.ncbi.nlm.nih.gov/16686537 DM1OBHQ DI DM1OBHQ DM1OBHQ DN 4-tert-butyl-N-(quinolin-3-yl)benzamide DM1OBHQ TI TTMI6F5 DM1OBHQ TN Transient receptor potential cation channel V1 (TRPV1) DM1OBHQ MA Inhibitor DM1OBHQ RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DM1OBHQ RU https://pubmed.ncbi.nlm.nih.gov/18359227 DM1OED2 DI DM1OED2 DM1OED2 DN 2-amino-4-methylpyridine DM1OED2 TI TTF10I9 DM1OED2 TN Nitric-oxide synthase inducible (NOS2) DM1OED2 MA Inhibitor DM1OED2 RN 2-Amino-4-methylpyridine as a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br J Pharmacol. 1996 Nov;119(6):1101-8. DM1OED2 RU https://pubmed.ncbi.nlm.nih.gov/8937711 DM1OED2 DI DM1OED2 DM1OED2 DN 2-amino-4-methylpyridine DM1OED2 TI TTZUFI5 DM1OED2 TN Nitric-oxide synthase brain (NOS1) DM1OED2 MA Inhibitor DM1OED2 RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DM1OED2 RU https://pubmed.ncbi.nlm.nih.gov/18849972 DM1OED2 DI DM1OED2 DM1OED2 DN 2-amino-4-methylpyridine DM1OED2 TI TTCM4B3 DM1OED2 TN Nitric-oxide synthase endothelial (NOS3) DM1OED2 MA Inhibitor DM1OED2 RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DM1OED2 RU https://pubmed.ncbi.nlm.nih.gov/18849972 DM1OHF8 DI DM1OHF8 DM1OHF8 DN lysergol DM1OHF8 TI TT6MSOK DM1OHF8 TN 5-HT 1D receptor (HTR1D) DM1OHF8 MA Agonist DM1OHF8 RN Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4. DM1OHF8 RU https://pubmed.ncbi.nlm.nih.gov/1565658 DM1OHF8 DI DM1OHF8 DM1OHF8 DN lysergol DM1OHF8 TI TTK8CXU DM1OHF8 TN 5-HT 1B receptor (HTR1B) DM1OHF8 MA Agonist DM1OHF8 RN Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. DM1OHF8 RU https://pubmed.ncbi.nlm.nih.gov/8863519 DM1OHF8 DI DM1OHF8 DM1OHF8 DN lysergol DM1OHF8 TI TTCPG9S DM1OHF8 TN 5-HT 1E receptor (HTR1E) DM1OHF8 MA Agonist DM1OHF8 RN Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. DM1OHF8 RU https://pubmed.ncbi.nlm.nih.gov/8863519 DM1OKN0 DI DM1OKN0 DM1OKN0 DN DIMETHYLSPINGOSINE DM1OKN0 TI TTCN0M9 DM1OKN0 TN Sphingosine kinase 2 (SPHK2) DM1OKN0 MA Inhibitor DM1OKN0 RN Synthesis and evaluation of sphingosine analogues as inhibitors of sphingosine kinases. J Med Chem. 2009 Jun 25;52(12):3618-26. DM1OKN0 RU https://pubmed.ncbi.nlm.nih.gov/19469544 DM1OMSW DI DM1OMSW DM1OMSW DN IDN-5390 DM1OMSW TI TTYFKSZ DM1OMSW TN Tubulin beta (TUBB) DM1OMSW MA Modulator DM1OMSW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DM1OMSW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DM1ONBT DI DM1ONBT DM1ONBT DN 4,4'-dihydroxyoctafluoroazobenzene DM1ONBT TI TTTU72V DM1ONBT TN Steroid 5-alpha-reductase 1 (SRD5A1) DM1ONBT MA Inhibitor DM1ONBT RN Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5. DM1ONBT RU https://pubmed.ncbi.nlm.nih.gov/2391687 DM1ONBT DI DM1ONBT DM1ONBT DN 4,4'-dihydroxyoctafluoroazobenzene DM1ONBT TI TTT02K8 DM1ONBT TN Steroid 5-alpha-reductase 2 (SRD5A2) DM1ONBT MA Inhibitor DM1ONBT RN Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5. DM1ONBT RU https://pubmed.ncbi.nlm.nih.gov/2391687 DM1OPYT DI DM1OPYT DM1OPYT DN KNI-10315 DM1OPYT TI TTXMNHO DM1OPYT TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM1OPYT MA Inhibitor DM1OPYT RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DM1OPYT RU https://pubmed.ncbi.nlm.nih.gov/17400453 DM1OPZ9 DI DM1OPZ9 DM1OPZ9 DN R396 DM1OPZ9 TI TTYO0A3 DM1OPZ9 TN Substance-K receptor (TACR2) DM1OPZ9 MA Antagonist DM1OPZ9 RN Characterization of the binding sites of [3H]SR 48968, a potent nonpeptide radioligand antagonist of the neurokinin-2 receptor. Biochem Biophys Res Commun. 1993 Mar 31;191(3):1172-7. DM1OPZ9 RU https://pubmed.ncbi.nlm.nih.gov/7682062 DM1OS6M DI DM1OS6M DM1OS6M DN PMID8709131C2a (+) DM1OS6M TI TTFQEO5 DM1OS6M TN Squalene synthetase (FDFT1) DM1OS6M MA Inhibitor DM1OS6M RN Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9. DM1OS6M RU https://pubmed.ncbi.nlm.nih.gov/8709131 DM1OVSW DI DM1OVSW DM1OVSW DN ISIS 114527 DM1OVSW TI TTY3BRA DM1OVSW TN ZNF217 messenger RNA (ZNF217 mRNA) DM1OVSW RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DM1OVSW RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DM1OZPN DI DM1OZPN DM1OZPN DN XR-9544 DM1OZPN TI TT3OT40 DM1OZPN TN Multidrug resistance protein 1 (ABCB1) DM1OZPN MA Inhibitor DM1OZPN RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DM1OZPN RU https://pubmed.ncbi.nlm.nih.gov/18083034 DM1OZPN DI DM1OZPN DM1OZPN DN XR-9544 DM1OZPN TI TTOI92F DM1OZPN TN Multidrug resistance-associated protein 1 (ABCC1) DM1OZPN MA Inhibitor DM1OZPN RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DM1OZPN RU https://pubmed.ncbi.nlm.nih.gov/18083034 DM1P830 DI DM1P830 DM1P830 DN recAAT, PPL Therapeutics/Bayer DM1P830 TI TT2WR1T DM1P830 TN Cationic trypsinogen (PRSS1) DM1P830 MA Modulator DM1P830 RN Reduction in neutrophil elastase concentration by recombinant alphal-antitrypsin (recAAT) does not alter bacterial loading in the sputum of cystic ... Br J Biomed Sci. 2004;61(3):146-7. DM1P830 RU https://www.ncbi.nlm.nih.gov/pubmed/15462261 DM1PCEM DI DM1PCEM DM1PCEM DN (E)-N-(4-methoxyphenyl)undec-2-enamide DM1PCEM TI TT6OEDT DM1PCEM TN Cannabinoid receptor 1 (CB1) DM1PCEM MA Inhibitor DM1PCEM RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM1PCEM RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM1PCEM DI DM1PCEM DM1PCEM DN (E)-N-(4-methoxyphenyl)undec-2-enamide DM1PCEM TI TTMSFAW DM1PCEM TN Cannabinoid receptor 2 (CB2) DM1PCEM MA Inhibitor DM1PCEM RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM1PCEM RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM1PCIX DI DM1PCIX DM1PCIX DN (E)-5-Styrylisatin DM1PCIX TI TT3WG5C DM1PCIX TN Monoamine oxidase type A (MAO-A) DM1PCIX MA Inhibitor DM1PCIX RN Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. DM1PCIX RU https://pubmed.ncbi.nlm.nih.gov/19342233 DM1PCIX DI DM1PCIX DM1PCIX DN (E)-5-Styrylisatin DM1PCIX TI TTGP7BY DM1PCIX TN Monoamine oxidase type B (MAO-B) DM1PCIX MA Inhibitor DM1PCIX RN Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. DM1PCIX RU https://pubmed.ncbi.nlm.nih.gov/19342233 DM1PKWA DI DM1PKWA DM1PKWA DN KNI-10155 DM1PKWA TI TTXMNHO DM1PKWA TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM1PKWA MA Inhibitor DM1PKWA RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DM1PKWA RU https://pubmed.ncbi.nlm.nih.gov/18952439 DM1PMR3 DI DM1PMR3 DM1PMR3 DN Sterculic acid DM1PMR3 TI TT6RIOV DM1PMR3 TN Acyl-CoA desaturase (SCD) DM1PMR3 MA Inhibitor DM1PMR3 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DM1PMR3 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DM1POEA DI DM1POEA DM1POEA DN 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone DM1POEA TI TT1MPAY DM1POEA TN GABA(A) receptor alpha-1 (GABRA1) DM1POEA MA Inhibitor DM1POEA RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1POEA RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1POEA DI DM1POEA DM1POEA DN 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone DM1POEA TI TTZA1NY DM1POEA TN GABA(A) receptor beta-2 (GABRB2) DM1POEA MA Inhibitor DM1POEA RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1POEA RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1POEA DI DM1POEA DM1POEA DN 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone DM1POEA TI TTNJYV2 DM1POEA TN Gamma-aminobutyric acid receptor (GAR) DM1POEA MA Inhibitor DM1POEA RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1POEA RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1POEA DI DM1POEA DM1POEA DN 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone DM1POEA TI TT37EDJ DM1POEA TN GABA(A) receptor alpha-3 (GABRA3) DM1POEA MA Inhibitor DM1POEA RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1POEA RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1POEA DI DM1POEA DM1POEA DN 6-ethyl-3-(3-methylbutoxycarbonyl)-4-quinolone DM1POEA TI TT06RH5 DM1POEA TN GABA(A) receptor gamma-2 (GABRG2) DM1POEA MA Inhibitor DM1POEA RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM1POEA RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM1PSR7 DI DM1PSR7 DM1PSR7 DN N-(4,6-diphenylpyrimidin-2-yl)-4-chlorobenzamide DM1PSR7 TI TTJFY5U DM1PSR7 TN Adenosine A3 receptor (ADORA3) DM1PSR7 MA Inhibitor DM1PSR7 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM1PSR7 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM1PSRQ DI DM1PSRQ DM1PSRQ DN 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine DM1PSRQ TI TTSQIFT DM1PSRQ TN 5-HT 1A receptor (HTR1A) DM1PSRQ MA Inhibitor DM1PSRQ RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DM1PSRQ RU https://pubmed.ncbi.nlm.nih.gov/17064079 DM1PSRQ DI DM1PSRQ DM1PSRQ DN 2-{[2-(2-phenylethyl)phenoxy]methyl}pyridine DM1PSRQ TI TTEX248 DM1PSRQ TN Dopamine D2 receptor (D2R) DM1PSRQ MA Inhibitor DM1PSRQ RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DM1PSRQ RU https://pubmed.ncbi.nlm.nih.gov/17064079 DM1PWX2 DI DM1PWX2 DM1PWX2 DN Grassystatin a DM1PWX2 TI TT6KIOT DM1PWX2 TN Caspase-11 (CASP11) DM1PWX2 MA Inhibitor DM1PWX2 RN Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47. DM1PWX2 RU https://pubmed.ncbi.nlm.nih.gov/19715320 DM1PWX2 DI DM1PWX2 DM1PWX2 DN Grassystatin a DM1PWX2 TI TT2WR1T DM1PWX2 TN Cationic trypsinogen (PRSS1) DM1PWX2 MA Inhibitor DM1PWX2 RN Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47. DM1PWX2 RU https://pubmed.ncbi.nlm.nih.gov/19715320 DM1PWX2 DI DM1PWX2 DM1PWX2 DN Grassystatin a DM1PWX2 TI TTPT2QI DM1PWX2 TN Cathepsin D (CTSD) DM1PWX2 MA Inhibitor DM1PWX2 RN Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47. DM1PWX2 RU https://pubmed.ncbi.nlm.nih.gov/19715320 DM1PWX2 DI DM1PWX2 DM1PWX2 DN Grassystatin a DM1PWX2 TI TT3NKIB DM1PWX2 TN Pancreatic elastase 1 (CELA1) DM1PWX2 MA Inhibitor DM1PWX2 RN Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47. DM1PWX2 RU https://pubmed.ncbi.nlm.nih.gov/19715320 DM1PWX2 DI DM1PWX2 DM1PWX2 DN Grassystatin a DM1PWX2 TI TTP86E2 DM1PWX2 TN Plasminogen (PLG) DM1PWX2 MA Inhibitor DM1PWX2 RN Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47. DM1PWX2 RU https://pubmed.ncbi.nlm.nih.gov/19715320 DM1PWX2 DI DM1PWX2 DM1PWX2 DN Grassystatin a DM1PWX2 TI TTM1TDX DM1PWX2 TN Tryptase alpha/beta-1 (Tryptase) DM1PWX2 MA Inhibitor DM1PWX2 RN Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47. DM1PWX2 RU https://pubmed.ncbi.nlm.nih.gov/19715320 DM1Q0BF DI DM1Q0BF DM1Q0BF DN 5-deoxyabyssinin II DM1Q0BF TI TTELIN2 DM1Q0BF TN PTPN1 messenger RNA (PTPN1 mRNA) DM1Q0BF MA Inhibitor DM1Q0BF RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DM1Q0BF RU https://pubmed.ncbi.nlm.nih.gov/17489632 DM1Q0TM DI DM1Q0TM DM1Q0TM DN 1-(2,3-DICHLOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX) DM1Q0TM TI TTOZRK6 DM1Q0TM TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM1Q0TM MA Inhibitor DM1Q0TM RN 5-Functionalized indazoles as glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 May 15;20(10):3017-20. DM1Q0TM RU https://pubmed.ncbi.nlm.nih.gov/20427184 DM1Q36W DI DM1Q36W DM1Q36W DN 1-(1-Benzo[b]thiophen-2-yl-cyclopentyl)-azepane DM1Q36W TI TTVBI8W DM1Q36W TN Dopamine transporter (DAT) DM1Q36W MA Inhibitor DM1Q36W RN Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93. DM1Q36W RU https://pubmed.ncbi.nlm.nih.gov/8098066 DM1Q5KV DI DM1Q5KV DM1Q5KV DN 4-(3-Bromo-phenylamino)-quinazoline-6,7-diol DM1Q5KV TI TTGKNB4 DM1Q5KV TN Epidermal growth factor receptor (EGFR) DM1Q5KV MA Inhibitor DM1Q5KV RN Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28. DM1Q5KV RU https://pubmed.ncbi.nlm.nih.gov/8632415 DM1Q83B DI DM1Q83B DM1Q83B DN Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro DM1Q83B TI TTB2MXP DM1Q83B TN Angiotensinogenase renin (REN) DM1Q83B MA Inhibitor DM1Q83B RN Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61. DM1Q83B RU https://pubmed.ncbi.nlm.nih.gov/6267277 DM1QBXM DI DM1QBXM DM1QBXM DN VT-310 DM1QBXM TI TTJTRMK DM1QBXM TN Interleukin 10 receptor (IL10RB) DM1QBXM MA Modulator DM1QBXM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900). DM1QBXM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1900 DM1QDG0 DI DM1QDG0 DM1QDG0 DN PMID24900635C21 DM1QDG0 TI TTAIQSN DM1QDG0 TN Receptor-interacting protein 1 (RIPK1) DM1QDG0 MA Inhibitor DM1QDG0 RN Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med Chem Lett. 2013 Nov 4;4(12):1238-43. DM1QDG0 RU https://pubmed.ncbi.nlm.nih.gov/24900635 DM1QIPZ DI DM1QIPZ DM1QIPZ DN quinoline 2 DM1QIPZ TI TT2EDHU DM1QIPZ TN Insulin-degrading enzyme (IDE) DM1QIPZ MA Inhibitor DM1QIPZ RN Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo. J Biol Chem. 2015 Aug 14;290(33):20044-59. DM1QIPZ RU https://pubmed.ncbi.nlm.nih.gov/26085101 DM1QJIV DI DM1QJIV DM1QJIV DN AL5300 DM1QJIV TI TTANPDJ DM1QJIV TN Carbonic anhydrase II (CA-II) DM1QJIV MA Inhibitor DM1QJIV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1QJIV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1QKNU DI DM1QKNU DM1QKNU DN 3-[5-(3-nitrophenyl)thiophen-2-yl]propanoic acid DM1QKNU TI TTFBNVI DM1QKNU TN Aldose reductase (AKR1B1) DM1QKNU MA Inhibitor DM1QKNU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM1QKNU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM1QKVL DI DM1QKVL DM1QKVL DN VRC3375 DM1QKVL TI TTICO5G DM1QKVL TN Staphylococcus Peptide deformylase (Stap-coc def) DM1QKVL MA Inhibitor DM1QKVL RN Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob Agents Chemother. 2004 Jan;48(1):250-61. DM1QKVL RU https://pubmed.ncbi.nlm.nih.gov/14693547 DM1QLB0 DI DM1QLB0 DM1QLB0 DN ISIS 144379 DM1QLB0 TI TT5S8DR DM1QLB0 TN APOA1 messenger RNA (APOA1 mRNA) DM1QLB0 RN US patent application no. 7,259,150, Modulation of apolipoprotein (a) expression. DM1QLB0 RU http://www.patentbuddy.com/Patent/7259150?ft=true&sr=true DM1QOY0 DI DM1QOY0 DM1QOY0 DN alpha-conotoxin PnIA DM1QOY0 TI TTH2QRX DM1QOY0 TN Neuronal acetylcholine receptor alpha-5 (CHRNA5) DM1QOY0 MA Antagonist DM1QOY0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 466). DM1QOY0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=466 DM1QOY0 DI DM1QOY0 DM1QOY0 DN alpha-conotoxin PnIA DM1QOY0 TI TTH18TF DM1QOY0 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM1QOY0 MA Antagonist DM1QOY0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DM1QOY0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DM1QPA4 DI DM1QPA4 DM1QPA4 DN (+)-SK&F10047 DM1QPA4 TI TT5TPI6 DM1QPA4 TN Opioid receptor sigma 1 (OPRS1) DM1QPA4 MA Agonist DM1QPA4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2552). DM1QPA4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2552 DM1QPG7 DI DM1QPG7 DM1QPG7 DN LVVYPWT DM1QPG7 TI TT2THBD DM1QPG7 TN P2X purinoceptor 3 (P2RX3) DM1QPG7 MA Inhibitor DM1QPG7 RN Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7. DM1QPG7 RU https://pubmed.ncbi.nlm.nih.gov/17676725 DM1QTN5 DI DM1QTN5 DM1QTN5 DN FGGFTGARKSARKVANQ DM1QTN5 TI TTNT7K8 DM1QTN5 TN Nociceptin receptor (OPRL1) DM1QTN5 MA Inhibitor DM1QTN5 RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DM1QTN5 RU https://pubmed.ncbi.nlm.nih.gov/18818087 DM1QXFI DI DM1QXFI DM1QXFI DN PMID18800762C19 DM1QXFI TI TTIKWV4 DM1QXFI TN Geranyltranstransferase (FDPS) DM1QXFI MA Inhibitor DM1QXFI RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DM1QXFI RU https://pubmed.ncbi.nlm.nih.gov/18800762 DM1QYS8 DI DM1QYS8 DM1QYS8 DN 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol DM1QYS8 TI TTNT7K8 DM1QYS8 TN Nociceptin receptor (OPRL1) DM1QYS8 MA Inhibitor DM1QYS8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM1QYS8 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM1QYS8 DI DM1QYS8 DM1QYS8 DN 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol DM1QYS8 TI TTKWM86 DM1QYS8 TN Opioid receptor mu (MOP) DM1QYS8 MA Inhibitor DM1QYS8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM1QYS8 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM1QYS8 DI DM1QYS8 DM1QYS8 DN 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol DM1QYS8 TI TTQW87Y DM1QYS8 TN Opioid receptor kappa (OPRK1) DM1QYS8 MA Inhibitor DM1QYS8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM1QYS8 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM1QYS8 DI DM1QYS8 DM1QYS8 DN 1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol DM1QYS8 TI TT27RFC DM1QYS8 TN Opioid receptor delta (OPRD1) DM1QYS8 MA Inhibitor DM1QYS8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM1QYS8 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM1QZ9X DI DM1QZ9X DM1QZ9X DN Tyr-Pro-Phe-D-Val-Bn DM1QZ9X TI TTKWM86 DM1QZ9X TN Opioid receptor mu (MOP) DM1QZ9X MA Inhibitor DM1QZ9X RN Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. DM1QZ9X RU https://pubmed.ncbi.nlm.nih.gov/19679474 DM1R0WC DI DM1R0WC DM1R0WC DN NIS-62949 DM1R0WC TI TTZ97H5 DM1R0WC TN Phosphodiesterase 4A (PDE4A) DM1R0WC MA Inhibitor DM1R0WC RN Pharmacology of a novel, orally active PDE4 inhibitor. Pharmacology. 2009;83(5):275-86. DM1R0WC RU https://pubmed.ncbi.nlm.nih.gov/19321962 DM1R5SF DI DM1R5SF DM1R5SF DN (5-Phenyl-oxazol-2-yl)-m-tolyl-amine DM1R5SF TI TT1VAUK DM1R5SF TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM1R5SF MA Inhibitor DM1R5SF RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DM1R5SF RU https://pubmed.ncbi.nlm.nih.gov/15743202 DM1R5SF DI DM1R5SF DM1R5SF DN (5-Phenyl-oxazol-2-yl)-m-tolyl-amine DM1R5SF TI TTUTJGQ DM1R5SF TN Vascular endothelial growth factor receptor 2 (KDR) DM1R5SF MA Inhibitor DM1R5SF RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DM1R5SF RU https://pubmed.ncbi.nlm.nih.gov/15743202 DM1R5SF DI DM1R5SF DM1R5SF DN (5-Phenyl-oxazol-2-yl)-m-tolyl-amine DM1R5SF TI TTDCBX5 DM1R5SF TN Vascular endothelial growth factor receptor 3 (FLT-4) DM1R5SF MA Inhibitor DM1R5SF RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DM1R5SF RU https://pubmed.ncbi.nlm.nih.gov/15743202 DM1R8MW DI DM1R8MW DM1R8MW DN WS-3 DM1R8MW TI TTXDKTO DM1R8MW TN Long transient receptor potential channel 8 (TRPM8) DM1R8MW MA Activator DM1R8MW RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DM1R8MW RU https://pubmed.ncbi.nlm.nih.gov/14757700 DM1RE9Q DI DM1RE9Q DM1RE9Q DN 2,3,4,5-Tetrahydro-1H-benzo[c]azepine DM1RE9Q TI TTWM4TY DM1RE9Q TN Adrenergic receptor alpha-2B (ADRA2B) DM1RE9Q MA Inhibitor DM1RE9Q RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM1RE9Q RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM1RE9Q DI DM1RE9Q DM1RE9Q DN 2,3,4,5-Tetrahydro-1H-benzo[c]azepine DM1RE9Q TI TTWG9A4 DM1RE9Q TN Adrenergic receptor alpha-2A (ADRA2A) DM1RE9Q MA Inhibitor DM1RE9Q RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM1RE9Q RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM1RE9Q DI DM1RE9Q DM1RE9Q DN 2,3,4,5-Tetrahydro-1H-benzo[c]azepine DM1RE9Q TI TT2NUT5 DM1RE9Q TN Adrenergic receptor alpha-2C (ADRA2C) DM1RE9Q MA Inhibitor DM1RE9Q RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM1RE9Q RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM1REKQ DI DM1REKQ DM1REKQ DN ISIS 109354 DM1REKQ TI TT1MS7X DM1REKQ TN PKC-theta messenger RNA (PRKCQ mRNA) DM1REKQ RN US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression. DM1REKQ RU http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true DM1RM3H DI DM1RM3H DM1RM3H DN 4',5,7-trihydroxy-6,8-dimethylisoflavone DM1RM3H TI TTZAYWL DM1RM3H TN Estrogen receptor (ESR) DM1RM3H MA Inhibitor DM1RM3H RN Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53. DM1RM3H RU https://pubmed.ncbi.nlm.nih.gov/12502307 DM1RM3H DI DM1RM3H DM1RM3H DN 4',5,7-trihydroxy-6,8-dimethylisoflavone DM1RM3H TI TTOM3J0 DM1RM3H TN Estrogen receptor beta (ESR2) DM1RM3H MA Inhibitor DM1RM3H RN Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53. DM1RM3H RU https://pubmed.ncbi.nlm.nih.gov/12502307 DM1RP5Q DI DM1RP5Q DM1RP5Q DN K00592a DM1RP5Q TI TTOU65C DM1RP5Q TN Tyrosine-protein kinase SYK (SYK) DM1RP5Q MA Inhibitor DM1RP5Q RN Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem. 2005 Aug 15;13(16):4936-51. DM1RP5Q RU https://pubmed.ncbi.nlm.nih.gov/15990316 DM1RP5Q DI DM1RP5Q DM1RP5Q DN K00592a DM1RP5Q TI TTUMHT8 DM1RP5Q TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DM1RP5Q MA Inhibitor DM1RP5Q RN Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem. 2005 Aug 15;13(16):4936-51. DM1RP5Q RU https://pubmed.ncbi.nlm.nih.gov/15990316 DM1RSCP DI DM1RSCP DM1RSCP DN 2alpha-Hydroxyurs-12-en-28-oic acid DM1RSCP TI TTZHY6R DM1RSCP TN Glycogen phosphorylase muscle form (GP) DM1RSCP MA Inhibitor DM1RSCP RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DM1RSCP RU https://pubmed.ncbi.nlm.nih.gov/19642687 DM1RW4U DI DM1RW4U DM1RW4U DN [2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine DM1RW4U TI TTJS8PY DM1RW4U TN 5-HT 6 receptor (HTR6) DM1RW4U MA Inhibitor DM1RW4U RN Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4569-73. DM1RW4U RU https://pubmed.ncbi.nlm.nih.gov/15357994 DM1RY6Q DI DM1RY6Q DM1RY6Q DN GX-G6 DM1RY6Q TI TTVIMDE DM1RY6Q TN Glucagon-like peptide 1 receptor (GLP1R) DM1RY6Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DM1RY6Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DM1RYH9 DI DM1RYH9 DM1RYH9 DN (24E)-3beta-hydroxy-7,24-euphadien-26-oic acid DM1RYH9 TI TTIU7X1 DM1RYH9 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM1RYH9 MA Inhibitor DM1RYH9 RN A new 7,8-euphadien-type triterpenoid from Brackenridgea nitida and Bleasdalea bleasdalei that inhibits DNA polymerase beta. J Nat Prod. 2000 Oct;63(10):1356-60. DM1RYH9 RU https://pubmed.ncbi.nlm.nih.gov/11076551 DM1S209 DI DM1S209 DM1S209 DN TENELLONE A DM1S209 TI TTZC6DR DM1S209 TN cGMP-dependent protein kinase (cGK) DM1S209 MA Inhibitor DM1S209 RN Tenellones A and B from a Diaporthe sp.: two highly substituted benzophenone inhibitors of parasite cGMP-dependent protein kinase activity. J Nat Prod. 2005 Apr;68(4):611-3. DM1S209 RU https://pubmed.ncbi.nlm.nih.gov/15844962 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TTPC4TU DM1S5CB TN 5-HT 3A receptor (HTR3A) DM1S5CB MA Agonist DM1S5CB RN Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro. Eur J Pharmacol. 2000 Dec 8;409(2):195-201. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/11104834 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TTK8CXU DM1S5CB TN 5-HT 1B receptor (HTR1B) DM1S5CB MA Agonist DM1S5CB RN Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/1565658 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TTR6K75 DM1S5CB TN 5-HT 3B receptor (HTR3B) DM1S5CB MA Agonist DM1S5CB RN The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature. 1999 Jan 28;397(6717):359-63. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/9950429 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TT0MI3F DM1S5CB TN 5-HT 1F receptor (HTR1F) DM1S5CB MA Agonist DM1S5CB RN Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/8380639 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TTCPG9S DM1S5CB TN 5-HT 1E receptor (HTR1E) DM1S5CB MA Agonist DM1S5CB RN Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/8380639 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TT6MSOK DM1S5CB TN 5-HT 1D receptor (HTR1D) DM1S5CB MA Agonist DM1S5CB RN Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/8967979 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TTJS8PY DM1S5CB TN 5-HT 6 receptor (HTR6) DM1S5CB MA Agonist DM1S5CB RN Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology. 1997 Apr-May;36(4-5):713-20. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/9225298 DM1S5CB DI DM1S5CB DM1S5CB DN 2-methyl-5-HT DM1S5CB TI TT0K1SC DM1S5CB TN 5-HT 2B receptor (HTR2B) DM1S5CB MA Agonist DM1S5CB RN Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. DM1S5CB RU https://pubmed.ncbi.nlm.nih.gov/8450835 DM1S9DB DI DM1S9DB DM1S9DB DN 6-iodo-nordihydrocapsaicin DM1S9DB TI TTMI6F5 DM1S9DB TN Transient receptor potential cation channel V1 (TRPV1) DM1S9DB MA Blocker (channel blocker) DM1S9DB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DM1S9DB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DM1SABZ DI DM1SABZ DM1SABZ DN Nocardimicin D DM1SABZ TI TTQ13Z5 DM1SABZ TN Muscarinic acetylcholine receptor M3 (CHRM3) DM1SABZ MA Inhibitor DM1SABZ RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DM1SABZ RU https://pubmed.ncbi.nlm.nih.gov/16038549 DM1SAIX DI DM1SAIX DM1SAIX DN Cypate-[(RGD)3-NH2]2 DM1SAIX TI TTT1R2L DM1SAIX TN Integrin alpha-V (ITGAV) DM1SAIX MA Inhibitor DM1SAIX RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DM1SAIX RU https://pubmed.ncbi.nlm.nih.gov/16570923 DM1SAIX DI DM1SAIX DM1SAIX DN Cypate-[(RGD)3-NH2]2 DM1SAIX TI TTJA1ZO DM1SAIX TN ITGB3 messenger RNA (ITGB3 mRNA) DM1SAIX MA Inhibitor DM1SAIX RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DM1SAIX RU https://pubmed.ncbi.nlm.nih.gov/16570923 DM1SCU5 DI DM1SCU5 DM1SCU5 DN Nalorphine DM1SCU5 TI TTQW87Y DM1SCU5 TN Opioid receptor kappa (OPRK1) DM1SCU5 MA Agonist DM1SCU5 RN Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol. 1999 Nov 3;383(3):305-9. DM1SCU5 RU https://pubmed.ncbi.nlm.nih.gov/10594324 DM1SDN3 DI DM1SDN3 DM1SDN3 DN ISIS 23718 DM1SDN3 TI TTEWOHV DM1SDN3 TN Survivin messenger RNA (Survivin mRNA) DM1SDN3 RN US patent application no. 6,165,788, Antisense modulation of Survivin expression. DM1SDN3 RU http://www.patentbuddy.com/Patent/6165788?ft=true&sr=true DM1SDN8 DI DM1SDN8 DM1SDN8 DN HOMOERIODICTYOL DM1SDN8 TI TTI84H7 DM1SDN8 TN Cytochrome P450 1B1 (CYP1B1) DM1SDN8 MA Inhibitor DM1SDN8 RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM1SDN8 RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM1SEXA DI DM1SEXA DM1SEXA DN 7-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine DM1SEXA TI TT1RS9F DM1SEXA TN Acetylcholinesterase (AChE) DM1SEXA MA Inhibitor DM1SEXA RN The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex ) derivaties, Bioorg. Med. Chem. Lett. 2(8):861-864 (1992). DM1SEXA RU http://www.sciencedirect.com/science/article/pii/S0960894X00805454 DM1SIQD DI DM1SIQD DM1SIQD DN 2-(methylsulfonyl)naphthalene-1,4-diol DM1SIQD TI TTRVTMX DM1SIQD TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DM1SIQD MA Inhibitor DM1SIQD RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DM1SIQD RU https://pubmed.ncbi.nlm.nih.gov/18996691 DM1SJZ3 DI DM1SJZ3 DM1SJZ3 DN (S)-Rolipram DM1SJZ3 TI TTZ97H5 DM1SJZ3 TN Phosphodiesterase 4A (PDE4A) DM1SJZ3 MA Inhibitor DM1SJZ3 RN PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. DM1SJZ3 RU https://pubmed.ncbi.nlm.nih.gov/19304913 DM1SJZ3 DI DM1SJZ3 DM1SJZ3 DN (S)-Rolipram DM1SJZ3 TI TTVIAT9 DM1SJZ3 TN Phosphodiesterase 4B (PDE4B) DM1SJZ3 MA Inhibitor DM1SJZ3 RN PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. DM1SJZ3 RU https://pubmed.ncbi.nlm.nih.gov/19304913 DM1SJZ3 DI DM1SJZ3 DM1SJZ3 DN (S)-Rolipram DM1SJZ3 TI TTV5CGO DM1SJZ3 TN Phosphodiesterase 4 (PDE4) DM1SJZ3 MA Inhibitor DM1SJZ3 RN PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. DM1SJZ3 RU https://pubmed.ncbi.nlm.nih.gov/19304913 DM1SKNP DI DM1SKNP DM1SKNP DN KOSN1559 DM1SKNP TI TT78R5H DM1SKNP TN Heat shock protein 90 alpha (HSP90A) DM1SKNP MA Inhibitor DM1SKNP RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DM1SKNP RU https://pubmed.ncbi.nlm.nih.gov/18855578 DM1SN37 DI DM1SN37 DM1SN37 DN 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine DM1SN37 TI TTSQIFT DM1SN37 TN 5-HT 1A receptor (HTR1A) DM1SN37 MA Inhibitor DM1SN37 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM1SN37 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM1SN37 DI DM1SN37 DM1SN37 DN 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine DM1SN37 TI TT3ROYC DM1SN37 TN Serotonin transporter (SERT) DM1SN37 MA Inhibitor DM1SN37 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM1SN37 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM1SN37 DI DM1SN37 DM1SN37 DN 2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine DM1SN37 TI TTAWNKZ DM1SN37 TN Norepinephrine transporter (NET) DM1SN37 MA Inhibitor DM1SN37 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM1SN37 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM1SO62 DI DM1SO62 DM1SO62 DN 5,8-hydroxy-naphthoquinone DM1SO62 TI TT3PQ2Y DM1SO62 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM1SO62 MA Inhibitor DM1SO62 RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DM1SO62 RU https://pubmed.ncbi.nlm.nih.gov/10658902 DM1SON5 DI DM1SON5 DM1SON5 DN 5H-6-thia-4,5-diaza-chrysene 6,6-dioxide DM1SON5 TI TTSXVID DM1SON5 TN Nuclear factor NF-kappa-B (NFKB) DM1SON5 MA Inhibitor DM1SON5 RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DM1SON5 RU https://pubmed.ncbi.nlm.nih.gov/18024113 DM1SOT4 DI DM1SOT4 DM1SOT4 DN [Gly8]GLP-1(7-37)-NH2 DM1SOT4 TI TTVIMDE DM1SOT4 TN Glucagon-like peptide 1 receptor (GLP1R) DM1SOT4 MA Inhibitor DM1SOT4 RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DM1SOT4 RU https://pubmed.ncbi.nlm.nih.gov/18412318 DM1SP36 DI DM1SP36 DM1SP36 DN 4-(10H-Anthracen-9-ylidene)-1-methyl-piperidine DM1SP36 TI TTJQOD7 DM1SP36 TN 5-HT 2A receptor (HTR2A) DM1SP36 MA Inhibitor DM1SP36 RN Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6. DM1SP36 RU https://pubmed.ncbi.nlm.nih.gov/11229772 DM1T8IP DI DM1T8IP DM1T8IP DN 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid DM1T8IP TI TTNT2S6 DM1T8IP TN Fatty acid-binding protein 5 (FABP5) DM1T8IP MA Inhibitor DM1T8IP RN NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7. DM1T8IP RU https://pubmed.ncbi.nlm.nih.gov/16884313 DM1T8IP DI DM1T8IP DM1T8IP DN 2-(2,3-bis(2-chlorobenzyloxy)phenyl)acetic acid DM1T8IP TI TTHWMFZ DM1T8IP TN Fatty acid-binding protein 4 (FABP4) DM1T8IP MA Inhibitor DM1T8IP RN NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7. DM1T8IP RU https://pubmed.ncbi.nlm.nih.gov/16884313 DM1T95Y DI DM1T95Y DM1T95Y DN 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol DM1T95Y TI TT1MPAY DM1T95Y TN GABA(A) receptor alpha-1 (GABRA1) DM1T95Y MA Inhibitor DM1T95Y RN Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relatio... J Med Chem. 2010 Apr 22;53(8):3417-21. DM1T95Y RU https://pubmed.ncbi.nlm.nih.gov/20355712 DM1T95Y DI DM1T95Y DM1T95Y DN 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol DM1T95Y TI TTZA1NY DM1T95Y TN GABA(A) receptor beta-2 (GABRB2) DM1T95Y MA Inhibitor DM1T95Y RN Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relatio... J Med Chem. 2010 Apr 22;53(8):3417-21. DM1T95Y RU https://pubmed.ncbi.nlm.nih.gov/20355712 DM1T95Y DI DM1T95Y DM1T95Y DN 4-(biphenyl-3-yl)-5-(piperidin-4-yl)isoxazol-3-ol DM1T95Y TI TT06RH5 DM1T95Y TN GABA(A) receptor gamma-2 (GABRG2) DM1T95Y MA Inhibitor DM1T95Y RN Novel 4-(piperidin-4-yl)-1-hydroxypyrazoles as gamma-aminobutyric acid(A) receptor ligands: synthesis, pharmacology, and structure-activity relatio... J Med Chem. 2010 Apr 22;53(8):3417-21. DM1T95Y RU https://pubmed.ncbi.nlm.nih.gov/20355712 DM1T9LJ DI DM1T9LJ DM1T9LJ DN PMID23692593C20 DM1T9LJ TI TTS78AZ DM1T9LJ TN Prostate specific antigen (KLK3) DM1T9LJ MA Inhibitor DM1T9LJ RN Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. J Med Chem. 2013 Jun 13;56(11):4224-35. DM1T9LJ RU https://pubmed.ncbi.nlm.nih.gov/23692593 DM1TA5R DI DM1TA5R DM1TA5R DN N-(cis-9-cis-12-octadecadienyl)sulfamide DM1TA5R TI TT6OEDT DM1TA5R TN Cannabinoid receptor 1 (CB1) DM1TA5R MA Inhibitor DM1TA5R RN Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95. DM1TA5R RU https://pubmed.ncbi.nlm.nih.gov/19762126 DM1TAM9 DI DM1TAM9 DM1TAM9 DN oleoyl-thiophosphate DM1TAM9 TI TTQ6S1K DM1TAM9 TN Lysophosphatidic acid receptor 1 (LPAR1) DM1TAM9 MA Agonist DM1TAM9 RN Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin. 2010 Sep;31(9):1213-22. DM1TAM9 RU https://pubmed.ncbi.nlm.nih.gov/20729877 DM1TAM9 DI DM1TAM9 DM1TAM9 DN oleoyl-thiophosphate DM1TAM9 TI TTB7Y8I DM1TAM9 TN Lysophosphatidic acid receptor 2 (LPAR2) DM1TAM9 MA Agonist DM1TAM9 RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DM1TAM9 RU https://pubmed.ncbi.nlm.nih.gov/16033271 DM1TAM9 DI DM1TAM9 DM1TAM9 DN oleoyl-thiophosphate DM1TAM9 TI TTE2YJR DM1TAM9 TN Lysophosphatidate-3 receptor (LPAR3) DM1TAM9 MA Agonist DM1TAM9 RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DM1TAM9 RU https://pubmed.ncbi.nlm.nih.gov/16033271 DM1TK45 DI DM1TK45 DM1TK45 DN 2-((1H-imidazol-4-yl)methyl)pyridine DM1TK45 TI TT9JNIC DM1TK45 TN Histamine H3 receptor (H3R) DM1TK45 MA Inhibitor DM1TK45 RN Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem. 2010 Sep 9;53(17):6445-56. DM1TK45 RU https://pubmed.ncbi.nlm.nih.gov/20690643 DM1TNWG DI DM1TNWG DM1TNWG DN 1-propionyl-1H-indole-2,3-dione DM1TNWG TI TTMF541 DM1TNWG TN Liver carboxylesterase (CES1) DM1TNWG MA Inhibitor DM1TNWG RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM1TNWG RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM1TOFD DI DM1TOFD DM1TOFD DN 6-(1H-Indole-2-sulfonyl)-2H-pyridazin-3-one DM1TOFD TI TTFBNVI DM1TOFD TN Aldose reductase (AKR1B1) DM1TOFD MA Inhibitor DM1TOFD RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM1TOFD RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM1TQ7N DI DM1TQ7N DM1TQ7N DN I-5 DM1TQ7N TI TTRSMW9 DM1TQ7N TN Glycogen synthase kinase-3 beta (GSK-3B) DM1TQ7N MA Inhibitor DM1TQ7N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1TQ7N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1TQXO DI DM1TQXO DM1TQXO DN IMP-731 DM1TQXO TI TTNVXAW DM1TQXO TN Lymphocyte activation gene 3 protein (LAG3) DM1TQXO MA Modulator DM1TQXO RN IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5. DM1TQXO RU https://pubmed.ncbi.nlm.nih.gov/17394654 DM1TZNK DI DM1TZNK DM1TZNK DN 2-(4-(methylsulfonyl)phenyl)pyridine DM1TZNK TI TTVKILB DM1TZNK TN Prostaglandin G/H synthase 2 (COX-2) DM1TZNK MA Inhibitor DM1TZNK RN Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71. DM1TZNK RU https://pubmed.ncbi.nlm.nih.gov/20804197 DM1U29V DI DM1U29V DM1U29V DN WRC-0571 DM1U29V TI TTK25J1 DM1U29V TN Adenosine A1 receptor (ADORA1) DM1U29V MA Antagonist DM1U29V RN Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors. J Pharmacol Exp Ther. 1996 Feb;276(2):490-9. DM1U29V RU https://pubmed.ncbi.nlm.nih.gov/8632314 DM1U6P7 DI DM1U6P7 DM1U6P7 DN CP-409069 DM1U6P7 TI TTKPW01 DM1U6P7 TN Androgen receptor messenger RNA (AR mRNA) DM1U6P7 MA Inhibitor DM1U6P7 RN Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. DM1U6P7 RU https://pubmed.ncbi.nlm.nih.gov/12036351 DM1U6P7 DI DM1U6P7 DM1U6P7 DN CP-409069 DM1U6P7 TI TTOZRK6 DM1U6P7 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM1U6P7 MA Inhibitor DM1U6P7 RN Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. J Med Chem. 2010 Apr 22;53(8):3065-74. DM1U6P7 RU https://pubmed.ncbi.nlm.nih.gov/20334371 DM1U6P7 DI DM1U6P7 DM1U6P7 DN CP-409069 DM1U6P7 TI TTZAYWL DM1U6P7 TN Estrogen receptor (ESR) DM1U6P7 MA Inhibitor DM1U6P7 RN Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. DM1U6P7 RU https://pubmed.ncbi.nlm.nih.gov/12036351 DM1U6P7 DI DM1U6P7 DM1U6P7 DN CP-409069 DM1U6P7 TI TTOM3J0 DM1U6P7 TN Estrogen receptor beta (ESR2) DM1U6P7 MA Inhibitor DM1U6P7 RN Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. DM1U6P7 RU https://pubmed.ncbi.nlm.nih.gov/12036351 DM1U7MC DI DM1U7MC DM1U7MC DN (S)-1,7-Diphenyl-6(E)-hepten-3-ol DM1U7MC TI TT50QJ3 DM1U7MC TN Influenza Neuraminidase (Influ NA) DM1U7MC MA Inhibitor DM1U7MC RN Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86. DM1U7MC RU https://pubmed.ncbi.nlm.nih.gov/20014777 DM1UAQT DI DM1UAQT DM1UAQT DN VU0152099 DM1UAQT TI TTOXS3C DM1UAQT TN Muscarinic acetylcholine receptor (CHRM) DM1UAQT MA Modulator (allosteric modulator) DM1UAQT RN Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats. J Pharmacol Exp Ther. 2008 Dec;327(3):941-53. DM1UAQT RU https://pubmed.ncbi.nlm.nih.gov/18772318 DM1UAWP DI DM1UAWP DM1UAWP DN GlaxoSmithKline compound 6i DM1UAWP TI TTA93TL DM1UAWP TN P2Y purinoceptor 1 (P2RY1) DM1UAWP MA Antagonist DM1UAWP RN Tetrahydro-4-quinolinamines identified as novel P2Y(1) receptor antagonists. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6222-6. DM1UAWP RU https://pubmed.ncbi.nlm.nih.gov/18926700 DM1UBGQ DI DM1UBGQ DM1UBGQ DN 2-(4,6-dimethoxypyrimidin-2-yloxy)-5-hexylphenol DM1UBGQ TI TTVTX4N DM1UBGQ TN Bacterial Fatty acid synthetase I (Bact inhA) DM1UBGQ MA Inhibitor DM1UBGQ RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DM1UBGQ RU https://pubmed.ncbi.nlm.nih.gov/18457948 DM1UCZ9 DI DM1UCZ9 DM1UCZ9 DN N,N-diCPM[D-Pro-10]Dyn A-(1-11) DM1UCZ9 TI TTQW87Y DM1UCZ9 TN Opioid receptor kappa (OPRK1) DM1UCZ9 MA Inhibitor DM1UCZ9 RN Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9. DM1UCZ9 RU https://pubmed.ncbi.nlm.nih.gov/9276018 DM1UG2A DI DM1UG2A DM1UG2A DN 4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol DM1UG2A TI TTZAYWL DM1UG2A TN Estrogen receptor (ESR) DM1UG2A MA Inhibitor DM1UG2A RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM1UG2A RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM1UG2A DI DM1UG2A DM1UG2A DN 4-Benzo[d]isoxazol-3-yl-benzene-1,3-diol DM1UG2A TI TTOM3J0 DM1UG2A TN Estrogen receptor beta (ESR2) DM1UG2A MA Inhibitor DM1UG2A RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM1UG2A RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM1UGQN DI DM1UGQN DM1UGQN DN (8R,8'R)-4-hydroxycubebinone DM1UGQN TI TTXV4FI DM1UGQN TN Albendazole monooxygenase (CYP3A4) DM1UGQN MA Inhibitor DM1UGQN RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DM1UGQN RU https://pubmed.ncbi.nlm.nih.gov/15679319 DM1UK3G DI DM1UK3G DM1UK3G DN 4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole DM1UK3G TI TTBRKXS DM1UK3G TN Adrenergic receptor alpha-1B (ADRA1B) DM1UK3G MA Inhibitor DM1UK3G RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM1UK3G RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM1UK3G DI DM1UK3G DM1UK3G DN 4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole DM1UK3G TI TT34BHT DM1UK3G TN Adrenergic receptor alpha-1D (ADRA1D) DM1UK3G MA Inhibitor DM1UK3G RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM1UK3G RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM1UK3G DI DM1UK3G DM1UK3G DN 4-((Z)-1-Naphthalen-1-yl-propenyl)-1H-imidazole DM1UK3G TI TTNGILX DM1UK3G TN Adrenergic receptor alpha-1A (ADRA1A) DM1UK3G MA Inhibitor DM1UK3G RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM1UK3G RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM1ULEX DI DM1ULEX DM1ULEX DN 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine DM1ULEX TI TTAWNKZ DM1ULEX TN Norepinephrine transporter (NET) DM1ULEX MA Inhibitor DM1ULEX RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM1ULEX RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM1ULEX DI DM1ULEX DM1ULEX DN 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine DM1ULEX TI TTVBI8W DM1ULEX TN Dopamine transporter (DAT) DM1ULEX MA Inhibitor DM1ULEX RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM1ULEX RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM1ULEX DI DM1ULEX DM1ULEX DN 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine DM1ULEX TI TTSQIFT DM1ULEX TN 5-HT 1A receptor (HTR1A) DM1ULEX MA Inhibitor DM1ULEX RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM1ULEX RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM1ULEX DI DM1ULEX DM1ULEX DN 2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine DM1ULEX TI TT3ROYC DM1ULEX TN Serotonin transporter (SERT) DM1ULEX MA Inhibitor DM1ULEX RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM1ULEX RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM1UOWB DI DM1UOWB DM1UOWB DN 3-epi-masilinic acid DM1UOWB TI TTELIN2 DM1UOWB TN PTPN1 messenger RNA (PTPN1 mRNA) DM1UOWB MA Inhibitor DM1UOWB RN Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6618-22. DM1UOWB RU https://pubmed.ncbi.nlm.nih.gov/19846303 DM1UX89 DI DM1UX89 DM1UX89 DN 4-(5-(4-aminophenyl)thiophen-2-yl)phenol DM1UX89 TI TTE4KHA DM1UX89 TN Amyloid beta A4 protein (APP) DM1UX89 MA Inhibitor DM1UX89 RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DM1UX89 RU https://pubmed.ncbi.nlm.nih.gov/16325402 DM1UXHE DI DM1UXHE DM1UXHE DN 4-APPES DM1UXHE TI TTXJ47W DM1UXHE TN Metabotropic glutamate receptor 2 (mGluR2) DM1UXHE MA Modulator (allosteric modulator) DM1UXHE RN Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83. DM1UXHE RU https://pubmed.ncbi.nlm.nih.gov/15717213 DM1V0MD DI DM1V0MD DM1V0MD DN RPR-120844 DM1V0MD TI TTZUXYS DM1V0MD TN Vitamin K-dependent protein C (PROC) DM1V0MD MA Inhibitor DM1V0MD RN Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem. 1999 Sep 9;42(18):3557-71. DM1V0MD RU https://pubmed.ncbi.nlm.nih.gov/10479288 DM1V7EF DI DM1V7EF DM1V7EF DN 2-(4-Benzyl-piperazin-1-yl)-benzothiazole DM1V7EF TI TTR6K75 DM1V7EF TN 5-HT 3B receptor (HTR3B) DM1V7EF MA Inhibitor DM1V7EF RN Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties. J Med Chem. 1994 Apr 29;37(9):1320-5. DM1V7EF RU https://pubmed.ncbi.nlm.nih.gov/8176710 DM1V7EF DI DM1V7EF DM1V7EF DN 2-(4-Benzyl-piperazin-1-yl)-benzothiazole DM1V7EF TI TTPC4TU DM1V7EF TN 5-HT 3A receptor (HTR3A) DM1V7EF MA Inhibitor DM1V7EF RN Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties. J Med Chem. 1994 Apr 29;37(9):1320-5. DM1V7EF RU https://pubmed.ncbi.nlm.nih.gov/8176710 DM1V83P DI DM1V83P DM1V83P DN N-(4-(2-aminoethyl)phenyl)benzenesulfonamide DM1V83P TI TTJS8PY DM1V83P TN 5-HT 6 receptor (HTR6) DM1V83P MA Inhibitor DM1V83P RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DM1V83P RU https://pubmed.ncbi.nlm.nih.gov/16913710 DM1VCJP DI DM1VCJP DM1VCJP DN C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 DM1VCJP TI TT0MV2T DM1VCJP TN Melanocortin receptor 1 (MC1R) DM1VCJP MA Inhibitor DM1VCJP RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DM1VCJP RU https://pubmed.ncbi.nlm.nih.gov/18088090 DM1VCJP DI DM1VCJP DM1VCJP DN C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 DM1VCJP TI TTEOSZT DM1VCJP TN Melanocortin receptor (MCR) DM1VCJP MA Inhibitor DM1VCJP RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DM1VCJP RU https://pubmed.ncbi.nlm.nih.gov/18088090 DM1VCJP DI DM1VCJP DM1VCJP DN C[CO-2,3-pyrazine-CO-D-Nal(2)-Arg-Trp-Lys]-NH2 DM1VCJP TI TTNI91K DM1VCJP TN Melanocortin receptor 3 (MC3R) DM1VCJP MA Inhibitor DM1VCJP RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DM1VCJP RU https://pubmed.ncbi.nlm.nih.gov/18088090 DM1VDC3 DI DM1VDC3 DM1VDC3 DN 2-(3-chlorobenzyloxy)-6-chloroisonicotinonitrile DM1VDC3 TI TTHS256 DM1VDC3 TN Metabotropic glutamate receptor 5 (mGluR5) DM1VDC3 MA Inhibitor DM1VDC3 RN Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. DM1VDC3 RU https://pubmed.ncbi.nlm.nih.gov/16439120 DM1VE6S DI DM1VE6S DM1VE6S DN Acetyl-Ile-Glu-Thr-Asp-aldehyde DM1VE6S TI TTEVCT0 DM1VE6S TN Caspase-8 (CASP8) DM1VE6S MA Inhibitor DM1VE6S RN The atomic-resolution structure of human caspase-8, a key activator of apoptosis. Structure. 1999 Sep 15;7(9):1135-43. DM1VE6S RU https://pubmed.ncbi.nlm.nih.gov/10508785 DM1VE6S DI DM1VE6S DM1VE6S DN Acetyl-Ile-Glu-Thr-Asp-aldehyde DM1VE6S TI TT6SZNG DM1VE6S TN Caspase 8 messenger RNA (CASP8 mRNA) DM1VE6S MA Inhibitor DM1VE6S RN Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. J Med Chem. 2009 Apr 23;52(8):2188-91. DM1VE6S RU https://pubmed.ncbi.nlm.nih.gov/19326941 DM1VF6H DI DM1VF6H DM1VF6H DN BS 7581 DM1VF6H TI TTVG215 DM1VF6H TN Debrisoquine 4-hydroxylase (CYP2D6) DM1VF6H MA Inhibitor DM1VF6H RN Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30. DM1VF6H RU https://pubmed.ncbi.nlm.nih.gov/16610785 DM1VFLG DI DM1VFLG DM1VFLG DN H-Tyr-Tic-Cha-Phe-OH DM1VFLG TI TTKWM86 DM1VFLG TN Opioid receptor mu (MOP) DM1VFLG MA Inhibitor DM1VFLG RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DM1VFLG RU https://pubmed.ncbi.nlm.nih.gov/17228874 DM1VFLG DI DM1VFLG DM1VFLG DN H-Tyr-Tic-Cha-Phe-OH DM1VFLG TI TT27RFC DM1VFLG TN Opioid receptor delta (OPRD1) DM1VFLG MA Inhibitor DM1VFLG RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DM1VFLG RU https://pubmed.ncbi.nlm.nih.gov/17228874 DM1VHCL DI DM1VHCL DM1VHCL DN Allyl-trimethyl-ammonium DM1VHCL TI TT1RS9F DM1VHCL TN Acetylcholinesterase (AChE) DM1VHCL MA Inhibitor DM1VHCL RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DM1VHCL RU https://pubmed.ncbi.nlm.nih.gov/8978837 DM1VIHC DI DM1VIHC DM1VIHC DN NORSTEPHALAGINE DM1VIHC TI TTZFYLI DM1VIHC TN Dopamine D1 receptor (D1R) DM1VIHC MA Inhibitor DM1VIHC RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DM1VIHC RU https://pubmed.ncbi.nlm.nih.gov/17228858 DM1VIHC DI DM1VIHC DM1VIHC DN NORSTEPHALAGINE DM1VIHC TI TTVBI8W DM1VIHC TN Dopamine transporter (DAT) DM1VIHC MA Inhibitor DM1VIHC RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DM1VIHC RU https://pubmed.ncbi.nlm.nih.gov/8676127 DM1VJUZ DI DM1VJUZ DM1VJUZ DN (4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine DM1VJUZ TI TTZUFI5 DM1VJUZ TN Nitric-oxide synthase brain (NOS1) DM1VJUZ MA Inhibitor DM1VJUZ RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM1VJUZ RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM1VJUZ DI DM1VJUZ DM1VJUZ DN (4S,5S)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine DM1VJUZ TI TTF10I9 DM1VJUZ TN Nitric-oxide synthase inducible (NOS2) DM1VJUZ MA Inhibitor DM1VJUZ RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM1VJUZ RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM1VLMC DI DM1VLMC DM1VLMC DN 1-(3-Chloro-phenyl)-3-cyclohexyl-urea DM1VLMC TI TT7WVHI DM1VLMC TN Soluble epoxide hydrolase (EPHX2) DM1VLMC MA Inhibitor DM1VLMC RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DM1VLMC RU https://pubmed.ncbi.nlm.nih.gov/15887969 DM1VNEF DI DM1VNEF DM1VNEF DN 4-formylphenyl-O-beta-Dglucopyranoside DM1VNEF TI TT1RS9F DM1VNEF TN Acetylcholinesterase (AChE) DM1VNEF MA Inhibitor DM1VNEF RN Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. Eur J Med Chem. 2008 Jan;43(1):166-73. DM1VNEF RU https://pubmed.ncbi.nlm.nih.gov/17574306 DM1VQ4K DI DM1VQ4K DM1VQ4K DN Sp-Adenosine-3',5'-Cyclic-Monophosphorothioate DM1VQ4K TI TTNAHEX DM1VQ4K TN cAMP-dependent protein kinase A type I (PRKAR1A) DM1VQ4K MA Inhibitor DM1VQ4K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM1VQ4K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM1VSO9 DI DM1VSO9 DM1VSO9 DN N-Phenylethyl-ETAV DM1VSO9 TI TT9PB26 DM1VSO9 TN Presynaptic density protein 95 (DLG4) DM1VSO9 MA Inhibitor DM1VSO9 RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DM1VSO9 RU https://pubmed.ncbi.nlm.nih.gov/18811137 DM1VSOK DI DM1VSOK DM1VSOK DN 2-(3-(3-methoxyphenoxy)prop-1-ynyl)pyridine DM1VSOK TI TTHS256 DM1VSOK TN Metabotropic glutamate receptor 5 (mGluR5) DM1VSOK MA Inhibitor DM1VSOK RN A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5). Bioorg Med Chem Lett. 2006 Sep 15;16(18):4792-5. DM1VSOK RU https://pubmed.ncbi.nlm.nih.gov/16839764 DM1VTFU DI DM1VTFU DM1VTFU DN 3-Ethyl-3-methyl-dihydro-furan-2-one DM1VTFU TI TTZA1NY DM1VTFU TN GABA(A) receptor beta-2 (GABRB2) DM1VTFU MA Inhibitor DM1VTFU RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM1VTFU RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM1VTFU DI DM1VTFU DM1VTFU DN 3-Ethyl-3-methyl-dihydro-furan-2-one DM1VTFU TI TTNJYV2 DM1VTFU TN Gamma-aminobutyric acid receptor (GAR) DM1VTFU MA Inhibitor DM1VTFU RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM1VTFU RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM1VTFU DI DM1VTFU DM1VTFU DN 3-Ethyl-3-methyl-dihydro-furan-2-one DM1VTFU TI TT06RH5 DM1VTFU TN GABA(A) receptor gamma-2 (GABRG2) DM1VTFU MA Inhibitor DM1VTFU RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM1VTFU RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM1VTFU DI DM1VTFU DM1VTFU DN 3-Ethyl-3-methyl-dihydro-furan-2-one DM1VTFU TI TT1MPAY DM1VTFU TN GABA(A) receptor alpha-1 (GABRA1) DM1VTFU MA Inhibitor DM1VTFU RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM1VTFU RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM1W2GZ DI DM1W2GZ DM1W2GZ DN N-ethyl estradiol-16-methyl carboxamide DM1W2GZ TI TTIWB6L DM1W2GZ TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM1W2GZ MA Inhibitor DM1W2GZ RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM1W2GZ RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM1W3L9 DI DM1W3L9 DM1W3L9 DN 2-(N-Pyrrolidinyl)-3'-methoxypropiophenone DM1W3L9 TI TTVBI8W DM1W3L9 TN Dopamine transporter (DAT) DM1W3L9 MA Inhibitor DM1W3L9 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM1W3L9 RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM1W3L9 DI DM1W3L9 DM1W3L9 DN 2-(N-Pyrrolidinyl)-3'-methoxypropiophenone DM1W3L9 TI TTAWNKZ DM1W3L9 TN Norepinephrine transporter (NET) DM1W3L9 MA Inhibitor DM1W3L9 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM1W3L9 RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM1W5G9 DI DM1W5G9 DM1W5G9 DN GPCR39 pepducins DM1W5G9 TI TTTPCNU DM1W5G9 TN G-protein coupled receptor 39 (GPR39) DM1W5G9 MA Modulator DM1W5G9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 105). DM1W5G9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=105 DM1W8Y0 DI DM1W8Y0 DM1W8Y0 DN LG-888 DM1W8Y0 TI TT1290U DM1W8Y0 TN Coagulation factor VIII (F8) DM1W8Y0 MA Stimulator DM1W8Y0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM1W8Y0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM1WCJV DI DM1WCJV DM1WCJV DN (+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one DM1WCJV TI TT3WG5C DM1WCJV TN Monoamine oxidase type A (MAO-A) DM1WCJV MA Inhibitor DM1WCJV RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DM1WCJV RU https://pubmed.ncbi.nlm.nih.gov/20123154 DM1WCJV DI DM1WCJV DM1WCJV DN (+/-)-2-(4'-Butoxyphenyl)thiomorpholin-5-one DM1WCJV TI TTGP7BY DM1WCJV TN Monoamine oxidase type B (MAO-B) DM1WCJV MA Inhibitor DM1WCJV RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DM1WCJV RU https://pubmed.ncbi.nlm.nih.gov/20123154 DM1WJFR DI DM1WJFR DM1WJFR DN 7-Phenyl-naphthalen-2-ol DM1WJFR TI TTZAYWL DM1WJFR TN Estrogen receptor (ESR) DM1WJFR MA Inhibitor DM1WJFR RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM1WJFR RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM1WJFR DI DM1WJFR DM1WJFR DN 7-Phenyl-naphthalen-2-ol DM1WJFR TI TTOM3J0 DM1WJFR TN Estrogen receptor beta (ESR2) DM1WJFR MA Inhibitor DM1WJFR RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM1WJFR RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM1WMHO DI DM1WMHO DM1WMHO DN L-365,209 DM1WMHO TI TTSCIUP DM1WMHO TN Oxytocin receptor (OTR) DM1WMHO MA Antagonist DM1WMHO RN Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61. DM1WMHO RU https://pubmed.ncbi.nlm.nih.gov/7475979 DM1WPE3 DI DM1WPE3 DM1WPE3 DN 11-keto-ursolic acid DM1WPE3 TI TTN7BL9 DM1WPE3 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM1WPE3 MA Inhibitor DM1WPE3 RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DM1WPE3 RU https://pubmed.ncbi.nlm.nih.gov/20100662 DM1WZXL DI DM1WZXL DM1WZXL DN (4-hexylphenyl)(oxiran-2-yl)methanone DM1WZXL TI TTGER3L DM1WZXL TN Thyroid hormone receptor beta (THRB) DM1WZXL MA Inhibitor DM1WZXL RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM1WZXL RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM1X5JR DI DM1X5JR DM1X5JR DN Pyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione DM1X5JR TI TTVDSZ0 DM1X5JR TN Poly [ADP-ribose] polymerase 1 (PARP1) DM1X5JR MA Inhibitor DM1X5JR RN Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42. DM1X5JR RU https://pubmed.ncbi.nlm.nih.gov/16290935 DM1X5RY DI DM1X5RY DM1X5RY DN 2-N-Methylamino-1-(4-ethylthiophenyl)propane DM1X5RY TI TT3ROYC DM1X5RY TN Serotonin transporter (SERT) DM1X5RY MA Inhibitor DM1X5RY RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM1X5RY RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM1XAPO DI DM1XAPO DM1XAPO DN ISIS 29234 DM1XAPO TI TTYMGWX DM1XAPO TN PDK-1 messenger RNA (PDK-1 mRNA) DM1XAPO RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DM1XAPO RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DM1XE4F DI DM1XE4F DM1XE4F DN AZ-599 DM1XE4F TI TT6OEDT DM1XE4F TN Cannabinoid receptor 1 (CB1) DM1XE4F MA Agonist DM1XE4F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56). DM1XE4F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56 DM1XFE9 DI DM1XFE9 DM1XFE9 DN RECALL-VAX DM1XFE9 TI TTE4KHA DM1XFE9 TN Amyloid beta A4 protein (APP) DM1XFE9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM1XFE9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM1XH04 DI DM1XH04 DM1XH04 DN MCL-429 DM1XH04 TI TTKWM86 DM1XH04 TN Opioid receptor mu (MOP) DM1XH04 MA Inhibitor DM1XH04 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM1XH04 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM1XH04 DI DM1XH04 DM1XH04 DN MCL-429 DM1XH04 TI TTQW87Y DM1XH04 TN Opioid receptor kappa (OPRK1) DM1XH04 MA Inhibitor DM1XH04 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM1XH04 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM1XH04 DI DM1XH04 DM1XH04 DN MCL-429 DM1XH04 TI TT27RFC DM1XH04 TN Opioid receptor delta (OPRD1) DM1XH04 MA Inhibitor DM1XH04 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM1XH04 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM1XH8D DI DM1XH8D DM1XH8D DN N'-Acridin-9-yl-N,N-diethyl-butane-1,4-diamine DM1XH8D TI TTFK1JQ DM1XH8D TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM1XH8D MA Inhibitor DM1XH8D RN N-Acridin-9-yl-butane-1,4-diamine derivatives: high-affinity ligands of the alpha2delta subunit of voltage gated calcium channels. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1913-6. DM1XH8D RU https://pubmed.ncbi.nlm.nih.gov/15050626 DM1XHNW DI DM1XHNW DM1XHNW DN IRAK4 inhibitor rac-45 DM1XHNW TI TTKFVXR DM1XHNW TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DM1XHNW MA Inhibitor DM1XHNW RN IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3656-60. DM1XHNW RU https://pubmed.ncbi.nlm.nih.gov/18501603 DM1XJBE DI DM1XJBE DM1XJBE DN OLPADRONIC ACID SODIUM SALT DM1XJBE TI TTIKWV4 DM1XJBE TN Geranyltranstransferase (FDPS) DM1XJBE MA Modulator DM1XJBE RN Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999 Feb 16;255(2):491-4. DM1XJBE RU https://pubmed.ncbi.nlm.nih.gov/10049736 DM1XK68 DI DM1XK68 DM1XK68 DN 4-(mesitylthio)-2-methoxybenzonitrile DM1XK68 TI TTKPW01 DM1XK68 TN Androgen receptor messenger RNA (AR mRNA) DM1XK68 MA Inhibitor DM1XK68 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM1XK68 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM1XTJC DI DM1XTJC DM1XTJC DN 4,12,17-dehydroxyriccardin C DM1XTJC TI TTECBXN DM1XTJC TN Oxysterols receptor LXR-alpha (NR1H3) DM1XTJC MA Inhibitor DM1XTJC RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DM1XTJC RU https://pubmed.ncbi.nlm.nih.gov/18343126 DM1XV0O DI DM1XV0O DM1XV0O DN N-Phenyl-1-methyl-1H-indole-2-carboxamide DM1XV0O TI TT3WG5C DM1XV0O TN Monoamine oxidase type A (MAO-A) DM1XV0O MA Inhibitor DM1XV0O RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DM1XV0O RU https://pubmed.ncbi.nlm.nih.gov/18951803 DM1XY5F DI DM1XY5F DM1XY5F DN MN-462 DM1XY5F TI TTP18AY DM1XY5F TN Carboxypeptidase B2 (CPB2) DM1XY5F MA Inhibitor DM1XY5F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1594). DM1XY5F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1594 DM1XY7C DI DM1XY7C DM1XY7C DN (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone DM1XY7C TI TT6OEDT DM1XY7C TN Cannabinoid receptor 1 (CB1) DM1XY7C MA Inhibitor DM1XY7C RN Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9. DM1XY7C RU https://pubmed.ncbi.nlm.nih.gov/20047779 DM1XY7C DI DM1XY7C DM1XY7C DN (4-benzhydrylpiperazin-1-yl)(cyclohexyl)methanone DM1XY7C TI TTMSFAW DM1XY7C TN Cannabinoid receptor 2 (CB2) DM1XY7C MA Inhibitor DM1XY7C RN Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9. DM1XY7C RU https://pubmed.ncbi.nlm.nih.gov/20047779 DM1Y2F0 DI DM1Y2F0 DM1Y2F0 DN PBD150 DM1Y2F0 TI TTJ7YTV DM1Y2F0 TN Glutaminyl cyclase (QPCT) DM1Y2F0 MA Inhibitor DM1Y2F0 RN The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J Med Chem. 2006 Jan 26;49(2):664-77. DM1Y2F0 RU https://pubmed.ncbi.nlm.nih.gov/16420052 DM1Y6L8 DI DM1Y6L8 DM1Y6L8 DN 3-(decylthio)-1,1,1-trifluoropropan-2-one DM1Y6L8 TI TTMF541 DM1Y6L8 TN Liver carboxylesterase (CES1) DM1Y6L8 MA Inhibitor DM1Y6L8 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM1Y6L8 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM1Y6L8 DI DM1Y6L8 DM1Y6L8 DN 3-(decylthio)-1,1,1-trifluoropropan-2-one DM1Y6L8 TI TTDP1UC DM1Y6L8 TN Fatty acid amide hydrolase (FAAH) DM1Y6L8 MA Inhibitor DM1Y6L8 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM1Y6L8 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM1Y9MZ DI DM1Y9MZ DM1Y9MZ DN (R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DM1Y9MZ TI TTF10I9 DM1Y9MZ TN Nitric-oxide synthase inducible (NOS2) DM1Y9MZ MA Inhibitor DM1Y9MZ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DM1Y9MZ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DM1Y9MZ DI DM1Y9MZ DM1Y9MZ DN (R)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DM1Y9MZ TI TTZUFI5 DM1Y9MZ TN Nitric-oxide synthase brain (NOS1) DM1Y9MZ MA Inhibitor DM1Y9MZ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DM1Y9MZ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DM1YBJ2 DI DM1YBJ2 DM1YBJ2 DN (+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one DM1YBJ2 TI TT3WG5C DM1YBJ2 TN Monoamine oxidase type A (MAO-A) DM1YBJ2 MA Inhibitor DM1YBJ2 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DM1YBJ2 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DM1YBJ2 DI DM1YBJ2 DM1YBJ2 DN (+/-)-2-(4'-Ethoxyphenyl)thiomorpholin-5-one DM1YBJ2 TI TTGP7BY DM1YBJ2 TN Monoamine oxidase type B (MAO-B) DM1YBJ2 MA Inhibitor DM1YBJ2 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DM1YBJ2 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DM1YC0B DI DM1YC0B DM1YC0B DN (4-nitrophenyl)(10H-phenothiazin-10-yl)methanone DM1YC0B TI TTEB0GD DM1YC0B TN Cholinesterase (BCHE) DM1YC0B MA Inhibitor DM1YC0B RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DM1YC0B RU https://pubmed.ncbi.nlm.nih.gov/17681768 DM1YCQF DI DM1YCQF DM1YCQF DN dolichol phosphate DM1YCQF TI TT5DFHW DM1YCQF TN Mevalonate kinase (MVK) DM1YCQF MA Inhibitor DM1YCQF RN Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways. J Lipid Res. 1997 Nov;38(11):2216-23. DM1YCQF RU https://pubmed.ncbi.nlm.nih.gov/9392419 DM1YK42 DI DM1YK42 DM1YK42 DN 9-Methoxy-1,2,3,4-tetrahydro-anthracen-2-ylamine DM1YK42 TI TTSQIFT DM1YK42 TN 5-HT 1A receptor (HTR1A) DM1YK42 MA Inhibitor DM1YK42 RN Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993). DM1YK42 RU http://www.sciencedirect.com/science/article/pii/S0960894X0181009X DM1YK7M DI DM1YK7M DM1YK7M DN 2-methyl-6-(4-phenylbut-1-ynyl)pyridine DM1YK7M TI TTHS256 DM1YK7M TN Metabotropic glutamate receptor 5 (mGluR5) DM1YK7M MA Inhibitor DM1YK7M RN Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91. DM1YK7M RU https://pubmed.ncbi.nlm.nih.gov/16837196 DM1YLF6 DI DM1YLF6 DM1YLF6 DN PMID17574411C42 DM1YLF6 TI TTPADOQ DM1YLF6 TN HMG-CoA reductase (HMGCR) DM1YLF6 MA Inhibitor DM1YLF6 RN Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4531-7. DM1YLF6 RU https://pubmed.ncbi.nlm.nih.gov/17574411 DM1YN0F DI DM1YN0F DM1YN0F DN FGGFTGARKSARKWKNQ DM1YN0F TI TTNT7K8 DM1YN0F TN Nociceptin receptor (OPRL1) DM1YN0F MA Inhibitor DM1YN0F RN Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. DM1YN0F RU https://pubmed.ncbi.nlm.nih.gov/19577933 DM1YOVG DI DM1YOVG DM1YOVG DN PMID30247903-Compound-General structure34 DM1YOVG TI TT23XQV DM1YOVG TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM1YOVG MA Inhibitor DM1YOVG RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM1YOVG RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM1YUBX DI DM1YUBX DM1YUBX DN 9-N-METHYL-8-METHOXY-MANZAMINE A DM1YUBX TI TTRSMW9 DM1YUBX TN Glycogen synthase kinase-3 beta (GSK-3B) DM1YUBX MA Inhibitor DM1YUBX RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DM1YUBX RU https://pubmed.ncbi.nlm.nih.gov/17708655 DM1YZJ3 DI DM1YZJ3 DM1YZJ3 DN ZRCCNCSSKWCRDHSRCC DM1YZJ3 TI TT84DRB DM1YZJ3 TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DM1YZJ3 MA Inhibitor DM1YZJ3 RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DM1YZJ3 RU https://pubmed.ncbi.nlm.nih.gov/17724025 DM1Z3D7 DI DM1Z3D7 DM1Z3D7 DN PD-169316 DM1Z3D7 TI TTSJ6Q4 DM1Z3D7 TN LOX-5 messenger RNA (ALOX5 mRNA) DM1Z3D7 MA Inhibitor DM1Z3D7 RN 2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis, Bioorg. Med. Chem. Lett. 5(11):1171-1176 (1995). DM1Z3D7 RU http://www.sciencedirect.com/science/article/pii/0960894X9500189Z DM1Z3DG DI DM1Z3DG DM1Z3DG DN 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine DM1Z3DG TI TTSZLWK DM1Z3DG TN Aromatase (CYP19A1) DM1Z3DG MA Inhibitor DM1Z3DG RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM1Z3DG RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM1Z3DG DI DM1Z3DG DM1Z3DG DN 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine DM1Z3DG TI TTRA5BZ DM1Z3DG TN Steroid 17-alpha-monooxygenase (S17AH) DM1Z3DG MA Inhibitor DM1Z3DG RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM1Z3DG RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM1Z3DG DI DM1Z3DG DM1Z3DG DN 4-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine DM1Z3DG TI TTIQUX7 DM1Z3DG TN Steroid 11-beta-hydroxylase (CYP11B1) DM1Z3DG MA Inhibitor DM1Z3DG RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM1Z3DG RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM1Z3N6 DI DM1Z3N6 DM1Z3N6 DN 4-(6-morpholino-9H-purin-2-yl)phenol DM1Z3N6 TI TTCJG29 DM1Z3N6 TN Serine/threonine-protein kinase mTOR (mTOR) DM1Z3N6 MA Inhibitor DM1Z3N6 RN Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. DM1Z3N6 RU https://pubmed.ncbi.nlm.nih.gov/19969455 DM1Z5W8 DI DM1Z5W8 DM1Z5W8 DN ISIS 147788 DM1Z5W8 TI TTN1IE2 DM1Z5W8 TN APOB messenger RNA (APOB mRNA) DM1Z5W8 RN US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression. DM1Z5W8 RU http://www.patentbuddy.com/Patent/7407943?ft=true&sr=true DM1Z7QK DI DM1Z7QK DM1Z7QK DN KNI-10081 DM1Z7QK TI TTXMNHO DM1Z7QK TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM1Z7QK MA Inhibitor DM1Z7QK RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DM1Z7QK RU https://pubmed.ncbi.nlm.nih.gov/18952439 DM1ZBU3 DI DM1ZBU3 DM1ZBU3 DN BMS-193885 DM1ZBU3 TI TTRK9JT DM1ZBU3 TN Neuropeptide Y receptor type 1 (NPY1R) DM1ZBU3 MA Antagonist DM1ZBU3 RN Dihydropyridine neuropeptide Y Y(1) receptor antagonists. Bioorg Med Chem Lett. 2002 Feb 11;12(3):379-82. DM1ZBU3 RU https://pubmed.ncbi.nlm.nih.gov/11814801 DM1ZDFG DI DM1ZDFG DM1ZDFG DN BMS-404683 DM1ZDFG TI TT7WZIJ DM1ZDFG TN CAAX farnesyltransferase beta (FNTB) DM1ZDFG MA Inhibitor DM1ZDFG RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DM1ZDFG RU https://pubmed.ncbi.nlm.nih.gov/15916422 DM1ZDFG DI DM1ZDFG DM1ZDFG DN BMS-404683 DM1ZDFG TI TTXQKM3 DM1ZDFG TN Farnesyl protein transferase (Ftase) DM1ZDFG MA Inhibitor DM1ZDFG RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DM1ZDFG RU https://pubmed.ncbi.nlm.nih.gov/15916422 DM1ZDJ6 DI DM1ZDJ6 DM1ZDJ6 DN H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2 DM1ZDJ6 TI TT27RFC DM1ZDJ6 TN Opioid receptor delta (OPRD1) DM1ZDJ6 MA Inhibitor DM1ZDJ6 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DM1ZDJ6 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DM1ZDJ6 DI DM1ZDJ6 DM1ZDJ6 DN H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2 DM1ZDJ6 TI TTKWM86 DM1ZDJ6 TN Opioid receptor mu (MOP) DM1ZDJ6 MA Inhibitor DM1ZDJ6 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DM1ZDJ6 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DM1ZF3Y DI DM1ZF3Y DM1ZF3Y DN CH-4933468 DM1ZF3Y TI TTS64P2 DM1ZF3Y TN Androgen receptor (AR) DM1ZF3Y MA Antagonist DM1ZF3Y RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM1ZF3Y RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM1ZH2U DI DM1ZH2U DM1ZH2U DN Isosorbide-2-(butylcarbamate)-5-benzoate DM1ZH2U TI TTEB0GD DM1ZH2U TN Cholinesterase (BCHE) DM1ZH2U MA Inhibitor DM1ZH2U RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DM1ZH2U RU https://pubmed.ncbi.nlm.nih.gov/18817366 DM1ZM5R DI DM1ZM5R DM1ZM5R DN [(40-OH)MeLeu]4-Cyclosporin A DM1ZM5R TI TT84ETX DM1ZM5R TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM1ZM5R MA Inhibitor DM1ZM5R RN Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9. DM1ZM5R RU https://pubmed.ncbi.nlm.nih.gov/14643337 DM1ZMUN DI DM1ZMUN DM1ZMUN DN GNF-PF-4599 DM1ZMUN TI TTZPWGN DM1ZMUN TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DM1ZMUN MA Inhibitor DM1ZMUN RN 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105. DM1ZMUN RU https://pubmed.ncbi.nlm.nih.gov/17074493 DM1ZPGY DI DM1ZPGY DM1ZPGY DN N-phenethylquinoxaline-2-carboxamide DM1ZPGY TI TTVBPDM DM1ZPGY TN Metabotropic glutamate receptor 1 (mGluR1) DM1ZPGY MA Inhibitor DM1ZPGY RN Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90. DM1ZPGY RU https://pubmed.ncbi.nlm.nih.gov/17064898 DM201Q7 DI DM201Q7 DM201Q7 DN SB 239063 DM201Q7 TI TTVKILB DM201Q7 TN Prostaglandin G/H synthase 2 (COX-2) DM201Q7 MA Inhibitor DM201Q7 RN SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization. Pharm Res. 2001 Sep;18(9):1336-44. DM201Q7 RU https://pubmed.ncbi.nlm.nih.gov/11683250 DM201UM DI DM201UM DM201UM DN 4-(Indane-1-sulfonyl)-phenylamine DM201UM TI TTJS8PY DM201UM TN 5-HT 6 receptor (HTR6) DM201UM MA Inhibitor DM201UM RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DM201UM RU https://pubmed.ncbi.nlm.nih.gov/15808453 DM205TE DI DM205TE DM205TE DN ISIS 10303 DM205TE TI TT7A1BO DM205TE TN PKC-delta messenger RNA (PRKCD mRNA) DM205TE RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DM205TE RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DM206M1 DI DM206M1 DM206M1 DN 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol DM206M1 TI TTHY57M DM206M1 TN Matrix metalloproteinase-13 (MMP-13) DM206M1 MA Inhibitor DM206M1 RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DM206M1 RU https://pubmed.ncbi.nlm.nih.gov/10406637 DM206M1 DI DM206M1 DM206M1 DN 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol DM206M1 TI TTGA1IV DM206M1 TN Matrix metalloproteinase-8 (MMP-8) DM206M1 MA Inhibitor DM206M1 RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DM206M1 RU https://pubmed.ncbi.nlm.nih.gov/10406637 DM206M1 DI DM206M1 DM206M1 DN 3-(4-Methoxy-benzenesulfonyl)-cyclohexanethiol DM206M1 TI TTMX39J DM206M1 TN Matrix metalloproteinase-1 (MMP-1) DM206M1 MA Inhibitor DM206M1 RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DM206M1 RU https://pubmed.ncbi.nlm.nih.gov/10406637 DM207CQ DI DM207CQ DM207CQ DN 5-Chloro-3-ethyl-1-(4-fluoro-phenyl)-1H-indole DM207CQ TI TTQ6VDM DM207CQ TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM207CQ MA Inhibitor DM207CQ RN Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett. 2003 May 19;13(10):1829-35. DM207CQ RU https://pubmed.ncbi.nlm.nih.gov/12729675 DM20AJ4 DI DM20AJ4 DM20AJ4 DN VPC-94075 DM20AJ4 TI TTOHFIY DM20AJ4 TN Sphingosine kinase 1 (SPHK1) DM20AJ4 MA Inhibitor DM20AJ4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2204). DM20AJ4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2204 DM20DAG DI DM20DAG DM20DAG DN 6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium DM20DAG TI TT1RS9F DM20DAG TN Acetylcholinesterase (AChE) DM20DAG MA Inhibitor DM20DAG RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DM20DAG RU https://pubmed.ncbi.nlm.nih.gov/16945529 DM20DAG DI DM20DAG DM20DAG DN 6-hydroxy-1,2-dimethyl-9H-beta-carbolin-2-ium DM20DAG TI TTEB0GD DM20DAG TN Cholinesterase (BCHE) DM20DAG MA Inhibitor DM20DAG RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DM20DAG RU https://pubmed.ncbi.nlm.nih.gov/16945529 DM20DXS DI DM20DXS DM20DXS DN 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione DM20DXS TI TTSZLWK DM20DXS TN Aromatase (CYP19A1) DM20DXS MA Inhibitor DM20DXS RN Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9. DM20DXS RU https://pubmed.ncbi.nlm.nih.gov/3735304 DM20DXS DI DM20DXS DM20DXS DN 3-(4-Amino-phenyl)-3-pentyl-piperidine-2,6-dione DM20DXS TI TTSYVO6 DM20DXS TN Cholesterol desmolase (CYP11A1) DM20DXS MA Inhibitor DM20DXS RN Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9. DM20DXS RU https://pubmed.ncbi.nlm.nih.gov/3735304 DM20E13 DI DM20E13 DM20E13 DN PMID25408830C2 DM20E13 TI TTT46BN DM20E13 TN Bromodomain and PHD finger containing 1 (BRPF1) DM20E13 MA Inhibitor DM20E13 RN 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5. DM20E13 RU https://pubmed.ncbi.nlm.nih.gov/25408830 DM20E13 DI DM20E13 DM20E13 DN PMID25408830C2 DM20E13 TI TTRA6BO DM20E13 TN Bromodomain-containing protein 4 (BRD4) DM20E13 MA Inhibitor DM20E13 RN 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5. DM20E13 RU https://pubmed.ncbi.nlm.nih.gov/25408830 DM20PEO DI DM20PEO DM20PEO DN Ac-I[CV(2Nal)QDWGAHRC]T DM20PEO TI TTJGY7A DM20PEO TN Complement C3 (CO3) DM20PEO MA Inhibitor DM20PEO RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DM20PEO RU https://pubmed.ncbi.nlm.nih.gov/15634022 DM20Q5O DI DM20Q5O DM20Q5O DN SB-747651A DM20Q5O TI TTO6SGY DM20Q5O TN AKT3 messenger RNA (AKT3 mRNA) DM20Q5O MA Inhibitor DM20Q5O RN Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79. DM20Q5O RU https://pubmed.ncbi.nlm.nih.gov/18800763 DM20Q5O DI DM20Q5O DM20Q5O DN SB-747651A DM20Q5O TI TTZN7RP DM20Q5O TN Rho-associated protein kinase 1 (ROCK1) DM20Q5O MA Inhibitor DM20Q5O RN Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79. DM20Q5O RU https://pubmed.ncbi.nlm.nih.gov/18800763 DM20Q5O DI DM20Q5O DM20Q5O DN SB-747651A DM20Q5O TI TTG0U4H DM20Q5O TN Ribosomal protein S6 kinase beta-1 (S6K1) DM20Q5O MA Inhibitor DM20Q5O RN (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3407-11. DM20Q5O RU https://pubmed.ncbi.nlm.nih.gov/15955699 DM20Q5O DI DM20Q5O DM20Q5O DN SB-747651A DM20Q5O TI TTWTSCV DM20Q5O TN RAC-alpha serine/threonine-protein kinase (AKT1) DM20Q5O MA Inhibitor DM20Q5O RN Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-o... J Med Chem. 2008 Sep 25;51(18):5663-79. DM20Q5O RU https://pubmed.ncbi.nlm.nih.gov/18800763 DM20TFH DI DM20TFH DM20TFH DN PMID1656041C11ff DM20TFH TI TTPADOQ DM20TFH TN HMG-CoA reductase (HMGCR) DM20TFH MA Inhibitor DM20TFH RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83. DM20TFH RU https://pubmed.ncbi.nlm.nih.gov/1656041 DM20X8C DI DM20X8C DM20X8C DN 5'-O-[(L-Methionyl)-Sulphamoyl]Adenosine DM20X8C TI TTOJ46K DM20X8C TN Streptococcus Methionyl-tRNA synthetase (Stre-coc metG) DM20X8C MA Inhibitor DM20X8C RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM20X8C RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2104G DI DM2104G DM2104G DN (S)-2-amino-2-phenylpropanoic acid DM2104G TI TTFK1JQ DM2104G TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM2104G MA Inhibitor DM2104G RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DM2104G RU https://pubmed.ncbi.nlm.nih.gov/16380257 DM213MD DI DM213MD DM213MD DN M-Aminophenylboronic Acid DM213MD TI TTHI19T DM213MD TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM213MD MA Inhibitor DM213MD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM213MD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM218VZ DI DM218VZ DM218VZ DN [33P]2MeSADP DM218VZ TI TT1FE3L DM218VZ TN P2Y purinoceptor 13 (P2RY13) DM218VZ MA Agonist DM218VZ RN Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. DM218VZ RU https://pubmed.ncbi.nlm.nih.gov/12815166 DM21B46 DI DM21B46 DM21B46 DN [3H]ramosetron DM21B46 TI TTPC4TU DM21B46 TN 5-HT 3A receptor (HTR3A) DM21B46 MA Antagonist DM21B46 RN Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol. 1995 Sep;48(3):407-16. DM21B46 RU https://pubmed.ncbi.nlm.nih.gov/7565620 DM21CXZ DI DM21CXZ DM21CXZ DN (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone DM21CXZ TI TTGJCWZ DM21CXZ TN Fms-like tyrosine kinase 3 (FLT-3) DM21CXZ MA Inhibitor DM21CXZ RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM21CXZ RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM21CXZ DI DM21CXZ DM21CXZ DN (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone DM21CXZ TI TTI7421 DM21CXZ TN Platelet-derived growth factor receptor beta (PDGFRB) DM21CXZ MA Inhibitor DM21CXZ RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM21CXZ RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM21CXZ DI DM21CXZ DM21CXZ DN (1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone DM21CXZ TI TT8FYO9 DM21CXZ TN Platelet-derived growth factor receptor alpha (PDGFRA) DM21CXZ MA Inhibitor DM21CXZ RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM21CXZ RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM21CYI DI DM21CYI DM21CYI DN BMS-316810 DM21CYI TI TT7WZIJ DM21CYI TN CAAX farnesyltransferase beta (FNTB) DM21CYI MA Inhibitor DM21CYI RN Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1895-9. DM21CYI RU https://pubmed.ncbi.nlm.nih.gov/15780629 DM21JVF DI DM21JVF DM21JVF DN Cbz-Glu(OtBu)-Ala-LeuVSMe DM21JVF TI TTUMQVO DM21JVF TN Cathepsin S (CTSS) DM21JVF MA Inhibitor DM21JVF RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DM21JVF RU https://pubmed.ncbi.nlm.nih.gov/16686537 DM21K0E DI DM21K0E DM21K0E DN ISOTETRANDRINE DM21K0E TI TTVBI8W DM21K0E TN Dopamine transporter (DAT) DM21K0E MA Inhibitor DM21K0E RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DM21K0E RU https://pubmed.ncbi.nlm.nih.gov/8676127 DM21MAU DI DM21MAU DM21MAU DN 2-(3-methoxybenzylthio)-2-phenylacetic acid DM21MAU TI TTLUQ8E DM21MAU TN Hormone sensitive lipase (LIPE) DM21MAU MA Inhibitor DM21MAU RN Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94. DM21MAU RU https://pubmed.ncbi.nlm.nih.gov/18808096 DM21WOP DI DM21WOP DM21WOP DN WO2013026806C72 DM21WOP TI TTYGQ8A DM21WOP TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM21WOP MA Inhibitor DM21WOP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2010). DM21WOP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2010 DM21WOP DI DM21WOP DM21WOP DN WO2013026806C72 DM21WOP TI TTSBVFO DM21WOP TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM21WOP MA Inhibitor DM21WOP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2009). DM21WOP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2009 DM21XBO DI DM21XBO DM21XBO DN FGGFTGARKSARKRANQ DM21XBO TI TTNT7K8 DM21XBO TN Nociceptin receptor (OPRL1) DM21XBO MA Inhibitor DM21XBO RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DM21XBO RU https://pubmed.ncbi.nlm.nih.gov/18818087 DM21Z6H DI DM21Z6H DM21Z6H DN SB 649915 DM21Z6H TI TTSQIFT DM21Z6H TN 5-HT 1A receptor (HTR1A) DM21Z6H MA Antagonist DM21Z6H RN Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80. DM21Z6H RU https://pubmed.ncbi.nlm.nih.gov/15887956 DM21Z6H DI DM21Z6H DM21Z6H DN SB 649915 DM21Z6H TI TT6MSOK DM21Z6H TN 5-HT 1D receptor (HTR1D) DM21Z6H MA Antagonist DM21Z6H RN Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80. DM21Z6H RU https://pubmed.ncbi.nlm.nih.gov/15887956 DM21Z6H DI DM21Z6H DM21Z6H DN SB 649915 DM21Z6H TI TTK8CXU DM21Z6H TN 5-HT 1B receptor (HTR1B) DM21Z6H MA Antagonist DM21Z6H RN Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80. DM21Z6H RU https://pubmed.ncbi.nlm.nih.gov/15887956 DM21ZBU DI DM21ZBU DM21ZBU DN Breceptin DM21ZBU TI TTGY8IW DM21ZBU TN B2 bradykinin receptor (BDKRB2) DM21ZBU MA Modulator DM21ZBU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 42). DM21ZBU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=42 DM21ZCQ DI DM21ZCQ DM21ZCQ DN ISIS 31996 DM21ZCQ TI TT9H4P3 DM21ZCQ TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DM21ZCQ RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DM21ZCQ RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DM2348V DI DM2348V DM2348V DN PP-242 DM2348V TI TTC0V1J DM2348V TN PAS domain-containing serine/threonine-protein kinase (PASK) DM2348V MA Inhibitor DM2348V RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DM2348V RU https://pubmed.ncbi.nlm.nih.gov/18849971 DM2348V DI DM2348V DM2348V DN PP-242 DM2348V TI TTCJG29 DM2348V TN Serine/threonine-protein kinase mTOR (mTOR) DM2348V MA Inhibitor DM2348V RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DM2348V RU https://pubmed.ncbi.nlm.nih.gov/18849971 DM235CQ DI DM235CQ DM235CQ DN 1-Hydroxy-10H-anthracen-9-one DM235CQ TI TT2J34L DM235CQ TN Arachidonate 5-lipoxygenase (5-LOX) DM235CQ MA Inhibitor DM235CQ RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DM235CQ RU https://pubmed.ncbi.nlm.nih.gov/9371243 DM235Q4 DI DM235Q4 DM235Q4 DN 2-(hexylthiomethyl)-5-hydroxy-4H-pyran-4-one DM235Q4 TI TTULVH8 DM235Q4 TN Tyrosinase (TYR) DM235Q4 MA Inhibitor DM235Q4 RN Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71. DM235Q4 RU https://pubmed.ncbi.nlm.nih.gov/20934336 DM235XH DI DM235XH DM235XH DN Suberic bishydroxamic acid DM235XH TI TTBH0VX DM235XH TN Histone deacetylase (HDAC) DM235XH MA Inhibitor DM235XH RN Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. DM235XH RU https://pubmed.ncbi.nlm.nih.gov/16955068 DM2395E DI DM2395E DM2395E DN P'-geranyl 3,5,9-trihydroxy-3-methylnonanate 9-diphosphate DM2395E TI TTE5J6X DM2395E TN Diphosphomevalonate decarboxylase (MVD) DM2395E MA Inhibitor DM2395E RN Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6. DM2395E RU https://pubmed.ncbi.nlm.nih.gov/16524256 DM23CEI DI DM23CEI DM23CEI DN 3,8-dibromoboldine DM23CEI TI TTEX248 DM23CEI TN Dopamine D2 receptor (D2R) DM23CEI MA Inhibitor DM23CEI RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DM23CEI RU https://pubmed.ncbi.nlm.nih.gov/10785418 DM23CEI DI DM23CEI DM23CEI DN 3,8-dibromoboldine DM23CEI TI TTZFYLI DM23CEI TN Dopamine D1 receptor (D1R) DM23CEI MA Inhibitor DM23CEI RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DM23CEI RU https://pubmed.ncbi.nlm.nih.gov/10785418 DM23CEI DI DM23CEI DM23CEI DN 3,8-dibromoboldine DM23CEI TI TTLA931 DM23CEI TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM23CEI MA Inhibitor DM23CEI RN Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72. DM23CEI RU https://pubmed.ncbi.nlm.nih.gov/17391965 DM23E0R DI DM23E0R DM23E0R DN 4-Inden-(1E)-ylidenemethyl-phenylamine DM23E0R TI TTJS8PY DM23E0R TN 5-HT 6 receptor (HTR6) DM23E0R MA Inhibitor DM23E0R RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DM23E0R RU https://pubmed.ncbi.nlm.nih.gov/15808453 DM23GCK DI DM23GCK DM23GCK DN [Dcp1]Dyn A(1-11)-NH2 DM23GCK TI TT27RFC DM23GCK TN Opioid receptor delta (OPRD1) DM23GCK MA Inhibitor DM23GCK RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DM23GCK RU https://pubmed.ncbi.nlm.nih.gov/16913729 DM23GCK DI DM23GCK DM23GCK DN [Dcp1]Dyn A(1-11)-NH2 DM23GCK TI TTQW87Y DM23GCK TN Opioid receptor kappa (OPRK1) DM23GCK MA Inhibitor DM23GCK RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DM23GCK RU https://pubmed.ncbi.nlm.nih.gov/16913729 DM23GCK DI DM23GCK DM23GCK DN [Dcp1]Dyn A(1-11)-NH2 DM23GCK TI TTKWM86 DM23GCK TN Opioid receptor mu (MOP) DM23GCK MA Inhibitor DM23GCK RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DM23GCK RU https://pubmed.ncbi.nlm.nih.gov/16913729 DM23I8E DI DM23I8E DM23I8E DN 3-Prop-1-ynylquinoline-8-carboxamide DM23I8E TI TTVDSZ0 DM23I8E TN Poly [ADP-ribose] polymerase 1 (PARP1) DM23I8E MA Inhibitor DM23I8E RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DM23I8E RU https://pubmed.ncbi.nlm.nih.gov/19117416 DM23JIY DI DM23JIY DM23JIY DN 3-(4-cyanophenyl)quinoxaline-5-carboxamide DM23JIY TI TTVDSZ0 DM23JIY TN Poly [ADP-ribose] polymerase 1 (PARP1) DM23JIY MA Inhibitor DM23JIY RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DM23JIY RU https://pubmed.ncbi.nlm.nih.gov/19125579 DM23KNC DI DM23KNC DM23KNC DN C16-Fatty-Acyl-Substrate-Mimic DM23KNC TI TTVTX4N DM23KNC TN Bacterial Fatty acid synthetase I (Bact inhA) DM23KNC MA Inhibitor DM23KNC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM23KNC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM23PL4 DI DM23PL4 DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate DM23PL4 TI TT06RH5 DM23PL4 TN GABA(A) receptor gamma-2 (GABRG2) DM23PL4 MA Inhibitor DM23PL4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DM23PL4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DM23PL4 DI DM23PL4 DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate DM23PL4 TI TTBMV1G DM23PL4 TN GABA(A) receptor alpha-2 (GABRA2) DM23PL4 MA Inhibitor DM23PL4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DM23PL4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DM23PL4 DI DM23PL4 DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate DM23PL4 TI TT37EDJ DM23PL4 TN GABA(A) receptor alpha-3 (GABRA3) DM23PL4 MA Inhibitor DM23PL4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DM23PL4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DM23PL4 DI DM23PL4 DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate DM23PL4 TI TTNJYV2 DM23PL4 TN Gamma-aminobutyric acid receptor (GAR) DM23PL4 MA Inhibitor DM23PL4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DM23PL4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DM23PL4 DI DM23PL4 DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate DM23PL4 TI TTZA1NY DM23PL4 TN GABA(A) receptor beta-2 (GABRB2) DM23PL4 MA Inhibitor DM23PL4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DM23PL4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DM23PL4 DI DM23PL4 DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate DM23PL4 TI TTNZPQ1 DM23PL4 TN GABA(A) receptor alpha-5 (GABRA5) DM23PL4 MA Inhibitor DM23PL4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DM23PL4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DM23PL4 DI DM23PL4 DM23PL4 DN 5-[(1R)-1-ammonioethyl]isoxazol-3-olate DM23PL4 TI TT1MPAY DM23PL4 TN GABA(A) receptor alpha-1 (GABRA1) DM23PL4 MA Inhibitor DM23PL4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DM23PL4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DM23QND DI DM23QND DM23QND DN AD-0802 DM23QND TI TTE4KHA DM23QND TN Amyloid beta A4 protein (APP) DM23QND RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM23QND RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM23RUZ DI DM23RUZ DM23RUZ DN JWH-307 DM23RUZ TI TTMSFAW DM23RUZ TN Cannabinoid receptor 2 (CB2) DM23RUZ MA Inhibitor DM23RUZ RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM23RUZ RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM23RUZ DI DM23RUZ DM23RUZ DN JWH-307 DM23RUZ TI TT6OEDT DM23RUZ TN Cannabinoid receptor 1 (CB1) DM23RUZ MA Inhibitor DM23RUZ RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM23RUZ RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM23W58 DI DM23W58 DM23W58 DN (+/-)-6-(2-chlorophenyl)cyclohex-3-enamine DM23W58 TI TTDIGC1 DM23W58 TN Dipeptidyl peptidase 4 (DPP-4) DM23W58 MA Inhibitor DM23W58 RN Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)... J Med Chem. 2006 Nov 2;49(22):6439-42. DM23W58 RU https://pubmed.ncbi.nlm.nih.gov/17064063 DM23WOV DI DM23WOV DM23WOV DN 2-oxoguaia-1,4,11(13)-trien-12,8alpha-olide DM23WOV TI TTSXVID DM23WOV TN Nuclear factor NF-kappa-B (NFKB) DM23WOV MA Inhibitor DM23WOV RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DM23WOV RU https://pubmed.ncbi.nlm.nih.gov/16570920 DM23XGW DI DM23XGW DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one DM23XGW TI TTT6LFV DM23XGW TN Histone deacetylase 8 (HDAC8) DM23XGW MA Inhibitor DM23XGW RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM23XGW RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM23XGW DI DM23XGW DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one DM23XGW TI TTBH0VX DM23XGW TN Histone deacetylase (HDAC) DM23XGW MA Inhibitor DM23XGW RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM23XGW RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM23XGW DI DM23XGW DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one DM23XGW TI TT6R7JZ DM23XGW TN Histone deacetylase 1 (HDAC1) DM23XGW MA Inhibitor DM23XGW RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM23XGW RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM23XGW DI DM23XGW DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one DM23XGW TI TT5ZKDI DM23XGW TN Histone deacetylase 6 (HDAC6) DM23XGW MA Inhibitor DM23XGW RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM23XGW RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM23XGW DI DM23XGW DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one DM23XGW TI TTTQGH8 DM23XGW TN Histone deacetylase 4 (HDAC4) DM23XGW MA Inhibitor DM23XGW RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM23XGW RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM23XGW DI DM23XGW DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one DM23XGW TI TTYHPU6 DM23XGW TN Histone deacetylase 10 (HDAC10) DM23XGW MA Inhibitor DM23XGW RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM23XGW RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM23XGW DI DM23XGW DM23XGW DN 8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one DM23XGW TI TTSHTOI DM23XGW TN Histone deacetylase 2 (HDAC2) DM23XGW MA Inhibitor DM23XGW RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM23XGW RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM2403T DI DM2403T DM2403T DN 7n-Methyl-8-Hydroguanosine-5'-Diphosphate DM2403T TI TTZGCP6 DM2403T TN EIF4E messenger RNA (EIF4E mRNA) DM2403T MA Inhibitor DM2403T RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2403T RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM241YW DI DM241YW DM241YW DN CMP-6 DM241YW TI TTRMX3V DM241YW TN Janus kinase 2 (JAK-2) DM241YW MA Inhibitor DM241YW RN Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. DM241YW RU https://pubmed.ncbi.nlm.nih.gov/11934592 DM241YW DI DM241YW DM241YW DN CMP-6 DM241YW TI TTT7PJU DM241YW TN Janus kinase 3 (JAK-3) DM241YW MA Inhibitor DM241YW RN Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. DM241YW RU https://pubmed.ncbi.nlm.nih.gov/11934592 DM241YW DI DM241YW DM241YW DN CMP-6 DM241YW TI TTBYWP2 DM241YW TN TYK2 tyrosine kinase (TYK2) DM241YW MA Inhibitor DM241YW RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DM241YW RU https://pubmed.ncbi.nlm.nih.gov/18077363 DM245AB DI DM245AB DM245AB DN 3-Methoxybenzamide DM245AB TI TTVDSZ0 DM245AB TN Poly [ADP-ribose] polymerase 1 (PARP1) DM245AB MA Inhibitor DM245AB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM245AB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM248HC DI DM248HC DM248HC DN JMV 1803 DM248HC TI TTC1MVT DM248HC TN Gastrin-releasing peptide receptor (GRPR) DM248HC MA Inhibitor DM248HC RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DM248HC RU https://pubmed.ncbi.nlm.nih.gov/10882361 DM249GI DI DM249GI DM249GI DN 8-O-(4-toluenesulfonyl)manzamine A DM249GI TI TTRSMW9 DM249GI TN Glycogen synthase kinase-3 beta (GSK-3B) DM249GI MA Inhibitor DM249GI RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DM249GI RU https://pubmed.ncbi.nlm.nih.gov/17708655 DM24BG6 DI DM24BG6 DM24BG6 DN 3-(1,5-naphthyridin-3-yl)benzonitrile DM24BG6 TI TTHS256 DM24BG6 TN Metabotropic glutamate receptor 5 (mGluR5) DM24BG6 MA Inhibitor DM24BG6 RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DM24BG6 RU https://pubmed.ncbi.nlm.nih.gov/17936624 DM24E08 DI DM24E08 DM24E08 DN (2-Indol-1-yl-ethyl)-dimethyl-amine DM24E08 TI TTJQOD7 DM24E08 TN 5-HT 2A receptor (HTR2A) DM24E08 MA Inhibitor DM24E08 RN Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8. DM24E08 RU https://pubmed.ncbi.nlm.nih.gov/11755343 DM24L0S DI DM24L0S DM24L0S DN ISIS 16518 DM24L0S TI TT9TE0O DM24L0S TN Mdm2 messenger RNA (MDM2 mRNA) DM24L0S RN US patent application no. 6,238,921, Antisense oligonucleotide modulation of human mdm2 expression. DM24L0S RU http://www.patentbuddy.com/Patent/6238921?ft=true&sr=true DM24LNB DI DM24LNB DM24LNB DN YVAD DM24LNB TI TTCQIBE DM24LNB TN Caspase-1 (CASP1) DM24LNB MA Inhibitor DM24LNB RN Mice deficient in interleukin-1beta converting enzyme resist anorexia induced by central lipopolysaccharide. Am J Physiol. 1999 Nov;277(5 Pt 2):R1435-43. DM24LNB RU https://pubmed.ncbi.nlm.nih.gov/10564217 DM24MKI DI DM24MKI DM24MKI DN AR-mTOR-26 DM24MKI TI TTCJG29 DM24MKI TN Serine/threonine-protein kinase mTOR (mTOR) DM24MKI MA Inhibitor DM24MKI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DM24MKI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DM24OIX DI DM24OIX DM24OIX DN ZL006 DM24OIX TI TTMADVT DM24OIX TN PSD95-nNOS interaction (PSD95-nNOS PPI) DM24OIX MA Disrupter DM24OIX RN PSD95 and nNOS interaction as a novel molecular target to modulate conditioned fear: relevance to PTSD.Transl Psychiatry. 2018 Aug 14;8(1):155. DM24OIX RU https://pubmed.ncbi.nlm.nih.gov/30108200 DM257WX DI DM257WX DM257WX DN alpha3IA DM257WX TI TTNZPQ1 DM257WX TN GABA(A) receptor alpha-5 (GABRA5) DM257WX MA Modulator (allosteric modulator) DM257WX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DM257WX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DM257WX DI DM257WX DM257WX DN alpha3IA DM257WX TI TTEX6LM DM257WX TN GABA(A) receptor gamma-3 (GABRG3) DM257WX MA Modulator (allosteric modulator) DM257WX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DM257WX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DM257WX DI DM257WX DM257WX DN alpha3IA DM257WX TI TT37EDJ DM257WX TN GABA(A) receptor alpha-3 (GABRA3) DM257WX MA Modulator (allosteric modulator) DM257WX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DM257WX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DM257WX DI DM257WX DM257WX DN alpha3IA DM257WX TI TTBMV1G DM257WX TN GABA(A) receptor alpha-2 (GABRA2) DM257WX MA Modulator (allosteric modulator) DM257WX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DM257WX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DM25DR7 DI DM25DR7 DM25DR7 DN 4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 TI TTIQUX7 DM25DR7 TN Steroid 11-beta-hydroxylase (CYP11B1) DM25DR7 MA Inhibitor DM25DR7 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM25DR7 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM25DR7 DI DM25DR7 DM25DR7 DN 4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 TI TTRA5BZ DM25DR7 TN Steroid 17-alpha-monooxygenase (S17AH) DM25DR7 MA Inhibitor DM25DR7 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM25DR7 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM25DR7 DI DM25DR7 DM25DR7 DN 4-Indan-(1Z)-ylidenemethyl-pyridine DM25DR7 TI TTSZLWK DM25DR7 TN Aromatase (CYP19A1) DM25DR7 MA Inhibitor DM25DR7 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM25DR7 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM25EDB DI DM25EDB DM25EDB DN PRT-060096 DM25EDB TI TTZ1DT0 DM25EDB TN P2Y purinoceptor 12 (P2RY12) DM25EDB MA Antagonist DM25EDB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 328). DM25EDB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=328 DM25GS6 DI DM25GS6 DM25GS6 DN 4-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine DM25GS6 TI TTSZLWK DM25GS6 TN Aromatase (CYP19A1) DM25GS6 MA Inhibitor DM25GS6 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM25GS6 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM25JXM DI DM25JXM DM25JXM DN Ac-YR[CEH(pCl-dF)RWC]-NH2 DM25JXM TI TTEOSZT DM25JXM TN Melanocortin receptor (MCR) DM25JXM MA Inhibitor DM25JXM RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM25JXM RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM25JXM DI DM25JXM DM25JXM DN Ac-YR[CEH(pCl-dF)RWC]-NH2 DM25JXM TI TTNI91K DM25JXM TN Melanocortin receptor 3 (MC3R) DM25JXM MA Inhibitor DM25JXM RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM25JXM RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM25JXM DI DM25JXM DM25JXM DN Ac-YR[CEH(pCl-dF)RWC]-NH2 DM25JXM TI TTD0CIQ DM25JXM TN Melanocortin receptor 4 (MC4R) DM25JXM MA Inhibitor DM25JXM RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM25JXM RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM25JXM DI DM25JXM DM25JXM DN Ac-YR[CEH(pCl-dF)RWC]-NH2 DM25JXM TI TT0MV2T DM25JXM TN Melanocortin receptor 1 (MC1R) DM25JXM MA Inhibitor DM25JXM RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM25JXM RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM25K86 DI DM25K86 DM25K86 DN 3-Benzoyl-N-hydroxy-benzamide DM25K86 TI TT2J34L DM25K86 TN Arachidonate 5-lipoxygenase (5-LOX) DM25K86 MA Inhibitor DM25K86 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DM25K86 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DM25KZE DI DM25KZE DM25KZE DN HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 DM25KZE TI TTKWM86 DM25KZE TN Opioid receptor mu (MOP) DM25KZE MA Inhibitor DM25KZE RN The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21. DM25KZE RU https://pubmed.ncbi.nlm.nih.gov/19807094 DM25KZE DI DM25KZE DM25KZE DN HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 DM25KZE TI TT27RFC DM25KZE TN Opioid receptor delta (OPRD1) DM25KZE MA Inhibitor DM25KZE RN The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21. DM25KZE RU https://pubmed.ncbi.nlm.nih.gov/19807094 DM25KZE DI DM25KZE DM25KZE DN HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 DM25KZE TI TTQW87Y DM25KZE TN Opioid receptor kappa (OPRK1) DM25KZE MA Inhibitor DM25KZE RN The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21. DM25KZE RU https://pubmed.ncbi.nlm.nih.gov/19807094 DM25NLH DI DM25NLH DM25NLH DN N-1-isopropyltryptamine DM25NLH TI TTJQOD7 DM25NLH TN 5-HT 2A receptor (HTR2A) DM25NLH MA Agonist DM25NLH RN Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86. DM25NLH RU https://pubmed.ncbi.nlm.nih.gov/8114677 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTWJBZ5 DM260KD TN 5-HT 2C receptor (HTR2C) DM260KD MA Agonist DM260KD RN Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. 2000 Feb;35(2):144-50. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/10611640 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTK8CXU DM260KD TN 5-HT 1B receptor (HTR1B) DM260KD MA Agonist DM260KD RN Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3020-4. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/1557407 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTCPG9S DM260KD TN 5-HT 1E receptor (HTR1E) DM260KD MA Agonist DM260KD RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/14744596 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TT0MI3F DM260KD TN 5-HT 1F receptor (HTR1F) DM260KD MA Agonist DM260KD RN Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/9225282 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTRUFDT DM260KD TN 5-HT 5A receptor (HTR5A) DM260KD MA Agonist DM260KD RN Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/8549774 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TT6MSOK DM260KD TN 5-HT 1D receptor (HTR1D) DM260KD MA Agonist DM260KD RN Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/1652050 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTO9X1H DM260KD TN 5-HT 7 receptor (HTR7) DM260KD MA Agonist DM260KD RN Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/8394987 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTJQOD7 DM260KD TN 5-HT 2A receptor (HTR2A) DM260KD MA Agonist DM260KD RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTSQIFT DM260KD TN 5-HT 1A receptor (HTR1A) DM260KD MA Agonist DM260KD RN Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/9205951 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TTJS8PY DM260KD TN 5-HT 6 receptor (HTR6) DM260KD MA Agonist DM260KD RN Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996 Jan;66(1):47-56. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/8522988 DM260KD DI DM260KD DM260KD DN 5-CT DM260KD TI TT0K1SC DM260KD TN 5-HT 2B receptor (HTR2B) DM260KD MA Agonist DM260KD RN Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. DM260KD RU https://pubmed.ncbi.nlm.nih.gov/8450835 DM260RG DI DM260RG DM260RG DN 2-(3-bromophenyl)histamine DM260RG TI TTTIBOJ DM260RG TN Histamine H1 receptor (H1R) DM260RG MA Agonist DM260RG RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DM260RG RU https://pubmed.ncbi.nlm.nih.gov/12626648 DM260RG DI DM260RG DM260RG DN 2-(3-bromophenyl)histamine DM260RG TI TTXJ178 DM260RG TN Histamine H4 receptor (H4R) DM260RG MA Agonist DM260RG RN Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. DM260RG RU https://pubmed.ncbi.nlm.nih.gov/15947036 DM260TI DI DM260TI DM260TI DN (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine DM260TI TI TTVBI8W DM260TI TN Dopamine transporter (DAT) DM260TI MA Inhibitor DM260TI RN Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. DM260TI RU https://pubmed.ncbi.nlm.nih.gov/19640707 DM260TI DI DM260TI DM260TI DN (2R,3S)-2-[(3-Iodophenoxy)phenylmethyl]morpholine DM260TI TI TT3ROYC DM260TI TN Serotonin transporter (SERT) DM260TI MA Inhibitor DM260TI RN Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. DM260TI RU https://pubmed.ncbi.nlm.nih.gov/19640707 DM261B0 DI DM261B0 DM261B0 DN 2-Imidazol-1-yl-7-methoxy-3-phenyl-chromen-4-one DM261B0 TI TTSZLWK DM261B0 TN Aromatase (CYP19A1) DM261B0 MA Inhibitor DM261B0 RN Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem. 2005 Jun 2;13(12):4063-70. DM261B0 RU https://pubmed.ncbi.nlm.nih.gov/15911319 DM264XN DI DM264XN DM264XN DN ACPT-I DM264XN TI TTWRP2F DM264XN TN Metabotropic glutamate receptor 6 (mGluR6) DM264XN MA Agonist DM264XN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294). DM264XN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294 DM264XN DI DM264XN DM264XN DN ACPT-I DM264XN TI TTICZ1O DM264XN TN Metabotropic glutamate receptor 4 (mGluR4) DM264XN MA Agonist DM264XN RN Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. J Med Chem. 1997 Sep 12;40(19):3119-29. DM264XN RU https://pubmed.ncbi.nlm.nih.gov/9301676 DM264XN DI DM264XN DM264XN DN ACPT-I DM264XN TI TT0IFKL DM264XN TN Metabotropic glutamate receptor 8 (mGluR8) DM264XN MA Agonist DM264XN RN Pharmacological characterization of the rat metabotropic glutamate receptor type 8a revealed strong similarities and slight differences with the type 4a receptor. Eur J Pharmacol. 2000 Apr 7;394(1):17-26. DM264XN RU https://pubmed.ncbi.nlm.nih.gov/10771029 DM26AB4 DI DM26AB4 DM26AB4 DN L-Iso-Aspartate DM26AB4 TI TTICX3S DM26AB4 TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DM26AB4 MA Inhibitor DM26AB4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM26AB4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM26AHR DI DM26AHR DM26AHR DN SPI-1005 DM26AHR TI TTNHMO8 DM26AHR TN COVID-19 papain-like proteinase (PL-PRO) DM26AHR MA Inhibitor DM26AHR RN Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. DM26AHR RU https://pubmed.ncbi.nlm.nih.gov/32272481 DM26AMU DI DM26AMU DM26AMU DN AGK2 DM26AMU TI TTLKF5M DM26AMU TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DM26AMU MA Inhibitor DM26AMU RN Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science. 2007 Jul 27;317(5837):516-9. DM26AMU RU https://pubmed.ncbi.nlm.nih.gov/17588900 DM26GBV DI DM26GBV DM26GBV DN QA1 DM26GBV TI TTV1C0Z DM26GBV TN Neuropeptide S receptor (NPSR) DM26GBV MA Antagonist DM26GBV RN Synthesis and evaluation of a new series of Neuropeptide S receptor antagonists. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4700-3. DM26GBV RU https://pubmed.ncbi.nlm.nih.gov/20510609 DM26JYS DI DM26JYS DM26JYS DN PMID24359159C19a DM26JYS TI TTRMX3V DM26JYS TN Janus kinase 2 (JAK-2) DM26JYS MA Inhibitor DM26JYS RN Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. DM26JYS RU https://pubmed.ncbi.nlm.nih.gov/24359159 DM26JYS DI DM26JYS DM26JYS DN PMID24359159C19a DM26JYS TI TT6DM01 DM26JYS TN Janus kinase 1 (JAK-1) DM26JYS MA Inhibitor DM26JYS RN Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. DM26JYS RU https://pubmed.ncbi.nlm.nih.gov/24359159 DM26JYS DI DM26JYS DM26JYS DN PMID24359159C19a DM26JYS TI TTT7PJU DM26JYS TN Janus kinase 3 (JAK-3) DM26JYS MA Inhibitor DM26JYS RN Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. DM26JYS RU https://pubmed.ncbi.nlm.nih.gov/24359159 DM26KQG DI DM26KQG DM26KQG DN SUN-C8257 DM26KQG TI TT8VUE0 DM26KQG TN Chymase (CYM) DM26KQG MA Inhibitor DM26KQG RN Chymase inhibitor ameliorates eosinophilia in mice infected with Nippostrongylus brasiliensis. Int Arch Allergy Immunol. 2002 Jul;128(3):235-9. DM26KQG RU https://pubmed.ncbi.nlm.nih.gov/12119506 DM26M7E DI DM26M7E DM26M7E DN ISIS 222043 DM26M7E TI TTWPA54 DM26M7E TN HIF2-alpha messenger RNA (EPAS1 mRNA) DM26M7E RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DM26M7E RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DM26MIC DI DM26MIC DM26MIC DN 5-Nitro-2-(4-phenoxy-phenyl)-1H-benzoimidazole DM26MIC TI TT9ABMF DM26MIC TN Serine/threonine-protein kinase Chk2 (RAD53) DM26MIC MA Inhibitor DM26MIC RN Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. DM26MIC RU https://pubmed.ncbi.nlm.nih.gov/15771432 DM26NKG DI DM26NKG DM26NKG DN 2-tert-butoxy-9H-carbazole DM26NKG TI TTBGTCW DM26NKG TN Kinesin spindle messenger RNA (KIF11 mRNA) DM26NKG MA Inhibitor DM26NKG RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM26NKG RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM26R4P DI DM26R4P DM26R4P DN N-benzylacetimidamide hydrobromide DM26R4P TI TTF10I9 DM26R4P TN Nitric-oxide synthase inducible (NOS2) DM26R4P MA Inhibitor DM26R4P RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DM26R4P RU https://pubmed.ncbi.nlm.nih.gov/20933416 DM26SE7 DI DM26SE7 DM26SE7 DN TAM-67 DM26SE7 TI TTN3GBV DM26SE7 TN Transcription factor AP-1 (JUN) DM26SE7 MA Inhibitor DM26SE7 RN AP-1 blockade inhibits the growth of normal and malignant breast cells. Oncogene. 2001 May 17;20(22):2771-80. DM26SE7 RU https://pubmed.ncbi.nlm.nih.gov/11420689 DM26UKN DI DM26UKN DM26UKN DN GNF-PF-2224 DM26UKN TI TTSLI08 DM26UKN TN Adenosine receptor (ADOR) DM26UKN MA Antagonist DM26UKN RN Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600. DM26UKN RU https://pubmed.ncbi.nlm.nih.gov/11886528 DM26UKN DI DM26UKN DM26UKN DN GNF-PF-2224 DM26UKN TI TTJFY5U DM26UKN TN Adenosine A3 receptor (ADORA3) DM26UKN MA Inhibitor DM26UKN RN Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands. Bioorg Med Chem. 2010 Nov 15;18(22):7890-9. DM26UKN RU https://pubmed.ncbi.nlm.nih.gov/20937560 DM26UKN DI DM26UKN DM26UKN DN GNF-PF-2224 DM26UKN TI TTK25J1 DM26UKN TN Adenosine A1 receptor (ADORA1) DM26UKN MA Inhibitor DM26UKN RN Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600. DM26UKN RU https://pubmed.ncbi.nlm.nih.gov/11886528 DM26UKN DI DM26UKN DM26UKN DN GNF-PF-2224 DM26UKN TI TTM2AOE DM26UKN TN Adenosine A2a receptor (ADORA2A) DM26UKN MA Inhibitor DM26UKN RN Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine r... Eur J Med Chem. 2010 May;45(5):1739-45. DM26UKN RU https://pubmed.ncbi.nlm.nih.gov/20116907 DM26UKN DI DM26UKN DM26UKN DN GNF-PF-2224 DM26UKN TI TTNE7KG DM26UKN TN Adenosine A2b receptor (ADORA2B) DM26UKN MA Inhibitor DM26UKN RN Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist, Bioorg. Med. Chem. Lett. 6(17):2059-2062 (1996). DM26UKN RU http://www.sciencedirect.com/science/article/pii/0960894X9600368X DM26VFX DI DM26VFX DM26VFX DN Pro-His-Pro-Phe-His-Leu(CH2NH)Val-Ile-His-Lys DM26VFX TI TTB2MXP DM26VFX TN Angiotensinogenase renin (REN) DM26VFX MA Inhibitor DM26VFX RN Synthesis and biological activity of some transition-state inhibitors of human renin. J Med Chem. 1988 Sep;31(9):1839-46. DM26VFX RU https://pubmed.ncbi.nlm.nih.gov/3137345 DM27BKD DI DM27BKD DM27BKD DN RU78300 DM27BKD TI TT6PKBN DM27BKD TN Proto-oncogene c-Src (SRC) DM27BKD MA Inhibitor DM27BKD RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM27BKD RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM27CQJ DI DM27CQJ DM27CQJ DN 2-(4-(3-chlorophenyl)but-1-ynyl)-6-methylpyridine DM27CQJ TI TTHS256 DM27CQJ TN Metabotropic glutamate receptor 5 (mGluR5) DM27CQJ MA Inhibitor DM27CQJ RN Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91. DM27CQJ RU https://pubmed.ncbi.nlm.nih.gov/16837196 DM27FRY DI DM27FRY DM27FRY DN Erybreadin b DM27FRY TI TTELIN2 DM27FRY TN PTPN1 messenger RNA (PTPN1 mRNA) DM27FRY MA Inhibitor DM27FRY RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DM27FRY RU https://pubmed.ncbi.nlm.nih.gov/19836230 DM27GH0 DI DM27GH0 DM27GH0 DN 23-hydroxybetulinic acid DM27GH0 TI TTZHY6R DM27GH0 TN Glycogen phosphorylase muscle form (GP) DM27GH0 MA Inhibitor DM27GH0 RN Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54. DM27GH0 RU https://pubmed.ncbi.nlm.nih.gov/18517260 DM27GZC DI DM27GZC DM27GZC DN 2-PMPA DM27GZC TI TT9G4N0 DM27GZC TN Glutamate carboxypeptidase II (GCPII) DM27GZC MA Inhibitor DM27GZC RN Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat Med. 1999 Dec;5(12):1396-402. DM27GZC RU https://pubmed.ncbi.nlm.nih.gov/10581082 DM27HMT DI DM27HMT DM27HMT DN 4,9-Dihydro-3H-beta-carboline DM27HMT TI TT3WG5C DM27HMT TN Monoamine oxidase type A (MAO-A) DM27HMT MA Inhibitor DM27HMT RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM27HMT RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM27HMT DI DM27HMT DM27HMT DN 4,9-Dihydro-3H-beta-carboline DM27HMT TI TTGP7BY DM27HMT TN Monoamine oxidase type B (MAO-B) DM27HMT MA Inhibitor DM27HMT RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM27HMT RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM27HSO DI DM27HSO DM27HSO DN 3-(2-naphthyl)phenol DM27HSO TI TTIWB6L DM27HSO TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM27HSO MA Inhibitor DM27HSO RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DM27HSO RU https://pubmed.ncbi.nlm.nih.gov/18324762 DM27ILS DI DM27ILS DM27ILS DN Drug 311952 DM27ILS TI TTZ3S8C DM27ILS TN Presenilin 1 (PSEN1) DM27ILS MA Inhibitor DM27ILS RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DM27ILS RU https://pubmed.ncbi.nlm.nih.gov/15267231 DM27ILS DI DM27ILS DM27ILS DN Drug 311952 DM27ILS TI TTWN3F4 DM27ILS TN Presenilin 2 (PSEN2) DM27ILS MA Inhibitor DM27ILS RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DM27ILS RU https://pubmed.ncbi.nlm.nih.gov/15267231 DM27ILS DI DM27ILS DM27ILS DN Drug 311952 DM27ILS TI TT9W8GU DM27ILS TN Gamma-secretase (GS) DM27ILS MA Inhibitor DM27ILS RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DM27ILS RU https://pubmed.ncbi.nlm.nih.gov/15267231 DM27L53 DI DM27L53 DM27L53 DN N-(2-hexyloxy-4-nitrophenyl)methanesulfonamide DM27L53 TI TTSZLWK DM27L53 TN Aromatase (CYP19A1) DM27L53 MA Inhibitor DM27L53 RN Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9. DM27L53 RU https://pubmed.ncbi.nlm.nih.gov/16480277 DM27LNU DI DM27LNU DM27LNU DN [Mpa1, D-Tic2, Aib7]OT DM27LNU TI TTSCIUP DM27LNU TN Oxytocin receptor (OTR) DM27LNU MA Inhibitor DM27LNU RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DM27LNU RU https://pubmed.ncbi.nlm.nih.gov/17316912 DM27OGL DI DM27OGL DM27OGL DN 4-(8-Phenyl-oct-3-ynyl)-1H-imidazole DM27OGL TI TT9JNIC DM27OGL TN Histamine H3 receptor (H3R) DM27OGL MA Inhibitor DM27OGL RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DM27OGL RU https://pubmed.ncbi.nlm.nih.gov/9871722 DM27S6E DI DM27S6E DM27S6E DN cicloprolol DM27S6E TI TTMXGCW DM27S6E TN Adrenergic receptor beta-3 (ADRB3) DM27S6E MA Antagonist DM27S6E RN LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5. DM27S6E RU https://pubmed.ncbi.nlm.nih.gov/10079020 DM27TH9 DI DM27TH9 DM27TH9 DN (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine DM27TH9 TI TTNGILX DM27TH9 TN Adrenergic receptor alpha-1A (ADRA1A) DM27TH9 MA Inhibitor DM27TH9 RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM27TH9 RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM27TH9 DI DM27TH9 DM27TH9 DN (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine DM27TH9 TI TT2NUT5 DM27TH9 TN Adrenergic receptor alpha-2C (ADRA2C) DM27TH9 MA Inhibitor DM27TH9 RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM27TH9 RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM27TH9 DI DM27TH9 DM27TH9 DN (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine DM27TH9 TI TT34BHT DM27TH9 TN Adrenergic receptor alpha-1D (ADRA1D) DM27TH9 MA Inhibitor DM27TH9 RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM27TH9 RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM27TH9 DI DM27TH9 DM27TH9 DN (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine DM27TH9 TI TTBRKXS DM27TH9 TN Adrenergic receptor alpha-1B (ADRA1B) DM27TH9 MA Inhibitor DM27TH9 RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM27TH9 RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM27TH9 DI DM27TH9 DM27TH9 DN (2,6-Dichloro-phenyl)-(1H-imidazol-2-yl)-amine DM27TH9 TI TTWG9A4 DM27TH9 TN Adrenergic receptor alpha-2A (ADRA2A) DM27TH9 MA Inhibitor DM27TH9 RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM27TH9 RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM27TPM DI DM27TPM DM27TPM DN Trans-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine DM27TPM TI TT3WG5C DM27TPM TN Monoamine oxidase type A (MAO-A) DM27TPM MA Inhibitor DM27TPM RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DM27TPM RU https://pubmed.ncbi.nlm.nih.gov/18640844 DM27WCE DI DM27WCE DM27WCE DN NEUROTENSIN DM27WCE TI TTTUMEP DM27WCE TN Neurotensin receptor type 1 (NTSR1) DM27WCE MA Inhibitor DM27WCE RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DM27WCE RU https://pubmed.ncbi.nlm.nih.gov/18588282 DM27WDP DI DM27WDP DM27WDP DN (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one DM27WDP TI TTYMGWX DM27WDP TN PDK-1 messenger RNA (PDK-1 mRNA) DM27WDP MA Inhibitor DM27WDP RN Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. DM27WDP RU https://pubmed.ncbi.nlm.nih.gov/17531483 DM27WDP DI DM27WDP DM27WDP DN (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one DM27WDP TI TTWTSCV DM27WDP TN RAC-alpha serine/threonine-protein kinase (AKT1) DM27WDP MA Inhibitor DM27WDP RN Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. DM27WDP RU https://pubmed.ncbi.nlm.nih.gov/17531483 DM27WDP DI DM27WDP DM27WDP DN (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one DM27WDP TI TT4DXQT DM27WDP TN Proto-oncogene c-Ret (RET) DM27WDP MA Inhibitor DM27WDP RN Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. DM27WDP RU https://pubmed.ncbi.nlm.nih.gov/20117004 DM27YTF DI DM27YTF DM27YTF DN 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile DM27YTF TI TTUTJGQ DM27YTF TN Vascular endothelial growth factor receptor 2 (KDR) DM27YTF MA Inhibitor DM27YTF RN 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. DM27YTF RU https://pubmed.ncbi.nlm.nih.gov/17481894 DM27YTF DI DM27YTF DM27YTF DN 2-(p-toluidino)-4-phenylpyrimidine-5-carbonitrile DM27YTF TI TTH6V3D DM27YTF TN Cyclin-dependent kinase 1 (CDK1) DM27YTF MA Inhibitor DM27YTF RN 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. DM27YTF RU https://pubmed.ncbi.nlm.nih.gov/17481894 DM280AE DI DM280AE DM280AE DN ISIS 116359 DM280AE TI TTGECUM DM280AE TN Cot oncogene messenger RNA (MAP3K8 mRNA) DM280AE RN US patent application no. 6,265,216, Antisense modulation of cot oncogene expression. DM280AE RU http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true DM285MQ DI DM285MQ DM285MQ DN [125I]SD6 DM285MQ TI TT0WAIE DM285MQ TN Melatonin receptor type 1A (MTNR1A) DM285MQ MA Agonist DM285MQ RN New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci. 2013 Apr 25;14(5):8948-62. DM285MQ RU https://pubmed.ncbi.nlm.nih.gov/23698757 DM287UO DI DM287UO DM287UO DN 3-[11-(benzylmethylamino)undecyloxy]xanthen-9-one DM287UO TI TTEB0GD DM287UO TN Cholinesterase (BCHE) DM287UO MA Inhibitor DM287UO RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DM287UO RU https://pubmed.ncbi.nlm.nih.gov/17008100 DM28CLZ DI DM28CLZ DM28CLZ DN 2-Phenyl-1,2-dihydro-indazol-3-one DM28CLZ TI TTVKILB DM28CLZ TN Prostaglandin G/H synthase 2 (COX-2) DM28CLZ MA Inhibitor DM28CLZ RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM28CLZ RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM28CLZ DI DM28CLZ DM28CLZ DN 2-Phenyl-1,2-dihydro-indazol-3-one DM28CLZ TI TT8NGED DM28CLZ TN Prostaglandin G/H synthase 1 (COX-1) DM28CLZ MA Inhibitor DM28CLZ RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM28CLZ RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM28CLZ DI DM28CLZ DM28CLZ DN 2-Phenyl-1,2-dihydro-indazol-3-one DM28CLZ TI TT2J34L DM28CLZ TN Arachidonate 5-lipoxygenase (5-LOX) DM28CLZ MA Inhibitor DM28CLZ RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM28CLZ RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM28D9E DI DM28D9E DM28D9E DN (1R,2S)-1,2-diphenylethane-1,2-diamine DM28D9E TI TTDIGC1 DM28D9E TN Dipeptidyl peptidase 4 (DPP-4) DM28D9E MA Inhibitor DM28D9E RN In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9. DM28D9E RU https://pubmed.ncbi.nlm.nih.gov/16321524 DM28DEU DI DM28DEU DM28DEU DN 4-Imidazol-1-ylmethyl-1-nitrothioxanthen-9-one DM28DEU TI TTSZLWK DM28DEU TN Aromatase (CYP19A1) DM28DEU MA Inhibitor DM28DEU RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DM28DEU RU https://pubmed.ncbi.nlm.nih.gov/20568782 DM28DPY DI DM28DPY DM28DPY DN 6-(3-hydroxyphenyl)-2-morpholino-4H-chromen-4-one DM28DPY TI TTK3PY9 DM28DPY TN DNA-dependent protein kinase catalytic (PRKDC) DM28DPY MA Inhibitor DM28DPY RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DM28DPY RU https://pubmed.ncbi.nlm.nih.gov/16302822 DM28GQS DI DM28GQS DM28GQS DN 2,5-Bis-(3-cyclopentyloxy-4-methoxy-phenyl)-furan DM28GQS TI TTZ97H5 DM28GQS TN Phosphodiesterase 4A (PDE4A) DM28GQS MA Inhibitor DM28GQS RN Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6. DM28GQS RU https://pubmed.ncbi.nlm.nih.gov/10091677 DM28GZ7 DI DM28GZ7 DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one DM28GZ7 TI TTSHTOI DM28GZ7 TN Histone deacetylase 2 (HDAC2) DM28GZ7 MA Inhibitor DM28GZ7 RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM28GZ7 RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM28GZ7 DI DM28GZ7 DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one DM28GZ7 TI TTYHPU6 DM28GZ7 TN Histone deacetylase 10 (HDAC10) DM28GZ7 MA Inhibitor DM28GZ7 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM28GZ7 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM28GZ7 DI DM28GZ7 DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one DM28GZ7 TI TT6R7JZ DM28GZ7 TN Histone deacetylase 1 (HDAC1) DM28GZ7 MA Inhibitor DM28GZ7 RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM28GZ7 RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM28GZ7 DI DM28GZ7 DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one DM28GZ7 TI TT5ZKDI DM28GZ7 TN Histone deacetylase 6 (HDAC6) DM28GZ7 MA Inhibitor DM28GZ7 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM28GZ7 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM28GZ7 DI DM28GZ7 DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one DM28GZ7 TI TTTQGH8 DM28GZ7 TN Histone deacetylase 4 (HDAC4) DM28GZ7 MA Inhibitor DM28GZ7 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM28GZ7 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM28GZ7 DI DM28GZ7 DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one DM28GZ7 TI TTBH0VX DM28GZ7 TN Histone deacetylase (HDAC) DM28GZ7 MA Inhibitor DM28GZ7 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM28GZ7 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM28GZ7 DI DM28GZ7 DM28GZ7 DN 7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one DM28GZ7 TI TTT6LFV DM28GZ7 TN Histone deacetylase 8 (HDAC8) DM28GZ7 MA Inhibitor DM28GZ7 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM28GZ7 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM28IKN DI DM28IKN DM28IKN DN RWJ-387273 DM28IKN TI TTJ0IQB DM28IKN TN Phosphodiesterase 5A (PDE5A) DM28IKN MA Modulator DM28IKN RN DOI: 10.1021/op060099f DM28IKN RU http://pubs.acs.org/doi/abs/10.1021/op060099f DM28K0E DI DM28K0E DM28K0E DN SB290157 DM28K0E TI TTI6B3F DM28K0E TN C3a anaphylatoxin chemotactic receptor (C3AR1) DM28K0E MA Antagonist DM28K0E RN Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol. 2001 May 15;166(10):6341-8. DM28K0E RU https://pubmed.ncbi.nlm.nih.gov/11342658 DM28LNV DI DM28LNV DM28LNV DN 5,5-Diphenyl-2-iminohydantoin DM28LNV TI TT8JRS7 DM28LNV TN Beta-secretase (BACE) DM28LNV MA Inhibitor DM28LNV RN Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and... J Med Chem. 2010 Feb 11;53(3):951-65. DM28LNV RU https://pubmed.ncbi.nlm.nih.gov/20043696 DM28NAB DI DM28NAB DM28NAB DN 7-chloroindirubin-3-oxime DM28NAB TI TT9RTBL DM28NAB TN Aurora B messenger RNA (AURKB mRNA) DM28NAB MA Inhibitor DM28NAB RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM28NAB RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM28NAB DI DM28NAB DM28NAB DN 7-chloroindirubin-3-oxime DM28NAB TI TTLYXIT DM28NAB TN Aurora kinase C (AURKC) DM28NAB MA Inhibitor DM28NAB RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM28NAB RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM28NIU DI DM28NIU DM28NIU DN diphosphoglycolyl proline DM28NIU TI TTE5J6X DM28NIU TN Diphosphomevalonate decarboxylase (MVD) DM28NIU MA Inhibitor DM28NIU RN Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure. Arch Biochem Biophys. 2008 Dec 1;480(1):58-67. DM28NIU RU https://pubmed.ncbi.nlm.nih.gov/18823933 DM28TXP DI DM28TXP DM28TXP DN SYMBIOPOLYOL DM28TXP TI TTHCEF6 DM28TXP TN VCAM-1 messenger RNA (VCAM1 mRNA) DM28TXP MA Inhibitor DM28TXP RN Symbiopolyol, a VCAM-1 inhibitor from a symbiotic dinoflagellate of the jellyfish Mastigias papua. J Nat Prod. 2010 Jul 23;73(7):1318-22. DM28TXP RU https://pubmed.ncbi.nlm.nih.gov/20557071 DM28XTE DI DM28XTE DM28XTE DN 2-Furan-2-yl-3-phenethyl-3H-quinazolin-4-one DM28XTE TI TTBUYHA DM28XTE TN Extracellular calcium-sensing receptor (CASR) DM28XTE MA Inhibitor DM28XTE RN Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg Med Chem Lett. 2005 May 16;15(10):2537-40. DM28XTE RU https://pubmed.ncbi.nlm.nih.gov/15863312 DM28ZPT DI DM28ZPT DM28ZPT DN NE58018 DM28ZPT TI TTIKWV4 DM28ZPT TN Geranyltranstransferase (FDPS) DM28ZPT MA Inhibitor DM28ZPT RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DM28ZPT RU https://pubmed.ncbi.nlm.nih.gov/18327899 DM293XH DI DM293XH DM293XH DN Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine DM293XH TI TTAWNKZ DM293XH TN Norepinephrine transporter (NET) DM293XH MA Inhibitor DM293XH RN N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8. DM293XH RU https://pubmed.ncbi.nlm.nih.gov/16497500 DM293XH DI DM293XH DM293XH DN Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine DM293XH TI TT3ROYC DM293XH TN Serotonin transporter (SERT) DM293XH MA Inhibitor DM293XH RN N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8. DM293XH RU https://pubmed.ncbi.nlm.nih.gov/16497500 DM297MU DI DM297MU DM297MU DN (R)-EF-1520 DM297MU TI TTQBMPI DM297MU TN Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) DM297MU MA Inhibitor DM297MU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 932). DM297MU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=932 DM297MU DI DM297MU DM297MU DN (R)-EF-1520 DM297MU TI TTPRKM0 DM297MU TN GABA transporter GAT-1 (SLC6A1) DM297MU MA Inhibitor DM297MU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929). DM297MU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929 DM298KT DI DM298KT DM298KT DN ISIS 103612 DM298KT TI TTBWMKT DM298KT TN WWP1 messenger RNA (WWP1 mRNA) DM298KT RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM298KT RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM29EFJ DI DM29EFJ DM29EFJ DN phenylacetylrinvanil DM29EFJ TI TTMI6F5 DM29EFJ TN Transient receptor potential cation channel V1 (TRPV1) DM29EFJ MA Activator DM29EFJ RN Development of the first ultra-potent "capsaicinoid" agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic ... J Pharmacol Exp Ther. 2005 Feb;312(2):561-70. DM29EFJ RU https://pubmed.ncbi.nlm.nih.gov/15356216 DM29GUY DI DM29GUY DM29GUY DN PD-172938 DM29GUY TI TTEX248 DM29GUY TN Dopamine D2 receptor (D2R) DM29GUY MA Inhibitor DM29GUY RN Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1499-502. DM29GUY RU https://pubmed.ncbi.nlm.nih.gov/9873377 DM29I0Y DI DM29I0Y DM29I0Y DN ANTHRAQUINONE DM29I0Y TI TTR0SWN DM29I0Y TN M-phase inducer phosphatase 2 (MPIP2) DM29I0Y MA Inhibitor DM29I0Y RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DM29I0Y RU https://pubmed.ncbi.nlm.nih.gov/19028102 DM29L4D DI DM29L4D DM29L4D DN 8-Phenyl-2-piperidin-1-yl-chromen-4-one DM29L4D TI TTK3PY9 DM29L4D TN DNA-dependent protein kinase catalytic (PRKDC) DM29L4D MA Inhibitor DM29L4D RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DM29L4D RU https://pubmed.ncbi.nlm.nih.gov/15658870 DM29PTO DI DM29PTO DM29PTO DN Durhamycin A DM29PTO TI TTT3ZC9 DM29PTO TN Human immunodeficiency virus Tat protein (HIV tat) DM29PTO MA Inhibitor DM29PTO RN Durhamycin A, a potent inhibitor of HIV Tat transactivation. J Nat Prod. 2002 Aug;65(8):1091-5. DM29PTO RU https://pubmed.ncbi.nlm.nih.gov/12193009 DM29QLG DI DM29QLG DM29QLG DN 4-(2-(4-fluorobenzyloxy)phenyl)piperidine DM29QLG TI TTVBI8W DM29QLG TN Dopamine transporter (DAT) DM29QLG MA Inhibitor DM29QLG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM29QLG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM29QLG DI DM29QLG DM29QLG DN 4-(2-(4-fluorobenzyloxy)phenyl)piperidine DM29QLG TI TT3ROYC DM29QLG TN Serotonin transporter (SERT) DM29QLG MA Inhibitor DM29QLG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM29QLG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM29QLG DI DM29QLG DM29QLG DN 4-(2-(4-fluorobenzyloxy)phenyl)piperidine DM29QLG TI TTSQIFT DM29QLG TN 5-HT 1A receptor (HTR1A) DM29QLG MA Inhibitor DM29QLG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM29QLG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM29QLG DI DM29QLG DM29QLG DN 4-(2-(4-fluorobenzyloxy)phenyl)piperidine DM29QLG TI TTAWNKZ DM29QLG TN Norepinephrine transporter (NET) DM29QLG MA Inhibitor DM29QLG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM29QLG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM29QT4 DI DM29QT4 DM29QT4 DN N-(1-adamantyl)-N'-propylsulfamide DM29QT4 TI TT6OEDT DM29QT4 TN Cannabinoid receptor 1 (CB1) DM29QT4 MA Inhibitor DM29QT4 RN Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95. DM29QT4 RU https://pubmed.ncbi.nlm.nih.gov/19762126 DM29RO1 DI DM29RO1 DM29RO1 DN P-Nitrophenyl Glutamyl Anilide DM29RO1 TI TTF7WRM DM29RO1 TN Alanine/serine/cysteine transporter 2 (SLC1A5) DM29RO1 MA Inhibitor DM29RO1 RN Ngamma-aryl glutamine analogues as probes of the ASCT2 neutral amino acid transporter binding site. Bioorg Med Chem. 2005 Feb 15;13(4):1111-8. DM29RO1 RU https://pubmed.ncbi.nlm.nih.gov/15670919 DM29TVC DI DM29TVC DM29TVC DN FIG 1 DM29TVC TI TTN7BL9 DM29TVC TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM29TVC MA Inhibitor DM29TVC RN 4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3405-11. DM29TVC RU https://pubmed.ncbi.nlm.nih.gov/18440811 DM2A1DP DI DM2A1DP DM2A1DP DN Ribavirin DM2A1DP TI TTOA6YT DM2A1DP TN MERS-CoV RNA-directed RNA polymerase (RdRp) DM2A1DP MA Inhibitor DM2A1DP RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM2A1DP RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM2A1DP DI DM2A1DP DM2A1DP DN Ribavirin DM2A1DP TI TTKXI53 DM2A1DP TN SARS-CoV RNA-directed RNA polymerase (RdRp) DM2A1DP MA Inhibitor DM2A1DP RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM2A1DP RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM2A1DP DI DM2A1DP DM2A1DP DN Ribavirin DM2A1DP TI TTTU6X1 DM2A1DP TN HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM2A1DP MA Inhibitor DM2A1DP RN Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets. Nature. 2020 May 14. doi: 10.1038/s41586-020-2332-7. DM2A1DP RU https://pubmed.ncbi.nlm.nih.gov/32408336 DM2A1DP DI DM2A1DP DM2A1DP DN Ribavirin DM2A1DP TI TT3GRLK DM2A1DP TN HUMAN inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DM2A1DP MA Inhibitor DM2A1DP RN Proteomics of SARS-CoV-2-infected Host Cells Reveals Therapy Targets. Nature. 2020 May 14. doi: 10.1038/s41586-020-2332-7. DM2A1DP RU https://pubmed.ncbi.nlm.nih.gov/32408336 DM2AEO0 DI DM2AEO0 DM2AEO0 DN 1-(10-Bromoanthracen-9-yl)-2-aminopropane DM2AEO0 TI TTJQOD7 DM2AEO0 TN 5-HT 2A receptor (HTR2A) DM2AEO0 MA Inhibitor DM2AEO0 RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DM2AEO0 RU https://pubmed.ncbi.nlm.nih.gov/18296055 DM2AIE9 DI DM2AIE9 DM2AIE9 DN ABC-7 DM2AIE9 TI TTBQ3OC DM2AIE9 TN Macrophage-stimulating protein receptor (RON) DM2AIE9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1816). DM2AIE9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1816 DM2AOF8 DI DM2AOF8 DM2AOF8 DN AM-3840 DM2AOF8 TI TTUMQVO DM2AOF8 TN Cathepsin S (CTSS) DM2AOF8 MA Inhibitor DM2AOF8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DM2AOF8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DM2ATRC DI DM2ATRC DM2ATRC DN (2,2-dimethyl-1,3-dioxolan-4-yl)methyl sulfamate DM2ATRC TI TTANPDJ DM2ATRC TN Carbonic anhydrase II (CA-II) DM2ATRC MA Inhibitor DM2ATRC RN Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500. DM2ATRC RU https://pubmed.ncbi.nlm.nih.gov/16759092 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TT2LVK8 DM2AW0Z TN Carbonic anhydrase IX (CA-IX) DM2AW0Z MA Inhibitor DM2AW0Z RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TTCFSPE DM2AW0Z TN Carbonic anhydrase VI (CA-VI) DM2AW0Z MA Inhibitor DM2AW0Z RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TTEYTKG DM2AW0Z TN Carbonic anhydrase XIV (CA-XIV) DM2AW0Z MA Inhibitor DM2AW0Z RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/16039848 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TTANPDJ DM2AW0Z TN Carbonic anhydrase II (CA-II) DM2AW0Z MA Inhibitor DM2AW0Z RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/19846301 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TTSYM0R DM2AW0Z TN Carbonic anhydrase XII (CA-XII) DM2AW0Z MA Inhibitor DM2AW0Z RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/15686894 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TTUNARX DM2AW0Z TN Carbonic anhydrase (CA) DM2AW0Z MA Inhibitor DM2AW0Z RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TTZHA0O DM2AW0Z TN Carbonic anhydrase IV (CA-IV) DM2AW0Z MA Inhibitor DM2AW0Z RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/15686931 DM2AW0Z DI DM2AW0Z DM2AW0Z DN 2,4-Disulfamyltrifluoromethylaniline DM2AW0Z TI TTHQPL7 DM2AW0Z TN Carbonic anhydrase I (CA-I) DM2AW0Z MA Inhibitor DM2AW0Z RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DM2AW0Z RU https://pubmed.ncbi.nlm.nih.gov/19520577 DM2B0RX DI DM2B0RX DM2B0RX DN CFGGFTGARKCARK DM2B0RX TI TTNT7K8 DM2B0RX TN Nociceptin receptor (OPRL1) DM2B0RX MA Inhibitor DM2B0RX RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DM2B0RX RU https://pubmed.ncbi.nlm.nih.gov/11689089 DM2B4S5 DI DM2B4S5 DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide DM2B4S5 TI TTHQPL7 DM2B4S5 TN Carbonic anhydrase I (CA-I) DM2B4S5 MA Inhibitor DM2B4S5 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2B4S5 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2B4S5 DI DM2B4S5 DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide DM2B4S5 TI TTUNARX DM2B4S5 TN Carbonic anhydrase (CA) DM2B4S5 MA Inhibitor DM2B4S5 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2B4S5 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2B4S5 DI DM2B4S5 DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide DM2B4S5 TI TTSYM0R DM2B4S5 TN Carbonic anhydrase XII (CA-XII) DM2B4S5 MA Inhibitor DM2B4S5 RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DM2B4S5 RU https://pubmed.ncbi.nlm.nih.gov/15686894 DM2B4S5 DI DM2B4S5 DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide DM2B4S5 TI TTANPDJ DM2B4S5 TN Carbonic anhydrase II (CA-II) DM2B4S5 MA Inhibitor DM2B4S5 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2B4S5 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2B4S5 DI DM2B4S5 DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide DM2B4S5 TI TTEYTKG DM2B4S5 TN Carbonic anhydrase XIV (CA-XIV) DM2B4S5 MA Inhibitor DM2B4S5 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DM2B4S5 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DM2B4S5 DI DM2B4S5 DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide DM2B4S5 TI TTCFSPE DM2B4S5 TN Carbonic anhydrase VI (CA-VI) DM2B4S5 MA Inhibitor DM2B4S5 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2B4S5 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2B4S5 DI DM2B4S5 DM2B4S5 DN 6-Hydroxy-benzothiazole-2-sulfonic acid amide DM2B4S5 TI TT2LVK8 DM2B4S5 TN Carbonic anhydrase IX (CA-IX) DM2B4S5 MA Inhibitor DM2B4S5 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM2B4S5 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM2BKU8 DI DM2BKU8 DM2BKU8 DN K00244 DM2BKU8 TI TTLYXIT DM2BKU8 TN Aurora kinase C (AURKC) DM2BKU8 MA Inhibitor DM2BKU8 RN The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92. DM2BKU8 RU https://pubmed.ncbi.nlm.nih.gov/19447622 DM2BKU8 DI DM2BKU8 DM2BKU8 DN K00244 DM2BKU8 TI TTRSMW9 DM2BKU8 TN Glycogen synthase kinase-3 beta (GSK-3B) DM2BKU8 MA Inhibitor DM2BKU8 RN The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92. DM2BKU8 RU https://pubmed.ncbi.nlm.nih.gov/19447622 DM2BKU8 DI DM2BKU8 DM2BKU8 DN K00244 DM2BKU8 TI TT6PKBN DM2BKU8 TN Proto-oncogene c-Src (SRC) DM2BKU8 MA Inhibitor DM2BKU8 RN The discovery of the potent aurora inhibitor MK-0457 (VX-680). Bioorg Med Chem Lett. 2009 Jul 1;19(13):3586-92. DM2BKU8 RU https://pubmed.ncbi.nlm.nih.gov/19447622 DM2BMAZ DI DM2BMAZ DM2BMAZ DN AA-166 DM2BMAZ TI TTGKF90 DM2BMAZ TN Bone morphogenetic protein receptor (BMPR2) DM2BMAZ MA Agonist DM2BMAZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794). DM2BMAZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794 DM2BPIN DI DM2BPIN DM2BPIN DN 2-benzyl-N1-hydroxy-N3-phenethylmalonamide DM2BPIN TI TTPHMWB DM2BPIN TN Aminopeptidase N (ANPEP) DM2BPIN MA Inhibitor DM2BPIN RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DM2BPIN RU https://pubmed.ncbi.nlm.nih.gov/17326615 DM2BUKP DI DM2BUKP DM2BUKP DN PMID20483621C5n DM2BUKP TI TTPMQSO DM2BUKP TN ALK tyrosine kinase receptor (ALK) DM2BUKP MA Inhibitor DM2BUKP RN Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. DM2BUKP RU https://pubmed.ncbi.nlm.nih.gov/20483621 DM2BUKP DI DM2BUKP DM2BUKP DN PMID20483621C5n DM2BUKP TI TTMYK4Z DM2BUKP TN Doublecortin-like kinase 3 (DCLK3) DM2BUKP MA Inhibitor DM2BUKP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2007). DM2BUKP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2007 DM2BUKP DI DM2BUKP DM2BUKP DN PMID20483621C5n DM2BUKP TI TTE7RCU DM2BUKP TN MAPK/ERK kinase kinase 3 (MAP3K3) DM2BUKP MA Inhibitor DM2BUKP RN Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. DM2BUKP RU https://pubmed.ncbi.nlm.nih.gov/20483621 DM2BV6P DI DM2BV6P DM2BV6P DN 7-Hydroxy-2-(4-methoxy-benzyl)-chromen-4-one DM2BV6P TI TTFBNVI DM2BV6P TN Aldose reductase (AKR1B1) DM2BV6P MA Inhibitor DM2BV6P RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DM2BV6P RU https://pubmed.ncbi.nlm.nih.gov/10354396 DM2C6GB DI DM2C6GB DM2C6GB DN UR-PG131A DM2C6GB TI TTTIBOJ DM2C6GB TN Histamine H1 receptor (H1R) DM2C6GB MA Agonist DM2C6GB RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DM2C6GB RU https://pubmed.ncbi.nlm.nih.gov/16394198 DM2C7U0 DI DM2C7U0 DM2C7U0 DN 1-(4-Bromobenzyl)-1H-imidazole DM2C7U0 TI TTRA5BZ DM2C7U0 TN Steroid 17-alpha-monooxygenase (S17AH) DM2C7U0 MA Inhibitor DM2C7U0 RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DM2C7U0 RU https://pubmed.ncbi.nlm.nih.gov/16870430 DM2C7U0 DI DM2C7U0 DM2C7U0 DN 1-(4-Bromobenzyl)-1H-imidazole DM2C7U0 TI TTIQUX7 DM2C7U0 TN Steroid 11-beta-hydroxylase (CYP11B1) DM2C7U0 MA Inhibitor DM2C7U0 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM2C7U0 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM2C9X8 DI DM2C9X8 DM2C9X8 DN 3-phenyl-4-hydroxyquinolin-2(1H)-one DM2C9X8 TI TTLD29N DM2C9X8 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM2C9X8 MA Inhibitor DM2C9X8 RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DM2C9X8 RU https://pubmed.ncbi.nlm.nih.gov/16451052 DM2C9X8 DI DM2C9X8 DM2C9X8 DN 3-phenyl-4-hydroxyquinolin-2(1H)-one DM2C9X8 TI TTKJEMQ DM2C9X8 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM2C9X8 MA Inhibitor DM2C9X8 RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DM2C9X8 RU https://pubmed.ncbi.nlm.nih.gov/16451052 DM2C9X8 DI DM2C9X8 DM2C9X8 DN 3-phenyl-4-hydroxyquinolin-2(1H)-one DM2C9X8 TI TTN9D8E DM2C9X8 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM2C9X8 MA Inhibitor DM2C9X8 RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DM2C9X8 RU https://pubmed.ncbi.nlm.nih.gov/16451052 DM2CAI1 DI DM2CAI1 DM2CAI1 DN 2-(cyclohexylthiomethyl)-5-hydroxy-4H-pyran-4-one DM2CAI1 TI TTULVH8 DM2CAI1 TN Tyrosinase (TYR) DM2CAI1 MA Inhibitor DM2CAI1 RN Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71. DM2CAI1 RU https://pubmed.ncbi.nlm.nih.gov/20934336 DM2CBNG DI DM2CBNG DM2CBNG DN N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine DM2CBNG TI TT7WVHI DM2CBNG TN Soluble epoxide hydrolase (EPHX2) DM2CBNG MA Inhibitor DM2CBNG RN A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. DM2CBNG RU https://pubmed.ncbi.nlm.nih.gov/19700315 DM2CEWT DI DM2CEWT DM2CEWT DN Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DM2CEWT TI TTVFO0U DM2CEWT TN Gastrin/cholecystokinin type B receptor (CCKBR) DM2CEWT MA Inhibitor DM2CEWT RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM2CEWT RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM2CEWT DI DM2CEWT DM2CEWT DN Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DM2CEWT TI TTKWM86 DM2CEWT TN Opioid receptor mu (MOP) DM2CEWT MA Inhibitor DM2CEWT RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM2CEWT RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM2CEWT DI DM2CEWT DM2CEWT DN Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DM2CEWT TI TT27RFC DM2CEWT TN Opioid receptor delta (OPRD1) DM2CEWT MA Inhibitor DM2CEWT RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM2CEWT RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM2CEWT DI DM2CEWT DM2CEWT DN Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DM2CEWT TI TTCG0AL DM2CEWT TN Cholecystokinin receptor type A (CCKAR) DM2CEWT MA Inhibitor DM2CEWT RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM2CEWT RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM2CHX8 DI DM2CHX8 DM2CHX8 DN (+)-5-(5-bromothiophen-3-yl)-5-methyl-4-oxo-4,5-dihydro-furan-2-carboxylic acid DM2CHX8 TI TTWNV8U DM2CHX8 TN Nicotinic acid receptor (HCAR2) DM2CHX8 MA Agonist DM2CHX8 RN (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649-52. DM2CHX8 RU https://pubmed.ncbi.nlm.nih.gov/15929991 DM2CK7B DI DM2CK7B DM2CK7B DN HESPERADIN DM2CK7B TI TT9RTBL DM2CK7B TN Aurora B messenger RNA (AURKB mRNA) DM2CK7B MA Inhibitor DM2CK7B RN Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006 Feb 9;49(3):955-70. DM2CK7B RU https://pubmed.ncbi.nlm.nih.gov/16451062 DM2CKUZ DI DM2CKUZ DM2CKUZ DN apelin-13 DM2CKUZ TI TTJ8E43 DM2CKUZ TN Apelin receptor (APLNR) DM2CKUZ MA Agonist DM2CKUZ RN Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ. Biochemistry. 2003 Sep 2;42(34):10163-8. DM2CKUZ RU https://pubmed.ncbi.nlm.nih.gov/12939143 DM2CN0A DI DM2CN0A DM2CN0A DN UCL1848 DM2CN0A TI TT9R6BE DM2CN0A TN Calcium-activated potassium channel KCa2.1 (KCNN1) DM2CN0A MA Blocker (channel blocker) DM2CN0A RN The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines. Br J Pharmacol. 2000 Feb;129(4):627-30. DM2CN0A RU https://pubmed.ncbi.nlm.nih.gov/10683185 DM2CN0A DI DM2CN0A DM2CN0A DN UCL1848 DM2CN0A TI TT9JH25 DM2CN0A TN Calcium-activated potassium channel KCa2.3 (KCNN3) DM2CN0A MA Blocker (channel blocker) DM2CN0A RN SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34. DM2CN0A RU https://pubmed.ncbi.nlm.nih.gov/11533126 DM2CN0A DI DM2CN0A DM2CN0A DN UCL1848 DM2CN0A TI TT2T5M0 DM2CN0A TN Calcium-activated potassium channel KCa2.2 (KCNN2) DM2CN0A MA Blocker (channel blocker) DM2CN0A RN Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem. 2001 Apr 13;276(15):12249-56. DM2CN0A RU https://pubmed.ncbi.nlm.nih.gov/11278890 DM2COR5 DI DM2COR5 DM2COR5 DN N-Cyclohexyl-4-phenyl-butyramide DM2COR5 TI TT7WVHI DM2COR5 TN Soluble epoxide hydrolase (EPHX2) DM2COR5 MA Inhibitor DM2COR5 RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DM2COR5 RU https://pubmed.ncbi.nlm.nih.gov/15887969 DM2CP5J DI DM2CP5J DM2CP5J DN PMID7473541C19 DM2CP5J TI TTFQEO5 DM2CP5J TN Squalene synthetase (FDFT1) DM2CP5J MA Inhibitor DM2CP5J RN Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60. DM2CP5J RU https://pubmed.ncbi.nlm.nih.gov/7473541 DM2CS5A DI DM2CS5A DM2CS5A DN CGS-18320B DM2CS5A TI TTSZLWK DM2CS5A TN Aromatase (CYP19A1) DM2CS5A MA Inhibitor DM2CS5A RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM2CS5A RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM2CUEB DI DM2CUEB DM2CUEB DN N-methyl-N-ethyl estrone-16-methyl carboxamide DM2CUEB TI TTIWB6L DM2CUEB TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM2CUEB MA Inhibitor DM2CUEB RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM2CUEB RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM2CUNP DI DM2CUNP DM2CUNP DN GBR-12289 DM2CUNP TI TTVG215 DM2CUNP TN Debrisoquine 4-hydroxylase (CYP2D6) DM2CUNP MA Inhibitor DM2CUNP RN Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30. DM2CUNP RU https://pubmed.ncbi.nlm.nih.gov/16610785 DM2D1EJ DI DM2D1EJ DM2D1EJ DN 2,7-Bis(propionamido)anthraquinone DM2D1EJ TI TTQY2EJ DM2D1EJ TN TERT messenger RNA (TERT mRNA) DM2D1EJ MA Inhibitor DM2D1EJ RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM2D1EJ RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM2D4KY DI DM2D4KY DM2D4KY DN N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE DM2D4KY TI TT7HF4W DM2D4KY TN Cyclin-dependent kinase 2 (CDK2) DM2D4KY MA Inhibitor DM2D4KY RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM2D4KY RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM2D5HB DI DM2D5HB DM2D5HB DN 1-Methoxy-6-phenyl-6H-benzo[c]chromene DM2D5HB TI TTOZRK6 DM2D5HB TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM2D5HB MA Inhibitor DM2D5HB RN Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2079-82. DM2D5HB RU https://pubmed.ncbi.nlm.nih.gov/15080982 DM2D78W DI DM2D78W DM2D78W DN 2-ethynyl-N6-methoxyadenosine DM2D78W TI TTM2AOE DM2D78W TN Adenosine A2a receptor (ADORA2A) DM2D78W MA Inhibitor DM2D78W RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM2D78W RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM2D78W DI DM2D78W DM2D78W DN 2-ethynyl-N6-methoxyadenosine DM2D78W TI TTK25J1 DM2D78W TN Adenosine A1 receptor (ADORA1) DM2D78W MA Inhibitor DM2D78W RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM2D78W RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM2D78W DI DM2D78W DM2D78W DN 2-ethynyl-N6-methoxyadenosine DM2D78W TI TTJFY5U DM2D78W TN Adenosine A3 receptor (ADORA3) DM2D78W MA Inhibitor DM2D78W RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM2D78W RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM2D947 DI DM2D947 DM2D947 DN Phosphoenolpyruvate DM2D947 TI TTVNA43 DM2D947 TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DM2D947 MA Inhibitor DM2D947 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2D947 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2DAFS DI DM2DAFS DM2DAFS DN ATPA DM2DAFS TI TT0MYE2 DM2DAFS TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM2DAFS MA Agonist DM2DAFS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM2DAFS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM2DERW DI DM2DERW DM2DERW DN ELN-864709 DM2DERW TI TT056SO DM2DERW TN Stress-activated protein kinase JNK3 (JNK3) DM2DERW MA Inhibitor DM2DERW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1498). DM2DERW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1498 DM2DPYQ DI DM2DPYQ DM2DPYQ DN ASKH95 DM2DPYQ TI TTQR74A DM2DPYQ TN Proteinase activated receptor 2 (PAR2) DM2DPYQ MA Agonist DM2DPYQ RN Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest. 2003 Jan;111(1):35-41. DM2DPYQ RU https://pubmed.ncbi.nlm.nih.gov/12511586 DM2DTHV DI DM2DTHV DM2DTHV DN 6-fluoro-2-methyl-9H-carbazole DM2DTHV TI TTBGTCW DM2DTHV TN Kinesin spindle messenger RNA (KIF11 mRNA) DM2DTHV MA Inhibitor DM2DTHV RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM2DTHV RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM2DU80 DI DM2DU80 DM2DU80 DN SC-5003 DM2DU80 TI TTH9VL3 DM2DU80 TN Plasmodium Plasmepsin 1 (Malaria PLA1) DM2DU80 MA Inhibitor DM2DU80 RN Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43(3):305-41. DM2DU80 RU https://pubmed.ncbi.nlm.nih.gov/10669559 DM2DVNT DI DM2DVNT DM2DVNT DN (R)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid DM2DVNT TI TTFK1JQ DM2DVNT TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM2DVNT MA Inhibitor DM2DVNT RN Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32. DM2DVNT RU https://pubmed.ncbi.nlm.nih.gov/16099652 DM2DWUQ DI DM2DWUQ DM2DWUQ DN 5-Nonyl-5-phenyl-imidazolidine-2,4-dione DM2DWUQ TI TTAXZ0K DM2DWUQ TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DM2DWUQ MA Inhibitor DM2DWUQ RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DM2DWUQ RU https://pubmed.ncbi.nlm.nih.gov/10229624 DM2DWUQ DI DM2DWUQ DM2DWUQ DN 5-Nonyl-5-phenyl-imidazolidine-2,4-dione DM2DWUQ TI TTRK8B9 DM2DWUQ TN Sodium channel unspecific (NaC) DM2DWUQ MA Inhibitor DM2DWUQ RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DM2DWUQ RU https://pubmed.ncbi.nlm.nih.gov/10229624 DM2DXHO DI DM2DXHO DM2DXHO DN Ro092210 DM2DXHO TI TTK1N5G DM2DXHO TN MAPK/ERK kinase kinase 2 (MAP3K2) DM2DXHO MA Inhibitor DM2DXHO RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DM2DXHO RU https://pubmed.ncbi.nlm.nih.gov/11804650 DM2DXHO DI DM2DXHO DM2DXHO DN Ro092210 DM2DXHO TI TTQBCEJ DM2DXHO TN MAPK/ERK kinase kinase 1 (MAP3K1) DM2DXHO MA Inhibitor DM2DXHO RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DM2DXHO RU https://pubmed.ncbi.nlm.nih.gov/11804650 DM2DYAV DI DM2DYAV DM2DYAV DN Cacospongionolide E DM2DYAV TI TTO8QRU DM2DYAV TN Group IIA phospholipase A2 (GIIA sPLA2) DM2DYAV MA Inhibitor DM2DYAV RN A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5. DM2DYAV RU https://pubmed.ncbi.nlm.nih.gov/9677277 DM2DYAV DI DM2DYAV DM2DYAV DN Cacospongionolide E DM2DYAV TI TT9V5JH DM2DYAV TN Phospholipase A2 (PLA2G1B) DM2DYAV MA Inhibitor DM2DYAV RN A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5. DM2DYAV RU https://pubmed.ncbi.nlm.nih.gov/9677277 DM2E3X5 DI DM2E3X5 DM2E3X5 DN 2-Chlorophenol DM2E3X5 TI TTQBR95 DM2E3X5 TN Stress-activated protein kinase 2a (p38 alpha) DM2E3X5 MA Inhibitor DM2E3X5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2E3X5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2E5OX DI DM2E5OX DM2E5OX DN N-(6-phenoxypyridin-3-yl)-1H-indole-3-carboxamide DM2E5OX TI TTWJBZ5 DM2E5OX TN 5-HT 2C receptor (HTR2C) DM2E5OX MA Inhibitor DM2E5OX RN Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3844-7. DM2E5OX RU https://pubmed.ncbi.nlm.nih.gov/18602261 DM2E5VZ DI DM2E5VZ DM2E5VZ DN Cyclotheonamide E4 DM2E5VZ TI TT6L509 DM2E5VZ TN Coagulation factor IIa (F2) DM2E5VZ MA Inhibitor DM2E5VZ RN Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61. DM2E5VZ RU https://pubmed.ncbi.nlm.nih.gov/11908961 DM2EFLA DI DM2EFLA DM2EFLA DN D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) DM2EFLA TI TTKWM86 DM2EFLA TN Opioid receptor mu (MOP) DM2EFLA MA Inhibitor DM2EFLA RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DM2EFLA RU https://pubmed.ncbi.nlm.nih.gov/2878079 DM2EFLA DI DM2EFLA DM2EFLA DN D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) DM2EFLA TI TT27RFC DM2EFLA TN Opioid receptor delta (OPRD1) DM2EFLA MA Inhibitor DM2EFLA RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DM2EFLA RU https://pubmed.ncbi.nlm.nih.gov/2878079 DM2EMCW DI DM2EMCW DM2EMCW DN Antimycin A DM2EMCW TI TT3PQ2Y DM2EMCW TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM2EMCW MA Inhibitor DM2EMCW RN Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8. DM2EMCW RU https://pubmed.ncbi.nlm.nih.gov/7726490 DM2EOBM DI DM2EOBM DM2EOBM DN RWJ-69736 DM2EOBM TI TT34BHT DM2EOBM TN Adrenergic receptor alpha-1D (ADRA1D) DM2EOBM MA Inhibitor DM2EOBM RN Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6. DM2EOBM RU https://pubmed.ncbi.nlm.nih.gov/10843225 DM2EOBM DI DM2EOBM DM2EOBM DN RWJ-69736 DM2EOBM TI TTNGILX DM2EOBM TN Adrenergic receptor alpha-1A (ADRA1A) DM2EOBM MA Inhibitor DM2EOBM RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DM2EOBM RU https://pubmed.ncbi.nlm.nih.gov/15664832 DM2EOBM DI DM2EOBM DM2EOBM DN RWJ-69736 DM2EOBM TI TTBRKXS DM2EOBM TN Adrenergic receptor alpha-1B (ADRA1B) DM2EOBM MA Inhibitor DM2EOBM RN Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6. DM2EOBM RU https://pubmed.ncbi.nlm.nih.gov/10843225 DM2EPFZ DI DM2EPFZ DM2EPFZ DN 5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine DM2EPFZ TI TTJFY5U DM2EPFZ TN Adenosine A3 receptor (ADORA3) DM2EPFZ MA Inhibitor DM2EPFZ RN Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett. 2004 May 17;14(10):2443-6. DM2EPFZ RU https://pubmed.ncbi.nlm.nih.gov/15109629 DM2EPFZ DI DM2EPFZ DM2EPFZ DN 5-Butyl-8-phenyl-3H-[1,2,4]triazolo[5,1-i]purine DM2EPFZ TI TTM2AOE DM2EPFZ TN Adenosine A2a receptor (ADORA2A) DM2EPFZ MA Inhibitor DM2EPFZ RN Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands. Bioorg Med Chem Lett. 2004 May 17;14(10):2443-6. DM2EPFZ RU https://pubmed.ncbi.nlm.nih.gov/15109629 DM2EPM4 DI DM2EPM4 DM2EPM4 DN 2,7-Bis(acetamido)anthraquinone DM2EPM4 TI TTQY2EJ DM2EPM4 TN TERT messenger RNA (TERT mRNA) DM2EPM4 MA Inhibitor DM2EPM4 RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM2EPM4 RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM2ES7Z DI DM2ES7Z DM2ES7Z DN Melanocortin-4 Receptor antagonist DM2ES7Z TI TTD0CIQ DM2ES7Z TN Melanocortin receptor 4 (MC4R) DM2ES7Z MA Antagonist DM2ES7Z RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM2ES7Z RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM2ETXB DI DM2ETXB DM2ETXB DN 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine DM2ETXB TI TTAWNKZ DM2ETXB TN Norepinephrine transporter (NET) DM2ETXB MA Inhibitor DM2ETXB RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM2ETXB RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM2ETXB DI DM2ETXB DM2ETXB DN 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine DM2ETXB TI TTSQIFT DM2ETXB TN 5-HT 1A receptor (HTR1A) DM2ETXB MA Inhibitor DM2ETXB RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM2ETXB RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM2ETXB DI DM2ETXB DM2ETXB DN 3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine DM2ETXB TI TT3ROYC DM2ETXB TN Serotonin transporter (SERT) DM2ETXB MA Inhibitor DM2ETXB RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM2ETXB RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM2F6L9 DI DM2F6L9 DM2F6L9 DN H-Tyr-Pro-Phe-Ala-NH2 DM2F6L9 TI TTZPO1L DM2F6L9 TN Substance-P receptor (TACR1) DM2F6L9 MA Inhibitor DM2F6L9 RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DM2F6L9 RU https://pubmed.ncbi.nlm.nih.gov/20178322 DM2F6U3 DI DM2F6U3 DM2F6U3 DN 2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol DM2F6U3 TI TTZAYWL DM2F6U3 TN Estrogen receptor (ESR) DM2F6U3 MA Inhibitor DM2F6U3 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM2F6U3 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM2F6U3 DI DM2F6U3 DM2F6U3 DN 2-(4-Hydroxy-phenyl)-7-vinyl-benzooxazol-5-ol DM2F6U3 TI TTOM3J0 DM2F6U3 TN Estrogen receptor beta (ESR2) DM2F6U3 MA Inhibitor DM2F6U3 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM2F6U3 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM2F81A DI DM2F81A DM2F81A DN PMID9216829C5j DM2F81A TI TTFQEO5 DM2F81A TN Squalene synthetase (FDFT1) DM2F81A MA Inhibitor DM2F81A RN (1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent ... J Med Chem. 1997 Jul 4;40(14):2123-5. DM2F81A RU https://pubmed.ncbi.nlm.nih.gov/9216829 DM2FC5V DI DM2FC5V DM2FC5V DN S 18204 DM2FC5V TI TT2O84V DM2FC5V TN Thromboxane A2 receptor (TBXA2R) DM2FC5V MA Modulator DM2FC5V RN Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J Thromb Haemost. 2004 Mar;2(3):492-8. DM2FC5V RU https://www.ncbi.nlm.nih.gov/pubmed/15009468 DM2FDJN DI DM2FDJN DM2FDJN DN PMID23788657C1754-31 DM2FDJN TI TTOJ1NF DM2FDJN TN FMLP-related receptor I (FPR2) DM2FDJN MA Antagonist DM2FDJN RN Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries. Mol Pharmacol. 2013 Sep;84(3):314-24. DM2FDJN RU https://pubmed.ncbi.nlm.nih.gov/23788657 DM2FLDJ DI DM2FLDJ DM2FLDJ DN Alstiphyllanine D DM2FLDJ TI TTF8JAT DM2FLDJ TN SLC5A2 messenger RNA (SLC5A2 mRNA) DM2FLDJ MA Inhibitor DM2FLDJ RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DM2FLDJ RU https://pubmed.ncbi.nlm.nih.gov/20189404 DM2FLDJ DI DM2FLDJ DM2FLDJ DN Alstiphyllanine D DM2FLDJ TI TT2UE56 DM2FLDJ TN Sodium/glucose cotransporter 1 (SGLT1) DM2FLDJ MA Inhibitor DM2FLDJ RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DM2FLDJ RU https://pubmed.ncbi.nlm.nih.gov/20189404 DM2FLRQ DI DM2FLRQ DM2FLRQ DN DIDODECANOYLPHLOROGLUCINOL DM2FLRQ TI TTO8QRU DM2FLRQ TN Group IIA phospholipase A2 (GIIA sPLA2) DM2FLRQ MA Inhibitor DM2FLRQ RN Simplified YM-26734 inhibitors of secreted phospholipase A2 group IIA. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5415-9. DM2FLRQ RU https://pubmed.ncbi.nlm.nih.gov/18818074 DM2FTIC DI DM2FTIC DM2FTIC DN 2-NAP DM2FTIC TI TTCG0AL DM2FTIC TN Cholecystokinin receptor type A (CCKAR) DM2FTIC MA Antagonist DM2FTIC RN Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007 May;63(5):618-22. DM2FTIC RU https://pubmed.ncbi.nlm.nih.gov/17052250 DM2FYUM DI DM2FYUM DM2FYUM DN PMID24900824C2-13-1 DM2FYUM TI TT78309 DM2FYUM TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DM2FYUM MA Inhibitor DM2FYUM RN Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1. DM2FYUM RU https://pubmed.ncbi.nlm.nih.gov/24900824 DM2G5ZE DI DM2G5ZE DM2G5ZE DN MRS2211 DM2G5ZE TI TT1FE3L DM2G5ZE TN P2Y purinoceptor 13 (P2RY13) DM2G5ZE MA Antagonist DM2G5ZE RN Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol. 2005 Jul 15;70(2):266-74. DM2G5ZE RU https://pubmed.ncbi.nlm.nih.gov/15913566 DM2G8ON DI DM2G8ON DM2G8ON DN Dibutyl 2,2,2-trifluoro-1-phenylethyl phosphate DM2G8ON TI TTMF541 DM2G8ON TN Liver carboxylesterase (CES1) DM2G8ON MA Inhibitor DM2G8ON RN Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5528-30. DM2G8ON RU https://pubmed.ncbi.nlm.nih.gov/19717305 DM2GBEW DI DM2GBEW DM2GBEW DN Lobatamide A DM2GBEW TI TTTK3BH DM2GBEW TN Vacuolar-type proton ATPase (v-ATPase) DM2GBEW MA Inhibitor DM2GBEW RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DM2GBEW RU https://pubmed.ncbi.nlm.nih.gov/11259534 DM2GFI3 DI DM2GFI3 DM2GFI3 DN 6-(Benzofuran-2-sulfonyl)-2H-pyridazin-3-one DM2GFI3 TI TTFBNVI DM2GFI3 TN Aldose reductase (AKR1B1) DM2GFI3 MA Inhibitor DM2GFI3 RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM2GFI3 RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM2GH8X DI DM2GH8X DM2GH8X DN ISIS 114232 DM2GH8X TI TTWIJYH DM2GH8X TN E2F3 messenger RNA (E2F3 mRNA) DM2GH8X RN US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression. DM2GH8X RU http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true DM2GJZE DI DM2GJZE DM2GJZE DN 2-amino-3-(m-tolylamino)naphthalene-1,4-dione DM2GJZE TI TTM2AOE DM2GJZE TN Adenosine A2a receptor (ADORA2A) DM2GJZE MA Inhibitor DM2GJZE RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DM2GJZE RU https://pubmed.ncbi.nlm.nih.gov/20095623 DM2GO7N DI DM2GO7N DM2GO7N DN NSC-746457 DM2GO7N TI TT6R7JZ DM2GO7N TN Histone deacetylase 1 (HDAC1) DM2GO7N MA Inhibitor DM2GO7N RN Histone deacetylase inhibitors through click chemistry. J Med Chem. 2008 Dec 11;51(23):7417-27. DM2GO7N RU https://pubmed.ncbi.nlm.nih.gov/19007204 DM2GPF6 DI DM2GPF6 DM2GPF6 DN 2-Hydroxy-2-phenyl-nonanoic acid amide DM2GPF6 TI TTAXZ0K DM2GPF6 TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DM2GPF6 MA Inhibitor DM2GPF6 RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DM2GPF6 RU https://pubmed.ncbi.nlm.nih.gov/10229624 DM2GPF6 DI DM2GPF6 DM2GPF6 DN 2-Hydroxy-2-phenyl-nonanoic acid amide DM2GPF6 TI TTRK8B9 DM2GPF6 TN Sodium channel unspecific (NaC) DM2GPF6 MA Inhibitor DM2GPF6 RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DM2GPF6 RU https://pubmed.ncbi.nlm.nih.gov/10229624 DM2GUDZ DI DM2GUDZ DM2GUDZ DN 2-Imidazol-1-ylmethylxanthen-9-one DM2GUDZ TI TTSZLWK DM2GUDZ TN Aromatase (CYP19A1) DM2GUDZ MA Inhibitor DM2GUDZ RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DM2GUDZ RU https://pubmed.ncbi.nlm.nih.gov/20568782 DM2H0PQ DI DM2H0PQ DM2H0PQ DN TUG-424 DM2H0PQ TI TTB8FUC DM2H0PQ TN Free fatty acid receptor 1 (GPR40) DM2H0PQ MA Agonist DM2H0PQ RN Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem. 2008 Nov 27;51(22):7061-4. DM2H0PQ RU https://pubmed.ncbi.nlm.nih.gov/18947221 DM2H38V DI DM2H38V DM2H38V DN 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine DM2H38V TI TT3ROYC DM2H38V TN Serotonin transporter (SERT) DM2H38V MA Inhibitor DM2H38V RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM2H38V RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM2H38V DI DM2H38V DM2H38V DN 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine DM2H38V TI TTVBI8W DM2H38V TN Dopamine transporter (DAT) DM2H38V MA Inhibitor DM2H38V RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM2H38V RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM2H38V DI DM2H38V DM2H38V DN 1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine DM2H38V TI TTAWNKZ DM2H38V TN Norepinephrine transporter (NET) DM2H38V MA Inhibitor DM2H38V RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM2H38V RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM2H6KD DI DM2H6KD DM2H6KD DN 10-methoxy-ginkgolide C DM2H6KD TI TTZ8EM9 DM2H6KD TN Glycine receptor (GlyR) DM2H6KD MA Inhibitor DM2H6KD RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DM2H6KD RU https://pubmed.ncbi.nlm.nih.gov/17352465 DM2H6KD DI DM2H6KD DM2H6KD DN 10-methoxy-ginkgolide C DM2H6KD TI TTF45NW DM2H6KD TN Strychnine-binding glycine receptor (GLRA1) DM2H6KD MA Inhibitor DM2H6KD RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DM2H6KD RU https://pubmed.ncbi.nlm.nih.gov/17352465 DM2H8TV DI DM2H8TV DM2H8TV DN 2-arachidonyl glyceryl ether DM2H8TV TI TTNET8J DM2H8TV TN G-protein coupled receptor 55 (GPR55) DM2H8TV MA Agonist DM2H8TV RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DM2H8TV RU https://pubmed.ncbi.nlm.nih.gov/17876302 DM2H9ND DI DM2H9ND DM2H9ND DN 5-(3-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione DM2H9ND TI TTULVH8 DM2H9ND TN Tyrosinase (TYR) DM2H9ND MA Inhibitor DM2H9ND RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DM2H9ND RU https://pubmed.ncbi.nlm.nih.gov/20452224 DM2HBGL DI DM2HBGL DM2HBGL DN 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol DM2HBGL TI TTMX39J DM2HBGL TN Matrix metalloproteinase-1 (MMP-1) DM2HBGL MA Inhibitor DM2HBGL RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DM2HBGL RU https://pubmed.ncbi.nlm.nih.gov/10230616 DM2HBGL DI DM2HBGL DM2HBGL DN 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol DM2HBGL TI TTGA1IV DM2HBGL TN Matrix metalloproteinase-8 (MMP-8) DM2HBGL MA Inhibitor DM2HBGL RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DM2HBGL RU https://pubmed.ncbi.nlm.nih.gov/10406637 DM2HBGL DI DM2HBGL DM2HBGL DN 3-(4-Phenoxy-benzenesulfonyl)-propane-1-thiol DM2HBGL TI TTHY57M DM2HBGL TN Matrix metalloproteinase-13 (MMP-13) DM2HBGL MA Inhibitor DM2HBGL RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DM2HBGL RU https://pubmed.ncbi.nlm.nih.gov/10230616 DM2HC8L DI DM2HC8L DM2HC8L DN NSC-637993 DM2HC8L TI TTJLP0R DM2HC8L TN Quinone reductase 2 (NQO2) DM2HC8L MA Inhibitor DM2HC8L RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DM2HC8L RU https://pubmed.ncbi.nlm.nih.gov/20356739 DM2HCUK DI DM2HCUK DM2HCUK DN (5-phenyl-3H-benzo[d]imidazol-4-yl)methanamine DM2HCUK TI TTDIGC1 DM2HCUK TN Dipeptidyl peptidase 4 (DPP-4) DM2HCUK MA Inhibitor DM2HCUK RN Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2362-7. DM2HCUK RU https://pubmed.ncbi.nlm.nih.gov/18346892 DM2HGCB DI DM2HGCB DM2HGCB DN VU10010 DM2HGCB TI TTQ3JTF DM2HGCB TN Muscarinic acetylcholine receptor M4 (CHRM4) DM2HGCB MA Inhibitor DM2HGCB RN An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol. 2008 Jan;4(1):42-50. DM2HGCB RU https://pubmed.ncbi.nlm.nih.gov/18059262 DM2HGNU DI DM2HGNU DM2HGNU DN DL-TBOA DM2HGNU TI TT8WRDA DM2HGNU TN Excitatory amino acid transporter 1 (SLC1A3) DM2HGNU MA Inhibitor DM2HGNU RN DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201. DM2HGNU RU https://pubmed.ncbi.nlm.nih.gov/9463476 DM2HGNU DI DM2HGNU DM2HGNU DN DL-TBOA DM2HGNU TI TTG2A6F DM2HGNU TN Excitatory amino acid transporter 3 (SLC1A1) DM2HGNU MA Inhibitor DM2HGNU RN Syntheses of optically pure beta-hydroxyaspartate derivatives as glutamate transporter blockers. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2407-10. DM2HGNU RU https://pubmed.ncbi.nlm.nih.gov/11078189 DM2HGNU DI DM2HGNU DM2HGNU DN DL-TBOA DM2HGNU TI TTK41DM DM2HGNU TN Excitatory amino acid transporter 5 (SLC1A7) DM2HGNU MA Inhibitor DM2HGNU RN Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302. DM2HGNU RU https://pubmed.ncbi.nlm.nih.gov/11677257 DM2HGNU DI DM2HGNU DM2HGNU DN DL-TBOA DM2HGNU TI TT2F078 DM2HGNU TN Excitatory amino acid transporter 2 (SLC1A2) DM2HGNU MA Inhibitor DM2HGNU RN DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol Pharmacol. 1998 Feb;53(2):195-201. DM2HGNU RU https://pubmed.ncbi.nlm.nih.gov/9463476 DM2HGNU DI DM2HGNU DM2HGNU DN DL-TBOA DM2HGNU TI TT6KMPN DM2HGNU TN Excitatory amino acid transporter 4 (SLC1A6) DM2HGNU MA Inhibitor DM2HGNU RN Effects of threo-beta-hydroxyaspartate derivatives on excitatory amino acid transporters (EAAT4 and EAAT5). J Neurochem. 2001 Oct;79(2):297-302. DM2HGNU RU https://pubmed.ncbi.nlm.nih.gov/11677257 DM2HKCM DI DM2HKCM DM2HKCM DN 2-p-tolyl-4H-chromene-4-thione DM2HKCM TI TTGP7BY DM2HKCM TN Monoamine oxidase type B (MAO-B) DM2HKCM MA Inhibitor DM2HKCM RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM2HKCM RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM2HN4D DI DM2HN4D DM2HN4D DN Predicentrine methiodide DM2HN4D TI TT4H1MQ DM2HN4D TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DM2HN4D MA Inhibitor DM2HN4D RN Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72. DM2HN4D RU https://pubmed.ncbi.nlm.nih.gov/17391965 DM2HN4D DI DM2HN4D DM2HN4D DN Predicentrine methiodide DM2HN4D TI TT5KPZR DM2HN4D TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM2HN4D MA Inhibitor DM2HN4D RN Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72. DM2HN4D RU https://pubmed.ncbi.nlm.nih.gov/17391965 DM2HQ9O DI DM2HQ9O DM2HQ9O DN LY301875 DM2HQ9O TI TT8DBY3 DM2HQ9O TN Angiotensin II receptor type-1 (AGTR1) DM2HQ9O MA Antagonist DM2HQ9O RN Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors. Pharm Res. 2000 Dec;17(12):1482-8. DM2HQ9O RU https://pubmed.ncbi.nlm.nih.gov/11303957 DM2HVU8 DI DM2HVU8 DM2HVU8 DN PMID24673130C26 DM2HVU8 TI TT6NI13 DM2HVU8 TN MEK kinase kinase 4 (MAP4K4) DM2HVU8 MA Inhibitor DM2HVU8 RN Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization. J Med Chem. 2014 Apr 24;57(8):3484-93. DM2HVU8 RU https://pubmed.ncbi.nlm.nih.gov/24673130 DM2HVUW DI DM2HVUW DM2HVUW DN UR-12510 DM2HVUW TI TTQL5VC DM2HVUW TN Platelet-activating factor receptor (PTAFR) DM2HVUW MA Modulator DM2HVUW RN US patent application no. 6,673,908, Tumor necrosis factor receptor 2. DM2HVUW RU http://www.google.com/patents/US6673908 DM2HYEN DI DM2HYEN DM2HYEN DN dimethylethylamine DM2HYEN TI TTCO25G DM2HYEN TN Trace amine receptor 5 (TAAR5) DM2HYEN MA Agonist DM2HYEN RN Trace amine-associated receptors and their ligands. Br J Pharmacol. 2006 Dec;149(8):967-78. DM2HYEN RU https://pubmed.ncbi.nlm.nih.gov/17088868 DM2HZX8 DI DM2HZX8 DM2HZX8 DN (Z)-2,2-Dimethyl-1-oxazol-2-yl-octadec-9-en-1-one DM2HZX8 TI TTDP1UC DM2HZX8 TN Fatty acid amide hydrolase (FAAH) DM2HZX8 MA Inhibitor DM2HZX8 RN alpha-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and alpha-substitution. Bioorg Med Chem Lett. 2001 Jun 18;11(12):1517-20. DM2HZX8 RU https://pubmed.ncbi.nlm.nih.gov/11412972 DM2I13S DI DM2I13S DM2I13S DN 4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole DM2I13S TI TTAXZ0K DM2I13S TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DM2I13S MA Inhibitor DM2I13S RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DM2I13S RU https://pubmed.ncbi.nlm.nih.gov/15177465 DM2I13S DI DM2I13S DM2I13S DN 4-Biphenyl-4-yl-2-(1-propyl-butyl)-1H-imidazole DM2I13S TI TTRK8B9 DM2I13S TN Sodium channel unspecific (NaC) DM2I13S MA Inhibitor DM2I13S RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DM2I13S RU https://pubmed.ncbi.nlm.nih.gov/15177465 DM2I19P DI DM2I19P DM2I19P DN Barbituric acid derivative DM2I19P TI TTLA931 DM2I19P TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2I19P MA Antagonist DM2I19P RN Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. DM2I19P RU https://pubmed.ncbi.nlm.nih.gov/14579514 DM2I19P DI DM2I19P DM2I19P DN Barbituric acid derivative DM2I19P TI TT1MPAY DM2I19P TN GABA(A) receptor alpha-1 (GABRA1) DM2I19P MA Inhibitor DM2I19P RN Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. DM2I19P RU https://pubmed.ncbi.nlm.nih.gov/14579514 DM2I19P DI DM2I19P DM2I19P DN Barbituric acid derivative DM2I19P TI TTNZPQ1 DM2I19P TN GABA(A) receptor alpha-5 (GABRA5) DM2I19P MA Inhibitor DM2I19P RN Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. DM2I19P RU https://pubmed.ncbi.nlm.nih.gov/14579514 DM2I19P DI DM2I19P DM2I19P DN Barbituric acid derivative DM2I19P TI TT37EDJ DM2I19P TN GABA(A) receptor alpha-3 (GABRA3) DM2I19P MA Inhibitor DM2I19P RN Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. DM2I19P RU https://pubmed.ncbi.nlm.nih.gov/14579514 DM2I19P DI DM2I19P DM2I19P DN Barbituric acid derivative DM2I19P TI TT4H1MQ DM2I19P TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DM2I19P MA Antagonist DM2I19P RN Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. DM2I19P RU https://pubmed.ncbi.nlm.nih.gov/14579514 DM2I19P DI DM2I19P DM2I19P DN Barbituric acid derivative DM2I19P TI TTBMV1G DM2I19P TN GABA(A) receptor alpha-2 (GABRA2) DM2I19P MA Inhibitor DM2I19P RN Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. DM2I19P RU https://pubmed.ncbi.nlm.nih.gov/14579514 DM2I91C DI DM2I91C DM2I91C DN 7-(3-Hydroxy-phenyl)-naphthalen-2-ol DM2I91C TI TTIWB6L DM2I91C TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM2I91C MA Inhibitor DM2I91C RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DM2I91C RU https://pubmed.ncbi.nlm.nih.gov/18324762 DM2I91C DI DM2I91C DM2I91C DN 7-(3-Hydroxy-phenyl)-naphthalen-2-ol DM2I91C TI TTZAYWL DM2I91C TN Estrogen receptor (ESR) DM2I91C MA Inhibitor DM2I91C RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM2I91C RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM2I91C DI DM2I91C DM2I91C DN 7-(3-Hydroxy-phenyl)-naphthalen-2-ol DM2I91C TI TTOM3J0 DM2I91C TN Estrogen receptor beta (ESR2) DM2I91C MA Inhibitor DM2I91C RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM2I91C RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM2I95Z DI DM2I95Z DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z TI TTT6LFV DM2I95Z TN Histone deacetylase 8 (HDAC8) DM2I95Z MA Inhibitor DM2I95Z RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM2I95Z RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM2I95Z DI DM2I95Z DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z TI TTTQGH8 DM2I95Z TN Histone deacetylase 4 (HDAC4) DM2I95Z MA Inhibitor DM2I95Z RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM2I95Z RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM2I95Z DI DM2I95Z DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z TI TT5ZKDI DM2I95Z TN Histone deacetylase 6 (HDAC6) DM2I95Z MA Inhibitor DM2I95Z RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM2I95Z RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM2I95Z DI DM2I95Z DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z TI TT6R7JZ DM2I95Z TN Histone deacetylase 1 (HDAC1) DM2I95Z MA Inhibitor DM2I95Z RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM2I95Z RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM2I95Z DI DM2I95Z DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z TI TTBH0VX DM2I95Z TN Histone deacetylase (HDAC) DM2I95Z MA Inhibitor DM2I95Z RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM2I95Z RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM2I95Z DI DM2I95Z DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z TI TTSHTOI DM2I95Z TN Histone deacetylase 2 (HDAC2) DM2I95Z MA Inhibitor DM2I95Z RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM2I95Z RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM2I95Z DI DM2I95Z DM2I95Z DN 6-benzenesulfinylhexanoic acid hydroxamide DM2I95Z TI TTYHPU6 DM2I95Z TN Histone deacetylase 10 (HDAC10) DM2I95Z MA Inhibitor DM2I95Z RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM2I95Z RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM2IBND DI DM2IBND DM2IBND DN RESCOVITINE DM2IBND TI TTAMQ62 DM2IBND TN Cyclin A2 (CCNA2) DM2IBND MA Inhibitor DM2IBND RN Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem. 2010 Mar;45(3):1158-66. DM2IBND RU https://pubmed.ncbi.nlm.nih.gov/20045222 DM2IBND DI DM2IBND DM2IBND DN RESCOVITINE DM2IBND TI TT7HF4W DM2IBND TN Cyclin-dependent kinase 2 (CDK2) DM2IBND MA Inhibitor DM2IBND RN Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors. Eur J Med Chem. 2010 Mar;45(3):1158-66. DM2IBND RU https://pubmed.ncbi.nlm.nih.gov/20045222 DM2IGD1 DI DM2IGD1 DM2IGD1 DN MIP-1231 DM2IGD1 TI TTGPQ0F DM2IGD1 TN Prolyl endopeptidase FAP (FAP) DM2IGD1 MA Antagonist DM2IGD1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365). DM2IGD1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2365 DM2ILAH DI DM2ILAH DM2ILAH DN Y-c[D-Pen-D-(2')Nal-GSFC]KR-NH2 DM2ILAH TI TT6PKBN DM2ILAH TN Proto-oncogene c-Src (SRC) DM2ILAH MA Inhibitor DM2ILAH RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DM2ILAH RU https://pubmed.ncbi.nlm.nih.gov/9632358 DM2IP5F DI DM2IP5F DM2IP5F DN 6-bromo-N-(3-fluorophenyl)quinazolin-4-amine DM2IP5F TI TTHS256 DM2IP5F TN Metabotropic glutamate receptor 5 (mGluR5) DM2IP5F MA Inhibitor DM2IP5F RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DM2IP5F RU https://pubmed.ncbi.nlm.nih.gov/19854049 DM2IXO0 DI DM2IXO0 DM2IXO0 DN 3-[5-(4-hydroxyphenyl)-1,3-thiazol-2-yl]phenol DM2IXO0 TI TTIWB6L DM2IXO0 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM2IXO0 MA Inhibitor DM2IXO0 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM2IXO0 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM2IYAP DI DM2IYAP DM2IYAP DN 3-(2-propyn-1-yl)thymidine DM2IYAP TI TTP3QRF DM2IYAP TN Thymidine kinase 1 (TK1) DM2IYAP MA Inhibitor DM2IYAP RN Synthesis, in vitro, and in silico evaluation of organometallic technetium and rhenium thymidine complexes with retained substrate activity toward ... J Med Chem. 2008 Nov 13;51(21):6689-98. DM2IYAP RU https://pubmed.ncbi.nlm.nih.gov/18837546 DM2IZA3 DI DM2IZA3 DM2IZA3 DN 4-Methyl-1,1':4',1''-terphenyl-3,4''-diol DM2IZA3 TI TTIWB6L DM2IZA3 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM2IZA3 MA Inhibitor DM2IZA3 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM2IZA3 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM2J0UN DI DM2J0UN DM2J0UN DN SAR-106881 DM2J0UN TI TTRLW2X DM2J0UN TN Fibroblast growth factor receptor 1 (FGFR1) DM2J0UN MA Agonist DM2J0UN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). DM2J0UN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808 DM2J1FA DI DM2J1FA DM2J1FA DN BRL-54504AX DM2J1FA TI TTNJYV2 DM2J1FA TN Gamma-aminobutyric acid receptor (GAR) DM2J1FA MA Inhibitor DM2J1FA RN Isosteric replacement of the indole nucleus by benzothiophene in a series of pyrido[2,3-b]indoles with potential anxiolytic activity, Bioorg. Med. Chem. Lett. 5(22):2589-2592 (1995). DM2J1FA RU http://www.sciencedirect.com/science/article/pii/0960894X95004508 DM2J5WH DI DM2J5WH DM2J5WH DN 1-allyl-5'-O-tritylinosine DM2J5WH TI TTO0IB8 DM2J5WH TN Thymidine phosphorylase (TYMP) DM2J5WH MA Inhibitor DM2J5WH RN 5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70. DM2J5WH RU https://pubmed.ncbi.nlm.nih.gov/16942029 DM2J63V DI DM2J63V DM2J63V DN 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile DM2J63V TI TTK3PY9 DM2J63V TN DNA-dependent protein kinase catalytic (PRKDC) DM2J63V MA Inhibitor DM2J63V RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM2J63V RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM2J9RI DI DM2J9RI DM2J9RI DN (10H-phenothiazin-10-yl)(m-tolyl)methanone DM2J9RI TI TTEB0GD DM2J9RI TN Cholinesterase (BCHE) DM2J9RI MA Inhibitor DM2J9RI RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DM2J9RI RU https://pubmed.ncbi.nlm.nih.gov/17681768 DM2JBQI DI DM2JBQI DM2JBQI DN 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one DM2JBQI TI TTTSEPU DM2JBQI TN Thyroid hormone receptor alpha (THRA) DM2JBQI MA Inhibitor DM2JBQI RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM2JBQI RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM2JBQI DI DM2JBQI DM2JBQI DN 3-(dibutylamino)-1-(4-hexylphenyl)propan-1-one DM2JBQI TI TTGER3L DM2JBQI TN Thyroid hormone receptor beta (THRB) DM2JBQI MA Inhibitor DM2JBQI RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM2JBQI RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM2JE5F DI DM2JE5F DM2JE5F DN Cyclic LVVYPWT DM2JE5F TI TT2THBD DM2JE5F TN P2X purinoceptor 3 (P2RX3) DM2JE5F MA Inhibitor DM2JE5F RN Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7. DM2JE5F RU https://pubmed.ncbi.nlm.nih.gov/17676725 DM2JG49 DI DM2JG49 DM2JG49 DN 2-(4-Azido-phenyl)-8-methoxy-3H-quinazolin-4-one DM2JG49 TI TTVDSZ0 DM2JG49 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM2JG49 MA Inhibitor DM2JG49 RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DM2JG49 RU https://pubmed.ncbi.nlm.nih.gov/9857092 DM2JPD4 DI DM2JPD4 DM2JPD4 DN NSC-93394 DM2JPD4 TI TTNJYV2 DM2JPD4 TN Gamma-aminobutyric acid receptor (GAR) DM2JPD4 MA Inhibitor DM2JPD4 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM2JPD4 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM2JPD4 DI DM2JPD4 DM2JPD4 DN NSC-93394 DM2JPD4 TI TT1MPAY DM2JPD4 TN GABA(A) receptor alpha-1 (GABRA1) DM2JPD4 MA Inhibitor DM2JPD4 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM2JPD4 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM2JPX7 DI DM2JPX7 DM2JPX7 DN BRIFENTANIL DM2JPX7 TI TTN4QDT DM2JPX7 TN Opioid receptor (OPR) DM2JPX7 MA Modulator DM2JPX7 RN Synthesis and pharmacological evaluation of a series of new 3-methyl-1,4-disubstituted-piperidine analgesics. J Med Chem. 1990 Oct;33(10):2876-82. DM2JPX7 RU https://pubmed.ncbi.nlm.nih.gov/2170652 DM2JUTB DI DM2JUTB DM2JUTB DN PARA-(BENZOYL)-PHENYLALANINE DM2JUTB TI TTELIN2 DM2JUTB TN PTPN1 messenger RNA (PTPN1 mRNA) DM2JUTB MA Inhibitor DM2JUTB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM2JUTB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM2JYQA DI DM2JYQA DM2JYQA DN S109 DM2JYQA TI TTCJUR4 DM2JYQA TN Exportin-1 (XPO1) DM2JYQA MA Inhibitor DM2JYQA RN Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-B signaling pathway. Cancer Cell Int. 2020 Mar 30;20:97. DM2JYQA RU https://pubmed.ncbi.nlm.nih.gov/32256206 DM2JZ84 DI DM2JZ84 DM2JZ84 DN 2-Cyclohexylethynyl-pyridine DM2JZ84 TI TTHS256 DM2JZ84 TN Metabotropic glutamate receptor 5 (mGluR5) DM2JZ84 MA Inhibitor DM2JZ84 RN Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4589-93. DM2JZ84 RU https://pubmed.ncbi.nlm.nih.gov/16115767 DM2K0AJ DI DM2K0AJ DM2K0AJ DN N-(2-amino-5-(thiazol-2-yl)phenyl)benzamide DM2K0AJ TI TTSHTOI DM2K0AJ TN Histone deacetylase 2 (HDAC2) DM2K0AJ MA Inhibitor DM2K0AJ RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DM2K0AJ RU https://pubmed.ncbi.nlm.nih.gov/20392638 DM2K0RD DI DM2K0RD DM2K0RD DN ISIS 29139 DM2K0RD TI TTO6SGY DM2K0RD TN AKT3 messenger RNA (AKT3 mRNA) DM2K0RD RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DM2K0RD RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DM2K16M DI DM2K16M DM2K16M DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 DM2K16M TI TT27RFC DM2K16M TN Opioid receptor delta (OPRD1) DM2K16M MA Inhibitor DM2K16M RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM2K16M RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM2K16M DI DM2K16M DM2K16M DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 DM2K16M TI TTZPO1L DM2K16M TN Substance-P receptor (TACR1) DM2K16M MA Inhibitor DM2K16M RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM2K16M RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM2K16M DI DM2K16M DM2K16M DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 DM2K16M TI TTKWM86 DM2K16M TN Opioid receptor mu (MOP) DM2K16M MA Inhibitor DM2K16M RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM2K16M RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM2K51S DI DM2K51S DM2K51S DN 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid DM2K51S TI TTSJ542 DM2K51S TN Integrin alpha-2 (ITGA2) DM2K51S MA Inhibitor DM2K51S RN Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. DM2K51S RU https://pubmed.ncbi.nlm.nih.gov/16919941 DM2K51S DI DM2K51S DM2K51S DN 3-(3-(carbamoyl)benzamido)-3-phenylpropanoic acid DM2K51S TI TTJA1ZO DM2K51S TN ITGB3 messenger RNA (ITGB3 mRNA) DM2K51S MA Inhibitor DM2K51S RN Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. DM2K51S RU https://pubmed.ncbi.nlm.nih.gov/16919941 DM2K59V DI DM2K59V DM2K59V DN 3'thiacytidine DM2K59V TI TT84ETX DM2K59V TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM2K59V MA Inhibitor DM2K59V RN Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother. 1993 Jul;32 Suppl A:133-8. DM2K59V RU https://pubmed.ncbi.nlm.nih.gov/8407695 DM2K6I8 DI DM2K6I8 DM2K6I8 DN Ryanodine DM2K6I8 TI TTU5CIX DM2K6I8 TN Ryanodine receptor 1 (RYR1) DM2K6I8 MA Antagonist DM2K6I8 RN The contribution of inositol 1,4,5-trisphosphate and ryanodine receptors to agonist-induced Ca(2+) signaling of airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2009 Aug;297(2):L347-61. DM2K6I8 RU https://pubmed.ncbi.nlm.nih.gov/19465516 DM2K74C DI DM2K74C DM2K74C DN ISIS 112001 DM2K74C TI TTPJ9XK DM2K74C TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DM2K74C RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DM2K74C RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DM2K7TX DI DM2K7TX DM2K7TX DN 1-adamantan-1-yl-3-(1-propyl-piperidin-4-yl)-urea DM2K7TX TI TT7WVHI DM2K7TX TN Soluble epoxide hydrolase (EPHX2) DM2K7TX MA Inhibitor DM2K7TX RN Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. DM2K7TX RU https://pubmed.ncbi.nlm.nih.gov/16870439 DM2K81B DI DM2K81B DM2K81B DN KMS-88009 DM2K81B TI TTE4KHA DM2K81B TN Amyloid beta A4 protein (APP) DM2K81B MA Inhibitor DM2K81B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM2K81B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM2KAG5 DI DM2KAG5 DM2KAG5 DN 4-(piperazin-1-yl)thieno[3,2-d]pyrimidine DM2KAG5 TI TTWJBZ5 DM2KAG5 TN 5-HT 2C receptor (HTR2C) DM2KAG5 MA Inhibitor DM2KAG5 RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DM2KAG5 RU https://pubmed.ncbi.nlm.nih.gov/19914063 DM2KBOU DI DM2KBOU DM2KBOU DN (R)-flurocarazolol DM2KBOU TI TTK8CXU DM2KBOU TN 5-HT 1B receptor (HTR1B) DM2KBOU MA Antagonist DM2KBOU RN The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4. DM2KBOU RU https://pubmed.ncbi.nlm.nih.gov/11512051 DM2KBOU DI DM2KBOU DM2KBOU DN (R)-flurocarazolol DM2KBOU TI TTSQIFT DM2KBOU TN 5-HT 1A receptor (HTR1A) DM2KBOU MA Antagonist DM2KBOU RN The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4. DM2KBOU RU https://pubmed.ncbi.nlm.nih.gov/11512051 DM2KECW DI DM2KECW DM2KECW DN ISIS 110074 DM2KECW TI TTK1V5Q DM2KECW TN Nucleolin messenger RNA (NCL mRNA) DM2KECW RN US patent application no. 6,165,786, Antisense modulation of nucleolin expression. DM2KECW RU http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true DM2KEW6 DI DM2KEW6 DM2KEW6 DN 3R14S-OCHRATOXIN A DM2KEW6 TI TTTQR47 DM2KEW6 TN Solute carrier family 22 member 8 (SLC22A8) DM2KEW6 MA Inhibitor DM2KEW6 RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DM2KEW6 RU https://pubmed.ncbi.nlm.nih.gov/17553798 DM2KFQ5 DI DM2KFQ5 DM2KFQ5 DN SK&F-29661 DM2KFQ5 TI TTWG9A4 DM2KFQ5 TN Adrenergic receptor alpha-2A (ADRA2A) DM2KFQ5 MA Inhibitor DM2KFQ5 RN Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoqui... Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7. DM2KFQ5 RU https://pubmed.ncbi.nlm.nih.gov/15686930 DM2KMNU DI DM2KMNU DM2KMNU DN EQ-1280 DM2KMNU TI TTN7BL9 DM2KMNU TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM2KMNU MA Inhibitor DM2KMNU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763). DM2KMNU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763 DM2KT17 DI DM2KT17 DM2KT17 DN GSK-1842799C DM2KT17 TI TT9JZCK DM2KT17 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM2KT17 MA Agonist DM2KT17 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275). DM2KT17 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275 DM2KUEV DI DM2KUEV DM2KUEV DN Fsn-0503 DM2KUEV TI TTUMQVO DM2KUEV TN Cathepsin S (CTSS) DM2KUEV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DM2KUEV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DM2KXFS DI DM2KXFS DM2KXFS DN 3-[(1s)-1-(Dimethylamino)Ethyl]Phenol DM2KXFS TI TT1RS9F DM2KXFS TN Acetylcholinesterase (AChE) DM2KXFS MA Inhibitor DM2KXFS RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM2KXFS RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM2L3CJ DI DM2L3CJ DM2L3CJ DN MRS2693 DM2L3CJ TI TTNVSKA DM2L3CJ TN P2Y purinoceptor 6 (P2RY6) DM2L3CJ MA Agonist DM2L3CJ RN Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J Med Chem. 2006 Sep 7;49(18):5532-43. DM2L3CJ RU https://pubmed.ncbi.nlm.nih.gov/16942026 DM2L3PE DI DM2L3PE DM2L3PE DN Hyperforin DM2L3PE TI TT2J34L DM2L3PE TN Arachidonate 5-lipoxygenase (5-LOX) DM2L3PE MA Inhibitor DM2L3PE RN Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002 Dec 15;64(12):1767-75. DM2L3PE RU https://pubmed.ncbi.nlm.nih.gov/12445866 DM2L3PE DI DM2L3PE DM2L3PE DN Hyperforin DM2L3PE TI TT7LCTF DM2L3PE TN Pregnane X receptor (NR1I2) DM2L3PE MA Binder DM2L3PE RN Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther. 2009 Apr;329(1):141-9. DM2L3PE RU https://pubmed.ncbi.nlm.nih.gov/19147857 DM2L3PE DI DM2L3PE DM2L3PE DN Hyperforin DM2L3PE TI TT8NGED DM2L3PE TN Prostaglandin G/H synthase 1 (COX-1) DM2L3PE MA Inhibitor DM2L3PE RN Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol. 2002 Dec 15;64(12):1767-75. DM2L3PE RU https://pubmed.ncbi.nlm.nih.gov/12445866 DM2L6OZ DI DM2L6OZ DM2L6OZ DN 27-hydroxycholesterol DM2L6OZ TI TTME5YJ DM2L6OZ TN EBV-induced G-protein coupled receptor 2 (GPR183) DM2L6OZ MA Agonist DM2L6OZ RN Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23. DM2L6OZ RU https://pubmed.ncbi.nlm.nih.gov/21796211 DM2L6OZ DI DM2L6OZ DM2L6OZ DN 27-hydroxycholesterol DM2L6OZ TI TTECBXN DM2L6OZ TN Oxysterols receptor LXR-alpha (NR1H3) DM2L6OZ MA Agonist DM2L6OZ RN 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87. DM2L6OZ RU https://pubmed.ncbi.nlm.nih.gov/11504730 DM2L6OZ DI DM2L6OZ DM2L6OZ DN 27-hydroxycholesterol DM2L6OZ TI TTXA6PH DM2L6OZ TN Oxysterols receptor LXR-beta (NR1H2) DM2L6OZ MA Agonist DM2L6OZ RN 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87. DM2L6OZ RU https://pubmed.ncbi.nlm.nih.gov/11504730 DM2LA9X DI DM2LA9X DM2LA9X DN [3H]p-MPPF DM2LA9X TI TTSQIFT DM2LA9X TN 5-HT 1A receptor (HTR1A) DM2LA9X MA Antagonist DM2LA9X RN Ligand binding characteristics of the human serotonin1A receptor heterologously expressed in CHO cells. Biosci Rep. 2004 Apr;24(2):101-15. DM2LA9X RU https://pubmed.ncbi.nlm.nih.gov/15628665 DM2LBFW DI DM2LBFW DM2LBFW DN 3-Hydroxyhippuric acid DM2LBFW TI TTWQM3J DM2LBFW TN Kynureninase (KYNU) DM2LBFW MA Inhibitor DM2LBFW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM2LBFW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM2LJFZ DI DM2LJFZ DM2LJFZ DN 4-hydroxy-2-nonenal DM2LJFZ TI TTRPDBG DM2LJFZ TN Inhibitor of nuclear factor kappa-B kinase (IKK) DM2LJFZ MA Inhibitor DM2LJFZ RN IkappaB kinase, a molecular target for inhibition by 4-hydroxy-2-nonenal. J Biol Chem. 2001 May 25;276(21):18223-8. DM2LJFZ RU https://pubmed.ncbi.nlm.nih.gov/11359792 DM2LWNF DI DM2LWNF DM2LWNF DN COV08-0064 DM2LWNF TI TTSHG0T DM2LWNF TN Toll-like receptor 9 (TLR9) DM2LWNF MA Agonist DM2LWNF RN The novel TLR9 antagonist COV08-0064 protects from ischemia/reperfusion injury in non-steatotic and steatotic mice livers. Biochem Pharmacol. 2016 Jul 15;112:90-101. DM2LWNF RU https://pubmed.ncbi.nlm.nih.gov/27157410 DM2MCK1 DI DM2MCK1 DM2MCK1 DN 2-Amino-6-(3-cyano-phenylsulfanyl)-benzonitrile DM2MCK1 TI TT84ETX DM2MCK1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM2MCK1 MA Inhibitor DM2MCK1 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM2MCK1 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM2MGSO DI DM2MGSO DM2MGSO DN N-(4'-isopropyl-4-biphenylyl)urea DM2MGSO TI TTBGTCW DM2MGSO TN Kinesin spindle messenger RNA (KIF11 mRNA) DM2MGSO MA Inhibitor DM2MGSO RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DM2MGSO RU https://pubmed.ncbi.nlm.nih.gov/17725339 DM2MH6J DI DM2MH6J DM2MH6J DN 2-N-Hydroxyamino-1-(4-ethylthiophenyl)butane DM2MH6J TI TT3ROYC DM2MH6J TN Serotonin transporter (SERT) DM2MH6J MA Inhibitor DM2MH6J RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM2MH6J RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM2MIJY DI DM2MIJY DM2MIJY DN 7-Cyclopentyloxy-3-(4-hydroxyphenyl)chromen-4-one DM2MIJY TI TTZAYWL DM2MIJY TN Estrogen receptor (ESR) DM2MIJY MA Inhibitor DM2MIJY RN Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26;53(16):6153-63. DM2MIJY RU https://pubmed.ncbi.nlm.nih.gov/20669983 DM2MJ9F DI DM2MJ9F DM2MJ9F DN 6-bromo-N-m-tolylquinazolin-4-amine DM2MJ9F TI TTHS256 DM2MJ9F TN Metabotropic glutamate receptor 5 (mGluR5) DM2MJ9F MA Inhibitor DM2MJ9F RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DM2MJ9F RU https://pubmed.ncbi.nlm.nih.gov/19854049 DM2MPWC DI DM2MPWC DM2MPWC DN 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol DM2MPWC TI TTNT7K8 DM2MPWC TN Nociceptin receptor (OPRL1) DM2MPWC MA Inhibitor DM2MPWC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM2MPWC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM2MPWC DI DM2MPWC DM2MPWC DN 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol DM2MPWC TI TTKWM86 DM2MPWC TN Opioid receptor mu (MOP) DM2MPWC MA Inhibitor DM2MPWC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM2MPWC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM2MPWC DI DM2MPWC DM2MPWC DN 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol DM2MPWC TI TTQW87Y DM2MPWC TN Opioid receptor kappa (OPRK1) DM2MPWC MA Inhibitor DM2MPWC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM2MPWC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM2MPWC DI DM2MPWC DM2MPWC DN 4-phenyl-1-(phenyl(o-tolyl)methyl)piperidin-4-ol DM2MPWC TI TT27RFC DM2MPWC TN Opioid receptor delta (OPRD1) DM2MPWC MA Inhibitor DM2MPWC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM2MPWC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM2MSEF DI DM2MSEF DM2MSEF DN 4'-(2-butylbenzofuran-3-yl)biphenyl-4-ol DM2MSEF TI TTELIN2 DM2MSEF TN PTPN1 messenger RNA (PTPN1 mRNA) DM2MSEF MA Inhibitor DM2MSEF RN Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2009 Apr 1;17(7):2658-72. DM2MSEF RU https://pubmed.ncbi.nlm.nih.gov/19297174 DM2MV9O DI DM2MV9O DM2MV9O DN DIRLOTAPIDE DM2MV9O TI TTUS1RD DM2MV9O TN Microsomal triglyceride transfer protein (MTTP) DM2MV9O MA Inhibitor DM2MV9O RN In vitro and in vivo profile of 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlota... Bioorg Med Chem Lett. 2007 Apr 1;17(7):1996-9. DM2MV9O RU https://pubmed.ncbi.nlm.nih.gov/17276061 DM2MXIK DI DM2MXIK DM2MXIK DN IQM-97423 DM2MXIK TI TTCG0AL DM2MXIK TN Cholecystokinin receptor type A (CCKAR) DM2MXIK MA Antagonist DM2MXIK RN Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis. Pharmacology. 2004 Oct;72(2):68-76. DM2MXIK RU https://pubmed.ncbi.nlm.nih.gov/15331911 DM2MYKC DI DM2MYKC DM2MYKC DN biphenylindanone A DM2MYKC TI TTXJ47W DM2MYKC TN Metabotropic glutamate receptor 2 (mGluR2) DM2MYKC MA Modulator (allosteric modulator) DM2MYKC RN Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4354-8. DM2MYKC RU https://pubmed.ncbi.nlm.nih.gov/16046122 DM2N3BA DI DM2N3BA DM2N3BA DN R-N6-(phenylisopropyl)adenosine DM2N3BA TI TTNE7KG DM2N3BA TN Adenosine A2b receptor (ADORA2B) DM2N3BA MA Agonist DM2N3BA RN Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91. DM2N3BA RU https://pubmed.ncbi.nlm.nih.gov/6253037 DM2N3BA DI DM2N3BA DM2N3BA DN R-N6-(phenylisopropyl)adenosine DM2N3BA TI TTK25J1 DM2N3BA TN Adenosine A1 receptor (ADORA1) DM2N3BA MA Inhibitor DM2N3BA RN Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9. DM2N3BA RU https://pubmed.ncbi.nlm.nih.gov/9459566 DM2N3BA DI DM2N3BA DM2N3BA DN R-N6-(phenylisopropyl)adenosine DM2N3BA TI TTM2AOE DM2N3BA TN Adenosine A2a receptor (ADORA2A) DM2N3BA MA Inhibitor DM2N3BA RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DM2N3BA RU https://pubmed.ncbi.nlm.nih.gov/17378544 DM2N3BA DI DM2N3BA DM2N3BA DN R-N6-(phenylisopropyl)adenosine DM2N3BA TI TTJFY5U DM2N3BA TN Adenosine A3 receptor (ADORA3) DM2N3BA MA Inhibitor DM2N3BA RN Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology. 1993;46(2):91-100. DM2N3BA RU https://pubmed.ncbi.nlm.nih.gov/8441759 DM2N3TG DI DM2N3TG DM2N3TG DN N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide DM2N3TG TI TTRA5BZ DM2N3TG TN Steroid 17-alpha-monooxygenase (S17AH) DM2N3TG MA Inhibitor DM2N3TG RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM2N3TG RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM2N3TG DI DM2N3TG DM2N3TG DN N-(4'-Isonicotinoylbiphenyl-3-yl)acetamide DM2N3TG TI TTIQUX7 DM2N3TG TN Steroid 11-beta-hydroxylase (CYP11B1) DM2N3TG MA Inhibitor DM2N3TG RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM2N3TG RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM2N4BJ DI DM2N4BJ DM2N4BJ DN 4-fluorobenzaldehyde O-benzoyloxime DM2N4BJ TI TTDNFMT DM2N4BJ TN Platelet-activating factor acetylhydrolase (PLA2G7) DM2N4BJ MA Inhibitor DM2N4BJ RN Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5576-9. DM2N4BJ RU https://pubmed.ncbi.nlm.nih.gov/16919943 DM2N8JX DI DM2N8JX DM2N8JX DN ISIS 111118 DM2N8JX TI TTOM97J DM2N8JX TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DM2N8JX RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DM2N8JX RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DM2N8TW DI DM2N8TW DM2N8TW DN 7alpha,25-dihydroxycholesterol DM2N8TW TI TTME5YJ DM2N8TW TN EBV-induced G-protein coupled receptor 2 (GPR183) DM2N8TW MA Agonist DM2N8TW RN Oxysterols direct immune cell migration via EBI2. Nature. 2011 Jul 27;475(7357):524-7. DM2N8TW RU https://pubmed.ncbi.nlm.nih.gov/21796212 DM2N9Y8 DI DM2N9Y8 DM2N9Y8 DN example 41 (WO2012028563) DM2N9Y8 TI TT69DB8 DM2N9Y8 TN Beta-site APP-cleaving enzyme 2 (BACE2) DM2N9Y8 MA Inhibitor DM2N9Y8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2331). DM2N9Y8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2331 DM2ND3U DI DM2ND3U DM2ND3U DN Ac-RYYRIK-K-(NH2)-YAFGYPS DM2ND3U TI TTKWM86 DM2ND3U TN Opioid receptor mu (MOP) DM2ND3U MA Inhibitor DM2ND3U RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DM2ND3U RU https://pubmed.ncbi.nlm.nih.gov/16814543 DM2ND3U DI DM2ND3U DM2ND3U DN Ac-RYYRIK-K-(NH2)-YAFGYPS DM2ND3U TI TTNT7K8 DM2ND3U TN Nociceptin receptor (OPRL1) DM2ND3U MA Inhibitor DM2ND3U RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DM2ND3U RU https://pubmed.ncbi.nlm.nih.gov/16814543 DM2NEX4 DI DM2NEX4 DM2NEX4 DN 2-Oxa-spiro[4.4]nonan-1-one DM2NEX4 TI TT06RH5 DM2NEX4 TN GABA(A) receptor gamma-2 (GABRG2) DM2NEX4 MA Inhibitor DM2NEX4 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM2NEX4 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM2NEX4 DI DM2NEX4 DM2NEX4 DN 2-Oxa-spiro[4.4]nonan-1-one DM2NEX4 TI TTNJYV2 DM2NEX4 TN Gamma-aminobutyric acid receptor (GAR) DM2NEX4 MA Inhibitor DM2NEX4 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM2NEX4 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM2NEX4 DI DM2NEX4 DM2NEX4 DN 2-Oxa-spiro[4.4]nonan-1-one DM2NEX4 TI TTZA1NY DM2NEX4 TN GABA(A) receptor beta-2 (GABRB2) DM2NEX4 MA Inhibitor DM2NEX4 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM2NEX4 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM2NEX4 DI DM2NEX4 DM2NEX4 DN 2-Oxa-spiro[4.4]nonan-1-one DM2NEX4 TI TT1MPAY DM2NEX4 TN GABA(A) receptor alpha-1 (GABRA1) DM2NEX4 MA Inhibitor DM2NEX4 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM2NEX4 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM2NHVX DI DM2NHVX DM2NHVX DN N-(naphthalen-2-yl)benzo[d]isoxazol-3-amine DM2NHVX TI TT7WVHI DM2NHVX TN Soluble epoxide hydrolase (EPHX2) DM2NHVX MA Inhibitor DM2NHVX RN A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. DM2NHVX RU https://pubmed.ncbi.nlm.nih.gov/19700315 DM2NX4K DI DM2NX4K DM2NX4K DN 2'-Nitro-biphenyl-4-carboxylic acid hydroxyamide DM2NX4K TI TT2J34L DM2NX4K TN Arachidonate 5-lipoxygenase (5-LOX) DM2NX4K MA Inhibitor DM2NX4K RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DM2NX4K RU https://pubmed.ncbi.nlm.nih.gov/2308149 DM2OCZ8 DI DM2OCZ8 DM2OCZ8 DN doxorubicin-peptide-PEG conjugate DM2OCZ8 TI TTUTN1I DM2OCZ8 TN Human Deoxyribonucleic acid (hDNA) DM2OCZ8 MA Modulator DM2OCZ8 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM2OCZ8 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM2OCZ8 DI DM2OCZ8 DM2OCZ8 DN doxorubicin-peptide-PEG conjugate DM2OCZ8 TI TT0IHXV DM2OCZ8 TN DNA topoisomerase II (TOP2) DM2OCZ8 MA Modulator DM2OCZ8 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM2OCZ8 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM2OE1W DI DM2OE1W DM2OE1W DN 2-Aminoethanimidic Acid DM2OE1W TI TTF2LRI DM2OE1W TN Cathepsin B (CTSB) DM2OE1W MA Inhibitor DM2OE1W RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2OE1W RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2OGZ5 DI DM2OGZ5 DM2OGZ5 DN Morin DM2OGZ5 TI TTOM3J0 DM2OGZ5 TN Estrogen receptor beta (ESR2) DM2OGZ5 MA Inhibitor DM2OGZ5 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM2OGZ5 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM2OGZ5 DI DM2OGZ5 DM2OGZ5 DN Morin DM2OGZ5 TI TTHPFTS DM2OGZ5 TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DM2OGZ5 MA Inhibitor DM2OGZ5 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DM2OGZ5 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DM2OGZ5 DI DM2OGZ5 DM2OGZ5 DN Morin DM2OGZ5 TI TTA592U DM2OGZ5 TN Urate anion exchanger 1 (URAT1) DM2OGZ5 MA Inhibitor DM2OGZ5 RN Morin (3,5,7,2',4'-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) express... Drug Metab Dispos. 2007 Jun;35(6):981-6. DM2OGZ5 RU https://pubmed.ncbi.nlm.nih.gov/17325024 DM2OGZ5 DI DM2OGZ5 DM2OGZ5 DN Morin DM2OGZ5 TI TT7AOUD DM2OGZ5 TN Fatty acid synthase (FASN) DM2OGZ5 MA Inhibitor DM2OGZ5 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DM2OGZ5 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DM2OGZ5 DI DM2OGZ5 DM2OGZ5 DN Morin DM2OGZ5 TI TTBE4IR DM2OGZ5 TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DM2OGZ5 MA Inhibitor DM2OGZ5 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DM2OGZ5 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DM2OGZ5 DI DM2OGZ5 DM2OGZ5 DN Morin DM2OGZ5 TI TTL53M6 DM2OGZ5 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM2OGZ5 MA Inhibitor DM2OGZ5 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM2OGZ5 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM2OGZ5 DI DM2OGZ5 DM2OGZ5 DN Morin DM2OGZ5 TI TTNX2CS DM2OGZ5 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM2OGZ5 MA Inhibitor DM2OGZ5 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DM2OGZ5 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DM2OHVJ DI DM2OHVJ DM2OHVJ DN N-(4-Phenylthiazol-2-yl)isonicotinamide DM2OHVJ TI TTVDSZ0 DM2OHVJ TN Poly [ADP-ribose] polymerase 1 (PARP1) DM2OHVJ MA Inhibitor DM2OHVJ RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DM2OHVJ RU https://pubmed.ncbi.nlm.nih.gov/19125579 DM2OLGQ DI DM2OLGQ DM2OLGQ DN SNAP-5150 DM2OLGQ TI TT2NUT5 DM2OLGQ TN Adrenergic receptor alpha-2C (ADRA2C) DM2OLGQ MA Inhibitor DM2OLGQ RN Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8. DM2OLGQ RU https://pubmed.ncbi.nlm.nih.gov/10522703 DM2OLGQ DI DM2OLGQ DM2OLGQ DN SNAP-5150 DM2OLGQ TI TTWM4TY DM2OLGQ TN Adrenergic receptor alpha-2B (ADRA2B) DM2OLGQ MA Inhibitor DM2OLGQ RN Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8. DM2OLGQ RU https://pubmed.ncbi.nlm.nih.gov/10522703 DM2OLGQ DI DM2OLGQ DM2OLGQ DN SNAP-5150 DM2OLGQ TI TTWG9A4 DM2OLGQ TN Adrenergic receptor alpha-2A (ADRA2A) DM2OLGQ MA Inhibitor DM2OLGQ RN Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8. DM2OLGQ RU https://pubmed.ncbi.nlm.nih.gov/10522703 DM2OR8E DI DM2OR8E DM2OR8E DN 4-(4-methoxy-benzylideneamino)-benzenesulfonamide DM2OR8E TI TTVKILB DM2OR8E TN Prostaglandin G/H synthase 2 (COX-2) DM2OR8E MA Inhibitor DM2OR8E RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DM2OR8E RU https://pubmed.ncbi.nlm.nih.gov/18063374 DM2OUG0 DI DM2OUG0 DM2OUG0 DN 2-tosylnaphthalene DM2OUG0 TI TTRVTMX DM2OUG0 TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DM2OUG0 MA Inhibitor DM2OUG0 RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DM2OUG0 RU https://pubmed.ncbi.nlm.nih.gov/18996691 DM2OZBL DI DM2OZBL DM2OZBL DN Howiinol A (GHM-10) DM2OZBL TI TT0IHXV DM2OZBL TN DNA topoisomerase II (TOP2) DM2OZBL MA Inhibitor DM2OZBL RN Anticancer effect of Howiinol A and its mechanism of action. J Asian Nat Prod Res. 1999;2(1):1-19. DM2OZBL RU https://pubmed.ncbi.nlm.nih.gov/11261201 DM2P0I4 DI DM2P0I4 DM2P0I4 DN PXVX-0103 DM2P0I4 TI TTF4CAM DM2P0I4 TN Influenza Hemagglutinin (Influ HA) DM2P0I4 MA Modulator DM2P0I4 RN Company report (PaxVax) DM2P0I4 RU http://paxvax.com/other-diseases/h5n1-avian-influenza DM2P6I8 DI DM2P6I8 DM2P6I8 DN RJM-0035-K002 DM2P6I8 TI TTL69WB DM2P6I8 TN Angiotensin-converting enzyme (ACE) DM2P6I8 MA Inhibitor DM2P6I8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1613). DM2P6I8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1613 DM2P7YX DI DM2P7YX DM2P7YX DN 1-(2-Ethoxy-phenyl)-piperazine DM2P7YX TI TTSQIFT DM2P7YX TN 5-HT 1A receptor (HTR1A) DM2P7YX MA Inhibitor DM2P7YX RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM2P7YX RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM2P7YX DI DM2P7YX DM2P7YX DN 1-(2-Ethoxy-phenyl)-piperazine DM2P7YX TI TT6MSOK DM2P7YX TN 5-HT 1D receptor (HTR1D) DM2P7YX MA Inhibitor DM2P7YX RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM2P7YX RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM2P9L5 DI DM2P9L5 DM2P9L5 DN 2-(4-Amino-phenyl)-benzo[h]chromen-4-one DM2P9L5 TI TTK3PY9 DM2P9L5 TN DNA-dependent protein kinase catalytic (PRKDC) DM2P9L5 MA Inhibitor DM2P9L5 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DM2P9L5 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DM2PDGO DI DM2PDGO DM2PDGO DN 2-EPI-2-THIOSALVINORIN A DM2PDGO TI TTQW87Y DM2PDGO TN Opioid receptor kappa (OPRK1) DM2PDGO MA Inhibitor DM2PDGO RN Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32. DM2PDGO RU https://pubmed.ncbi.nlm.nih.gov/17303418 DM2PIAZ DI DM2PIAZ DM2PIAZ DN ISIS 133243 DM2PIAZ TI TTZN92A DM2PIAZ TN DUSP5 messenger RNA (DUSP5 mRNA) DM2PIAZ RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DM2PIAZ RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DM2PQFE DI DM2PQFE DM2PQFE DN 1-(1-p-tolylethylidene)thiosemicarbazide DM2PQFE TI TTULVH8 DM2PQFE TN Tyrosinase (TYR) DM2PQFE MA Inhibitor DM2PQFE RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DM2PQFE RU https://pubmed.ncbi.nlm.nih.gov/18326070 DM2PRHX DI DM2PRHX DM2PRHX DN AR-HO29953XX DM2PRHX TI TTTO43N DM2PRHX TN Endothelial plasminogen activator inhibitor (SERPINE1) DM2PRHX MA Inhibitor DM2PRHX RN Synthesis and SAR of 2-carboxylic acid indoles as inhibitors of plasminogen activator inhibitor-1. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3514-8. DM2PRHX RU https://pubmed.ncbi.nlm.nih.gov/15982877 DM2PS89 DI DM2PS89 DM2PS89 DN 4-Hydroxy-3,5-diisopropyl-benzaldehyde DM2PS89 TI TTNJYV2 DM2PS89 TN Gamma-aminobutyric acid receptor (GAR) DM2PS89 MA Inhibitor DM2PS89 RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DM2PS89 RU https://pubmed.ncbi.nlm.nih.gov/9599235 DM2PW8T DI DM2PW8T DM2PW8T DN [3H]7-OH-DPAT DM2PW8T TI TT4C8EA DM2PW8T TN Dopamine D3 receptor (D3R) DM2PW8T MA Agonist DM2PW8T RN Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT. J Neuroimmunol. 1995 May;58(2):139-44. DM2PW8T RU https://pubmed.ncbi.nlm.nih.gov/7759603 DM2PW8T DI DM2PW8T DM2PW8T DN [3H]7-OH-DPAT DM2PW8T TI TTEX248 DM2PW8T TN Dopamine D2 receptor (D2R) DM2PW8T MA Inhibitor DM2PW8T RN Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19. DM2PW8T RU https://pubmed.ncbi.nlm.nih.gov/19053758 DM2PYE7 DI DM2PYE7 DM2PYE7 DN FGGFTGCRKSARKC DM2PYE7 TI TTNT7K8 DM2PYE7 TN Nociceptin receptor (OPRL1) DM2PYE7 MA Inhibitor DM2PYE7 RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DM2PYE7 RU https://pubmed.ncbi.nlm.nih.gov/11689089 DM2PZ1B DI DM2PZ1B DM2PZ1B DN 2-(1H-Imidazol-4-yl)benzene-1,3-diol DM2PZ1B TI TTZJYKH DM2PZ1B TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM2PZ1B MA Inhibitor DM2PZ1B RN Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77. DM2PZ1B RU https://pubmed.ncbi.nlm.nih.gov/18665584 DM2Q0VB DI DM2Q0VB DM2Q0VB DN 4-benzyl-2,6-diisobutylamino-pyrimidine DM2Q0VB TI TTZAYWL DM2Q0VB TN Estrogen receptor (ESR) DM2Q0VB MA Inhibitor DM2Q0VB RN Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30. DM2Q0VB RU https://pubmed.ncbi.nlm.nih.gov/18785725 DM2Q19U DI DM2Q19U DM2Q19U DN Equilin DM2Q19U TI TTAHMI6 DM2Q19U TN HUMAN estrogen receptor (ESR1) DM2Q19U MA Inhibitor DM2Q19U RN Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients. J Pharm Pharm Sci. 2020;23(1):75-85. DM2Q19U RU https://pubmed.ncbi.nlm.nih.gov/32324533 DM2Q3CL DI DM2Q3CL DM2Q3CL DN Dimemorfan DM2Q3CL TI TT5TPI6 DM2Q3CL TN Opioid receptor sigma 1 (OPRS1) DM2Q3CL MA Agonist DM2Q3CL RN Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. J Neurochem. 2008 Jan;104(2):558-72. DM2Q3CL RU https://pubmed.ncbi.nlm.nih.gov/18173806 DM2Q6JY DI DM2Q6JY DM2Q6JY DN quadazocine DM2Q6JY TI TT27RFC DM2Q6JY TN Opioid receptor delta (OPRD1) DM2Q6JY MA Antagonist DM2Q6JY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DM2Q6JY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DM2Q6JY DI DM2Q6JY DM2Q6JY DN quadazocine DM2Q6JY TI TTQW87Y DM2Q6JY TN Opioid receptor kappa (OPRK1) DM2Q6JY MA Antagonist DM2Q6JY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). DM2Q6JY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 DM2Q6JY DI DM2Q6JY DM2Q6JY DN quadazocine DM2Q6JY TI TTKWM86 DM2Q6JY TN Opioid receptor mu (MOP) DM2Q6JY MA Antagonist DM2Q6JY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DM2Q6JY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DM2Q79X DI DM2Q79X DM2Q79X DN PMID16242323C16 DM2Q79X TI TTK3C21 DM2Q79X TN Acetoacetyl-CoA thiolase (ACAT1) DM2Q79X MA Inhibitor DM2Q79X RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DM2Q79X RU https://pubmed.ncbi.nlm.nih.gov/16242323 DM2QD45 DI DM2QD45 DM2QD45 DN 3-methoxy-4-(m-tolyloxy)benzonitrile DM2QD45 TI TTKPW01 DM2QD45 TN Androgen receptor messenger RNA (AR mRNA) DM2QD45 MA Inhibitor DM2QD45 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM2QD45 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM2QDXW DI DM2QDXW DM2QDXW DN [D-Gln3,Ncy(SO,isopropyl)7]acyline DM2QDXW TI TT8R70G DM2QDXW TN Gonadotropin-releasing hormone receptor (GNRHR) DM2QDXW MA Inhibitor DM2QDXW RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM2QDXW RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM2QJ5A DI DM2QJ5A DM2QJ5A DN 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one DM2QJ5A TI TTN9D8E DM2QJ5A TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM2QJ5A MA Inhibitor DM2QJ5A RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DM2QJ5A RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DM2QJ5A DI DM2QJ5A DM2QJ5A DN 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one DM2QJ5A TI TTKJEMQ DM2QJ5A TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM2QJ5A MA Inhibitor DM2QJ5A RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DM2QJ5A RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DM2QJ5A DI DM2QJ5A DM2QJ5A DN 4-Bromo-5,7-dichloro-3-hydroxy-1H-quinolin-2-one DM2QJ5A TI TTLD29N DM2QJ5A TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM2QJ5A MA Inhibitor DM2QJ5A RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DM2QJ5A RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DM2QJKZ DI DM2QJKZ DM2QJKZ DN SB 258585 DM2QJKZ TI TTJS8PY DM2QJKZ TN 5-HT 6 receptor (HTR6) DM2QJKZ MA Antagonist DM2QJKZ RN 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse. 2002 Sep 1;45(3):191-9. DM2QJKZ RU https://pubmed.ncbi.nlm.nih.gov/12112397 DM2QN0S DI DM2QN0S DM2QN0S DN R-87027 DM2QN0S TI TT84ETX DM2QN0S TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM2QN0S MA Inhibitor DM2QN0S RN Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. J Med Chem. 1998 Dec 17;41(26):5272-86. DM2QN0S RU https://pubmed.ncbi.nlm.nih.gov/9857095 DM2QPHE DI DM2QPHE DM2QPHE DN 5-bromo-1H-indazole DM2QPHE TI TTZUFI5 DM2QPHE TN Nitric-oxide synthase brain (NOS1) DM2QPHE MA Inhibitor DM2QPHE RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DM2QPHE RU https://pubmed.ncbi.nlm.nih.gov/17395463 DM2QYXN DI DM2QYXN DM2QYXN DN RTI-219 DM2QYXN TI TTAWNKZ DM2QYXN TN Norepinephrine transporter (NET) DM2QYXN MA Inhibitor DM2QYXN RN Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95. DM2QYXN RU https://pubmed.ncbi.nlm.nih.gov/17602602 DM2QYXN DI DM2QYXN DM2QYXN DN RTI-219 DM2QYXN TI TT3ROYC DM2QYXN TN Serotonin transporter (SERT) DM2QYXN MA Inhibitor DM2QYXN RN Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95. DM2QYXN RU https://pubmed.ncbi.nlm.nih.gov/17602602 DM2QYXN DI DM2QYXN DM2QYXN DN RTI-219 DM2QYXN TI TTVBI8W DM2QYXN TN Dopamine transporter (DAT) DM2QYXN MA Inhibitor DM2QYXN RN Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95. DM2QYXN RU https://pubmed.ncbi.nlm.nih.gov/17602602 DM2R5F9 DI DM2R5F9 DM2R5F9 DN AFLATREME DM2R5F9 TI TTNJYV2 DM2R5F9 TN Gamma-aminobutyric acid receptor (GAR) DM2R5F9 MA Inhibitor DM2R5F9 RN Partial structures of the fungal toxin aflatrem, methyl-substituted 6,8-dioxabicyclo[3.2.1]octan-2-ones have anticonvulsant activity, Bioorg. Med. Chem. Lett. 5(3):265-270 (1995). DM2R5F9 RU http://www.sciencedirect.com/science/article/pii/0960894X9500021K DM2R94W DI DM2R94W DM2R94W DN PMID21536437C15c DM2R94W TI TTXSU2Y DM2R94W TN Aggrecanase (ADAMTS5) DM2R94W MA Inhibitor DM2R94W RN Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3301-6. DM2R94W RU https://pubmed.ncbi.nlm.nih.gov/21536437 DM2RA4N DI DM2RA4N DM2RA4N DN 8-(3-Bromobenzyloxy)caffeine DM2RA4N TI TT3WG5C DM2RA4N TN Monoamine oxidase type A (MAO-A) DM2RA4N MA Inhibitor DM2RA4N RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DM2RA4N RU https://pubmed.ncbi.nlm.nih.gov/20093036 DM2RA4N DI DM2RA4N DM2RA4N DN 8-(3-Bromobenzyloxy)caffeine DM2RA4N TI TTGP7BY DM2RA4N TN Monoamine oxidase type B (MAO-B) DM2RA4N MA Inhibitor DM2RA4N RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DM2RA4N RU https://pubmed.ncbi.nlm.nih.gov/20093036 DM2REIN DI DM2REIN DM2REIN DN (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid DM2REIN TI TTT2SVW DM2REIN TN PPAR-gamma messenger RNA (PPARG mRNA) DM2REIN MA Inhibitor DM2REIN RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DM2REIN RU https://pubmed.ncbi.nlm.nih.gov/19719236 DM2REIN DI DM2REIN DM2REIN DN (9Z,12E)-12-nitrooctadeca-9,12-dienoic acid DM2REIN TI TTJ584C DM2REIN TN Peroxisome proliferator-activated receptor alpha (PPARA) DM2REIN MA Inhibitor DM2REIN RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DM2REIN RU https://pubmed.ncbi.nlm.nih.gov/19719236 DM2RFOB DI DM2RFOB DM2RFOB DN 7-(3,5-dimethoxyphenyl)-1,6-naphthyridine DM2RFOB TI TTHS256 DM2RFOB TN Metabotropic glutamate receptor 5 (mGluR5) DM2RFOB MA Inhibitor DM2RFOB RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DM2RFOB RU https://pubmed.ncbi.nlm.nih.gov/17936624 DM2RIHT DI DM2RIHT DM2RIHT DN 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine DM2RIHT TI TTSZLWK DM2RIHT TN Aromatase (CYP19A1) DM2RIHT MA Inhibitor DM2RIHT RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM2RIHT RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM2RIHT DI DM2RIHT DM2RIHT DN 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine DM2RIHT TI TTRA5BZ DM2RIHT TN Steroid 17-alpha-monooxygenase (S17AH) DM2RIHT MA Inhibitor DM2RIHT RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM2RIHT RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM2RIHT DI DM2RIHT DM2RIHT DN 5-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyrimidine DM2RIHT TI TTIQUX7 DM2RIHT TN Steroid 11-beta-hydroxylase (CYP11B1) DM2RIHT MA Inhibitor DM2RIHT RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM2RIHT RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM2RJYO DI DM2RJYO DM2RJYO DN octyl thiophosphatidic acid DM2RJYO TI TTABCJ6 DM2RJYO TN Lysophosphatidic acid receptor 5 (LPAR5) DM2RJYO MA Agonist DM2RJYO RN Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19. DM2RJYO RU https://pubmed.ncbi.nlm.nih.gov/19366702 DM2RKD6 DI DM2RKD6 DM2RKD6 DN 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide DM2RKD6 TI TTBH0VX DM2RKD6 TN Histone deacetylase (HDAC) DM2RKD6 MA Inhibitor DM2RKD6 RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM2RKD6 RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM2RKD6 DI DM2RKD6 DM2RKD6 DN 2,2-bis(4-chlorophenyl)-N-hydroxyacetamide DM2RKD6 TI TTTQGH8 DM2RKD6 TN Histone deacetylase 4 (HDAC4) DM2RKD6 MA Inhibitor DM2RKD6 RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM2RKD6 RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM2RLXF DI DM2RLXF DM2RLXF DN S-Benzyl-brassinin DM2RLXF TI TTZJYKH DM2RLXF TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM2RLXF MA Inhibitor DM2RLXF RN Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006 Jan 26;49(2):684-92. DM2RLXF RU https://pubmed.ncbi.nlm.nih.gov/16420054 DM2RN0S DI DM2RN0S DM2RN0S DN tagitinin A DM2RN0S TI TTT2SVW DM2RN0S TN PPAR-gamma messenger RNA (PPARG mRNA) DM2RN0S MA Agonist DM2RN0S RN Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2954-8. DM2RN0S RU https://pubmed.ncbi.nlm.nih.gov/22424975 DM2S496 DI DM2S496 DM2S496 DN Redoxal DM2S496 TI TT3PQ2Y DM2S496 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM2S496 MA Inhibitor DM2S496 RN Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem. 2002 Nov 1;277(44):41827-34. DM2S496 RU https://pubmed.ncbi.nlm.nih.gov/12189151 DM2S496 DI DM2S496 DM2S496 DN Redoxal DM2S496 TI TT6EO5L DM2S496 TN Erbb2 tyrosine kinase receptor (HER2) DM2S496 RN A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res. 2002 Jun;8(6):1710-9. DM2S496 RU https://pubmed.ncbi.nlm.nih.gov/12060608 DM2S5EJ DI DM2S5EJ DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ TI TT8QL1J DM2S5EJ TN Protein kinase C theta (PRKCQ) DM2S5EJ MA Inhibitor DM2S5EJ RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DM2S5EJ RU https://pubmed.ncbi.nlm.nih.gov/10465561 DM2S5EJ DI DM2S5EJ DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ TI TTRFOXJ DM2S5EJ TN Protein kinase C gamma (PRKCG) DM2S5EJ MA Inhibitor DM2S5EJ RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DM2S5EJ RU https://pubmed.ncbi.nlm.nih.gov/10465561 DM2S5EJ DI DM2S5EJ DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ TI TTYPXQF DM2S5EJ TN Protein kinase C beta (PRKCB) DM2S5EJ MA Inhibitor DM2S5EJ RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DM2S5EJ RU https://pubmed.ncbi.nlm.nih.gov/10465561 DM2S5EJ DI DM2S5EJ DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ TI TTFJ8Q1 DM2S5EJ TN Protein kinase C alpha (PRKCA) DM2S5EJ MA Inhibitor DM2S5EJ RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DM2S5EJ RU https://pubmed.ncbi.nlm.nih.gov/10465561 DM2S5EJ DI DM2S5EJ DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ TI TTUWGRA DM2S5EJ TN Protein kinase C zeta (PRKCZ) DM2S5EJ MA Inhibitor DM2S5EJ RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DM2S5EJ RU https://pubmed.ncbi.nlm.nih.gov/10465561 DM2S5EJ DI DM2S5EJ DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ TI TT9WJ8U DM2S5EJ TN Protein kinase C delta (PRKCD) DM2S5EJ MA Inhibitor DM2S5EJ RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DM2S5EJ RU https://pubmed.ncbi.nlm.nih.gov/10465561 DM2S5EJ DI DM2S5EJ DM2S5EJ DN [2,2':5',2'']Terthiophene-4-carbaldehyde DM2S5EJ TI TTBZ7OD DM2S5EJ TN Protein kinase C epsilon (PRKCE) DM2S5EJ MA Inhibitor DM2S5EJ RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DM2S5EJ RU https://pubmed.ncbi.nlm.nih.gov/10465561 DM2S5ZF DI DM2S5ZF DM2S5ZF DN NS1738 DM2S5ZF TI TT5KPZR DM2S5ZF TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM2S5ZF MA Blocker (channel blocker) DM2S5ZF RN An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. DM2S5ZF RU https://pubmed.ncbi.nlm.nih.gov/17625074 DM2S5ZF DI DM2S5ZF DM2S5ZF DN NS1738 DM2S5ZF TI TTH18TF DM2S5ZF TN Muscarinic acetylcholine receptor M5 (CHRM5) DM2S5ZF MA Blocker (channel blocker) DM2S5ZF RN An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. DM2S5ZF RU https://pubmed.ncbi.nlm.nih.gov/17625074 DM2S5ZF DI DM2S5ZF DM2S5ZF DN NS1738 DM2S5ZF TI TTLA931 DM2S5ZF TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM2S5ZF MA Modulator (allosteric modulator) DM2S5ZF RN An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther. 2007 Oct;323(1):294-307. DM2S5ZF RU https://pubmed.ncbi.nlm.nih.gov/17625074 DM2SCM7 DI DM2SCM7 DM2SCM7 DN RS-39066 DM2SCM7 TI TTMX39J DM2SCM7 TN Matrix metalloproteinase-1 (MMP-1) DM2SCM7 MA Inhibitor DM2SCM7 RN Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996). DM2SCM7 RU http://www.sciencedirect.com/science/article/pii/S0960894X96002831 DM2SCM7 DI DM2SCM7 DM2SCM7 DN RS-39066 DM2SCM7 TI TTUZ2L5 DM2SCM7 TN Matrix metalloproteinase-3 (MMP-3) DM2SCM7 MA Inhibitor DM2SCM7 RN Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996). DM2SCM7 RU http://www.sciencedirect.com/science/article/pii/S0960894X96002831 DM2SCM7 DI DM2SCM7 DM2SCM7 DN RS-39066 DM2SCM7 TI TTMTWOS DM2SCM7 TN Matrix metalloproteinase-7 (MMP-7) DM2SCM7 MA Inhibitor DM2SCM7 RN Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2 P3 Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996). DM2SCM7 RU http://www.sciencedirect.com/science/article/pii/S0960894X96002831 DM2SEFR DI DM2SEFR DM2SEFR DN 5-Bromo-4,9-dihydro-3H-beta-carboline DM2SEFR TI TT3WG5C DM2SEFR TN Monoamine oxidase type A (MAO-A) DM2SEFR MA Inhibitor DM2SEFR RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM2SEFR RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM2SEFR DI DM2SEFR DM2SEFR DN 5-Bromo-4,9-dihydro-3H-beta-carboline DM2SEFR TI TTGP7BY DM2SEFR TN Monoamine oxidase type B (MAO-B) DM2SEFR MA Inhibitor DM2SEFR RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM2SEFR RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM2SEXH DI DM2SEXH DM2SEXH DN 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one DM2SEXH TI TTVBI8W DM2SEXH TN Dopamine transporter (DAT) DM2SEXH MA Inhibitor DM2SEXH RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM2SEXH RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM2SEXH DI DM2SEXH DM2SEXH DN 1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one DM2SEXH TI TTAWNKZ DM2SEXH TN Norepinephrine transporter (NET) DM2SEXH MA Inhibitor DM2SEXH RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM2SEXH RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM2SKP7 DI DM2SKP7 DM2SKP7 DN 5-Chloro-N-(4-ethylphenyl)benzo[d]oxazol-2-amine DM2SKP7 TI TT2J34L DM2SKP7 TN Arachidonate 5-lipoxygenase (5-LOX) DM2SKP7 MA Inhibitor DM2SKP7 RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DM2SKP7 RU https://pubmed.ncbi.nlm.nih.gov/20870413 DM2SNR0 DI DM2SNR0 DM2SNR0 DN 1-(3-Fluoro-phenyl)-piperazine DM2SNR0 TI TT6MSOK DM2SNR0 TN 5-HT 1D receptor (HTR1D) DM2SNR0 MA Inhibitor DM2SNR0 RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM2SNR0 RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM2SNR0 DI DM2SNR0 DM2SNR0 DN 1-(3-Fluoro-phenyl)-piperazine DM2SNR0 TI TTSQIFT DM2SNR0 TN 5-HT 1A receptor (HTR1A) DM2SNR0 MA Inhibitor DM2SNR0 RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM2SNR0 RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM2SNXB DI DM2SNXB DM2SNXB DN N-(R-Carboxy-Ethyl)-Alpha-(S)-(2-Phenylethyl) DM2SNXB TI TTXMNHO DM2SNXB TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM2SNXB MA Inhibitor DM2SNXB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2SNXB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2SZ3F DI DM2SZ3F DM2SZ3F DN SB-612111 DM2SZ3F TI TTNT7K8 DM2SZ3F TN Nociceptin receptor (OPRL1) DM2SZ3F MA Antagonist DM2SZ3F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). DM2SZ3F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 DM2T1CD DI DM2T1CD DM2T1CD DN 1-(1-Benzo[b]thiophen-2-yl-cycloheptyl)-azepane DM2T1CD TI TTVBI8W DM2T1CD TN Dopamine transporter (DAT) DM2T1CD MA Inhibitor DM2T1CD RN Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93. DM2T1CD RU https://pubmed.ncbi.nlm.nih.gov/8098066 DM2T4NL DI DM2T4NL DM2T4NL DN 1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol DM2T4NL TI TTOM3J0 DM2T4NL TN Estrogen receptor beta (ESR2) DM2T4NL MA Inhibitor DM2T4NL RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM2T4NL RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM2T4NL DI DM2T4NL DM2T4NL DN 1-Bromo-6-(4-hydroxy-phenyl)-naphthalen-2-ol DM2T4NL TI TTZAYWL DM2T4NL TN Estrogen receptor (ESR) DM2T4NL MA Inhibitor DM2T4NL RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM2T4NL RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM2T5OV DI DM2T5OV DM2T5OV DN DC-EBIO DM2T5OV TI TT7M9I6 DM2T5OV TN Calcium-activated potassium channel KCa3.1 (KCNN4) DM2T5OV MA Activator DM2T5OV RN Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2001 Feb;296(2):600-11. DM2T5OV RU https://pubmed.ncbi.nlm.nih.gov/11160649 DM2T5OV DI DM2T5OV DM2T5OV DN DC-EBIO DM2T5OV TI TT2T5M0 DM2T5OV TN Calcium-activated potassium channel KCa2.2 (KCNN2) DM2T5OV MA Activator DM2T5OV RN Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of ... J Biol Chem. 2005 Dec 16;280(50):41404-11. DM2T5OV RU https://pubmed.ncbi.nlm.nih.gov/16239218 DM2T5OV DI DM2T5OV DM2T5OV DN DC-EBIO DM2T5OV TI TT9JH25 DM2T5OV TN Calcium-activated potassium channel KCa2.3 (KCNN3) DM2T5OV MA Activator DM2T5OV RN Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57. DM2T5OV RU https://pubmed.ncbi.nlm.nih.gov/17584055 DM2TFJE DI DM2TFJE DM2TFJE DN N-(5-chlorobenzo[d]oxazol-2-yl)benzenesulfonamide DM2TFJE TI TTWHDVK DM2TFJE TN Fructose-1,6-bisphosphatase (FBP) DM2TFJE MA Inhibitor DM2TFJE RN Benzoxazole benzenesulfonamides as allosteric inhibitors of fructose-1,6-bisphosphatase. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1807-10. DM2TFJE RU https://pubmed.ncbi.nlm.nih.gov/16446092 DM2THVK DI DM2THVK DM2THVK DN 1-(4-Cyanobenzyl)-5-formyl-1H-imidazole DM2THVK TI TTIQUX7 DM2THVK TN Steroid 11-beta-hydroxylase (CYP11B1) DM2THVK MA Inhibitor DM2THVK RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM2THVK RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM2TIO1 DI DM2TIO1 DM2TIO1 DN ISIS 3300 DM2TIO1 TI TT4SCBE DM2TIO1 TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DM2TIO1 RN US patent application no. 5,767,102, Antisense composition and method for treatment of CMV infection. DM2TIO1 RU http://www.patentbuddy.com/Patent/5767102?ft=true&sr=true DM2TIU3 DI DM2TIU3 DM2TIU3 DN ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine DM2TIU3 TI TTAWNKZ DM2TIU3 TN Norepinephrine transporter (NET) DM2TIU3 MA Inhibitor DM2TIU3 RN Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8. DM2TIU3 RU https://pubmed.ncbi.nlm.nih.gov/18667309 DM2TIU3 DI DM2TIU3 DM2TIU3 DN ((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine DM2TIU3 TI TT3ROYC DM2TIU3 TN Serotonin transporter (SERT) DM2TIU3 MA Inhibitor DM2TIU3 RN Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8. DM2TIU3 RU https://pubmed.ncbi.nlm.nih.gov/18667309 DM2TNCK DI DM2TNCK DM2TNCK DN 7-(4-(dimethylamino)phenoxy)-N-hydroxyheptanamide DM2TNCK TI TT6R7JZ DM2TNCK TN Histone deacetylase 1 (HDAC1) DM2TNCK MA Inhibitor DM2TNCK RN Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41. DM2TNCK RU https://pubmed.ncbi.nlm.nih.gov/17046252 DM2TNWO DI DM2TNWO DM2TNWO DN 5-isopropyl-2-(phenylamino)thiazol-4(5H)-one DM2TNWO TI TTN7BL9 DM2TNWO TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM2TNWO MA Inhibitor DM2TNWO RN The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6056-61. DM2TNWO RU https://pubmed.ncbi.nlm.nih.gov/17919905 DM2TP4Q DI DM2TP4Q DM2TP4Q DN PG-01037 DM2TP4Q TI TTWJBZ5 DM2TP4Q TN 5-HT 2C receptor (HTR2C) DM2TP4Q MA Inhibitor DM2TP4Q RN Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46. DM2TP4Q RU https://pubmed.ncbi.nlm.nih.gov/17672446 DM2TP4Q DI DM2TP4Q DM2TP4Q DN PG-01037 DM2TP4Q TI TTEX248 DM2TP4Q TN Dopamine D2 receptor (D2R) DM2TP4Q MA Inhibitor DM2TP4Q RN Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46. DM2TP4Q RU https://pubmed.ncbi.nlm.nih.gov/17672446 DM2TP4Q DI DM2TP4Q DM2TP4Q DN PG-01037 DM2TP4Q TI TTE0A2F DM2TP4Q TN Dopamine D4 receptor (D4R) DM2TP4Q MA Inhibitor DM2TP4Q RN Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46. DM2TP4Q RU https://pubmed.ncbi.nlm.nih.gov/17672446 DM2TP4Q DI DM2TP4Q DM2TP4Q DN PG-01037 DM2TP4Q TI TTSQIFT DM2TP4Q TN 5-HT 1A receptor (HTR1A) DM2TP4Q MA Inhibitor DM2TP4Q RN Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46. DM2TP4Q RU https://pubmed.ncbi.nlm.nih.gov/17672446 DM2TP4Q DI DM2TP4Q DM2TP4Q DN PG-01037 DM2TP4Q TI TTJQOD7 DM2TP4Q TN 5-HT 2A receptor (HTR2A) DM2TP4Q MA Inhibitor DM2TP4Q RN Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46. DM2TP4Q RU https://pubmed.ncbi.nlm.nih.gov/17672446 DM2TP4Q DI DM2TP4Q DM2TP4Q DN PG-01037 DM2TP4Q TI TT4C8EA DM2TP4Q TN Dopamine D3 receptor (D3R) DM2TP4Q MA Inhibitor DM2TP4Q RN Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46. DM2TP4Q RU https://pubmed.ncbi.nlm.nih.gov/17672446 DM2TRIZ DI DM2TRIZ DM2TRIZ DN SP-08 DM2TRIZ TI TTE4KHA DM2TRIZ TN Amyloid beta A4 protein (APP) DM2TRIZ MA Inhibitor DM2TRIZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM2TRIZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM2TU6W DI DM2TU6W DM2TU6W DN 2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine DM2TU6W TI TTK8CXU DM2TU6W TN 5-HT 1B receptor (HTR1B) DM2TU6W MA Agonist DM2TU6W RN Identification of an amino acid residue important for binding of methiothepin and sumatriptan to the human 5-HT(1B) receptor. Eur J Pharmacol. 1999 Sep 10;380(2-3):171-81. DM2TU6W RU https://pubmed.ncbi.nlm.nih.gov/10513577 DM2TU6W DI DM2TU6W DM2TU6W DN 2-(5-Nonyloxy-1H-indol-3-yl)-ethylamine DM2TU6W TI TT6MSOK DM2TU6W TN 5-HT 1D receptor (HTR1D) DM2TU6W MA Inhibitor DM2TU6W RN 5-(Nonyloxy)tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor agonist. J Med Chem. 1994 Sep 2;37(18):2828-30. DM2TU6W RU https://pubmed.ncbi.nlm.nih.gov/8071931 DM2TWSZ DI DM2TWSZ DM2TWSZ DN AdoC(Dpr)2AlaArg6 DM2TWSZ TI TTER6YH DM2TWSZ TN Casein kinase II alpha (CSNK2A1) DM2TWSZ MA Inhibitor DM2TWSZ RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DM2TWSZ RU https://pubmed.ncbi.nlm.nih.gov/10360754 DM2TWSZ DI DM2TWSZ DM2TWSZ DN AdoC(Dpr)2AlaArg6 DM2TWSZ TI TTNAHEX DM2TWSZ TN cAMP-dependent protein kinase A type I (PRKAR1A) DM2TWSZ MA Inhibitor DM2TWSZ RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DM2TWSZ RU https://pubmed.ncbi.nlm.nih.gov/10360754 DM2TWSZ DI DM2TWSZ DM2TWSZ DN AdoC(Dpr)2AlaArg6 DM2TWSZ TI TTW4Y2M DM2TWSZ TN cAMP protein kinase type II-beta (PRKAR2B) DM2TWSZ MA Inhibitor DM2TWSZ RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DM2TWSZ RU https://pubmed.ncbi.nlm.nih.gov/10360754 DM2TY43 DI DM2TY43 DM2TY43 DN H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph DM2TY43 TI TT27RFC DM2TY43 TN Opioid receptor delta (OPRD1) DM2TY43 MA Inhibitor DM2TY43 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DM2TY43 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DM2TY43 DI DM2TY43 DM2TY43 DN H-Dmt-Tic-Lys(Ac)-NH-CH2-Ph DM2TY43 TI TTKWM86 DM2TY43 TN Opioid receptor mu (MOP) DM2TY43 MA Inhibitor DM2TY43 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DM2TY43 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DM2U1N5 DI DM2U1N5 DM2U1N5 DN 2-Cyclohex-1-enylethynyl-pyridine DM2U1N5 TI TTHS256 DM2U1N5 TN Metabotropic glutamate receptor 5 (mGluR5) DM2U1N5 MA Inhibitor DM2U1N5 RN Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4589-93. DM2U1N5 RU https://pubmed.ncbi.nlm.nih.gov/16115767 DM2U4NW DI DM2U4NW DM2U4NW DN PMID18155906C16f DM2U4NW TI TTPADOQ DM2U4NW TN HMG-CoA reductase (HMGCR) DM2U4NW MA Inhibitor DM2U4NW RN Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1151-6. DM2U4NW RU https://pubmed.ncbi.nlm.nih.gov/18155906 DM2U4VI DI DM2U4VI DM2U4VI DN Tyr-Pro-Phe-Phe-NHCH3 DM2U4VI TI TTKWM86 DM2U4VI TN Opioid receptor mu (MOP) DM2U4VI MA Inhibitor DM2U4VI RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DM2U4VI RU https://pubmed.ncbi.nlm.nih.gov/18490168 DM2U4VI DI DM2U4VI DM2U4VI DN Tyr-Pro-Phe-Phe-NHCH3 DM2U4VI TI TT27RFC DM2U4VI TN Opioid receptor delta (OPRD1) DM2U4VI MA Inhibitor DM2U4VI RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DM2U4VI RU https://pubmed.ncbi.nlm.nih.gov/18490168 DM2U9RY DI DM2U9RY DM2U9RY DN 3-amino-5-(4-chlorophenyl)thiophene-2-carboxamide DM2U9RY TI TTJ3E9X DM2U9RY TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM2U9RY MA Inhibitor DM2U9RY RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DM2U9RY RU https://pubmed.ncbi.nlm.nih.gov/16686533 DM2U9SR DI DM2U9SR DM2U9SR DN PSN375963 DM2U9SR TI TT7QNVC DM2U9SR TN Glucose-dependent insulinotropic receptor (GPR119) DM2U9SR MA Agonist DM2U9SR RN Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006 Mar;3(3):167-75. DM2U9SR RU https://pubmed.ncbi.nlm.nih.gov/16517404 DM2UBQ8 DI DM2UBQ8 DM2UBQ8 DN LIM-5310 DM2UBQ8 TI TTU81IF DM2UBQ8 TN Transporter unspecfic (TP) DM2UBQ8 MA Activator DM2UBQ8 RN Limerick BioPharma, Inc. Pharmaceuticals & Healthcare. Deals and Alliances Profile. Limerick BioPharma, Inc. Nov-2014. DM2UBQ8 RU http://store.globaldata.com/company-reports/pharmaceuticals-and-healthcare/limerick-biopharma-inc-pharmaceuticals--healthcare-deals-and-alliances-profile#.Vh39_qToumQ DM2UFXE DI DM2UFXE DM2UFXE DN 1-benzyl-1H-indole-2,3-dione DM2UFXE TI TTMF541 DM2UFXE TN Liver carboxylesterase (CES1) DM2UFXE MA Inhibitor DM2UFXE RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM2UFXE RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM2UJM8 DI DM2UJM8 DM2UJM8 DN CCP DM2UJM8 TI TTMN4HY DM2UJM8 TN N-acylethanolamine-hydrolyzing acidamidase (NAAA) DM2UJM8 MA Inhibitor DM2UJM8 RN N-cyclohexanecarbonylpentadecylamine: a selective inhibitor of the acid amidase hydrolysing N-acylethanolamines, as a tool to distinguish acid amidase from fatty acid amide hydrolase. Biochem J. 2004Apr 1;379(Pt 1):99-106. DM2UJM8 RU https://pubmed.ncbi.nlm.nih.gov/14686878 DM2UMK8 DI DM2UMK8 DM2UMK8 DN SUVN-507 DM2UMK8 TI TTJS8PY DM2UMK8 TN 5-HT 6 receptor (HTR6) DM2UMK8 MA Antagonist DM2UMK8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11). DM2UMK8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11 DM2UPQG DI DM2UPQG DM2UPQG DN 3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one DM2UPQG TI TTGP7BY DM2UPQG TN Monoamine oxidase type B (MAO-B) DM2UPQG MA Inhibitor DM2UPQG RN Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71. DM2UPQG RU https://pubmed.ncbi.nlm.nih.gov/17910428 DM2UPSV DI DM2UPSV DM2UPSV DN NSC-345763 DM2UPSV TI TTHVCUP DM2UPSV TN DNA [cytosine-5]-methyltransferase (DNMT) DM2UPSV MA Inhibitor DM2UPSV RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM2UPSV RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM2UPSV DI DM2UPSV DM2UPSV DN NSC-345763 DM2UPSV TI TT6VZ78 DM2UPSV TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM2UPSV MA Inhibitor DM2UPSV RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM2UPSV RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM2UQ0R DI DM2UQ0R DM2UQ0R DN 9-(2-Hydroxypropyl)-9H-adenine DM2UQ0R TI TTM2AOE DM2UQ0R TN Adenosine A2a receptor (ADORA2A) DM2UQ0R MA Inhibitor DM2UQ0R RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM2UQ0R RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM2URTK DI DM2URTK DM2URTK DN N-(3-(1H-indol-4-yloxy)propyl)cyclopentanamine DM2URTK TI TTSQIFT DM2URTK TN 5-HT 1A receptor (HTR1A) DM2URTK MA Inhibitor DM2URTK RN Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4. DM2URTK RU https://pubmed.ncbi.nlm.nih.gov/17804228 DM2URWO DI DM2URWO DM2URWO DN HLL1-Fab-A3B3 DM2URWO TI TTY6DTE DM2URWO TN Carcinoembryonic antigen CEA (CD66e) DM2URWO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2836). DM2URWO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2836 DM2UTEA DI DM2UTEA DM2UTEA DN 7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one DM2UTEA TI TTSZLWK DM2UTEA TN Aromatase (CYP19A1) DM2UTEA MA Inhibitor DM2UTEA RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DM2UTEA RU https://pubmed.ncbi.nlm.nih.gov/19072235 DM2UWDR DI DM2UWDR DM2UWDR DN 2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene DM2UWDR TI TTJ2PTI DM2UWDR TN Tubulin beta-2 chain (TUBB2) DM2UWDR MA Inhibitor DM2UWDR RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DM2UWDR RU https://pubmed.ncbi.nlm.nih.gov/17034147 DM2UWDR DI DM2UWDR DM2UWDR DN 2,3'-diamino-3,4,4',5-tetramethoxy-(Z)-stillbene DM2UWDR TI TTYFKSZ DM2UWDR TN Tubulin beta (TUBB) DM2UWDR MA Inhibitor DM2UWDR RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DM2UWDR RU https://pubmed.ncbi.nlm.nih.gov/17034147 DM2UYCS DI DM2UYCS DM2UYCS DN 4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide DM2UYCS TI TTANPDJ DM2UYCS TN Carbonic anhydrase II (CA-II) DM2UYCS MA Inhibitor DM2UYCS RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DM2UYCS RU https://pubmed.ncbi.nlm.nih.gov/15501040 DM2UYCS DI DM2UYCS DM2UYCS DN 4-Chloro-N-(5-sulfamoyl-indan-2-yl)-benzamide DM2UYCS TI TTHQPL7 DM2UYCS TN Carbonic anhydrase I (CA-I) DM2UYCS MA Inhibitor DM2UYCS RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DM2UYCS RU https://pubmed.ncbi.nlm.nih.gov/15501040 DM2V3S8 DI DM2V3S8 DM2V3S8 DN 4'-bromo-3-(imidazolylmethyl)flavone DM2V3S8 TI TTSZLWK DM2V3S8 TN Aromatase (CYP19A1) DM2V3S8 MA Inhibitor DM2V3S8 RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DM2V3S8 RU https://pubmed.ncbi.nlm.nih.gov/16854084 DM2V45Z DI DM2V45Z DM2V45Z DN 3-fluoro-5-(2-methylquinolin-7-yl)benzonitrile DM2V45Z TI TTHS256 DM2V45Z TN Metabotropic glutamate receptor 5 (mGluR5) DM2V45Z MA Inhibitor DM2V45Z RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DM2V45Z RU https://pubmed.ncbi.nlm.nih.gov/17590335 DM2V4MJ DI DM2V4MJ DM2V4MJ DN PMID24900699C68 DM2V4MJ TI TTSBVFO DM2V4MJ TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM2V4MJ MA Inhibitor DM2V4MJ RN Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3. DM2V4MJ RU https://pubmed.ncbi.nlm.nih.gov/24900699 DM2V4MJ DI DM2V4MJ DM2V4MJ DN PMID24900699C68 DM2V4MJ TI TTYGQ8A DM2V4MJ TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM2V4MJ MA Inhibitor DM2V4MJ RN Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Down's Syndrome or Alzheimer's Disease. ACS Med Chem Lett. 2013 Apr 26;4(6):502-3. DM2V4MJ RU https://pubmed.ncbi.nlm.nih.gov/24900699 DM2V7U1 DI DM2V7U1 DM2V7U1 DN FR-181157 DM2V7U1 TI TT79WV3 DM2V7U1 TN Prostaglandin E2 receptor EP4 (PTGER4) DM2V7U1 MA Inhibitor DM2V7U1 RN Discovery of diphenyloxazole and Ndelta-Z-ornithine derivatives as highly potent and selective human prostaglandin EP(4) receptor antagonists. J Med Chem. 2005 May 5;48(9):3103-6. DM2V7U1 RU https://pubmed.ncbi.nlm.nih.gov/15857112 DM2V7U1 DI DM2V7U1 DM2V7U1 DN FR-181157 DM2V7U1 TI TTPNGDE DM2V7U1 TN Prostaglandin E2 receptor EP3 (PTGER3) DM2V7U1 MA Inhibitor DM2V7U1 RN Metabolism investigation leading to novel drug design: orally active prostacyclin mimetics. Part 4. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3284-7. DM2V7U1 RU https://pubmed.ncbi.nlm.nih.gov/15935659 DM2V7U1 DI DM2V7U1 DM2V7U1 DN FR-181157 DM2V7U1 TI TTOFYT1 DM2V7U1 TN Prostacyclin receptor (PTGIR) DM2V7U1 MA Inhibitor DM2V7U1 RN Replacing the cyclohexene-linker of FR181157 leading to novel IP receptor agonists: orally active prostacyclin mimetics. Part 6. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4861-4. DM2V7U1 RU https://pubmed.ncbi.nlm.nih.gov/16837197 DM2V9XI DI DM2V9XI DM2V9XI DN 6-(4-Hydroxy-phenyl)-naphthalen-1-ol DM2V9XI TI TTZAYWL DM2V9XI TN Estrogen receptor (ESR) DM2V9XI MA Inhibitor DM2V9XI RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM2V9XI RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM2V9XI DI DM2V9XI DM2V9XI DN 6-(4-Hydroxy-phenyl)-naphthalen-1-ol DM2V9XI TI TTIWB6L DM2V9XI TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM2V9XI MA Inhibitor DM2V9XI RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DM2V9XI RU https://pubmed.ncbi.nlm.nih.gov/18324762 DM2V9XI DI DM2V9XI DM2V9XI DN 6-(4-Hydroxy-phenyl)-naphthalen-1-ol DM2V9XI TI TTOM3J0 DM2V9XI TN Estrogen receptor beta (ESR2) DM2V9XI MA Inhibitor DM2V9XI RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM2V9XI RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM2VAJE DI DM2VAJE DM2VAJE DN 8-(3-methylbutyl)naringenin DM2VAJE TI TTZAYWL DM2VAJE TN Estrogen receptor (ESR) DM2VAJE MA Inhibitor DM2VAJE RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DM2VAJE RU https://pubmed.ncbi.nlm.nih.gov/17149865 DM2VAJE DI DM2VAJE DM2VAJE DN 8-(3-methylbutyl)naringenin DM2VAJE TI TTOM3J0 DM2VAJE TN Estrogen receptor beta (ESR2) DM2VAJE MA Inhibitor DM2VAJE RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DM2VAJE RU https://pubmed.ncbi.nlm.nih.gov/17149865 DM2VC0E DI DM2VC0E DM2VC0E DN 8-prenylapigenin DM2VC0E TI TTJ0IQB DM2VC0E TN Phosphodiesterase 5A (PDE5A) DM2VC0E MA Inhibitor DM2VC0E RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DM2VC0E RU https://pubmed.ncbi.nlm.nih.gov/18778098 DM2VEHG DI DM2VEHG DM2VEHG DN AH13205 DM2VEHG TI TT1ZAVI DM2VEHG TN Prostaglandin E2 receptor EP2 (PTGER2) DM2VEHG MA Agonist DM2VEHG RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM2VEHG RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM2VIDK DI DM2VIDK DM2VIDK DN Triphenylacetic acid methyl ester DM2VIDK TI TTMNI76 DM2VIDK TN Calcium-activated potassium channel (KCN) DM2VIDK MA Inhibitor DM2VIDK RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DM2VIDK RU https://pubmed.ncbi.nlm.nih.gov/18232633 DM2VJF4 DI DM2VJF4 DM2VJF4 DN Isopropyl 4-nitrophenyl dodecylphosphonate DM2VJF4 TI TT6OEDT DM2VJF4 TN Cannabinoid receptor 1 (CB1) DM2VJF4 MA Inhibitor DM2VJF4 RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DM2VJF4 RU https://pubmed.ncbi.nlm.nih.gov/18752948 DM2VJF4 DI DM2VJF4 DM2VJF4 DN Isopropyl 4-nitrophenyl dodecylphosphonate DM2VJF4 TI TTDP1UC DM2VJF4 TN Fatty acid amide hydrolase (FAAH) DM2VJF4 MA Inhibitor DM2VJF4 RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DM2VJF4 RU https://pubmed.ncbi.nlm.nih.gov/18752948 DM2VNLK DI DM2VNLK DM2VNLK DN 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzoic acid DM2VNLK TI TTK3PY9 DM2VNLK TN DNA-dependent protein kinase catalytic (PRKDC) DM2VNLK MA Inhibitor DM2VNLK RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM2VNLK RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM2VNUW DI DM2VNUW DM2VNUW DN ISIS 111105 DM2VNUW TI TTOM97J DM2VNUW TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DM2VNUW RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DM2VNUW RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DM2VOAS DI DM2VOAS DM2VOAS DN (S)-2-((4-phenoxyphenoxy)methyl)piperidine DM2VOAS TI TTXZEAJ DM2VOAS TN Leukotriene A-4 hydrolase (LTA4H) DM2VOAS MA Inhibitor DM2VOAS RN Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4. DM2VOAS RU https://pubmed.ncbi.nlm.nih.gov/20371179 DM2VQN5 DI DM2VQN5 DM2VQN5 DN VALIOLAMINE DM2VQN5 TI TTLPC70 DM2VQN5 TN Lysosomal alpha-glucosidase (GAA) DM2VQN5 MA Inhibitor DM2VQN5 RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DM2VQN5 RU https://pubmed.ncbi.nlm.nih.gov/18595718 DM2VZMC DI DM2VZMC DM2VZMC DN 18F-SMIBR-K5 DM2VZMC TI TT69TQN DM2VZMC TN Integrin alpha-V/beta-3 (ITGAV/B3) DM2VZMC MA Modulator DM2VZMC RN Synthesis of [18F]RGD-K5 by catalyzed [3 + 2] cycloaddition for imaging integrin alphavbeta3 expression in vivo. Nucl Med Biol. 2013 Jul;40(5):710-6. DM2VZMC RU https://pubmed.ncbi.nlm.nih.gov/23706550 DM2W0AD DI DM2W0AD DM2W0AD DN 5-p-Tolyl-1H-[1,2,3]triazole DM2W0AD TI TTZL0OI DM2W0AD TN Methionine aminopeptidase 2 (METAP2) DM2W0AD MA Inhibitor DM2W0AD RN 4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J Med Chem. 2005 Sep 8;48(18):5644-7. DM2W0AD RU https://pubmed.ncbi.nlm.nih.gov/16134930 DM2W4IQ DI DM2W4IQ DM2W4IQ DN A-795614 DM2W4IQ TI TTMI6F5 DM2W4IQ TN Transient receptor potential cation channel V1 (TRPV1) DM2W4IQ MA Inhibitor DM2W4IQ RN Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists. Bioorg Med Chem. 2008 Sep 15;16(18):8516-25. DM2W4IQ RU https://pubmed.ncbi.nlm.nih.gov/18722778 DM2W5VA DI DM2W5VA DM2W5VA DN FR167344 DM2W5VA TI TTGY8IW DM2W5VA TN B2 bradykinin receptor (BDKRB2) DM2W5VA MA Antagonist DM2W5VA RN Novel subtype-selective nonpeptide bradykinin receptor antagonists FR167344 and FR173657. Mol Pharmacol. 1997 Feb;51(2):171-6. DM2W5VA RU https://pubmed.ncbi.nlm.nih.gov/9203620 DM2W71L DI DM2W71L DM2W71L DN 2-chloro-N-(3-(3-chlorobenzamido)phenyl)benzamide DM2W71L TI TTHS256 DM2W71L TN Metabotropic glutamate receptor 5 (mGluR5) DM2W71L MA Inhibitor DM2W71L RN Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6. DM2W71L RU https://pubmed.ncbi.nlm.nih.gov/19875287 DM2W9NO DI DM2W9NO DM2W9NO DN N6-(3-Iodobenzyl)-2'-O-methyladenosine DM2W9NO TI TTJFY5U DM2W9NO TN Adenosine A3 receptor (ADORA3) DM2W9NO MA Inhibitor DM2W9NO RN Design, synthesis, and biological evaluation of LNA nucleosides as adenosine A3 receptor ligands. Bioorg Med Chem. 2007 Aug 15;15(16):5440-7. DM2W9NO RU https://pubmed.ncbi.nlm.nih.gov/17560111 DM2WEB9 DI DM2WEB9 DM2WEB9 DN Decylamine-N,N-Dimethyl-N-Oxide DM2WEB9 TI TT3PQ2Y DM2WEB9 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM2WEB9 MA Inhibitor DM2WEB9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2WEB9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2WIGO DI DM2WIGO DM2WIGO DN SR9238 DM2WIGO TI TTECBXN DM2WIGO TN Oxysterols receptor LXR-alpha (NR1H3) DM2WIGO MA Antagonist DM2WIGO RN A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67. DM2WIGO RU https://pubmed.ncbi.nlm.nih.gov/23237488 DM2WIGO DI DM2WIGO DM2WIGO DN SR9238 DM2WIGO TI TTXA6PH DM2WIGO TN Oxysterols receptor LXR-beta (NR1H2) DM2WIGO MA Antagonist DM2WIGO RN A liver-selective LXR inverse agonist that suppresses hepatic steatosis. ACS Chem Biol. 2013 Mar 15;8(3):559-67. DM2WIGO RU https://pubmed.ncbi.nlm.nih.gov/23237488 DM2WQ1E DI DM2WQ1E DM2WQ1E DN 1-METHYLXANTHINE DM2WQ1E TI TTM2AOE DM2WQ1E TN Adenosine A2a receptor (ADORA2A) DM2WQ1E MA Inhibitor DM2WQ1E RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DM2WQ1E RU https://pubmed.ncbi.nlm.nih.gov/3172141 DM2WQ1E DI DM2WQ1E DM2WQ1E DN 1-METHYLXANTHINE DM2WQ1E TI TTNE7KG DM2WQ1E TN Adenosine A2b receptor (ADORA2B) DM2WQ1E MA Inhibitor DM2WQ1E RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DM2WQ1E RU https://pubmed.ncbi.nlm.nih.gov/3172141 DM2WQ1E DI DM2WQ1E DM2WQ1E DN 1-METHYLXANTHINE DM2WQ1E TI TTK25J1 DM2WQ1E TN Adenosine A1 receptor (ADORA1) DM2WQ1E MA Inhibitor DM2WQ1E RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DM2WQ1E RU https://pubmed.ncbi.nlm.nih.gov/3172141 DM2WRED DI DM2WRED DM2WRED DN (+/-)-threo-N-(2-Phenylethyl)methylphenidate DM2WRED TI TTVBI8W DM2WRED TN Dopamine transporter (DAT) DM2WRED MA Inhibitor DM2WRED RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM2WRED RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM2WS8B DI DM2WS8B DM2WS8B DN D-AP4 DM2WS8B TI TT0IFKL DM2WS8B TN Metabotropic glutamate receptor 8 (mGluR8) DM2WS8B MA Agonist DM2WS8B RN Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97. DM2WS8B RU https://pubmed.ncbi.nlm.nih.gov/9473604 DM2WSG5 DI DM2WSG5 DM2WSG5 DN 1,3-Dibenzyl-3,7-dihydro-purine-2,6-dione DM2WSG5 TI TTM2AOE DM2WSG5 TN Adenosine A2a receptor (ADORA2A) DM2WSG5 MA Inhibitor DM2WSG5 RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DM2WSG5 RU https://pubmed.ncbi.nlm.nih.gov/3806581 DM2WUKF DI DM2WUKF DM2WUKF DN L-750,667 DM2WUKF TI TTE0A2F DM2WUKF TN Dopamine D4 receptor (D4R) DM2WUKF MA Antagonist DM2WUKF RN Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52. DM2WUKF RU https://pubmed.ncbi.nlm.nih.gov/10617689 DM2WUZA DI DM2WUZA DM2WUZA DN Sodium maleate DM2WUZA TI TTUNARX DM2WUZA TN Carbonic anhydrase (CA) DM2WUZA MA Inhibitor DM2WUZA RN Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with ali... Bioorg Med Chem. 2009 Apr 1;17(7):2654-7. DM2WUZA RU https://pubmed.ncbi.nlm.nih.gov/19297172 DM2WUZP DI DM2WUZP DM2WUZP DN 6-Isoquinolin-4-yl-3,4-dihydroquinolin-2(1H)-one DM2WUZP TI TTIQUX7 DM2WUZP TN Steroid 11-beta-hydroxylase (CYP11B1) DM2WUZP MA Inhibitor DM2WUZP RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DM2WUZP RU https://pubmed.ncbi.nlm.nih.gov/19049427 DM2WZCX DI DM2WZCX DM2WZCX DN 6-Nitroindazole DM2WZCX TI TTCM4B3 DM2WZCX TN Nitric-oxide synthase endothelial (NOS3) DM2WZCX MA Inhibitor DM2WZCX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2WZCX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2WZCX DI DM2WZCX DM2WZCX DN 6-Nitroindazole DM2WZCX TI TTF10I9 DM2WZCX TN Nitric-oxide synthase inducible (NOS2) DM2WZCX MA Inhibitor DM2WZCX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2WZCX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2X1NY DI DM2X1NY DM2X1NY DN PMID1992149C13 DM2X1NY TI TTPADOQ DM2X1NY TN HMG-CoA reductase (HMGCR) DM2X1NY MA Inhibitor DM2X1NY RN Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J Med Chem. 1991 Jan;34(1):463-6. DM2X1NY RU https://pubmed.ncbi.nlm.nih.gov/1992149 DM2X1SG DI DM2X1SG DM2X1SG DN Anti-cMET mab DM2X1SG TI TTNDSF4 DM2X1SG TN Proto-oncogene c-Met (MET) DM2X1SG MA Inhibitor DM2X1SG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM2X1SG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM2X3EV DI DM2X3EV DM2X3EV DN IkappaB-alphaM DM2X3EV TI TTSXVID DM2X3EV TN Nuclear factor NF-kappa-B (NFKB) DM2X3EV MA Inhibitor DM2X3EV RN An IkappaB-alpha mutant inhibits cytokine gene expression and proliferation in human vascular smooth muscle cells. J Surg Res. 2002 Feb;102(2):198-206. DM2X3EV RU https://pubmed.ncbi.nlm.nih.gov/11796019 DM2X5RT DI DM2X5RT DM2X5RT DN ISIS 116631 DM2X5RT TI TTQWAU1 DM2X5RT TN GSK3A messenger RNA (GSK3A mRNA) DM2X5RT RN US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression. DM2X5RT RU http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true DM2XAUY DI DM2XAUY DM2XAUY DN VL-0494 DM2XAUY TI TTCG0AL DM2XAUY TN Cholecystokinin receptor type A (CCKAR) DM2XAUY MA Inhibitor DM2XAUY RN Synthesis and evaluation of novel benzimidazole derivative [Bz-Im] and its radio/biological studies. Bioorg Med Chem Lett. 2007 May 15;17(10):2749-55. DM2XAUY RU https://pubmed.ncbi.nlm.nih.gov/17368898 DM2XB68 DI DM2XB68 DM2XB68 DN 6-isobutyl-4-methylpyridin-2-amine DM2XB68 TI TTZUFI5 DM2XB68 TN Nitric-oxide synthase brain (NOS1) DM2XB68 MA Inhibitor DM2XB68 RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DM2XB68 RU https://pubmed.ncbi.nlm.nih.gov/19323559 DM2XB68 DI DM2XB68 DM2XB68 DN 6-isobutyl-4-methylpyridin-2-amine DM2XB68 TI TTF10I9 DM2XB68 TN Nitric-oxide synthase inducible (NOS2) DM2XB68 MA Inhibitor DM2XB68 RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DM2XB68 RU https://pubmed.ncbi.nlm.nih.gov/19323559 DM2XB68 DI DM2XB68 DM2XB68 DN 6-isobutyl-4-methylpyridin-2-amine DM2XB68 TI TTCM4B3 DM2XB68 TN Nitric-oxide synthase endothelial (NOS3) DM2XB68 MA Inhibitor DM2XB68 RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DM2XB68 RU https://pubmed.ncbi.nlm.nih.gov/19323559 DM2XFGJ DI DM2XFGJ DM2XFGJ DN 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE DM2XFGJ TI TT6PKBN DM2XFGJ TN Proto-oncogene c-Src (SRC) DM2XFGJ MA Inhibitor DM2XFGJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM2XFGJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM2XI09 DI DM2XI09 DM2XI09 DN Adipate DM2XI09 TI TTTQR47 DM2XI09 TN Solute carrier family 22 member 8 (SLC22A8) DM2XI09 MA Inhibitor DM2XI09 RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DM2XI09 RU https://pubmed.ncbi.nlm.nih.gov/17553798 DM2XLHY DI DM2XLHY DM2XLHY DN N-benzyl-5-(4-chlorophenyl)nicotinamide DM2XLHY TI TT90XZ8 DM2XLHY TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM2XLHY MA Inhibitor DM2XLHY RN Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5. DM2XLHY RU https://pubmed.ncbi.nlm.nih.gov/20855211 DM2XRZL DI DM2XRZL DM2XRZL DN Tyr-D-Ala-Gly-NMePhe DM2XRZL TI TTKWM86 DM2XRZL TN Opioid receptor mu (MOP) DM2XRZL MA Inhibitor DM2XRZL RN Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. J Med Chem. 2009 Dec 10;52(23):7372-5. DM2XRZL RU https://pubmed.ncbi.nlm.nih.gov/19621878 DM2XT7S DI DM2XT7S DM2XT7S DN D-Eritadenine DM2XT7S TI TTE2KUJ DM2XT7S TN Adenosylhomocysteinase (AHCY) DM2XT7S MA Inhibitor DM2XT7S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2XT7S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2Y0AI DI DM2Y0AI DM2Y0AI DN Diminazene DM2Y0AI TI TTM3B5R DM2Y0AI TN Diamine oxidase (AOC1) DM2Y0AI MA Inhibitor DM2Y0AI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM2Y0AI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM2Y3P4 DI DM2Y3P4 DM2Y3P4 DN Chlorogenic acid DM2Y3P4 TI TT1KPBZ DM2Y3P4 TN Glucose-6-phosphate translocase (SLC37A4) DM2Y3P4 MA Inhibitor DM2Y3P4 RN Chlorogenic acid and synthetic chlorogenic acid derivatives: novel inhibitors of hepatic glucose-6-phosphate translocase. J Med Chem. 1997 Jan 17;40(2):137-45. DM2Y3P4 RU https://pubmed.ncbi.nlm.nih.gov/9003513 DM2Y4A6 DI DM2Y4A6 DM2Y4A6 DN 3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone DM2Y4A6 TI TTKWM86 DM2Y4A6 TN Opioid receptor mu (MOP) DM2Y4A6 MA Inhibitor DM2Y4A6 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DM2Y4A6 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DM2Y4A6 DI DM2Y4A6 DM2Y4A6 DN 3,6-bis(Dmt-Tic-NH-ethyl)-2(1H)-pyrazinone DM2Y4A6 TI TT27RFC DM2Y4A6 TN Opioid receptor delta (OPRD1) DM2Y4A6 MA Inhibitor DM2Y4A6 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DM2Y4A6 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DM2Y5AP DI DM2Y5AP DM2Y5AP DN N-(3,3-Dimethyl-butyl)-4-hexyloxy-benzamide DM2Y5AP TI TT846HF DM2Y5AP TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DM2Y5AP MA Inhibitor DM2Y5AP RN Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7. DM2Y5AP RU https://pubmed.ncbi.nlm.nih.gov/11689063 DM2Y9O4 DI DM2Y9O4 DM2Y9O4 DN 6-(2-Chloro-benzenesulfonyl)-2H-pyridazin-3-one DM2Y9O4 TI TTFBNVI DM2Y9O4 TN Aldose reductase (AKR1B1) DM2Y9O4 MA Inhibitor DM2Y9O4 RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM2Y9O4 RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM2YAUX DI DM2YAUX DM2YAUX DN 4(Z)-(5'-Deoxyadenosin-5'-ylidene)butanoic acid DM2YAUX TI TTE2KUJ DM2YAUX TN Adenosylhomocysteinase (AHCY) DM2YAUX MA Inhibitor DM2YAUX RN Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogues with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl u... Bioorg Med Chem. 2008 May 15;16(10):5424-33. DM2YAUX RU https://pubmed.ncbi.nlm.nih.gov/18457953 DM2YKHI DI DM2YKHI DM2YKHI DN 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole DM2YKHI TI TTQW87Y DM2YKHI TN Opioid receptor kappa (OPRK1) DM2YKHI MA Inhibitor DM2YKHI RN 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. DM2YKHI RU https://pubmed.ncbi.nlm.nih.gov/16632355 DM2YKHI DI DM2YKHI DM2YKHI DN 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole DM2YKHI TI TTNT7K8 DM2YKHI TN Nociceptin receptor (OPRL1) DM2YKHI MA Inhibitor DM2YKHI RN 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. DM2YKHI RU https://pubmed.ncbi.nlm.nih.gov/16632355 DM2YKHI DI DM2YKHI DM2YKHI DN 3-(1-benzylpiperidin-4-yl)-5-chloro-1H-indole DM2YKHI TI TTKWM86 DM2YKHI TN Opioid receptor mu (MOP) DM2YKHI MA Inhibitor DM2YKHI RN 3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3524-8. DM2YKHI RU https://pubmed.ncbi.nlm.nih.gov/16632355 DM2YL0T DI DM2YL0T DM2YL0T DN 5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol DM2YL0T TI TTOM3J0 DM2YL0T TN Estrogen receptor beta (ESR2) DM2YL0T MA Inhibitor DM2YL0T RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM2YL0T RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM2YL0T DI DM2YL0T DM2YL0T DN 5-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol DM2YL0T TI TTZAYWL DM2YL0T TN Estrogen receptor (ESR) DM2YL0T MA Inhibitor DM2YL0T RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM2YL0T RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM2YLBD DI DM2YLBD DM2YLBD DN 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine DM2YLBD TI TTIQUX7 DM2YLBD TN Steroid 11-beta-hydroxylase (CYP11B1) DM2YLBD MA Inhibitor DM2YLBD RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DM2YLBD RU https://pubmed.ncbi.nlm.nih.gov/16570918 DM2YLBD DI DM2YLBD DM2YLBD DN 3-(3-methyl-3,4-dihydronaphthalen-2-yl)pyridine DM2YLBD TI TTSZLWK DM2YLBD TN Aromatase (CYP19A1) DM2YLBD MA Inhibitor DM2YLBD RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DM2YLBD RU https://pubmed.ncbi.nlm.nih.gov/16570918 DM2YN37 DI DM2YN37 DM2YN37 DN 4-bromophenylboronic acid DM2YN37 TI TTHQPL7 DM2YN37 TN Carbonic anhydrase I (CA-I) DM2YN37 MA Inhibitor DM2YN37 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DM2YN37 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DM2YN37 DI DM2YN37 DM2YN37 DN 4-bromophenylboronic acid DM2YN37 TI TTUNARX DM2YN37 TN Carbonic anhydrase (CA) DM2YN37 MA Inhibitor DM2YN37 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DM2YN37 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DM2YN37 DI DM2YN37 DM2YN37 DN 4-bromophenylboronic acid DM2YN37 TI TTANPDJ DM2YN37 TN Carbonic anhydrase II (CA-II) DM2YN37 MA Inhibitor DM2YN37 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DM2YN37 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DM2YOVC DI DM2YOVC DM2YOVC DN LU32-176B DM2YOVC TI TTQBMPI DM2YOVC TN Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) DM2YOVC MA Inhibitor DM2YOVC RN First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anti... J Pharmacol Exp Ther. 2005 Feb;312(2):866-74. DM2YOVC RU https://pubmed.ncbi.nlm.nih.gov/15550575 DM2YOVC DI DM2YOVC DM2YOVC DN LU32-176B DM2YOVC TI TTPRKM0 DM2YOVC TN GABA transporter GAT-1 (SLC6A1) DM2YOVC MA Inhibitor DM2YOVC RN First demonstration of a functional role for central nervous system betaine/{gamma}-aminobutyric acid transporter (mGAT2) based on synergistic anti... J Pharmacol Exp Ther. 2005 Feb;312(2):866-74. DM2YOVC RU https://pubmed.ncbi.nlm.nih.gov/15550575 DM2YTXL DI DM2YTXL DM2YTXL DN BBT-009 DM2YTXL TI TTAUX24 DM2YTXL TN Erythropoietin Receptor (EPOR) DM2YTXL MA Stimulator DM2YTXL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DM2YTXL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DM2YVA1 DI DM2YVA1 DM2YVA1 DN 3-(trifluoromethyl)benzaldehyde thiosemicarbazone DM2YVA1 TI TTEAID7 DM2YVA1 TN Trypanosoma Cruzipain (Trypano CYSP) DM2YVA1 MA Inhibitor DM2YVA1 RN Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707. DM2YVA1 RU https://pubmed.ncbi.nlm.nih.gov/12061873 DM2YWRL DI DM2YWRL DM2YWRL DN AC-(D)PHE-PRO-BOROLYS-OH DM2YWRL TI TT6L509 DM2YWRL TN Coagulation factor IIa (F2) DM2YWRL MA Inhibitor DM2YWRL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM2YWRL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM2YZC5 DI DM2YZC5 DM2YZC5 DN N-benzyl[D-Pro-10]Dyn A-(1-11) DM2YZC5 TI TTQW87Y DM2YZC5 TN Opioid receptor kappa (OPRK1) DM2YZC5 MA Inhibitor DM2YZC5 RN Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9. DM2YZC5 RU https://pubmed.ncbi.nlm.nih.gov/9276018 DM2ZE8U DI DM2ZE8U DM2ZE8U DN 7-hydroxy-3-phenyl-2H-chromen-2-one DM2ZE8U TI TT6804T DM2ZE8U TN MIF messenger RNA (MIF mRNA) DM2ZE8U MA Inhibitor DM2ZE8U RN Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24. DM2ZE8U RU https://pubmed.ncbi.nlm.nih.gov/19090668 DM2ZLD7 DI DM2ZLD7 DM2ZLD7 DN Bisphenol A DM2ZLD7 TI TTKPW01 DM2ZLD7 TN Androgen receptor messenger RNA (AR mRNA) DM2ZLD7 MA Antagonist DM2ZLD7 RN Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERalpha-selective antagonist. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4031-6. DM2ZLD7 RU https://pubmed.ncbi.nlm.nih.gov/23768907 DM2ZLD7 DI DM2ZLD7 DM2ZLD7 DN Bisphenol A DM2ZLD7 TI TTOM3J0 DM2ZLD7 TN Estrogen receptor beta (ESR2) DM2ZLD7 MA Agonist DM2ZLD7 RN Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ERalpha-selective antagonist. Bioorg Med Chem Lett. 2013 Jul 15;23(14):4031-6. DM2ZLD7 RU https://pubmed.ncbi.nlm.nih.gov/23768907 DM2ZQBS DI DM2ZQBS DM2ZQBS DN N-(biphenyl-3-yl)benzo[d]isoxazol-3-amine DM2ZQBS TI TT7WVHI DM2ZQBS TN Soluble epoxide hydrolase (EPHX2) DM2ZQBS MA Inhibitor DM2ZQBS RN A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. DM2ZQBS RU https://pubmed.ncbi.nlm.nih.gov/19700315 DM2ZUFO DI DM2ZUFO DM2ZUFO DN 5-(3-benzylpyrrolidin-3-yl)-1-methyl-1H-indole DM2ZUFO TI TTQ6VDM DM2ZUFO TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM2ZUFO MA Inhibitor DM2ZUFO RN Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6. DM2ZUFO RU https://pubmed.ncbi.nlm.nih.gov/18954985 DM2ZXBR DI DM2ZXBR DM2ZXBR DN JWH-365 DM2ZXBR TI TT6OEDT DM2ZXBR TN Cannabinoid receptor 1 (CB1) DM2ZXBR MA Inhibitor DM2ZXBR RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM2ZXBR RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM2ZXBR DI DM2ZXBR DM2ZXBR DN JWH-365 DM2ZXBR TI TTMSFAW DM2ZXBR TN Cannabinoid receptor 2 (CB2) DM2ZXBR MA Inhibitor DM2ZXBR RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM2ZXBR RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM2ZYR8 DI DM2ZYR8 DM2ZYR8 DN PMID16516466C12c DM2ZYR8 TI TTS2TEI DM2ZYR8 TN ADAM metallopeptidase with thrombospondin 1 (ADAMTS1) DM2ZYR8 MA Inhibitor DM2ZYR8 RN Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2699-704. DM2ZYR8 RU https://pubmed.ncbi.nlm.nih.gov/16516466 DM30421 DI DM30421 DM30421 DN 4-[1-(4-hydroxyphenyl)-2-phenylhex-1-enyl]phenol DM30421 TI TTZAYWL DM30421 TN Estrogen receptor (ESR) DM30421 MA Inhibitor DM30421 RN Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64. DM30421 RU https://pubmed.ncbi.nlm.nih.gov/12431063 DM30E56 DI DM30E56 DM30E56 DN Vapill DM30E56 TI TT7HC21 DM30E56 TN Membrane copper amine oxidase (AOC3) DM30E56 MA Inhibitor DM30E56 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767). DM30E56 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767 DM30FNL DI DM30FNL DM30FNL DN 1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea DM30FNL TI TT0PG8F DM30FNL TN Cyclin-dependent kinase 4 (CDK4) DM30FNL MA Inhibitor DM30FNL RN Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. DM30FNL RU https://pubmed.ncbi.nlm.nih.gov/11741479 DM30GV2 DI DM30GV2 DM30GV2 DN 3-(4-aminophenyl)thieno[3,2-c]pyridin-4-amine DM30GV2 TI TTUTJGQ DM30GV2 TN Vascular endothelial growth factor receptor 2 (KDR) DM30GV2 MA Inhibitor DM30GV2 RN Thienopyridine urea inhibitors of KDR kinase. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1246-9. DM30GV2 RU https://pubmed.ncbi.nlm.nih.gov/17188869 DM30KXV DI DM30KXV DM30KXV DN N6-((+/-)-endo-norborn-2-yl)adenosine DM30KXV TI TTJFY5U DM30KXV TN Adenosine A3 receptor (ADORA3) DM30KXV MA Inhibitor DM30KXV RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DM30KXV RU https://pubmed.ncbi.nlm.nih.gov/19317449 DM30KXV DI DM30KXV DM30KXV DN N6-((+/-)-endo-norborn-2-yl)adenosine DM30KXV TI TTK25J1 DM30KXV TN Adenosine A1 receptor (ADORA1) DM30KXV MA Inhibitor DM30KXV RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DM30KXV RU https://pubmed.ncbi.nlm.nih.gov/19317449 DM30KXV DI DM30KXV DM30KXV DN N6-((+/-)-endo-norborn-2-yl)adenosine DM30KXV TI TTNE7KG DM30KXV TN Adenosine A2b receptor (ADORA2B) DM30KXV MA Inhibitor DM30KXV RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DM30KXV RU https://pubmed.ncbi.nlm.nih.gov/19317449 DM30KXV DI DM30KXV DM30KXV DN N6-((+/-)-endo-norborn-2-yl)adenosine DM30KXV TI TTM2AOE DM30KXV TN Adenosine A2a receptor (ADORA2A) DM30KXV MA Inhibitor DM30KXV RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DM30KXV RU https://pubmed.ncbi.nlm.nih.gov/19317449 DM30LI6 DI DM30LI6 DM30LI6 DN N-allyl[D-Pro-10]Dyn A-(1-11) DM30LI6 TI TTQW87Y DM30LI6 TN Opioid receptor kappa (OPRK1) DM30LI6 MA Inhibitor DM30LI6 RN Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9. DM30LI6 RU https://pubmed.ncbi.nlm.nih.gov/9276018 DM30M9H DI DM30M9H DM30M9H DN 1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione DM30M9H TI TTEAID7 DM30M9H TN Trypanosoma Cruzipain (Trypano CYSP) DM30M9H MA Inhibitor DM30M9H RN Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30. DM30M9H RU https://pubmed.ncbi.nlm.nih.gov/14505663 DM30RNY DI DM30RNY DM30RNY DN 2,5-bis(4-methoxyphenyl)thiophene DM30RNY TI TTE4KHA DM30RNY TN Amyloid beta A4 protein (APP) DM30RNY MA Inhibitor DM30RNY RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DM30RNY RU https://pubmed.ncbi.nlm.nih.gov/16325402 DM30WDL DI DM30WDL DM30WDL DN SYM2081 DM30WDL TI TTO6LI7 DM30WDL TN Glutamate receptor ionotropic kainate 5 (GRIK5) DM30WDL MA Agonist DM30WDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454). DM30WDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454 DM30WDL DI DM30WDL DM30WDL DN SYM2081 DM30WDL TI TT2F078 DM30WDL TN Excitatory amino acid transporter 2 (SLC1A2) DM30WDL MA Inhibitor DM30WDL RN Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol. 1997 May;51(5):809-15. DM30WDL RU https://pubmed.ncbi.nlm.nih.gov/9145919 DM30WDL DI DM30WDL DM30WDL DN SYM2081 DM30WDL TI TT0MYE2 DM30WDL TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM30WDL MA Agonist DM30WDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM30WDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM30WDL DI DM30WDL DM30WDL DN SYM2081 DM30WDL TI TT0K5RG DM30WDL TN Glutamate receptor ionotropic kainate 2 (GRIK2) DM30WDL MA Agonist DM30WDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451). DM30WDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451 DM30WDL DI DM30WDL DM30WDL DN SYM2081 DM30WDL TI TTQV6BO DM30WDL TN Glutamate receptor ionotropic kainate 4 (GluK4) DM30WDL MA Agonist DM30WDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453). DM30WDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453 DM30WDL DI DM30WDL DM30WDL DN SYM2081 DM30WDL TI TTNP6O2 DM30WDL TN Glutamate receptor ionotropic kainate 3 (GluK3) DM30WDL MA Agonist DM30WDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452). DM30WDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=452 DM30WDL DI DM30WDL DM30WDL DN SYM2081 DM30WDL TI TT8WRDA DM30WDL TN Excitatory amino acid transporter 1 (SLC1A3) DM30WDL MA Modulator DM30WDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 868). DM30WDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=868 DM30YQF DI DM30YQF DM30YQF DN (Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid DM30YQF TI TTGER3L DM30YQF TN Thyroid hormone receptor beta (THRB) DM30YQF MA Inhibitor DM30YQF RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM30YQF RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM30YQF DI DM30YQF DM30YQF DN (Z)-4-(4-hexylphenylamino)-4-oxobut-2-enoic acid DM30YQF TI TTTSEPU DM30YQF TN Thyroid hormone receptor alpha (THRA) DM30YQF MA Inhibitor DM30YQF RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM30YQF RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM314ZE DI DM314ZE DM314ZE DN 3-(3-Phenyl-ureido)-benzenesulfonamide DM314ZE TI TTSYM0R DM314ZE TN Carbonic anhydrase XII (CA-XII) DM314ZE MA Inhibitor DM314ZE RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM314ZE RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM314ZE DI DM314ZE DM314ZE DN 3-(3-Phenyl-ureido)-benzenesulfonamide DM314ZE TI TTANPDJ DM314ZE TN Carbonic anhydrase II (CA-II) DM314ZE MA Inhibitor DM314ZE RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM314ZE RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM314ZE DI DM314ZE DM314ZE DN 3-(3-Phenyl-ureido)-benzenesulfonamide DM314ZE TI TT2LVK8 DM314ZE TN Carbonic anhydrase IX (CA-IX) DM314ZE MA Inhibitor DM314ZE RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM314ZE RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM314ZE DI DM314ZE DM314ZE DN 3-(3-Phenyl-ureido)-benzenesulfonamide DM314ZE TI TTHQPL7 DM314ZE TN Carbonic anhydrase I (CA-I) DM314ZE MA Inhibitor DM314ZE RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM314ZE RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM315VL DI DM315VL DM315VL DN GTx-027 DM315VL TI TTS64P2 DM315VL TN Androgen receptor (AR) DM315VL MA Modulator DM315VL RN Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling. PLoS One. 2014 Jul 29;9(7):e103202. DM315VL RU https://pubmed.ncbi.nlm.nih.gov/25072326 DM31AXO DI DM31AXO DM31AXO DN Isogemichalcone C DM31AXO TI TTSZLWK DM31AXO TN Aromatase (CYP19A1) DM31AXO MA Inhibitor DM31AXO RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DM31AXO RU https://pubmed.ncbi.nlm.nih.gov/11678652 DM31CVR DI DM31CVR DM31CVR DN 1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine DM31CVR TI TTSQIFT DM31CVR TN 5-HT 1A receptor (HTR1A) DM31CVR MA Inhibitor DM31CVR RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DM31CVR RU https://pubmed.ncbi.nlm.nih.gov/3701781 DM31CVR DI DM31CVR DM31CVR DN 1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine DM31CVR TI TTJQOD7 DM31CVR TN 5-HT 2A receptor (HTR2A) DM31CVR MA Inhibitor DM31CVR RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DM31CVR RU https://pubmed.ncbi.nlm.nih.gov/3701781 DM31CVR DI DM31CVR DM31CVR DN 1-(2,5-Dimethoxy-4-methyl-phenyl)-piperazine DM31CVR TI TT6MSOK DM31CVR TN 5-HT 1D receptor (HTR1D) DM31CVR MA Inhibitor DM31CVR RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DM31CVR RU https://pubmed.ncbi.nlm.nih.gov/3701781 DM31CZK DI DM31CZK DM31CZK DN NSC-94891 DM31CZK TI TTSZLWK DM31CZK TN Aromatase (CYP19A1) DM31CZK MA Inhibitor DM31CZK RN An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7. DM31CZK RU https://pubmed.ncbi.nlm.nih.gov/19500885 DM31E6J DI DM31E6J DM31E6J DN 2-Methoxy-N-(3-methyl-2-phenyl-butyl)-benzamide DM31E6J TI TTY3UE6 DM31E6J TN Voltage-gated potassium channel Kv1.3 (KCNA3) DM31E6J MA Inhibitor DM31E6J RN Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorg Med Chem Lett. 2003 Mar 24;13(6):1161-4. DM31E6J RU https://pubmed.ncbi.nlm.nih.gov/12643934 DM31JAZ DI DM31JAZ DM31JAZ DN 3-(3-(carbamoyl)benzamido)propanoic acid DM31JAZ TI TTSJ542 DM31JAZ TN Integrin alpha-2 (ITGA2) DM31JAZ MA Inhibitor DM31JAZ RN Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. DM31JAZ RU https://pubmed.ncbi.nlm.nih.gov/16919941 DM31JAZ DI DM31JAZ DM31JAZ DN 3-(3-(carbamoyl)benzamido)propanoic acid DM31JAZ TI TTJA1ZO DM31JAZ TN ITGB3 messenger RNA (ITGB3 mRNA) DM31JAZ MA Inhibitor DM31JAZ RN Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. DM31JAZ RU https://pubmed.ncbi.nlm.nih.gov/16919941 DM31MY0 DI DM31MY0 DM31MY0 DN 2-(4-Hydroxy-phenyl)-benzooxazol-6-ol DM31MY0 TI TTZAYWL DM31MY0 TN Estrogen receptor (ESR) DM31MY0 MA Inhibitor DM31MY0 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM31MY0 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM31MY0 DI DM31MY0 DM31MY0 DN 2-(4-Hydroxy-phenyl)-benzooxazol-6-ol DM31MY0 TI TTOM3J0 DM31MY0 TN Estrogen receptor beta (ESR2) DM31MY0 MA Inhibitor DM31MY0 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM31MY0 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM31NXF DI DM31NXF DM31NXF DN L-366,948 DM31NXF TI TTSCIUP DM31NXF TN Oxytocin receptor (OTR) DM31NXF MA Antagonist DM31NXF RN Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61. DM31NXF RU https://pubmed.ncbi.nlm.nih.gov/7475979 DM31OGF DI DM31OGF DM31OGF DN U0126 DM31OGF TI TTVOE6D DM31OGF TN Mitogen-activated protein kinase (MAPK) DM31OGF MA Inhibitor DM31OGF RN Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11569-74. DM31OGF RU https://pubmed.ncbi.nlm.nih.gov/11504919 DM31OGF DI DM31OGF DM31OGF DN U0126 DM31OGF TI TTK1N5G DM31OGF TN MAPK/ERK kinase kinase 2 (MAP3K2) DM31OGF MA Inhibitor DM31OGF RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DM31OGF RU https://pubmed.ncbi.nlm.nih.gov/11804650 DM31OGF DI DM31OGF DM31OGF DN U0126 DM31OGF TI TTQBCEJ DM31OGF TN MAPK/ERK kinase kinase 1 (MAP3K1) DM31OGF MA Inhibitor DM31OGF RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DM31OGF RU https://pubmed.ncbi.nlm.nih.gov/11804650 DM31OGF DI DM31OGF DM31OGF DN U0126 DM31OGF TI TTCZO0Q DM31OGF TN Mitogen-activated protein kinase kinase (MAPKK) DM31OGF MA Inhibitor DM31OGF RN Transcriptional regulation of basal cyclooxygenase-2 expression in murine lung tumor-derived cell lines by CCAAT/enhancer-binding protein and activating transcription factor/cAMP response element-binding protein. Mol Pharmacol. 2002 Aug;62(2):326-33. DM31OGF RU https://pubmed.ncbi.nlm.nih.gov/12130685 DM31OSD DI DM31OSD DM31OSD DN (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone DM31OSD TI TTMF8H9 DM31OSD TN Plasma kallikrein (KLKB1) DM31OSD MA Inhibitor DM31OSD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DM31OSD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DM31OSD DI DM31OSD DM31OSD DN (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone DM31OSD TI TT6L509 DM31OSD TN Coagulation factor IIa (F2) DM31OSD MA Inhibitor DM31OSD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DM31OSD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DM31OSD DI DM31OSD DM31OSD DN (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone DM31OSD TI TTPLTSQ DM31OSD TN Neutrophil elastase (NE) DM31OSD MA Inhibitor DM31OSD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DM31OSD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DM31OSD DI DM31OSD DM31OSD DN (4-bromo-1H-pyrazol-1-yl)(p-tolyl)methanone DM31OSD TI TTGY7WI DM31OSD TN Urokinase-type plasminogen activator (PLAU) DM31OSD MA Inhibitor DM31OSD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DM31OSD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DM31QEY DI DM31QEY DM31QEY DN PMID32321856-compound-11b DM31QEY TI TTNHMO8 DM31QEY TN COVID-19 papain-like proteinase (PL-PRO) DM31QEY MA Inhibitor DM31QEY RN Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science. 2020 Apr 22;eabb4489. DM31QEY RU https://pubmed.ncbi.nlm.nih.gov/32321856 DM31SNW DI DM31SNW DM31SNW DN (2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine DM31SNW TI TTWJBZ5 DM31SNW TN 5-HT 2C receptor (HTR2C) DM31SNW MA Inhibitor DM31SNW RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DM31SNW RU https://pubmed.ncbi.nlm.nih.gov/18035544 DM31SNW DI DM31SNW DM31SNW DN (2S)-1-(6-fluoro-1H-indazol-1-yl)propan-2-amine DM31SNW TI TTJQOD7 DM31SNW TN 5-HT 2A receptor (HTR2A) DM31SNW MA Inhibitor DM31SNW RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DM31SNW RU https://pubmed.ncbi.nlm.nih.gov/18035544 DM31V7K DI DM31V7K DM31V7K DN VU10007 DM31V7K TI TTQ3JTF DM31V7K TN Muscarinic acetylcholine receptor M4 (CHRM4) DM31V7K MA Inhibitor DM31V7K RN An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol. 2008 Jan;4(1):42-50. DM31V7K RU https://pubmed.ncbi.nlm.nih.gov/18059262 DM31VLA DI DM31VLA DM31VLA DN 6-Iodo-2-piperazin-1-yl-quinoline DM31VLA TI TT3ROYC DM31VLA TN Serotonin transporter (SERT) DM31VLA MA Inhibitor DM31VLA RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DM31VLA RU https://pubmed.ncbi.nlm.nih.gov/10915050 DM31WYF DI DM31WYF DM31WYF DN 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one DM31WYF TI TTEB0GD DM31WYF TN Cholinesterase (BCHE) DM31WYF MA Inhibitor DM31WYF RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DM31WYF RU https://pubmed.ncbi.nlm.nih.gov/17008100 DM31WYF DI DM31WYF DM31WYF DN 3-[8-(benzylmethylamino)octyloxy]xanthen-9-one DM31WYF TI TT1RS9F DM31WYF TN Acetylcholinesterase (AChE) DM31WYF MA Inhibitor DM31WYF RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DM31WYF RU https://pubmed.ncbi.nlm.nih.gov/17008100 DM31YGM DI DM31YGM DM31YGM DN Monoctanoin component C DM31YGM TI TTRFOXJ DM31YGM TN Protein kinase C gamma (PRKCG) DM31YGM MA Inhibitor DM31YGM RN Synthesis and characterization of the second cysteine-rich region of mouse skin PKCGh, Bioorg. Med. Chem. Lett. 6(4):353-356 (1996). DM31YGM RU http://www.sciencedirect.com/science/article/pii/0960894X96000261 DM3209T DI DM3209T DM3209T DN Z-Ala-Leu-Nal-Agly-Ile-Val-OMe DM3209T TI TTF2LRI DM3209T TN Cathepsin B (CTSB) DM3209T MA Inhibitor DM3209T RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM3209T RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM3209T DI DM3209T DM3209T DN Z-Ala-Leu-Nal-Agly-Ile-Val-OMe DM3209T TI TTDZN01 DM3209T TN Cathepsin K (CTSK) DM3209T MA Inhibitor DM3209T RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM3209T RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM320RW DI DM320RW DM320RW DN 2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide DM320RW TI TTK25J1 DM320RW TN Adenosine A1 receptor (ADORA1) DM320RW MA Inhibitor DM320RW RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DM320RW RU https://pubmed.ncbi.nlm.nih.gov/18411049 DM320RW DI DM320RW DM320RW DN 2-amino-N-benzyl-6-phenyl-9H-purine-9-carboxamide DM320RW TI TTM2AOE DM320RW TN Adenosine A2a receptor (ADORA2A) DM320RW MA Inhibitor DM320RW RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DM320RW RU https://pubmed.ncbi.nlm.nih.gov/18411049 DM325YR DI DM325YR DM325YR DN GSK-280 DM325YR TI TTQBR95 DM325YR TN Stress-activated protein kinase 2a (p38 alpha) DM325YR MA Inhibitor DM325YR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499). DM325YR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499 DM326GJ DI DM326GJ DM326GJ DN H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2 DM326GJ TI TTKWM86 DM326GJ TN Opioid receptor mu (MOP) DM326GJ MA Inhibitor DM326GJ RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DM326GJ RU https://pubmed.ncbi.nlm.nih.gov/16759107 DM326GJ DI DM326GJ DM326GJ DN H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2 DM326GJ TI TT27RFC DM326GJ TN Opioid receptor delta (OPRD1) DM326GJ MA Inhibitor DM326GJ RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DM326GJ RU https://pubmed.ncbi.nlm.nih.gov/16759107 DM326VN DI DM326VN DM326VN DN COLCHINOL DM326VN TI TTYFKSZ DM326VN TN Tubulin beta (TUBB) DM326VN MA Inhibitor DM326VN RN Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5154-9. DM326VN RU https://pubmed.ncbi.nlm.nih.gov/16198562 DM326VN DI DM326VN DM326VN DN COLCHINOL DM326VN TI TTML2WA DM326VN TN Tubulin (TUB) DM326VN MA Inhibitor DM326VN RN Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5154-9. DM326VN RU https://pubmed.ncbi.nlm.nih.gov/16198562 DM32FKD DI DM32FKD DM32FKD DN PF-228 DM32FKD TI TTQYF7G DM32FKD TN Cyclin-dependent kinase 7 (CDK7) DM32FKD MA Inhibitor DM32FKD RN Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. DM32FKD RU https://pubmed.ncbi.nlm.nih.gov/17395594 DM32FKD DI DM32FKD DM32FKD DN PF-228 DM32FKD TI TTJ3E9X DM32FKD TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM32FKD MA Inhibitor DM32FKD RN Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. DM32FKD RU https://pubmed.ncbi.nlm.nih.gov/17395594 DM32FKD DI DM32FKD DM32FKD DN PF-228 DM32FKD TI TT7HF4W DM32FKD TN Cyclin-dependent kinase 2 (CDK2) DM32FKD MA Inhibitor DM32FKD RN Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. DM32FKD RU https://pubmed.ncbi.nlm.nih.gov/17395594 DM32FKD DI DM32FKD DM32FKD DN PF-228 DM32FKD TI TTON5IT DM32FKD TN Focal adhesion kinase 1 (FAK) DM32FKD MA Inhibitor DM32FKD RN Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. DM32FKD RU https://pubmed.ncbi.nlm.nih.gov/17395594 DM32FKD DI DM32FKD DM32FKD DN PF-228 DM32FKD TI TTH6V3D DM32FKD TN Cyclin-dependent kinase 1 (CDK1) DM32FKD MA Inhibitor DM32FKD RN Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. DM32FKD RU https://pubmed.ncbi.nlm.nih.gov/17395594 DM32FKD DI DM32FKD DM32FKD DN PF-228 DM32FKD TI TTRSMW9 DM32FKD TN Glycogen synthase kinase-3 beta (GSK-3B) DM32FKD MA Inhibitor DM32FKD RN Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52. DM32FKD RU https://pubmed.ncbi.nlm.nih.gov/17395594 DM32IAB DI DM32IAB DM32IAB DN [3H]S0139 DM32IAB TI TTKRD0G DM32IAB TN Endothelin A receptor (EDNRA) DM32IAB MA Antagonist DM32IAB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 219). DM32IAB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=219 DM32MIE DI DM32MIE DM32MIE DN 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol DM32MIE TI TTJQOD7 DM32MIE TN 5-HT 2A receptor (HTR2A) DM32MIE MA Inhibitor DM32MIE RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM32MIE RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM32MIE DI DM32MIE DM32MIE DN 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol DM32MIE TI TT0K1SC DM32MIE TN 5-HT 2B receptor (HTR2B) DM32MIE MA Inhibitor DM32MIE RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM32MIE RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM32MIE DI DM32MIE DM32MIE DN 3-(2-Dimethylamino-ethyl)-1H-indol-6-ol DM32MIE TI TTWJBZ5 DM32MIE TN 5-HT 2C receptor (HTR2C) DM32MIE MA Inhibitor DM32MIE RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM32MIE RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM32O0L DI DM32O0L DM32O0L DN Edatrexate DM32O0L TI TT9SL3Q DM32O0L TN Polypeptide deformylase (PDF) DM32O0L MA Inhibitor DM32O0L RN Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99. DM32O0L RU https://pubmed.ncbi.nlm.nih.gov/12494465 DM32OQB DI DM32OQB DM32OQB DN 8-benzyl-9H-purine-2,6-diamine DM32OQB TI TT9SL3Q DM32OQB TN Polypeptide deformylase (PDF) DM32OQB MA Inhibitor DM32OQB RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DM32OQB RU https://pubmed.ncbi.nlm.nih.gov/20117005 DM32PJ5 DI DM32PJ5 DM32PJ5 DN (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile DM32PJ5 TI TTAWNKZ DM32PJ5 TN Norepinephrine transporter (NET) DM32PJ5 MA Inhibitor DM32PJ5 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM32PJ5 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM32PJ5 DI DM32PJ5 DM32PJ5 DN (S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile DM32PJ5 TI TT3ROYC DM32PJ5 TN Serotonin transporter (SERT) DM32PJ5 MA Inhibitor DM32PJ5 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM32PJ5 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM32WSM DI DM32WSM DM32WSM DN 1-Phenethyl-3-[1,3,4]thiadiazol-2-yl-thiourea DM32WSM TI TT84ETX DM32WSM TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM32WSM MA Inhibitor DM32WSM RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM32WSM RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM32XGR DI DM32XGR DM32XGR DN ISIS 134604 DM32XGR TI TTKW4ML DM32XGR TN Caspase 6 messenger RNA (CASP6 mRNA) DM32XGR RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DM32XGR RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DM32YID DI DM32YID DM32YID DN N-methyl estradiol-16-methyl carboxamide DM32YID TI TTIWB6L DM32YID TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM32YID MA Inhibitor DM32YID RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM32YID RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM32ZIC DI DM32ZIC DM32ZIC DN RS 100235 DM32ZIC TI TT07C3Y DM32ZIC TN 5-HT 4 receptor (HTR4) DM32ZIC MA Antagonist DM32ZIC RN New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket. Br J Pharmacol. 2004 Oct;143(3):361-70. DM32ZIC RU https://pubmed.ncbi.nlm.nih.gov/15351779 DM340FH DI DM340FH DM340FH DN Cinnamic acid DM340FH TI TTXMI0C DM340FH TN Phosphomevalonate kinase (PMVK) DM340FH MA Inhibitor DM340FH RN Inhibition of rat liver mevalonate pyrophosphate decarboxylase and mevalonate phosphate kinase by phenyl and phenolic compounds. Biochem J. 1979 Jul 1;181(1):143-51. DM340FH RU https://pubmed.ncbi.nlm.nih.gov/226078 DM340FH DI DM340FH DM340FH DN Cinnamic acid DM340FH TI TTWNV8U DM340FH TN Nicotinic acid receptor (HCAR2) DM340FH MA Agonist DM340FH RN Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res. 2009 May;50(5):908-14. DM340FH RU https://pubmed.ncbi.nlm.nih.gov/19136666 DM346KA DI DM346KA DM346KA DN Sch-900875 DM346KA TI TT1UCIJ DM346KA TN C-X-C chemokine receptor type 3 (CXCR3) DM346KA MA Antagonist DM346KA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 70). DM346KA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=70 DM3492O DI DM3492O DM3492O DN MELOSMINE DM3492O TI TTZFYLI DM3492O TN Dopamine D1 receptor (D1R) DM3492O MA Inhibitor DM3492O RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DM3492O RU https://pubmed.ncbi.nlm.nih.gov/17228858 DM34AYV DI DM34AYV DM34AYV DN LU-AA33810 DM34AYV TI TTY6EWA DM34AYV TN Neuropeptide Y receptor type 5 (NPY5R) DM34AYV MA Antagonist DM34AYV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 308). DM34AYV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=308 DM34IX5 DI DM34IX5 DM34IX5 DN 2,2-Dimethoxy-1,2-diphenyl-ethanone DM34IX5 TI TTMF541 DM34IX5 TN Liver carboxylesterase (CES1) DM34IX5 MA Inhibitor DM34IX5 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DM34IX5 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DM34L89 DI DM34L89 DM34L89 DN 4,5-Dimethoxy-10H-anthracen-9-one DM34L89 TI TT2J34L DM34L89 TN Arachidonate 5-lipoxygenase (5-LOX) DM34L89 MA Inhibitor DM34L89 RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DM34L89 RU https://pubmed.ncbi.nlm.nih.gov/9371243 DM34P90 DI DM34P90 DM34P90 DN AR-7947 DM34P90 TI TT7QNVC DM34P90 TN Glucose-dependent insulinotropic receptor (GPR119) DM34P90 MA Modulator DM34P90 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DM34P90 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DM34R10 DI DM34R10 DM34R10 DN N-(4,5-diphenylpyrimidin-2-yl)acetamide DM34R10 TI TTJFY5U DM34R10 TN Adenosine A3 receptor (ADORA3) DM34R10 MA Inhibitor DM34R10 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM34R10 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM34R10 DI DM34R10 DM34R10 DN N-(4,5-diphenylpyrimidin-2-yl)acetamide DM34R10 TI TTK25J1 DM34R10 TN Adenosine A1 receptor (ADORA1) DM34R10 MA Inhibitor DM34R10 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM34R10 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM34W56 DI DM34W56 DM34W56 DN AZD-7806 DM34W56 TI TTPI1M5 DM34W56 TN Ileal sodium/bile acid cotransporter (SLC10A2) DM34W56 MA Modulator DM34W56 RN Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84. DM34W56 RU https://pubmed.ncbi.nlm.nih.gov/23215781 DM351EA DI DM351EA DM351EA DN 1,2-bis(2,6-difluorophenyl)ethane-1,2-dione DM351EA TI TTMF541 DM351EA TN Liver carboxylesterase (CES1) DM351EA MA Inhibitor DM351EA RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM351EA RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM351NL DI DM351NL DM351NL DN Ac-ICV(1MeW)QDWGAHRCT-NH2 DM351NL TI TTJGY7A DM351NL TN Complement C3 (CO3) DM351NL MA Inhibitor DM351NL RN Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22. DM351NL RU https://pubmed.ncbi.nlm.nih.gov/16854067 DM35CKE DI DM35CKE DM35CKE DN DprwFwLL-NH2 DM35CKE TI TTWDC17 DM35CKE TN Growth hormone secretagogue receptor 1 (GHSR) DM35CKE MA Inhibitor DM35CKE RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DM35CKE RU https://pubmed.ncbi.nlm.nih.gov/17371869 DM35FH8 DI DM35FH8 DM35FH8 DN PMID23916253C17 DM35FH8 TI TTY2KP7 DM35FH8 TN Leucyl-cysteinyl aminopeptidase (LNPEP) DM35FH8 MA Inhibitor DM35FH8 RN Novel selective inhibitors of aminopeptidases that generate antigenic peptides. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4832-6. DM35FH8 RU https://pubmed.ncbi.nlm.nih.gov/23916253 DM35FH8 DI DM35FH8 DM35FH8 DN PMID23916253C17 DM35FH8 TI TT60XFL DM35FH8 TN Adipocyte-derived leucine aminopeptidase (ERAP1) DM35FH8 MA Inhibitor DM35FH8 RN Novel selective inhibitors of aminopeptidases that generate antigenic peptides. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4832-6. DM35FH8 RU https://pubmed.ncbi.nlm.nih.gov/23916253 DM35FH8 DI DM35FH8 DM35FH8 DN PMID23916253C17 DM35FH8 TI TTVGS1C DM35FH8 TN Endoplasmic reticulum aminopeptidase 2 (ERAP2) DM35FH8 MA Inhibitor DM35FH8 RN Novel selective inhibitors of aminopeptidases that generate antigenic peptides. Bioorg Med Chem Lett. 2013 Sep 1;23(17):4832-6. DM35FH8 RU https://pubmed.ncbi.nlm.nih.gov/23916253 DM35JQS DI DM35JQS DM35JQS DN 2-Thiazol-5-ylmethyl-1,2-dihydro-indazol-3-one DM35JQS TI TT2J34L DM35JQS TN Arachidonate 5-lipoxygenase (5-LOX) DM35JQS MA Inhibitor DM35JQS RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM35JQS RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM35NF6 DI DM35NF6 DM35NF6 DN SRI-224 DM35NF6 TI TTULVH8 DM35NF6 TN Tyrosinase (TYR) DM35NF6 MA Inhibitor DM35NF6 RN Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6157-60. DM35NF6 RU https://pubmed.ncbi.nlm.nih.gov/19800229 DM35PIJ DI DM35PIJ DM35PIJ DN Cyclobutyl DM35PIJ TI TTJS7O4 DM35PIJ TN Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2) DM35PIJ MA Inhibitor DM35PIJ RN Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agents. J Antimicrob Chemother. 2004 Jul;54(1):56-9. DM35PIJ RU https://pubmed.ncbi.nlm.nih.gov/15150165 DM35RFH DI DM35RFH DM35RFH DN AAL-993 DM35RFH TI TTRLW2X DM35RFH TN Fibroblast growth factor receptor 1 (FGFR1) DM35RFH MA Inhibitor DM35RFH RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM35RFH RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM35RFH DI DM35RFH DM35RFH DN AAL-993 DM35RFH TI TT2Q6G1 DM35RFH TN Vascular endothelial growth factor receptor 1 (FLT-1) DM35RFH MA Inhibitor DM35RFH RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM35RFH RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM35RFH DI DM35RFH DM35RFH DN AAL-993 DM35RFH TI TT1VAUK DM35RFH TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM35RFH MA Inhibitor DM35RFH RN Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9. DM35RFH RU https://pubmed.ncbi.nlm.nih.gov/16460936 DM35RFH DI DM35RFH DM35RFH DN AAL-993 DM35RFH TI TTUTJGQ DM35RFH TN Vascular endothelial growth factor receptor 2 (KDR) DM35RFH MA Inhibitor DM35RFH RN Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. DM35RFH RU https://pubmed.ncbi.nlm.nih.gov/12477352 DM35V46 DI DM35V46 DM35V46 DN NSC-677939 DM35V46 TI TTJLP0R DM35V46 TN Quinone reductase 2 (NQO2) DM35V46 MA Inhibitor DM35V46 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM35V46 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM35VEI DI DM35VEI DM35VEI DN 3-(Benzyloxy)Pyridin-2-Amine DM35VEI TI TTQBR95 DM35VEI TN Stress-activated protein kinase 2a (p38 alpha) DM35VEI MA Inhibitor DM35VEI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM35VEI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM35VEI DI DM35VEI DM35VEI DN 3-(Benzyloxy)Pyridin-2-Amine DM35VEI TI TTXZEAJ DM35VEI TN Leukotriene A-4 hydrolase (LTA4H) DM35VEI MA Inhibitor DM35VEI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM35VEI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM35WFL DI DM35WFL DM35WFL DN ISIS 330031 DM35WFL TI TTWRN6M DM35WFL TN CRP messenger RNA (CRP mRNA) DM35WFL RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DM35WFL RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DM35ZLK DI DM35ZLK DM35ZLK DN Cyclo-[-Arg-Gly-Asp-Amp24-] DM35ZLK TI TTT1R2L DM35ZLK TN Integrin alpha-V (ITGAV) DM35ZLK MA Inhibitor DM35ZLK RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DM35ZLK RU https://pubmed.ncbi.nlm.nih.gov/18303826 DM35ZLK DI DM35ZLK DM35ZLK DN Cyclo-[-Arg-Gly-Asp-Amp24-] DM35ZLK TI TTJA1ZO DM35ZLK TN ITGB3 messenger RNA (ITGB3 mRNA) DM35ZLK MA Inhibitor DM35ZLK RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DM35ZLK RU https://pubmed.ncbi.nlm.nih.gov/18303826 DM360VU DI DM360VU DM360VU DN L-652731 DM360VU TI TTQL5VC DM360VU TN Platelet-activating factor receptor (PTAFR) DM360VU MA Inhibitor DM360VU RN Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,... J Med Chem. 1992 Sep 18;35(19):3474-82. DM360VU RU https://pubmed.ncbi.nlm.nih.gov/1404229 DM367MF DI DM367MF DM367MF DN AC-7954 DM367MF TI TTW5UDX DM367MF TN Urotensin II receptor (UTS2R) DM367MF MA Agonist DM367MF RN Isochromanone-based urotensin-II receptor agonists. Bioorg Med Chem. 2005 Apr 15;13(8):3057-68. DM367MF RU https://pubmed.ncbi.nlm.nih.gov/15781415 DM36D0F DI DM36D0F DM36D0F DN d-CCPene DM36D0F TI TTKJEMQ DM36D0F TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM36D0F MA Antagonist DM36D0F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DM36D0F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DM36D0F DI DM36D0F DM36D0F DN d-CCPene DM36D0F TI TTN9D8E DM36D0F TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM36D0F MA Antagonist DM36D0F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DM36D0F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DM36D0F DI DM36D0F DM36D0F DN d-CCPene DM36D0F TI TT5POTG DM36D0F TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DM36D0F MA Antagonist DM36D0F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DM36D0F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DM36D0F DI DM36D0F DM36D0F DN d-CCPene DM36D0F TI TT1M8OW DM36D0F TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DM36D0F MA Antagonist DM36D0F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DM36D0F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DM36HBK DI DM36HBK DM36HBK DN C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 DM36HBK TI TTD0CIQ DM36HBK TN Melanocortin receptor 4 (MC4R) DM36HBK MA Inhibitor DM36HBK RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM36HBK RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM36HBK DI DM36HBK DM36HBK DN C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 DM36HBK TI TTNI91K DM36HBK TN Melanocortin receptor 3 (MC3R) DM36HBK MA Inhibitor DM36HBK RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM36HBK RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM36HBK DI DM36HBK DM36HBK DN C[Nle-His-D-Nal(2')-Arg-Trp-Glu]-NH2 DM36HBK TI TTEOSZT DM36HBK TN Melanocortin receptor (MCR) DM36HBK MA Inhibitor DM36HBK RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM36HBK RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM36JUD DI DM36JUD DM36JUD DN 4-hexyl resorcinol DM36JUD TI TTULVH8 DM36JUD TN Tyrosinase (TYR) DM36JUD MA Inhibitor DM36JUD RN PEG-immobilization of cardol and soluble polymer-supported synthesis of some cardol-coumarin derivatives: preliminary evaluation of their inhibitor... Bioorg Med Chem Lett. 2009 Jan 1;19(1):36-9. DM36JUD RU https://pubmed.ncbi.nlm.nih.gov/19054671 DM36KW9 DI DM36KW9 DM36KW9 DN Thiophosphoric acid decyl ester DM36KW9 TI TTQ6S1K DM36KW9 TN Lysophosphatidic acid receptor 1 (LPAR1) DM36KW9 MA Inhibitor DM36KW9 RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DM36KW9 RU https://pubmed.ncbi.nlm.nih.gov/16033271 DM36PHM DI DM36PHM DM36PHM DN 4-hydroxylonchocarpin DM36PHM TI TTUMGNO DM36PHM TN Ornithine decarboxylase (ODC1) DM36PHM MA Inhibitor DM36PHM RN New bioactive flavonoids and stilbenes in cub resin insecticide. J Nat Prod. 1999 Feb;62(2):205-10. DM36PHM RU https://pubmed.ncbi.nlm.nih.gov/10075742 DM36SRT DI DM36SRT DM36SRT DN ISIS 347577 DM36SRT TI TTNBTCW DM36SRT TN eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) DM36SRT RN US patent application no. 7,468,431, Modulation of eIF4E-BP2 expression. DM36SRT RU http://www.patentbuddy.com/Patent/7468431?ft=true&sr=true DM36VA0 DI DM36VA0 DM36VA0 DN 3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid DM36VA0 TI TTTSEPU DM36VA0 TN Thyroid hormone receptor alpha (THRA) DM36VA0 MA Inhibitor DM36VA0 RN Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg Med Chem Lett. 2007 Apr 1;17(7):2018-21. DM36VA0 RU https://pubmed.ncbi.nlm.nih.gov/17254783 DM36VA0 DI DM36VA0 DM36VA0 DN 3-(4-(benzyloxy)-3,5-dibromophenyl)propanoic acid DM36VA0 TI TTGER3L DM36VA0 TN Thyroid hormone receptor beta (THRB) DM36VA0 MA Inhibitor DM36VA0 RN Thyroid receptor ligands. Part 7: Indirect antagonists of the thyroid hormone receptor with improved affinity. Bioorg Med Chem Lett. 2007 Apr 1;17(7):2018-21. DM36VA0 RU https://pubmed.ncbi.nlm.nih.gov/17254783 DM36VKH DI DM36VKH DM36VKH DN Bis(5-acetoxybenzo[b]furan-2-yl)methanone DM36VKH TI TTI7421 DM36VKH TN Platelet-derived growth factor receptor beta (PDGFRB) DM36VKH MA Inhibitor DM36VKH RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DM36VKH RU https://pubmed.ncbi.nlm.nih.gov/17210255 DM36VKH DI DM36VKH DM36VKH DN Bis(5-acetoxybenzo[b]furan-2-yl)methanone DM36VKH TI TTGJCWZ DM36VKH TN Fms-like tyrosine kinase 3 (FLT-3) DM36VKH MA Inhibitor DM36VKH RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DM36VKH RU https://pubmed.ncbi.nlm.nih.gov/17210255 DM36W9M DI DM36W9M DM36W9M DN JWH-305 DM36W9M TI TTMSFAW DM36W9M TN Cannabinoid receptor 2 (CB2) DM36W9M MA Inhibitor DM36W9M RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DM36W9M RU https://pubmed.ncbi.nlm.nih.gov/16005223 DM371WE DI DM371WE DM371WE DN 5-Formyl-6-Hydrofolic Acid DM371WE TI TT9SL3Q DM371WE TN Polypeptide deformylase (PDF) DM371WE MA Inhibitor DM371WE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM371WE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM372EG DI DM372EG DM372EG DN 1-(4-Cyanobenzyl)-5-(4-pyridyl)-1H-imidazole DM372EG TI TTIQUX7 DM372EG TN Steroid 11-beta-hydroxylase (CYP11B1) DM372EG MA Inhibitor DM372EG RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM372EG RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM376J2 DI DM376J2 DM376J2 DN D-tartaric acid DM376J2 TI TTHZQP0 DM376J2 TN Triggering receptor expressed on monocytes 1 (TREM1) DM376J2 MA Inhibitor DM376J2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM376J2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM37C25 DI DM37C25 DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 TI TT6X50U DM37C25 TN Matrix metalloproteinase-9 (MMP-9) DM37C25 MA Inhibitor DM37C25 RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM37C25 RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM37C25 DI DM37C25 DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 TI TTLM12X DM37C25 TN Matrix metalloproteinase-2 (MMP-2) DM37C25 MA Inhibitor DM37C25 RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM37C25 RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM37C25 DI DM37C25 DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 TI TTGA1IV DM37C25 TN Matrix metalloproteinase-8 (MMP-8) DM37C25 MA Inhibitor DM37C25 RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM37C25 RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM37C25 DI DM37C25 DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 TI TTHY57M DM37C25 TN Matrix metalloproteinase-13 (MMP-13) DM37C25 MA Inhibitor DM37C25 RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM37C25 RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM37C25 DI DM37C25 DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 TI TTXZ0KQ DM37C25 TN Matrix metalloproteinase-12 (MMP-12) DM37C25 MA Inhibitor DM37C25 RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM37C25 RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM37C25 DI DM37C25 DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 TI TTJ4QE7 DM37C25 TN Matrix metalloproteinase-14 (MMP-14) DM37C25 MA Inhibitor DM37C25 RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM37C25 RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM37C25 DI DM37C25 DM37C25 DN [2-(Biphenyl-4-sulfonyl)phenyl]acetic Acid DM37C25 TI TTYRF5E DM37C25 TN Matrix metalloproteinase-21 (MMP-21) DM37C25 MA Inhibitor DM37C25 RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM37C25 RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM37GWL DI DM37GWL DM37GWL DN Benzamidine DM37GWL TI TT2WR1T DM37GWL TN Cationic trypsinogen (PRSS1) DM37GWL MA Inhibitor DM37GWL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM37GWL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM37GWL DI DM37GWL DM37GWL DN Benzamidine DM37GWL TI TTLPF4X DM37GWL TN Kallikrein-6 (KLK6) DM37GWL MA Inhibitor DM37GWL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM37GWL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM37GWL DI DM37GWL DM37GWL DN Benzamidine DM37GWL TI TTGY7WI DM37GWL TN Urokinase-type plasminogen activator (PLAU) DM37GWL MA Inhibitor DM37GWL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM37GWL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM37GWL DI DM37GWL DM37GWL DN Benzamidine DM37GWL TI TTPRO7W DM37GWL TN Suppressor of tumorigenicity 14 protein (ST14) DM37GWL MA Inhibitor DM37GWL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM37GWL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM37GYA DI DM37GYA DM37GYA DN BzATP DM37GYA TI TTJW7B3 DM37GYA TN P2X purinoceptor 1 (P2RX1) DM37GYA MA Agonist DM37GYA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478). DM37GYA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478 DM37GYA DI DM37GYA DM37GYA DN BzATP DM37GYA TI TTYXPCO DM37GYA TN P2Y purinoceptor 11 (P2RY11) DM37GYA MA Agonist DM37GYA RN Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206. DM37GYA RU https://pubmed.ncbi.nlm.nih.gov/10578132 DM37GYA DI DM37GYA DM37GYA DN BzATP DM37GYA TI TT2THBD DM37GYA TN P2X purinoceptor 3 (P2RX3) DM37GYA MA Agonist DM37GYA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480). DM37GYA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=480 DM37I92 DI DM37I92 DM37I92 DN RPR-108514A DM37I92 TI TTI7421 DM37I92 TN Platelet-derived growth factor receptor beta (PDGFRB) DM37I92 MA Inhibitor DM37I92 RN The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):421-424 (1997). DM37I92 RU http://www.sciencedirect.com/science/article/pii/S0960894X97000358 DM37I92 DI DM37I92 DM37I92 DN RPR-108514A DM37I92 TI TT8FYO9 DM37I92 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM37I92 MA Inhibitor DM37I92 RN The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):421-424 (1997). DM37I92 RU http://www.sciencedirect.com/science/article/pii/S0960894X97000358 DM37KG6 DI DM37KG6 DM37KG6 DN 5-(2-(3-chlorophenyl)ethynyl)pyrimidine DM37KG6 TI TTHS256 DM37KG6 TN Metabotropic glutamate receptor 5 (mGluR5) DM37KG6 MA Inhibitor DM37KG6 RN Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. DM37KG6 RU https://pubmed.ncbi.nlm.nih.gov/18550372 DM37ORC DI DM37ORC DM37ORC DN GNF-PF-826 DM37ORC TI TT9JZCK DM37ORC TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM37ORC MA Inhibitor DM37ORC RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM37ORC RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM37ORC DI DM37ORC DM37ORC DN GNF-PF-826 DM37ORC TI TT124R0 DM37ORC TN Nuclear receptor coactivator 3 (NCOA3) DM37ORC MA Inhibitor DM37ORC RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM37ORC RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM37QE8 DI DM37QE8 DM37QE8 DN 3-methoxy-4-(p-tolyloxy)benzonitrile DM37QE8 TI TTKPW01 DM37QE8 TN Androgen receptor messenger RNA (AR mRNA) DM37QE8 MA Inhibitor DM37QE8 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM37QE8 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM37R5F DI DM37R5F DM37R5F DN ISIS 29219 DM37R5F TI TTYMGWX DM37R5F TN PDK-1 messenger RNA (PDK-1 mRNA) DM37R5F RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DM37R5F RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DM37RI9 DI DM37RI9 DM37RI9 DN 1-(3-Phenyl-propyl)-3-thiazol-2-yl-thiourea DM37RI9 TI TT84ETX DM37RI9 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM37RI9 MA Inhibitor DM37RI9 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM37RI9 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM37S5C DI DM37S5C DM37S5C DN 2-p-tolyl-4,5-dihydro-1H-imidazole DM37S5C TI TTGP7BY DM37S5C TN Monoamine oxidase type B (MAO-B) DM37S5C MA Inhibitor DM37S5C RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DM37S5C RU https://pubmed.ncbi.nlm.nih.gov/19064321 DM37T5L DI DM37T5L DM37T5L DN 5-bromo-N-(quinolin-8-yl)thiophene-2-sulfonamide DM37T5L TI TTSXVID DM37T5L TN Nuclear factor NF-kappa-B (NFKB) DM37T5L MA Inhibitor DM37T5L RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DM37T5L RU https://pubmed.ncbi.nlm.nih.gov/18024113 DM37VYR DI DM37VYR DM37VYR DN ISIS 107772 DM37VYR TI TTELIN2 DM37VYR TN PTPN1 messenger RNA (PTPN1 mRNA) DM37VYR RN US patent application no. 6,261,840, Antisense modulation of PTP1B expression. DM37VYR RU http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true DM37X04 DI DM37X04 DM37X04 DN 3-((4-aminophenyl)diazenyl)benzenesulfonamide DM37X04 TI TT2LVK8 DM37X04 TN Carbonic anhydrase IX (CA-IX) DM37X04 MA Inhibitor DM37X04 RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DM37X04 RU https://pubmed.ncbi.nlm.nih.gov/19773173 DM37X04 DI DM37X04 DM37X04 DN 3-((4-aminophenyl)diazenyl)benzenesulfonamide DM37X04 TI TTSYM0R DM37X04 TN Carbonic anhydrase XII (CA-XII) DM37X04 MA Inhibitor DM37X04 RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DM37X04 RU https://pubmed.ncbi.nlm.nih.gov/19773173 DM37X04 DI DM37X04 DM37X04 DN 3-((4-aminophenyl)diazenyl)benzenesulfonamide DM37X04 TI TTANPDJ DM37X04 TN Carbonic anhydrase II (CA-II) DM37X04 MA Inhibitor DM37X04 RN Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32. DM37X04 RU https://pubmed.ncbi.nlm.nih.gov/19651511 DM37YJH DI DM37YJH DM37YJH DN SRA880 DM37YJH TI TTIND6G DM37YJH TN Somatostatin receptor type 1 (SSTR1) DM37YJH MA Antagonist DM37YJH RN SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. Neurosci Lett. 2004 May 6;361(1-3):132-5. DM37YJH RU https://pubmed.ncbi.nlm.nih.gov/15135911 DM384PH DI DM384PH DM384PH DN PMID1895299C6v DM384PH TI TTPADOQ DM384PH TN HMG-CoA reductase (HMGCR) DM384PH MA Inhibitor DM384PH RN Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety. J Med Chem. 1991 Sep;34(9):2804-15. DM384PH RU https://pubmed.ncbi.nlm.nih.gov/1895299 DM386JM DI DM386JM DM386JM DN Rec 15/2615 DM386JM TI TTBRKXS DM386JM TN Adrenergic receptor alpha-1B (ADRA1B) DM386JM MA Antagonist DM386JM RN Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. J Pharmacol Exp Ther. 1997 Jun;281(3):1284-93. DM386JM RU https://pubmed.ncbi.nlm.nih.gov/9190864 DM38F9T DI DM38F9T DM38F9T DN YM-348 DM38F9T TI TTJQOD7 DM38F9T TN 5-HT 2A receptor (HTR2A) DM38F9T MA Inhibitor DM38F9T RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DM38F9T RU https://pubmed.ncbi.nlm.nih.gov/18083579 DM38F9T DI DM38F9T DM38F9T DN YM-348 DM38F9T TI TT0K1SC DM38F9T TN 5-HT 2B receptor (HTR2B) DM38F9T MA Inhibitor DM38F9T RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DM38F9T RU https://pubmed.ncbi.nlm.nih.gov/18083579 DM38F9T DI DM38F9T DM38F9T DN YM-348 DM38F9T TI TTWJBZ5 DM38F9T TN 5-HT 2C receptor (HTR2C) DM38F9T MA Inhibitor DM38F9T RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DM38F9T RU https://pubmed.ncbi.nlm.nih.gov/18083579 DM38HKE DI DM38HKE DM38HKE DN 7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol DM38HKE TI TTOM3J0 DM38HKE TN Estrogen receptor beta (ESR2) DM38HKE MA Inhibitor DM38HKE RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DM38HKE RU https://pubmed.ncbi.nlm.nih.gov/15341953 DM38HKE DI DM38HKE DM38HKE DN 7-Chloro-2-(4-hydroxy-phenyl)-benzofuran-5-ol DM38HKE TI TTZAYWL DM38HKE TN Estrogen receptor (ESR) DM38HKE MA Inhibitor DM38HKE RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DM38HKE RU https://pubmed.ncbi.nlm.nih.gov/15341953 DM38JMK DI DM38JMK DM38JMK DN PSAB-OFP DM38JMK TI TTLA931 DM38JMK TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM38JMK MA Agonist DM38JMK RN PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur J Pharmacol. 2002 Oct 4;452(2):137-44. DM38JMK RU https://pubmed.ncbi.nlm.nih.gov/12354563 DM38L1B DI DM38L1B DM38L1B DN JB-1 DM38L1B TI TTHRID2 DM38L1B TN Insulin-like growth factor I receptor (IGF1R) DM38L1B MA Inhibitor DM38L1B RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM38L1B RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM38L6U DI DM38L6U DM38L6U DN [Lys8(Alexa 546) ]PVA DM38L6U TI TT4TFGN DM38L6U TN Vasopressin V1a receptor (V1AR) DM38L6U MA Inhibitor DM38L6U RN Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85. DM38L6U RU https://pubmed.ncbi.nlm.nih.gov/17850055 DM38L6U DI DM38L6U DM38L6U DN [Lys8(Alexa 546) ]PVA DM38L6U TI TTSCIUP DM38L6U TN Oxytocin receptor (OTR) DM38L6U MA Inhibitor DM38L6U RN Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85. DM38L6U RU https://pubmed.ncbi.nlm.nih.gov/17850055 DM38MU1 DI DM38MU1 DM38MU1 DN CD3254 DM38MU1 TI TT6PEUO DM38MU1 TN Retinoic acid receptor RXR-alpha (RXRA) DM38MU1 MA Agonist DM38MU1 RN Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92. DM38MU1 RU https://pubmed.ncbi.nlm.nih.gov/11805839 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTGA1IV DM38N2K TN Matrix metalloproteinase-8 (MMP-8) DM38N2K MA Inhibitor DM38N2K RN Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J Med Chem. 1999 Nov 4;42(22):4547-62. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/10579818 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TT2LVK8 DM38N2K TN Carbonic anhydrase IX (CA-IX) DM38N2K MA Inhibitor DM38N2K RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/17276072 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TT6X50U DM38N2K TN Matrix metalloproteinase-9 (MMP-9) DM38N2K MA Inhibitor DM38N2K RN Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/10397503 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTMTWOS DM38N2K TN Matrix metalloproteinase-7 (MMP-7) DM38N2K MA Inhibitor DM38N2K RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/17127067 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTMX39J DM38N2K TN Matrix metalloproteinase-1 (MMP-1) DM38N2K MA Inhibitor DM38N2K RN The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/16338135 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTYG6BU DM38N2K TN Aggrecanase-1 (ADAMTS4) DM38N2K MA Inhibitor DM38N2K RN Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):311-6. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/16275085 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTLM12X DM38N2K TN Matrix metalloproteinase-2 (MMP-2) DM38N2K MA Inhibitor DM38N2K RN Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors. Bioorg Med Chem Lett. 1999 Jun 21;9(12):1691-6. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/10397503 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTJ4QE7 DM38N2K TN Matrix metalloproteinase-14 (MMP-14) DM38N2K MA Inhibitor DM38N2K RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/17127067 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTANPDJ DM38N2K TN Carbonic anhydrase II (CA-II) DM38N2K MA Inhibitor DM38N2K RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/17276072 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTHY57M DM38N2K TN Matrix metalloproteinase-13 (MMP-13) DM38N2K MA Inhibitor DM38N2K RN Heterocycle-based MMP inhibitors with P2' substituents. Bioorg Med Chem Lett. 2001 Apr 23;11(8):1009-13. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/11327577 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTIQSC1 DM38N2K TN Bacterial Lethal factor (Bact lef) DM38N2K MA Inhibitor DM38N2K RN The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/16338135 DM38N2K DI DM38N2K DM38N2K DN MMI270 DM38N2K TI TTUZ2L5 DM38N2K TN Matrix metalloproteinase-3 (MMP-3) DM38N2K MA Inhibitor DM38N2K RN Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72. DM38N2K RU https://pubmed.ncbi.nlm.nih.gov/12209155 DM38Q7W DI DM38Q7W DM38Q7W DN 1,2-bis(4-fluorophenyl)ethane-1,2-dione DM38Q7W TI TTMF541 DM38Q7W TN Liver carboxylesterase (CES1) DM38Q7W MA Inhibitor DM38Q7W RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM38Q7W RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM38TLN DI DM38TLN DM38TLN DN XANTHOSTIGMINE DM38TLN TI TTEB0GD DM38TLN TN Cholinesterase (BCHE) DM38TLN MA Inhibitor DM38TLN RN Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkox... J Med Chem. 1998 Oct 8;41(21):3976-86. DM38TLN RU https://pubmed.ncbi.nlm.nih.gov/9767635 DM38TLN DI DM38TLN DM38TLN DN XANTHOSTIGMINE DM38TLN TI TT1RS9F DM38TLN TN Acetylcholinesterase (AChE) DM38TLN MA Inhibitor DM38TLN RN Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkox... J Med Chem. 1998 Oct 8;41(21):3976-86. DM38TLN RU https://pubmed.ncbi.nlm.nih.gov/9767635 DM38XWZ DI DM38XWZ DM38XWZ DN NAEPA DM38XWZ TI TTQ6S1K DM38XWZ TN Lysophosphatidic acid receptor 1 (LPAR1) DM38XWZ MA Agonist DM38XWZ RN LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31. DM38XWZ RU https://pubmed.ncbi.nlm.nih.gov/18781939 DM38XWZ DI DM38XWZ DM38XWZ DN NAEPA DM38XWZ TI TTE2YJR DM38XWZ TN Lysophosphatidate-3 receptor (LPAR3) DM38XWZ MA Agonist DM38XWZ RN LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31. DM38XWZ RU https://pubmed.ncbi.nlm.nih.gov/18781939 DM38XWZ DI DM38XWZ DM38XWZ DN NAEPA DM38XWZ TI TTB7Y8I DM38XWZ TN Lysophosphatidic acid receptor 2 (LPAR2) DM38XWZ MA Agonist DM38XWZ RN LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31. DM38XWZ RU https://pubmed.ncbi.nlm.nih.gov/18781939 DM38YZ4 DI DM38YZ4 DM38YZ4 DN 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol DM38YZ4 TI TTZAYWL DM38YZ4 TN Estrogen receptor (ESR) DM38YZ4 MA Inhibitor DM38YZ4 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM38YZ4 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM38YZ4 DI DM38YZ4 DM38YZ4 DN 4-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol DM38YZ4 TI TTOM3J0 DM38YZ4 TN Estrogen receptor beta (ESR2) DM38YZ4 MA Inhibitor DM38YZ4 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM38YZ4 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM392QT DI DM392QT DM392QT DN Trans-2-fluoro-2-p-tolylcyclopropanamine DM392QT TI TTGP7BY DM392QT TN Monoamine oxidase type B (MAO-B) DM392QT MA Inhibitor DM392QT RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DM392QT RU https://pubmed.ncbi.nlm.nih.gov/18640844 DM392QT DI DM392QT DM392QT DN Trans-2-fluoro-2-p-tolylcyclopropanamine DM392QT TI TT3WG5C DM392QT TN Monoamine oxidase type A (MAO-A) DM392QT MA Inhibitor DM392QT RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DM392QT RU https://pubmed.ncbi.nlm.nih.gov/18640844 DM396OK DI DM396OK DM396OK DN (-)-7-N-methyldibromophakellin DM396OK TI TT12ABZ DM396OK TN Arachidonate 12-lipoxygenase (12-LOX) DM396OK MA Inhibitor DM396OK RN An analysis of phakellin and oroidin structures stimulated by further study of an Agelas sponge. J Nat Prod. 2004 Aug;67(8):1256-61. DM396OK RU https://pubmed.ncbi.nlm.nih.gov/15332838 DM39AFU DI DM39AFU DM39AFU DN (1R,2S)-N-Arachidonoylcyclopropanolamide DM39AFU TI TTMSFAW DM39AFU TN Cannabinoid receptor 2 (CB2) DM39AFU MA Inhibitor DM39AFU RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DM39AFU RU https://pubmed.ncbi.nlm.nih.gov/19361197 DM39AFU DI DM39AFU DM39AFU DN (1R,2S)-N-Arachidonoylcyclopropanolamide DM39AFU TI TT6OEDT DM39AFU TN Cannabinoid receptor 1 (CB1) DM39AFU MA Inhibitor DM39AFU RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DM39AFU RU https://pubmed.ncbi.nlm.nih.gov/19361197 DM39FSQ DI DM39FSQ DM39FSQ DN Racemic DOI DM39FSQ TI TT0K1SC DM39FSQ TN 5-HT 2B receptor (HTR2B) DM39FSQ MA Inhibitor DM39FSQ RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DM39FSQ RU https://pubmed.ncbi.nlm.nih.gov/18983139 DM39FSQ DI DM39FSQ DM39FSQ DN Racemic DOI DM39FSQ TI TTJQOD7 DM39FSQ TN 5-HT 2A receptor (HTR2A) DM39FSQ MA Inhibitor DM39FSQ RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DM39FSQ RU https://pubmed.ncbi.nlm.nih.gov/18296055 DM39LS5 DI DM39LS5 DM39LS5 DN PBC-264 DM39LS5 TI TTVFO0U DM39LS5 TN Gastrin/cholecystokinin type B receptor (CCKBR) DM39LS5 MA Agonist DM39LS5 RN His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity. Eur J Pharmacol. 1996 Jan 18;296(1):97-106. DM39LS5 RU https://pubmed.ncbi.nlm.nih.gov/8720482 DM39UMT DI DM39UMT DM39UMT DN Cyclo[DAsp7,Lys10]N/OFQ(1-13)NH2 DM39UMT TI TTNT7K8 DM39UMT TN Nociceptin receptor (OPRL1) DM39UMT MA Inhibitor DM39UMT RN High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7. DM39UMT RU https://pubmed.ncbi.nlm.nih.gov/18624395 DM39VT6 DI DM39VT6 DM39VT6 DN 6-bromo-2'-de-N-methylaplysinopsin DM39VT6 TI TTWJBZ5 DM39VT6 TN 5-HT 2C receptor (HTR2C) DM39VT6 MA Inhibitor DM39VT6 RN New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80. DM39VT6 RU https://pubmed.ncbi.nlm.nih.gov/11975483 DM39W5K DI DM39W5K DM39W5K DN (6-methylthio-2-naphthyl)isopropylamine DM39W5K TI TT3WG5C DM39W5K TN Monoamine oxidase type A (MAO-A) DM39W5K MA Inhibitor DM39W5K RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DM39W5K RU https://pubmed.ncbi.nlm.nih.gov/19243954 DM39XMT DI DM39XMT DM39XMT DN 3-(4-Amino-phenyl)-3-propyl-piperidine-2,6-dione DM39XMT TI TTSZLWK DM39XMT TN Aromatase (CYP19A1) DM39XMT MA Inhibitor DM39XMT RN Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9. DM39XMT RU https://pubmed.ncbi.nlm.nih.gov/3735304 DM39YW1 DI DM39YW1 DM39YW1 DN MCL-182 DM39YW1 TI TTQW87Y DM39YW1 TN Opioid receptor kappa (OPRK1) DM39YW1 MA Inhibitor DM39YW1 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DM39YW1 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DM39YW1 DI DM39YW1 DM39YW1 DN MCL-182 DM39YW1 TI TT27RFC DM39YW1 TN Opioid receptor delta (OPRD1) DM39YW1 MA Inhibitor DM39YW1 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DM39YW1 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DM39YW1 DI DM39YW1 DM39YW1 DN MCL-182 DM39YW1 TI TTKWM86 DM39YW1 TN Opioid receptor mu (MOP) DM39YW1 MA Inhibitor DM39YW1 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DM39YW1 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DM3A0TE DI DM3A0TE DM3A0TE DN GRI977143 DM3A0TE TI TTB7Y8I DM3A0TE TN Lysophosphatidic acid receptor 2 (LPAR2) DM3A0TE MA Agonist DM3A0TE RN Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73. DM3A0TE RU https://pubmed.ncbi.nlm.nih.gov/22968304 DM3ACVD DI DM3ACVD DM3ACVD DN 4-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine DM3ACVD TI TTIQUX7 DM3ACVD TN Steroid 11-beta-hydroxylase (CYP11B1) DM3ACVD MA Inhibitor DM3ACVD RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DM3ACVD RU https://pubmed.ncbi.nlm.nih.gov/16570918 DM3AD7E DI DM3AD7E DM3AD7E DN 1-(1-Biphenyl-4-yl-pentyl)-1H-imidazole DM3AD7E TI TTRA5BZ DM3AD7E TN Steroid 17-alpha-monooxygenase (S17AH) DM3AD7E MA Inhibitor DM3AD7E RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DM3AD7E RU https://pubmed.ncbi.nlm.nih.gov/18674917 DM3AFXM DI DM3AFXM DM3AFXM DN 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one DM3AFXM TI TTK25J1 DM3AFXM TN Adenosine A1 receptor (ADORA1) DM3AFXM MA Inhibitor DM3AFXM RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DM3AFXM RU https://pubmed.ncbi.nlm.nih.gov/17665891 DM3AGJH DI DM3AGJH DM3AGJH DN N-(3-chlorophenyl)-6-fluoroquinazolin-4-amine DM3AGJH TI TTHS256 DM3AGJH TN Metabotropic glutamate receptor 5 (mGluR5) DM3AGJH MA Inhibitor DM3AGJH RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DM3AGJH RU https://pubmed.ncbi.nlm.nih.gov/19854049 DM3AGUQ DI DM3AGUQ DM3AGUQ DN EMD-386088 DM3AGUQ TI TTJS8PY DM3AGUQ TN 5-HT 6 receptor (HTR6) DM3AGUQ MA Agonist DM3AGUQ RN 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4230-4. DM3AGUQ RU https://pubmed.ncbi.nlm.nih.gov/16055331 DM3ALJD DI DM3ALJD DM3ALJD DN (Z)-5-Benzylidene-2-thioxothiazolidin-4-one DM3ALJD TI TT1K6Q4 DM3ALJD TN Arylamine N-acetyltransferase (NAT) DM3ALJD MA Inhibitor DM3ALJD RN Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18. DM3ALJD RU https://pubmed.ncbi.nlm.nih.gov/19059786 DM3ARWX DI DM3ARWX DM3ARWX DN PMID9216829C5m DM3ARWX TI TTFQEO5 DM3ARWX TN Squalene synthetase (FDFT1) DM3ARWX MA Inhibitor DM3ARWX RN (1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl) amino]carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent ... J Med Chem. 1997 Jul 4;40(14):2123-5. DM3ARWX RU https://pubmed.ncbi.nlm.nih.gov/9216829 DM3AW8X DI DM3AW8X DM3AW8X DN Nerve growth factor conjugated RAP peptide DM3AW8X TI TTEDJN4 DM3AW8X TN Low-affinity nerve growth factor receptor (NGFR) DM3AW8X MA Modulator DM3AW8X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DM3AW8X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DM3AWMF DI DM3AWMF DM3AWMF DN SB-203347 DM3AWMF TI TT9V5JH DM3AWMF TN Phospholipase A2 (PLA2G1B) DM3AWMF MA Modulator DM3AWMF RN SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine... J Pharmacol Exp Ther. 1995 Sep;274(3):1254-62. DM3AWMF RU https://www.ncbi.nlm.nih.gov/pubmed/7562496 DM3AWPB DI DM3AWPB DM3AWPB DN Relcovaptan DM3AWPB TI TT4TFGN DM3AWPB TN Vasopressin V1a receptor (V1AR) DM3AWPB MA Inhibitor DM3AWPB RN Binding of [3H] SR 49059, a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem Biophys Res Commun. 1994 Feb 28;199(1):353-60. DM3AWPB RU https://pubmed.ncbi.nlm.nih.gov/8123034 DM3AZPD DI DM3AZPD DM3AZPD DN PSB-0739 DM3AZPD TI TTZ1DT0 DM3AZPD TN P2Y purinoceptor 12 (P2RY12) DM3AZPD MA Inhibitor DM3AZPD RN High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem. 2009 Jun 25;52(12):3784-93. DM3AZPD RU https://pubmed.ncbi.nlm.nih.gov/19463000 DM3B1CE DI DM3B1CE DM3B1CE DN 4-phenylthiazole-2-thiol DM3B1CE TI TTZJYKH DM3B1CE TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM3B1CE MA Inhibitor DM3B1CE RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DM3B1CE RU https://pubmed.ncbi.nlm.nih.gov/20055453 DM3B2TG DI DM3B2TG DM3B2TG DN 4-Biphenyl-2-ylethynyl-2-methyl-thiazole DM3B2TG TI TTHS256 DM3B2TG TN Metabotropic glutamate receptor 5 (mGluR5) DM3B2TG MA Inhibitor DM3B2TG RN 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6. DM3B2TG RU https://pubmed.ncbi.nlm.nih.gov/15225713 DM3B6A8 DI DM3B6A8 DM3B6A8 DN 5-Phenyl-pentanoic acid benzyl-hydroxy-amide DM3B6A8 TI TTVKILB DM3B6A8 TN Prostaglandin G/H synthase 2 (COX-2) DM3B6A8 MA Inhibitor DM3B6A8 RN Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from plat... J Med Chem. 1989 Aug;32(8):1836-42. DM3B6A8 RU https://pubmed.ncbi.nlm.nih.gov/2502629 DM3B6A8 DI DM3B6A8 DM3B6A8 DN 5-Phenyl-pentanoic acid benzyl-hydroxy-amide DM3B6A8 TI TT8NGED DM3B6A8 TN Prostaglandin G/H synthase 1 (COX-1) DM3B6A8 MA Inhibitor DM3B6A8 RN Differential effects of a series of hydroxamic acid derivatives on 5-lipoxygenase and cyclooxygenase from neutrophils and 12-lipoxygenase from plat... J Med Chem. 1989 Aug;32(8):1836-42. DM3B6A8 RU https://pubmed.ncbi.nlm.nih.gov/2502629 DM3B6IN DI DM3B6IN DM3B6IN DN 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol DM3B6IN TI TTOM3J0 DM3B6IN TN Estrogen receptor beta (ESR2) DM3B6IN MA Inhibitor DM3B6IN RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM3B6IN RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM3B6IN DI DM3B6IN DM3B6IN DN 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-6-ol DM3B6IN TI TTZAYWL DM3B6IN TN Estrogen receptor (ESR) DM3B6IN MA Inhibitor DM3B6IN RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM3B6IN RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM3B8R1 DI DM3B8R1 DM3B8R1 DN Tagetitoxin DM3B8R1 TI TTS31JH DM3B8R1 TN Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB) DM3B8R1 MA Inhibitor DM3B8R1 RN Synthesis of the bicyclic core of tagetitoxin. Chem Commun (Camb). 2006 Mar 21;(11):1197-9. DM3B8R1 RU https://pubmed.ncbi.nlm.nih.gov/16518489 DM3BEF7 DI DM3BEF7 DM3BEF7 DN Rimantadine isomer 2 DM3BEF7 TI TTXT3PU DM3BEF7 TN Influenza M2 protein (Influ M) DM3BEF7 MA Inhibitor DM3BEF7 RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DM3BEF7 RU https://pubmed.ncbi.nlm.nih.gov/17139286 DM3BEKV DI DM3BEKV DM3BEKV DN SC-54701A DM3BEKV TI TTJA1ZO DM3BEKV TN ITGB3 messenger RNA (ITGB3 mRNA) DM3BEKV MA Inhibitor DM3BEKV RN Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists. J Med Chem. 1997 Aug 29;40(18):2843-57. DM3BEKV RU https://pubmed.ncbi.nlm.nih.gov/9288166 DM3BFX0 DI DM3BFX0 DM3BFX0 DN 3-Benzyl-4-hydroxy-2H-chromen-2-one DM3BFX0 TI TT8XK6L DM3BFX0 TN Quinone reductase 1 (NQO1) DM3BFX0 MA Inhibitor DM3BFX0 RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DM3BFX0 RU https://pubmed.ncbi.nlm.nih.gov/19877692 DM3BI7R DI DM3BI7R DM3BI7R DN GSK-2334470 DM3BI7R TI TT9QBI6 DM3BI7R TN Phosphoinositide dependent protein kinase-1 (PDPK1) DM3BI7R MA Inhibitor DM3BI7R RN Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma. Oncogene. 2014 Aug 21;33(34):4330-9. DM3BI7R RU https://pubmed.ncbi.nlm.nih.gov/24037523 DM3BL0G DI DM3BL0G DM3BL0G DN IODOINDOMETHACIN DM3BL0G TI TT8NGED DM3BL0G TN Prostaglandin G/H synthase 1 (COX-1) DM3BL0G MA Inhibitor DM3BL0G RN In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. DM3BL0G RU https://pubmed.ncbi.nlm.nih.gov/20188577 DM3BL45 DI DM3BL45 DM3BL45 DN 3-methyl-6-(trifluoromethyl)-9H-carbazole DM3BL45 TI TTBGTCW DM3BL45 TN Kinesin spindle messenger RNA (KIF11 mRNA) DM3BL45 MA Inhibitor DM3BL45 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM3BL45 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM3BOQA DI DM3BOQA DM3BOQA DN Beta-L-fucose DM3BOQA TI TT1RS9F DM3BOQA TN Acetylcholinesterase (AChE) DM3BOQA MA Inhibitor DM3BOQA RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM3BOQA RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM3BQHO DI DM3BQHO DM3BQHO DN [125I]ICYP DM3BQHO TI TTMXGCW DM3BQHO TN Adrenergic receptor beta-3 (ADRB3) DM3BQHO MA Agonist DM3BQHO RN Stereoselectivity for interactions of agonists and antagonists at mouse, rat and human beta3-adrenoceptors. Eur J Pharmacol. 2004 Jan 26;484(2-3):323-31. DM3BQHO RU https://pubmed.ncbi.nlm.nih.gov/14744619 DM3BQO0 DI DM3BQO0 DM3BQO0 DN 3-(2-N-Piperidyl-acetamino)-rutaecarpine DM3BQO0 TI TT1RS9F DM3BQO0 TN Acetylcholinesterase (AChE) DM3BQO0 MA Inhibitor DM3BQO0 RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DM3BQO0 RU https://pubmed.ncbi.nlm.nih.gov/20079560 DM3BRYJ DI DM3BRYJ DM3BRYJ DN 3alpha-(2'-Indolecarbonyloxy)-nortropane DM3BRYJ TI TTPC4TU DM3BRYJ TN 5-HT 3A receptor (HTR3A) DM3BRYJ MA Inhibitor DM3BRYJ RN Synthesis of heteroaromatic tropeines and heterogeneous binding to glycine receptors. Bioorg Med Chem. 2009 Oct 1;17(19):6872-8. DM3BRYJ RU https://pubmed.ncbi.nlm.nih.gov/19726200 DM3BUP6 DI DM3BUP6 DM3BUP6 DN Ac-WVTHQLAGLLSQSGGVVRKNFVPTDVGPFAF-NH2 DM3BUP6 TI TTVSFJW DM3BUP6 TN Calcitonin gene-related peptide 1 (CALCA) DM3BUP6 MA Inhibitor DM3BUP6 RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DM3BUP6 RU https://pubmed.ncbi.nlm.nih.gov/19053766 DM3BV5S DI DM3BV5S DM3BV5S DN SB-381320 DM3BV5S TI TTDNFMT DM3BV5S TN Platelet-activating factor acetylhydrolase (PLA2G7) DM3BV5S MA Inhibitor DM3BV5S RN (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1525-7. DM3BV5S RU https://pubmed.ncbi.nlm.nih.gov/15713421 DM3BWTM DI DM3BWTM DM3BWTM DN DX-2500 DM3BWTM TI TTPY4SE DM3BWTM TN Immunoglobulin Fc receptor (FCR) DM3BWTM RN Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Front Immunol. 2015; 6: 176. DM3BWTM RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407741/ DM3BXUJ DI DM3BXUJ DM3BXUJ DN Azapeptide DM3BXUJ TI TTWXB3E DM3BXUJ TN Hepatitis C virus NS3 helicase (HCV NS3) DM3BXUJ MA Inhibitor DM3BXUJ RN Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1005-8. DM3BXUJ RU https://pubmed.ncbi.nlm.nih.gov/11909704 DM3BZ7S DI DM3BZ7S DM3BZ7S DN NSC-93405 DM3BZ7S TI TTGP7BY DM3BZ7S TN Monoamine oxidase type B (MAO-B) DM3BZ7S MA Inhibitor DM3BZ7S RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM3BZ7S RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM3C0P2 DI DM3C0P2 DM3C0P2 DN N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide DM3C0P2 TI TTW0CMT DM3C0P2 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DM3C0P2 MA Inhibitor DM3C0P2 RN Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2823-7. DM3C0P2 RU https://pubmed.ncbi.nlm.nih.gov/15125940 DM3C2VA DI DM3C2VA DM3C2VA DN Novo Nordisk a/S Compound DM3C2VA TI TTELIN2 DM3C2VA TN PTPN1 messenger RNA (PTPN1 mRNA) DM3C2VA MA Inhibitor DM3C2VA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3C2VA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3C6X2 DI DM3C6X2 DM3C6X2 DN ME67 DM3C6X2 TI TT953CX DM3C6X2 TN Motilin receptor (MLNR) DM3C6X2 MA Agonist DM3C6X2 RN Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. DM3C6X2 RU https://pubmed.ncbi.nlm.nih.gov/15764739 DM3C8PJ DI DM3C8PJ DM3C8PJ DN N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine DM3C8PJ TI TTJFY5U DM3C8PJ TN Adenosine A3 receptor (ADORA3) DM3C8PJ MA Inhibitor DM3C8PJ RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM3C8PJ RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM3C8PJ DI DM3C8PJ DM3C8PJ DN N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine DM3C8PJ TI TTK25J1 DM3C8PJ TN Adenosine A1 receptor (ADORA1) DM3C8PJ MA Inhibitor DM3C8PJ RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM3C8PJ RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM3C8PJ DI DM3C8PJ DM3C8PJ DN N*6*-Cyclohexyl-N*2*-phenyl-9H-purine-2,6-diamine DM3C8PJ TI TTM2AOE DM3C8PJ TN Adenosine A2a receptor (ADORA2A) DM3C8PJ MA Inhibitor DM3C8PJ RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM3C8PJ RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM3CQIZ DI DM3CQIZ DM3CQIZ DN Triphenylmethanamine DM3CQIZ TI TTMNI76 DM3CQIZ TN Calcium-activated potassium channel (KCN) DM3CQIZ MA Inhibitor DM3CQIZ RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DM3CQIZ RU https://pubmed.ncbi.nlm.nih.gov/18232633 DM3CQV6 DI DM3CQV6 DM3CQV6 DN DIASTEREOMER 2 DM3CQV6 TI TTNVEIR DM3CQV6 TN Prostaglandin D2 receptor (PTGDR) DM3CQV6 MA Inhibitor DM3CQV6 RN Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. DM3CQV6 RU https://pubmed.ncbi.nlm.nih.gov/17300164 DM3CWFR DI DM3CWFR DM3CWFR DN Ethyl-indol-1-yl-pyridin-4-yl-amine DM3CWFR TI TT2NUT5 DM3CWFR TN Adrenergic receptor alpha-2C (ADRA2C) DM3CWFR MA Inhibitor DM3CWFR RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM3CWFR RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM3CWFR DI DM3CWFR DM3CWFR DN Ethyl-indol-1-yl-pyridin-4-yl-amine DM3CWFR TI TTWG9A4 DM3CWFR TN Adrenergic receptor alpha-2A (ADRA2A) DM3CWFR MA Inhibitor DM3CWFR RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM3CWFR RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM3CWFR DI DM3CWFR DM3CWFR DN Ethyl-indol-1-yl-pyridin-4-yl-amine DM3CWFR TI TTWM4TY DM3CWFR TN Adrenergic receptor alpha-2B (ADRA2B) DM3CWFR MA Inhibitor DM3CWFR RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM3CWFR RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM3CZVW DI DM3CZVW DM3CZVW DN N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide DM3CZVW TI TTANPDJ DM3CZVW TN Carbonic anhydrase II (CA-II) DM3CZVW MA Inhibitor DM3CZVW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3CZVW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3D21X DI DM3D21X DM3D21X DN ML218 DM3D21X TI TTZPWGN DM3D21X TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DM3D21X MA Blocker (channel blocker) DM3D21X RN The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742. DM3D21X RU https://pubmed.ncbi.nlm.nih.gov/22368764 DM3D21X DI DM3D21X DM3D21X DN ML218 DM3D21X TI TT729IR DM3D21X TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM3D21X MA Blocker (channel blocker) DM3D21X RN The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742. DM3D21X RU https://pubmed.ncbi.nlm.nih.gov/22368764 DM3D21X DI DM3D21X DM3D21X DN ML218 DM3D21X TI TTQZFTH DM3D21X TN Voltage-gated calcium channel alpha Cav3.3 (CACNA1I) DM3D21X MA Blocker (channel blocker) DM3D21X RN The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742. DM3D21X RU https://pubmed.ncbi.nlm.nih.gov/22368764 DM3D2R4 DI DM3D2R4 DM3D2R4 DN GW0072 DM3D2R4 TI TTT2SVW DM3D2R4 TN PPAR-gamma messenger RNA (PPARG mRNA) DM3D2R4 MA Agonist DM3D2R4 RN A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6102-6. DM3D2R4 RU https://pubmed.ncbi.nlm.nih.gov/10339548 DM3D8OK DI DM3D8OK DM3D8OK DN 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL DM3D8OK TI TT6L509 DM3D8OK TN Coagulation factor IIa (F2) DM3D8OK MA Inhibitor DM3D8OK RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM3D8OK RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM3D8WI DI DM3D8WI DM3D8WI DN 2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine DM3D8WI TI TTJS8PY DM3D8WI TN 5-HT 6 receptor (HTR6) DM3D8WI MA Inhibitor DM3D8WI RN Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. J Med Chem. 2007 Nov 15;50(23):5535-8. DM3D8WI RU https://pubmed.ncbi.nlm.nih.gov/17948978 DM3D9XY DI DM3D9XY DM3D9XY DN interleukin-2, Roussel Uclaf DM3D9XY TI TTF89GD DM3D9XY TN Interleukin-2 (IL2) DM3D9XY MA Modulator DM3D9XY RN Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. Eur Cytokine Netw. 2000 Mar;11(1):91-8. DM3D9XY RU https://www.ncbi.nlm.nih.gov/pubmed/10705305 DM3DB8X DI DM3DB8X DM3DB8X DN Icariside II DM3DB8X TI TTJ0IQB DM3DB8X TN Phosphodiesterase 5A (PDE5A) DM3DB8X MA Inhibitor DM3DB8X RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DM3DB8X RU https://pubmed.ncbi.nlm.nih.gov/18778098 DM3DCR9 DI DM3DCR9 DM3DCR9 DN PMID19931453C16m DM3DCR9 TI TTHS256 DM3DCR9 TN Metabotropic glutamate receptor 5 (mGluR5) DM3DCR9 MA Modulator (allosteric modulator) DM3DCR9 RN Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):184-8. DM3DCR9 RU https://pubmed.ncbi.nlm.nih.gov/19931453 DM3DE98 DI DM3DE98 DM3DE98 DN ISIS 298700 DM3DE98 TI TTSN6QU DM3DE98 TN HIF1-alpha messenger RNA (HIF1A mRNA) DM3DE98 RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DM3DE98 RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DM3DE9Z DI DM3DE9Z DM3DE9Z DN 2-allylisoquinoline-1,3,4-trione DM3DE9Z TI TTPF2QI DM3DE9Z TN Caspase-3 (CASP3) DM3DE9Z MA Inhibitor DM3DE9Z RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DM3DE9Z RU https://pubmed.ncbi.nlm.nih.gov/16509578 DM3DERI DI DM3DERI DM3DERI DN alkyl glycerol phosphate 18:1 DM3DERI TI TTABCJ6 DM3DERI TN Lysophosphatidic acid receptor 5 (LPAR5) DM3DERI MA Agonist DM3DERI RN Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19. DM3DERI RU https://pubmed.ncbi.nlm.nih.gov/19366702 DM3DNFQ DI DM3DNFQ DM3DNFQ DN 2-Methyl-3-(2-Aminothiazolo)Propanal DM3DNFQ TI TTB2MXP DM3DNFQ TN Angiotensinogenase renin (REN) DM3DNFQ MA Inhibitor DM3DNFQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM3DNFQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM3DOI7 DI DM3DOI7 DM3DOI7 DN LY320954 DM3DOI7 TI TTJQOD7 DM3DOI7 TN 5-HT 2A receptor (HTR2A) DM3DOI7 MA Antagonist DM3DOI7 RN A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68. DM3DOI7 RU https://pubmed.ncbi.nlm.nih.gov/8845011 DM3DPSO DI DM3DPSO DM3DPSO DN ANA-5 DM3DPSO TI TTE4KHA DM3DPSO TN Amyloid beta A4 protein (APP) DM3DPSO MA Inhibitor DM3DPSO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM3DPSO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM3DPZ8 DI DM3DPZ8 DM3DPZ8 DN N-Hydroxy-N'-(4-methylphenyl)octanediamide DM3DPZ8 TI TT6R7JZ DM3DPZ8 TN Histone deacetylase 1 (HDAC1) DM3DPZ8 MA Inhibitor DM3DPZ8 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM3DPZ8 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM3DPZ8 DI DM3DPZ8 DM3DPZ8 DN N-Hydroxy-N'-(4-methylphenyl)octanediamide DM3DPZ8 TI TTBH0VX DM3DPZ8 TN Histone deacetylase (HDAC) DM3DPZ8 MA Inhibitor DM3DPZ8 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM3DPZ8 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM3DR6J DI DM3DR6J DM3DR6J DN Di(1H-indol-2-yl)methanone DM3DR6J TI TT8FYO9 DM3DR6J TN Platelet-derived growth factor receptor alpha (PDGFRA) DM3DR6J MA Inhibitor DM3DR6J RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM3DR6J RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM3DR6J DI DM3DR6J DM3DR6J DN Di(1H-indol-2-yl)methanone DM3DR6J TI TTGJCWZ DM3DR6J TN Fms-like tyrosine kinase 3 (FLT-3) DM3DR6J MA Inhibitor DM3DR6J RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM3DR6J RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM3DR6J DI DM3DR6J DM3DR6J DN Di(1H-indol-2-yl)methanone DM3DR6J TI TTI7421 DM3DR6J TN Platelet-derived growth factor receptor beta (PDGFRB) DM3DR6J MA Inhibitor DM3DR6J RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM3DR6J RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM3DW6A DI DM3DW6A DM3DW6A DN NSC-640556 DM3DW6A TI TTJLP0R DM3DW6A TN Quinone reductase 2 (NQO2) DM3DW6A MA Inhibitor DM3DW6A RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM3DW6A RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM3DXM0 DI DM3DXM0 DM3DXM0 DN GW1100 DM3DXM0 TI TTB8FUC DM3DXM0 TN Free fatty acid receptor 1 (GPR40) DM3DXM0 MA Antagonist DM3DXM0 RN Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small... Br J Pharmacol. 2006 Jul;148(5):619-28. DM3DXM0 RU https://pubmed.ncbi.nlm.nih.gov/16702987 DM3E4QR DI DM3E4QR DM3E4QR DN ACN-1052 DM3E4QR TI TTJFY5U DM3E4QR TN Adenosine A3 receptor (ADORA3) DM3E4QR MA Antagonist DM3E4QR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 21). DM3E4QR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21 DM3E98I DI DM3E98I DM3E98I DN 3,5-dimethyl PPP DM3E98I TI TTVBPDM DM3E98I TN Metabotropic glutamate receptor 1 (mGluR1) DM3E98I MA Modulator (allosteric modulator) DM3E98I RN Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg Med Chem. 2003 Jan 17;11(2):171-83. DM3E98I RU https://pubmed.ncbi.nlm.nih.gov/12470711 DM3EBFS DI DM3EBFS DM3EBFS DN 1-(3-(3-morpholinopropoxy)phenyl)-3-phenylurea DM3EBFS TI TT7WVHI DM3EBFS TN Soluble epoxide hydrolase (EPHX2) DM3EBFS MA Inhibitor DM3EBFS RN Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63. DM3EBFS RU https://pubmed.ncbi.nlm.nih.gov/19520575 DM3EBYD DI DM3EBYD DM3EBYD DN 2-(pyridin-2-yl)-4-(m-tolylthio)pyrimidine DM3EBYD TI TTHS256 DM3EBYD TN Metabotropic glutamate receptor 5 (mGluR5) DM3EBYD MA Inhibitor DM3EBYD RN Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9. DM3EBYD RU https://pubmed.ncbi.nlm.nih.gov/16481165 DM3EDBO DI DM3EDBO DM3EDBO DN 6-(4-Fluorobutyl)-4-methylpyridin-2-amine DM3EDBO TI TTF10I9 DM3EDBO TN Nitric-oxide synthase inducible (NOS2) DM3EDBO MA Inhibitor DM3EDBO RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DM3EDBO RU https://pubmed.ncbi.nlm.nih.gov/19323559 DM3EDQ1 DI DM3EDQ1 DM3EDQ1 DN 3-(pyridin-3-yl)prop-2-yn-1-amine DM3EDQ1 TI TTXV4FI DM3EDQ1 TN Albendazole monooxygenase (CYP3A4) DM3EDQ1 MA Inhibitor DM3EDQ1 RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DM3EDQ1 RU https://pubmed.ncbi.nlm.nih.gov/17125252 DM3EIBU DI DM3EIBU DM3EIBU DN BREMAZOCINE DM3EIBU TI TTKWM86 DM3EIBU TN Opioid receptor mu (MOP) DM3EIBU MA Inhibitor DM3EIBU RN Electrophilic alpha-methylene-gamma-lactone and isothiocyanate opioid ligands related to etorphine. J Med Chem. 1990 Aug;33(8):2286-96. DM3EIBU RU https://pubmed.ncbi.nlm.nih.gov/2165166 DM3EIWC DI DM3EIWC DM3EIWC DN 3-cyano-N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide DM3EIWC TI TTHS256 DM3EIWC TN Metabotropic glutamate receptor 5 (mGluR5) DM3EIWC MA Inhibitor DM3EIWC RN Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44. DM3EIWC RU https://pubmed.ncbi.nlm.nih.gov/16722652 DM3ELPS DI DM3ELPS DM3ELPS DN PMID21757343C30 DM3ELPS TI TTHS256 DM3ELPS TN Metabotropic glutamate receptor 5 (mGluR5) DM3ELPS MA Modulator (allosteric modulator) DM3ELPS RN 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4891-9. DM3ELPS RU https://pubmed.ncbi.nlm.nih.gov/21757343 DM3EMLB DI DM3EMLB DM3EMLB DN ISIS 101995 DM3EMLB TI TTON5JB DM3EMLB TN MADH6 messenger RNA (MADH6 mRNA) DM3EMLB RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DM3EMLB RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DM3EP59 DI DM3EP59 DM3EP59 DN MK-7725 DM3EP59 TI TTKYEPM DM3EP59 TN Bombesin-like receptor 3 (BRS3) DM3EP59 MA Agonist DM3EP59 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8502). DM3EP59 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8502 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTR5TV4 DM3EV9N TN ERBB2 messenger RNA (HER2 mRNA) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TT7HF4W DM3EV9N TN Cyclin-dependent kinase 2 (CDK2) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTGKNB4 DM3EV9N TN Epidermal growth factor receptor (EGFR) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TT9P6OW DM3EV9N TN G2/mitotic-specific cyclin B1 (CCNB1) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTBZ7OD DM3EV9N TN Protein kinase C epsilon (PRKCE) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTRFOXJ DM3EV9N TN Protein kinase C gamma (PRKCG) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTCEJ4F DM3EV9N TN G1/S-specific cyclin-E1 (CCNE1) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTH6V3D DM3EV9N TN Cyclin-dependent kinase 1 (CDK1) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTFCJ7S DM3EV9N TN G1/S-specific cyclin-D1 (CCND1) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TT0PG8F DM3EV9N TN Cyclin-dependent kinase 4 (CDK4) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TTFJ8Q1 DM3EV9N TN Protein kinase C alpha (PRKCA) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EV9N DI DM3EV9N DM3EV9N DN 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N TI TT9VGXW DM3EV9N TN Angiopoietin 1 receptor (TEK) DM3EV9N MA Inhibitor DM3EV9N RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DM3EV9N RU https://pubmed.ncbi.nlm.nih.gov/16480264 DM3EYOL DI DM3EYOL DM3EYOL DN 1-(3-(3-phenylpropoxy)propyl)piperidine DM3EYOL TI TT9JNIC DM3EYOL TN Histamine H3 receptor (H3R) DM3EYOL MA Inhibitor DM3EYOL RN Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36. DM3EYOL RU https://pubmed.ncbi.nlm.nih.gov/18774720 DM3EZ9Q DI DM3EZ9Q DM3EZ9Q DN PMID12723954C21b DM3EZ9Q TI TTHYDUM DM3EZ9Q TN Bombesin receptor (BS) DM3EZ9Q MA Agonist DM3EZ9Q RN Design of selective peptidomimetic agonists for the human orphan receptor BRS-3. J Med Chem. 2003 May 8;46(10):1918-30. DM3EZ9Q RU https://pubmed.ncbi.nlm.nih.gov/12723954 DM3EZDG DI DM3EZDG DM3EZDG DN Org-37663 DM3EZDG TI TTZAYWL DM3EZDG TN Estrogen receptor (ESR) DM3EZDG MA Modulator DM3EZDG RN The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine.Arthritis Rheum.2010 Feb;62(2):351-8. DM3EZDG RU https://www.ncbi.nlm.nih.gov/pubmed/20112368 DM3F25L DI DM3F25L DM3F25L DN Thiamin Diphosphate DM3F25L TI TTUTN1I DM3F25L TN Human Deoxyribonucleic acid (hDNA) DM3F25L MA Inhibitor DM3F25L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3F25L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3F427 DI DM3F427 DM3F427 DN EphB4-131 DM3F427 TI TTI4ZX2 DM3F427 TN Ephrin type-B receptor 4 (EPHB4) DM3F427 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1833). DM3F427 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1833 DM3F4IQ DI DM3F4IQ DM3F4IQ DN HTS-05058 DM3F4IQ TI TTGKNB4 DM3F4IQ TN Epidermal growth factor receptor (EGFR) DM3F4IQ MA Inhibitor DM3F4IQ RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DM3F4IQ RU https://pubmed.ncbi.nlm.nih.gov/18077363 DM3F56O DI DM3F56O DM3F56O DN (R)-4-amino-2-methylbutanoic acid DM3F56O TI TTNJYV2 DM3F56O TN Gamma-aminobutyric acid receptor (GAR) DM3F56O MA Inhibitor DM3F56O RN Enantioselective actions of 4-amino-3-hydroxybutanoic acid and (3-amino-2-hydroxypropyl)methylphosphinic acid at recombinant GABA(C) receptors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):402-4. DM3F56O RU https://pubmed.ncbi.nlm.nih.gov/17981464 DM3F7SD DI DM3F7SD DM3F7SD DN PS-777621 DM3F7SD TI TTH9VL3 DM3F7SD TN Plasmodium Plasmepsin 1 (Malaria PLA1) DM3F7SD MA Inhibitor DM3F7SD RN High antiplasmodial activity of novel plasmepsins I and II inhibitors. J Med Chem. 2006 Dec 14;49(25):7440-9. DM3F7SD RU https://pubmed.ncbi.nlm.nih.gov/17149873 DM3F7SD DI DM3F7SD DM3F7SD DN PS-777621 DM3F7SD TI TTXMNHO DM3F7SD TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM3F7SD MA Inhibitor DM3F7SD RN High antiplasmodial activity of novel plasmepsins I and II inhibitors. J Med Chem. 2006 Dec 14;49(25):7440-9. DM3F7SD RU https://pubmed.ncbi.nlm.nih.gov/17149873 DM3FBAZ DI DM3FBAZ DM3FBAZ DN {2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine DM3FBAZ TI TTAWNKZ DM3FBAZ TN Norepinephrine transporter (NET) DM3FBAZ MA Inhibitor DM3FBAZ RN Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(p... Bioorg Med Chem. 2009 Nov 15;17(22):7802-15. DM3FBAZ RU https://pubmed.ncbi.nlm.nih.gov/19836247 DM3FBLT DI DM3FBLT DM3FBLT DN 2-(3-benzenesulfonyl)phenyl-1-aminoethane DM3FBLT TI TTJS8PY DM3FBLT TN 5-HT 6 receptor (HTR6) DM3FBLT MA Inhibitor DM3FBLT RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DM3FBLT RU https://pubmed.ncbi.nlm.nih.gov/16913710 DM3FCAI DI DM3FCAI DM3FCAI DN N-(5'-Phosphopyridoxyl)-D-Alanine DM3FCAI TI TT6TMZU DM3FCAI TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DM3FCAI MA Inhibitor DM3FCAI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3FCAI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3FH02 DI DM3FH02 DM3FH02 DN Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 TI TT84ETX DM3FH02 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3FH02 MA Inhibitor DM3FH02 RN Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9. DM3FH02 RU https://pubmed.ncbi.nlm.nih.gov/11026542 DM3FH02 DI DM3FH02 DM3FH02 DN Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 TI TTGBPJE DM3FH02 TN PI3-kinase delta (PIK3CD) DM3FH02 MA Inhibitor DM3FH02 RN LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. DM3FH02 RU https://pubmed.ncbi.nlm.nih.gov/11294389 DM3FH02 DI DM3FH02 DM3FH02 DN Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 TI TT9H4P3 DM3FH02 TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DM3FH02 MA Inhibitor DM3FH02 RN LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. DM3FH02 RU https://pubmed.ncbi.nlm.nih.gov/11294389 DM3FH02 DI DM3FH02 DM3FH02 DN Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 TI TTK3PY9 DM3FH02 TN DNA-dependent protein kinase catalytic (PRKDC) DM3FH02 MA Inhibitor DM3FH02 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DM3FH02 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DM3FH02 DI DM3FH02 DM3FH02 DN Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 TI TTCJG29 DM3FH02 TN Serine/threonine-protein kinase mTOR (mTOR) DM3FH02 MA Inhibitor DM3FH02 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DM3FH02 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DM3FH02 DI DM3FH02 DM3FH02 DN Ethyl 1-[(1H-benzimidazol-2(3H)one-5-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM3FH02 TI TTHBTOP DM3FH02 TN PI3-kinase gamma (PIK3CG) DM3FH02 MA Inhibitor DM3FH02 RN LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. DM3FH02 RU https://pubmed.ncbi.nlm.nih.gov/11294389 DM3FHJK DI DM3FHJK DM3FHJK DN 1-(2,5-Dimethyl-1H-pyrrol-1-yl)thiourea DM3FHJK TI TTULVH8 DM3FHJK TN Tyrosinase (TYR) DM3FHJK MA Inhibitor DM3FHJK RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DM3FHJK RU https://pubmed.ncbi.nlm.nih.gov/18524420 DM3FOKL DI DM3FOKL DM3FOKL DN N-(6-(pyridin-3-yl)-1H-indazol-3-yl)butyramide DM3FOKL TI TTRSMW9 DM3FOKL TN Glycogen synthase kinase-3 beta (GSK-3B) DM3FOKL MA Inhibitor DM3FOKL RN Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9. DM3FOKL RU https://pubmed.ncbi.nlm.nih.gov/20189807 DM3FP47 DI DM3FP47 DM3FP47 DN CGNLSTCMLGTYTQDFc[DKFHO]FPQTAIGVGAP-amide DM3FP47 TI TTLWS2O DM3FP47 TN Calcitonin receptor (CALCR) DM3FP47 MA Inhibitor DM3FP47 RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DM3FP47 RU https://pubmed.ncbi.nlm.nih.gov/11855991 DM3FP6J DI DM3FP6J DM3FP6J DN 1-(3-nitropyridin-2-yl)-4-tosylpiperazine DM3FP6J TI TTN7BL9 DM3FP6J TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM3FP6J MA Inhibitor DM3FP6J RN Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6. DM3FP6J RU https://pubmed.ncbi.nlm.nih.gov/18511278 DM3FQYS DI DM3FQYS DM3FQYS DN (R,R)-(-)-fenoterol DM3FQYS TI TT2CJVK DM3FQYS TN Adrenergic receptor beta-2 (ADRB2) DM3FQYS MA Inhibitor DM3FQYS RN Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15. DM3FQYS RU https://pubmed.ncbi.nlm.nih.gov/17506540 DM3FQYS DI DM3FQYS DM3FQYS DN (R,R)-(-)-fenoterol DM3FQYS TI TTR6W5O DM3FQYS TN Adrenergic receptor beta-1 (ADRB1) DM3FQYS MA Inhibitor DM3FQYS RN Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15. DM3FQYS RU https://pubmed.ncbi.nlm.nih.gov/17506540 DM3FS62 DI DM3FS62 DM3FS62 DN O-spiroketal glucoside DM3FS62 TI TT2UE56 DM3FS62 TN Sodium/glucose cotransporter 1 (SGLT1) DM3FS62 MA Inhibitor DM3FS62 RN ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32. DM3FS62 RU https://pubmed.ncbi.nlm.nih.gov/20576578 DM3FS62 DI DM3FS62 DM3FS62 DN O-spiroketal glucoside DM3FS62 TI TTF8JAT DM3FS62 TN SLC5A2 messenger RNA (SLC5A2 mRNA) DM3FS62 MA Inhibitor DM3FS62 RN ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem. 2010 Jun 15;18(12):4422-32. DM3FS62 RU https://pubmed.ncbi.nlm.nih.gov/20576578 DM3FW9Q DI DM3FW9Q DM3FW9Q DN N-(4-Sulfamoyl-phenyl)-butyramide DM3FW9Q TI TT2LVK8 DM3FW9Q TN Carbonic anhydrase IX (CA-IX) DM3FW9Q MA Inhibitor DM3FW9Q RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM3FW9Q RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM3FW9Q DI DM3FW9Q DM3FW9Q DN N-(4-Sulfamoyl-phenyl)-butyramide DM3FW9Q TI TTSYM0R DM3FW9Q TN Carbonic anhydrase XII (CA-XII) DM3FW9Q MA Inhibitor DM3FW9Q RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM3FW9Q RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM3FW9Q DI DM3FW9Q DM3FW9Q DN N-(4-Sulfamoyl-phenyl)-butyramide DM3FW9Q TI TTANPDJ DM3FW9Q TN Carbonic anhydrase II (CA-II) DM3FW9Q MA Inhibitor DM3FW9Q RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM3FW9Q RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM3FW9Q DI DM3FW9Q DM3FW9Q DN N-(4-Sulfamoyl-phenyl)-butyramide DM3FW9Q TI TTHQPL7 DM3FW9Q TN Carbonic anhydrase I (CA-I) DM3FW9Q MA Inhibitor DM3FW9Q RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM3FW9Q RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM3FXPV DI DM3FXPV DM3FXPV DN S-(N-4bromophenyl-N-hydroxycarbamoyl)glutathione DM3FXPV TI TTV9A7R DM3FXPV TN Lactoylglutathione lyase (GLO1) DM3FXPV MA Inhibitor DM3FXPV RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DM3FXPV RU https://pubmed.ncbi.nlm.nih.gov/11052803 DM3FXRC DI DM3FXRC DM3FXRC DN 7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene DM3FXRC TI TTNJYV2 DM3FXRC TN Gamma-aminobutyric acid receptor (GAR) DM3FXRC MA Inhibitor DM3FXRC RN Synthesis of 7,12-dihydropyrido[3,4-b:5,4-b']diindoles. A novel class of rigid, planar benzodiazepine receptor ligands. J Med Chem. 1987 Mar;30(3):456-8. DM3FXRC RU https://pubmed.ncbi.nlm.nih.gov/3029372 DM3FXRC DI DM3FXRC DM3FXRC DN 7,12-Dihydro-5,7,12-triaza-indeno[1,2-a]fluorene DM3FXRC TI TT1MPAY DM3FXRC TN GABA(A) receptor alpha-1 (GABRA1) DM3FXRC MA Inhibitor DM3FXRC RN Synthesis of 7,12-dihydropyrido[3,4-b:5,4-b']diindoles. A novel class of rigid, planar benzodiazepine receptor ligands. J Med Chem. 1987 Mar;30(3):456-8. DM3FXRC RU https://pubmed.ncbi.nlm.nih.gov/3029372 DM3FYUM DI DM3FYUM DM3FYUM DN RO 244383 DM3FYUM TI TTJP4SM DM3FYUM TN Bacterial Penicillin binding protein (Bact PBP) DM3FYUM MA Modulator DM3FYUM RN Mechanisms of resistance to cephalosporin antibiotics.Drugs.1987;34 Suppl 2:64-88. DM3FYUM RU https://www.ncbi.nlm.nih.gov/pubmed/3319506 DM3FZ6P DI DM3FZ6P DM3FZ6P DN IODIDE DM3FZ6P TI TTANPDJ DM3FZ6P TN Carbonic anhydrase II (CA-II) DM3FZ6P MA Inhibitor DM3FZ6P RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DM3FZ6P RU https://pubmed.ncbi.nlm.nih.gov/15454240 DM3FZ6P DI DM3FZ6P DM3FZ6P DN IODIDE DM3FZ6P TI TTHQPL7 DM3FZ6P TN Carbonic anhydrase I (CA-I) DM3FZ6P MA Inhibitor DM3FZ6P RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DM3FZ6P RU https://pubmed.ncbi.nlm.nih.gov/15454240 DM3G6LY DI DM3G6LY DM3G6LY DN 9-Deazahypoxanthine DM3G6LY TI TTMCF1Y DM3G6LY TN Purine nucleoside phosphorylase (PNP) DM3G6LY MA Inhibitor DM3G6LY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3G6LY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3G6OK DI DM3G6OK DM3G6OK DN VUF-5297 DM3G6OK TI TT9JNIC DM3G6OK TN Histamine H3 receptor (H3R) DM3G6OK MA Inhibitor DM3G6OK RN Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist f... J Med Chem. 2003 May 8;46(10):1980-8. DM3G6OK RU https://pubmed.ncbi.nlm.nih.gov/12723960 DM3G8I7 DI DM3G8I7 DM3G8I7 DN 7-bromoindirubin-3-acetoxime DM3G8I7 TI TTLYXIT DM3G8I7 TN Aurora kinase C (AURKC) DM3G8I7 MA Inhibitor DM3G8I7 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM3G8I7 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM3GADP DI DM3GADP DM3GADP DN VE-04051645 DM3GADP TI TT6L509 DM3GADP TN Coagulation factor IIa (F2) DM3GADP MA Inhibitor DM3GADP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DM3GADP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DM3GJ07 DI DM3GJ07 DM3GJ07 DN SDZ-PDI-747 DM3GJ07 TI TTV5CGO DM3GJ07 TN Phosphodiesterase 4 (PDE4) DM3GJ07 MA Modulator DM3GJ07 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM3GJ07 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM3GLMP DI DM3GLMP DM3GLMP DN Cypate-[(RGD)4-NH2]1 DM3GLMP TI TTJA1ZO DM3GLMP TN ITGB3 messenger RNA (ITGB3 mRNA) DM3GLMP MA Inhibitor DM3GLMP RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DM3GLMP RU https://pubmed.ncbi.nlm.nih.gov/16570923 DM3GLMP DI DM3GLMP DM3GLMP DN Cypate-[(RGD)4-NH2]1 DM3GLMP TI TTT1R2L DM3GLMP TN Integrin alpha-V (ITGAV) DM3GLMP MA Inhibitor DM3GLMP RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DM3GLMP RU https://pubmed.ncbi.nlm.nih.gov/16570923 DM3GM8E DI DM3GM8E DM3GM8E DN D[Val4]AVP DM3GM8E TI TTK8R02 DM3GM8E TN Vasopressin V2 receptor (V2R) DM3GM8E MA Inhibitor DM3GM8E RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM3GM8E RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM3GM8E DI DM3GM8E DM3GM8E DN D[Val4]AVP DM3GM8E TI TTSCIUP DM3GM8E TN Oxytocin receptor (OTR) DM3GM8E MA Inhibitor DM3GM8E RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM3GM8E RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM3GM8E DI DM3GM8E DM3GM8E DN D[Val4]AVP DM3GM8E TI TTL9MHW DM3GM8E TN Vasopressin V1b receptor (V1BR) DM3GM8E MA Inhibitor DM3GM8E RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM3GM8E RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM3GM8E DI DM3GM8E DM3GM8E DN D[Val4]AVP DM3GM8E TI TT4TFGN DM3GM8E TN Vasopressin V1a receptor (V1AR) DM3GM8E MA Inhibitor DM3GM8E RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM3GM8E RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM3GQN2 DI DM3GQN2 DM3GQN2 DN 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol DM3GQN2 TI TTZAYWL DM3GQN2 TN Estrogen receptor (ESR) DM3GQN2 MA Inhibitor DM3GQN2 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM3GQN2 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM3GQN2 DI DM3GQN2 DM3GQN2 DN 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol DM3GQN2 TI TTOM3J0 DM3GQN2 TN Estrogen receptor beta (ESR2) DM3GQN2 MA Inhibitor DM3GQN2 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM3GQN2 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM3GS2X DI DM3GS2X DM3GS2X DN S-2238 DM3GS2X TI TT6L509 DM3GS2X TN Coagulation factor IIa (F2) DM3GS2X MA Inhibitor DM3GS2X RN Screening for selective thrombin inhibitors in mushrooms. Blood Coagul Fibrinolysis. 2001 Mar;12(2):123-8. DM3GS2X RU https://pubmed.ncbi.nlm.nih.gov/11302474 DM3GSPX DI DM3GSPX DM3GSPX DN Ac-His-DPhe(pI)-Arg-Trp-NH2 DM3GSPX TI TTEOSZT DM3GSPX TN Melanocortin receptor (MCR) DM3GSPX MA Inhibitor DM3GSPX RN Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93. DM3GSPX RU https://pubmed.ncbi.nlm.nih.gov/18800761 DM3GTV0 DI DM3GTV0 DM3GTV0 DN 2,7-Bis[2-(butylamino)acetamido]anthraquinone DM3GTV0 TI TTQY2EJ DM3GTV0 TN TERT messenger RNA (TERT mRNA) DM3GTV0 MA Inhibitor DM3GTV0 RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM3GTV0 RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM3GUFI DI DM3GUFI DM3GUFI DN 4-(butyl(methyl)amino)-N-(quinolin-3-yl)benzamide DM3GUFI TI TTMI6F5 DM3GUFI TN Transient receptor potential cation channel V1 (TRPV1) DM3GUFI MA Inhibitor DM3GUFI RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DM3GUFI RU https://pubmed.ncbi.nlm.nih.gov/18359227 DM3GYNM DI DM3GYNM DM3GYNM DN PMID18295483C2 DM3GYNM TI TTIKWV4 DM3GYNM TN Geranyltranstransferase (FDPS) DM3GYNM MA Inhibitor DM3GYNM RN Design and structure-activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg Med Chem Lett.2008 Mar 15;18(6):1840-4. DM3GYNM RU https://pubmed.ncbi.nlm.nih.gov/18295483 DM3H0CX DI DM3H0CX DM3H0CX DN [D-Gln3,D-Ncy(SO2,isopropyl)7]acyline DM3H0CX TI TT8R70G DM3H0CX TN Gonadotropin-releasing hormone receptor (GNRHR) DM3H0CX MA Inhibitor DM3H0CX RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM3H0CX RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM3H56L DI DM3H56L DM3H56L DN 3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one DM3H56L TI TTZAYWL DM3H56L TN Estrogen receptor (ESR) DM3H56L MA Inhibitor DM3H56L RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM3H56L RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM3H56L DI DM3H56L DM3H56L DN 3-hydroxy-8,10-dimethyl-6H-benzo[c]chromen-6-one DM3H56L TI TTOM3J0 DM3H56L TN Estrogen receptor beta (ESR2) DM3H56L MA Inhibitor DM3H56L RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM3H56L RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM3H9ZY DI DM3H9ZY DM3H9ZY DN LB30812 DM3H9ZY TI TT6L509 DM3H9ZY TN Coagulation factor IIa (F2) DM3H9ZY MA Inhibitor DM3H9ZY RN Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. J Med Chem. 2003 Aug 14;46(17):3612-22. DM3H9ZY RU https://pubmed.ncbi.nlm.nih.gov/12904065 DM3HANW DI DM3HANW DM3HANW DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol DM3HANW TI TTLD29N DM3HANW TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM3HANW MA Inhibitor DM3HANW RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DM3HANW RU https://pubmed.ncbi.nlm.nih.gov/15056006 DM3HANW DI DM3HANW DM3HANW DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-4-ol DM3HANW TI TTN9D8E DM3HANW TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM3HANW MA Inhibitor DM3HANW RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DM3HANW RU https://pubmed.ncbi.nlm.nih.gov/15056006 DM3HJX7 DI DM3HJX7 DM3HJX7 DN Ibogaine DM3HJX7 TI TTMT0HG DM3HJX7 TN Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3) DM3HJX7 MA Antagonist DM3HJX7 RN Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol. 2002 Mar 1;438(1-2):99-105. DM3HJX7 RU https://pubmed.ncbi.nlm.nih.gov/11906717 DM3HWQY DI DM3HWQY DM3HWQY DN (+/-)-threo-N-(4-Chlorobenzyl)methylphenidate DM3HWQY TI TTVBI8W DM3HWQY TN Dopamine transporter (DAT) DM3HWQY MA Inhibitor DM3HWQY RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM3HWQY RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM3HYU8 DI DM3HYU8 DM3HYU8 DN Acetoacetyl-Coenzyme A DM3HYU8 TI TTS0EZJ DM3HYU8 TN Hydroxymethylglutaryl-CoA synthase 2 (HMGCS2) DM3HYU8 MA Inhibitor DM3HYU8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3HYU8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3HYU8 DI DM3HYU8 DM3HYU8 DN Acetoacetyl-Coenzyme A DM3HYU8 TI TT8HWCD DM3HYU8 TN Staphylococcus DHNA-CoA synthase (Stap-coc menB) DM3HYU8 MA Inhibitor DM3HYU8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3HYU8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3I0WZ DI DM3I0WZ DM3I0WZ DN N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile DM3I0WZ TI TTDZN01 DM3I0WZ TN Cathepsin K (CTSK) DM3I0WZ MA Inhibitor DM3I0WZ RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DM3I0WZ RU https://pubmed.ncbi.nlm.nih.gov/16302809 DM3I0WZ DI DM3I0WZ DM3I0WZ DN N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile DM3I0WZ TI TT36ETB DM3I0WZ TN Cathepsin L (CTSL) DM3I0WZ MA Inhibitor DM3I0WZ RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DM3I0WZ RU https://pubmed.ncbi.nlm.nih.gov/16302809 DM3I0WZ DI DM3I0WZ DM3I0WZ DN N-(tert-butoxycarbonyl)-methionyl-glycine-nitrile DM3I0WZ TI TTUMQVO DM3I0WZ TN Cathepsin S (CTSS) DM3I0WZ MA Inhibitor DM3I0WZ RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DM3I0WZ RU https://pubmed.ncbi.nlm.nih.gov/16302809 DM3I15D DI DM3I15D DM3I15D DN 3-(4-Amino-phenyl)-3-ethyl-pyrrolidine-2,5-dione DM3I15D TI TTSZLWK DM3I15D TN Aromatase (CYP19A1) DM3I15D MA Inhibitor DM3I15D RN Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3. DM3I15D RU https://pubmed.ncbi.nlm.nih.gov/3754286 DM3I2US DI DM3I2US DM3I2US DN SL422 DM3I2US TI TTNP4CU DM3I2US TN Matrix metalloproteinase-16 (MMP-16) DM3I2US MA Inhibitor DM3I2US RN Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. DM3I2US RU https://pubmed.ncbi.nlm.nih.gov/11472217 DM3I2US DI DM3I2US DM3I2US DN SL422 DM3I2US TI TTMTWOS DM3I2US TN Matrix metalloproteinase-7 (MMP-7) DM3I2US MA Inhibitor DM3I2US RN Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. DM3I2US RU https://pubmed.ncbi.nlm.nih.gov/11472217 DM3I2US DI DM3I2US DM3I2US DN SL422 DM3I2US TI TTHY57M DM3I2US TN Matrix metalloproteinase-13 (MMP-13) DM3I2US MA Inhibitor DM3I2US RN Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. DM3I2US RU https://pubmed.ncbi.nlm.nih.gov/11472217 DM3I2US DI DM3I2US DM3I2US DN SL422 DM3I2US TI TT6AZXG DM3I2US TN TNF alpha converting enzyme (ADAM17) DM3I2US MA Inhibitor DM3I2US RN Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. DM3I2US RU https://pubmed.ncbi.nlm.nih.gov/11472217 DM3I2US DI DM3I2US DM3I2US DN SL422 DM3I2US TI TT6X50U DM3I2US TN Matrix metalloproteinase-9 (MMP-9) DM3I2US MA Inhibitor DM3I2US RN Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. DM3I2US RU https://pubmed.ncbi.nlm.nih.gov/11472217 DM3I2US DI DM3I2US DM3I2US DN SL422 DM3I2US TI TTGA1IV DM3I2US TN Matrix metalloproteinase-8 (MMP-8) DM3I2US MA Inhibitor DM3I2US RN Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. DM3I2US RU https://pubmed.ncbi.nlm.nih.gov/11472217 DM3I2US DI DM3I2US DM3I2US DN SL422 DM3I2US TI TTNSTO3 DM3I2US TN Matrix metalloproteinase-15 (MMP-15) DM3I2US MA Inhibitor DM3I2US RN Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo. J Med Chem. 2001 Aug 2;44(16):2636-60. DM3I2US RU https://pubmed.ncbi.nlm.nih.gov/11472217 DM3I6PS DI DM3I6PS DM3I6PS DN 13-(3-Pentyluredo)tridec-8(Z)-enoic acid DM3I6PS TI TT7WVHI DM3I6PS TN Soluble epoxide hydrolase (EPHX2) DM3I6PS MA Inhibitor DM3I6PS RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM3I6PS RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM3I7EL DI DM3I7EL DM3I7EL DN 2-benzyl-5-mercaptopentanoic acid DM3I7EL TI TT9G4N0 DM3I7EL TN Glutamate carboxypeptidase II (GCPII) DM3I7EL MA Inhibitor DM3I7EL RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DM3I7EL RU https://pubmed.ncbi.nlm.nih.gov/16686531 DM3I8A1 DI DM3I8A1 DM3I8A1 DN BENZENESULFONAMIDE DM3I8A1 TI TTHQPL7 DM3I8A1 TN Carbonic anhydrase I (CA-I) DM3I8A1 MA Inhibitor DM3I8A1 RN Ligand-directed tosyl chemistry for protein labeling in vivo. Nat Chem Biol. 2009 May;5(5):341-3. DM3I8A1 RU https://pubmed.ncbi.nlm.nih.gov/19330012 DM3I9JG DI DM3I9JG DM3I9JG DN UCCF-339 DM3I9JG TI TTRLZHP DM3I9JG TN cAMP-dependent chloride channel (CFTR) DM3I9JG MA Activator DM3I9JG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DM3I9JG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DM3IMXF DI DM3IMXF DM3IMXF DN N-(2,4-dihydroxybenzyl)-3,4-dihydroxybenzamide DM3IMXF TI TTULVH8 DM3IMXF TN Tyrosinase (TYR) DM3IMXF MA Inhibitor DM3IMXF RN N-Benzylbenzamides: a new class of potent tyrosinase inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2682-4. DM3IMXF RU https://pubmed.ncbi.nlm.nih.gov/16513349 DM3INUK DI DM3INUK DM3INUK DN GNF-PF-117 DM3INUK TI TTYFKSZ DM3INUK TN Tubulin beta (TUBB) DM3INUK MA Inhibitor DM3INUK RN Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agent... J Med Chem. 1993 Apr 30;36(9):1146-56. DM3INUK RU https://pubmed.ncbi.nlm.nih.gov/8387598 DM3INUK DI DM3INUK DM3INUK DN GNF-PF-117 DM3INUK TI TTML2WA DM3INUK TN Tubulin (TUB) DM3INUK MA Inhibitor DM3INUK RN Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agent... J Med Chem. 1993 Apr 30;36(9):1146-56. DM3INUK RU https://pubmed.ncbi.nlm.nih.gov/8387598 DM3INX7 DI DM3INX7 DM3INX7 DN EPZ015666 DM3INX7 TI TTR1D7X DM3INX7 TN Protein arginine methyltransferase 5 (PRMT5) DM3INX7 MA Inhibitor DM3INX7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1256). DM3INX7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1256 DM3IOLR DI DM3IOLR DM3IOLR DN YM-202074 DM3IOLR TI TTVBPDM DM3IOLR TN Metabotropic glutamate receptor 1 (mGluR1) DM3IOLR MA Modulator (allosteric modulator) DM3IOLR RN Neuroprotective effects of the selective type 1 metabotropic glutamate receptor antagonist YM-202074 in rat stroke models. Brain Res. 2008 Jan 29;1191:168-79. DM3IOLR RU https://pubmed.ncbi.nlm.nih.gov/18164695 DM3IOR0 DI DM3IOR0 DM3IOR0 DN anti-BrP-LPA DM3IOR0 TI TTQ6S1K DM3IOR0 TN Lysophosphatidic acid receptor 1 (LPAR1) DM3IOR0 MA Antagonist DM3IOR0 RN Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9. DM3IOR0 RU https://pubmed.ncbi.nlm.nih.gov/19509223 DM3IPYV DI DM3IPYV DM3IPYV DN BPH-675 DM3IPYV TI TTIKWV4 DM3IPYV TN Geranyltranstransferase (FDPS) DM3IPYV MA Inhibitor DM3IPYV RN Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. DM3IPYV RU https://pubmed.ncbi.nlm.nih.gov/17535895 DM3IR7W DI DM3IR7W DM3IR7W DN ISIS 25113 DM3IR7W TI TT8H9GB DM3IR7W TN MEK2 messenger RNA (MEK2 mRNA) DM3IR7W RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DM3IR7W RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DM3IR8Y DI DM3IR8Y DM3IR8Y DN 4-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine DM3IR8Y TI TTSZLWK DM3IR8Y TN Aromatase (CYP19A1) DM3IR8Y MA Inhibitor DM3IR8Y RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM3IR8Y RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM3IWP5 DI DM3IWP5 DM3IWP5 DN NRT-300 DM3IWP5 TI TTKWM86 DM3IWP5 TN Opioid receptor mu (MOP) DM3IWP5 MA Modulator DM3IWP5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DM3IWP5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DM3IX2E DI DM3IX2E DM3IX2E DN M5 DM3IX2E TI TTP86E2 DM3IX2E TN Plasminogen (PLG) DM3IX2E MA Activator DM3IX2E RN Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. DM3IX2E RU https://pubmed.ncbi.nlm.nih.gov/23694890 DM3IXEA DI DM3IXEA DM3IXEA DN RF9 DM3IXEA TI TTEP027 DM3IXEA TN Neuropeptide FF receptor 1 (NPFFR1) DM3IXEA MA Antagonist DM3IXEA RN RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):466-71. DM3IXEA RU https://pubmed.ncbi.nlm.nih.gov/16407169 DM3IXEA DI DM3IXEA DM3IXEA DN RF9 DM3IXEA TI TTXYNDJ DM3IXEA TN Neuropeptide FF receptor 2 (NPFFR2) DM3IXEA MA Antagonist DM3IXEA RN RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci U S A. 2006 Jan 10;103(2):466-71. DM3IXEA RU https://pubmed.ncbi.nlm.nih.gov/16407169 DM3IZOP DI DM3IZOP DM3IZOP DN CRA_8696 DM3IZOP TI TT6L509 DM3IZOP TN Coagulation factor IIa (F2) DM3IZOP MA Inhibitor DM3IZOP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM3IZOP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM3IZOP DI DM3IZOP DM3IZOP DN CRA_8696 DM3IZOP TI TTGY7WI DM3IZOP TN Urokinase-type plasminogen activator (PLAU) DM3IZOP MA Inhibitor DM3IZOP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM3IZOP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM3J5MR DI DM3J5MR DM3J5MR DN N-Hydroxy-E-3-(4'-chlorobiphenyl-4-yl)-acrylamide DM3J5MR TI TTSHTOI DM3J5MR TN Histone deacetylase 2 (HDAC2) DM3J5MR MA Inhibitor DM3J5MR RN Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12. DM3J5MR RU https://pubmed.ncbi.nlm.nih.gov/19084294 DM3J6HM DI DM3J6HM DM3J6HM DN CGP-35582 DM3J6HM TI TTDCVZW DM3J6HM TN Gamma-aminobutyric acid B receptor (GABBR) DM3J6HM MA Inhibitor DM3J6HM RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DM3J6HM RU https://pubmed.ncbi.nlm.nih.gov/7650684 DM3J746 DI DM3J746 DM3J746 DN PMID3514912C9 DM3J746 TI TTAHE2N DM3J746 TN Acrosin (ACR) DM3J746 MA Inhibitor DM3J746 RN Synthesis and inhibition of human acrosin and trypsin and acute toxicity of aryl 4-guanidinobenzoates. J Med Chem. 1986 Apr;29(4):514-9. DM3J746 RU https://pubmed.ncbi.nlm.nih.gov/3514912 DM3J746 DI DM3J746 DM3J746 DN PMID3514912C9 DM3J746 TI TT2WR1T DM3J746 TN Cationic trypsinogen (PRSS1) DM3J746 MA Inhibitor DM3J746 RN Synthesis and inhibition of human acrosin and trypsin and acute toxicity of aryl 4-guanidinobenzoates. J Med Chem. 1986 Apr;29(4):514-9. DM3J746 RU https://pubmed.ncbi.nlm.nih.gov/3514912 DM3JB6S DI DM3JB6S DM3JB6S DN 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole DM3JB6S TI TTER6YH DM3JB6S TN Casein kinase II alpha (CSNK2A1) DM3JB6S MA Inhibitor DM3JB6S RN Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. DM3JB6S RU https://pubmed.ncbi.nlm.nih.gov/19414254 DM3JBLK DI DM3JBLK DM3JBLK DN PIK-93 DM3JBLK TI TTNPL3B DM3JBLK TN Phosphatidylinositol-4-kinase beta (PI4KB) DM3JBLK MA Inhibitor DM3JBLK RN A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. DM3JBLK RU https://pubmed.ncbi.nlm.nih.gov/16647110 DM3JGVF DI DM3JGVF DM3JGVF DN 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF TI TTWG9A4 DM3JGVF TN Adrenergic receptor alpha-2A (ADRA2A) DM3JGVF MA Inhibitor DM3JGVF RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM3JGVF RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM3JGVF DI DM3JGVF DM3JGVF DN 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF TI TT3WG5C DM3JGVF TN Monoamine oxidase type A (MAO-A) DM3JGVF MA Inhibitor DM3JGVF RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM3JGVF RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM3JGVF DI DM3JGVF DM3JGVF DN 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF TI TTGP7BY DM3JGVF TN Monoamine oxidase type B (MAO-B) DM3JGVF MA Inhibitor DM3JGVF RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM3JGVF RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM3JGVF DI DM3JGVF DM3JGVF DN 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF TI TTJQOD7 DM3JGVF TN 5-HT 2A receptor (HTR2A) DM3JGVF MA Inhibitor DM3JGVF RN Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8. DM3JGVF RU https://pubmed.ncbi.nlm.nih.gov/11755343 DM3JGVF DI DM3JGVF DM3JGVF DN 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF TI TTWM4TY DM3JGVF TN Adrenergic receptor alpha-2B (ADRA2B) DM3JGVF MA Inhibitor DM3JGVF RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM3JGVF RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM3JGVF DI DM3JGVF DM3JGVF DN 1,2,3,4-Tetrahydro-pyrazino[1,2-a]indole DM3JGVF TI TT2NUT5 DM3JGVF TN Adrenergic receptor alpha-2C (ADRA2C) DM3JGVF MA Inhibitor DM3JGVF RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM3JGVF RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM3JHRC DI DM3JHRC DM3JHRC DN [Leu8,des-Arg9]bradykinin DM3JHRC TI TTGY8IW DM3JHRC TN B2 bradykinin receptor (BDKRB2) DM3JHRC MA Agonist DM3JHRC RN Partial agonists and full antagonists at the human and murine bradykinin B1 receptors. Can J Physiol Pharmacol. 1997 Jun;75(6):735-40. DM3JHRC RU https://pubmed.ncbi.nlm.nih.gov/9276157 DM3JHVL DI DM3JHVL DM3JHVL DN 1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one DM3JHVL TI TTDP1UC DM3JHVL TN Fatty acid amide hydrolase (FAAH) DM3JHVL MA Inhibitor DM3JHVL RN 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52. DM3JHVL RU https://pubmed.ncbi.nlm.nih.gov/20005725 DM3JHVL DI DM3JHVL DM3JHVL DN 1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one DM3JHVL TI TTT1JVS DM3JHVL TN Cytosolic phospholipase A2 (GIVA cPLA2) DM3JHVL MA Inhibitor DM3JHVL RN 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52. DM3JHVL RU https://pubmed.ncbi.nlm.nih.gov/20005725 DM3JM7V DI DM3JM7V DM3JM7V DN 2-(2-Amino-ethyl)-7-imino-azepane DM3JM7V TI TTF10I9 DM3JM7V TN Nitric-oxide synthase inducible (NOS2) DM3JM7V MA Inhibitor DM3JM7V RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DM3JM7V RU https://pubmed.ncbi.nlm.nih.gov/11551770 DM3JM7V DI DM3JM7V DM3JM7V DN 2-(2-Amino-ethyl)-7-imino-azepane DM3JM7V TI TTZUFI5 DM3JM7V TN Nitric-oxide synthase brain (NOS1) DM3JM7V MA Inhibitor DM3JM7V RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DM3JM7V RU https://pubmed.ncbi.nlm.nih.gov/11551770 DM3JNRC DI DM3JNRC DM3JNRC DN AL-6802 DM3JNRC TI TTGKNB4 DM3JNRC TN Epidermal growth factor receptor (EGFR) DM3JNRC MA Modulator DM3JNRC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM3JNRC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM3JQYD DI DM3JQYD DM3JQYD DN N-propylnorlitebamine DM3JQYD TI TT1RS9F DM3JQYD TN Acetylcholinesterase (AChE) DM3JQYD MA Inhibitor DM3JQYD RN Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50. DM3JQYD RU https://pubmed.ncbi.nlm.nih.gov/9461651 DM3JURW DI DM3JURW DM3JURW DN 2,6-Diphenyl-pyrimidin-4-ylamine DM3JURW TI TTK25J1 DM3JURW TN Adenosine A1 receptor (ADORA1) DM3JURW MA Inhibitor DM3JURW RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DM3JURW RU https://pubmed.ncbi.nlm.nih.gov/18258439 DM3JURW DI DM3JURW DM3JURW DN 2,6-Diphenyl-pyrimidin-4-ylamine DM3JURW TI TTM2AOE DM3JURW TN Adenosine A2a receptor (ADORA2A) DM3JURW MA Inhibitor DM3JURW RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DM3JURW RU https://pubmed.ncbi.nlm.nih.gov/18258439 DM3K1EO DI DM3K1EO DM3K1EO DN 8-Iodo-Guanine DM3K1EO TI TTMCF1Y DM3K1EO TN Purine nucleoside phosphorylase (PNP) DM3K1EO MA Inhibitor DM3K1EO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3K1EO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3K2TI DI DM3K2TI DM3K2TI DN (2R)-2-Methyl-4,5-dideoxy DM3K2TI TI TTZ3IFB DM3K2TI TN Phosphogluconate dehydrogenase (PGD) DM3K2TI MA Inhibitor DM3K2TI RN Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg Med Chem. 2003 Jul 17;11(14):3205-14. DM3K2TI RU https://pubmed.ncbi.nlm.nih.gov/12818683 DM3K5RI DI DM3K5RI DM3K5RI DN 1,2-bis(3,5-difluorophenyl)ethane-1,2-dione DM3K5RI TI TTMF541 DM3K5RI TN Liver carboxylesterase (CES1) DM3K5RI MA Inhibitor DM3K5RI RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM3K5RI RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM3K8PT DI DM3K8PT DM3K8PT DN Va-RYYRIK-NH2 DM3K8PT TI TTNT7K8 DM3K8PT TN Nociceptin receptor (OPRL1) DM3K8PT MA Inhibitor DM3K8PT RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DM3K8PT RU https://pubmed.ncbi.nlm.nih.gov/18068993 DM3KAY5 DI DM3KAY5 DM3KAY5 DN PD-117558 DM3KAY5 TI TTN6J5F DM3KAY5 TN Bacterial DNA gyrase (Bact gyrase) DM3KAY5 MA Modulator DM3KAY5 RN 1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids.New quantitative structure-activity relationships at N1 for the quinolone antibacterials.J Med Chem.1988 May;31(5):991-1001. DM3KAY5 RU https://www.ncbi.nlm.nih.gov/pubmed/2834557 DM3KB4H DI DM3KB4H DM3KB4H DN CVS-2359 DM3KB4H TI TT2WR1T DM3KB4H TN Cationic trypsinogen (PRSS1) DM3KB4H MA Inhibitor DM3KB4H RN Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1203-8. DM3KB4H RU https://pubmed.ncbi.nlm.nih.gov/11934589 DM3KCL1 DI DM3KCL1 DM3KCL1 DN 4-(4-m-Tolylamino-phthalazin-1-yl)-benzamide DM3KCL1 TI TTUTJGQ DM3KCL1 TN Vascular endothelial growth factor receptor 2 (KDR) DM3KCL1 MA Inhibitor DM3KCL1 RN Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8. DM3KCL1 RU https://pubmed.ncbi.nlm.nih.gov/16143524 DM3KJ45 DI DM3KJ45 DM3KJ45 DN [3H]estradiol-17beta-glucuronide DM3KJ45 TI TTU86P0 DM3KJ45 TN Liver organic anion transporter 2 (SLCO1B3) DM3KJ45 MA Modulator DM3KJ45 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1221). DM3KJ45 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1221 DM3KJ45 DI DM3KJ45 DM3KJ45 DN [3H]estradiol-17beta-glucuronide DM3KJ45 TI TTFGXEB DM3KJ45 TN Liver organic anion transporter 1 (SLCO1B1) DM3KJ45 MA Modulator DM3KJ45 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1220). DM3KJ45 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1220 DM3KN2F DI DM3KN2F DM3KN2F DN SNAP-7915 DM3KN2F TI TTNGILX DM3KN2F TN Adrenergic receptor alpha-1A (ADRA1A) DM3KN2F MA Inhibitor DM3KN2F RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DM3KN2F RU https://pubmed.ncbi.nlm.nih.gov/15664832 DM3KNSY DI DM3KNSY DM3KNSY DN N-(9H-beta-Carbolin-3-yl)-formamide DM3KNSY TI TT1MPAY DM3KNSY TN GABA(A) receptor alpha-1 (GABRA1) DM3KNSY MA Inhibitor DM3KNSY RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DM3KNSY RU https://pubmed.ncbi.nlm.nih.gov/2989520 DM3KNSY DI DM3KNSY DM3KNSY DN N-(9H-beta-Carbolin-3-yl)-formamide DM3KNSY TI TTNJYV2 DM3KNSY TN Gamma-aminobutyric acid receptor (GAR) DM3KNSY MA Inhibitor DM3KNSY RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DM3KNSY RU https://pubmed.ncbi.nlm.nih.gov/2989520 DM3KU46 DI DM3KU46 DM3KU46 DN THIIC DM3KU46 TI TTXJ47W DM3KU46 TN Metabotropic glutamate receptor 2 (mGluR2) DM3KU46 MA Modulator (allosteric modulator) DM3KU46 RN N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther. 2011 Jan;336(1):165-77. DM3KU46 RU https://pubmed.ncbi.nlm.nih.gov/20947638 DM3KWER DI DM3KWER DM3KWER DN JWH-404 DM3KWER TI TTMSFAW DM3KWER TN Cannabinoid receptor 2 (CB2) DM3KWER MA Inhibitor DM3KWER RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM3KWER RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM3KWER DI DM3KWER DM3KWER DN JWH-404 DM3KWER TI TT6OEDT DM3KWER TN Cannabinoid receptor 1 (CB1) DM3KWER MA Inhibitor DM3KWER RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM3KWER RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM3KZ7P DI DM3KZ7P DM3KZ7P DN Angiostatin/paclitaxel/carboplatin DM3KZ7P TI TT63KYR DM3KZ7P TN Tubulin beta-1 chain (TUBB1) DM3KZ7P MA Modulator DM3KZ7P RN Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850). Pharm Res. 2005 Mar;22(3):347-55. DM3KZ7P RU https://pubmed.ncbi.nlm.nih.gov/15835739 DM3L0F8 DI DM3L0F8 DM3L0F8 DN 3-iodothyronamine DM3L0F8 TI TTIU98M DM3L0F8 TN Trace amine-associated receptor-1 (TAAR1) DM3L0F8 MA Agonist DM3L0F8 RN Exploring the structure-activity relationship of the ethylamine portion of 3-iodothyronamine for rat and mouse trace amine-associated receptor 1. J Med Chem. 2007 Jun 14;50(12):2787-98. DM3L0F8 RU https://pubmed.ncbi.nlm.nih.gov/17497842 DM3L2OI DI DM3L2OI DM3L2OI DN 6-(4-Hydroxy-phenyl)-naphthalen-2-ol DM3L2OI TI TTZAYWL DM3L2OI TN Estrogen receptor (ESR) DM3L2OI MA Inhibitor DM3L2OI RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM3L2OI RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM3L2OI DI DM3L2OI DM3L2OI DN 6-(4-Hydroxy-phenyl)-naphthalen-2-ol DM3L2OI TI TTOM3J0 DM3L2OI TN Estrogen receptor beta (ESR2) DM3L2OI MA Inhibitor DM3L2OI RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM3L2OI RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM3L5I6 DI DM3L5I6 DM3L5I6 DN 4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine DM3L5I6 TI TTJS8PY DM3L5I6 TN 5-HT 6 receptor (HTR6) DM3L5I6 MA Inhibitor DM3L5I6 RN Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3793-6. DM3L5I6 RU https://pubmed.ncbi.nlm.nih.gov/16709453 DM3L76R DI DM3L76R DM3L76R DN 4-methoxyphenyl 10H-phenothiazine-10-carboxylate DM3L76R TI TTEB0GD DM3L76R TN Cholinesterase (BCHE) DM3L76R MA Inhibitor DM3L76R RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DM3L76R RU https://pubmed.ncbi.nlm.nih.gov/18570368 DM3LCDK DI DM3LCDK DM3LCDK DN AIDA DM3LCDK TI TTVBPDM DM3LCDK TN Metabotropic glutamate receptor 1 (mGluR1) DM3LCDK MA Antagonist DM3LCDK RN [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93. DM3LCDK RU https://pubmed.ncbi.nlm.nih.gov/12695537 DM3LDFB DI DM3LDFB DM3LDFB DN Simoctocog alfa DM3LDFB TI TT1290U DM3LDFB TN Coagulation factor VIII (F8) DM3LDFB MA Modulator DM3LDFB RN A new recombinant factor VIII: from genetics to clinical use DM3LDFB RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517516 DM3LGOT DI DM3LGOT DM3LGOT DN 4-(3-bromophenoxy)-6-chloroquinazoline DM3LGOT TI TTHS256 DM3LGOT TN Metabotropic glutamate receptor 5 (mGluR5) DM3LGOT MA Inhibitor DM3LGOT RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DM3LGOT RU https://pubmed.ncbi.nlm.nih.gov/19854049 DM3LM6B DI DM3LM6B DM3LM6B DN 3-phenyl-cyclosal-d4TMP DM3LM6B TI TTEB0GD DM3LM6B TN Cholinesterase (BCHE) DM3LM6B MA Inhibitor DM3LM6B RN Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46. DM3LM6B RU https://pubmed.ncbi.nlm.nih.gov/17328534 DM3LMIS DI DM3LMIS DM3LMIS DN 5-fluoro-6-iodo-UMP DM3LMIS TI TTAFJUD DM3LMIS TN Orotidine 5'-monophosphate decarboxylase (UMPS) DM3LMIS MA Inhibitor DM3LMIS RN Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58. DM3LMIS RU https://pubmed.ncbi.nlm.nih.gov/19260677 DM3LQF4 DI DM3LQF4 DM3LQF4 DN SB 204741 DM3LQF4 TI TTWJBZ5 DM3LQF4 TN 5-HT 2C receptor (HTR2C) DM3LQF4 MA Antagonist DM3LQF4 RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM3LQF4 RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM3LQF4 DI DM3LQF4 DM3LQF4 DN SB 204741 DM3LQF4 TI TT0K1SC DM3LQF4 TN 5-HT 2B receptor (HTR2B) DM3LQF4 MA Antagonist DM3LQF4 RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM3LQF4 RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM3LQFK DI DM3LQFK DM3LQFK DN (R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline DM3LQFK TI TTQ6VDM DM3LQFK TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM3LQFK MA Inhibitor DM3LQFK RN In vitro studies on a class of quinoline containing histamine H3 antagonists. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300. DM3LQFK RU https://pubmed.ncbi.nlm.nih.gov/20457525 DM3LQFK DI DM3LQFK DM3LQFK DN (R)-6-(2-(2-methylpyrrolidin-1-yl)ethyl)quinoline DM3LQFK TI TT9JNIC DM3LQFK TN Histamine H3 receptor (H3R) DM3LQFK MA Inhibitor DM3LQFK RN In vitro studies on a class of quinoline containing histamine H3 antagonists. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3295-300. DM3LQFK RU https://pubmed.ncbi.nlm.nih.gov/20457525 DM3LY0Q DI DM3LY0Q DM3LY0Q DN 5'-Methylthio-ImmH DM3LY0Q TI TTMCF1Y DM3LY0Q TN Purine nucleoside phosphorylase (PNP) DM3LY0Q MA Inhibitor DM3LY0Q RN Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3. DM3LY0Q RU https://pubmed.ncbi.nlm.nih.gov/18778937 DM3M1LA DI DM3M1LA DM3M1LA DN CP-809101 DM3M1LA TI TTWJBZ5 DM3M1LA TN 5-HT 2C receptor (HTR2C) DM3M1LA MA Agonist DM3M1LA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8). DM3M1LA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8 DM3M4RA DI DM3M4RA DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine DM3M4RA TI TTO9X1H DM3M4RA TN 5-HT 7 receptor (HTR7) DM3M4RA MA Agonist DM3M4RA RN Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4. DM3M4RA RU https://pubmed.ncbi.nlm.nih.gov/8394362 DM3M4RA DI DM3M4RA DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine DM3M4RA TI TT34BHT DM3M4RA TN Adrenergic receptor alpha-1D (ADRA1D) DM3M4RA MA Inhibitor DM3M4RA RN Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4. DM3M4RA RU https://pubmed.ncbi.nlm.nih.gov/1648138 DM3M4RA DI DM3M4RA DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine DM3M4RA TI TT6MSOK DM3M4RA TN 5-HT 1D receptor (HTR1D) DM3M4RA MA Inhibitor DM3M4RA RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM3M4RA RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM3M4RA DI DM3M4RA DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine DM3M4RA TI TTNGILX DM3M4RA TN Adrenergic receptor alpha-1A (ADRA1A) DM3M4RA MA Inhibitor DM3M4RA RN Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4. DM3M4RA RU https://pubmed.ncbi.nlm.nih.gov/1648138 DM3M4RA DI DM3M4RA DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine DM3M4RA TI TTJQOD7 DM3M4RA TN 5-HT 2A receptor (HTR2A) DM3M4RA MA Inhibitor DM3M4RA RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DM3M4RA RU https://pubmed.ncbi.nlm.nih.gov/3701781 DM3M4RA DI DM3M4RA DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine DM3M4RA TI TTSQIFT DM3M4RA TN 5-HT 1A receptor (HTR1A) DM3M4RA MA Inhibitor DM3M4RA RN Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4. DM3M4RA RU https://pubmed.ncbi.nlm.nih.gov/1648138 DM3M4RA DI DM3M4RA DM3M4RA DN 1-(2-Methoxy-phenyl)-piperazine DM3M4RA TI TTJS8PY DM3M4RA TN 5-HT 6 receptor (HTR6) DM3M4RA MA Inhibitor DM3M4RA RN 1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11. DM3M4RA RU https://pubmed.ncbi.nlm.nih.gov/15745826 DM3M5AW DI DM3M5AW DM3M5AW DN CR-4174 DM3M5AW TI TTVKILB DM3M5AW TN Prostaglandin G/H synthase 2 (COX-2) DM3M5AW MA Inhibitor DM3M5AW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376). DM3M5AW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376 DM3M652 DI DM3M652 DM3M652 DN Daio-Orengedokuto (DOT) DM3M652 TI TTXMY0J DM3M652 TN Pancreatic triacylglycerol lipase (PNLIP) DM3M652 MA Inhibitor DM3M652 RN Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5. DM3M652 RU https://pubmed.ncbi.nlm.nih.gov/12419956 DM3MAEQ DI DM3MAEQ DM3MAEQ DN 3,4,6-Trihydroxy-2-(4-hydroxy-phenyl)-inden-1-one DM3MAEQ TI TTOM3J0 DM3MAEQ TN Estrogen receptor beta (ESR2) DM3MAEQ MA Inhibitor DM3MAEQ RN Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42. DM3MAEQ RU https://pubmed.ncbi.nlm.nih.gov/15876535 DM3MBGV DI DM3MBGV DM3MBGV DN [3H]sumatriptan DM3MBGV TI TT6MSOK DM3MBGV TN 5-HT 1D receptor (HTR1D) DM3MBGV MA Agonist DM3MBGV RN Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. DM3MBGV RU https://pubmed.ncbi.nlm.nih.gov/10193663 DM3MBGV DI DM3MBGV DM3MBGV DN [3H]sumatriptan DM3MBGV TI TTK8CXU DM3MBGV TN 5-HT 1B receptor (HTR1B) DM3MBGV MA Agonist DM3MBGV RN Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. DM3MBGV RU https://pubmed.ncbi.nlm.nih.gov/10193663 DM3MEQB DI DM3MEQB DM3MEQB DN (R/S)-2-((4-benzylphenoxy)methyl)piperazine DM3MEQB TI TTXZEAJ DM3MEQB TN Leukotriene A-4 hydrolase (LTA4H) DM3MEQB MA Inhibitor DM3MEQB RN Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4. DM3MEQB RU https://pubmed.ncbi.nlm.nih.gov/20371179 DM3MID9 DI DM3MID9 DM3MID9 DN KYS-05001 DM3MID9 TI TTZPWGN DM3MID9 TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DM3MID9 MA Inhibitor DM3MID9 RN 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84. DM3MID9 RU https://pubmed.ncbi.nlm.nih.gov/15177437 DM3MID9 DI DM3MID9 DM3MID9 DN KYS-05001 DM3MID9 TI TT729IR DM3MID9 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM3MID9 MA Inhibitor DM3MID9 RN Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3. DM3MID9 RU https://pubmed.ncbi.nlm.nih.gov/17869104 DM3MK8S DI DM3MK8S DM3MK8S DN [3H]vesamicol DM3MK8S TI TTV8KWS DM3MK8S TN Vesicular acetylcholine transporter (SLC18A3) DM3MK8S MA Modulator DM3MK8S RN Active transport of acetylcholine by the human vesicular acetylcholine transporter. J Biol Chem. 1996 Nov 1;271(44):27229-32. DM3MK8S RU https://pubmed.ncbi.nlm.nih.gov/8910293 DM3MK9Z DI DM3MK9Z DM3MK9Z DN G3139 + Paclitaxel DM3MK9Z TI TTFOUV4 DM3MK9Z TN BCL-2 messenger RNA (BCL2 mRNA) DM3MK9Z RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM3MK9Z RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM3ML0N DI DM3ML0N DM3ML0N DN Tramazoline DM3ML0N TI TTWG9A4 DM3ML0N TN Adrenergic receptor alpha-2A (ADRA2A) DM3ML0N MA Inhibitor DM3ML0N RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DM3ML0N RU https://pubmed.ncbi.nlm.nih.gov/6296387 DM3ML0N DI DM3ML0N DM3ML0N DN Tramazoline DM3ML0N TI TTWM4TY DM3ML0N TN Adrenergic receptor alpha-2B (ADRA2B) DM3ML0N MA Inhibitor DM3ML0N RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DM3ML0N RU https://pubmed.ncbi.nlm.nih.gov/6296387 DM3ML0N DI DM3ML0N DM3ML0N DN Tramazoline DM3ML0N TI TT2NUT5 DM3ML0N TN Adrenergic receptor alpha-2C (ADRA2C) DM3ML0N MA Inhibitor DM3ML0N RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DM3ML0N RU https://pubmed.ncbi.nlm.nih.gov/6296387 DM3MSZN DI DM3MSZN DM3MSZN DN 5,N-Dihydroxythalidomide DM3MSZN TI TTUV8G9 DM3MSZN TN Progesterone receptor (PGR) DM3MSZN MA Inhibitor DM3MSZN RN Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54. DM3MSZN RU https://pubmed.ncbi.nlm.nih.gov/18586498 DM3MUF1 DI DM3MUF1 DM3MUF1 DN 4-amino-2H-chromen-2-one DM3MUF1 TI TT8XK6L DM3MUF1 TN Quinone reductase 1 (NQO1) DM3MUF1 MA Inhibitor DM3MUF1 RN Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human panc... J Med Chem. 2007 Dec 13;50(25):6316-25. DM3MUF1 RU https://pubmed.ncbi.nlm.nih.gov/17999461 DM3MVSD DI DM3MVSD DM3MVSD DN 5-Methylsulfanyl-thiophene-2-carboxamidine DM3MVSD TI TTGY7WI DM3MVSD TN Urokinase-type plasminogen activator (PLAU) DM3MVSD MA Inhibitor DM3MVSD RN Design and synthesis of 4,5-disubstituted-thiophene-2-amidines as potent urokinase inhibitors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):491-5. DM3MVSD RU https://pubmed.ncbi.nlm.nih.gov/11814826 DM3MXI5 DI DM3MXI5 DM3MXI5 DN 7-methoxy-1-naphthylpiperazine DM3MXI5 TI TTK8CXU DM3MXI5 TN 5-HT 1B receptor (HTR1B) DM3MXI5 MA Agonist DM3MXI5 RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DM3MXI5 RU https://pubmed.ncbi.nlm.nih.gov/9397179 DM3MXI5 DI DM3MXI5 DM3MXI5 DN 7-methoxy-1-naphthylpiperazine DM3MXI5 TI TT6MSOK DM3MXI5 TN 5-HT 1D receptor (HTR1D) DM3MXI5 MA Agonist DM3MXI5 RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DM3MXI5 RU https://pubmed.ncbi.nlm.nih.gov/9397179 DM3MXI5 DI DM3MXI5 DM3MXI5 DN 7-methoxy-1-naphthylpiperazine DM3MXI5 TI TTSQIFT DM3MXI5 TN 5-HT 1A receptor (HTR1A) DM3MXI5 MA Agonist DM3MXI5 RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DM3MXI5 RU https://pubmed.ncbi.nlm.nih.gov/9397179 DM3N9O5 DI DM3N9O5 DM3N9O5 DN 4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide DM3N9O5 TI TTDCBX5 DM3N9O5 TN Vascular endothelial growth factor receptor 3 (FLT-4) DM3N9O5 MA Inhibitor DM3N9O5 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DM3N9O5 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DM3N9O5 DI DM3N9O5 DM3N9O5 DN 4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide DM3N9O5 TI TT1VAUK DM3N9O5 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM3N9O5 MA Inhibitor DM3N9O5 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DM3N9O5 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DM3N9O5 DI DM3N9O5 DM3N9O5 DN 4-(5-Phenyl-oxazol-2-ylamino)-benzenesulfonamide DM3N9O5 TI TTUTJGQ DM3N9O5 TN Vascular endothelial growth factor receptor 2 (KDR) DM3N9O5 MA Inhibitor DM3N9O5 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DM3N9O5 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DM3NBQ6 DI DM3NBQ6 DM3NBQ6 DN rose bengal (photoactivated) DM3NBQ6 TI TTXF0ZW DM3NBQ6 TN Inward rectifier potassium channel Kir2.3 (KCNJ4) DM3NBQ6 MA Inhibitor (gating inhibitor) DM3NBQ6 RN Susceptibility of cloned K+ channels to reactive oxygen species. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11796-800. DM3NBQ6 RU https://pubmed.ncbi.nlm.nih.gov/8524851 DM3NCM1 DI DM3NCM1 DM3NCM1 DN Alpha-D-Mannose-6-Phosphate DM3NCM1 TI TTLP3GX DM3NCM1 TN Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC) DM3NCM1 MA Inhibitor DM3NCM1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3NCM1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3NCM1 DI DM3NCM1 DM3NCM1 DN Alpha-D-Mannose-6-Phosphate DM3NCM1 TI TT95ICL DM3NCM1 TN Mannose-6-phosphate receptor (M6PR) DM3NCM1 MA Inhibitor DM3NCM1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3NCM1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3NDWK DI DM3NDWK DM3NDWK DN MK-1925 DM3NDWK TI TTQW87Y DM3NDWK TN Opioid receptor kappa (OPRK1) DM3NDWK MA Inhibitor DM3NDWK RN Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32. DM3NDWK RU https://pubmed.ncbi.nlm.nih.gov/19564110 DM3NDWK DI DM3NDWK DM3NDWK DN MK-1925 DM3NDWK TI TTQ6VDM DM3NDWK TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM3NDWK MA Inhibitor DM3NDWK RN Identification of MK-1925: a selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4729-32. DM3NDWK RU https://pubmed.ncbi.nlm.nih.gov/19564110 DM3NEYB DI DM3NEYB DM3NEYB DN 4-(1-cyclopentyl-7-fluoro-1H-indazol-3-yl)phenol DM3NEYB TI TTZAYWL DM3NEYB TN Estrogen receptor (ESR) DM3NEYB MA Inhibitor DM3NEYB RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DM3NEYB RU https://pubmed.ncbi.nlm.nih.gov/15588074 DM3NQDW DI DM3NQDW DM3NQDW DN NSC-125034 DM3NQDW TI TT12ABZ DM3NQDW TN Arachidonate 12-lipoxygenase (12-LOX) DM3NQDW MA Inhibitor DM3NQDW RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DM3NQDW RU https://pubmed.ncbi.nlm.nih.gov/17826100 DM3NUKX DI DM3NUKX DM3NUKX DN PP2-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O) DM3NUKX TI TTB2MXP DM3NUKX TN Angiotensinogenase renin (REN) DM3NUKX MA Inhibitor DM3NUKX RN Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42. DM3NUKX RU https://pubmed.ncbi.nlm.nih.gov/1995887 DM3NUMG DI DM3NUMG DM3NUMG DN 5-methoxy-2-(4-dimethylaminophenyl)benzofuran DM3NUMG TI TTE4KHA DM3NUMG TN Amyloid beta A4 protein (APP) DM3NUMG MA Inhibitor DM3NUMG RN Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. DM3NUMG RU https://pubmed.ncbi.nlm.nih.gov/16640332 DM3NVLB DI DM3NVLB DM3NVLB DN 1-(4-Methylpent-3-en-2-ylidene)thiosemicarbazide DM3NVLB TI TTULVH8 DM3NVLB TN Tyrosinase (TYR) DM3NVLB MA Inhibitor DM3NVLB RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DM3NVLB RU https://pubmed.ncbi.nlm.nih.gov/18524420 DM3NXMB DI DM3NXMB DM3NXMB DN VU0360172 DM3NXMB TI TTHS256 DM3NXMB TN Metabotropic glutamate receptor 5 (mGluR5) DM3NXMB MA Modulator (allosteric modulator) DM3NXMB RN Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010 Dec;78(6):1105-23. DM3NXMB RU https://pubmed.ncbi.nlm.nih.gov/20923853 DM3O4FI DI DM3O4FI DM3O4FI DN (+/-)-threo-3-Fluororitalinol DM3O4FI TI TTVBI8W DM3O4FI TN Dopamine transporter (DAT) DM3O4FI MA Inhibitor DM3O4FI RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM3O4FI RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM3O78D DI DM3O78D DM3O78D DN PO3 2-Leu-Trp-O-3K DM3O78D TI TTQ9RYT DM3O78D TN Endothelin-converting enzyme 1 (ECE1) DM3O78D MA Inhibitor DM3O78D RN Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994). DM3O78D RU http://www.sciencedirect.com/science/article/pii/S0960894X01803413 DM3O9YW DI DM3O9YW DM3O9YW DN O-Phosphoethanolamine DM3O9YW TI TTYPXQF DM3O9YW TN Protein kinase C beta (PRKCB) DM3O9YW MA Inhibitor DM3O9YW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3O9YW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3OEP4 DI DM3OEP4 DM3OEP4 DN ML221 DM3OEP4 TI TTJ8E43 DM3OEP4 TN Apelin receptor (APLNR) DM3OEP4 MA Antagonist DM3OEP4 RN Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett. 2012 Nov 1;22(21):6656-60. DM3OEP4 RU https://pubmed.ncbi.nlm.nih.gov/23010269 DM3OLM6 DI DM3OLM6 DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide DM3OLM6 TI TTT6LFV DM3OLM6 TN Histone deacetylase 8 (HDAC8) DM3OLM6 MA Inhibitor DM3OLM6 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM3OLM6 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM3OLM6 DI DM3OLM6 DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide DM3OLM6 TI TTTQGH8 DM3OLM6 TN Histone deacetylase 4 (HDAC4) DM3OLM6 MA Inhibitor DM3OLM6 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM3OLM6 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM3OLM6 DI DM3OLM6 DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide DM3OLM6 TI TT5ZKDI DM3OLM6 TN Histone deacetylase 6 (HDAC6) DM3OLM6 MA Inhibitor DM3OLM6 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM3OLM6 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM3OLM6 DI DM3OLM6 DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide DM3OLM6 TI TT6R7JZ DM3OLM6 TN Histone deacetylase 1 (HDAC1) DM3OLM6 MA Inhibitor DM3OLM6 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM3OLM6 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM3OLM6 DI DM3OLM6 DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide DM3OLM6 TI TTBH0VX DM3OLM6 TN Histone deacetylase (HDAC) DM3OLM6 MA Inhibitor DM3OLM6 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM3OLM6 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM3OLM6 DI DM3OLM6 DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide DM3OLM6 TI TTSHTOI DM3OLM6 TN Histone deacetylase 2 (HDAC2) DM3OLM6 MA Inhibitor DM3OLM6 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM3OLM6 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM3OLM6 DI DM3OLM6 DM3OLM6 DN 6-phenylsulfanylhexanoic acid hydroxamide DM3OLM6 TI TTYHPU6 DM3OLM6 TN Histone deacetylase 10 (HDAC10) DM3OLM6 MA Inhibitor DM3OLM6 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DM3OLM6 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DM3OMLU DI DM3OMLU DM3OMLU DN 7-chloro-3-hydroxyquinazoline-2,4-dione DM3OMLU TI TTVPQTF DM3OMLU TN Glutamate receptor AMPA 1 (GRIA1) DM3OMLU MA Inhibitor DM3OMLU RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DM3OMLU RU https://pubmed.ncbi.nlm.nih.gov/17004715 DM3OMLU DI DM3OMLU DM3OMLU DN 7-chloro-3-hydroxyquinazoline-2,4-dione DM3OMLU TI TTN9D8E DM3OMLU TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM3OMLU MA Inhibitor DM3OMLU RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DM3OMLU RU https://pubmed.ncbi.nlm.nih.gov/17004715 DM3OMLU DI DM3OMLU DM3OMLU DN 7-chloro-3-hydroxyquinazoline-2,4-dione DM3OMLU TI TTKJEMQ DM3OMLU TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM3OMLU MA Inhibitor DM3OMLU RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DM3OMLU RU https://pubmed.ncbi.nlm.nih.gov/17004715 DM3OMLU DI DM3OMLU DM3OMLU DN 7-chloro-3-hydroxyquinazoline-2,4-dione DM3OMLU TI TTAN6JD DM3OMLU TN Glutamate receptor AMPA (GRIA) DM3OMLU MA Inhibitor DM3OMLU RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DM3OMLU RU https://pubmed.ncbi.nlm.nih.gov/17004715 DM3OMLU DI DM3OMLU DM3OMLU DN 7-chloro-3-hydroxyquinazoline-2,4-dione DM3OMLU TI TTLD29N DM3OMLU TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM3OMLU MA Inhibitor DM3OMLU RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DM3OMLU RU https://pubmed.ncbi.nlm.nih.gov/17004715 DM3OPNE DI DM3OPNE DM3OPNE DN (35)S-labeled oligonucleotide DM3OPNE TI TTSXP1G DM3OPNE TN Protein kinase A alpha messenger RNA (PKA-alpha mRNA) DM3OPNE RN Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A. 1999 Nov23;96(24):13989-94. DM3OPNE RU https://pubmed.ncbi.nlm.nih.gov/10570186 DM3OPNE DI DM3OPNE DM3OPNE DN (35)S-labeled oligonucleotide DM3OPNE TI TTXQFV2 DM3OPNE TN Protein kinase A Ri alpha messenger RNA (PKA-Ri-alpha mRNA) DM3OPNE RN Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A. 1999 Nov23;96(24):13989-94. DM3OPNE RU https://pubmed.ncbi.nlm.nih.gov/10570186 DM3ORGM DI DM3ORGM DM3ORGM DN NADA DM3ORGM TI TTMI6F5 DM3ORGM TN Transient receptor potential cation channel V1 (TRPV1) DM3ORGM MA Blocker (channel blocker) DM3ORGM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DM3ORGM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DM3ORGM DI DM3ORGM DM3ORGM DN NADA DM3ORGM TI TTXDKTO DM3ORGM TN Long transient receptor potential channel 8 (TRPM8) DM3ORGM MA Blocker (channel blocker) DM3ORGM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500). DM3ORGM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=500 DM3OTZY DI DM3OTZY DM3OTZY DN 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran DM3OTZY TI TTVBI8W DM3OTZY TN Dopamine transporter (DAT) DM3OTZY MA Inhibitor DM3OTZY RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM3OTZY RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM3OTZY DI DM3OTZY DM3OTZY DN 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran DM3OTZY TI TT3ROYC DM3OTZY TN Serotonin transporter (SERT) DM3OTZY MA Inhibitor DM3OTZY RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM3OTZY RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM3OTZY DI DM3OTZY DM3OTZY DN 2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran DM3OTZY TI TTAWNKZ DM3OTZY TN Norepinephrine transporter (NET) DM3OTZY MA Inhibitor DM3OTZY RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM3OTZY RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM3P79O DI DM3P79O DM3P79O DN 5,7-Dimethyl-3-thiophen-3-yl-quinoline DM3P79O TI TTI7421 DM3P79O TN Platelet-derived growth factor receptor beta (PDGFRB) DM3P79O MA Inhibitor DM3P79O RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM3P79O RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM3P79O DI DM3P79O DM3P79O DN 5,7-Dimethyl-3-thiophen-3-yl-quinoline DM3P79O TI TT8FYO9 DM3P79O TN Platelet-derived growth factor receptor alpha (PDGFRA) DM3P79O MA Inhibitor DM3P79O RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM3P79O RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM3P7W5 DI DM3P7W5 DM3P7W5 DN IDD552 DM3P7W5 TI TTFBNVI DM3P7W5 TN Aldose reductase (AKR1B1) DM3P7W5 MA Inhibitor DM3P7W5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3P7W5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3PAS4 DI DM3PAS4 DM3PAS4 DN Pyridobenzimidazole DM3PAS4 TI TTZMS1L DM3PAS4 TN Fungal Papulacandin B resistance protein 1 (Fung FKS1) DM3PAS4 MA Inhibitor DM3PAS4 RN Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. DM3PAS4 RU https://pubmed.ncbi.nlm.nih.gov/19463273 DM3PIHV DI DM3PIHV DM3PIHV DN MCL-154 DM3PIHV TI TT27RFC DM3PIHV TN Opioid receptor delta (OPRD1) DM3PIHV MA Inhibitor DM3PIHV RN Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. DM3PIHV RU https://pubmed.ncbi.nlm.nih.gov/20144870 DM3PIHV DI DM3PIHV DM3PIHV DN MCL-154 DM3PIHV TI TTQW87Y DM3PIHV TN Opioid receptor kappa (OPRK1) DM3PIHV MA Inhibitor DM3PIHV RN Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. DM3PIHV RU https://pubmed.ncbi.nlm.nih.gov/20144870 DM3PIHV DI DM3PIHV DM3PIHV DN MCL-154 DM3PIHV TI TTKWM86 DM3PIHV TN Opioid receptor mu (MOP) DM3PIHV MA Inhibitor DM3PIHV RN Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. DM3PIHV RU https://pubmed.ncbi.nlm.nih.gov/20144870 DM3PK2G DI DM3PK2G DM3PK2G DN ISIS 103616 DM3PK2G TI TTBWMKT DM3PK2G TN WWP1 messenger RNA (WWP1 mRNA) DM3PK2G RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM3PK2G RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM3PRHF DI DM3PRHF DM3PRHF DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Ala-) DM3PRHF TI TTBID49 DM3PRHF TN C-X-C chemokine receptor type 4 (CXCR4) DM3PRHF MA Inhibitor DM3PRHF RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DM3PRHF RU https://pubmed.ncbi.nlm.nih.gov/17228861 DM3PVGC DI DM3PVGC DM3PVGC DN ISIS 9005 DM3PVGC TI TTR5TV4 DM3PVGC TN ERBB2 messenger RNA (HER2 mRNA) DM3PVGC RN US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression. DM3PVGC RU http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true DM3PWK7 DI DM3PWK7 DM3PWK7 DN 2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide DM3PWK7 TI TTJ4QE7 DM3PWK7 TN Matrix metalloproteinase-14 (MMP-14) DM3PWK7 MA Inhibitor DM3PWK7 RN Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35. DM3PWK7 RU https://pubmed.ncbi.nlm.nih.gov/20180536 DM3PWK7 DI DM3PWK7 DM3PWK7 DN 2-(biphenyl-4-ylsulfonamido)-N-hydroxyacetamide DM3PWK7 TI TT6AZXG DM3PWK7 TN TNF alpha converting enzyme (ADAM17) DM3PWK7 MA Inhibitor DM3PWK7 RN Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35. DM3PWK7 RU https://pubmed.ncbi.nlm.nih.gov/20180536 DM3PZUX DI DM3PZUX DM3PZUX DN ISIS 4759 DM3PZUX TI TT1PL7M DM3PZUX TN E-selectin messenger RNA (SELE mRNA) DM3PZUX RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DM3PZUX RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DM3Q0JL DI DM3Q0JL DM3Q0JL DN L-5-iodo-2'-deoxyuridine DM3Q0JL TI TTP3QRF DM3Q0JL TN Thymidine kinase 1 (TK1) DM3Q0JL MA Inhibitor DM3Q0JL RN Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. DM3Q0JL RU https://pubmed.ncbi.nlm.nih.gov/17438061 DM3Q5NO DI DM3Q5NO DM3Q5NO DN MRS1505 DM3Q5NO TI TTJFY5U DM3Q5NO TN Adenosine A3 receptor (ADORA3) DM3Q5NO MA Antagonist DM3Q5NO RN Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201. DM3Q5NO RU https://pubmed.ncbi.nlm.nih.gov/9703464 DM3Q5SU DI DM3Q5SU DM3Q5SU DN Ac-I[CVYQDWGAHRC]T-NH2 DM3Q5SU TI TTJGY7A DM3Q5SU TN Complement C3 (CO3) DM3Q5SU MA Inhibitor DM3Q5SU RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DM3Q5SU RU https://pubmed.ncbi.nlm.nih.gov/15634022 DM3QE8P DI DM3QE8P DM3QE8P DN Turmeric extracts DM3QE8P TI TTE4KHA DM3QE8P TN Amyloid beta A4 protein (APP) DM3QE8P MA Inhibitor DM3QE8P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM3QE8P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM3QFCV DI DM3QFCV DM3QFCV DN 5-(4-Phenylbutoxy)psoralen DM3QFCV TI TTY3UE6 DM3QFCV TN Voltage-gated potassium channel Kv1.3 (KCNA3) DM3QFCV MA Inhibitor DM3QFCV RN Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Mol Pharmacol. 2004 Jun;65(6):1364-74. DM3QFCV RU https://pubmed.ncbi.nlm.nih.gov/15155830 DM3QJVT DI DM3QJVT DM3QJVT DN 4-(3H-Inden-1-ylmethyl)-phenylamine DM3QJVT TI TTJS8PY DM3QJVT TN 5-HT 6 receptor (HTR6) DM3QJVT MA Inhibitor DM3QJVT RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DM3QJVT RU https://pubmed.ncbi.nlm.nih.gov/15808453 DM3QUCS DI DM3QUCS DM3QUCS DN L-708474 DM3QUCS TI TTCG0AL DM3QUCS TN Cholecystokinin receptor type A (CCKAR) DM3QUCS MA Inhibitor DM3QUCS RN High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem. 1994 Mar 18;37(6):719-21. DM3QUCS RU https://pubmed.ncbi.nlm.nih.gov/8145219 DM3QV95 DI DM3QV95 DM3QV95 DN 8-(2,3,4-trimethoxyphenyl)-9H-purine-2,6-diamine DM3QV95 TI TT9SL3Q DM3QV95 TN Polypeptide deformylase (PDF) DM3QV95 MA Inhibitor DM3QV95 RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DM3QV95 RU https://pubmed.ncbi.nlm.nih.gov/20117005 DM3QVOB DI DM3QVOB DM3QVOB DN Cyclo(RGDfV) (control) DM3QVOB TI TTT1R2L DM3QVOB TN Integrin alpha-V (ITGAV) DM3QVOB MA Inhibitor DM3QVOB RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DM3QVOB RU https://pubmed.ncbi.nlm.nih.gov/16570923 DM3QVOB DI DM3QVOB DM3QVOB DN Cyclo(RGDfV) (control) DM3QVOB TI TTJA1ZO DM3QVOB TN ITGB3 messenger RNA (ITGB3 mRNA) DM3QVOB MA Inhibitor DM3QVOB RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DM3QVOB RU https://pubmed.ncbi.nlm.nih.gov/16570923 DM3QWZU DI DM3QWZU DM3QWZU DN N-(2,4-dimethoxyphenethyl)docos-13-enamide DM3QWZU TI TT6OEDT DM3QWZU TN Cannabinoid receptor 1 (CB1) DM3QWZU MA Inhibitor DM3QWZU RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM3QWZU RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM3R2D1 DI DM3R2D1 DM3R2D1 DN 4-(2'-(trifluoromethoxy)biphenyl-3-yl)thiazole DM3R2D1 TI TT4G2JS DM3R2D1 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DM3R2D1 MA Inhibitor DM3R2D1 RN Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40. DM3R2D1 RU https://pubmed.ncbi.nlm.nih.gov/20709552 DM3R4ZF DI DM3R4ZF DM3R4ZF DN HI-236 DM3R4ZF TI TT84ETX DM3R4ZF TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3R4ZF MA Inhibitor DM3R4ZF RN Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90. DM3R4ZF RU https://pubmed.ncbi.nlm.nih.gov/10636251 DM3R8OM DI DM3R8OM DM3R8OM DN 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL DM3R8OM TI TTZAYWL DM3R8OM TN Estrogen receptor (ESR) DM3R8OM MA Inhibitor DM3R8OM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM3R8OM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM3R8YL DI DM3R8YL DM3R8YL DN Erythropoietin DM3R8YL TI TTAUX24 DM3R8YL TN Erythropoietin Receptor (EPOR) DM3R8YL MA Stimulator DM3R8YL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DM3R8YL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DM3RCA9 DI DM3RCA9 DM3RCA9 DN 2-(o-toluidino)-5-ethylthiazol-4(5H)-one DM3RCA9 TI TTN7BL9 DM3RCA9 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM3RCA9 MA Inhibitor DM3RCA9 RN 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure an... J Med Chem. 2008 May 22;51(10):2933-43. DM3RCA9 RU https://pubmed.ncbi.nlm.nih.gov/18419108 DM3RE2D DI DM3RE2D DM3RE2D DN 1-adamantan-1-yl-3-(4-pentyloxybutyl)urea DM3RE2D TI TT7WVHI DM3RE2D TN Soluble epoxide hydrolase (EPHX2) DM3RE2D MA Inhibitor DM3RE2D RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DM3RE2D RU https://pubmed.ncbi.nlm.nih.gov/17894481 DM3RGLE DI DM3RGLE DM3RGLE DN 1-(3-Nitro-benzyl)-1H-indole-5-carboxamidine DM3RGLE TI TT2WR1T DM3RGLE TN Cationic trypsinogen (PRSS1) DM3RGLE MA Inhibitor DM3RGLE RN Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8. DM3RGLE RU https://pubmed.ncbi.nlm.nih.gov/6219223 DM3RGPF DI DM3RGPF DM3RGPF DN PERSICARIN DM3RGPF TI TT7RJY8 DM3RGPF TN Xanthine dehydrogenase/oxidase (XDH) DM3RGPF MA Inhibitor DM3RGPF RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DM3RGPF RU https://pubmed.ncbi.nlm.nih.gov/3379415 DM3RP25 DI DM3RP25 DM3RP25 DN NAVPNLRGDLQVLAQKVART DM3RP25 TI TTT1R2L DM3RP25 TN Integrin alpha-V (ITGAV) DM3RP25 MA Inhibitor DM3RP25 RN Structure-function analysis of Arg-Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem. 2007 Mar 30;282(13):9657-65. DM3RP25 RU https://pubmed.ncbi.nlm.nih.gov/17244604 DM3RQHG DI DM3RQHG DM3RQHG DN N-(3-chlorophenyl)-3-cyano-5-fluorobenzamide DM3RQHG TI TTHS256 DM3RQHG TN Metabotropic glutamate receptor 5 (mGluR5) DM3RQHG MA Inhibitor DM3RQHG RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DM3RQHG RU https://pubmed.ncbi.nlm.nih.gov/20598884 DM3RSYO DI DM3RSYO DM3RSYO DN EM-1745 DM3RSYO TI TTIWB6L DM3RSYO TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM3RSYO MA Inhibitor DM3RSYO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3RSYO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3RUT8 DI DM3RUT8 DM3RUT8 DN MG-101 DM3RUT8 TI TTU7ZMG DM3RUT8 TN Proteasome (PS) DM3RUT8 MA Modulator DM3RUT8 RN Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study.J Mol Model.2009 Dec;15(12):1481-90. DM3RUT8 RU https://www.ncbi.nlm.nih.gov/pubmed/19440739 DM3RVUY DI DM3RVUY DM3RVUY DN ISIS 102599 DM3RVUY TI TT5U49F DM3RVUY TN PRKACA messenger RNA (PRKACA mRNA) DM3RVUY RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DM3RVUY RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DM3RYUZ DI DM3RYUZ DM3RYUZ DN MCP-205 DM3RYUZ TI TT27RFC DM3RYUZ TN Opioid receptor delta (OPRD1) DM3RYUZ MA Agonist DM3RYUZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DM3RYUZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DM3S26I DI DM3S26I DM3S26I DN 2-(3,4-dimethoxybenzamido)thiophene-3-carboxamide DM3S26I TI TTGJCWZ DM3S26I TN Fms-like tyrosine kinase 3 (FLT-3) DM3S26I MA Inhibitor DM3S26I RN Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3282-6. DM3S26I RU https://pubmed.ncbi.nlm.nih.gov/16580199 DM3S2P8 DI DM3S2P8 DM3S2P8 DN 4-Methylbenzenemethanethiol DM3S2P8 TI TTZJYKH DM3S2P8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM3S2P8 MA Inhibitor DM3S2P8 RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DM3S2P8 RU https://pubmed.ncbi.nlm.nih.gov/20688518 DM3S5UC DI DM3S5UC DM3S5UC DN ML-3163 DM3S5UC TI TTXV4FI DM3S5UC TN Albendazole monooxygenase (CYP3A4) DM3S5UC MA Inhibitor DM3S5UC RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DM3S5UC RU https://pubmed.ncbi.nlm.nih.gov/12852754 DM3S5UC DI DM3S5UC DM3S5UC DN ML-3163 DM3S5UC TI TT73U6C DM3S5UC TN Stress-activated protein kinase 2b (p38 beta) DM3S5UC MA Inhibitor DM3S5UC RN From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40. DM3S5UC RU https://pubmed.ncbi.nlm.nih.gov/12061876 DM3S5UC DI DM3S5UC DM3S5UC DN ML-3163 DM3S5UC TI TTQBR95 DM3S5UC TN Stress-activated protein kinase 2a (p38 alpha) DM3S5UC MA Inhibitor DM3S5UC RN From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40. DM3S5UC RU https://pubmed.ncbi.nlm.nih.gov/12061876 DM3S5UC DI DM3S5UC DM3S5UC DN ML-3163 DM3S5UC TI TTVG215 DM3S5UC TN Debrisoquine 4-hydroxylase (CYP2D6) DM3S5UC MA Inhibitor DM3S5UC RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DM3S5UC RU https://pubmed.ncbi.nlm.nih.gov/12852754 DM3S5UC DI DM3S5UC DM3S5UC DN ML-3163 DM3S5UC TI TTYT93M DM3S5UC TN MAP kinase p38 (MAPK12) DM3S5UC MA Inhibitor DM3S5UC RN From imidazoles to pyrimidines: new inhibitors of cytokine release. J Med Chem. 2002 Jun 20;45(13):2733-40. DM3S5UC RU https://pubmed.ncbi.nlm.nih.gov/12061876 DM3S790 DI DM3S790 DM3S790 DN Pentanoic acid (4,6-diphenylpyrimidin-2-yl)amide DM3S790 TI TTK25J1 DM3S790 TN Adenosine A1 receptor (ADORA1) DM3S790 MA Inhibitor DM3S790 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM3S790 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM3SF5M DI DM3SF5M DM3SF5M DN N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide DM3SF5M TI TT3WG5C DM3SF5M TN Monoamine oxidase type A (MAO-A) DM3SF5M MA Inhibitor DM3SF5M RN Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66. DM3SF5M RU https://pubmed.ncbi.nlm.nih.gov/20674099 DM3SF5M DI DM3SF5M DM3SF5M DN N-(2-Methyl-1H-indol-5-yl)cyclohexanecarboxamide DM3SF5M TI TTGP7BY DM3SF5M TN Monoamine oxidase type B (MAO-B) DM3SF5M MA Inhibitor DM3SF5M RN Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66. DM3SF5M RU https://pubmed.ncbi.nlm.nih.gov/20674099 DM3SLZK DI DM3SLZK DM3SLZK DN Guanosine-5'-Monophosphate DM3SLZK TI TTIU7X1 DM3SLZK TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM3SLZK MA Inhibitor DM3SLZK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3SLZK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3SLZK DI DM3SLZK DM3SLZK DN Guanosine-5'-Monophosphate DM3SLZK TI TTJ0IQB DM3SLZK TN Phosphodiesterase 5A (PDE5A) DM3SLZK MA Inhibitor DM3SLZK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3SLZK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3SLZK DI DM3SLZK DM3SLZK DN Guanosine-5'-Monophosphate DM3SLZK TI TT1U2YM DM3SLZK TN Cytomegalovirus DNA polymerase (CMV UL54) DM3SLZK MA Inhibitor DM3SLZK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3SLZK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3SLZK DI DM3SLZK DM3SLZK DN Guanosine-5'-Monophosphate DM3SLZK TI TTBL49X DM3SLZK TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DM3SLZK MA Inhibitor DM3SLZK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3SLZK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3SLZK DI DM3SLZK DM3SLZK DN Guanosine-5'-Monophosphate DM3SLZK TI TT9PB26 DM3SLZK TN Presynaptic density protein 95 (DLG4) DM3SLZK MA Inhibitor DM3SLZK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3SLZK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3SOFX DI DM3SOFX DM3SOFX DN 3-Hydroxy-7-(3-hydroxyphenyl)-1-naphthonitrile DM3SOFX TI TTIWB6L DM3SOFX TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM3SOFX MA Inhibitor DM3SOFX RN Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98. DM3SOFX RU https://pubmed.ncbi.nlm.nih.gov/18630892 DM3SQBH DI DM3SQBH DM3SQBH DN 1-(3-Chlorobenzyl)-1H-imidazole DM3SQBH TI TTIQUX7 DM3SQBH TN Steroid 11-beta-hydroxylase (CYP11B1) DM3SQBH MA Inhibitor DM3SQBH RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM3SQBH RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM3SQEY DI DM3SQEY DM3SQEY DN 5-(4-Methoxyphenoxy)-2,4-Quinazolinediamine DM3SQEY TI TT9SL3Q DM3SQEY TN Polypeptide deformylase (PDF) DM3SQEY MA Inhibitor DM3SQEY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3SQEY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3ST2Y DI DM3ST2Y DM3ST2Y DN (2E, 6E)-farnesylbisphosphonate DM3ST2Y TI TTIKWV4 DM3ST2Y TN Geranyltranstransferase (FDPS) DM3ST2Y MA Inhibitor DM3ST2Y RN Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg Med Chem. 2008 Jan 1;16(1):390-9. DM3ST2Y RU https://pubmed.ncbi.nlm.nih.gov/17905588 DM3SUKX DI DM3SUKX DM3SUKX DN SK&F-89626 DM3SUKX TI TTEX248 DM3SUKX TN Dopamine D2 receptor (D2R) DM3SUKX MA Inhibitor DM3SUKX RN trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem. 1990 Jun;33(6):1756-64. DM3SUKX RU https://pubmed.ncbi.nlm.nih.gov/1971308 DM3SUKX DI DM3SUKX DM3SUKX DN SK&F-89626 DM3SUKX TI TTZFYLI DM3SUKX TN Dopamine D1 receptor (D1R) DM3SUKX MA Inhibitor DM3SUKX RN trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem. 1990 Jun;33(6):1756-64. DM3SUKX RU https://pubmed.ncbi.nlm.nih.gov/1971308 DM3SYH5 DI DM3SYH5 DM3SYH5 DN GNF-PF-67 DM3SYH5 TI TT78R5H DM3SYH5 TN Heat shock protein 90 alpha (HSP90A) DM3SYH5 MA Inhibitor DM3SYH5 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM3SYH5 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM3T4JF DI DM3T4JF DM3T4JF DN [Mpa1, D-Tyr(Et)2, D-Tic7]OT DM3T4JF TI TTSCIUP DM3T4JF TN Oxytocin receptor (OTR) DM3T4JF MA Inhibitor DM3T4JF RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DM3T4JF RU https://pubmed.ncbi.nlm.nih.gov/17316912 DM3T612 DI DM3T612 DM3T612 DN 7-Hydroxy-4-phenylcoumarin DM3T612 TI TTFBNVI DM3T612 TN Aldose reductase (AKR1B1) DM3T612 MA Inhibitor DM3T612 RN 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5630-3. DM3T612 RU https://pubmed.ncbi.nlm.nih.gov/20805028 DM3TDEO DI DM3TDEO DM3TDEO DN NSC-348926 DM3TDEO TI TTHVCUP DM3TDEO TN DNA [cytosine-5]-methyltransferase (DNMT) DM3TDEO MA Inhibitor DM3TDEO RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM3TDEO RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM3TDEO DI DM3TDEO DM3TDEO DN NSC-348926 DM3TDEO TI TT6VZ78 DM3TDEO TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM3TDEO MA Inhibitor DM3TDEO RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM3TDEO RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM3TF9Y DI DM3TF9Y DM3TF9Y DN 4-(methyl(nonyl)amino)-N-(quinolin-3-yl)benzamide DM3TF9Y TI TTMI6F5 DM3TF9Y TN Transient receptor potential cation channel V1 (TRPV1) DM3TF9Y MA Inhibitor DM3TF9Y RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DM3TF9Y RU https://pubmed.ncbi.nlm.nih.gov/18359227 DM3TI6L DI DM3TI6L DM3TI6L DN WR-190706 DM3TI6L TI TTSFWA7 DM3TI6L TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DM3TI6L MA Inhibitor DM3TI6L RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DM3TI6L RU https://pubmed.ncbi.nlm.nih.gov/19250824 DM3TIJD DI DM3TIJD DM3TIJD DN ISIS 103669 DM3TIJD TI TT6TU05 DM3TIJD TN WWP2 messenger RNA (WWP2 mRNA) DM3TIJD RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM3TIJD RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM3TMUK DI DM3TMUK DM3TMUK DN DT-831j DM3TMUK TI TTCIHJA DM3TMUK TN Coagulation factor Xa (F10) DM3TMUK MA Antagonist DM3TMUK RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DM3TMUK RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM3TO27 DI DM3TO27 DM3TO27 DN saclofen DM3TO27 TI TTDCVZW DM3TO27 TN Gamma-aminobutyric acid B receptor (GABBR) DM3TO27 MA Antagonist DM3TO27 RN Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46. DM3TO27 RU https://pubmed.ncbi.nlm.nih.gov/9069281 DM3TPMO DI DM3TPMO DM3TPMO DN 5'-(N-ethyl-N-isopropyl)amiloride DM3TPMO TI TTGSEFH DM3TPMO TN Sodium/hydrogen exchanger 1 (SLC9A1) DM3TPMO MA Inhibitor DM3TPMO RN NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous ... J Biol Chem. 2007 Jul 6;282(27):19716-27. DM3TPMO RU https://pubmed.ncbi.nlm.nih.gov/17493937 DM3TW9V DI DM3TW9V DM3TW9V DN (S)-3-hydroxy-3-methylglutaryl-CoA DM3TW9V TI TTQF4TK DM3TW9V TN Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1) DM3TW9V MA Inhibitor DM3TW9V RN A visible wavelength spectrophotometric assay suitable for high-throughput screening of 3-hydroxy-3-methylglutaryl-CoA synthase. Anal Biochem. 2010 Jan 1;396(1):96-102. DM3TW9V RU https://pubmed.ncbi.nlm.nih.gov/19706283 DM3TWBU DI DM3TWBU DM3TWBU DN BRL54443 DM3TWBU TI TTCPG9S DM3TWBU TN 5-HT 1E receptor (HTR1E) DM3TWBU MA Agonist DM3TWBU RN Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther. 2001 Apr;297(1):88-95. DM3TWBU RU https://pubmed.ncbi.nlm.nih.gov/11259531 DM3U0Z6 DI DM3U0Z6 DM3U0Z6 DN ISIS 156472 DM3U0Z6 TI TTILUKB DM3U0Z6 TN IRAK4 messenger RNA (IRAK4 mRNA) DM3U0Z6 RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DM3U0Z6 RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DM3UBR5 DI DM3UBR5 DM3UBR5 DN 6-phenyl-3-(pyridin-4-yl)-1H-indole DM3UBR5 TI TTTB4UP DM3UBR5 TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM3UBR5 MA Inhibitor DM3UBR5 RN Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42. DM3UBR5 RU https://pubmed.ncbi.nlm.nih.gov/16483773 DM3UCWM DI DM3UCWM DM3UCWM DN FE-999040 DM3UCWM TI TTGPQ0F DM3UCWM TN Prolyl endopeptidase FAP (FAP) DM3UCWM MA Inhibitor DM3UCWM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365). DM3UCWM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2365 DM3UE42 DI DM3UE42 DM3UE42 DN 4-arylphthalazin-1(2H)-3,4-Di-F DM3UE42 TI TTX4RTB DM3UE42 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM3UE42 MA Antagonist DM3UE42 RN 4-arylphthalazin-1(2H)-one derivatives as potent antagonists of the melanin concentrating hormone receptor 1 (MCH-R1). Bioorg Med Chem Lett. 2012 Jan 1;22(1):427-30. DM3UE42 RU https://pubmed.ncbi.nlm.nih.gov/22137790 DM3UGMD DI DM3UGMD DM3UGMD DN L-168049 DM3UGMD TI TT9O6WS DM3UGMD TN Glucagon receptor (GCGR) DM3UGMD MA Antagonist DM3UGMD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 251). DM3UGMD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251 DM3UHDW DI DM3UHDW DM3UHDW DN 1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene DM3UHDW TI TTSQIFT DM3UHDW TN 5-HT 1A receptor (HTR1A) DM3UHDW MA Inhibitor DM3UHDW RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DM3UHDW RU https://pubmed.ncbi.nlm.nih.gov/17064079 DM3UHDW DI DM3UHDW DM3UHDW DN 1-[(3-methoxybenzyl)oxy]-2-(2-phenylethyl)benzene DM3UHDW TI TTEX248 DM3UHDW TN Dopamine D2 receptor (D2R) DM3UHDW MA Inhibitor DM3UHDW RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DM3UHDW RU https://pubmed.ncbi.nlm.nih.gov/17064079 DM3UMYD DI DM3UMYD DM3UMYD DN 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine DM3UMYD TI TT2WR1T DM3UMYD TN Cationic trypsinogen (PRSS1) DM3UMYD MA Inhibitor DM3UMYD RN Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71. DM3UMYD RU https://pubmed.ncbi.nlm.nih.gov/11495587 DM3UMYD DI DM3UMYD DM3UMYD DN 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine DM3UMYD TI TT6L509 DM3UMYD TN Coagulation factor IIa (F2) DM3UMYD MA Inhibitor DM3UMYD RN Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71. DM3UMYD RU https://pubmed.ncbi.nlm.nih.gov/11495587 DM3UMYD DI DM3UMYD DM3UMYD DN 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine DM3UMYD TI TTP86E2 DM3UMYD TN Plasminogen (PLG) DM3UMYD MA Inhibitor DM3UMYD RN Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71. DM3UMYD RU https://pubmed.ncbi.nlm.nih.gov/11495587 DM3UMYD DI DM3UMYD DM3UMYD DN 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine DM3UMYD TI TTGY7WI DM3UMYD TN Urokinase-type plasminogen activator (PLAU) DM3UMYD MA Inhibitor DM3UMYD RN Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71. DM3UMYD RU https://pubmed.ncbi.nlm.nih.gov/11495587 DM3UMYD DI DM3UMYD DM3UMYD DN 2-(2-Hydroxy-phenyl)-1H-indole-5-carboxamidine DM3UMYD TI TTXAGYU DM3UMYD TN Tissue-type plasminogen activator (PLAT) DM3UMYD MA Inhibitor DM3UMYD RN Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasmi... J Med Chem. 2001 Aug 16;44(17):2753-71. DM3UMYD RU https://pubmed.ncbi.nlm.nih.gov/11495587 DM3UPAE DI DM3UPAE DM3UPAE DN Salvinorin B tetrahydropyran-2-yl ether DM3UPAE TI TTQW87Y DM3UPAE TN Opioid receptor kappa (OPRK1) DM3UPAE MA Inhibitor DM3UPAE RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DM3UPAE RU https://pubmed.ncbi.nlm.nih.gov/17981041 DM3UR1E DI DM3UR1E DM3UR1E DN Indirubin-3-acetoxime DM3UR1E TI TT9RTBL DM3UR1E TN Aurora B messenger RNA (AURKB mRNA) DM3UR1E MA Inhibitor DM3UR1E RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM3UR1E RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM3UR1E DI DM3UR1E DM3UR1E DN Indirubin-3-acetoxime DM3UR1E TI TTLYXIT DM3UR1E TN Aurora kinase C (AURKC) DM3UR1E MA Inhibitor DM3UR1E RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM3UR1E RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM3UR1E DI DM3UR1E DM3UR1E DN Indirubin-3-acetoxime DM3UR1E TI TTPS3C0 DM3UR1E TN Aurora kinase A (AURKA) DM3UR1E MA Inhibitor DM3UR1E RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM3UR1E RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM3URJG DI DM3URJG DM3URJG DN 2,3-Dihydro-1H-indol-5-ol DM3URJG TI TTEX248 DM3URJG TN Dopamine D2 receptor (D2R) DM3URJG MA Inhibitor DM3URJG RN D4 dopamine receptor-selective compounds from the Chinese plant Phoebe chekiangensis, Bioorg. Med. Chem. Lett. 7(9):1207-1212 (1997). DM3URJG RU http://www.sciencedirect.com/science/article/pii/S0960894X97001947 DM3USOR DI DM3USOR DM3USOR DN 2,5-bis(4-nitrophenyl)thiophene DM3USOR TI TTE4KHA DM3USOR TN Amyloid beta A4 protein (APP) DM3USOR MA Inhibitor DM3USOR RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DM3USOR RU https://pubmed.ncbi.nlm.nih.gov/16325402 DM3UY74 DI DM3UY74 DM3UY74 DN 2-oxoguaia-1,4(15), 11(13)-trien-12,8beta-olide DM3UY74 TI TTSXVID DM3UY74 TN Nuclear factor NF-kappa-B (NFKB) DM3UY74 MA Inhibitor DM3UY74 RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DM3UY74 RU https://pubmed.ncbi.nlm.nih.gov/16570920 DM3V0HA DI DM3V0HA DM3V0HA DN FR230513 DM3V0HA TI TTLP57V DM3V0HA TN Adenosine deaminase (ADA) DM3V0HA MA Inhibitor DM3V0HA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM3V0HA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM3V4XG DI DM3V4XG DM3V4XG DN H-Cpa-c[pen-Gly-Phe-pen]OH DM3V4XG TI TT27RFC DM3V4XG TN Opioid receptor delta (OPRD1) DM3V4XG MA Inhibitor DM3V4XG RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM3V4XG RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM3V5AB DI DM3V5AB DM3V5AB DN 2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol DM3V5AB TI TTW0CMT DM3V5AB TN Voltage-gated potassium channel Kv1.5 (KCNA5) DM3V5AB MA Inhibitor DM3V5AB RN Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. DM3V5AB RU https://pubmed.ncbi.nlm.nih.gov/20304642 DM3VF9M DI DM3VF9M DM3VF9M DN C-(1-Hydrogyl-Beta-D-Glucopyranosyl) Formamide DM3VF9M TI TTZHY6R DM3VF9M TN Glycogen phosphorylase muscle form (GP) DM3VF9M MA Inhibitor DM3VF9M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3VF9M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3VH7F DI DM3VH7F DM3VH7F DN 2-(2-Bromo-benzoyl)-cyclohexane-1,3-dione DM3VH7F TI TT8DSFC DM3VH7F TN Hydroxyphenylpyruvate dioxygenase (HPD) DM3VH7F MA Inhibitor DM3VH7F RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DM3VH7F RU https://pubmed.ncbi.nlm.nih.gov/10853644 DM3VJEZ DI DM3VJEZ DM3VJEZ DN 2-Amino-6-(2-bromo-benzenesulfonyl)-benzonitrile DM3VJEZ TI TT84ETX DM3VJEZ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM3VJEZ MA Inhibitor DM3VJEZ RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM3VJEZ RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM3VJLZ DI DM3VJLZ DM3VJLZ DN 2-(benzylideneamino)ethanesulfonamide DM3VJLZ TI TTANPDJ DM3VJLZ TN Carbonic anhydrase II (CA-II) DM3VJLZ MA Inhibitor DM3VJLZ RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DM3VJLZ RU https://pubmed.ncbi.nlm.nih.gov/19796939 DM3VL7G DI DM3VL7G DM3VL7G DN Phosphoramidon DM3VL7G TI TT1BGDH DM3VL7G TN Endothelin-converting enzyme (ECE) DM3VL7G MA Inhibitor DM3VL7G RN In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharmacol. 1998 Mar 1;55(5):697-701. DM3VL7G RU https://pubmed.ncbi.nlm.nih.gov/9515580 DM3VL7G DI DM3VL7G DM3VL7G DN Phosphoramidon DM3VL7G TI TT5TKPM DM3VL7G TN Neutral endopeptidase (MME) DM3VL7G MA Inhibitor DM3VL7G RN Neprilysin, a novel target for ultraviolet B regulation of melanogenesis via melanocortins. J Invest Dermatol. 2000 Sep;115(3):381-7. DM3VL7G RU https://pubmed.ncbi.nlm.nih.gov/10951272 DM3VME7 DI DM3VME7 DM3VME7 DN 6-(2-Dipropylamino-ethyl)-biphenyl-2,3,4'-triol DM3VME7 TI TTZFYLI DM3VME7 TN Dopamine D1 receptor (D1R) DM3VME7 MA Inhibitor DM3VME7 RN Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12. DM3VME7 RU https://pubmed.ncbi.nlm.nih.gov/3761310 DM3VNYQ DI DM3VNYQ DM3VNYQ DN Pyr3 DM3VNYQ TI TTNVC34 DM3VNYQ TN Short transient receptor potential channel 3 (TRPC3) DM3VNYQ MA Blocker (channel blocker) DM3VNYQ RN Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5400-5. DM3VNYQ RU https://pubmed.ncbi.nlm.nih.gov/19289841 DM3VOPQ DI DM3VOPQ DM3VOPQ DN SEBACIC ACID DM3VOPQ TI TTQO71U DM3VOPQ TN Hemoglobin (HB) DM3VOPQ MA Inhibitor DM3VOPQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM3VOPQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM3VT8M DI DM3VT8M DM3VT8M DN [2-(Purin-9-yl)ethyl]-bisphosphonic acid DM3VT8M TI TTIKWV4 DM3VT8M TN Geranyltranstransferase (FDPS) DM3VT8M MA Inhibitor DM3VT8M RN Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7. DM3VT8M RU https://pubmed.ncbi.nlm.nih.gov/18937434 DM3VTLG DI DM3VTLG DM3VTLG DN UR-PG153 DM3VTLG TI TTTIBOJ DM3VTLG TN Histamine H1 receptor (H1R) DM3VTLG MA Agonist DM3VTLG RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DM3VTLG RU https://pubmed.ncbi.nlm.nih.gov/16394198 DM3VYNJ DI DM3VYNJ DM3VYNJ DN 3-anilino-5-benzylthio-1,2,4-triazole DM3VYNJ TI TTZL0OI DM3VYNJ TN Methionine aminopeptidase 2 (METAP2) DM3VYNJ MA Inhibitor DM3VYNJ RN Highly potent inhibitors of methionine aminopeptidase-2 based on a 1,2,4-triazole pharmacophore. J Med Chem. 2007 Aug 9;50(16):3777-85. DM3VYNJ RU https://pubmed.ncbi.nlm.nih.gov/17636946 DM3W1T4 DI DM3W1T4 DM3W1T4 DN BIS(18)-HUPERZINE B DM3W1T4 TI TT1RS9F DM3W1T4 TN Acetylcholinesterase (AChE) DM3W1T4 MA Inhibitor DM3W1T4 RN Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7. DM3W1T4 RU https://pubmed.ncbi.nlm.nih.gov/15689148 DM3W2OE DI DM3W2OE DM3W2OE DN Lauryl Dimethylamine-N-Oxide DM3W2OE TI TTH0KSX DM3W2OE TN Rhodopsin (RHO) DM3W2OE MA Inhibitor DM3W2OE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3W2OE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3W2OE DI DM3W2OE DM3W2OE DN Lauryl Dimethylamine-N-Oxide DM3W2OE TI TTGP7BY DM3W2OE TN Monoamine oxidase type B (MAO-B) DM3W2OE MA Inhibitor DM3W2OE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3W2OE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3W2OE DI DM3W2OE DM3W2OE DN Lauryl Dimethylamine-N-Oxide DM3W2OE TI TT3PQ2Y DM3W2OE TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM3W2OE MA Inhibitor DM3W2OE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3W2OE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3W68X DI DM3W68X DM3W68X DN AcAsp-Glu-Dif-Ile-Cha-Cys-Iqc-Nle-Thr-TyrNH2 DM3W68X TI TTWXB3E DM3W68X TN Hepatitis C virus NS3 helicase (HCV NS3) DM3W68X MA Inhibitor DM3W68X RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DM3W68X RU https://pubmed.ncbi.nlm.nih.gov/15633995 DM3W6PQ DI DM3W6PQ DM3W6PQ DN CT-003230 DM3W6PQ TI TTE4KHA DM3W6PQ TN Amyloid beta A4 protein (APP) DM3W6PQ MA Inhibitor DM3W6PQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM3W6PQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM3W8R0 DI DM3W8R0 DM3W8R0 DN ISIS 111120 DM3W8R0 TI TTOM97J DM3W8R0 TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DM3W8R0 RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DM3W8R0 RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DM3W9FQ DI DM3W9FQ DM3W9FQ DN H-Dmt-Tic-Asp-NH-Ph DM3W9FQ TI TTKWM86 DM3W9FQ TN Opioid receptor mu (MOP) DM3W9FQ MA Inhibitor DM3W9FQ RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM3W9FQ RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM3W9FQ DI DM3W9FQ DM3W9FQ DN H-Dmt-Tic-Asp-NH-Ph DM3W9FQ TI TT27RFC DM3W9FQ TN Opioid receptor delta (OPRD1) DM3W9FQ MA Inhibitor DM3W9FQ RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM3W9FQ RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM3WAG6 DI DM3WAG6 DM3WAG6 DN ADX71743 DM3WAG6 TI TT0I76D DM3WAG6 TN Metabotropic glutamate receptor 7 (mGluR7) DM3WAG6 MA Modulator (allosteric modulator) DM3WAG6 RN ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2013 Mar;344(3):624-36. DM3WAG6 RU https://pubmed.ncbi.nlm.nih.gov/23257312 DM3WBKN DI DM3WBKN DM3WBKN DN BMS-561388 DM3WBKN TI TT7EFHR DM3WBKN TN Corticotropin-releasing factor receptor 1 (CRHR1) DM3WBKN MA Inhibitor DM3WBKN RN 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists. J Med Chem. 2009 May 14;52(9):3073-83. DM3WBKN RU https://pubmed.ncbi.nlm.nih.gov/19361210 DM3WBZP DI DM3WBZP DM3WBZP DN N-(1-benzofuran-3-ylmethyl)sulfamide DM3WBZP TI TTANPDJ DM3WBZP TN Carbonic anhydrase II (CA-II) DM3WBZP MA Inhibitor DM3WBZP RN Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into huma... J Med Chem. 2009 Dec 10;52(23):7528-36. DM3WBZP RU https://pubmed.ncbi.nlm.nih.gov/19388676 DM3WDOY DI DM3WDOY DM3WDOY DN [(2-aminooxyethyl)methylamino]-5'-deoxyadenosine DM3WDOY TI TTBFROQ DM3WDOY TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DM3WDOY MA Inhibitor DM3WDOY RN New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407. DM3WDOY RU https://pubmed.ncbi.nlm.nih.gov/19209891 DM3WEQA DI DM3WEQA DM3WEQA DN 8-(3-Methoxy-3-methyl-butoxy)-quinolin-2-ylamine DM3WEQA TI TTX4RTB DM3WEQA TN Melanin-concentrating hormone receptor 1 (MCHR1) DM3WEQA MA Inhibitor DM3WEQA RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM3WEQA RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM3WOHI DI DM3WOHI DM3WOHI DN 2-phenyl-1,8-naphthyridine DM3WOHI TI TTHS256 DM3WOHI TN Metabotropic glutamate receptor 5 (mGluR5) DM3WOHI MA Inhibitor DM3WOHI RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DM3WOHI RU https://pubmed.ncbi.nlm.nih.gov/17936624 DM3WPO4 DI DM3WPO4 DM3WPO4 DN BRL 44408 DM3WPO4 TI TTWG9A4 DM3WPO4 TN Adrenergic receptor alpha-2A (ADRA2A) DM3WPO4 MA Antagonist DM3WPO4 RN Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. DM3WPO4 RU https://pubmed.ncbi.nlm.nih.gov/11481271 DM3WTDL DI DM3WTDL DM3WTDL DN N-2-phenylethyl-1H-pyrrole-2-carboxamide DM3WTDL TI TT3WG5C DM3WTDL TN Monoamine oxidase type A (MAO-A) DM3WTDL MA Inhibitor DM3WTDL RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM3WTDL RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM3WXET DI DM3WXET DM3WXET DN 1-(2-Hydroxy-3-nitro-phenyl)-3-phenyl-urea DM3WXET TI TT30C9G DM3WXET TN C-X-C chemokine receptor type 2 (CXCR2) DM3WXET MA Inhibitor DM3WXET RN Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem. 2004 Mar 11;47(6):1319-21. DM3WXET RU https://pubmed.ncbi.nlm.nih.gov/14998320 DM3X50C DI DM3X50C DM3X50C DN Benzyl-(2-phenyl-quinazolin-4-yl)-amine DM3X50C TI TTVIAT9 DM3X50C TN Phosphodiesterase 4B (PDE4B) DM3X50C MA Inhibitor DM3X50C RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DM3X50C RU https://pubmed.ncbi.nlm.nih.gov/7658441 DM3X50C DI DM3X50C DM3X50C DN Benzyl-(2-phenyl-quinazolin-4-yl)-amine DM3X50C TI TTVBI8W DM3X50C TN Dopamine transporter (DAT) DM3X50C MA Inhibitor DM3X50C RN Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8. DM3X50C RU https://pubmed.ncbi.nlm.nih.gov/12127543 DM3X50C DI DM3X50C DM3X50C DN Benzyl-(2-phenyl-quinazolin-4-yl)-amine DM3X50C TI TTZ97H5 DM3X50C TN Phosphodiesterase 4A (PDE4A) DM3X50C MA Inhibitor DM3X50C RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DM3X50C RU https://pubmed.ncbi.nlm.nih.gov/7658441 DM3XCM1 DI DM3XCM1 DM3XCM1 DN ASP-2002 DM3XCM1 TI TT4BT06 DM3XCM1 TN Integrin alpha-4 (ITGA4) DM3XCM1 MA Antagonist DM3XCM1 RN Asphelia to Present at C21 BioVentures Conference in Napa, CA. 10th Annual C21 BioVentures. May 15, 2008. DM3XCM1 RU http://www.businesswire.com/news/home/20080515005310/en/Asphelia-Present-C21-BioVentures-Conference-Napa-CA#.VhskvPmqpBc DM3XHBR DI DM3XHBR DM3XHBR DN ISIS 116508 DM3XHBR TI TTUI35N DM3XHBR TN C/EBP beta messenger RNA (CEBPB mRNA) DM3XHBR RN US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression. DM3XHBR RU http://www.patentbuddy.com/Patent/6271030?ft=true&sr=true DM3XHIY DI DM3XHIY DM3XHIY DN Ac-FWKY-NH2 DM3XHIY TI TTW5UDX DM3XHIY TN Urotensin II receptor (UTS2R) DM3XHIY MA Inhibitor DM3XHIY RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DM3XHIY RU https://pubmed.ncbi.nlm.nih.gov/20043680 DM3XMKJ DI DM3XMKJ DM3XMKJ DN 5-(2-(3,5-difluorophenyl)ethynyl)pyrimidine DM3XMKJ TI TTHS256 DM3XMKJ TN Metabotropic glutamate receptor 5 (mGluR5) DM3XMKJ MA Inhibitor DM3XMKJ RN Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. DM3XMKJ RU https://pubmed.ncbi.nlm.nih.gov/18550372 DM3XOVL DI DM3XOVL DM3XOVL DN 3-(4-hydroxyphenyl)-6-methyl-2H-chromen-2-one DM3XOVL TI TTGP7BY DM3XOVL TN Monoamine oxidase type B (MAO-B) DM3XOVL MA Inhibitor DM3XOVL RN Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5053-5. DM3XOVL RU https://pubmed.ncbi.nlm.nih.gov/19628387 DM3XQDH DI DM3XQDH DM3XQDH DN JQ1 DM3XQDH TI TTNISW6 DM3XQDH TN HUMAN bromodomain-containing protein 2 (BRD2) DM3XQDH MA Inhibitor DM3XQDH RN Uncovering the Role of BRD2 in COVID-19. 2020-03-19 DM3XQDH RU https://www.caymanchem.com/news/uncovering-the-role-of-brd2-in-covid-19 DM3XRJT DI DM3XRJT DM3XRJT DN PRAVADOLINE DM3XRJT TI TT6OEDT DM3XRJT TN Cannabinoid receptor 1 (CB1) DM3XRJT MA Inhibitor DM3XRJT RN Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists, Bioorg. Med. Chem. Lett. 5(4):381-386 (1995). DM3XRJT RU http://www.sciencedirect.com/science/article/pii/0960894X9500040Z DM3XRJT DI DM3XRJT DM3XRJT DN PRAVADOLINE DM3XRJT TI TTMSFAW DM3XRJT TN Cannabinoid receptor 2 (CB2) DM3XRJT MA Inhibitor DM3XRJT RN Morpholinoalkylindenes as antinociceptive agents: Novel cannabinoid receptor agonists, Bioorg. Med. Chem. Lett. 5(4):381-386 (1995). DM3XRJT RU http://www.sciencedirect.com/science/article/pii/0960894X9500040Z DM3Y09Z DI DM3Y09Z DM3Y09Z DN SR-3850 DM3Y09Z TI TTGWKQJ DM3Y09Z TN Rho-associated protein kinase 2 (ROCK2) DM3Y09Z MA Inhibitor DM3Y09Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504). DM3Y09Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504 DM3Y09Z DI DM3Y09Z DM3Y09Z DN SR-3850 DM3Y09Z TI TTZN7RP DM3Y09Z TN Rho-associated protein kinase 1 (ROCK1) DM3Y09Z MA Inhibitor DM3Y09Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503). DM3Y09Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503 DM3Y1TZ DI DM3Y1TZ DM3Y1TZ DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Sar-) DM3Y1TZ TI TTBID49 DM3Y1TZ TN C-X-C chemokine receptor type 4 (CXCR4) DM3Y1TZ MA Inhibitor DM3Y1TZ RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DM3Y1TZ RU https://pubmed.ncbi.nlm.nih.gov/17228861 DM3YE5X DI DM3YE5X DM3YE5X DN UR-60427 DM3YE5X TI TTXJ178 DM3YE5X TN Histamine H4 receptor (H4R) DM3YE5X MA Agonist DM3YE5X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 265). DM3YE5X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=265 DM3YFG9 DI DM3YFG9 DM3YFG9 DN Hexylcarbamoyl fluorouracil DM3YFG9 TI TTNHMO8 DM3YFG9 TN COVID-19 papain-like proteinase (PL-PRO) DM3YFG9 MA Inhibitor DM3YFG9 RN Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. DM3YFG9 RU https://pubmed.ncbi.nlm.nih.gov/32272481 DM3YGWL DI DM3YGWL DM3YGWL DN Alpha-Methylisocitric Acid DM3YGWL TI TTMTF2P DM3YGWL TN Citrate hydro-lyase (ACO2) DM3YGWL MA Inhibitor DM3YGWL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3YGWL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3YI5G DI DM3YI5G DM3YI5G DN 1-(4-Chloro-phenyl)-3-(3,3-diphenyl-allyl)-urea DM3YI5G TI TTCG0AL DM3YI5G TN Cholecystokinin receptor type A (CCKAR) DM3YI5G MA Inhibitor DM3YI5G RN Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9. DM3YI5G RU https://pubmed.ncbi.nlm.nih.gov/1552499 DM3YI9P DI DM3YI9P DM3YI9P DN 2-Amino-N,3,3-Trimethylbutanamide DM3YI9P TI TT6X50U DM3YI9P TN Matrix metalloproteinase-9 (MMP-9) DM3YI9P MA Inhibitor DM3YI9P RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3YI9P RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3YJXF DI DM3YJXF DM3YJXF DN IN-1130 DM3YJXF TI TTQBR95 DM3YJXF TN Stress-activated protein kinase 2a (p38 alpha) DM3YJXF MA Inhibitor DM3YJXF RN Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10. DM3YJXF RU https://pubmed.ncbi.nlm.nih.gov/18571921 DM3YJXF DI DM3YJXF DM3YJXF DN IN-1130 DM3YJXF TI TTP4520 DM3YJXF TN TGF-beta receptor type I (TGFBR1) DM3YJXF MA Inhibitor DM3YJXF RN Synthesis and biological evaluation of 4(5)-(6-methylpyridin-2-yl)imidazoles and -pyrazoles as transforming growth factor-beta type 1 receptor kina... Bioorg Med Chem. 2010 Jun 15;18(12):4459-67. DM3YJXF RU https://pubmed.ncbi.nlm.nih.gov/20472445 DM3YO72 DI DM3YO72 DM3YO72 DN 3-hydroxy-3-methyl-6-phosphohexanoic acid DM3YO72 TI TTXMI0C DM3YO72 TN Phosphomevalonate kinase (PMVK) DM3YO72 MA Inhibitor DM3YO72 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 641). DM3YO72 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=641 DM3YSNX DI DM3YSNX DM3YSNX DN 6,7-Dimethoxy-4-(3-nitro-phenoxy)-quinoline DM3YSNX TI TTI7421 DM3YSNX TN Platelet-derived growth factor receptor beta (PDGFRB) DM3YSNX MA Inhibitor DM3YSNX RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DM3YSNX RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DM3Z6F4 DI DM3Z6F4 DM3Z6F4 DN PMID23147077C10 DM3Z6F4 TI TTOQCD8 DM3Z6F4 TN Apoptosis signal-regulating kinase 1 (MAP3K5) DM3Z6F4 MA Inhibitor DM3Z6F4 RN Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9. DM3Z6F4 RU https://pubmed.ncbi.nlm.nih.gov/23147077 DM3Z6F4 DI DM3Z6F4 DM3Z6F4 DN PMID23147077C10 DM3Z6F4 TI TT64GC2 DM3Z6F4 TN Apoptosis signal-regulating kinase 2 (MAP3K6) DM3Z6F4 MA Inhibitor DM3Z6F4 RN Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7326-9. DM3Z6F4 RU https://pubmed.ncbi.nlm.nih.gov/23147077 DM3Z6G4 DI DM3Z6G4 DM3Z6G4 DN 5S-HETE DM3Z6G4 TI TT2J34L DM3Z6G4 TN Arachidonate 5-lipoxygenase (5-LOX) DM3Z6G4 MA Inhibitor DM3Z6G4 RN Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. DM3Z6G4 RU https://pubmed.ncbi.nlm.nih.gov/10940813 DM3Z6G4 DI DM3Z6G4 DM3Z6G4 DN 5S-HETE DM3Z6G4 TI TT7WBSV DM3Z6G4 TN Oxoeicosanoid receptor 1 (OXER1) DM3Z6G4 MA Agonist DM3Z6G4 RN TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun. 2005 Sep 9;334(4):987-95. DM3Z6G4 RU https://pubmed.ncbi.nlm.nih.gov/16039985 DM3Z6G4 DI DM3Z6G4 DM3Z6G4 DN 5S-HETE DM3Z6G4 TI TTMI6F5 DM3Z6G4 TN Transient receptor potential cation channel V1 (TRPV1) DM3Z6G4 MA Activator DM3Z6G4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DM3Z6G4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DM3Z6TI DI DM3Z6TI DM3Z6TI DN S33005 DM3Z6TI TI TT3ROYC DM3Z6TI TN Serotonin transporter (SERT) DM3Z6TI MA Inhibitor DM3Z6TI RN Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. DM3Z6TI RU https://pubmed.ncbi.nlm.nih.gov/17017959 DM3Z6TI DI DM3Z6TI DM3Z6TI DN S33005 DM3Z6TI TI TTAWNKZ DM3Z6TI TN Norepinephrine transporter (NET) DM3Z6TI MA Inhibitor DM3Z6TI RN Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. DM3Z6TI RU https://pubmed.ncbi.nlm.nih.gov/17017959 DM3ZBGQ DI DM3ZBGQ DM3ZBGQ DN G3139 + cytarabine (ARA-C) DM3ZBGQ TI TTFOUV4 DM3ZBGQ TN BCL-2 messenger RNA (BCL2 mRNA) DM3ZBGQ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM3ZBGQ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM3ZHBO DI DM3ZHBO DM3ZHBO DN N'-Pyridoxyl-Lysine-5'-Monophosphate DM3ZHBO TI TTUMGNO DM3ZHBO TN Ornithine decarboxylase (ODC1) DM3ZHBO MA Inhibitor DM3ZHBO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3ZHBO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3ZHBO DI DM3ZHBO DM3ZHBO DN N'-Pyridoxyl-Lysine-5'-Monophosphate DM3ZHBO TI TTDU0HP DM3ZHBO TN Bacterial Cystathionine gamma-synthase (Bact metB) DM3ZHBO MA Inhibitor DM3ZHBO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3ZHBO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3ZHBO DI DM3ZHBO DM3ZHBO DN N'-Pyridoxyl-Lysine-5'-Monophosphate DM3ZHBO TI TTZHY6R DM3ZHBO TN Glycogen phosphorylase muscle form (GP) DM3ZHBO MA Inhibitor DM3ZHBO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3ZHBO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3ZHBO DI DM3ZHBO DM3ZHBO DN N'-Pyridoxyl-Lysine-5'-Monophosphate DM3ZHBO TI TT1UY5C DM3ZHBO TN Pseudomonas Methionine gamma-lyase (Pseudo mdeA) DM3ZHBO MA Inhibitor DM3ZHBO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM3ZHBO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM3ZIDT DI DM3ZIDT DM3ZIDT DN CP-126998 DM3ZIDT TI TT1RS9F DM3ZIDT TN Acetylcholinesterase (AChE) DM3ZIDT MA Modulator DM3ZIDT RN PET imaging of brain acetylcholinesterase using [11C]CP-126,998, a brain selective enzyme inhibitor. Synapse. 2002 Jul;45(1):1-9. DM3ZIDT RU https://www.ncbi.nlm.nih.gov/pubmed/12112408 DM3ZNF9 DI DM3ZNF9 DM3ZNF9 DN JNJ-1661010 DM3ZNF9 TI TTDP1UC DM3ZNF9 TN Fatty acid amide hydrolase (FAAH) DM3ZNF9 MA Inhibitor DM3ZNF9 RN Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4838-43. DM3ZNF9 RU https://pubmed.ncbi.nlm.nih.gov/18693015 DM3ZR7A DI DM3ZR7A DM3ZR7A DN 3alpha,24-dihydroxyolean-12-en-27-oic acid DM3ZR7A TI TTELIN2 DM3ZR7A TN PTPN1 messenger RNA (PTPN1 mRNA) DM3ZR7A MA Inhibitor DM3ZR7A RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DM3ZR7A RU https://pubmed.ncbi.nlm.nih.gov/16580200 DM3ZUH2 DI DM3ZUH2 DM3ZUH2 DN VU0361747 DM3ZUH2 TI TTHS256 DM3ZUH2 TN Metabotropic glutamate receptor 5 (mGluR5) DM3ZUH2 MA Modulator (allosteric modulator) DM3ZUH2 RN Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol.2012 Feb;81(2):120-33. DM3ZUH2 RU https://pubmed.ncbi.nlm.nih.gov/22021324 DM3ZWNI DI DM3ZWNI DM3ZWNI DN 2-Morpholin-4-yl-benzo[h]chromene-4-thione DM3ZWNI TI TTK3PY9 DM3ZWNI TN DNA-dependent protein kinase catalytic (PRKDC) DM3ZWNI MA Inhibitor DM3ZWNI RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DM3ZWNI RU https://pubmed.ncbi.nlm.nih.gov/15658870 DM408U3 DI DM408U3 DM408U3 DN Propan-2-one O-4-(pentyloxy)phenylcarbamoyl oxime DM408U3 TI TTDP1UC DM408U3 TN Fatty acid amide hydrolase (FAAH) DM408U3 MA Inhibitor DM408U3 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM408U3 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM40E1T DI DM40E1T DM40E1T DN 4,3'',5''-trimethoxy-[1,1':3',1'']-terphenyl DM40E1T TI TTS7G69 DM40E1T TN Fusion protein Bcr-Abl (Bcr-Abl) DM40E1T MA Inhibitor DM40E1T RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DM40E1T RU https://pubmed.ncbi.nlm.nih.gov/16686543 DM40GJ8 DI DM40GJ8 DM40GJ8 DN 3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol DM40GJ8 TI TTIWB6L DM40GJ8 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM40GJ8 MA Inhibitor DM40GJ8 RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DM40GJ8 RU https://pubmed.ncbi.nlm.nih.gov/18855374 DM40GJ8 DI DM40GJ8 DM40GJ8 DN 3-[5-(4-Hydroxyphenyl)-3-thienyl]phenol DM40GJ8 TI TTXV4FI DM40GJ8 TN Albendazole monooxygenase (CYP3A4) DM40GJ8 MA Inhibitor DM40GJ8 RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DM40GJ8 RU https://pubmed.ncbi.nlm.nih.gov/18855374 DM40HWI DI DM40HWI DM40HWI DN PK-44 DM40HWI TI TTDIGC1 DM40HWI TN Dipeptidyl peptidase 4 (DPP-4) DM40HWI MA Inhibitor DM40HWI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DM40HWI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DM40LQ9 DI DM40LQ9 DM40LQ9 DN 6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol DM40LQ9 TI TTRA5BZ DM40LQ9 TN Steroid 17-alpha-monooxygenase (S17AH) DM40LQ9 MA Inhibitor DM40LQ9 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM40LQ9 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM40LQ9 DI DM40LQ9 DM40LQ9 DN 6-[4-(Pyridin-4-ylmethyl)phenyl]naphthalen-2-ol DM40LQ9 TI TTIQUX7 DM40LQ9 TN Steroid 11-beta-hydroxylase (CYP11B1) DM40LQ9 MA Inhibitor DM40LQ9 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM40LQ9 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM40PT5 DI DM40PT5 DM40PT5 DN PGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 DM40PT5 TI TT8R70G DM40PT5 TN Gonadotropin-releasing hormone receptor (GNRHR) DM40PT5 MA Inhibitor DM40PT5 RN Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J Med Chem. 2006 Jan 26;49(2):637-47. DM40PT5 RU https://pubmed.ncbi.nlm.nih.gov/16420049 DM40RS3 DI DM40RS3 DM40RS3 DN 2-(3-Hydroxy-phenyl)-6-methyl-chromen-4-one DM40RS3 TI TTNJYV2 DM40RS3 TN Gamma-aminobutyric acid receptor (GAR) DM40RS3 MA Inhibitor DM40RS3 RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DM40RS3 RU https://pubmed.ncbi.nlm.nih.gov/12213060 DM40SNY DI DM40SNY DM40SNY DN 3,3'-(3-Methylthiene-2,5-diyl]diphenol DM40SNY TI TTIWB6L DM40SNY TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM40SNY MA Inhibitor DM40SNY RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM40SNY RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM40TBU DI DM40TBU DM40TBU DN Coumestrol DM40TBU TI TTOM3J0 DM40TBU TN Estrogen receptor beta (ESR2) DM40TBU MA Inhibitor DM40TBU RN Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6. DM40TBU RU https://pubmed.ncbi.nlm.nih.gov/15887952 DM40TBU DI DM40TBU DM40TBU DN Coumestrol DM40TBU TI TTZAYWL DM40TBU TN Estrogen receptor (ESR) DM40TBU MA Inhibitor DM40TBU RN Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6. DM40TBU RU https://pubmed.ncbi.nlm.nih.gov/15887952 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TT2LVK8 DM40ZCA TN Carbonic anhydrase IX (CA-IX) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TTCFSPE DM40ZCA TN Carbonic anhydrase VI (CA-VI) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TTEYTKG DM40ZCA TN Carbonic anhydrase XIV (CA-XIV) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TTANPDJ DM40ZCA TN Carbonic anhydrase II (CA-II) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TTSYM0R DM40ZCA TN Carbonic anhydrase XII (CA-XII) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TTZHA0O DM40ZCA TN Carbonic anhydrase IV (CA-IV) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TTUNARX DM40ZCA TN Carbonic anhydrase (CA) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM40ZCA DI DM40ZCA DM40ZCA DN Octyl sulfamate DM40ZCA TI TTHQPL7 DM40ZCA TN Carbonic anhydrase I (CA-I) DM40ZCA MA Inhibitor DM40ZCA RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DM40ZCA RU https://pubmed.ncbi.nlm.nih.gov/19731956 DM412IV DI DM412IV DM412IV DN Y-40613 DM412IV TI TT8VUE0 DM412IV TN Chymase (CYM) DM412IV MA Inhibitor DM412IV RN Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. Jpn J Pharmacol. 2002 Nov;90(3):214-7. DM412IV RU https://pubmed.ncbi.nlm.nih.gov/12499574 DM412RI DI DM412RI DM412RI DN 2-Hydroxycarbamoyl-pentanedioic acid DM412RI TI TT9G4N0 DM412RI TN Glutamate carboxypeptidase II (GCPII) DM412RI MA Inhibitor DM412RI RN Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100. DM412RI RU https://pubmed.ncbi.nlm.nih.gov/12798312 DM413XJ DI DM413XJ DM413XJ DN MERIOLIN 2 DM413XJ TI TT7HF4W DM413XJ TN Cyclin-dependent kinase 2 (CDK2) DM413XJ MA Inhibitor DM413XJ RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM413XJ RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM413XJ DI DM413XJ DM413XJ DN MERIOLIN 2 DM413XJ TI TTAMQ62 DM413XJ TN Cyclin A2 (CCNA2) DM413XJ MA Inhibitor DM413XJ RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM413XJ RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM413XJ DI DM413XJ DM413XJ DN MERIOLIN 2 DM413XJ TI TT1LVF2 DM413XJ TN Cyclin-dependent kinase 9 (CDK9) DM413XJ MA Inhibitor DM413XJ RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM413XJ RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM413ZB DI DM413ZB DM413ZB DN 2-Aminomethyl-5-(phenyl)tetrahydrofuran DM413ZB TI TT3ROYC DM413ZB TN Serotonin transporter (SERT) DM413ZB MA Inhibitor DM413ZB RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM413ZB RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM413ZB DI DM413ZB DM413ZB DN 2-Aminomethyl-5-(phenyl)tetrahydrofuran DM413ZB TI TTVBI8W DM413ZB TN Dopamine transporter (DAT) DM413ZB MA Inhibitor DM413ZB RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM413ZB RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM413ZB DI DM413ZB DM413ZB DN 2-Aminomethyl-5-(phenyl)tetrahydrofuran DM413ZB TI TTAWNKZ DM413ZB TN Norepinephrine transporter (NET) DM413ZB MA Inhibitor DM413ZB RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DM413ZB RU https://pubmed.ncbi.nlm.nih.gov/19201198 DM415DB DI DM415DB DM415DB DN 4-Amino-3-(5-chloro-thiophen-2-yl)-butyric acid DM415DB TI TTDCVZW DM415DB TN Gamma-aminobutyric acid B receptor (GABBR) DM415DB MA Inhibitor DM415DB RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DM415DB RU https://pubmed.ncbi.nlm.nih.gov/1652022 DM415ZX DI DM415ZX DM415ZX DN HCGRPalpha DM415ZX TI TTY6O0Q DM415ZX TN Calcitonin gene-related peptide receptor (CGRPR) DM415ZX MA Inhibitor DM415ZX RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DM415ZX RU https://pubmed.ncbi.nlm.nih.gov/18983139 DM4186A DI DM4186A DM4186A DN 8-(4-chlorophenyl)-2-morpholin-4-ylchromen-4-one DM4186A TI TTK3PY9 DM4186A TN DNA-dependent protein kinase catalytic (PRKDC) DM4186A MA Inhibitor DM4186A RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DM4186A RU https://pubmed.ncbi.nlm.nih.gov/16302822 DM41B62 DI DM41B62 DM41B62 DN ISIS 25551 DM41B62 TI TTP2U16 DM41B62 TN RhoA messenger RNA (RHOA mRNA) DM41B62 RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DM41B62 RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DM41C8E DI DM41C8E DM41C8E DN N,N-dimethyl(pyridin-3-yl)methanamine DM41C8E TI TT4H1MQ DM41C8E TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DM41C8E MA Inhibitor DM41C8E RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DM41C8E RU https://pubmed.ncbi.nlm.nih.gov/16412637 DM41C8E DI DM41C8E DM41C8E DN N,N-dimethyl(pyridin-3-yl)methanamine DM41C8E TI TT5KPZR DM41C8E TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM41C8E MA Inhibitor DM41C8E RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DM41C8E RU https://pubmed.ncbi.nlm.nih.gov/16412637 DM41HMZ DI DM41HMZ DM41HMZ DN 3-(2-methylquinolin-7-yl)phenol DM41HMZ TI TTHS256 DM41HMZ TN Metabotropic glutamate receptor 5 (mGluR5) DM41HMZ MA Inhibitor DM41HMZ RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DM41HMZ RU https://pubmed.ncbi.nlm.nih.gov/17590335 DM41JIB DI DM41JIB DM41JIB DN N-Hydroxycarbamoylmethyl-4-methoxy-benzamide DM41JIB TI TTMX39J DM41JIB TN Matrix metalloproteinase-1 (MMP-1) DM41JIB MA Inhibitor DM41JIB RN Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96. DM41JIB RU https://pubmed.ncbi.nlm.nih.gov/16220975 DM41LV6 DI DM41LV6 DM41LV6 DN 15S-HPETE DM41LV6 TI TTMI6F5 DM41LV6 TN Transient receptor potential cation channel V1 (TRPV1) DM41LV6 MA Activator DM41LV6 RN Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60. DM41LV6 RU https://pubmed.ncbi.nlm.nih.gov/10823958 DM41MS3 DI DM41MS3 DM41MS3 DN L-leucyl-L-prolinamide DM41MS3 TI TTQ7R2V DM41MS3 TN Tripeptidyl-peptidase II (TPP2) DM41MS3 MA Inhibitor DM41MS3 RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DM41MS3 RU https://pubmed.ncbi.nlm.nih.gov/16279793 DM41R2O DI DM41R2O DM41R2O DN 1,1,1-Trifluoro-8-phenoxy-octan-2-one DM41R2O TI TT6R7JZ DM41R2O TN Histone deacetylase 1 (HDAC1) DM41R2O MA Inhibitor DM41R2O RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM41R2O RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM41R2O DI DM41R2O DM41R2O DN 1,1,1-Trifluoro-8-phenoxy-octan-2-one DM41R2O TI TTSHTOI DM41R2O TN Histone deacetylase 2 (HDAC2) DM41R2O MA Inhibitor DM41R2O RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM41R2O RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM41RZX DI DM41RZX DM41RZX DN 2,6-bis(4-tolyl)-9H-purine DM41RZX TI TTK25J1 DM41RZX TN Adenosine A1 receptor (ADORA1) DM41RZX MA Inhibitor DM41RZX RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM41RZX RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM41RZX DI DM41RZX DM41RZX DN 2,6-bis(4-tolyl)-9H-purine DM41RZX TI TTJFY5U DM41RZX TN Adenosine A3 receptor (ADORA3) DM41RZX MA Inhibitor DM41RZX RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM41RZX RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM41TQB DI DM41TQB DM41TQB DN N*2*-Benzyl-N*6*-cyclohexyl-9H-purine-2,6-diamine DM41TQB TI TTJFY5U DM41TQB TN Adenosine A3 receptor (ADORA3) DM41TQB MA Inhibitor DM41TQB RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM41TQB RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM41UYN DI DM41UYN DM41UYN DN 2-(6-Methoxy-indole-1-sulfonyl)-benzoic acid DM41UYN TI TTHWMFZ DM41UYN TN Fatty acid-binding protein 4 (FABP4) DM41UYN MA Inhibitor DM41UYN RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DM41UYN RU https://pubmed.ncbi.nlm.nih.gov/15357969 DM4235F DI DM4235F DM4235F DN 2-Cl-ADP(alpha-BH3) DM4235F TI TTA93TL DM4235F TN P2Y purinoceptor 1 (P2RY1) DM4235F MA Agonist DM4235F RN Highly efficient biocompatible neuroprotectants with dual activity as antioxidants and P2Y receptor agonists. J Med Chem. 2013 Jun 27;56(12):4938-52. DM4235F RU https://pubmed.ncbi.nlm.nih.gov/23751098 DM42A1F DI DM42A1F DM42A1F DN SCH-210971 DM42A1F TI TT2CEJG DM42A1F TN C-C chemokine receptor type 5 (CCR5) DM42A1F MA Inhibitor DM42A1F RN Chemokine receptor CCR-5 inhibitors produced by Chaetomium globosum. J Nat Prod. 2006 Jul;69(7):1025-8. DM42A1F RU https://pubmed.ncbi.nlm.nih.gov/16872138 DM42B5D DI DM42B5D DM42B5D DN [14C]acetylCoA DM42B5D TI TTLJKZ0 DM42B5D TN Acetyl-CoA transporter (SLC33A1) DM42B5D MA Modulator DM42B5D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1134). DM42B5D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1134 DM42BGX DI DM42BGX DM42BGX DN L-689065 DM42BGX TI TTSJ6Q4 DM42BGX TN LOX-5 messenger RNA (ALOX5 mRNA) DM42BGX MA Inhibitor DM42BGX RN Substituted thiopyrano[2,3,4-c,d]indoles as potent, selective, and orally active inhibitors of 5-lipoxygenase. Synthesis and biological evaluation ... J Med Chem. 1993 Sep 17;36(19):2771-87. DM42BGX RU https://pubmed.ncbi.nlm.nih.gov/8410991 DM42ENF DI DM42ENF DM42ENF DN IPRONIAZIDE DM42ENF TI TT3WG5C DM42ENF TN Monoamine oxidase type A (MAO-A) DM42ENF MA Inhibitor DM42ENF RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM42ENF RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM42ENF DI DM42ENF DM42ENF DN IPRONIAZIDE DM42ENF TI TTGP7BY DM42ENF TN Monoamine oxidase type B (MAO-B) DM42ENF MA Inhibitor DM42ENF RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM42ENF RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM42EVG DI DM42EVG DM42EVG DN Ganoderic acid A DM42EVG TI TT9H85R DM42EVG TN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DM42EVG MA Inhibitor DM42EVG RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DM42EVG RU https://pubmed.ncbi.nlm.nih.gov/20100662 DM42IY7 DI DM42IY7 DM42IY7 DN 1-Guanidinium-7-Aminoheptane DM42IY7 TI TTBO2A9 DM42IY7 TN Deoxyhypusine synthase (DHPS) DM42IY7 MA Inhibitor DM42IY7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM42IY7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM42LSO DI DM42LSO DM42LSO DN ISIS 119286 DM42LSO TI TTKS60G DM42LSO TN STXBP4 messenger RNA (STXBP4 mRNA) DM42LSO RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DM42LSO RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DM42M6I DI DM42M6I DM42M6I DN Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid DM42M6I TI TTHI19T DM42M6I TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM42M6I MA Inhibitor DM42M6I RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DM42M6I RU https://pubmed.ncbi.nlm.nih.gov/20527888 DM42UK5 DI DM42UK5 DM42UK5 DN Ro5203280 DM42UK5 TI TTIYVQP DM42UK5 TN Polo-like kinase 1 (PLK1) DM42UK5 MA Inhibitor DM42UK5 RN Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401. DM42UK5 RU https://pubmed.ncbi.nlm.nih.gov/23686835 DM42WFH DI DM42WFH DM42WFH DN Tert-Butyl(1s)-1-Cyclohexyl-2-Oxoethylcarbamate DM42WFH TI TTDZN01 DM42WFH TN Cathepsin K (CTSK) DM42WFH MA Inhibitor DM42WFH RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM42WFH RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM435QN DI DM435QN DM435QN DN (S)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate DM435QN TI TT9JNIC DM435QN TN Histamine H3 receptor (H3R) DM435QN MA Inhibitor DM435QN RN Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6682-5. DM435QN RU https://pubmed.ncbi.nlm.nih.gov/19846299 DM43CIK DI DM43CIK DM43CIK DN 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide DM43CIK TI TTANPDJ DM43CIK TN Carbonic anhydrase II (CA-II) DM43CIK MA Inhibitor DM43CIK RN Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J Med Chem. 2009 Jul 9;52(13):4063-7. DM43CIK RU https://pubmed.ncbi.nlm.nih.gov/19438226 DM43CIK DI DM43CIK DM43CIK DN 3-phenyl-5-sulfamoyl-1H-indole-2-carboxamide DM43CIK TI TTHQPL7 DM43CIK TN Carbonic anhydrase I (CA-I) DM43CIK MA Inhibitor DM43CIK RN Discovery of low nanomolar and subnanomolar inhibitors of the mycobacterial beta-carbonic anhydrases Rv1284 and Rv3273. J Med Chem. 2009 Jul 9;52(13):4063-7. DM43CIK RU https://pubmed.ncbi.nlm.nih.gov/19438226 DM43G5Z DI DM43G5Z DM43G5Z DN inositol 2,4,5-trisphosphate DM43G5Z TI TTK9OV3 DM43G5Z TN IP3 receptor isoform 2 (IP3R2) DM43G5Z MA Activator DM43G5Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 744). DM43G5Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=744 DM43G5Z DI DM43G5Z DM43G5Z DN inositol 2,4,5-trisphosphate DM43G5Z TI TT5HWAT DM43G5Z TN IP3 receptor isoform 1 (ITPR1) DM43G5Z MA Activator DM43G5Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743). DM43G5Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743 DM43K1D DI DM43K1D DM43K1D DN PNU-248686A DM43K1D TI TT1GHVO DM43K1D TN Matrix metalloproteinase (MMP) DM43K1D MA Modulator DM43K1D RN Determination of PNU-248686A, a novel matrix metalloproteinase inhibitor, in human plasma by liquid chromatography-tandem mass spectrometry, following protein precipitation in the 96-well plate format. J Chromatogr A. 2003 Feb 14;987(1-2):249-56. DM43K1D RU https://pubmed.ncbi.nlm.nih.gov/12613819 DM43K85 DI DM43K85 DM43K85 DN SB 204070 DM43K85 TI TT07C3Y DM43K85 TN 5-HT 4 receptor (HTR4) DM43K85 MA Antagonist DM43K85 RN [3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9. DM43K85 RU https://pubmed.ncbi.nlm.nih.gov/9225293 DM43O2U DI DM43O2U DM43O2U DN Z-Pro-Prolinal DM43O2U TI TTNGKET DM43O2U TN Prolyl endopeptidase (PREP) DM43O2U MA Inhibitor DM43O2U RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM43O2U RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM43ODJ DI DM43ODJ DM43ODJ DN H87/07 DM43ODJ TI TTMXGCW DM43ODJ TN Adrenergic receptor beta-3 (ADRB3) DM43ODJ MA Antagonist DM43ODJ RN LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5. DM43ODJ RU https://pubmed.ncbi.nlm.nih.gov/10079020 DM43QHV DI DM43QHV DM43QHV DN N-(3,5-dimethoxyphenyl)-4-methyl-2-nitrobenzamide DM43QHV TI TTVTX4N DM43QHV TN Bacterial Fatty acid synthetase I (Bact inhA) DM43QHV MA Inhibitor DM43QHV RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DM43QHV RU https://pubmed.ncbi.nlm.nih.gov/19428156 DM43Z2J DI DM43Z2J DM43Z2J DN 4-(cyclopropylmethylthio)-2-methoxybenzonitrile DM43Z2J TI TTKPW01 DM43Z2J TN Androgen receptor messenger RNA (AR mRNA) DM43Z2J MA Inhibitor DM43Z2J RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM43Z2J RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM458IH DI DM458IH DM458IH DN OAADPR DM458IH TI TTEBMN7 DM458IH TN Long transient receptor potential channel 2 (TRPM2) DM458IH MA Activator DM458IH RN Metabolite of SIR2 reaction modulates TRPM2 ion channel. J Biol Chem. 2006 May 19;281(20):14057-65. DM458IH RU https://pubmed.ncbi.nlm.nih.gov/16565078 DM45HVR DI DM45HVR DM45HVR DN PT-307 DM45HVR TI TT84ETX DM45HVR TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM45HVR MA Inhibitor DM45HVR RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM45HVR RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM45K8W DI DM45K8W DM45K8W DN FANA DM45K8W TI TT50QJ3 DM45K8W TN Influenza Neuraminidase (Influ NA) DM45K8W MA Inhibitor DM45K8W RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DM45K8W RU https://pubmed.ncbi.nlm.nih.gov/17139286 DM45MGZ DI DM45MGZ DM45MGZ DN NC-2500 DM45MGZ TI TT7RJY8 DM45MGZ TN Xanthine dehydrogenase/oxidase (XDH) DM45MGZ MA Inhibitor DM45MGZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2646). DM45MGZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2646 DM45N6U DI DM45N6U DM45N6U DN 4-Methylimidazole DM45N6U TI TTANPDJ DM45N6U TN Carbonic anhydrase II (CA-II) DM45N6U MA Inhibitor DM45N6U RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM45N6U RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM45NF1 DI DM45NF1 DM45NF1 DN 1,1,1,2,2,3,3-heptafluoro-8-phenyloctan-4-ol DM45NF1 TI TTT1JVS DM45NF1 TN Cytosolic phospholipase A2 (GIVA cPLA2) DM45NF1 MA Inhibitor DM45NF1 RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DM45NF1 RU https://pubmed.ncbi.nlm.nih.gov/20369880 DM45RTZ DI DM45RTZ DM45RTZ DN peptide 4 DM45RTZ TI TTQ7R2V DM45RTZ TN Tripeptidyl-peptidase II (TPP2) DM45RTZ MA Inhibitor DM45RTZ RN Use of lantibiotic synthetases for the preparation of bioactive constrained peptides. Bioorg Med Chem Lett. 2008 May 15;18(10):3025-8. DM45RTZ RU https://pubmed.ncbi.nlm.nih.gov/18294843 DM45VRX DI DM45VRX DM45VRX DN 5-(isopropylamino)quinolin-8-ol DM45VRX TI TTZJYKH DM45VRX TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM45VRX MA Inhibitor DM45VRX RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DM45VRX RU https://pubmed.ncbi.nlm.nih.gov/20055453 DM45WUZ DI DM45WUZ DM45WUZ DN ISIS 24453 DM45WUZ TI TTJMF9P DM45WUZ TN ITGA4 messenger RNA (ITGA4 mRNA) DM45WUZ RN US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression. DM45WUZ RU http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true DM45ZLW DI DM45ZLW DM45ZLW DN C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 DM45ZLW TI TTNI91K DM45ZLW TN Melanocortin receptor 3 (MC3R) DM45ZLW MA Inhibitor DM45ZLW RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM45ZLW RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM45ZLW DI DM45ZLW DM45ZLW DN C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 DM45ZLW TI TTEOSZT DM45ZLW TN Melanocortin receptor (MCR) DM45ZLW MA Inhibitor DM45ZLW RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM45ZLW RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM45ZLW DI DM45ZLW DM45ZLW DN C[Nle-Val-D-Phe-Arg-Trp-Glu]-NH2 DM45ZLW TI TTD0CIQ DM45ZLW TN Melanocortin receptor 4 (MC4R) DM45ZLW MA Inhibitor DM45ZLW RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM45ZLW RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM463S2 DI DM463S2 DM463S2 DN CORYMBONE B DM463S2 TI TT4J8MF DM463S2 TN Thyrotropin-releasing hormone receptor (TRHR) DM463S2 MA Inhibitor DM463S2 RN Corymbones A and B, phloroglucinols with thyrotropin releasing hormone receptor 2 binding affinity from the flowers of Corymbia peltata. J Nat Prod. 2008 May;71(5):881-3. DM463S2 RU https://pubmed.ncbi.nlm.nih.gov/18412395 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTK25J1 DM46F5X TN Adenosine A1 receptor (ADORA1) DM46F5X MA Antagonist DM46F5X RN Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994 Dec 23;269(51):32077-84. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/7798201 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTSKMI8 DM46F5X TN Phosphodiesterase 4D (PDE4D) DM46F5X MA Inhibitor DM46F5X RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTJ0IQB DM46F5X TN Phosphodiesterase 5A (PDE5A) DM46F5X MA Inhibitor DM46F5X RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTJGW1Z DM46F5X TN Phosphodiesterase 2A (PDE2A) DM46F5X MA Inhibitor DM46F5X RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TT06AWU DM46F5X TN Phosphodiesterase 3A (PDE3A) DM46F5X MA Inhibitor DM46F5X RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/2985781 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTHQENC DM46F5X TN Phosphodiesterase 1 (PDE1) DM46F5X MA Inhibitor DM46F5X RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/2985781 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTM2AOE DM46F5X TN Adenosine A2a receptor (ADORA2A) DM46F5X MA Inhibitor DM46F5X RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/3806581 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTVIAT9 DM46F5X TN Phosphodiesterase 4B (PDE4B) DM46F5X MA Inhibitor DM46F5X RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/2985781 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTNE7KG DM46F5X TN Adenosine A2b receptor (ADORA2B) DM46F5X MA Inhibitor DM46F5X RN Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/6279840 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTZ97H5 DM46F5X TN Phosphodiesterase 4A (PDE4A) DM46F5X MA Inhibitor DM46F5X RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/2985781 DM46F5X DI DM46F5X DM46F5X DN isobutylmethylxanthine DM46F5X TI TTJFY5U DM46F5X TN Adenosine A3 receptor (ADORA3) DM46F5X MA Inhibitor DM46F5X RN Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207. DM46F5X RU https://pubmed.ncbi.nlm.nih.gov/6279840 DM46GLQ DI DM46GLQ DM46GLQ DN 6-butyl-2,4-dipropylaminopyrimidine DM46GLQ TI TTZAYWL DM46GLQ TN Estrogen receptor (ESR) DM46GLQ MA Inhibitor DM46GLQ RN Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30. DM46GLQ RU https://pubmed.ncbi.nlm.nih.gov/18785725 DM46HAS DI DM46HAS DM46HAS DN GC-2107 DM46HAS TI TTCIHJA DM46HAS TN Coagulation factor Xa (F10) DM46HAS MA Inhibitor DM46HAS RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DM46HAS RU https://pubmed.ncbi.nlm.nih.gov/22844656 DM46ID2 DI DM46ID2 DM46ID2 DN 3-isopropylnaphthalene-1,2-dione DM46ID2 TI TTLZS4Q DM46ID2 TN M-phase inducer phosphatase 1 (MPIP1) DM46ID2 MA Inhibitor DM46ID2 RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DM46ID2 RU https://pubmed.ncbi.nlm.nih.gov/16434190 DM46J2H DI DM46J2H DM46J2H DN 7-hydroxy-3-(4-hydroxyphenyl)-3H-quinazolin-4-one DM46J2H TI TTOM3J0 DM46J2H TN Estrogen receptor beta (ESR2) DM46J2H MA Inhibitor DM46J2H RN Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55. DM46J2H RU https://pubmed.ncbi.nlm.nih.gov/16610787 DM46MKY DI DM46MKY DM46MKY DN 2,3-dihydro-1H-indene-5-sulfonamide DM46MKY TI TTANPDJ DM46MKY TN Carbonic anhydrase II (CA-II) DM46MKY MA Inhibitor DM46MKY RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM46MKY RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM46MKY DI DM46MKY DM46MKY DN 2,3-dihydro-1H-indene-5-sulfonamide DM46MKY TI TTUNARX DM46MKY TN Carbonic anhydrase (CA) DM46MKY MA Inhibitor DM46MKY RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DM46MKY RU https://pubmed.ncbi.nlm.nih.gov/18406497 DM46MKY DI DM46MKY DM46MKY DN 2,3-dihydro-1H-indene-5-sulfonamide DM46MKY TI TTHQPL7 DM46MKY TN Carbonic anhydrase I (CA-I) DM46MKY MA Inhibitor DM46MKY RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DM46MKY RU https://pubmed.ncbi.nlm.nih.gov/15501040 DM46MKY DI DM46MKY DM46MKY DN 2,3-dihydro-1H-indene-5-sulfonamide DM46MKY TI TTEYTKG DM46MKY TN Carbonic anhydrase XIV (CA-XIV) DM46MKY MA Inhibitor DM46MKY RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DM46MKY RU https://pubmed.ncbi.nlm.nih.gov/18406497 DM46MKY DI DM46MKY DM46MKY DN 2,3-dihydro-1H-indene-5-sulfonamide DM46MKY TI TTSYM0R DM46MKY TN Carbonic anhydrase XII (CA-XII) DM46MKY MA Inhibitor DM46MKY RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DM46MKY RU https://pubmed.ncbi.nlm.nih.gov/18406497 DM46VT2 DI DM46VT2 DM46VT2 DN 7-(trifluoromethyl)-1H-indole-2,3-dione DM46VT2 TI TTMF541 DM46VT2 TN Liver carboxylesterase (CES1) DM46VT2 MA Inhibitor DM46VT2 RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM46VT2 RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM471P5 DI DM471P5 DM471P5 DN 4-hydroxybenzaldehyde DM471P5 TI TTT2LD9 DM471P5 TN GABA transaminase (ABAT) DM471P5 MA Inhibitor DM471P5 RN Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4. DM471P5 RU https://pubmed.ncbi.nlm.nih.gov/19138517 DM471P5 DI DM471P5 DM471P5 DN 4-hydroxybenzaldehyde DM471P5 TI TTGP7BY DM471P5 TN Monoamine oxidase type B (MAO-B) DM471P5 MA Inhibitor DM471P5 RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM471P5 RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM4758S DI DM4758S DM4758S DN 3hydroxy-1-methyl-1-phenylurea DM4758S TI TTULVH8 DM4758S TN Tyrosinase (TYR) DM4758S MA Inhibitor DM4758S RN Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10. DM4758S RU https://pubmed.ncbi.nlm.nih.gov/18501598 DM478XZ DI DM478XZ DM478XZ DN Des-AA1,2,5-[(NalphaMe)Lys4,D-Nal8,IAmp9]SRIF DM478XZ TI TTIND6G DM478XZ TN Somatostatin receptor type 1 (SSTR1) DM478XZ MA Inhibitor DM478XZ RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM478XZ RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM47B2O DI DM47B2O DM47B2O DN ISIS 32035 DM47B2O TI TT9H4P3 DM47B2O TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DM47B2O RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DM47B2O RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DM47BEG DI DM47BEG DM47BEG DN (3R,4S)-293B DM47BEG TI TT846HF DM47BEG TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DM47BEG MA Blocker (channel blocker) DM47BEG RN A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54. DM47BEG RU https://pubmed.ncbi.nlm.nih.gov/11739240 DM47CO1 DI DM47CO1 DM47CO1 DN Okadaic acid DM47CO1 TI TTG8HIM DM47CO1 TN Dual specificity protein phosphatase 1 (DUSP1) DM47CO1 MA Inhibitor DM47CO1 RN Inhibition of protein phosphatase 1 stimulates secretion of Alzheimer amyloid precursor protein. Mol Med. 1995 Jul;1(5):535-41. DM47CO1 RU https://pubmed.ncbi.nlm.nih.gov/8529119 DM47F9I DI DM47F9I DM47F9I DN PT-101 DM47F9I TI TT84ETX DM47F9I TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM47F9I MA Inhibitor DM47F9I RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM47F9I RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM47IFL DI DM47IFL DM47IFL DN 4-nitrophenylsulfamide DM47IFL TI TTANPDJ DM47IFL TN Carbonic anhydrase II (CA-II) DM47IFL MA Inhibitor DM47IFL RN Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500. DM47IFL RU https://pubmed.ncbi.nlm.nih.gov/16759092 DM47JFS DI DM47JFS DM47JFS DN Desethyl isoquine DM47JFS TI TTVG215 DM47JFS TN Debrisoquine 4-hydroxylase (CYP2D6) DM47JFS MA Inhibitor DM47JFS RN Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for ... J Med Chem. 2009 Mar 12;52(5):1408-15. DM47JFS RU https://pubmed.ncbi.nlm.nih.gov/19222165 DM47TSV DI DM47TSV DM47TSV DN Repinotan DM47TSV TI TTSQIFT DM47TSV TN 5-HT 1A receptor (HTR1A) DM47TSV MA Antagonist DM47TSV RN Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist. J Pharmacol Exp Ther. 1998 Mar;284(3):1082-94. DM47TSV RU https://pubmed.ncbi.nlm.nih.gov/9495870 DM47XR8 DI DM47XR8 DM47XR8 DN N-(5-Amino-6-oxo-heptyl)-acetamidine DM47XR8 TI TTCM4B3 DM47XR8 TN Nitric-oxide synthase endothelial (NOS3) DM47XR8 MA Inhibitor DM47XR8 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM47XR8 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM47XR8 DI DM47XR8 DM47XR8 DN N-(5-Amino-6-oxo-heptyl)-acetamidine DM47XR8 TI TTF10I9 DM47XR8 TN Nitric-oxide synthase inducible (NOS2) DM47XR8 MA Inhibitor DM47XR8 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM47XR8 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM47XR8 DI DM47XR8 DM47XR8 DN N-(5-Amino-6-oxo-heptyl)-acetamidine DM47XR8 TI TTZUFI5 DM47XR8 TN Nitric-oxide synthase brain (NOS1) DM47XR8 MA Inhibitor DM47XR8 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM47XR8 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM47ZWK DI DM47ZWK DM47ZWK DN 3'-Oxo-Adenosine DM47ZWK TI TTE2KUJ DM47ZWK TN Adenosylhomocysteinase (AHCY) DM47ZWK MA Inhibitor DM47ZWK RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM47ZWK RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM483BG DI DM483BG DM483BG DN H-Dmt-Tic-D-Asp-N(Me)-Ph DM483BG TI TTKWM86 DM483BG TN Opioid receptor mu (MOP) DM483BG MA Inhibitor DM483BG RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM483BG RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM483BG DI DM483BG DM483BG DN H-Dmt-Tic-D-Asp-N(Me)-Ph DM483BG TI TT27RFC DM483BG TN Opioid receptor delta (OPRD1) DM483BG MA Inhibitor DM483BG RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM483BG RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM487FU DI DM487FU DM487FU DN Ingenol-3-bezoate DM487FU TI TT9WJ8U DM487FU TN Protein kinase C delta (PRKCD) DM487FU MA Inhibitor DM487FU RN Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method a... J Med Chem. 2001 May 24;44(11):1690-701. DM487FU RU https://pubmed.ncbi.nlm.nih.gov/11356104 DM487HF DI DM487HF DM487HF DN TUG-770 DM487HF TI TTB8FUC DM487HF TN Free fatty acid receptor 1 (GPR40) DM487HF MA Agonist DM487HF RN Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. ACS Med Chem Lett. 2013 May 9;4(5):441-445. DM487HF RU https://pubmed.ncbi.nlm.nih.gov/23687558 DM48AV3 DI DM48AV3 DM48AV3 DN GWTLNSAGYLLGPrPKPQQwFwLL-CONH2 DM48AV3 TI TTBPW3J DM48AV3 TN Galanin receptor type 2 (GAL2-R) DM48AV3 MA Inhibitor DM48AV3 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM48AV3 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM48AV3 DI DM48AV3 DM48AV3 DN GWTLNSAGYLLGPrPKPQQwFwLL-CONH2 DM48AV3 TI TTX3HNZ DM48AV3 TN Galanin receptor type 1 (GAL1-R) DM48AV3 MA Inhibitor DM48AV3 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM48AV3 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM48C7G DI DM48C7G DM48C7G DN 2-(benzyloxy)-N7-hydroxy-N1-phenylheptanediamide DM48C7G TI TTSHTOI DM48C7G TN Histone deacetylase 2 (HDAC2) DM48C7G MA Inhibitor DM48C7G RN Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. DM48C7G RU https://pubmed.ncbi.nlm.nih.gov/17892933 DM48F3D DI DM48F3D DM48F3D DN HU210 DM48F3D TI TT6OEDT DM48F3D TN Cannabinoid receptor 1 (CB1) DM48F3D MA Agonist DM48F3D RN The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004 Apr;113(8):1202-9. DM48F3D RU https://pubmed.ncbi.nlm.nih.gov/15085199 DM48HR9 DI DM48HR9 DM48HR9 DN PMID21802293C66 DM48HR9 TI TT7YMXZ DM48HR9 TN Tyrosine-protein kinase Srms (SRMS) DM48HR9 MA Inhibitor DM48HR9 RN Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships. Bioorg Med Chem Lett. 2011 Sep 15;21(18):5533-7. DM48HR9 RU https://pubmed.ncbi.nlm.nih.gov/21802293 DM48ISZ DI DM48ISZ DM48ISZ DN 1-(4-methyl-benzyl)-1H-imidazole DM48ISZ TI TTRA5BZ DM48ISZ TN Steroid 17-alpha-monooxygenase (S17AH) DM48ISZ MA Inhibitor DM48ISZ RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DM48ISZ RU https://pubmed.ncbi.nlm.nih.gov/16750362 DM48JMC DI DM48JMC DM48JMC DN 8-O-(4-chlorobenzenesulfonyl)manzamine F DM48JMC TI TTRSMW9 DM48JMC TN Glycogen synthase kinase-3 beta (GSK-3B) DM48JMC MA Inhibitor DM48JMC RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DM48JMC RU https://pubmed.ncbi.nlm.nih.gov/17708655 DM48MC3 DI DM48MC3 DM48MC3 DN WAY-256805 DM48MC3 TI TTAWNKZ DM48MC3 TN Norepinephrine transporter (NET) DM48MC3 MA Inhibitor DM48MC3 RN Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J Med Chem. 2008 Jul 10;51(13):4038-49. DM48MC3 RU https://pubmed.ncbi.nlm.nih.gov/18557608 DM48MHL DI DM48MHL DM48MHL DN WS-12 DM48MHL TI TTXDKTO DM48MHL TN Long transient receptor potential channel 8 (TRPM8) DM48MHL MA Activator DM48MHL RN Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship. J Pharm Pharm Sci. 2010;13(2):242-53. DM48MHL RU https://pubmed.ncbi.nlm.nih.gov/20816009 DM48QTG DI DM48QTG DM48QTG DN Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys) DM48QTG TI TTKRD0G DM48QTG TN Endothelin A receptor (EDNRA) DM48QTG MA Inhibitor DM48QTG RN Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994). DM48QTG RU http://www.sciencedirect.com/science/article/pii/S0960894X01801566 DM48QTG DI DM48QTG DM48QTG DN Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Ser-Val-Tyr-Phe-Cys) DM48QTG TI TT3ZTGU DM48QTG TN Endothelin B receptor (EDNRB) DM48QTG MA Inhibitor DM48QTG RN Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994). DM48QTG RU http://www.sciencedirect.com/science/article/pii/S0960894X01801566 DM48SML DI DM48SML DM48SML DN (R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine DM48SML TI TTZFYLI DM48SML TN Dopamine D1 receptor (D1R) DM48SML MA Inhibitor DM48SML RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DM48SML RU https://pubmed.ncbi.nlm.nih.gov/18251489 DM48SML DI DM48SML DM48SML DN (R)-(-)-N-propyl-2-methoxy-11-hydroxynoraporphine DM48SML TI TTEX248 DM48SML TN Dopamine D2 receptor (D2R) DM48SML MA Inhibitor DM48SML RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DM48SML RU https://pubmed.ncbi.nlm.nih.gov/18251489 DM48TIN DI DM48TIN DM48TIN DN 1-guanidino-7-isoquinolinesulphonamide DM48TIN TI TTGY7WI DM48TIN TN Urokinase-type plasminogen activator (PLAU) DM48TIN MA Inhibitor DM48TIN RN Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. DM48TIN RU https://pubmed.ncbi.nlm.nih.gov/17447747 DM48TIN DI DM48TIN DM48TIN DN 1-guanidino-7-isoquinolinesulphonamide DM48TIN TI TTP86E2 DM48TIN TN Plasminogen (PLG) DM48TIN MA Inhibitor DM48TIN RN Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. DM48TIN RU https://pubmed.ncbi.nlm.nih.gov/17447747 DM48VJR DI DM48VJR DM48VJR DN B-Nonylglucoside DM48VJR TI TTH0KSX DM48VJR TN Rhodopsin (RHO) DM48VJR MA Inhibitor DM48VJR RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM48VJR RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM48VJR DI DM48VJR DM48VJR DN B-Nonylglucoside DM48VJR TI TTXMY0J DM48VJR TN Pancreatic triacylglycerol lipase (PNLIP) DM48VJR MA Inhibitor DM48VJR RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM48VJR RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM48XV0 DI DM48XV0 DM48XV0 DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 DM48XV0 TI TTQW87Y DM48XV0 TN Opioid receptor kappa (OPRK1) DM48XV0 MA Inhibitor DM48XV0 RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DM48XV0 RU https://pubmed.ncbi.nlm.nih.gov/17315860 DM48XV0 DI DM48XV0 DM48XV0 DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 DM48XV0 TI TT27RFC DM48XV0 TN Opioid receptor delta (OPRD1) DM48XV0 MA Inhibitor DM48XV0 RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DM48XV0 RU https://pubmed.ncbi.nlm.nih.gov/17315860 DM48XV0 DI DM48XV0 DM48XV0 DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]NH2 DM48XV0 TI TTKWM86 DM48XV0 TN Opioid receptor mu (MOP) DM48XV0 MA Inhibitor DM48XV0 RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DM48XV0 RU https://pubmed.ncbi.nlm.nih.gov/17315860 DM48Y9E DI DM48Y9E DM48Y9E DN JNJ-38158471 DM48Y9E TI TTUTJGQ DM48Y9E TN Vascular endothelial growth factor receptor 2 (KDR) DM48Y9E MA Inhibitor DM48Y9E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM48Y9E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM48Z5Y DI DM48Z5Y DM48Z5Y DN 4-(3,5-difluorophenylethynyl)-2-methylthiazole DM48Z5Y TI TTHS256 DM48Z5Y TN Metabotropic glutamate receptor 5 (mGluR5) DM48Z5Y MA Inhibitor DM48Z5Y RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DM48Z5Y RU https://pubmed.ncbi.nlm.nih.gov/16451073 DM490BL DI DM490BL DM490BL DN 2-(heptylthiomethyl)-5-hydroxy-4H-pyran-4-one DM490BL TI TTULVH8 DM490BL TN Tyrosinase (TYR) DM490BL MA Inhibitor DM490BL RN Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71. DM490BL RU https://pubmed.ncbi.nlm.nih.gov/20934336 DM4912P DI DM4912P DM4912P DN 7-Mercapto-heptanoic acid phenylamide DM4912P TI TTYHPU6 DM4912P TN Histone deacetylase 10 (HDAC10) DM4912P MA Inhibitor DM4912P RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM4912P RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM4912P DI DM4912P DM4912P DN 7-Mercapto-heptanoic acid phenylamide DM4912P TI TTSHTOI DM4912P TN Histone deacetylase 2 (HDAC2) DM4912P MA Inhibitor DM4912P RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM4912P RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM4912P DI DM4912P DM4912P DN 7-Mercapto-heptanoic acid phenylamide DM4912P TI TTT6LFV DM4912P TN Histone deacetylase 8 (HDAC8) DM4912P MA Inhibitor DM4912P RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM4912P RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM4912P DI DM4912P DM4912P DN 7-Mercapto-heptanoic acid phenylamide DM4912P TI TTBH0VX DM4912P TN Histone deacetylase (HDAC) DM4912P MA Inhibitor DM4912P RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM4912P RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM4912P DI DM4912P DM4912P DN 7-Mercapto-heptanoic acid phenylamide DM4912P TI TTTQGH8 DM4912P TN Histone deacetylase 4 (HDAC4) DM4912P MA Inhibitor DM4912P RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM4912P RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM4912P DI DM4912P DM4912P DN 7-Mercapto-heptanoic acid phenylamide DM4912P TI TT5ZKDI DM4912P TN Histone deacetylase 6 (HDAC6) DM4912P MA Inhibitor DM4912P RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM4912P RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM4912P DI DM4912P DM4912P DN 7-Mercapto-heptanoic acid phenylamide DM4912P TI TT6R7JZ DM4912P TN Histone deacetylase 1 (HDAC1) DM4912P MA Inhibitor DM4912P RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM4912P RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM491FJ DI DM491FJ DM491FJ DN 4-phenyl-1-(1-phenylpropan-2-yl)piperidin-4-ol DM491FJ TI TTNT7K8 DM491FJ TN Nociceptin receptor (OPRL1) DM491FJ MA Inhibitor DM491FJ RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM491FJ RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM491YV DI DM491YV DM491YV DN 3-((1H-imidazol-1-yl)methyl)-9H-xanthen-9-one DM491YV TI TTSZLWK DM491YV TN Aromatase (CYP19A1) DM491YV MA Inhibitor DM491YV RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DM491YV RU https://pubmed.ncbi.nlm.nih.gov/20568782 DM493GU DI DM493GU DM493GU DN 5-oxo-20-HETE DM493GU TI TT7WBSV DM493GU TN Oxoeicosanoid receptor 1 (OXER1) DM493GU MA Agonist DM493GU RN Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. J Immunol. 1996 Jan 1;156(1):336-42. DM493GU RU https://pubmed.ncbi.nlm.nih.gov/8598482 DM496RP DI DM496RP DM496RP DN Fluphenazine DM496RP TI TTAIY2U DM496RP TN HUMAN clathrin-mediated endocytosis (RME) DM496RP MA Inhibitor DM496RP RN Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. DM496RP RU https://pubmed.ncbi.nlm.nih.gov/24841273 DM49AYM DI DM49AYM DM49AYM DN S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea DM49AYM TI TTZUFI5 DM49AYM TN Nitric-oxide synthase brain (NOS1) DM49AYM MA Inhibitor DM49AYM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM49AYM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TTEYTKG DM49B18 TN Carbonic anhydrase XIV (CA-XIV) DM49B18 MA Inhibitor DM49B18 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TTCFSPE DM49B18 TN Carbonic anhydrase VI (CA-VI) DM49B18 MA Inhibitor DM49B18 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TT2LVK8 DM49B18 TN Carbonic anhydrase IX (CA-IX) DM49B18 MA Inhibitor DM49B18 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TTSYM0R DM49B18 TN Carbonic anhydrase XII (CA-XII) DM49B18 MA Inhibitor DM49B18 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TTANPDJ DM49B18 TN Carbonic anhydrase II (CA-II) DM49B18 MA Inhibitor DM49B18 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TTZHA0O DM49B18 TN Carbonic anhydrase IV (CA-IV) DM49B18 MA Inhibitor DM49B18 RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/15686931 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TTUNARX DM49B18 TN Carbonic anhydrase (CA) DM49B18 MA Inhibitor DM49B18 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DM49B18 DI DM49B18 DM49B18 DN 4-Hydrazino-benzenesulfonamide DM49B18 TI TTHQPL7 DM49B18 TN Carbonic anhydrase I (CA-I) DM49B18 MA Inhibitor DM49B18 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DM49B18 RU https://pubmed.ncbi.nlm.nih.gov/15771455 DM49BFM DI DM49BFM DM49BFM DN BPH-629 DM49BFM TI TTIKWV4 DM49BFM TN Geranyltranstransferase (FDPS) DM49BFM MA Inhibitor DM49BFM RN Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. DM49BFM RU https://pubmed.ncbi.nlm.nih.gov/17535895 DM49F6Z DI DM49F6Z DM49F6Z DN 5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione DM49F6Z TI TTRAMF0 DM49F6Z TN Plasmodium Cytochrome B (Malaria MT-CYB) DM49F6Z MA Inhibitor DM49F6Z RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM49F6Z RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM49HIO DI DM49HIO DM49HIO DN N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine DM49HIO TI TT6OEDT DM49HIO TN Cannabinoid receptor 1 (CB1) DM49HIO MA Inhibitor DM49HIO RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DM49HIO RU https://pubmed.ncbi.nlm.nih.gov/16570929 DM49HIO DI DM49HIO DM49HIO DN N-arachidonoyl-O-(2-hydroxyethyl)hydroxylamine DM49HIO TI TTMSFAW DM49HIO TN Cannabinoid receptor 2 (CB2) DM49HIO MA Inhibitor DM49HIO RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DM49HIO RU https://pubmed.ncbi.nlm.nih.gov/16570929 DM49MYE DI DM49MYE DM49MYE DN PF-877423 DM49MYE TI TTN7BL9 DM49MYE TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM49MYE MA Inhibitor DM49MYE RN The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2010 May 1;20(9):2897-902. DM49MYE RU https://pubmed.ncbi.nlm.nih.gov/20363126 DM49PR1 DI DM49PR1 DM49PR1 DN 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole DM49PR1 TI TTBRKXS DM49PR1 TN Adrenergic receptor alpha-1B (ADRA1B) DM49PR1 MA Inhibitor DM49PR1 RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM49PR1 RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM49PR1 DI DM49PR1 DM49PR1 DN 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole DM49PR1 TI TT34BHT DM49PR1 TN Adrenergic receptor alpha-1D (ADRA1D) DM49PR1 MA Inhibitor DM49PR1 RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM49PR1 RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM49PR1 DI DM49PR1 DM49PR1 DN 4-(1-Naphthalen-1-yl-vinyl)-1H-imidazole DM49PR1 TI TTNGILX DM49PR1 TN Adrenergic receptor alpha-1A (ADRA1A) DM49PR1 MA Inhibitor DM49PR1 RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM49PR1 RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM49RWY DI DM49RWY DM49RWY DN 7-Hydroxy-6-nitro-2-phenyl-chromen-4-one DM49RWY TI TTFBNVI DM49RWY TN Aldose reductase (AKR1B1) DM49RWY MA Inhibitor DM49RWY RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DM49RWY RU https://pubmed.ncbi.nlm.nih.gov/10354396 DM49YTN DI DM49YTN DM49YTN DN (3r)-1-Acetyl-3-Methylpiperidine DM49YTN TI TTL2ADK DM49YTN TN Rotamase A (PPIA) DM49YTN MA Inhibitor DM49YTN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM49YTN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4A0NP DI DM4A0NP DM4A0NP DN SOPHORICOSIDE DM4A0NP TI TTPREZD DM4A0NP TN Interleukin-5 (IL5) DM4A0NP MA Inhibitor DM4A0NP RN Design and synthesis of novel hydroxyalkylaminomethylchromones for their IL-5 inhibitory activity. Bioorg Med Chem. 2010 Jul 1;18(13):4625-9. DM4A0NP RU https://pubmed.ncbi.nlm.nih.gov/20627591 DM4A1KJ DI DM4A1KJ DM4A1KJ DN UNC0638 DM4A1KJ TI TTS6RZT DM4A1KJ TN Histone-lysine N-methyltransferase EHMT2 (EHMT2) DM4A1KJ MA Inhibitor DM4A1KJ RN A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74. DM4A1KJ RU https://pubmed.ncbi.nlm.nih.gov/21743462 DM4A1KJ DI DM4A1KJ DM4A1KJ DN UNC0638 DM4A1KJ TI TTOFXD7 DM4A1KJ TN Euchromatic histone-lysine N-methyltransferase 1 (EHMT1) DM4A1KJ MA Inhibitor DM4A1KJ RN A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011 Jul 10;7(8):566-74. DM4A1KJ RU https://pubmed.ncbi.nlm.nih.gov/21743462 DM4A1TF DI DM4A1TF DM4A1TF DN Cyclo(1,11)H-ESIYDPGDDIK-OH DM4A1TF TI TTJDUNO DM4A1TF TN T-cell surface antigen CD2 (CD2) DM4A1TF MA Inhibitor DM4A1TF RN Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36. DM4A1TF RU https://pubmed.ncbi.nlm.nih.gov/19123855 DM4A527 DI DM4A527 DM4A527 DN 2-dibenzofuran-4-yl-6-morpholin-4-yl-pyran-4-one DM4A527 TI TTK3PY9 DM4A527 TN DNA-dependent protein kinase catalytic (PRKDC) DM4A527 MA Inhibitor DM4A527 RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM4A527 RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM4A761 DI DM4A761 DM4A761 DN JWH-297 DM4A761 TI TT6OEDT DM4A761 TN Cannabinoid receptor 1 (CB1) DM4A761 MA Inhibitor DM4A761 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM4A761 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM4A761 DI DM4A761 DM4A761 DN JWH-297 DM4A761 TI TTMSFAW DM4A761 TN Cannabinoid receptor 2 (CB2) DM4A761 MA Inhibitor DM4A761 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM4A761 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM4ABTN DI DM4ABTN DM4ABTN DN 1-[(n-hex-1-ylamino)ethyl]-1,1-bisphosphonic acid DM4ABTN TI TTIKWV4 DM4ABTN TN Geranyltranstransferase (FDPS) DM4ABTN MA Inhibitor DM4ABTN RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DM4ABTN RU https://pubmed.ncbi.nlm.nih.gov/18096393 DM4AEGQ DI DM4AEGQ DM4AEGQ DN HALOXYSTEROL A DM4AEGQ TI TTEB0GD DM4AEGQ TN Cholinesterase (BCHE) DM4AEGQ MA Inhibitor DM4AEGQ RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DM4AEGQ RU https://pubmed.ncbi.nlm.nih.gov/16274989 DM4AEGQ DI DM4AEGQ DM4AEGQ DN HALOXYSTEROL A DM4AEGQ TI TT1RS9F DM4AEGQ TN Acetylcholinesterase (AChE) DM4AEGQ MA Inhibitor DM4AEGQ RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DM4AEGQ RU https://pubmed.ncbi.nlm.nih.gov/16274989 DM4AI91 DI DM4AI91 DM4AI91 DN Endo-CD DM4AI91 TI TT63DI9 DM4AI91 TN Endostatin (COL18A1) DM4AI91 MA Modulator DM4AI91 RN Dual targeting of tumor angiogenesis and chemotherapy by endostatin-cytosine deaminase-uracil phosphoribosyltransferase.Mol Cancer Ther.2011 Aug;10(8):1327-36. DM4AI91 RU https://www.ncbi.nlm.nih.gov/pubmed/21610170 DM4AONZ DI DM4AONZ DM4AONZ DN MRS1523 DM4AONZ TI TTNE7KG DM4AONZ TN Adenosine A2b receptor (ADORA2B) DM4AONZ MA Antagonist DM4AONZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20). DM4AONZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20 DM4AONZ DI DM4AONZ DM4AONZ DN MRS1523 DM4AONZ TI TTK25J1 DM4AONZ TN Adenosine A1 receptor (ADORA1) DM4AONZ MA Antagonist DM4AONZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18). DM4AONZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18 DM4AONZ DI DM4AONZ DM4AONZ DN MRS1523 DM4AONZ TI TTJFY5U DM4AONZ TN Adenosine A3 receptor (ADORA3) DM4AONZ MA Antagonist DM4AONZ RN Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201. DM4AONZ RU https://pubmed.ncbi.nlm.nih.gov/9703464 DM4ATCI DI DM4ATCI DM4ATCI DN CAPSAZEPINE DM4ATCI TI TTKP2SU DM4ATCI TN Transient receptor potential cation channel V4 (TRPV4) DM4ATCI MA Inhibitor DM4ATCI RN Chain-branched acyclic phenethylthiocarbamates as vanilloid receptor antagonists. Bioorg Med Chem Lett. 2003 May 5;13(9):1549-52. DM4ATCI RU https://pubmed.ncbi.nlm.nih.gov/12699752 DM4ATCI DI DM4ATCI DM4ATCI DN CAPSAZEPINE DM4ATCI TI TTMI6F5 DM4ATCI TN Transient receptor potential cation channel V1 (TRPV1) DM4ATCI MA Inhibitor DM4ATCI RN The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem. 2007 May 31;50(11):2589-96. DM4ATCI RU https://pubmed.ncbi.nlm.nih.gov/17489570 DM4ATLM DI DM4ATLM DM4ATLM DN PMID23084894C9n DM4ATLM TI TTVBPDM DM4ATLM TN Metabotropic glutamate receptor 1 (mGluR1) DM4ATLM MA Modulator (allosteric modulator) DM4ATLM RN Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7223-6. DM4ATLM RU https://pubmed.ncbi.nlm.nih.gov/23084894 DM4AUCE DI DM4AUCE DM4AUCE DN KNI-10372 DM4AUCE TI TTXMNHO DM4AUCE TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM4AUCE MA Inhibitor DM4AUCE RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DM4AUCE RU https://pubmed.ncbi.nlm.nih.gov/17400453 DM4AUFR DI DM4AUFR DM4AUFR DN [Sar1,Tdf2]AngII DM4AUFR TI TT8DBY3 DM4AUFR TN Angiotensin II receptor type-1 (AGTR1) DM4AUFR MA Inhibitor DM4AUFR RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DM4AUFR RU https://pubmed.ncbi.nlm.nih.gov/20146480 DM4AYC2 DI DM4AYC2 DM4AYC2 DN Undecylamine-n,n-dimethyl-n-oxide DM4AYC2 TI TT3PQ2Y DM4AYC2 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM4AYC2 MA Inhibitor DM4AYC2 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM4AYC2 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM4AZG9 DI DM4AZG9 DM4AZG9 DN ISIS 25081 DM4AZG9 TI TT8H9GB DM4AZG9 TN MEK2 messenger RNA (MEK2 mRNA) DM4AZG9 RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DM4AZG9 RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DM4B2EN DI DM4B2EN DM4B2EN DN 1-(2-Pyridin-2-yl-ethyl)-3-thiazol-2-yl-thiourea DM4B2EN TI TT84ETX DM4B2EN TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4B2EN MA Inhibitor DM4B2EN RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM4B2EN RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM4B35Y DI DM4B35Y DM4B35Y DN ISIS 110066 DM4B35Y TI TTK1V5Q DM4B35Y TN Nucleolin messenger RNA (NCL mRNA) DM4B35Y RN US patent application no. 6,165,786, Antisense modulation of nucleolin expression. DM4B35Y RU http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true DM4B5JY DI DM4B5JY DM4B5JY DN 3-(trifluoromethyl)phenylboronic acid DM4B5JY TI TTDP1UC DM4B5JY TN Fatty acid amide hydrolase (FAAH) DM4B5JY MA Inhibitor DM4B5JY RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DM4B5JY RU https://pubmed.ncbi.nlm.nih.gov/18983140 DM4B6FO DI DM4B6FO DM4B6FO DN Receptor-Fc fusion proteins DM4B6FO TI TTWMIDN DM4B6FO TN B-cell-activating factor (TNFSF13B) DM4B6FO RN BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets. 2003 Feb;7(1):115-23. DM4B6FO RU https://pubmed.ncbi.nlm.nih.gov/12556207 DM4B73F DI DM4B73F DM4B73F DN 4'-(6-Methoxypyridin-3-yl)biphenyl-3-ol DM4B73F TI TTIWB6L DM4B73F TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM4B73F MA Inhibitor DM4B73F RN Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505. DM4B73F RU https://pubmed.ncbi.nlm.nih.gov/20413314 DM4BDEY DI DM4BDEY DM4BDEY DN PD-4074 DM4BDEY TI TTW4N16 DM4BDEY TN Neuropeptide Y receptor type 4 (NPY4R) DM4BDEY MA Agonist DM4BDEY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 307). DM4BDEY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=307 DM4BF1P DI DM4BF1P DM4BF1P DN PMID30247903-Compound-General structure26 DM4BF1P TI TT23XQV DM4BF1P TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM4BF1P MA Inhibitor DM4BF1P RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM4BF1P RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM4BFHR DI DM4BFHR DM4BFHR DN 2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile DM4BFHR TI TTGKNB4 DM4BFHR TN Epidermal growth factor receptor (EGFR) DM4BFHR MA Inhibitor DM4BFHR RN Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907. DM4BFHR RU https://pubmed.ncbi.nlm.nih.gov/1676428 DM4BFPE DI DM4BFPE DM4BFPE DN 4-[1-(4-hydroxyphenyl)-2-phenylvinyl]phenol DM4BFPE TI TTZAYWL DM4BFPE TN Estrogen receptor (ESR) DM4BFPE MA Inhibitor DM4BFPE RN Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64. DM4BFPE RU https://pubmed.ncbi.nlm.nih.gov/12431063 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TT2NUT5 DM4BP7S TN Adrenergic receptor alpha-2C (ADRA2C) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TT3ROYC DM4BP7S TN Serotonin transporter (SERT) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TTNGILX DM4BP7S TN Adrenergic receptor alpha-1A (ADRA1A) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TTWM4TY DM4BP7S TN Adrenergic receptor alpha-2B (ADRA2B) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TT4C8EA DM4BP7S TN Dopamine D3 receptor (D3R) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TTVBI8W DM4BP7S TN Dopamine transporter (DAT) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TTZPO1L DM4BP7S TN Substance-P receptor (TACR1) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TTWG9A4 DM4BP7S TN Adrenergic receptor alpha-2A (ADRA2A) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BP7S DI DM4BP7S DM4BP7S DN R-226161 DM4BP7S TI TTTIBOJ DM4BP7S TN Histamine H1 receptor (H1R) DM4BP7S MA Inhibitor DM4BP7S RN Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-a... Bioorg Med Chem. 2007 Jun 1;15(11):3649-60. DM4BP7S RU https://pubmed.ncbi.nlm.nih.gov/17407815 DM4BPL1 DI DM4BPL1 DM4BPL1 DN 4-(Methylhydrazino)-3-pyridinesulfonamide DM4BPL1 TI TTEYTKG DM4BPL1 TN Carbonic anhydrase XIV (CA-XIV) DM4BPL1 MA Inhibitor DM4BPL1 RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM4BPL1 RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM4BPL1 DI DM4BPL1 DM4BPL1 DN 4-(Methylhydrazino)-3-pyridinesulfonamide DM4BPL1 TI TT2LVK8 DM4BPL1 TN Carbonic anhydrase IX (CA-IX) DM4BPL1 MA Inhibitor DM4BPL1 RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM4BPL1 RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM4BPL1 DI DM4BPL1 DM4BPL1 DN 4-(Methylhydrazino)-3-pyridinesulfonamide DM4BPL1 TI TTSYM0R DM4BPL1 TN Carbonic anhydrase XII (CA-XII) DM4BPL1 MA Inhibitor DM4BPL1 RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM4BPL1 RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM4BPL1 DI DM4BPL1 DM4BPL1 DN 4-(Methylhydrazino)-3-pyridinesulfonamide DM4BPL1 TI TTANPDJ DM4BPL1 TN Carbonic anhydrase II (CA-II) DM4BPL1 MA Inhibitor DM4BPL1 RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM4BPL1 RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM4BPL1 DI DM4BPL1 DM4BPL1 DN 4-(Methylhydrazino)-3-pyridinesulfonamide DM4BPL1 TI TTHQPL7 DM4BPL1 TN Carbonic anhydrase I (CA-I) DM4BPL1 MA Inhibitor DM4BPL1 RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM4BPL1 RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM4BQ1W DI DM4BQ1W DM4BQ1W DN 2-Amino-6-p-tolylsulfanyl-benzonitrile DM4BQ1W TI TT84ETX DM4BQ1W TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM4BQ1W MA Inhibitor DM4BQ1W RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM4BQ1W RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM4BQFW DI DM4BQFW DM4BQFW DN omega-conotoxin GVIA DM4BQFW TI TT4FDG6 DM4BQFW TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM4BQFW MA Blocker (channel blocker) DM4BQFW RN Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44. DM4BQFW RU https://pubmed.ncbi.nlm.nih.gov/10938268 DM4BQFW DI DM4BQFW DM4BQFW DN omega-conotoxin GVIA DM4BQFW TI TTX4QDJ DM4BQFW TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DM4BQFW MA Blocker (channel blocker) DM4BQFW RN Novel omega-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem. 2000 Nov 10;275(45):35335-44. DM4BQFW RU https://pubmed.ncbi.nlm.nih.gov/10938268 DM4BWMO DI DM4BWMO DM4BWMO DN Acerogenin A DM4BWMO TI TT2UE56 DM4BWMO TN Sodium/glucose cotransporter 1 (SGLT1) DM4BWMO MA Inhibitor DM4BWMO RN Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4. DM4BWMO RU https://pubmed.ncbi.nlm.nih.gov/20036535 DM4BY5J DI DM4BY5J DM4BY5J DN [3H]OSIP339391 DM4BY5J TI TTNE7KG DM4BY5J TN Adenosine A2b receptor (ADORA2B) DM4BY5J MA Antagonist DM4BY5J RN [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem Pharmacol. 2004 Jul 15;68(2):305-12. DM4BY5J RU https://pubmed.ncbi.nlm.nih.gov/15194002 DM4BY5J DI DM4BY5J DM4BY5J DN [3H]OSIP339391 DM4BY5J TI TTJFY5U DM4BY5J TN Adenosine A3 receptor (ADORA3) DM4BY5J MA Inhibitor DM4BY5J RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DM4BY5J RU https://pubmed.ncbi.nlm.nih.gov/20537438 DM4BY5J DI DM4BY5J DM4BY5J DN [3H]OSIP339391 DM4BY5J TI TTM2AOE DM4BY5J TN Adenosine A2a receptor (ADORA2A) DM4BY5J MA Inhibitor DM4BY5J RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DM4BY5J RU https://pubmed.ncbi.nlm.nih.gov/20537438 DM4BY5J DI DM4BY5J DM4BY5J DN [3H]OSIP339391 DM4BY5J TI TTK25J1 DM4BY5J TN Adenosine A1 receptor (ADORA1) DM4BY5J MA Inhibitor DM4BY5J RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DM4BY5J RU https://pubmed.ncbi.nlm.nih.gov/20537438 DM4BYEQ DI DM4BYEQ DM4BYEQ DN [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine DM4BYEQ TI TT3ROYC DM4BYEQ TN Serotonin transporter (SERT) DM4BYEQ MA Inhibitor DM4BYEQ RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DM4BYEQ RU https://pubmed.ncbi.nlm.nih.gov/15115403 DM4BYEQ DI DM4BYEQ DM4BYEQ DN [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine DM4BYEQ TI TTAWNKZ DM4BYEQ TN Norepinephrine transporter (NET) DM4BYEQ MA Inhibitor DM4BYEQ RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DM4BYEQ RU https://pubmed.ncbi.nlm.nih.gov/15115403 DM4BYEQ DI DM4BYEQ DM4BYEQ DN [3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine DM4BYEQ TI TTVBI8W DM4BYEQ TN Dopamine transporter (DAT) DM4BYEQ MA Inhibitor DM4BYEQ RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DM4BYEQ RU https://pubmed.ncbi.nlm.nih.gov/15115403 DM4BZ2L DI DM4BZ2L DM4BZ2L DN PMID1738140C9 DM4BZ2L TI TTGMFY7 DM4BZ2L TN Aspartyl aminopeptidase (DNPEP) DM4BZ2L MA Inhibitor DM4BZ2L RN Alpha-Keto amide inhibitors of aminopeptidases. J Med Chem. 1992 Feb 7;35(3):451-6. DM4BZ2L RU https://pubmed.ncbi.nlm.nih.gov/1738140 DM4BZEC DI DM4BZEC DM4BZEC DN GCCSHPACAGNNQHIC* DM4BZEC TI TT5KPZR DM4BZEC TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM4BZEC MA Inhibitor DM4BZEC RN Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45. DM4BZEC RU https://pubmed.ncbi.nlm.nih.gov/16033252 DM4BZEC DI DM4BZEC DM4BZEC DN GCCSHPACAGNNQHIC* DM4BZEC TI TTLA931 DM4BZEC TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM4BZEC MA Inhibitor DM4BZEC RN Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45. DM4BZEC RU https://pubmed.ncbi.nlm.nih.gov/16033252 DM4C70S DI DM4C70S DM4C70S DN Octahydro-isoindol-(1Z)-ylideneamine DM4C70S TI TTF10I9 DM4C70S TN Nitric-oxide synthase inducible (NOS2) DM4C70S MA Inhibitor DM4C70S RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM4C70S RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM4C70S DI DM4C70S DM4C70S DN Octahydro-isoindol-(1Z)-ylideneamine DM4C70S TI TTZUFI5 DM4C70S TN Nitric-oxide synthase brain (NOS1) DM4C70S MA Inhibitor DM4C70S RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM4C70S RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM4C9H2 DI DM4C9H2 DM4C9H2 DN 2-(3-Methoxy-phenyl)-1-methyl-ethylamine DM4C9H2 TI TTJQOD7 DM4C9H2 TN 5-HT 2A receptor (HTR2A) DM4C9H2 MA Inhibitor DM4C9H2 RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM4C9H2 RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM4C9H2 DI DM4C9H2 DM4C9H2 DN 2-(3-Methoxy-phenyl)-1-methyl-ethylamine DM4C9H2 TI TTSQIFT DM4C9H2 TN 5-HT 1A receptor (HTR1A) DM4C9H2 MA Inhibitor DM4C9H2 RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM4C9H2 RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM4C9H2 DI DM4C9H2 DM4C9H2 DN 2-(3-Methoxy-phenyl)-1-methyl-ethylamine DM4C9H2 TI TT6MSOK DM4C9H2 TN 5-HT 1D receptor (HTR1D) DM4C9H2 MA Inhibitor DM4C9H2 RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM4C9H2 RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM4CDIB DI DM4CDIB DM4CDIB DN L-655708 DM4CDIB TI TTNZPQ1 DM4CDIB TN GABA(A) receptor alpha-5 (GABRA5) DM4CDIB MA Inhibitor DM4CDIB RN 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22. DM4CDIB RU https://pubmed.ncbi.nlm.nih.gov/15027873 DM4CDIB DI DM4CDIB DM4CDIB DN L-655708 DM4CDIB TI TT1MPAY DM4CDIB TN GABA(A) receptor alpha-1 (GABRA1) DM4CDIB MA Inhibitor DM4CDIB RN 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22. DM4CDIB RU https://pubmed.ncbi.nlm.nih.gov/15027873 DM4CDIB DI DM4CDIB DM4CDIB DN L-655708 DM4CDIB TI TT37EDJ DM4CDIB TN GABA(A) receptor alpha-3 (GABRA3) DM4CDIB MA Inhibitor DM4CDIB RN 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22. DM4CDIB RU https://pubmed.ncbi.nlm.nih.gov/15027873 DM4CDIB DI DM4CDIB DM4CDIB DN L-655708 DM4CDIB TI TTNJYV2 DM4CDIB TN Gamma-aminobutyric acid receptor (GAR) DM4CDIB MA Inhibitor DM4CDIB RN 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22. DM4CDIB RU https://pubmed.ncbi.nlm.nih.gov/15027873 DM4CDIB DI DM4CDIB DM4CDIB DN L-655708 DM4CDIB TI TTBMV1G DM4CDIB TN GABA(A) receptor alpha-2 (GABRA2) DM4CDIB MA Inhibitor DM4CDIB RN 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22. DM4CDIB RU https://pubmed.ncbi.nlm.nih.gov/15027873 DM4CDIB DI DM4CDIB DM4CDIB DN L-655708 DM4CDIB TI TT06RH5 DM4CDIB TN GABA(A) receptor gamma-2 (GABRG2) DM4CDIB MA Inhibitor DM4CDIB RN 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor li... J Med Chem. 2004 Mar 25;47(7):1807-22. DM4CDIB RU https://pubmed.ncbi.nlm.nih.gov/15027873 DM4CDYG DI DM4CDYG DM4CDYG DN N,N-Dimethyl-1'H-phenothiazine-1'-carboxamide DM4CDYG TI TTEB0GD DM4CDYG TN Cholinesterase (BCHE) DM4CDYG MA Inhibitor DM4CDYG RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM4CDYG RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM4CEQP DI DM4CEQP DM4CEQP DN 1,1,1-Trifluoro-tridecan-2-one DM4CEQP TI TTDP1UC DM4CEQP TN Fatty acid amide hydrolase (FAAH) DM4CEQP MA Inhibitor DM4CEQP RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DM4CEQP RU https://pubmed.ncbi.nlm.nih.gov/15771430 DM4CI57 DI DM4CI57 DM4CI57 DN SCH-68631 DM4CI57 TI TTWXB3E DM4CI57 TN Hepatitis C virus NS3 helicase (HCV NS3) DM4CI57 MA Inhibitor DM4CI57 RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DM4CI57 RU https://pubmed.ncbi.nlm.nih.gov/15633995 DM4CV1E DI DM4CV1E DM4CV1E DN 8-Bromo-Adenosine-5'-Monophosphate DM4CV1E TI TTVIAT9 DM4CV1E TN Phosphodiesterase 4B (PDE4B) DM4CV1E MA Inhibitor DM4CV1E RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM4CV1E RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM4CYKE DI DM4CYKE DM4CYKE DN Acylureido penicillin mezlocillin DM4CYKE TI TT85JMW DM4CYKE TN Bacterial Penicillin binding protein 3 (Bact mrcA) DM4CYKE MA Binder DM4CYKE RN Microbiology, pharmacology, and clinical use of mezlocillin sodium. Pharmacotherapy. 1982 Nov-Dec;2(6):300-12. DM4CYKE RU https://pubmed.ncbi.nlm.nih.gov/6220263 DM4CZ5B DI DM4CZ5B DM4CZ5B DN Bip-tyr-thr-pro-thr(obzl)-gly DM4CZ5B TI TTVBI8W DM4CZ5B TN Dopamine transporter (DAT) DM4CZ5B MA Inhibitor DM4CZ5B RN Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. DM4CZ5B RU https://pubmed.ncbi.nlm.nih.gov/16821765 DM4D1UT DI DM4D1UT DM4D1UT DN 2-(3-Methylsulfanyl-propyl)-pentanedioic acid DM4D1UT TI TT9G4N0 DM4D1UT TN Glutamate carboxypeptidase II (GCPII) DM4D1UT MA Inhibitor DM4D1UT RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DM4D1UT RU https://pubmed.ncbi.nlm.nih.gov/12723961 DM4D6ZB DI DM4D6ZB DM4D6ZB DN BMS-1 DM4D6ZB TI TTDP1UC DM4D6ZB TN Fatty acid amide hydrolase (FAAH) DM4D6ZB MA Inhibitor DM4D6ZB RN Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem. 2009 Jan 8;52(1):170-80. DM4D6ZB RU https://pubmed.ncbi.nlm.nih.gov/19072118 DM4D7V6 DI DM4D7V6 DM4D7V6 DN Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine DM4D7V6 TI TTVBI8W DM4D7V6 TN Dopamine transporter (DAT) DM4D7V6 MA Inhibitor DM4D7V6 RN Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9. DM4D7V6 RU https://pubmed.ncbi.nlm.nih.gov/18621528 DM4D7V6 DI DM4D7V6 DM4D7V6 DN Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine DM4D7V6 TI TT3ROYC DM4D7V6 TN Serotonin transporter (SERT) DM4D7V6 MA Inhibitor DM4D7V6 RN Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9. DM4D7V6 RU https://pubmed.ncbi.nlm.nih.gov/18621528 DM4D7V6 DI DM4D7V6 DM4D7V6 DN Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine DM4D7V6 TI TTAWNKZ DM4D7V6 TN Norepinephrine transporter (NET) DM4D7V6 MA Inhibitor DM4D7V6 RN Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9. DM4D7V6 RU https://pubmed.ncbi.nlm.nih.gov/18621528 DM4D9T3 DI DM4D9T3 DM4D9T3 DN KNI-10742 DM4D9T3 TI TTXMNHO DM4D9T3 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM4D9T3 MA Inhibitor DM4D9T3 RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DM4D9T3 RU https://pubmed.ncbi.nlm.nih.gov/20634066 DM4DB0W DI DM4DB0W DM4DB0W DN NTE-2 DM4DB0W TI TT2EDHU DM4DB0W TN Insulin-degrading enzyme (IDE) DM4DB0W MA Inhibitor DM4DB0W RN Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo. J Biol Chem. 2015 Aug 14;290(33):20044-59. DM4DB0W RU https://pubmed.ncbi.nlm.nih.gov/26085101 DM4DFUS DI DM4DFUS DM4DFUS DN 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenol DM4DFUS TI TTI7421 DM4DFUS TN Platelet-derived growth factor receptor beta (PDGFRB) DM4DFUS MA Inhibitor DM4DFUS RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DM4DFUS RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DM4DG1Y DI DM4DG1Y DM4DG1Y DN Naringin DM4DG1Y TI TTUGD21 DM4DG1Y TN Sodium-independent organic anion transporter (SLCO1A2) DM4DG1Y MA Inhibitor DM4DG1Y RN Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin Pharmacol Ther. 2007 Apr;81(4):495-502. DM4DG1Y RU https://pubmed.ncbi.nlm.nih.gov/17301733 DM4DIS3 DI DM4DIS3 DM4DIS3 DN Methyl 9H-carbazole-2-carboxylate DM4DIS3 TI TTBGTCW DM4DIS3 TN Kinesin spindle messenger RNA (KIF11 mRNA) DM4DIS3 MA Inhibitor DM4DIS3 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM4DIS3 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM4DSE7 DI DM4DSE7 DM4DSE7 DN CGS-13767 DM4DSE7 TI TT1MPAY DM4DSE7 TN GABA(A) receptor alpha-1 (GABRA1) DM4DSE7 MA Inhibitor DM4DSE7 RN Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90. DM4DSE7 RU https://pubmed.ncbi.nlm.nih.gov/1846920 DM4DSE7 DI DM4DSE7 DM4DSE7 DN CGS-13767 DM4DSE7 TI TTZA1NY DM4DSE7 TN GABA(A) receptor beta-2 (GABRB2) DM4DSE7 MA Inhibitor DM4DSE7 RN Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90. DM4DSE7 RU https://pubmed.ncbi.nlm.nih.gov/1846920 DM4DSE7 DI DM4DSE7 DM4DSE7 DN CGS-13767 DM4DSE7 TI TTNJYV2 DM4DSE7 TN Gamma-aminobutyric acid receptor (GAR) DM4DSE7 MA Inhibitor DM4DSE7 RN Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90. DM4DSE7 RU https://pubmed.ncbi.nlm.nih.gov/1846920 DM4DSE7 DI DM4DSE7 DM4DSE7 DN CGS-13767 DM4DSE7 TI TT06RH5 DM4DSE7 TN GABA(A) receptor gamma-2 (GABRG2) DM4DSE7 MA Inhibitor DM4DSE7 RN Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90. DM4DSE7 RU https://pubmed.ncbi.nlm.nih.gov/1846920 DM4E6H1 DI DM4E6H1 DM4E6H1 DN AKNADILACTAM DM4E6H1 TI TT27RFC DM4E6H1 TN Opioid receptor delta (OPRD1) DM4E6H1 MA Inhibitor DM4E6H1 RN Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91. DM4E6H1 RU https://pubmed.ncbi.nlm.nih.gov/20426456 DM4E6HW DI DM4E6HW DM4E6HW DN 4-MPPTS DM4E6HW TI TTXJ47W DM4E6HW TN Metabotropic glutamate receptor 2 (mGluR2) DM4E6HW MA Modulator (allosteric modulator) DM4E6HW RN SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3099-102. DM4E6HW RU https://pubmed.ncbi.nlm.nih.gov/15149652 DM4E6Y8 DI DM4E6Y8 DM4E6Y8 DN ISIS 113187 DM4E6Y8 TI TTHJT3X DM4E6Y8 TN STAT3 messenger RNA (STAT3 mRNA) DM4E6Y8 RN US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression. DM4E6Y8 RU http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true DM4E8C9 DI DM4E8C9 DM4E8C9 DN N,N-Diisopropyl-1'H-phenothiazine-1'-carboxamide DM4E8C9 TI TTEB0GD DM4E8C9 TN Cholinesterase (BCHE) DM4E8C9 MA Inhibitor DM4E8C9 RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM4E8C9 RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM4E8NJ DI DM4E8NJ DM4E8NJ DN N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea DM4E8NJ TI TT2J34L DM4E8NJ TN Arachidonate 5-lipoxygenase (5-LOX) DM4E8NJ MA Inhibitor DM4E8NJ RN Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. J Med Chem. 1997 Feb 28;40(5):819-24. DM4E8NJ RU https://pubmed.ncbi.nlm.nih.gov/9057869 DM4E8NJ DI DM4E8NJ DM4E8NJ DN N-hydroxy-N-[1-(4-isobutylphenyl)ethyl]urea DM4E8NJ TI TTSJ6Q4 DM4E8NJ TN LOX-5 messenger RNA (ALOX5 mRNA) DM4E8NJ MA Inhibitor DM4E8NJ RN Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors. J Med Chem. 1997 Feb 28;40(5):819-24. DM4E8NJ RU https://pubmed.ncbi.nlm.nih.gov/9057869 DM4E9J2 DI DM4E9J2 DM4E9J2 DN S-(N-pentyl-N-hydroxycarbamoyl)glutathione DM4E9J2 TI TTV9A7R DM4E9J2 TN Lactoylglutathione lyase (GLO1) DM4E9J2 MA Inhibitor DM4E9J2 RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DM4E9J2 RU https://pubmed.ncbi.nlm.nih.gov/11052803 DM4EC0J DI DM4EC0J DM4EC0J DN 4-(6-Cyclopentyl-hex-3-ynyl)-1H-imidazole DM4EC0J TI TT9JNIC DM4EC0J TN Histamine H3 receptor (H3R) DM4EC0J MA Inhibitor DM4EC0J RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DM4EC0J RU https://pubmed.ncbi.nlm.nih.gov/9871722 DM4EH2J DI DM4EH2J DM4EH2J DN (5-Bromo-pentyl)-trimethyl-ammonium DM4EH2J TI TT1RS9F DM4EH2J TN Acetylcholinesterase (AChE) DM4EH2J MA Inhibitor DM4EH2J RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DM4EH2J RU https://pubmed.ncbi.nlm.nih.gov/8978837 DM4EIQ3 DI DM4EIQ3 DM4EIQ3 DN 2-fluorophenyl 4-butoxybenzylcarbamate DM4EIQ3 TI TTDP1UC DM4EIQ3 TN Fatty acid amide hydrolase (FAAH) DM4EIQ3 MA Inhibitor DM4EIQ3 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM4EIQ3 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM4EKHR DI DM4EKHR DM4EKHR DN DSR-17759 DM4EKHR TI TT9O6WS DM4EKHR TN Glucagon receptor (GCGR) DM4EKHR MA Antagonist DM4EKHR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 251). DM4EKHR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251 DM4EL6M DI DM4EL6M DM4EL6M DN 3-chloro-N-(4-methylthiazol-2-yl)benzamide DM4EL6M TI TTHS256 DM4EL6M TN Metabotropic glutamate receptor 5 (mGluR5) DM4EL6M MA Inhibitor DM4EL6M RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DM4EL6M RU https://pubmed.ncbi.nlm.nih.gov/16678408 DM4ENGI DI DM4ENGI DM4ENGI DN 4-[2-(3,5-Dimethoxy-phenyl)-vinyl]-pyridine DM4ENGI TI TTI84H7 DM4ENGI TN Cytochrome P450 1B1 (CYP1B1) DM4ENGI MA Inhibitor DM4ENGI RN Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. DM4ENGI RU https://pubmed.ncbi.nlm.nih.gov/11754588 DM4ERYF DI DM4ERYF DM4ERYF DN 3-demethoxy-3-L-fucopyranosylaminothiocolchicine DM4ERYF TI TT1MPAY DM4ERYF TN GABA(A) receptor alpha-1 (GABRA1) DM4ERYF MA Inhibitor DM4ERYF RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM4ERYF RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM4ERYF DI DM4ERYF DM4ERYF DN 3-demethoxy-3-L-fucopyranosylaminothiocolchicine DM4ERYF TI TTF45NW DM4ERYF TN Strychnine-binding glycine receptor (GLRA1) DM4ERYF MA Inhibitor DM4ERYF RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM4ERYF RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM4ERYF DI DM4ERYF DM4ERYF DN 3-demethoxy-3-L-fucopyranosylaminothiocolchicine DM4ERYF TI TT06RH5 DM4ERYF TN GABA(A) receptor gamma-2 (GABRG2) DM4ERYF MA Inhibitor DM4ERYF RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM4ERYF RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM4ERYF DI DM4ERYF DM4ERYF DN 3-demethoxy-3-L-fucopyranosylaminothiocolchicine DM4ERYF TI TTZ8EM9 DM4ERYF TN Glycine receptor (GlyR) DM4ERYF MA Inhibitor DM4ERYF RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM4ERYF RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM4ERYF DI DM4ERYF DM4ERYF DN 3-demethoxy-3-L-fucopyranosylaminothiocolchicine DM4ERYF TI TTNJYV2 DM4ERYF TN Gamma-aminobutyric acid receptor (GAR) DM4ERYF MA Inhibitor DM4ERYF RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM4ERYF RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM4ERYF DI DM4ERYF DM4ERYF DN 3-demethoxy-3-L-fucopyranosylaminothiocolchicine DM4ERYF TI TTZA1NY DM4ERYF TN GABA(A) receptor beta-2 (GABRB2) DM4ERYF MA Inhibitor DM4ERYF RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM4ERYF RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM4EX8Y DI DM4EX8Y DM4EX8Y DN diamide 7 DM4EX8Y TI TT5Y4EM DM4EX8Y TN N-formyl peptide receptor (FPR1) DM4EX8Y MA Antagonist DM4EX8Y RN Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett. 2011 May 15;21(10):2991-7. DM4EX8Y RU https://pubmed.ncbi.nlm.nih.gov/21486695 DM4EY5S DI DM4EY5S DM4EY5S DN 2,4-dichloro-5-sulfamoylbenzoic acid DM4EY5S TI TTANPDJ DM4EY5S TN Carbonic anhydrase II (CA-II) DM4EY5S MA Inhibitor DM4EY5S RN Synthesis, characterization and antiglaucoma activity of a novel proton transfer compound and a mixed-ligand Zn(II) complex. Bioorg Med Chem. 2010 Jan 15;18(2):930-8. DM4EY5S RU https://pubmed.ncbi.nlm.nih.gov/20006931 DM4EY5S DI DM4EY5S DM4EY5S DN 2,4-dichloro-5-sulfamoylbenzoic acid DM4EY5S TI TTHQPL7 DM4EY5S TN Carbonic anhydrase I (CA-I) DM4EY5S MA Inhibitor DM4EY5S RN Synthesis, characterization and antiglaucoma activity of a novel proton transfer compound and a mixed-ligand Zn(II) complex. Bioorg Med Chem. 2010 Jan 15;18(2):930-8. DM4EY5S RU https://pubmed.ncbi.nlm.nih.gov/20006931 DM4EZOB DI DM4EZOB DM4EZOB DN 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine DM4EZOB TI TTWM4TY DM4EZOB TN Adrenergic receptor alpha-2B (ADRA2B) DM4EZOB MA Inhibitor DM4EZOB RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM4EZOB RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM4EZOB DI DM4EZOB DM4EZOB DN 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine DM4EZOB TI TTWG9A4 DM4EZOB TN Adrenergic receptor alpha-2A (ADRA2A) DM4EZOB MA Inhibitor DM4EZOB RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM4EZOB RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM4EZOB DI DM4EZOB DM4EZOB DN 2,3,4,5-Tetrahydro-1H-benzo[e][1,4]diazepine DM4EZOB TI TT2NUT5 DM4EZOB TN Adrenergic receptor alpha-2C (ADRA2C) DM4EZOB MA Inhibitor DM4EZOB RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM4EZOB RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM4F1GJ DI DM4F1GJ DM4F1GJ DN 1-[4-(Benzothiazol-2-yloxy)benzyl]piperidin-4-ol DM4F1GJ TI TTXZEAJ DM4F1GJ TN Leukotriene A-4 hydrolase (LTA4H) DM4F1GJ MA Inhibitor DM4F1GJ RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DM4F1GJ RU https://pubmed.ncbi.nlm.nih.gov/18588282 DM4F5OG DI DM4F5OG DM4F5OG DN 6-hydroxy-3-(3',5'-dihydroxyphenyl)coumarin DM4F5OG TI TT34BHT DM4F5OG TN Adrenergic receptor alpha-1D (ADRA1D) DM4F5OG MA Inhibitor DM4F5OG RN Design, synthesis, and vasorelaxant and platelet antiaggregatory activities of coumarin-resveratrol hybrids. Bioorg Med Chem Lett. 2006 Jan 15;16(2):257-61. DM4F5OG RU https://pubmed.ncbi.nlm.nih.gov/16275073 DM4F96I DI DM4F96I DM4F96I DN KKHT-11018 DM4F96I TI TT729IR DM4F96I TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM4F96I MA Inhibitor DM4F96I RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DM4F96I RU https://pubmed.ncbi.nlm.nih.gov/17035033 DM4FASR DI DM4FASR DM4FASR DN Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2 DM4FASR TI TTKWM86 DM4FASR TN Opioid receptor mu (MOP) DM4FASR MA Inhibitor DM4FASR RN Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52. DM4FASR RU https://pubmed.ncbi.nlm.nih.gov/9288177 DM4FASR DI DM4FASR DM4FASR DN Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2 DM4FASR TI TT27RFC DM4FASR TN Opioid receptor delta (OPRD1) DM4FASR MA Inhibitor DM4FASR RN Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52. DM4FASR RU https://pubmed.ncbi.nlm.nih.gov/9288177 DM4FC9O DI DM4FC9O DM4FC9O DN 4-(3,5-Dimethoxyphenethyl)benzenamine DM4FC9O TI TTSZLWK DM4FC9O TN Aromatase (CYP19A1) DM4FC9O MA Inhibitor DM4FC9O RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DM4FC9O RU https://pubmed.ncbi.nlm.nih.gov/20558073 DM4FEU8 DI DM4FEU8 DM4FEU8 DN C-178 DM4FEU8 TI TTT402Y DM4FEU8 TN Stimulator of interferon genes protein (TMEM173) DM4FEU8 MA Agonist DM4FEU8 RN Targeting STING with covalent small-molecule inhibitors. Nature. 2018 Jul;559(7713):269-273. DM4FEU8 RU https://pubmed.ncbi.nlm.nih.gov/29973723 DM4FG32 DI DM4FG32 DM4FG32 DN MK-11 DM4FG32 TI TTD0CIQ DM4FG32 TN Melanocortin receptor 4 (MC4R) DM4FG32 MA Inhibitor DM4FG32 RN Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50. DM4FG32 RU https://pubmed.ncbi.nlm.nih.gov/12036373 DM4FG32 DI DM4FG32 DM4FG32 DN MK-11 DM4FG32 TI TTEOSZT DM4FG32 TN Melanocortin receptor (MCR) DM4FG32 MA Inhibitor DM4FG32 RN Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50. DM4FG32 RU https://pubmed.ncbi.nlm.nih.gov/12036373 DM4FG32 DI DM4FG32 DM4FG32 DN MK-11 DM4FG32 TI TTNI91K DM4FG32 TN Melanocortin receptor 3 (MC3R) DM4FG32 MA Inhibitor DM4FG32 RN Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50. DM4FG32 RU https://pubmed.ncbi.nlm.nih.gov/12036373 DM4FIZJ DI DM4FIZJ DM4FIZJ DN HuMax-CD38b DM4FIZJ TI TTPURFN DM4FIZJ TN Cyclic ADP-ribose hydrolase 1 (CD38) DM4FIZJ MA Modulator DM4FIZJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2766). DM4FIZJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2766 DM4FJHO DI DM4FJHO DM4FJHO DN (5-Methoxy-chroman-3-yl)-dipropyl-amine DM4FJHO TI TTEX248 DM4FJHO TN Dopamine D2 receptor (D2R) DM4FJHO MA Inhibitor DM4FJHO RN 3-amino-3,4-dihydro-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 2. Synthesis and quantitative structure... J Med Chem. 1996 Oct 11;39(21):4285-98. DM4FJHO RU https://pubmed.ncbi.nlm.nih.gov/8863806 DM4FKR1 DI DM4FKR1 DM4FKR1 DN H-Arg-Arg-Pro-Tyr-Ile-N-Me-Leu-OH DM4FKR1 TI TTTUMEP DM4FKR1 TN Neurotensin receptor type 1 (NTSR1) DM4FKR1 MA Inhibitor DM4FKR1 RN Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68. DM4FKR1 RU https://pubmed.ncbi.nlm.nih.gov/18809332 DM4FLK6 DI DM4FLK6 DM4FLK6 DN 4-propyl-N-(quinolin-3-yl)benzamide DM4FLK6 TI TTMI6F5 DM4FLK6 TN Transient receptor potential cation channel V1 (TRPV1) DM4FLK6 MA Inhibitor DM4FLK6 RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DM4FLK6 RU https://pubmed.ncbi.nlm.nih.gov/18359227 DM4FMGJ DI DM4FMGJ DM4FMGJ DN L-798,106 DM4FMGJ TI TTPNGDE DM4FMGJ TN Prostaglandin E2 receptor EP3 (PTGER3) DM4FMGJ MA Antagonist DM4FMGJ RN Dual modulation of urinary bladder activity and urine flow by prostanoid EP3 receptors in the conscious rat. Br J Pharmacol. 2009 Sep;158(1):372-81. DM4FMGJ RU https://pubmed.ncbi.nlm.nih.gov/19486006 DM4FMPJ DI DM4FMPJ DM4FMPJ DN CGEN-855 DM4FMPJ TI TT5Y4EM DM4FMPJ TN N-formyl peptide receptor (FPR1) DM4FMPJ MA Agonist DM4FMPJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 222). DM4FMPJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=222 DM4FMZP DI DM4FMZP DM4FMZP DN N-Methylmesoporphyrin DM4FMZP TI TTQ6VF4 DM4FMZP TN Ferrochelatase (FECH) DM4FMZP MA Inhibitor DM4FMZP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4FMZP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4FR71 DI DM4FR71 DM4FR71 DN muramyl dipeptide DM4FR71 TI TTQX29T DM4FR71 TN NLR pyrin domain containing 1 (NLRP1) DM4FR71 MA Agonist DM4FR71 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1768). DM4FR71 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1768 DM4FR71 DI DM4FR71 DM4FR71 DN muramyl dipeptide DM4FR71 TI TTYPUHA DM4FR71 TN Pattern recognition receptor NOD2 (NOD2) DM4FR71 MA Agonist DM4FR71 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1763). DM4FR71 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1763 DM4FSTL DI DM4FSTL DM4FSTL DN (1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl DM4FSTL TI TTM2AOE DM4FSTL TN Adenosine A2a receptor (ADORA2A) DM4FSTL MA Inhibitor DM4FSTL RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DM4FSTL RU https://pubmed.ncbi.nlm.nih.gov/2002461 DM4FSTL DI DM4FSTL DM4FSTL DN (1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl DM4FSTL TI TTK25J1 DM4FSTL TN Adenosine A1 receptor (ADORA1) DM4FSTL MA Inhibitor DM4FSTL RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DM4FSTL RU https://pubmed.ncbi.nlm.nih.gov/2002461 DM4FSTL DI DM4FSTL DM4FSTL DN (1H-Imidazo[4,5-c]quinolin-4-yl)-phenyl-amine HCl DM4FSTL TI TTNE7KG DM4FSTL TN Adenosine A2b receptor (ADORA2B) DM4FSTL MA Inhibitor DM4FSTL RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DM4FSTL RU https://pubmed.ncbi.nlm.nih.gov/2002461 DM4FSXK DI DM4FSXK DM4FSXK DN Bip-tyr(3bzl)-thr-pro-lys-thr DM4FSXK TI TTVBI8W DM4FSXK TN Dopamine transporter (DAT) DM4FSXK MA Inhibitor DM4FSXK RN Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. DM4FSXK RU https://pubmed.ncbi.nlm.nih.gov/16821765 DM4FVDS DI DM4FVDS DM4FVDS DN CAM-2036 DM4FVDS TI TTVIMDE DM4FVDS TN Glucagon-like peptide 1 receptor (GLP1R) DM4FVDS MA Agonist DM4FVDS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DM4FVDS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DM4FW3H DI DM4FW3H DM4FW3H DN ETICLOPRIDE DM4FW3H TI TTEX248 DM4FW3H TN Dopamine D2 receptor (D2R) DM4FW3H MA Inhibitor DM4FW3H RN Potential antipsychotic agents 5. Synthesis and antidopaminergic properties of substituted 5,6-dimethoxysalicylamides and related compounds. J Med Chem. 1990 Apr;33(4):1155-63. DM4FW3H RU https://pubmed.ncbi.nlm.nih.gov/1969484 DM4G09S DI DM4G09S DM4G09S DN SB-505124 DM4G09S TI TTP4520 DM4G09S TN TGF-beta receptor type I (TGFBR1) DM4G09S MA Inhibitor DM4G09S RN Synthesis and biological evaluation of 2-pyridyl-substituted pyrazoles and imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4228-4232 (2010). DM4G09S RU http://www.sciencedirect.com/science/article/pii/S0960894X10006736 DM4G0NH DI DM4G0NH DM4G0NH DN 1-(4-aminophenylsulfonyl)-3-(2-mercaptoethyl)urea DM4G0NH TI TTWHDVK DM4G0NH TN Fructose-1,6-bisphosphatase (FBP) DM4G0NH MA Inhibitor DM4G0NH RN Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12. DM4G0NH RU https://pubmed.ncbi.nlm.nih.gov/18650089 DM4G2IE DI DM4G2IE DM4G2IE DN 1,3-Diallyl-7-methyl-3,7-dihydro-purine-2,6-dione DM4G2IE TI TTM2AOE DM4G2IE TN Adenosine A2a receptor (ADORA2A) DM4G2IE MA Inhibitor DM4G2IE RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DM4G2IE RU https://pubmed.ncbi.nlm.nih.gov/3806581 DM4G3FS DI DM4G3FS DM4G3FS DN 2-methoxy-alpha,beta-didehydro-agomelatine DM4G3FS TI TT0WAIE DM4G3FS TN Melatonin receptor type 1A (MTNR1A) DM4G3FS MA Agonist DM4G3FS RN Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors. Bioorg Med Chem Lett. 2013 Jan 15;23(2):430-4. DM4G3FS RU https://pubmed.ncbi.nlm.nih.gov/23265885 DM4G60V DI DM4G60V DM4G60V DN AC265347 DM4G60V TI TTBUYHA DM4G60V TN Extracellular calcium-sensing receptor (CASR) DM4G60V MA Modulator (allosteric modulator) DM4G60V RN Characterization of highly efficacious allosteric agonists of the human calcium-sensing receptor. J Pharmacol Exp Ther. 2011 Apr;337(1):275-84. DM4G60V RU https://pubmed.ncbi.nlm.nih.gov/21239511 DM4G6BT DI DM4G6BT DM4G6BT DN N,N'-(1',3'-propylene)-bis-(-)-nor-MEP DM4G6BT TI TTEB0GD DM4G6BT TN Cholinesterase (BCHE) DM4G6BT MA Inhibitor DM4G6BT RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DM4G6BT RU https://pubmed.ncbi.nlm.nih.gov/18333606 DM4G6LJ DI DM4G6LJ DM4G6LJ DN N-phenethyl-2-phenylquinoline-4-carboxamide DM4G6LJ TI TTBPGLU DM4G6LJ TN Neuromedin-K receptor (TACR3) DM4G6LJ MA Inhibitor DM4G6LJ RN Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem. 2010 Nov 25;53(22):8080-8. DM4G6LJ RU https://pubmed.ncbi.nlm.nih.gov/21047106 DM4G8WX DI DM4G8WX DM4G8WX DN Pyridine-2,4-dicarboxylic acid DM4G8WX TI TTMHFRY DM4G8WX TN HIF-prolyl hydroxylase 1 (HPH-1) DM4G8WX MA Inhibitor DM4G8WX RN Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone de... J Med Chem. 2010 Aug 12;53(15):5629-38. DM4G8WX RU https://pubmed.ncbi.nlm.nih.gov/20684604 DM4GASE DI DM4GASE DM4GASE DN KNI-10088 DM4GASE TI TTXMNHO DM4GASE TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM4GASE MA Inhibitor DM4GASE RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DM4GASE RU https://pubmed.ncbi.nlm.nih.gov/18952439 DM4GLZU DI DM4GLZU DM4GLZU DN alpha-fluoromethylenephosphonate DM4GLZU TI TTE2YJR DM4GLZU TN Lysophosphatidate-3 receptor (LPAR3) DM4GLZU MA Agonist DM4GLZU RN Structure-activity relationships of fluorinated lysophosphatidic acid analogues. J Med Chem. 2005 May 5;48(9):3319-27. DM4GLZU RU https://pubmed.ncbi.nlm.nih.gov/15857137 DM4GN0E DI DM4GN0E DM4GN0E DN 2-(2-Methyl-benzoyl)-cyclohexane-1,3-dione DM4GN0E TI TT8DSFC DM4GN0E TN Hydroxyphenylpyruvate dioxygenase (HPD) DM4GN0E MA Inhibitor DM4GN0E RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DM4GN0E RU https://pubmed.ncbi.nlm.nih.gov/10853644 DM4GRK8 DI DM4GRK8 DM4GRK8 DN N-(6-(pyridin-4-yl)-1H-indazol-3-yl)butyramide DM4GRK8 TI TTRSMW9 DM4GRK8 TN Glycogen synthase kinase-3 beta (GSK-3B) DM4GRK8 MA Inhibitor DM4GRK8 RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DM4GRK8 RU https://pubmed.ncbi.nlm.nih.gov/20167481 DM4GSHY DI DM4GSHY DM4GSHY DN KA-10X DM4GSHY TI TTW2R9X DM4GSHY TN GTPase NRas (NRAS) DM4GSHY MA Antagonist DM4GSHY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823). DM4GSHY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2823 DM4GU29 DI DM4GU29 DM4GU29 DN 4-[3-(4-Methoxy-phenoxy)-propyl]-1H-imidazole DM4GU29 TI TT9JNIC DM4GU29 TN Histamine H3 receptor (H3R) DM4GU29 MA Inhibitor DM4GU29 RN Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):951-4. DM4GU29 RU https://pubmed.ncbi.nlm.nih.gov/11294398 DM4GWAH DI DM4GWAH DM4GWAH DN 3-benzyl-2-mercapto-6-nitroquinazolin-4(3H)-one DM4GWAH TI TT9SL3Q DM4GWAH TN Polypeptide deformylase (PDF) DM4GWAH MA Inhibitor DM4GWAH RN Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63. DM4GWAH RU https://pubmed.ncbi.nlm.nih.gov/20350811 DM4GWJO DI DM4GWJO DM4GWJO DN 3-(biphenyl-4-yl)-1-(oxazol-2-yl)propan-1-one DM4GWJO TI TTDP1UC DM4GWJO TN Fatty acid amide hydrolase (FAAH) DM4GWJO MA Inhibitor DM4GWJO RN Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Feb 28;51(4):937-47. DM4GWJO RU https://pubmed.ncbi.nlm.nih.gov/18247553 DM4GZUJ DI DM4GZUJ DM4GZUJ DN Cysteine Sulfenic Acid DM4GZUJ TI TTELIN2 DM4GZUJ TN PTPN1 messenger RNA (PTPN1 mRNA) DM4GZUJ MA Inhibitor DM4GZUJ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM4GZUJ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM4GZUJ DI DM4GZUJ DM4GZUJ DN Cysteine Sulfenic Acid DM4GZUJ TI TTR0SWN DM4GZUJ TN M-phase inducer phosphatase 2 (MPIP2) DM4GZUJ MA Inhibitor DM4GZUJ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM4GZUJ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM4GZUJ DI DM4GZUJ DM4GZUJ DN Cysteine Sulfenic Acid DM4GZUJ TI TT6PKBN DM4GZUJ TN Proto-oncogene c-Src (SRC) DM4GZUJ MA Inhibitor DM4GZUJ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM4GZUJ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM4GZUJ DI DM4GZUJ DM4GZUJ DN Cysteine Sulfenic Acid DM4GZUJ TI TTJGY7A DM4GZUJ TN Complement C3 (CO3) DM4GZUJ MA Inhibitor DM4GZUJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4GZUJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4H1JO DI DM4H1JO DM4H1JO DN (+/-)-7-fluoro-2-p-tolylchroman-4-one DM4H1JO TI TTGP7BY DM4H1JO TN Monoamine oxidase type B (MAO-B) DM4H1JO MA Inhibitor DM4H1JO RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM4H1JO RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM4H6PC DI DM4H6PC DM4H6PC DN 2-Phenethyl-4,5-dihydro-1H-imidazole DM4H6PC TI TT3WG5C DM4H6PC TN Monoamine oxidase type A (MAO-A) DM4H6PC MA Inhibitor DM4H6PC RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM4H6PC RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM4H6PC DI DM4H6PC DM4H6PC DN 2-Phenethyl-4,5-dihydro-1H-imidazole DM4H6PC TI TTGP7BY DM4H6PC TN Monoamine oxidase type B (MAO-B) DM4H6PC MA Inhibitor DM4H6PC RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM4H6PC RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM4H7D5 DI DM4H7D5 DM4H7D5 DN PHA-767491 DM4H7D5 TI TTSMTDI DM4H7D5 TN CDC7-related kinase (CDC7) DM4H7D5 MA Modulator DM4H7D5 RN Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255-64. DM4H7D5 RU https://www.ncbi.nlm.nih.gov/pubmed/19920912 DM4HB7S DI DM4HB7S DM4HB7S DN N-(1-benzylpiperidin-4-yl)-3,5-dimethoxybenzamide DM4HB7S TI TTX4RTB DM4HB7S TN Melanin-concentrating hormone receptor 1 (MCHR1) DM4HB7S MA Inhibitor DM4HB7S RN Identification of substituted 4-aminopiperidines and 3-aminopyrrolidines as potent MCH-R1 antagonists for the treatment of obesity. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5445-50. DM4HB7S RU https://pubmed.ncbi.nlm.nih.gov/16879961 DM4HE1V DI DM4HE1V DM4HE1V DN Pseudopalmatine trifluoroacetate DM4HE1V TI TT1RS9F DM4HE1V TN Acetylcholinesterase (AChE) DM4HE1V MA Inhibitor DM4HE1V RN Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation. J Nat Prod. 2010 Oct 22;73(10):1632-5. DM4HE1V RU https://pubmed.ncbi.nlm.nih.gov/20828184 DM4HJZI DI DM4HJZI DM4HJZI DN 7-fluoro-2-(4-fluorophenyl)-4H-chromene-4-thione DM4HJZI TI TTGP7BY DM4HJZI TN Monoamine oxidase type B (MAO-B) DM4HJZI MA Inhibitor DM4HJZI RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM4HJZI RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM4HKC8 DI DM4HKC8 DM4HKC8 DN Anti-GnRH Spiegelmer DM4HKC8 TI TT0ID4A DM4HKC8 TN Leutinizing-hormone-releasing hormone (GNRH1) DM4HKC8 MA Inhibitor DM4HKC8 RN In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8898-902. DM4HKC8 RU https://pubmed.ncbi.nlm.nih.gov/12070349 DM4HLK3 DI DM4HLK3 DM4HLK3 DN GSK-1838705A DM4HLK3 TI TTIXKA4 DM4HLK3 TN Ribosomal protein S6 kinase alpha-1 (RSK1) DM4HLK3 MA Inhibitor DM4HLK3 RN GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. DM4HLK3 RU https://pubmed.ncbi.nlm.nih.gov/19825801 DM4HLK3 DI DM4HLK3 DM4HLK3 DN GSK-1838705A DM4HLK3 TI TTCBFJO DM4HLK3 TN Insulin receptor (INSR) DM4HLK3 MA Inhibitor DM4HLK3 RN GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. DM4HLK3 RU https://pubmed.ncbi.nlm.nih.gov/19825801 DM4HLK3 DI DM4HLK3 DM4HLK3 DN GSK-1838705A DM4HLK3 TI TTPMQSO DM4HLK3 TN ALK tyrosine kinase receptor (ALK) DM4HLK3 MA Inhibitor DM4HLK3 RN GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther. 2009 Oct;8(10):2811-20. DM4HLK3 RU https://pubmed.ncbi.nlm.nih.gov/19825801 DM4HLK3 DI DM4HLK3 DM4HLK3 DN GSK-1838705A DM4HLK3 TI TTQFBMY DM4HLK3 TN IGF1R messenger RNA (IGF1R mRNA) DM4HLK3 MA Inhibitor DM4HLK3 RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DM4HLK3 RU https://pubmed.ncbi.nlm.nih.gov/22037378 DM4HLO5 DI DM4HLO5 DM4HLO5 DN [125I]PD151242 DM4HLO5 TI TTKRD0G DM4HLO5 TN Endothelin A receptor (EDNRA) DM4HLO5 MA Antagonist DM4HLO5 RN [125I]-PD151242: a selective radioligand for human ETA receptors. Br J Pharmacol. 1994 Jan;111(1):4-6. DM4HLO5 RU https://pubmed.ncbi.nlm.nih.gov/8012722 DM4HRIX DI DM4HRIX DM4HRIX DN 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone DM4HRIX TI TTNJYV2 DM4HRIX TN Gamma-aminobutyric acid receptor (GAR) DM4HRIX MA Inhibitor DM4HRIX RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM4HRIX RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM4HRIX DI DM4HRIX DM4HRIX DN 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone DM4HRIX TI TT06RH5 DM4HRIX TN GABA(A) receptor gamma-2 (GABRG2) DM4HRIX MA Inhibitor DM4HRIX RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM4HRIX RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM4HRIX DI DM4HRIX DM4HRIX DN 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone DM4HRIX TI TTZA1NY DM4HRIX TN GABA(A) receptor beta-2 (GABRB2) DM4HRIX MA Inhibitor DM4HRIX RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM4HRIX RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM4HRIX DI DM4HRIX DM4HRIX DN 6-bromo-3-ethoxycarbonyl-2-methyl-4-quinolone DM4HRIX TI TT1MPAY DM4HRIX TN GABA(A) receptor alpha-1 (GABRA1) DM4HRIX MA Inhibitor DM4HRIX RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM4HRIX RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM4HS92 DI DM4HS92 DM4HS92 DN 1-Methyl-5-(4-phenylazo-phenyl)-piperidin-2-one DM4HS92 TI TTTU72V DM4HS92 TN Steroid 5-alpha-reductase 1 (SRD5A1) DM4HS92 MA Inhibitor DM4HS92 RN Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11. DM4HS92 RU https://pubmed.ncbi.nlm.nih.gov/10987415 DM4HUO1 DI DM4HUO1 DM4HUO1 DN 7-(2-(1H-imidazol-1-yl)ethoxy)-2H-chromen-2-one DM4HUO1 TI TTSZLWK DM4HUO1 TN Aromatase (CYP19A1) DM4HUO1 MA Inhibitor DM4HUO1 RN Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem. 2004 Dec 30;47(27):6792-803. DM4HUO1 RU https://pubmed.ncbi.nlm.nih.gov/15615528 DM4I0B1 DI DM4I0B1 DM4I0B1 DN 7-Propyl-7H-adenine DM4I0B1 TI TTM2AOE DM4I0B1 TN Adenosine A2a receptor (ADORA2A) DM4I0B1 MA Inhibitor DM4I0B1 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM4I0B1 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM4I2NR DI DM4I2NR DM4I2NR DN MANGOSTENONE G DM4I2NR TI TT50QJ3 DM4I2NR TN Influenza Neuraminidase (Influ NA) DM4I2NR MA Inhibitor DM4I2NR RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DM4I2NR RU https://pubmed.ncbi.nlm.nih.gov/20696581 DM4I5Z3 DI DM4I5Z3 DM4I5Z3 DN Dicaffeoylquinic acids DM4I5Z3 TI TT5FH9Y DM4I5Z3 TN Human immunodeficiency virus Integrase (HIV IN) DM4I5Z3 MA Inhibitor DM4I5Z3 RN Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 1998 Jan;42(1):140-6. DM4I5Z3 RU https://pubmed.ncbi.nlm.nih.gov/9449274 DM4I6MD DI DM4I6MD DM4I6MD DN NICARBAZIN DM4I6MD TI TTDP1UC DM4I6MD TN Fatty acid amide hydrolase (FAAH) DM4I6MD MA Inhibitor DM4I6MD RN Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inh... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6793-6. DM4I6MD RU https://pubmed.ncbi.nlm.nih.gov/19850474 DM4IA92 DI DM4IA92 DM4IA92 DN N-(3-Phenyl-[1,2,4]thiadiazol-5-yl)-benzamide DM4IA92 TI TTM2AOE DM4IA92 TN Adenosine A2a receptor (ADORA2A) DM4IA92 MA Inhibitor DM4IA92 RN Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62. DM4IA92 RU https://pubmed.ncbi.nlm.nih.gov/11262085 DM4IABG DI DM4IABG DM4IABG DN PMID17480064C16 DM4IABG TI TTFS4VU DM4IABG TN MAPK-activated protein kinase 3 (MAPKAPK3) DM4IABG MA Inhibitor DM4IABG RN Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54. DM4IABG RU https://pubmed.ncbi.nlm.nih.gov/17480064 DM4IABG DI DM4IABG DM4IABG DN PMID17480064C16 DM4IABG TI TT3UJ7Z DM4IABG TN MAPK-activated protein kinase 5 (MAPKAPK5) DM4IABG MA Inhibitor DM4IABG RN Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54. DM4IABG RU https://pubmed.ncbi.nlm.nih.gov/17480064 DM4IABG DI DM4IABG DM4IABG DN PMID17480064C16 DM4IABG TI TTMUG9D DM4IABG TN MAPK-activated protein kinase 2 (MAPKAPK2) DM4IABG MA Inhibitor DM4IABG RN Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54. DM4IABG RU https://pubmed.ncbi.nlm.nih.gov/17480064 DM4IELQ DI DM4IELQ DM4IELQ DN LY2119620 DM4IELQ TI TTOXS3C DM4IELQ TN Muscarinic acetylcholine receptor (CHRM) DM4IELQ MA Modulator (allosteric modulator) DM4IELQ RN Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Mol Pharmacol. 2014 Jul;86(1):106-15. DM4IELQ RU https://pubmed.ncbi.nlm.nih.gov/24807965 DM4IEWG DI DM4IEWG DM4IEWG DN N-(2-chlorobenzyl)-5-(4-chlorophenyl)nicotinamide DM4IEWG TI TT90XZ8 DM4IEWG TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM4IEWG MA Inhibitor DM4IEWG RN Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5. DM4IEWG RU https://pubmed.ncbi.nlm.nih.gov/20855211 DM4IFPQ DI DM4IFPQ DM4IFPQ DN 2,6,8-triphenyl-9H-purine DM4IFPQ TI TTM2AOE DM4IFPQ TN Adenosine A2a receptor (ADORA2A) DM4IFPQ MA Inhibitor DM4IFPQ RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM4IFPQ RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM4IFPQ DI DM4IFPQ DM4IFPQ DN 2,6,8-triphenyl-9H-purine DM4IFPQ TI TTK25J1 DM4IFPQ TN Adenosine A1 receptor (ADORA1) DM4IFPQ MA Inhibitor DM4IFPQ RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM4IFPQ RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM4IFPQ DI DM4IFPQ DM4IFPQ DN 2,6,8-triphenyl-9H-purine DM4IFPQ TI TTJFY5U DM4IFPQ TN Adenosine A3 receptor (ADORA3) DM4IFPQ MA Inhibitor DM4IFPQ RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM4IFPQ RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM4IJXW DI DM4IJXW DM4IJXW DN 2-MOE phosphorothioate gapmers DM4IJXW TI TTZQTY2 DM4IJXW TN DMPK messenger RNA (DMPK mRNA) DM4IJXW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1505). DM4IJXW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1505 DM4IKBV DI DM4IKBV DM4IKBV DN Trifluoromethionine DM4IKBV TI TT1UY5C DM4IKBV TN Pseudomonas Methionine gamma-lyase (Pseudo mdeA) DM4IKBV MA Inhibitor DM4IKBV RN Kinetic characterization of methionine gamma-lyases from the enteric protozoan parasite Entamoeba histolytica against physiological substrates and trifluoromethionine, a promising lead compound against amoebiasis. FEBS J. 2008 Feb;275(3):548-60. DM4IKBV RU https://pubmed.ncbi.nlm.nih.gov/18199285 DM4IMON DI DM4IMON DM4IMON DN 1-(5-Pyridin-2-yl-oxazol-2-yl)-octadec-9-yn-1-one DM4IMON TI TTDP1UC DM4IMON TN Fatty acid amide hydrolase (FAAH) DM4IMON MA Inhibitor DM4IMON RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DM4IMON RU https://pubmed.ncbi.nlm.nih.gov/15771430 DM4INSG DI DM4INSG DM4INSG DN (-)-pinoresinol DM4INSG TI TTN9T81 DM4INSG TN Arachidonate 15-lipoxygenase (15-LOX) DM4INSG MA Inhibitor DM4INSG RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DM4INSG RU https://pubmed.ncbi.nlm.nih.gov/17378609 DM4INSG DI DM4INSG DM4INSG DN (-)-pinoresinol DM4INSG TI TTSJ6Q4 DM4INSG TN LOX-5 messenger RNA (ALOX5 mRNA) DM4INSG MA Inhibitor DM4INSG RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DM4INSG RU https://pubmed.ncbi.nlm.nih.gov/17378609 DM4IRU5 DI DM4IRU5 DM4IRU5 DN Phosphomethylphosphonic Acid Guanylate Ester DM4IRU5 TI TT4W1VJ DM4IRU5 TN Bacterial Celldivision protein FtsZ (Bact ftsZ) DM4IRU5 MA Inhibitor DM4IRU5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4IRU5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4IUCW DI DM4IUCW DM4IUCW DN H-Dmt-Tic-NH-CH2-Boa DM4IUCW TI TTKWM86 DM4IUCW TN Opioid receptor mu (MOP) DM4IUCW MA Inhibitor DM4IUCW RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DM4IUCW RU https://pubmed.ncbi.nlm.nih.gov/18178091 DM4IUCW DI DM4IUCW DM4IUCW DN H-Dmt-Tic-NH-CH2-Boa DM4IUCW TI TT27RFC DM4IUCW TN Opioid receptor delta (OPRD1) DM4IUCW MA Inhibitor DM4IUCW RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DM4IUCW RU https://pubmed.ncbi.nlm.nih.gov/18178091 DM4IXJA DI DM4IXJA DM4IXJA DN [4Aph(CO-NH-(C2H4O)2-C2H5)5]degarelix DM4IXJA TI TT8R70G DM4IXJA TN Gonadotropin-releasing hormone receptor (GNRHR) DM4IXJA MA Inhibitor DM4IXJA RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DM4IXJA RU https://pubmed.ncbi.nlm.nih.gov/16759096 DM4IXUQ DI DM4IXUQ DM4IXUQ DN Alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen DM4IXUQ TI TTCGSZ4 DM4IXUQ TN Pancreatic alpha-amylase (AMY2A) DM4IXUQ MA Inhibitor DM4IXUQ RN Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30. DM4IXUQ RU https://pubmed.ncbi.nlm.nih.gov/18553919 DM4J8B9 DI DM4J8B9 DM4J8B9 DN 2-Thiophen-2-ylmethyl-1,2-dihydro-indazol-3-one DM4J8B9 TI TT2J34L DM4J8B9 TN Arachidonate 5-lipoxygenase (5-LOX) DM4J8B9 MA Inhibitor DM4J8B9 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM4J8B9 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM4JG60 DI DM4JG60 DM4JG60 DN 9-benzyl-6-(4-methylpiperazin-1-yl)-9H-purine DM4JG60 TI TTXJ178 DM4JG60 TN Histamine H4 receptor (H4R) DM4JG60 MA Inhibitor DM4JG60 RN 2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96. DM4JG60 RU https://pubmed.ncbi.nlm.nih.gov/19773175 DM4JG9S DI DM4JG9S DM4JG9S DN 9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide DM4JG9S TI TTEB0GD DM4JG9S TN Cholinesterase (BCHE) DM4JG9S MA Inhibitor DM4JG9S RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DM4JG9S RU https://pubmed.ncbi.nlm.nih.gov/20471843 DM4JG9S DI DM4JG9S DM4JG9S DN 9-O-[3-(4-Bromo-phenoxyl)butyl]-berberine bromide DM4JG9S TI TT1RS9F DM4JG9S TN Acetylcholinesterase (AChE) DM4JG9S MA Inhibitor DM4JG9S RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DM4JG9S RU https://pubmed.ncbi.nlm.nih.gov/20471843 DM4JM50 DI DM4JM50 DM4JM50 DN DEPX DM4JM50 TI TTNE7KG DM4JM50 TN Adenosine A2b receptor (ADORA2B) DM4JM50 MA Antagonist DM4JM50 RN Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13. DM4JM50 RU https://pubmed.ncbi.nlm.nih.gov/10496952 DM4JM50 DI DM4JM50 DM4JM50 DN DEPX DM4JM50 TI TTK25J1 DM4JM50 TN Adenosine A1 receptor (ADORA1) DM4JM50 MA Inhibitor DM4JM50 RN 125I-labeled 8-phenylxanthine derivatives: antagonist radioligands for adenosine A1 receptors. J Med Chem. 1988 Apr;31(4):745-51. DM4JM50 RU https://pubmed.ncbi.nlm.nih.gov/3351850 DM4JNUH DI DM4JNUH DM4JNUH DN IN1479 DM4JNUH TI TTGJCWZ DM4JNUH TN Fms-like tyrosine kinase 3 (FLT-3) DM4JNUH MA Inhibitor DM4JNUH RN Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. J MedChem. 2006 Jul 27;49(15):4451-4. DM4JNUH RU https://pubmed.ncbi.nlm.nih.gov/16854049 DM4JNY9 DI DM4JNY9 DM4JNY9 DN AC55649 DM4JNY9 TI TTISP28 DM4JNY9 TN Retinoic acid receptor beta (RARB) DM4JNY9 MA Agonist DM4JNY9 RN Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9. DM4JNY9 RU https://pubmed.ncbi.nlm.nih.gov/16302793 DM4JP8L DI DM4JP8L DM4JP8L DN H-Dmt-Tic-Asp-N(Me)-Ph DM4JP8L TI TT27RFC DM4JP8L TN Opioid receptor delta (OPRD1) DM4JP8L MA Inhibitor DM4JP8L RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM4JP8L RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM4JP8L DI DM4JP8L DM4JP8L DN H-Dmt-Tic-Asp-N(Me)-Ph DM4JP8L TI TTKWM86 DM4JP8L TN Opioid receptor mu (MOP) DM4JP8L MA Inhibitor DM4JP8L RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM4JP8L RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM4JQCR DI DM4JQCR DM4JQCR DN (2S,3R)-3-(6-amino-9H-purin-9-yl)nonan-2-ol DM4JQCR TI TTLP57V DM4JQCR TN Adenosine deaminase (ADA) DM4JQCR MA Inhibitor DM4JQCR RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM4JQCR RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM4JWMA DI DM4JWMA DM4JWMA DN PMID23642479C17 DM4JWMA TI TTYGQ8A DM4JWMA TN Dual-specificity tyrosine-phosphorylation regulated kinase 1B (DYRK1B) DM4JWMA MA Inhibitor DM4JWMA RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DM4JWMA RU https://pubmed.ncbi.nlm.nih.gov/23642479 DM4JWMA DI DM4JWMA DM4JWMA DN PMID23642479C17 DM4JWMA TI TTE6YDG DM4JWMA TN CDC-like kinase 1 (CLK1) DM4JWMA MA Inhibitor DM4JWMA RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DM4JWMA RU https://pubmed.ncbi.nlm.nih.gov/23642479 DM4JWMA DI DM4JWMA DM4JWMA DN PMID23642479C17 DM4JWMA TI TT85TPS DM4JWMA TN CDC-like kinase 2 (CLK2) DM4JWMA MA Inhibitor DM4JWMA RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DM4JWMA RU https://pubmed.ncbi.nlm.nih.gov/23642479 DM4JWMA DI DM4JWMA DM4JWMA DN PMID23642479C17 DM4JWMA TI TTSBVFO DM4JWMA TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DM4JWMA MA Inhibitor DM4JWMA RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DM4JWMA RU https://pubmed.ncbi.nlm.nih.gov/23642479 DM4JWMA DI DM4JWMA DM4JWMA DN PMID23642479C17 DM4JWMA TI TT1RFQP DM4JWMA TN CDC-like kinase 4 (CLK4) DM4JWMA MA Inhibitor DM4JWMA RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DM4JWMA RU https://pubmed.ncbi.nlm.nih.gov/23642479 DM4JZ9A DI DM4JZ9A DM4JZ9A DN GNF-PF-1694 DM4JZ9A TI TT2CJVK DM4JZ9A TN Adrenergic receptor beta-2 (ADRB2) DM4JZ9A MA Inhibitor DM4JZ9A RN Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5391-5. DM4JZ9A RU https://pubmed.ncbi.nlm.nih.gov/18829308 DM4K8N2 DI DM4K8N2 DM4K8N2 DN 5-nitroindirubin-3'-oxime DM4K8N2 TI TT7HF4W DM4K8N2 TN Cyclin-dependent kinase 2 (CDK2) DM4K8N2 MA Inhibitor DM4K8N2 RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM4K8N2 RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM4K8N2 DI DM4K8N2 DM4K8N2 DN 5-nitroindirubin-3'-oxime DM4K8N2 TI TTCEJ4F DM4K8N2 TN G1/S-specific cyclin-E1 (CCNE1) DM4K8N2 MA Inhibitor DM4K8N2 RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM4K8N2 RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM4KCYU DI DM4KCYU DM4KCYU DN [3H]8-OH-DPAT DM4KCYU TI TTK8CXU DM4KCYU TN 5-HT 1B receptor (HTR1B) DM4KCYU MA Agonist DM4KCYU RN Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53. DM4KCYU RU https://pubmed.ncbi.nlm.nih.gov/10431754 DM4KCYU DI DM4KCYU DM4KCYU DN [3H]8-OH-DPAT DM4KCYU TI TT6MSOK DM4KCYU TN 5-HT 1D receptor (HTR1D) DM4KCYU MA Agonist DM4KCYU RN Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53. DM4KCYU RU https://pubmed.ncbi.nlm.nih.gov/10431754 DM4KCYU DI DM4KCYU DM4KCYU DN [3H]8-OH-DPAT DM4KCYU TI TTSQIFT DM4KCYU TN 5-HT 1A receptor (HTR1A) DM4KCYU MA Agonist DM4KCYU RN Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10. DM4KCYU RU https://pubmed.ncbi.nlm.nih.gov/11101361 DM4KM91 DI DM4KM91 DM4KM91 DN MSVIII-19 DM4KM91 TI TT0MYE2 DM4KM91 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM4KM91 MA Antagonist DM4KM91 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM4KM91 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM4KMDB DI DM4KMDB DM4KMDB DN 6-(Biphenyl-2-sulfonyl)-2H-pyridazin-3-one DM4KMDB TI TTFBNVI DM4KMDB TN Aldose reductase (AKR1B1) DM4KMDB MA Inhibitor DM4KMDB RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM4KMDB RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM4KP5M DI DM4KP5M DM4KP5M DN 8-(2,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine DM4KP5M TI TT9SL3Q DM4KP5M TN Polypeptide deformylase (PDF) DM4KP5M MA Inhibitor DM4KP5M RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DM4KP5M RU https://pubmed.ncbi.nlm.nih.gov/20117005 DM4KQUS DI DM4KQUS DM4KQUS DN Ac-Asp-Glu-Val-Asp-CHO DM4KQUS TI TTPF2QI DM4KQUS TN Caspase-3 (CASP3) DM4KQUS MA Inhibitor DM4KQUS RN Design and synthesis of a potent and selective peptidomimetic inhibitor of caspase-3. J Med Chem. 2004 Dec 16;47(26):6455-8. DM4KQUS RU https://pubmed.ncbi.nlm.nih.gov/15588079 DM4KS27 DI DM4KS27 DM4KS27 DN 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid DM4KS27 TI TT0K6EO DM4KS27 TN Stress-activated protein kinase JNK1 (JNK1) DM4KS27 MA Inhibitor DM4KS27 RN Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. DM4KS27 RU https://pubmed.ncbi.nlm.nih.gov/17107797 DM4KXIM DI DM4KXIM DM4KXIM DN DIOSMETIN DM4KXIM TI TTI84H7 DM4KXIM TN Cytochrome P450 1B1 (CYP1B1) DM4KXIM MA Inhibitor DM4KXIM RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM4KXIM RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM4KZ1W DI DM4KZ1W DM4KZ1W DN Cyclopentylcytosine DM4KZ1W TI TTN12BZ DM4KZ1W TN CTP synthase (CTPS1) DM4KZ1W MA Inhibitor DM4KZ1W RN Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75. DM4KZ1W RU https://pubmed.ncbi.nlm.nih.gov/8250543 DM4L0R7 DI DM4L0R7 DM4L0R7 DN Maleic Acid DM4L0R7 TI TTRTKPV DM4L0R7 TN Trypanosoma Trypanothione reductase (Trypano TPR) DM4L0R7 MA Inhibitor DM4L0R7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM4L0R7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM4L0R7 DI DM4L0R7 DM4L0R7 DN Maleic Acid DM4L0R7 TI TTU507L DM4L0R7 TN Cytoplasmic aspartate aminotransferase (GOT1) DM4L0R7 MA Inhibitor DM4L0R7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM4L0R7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM4L7NE DI DM4L7NE DM4L7NE DN ISIS 298702 DM4L7NE TI TTSN6QU DM4L7NE TN HIF1-alpha messenger RNA (HIF1A mRNA) DM4L7NE RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DM4L7NE RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DM4LCRS DI DM4LCRS DM4LCRS DN 2-phenylethynyl-5,6,7,8-tetrahydro-quinoline DM4LCRS TI TTHS256 DM4LCRS TN Metabotropic glutamate receptor 5 (mGluR5) DM4LCRS MA Inhibitor DM4LCRS RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DM4LCRS RU https://pubmed.ncbi.nlm.nih.gov/18173231 DM4LD1Y DI DM4LD1Y DM4LD1Y DN ISIS 6755 DM4LD1Y TI TTBLG3H DM4LD1Y TN P120 messenger RNA (NOP2 mRNA) DM4LD1Y RN US patent application no. 5,814,619, Oligonucleotide inhibition of P120. DM4LD1Y RU http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true DM4LEUT DI DM4LEUT DM4LEUT DN PMID24210504C1o DM4LEUT TI TTTCXO0 DM4LEUT TN G protein-coupled receptor kinase 5 (GRK5) DM4LEUT MA Inhibitor DM4LEUT RN Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6. DM4LEUT RU https://pubmed.ncbi.nlm.nih.gov/24210504 DM4LEUT DI DM4LEUT DM4LEUT DN PMID24210504C1o DM4LEUT TI TTAZ3MN DM4LEUT TN Beta-adrenergic receptor kinase 1 (ADRBK1) DM4LEUT MA Inhibitor DM4LEUT RN Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6. DM4LEUT RU https://pubmed.ncbi.nlm.nih.gov/24210504 DM4LEUT DI DM4LEUT DM4LEUT DN PMID24210504C1o DM4LEUT TI TTNDSF4 DM4LEUT TN Proto-oncogene c-Met (MET) DM4LEUT MA Inhibitor DM4LEUT RN Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. Bioorg Med Chem Lett. 2013 Dec 15;23(24):6711-6. DM4LEUT RU https://pubmed.ncbi.nlm.nih.gov/24210504 DM4LIHQ DI DM4LIHQ DM4LIHQ DN C6S DM4LIHQ TI TTKWM86 DM4LIHQ TN Opioid receptor mu (MOP) DM4LIHQ MA Inhibitor DM4LIHQ RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM4LIHQ RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM4LIUC DI DM4LIUC DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC TI TT8QL1J DM4LIUC TN Protein kinase C theta (PRKCQ) DM4LIUC MA Inhibitor DM4LIUC RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM4LIUC RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM4LIUC DI DM4LIUC DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC TI TTUWGRA DM4LIUC TN Protein kinase C zeta (PRKCZ) DM4LIUC MA Inhibitor DM4LIUC RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM4LIUC RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM4LIUC DI DM4LIUC DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC TI TTFJ8Q1 DM4LIUC TN Protein kinase C alpha (PRKCA) DM4LIUC MA Inhibitor DM4LIUC RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM4LIUC RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM4LIUC DI DM4LIUC DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC TI TTYPXQF DM4LIUC TN Protein kinase C beta (PRKCB) DM4LIUC MA Inhibitor DM4LIUC RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM4LIUC RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM4LIUC DI DM4LIUC DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC TI TTRFOXJ DM4LIUC TN Protein kinase C gamma (PRKCG) DM4LIUC MA Inhibitor DM4LIUC RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM4LIUC RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM4LIUC DI DM4LIUC DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC TI TT9WJ8U DM4LIUC TN Protein kinase C delta (PRKCD) DM4LIUC MA Inhibitor DM4LIUC RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM4LIUC RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM4LIUC DI DM4LIUC DM4LIUC DN 4-cycloheptyliden(4-hydroxyphenyl)methylphenol DM4LIUC TI TTBZ7OD DM4LIUC TN Protein kinase C epsilon (PRKCE) DM4LIUC MA Inhibitor DM4LIUC RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM4LIUC RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM4LMPD DI DM4LMPD DM4LMPD DN 2-Hydroxymethyl-3-hydroxymorphinan DM4LMPD TI TTQW87Y DM4LMPD TN Opioid receptor kappa (OPRK1) DM4LMPD MA Inhibitor DM4LMPD RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM4LMPD RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM4LMPD DI DM4LMPD DM4LMPD DN 2-Hydroxymethyl-3-hydroxymorphinan DM4LMPD TI TT27RFC DM4LMPD TN Opioid receptor delta (OPRD1) DM4LMPD MA Inhibitor DM4LMPD RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM4LMPD RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM4LMPD DI DM4LMPD DM4LMPD DN 2-Hydroxymethyl-3-hydroxymorphinan DM4LMPD TI TTKWM86 DM4LMPD TN Opioid receptor mu (MOP) DM4LMPD MA Inhibitor DM4LMPD RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM4LMPD RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM4LTE3 DI DM4LTE3 DM4LTE3 DN R-PSOP DM4LTE3 TI TT2L6C5 DM4LTE3 TN Neuromedin-U receptor 2 (NMUR2) DM4LTE3 MA Antagonist DM4LTE3 RN Discovery and pharmacological characterization of a small-molecule antagonist at neuromedin U receptor NMUR2. J Pharmacol Exp Ther. 2009 Jul;330(1):268-75. DM4LTE3 RU https://pubmed.ncbi.nlm.nih.gov/19369576 DM4M12J DI DM4M12J DM4M12J DN N-(6-(4-fluorophenyl)-1H-indazol-3-yl)butyramide DM4M12J TI TTRSMW9 DM4M12J TN Glycogen synthase kinase-3 beta (GSK-3B) DM4M12J MA Inhibitor DM4M12J RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DM4M12J RU https://pubmed.ncbi.nlm.nih.gov/20167481 DM4M2VU DI DM4M2VU DM4M2VU DN 10-Benzoyl-1,8-dihydroxy-10H-anthracen-9-one DM4M2VU TI TT2J34L DM4M2VU TN Arachidonate 5-lipoxygenase (5-LOX) DM4M2VU MA Inhibitor DM4M2VU RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DM4M2VU RU https://pubmed.ncbi.nlm.nih.gov/9371243 DM4M3C8 DI DM4M3C8 DM4M3C8 DN furtrethonium DM4M3C8 TI TTOXS3C DM4M3C8 TN Muscarinic acetylcholine receptor (CHRM) DM4M3C8 MA Agonist DM4M3C8 RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DM4M3C8 RU https://pubmed.ncbi.nlm.nih.gov/9224827 DM4M3C8 DI DM4M3C8 DM4M3C8 DN furtrethonium DM4M3C8 TI TTQ13Z5 DM4M3C8 TN Muscarinic acetylcholine receptor M3 (CHRM3) DM4M3C8 MA Agonist DM4M3C8 RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DM4M3C8 RU https://pubmed.ncbi.nlm.nih.gov/9224827 DM4M3OP DI DM4M3OP DM4M3OP DN C[L-Phe-D-pro-L-Tyr(OMe)-D-trp] DM4M3OP TI TTQW87Y DM4M3OP TN Opioid receptor kappa (OPRK1) DM4M3OP MA Inhibitor DM4M3OP RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM4M3OP RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM4M3OP DI DM4M3OP DM4M3OP DN C[L-Phe-D-pro-L-Tyr(OMe)-D-trp] DM4M3OP TI TTKWM86 DM4M3OP TN Opioid receptor mu (MOP) DM4M3OP MA Inhibitor DM4M3OP RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM4M3OP RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM4M6LR DI DM4M6LR DM4M6LR DN 3alpha-O-trans-p-coumaroyl-7-labden-15-oic acid DM4M6LR TI TTIU7X1 DM4M6LR TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM4M6LR MA Inhibitor DM4M6LR RN Harbinatic acid, a novel and potent DNA polymerase beta inhibitor from Hardwickia binata. J Nat Prod. 1999 Jul;62(7):1000-2. DM4M6LR RU https://pubmed.ncbi.nlm.nih.gov/10425125 DM4M91Z DI DM4M91Z DM4M91Z DN Full-length Factor VIII molecule DM4M91Z TI TT1290U DM4M91Z TN Coagulation factor VIII (F8) DM4M91Z MA Modulator DM4M91Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM4M91Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM4MAZ1 DI DM4MAZ1 DM4MAZ1 DN (4-chloro-1H-pyrazol-1-yl)(o-tolyl)methanone DM4MAZ1 TI TTPLTSQ DM4MAZ1 TN Neutrophil elastase (NE) DM4MAZ1 MA Inhibitor DM4MAZ1 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DM4MAZ1 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DM4MGAQ DI DM4MGAQ DM4MGAQ DN lysergic acid DM4MGAQ TI TTRUFDT DM4MGAQ TN 5-HT 5A receptor (HTR5A) DM4MGAQ MA Agonist DM4MGAQ RN Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6. DM4MGAQ RU https://pubmed.ncbi.nlm.nih.gov/8549774 DM4MGAQ DI DM4MGAQ DM4MGAQ DN lysergic acid DM4MGAQ TI TT6MSOK DM4MGAQ TN 5-HT 1D receptor (HTR1D) DM4MGAQ MA Agonist DM4MGAQ RN Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80. DM4MGAQ RU https://pubmed.ncbi.nlm.nih.gov/8967979 DM4MIXK DI DM4MIXK DM4MIXK DN 2-(1-Imidazol-1-yl-ethyl)-9H-carbazole DM4MIXK TI TTRA5BZ DM4MIXK TN Steroid 17-alpha-monooxygenase (S17AH) DM4MIXK MA Inhibitor DM4MIXK RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DM4MIXK RU https://pubmed.ncbi.nlm.nih.gov/18674917 DM4MKIX DI DM4MKIX DM4MKIX DN Ploglitazone DM4MKIX TI TTT2SVW DM4MKIX TN PPAR-gamma messenger RNA (PPARG mRNA) DM4MKIX MA Inhibitor DM4MKIX RN Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem. 2004 Aug 12;47(17):4118-27. DM4MKIX RU https://pubmed.ncbi.nlm.nih.gov/15293980 DM4MP69 DI DM4MP69 DM4MP69 DN Ac-Cys-Ile-Tyr-Lys-Tyr-Phe(4-NO2) DM4MP69 TI TT6PKBN DM4MP69 TN Proto-oncogene c-Src (SRC) DM4MP69 MA Inhibitor DM4MP69 RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DM4MP69 RU https://pubmed.ncbi.nlm.nih.gov/16722659 DM4MPVE DI DM4MPVE DM4MPVE DN Threo-ritalinol hydrochloride DM4MPVE TI TTVBI8W DM4MPVE TN Dopamine transporter (DAT) DM4MPVE MA Inhibitor DM4MPVE RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM4MPVE RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM4MUXT DI DM4MUXT DM4MUXT DN BIFENOX DM4MUXT TI TTLUQ8E DM4MUXT TN Hormone sensitive lipase (LIPE) DM4MUXT MA Inhibitor DM4MUXT RN Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94. DM4MUXT RU https://pubmed.ncbi.nlm.nih.gov/18808096 DM4MXOB DI DM4MXOB DM4MXOB DN AMI-1 DM4MXOB TI TTVOJAI DM4MXOB TN Protein arginine methyltransferase 1 (PRMT1) DM4MXOB MA Inhibitor DM4MXOB RN Small molecule regulators of protein arginine methyltransferases. J Biol Chem. 2004 Jun 4;279(23):23892-9. DM4MXOB RU https://pubmed.ncbi.nlm.nih.gov/15056663 DM4MYAR DI DM4MYAR DM4MYAR DN 2,7-Bis(chloroacetamido)anthraquinone DM4MYAR TI TTQY2EJ DM4MYAR TN TERT messenger RNA (TERT mRNA) DM4MYAR MA Inhibitor DM4MYAR RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM4MYAR RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM4MZQW DI DM4MZQW DM4MZQW DN BETP DM4MZQW TI TTVIMDE DM4MZQW TN Glucagon-like peptide 1 receptor (GLP1R) DM4MZQW MA Modulator (allosteric modulator) DM4MZQW RN A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification. Nat Chem Biol. 2014 Aug;10(8):629-31. DM4MZQW RU https://pubmed.ncbi.nlm.nih.gov/24997604 DM4N0LB DI DM4N0LB DM4N0LB DN 2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol DM4N0LB TI TTOM3J0 DM4N0LB TN Estrogen receptor beta (ESR2) DM4N0LB MA Inhibitor DM4N0LB RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM4N0LB RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM4N0LB DI DM4N0LB DM4N0LB DN 2-(4-Hydroxy-phenyl)-4-methoxy-quinolin-6-ol DM4N0LB TI TTZAYWL DM4N0LB TN Estrogen receptor (ESR) DM4N0LB MA Inhibitor DM4N0LB RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM4N0LB RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM4NAC9 DI DM4NAC9 DM4NAC9 DN PMID23357634C24d DM4NAC9 TI TTHS256 DM4NAC9 TN Metabotropic glutamate receptor 5 (mGluR5) DM4NAC9 MA Modulator (allosteric modulator) DM4NAC9 RN Discovery and structure-activity relationship of 1,3-cyclohexyl amide derivatives as novel mGluR5 negative allosteric modulators. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1398-406. DM4NAC9 RU https://pubmed.ncbi.nlm.nih.gov/23357634 DM4NBUH DI DM4NBUH DM4NBUH DN 1-D-glucopyranosyl cytosine DM4NBUH TI TTZHY6R DM4NBUH TN Glycogen phosphorylase muscle form (GP) DM4NBUH MA Inhibitor DM4NBUH RN 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modellin... Bioorg Med Chem. 2010 May 15;18(10):3413-25. DM4NBUH RU https://pubmed.ncbi.nlm.nih.gov/20430629 DM4NBX0 DI DM4NBX0 DM4NBX0 DN ISIS 122971 DM4NBX0 TI TTJZNIG DM4NBX0 TN MEKK3 messenger RNA (MAP3K3 mRNA) DM4NBX0 RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DM4NBX0 RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DM4NEOU DI DM4NEOU DM4NEOU DN 4-(4-Fluoro-benzyl)-piperidine hydrochloride DM4NEOU TI TTJQOD7 DM4NEOU TN 5-HT 2A receptor (HTR2A) DM4NEOU MA Inhibitor DM4NEOU RN Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10. DM4NEOU RU https://pubmed.ncbi.nlm.nih.gov/1479590 DM4NGUL DI DM4NGUL DM4NGUL DN 1-Benzyl-4-(4-phenylpiperazin-1-yl)phthalazine DM4NGUL TI TT8J1S3 DM4NGUL TN Smoothened homolog (SMO) DM4NGUL MA Inhibitor DM4NGUL RN 1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity. J Med Chem. 2009 Jul 9;52(13):3954-68. DM4NGUL RU https://pubmed.ncbi.nlm.nih.gov/19469545 DM4NQY6 DI DM4NQY6 DM4NQY6 DN 5-iodo-1H-indazole DM4NQY6 TI TTZUFI5 DM4NQY6 TN Nitric-oxide synthase brain (NOS1) DM4NQY6 MA Inhibitor DM4NQY6 RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DM4NQY6 RU https://pubmed.ncbi.nlm.nih.gov/17395463 DM4NRG5 DI DM4NRG5 DM4NRG5 DN PMID22266036C12e DM4NRG5 TI TTVBPDM DM4NRG5 TN Metabotropic glutamate receptor 1 (mGluR1) DM4NRG5 MA Modulator (allosteric modulator) DM4NRG5 RN Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1575-8. DM4NRG5 RU https://pubmed.ncbi.nlm.nih.gov/22266036 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TTBMV1G DM4NW3U TN GABA(A) receptor alpha-2 (GABRA2) DM4NW3U MA Inhibitor DM4NW3U RN The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8. DM4NW3U RU https://pubmed.ncbi.nlm.nih.gov/20646926 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TT06RH5 DM4NW3U TN GABA(A) receptor gamma-2 (GABRG2) DM4NW3U MA Inhibitor DM4NW3U RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM4NW3U RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TT37EDJ DM4NW3U TN GABA(A) receptor alpha-3 (GABRA3) DM4NW3U MA Inhibitor DM4NW3U RN The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8. DM4NW3U RU https://pubmed.ncbi.nlm.nih.gov/20646926 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TTNJYV2 DM4NW3U TN Gamma-aminobutyric acid receptor (GAR) DM4NW3U MA Inhibitor DM4NW3U RN The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8. DM4NW3U RU https://pubmed.ncbi.nlm.nih.gov/20646926 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TTNZPQ1 DM4NW3U TN GABA(A) receptor alpha-5 (GABRA5) DM4NW3U MA Inhibitor DM4NW3U RN The GABA(A) receptor as a target for photochromic molecules. Bioorg Med Chem. 2010 Nov 15;18(22):7731-8. DM4NW3U RU https://pubmed.ncbi.nlm.nih.gov/20646926 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TT1MPAY DM4NW3U TN GABA(A) receptor alpha-1 (GABRA1) DM4NW3U MA Inhibitor DM4NW3U RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM4NW3U RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TTZA1NY DM4NW3U TN GABA(A) receptor beta-2 (GABRB2) DM4NW3U MA Inhibitor DM4NW3U RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM4NW3U RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM4NW3U DI DM4NW3U DM4NW3U DN Ro-15-3505 DM4NW3U TI TTEX6LM DM4NW3U TN GABA(A) receptor gamma-3 (GABRG3) DM4NW3U MA Modulator DM4NW3U RN Molecular structure and stereoelectronic properties of sarmazenil--a weak inverse agonist at the omega modulatory sites (benzodiazepine receptors):... Bioorg Med Chem. 1998 Oct;6(10):1745-57. DM4NW3U RU https://www.ncbi.nlm.nih.gov/pubmed/9839004 DM4NXRO DI DM4NXRO DM4NXRO DN [3H]devazepide DM4NXRO TI TTCG0AL DM4NXRO TN Cholecystokinin receptor type A (CCKAR) DM4NXRO MA Antagonist DM4NXRO RN Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol. 1986 Sep;30(3):212-7. DM4NXRO RU https://pubmed.ncbi.nlm.nih.gov/3018478 DM4NY9H DI DM4NY9H DM4NY9H DN Heptanoic Acid DM4NY9H TI TT9V5JH DM4NY9H TN Phospholipase A2 (PLA2G1B) DM4NY9H MA Inhibitor DM4NY9H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM4NY9H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM4O2VC DI DM4O2VC DM4O2VC DN 3,3'-(1,2,4-Thiadiazol-2,5-diyl)diphenol DM4O2VC TI TTIWB6L DM4O2VC TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM4O2VC MA Inhibitor DM4O2VC RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DM4O2VC RU https://pubmed.ncbi.nlm.nih.gov/18855374 DM4O69H DI DM4O69H DM4O69H DN CAY 10471 DM4O69H TI TTQDMX5 DM4O69H TN Prostaglandin D2 receptor 2 (PTGDR2) DM4O69H MA Agonist DM4O69H RN Minor structural modifications convert the dual TP/CRTH2 antagonist ramatroban into a highly selective and potent CRTH2 antagonist. J Med Chem. 2005 Feb 24;48(4):897-900. DM4O69H RU https://pubmed.ncbi.nlm.nih.gov/15715457 DM4O6I5 DI DM4O6I5 DM4O6I5 DN 5-Iodouracil DM4O6I5 TI TTZPS91 DM4O6I5 TN Dihydrothymine dehydrogenase (DPYD) DM4O6I5 MA Inhibitor DM4O6I5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4O6I5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4OCAH DI DM4OCAH DM4OCAH DN AMTB DM4OCAH TI TTXDKTO DM4OCAH TN Long transient receptor potential channel 8 (TRPM8) DM4OCAH MA Blocker (channel blocker) DM4OCAH RN AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am J Physiol Renal Physiol. 2008 Sep;295(3):F803-10. DM4OCAH RU https://pubmed.ncbi.nlm.nih.gov/18562636 DM4OF6C DI DM4OF6C DM4OF6C DN ISIS 134606 DM4OF6C TI TTKW4ML DM4OF6C TN Caspase 6 messenger RNA (CASP6 mRNA) DM4OF6C RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DM4OF6C RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DM4OLAZ DI DM4OLAZ DM4OLAZ DN MOLEPHANTIN DM4OLAZ TI TTSXVID DM4OLAZ TN Nuclear factor NF-kappa-B (NFKB) DM4OLAZ MA Inhibitor DM4OLAZ RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DM4OLAZ RU https://pubmed.ncbi.nlm.nih.gov/15537359 DM4OQWZ DI DM4OQWZ DM4OQWZ DN Malate Like Intermediate DM4OQWZ TI TTHDSE2 DM4OQWZ TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM4OQWZ MA Inhibitor DM4OQWZ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM4OQWZ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM4OQZX DI DM4OQZX DM4OQZX DN PD123177 DM4OQZX TI TTQVOEI DM4OQZX TN Angiotensin II receptor type-2 (AGTR2) DM4OQZX MA Antagonist DM4OQZX RN Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol. 1990 Mar;37(3):347-51. DM4OQZX RU https://pubmed.ncbi.nlm.nih.gov/2314387 DM4OSFD DI DM4OSFD DM4OSFD DN BAS-00387328 DM4OSFD TI TT3PJMV DM4OSFD TN Tyrosine-protein kinase ABL1 (ABL) DM4OSFD MA Inhibitor DM4OSFD RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DM4OSFD RU https://pubmed.ncbi.nlm.nih.gov/16722646 DM4OSFD DI DM4OSFD DM4OSFD DN BAS-00387328 DM4OSFD TI TT6PKBN DM4OSFD TN Proto-oncogene c-Src (SRC) DM4OSFD MA Inhibitor DM4OSFD RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DM4OSFD RU https://pubmed.ncbi.nlm.nih.gov/16722646 DM4OT8M DI DM4OT8M DM4OT8M DN bantag-1 DM4OT8M TI TTHYDUM DM4OT8M TN Bombesin receptor (BS) DM4OT8M MA Antagonist DM4OT8M RN Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16. DM4OT8M RU https://pubmed.ncbi.nlm.nih.gov/23892571 DM4OT8M DI DM4OT8M DM4OT8M DN bantag-1 DM4OT8M TI TTC1MVT DM4OT8M TN Gastrin-releasing peptide receptor (GRPR) DM4OT8M MA Antagonist DM4OT8M RN Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16. DM4OT8M RU https://pubmed.ncbi.nlm.nih.gov/23892571 DM4OWM6 DI DM4OWM6 DM4OWM6 DN 1-hexadecyl-1H-indole-2,3-dione DM4OWM6 TI TTMF541 DM4OWM6 TN Liver carboxylesterase (CES1) DM4OWM6 MA Inhibitor DM4OWM6 RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM4OWM6 RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM4P15C DI DM4P15C DM4P15C DN ISIS 25547 DM4P15C TI TTP2U16 DM4P15C TN RhoA messenger RNA (RHOA mRNA) DM4P15C RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DM4P15C RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DM4P3CW DI DM4P3CW DM4P3CW DN 2-methyl-4-(m-tolylethynyl)thiazole DM4P3CW TI TTHS256 DM4P3CW TN Metabotropic glutamate receptor 5 (mGluR5) DM4P3CW MA Inhibitor DM4P3CW RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DM4P3CW RU https://pubmed.ncbi.nlm.nih.gov/16451073 DM4P9LJ DI DM4P9LJ DM4P9LJ DN MiR-375 DM4P9LJ TI TTYMGWX DM4P9LJ TN PDK-1 messenger RNA (PDK-1 mRNA) DM4P9LJ MA Binder DM4P9LJ RN miR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes. 2008 Oct;57(10):2708-17. DM4P9LJ RU https://pubmed.ncbi.nlm.nih.gov/18591395 DM4PGRU DI DM4PGRU DM4PGRU DN ISIS 23459 DM4PGRU TI TTAIWZN DM4PGRU TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DM4PGRU RN US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression. DM4PGRU RU http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true DM4PLSU DI DM4PLSU DM4PLSU DN 3-fluoro-4'-(1-(pyridin-4-yl)propyl)biphenyl-4-ol DM4PLSU TI TTRA5BZ DM4PLSU TN Steroid 17-alpha-monooxygenase (S17AH) DM4PLSU MA Inhibitor DM4PLSU RN Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors. J Med Chem. 2010 Jul 8;53(13):5049-53. DM4PLSU RU https://pubmed.ncbi.nlm.nih.gov/20550118 DM4PM1G DI DM4PM1G DM4PM1G DN ISIS 13920 DM4PM1G TI TT28ZON DM4PM1G TN H-ras messenger RNA (HRAS mRNA) DM4PM1G RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DM4PM1G RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DM4PTR3 DI DM4PTR3 DM4PTR3 DN N-(3,3-Diphenyl-propyl)-2-pyridine-3-ylacetamide DM4PTR3 TI TT7WVHI DM4PTR3 TN Soluble epoxide hydrolase (EPHX2) DM4PTR3 MA Inhibitor DM4PTR3 RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DM4PTR3 RU https://pubmed.ncbi.nlm.nih.gov/19746975 DM4PWDJ DI DM4PWDJ DM4PWDJ DN CMI-489 DM4PWDJ TI TT4H1MQ DM4PWDJ TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DM4PWDJ MA Inhibitor DM4PWDJ RN Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91. DM4PWDJ RU https://pubmed.ncbi.nlm.nih.gov/17994682 DM4PWDJ DI DM4PWDJ DM4PWDJ DN CMI-489 DM4PWDJ TI TT5KPZR DM4PWDJ TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM4PWDJ MA Inhibitor DM4PWDJ RN Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91. DM4PWDJ RU https://pubmed.ncbi.nlm.nih.gov/17994682 DM4PZ37 DI DM4PZ37 DM4PZ37 DN PMID25703523C7d DM4PZ37 TI TTRA6BO DM4PZ37 TN Bromodomain-containing protein 4 (BRD4) DM4PZ37 MA Inhibitor DM4PZ37 RN 9H-purine scaffold reveals induced-fit pocket plasticity of the BRD9 bromodomain. J Med Chem. 2015 Mar 26;58(6):2718-36. DM4PZ37 RU https://pubmed.ncbi.nlm.nih.gov/25703523 DM4Q2HZ DI DM4Q2HZ DM4Q2HZ DN EVT-501 DM4Q2HZ TI TT9JNIC DM4Q2HZ TN Histamine H3 receptor (H3R) DM4Q2HZ MA Antagonist DM4Q2HZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DM4Q2HZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DM4Q3JO DI DM4Q3JO DM4Q3JO DN ISIS 116414 DM4Q3JO TI TTGECUM DM4Q3JO TN Cot oncogene messenger RNA (MAP3K8 mRNA) DM4Q3JO RN US patent application no. 6,265,216, Antisense modulation of cot oncogene expression. DM4Q3JO RU http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true DM4Q5DO DI DM4Q5DO DM4Q5DO DN VX-467 DM4Q5DO TI TTT7PJU DM4Q5DO TN Janus kinase 3 (JAK-3) DM4Q5DO MA Inhibitor DM4Q5DO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). DM4Q5DO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049 DM4Q5TX DI DM4Q5TX DM4Q5TX DN 6-fluoro-5-phenylpyrimidine-2,4(1H,3H)-dione DM4Q5TX TI TTO0IB8 DM4Q5TX TN Thymidine phosphorylase (TYMP) DM4Q5TX MA Inhibitor DM4Q5TX RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DM4Q5TX RU https://pubmed.ncbi.nlm.nih.gov/17963370 DM4Q86B DI DM4Q86B DM4Q86B DN N1-[4-(Phenylmethoxy)phenyl]-D-aspartamine DM4Q86B TI TTXZEAJ DM4Q86B TN Leukotriene A-4 hydrolase (LTA4H) DM4Q86B MA Inhibitor DM4Q86B RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DM4Q86B RU https://pubmed.ncbi.nlm.nih.gov/18394906 DM4QB3G DI DM4QB3G DM4QB3G DN 5-Methyl-pyrrolidin-(2Z)-ylideneamine DM4QB3G TI TTF10I9 DM4QB3G TN Nitric-oxide synthase inducible (NOS2) DM4QB3G MA Inhibitor DM4QB3G RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM4QB3G RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM4QB3G DI DM4QB3G DM4QB3G DN 5-Methyl-pyrrolidin-(2Z)-ylideneamine DM4QB3G TI TTZUFI5 DM4QB3G TN Nitric-oxide synthase brain (NOS1) DM4QB3G MA Inhibitor DM4QB3G RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM4QB3G RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM4QB3G DI DM4QB3G DM4QB3G DN 5-Methyl-pyrrolidin-(2Z)-ylideneamine DM4QB3G TI TTCM4B3 DM4QB3G TN Nitric-oxide synthase endothelial (NOS3) DM4QB3G MA Inhibitor DM4QB3G RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM4QB3G RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM4QC0R DI DM4QC0R DM4QC0R DN 5-hydroxy-2-(4-methylaminophenyl)benzofuran DM4QC0R TI TTE4KHA DM4QC0R TN Amyloid beta A4 protein (APP) DM4QC0R MA Inhibitor DM4QC0R RN Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. DM4QC0R RU https://pubmed.ncbi.nlm.nih.gov/16640332 DM4QDZV DI DM4QDZV DM4QDZV DN 2',4'-dicyanobiphenyl-4-yl sulfamate DM4QDZV TI TTHM0R1 DM4QDZV TN Steryl-sulfatase (STS) DM4QDZV MA Inhibitor DM4QDZV RN Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70. DM4QDZV RU https://pubmed.ncbi.nlm.nih.gov/20148564 DM4QJPU DI DM4QJPU DM4QJPU DN Glaxo-11p DM4QJPU TI TTCG0AL DM4QJPU TN Cholecystokinin receptor type A (CCKAR) DM4QJPU MA Agonist DM4QJPU RN Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J Med Chem. 1996 Jan 19;39(2):562-9. DM4QJPU RU https://pubmed.ncbi.nlm.nih.gov/8558528 DM4QK0T DI DM4QK0T DM4QK0T DN tifluadom DM4QK0T TI TTQW87Y DM4QK0T TN Opioid receptor kappa (OPRK1) DM4QK0T MA Agonist DM4QK0T RN Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997 Aug;282(2):676-84. DM4QK0T RU https://pubmed.ncbi.nlm.nih.gov/9262330 DM4QKVN DI DM4QKVN DM4QKVN DN CAULERPIN DM4QKVN TI TTELIN2 DM4QKVN TN PTPN1 messenger RNA (PTPN1 mRNA) DM4QKVN MA Inhibitor DM4QKVN RN Two novel aromatic valerenane-type sesquiterpenes from the Chinese green alga Caulerpa taxifolia. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2947-50. DM4QKVN RU https://pubmed.ncbi.nlm.nih.gov/16563751 DM4QR2C DI DM4QR2C DM4QR2C DN N-(4-hydroxyphenylpropanyl)-spermine DM4QR2C TI TTAN6JD DM4QR2C TN Glutamate receptor AMPA (GRIA) DM4QR2C MA Inhibitor DM4QR2C RN Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7. DM4QR2C RU https://pubmed.ncbi.nlm.nih.gov/20096591 DM4QR2C DI DM4QR2C DM4QR2C DN N-(4-hydroxyphenylpropanyl)-spermine DM4QR2C TI TTVPQTF DM4QR2C TN Glutamate receptor AMPA 1 (GRIA1) DM4QR2C MA Inhibitor DM4QR2C RN Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7. DM4QR2C RU https://pubmed.ncbi.nlm.nih.gov/20096591 DM4QRV9 DI DM4QRV9 DM4QRV9 DN 3-(1-Propyl-pyrrolidin-3-yl)-phenol DM4QRV9 TI TTSQIFT DM4QRV9 TN 5-HT 1A receptor (HTR1A) DM4QRV9 MA Inhibitor DM4QRV9 RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DM4QRV9 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DM4QRV9 DI DM4QRV9 DM4QRV9 DN 3-(1-Propyl-pyrrolidin-3-yl)-phenol DM4QRV9 TI TTEX248 DM4QRV9 TN Dopamine D2 receptor (D2R) DM4QRV9 MA Inhibitor DM4QRV9 RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DM4QRV9 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DM4QRV9 DI DM4QRV9 DM4QRV9 DN 3-(1-Propyl-pyrrolidin-3-yl)-phenol DM4QRV9 TI TT4C8EA DM4QRV9 TN Dopamine D3 receptor (D3R) DM4QRV9 MA Inhibitor DM4QRV9 RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DM4QRV9 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DM4QYEF DI DM4QYEF DM4QYEF DN 8-OH-MANZAMINE A DM4QYEF TI TTRSMW9 DM4QYEF TN Glycogen synthase kinase-3 beta (GSK-3B) DM4QYEF MA Inhibitor DM4QYEF RN Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40. DM4QYEF RU https://pubmed.ncbi.nlm.nih.gov/16872140 DM4R2EX DI DM4R2EX DM4R2EX DN 8-acetyl-7-(benzyloxy)-2H-chromen-2-one DM4R2EX TI TT2LVK8 DM4R2EX TN Carbonic anhydrase IX (CA-IX) DM4R2EX MA Inhibitor DM4R2EX RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DM4R2EX RU https://pubmed.ncbi.nlm.nih.gov/21067924 DM4R657 DI DM4R657 DM4R657 DN toxaphene DM4R657 TI TTPNQAC DM4R657 TN Estrogen-related receptor-alpha (ESRRA) DM4R657 MA Antagonist DM4R657 RN Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res. 1999 Sep 15;59(18):4519-24. DM4R657 RU https://pubmed.ncbi.nlm.nih.gov/10493499 DM4R7X8 DI DM4R7X8 DM4R7X8 DN 10-hydroxy-18-methoxybetaenone DM4R7X8 TI TT0PG8F DM4R7X8 TN Cyclin-dependent kinase 4 (CDK4) DM4R7X8 MA Inhibitor DM4R7X8 RN Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45. DM4R7X8 RU https://pubmed.ncbi.nlm.nih.gov/10869191 DM4R7X8 DI DM4R7X8 DM4R7X8 DN 10-hydroxy-18-methoxybetaenone DM4R7X8 TI TTGKNB4 DM4R7X8 TN Epidermal growth factor receptor (EGFR) DM4R7X8 MA Inhibitor DM4R7X8 RN Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45. DM4R7X8 RU https://pubmed.ncbi.nlm.nih.gov/10869191 DM4RD2S DI DM4RD2S DM4RD2S DN 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid DM4RD2S TI TTGKIED DM4RD2S TN Fibroblast growth factor-2 (FGF2) DM4RD2S MA Inhibitor DM4RD2S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4RD2S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4RDVO DI DM4RDVO DM4RDVO DN UNC9975 DM4RDVO TI TTEX248 DM4RDVO TN Dopamine D2 receptor (D2R) DM4RDVO MA Agonist DM4RDVO RN Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93. DM4RDVO RU https://pubmed.ncbi.nlm.nih.gov/22025698 DM4RGCX DI DM4RGCX DM4RGCX DN Octanoic acid biphenyl-2-ylamide DM4RGCX TI TTK3C21 DM4RGCX TN Acetoacetyl-CoA thiolase (ACAT1) DM4RGCX MA Inhibitor DM4RGCX RN Biphenyl versus phenylpyridazine derivatives: the role of the heterocycle in a series of acyl-CoA:cholesterol acyl transferase inhibitors. J Med Chem. 2008 Mar 13;51(5):1474-7. DM4RGCX RU https://pubmed.ncbi.nlm.nih.gov/18284184 DM4RHEZ DI DM4RHEZ DM4RHEZ DN SK&F-86466 DM4RHEZ TI TTNGILX DM4RHEZ TN Adrenergic receptor alpha-1A (ADRA1A) DM4RHEZ MA Inhibitor DM4RHEZ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DM4RHEZ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DM4RHEZ DI DM4RHEZ DM4RHEZ DN SK&F-86466 DM4RHEZ TI TT34BHT DM4RHEZ TN Adrenergic receptor alpha-1D (ADRA1D) DM4RHEZ MA Inhibitor DM4RHEZ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DM4RHEZ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DM4RHEZ DI DM4RHEZ DM4RHEZ DN SK&F-86466 DM4RHEZ TI TTBRKXS DM4RHEZ TN Adrenergic receptor alpha-1B (ADRA1B) DM4RHEZ MA Inhibitor DM4RHEZ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DM4RHEZ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DM4RNOE DI DM4RNOE DM4RNOE DN 3,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide DM4RNOE TI TTK25J1 DM4RNOE TN Adenosine A1 receptor (ADORA1) DM4RNOE MA Inhibitor DM4RNOE RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DM4RNOE RU https://pubmed.ncbi.nlm.nih.gov/11454470 DM4RP0A DI DM4RP0A DM4RP0A DN Semiplenamide G DM4RP0A TI TT6OEDT DM4RP0A TN Cannabinoid receptor 1 (CB1) DM4RP0A MA Inhibitor DM4RP0A RN Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Nat Prod. 2003 Oct;66(10):1364-8. DM4RP0A RU https://pubmed.ncbi.nlm.nih.gov/14575438 DM4RPBJ DI DM4RPBJ DM4RPBJ DN NSC-26699 DM4RPBJ TI TT9NVXQ DM4RPBJ TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DM4RPBJ MA Inhibitor DM4RPBJ RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DM4RPBJ RU https://pubmed.ncbi.nlm.nih.gov/15615517 DM4RS9N DI DM4RS9N DM4RS9N DN 2,6-diamino-5-nitrosopyrimidin-4(3H)-one DM4RS9N TI TT4ILYC DM4RS9N TN Bacterial Dihydropteroate synthetase (Bact folP) DM4RS9N MA Inhibitor DM4RS9N RN Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem. 2010 Jan 14;53(1):166-77. DM4RS9N RU https://pubmed.ncbi.nlm.nih.gov/19899766 DM4RVGO DI DM4RVGO DM4RVGO DN H-89 DM4RVGO TI TT5U49F DM4RVGO TN PRKACA messenger RNA (PRKACA mRNA) DM4RVGO MA Inhibitor DM4RVGO RN Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem. 1990 Mar 25;265(9):5267-72. DM4RVGO RU https://pubmed.ncbi.nlm.nih.gov/2156866 DM4RZ9A DI DM4RZ9A DM4RZ9A DN BIA DM4RZ9A TI TTKWFB8 DM4RZ9A TN Catechol-O-methyl-transferase (COMT) DM4RZ9A MA Inhibitor DM4RZ9A RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM4RZ9A RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM4RZSB DI DM4RZSB DM4RZSB DN GNF-PF-3037 DM4RZSB TI TTOM3J0 DM4RZSB TN Estrogen receptor beta (ESR2) DM4RZSB MA Inhibitor DM4RZSB RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM4RZSB RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM4RZSB DI DM4RZSB DM4RZSB DN GNF-PF-3037 DM4RZSB TI TTT2SVW DM4RZSB TN PPAR-gamma messenger RNA (PPARG mRNA) DM4RZSB MA Inhibitor DM4RZSB RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM4RZSB RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM4S1Y6 DI DM4S1Y6 DM4S1Y6 DN AH23848 DM4S1Y6 TI TT2O84V DM4S1Y6 TN Thromboxane A2 receptor (TBXA2R) DM4S1Y6 MA Antagonist DM4S1Y6 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM4S1Y6 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM4S1Y6 DI DM4S1Y6 DM4S1Y6 DN AH23848 DM4S1Y6 TI TT79WV3 DM4S1Y6 TN Prostaglandin E2 receptor EP4 (PTGER4) DM4S1Y6 MA Antagonist DM4S1Y6 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM4S1Y6 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM4S279 DI DM4S279 DM4S279 DN Adamantan-1-yl-(4-ethyl-piperazin-1-yl)-methanone DM4S279 TI TTN7BL9 DM4S279 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM4S279 MA Inhibitor DM4S279 RN Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43. DM4S279 RU https://pubmed.ncbi.nlm.nih.gov/17350260 DM4S5TQ DI DM4S5TQ DM4S5TQ DN S22153 DM4S5TQ TI TT0WAIE DM4S5TQ TN Melatonin receptor type 1A (MTNR1A) DM4S5TQ MA Antagonist DM4S5TQ RN New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. DM4S5TQ RU https://pubmed.ncbi.nlm.nih.gov/12764576 DM4S81A DI DM4S81A DM4S81A DN indanidine DM4S81A TI TT2NUT5 DM4S81A TN Adrenergic receptor alpha-2C (ADRA2C) DM4S81A MA Agonist DM4S81A RN Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. DM4S81A RU https://pubmed.ncbi.nlm.nih.gov/7969082 DM4S86L DI DM4S86L DM4S86L DN 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione DM4S86L TI TT6X50U DM4S86L TN Matrix metalloproteinase-9 (MMP-9) DM4S86L MA Inhibitor DM4S86L RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DM4S86L RU https://pubmed.ncbi.nlm.nih.gov/11327602 DM4S86L DI DM4S86L DM4S86L DN 5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione DM4S86L TI TTLM12X DM4S86L TN Matrix metalloproteinase-2 (MMP-2) DM4S86L MA Inhibitor DM4S86L RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DM4S86L RU https://pubmed.ncbi.nlm.nih.gov/11327602 DM4SEMA DI DM4SEMA DM4SEMA DN EMD 56551 DM4SEMA TI TTSQIFT DM4SEMA TN 5-HT 1A receptor (HTR1A) DM4SEMA MA Modulator DM4SEMA RN Diagnosis of migraine with aura, depression and anxiety from allelic variations in dopaminergic genes DM4SEMA RU https://www.google.com/patents/WO1998007426A1 DM4SFKW DI DM4SFKW DM4SFKW DN Org-36764 DM4SFKW TI TT4QPUL DM4SFKW TN Antithrombin-III (ATIII) DM4SFKW MA Modulator DM4SFKW RN Pre-clinical pharmacological profile of the novel glycoconjugate Org 36764 with both factor Xa and thrombin (IIa) inhibitory activities. Thromb Haemost. 2000 Oct;84(4):611-20. DM4SFKW RU https://www.ncbi.nlm.nih.gov/pubmed/11057859 DM4SGVF DI DM4SGVF DM4SGVF DN PUKATEINE DM4SGVF TI TTEX248 DM4SGVF TN Dopamine D2 receptor (D2R) DM4SGVF MA Inhibitor DM4SGVF RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DM4SGVF RU https://pubmed.ncbi.nlm.nih.gov/17228858 DM4SGVF DI DM4SGVF DM4SGVF DN PUKATEINE DM4SGVF TI TTZFYLI DM4SGVF TN Dopamine D1 receptor (D1R) DM4SGVF MA Inhibitor DM4SGVF RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DM4SGVF RU https://pubmed.ncbi.nlm.nih.gov/17228858 DM4SKYA DI DM4SKYA DM4SKYA DN CLEMATOMANDSHURICA SAPONIN A DM4SKYA TI TTVKILB DM4SKYA TN Prostaglandin G/H synthase 2 (COX-2) DM4SKYA MA Inhibitor DM4SKYA RN Triterpene saponins from clematis mandshurica. J Nat Prod. 2006 Nov;69(11):1591-5. DM4SKYA RU https://pubmed.ncbi.nlm.nih.gov/17125227 DM4SPV7 DI DM4SPV7 DM4SPV7 DN 4-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol DM4SPV7 TI TTULVH8 DM4SPV7 TN Tyrosinase (TYR) DM4SPV7 MA Inhibitor DM4SPV7 RN Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4. DM4SPV7 RU https://pubmed.ncbi.nlm.nih.gov/17064896 DM4SRL7 DI DM4SRL7 DM4SRL7 DN Nocardimicin C DM4SRL7 TI TTQ13Z5 DM4SRL7 TN Muscarinic acetylcholine receptor M3 (CHRM3) DM4SRL7 MA Inhibitor DM4SRL7 RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DM4SRL7 RU https://pubmed.ncbi.nlm.nih.gov/16038549 DM4SWJ7 DI DM4SWJ7 DM4SWJ7 DN 5-amino-2-p-tolyl-oxazole-4-carboxylic acid amide DM4SWJ7 TI TTJ3E9X DM4SWJ7 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DM4SWJ7 MA Inhibitor DM4SWJ7 RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DM4SWJ7 RU https://pubmed.ncbi.nlm.nih.gov/16686533 DM4SWQA DI DM4SWQA DM4SWQA DN Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA TI TTRK9JT DM4SWQA TN Neuropeptide Y receptor type 1 (NPY1R) DM4SWQA MA Inhibitor DM4SWQA RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM4SWQA RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM4SWQA DI DM4SWQA DM4SWQA DN Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA TI TTW4N16 DM4SWQA TN Neuropeptide Y receptor type 4 (NPY4R) DM4SWQA MA Inhibitor DM4SWQA RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM4SWQA RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM4SWQA DI DM4SWQA DM4SWQA DN Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA TI TTJ6WK9 DM4SWQA TN Neuropeptide Y receptor type 2 (NPY2R) DM4SWQA MA Inhibitor DM4SWQA RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM4SWQA RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM4SWYX DI DM4SWYX DM4SWYX DN DECIDIUM DM4SWYX TI TT1RS9F DM4SWYX TN Acetylcholinesterase (AChE) DM4SWYX MA Inhibitor DM4SWYX RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DM4SWYX RU https://pubmed.ncbi.nlm.nih.gov/18479118 DM4SXIT DI DM4SXIT DM4SXIT DN SP-650003 DM4SXIT TI TTSXVID DM4SXIT TN Nuclear factor NF-kappa-B (NFKB) DM4SXIT MA Modulator DM4SXIT RN Book (Current Pharmaceutical Design) DM4SXIT RU https://books.google.com.hk/books?id=ZbENzZB8BwwC&pg=PA523&lpg=PA523&dq=SP-650003&source=bl&ots=n0z8_atusD&sig=HB0ARlN36liy5QcqXckEZyeYPpc&hl=zh-CN&sa=X&ved=0ahUKEwj27ubRtKTKAhUHnZQKHfWTDGoQ6AEIHTAA#v=onepage&q=SP-650003&f=false DM4T0ZF DI DM4T0ZF DM4T0ZF DN TNFmab DM4T0ZF TI TTG043C DM4T0ZF TN Tumor necrosis factor receptor type I (TNF-R1) DM4T0ZF RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DM4T0ZF RU https://pubmed.ncbi.nlm.nih.gov/15507622 DM4T2R3 DI DM4T2R3 DM4T2R3 DN RPR260243 DM4T2R3 TI TTQ6VDM DM4T2R3 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM4T2R3 MA Activator DM4T2R3 RN Discovery of a small molecule activator of the human ether-a-go-go-related gene (HERG) cardiac K+ channel. Mol Pharmacol. 2005 Mar;67(3):827-36. DM4T2R3 RU https://pubmed.ncbi.nlm.nih.gov/15548764 DM4T5DY DI DM4T5DY DM4T5DY DN FGIN-1-27 DM4T5DY TI TTPTXIN DM4T5DY TN Translocator protein (TSPO) DM4T5DY MA Binder DM4T5DY RN Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001 Nov 30;85(11):1771-80. DM4T5DY RU https://pubmed.ncbi.nlm.nih.gov/11742501 DM4T62U DI DM4T62U DM4T62U DN CTP DM4T62U TI TT24DGP DM4T62U TN P2Y purinoceptor 4 (P2RY4) DM4T62U MA Agonist DM4T62U RN ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31. DM4T62U RU https://pubmed.ncbi.nlm.nih.gov/10779375 DM4T8KV DI DM4T8KV DM4T8KV DN RQ-00201894 DM4T8KV TI TT953CX DM4T8KV TN Motilin receptor (MLNR) DM4T8KV MA Agonist DM4T8KV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297). DM4T8KV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297 DM4TFMA DI DM4TFMA DM4TFMA DN 3-[5-(4-hydroxyphenyl)-1,3-oxazol-2-yl]phenol DM4TFMA TI TTIWB6L DM4TFMA TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM4TFMA MA Inhibitor DM4TFMA RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DM4TFMA RU https://pubmed.ncbi.nlm.nih.gov/18855374 DM4TFN6 DI DM4TFN6 DM4TFN6 DN 1-aminobutylphosphonic acid DM4TFN6 TI TTPHMWB DM4TFN6 TN Aminopeptidase N (ANPEP) DM4TFN6 MA Inhibitor DM4TFN6 RN New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6. DM4TFN6 RU https://pubmed.ncbi.nlm.nih.gov/20347318 DM4TIXY DI DM4TIXY DM4TIXY DN 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol DM4TIXY TI TTK25J1 DM4TIXY TN Adenosine A1 receptor (ADORA1) DM4TIXY MA Inhibitor DM4TIXY RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM4TIXY RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM4TIXY DI DM4TIXY DM4TIXY DN 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol DM4TIXY TI TTM2AOE DM4TIXY TN Adenosine A2a receptor (ADORA2A) DM4TIXY MA Inhibitor DM4TIXY RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM4TIXY RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM4TIXY DI DM4TIXY DM4TIXY DN 5,7-diphenyl-3H-imidazo[4,5-b]pyridin-2-ol DM4TIXY TI TTJFY5U DM4TIXY TN Adenosine A3 receptor (ADORA3) DM4TIXY MA Inhibitor DM4TIXY RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM4TIXY RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM4TN73 DI DM4TN73 DM4TN73 DN PMID26155854C57 DM4TN73 TI TT9A0HI DM4TN73 TN ATPase family AAA domain containing 2 (ATAD2) DM4TN73 MA Inhibitor DM4TN73 RN Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. J Med Chem. 2015 Jul 23;58(14):5649-73. DM4TN73 RU https://pubmed.ncbi.nlm.nih.gov/26155854 DM4TR0D DI DM4TR0D DM4TR0D DN Dihydromorphine DM4TR0D TI TTKWM86 DM4TR0D TN Opioid receptor mu (MOP) DM4TR0D MA Agonist DM4TR0D RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM4TR0D RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM4TR0D DI DM4TR0D DM4TR0D DN Dihydromorphine DM4TR0D TI TTQW87Y DM4TR0D TN Opioid receptor kappa (OPRK1) DM4TR0D MA Agonist DM4TR0D RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM4TR0D RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM4TR0D DI DM4TR0D DM4TR0D DN Dihydromorphine DM4TR0D TI TT21AKM DM4TR0D TN Corticotropin-lipotropin (POMC) DM4TR0D MA Agonist DM4TR0D RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM4TR0D RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM4TR0D DI DM4TR0D DM4TR0D DN Dihydromorphine DM4TR0D TI TT27RFC DM4TR0D TN Opioid receptor delta (OPRD1) DM4TR0D MA Agonist DM4TR0D RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM4TR0D RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM4TSVC DI DM4TSVC DM4TSVC DN 1-hydroxy-3-phenylurea DM4TSVC TI TTULVH8 DM4TSVC TN Tyrosinase (TYR) DM4TSVC MA Inhibitor DM4TSVC RN Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10. DM4TSVC RU https://pubmed.ncbi.nlm.nih.gov/18501598 DM4TWRJ DI DM4TWRJ DM4TWRJ DN 8-Phenyloctylcarbamic Acid Biphenyl-3-yl Ester DM4TWRJ TI TTDP1UC DM4TWRJ TN Fatty acid amide hydrolase (FAAH) DM4TWRJ MA Inhibitor DM4TWRJ RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DM4TWRJ RU https://pubmed.ncbi.nlm.nih.gov/18507372 DM4TX9O DI DM4TX9O DM4TX9O DN 6-o-tolylquinazolin-2-amine DM4TX9O TI TTQBR95 DM4TX9O TN Stress-activated protein kinase 2a (p38 alpha) DM4TX9O MA Inhibitor DM4TX9O RN Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. DM4TX9O RU https://pubmed.ncbi.nlm.nih.gov/16970394 DM4TX9O DI DM4TX9O DM4TX9O DN 6-o-tolylquinazolin-2-amine DM4TX9O TI TT860QF DM4TX9O TN LCK tyrosine protein kinase (LCK) DM4TX9O MA Inhibitor DM4TX9O RN Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. DM4TX9O RU https://pubmed.ncbi.nlm.nih.gov/16970394 DM4TX9O DI DM4TX9O DM4TX9O DN 6-o-tolylquinazolin-2-amine DM4TX9O TI TTUTJGQ DM4TX9O TN Vascular endothelial growth factor receptor 2 (KDR) DM4TX9O MA Inhibitor DM4TX9O RN Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. DM4TX9O RU https://pubmed.ncbi.nlm.nih.gov/16970394 DM4TX9O DI DM4TX9O DM4TX9O DN 6-o-tolylquinazolin-2-amine DM4TX9O TI TTT7PJU DM4TX9O TN Janus kinase 3 (JAK-3) DM4TX9O MA Inhibitor DM4TX9O RN Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity. J Med Chem. 2006 Sep 21;49(19):5671-86. DM4TX9O RU https://pubmed.ncbi.nlm.nih.gov/16970394 DM4U0L1 DI DM4U0L1 DM4U0L1 DN Hexanoic acid 2,5-diphenyl-thiazol-4-yl ester DM4U0L1 TI TT2J34L DM4U0L1 TN Arachidonate 5-lipoxygenase (5-LOX) DM4U0L1 MA Inhibitor DM4U0L1 RN 4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65. DM4U0L1 RU https://pubmed.ncbi.nlm.nih.gov/2066989 DM4UD8C DI DM4UD8C DM4UD8C DN 3-(1-Methyl-piperidin-3-yl)-2-phenyl-1H-indole DM4UD8C TI TTQ6VDM DM4UD8C TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM4UD8C MA Inhibitor DM4UD8C RN 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14. DM4UD8C RU https://pubmed.ncbi.nlm.nih.gov/11334570 DM4UL1G DI DM4UL1G DM4UL1G DN Oxindole 95 DM4UL1G TI TTL4Q97 DM4UL1G TN Cyclin-dependent kinase 5 (CDK5) DM4UL1G MA Inhibitor DM4UL1G RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DM4UL1G RU https://pubmed.ncbi.nlm.nih.gov/12237154 DM4UL1G DI DM4UL1G DM4UL1G DN Oxindole 95 DM4UL1G TI TT7HF4W DM4UL1G TN Cyclin-dependent kinase 2 (CDK2) DM4UL1G MA Inhibitor DM4UL1G RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DM4UL1G RU https://pubmed.ncbi.nlm.nih.gov/12237154 DM4UQBI DI DM4UQBI DM4UQBI DN (+/-)-threo-3',5'-Dichloromethylphenidate DM4UQBI TI TTVBI8W DM4UQBI TN Dopamine transporter (DAT) DM4UQBI MA Inhibitor DM4UQBI RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM4UQBI RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM4URBO DI DM4URBO DM4URBO DN [3H]GR 125,743 DM4URBO TI TTK8CXU DM4URBO TN 5-HT 1B receptor (HTR1B) DM4URBO MA Antagonist DM4URBO RN Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 1999 Jul 30;456(1):63-7. DM4URBO RU https://pubmed.ncbi.nlm.nih.gov/10452531 DM4URBO DI DM4URBO DM4URBO DN [3H]GR 125,743 DM4URBO TI TT6MSOK DM4URBO TN 5-HT 1D receptor (HTR1D) DM4URBO MA Antagonist DM4URBO RN Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 1999 Jul 30;456(1):63-7. DM4URBO RU https://pubmed.ncbi.nlm.nih.gov/10452531 DM4URMA DI DM4URMA DM4URMA DN R,R-THC DM4URMA TI TTOM3J0 DM4URMA TN Estrogen receptor beta (ESR2) DM4URMA MA Antagonist DM4URMA RN Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. J Med Chem. 1999 Jul 1;42(13):2456-68. DM4URMA RU https://pubmed.ncbi.nlm.nih.gov/10395487 DM4URMA DI DM4URMA DM4URMA DN R,R-THC DM4URMA TI TTZAYWL DM4URMA TN Estrogen receptor (ESR) DM4URMA MA Agonist DM4URMA RN Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology. 1999 Feb;140(2):800-4. DM4URMA RU https://pubmed.ncbi.nlm.nih.gov/9927308 DM4UW65 DI DM4UW65 DM4UW65 DN 7-hydroxy-2-phenylchroman-4-one DM4UW65 TI TTSZLWK DM4UW65 TN Aromatase (CYP19A1) DM4UW65 MA Inhibitor DM4UW65 RN New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80. DM4UW65 RU https://pubmed.ncbi.nlm.nih.gov/18042388 DM4UWKR DI DM4UWKR DM4UWKR DN PMID18800762C11 DM4UWKR TI TTIKWV4 DM4UWKR TN Geranyltranstransferase (FDPS) DM4UWKR MA Inhibitor DM4UWKR RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DM4UWKR RU https://pubmed.ncbi.nlm.nih.gov/18800762 DM4UWYF DI DM4UWYF DM4UWYF DN Ethyl 3-(pyridin-4-yl)-1H-indole-6-carboxylate DM4UWYF TI TTTB4UP DM4UWYF TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM4UWYF MA Inhibitor DM4UWYF RN Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42. DM4UWYF RU https://pubmed.ncbi.nlm.nih.gov/16483773 DM4UXT1 DI DM4UXT1 DM4UXT1 DN Tyramine DM4UXT1 TI TTIU98M DM4UXT1 TN Trace amine-associated receptor-1 (TAAR1) DM4UXT1 MA Agonist DM4UXT1 RN Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One. 2011;6(10):e27073. DM4UXT1 RU https://pubmed.ncbi.nlm.nih.gov/22073124 DM4UZ6V DI DM4UZ6V DM4UZ6V DN EB-47 DM4UZ6V TI TTVDSZ0 DM4UZ6V TN Poly [ADP-ribose] polymerase 1 (PARP1) DM4UZ6V MA Inhibitor DM4UZ6V RN Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. DM4UZ6V RU https://pubmed.ncbi.nlm.nih.gov/15864271 DM4V2ZO DI DM4V2ZO DM4V2ZO DN 2-(Phosphonooxy)Butanoic Acid DM4V2ZO TI TTVNA43 DM4V2ZO TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DM4V2ZO MA Inhibitor DM4V2ZO RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM4V2ZO RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM4V5RU DI DM4V5RU DM4V5RU DN 8-Bromo-4,9-dihydro-3H-beta-carboline DM4V5RU TI TT3WG5C DM4V5RU TN Monoamine oxidase type A (MAO-A) DM4V5RU MA Inhibitor DM4V5RU RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM4V5RU RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM4V5RU DI DM4V5RU DM4V5RU DN 8-Bromo-4,9-dihydro-3H-beta-carboline DM4V5RU TI TTJQOD7 DM4V5RU TN 5-HT 2A receptor (HTR2A) DM4V5RU MA Inhibitor DM4V5RU RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DM4V5RU RU https://pubmed.ncbi.nlm.nih.gov/14643338 DM4V5RU DI DM4V5RU DM4V5RU DN 8-Bromo-4,9-dihydro-3H-beta-carboline DM4V5RU TI TTGP7BY DM4V5RU TN Monoamine oxidase type B (MAO-B) DM4V5RU MA Inhibitor DM4V5RU RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM4V5RU RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM4V63W DI DM4V63W DM4V63W DN 2,7-Bis[3-(butylamino)propionamido]anthraquinone DM4V63W TI TTQY2EJ DM4V63W TN TERT messenger RNA (TERT mRNA) DM4V63W MA Inhibitor DM4V63W RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM4V63W RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM4V6JE DI DM4V6JE DM4V6JE DN 1H-Pyrazole-3-carboxylic acid DM4V6JE TI TTWNV8U DM4V6JE TN Nicotinic acid receptor (HCAR2) DM4V6JE MA Inhibitor DM4V6JE RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DM4V6JE RU https://pubmed.ncbi.nlm.nih.gov/12930155 DM4V7AS DI DM4V7AS DM4V7AS DN N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide DM4V7AS TI TT32JK8 DM4V7AS TN Melatonin receptor type 1B (MTNR1B) DM4V7AS MA Inhibitor DM4V7AS RN Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62. DM4V7AS RU https://pubmed.ncbi.nlm.nih.gov/18372181 DM4V7AS DI DM4V7AS DM4V7AS DN N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamide DM4V7AS TI TT0WAIE DM4V7AS TN Melatonin receptor type 1A (MTNR1A) DM4V7AS MA Inhibitor DM4V7AS RN Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62. DM4V7AS RU https://pubmed.ncbi.nlm.nih.gov/18372181 DM4V9IB DI DM4V9IB DM4V9IB DN 1-(5-(pyridin-2-yl)oxazol-2-yl)dodecan-1-one DM4V9IB TI TTDP1UC DM4V9IB TN Fatty acid amide hydrolase (FAAH) DM4V9IB MA Inhibitor DM4V9IB RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DM4V9IB RU https://pubmed.ncbi.nlm.nih.gov/18053726 DM4VADN DI DM4VADN DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN TI TTHY57M DM4VADN TN Matrix metalloproteinase-13 (MMP-13) DM4VADN MA Inhibitor DM4VADN RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM4VADN RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM4VADN DI DM4VADN DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN TI TTXZ0KQ DM4VADN TN Matrix metalloproteinase-12 (MMP-12) DM4VADN MA Inhibitor DM4VADN RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM4VADN RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM4VADN DI DM4VADN DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN TI TT6X50U DM4VADN TN Matrix metalloproteinase-9 (MMP-9) DM4VADN MA Inhibitor DM4VADN RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM4VADN RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM4VADN DI DM4VADN DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN TI TTLM12X DM4VADN TN Matrix metalloproteinase-2 (MMP-2) DM4VADN MA Inhibitor DM4VADN RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM4VADN RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM4VADN DI DM4VADN DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN TI TTGA1IV DM4VADN TN Matrix metalloproteinase-8 (MMP-8) DM4VADN MA Inhibitor DM4VADN RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM4VADN RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM4VADN DI DM4VADN DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN TI TTYRF5E DM4VADN TN Matrix metalloproteinase-21 (MMP-21) DM4VADN MA Inhibitor DM4VADN RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM4VADN RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM4VADN DI DM4VADN DM4VADN DN N-Hydroxy-2-(4-phenoxy-benzenesulfonyl)benzamide DM4VADN TI TTJ4QE7 DM4VADN TN Matrix metalloproteinase-14 (MMP-14) DM4VADN MA Inhibitor DM4VADN RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM4VADN RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM4VBDW DI DM4VBDW DM4VBDW DN H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac DM4VBDW TI TT27RFC DM4VBDW TN Opioid receptor delta (OPRD1) DM4VBDW MA Inhibitor DM4VBDW RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DM4VBDW RU https://pubmed.ncbi.nlm.nih.gov/16509592 DM4VBDW DI DM4VBDW DM4VBDW DN H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac DM4VBDW TI TTKWM86 DM4VBDW TN Opioid receptor mu (MOP) DM4VBDW MA Inhibitor DM4VBDW RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DM4VBDW RU https://pubmed.ncbi.nlm.nih.gov/16509592 DM4VDMP DI DM4VDMP DM4VDMP DN silahexocyclium DM4VDMP TI TTOXS3C DM4VDMP TN Muscarinic acetylcholine receptor (CHRM) DM4VDMP MA Antagonist DM4VDMP RN Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. DM4VDMP RU https://pubmed.ncbi.nlm.nih.gov/2704370 DM4VDMP DI DM4VDMP DM4VDMP DN silahexocyclium DM4VDMP TI TTQ13Z5 DM4VDMP TN Muscarinic acetylcholine receptor M3 (CHRM3) DM4VDMP MA Antagonist DM4VDMP RN Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. DM4VDMP RU https://pubmed.ncbi.nlm.nih.gov/2704370 DM4VEU2 DI DM4VEU2 DM4VEU2 DN Dmt-Pro-Dmt-Phe-NH2 DM4VEU2 TI TT27RFC DM4VEU2 TN Opioid receptor delta (OPRD1) DM4VEU2 MA Inhibitor DM4VEU2 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM4VEU2 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM4VEU2 DI DM4VEU2 DM4VEU2 DN Dmt-Pro-Dmt-Phe-NH2 DM4VEU2 TI TTQW87Y DM4VEU2 TN Opioid receptor kappa (OPRK1) DM4VEU2 MA Inhibitor DM4VEU2 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM4VEU2 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM4VEU2 DI DM4VEU2 DM4VEU2 DN Dmt-Pro-Dmt-Phe-NH2 DM4VEU2 TI TTKWM86 DM4VEU2 TN Opioid receptor mu (MOP) DM4VEU2 MA Inhibitor DM4VEU2 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM4VEU2 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM4VQN8 DI DM4VQN8 DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one DM4VQN8 TI TTTQGH8 DM4VQN8 TN Histone deacetylase 4 (HDAC4) DM4VQN8 MA Inhibitor DM4VQN8 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM4VQN8 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM4VQN8 DI DM4VQN8 DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one DM4VQN8 TI TT5ZKDI DM4VQN8 TN Histone deacetylase 6 (HDAC6) DM4VQN8 MA Inhibitor DM4VQN8 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM4VQN8 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM4VQN8 DI DM4VQN8 DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one DM4VQN8 TI TT6R7JZ DM4VQN8 TN Histone deacetylase 1 (HDAC1) DM4VQN8 MA Inhibitor DM4VQN8 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM4VQN8 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM4VQN8 DI DM4VQN8 DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one DM4VQN8 TI TTBH0VX DM4VQN8 TN Histone deacetylase (HDAC) DM4VQN8 MA Inhibitor DM4VQN8 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM4VQN8 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM4VQN8 DI DM4VQN8 DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one DM4VQN8 TI TTT6LFV DM4VQN8 TN Histone deacetylase 8 (HDAC8) DM4VQN8 MA Inhibitor DM4VQN8 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM4VQN8 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM4VQN8 DI DM4VQN8 DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one DM4VQN8 TI TTSHTOI DM4VQN8 TN Histone deacetylase 2 (HDAC2) DM4VQN8 MA Inhibitor DM4VQN8 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM4VQN8 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM4VQN8 DI DM4VQN8 DM4VQN8 DN 7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one DM4VQN8 TI TTYHPU6 DM4VQN8 TN Histone deacetylase 10 (HDAC10) DM4VQN8 MA Inhibitor DM4VQN8 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM4VQN8 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM4VQNE DI DM4VQNE DM4VQNE DN [18F]FITM DM4VQNE TI TTVBPDM DM4VQNE TN Metabotropic glutamate receptor 1 (mGluR1) DM4VQNE MA Modulator (allosteric modulator) DM4VQNE RN Radiosynthesis and preliminary evaluation of 4-[18F]fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1. Bioorg Med Chem Lett. 2011 May 15;21(10):2998-3001. DM4VQNE RU https://pubmed.ncbi.nlm.nih.gov/21470858 DM4VT0Q DI DM4VT0Q DM4VT0Q DN 3,5-difluorophenol DM4VT0Q TI TTUNARX DM4VT0Q TN Carbonic anhydrase (CA) DM4VT0Q MA Inhibitor DM4VT0Q RN Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. DM4VT0Q RU https://pubmed.ncbi.nlm.nih.gov/18501600 DM4VTM2 DI DM4VTM2 DM4VTM2 DN 8-Cyclobutylmethoxy-quinolin-2-ylamine DM4VTM2 TI TTX4RTB DM4VTM2 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM4VTM2 MA Inhibitor DM4VTM2 RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM4VTM2 RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM4VYP0 DI DM4VYP0 DM4VYP0 DN CONESSINE DM4VYP0 TI TT9JNIC DM4VYP0 TN Histamine H3 receptor (H3R) DM4VYP0 MA Inhibitor DM4VYP0 RN Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-acti... J Med Chem. 2009 Aug 13;52(15):4640-9. DM4VYP0 RU https://pubmed.ncbi.nlm.nih.gov/19588934 DM4VYP0 DI DM4VYP0 DM4VYP0 DN CONESSINE DM4VYP0 TI TTRTKPV DM4VYP0 TN Trypanosoma Trypanothione reductase (Trypano TPR) DM4VYP0 MA Inhibitor DM4VYP0 RN The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95. DM4VYP0 RU https://pubmed.ncbi.nlm.nih.gov/18558492 DM4VYP0 DI DM4VYP0 DM4VYP0 DN CONESSINE DM4VYP0 TI TT2NUT5 DM4VYP0 TN Adrenergic receptor alpha-2C (ADRA2C) DM4VYP0 MA Inhibitor DM4VYP0 RN The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11;51(17):5423-30. DM4VYP0 RU https://pubmed.ncbi.nlm.nih.gov/18683917 DM4VZCW DI DM4VZCW DM4VZCW DN Polyinosinic:polycytidylic acid DM4VZCW TI TT1CN09 DM4VZCW TN HUMAN toll-like receptor 3 (TLR3) DM4VZCW MA Agonist DM4VZCW RN Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development. J Immunol Res. 2019 Apr 7;2019:6491738. doi: 10.1155/2019/6491738. DM4VZCW RU https://pubmed.ncbi.nlm.nih.gov/31089478 DM4VZPU DI DM4VZPU DM4VZPU DN ISIS 2177 DM4VZPU TI TTSJ6Q4 DM4VZPU TN LOX-5 messenger RNA (ALOX5 mRNA) DM4VZPU RN US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism. DM4VZPU RU http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true DM4W1E8 DI DM4W1E8 DM4W1E8 DN Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride DM4W1E8 TI TT3ROYC DM4W1E8 TN Serotonin transporter (SERT) DM4W1E8 MA Inhibitor DM4W1E8 RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM4W1E8 RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM4W1E8 DI DM4W1E8 DM4W1E8 DN Threo-1-aza-5-phenyl[4.4.0]decane hydrochloride DM4W1E8 TI TTVBI8W DM4W1E8 TN Dopamine transporter (DAT) DM4W1E8 MA Inhibitor DM4W1E8 RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM4W1E8 RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM4W5X8 DI DM4W5X8 DM4W5X8 DN Palmitoleic Acid DM4W5X8 TI TT0OFWN DM4W5X8 TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DM4W5X8 MA Inhibitor DM4W5X8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4W5X8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4WEGM DI DM4WEGM DM4WEGM DN 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine DM4WEGM TI TTAWNKZ DM4WEGM TN Norepinephrine transporter (NET) DM4WEGM MA Inhibitor DM4WEGM RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM4WEGM RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM4WEGM DI DM4WEGM DM4WEGM DN 1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine DM4WEGM TI TT3ROYC DM4WEGM TN Serotonin transporter (SERT) DM4WEGM MA Inhibitor DM4WEGM RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM4WEGM RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM4WI0Y DI DM4WI0Y DM4WI0Y DN 4-(3-nitrobenzylthio)-2-aminobutanoic acid DM4WI0Y TI TTFK1JQ DM4WI0Y TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM4WI0Y MA Inhibitor DM4WI0Y RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DM4WI0Y RU https://pubmed.ncbi.nlm.nih.gov/16380257 DM4WJX3 DI DM4WJX3 DM4WJX3 DN 3-methoxy-N-(4-methylthiazol-2-yl)benzamide DM4WJX3 TI TTHS256 DM4WJX3 TN Metabotropic glutamate receptor 5 (mGluR5) DM4WJX3 MA Inhibitor DM4WJX3 RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DM4WJX3 RU https://pubmed.ncbi.nlm.nih.gov/16678408 DM4WJX3 DI DM4WJX3 DM4WJX3 DN 3-methoxy-N-(4-methylthiazol-2-yl)benzamide DM4WJX3 TI TTSJ6Q4 DM4WJX3 TN LOX-5 messenger RNA (ALOX5 mRNA) DM4WJX3 MA Inhibitor DM4WJX3 RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DM4WJX3 RU https://pubmed.ncbi.nlm.nih.gov/17461565 DM4WMGK DI DM4WMGK DM4WMGK DN 7-methoxy-2-p-tolyl-4H-chromene-4-thione DM4WMGK TI TTGP7BY DM4WMGK TN Monoamine oxidase type B (MAO-B) DM4WMGK MA Inhibitor DM4WMGK RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM4WMGK RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM4WOT6 DI DM4WOT6 DM4WOT6 DN 2-(3-phenylthio)phenyl)-1-aminoethane DM4WOT6 TI TTJS8PY DM4WOT6 TN 5-HT 6 receptor (HTR6) DM4WOT6 MA Inhibitor DM4WOT6 RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DM4WOT6 RU https://pubmed.ncbi.nlm.nih.gov/16913710 DM4WQHU DI DM4WQHU DM4WQHU DN Statin DM4WQHU TI TTPADOQ DM4WQHU TN HMG-CoA reductase (HMGCR) DM4WQHU MA Modulator DM4WQHU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639). DM4WQHU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639 DM4WS3R DI DM4WS3R DM4WS3R DN GSK-9772 DM4WS3R TI TTECBXN DM4WS3R TN Oxysterols receptor LXR-alpha (NR1H3) DM4WS3R MA Inhibitor DM4WS3R RN Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65. DM4WS3R RU https://pubmed.ncbi.nlm.nih.gov/18800767 DM4WS3R DI DM4WS3R DM4WS3R DN GSK-9772 DM4WS3R TI TTXA6PH DM4WS3R TN Oxysterols receptor LXR-beta (NR1H2) DM4WS3R MA Inhibitor DM4WS3R RN Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65. DM4WS3R RU https://pubmed.ncbi.nlm.nih.gov/18800767 DM4WTCE DI DM4WTCE DM4WTCE DN TP-801 DM4WTCE TI TTNDSF4 DM4WTCE TN Proto-oncogene c-Met (MET) DM4WTCE MA Inhibitor DM4WTCE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM4WTCE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM4WVMU DI DM4WVMU DM4WVMU DN AFP-07 DM4WVMU TI TTOFYT1 DM4WVMU TN Prostacyclin receptor (PTGIR) DM4WVMU MA Agonist DM4WVMU RN 7,7-Difluoroprostacyclin derivative, AFP-07, a highly selective and potent agonist for the prostacyclin receptor. Prostaglandins. 1997 Feb;53(2):83-90. DM4WVMU RU https://pubmed.ncbi.nlm.nih.gov/9112287 DM4WVSB DI DM4WVSB DM4WVSB DN 5-bromo-2-(4-chlorophenylsulfonamido)benzoic acid DM4WVSB TI TTZL0OI DM4WVSB TN Methionine aminopeptidase 2 (METAP2) DM4WVSB MA Inhibitor DM4WVSB RN Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. DM4WVSB RU https://pubmed.ncbi.nlm.nih.gov/16632353 DM4WXD2 DI DM4WXD2 DM4WXD2 DN [2-Phenylacetophenone]thiosemicarbazone DM4WXD2 TI TT36ETB DM4WXD2 TN Cathepsin L (CTSL) DM4WXD2 MA Inhibitor DM4WXD2 RN Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. DM4WXD2 RU https://pubmed.ncbi.nlm.nih.gov/20933415 DM4X0SJ DI DM4X0SJ DM4X0SJ DN 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline DM4X0SJ TI TT3WG5C DM4X0SJ TN Monoamine oxidase type A (MAO-A) DM4X0SJ MA Inhibitor DM4X0SJ RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DM4X0SJ RU https://pubmed.ncbi.nlm.nih.gov/19064321 DM4X0SJ DI DM4X0SJ DM4X0SJ DN 2-(4,5-dihydro-1H-imidazol-2-yl)quinoline DM4X0SJ TI TTGP7BY DM4X0SJ TN Monoamine oxidase type B (MAO-B) DM4X0SJ MA Inhibitor DM4X0SJ RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DM4X0SJ RU https://pubmed.ncbi.nlm.nih.gov/19064321 DM4X0WY DI DM4X0WY DM4X0WY DN N-Omega-Propyl-L-Arginine DM4X0WY TI TTF10I9 DM4X0WY TN Nitric-oxide synthase inducible (NOS2) DM4X0WY MA Inhibitor DM4X0WY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4X0WY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4X0WY DI DM4X0WY DM4X0WY DN N-Omega-Propyl-L-Arginine DM4X0WY TI TTZUFI5 DM4X0WY TN Nitric-oxide synthase brain (NOS1) DM4X0WY MA Inhibitor DM4X0WY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4X0WY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4X18V DI DM4X18V DM4X18V DN 9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine DM4X18V TI TTK25J1 DM4X18V TN Adenosine A1 receptor (ADORA1) DM4X18V MA Inhibitor DM4X18V RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DM4X18V RU https://pubmed.ncbi.nlm.nih.gov/18411049 DM4X18V DI DM4X18V DM4X18V DN 9-(3-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine DM4X18V TI TTM2AOE DM4X18V TN Adenosine A2a receptor (ADORA2A) DM4X18V MA Inhibitor DM4X18V RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DM4X18V RU https://pubmed.ncbi.nlm.nih.gov/18411049 DM4X2GH DI DM4X2GH DM4X2GH DN SKL-PD DM4X2GH TI TTGP7BY DM4X2GH TN Monoamine oxidase type B (MAO-B) DM4X2GH MA Inhibitor DM4X2GH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DM4X2GH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DM4X6I9 DI DM4X6I9 DM4X6I9 DN 2-(Benzylamino)-6-(3-acetamidophenyl)pyrazine DM4X6I9 TI TT0EOB8 DM4X6I9 TN B-Raf messenger RNA (BRAF mRNA) DM4X6I9 MA Inhibitor DM4X6I9 RN Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem. 2006 Jan 12;49(1):407-16. DM4X6I9 RU https://pubmed.ncbi.nlm.nih.gov/16392826 DM4X9GW DI DM4X9GW DM4X9GW DN (Z)-5-octadecen-7,9-diynoic acid DM4X9GW TI TTPADOQ DM4X9GW TN HMG-CoA reductase (HMGCR) DM4X9GW MA Inhibitor DM4X9GW RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DM4X9GW RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DM4XEHR DI DM4XEHR DM4XEHR DN (R)-2-Amino-7-phosphono-heptanoic acid DM4XEHR TI TTN9D8E DM4XEHR TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM4XEHR MA Inhibitor DM4XEHR RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DM4XEHR RU https://pubmed.ncbi.nlm.nih.gov/15801853 DM4XEHR DI DM4XEHR DM4XEHR DN (R)-2-Amino-7-phosphono-heptanoic acid DM4XEHR TI TTKJEMQ DM4XEHR TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM4XEHR MA Inhibitor DM4XEHR RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DM4XEHR RU https://pubmed.ncbi.nlm.nih.gov/15801853 DM4XEHR DI DM4XEHR DM4XEHR DN (R)-2-Amino-7-phosphono-heptanoic acid DM4XEHR TI TTLD29N DM4XEHR TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM4XEHR MA Inhibitor DM4XEHR RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DM4XEHR RU https://pubmed.ncbi.nlm.nih.gov/15801853 DM4XFJI DI DM4XFJI DM4XFJI DN 2-(4-cyano-2-cyclohexylphenoxy)acetic acid DM4XFJI TI TTQDMX5 DM4XFJI TN Prostaglandin D2 receptor 2 (PTGDR2) DM4XFJI MA Inhibitor DM4XFJI RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DM4XFJI RU https://pubmed.ncbi.nlm.nih.gov/17531480 DM4XFOH DI DM4XFOH DM4XFOH DN [N-Me,des-Sar]Gal-B2 DM4XFOH TI TTX3HNZ DM4XFOH TN Galanin receptor type 1 (GAL1-R) DM4XFOH MA Inhibitor DM4XFOH RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM4XFOH RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM4XFOH DI DM4XFOH DM4XFOH DN [N-Me,des-Sar]Gal-B2 DM4XFOH TI TTBPW3J DM4XFOH TN Galanin receptor type 2 (GAL2-R) DM4XFOH MA Inhibitor DM4XFOH RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM4XFOH RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM4XGFW DI DM4XGFW DM4XGFW DN 5-(piperidin-4-yl)isothiazol-3-ol DM4XGFW TI TTNJYV2 DM4XGFW TN Gamma-aminobutyric acid receptor (GAR) DM4XGFW MA Inhibitor DM4XGFW RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DM4XGFW RU https://pubmed.ncbi.nlm.nih.gov/16480274 DM4XGFW DI DM4XGFW DM4XGFW DN 5-(piperidin-4-yl)isothiazol-3-ol DM4XGFW TI TT06RH5 DM4XGFW TN GABA(A) receptor gamma-2 (GABRG2) DM4XGFW MA Inhibitor DM4XGFW RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DM4XGFW RU https://pubmed.ncbi.nlm.nih.gov/16480274 DM4XGFW DI DM4XGFW DM4XGFW DN 5-(piperidin-4-yl)isothiazol-3-ol DM4XGFW TI TT1MPAY DM4XGFW TN GABA(A) receptor alpha-1 (GABRA1) DM4XGFW MA Inhibitor DM4XGFW RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DM4XGFW RU https://pubmed.ncbi.nlm.nih.gov/16480274 DM4XILF DI DM4XILF DM4XILF DN 1-(1-Biphenyl-4-yl-butyl)-1H-imidazole DM4XILF TI TTRA5BZ DM4XILF TN Steroid 17-alpha-monooxygenase (S17AH) DM4XILF MA Inhibitor DM4XILF RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DM4XILF RU https://pubmed.ncbi.nlm.nih.gov/18674917 DM4XKYN DI DM4XKYN DM4XKYN DN 2-morpholino-7-(2-phenylethynyl)-4H-chromen-4-one DM4XKYN TI TT06AWU DM4XKYN TN Phosphodiesterase 3A (PDE3A) DM4XKYN MA Inhibitor DM4XKYN RN Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73. DM4XKYN RU https://pubmed.ncbi.nlm.nih.gov/16290931 DM4XL8Z DI DM4XL8Z DM4XL8Z DN 2-(2,4-dichlorophenoxy)-5-(2-methylbutyl)phenol DM4XL8Z TI TTNX2CS DM4XL8Z TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM4XL8Z MA Inhibitor DM4XL8Z RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DM4XL8Z RU https://pubmed.ncbi.nlm.nih.gov/19217192 DM4XMZW DI DM4XMZW DM4XMZW DN BH4 DM4XMZW TI TTGSVH2 DM4XMZW TN Phenylalanine hydroxylase (PAH) DM4XMZW MA Modulator DM4XMZW RN Company report of BioMarin DM4XMZW RU http://www.biomarin.com/products/kuvan (Kuvan is the first and only FDA-approved medication for PKU to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4-) responsive PKU.) DM4XVLB DI DM4XVLB DM4XVLB DN RGS4 inhibitor 13 DM4XVLB TI TTGTKX9 DM4XVLB TN Regulator of G-protein signaling 4 (RGS4) DM4XVLB MA Inhibitor DM4XVLB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2811). DM4XVLB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811 DM4XVLB DI DM4XVLB DM4XVLB DN RGS4 inhibitor 13 DM4XVLB TI TTWME23 DM4XVLB TN Regulator of G-protein signaling 8 (RGS8) DM4XVLB MA Inhibitor DM4XVLB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2813). DM4XVLB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813 DM4XWAU DI DM4XWAU DM4XWAU DN S-(4-Methoxybenzyl)isothiourea hydrochloride DM4XWAU TI TTZJYKH DM4XWAU TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM4XWAU MA Inhibitor DM4XWAU RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DM4XWAU RU https://pubmed.ncbi.nlm.nih.gov/20688518 DM4XWME DI DM4XWME DM4XWME DN 3-(2-cinnamylphenyl)acrylic acid DM4XWME TI TT1ZAVI DM4XWME TN Prostaglandin E2 receptor EP2 (PTGER2) DM4XWME MA Inhibitor DM4XWME RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM4XWME RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM4XWME DI DM4XWME DM4XWME DN 3-(2-cinnamylphenyl)acrylic acid DM4XWME TI TTPNGDE DM4XWME TN Prostaglandin E2 receptor EP3 (PTGER3) DM4XWME MA Inhibitor DM4XWME RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM4XWME RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM4XWME DI DM4XWME DM4XWME DN 3-(2-cinnamylphenyl)acrylic acid DM4XWME TI TT79WV3 DM4XWME TN Prostaglandin E2 receptor EP4 (PTGER4) DM4XWME MA Inhibitor DM4XWME RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM4XWME RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM4Y8EQ DI DM4Y8EQ DM4Y8EQ DN ISIS 122975 DM4Y8EQ TI TTJZNIG DM4Y8EQ TN MEKK3 messenger RNA (MAP3K3 mRNA) DM4Y8EQ RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DM4Y8EQ RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DM4Y9U3 DI DM4Y9U3 DM4Y9U3 DN 9-(2-aminoethyl)-9,10-dihydroanthracene DM4Y9U3 TI TTTIBOJ DM4Y9U3 TN Histamine H1 receptor (H1R) DM4Y9U3 MA Inhibitor DM4Y9U3 RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DM4Y9U3 RU https://pubmed.ncbi.nlm.nih.gov/19700330 DM4Y9U3 DI DM4Y9U3 DM4Y9U3 DN 9-(2-aminoethyl)-9,10-dihydroanthracene DM4Y9U3 TI TTJQOD7 DM4Y9U3 TN 5-HT 2A receptor (HTR2A) DM4Y9U3 MA Inhibitor DM4Y9U3 RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DM4Y9U3 RU https://pubmed.ncbi.nlm.nih.gov/19700330 DM4YAD6 DI DM4YAD6 DM4YAD6 DN 8-Bromo-9-ethyl-9H-adenine DM4YAD6 TI TTNE7KG DM4YAD6 TN Adenosine A2b receptor (ADORA2B) DM4YAD6 MA Inhibitor DM4YAD6 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM4YAD6 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM4YAD6 DI DM4YAD6 DM4YAD6 DN 8-Bromo-9-ethyl-9H-adenine DM4YAD6 TI TTM2AOE DM4YAD6 TN Adenosine A2a receptor (ADORA2A) DM4YAD6 MA Inhibitor DM4YAD6 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM4YAD6 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM4YAD6 DI DM4YAD6 DM4YAD6 DN 8-Bromo-9-ethyl-9H-adenine DM4YAD6 TI TTK25J1 DM4YAD6 TN Adenosine A1 receptor (ADORA1) DM4YAD6 MA Inhibitor DM4YAD6 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM4YAD6 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM4YFU5 DI DM4YFU5 DM4YFU5 DN 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine DM4YFU5 TI TT9P6OW DM4YFU5 TN G2/mitotic-specific cyclin B1 (CCNB1) DM4YFU5 MA Inhibitor DM4YFU5 RN Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86. DM4YFU5 RU https://pubmed.ncbi.nlm.nih.gov/19879023 DM4YFU5 DI DM4YFU5 DM4YFU5 DN 4-(Quinolin-3-yl)-N-p-tolylpyrimidin-2-amine DM4YFU5 TI TTH6V3D DM4YFU5 TN Cyclin-dependent kinase 1 (CDK1) DM4YFU5 MA Inhibitor DM4YFU5 RN Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86. DM4YFU5 RU https://pubmed.ncbi.nlm.nih.gov/19879023 DM4YJQG DI DM4YJQG DM4YJQG DN ISIS 10639 DM4YJQG TI TTOM5AU DM4YJQG TN c-Fos messenger RNA (c-Fos mRNA) DM4YJQG RN US patent application no. 6,312,900, Antisense oligonucleotide compositions and methods for the modulation of activating protein 1. DM4YJQG RU http://www.patentbuddy.com/Patent/6312900?ft=true&sr=true DM4YL5Q DI DM4YL5Q DM4YL5Q DN 3-ethoxycarbonylpyroglutamate DM4YL5Q TI TTHI19T DM4YL5Q TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM4YL5Q MA Inhibitor DM4YL5Q RN Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7. DM4YL5Q RU https://pubmed.ncbi.nlm.nih.gov/19467869 DM4YP3Q DI DM4YP3Q DM4YP3Q DN 6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol DM4YP3Q TI TTZAYWL DM4YP3Q TN Estrogen receptor (ESR) DM4YP3Q MA Inhibitor DM4YP3Q RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM4YP3Q RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM4YP3Q DI DM4YP3Q DM4YP3Q DN 6-(3-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol DM4YP3Q TI TTOM3J0 DM4YP3Q TN Estrogen receptor beta (ESR2) DM4YP3Q MA Inhibitor DM4YP3Q RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM4YP3Q RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM4YQR2 DI DM4YQR2 DM4YQR2 DN xestospongin C DM4YQR2 TI TT5HWAT DM4YQR2 TN IP3 receptor isoform 1 (ITPR1) DM4YQR2 MA Antagonist DM4YQR2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743). DM4YQR2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743 DM4YQV0 DI DM4YQV0 DM4YQV0 DN MK-771 DM4YQV0 TI TT4J8MF DM4YQV0 TN Thyrotropin-releasing hormone receptor (TRHR) DM4YQV0 MA Modulator DM4YQV0 RN TRH analog MK-771 reverses neurochemical and learning deficits in medial septal-lesioned rats. Peptides. 1989 Jan-Feb;10(1):121-4. DM4YQV0 RU https://www.ncbi.nlm.nih.gov/pubmed/2501767 DM4YRAH DI DM4YRAH DM4YRAH DN Mycophenolic hydroxamic acid DM4YRAH TI TTZFTY4 DM4YRAH TN Amidophosphoribosyltransferase (PPAT) DM4YRAH MA Inhibitor DM4YRAH RN Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycoph... Bioorg Med Chem. 2010 Nov 15;18(22):8106-11. DM4YRAH RU https://pubmed.ncbi.nlm.nih.gov/20934342 DM4YRAH DI DM4YRAH DM4YRAH DN Mycophenolic hydroxamic acid DM4YRAH TI TTTB4UP DM4YRAH TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM4YRAH MA Inhibitor DM4YRAH RN Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase and differentiation induction of K562 cells among the mycoph... Bioorg Med Chem. 2010 Nov 15;18(22):8106-11. DM4YRAH RU https://pubmed.ncbi.nlm.nih.gov/20934342 DM4YTFP DI DM4YTFP DM4YTFP DN Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 DM4YTFP TI TTKWM86 DM4YTFP TN Opioid receptor mu (MOP) DM4YTFP MA Inhibitor DM4YTFP RN Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5. DM4YTFP RU https://pubmed.ncbi.nlm.nih.gov/8289187 DM4YTFP DI DM4YTFP DM4YTFP DN Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 DM4YTFP TI TT27RFC DM4YTFP TN Opioid receptor delta (OPRD1) DM4YTFP MA Inhibitor DM4YTFP RN Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5. DM4YTFP RU https://pubmed.ncbi.nlm.nih.gov/8289187 DM4YWEL DI DM4YWEL DM4YWEL DN 1-(3,4-dichlorophenyl)-2-(phenylsulfonyl)ethanone DM4YWEL TI TTN7BL9 DM4YWEL TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM4YWEL MA Inhibitor DM4YWEL RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DM4YWEL RU https://pubmed.ncbi.nlm.nih.gov/17490884 DM4YWQN DI DM4YWQN DM4YWQN DN 4-(2-thienyl)benzene-1,2-diamine DM4YWQN TI TTQ6VDM DM4YWQN TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM4YWQN MA Inhibitor DM4YWQN RN Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1168-72. DM4YWQN RU https://pubmed.ncbi.nlm.nih.gov/19138845 DM4Z15M DI DM4Z15M DM4Z15M DN 8-Octyl-benzolactam-V9 DM4Z15M TI TTONI0R DM4Z15M TN PKC-eta messenger RNA (PRKCH mRNA) DM4Z15M MA Inhibitor DM4Z15M RN Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8. DM4Z15M RU https://pubmed.ncbi.nlm.nih.gov/16640328 DM4Z15M DI DM4Z15M DM4Z15M DN 8-Octyl-benzolactam-V9 DM4Z15M TI TT1MS7X DM4Z15M TN PKC-theta messenger RNA (PRKCQ mRNA) DM4Z15M MA Inhibitor DM4Z15M RN Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8. DM4Z15M RU https://pubmed.ncbi.nlm.nih.gov/16640328 DM4Z15M DI DM4Z15M DM4Z15M DN 8-Octyl-benzolactam-V9 DM4Z15M TI TTRFOXJ DM4Z15M TN Protein kinase C gamma (PRKCG) DM4Z15M MA Inhibitor DM4Z15M RN Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8. DM4Z15M RU https://pubmed.ncbi.nlm.nih.gov/16640328 DM4Z15M DI DM4Z15M DM4Z15M DN 8-Octyl-benzolactam-V9 DM4Z15M TI TT7A1BO DM4Z15M TN PKC-delta messenger RNA (PRKCD mRNA) DM4Z15M MA Inhibitor DM4Z15M RN Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8. DM4Z15M RU https://pubmed.ncbi.nlm.nih.gov/16640328 DM4Z15M DI DM4Z15M DM4Z15M DN 8-Octyl-benzolactam-V9 DM4Z15M TI TT57MT2 DM4Z15M TN PKC-epsilon messenger RNA (PRKCE mRNA) DM4Z15M MA Inhibitor DM4Z15M RN Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8. DM4Z15M RU https://pubmed.ncbi.nlm.nih.gov/16640328 DM4Z56O DI DM4Z56O DM4Z56O DN 2-nitro-N-(quinolin-8-yl)benzenesulfonamide DM4Z56O TI TTSXVID DM4Z56O TN Nuclear factor NF-kappa-B (NFKB) DM4Z56O MA Inhibitor DM4Z56O RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DM4Z56O RU https://pubmed.ncbi.nlm.nih.gov/18024113 DM4Z7TU DI DM4Z7TU DM4Z7TU DN 4-Sulfamoyloxy-benzoic acid nonyl ester DM4Z7TU TI TTHM0R1 DM4Z7TU TN Steryl-sulfatase (STS) DM4Z7TU MA Inhibitor DM4Z7TU RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DM4Z7TU RU https://pubmed.ncbi.nlm.nih.gov/14741252 DM4ZANH DI DM4ZANH DM4ZANH DN [11C]DTBZ DM4ZANH TI TTNZRI3 DM4ZANH TN Synaptic vesicle amine transporter (SLC18A2) DM4ZANH MA Inhibitor DM4ZANH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1012). DM4ZANH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1012 DM4ZJR5 DI DM4ZJR5 DM4ZJR5 DN Tyr-Pro-D-Phe-D-Pro-NH2 DM4ZJR5 TI TT27RFC DM4ZJR5 TN Opioid receptor delta (OPRD1) DM4ZJR5 MA Inhibitor DM4ZJR5 RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DM4ZJR5 RU https://pubmed.ncbi.nlm.nih.gov/8384662 DM4ZJR5 DI DM4ZJR5 DM4ZJR5 DN Tyr-Pro-D-Phe-D-Pro-NH2 DM4ZJR5 TI TTKWM86 DM4ZJR5 TN Opioid receptor mu (MOP) DM4ZJR5 MA Inhibitor DM4ZJR5 RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DM4ZJR5 RU https://pubmed.ncbi.nlm.nih.gov/8384662 DM4ZLUH DI DM4ZLUH DM4ZLUH DN LUPEOL DM4ZLUH TI TT0IHXV DM4ZLUH TN DNA topoisomerase II (TOP2) DM4ZLUH MA Inhibitor DM4ZLUH RN Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity. J Nat Prod. 2001 Dec;64(12):1545-7. DM4ZLUH RU https://pubmed.ncbi.nlm.nih.gov/11754608 DM4ZMG6 DI DM4ZMG6 DM4ZMG6 DN N-n-hexyl-7-methoxytacrine hydrochloride DM4ZMG6 TI TT1RS9F DM4ZMG6 TN Acetylcholinesterase (AChE) DM4ZMG6 MA Inhibitor DM4ZMG6 RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DM4ZMG6 RU https://pubmed.ncbi.nlm.nih.gov/20817518 DM4ZMG6 DI DM4ZMG6 DM4ZMG6 DN N-n-hexyl-7-methoxytacrine hydrochloride DM4ZMG6 TI TTEB0GD DM4ZMG6 TN Cholinesterase (BCHE) DM4ZMG6 MA Inhibitor DM4ZMG6 RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DM4ZMG6 RU https://pubmed.ncbi.nlm.nih.gov/20817518 DM4ZNOU DI DM4ZNOU DM4ZNOU DN ML 10375 DM4ZNOU TI TT07C3Y DM4ZNOU TN 5-HT 4 receptor (HTR4) DM4ZNOU MA Antagonist DM4ZNOU RN Exploration of the ligand binding site of the human 5-HT(4) receptor by site-directed mutagenesis and molecular modeling. Br J Pharmacol. 2000 Jun;130(3):527-38. DM4ZNOU RU https://pubmed.ncbi.nlm.nih.gov/10821780 DM4ZTF1 DI DM4ZTF1 DM4ZTF1 DN N-(3-(2,5-dimethoxyphenyl)propyl)acetamide DM4ZTF1 TI TT32JK8 DM4ZTF1 TN Melatonin receptor type 1B (MTNR1B) DM4ZTF1 MA Inhibitor DM4ZTF1 RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DM4ZTF1 RU https://pubmed.ncbi.nlm.nih.gov/20227878 DM4ZTF1 DI DM4ZTF1 DM4ZTF1 DN N-(3-(2,5-dimethoxyphenyl)propyl)acetamide DM4ZTF1 TI TT0WAIE DM4ZTF1 TN Melatonin receptor type 1A (MTNR1A) DM4ZTF1 MA Inhibitor DM4ZTF1 RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DM4ZTF1 RU https://pubmed.ncbi.nlm.nih.gov/20227878 DM4ZWOD DI DM4ZWOD DM4ZWOD DN C[RGDf-(R)-N-Me-alpha-TfmF] DM4ZWOD TI TTJA1ZO DM4ZWOD TN ITGB3 messenger RNA (ITGB3 mRNA) DM4ZWOD MA Inhibitor DM4ZWOD RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DM4ZWOD RU https://pubmed.ncbi.nlm.nih.gov/16509596 DM4ZWOD DI DM4ZWOD DM4ZWOD DN C[RGDf-(R)-N-Me-alpha-TfmF] DM4ZWOD TI TTT1R2L DM4ZWOD TN Integrin alpha-V (ITGAV) DM4ZWOD MA Inhibitor DM4ZWOD RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DM4ZWOD RU https://pubmed.ncbi.nlm.nih.gov/16509596 DM4ZY79 DI DM4ZY79 DM4ZY79 DN [Pterin-6-Yl Methanyl]-Phosphonophosphate DM4ZY79 TI TT4ILYC DM4ZY79 TN Bacterial Dihydropteroate synthetase (Bact folP) DM4ZY79 MA Inhibitor DM4ZY79 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4ZY79 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4ZY79 DI DM4ZY79 DM4ZY79 DN [Pterin-6-Yl Methanyl]-Phosphonophosphate DM4ZY79 TI TT38ECI DM4ZY79 TN Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) DM4ZY79 MA Inhibitor DM4ZY79 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM4ZY79 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM4ZYKV DI DM4ZYKV DM4ZYKV DN SERMs DM4ZYKV TI TTZAYWL DM4ZYKV TN Estrogen receptor (ESR) DM4ZYKV MA Modulator DM4ZYKV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DM4ZYKV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DM4ZYRP DI DM4ZYRP DM4ZYRP DN Isosorbide-2-(cyclohexylcarbamate)-5-mononitrate DM4ZYRP TI TTEB0GD DM4ZYRP TN Cholinesterase (BCHE) DM4ZYRP MA Inhibitor DM4ZYRP RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DM4ZYRP RU https://pubmed.ncbi.nlm.nih.gov/18817366 DM5073T DI DM5073T DM5073T DN 3-AMINO-AZACYCLOTRIDECAN-2-ONE DM5073T TI TTGA1IV DM5073T TN Matrix metalloproteinase-8 (MMP-8) DM5073T MA Inhibitor DM5073T RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5073T RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM508BS DI DM508BS DM508BS DN ISIS 109351 DM508BS TI TT1MS7X DM508BS TN PKC-theta messenger RNA (PRKCQ mRNA) DM508BS RN US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression. DM508BS RU http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true DM50BTA DI DM50BTA DM50BTA DN Acetic acid 2-heptylselanyl-phenyl ester DM50BTA TI TT8NGED DM50BTA TN Prostaglandin G/H synthase 1 (COX-1) DM50BTA MA Inhibitor DM50BTA RN Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18. DM50BTA RU https://pubmed.ncbi.nlm.nih.gov/9822550 DM50E6R DI DM50E6R DM50E6R DN PMID15686906C17 DM50E6R TI TTPADOQ DM50E6R TN HMG-CoA reductase (HMGCR) DM50E6R MA Inhibitor DM50E6R RN Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparativemolecular similarity indices analysis (CoMSIA). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1027-32. DM50E6R RU https://pubmed.ncbi.nlm.nih.gov/15686906 DM50FW1 DI DM50FW1 DM50FW1 DN 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol DM50FW1 TI TTZAYWL DM50FW1 TN Estrogen receptor (ESR) DM50FW1 MA Inhibitor DM50FW1 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM50FW1 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM50FW1 DI DM50FW1 DM50FW1 DN 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-6-ol DM50FW1 TI TTOM3J0 DM50FW1 TN Estrogen receptor beta (ESR2) DM50FW1 MA Inhibitor DM50FW1 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM50FW1 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM50GS7 DI DM50GS7 DM50GS7 DN 1-Aminomethyl-isochroman-5,6-diol DM50GS7 TI TTEX248 DM50GS7 TN Dopamine D2 receptor (D2R) DM50GS7 MA Inhibitor DM50GS7 RN (1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50. DM50GS7 RU https://pubmed.ncbi.nlm.nih.gov/1977907 DM50GS7 DI DM50GS7 DM50GS7 DN 1-Aminomethyl-isochroman-5,6-diol DM50GS7 TI TTZFYLI DM50GS7 TN Dopamine D1 receptor (D1R) DM50GS7 MA Inhibitor DM50GS7 RN (1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50. DM50GS7 RU https://pubmed.ncbi.nlm.nih.gov/1977907 DM50NKS DI DM50NKS DM50NKS DN N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide DM50NKS TI TTJ4QE7 DM50NKS TN Matrix metalloproteinase-14 (MMP-14) DM50NKS MA Inhibitor DM50NKS RN Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35. DM50NKS RU https://pubmed.ncbi.nlm.nih.gov/20180536 DM50NKS DI DM50NKS DM50NKS DN N-hydroxy-2-(4-methoxyphenylsulfonamido)acetamide DM50NKS TI TT6AZXG DM50NKS TN TNF alpha converting enzyme (ADAM17) DM50NKS MA Inhibitor DM50NKS RN Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35. DM50NKS RU https://pubmed.ncbi.nlm.nih.gov/20180536 DM50QBR DI DM50QBR DM50QBR DN MRS1062 DM50QBR TI TTK25J1 DM50QBR TN Adenosine A1 receptor (ADORA1) DM50QBR MA Antagonist DM50QBR RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM50QBR RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM50QMB DI DM50QMB DM50QMB DN Benzoin DM50QMB TI TTMF541 DM50QMB TN Liver carboxylesterase (CES1) DM50QMB MA Inhibitor DM50QMB RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM50QMB RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM50RUD DI DM50RUD DM50RUD DN brucine DM50RUD TI TTQ13Z5 DM50RUD TN Muscarinic acetylcholine receptor M3 (CHRM3) DM50RUD MA Modulator (allosteric modulator) DM50RUD RN Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89. DM50RUD RU https://pubmed.ncbi.nlm.nih.gov/9495826 DM50RUD DI DM50RUD DM50RUD DN brucine DM50RUD TI TTOXS3C DM50RUD TN Muscarinic acetylcholine receptor (CHRM) DM50RUD MA Modulator (allosteric modulator) DM50RUD RN Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89. DM50RUD RU https://pubmed.ncbi.nlm.nih.gov/9495826 DM50TCG DI DM50TCG DM50TCG DN Nogalamycin DM50TCG TI TTGTQHC DM50TCG TN DNA topoisomerase I (TOP1) DM50TCG MA Intercalator DM50TCG RN Structure, dynamics and hydration of the nogalamycin-d(ATGCAT)2Complex determined by NMR and molecular dynamics simulations in solution. J Mol Biol. 1999 Jul 16;290(3):699-716. DM50TCG RU https://pubmed.ncbi.nlm.nih.gov/10395824 DM50WFM DI DM50WFM DM50WFM DN [3H]5-oxo-ETE DM50WFM TI TT7WBSV DM50WFM TN Oxoeicosanoid receptor 1 (OXER1) DM50WFM MA Agonist DM50WFM RN Receptors for the 5-oxo class of eicosanoids in neutrophils. J Biol Chem. 1998 Dec 4;273(49):32535-41. DM50WFM RU https://pubmed.ncbi.nlm.nih.gov/9829988 DM50ZQP DI DM50ZQP DM50ZQP DN 2,5-dimethoxy-4-bromophenethylamine DM50ZQP TI TTJQOD7 DM50ZQP TN 5-HT 2A receptor (HTR2A) DM50ZQP MA Inhibitor DM50ZQP RN 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agoni... J Med Chem. 2006 Sep 21;49(19):5794-803. DM50ZQP RU https://pubmed.ncbi.nlm.nih.gov/16970404 DM512OP DI DM512OP DM512OP DN Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG DM512OP TI TTKWM86 DM512OP TN Opioid receptor mu (MOP) DM512OP MA Inhibitor DM512OP RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DM512OP RU https://pubmed.ncbi.nlm.nih.gov/16814543 DM512OP DI DM512OP DM512OP DN Ac-RYYRIK-GGG-K-(NH2)-YAFGYPS-GG DM512OP TI TTNT7K8 DM512OP TN Nociceptin receptor (OPRL1) DM512OP MA Inhibitor DM512OP RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DM512OP RU https://pubmed.ncbi.nlm.nih.gov/16814543 DM513QY DI DM513QY DM513QY DN KATSUMADAIN A DM513QY TI TT50QJ3 DM513QY TN Influenza Neuraminidase (Influ NA) DM513QY MA Inhibitor DM513QY RN Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86. DM513QY RU https://pubmed.ncbi.nlm.nih.gov/20014777 DM514L0 DI DM514L0 DM514L0 DN CGS-314447 DM514L0 TI TT5TKPM DM514L0 TN Neutral endopeptidase (MME) DM514L0 MA Inhibitor DM514L0 RN Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11, Bioorg. Med. Chem. Lett. 7(8):1059-1064 (1997). DM514L0 RU http://www.sciencedirect.com/science/article/pii/S0960894X97001595 DM516B4 DI DM516B4 DM516B4 DN 6,7-Dimethoxy-3-phenyl-quinoline DM516B4 TI TT8FYO9 DM516B4 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM516B4 MA Inhibitor DM516B4 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM516B4 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM516B4 DI DM516B4 DM516B4 DN 6,7-Dimethoxy-3-phenyl-quinoline DM516B4 TI TTI7421 DM516B4 TN Platelet-derived growth factor receptor beta (PDGFRB) DM516B4 MA Inhibitor DM516B4 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM516B4 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM516NE DI DM516NE DM516NE DN 8-Phenyl-octanoic acid hydroxyamide DM516NE TI TTSHTOI DM516NE TN Histone deacetylase 2 (HDAC2) DM516NE MA Inhibitor DM516NE RN A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. DM516NE RU https://pubmed.ncbi.nlm.nih.gov/14552787 DM516NE DI DM516NE DM516NE DN 8-Phenyl-octanoic acid hydroxyamide DM516NE TI TT6R7JZ DM516NE TN Histone deacetylase 1 (HDAC1) DM516NE MA Inhibitor DM516NE RN A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. DM516NE RU https://pubmed.ncbi.nlm.nih.gov/14552787 DM5176Y DI DM5176Y DM5176Y DN [3H]N-methylspiperone DM5176Y TI TTE0A2F DM5176Y TN Dopamine D4 receptor (D4R) DM5176Y MA Antagonist DM5176Y RN Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52. DM5176Y RU https://pubmed.ncbi.nlm.nih.gov/10617689 DM5176Y DI DM5176Y DM5176Y DN [3H]N-methylspiperone DM5176Y TI TTEX248 DM5176Y TN Dopamine D2 receptor (D2R) DM5176Y MA Antagonist DM5176Y RN Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52. DM5176Y RU https://pubmed.ncbi.nlm.nih.gov/10617689 DM5176Y DI DM5176Y DM5176Y DN [3H]N-methylspiperone DM5176Y TI TTJQOD7 DM5176Y TN 5-HT 2A receptor (HTR2A) DM5176Y MA Antagonist DM5176Y RN Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 2000 Nov;58(5):877-86. DM5176Y RU https://pubmed.ncbi.nlm.nih.gov/11040033 DM51B74 DI DM51B74 DM51B74 DN L-779450 DM51B74 TI TTQBR95 DM51B74 TN Stress-activated protein kinase 2a (p38 alpha) DM51B74 MA Inhibitor DM51B74 RN The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. DM51B74 RU https://pubmed.ncbi.nlm.nih.gov/16260133 DM51B74 DI DM51B74 DM51B74 DN L-779450 DM51B74 TI TT73U6C DM51B74 TN Stress-activated protein kinase 2b (p38 beta) DM51B74 MA Inhibitor DM51B74 RN The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. DM51B74 RU https://pubmed.ncbi.nlm.nih.gov/16260133 DM51B74 DI DM51B74 DM51B74 DN L-779450 DM51B74 TI TT860QF DM51B74 TN LCK tyrosine protein kinase (LCK) DM51B74 MA Inhibitor DM51B74 RN The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. DM51B74 RU https://pubmed.ncbi.nlm.nih.gov/16260133 DM51B74 DI DM51B74 DM51B74 DN L-779450 DM51B74 TI TTRSMW9 DM51B74 TN Glycogen synthase kinase-3 beta (GSK-3B) DM51B74 MA Inhibitor DM51B74 RN The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. DM51B74 RU https://pubmed.ncbi.nlm.nih.gov/16260133 DM51B74 DI DM51B74 DM51B74 DN L-779450 DM51B74 TI TT0EOB8 DM51B74 TN B-Raf messenger RNA (BRAF mRNA) DM51B74 MA Inhibitor DM51B74 RN The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81. DM51B74 RU https://pubmed.ncbi.nlm.nih.gov/16260133 DM51DW6 DI DM51DW6 DM51DW6 DN NAADP DM51DW6 TI TTEBMN7 DM51DW6 TN Long transient receptor potential channel 2 (TRPM2) DM51DW6 MA Activator DM51DW6 RN Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB J. 2006 May;20(7):962-4. DM51DW6 RU https://pubmed.ncbi.nlm.nih.gov/16585058 DM51DW6 DI DM51DW6 DM51DW6 DN NAADP DM51DW6 TI TTYXPCO DM51DW6 TN P2Y purinoceptor 11 (P2RY11) DM51DW6 MA Agonist DM51DW6 RN NAADP+ is an agonist of the human P2Y11 purinergic receptor. Cell Calcium. 2008 Apr;43(4):344-55. DM51DW6 RU https://pubmed.ncbi.nlm.nih.gov/17707504 DM51FL9 DI DM51FL9 DM51FL9 DN 8-Bromo-6-methyl-3-(4'-methoxyphenyl)coumarin DM51FL9 TI TTGP7BY DM51FL9 TN Monoamine oxidase type B (MAO-B) DM51FL9 MA Inhibitor DM51FL9 RN New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5157-60. DM51FL9 RU https://pubmed.ncbi.nlm.nih.gov/20659799 DM51MRV DI DM51MRV DM51MRV DN 9-(3-aminopropoxy)-7H-furo[3,2-g]chromen-7-one DM51MRV TI TT3WG5C DM51MRV TN Monoamine oxidase type A (MAO-A) DM51MRV MA Inhibitor DM51MRV RN A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56. DM51MRV RU https://pubmed.ncbi.nlm.nih.gov/16451079 DM51S0B DI DM51S0B DM51S0B DN NP16 DM51S0B TI TTR5YAZ DM51S0B TN Staphylococcus Dehydrosqualene desaturase (Stap-coc crtN) DM51S0B MA Inhibitor DM51S0B RN Dehydrosqualene Desaturase as a Novel Target for Anti-Virulence Therapy against Staphylococcus aureus.MBio. 2017 Sep 5;8(5). pii: e01224-17. DM51S0B RU https://pubmed.ncbi.nlm.nih.gov/28874472 DM51XDA DI DM51XDA DM51XDA DN 4-(6-Methoxynaphthalen-2-yl)isoquinoline DM51XDA TI TTXV4FI DM51XDA TN Albendazole monooxygenase (CYP3A4) DM51XDA MA Inhibitor DM51XDA RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DM51XDA RU https://pubmed.ncbi.nlm.nih.gov/18672861 DM51XDA DI DM51XDA DM51XDA DN 4-(6-Methoxynaphthalen-2-yl)isoquinoline DM51XDA TI TTIQUX7 DM51XDA TN Steroid 11-beta-hydroxylase (CYP11B1) DM51XDA MA Inhibitor DM51XDA RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DM51XDA RU https://pubmed.ncbi.nlm.nih.gov/18672861 DM521S4 DI DM521S4 DM521S4 DN (+)-(1R,1'S)-thaligrisine hydrochloride DM521S4 TI TTZFYLI DM521S4 TN Dopamine D1 receptor (D1R) DM521S4 MA Inhibitor DM521S4 RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DM521S4 RU https://pubmed.ncbi.nlm.nih.gov/1431946 DM521S4 DI DM521S4 DM521S4 DN (+)-(1R,1'S)-thaligrisine hydrochloride DM521S4 TI TTEX248 DM521S4 TN Dopamine D2 receptor (D2R) DM521S4 MA Inhibitor DM521S4 RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DM521S4 RU https://pubmed.ncbi.nlm.nih.gov/1431946 DM526C9 DI DM526C9 DM526C9 DN CX-9051 DM526C9 TI TTVKILB DM526C9 TN Prostaglandin G/H synthase 2 (COX-2) DM526C9 MA Inhibitor DM526C9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376). DM526C9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376 DM5279R DI DM5279R DM5279R DN 4-(3,5-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline DM5279R TI TTI7421 DM5279R TN Platelet-derived growth factor receptor beta (PDGFRB) DM5279R MA Inhibitor DM5279R RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DM5279R RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DM527XP DI DM527XP DM527XP DN D-Gluconhydroximo-1,5-Lactam DM527XP TI TTA0OSE DM527XP TN Lactase-phlorizin hydrolase (LCT) DM527XP MA Inhibitor DM527XP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM527XP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTEX248 DM52CPU TN Dopamine D2 receptor (D2R) DM52CPU MA Inhibitor DM52CPU RN Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/9406603 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTNGILX DM52CPU TN Adrenergic receptor alpha-1A (ADRA1A) DM52CPU MA Inhibitor DM52CPU RN Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/9406603 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTE0A2F DM52CPU TN Dopamine D4 receptor (D4R) DM52CPU MA Inhibitor DM52CPU RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/7108902 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTJQOD7 DM52CPU TN 5-HT 2A receptor (HTR2A) DM52CPU MA Inhibitor DM52CPU RN Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/9406603 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTZFYLI DM52CPU TN Dopamine D1 receptor (D1R) DM52CPU MA Inhibitor DM52CPU RN Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/9406603 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTQ3JTF DM52CPU TN Muscarinic acetylcholine receptor M4 (CHRM4) DM52CPU MA Inhibitor DM52CPU RN Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/1967652 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TT34BHT DM52CPU TN Adrenergic receptor alpha-1D (ADRA1D) DM52CPU MA Inhibitor DM52CPU RN Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/9406603 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTH18TF DM52CPU TN Muscarinic acetylcholine receptor M5 (CHRM5) DM52CPU MA Inhibitor DM52CPU RN Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/1967652 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTS2PH3 DM52CPU TN Dopamine D5 receptor (D5R) DM52CPU MA Inhibitor DM52CPU RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/7108902 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TT4C8EA DM52CPU TN Dopamine D3 receptor (D3R) DM52CPU MA Inhibitor DM52CPU RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/7108902 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTQ13Z5 DM52CPU TN Muscarinic acetylcholine receptor M3 (CHRM3) DM52CPU MA Inhibitor DM52CPU RN Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/1967652 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTBRKXS DM52CPU TN Adrenergic receptor alpha-1B (ADRA1B) DM52CPU MA Inhibitor DM52CPU RN Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. J Med Chem. 1997 Dec 5;40(25):4146-53. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/9406603 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTZ9SOR DM52CPU TN Muscarinic acetylcholine receptor M1 (CHRM1) DM52CPU MA Inhibitor DM52CPU RN Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/1967652 DM52CPU DI DM52CPU DM52CPU DN ISOCLOZAPINE DM52CPU TI TTYEG6Q DM52CPU TN Muscarinic acetylcholine receptor M2 (CHRM2) DM52CPU MA Inhibitor DM52CPU RN Chloro-substituted, sterically hindered 5,11-dicarbo analogues of clozapine as potential chiral antipsychotic agents. J Med Chem. 1990 Feb;33(2):809-14. DM52CPU RU https://pubmed.ncbi.nlm.nih.gov/1967652 DM52H1D DI DM52H1D DM52H1D DN Phenyl 10H-phenothiazine-10-carboxylate DM52H1D TI TTEB0GD DM52H1D TN Cholinesterase (BCHE) DM52H1D MA Inhibitor DM52H1D RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DM52H1D RU https://pubmed.ncbi.nlm.nih.gov/18570368 DM52ITO DI DM52ITO DM52ITO DN NI-57 DM52ITO TI TTT09OB DM52ITO TN Bromodomain-containing protein 1 (BRD1) DM52ITO MA Inhibitor DM52ITO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2724). DM52ITO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2724 DM52ITO DI DM52ITO DM52ITO DN NI-57 DM52ITO TI TTT46BN DM52ITO TN Bromodomain and PHD finger containing 1 (BRPF1) DM52ITO MA Inhibitor DM52ITO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2730). DM52ITO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2730 DM52ITO DI DM52ITO DM52ITO DN NI-57 DM52ITO TI TT1CHFI DM52ITO TN Bromodomain and PHD finger containing 3 (BRPF3) DM52ITO MA Inhibitor DM52ITO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2731). DM52ITO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2731 DM52NMU DI DM52NMU DM52NMU DN 4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine DM52NMU TI TTRA5BZ DM52NMU TN Steroid 17-alpha-monooxygenase (S17AH) DM52NMU MA Inhibitor DM52NMU RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM52NMU RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM52NMU DI DM52NMU DM52NMU DN 4-(4'-Fluoro-biphenyl-4-ylmethyl)pyridine DM52NMU TI TTIQUX7 DM52NMU TN Steroid 11-beta-hydroxylase (CYP11B1) DM52NMU MA Inhibitor DM52NMU RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM52NMU RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM52NOI DI DM52NOI DM52NOI DN NSC-656158 DM52NOI TI TT056SO DM52NOI TN Stress-activated protein kinase JNK3 (JNK3) DM52NOI MA Inhibitor DM52NOI RN Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumo... J Med Chem. 2010 Feb 25;53(4):1616-26. DM52NOI RU https://pubmed.ncbi.nlm.nih.gov/20102207 DM52NOI DI DM52NOI DM52NOI DN NSC-656158 DM52NOI TI TT3WG5C DM52NOI TN Monoamine oxidase type A (MAO-A) DM52NOI MA Inhibitor DM52NOI RN Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumo... J Med Chem. 2010 Feb 25;53(4):1616-26. DM52NOI RU https://pubmed.ncbi.nlm.nih.gov/20102207 DM52SDO DI DM52SDO DM52SDO DN 6-Methoxy-3-pyridin-4-yl-quinoline DM52SDO TI TT8FYO9 DM52SDO TN Platelet-derived growth factor receptor alpha (PDGFRA) DM52SDO MA Inhibitor DM52SDO RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM52SDO RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM52SDO DI DM52SDO DM52SDO DN 6-Methoxy-3-pyridin-4-yl-quinoline DM52SDO TI TTI7421 DM52SDO TN Platelet-derived growth factor receptor beta (PDGFRB) DM52SDO MA Inhibitor DM52SDO RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM52SDO RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM52T90 DI DM52T90 DM52T90 DN Ac-ICV(5MeW)QDWGAHRCT-NH2 DM52T90 TI TTJGY7A DM52T90 TN Complement C3 (CO3) DM52T90 MA Inhibitor DM52T90 RN Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22. DM52T90 RU https://pubmed.ncbi.nlm.nih.gov/16854067 DM52UGS DI DM52UGS DM52UGS DN ISIS 112711 DM52UGS TI TT6804T DM52UGS TN MIF messenger RNA (MIF mRNA) DM52UGS RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DM52UGS RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DM52UOM DI DM52UOM DM52UOM DN 7alpha,27-dihydroxycholesterol DM52UOM TI TTME5YJ DM52UOM TN EBV-induced G-protein coupled receptor 2 (GPR183) DM52UOM MA Agonist DM52UOM RN Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23. DM52UOM RU https://pubmed.ncbi.nlm.nih.gov/21796211 DM52WGH DI DM52WGH DM52WGH DN tannic acid DM52WGH TI TTOJI4S DM52WGH TN Calcium-dependent chloride channel anoctamin (ANO) DM52WGH MA Blocker (channel blocker) DM52WGH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708). DM52WGH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708 DM52Y3Q DI DM52Y3Q DM52Y3Q DN 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol DM52Y3Q TI TTCBFJO DM52Y3Q TN Insulin receptor (INSR) DM52Y3Q MA Inhibitor DM52Y3Q RN ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11. DM52Y3Q RU https://pubmed.ncbi.nlm.nih.gov/17376430 DM52Y3Q DI DM52Y3Q DM52Y3Q DN 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol DM52Y3Q TI TTHRID2 DM52Y3Q TN Insulin-like growth factor I receptor (IGF1R) DM52Y3Q MA Inhibitor DM52Y3Q RN ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11. DM52Y3Q RU https://pubmed.ncbi.nlm.nih.gov/17376430 DM52ZWB DI DM52ZWB DM52ZWB DN ISIS 191731 DM52ZWB TI TT0GV3R DM52ZWB TN DGAT1 messenger RNA (DGAT1 mRNA) DM52ZWB RN US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression. DM52ZWB RU http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true DM53079 DI DM53079 DM53079 DN DVDAVP DM53079 TI TT4TFGN DM53079 TN Vasopressin V1a receptor (V1AR) DM53079 MA Inhibitor DM53079 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM53079 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM53079 DI DM53079 DM53079 DN DVDAVP DM53079 TI TTK8R02 DM53079 TN Vasopressin V2 receptor (V2R) DM53079 MA Inhibitor DM53079 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM53079 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM530OW DI DM530OW DM530OW DN 3'-carbamoylbiphenyl-3-yl 6-phenylhexylcarbamate DM530OW TI TTDP1UC DM530OW TN Fatty acid amide hydrolase (FAAH) DM530OW MA Inhibitor DM530OW RN Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43. DM530OW RU https://pubmed.ncbi.nlm.nih.gov/18983142 DM536IA DI DM536IA DM536IA DN 2-methyl-6-(3-(phenylthio)prop-1-ynyl)pyridine DM536IA TI TTHS256 DM536IA TN Metabotropic glutamate receptor 5 (mGluR5) DM536IA MA Inhibitor DM536IA RN Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91. DM536IA RU https://pubmed.ncbi.nlm.nih.gov/16837196 DM537OH DI DM537OH DM537OH DN Clobenpropit DM537OH TI TTXJ178 DM537OH TN Histamine H4 receptor (H4R) DM537OH MA Agonist DM537OH RN Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: synthesis, pharmacological evaluation, and cross-target QSAR s... Bioorg Med Chem. 2009 Jun 1;17(11):3987-94. DM537OH RU https://pubmed.ncbi.nlm.nih.gov/19414267 DM537OH DI DM537OH DM537OH DN Clobenpropit DM537OH TI TT9JNIC DM537OH TN Histamine H3 receptor (H3R) DM537OH MA Antagonist DM537OH RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM537OH RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM53A1R DI DM53A1R DM53A1R DN 7-Chloro-3-pyridin-4-yl-quinoline DM53A1R TI TT8FYO9 DM53A1R TN Platelet-derived growth factor receptor alpha (PDGFRA) DM53A1R MA Inhibitor DM53A1R RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM53A1R RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM53A1R DI DM53A1R DM53A1R DN 7-Chloro-3-pyridin-4-yl-quinoline DM53A1R TI TTI7421 DM53A1R TN Platelet-derived growth factor receptor beta (PDGFRB) DM53A1R MA Inhibitor DM53A1R RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM53A1R RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM53AS0 DI DM53AS0 DM53AS0 DN N-isoleucylthiazolidine DM53AS0 TI TTDIGC1 DM53AS0 TN Dipeptidyl peptidase 4 (DPP-4) DM53AS0 MA Inhibitor DM53AS0 RN 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioava... J Med Chem. 2006 Jan 12;49(1):373-80. DM53AS0 RU https://pubmed.ncbi.nlm.nih.gov/16392822 DM53CLY DI DM53CLY DM53CLY DN 5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline DM53CLY TI TT8FYO9 DM53CLY TN Platelet-derived growth factor receptor alpha (PDGFRA) DM53CLY MA Inhibitor DM53CLY RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM53CLY RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM53CLY DI DM53CLY DM53CLY DN 5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline DM53CLY TI TTI7421 DM53CLY TN Platelet-derived growth factor receptor beta (PDGFRB) DM53CLY MA Inhibitor DM53CLY RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM53CLY RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM53G1V DI DM53G1V DM53G1V DN 1-adamantan-1-yl-3-(4-hydroxybutyl)urea DM53G1V TI TT7WVHI DM53G1V TN Soluble epoxide hydrolase (EPHX2) DM53G1V MA Inhibitor DM53G1V RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DM53G1V RU https://pubmed.ncbi.nlm.nih.gov/17894481 DM53KRA DI DM53KRA DM53KRA DN ALF-421 DM53KRA TI TTG043C DM53KRA TN Tumor necrosis factor receptor type I (TNF-R1) DM53KRA MA Modulator DM53KRA RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DM53KRA RU https://pubmed.ncbi.nlm.nih.gov/15507622 DM53KZX DI DM53KZX DM53KZX DN DOM DM53KZX TI TTJQOD7 DM53KZX TN 5-HT 2A receptor (HTR2A) DM53KZX MA Inhibitor DM53KZX RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DM53KZX RU https://pubmed.ncbi.nlm.nih.gov/18296055 DM53R94 DI DM53R94 DM53R94 DN AGN-190383 DM53R94 TI TT9V5JH DM53R94 TN Phospholipase A2 (PLA2G1B) DM53R94 MA Modulator DM53R94 RN AGN 190383, a novel phospholipase inhibitor with topical anti-inflammatory activity. Agents Actions. 1991 Sep;34(1-2):70-2. DM53R94 RU https://www.ncbi.nlm.nih.gov/pubmed/1793055 DM53T8Q DI DM53T8Q DM53T8Q DN 2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile DM53T8Q TI TTM2AOE DM53T8Q TN Adenosine A2a receptor (ADORA2A) DM53T8Q MA Inhibitor DM53T8Q RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DM53T8Q RU https://pubmed.ncbi.nlm.nih.gov/18637670 DM53T8Q DI DM53T8Q DM53T8Q DN 2-Amino-4,6-di-thiophen-2-yl-nicotinonitrile DM53T8Q TI TTK25J1 DM53T8Q TN Adenosine A1 receptor (ADORA1) DM53T8Q MA Inhibitor DM53T8Q RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DM53T8Q RU https://pubmed.ncbi.nlm.nih.gov/18637670 DM53VA8 DI DM53VA8 DM53VA8 DN CVT-7124 DM53VA8 TI TTNE7KG DM53VA8 TN Adenosine A2b receptor (ADORA2B) DM53VA8 MA Inhibitor DM53VA8 RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DM53VA8 RU https://pubmed.ncbi.nlm.nih.gov/20537438 DM53ZGY DI DM53ZGY DM53ZGY DN citral DM53ZGY TI TT946IA DM53ZGY TN Transient receptor potential cation channel V3 (TRPV3) DM53ZGY MA Activator DM53ZGY RN Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One. 2008 May 7;3(5):e2082. DM53ZGY RU https://pubmed.ncbi.nlm.nih.gov/18461159 DM53ZGY DI DM53ZGY DM53ZGY DN citral DM53ZGY TI TTBECWA DM53ZGY TN Transient receptor potential cation channel V2 (TRPV2) DM53ZGY MA Blocker (channel blocker) DM53ZGY RN Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One. 2008 May 7;3(5):e2082. DM53ZGY RU https://pubmed.ncbi.nlm.nih.gov/18461159 DM5421R DI DM5421R DM5421R DN PD164333 DM5421R TI TTKRD0G DM5421R TN Endothelin A receptor (EDNRA) DM5421R MA Antagonist DM5421R RN Characterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues. Br J Pharmacol. 1998 Jan;123(2):223-30. DM5421R RU https://pubmed.ncbi.nlm.nih.gov/9489609 DM542I9 DI DM542I9 DM542I9 DN 1,2-dihydro-2-oxoquinazoline-4-carboxyanilide DM542I9 TI TTJFY5U DM542I9 TN Adenosine A3 receptor (ADORA3) DM542I9 MA Inhibitor DM542I9 RN Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606. DM542I9 RU https://pubmed.ncbi.nlm.nih.gov/18047262 DM5497S DI DM5497S DM5497S DN 3-(aminomethyl)-4-(furan-2-yl)butanoic acid DM5497S TI TTFK1JQ DM5497S TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM5497S MA Inhibitor DM5497S RN Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32. DM5497S RU https://pubmed.ncbi.nlm.nih.gov/16099652 DM54A3W DI DM54A3W DM54A3W DN 4-methoxy-9-aminomethyl-9,10-dihydroanthracene DM54A3W TI TTJQOD7 DM54A3W TN 5-HT 2A receptor (HTR2A) DM54A3W MA Inhibitor DM54A3W RN Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71. DM54A3W RU https://pubmed.ncbi.nlm.nih.gov/18774714 DM54AKV DI DM54AKV DM54AKV DN 10S-hydroxylobelane DM54AKV TI TT3ROYC DM54AKV TN Serotonin transporter (SERT) DM54AKV MA Inhibitor DM54AKV RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DM54AKV RU https://pubmed.ncbi.nlm.nih.gov/16905316 DM54AKV DI DM54AKV DM54AKV DN 10S-hydroxylobelane DM54AKV TI TTVBI8W DM54AKV TN Dopamine transporter (DAT) DM54AKV MA Inhibitor DM54AKV RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DM54AKV RU https://pubmed.ncbi.nlm.nih.gov/16905316 DM54CKZ DI DM54CKZ DM54CKZ DN D-211B DM54CKZ TI TT3ROYC DM54CKZ TN Serotonin transporter (SERT) DM54CKZ MA Inhibitor DM54CKZ RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM54CKZ RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM54CKZ DI DM54CKZ DM54CKZ DN D-211B DM54CKZ TI TTAWNKZ DM54CKZ TN Norepinephrine transporter (NET) DM54CKZ MA Inhibitor DM54CKZ RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM54CKZ RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM54CKZ DI DM54CKZ DM54CKZ DN D-211B DM54CKZ TI TTVBI8W DM54CKZ TN Dopamine transporter (DAT) DM54CKZ MA Inhibitor DM54CKZ RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM54CKZ RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM54D1G DI DM54D1G DM54D1G DN Lisinopril DM54D1G TI TTGFNPD DM54D1G TN HUMAN angiotensin-converting enzyme (ACE) DM54D1G MA Inhibitor DM54D1G RN Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219. DM54D1G RU https://pubmed.ncbi.nlm.nih.gov/32233755 DM54FRI DI DM54FRI DM54FRI DN 9-Methylguanine DM54FRI TI TTG9CFY DM54FRI TN Bacterial Dihydroneopterinaldolase (Bact folB) DM54FRI MA Inhibitor DM54FRI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM54FRI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM54M6C DI DM54M6C DM54M6C DN 2-(2-(2,5-dichlorophenylamino)phenyl)acetic acid DM54M6C TI TTCTE1G DM54M6C TN Interleukin-8 (IL8) DM54M6C MA Inhibitor DM54M6C RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DM54M6C RU https://pubmed.ncbi.nlm.nih.gov/19560921 DM54MDH DI DM54MDH DM54MDH DN 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol DM54MDH TI TT9H4P3 DM54MDH TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DM54MDH MA Inhibitor DM54MDH RN Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. DM54MDH RU https://pubmed.ncbi.nlm.nih.gov/17601739 DM54MDH DI DM54MDH DM54MDH DN 3-(4-morpholinothieno[3,2-d]pyrimidin-2-yl)phenol DM54MDH TI TTHBTOP DM54MDH TN PI3-kinase gamma (PIK3CG) DM54MDH MA Inhibitor DM54MDH RN Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. DM54MDH RU https://pubmed.ncbi.nlm.nih.gov/17601739 DM54MOP DI DM54MOP DM54MOP DN 4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine DM54MOP TI TTAMQ62 DM54MOP TN Cyclin A2 (CCNA2) DM54MOP MA Inhibitor DM54MOP RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DM54MOP RU https://pubmed.ncbi.nlm.nih.gov/17064068 DM54MOP DI DM54MOP DM54MOP DN 4-(phenyldiazenyl)-1H-pyrazole-3,5-diamine DM54MOP TI TT1LVF2 DM54MOP TN Cyclin-dependent kinase 9 (CDK9) DM54MOP MA Inhibitor DM54MOP RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DM54MOP RU https://pubmed.ncbi.nlm.nih.gov/17064068 DM54O1Z DI DM54O1Z DM54O1Z DN Oleic acid DM54O1Z TI TTHWMFZ DM54O1Z TN Fatty acid-binding protein 4 (FABP4) DM54O1Z MA Inhibitor DM54O1Z RN Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3675-9. DM54O1Z RU https://pubmed.ncbi.nlm.nih.gov/20471252 DM54O1Z DI DM54O1Z DM54O1Z DN Oleic acid DM54O1Z TI TTIV96N DM54O1Z TN Fatty acid-binding protein 1 (FABP1) DM54O1Z MA Inhibitor DM54O1Z RN Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64. DM54O1Z RU https://pubmed.ncbi.nlm.nih.gov/18533710 DM54OKX DI DM54OKX DM54OKX DN Thenoyltrifluoroacetone DM54OKX TI TTMF541 DM54OKX TN Liver carboxylesterase (CES1) DM54OKX MA Inhibitor DM54OKX RN Zhang JG, Fariss MW: Thenoyltrifluoroacetone, a potent inhibitor of carboxylesterase activity. Biochem Pharmacol. 2002 Feb 15;63(4):751-4. DM54OKX RU https://pubmed.ncbi.nlm.nih.gov/11992644 DM54T8J DI DM54T8J DM54T8J DN DAB-486-IL-2 DM54T8J TI TT9721Y DM54T8J TN Interleukin 2 receptor beta (IL2RB) DM54T8J MA Modulator DM54T8J RN Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur J Immunol. 1992 Mar;22(3):697-702. DM54T8J RU https://www.ncbi.nlm.nih.gov/pubmed/1547815 DM54ZKU DI DM54ZKU DM54ZKU DN 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine DM54ZKU TI TTAWNKZ DM54ZKU TN Norepinephrine transporter (NET) DM54ZKU MA Inhibitor DM54ZKU RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM54ZKU RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM54ZKU DI DM54ZKU DM54ZKU DN 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine DM54ZKU TI TTQ6VDM DM54ZKU TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM54ZKU MA Inhibitor DM54ZKU RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM54ZKU RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM54ZKU DI DM54ZKU DM54ZKU DN 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine DM54ZKU TI TTVBI8W DM54ZKU TN Dopamine transporter (DAT) DM54ZKU MA Inhibitor DM54ZKU RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM54ZKU RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM54ZKU DI DM54ZKU DM54ZKU DN 1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine DM54ZKU TI TT3ROYC DM54ZKU TN Serotonin transporter (SERT) DM54ZKU MA Inhibitor DM54ZKU RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM54ZKU RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM561MH DI DM561MH DM561MH DN 2-Methyl-1,2-di-pyridin-3-yl-propyliodide DM561MH TI TTIQUX7 DM561MH TN Steroid 11-beta-hydroxylase (CYP11B1) DM561MH MA Inhibitor DM561MH RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DM561MH RU https://pubmed.ncbi.nlm.nih.gov/6606707 DM561Z7 DI DM561Z7 DM561Z7 DN N4-(3-chlorophenyl)quinazoline-4,6-diamine DM561Z7 TI TTGKNB4 DM561Z7 TN Epidermal growth factor receptor (EGFR) DM561Z7 MA Inhibitor DM561Z7 RN Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discover... J Med Chem. 2007 May 31;50(11):2605-8. DM561Z7 RU https://pubmed.ncbi.nlm.nih.gov/17472358 DM563PZ DI DM563PZ DM563PZ DN Corosolic acid DM563PZ TI TTN7BL9 DM563PZ TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM563PZ MA Inhibitor DM563PZ RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DM563PZ RU https://pubmed.ncbi.nlm.nih.gov/20100662 DM568CK DI DM568CK DM568CK DN 3-Phenyl-1-propyl-piperidine hydrochloride DM568CK TI TTEX248 DM568CK TN Dopamine D2 receptor (D2R) DM568CK MA Inhibitor DM568CK RN New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8. DM568CK RU https://pubmed.ncbi.nlm.nih.gov/12502370 DM56A89 DI DM56A89 DM56A89 DN ISIS 113903 DM56A89 TI TTIX0ZU DM56A89 TN MEKK2 messenger RNA (MAP3K2 mRNA) DM56A89 RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DM56A89 RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DM56EW7 DI DM56EW7 DM56EW7 DN 8-Methoxy-2-phenyl-3H-quinazolin-4-one DM56EW7 TI TTVDSZ0 DM56EW7 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM56EW7 MA Inhibitor DM56EW7 RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DM56EW7 RU https://pubmed.ncbi.nlm.nih.gov/9857092 DM56EZC DI DM56EZC DM56EZC DN ISIS 3246 DM56EZC TI TT4SCBE DM56EZC TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DM56EZC RN US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections. DM56EZC RU http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true DM56KDV DI DM56KDV DM56KDV DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl DM56KDV TI TTZPO1L DM56KDV TN Substance-P receptor (TACR1) DM56KDV MA Inhibitor DM56KDV RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM56KDV RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM56KDV DI DM56KDV DM56KDV DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl DM56KDV TI TT27RFC DM56KDV TN Opioid receptor delta (OPRD1) DM56KDV MA Inhibitor DM56KDV RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM56KDV RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM56KDV DI DM56KDV DM56KDV DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl DM56KDV TI TTKWM86 DM56KDV TN Opioid receptor mu (MOP) DM56KDV MA Inhibitor DM56KDV RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DM56KDV RU https://pubmed.ncbi.nlm.nih.gov/18266313 DM56MOV DI DM56MOV DM56MOV DN Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV TI TTW4N16 DM56MOV TN Neuropeptide Y receptor type 4 (NPY4R) DM56MOV MA Inhibitor DM56MOV RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM56MOV RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM56MOV DI DM56MOV DM56MOV DN Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV TI TTJ6WK9 DM56MOV TN Neuropeptide Y receptor type 2 (NPY2R) DM56MOV MA Inhibitor DM56MOV RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM56MOV RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM56MOV DI DM56MOV DM56MOV DN Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV TI TTRK9JT DM56MOV TN Neuropeptide Y receptor type 1 (NPY1R) DM56MOV MA Inhibitor DM56MOV RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM56MOV RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM56NK4 DI DM56NK4 DM56NK4 DN 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine DM56NK4 TI TTAWNKZ DM56NK4 TN Norepinephrine transporter (NET) DM56NK4 MA Inhibitor DM56NK4 RN Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12. DM56NK4 RU https://pubmed.ncbi.nlm.nih.gov/3735309 DM56NK4 DI DM56NK4 DM56NK4 DN 2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine DM56NK4 TI TTVBI8W DM56NK4 TN Dopamine transporter (DAT) DM56NK4 MA Inhibitor DM56NK4 RN Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12. DM56NK4 RU https://pubmed.ncbi.nlm.nih.gov/3735309 DM56P1I DI DM56P1I DM56P1I DN N-Hydroxy-2-(4-methoxy-benzenesulfonyl)benzamide DM56P1I TI TTXZ0KQ DM56P1I TN Matrix metalloproteinase-12 (MMP-12) DM56P1I MA Inhibitor DM56P1I RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DM56P1I RU https://pubmed.ncbi.nlm.nih.gov/19775099 DM56PBI DI DM56PBI DM56PBI DN PD-135478 DM56PBI TI TTEX248 DM56PBI TN Dopamine D2 receptor (D2R) DM56PBI MA Inhibitor DM56PBI RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DM56PBI RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DM56RAX DI DM56RAX DM56RAX DN pentanoic acid DM56RAX TI TTXDOHN DM56RAX TN Free fatty acid receptor 3 (FFAR3) DM56RAX MA Agonist DM56RAX RN Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1045-50. DM56RAX RU https://pubmed.ncbi.nlm.nih.gov/14722361 DM56RAX DI DM56RAX DM56RAX DN pentanoic acid DM56RAX TI TT0FYAN DM56RAX TN Free fatty acid receptor 2 (FFAR2) DM56RAX MA Agonist DM56RAX RN The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem. 2003 Mar 28;278(13):11312-9. DM56RAX RU https://pubmed.ncbi.nlm.nih.gov/12496283 DM56TVA DI DM56TVA DM56TVA DN 5-oxo-ODE DM56TVA TI TT7WBSV DM56TVA TN Oxoeicosanoid receptor 1 (OXER1) DM56TVA MA Agonist DM56TVA RN Human neutrophils convert the sebum-derived polyunsaturated fatty acid Sebaleic acid to a potent granulocyte chemoattractant. J Biol Chem. 2008 Apr 25;283(17):11234-43. DM56TVA RU https://pubmed.ncbi.nlm.nih.gov/18287092 DM573UT DI DM573UT DM573UT DN Propan-2-one O-4-ethoxyphenylcarbamoyl oxime DM573UT TI TTDP1UC DM573UT TN Fatty acid amide hydrolase (FAAH) DM573UT MA Inhibitor DM573UT RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM573UT RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM5782Z DI DM5782Z DM5782Z DN FM1-10 DM5782Z TI TTQ3JTF DM5782Z TN Muscarinic acetylcholine receptor M4 (CHRM4) DM5782Z MA Inhibitor DM5782Z RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DM5782Z RU https://pubmed.ncbi.nlm.nih.gov/18042383 DM5782Z DI DM5782Z DM5782Z DN FM1-10 DM5782Z TI TTQ13Z5 DM5782Z TN Muscarinic acetylcholine receptor M3 (CHRM3) DM5782Z MA Inhibitor DM5782Z RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DM5782Z RU https://pubmed.ncbi.nlm.nih.gov/18042383 DM5782Z DI DM5782Z DM5782Z DN FM1-10 DM5782Z TI TTH18TF DM5782Z TN Muscarinic acetylcholine receptor M5 (CHRM5) DM5782Z MA Inhibitor DM5782Z RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DM5782Z RU https://pubmed.ncbi.nlm.nih.gov/18042383 DM5782Z DI DM5782Z DM5782Z DN FM1-10 DM5782Z TI TTYEG6Q DM5782Z TN Muscarinic acetylcholine receptor M2 (CHRM2) DM5782Z MA Inhibitor DM5782Z RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DM5782Z RU https://pubmed.ncbi.nlm.nih.gov/18042383 DM5782Z DI DM5782Z DM5782Z DN FM1-10 DM5782Z TI TTZ9SOR DM5782Z TN Muscarinic acetylcholine receptor M1 (CHRM1) DM5782Z MA Inhibitor DM5782Z RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DM5782Z RU https://pubmed.ncbi.nlm.nih.gov/18042383 DM57BXZ DI DM57BXZ DM57BXZ DN KYS-05080 DM57BXZ TI TT729IR DM57BXZ TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM57BXZ MA Inhibitor DM57BXZ RN T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. DM57BXZ RU https://pubmed.ncbi.nlm.nih.gov/18585035 DM57BXZ DI DM57BXZ DM57BXZ DN KYS-05080 DM57BXZ TI TTZPWGN DM57BXZ TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DM57BXZ MA Inhibitor DM57BXZ RN Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. DM57BXZ RU https://pubmed.ncbi.nlm.nih.gov/17064894 DM57GQN DI DM57GQN DM57GQN DN N-(2-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide DM57GQN TI TTVTX4N DM57GQN TN Bacterial Fatty acid synthetase I (Bact inhA) DM57GQN MA Inhibitor DM57GQN RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DM57GQN RU https://pubmed.ncbi.nlm.nih.gov/18457948 DM57LVW DI DM57LVW DM57LVW DN (-)-cubebin DM57LVW TI TTXV4FI DM57LVW TN Albendazole monooxygenase (CYP3A4) DM57LVW MA Inhibitor DM57LVW RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DM57LVW RU https://pubmed.ncbi.nlm.nih.gov/15679319 DM57SVW DI DM57SVW DM57SVW DN Benzamil DM57SVW TI TTQM7TE DM57SVW TN Amiloride-sensitive sodium channel (ENaC) DM57SVW MA Blocker (channel blocker) DM57SVW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 742). DM57SVW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=742 DM57SVW DI DM57SVW DM57SVW DN Benzamil DM57SVW TI TTAHD89 DM57SVW TN Polycystic kidney disease 2-like 1 (TRPP2) DM57SVW MA Blocker (channel blocker) DM57SVW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505). DM57SVW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=505 DM57SVW DI DM57SVW DM57SVW DN Benzamil DM57SVW TI TTLGDIS DM57SVW TN Acid-sensing ion channel 3 (ASIC3) DM57SVW MA Blocker (channel blocker) DM57SVW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 684). DM57SVW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=684 DM57TIU DI DM57TIU DM57TIU DN [4Aph(CO-NH-OCH3)5,D-4Aph(CO-NH-OCH3)6]degarelix DM57TIU TI TT8R70G DM57TIU TN Gonadotropin-releasing hormone receptor (GNRHR) DM57TIU MA Inhibitor DM57TIU RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DM57TIU RU https://pubmed.ncbi.nlm.nih.gov/16759096 DM57TN3 DI DM57TN3 DM57TN3 DN JWH-405 DM57TN3 TI TTMSFAW DM57TN3 TN Cannabinoid receptor 2 (CB2) DM57TN3 MA Inhibitor DM57TN3 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM57TN3 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM57TN3 DI DM57TN3 DM57TN3 DN JWH-405 DM57TN3 TI TT6OEDT DM57TN3 TN Cannabinoid receptor 1 (CB1) DM57TN3 MA Inhibitor DM57TN3 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM57TN3 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM57UB9 DI DM57UB9 DM57UB9 DN RO5166017 DM57UB9 TI TTIU98M DM57UB9 TN Trace amine-associated receptor-1 (TAAR1) DM57UB9 MA Agonist DM57UB9 RN TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8485-90. DM57UB9 RU https://pubmed.ncbi.nlm.nih.gov/21525407 DM57Z8J DI DM57Z8J DM57Z8J DN LDN-214117 DM57Z8J TI TTP4520 DM57Z8J TN TGF-beta receptor type I (TGFBR1) DM57Z8J MA Inhibitor DM57Z8J RN Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15. DM57Z8J RU https://pubmed.ncbi.nlm.nih.gov/25101911 DM57Z8J DI DM57Z8J DM57Z8J DN LDN-214117 DM57Z8J TI TTJNBQA DM57Z8J TN Activin receptor-like kinase 2 (ALK-2) DM57Z8J MA Inhibitor DM57Z8J RN Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15. DM57Z8J RU https://pubmed.ncbi.nlm.nih.gov/25101911 DM57Z8J DI DM57Z8J DM57Z8J DN LDN-214117 DM57Z8J TI TTGYPTC DM57Z8J TN Activin receptor-like kinase-1 (ACVRL1) DM57Z8J MA Inhibitor DM57Z8J RN Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15. DM57Z8J RU https://pubmed.ncbi.nlm.nih.gov/25101911 DM57Z8J DI DM57Z8J DM57Z8J DN LDN-214117 DM57Z8J TI TTGKF90 DM57Z8J TN Bone morphogenetic protein receptor (BMPR2) DM57Z8J MA Inhibitor DM57Z8J RN Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J Med Chem. 2014 Oct 9;57(19):7900-15. DM57Z8J RU https://pubmed.ncbi.nlm.nih.gov/25101911 DM57ZMJ DI DM57ZMJ DM57ZMJ DN 3-(1,1-Dimethyl-2-phenyl-ethyl)-pyridine DM57ZMJ TI TTIQUX7 DM57ZMJ TN Steroid 11-beta-hydroxylase (CYP11B1) DM57ZMJ MA Inhibitor DM57ZMJ RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DM57ZMJ RU https://pubmed.ncbi.nlm.nih.gov/6606707 DM584T6 DI DM584T6 DM584T6 DN SCH-205831 DM584T6 TI TTL935N DM584T6 TN Proteinase activated receptor 1 (F2R) DM584T6 MA Inhibitor DM584T6 RN Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13. DM584T6 RU https://pubmed.ncbi.nlm.nih.gov/17574850 DM589XM DI DM589XM DM589XM DN S-19528 DM589XM TI TTRK9JT DM589XM TN Neuropeptide Y receptor type 1 (NPY1R) DM589XM MA Antagonist DM589XM RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM589XM RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM589XM DI DM589XM DM589XM DN S-19528 DM589XM TI TTY6EWA DM589XM TN Neuropeptide Y receptor type 5 (NPY5R) DM589XM MA Antagonist DM589XM RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DM589XM RU https://pubmed.ncbi.nlm.nih.gov/16634704 DM589XV DI DM589XV DM589XV DN AMG 9810 DM589XV TI TTMI6F5 DM589XV TN Transient receptor potential cation channel V1 (TRPV1) DM589XV MA Blocker (channel blocker) DM589XV RN AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyp... J Pharmacol Exp Ther. 2005 Apr;313(1):474-84. DM589XV RU https://pubmed.ncbi.nlm.nih.gov/15615864 DM58A0W DI DM58A0W DM58A0W DN methoprene acid DM58A0W TI TT6PEUO DM58A0W TN Retinoic acid receptor RXR-alpha (RXRA) DM58A0W MA Agonist DM58A0W RN Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):6157-60. DM58A0W RU https://pubmed.ncbi.nlm.nih.gov/7597096 DM58DGY DI DM58DGY DM58DGY DN IM-12 DM58DGY TI TTRSMW9 DM58DGY TN Glycogen synthase kinase-3 beta (GSK-3B) DM58DGY MA Inhibitor DM58DGY RN Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells. Bioorg Med Chem. 2010 Sep 15;18(18):6785-95. DM58DGY RU https://pubmed.ncbi.nlm.nih.gov/20708937 DM58GRA DI DM58GRA DM58GRA DN 3-(benzo[b]thiophen-5-yl)-3-benzylpyrrolidine DM58GRA TI TTQ6VDM DM58GRA TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM58GRA MA Inhibitor DM58GRA RN Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6. DM58GRA RU https://pubmed.ncbi.nlm.nih.gov/18954985 DM58JFR DI DM58JFR DM58JFR DN FVPTDVG-Tic-FAF-Tic DM58JFR TI TTY6O0Q DM58JFR TN Calcitonin gene-related peptide receptor (CGRPR) DM58JFR MA Inhibitor DM58JFR RN Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24. DM58JFR RU https://pubmed.ncbi.nlm.nih.gov/16420047 DM58KHY DI DM58KHY DM58KHY DN dihydrosphingosine-1-phosphate DM58KHY TI TTZ8C5Q DM58KHY TN Sphingosine-1-phosphate receptor 4 (S1PR4) DM58KHY MA Agonist DM58KHY RN Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun. 2002 Sep 27;297(3):600-6. DM58KHY RU https://pubmed.ncbi.nlm.nih.gov/12270137 DM58KHY DI DM58KHY DM58KHY DN dihydrosphingosine-1-phosphate DM58KHY TI TT2D5VM DM58KHY TN G-protein coupled receptor 63 (GPR63) DM58KHY MA Agonist DM58KHY RN Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal. 2003 Apr;15(4):435-46. DM58KHY RU https://pubmed.ncbi.nlm.nih.gov/12618218 DM58O3I DI DM58O3I DM58O3I DN NE21650 DM58O3I TI TTIKWV4 DM58O3I TN Geranyltranstransferase (FDPS) DM58O3I MA Inhibitor DM58O3I RN Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun. 2002 Jan 18;290(2):869-73. DM58O3I RU https://pubmed.ncbi.nlm.nih.gov/11785983 DM58S47 DI DM58S47 DM58S47 DN 1-(3-Bromomethyl-phenyl)-2,2,2-trifluoro-ethanone DM58S47 TI TT1RS9F DM58S47 TN Acetylcholinesterase (AChE) DM58S47 MA Inhibitor DM58S47 RN A structure-based design approach to the development of novel, reversible AChE inhibitors. J Med Chem. 2001 Sep 27;44(20):3203-15. DM58S47 RU https://pubmed.ncbi.nlm.nih.gov/11563919 DM58XF6 DI DM58XF6 DM58XF6 DN 9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide DM58XF6 TI TTEB0GD DM58XF6 TN Cholinesterase (BCHE) DM58XF6 MA Inhibitor DM58XF6 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DM58XF6 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DM58XF6 DI DM58XF6 DM58XF6 DN 9-O-[4-(Phenylol-1-yloxy)butyl]berberine bromide DM58XF6 TI TT1RS9F DM58XF6 TN Acetylcholinesterase (AChE) DM58XF6 MA Inhibitor DM58XF6 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DM58XF6 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DM58XJN DI DM58XJN DM58XJN DN Desmethylastemizole DM58XJN TI TTQ6VDM DM58XJN TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM58XJN MA Blocker DM58XJN RN Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole. J Cardiovasc Electrophysiol. 1999 Jun;10(6):836-43. DM58XJN RU https://pubmed.ncbi.nlm.nih.gov/10376921 DM58XT1 DI DM58XT1 DM58XT1 DN ISIS 109113 DM58XT1 TI TTQSMFG DM58XT1 TN Talin messenger RNA (TLN1 mRNA) DM58XT1 RN US patent application no. 6,372,492, Antisense modulation of talin expression. DM58XT1 RU http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true DM58YDV DI DM58YDV DM58YDV DN Bis(14)-Huperzine B DM58YDV TI TT1RS9F DM58YDV TN Acetylcholinesterase (AChE) DM58YDV MA Inhibitor DM58YDV RN Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7. DM58YDV RU https://pubmed.ncbi.nlm.nih.gov/15689148 DM592FB DI DM592FB DM592FB DN 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine DM592FB TI TTWJBZ5 DM592FB TN 5-HT 2C receptor (HTR2C) DM592FB MA Inhibitor DM592FB RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DM592FB RU https://pubmed.ncbi.nlm.nih.gov/18083579 DM592FB DI DM592FB DM592FB DN 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine DM592FB TI TT0K1SC DM592FB TN 5-HT 2B receptor (HTR2B) DM592FB MA Inhibitor DM592FB RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DM592FB RU https://pubmed.ncbi.nlm.nih.gov/18083579 DM592FB DI DM592FB DM592FB DN 6,7-dichloro-2,3,4,5-tetrahydro-1H-3-benzazepine DM592FB TI TTJQOD7 DM592FB TN 5-HT 2A receptor (HTR2A) DM592FB MA Inhibitor DM592FB RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DM592FB RU https://pubmed.ncbi.nlm.nih.gov/18083579 DM592YS DI DM592YS DM592YS DN 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide DM592YS TI TTFPQV7 DM592YS TN Galectin-3 (LGALS3) DM592YS MA Inhibitor DM592YS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM592YS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5971G DI DM5971G DM5971G DN C4X-101 DM5971G TI TT4J8MF DM5971G TN Thyrotropin-releasing hormone receptor (TRHR) DM5971G MA Inhibitor DM5971G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 363). DM5971G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=363 DM59CR0 DI DM59CR0 DM59CR0 DN MONODICTYOCHROMONE B DM59CR0 TI TTSZLWK DM59CR0 TN Aromatase (CYP19A1) DM59CR0 MA Inhibitor DM59CR0 RN Monodictyochromes A and B, dimeric xanthone derivatives from the marine algicolous fungus Monodictys putredinis. J Nat Prod. 2008 Nov;71(11):1793-9. DM59CR0 RU https://pubmed.ncbi.nlm.nih.gov/18939864 DM59G40 DI DM59G40 DM59G40 DN Rimeporide DM59G40 TI TT70SZ3 DM59G40 TN Sodium/hydrogen exchanger (SLC) DM59G40 MA Inhibitor DM59G40 RN Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy. Circulation. 2007 Mar 6;115(9):1090-100. DM59G40 RU https://pubmed.ncbi.nlm.nih.gov/17339567 DM59VBG DI DM59VBG DM59VBG DN 2-(3-Isobutyl-phenyl)-propionic acid DM59VBG TI TT30C9G DM59VBG TN C-X-C chemokine receptor type 2 (CXCR2) DM59VBG MA Inhibitor DM59VBG RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM59VBG RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM59VBG DI DM59VBG DM59VBG DN 2-(3-Isobutyl-phenyl)-propionic acid DM59VBG TI TTMWT8Z DM59VBG TN C-X-C chemokine receptor type 1 (CXCR1) DM59VBG MA Inhibitor DM59VBG RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DM59VBG RU https://pubmed.ncbi.nlm.nih.gov/15974585 DM5A8KR DI DM5A8KR DM5A8KR DN phenylacetyl-Ala,DTrp-phenthylamide DM5A8KR TI TTHYDUM DM5A8KR TN Bombesin receptor (BS) DM5A8KR MA Agonist DM5A8KR RN Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells. Peptides. 2010 Aug;31(8):1569-78. DM5A8KR RU https://pubmed.ncbi.nlm.nih.gov/20438784 DM5ACNU DI DM5ACNU DM5ACNU DN 2'-hydroxy-3,4,5-trimethoxychalcone DM5ACNU TI TTVKILB DM5ACNU TN Prostaglandin G/H synthase 2 (COX-2) DM5ACNU MA Inhibitor DM5ACNU RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DM5ACNU RU https://pubmed.ncbi.nlm.nih.gov/19233646 DM5AOFW DI DM5AOFW DM5AOFW DN Digitoxigenin DM5AOFW TI TTWK8D0 DM5AOFW TN Sodium pump subunit alpha-1 (ATP1A1) DM5AOFW MA Inhibitor DM5AOFW RN 17beta-O-Aminoalkyloximes of 5beta-androstane-3beta,14beta-diol with digitalis-like activity: synthesis, cardiotonic activity, structure-activity r... J Med Chem. 2000 Jun 15;43(12):2332-49. DM5AOFW RU https://pubmed.ncbi.nlm.nih.gov/10882359 DM5APGL DI DM5APGL DM5APGL DN ISIS 101996 DM5APGL TI TTON5JB DM5APGL TN MADH6 messenger RNA (MADH6 mRNA) DM5APGL RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DM5APGL RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DM5ARHI DI DM5ARHI DM5ARHI DN DELTA 8-TETRAHYDROCANNOBINOL DM5ARHI TI TT6OEDT DM5ARHI TN Cannabinoid receptor 1 (CB1) DM5ARHI MA Inhibitor DM5ARHI RN Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands. J Med Chem. 2008 Oct 23;51(20):6393-9. DM5ARHI RU https://pubmed.ncbi.nlm.nih.gov/18826296 DM5ARHI DI DM5ARHI DM5ARHI DN DELTA 8-TETRAHYDROCANNOBINOL DM5ARHI TI TTMSFAW DM5ARHI TN Cannabinoid receptor 2 (CB2) DM5ARHI MA Inhibitor DM5ARHI RN Bornyl- and isobornyl-Delta8-tetrahydrocannabinols: a novel class of cannabinergic ligands. J Med Chem. 2008 Oct 23;51(20):6393-9. DM5ARHI RU https://pubmed.ncbi.nlm.nih.gov/18826296 DM5AVG3 DI DM5AVG3 DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide DM5AVG3 TI TTT6LFV DM5AVG3 TN Histone deacetylase 8 (HDAC8) DM5AVG3 MA Inhibitor DM5AVG3 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM5AVG3 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM5AVG3 DI DM5AVG3 DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide DM5AVG3 TI TT5ZKDI DM5AVG3 TN Histone deacetylase 6 (HDAC6) DM5AVG3 MA Inhibitor DM5AVG3 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM5AVG3 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM5AVG3 DI DM5AVG3 DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide DM5AVG3 TI TT6R7JZ DM5AVG3 TN Histone deacetylase 1 (HDAC1) DM5AVG3 MA Inhibitor DM5AVG3 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM5AVG3 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM5AVG3 DI DM5AVG3 DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide DM5AVG3 TI TTTQGH8 DM5AVG3 TN Histone deacetylase 4 (HDAC4) DM5AVG3 MA Inhibitor DM5AVG3 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM5AVG3 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM5AVG3 DI DM5AVG3 DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide DM5AVG3 TI TTBH0VX DM5AVG3 TN Histone deacetylase (HDAC) DM5AVG3 MA Inhibitor DM5AVG3 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM5AVG3 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM5AVG3 DI DM5AVG3 DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide DM5AVG3 TI TTSHTOI DM5AVG3 TN Histone deacetylase 2 (HDAC2) DM5AVG3 MA Inhibitor DM5AVG3 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM5AVG3 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM5AVG3 DI DM5AVG3 DM5AVG3 DN 4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide DM5AVG3 TI TTYHPU6 DM5AVG3 TN Histone deacetylase 10 (HDAC10) DM5AVG3 MA Inhibitor DM5AVG3 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM5AVG3 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM5BAJ9 DI DM5BAJ9 DM5BAJ9 DN 20-HETE DM5BAJ9 TI TTRBT3W DM5BAJ9 TN Short transient receptor potential channel 6 (TRPC6) DM5BAJ9 MA Activator DM5BAJ9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491). DM5BAJ9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491 DM5BATX DI DM5BATX DM5BATX DN STS-T4 DM5BATX TI TTIHYA4 DM5BATX TN Thrombopoietin receptor (MPL) DM5BATX MA Agonist DM5BATX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DM5BATX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DM5BFL4 DI DM5BFL4 DM5BFL4 DN YM 471 DM5BFL4 TI TT4TFGN DM5BFL4 TN Vasopressin V1a receptor (V1AR) DM5BFL4 MA Antagonist DM5BFL4 RN Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol. 2001 Jul;133(5):746-54. DM5BFL4 RU https://pubmed.ncbi.nlm.nih.gov/11429400 DM5BFL4 DI DM5BFL4 DM5BFL4 DN YM 471 DM5BFL4 TI TTK8R02 DM5BFL4 TN Vasopressin V2 receptor (V2R) DM5BFL4 MA Antagonist DM5BFL4 RN Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol. 2001 Jul;133(5):746-54. DM5BFL4 RU https://pubmed.ncbi.nlm.nih.gov/11429400 DM5BFL4 DI DM5BFL4 DM5BFL4 DN YM 471 DM5BFL4 TI TTL9MHW DM5BFL4 TN Vasopressin V1b receptor (V1BR) DM5BFL4 MA Antagonist DM5BFL4 RN Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells. Br J Pharmacol. 2001 Jul;133(5):746-54. DM5BFL4 RU https://pubmed.ncbi.nlm.nih.gov/11429400 DM5BH7J DI DM5BH7J DM5BH7J DN Anti-CD28 DM5BH7J TI TTQ13FT DM5BH7J TN T-cell-specific surface glycoprotein CD28 (CD28) DM5BH7J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863). DM5BH7J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2863 DM5BMA9 DI DM5BMA9 DM5BMA9 DN ONO-8809 DM5BMA9 TI TT2O84V DM5BMA9 TN Thromboxane A2 receptor (TBXA2R) DM5BMA9 MA Antagonist DM5BMA9 RN Anti-thrombotic effect of ONO-8809, a novel TXA2/PG endoperoxide receptor antagonist. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:599-602. DM5BMA9 RU https://pubmed.ncbi.nlm.nih.gov/1825384 DM5BN41 DI DM5BN41 DM5BN41 DN 4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol DM5BN41 TI TTMSFAW DM5BN41 TN Cannabinoid receptor 2 (CB2) DM5BN41 MA Inhibitor DM5BN41 RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DM5BN41 RU https://pubmed.ncbi.nlm.nih.gov/17507224 DM5BN41 DI DM5BN41 DM5BN41 DN 4-(1,1-dimethyl-heptyl)-3'-methoxy-biphenyl-2-ol DM5BN41 TI TT6OEDT DM5BN41 TN Cannabinoid receptor 1 (CB1) DM5BN41 MA Inhibitor DM5BN41 RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DM5BN41 RU https://pubmed.ncbi.nlm.nih.gov/17507224 DM5BSVQ DI DM5BSVQ DM5BSVQ DN ISIS 103486 DM5BSVQ TI TT1GV6C DM5BSVQ TN DUSP9 messenger RNA (DUSP9 mRNA) DM5BSVQ RN US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression. DM5BSVQ RU http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true DM5BUXZ DI DM5BUXZ DM5BUXZ DN 10-Acetyl-1,8-dihydroxy-10H-anthracen-9-one DM5BUXZ TI TT2J34L DM5BUXZ TN Arachidonate 5-lipoxygenase (5-LOX) DM5BUXZ MA Inhibitor DM5BUXZ RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DM5BUXZ RU https://pubmed.ncbi.nlm.nih.gov/9371243 DM5C1ND DI DM5C1ND DM5C1ND DN PT-314 DM5C1ND TI TT84ETX DM5C1ND TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM5C1ND MA Inhibitor DM5C1ND RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM5C1ND RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM5C7I8 DI DM5C7I8 DM5C7I8 DN 1-(3,4-dihydronaphthalen-1-yl)ethanone DM5C7I8 TI TTEAID7 DM5C7I8 TN Trypanosoma Cruzipain (Trypano CYSP) DM5C7I8 MA Inhibitor DM5C7I8 RN Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4405-9. DM5C7I8 RU https://pubmed.ncbi.nlm.nih.gov/16781147 DM5C86M DI DM5C86M DM5C86M DN ISIS 9069 DM5C86M TI TT5TURO DM5C86M TN A-Raf messenger RNA (ARAF mRNA) DM5C86M RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DM5C86M RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DM5C9VI DI DM5C9VI DM5C9VI DN MNI-136 DM5C9VI TI TTXJ47W DM5C9VI TN Metabotropic glutamate receptor 2 (mGluR2) DM5C9VI MA Modulator (allosteric modulator) DM5C9VI RN A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64. DM5C9VI RU https://pubmed.ncbi.nlm.nih.gov/17416742 DM5C9VI DI DM5C9VI DM5C9VI DN MNI-136 DM5C9VI TI TT8A9EF DM5C9VI TN Metabotropic glutamate receptor 3 (mGluR3) DM5C9VI MA Modulator (allosteric modulator) DM5C9VI RN A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64. DM5C9VI RU https://pubmed.ncbi.nlm.nih.gov/17416742 DM5CBQ9 DI DM5CBQ9 DM5CBQ9 DN Cyclo(1,10)H-EIYDPGDDIK-OH DM5CBQ9 TI TTJDUNO DM5CBQ9 TN T-cell surface antigen CD2 (CD2) DM5CBQ9 MA Inhibitor DM5CBQ9 RN Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36. DM5CBQ9 RU https://pubmed.ncbi.nlm.nih.gov/19123855 DM5CEG8 DI DM5CEG8 DM5CEG8 DN 2-(Sulfanylmethyl)phenylphosphonic acid DM5CEG8 TI TTHI19T DM5CEG8 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM5CEG8 MA Inhibitor DM5CEG8 RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DM5CEG8 RU https://pubmed.ncbi.nlm.nih.gov/20527888 DM5CGXB DI DM5CGXB DM5CGXB DN BX 471 DM5CGXB TI TTC24WT DM5CGXB TN C-C chemokine receptor type 1 (CCR1) DM5CGXB MA Antagonist DM5CGXB RN Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000 Jun 23;275(25):19000-8. DM5CGXB RU https://pubmed.ncbi.nlm.nih.gov/10748002 DM5CI2P DI DM5CI2P DM5CI2P DN RK-682 DM5CI2P TI TTELIN2 DM5CI2P TN PTPN1 messenger RNA (PTPN1 mRNA) DM5CI2P MA Inhibitor DM5CI2P RN Prenylflavonoids from Glycyrrhiza uralensis and their protein tyrosine phosphatase-1B inhibitory activities. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5398-401. DM5CI2P RU https://pubmed.ncbi.nlm.nih.gov/20724155 DM5CL8B DI DM5CL8B DM5CL8B DN (R)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine DM5CL8B TI TT9JNIC DM5CL8B TN Histamine H3 receptor (H3R) DM5CL8B MA Inhibitor DM5CL8B RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DM5CL8B RU https://pubmed.ncbi.nlm.nih.gov/18077160 DM5CMA8 DI DM5CMA8 DM5CMA8 DN ISOFORMONENTIN DM5CMA8 TI TTFLN4T DM5CMA8 TN Mitochondrial aldehyde dehydrogenase (ALDH2) DM5CMA8 MA Inhibitor DM5CMA8 RN Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. J Med Chem. 2008 Aug 14;51(15):4482-7. DM5CMA8 RU https://pubmed.ncbi.nlm.nih.gov/18613661 DM5COQ9 DI DM5COQ9 DM5COQ9 DN N-(2,4-dichlorophenyl)-2-nitrobenzamide DM5COQ9 TI TTVTX4N DM5COQ9 TN Bacterial Fatty acid synthetase I (Bact inhA) DM5COQ9 MA Inhibitor DM5COQ9 RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DM5COQ9 RU https://pubmed.ncbi.nlm.nih.gov/19428156 DM5CPBK DI DM5CPBK DM5CPBK DN 4-tert-butyl-N-phenylthiazol-2-amine DM5CPBK TI TT7HQD0 DM5CPBK TN C-C chemokine receptor type 4 (CCR4) DM5CPBK MA Inhibitor DM5CPBK RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DM5CPBK RU https://pubmed.ncbi.nlm.nih.gov/16497499 DM5CPJ2 DI DM5CPJ2 DM5CPJ2 DN BAY-73-1449 DM5CPJ2 TI TTOFYT1 DM5CPJ2 TN Prostacyclin receptor (PTGIR) DM5CPJ2 MA Antagonist DM5CPJ2 RN Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat. Eur J Pharmacol. 2008 Aug 20;590(1-3):322-6. DM5CPJ2 RU https://pubmed.ncbi.nlm.nih.gov/18603238 DM5CR2E DI DM5CR2E DM5CR2E DN N-methylstephuline DM5CR2E TI TT27RFC DM5CR2E TN Opioid receptor delta (OPRD1) DM5CR2E MA Inhibitor DM5CR2E RN Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91. DM5CR2E RU https://pubmed.ncbi.nlm.nih.gov/20426456 DM5CS8U DI DM5CS8U DM5CS8U DN [Ncy(isopropyl)7]acyline DM5CS8U TI TT8R70G DM5CS8U TN Gonadotropin-releasing hormone receptor (GNRHR) DM5CS8U MA Inhibitor DM5CS8U RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM5CS8U RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM5CWM0 DI DM5CWM0 DM5CWM0 DN 2,5-didesoxy-3-ATP DM5CWM0 TI TT2QM9D DM5CWM0 TN Adenylate cyclase (ADCY) DM5CWM0 MA Inhibitor DM5CWM0 RN Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64. DM5CWM0 RU https://pubmed.ncbi.nlm.nih.gov/18630896 DM5D09Q DI DM5D09Q DM5D09Q DN 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline DM5D09Q TI TT34BHT DM5D09Q TN Adrenergic receptor alpha-1D (ADRA1D) DM5D09Q MA Inhibitor DM5D09Q RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DM5D09Q RU https://pubmed.ncbi.nlm.nih.gov/12729659 DM5D09Q DI DM5D09Q DM5D09Q DN 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline DM5D09Q TI TTBRKXS DM5D09Q TN Adrenergic receptor alpha-1B (ADRA1B) DM5D09Q MA Inhibitor DM5D09Q RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DM5D09Q RU https://pubmed.ncbi.nlm.nih.gov/12729659 DM5D09Q DI DM5D09Q DM5D09Q DN 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline DM5D09Q TI TTN9D8E DM5D09Q TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM5D09Q MA Inhibitor DM5D09Q RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DM5D09Q RU https://pubmed.ncbi.nlm.nih.gov/12729659 DM5D09Q DI DM5D09Q DM5D09Q DN 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline DM5D09Q TI TTNGILX DM5D09Q TN Adrenergic receptor alpha-1A (ADRA1A) DM5D09Q MA Inhibitor DM5D09Q RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DM5D09Q RU https://pubmed.ncbi.nlm.nih.gov/12729659 DM5D09Q DI DM5D09Q DM5D09Q DN 2-Pyridin-4-yl-1,2,3,4-tetrahydro-isoquinoline DM5D09Q TI TTLD29N DM5D09Q TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM5D09Q MA Inhibitor DM5D09Q RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DM5D09Q RU https://pubmed.ncbi.nlm.nih.gov/12729659 DM5D3SN DI DM5D3SN DM5D3SN DN PMID24999562C6b DM5D3SN TI TT2L6C5 DM5D3SN TN Neuromedin-U receptor 2 (NMUR2) DM5D3SN MA Agonist DM5D3SN RN Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. J Med Chem. 2014 Aug 14;57(15):6583-93. DM5D3SN RU https://pubmed.ncbi.nlm.nih.gov/24999562 DM5D892 DI DM5D892 DM5D892 DN L-791943 DM5D892 TI TTZ97H5 DM5D892 TN Phosphodiesterase 4A (PDE4A) DM5D892 MA Inhibitor DM5D892 RN Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1457-61. DM5D892 RU https://pubmed.ncbi.nlm.nih.gov/12031319 DM5D9UT DI DM5D9UT DM5D9UT DN RU-59063 DM5D9UT TI TTS64P2 DM5D9UT TN Androgen receptor (AR) DM5D9UT MA Inhibitor DM5D9UT RN Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7. DM5D9UT RU https://pubmed.ncbi.nlm.nih.gov/10966753 DM5D9YK DI DM5D9YK DM5D9YK DN Choline DM5D9YK TI TTF4E0J DM5D9YK TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM5D9YK MA Inhibitor DM5D9YK RN Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8. DM5D9YK RU https://pubmed.ncbi.nlm.nih.gov/15050613 DM5DCPF DI DM5DCPF DM5DCPF DN 8-Bromo-9-(2-butyl)-9H-adenine DM5DCPF TI TTNE7KG DM5DCPF TN Adenosine A2b receptor (ADORA2B) DM5DCPF MA Inhibitor DM5DCPF RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM5DCPF RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM5DCPF DI DM5DCPF DM5DCPF DN 8-Bromo-9-(2-butyl)-9H-adenine DM5DCPF TI TTM2AOE DM5DCPF TN Adenosine A2a receptor (ADORA2A) DM5DCPF MA Inhibitor DM5DCPF RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM5DCPF RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM5DCPF DI DM5DCPF DM5DCPF DN 8-Bromo-9-(2-butyl)-9H-adenine DM5DCPF TI TTK25J1 DM5DCPF TN Adenosine A1 receptor (ADORA1) DM5DCPF MA Inhibitor DM5DCPF RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM5DCPF RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM5DKUY DI DM5DKUY DM5DKUY DN ISONIPECOTAMIDE DM5DKUY TI TTJA1ZO DM5DKUY TN ITGB3 messenger RNA (ITGB3 mRNA) DM5DKUY MA Inhibitor DM5DKUY RN Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32. DM5DKUY RU https://pubmed.ncbi.nlm.nih.gov/15380233 DM5DKUY DI DM5DKUY DM5DKUY DN ISONIPECOTAMIDE DM5DKUY TI TTT1R2L DM5DKUY TN Integrin alpha-V (ITGAV) DM5DKUY MA Inhibitor DM5DKUY RN Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5227-32. DM5DKUY RU https://pubmed.ncbi.nlm.nih.gov/15380233 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTST7KB DM5DMCH TN Fibroblast growth factor receptor 3 (FGFR3) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TT8FYO9 DM5DMCH TN Platelet-derived growth factor receptor alpha (PDGFRA) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTGJVQM DM5DMCH TN Fibroblast growth factor receptor 2 (FGFR2) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTUTJGQ DM5DMCH TN Vascular endothelial growth factor receptor 2 (KDR) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TT1KX2S DM5DMCH TN FGFR4 messenger RNA (FGFR4 mRNA) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TT5U49F DM5DMCH TN PRKACA messenger RNA (PRKACA mRNA) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TT2B9KF DM5DMCH TN Fyn tyrosine protein kinase (FYN) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTW4Y2M DM5DMCH TN cAMP protein kinase type II-beta (PRKAR2B) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTYVI76 DM5DMCH TN Fungal Protein kinase A (Fung ypkA) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTI7421 DM5DMCH TN Platelet-derived growth factor receptor beta (PDGFRB) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTRLW2X DM5DMCH TN Fibroblast growth factor receptor 1 (FGFR1) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TT4TQBX DM5DMCH TN Extracellular signal-regulated kinase 2 (ERK2) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DMCH DI DM5DMCH DM5DMCH DN Ro-4396686 DM5DMCH TI TTGKNB4 DM5DMCH TN Epidermal growth factor receptor (EGFR) DM5DMCH MA Inhibitor DM5DMCH RN Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. DM5DMCH RU https://pubmed.ncbi.nlm.nih.gov/16460940 DM5DOAF DI DM5DOAF DM5DOAF DN (1S,3R)-ACPD DM5DOAF TI TTWRP2F DM5DOAF TN Metabotropic glutamate receptor 6 (mGluR6) DM5DOAF MA Agonist DM5DOAF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294). DM5DOAF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294 DM5DOAF DI DM5DOAF DM5DOAF DN (1S,3R)-ACPD DM5DOAF TI TT0I76D DM5DOAF TN Metabotropic glutamate receptor 7 (mGluR7) DM5DOAF MA Agonist DM5DOAF RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DM5DOAF RU https://pubmed.ncbi.nlm.nih.gov/11138847 DM5DOAF DI DM5DOAF DM5DOAF DN (1S,3R)-ACPD DM5DOAF TI TTVBPDM DM5DOAF TN Metabotropic glutamate receptor 1 (mGluR1) DM5DOAF MA Agonist DM5DOAF RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DM5DOAF RU https://pubmed.ncbi.nlm.nih.gov/11080213 DM5DOAF DI DM5DOAF DM5DOAF DN (1S,3R)-ACPD DM5DOAF TI TT0IFKL DM5DOAF TN Metabotropic glutamate receptor 8 (mGluR8) DM5DOAF MA Agonist DM5DOAF RN Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97. DM5DOAF RU https://pubmed.ncbi.nlm.nih.gov/9473604 DM5DOAF DI DM5DOAF DM5DOAF DN (1S,3R)-ACPD DM5DOAF TI TTHS256 DM5DOAF TN Metabotropic glutamate receptor 5 (mGluR5) DM5DOAF MA Agonist DM5DOAF RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DM5DOAF RU https://pubmed.ncbi.nlm.nih.gov/11080213 DM5DOAF DI DM5DOAF DM5DOAF DN (1S,3R)-ACPD DM5DOAF TI TT8A9EF DM5DOAF TN Metabotropic glutamate receptor 3 (mGluR3) DM5DOAF MA Agonist DM5DOAF RN [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. DM5DOAF RU https://pubmed.ncbi.nlm.nih.gov/10530814 DM5DOAF DI DM5DOAF DM5DOAF DN (1S,3R)-ACPD DM5DOAF TI TTXJ47W DM5DOAF TN Metabotropic glutamate receptor 2 (mGluR2) DM5DOAF MA Agonist DM5DOAF RN [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. DM5DOAF RU https://pubmed.ncbi.nlm.nih.gov/10530814 DM5DOEC DI DM5DOEC DM5DOEC DN Hydroxyclemastine DM5DOEC TI TTTIBOJ DM5DOEC TN Histamine H1 receptor (H1R) DM5DOEC MA Antagonist DM5DOEC RN Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol. 2008 Dec;128(12):2783-91. DM5DOEC RU https://pubmed.ncbi.nlm.nih.gov/18548114 DM5DPHO DI DM5DPHO DM5DPHO DN BIPHENYL-4-YL-ACETALDEHYDE DM5DPHO TI TT36ETB DM5DPHO TN Cathepsin L (CTSL) DM5DPHO MA Inhibitor DM5DPHO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5DPHO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5DPM4 DI DM5DPM4 DM5DPM4 DN Diazacholesterol DM5DPM4 TI TTTK0NH DM5DPM4 TN Delta(24)-sterol reductase (DHCR24) DM5DPM4 MA Inhibitor DM5DPM4 RN Antilipemic drug-induced skin manifestations. Hautarzt. 1995 Feb;46(2):76-80. DM5DPM4 RU https://pubmed.ncbi.nlm.nih.gov/7706076 DM5DRIZ DI DM5DRIZ DM5DRIZ DN Tyr-Pro-Phe-Phe-N(CH3)2 DM5DRIZ TI TT27RFC DM5DRIZ TN Opioid receptor delta (OPRD1) DM5DRIZ MA Inhibitor DM5DRIZ RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DM5DRIZ RU https://pubmed.ncbi.nlm.nih.gov/18490168 DM5DRIZ DI DM5DRIZ DM5DRIZ DN Tyr-Pro-Phe-Phe-N(CH3)2 DM5DRIZ TI TTKWM86 DM5DRIZ TN Opioid receptor mu (MOP) DM5DRIZ MA Inhibitor DM5DRIZ RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DM5DRIZ RU https://pubmed.ncbi.nlm.nih.gov/18490168 DM5DTMQ DI DM5DTMQ DM5DTMQ DN KSG-LDTKNYKQTSV DM5DTMQ TI TT9PB26 DM5DTMQ TN Presynaptic density protein 95 (DLG4) DM5DTMQ MA Inhibitor DM5DTMQ RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DM5DTMQ RU https://pubmed.ncbi.nlm.nih.gov/18811137 DM5DTZR DI DM5DTZR DM5DTZR DN COOH DM5DTZR TI TTT2SVW DM5DTZR TN PPAR-gamma messenger RNA (PPARG mRNA) DM5DTZR MA Agonist DM5DTZR RN PPAR-gamma activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion.Diabetes. 2003 Feb;52(2):291-9. DM5DTZR RU https://pubmed.ncbi.nlm.nih.gov/12540599 DM5E03C DI DM5E03C DM5E03C DN 4-hexyl-N-(quinolin-3-yl)benzamide DM5E03C TI TTMI6F5 DM5E03C TN Transient receptor potential cation channel V1 (TRPV1) DM5E03C MA Inhibitor DM5E03C RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DM5E03C RU https://pubmed.ncbi.nlm.nih.gov/18359227 DM5E1DC DI DM5E1DC DM5E1DC DN 2-hydroxygarveatin E DM5E1DC TI TTZJYKH DM5E1DC TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5E1DC MA Inhibitor DM5E1DC RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DM5E1DC RU https://pubmed.ncbi.nlm.nih.gov/17067170 DM5E21C DI DM5E21C DM5E21C DN CASUARIIN DM5E21C TI TTCIHJA DM5E21C TN Coagulation factor Xa (F10) DM5E21C MA Inhibitor DM5E21C RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DM5E21C RU https://pubmed.ncbi.nlm.nih.gov/9834152 DM5E21C DI DM5E21C DM5E21C DN CASUARIIN DM5E21C TI TT6L509 DM5E21C TN Coagulation factor IIa (F2) DM5E21C MA Inhibitor DM5E21C RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DM5E21C RU https://pubmed.ncbi.nlm.nih.gov/9834152 DM5E74G DI DM5E74G DM5E74G DN 2-Phenoxymethyl-4,5-dihydro-1H-imidazole DM5E74G TI TTGP7BY DM5E74G TN Monoamine oxidase type B (MAO-B) DM5E74G MA Inhibitor DM5E74G RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM5E74G RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM5E74G DI DM5E74G DM5E74G DN 2-Phenoxymethyl-4,5-dihydro-1H-imidazole DM5E74G TI TT3WG5C DM5E74G TN Monoamine oxidase type A (MAO-A) DM5E74G MA Inhibitor DM5E74G RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DM5E74G RU https://pubmed.ncbi.nlm.nih.gov/14698196 DM5E7OC DI DM5E7OC DM5E7OC DN N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide DM5E7OC TI TTANPDJ DM5E7OC TN Carbonic anhydrase II (CA-II) DM5E7OC MA Inhibitor DM5E7OC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DM5E7OC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DM5E7OC DI DM5E7OC DM5E7OC DN N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide DM5E7OC TI TTZHA0O DM5E7OC TN Carbonic anhydrase IV (CA-IV) DM5E7OC MA Inhibitor DM5E7OC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DM5E7OC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DM5E7OC DI DM5E7OC DM5E7OC DN N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide DM5E7OC TI TTUNARX DM5E7OC TN Carbonic anhydrase (CA) DM5E7OC MA Inhibitor DM5E7OC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DM5E7OC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DM5E7OC DI DM5E7OC DM5E7OC DN N-(5-tert-butyl-1,3,4-thiadiazol-2-yl)sulfamide DM5E7OC TI TTHQPL7 DM5E7OC TN Carbonic anhydrase I (CA-I) DM5E7OC MA Inhibitor DM5E7OC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DM5E7OC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DM5ECDM DI DM5ECDM DM5ECDM DN AGN-34 DM5ECDM TI TTS4UGC DM5ECDM TN Farnesoid X-activated receptor (FXR) DM5ECDM MA Inhibitor DM5ECDM RN Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403. DM5ECDM RU https://pubmed.ncbi.nlm.nih.gov/16107136 DM5ECDM DI DM5ECDM DM5ECDM DN AGN-34 DM5ECDM TI TTH029C DM5ECDM TN Retinoic acid receptor RXR-gamma (RXRG) DM5ECDM MA Inhibitor DM5ECDM RN Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403. DM5ECDM RU https://pubmed.ncbi.nlm.nih.gov/16107136 DM5ECDM DI DM5ECDM DM5ECDM DN AGN-34 DM5ECDM TI TT6PEUO DM5ECDM TN Retinoic acid receptor RXR-alpha (RXRA) DM5ECDM MA Inhibitor DM5ECDM RN Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403. DM5ECDM RU https://pubmed.ncbi.nlm.nih.gov/16107136 DM5ECDM DI DM5ECDM DM5ECDM DN AGN-34 DM5ECDM TI TTKLV96 DM5ECDM TN Retinoic acid receptor RXR-beta (RXRB) DM5ECDM MA Inhibitor DM5ECDM RN Farnesoid X receptor: from structure to potential clinical applications. J Med Chem. 2005 Aug 25;48(17):5383-403. DM5ECDM RU https://pubmed.ncbi.nlm.nih.gov/16107136 DM5EF71 DI DM5EF71 DM5EF71 DN N-(2,6-diphenylpyrimidin-4-yl)butyramide DM5EF71 TI TTJFY5U DM5EF71 TN Adenosine A3 receptor (ADORA3) DM5EF71 MA Inhibitor DM5EF71 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM5EF71 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM5EF71 DI DM5EF71 DM5EF71 DN N-(2,6-diphenylpyrimidin-4-yl)butyramide DM5EF71 TI TTM2AOE DM5EF71 TN Adenosine A2a receptor (ADORA2A) DM5EF71 MA Inhibitor DM5EF71 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM5EF71 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM5EF71 DI DM5EF71 DM5EF71 DN N-(2,6-diphenylpyrimidin-4-yl)butyramide DM5EF71 TI TTK25J1 DM5EF71 TN Adenosine A1 receptor (ADORA1) DM5EF71 MA Inhibitor DM5EF71 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM5EF71 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM5EJLD DI DM5EJLD DM5EJLD DN 3-[2-(5-Chloro-2-thienyl)pyridin-4-yl]phenol DM5EJLD TI TTIWB6L DM5EJLD TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM5EJLD MA Inhibitor DM5EJLD RN Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505. DM5EJLD RU https://pubmed.ncbi.nlm.nih.gov/20413314 DM5EKF4 DI DM5EKF4 DM5EKF4 DN (4S,5S)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine DM5EKF4 TI TTF10I9 DM5EKF4 TN Nitric-oxide synthase inducible (NOS2) DM5EKF4 MA Inhibitor DM5EKF4 RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM5EKF4 RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM5EO3F DI DM5EO3F DM5EO3F DN GSK-334429 DM5EO3F TI TT9JNIC DM5EO3F TN Histamine H3 receptor (H3R) DM5EO3F MA Antagonist DM5EO3F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DM5EO3F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DM5EP3V DI DM5EP3V DM5EP3V DN 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide DM5EP3V TI TT2LVK8 DM5EP3V TN Carbonic anhydrase IX (CA-IX) DM5EP3V MA Inhibitor DM5EP3V RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DM5EP3V RU https://pubmed.ncbi.nlm.nih.gov/19773173 DM5EP3V DI DM5EP3V DM5EP3V DN 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide DM5EP3V TI TTSYM0R DM5EP3V TN Carbonic anhydrase XII (CA-XII) DM5EP3V MA Inhibitor DM5EP3V RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DM5EP3V RU https://pubmed.ncbi.nlm.nih.gov/19773173 DM5EP3V DI DM5EP3V DM5EP3V DN 4-((4-hydroxyphenyl)diazenyl)benzenesulfonamide DM5EP3V TI TTANPDJ DM5EP3V TN Carbonic anhydrase II (CA-II) DM5EP3V MA Inhibitor DM5EP3V RN Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32. DM5EP3V RU https://pubmed.ncbi.nlm.nih.gov/19651511 DM5EQ7F DI DM5EQ7F DM5EQ7F DN MK-3901 DM5EQ7F TI TT2THBD DM5EQ7F TN P2X purinoceptor 3 (P2RX3) DM5EQ7F MA Antagonist DM5EQ7F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 480). DM5EQ7F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=480 DM5EQJU DI DM5EQJU DM5EQJU DN 7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM5EQJU TI TT06AWU DM5EQJU TN Phosphodiesterase 3A (PDE3A) DM5EQJU MA Inhibitor DM5EQJU RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DM5EQJU RU https://pubmed.ncbi.nlm.nih.gov/1654430 DM5ETL9 DI DM5ETL9 DM5ETL9 DN 2-[3-(Pyridin-4-yloxy)-benzoylamino]-benzoic acid DM5ETL9 TI TTRVTMX DM5ETL9 TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DM5ETL9 MA Inhibitor DM5ETL9 RN Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609. DM5ETL9 RU https://pubmed.ncbi.nlm.nih.gov/15743201 DM5EWIK DI DM5EWIK DM5EWIK DN NEODYSIDENIN DM5EWIK TI TT12ABZ DM5EWIK TN Arachidonate 12-lipoxygenase (12-LOX) DM5EWIK MA Inhibitor DM5EWIK RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DM5EWIK RU https://pubmed.ncbi.nlm.nih.gov/17826100 DM5EWQN DI DM5EWQN DM5EWQN DN SB-210313 DM5EWQN TI TTVG215 DM5EWQN TN Debrisoquine 4-hydroxylase (CYP2D6) DM5EWQN MA Inhibitor DM5EWQN RN Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6. DM5EWQN RU https://pubmed.ncbi.nlm.nih.gov/9873686 DM5F04D DI DM5F04D DM5F04D DN N1-(3,3-diphenylpropyl)-N3-hydroxymalonamide DM5F04D TI TTPHMWB DM5F04D TN Aminopeptidase N (ANPEP) DM5F04D MA Inhibitor DM5F04D RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DM5F04D RU https://pubmed.ncbi.nlm.nih.gov/17326615 DM5F13I DI DM5F13I DM5F13I DN 4-(3-Phenoxy-propyl)-1H-imidazole DM5F13I TI TT9JNIC DM5F13I TN Histamine H3 receptor (H3R) DM5F13I MA Inhibitor DM5F13I RN Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):951-4. DM5F13I RU https://pubmed.ncbi.nlm.nih.gov/11294398 DM5F27T DI DM5F27T DM5F27T DN N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX) DM5F27T TI TT6OEDT DM5F27T TN Cannabinoid receptor 1 (CB1) DM5F27T MA Inhibitor DM5F27T RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM5F27T RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM5F27T DI DM5F27T DM5F27T DN N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXY-2-METHYLPROPANAMIDE (ENANTIOMERIC MIX) DM5F27T TI TTMSFAW DM5F27T TN Cannabinoid receptor 2 (CB2) DM5F27T MA Inhibitor DM5F27T RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM5F27T RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM5F4Q6 DI DM5F4Q6 DM5F4Q6 DN ISIS 112023 DM5F4Q6 TI TTPJ9XK DM5F4Q6 TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DM5F4Q6 RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DM5F4Q6 RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DM5FA74 DI DM5FA74 DM5FA74 DN 5-[5-Methoxy-indan-(1E)-ylidenemethyl]-thiazole DM5FA74 TI TTSZLWK DM5FA74 TN Aromatase (CYP19A1) DM5FA74 MA Inhibitor DM5FA74 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM5FA74 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM5FAUY DI DM5FAUY DM5FAUY DN JWH-292 DM5FAUY TI TT6OEDT DM5FAUY TN Cannabinoid receptor 1 (CB1) DM5FAUY MA Inhibitor DM5FAUY RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM5FAUY RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM5FAUY DI DM5FAUY DM5FAUY DN JWH-292 DM5FAUY TI TTMSFAW DM5FAUY TN Cannabinoid receptor 2 (CB2) DM5FAUY MA Inhibitor DM5FAUY RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM5FAUY RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM5FHO4 DI DM5FHO4 DM5FHO4 DN 2-Tosylnaphthalene-1,4-diol DM5FHO4 TI TTRVTMX DM5FHO4 TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DM5FHO4 MA Inhibitor DM5FHO4 RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DM5FHO4 RU https://pubmed.ncbi.nlm.nih.gov/18996691 DM5FQH8 DI DM5FQH8 DM5FQH8 DN N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]lauramide DM5FQH8 TI TTMI6F5 DM5FQH8 TN Transient receptor potential cation channel V1 (TRPV1) DM5FQH8 MA Inhibitor DM5FQH8 RN New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69. DM5FQH8 RU https://pubmed.ncbi.nlm.nih.gov/18027904 DM5FRV2 DI DM5FRV2 DM5FRV2 DN 4'-Methoxy-5,3'-dipropyl-biphenyl-2ol DM5FRV2 TI TTSJ6Q4 DM5FRV2 TN LOX-5 messenger RNA (ALOX5 mRNA) DM5FRV2 MA Inhibitor DM5FRV2 RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DM5FRV2 RU https://pubmed.ncbi.nlm.nih.gov/19481465 DM5FRV2 DI DM5FRV2 DM5FRV2 DN 4'-Methoxy-5,3'-dipropyl-biphenyl-2ol DM5FRV2 TI TT8NGED DM5FRV2 TN Prostaglandin G/H synthase 1 (COX-1) DM5FRV2 MA Inhibitor DM5FRV2 RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DM5FRV2 RU https://pubmed.ncbi.nlm.nih.gov/19481465 DM5FRXN DI DM5FRXN DM5FRXN DN FGGFTGARKSARKYANQ DM5FRXN TI TTNT7K8 DM5FRXN TN Nociceptin receptor (OPRL1) DM5FRXN MA Inhibitor DM5FRXN RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DM5FRXN RU https://pubmed.ncbi.nlm.nih.gov/18818087 DM5FWYG DI DM5FWYG DM5FWYG DN 4-Methyl-3,6-dihydro-1H-pyridin-(2Z)-ylideneamine DM5FWYG TI TTCM4B3 DM5FWYG TN Nitric-oxide synthase endothelial (NOS3) DM5FWYG MA Inhibitor DM5FWYG RN Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4. DM5FWYG RU https://pubmed.ncbi.nlm.nih.gov/12161118 DM5FZBI DI DM5FZBI DM5FZBI DN 6-iodo-4'-hydroxyflavone DM5FZBI TI TTE4KHA DM5FZBI TN Amyloid beta A4 protein (APP) DM5FZBI MA Inhibitor DM5FZBI RN Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60. DM5FZBI RU https://pubmed.ncbi.nlm.nih.gov/16279784 DM5FZDI DI DM5FZDI DM5FZDI DN 6-Chloro-2-phenyl-chromen-4-one DM5FZDI TI TT1MPAY DM5FZDI TN GABA(A) receptor alpha-1 (GABRA1) DM5FZDI MA Inhibitor DM5FZDI RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM5FZDI RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM5FZDI DI DM5FZDI DM5FZDI DN 6-Chloro-2-phenyl-chromen-4-one DM5FZDI TI TTNJYV2 DM5FZDI TN Gamma-aminobutyric acid receptor (GAR) DM5FZDI MA Inhibitor DM5FZDI RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM5FZDI RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM5G0IM DI DM5G0IM DM5G0IM DN JMV180 DM5G0IM TI TTCG0AL DM5G0IM TN Cholecystokinin receptor type A (CCKAR) DM5G0IM MA Agonist DM5G0IM RN Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. Biochem Biophys Res Commun. 1995 Aug 24;213(3):845-52. DM5G0IM RU https://pubmed.ncbi.nlm.nih.gov/7654246 DM5G1RP DI DM5G1RP DM5G1RP DN PMID24793972C2 DM5G1RP TI TTMRQY1 DM5G1RP TN Striatum-specific G-protein coupled receptor (GPR88) DM5G1RP MA Agonist DM5G1RP RN Synthesis, pharmacological characterization, and structure-activity relationship studies of small molecular agonists for the orphan GPR88 receptor. ACS Chem Neurosci. 2014 Jul 16;5(7):576-87. DM5G1RP RU https://pubmed.ncbi.nlm.nih.gov/24793972 DM5G1SF DI DM5G1SF DM5G1SF DN ELND-007 DM5G1SF TI TTE4KHA DM5G1SF TN Amyloid beta A4 protein (APP) DM5G1SF MA Inhibitor DM5G1SF RN Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease Volume 82, October 2015, Pages 385-396. DM5G1SF RU http://www.sciencedirect.com/science/article/pii/S096999611530022X DM5G307 DI DM5G307 DM5G307 DN LFA703 DM5G307 TI TT48WR6 DM5G307 TN Integrin alpha-L (ITGAL) DM5G307 MA Inhibitor DM5G307 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5G307 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5G3NU DI DM5G3NU DM5G3NU DN 4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine DM5G3NU TI TTF10I9 DM5G3NU TN Nitric-oxide synthase inducible (NOS2) DM5G3NU MA Inhibitor DM5G3NU RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM5G3NU RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM5G3NU DI DM5G3NU DM5G3NU DN 4-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine DM5G3NU TI TTZUFI5 DM5G3NU TN Nitric-oxide synthase brain (NOS1) DM5G3NU MA Inhibitor DM5G3NU RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM5G3NU RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM5G4O7 DI DM5G4O7 DM5G4O7 DN DI-O-METHYLENDIANDRIN A DM5G4O7 TI TTOZRK6 DM5G4O7 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM5G4O7 MA Inhibitor DM5G4O7 RN Endiandrin A, a potent glucocorticoid receptor binder isolated from the Australian plant Endiandra anthropophagorum. J Nat Prod. 2007 Jul;70(7):1118-21. DM5G4O7 RU https://pubmed.ncbi.nlm.nih.gov/17583952 DM5G91Z DI DM5G91Z DM5G91Z DN Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate DM5G91Z TI TT37EDJ DM5G91Z TN GABA(A) receptor alpha-3 (GABRA3) DM5G91Z MA Inhibitor DM5G91Z RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM5G91Z RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM5G91Z DI DM5G91Z DM5G91Z DN Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate DM5G91Z TI TTBMV1G DM5G91Z TN GABA(A) receptor alpha-2 (GABRA2) DM5G91Z MA Inhibitor DM5G91Z RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM5G91Z RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM5G91Z DI DM5G91Z DM5G91Z DN Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate DM5G91Z TI TT1MPAY DM5G91Z TN GABA(A) receptor alpha-1 (GABRA1) DM5G91Z MA Inhibitor DM5G91Z RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM5G91Z RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM5G91Z DI DM5G91Z DM5G91Z DN Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate DM5G91Z TI TTNJYV2 DM5G91Z TN Gamma-aminobutyric acid receptor (GAR) DM5G91Z MA Inhibitor DM5G91Z RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM5G91Z RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM5G91Z DI DM5G91Z DM5G91Z DN Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate DM5G91Z TI TT06RH5 DM5G91Z TN GABA(A) receptor gamma-2 (GABRG2) DM5G91Z MA Inhibitor DM5G91Z RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM5G91Z RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM5G91Z DI DM5G91Z DM5G91Z DN Ethyl 6-iodo-9H-pyrido[3,4-b]indole-3-carboxylate DM5G91Z TI TTNZPQ1 DM5G91Z TN GABA(A) receptor alpha-5 (GABRA5) DM5G91Z MA Inhibitor DM5G91Z RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM5G91Z RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM5GAOZ DI DM5GAOZ DM5GAOZ DN 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide DM5GAOZ TI TT0K6EO DM5GAOZ TN Stress-activated protein kinase JNK1 (JNK1) DM5GAOZ MA Inhibitor DM5GAOZ RN Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. DM5GAOZ RU https://pubmed.ncbi.nlm.nih.gov/17107797 DM5GELS DI DM5GELS DM5GELS DN 1-Methyl-2-Oxy-5,5-Dimethyl Pyrrolidine DM5GELS TI TTB2MXP DM5GELS TN Angiotensinogenase renin (REN) DM5GELS MA Inhibitor DM5GELS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5GELS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5GEUN DI DM5GEUN DM5GEUN DN ERYTHRIBYSSIN A DM5GEUN TI TTELIN2 DM5GEUN TN PTPN1 messenger RNA (PTPN1 mRNA) DM5GEUN MA Inhibitor DM5GEUN RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DM5GEUN RU https://pubmed.ncbi.nlm.nih.gov/19836230 DM5GILS DI DM5GILS DM5GILS DN Sri-9439 DM5GILS TI TT9SL3Q DM5GILS TN Polypeptide deformylase (PDF) DM5GILS MA Inhibitor DM5GILS RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM5GILS RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM5GIUY DI DM5GIUY DM5GIUY DN RXP-470 DM5GIUY TI TTXZ0KQ DM5GIUY TN Matrix metalloproteinase-12 (MMP-12) DM5GIUY MA Inhibitor DM5GIUY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636). DM5GIUY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636 DM5GL23 DI DM5GL23 DM5GL23 DN PMID25408830C1 DM5GL23 TI TTRA6BO DM5GL23 TN Bromodomain-containing protein 4 (BRD4) DM5GL23 MA Inhibitor DM5GL23 RN 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5. DM5GL23 RU https://pubmed.ncbi.nlm.nih.gov/25408830 DM5GL23 DI DM5GL23 DM5GL23 DN PMID25408830C1 DM5GL23 TI TTT46BN DM5GL23 TN Bromodomain and PHD finger containing 1 (BRPF1) DM5GL23 MA Inhibitor DM5GL23 RN 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5. DM5GL23 RU https://pubmed.ncbi.nlm.nih.gov/25408830 DM5GLJ2 DI DM5GLJ2 DM5GLJ2 DN D-257C DM5GLJ2 TI TTAWNKZ DM5GLJ2 TN Norepinephrine transporter (NET) DM5GLJ2 MA Inhibitor DM5GLJ2 RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM5GLJ2 RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM5GLJ2 DI DM5GLJ2 DM5GLJ2 DN D-257C DM5GLJ2 TI TTVBI8W DM5GLJ2 TN Dopamine transporter (DAT) DM5GLJ2 MA Inhibitor DM5GLJ2 RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM5GLJ2 RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM5GLJ2 DI DM5GLJ2 DM5GLJ2 DN D-257C DM5GLJ2 TI TT3ROYC DM5GLJ2 TN Serotonin transporter (SERT) DM5GLJ2 MA Inhibitor DM5GLJ2 RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM5GLJ2 RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM5GLP7 DI DM5GLP7 DM5GLP7 DN Ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate DM5GLP7 TI TTD0652 DM5GLP7 TN Proteinase activated receptor 4 (F2RL3) DM5GLP7 MA Inhibitor DM5GLP7 RN Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg Med Chem. 2008 Feb 1;16(3):1262-78. DM5GLP7 RU https://pubmed.ncbi.nlm.nih.gov/17988878 DM5GMOJ DI DM5GMOJ DM5GMOJ DN NEORAUTENOL DM5GMOJ TI TTELIN2 DM5GMOJ TN PTPN1 messenger RNA (PTPN1 mRNA) DM5GMOJ MA Inhibitor DM5GMOJ RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DM5GMOJ RU https://pubmed.ncbi.nlm.nih.gov/19836230 DM5GMOJ DI DM5GMOJ DM5GMOJ DN NEORAUTENOL DM5GMOJ TI TT50QJ3 DM5GMOJ TN Influenza Neuraminidase (Influ NA) DM5GMOJ MA Inhibitor DM5GMOJ RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DM5GMOJ RU https://pubmed.ncbi.nlm.nih.gov/20363636 DM5GN46 DI DM5GN46 DM5GN46 DN (3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid DM5GN46 TI TTGER3L DM5GN46 TN Thyroid hormone receptor beta (THRB) DM5GN46 MA Inhibitor DM5GN46 RN Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7. DM5GN46 RU https://pubmed.ncbi.nlm.nih.gov/15857115 DM5GN46 DI DM5GN46 DM5GN46 DN (3,5-Dibromo-4-hexyloxy-phenyl)-acetic acid DM5GN46 TI TTTSEPU DM5GN46 TN Thyroid hormone receptor alpha (THRA) DM5GN46 MA Inhibitor DM5GN46 RN Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7. DM5GN46 RU https://pubmed.ncbi.nlm.nih.gov/15857115 DM5GNFO DI DM5GNFO DM5GNFO DN LAWSARITOL DM5GNFO TI TTEB0GD DM5GNFO TN Cholinesterase (BCHE) DM5GNFO MA Inhibitor DM5GNFO RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DM5GNFO RU https://pubmed.ncbi.nlm.nih.gov/16274989 DM5GNFO DI DM5GNFO DM5GNFO DN LAWSARITOL DM5GNFO TI TT1RS9F DM5GNFO TN Acetylcholinesterase (AChE) DM5GNFO MA Inhibitor DM5GNFO RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DM5GNFO RU https://pubmed.ncbi.nlm.nih.gov/16274989 DM5GSXC DI DM5GSXC DM5GSXC DN [Mpa1, D-Tyr(Et)2, D-Tic7, Aib9]OT DM5GSXC TI TTSCIUP DM5GSXC TN Oxytocin receptor (OTR) DM5GSXC MA Inhibitor DM5GSXC RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DM5GSXC RU https://pubmed.ncbi.nlm.nih.gov/17316912 DM5GTHE DI DM5GTHE DM5GTHE DN PD 154740 DM5GTHE TI TTBPGLU DM5GTHE TN Neuromedin-K receptor (TACR3) DM5GTHE MA Antagonist DM5GTHE RN Two classes of structurally different antagonists display similar species preference for the human tachykinin neurokinin3 receptor. Mol Pharmacol. 1995 Oct;48(4):711-6. DM5GTHE RU https://pubmed.ncbi.nlm.nih.gov/7476898 DM5GVZJ DI DM5GVZJ DM5GVZJ DN PEG-EPO DM5GVZJ TI TTAUX24 DM5GVZJ TN Erythropoietin Receptor (EPOR) DM5GVZJ MA Stimulator DM5GVZJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DM5GVZJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DM5GXIS DI DM5GXIS DM5GXIS DN N-methylbicuculline DM5GXIS TI TTAN6JD DM5GXIS TN Glutamate receptor AMPA (GRIA) DM5GXIS MA Antagonist DM5GXIS RN GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. Br J Pharmacol. 2001 Oct;134(4):896-904. DM5GXIS RU https://pubmed.ncbi.nlm.nih.gov/11606331 DM5GY6Z DI DM5GY6Z DM5GY6Z DN PH-709829 DM5GY6Z TI TTPC4TU DM5GY6Z TN 5-HT 3A receptor (HTR3A) DM5GY6Z MA Inhibitor DM5GY6Z RN Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor:... Bioorg Med Chem Lett. 2008 Jun 15;18(12):3611-5. DM5GY6Z RU https://pubmed.ncbi.nlm.nih.gov/18490160 DM5GY6Z DI DM5GY6Z DM5GY6Z DN PH-709829 DM5GY6Z TI TTLA931 DM5GY6Z TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM5GY6Z MA Inhibitor DM5GY6Z RN Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor:... Bioorg Med Chem Lett. 2008 Jun 15;18(12):3611-5. DM5GY6Z RU https://pubmed.ncbi.nlm.nih.gov/18490160 DM5H4KE DI DM5H4KE DM5H4KE DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DM5H4KE TI TTMSFAW DM5H4KE TN Cannabinoid receptor 2 (CB2) DM5H4KE MA Inhibitor DM5H4KE RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM5H4KE RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM5H4KE DI DM5H4KE DM5H4KE DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(1-HYDROXY-2-METHYLPROPAN-2-YL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DM5H4KE TI TT6OEDT DM5H4KE TN Cannabinoid receptor 1 (CB1) DM5H4KE MA Inhibitor DM5H4KE RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DM5H4KE RU https://pubmed.ncbi.nlm.nih.gov/20483606 DM5H73W DI DM5H73W DM5H73W DN 10-Hydroxy-infractopicrin DM5H73W TI TT1RS9F DM5H73W TN Acetylcholinesterase (AChE) DM5H73W MA Inhibitor DM5H73W RN Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg Med Chem. 2010 Mar 15;18(6):2173-2177. DM5H73W RU https://pubmed.ncbi.nlm.nih.gov/20176490 DM5H9QT DI DM5H9QT DM5H9QT DN 3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol DM5H9QT TI TTZAYWL DM5H9QT TN Estrogen receptor (ESR) DM5H9QT MA Inhibitor DM5H9QT RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM5H9QT RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM5H9QT DI DM5H9QT DM5H9QT DN 3-(6-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol DM5H9QT TI TTOM3J0 DM5H9QT TN Estrogen receptor beta (ESR2) DM5H9QT MA Inhibitor DM5H9QT RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM5H9QT RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM5HEIR DI DM5HEIR DM5HEIR DN TDI-0079 DM5HEIR TI TT6RVLG DM5HEIR TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DM5HEIR MA Modulator DM5HEIR RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DM5HEIR RU https://pubmed.ncbi.nlm.nih.gov/16914587 DM5HRNM DI DM5HRNM DM5HRNM DN C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 DM5HRNM TI TTEOSZT DM5HRNM TN Melanocortin receptor (MCR) DM5HRNM MA Inhibitor DM5HRNM RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM5HRNM RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM5HRNM DI DM5HRNM DM5HRNM DN C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 DM5HRNM TI TTNI91K DM5HRNM TN Melanocortin receptor 3 (MC3R) DM5HRNM MA Inhibitor DM5HRNM RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM5HRNM RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM5HRNM DI DM5HRNM DM5HRNM DN C[Nle-His-D-Phe-Arg-Trp-Glu]-NH2 DM5HRNM TI TTD0CIQ DM5HRNM TN Melanocortin receptor 4 (MC4R) DM5HRNM MA Inhibitor DM5HRNM RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM5HRNM RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM5HUY0 DI DM5HUY0 DM5HUY0 DN SP2456 DM5HUY0 TI TTF89GD DM5HUY0 TN Interleukin-2 (IL2) DM5HUY0 MA Inhibitor DM5HUY0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5HUY0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5HV4W DI DM5HV4W DM5HV4W DN Rolicyclidine DM5HV4W TI TTEX248 DM5HV4W TN Dopamine D2 receptor (D2R) DM5HV4W MA Inhibitor DM5HV4W RN 4-Acetoxy-7-chloro-3-(3-(-4-[11C]methoxybenzyl)phenyl)-2(1H)-quinolone Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. DM5HV4W RU https://pubmed.ncbi.nlm.nih.gov/20641908 DM5HWZY DI DM5HWZY DM5HWZY DN Hydroxyalanine DM5HWZY TI TTBFROQ DM5HWZY TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DM5HWZY MA Inhibitor DM5HWZY RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM5HWZY RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM5I6O2 DI DM5I6O2 DM5I6O2 DN 4-(3-methylpyridin-2-yl)-N-p-tolylbenzamide DM5I6O2 TI TTMI6F5 DM5I6O2 TN Transient receptor potential cation channel V1 (TRPV1) DM5I6O2 MA Inhibitor DM5I6O2 RN From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5217-21. DM5I6O2 RU https://pubmed.ncbi.nlm.nih.gov/16870426 DM5I7PL DI DM5I7PL DM5I7PL DN MRS1706 DM5I7PL TI TTNE7KG DM5I7PL TN Adenosine A2b receptor (ADORA2B) DM5I7PL MA Antagonist DM5I7PL RN Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72. DM5I7PL RU https://pubmed.ncbi.nlm.nih.gov/10737749 DM5IA9W DI DM5IA9W DM5IA9W DN droxinostat DM5IA9W TI TT4YWTO DM5IA9W TN Histone deacetylase 3 (HDAC3) DM5IA9W MA Inhibitor DM5IA9W RN Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56. DM5IA9W RU https://pubmed.ncbi.nlm.nih.gov/20053768 DM5IA9W DI DM5IA9W DM5IA9W DN droxinostat DM5IA9W TI TTT6LFV DM5IA9W TN Histone deacetylase 8 (HDAC8) DM5IA9W MA Inhibitor DM5IA9W RN Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56. DM5IA9W RU https://pubmed.ncbi.nlm.nih.gov/20053768 DM5IA9W DI DM5IA9W DM5IA9W DN droxinostat DM5IA9W TI TT5ZKDI DM5IA9W TN Histone deacetylase 6 (HDAC6) DM5IA9W MA Inhibitor DM5IA9W RN Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010 Jan;9(1):246-56. DM5IA9W RU https://pubmed.ncbi.nlm.nih.gov/20053768 DM5IAXN DI DM5IAXN DM5IAXN DN L-739758 DM5IAXN TI TTJA1ZO DM5IAXN TN ITGB3 messenger RNA (ITGB3 mRNA) DM5IAXN MA Inhibitor DM5IAXN RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DM5IAXN RU https://pubmed.ncbi.nlm.nih.gov/10999999 DM5IG4F DI DM5IG4F DM5IG4F DN PPG DM5IG4F TI TT0I76D DM5IG4F TN Metabotropic glutamate receptor 7 (mGluR7) DM5IG4F MA Agonist DM5IG4F RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DM5IG4F RU https://pubmed.ncbi.nlm.nih.gov/11138847 DM5IGN7 DI DM5IGN7 DM5IGN7 DN OSI-75 DM5IGN7 TI TTGKNB4 DM5IGN7 TN Epidermal growth factor receptor (EGFR) DM5IGN7 MA Inhibitor DM5IGN7 RN Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37. DM5IGN7 RU https://pubmed.ncbi.nlm.nih.gov/11743214 DM5IGOL DI DM5IGOL DM5IGOL DN 8-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM5IGOL TI TT06AWU DM5IGOL TN Phosphodiesterase 3A (PDE3A) DM5IGOL MA Inhibitor DM5IGOL RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DM5IGOL RU https://pubmed.ncbi.nlm.nih.gov/1654430 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TTDLNGZ DM5IHYP TN Glucokinase (GCK) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TTVTX4N DM5IHYP TN Bacterial Fatty acid synthetase I (Bact inhA) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TT8NGED DM5IHYP TN Prostaglandin G/H synthase 1 (COX-1) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TTNX2CS DM5IHYP TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TTZHY6R DM5IHYP TN Glycogen phosphorylase muscle form (GP) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TTCGSZ4 DM5IHYP TN Pancreatic alpha-amylase (AMY2A) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TTHCF4J DM5IHYP TN Alpha-glucosidase (GLA) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IHYP DI DM5IHYP DM5IHYP DN Beta-D-Glucose DM5IHYP TI TTUTN1I DM5IHYP TN Human Deoxyribonucleic acid (hDNA) DM5IHYP MA Inhibitor DM5IHYP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5IHYP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5IJSW DI DM5IJSW DM5IJSW DN 2,5-imino-2,5,6-trideoxy-D-manno-heptitol DM5IJSW TI TTLPC70 DM5IJSW TN Lysosomal alpha-glucosidase (GAA) DM5IJSW MA Inhibitor DM5IJSW RN Nitrogen-containing furanose and pyranose analogues from Hyacinthus orientalis. J Nat Prod. 1998 May;61(5):625-8. DM5IJSW RU https://pubmed.ncbi.nlm.nih.gov/9599261 DM5ILK1 DI DM5ILK1 DM5ILK1 DN (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM5ILK1 TI TTAWNKZ DM5ILK1 TN Norepinephrine transporter (NET) DM5ILK1 MA Inhibitor DM5ILK1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM5ILK1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM5ILK1 DI DM5ILK1 DM5ILK1 DN (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM5ILK1 TI TTQ6VDM DM5ILK1 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM5ILK1 MA Inhibitor DM5ILK1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM5ILK1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM5ILK1 DI DM5ILK1 DM5ILK1 DN (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM5ILK1 TI TTVBI8W DM5ILK1 TN Dopamine transporter (DAT) DM5ILK1 MA Inhibitor DM5ILK1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM5ILK1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM5ILK1 DI DM5ILK1 DM5ILK1 DN (S)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM5ILK1 TI TT3ROYC DM5ILK1 TN Serotonin transporter (SERT) DM5ILK1 MA Inhibitor DM5ILK1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM5ILK1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM5ISQK DI DM5ISQK DM5ISQK DN Correloid DM5ISQK TI TTY3UE6 DM5ISQK TN Voltage-gated potassium channel Kv1.3 (KCNA3) DM5ISQK MA Inhibitor DM5ISQK RN Potent Kv1.3 inhibitors from correolide-modification of the C18 position. Bioorg Med Chem Lett. 2005 Jan 17;15(2):447-51. DM5ISQK RU https://pubmed.ncbi.nlm.nih.gov/15603971 DM5IXOS DI DM5IXOS DM5IXOS DN RP-52770 DM5IXOS TI TTQL5VC DM5IXOS TN Platelet-activating factor receptor (PTAFR) DM5IXOS MA Antagonist DM5IXOS RN [3H]52770 RP, a platelet-activating factor receptor antagonist, and tritiated platelet-activating factor label a common specific binding site in human polymorphonuclear leukocytes. J Pharmacol Exp Ther. 1988 Feb;244(2):709-15. DM5IXOS RU https://pubmed.ncbi.nlm.nih.gov/2831350 DM5J0H3 DI DM5J0H3 DM5J0H3 DN Propan-2-one O-4-(hexyloxy)phenylcarbamoyl oxime DM5J0H3 TI TTDP1UC DM5J0H3 TN Fatty acid amide hydrolase (FAAH) DM5J0H3 MA Inhibitor DM5J0H3 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM5J0H3 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM5J1TX DI DM5J1TX DM5J1TX DN 3-Chloroboldine DM5J1TX TI TTZFYLI DM5J1TX TN Dopamine D1 receptor (D1R) DM5J1TX MA Inhibitor DM5J1TX RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DM5J1TX RU https://pubmed.ncbi.nlm.nih.gov/10785418 DM5J1TX DI DM5J1TX DM5J1TX DN 3-Chloroboldine DM5J1TX TI TTEX248 DM5J1TX TN Dopamine D2 receptor (D2R) DM5J1TX MA Inhibitor DM5J1TX RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DM5J1TX RU https://pubmed.ncbi.nlm.nih.gov/10785418 DM5J4NA DI DM5J4NA DM5J4NA DN PD 165929 DM5J4NA TI TTHYDUM DM5J4NA TN Bombesin receptor (BS) DM5J4NA MA Antagonist DM5J4NA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 38). DM5J4NA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=38 DM5J6IT DI DM5J6IT DM5J6IT DN 2-morpholino-4H-benzo[g]chromen-4-one DM5J6IT TI TTK3PY9 DM5J6IT TN DNA-dependent protein kinase catalytic (PRKDC) DM5J6IT MA Inhibitor DM5J6IT RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DM5J6IT RU https://pubmed.ncbi.nlm.nih.gov/16302822 DM5J7O8 DI DM5J7O8 DM5J7O8 DN 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol DM5J7O8 TI TTLD29N DM5J7O8 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM5J7O8 MA Inhibitor DM5J7O8 RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DM5J7O8 RU https://pubmed.ncbi.nlm.nih.gov/9719603 DM5J7O8 DI DM5J7O8 DM5J7O8 DN 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol DM5J7O8 TI TTN9D8E DM5J7O8 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM5J7O8 MA Inhibitor DM5J7O8 RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DM5J7O8 RU https://pubmed.ncbi.nlm.nih.gov/9719603 DM5J7O8 DI DM5J7O8 DM5J7O8 DN 4-[2-(5-Phenyl-pentylamino)-ethyl]-phenol DM5J7O8 TI TTKJEMQ DM5J7O8 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM5J7O8 MA Inhibitor DM5J7O8 RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DM5J7O8 RU https://pubmed.ncbi.nlm.nih.gov/9719603 DM5JB9D DI DM5JB9D DM5JB9D DN 6-methoxykaempferol 3-O-beta-D-robinobioside DM5JB9D TI TTFBNVI DM5JB9D TN Aldose reductase (AKR1B1) DM5JB9D MA Inhibitor DM5JB9D RN Flavonoids with anti-cataract activity from Brickellia arguta. J Nat Prod. 1984 Mar-Apr;47(2):316-9. DM5JB9D RU https://pubmed.ncbi.nlm.nih.gov/6429283 DM5JDYO DI DM5JDYO DM5JDYO DN 4-(1H-IMIDAZOL-1-YL)PHENOL DM5JDYO TI TTF10I9 DM5JDYO TN Nitric-oxide synthase inducible (NOS2) DM5JDYO MA Inhibitor DM5JDYO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5JDYO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5JFKX DI DM5JFKX DM5JFKX DN DEOXY SALVINORIN A DM5JFKX TI TTQW87Y DM5JFKX TN Opioid receptor kappa (OPRK1) DM5JFKX MA Inhibitor DM5JFKX RN Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85. DM5JFKX RU https://pubmed.ncbi.nlm.nih.gov/16777411 DM5JHT6 DI DM5JHT6 DM5JHT6 DN 2-morpholin-4-yl-8-thiophen-2-ylchromen-4-one DM5JHT6 TI TTK3PY9 DM5JHT6 TN DNA-dependent protein kinase catalytic (PRKDC) DM5JHT6 MA Inhibitor DM5JHT6 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DM5JHT6 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DM5JHUN DI DM5JHUN DM5JHUN DN CHROMOTROPATE DM5JHUN TI TTELIN2 DM5JHUN TN PTPN1 messenger RNA (PTPN1 mRNA) DM5JHUN MA Inhibitor DM5JHUN RN Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6. DM5JHUN RU https://pubmed.ncbi.nlm.nih.gov/15050628 DM5JKNF DI DM5JKNF DM5JKNF DN Silvestrol DM5JKNF TI TTIGYVZ DM5JKNF TN HUMAN eukaryotic initiation factor-4A (eIF4A) DM5JKNF MA Inhibitor DM5JKNF RN Broad-spectrum antiviral activity of the eIF4A inhibitor silvestrol against corona- and picornaviruses. Antiviral Res. 2018 Feb;150:123-129. DM5JKNF RU https://pubmed.ncbi.nlm.nih.gov/29258862 DM5JN3P DI DM5JN3P DM5JN3P DN ANALOGUE A DM5JN3P TI TTTSOUD DM5JN3P TN Candida Cytochrome P450 51 (Candi ERG11) DM5JN3P MA Inhibitor DM5JN3P RN Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500. DM5JN3P RU https://pubmed.ncbi.nlm.nih.gov/17194716 DM5JSXI DI DM5JSXI DM5JSXI DN A-641359 DM5JSXI TI TT860QF DM5JSXI TN LCK tyrosine protein kinase (LCK) DM5JSXI MA Inhibitor DM5JSXI RN Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22. DM5JSXI RU https://pubmed.ncbi.nlm.nih.gov/16216497 DM5JV8G DI DM5JV8G DM5JV8G DN 7,3',4'-trihydroxyisoflavone DM5JV8G TI TTULVH8 DM5JV8G TN Tyrosinase (TYR) DM5JV8G MA Inhibitor DM5JV8G RN Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1162-4. DM5JV8G RU https://pubmed.ncbi.nlm.nih.gov/20022495 DM5JWEY DI DM5JWEY DM5JWEY DN 6-(4-Fluoro-phenylsulfanyl)-9H-purine DM5JWEY TI TTQBR95 DM5JWEY TN Stress-activated protein kinase 2a (p38 alpha) DM5JWEY MA Inhibitor DM5JWEY RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DM5JWEY RU https://pubmed.ncbi.nlm.nih.gov/15689155 DM5JZUB DI DM5JZUB DM5JZUB DN AMA DM5JZUB TI TTV9GOF DM5JZUB TN Histidine decarboxylase (HDC) DM5JZUB MA Inhibitor DM5JZUB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1274). DM5JZUB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1274 DM5K0EI DI DM5K0EI DM5K0EI DN Adamantan-1-yl-piperazin-1-yl-methanone DM5K0EI TI TTN7BL9 DM5K0EI TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM5K0EI MA Inhibitor DM5K0EI RN Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43. DM5K0EI RU https://pubmed.ncbi.nlm.nih.gov/17350260 DM5K3D2 DI DM5K3D2 DM5K3D2 DN N,N-Diethyl-1'H-phenothiazine-1'-carboxamide DM5K3D2 TI TTEB0GD DM5K3D2 TN Cholinesterase (BCHE) DM5K3D2 MA Inhibitor DM5K3D2 RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM5K3D2 RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM5K6ZE DI DM5K6ZE DM5K6ZE DN UH-232 DM5K6ZE TI TTE0A2F DM5K6ZE TN Dopamine D4 receptor (D4R) DM5K6ZE MA Inhibitor DM5K6ZE RN (Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997). DM5K6ZE RU http://www.sciencedirect.com/science/article/pii/S0960894X97100683 DM5K6ZE DI DM5K6ZE DM5K6ZE DN UH-232 DM5K6ZE TI TTEX248 DM5K6ZE TN Dopamine D2 receptor (D2R) DM5K6ZE MA Inhibitor DM5K6ZE RN (Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997). DM5K6ZE RU http://www.sciencedirect.com/science/article/pii/S0960894X97100683 DM5K6ZE DI DM5K6ZE DM5K6ZE DN UH-232 DM5K6ZE TI TTSQIFT DM5K6ZE TN 5-HT 1A receptor (HTR1A) DM5K6ZE MA Inhibitor DM5K6ZE RN (Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997). DM5K6ZE RU http://www.sciencedirect.com/science/article/pii/S0960894X97100683 DM5K6ZE DI DM5K6ZE DM5K6ZE DN UH-232 DM5K6ZE TI TT4C8EA DM5K6ZE TN Dopamine D3 receptor (D3R) DM5K6ZE MA Inhibitor DM5K6ZE RN (Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997). DM5K6ZE RU http://www.sciencedirect.com/science/article/pii/S0960894X97100683 DM5KAH6 DI DM5KAH6 DM5KAH6 DN 1-(2-Isopropoxy-phenyl)-piperazine DM5KAH6 TI TTSQIFT DM5KAH6 TN 5-HT 1A receptor (HTR1A) DM5KAH6 MA Inhibitor DM5KAH6 RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM5KAH6 RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM5KAH6 DI DM5KAH6 DM5KAH6 DN 1-(2-Isopropoxy-phenyl)-piperazine DM5KAH6 TI TT6MSOK DM5KAH6 TN 5-HT 1D receptor (HTR1D) DM5KAH6 MA Inhibitor DM5KAH6 RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM5KAH6 RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM5KFBP DI DM5KFBP DM5KFBP DN KRP-107 DM5KFBP TI TT9JZCK DM5KFBP TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM5KFBP MA Modulator DM5KFBP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275). DM5KFBP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275 DM5KGQO DI DM5KGQO DM5KGQO DN ISIS 6717 DM5KGQO TI TTAN5W2 DM5KGQO TN Raf messenger RNA (Raf mRNA) DM5KGQO RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DM5KGQO RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DM5KNCX DI DM5KNCX DM5KNCX DN N-cetylgallate DM5KNCX TI TTE14XG DM5KNCX TN Squalene monooxygenase (SQLE) DM5KNCX MA Inhibitor DM5KNCX RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DM5KNCX RU https://pubmed.ncbi.nlm.nih.gov/11520216 DM5KNMD DI DM5KNMD DM5KNMD DN spiramide DM5KNMD TI TT0K1SC DM5KNMD TN 5-HT 2B receptor (HTR2B) DM5KNMD MA Antagonist DM5KNMD RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM5KNMD RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM5KNMD DI DM5KNMD DM5KNMD DN spiramide DM5KNMD TI TTJQOD7 DM5KNMD TN 5-HT 2A receptor (HTR2A) DM5KNMD MA Antagonist DM5KNMD RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM5KNMD RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM5KNMD DI DM5KNMD DM5KNMD DN spiramide DM5KNMD TI TTWJBZ5 DM5KNMD TN 5-HT 2C receptor (HTR2C) DM5KNMD MA Antagonist DM5KNMD RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM5KNMD RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM5KO80 DI DM5KO80 DM5KO80 DN G3139 + Thalidomide DM5KO80 TI TTFOUV4 DM5KO80 TN BCL-2 messenger RNA (BCL2 mRNA) DM5KO80 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM5KO80 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM5KR4B DI DM5KR4B DM5KR4B DN 2-Chloro-5-(2-methylquinolin-7-yl)nicotinonitrile DM5KR4B TI TTHS256 DM5KR4B TN Metabotropic glutamate receptor 5 (mGluR5) DM5KR4B MA Inhibitor DM5KR4B RN Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35. DM5KR4B RU https://pubmed.ncbi.nlm.nih.gov/20382541 DM5KU8S DI DM5KU8S DM5KU8S DN 1-oleoyl glycerol DM5KU8S TI TT7QNVC DM5KU8S TN Glucose-dependent insulinotropic receptor (GPR119) DM5KU8S MA Agonist DM5KU8S RN 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab. 2011 Sep;96(9):E1409-17. DM5KU8S RU https://pubmed.ncbi.nlm.nih.gov/21778222 DM5KXFI DI DM5KXFI DM5KXFI DN NUTLIN-3 DM5KXFI TI TT7SBF5 DM5KXFI TN Cellular tumor antigen p53 (TP53) DM5KXFI MA Inhibitor DM5KXFI RN Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein intera... J Med Chem. 2009 Nov 26;52(22):7044-53. DM5KXFI RU https://pubmed.ncbi.nlm.nih.gov/19856920 DM5KXFI DI DM5KXFI DM5KXFI DN NUTLIN-3 DM5KXFI TI TT9TE0O DM5KXFI TN Mdm2 messenger RNA (MDM2 mRNA) DM5KXFI MA Inhibitor DM5KXFI RN Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature. 2007 Dec 13;450(7172):1001-9. DM5KXFI RU https://pubmed.ncbi.nlm.nih.gov/18075579 DM5KZ74 DI DM5KZ74 DM5KZ74 DN 1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea DM5KZ74 TI TTPC4TU DM5KZ74 TN 5-HT 3A receptor (HTR3A) DM5KZ74 MA Inhibitor DM5KZ74 RN Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and... J Med Chem. 2010 Jun 10;53(11):4379-89. DM5KZ74 RU https://pubmed.ncbi.nlm.nih.gov/20465311 DM5L23N DI DM5L23N DM5L23N DN JNJ-5207852 DM5L23N TI TT9JNIC DM5L23N TN Histamine H3 receptor (H3R) DM5L23N MA Antagonist DM5L23N RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM5L23N RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM5L387 DI DM5L387 DM5L387 DN ISIS 6553 DM5L387 TI TTONI0R DM5L387 TN PKC-eta messenger RNA (PRKCH mRNA) DM5L387 RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DM5L387 RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DM5L40C DI DM5L40C DM5L40C DN 8-Nitro-6H,11H-indeno[1,2-c]isoquinolin-5-one DM5L40C TI TTVDSZ0 DM5L40C TN Poly [ADP-ribose] polymerase 1 (PARP1) DM5L40C MA Inhibitor DM5L40C RN Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3. DM5L40C RU https://pubmed.ncbi.nlm.nih.gov/16078828 DM5L4WP DI DM5L4WP DM5L4WP DN 4-(2-carboxy-5-mercaptopentyl)benzoic acid DM5L4WP TI TT9G4N0 DM5L4WP TN Glutamate carboxypeptidase II (GCPII) DM5L4WP MA Inhibitor DM5L4WP RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DM5L4WP RU https://pubmed.ncbi.nlm.nih.gov/16686531 DM5L7D3 DI DM5L7D3 DM5L7D3 DN [3H]oxotremorine-M DM5L7D3 TI TTOXS3C DM5L7D3 TN Muscarinic acetylcholine receptor (CHRM) DM5L7D3 MA Agonist DM5L7D3 RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DM5L7D3 RU https://pubmed.ncbi.nlm.nih.gov/9224827 DM5L7D3 DI DM5L7D3 DM5L7D3 DN [3H]oxotremorine-M DM5L7D3 TI TTQ13Z5 DM5L7D3 TN Muscarinic acetylcholine receptor M3 (CHRM3) DM5L7D3 MA Agonist DM5L7D3 RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DM5L7D3 RU https://pubmed.ncbi.nlm.nih.gov/9224827 DM5L8WX DI DM5L8WX DM5L8WX DN (1-hydroxy-1-phosphono-heptyl)-phosphonic acid DM5L8WX TI TTIKWV4 DM5L8WX TN Geranyltranstransferase (FDPS) DM5L8WX MA Inhibitor DM5L8WX RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DM5L8WX RU https://pubmed.ncbi.nlm.nih.gov/18096393 DM5LBCH DI DM5LBCH DM5LBCH DN 6-(4-Methoxy-benzenesulfonyl)-2H-pyridazin-3-one DM5LBCH TI TTFBNVI DM5LBCH TN Aldose reductase (AKR1B1) DM5LBCH MA Inhibitor DM5LBCH RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM5LBCH RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM5LBQM DI DM5LBQM DM5LBQM DN ISIS 23705 DM5LBQM TI TTEWOHV DM5LBQM TN Survivin messenger RNA (Survivin mRNA) DM5LBQM RN US patent application no. 6,165,788, Antisense modulation of Survivin expression. DM5LBQM RU http://www.patentbuddy.com/Patent/6165788?ft=true&sr=true DM5LC3D DI DM5LC3D DM5LC3D DN N-1-isopropyl-5-MeOT DM5LC3D TI TTJQOD7 DM5LC3D TN 5-HT 2A receptor (HTR2A) DM5LC3D MA Agonist DM5LC3D RN Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86. DM5LC3D RU https://pubmed.ncbi.nlm.nih.gov/8114677 DM5LEOR DI DM5LEOR DM5LEOR DN JNJ-28583867 DM5LEOR TI TT9JNIC DM5LEOR TN Histamine H3 receptor (H3R) DM5LEOR MA Inhibitor DM5LEOR RN Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):39-43. DM5LEOR RU https://pubmed.ncbi.nlm.nih.gov/18060777 DM5LEOR DI DM5LEOR DM5LEOR DN JNJ-28583867 DM5LEOR TI TT3ROYC DM5LEOR TN Serotonin transporter (SERT) DM5LEOR MA Inhibitor DM5LEOR RN Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):39-43. DM5LEOR RU https://pubmed.ncbi.nlm.nih.gov/18060777 DM5LFYN DI DM5LFYN DM5LFYN DN Alpha-ketoglutaric acid DM5LFYN TI TTAS1QK DM5LFYN TN Oxoglutarate receptor (OXGR1) DM5LFYN MA Agonist DM5LFYN RN Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609. DM5LFYN RU https://pubmed.ncbi.nlm.nih.gov/23396314 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TTS7G69 DM5LR2B TN Fusion protein Bcr-Abl (Bcr-Abl) DM5LR2B MA Inhibitor DM5LR2B RN Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 2002 Dec 15;62(24):7149-53. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/12499247 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TT4ILYC DM5LR2B TN Bacterial Dihydropteroate synthetase (Bact folP) DM5LR2B MA Inhibitor DM5LR2B RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/15934867 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TT8FYO9 DM5LR2B TN Platelet-derived growth factor receptor alpha (PDGFRA) DM5LR2B MA Inhibitor DM5LR2B RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TT6PKBN DM5LR2B TN Proto-oncogene c-Src (SRC) DM5LR2B MA Inhibitor DM5LR2B RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TT860QF DM5LR2B TN LCK tyrosine protein kinase (LCK) DM5LR2B MA Inhibitor DM5LR2B RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TTGKNB4 DM5LR2B TN Epidermal growth factor receptor (EGFR) DM5LR2B MA Inhibitor DM5LR2B RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TTRLW2X DM5LR2B TN Fibroblast growth factor receptor 1 (FGFR1) DM5LR2B MA Inhibitor DM5LR2B RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM5LR2B DI DM5LR2B DM5LR2B DN HKI-9924129 DM5LR2B TI TTI7421 DM5LR2B TN Platelet-derived growth factor receptor beta (PDGFRB) DM5LR2B MA Inhibitor DM5LR2B RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM5LR2B RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM5LSY9 DI DM5LSY9 DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one DM5LSY9 TI TTT6LFV DM5LSY9 TN Histone deacetylase 8 (HDAC8) DM5LSY9 MA Inhibitor DM5LSY9 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM5LSY9 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM5LSY9 DI DM5LSY9 DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one DM5LSY9 TI TTBH0VX DM5LSY9 TN Histone deacetylase (HDAC) DM5LSY9 MA Inhibitor DM5LSY9 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM5LSY9 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM5LSY9 DI DM5LSY9 DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one DM5LSY9 TI TTTQGH8 DM5LSY9 TN Histone deacetylase 4 (HDAC4) DM5LSY9 MA Inhibitor DM5LSY9 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM5LSY9 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM5LSY9 DI DM5LSY9 DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one DM5LSY9 TI TT6R7JZ DM5LSY9 TN Histone deacetylase 1 (HDAC1) DM5LSY9 MA Inhibitor DM5LSY9 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM5LSY9 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM5LSY9 DI DM5LSY9 DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one DM5LSY9 TI TT5ZKDI DM5LSY9 TN Histone deacetylase 6 (HDAC6) DM5LSY9 MA Inhibitor DM5LSY9 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM5LSY9 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM5LSY9 DI DM5LSY9 DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one DM5LSY9 TI TTYHPU6 DM5LSY9 TN Histone deacetylase 10 (HDAC10) DM5LSY9 MA Inhibitor DM5LSY9 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM5LSY9 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM5LSY9 DI DM5LSY9 DM5LSY9 DN (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one DM5LSY9 TI TTSHTOI DM5LSY9 TN Histone deacetylase 2 (HDAC2) DM5LSY9 MA Inhibitor DM5LSY9 RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DM5LSY9 RU https://pubmed.ncbi.nlm.nih.gov/14592473 DM5LUED DI DM5LUED DM5LUED DN 3-keto-lithocholic acid DM5LUED TI TT7LCTF DM5LUED TN Pregnane X receptor (NR1I2) DM5LUED MA Agonist DM5LUED RN The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3369-74. DM5LUED RU https://pubmed.ncbi.nlm.nih.gov/11248085 DM5LUED DI DM5LUED DM5LUED DN 3-keto-lithocholic acid DM5LUED TI TTK59TV DM5LUED TN Vitamin D3 receptor (VDR) DM5LUED MA Agonist DM5LUED RN Vitamin D receptor as an intestinal bile acid sensor. Science. 2002 May 17;296(5571):1313-6. DM5LUED RU https://pubmed.ncbi.nlm.nih.gov/12016314 DM5LUF4 DI DM5LUF4 DM5LUF4 DN 6-(4-Chloro-phenylamino)-1H-pyrimidine-2,4-dione DM5LUF4 TI TTIU7X1 DM5LUF4 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM5LUF4 MA Inhibitor DM5LUF4 RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DM5LUF4 RU https://pubmed.ncbi.nlm.nih.gov/6767030 DM5LVD2 DI DM5LVD2 DM5LVD2 DN 1,10-phenanthroline-5,6-dione DM5LVD2 TI TTMF541 DM5LVD2 TN Liver carboxylesterase (CES1) DM5LVD2 MA Inhibitor DM5LVD2 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DM5LVD2 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DM5LVIR DI DM5LVIR DM5LVIR DN [2-(6-Chloro-purin-9-yl)ethyl]-bisphosphonic acid DM5LVIR TI TTIKWV4 DM5LVIR TN Geranyltranstransferase (FDPS) DM5LVIR MA Inhibitor DM5LVIR RN Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7. DM5LVIR RU https://pubmed.ncbi.nlm.nih.gov/18937434 DM5LY1H DI DM5LY1H DM5LY1H DN Leptin DM5LY1H TI TT0HD6V DM5LY1H TN Leptin receptor (LEPR) DM5LY1H MA Modulator DM5LY1H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DM5LY1H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DM5LYKW DI DM5LYKW DM5LYKW DN YGGWL-NH2 DM5LYKW TI TTKWM86 DM5LYKW TN Opioid receptor mu (MOP) DM5LYKW MA Inhibitor DM5LYKW RN Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. DM5LYKW RU https://pubmed.ncbi.nlm.nih.gov/18329886 DM5MBX7 DI DM5MBX7 DM5MBX7 DN Sabadinine DM5MBX7 TI TTJLVBO DM5MBX7 TN Coronavirus Main proteinase (CoV 1a) DM5MBX7 MA Inhibitor DM5MBX7 RN Sabadinine: a potential non-peptide anti-severe acute-respiratory-syndrome agent identified using structure-aided design. J Med Chem. 2004 Feb 26;47(5):1079-80. DM5MBX7 RU https://pubmed.ncbi.nlm.nih.gov/14971887 DM5MHO6 DI DM5MHO6 DM5MHO6 DN 4-Hept-3-ynyl-1H-imidazole DM5MHO6 TI TT9JNIC DM5MHO6 TN Histamine H3 receptor (H3R) DM5MHO6 MA Inhibitor DM5MHO6 RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DM5MHO6 RU https://pubmed.ncbi.nlm.nih.gov/9871722 DM5MJ3I DI DM5MJ3I DM5MJ3I DN 5-benzyl-2-(2,4-dichlorophenoxy)phenol DM5MJ3I TI TTNX2CS DM5MJ3I TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM5MJ3I MA Inhibitor DM5MJ3I RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DM5MJ3I RU https://pubmed.ncbi.nlm.nih.gov/19217192 DM5MKEI DI DM5MKEI DM5MKEI DN 2-(3,4-Dihydroxy-phenyl)-7-hydroxy-chromen-4-one DM5MKEI TI TTFBNVI DM5MKEI TN Aldose reductase (AKR1B1) DM5MKEI MA Inhibitor DM5MKEI RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DM5MKEI RU https://pubmed.ncbi.nlm.nih.gov/10354396 DM5MLZ0 DI DM5MLZ0 DM5MLZ0 DN (+/-)-threo-3',4'-Dichlororitalinol methyl ether DM5MLZ0 TI TTVBI8W DM5MLZ0 TN Dopamine transporter (DAT) DM5MLZ0 MA Inhibitor DM5MLZ0 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM5MLZ0 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM5MOLY DI DM5MOLY DM5MOLY DN HELENAQUINONE DM5MOLY TI TT9V5JH DM5MOLY TN Phospholipase A2 (PLA2G1B) DM5MOLY MA Inhibitor DM5MOLY RN New bioactive halenaquinone derivatives from South Pacific marine sponges of the genus Xestospongia. Bioorg Med Chem. 2010 Aug 15;18(16):6006-11. DM5MOLY RU https://pubmed.ncbi.nlm.nih.gov/20634081 DM5MZHP DI DM5MZHP DM5MZHP DN butaprost (free acid form) DM5MZHP TI TTOFYT1 DM5MZHP TN Prostacyclin receptor (PTGIR) DM5MZHP MA Agonist DM5MZHP RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM5MZHP RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM5MZHP DI DM5MZHP DM5MZHP DN butaprost (free acid form) DM5MZHP TI TT1ZAVI DM5MZHP TN Prostaglandin E2 receptor EP2 (PTGER2) DM5MZHP MA Agonist DM5MZHP RN Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51. DM5MZHP RU https://pubmed.ncbi.nlm.nih.gov/10462542 DM5MZHP DI DM5MZHP DM5MZHP DN butaprost (free acid form) DM5MZHP TI TTPNGDE DM5MZHP TN Prostaglandin E2 receptor EP3 (PTGER3) DM5MZHP MA Agonist DM5MZHP RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM5MZHP RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM5MZHP DI DM5MZHP DM5MZHP DN butaprost (free acid form) DM5MZHP TI TT2O84V DM5MZHP TN Thromboxane A2 receptor (TBXA2R) DM5MZHP MA Agonist DM5MZHP RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM5MZHP RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM5MZHP DI DM5MZHP DM5MZHP DN butaprost (free acid form) DM5MZHP TI TT79WV3 DM5MZHP TN Prostaglandin E2 receptor EP4 (PTGER4) DM5MZHP MA Agonist DM5MZHP RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM5MZHP RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM5MZHP DI DM5MZHP DM5MZHP DN butaprost (free acid form) DM5MZHP TI TTNVEIR DM5MZHP TN Prostaglandin D2 receptor (PTGDR) DM5MZHP MA Agonist DM5MZHP RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM5MZHP RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM5N1JX DI DM5N1JX DM5N1JX DN 5-methoxy-2-(4-methylaminophenyl)benzofuran DM5N1JX TI TTE4KHA DM5N1JX TN Amyloid beta A4 protein (APP) DM5N1JX MA Inhibitor DM5N1JX RN Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. DM5N1JX RU https://pubmed.ncbi.nlm.nih.gov/16640332 DM5N6YE DI DM5N6YE DM5N6YE DN Bbs-Arg-(D-Pip)-Gly-S-(GS)13-Gly-Hir DM5N6YE TI TT6L509 DM5N6YE TN Coagulation factor IIa (F2) DM5N6YE MA Inhibitor DM5N6YE RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DM5N6YE RU https://pubmed.ncbi.nlm.nih.gov/16202582 DM5NBVG DI DM5NBVG DM5NBVG DN PF-03800130 DM5NBVG TI TTEX248 DM5NBVG TN Dopamine D2 receptor (D2R) DM5NBVG MA Agonist DM5NBVG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215). DM5NBVG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215 DM5NFB6 DI DM5NFB6 DM5NFB6 DN 14-(n-Hexylamino)-14-oxotetradec-8(Z)-enoic acid DM5NFB6 TI TT7WVHI DM5NFB6 TN Soluble epoxide hydrolase (EPHX2) DM5NFB6 MA Inhibitor DM5NFB6 RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM5NFB6 RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM5NFEA DI DM5NFEA DM5NFEA DN CYM2503 DM5NFEA TI TTOPAY7 DM5NFEA TN Galanin receptor (GAL-R) DM5NFEA MA Modulator (allosteric modulator) DM5NFEA RN GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models. Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15229-34. DM5NFEA RU https://pubmed.ncbi.nlm.nih.gov/20660766 DM5NIE7 DI DM5NIE7 DM5NIE7 DN 3-(5-phenyl-2-thienyl)phenol DM5NIE7 TI TTIWB6L DM5NIE7 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM5NIE7 MA Inhibitor DM5NIE7 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM5NIE7 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM5NLQE DI DM5NLQE DM5NLQE DN 2-(2-phenethylphenyl)isoindoline-1,3-dione DM5NLQE TI TTECBXN DM5NLQE TN Oxysterols receptor LXR-alpha (NR1H3) DM5NLQE MA Inhibitor DM5NLQE RN Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. DM5NLQE RU https://pubmed.ncbi.nlm.nih.gov/19539483 DM5NMVP DI DM5NMVP DM5NMVP DN Ac-I[CV(Bta)QDWGAHRC]T DM5NMVP TI TTJGY7A DM5NMVP TN Complement C3 (CO3) DM5NMVP MA Inhibitor DM5NMVP RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DM5NMVP RU https://pubmed.ncbi.nlm.nih.gov/15634022 DM5NOSM DI DM5NOSM DM5NOSM DN N-(4-methoxyphenethyl)oleamide DM5NOSM TI TT6OEDT DM5NOSM TN Cannabinoid receptor 1 (CB1) DM5NOSM MA Inhibitor DM5NOSM RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM5NOSM RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM5NQUA DI DM5NQUA DM5NQUA DN C(his-D-phe-arg-trp-Aoc) DM5NQUA TI TTD0CIQ DM5NQUA TN Melanocortin receptor 4 (MC4R) DM5NQUA MA Inhibitor DM5NQUA RN Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6. DM5NQUA RU https://pubmed.ncbi.nlm.nih.gov/16678415 DM5NVHO DI DM5NVHO DM5NVHO DN 1-[6-(triphenylmethoxy)hexyl]thymine DM5NVHO TI TT7KNZQ DM5NVHO TN Thymidine kinase 2 (Mt-TK2) DM5NVHO MA Inhibitor DM5NVHO RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DM5NVHO RU https://pubmed.ncbi.nlm.nih.gov/17181158 DM5NVHO DI DM5NVHO DM5NVHO DN 1-[6-(triphenylmethoxy)hexyl]thymine DM5NVHO TI TTP3QRF DM5NVHO TN Thymidine kinase 1 (TK1) DM5NVHO MA Inhibitor DM5NVHO RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DM5NVHO RU https://pubmed.ncbi.nlm.nih.gov/17181158 DM5NVIO DI DM5NVIO DM5NVIO DN N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP DM5NVIO TI TTEB0GD DM5NVIO TN Cholinesterase (BCHE) DM5NVIO MA Inhibitor DM5NVIO RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DM5NVIO RU https://pubmed.ncbi.nlm.nih.gov/18333606 DM5NVIO DI DM5NVIO DM5NVIO DN N,N'-(1',11'-undecydene)-bis-(-)-nor-MEP DM5NVIO TI TT1RS9F DM5NVIO TN Acetylcholinesterase (AChE) DM5NVIO MA Inhibitor DM5NVIO RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DM5NVIO RU https://pubmed.ncbi.nlm.nih.gov/18333606 DM5NYWV DI DM5NYWV DM5NYWV DN UH-301 DM5NYWV TI TTNGILX DM5NYWV TN Adrenergic receptor alpha-1A (ADRA1A) DM5NYWV MA Inhibitor DM5NYWV RN N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7. DM5NYWV RU https://pubmed.ncbi.nlm.nih.gov/9111299 DM5NYWV DI DM5NYWV DM5NYWV DN UH-301 DM5NYWV TI TTEX248 DM5NYWV TN Dopamine D2 receptor (D2R) DM5NYWV MA Inhibitor DM5NYWV RN N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7. DM5NYWV RU https://pubmed.ncbi.nlm.nih.gov/9111299 DM5NYWV DI DM5NYWV DM5NYWV DN UH-301 DM5NYWV TI TTSQIFT DM5NYWV TN 5-HT 1A receptor (HTR1A) DM5NYWV MA Inhibitor DM5NYWV RN N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7. DM5NYWV RU https://pubmed.ncbi.nlm.nih.gov/9111299 DM5NYWV DI DM5NYWV DM5NYWV DN UH-301 DM5NYWV TI TT34BHT DM5NYWV TN Adrenergic receptor alpha-1D (ADRA1D) DM5NYWV MA Inhibitor DM5NYWV RN N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7. DM5NYWV RU https://pubmed.ncbi.nlm.nih.gov/9111299 DM5NYWV DI DM5NYWV DM5NYWV DN UH-301 DM5NYWV TI TTBRKXS DM5NYWV TN Adrenergic receptor alpha-1B (ADRA1B) DM5NYWV MA Inhibitor DM5NYWV RN N-[2-[(substituted chroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamines: synthesis and wide range of antagonism at the human 5-HT1A receptor. J Med Chem. 1997 Apr 11;40(8):1252-7. DM5NYWV RU https://pubmed.ncbi.nlm.nih.gov/9111299 DM5O0CM DI DM5O0CM DM5O0CM DN L-772,405 DM5O0CM TI TTSQIFT DM5O0CM TN 5-HT 1A receptor (HTR1A) DM5O0CM MA Agonist DM5O0CM RN 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem. 1999 Dec 2;42(24):4981-5001. DM5O0CM RU https://pubmed.ncbi.nlm.nih.gov/10585208 DM5O0CM DI DM5O0CM DM5O0CM DN L-772,405 DM5O0CM TI TT6MSOK DM5O0CM TN 5-HT 1D receptor (HTR1D) DM5O0CM MA Antagonist DM5O0CM RN 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem. 1999 Dec 2;42(24):4981-5001. DM5O0CM RU https://pubmed.ncbi.nlm.nih.gov/10585208 DM5O0CM DI DM5O0CM DM5O0CM DN L-772,405 DM5O0CM TI TTK8CXU DM5O0CM TN 5-HT 1B receptor (HTR1B) DM5O0CM MA Agonist DM5O0CM RN 3-[3-(Piperidin-1-yl)propyl]indoles as highly selective h5-HT(1D) receptor agonists. J Med Chem. 1999 Dec 2;42(24):4981-5001. DM5O0CM RU https://pubmed.ncbi.nlm.nih.gov/10585208 DM5O2MJ DI DM5O2MJ DM5O2MJ DN NEUROKININ B DM5O2MJ TI TTBPGLU DM5O2MJ TN Neuromedin-K receptor (TACR3) DM5O2MJ MA Inhibitor DM5O2MJ RN The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design, Bioorg. Med. Chem. Lett. 4(14):1679-1684 (1994). DM5O2MJ RU http://www.sciencedirect.com/science/article/pii/S0960894X00803601 DM5O4L8 DI DM5O4L8 DM5O4L8 DN ISIS 188782 DM5O4L8 TI TTLRVIA DM5O4L8 TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DM5O4L8 RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DM5O4L8 RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DM5OHIY DI DM5OHIY DM5OHIY DN BPKDi DM5OHIY TI TTSLUMT DM5OHIY TN Protein kinase D (PRKD1) DM5OHIY MA Inhibitor DM5OHIY RN Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92. DM5OHIY RU https://pubmed.ncbi.nlm.nih.gov/20580776 DM5OHVN DI DM5OHVN DM5OHVN DN Lophocladine a DM5OHVN TI TT27RFC DM5OHVN TN Opioid receptor delta (OPRD1) DM5OHVN MA Inhibitor DM5OHVN RN Lophocladines, bioactive alkaloids from the red alga Lophocladia sp. J Nat Prod. 2006 Apr;69(4):640-4. DM5OHVN RU https://pubmed.ncbi.nlm.nih.gov/16643042 DM5OR96 DI DM5OR96 DM5OR96 DN 3-Hydroxy-piperidine-4-carboxylic acid DM5OR96 TI TTNJYV2 DM5OR96 TN Gamma-aminobutyric acid receptor (GAR) DM5OR96 MA Inhibitor DM5OR96 RN Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62. DM5OR96 RU https://pubmed.ncbi.nlm.nih.gov/6292417 DM5OW91 DI DM5OW91 DM5OW91 DN 2-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate DM5OW91 TI TTDP1UC DM5OW91 TN Fatty acid amide hydrolase (FAAH) DM5OW91 MA Inhibitor DM5OW91 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM5OW91 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM5OYWF DI DM5OYWF DM5OYWF DN 2',5'-DIDEOXY-ADENOSINE 3'-MONOPHOSPHATE DM5OYWF TI TTBQ9IM DM5OYWF TN Adenylate cyclase type 2 (ADCY2) DM5OYWF MA Inhibitor DM5OYWF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5OYWF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5P01L DI DM5P01L DM5P01L DN 1-propyl-5'-O-tritylinosine DM5P01L TI TTO0IB8 DM5P01L TN Thymidine phosphorylase (TYMP) DM5P01L MA Inhibitor DM5P01L RN 5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70. DM5P01L RU https://pubmed.ncbi.nlm.nih.gov/16942029 DM5P1NZ DI DM5P1NZ DM5P1NZ DN PREUSSOMERIN DM5P1NZ TI TT7WZIJ DM5P1NZ TN CAAX farnesyltransferase beta (FNTB) DM5P1NZ MA Inhibitor DM5P1NZ RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DM5P1NZ RU https://pubmed.ncbi.nlm.nih.gov/9301658 DM5P7TR DI DM5P7TR DM5P7TR DN CGS-23885 DM5P7TR TI TT2J34L DM5P7TR TN Arachidonate 5-lipoxygenase (5-LOX) DM5P7TR MA Modulator DM5P7TR RN Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an exp... Naunyn Schmiedebergs Arch Pharmacol. 1997 Apr;355(4):470-4. DM5P7TR RU https://www.ncbi.nlm.nih.gov/pubmed/9109363 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTXABCW DM5PATM TN NT-3 growth factor receptor (TrkC) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTI7FDX DM5PATM TN WNK lysine-deficient protein kinase 3 (WNK3) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTI5WS6 DM5PATM TN Phosphorylase kinase testis gamma 2 (PHKG2) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTPOGS1 DM5PATM TN Tyrosine-protein kinase Fgr (FGR) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TT6B75U DM5PATM TN ABL messenger RNA (ABL mRNA) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTGM6VW DM5PATM TN Tyrosine-protein kinase BTK (ATK) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTRLW2X DM5PATM TN Fibroblast growth factor receptor 1 (FGFR1) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTA3Z2W DM5PATM TN Testis-specific serine kinase 2 (TSSK2) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TT1H6LC DM5PATM TN Salt-inducible kinase 1 (SIK1) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PATM DI DM5PATM DM5PATM DN PMID24900538C2c DM5PATM TI TTGJCWZ DM5PATM TN Fms-like tyrosine kinase 3 (FLT-3) DM5PATM MA Inhibitor DM5PATM RN Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors. ACS Med Chem Lett. 2012 Jul 26;3(9):705-9. DM5PATM RU https://pubmed.ncbi.nlm.nih.gov/24900538 DM5PD0G DI DM5PD0G DM5PD0G DN MT-062 DM5PD0G TI TTGKNB4 DM5PD0G TN Epidermal growth factor receptor (EGFR) DM5PD0G MA Inhibitor DM5PD0G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM5PD0G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM5PTB9 DI DM5PTB9 DM5PTB9 DN 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol DM5PTB9 TI TTHY57M DM5PTB9 TN Matrix metalloproteinase-13 (MMP-13) DM5PTB9 MA Inhibitor DM5PTB9 RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DM5PTB9 RU https://pubmed.ncbi.nlm.nih.gov/10230616 DM5PTB9 DI DM5PTB9 DM5PTB9 DN 4-(4-Methoxy-benzenesulfonyl)-butane-2-thiol DM5PTB9 TI TTMX39J DM5PTB9 TN Matrix metalloproteinase-1 (MMP-1) DM5PTB9 MA Inhibitor DM5PTB9 RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DM5PTB9 RU https://pubmed.ncbi.nlm.nih.gov/10230616 DM5PTQX DI DM5PTQX DM5PTQX DN ISIS 101986 DM5PTQX TI TTON5JB DM5PTQX TN MADH6 messenger RNA (MADH6 mRNA) DM5PTQX RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DM5PTQX RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DM5PWQM DI DM5PWQM DM5PWQM DN 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide DM5PWQM TI TTBH0VX DM5PWQM TN Histone deacetylase (HDAC) DM5PWQM MA Inhibitor DM5PWQM RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM5PWQM RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM5PWQM DI DM5PWQM DM5PWQM DN 2,2-bis(4-fluorophenyl)-N-hydroxyacetamide DM5PWQM TI TTTQGH8 DM5PWQM TN Histone deacetylase 4 (HDAC4) DM5PWQM MA Inhibitor DM5PWQM RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM5PWQM RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM5PXN4 DI DM5PXN4 DM5PXN4 DN ISIS 25554 DM5PXN4 TI TTP2U16 DM5PXN4 TN RhoA messenger RNA (RHOA mRNA) DM5PXN4 RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DM5PXN4 RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DM5PXQU DI DM5PXQU DM5PXQU DN 2-oleoyl glycerol DM5PXQU TI TT7QNVC DM5PXQU TN Glucose-dependent insulinotropic receptor (GPR119) DM5PXQU MA Agonist DM5PXQU RN 2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab. 2011 Sep;96(9):E1409-17. DM5PXQU RU https://pubmed.ncbi.nlm.nih.gov/21778222 DM5Q08F DI DM5Q08F DM5Q08F DN [11C]GlySar DM5Q08F TI TT27Q3A DM5Q08F TN Solute carrier family 15 member 2 (SLC15A2) DM5Q08F MA Modulator DM5Q08F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985). DM5Q08F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985 DM5Q08F DI DM5Q08F DM5Q08F DN [11C]GlySar DM5Q08F TI TT5LF3C DM5Q08F TN Solute carrier family 15 member 1 (SLC15A1) DM5Q08F MA Modulator DM5Q08F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 984). DM5Q08F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=984 DM5Q12D DI DM5Q12D DM5Q12D DN ISIS 13740 DM5Q12D TI TT0EOB8 DM5Q12D TN B-Raf messenger RNA (BRAF mRNA) DM5Q12D RN US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression. DM5Q12D RU http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true DM5Q71U DI DM5Q71U DM5Q71U DN N6-(4-hydroxybenzyl)adenine riboside DM5Q71U TI TTM2AOE DM5Q71U TN Adenosine A2a receptor (ADORA2A) DM5Q71U MA Inhibitor DM5Q71U RN Neuroprotective principles from Gastrodia elata. J Nat Prod. 2007 Apr;70(4):571-4. DM5Q71U RU https://pubmed.ncbi.nlm.nih.gov/17381154 DM5Q7K8 DI DM5Q7K8 DM5Q7K8 DN Triethyl 2-aminopropane-1,2,3-tricarboxylate DM5Q7K8 TI TTHI19T DM5Q7K8 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM5Q7K8 MA Inhibitor DM5Q7K8 RN Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7. DM5Q7K8 RU https://pubmed.ncbi.nlm.nih.gov/19467869 DM5Q9FG DI DM5Q9FG DM5Q9FG DN NMB-T-BMX-OS01 DM5Q9FG TI TTT6LFV DM5Q9FG TN Histone deacetylase 8 (HDAC8) DM5Q9FG MA Inhibitor DM5Q9FG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2619). DM5Q9FG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2619 DM5QDK9 DI DM5QDK9 DM5QDK9 DN (4-bromo-1H-pyrazol-1-yl)(o-tolyl)methanone DM5QDK9 TI TTPLTSQ DM5QDK9 TN Neutrophil elastase (NE) DM5QDK9 MA Inhibitor DM5QDK9 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DM5QDK9 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DM5QEP4 DI DM5QEP4 DM5QEP4 DN ISIS 113176 DM5QEP4 TI TTHJT3X DM5QEP4 TN STAT3 messenger RNA (STAT3 mRNA) DM5QEP4 RN US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression. DM5QEP4 RU http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true DM5QEUC DI DM5QEUC DM5QEUC DN 2,6-dihydroxy-1,7-dimethoxyxanthone DM5QEUC TI TTVKILB DM5QEUC TN Prostaglandin G/H synthase 2 (COX-2) DM5QEUC MA Inhibitor DM5QEUC RN Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8. DM5QEUC RU https://pubmed.ncbi.nlm.nih.gov/16252917 DM5QLGH DI DM5QLGH DM5QLGH DN 1-(4-hexylphenyl)-3-(propylamino)propan-1-one DM5QLGH TI TTGER3L DM5QLGH TN Thyroid hormone receptor beta (THRB) DM5QLGH MA Inhibitor DM5QLGH RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM5QLGH RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM5QS17 DI DM5QS17 DM5QS17 DN ED1 DM5QS17 TI TTPLTSQ DM5QS17 TN Neutrophil elastase (NE) DM5QS17 RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DM5QS17 RU https://pubmed.ncbi.nlm.nih.gov/18095918 DM5QUJV DI DM5QUJV DM5QUJV DN Drug 311383 DM5QUJV TI TTZ3S8C DM5QUJV TN Presenilin 1 (PSEN1) DM5QUJV MA Inhibitor DM5QUJV RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DM5QUJV RU https://pubmed.ncbi.nlm.nih.gov/15267231 DM5QUJV DI DM5QUJV DM5QUJV DN Drug 311383 DM5QUJV TI TTWN3F4 DM5QUJV TN Presenilin 2 (PSEN2) DM5QUJV MA Inhibitor DM5QUJV RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DM5QUJV RU https://pubmed.ncbi.nlm.nih.gov/15267231 DM5QUJV DI DM5QUJV DM5QUJV DN Drug 311383 DM5QUJV TI TT9W8GU DM5QUJV TN Gamma-secretase (GS) DM5QUJV MA Inhibitor DM5QUJV RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DM5QUJV RU https://pubmed.ncbi.nlm.nih.gov/15267231 DM5QV19 DI DM5QV19 DM5QV19 DN 2'-Hydroxy-3-methoxy-biphenyl-4-carbonitrile DM5QV19 TI TTKPW01 DM5QV19 TN Androgen receptor messenger RNA (AR mRNA) DM5QV19 MA Inhibitor DM5QV19 RN Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4. DM5QV19 RU https://pubmed.ncbi.nlm.nih.gov/18921992 DM5QWED DI DM5QWED DM5QWED DN ISIS 183912 DM5QWED TI TTBGTCW DM5QWED TN Kinesin spindle messenger RNA (KIF11 mRNA) DM5QWED RN US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression. DM5QWED RU http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true DM5QZDL DI DM5QZDL DM5QZDL DN 3-Hydroxy-4-phenyl-5H-furan-2-one DM5QZDL TI TT8DSFC DM5QZDL TN Hydroxyphenylpyruvate dioxygenase (HPD) DM5QZDL MA Inhibitor DM5QZDL RN Design, synthesis, and evaluation of postulated transient intermediate and substrate analogues as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1709-13. DM5QZDL RU https://pubmed.ncbi.nlm.nih.gov/12067543 DM5R3ZG DI DM5R3ZG DM5R3ZG DN N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide DM5R3ZG TI TT6R7JZ DM5R3ZG TN Histone deacetylase 1 (HDAC1) DM5R3ZG MA Inhibitor DM5R3ZG RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM5R3ZG RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM5R3ZG DI DM5R3ZG DM5R3ZG DN N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide DM5R3ZG TI TTBH0VX DM5R3ZG TN Histone deacetylase (HDAC) DM5R3ZG MA Inhibitor DM5R3ZG RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM5R3ZG RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM5R6T4 DI DM5R6T4 DM5R6T4 DN 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol DM5R6T4 TI TTKWM86 DM5R6T4 TN Opioid receptor mu (MOP) DM5R6T4 MA Inhibitor DM5R6T4 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM5R6T4 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM5R6T4 DI DM5R6T4 DM5R6T4 DN 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol DM5R6T4 TI TTNT7K8 DM5R6T4 TN Nociceptin receptor (OPRL1) DM5R6T4 MA Inhibitor DM5R6T4 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM5R6T4 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM5R6T4 DI DM5R6T4 DM5R6T4 DN 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol DM5R6T4 TI TTQW87Y DM5R6T4 TN Opioid receptor kappa (OPRK1) DM5R6T4 MA Inhibitor DM5R6T4 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM5R6T4 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM5R6T4 DI DM5R6T4 DM5R6T4 DN 4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol DM5R6T4 TI TT27RFC DM5R6T4 TN Opioid receptor delta (OPRD1) DM5R6T4 MA Inhibitor DM5R6T4 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM5R6T4 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM5R8KU DI DM5R8KU DM5R8KU DN 1-(4-Methoxy-phenyl)-2-phenyl-ethane-1,2-dione DM5R8KU TI TTMF541 DM5R8KU TN Liver carboxylesterase (CES1) DM5R8KU MA Inhibitor DM5R8KU RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DM5R8KU RU https://pubmed.ncbi.nlm.nih.gov/15828829 DM5RE71 DI DM5RE71 DM5RE71 DN 1-(2-Chloro-phenyl)-piperazine DM5RE71 TI TTNGILX DM5RE71 TN Adrenergic receptor alpha-1A (ADRA1A) DM5RE71 MA Inhibitor DM5RE71 RN Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4. DM5RE71 RU https://pubmed.ncbi.nlm.nih.gov/1648138 DM5RE71 DI DM5RE71 DM5RE71 DN 1-(2-Chloro-phenyl)-piperazine DM5RE71 TI TTSQIFT DM5RE71 TN 5-HT 1A receptor (HTR1A) DM5RE71 MA Inhibitor DM5RE71 RN Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4. DM5RE71 RU https://pubmed.ncbi.nlm.nih.gov/1648138 DM5RE71 DI DM5RE71 DM5RE71 DN 1-(2-Chloro-phenyl)-piperazine DM5RE71 TI TT34BHT DM5RE71 TN Adrenergic receptor alpha-1D (ADRA1D) DM5RE71 MA Inhibitor DM5RE71 RN Pyrimido[5,4-b]indole derivatives. 1. A new class of potent and selective alpha 1 adrenoceptor ligands. J Med Chem. 1991 Jun;34(6):1850-4. DM5RE71 RU https://pubmed.ncbi.nlm.nih.gov/1648138 DM5REQ9 DI DM5REQ9 DM5REQ9 DN 1-phenylthio-N,N-dimethyltryptamine DM5REQ9 TI TTJS8PY DM5REQ9 TN 5-HT 6 receptor (HTR6) DM5REQ9 MA Inhibitor DM5REQ9 RN Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J Med Chem. 2008 Feb 14;51(3):603-11. DM5REQ9 RU https://pubmed.ncbi.nlm.nih.gov/18201064 DM5RFCN DI DM5RFCN DM5RFCN DN 8-Butoxy-quinolin-2-ylamine DM5RFCN TI TTX4RTB DM5RFCN TN Melanin-concentrating hormone receptor 1 (MCHR1) DM5RFCN MA Inhibitor DM5RFCN RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM5RFCN RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM5RG7J DI DM5RG7J DM5RG7J DN LY215840 DM5RG7J TI TTJQOD7 DM5RG7J TN 5-HT 2A receptor (HTR2A) DM5RG7J MA Antagonist DM5RG7J RN Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86. DM5RG7J RU https://pubmed.ncbi.nlm.nih.gov/8114677 DM5RI4H DI DM5RI4H DM5RI4H DN 5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one DM5RI4H TI TTHQPL7 DM5RI4H TN Carbonic anhydrase I (CA-I) DM5RI4H MA Inhibitor DM5RI4H RN A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies. Bioorg Med Chem. 2010 Jun 15;18(12):4468-74. DM5RI4H RU https://pubmed.ncbi.nlm.nih.gov/20554206 DM5RI4H DI DM5RI4H DM5RI4H DN 5-hydroxy-1-tosyl-1H-pyrrol-2(5H)-one DM5RI4H TI TTANPDJ DM5RI4H TN Carbonic anhydrase II (CA-II) DM5RI4H MA Inhibitor DM5RI4H RN A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies. Bioorg Med Chem. 2010 Jun 15;18(12):4468-74. DM5RI4H RU https://pubmed.ncbi.nlm.nih.gov/20554206 DM5RIB0 DI DM5RIB0 DM5RIB0 DN PMID19191557C21 DM5RIB0 TI TTFQEO5 DM5RIB0 TN Squalene synthetase (FDFT1) DM5RIB0 MA Inhibitor DM5RIB0 RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DM5RIB0 RU https://pubmed.ncbi.nlm.nih.gov/19191557 DM5ROS1 DI DM5ROS1 DM5ROS1 DN (1R,2R)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine DM5ROS1 TI TT9JNIC DM5ROS1 TN Histamine H3 receptor (H3R) DM5ROS1 MA Inhibitor DM5ROS1 RN A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9. DM5ROS1 RU https://pubmed.ncbi.nlm.nih.gov/7752184 DM5RVO0 DI DM5RVO0 DM5RVO0 DN MC-1301 DM5RVO0 TI TTK59TV DM5RVO0 TN Vitamin D3 receptor (VDR) DM5RVO0 MA Modulator DM5RVO0 RN Effects of 1,25-dihydroxyvitamin D3 and its 20-epi analogues (MC 1288, MC 1301, KH 1060), on clonal keratinocyte growth: evidence for differentiati... Br J Pharmacol. 1997 Mar;120(6):1119-27. DM5RVO0 RU https://www.ncbi.nlm.nih.gov/pubmed/9134225 DM5RX0K DI DM5RX0K DM5RX0K DN 6-(1H-Benzoimidazol-2-yl)-benzocyclohepten-7-one DM5RX0K TI TTUTJGQ DM5RX0K TN Vascular endothelial growth factor receptor 2 (KDR) DM5RX0K MA Inhibitor DM5RX0K RN Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmaco... Bioorg Med Chem Lett. 2004 Jan 19;14(2):351-5. DM5RX0K RU https://pubmed.ncbi.nlm.nih.gov/14698157 DM5S0BY DI DM5S0BY DM5S0BY DN 2-N-Allylamino-1-(4-methylthiophenyl)propan DM5S0BY TI TT3ROYC DM5S0BY TN Serotonin transporter (SERT) DM5S0BY MA Inhibitor DM5S0BY RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM5S0BY RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM5S1DW DI DM5S1DW DM5S1DW DN 2-Chloro-N-(3-morpholinopropyl)nicotinamide DM5S1DW TI TTGP7BY DM5S1DW TN Monoamine oxidase type B (MAO-B) DM5S1DW MA Inhibitor DM5S1DW RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM5S1DW RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM5S1DW DI DM5S1DW DM5S1DW DN 2-Chloro-N-(3-morpholinopropyl)nicotinamide DM5S1DW TI TT3WG5C DM5S1DW TN Monoamine oxidase type A (MAO-A) DM5S1DW MA Inhibitor DM5S1DW RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM5S1DW RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM5S4AO DI DM5S4AO DM5S4AO DN H-Ala-Pro-Phe-Phe-NH2 DM5S4AO TI TTZPO1L DM5S4AO TN Substance-P receptor (TACR1) DM5S4AO MA Inhibitor DM5S4AO RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DM5S4AO RU https://pubmed.ncbi.nlm.nih.gov/20178322 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTJLP0R DM5S4GK TN Quinone reductase 2 (NQO2) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTZUFI5 DM5S4GK TN Nitric-oxide synthase brain (NOS1) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTZPS91 DM5S4GK TN Dihydrothymine dehydrogenase (DPYD) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTBKQL3 DM5S4GK TN Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTAEOJ4 DM5S4GK TN Bacterial UDP-N-acetylenolpyruvylglucosamine reductase (Bact murB) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTHDSE2 DM5S4GK TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TT7RJY8 DM5S4GK TN Xanthine dehydrogenase/oxidase (XDH) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTEP6RV DM5S4GK TN Glutathione reductase (GR) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TT8XK6L DM5S4GK TN Quinone reductase 1 (NQO1) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTRTKPV DM5S4GK TN Trypanosoma Trypanothione reductase (Trypano TPR) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TT3WG5C DM5S4GK TN Monoamine oxidase type A (MAO-A) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTNAW8S DM5S4GK TN Bacterial Flavohemoglobin (Bact hmp) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTR7UJ3 DM5S4GK TN Cytoplasmic thioredoxin reductase (TXNRD1) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S4GK DI DM5S4GK DM5S4GK DN Flavin-Adenine Dinucleotide DM5S4GK TI TTGP7BY DM5S4GK TN Monoamine oxidase type B (MAO-B) DM5S4GK MA Inhibitor DM5S4GK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5S4GK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5S7IG DI DM5S7IG DM5S7IG DN Irbesartan DM5S7IG TI TTPKMXQ DM5S7IG TN HUMAN type-1 angiotensin II receptor (AGTR1) DM5S7IG MA Antagonist DM5S7IG RN Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020 Mar 4. DM5S7IG RU https://pubmed.ncbi.nlm.nih.gov/32129518 DM5SATN DI DM5SATN DM5SATN DN CGP-49870 DM5SATN TI TT8DBY3 DM5SATN TN Angiotensin II receptor type-1 (AGTR1) DM5SATN MA Modulator DM5SATN RN Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists DM5SATN RU https://www.google.com/patents/US20050288272 DM5SDV9 DI DM5SDV9 DM5SDV9 DN Bb-3497 DM5SDV9 TI TTICO5G DM5SDV9 TN Staphylococcus Peptide deformylase (Stap-coc def) DM5SDV9 MA Inhibitor DM5SDV9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5SDV9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5SJX8 DI DM5SJX8 DM5SJX8 DN Ac-YK[CEHdFRWC]-NH2 DM5SJX8 TI TTNI91K DM5SJX8 TN Melanocortin receptor 3 (MC3R) DM5SJX8 MA Inhibitor DM5SJX8 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM5SJX8 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM5SJX8 DI DM5SJX8 DM5SJX8 DN Ac-YK[CEHdFRWC]-NH2 DM5SJX8 TI TT0MV2T DM5SJX8 TN Melanocortin receptor 1 (MC1R) DM5SJX8 MA Inhibitor DM5SJX8 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM5SJX8 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM5SJX8 DI DM5SJX8 DM5SJX8 DN Ac-YK[CEHdFRWC]-NH2 DM5SJX8 TI TTD0CIQ DM5SJX8 TN Melanocortin receptor 4 (MC4R) DM5SJX8 MA Inhibitor DM5SJX8 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM5SJX8 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM5SM8X DI DM5SM8X DM5SM8X DN 3'-THIO-THYMIDINE-5'-PHOSPHATE DM5SM8X TI TT4NVEM DM5SM8X TN DNA topoisomerase II beta (TOP2B) DM5SM8X MA Inhibitor DM5SM8X RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5SM8X RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5SNMQ DI DM5SNMQ DM5SNMQ DN BMS-245782 DM5SNMQ TI TTRK9JT DM5SNMQ TN Neuropeptide Y receptor type 1 (NPY1R) DM5SNMQ MA Inhibitor DM5SNMQ RN Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):5975-8. DM5SNMQ RU https://pubmed.ncbi.nlm.nih.gov/15546711 DM5SOR4 DI DM5SOR4 DM5SOR4 DN L-759,656 DM5SOR4 TI TTMSFAW DM5SOR4 TN Cannabinoid receptor 2 (CB2) DM5SOR4 MA Agonist DM5SOR4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DM5SOR4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DM5SQVC DI DM5SQVC DM5SQVC DN 3-ammoniopropane-1-sulfinate DM5SQVC TI TTDCVZW DM5SQVC TN Gamma-aminobutyric acid B receptor (GABBR) DM5SQVC MA Inhibitor DM5SQVC RN A study of 3-amino-N-hydroxypropanesulfonamide derivatives as potential GABAB agonists and their fragmentation to 3-aminopropanesulfinic acid, Bioorg. Med. Chem. Lett. 6(14):1709-1714 (1996). DM5SQVC RU http://www.sciencedirect.com/science/article/pii/0960894X96003071 DM5SQVC DI DM5SQVC DM5SQVC DN 3-ammoniopropane-1-sulfinate DM5SQVC TI TTNJYV2 DM5SQVC TN Gamma-aminobutyric acid receptor (GAR) DM5SQVC MA Inhibitor DM5SQVC RN A study of 3-amino-N-hydroxypropanesulfonamide derivatives as potential GABAB agonists and their fragmentation to 3-aminopropanesulfinic acid, Bioorg. Med. Chem. Lett. 6(14):1709-1714 (1996). DM5SQVC RU http://www.sciencedirect.com/science/article/pii/0960894X96003071 DM5SRT1 DI DM5SRT1 DM5SRT1 DN [123I]iodoproxyfan DM5SRT1 TI TT9JNIC DM5SRT1 TN Histamine H3 receptor (H3R) DM5SRT1 MA Antagonist DM5SRT1 RN Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol. 2000 Dec;131(7):1247-50. DM5SRT1 RU https://pubmed.ncbi.nlm.nih.gov/11090094 DM5SU6N DI DM5SU6N DM5SU6N DN PMID7650673C4q DM5SU6N TI TTFQEO5 DM5SU6N TN Squalene synthetase (FDFT1) DM5SU6N MA Inhibitor DM5SU6N RN (Aryloxy)methylsilane derivatives as new cholesterol biosynthesis inhibitors: synthesis and hypocholesterolemic activity of a new class of squalene epoxidase inhibitors. J Med Chem. 1995 Aug 18;38(17):3207-16. DM5SU6N RU https://pubmed.ncbi.nlm.nih.gov/7650673 DM5SULN DI DM5SULN DM5SULN DN Haloxyfop DM5SULN TI TTYAWV0 DM5SULN TN Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) DM5SULN MA Binder DM5SULN RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DM5SULN RU https://pubmed.ncbi.nlm.nih.gov/11768328 DM5SUYP DI DM5SUYP DM5SUYP DN H-Apa-ala-Gly-Phe-leu-OH DM5SUYP TI TTKWM86 DM5SUYP TN Opioid receptor mu (MOP) DM5SUYP MA Inhibitor DM5SUYP RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM5SUYP RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM5SUYP DI DM5SUYP DM5SUYP DN H-Apa-ala-Gly-Phe-leu-OH DM5SUYP TI TT27RFC DM5SUYP TN Opioid receptor delta (OPRD1) DM5SUYP MA Inhibitor DM5SUYP RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM5SUYP RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM5SWI1 DI DM5SWI1 DM5SWI1 DN [3H]4NMPB DM5SWI1 TI TTOXS3C DM5SWI1 TN Muscarinic acetylcholine receptor (CHRM) DM5SWI1 MA Antagonist DM5SWI1 RN Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover. EMBO J. 1988 Oct;7(10):3031-5. DM5SWI1 RU https://pubmed.ncbi.nlm.nih.gov/2846274 DM5SWL7 DI DM5SWL7 DM5SWL7 DN 1-benzhydryl-4-(4,4-diphenylbutyl)piperazine DM5SWL7 TI TTFK1JQ DM5SWL7 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM5SWL7 MA Inhibitor DM5SWL7 RN Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. DM5SWL7 RU https://pubmed.ncbi.nlm.nih.gov/19815411 DM5SXYI DI DM5SXYI DM5SXYI DN 2,6-diphenyl-9H-purine DM5SXYI TI TTM2AOE DM5SXYI TN Adenosine A2a receptor (ADORA2A) DM5SXYI MA Inhibitor DM5SXYI RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM5SXYI RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM5SXYI DI DM5SXYI DM5SXYI DN 2,6-diphenyl-9H-purine DM5SXYI TI TTK25J1 DM5SXYI TN Adenosine A1 receptor (ADORA1) DM5SXYI MA Inhibitor DM5SXYI RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM5SXYI RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM5SXYI DI DM5SXYI DM5SXYI DN 2,6-diphenyl-9H-purine DM5SXYI TI TTJFY5U DM5SXYI TN Adenosine A3 receptor (ADORA3) DM5SXYI MA Inhibitor DM5SXYI RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM5SXYI RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM5SYTW DI DM5SYTW DM5SYTW DN PD-81723 DM5SYTW TI TTK25J1 DM5SYTW TN Adenosine A1 receptor (ADORA1) DM5SYTW MA Inhibitor DM5SYTW RN Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of t... J Med Chem. 2008 Sep 25;51(18):5875-9. DM5SYTW RU https://pubmed.ncbi.nlm.nih.gov/18729349 DM5SZHR DI DM5SZHR DM5SZHR DN 6-amino-5-bromouracil DM5SZHR TI TTO0IB8 DM5SZHR TN Thymidine phosphorylase (TYMP) DM5SZHR MA Inhibitor DM5SZHR RN Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors. Eur J Med Chem. 2008 Jun;43(6):1248-60. DM5SZHR RU https://pubmed.ncbi.nlm.nih.gov/17870212 DM5T23S DI DM5T23S DM5T23S DN N-Cyclobutyl-1'H-phenothiazine-1'-carboxamide DM5T23S TI TTEB0GD DM5T23S TN Cholinesterase (BCHE) DM5T23S MA Inhibitor DM5T23S RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM5T23S RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM5T2FR DI DM5T2FR DM5T2FR DN PMID18800762C14 DM5T2FR TI TTIKWV4 DM5T2FR TN Geranyltranstransferase (FDPS) DM5T2FR MA Inhibitor DM5T2FR RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DM5T2FR RU https://pubmed.ncbi.nlm.nih.gov/18800762 DM5T401 DI DM5T401 DM5T401 DN CNX-011 DM5T401 TI TTB8FUC DM5T401 TN Free fatty acid receptor 1 (GPR40) DM5T401 MA Agonist DM5T401 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 225). DM5T401 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=225 DM5T4Y1 DI DM5T4Y1 DM5T4Y1 DN SKL-19014 DM5T4Y1 TI TTDLNGZ DM5T4Y1 TN Glucokinase (GCK) DM5T4Y1 MA Activator DM5T4Y1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798). DM5T4Y1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798 DM5T64L DI DM5T64L DM5T64L DN CHF-5480 DM5T64L TI TTZ97H5 DM5T64L TN Phosphodiesterase 4A (PDE4A) DM5T64L MA Inhibitor DM5T64L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DM5T64L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DM5T64L DI DM5T64L DM5T64L DN CHF-5480 DM5T64L TI TTSKMI8 DM5T64L TN Phosphodiesterase 4D (PDE4D) DM5T64L MA Inhibitor DM5T64L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DM5T64L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DM5T64L DI DM5T64L DM5T64L DN CHF-5480 DM5T64L TI TTVIAT9 DM5T64L TN Phosphodiesterase 4B (PDE4B) DM5T64L MA Inhibitor DM5T64L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DM5T64L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DM5T6AM DI DM5T6AM DM5T6AM DN 3-hydroxydesaminokynurenine DM5T6AM TI TTWQM3J DM5T6AM TN Kynureninase (KYNU) DM5T6AM MA Inhibitor DM5T6AM RN Comparative inhibition by substrate analogues 3-methoxy- and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 2003 Sep 24;4:13. DM5T6AM RU https://pubmed.ncbi.nlm.nih.gov/14505498 DM5TDEW DI DM5TDEW DM5TDEW DN A-846714 DM5TDEW TI TTXJ178 DM5TDEW TN Histamine H4 receptor (H4R) DM5TDEW MA Inhibitor DM5TDEW RN Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and... J Med Chem. 2008 Oct 23;51(20):6547-57. DM5TDEW RU https://pubmed.ncbi.nlm.nih.gov/18817367 DM5TDFQ DI DM5TDFQ DM5TDFQ DN [3H]nitrobenzylmercaptopurine ribonucleoside DM5TDFQ TI TTLXAKE DM5TDFQ TN Solute carrier family 29 member 1 (SLC29A1) DM5TDFQ MA Modulator DM5TDFQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1117). DM5TDFQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1117 DM5TH2W DI DM5TH2W DM5TH2W DN (R)-3-(2-naphthamido)-4-m-tolylbutanoic acid DM5TH2W TI TTJNTSI DM5TH2W TN Rotamase Pin1 (PIN1) DM5TH2W MA Inhibitor DM5TH2W RN Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. DM5TH2W RU https://pubmed.ncbi.nlm.nih.gov/20207139 DM5TL2S DI DM5TL2S DM5TL2S DN PMID2153213C13g DM5TL2S TI TTPADOQ DM5TL2S TN HMG-CoA reductase (HMGCR) DM5TL2S MA Inhibitor DM5TL2S RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DM5TL2S RU https://pubmed.ncbi.nlm.nih.gov/2153213 DM5TOX2 DI DM5TOX2 DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one DM5TOX2 TI TTZHA0O DM5TOX2 TN Carbonic anhydrase IV (CA-IV) DM5TOX2 MA Inhibitor DM5TOX2 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM5TOX2 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM5TOX2 DI DM5TOX2 DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one DM5TOX2 TI TTUNARX DM5TOX2 TN Carbonic anhydrase (CA) DM5TOX2 MA Inhibitor DM5TOX2 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM5TOX2 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM5TOX2 DI DM5TOX2 DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one DM5TOX2 TI TTSYM0R DM5TOX2 TN Carbonic anhydrase XII (CA-XII) DM5TOX2 MA Inhibitor DM5TOX2 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM5TOX2 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM5TOX2 DI DM5TOX2 DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one DM5TOX2 TI TTANPDJ DM5TOX2 TN Carbonic anhydrase II (CA-II) DM5TOX2 MA Inhibitor DM5TOX2 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM5TOX2 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM5TOX2 DI DM5TOX2 DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one DM5TOX2 TI TTEYTKG DM5TOX2 TN Carbonic anhydrase XIV (CA-XIV) DM5TOX2 MA Inhibitor DM5TOX2 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM5TOX2 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM5TOX2 DI DM5TOX2 DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one DM5TOX2 TI TT2LVK8 DM5TOX2 TN Carbonic anhydrase IX (CA-IX) DM5TOX2 MA Inhibitor DM5TOX2 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM5TOX2 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM5TOX2 DI DM5TOX2 DM5TOX2 DN 6-(hydroxymethyl)-2H-chromen-2-one DM5TOX2 TI TTCFSPE DM5TOX2 TN Carbonic anhydrase VI (CA-VI) DM5TOX2 MA Inhibitor DM5TOX2 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM5TOX2 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM5TPEJ DI DM5TPEJ DM5TPEJ DN N-benzyl-4-hydroxy-N-phenylbenzenesulfonamide DM5TPEJ TI TTZAYWL DM5TPEJ TN Estrogen receptor (ESR) DM5TPEJ MA Inhibitor DM5TPEJ RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DM5TPEJ RU https://pubmed.ncbi.nlm.nih.gov/16300947 DM5TQ2O DI DM5TQ2O DM5TQ2O DN Galangin DM5TQ2O TI TTJFY5U DM5TQ2O TN Adenosine A3 receptor (ADORA3) DM5TQ2O MA Inhibitor DM5TQ2O RN Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8. DM5TQ2O RU https://pubmed.ncbi.nlm.nih.gov/8576921 DM5TQ2O DI DM5TQ2O DM5TQ2O DN Galangin DM5TQ2O TI TTI84H7 DM5TQ2O TN Cytochrome P450 1B1 (CYP1B1) DM5TQ2O MA Inhibitor DM5TQ2O RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM5TQ2O RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM5TQ2O DI DM5TQ2O DM5TQ2O DN Galangin DM5TQ2O TI TTM2AOE DM5TQ2O TN Adenosine A2a receptor (ADORA2A) DM5TQ2O MA Inhibitor DM5TQ2O RN Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem. 1997 Aug 1;40(16):2588-95. DM5TQ2O RU https://pubmed.ncbi.nlm.nih.gov/9258366 DM5TR49 DI DM5TR49 DM5TR49 DN XMT-1191 DM5TR49 TI TTZL0OI DM5TR49 TN Methionine aminopeptidase 2 (METAP2) DM5TR49 MA Inhibitor DM5TR49 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1573). DM5TR49 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1573 DM5TSJF DI DM5TSJF DM5TSJF DN 8-(2,4,6-trimethoxyphenyl)-9H-purine-2,6-diamine DM5TSJF TI TT9SL3Q DM5TSJF TN Polypeptide deformylase (PDF) DM5TSJF MA Inhibitor DM5TSJF RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DM5TSJF RU https://pubmed.ncbi.nlm.nih.gov/20117005 DM5TU98 DI DM5TU98 DM5TU98 DN 4-hydroxy-N-phenyl-N-propylbenzenesulfonamide DM5TU98 TI TTZAYWL DM5TU98 TN Estrogen receptor (ESR) DM5TU98 MA Inhibitor DM5TU98 RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DM5TU98 RU https://pubmed.ncbi.nlm.nih.gov/16300947 DM5TXY1 DI DM5TXY1 DM5TXY1 DN 7,8-Dihydroneopterin DM5TXY1 TI TTG9CFY DM5TXY1 TN Bacterial Dihydroneopterinaldolase (Bact folB) DM5TXY1 MA Inhibitor DM5TXY1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5TXY1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5TYMG DI DM5TYMG DM5TYMG DN LY86057 DM5TYMG TI TT0K1SC DM5TYMG TN 5-HT 2B receptor (HTR2B) DM5TYMG MA Antagonist DM5TYMG RN Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. DM5TYMG RU https://pubmed.ncbi.nlm.nih.gov/8450835 DM5TYMG DI DM5TYMG DM5TYMG DN LY86057 DM5TYMG TI TTJQOD7 DM5TYMG TN 5-HT 2A receptor (HTR2A) DM5TYMG MA Antagonist DM5TYMG RN Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86. DM5TYMG RU https://pubmed.ncbi.nlm.nih.gov/8114677 DM5TZ1J DI DM5TZ1J DM5TZ1J DN H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid DM5TZ1J TI TT27RFC DM5TZ1J TN Opioid receptor delta (OPRD1) DM5TZ1J MA Inhibitor DM5TZ1J RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM5TZ1J RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM5TZ1J DI DM5TZ1J DM5TZ1J DN H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid DM5TZ1J TI TTKWM86 DM5TZ1J TN Opioid receptor mu (MOP) DM5TZ1J MA Inhibitor DM5TZ1J RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DM5TZ1J RU https://pubmed.ncbi.nlm.nih.gov/18680274 DM5U1LN DI DM5U1LN DM5U1LN DN aloisine A DM5U1LN TI TTQWAU1 DM5U1LN TN GSK3A messenger RNA (GSK3A mRNA) DM5U1LN MA Inhibitor DM5U1LN RN Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. DM5U1LN RU https://pubmed.ncbi.nlm.nih.gov/12519061 DM5U1LN DI DM5U1LN DM5U1LN DN aloisine A DM5U1LN TI TTH6V3D DM5U1LN TN Cyclin-dependent kinase 1 (CDK1) DM5U1LN MA Inhibitor DM5U1LN RN Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. DM5U1LN RU https://pubmed.ncbi.nlm.nih.gov/12519061 DM5U1LN DI DM5U1LN DM5U1LN DN aloisine A DM5U1LN TI TT7HF4W DM5U1LN TN Cyclin-dependent kinase 2 (CDK2) DM5U1LN MA Inhibitor DM5U1LN RN Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. DM5U1LN RU https://pubmed.ncbi.nlm.nih.gov/12519061 DM5U1LN DI DM5U1LN DM5U1LN DN aloisine A DM5U1LN TI TTL4Q97 DM5U1LN TN Cyclin-dependent kinase 5 (CDK5) DM5U1LN MA Inhibitor DM5U1LN RN Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. DM5U1LN RU https://pubmed.ncbi.nlm.nih.gov/12519061 DM5U1LN DI DM5U1LN DM5U1LN DN aloisine A DM5U1LN TI TTCEJ4F DM5U1LN TN G1/S-specific cyclin-E1 (CCNE1) DM5U1LN MA Inhibitor DM5U1LN RN Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. DM5U1LN RU https://pubmed.ncbi.nlm.nih.gov/12519061 DM5U1LN DI DM5U1LN DM5U1LN DN aloisine A DM5U1LN TI TTAMQ62 DM5U1LN TN Cyclin A2 (CCNA2) DM5U1LN MA Inhibitor DM5U1LN RN Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36. DM5U1LN RU https://pubmed.ncbi.nlm.nih.gov/12519061 DM5U1M8 DI DM5U1M8 DM5U1M8 DN (Z)-5-Decylidene-2-thioxothiazolidin-4-one DM5U1M8 TI TT1K6Q4 DM5U1M8 TN Arylamine N-acetyltransferase (NAT) DM5U1M8 MA Inhibitor DM5U1M8 RN Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18. DM5U1M8 RU https://pubmed.ncbi.nlm.nih.gov/19059786 DM5U6ZW DI DM5U6ZW DM5U6ZW DN 4-tert-butyl-N-(naphthalen-1-yl)oxazol-2-amine DM5U6ZW TI TT7HQD0 DM5U6ZW TN C-C chemokine receptor type 4 (CCR4) DM5U6ZW MA Inhibitor DM5U6ZW RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DM5U6ZW RU https://pubmed.ncbi.nlm.nih.gov/16497499 DM5UFZX DI DM5UFZX DM5UFZX DN Diazaborines DM5UFZX TI TTNSXG2 DM5UFZX TN Human immunodeficiency virus TAR RNA (HIV TAR-RNA) DM5UFZX MA Inhibitor DM5UFZX RN Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry. 2001 Dec 25;40(51):15612-23. DM5UFZX RU https://pubmed.ncbi.nlm.nih.gov/11747436 DM5UFZX DI DM5UFZX DM5UFZX DN Diazaborines DM5UFZX TI TT283NK DM5UFZX TN Bacterial NADH-dependent enoyl-ACP reductase 2 (Bact fabI2) DM5UFZX MA Inhibitor DM5UFZX RN Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97. DM5UFZX RU https://pubmed.ncbi.nlm.nih.gov/11591436 DM5UFZX DI DM5UFZX DM5UFZX DN Diazaborines DM5UFZX TI TTCH81V DM5UFZX TN Bacterial NADH-dependent enoyl-ACP reductase 1 (Bact fabI1) DM5UFZX MA Inhibitor DM5UFZX RN Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97. DM5UFZX RU https://pubmed.ncbi.nlm.nih.gov/11591436 DM5UFZX DI DM5UFZX DM5UFZX DN Diazaborines DM5UFZX TI TTNX2CS DM5UFZX TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM5UFZX MA Inhibitor DM5UFZX RN Lipid biosynthesis as a target for antibacterial agents. Prog Lipid Res. 2001 Nov;40(6):467-97. DM5UFZX RU https://pubmed.ncbi.nlm.nih.gov/11591436 DM5UL3F DI DM5UL3F DM5UL3F DN 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine DM5UL3F TI TTP3QRF DM5UL3F TN Thymidine kinase 1 (TK1) DM5UL3F MA Inhibitor DM5UL3F RN 3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase. J Med Chem. 2010 Apr 8;53(7):2902-12. DM5UL3F RU https://pubmed.ncbi.nlm.nih.gov/20218622 DM5UNBW DI DM5UNBW DM5UNBW DN 4-Phenylimidazole DM5UNBW TI TTZJYKH DM5UNBW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM5UNBW MA Inhibitor DM5UNBW RN Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77. DM5UNBW RU https://pubmed.ncbi.nlm.nih.gov/18665584 DM5UOFY DI DM5UOFY DM5UOFY DN (R)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one DM5UOFY TI TTGP7BY DM5UOFY TN Monoamine oxidase type B (MAO-B) DM5UOFY MA Inhibitor DM5UOFY RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM5UOFY RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM5UOYM DI DM5UOYM DM5UOYM DN GR-45809 DM5UOYM TI TTQW87Y DM5UOYM TN Opioid receptor kappa (OPRK1) DM5UOYM MA Modulator DM5UOYM RN J. Med. Chem. 1993,36, 2075-2083 DM5UOYM RU http://pubs.acs.org/doi/pdf/10.1021/jm00067a004 DM5UWH9 DI DM5UWH9 DM5UWH9 DN 1-Ethyl-3-imidazol-1-ylmethyl-1H-indole DM5UWH9 TI TTIQUX7 DM5UWH9 TN Steroid 11-beta-hydroxylase (CYP11B1) DM5UWH9 MA Inhibitor DM5UWH9 RN Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues. J Med Chem. 1986 Mar;29(3):342-6. DM5UWH9 RU https://pubmed.ncbi.nlm.nih.gov/3081722 DM5V3M1 DI DM5V3M1 DM5V3M1 DN (2S)-abyssinone II DM5V3M1 TI TTSZLWK DM5V3M1 TN Aromatase (CYP19A1) DM5V3M1 MA Inhibitor DM5V3M1 RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DM5V3M1 RU https://pubmed.ncbi.nlm.nih.gov/11678652 DM5V3S7 DI DM5V3S7 DM5V3S7 DN Ezetimibe-glucuronide DM5V3S7 TI TTPD1CN DM5V3S7 TN Niemann-Pick C1-like protein 1 (NPC1L1) DM5V3S7 MA Inhibitor DM5V3S7 RN Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2965-8. DM5V3S7 RU https://pubmed.ncbi.nlm.nih.gov/19410454 DM5VDU2 DI DM5VDU2 DM5VDU2 DN HBN-2 DM5VDU2 TI TTTUMEP DM5VDU2 TN Neurotensin receptor type 1 (NTSR1) DM5VDU2 MA Modulator DM5VDU2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309). DM5VDU2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=309 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TT4C8EA DM5VJAF TN Dopamine D3 receptor (D3R) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTJS8PY DM5VJAF TN 5-HT 6 receptor (HTR6) DM5VJAF MA Inhibitor DM5VJAF RN Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/19346128 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTZFYLI DM5VJAF TN Dopamine D1 receptor (D1R) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTJQOD7 DM5VJAF TN 5-HT 2A receptor (HTR2A) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTSQIFT DM5VJAF TN 5-HT 1A receptor (HTR1A) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTE0A2F DM5VJAF TN Dopamine D4 receptor (D4R) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTO9X1H DM5VJAF TN 5-HT 7 receptor (HTR7) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTEX248 DM5VJAF TN Dopamine D2 receptor (D2R) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJAF DI DM5VJAF DM5VJAF DN SB-271046 DM5VJAF TI TTWJBZ5 DM5VJAF TN 5-HT 2C receptor (HTR2C) DM5VJAF MA Inhibitor DM5VJAF RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DM5VJAF RU https://pubmed.ncbi.nlm.nih.gov/18053713 DM5VJQP DI DM5VJQP DM5VJQP DN TG-1031 DM5VJQP TI TTBHFYQ DM5VJQP TN Mucin-1 (MUC1) DM5VJQP MA Modulator DM5VJQP RN Technology evaluation: TG-1031, Transgene SA.Curr Opin Mol Ther.2000 Feb;2(1):106-11. DM5VJQP RU https://www.ncbi.nlm.nih.gov/pubmed/11249647 DM5VJQP DI DM5VJQP DM5VJQP DN TG-1031 DM5VJQP TI TTF89GD DM5VJQP TN Interleukin-2 (IL2) DM5VJQP MA Modulator DM5VJQP RN Technology evaluation: TG-1031, Transgene SA.Curr Opin Mol Ther.2000 Feb;2(1):106-11. DM5VJQP RU https://www.ncbi.nlm.nih.gov/pubmed/11249647 DM5VLIE DI DM5VLIE DM5VLIE DN 1,2,3,4-Tetrahydro-isoquinolin-7-ol DM5VLIE TI TTWG9A4 DM5VLIE TN Adrenergic receptor alpha-2A (ADRA2A) DM5VLIE MA Inhibitor DM5VLIE RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DM5VLIE RU https://pubmed.ncbi.nlm.nih.gov/9406590 DM5VLIE DI DM5VLIE DM5VLIE DN 1,2,3,4-Tetrahydro-isoquinolin-7-ol DM5VLIE TI TTWM4TY DM5VLIE TN Adrenergic receptor alpha-2B (ADRA2B) DM5VLIE MA Inhibitor DM5VLIE RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DM5VLIE RU https://pubmed.ncbi.nlm.nih.gov/9406590 DM5VLIE DI DM5VLIE DM5VLIE DN 1,2,3,4-Tetrahydro-isoquinolin-7-ol DM5VLIE TI TT2NUT5 DM5VLIE TN Adrenergic receptor alpha-2C (ADRA2C) DM5VLIE MA Inhibitor DM5VLIE RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DM5VLIE RU https://pubmed.ncbi.nlm.nih.gov/9406590 DM5VN3D DI DM5VN3D DM5VN3D DN 4-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine DM5VN3D TI TTSZLWK DM5VN3D TN Aromatase (CYP19A1) DM5VN3D MA Inhibitor DM5VN3D RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM5VN3D RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM5VQ8E DI DM5VQ8E DM5VQ8E DN A-224940 DM5VQ8E TI TTX4RTB DM5VQ8E TN Melanin-concentrating hormone receptor 1 (MCHR1) DM5VQ8E MA Inhibitor DM5VQ8E RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 3. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4883-6. DM5VQ8E RU https://pubmed.ncbi.nlm.nih.gov/15341944 DM5VWCI DI DM5VWCI DM5VWCI DN Ly231514 Tetra Glu DM5VWCI TI TTU6BFZ DM5VWCI TN Candida Thymidylate synthase (Candi TMP1) DM5VWCI MA Inhibitor DM5VWCI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5VWCI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5W1VF DI DM5W1VF DM5W1VF DN FGGFTGARKSARKAANQ DM5W1VF TI TTNT7K8 DM5W1VF TN Nociceptin receptor (OPRL1) DM5W1VF MA Inhibitor DM5W1VF RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DM5W1VF RU https://pubmed.ncbi.nlm.nih.gov/18818087 DM5W2VK DI DM5W2VK DM5W2VK DN N-allylnorlitebamine DM5W2VK TI TT1RS9F DM5W2VK TN Acetylcholinesterase (AChE) DM5W2VK MA Inhibitor DM5W2VK RN Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50. DM5W2VK RU https://pubmed.ncbi.nlm.nih.gov/9461651 DM5W9GR DI DM5W9GR DM5W9GR DN WR-289009 DM5W9GR TI TTSFWA7 DM5W9GR TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DM5W9GR MA Inhibitor DM5W9GR RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DM5W9GR RU https://pubmed.ncbi.nlm.nih.gov/19250824 DM5WAM8 DI DM5WAM8 DM5WAM8 DN VER-2692 DM5WAM8 TI TTJQOD7 DM5WAM8 TN 5-HT 2A receptor (HTR2A) DM5WAM8 MA Inhibitor DM5WAM8 RN Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. DM5WAM8 RU https://pubmed.ncbi.nlm.nih.gov/16257207 DM5WAM8 DI DM5WAM8 DM5WAM8 DN VER-2692 DM5WAM8 TI TT0K1SC DM5WAM8 TN 5-HT 2B receptor (HTR2B) DM5WAM8 MA Inhibitor DM5WAM8 RN Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. DM5WAM8 RU https://pubmed.ncbi.nlm.nih.gov/16257207 DM5WAM8 DI DM5WAM8 DM5WAM8 DN VER-2692 DM5WAM8 TI TTWJBZ5 DM5WAM8 TN 5-HT 2C receptor (HTR2C) DM5WAM8 MA Inhibitor DM5WAM8 RN Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. DM5WAM8 RU https://pubmed.ncbi.nlm.nih.gov/16257207 DM5WBMY DI DM5WBMY DM5WBMY DN 1-(10H-phenothiazin-10-yl)-2-phenylethanone DM5WBMY TI TTEB0GD DM5WBMY TN Cholinesterase (BCHE) DM5WBMY MA Inhibitor DM5WBMY RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DM5WBMY RU https://pubmed.ncbi.nlm.nih.gov/17681768 DM5WEFK DI DM5WEFK DM5WEFK DN Dmt-Pro-3,5Dmp-Phe-NH2 DM5WEFK TI TTQW87Y DM5WEFK TN Opioid receptor kappa (OPRK1) DM5WEFK MA Inhibitor DM5WEFK RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM5WEFK RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM5WEFK DI DM5WEFK DM5WEFK DN Dmt-Pro-3,5Dmp-Phe-NH2 DM5WEFK TI TT27RFC DM5WEFK TN Opioid receptor delta (OPRD1) DM5WEFK MA Inhibitor DM5WEFK RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM5WEFK RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM5WEFK DI DM5WEFK DM5WEFK DN Dmt-Pro-3,5Dmp-Phe-NH2 DM5WEFK TI TTKWM86 DM5WEFK TN Opioid receptor mu (MOP) DM5WEFK MA Inhibitor DM5WEFK RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM5WEFK RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM5WETL DI DM5WETL DM5WETL DN (S)-FTY720P DM5WETL TI TT9JZCK DM5WETL TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM5WETL MA Inhibitor DM5WETL RN Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol. 2009 Jun;5(6):428-34. DM5WETL RU https://pubmed.ncbi.nlm.nih.gov/19430484 DM5WFQM DI DM5WFQM DM5WFQM DN BIS(9)-HUPERZINE B DM5WFQM TI TT1RS9F DM5WFQM TN Acetylcholinesterase (AChE) DM5WFQM MA Inhibitor DM5WFQM RN Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7. DM5WFQM RU https://pubmed.ncbi.nlm.nih.gov/15689148 DM5WH6R DI DM5WH6R DM5WH6R DN (C8-R)-Hydantocidin 5'-Phosphate DM5WH6R TI TTYQ4AE DM5WH6R TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DM5WH6R MA Inhibitor DM5WH6R RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5WH6R RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5WJBH DI DM5WJBH DM5WJBH DN (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine DM5WJBH TI TT2NUT5 DM5WJBH TN Adrenergic receptor alpha-2C (ADRA2C) DM5WJBH MA Inhibitor DM5WJBH RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM5WJBH RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM5WJBH DI DM5WJBH DM5WJBH DN (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine DM5WJBH TI TTWM4TY DM5WJBH TN Adrenergic receptor alpha-2B (ADRA2B) DM5WJBH MA Inhibitor DM5WJBH RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM5WJBH RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM5WJBH DI DM5WJBH DM5WJBH DN (3-Ethyl-indol-1-yl)-propyl-pyridin-4-yl-amine DM5WJBH TI TTWG9A4 DM5WJBH TN Adrenergic receptor alpha-2A (ADRA2A) DM5WJBH MA Inhibitor DM5WJBH RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DM5WJBH RU https://pubmed.ncbi.nlm.nih.gov/8558529 DM5WMXJ DI DM5WMXJ DM5WMXJ DN MR-1526 DM5WMXJ TI TTQW87Y DM5WMXJ TN Opioid receptor kappa (OPRK1) DM5WMXJ MA Inhibitor DM5WMXJ RN Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44. DM5WMXJ RU https://pubmed.ncbi.nlm.nih.gov/1652019 DM5WMXJ DI DM5WMXJ DM5WMXJ DN MR-1526 DM5WMXJ TI TTKWM86 DM5WMXJ TN Opioid receptor mu (MOP) DM5WMXJ MA Inhibitor DM5WMXJ RN Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44. DM5WMXJ RU https://pubmed.ncbi.nlm.nih.gov/1652019 DM5WNH8 DI DM5WNH8 DM5WNH8 DN Mahureone D DM5WNH8 TI TTIU7X1 DM5WNH8 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM5WNH8 MA Inhibitor DM5WNH8 RN Acylphloroglucinol derivatives from Mahurea palustris. J Nat Prod. 2005 Jul;68(7):979-84. DM5WNH8 RU https://pubmed.ncbi.nlm.nih.gov/16038535 DM5WOK8 DI DM5WOK8 DM5WOK8 DN 1-(3,5-bis(trifluoromethyl)benzyl)-1H-imidazole DM5WOK8 TI TTRA5BZ DM5WOK8 TN Steroid 17-alpha-monooxygenase (S17AH) DM5WOK8 MA Inhibitor DM5WOK8 RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DM5WOK8 RU https://pubmed.ncbi.nlm.nih.gov/16750362 DM5WOSM DI DM5WOSM DM5WOSM DN 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine DM5WOSM TI TTM2AOE DM5WOSM TN Adenosine A2a receptor (ADORA2A) DM5WOSM MA Inhibitor DM5WOSM RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DM5WOSM RU https://pubmed.ncbi.nlm.nih.gov/17665891 DM5WOSM DI DM5WOSM DM5WOSM DN 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4-amine DM5WOSM TI TTK25J1 DM5WOSM TN Adenosine A1 receptor (ADORA1) DM5WOSM MA Inhibitor DM5WOSM RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DM5WOSM RU https://pubmed.ncbi.nlm.nih.gov/17665891 DM5WR0L DI DM5WR0L DM5WR0L DN ASC-201 DM5WR0L TI TTDIGC1 DM5WR0L TN Dipeptidyl peptidase 4 (DPP-4) DM5WR0L MA Inhibitor DM5WR0L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DM5WR0L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DM5WV13 DI DM5WV13 DM5WV13 DN AD-5061 DM5WV13 TI TTJ584C DM5WV13 TN Peroxisome proliferator-activated receptor alpha (PPARA) DM5WV13 MA Agonist DM5WV13 RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM5WV13 RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM5WV13 DI DM5WV13 DM5WV13 DN AD-5061 DM5WV13 TI TTT2SVW DM5WV13 TN PPAR-gamma messenger RNA (PPARG mRNA) DM5WV13 MA Agonist DM5WV13 RN A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26. DM5WV13 RU https://pubmed.ncbi.nlm.nih.gov/15219816 DM5X0JS DI DM5X0JS DM5X0JS DN I-ABOPX DM5X0JS TI TTJFY5U DM5X0JS TN Adenosine A3 receptor (ADORA3) DM5X0JS MA Antagonist DM5X0JS RN Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365-9. DM5X0JS RU https://pubmed.ncbi.nlm.nih.gov/8234299 DM5X0JS DI DM5X0JS DM5X0JS DN I-ABOPX DM5X0JS TI TTNE7KG DM5X0JS TN Adenosine A2b receptor (ADORA2B) DM5X0JS MA Antagonist DM5X0JS RN Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13. DM5X0JS RU https://pubmed.ncbi.nlm.nih.gov/10496952 DM5XEZI DI DM5XEZI DM5XEZI DN Isosorbide-2-benzylcarbamate-5-(o-toluate) DM5XEZI TI TTEB0GD DM5XEZI TN Cholinesterase (BCHE) DM5XEZI MA Inhibitor DM5XEZI RN Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2010 Feb 11;53(3):1190-9. DM5XEZI RU https://pubmed.ncbi.nlm.nih.gov/20067290 DM5XHA6 DI DM5XHA6 DM5XHA6 DN D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide DM5XHA6 TI TT6L509 DM5XHA6 TN Coagulation factor IIa (F2) DM5XHA6 MA Inhibitor DM5XHA6 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5XHA6 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5XMI9 DI DM5XMI9 DM5XMI9 DN 4-Methylamino-benzenesulfonamide DM5XMI9 TI TTANPDJ DM5XMI9 TN Carbonic anhydrase II (CA-II) DM5XMI9 MA Inhibitor DM5XMI9 RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DM5XMI9 RU https://pubmed.ncbi.nlm.nih.gov/15686894 DM5XMI9 DI DM5XMI9 DM5XMI9 DN 4-Methylamino-benzenesulfonamide DM5XMI9 TI TTSYM0R DM5XMI9 TN Carbonic anhydrase XII (CA-XII) DM5XMI9 MA Inhibitor DM5XMI9 RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DM5XMI9 RU https://pubmed.ncbi.nlm.nih.gov/15686894 DM5XSMN DI DM5XSMN DM5XSMN DN [3H]Ro 63-0563 DM5XSMN TI TTJS8PY DM5XSMN TN 5-HT 6 receptor (HTR6) DM5XSMN MA Antagonist DM5XSMN RN The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol. 1998 Sep;54(3):577-83. DM5XSMN RU https://pubmed.ncbi.nlm.nih.gov/9730917 DM5XYFN DI DM5XYFN DM5XYFN DN Ethyl 3-(biphenyl-3-ylamino)-2-cyanoacrylate DM5XYFN TI TT3PQ2Y DM5XYFN TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM5XYFN MA Inhibitor DM5XYFN RN Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91. DM5XYFN RU https://pubmed.ncbi.nlm.nih.gov/17228860 DM5XZYB DI DM5XZYB DM5XZYB DN Azide DM5XZYB TI TTHQPL7 DM5XZYB TN Carbonic anhydrase I (CA-I) DM5XZYB MA Inhibitor DM5XZYB RN Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73. DM5XZYB RU https://pubmed.ncbi.nlm.nih.gov/15501038 DM5XZYB DI DM5XZYB DM5XZYB DN Azide DM5XZYB TI TT2LVK8 DM5XZYB TN Carbonic anhydrase IX (CA-IX) DM5XZYB MA Inhibitor DM5XZYB RN Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73. DM5XZYB RU https://pubmed.ncbi.nlm.nih.gov/15501038 DM5XZYB DI DM5XZYB DM5XZYB DN Azide DM5XZYB TI TTANPDJ DM5XZYB TN Carbonic anhydrase II (CA-II) DM5XZYB MA Inhibitor DM5XZYB RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DM5XZYB RU https://pubmed.ncbi.nlm.nih.gov/15454240 DM5Y2M8 DI DM5Y2M8 DM5Y2M8 DN BENZIL DM5Y2M8 TI TTMF541 DM5Y2M8 TN Liver carboxylesterase (CES1) DM5Y2M8 MA Inhibitor DM5Y2M8 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM5Y2M8 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM5YC2K DI DM5YC2K DM5YC2K DN 2-Phenyl-3-(2-piperidin-1-yl-ethyl)-1H-indole DM5YC2K TI TTJQOD7 DM5YC2K TN 5-HT 2A receptor (HTR2A) DM5YC2K MA Inhibitor DM5YC2K RN 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3. DM5YC2K RU https://pubmed.ncbi.nlm.nih.gov/11133072 DM5YJP3 DI DM5YJP3 DM5YJP3 DN 2-(tert-Butylamino)-3'-fluoropropiophenone DM5YJP3 TI TTVBI8W DM5YJP3 TN Dopamine transporter (DAT) DM5YJP3 MA Inhibitor DM5YJP3 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DM5YJP3 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DM5YR4S DI DM5YR4S DM5YR4S DN GWTLNSAGYLLGPRHYINLITRQRY-CONH2 DM5YR4S TI TTX3HNZ DM5YR4S TN Galanin receptor type 1 (GAL1-R) DM5YR4S MA Inhibitor DM5YR4S RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM5YR4S RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM5YR4S DI DM5YR4S DM5YR4S DN GWTLNSAGYLLGPRHYINLITRQRY-CONH2 DM5YR4S TI TTBPW3J DM5YR4S TN Galanin receptor type 2 (GAL2-R) DM5YR4S MA Inhibitor DM5YR4S RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM5YR4S RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM5Z0O6 DI DM5Z0O6 DM5Z0O6 DN 3-Amino-4-Oxybenzyl-2-Butanone DM5Z0O6 TI TTF2LRI DM5Z0O6 TN Cathepsin B (CTSB) DM5Z0O6 MA Inhibitor DM5Z0O6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM5Z0O6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM5Z4JR DI DM5Z4JR DM5Z4JR DN PMID30247903-Compound-General structure14 DM5Z4JR TI TTNBFWK DM5Z4JR TN Programmed cell death protein 1 (PD-1) DM5Z4JR MA antagonist DM5Z4JR RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM5Z4JR RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM5Z64L DI DM5Z64L DM5Z64L DN 4-[4-(benzhydryloxy)piperidino]butyl benzoate DM5Z64L TI TT1RS9F DM5Z64L TN Acetylcholinesterase (AChE) DM5Z64L MA Inhibitor DM5Z64L RN Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. DM5Z64L RU https://pubmed.ncbi.nlm.nih.gov/17681794 DM5Z6XG DI DM5Z6XG DM5Z6XG DN 1,6-bis(4-m-tolylpiperazin-1-yl)hexane DM5Z6XG TI TTQ6VDM DM5Z6XG TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM5Z6XG MA Inhibitor DM5Z6XG RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DM5Z6XG RU https://pubmed.ncbi.nlm.nih.gov/20481570 DM5Z6XG DI DM5Z6XG DM5Z6XG DN 1,6-bis(4-m-tolylpiperazin-1-yl)hexane DM5Z6XG TI TTEX248 DM5Z6XG TN Dopamine D2 receptor (D2R) DM5Z6XG MA Inhibitor DM5Z6XG RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DM5Z6XG RU https://pubmed.ncbi.nlm.nih.gov/20481570 DM5Z6XG DI DM5Z6XG DM5Z6XG DN 1,6-bis(4-m-tolylpiperazin-1-yl)hexane DM5Z6XG TI TTJQOD7 DM5Z6XG TN 5-HT 2A receptor (HTR2A) DM5Z6XG MA Inhibitor DM5Z6XG RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DM5Z6XG RU https://pubmed.ncbi.nlm.nih.gov/20481570 DM5Z6XG DI DM5Z6XG DM5Z6XG DN 1,6-bis(4-m-tolylpiperazin-1-yl)hexane DM5Z6XG TI TTSQIFT DM5Z6XG TN 5-HT 1A receptor (HTR1A) DM5Z6XG MA Inhibitor DM5Z6XG RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DM5Z6XG RU https://pubmed.ncbi.nlm.nih.gov/20481570 DM5ZAS6 DI DM5ZAS6 DM5ZAS6 DN Pyrrolidine dithiocarbamate DM5ZAS6 TI TTSXVID DM5ZAS6 TN Nuclear factor NF-kappa-B (NFKB) DM5ZAS6 MA Inhibitor DM5ZAS6 RN Simulated ischemia induces renal tubular cell apoptosis through a nuclear factor-kappaB dependent mechanism. J Urol. 2002 Jul;168(1):248-52. DM5ZAS6 RU https://pubmed.ncbi.nlm.nih.gov/12050551 DM5ZBF3 DI DM5ZBF3 DM5ZBF3 DN TRIAZOLOPYRIMIDINE DM5ZBF3 TI TT7HF4W DM5ZBF3 TN Cyclin-dependent kinase 2 (CDK2) DM5ZBF3 MA Inhibitor DM5ZBF3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM5ZBF3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM5ZE7F DI DM5ZE7F DM5ZE7F DN Salvinorin B 1-ethoxyethyl ether DM5ZE7F TI TTQW87Y DM5ZE7F TN Opioid receptor kappa (OPRK1) DM5ZE7F MA Inhibitor DM5ZE7F RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DM5ZE7F RU https://pubmed.ncbi.nlm.nih.gov/17981041 DM5ZEPD DI DM5ZEPD DM5ZEPD DN SCH79687 DM5ZEPD TI TT9JNIC DM5ZEPD TN Histamine H3 receptor (H3R) DM5ZEPD MA Antagonist DM5ZEPD RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM5ZEPD RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM5ZGSO DI DM5ZGSO DM5ZGSO DN ISIS 9062 DM5ZGSO TI TT5TURO DM5ZGSO TN A-Raf messenger RNA (ARAF mRNA) DM5ZGSO RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DM5ZGSO RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DM5ZILV DI DM5ZILV DM5ZILV DN Silicon-modified indomethacin DM5ZILV TI TTVKILB DM5ZILV TN Prostaglandin G/H synthase 2 (COX-2) DM5ZILV MA Inhibitor DM5ZILV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376). DM5ZILV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376 DM5ZIUW DI DM5ZIUW DM5ZIUW DN (D)-Phe-(D)-Phe-NH2 DM5ZIUW TI TTZPO1L DM5ZIUW TN Substance-P receptor (TACR1) DM5ZIUW MA Inhibitor DM5ZIUW RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DM5ZIUW RU https://pubmed.ncbi.nlm.nih.gov/20178322 DM5ZJ3G DI DM5ZJ3G DM5ZJ3G DN OL-92 DM5ZJ3G TI TTDP1UC DM5ZJ3G TN Fatty acid amide hydrolase (FAAH) DM5ZJ3G MA Inhibitor DM5ZJ3G RN Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem. 2009 Jan 8;52(1):170-80. DM5ZJ3G RU https://pubmed.ncbi.nlm.nih.gov/19072118 DM5ZQK1 DI DM5ZQK1 DM5ZQK1 DN 4-Hydroxy-pent-2-enoic acid DM5ZQK1 TI TT6TKEN DM5ZQK1 TN Gamma-hydroxybutyrate receptor (SLC52A2) DM5ZQK1 MA Inhibitor DM5ZQK1 RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DM5ZQK1 RU https://pubmed.ncbi.nlm.nih.gov/3361576 DM5ZR4S DI DM5ZR4S DM5ZR4S DN [D-Dap(CO-NH-OCH3)3]degarelix DM5ZR4S TI TT8R70G DM5ZR4S TN Gonadotropin-releasing hormone receptor (GNRHR) DM5ZR4S MA Inhibitor DM5ZR4S RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DM5ZR4S RU https://pubmed.ncbi.nlm.nih.gov/16759096 DM5ZTJL DI DM5ZTJL DM5ZTJL DN Calmidazolium DM5ZTJL TI TTV3NH6 DM5ZTJL TN Calmodulin (CALM) DM5ZTJL MA Inhibitor DM5ZTJL RN Calmidazolium evokes high calcium fluctuations in Plasmodium falciparum. Cell Signal. 2016 Mar;28(3):125-135. DM5ZTJL RU https://pubmed.ncbi.nlm.nih.gov/26689736 DM5ZTXL DI DM5ZTXL DM5ZTXL DN (11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid DM5ZTXL TI TTVKILB DM5ZTXL TN Prostaglandin G/H synthase 2 (COX-2) DM5ZTXL MA Inhibitor DM5ZTXL RN Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41. DM5ZTXL RU https://pubmed.ncbi.nlm.nih.gov/3488405 DM5ZTXL DI DM5ZTXL DM5ZTXL DN (11H-Dibenzo[b,e][1,4]dioxepin-7-yl)-acetic acid DM5ZTXL TI TT8NGED DM5ZTXL TN Prostaglandin G/H synthase 1 (COX-1) DM5ZTXL MA Inhibitor DM5ZTXL RN Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41. DM5ZTXL RU https://pubmed.ncbi.nlm.nih.gov/3488405 DM5ZTXO DI DM5ZTXO DM5ZTXO DN 4-(3,4-dimethylbenzylthio)-2-aminobutanoic acid DM5ZTXO TI TTFK1JQ DM5ZTXO TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM5ZTXO MA Inhibitor DM5ZTXO RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DM5ZTXO RU https://pubmed.ncbi.nlm.nih.gov/16380257 DM5ZU1V DI DM5ZU1V DM5ZU1V DN PSI 7851 DM5ZU1V TI TTMVBWH DM5ZU1V TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DM5ZU1V MA Modulator DM5ZU1V RN Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977.J Biol Chem.2010 Nov 5;285(45):34337-47. DM5ZU1V RU https://www.ncbi.nlm.nih.gov/pubmed/20801890 DM60AJ2 DI DM60AJ2 DM60AJ2 DN 2-PHENYLAMINO-4-METHYL-5-ACETYL THIAZOLE DM60AJ2 TI TTPH97Y DM60AJ2 TN Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA) DM60AJ2 MA Inhibitor DM60AJ2 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM60AJ2 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM60CBI DI DM60CBI DM60CBI DN ISIS 10373 DM60CBI TI TT53XHB DM60CBI TN CD86 messenger RNA (CD86 mRNA) DM60CBI RN US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein. DM60CBI RU http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true DM60HU5 DI DM60HU5 DM60HU5 DN Tellimagrandin II DM60HU5 TI TTCIHJA DM60HU5 TN Coagulation factor Xa (F10) DM60HU5 MA Inhibitor DM60HU5 RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DM60HU5 RU https://pubmed.ncbi.nlm.nih.gov/9834152 DM60HU5 DI DM60HU5 DM60HU5 DN Tellimagrandin II DM60HU5 TI TT6L509 DM60HU5 TN Coagulation factor IIa (F2) DM60HU5 MA Inhibitor DM60HU5 RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DM60HU5 RU https://pubmed.ncbi.nlm.nih.gov/9834152 DM60K7H DI DM60K7H DM60K7H DN 3-amino-3-demethoxythiocolchicine DM60K7H TI TT1MPAY DM60K7H TN GABA(A) receptor alpha-1 (GABRA1) DM60K7H MA Inhibitor DM60K7H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM60K7H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM60K7H DI DM60K7H DM60K7H DN 3-amino-3-demethoxythiocolchicine DM60K7H TI TTZA1NY DM60K7H TN GABA(A) receptor beta-2 (GABRB2) DM60K7H MA Inhibitor DM60K7H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM60K7H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM60K7H DI DM60K7H DM60K7H DN 3-amino-3-demethoxythiocolchicine DM60K7H TI TTNJYV2 DM60K7H TN Gamma-aminobutyric acid receptor (GAR) DM60K7H MA Inhibitor DM60K7H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM60K7H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM60K7H DI DM60K7H DM60K7H DN 3-amino-3-demethoxythiocolchicine DM60K7H TI TT06RH5 DM60K7H TN GABA(A) receptor gamma-2 (GABRG2) DM60K7H MA Inhibitor DM60K7H RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DM60K7H RU https://pubmed.ncbi.nlm.nih.gov/16942030 DM60LT9 DI DM60LT9 DM60LT9 DN ISIS 102609 DM60LT9 TI TT5U49F DM60LT9 TN PRKACA messenger RNA (PRKACA mRNA) DM60LT9 RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DM60LT9 RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DM60N3C DI DM60N3C DM60N3C DN ztz240 DM60N3C TI TTPXI3S DM60N3C TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DM60N3C MA Activator DM60N3C RN Isoform-specific prolongation of Kv7 (KCNQ) potassium channel opening mediated by new molecular determinants for drug-channel interactions. J Biol Chem. 2010 Sep 3;285(36):28322-32. DM60N3C RU https://pubmed.ncbi.nlm.nih.gov/20584905 DM60Q1B DI DM60Q1B DM60Q1B DN 3-Pyridin-3-yl-quinoline-6,7-diol DM60Q1B TI TTI7421 DM60Q1B TN Platelet-derived growth factor receptor beta (PDGFRB) DM60Q1B MA Inhibitor DM60Q1B RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM60Q1B RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM60Q1B DI DM60Q1B DM60Q1B DN 3-Pyridin-3-yl-quinoline-6,7-diol DM60Q1B TI TT8FYO9 DM60Q1B TN Platelet-derived growth factor receptor alpha (PDGFRA) DM60Q1B MA Inhibitor DM60Q1B RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM60Q1B RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM60RWZ DI DM60RWZ DM60RWZ DN 2-(2-chlorophenyl)-2,2-diphenylethanamide DM60RWZ TI TTMNI76 DM60RWZ TN Calcium-activated potassium channel (KCN) DM60RWZ MA Inhibitor DM60RWZ RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DM60RWZ RU https://pubmed.ncbi.nlm.nih.gov/18232633 DM60V4N DI DM60V4N DM60V4N DN ISIS 114184 DM60V4N TI TTWIJYH DM60V4N TN E2F3 messenger RNA (E2F3 mRNA) DM60V4N RN US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression. DM60V4N RU http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true DM60Y3Q DI DM60Y3Q DM60Y3Q DN SK&F-64139 DM60Y3Q TI TTWM4TY DM60Y3Q TN Adrenergic receptor alpha-2B (ADRA2B) DM60Y3Q MA Inhibitor DM60Y3Q RN Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33. DM60Y3Q RU https://pubmed.ncbi.nlm.nih.gov/16942016 DM60Y3Q DI DM60Y3Q DM60Y3Q DN SK&F-64139 DM60Y3Q TI TT2NUT5 DM60Y3Q TN Adrenergic receptor alpha-2C (ADRA2C) DM60Y3Q MA Inhibitor DM60Y3Q RN Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33. DM60Y3Q RU https://pubmed.ncbi.nlm.nih.gov/16942016 DM60Y3Q DI DM60Y3Q DM60Y3Q DN SK&F-64139 DM60Y3Q TI TTWG9A4 DM60Y3Q TN Adrenergic receptor alpha-2A (ADRA2A) DM60Y3Q MA Inhibitor DM60Y3Q RN Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33. DM60Y3Q RU https://pubmed.ncbi.nlm.nih.gov/16942016 DM60Y8M DI DM60Y8M DM60Y8M DN 1-Adamantan-1-ylmethyl-3-thiazol-2-yl-thiourea DM60Y8M TI TT84ETX DM60Y8M TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM60Y8M MA Inhibitor DM60Y8M RN Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8. DM60Y8M RU https://pubmed.ncbi.nlm.nih.gov/11229762 DM60YGF DI DM60YGF DM60YGF DN 3-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide DM60YGF TI TTL2ADK DM60YGF TN Rotamase A (PPIA) DM60YGF MA Inhibitor DM60YGF RN Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem. 2006 Feb 9;49(3):900-10. DM60YGF RU https://pubmed.ncbi.nlm.nih.gov/16451056 DM613NQ DI DM613NQ DM613NQ DN PMID18790648C10 DM613NQ TI TTZW4MV DM613NQ TN Matrix metalloproteinase-11 (MMP-11) DM613NQ MA Inhibitor DM613NQ RN Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94. DM613NQ RU https://pubmed.ncbi.nlm.nih.gov/18790648 DM619EU DI DM619EU DM619EU DN PFI-3 DM619EU TI TTVQEZS DM619EU TN Mitotic growth and transcription activator (BAF190A) DM619EU MA Inhibitor DM619EU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2740). DM619EU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2740 DM619EU DI DM619EU DM619EU DN PFI-3 DM619EU TI TTH8ZRL DM619EU TN Polybromo-1 (PBRM1) DM619EU MA Inhibitor DM619EU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2738). DM619EU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2738 DM61CHU DI DM61CHU DM61CHU DN 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid DM61CHU TI TT79WV3 DM61CHU TN Prostaglandin E2 receptor EP4 (PTGER4) DM61CHU MA Inhibitor DM61CHU RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM61CHU RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM61CHU DI DM61CHU DM61CHU DN 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid DM61CHU TI TT1ZAVI DM61CHU TN Prostaglandin E2 receptor EP2 (PTGER2) DM61CHU MA Inhibitor DM61CHU RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM61CHU RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM61CHU DI DM61CHU DM61CHU DN 3-(2-(4-methoxycinnamyl)phenyl)acrylic acid DM61CHU TI TTPNGDE DM61CHU TN Prostaglandin E2 receptor EP3 (PTGER3) DM61CHU MA Inhibitor DM61CHU RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM61CHU RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM61CJK DI DM61CJK DM61CJK DN 4-Sulfonamide-[1-(4-Aminobutane)]Benzamide DM61CJK TI TTANPDJ DM61CJK TN Carbonic anhydrase II (CA-II) DM61CJK MA Inhibitor DM61CJK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM61CJK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM61CMS DI DM61CMS DM61CMS DN H-Dmt-Aba-Gly-NH-CH2-Ph DM61CMS TI TT27RFC DM61CMS TN Opioid receptor delta (OPRD1) DM61CMS MA Inhibitor DM61CMS RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DM61CMS RU https://pubmed.ncbi.nlm.nih.gov/16789756 DM61CMS DI DM61CMS DM61CMS DN H-Dmt-Aba-Gly-NH-CH2-Ph DM61CMS TI TTKWM86 DM61CMS TN Opioid receptor mu (MOP) DM61CMS MA Inhibitor DM61CMS RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DM61CMS RU https://pubmed.ncbi.nlm.nih.gov/16789756 DM61F5W DI DM61F5W DM61F5W DN BUFROLIN DM61F5W TI TTHQENC DM61F5W TN Phosphodiesterase 1 (PDE1) DM61F5W MA Inhibitor DM61F5W RN A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45. DM61F5W RU https://pubmed.ncbi.nlm.nih.gov/2985781 DM61FB0 DI DM61FB0 DM61FB0 DN EC18 DM61FB0 TI TTQP04A DM61FB0 TN Hyperpolarization cyclic nucleotide-gated channel 4 (HCN4) DM61FB0 MA Blocker (channel blocker) DM61FB0 RN Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue. Br J Pharmacol. 2012 May;166(2):602-16. DM61FB0 RU https://pubmed.ncbi.nlm.nih.gov/22091830 DM61FYM DI DM61FYM DM61FYM DN ISIS 103620 DM61FYM TI TTBWMKT DM61FYM TN WWP1 messenger RNA (WWP1 mRNA) DM61FYM RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM61FYM RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM61G0I DI DM61G0I DM61G0I DN H-Aba-ala-Gly-Phe-leu-OH DM61G0I TI TT27RFC DM61G0I TN Opioid receptor delta (OPRD1) DM61G0I MA Inhibitor DM61G0I RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM61G0I RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM61G0I DI DM61G0I DM61G0I DN H-Aba-ala-Gly-Phe-leu-OH DM61G0I TI TTKWM86 DM61G0I TN Opioid receptor mu (MOP) DM61G0I MA Inhibitor DM61G0I RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM61G0I RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM61GPQ DI DM61GPQ DM61GPQ DN KYS-05064 DM61GPQ TI TT729IR DM61GPQ TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM61GPQ MA Inhibitor DM61GPQ RN 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105. DM61GPQ RU https://pubmed.ncbi.nlm.nih.gov/17074493 DM61H07 DI DM61H07 DM61H07 DN AZAKENPAULLONE DM61H07 TI TTRSMW9 DM61H07 TN Glycogen synthase kinase-3 beta (GSK-3B) DM61H07 MA Inhibitor DM61H07 RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DM61H07 RU https://pubmed.ncbi.nlm.nih.gov/14698171 DM61H07 DI DM61H07 DM61H07 DN AZAKENPAULLONE DM61H07 TI TTH6V3D DM61H07 TN Cyclin-dependent kinase 1 (CDK1) DM61H07 MA Inhibitor DM61H07 RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DM61H07 RU https://pubmed.ncbi.nlm.nih.gov/14698171 DM61H07 DI DM61H07 DM61H07 DN AZAKENPAULLONE DM61H07 TI TTL4Q97 DM61H07 TN Cyclin-dependent kinase 5 (CDK5) DM61H07 MA Inhibitor DM61H07 RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DM61H07 RU https://pubmed.ncbi.nlm.nih.gov/14698171 DM61H07 DI DM61H07 DM61H07 DN AZAKENPAULLONE DM61H07 TI TT9P6OW DM61H07 TN G2/mitotic-specific cyclin B1 (CCNB1) DM61H07 MA Inhibitor DM61H07 RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DM61H07 RU https://pubmed.ncbi.nlm.nih.gov/14698171 DM61RG2 DI DM61RG2 DM61RG2 DN [Tyr-Pro-Phe-NH-]2 DM61RG2 TI TTKWM86 DM61RG2 TN Opioid receptor mu (MOP) DM61RG2 MA Inhibitor DM61RG2 RN Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50. DM61RG2 RU https://pubmed.ncbi.nlm.nih.gov/15780619 DM61V5W DI DM61V5W DM61V5W DN CSNLSTCVLGKLSQELNKLHBYPRTNTGSGTP-amide DM61V5W TI TTLWS2O DM61V5W TN Calcitonin receptor (CALCR) DM61V5W MA Inhibitor DM61V5W RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DM61V5W RU https://pubmed.ncbi.nlm.nih.gov/11855991 DM61VHF DI DM61VHF DM61VHF DN RPR-118071 DM61VHF TI TTZUXYS DM61VHF TN Vitamin K-dependent protein C (PROC) DM61VHF MA Inhibitor DM61VHF RN Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa. J Med Chem. 1999 Sep 9;42(18):3557-71. DM61VHF RU https://pubmed.ncbi.nlm.nih.gov/10479288 DM61VJO DI DM61VJO DM61VJO DN 8-chloro-3,4-dihydroquinazolin-2-amine DM61VJO TI TTRUFDT DM61VJO TN 5-HT 5A receptor (HTR5A) DM61VJO MA Inhibitor DM61VJO RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DM61VJO RU https://pubmed.ncbi.nlm.nih.gov/17998160 DM62351 DI DM62351 DM62351 DN 4-[4-(6-methoxynaphthalen-2-yl)benzyl]pyridine DM62351 TI TTRA5BZ DM62351 TN Steroid 17-alpha-monooxygenase (S17AH) DM62351 MA Inhibitor DM62351 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM62351 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM624WO DI DM624WO DM624WO DN AL5927 DM624WO TI TTANPDJ DM624WO TN Carbonic anhydrase II (CA-II) DM624WO MA Inhibitor DM624WO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM624WO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM629TD DI DM629TD DM629TD DN NS5818 DM629TD TI TTST1AJ DM629TD TN Chloride channel protein 7 (ClC-7) DM629TD MA Blocker (channel blocker) DM629TD RN The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One. 2010 Sep 7;5(9):e12585. DM629TD RU https://pubmed.ncbi.nlm.nih.gov/20830208 DM62FEH DI DM62FEH DM62FEH DN 11-Propionyloxy-N-n-propylnoraporphine DM62FEH TI TTJQOD7 DM62FEH TN 5-HT 2A receptor (HTR2A) DM62FEH MA Inhibitor DM62FEH RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DM62FEH RU https://pubmed.ncbi.nlm.nih.gov/18783955 DM62FEH DI DM62FEH DM62FEH DN 11-Propionyloxy-N-n-propylnoraporphine DM62FEH TI TTZFYLI DM62FEH TN Dopamine D1 receptor (D1R) DM62FEH MA Inhibitor DM62FEH RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DM62FEH RU https://pubmed.ncbi.nlm.nih.gov/18783955 DM62IBX DI DM62IBX DM62IBX DN DC-9703 DM62IBX TI TTCBFJO DM62IBX TN Insulin receptor (INSR) DM62IBX MA Modulator DM62IBX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM62IBX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM62PAU DI DM62PAU DM62PAU DN 7-phenyl-1-(4-phenyloxazol-2-yl)heptan-1-one DM62PAU TI TTDP1UC DM62PAU TN Fatty acid amide hydrolase (FAAH) DM62PAU MA Inhibitor DM62PAU RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DM62PAU RU https://pubmed.ncbi.nlm.nih.gov/18639454 DM62PI8 DI DM62PI8 DM62PI8 DN QCP DM62PI8 TI TT2UE56 DM62PI8 TN Sodium/glucose cotransporter 1 (SGLT1) DM62PI8 MA Inhibitor DM62PI8 RN Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13. DM62PI8 RU https://pubmed.ncbi.nlm.nih.gov/17686765 DM62XC3 DI DM62XC3 DM62XC3 DN 4,6-Dichloro-1H-indole-2-carboxylic acid DM62XC3 TI TTWHDVK DM62XC3 TN Fructose-1,6-bisphosphatase (FBP) DM62XC3 MA Inhibitor DM62XC3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM62XC3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM62XC3 DI DM62XC3 DM62XC3 DN 4,6-Dichloro-1H-indole-2-carboxylic acid DM62XC3 TI TTKJEMQ DM62XC3 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM62XC3 MA Inhibitor DM62XC3 RN 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. DM62XC3 RU https://pubmed.ncbi.nlm.nih.gov/2146391 DM62XC3 DI DM62XC3 DM62XC3 DN 4,6-Dichloro-1H-indole-2-carboxylic acid DM62XC3 TI TTN9D8E DM62XC3 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM62XC3 MA Inhibitor DM62XC3 RN 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. DM62XC3 RU https://pubmed.ncbi.nlm.nih.gov/2146391 DM62XC3 DI DM62XC3 DM62XC3 DN 4,6-Dichloro-1H-indole-2-carboxylic acid DM62XC3 TI TTLD29N DM62XC3 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM62XC3 MA Inhibitor DM62XC3 RN 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. DM62XC3 RU https://pubmed.ncbi.nlm.nih.gov/2146391 DM62Y1S DI DM62Y1S DM62Y1S DN 3-bromo-N-(6-methylpyridin-2-yl)benzamide DM62Y1S TI TTHS256 DM62Y1S TN Metabotropic glutamate receptor 5 (mGluR5) DM62Y1S MA Inhibitor DM62Y1S RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DM62Y1S RU https://pubmed.ncbi.nlm.nih.gov/16678408 DM62ZRE DI DM62ZRE DM62ZRE DN 4-(2-nitrovinyl)benzene-1,2-diol DM62ZRE TI TTGKNB4 DM62ZRE TN Epidermal growth factor receptor (EGFR) DM62ZRE MA Inhibitor DM62ZRE RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DM62ZRE RU https://pubmed.ncbi.nlm.nih.gov/1479375 DM63BI9 DI DM63BI9 DM63BI9 DN 3-(6-Bromo-naphthalen-2-yl)-pyridine DM63BI9 TI TTIQUX7 DM63BI9 TN Steroid 11-beta-hydroxylase (CYP11B1) DM63BI9 MA Inhibitor DM63BI9 RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DM63BI9 RU https://pubmed.ncbi.nlm.nih.gov/16220979 DM63FN5 DI DM63FN5 DM63FN5 DN [D-Ncy(methyl)4]acyline DM63FN5 TI TT8R70G DM63FN5 TN Gonadotropin-releasing hormone receptor (GNRHR) DM63FN5 MA Inhibitor DM63FN5 RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM63FN5 RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM63G4R DI DM63G4R DM63G4R DN NSC-625487 DM63G4R TI TT84ETX DM63G4R TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM63G4R MA Inhibitor DM63G4R RN Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors. Antivir Chem Chemother. 1999 Jul;10(4):211-7. DM63G4R RU https://pubmed.ncbi.nlm.nih.gov/10480739 DM63IKF DI DM63IKF DM63IKF DN 3-[1-(4-Cyanobenzyl)-1H-imidazol-5-yl]-1-propanol DM63IKF TI TTIQUX7 DM63IKF TN Steroid 11-beta-hydroxylase (CYP11B1) DM63IKF MA Inhibitor DM63IKF RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM63IKF RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM63LOX DI DM63LOX DM63LOX DN JWH-323 DM63LOX TI TTMSFAW DM63LOX TN Cannabinoid receptor 2 (CB2) DM63LOX MA Inhibitor DM63LOX RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM63LOX RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM63NGW DI DM63NGW DM63NGW DN RS-100302 DM63NGW TI TTW0CMT DM63NGW TN Voltage-gated potassium channel Kv1.5 (KCNA5) DM63NGW MA Blocker DM63NGW RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DM63NGW RU https://pubmed.ncbi.nlm.nih.gov/15934869 DM63T9D DI DM63T9D DM63T9D DN 3-(2-phenyl-6-(thiophen-2-yl)pyridin-4-yl)-phenol DM63T9D TI TT0IHXV DM63T9D TN DNA topoisomerase II (TOP2) DM63T9D MA Inhibitor DM63T9D RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DM63T9D RU https://pubmed.ncbi.nlm.nih.gov/20392646 DM63YJV DI DM63YJV DM63YJV DN N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide DM63YJV TI TT6OEDT DM63YJV TN Cannabinoid receptor 1 (CB1) DM63YJV MA Inhibitor DM63YJV RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DM63YJV RU https://pubmed.ncbi.nlm.nih.gov/19053765 DM63YJV DI DM63YJV DM63YJV DN N-(1H-indazol-5-yl)icosa-5,8,11,14-tetraenamide DM63YJV TI TTMSFAW DM63YJV TN Cannabinoid receptor 2 (CB2) DM63YJV MA Inhibitor DM63YJV RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DM63YJV RU https://pubmed.ncbi.nlm.nih.gov/19053765 DM64093 DI DM64093 DM64093 DN 2-N-Ethylamino-1-(4-ethylthiophenyl)propane DM64093 TI TT3ROYC DM64093 TN Serotonin transporter (SERT) DM64093 MA Inhibitor DM64093 RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM64093 RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM645FP DI DM645FP DM645FP DN SCOPOLETIN DM645FP TI TTN9T81 DM645FP TN Arachidonate 15-lipoxygenase (15-LOX) DM645FP MA Inhibitor DM645FP RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DM645FP RU https://pubmed.ncbi.nlm.nih.gov/17378609 DM64JE8 DI DM64JE8 DM64JE8 DN 2-phenylpyrazolo-[1,5-a]pyridine-7-carboxamide DM64JE8 TI TTVDSZ0 DM64JE8 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM64JE8 MA Inhibitor DM64JE8 RN Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85. DM64JE8 RU https://pubmed.ncbi.nlm.nih.gov/19873981 DM64KOZ DI DM64KOZ DM64KOZ DN 6-Bromo-4,9-dihydro-3H-beta-carboline DM64KOZ TI TT3WG5C DM64KOZ TN Monoamine oxidase type A (MAO-A) DM64KOZ MA Inhibitor DM64KOZ RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM64KOZ RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM64KOZ DI DM64KOZ DM64KOZ DN 6-Bromo-4,9-dihydro-3H-beta-carboline DM64KOZ TI TTGP7BY DM64KOZ TN Monoamine oxidase type B (MAO-B) DM64KOZ MA Inhibitor DM64KOZ RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM64KOZ RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM64L9I DI DM64L9I DM64L9I DN CyPPA DM64L9I TI TT2T5M0 DM64L9I TN Calcium-activated potassium channel KCa2.2 (KCNN2) DM64L9I MA Activator DM64L9I RN Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65. DM64L9I RU https://pubmed.ncbi.nlm.nih.gov/17486140 DM64L9I DI DM64L9I DM64L9I DN CyPPA DM64L9I TI TT9JH25 DM64L9I TN Calcium-activated potassium channel KCa2.3 (KCNN3) DM64L9I MA Activator DM64L9I RN Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65. DM64L9I RU https://pubmed.ncbi.nlm.nih.gov/17486140 DM64NBG DI DM64NBG DM64NBG DN KNI-10216 DM64NBG TI TTXMNHO DM64NBG TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM64NBG MA Inhibitor DM64NBG RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DM64NBG RU https://pubmed.ncbi.nlm.nih.gov/18952439 DM64THP DI DM64THP DM64THP DN 4-(1-Naphthalen-1-yl-propyl)-1H-imidazole DM64THP TI TT34BHT DM64THP TN Adrenergic receptor alpha-1D (ADRA1D) DM64THP MA Inhibitor DM64THP RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM64THP RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM64THP DI DM64THP DM64THP DN 4-(1-Naphthalen-1-yl-propyl)-1H-imidazole DM64THP TI TTBRKXS DM64THP TN Adrenergic receptor alpha-1B (ADRA1B) DM64THP MA Inhibitor DM64THP RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM64THP RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM64THP DI DM64THP DM64THP DN 4-(1-Naphthalen-1-yl-propyl)-1H-imidazole DM64THP TI TTNGILX DM64THP TN Adrenergic receptor alpha-1A (ADRA1A) DM64THP MA Inhibitor DM64THP RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DM64THP RU https://pubmed.ncbi.nlm.nih.gov/8709134 DM64WSV DI DM64WSV DM64WSV DN 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol DM64WSV TI TTLD29N DM64WSV TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM64WSV MA Inhibitor DM64WSV RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DM64WSV RU https://pubmed.ncbi.nlm.nih.gov/9719603 DM64WSV DI DM64WSV DM64WSV DN 4-[2-(3-Phenyl-propylamino)-ethyl]-phenol DM64WSV TI TTN9D8E DM64WSV TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM64WSV MA Inhibitor DM64WSV RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DM64WSV RU https://pubmed.ncbi.nlm.nih.gov/9719603 DM64X25 DI DM64X25 DM64X25 DN AMPE4L DM64X25 TI TTVIMDE DM64X25 TN Glucagon-like peptide 1 receptor (GLP1R) DM64X25 MA Modulator DM64X25 RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DM64X25 RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DM64X25 DI DM64X25 DM64X25 DN AMPE4L DM64X25 TI TT0HD6V DM64X25 TN Leptin receptor (LEPR) DM64X25 MA Modulator DM64X25 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DM64X25 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DM653RM DI DM653RM DM653RM DN N-hydroxy-5-(pyridin-4-yl)thiophene-2-carboxamide DM653RM TI TT6R7JZ DM653RM TN Histone deacetylase 1 (HDAC1) DM653RM MA Inhibitor DM653RM RN Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. DM653RM RU https://pubmed.ncbi.nlm.nih.gov/17107790 DM65B7Y DI DM65B7Y DM65B7Y DN AdoC(betaAsp)2AlaArg6 DM65B7Y TI TTW4Y2M DM65B7Y TN cAMP protein kinase type II-beta (PRKAR2B) DM65B7Y MA Inhibitor DM65B7Y RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DM65B7Y RU https://pubmed.ncbi.nlm.nih.gov/10360754 DM65B7Y DI DM65B7Y DM65B7Y DN AdoC(betaAsp)2AlaArg6 DM65B7Y TI TTNAHEX DM65B7Y TN cAMP-dependent protein kinase A type I (PRKAR1A) DM65B7Y MA Inhibitor DM65B7Y RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DM65B7Y RU https://pubmed.ncbi.nlm.nih.gov/10360754 DM65BDN DI DM65BDN DM65BDN DN [18F]altanserin DM65BDN TI TTJQOD7 DM65BDN TN 5-HT 2A receptor (HTR2A) DM65BDN MA Antagonist DM65BDN RN Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Res. 1996 Nov 25;68(1):11-22. DM65BDN RU https://pubmed.ncbi.nlm.nih.gov/9027929 DM65GQD DI DM65GQD DM65GQD DN VA-118020 DM65GQD TI TT5T3P6 DM65GQD TN Tissue kallikrein (KLK1) DM65GQD MA Inhibitor DM65GQD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2865). DM65GQD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2865 DM65IF1 DI DM65IF1 DM65IF1 DN 2-(4-Phenoxy-benzyl)-1H-benzoimidazole DM65IF1 TI TTN9D8E DM65IF1 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM65IF1 MA Inhibitor DM65IF1 RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DM65IF1 RU https://pubmed.ncbi.nlm.nih.gov/15056006 DM65IF1 DI DM65IF1 DM65IF1 DN 2-(4-Phenoxy-benzyl)-1H-benzoimidazole DM65IF1 TI TTLD29N DM65IF1 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM65IF1 MA Inhibitor DM65IF1 RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DM65IF1 RU https://pubmed.ncbi.nlm.nih.gov/15056006 DM65SQK DI DM65SQK DM65SQK DN GRANULATIMIDE DM65SQK TI TTTU902 DM65SQK TN Checkpoint kinase-1 (CHK1) DM65SQK MA Inhibitor DM65SQK RN Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3... Eur J Med Chem. 2008 Feb;43(2):282-92. DM65SQK RU https://pubmed.ncbi.nlm.nih.gov/17502122 DM65TUP DI DM65TUP DM65TUP DN AFC-5128 DM65TUP TI TT473XN DM65TUP TN P2X purinoceptor 7 (P2RX7) DM65TUP MA Antagonist DM65TUP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484). DM65TUP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484 DM65VLB DI DM65VLB DM65VLB DN FTIDC DM65VLB TI TTVBPDM DM65VLB TN Metabotropic glutamate receptor 1 (mGluR1) DM65VLB MA Modulator (allosteric modulator) DM65VLB RN Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-... J Pharmacol Exp Ther. 2007 Jun;321(3):1144-53. DM65VLB RU https://pubmed.ncbi.nlm.nih.gov/17360958 DM65WZ7 DI DM65WZ7 DM65WZ7 DN 5-benzhydryl-1,3,4-oxadiazole-2(3H)-thione DM65WZ7 TI TTULVH8 DM65WZ7 TN Tyrosinase (TYR) DM65WZ7 MA Inhibitor DM65WZ7 RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DM65WZ7 RU https://pubmed.ncbi.nlm.nih.gov/20452224 DM65XZJ DI DM65XZJ DM65XZJ DN 5-deoxy-5-phosphono-D-arabinonate DM65XZJ TI TTZ3IFB DM65XZJ TN Phosphogluconate dehydrogenase (PGD) DM65XZJ MA Inhibitor DM65XZJ RN Sugar derivatives as new 6-phosphogluconate dehydrogenase inhibitors selective for the parasite Trypanosoma brucei. Bioorg Med Chem. 2003 Apr 3;11(7):1207-14. DM65XZJ RU https://pubmed.ncbi.nlm.nih.gov/12628648 DM67549 DI DM67549 DM67549 DN EC33 DM67549 TI TT9PBIL DM67549 TN Glutamyl aminopeptidase (ENPEP) DM67549 MA Inhibitor DM67549 RN Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. Biochem Soc Trans. 2000;28(4):435-40. DM67549 RU https://pubmed.ncbi.nlm.nih.gov/10961935 DM678IB DI DM678IB DM678IB DN Rapamycin Immunosuppressant Drug DM678IB TI TTMW94E DM678IB TN FK506-binding protein 1A (FKBP1A) DM678IB MA Inhibitor DM678IB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM678IB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM679RC DI DM679RC DM679RC DN 1-benzhydryl-4-p-tolylpiperidin-4-ol DM679RC TI TTNT7K8 DM679RC TN Nociceptin receptor (OPRL1) DM679RC MA Inhibitor DM679RC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM679RC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM679RC DI DM679RC DM679RC DN 1-benzhydryl-4-p-tolylpiperidin-4-ol DM679RC TI TTKWM86 DM679RC TN Opioid receptor mu (MOP) DM679RC MA Inhibitor DM679RC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM679RC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM679RC DI DM679RC DM679RC DN 1-benzhydryl-4-p-tolylpiperidin-4-ol DM679RC TI TTQW87Y DM679RC TN Opioid receptor kappa (OPRK1) DM679RC MA Inhibitor DM679RC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM679RC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM679RC DI DM679RC DM679RC DN 1-benzhydryl-4-p-tolylpiperidin-4-ol DM679RC TI TT27RFC DM679RC TN Opioid receptor delta (OPRD1) DM679RC MA Inhibitor DM679RC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DM679RC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DM67A4U DI DM67A4U DM67A4U DN 4-(3-Methyl-indole-1-sulfonyl)-phenylamine DM67A4U TI TTJS8PY DM67A4U TN 5-HT 6 receptor (HTR6) DM67A4U MA Inhibitor DM67A4U RN 1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11. DM67A4U RU https://pubmed.ncbi.nlm.nih.gov/15745826 DM67B8S DI DM67B8S DM67B8S DN 3-(2-carboxy-3-mercaptopropyl)benzoic acid DM67B8S TI TT9G4N0 DM67B8S TN Glutamate carboxypeptidase II (GCPII) DM67B8S MA Inhibitor DM67B8S RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DM67B8S RU https://pubmed.ncbi.nlm.nih.gov/16686531 DM67CAY DI DM67CAY DM67CAY DN Cyclo[Ac-Cys-Ile-Phe]-Lys-Tyr-Tyr DM67CAY TI TT6PKBN DM67CAY TN Proto-oncogene c-Src (SRC) DM67CAY MA Inhibitor DM67CAY RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DM67CAY RU https://pubmed.ncbi.nlm.nih.gov/16722659 DM67DVU DI DM67DVU DM67DVU DN 3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine DM67DVU TI TTSZLWK DM67DVU TN Aromatase (CYP19A1) DM67DVU MA Inhibitor DM67DVU RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DM67DVU RU https://pubmed.ncbi.nlm.nih.gov/16220979 DM67DVU DI DM67DVU DM67DVU DN 3-(5-Chloro-6-methoxy-naphthalen-2-yl)-pyridine DM67DVU TI TTIQUX7 DM67DVU TN Steroid 11-beta-hydroxylase (CYP11B1) DM67DVU MA Inhibitor DM67DVU RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DM67DVU RU https://pubmed.ncbi.nlm.nih.gov/16220979 DM67FQ1 DI DM67FQ1 DM67FQ1 DN GlyH-101 DM67FQ1 TI TTRLZHP DM67FQ1 TN cAMP-dependent chloride channel (CFTR) DM67FQ1 MA Blocker (channel blocker) DM67FQ1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DM67FQ1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DM67KWM DI DM67KWM DM67KWM DN LGD-5552 DM67KWM TI TTKPW01 DM67KWM TN Androgen receptor messenger RNA (AR mRNA) DM67KWM MA Inhibitor DM67KWM RN Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. DM67KWM RU https://pubmed.ncbi.nlm.nih.gov/18032610 DM67KWM DI DM67KWM DM67KWM DN LGD-5552 DM67KWM TI TTOZRK6 DM67KWM TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM67KWM MA Inhibitor DM67KWM RN Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. DM67KWM RU https://pubmed.ncbi.nlm.nih.gov/18032610 DM67KWM DI DM67KWM DM67KWM DN LGD-5552 DM67KWM TI TTUV8G9 DM67KWM TN Progesterone receptor (PGR) DM67KWM MA Inhibitor DM67KWM RN Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. DM67KWM RU https://pubmed.ncbi.nlm.nih.gov/18032610 DM67KWM DI DM67KWM DM67KWM DN LGD-5552 DM67KWM TI TT26PHO DM67KWM TN Mineralocorticoid receptor (MR) DM67KWM MA Inhibitor DM67KWM RN Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19244-9. DM67KWM RU https://pubmed.ncbi.nlm.nih.gov/18032610 DM67Q3C DI DM67Q3C DM67Q3C DN ISIS 100939 DM67Q3C TI TTW8TJI DM67Q3C TN MEKK1 messenger RNA (MAP3K1 mRNA) DM67Q3C RN US patent application no. 6,168,950, Antisense modulation of MEKK1 expression. DM67Q3C RU http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true DM67QDT DI DM67QDT DM67QDT DN 3-Hydroxypyruvic Acid DM67QDT TI TTNS6X4 DM67QDT TN Bacterial Triosephosphate isomerase (Bact TPI) DM67QDT MA Inhibitor DM67QDT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM67QDT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM67XSW DI DM67XSW DM67XSW DN N-(3,4-dihydroxybenzyl)oleamide DM67XSW TI TTIQSC1 DM67XSW TN Bacterial Lethal factor (Bact lef) DM67XSW MA Inhibitor DM67XSW RN Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70. DM67XSW RU https://pubmed.ncbi.nlm.nih.gov/18314330 DM67Z81 DI DM67Z81 DM67Z81 DN 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol DM67Z81 TI TTOM3J0 DM67Z81 TN Estrogen receptor beta (ESR2) DM67Z81 MA Inhibitor DM67Z81 RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM67Z81 RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM67Z81 DI DM67Z81 DM67Z81 DN 4,7-dimethyl-6H-benzo[c]chromene-3,8-diol DM67Z81 TI TTZAYWL DM67Z81 TN Estrogen receptor (ESR) DM67Z81 MA Inhibitor DM67Z81 RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM67Z81 RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM680XO DI DM680XO DM680XO DN NI-1201 DM680XO TI TT0E5SK DM680XO TN Interleukin 6 receptor (IL6R) DM680XO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310). DM680XO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310 DM6839G DI DM6839G DM6839G DN H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638) DM6839G TI TTG5QIA DM6839G TN B1 bradykinin receptor (BDKRB1) DM6839G MA Inhibitor DM6839G RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DM6839G RU https://pubmed.ncbi.nlm.nih.gov/10882364 DM6839G DI DM6839G DM6839G DN H-DArg-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1638) DM6839G TI TTGY8IW DM6839G TN B2 bradykinin receptor (BDKRB2) DM6839G MA Inhibitor DM6839G RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DM6839G RU https://pubmed.ncbi.nlm.nih.gov/10882364 DM689TH DI DM689TH DM689TH DN 13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid DM689TH TI TT7WVHI DM689TH TN Soluble epoxide hydrolase (EPHX2) DM689TH MA Inhibitor DM689TH RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM689TH RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM68IPZ DI DM68IPZ DM68IPZ DN 9-Deazaguanine DM68IPZ TI TTBL49X DM68IPZ TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DM68IPZ MA Inhibitor DM68IPZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM68IPZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM68JI5 DI DM68JI5 DM68JI5 DN Sazetidine-A DM68JI5 TI TTWNV8U DM68JI5 TN Nicotinic acid receptor (HCAR2) DM68JI5 MA Binder DM68JI5 RN Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8. DM68JI5 RU https://pubmed.ncbi.nlm.nih.gov/24900372 DM68JNY DI DM68JNY DM68JNY DN PI1 DM68JNY TI TTV1C0Z DM68JNY TN Neuropeptide S receptor (NPSR) DM68JNY MA Antagonist DM68JNY RN Tricyclic imidazole antagonists of the Neuropeptide S Receptor. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4704-8. DM68JNY RU https://pubmed.ncbi.nlm.nih.gov/20615693 DM68QY0 DI DM68QY0 DM68QY0 DN AR244555 DM68QY0 TI TTOISYB DM68QY0 TN Proto-oncogene Mas (MAS) DM68QY0 MA Antagonist DM68QY0 RN Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H299-311. DM68QY0 RU https://pubmed.ncbi.nlm.nih.gov/22003054 DM68S9F DI DM68S9F DM68S9F DN 4-(DIMETHYLAMINO)BUTYL IMIDOTHIOCARBAMATE DM68S9F TI TT2B6EV DM68S9F TN Histamine N-methyltransferase (HNMT) DM68S9F MA Inhibitor DM68S9F RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM68S9F RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM68XFZ DI DM68XFZ DM68XFZ DN (S)-TBPG DM68XFZ TI TTVBPDM DM68XFZ TN Metabotropic glutamate receptor 1 (mGluR1) DM68XFZ MA Antagonist DM68XFZ RN Synthesis and biological evaluation of 2-(3'-(1H-tetrazol-5-yl) bicyclo[1.1.1]pent-1-yl)glycine (S-TBPG), a novel mGlu1 receptor antagonist. Bioorg Med Chem. 2001 Feb;9(2):221-7. DM68XFZ RU https://pubmed.ncbi.nlm.nih.gov/11249114 DM692XV DI DM692XV DM692XV DN ODN-2088 DM692XV TI TTSHG0T DM692XV TN Toll-like receptor 9 (TLR9) DM692XV MA Antagonist DM692XV RN Toll-like receptor 9 antagonism modulates astrocyte function and preserves proximal axons following spinal cord injury. Brain Behav Immun. 2019 Aug;80:328-343. DM692XV RU https://pubmed.ncbi.nlm.nih.gov/30953770 DM69FKN DI DM69FKN DM69FKN DN Z-Arg-Leu-Val-Agly-Ala-Gly-NH2 DM69FKN TI TTF2LRI DM69FKN TN Cathepsin B (CTSB) DM69FKN MA Inhibitor DM69FKN RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM69FKN RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM69FKN DI DM69FKN DM69FKN DN Z-Arg-Leu-Val-Agly-Ala-Gly-NH2 DM69FKN TI TTDZN01 DM69FKN TN Cathepsin K (CTSK) DM69FKN MA Inhibitor DM69FKN RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM69FKN RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM69LKB DI DM69LKB DM69LKB DN Pyrazolo[1,5-a]pyrimidine-3-carboxylate DM69LKB TI TT0EOB8 DM69LKB TN B-Raf messenger RNA (BRAF mRNA) DM69LKB MA Inhibitor DM69LKB RN Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2735-8. DM69LKB RU https://pubmed.ncbi.nlm.nih.gov/19362830 DM69MKU DI DM69MKU DM69MKU DN F3 DM69MKU TI TTTIBVP DM69MKU TN Inward rectifier potassium channel Kir3.2 (KCNJ6) DM69MKU MA Inhibitor (gating inhibitor) DM69MKU RN Differential effects of general anesthetics on G protein-coupled inwardly rectifying and other potassium channels. Anesthesiology. 2001 Jul;95(1):144-53. DM69MKU RU https://pubmed.ncbi.nlm.nih.gov/11465552 DM69O3S DI DM69O3S DM69O3S DN OCID-2987 DM69O3S TI TTZ97H5 DM69O3S TN Phosphodiesterase 4A (PDE4A) DM69O3S MA Inhibitor DM69O3S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DM69O3S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DM69O3S DI DM69O3S DM69O3S DN OCID-2987 DM69O3S TI TTVIAT9 DM69O3S TN Phosphodiesterase 4B (PDE4B) DM69O3S MA Inhibitor DM69O3S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DM69O3S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DM69O3S DI DM69O3S DM69O3S DN OCID-2987 DM69O3S TI TTSKMI8 DM69O3S TN Phosphodiesterase 4D (PDE4D) DM69O3S MA Inhibitor DM69O3S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DM69O3S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DM69OVM DI DM69OVM DM69OVM DN D[Arg4,Lys8]VP DM69OVM TI TTK8R02 DM69OVM TN Vasopressin V2 receptor (V2R) DM69OVM MA Inhibitor DM69OVM RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM69OVM RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM69OVM DI DM69OVM DM69OVM DN D[Arg4,Lys8]VP DM69OVM TI TT4TFGN DM69OVM TN Vasopressin V1a receptor (V1AR) DM69OVM MA Inhibitor DM69OVM RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM69OVM RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM69OVM DI DM69OVM DM69OVM DN D[Arg4,Lys8]VP DM69OVM TI TTSCIUP DM69OVM TN Oxytocin receptor (OTR) DM69OVM MA Inhibitor DM69OVM RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM69OVM RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM69OVM DI DM69OVM DM69OVM DN D[Arg4,Lys8]VP DM69OVM TI TTL9MHW DM69OVM TN Vasopressin V1b receptor (V1BR) DM69OVM MA Inhibitor DM69OVM RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM69OVM RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM69T3A DI DM69T3A DM69T3A DN 1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione DM69T3A TI TTP86E2 DM69T3A TN Plasminogen (PLG) DM69T3A MA Inhibitor DM69T3A RN Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4. DM69T3A RU https://pubmed.ncbi.nlm.nih.gov/11086715 DM69X2Z DI DM69X2Z DM69X2Z DN AL-309 DM69X2Z TI TTML2WA DM69X2Z TN Tubulin (TUB) DM69X2Z MA Modulator DM69X2Z RN Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603-12. DM69X2Z RU https://pubmed.ncbi.nlm.nih.gov/21728979 DM69XT3 DI DM69XT3 DM69XT3 DN ISONEORAUTENOL DM69XT3 TI TT50QJ3 DM69XT3 TN Influenza Neuraminidase (Influ NA) DM69XT3 MA Inhibitor DM69XT3 RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DM69XT3 RU https://pubmed.ncbi.nlm.nih.gov/20363636 DM6A08D DI DM6A08D DM6A08D DN WS-50030 DM6A08D TI TTEX248 DM6A08D TN Dopamine D2 receptor (D2R) DM6A08D MA Agonist DM6A08D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215). DM6A08D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215 DM6A4LM DI DM6A4LM DM6A4LM DN 5,6-Bis-p-tolylamino-isoindole-1,3-dione DM6A4LM TI TTGKNB4 DM6A4LM TN Epidermal growth factor receptor (EGFR) DM6A4LM MA Inhibitor DM6A4LM RN Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27. DM6A4LM RU https://pubmed.ncbi.nlm.nih.gov/8151612 DM6A80U DI DM6A80U DM6A80U DN 3-Butyl-[1,4]thiazepan-(5E)-ylideneamine DM6A80U TI TTZUFI5 DM6A80U TN Nitric-oxide synthase brain (NOS1) DM6A80U MA Inhibitor DM6A80U RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DM6A80U RU https://pubmed.ncbi.nlm.nih.gov/15501067 DM6A80U DI DM6A80U DM6A80U DN 3-Butyl-[1,4]thiazepan-(5E)-ylideneamine DM6A80U TI TTF10I9 DM6A80U TN Nitric-oxide synthase inducible (NOS2) DM6A80U MA Inhibitor DM6A80U RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DM6A80U RU https://pubmed.ncbi.nlm.nih.gov/15501067 DM6A902 DI DM6A902 DM6A902 DN 5-propenyl-2'-deoxyuridine triphosphate DM6A902 TI TTIU7X1 DM6A902 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM6A902 MA Inhibitor DM6A902 RN Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. JMed Virol. 1988 Dec;26(4):353-62. DM6A902 RU https://pubmed.ncbi.nlm.nih.gov/3145322 DM6ADJM DI DM6ADJM DM6ADJM DN 4-Butyl-1-[3-(phenylpropoxy)propyl]piperidine DM6ADJM TI TT9JNIC DM6ADJM TN Histamine H3 receptor (H3R) DM6ADJM MA Inhibitor DM6ADJM RN Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36. DM6ADJM RU https://pubmed.ncbi.nlm.nih.gov/18774720 DM6AHO4 DI DM6AHO4 DM6AHO4 DN 4-Hydroxy-3-methyl-butyric acid DM6AHO4 TI TT6TKEN DM6AHO4 TN Gamma-hydroxybutyrate receptor (SLC52A2) DM6AHO4 MA Inhibitor DM6AHO4 RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DM6AHO4 RU https://pubmed.ncbi.nlm.nih.gov/3361576 DM6AJMC DI DM6AJMC DM6AJMC DN ISIS 109353 DM6AJMC TI TT1MS7X DM6AJMC TN PKC-theta messenger RNA (PRKCQ mRNA) DM6AJMC RN US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression. DM6AJMC RU http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true DM6AQ2X DI DM6AQ2X DM6AQ2X DN ISIS 25127 DM6AQ2X TI TT8H9GB DM6AQ2X TN MEK2 messenger RNA (MEK2 mRNA) DM6AQ2X RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DM6AQ2X RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DM6ARQF DI DM6ARQF DM6ARQF DN 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one DM6ARQF TI TTAWNKZ DM6ARQF TN Norepinephrine transporter (NET) DM6ARQF MA Inhibitor DM6ARQF RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DM6ARQF RU https://pubmed.ncbi.nlm.nih.gov/16480278 DM6ARQF DI DM6ARQF DM6ARQF DN 1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one DM6ARQF TI TTVBI8W DM6ARQF TN Dopamine transporter (DAT) DM6ARQF MA Inhibitor DM6ARQF RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DM6ARQF RU https://pubmed.ncbi.nlm.nih.gov/16480278 DM6AS0P DI DM6AS0P DM6AS0P DN SC46275 DM6AS0P TI TTPNGDE DM6AS0P TN Prostaglandin E2 receptor EP3 (PTGER3) DM6AS0P MA Agonist DM6AS0P RN Investigation of the pronounced synergism between prostaglandin E2 and other constrictor agents on rat femoral artery. Prostaglandins Leukot Essent Fatty Acids. 2006 Jun;74(6):401-15. DM6AS0P RU https://pubmed.ncbi.nlm.nih.gov/16737803 DM6AUHR DI DM6AUHR DM6AUHR DN (2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime DM6AUHR TI TT7HF4W DM6AUHR TN Cyclin-dependent kinase 2 (CDK2) DM6AUHR MA Inhibitor DM6AUHR RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM6AUHR RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM6AUHR DI DM6AUHR DM6AUHR DN (2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime DM6AUHR TI TTCEJ4F DM6AUHR TN G1/S-specific cyclin-E1 (CCNE1) DM6AUHR MA Inhibitor DM6AUHR RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM6AUHR RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM6AV2S DI DM6AV2S DM6AV2S DN 1-Amino-6-Cyclohex-3-Enylmethyloxypurine DM6AV2S TI TT7HF4W DM6AV2S TN Cyclin-dependent kinase 2 (CDK2) DM6AV2S MA Inhibitor DM6AV2S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6AV2S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6AYDL DI DM6AYDL DM6AYDL DN 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One DM6AYDL TI TTDIGC1 DM6AYDL TN Dipeptidyl peptidase 4 (DPP-4) DM6AYDL MA Inhibitor DM6AYDL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6AYDL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6B14Q DI DM6B14Q DM6B14Q DN 1-(1,3,4-thiadiazol-2-yl)octadec-9-en-1-one DM6B14Q TI TTDP1UC DM6B14Q TN Fatty acid amide hydrolase (FAAH) DM6B14Q MA Inhibitor DM6B14Q RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DM6B14Q RU https://pubmed.ncbi.nlm.nih.gov/18630870 DM6B9CK DI DM6B9CK DM6B9CK DN AF-3473 DM6B9CK TI TT07C3Y DM6B9CK TN 5-HT 4 receptor (HTR4) DM6B9CK MA Antagonist DM6B9CK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DM6B9CK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DM6B9ZG DI DM6B9ZG DM6B9ZG DN garcinol DM6B9ZG TI TTH4VJL DM6B9ZG TN Histone acetyltransferase KAT6B (KAT6B) DM6B9ZG MA Inhibitor DM6B9ZG RN Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene e... J Biol Chem. 2004 Aug 6;279(32):33716-26. DM6B9ZG RU https://pubmed.ncbi.nlm.nih.gov/15155757 DM6B9ZG DI DM6B9ZG DM6B9ZG DN garcinol DM6B9ZG TI TTVK7SB DM6B9ZG TN Histone acetyltransferase KAT2B (KAT2B) DM6B9ZG MA Inhibitor DM6B9ZG RN Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene e... J Biol Chem. 2004 Aug 6;279(32):33716-26. DM6B9ZG RU https://pubmed.ncbi.nlm.nih.gov/15155757 DM6BA5L DI DM6BA5L DM6BA5L DN (2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime DM6BA5L TI TT7HF4W DM6BA5L TN Cyclin-dependent kinase 2 (CDK2) DM6BA5L MA Inhibitor DM6BA5L RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM6BA5L RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM6BA5L DI DM6BA5L DM6BA5L DN (2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime DM6BA5L TI TTCEJ4F DM6BA5L TN G1/S-specific cyclin-E1 (CCNE1) DM6BA5L MA Inhibitor DM6BA5L RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM6BA5L RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM6BANS DI DM6BANS DM6BANS DN Miller-9E-enolide DM6BANS TI TTSXVID DM6BANS TN Nuclear factor NF-kappa-B (NFKB) DM6BANS MA Inhibitor DM6BANS RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DM6BANS RU https://pubmed.ncbi.nlm.nih.gov/16570920 DM6BH7K DI DM6BH7K DM6BH7K DN ISIS 103601 DM6BH7K TI TTBWMKT DM6BH7K TN WWP1 messenger RNA (WWP1 mRNA) DM6BH7K RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM6BH7K RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM6BHUF DI DM6BHUF DM6BHUF DN 2-(furan-2-yl)-6-morpholino-4H-pyran-4-one DM6BHUF TI TTK3PY9 DM6BHUF TN DNA-dependent protein kinase catalytic (PRKDC) DM6BHUF MA Inhibitor DM6BHUF RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM6BHUF RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM6BIOP DI DM6BIOP DM6BIOP DN 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine DM6BIOP TI TTM2AOE DM6BIOP TN Adenosine A2a receptor (ADORA2A) DM6BIOP MA Inhibitor DM6BIOP RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DM6BIOP RU https://pubmed.ncbi.nlm.nih.gov/17378544 DM6BIOP DI DM6BIOP DM6BIOP DN 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine DM6BIOP TI TTK25J1 DM6BIOP TN Adenosine A1 receptor (ADORA1) DM6BIOP MA Inhibitor DM6BIOP RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DM6BIOP RU https://pubmed.ncbi.nlm.nih.gov/17378544 DM6BIOP DI DM6BIOP DM6BIOP DN 2-(3''-(5''-hydroxyindolyl)ethyloxy)adenosine DM6BIOP TI TTJFY5U DM6BIOP TN Adenosine A3 receptor (ADORA3) DM6BIOP MA Inhibitor DM6BIOP RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DM6BIOP RU https://pubmed.ncbi.nlm.nih.gov/17378544 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TTK8CXU DM6BIWK TN 5-HT 1B receptor (HTR1B) DM6BIWK MA Agonist DM6BIWK RN Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/8863519 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TT6MSOK DM6BIWK TN 5-HT 1D receptor (HTR1D) DM6BIWK MA Agonist DM6BIWK RN Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/1565658 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TTJS8PY DM6BIWK TN 5-HT 6 receptor (HTR6) DM6BIWK MA Agonist DM6BIWK RN Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/7680751 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TTSQIFT DM6BIWK TN 5-HT 1A receptor (HTR1A) DM6BIWK MA Agonist DM6BIWK RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/9397179 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TT0MI3F DM6BIWK TN 5-HT 1F receptor (HTR1F) DM6BIWK MA Antagonist DM6BIWK RN Cloning and characterization of the guinea pig 5-HT1F receptor subtype: a comparison of the pharmacological profile to the human species homolog. Neuropharmacology. 1997 Apr-May;36(4-5):569-76. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/9225282 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TT0K1SC DM6BIWK TN 5-HT 2B receptor (HTR2B) DM6BIWK MA Antagonist DM6BIWK RN Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/8450835 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TTCPG9S DM6BIWK TN 5-HT 1E receptor (HTR1E) DM6BIWK MA Antagonist DM6BIWK RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/14744596 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TTO9X1H DM6BIWK TN 5-HT 7 receptor (HTR7) DM6BIWK MA Agonist DM6BIWK RN Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/8226867 DM6BIWK DI DM6BIWK DM6BIWK DN 1-naphthylpiperazine DM6BIWK TI TTJQOD7 DM6BIWK TN 5-HT 2A receptor (HTR2A) DM6BIWK MA Inhibitor DM6BIWK RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DM6BIWK RU https://pubmed.ncbi.nlm.nih.gov/3783595 DM6BNQR DI DM6BNQR DM6BNQR DN NORBOLDINE DM6BNQR TI TTVBI8W DM6BNQR TN Dopamine transporter (DAT) DM6BNQR MA Inhibitor DM6BNQR RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DM6BNQR RU https://pubmed.ncbi.nlm.nih.gov/8676127 DM6BON2 DI DM6BON2 DM6BON2 DN (S)-zacopride DM6BON2 TI TTR6K75 DM6BON2 TN 5-HT 3B receptor (HTR3B) DM6BON2 MA Antagonist DM6BON2 RN Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4. DM6BON2 RU https://pubmed.ncbi.nlm.nih.gov/11489465 DM6BON2 DI DM6BON2 DM6BON2 DN (S)-zacopride DM6BON2 TI TTPC4TU DM6BON2 TN 5-HT 3A receptor (HTR3A) DM6BON2 MA Antagonist DM6BON2 RN Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4. DM6BON2 RU https://pubmed.ncbi.nlm.nih.gov/11489465 DM6BRLA DI DM6BRLA DM6BRLA DN CP-294838 DM6BRLA TI TTFQEO5 DM6BRLA TN Squalene synthetase (FDFT1) DM6BRLA MA Inhibitor DM6BRLA RN Truncation of human squalene synthase yields active, crystallizable protein. Arch Biochem Biophys. 1998 Feb 15;350(2):283-90. DM6BRLA RU https://pubmed.ncbi.nlm.nih.gov/9473303 DM6BRTF DI DM6BRTF DM6BRTF DN A-794278 DM6BRTF TI TTVBPDM DM6BRTF TN Metabotropic glutamate receptor 1 (mGluR1) DM6BRTF MA Modulator (allosteric modulator) DM6BRTF RN Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem. 2005 Nov 17;48(23):7374-88. DM6BRTF RU https://pubmed.ncbi.nlm.nih.gov/16279797 DM6BWGQ DI DM6BWGQ DM6BWGQ DN Lobatamide F DM6BWGQ TI TTTK3BH DM6BWGQ TN Vacuolar-type proton ATPase (v-ATPase) DM6BWGQ MA Inhibitor DM6BWGQ RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DM6BWGQ RU https://pubmed.ncbi.nlm.nih.gov/11259534 DM6C8K1 DI DM6C8K1 DM6C8K1 DN [4Aph(CO-NH-OCH3)5]degarelix DM6C8K1 TI TT8R70G DM6C8K1 TN Gonadotropin-releasing hormone receptor (GNRHR) DM6C8K1 MA Inhibitor DM6C8K1 RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DM6C8K1 RU https://pubmed.ncbi.nlm.nih.gov/16759096 DM6CAYV DI DM6CAYV DM6CAYV DN 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol DM6CAYV TI TTML2WA DM6CAYV TN Tubulin (TUB) DM6CAYV MA Inhibitor DM6CAYV RN Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett. 2001 Jan 8;11(1):51-4. DM6CAYV RU https://pubmed.ncbi.nlm.nih.gov/11140732 DM6CAYV DI DM6CAYV DM6CAYV DN 2-Methoxy-5-(3,4,5-trimethoxy-phenoxy)-phenol DM6CAYV TI TTYFKSZ DM6CAYV TN Tubulin beta (TUBB) DM6CAYV MA Inhibitor DM6CAYV RN Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers. Bioorg Med Chem Lett. 2001 Jan 8;11(1):51-4. DM6CAYV RU https://pubmed.ncbi.nlm.nih.gov/11140732 DM6CBTE DI DM6CBTE DM6CBTE DN 3,5-di(pyridin-4-yl)-1H-1,2,4-triazole DM6CBTE TI TT7RJY8 DM6CBTE TN Xanthine dehydrogenase/oxidase (XDH) DM6CBTE MA Inhibitor DM6CBTE RN Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9. DM6CBTE RU https://pubmed.ncbi.nlm.nih.gov/19783139 DM6CEVB DI DM6CEVB DM6CEVB DN All-trans-retinal DM6CEVB TI TT8SJGB DM6CEVB TN Cyclic nucleotide-gated channel alpha-2 (CNGA2) DM6CEVB MA Inhibitor (gating inhibitor) DM6CEVB RN All-trans-retinal shuts down rod cyclic nucleotide-gated ion channels: a novel role for photoreceptor retinoids in the response to bright light Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8372-7. DM6CEVB RU https://pubmed.ncbi.nlm.nih.gov/12034887 DM6CRVS DI DM6CRVS DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide DM6CRVS TI TTT6LFV DM6CRVS TN Histone deacetylase 8 (HDAC8) DM6CRVS MA Inhibitor DM6CRVS RN Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. DM6CRVS RU https://pubmed.ncbi.nlm.nih.gov/15109636 DM6CRVS DI DM6CRVS DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide DM6CRVS TI TT6R7JZ DM6CRVS TN Histone deacetylase 1 (HDAC1) DM6CRVS MA Inhibitor DM6CRVS RN Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. DM6CRVS RU https://pubmed.ncbi.nlm.nih.gov/15109636 DM6CRVS DI DM6CRVS DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide DM6CRVS TI TT5ZKDI DM6CRVS TN Histone deacetylase 6 (HDAC6) DM6CRVS MA Inhibitor DM6CRVS RN Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. DM6CRVS RU https://pubmed.ncbi.nlm.nih.gov/15109636 DM6CRVS DI DM6CRVS DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide DM6CRVS TI TTTQGH8 DM6CRVS TN Histone deacetylase 4 (HDAC4) DM6CRVS MA Inhibitor DM6CRVS RN Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. DM6CRVS RU https://pubmed.ncbi.nlm.nih.gov/15109636 DM6CRVS DI DM6CRVS DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide DM6CRVS TI TTBH0VX DM6CRVS TN Histone deacetylase (HDAC) DM6CRVS MA Inhibitor DM6CRVS RN Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. DM6CRVS RU https://pubmed.ncbi.nlm.nih.gov/15109636 DM6CRVS DI DM6CRVS DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide DM6CRVS TI TTSHTOI DM6CRVS TN Histone deacetylase 2 (HDAC2) DM6CRVS MA Inhibitor DM6CRVS RN Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. DM6CRVS RU https://pubmed.ncbi.nlm.nih.gov/15109636 DM6CRVS DI DM6CRVS DM6CRVS DN 5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide DM6CRVS TI TTYHPU6 DM6CRVS TN Histone deacetylase 10 (HDAC10) DM6CRVS MA Inhibitor DM6CRVS RN Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides. Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81. DM6CRVS RU https://pubmed.ncbi.nlm.nih.gov/15109636 DM6CWBO DI DM6CWBO DM6CWBO DN (+/-)-threo-N-(2-Methylfuran)methylphenidate DM6CWBO TI TTVBI8W DM6CWBO TN Dopamine transporter (DAT) DM6CWBO MA Inhibitor DM6CWBO RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM6CWBO RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM6CZAN DI DM6CZAN DM6CZAN DN 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine DM6CZAN TI TTM2AOE DM6CZAN TN Adenosine A2a receptor (ADORA2A) DM6CZAN MA Inhibitor DM6CZAN RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DM6CZAN RU https://pubmed.ncbi.nlm.nih.gov/2002461 DM6CZAN DI DM6CZAN DM6CZAN DN 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine DM6CZAN TI TTK25J1 DM6CZAN TN Adenosine A1 receptor (ADORA1) DM6CZAN MA Inhibitor DM6CZAN RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DM6CZAN RU https://pubmed.ncbi.nlm.nih.gov/2002461 DM6CZAN DI DM6CZAN DM6CZAN DN 2-Cyclopentyl-1H-imidazo[4,5-c]quinolin-4-ylamine DM6CZAN TI TTNE7KG DM6CZAN TN Adenosine A2b receptor (ADORA2B) DM6CZAN MA Inhibitor DM6CZAN RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DM6CZAN RU https://pubmed.ncbi.nlm.nih.gov/2002461 DM6D0JC DI DM6D0JC DM6D0JC DN Neo-kauluamine DM6D0JC TI TTRSMW9 DM6D0JC TN Glycogen synthase kinase-3 beta (GSK-3B) DM6D0JC MA Inhibitor DM6D0JC RN Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40. DM6D0JC RU https://pubmed.ncbi.nlm.nih.gov/16872140 DM6D0ZS DI DM6D0ZS DM6D0ZS DN H-Tyr-Gly-Gly-Phe-Met-NH2 DM6D0ZS TI TTQW87Y DM6D0ZS TN Opioid receptor kappa (OPRK1) DM6D0ZS MA Inhibitor DM6D0ZS RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM6D0ZS RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM6D0ZS DI DM6D0ZS DM6D0ZS DN H-Tyr-Gly-Gly-Phe-Met-NH2 DM6D0ZS TI TT27RFC DM6D0ZS TN Opioid receptor delta (OPRD1) DM6D0ZS MA Inhibitor DM6D0ZS RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM6D0ZS RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM6D0ZS DI DM6D0ZS DM6D0ZS DN H-Tyr-Gly-Gly-Phe-Met-NH2 DM6D0ZS TI TTKWM86 DM6D0ZS TN Opioid receptor mu (MOP) DM6D0ZS MA Inhibitor DM6D0ZS RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM6D0ZS RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM6D18M DI DM6D18M DM6D18M DN (+/-)-threo-N-Methyl-30-methylmethylphenidate DM6D18M TI TTVBI8W DM6D18M TN Dopamine transporter (DAT) DM6D18M MA Inhibitor DM6D18M RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM6D18M RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM6D1BQ DI DM6D1BQ DM6D1BQ DN 2,6-diphenyl-8-tButyl-1-deazapurine DM6D1BQ TI TTM2AOE DM6D1BQ TN Adenosine A2a receptor (ADORA2A) DM6D1BQ MA Inhibitor DM6D1BQ RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM6D1BQ RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM6D1BQ DI DM6D1BQ DM6D1BQ DN 2,6-diphenyl-8-tButyl-1-deazapurine DM6D1BQ TI TTK25J1 DM6D1BQ TN Adenosine A1 receptor (ADORA1) DM6D1BQ MA Inhibitor DM6D1BQ RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM6D1BQ RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM6D1BQ DI DM6D1BQ DM6D1BQ DN 2,6-diphenyl-8-tButyl-1-deazapurine DM6D1BQ TI TTJFY5U DM6D1BQ TN Adenosine A3 receptor (ADORA3) DM6D1BQ MA Inhibitor DM6D1BQ RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM6D1BQ RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM6D3NQ DI DM6D3NQ DM6D3NQ DN Affinitak + Cisplatin DM6D3NQ TI TT2MI95 DM6D3NQ TN PKC-alpha messenger RNA (PRKCA mRNA) DM6D3NQ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM6D3NQ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM6DEOC DI DM6DEOC DM6DEOC DN 5-Methyl-4-propyl-pyrrolidin-(2Z)-ylideneamine DM6DEOC TI TTF10I9 DM6DEOC TN Nitric-oxide synthase inducible (NOS2) DM6DEOC MA Inhibitor DM6DEOC RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM6DEOC RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM6DEZ4 DI DM6DEZ4 DM6DEZ4 DN N-(1'-Phenyl-ethyl) estradiol-16-carboxamide DM6DEZ4 TI TTIWB6L DM6DEZ4 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM6DEZ4 MA Inhibitor DM6DEZ4 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM6DEZ4 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM6DH15 DI DM6DH15 DM6DH15 DN (2-Chloro-ethyl)-trimethyl-ammonium chloride DM6DH15 TI TT1RS9F DM6DH15 TN Acetylcholinesterase (AChE) DM6DH15 MA Inhibitor DM6DH15 RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DM6DH15 RU https://pubmed.ncbi.nlm.nih.gov/8978837 DM6DM4L DI DM6DM4L DM6DM4L DN N-methyl-N-ethyl estradiol-16-carboxamide DM6DM4L TI TTIWB6L DM6DM4L TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM6DM4L MA Inhibitor DM6DM4L RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM6DM4L RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM6DOVL DI DM6DOVL DM6DOVL DN 9-Methyl-9H-adenine DM6DOVL TI TTK25J1 DM6DOVL TN Adenosine A1 receptor (ADORA1) DM6DOVL MA Inhibitor DM6DOVL RN Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique aden... J Med Chem. 2004 Apr 22;47(9):2243-55. DM6DOVL RU https://pubmed.ncbi.nlm.nih.gov/15084123 DM6DOVL DI DM6DOVL DM6DOVL DN 9-Methyl-9H-adenine DM6DOVL TI TTM2AOE DM6DOVL TN Adenosine A2a receptor (ADORA2A) DM6DOVL MA Inhibitor DM6DOVL RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM6DOVL RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM6DRFC DI DM6DRFC DM6DRFC DN NVP 231 DM6DRFC TI TT9XRNV DM6DRFC TN Ceramide kinase (CERK) DM6DRFC MA Inhibitor DM6DRFC RN Targeting ceramide metabolism with a potent and specific ceramide kinase inhibitor. Mol Pharmacol. 2008 Oct;74(4):925-32. DM6DRFC RU https://pubmed.ncbi.nlm.nih.gov/18612076 DM6DSNI DI DM6DSNI DM6DSNI DN 4'-(2-methyl-1-(pyridin-4-yl)propyl)biphenyl-3-ol DM6DSNI TI TTRA5BZ DM6DSNI TN Steroid 17-alpha-monooxygenase (S17AH) DM6DSNI MA Inhibitor DM6DSNI RN Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors. J Med Chem. 2010 Jul 8;53(13):5049-53. DM6DSNI RU https://pubmed.ncbi.nlm.nih.gov/20550118 DM6DT9Z DI DM6DT9Z DM6DT9Z DN S-Ethyl-N-Phenyl-Isothiourea DM6DT9Z TI TTZUFI5 DM6DT9Z TN Nitric-oxide synthase brain (NOS1) DM6DT9Z MA Inhibitor DM6DT9Z RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6DT9Z RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6DT9Z DI DM6DT9Z DM6DT9Z DN S-Ethyl-N-Phenyl-Isothiourea DM6DT9Z TI TTCM4B3 DM6DT9Z TN Nitric-oxide synthase endothelial (NOS3) DM6DT9Z MA Inhibitor DM6DT9Z RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6DT9Z RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6DV90 DI DM6DV90 DM6DV90 DN C[-Arg-Gly-Asp-Acpca22-] DM6DV90 TI TTJA1ZO DM6DV90 TN ITGB3 messenger RNA (ITGB3 mRNA) DM6DV90 MA Inhibitor DM6DV90 RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DM6DV90 RU https://pubmed.ncbi.nlm.nih.gov/16302808 DM6DV90 DI DM6DV90 DM6DV90 DN C[-Arg-Gly-Asp-Acpca22-] DM6DV90 TI TTT1R2L DM6DV90 TN Integrin alpha-V (ITGAV) DM6DV90 MA Inhibitor DM6DV90 RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DM6DV90 RU https://pubmed.ncbi.nlm.nih.gov/16302808 DM6DYZ0 DI DM6DYZ0 DM6DYZ0 DN ANOLOBINE DM6DYZ0 TI TTVBI8W DM6DYZ0 TN Dopamine transporter (DAT) DM6DYZ0 MA Inhibitor DM6DYZ0 RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DM6DYZ0 RU https://pubmed.ncbi.nlm.nih.gov/8676127 DM6DYZ0 DI DM6DYZ0 DM6DYZ0 DN ANOLOBINE DM6DYZ0 TI TTEX248 DM6DYZ0 TN Dopamine D2 receptor (D2R) DM6DYZ0 MA Inhibitor DM6DYZ0 RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DM6DYZ0 RU https://pubmed.ncbi.nlm.nih.gov/17228858 DM6E04T DI DM6E04T DM6E04T DN 2-benzyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one DM6E04T TI TTJFY5U DM6E04T TN Adenosine A3 receptor (ADORA3) DM6E04T MA Inhibitor DM6E04T RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DM6E04T RU https://pubmed.ncbi.nlm.nih.gov/17665891 DM6E7TA DI DM6E7TA DM6E7TA DN 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane DM6E7TA TI TTVBI8W DM6E7TA TN Dopamine transporter (DAT) DM6E7TA MA Inhibitor DM6E7TA RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DM6E7TA RU https://pubmed.ncbi.nlm.nih.gov/18539031 DM6E7TA DI DM6E7TA DM6E7TA DN 1-Biphenyl-4-yl-3-aza-bicyclo[3.1.0]hexane DM6E7TA TI TT3ROYC DM6E7TA TN Serotonin transporter (SERT) DM6E7TA MA Inhibitor DM6E7TA RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DM6E7TA RU https://pubmed.ncbi.nlm.nih.gov/18539031 DM6EA9B DI DM6EA9B DM6EA9B DN Glu-Pro-Gln-F2Pmp-Glu-Glu-Ile-Pro-Ile-Tyr-Leu DM6EA9B TI TT6PKBN DM6EA9B TN Proto-oncogene c-Src (SRC) DM6EA9B MA Inhibitor DM6EA9B RN The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands, Bioorg. Med. Chem. Lett. 7(14):1909-1914 (1997). DM6EA9B RU http://www.sciencedirect.com/science/article/pii/S0960894X9700334X DM6EAHF DI DM6EAHF DM6EAHF DN [N40,Pro1,Tyr4,Nle 14]BB DM6EAHF TI TTC1MVT DM6EAHF TN Gastrin-releasing peptide receptor (GRPR) DM6EAHF MA Inhibitor DM6EAHF RN Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10. DM6EAHF RU https://pubmed.ncbi.nlm.nih.gov/15634004 DM6EF1L DI DM6EF1L DM6EF1L DN 1-Benzo[b]thiophen-2-yl-cyclopentylamine DM6EF1L TI TTVBI8W DM6EF1L TN Dopamine transporter (DAT) DM6EF1L MA Inhibitor DM6EF1L RN Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93. DM6EF1L RU https://pubmed.ncbi.nlm.nih.gov/8098066 DM6EFLV DI DM6EFLV DM6EFLV DN 4-phenyl-1-(1-phenylethyl)piperidin-4-ol DM6EFLV TI TTKWM86 DM6EFLV TN Opioid receptor mu (MOP) DM6EFLV MA Inhibitor DM6EFLV RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM6EFLV RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM6EFLV DI DM6EFLV DM6EFLV DN 4-phenyl-1-(1-phenylethyl)piperidin-4-ol DM6EFLV TI TTNT7K8 DM6EFLV TN Nociceptin receptor (OPRL1) DM6EFLV MA Inhibitor DM6EFLV RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM6EFLV RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM6EFLV DI DM6EFLV DM6EFLV DN 4-phenyl-1-(1-phenylethyl)piperidin-4-ol DM6EFLV TI TTQW87Y DM6EFLV TN Opioid receptor kappa (OPRK1) DM6EFLV MA Inhibitor DM6EFLV RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM6EFLV RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM6EFN2 DI DM6EFN2 DM6EFN2 DN 9-chlorobenzo[h]isoquinolin-1(2H)-one DM6EFN2 TI TTTU902 DM6EFN2 TN Checkpoint kinase-1 (CHK1) DM6EFN2 MA Inhibitor DM6EFN2 RN Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6280-5. DM6EFN2 RU https://pubmed.ncbi.nlm.nih.gov/17900896 DM6EICU DI DM6EICU DM6EICU DN N-[O-Phosphono-Pyridoxyl]-Isoleucine DM6EICU TI TTF9OQ6 DM6EICU TN Branched-chain-amino-acid transaminase 2 (BCAT2) DM6EICU MA Inhibitor DM6EICU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6EICU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6EIVM DI DM6EIVM DM6EIVM DN Telomestatin DM6EIVM TI TTUJFD0 DM6EIVM TN Telomerase reverse transcriptase (TERT) DM6EIVM MA Inhibitor DM6EIVM RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM6EIVM RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM6EJQ4 DI DM6EJQ4 DM6EJQ4 DN N-(3,3-Dimethyl-cyclopentyl)-4-hexyloxy-benzamide DM6EJQ4 TI TT846HF DM6EJQ4 TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DM6EJQ4 MA Inhibitor DM6EJQ4 RN Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7. DM6EJQ4 RU https://pubmed.ncbi.nlm.nih.gov/11689063 DM6EMGJ DI DM6EMGJ DM6EMGJ DN 2-Benzylaminomethyl-3-hydroxymorphinan DM6EMGJ TI TTQW87Y DM6EMGJ TN Opioid receptor kappa (OPRK1) DM6EMGJ MA Inhibitor DM6EMGJ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM6EMGJ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM6EMGJ DI DM6EMGJ DM6EMGJ DN 2-Benzylaminomethyl-3-hydroxymorphinan DM6EMGJ TI TTKWM86 DM6EMGJ TN Opioid receptor mu (MOP) DM6EMGJ MA Inhibitor DM6EMGJ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM6EMGJ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM6ESXB DI DM6ESXB DM6ESXB DN 4-(4-p-Tolylamino-phthalazin-1-yl)-benzamide DM6ESXB TI TTUTJGQ DM6ESXB TN Vascular endothelial growth factor receptor 2 (KDR) DM6ESXB MA Inhibitor DM6ESXB RN Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8. DM6ESXB RU https://pubmed.ncbi.nlm.nih.gov/16143524 DM6EYQ2 DI DM6EYQ2 DM6EYQ2 DN (RS/SR)-2-[1-(3,4-dichlorophenyl)butyl]piperidine DM6EYQ2 TI TTVBI8W DM6EYQ2 TN Dopamine transporter (DAT) DM6EYQ2 MA Inhibitor DM6EYQ2 RN Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. DM6EYQ2 RU https://pubmed.ncbi.nlm.nih.gov/17228864 DM6F0C4 DI DM6F0C4 DM6F0C4 DN 2-Benzylsulfanyl-6-chloro-pyrimidin-4-ylamine DM6F0C4 TI TT84ETX DM6F0C4 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6F0C4 MA Inhibitor DM6F0C4 RN Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV. J Med Chem. 1998 Sep 24;41(20):3793-803. DM6F0C4 RU https://pubmed.ncbi.nlm.nih.gov/9748354 DM6F0VR DI DM6F0VR DM6F0VR DN VPC12249 DM6F0VR TI TTE2YJR DM6F0VR TN Lysophosphatidate-3 receptor (LPAR3) DM6F0VR MA Antagonist DM6F0VR RN Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80. DM6F0VR RU https://pubmed.ncbi.nlm.nih.gov/11723223 DM6F0VR DI DM6F0VR DM6F0VR DN VPC12249 DM6F0VR TI TTDYP7I DM6F0VR TN Sphingosine-1-phosphate receptor 3 (S1PR3) DM6F0VR MA Agonist DM6F0VR RN Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77. DM6F0VR RU https://pubmed.ncbi.nlm.nih.gov/17113298 DM6F0VR DI DM6F0VR DM6F0VR DN VPC12249 DM6F0VR TI TTQ6S1K DM6F0VR TN Lysophosphatidic acid receptor 1 (LPAR1) DM6F0VR MA Antagonist DM6F0VR RN Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80. DM6F0VR RU https://pubmed.ncbi.nlm.nih.gov/11723223 DM6F3HV DI DM6F3HV DM6F3HV DN NSC-649091 DM6F3HV TI TTJLP0R DM6F3HV TN Quinone reductase 2 (NQO2) DM6F3HV MA Inhibitor DM6F3HV RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM6F3HV RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM6F8DM DI DM6F8DM DM6F8DM DN CT-98024 DM6F8DM TI TTRSMW9 DM6F8DM TN Glycogen synthase kinase-3 beta (GSK-3B) DM6F8DM MA Inhibitor DM6F8DM RN Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. DM6F8DM RU https://pubmed.ncbi.nlm.nih.gov/20138512 DM6FDAY DI DM6FDAY DM6FDAY DN 1-(5-(pyridin-2-yl)oxazol-2-yl)pentan-1-one DM6FDAY TI TTDP1UC DM6FDAY TN Fatty acid amide hydrolase (FAAH) DM6FDAY MA Inhibitor DM6FDAY RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DM6FDAY RU https://pubmed.ncbi.nlm.nih.gov/18053726 DM6FEMV DI DM6FEMV DM6FEMV DN YH-1238 DM6FEMV TI TTLOKXP DM6FEMV TN Gastric H(+)/K(+) ATPase (Proton pump) DM6FEMV MA Modulator DM6FEMV RN Compositions for improving gastrointestinal nutrient and drug absorption DM6FEMV RU https://www.google.com/patents/US20080193531 DM6FHQD DI DM6FHQD DM6FHQD DN Beta,beta-dimethylmelatonin DM6FHQD TI TT32JK8 DM6FHQD TN Melatonin receptor type 1B (MTNR1B) DM6FHQD MA Inhibitor DM6FHQD RN Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19. DM6FHQD RU https://pubmed.ncbi.nlm.nih.gov/16759094 DM6FHQD DI DM6FHQD DM6FHQD DN Beta,beta-dimethylmelatonin DM6FHQD TI TT0WAIE DM6FHQD TN Melatonin receptor type 1A (MTNR1A) DM6FHQD MA Inhibitor DM6FHQD RN Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19. DM6FHQD RU https://pubmed.ncbi.nlm.nih.gov/16759094 DM6FHWZ DI DM6FHWZ DM6FHWZ DN 3-(6-Amino-purin-9-yl)-non-5-en-2-ol DM6FHWZ TI TTLP57V DM6FHWZ TN Adenosine deaminase (ADA) DM6FHWZ MA Inhibitor DM6FHWZ RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DM6FHWZ RU https://pubmed.ncbi.nlm.nih.gov/11101360 DM6FLXW DI DM6FLXW DM6FLXW DN 1-Hydroxyamine-2-Isobutylmalonic Acid DM6FLXW TI TTGA1IV DM6FLXW TN Matrix metalloproteinase-8 (MMP-8) DM6FLXW MA Inhibitor DM6FLXW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6FLXW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6FMO1 DI DM6FMO1 DM6FMO1 DN 4-Imidazol-1-ylmethyl-2-nitroxanthen-9-one DM6FMO1 TI TTSZLWK DM6FMO1 TN Aromatase (CYP19A1) DM6FMO1 MA Inhibitor DM6FMO1 RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DM6FMO1 RU https://pubmed.ncbi.nlm.nih.gov/20568782 DM6FNVC DI DM6FNVC DM6FNVC DN 6-Hydroxyflavanone DM6FNVC TI TTKPW01 DM6FNVC TN Androgen receptor messenger RNA (AR mRNA) DM6FNVC MA Inhibitor DM6FNVC RN Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. DM6FNVC RU https://pubmed.ncbi.nlm.nih.gov/19592245 DM6FSUW DI DM6FSUW DM6FSUW DN 5-oxo-C20:3 DM6FSUW TI TT7WBSV DM6FSUW TN Oxoeicosanoid receptor 1 (OXER1) DM6FSUW MA Agonist DM6FSUW RN Structural requirements for activation of the 5-oxo-6E,8Z, 11Z,14Z-eicosatetraenoic acid (5-oxo-ETE) receptor: identification of a mead acid metabolite with potent agonist activity. J Pharmacol Exp Ther. 2008 May;325(2):698-707. DM6FSUW RU https://pubmed.ncbi.nlm.nih.gov/18292294 DM6FVCE DI DM6FVCE DM6FVCE DN Sergliflozin A DM6FVCE TI TTF8JAT DM6FVCE TN SLC5A2 messenger RNA (SLC5A2 mRNA) DM6FVCE MA Inhibitor DM6FVCE RN Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. Bioorg Med Chem. 2010 Mar 15;18(6):2178-2194. DM6FVCE RU https://pubmed.ncbi.nlm.nih.gov/20181486 DM6FVDO DI DM6FVDO DM6FVDO DN Isosorbide-2-benzyl carbamate DM6FVDO TI TTEB0GD DM6FVDO TN Cholinesterase (BCHE) DM6FVDO MA Inhibitor DM6FVDO RN Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor. J Med Chem. 2010 Feb 11;53(3):1190-9. DM6FVDO RU https://pubmed.ncbi.nlm.nih.gov/20067290 DM6FVZW DI DM6FVZW DM6FVZW DN R-dimethindene DM6FVZW TI TTQ6VDM DM6FVZW TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM6FVZW MA Inhibitor DM6FVZW RN Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10. DM6FVZW RU https://pubmed.ncbi.nlm.nih.gov/19663387 DM6FVZW DI DM6FVZW DM6FVZW DN R-dimethindene DM6FVZW TI TTZ9SOR DM6FVZW TN Muscarinic acetylcholine receptor M1 (CHRM1) DM6FVZW MA Inhibitor DM6FVZW RN Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10. DM6FVZW RU https://pubmed.ncbi.nlm.nih.gov/19663387 DM6FVZW DI DM6FVZW DM6FVZW DN R-dimethindene DM6FVZW TI TTTIBOJ DM6FVZW TN Histamine H1 receptor (H1R) DM6FVZW MA Inhibitor DM6FVZW RN Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia. J Med Chem. 2009 Sep 10;52(17):5307-10. DM6FVZW RU https://pubmed.ncbi.nlm.nih.gov/19663387 DM6GFRP DI DM6GFRP DM6GFRP DN N-(4-iodophenyl)-4-(trifluoromethoxy)benzamide DM6GFRP TI TTMI6F5 DM6GFRP TN Transient receptor potential cation channel V1 (TRPV1) DM6GFRP MA Inhibitor DM6GFRP RN Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1072-8. DM6GFRP RU https://pubmed.ncbi.nlm.nih.gov/18155908 DM6GI4Z DI DM6GI4Z DM6GI4Z DN 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one DM6GI4Z TI TT6R7JZ DM6GI4Z TN Histone deacetylase 1 (HDAC1) DM6GI4Z MA Inhibitor DM6GI4Z RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM6GI4Z RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM6GI4Z DI DM6GI4Z DM6GI4Z DN 1,1,1-Trifluoro-8-(4-phenoxy-phenoxy)-octan-2-one DM6GI4Z TI TTSHTOI DM6GI4Z TN Histone deacetylase 2 (HDAC2) DM6GI4Z MA Inhibitor DM6GI4Z RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DM6GI4Z RU https://pubmed.ncbi.nlm.nih.gov/12419380 DM6GLEA DI DM6GLEA DM6GLEA DN 2-(3-Phenoxy-benzoylamino)-benzoic acid DM6GLEA TI TTRVTMX DM6GLEA TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DM6GLEA MA Inhibitor DM6GLEA RN Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609. DM6GLEA RU https://pubmed.ncbi.nlm.nih.gov/15743201 DM6GLSF DI DM6GLSF DM6GLSF DN UK-129485 DM6GLSF TI TT84ETX DM6GLSF TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6GLSF MA Inhibitor DM6GLSF RN Imidazo[2 3 :6,5]dipyrido[3,2-b:2 3 e]-1,4-diazepines: non-nucleoside HIV-1 reverse transcriptase inhibitors with greater enzyme affinity than nevirapine, Bioorg. Med. Chem. Lett. 2(12):1745-1750(1992). DM6GLSF RU http://www.sciencedirect.com/science/article/pii/S0960894X00804680 DM6GO2I DI DM6GO2I DM6GO2I DN 5-(piperidin-4-yl)isoxazol-3-ol DM6GO2I TI TT06RH5 DM6GO2I TN GABA(A) receptor gamma-2 (GABRG2) DM6GO2I MA Inhibitor DM6GO2I RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM6GO2I RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM6GO2I DI DM6GO2I DM6GO2I DN 5-(piperidin-4-yl)isoxazol-3-ol DM6GO2I TI TTNJYV2 DM6GO2I TN Gamma-aminobutyric acid receptor (GAR) DM6GO2I MA Inhibitor DM6GO2I RN 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships. J Med Chem. 2007 Apr 19;50(8):1988-92. DM6GO2I RU https://pubmed.ncbi.nlm.nih.gov/17375905 DM6GO2I DI DM6GO2I DM6GO2I DN 5-(piperidin-4-yl)isoxazol-3-ol DM6GO2I TI TTZA1NY DM6GO2I TN GABA(A) receptor beta-2 (GABRB2) DM6GO2I MA Inhibitor DM6GO2I RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM6GO2I RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM6GO2I DI DM6GO2I DM6GO2I DN 5-(piperidin-4-yl)isoxazol-3-ol DM6GO2I TI TT1MPAY DM6GO2I TN GABA(A) receptor alpha-1 (GABRA1) DM6GO2I MA Inhibitor DM6GO2I RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM6GO2I RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM6GTBC DI DM6GTBC DM6GTBC DN Beta-1-C-butenyl-1-deoxygalactonojirimycin DM6GTBC TI TTIS03D DM6GTBC TN Alpha-galactosidase A (GLA) DM6GTBC MA Inhibitor DM6GTBC RN 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4. DM6GTBC RU https://pubmed.ncbi.nlm.nih.gov/20457528 DM6GWAC DI DM6GWAC DM6GWAC DN DDATHF DM6GWAC TI TT9SL3Q DM6GWAC TN Polypeptide deformylase (PDF) DM6GWAC MA Inhibitor DM6GWAC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6GWAC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6GWAC DI DM6GWAC DM6GWAC DN DDATHF DM6GWAC TI TTCSJBZ DM6GWAC TN GAR transformylase (GART) DM6GWAC MA Modulator DM6GWAC RN Rational design, synthesis, evaluation, and crystal structure of a potent inhibitor of human GAR Tfase: 10-(trifluoroacetyl)-5,10-dideazaacyclic-5,... Biochemistry. 2003 May 27;42(20):6043-56. DM6GWAC RU https://www.ncbi.nlm.nih.gov/pubmed/12755606 DM6GWRB DI DM6GWRB DM6GWRB DN 6-Phenylsulfanylmethyl-pteridine-2,4-diamine DM6GWRB TI TT9SL3Q DM6GWRB TN Polypeptide deformylase (PDF) DM6GWRB MA Inhibitor DM6GWRB RN Nonclassical 2,4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gon... J Med Chem. 1996 Apr 26;39(9):1836-45. DM6GWRB RU https://pubmed.ncbi.nlm.nih.gov/8627607 DM6H0FW DI DM6H0FW DM6H0FW DN ((Z)-3-Amino-propenyl)-methyl-phosphinic acid DM6H0FW TI TTDCVZW DM6H0FW TN Gamma-aminobutyric acid B receptor (GABBR) DM6H0FW MA Inhibitor DM6H0FW RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DM6H0FW RU https://pubmed.ncbi.nlm.nih.gov/7650684 DM6H52B DI DM6H52B DM6H52B DN 3-(2-carboxy-5-mercaptopentyl)benzoic acid DM6H52B TI TT9G4N0 DM6H52B TN Glutamate carboxypeptidase II (GCPII) DM6H52B MA Inhibitor DM6H52B RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DM6H52B RU https://pubmed.ncbi.nlm.nih.gov/16686531 DM6H8JM DI DM6H8JM DM6H8JM DN Ro-04-6790 DM6H8JM TI TTJS8PY DM6H8JM TN 5-HT 6 receptor (HTR6) DM6H8JM MA Inhibitor DM6H8JM RN Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87. DM6H8JM RU https://pubmed.ncbi.nlm.nih.gov/19159187 DM6HDKQ DI DM6HDKQ DM6HDKQ DN [3H]mibolerone DM6HDKQ TI TTKPW01 DM6HDKQ TN Androgen receptor messenger RNA (AR mRNA) DM6HDKQ MA Agonist DM6HDKQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628). DM6HDKQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628 DM6HDKQ DI DM6HDKQ DM6HDKQ DN [3H]mibolerone DM6HDKQ TI TTS64P2 DM6HDKQ TN Androgen receptor (AR) DM6HDKQ MA Inhibitor DM6HDKQ RN Design, synthesis, and pharmacological characterization of 4-[4, 4-dimethyl-3-(4-hydroxybutyl)-5-oxo-2-thioxo-1-imidazolidinyl]- 2-iodobenzonitrile... J Med Chem. 2000 Aug 24;43(17):3344-7. DM6HDKQ RU https://pubmed.ncbi.nlm.nih.gov/10966753 DM6HEXG DI DM6HEXG DM6HEXG DN [D-Ncy(SO,methyl)4]acyline DM6HEXG TI TT8R70G DM6HEXG TN Gonadotropin-releasing hormone receptor (GNRHR) DM6HEXG MA Inhibitor DM6HEXG RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM6HEXG RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM6HGK4 DI DM6HGK4 DM6HGK4 DN N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide DM6HGK4 TI TTJFY5U DM6HGK4 TN Adenosine A3 receptor (ADORA3) DM6HGK4 MA Inhibitor DM6HGK4 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM6HGK4 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM6HGK4 DI DM6HGK4 DM6HGK4 DN N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide DM6HGK4 TI TTM2AOE DM6HGK4 TN Adenosine A2a receptor (ADORA2A) DM6HGK4 MA Inhibitor DM6HGK4 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM6HGK4 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM6HGK4 DI DM6HGK4 DM6HGK4 DN N-(2,6-diphenylpyrimidin-4-yl)-3-methylbutyramide DM6HGK4 TI TTK25J1 DM6HGK4 TN Adenosine A1 receptor (ADORA1) DM6HGK4 MA Inhibitor DM6HGK4 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM6HGK4 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM6HGUL DI DM6HGUL DM6HGUL DN 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine DM6HGUL TI TTBFROQ DM6HGUL TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DM6HGUL MA Inhibitor DM6HGUL RN S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77. DM6HGUL RU https://pubmed.ncbi.nlm.nih.gov/1301596 DM6HGUL DI DM6HGUL DM6HGUL DN 5'-deoxy-5'-[(3-hydrazinopropyl)methylamino]adenosine DM6HGUL TI TTVF2BJ DM6HGUL TN Lactosylceramide alpha-2,3-sialyltransferase (ST3GAL5) DM6HGUL MA Inhibitor DM6HGUL RN S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77. DM6HGUL RU https://pubmed.ncbi.nlm.nih.gov/1301596 DM6HI8W DI DM6HI8W DM6HI8W DN trans-3-ACPBPA DM6HI8W TI TT4N6D8 DM6HI8W TN GABA(A) receptor rho3 (GABRR3) DM6HI8W MA Antagonist DM6HI8W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DM6HI8W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DM6HI8W DI DM6HI8W DM6HI8W DN trans-3-ACPBPA DM6HI8W TI TT6XFEU DM6HI8W TN GABA(A) receptor rho1 (GABRR1) DM6HI8W MA Antagonist DM6HI8W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DM6HI8W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DM6HI8W DI DM6HI8W DM6HI8W DN trans-3-ACPBPA DM6HI8W TI TTQMXLS DM6HI8W TN GABA(A) receptor rho2 (GABRR2) DM6HI8W MA Antagonist DM6HI8W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DM6HI8W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DM6HKEC DI DM6HKEC DM6HKEC DN Nor-binaltorphimine dihydrochloride DM6HKEC TI TTQW87Y DM6HKEC TN Opioid receptor kappa (OPRK1) DM6HKEC MA Antagonist DM6HKEC RN Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesth Analg. 2003 Dec;97(6):1776-83. DM6HKEC RU https://pubmed.ncbi.nlm.nih.gov/14633559 DM6HM5S DI DM6HM5S DM6HM5S DN N1-(2-aminoethyl)ethane-1,2-diamine DM6HM5S TI TTUNARX DM6HM5S TN Carbonic anhydrase (CA) DM6HM5S MA Inhibitor DM6HM5S RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DM6HM5S RU https://pubmed.ncbi.nlm.nih.gov/20590092 DM6HM5S DI DM6HM5S DM6HM5S DN N1-(2-aminoethyl)ethane-1,2-diamine DM6HM5S TI TTSYM0R DM6HM5S TN Carbonic anhydrase XII (CA-XII) DM6HM5S MA Inhibitor DM6HM5S RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DM6HM5S RU https://pubmed.ncbi.nlm.nih.gov/20590092 DM6HM5S DI DM6HM5S DM6HM5S DN N1-(2-aminoethyl)ethane-1,2-diamine DM6HM5S TI TT2LVK8 DM6HM5S TN Carbonic anhydrase IX (CA-IX) DM6HM5S MA Inhibitor DM6HM5S RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DM6HM5S RU https://pubmed.ncbi.nlm.nih.gov/20590092 DM6HM5S DI DM6HM5S DM6HM5S DN N1-(2-aminoethyl)ethane-1,2-diamine DM6HM5S TI TTCFSPE DM6HM5S TN Carbonic anhydrase VI (CA-VI) DM6HM5S MA Inhibitor DM6HM5S RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DM6HM5S RU https://pubmed.ncbi.nlm.nih.gov/20590092 DM6HM5S DI DM6HM5S DM6HM5S DN N1-(2-aminoethyl)ethane-1,2-diamine DM6HM5S TI TTEYTKG DM6HM5S TN Carbonic anhydrase XIV (CA-XIV) DM6HM5S MA Inhibitor DM6HM5S RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DM6HM5S RU https://pubmed.ncbi.nlm.nih.gov/20590092 DM6HMBW DI DM6HMBW DM6HMBW DN N-Ethyl-2-phenylnorapomorphine hydrochloride DM6HMBW TI TTEX248 DM6HMBW TN Dopamine D2 receptor (D2R) DM6HMBW MA Inhibitor DM6HMBW RN N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62. DM6HMBW RU https://pubmed.ncbi.nlm.nih.gov/19454369 DM6HPYN DI DM6HPYN DM6HPYN DN 3-(2-carboxy-4-mercaptobutyl)benzoic acid DM6HPYN TI TT9G4N0 DM6HPYN TN Glutamate carboxypeptidase II (GCPII) DM6HPYN MA Inhibitor DM6HPYN RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DM6HPYN RU https://pubmed.ncbi.nlm.nih.gov/16686531 DM6HQDL DI DM6HQDL DM6HQDL DN CYANATE DM6HQDL TI TTHQPL7 DM6HQDL TN Carbonic anhydrase I (CA-I) DM6HQDL MA Inhibitor DM6HQDL RN Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73. DM6HQDL RU https://pubmed.ncbi.nlm.nih.gov/15501038 DM6HZ8D DI DM6HZ8D DM6HZ8D DN Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF DM6HZ8D TI TTAE1BR DM6HZ8D TN Somatostatin receptor type 4 (SSTR4) DM6HZ8D MA Inhibitor DM6HZ8D RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DM6HZ8D RU https://pubmed.ncbi.nlm.nih.gov/15658865 DM6HZ8D DI DM6HZ8D DM6HZ8D DN Des-AA1,2,4,5,6,12,13-[D-Trp8]SRIF DM6HZ8D TI TTZ6T9E DM6HZ8D TN Somatostatin receptor type 2 (SSTR2) DM6HZ8D MA Inhibitor DM6HZ8D RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DM6HZ8D RU https://pubmed.ncbi.nlm.nih.gov/15658865 DM6HZVC DI DM6HZVC DM6HZVC DN T134 DM6HZVC TI TTBID49 DM6HZVC TN C-X-C chemokine receptor type 4 (CXCR4) DM6HZVC MA Antagonist DM6HZVC RN A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82. DM6HZVC RU https://pubmed.ncbi.nlm.nih.gov/9918823 DM6I1NQ DI DM6I1NQ DM6I1NQ DN 2-(4-bromo-2-cyclohexylphenoxy)acetic acid DM6I1NQ TI TTQDMX5 DM6I1NQ TN Prostaglandin D2 receptor 2 (PTGDR2) DM6I1NQ MA Inhibitor DM6I1NQ RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DM6I1NQ RU https://pubmed.ncbi.nlm.nih.gov/17531480 DM6I5K1 DI DM6I5K1 DM6I5K1 DN 7-(piperidin-4-ylmethoxy)-2-naphthonitrile DM6I5K1 TI TTPC4TU DM6I5K1 TN 5-HT 3A receptor (HTR3A) DM6I5K1 MA Inhibitor DM6I5K1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM6I5K1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM6I5K1 DI DM6I5K1 DM6I5K1 DN 7-(piperidin-4-ylmethoxy)-2-naphthonitrile DM6I5K1 TI TT3ROYC DM6I5K1 TN Serotonin transporter (SERT) DM6I5K1 MA Inhibitor DM6I5K1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM6I5K1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM6I5K1 DI DM6I5K1 DM6I5K1 DN 7-(piperidin-4-ylmethoxy)-2-naphthonitrile DM6I5K1 TI TTQ6VDM DM6I5K1 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM6I5K1 MA Inhibitor DM6I5K1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM6I5K1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM6I5K1 DI DM6I5K1 DM6I5K1 DN 7-(piperidin-4-ylmethoxy)-2-naphthonitrile DM6I5K1 TI TTVBI8W DM6I5K1 TN Dopamine transporter (DAT) DM6I5K1 MA Inhibitor DM6I5K1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM6I5K1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM6I5K1 DI DM6I5K1 DM6I5K1 DN 7-(piperidin-4-ylmethoxy)-2-naphthonitrile DM6I5K1 TI TTAWNKZ DM6I5K1 TN Norepinephrine transporter (NET) DM6I5K1 MA Inhibitor DM6I5K1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM6I5K1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM6I5MU DI DM6I5MU DM6I5MU DN Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine DM6I5MU TI TTVIAT9 DM6I5MU TN Phosphodiesterase 4B (PDE4B) DM6I5MU MA Inhibitor DM6I5MU RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DM6I5MU RU https://pubmed.ncbi.nlm.nih.gov/7658441 DM6I5MU DI DM6I5MU DM6I5MU DN Benzyl-(2-imidazol-1-yl-quinazolin-4-yl)-amine DM6I5MU TI TTZ97H5 DM6I5MU TN Phosphodiesterase 4A (PDE4A) DM6I5MU MA Inhibitor DM6I5MU RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DM6I5MU RU https://pubmed.ncbi.nlm.nih.gov/7658441 DM6I90F DI DM6I90F DM6I90F DN 2,7-Bis[3-(propylamino)propionamido]anthraquinone DM6I90F TI TTQY2EJ DM6I90F TN TERT messenger RNA (TERT mRNA) DM6I90F MA Inhibitor DM6I90F RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM6I90F RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM6ICRJ DI DM6ICRJ DM6ICRJ DN 2,2-bis-(3-fluorophenyl)-2-phenylacetamide DM6ICRJ TI TTMNI76 DM6ICRJ TN Calcium-activated potassium channel (KCN) DM6ICRJ MA Inhibitor DM6ICRJ RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DM6ICRJ RU https://pubmed.ncbi.nlm.nih.gov/18232633 DM6ID8P DI DM6ID8P DM6ID8P DN NSC-106084 DM6ID8P TI TTHVCUP DM6ID8P TN DNA [cytosine-5]-methyltransferase (DNMT) DM6ID8P MA Inhibitor DM6ID8P RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM6ID8P RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM6ID8P DI DM6ID8P DM6ID8P DN NSC-106084 DM6ID8P TI TT6VZ78 DM6ID8P TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM6ID8P MA Inhibitor DM6ID8P RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DM6ID8P RU https://pubmed.ncbi.nlm.nih.gov/20006515 DM6IF8N DI DM6IF8N DM6IF8N DN NSC-300853 DM6IF8N TI TTJLP0R DM6IF8N TN Quinone reductase 2 (NQO2) DM6IF8N MA Inhibitor DM6IF8N RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM6IF8N RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM6IG5J DI DM6IG5J DM6IG5J DN UBP141 DM6IG5J TI TTKJEMQ DM6IG5J TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM6IG5J MA Antagonist DM6IG5J RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DM6IG5J RU https://pubmed.ncbi.nlm.nih.gov/15801853 DM6IG5J DI DM6IG5J DM6IG5J DN UBP141 DM6IG5J TI TTN9D8E DM6IG5J TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM6IG5J MA Antagonist DM6IG5J RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DM6IG5J RU https://pubmed.ncbi.nlm.nih.gov/15801853 DM6IG5J DI DM6IG5J DM6IG5J DN UBP141 DM6IG5J TI TT5POTG DM6IG5J TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DM6IG5J MA Antagonist DM6IG5J RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DM6IG5J RU https://pubmed.ncbi.nlm.nih.gov/15801853 DM6IG5J DI DM6IG5J DM6IG5J DN UBP141 DM6IG5J TI TT1M8OW DM6IG5J TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DM6IG5J MA Antagonist DM6IG5J RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DM6IG5J RU https://pubmed.ncbi.nlm.nih.gov/15801853 DM6IG7P DI DM6IG7P DM6IG7P DN JWH-370 DM6IG7P TI TTMSFAW DM6IG7P TN Cannabinoid receptor 2 (CB2) DM6IG7P MA Inhibitor DM6IG7P RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM6IG7P RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM6IG7P DI DM6IG7P DM6IG7P DN JWH-370 DM6IG7P TI TT6OEDT DM6IG7P TN Cannabinoid receptor 1 (CB1) DM6IG7P MA Inhibitor DM6IG7P RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM6IG7P RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM6IH4F DI DM6IH4F DM6IH4F DN WIN-35065 DM6IH4F TI TT3ROYC DM6IH4F TN Serotonin transporter (SERT) DM6IH4F MA Inhibitor DM6IH4F RN Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95. DM6IH4F RU https://pubmed.ncbi.nlm.nih.gov/17602602 DM6IH4F DI DM6IH4F DM6IH4F DN WIN-35065 DM6IH4F TI TTVBI8W DM6IH4F TN Dopamine transporter (DAT) DM6IH4F MA Inhibitor DM6IH4F RN Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95. DM6IH4F RU https://pubmed.ncbi.nlm.nih.gov/17602602 DM6IP17 DI DM6IP17 DM6IP17 DN AcAsp-Glu-Dif-Ile-Cha-Cys DM6IP17 TI TTWXB3E DM6IP17 TN Hepatitis C virus NS3 helicase (HCV NS3) DM6IP17 MA Inhibitor DM6IP17 RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DM6IP17 RU https://pubmed.ncbi.nlm.nih.gov/11206459 DM6IRN4 DI DM6IRN4 DM6IRN4 DN [3H]RX821002 DM6IRN4 TI TT2NUT5 DM6IRN4 TN Adrenergic receptor alpha-2C (ADRA2C) DM6IRN4 MA Antagonist DM6IRN4 RN Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol. 1994 Jan 24;252(1):43-9. DM6IRN4 RU https://pubmed.ncbi.nlm.nih.gov/7908642 DM6IRN4 DI DM6IRN4 DM6IRN4 DN [3H]RX821002 DM6IRN4 TI TTWM4TY DM6IRN4 TN Adrenergic receptor alpha-2B (ADRA2B) DM6IRN4 MA Antagonist DM6IRN4 RN Further characterization of human alpha 2-adrenoceptor subtypes: [3H]RX821002 binding and definition of additional selective drugs. Eur J Pharmacol. 1994 Jan 24;252(1):43-9. DM6IRN4 RU https://pubmed.ncbi.nlm.nih.gov/7908642 DM6IRN4 DI DM6IRN4 DM6IRN4 DN [3H]RX821002 DM6IRN4 TI TTNGILX DM6IRN4 TN Adrenergic receptor alpha-1A (ADRA1A) DM6IRN4 MA Inhibitor DM6IRN4 RN Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3. DM6IRN4 RU https://pubmed.ncbi.nlm.nih.gov/2876101 DM6IRN4 DI DM6IRN4 DM6IRN4 DN [3H]RX821002 DM6IRN4 TI TTBRKXS DM6IRN4 TN Adrenergic receptor alpha-1B (ADRA1B) DM6IRN4 MA Inhibitor DM6IRN4 RN Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3. DM6IRN4 RU https://pubmed.ncbi.nlm.nih.gov/2876101 DM6IRN4 DI DM6IRN4 DM6IRN4 DN [3H]RX821002 DM6IRN4 TI TTWG9A4 DM6IRN4 TN Adrenergic receptor alpha-2A (ADRA2A) DM6IRN4 MA Inhibitor DM6IRN4 RN Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3. DM6IRN4 RU https://pubmed.ncbi.nlm.nih.gov/2876101 DM6IRN4 DI DM6IRN4 DM6IRN4 DN [3H]RX821002 DM6IRN4 TI TT34BHT DM6IRN4 TN Adrenergic receptor alpha-1D (ADRA1D) DM6IRN4 MA Inhibitor DM6IRN4 RN Alpha-adrenoreceptor reagents. 4. Resolution of some potent selective prejunctional alpha 2-adrenoreceptor antagonists. J Med Chem. 1986 Oct;29(10):2000-3. DM6IRN4 RU https://pubmed.ncbi.nlm.nih.gov/2876101 DM6ITNG DI DM6ITNG DM6ITNG DN Forskolin DM6ITNG TI TTBQ9IM DM6ITNG TN Adenylate cyclase type 2 (ADCY2) DM6ITNG MA Inhibitor DM6ITNG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6ITNG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6IWCZ DI DM6IWCZ DM6IWCZ DN JWH-252 DM6IWCZ TI TTMSFAW DM6IWCZ TN Cannabinoid receptor 2 (CB2) DM6IWCZ MA Inhibitor DM6IWCZ RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DM6IWCZ RU https://pubmed.ncbi.nlm.nih.gov/16005223 DM6J1AK DI DM6J1AK DM6J1AK DN 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane DM6J1AK TI TT3ROYC DM6J1AK TN Serotonin transporter (SERT) DM6J1AK MA Inhibitor DM6J1AK RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DM6J1AK RU https://pubmed.ncbi.nlm.nih.gov/18539031 DM6J1AK DI DM6J1AK DM6J1AK DN 1-(thiophen-2-yl)-3-aza-bicyclo[3.1.0]hexane DM6J1AK TI TTVBI8W DM6J1AK TN Dopamine transporter (DAT) DM6J1AK MA Inhibitor DM6J1AK RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DM6J1AK RU https://pubmed.ncbi.nlm.nih.gov/18539031 DM6J1BY DI DM6J1BY DM6J1BY DN LIVIDOMYCIN A DM6J1BY TI TTQY2EJ DM6J1BY TN TERT messenger RNA (TERT mRNA) DM6J1BY MA Inhibitor DM6J1BY RN Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3467-71. DM6J1BY RU https://pubmed.ncbi.nlm.nih.gov/15177454 DM6J2UZ DI DM6J2UZ DM6J2UZ DN MCC950 DM6J2UZ TI TT4EN8X DM6J2UZ TN Caterpiller protein 1.1 (NLRP3) DM6J2UZ MA Inhibitor DM6J2UZ RN A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015 Mar;21(3):248-55. DM6J2UZ RU https://pubmed.ncbi.nlm.nih.gov/25686105 DM6J57N DI DM6J57N DM6J57N DN ABT-670 DM6J57N TI TTE0A2F DM6J57N TN Dopamine D4 receptor (D4R) DM6J57N MA Inhibitor DM6J57N RN Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 ago... J Med Chem. 2006 Dec 14;49(25):7450-65. DM6J57N RU https://pubmed.ncbi.nlm.nih.gov/17149874 DM6J5KY DI DM6J5KY DM6J5KY DN PMID8410973C3 DM6J5KY TI TT7K6AD DM6J5KY TN Progastricsin pepsinogen C (PGC) DM6J5KY MA Inhibitor DM6J5KY RN Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20. DM6J5KY RU https://pubmed.ncbi.nlm.nih.gov/8410973 DM6J5KY DI DM6J5KY DM6J5KY DN PMID8410973C3 DM6J5KY TI TTLXC4Q DM6J5KY TN Cathepsin E (CTSE) DM6J5KY MA Inhibitor DM6J5KY RN Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20. DM6J5KY RU https://pubmed.ncbi.nlm.nih.gov/8410973 DM6J5KY DI DM6J5KY DM6J5KY DN PMID8410973C3 DM6J5KY TI TTPT2QI DM6J5KY TN Cathepsin D (CTSD) DM6J5KY MA Inhibitor DM6J5KY RN Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20. DM6J5KY RU https://pubmed.ncbi.nlm.nih.gov/8410973 DM6J5KY DI DM6J5KY DM6J5KY DN PMID8410973C3 DM6J5KY TI TTKZ864 DM6J5KY TN Pepsinogen-5 (PGA5) DM6J5KY MA Inhibitor DM6J5KY RN Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20. DM6J5KY RU https://pubmed.ncbi.nlm.nih.gov/8410973 DM6J7OQ DI DM6J7OQ DM6J7OQ DN WX-037 DM6J7OQ TI TTHBTOP DM6J7OQ TN PI3-kinase gamma (PIK3CG) DM6J7OQ MA Inhibitor DM6J7OQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DM6J7OQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DM6JAFM DI DM6JAFM DM6JAFM DN Des-AA1,2,5-[D-Nal8,IAmp9]SRIF DM6JAFM TI TTIND6G DM6JAFM TN Somatostatin receptor type 1 (SSTR1) DM6JAFM MA Inhibitor DM6JAFM RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM6JAFM RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM6JB32 DI DM6JB32 DM6JB32 DN BCX-1898 DM6JB32 TI TT50QJ3 DM6JB32 TN Influenza Neuraminidase (Influ NA) DM6JB32 MA Inhibitor DM6JB32 RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DM6JB32 RU https://pubmed.ncbi.nlm.nih.gov/17139286 DM6JDIY DI DM6JDIY DM6JDIY DN 2-bromophenol DM6JDIY TI TTU6BFZ DM6JDIY TN Candida Thymidylate synthase (Candi TMP1) DM6JDIY MA Inhibitor DM6JDIY RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM6JDIY RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM6JF7T DI DM6JF7T DM6JF7T DN TSERaM DM6JF7T TI TTZAYWL DM6JF7T TN Estrogen receptor (ESR) DM6JF7T MA Modulator DM6JF7T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DM6JF7T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DM6JKL7 DI DM6JKL7 DM6JKL7 DN XMetS DM6JKL7 TI TTCBFJO DM6JKL7 TN Insulin receptor (INSR) DM6JKL7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM6JKL7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM6JNT5 DI DM6JNT5 DM6JNT5 DN 2-phenoxy-3-(piperidin-4-yl)pyridine DM6JNT5 TI TT3ROYC DM6JNT5 TN Serotonin transporter (SERT) DM6JNT5 MA Inhibitor DM6JNT5 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM6JNT5 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM6JNT5 DI DM6JNT5 DM6JNT5 DN 2-phenoxy-3-(piperidin-4-yl)pyridine DM6JNT5 TI TTSQIFT DM6JNT5 TN 5-HT 1A receptor (HTR1A) DM6JNT5 MA Inhibitor DM6JNT5 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM6JNT5 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM6JNT5 DI DM6JNT5 DM6JNT5 DN 2-phenoxy-3-(piperidin-4-yl)pyridine DM6JNT5 TI TTVBI8W DM6JNT5 TN Dopamine transporter (DAT) DM6JNT5 MA Inhibitor DM6JNT5 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM6JNT5 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM6JNT5 DI DM6JNT5 DM6JNT5 DN 2-phenoxy-3-(piperidin-4-yl)pyridine DM6JNT5 TI TTAWNKZ DM6JNT5 TN Norepinephrine transporter (NET) DM6JNT5 MA Inhibitor DM6JNT5 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM6JNT5 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM6JTNW DI DM6JTNW DM6JTNW DN 3-(2,5-Dioxo-pyrrolidin-1-yl)-benzoic acid DM6JTNW TI TT1RS9F DM6JTNW TN Acetylcholinesterase (AChE) DM6JTNW MA Inhibitor DM6JTNW RN Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives. Bioorg Med Chem Lett. 2003 May 19;13(10):1825-7. DM6JTNW RU https://pubmed.ncbi.nlm.nih.gov/12729674 DM6JVOP DI DM6JVOP DM6JVOP DN ISIS 122985 DM6JVOP TI TTJZNIG DM6JVOP TN MEKK3 messenger RNA (MAP3K3 mRNA) DM6JVOP RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DM6JVOP RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DM6JYWQ DI DM6JYWQ DM6JYWQ DN 3-oxoolean-12-en-27-oic acid DM6JYWQ TI TTELIN2 DM6JYWQ TN PTPN1 messenger RNA (PTPN1 mRNA) DM6JYWQ MA Inhibitor DM6JYWQ RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DM6JYWQ RU https://pubmed.ncbi.nlm.nih.gov/16580200 DM6K123 DI DM6K123 DM6K123 DN CSC-500297 DM6K123 TI TTWJBZ5 DM6K123 TN 5-HT 2C receptor (HTR2C) DM6K123 MA Agonist DM6K123 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8). DM6K123 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=8 DM6K3G7 DI DM6K3G7 DM6K3G7 DN PEGylated PYY-3-36 DM6K3G7 TI TTJ6WK9 DM6K3G7 TN Neuropeptide Y receptor type 2 (NPY2R) DM6K3G7 MA Modulator DM6K3G7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 306). DM6K3G7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=306 DM6K5NF DI DM6K5NF DM6K5NF DN 7-Iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one DM6K5NF TI TT06AWU DM6K5NF TN Phosphodiesterase 3A (PDE3A) DM6K5NF MA Inhibitor DM6K5NF RN Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoim... J Med Chem. 1988 Nov;31(11):2136-45. DM6K5NF RU https://pubmed.ncbi.nlm.nih.gov/2846839 DM6K7BI DI DM6K7BI DM6K7BI DN 3-Ethoxy-9H-beta-carboline DM6K7BI TI TT1MPAY DM6K7BI TN GABA(A) receptor alpha-1 (GABRA1) DM6K7BI MA Inhibitor DM6K7BI RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DM6K7BI RU https://pubmed.ncbi.nlm.nih.gov/2842507 DM6K7BI DI DM6K7BI DM6K7BI DN 3-Ethoxy-9H-beta-carboline DM6K7BI TI TT06RH5 DM6K7BI TN GABA(A) receptor gamma-2 (GABRG2) DM6K7BI MA Inhibitor DM6K7BI RN Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52. DM6K7BI RU https://pubmed.ncbi.nlm.nih.gov/9651158 DM6K7BI DI DM6K7BI DM6K7BI DN 3-Ethoxy-9H-beta-carboline DM6K7BI TI TTBMV1G DM6K7BI TN GABA(A) receptor alpha-2 (GABRA2) DM6K7BI MA Inhibitor DM6K7BI RN Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52. DM6K7BI RU https://pubmed.ncbi.nlm.nih.gov/9651158 DM6K7BI DI DM6K7BI DM6K7BI DN 3-Ethoxy-9H-beta-carboline DM6K7BI TI TTNJYV2 DM6K7BI TN Gamma-aminobutyric acid receptor (GAR) DM6K7BI MA Inhibitor DM6K7BI RN Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52. DM6K7BI RU https://pubmed.ncbi.nlm.nih.gov/9651158 DM6K7BI DI DM6K7BI DM6K7BI DN 3-Ethoxy-9H-beta-carboline DM6K7BI TI TTNZPQ1 DM6K7BI TN GABA(A) receptor alpha-5 (GABRA5) DM6K7BI MA Inhibitor DM6K7BI RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM6K7BI RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM6K7BI DI DM6K7BI DM6K7BI DN 3-Ethoxy-9H-beta-carboline DM6K7BI TI TT37EDJ DM6K7BI TN GABA(A) receptor alpha-3 (GABRA3) DM6K7BI MA Inhibitor DM6K7BI RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM6K7BI RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM6KFCO DI DM6KFCO DM6KFCO DN D-254C DM6KFCO TI TTVBI8W DM6KFCO TN Dopamine transporter (DAT) DM6KFCO MA Inhibitor DM6KFCO RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM6KFCO RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM6KFCO DI DM6KFCO DM6KFCO DN D-254C DM6KFCO TI TTAWNKZ DM6KFCO TN Norepinephrine transporter (NET) DM6KFCO MA Inhibitor DM6KFCO RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM6KFCO RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM6KFCO DI DM6KFCO DM6KFCO DN D-254C DM6KFCO TI TT3ROYC DM6KFCO TN Serotonin transporter (SERT) DM6KFCO MA Inhibitor DM6KFCO RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DM6KFCO RU https://pubmed.ncbi.nlm.nih.gov/18249549 DM6KIG0 DI DM6KIG0 DM6KIG0 DN 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid DM6KIG0 TI TTXZ0KQ DM6KIG0 TN Matrix metalloproteinase-12 (MMP-12) DM6KIG0 MA Inhibitor DM6KIG0 RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DM6KIG0 RU https://pubmed.ncbi.nlm.nih.gov/16420030 DM6KIG0 DI DM6KIG0 DM6KIG0 DN 4-(4-(dec-1-ynyl)phenyl)-4-oxobutanoic acid DM6KIG0 TI TTLM12X DM6KIG0 TN Matrix metalloproteinase-2 (MMP-2) DM6KIG0 MA Inhibitor DM6KIG0 RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DM6KIG0 RU https://pubmed.ncbi.nlm.nih.gov/16420030 DM6KJ3D DI DM6KJ3D DM6KJ3D DN (R)-2-((4-phenoxyphenoxy)methyl)piperidine DM6KJ3D TI TTXZEAJ DM6KJ3D TN Leukotriene A-4 hydrolase (LTA4H) DM6KJ3D MA Inhibitor DM6KJ3D RN Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4. DM6KJ3D RU https://pubmed.ncbi.nlm.nih.gov/20371179 DM6KNMB DI DM6KNMB DM6KNMB DN 3-azageranylgeranyl diphosphate DM6KNMB TI TTIKWV4 DM6KNMB TN Geranyltranstransferase (FDPS) DM6KNMB MA Inhibitor DM6KNMB RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem. 2002 May 23;45(11):2185-96. DM6KNMB RU https://pubmed.ncbi.nlm.nih.gov/12014956 DM6KQXF DI DM6KQXF DM6KQXF DN ARP100 DM6KQXF TI TT6X50U DM6KQXF TN Matrix metalloproteinase-9 (MMP-9) DM6KQXF MA Inhibitor DM6KQXF RN Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxy... Bioorg Med Chem. 2006 Jun 15;14(12):4260-76. DM6KQXF RU https://pubmed.ncbi.nlm.nih.gov/16483784 DM6KSN9 DI DM6KSN9 DM6KSN9 DN 5-(4'-benzoylbiphenyl-4-yl)-2-furoic acid DM6KSN9 TI TT9INHD DM6KSN9 TN Creatine kinase (CK) DM6KSN9 MA Inhibitor DM6KSN9 RN NMR screening applied to the fragment-based generation of inhibitors of creatine kinase exploiting a new interaction proximate to the ATP binding s... J Med Chem. 2007 Apr 19;50(8):1865-75. DM6KSN9 RU https://pubmed.ncbi.nlm.nih.gov/17375903 DM6KUV9 DI DM6KUV9 DM6KUV9 DN ISIS 102660 DM6KUV9 TI TT5U49F DM6KUV9 TN PRKACA messenger RNA (PRKACA mRNA) DM6KUV9 RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DM6KUV9 RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DM6KVIA DI DM6KVIA DM6KVIA DN PF-3644022 DM6KVIA TI TTMUG9D DM6KVIA TN MAPK-activated protein kinase 2 (MAPKAPK2) DM6KVIA MA Inhibitor DM6KVIA RN A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther. 2010 Jun;333(3):797-807. DM6KVIA RU https://pubmed.ncbi.nlm.nih.gov/20237073 DM6KVO0 DI DM6KVO0 DM6KVO0 DN 6-Hydroxy-N-(2-morpholinoethyl)nicotinamide DM6KVO0 TI TT3WG5C DM6KVO0 TN Monoamine oxidase type A (MAO-A) DM6KVO0 MA Inhibitor DM6KVO0 RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM6KVO0 RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM6L0KZ DI DM6L0KZ DM6L0KZ DN (2S)-euchrenone a7 DM6L0KZ TI TTSZLWK DM6L0KZ TN Aromatase (CYP19A1) DM6L0KZ MA Inhibitor DM6L0KZ RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DM6L0KZ RU https://pubmed.ncbi.nlm.nih.gov/11678652 DM6L4J8 DI DM6L4J8 DM6L4J8 DN 3-(furan-3-yl)-1-methyl-1H-indole DM6L4J8 TI TTTB4UP DM6L4J8 TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM6L4J8 MA Inhibitor DM6L4J8 RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DM6L4J8 RU https://pubmed.ncbi.nlm.nih.gov/16483769 DM6LGHU DI DM6LGHU DM6LGHU DN (-)-DEBROMOFLUSTRAMINE B DM6LGHU TI TTEB0GD DM6LGHU TN Cholinesterase (BCHE) DM6LGHU MA Inhibitor DM6LGHU RN Synthesis and biological evaluation of (-)- and (+)-debromoflustramine B and its analogues as selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Sep 11;51(17):5271-84. DM6LGHU RU https://pubmed.ncbi.nlm.nih.gov/18686941 DM6LPIG DI DM6LPIG DM6LPIG DN BMS-265246 DM6LPIG TI TTH6V3D DM6LPIG TN Cyclin-dependent kinase 1 (CDK1) DM6LPIG MA Inhibitor DM6LPIG RN A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54. DM6LPIG RU https://pubmed.ncbi.nlm.nih.gov/21216932 DM6LPIG DI DM6LPIG DM6LPIG DN BMS-265246 DM6LPIG TI TT7HF4W DM6LPIG TN Cyclin-dependent kinase 2 (CDK2) DM6LPIG MA Inhibitor DM6LPIG RN A robust high-content imaging approach for probing the mechanism of action and phenotypic outcomes of cell-cycle modulators. Mol Cancer Ther. 2011 Feb;10(2):242-54. DM6LPIG RU https://pubmed.ncbi.nlm.nih.gov/21216932 DM6LWR2 DI DM6LWR2 DM6LWR2 DN 1-(3-chloropyridin-2-yl)-4-tosylpiperazine DM6LWR2 TI TTN7BL9 DM6LWR2 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM6LWR2 MA Inhibitor DM6LWR2 RN Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6. DM6LWR2 RU https://pubmed.ncbi.nlm.nih.gov/18511278 DM6M5A4 DI DM6M5A4 DM6M5A4 DN 9-[9-(beta-Carboline-9-yl)nonyl]-beta-carboline DM6M5A4 TI TTEB0GD DM6M5A4 TN Cholinesterase (BCHE) DM6M5A4 MA Inhibitor DM6M5A4 RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DM6M5A4 RU https://pubmed.ncbi.nlm.nih.gov/20361801 DM6M8Y3 DI DM6M8Y3 DM6M8Y3 DN 2-tert-butyl-9H-carbazole DM6M8Y3 TI TTBGTCW DM6M8Y3 TN Kinesin spindle messenger RNA (KIF11 mRNA) DM6M8Y3 MA Inhibitor DM6M8Y3 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM6M8Y3 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM6MQCI DI DM6MQCI DM6MQCI DN 4-(Allylamino)-3-pyridinesulfonamide DM6MQCI TI TTHQPL7 DM6MQCI TN Carbonic anhydrase I (CA-I) DM6MQCI MA Inhibitor DM6MQCI RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM6MQCI RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM6MQCI DI DM6MQCI DM6MQCI DN 4-(Allylamino)-3-pyridinesulfonamide DM6MQCI TI TTANPDJ DM6MQCI TN Carbonic anhydrase II (CA-II) DM6MQCI MA Inhibitor DM6MQCI RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM6MQCI RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM6MQCI DI DM6MQCI DM6MQCI DN 4-(Allylamino)-3-pyridinesulfonamide DM6MQCI TI TTSYM0R DM6MQCI TN Carbonic anhydrase XII (CA-XII) DM6MQCI MA Inhibitor DM6MQCI RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM6MQCI RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM6MQCI DI DM6MQCI DM6MQCI DN 4-(Allylamino)-3-pyridinesulfonamide DM6MQCI TI TT2LVK8 DM6MQCI TN Carbonic anhydrase IX (CA-IX) DM6MQCI MA Inhibitor DM6MQCI RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM6MQCI RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM6MQCI DI DM6MQCI DM6MQCI DN 4-(Allylamino)-3-pyridinesulfonamide DM6MQCI TI TTEYTKG DM6MQCI TN Carbonic anhydrase XIV (CA-XIV) DM6MQCI MA Inhibitor DM6MQCI RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM6MQCI RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM6MR82 DI DM6MR82 DM6MR82 DN 2-(1H-Imidazol-4-yl)phenol DM6MR82 TI TTZJYKH DM6MR82 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM6MR82 MA Inhibitor DM6MR82 RN Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77. DM6MR82 RU https://pubmed.ncbi.nlm.nih.gov/18665584 DM6MRSC DI DM6MRSC DM6MRSC DN Adociasulfate-2 DM6MRSC TI TTBGTCW DM6MRSC TN Kinesin spindle messenger RNA (KIF11 mRNA) DM6MRSC MA Inhibitor DM6MRSC RN Inhibition of kinesin motor proteins by adociasulfate-2. J Med Chem. 2006 Aug 10;49(16):4857-60. DM6MRSC RU https://pubmed.ncbi.nlm.nih.gov/16884297 DM6MWDH DI DM6MWDH DM6MWDH DN AS-1708727 DM6MWDH TI TTHAVTS DM6MWDH TN Forkhead box protein O1A (FOXO1) DM6MWDH MA Modulator DM6MWDH RN Effects of the novel Foxo1 inhibitor AS1708727 on plasma glucose and triglyceride levels in diabetic db/db mice. Eur J Pharmacol. 2010 Oct 25;645(1-3):185-91. DM6MWDH RU https://pubmed.ncbi.nlm.nih.gov/20655898 DM6MYGX DI DM6MYGX DM6MYGX DN Riccardin C DM6MYGX TI TTXA6PH DM6MYGX TN Oxysterols receptor LXR-beta (NR1H2) DM6MYGX MA Inhibitor DM6MYGX RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DM6MYGX RU https://pubmed.ncbi.nlm.nih.gov/18343126 DM6MYGX DI DM6MYGX DM6MYGX DN Riccardin C DM6MYGX TI TTECBXN DM6MYGX TN Oxysterols receptor LXR-alpha (NR1H3) DM6MYGX MA Inhibitor DM6MYGX RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DM6MYGX RU https://pubmed.ncbi.nlm.nih.gov/18343126 DM6N98E DI DM6N98E DM6N98E DN 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol DM6N98E TI TTOM3J0 DM6N98E TN Estrogen receptor beta (ESR2) DM6N98E MA Inhibitor DM6N98E RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM6N98E RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM6N98E DI DM6N98E DM6N98E DN 4,6,10-trimethyl-6H-benzo[c]chromene-3,8-diol DM6N98E TI TTZAYWL DM6N98E TN Estrogen receptor (ESR) DM6N98E MA Inhibitor DM6N98E RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DM6N98E RU https://pubmed.ncbi.nlm.nih.gov/16412638 DM6NC8G DI DM6NC8G DM6NC8G DN N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide DM6NC8G TI TT0PG8F DM6NC8G TN Cyclin-dependent kinase 4 (CDK4) DM6NC8G MA Inhibitor DM6NC8G RN Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39. DM6NC8G RU https://pubmed.ncbi.nlm.nih.gov/18650093 DM6NFO0 DI DM6NFO0 DM6NFO0 DN 3beta-hydroxyurs-12-en-27-oic acid DM6NFO0 TI TTELIN2 DM6NFO0 TN PTPN1 messenger RNA (PTPN1 mRNA) DM6NFO0 MA Inhibitor DM6NFO0 RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DM6NFO0 RU https://pubmed.ncbi.nlm.nih.gov/16580200 DM6NL2B DI DM6NL2B DM6NL2B DN PMID18412317C13b DM6NL2B TI TTPADOQ DM6NL2B TN HMG-CoA reductase (HMGCR) DM6NL2B MA Inhibitor DM6NL2B RN (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. J Med Chem. 2008 May 8;51(9):2722-33. DM6NL2B RU https://pubmed.ncbi.nlm.nih.gov/18412317 DM6NM8V DI DM6NM8V DM6NM8V DN APLYSAMINE DM6NM8V TI TT9JNIC DM6NM8V TN Histamine H3 receptor (H3R) DM6NM8V MA Inhibitor DM6NM8V RN The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11;51(17):5423-30. DM6NM8V RU https://pubmed.ncbi.nlm.nih.gov/18683917 DM6NPUM DI DM6NPUM DM6NPUM DN CALCEOLARIOSIDE A DM6NPUM TI TTFJ8Q1 DM6NPUM TN Protein kinase C alpha (PRKCA) DM6NPUM MA Inhibitor DM6NPUM RN Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2. DM6NPUM RU https://pubmed.ncbi.nlm.nih.gov/9834166 DM6NS7H DI DM6NS7H DM6NS7H DN nexturastat A DM6NS7H TI TT6R7JZ DM6NS7H TN Histone deacetylase 1 (HDAC1) DM6NS7H MA Inhibitor DM6NS7H RN Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9. DM6NS7H RU https://pubmed.ncbi.nlm.nih.gov/23009203 DM6NS7H DI DM6NS7H DM6NS7H DN nexturastat A DM6NS7H TI TT5ZKDI DM6NS7H TN Histone deacetylase 6 (HDAC6) DM6NS7H MA Inhibitor DM6NS7H RN Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012 Nov 26;55(22):9891-9. DM6NS7H RU https://pubmed.ncbi.nlm.nih.gov/23009203 DM6NX4H DI DM6NX4H DM6NX4H DN PKI-402 DM6NX4H TI TTHBTOP DM6NX4H TN PI3-kinase gamma (PIK3CG) DM6NX4H MA Inhibitor DM6NX4H RN Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: di... J Med Chem. 2010 Jan 28;53(2):798-810. DM6NX4H RU https://pubmed.ncbi.nlm.nih.gov/19968288 DM6NZFH DI DM6NZFH DM6NZFH DN TTH 03-001 DM6NZFH TI TTNVEIR DM6NZFH TN Prostaglandin D2 receptor (PTGDR) DM6NZFH MA Modulator DM6NZFH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 338). DM6NZFH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=338 DM6O0PD DI DM6O0PD DM6O0PD DN SN-23 DM6O0PD TI TT27RFC DM6O0PD TN Opioid receptor delta (OPRD1) DM6O0PD MA Inhibitor DM6O0PD RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DM6O0PD RU https://pubmed.ncbi.nlm.nih.gov/19362480 DM6O0PD DI DM6O0PD DM6O0PD DN SN-23 DM6O0PD TI TTQW87Y DM6O0PD TN Opioid receptor kappa (OPRK1) DM6O0PD MA Inhibitor DM6O0PD RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DM6O0PD RU https://pubmed.ncbi.nlm.nih.gov/19362480 DM6O0PD DI DM6O0PD DM6O0PD DN SN-23 DM6O0PD TI TTKWM86 DM6O0PD TN Opioid receptor mu (MOP) DM6O0PD MA Inhibitor DM6O0PD RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DM6O0PD RU https://pubmed.ncbi.nlm.nih.gov/19362480 DM6O1SY DI DM6O1SY DM6O1SY DN 2-N-Ethylamino-1-(4-methylthiophenyl)propane DM6O1SY TI TT3ROYC DM6O1SY TN Serotonin transporter (SERT) DM6O1SY MA Inhibitor DM6O1SY RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM6O1SY RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM6O2BR DI DM6O2BR DM6O2BR DN EMPA DM6O2BR TI TT9N02I DM6O2BR TN Orexin receptor type 2 (HCRTR2) DM6O2BR MA Antagonist DM6O2BR RN Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol. 2009 Apr;156(8):1326-41. DM6O2BR RU https://pubmed.ncbi.nlm.nih.gov/19751316 DM6O4EZ DI DM6O4EZ DM6O4EZ DN C[Glu19-Lys23][Gly8]GLP-1(7-37)-NH2 DM6O4EZ TI TTVIMDE DM6O4EZ TN Glucagon-like peptide 1 receptor (GLP1R) DM6O4EZ MA Inhibitor DM6O4EZ RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DM6O4EZ RU https://pubmed.ncbi.nlm.nih.gov/18412318 DM6O7MK DI DM6O7MK DM6O7MK DN PMID24412111C9f DM6O7MK TI TTHYDUM DM6O7MK TN Bombesin receptor (BS) DM6O7MK MA Agonist DM6O7MK RN Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration. Bioorg Med Chem Lett. 2014 Feb 1;24(3):750-5. DM6O7MK RU https://pubmed.ncbi.nlm.nih.gov/24412111 DM6O9DQ DI DM6O9DQ DM6O9DQ DN SNG-8023 DM6O9DQ TI TTZAYWL DM6O9DQ TN Estrogen receptor (ESR) DM6O9DQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DM6O9DQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DM6OCU5 DI DM6OCU5 DM6OCU5 DN 3-(N-propylpiperidin-4-yl)phenol DM6OCU5 TI TTEX248 DM6OCU5 TN Dopamine D2 receptor (D2R) DM6OCU5 MA Inhibitor DM6OCU5 RN Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20. DM6OCU5 RU https://pubmed.ncbi.nlm.nih.gov/20155917 DM6ODAS DI DM6ODAS DM6ODAS DN Eusynstyelamide C DM6ODAS TI TTZUFI5 DM6ODAS TN Nitric-oxide synthase brain (NOS1) DM6ODAS MA Inhibitor DM6ODAS RN Eusynstyelamides A, B, and C, nNOS inhibitors, from the ascidian Eusynstyela latericius. J Nat Prod. 2009 Jun;72(6):1115-20. DM6ODAS RU https://pubmed.ncbi.nlm.nih.gov/19505081 DM6OGR9 DI DM6OGR9 DM6OGR9 DN Z-leu-Val-Agly-Val-OBzl DM6OGR9 TI TTDZN01 DM6OGR9 TN Cathepsin K (CTSK) DM6OGR9 MA Inhibitor DM6OGR9 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM6OGR9 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM6OGR9 DI DM6OGR9 DM6OGR9 DN Z-leu-Val-Agly-Val-OBzl DM6OGR9 TI TTF2LRI DM6OGR9 TN Cathepsin B (CTSB) DM6OGR9 MA Inhibitor DM6OGR9 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM6OGR9 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM6OHVU DI DM6OHVU DM6OHVU DN iperoxo DM6OHVU TI TTOXS3C DM6OHVU TN Muscarinic acetylcholine receptor (CHRM) DM6OHVU MA Agonist DM6OHVU RN Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br J Pharmacol. 2013 May;169(2):357-70. DM6OHVU RU https://pubmed.ncbi.nlm.nih.gov/23062057 DM6ONY7 DI DM6ONY7 DM6ONY7 DN Ac-Phe-D-Thr(PO3H2)-Pip-Nal-Gln-NH2 DM6ONY7 TI TTJNTSI DM6ONY7 TN Rotamase Pin1 (PIN1) DM6ONY7 MA Inhibitor DM6ONY7 RN Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries. J Med Chem. 2006 Apr 6;49(7):2147-50. DM6ONY7 RU https://pubmed.ncbi.nlm.nih.gov/16570909 DM6OTGE DI DM6OTGE DM6OTGE DN L-783483 DM6OTGE TI TTT2SVW DM6OTGE TN PPAR-gamma messenger RNA (PPARG mRNA) DM6OTGE MA Agonist DM6OTGE RN Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25. DM6OTGE RU https://pubmed.ncbi.nlm.nih.gov/10037770 DM6OTGE DI DM6OTGE DM6OTGE DN L-783483 DM6OTGE TI TTECBXN DM6OTGE TN Oxysterols receptor LXR-alpha (NR1H3) DM6OTGE MA Agonist DM6OTGE RN A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58. DM6OTGE RU https://pubmed.ncbi.nlm.nih.gov/12072387 DM6OTGE DI DM6OTGE DM6OTGE DN L-783483 DM6OTGE TI TT2JWF6 DM6OTGE TN Peroxisome proliferator-activated receptor delta (PPARD) DM6OTGE MA Agonist DM6OTGE RN Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25. DM6OTGE RU https://pubmed.ncbi.nlm.nih.gov/10037770 DM6OTGE DI DM6OTGE DM6OTGE DN L-783483 DM6OTGE TI TTXA6PH DM6OTGE TN Oxysterols receptor LXR-beta (NR1H2) DM6OTGE MA Agonist DM6OTGE RN A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58. DM6OTGE RU https://pubmed.ncbi.nlm.nih.gov/12072387 DM6OUW0 DI DM6OUW0 DM6OUW0 DN (S)-2-amino-3-(benzylthio)propanoic acid DM6OUW0 TI TTFK1JQ DM6OUW0 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM6OUW0 MA Inhibitor DM6OUW0 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DM6OUW0 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DM6P1UA DI DM6P1UA DM6P1UA DN JNJ-10191584 DM6P1UA TI TTXJ178 DM6P1UA TN Histamine H4 receptor (H4R) DM6P1UA MA Antagonist DM6P1UA RN Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5251-6. DM6P1UA RU https://pubmed.ncbi.nlm.nih.gov/15454206 DM6P20R DI DM6P20R DM6P20R DN 2-(allyloxy)-N8-hydroxy-N1-phenyloctanediamide DM6P20R TI TTSHTOI DM6P20R TN Histone deacetylase 2 (HDAC2) DM6P20R MA Inhibitor DM6P20R RN Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. DM6P20R RU https://pubmed.ncbi.nlm.nih.gov/17892933 DM6P35D DI DM6P35D DM6P35D DN (3-Tetradecylamino-cyclohexyl)-phosphonic acid DM6P35D TI TT9JZCK DM6P35D TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM6P35D MA Inhibitor DM6P35D RN Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6. DM6P35D RU https://pubmed.ncbi.nlm.nih.gov/15341940 DM6P3Z8 DI DM6P3Z8 DM6P3Z8 DN 2'-5'dideoxyuridine DM6P3Z8 TI TTU6BFZ DM6P3Z8 TN Candida Thymidylate synthase (Candi TMP1) DM6P3Z8 MA Inhibitor DM6P3Z8 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM6P3Z8 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM6PA1S DI DM6PA1S DM6PA1S DN Arg-Pro-Lys-Pro-Ala-Gln-Phe-Phe-Gly-Leu-Met-NH2 DM6PA1S TI TTZPO1L DM6PA1S TN Substance-P receptor (TACR1) DM6PA1S MA Inhibitor DM6PA1S RN Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6. DM6PA1S RU https://pubmed.ncbi.nlm.nih.gov/18067242 DM6PAXD DI DM6PAXD DM6PAXD DN Cytidine-5'-Monophosphate DM6PAXD TI TTMFYEC DM6PAXD TN Streptococcus Cytidylate kinase (Stre-coc cmk) DM6PAXD MA Inhibitor DM6PAXD RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM6PAXD RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM6PAXD DI DM6PAXD DM6PAXD DN Cytidine-5'-Monophosphate DM6PAXD TI TTQ8J1V DM6PAXD TN Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) DM6PAXD MA Inhibitor DM6PAXD RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM6PAXD RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM6PFG0 DI DM6PFG0 DM6PFG0 DN CMET Avimer polypeptides DM6PFG0 TI TTNDSF4 DM6PFG0 TN Proto-oncogene c-Met (MET) DM6PFG0 MA Inhibitor DM6PFG0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM6PFG0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM6PIL2 DI DM6PIL2 DM6PIL2 DN 1-benzhydryl-4-ethoxy-4-phenylpiperidine DM6PIL2 TI TTQW87Y DM6PIL2 TN Opioid receptor kappa (OPRK1) DM6PIL2 MA Inhibitor DM6PIL2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM6PIL2 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM6PIL2 DI DM6PIL2 DM6PIL2 DN 1-benzhydryl-4-ethoxy-4-phenylpiperidine DM6PIL2 TI TT27RFC DM6PIL2 TN Opioid receptor delta (OPRD1) DM6PIL2 MA Inhibitor DM6PIL2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM6PIL2 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM6PIL2 DI DM6PIL2 DM6PIL2 DN 1-benzhydryl-4-ethoxy-4-phenylpiperidine DM6PIL2 TI TTNT7K8 DM6PIL2 TN Nociceptin receptor (OPRL1) DM6PIL2 MA Inhibitor DM6PIL2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM6PIL2 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM6PIL2 DI DM6PIL2 DM6PIL2 DN 1-benzhydryl-4-ethoxy-4-phenylpiperidine DM6PIL2 TI TTKWM86 DM6PIL2 TN Opioid receptor mu (MOP) DM6PIL2 MA Inhibitor DM6PIL2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DM6PIL2 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DM6PMFJ DI DM6PMFJ DM6PMFJ DN 4-(2,3-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline DM6PMFJ TI TTI7421 DM6PMFJ TN Platelet-derived growth factor receptor beta (PDGFRB) DM6PMFJ MA Inhibitor DM6PMFJ RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DM6PMFJ RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DM6PO0N DI DM6PO0N DM6PO0N DN ISIS 112690 DM6PO0N TI TT6804T DM6PO0N TN MIF messenger RNA (MIF mRNA) DM6PO0N RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DM6PO0N RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DM6PO49 DI DM6PO49 DM6PO49 DN [3H]NFPS DM6PO49 TI TTHJTF7 DM6PO49 TN Glycine transporter GlyT-1 (SLC6A9) DM6PO49 MA Modulator DM6PO49 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DM6PO49 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DM6PQ5V DI DM6PQ5V DM6PQ5V DN 4-amino-N-(2-chlorophenyl)benzenesulfonamide DM6PQ5V TI TT8NGED DM6PQ5V TN Prostaglandin G/H synthase 1 (COX-1) DM6PQ5V MA Inhibitor DM6PQ5V RN Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21. DM6PQ5V RU https://pubmed.ncbi.nlm.nih.gov/17079150 DM6PQ8D DI DM6PQ8D DM6PQ8D DN (S,S)-(-)-bis(12)-hupyridone DM6PQ8D TI TT1RS9F DM6PQ8D TN Acetylcholinesterase (AChE) DM6PQ8D MA Inhibitor DM6PQ8D RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DM6PQ8D RU https://pubmed.ncbi.nlm.nih.gov/18479118 DM6PV4W DI DM6PV4W DM6PV4W DN 2-(tert-butylamino)-1-m-tolylpropan-1-one DM6PV4W TI TTAWNKZ DM6PV4W TN Norepinephrine transporter (NET) DM6PV4W MA Inhibitor DM6PV4W RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM6PV4W RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM6PV4W DI DM6PV4W DM6PV4W DN 2-(tert-butylamino)-1-m-tolylpropan-1-one DM6PV4W TI TTVBI8W DM6PV4W TN Dopamine transporter (DAT) DM6PV4W MA Inhibitor DM6PV4W RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM6PV4W RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM6PXMJ DI DM6PXMJ DM6PXMJ DN N5-[4-(4-(3-Furyl)phenoxy)phenyl]-L-glutamamide DM6PXMJ TI TTXZEAJ DM6PXMJ TN Leukotriene A-4 hydrolase (LTA4H) DM6PXMJ MA Inhibitor DM6PXMJ RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DM6PXMJ RU https://pubmed.ncbi.nlm.nih.gov/18394906 DM6PZ45 DI DM6PZ45 DM6PZ45 DN AcAsp-Glu-Dif-Lys-Cha-Cys DM6PZ45 TI TTWXB3E DM6PZ45 TN Hepatitis C virus NS3 helicase (HCV NS3) DM6PZ45 MA Inhibitor DM6PZ45 RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DM6PZ45 RU https://pubmed.ncbi.nlm.nih.gov/11206459 DM6Q3M7 DI DM6Q3M7 DM6Q3M7 DN 6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol DM6Q3M7 TI TTZAYWL DM6Q3M7 TN Estrogen receptor (ESR) DM6Q3M7 MA Inhibitor DM6Q3M7 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM6Q3M7 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM6Q3M7 DI DM6Q3M7 DM6Q3M7 DN 6-(2-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol DM6Q3M7 TI TTOM3J0 DM6Q3M7 TN Estrogen receptor beta (ESR2) DM6Q3M7 MA Inhibitor DM6Q3M7 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM6Q3M7 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM6QDNH DI DM6QDNH DM6QDNH DN 9-(Aminomethyl)-9,10-dihydroanthracene DM6QDNH TI TTTIBOJ DM6QDNH TN Histamine H1 receptor (H1R) DM6QDNH MA Inhibitor DM6QDNH RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DM6QDNH RU https://pubmed.ncbi.nlm.nih.gov/19700330 DM6QDNH DI DM6QDNH DM6QDNH DN 9-(Aminomethyl)-9,10-dihydroanthracene DM6QDNH TI TTJQOD7 DM6QDNH TN 5-HT 2A receptor (HTR2A) DM6QDNH MA Inhibitor DM6QDNH RN Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6. DM6QDNH RU https://pubmed.ncbi.nlm.nih.gov/11229772 DM6QERS DI DM6QERS DM6QERS DN PSB603 DM6QERS TI TTNE7KG DM6QERS TN Adenosine A2b receptor (ADORA2B) DM6QERS MA Antagonist DM6QERS RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DM6QERS RU https://pubmed.ncbi.nlm.nih.gov/19569717 DM6QERS DI DM6QERS DM6QERS DN PSB603 DM6QERS TI TTK25J1 DM6QERS TN Adenosine A1 receptor (ADORA1) DM6QERS MA Antagonist DM6QERS RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DM6QERS RU https://pubmed.ncbi.nlm.nih.gov/19569717 DM6QERS DI DM6QERS DM6QERS DN PSB603 DM6QERS TI TTJFY5U DM6QERS TN Adenosine A3 receptor (ADORA3) DM6QERS MA Antagonist DM6QERS RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DM6QERS RU https://pubmed.ncbi.nlm.nih.gov/19569717 DM6QHIA DI DM6QHIA DM6QHIA DN 5-fluoro-6-amino-UMP DM6QHIA TI TTAFJUD DM6QHIA TN Orotidine 5'-monophosphate decarboxylase (UMPS) DM6QHIA MA Inhibitor DM6QHIA RN Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58. DM6QHIA RU https://pubmed.ncbi.nlm.nih.gov/19260677 DM6QK7E DI DM6QK7E DM6QK7E DN N-benzyl-N-isobutylpiperidin-4-amine DM6QK7E TI TTAWNKZ DM6QK7E TN Norepinephrine transporter (NET) DM6QK7E MA Inhibitor DM6QK7E RN N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8. DM6QK7E RU https://pubmed.ncbi.nlm.nih.gov/16497500 DM6QK7E DI DM6QK7E DM6QK7E DN N-benzyl-N-isobutylpiperidin-4-amine DM6QK7E TI TT3ROYC DM6QK7E TN Serotonin transporter (SERT) DM6QK7E MA Inhibitor DM6QK7E RN N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8. DM6QK7E RU https://pubmed.ncbi.nlm.nih.gov/16497500 DM6QU5B DI DM6QU5B DM6QU5B DN 1-phenyl-3-(1,3,4-thiadiazol-2-yl)thiourea DM6QU5B TI TT6804T DM6QU5B TN MIF messenger RNA (MIF mRNA) DM6QU5B MA Inhibitor DM6QU5B RN An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. DM6QU5B RU https://pubmed.ncbi.nlm.nih.gov/20639113 DM6QULO DI DM6QULO DM6QULO DN 1-Butyl-4-(2-methoxy-phenyl)-piperazine DM6QULO TI TTJQOD7 DM6QULO TN 5-HT 2A receptor (HTR2A) DM6QULO MA Inhibitor DM6QULO RN Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60. DM6QULO RU https://pubmed.ncbi.nlm.nih.gov/8064802 DM6QULO DI DM6QULO DM6QULO DN 1-Butyl-4-(2-methoxy-phenyl)-piperazine DM6QULO TI TTSQIFT DM6QULO TN 5-HT 1A receptor (HTR1A) DM6QULO MA Inhibitor DM6QULO RN Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60. DM6QULO RU https://pubmed.ncbi.nlm.nih.gov/8064802 DM6QXYE DI DM6QXYE DM6QXYE DN PMID2153213C2f DM6QXYE TI TTPADOQ DM6QXYE TN HMG-CoA reductase (HMGCR) DM6QXYE MA Inhibitor DM6QXYE RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DM6QXYE RU https://pubmed.ncbi.nlm.nih.gov/2153213 DM6QZPH DI DM6QZPH DM6QZPH DN N-(2-adamantyl)-N'-propylsulfamide DM6QZPH TI TT6OEDT DM6QZPH TN Cannabinoid receptor 1 (CB1) DM6QZPH MA Inhibitor DM6QZPH RN Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95. DM6QZPH RU https://pubmed.ncbi.nlm.nih.gov/19762126 DM6QZTB DI DM6QZTB DM6QZTB DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM6QZTB TI TTAWNKZ DM6QZTB TN Norepinephrine transporter (NET) DM6QZTB MA Inhibitor DM6QZTB RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM6QZTB RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM6QZTB DI DM6QZTB DM6QZTB DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM6QZTB TI TTVBI8W DM6QZTB TN Dopamine transporter (DAT) DM6QZTB MA Inhibitor DM6QZTB RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM6QZTB RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM6QZTB DI DM6QZTB DM6QZTB DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM6QZTB TI TT3ROYC DM6QZTB TN Serotonin transporter (SERT) DM6QZTB MA Inhibitor DM6QZTB RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM6QZTB RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM6R1XH DI DM6R1XH DM6R1XH DN 2-[4-(2-Thienyl)phenyl]-4-methylmorpholin-2-ol DM6R1XH TI TTFQEO5 DM6R1XH TN Squalene synthetase (FDFT1) DM6R1XH MA Inhibitor DM6R1XH RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DM6R1XH RU https://pubmed.ncbi.nlm.nih.gov/18754614 DM6R43J DI DM6R43J DM6R43J DN 4-((benzylideneamino)methyl)benzenesulfonamide DM6R43J TI TTANPDJ DM6R43J TN Carbonic anhydrase II (CA-II) DM6R43J MA Inhibitor DM6R43J RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DM6R43J RU https://pubmed.ncbi.nlm.nih.gov/19796939 DM6R4MG DI DM6R4MG DM6R4MG DN 2-(4-benzylphenoxy)ethanamine DM6R4MG TI TTXZEAJ DM6R4MG TN Leukotriene A-4 hydrolase (LTA4H) DM6R4MG MA Inhibitor DM6R4MG RN Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52. DM6R4MG RU https://pubmed.ncbi.nlm.nih.gov/18952425 DM6R4X8 DI DM6R4X8 DM6R4X8 DN BAS-00672722 DM6R4X8 TI TT3PJMV DM6R4X8 TN Tyrosine-protein kinase ABL1 (ABL) DM6R4X8 MA Inhibitor DM6R4X8 RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DM6R4X8 RU https://pubmed.ncbi.nlm.nih.gov/16722646 DM6R4X8 DI DM6R4X8 DM6R4X8 DN BAS-00672722 DM6R4X8 TI TT6PKBN DM6R4X8 TN Proto-oncogene c-Src (SRC) DM6R4X8 MA Inhibitor DM6R4X8 RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DM6R4X8 RU https://pubmed.ncbi.nlm.nih.gov/16722646 DM6R5HU DI DM6R5HU DM6R5HU DN 3-(1-Methyl-piperidin-4-yl)-2-phenyl-1H-indole DM6R5HU TI TTJQOD7 DM6R5HU TN 5-HT 2A receptor (HTR2A) DM6R5HU MA Inhibitor DM6R5HU RN 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3. DM6R5HU RU https://pubmed.ncbi.nlm.nih.gov/11133072 DM6R5YW DI DM6R5YW DM6R5YW DN ISIS 109112 DM6R5YW TI TTQSMFG DM6R5YW TN Talin messenger RNA (TLN1 mRNA) DM6R5YW RN US patent application no. 6,372,492, Antisense modulation of talin expression. DM6R5YW RU http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true DM6R98Y DI DM6R98Y DM6R98Y DN 2-Amino-6-(3-bromo-benzenesulfinyl)-benzonitrile DM6R98Y TI TT84ETX DM6R98Y TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM6R98Y MA Inhibitor DM6R98Y RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM6R98Y RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM6RA20 DI DM6RA20 DM6RA20 DN NM-2014 DM6RA20 TI TTG043C DM6RA20 TN Tumor necrosis factor receptor type I (TNF-R1) DM6RA20 MA Modulator DM6RA20 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870). DM6RA20 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870 DM6RCES DI DM6RCES DM6RCES DN LL-6531 DM6RCES TI TTJ584C DM6RCES TN Peroxisome proliferator-activated receptor alpha (PPARA) DM6RCES MA Modulator DM6RCES RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593). DM6RCES RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593 DM6RH19 DI DM6RH19 DM6RH19 DN LB42908 DM6RH19 TI TT7WZIJ DM6RH19 TN CAAX farnesyltransferase beta (FNTB) DM6RH19 MA Inhibitor DM6RH19 RN A novel class of highly potent, selective, and non-peptidic inhibitor of Ras farnesyltransferase (FTase). Bioorg Med Chem Lett. 2001 Dec 3;11(23):3069-72. DM6RH19 RU https://pubmed.ncbi.nlm.nih.gov/11714612 DM6RJOI DI DM6RJOI DM6RJOI DN OXENDLONE DM6RJOI TI TTS64P2 DM6RJOI TN Androgen receptor (AR) DM6RJOI MA Inhibitor DM6RJOI RN Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002. DM6RJOI RU https://pubmed.ncbi.nlm.nih.gov/9358642 DM6RKOC DI DM6RKOC DM6RKOC DN L-Isofagomine DM6RKOC TI TT1B5PU DM6RKOC TN Glucosylceramidase (GBA) DM6RKOC MA Inhibitor DM6RKOC RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DM6RKOC RU https://pubmed.ncbi.nlm.nih.gov/18595718 DM6RO2L DI DM6RO2L DM6RO2L DN 1-(3,3-Diphenyl-allyl)-3-m-tolyl-urea DM6RO2L TI TTCG0AL DM6RO2L TN Cholecystokinin receptor type A (CCKAR) DM6RO2L MA Inhibitor DM6RO2L RN Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9. DM6RO2L RU https://pubmed.ncbi.nlm.nih.gov/1552499 DM6RSZ9 DI DM6RSZ9 DM6RSZ9 DN [3H]U69593 DM6RSZ9 TI TTQW87Y DM6RSZ9 TN Opioid receptor kappa (OPRK1) DM6RSZ9 MA Agonist DM6RSZ9 RN [3H]U-69593 a highly selective ligand for the opioid kappa receptor. Eur J Pharmacol. 1985 Feb 26;109(2):281-4. DM6RSZ9 RU https://pubmed.ncbi.nlm.nih.gov/2986999 DM6RSZ9 DI DM6RSZ9 DM6RSZ9 DN [3H]U69593 DM6RSZ9 TI TTKWM86 DM6RSZ9 TN Opioid receptor mu (MOP) DM6RSZ9 MA Inhibitor DM6RSZ9 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM6RSZ9 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM6RV9L DI DM6RV9L DM6RV9L DN 4-(3-fluorophenylethynyl)-2-thiazolylamine DM6RV9L TI TTHS256 DM6RV9L TN Metabotropic glutamate receptor 5 (mGluR5) DM6RV9L MA Inhibitor DM6RV9L RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DM6RV9L RU https://pubmed.ncbi.nlm.nih.gov/16451073 DM6RVB3 DI DM6RVB3 DM6RVB3 DN 4-Pyridin-2-yl-5-quinolin-4-yl-thiazol-2-ylamine DM6RVB3 TI TTP4520 DM6RVB3 TN TGF-beta receptor type I (TGFBR1) DM6RVB3 MA Inhibitor DM6RVB3 RN Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506. DM6RVB3 RU https://pubmed.ncbi.nlm.nih.gov/15317461 DM6RVTO DI DM6RVTO DM6RVTO DN PD159790 DM6RVTO TI TTQ9RYT DM6RVTO TN Endothelin-converting enzyme 1 (ECE1) DM6RVTO MA Inhibitor DM6RVTO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1615). DM6RVTO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1615 DM6RY4F DI DM6RY4F DM6RY4F DN PMID22861813C8a DM6RY4F TI TT5NILS DM6RY4F TN Cathepsin A (CTSA) DM6RY4F MA Inhibitor DM6RY4F RN Novel beta-amino acid derivatives as inhibitors of cathepsin A. J Med Chem. 2012 Sep 13;55(17):7636-49. DM6RY4F RU https://pubmed.ncbi.nlm.nih.gov/22861813 DM6S28U DI DM6S28U DM6S28U DN 3-(5-((methylthio)methyl)furan-2-yl)pyridine DM6S28U TI TTXV4FI DM6S28U TN Albendazole monooxygenase (CYP3A4) DM6S28U MA Inhibitor DM6S28U RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DM6S28U RU https://pubmed.ncbi.nlm.nih.gov/17125252 DM6S742 DI DM6S742 DM6S742 DN Ro-65-7219 DM6S742 TI TTB2MXP DM6S742 TN Angiotensinogenase renin (REN) DM6S742 MA Inhibitor DM6S742 RN Direct renin inhibitors as a new therapy for hypertension. J Med Chem. 2010 Nov 11;53(21):7490-520. DM6S742 RU https://pubmed.ncbi.nlm.nih.gov/20731374 DM6SBPI DI DM6SBPI DM6SBPI DN 2,3-Didehydroalanine DM6SBPI TI TT3DQUT DM6SBPI TN Bacterial Lantibiotic mersacidin (Bact glmM) DM6SBPI MA Inhibitor DM6SBPI RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM6SBPI RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM6SC5K DI DM6SC5K DM6SC5K DN SCH-24518 DM6SC5K TI TTEX248 DM6SC5K TN Dopamine D2 receptor (D2R) DM6SC5K MA Inhibitor DM6SC5K RN Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J Med Chem. 1988 Oct;31(10):1941-6. DM6SC5K RU https://pubmed.ncbi.nlm.nih.gov/3050089 DM6SC5K DI DM6SC5K DM6SC5K DN SCH-24518 DM6SC5K TI TTZFYLI DM6SC5K TN Dopamine D1 receptor (D1R) DM6SC5K MA Inhibitor DM6SC5K RN Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands. J Med Chem. 1988 Oct;31(10):1941-6. DM6SC5K RU https://pubmed.ncbi.nlm.nih.gov/3050089 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTPXI3S DM6SFYH TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000 Sep;58(3):591-600. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/10953053 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTBECWA DM6SFYH TN Transient receptor potential cation channel V2 (TRPV2) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/17673572 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTJ2W69 DM6SFYH TN Voltage-gated potassium channel Kv1.6 (KCNA6) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J. 1990 Jun;9(6):1749-56. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/2347305 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTGJFK1 DM6SFYH TN Calcium-activated potassium channel KCa4.1 (KCNT1) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN For K+ channels, Na+ is the new Ca2+. Trends Neurosci. 2005 Aug;28(8):422-8. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/15979166 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTSF1KH DM6SFYH TN Aquaporin-1 (AQP1) DM6SFYH MA Inhibitor DM6SFYH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 688). DM6SFYH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=688 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT2T5M0 DM6SFYH TN Calcium-activated potassium channel KCa2.2 (KCNN2) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/20359520 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTXF0ZW DM6SFYH TN Inward rectifier potassium channel Kir2.3 (KCNJ4) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Cloning and expression of a novel human brain inward rectifier potassium channel. J Biol Chem. 1994 Aug 12;269(32):20468-74. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/8051145 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTT4Y0X DM6SFYH TN Voltage-gated potassium channel Kv1.8 (KCNA10) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN KCNA10: a novel ion channel functionally related to both voltage-gated potassium and CNG cation channels. Am J Physiol Renal Physiol. 2000 Jun;278(6):F1013-21. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/10836990 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT9JH25 DM6SFYH TN Calcium-activated potassium channel KCa2.3 (KCNN3) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/20359520 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTVFB0O DM6SFYH TN Voltage-gated potassium channel Kv1.2 (KCNA2) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/7517498 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTALSY9 DM6SFYH TN Voltage-gated potassium channel Kv3.3 (KCNC3) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Cloning of ShIII (Shaw-like) cDNAs encoding a novel high-voltage-activating, TEA-sensitive, type-A K+ channel. Proc Biol Sci. 1992 Apr 22;248(1321):9-18. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/1381835 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT5PFNG DM6SFYH TN Voltage-gated potassium channel Kv2.2 (KCNB2) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Molecular identification of a component of delayed rectifier current in gastrointestinal smooth muscles. Am J Physiol. 1998 May;274(5 Pt 1):G901-11. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/9612272 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTS3DIK DM6SFYH TN Voltage-gated potassium channel Kv1.1 (KCNA1) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/7517498 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTY3UE6 DM6SFYH TN Voltage-gated potassium channel Kv1.3 (KCNA3) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/7517498 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT9R6BE DM6SFYH TN Calcium-activated potassium channel KCa2.1 (KCNN1) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/20359520 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTLU5FO DM6SFYH TN Calcium-activated potassium channel KCa4.2 (KCNT2) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci. 2006 May 10;26(19):5059-68. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/16687497 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTWVL5Q DM6SFYH TN Voltage-gated potassium channel Kv7.5 (KCNQ5) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000 Aug 4;275(31):24089-95. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/10816588 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT8HGRW DM6SFYH TN Voltage-gated potassium channel Kv7.4 (KCNQ4) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Homomeric and heteromeric assembly of KCNQ (Kv7) K+ channels assayed by total internal reflection fluorescence/fluorescence resonance energy transfer and patch clamp analysis. J Biol Chem. 2008 Nov 7;283(45):30668-76. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/18786918 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTVUWHQ DM6SFYH TN Voltage-gated potassium channel Kv3.1 (KCNC1) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/7517498 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTIVDM3 DM6SFYH TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Differential tetraethylammonium sensitivity of KCNQ1-4 potassium channels. Br J Pharmacol. 2000 Feb;129(3):413-5. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/10711337 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT1AQ50 DM6SFYH TN Charybdotoxin receptor beta-4 (BKbeta4) DM6SFYH MA Inhibitor DM6SFYH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 380). DM6SFYH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=380 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT4DI0J DM6SFYH TN Voltage-gated potassium channel Kv4.1 (KCND1) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Endogenous Kv channels in human embryonic kidney (HEK-293) cells. Mol Cell Biochem. 2002 Sep;238(1-2):69-79. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/12349911 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTI9XK6 DM6SFYH TN Calcium-activated potassium channel KCa5.1 (KCNU1) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Block of mouse Slo1 and Slo3 K+ channels by CTX, IbTX, TEA, 4-AP and quinidine. Channels (Austin). 2010 Jan-Feb;4(1):22-41. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/19934650 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT5OEKU DM6SFYH TN Voltage-gated potassium channel Kv2.1 (KCNB1) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Modulation of Kv2.1 channel gating and TEA sensitivity by distinct domains of SNAP-25. Biochem J. 2006 Jun 1;396(2):363-9. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/16478442 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTW0CMT DM6SFYH TN Voltage-gated potassium channel Kv1.5 (KCNA5) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/7517498 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTODZF1 DM6SFYH TN Voltage-gated potassium channel Kv3.4 (KCNC4) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Characterization of a Shaw-related potassium channel family in rat brain. EMBO J. 1992 Jul;11(7):2473-86. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/1378392 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTGK3ZO DM6SFYH TN Voltage-gated potassium channel Kv3.2 (KCNC2) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Gating, modulation and subunit composition of voltage-gated K(+) channels in dendritic inhibitory interneurones of rat hippocampus. J Physiol. 2002 Jan 15;538(Pt 2):405-19. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/11790809 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTCVBT7 DM6SFYH TN Voltage-gated potassium channel Kv1.7 (KCNA7) DM6SFYH MA Blocker (channel blocker) DM6SFYH RN Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). Eur J Hum Genet. 2002 Jan;10(1):36-43. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/11896454 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TT7HXSL DM6SFYH TN Multidrug and toxin extrusion protein 2 (MATE2) DM6SFYH MA Modulator DM6SFYH RN Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/17509534 DM6SFYH DI DM6SFYH DM6SFYH DN [14C]TEA DM6SFYH TI TTMHCGA DM6SFYH TN Solute carrier family 47 member 1 (SLC47A1) DM6SFYH MA Modulator DM6SFYH RN Molecular cloning, functional characterization and tissue distribution of rat H+/organic cation antiporter MATE1. Pharm Res. 2006 Aug;23(8):1696-701. DM6SFYH RU https://pubmed.ncbi.nlm.nih.gov/16850272 DM6SI78 DI DM6SI78 DM6SI78 DN 4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide DM6SI78 TI TT1VAUK DM6SI78 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM6SI78 MA Inhibitor DM6SI78 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DM6SI78 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DM6SI78 DI DM6SI78 DM6SI78 DN 4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide DM6SI78 TI TTUTJGQ DM6SI78 TN Vascular endothelial growth factor receptor 2 (KDR) DM6SI78 MA Inhibitor DM6SI78 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DM6SI78 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DM6SI78 DI DM6SI78 DM6SI78 DN 4-Chloro-N-(2-methyl-benzoyl)-benzenesulfonamide DM6SI78 TI TTDCBX5 DM6SI78 TN Vascular endothelial growth factor receptor 3 (FLT-4) DM6SI78 MA Inhibitor DM6SI78 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DM6SI78 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DM6SIA4 DI DM6SIA4 DM6SIA4 DN 4-(butylthio)-2-(trifluoromethyl)benzonitrile DM6SIA4 TI TTKPW01 DM6SIA4 TN Androgen receptor messenger RNA (AR mRNA) DM6SIA4 MA Inhibitor DM6SIA4 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM6SIA4 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM6SM4N DI DM6SM4N DM6SM4N DN UR-PG55B DM6SM4N TI TTTIBOJ DM6SM4N TN Histamine H1 receptor (H1R) DM6SM4N MA Agonist DM6SM4N RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DM6SM4N RU https://pubmed.ncbi.nlm.nih.gov/16394198 DM6SQ9A DI DM6SQ9A DM6SQ9A DN RO4988546 DM6SQ9A TI TTXJ47W DM6SQ9A TN Metabotropic glutamate receptor 2 (mGluR2) DM6SQ9A MA Modulator (allosteric modulator) DM6SQ9A RN Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol. 2011 Sep;164(2b):521-37. DM6SQ9A RU https://pubmed.ncbi.nlm.nih.gov/21470207 DM6SV7I DI DM6SV7I DM6SV7I DN (N)methanocarba-UTP DM6SV7I TI TT24DGP DM6SV7I TN P2Y purinoceptor 4 (P2RY4) DM6SV7I MA Agonist DM6SV7I RN Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem. 2002 Jan 3;45(1):208-18. DM6SV7I RU https://pubmed.ncbi.nlm.nih.gov/11754592 DM6SYMH DI DM6SYMH DM6SYMH DN Mumbaistatin DM6SYMH TI TT1KPBZ DM6SYMH TN Glucose-6-phosphate translocase (SLC37A4) DM6SYMH MA Inhibitor DM6SYMH RN Studies toward the total synthesis of mumbaistatin, a highly potent glucose-6-phosphate translocase inhibitor. Synthesis of a mumbaistatin analogue. J Org Chem. 2002 Dec 27;67(26):9248-56. DM6SYMH RU https://pubmed.ncbi.nlm.nih.gov/12492326 DM6SZVE DI DM6SZVE DM6SZVE DN PNU-87663 DM6SZVE TI TT4QPUL DM6SZVE TN Antithrombin-III (ATIII) DM6SZVE MA Modulator DM6SZVE RN List of drugs in development for neurodegenerative diseases.Update June 2004.Neurodegener Dis.2004;1(2-3):113-52. DM6SZVE RU https://www.ncbi.nlm.nih.gov/pubmed/16908983 DM6T09B DI DM6T09B DM6T09B DN Ac-Glu-Cha-Cys DM6T09B TI TTWXB3E DM6T09B TN Hepatitis C virus NS3 helicase (HCV NS3) DM6T09B MA Inhibitor DM6T09B RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DM6T09B RU https://pubmed.ncbi.nlm.nih.gov/11206459 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TTYHPU6 DM6T0IQ TN Histone deacetylase 10 (HDAC10) DM6T0IQ MA Inhibitor DM6T0IQ RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TTSHTOI DM6T0IQ TN Histone deacetylase 2 (HDAC2) DM6T0IQ MA Inhibitor DM6T0IQ RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TTT6LFV DM6T0IQ TN Histone deacetylase 8 (HDAC8) DM6T0IQ MA Inhibitor DM6T0IQ RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TTGRHIB DM6T0IQ TN UDP-glucose 4-epimerase (GALE) DM6T0IQ MA Inhibitor DM6T0IQ RN Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5744-7. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/16962325 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TTBH0VX DM6T0IQ TN Histone deacetylase (HDAC) DM6T0IQ MA Inhibitor DM6T0IQ RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TT5ZKDI DM6T0IQ TN Histone deacetylase 6 (HDAC6) DM6T0IQ MA Inhibitor DM6T0IQ RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TT6R7JZ DM6T0IQ TN Histone deacetylase 1 (HDAC1) DM6T0IQ MA Inhibitor DM6T0IQ RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM6T0IQ DI DM6T0IQ DM6T0IQ DN PSAMMAPLIN A DM6T0IQ TI TTTQGH8 DM6T0IQ TN Histone deacetylase 4 (HDAC4) DM6T0IQ MA Inhibitor DM6T0IQ RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DM6T0IQ RU https://pubmed.ncbi.nlm.nih.gov/14613312 DM6T5K4 DI DM6T5K4 DM6T5K4 DN 3-phenyl-4-(phenylamino)-1H-pyrrole-2,5-dione DM6T5K4 TI TTRSMW9 DM6T5K4 TN Glycogen synthase kinase-3 beta (GSK-3B) DM6T5K4 MA Inhibitor DM6T5K4 RN Novel GSK-3beta inhibitors from sequential virtual screening. Bioorg Med Chem. 2008 Jan 15;16(2):636-43. DM6T5K4 RU https://pubmed.ncbi.nlm.nih.gov/18006321 DM6T8YM DI DM6T8YM DM6T8YM DN Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DM6T8YM TI TTH18TF DM6T8YM TN Muscarinic acetylcholine receptor M5 (CHRM5) DM6T8YM MA Inhibitor DM6T8YM RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DM6T8YM RU https://pubmed.ncbi.nlm.nih.gov/10891110 DM6T8YM DI DM6T8YM DM6T8YM DN Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DM6T8YM TI TTQ13Z5 DM6T8YM TN Muscarinic acetylcholine receptor M3 (CHRM3) DM6T8YM MA Inhibitor DM6T8YM RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DM6T8YM RU https://pubmed.ncbi.nlm.nih.gov/10891110 DM6T8YM DI DM6T8YM DM6T8YM DN Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DM6T8YM TI TTQ3JTF DM6T8YM TN Muscarinic acetylcholine receptor M4 (CHRM4) DM6T8YM MA Inhibitor DM6T8YM RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DM6T8YM RU https://pubmed.ncbi.nlm.nih.gov/10891110 DM6T8YM DI DM6T8YM DM6T8YM DN Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DM6T8YM TI TTZ9SOR DM6T8YM TN Muscarinic acetylcholine receptor M1 (CHRM1) DM6T8YM MA Inhibitor DM6T8YM RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DM6T8YM RU https://pubmed.ncbi.nlm.nih.gov/10891110 DM6T8YM DI DM6T8YM DM6T8YM DN Benzoic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DM6T8YM TI TTYEG6Q DM6T8YM TN Muscarinic acetylcholine receptor M2 (CHRM2) DM6T8YM MA Inhibitor DM6T8YM RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DM6T8YM RU https://pubmed.ncbi.nlm.nih.gov/10891110 DM6TEWZ DI DM6TEWZ DM6TEWZ DN IDN-6384 DM6TEWZ TI TTGTQHC DM6TEWZ TN DNA topoisomerase I (TOP1) DM6TEWZ MA Inhibitor DM6TEWZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DM6TEWZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DM6TFPY DI DM6TFPY DM6TFPY DN PMID24900237C15 DM6TFPY TI TTYENHQ DM6TFPY TN Unc-51 like kinase 3 (ULK3) DM6TFPY MA Inhibitor DM6TFPY RN Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010 Sep 1;1(9):493-8. DM6TFPY RU https://pubmed.ncbi.nlm.nih.gov/24900237 DM6TFPY DI DM6TFPY DM6TFPY DN PMID24900237C15 DM6TFPY TI TTPMQSO DM6TFPY TN ALK tyrosine kinase receptor (ALK) DM6TFPY MA Inhibitor DM6TFPY RN Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010 Sep 1;1(9):493-8. DM6TFPY RU https://pubmed.ncbi.nlm.nih.gov/24900237 DM6TFPY DI DM6TFPY DM6TFPY DN PMID24900237C15 DM6TFPY TI TTCBFJO DM6TFPY TN Insulin receptor (INSR) DM6TFPY MA Inhibitor DM6TFPY RN Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity. ACS Med Chem Lett. 2010 Sep 1;1(9):493-8. DM6TFPY RU https://pubmed.ncbi.nlm.nih.gov/24900237 DM6TIQX DI DM6TIQX DM6TIQX DN Dodecanoic acid adamantan-1-ylamide DM6TIQX TI TT7WVHI DM6TIQX TN Soluble epoxide hydrolase (EPHX2) DM6TIQX MA Inhibitor DM6TIQX RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DM6TIQX RU https://pubmed.ncbi.nlm.nih.gov/15887969 DM6TJFU DI DM6TJFU DM6TJFU DN CINANSERIN DM6TJFU TI TTJQOD7 DM6TJFU TN 5-HT 2A receptor (HTR2A) DM6TJFU MA Inhibitor DM6TJFU RN Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12. DM6TJFU RU https://pubmed.ncbi.nlm.nih.gov/3543362 DM6TM1L DI DM6TM1L DM6TM1L DN 5-desgalloylstachyurin DM6TM1L TI TTCIHJA DM6TM1L TN Coagulation factor Xa (F10) DM6TM1L MA Inhibitor DM6TM1L RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DM6TM1L RU https://pubmed.ncbi.nlm.nih.gov/9834152 DM6TM1L DI DM6TM1L DM6TM1L DN 5-desgalloylstachyurin DM6TM1L TI TT6L509 DM6TM1L TN Coagulation factor IIa (F2) DM6TM1L MA Inhibitor DM6TM1L RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DM6TM1L RU https://pubmed.ncbi.nlm.nih.gov/9834152 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TTHCF4J DM6TU84 TN Alpha-glucosidase (GLA) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TTELIN2 DM6TU84 TN PTPN1 messenger RNA (PTPN1 mRNA) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TTXWASR DM6TU84 TN Intestinal maltase-glucoamylase (MGAM) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TTR0SWN DM6TU84 TN M-phase inducer phosphatase 2 (MPIP2) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TT7HF4W DM6TU84 TN Cyclin-dependent kinase 2 (CDK2) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TTDS503 DM6TU84 TN Beta-crystallin B1 (CRYBB1) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TTNGKET DM6TU84 TN Prolyl endopeptidase (PREP) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TU84 DI DM6TU84 DM6TU84 DN Double Oxidized Cysteine DM6TU84 TI TTICO5G DM6TU84 TN Staphylococcus Peptide deformylase (Stap-coc def) DM6TU84 MA Inhibitor DM6TU84 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6TU84 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6TVAX DI DM6TVAX DM6TVAX DN Disulergine DM6TVAX TI TTO9X1H DM6TVAX TN 5-HT 7 receptor (HTR7) DM6TVAX MA Inhibitor DM6TVAX RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DM6TVAX RU https://pubmed.ncbi.nlm.nih.gov/12825922 DM6TYD0 DI DM6TYD0 DM6TYD0 DN PMID24900283C8a DM6TYD0 TI TTHYDUM DM6TYD0 TN Bombesin receptor (BS) DM6TYD0 MA Agonist DM6TYD0 RN Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality. ACS Med Chem Lett. 2011 Oct 3;2(12):933-7. DM6TYD0 RU https://pubmed.ncbi.nlm.nih.gov/24900283 DM6TYRA DI DM6TYRA DM6TYRA DN Cbz-Val-Pro-Val-(2-benzoxazole) DM6TYRA TI TTPLTSQ DM6TYRA TN Neutrophil elastase (NE) DM6TYRA MA Inhibitor DM6TYRA RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DM6TYRA RU https://pubmed.ncbi.nlm.nih.gov/18053726 DM6U074 DI DM6U074 DM6U074 DN 3-Pyridin-4-yl-quinoline DM6U074 TI TT8FYO9 DM6U074 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM6U074 MA Inhibitor DM6U074 RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM6U074 RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM6U074 DI DM6U074 DM6U074 DN 3-Pyridin-4-yl-quinoline DM6U074 TI TTI7421 DM6U074 TN Platelet-derived growth factor receptor beta (PDGFRB) DM6U074 MA Inhibitor DM6U074 RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM6U074 RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM6U8SL DI DM6U8SL DM6U8SL DN N-(2,4-dihydroxybenzyl)-3,5-dihydroxybenzamide DM6U8SL TI TTULVH8 DM6U8SL TN Tyrosinase (TYR) DM6U8SL MA Inhibitor DM6U8SL RN N-Benzylbenzamides: a new class of potent tyrosinase inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2682-4. DM6U8SL RU https://pubmed.ncbi.nlm.nih.gov/16513349 DM6U9CY DI DM6U9CY DM6U9CY DN 6-iodo-4'-methoxyflavone DM6U9CY TI TTE4KHA DM6U9CY TN Amyloid beta A4 protein (APP) DM6U9CY MA Inhibitor DM6U9CY RN Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60. DM6U9CY RU https://pubmed.ncbi.nlm.nih.gov/16279784 DM6UAV7 DI DM6UAV7 DM6UAV7 DN hexahydrosiladifenidol DM6UAV7 TI TTQ13Z5 DM6UAV7 TN Muscarinic acetylcholine receptor M3 (CHRM3) DM6UAV7 MA Antagonist DM6UAV7 RN Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. DM6UAV7 RU https://pubmed.ncbi.nlm.nih.gov/2704370 DM6UAV7 DI DM6UAV7 DM6UAV7 DN hexahydrosiladifenidol DM6UAV7 TI TTOXS3C DM6UAV7 TN Muscarinic acetylcholine receptor (CHRM) DM6UAV7 MA Antagonist DM6UAV7 RN Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. DM6UAV7 RU https://pubmed.ncbi.nlm.nih.gov/2704370 DM6UC8Y DI DM6UC8Y DM6UC8Y DN N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide DM6UC8Y TI TTQBR95 DM6UC8Y TN Stress-activated protein kinase 2a (p38 alpha) DM6UC8Y MA Inhibitor DM6UC8Y RN Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9. DM6UC8Y RU https://pubmed.ncbi.nlm.nih.gov/16169718 DM6UP25 DI DM6UP25 DM6UP25 DN 6-cyclohexylmethyloxy-2-(4'-hydroxyanilino)purine DM6UP25 TI TT7HF4W DM6UP25 TN Cyclin-dependent kinase 2 (CDK2) DM6UP25 MA Inhibitor DM6UP25 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6UP25 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6USPC DI DM6USPC DM6USPC DN TRISMETHOXYRESVERATROL DM6USPC TI TT3OT40 DM6USPC TN Multidrug resistance protein 1 (ABCB1) DM6USPC MA Inhibitor DM6USPC RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DM6USPC RU https://pubmed.ncbi.nlm.nih.gov/16686543 DM6USPC DI DM6USPC DM6USPC DN TRISMETHOXYRESVERATROL DM6USPC TI TTI84H7 DM6USPC TN Cytochrome P450 1B1 (CYP1B1) DM6USPC MA Inhibitor DM6USPC RN Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. DM6USPC RU https://pubmed.ncbi.nlm.nih.gov/11754588 DM6USPC DI DM6USPC DM6USPC DN TRISMETHOXYRESVERATROL DM6USPC TI TT3PJMV DM6USPC TN Tyrosine-protein kinase ABL1 (ABL) DM6USPC MA Inhibitor DM6USPC RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DM6USPC RU https://pubmed.ncbi.nlm.nih.gov/16686543 DM6UWKL DI DM6UWKL DM6UWKL DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc DM6UWKL TI TT27RFC DM6UWKL TN Opioid receptor delta (OPRD1) DM6UWKL MA Inhibitor DM6UWKL RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DM6UWKL RU https://pubmed.ncbi.nlm.nih.gov/16509592 DM6UWKL DI DM6UWKL DM6UWKL DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc DM6UWKL TI TTKWM86 DM6UWKL TN Opioid receptor mu (MOP) DM6UWKL MA Inhibitor DM6UWKL RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DM6UWKL RU https://pubmed.ncbi.nlm.nih.gov/16509592 DM6UWVB DI DM6UWVB DM6UWVB DN FR117016 DM6UWVB TI TTLP57V DM6UWVB TN Adenosine deaminase (ADA) DM6UWVB MA Inhibitor DM6UWVB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM6UWVB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM6V91D DI DM6V91D DM6V91D DN 2-(3-benzylquinoxalin-2-ylamino)ethanol DM6V91D TI TT3WG5C DM6V91D TN Monoamine oxidase type A (MAO-A) DM6V91D MA Inhibitor DM6V91D RN Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6. DM6V91D RU https://pubmed.ncbi.nlm.nih.gov/16356714 DM6V9SC DI DM6V9SC DM6V9SC DN ATL-844 DM6V9SC TI TTNE7KG DM6V9SC TN Adenosine A2b receptor (ADORA2B) DM6V9SC MA Antagonist DM6V9SC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20). DM6V9SC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20 DM6VCI3 DI DM6VCI3 DM6VCI3 DN 1,10-bis(pyridinium)-decane dibromide DM6VCI3 TI TT1RS9F DM6VCI3 TN Acetylcholinesterase (AChE) DM6VCI3 MA Inhibitor DM6VCI3 RN Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6. DM6VCI3 RU https://pubmed.ncbi.nlm.nih.gov/20138518 DM6VCI3 DI DM6VCI3 DM6VCI3 DN 1,10-bis(pyridinium)-decane dibromide DM6VCI3 TI TTEB0GD DM6VCI3 TN Cholinesterase (BCHE) DM6VCI3 MA Inhibitor DM6VCI3 RN Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6. DM6VCI3 RU https://pubmed.ncbi.nlm.nih.gov/20138518 DM6VEON DI DM6VEON DM6VEON DN N-chloromethyl-brucine DM6VEON TI TTOXS3C DM6VEON TN Muscarinic acetylcholine receptor (CHRM) DM6VEON MA Modulator (allosteric modulator) DM6VEON RN Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89. DM6VEON RU https://pubmed.ncbi.nlm.nih.gov/9495826 DM6VEON DI DM6VEON DM6VEON DN N-chloromethyl-brucine DM6VEON TI TTQ13Z5 DM6VEON TN Muscarinic acetylcholine receptor M3 (CHRM3) DM6VEON MA Modulator (allosteric modulator) DM6VEON RN Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89. DM6VEON RU https://pubmed.ncbi.nlm.nih.gov/9495826 DM6VG8K DI DM6VG8K DM6VG8K DN PMID2296036C2g DM6VG8K TI TTPADOQ DM6VG8K TN HMG-CoA reductase (HMGCR) DM6VG8K MA Inhibitor DM6VG8K RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60. DM6VG8K RU https://pubmed.ncbi.nlm.nih.gov/2296036 DM6VH7A DI DM6VH7A DM6VH7A DN Alpha-D-Fucose DM6VH7A TI TTSZDQU DM6VH7A TN Lactotransferrin (LTF) DM6VH7A MA Inhibitor DM6VH7A RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6VH7A RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6VPF4 DI DM6VPF4 DM6VPF4 DN 5,6,7-Trimethyl-2-p-tolyl-chromen-4-one DM6VPF4 TI TTJFY5U DM6VPF4 TN Adenosine A3 receptor (ADORA3) DM6VPF4 MA Inhibitor DM6VPF4 RN Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8. DM6VPF4 RU https://pubmed.ncbi.nlm.nih.gov/8576921 DM6VQEO DI DM6VQEO DM6VQEO DN 2-(4-Cyclopentyl-piperazin-1-yl)-quinoline DM6VQEO TI TT9JNIC DM6VQEO TN Histamine H3 receptor (H3R) DM6VQEO MA Inhibitor DM6VQEO RN 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11. DM6VQEO RU https://pubmed.ncbi.nlm.nih.gov/15634025 DM6VQZ7 DI DM6VQZ7 DM6VQZ7 DN SP203 DM6VQZ7 TI TTHS256 DM6VQZ7 TN Metabotropic glutamate receptor 5 (mGluR5) DM6VQZ7 MA Modulator (allosteric modulator) DM6VQZ7 RN Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging mo... J Med Chem. 2007 Jul 12;50(14):3256-66. DM6VQZ7 RU https://pubmed.ncbi.nlm.nih.gov/17571866 DM6VY3P DI DM6VY3P DM6VY3P DN NSC-94258 DM6VY3P TI TTFBNVI DM6VY3P TN Aldose reductase (AKR1B1) DM6VY3P MA Inhibitor DM6VY3P RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DM6VY3P RU https://pubmed.ncbi.nlm.nih.gov/10354396 DM6VY3P DI DM6VY3P DM6VY3P DN NSC-94258 DM6VY3P TI TTSZLWK DM6VY3P TN Aromatase (CYP19A1) DM6VY3P MA Inhibitor DM6VY3P RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM6VY3P RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM6VY3P DI DM6VY3P DM6VY3P DN NSC-94258 DM6VY3P TI TTIWB6L DM6VY3P TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM6VY3P MA Inhibitor DM6VY3P RN Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99. DM6VY3P RU https://pubmed.ncbi.nlm.nih.gov/18533708 DM6VZ3T DI DM6VZ3T DM6VZ3T DN JWH-344 DM6VZ3T TI TT6OEDT DM6VZ3T TN Cannabinoid receptor 1 (CB1) DM6VZ3T MA Inhibitor DM6VZ3T RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM6VZ3T RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM6VZ3T DI DM6VZ3T DM6VZ3T DN JWH-344 DM6VZ3T TI TTMSFAW DM6VZ3T TN Cannabinoid receptor 2 (CB2) DM6VZ3T MA Inhibitor DM6VZ3T RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM6VZ3T RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM6VZ4S DI DM6VZ4S DM6VZ4S DN Propan-2-one O-4-(octyloxy)phenylcarbamoyl oxime DM6VZ4S TI TTDP1UC DM6VZ4S TN Fatty acid amide hydrolase (FAAH) DM6VZ4S MA Inhibitor DM6VZ4S RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM6VZ4S RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM6W0QI DI DM6W0QI DM6W0QI DN 5-Biphenyl-4-ylmethyl-1-isobutyl-1H-tetrazole DM6W0QI TI TTMSFAW DM6W0QI TN Cannabinoid receptor 2 (CB2) DM6W0QI MA Inhibitor DM6W0QI RN New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4. DM6W0QI RU https://pubmed.ncbi.nlm.nih.gov/18424134 DM6W27F DI DM6W27F DM6W27F DN LEUCOSCEPTOSIDE A DM6W27F TI TTFJ8Q1 DM6W27F TN Protein kinase C alpha (PRKCA) DM6W27F MA Inhibitor DM6W27F RN Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2. DM6W27F RU https://pubmed.ncbi.nlm.nih.gov/9834166 DM6W4LR DI DM6W4LR DM6W4LR DN [Mpa1, D-Tyr(Et)2, Pip7]OT DM6W4LR TI TTSCIUP DM6W4LR TN Oxytocin receptor (OTR) DM6W4LR MA Inhibitor DM6W4LR RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DM6W4LR RU https://pubmed.ncbi.nlm.nih.gov/17316912 DM6W73A DI DM6W73A DM6W73A DN PMID17574411C41 DM6W73A TI TTPADOQ DM6W73A TN HMG-CoA reductase (HMGCR) DM6W73A MA Inhibitor DM6W73A RN Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4531-7. DM6W73A RU https://pubmed.ncbi.nlm.nih.gov/17574411 DM6W9LA DI DM6W9LA DM6W9LA DN CT-5357 DM6W9LA TI TTV5CGO DM6W9LA TN Phosphodiesterase 4 (PDE4) DM6W9LA MA Modulator DM6W9LA RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DM6W9LA RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DM6WD8T DI DM6WD8T DM6WD8T DN 6,7-Dimethoxy-3-thiophen-2-yl-quinoline DM6WD8T TI TT8FYO9 DM6WD8T TN Platelet-derived growth factor receptor alpha (PDGFRA) DM6WD8T MA Inhibitor DM6WD8T RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM6WD8T RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM6WD8T DI DM6WD8T DM6WD8T DN 6,7-Dimethoxy-3-thiophen-2-yl-quinoline DM6WD8T TI TTI7421 DM6WD8T TN Platelet-derived growth factor receptor beta (PDGFRB) DM6WD8T MA Inhibitor DM6WD8T RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM6WD8T RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM6WHIA DI DM6WHIA DM6WHIA DN 9H-carbazole-2-carbaldehyde DM6WHIA TI TTBGTCW DM6WHIA TN Kinesin spindle messenger RNA (KIF11 mRNA) DM6WHIA MA Inhibitor DM6WHIA RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM6WHIA RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM6WJ4K DI DM6WJ4K DM6WJ4K DN 4-Hydroxy-1,2,5-Oxadiazole-3-Carboxylic Acid DM6WJ4K TI TTAZHU0 DM6WJ4K TN L-lactate dehydrogenase (LDH) DM6WJ4K MA Inhibitor DM6WJ4K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6WJ4K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6WPIS DI DM6WPIS DM6WPIS DN L-Serine DM6WPIS TI TTI1PRE DM6WPIS TN G-protein coupled receptor GPCR33 (GPRC6A) DM6WPIS MA Agonist DM6WPIS RN Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97. DM6WPIS RU https://pubmed.ncbi.nlm.nih.gov/15576628 DM6WTLZ DI DM6WTLZ DM6WTLZ DN (R)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one DM6WTLZ TI TTGP7BY DM6WTLZ TN Monoamine oxidase type B (MAO-B) DM6WTLZ MA Inhibitor DM6WTLZ RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM6WTLZ RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM6WX1A DI DM6WX1A DM6WX1A DN CCX-662 DM6WX1A TI TTRQJTC DM6WX1A TN C-X-C chemokine receptor type 7 (ACKR3) DM6WX1A MA Antagonist DM6WX1A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 80). DM6WX1A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=80 DM6WXJO DI DM6WXJO DM6WXJO DN (2S)-aminobutyryl-L-proline n-propylamide DM6WXJO TI TTQ7R2V DM6WXJO TN Tripeptidyl-peptidase II (TPP2) DM6WXJO MA Inhibitor DM6WXJO RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DM6WXJO RU https://pubmed.ncbi.nlm.nih.gov/16279793 DM6WYGC DI DM6WYGC DM6WYGC DN Sodium trithiocarbonate DM6WYGC TI TTHQPL7 DM6WYGC TN Carbonic anhydrase I (CA-I) DM6WYGC MA Inhibitor DM6WYGC RN Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1855-7. DM6WYGC RU https://pubmed.ncbi.nlm.nih.gov/19269822 DM6WYGC DI DM6WYGC DM6WYGC DN Sodium trithiocarbonate DM6WYGC TI TTZHA0O DM6WYGC TN Carbonic anhydrase IV (CA-IV) DM6WYGC MA Inhibitor DM6WYGC RN Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1855-7. DM6WYGC RU https://pubmed.ncbi.nlm.nih.gov/19269822 DM6WYGC DI DM6WYGC DM6WYGC DN Sodium trithiocarbonate DM6WYGC TI TTANPDJ DM6WYGC TN Carbonic anhydrase II (CA-II) DM6WYGC MA Inhibitor DM6WYGC RN Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1855-7. DM6WYGC RU https://pubmed.ncbi.nlm.nih.gov/19269822 DM6X5TZ DI DM6X5TZ DM6X5TZ DN 3-Isobutoxy-9H-beta-carboline DM6X5TZ TI TTNJYV2 DM6X5TZ TN Gamma-aminobutyric acid receptor (GAR) DM6X5TZ MA Inhibitor DM6X5TZ RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DM6X5TZ RU https://pubmed.ncbi.nlm.nih.gov/1331452 DM6X5TZ DI DM6X5TZ DM6X5TZ DN 3-Isobutoxy-9H-beta-carboline DM6X5TZ TI TT1MPAY DM6X5TZ TN GABA(A) receptor alpha-1 (GABRA1) DM6X5TZ MA Inhibitor DM6X5TZ RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DM6X5TZ RU https://pubmed.ncbi.nlm.nih.gov/1331452 DM6X5TZ DI DM6X5TZ DM6X5TZ DN 3-Isobutoxy-9H-beta-carboline DM6X5TZ TI TTNZPQ1 DM6X5TZ TN GABA(A) receptor alpha-5 (GABRA5) DM6X5TZ MA Inhibitor DM6X5TZ RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM6X5TZ RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM6X5TZ DI DM6X5TZ DM6X5TZ DN 3-Isobutoxy-9H-beta-carboline DM6X5TZ TI TT06RH5 DM6X5TZ TN GABA(A) receptor gamma-2 (GABRG2) DM6X5TZ MA Inhibitor DM6X5TZ RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM6X5TZ RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM6X5TZ DI DM6X5TZ DM6X5TZ DN 3-Isobutoxy-9H-beta-carboline DM6X5TZ TI TT37EDJ DM6X5TZ TN GABA(A) receptor alpha-3 (GABRA3) DM6X5TZ MA Inhibitor DM6X5TZ RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM6X5TZ RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM6X5TZ DI DM6X5TZ DM6X5TZ DN 3-Isobutoxy-9H-beta-carboline DM6X5TZ TI TTBMV1G DM6X5TZ TN GABA(A) receptor alpha-2 (GABRA2) DM6X5TZ MA Inhibitor DM6X5TZ RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM6X5TZ RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM6X8GN DI DM6X8GN DM6X8GN DN 2-Methoxyethyl 18-methoxycoronaridinate DM6X8GN TI TTTVAFQ DM6X8GN TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DM6X8GN MA Inhibitor DM6X8GN RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DM6X8GN RU https://pubmed.ncbi.nlm.nih.gov/12801235 DM6X9J3 DI DM6X9J3 DM6X9J3 DN 1-(1-Naphthyl)-2-aminopropane DM6X9J3 TI TT3WG5C DM6X9J3 TN Monoamine oxidase type A (MAO-A) DM6X9J3 MA Inhibitor DM6X9J3 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DM6X9J3 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DM6X9RQ DI DM6X9RQ DM6X9RQ DN ISIS 20579 DM6X9RQ TI TTSRXJW DM6X9RQ TN G-alpha-11 messenger RNA (GNA11 mRNA) DM6X9RQ RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DM6X9RQ RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DM6XC0M DI DM6XC0M DM6XC0M DN 3-(4-dimethylamino-benzylidenyl)-2-indolinone DM6XC0M TI TTI7421 DM6XC0M TN Platelet-derived growth factor receptor beta (PDGFRB) DM6XC0M MA Inhibitor DM6XC0M RN Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endo... Bioorg Med Chem. 2010 May 15;18(10):3575-87. DM6XC0M RU https://pubmed.ncbi.nlm.nih.gov/20403700 DM6XCPV DI DM6XCPV DM6XCPV DN 1-(2-(2-fluorobenzyloxy)phenyl)piperazine DM6XCPV TI TTSQIFT DM6XCPV TN 5-HT 1A receptor (HTR1A) DM6XCPV MA Inhibitor DM6XCPV RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM6XCPV RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM6XCPV DI DM6XCPV DM6XCPV DN 1-(2-(2-fluorobenzyloxy)phenyl)piperazine DM6XCPV TI TT3ROYC DM6XCPV TN Serotonin transporter (SERT) DM6XCPV MA Inhibitor DM6XCPV RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM6XCPV RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM6XCPV DI DM6XCPV DM6XCPV DN 1-(2-(2-fluorobenzyloxy)phenyl)piperazine DM6XCPV TI TTAWNKZ DM6XCPV TN Norepinephrine transporter (NET) DM6XCPV MA Inhibitor DM6XCPV RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM6XCPV RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM6XDZA DI DM6XDZA DM6XDZA DN N7-hydroxy-2-methoxy-N1-phenylheptanediamide DM6XDZA TI TTSHTOI DM6XDZA TN Histone deacetylase 2 (HDAC2) DM6XDZA MA Inhibitor DM6XDZA RN Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. DM6XDZA RU https://pubmed.ncbi.nlm.nih.gov/17892933 DM6XFMT DI DM6XFMT DM6XFMT DN 1-Methyl-4-p-tolyl-piperidine-4-carbonitrile DM6XFMT TI TT3ROYC DM6XFMT TN Serotonin transporter (SERT) DM6XFMT MA Inhibitor DM6XFMT RN Synthesis, dopamine and serotonin transporter binding affinities of novel analogues of meperidine. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3273-6. DM6XFMT RU https://pubmed.ncbi.nlm.nih.gov/10612583 DM6XGFE DI DM6XGFE DM6XGFE DN NC1153 DM6XGFE TI TTT7PJU DM6XGFE TN Janus kinase 3 (JAK-3) DM6XGFE MA Inhibitor DM6XGFE RN Immunotherapy for De Novo renal transplantation: what's in the pipeline Drugs. 2006;66(13):1665-84. DM6XGFE RU https://pubmed.ncbi.nlm.nih.gov/16978033 DM6XHUZ DI DM6XHUZ DM6XHUZ DN PD176078 DM6XHUZ TI TTXHYV6 DM6XHUZ TN Voltage-gated L-type calcium channel (L-CaC) DM6XHUZ MA Blocker DM6XHUZ RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DM6XHUZ RU https://pubmed.ncbi.nlm.nih.gov/19442208 DM6XLZ0 DI DM6XLZ0 DM6XLZ0 DN 4-Benzyl-1-chroman-2-ylmethyl-piperidine DM6XLZ0 TI TTEX248 DM6XLZ0 TN Dopamine D2 receptor (D2R) DM6XLZ0 MA Inhibitor DM6XLZ0 RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DM6XLZ0 RU https://pubmed.ncbi.nlm.nih.gov/15634021 DM6XLZ0 DI DM6XLZ0 DM6XLZ0 DN 4-Benzyl-1-chroman-2-ylmethyl-piperidine DM6XLZ0 TI TTSQIFT DM6XLZ0 TN 5-HT 1A receptor (HTR1A) DM6XLZ0 MA Inhibitor DM6XLZ0 RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DM6XLZ0 RU https://pubmed.ncbi.nlm.nih.gov/15634021 DM6XM1D DI DM6XM1D DM6XM1D DN RO116-9132/238 DM6XM1D TI TTU3Y87 DM6XM1D TN CCR3 messenger RNA (CCR3 mRNA) DM6XM1D MA Antagonist DM6XM1D RN Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9. DM6XM1D RU https://pubmed.ncbi.nlm.nih.gov/12070060 DM6XO72 DI DM6XO72 DM6XO72 DN BRL 52974 DM6XO72 TI TTQW87Y DM6XO72 TN Opioid receptor kappa (OPRK1) DM6XO72 MA Agonist DM6XO72 RN The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. DM6XO72 RU https://pubmed.ncbi.nlm.nih.gov/10640321 DM6XTBI DI DM6XTBI DM6XTBI DN 3-(4-aminophenyl)quinoxaline-5-carboxamide DM6XTBI TI TTVDSZ0 DM6XTBI TN Poly [ADP-ribose] polymerase 1 (PARP1) DM6XTBI MA Inhibitor DM6XTBI RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DM6XTBI RU https://pubmed.ncbi.nlm.nih.gov/19125579 DM6XYCU DI DM6XYCU DM6XYCU DN N-methyl LTC4 DM6XYCU TI TTGKOY9 DM6XYCU TN Leukotriene CysLT1 receptor (CYSLTR1) DM6XYCU MA Agonist DM6XYCU RN Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8. DM6XYCU RU https://pubmed.ncbi.nlm.nih.gov/21078884 DM6XYCU DI DM6XYCU DM6XYCU DN N-methyl LTC4 DM6XYCU TI TT0PZR5 DM6XYCU TN Leukotriene CysLT2 receptor (CYSLTR2) DM6XYCU MA Agonist DM6XYCU RN Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8. DM6XYCU RU https://pubmed.ncbi.nlm.nih.gov/21078884 DM6Y1QF DI DM6Y1QF DM6Y1QF DN BMS-488516 DM6Y1QF TI TT3C80U DM6Y1QF TN T-cell-specific kinase (ITK) DM6Y1QF MA Inhibitor DM6Y1QF RN Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3. DM6Y1QF RU https://pubmed.ncbi.nlm.nih.gov/2115893 DM6Y2KW DI DM6Y2KW DM6Y2KW DN 3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile DM6Y2KW TI TTEAID7 DM6Y2KW TN Trypanosoma Cruzipain (Trypano CYSP) DM6Y2KW MA Inhibitor DM6Y2KW RN Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51. DM6Y2KW RU https://pubmed.ncbi.nlm.nih.gov/19908840 DM6Y2XG DI DM6Y2XG DM6Y2XG DN LY-389795 DM6Y2XG TI TT8A9EF DM6Y2XG TN Metabotropic glutamate receptor 3 (mGluR3) DM6Y2XG MA Inhibitor DM6Y2XG RN Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40. DM6Y2XG RU https://pubmed.ncbi.nlm.nih.gov/17228865 DM6Y2XG DI DM6Y2XG DM6Y2XG DN LY-389795 DM6Y2XG TI TTXJ47W DM6Y2XG TN Metabotropic glutamate receptor 2 (mGluR2) DM6Y2XG MA Inhibitor DM6Y2XG RN Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40. DM6Y2XG RU https://pubmed.ncbi.nlm.nih.gov/17228865 DM6Y2XK DI DM6Y2XK DM6Y2XK DN 3-(1H-indol-3-yl)-N,N-dimethylpropan-1-amine DM6Y2XK TI TT3ROYC DM6Y2XK TN Serotonin transporter (SERT) DM6Y2XK MA Inhibitor DM6Y2XK RN Conformationally restricted homotryptamines. Part 4: Heterocyclic and naphthyl analogs of a potent selective serotonin reuptake inhibitor. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5647-51. DM6Y2XK RU https://pubmed.ncbi.nlm.nih.gov/17766113 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTUNARX DM6Y3A0 TN Carbonic anhydrase (CA) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTZHA0O DM6Y3A0 TN Carbonic anhydrase IV (CA-IV) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTHQPL7 DM6Y3A0 TN Carbonic anhydrase I (CA-I) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTEYTKG DM6Y3A0 TN Carbonic anhydrase XIV (CA-XIV) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTCFSPE DM6Y3A0 TN Carbonic anhydrase VI (CA-VI) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTE5VG0 DM6Y3A0 TN P-selectin (SELP) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/17302397 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TT2LVK8 DM6Y3A0 TN Carbonic anhydrase IX (CA-IX) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTSYM0R DM6Y3A0 TN Carbonic anhydrase XII (CA-XII) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y3A0 DI DM6Y3A0 DM6Y3A0 DN GALLICACID DM6Y3A0 TI TTANPDJ DM6Y3A0 TN Carbonic anhydrase II (CA-II) DM6Y3A0 MA Inhibitor DM6Y3A0 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM6Y3A0 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM6Y7QM DI DM6Y7QM DM6Y7QM DN R116031 DM6Y7QM TI TTZPO1L DM6Y7QM TN Substance-P receptor (TACR1) DM6Y7QM MA Antagonist DM6Y7QM RN Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist. J Pharmacol Exp Ther. 2002 Aug;302(2):696-709. DM6Y7QM RU https://pubmed.ncbi.nlm.nih.gov/12130734 DM6YBZR DI DM6YBZR DM6YBZR DN 5-Chloro-2-methyl-3H-quinazolin-4-one DM6YBZR TI TTVDSZ0 DM6YBZR TN Poly [ADP-ribose] polymerase 1 (PARP1) DM6YBZR MA Inhibitor DM6YBZR RN Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem. 2004 Aug 12;47(17):4151-4. DM6YBZR RU https://pubmed.ncbi.nlm.nih.gov/15293985 DM6YD3U DI DM6YD3U DM6YD3U DN 6-fluorotryptophan DM6YD3U TI TT3KLDP DM6YD3U TN L-Tryptophan hydroxylase 2 (TPH2) DM6YD3U MA Inhibitor DM6YD3U RN (+)-6-fluorotryptophan, an inhibitor of tryptophan hydroxylase: sleep and wakefulness in the rat. Neuropharmacology. 1981 Apr;20(4):335-9. DM6YD3U RU https://pubmed.ncbi.nlm.nih.gov/6457252 DM6YD3U DI DM6YD3U DM6YD3U DN 6-fluorotryptophan DM6YD3U TI TTZSJHV DM6YD3U TN Tryptophan 5-hydroxylase 1 (TPH1) DM6YD3U MA Inhibitor DM6YD3U RN (+)-6-fluorotryptophan, an inhibitor of tryptophan hydroxylase: sleep and wakefulness in the rat. Neuropharmacology. 1981 Apr;20(4):335-9. DM6YD3U RU https://pubmed.ncbi.nlm.nih.gov/6457252 DM6YEW4 DI DM6YEW4 DM6YEW4 DN Methyl Mercury Ion DM6YEW4 TI TTANPDJ DM6YEW4 TN Carbonic anhydrase II (CA-II) DM6YEW4 MA Inhibitor DM6YEW4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6YEW4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6YEW4 DI DM6YEW4 DM6YEW4 DN Methyl Mercury Ion DM6YEW4 TI TTR0SWN DM6YEW4 TN M-phase inducer phosphatase 2 (MPIP2) DM6YEW4 MA Inhibitor DM6YEW4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6YEW4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6YGQ3 DI DM6YGQ3 DM6YGQ3 DN (6-Methoxy-2-naphthyl)-2-aminopropane DM6YGQ3 TI TT3WG5C DM6YGQ3 TN Monoamine oxidase type A (MAO-A) DM6YGQ3 MA Inhibitor DM6YGQ3 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DM6YGQ3 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DM6YGQ3 DI DM6YGQ3 DM6YGQ3 DN (6-Methoxy-2-naphthyl)-2-aminopropane DM6YGQ3 TI TTGP7BY DM6YGQ3 TN Monoamine oxidase type B (MAO-B) DM6YGQ3 MA Inhibitor DM6YGQ3 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DM6YGQ3 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DM6YHBR DI DM6YHBR DM6YHBR DN 6-O-Phosphoryl Inosine Monophosphate DM6YHBR TI TTYQ4AE DM6YHBR TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DM6YHBR MA Inhibitor DM6YHBR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM6YHBR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM6YJOU DI DM6YJOU DM6YJOU DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile DM6YJOU TI TTAWNKZ DM6YJOU TN Norepinephrine transporter (NET) DM6YJOU MA Inhibitor DM6YJOU RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM6YJOU RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM6YJOU DI DM6YJOU DM6YJOU DN 3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile DM6YJOU TI TT3ROYC DM6YJOU TN Serotonin transporter (SERT) DM6YJOU MA Inhibitor DM6YJOU RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM6YJOU RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM6YON7 DI DM6YON7 DM6YON7 DN 4-Indan-1-ylmethyl-phenylamine DM6YON7 TI TTJS8PY DM6YON7 TN 5-HT 6 receptor (HTR6) DM6YON7 MA Inhibitor DM6YON7 RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DM6YON7 RU https://pubmed.ncbi.nlm.nih.gov/15808453 DM6YRVT DI DM6YRVT DM6YRVT DN Tyr-Pro-Phe-D-Phg-NH2 DM6YRVT TI TTKWM86 DM6YRVT TN Opioid receptor mu (MOP) DM6YRVT MA Inhibitor DM6YRVT RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DM6YRVT RU https://pubmed.ncbi.nlm.nih.gov/16682191 DM6YSG3 DI DM6YSG3 DM6YSG3 DN LIQUIRTIGENIN DM6YSG3 TI TT7RJY8 DM6YSG3 TN Xanthine dehydrogenase/oxidase (XDH) DM6YSG3 MA Inhibitor DM6YSG3 RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DM6YSG3 RU https://pubmed.ncbi.nlm.nih.gov/3379415 DM6YSG3 DI DM6YSG3 DM6YSG3 DN LIQUIRTIGENIN DM6YSG3 TI TTSZLWK DM6YSG3 TN Aromatase (CYP19A1) DM6YSG3 MA Inhibitor DM6YSG3 RN Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70. DM6YSG3 RU https://pubmed.ncbi.nlm.nih.gov/18778944 DM6Z3I8 DI DM6Z3I8 DM6Z3I8 DN 3-chloro-4-(o-tolylthio)benzonitrile DM6Z3I8 TI TTKPW01 DM6Z3I8 TN Androgen receptor messenger RNA (AR mRNA) DM6Z3I8 MA Inhibitor DM6Z3I8 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM6Z3I8 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM6Z5EK DI DM6Z5EK DM6Z5EK DN 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK TI TTSZLWK DM6Z5EK TN Aromatase (CYP19A1) DM6Z5EK MA Inhibitor DM6Z5EK RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM6Z5EK RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM6Z5EK DI DM6Z5EK DM6Z5EK DN 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK TI TTRA5BZ DM6Z5EK TN Steroid 17-alpha-monooxygenase (S17AH) DM6Z5EK MA Inhibitor DM6Z5EK RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM6Z5EK RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM6Z5EK DI DM6Z5EK DM6Z5EK DN 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diol DM6Z5EK TI TTIQUX7 DM6Z5EK TN Steroid 11-beta-hydroxylase (CYP11B1) DM6Z5EK MA Inhibitor DM6Z5EK RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM6Z5EK RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM6Z9U4 DI DM6Z9U4 DM6Z9U4 DN 2-(4-Chlorophenyl)-2H-indazole-7-carboxamide DM6Z9U4 TI TTVDSZ0 DM6Z9U4 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM6Z9U4 MA Inhibitor DM6Z9U4 RN Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85. DM6Z9U4 RU https://pubmed.ncbi.nlm.nih.gov/19873981 DM6ZHWS DI DM6ZHWS DM6ZHWS DN H-Tyr-D-Ala-Aic-Asp-Val-Val-Gly-NH2 DM6ZHWS TI TTKWM86 DM6ZHWS TN Opioid receptor mu (MOP) DM6ZHWS MA Inhibitor DM6ZHWS RN Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56. DM6ZHWS RU https://pubmed.ncbi.nlm.nih.gov/8254604 DM6ZME7 DI DM6ZME7 DM6ZME7 DN ISIS 103489 DM6ZME7 TI TT1GV6C DM6ZME7 TN DUSP9 messenger RNA (DUSP9 mRNA) DM6ZME7 RN US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression. DM6ZME7 RU http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true DM6ZNR3 DI DM6ZNR3 DM6ZNR3 DN 2-(2,4-dichlorophenoxy)-5-phenethylphenol DM6ZNR3 TI TTNX2CS DM6ZNR3 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM6ZNR3 MA Inhibitor DM6ZNR3 RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DM6ZNR3 RU https://pubmed.ncbi.nlm.nih.gov/19217192 DM6ZOW4 DI DM6ZOW4 DM6ZOW4 DN PMID3941405C3d DM6ZOW4 TI TT4H0V2 DM6ZOW4 TN Dipeptidyl peptidase I (CTSC) DM6ZOW4 MA Inhibitor DM6ZOW4 RN Carboxyl-modified amino acids and peptides as protease inhibitors. J Med Chem. 1986 Jan;29(1):104-11. DM6ZOW4 RU https://pubmed.ncbi.nlm.nih.gov/3941405 DM6ZX1O DI DM6ZX1O DM6ZX1O DN 12S-HPETE DM6ZX1O TI TTMI6F5 DM6ZX1O TN Transient receptor potential cation channel V1 (TRPV1) DM6ZX1O MA Activator DM6ZX1O RN Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60. DM6ZX1O RU https://pubmed.ncbi.nlm.nih.gov/10823958 DM702WR DI DM702WR DM702WR DN LTC4 DM702WR TI TTGKOY9 DM702WR TN Leukotriene CysLT1 receptor (CYSLTR1) DM702WR MA Agonist DM702WR RN Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999 Jun 24;399(6738):789-93. DM702WR RU https://pubmed.ncbi.nlm.nih.gov/10391245 DM702WR DI DM702WR DM702WR DN LTC4 DM702WR TI TTMPART DM702WR TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DM702WR MA Agonist DM702WR RN The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27. DM702WR RU https://pubmed.ncbi.nlm.nih.gov/16990797 DM702WR DI DM702WR DM702WR DN LTC4 DM702WR TI TT0PZR5 DM702WR TN Leukotriene CysLT2 receptor (CYSLTR2) DM702WR MA Agonist DM702WR RN Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8. DM702WR RU https://pubmed.ncbi.nlm.nih.gov/11093801 DM704R5 DI DM704R5 DM704R5 DN 3-(6-Methoxynaphthalen-2-yl)-5-phenylpyridine DM704R5 TI TTIQUX7 DM704R5 TN Steroid 11-beta-hydroxylase (CYP11B1) DM704R5 MA Inhibitor DM704R5 RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DM704R5 RU https://pubmed.ncbi.nlm.nih.gov/18672861 DM704TL DI DM704TL DM704TL DN SB-207043 DM704TL TI TTJA1ZO DM704TL TN ITGB3 messenger RNA (ITGB3 mRNA) DM704TL MA Inhibitor DM704TL RN Preparation and Properties of a fibrinogen receptor antagonist containing the Arg-Gly-Asp sequence and nitroxide radicals, Bioorg. Med. Chem. Lett. 3(6):1179-1184 (1993). DM704TL RU http://www.sciencedirect.com/science/article/pii/S0960894X00803108 DM70H6P DI DM70H6P DM70H6P DN ADX-88178 DM70H6P TI TTICZ1O DM70H6P TN Metabotropic glutamate receptor 4 (mGluR4) DM70H6P MA Modulator DM70H6P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292). DM70H6P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=292 DM70HYT DI DM70HYT DM70HYT DN Tyr-Pro-Phe-Phg-NH2 DM70HYT TI TTKWM86 DM70HYT TN Opioid receptor mu (MOP) DM70HYT MA Inhibitor DM70HYT RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DM70HYT RU https://pubmed.ncbi.nlm.nih.gov/16682191 DM70I3V DI DM70I3V DM70I3V DN 7-fluoroindirubin-3-acetoxime DM70I3V TI TT9RTBL DM70I3V TN Aurora B messenger RNA (AURKB mRNA) DM70I3V MA Inhibitor DM70I3V RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM70I3V RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM70I3V DI DM70I3V DM70I3V DN 7-fluoroindirubin-3-acetoxime DM70I3V TI TTLYXIT DM70I3V TN Aurora kinase C (AURKC) DM70I3V MA Inhibitor DM70I3V RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DM70I3V RU https://pubmed.ncbi.nlm.nih.gov/17665890 DM70MPJ DI DM70MPJ DM70MPJ DN 9-Ethyl-2-methyl-beta-carboline-2-ium iodide DM70MPJ TI TT1RS9F DM70MPJ TN Acetylcholinesterase (AChE) DM70MPJ MA Inhibitor DM70MPJ RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DM70MPJ RU https://pubmed.ncbi.nlm.nih.gov/20361801 DM70MPJ DI DM70MPJ DM70MPJ DN 9-Ethyl-2-methyl-beta-carboline-2-ium iodide DM70MPJ TI TTEB0GD DM70MPJ TN Cholinesterase (BCHE) DM70MPJ MA Inhibitor DM70MPJ RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DM70MPJ RU https://pubmed.ncbi.nlm.nih.gov/20361801 DM70MRZ DI DM70MRZ DM70MRZ DN 4-(hexyl(methyl)amino)-N-(quinolin-3-yl)benzamide DM70MRZ TI TTMI6F5 DM70MRZ TN Transient receptor potential cation channel V1 (TRPV1) DM70MRZ MA Inhibitor DM70MRZ RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DM70MRZ RU https://pubmed.ncbi.nlm.nih.gov/18359227 DM70ODN DI DM70ODN DM70ODN DN 1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene DM70ODN TI TTE4KHA DM70ODN TN Amyloid beta A4 protein (APP) DM70ODN MA Inhibitor DM70ODN RN Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. DM70ODN RU https://pubmed.ncbi.nlm.nih.gov/16640346 DM70OIC DI DM70OIC DM70OIC DN DIHYDRORALOXIFENE DM70OIC TI TTOM3J0 DM70OIC TN Estrogen receptor beta (ESR2) DM70OIC MA Inhibitor DM70OIC RN Synthesis and biological activity of trans-2,3-dihydroraloxifene. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40. DM70OIC RU https://pubmed.ncbi.nlm.nih.gov/10328300 DM70OIC DI DM70OIC DM70OIC DN DIHYDRORALOXIFENE DM70OIC TI TTZAYWL DM70OIC TN Estrogen receptor (ESR) DM70OIC MA Inhibitor DM70OIC RN Synthesis and biological activity of trans-2,3-dihydroraloxifene. Bioorg Med Chem Lett. 1999 Apr 19;9(8):1137-40. DM70OIC RU https://pubmed.ncbi.nlm.nih.gov/10328300 DM70RDZ DI DM70RDZ DM70RDZ DN Metrenperone DM70RDZ TI TTYSN63 DM70RDZ TN 5-HT 2 receptor (5HT2R) DM70RDZ MA Antagonist DM70RDZ RN Cardiovascular response to intravenous administration of 5-hydroxytryptamine after type-2 receptor blockade, by metrenperone, in healthy calves. Vet J. 1999 Jan;157(1):31-7. DM70RDZ RU https://pubmed.ncbi.nlm.nih.gov/10030126 DM70SEQ DI DM70SEQ DM70SEQ DN PMID18800762C16 DM70SEQ TI TTIKWV4 DM70SEQ TN Geranyltranstransferase (FDPS) DM70SEQ MA Inhibitor DM70SEQ RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DM70SEQ RU https://pubmed.ncbi.nlm.nih.gov/18800762 DM70UQR DI DM70UQR DM70UQR DN FR221647 DM70UQR TI TTLP57V DM70UQR TN Adenosine deaminase (ADA) DM70UQR MA Inhibitor DM70UQR RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM70UQR RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM70YRT DI DM70YRT DM70YRT DN CRA_10655 DM70YRT TI TTGY7WI DM70YRT TN Urokinase-type plasminogen activator (PLAU) DM70YRT MA Inhibitor DM70YRT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM70YRT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM70YTF DI DM70YTF DM70YTF DN HTS-466284 DM70YTF TI TTP4520 DM70YTF TN TGF-beta receptor type I (TGFBR1) DM70YTF MA Inhibitor DM70YTF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM70YTF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM70ZIF DI DM70ZIF DM70ZIF DN (R)-2,11-Diaminoaporphine DM70ZIF TI TTSQIFT DM70ZIF TN 5-HT 1A receptor (HTR1A) DM70ZIF MA Inhibitor DM70ZIF RN Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. DM70ZIF RU https://pubmed.ncbi.nlm.nih.gov/18562201 DM70ZIF DI DM70ZIF DM70ZIF DN (R)-2,11-Diaminoaporphine DM70ZIF TI TTZFYLI DM70ZIF TN Dopamine D1 receptor (D1R) DM70ZIF MA Inhibitor DM70ZIF RN Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. DM70ZIF RU https://pubmed.ncbi.nlm.nih.gov/18562201 DM710KZ DI DM710KZ DM710KZ DN MG-1101 DM710KZ TI TT6F7GZ DM710KZ TN Parathyroid hormone (PTH) DM710KZ MA Modulator DM710KZ RN Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.J Bone Miner Res.2012 Aug;27(8):1811-20. DM710KZ RU https://www.ncbi.nlm.nih.gov/pubmed/22492501 DM715AS DI DM715AS DM715AS DN (S)-flurocarazolol DM715AS TI TTSQIFT DM715AS TN 5-HT 1A receptor (HTR1A) DM715AS MA Antagonist DM715AS RN The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4. DM715AS RU https://pubmed.ncbi.nlm.nih.gov/11512051 DM715AS DI DM715AS DM715AS DN (S)-flurocarazolol DM715AS TI TTK8CXU DM715AS TN 5-HT 1B receptor (HTR1B) DM715AS MA Antagonist DM715AS RN The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl). 2001 Aug;157(1):111-4. DM715AS RU https://pubmed.ncbi.nlm.nih.gov/11512051 DM715EC DI DM715EC DM715EC DN 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol DM715EC TI TTOM3J0 DM715EC TN Estrogen receptor beta (ESR2) DM715EC MA Inhibitor DM715EC RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM715EC RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM715EC DI DM715EC DM715EC DN 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-5-ol DM715EC TI TTZAYWL DM715EC TN Estrogen receptor (ESR) DM715EC MA Inhibitor DM715EC RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM715EC RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM71BIC DI DM71BIC DM71BIC DN LOR-220 DM71BIC TI TTHBTOP DM71BIC TN PI3-kinase gamma (PIK3CG) DM71BIC MA Inhibitor DM71BIC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DM71BIC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DM71EMN DI DM71EMN DM71EMN DN 3-(ethoxycarbonyl)phenylboronic acid DM71EMN TI TTDP1UC DM71EMN TN Fatty acid amide hydrolase (FAAH) DM71EMN MA Inhibitor DM71EMN RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DM71EMN RU https://pubmed.ncbi.nlm.nih.gov/18983140 DM71EUO DI DM71EUO DM71EUO DN 3-(4-Chlorophenyl)-2-nortropene DM71EUO TI TT3ROYC DM71EUO TN Serotonin transporter (SERT) DM71EUO MA Inhibitor DM71EUO RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DM71EUO RU https://pubmed.ncbi.nlm.nih.gov/19896846 DM71EUO DI DM71EUO DM71EUO DN 3-(4-Chlorophenyl)-2-nortropene DM71EUO TI TTVBI8W DM71EUO TN Dopamine transporter (DAT) DM71EUO MA Inhibitor DM71EUO RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DM71EUO RU https://pubmed.ncbi.nlm.nih.gov/19896846 DM71H65 DI DM71H65 DM71H65 DN ISIS 16121 DM71H65 TI TTHMYB1 DM71H65 TN E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA) DM71H65 RN US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression. DM71H65 RU http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true DM71HQL DI DM71HQL DM71HQL DN Tideglusib DM71HQL TI TTNHMO8 DM71HQL TN COVID-19 papain-like proteinase (PL-PRO) DM71HQL MA Inhibitor DM71HQL RN Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. DM71HQL RU https://pubmed.ncbi.nlm.nih.gov/32272481 DM71MO2 DI DM71MO2 DM71MO2 DN N6-Benzyl Adenosine-5'-Diphosphate DM71MO2 TI TT6PKBN DM71MO2 TN Proto-oncogene c-Src (SRC) DM71MO2 MA Inhibitor DM71MO2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM71MO2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM71P2O DI DM71P2O DM71P2O DN Tyr-Pro-Phe-Hfe-NH2 DM71P2O TI TTKWM86 DM71P2O TN Opioid receptor mu (MOP) DM71P2O MA Inhibitor DM71P2O RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DM71P2O RU https://pubmed.ncbi.nlm.nih.gov/16682191 DM71WQT DI DM71WQT DM71WQT DN AR-C133057XX DM71WQT TI TTF10I9 DM71WQT TN Nitric-oxide synthase inducible (NOS2) DM71WQT MA Inhibitor DM71WQT RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DM71WQT RU https://pubmed.ncbi.nlm.nih.gov/18849972 DM71WQT DI DM71WQT DM71WQT DN AR-C133057XX DM71WQT TI TTZUFI5 DM71WQT TN Nitric-oxide synthase brain (NOS1) DM71WQT MA Inhibitor DM71WQT RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DM71WQT RU https://pubmed.ncbi.nlm.nih.gov/18849972 DM7204O DI DM7204O DM7204O DN (E)-4-(2-(thiophen-2-yl)vinyl)benzenesulfonamide DM7204O TI TTVKILB DM7204O TN Prostaglandin G/H synthase 2 (COX-2) DM7204O MA Inhibitor DM7204O RN Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41. DM7204O RU https://pubmed.ncbi.nlm.nih.gov/20970329 DM724JF DI DM724JF DM724JF DN 5,7-Dimethoxy-3-pyridin-4-yl-quinoline DM724JF TI TT8FYO9 DM724JF TN Platelet-derived growth factor receptor alpha (PDGFRA) DM724JF MA Inhibitor DM724JF RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM724JF RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM724JF DI DM724JF DM724JF DN 5,7-Dimethoxy-3-pyridin-4-yl-quinoline DM724JF TI TTI7421 DM724JF TN Platelet-derived growth factor receptor beta (PDGFRB) DM724JF MA Inhibitor DM724JF RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DM724JF RU https://pubmed.ncbi.nlm.nih.gov/8064792 DM725FL DI DM725FL DM725FL DN PYY(22-36) DM725FL TI TTRK9JT DM725FL TN Neuropeptide Y receptor type 1 (NPY1R) DM725FL MA Inhibitor DM725FL RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DM725FL RU https://pubmed.ncbi.nlm.nih.gov/17055726 DM725FL DI DM725FL DM725FL DN PYY(22-36) DM725FL TI TTJ6WK9 DM725FL TN Neuropeptide Y receptor type 2 (NPY2R) DM725FL MA Inhibitor DM725FL RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DM725FL RU https://pubmed.ncbi.nlm.nih.gov/17055726 DM728RW DI DM728RW DM728RW DN BLX-301 DM728RW TI TTUE541 DM728RW TN Leukocyte surface antigen Leu-16 (CD20) DM728RW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DM728RW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DM7293Q DI DM7293Q DM7293Q DN CX-1001 DM7293Q TI TT3ROYC DM7293Q TN Serotonin transporter (SERT) DM7293Q MA Binder DM7293Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 928). DM7293Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=928 DM72AT8 DI DM72AT8 DM72AT8 DN Proxyfan DM72AT8 TI TT9JNIC DM72AT8 TN Histamine H3 receptor (H3R) DM72AT8 MA Antagonist DM72AT8 RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM72AT8 RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM72B86 DI DM72B86 DM72B86 DN GR 125487 DM72B86 TI TT07C3Y DM72B86 TN 5-HT 4 receptor (HTR4) DM72B86 MA Antagonist DM72B86 RN Cloning, expression and pharmacology of the mouse 5-HT(4L) receptor. FEBS Lett. 1996 Nov 25;398(1):19-25. DM72B86 RU https://pubmed.ncbi.nlm.nih.gov/8946946 DM72BSO DI DM72BSO DM72BSO DN N-(2-benzyl),N-(1-methylpyrrol-2-ylmethyl)amine DM72BSO TI TT3WG5C DM72BSO TN Monoamine oxidase type A (MAO-A) DM72BSO MA Inhibitor DM72BSO RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM72BSO RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM72DO1 DI DM72DO1 DM72DO1 DN EPI-0030 DM72DO1 TI TTUTJGQ DM72DO1 TN Vascular endothelial growth factor receptor 2 (KDR) DM72DO1 MA Modulator DM72DO1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DM72DO1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DM72EM9 DI DM72EM9 DM72EM9 DN 8-(3,3-Dimethyl-butoxy)-quinolin-2-ylamine DM72EM9 TI TTX4RTB DM72EM9 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM72EM9 MA Inhibitor DM72EM9 RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM72EM9 RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM72ES1 DI DM72ES1 DM72ES1 DN R(-)amphetamine DM72ES1 TI TTIU98M DM72ES1 TN Trace amine-associated receptor-1 (TAAR1) DM72ES1 MA Agonist DM72ES1 RN The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav. 2007 Oct;6(7):628-39. DM72ES1 RU https://pubmed.ncbi.nlm.nih.gov/17212650 DM72GLY DI DM72GLY DM72GLY DN MCL-1-specific antisense oligonucleotide + nilotinib (AMN107) DM72GLY TI TTN6ORK DM72GLY TN Mcl-1 messenger RNA (MCL-1 mRNA) DM72GLY RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM72GLY RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM72HW3 DI DM72HW3 DM72HW3 DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-L-Ala-) DM72HW3 TI TTBID49 DM72HW3 TN C-X-C chemokine receptor type 4 (CXCR4) DM72HW3 MA Inhibitor DM72HW3 RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DM72HW3 RU https://pubmed.ncbi.nlm.nih.gov/17228861 DM72US0 DI DM72US0 DM72US0 DN MRE 3008F20 DM72US0 TI TTNE7KG DM72US0 TN Adenosine A2b receptor (ADORA2B) DM72US0 MA Antagonist DM72US0 RN Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64. DM72US0 RU https://pubmed.ncbi.nlm.nih.gov/16518376 DM72US0 DI DM72US0 DM72US0 DN MRE 3008F20 DM72US0 TI TTK25J1 DM72US0 TN Adenosine A1 receptor (ADORA1) DM72US0 MA Antagonist DM72US0 RN Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64. DM72US0 RU https://pubmed.ncbi.nlm.nih.gov/16518376 DM72US0 DI DM72US0 DM72US0 DN MRE 3008F20 DM72US0 TI TTJFY5U DM72US0 TN Adenosine A3 receptor (ADORA3) DM72US0 MA Agonist DM72US0 RN [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. DM72US0 RU https://pubmed.ncbi.nlm.nih.gov/10779381 DM72WQ3 DI DM72WQ3 DM72WQ3 DN Kodaistatin C DM72WQ3 TI TT1KPBZ DM72WQ3 TN Glucose-6-phosphate translocase (SLC37A4) DM72WQ3 MA Inhibitor DM72WQ3 RN Kodaistatins, novel inhibitors of glucose-6-phosphate translocase T1 from Aspergillus terreus thom DSM 11247. Isolation and structural elucidation. J Antibiot (Tokyo). 2000 Jul;53(7):677-86. DM72WQ3 RU https://pubmed.ncbi.nlm.nih.gov/10994809 DM734QB DI DM734QB DM734QB DN GSK-3beta inhibitor XI DM734QB TI TTRSMW9 DM734QB TN Glycogen synthase kinase-3 beta (GSK-3B) DM734QB MA Inhibitor DM734QB RN Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Bioorg Med Chem. 2004 Jun 15;12(12):3167-85. DM734QB RU https://pubmed.ncbi.nlm.nih.gov/15158785 DM736T8 DI DM736T8 DM736T8 DN PT-401 DM736T8 TI TTAUX24 DM736T8 TN Erythropoietin Receptor (EPOR) DM736T8 MA Stimulator DM736T8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DM736T8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DM7390Y DI DM7390Y DM7390Y DN ethyketazocine DM7390Y TI TT27RFC DM7390Y TN Opioid receptor delta (OPRD1) DM7390Y MA Agonist DM7390Y RN Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40. DM7390Y RU https://pubmed.ncbi.nlm.nih.gov/8393575 DM7390Y DI DM7390Y DM7390Y DN ethyketazocine DM7390Y TI TTQW87Y DM7390Y TN Opioid receptor kappa (OPRK1) DM7390Y MA Agonist DM7390Y RN Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997 Aug;282(2):676-84. DM7390Y RU https://pubmed.ncbi.nlm.nih.gov/9262330 DM7391H DI DM7391H DM7391H DN 2-Amino-6-(2-chloro-phenylsulfanyl)-benzonitrile DM7391H TI TT84ETX DM7391H TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM7391H MA Inhibitor DM7391H RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM7391H RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM739SQ DI DM739SQ DM739SQ DN 4-methoxyphenyl 1-(4-butoxyphenyl)propylcarbamate DM739SQ TI TTDP1UC DM739SQ TN Fatty acid amide hydrolase (FAAH) DM739SQ MA Inhibitor DM739SQ RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM739SQ RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM73AEL DI DM73AEL DM73AEL DN YM44781 DM73AEL TI TTYO0A3 DM73AEL TN Substance-K receptor (TACR2) DM73AEL MA Antagonist DM73AEL RN Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model. Pharmacology. 2002 May;65(2):96-102. DM73AEL RU https://pubmed.ncbi.nlm.nih.gov/11937780 DM73E0G DI DM73E0G DM73E0G DN ST-2741 DM73E0G TI TT5ZKDI DM73E0G TN Histone deacetylase 6 (HDAC6) DM73E0G MA Inhibitor DM73E0G RN Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3. DM73E0G RU https://pubmed.ncbi.nlm.nih.gov/19359173 DM73F5A DI DM73F5A DM73F5A DN 1,2,4-Triazole DM73F5A TI TTANPDJ DM73F5A TN Carbonic anhydrase II (CA-II) DM73F5A MA Inhibitor DM73F5A RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM73F5A RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM73FWA DI DM73FWA DM73FWA DN 2-Amino-1-(4-ethylthiophenyl)butane DM73FWA TI TT3ROYC DM73FWA TN Serotonin transporter (SERT) DM73FWA MA Inhibitor DM73FWA RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM73FWA RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM73NIE DI DM73NIE DM73NIE DN ISIS 138647 DM73NIE TI TTTEOPU DM73NIE TN Helicase-moi messenger RNA (DICER1 mRNA) DM73NIE RN US patent application no. 7,427,470, Antisense modulation of helicase-moi expression. DM73NIE RU http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true DM73O2A DI DM73O2A DM73O2A DN 9-Phenyl-9H-purin-6-ylamine DM73O2A TI TTK25J1 DM73O2A TN Adenosine A1 receptor (ADORA1) DM73O2A MA Inhibitor DM73O2A RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DM73O2A RU https://pubmed.ncbi.nlm.nih.gov/1895305 DM73OTF DI DM73OTF DM73OTF DN DIHYDROKAEMPFEROL DM73OTF TI TT7RJY8 DM73OTF TN Xanthine dehydrogenase/oxidase (XDH) DM73OTF MA Inhibitor DM73OTF RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DM73OTF RU https://pubmed.ncbi.nlm.nih.gov/3379415 DM73PXI DI DM73PXI DM73PXI DN N,N-Dimethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide DM73PXI TI TTPTXIN DM73PXI TN Translocator protein (TSPO) DM73PXI MA Inhibitor DM73PXI RN Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20. DM73PXI RU https://pubmed.ncbi.nlm.nih.gov/8411007 DM73SC6 DI DM73SC6 DM73SC6 DN SK509 DM73SC6 TI TTCIHJA DM73SC6 TN Coagulation factor Xa (F10) DM73SC6 MA Inhibitor DM73SC6 RN The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49. DM73SC6 RU https://pubmed.ncbi.nlm.nih.gov/11899249 DM73SC6 DI DM73SC6 DM73SC6 DN SK509 DM73SC6 TI TTJVCG0 DM73SC6 TN Bacterial Sporulation kinase A (Bact kinA) DM73SC6 MA Inhibitor DM73SC6 RN Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem. 2002 Apr;10(4):855-67. DM73SC6 RU https://pubmed.ncbi.nlm.nih.gov/11836091 DM73TPQ DI DM73TPQ DM73TPQ DN (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid DM73TPQ TI TTZMAO3 DM73TPQ TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM73TPQ MA Inhibitor DM73TPQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM73TPQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM73WB2 DI DM73WB2 DM73WB2 DN KNI-10762 DM73WB2 TI TTXMNHO DM73WB2 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM73WB2 MA Inhibitor DM73WB2 RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DM73WB2 RU https://pubmed.ncbi.nlm.nih.gov/20634066 DM73ZHV DI DM73ZHV DM73ZHV DN N-benzyl-1H-pyrrole-2-carboxamide DM73ZHV TI TT3WG5C DM73ZHV TN Monoamine oxidase type A (MAO-A) DM73ZHV MA Inhibitor DM73ZHV RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM73ZHV RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM73ZMG DI DM73ZMG DM73ZMG DN C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 DM73ZMG TI TTD0CIQ DM73ZMG TN Melanocortin receptor 4 (MC4R) DM73ZMG MA Inhibitor DM73ZMG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM73ZMG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM73ZMG DI DM73ZMG DM73ZMG DN C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 DM73ZMG TI TT0MV2T DM73ZMG TN Melanocortin receptor 1 (MC1R) DM73ZMG MA Inhibitor DM73ZMG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM73ZMG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM73ZMG DI DM73ZMG DM73ZMG DN C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 DM73ZMG TI TTEOSZT DM73ZMG TN Melanocortin receptor (MCR) DM73ZMG MA Inhibitor DM73ZMG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM73ZMG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM73ZMG DI DM73ZMG DM73ZMG DN C[Nle-Nle-D-Nal(2')-Arg-Trp-Glu]-NH2 DM73ZMG TI TTNI91K DM73ZMG TN Melanocortin receptor 3 (MC3R) DM73ZMG MA Inhibitor DM73ZMG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM73ZMG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM742IJ DI DM742IJ DM742IJ DN 2-Piperazin-1-yl-benzonitrile DM742IJ TI TTSQIFT DM742IJ TN 5-HT 1A receptor (HTR1A) DM742IJ MA Inhibitor DM742IJ RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM742IJ RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM742IJ DI DM742IJ DM742IJ DN 2-Piperazin-1-yl-benzonitrile DM742IJ TI TT6MSOK DM742IJ TN 5-HT 1D receptor (HTR1D) DM742IJ MA Inhibitor DM742IJ RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM742IJ RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM742L9 DI DM742L9 DM742L9 DN [11C]xanomeline DM742L9 TI TTOXS3C DM742L9 TN Muscarinic acetylcholine receptor (CHRM) DM742L9 MA Agonist DM742L9 RN PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. Dementia. 1996 Jul-Aug;7(4):187-95. DM742L9 RU https://pubmed.ncbi.nlm.nih.gov/8835881 DM743XB DI DM743XB DM743XB DN BAY 50-7952 DM743XB TI TTS7LWX DM743XB TN Bacterial DNA gyrase B (Bact gyrB) DM743XB MA Inhibitor DM743XB RN seco-Cyclothialidines: new concise synthesis, inhibitory activity toward bacterial and human DNA topoisomerases, and antibacterial properties. J Med Chem. 2001 Feb 15;44(4):619-26. DM743XB RU https://pubmed.ncbi.nlm.nih.gov/11170652 DM74G6Q DI DM74G6Q DM74G6Q DN 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol DM74G6Q TI TTN9D8E DM74G6Q TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM74G6Q MA Inhibitor DM74G6Q RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DM74G6Q RU https://pubmed.ncbi.nlm.nih.gov/10425109 DM74G6Q DI DM74G6Q DM74G6Q DN 4-[2-(4-Benzyl-piperidin-1-yl)-ethoxy]-phenol DM74G6Q TI TTLD29N DM74G6Q TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM74G6Q MA Inhibitor DM74G6Q RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DM74G6Q RU https://pubmed.ncbi.nlm.nih.gov/10425109 DM74GWO DI DM74GWO DM74GWO DN 4-Carbazol-9-yl-butyric acid DM74GWO TI TTHWMFZ DM74GWO TN Fatty acid-binding protein 4 (FABP4) DM74GWO MA Inhibitor DM74GWO RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DM74GWO RU https://pubmed.ncbi.nlm.nih.gov/15357969 DM74GWO DI DM74GWO DM74GWO DN 4-Carbazol-9-yl-butyric acid DM74GWO TI TTNT2S6 DM74GWO TN Fatty acid-binding protein 5 (FABP5) DM74GWO MA Inhibitor DM74GWO RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DM74GWO RU https://pubmed.ncbi.nlm.nih.gov/15357969 DM74IWX DI DM74IWX DM74IWX DN (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM74IWX TI TT3ROYC DM74IWX TN Serotonin transporter (SERT) DM74IWX MA Inhibitor DM74IWX RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM74IWX RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM74IWX DI DM74IWX DM74IWX DN (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM74IWX TI TTVBI8W DM74IWX TN Dopamine transporter (DAT) DM74IWX MA Inhibitor DM74IWX RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM74IWX RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM74IWX DI DM74IWX DM74IWX DN (R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol DM74IWX TI TTAWNKZ DM74IWX TN Norepinephrine transporter (NET) DM74IWX MA Inhibitor DM74IWX RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DM74IWX RU https://pubmed.ncbi.nlm.nih.gov/20471260 DM74J10 DI DM74J10 DM74J10 DN LSP1-2111 DM74J10 TI TT0I76D DM74J10 TN Metabotropic glutamate receptor 7 (mGluR7) DM74J10 MA Agonist DM74J10 RN Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009 Oct;23(10):3619-28. DM74J10 RU https://pubmed.ncbi.nlm.nih.gov/19525404 DM74J10 DI DM74J10 DM74J10 DN LSP1-2111 DM74J10 TI TTICZ1O DM74J10 TN Metabotropic glutamate receptor 4 (mGluR4) DM74J10 MA Agonist DM74J10 RN Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009 Oct;23(10):3619-28. DM74J10 RU https://pubmed.ncbi.nlm.nih.gov/19525404 DM74J10 DI DM74J10 DM74J10 DN LSP1-2111 DM74J10 TI TTWRP2F DM74J10 TN Metabotropic glutamate receptor 6 (mGluR6) DM74J10 MA Agonist DM74J10 RN Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009 Oct;23(10):3619-28. DM74J10 RU https://pubmed.ncbi.nlm.nih.gov/19525404 DM74JL8 DI DM74JL8 DM74JL8 DN 5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole DM74JL8 TI TTRAMF0 DM74JL8 TN Plasmodium Cytochrome B (Malaria MT-CYB) DM74JL8 MA Inhibitor DM74JL8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM74JL8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM74KHG DI DM74KHG DM74KHG DN N-{4-[(benzylamino)sulfonyl]-1-naphthyl}benzamide DM74KHG TI TTE836A DM74KHG TN C-C chemokine receptor type 8 (CCR8) DM74KHG MA Inhibitor DM74KHG RN Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84. DM74KHG RU https://pubmed.ncbi.nlm.nih.gov/17266208 DM74R0E DI DM74R0E DM74R0E DN 1-((R)-2-aminopropyl)-1H-indazol-6-ol DM74R0E TI TTJQOD7 DM74R0E TN 5-HT 2A receptor (HTR2A) DM74R0E MA Inhibitor DM74R0E RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM74R0E RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM74R0E DI DM74R0E DM74R0E DN 1-((R)-2-aminopropyl)-1H-indazol-6-ol DM74R0E TI TT0K1SC DM74R0E TN 5-HT 2B receptor (HTR2B) DM74R0E MA Inhibitor DM74R0E RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM74R0E RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM74R0E DI DM74R0E DM74R0E DN 1-((R)-2-aminopropyl)-1H-indazol-6-ol DM74R0E TI TTWJBZ5 DM74R0E TN 5-HT 2C receptor (HTR2C) DM74R0E MA Inhibitor DM74R0E RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM74R0E RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM74RMP DI DM74RMP DM74RMP DN 1-phenyl-1H-indole-2,3-dione DM74RMP TI TTMF541 DM74RMP TN Liver carboxylesterase (CES1) DM74RMP MA Inhibitor DM74RMP RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM74RMP RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM74X5O DI DM74X5O DM74X5O DN 2'-3'-dideoxy-7-deaza-guaninetriphosphate DM74X5O TI TT84ETX DM74X5O TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM74X5O MA Inhibitor DM74X5O RN Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700. DM74X5O RU https://pubmed.ncbi.nlm.nih.gov/15801860 DM751OH DI DM751OH DM751OH DN Rotungenic acid DM751OH TI TTELIN2 DM751OH TN PTPN1 messenger RNA (PTPN1 mRNA) DM751OH MA Inhibitor DM751OH RN Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8. DM751OH RU https://pubmed.ncbi.nlm.nih.gov/18798681 DM75EAT DI DM75EAT DM75EAT DN (4-Fluoro-phenyl)-(9H-purin-6-yl)-amine DM75EAT TI TTZN7RP DM75EAT TN Rho-associated protein kinase 1 (ROCK1) DM75EAT MA Inhibitor DM75EAT RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DM75EAT RU https://pubmed.ncbi.nlm.nih.gov/15689155 DM75F1Q DI DM75F1Q DM75F1Q DN 3-[4-(4-phenoxybenzoyl)phenyl]propanoic acid DM75F1Q TI TTT02K8 DM75F1Q TN Steroid 5-alpha-reductase 2 (SRD5A2) DM75F1Q MA Inhibitor DM75F1Q RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DM75F1Q RU https://pubmed.ncbi.nlm.nih.gov/16420060 DM75OHG DI DM75OHG DM75OHG DN (E)-4-Methyl-6-(prop-1-enyl)pyridin-2-amine DM75OHG TI TTF10I9 DM75OHG TN Nitric-oxide synthase inducible (NOS2) DM75OHG MA Inhibitor DM75OHG RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DM75OHG RU https://pubmed.ncbi.nlm.nih.gov/19323559 DM75OR8 DI DM75OR8 DM75OR8 DN 1,2-dicyclohexylethane-1,2-dione DM75OR8 TI TTMF541 DM75OR8 TN Liver carboxylesterase (CES1) DM75OR8 MA Inhibitor DM75OR8 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DM75OR8 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DM75Q34 DI DM75Q34 DM75Q34 DN NADPH DM75Q34 TI TTBE4IR DM75Q34 TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DM75Q34 MA Cofactor DM75Q34 RN Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochem Biophys Res Commun. 2003 Mar 28;303(1):387-92. DM75Q34 RU https://pubmed.ncbi.nlm.nih.gov/12646215 DM75SO4 DI DM75SO4 DM75SO4 DN Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide DM75SO4 TI TTZPWGN DM75SO4 TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DM75SO4 MA Inhibitor DM75SO4 RN Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8. DM75SO4 RU https://pubmed.ncbi.nlm.nih.gov/16876404 DM75SO4 DI DM75SO4 DM75SO4 DN Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide DM75SO4 TI TT729IR DM75SO4 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM75SO4 MA Inhibitor DM75SO4 RN Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8. DM75SO4 RU https://pubmed.ncbi.nlm.nih.gov/16876404 DM75TJ1 DI DM75TJ1 DM75TJ1 DN 2,4-difluorophenyl 4-butoxybenzylcarbamate DM75TJ1 TI TTDP1UC DM75TJ1 TN Fatty acid amide hydrolase (FAAH) DM75TJ1 MA Inhibitor DM75TJ1 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM75TJ1 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM75U9X DI DM75U9X DM75U9X DN Benzimidazole 5-carboxamide DM75U9X TI TT84ETX DM75U9X TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM75U9X MA Inhibitor DM75U9X RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DM75U9X RU https://pubmed.ncbi.nlm.nih.gov/18764719 DM75UK8 DI DM75UK8 DM75UK8 DN AMD3101 DM75UK8 TI TT2BVUA DM75UK8 TN C-X-C chemokine receptor type 6 (CXCR6) DM75UK8 MA Antagonist DM75UK8 RN Opportunities and challenges in targeting HIV entry. Curr Opin Pharmacol. 2002 Oct;2(5):529-33. DM75UK8 RU https://pubmed.ncbi.nlm.nih.gov/12324254 DM75VHN DI DM75VHN DM75VHN DN FR191413 DM75VHN TI TTGY8IW DM75VHN TN B2 bradykinin receptor (BDKRB2) DM75VHN MA Agonist DM75VHN RN Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks. J Med Chem. 2004 May 20;47(11):2853-63. DM75VHN RU https://pubmed.ncbi.nlm.nih.gov/15139763 DM75WN4 DI DM75WN4 DM75WN4 DN 2-[(2-methyl-4-thiazolyl)ethynyl]pyrazine DM75WN4 TI TTHS256 DM75WN4 TN Metabotropic glutamate receptor 5 (mGluR5) DM75WN4 MA Inhibitor DM75WN4 RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DM75WN4 RU https://pubmed.ncbi.nlm.nih.gov/16451073 DM762FY DI DM762FY DM762FY DN 5-propenyl-arabinofuranosyluracil 5'-triphosphate DM762FY TI TTIU7X1 DM762FY TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM762FY MA Inhibitor DM762FY RN Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. JMed Virol. 1988 Dec;26(4):353-62. DM762FY RU https://pubmed.ncbi.nlm.nih.gov/3145322 DM762G3 DI DM762G3 DM762G3 DN 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin DM762G3 TI TT3WG5C DM762G3 TN Monoamine oxidase type A (MAO-A) DM762G3 MA Inhibitor DM762G3 RN Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007 Nov 15;50(23):5848-52. DM762G3 RU https://pubmed.ncbi.nlm.nih.gov/17915852 DM762G3 DI DM762G3 DM762G3 DN 7-(3-chlorobenzyloxy)-4-carboxaldehyde-coumarin DM762G3 TI TTGP7BY DM762G3 TN Monoamine oxidase type B (MAO-B) DM762G3 MA Inhibitor DM762G3 RN Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem. 2007 Nov 15;50(23):5848-52. DM762G3 RU https://pubmed.ncbi.nlm.nih.gov/17915852 DM762HQ DI DM762HQ DM762HQ DN Ethyl 2-(2-oxohexadecanamido)acetate DM762HQ TI TTT1JVS DM762HQ TN Cytosolic phospholipase A2 (GIVA cPLA2) DM762HQ MA Inhibitor DM762HQ RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DM762HQ RU https://pubmed.ncbi.nlm.nih.gov/18993078 DM769YQ DI DM769YQ DM769YQ DN PMID7932551C9 DM769YQ TI TTPADOQ DM769YQ TN HMG-CoA reductase (HMGCR) DM769YQ MA Inhibitor DM769YQ RN Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors. The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system. J Med Chem. 1994 Sep 30;37(20):3240-6. DM769YQ RU https://pubmed.ncbi.nlm.nih.gov/7932551 DM76AUO DI DM76AUO DM76AUO DN Folate gamma-L-phenylalaninehydroxamic acid DM76AUO TI TTMTWOS DM76AUO TN Matrix metalloproteinase-7 (MMP-7) DM76AUO MA Inhibitor DM76AUO RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DM76AUO RU https://pubmed.ncbi.nlm.nih.gov/17127067 DM76BGZ DI DM76BGZ DM76BGZ DN Dihydroorotate DM76BGZ TI TT09NOX DM76BGZ TN Plasmodium Dihydroorotase (Malaria dho) DM76BGZ MA Inhibitor DM76BGZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM76BGZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM76BGZ DI DM76BGZ DM76BGZ DN Dihydroorotate DM76BGZ TI TT3PQ2Y DM76BGZ TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM76BGZ MA Inhibitor DM76BGZ RN Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16. DM76BGZ RU https://pubmed.ncbi.nlm.nih.gov/2847745 DM76BXY DI DM76BXY DM76BXY DN Tamoxifen ethyl bromide DM76BXY TI TTZAYWL DM76BXY TN Estrogen receptor (ESR) DM76BXY MA Inhibitor DM76BXY RN Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. DM76BXY RU https://pubmed.ncbi.nlm.nih.gov/20621492 DM76CLF DI DM76CLF DM76CLF DN N1-dansyl-spermine DM76CLF TI TT1M8OW DM76CLF TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DM76CLF MA Blocker (channel blocker) DM76CLF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DM76CLF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DM76CLF DI DM76CLF DM76CLF DN N1-dansyl-spermine DM76CLF TI TT5POTG DM76CLF TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DM76CLF MA Blocker (channel blocker) DM76CLF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DM76CLF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DM76CLF DI DM76CLF DM76CLF DN N1-dansyl-spermine DM76CLF TI TTN9D8E DM76CLF TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM76CLF MA Blocker (channel blocker) DM76CLF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DM76CLF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DM76CLF DI DM76CLF DM76CLF DN N1-dansyl-spermine DM76CLF TI TTKJEMQ DM76CLF TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM76CLF MA Blocker (channel blocker) DM76CLF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DM76CLF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DM76CUP DI DM76CUP DM76CUP DN SECOCULARIDINE DM76CUP TI TTVBI8W DM76CUP TN Dopamine transporter (DAT) DM76CUP MA Inhibitor DM76CUP RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DM76CUP RU https://pubmed.ncbi.nlm.nih.gov/8676127 DM76CYG DI DM76CYG DM76CYG DN ISIS 116507 DM76CYG TI TTUI35N DM76CYG TN C/EBP beta messenger RNA (CEBPB mRNA) DM76CYG RN US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression. DM76CYG RU http://www.patentbuddy.com/Patent/6271030?ft=true&sr=true DM76EPH DI DM76EPH DM76EPH DN thio-BCTC DM76EPH TI TTXDKTO DM76EPH TN Long transient receptor potential channel 8 (TRPM8) DM76EPH MA Blocker (channel blocker) DM76EPH RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DM76EPH RU https://pubmed.ncbi.nlm.nih.gov/14757700 DM76H35 DI DM76H35 DM76H35 DN ISIS 20577 DM76H35 TI TTSRXJW DM76H35 TN G-alpha-11 messenger RNA (GNA11 mRNA) DM76H35 RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DM76H35 RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DM76JVB DI DM76JVB DM76JVB DN 1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol DM76JVB TI TTWJBZ5 DM76JVB TN 5-HT 2C receptor (HTR2C) DM76JVB MA Inhibitor DM76JVB RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM76JVB RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM76JVB DI DM76JVB DM76JVB DN 1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol DM76JVB TI TT0K1SC DM76JVB TN 5-HT 2B receptor (HTR2B) DM76JVB MA Inhibitor DM76JVB RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM76JVB RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM76JVB DI DM76JVB DM76JVB DN 1-((S)-2-aminopropyl)-7-fluoro-1H-indazol-6-ol DM76JVB TI TTJQOD7 DM76JVB TN 5-HT 2A receptor (HTR2A) DM76JVB MA Inhibitor DM76JVB RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM76JVB RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM76Q2B DI DM76Q2B DM76Q2B DN D[Arg4]AVP DM76Q2B TI TTK8R02 DM76Q2B TN Vasopressin V2 receptor (V2R) DM76Q2B MA Inhibitor DM76Q2B RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM76Q2B RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM76Q2B DI DM76Q2B DM76Q2B DN D[Arg4]AVP DM76Q2B TI TTSCIUP DM76Q2B TN Oxytocin receptor (OTR) DM76Q2B MA Inhibitor DM76Q2B RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM76Q2B RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM76Q2B DI DM76Q2B DM76Q2B DN D[Arg4]AVP DM76Q2B TI TTL9MHW DM76Q2B TN Vasopressin V1b receptor (V1BR) DM76Q2B MA Inhibitor DM76Q2B RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM76Q2B RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM76Q2B DI DM76Q2B DM76Q2B DN D[Arg4]AVP DM76Q2B TI TT4TFGN DM76Q2B TN Vasopressin V1a receptor (V1AR) DM76Q2B MA Inhibitor DM76Q2B RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM76Q2B RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM76SZK DI DM76SZK DM76SZK DN (R)-1-(3-methoxyphenethyl)-2-methylpyrrolidine DM76SZK TI TT9JNIC DM76SZK TN Histamine H3 receptor (H3R) DM76SZK MA Inhibitor DM76SZK RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DM76SZK RU https://pubmed.ncbi.nlm.nih.gov/18077160 DM76TSG DI DM76TSG DM76TSG DN Phosphatidylserine DM76TSG TI TT5Z1WV DM76TSG TN Adhesion G protein-coupled receptor B1 (BAI1) DM76TSG MA Agonist DM76TSG RN BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature. 2007 Nov 15;450(7168):430-4. DM76TSG RU https://pubmed.ncbi.nlm.nih.gov/17960134 DM76UJY DI DM76UJY DM76UJY DN E[c(RGDyK)]2 DM76UJY TI TTT1R2L DM76UJY TN Integrin alpha-V (ITGAV) DM76UJY MA Inhibitor DM76UJY RN Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106. DM76UJY RU https://pubmed.ncbi.nlm.nih.gov/15715477 DM76UJY DI DM76UJY DM76UJY DN E[c(RGDyK)]2 DM76UJY TI TTJA1ZO DM76UJY TN ITGB3 messenger RNA (ITGB3 mRNA) DM76UJY MA Inhibitor DM76UJY RN Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106. DM76UJY RU https://pubmed.ncbi.nlm.nih.gov/15715477 DM781L6 DI DM781L6 DM781L6 DN 1-Benzenesulfonyl-2-nitro-benzene DM781L6 TI TT84ETX DM781L6 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM781L6 MA Inhibitor DM781L6 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM781L6 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM783BP DI DM783BP DM783BP DN LLZ16407 DM783BP TI TTK1N5G DM783BP TN MAPK/ERK kinase kinase 2 (MAP3K2) DM783BP MA Inhibitor DM783BP RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DM783BP RU https://pubmed.ncbi.nlm.nih.gov/11804650 DM784AU DI DM784AU DM784AU DN Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone DM784AU TI TT36ETB DM784AU TN Cathepsin L (CTSL) DM784AU MA Inhibitor DM784AU RN Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. DM784AU RU https://pubmed.ncbi.nlm.nih.gov/20933415 DM784AU DI DM784AU DM784AU DN Bis(3-bromophenyl)(4-hydroxy)thiosemicarbazone DM784AU TI TTF2LRI DM784AU TN Cathepsin B (CTSB) DM784AU MA Inhibitor DM784AU RN Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. DM784AU RU https://pubmed.ncbi.nlm.nih.gov/20933415 DM7850H DI DM7850H DM7850H DN GNF-PF-5134 DM7850H TI TTL53M6 DM7850H TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DM7850H MA Inhibitor DM7850H RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM7850H RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM7850H DI DM7850H DM7850H DN GNF-PF-5134 DM7850H TI TT915ZD DM7850H TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DM7850H MA Inhibitor DM7850H RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM7850H RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM78A6F DI DM78A6F DM78A6F DN KNI-10113 DM78A6F TI TTXMNHO DM78A6F TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM78A6F MA Inhibitor DM78A6F RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DM78A6F RU https://pubmed.ncbi.nlm.nih.gov/18952439 DM78AJ1 DI DM78AJ1 DM78AJ1 DN 1-(pyridin-4-yl)piperazine DM78AJ1 TI TT3T17P DM78AJ1 TN Phospholipase D1 (PLD1) DM78AJ1 MA Inhibitor DM78AJ1 RN Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privil... Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3. DM78AJ1 RU https://pubmed.ncbi.nlm.nih.gov/19299128 DM78B4A DI DM78B4A DM78B4A DN RO-054520 DM78B4A TI TT1MPAY DM78B4A TN GABA(A) receptor alpha-1 (GABRA1) DM78B4A MA Inhibitor DM78B4A RN Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988 Dec;31(12):2235-46. DM78B4A RU https://pubmed.ncbi.nlm.nih.gov/2848124 DM78B4A DI DM78B4A DM78B4A DN RO-054520 DM78B4A TI TTNJYV2 DM78B4A TN Gamma-aminobutyric acid receptor (GAR) DM78B4A MA Inhibitor DM78B4A RN Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988 Dec;31(12):2235-46. DM78B4A RU https://pubmed.ncbi.nlm.nih.gov/2848124 DM78BDU DI DM78BDU DM78BDU DN ISIS 2686 DM78BDU TI TT1PL7M DM78BDU TN E-selectin messenger RNA (SELE mRNA) DM78BDU RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DM78BDU RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DM78C5A DI DM78C5A DM78C5A DN 7-butoxy-2H-chromen-2-one DM78C5A TI TTEYTKG DM78C5A TN Carbonic anhydrase XIV (CA-XIV) DM78C5A MA Inhibitor DM78C5A RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM78C5A RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM78C5A DI DM78C5A DM78C5A DN 7-butoxy-2H-chromen-2-one DM78C5A TI TT2LVK8 DM78C5A TN Carbonic anhydrase IX (CA-IX) DM78C5A MA Inhibitor DM78C5A RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM78C5A RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM78C5A DI DM78C5A DM78C5A DN 7-butoxy-2H-chromen-2-one DM78C5A TI TTCFSPE DM78C5A TN Carbonic anhydrase VI (CA-VI) DM78C5A MA Inhibitor DM78C5A RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM78C5A RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM78C5A DI DM78C5A DM78C5A DN 7-butoxy-2H-chromen-2-one DM78C5A TI TTSYM0R DM78C5A TN Carbonic anhydrase XII (CA-XII) DM78C5A MA Inhibitor DM78C5A RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM78C5A RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM78C5A DI DM78C5A DM78C5A DN 7-butoxy-2H-chromen-2-one DM78C5A TI TTUNARX DM78C5A TN Carbonic anhydrase (CA) DM78C5A MA Inhibitor DM78C5A RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM78C5A RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM78DO6 DI DM78DO6 DM78DO6 DN ONO-AE2-227 DM78DO6 TI TTPNGDE DM78DO6 TN Prostaglandin E2 receptor EP3 (PTGER3) DM78DO6 MA Antagonist DM78DO6 RN Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002 Jan 1;62(1):28-32. DM78DO6 RU https://pubmed.ncbi.nlm.nih.gov/11782353 DM78DO6 DI DM78DO6 DM78DO6 DN ONO-AE2-227 DM78DO6 TI TT79WV3 DM78DO6 TN Prostaglandin E2 receptor EP4 (PTGER4) DM78DO6 MA Antagonist DM78DO6 RN Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 2002 Jan 1;62(1):28-32. DM78DO6 RU https://pubmed.ncbi.nlm.nih.gov/11782353 DM78F6A DI DM78F6A DM78F6A DN MCL-1-specific antisense oligonucleotide + midostaurin(PKC412) DM78F6A TI TTN6ORK DM78F6A TN Mcl-1 messenger RNA (MCL-1 mRNA) DM78F6A RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM78F6A RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM78FWG DI DM78FWG DM78FWG DN 3-cis-p-coumaroyl maslinic acid DM78FWG TI TTIU7X1 DM78FWG TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM78FWG MA Inhibitor DM78FWG RN DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3. DM78FWG RU https://pubmed.ncbi.nlm.nih.gov/10654414 DM78I2W DI DM78I2W DM78I2W DN FGGFTGARKSARKL DM78I2W TI TTNT7K8 DM78I2W TN Nociceptin receptor (OPRL1) DM78I2W MA Inhibitor DM78I2W RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DM78I2W RU https://pubmed.ncbi.nlm.nih.gov/11689089 DM78I4P DI DM78I4P DM78I4P DN 6-Chloro-N-(3-morpholinopropyl)nicotinamide DM78I4P TI TT3WG5C DM78I4P TN Monoamine oxidase type A (MAO-A) DM78I4P MA Inhibitor DM78I4P RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM78I4P RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM78KYC DI DM78KYC DM78KYC DN GW 627368 DM78KYC TI TT79WV3 DM78KYC TN Prostaglandin E2 receptor EP4 (PTGER4) DM78KYC MA Antagonist DM78KYC RN Piglet saphenous vein contains multiple relaxatory prostanoid receptors: evidence for EP4, EP2, DP and IP receptor subtypes. Br J Pharmacol. 2005 Feb;144(3):405-15. DM78KYC RU https://pubmed.ncbi.nlm.nih.gov/15655509 DM78NOM DI DM78NOM DM78NOM DN furin inhibitor peptide DM78NOM TI TTK3VYC DM78NOM TN Proprotein convertase subtilisin/kexin type 4 (PCSK4) DM78NOM MA Inhibitor DM78NOM RN Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53. DM78NOM RU https://pubmed.ncbi.nlm.nih.gov/17537721 DM78NOM DI DM78NOM DM78NOM DN furin inhibitor peptide DM78NOM TI TTD30LY DM78NOM TN Proprotein convertase subtilisin/kexin type 7 (PCSK7) DM78NOM MA Inhibitor DM78NOM RN Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53. DM78NOM RU https://pubmed.ncbi.nlm.nih.gov/17537721 DM78NOM DI DM78NOM DM78NOM DN furin inhibitor peptide DM78NOM TI TT75LN9 DM78NOM TN Proprotein convertase subtilisin/kexin type 6 (PCSK6) DM78NOM MA Inhibitor DM78NOM RN Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53. DM78NOM RU https://pubmed.ncbi.nlm.nih.gov/17537721 DM78NOM DI DM78NOM DM78NOM DN furin inhibitor peptide DM78NOM TI TTPFWHU DM78NOM TN Proprotein convertase subtilisin/kexin type 5 (PCSK5) DM78NOM MA Inhibitor DM78NOM RN Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53. DM78NOM RU https://pubmed.ncbi.nlm.nih.gov/17537721 DM78NOM DI DM78NOM DM78NOM DN furin inhibitor peptide DM78NOM TI TTH9WF6 DM78NOM TN Dibasic-processing enzyme (Furin) DM78NOM MA Inhibitor DM78NOM RN Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J Biol Chem. 2007 Jul 20;282(29):20847-53. DM78NOM RU https://pubmed.ncbi.nlm.nih.gov/17537721 DM78PFN DI DM78PFN DM78PFN DN Dmt-Pro-Mmp-Phe-NH2 DM78PFN TI TTQW87Y DM78PFN TN Opioid receptor kappa (OPRK1) DM78PFN MA Inhibitor DM78PFN RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM78PFN RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM78PFN DI DM78PFN DM78PFN DN Dmt-Pro-Mmp-Phe-NH2 DM78PFN TI TT27RFC DM78PFN TN Opioid receptor delta (OPRD1) DM78PFN MA Inhibitor DM78PFN RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM78PFN RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM78PFN DI DM78PFN DM78PFN DN Dmt-Pro-Mmp-Phe-NH2 DM78PFN TI TTKWM86 DM78PFN TN Opioid receptor mu (MOP) DM78PFN MA Inhibitor DM78PFN RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DM78PFN RU https://pubmed.ncbi.nlm.nih.gov/17497839 DM78PR5 DI DM78PR5 DM78PR5 DN Cyclopentane amide derivatives 1 DM78PR5 TI TT50QJ3 DM78PR5 TN Influenza Neuraminidase (Influ NA) DM78PR5 MA Inhibitor DM78PR5 RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DM78PR5 RU https://pubmed.ncbi.nlm.nih.gov/17139286 DM78UPQ DI DM78UPQ DM78UPQ DN 1,3-Bis-(3-imidazolidin-2-yl-phenyl)-urea DM78UPQ TI TT1RS9F DM78UPQ TN Acetylcholinesterase (AChE) DM78UPQ MA Inhibitor DM78UPQ RN Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J Med Chem. 2004 Sep 23;47(20):4818-28. DM78UPQ RU https://pubmed.ncbi.nlm.nih.gov/15369385 DM78Z9D DI DM78Z9D DM78Z9D DN LVVAPWT DM78Z9D TI TT2THBD DM78Z9D TN P2X purinoceptor 3 (P2RX3) DM78Z9D MA Inhibitor DM78Z9D RN Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7. DM78Z9D RU https://pubmed.ncbi.nlm.nih.gov/17676725 DM796AX DI DM796AX DM796AX DN N-methyl-N-(prop-2-ynyl)-1H-pyrrole-2-carboxamide DM796AX TI TT3WG5C DM796AX TN Monoamine oxidase type A (MAO-A) DM796AX MA Inhibitor DM796AX RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM796AX RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM79DSN DI DM79DSN DM79DSN DN ABTAA DM79DSN TI TTKLQTJ DM79DSN TN Angiopoietin-2 (ANGPT2) DM79DSN MA Binder DM79DSN RN Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55. DM79DSN RU https://pubmed.ncbi.nlm.nih.gov/27099174 DM79DSN DI DM79DSN DM79DSN DN ABTAA DM79DSN TI TT9VGXW DM79DSN TN Angiopoietin 1 receptor (TEK) DM79DSN MA Activator DM79DSN RN Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55. DM79DSN RU https://pubmed.ncbi.nlm.nih.gov/27099174 DM79E2K DI DM79E2K DM79E2K DN Aminodeoxykanamycin DM79E2K TI TT38DW5 DM79E2K TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DM79E2K MA Inhibitor DM79E2K RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DM79E2K RU https://pubmed.ncbi.nlm.nih.gov/11102874 DM79JVK DI DM79JVK DM79JVK DN 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine DM79JVK TI TT6MSOK DM79JVK TN 5-HT 1D receptor (HTR1D) DM79JVK MA Inhibitor DM79JVK RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM79JVK RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM79JVK DI DM79JVK DM79JVK DN 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine DM79JVK TI TTSQIFT DM79JVK TN 5-HT 1A receptor (HTR1A) DM79JVK MA Inhibitor DM79JVK RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM79JVK RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM79JVK DI DM79JVK DM79JVK DN 2-(4-Bromo-2-methoxy-phenyl)-1-methyl-ethylamine DM79JVK TI TTJQOD7 DM79JVK TN 5-HT 2A receptor (HTR2A) DM79JVK MA Inhibitor DM79JVK RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DM79JVK RU https://pubmed.ncbi.nlm.nih.gov/3950904 DM79KLR DI DM79KLR DM79KLR DN nafadotride DM79KLR TI TT4C8EA DM79KLR TN Dopamine D3 receptor (D3R) DM79KLR MA Antagonist DM79KLR RN Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995 Dec;275(3):1239-46. DM79KLR RU https://pubmed.ncbi.nlm.nih.gov/8531087 DM79KLR DI DM79KLR DM79KLR DN nafadotride DM79KLR TI TTEX248 DM79KLR TN Dopamine D2 receptor (D2R) DM79KLR MA Antagonist DM79KLR RN Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995 Dec;275(3):1239-46. DM79KLR RU https://pubmed.ncbi.nlm.nih.gov/8531087 DM79KLR DI DM79KLR DM79KLR DN nafadotride DM79KLR TI TTE0A2F DM79KLR TN Dopamine D4 receptor (D4R) DM79KLR MA Antagonist DM79KLR RN Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52. DM79KLR RU https://pubmed.ncbi.nlm.nih.gov/10617689 DM79KLR DI DM79KLR DM79KLR DN nafadotride DM79KLR TI TTSQIFT DM79KLR TN 5-HT 1A receptor (HTR1A) DM79KLR MA Agonist DM79KLR RN Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. DM79KLR RU https://pubmed.ncbi.nlm.nih.gov/9760039 DM79QC2 DI DM79QC2 DM79QC2 DN S-methyl 4-methyl-4-morpholinopent-2-ynethioate DM79QC2 TI TTB6UM0 DM79QC2 TN Fatty aldehyde dehydrogenase (ALDH3A2) DM79QC2 MA Inhibitor DM79QC2 RN Aldehyde dehydrogenase inhibitors: alpha,beta-acetylenic N-substituted aminothiolesters are reversible growth inhibitors of normal epithelial but i... Eur J Med Chem. 2008 May;43(5):906-16. DM79QC2 RU https://pubmed.ncbi.nlm.nih.gov/17692435 DM79VQM DI DM79VQM DM79VQM DN 8-cyclohexyl-6-(4-tolyl)-2-phenyl-9H-purine DM79VQM TI TTK25J1 DM79VQM TN Adenosine A1 receptor (ADORA1) DM79VQM MA Inhibitor DM79VQM RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DM79VQM RU https://pubmed.ncbi.nlm.nih.gov/16686529 DM79XSF DI DM79XSF DM79XSF DN ETP-45658 DM79XSF TI TTWR6YK DM79XSF TN PI3-kinase (PIK3C) DM79XSF MA Inhibitor DM79XSF RN A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes. Breast Cancer Res. 2014 Dec 9;16(6):482. DM79XSF RU https://pubmed.ncbi.nlm.nih.gov/25488803 DM79YZN DI DM79YZN DM79YZN DN Etorphine DM79YZN TI TT27RFC DM79YZN TN Opioid receptor delta (OPRD1) DM79YZN MA Agonist DM79YZN RN Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation. J Pharmacol Exp Ther. 2001 Sep;298(3):1015-20. DM79YZN RU https://pubmed.ncbi.nlm.nih.gov/11504798 DM79YZN DI DM79YZN DM79YZN DN Etorphine DM79YZN TI TTKWM86 DM79YZN TN Opioid receptor mu (MOP) DM79YZN MA Agonist DM79YZN RN Internalization of mu-opioid receptors produced by etorphine in the rat locus coeruleus. Neuroscience. 2001;108(3):467-77. DM79YZN RU https://pubmed.ncbi.nlm.nih.gov/11738260 DM79ZOV DI DM79ZOV DM79ZOV DN 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one DM79ZOV TI TTK3PY9 DM79ZOV TN DNA-dependent protein kinase catalytic (PRKDC) DM79ZOV MA Inhibitor DM79ZOV RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DM79ZOV RU https://pubmed.ncbi.nlm.nih.gov/15658870 DM79ZOV DI DM79ZOV DM79ZOV DN 2-Morpholin-4-yl-pyrimido[2,1-a]isoquinolin-4-one DM79ZOV TI TTCJG29 DM79ZOV TN Serine/threonine-protein kinase mTOR (mTOR) DM79ZOV MA Inhibitor DM79ZOV RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DM79ZOV RU https://pubmed.ncbi.nlm.nih.gov/15658870 DM7A3GO DI DM7A3GO DM7A3GO DN 2-Phenyl-5-(2-methylthiazol-4ylethynyl)pyridine DM7A3GO TI TTHS256 DM7A3GO TN Metabotropic glutamate receptor 5 (mGluR5) DM7A3GO MA Inhibitor DM7A3GO RN Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75. DM7A3GO RU https://pubmed.ncbi.nlm.nih.gov/19445453 DM7A50Z DI DM7A50Z DM7A50Z DN 1-Cyclohexylidenethiosemicarbazide DM7A50Z TI TTULVH8 DM7A50Z TN Tyrosinase (TYR) DM7A50Z MA Inhibitor DM7A50Z RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DM7A50Z RU https://pubmed.ncbi.nlm.nih.gov/18524420 DM7A8PX DI DM7A8PX DM7A8PX DN AS-1522489-00 DM7A8PX TI TTHJTF7 DM7A8PX TN Glycine transporter GlyT-1 (SLC6A9) DM7A8PX MA Inhibitor DM7A8PX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DM7A8PX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DM7AG6Y DI DM7AG6Y DM7AG6Y DN 3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one DM7AG6Y TI TTMF541 DM7AG6Y TN Liver carboxylesterase (CES1) DM7AG6Y MA Inhibitor DM7AG6Y RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM7AG6Y RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM7AG6Y DI DM7AG6Y DM7AG6Y DN 3-(dodecylsulfinyl)-1,1,1-trifluoropropan-2-one DM7AG6Y TI TTDP1UC DM7AG6Y TN Fatty acid amide hydrolase (FAAH) DM7AG6Y MA Inhibitor DM7AG6Y RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM7AG6Y RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM7AHNF DI DM7AHNF DM7AHNF DN iodoaminopotentidine DM7AHNF TI TTQHJ1K DM7AHNF TN Histamine H2 receptor (H2R) DM7AHNF MA Antagonist DM7AHNF RN Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells. Br J Pharmacol. 1997 Nov;122(5):867-74. DM7AHNF RU https://pubmed.ncbi.nlm.nih.gov/9384502 DM7AJER DI DM7AJER DM7AJER DN PMID25719566C1 DM7AJER TI TT6K8YG DM7AJER TN Bromodomain adjacent to zinc finger 2B (BAZ2B) DM7AJER MA Inhibitor DM7AJER RN Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9. DM7AJER RU https://pubmed.ncbi.nlm.nih.gov/25719566 DM7ANE3 DI DM7ANE3 DM7ANE3 DN 6-Benzyl-2-sec-butylsulfanyl-3H-pyrimidin-4-one DM7ANE3 TI TT84ETX DM7ANE3 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM7ANE3 MA Inhibitor DM7ANE3 RN 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine d... J Med Chem. 1999 Feb 25;42(4):619-27. DM7ANE3 RU https://pubmed.ncbi.nlm.nih.gov/10052969 DM7AOGD DI DM7AOGD DM7AOGD DN 4-Benzoimidazol-1-yl-phenylamine DM7AOGD TI TTI7421 DM7AOGD TN Platelet-derived growth factor receptor beta (PDGFRB) DM7AOGD MA Inhibitor DM7AOGD RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DM7AOGD RU https://pubmed.ncbi.nlm.nih.gov/9876115 DM7AOGD DI DM7AOGD DM7AOGD DN 4-Benzoimidazol-1-yl-phenylamine DM7AOGD TI TT8FYO9 DM7AOGD TN Platelet-derived growth factor receptor alpha (PDGFRA) DM7AOGD MA Inhibitor DM7AOGD RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DM7AOGD RU https://pubmed.ncbi.nlm.nih.gov/9876115 DM7AORH DI DM7AORH DM7AORH DN 3,6-Dihydroxy-Xanthene-9-Propionic Acid DM7AORH TI TTEP6RV DM7AORH TN Glutathione reductase (GR) DM7AORH MA Inhibitor DM7AORH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7AORH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7AW0X DI DM7AW0X DM7AW0X DN Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate DM7AW0X TI TT6TMZU DM7AW0X TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DM7AW0X MA Inhibitor DM7AW0X RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7AW0X RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7AXRF DI DM7AXRF DM7AXRF DN PMID18445527C67 DM7AXRF TI TTA93TL DM7AXRF TN P2Y purinoceptor 1 (P2RY1) DM7AXRF MA Antagonist DM7AXRF RN P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3338-43. DM7AXRF RU https://pubmed.ncbi.nlm.nih.gov/18445527 DM7AY6K DI DM7AY6K DM7AY6K DN PD 176252 DM7AY6K TI TTHYDUM DM7AY6K TN Bombesin receptor (BS) DM7AY6K MA Antagonist DM7AY6K RN Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides. 2009 Aug;30(8):1473-86. DM7AY6K RU https://pubmed.ncbi.nlm.nih.gov/19463875 DM7AY6K DI DM7AY6K DM7AY6K DN PD 176252 DM7AY6K TI TTC1MVT DM7AY6K TN Gastrin-releasing peptide receptor (GRPR) DM7AY6K MA Antagonist DM7AY6K RN PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2589-94. DM7AY6K RU https://pubmed.ncbi.nlm.nih.gov/9873586 DM7AYH4 DI DM7AYH4 DM7AYH4 DN EGFR inhibitor DM7AYH4 TI TTGKNB4 DM7AYH4 TN Epidermal growth factor receptor (EGFR) DM7AYH4 MA Inhibitor DM7AYH4 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DM7AYH4 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DM7B1VT DI DM7B1VT DM7B1VT DN 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol DM7B1VT TI TTHY57M DM7B1VT TN Matrix metalloproteinase-13 (MMP-13) DM7B1VT MA Inhibitor DM7B1VT RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DM7B1VT RU https://pubmed.ncbi.nlm.nih.gov/10230616 DM7B1VT DI DM7B1VT DM7B1VT DN 3-(4-Methoxy-benzenesulfonyl)-propane-1-thiol DM7B1VT TI TTGA1IV DM7B1VT TN Matrix metalloproteinase-8 (MMP-8) DM7B1VT MA Inhibitor DM7B1VT RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DM7B1VT RU https://pubmed.ncbi.nlm.nih.gov/10406637 DM7B5HA DI DM7B5HA DM7B5HA DN GB-12819 DM7B5HA TI TTVG215 DM7B5HA TN Debrisoquine 4-hydroxylase (CYP2D6) DM7B5HA MA Inhibitor DM7B5HA RN Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30. DM7B5HA RU https://pubmed.ncbi.nlm.nih.gov/16610785 DM7B5HA DI DM7B5HA DM7B5HA DN GB-12819 DM7B5HA TI TTVBI8W DM7B5HA TN Dopamine transporter (DAT) DM7B5HA MA Inhibitor DM7B5HA RN Synthesis and dopamine transporter binding affinities of 3alpha-benzyl-8-(diarylmethoxyethyl)-8-azabicyclo[3.2.1]octanes. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2387-90. DM7B5HA RU https://pubmed.ncbi.nlm.nih.gov/12161139 DM7BAU2 DI DM7BAU2 DM7BAU2 DN 1,2,5,6-tetrahydro pyrido[1,2-a]quinolin-3-one DM7BAU2 TI TTTU72V DM7BAU2 TN Steroid 5-alpha-reductase 1 (SRD5A1) DM7BAU2 MA Inhibitor DM7BAU2 RN Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem. 2000 Oct 5;43(20):3718-35. DM7BAU2 RU https://pubmed.ncbi.nlm.nih.gov/11020287 DM7BC50 DI DM7BC50 DM7BC50 DN 2-(3-chlorophenyl)-7-methyl-1,8-naphthyridine DM7BC50 TI TTHS256 DM7BC50 TN Metabotropic glutamate receptor 5 (mGluR5) DM7BC50 MA Inhibitor DM7BC50 RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DM7BC50 RU https://pubmed.ncbi.nlm.nih.gov/17936624 DM7BHYS DI DM7BHYS DM7BHYS DN 2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline DM7BHYS TI TTJFY5U DM7BHYS TN Adenosine A3 receptor (ADORA3) DM7BHYS MA Inhibitor DM7BHYS RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DM7BHYS RU https://pubmed.ncbi.nlm.nih.gov/16366607 DM7BHYS DI DM7BHYS DM7BHYS DN 2-(4-chloro-1H-benzo[d]imidazol-2-yl)quinoxaline DM7BHYS TI TTK25J1 DM7BHYS TN Adenosine A1 receptor (ADORA1) DM7BHYS MA Inhibitor DM7BHYS RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DM7BHYS RU https://pubmed.ncbi.nlm.nih.gov/16366607 DM7BIJH DI DM7BIJH DM7BIJH DN 6-(benzylamino)-9-butyl-9H-purine-2-carbonitrile DM7BIJH TI TT36ETB DM7BIJH TN Cathepsin L (CTSL) DM7BIJH MA Inhibitor DM7BIJH RN Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem. 2008 Feb 14;51(3):545-52. DM7BIJH RU https://pubmed.ncbi.nlm.nih.gov/18173229 DM7BK9A DI DM7BK9A DM7BK9A DN (6-Butoxy-2-naphthyl)-2-aminopropane DM7BK9A TI TT3WG5C DM7BK9A TN Monoamine oxidase type A (MAO-A) DM7BK9A MA Inhibitor DM7BK9A RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DM7BK9A RU https://pubmed.ncbi.nlm.nih.gov/19243954 DM7BKUQ DI DM7BKUQ DM7BKUQ DN N'-(2-fluorobenzoyl)-2-naphthohydrazide DM7BKUQ TI TTSFWA7 DM7BKUQ TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DM7BKUQ MA Inhibitor DM7BKUQ RN Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010). DM7BKUQ RU http://www.sciencedirect.com/science/article/pii/S0960894X10006803 DM7BL04 DI DM7BL04 DM7BL04 DN 2,2-dimethyl-3-methyleneheptadecane DM7BL04 TI TTMF541 DM7BL04 TN Liver carboxylesterase (CES1) DM7BL04 MA Inhibitor DM7BL04 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM7BL04 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM7BL04 DI DM7BL04 DM7BL04 DN 2,2-dimethyl-3-methyleneheptadecane DM7BL04 TI TTDP1UC DM7BL04 TN Fatty acid amide hydrolase (FAAH) DM7BL04 MA Inhibitor DM7BL04 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM7BL04 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM7BQ65 DI DM7BQ65 DM7BQ65 DN 4-Hydroxy-2-Butanone DM7BQ65 TI TTMW94E DM7BQ65 TN FK506-binding protein 1A (FKBP1A) DM7BQ65 MA Inhibitor DM7BQ65 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7BQ65 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7BTNF DI DM7BTNF DM7BTNF DN XT-101 DM7BTNF TI TTJTRMK DM7BTNF TN Interleukin 10 receptor (IL10RB) DM7BTNF MA Modulator DM7BTNF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900). DM7BTNF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1900 DM7BWG5 DI DM7BWG5 DM7BWG5 DN 5-BODMT DM7BWG5 TI TT0MI3F DM7BWG5 TN 5-HT 1F receptor (HTR1F) DM7BWG5 MA Agonist DM7BWG5 RN Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-7. DM7BWG5 RU https://pubmed.ncbi.nlm.nih.gov/21422162 DM7BWG5 DI DM7BWG5 DM7BWG5 DN 5-BODMT DM7BWG5 TI TTCPG9S DM7BWG5 TN 5-HT 1E receptor (HTR1E) DM7BWG5 MA Agonist DM7BWG5 RN Toward selective drug development for the human 5-hydroxytryptamine 1E receptor: a comparison of 5-hydroxytryptamine 1E and 1F receptor structure-affinity relationships. J Pharmacol Exp Ther. 2011 Jun;337(3):860-7. DM7BWG5 RU https://pubmed.ncbi.nlm.nih.gov/21422162 DM7BXHQ DI DM7BXHQ DM7BXHQ DN GNF-PF-3878 DM7BXHQ TI TTWG9A4 DM7BXHQ TN Adrenergic receptor alpha-2A (ADRA2A) DM7BXHQ MA Inhibitor DM7BXHQ RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DM7BXHQ RU https://pubmed.ncbi.nlm.nih.gov/17034141 DM7BXHQ DI DM7BXHQ DM7BXHQ DN GNF-PF-3878 DM7BXHQ TI TT2NUT5 DM7BXHQ TN Adrenergic receptor alpha-2C (ADRA2C) DM7BXHQ MA Inhibitor DM7BXHQ RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DM7BXHQ RU https://pubmed.ncbi.nlm.nih.gov/17034141 DM7BXHQ DI DM7BXHQ DM7BXHQ DN GNF-PF-3878 DM7BXHQ TI TTWM4TY DM7BXHQ TN Adrenergic receptor alpha-2B (ADRA2B) DM7BXHQ MA Inhibitor DM7BXHQ RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DM7BXHQ RU https://pubmed.ncbi.nlm.nih.gov/17034141 DM7BY4T DI DM7BY4T DM7BY4T DN (+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one DM7BY4T TI TTGP7BY DM7BY4T TN Monoamine oxidase type B (MAO-B) DM7BY4T MA Inhibitor DM7BY4T RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DM7BY4T RU https://pubmed.ncbi.nlm.nih.gov/20123154 DM7BY4T DI DM7BY4T DM7BY4T DN (+/-)-2-(4'-Methoxyphenyl)thiomorpholin-5-one DM7BY4T TI TT3WG5C DM7BY4T TN Monoamine oxidase type A (MAO-A) DM7BY4T MA Inhibitor DM7BY4T RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DM7BY4T RU https://pubmed.ncbi.nlm.nih.gov/20123154 DM7BYG8 DI DM7BYG8 DM7BYG8 DN KYS-05057 DM7BYG8 TI TT729IR DM7BYG8 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM7BYG8 MA Inhibitor DM7BYG8 RN T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. DM7BYG8 RU https://pubmed.ncbi.nlm.nih.gov/18585035 DM7C148 DI DM7C148 DM7C148 DN (R)-(+)-coclaurine DM7C148 TI TTEX248 DM7C148 TN Dopamine D2 receptor (D2R) DM7C148 MA Inhibitor DM7C148 RN Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J Nat Prod. 1998 Jun 26;61(6):709-12. DM7C148 RU https://pubmed.ncbi.nlm.nih.gov/9644051 DM7C148 DI DM7C148 DM7C148 DN (R)-(+)-coclaurine DM7C148 TI TTZFYLI DM7C148 TN Dopamine D1 receptor (D1R) DM7C148 MA Inhibitor DM7C148 RN Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J Nat Prod. 1998 Jun 26;61(6):709-12. DM7C148 RU https://pubmed.ncbi.nlm.nih.gov/9644051 DM7C3VD DI DM7C3VD DM7C3VD DN 1-(4-Cyanobenzyl)-5-(4-fluorophenyl)-1H-imidazole DM7C3VD TI TTIQUX7 DM7C3VD TN Steroid 11-beta-hydroxylase (CYP11B1) DM7C3VD MA Inhibitor DM7C3VD RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM7C3VD RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM7CJNE DI DM7CJNE DM7CJNE DN U92016A DM7CJNE TI TTSQIFT DM7CJNE TN 5-HT 1A receptor (HTR1A) DM7CJNE MA Agonist DM7CJNE RN Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist. J Pharmacol Exp Ther. 1994 Nov;271(2):875-83. DM7CJNE RU https://pubmed.ncbi.nlm.nih.gov/7965808 DM7CM3F DI DM7CM3F DM7CM3F DN N-(3-phenoxypyridin-4-yl)methanesulfonamide DM7CM3F TI TT8NGED DM7CM3F TN Prostaglandin G/H synthase 1 (COX-1) DM7CM3F MA Inhibitor DM7CM3F RN Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71. DM7CM3F RU https://pubmed.ncbi.nlm.nih.gov/19791801 DM7COAM DI DM7COAM DM7COAM DN [HO1][Orn8(5/6C-Rhm)]VT DM7COAM TI TTSCIUP DM7COAM TN Oxytocin receptor (OTR) DM7COAM MA Inhibitor DM7COAM RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM7COAM RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM7COAM DI DM7COAM DM7COAM DN [HO1][Orn8(5/6C-Rhm)]VT DM7COAM TI TT4TFGN DM7COAM TN Vasopressin V1a receptor (V1AR) DM7COAM MA Inhibitor DM7COAM RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM7COAM RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM7COSH DI DM7COSH DM7COSH DN (R,S)-4-phosphonophenylglycine DM7COSH TI TT0IFKL DM7COSH TN Metabotropic glutamate receptor 8 (mGluR8) DM7COSH MA Agonist DM7COSH RN Anticonvulsant activity of a metabotropic glutamate receptor 8 preferential agonist, (R,S)-4-phosphonophenylglycine. Eur J Pharmacol. 1999 Oct 21;383(1):23-7. DM7COSH RU https://pubmed.ncbi.nlm.nih.gov/10556677 DM7CPBU DI DM7CPBU DM7CPBU DN L-748337 DM7CPBU TI TTMXGCW DM7CPBU TN Adrenergic receptor beta-3 (ADRB3) DM7CPBU MA Antagonist DM7CPBU RN Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1999 Aug;290(2):649-55. DM7CPBU RU https://pubmed.ncbi.nlm.nih.gov/10411574 DM7CTVE DI DM7CTVE DM7CTVE DN ISIS 119284 DM7CTVE TI TTKS60G DM7CTVE TN STXBP4 messenger RNA (STXBP4 mRNA) DM7CTVE RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DM7CTVE RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DM7CWQY DI DM7CWQY DM7CWQY DN PUNICAFOLIN DM7CWQY TI TTFJ8Q1 DM7CWQY TN Protein kinase C alpha (PRKCA) DM7CWQY MA Inhibitor DM7CWQY RN Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992). DM7CWQY RU http://www.sciencedirect.com/science/article/pii/S0960894X01810726 DM7CWQY DI DM7CWQY DM7CWQY DN PUNICAFOLIN DM7CWQY TI TTYPXQF DM7CWQY TN Protein kinase C beta (PRKCB) DM7CWQY MA Inhibitor DM7CWQY RN Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992). DM7CWQY RU http://www.sciencedirect.com/science/article/pii/S0960894X01810726 DM7D3GL DI DM7D3GL DM7D3GL DN N-(2-Acetamido)Iminodiacetic Acid DM7D3GL TI TTICO5G DM7D3GL TN Staphylococcus Peptide deformylase (Stap-coc def) DM7D3GL MA Inhibitor DM7D3GL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7D3GL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7D519 DI DM7D519 DM7D519 DN BMS-345541 DM7D519 TI TTRPDBG DM7D519 TN Inhibitor of nuclear factor kappa-B kinase (IKK) DM7D519 MA Inhibitor DM7D519 RN A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum. 2003 Sep;48(9):2652-9. DM7D519 RU https://pubmed.ncbi.nlm.nih.gov/13130486 DM7D52Z DI DM7D52Z DM7D52Z DN 677T DM7D52Z TI TTQWOU1 DM7D52Z TN MTHFR messenger RNA (MTHFR mRNA) DM7D52Z RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DM7D52Z RU https://pubmed.ncbi.nlm.nih.gov/21948793 DM7D6JV DI DM7D6JV DM7D6JV DN dioleoylphosphatidic acid DM7D6JV TI TT2D5VM DM7D6JV TN G-protein coupled receptor 63 (GPR63) DM7D6JV MA Agonist DM7D6JV RN Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63. Cell Signal. 2003 Apr;15(4):435-46. DM7D6JV RU https://pubmed.ncbi.nlm.nih.gov/12618218 DM7DBTZ DI DM7DBTZ DM7DBTZ DN Alpha-methylalanyl-L-proline butylamide DM7DBTZ TI TTQ7R2V DM7DBTZ TN Tripeptidyl-peptidase II (TPP2) DM7DBTZ MA Inhibitor DM7DBTZ RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DM7DBTZ RU https://pubmed.ncbi.nlm.nih.gov/16279793 DM7DL03 DI DM7DL03 DM7DL03 DN 1-Acetoxy-2-tert-butyldimethylsilyl-oxylycorine DM7DL03 TI TTXV4FI DM7DL03 TN Albendazole monooxygenase (CYP3A4) DM7DL03 MA Inhibitor DM7DL03 RN Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7. DM7DL03 RU https://pubmed.ncbi.nlm.nih.gov/19428250 DM7DOY3 DI DM7DOY3 DM7DOY3 DN ISIS 103747 DM7DOY3 TI TT6TU05 DM7DOY3 TN WWP2 messenger RNA (WWP2 mRNA) DM7DOY3 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM7DOY3 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM7DRO4 DI DM7DRO4 DM7DRO4 DN Ribavirin + lopinavir + ritonavir + interferon alfa-2a DM7DRO4 TI TTWOH4Q DM7DRO4 TN MERS-CoV 3C-like proteinase (3CLpro) DM7DRO4 MA Inhibitor DM7DRO4 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DM7DRO4 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DM7DRO4 DI DM7DRO4 DM7DRO4 DN Ribavirin + lopinavir + ritonavir + interferon alfa-2a DM7DRO4 TI TTOA6YT DM7DRO4 TN MERS-CoV RNA-directed RNA polymerase (RdRp) DM7DRO4 MA Inhibitor DM7DRO4 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM7DRO4 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM7DT20 DI DM7DT20 DM7DT20 DN Mimovax DM7DT20 TI TTE4KHA DM7DT20 TN Amyloid beta A4 protein (APP) DM7DT20 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM7DT20 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM7DTRM DI DM7DTRM DM7DTRM DN 1-methoxy-3-(3-(pyridin-4-yl)-1H-indol-6-yl)urea DM7DTRM TI TTTB4UP DM7DTRM TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM7DTRM MA Inhibitor DM7DTRM RN Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42. DM7DTRM RU https://pubmed.ncbi.nlm.nih.gov/16483773 DM7DW0G DI DM7DW0G DM7DW0G DN 4-formylphenyl-O-beta-D-ribopyranoside DM7DW0G TI TT1RS9F DM7DW0G TN Acetylcholinesterase (AChE) DM7DW0G MA Inhibitor DM7DW0G RN Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors. Eur J Med Chem. 2008 Jan;43(1):166-73. DM7DW0G RU https://pubmed.ncbi.nlm.nih.gov/17574306 DM7DWVL DI DM7DWVL DM7DWVL DN 1,1,1-Trifluoro-9-phenyl-nonan-2-one DM7DWVL TI TTDP1UC DM7DWVL TN Fatty acid amide hydrolase (FAAH) DM7DWVL MA Inhibitor DM7DWVL RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DM7DWVL RU https://pubmed.ncbi.nlm.nih.gov/15771430 DM7E391 DI DM7E391 DM7E391 DN PF-3900422 DM7E391 TI TT9JNIC DM7E391 TN Histamine H3 receptor (H3R) DM7E391 MA Antagonist DM7E391 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DM7E391 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DM7E4JU DI DM7E4JU DM7E4JU DN 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol DM7E4JU TI TTNJYV2 DM7E4JU TN Gamma-aminobutyric acid receptor (GAR) DM7E4JU MA Inhibitor DM7E4JU RN 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships. J Med Chem. 2007 Apr 19;50(8):1988-92. DM7E4JU RU https://pubmed.ncbi.nlm.nih.gov/17375905 DM7E4JU DI DM7E4JU DM7E4JU DN 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol DM7E4JU TI TT06RH5 DM7E4JU TN GABA(A) receptor gamma-2 (GABRG2) DM7E4JU MA Inhibitor DM7E4JU RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM7E4JU RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM7E4JU DI DM7E4JU DM7E4JU DN 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol DM7E4JU TI TTZA1NY DM7E4JU TN GABA(A) receptor beta-2 (GABRB2) DM7E4JU MA Inhibitor DM7E4JU RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM7E4JU RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM7E4JU DI DM7E4JU DM7E4JU DN 4-Phenyl-5-piperidin-4-yl-isoxazol-3-ol DM7E4JU TI TT1MPAY DM7E4JU TN GABA(A) receptor alpha-1 (GABRA1) DM7E4JU MA Inhibitor DM7E4JU RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM7E4JU RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM7EBQL DI DM7EBQL DM7EBQL DN 5-hexyl-2-(3-nitrophenoxy)phenol DM7EBQL TI TTVTX4N DM7EBQL TN Bacterial Fatty acid synthetase I (Bact inhA) DM7EBQL MA Inhibitor DM7EBQL RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DM7EBQL RU https://pubmed.ncbi.nlm.nih.gov/18457948 DM7EKAF DI DM7EKAF DM7EKAF DN Dimethylthiambutene DM7EKAF TI TT27RFC DM7EKAF TN Opioid receptor delta (OPRD1) DM7EKAF MA Agonist DM7EKAF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7EKAF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7EKAF DI DM7EKAF DM7EKAF DN Dimethylthiambutene DM7EKAF TI TTKWM86 DM7EKAF TN Opioid receptor mu (MOP) DM7EKAF MA Agonist DM7EKAF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7EKAF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7EKH3 DI DM7EKH3 DM7EKH3 DN Bip-tyr-thr-pro-lys-thr DM7EKH3 TI TTVBI8W DM7EKH3 TN Dopamine transporter (DAT) DM7EKH3 MA Inhibitor DM7EKH3 RN Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. DM7EKH3 RU https://pubmed.ncbi.nlm.nih.gov/16821765 DM7EQ06 DI DM7EQ06 DM7EQ06 DN 4-azidobenzenesulfonamide DM7EQ06 TI TTANPDJ DM7EQ06 TN Carbonic anhydrase II (CA-II) DM7EQ06 MA Inhibitor DM7EQ06 RN Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4624-7. DM7EQ06 RU https://pubmed.ncbi.nlm.nih.gov/18644716 DM7EQ06 DI DM7EQ06 DM7EQ06 DN 4-azidobenzenesulfonamide DM7EQ06 TI TT2LVK8 DM7EQ06 TN Carbonic anhydrase IX (CA-IX) DM7EQ06 MA Inhibitor DM7EQ06 RN Inhibition of carbonic anhydrase isozymes with benzene sulfonamides incorporating thio, sulfinyl and sulfonyl glycoside moieties. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2273-6. DM7EQ06 RU https://pubmed.ncbi.nlm.nih.gov/19286378 DM7EQ06 DI DM7EQ06 DM7EQ06 DN 4-azidobenzenesulfonamide DM7EQ06 TI TTHQPL7 DM7EQ06 TN Carbonic anhydrase I (CA-I) DM7EQ06 MA Inhibitor DM7EQ06 RN Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4624-7. DM7EQ06 RU https://pubmed.ncbi.nlm.nih.gov/18644716 DM7EQ06 DI DM7EQ06 DM7EQ06 DN 4-azidobenzenesulfonamide DM7EQ06 TI TTUNARX DM7EQ06 TN Carbonic anhydrase (CA) DM7EQ06 MA Inhibitor DM7EQ06 RN Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4624-7. DM7EQ06 RU https://pubmed.ncbi.nlm.nih.gov/18644716 DM7ERYJ DI DM7ERYJ DM7ERYJ DN 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ TI TTVG215 DM7ERYJ TN Debrisoquine 4-hydroxylase (CYP2D6) DM7ERYJ MA Inhibitor DM7ERYJ RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM7ERYJ RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM7ERYJ DI DM7ERYJ DM7ERYJ DN 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ TI TTXV4FI DM7ERYJ TN Albendazole monooxygenase (CYP3A4) DM7ERYJ MA Inhibitor DM7ERYJ RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM7ERYJ RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM7ERYJ DI DM7ERYJ DM7ERYJ DN 4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol DM7ERYJ TI TTIWB6L DM7ERYJ TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM7ERYJ MA Inhibitor DM7ERYJ RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DM7ERYJ RU https://pubmed.ncbi.nlm.nih.gov/19831396 DM7EUOX DI DM7EUOX DM7EUOX DN 2-(4-chlorophenyl)-6-morpholino-4H-pyran-4-one DM7EUOX TI TTK3PY9 DM7EUOX TN DNA-dependent protein kinase catalytic (PRKDC) DM7EUOX MA Inhibitor DM7EUOX RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM7EUOX RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM7EVQX DI DM7EVQX DM7EVQX DN ISIS 32003 DM7EVQX TI TT9H4P3 DM7EVQX TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DM7EVQX RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DM7EVQX RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DM7EWDN DI DM7EWDN DM7EWDN DN 6-Hydroxymethylpterin DM7EWDN TI TT38ECI DM7EWDN TN Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) DM7EWDN MA Inhibitor DM7EWDN RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM7EWDN RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM7EZBU DI DM7EZBU DM7EZBU DN MRS2698 DM7EZBU TI TTOZHQC DM7EZBU TN P2Y purinoceptor 2 (P2RY2) DM7EZBU MA Agonist DM7EZBU RN Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. J Med Chem. 2007 Mar 22;50(6):1166-76. DM7EZBU RU https://pubmed.ncbi.nlm.nih.gov/17302398 DM7F38J DI DM7F38J DM7F38J DN 4-isopropyl-2-(phenoxymethyl)morpholine DM7F38J TI TT9JNIC DM7F38J TN Histamine H3 receptor (H3R) DM7F38J MA Inhibitor DM7F38J RN 2-Aryloxymethylmorpholine histamine H(3) antagonists. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5796-9. DM7F38J RU https://pubmed.ncbi.nlm.nih.gov/18922693 DM7F3RY DI DM7F3RY DM7F3RY DN Nitrobenzylthioinosine DM7F3RY TI TTLXAKE DM7F3RY TN Solute carrier family 29 member 1 (SLC29A1) DM7F3RY MA Inhibitor DM7F3RY RN The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. Mol Pharmacol. 2008 Nov;74(5):1372-80. DM7F3RY RU https://pubmed.ncbi.nlm.nih.gov/18669604 DM7F3SE DI DM7F3SE DM7F3SE DN LU302872 DM7F3SE TI TT3ZTGU DM7F3SE TN Endothelin B receptor (EDNRB) DM7F3SE MA Antagonist DM7F3SE RN Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S. DM7F3SE RU https://pubmed.ncbi.nlm.nih.gov/12193103 DM7F3SE DI DM7F3SE DM7F3SE DN LU302872 DM7F3SE TI TTKRD0G DM7F3SE TN Endothelin A receptor (EDNRA) DM7F3SE MA Antagonist DM7F3SE RN Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S. DM7F3SE RU https://pubmed.ncbi.nlm.nih.gov/12193103 DM7FM8V DI DM7FM8V DM7FM8V DN PT-308 DM7FM8V TI TT84ETX DM7FM8V TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM7FM8V MA Inhibitor DM7FM8V RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM7FM8V RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM7FMWS DI DM7FMWS DM7FMWS DN 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DM7FMWS TI TT1MPAY DM7FMWS TN GABA(A) receptor alpha-1 (GABRA1) DM7FMWS MA Inhibitor DM7FMWS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM7FMWS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM7FMWS DI DM7FMWS DM7FMWS DN 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DM7FMWS TI TTNJYV2 DM7FMWS TN Gamma-aminobutyric acid receptor (GAR) DM7FMWS MA Inhibitor DM7FMWS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM7FMWS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM7FMWS DI DM7FMWS DM7FMWS DN 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DM7FMWS TI TT06RH5 DM7FMWS TN GABA(A) receptor gamma-2 (GABRG2) DM7FMWS MA Inhibitor DM7FMWS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM7FMWS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM7FMWS DI DM7FMWS DM7FMWS DN 6,9-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DM7FMWS TI TTZA1NY DM7FMWS TN GABA(A) receptor beta-2 (GABRB2) DM7FMWS MA Inhibitor DM7FMWS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DM7FMWS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DM7FPX8 DI DM7FPX8 DM7FPX8 DN Ethyl 7-hydroxy-2-oxo-2H-chromene-3-carboxylate DM7FPX8 TI TT6804T DM7FPX8 TN MIF messenger RNA (MIF mRNA) DM7FPX8 MA Inhibitor DM7FPX8 RN Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24. DM7FPX8 RU https://pubmed.ncbi.nlm.nih.gov/19090668 DM7FPZV DI DM7FPZV DM7FPZV DN ISIS 23454 DM7FPZV TI TTAIWZN DM7FPZV TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DM7FPZV RN US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression. DM7FPZV RU http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true DM7FQD0 DI DM7FQD0 DM7FQD0 DN VK-11 DM7FQD0 TI TTE4KHA DM7FQD0 TN Amyloid beta A4 protein (APP) DM7FQD0 MA Inhibitor DM7FQD0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM7FQD0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM7FQVC DI DM7FQVC DM7FQVC DN 3-(3'-furyl)-aniline DM7FQVC TI TTAWNKZ DM7FQVC TN Norepinephrine transporter (NET) DM7FQVC MA Inhibitor DM7FQVC RN Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32. DM7FQVC RU https://pubmed.ncbi.nlm.nih.gov/17367122 DM7FSZM DI DM7FSZM DM7FSZM DN 8-Methyl-2-(4-nitro-phenyl)-3H-quinazolin-4-one DM7FSZM TI TTVDSZ0 DM7FSZM TN Poly [ADP-ribose] polymerase 1 (PARP1) DM7FSZM MA Inhibitor DM7FSZM RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DM7FSZM RU https://pubmed.ncbi.nlm.nih.gov/9857092 DM7FT8D DI DM7FT8D DM7FT8D DN N,O-Didansyl-L-Tyrosine DM7FT8D TI TTU6BFZ DM7FT8D TN Candida Thymidylate synthase (Candi TMP1) DM7FT8D MA Inhibitor DM7FT8D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7FT8D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7FWK8 DI DM7FWK8 DM7FWK8 DN 1-(4-(benzyloxy)phenyl)-3-hydroxyurea DM7FWK8 TI TTULVH8 DM7FWK8 TN Tyrosinase (TYR) DM7FWK8 MA Inhibitor DM7FWK8 RN Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10. DM7FWK8 RU https://pubmed.ncbi.nlm.nih.gov/18501598 DM7FZHI DI DM7FZHI DM7FZHI DN (+)-Myristinin A DM7FZHI TI TTIU7X1 DM7FZHI TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM7FZHI MA Inhibitor DM7FZHI RN (+)-Myristinins A and D from Knema elegans, which inhibit DNA polymerase beta and cleave DNA. J Nat Prod. 2005 Nov;68(11):1625-8. DM7FZHI RU https://pubmed.ncbi.nlm.nih.gov/16309311 DM7FZU2 DI DM7FZU2 DM7FZU2 DN 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 TI TTSQIFT DM7FZU2 TN 5-HT 1A receptor (HTR1A) DM7FZU2 MA Inhibitor DM7FZU2 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DM7FZU2 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DM7FZU2 DI DM7FZU2 DM7FZU2 DN 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 TI TTO9X1H DM7FZU2 TN 5-HT 7 receptor (HTR7) DM7FZU2 MA Inhibitor DM7FZU2 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DM7FZU2 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DM7FZU2 DI DM7FZU2 DM7FZU2 DN 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 TI TT6MSOK DM7FZU2 TN 5-HT 1D receptor (HTR1D) DM7FZU2 MA Inhibitor DM7FZU2 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DM7FZU2 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DM7FZU2 DI DM7FZU2 DM7FZU2 DN 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 TI TTRUFDT DM7FZU2 TN 5-HT 5A receptor (HTR5A) DM7FZU2 MA Inhibitor DM7FZU2 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DM7FZU2 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DM7FZU2 DI DM7FZU2 DM7FZU2 DN 5-chloro-4-methyl-3,4-dihydroquinazolin-2-amine DM7FZU2 TI TTWJBZ5 DM7FZU2 TN 5-HT 2C receptor (HTR2C) DM7FZU2 MA Inhibitor DM7FZU2 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DM7FZU2 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DM7G2AB DI DM7G2AB DM7G2AB DN 1-(1-Adamantyl)-3-(1-propionylpiperidin-4-yl)urea DM7G2AB TI TT7WVHI DM7G2AB TN Soluble epoxide hydrolase (EPHX2) DM7G2AB MA Inhibitor DM7G2AB RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DM7G2AB RU https://pubmed.ncbi.nlm.nih.gov/20812725 DM7G8KR DI DM7G8KR DM7G8KR DN KR-62436 DM7G8KR TI TTDIGC1 DM7G8KR TN Dipeptidyl peptidase 4 (DPP-4) DM7G8KR MA Inhibitor DM7G8KR RN Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. Bioorg Med Chem. 2009 Mar 1;17(5):1783-802. DM7G8KR RU https://pubmed.ncbi.nlm.nih.gov/19217790 DM7GBDX DI DM7GBDX DM7GBDX DN N-Formylmethionine DM7GBDX TI TTNFESW DM7GBDX TN Glutamate--cysteine ligase modifier (GCLM) DM7GBDX MA Inhibitor DM7GBDX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7GBDX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7GBDX DI DM7GBDX DM7GBDX DN N-Formylmethionine DM7GBDX TI TT4QPUL DM7GBDX TN Antithrombin-III (ATIII) DM7GBDX MA Inhibitor DM7GBDX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7GBDX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7GBDX DI DM7GBDX DM7GBDX DN N-Formylmethionine DM7GBDX TI TTTJF7V DM7GBDX TN NADH dehydrogenase (MT-ND3) DM7GBDX MA Inhibitor DM7GBDX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7GBDX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7GDEK DI DM7GDEK DM7GDEK DN 1-benzylpiperidine hydrochloride DM7GDEK TI TTVBI8W DM7GDEK TN Dopamine transporter (DAT) DM7GDEK MA Inhibitor DM7GDEK RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM7GDEK RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM7GDEK DI DM7GDEK DM7GDEK DN 1-benzylpiperidine hydrochloride DM7GDEK TI TT3ROYC DM7GDEK TN Serotonin transporter (SERT) DM7GDEK MA Inhibitor DM7GDEK RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM7GDEK RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM7GI94 DI DM7GI94 DM7GI94 DN (2R,3S,4S,5R)-2-propylpiperidine-3,4,5-triol DM7GI94 TI TT1B5PU DM7GI94 TN Glucosylceramidase (GBA) DM7GI94 MA Inhibitor DM7GI94 RN Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors. Bioorg Med Chem. 2010 Apr 1;18(7):2645-50. DM7GI94 RU https://pubmed.ncbi.nlm.nih.gov/20231099 DM7GIZL DI DM7GIZL DM7GIZL DN 1-(4-butoxyphenyl)propan-2-amine DM7GIZL TI TT3WG5C DM7GIZL TN Monoamine oxidase type A (MAO-A) DM7GIZL MA Inhibitor DM7GIZL RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DM7GIZL RU https://pubmed.ncbi.nlm.nih.gov/19243954 DM7GN3E DI DM7GN3E DM7GN3E DN PT-312 DM7GN3E TI TT84ETX DM7GN3E TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM7GN3E MA Inhibitor DM7GN3E RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM7GN3E RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM7GUDC DI DM7GUDC DM7GUDC DN BMS-189323 DM7GUDC TI TTRK9JT DM7GUDC TN Neuropeptide Y receptor type 1 (NPY1R) DM7GUDC MA Inhibitor DM7GUDC RN Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY1 receptor antagonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):5975-8. DM7GUDC RU https://pubmed.ncbi.nlm.nih.gov/15546711 DM7GVYF DI DM7GVYF DM7GVYF DN [125I]BE-2254 DM7GVYF TI TT2NUT5 DM7GVYF TN Adrenergic receptor alpha-2C (ADRA2C) DM7GVYF MA Antagonist DM7GVYF RN Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42. DM7GVYF RU https://pubmed.ncbi.nlm.nih.gov/7815325 DM7GVYF DI DM7GVYF DM7GVYF DN [125I]BE-2254 DM7GVYF TI TTBRKXS DM7GVYF TN Adrenergic receptor alpha-1B (ADRA1B) DM7GVYF MA Antagonist DM7GVYF RN Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J Pharmacol Exp Ther. 1995 Jan;272(1):134-42. DM7GVYF RU https://pubmed.ncbi.nlm.nih.gov/7815325 DM7GW4P DI DM7GW4P DM7GW4P DN 4-oxo-4H-chromene-3-carboxylic acid DM7GW4P TI TTGP7BY DM7GW4P TN Monoamine oxidase type B (MAO-B) DM7GW4P MA Inhibitor DM7GW4P RN Chromone-2- and -3-carboxylic acids inhibit differently monoamine oxidases A and B. Bioorg Med Chem Lett. 2010 May 1;20(9):2709-12. DM7GW4P RU https://pubmed.ncbi.nlm.nih.gov/20382016 DM7GX1S DI DM7GX1S DM7GX1S DN GARVEATIN A DM7GX1S TI TTZJYKH DM7GX1S TN Indoleamine 2,3-dioxygenase 1 (IDO1) DM7GX1S MA Inhibitor DM7GX1S RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DM7GX1S RU https://pubmed.ncbi.nlm.nih.gov/17067170 DM7H34U DI DM7H34U DM7H34U DN 2,3,3-Triphenyl-acrylonitrile DM7H34U TI TT8QL1J DM7H34U TN Protein kinase C theta (PRKCQ) DM7H34U MA Inhibitor DM7H34U RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7H34U RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7H34U DI DM7H34U DM7H34U DN 2,3,3-Triphenyl-acrylonitrile DM7H34U TI TTFJ8Q1 DM7H34U TN Protein kinase C alpha (PRKCA) DM7H34U MA Inhibitor DM7H34U RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7H34U RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7H34U DI DM7H34U DM7H34U DN 2,3,3-Triphenyl-acrylonitrile DM7H34U TI TTYPXQF DM7H34U TN Protein kinase C beta (PRKCB) DM7H34U MA Inhibitor DM7H34U RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7H34U RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7H34U DI DM7H34U DM7H34U DN 2,3,3-Triphenyl-acrylonitrile DM7H34U TI TTUWGRA DM7H34U TN Protein kinase C zeta (PRKCZ) DM7H34U MA Inhibitor DM7H34U RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7H34U RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7H34U DI DM7H34U DM7H34U DN 2,3,3-Triphenyl-acrylonitrile DM7H34U TI TTRFOXJ DM7H34U TN Protein kinase C gamma (PRKCG) DM7H34U MA Inhibitor DM7H34U RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7H34U RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7H34U DI DM7H34U DM7H34U DN 2,3,3-Triphenyl-acrylonitrile DM7H34U TI TTBZ7OD DM7H34U TN Protein kinase C epsilon (PRKCE) DM7H34U MA Inhibitor DM7H34U RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7H34U RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7H34U DI DM7H34U DM7H34U DN 2,3,3-Triphenyl-acrylonitrile DM7H34U TI TT9WJ8U DM7H34U TN Protein kinase C delta (PRKCD) DM7H34U MA Inhibitor DM7H34U RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7H34U RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7H3JN DI DM7H3JN DM7H3JN DN [3H]CGS19755 DM7H3JN TI TT1M8OW DM7H3JN TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DM7H3JN MA Antagonist DM7H3JN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DM7H3JN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DM7H3JN DI DM7H3JN DM7H3JN DN [3H]CGS19755 DM7H3JN TI TTN9D8E DM7H3JN TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM7H3JN MA Antagonist DM7H3JN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DM7H3JN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DM7H3JN DI DM7H3JN DM7H3JN DN [3H]CGS19755 DM7H3JN TI TT5POTG DM7H3JN TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DM7H3JN MA Antagonist DM7H3JN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DM7H3JN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DM7H3JN DI DM7H3JN DM7H3JN DN [3H]CGS19755 DM7H3JN TI TTKJEMQ DM7H3JN TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM7H3JN MA Antagonist DM7H3JN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DM7H3JN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DM7H3JN DI DM7H3JN DM7H3JN DN [3H]CGS19755 DM7H3JN TI TTLD29N DM7H3JN TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM7H3JN MA Antagonist DM7H3JN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DM7H3JN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DM7H5KY DI DM7H5KY DM7H5KY DN PHASEOLIN DM7H5KY TI TT50QJ3 DM7H5KY TN Influenza Neuraminidase (Influ NA) DM7H5KY MA Inhibitor DM7H5KY RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DM7H5KY RU https://pubmed.ncbi.nlm.nih.gov/20363636 DM7HF4I DI DM7HF4I DM7HF4I DN (3-Amino-1-hydroxy-propyl)-methyl-phosphinic acid DM7HF4I TI TTDCVZW DM7HF4I TN Gamma-aminobutyric acid B receptor (GABBR) DM7HF4I MA Inhibitor DM7HF4I RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DM7HF4I RU https://pubmed.ncbi.nlm.nih.gov/7650684 DM7HGX8 DI DM7HGX8 DM7HGX8 DN aloisine DM7HGX8 TI TTUMHT8 DM7HGX8 TN Tyrosine-protein kinase ZAP-70 (ZAP-70) DM7HGX8 MA Inhibitor DM7HGX8 RN Identification of binding specificity-determining features in protein families. J Med Chem. 2012 Mar 8;55(5):1926-39. DM7HGX8 RU https://pubmed.ncbi.nlm.nih.gov/22289061 DM7HGX8 DI DM7HGX8 DM7HGX8 DN aloisine DM7HGX8 TI TTTEFBV DM7HGX8 TN Focal adhesion kinase 2 (PTK2B) DM7HGX8 MA Inhibitor DM7HGX8 RN Identification of binding specificity-determining features in protein families. J Med Chem. 2012 Mar 8;55(5):1926-39. DM7HGX8 RU https://pubmed.ncbi.nlm.nih.gov/22289061 DM7HGX8 DI DM7HGX8 DM7HGX8 DN aloisine DM7HGX8 TI TT7HF4W DM7HGX8 TN Cyclin-dependent kinase 2 (CDK2) DM7HGX8 MA Inhibitor DM7HGX8 RN Identification of binding specificity-determining features in protein families. J Med Chem. 2012 Mar 8;55(5):1926-39. DM7HGX8 RU https://pubmed.ncbi.nlm.nih.gov/22289061 DM7HKIF DI DM7HKIF DM7HKIF DN 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione DM7HKIF TI TTLD29N DM7HKIF TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM7HKIF MA Inhibitor DM7HKIF RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DM7HKIF RU https://pubmed.ncbi.nlm.nih.gov/8917653 DM7HKIF DI DM7HKIF DM7HKIF DN 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione DM7HKIF TI TTKJEMQ DM7HKIF TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM7HKIF MA Inhibitor DM7HKIF RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DM7HKIF RU https://pubmed.ncbi.nlm.nih.gov/8917653 DM7HKIF DI DM7HKIF DM7HKIF DN 3-Hydroxy-8-methyl-1H-benzo[b]azepine-2,5-dione DM7HKIF TI TTN9D8E DM7HKIF TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM7HKIF MA Inhibitor DM7HKIF RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DM7HKIF RU https://pubmed.ncbi.nlm.nih.gov/8917653 DM7HMNP DI DM7HMNP DM7HMNP DN 8-(3-Chlorobenzyloxy)caffeine DM7HMNP TI TT3WG5C DM7HMNP TN Monoamine oxidase type A (MAO-A) DM7HMNP MA Inhibitor DM7HMNP RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DM7HMNP RU https://pubmed.ncbi.nlm.nih.gov/20093036 DM7HMNP DI DM7HMNP DM7HMNP DN 8-(3-Chlorobenzyloxy)caffeine DM7HMNP TI TTGP7BY DM7HMNP TN Monoamine oxidase type B (MAO-B) DM7HMNP MA Inhibitor DM7HMNP RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DM7HMNP RU https://pubmed.ncbi.nlm.nih.gov/20093036 DM7HN4Z DI DM7HN4Z DM7HN4Z DN 2-(2'-methyl-biphenyl-3-yl)-ethylamine DM7HN4Z TI TTSQIFT DM7HN4Z TN 5-HT 1A receptor (HTR1A) DM7HN4Z MA Inhibitor DM7HN4Z RN Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22. DM7HN4Z RU https://pubmed.ncbi.nlm.nih.gov/17419056 DM7HN4Z DI DM7HN4Z DM7HN4Z DN 2-(2'-methyl-biphenyl-3-yl)-ethylamine DM7HN4Z TI TTO9X1H DM7HN4Z TN 5-HT 7 receptor (HTR7) DM7HN4Z MA Inhibitor DM7HN4Z RN Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22. DM7HN4Z RU https://pubmed.ncbi.nlm.nih.gov/17419056 DM7HNPJ DI DM7HNPJ DM7HNPJ DN 6-benzyl-3-propylaminocarbonyl-4-quinolone DM7HNPJ TI TT1MPAY DM7HNPJ TN GABA(A) receptor alpha-1 (GABRA1) DM7HNPJ MA Inhibitor DM7HNPJ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM7HNPJ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM7HNPJ DI DM7HNPJ DM7HNPJ DN 6-benzyl-3-propylaminocarbonyl-4-quinolone DM7HNPJ TI TTZA1NY DM7HNPJ TN GABA(A) receptor beta-2 (GABRB2) DM7HNPJ MA Inhibitor DM7HNPJ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM7HNPJ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM7HNPJ DI DM7HNPJ DM7HNPJ DN 6-benzyl-3-propylaminocarbonyl-4-quinolone DM7HNPJ TI TTNJYV2 DM7HNPJ TN Gamma-aminobutyric acid receptor (GAR) DM7HNPJ MA Inhibitor DM7HNPJ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM7HNPJ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM7HNPJ DI DM7HNPJ DM7HNPJ DN 6-benzyl-3-propylaminocarbonyl-4-quinolone DM7HNPJ TI TT06RH5 DM7HNPJ TN GABA(A) receptor gamma-2 (GABRG2) DM7HNPJ MA Inhibitor DM7HNPJ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM7HNPJ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM7HSCI DI DM7HSCI DM7HSCI DN A-420983 DM7HSCI TI TT9VGXW DM7HSCI TN Angiopoietin 1 receptor (TEK) DM7HSCI MA Inhibitor DM7HSCI RN A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6. DM7HSCI RU https://pubmed.ncbi.nlm.nih.gov/15109663 DM7HSCI DI DM7HSCI DM7HSCI DN A-420983 DM7HSCI TI TT6PKBN DM7HSCI TN Proto-oncogene c-Src (SRC) DM7HSCI MA Inhibitor DM7HSCI RN A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6. DM7HSCI RU https://pubmed.ncbi.nlm.nih.gov/15109663 DM7HSCI DI DM7HSCI DM7HSCI DN A-420983 DM7HSCI TI TT860QF DM7HSCI TN LCK tyrosine protein kinase (LCK) DM7HSCI MA Inhibitor DM7HSCI RN A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. Bioorg Med Chem Lett. 2004 May 17;14(10):2613-6. DM7HSCI RU https://pubmed.ncbi.nlm.nih.gov/15109663 DM7HYPZ DI DM7HYPZ DM7HYPZ DN PMID17574412C33 DM7HYPZ TI TTPADOQ DM7HYPZ TN HMG-CoA reductase (HMGCR) DM7HYPZ MA Inhibitor DM7HYPZ RN Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4538-44. DM7HYPZ RU https://pubmed.ncbi.nlm.nih.gov/17574412 DM7I21V DI DM7I21V DM7I21V DN 4-(4-(thiophen-3-yl)benzyl)pyridine DM7I21V TI TTIQUX7 DM7I21V TN Steroid 11-beta-hydroxylase (CYP11B1) DM7I21V MA Inhibitor DM7I21V RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM7I21V RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM7I21V DI DM7I21V DM7I21V DN 4-(4-(thiophen-3-yl)benzyl)pyridine DM7I21V TI TTRA5BZ DM7I21V TN Steroid 17-alpha-monooxygenase (S17AH) DM7I21V MA Inhibitor DM7I21V RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM7I21V RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM7I2TD DI DM7I2TD DM7I2TD DN N-hydroxy-2,2-diphenylpropanamide DM7I2TD TI TTBH0VX DM7I2TD TN Histone deacetylase (HDAC) DM7I2TD MA Inhibitor DM7I2TD RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM7I2TD RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM7I2TD DI DM7I2TD DM7I2TD DN N-hydroxy-2,2-diphenylpropanamide DM7I2TD TI TTTQGH8 DM7I2TD TN Histone deacetylase 4 (HDAC4) DM7I2TD MA Inhibitor DM7I2TD RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DM7I2TD RU https://pubmed.ncbi.nlm.nih.gov/19699639 DM7I341 DI DM7I341 DM7I341 DN PMID21155570C14 DM7I341 TI TTXJ47W DM7I341 TN Metabotropic glutamate receptor 2 (mGluR2) DM7I341 MA Modulator (allosteric modulator) DM7I341 RN Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem. 2011 Jan 13;54(1):342-53. DM7I341 RU https://pubmed.ncbi.nlm.nih.gov/21155570 DM7I6U8 DI DM7I6U8 DM7I6U8 DN MCL-450 DM7I6U8 TI TTKWM86 DM7I6U8 TN Opioid receptor mu (MOP) DM7I6U8 MA Inhibitor DM7I6U8 RN New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3. DM7I6U8 RU https://pubmed.ncbi.nlm.nih.gov/16942040 DM7I6U8 DI DM7I6U8 DM7I6U8 DN MCL-450 DM7I6U8 TI TTQW87Y DM7I6U8 TN Opioid receptor kappa (OPRK1) DM7I6U8 MA Inhibitor DM7I6U8 RN New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3. DM7I6U8 RU https://pubmed.ncbi.nlm.nih.gov/16942040 DM7I6U8 DI DM7I6U8 DM7I6U8 DN MCL-450 DM7I6U8 TI TT27RFC DM7I6U8 TN Opioid receptor delta (OPRD1) DM7I6U8 MA Inhibitor DM7I6U8 RN New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3. DM7I6U8 RU https://pubmed.ncbi.nlm.nih.gov/16942040 DM7IEL2 DI DM7IEL2 DM7IEL2 DN FD-1 DM7IEL2 TI TT8R70G DM7IEL2 TN Gonadotropin-releasing hormone receptor (GNRHR) DM7IEL2 MA Antagonist DM7IEL2 RN Amiloride derivatives and a nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing hormone receptor. Mol Pharmacol. 2008 Jun;73(6):1808-15. DM7IEL2 RU https://pubmed.ncbi.nlm.nih.gov/18344315 DM7IEU2 DI DM7IEU2 DM7IEU2 DN H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH DM7IEU2 TI TT27RFC DM7IEU2 TN Opioid receptor delta (OPRD1) DM7IEU2 MA Inhibitor DM7IEU2 RN Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5. DM7IEU2 RU https://pubmed.ncbi.nlm.nih.gov/19827750 DM7IEU2 DI DM7IEU2 DM7IEU2 DN H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH DM7IEU2 TI TTKWM86 DM7IEU2 TN Opioid receptor mu (MOP) DM7IEU2 MA Inhibitor DM7IEU2 RN Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5. DM7IEU2 RU https://pubmed.ncbi.nlm.nih.gov/19827750 DM7IGRT DI DM7IGRT DM7IGRT DN Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl DM7IGRT TI TTF2LRI DM7IGRT TN Cathepsin B (CTSB) DM7IGRT MA Inhibitor DM7IGRT RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM7IGRT RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM7IGRT DI DM7IGRT DM7IGRT DN Z-Ala-Leu-lle-Agly-Ile-Val-NHBzl DM7IGRT TI TTDZN01 DM7IGRT TN Cathepsin K (CTSK) DM7IGRT MA Inhibitor DM7IGRT RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM7IGRT RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM7IHUK DI DM7IHUK DM7IHUK DN 3-[7'-(Methoxy)-napht-2'-yl]-quinuclidine-2-ene DM7IHUK TI TTFQEO5 DM7IHUK TN Squalene synthetase (FDFT1) DM7IHUK MA Inhibitor DM7IHUK RN Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61. DM7IHUK RU https://pubmed.ncbi.nlm.nih.gov/17709461 DM7IK68 DI DM7IK68 DM7IK68 DN MRS 2219 DM7IK68 TI TTJW7B3 DM7IK68 TN P2X purinoceptor 1 (P2RX1) DM7IK68 MA Modulator (allosteric modulator) DM7IK68 RN A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem. 1998 Jun 18;41(13):2201-6. DM7IK68 RU https://pubmed.ncbi.nlm.nih.gov/9632352 DM7J0YG DI DM7J0YG DM7J0YG DN Phenyl-Uridine-5'-Diphosphate DM7J0YG TI TTGRHIB DM7J0YG TN UDP-glucose 4-epimerase (GALE) DM7J0YG MA Inhibitor DM7J0YG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7J0YG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7J3K0 DI DM7J3K0 DM7J3K0 DN AdcAhxArg6 DM7J3K0 TI TTNAHEX DM7J3K0 TN cAMP-dependent protein kinase A type I (PRKAR1A) DM7J3K0 MA Inhibitor DM7J3K0 RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DM7J3K0 RU https://pubmed.ncbi.nlm.nih.gov/12941328 DM7J3K0 DI DM7J3K0 DM7J3K0 DN AdcAhxArg6 DM7J3K0 TI TTW4Y2M DM7J3K0 TN cAMP protein kinase type II-beta (PRKAR2B) DM7J3K0 MA Inhibitor DM7J3K0 RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DM7J3K0 RU https://pubmed.ncbi.nlm.nih.gov/12941328 DM7J9O6 DI DM7J9O6 DM7J9O6 DN Ac-WKY-NH2 DM7J9O6 TI TTW5UDX DM7J9O6 TN Urotensin II receptor (UTS2R) DM7J9O6 MA Inhibitor DM7J9O6 RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DM7J9O6 RU https://pubmed.ncbi.nlm.nih.gov/20043680 DM7JKLM DI DM7JKLM DM7JKLM DN PMID1527791C29 DM7JKLM TI TTPADOQ DM7JKLM TN HMG-CoA reductase (HMGCR) DM7JKLM MA Inhibitor DM7JKLM RN Synthesis and biological evaluation of dihydroeptastatin, a novel inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem. 1992 Sep 4;35(18):3388-93. DM7JKLM RU https://pubmed.ncbi.nlm.nih.gov/1527791 DM7JMCI DI DM7JMCI DM7JMCI DN 1,2,3,4,4a,5-hexahydrophenanthridin-6(10bH)-one DM7JMCI TI TTVDSZ0 DM7JMCI TN Poly [ADP-ribose] polymerase 1 (PARP1) DM7JMCI MA Inhibitor DM7JMCI RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DM7JMCI RU https://pubmed.ncbi.nlm.nih.gov/19125579 DM7JQDS DI DM7JQDS DM7JQDS DN JWH-120 DM7JQDS TI TT6OEDT DM7JQDS TN Cannabinoid receptor 1 (CB1) DM7JQDS MA Inhibitor DM7JQDS RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DM7JQDS RU https://pubmed.ncbi.nlm.nih.gov/19143566 DM7JQDS DI DM7JQDS DM7JQDS DN JWH-120 DM7JQDS TI TTMSFAW DM7JQDS TN Cannabinoid receptor 2 (CB2) DM7JQDS MA Inhibitor DM7JQDS RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DM7JQDS RU https://pubmed.ncbi.nlm.nih.gov/19143566 DM7JRHB DI DM7JRHB DM7JRHB DN PMID21596927C101 DM7JRHB TI TTAZ3MN DM7JRHB TN Beta-adrenergic receptor kinase 1 (ADRBK1) DM7JRHB MA Inhibitor DM7JRHB RN Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol. 2011 Aug;80(2):294-303. DM7JRHB RU https://pubmed.ncbi.nlm.nih.gov/21596927 DM7JRHB DI DM7JRHB DM7JRHB DN PMID21596927C101 DM7JRHB TI TT5A4DX DM7JRHB TN Beta-adrenergic receptor kinase 2 (ADRBK2) DM7JRHB MA Inhibitor DM7JRHB RN Molecular mechanism of selectivity among G protein-coupled receptor kinase 2 inhibitors. Mol Pharmacol. 2011 Aug;80(2):294-303. DM7JRHB RU https://pubmed.ncbi.nlm.nih.gov/21596927 DM7JSQL DI DM7JSQL DM7JSQL DN [4',4''']-biflavone DM7JSQL TI TTT1JVS DM7JSQL TN Cytosolic phospholipase A2 (GIVA cPLA2) DM7JSQL MA Inhibitor DM7JSQL RN Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43. DM7JSQL RU https://pubmed.ncbi.nlm.nih.gov/17826099 DM7JUK0 DI DM7JUK0 DM7JUK0 DN 2-(2,6-Dimethyl-benzyl)-4,5-dihydro-1H-imidazole DM7JUK0 TI TT6MSOK DM7JUK0 TN 5-HT 1D receptor (HTR1D) DM7JUK0 MA Inhibitor DM7JUK0 RN 2-(Anilino)imidazolines and 2-(benzyl)imidazoline derivatives as h5-HT1D serotonin receptor ligands. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4697-9. DM7JUK0 RU https://pubmed.ncbi.nlm.nih.gov/15324890 DM7K0B3 DI DM7K0B3 DM7K0B3 DN 1-stearoyl-lysophosphatidylcholine DM7K0B3 TI TT7QNVC DM7K0B3 TN Glucose-dependent insulinotropic receptor (GPR119) DM7K0B3 MA Agonist DM7K0B3 RN Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51. DM7K0B3 RU https://pubmed.ncbi.nlm.nih.gov/15607732 DM7K0PH DI DM7K0PH DM7K0PH DN HI-281 DM7K0PH TI TT84ETX DM7K0PH TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM7K0PH MA Inhibitor DM7K0PH RN Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8. DM7K0PH RU https://pubmed.ncbi.nlm.nih.gov/10386942 DM7K14V DI DM7K14V DM7K14V DN Estradiol 17-O-sulfamate DM7K14V TI TTHM0R1 DM7K14V TN Steryl-sulfatase (STS) DM7K14V MA Inhibitor DM7K14V RN 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96. DM7K14V RU https://pubmed.ncbi.nlm.nih.gov/17181151 DM7K19L DI DM7K19L DM7K19L DN ISIS 2974 DM7K19L TI TTA1L39 DM7K19L TN ICAM1 messenger RNA (ICAM1 mRNA) DM7K19L RN US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion. DM7K19L RU http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true DM7K2DN DI DM7K2DN DM7K2DN DN 8alpha,19-dihydroxylabd-13 E-en-15-oic acid DM7K2DN TI TTVKILB DM7K2DN TN Prostaglandin G/H synthase 2 (COX-2) DM7K2DN MA Inhibitor DM7K2DN RN Cyclooxygenase (COX)-1 and -2 inhibitory labdane diterpenes from Crassocephalum mannii. J Nat Prod. 2008 Jun;71(6):1070-3. DM7K2DN RU https://pubmed.ncbi.nlm.nih.gov/18473477 DM7K360 DI DM7K360 DM7K360 DN AL-408 DM7K360 TI TTS87KH DM7K360 TN Microtubule-associated protein tau (MAPT) DM7K360 MA Modulator DM7K360 RN Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. DM7K360 RU https://pubmed.ncbi.nlm.nih.gov/21902667 DM7K36E DI DM7K36E DM7K36E DN NB-325 DM7K36E TI TTBID49 DM7K36E TN C-X-C chemokine receptor type 4 (CXCR4) DM7K36E MA Modulator DM7K36E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DM7K36E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DM7K5Z3 DI DM7K5Z3 DM7K5Z3 DN KYS-05071 DM7K5Z3 TI TT729IR DM7K5Z3 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM7K5Z3 MA Inhibitor DM7K5Z3 RN Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5014-7. DM7K5Z3 RU https://pubmed.ncbi.nlm.nih.gov/16876410 DM7KD5Y DI DM7KD5Y DM7KD5Y DN Azithromycin-N-benzyltriazolylhexahydroxamic Acid DM7KD5Y TI TTT6LFV DM7KD5Y TN Histone deacetylase 8 (HDAC8) DM7KD5Y MA Inhibitor DM7KD5Y RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DM7KD5Y RU https://pubmed.ncbi.nlm.nih.gov/19093884 DM7KD5Y DI DM7KD5Y DM7KD5Y DN Azithromycin-N-benzyltriazolylhexahydroxamic Acid DM7KD5Y TI TT6R7JZ DM7KD5Y TN Histone deacetylase 1 (HDAC1) DM7KD5Y MA Inhibitor DM7KD5Y RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DM7KD5Y RU https://pubmed.ncbi.nlm.nih.gov/19093884 DM7KDNM DI DM7KDNM DM7KDNM DN (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone DM7KDNM TI TT8FYO9 DM7KDNM TN Platelet-derived growth factor receptor alpha (PDGFRA) DM7KDNM MA Inhibitor DM7KDNM RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM7KDNM RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM7KDNM DI DM7KDNM DM7KDNM DN (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone DM7KDNM TI TTI7421 DM7KDNM TN Platelet-derived growth factor receptor beta (PDGFRB) DM7KDNM MA Inhibitor DM7KDNM RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM7KDNM RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM7KDNM DI DM7KDNM DM7KDNM DN (1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone DM7KDNM TI TTGJCWZ DM7KDNM TN Fms-like tyrosine kinase 3 (FLT-3) DM7KDNM MA Inhibitor DM7KDNM RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM7KDNM RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM7KDQV DI DM7KDQV DM7KDQV DN 2-Hex-5-enyl-5-non-8-enyl-pyrrolidine DM7KDQV TI TT1RS9F DM7KDQV TN Acetylcholinesterase (AChE) DM7KDQV MA Inhibitor DM7KDQV RN Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995). DM7KDQV RU http://www.sciencedirect.com/science/article/pii/0960894X9500179W DM7KIVX DI DM7KIVX DM7KIVX DN MT-001 DM7KIVX TI TTPADOQ DM7KIVX TN HMG-CoA reductase (HMGCR) DM7KIVX MA Modulator DM7KIVX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639). DM7KIVX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639 DM7KQXL DI DM7KQXL DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione DM7KQXL TI TTT6LFV DM7KQXL TN Histone deacetylase 8 (HDAC8) DM7KQXL MA Inhibitor DM7KQXL RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DM7KQXL RU https://pubmed.ncbi.nlm.nih.gov/18294844 DM7KQXL DI DM7KQXL DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione DM7KQXL TI TTTQGH8 DM7KQXL TN Histone deacetylase 4 (HDAC4) DM7KQXL MA Inhibitor DM7KQXL RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DM7KQXL RU https://pubmed.ncbi.nlm.nih.gov/18294844 DM7KQXL DI DM7KQXL DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione DM7KQXL TI TT6R7JZ DM7KQXL TN Histone deacetylase 1 (HDAC1) DM7KQXL MA Inhibitor DM7KQXL RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DM7KQXL RU https://pubmed.ncbi.nlm.nih.gov/18294844 DM7KQXL DI DM7KQXL DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione DM7KQXL TI TT5ZKDI DM7KQXL TN Histone deacetylase 6 (HDAC6) DM7KQXL MA Inhibitor DM7KQXL RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DM7KQXL RU https://pubmed.ncbi.nlm.nih.gov/18294844 DM7KQXL DI DM7KQXL DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione DM7KQXL TI TTBH0VX DM7KQXL TN Histone deacetylase (HDAC) DM7KQXL MA Inhibitor DM7KQXL RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DM7KQXL RU https://pubmed.ncbi.nlm.nih.gov/18294844 DM7KQXL DI DM7KQXL DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione DM7KQXL TI TTSHTOI DM7KQXL TN Histone deacetylase 2 (HDAC2) DM7KQXL MA Inhibitor DM7KQXL RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DM7KQXL RU https://pubmed.ncbi.nlm.nih.gov/18294844 DM7KQXL DI DM7KQXL DM7KQXL DN 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione DM7KQXL TI TTYHPU6 DM7KQXL TN Histone deacetylase 10 (HDAC10) DM7KQXL MA Inhibitor DM7KQXL RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DM7KQXL RU https://pubmed.ncbi.nlm.nih.gov/18294844 DM7KSRG DI DM7KSRG DM7KSRG DN ISIS 6442 DM7KSRG TI TTONI0R DM7KSRG TN PKC-eta messenger RNA (PRKCH mRNA) DM7KSRG RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DM7KSRG RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DM7KU1X DI DM7KU1X DM7KU1X DN 1-benzhydryl-4-phenylpiperidin-4-ol DM7KU1X TI TTKWM86 DM7KU1X TN Opioid receptor mu (MOP) DM7KU1X MA Inhibitor DM7KU1X RN The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. DM7KU1X RU https://pubmed.ncbi.nlm.nih.gov/19339177 DM7KU1X DI DM7KU1X DM7KU1X DN 1-benzhydryl-4-phenylpiperidin-4-ol DM7KU1X TI TTNT7K8 DM7KU1X TN Nociceptin receptor (OPRL1) DM7KU1X MA Inhibitor DM7KU1X RN The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. DM7KU1X RU https://pubmed.ncbi.nlm.nih.gov/19339177 DM7KU1X DI DM7KU1X DM7KU1X DN 1-benzhydryl-4-phenylpiperidin-4-ol DM7KU1X TI TTQW87Y DM7KU1X TN Opioid receptor kappa (OPRK1) DM7KU1X MA Inhibitor DM7KU1X RN The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. DM7KU1X RU https://pubmed.ncbi.nlm.nih.gov/19339177 DM7KU1X DI DM7KU1X DM7KU1X DN 1-benzhydryl-4-phenylpiperidin-4-ol DM7KU1X TI TT27RFC DM7KU1X TN Opioid receptor delta (OPRD1) DM7KU1X MA Inhibitor DM7KU1X RN The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23. DM7KU1X RU https://pubmed.ncbi.nlm.nih.gov/19339177 DM7KX2V DI DM7KX2V DM7KX2V DN N4-phenylethoxycytidine-5'-triphosphate DM7KX2V TI TT24DGP DM7KX2V TN P2Y purinoceptor 4 (P2RY4) DM7KX2V MA Agonist DM7KX2V RN Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33. DM7KX2V RU https://pubmed.ncbi.nlm.nih.gov/21528910 DM7L3DE DI DM7L3DE DM7L3DE DN NSC-78021 DM7L3DE TI TTJLP0R DM7L3DE TN Quinone reductase 2 (NQO2) DM7L3DE MA Inhibitor DM7L3DE RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM7L3DE RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM7L51U DI DM7L51U DM7L51U DN VU0400195 DM7L51U TI TTICZ1O DM7L51U TN Metabotropic glutamate receptor 4 (mGluR4) DM7L51U MA Modulator (allosteric modulator) DM7L51U RN Discovery, synthesis, and structure-activity relationship development of a series of N-4-(2,5-dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): characterization of a novel positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu(4)) with oral efficacy in an antiparkinsonian animal model. J Med Chem. 2011 Nov 10;54(21):7639-47. DM7L51U RU https://pubmed.ncbi.nlm.nih.gov/21966889 DM7LARD DI DM7LARD DM7LARD DN SB218078 DM7LARD TI TTTU902 DM7LARD TN Checkpoint kinase-1 (CHK1) DM7LARD MA Inhibitor DM7LARD RN Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade. Biochem Pharmacol. 2016 Apr 1;105:23-33. DM7LARD RU https://pubmed.ncbi.nlm.nih.gov/26850987 DM7LBEG DI DM7LBEG DM7LBEG DN 2-(4-Amino-phenyl)-8-hydroxy-3H-quinazolin-4-one DM7LBEG TI TTVDSZ0 DM7LBEG TN Poly [ADP-ribose] polymerase 1 (PARP1) DM7LBEG MA Inhibitor DM7LBEG RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DM7LBEG RU https://pubmed.ncbi.nlm.nih.gov/9857092 DM7LCPW DI DM7LCPW DM7LCPW DN C[-Arg-Gly-Asp-Acpca36-] DM7LCPW TI TTT1R2L DM7LCPW TN Integrin alpha-V (ITGAV) DM7LCPW MA Inhibitor DM7LCPW RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DM7LCPW RU https://pubmed.ncbi.nlm.nih.gov/16302808 DM7LCPW DI DM7LCPW DM7LCPW DN C[-Arg-Gly-Asp-Acpca36-] DM7LCPW TI TTJA1ZO DM7LCPW TN ITGB3 messenger RNA (ITGB3 mRNA) DM7LCPW MA Inhibitor DM7LCPW RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DM7LCPW RU https://pubmed.ncbi.nlm.nih.gov/16302808 DM7LGAF DI DM7LGAF DM7LGAF DN E6801 DM7LGAF TI TTJS8PY DM7LGAF TN 5-HT 6 receptor (HTR6) DM7LGAF MA Agonist DM7LGAF RN Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95. DM7LGAF RU https://pubmed.ncbi.nlm.nih.gov/15771424 DM7LGDC DI DM7LGDC DM7LGDC DN 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DM7LGDC TI TTML2WA DM7LGDC TN Tubulin (TUB) DM7LGDC MA Inhibitor DM7LGDC RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DM7LGDC RU https://pubmed.ncbi.nlm.nih.gov/9301667 DM7LGDC DI DM7LGDC DM7LGDC DN 7-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DM7LGDC TI TTYFKSZ DM7LGDC TN Tubulin beta (TUBB) DM7LGDC MA Inhibitor DM7LGDC RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DM7LGDC RU https://pubmed.ncbi.nlm.nih.gov/9301667 DM7LMD6 DI DM7LMD6 DM7LMD6 DN 3-(4-Benzyl-piperidin-1-ylmethyl)-chromen-4-one DM7LMD6 TI TTSQIFT DM7LMD6 TN 5-HT 1A receptor (HTR1A) DM7LMD6 MA Inhibitor DM7LMD6 RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DM7LMD6 RU https://pubmed.ncbi.nlm.nih.gov/15634021 DM7LN53 DI DM7LN53 DM7LN53 DN 4-cyclopentyliden(4-hydroxyphenyl)methylphenol DM7LN53 TI TTRFOXJ DM7LN53 TN Protein kinase C gamma (PRKCG) DM7LN53 MA Inhibitor DM7LN53 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7LN53 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7LN53 DI DM7LN53 DM7LN53 DN 4-cyclopentyliden(4-hydroxyphenyl)methylphenol DM7LN53 TI TTYPXQF DM7LN53 TN Protein kinase C beta (PRKCB) DM7LN53 MA Inhibitor DM7LN53 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7LN53 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7LN53 DI DM7LN53 DM7LN53 DN 4-cyclopentyliden(4-hydroxyphenyl)methylphenol DM7LN53 TI TTFJ8Q1 DM7LN53 TN Protein kinase C alpha (PRKCA) DM7LN53 MA Inhibitor DM7LN53 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM7LN53 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM7LOHK DI DM7LOHK DM7LOHK DN 2-(Oxalyl-Amino)-Benzoic Acid DM7LOHK TI TTELIN2 DM7LOHK TN PTPN1 messenger RNA (PTPN1 mRNA) DM7LOHK MA Inhibitor DM7LOHK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7LOHK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7LPI4 DI DM7LPI4 DM7LPI4 DN ISIS 11223 DM7LPI4 TI TTRE6AX DM7LPI4 TN Bcl-x messenger RNA (BCL2L1 mRNA) DM7LPI4 RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DM7LPI4 RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DM7LPON DI DM7LPON DM7LPON DN 4-Methyl-5,6-dihydro-pyrido[1,2-a]quinolin-3-one DM7LPON TI TTTU72V DM7LPON TN Steroid 5-alpha-reductase 1 (SRD5A1) DM7LPON MA Inhibitor DM7LPON RN Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem. 2000 Oct 5;43(20):3718-35. DM7LPON RU https://pubmed.ncbi.nlm.nih.gov/11020287 DM7LUI2 DI DM7LUI2 DM7LUI2 DN PMID30247903-Compound-General structure5 DM7LUI2 TI TT8ZLTI DM7LUI2 TN Programmed cell death 1 ligand 1 (PD-L1) DM7LUI2 MA Inhibitor DM7LUI2 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM7LUI2 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM7LV5A DI DM7LV5A DM7LV5A DN 4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine DM7LV5A TI TTVG215 DM7LV5A TN Debrisoquine 4-hydroxylase (CYP2D6) DM7LV5A MA Inhibitor DM7LV5A RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DM7LV5A RU https://pubmed.ncbi.nlm.nih.gov/14698153 DM7LV5A DI DM7LV5A DM7LV5A DN 4-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine DM7LV5A TI TTXV4FI DM7LV5A TN Albendazole monooxygenase (CYP3A4) DM7LV5A MA Inhibitor DM7LV5A RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DM7LV5A RU https://pubmed.ncbi.nlm.nih.gov/14698153 DM7LVKP DI DM7LVKP DM7LVKP DN 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine DM7LVKP TI TTM2AOE DM7LVKP TN Adenosine A2a receptor (ADORA2A) DM7LVKP MA Inhibitor DM7LVKP RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DM7LVKP RU https://pubmed.ncbi.nlm.nih.gov/18411049 DM7LVKP DI DM7LVKP DM7LVKP DN 4-(furan-2-yl)thieno[3,2-d]pyrimidin-2-amine DM7LVKP TI TTK25J1 DM7LVKP TN Adenosine A1 receptor (ADORA1) DM7LVKP MA Inhibitor DM7LVKP RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DM7LVKP RU https://pubmed.ncbi.nlm.nih.gov/18411049 DM7LZJ3 DI DM7LZJ3 DM7LZJ3 DN STX DM7LZJ3 TI TTZAYWL DM7LZJ3 TN Estrogen receptor (ESR) DM7LZJ3 MA Modulator DM7LZJ3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DM7LZJ3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DM7M1RZ DI DM7M1RZ DM7M1RZ DN 5-hydroxy-2-(propylthiomethyl)-4H-pyran-4-one DM7M1RZ TI TTULVH8 DM7M1RZ TN Tyrosinase (TYR) DM7M1RZ MA Inhibitor DM7M1RZ RN Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71. DM7M1RZ RU https://pubmed.ncbi.nlm.nih.gov/20934336 DM7M1UB DI DM7M1UB DM7M1UB DN ISIS 116362 DM7M1UB TI TTGECUM DM7M1UB TN Cot oncogene messenger RNA (MAP3K8 mRNA) DM7M1UB RN US patent application no. 6,265,216, Antisense modulation of cot oncogene expression. DM7M1UB RU http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true DM7M58P DI DM7M58P DM7M58P DN 6-hydroxydopa quinone DM7M58P TI TT7HC21 DM7M58P TN Membrane copper amine oxidase (AOC3) DM7M58P MA Inhibitor DM7M58P RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7M58P RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7M5AF DI DM7M5AF DM7M5AF DN pamoic acid DM7M5AF TI TT254XD DM7M5AF TN Kynurenic acid receptor (GPR35) DM7M5AF MA Agonist DM7M5AF RN Identification of novel species-selective agonists of the G-protein-coupled receptor GPR35 that promote recruitment of beta-arrestin-2 and activate Galpha13. Biochem J. 2010 Dec 15;432(3):451-9. DM7M5AF RU https://pubmed.ncbi.nlm.nih.gov/20919992 DM7M5VY DI DM7M5VY DM7M5VY DN NITROCEFIN DM7M5VY TI TTLP6GN DM7M5VY TN Bacterial DD-carboxypeptidase (Bact vanYB) DM7M5VY MA Inhibitor DM7M5VY RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM7M5VY RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM7M6T3 DI DM7M6T3 DM7M6T3 DN 2-(trifluoromethyl)-9H-carbazole DM7M6T3 TI TTBGTCW DM7M6T3 TN Kinesin spindle messenger RNA (KIF11 mRNA) DM7M6T3 MA Inhibitor DM7M6T3 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM7M6T3 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM7M9CL DI DM7M9CL DM7M9CL DN 2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile DM7M9CL TI TTK25J1 DM7M9CL TN Adenosine A1 receptor (ADORA1) DM7M9CL MA Inhibitor DM7M9CL RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DM7M9CL RU https://pubmed.ncbi.nlm.nih.gov/18637670 DM7M9CL DI DM7M9CL DM7M9CL DN 2-Amino-6-phenyl-4-thiophen-2-yl-nicotinonitrile DM7M9CL TI TTM2AOE DM7M9CL TN Adenosine A2a receptor (ADORA2A) DM7M9CL MA Inhibitor DM7M9CL RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DM7M9CL RU https://pubmed.ncbi.nlm.nih.gov/18637670 DM7M9O2 DI DM7M9O2 DM7M9O2 DN Benzylcarbamic Acid Biphenyl-3-yl Ester DM7M9O2 TI TTDP1UC DM7M9O2 TN Fatty acid amide hydrolase (FAAH) DM7M9O2 MA Inhibitor DM7M9O2 RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DM7M9O2 RU https://pubmed.ncbi.nlm.nih.gov/18507372 DM7MHQD DI DM7MHQD DM7MHQD DN N-(4-Sulfamoyl-phenyl)-propionamide DM7MHQD TI TTHQPL7 DM7MHQD TN Carbonic anhydrase I (CA-I) DM7MHQD MA Inhibitor DM7MHQD RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM7MHQD RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM7MHQD DI DM7MHQD DM7MHQD DN N-(4-Sulfamoyl-phenyl)-propionamide DM7MHQD TI TTSYM0R DM7MHQD TN Carbonic anhydrase XII (CA-XII) DM7MHQD MA Inhibitor DM7MHQD RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM7MHQD RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM7MHQD DI DM7MHQD DM7MHQD DN N-(4-Sulfamoyl-phenyl)-propionamide DM7MHQD TI TTANPDJ DM7MHQD TN Carbonic anhydrase II (CA-II) DM7MHQD MA Inhibitor DM7MHQD RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM7MHQD RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM7MHQD DI DM7MHQD DM7MHQD DN N-(4-Sulfamoyl-phenyl)-propionamide DM7MHQD TI TT2LVK8 DM7MHQD TN Carbonic anhydrase IX (CA-IX) DM7MHQD MA Inhibitor DM7MHQD RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DM7MHQD RU https://pubmed.ncbi.nlm.nih.gov/16168653 DM7MNOX DI DM7MNOX DM7MNOX DN C7/3-phth DM7MNOX TI TTOXS3C DM7MNOX TN Muscarinic acetylcholine receptor (CHRM) DM7MNOX MA Modulator (allosteric modulator) DM7MNOX RN Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis-(dimethyl-3'-phthalimidopropyl) ammonium bromide (C7/3-phth) at cloned muscarinic acetylcholine receptors. Biochem Pharmacol. 1999 Jan 15;57(2):171-9. DM7MNOX RU https://pubmed.ncbi.nlm.nih.gov/9890565 DM7MSGK DI DM7MSGK DM7MSGK DN SM 21 DM7MSGK TI TT9NXW4 DM7MSGK TN Sigma intracellular receptor 2 (TMEM97) DM7MSGK MA Antagonist DM7MSGK RN The analgesic tropane analogue (+/-)-SM 21 has a high affinity for sigma2 receptors. Life Sci. 1999;64(10):PL131-7. DM7MSGK RU https://pubmed.ncbi.nlm.nih.gov/10096443 DM7MUJ3 DI DM7MUJ3 DM7MUJ3 DN HITOPK-032 DM7MUJ3 TI TTMY6BZ DM7MUJ3 TN PDZ binding kinase (PBK) DM7MUJ3 MA Inhibitor DM7MUJ3 RN PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.Oncotarget. 2016 May 3;7(18):26604-16. DM7MUJ3 RU https://pubmed.ncbi.nlm.nih.gov/27049917 DM7MUZ1 DI DM7MUZ1 DM7MUZ1 DN 2-Hydroxymethyl-Pyrrolidine-3,4-Diol DM7MUZ1 TI TTMCF1Y DM7MUZ1 TN Purine nucleoside phosphorylase (PNP) DM7MUZ1 MA Inhibitor DM7MUZ1 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM7MUZ1 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM7MZ2V DI DM7MZ2V DM7MZ2V DN Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V TI TTZ6T9E DM7MZ2V TN Somatostatin receptor type 2 (SSTR2) DM7MZ2V MA Inhibitor DM7MZ2V RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM7MZ2V RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM7MZ2V DI DM7MZ2V DM7MZ2V DN Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V TI TTAE1BR DM7MZ2V TN Somatostatin receptor type 4 (SSTR4) DM7MZ2V MA Inhibitor DM7MZ2V RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM7MZ2V RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM7MZ2V DI DM7MZ2V DM7MZ2V DN Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V TI TTIND6G DM7MZ2V TN Somatostatin receptor type 1 (SSTR1) DM7MZ2V MA Inhibitor DM7MZ2V RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM7MZ2V RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM7MZ2V DI DM7MZ2V DM7MZ2V DN Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V TI TTJX3UE DM7MZ2V TN Somatostatin receptor type 3 (SSTR3) DM7MZ2V MA Inhibitor DM7MZ2V RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM7MZ2V RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM7MZ2V DI DM7MZ2V DM7MZ2V DN Des-AA1,2,5-[D-Trp8,Tyr11]SRIF DM7MZ2V TI TT2BC4G DM7MZ2V TN Somatostatin receptor type 5 (SSTR5) DM7MZ2V MA Inhibitor DM7MZ2V RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM7MZ2V RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM7NGV1 DI DM7NGV1 DM7NGV1 DN 2-(3'-Vinyl-biphenyl-4-yl)-propionic acid DM7NGV1 TI TT8NGED DM7NGV1 TN Prostaglandin G/H synthase 1 (COX-1) DM7NGV1 MA Inhibitor DM7NGV1 RN Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12. DM7NGV1 RU https://pubmed.ncbi.nlm.nih.gov/10091674 DM7NHRV DI DM7NHRV DM7NHRV DN N-benzyl-6-(3,3,3-trifluoropropoxy)nicotinamide DM7NHRV TI TT7WVHI DM7NHRV TN Soluble epoxide hydrolase (EPHX2) DM7NHRV MA Inhibitor DM7NHRV RN Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. DM7NHRV RU https://pubmed.ncbi.nlm.nih.gov/19758802 DM7NJI2 DI DM7NJI2 DM7NJI2 DN NDC-1022 DM7NJI2 TI TTOM3J0 DM7NJI2 TN Estrogen receptor beta (ESR2) DM7NJI2 MA Agonist DM7NJI2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621). DM7NJI2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621 DM7NKRO DI DM7NKRO DM7NKRO DN ISIS 23559 DM7NKRO TI TT1F8OQ DM7NKRO TN IKKA messenger RNA (IKKA mRNA) DM7NKRO RN US patent application no. 6,395,545, Antisense modulation of inhibitor-kappa B kinase-alpha expression. DM7NKRO RU http://www.patentbuddy.com/Patent/6395545?ft=true&sr=true DM7NRK5 DI DM7NRK5 DM7NRK5 DN Verdoheme DM7NRK5 TI TTI6V2A DM7NRK5 TN Heme oxygenase 1 (HMOX1) DM7NRK5 MA Inhibitor DM7NRK5 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM7NRK5 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM7NSRI DI DM7NSRI DM7NSRI DN 16-(pyridin-4-yl)methyl-estradiol DM7NSRI TI TTIWB6L DM7NSRI TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM7NSRI MA Inhibitor DM7NSRI RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM7NSRI RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM7NXMB DI DM7NXMB DM7NXMB DN [HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL DM7NXMB TI TTICO5G DM7NXMB TN Staphylococcus Peptide deformylase (Stap-coc def) DM7NXMB MA Inhibitor DM7NXMB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM7NXMB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM7O1F3 DI DM7O1F3 DM7O1F3 DN N-(quinolin-8-yl)thiophene-2-sulfonamide DM7O1F3 TI TTSXVID DM7O1F3 TN Nuclear factor NF-kappa-B (NFKB) DM7O1F3 MA Inhibitor DM7O1F3 RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DM7O1F3 RU https://pubmed.ncbi.nlm.nih.gov/18024113 DM7O1IW DI DM7O1IW DM7O1IW DN D-mannose 1-phosphate DM7O1IW TI TTLP3GX DM7O1IW TN Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC) DM7O1IW MA Inhibitor DM7O1IW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7O1IW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7O2K1 DI DM7O2K1 DM7O2K1 DN VER-3323 DM7O2K1 TI TT0K1SC DM7O2K1 TN 5-HT 2B receptor (HTR2B) DM7O2K1 MA Inhibitor DM7O2K1 RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DM7O2K1 RU https://pubmed.ncbi.nlm.nih.gov/15081042 DM7O2K1 DI DM7O2K1 DM7O2K1 DN VER-3323 DM7O2K1 TI TTJQOD7 DM7O2K1 TN 5-HT 2A receptor (HTR2A) DM7O2K1 MA Inhibitor DM7O2K1 RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DM7O2K1 RU https://pubmed.ncbi.nlm.nih.gov/15081042 DM7O2K1 DI DM7O2K1 DM7O2K1 DN VER-3323 DM7O2K1 TI TTWJBZ5 DM7O2K1 TN 5-HT 2C receptor (HTR2C) DM7O2K1 MA Inhibitor DM7O2K1 RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DM7O2K1 RU https://pubmed.ncbi.nlm.nih.gov/15081042 DM7O5WS DI DM7O5WS DM7O5WS DN N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide DM7O5WS TI TTDP1UC DM7O5WS TN Fatty acid amide hydrolase (FAAH) DM7O5WS MA Inhibitor DM7O5WS RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DM7O5WS RU https://pubmed.ncbi.nlm.nih.gov/19053765 DM7O5WS DI DM7O5WS DM7O5WS DN N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide DM7O5WS TI TT6OEDT DM7O5WS TN Cannabinoid receptor 1 (CB1) DM7O5WS MA Inhibitor DM7O5WS RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DM7O5WS RU https://pubmed.ncbi.nlm.nih.gov/19053765 DM7O5WS DI DM7O5WS DM7O5WS DN N-(4-hydroxybenzyl)icosa-5,8,11,14-tetraenamide DM7O5WS TI TTMSFAW DM7O5WS TN Cannabinoid receptor 2 (CB2) DM7O5WS MA Inhibitor DM7O5WS RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DM7O5WS RU https://pubmed.ncbi.nlm.nih.gov/19053765 DM7OA4R DI DM7OA4R DM7OA4R DN N-[3'-(trifluoromethyl)-4-biphenylyl]urea DM7OA4R TI TTBGTCW DM7OA4R TN Kinesin spindle messenger RNA (KIF11 mRNA) DM7OA4R MA Inhibitor DM7OA4R RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DM7OA4R RU https://pubmed.ncbi.nlm.nih.gov/17725339 DM7OF6N DI DM7OF6N DM7OF6N DN Brodimoprim-4,6-Dicarboxylate DM7OF6N TI TT9SL3Q DM7OF6N TN Polypeptide deformylase (PDF) DM7OF6N MA Inhibitor DM7OF6N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7OF6N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7OGLI DI DM7OGLI DM7OGLI DN 1-(7-Hydroxy-naphthalen-1-yl)-3-pyridin-2-yl-urea DM7OGLI TI TT0PG8F DM7OGLI TN Cyclin-dependent kinase 4 (CDK4) DM7OGLI MA Inhibitor DM7OGLI RN Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. DM7OGLI RU https://pubmed.ncbi.nlm.nih.gov/11741479 DM7OHSX DI DM7OHSX DM7OHSX DN 2-phenylpiperidine hydrochloride DM7OHSX TI TTVBI8W DM7OHSX TN Dopamine transporter (DAT) DM7OHSX MA Inhibitor DM7OHSX RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM7OHSX RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM7OIY8 DI DM7OIY8 DM7OIY8 DN C[L-Tyr-D-pro-L-Phe-D-trp] DM7OIY8 TI TTKWM86 DM7OIY8 TN Opioid receptor mu (MOP) DM7OIY8 MA Inhibitor DM7OIY8 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM7OIY8 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM7OIY8 DI DM7OIY8 DM7OIY8 DN C[L-Tyr-D-pro-L-Phe-D-trp] DM7OIY8 TI TTQW87Y DM7OIY8 TN Opioid receptor kappa (OPRK1) DM7OIY8 MA Inhibitor DM7OIY8 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM7OIY8 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM7OJ5Q DI DM7OJ5Q DM7OJ5Q DN PMID22607879CR-(-)-5f DM7OJ5Q TI TT5Y4EM DM7OJ5Q TN N-formyl peptide receptor (FPR1) DM7OJ5Q MA Agonist DM7OJ5Q RN Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92. DM7OJ5Q RU https://pubmed.ncbi.nlm.nih.gov/22607879 DM7OJ5Q DI DM7OJ5Q DM7OJ5Q DN PMID22607879CR-(-)-5f DM7OJ5Q TI TTOJ1NF DM7OJ5Q TN FMLP-related receptor I (FPR2) DM7OJ5Q MA Agonist DM7OJ5Q RN Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists. Bioorg Med Chem. 2012 Jun 15;20(12):3781-92. DM7OJ5Q RU https://pubmed.ncbi.nlm.nih.gov/22607879 DM7OPCH DI DM7OPCH DM7OPCH DN Apogossypol DM7OPCH TI TTJGNVC DM7OPCH TN Apoptosis regulator Bcl-2 (BCL-2) DM7OPCH MA Inhibitor DM7OPCH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7920). DM7OPCH RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7920 DM7OSZI DI DM7OSZI DM7OSZI DN ISIS 122976 DM7OSZI TI TTJZNIG DM7OSZI TN MEKK3 messenger RNA (MAP3K3 mRNA) DM7OSZI RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DM7OSZI RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DM7OZ2T DI DM7OZ2T DM7OZ2T DN N8-hydroxy-2-methoxy-N1-phenyloctanediamide DM7OZ2T TI TTSHTOI DM7OZ2T TN Histone deacetylase 2 (HDAC2) DM7OZ2T MA Inhibitor DM7OZ2T RN Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. DM7OZ2T RU https://pubmed.ncbi.nlm.nih.gov/17892933 DM7P0H6 DI DM7P0H6 DM7P0H6 DN Y-c[D-Pen-(2R,3S)-2-Me-(2')Nal-GSFC]KR-NH2 DM7P0H6 TI TT6PKBN DM7P0H6 TN Proto-oncogene c-Src (SRC) DM7P0H6 MA Inhibitor DM7P0H6 RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DM7P0H6 RU https://pubmed.ncbi.nlm.nih.gov/9632358 DM7P3IZ DI DM7P3IZ DM7P3IZ DN 3-aminobenzamide DM7P3IZ TI TTVDSZ0 DM7P3IZ TN Poly [ADP-ribose] polymerase 1 (PARP1) DM7P3IZ MA Inhibitor DM7P3IZ RN Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001 Jan;7(1):108-13. DM7P3IZ RU https://pubmed.ncbi.nlm.nih.gov/11135624 DM7P3N5 DI DM7P3N5 DM7P3N5 DN 1-DODECANOL DM7P3N5 TI TTDP1UC DM7P3N5 TN Fatty acid amide hydrolase (FAAH) DM7P3N5 MA Inhibitor DM7P3N5 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM7P3N5 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM7P5VM DI DM7P5VM DM7P5VM DN (E)-2-(4-fluorostyryl)-5-(phenylsulfonyl)pyridine DM7P5VM TI TTJQOD7 DM7P5VM TN 5-HT 2A receptor (HTR2A) DM7P5VM MA Inhibitor DM7P5VM RN 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8. DM7P5VM RU https://pubmed.ncbi.nlm.nih.gov/17314044 DM7PHO4 DI DM7PHO4 DM7PHO4 DN 3-Isopropoxy-9H-beta-carboline DM7PHO4 TI TT1MPAY DM7PHO4 TN GABA(A) receptor alpha-1 (GABRA1) DM7PHO4 MA Inhibitor DM7PHO4 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DM7PHO4 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DM7PHO4 DI DM7PHO4 DM7PHO4 DN 3-Isopropoxy-9H-beta-carboline DM7PHO4 TI TTNJYV2 DM7PHO4 TN Gamma-aminobutyric acid receptor (GAR) DM7PHO4 MA Inhibitor DM7PHO4 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DM7PHO4 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DM7PJN9 DI DM7PJN9 DM7PJN9 DN 8-Hexyloxy-quinolin-2-ylamine DM7PJN9 TI TTX4RTB DM7PJN9 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM7PJN9 MA Inhibitor DM7PJN9 RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM7PJN9 RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM7PNOK DI DM7PNOK DM7PNOK DN DTS-108 DM7PNOK TI TTGTQHC DM7PNOK TN DNA topoisomerase I (TOP1) DM7PNOK MA Inhibitor DM7PNOK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DM7PNOK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DM7PR5E DI DM7PR5E DM7PR5E DN Gal-B5 DM7PR5E TI TTX3HNZ DM7PR5E TN Galanin receptor type 1 (GAL1-R) DM7PR5E MA Inhibitor DM7PR5E RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM7PR5E RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM7PR5E DI DM7PR5E DM7PR5E DN Gal-B5 DM7PR5E TI TTBPW3J DM7PR5E TN Galanin receptor type 2 (GAL2-R) DM7PR5E MA Inhibitor DM7PR5E RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DM7PR5E RU https://pubmed.ncbi.nlm.nih.gov/20121116 DM7PRDY DI DM7PRDY DM7PRDY DN methylhistaprodifen DM7PRDY TI TTTIBOJ DM7PRDY TN Histamine H1 receptor (H1R) DM7PRDY MA Agonist DM7PRDY RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DM7PRDY RU https://pubmed.ncbi.nlm.nih.gov/12626648 DM7PWOL DI DM7PWOL DM7PWOL DN 4'-hydroxy-6,3',5'-triprenylisoflavonone DM7PWOL TI TT9V5JH DM7PWOL TN Phospholipase A2 (PLA2G1B) DM7PWOL MA Inhibitor DM7PWOL RN Phospholipase A2 Inhibitors from an Erythrina Species from Samoa J. Nat. Prod. 60(6):537-539 (1997). DM7PWOL RU http://pubs.acs.org/doi/abs/10.1021/np960533e DM7Q12B DI DM7Q12B DM7Q12B DN Salvinorin B butoxymethyl ether DM7Q12B TI TTQW87Y DM7Q12B TN Opioid receptor kappa (OPRK1) DM7Q12B MA Inhibitor DM7Q12B RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DM7Q12B RU https://pubmed.ncbi.nlm.nih.gov/17981041 DM7Q6M0 DI DM7Q6M0 DM7Q6M0 DN Formaldehyde DM7Q6M0 TI TTELV3W DM7Q6M0 TN Transformation-sensitive protein p120 (TRPA1) DM7Q6M0 MA Activator DM7Q6M0 RN An ion channel essential for sensing chemical damage. J Neurosci. 2007 Oct 17;27(42):11412-5. DM7Q6M0 RU https://pubmed.ncbi.nlm.nih.gov/17942735 DM7Q6M0 DI DM7Q6M0 DM7Q6M0 DN Formaldehyde DM7Q6M0 TI TTLP6GN DM7Q6M0 TN Bacterial DD-carboxypeptidase (Bact vanYB) DM7Q6M0 MA Inhibitor DM7Q6M0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7Q6M0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7QAES DI DM7QAES DM7QAES DN H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 DM7QAES TI TTKWM86 DM7QAES TN Opioid receptor mu (MOP) DM7QAES MA Inhibitor DM7QAES RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DM7QAES RU https://pubmed.ncbi.nlm.nih.gov/17315860 DM7QAES DI DM7QAES DM7QAES DN H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 DM7QAES TI TTQW87Y DM7QAES TN Opioid receptor kappa (OPRK1) DM7QAES MA Inhibitor DM7QAES RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DM7QAES RU https://pubmed.ncbi.nlm.nih.gov/17315860 DM7QAES DI DM7QAES DM7QAES DN H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 DM7QAES TI TT27RFC DM7QAES TN Opioid receptor delta (OPRD1) DM7QAES MA Inhibitor DM7QAES RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DM7QAES RU https://pubmed.ncbi.nlm.nih.gov/17315860 DM7QAKB DI DM7QAKB DM7QAKB DN [Thr4,Gly7]OT DM7QAKB TI TTSCIUP DM7QAKB TN Oxytocin receptor (OTR) DM7QAKB MA Agonist DM7QAKB RN [3H]-[Thr4,Gly7]OT: a highly selective ligand for central and peripheral OT receptors. Am J Physiol. 1988 Jan;254(1 Pt 1):E31-8. DM7QAKB RU https://pubmed.ncbi.nlm.nih.gov/2827511 DM7QAKB DI DM7QAKB DM7QAKB DN [Thr4,Gly7]OT DM7QAKB TI TT4TFGN DM7QAKB TN Vasopressin V1a receptor (V1AR) DM7QAKB MA Agonist DM7QAKB RN Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44. DM7QAKB RU https://pubmed.ncbi.nlm.nih.gov/9334232 DM7QE1J DI DM7QE1J DM7QE1J DN [3H](+)-isradipine DM7QE1J TI TT7RGTM DM7QE1J TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DM7QE1J MA Inhibitor (gating inhibitor) DM7QE1J RN alpha 1D (Cav1.3) subunits can form l-type Ca2+ channels activating at negative voltages. J Biol Chem. 2001 Jun 22;276(25):22100-6. DM7QE1J RU https://pubmed.ncbi.nlm.nih.gov/11285265 DM7QE1J DI DM7QE1J DM7QE1J DN [3H](+)-isradipine DM7QE1J TI TTZIFHC DM7QE1J TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DM7QE1J MA Inhibitor (gating inhibitor) DM7QE1J RN Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J Clin Invest. 2004 May;113(10):1430-9. DM7QE1J RU https://pubmed.ncbi.nlm.nih.gov/15146240 DM7QE1J DI DM7QE1J DM7QE1J DN [3H](+)-isradipine DM7QE1J TI TT94HRF DM7QE1J TN Voltage-gated calcium channel alpha Cav1.1 (CACNA1S) DM7QE1J MA Inhibitor (gating inhibitor) DM7QE1J RN Biochemical characterization of plasma membrane isolated from human skeletal muscle. FEBS Lett. 1985 Sep 2;188(2):222-6. DM7QE1J RU https://pubmed.ncbi.nlm.nih.gov/2411596 DM7QE51 DI DM7QE51 DM7QE51 DN I-309 DM7QE51 TI TTE836A DM7QE51 TN C-C chemokine receptor type 8 (CCR8) DM7QE51 MA Binder DM7QE51 RN The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol. 1998 Jul 15;161(2):547-51. DM7QE51 RU https://pubmed.ncbi.nlm.nih.gov/9670926 DM7QK5C DI DM7QK5C DM7QK5C DN 2-(4-bromo-2-(hydroxymethyl)phenoxy)acetic acid DM7QK5C TI TTQDMX5 DM7QK5C TN Prostaglandin D2 receptor 2 (PTGDR2) DM7QK5C MA Inhibitor DM7QK5C RN Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41. DM7QK5C RU https://pubmed.ncbi.nlm.nih.gov/17154491 DM7QX03 DI DM7QX03 DM7QX03 DN N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide DM7QX03 TI TTHQPL7 DM7QX03 TN Carbonic anhydrase I (CA-I) DM7QX03 MA Inhibitor DM7QX03 RN Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Med Chem. 2010 Jul 15;18(14):5081-9. DM7QX03 RU https://pubmed.ncbi.nlm.nih.gov/20580561 DM7QX03 DI DM7QX03 DM7QX03 DN N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide DM7QX03 TI TT2LVK8 DM7QX03 TN Carbonic anhydrase IX (CA-IX) DM7QX03 MA Inhibitor DM7QX03 RN Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Med Chem. 2010 Jul 15;18(14):5081-9. DM7QX03 RU https://pubmed.ncbi.nlm.nih.gov/20580561 DM7QX03 DI DM7QX03 DM7QX03 DN N-(4-sulfamoylphenylethyl)-4-sulfamoylbenzamide DM7QX03 TI TTANPDJ DM7QX03 TN Carbonic anhydrase II (CA-II) DM7QX03 MA Inhibitor DM7QX03 RN Pteridine-sulfonamide conjugates as dual inhibitors of carbonic anhydrases and dihydrofolate reductase with potential antitumor activity. Bioorg Med Chem. 2010 Jul 15;18(14):5081-9. DM7QX03 RU https://pubmed.ncbi.nlm.nih.gov/20580561 DM7R1XS DI DM7R1XS DM7R1XS DN JWH-441 DM7R1XS TI TTMSFAW DM7R1XS TN Cannabinoid receptor 2 (CB2) DM7R1XS MA Inhibitor DM7R1XS RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DM7R1XS RU https://pubmed.ncbi.nlm.nih.gov/20621488 DM7R53M DI DM7R53M DM7R53M DN ISIS 112022 DM7R53M TI TTPJ9XK DM7R53M TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DM7R53M RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DM7R53M RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DM7R605 DI DM7R605 DM7R605 DN AM-630 DM7R605 TI TTMSFAW DM7R605 TN Cannabinoid receptor 2 (CB2) DM7R605 MA Inhibitor DM7R605 RN New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10. DM7R605 RU https://pubmed.ncbi.nlm.nih.gov/17942307 DM7R605 DI DM7R605 DM7R605 DN AM-630 DM7R605 TI TT6OEDT DM7R605 TN Cannabinoid receptor 1 (CB1) DM7R605 MA Inhibitor DM7R605 RN New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10. DM7R605 RU https://pubmed.ncbi.nlm.nih.gov/17942307 DM7R8DJ DI DM7R8DJ DM7R8DJ DN A-582941 DM7R8DJ TI TTLA931 DM7R8DJ TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM7R8DJ MA Agonist DM7R8DJ RN Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci. 2007 Sep 26;27(39):10578-87. DM7R8DJ RU https://pubmed.ncbi.nlm.nih.gov/17898229 DM7RDGH DI DM7RDGH DM7RDGH DN ENDIANDRIN A DM7RDGH TI TTOZRK6 DM7RDGH TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM7RDGH MA Inhibitor DM7RDGH RN Endiandrin A, a potent glucocorticoid receptor binder isolated from the Australian plant Endiandra anthropophagorum. J Nat Prod. 2007 Jul;70(7):1118-21. DM7RDGH RU https://pubmed.ncbi.nlm.nih.gov/17583952 DM7RELC DI DM7RELC DM7RELC DN AcPYY(26-36) DM7RELC TI TTJ6WK9 DM7RELC TN Neuropeptide Y receptor type 2 (NPY2R) DM7RELC MA Inhibitor DM7RELC RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DM7RELC RU https://pubmed.ncbi.nlm.nih.gov/17055726 DM7RFUC DI DM7RFUC DM7RFUC DN KwFwLL-NH2 DM7RFUC TI TTWDC17 DM7RFUC TN Growth hormone secretagogue receptor 1 (GHSR) DM7RFUC MA Inhibitor DM7RFUC RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DM7RFUC RU https://pubmed.ncbi.nlm.nih.gov/17371869 DM7ROJI DI DM7ROJI DM7ROJI DN E-6-O-p-methoxycinnamoyl scandoside methyl ester DM7ROJI TI TTPLTSQ DM7ROJI TN Neutrophil elastase (NE) DM7ROJI MA Inhibitor DM7ROJI RN Evaluation of human neutrophil elastase inhibitory effect of iridoid glycosides from Hedyotis diffusa. Bioorg Med Chem Lett. 2010 Jan 15;20(2):513-5. DM7ROJI RU https://pubmed.ncbi.nlm.nih.gov/20004577 DM7RPQ4 DI DM7RPQ4 DM7RPQ4 DN BN-81,674 DM7RPQ4 TI TTJX3UE DM7RPQ4 TN Somatostatin receptor type 3 (SSTR3) DM7RPQ4 MA Agonist DM7RPQ4 RN Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem. 2001 Aug 30;44(18):2990-3000. DM7RPQ4 RU https://pubmed.ncbi.nlm.nih.gov/11520208 DM7RUNT DI DM7RUNT DM7RUNT DN 2-Pyridin-3-yl-7-aza-bicyclo[2.2.1]heptane DM7RUNT TI TTF4E0J DM7RUNT TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM7RUNT MA Inhibitor DM7RUNT RN Epibatidine structure-activity relationships. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1889-96. DM7RUNT RU https://pubmed.ncbi.nlm.nih.gov/15050621 DM7RWQT DI DM7RWQT DM7RWQT DN 3-Phenanthren-9-yl-pyridine DM7RWQT TI TTIQUX7 DM7RWQT TN Steroid 11-beta-hydroxylase (CYP11B1) DM7RWQT MA Inhibitor DM7RWQT RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DM7RWQT RU https://pubmed.ncbi.nlm.nih.gov/16220979 DM7RXQ6 DI DM7RXQ6 DM7RXQ6 DN androstenol DM7RXQ6 TI TTRANFM DM7RXQ6 TN Orphan nuclear receptor NR1I3 (NR1I3) DM7RXQ6 MA Antagonist DM7RXQ6 RN Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature. 1998 Oct 8;395(6702):612-5. DM7RXQ6 RU https://pubmed.ncbi.nlm.nih.gov/9783588 DM7S1D5 DI DM7S1D5 DM7S1D5 DN 1,2-Di(berberine-9-O-yl)ethane dibromide DM7S1D5 TI TTEB0GD DM7S1D5 TN Cholinesterase (BCHE) DM7S1D5 MA Inhibitor DM7S1D5 RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DM7S1D5 RU https://pubmed.ncbi.nlm.nih.gov/20471843 DM7S1D5 DI DM7S1D5 DM7S1D5 DN 1,2-Di(berberine-9-O-yl)ethane dibromide DM7S1D5 TI TT1RS9F DM7S1D5 TN Acetylcholinesterase (AChE) DM7S1D5 MA Inhibitor DM7S1D5 RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DM7S1D5 RU https://pubmed.ncbi.nlm.nih.gov/20471843 DM7S5Y4 DI DM7S5Y4 DM7S5Y4 DN NBI-59159 DM7S5Y4 TI TTG2A6F DM7S5Y4 TN Excitatory amino acid transporter 3 (SLC1A1) DM7S5Y4 MA Inhibitor DM7S5Y4 RN Ligands targeting the excitatory amino acid transporters (EAATs). Curr Top Med Chem. 2006;6(17):1897-906. DM7S5Y4 RU https://pubmed.ncbi.nlm.nih.gov/17017964 DM7S63O DI DM7S63O DM7S63O DN SB 227122 DM7S63O TI TT27RFC DM7S63O TN Opioid receptor delta (OPRD1) DM7S63O MA Agonist DM7S63O RN The antitussive activity of delta-opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther. 2000 Feb;292(2):803-9. DM7S63O RU https://pubmed.ncbi.nlm.nih.gov/10640321 DM7SCM3 DI DM7SCM3 DM7SCM3 DN PMID18754614C8 DM7SCM3 TI TTFQEO5 DM7SCM3 TN Squalene synthetase (FDFT1) DM7SCM3 MA Inhibitor DM7SCM3 RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DM7SCM3 RU https://pubmed.ncbi.nlm.nih.gov/18754614 DM7SDNI DI DM7SDNI DM7SDNI DN PMID10395480C6 DM7SDNI TI TTI9MBZ DM7SDNI TN X-prolyl aminopeptidase 2 (XPNPEP2) DM7SDNI MA Inhibitor DM7SDNI RN Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme. J Med Chem. 1999 Jul 1;42(13):2394-402. DM7SDNI RU https://pubmed.ncbi.nlm.nih.gov/10395480 DM7SEM1 DI DM7SEM1 DM7SEM1 DN N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine DM7SEM1 TI TT27RFC DM7SEM1 TN Opioid receptor delta (OPRD1) DM7SEM1 MA Inhibitor DM7SEM1 RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM7SEM1 RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM7SEM1 DI DM7SEM1 DM7SEM1 DN N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine DM7SEM1 TI TTKWM86 DM7SEM1 TN Opioid receptor mu (MOP) DM7SEM1 MA Inhibitor DM7SEM1 RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM7SEM1 RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM7SEM1 DI DM7SEM1 DM7SEM1 DN N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine DM7SEM1 TI TTQW87Y DM7SEM1 TN Opioid receptor kappa (OPRK1) DM7SEM1 MA Inhibitor DM7SEM1 RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DM7SEM1 RU https://pubmed.ncbi.nlm.nih.gov/19928862 DM7SHQ1 DI DM7SHQ1 DM7SHQ1 DN Amythiamicin DM7SHQ1 TI TTG45NU DM7SHQ1 TN Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1) DM7SHQ1 MA Binder DM7SHQ1 RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DM7SHQ1 RU https://pubmed.ncbi.nlm.nih.gov/11768328 DM7SLAM DI DM7SLAM DM7SLAM DN Gymnochrome E DM7SLAM TI TT6R7JZ DM7SLAM TN Histone deacetylase 1 (HDAC1) DM7SLAM MA Inhibitor DM7SLAM RN Gymnochromes E and F, cytotoxic phenanthroperylenequinones from a deep-water crinoid, Holopus rangii. J Nat Prod. 2010 Apr 23;73(4):712-5. DM7SLAM RU https://pubmed.ncbi.nlm.nih.gov/20158243 DM7SNU0 DI DM7SNU0 DM7SNU0 DN BW-A137C DM7SNU0 TI TT2J34L DM7SNU0 TN Arachidonate 5-lipoxygenase (5-LOX) DM7SNU0 MA Modulator DM7SNU0 RN Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: effects on bronchial anaphylaxis in anaesthetized guinea-pigs. Br J Pharmacol. 1988 Jun;94(2):540-6. DM7SNU0 RU https://www.ncbi.nlm.nih.gov/pubmed/3395791 DM7SPRJ DI DM7SPRJ DM7SPRJ DN GNF-PF-78 DM7SPRJ TI TT124R0 DM7SPRJ TN Nuclear receptor coactivator 3 (NCOA3) DM7SPRJ MA Inhibitor DM7SPRJ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM7SPRJ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM7SPRJ DI DM7SPRJ DM7SPRJ DN GNF-PF-78 DM7SPRJ TI TT9JZCK DM7SPRJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM7SPRJ MA Inhibitor DM7SPRJ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM7SPRJ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM7SQ4H DI DM7SQ4H DM7SQ4H DN 1,1-diphenyl-3-(phenylsulfonyl)propan-2-one DM7SQ4H TI TTN7BL9 DM7SQ4H TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM7SQ4H MA Inhibitor DM7SQ4H RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DM7SQ4H RU https://pubmed.ncbi.nlm.nih.gov/17490884 DM7STF6 DI DM7STF6 DM7STF6 DN [Lys8(Alexa 488) ]PVA DM7STF6 TI TTL9MHW DM7STF6 TN Vasopressin V1b receptor (V1BR) DM7STF6 MA Inhibitor DM7STF6 RN Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85. DM7STF6 RU https://pubmed.ncbi.nlm.nih.gov/17850055 DM7STF6 DI DM7STF6 DM7STF6 DN [Lys8(Alexa 488) ]PVA DM7STF6 TI TTSCIUP DM7STF6 TN Oxytocin receptor (OTR) DM7STF6 MA Inhibitor DM7STF6 RN Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85. DM7STF6 RU https://pubmed.ncbi.nlm.nih.gov/17850055 DM7STF6 DI DM7STF6 DM7STF6 DN [Lys8(Alexa 488) ]PVA DM7STF6 TI TT4TFGN DM7STF6 TN Vasopressin V1a receptor (V1AR) DM7STF6 MA Inhibitor DM7STF6 RN Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85. DM7STF6 RU https://pubmed.ncbi.nlm.nih.gov/17850055 DM7SUTQ DI DM7SUTQ DM7SUTQ DN N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide DM7SUTQ TI TTGP7BY DM7SUTQ TN Monoamine oxidase type B (MAO-B) DM7SUTQ MA Inhibitor DM7SUTQ RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DM7SUTQ RU https://pubmed.ncbi.nlm.nih.gov/19267475 DM7SVLZ DI DM7SVLZ DM7SVLZ DN Cytotoxin Peptide Conjugate DM7SVLZ TI TTJX3UE DM7SVLZ TN Somatostatin receptor type 3 (SSTR3) DM7SVLZ MA Inhibitor DM7SVLZ RN An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803. DM7SVLZ RU https://pubmed.ncbi.nlm.nih.gov/12617894 DM7SVLZ DI DM7SVLZ DM7SVLZ DN Cytotoxin Peptide Conjugate DM7SVLZ TI TT2BC4G DM7SVLZ TN Somatostatin receptor type 5 (SSTR5) DM7SVLZ MA Inhibitor DM7SVLZ RN An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803. DM7SVLZ RU https://pubmed.ncbi.nlm.nih.gov/12617894 DM7SVLZ DI DM7SVLZ DM7SVLZ DN Cytotoxin Peptide Conjugate DM7SVLZ TI TTAE1BR DM7SVLZ TN Somatostatin receptor type 4 (SSTR4) DM7SVLZ MA Inhibitor DM7SVLZ RN An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803. DM7SVLZ RU https://pubmed.ncbi.nlm.nih.gov/12617894 DM7SVLZ DI DM7SVLZ DM7SVLZ DN Cytotoxin Peptide Conjugate DM7SVLZ TI TTZ6T9E DM7SVLZ TN Somatostatin receptor type 2 (SSTR2) DM7SVLZ MA Inhibitor DM7SVLZ RN An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803. DM7SVLZ RU https://pubmed.ncbi.nlm.nih.gov/12617894 DM7SVLZ DI DM7SVLZ DM7SVLZ DN Cytotoxin Peptide Conjugate DM7SVLZ TI TTIND6G DM7SVLZ TN Somatostatin receptor type 1 (SSTR1) DM7SVLZ MA Inhibitor DM7SVLZ RN An adjustable release rate linking strategy for cytotoxin-peptide conjugates. Bioorg Med Chem Lett. 2003 Mar 10;13(5):799-803. DM7SVLZ RU https://pubmed.ncbi.nlm.nih.gov/12617894 DM7T2VQ DI DM7T2VQ DM7T2VQ DN Pyrimidinyl acylthiourea DM7T2VQ TI TTSUKYD DM7T2VQ TN Virus RNA-dependent RNA polymerase (Viru RdRP) DM7T2VQ MA Inhibitor DM7T2VQ RN Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9. DM7T2VQ RU https://pubmed.ncbi.nlm.nih.gov/18955536 DM7T3CU DI DM7T3CU DM7T3CU DN 4-Morpholin-4-yl-chromen-2-one DM7T3CU TI TTK3PY9 DM7T3CU TN DNA-dependent protein kinase catalytic (PRKDC) DM7T3CU MA Inhibitor DM7T3CU RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DM7T3CU RU https://pubmed.ncbi.nlm.nih.gov/15658870 DM7T80N DI DM7T80N DM7T80N DN Nitroarginine DM7T80N TI TTZUFI5 DM7T80N TN Nitric-oxide synthase brain (NOS1) DM7T80N MA Inhibitor DM7T80N RN Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 2001 Nov 13;40(45):13448-55. DM7T80N RU https://pubmed.ncbi.nlm.nih.gov/11695891 DM7T80N DI DM7T80N DM7T80N DN Nitroarginine DM7T80N TI TTCM4B3 DM7T80N TN Nitric-oxide synthase endothelial (NOS3) DM7T80N MA Inhibitor DM7T80N RN Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism. Biochemistry. 2001 Nov 13;40(45):13448-55. DM7T80N RU https://pubmed.ncbi.nlm.nih.gov/11695891 DM7T8BE DI DM7T8BE DM7T8BE DN PMID15482906C10 DM7T8BE TI TTHS256 DM7T8BE TN Metabotropic glutamate receptor 5 (mGluR5) DM7T8BE MA Modulator (allosteric modulator) DM7T8BE RN 2-(2-[3-(pyridin-3-yloxy)phenyl]-2H-tetrazol-5-yl) pyridine: a highly potent, orally active, metabotropic glutamate subtype 5 (mGlu5) receptor antagonist. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5473-6. DM7T8BE RU https://pubmed.ncbi.nlm.nih.gov/15482906 DM7T96M DI DM7T96M DM7T96M DN Cyprodine DM7T96M TI TTN4QDT DM7T96M TN Opioid receptor (OPR) DM7T96M MA Antagonist DM7T96M RN Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. DM7T96M RU https://pubmed.ncbi.nlm.nih.gov/17016425 DM7TBUJ DI DM7TBUJ DM7TBUJ DN 2-(4-phenoxyphenoxy)ethanamine DM7TBUJ TI TTO8QRU DM7TBUJ TN Group IIA phospholipase A2 (GIIA sPLA2) DM7TBUJ MA Inhibitor DM7TBUJ RN Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8. DM7TBUJ RU https://pubmed.ncbi.nlm.nih.gov/19090779 DM7TBUJ DI DM7TBUJ DM7TBUJ DN 2-(4-phenoxyphenoxy)ethanamine DM7TBUJ TI TTXZEAJ DM7TBUJ TN Leukotriene A-4 hydrolase (LTA4H) DM7TBUJ MA Inhibitor DM7TBUJ RN Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52. DM7TBUJ RU https://pubmed.ncbi.nlm.nih.gov/18952425 DM7TILD DI DM7TILD DM7TILD DN PT-309 DM7TILD TI TT84ETX DM7TILD TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM7TILD MA Inhibitor DM7TILD RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM7TILD RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM7TOGW DI DM7TOGW DM7TOGW DN antarelix DM7TOGW TI TT8R70G DM7TOGW TN Gonadotropin-releasing hormone receptor (GNRHR) DM7TOGW MA Antagonist DM7TOGW RN Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23. DM7TOGW RU https://pubmed.ncbi.nlm.nih.gov/9300077 DM7TRSB DI DM7TRSB DM7TRSB DN ISIS 9022 DM7TRSB TI TTBSN0L DM7TRSB TN PKC-zeta messenger RNA (PRKCZ mRNA) DM7TRSB RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DM7TRSB RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DM7TU1I DI DM7TU1I DM7TU1I DN Cis-N-oleoylcyclopropanolamide DM7TU1I TI TT6OEDT DM7TU1I TN Cannabinoid receptor 1 (CB1) DM7TU1I MA Inhibitor DM7TU1I RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DM7TU1I RU https://pubmed.ncbi.nlm.nih.gov/19361197 DM7TU1I DI DM7TU1I DM7TU1I DN Cis-N-oleoylcyclopropanolamide DM7TU1I TI TTMSFAW DM7TU1I TN Cannabinoid receptor 2 (CB2) DM7TU1I MA Inhibitor DM7TU1I RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DM7TU1I RU https://pubmed.ncbi.nlm.nih.gov/19361197 DM7TW4C DI DM7TW4C DM7TW4C DN KNI-10741 DM7TW4C TI TTXMNHO DM7TW4C TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM7TW4C MA Inhibitor DM7TW4C RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DM7TW4C RU https://pubmed.ncbi.nlm.nih.gov/20634066 DM7TX3D DI DM7TX3D DM7TX3D DN CM-156 DM7TX3D TI TT5TPI6 DM7TX3D TN Opioid receptor sigma 1 (OPRS1) DM7TX3D MA Antagonist DM7TX3D RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DM7TX3D RU https://pubmed.ncbi.nlm.nih.gov/24648790 DM7U02R DI DM7U02R DM7U02R DN (3-Chloro-phenyl)-piperazin-1-yl-methanone DM7U02R TI TTSQIFT DM7U02R TN 5-HT 1A receptor (HTR1A) DM7U02R MA Inhibitor DM7U02R RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DM7U02R RU https://pubmed.ncbi.nlm.nih.gov/3701781 DM7U02R DI DM7U02R DM7U02R DN (3-Chloro-phenyl)-piperazin-1-yl-methanone DM7U02R TI TT6MSOK DM7U02R TN 5-HT 1D receptor (HTR1D) DM7U02R MA Inhibitor DM7U02R RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DM7U02R RU https://pubmed.ncbi.nlm.nih.gov/3701781 DM7U0XW DI DM7U0XW DM7U0XW DN 1-[(3-Methoxybenzyl)amino]ethaniminium chloride DM7U0XW TI TTZUFI5 DM7U0XW TN Nitric-oxide synthase brain (NOS1) DM7U0XW MA Inhibitor DM7U0XW RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DM7U0XW RU https://pubmed.ncbi.nlm.nih.gov/20933416 DM7U2BE DI DM7U2BE DM7U2BE DN Alloxazine DM7U2BE TI TTNE7KG DM7U2BE TN Adenosine A2b receptor (ADORA2B) DM7U2BE MA Inhibitor DM7U2BE RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DM7U2BE RU https://pubmed.ncbi.nlm.nih.gov/16250647 DM7U2BE DI DM7U2BE DM7U2BE DN Alloxazine DM7U2BE TI TTM2AOE DM7U2BE TN Adenosine A2a receptor (ADORA2A) DM7U2BE MA Inhibitor DM7U2BE RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DM7U2BE RU https://pubmed.ncbi.nlm.nih.gov/16250647 DM7U31Q DI DM7U31Q DM7U31Q DN 1,3,9,9a-Tetrahydro-imidazo[4,5-b]quinolin-2-one DM7U31Q TI TT06AWU DM7U31Q TN Phosphodiesterase 3A (PDE3A) DM7U31Q MA Inhibitor DM7U31Q RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DM7U31Q RU https://pubmed.ncbi.nlm.nih.gov/1654430 DM7U3RM DI DM7U3RM DM7U3RM DN PMID16242323C15b DM7U3RM TI TTK3C21 DM7U3RM TN Acetoacetyl-CoA thiolase (ACAT1) DM7U3RM MA Inhibitor DM7U3RM RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DM7U3RM RU https://pubmed.ncbi.nlm.nih.gov/16242323 DM7U491 DI DM7U491 DM7U491 DN Heparin-Cantithrombin III DM7U491 TI TT6L509 DM7U491 TN Coagulation factor IIa (F2) DM7U491 MA Inhibitor DM7U491 RN Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug;23(15):1142-4. DM7U491 RU https://pubmed.ncbi.nlm.nih.gov/12127916 DM7U4OT DI DM7U4OT DM7U4OT DN ADS-100380 DM7U4OT TI TT6R7JZ DM7U4OT TN Histone deacetylase 1 (HDAC1) DM7U4OT MA Inhibitor DM7U4OT RN Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. DM7U4OT RU https://pubmed.ncbi.nlm.nih.gov/17107790 DM7U58O DI DM7U58O DM7U58O DN 6-Bromo-2-(2-nitro-phenyl)-chromen-4-one DM7U58O TI TT1MPAY DM7U58O TN GABA(A) receptor alpha-1 (GABRA1) DM7U58O MA Inhibitor DM7U58O RN 6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997). DM7U58O RU http://www.sciencedirect.com/science/article/pii/S0960894X97000206 DM7U58O DI DM7U58O DM7U58O DN 6-Bromo-2-(2-nitro-phenyl)-chromen-4-one DM7U58O TI TTNJYV2 DM7U58O TN Gamma-aminobutyric acid receptor (GAR) DM7U58O MA Inhibitor DM7U58O RN 6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997). DM7U58O RU http://www.sciencedirect.com/science/article/pii/S0960894X97000206 DM7U6S0 DI DM7U6S0 DM7U6S0 DN 1,3,5-triphenylimidazolidine-2,4-dione DM7U6S0 TI TT6OEDT DM7U6S0 TN Cannabinoid receptor 1 (CB1) DM7U6S0 MA Inhibitor DM7U6S0 RN Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cann... J Med Chem. 2006 Feb 9;49(3):872-82. DM7U6S0 RU https://pubmed.ncbi.nlm.nih.gov/16451053 DM7U81L DI DM7U81L DM7U81L DN N-Benzoyl-N'-Beta-D-Glucopyranosyl Urea DM7U81L TI TTZHY6R DM7U81L TN Glycogen phosphorylase muscle form (GP) DM7U81L MA Inhibitor DM7U81L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7U81L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7U8ID DI DM7U8ID DM7U8ID DN 6,7-Diphenyl-pteridine-2,4-diamine DM7U8ID TI TT9SL3Q DM7U8ID TN Polypeptide deformylase (PDF) DM7U8ID MA Inhibitor DM7U8ID RN Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three ... J Med Chem. 2003 Apr 24;46(9):1726-36. DM7U8ID RU https://pubmed.ncbi.nlm.nih.gov/12699390 DM7U8LD DI DM7U8LD DM7U8LD DN 1,1,1,2,2-Pentafluoro-8-phenyl-octan-3-one DM7U8LD TI TTT1JVS DM7U8LD TN Cytosolic phospholipase A2 (GIVA cPLA2) DM7U8LD MA Inhibitor DM7U8LD RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DM7U8LD RU https://pubmed.ncbi.nlm.nih.gov/19053783 DM7UHJS DI DM7UHJS DM7UHJS DN 17-dehydroxyriccardin C DM7UHJS TI TTECBXN DM7UHJS TN Oxysterols receptor LXR-alpha (NR1H3) DM7UHJS MA Inhibitor DM7UHJS RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DM7UHJS RU https://pubmed.ncbi.nlm.nih.gov/18343126 DM7UHJS DI DM7UHJS DM7UHJS DN 17-dehydroxyriccardin C DM7UHJS TI TTXA6PH DM7UHJS TN Oxysterols receptor LXR-beta (NR1H2) DM7UHJS MA Inhibitor DM7UHJS RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DM7UHJS RU https://pubmed.ncbi.nlm.nih.gov/18343126 DM7UK56 DI DM7UK56 DM7UK56 DN 1-furan-2-yl-3-pyridin-2-yl-propenone (FPP-3) DM7UK56 TI TT2J34L DM7UK56 TN Arachidonate 5-lipoxygenase (5-LOX) DM7UK56 MA Inhibitor DM7UK56 RN The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced ... Vascul Pharmacol. 2009 Mar-Apr;50(3-4):123-31. DM7UK56 RU https://pubmed.ncbi.nlm.nih.gov/19068239 DM7UP4E DI DM7UP4E DM7UP4E DN FR-104 DM7UP4E TI TTQ13FT DM7UP4E TN T-cell-specific surface glycoprotein CD28 (CD28) DM7UP4E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2863). DM7UP4E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2863 DM7URMW DI DM7URMW DM7URMW DN 3-[1-(4-Bromobenzyl)-1H-imidazol-5-yl]-1-propanol DM7URMW TI TTIQUX7 DM7URMW TN Steroid 11-beta-hydroxylase (CYP11B1) DM7URMW MA Inhibitor DM7URMW RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM7URMW RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM7US1H DI DM7US1H DM7US1H DN Eugenol DM7US1H TI TTKPW01 DM7US1H TN Androgen receptor messenger RNA (AR mRNA) DM7US1H MA Inhibitor DM7US1H RN Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4. DM7US1H RU https://pubmed.ncbi.nlm.nih.gov/20226658 DM7US1H DI DM7US1H DM7US1H DN Eugenol DM7US1H TI TTGP7BY DM7US1H TN Monoamine oxidase type B (MAO-B) DM7US1H MA Inhibitor DM7US1H RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DM7US1H RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DM7UVOD DI DM7UVOD DM7UVOD DN DH97 DM7UVOD TI TT0WAIE DM7UVOD TN Melatonin receptor type 1A (MTNR1A) DM7UVOD MA Antagonist DM7UVOD RN Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores. Naunyn Schmiedebergs Arch Pharmacol. 1998 Nov;358(5):522-8. DM7UVOD RU https://pubmed.ncbi.nlm.nih.gov/9840420 DM7V025 DI DM7V025 DM7V025 DN N-Phenyl-1H-indole-2-carboxamide DM7V025 TI TT3WG5C DM7V025 TN Monoamine oxidase type A (MAO-A) DM7V025 MA Inhibitor DM7V025 RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DM7V025 RU https://pubmed.ncbi.nlm.nih.gov/18951803 DM7V025 DI DM7V025 DM7V025 DN N-Phenyl-1H-indole-2-carboxamide DM7V025 TI TTGP7BY DM7V025 TN Monoamine oxidase type B (MAO-B) DM7V025 MA Inhibitor DM7V025 RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DM7V025 RU https://pubmed.ncbi.nlm.nih.gov/18951803 DM7V2LG DI DM7V2LG DM7V2LG DN Chrysin DM7V2LG TI TTFBNVI DM7V2LG TN Aldose reductase (AKR1B1) DM7V2LG MA Inhibitor DM7V2LG RN Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem. 2010 May 1;18(9):3020-5. DM7V2LG RU https://pubmed.ncbi.nlm.nih.gov/20395149 DM7V2LG DI DM7V2LG DM7V2LG DN Chrysin DM7V2LG TI TTI84H7 DM7V2LG TN Cytochrome P450 1B1 (CYP1B1) DM7V2LG MA Inhibitor DM7V2LG RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM7V2LG RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM7V2LG DI DM7V2LG DM7V2LG DN Chrysin DM7V2LG TI TTSZLWK DM7V2LG TN Aromatase (CYP19A1) DM7V2LG MA Inhibitor DM7V2LG RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM7V2LG RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM7V2LG DI DM7V2LG DM7V2LG DN Chrysin DM7V2LG TI TTBE4IR DM7V2LG TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DM7V2LG MA Inhibitor DM7V2LG RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DM7V2LG RU https://pubmed.ncbi.nlm.nih.gov/16722653 DM7V2LG DI DM7V2LG DM7V2LG DN Chrysin DM7V2LG TI TTO0FDJ DM7V2LG TN Cyclin-dependent kinase 6 (CDK6) DM7V2LG MA Inhibitor DM7V2LG RN Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43. DM7V2LG RU https://pubmed.ncbi.nlm.nih.gov/15689157 DM7V30L DI DM7V30L DM7V30L DN L-norleucyl-L-prolinamide DM7V30L TI TTQ7R2V DM7V30L TN Tripeptidyl-peptidase II (TPP2) DM7V30L MA Inhibitor DM7V30L RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DM7V30L RU https://pubmed.ncbi.nlm.nih.gov/16279793 DM7V58G DI DM7V58G DM7V58G DN MG149 DM7V58G TI TTH4VJL DM7V58G TN Histone acetyltransferase KAT6B (KAT6B) DM7V58G MA Inhibitor DM7V58G RN 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site. Eur J Med Chem. 2012 Jan;47(1):337-44. DM7V58G RU https://pubmed.ncbi.nlm.nih.gov/22100137 DM7V8DZ DI DM7V8DZ DM7V8DZ DN Ribose-1-Phosphate DM7V8DZ TI TTMCF1Y DM7V8DZ TN Purine nucleoside phosphorylase (PNP) DM7V8DZ MA Inhibitor DM7V8DZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7V8DZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7VAJX DI DM7VAJX DM7VAJX DN CTOP DM7VAJX TI TTKWM86 DM7VAJX TN Opioid receptor mu (MOP) DM7VAJX MA Antagonist DM7VAJX RN Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4. DM7VAJX RU https://pubmed.ncbi.nlm.nih.gov/8114680 DM7VAJX DI DM7VAJX DM7VAJX DN CTOP DM7VAJX TI TT27RFC DM7VAJX TN Opioid receptor delta (OPRD1) DM7VAJX MA Inhibitor DM7VAJX RN Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70. DM7VAJX RU https://pubmed.ncbi.nlm.nih.gov/18800771 DM7VAT0 DI DM7VAT0 DM7VAT0 DN ISIS 3804 DM7VAT0 TI TTHCEF6 DM7VAT0 TN VCAM-1 messenger RNA (VCAM1 mRNA) DM7VAT0 RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DM7VAT0 RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DM7VBSY DI DM7VBSY DM7VBSY DN Sulfamic acid 16-sulfamoyloxy-hexadecyl ester DM7VBSY TI TTHQPL7 DM7VBSY TN Carbonic anhydrase I (CA-I) DM7VBSY MA Inhibitor DM7VBSY RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DM7VBSY RU https://pubmed.ncbi.nlm.nih.gov/15664816 DM7VBSY DI DM7VBSY DM7VBSY DN Sulfamic acid 16-sulfamoyloxy-hexadecyl ester DM7VBSY TI TT2LVK8 DM7VBSY TN Carbonic anhydrase IX (CA-IX) DM7VBSY MA Inhibitor DM7VBSY RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DM7VBSY RU https://pubmed.ncbi.nlm.nih.gov/15664816 DM7VBSY DI DM7VBSY DM7VBSY DN Sulfamic acid 16-sulfamoyloxy-hexadecyl ester DM7VBSY TI TTANPDJ DM7VBSY TN Carbonic anhydrase II (CA-II) DM7VBSY MA Inhibitor DM7VBSY RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DM7VBSY RU https://pubmed.ncbi.nlm.nih.gov/15664816 DM7VCDF DI DM7VCDF DM7VCDF DN VU0285683 DM7VCDF TI TTHS256 DM7VCDF TN Metabotropic glutamate receptor 5 (mGluR5) DM7VCDF MA Modulator (allosteric modulator) DM7VCDF RN Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol Pharmacol. 2010 Dec;78(6):1105-23. DM7VCDF RU https://pubmed.ncbi.nlm.nih.gov/20923853 DM7VJPX DI DM7VJPX DM7VJPX DN 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol DM7VJPX TI TTWJBZ5 DM7VJPX TN 5-HT 2C receptor (HTR2C) DM7VJPX MA Inhibitor DM7VJPX RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM7VJPX RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM7VJPX DI DM7VJPX DM7VJPX DN 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol DM7VJPX TI TTJQOD7 DM7VJPX TN 5-HT 2A receptor (HTR2A) DM7VJPX MA Inhibitor DM7VJPX RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM7VJPX RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM7VJPX DI DM7VJPX DM7VJPX DN 3-(2-Pyrrolidin-1-yl-ethyl)-1H-indol-4-ol DM7VJPX TI TT0K1SC DM7VJPX TN 5-HT 2B receptor (HTR2B) DM7VJPX MA Inhibitor DM7VJPX RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM7VJPX RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM7VN9P DI DM7VN9P DM7VN9P DN N-(2-amino-5-(benzofuran-2-yl)phenyl)benzamide DM7VN9P TI TTSHTOI DM7VN9P TN Histone deacetylase 2 (HDAC2) DM7VN9P MA Inhibitor DM7VN9P RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DM7VN9P RU https://pubmed.ncbi.nlm.nih.gov/20392638 DM7VP90 DI DM7VP90 DM7VP90 DN 8-Azaguanine DM7VP90 TI TTMCF1Y DM7VP90 TN Purine nucleoside phosphorylase (PNP) DM7VP90 MA Inhibitor DM7VP90 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM7VP90 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM7VQH8 DI DM7VQH8 DM7VQH8 DN ISIS 16108 DM7VQH8 TI TTHMYB1 DM7VQH8 TN E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA) DM7VQH8 RN US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression. DM7VQH8 RU http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true DM7VQTO DI DM7VQTO DM7VQTO DN MRK016 DM7VQTO TI TTBMV1G DM7VQTO TN GABA(A) receptor alpha-2 (GABRA2) DM7VQTO MA Modulator DM7VQTO RN A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.Biol Psychiatry.2011 Mar 1;69(5):442-9. DM7VQTO RU https://www.ncbi.nlm.nih.gov/pubmed/21145041 DM7VQTO DI DM7VQTO DM7VQTO DN MRK016 DM7VQTO TI TT37EDJ DM7VQTO TN GABA(A) receptor alpha-3 (GABRA3) DM7VQTO MA Modulator DM7VQTO RN A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.Biol Psychiatry.2011 Mar 1;69(5):442-9. DM7VQTO RU https://www.ncbi.nlm.nih.gov/pubmed/21145041 DM7VT3P DI DM7VT3P DM7VT3P DN 8-(1-Methyl-butoxy)-quinolin-2-ylamine DM7VT3P TI TTX4RTB DM7VT3P TN Melanin-concentrating hormone receptor 1 (MCHR1) DM7VT3P MA Inhibitor DM7VT3P RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM7VT3P RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM7W25U DI DM7W25U DM7W25U DN 1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole DM7W25U TI TTJS8PY DM7W25U TN 5-HT 6 receptor (HTR6) DM7W25U MA Inhibitor DM7W25U RN Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302. DM7W25U RU https://pubmed.ncbi.nlm.nih.gov/16183286 DM7W2ME DI DM7W2ME DM7W2ME DN A61603 DM7W2ME TI TT2NUT5 DM7W2ME TN Adrenergic receptor alpha-2C (ADRA2C) DM7W2ME MA Agonist DM7W2ME RN A-61603, a potent alpha 1-adrenergic receptor agonist, selective for the alpha 1A receptor subtype. J Pharmacol Exp Ther. 1995 Jul;274(1):97-103. DM7W2ME RU https://pubmed.ncbi.nlm.nih.gov/7616455 DM7W9MT DI DM7W9MT DM7W9MT DN KF 17837S DM7W9MT TI TTNE7KG DM7W9MT TN Adenosine A2b receptor (ADORA2B) DM7W9MT MA Antagonist DM7W9MT RN Characterization of human A2A adenosine receptors with the antagonist radioligand [3H]-SCH 58261. Br J Pharmacol. 1997 Jun;121(3):353-60. DM7W9MT RU https://pubmed.ncbi.nlm.nih.gov/9179373 DM7WFZ8 DI DM7WFZ8 DM7WFZ8 DN Formononetin DM7WFZ8 TI TTF8JAT DM7WFZ8 TN SLC5A2 messenger RNA (SLC5A2 mRNA) DM7WFZ8 MA Inhibitor DM7WFZ8 RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DM7WFZ8 RU https://pubmed.ncbi.nlm.nih.gov/17374486 DM7WH82 DI DM7WH82 DM7WH82 DN 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid DM7WH82 TI TTHQPL7 DM7WH82 TN Carbonic anhydrase I (CA-I) DM7WH82 MA Inhibitor DM7WH82 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM7WH82 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM7WH82 DI DM7WH82 DM7WH82 DN 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid DM7WH82 TI TTUNARX DM7WH82 TN Carbonic anhydrase (CA) DM7WH82 MA Inhibitor DM7WH82 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM7WH82 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM7WH82 DI DM7WH82 DM7WH82 DN 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid DM7WH82 TI TTANPDJ DM7WH82 TN Carbonic anhydrase II (CA-II) DM7WH82 MA Inhibitor DM7WH82 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM7WH82 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM7WH82 DI DM7WH82 DM7WH82 DN 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid DM7WH82 TI TTSYM0R DM7WH82 TN Carbonic anhydrase XII (CA-XII) DM7WH82 MA Inhibitor DM7WH82 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM7WH82 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM7WH82 DI DM7WH82 DM7WH82 DN 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid DM7WH82 TI TT2LVK8 DM7WH82 TN Carbonic anhydrase IX (CA-IX) DM7WH82 MA Inhibitor DM7WH82 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM7WH82 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM7WH82 DI DM7WH82 DM7WH82 DN 6-methoxy-2-oxo-2H-chromene-3-carboxylic acid DM7WH82 TI TTEYTKG DM7WH82 TN Carbonic anhydrase XIV (CA-XIV) DM7WH82 MA Inhibitor DM7WH82 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM7WH82 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM7WJ6F DI DM7WJ6F DM7WJ6F DN AS94 DM7WJ6F TI TTNE7KG DM7WJ6F TN Adenosine A2b receptor (ADORA2B) DM7WJ6F MA Antagonist DM7WJ6F RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DM7WJ6F RU https://pubmed.ncbi.nlm.nih.gov/16219300 DM7WJOY DI DM7WJOY DM7WJOY DN 1-(1-(pyrazin-2-yl)ethylidene)thiosemicarbazide DM7WJOY TI TTULVH8 DM7WJOY TN Tyrosinase (TYR) DM7WJOY MA Inhibitor DM7WJOY RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DM7WJOY RU https://pubmed.ncbi.nlm.nih.gov/18326070 DM7WPGN DI DM7WPGN DM7WPGN DN 4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME DM7WPGN TI TT2AST1 DM7WPGN TN Macrophage migration inhibitory factor (MIF) DM7WPGN MA Inhibitor DM7WPGN RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM7WPGN RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM7WPQC DI DM7WPQC DM7WPQC DN 3-(4-methoxyphenyl)quinoxaline-5-carboxamide DM7WPQC TI TTVDSZ0 DM7WPQC TN Poly [ADP-ribose] polymerase 1 (PARP1) DM7WPQC MA Inhibitor DM7WPQC RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DM7WPQC RU https://pubmed.ncbi.nlm.nih.gov/19125579 DM7WTKJ DI DM7WTKJ DM7WTKJ DN AMR-SIX-1 DM7WTKJ TI TTJS8PY DM7WTKJ TN 5-HT 6 receptor (HTR6) DM7WTKJ MA Modulator DM7WTKJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11). DM7WTKJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11 DM7WYCM DI DM7WYCM DM7WYCM DN 6-aza-uridine monophosphate DM7WYCM TI TTV7Y40 DM7WYCM TN Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF) DM7WYCM MA Inhibitor DM7WYCM RN Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics. J Med Chem. 2006 Aug 10;49(16):4937-45. DM7WYCM RU https://pubmed.ncbi.nlm.nih.gov/16884305 DM7WYNT DI DM7WYNT DM7WYNT DN 6-(4-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one DM7WYNT TI TTFBNVI DM7WYNT TN Aldose reductase (AKR1B1) DM7WYNT MA Inhibitor DM7WYNT RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM7WYNT RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM7X2AY DI DM7X2AY DM7X2AY DN 4-((pyridin-4-ylthio)methyl)benzene-1,2-diol DM7X2AY TI TT6804T DM7X2AY TN MIF messenger RNA (MIF mRNA) DM7X2AY MA Inhibitor DM7X2AY RN Classification of chemical compounds by protein-compound docking for use in designing a focused library. J Med Chem. 2006 Jan 26;49(2):523-33. DM7X2AY RU https://pubmed.ncbi.nlm.nih.gov/16420039 DM7X59V DI DM7X59V DM7X59V DN 4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile DM7X59V TI TTK25J1 DM7X59V TN Adenosine A1 receptor (ADORA1) DM7X59V MA Inhibitor DM7X59V RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DM7X59V RU https://pubmed.ncbi.nlm.nih.gov/18258439 DM7X59V DI DM7X59V DM7X59V DN 4-Amino-2,6-diphenyl-pyrimidine-5-carbonitrile DM7X59V TI TTM2AOE DM7X59V TN Adenosine A2a receptor (ADORA2A) DM7X59V MA Inhibitor DM7X59V RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DM7X59V RU https://pubmed.ncbi.nlm.nih.gov/18258439 DM7X5BP DI DM7X5BP DM7X5BP DN 1-amino-4-methoxyanthracene-9,10-dione DM7X5BP TI TTM2AOE DM7X5BP TN Adenosine A2a receptor (ADORA2A) DM7X5BP MA Inhibitor DM7X5BP RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DM7X5BP RU https://pubmed.ncbi.nlm.nih.gov/20095623 DM7X8MH DI DM7X8MH DM7X8MH DN THIOCITRULLINE DM7X8MH TI TTZUFI5 DM7X8MH TN Nitric-oxide synthase brain (NOS1) DM7X8MH MA Inhibitor DM7X8MH RN Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5. DM7X8MH RU https://pubmed.ncbi.nlm.nih.gov/15911272 DM7X8MH DI DM7X8MH DM7X8MH DN THIOCITRULLINE DM7X8MH TI TTF10I9 DM7X8MH TN Nitric-oxide synthase inducible (NOS2) DM7X8MH MA Inhibitor DM7X8MH RN Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5. DM7X8MH RU https://pubmed.ncbi.nlm.nih.gov/15911272 DM7X8MH DI DM7X8MH DM7X8MH DN THIOCITRULLINE DM7X8MH TI TTCM4B3 DM7X8MH TN Nitric-oxide synthase endothelial (NOS3) DM7X8MH MA Inhibitor DM7X8MH RN Evaluation of 3-substituted arginine analogs as selective inhibitors of human nitric oxide synthase isozymes. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2881-5. DM7X8MH RU https://pubmed.ncbi.nlm.nih.gov/15911272 DM7XC6B DI DM7XC6B DM7XC6B DN Beta-endorphin DM7XC6B TI TT27RFC DM7XC6B TN Opioid receptor delta (OPRD1) DM7XC6B MA Agonist DM7XC6B RN Cross-linking of human [125I]beta-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex. J Pharmacol Exp Ther. 1990 Apr;253(1):419-26. DM7XC6B RU https://pubmed.ncbi.nlm.nih.gov/2158552 DM7XC6B DI DM7XC6B DM7XC6B DN Beta-endorphin DM7XC6B TI TTQW87Y DM7XC6B TN Opioid receptor kappa (OPRK1) DM7XC6B MA Antagonist DM7XC6B RN Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7. DM7XC6B RU https://pubmed.ncbi.nlm.nih.gov/8380443 DM7XC6B DI DM7XC6B DM7XC6B DN Beta-endorphin DM7XC6B TI TTKWM86 DM7XC6B TN Opioid receptor mu (MOP) DM7XC6B MA Antagonist DM7XC6B RN Beta-endorphin is a potent inhibitor of thymidine incorporation into DNA via mu- and kappa-opioid receptors in fetal rat brain cell aggregates in culture. J Neurochem. 1993 Feb;60(2):765-7. DM7XC6B RU https://pubmed.ncbi.nlm.nih.gov/8380443 DM7XDCF DI DM7XDCF DM7XDCF DN 3-Benzenesulfonyl-heptanoic acid hydroxyamide DM7XDCF TI TTMX39J DM7XDCF TN Matrix metalloproteinase-1 (MMP-1) DM7XDCF MA Inhibitor DM7XDCF RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DM7XDCF RU https://pubmed.ncbi.nlm.nih.gov/10882358 DM7XDCF DI DM7XDCF DM7XDCF DN 3-Benzenesulfonyl-heptanoic acid hydroxyamide DM7XDCF TI TTHY57M DM7XDCF TN Matrix metalloproteinase-13 (MMP-13) DM7XDCF MA Inhibitor DM7XDCF RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DM7XDCF RU https://pubmed.ncbi.nlm.nih.gov/10882358 DM7XDCF DI DM7XDCF DM7XDCF DN 3-Benzenesulfonyl-heptanoic acid hydroxyamide DM7XDCF TI TTXZ0KQ DM7XDCF TN Matrix metalloproteinase-12 (MMP-12) DM7XDCF MA Inhibitor DM7XDCF RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DM7XDCF RU https://pubmed.ncbi.nlm.nih.gov/10882358 DM7XDCF DI DM7XDCF DM7XDCF DN 3-Benzenesulfonyl-heptanoic acid hydroxyamide DM7XDCF TI TTMTWOS DM7XDCF TN Matrix metalloproteinase-7 (MMP-7) DM7XDCF MA Inhibitor DM7XDCF RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DM7XDCF RU https://pubmed.ncbi.nlm.nih.gov/10882358 DM7XDLO DI DM7XDLO DM7XDLO DN 2-(3-Bromo-phenyl)-chromen-4-one DM7XDLO TI TTNJYV2 DM7XDLO TN Gamma-aminobutyric acid receptor (GAR) DM7XDLO MA Inhibitor DM7XDLO RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM7XDLO RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM7XDLO DI DM7XDLO DM7XDLO DN 2-(3-Bromo-phenyl)-chromen-4-one DM7XDLO TI TT1MPAY DM7XDLO TN GABA(A) receptor alpha-1 (GABRA1) DM7XDLO MA Inhibitor DM7XDLO RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM7XDLO RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM7XEIY DI DM7XEIY DM7XEIY DN KNI-10538 DM7XEIY TI TTXMNHO DM7XEIY TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM7XEIY MA Inhibitor DM7XEIY RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DM7XEIY RU https://pubmed.ncbi.nlm.nih.gov/20634066 DM7XER1 DI DM7XER1 DM7XER1 DN N-phenyl-5,6-dip-tolylpyrazine-2-carboxamide DM7XER1 TI TT6OEDT DM7XER1 TN Cannabinoid receptor 1 (CB1) DM7XER1 MA Inhibitor DM7XER1 RN Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. DM7XER1 RU https://pubmed.ncbi.nlm.nih.gov/17513109 DM7XHDC DI DM7XHDC DM7XHDC DN AL-209 DM7XHDC TI TTML2WA DM7XHDC TN Tubulin (TUB) DM7XHDC MA Modulator DM7XHDC RN Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des. 2011;17(25):2603-12. DM7XHDC RU https://pubmed.ncbi.nlm.nih.gov/21728979 DM7XIH3 DI DM7XIH3 DM7XIH3 DN (E)-N-(4-Phenylthiazol-2-yl) cinnamamide DM7XIH3 TI TTVDSZ0 DM7XIH3 TN Poly [ADP-ribose] polymerase 1 (PARP1) DM7XIH3 MA Inhibitor DM7XIH3 RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DM7XIH3 RU https://pubmed.ncbi.nlm.nih.gov/19125579 DM7XIK5 DI DM7XIK5 DM7XIK5 DN N-methyl estrone-16-methyl carboxamide DM7XIK5 TI TTIWB6L DM7XIK5 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM7XIK5 MA Inhibitor DM7XIK5 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DM7XIK5 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DM7XISZ DI DM7XISZ DM7XISZ DN HYG-440 DM7XISZ TI TTS64P2 DM7XISZ TN Androgen receptor (AR) DM7XISZ MA Antagonist DM7XISZ RN Clinical pipeline report, company report or official report of Hygeia Therapeutics. DM7XISZ RU http://www.hygeiatherapeutics.com/HYG-440.html DM7XK28 DI DM7XK28 DM7XK28 DN Benzylsulfinic Acid DM7XK28 TI TT8VUE0 DM7XK28 TN Chymase (CYM) DM7XK28 MA Inhibitor DM7XK28 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM7XK28 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM7XK28 DI DM7XK28 DM7XK28 DN Benzylsulfinic Acid DM7XK28 TI TT25MVL DM7XK28 TN Serine protease hepsin (HPN) DM7XK28 MA Inhibitor DM7XK28 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM7XK28 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM7XN2J DI DM7XN2J DM7XN2J DN Butoxamine DM7XN2J TI TT2CJVK DM7XN2J TN Adrenergic receptor beta-2 (ADRB2) DM7XN2J MA Antagonist DM7XN2J RN Partial agonistic effects of carteolol on atypical beta-adrenoceptors in the guinea pig gastric fundus. Jpn J Pharmacol. 2000 Nov;84(3):287-92. DM7XN2J RU https://pubmed.ncbi.nlm.nih.gov/11138729 DM7XTHD DI DM7XTHD DM7XTHD DN Piriqualone DM7XTHD TI TTAN6JD DM7XTHD TN Glutamate receptor AMPA (GRIA) DM7XTHD MA Inhibitor DM7XTHD RN Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antag... Bioorg Med Chem Lett. 2001 Jan 22;11(2):177-81. DM7XTHD RU https://pubmed.ncbi.nlm.nih.gov/11206453 DM7XTHD DI DM7XTHD DM7XTHD DN Piriqualone DM7XTHD TI TTVPQTF DM7XTHD TN Glutamate receptor AMPA 1 (GRIA1) DM7XTHD MA Inhibitor DM7XTHD RN Atropisomeric quinazolin-4-one derivatives are potent noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antag... Bioorg Med Chem Lett. 2001 Jan 22;11(2):177-81. DM7XTHD RU https://pubmed.ncbi.nlm.nih.gov/11206453 DM7XY41 DI DM7XY41 DM7XY41 DN Ac-dR[CEHdFRWC]-NH2 DM7XY41 TI TTNI91K DM7XY41 TN Melanocortin receptor 3 (MC3R) DM7XY41 MA Inhibitor DM7XY41 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM7XY41 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM7XY41 DI DM7XY41 DM7XY41 DN Ac-dR[CEHdFRWC]-NH2 DM7XY41 TI TTD0CIQ DM7XY41 TN Melanocortin receptor 4 (MC4R) DM7XY41 MA Inhibitor DM7XY41 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM7XY41 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM7XY41 DI DM7XY41 DM7XY41 DN Ac-dR[CEHdFRWC]-NH2 DM7XY41 TI TT0MV2T DM7XY41 TN Melanocortin receptor 1 (MC1R) DM7XY41 MA Inhibitor DM7XY41 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DM7XY41 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DM7Y0G6 DI DM7Y0G6 DM7Y0G6 DN PASBN DM7Y0G6 TI TT6PKBN DM7Y0G6 TN Proto-oncogene c-Src (SRC) DM7Y0G6 MA Inhibitor DM7Y0G6 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM7Y0G6 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM7Y1SO DI DM7Y1SO DM7Y1SO DN UNC0642 DM7Y1SO TI TTS6RZT DM7Y1SO TN Histone-lysine N-methyltransferase EHMT2 (EHMT2) DM7Y1SO MA Inhibitor DM7Y1SO RN Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-42. DM7Y1SO RU https://pubmed.ncbi.nlm.nih.gov/24102134 DM7Y1SO DI DM7Y1SO DM7Y1SO DN UNC0642 DM7Y1SO TI TTOFXD7 DM7Y1SO TN Euchromatic histone-lysine N-methyltransferase 1 (EHMT1) DM7Y1SO MA Inhibitor DM7Y1SO RN Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013 Nov 14;56(21):8931-42. DM7Y1SO RU https://pubmed.ncbi.nlm.nih.gov/24102134 DM7Y1ZD DI DM7Y1ZD DM7Y1ZD DN 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine DM7Y1ZD TI TT3ROYC DM7Y1ZD TN Serotonin transporter (SERT) DM7Y1ZD MA Inhibitor DM7Y1ZD RN Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104. DM7Y1ZD RU https://pubmed.ncbi.nlm.nih.gov/17391962 DM7Y1ZD DI DM7Y1ZD DM7Y1ZD DN 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine DM7Y1ZD TI TTVBI8W DM7Y1ZD TN Dopamine transporter (DAT) DM7Y1ZD MA Inhibitor DM7Y1ZD RN Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104. DM7Y1ZD RU https://pubmed.ncbi.nlm.nih.gov/17391962 DM7Y1ZD DI DM7Y1ZD DM7Y1ZD DN 4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine DM7Y1ZD TI TTAWNKZ DM7Y1ZD TN Norepinephrine transporter (NET) DM7Y1ZD MA Inhibitor DM7Y1ZD RN Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104. DM7Y1ZD RU https://pubmed.ncbi.nlm.nih.gov/17391962 DM7Y5AN DI DM7Y5AN DM7Y5AN DN 1S,2R-milnacipran DM7Y5AN TI TTAWNKZ DM7Y5AN TN Norepinephrine transporter (NET) DM7Y5AN MA Inhibitor DM7Y5AN RN Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72. DM7Y5AN RU https://pubmed.ncbi.nlm.nih.gov/18954038 DM7Y5AN DI DM7Y5AN DM7Y5AN DN 1S,2R-milnacipran DM7Y5AN TI TTVBI8W DM7Y5AN TN Dopamine transporter (DAT) DM7Y5AN MA Inhibitor DM7Y5AN RN Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72. DM7Y5AN RU https://pubmed.ncbi.nlm.nih.gov/18954038 DM7Y5AN DI DM7Y5AN DM7Y5AN DN 1S,2R-milnacipran DM7Y5AN TI TT3ROYC DM7Y5AN TN Serotonin transporter (SERT) DM7Y5AN MA Inhibitor DM7Y5AN RN Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72. DM7Y5AN RU https://pubmed.ncbi.nlm.nih.gov/18954038 DM7Y6AL DI DM7Y6AL DM7Y6AL DN AMINOFENTANYL DM7Y6AL TI TTKWM86 DM7Y6AL TN Opioid receptor mu (MOP) DM7Y6AL MA Inhibitor DM7Y6AL RN Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50. DM7Y6AL RU https://pubmed.ncbi.nlm.nih.gov/16828552 DM7Y6AL DI DM7Y6AL DM7Y6AL DN AMINOFENTANYL DM7Y6AL TI TT27RFC DM7Y6AL TN Opioid receptor delta (OPRD1) DM7Y6AL MA Inhibitor DM7Y6AL RN Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50. DM7Y6AL RU https://pubmed.ncbi.nlm.nih.gov/16828552 DM7Y9AD DI DM7Y9AD DM7Y9AD DN Microxine DM7Y9AD TI TTH6V3D DM7Y9AD TN Cyclin-dependent kinase 1 (CDK1) DM7Y9AD MA Inhibitor DM7Y9AD RN Microxine, a new cdc2 kinase inhibitor from the Australian marine sponge Microxina species. J Nat Prod. 2001 Apr;64(4):525-6. DM7Y9AD RU https://pubmed.ncbi.nlm.nih.gov/11325241 DM7Y9AD DI DM7Y9AD DM7Y9AD DN Microxine DM7Y9AD TI TTVKILB DM7Y9AD TN Prostaglandin G/H synthase 2 (COX-2) DM7Y9AD MA Inhibitor DM7Y9AD RN Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts. Biochem Biophys Res Commun. 1994 Jan 28;198(2):536-45. DM7Y9AD RU https://pubmed.ncbi.nlm.nih.gov/8297363 DM7YAE0 DI DM7YAE0 DM7YAE0 DN kallstroemin D DM7YAE0 TI TT1UCIJ DM7YAE0 TN C-X-C chemokine receptor type 3 (CXCR3) DM7YAE0 MA Antagonist DM7YAE0 RN Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol Divers. 2005;9(1-3):123-9. DM7YAE0 RU https://pubmed.ncbi.nlm.nih.gov/15789559 DM7YB08 DI DM7YB08 DM7YB08 DN SYL-040003 DM7YB08 TI TTZHA0O DM7YB08 TN Carbonic anhydrase IV (CA-IV) DM7YB08 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2599). DM7YB08 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2599 DM7YGJO DI DM7YGJO DM7YGJO DN 5-Mercapto-pentanoic acid DM7YGJO TI TT9G4N0 DM7YGJO TN Glutamate carboxypeptidase II (GCPII) DM7YGJO MA Inhibitor DM7YGJO RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DM7YGJO RU https://pubmed.ncbi.nlm.nih.gov/12723961 DM7YHBR DI DM7YHBR DM7YHBR DN Diethyl 2-((biphenyl-3-ylamino)methylene)malonate DM7YHBR TI TT3PQ2Y DM7YHBR TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM7YHBR MA Inhibitor DM7YHBR RN Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91. DM7YHBR RU https://pubmed.ncbi.nlm.nih.gov/17228860 DM7YION DI DM7YION DM7YION DN EP 171 DM7YION TI TT2O84V DM7YION TN Thromboxane A2 receptor (TBXA2R) DM7YION MA Agonist DM7YION RN EP 171: a high affinity thromboxane A2-mimetic, the actions of which are slowly reversed by receptor blockade. Br J Pharmacol. 1989 Apr;96(4):875-87. DM7YION RU https://pubmed.ncbi.nlm.nih.gov/2743082 DM7YLTS DI DM7YLTS DM7YLTS DN 2-(hex-1-ynyl)-N6-methoxyadenosine DM7YLTS TI TTM2AOE DM7YLTS TN Adenosine A2a receptor (ADORA2A) DM7YLTS MA Inhibitor DM7YLTS RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM7YLTS RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM7YLTS DI DM7YLTS DM7YLTS DN 2-(hex-1-ynyl)-N6-methoxyadenosine DM7YLTS TI TTK25J1 DM7YLTS TN Adenosine A1 receptor (ADORA1) DM7YLTS MA Inhibitor DM7YLTS RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM7YLTS RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM7YLTS DI DM7YLTS DM7YLTS DN 2-(hex-1-ynyl)-N6-methoxyadenosine DM7YLTS TI TTJFY5U DM7YLTS TN Adenosine A3 receptor (ADORA3) DM7YLTS MA Inhibitor DM7YLTS RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM7YLTS RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM7YOXW DI DM7YOXW DM7YOXW DN 4-thio-UTP DM7YOXW TI TTOZHQC DM7YOXW TN P2Y purinoceptor 2 (P2RY2) DM7YOXW MA Agonist DM7YOXW RN P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312. DM7YOXW RU https://pubmed.ncbi.nlm.nih.gov/16475938 DM7YQ26 DI DM7YQ26 DM7YQ26 DN Immethridine DM7YQ26 TI TT9JNIC DM7YQ26 TN Histamine H3 receptor (H3R) DM7YQ26 MA Agonist DM7YQ26 RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM7YQ26 RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM7YVUT DI DM7YVUT DM7YVUT DN L-731,988 DM7YVUT TI TT5FH9Y DM7YVUT TN Human immunodeficiency virus Integrase (HIV IN) DM7YVUT MA Inhibitor DM7YVUT RN Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6. DM7YVUT RU https://pubmed.ncbi.nlm.nih.gov/11502522 DM7YW3B DI DM7YW3B DM7YW3B DN 8-deoxy-neodysiherbaine DM7YW3B TI TT0MYE2 DM7YW3B TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM7YW3B MA Agonist DM7YW3B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM7YW3B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM7YXKL DI DM7YXKL DM7YXKL DN DM3A6S DM7YXKL TI TTKWM86 DM7YXKL TN Opioid receptor mu (MOP) DM7YXKL MA Inhibitor DM7YXKL RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM7YXKL RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM7Z19T DI DM7Z19T DM7Z19T DN 1-(2-(phenoxymethyl)phenyl)piperazine DM7Z19T TI TTVBI8W DM7Z19T TN Dopamine transporter (DAT) DM7Z19T MA Inhibitor DM7Z19T RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM7Z19T RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM7Z19T DI DM7Z19T DM7Z19T DN 1-(2-(phenoxymethyl)phenyl)piperazine DM7Z19T TI TTSQIFT DM7Z19T TN 5-HT 1A receptor (HTR1A) DM7Z19T MA Inhibitor DM7Z19T RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM7Z19T RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM7Z19T DI DM7Z19T DM7Z19T DN 1-(2-(phenoxymethyl)phenyl)piperazine DM7Z19T TI TT3ROYC DM7Z19T TN Serotonin transporter (SERT) DM7Z19T MA Inhibitor DM7Z19T RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM7Z19T RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM7Z19T DI DM7Z19T DM7Z19T DN 1-(2-(phenoxymethyl)phenyl)piperazine DM7Z19T TI TTAWNKZ DM7Z19T TN Norepinephrine transporter (NET) DM7Z19T MA Inhibitor DM7Z19T RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM7Z19T RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM7Z2WV DI DM7Z2WV DM7Z2WV DN PMID17556356C1a DM7Z2WV TI TTPNQAC DM7Z2WV TN Estrogen-related receptor-alpha (ESRRA) DM7Z2WV MA Antagonist DM7Z2WV RN Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J Biol Chem. 2007 Aug 10;282(32):23231-9. DM7Z2WV RU https://pubmed.ncbi.nlm.nih.gov/17556356 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TTN9D8E DM7Z892 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM7Z892 MA Agonist DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TTKJEMQ DM7Z892 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM7Z892 MA Agonist DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TT1M8OW DM7Z892 TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DM7Z892 MA Agonist DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TT5POTG DM7Z892 TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DM7Z892 MA Agonist DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TTLD29N DM7Z892 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM7Z892 MA Agonist DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TT2F078 DM7Z892 TN Excitatory amino acid transporter 2 (SLC1A2) DM7Z892 MA Modulator DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 869). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=869 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TT6KMPN DM7Z892 TN Excitatory amino acid transporter 4 (SLC1A6) DM7Z892 MA Modulator DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 871). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=871 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TT8WRDA DM7Z892 TN Excitatory amino acid transporter 1 (SLC1A3) DM7Z892 MA Modulator DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 868). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=868 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TTK41DM DM7Z892 TN Excitatory amino acid transporter 5 (SLC1A7) DM7Z892 MA Modulator DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 872). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=872 DM7Z892 DI DM7Z892 DM7Z892 DN D-aspartic acid DM7Z892 TI TTG2A6F DM7Z892 TN Excitatory amino acid transporter 3 (SLC1A1) DM7Z892 MA Modulator DM7Z892 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 870). DM7Z892 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=870 DM7ZF2K DI DM7ZF2K DM7ZF2K DN JWH-367 DM7ZF2K TI TT6OEDT DM7ZF2K TN Cannabinoid receptor 1 (CB1) DM7ZF2K MA Inhibitor DM7ZF2K RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM7ZF2K RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM7ZF2K DI DM7ZF2K DM7ZF2K DN JWH-367 DM7ZF2K TI TTMSFAW DM7ZF2K TN Cannabinoid receptor 2 (CB2) DM7ZF2K MA Inhibitor DM7ZF2K RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM7ZF2K RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM7ZIMS DI DM7ZIMS DM7ZIMS DN sphingosylphosphorylcholine DM7ZIMS TI TT3IPW2 DM7ZIMS TN G-protein coupled receptor 12 (GPR12) DM7ZIMS MA Agonist DM7ZIMS RN Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. J Neurosci. 2003 Feb 1;23(3):907-14. DM7ZIMS RU https://pubmed.ncbi.nlm.nih.gov/12574419 DM7ZJ4H DI DM7ZJ4H DM7ZJ4H DN cicaprost DM7ZJ4H TI TTOFYT1 DM7ZJ4H TN Prostacyclin receptor (PTGIR) DM7ZJ4H MA Agonist DM7ZJ4H RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM7ZJ4H RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM7ZJ4H DI DM7ZJ4H DM7ZJ4H DN cicaprost DM7ZJ4H TI TTG1QMU DM7ZJ4H TN Prostaglandin E2 receptor EP1 (PTGER1) DM7ZJ4H MA Agonist DM7ZJ4H RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM7ZJ4H RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM7ZJ4H DI DM7ZJ4H DM7ZJ4H DN cicaprost DM7ZJ4H TI TTPNGDE DM7ZJ4H TN Prostaglandin E2 receptor EP3 (PTGER3) DM7ZJ4H MA Agonist DM7ZJ4H RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM7ZJ4H RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM7ZJ4H DI DM7ZJ4H DM7ZJ4H DN cicaprost DM7ZJ4H TI TT1ZAVI DM7ZJ4H TN Prostaglandin E2 receptor EP2 (PTGER2) DM7ZJ4H MA Agonist DM7ZJ4H RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM7ZJ4H RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM7ZJ4H DI DM7ZJ4H DM7ZJ4H DN cicaprost DM7ZJ4H TI TT79WV3 DM7ZJ4H TN Prostaglandin E2 receptor EP4 (PTGER4) DM7ZJ4H MA Agonist DM7ZJ4H RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM7ZJ4H RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM7ZSVD DI DM7ZSVD DM7ZSVD DN ISODISPAR B DM7ZSVD TI TT84ETX DM7ZSVD TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM7ZSVD MA Inhibitor DM7ZSVD RN 4-Phenylcoumarins as HIV transcription inhibitors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4447-50. DM7ZSVD RU https://pubmed.ncbi.nlm.nih.gov/16137881 DM7ZWRN DI DM7ZWRN DM7ZWRN DN ACU-0101979 DM7ZWRN TI TTE4KHA DM7ZWRN TN Amyloid beta A4 protein (APP) DM7ZWRN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM7ZWRN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM801AO DI DM801AO DM801AO DN MRS1093 DM801AO TI TTJFY5U DM801AO TN Adenosine A3 receptor (ADORA3) DM801AO MA Antagonist DM801AO RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM801AO RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM801AO DI DM801AO DM801AO DN MRS1093 DM801AO TI TTK25J1 DM801AO TN Adenosine A1 receptor (ADORA1) DM801AO MA Antagonist DM801AO RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM801AO RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM801AO DI DM801AO DM801AO DN MRS1093 DM801AO TI TTNE7KG DM801AO TN Adenosine A2b receptor (ADORA2B) DM801AO MA Antagonist DM801AO RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM801AO RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM8023E DI DM8023E DM8023E DN (+/-)-oxiran-2-ylmethyl (9Z)-hexadec-9-enoate DM8023E TI TTDP1UC DM8023E TN Fatty acid amide hydrolase (FAAH) DM8023E MA Inhibitor DM8023E RN Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase. J Med Chem. 2007 Oct 4;50(20):5012-23. DM8023E RU https://pubmed.ncbi.nlm.nih.gov/17764163 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TTEYTKG DM802V7 TN Carbonic anhydrase XIV (CA-XIV) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TT2LVK8 DM802V7 TN Carbonic anhydrase IX (CA-IX) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TTCFSPE DM802V7 TN Carbonic anhydrase VI (CA-VI) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TTSYM0R DM802V7 TN Carbonic anhydrase XII (CA-XII) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TTANPDJ DM802V7 TN Carbonic anhydrase II (CA-II) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TTZHA0O DM802V7 TN Carbonic anhydrase IV (CA-IV) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TTUNARX DM802V7 TN Carbonic anhydrase (CA) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM802V7 DI DM802V7 DM802V7 DN Syringic Acid DM802V7 TI TTHQPL7 DM802V7 TN Carbonic anhydrase I (CA-I) DM802V7 MA Inhibitor DM802V7 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DM802V7 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DM80GFL DI DM80GFL DM80GFL DN 7,8,4'-trihydroxyisoflavone DM80GFL TI TTULVH8 DM80GFL TN Tyrosinase (TYR) DM80GFL MA Inhibitor DM80GFL RN Natural ortho-dihydroxyisoflavone derivatives from aged Korean fermented soybean paste as potent tyrosinase and melanin formation inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1162-4. DM80GFL RU https://pubmed.ncbi.nlm.nih.gov/20022495 DM80JOH DI DM80JOH DM80JOH DN (+/-)-threo-N-(2-Chlorobenzyl)methylphenidate DM80JOH TI TTVBI8W DM80JOH TN Dopamine transporter (DAT) DM80JOH MA Inhibitor DM80JOH RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM80JOH RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM80MTI DI DM80MTI DM80MTI DN 9-(3-Hydroxypropyl)-9H-adenine DM80MTI TI TTM2AOE DM80MTI TN Adenosine A2a receptor (ADORA2A) DM80MTI MA Inhibitor DM80MTI RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM80MTI RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM80QF9 DI DM80QF9 DM80QF9 DN H-8 DM80QF9 TI TTHIQMC DM80QF9 TN Cyclic nucleotide-gated channel alpha-1 (CNGA1) DM80QF9 MA Blocker (channel blocker) DM80QF9 RN Direct blockade of both cloned rat rod photoreceptor cyclic nucleotide-gated non-selective cation (CNG) channel alpha-subunit and native CNG channels from Xenopus rod outer segments by H-8, a non-specific cyclic nucleotide-dependent protein kinase inhibitor. Neurosci Lett. 1997 Sep 12;233(1):37-40. DM80QF9 RU https://pubmed.ncbi.nlm.nih.gov/9324234 DM80YI7 DI DM80YI7 DM80YI7 DN citric acid DM80YI7 TI TTKP2SU DM80YI7 TN Transient receptor potential cation channel V4 (TRPV4) DM80YI7 MA Activator DM80YI7 RN Impaired pressure sensation in mice lacking TRPV4. J Biol Chem. 2003 Jun 20;278(25):22664-8. DM80YI7 RU https://pubmed.ncbi.nlm.nih.gov/12692122 DM80YI7 DI DM80YI7 DM80YI7 DN citric acid DM80YI7 TI TTAHD89 DM80YI7 TN Polycystic kidney disease 2-like 1 (TRPP2) DM80YI7 MA Activator DM80YI7 RN Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12569-74. DM80YI7 RU https://pubmed.ncbi.nlm.nih.gov/16891422 DM80YI7 DI DM80YI7 DM80YI7 DN citric acid DM80YI7 TI TTTSOUD DM80YI7 TN Candida Cytochrome P450 51 (Candi ERG11) DM80YI7 MA Binder DM80YI7 RN Chemosensitization of fluconazole resistance in Saccharomyces cerevisiae and pathogenic fungi by a D-octapeptide derivative. Antimicrob Agents Chemother. 2004 Apr;48(4):1256-71. DM80YI7 RU https://pubmed.ncbi.nlm.nih.gov/15047528 DM8109D DI DM8109D DM8109D DN Oxazolidin-(2Z)-ylideneamine DM8109D TI TTF10I9 DM8109D TN Nitric-oxide synthase inducible (NOS2) DM8109D MA Inhibitor DM8109D RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM8109D RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM814EQ DI DM814EQ DM814EQ DN N-6547 DM814EQ TI TTEP6RV DM814EQ TN Glutathione reductase (GR) DM814EQ MA Inhibitor DM814EQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2613). DM814EQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2613 DM816Z2 DI DM816Z2 DM816Z2 DN NF449 DM816Z2 TI TTJW7B3 DM816Z2 TN P2X purinoceptor 1 (P2RX1) DM816Z2 MA Antagonist DM816Z2 RN Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57. DM816Z2 RU https://pubmed.ncbi.nlm.nih.gov/15072843 DM81AWU DI DM81AWU DM81AWU DN Pen(Acm)AQFRKEKETFC(Acm)-OH DM81AWU TI TTJDUNO DM81AWU TN T-cell surface antigen CD2 (CD2) DM81AWU MA Inhibitor DM81AWU RN Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation. J Med Chem. 2005 Oct 6;48(20):6236-49. DM81AWU RU https://pubmed.ncbi.nlm.nih.gov/16190751 DM81B4W DI DM81B4W DM81B4W DN [HO1][Thr4,Orn8(5/6C-Flu)]VT DM81B4W TI TT4TFGN DM81B4W TN Vasopressin V1a receptor (V1AR) DM81B4W MA Inhibitor DM81B4W RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM81B4W RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM81B4W DI DM81B4W DM81B4W DN [HO1][Thr4,Orn8(5/6C-Flu)]VT DM81B4W TI TTL9MHW DM81B4W TN Vasopressin V1b receptor (V1BR) DM81B4W MA Inhibitor DM81B4W RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM81B4W RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM81B4W DI DM81B4W DM81B4W DN [HO1][Thr4,Orn8(5/6C-Flu)]VT DM81B4W TI TTSCIUP DM81B4W TN Oxytocin receptor (OTR) DM81B4W MA Inhibitor DM81B4W RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DM81B4W RU https://pubmed.ncbi.nlm.nih.gov/12036367 DM81D90 DI DM81D90 DM81D90 DN 4-bromo-1H-indazole DM81D90 TI TTZUFI5 DM81D90 TN Nitric-oxide synthase brain (NOS1) DM81D90 MA Inhibitor DM81D90 RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DM81D90 RU https://pubmed.ncbi.nlm.nih.gov/17395463 DM81DTC DI DM81DTC DM81DTC DN 6-Benzenesulfonyl-2H-pyridazin-3-one DM81DTC TI TTFBNVI DM81DTC TN Aldose reductase (AKR1B1) DM81DTC MA Inhibitor DM81DTC RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM81DTC RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM81G2U DI DM81G2U DM81G2U DN 2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol DM81G2U TI TTZAYWL DM81G2U TN Estrogen receptor (ESR) DM81G2U MA Inhibitor DM81G2U RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM81G2U RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM81G2U DI DM81G2U DM81G2U DN 2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol DM81G2U TI TTOM3J0 DM81G2U TN Estrogen receptor beta (ESR2) DM81G2U MA Inhibitor DM81G2U RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DM81G2U RU https://pubmed.ncbi.nlm.nih.gov/16098741 DM81G2U DI DM81G2U DM81G2U DN 2-(4-Hydroxy-phenyl)-4-vinyl-quinolin-6-ol DM81G2U TI TTPNQAC DM81G2U TN Estrogen-related receptor-alpha (ESRRA) DM81G2U MA Inhibitor DM81G2U RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DM81G2U RU https://pubmed.ncbi.nlm.nih.gov/17482813 DM81J0O DI DM81J0O DM81J0O DN 2-fluorophenyl 4-(octyloxy)phenylcarbamate DM81J0O TI TTDP1UC DM81J0O TN Fatty acid amide hydrolase (FAAH) DM81J0O MA Inhibitor DM81J0O RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM81J0O RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM81JRF DI DM81JRF DM81JRF DN (E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin DM81JRF TI TTGKNB4 DM81JRF TN Epidermal growth factor receptor (EGFR) DM81JRF MA Inhibitor DM81JRF RN 5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9. DM81JRF RU https://pubmed.ncbi.nlm.nih.gov/19268405 DM81KD2 DI DM81KD2 DM81KD2 DN tiotidine DM81KD2 TI TTQHJ1K DM81KD2 TN Histamine H2 receptor (H2R) DM81KD2 MA Antagonist DM81KD2 RN Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells. Br J Pharmacol. 1997 Nov;122(5):867-74. DM81KD2 RU https://pubmed.ncbi.nlm.nih.gov/9384502 DM81RKT DI DM81RKT DM81RKT DN ONO-DI-004 DM81RKT TI TTG1QMU DM81RKT TN Prostaglandin E2 receptor EP1 (PTGER1) DM81RKT MA Agonist DM81RKT RN The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9. DM81RKT RU https://pubmed.ncbi.nlm.nih.gov/10746663 DM81WJK DI DM81WJK DM81WJK DN 2-(2-cyclohexylphenoxy)acetic acid DM81WJK TI TTQDMX5 DM81WJK TN Prostaglandin D2 receptor 2 (PTGDR2) DM81WJK MA Inhibitor DM81WJK RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DM81WJK RU https://pubmed.ncbi.nlm.nih.gov/17531480 DM823CD DI DM823CD DM823CD DN 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione DM823CD TI TTYEG6Q DM823CD TN Muscarinic acetylcholine receptor M2 (CHRM2) DM823CD MA Inhibitor DM823CD RN Design of dual acting anticonvulsant-antimuscarinic succinimide and hydantoin derivatives, Bioorg. Med. Chem. Lett. 7(8):979-984 (1997). DM823CD RU http://www.sciencedirect.com/science/article/pii/S0960894X97001431 DM823CD DI DM823CD DM823CD DN 2-(4-Diethylamino-but-2-ynyl)-isoindole-1,3-dione DM823CD TI TTZ9SOR DM823CD TN Muscarinic acetylcholine receptor M1 (CHRM1) DM823CD MA Inhibitor DM823CD RN Design of dual acting anticonvulsant-antimuscarinic succinimide and hydantoin derivatives, Bioorg. Med. Chem. Lett. 7(8):979-984 (1997). DM823CD RU http://www.sciencedirect.com/science/article/pii/S0960894X97001431 DM82C6Q DI DM82C6Q DM82C6Q DN Cyclo(-D-Tyr-Arg-Arg-Nal-Gly-) DM82C6Q TI TTBID49 DM82C6Q TN C-X-C chemokine receptor type 4 (CXCR4) DM82C6Q MA Inhibitor DM82C6Q RN Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4124-9. DM82C6Q RU https://pubmed.ncbi.nlm.nih.gov/18539453 DM82D9N DI DM82D9N DM82D9N DN 4-(2-cyanobenzylthio)-2-aminobutanoic acid DM82D9N TI TTFK1JQ DM82D9N TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM82D9N MA Inhibitor DM82D9N RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DM82D9N RU https://pubmed.ncbi.nlm.nih.gov/16380257 DM82DNL DI DM82DNL DM82DNL DN Nova-EPO DM82DNL TI TTAUX24 DM82DNL TN Erythropoietin Receptor (EPOR) DM82DNL MA Modulator DM82DNL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DM82DNL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DM82GH9 DI DM82GH9 DM82GH9 DN SB 699551 DM82GH9 TI TTRUFDT DM82GH9 TN 5-HT 5A receptor (HTR5A) DM82GH9 MA Antagonist DM82GH9 RN Discovery of a potent and selective 5-ht5A receptor antagonist by high-throughput chemistry. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4014-8. DM82GH9 RU https://pubmed.ncbi.nlm.nih.gov/16002289 DM82HW9 DI DM82HW9 DM82HW9 DN JMV 1719 DM82HW9 TI TTC1MVT DM82HW9 TN Gastrin-releasing peptide receptor (GRPR) DM82HW9 MA Inhibitor DM82HW9 RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DM82HW9 RU https://pubmed.ncbi.nlm.nih.gov/10882361 DM82KPQ DI DM82KPQ DM82KPQ DN BUTORPHAN DM82KPQ TI TTKWM86 DM82KPQ TN Opioid receptor mu (MOP) DM82KPQ MA Inhibitor DM82KPQ RN Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22. DM82KPQ RU https://pubmed.ncbi.nlm.nih.gov/10633042 DM82KPQ DI DM82KPQ DM82KPQ DN BUTORPHAN DM82KPQ TI TTQW87Y DM82KPQ TN Opioid receptor kappa (OPRK1) DM82KPQ MA Inhibitor DM82KPQ RN Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22. DM82KPQ RU https://pubmed.ncbi.nlm.nih.gov/10633042 DM82KPQ DI DM82KPQ DM82KPQ DN BUTORPHAN DM82KPQ TI TT27RFC DM82KPQ TN Opioid receptor delta (OPRD1) DM82KPQ MA Inhibitor DM82KPQ RN Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. DM82KPQ RU https://pubmed.ncbi.nlm.nih.gov/20144870 DM82SJP DI DM82SJP DM82SJP DN BMS270394 DM82SJP TI TT1Q3IE DM82SJP TN Retinoic acid receptor gamma (RARG) DM82SJP MA Agonist DM82SJP RN Enantiomer discrimination illustrated by high-resolution crystal structures of the human nuclear receptor hRARgamma. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6322-7. DM82SJP RU https://pubmed.ncbi.nlm.nih.gov/10841540 DM82X3J DI DM82X3J DM82X3J DN Ethyl 1-[(1H-benzotriazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate DM82X3J TI TT84ETX DM82X3J TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM82X3J MA Inhibitor DM82X3J RN Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9. DM82X3J RU https://pubmed.ncbi.nlm.nih.gov/11026542 DM82XAU DI DM82XAU DM82XAU DN NSC-77833 DM82XAU TI TTJLP0R DM82XAU TN Quinone reductase 2 (NQO2) DM82XAU MA Inhibitor DM82XAU RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM82XAU RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM82ZOM DI DM82ZOM DM82ZOM DN C[L-Phe-D-pro-L-mTyr-D-trp] DM82ZOM TI TTQW87Y DM82ZOM TN Opioid receptor kappa (OPRK1) DM82ZOM MA Inhibitor DM82ZOM RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM82ZOM RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM82ZOM DI DM82ZOM DM82ZOM DN C[L-Phe-D-pro-L-mTyr-D-trp] DM82ZOM TI TT27RFC DM82ZOM TN Opioid receptor delta (OPRD1) DM82ZOM MA Inhibitor DM82ZOM RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM82ZOM RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM82ZOM DI DM82ZOM DM82ZOM DN C[L-Phe-D-pro-L-mTyr-D-trp] DM82ZOM TI TTKWM86 DM82ZOM TN Opioid receptor mu (MOP) DM82ZOM MA Inhibitor DM82ZOM RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DM82ZOM RU https://pubmed.ncbi.nlm.nih.gov/19464172 DM830FW DI DM830FW DM830FW DN 3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one DM830FW TI TTGP7BY DM830FW TN Monoamine oxidase type B (MAO-B) DM830FW MA Inhibitor DM830FW RN Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71. DM830FW RU https://pubmed.ncbi.nlm.nih.gov/17910428 DM83951 DI DM83951 DM83951 DN AG-E-85378 DM83951 TI TTUTJGQ DM83951 TN Vascular endothelial growth factor receptor 2 (KDR) DM83951 MA Inhibitor DM83951 RN Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Bioorg Med Chem Lett. 2007 Nov 1;17(21):6003-8. DM83951 RU https://pubmed.ncbi.nlm.nih.gov/17869515 DM83AEM DI DM83AEM DM83AEM DN N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine DM83AEM TI TTGP7BY DM83AEM TN Monoamine oxidase type B (MAO-B) DM83AEM MA Inhibitor DM83AEM RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM83AEM RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM83AEM DI DM83AEM DM83AEM DN N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine DM83AEM TI TT3WG5C DM83AEM TN Monoamine oxidase type A (MAO-A) DM83AEM MA Inhibitor DM83AEM RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM83AEM RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM83C9N DI DM83C9N DM83C9N DN Para-sirtinol DM83C9N TI TTUF2HO DM83C9N TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DM83C9N MA Inhibitor DM83C9N RN Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95. DM83C9N RU https://pubmed.ncbi.nlm.nih.gov/16302818 DM83CDK DI DM83CDK DM83CDK DN Alexa-488-telenzepine DM83CDK TI TTOXS3C DM83CDK TN Muscarinic acetylcholine receptor (CHRM) DM83CDK MA Antagonist DM83CDK RN Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8. DM83CDK RU https://pubmed.ncbi.nlm.nih.gov/20133736 DM83EK9 DI DM83EK9 DM83EK9 DN ISIS 6958 DM83EK9 TI TTM8FR7 DM83EK9 TN KRAS messenger RNA (KRAS mRNA) DM83EK9 RN US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides. DM83EK9 RU http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true DM83L5Y DI DM83L5Y DM83L5Y DN RIP DM83L5Y TI TTL69WB DM83L5Y TN Angiotensin-converting enzyme (ACE) DM83L5Y MA Inhibitor DM83L5Y RN Difluorostatine- and difluorostatone-containing peptides as potent and specific renin inhibitors. J Med Chem. 1985 Nov;28(11):1553-5. DM83L5Y RU https://pubmed.ncbi.nlm.nih.gov/3906126 DM83QMZ DI DM83QMZ DM83QMZ DN Ro-37-9790 DM83QMZ TI TTUZ2L5 DM83QMZ TN Matrix metalloproteinase-3 (MMP-3) DM83QMZ MA Inhibitor DM83QMZ RN 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997). DM83QMZ RU http://www.sciencedirect.com/science/article/pii/S0960894X97003971 DM83QMZ DI DM83QMZ DM83QMZ DN Ro-37-9790 DM83QMZ TI TTLM12X DM83QMZ TN Matrix metalloproteinase-2 (MMP-2) DM83QMZ MA Inhibitor DM83QMZ RN 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997). DM83QMZ RU http://www.sciencedirect.com/science/article/pii/S0960894X97003971 DM83QMZ DI DM83QMZ DM83QMZ DN Ro-37-9790 DM83QMZ TI TTGA1IV DM83QMZ TN Matrix metalloproteinase-8 (MMP-8) DM83QMZ MA Inhibitor DM83QMZ RN 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997). DM83QMZ RU http://www.sciencedirect.com/science/article/pii/S0960894X97003971 DM83QMZ DI DM83QMZ DM83QMZ DN Ro-37-9790 DM83QMZ TI TT6X50U DM83QMZ TN Matrix metalloproteinase-9 (MMP-9) DM83QMZ MA Inhibitor DM83QMZ RN 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997). DM83QMZ RU http://www.sciencedirect.com/science/article/pii/S0960894X97003971 DM83QMZ DI DM83QMZ DM83QMZ DN Ro-37-9790 DM83QMZ TI TTHY57M DM83QMZ TN Matrix metalloproteinase-13 (MMP-13) DM83QMZ MA Inhibitor DM83QMZ RN 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997). DM83QMZ RU http://www.sciencedirect.com/science/article/pii/S0960894X97003971 DM83QMZ DI DM83QMZ DM83QMZ DN Ro-37-9790 DM83QMZ TI TTMX39J DM83QMZ TN Matrix metalloproteinase-1 (MMP-1) DM83QMZ MA Inhibitor DM83QMZ RN 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids, Bioorg. Med. Chem. Lett. 7(17):2299-2302 (1997). DM83QMZ RU http://www.sciencedirect.com/science/article/pii/S0960894X97003971 DM83THZ DI DM83THZ DM83THZ DN RQ-00203078 DM83THZ TI TTXDKTO DM83THZ TN Long transient receptor potential channel 8 (TRPM8) DM83THZ MA Antagonist DM83THZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500). DM83THZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=500 DM83TLC DI DM83TLC DM83TLC DN ISIS 109110 DM83TLC TI TTQSMFG DM83TLC TN Talin messenger RNA (TLN1 mRNA) DM83TLC RN US patent application no. 6,372,492, Antisense modulation of talin expression. DM83TLC RU http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true DM83VN6 DI DM83VN6 DM83VN6 DN 6-(3-Nitro-phenyl)-3H-benzothiazol-2-one DM83VN6 TI TTUV8G9 DM83VN6 TN Progesterone receptor (PGR) DM83VN6 MA Inhibitor DM83VN6 RN Synthesis and structure-activity relationship of novel 6-aryl-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as progesterone receptor modulators leading... J Med Chem. 2005 Aug 11;48(16):5092-5. DM83VN6 RU https://pubmed.ncbi.nlm.nih.gov/16078826 DM83WVF DI DM83WVF DM83WVF DN Apicidin DM83WVF TI TTBH0VX DM83WVF TN Histone deacetylase (HDAC) DM83WVF MA Inhibitor DM83WVF RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DM83WVF RU https://pubmed.ncbi.nlm.nih.gov/17896917 DM83Z6M DI DM83Z6M DM83Z6M DN PMID17929793C23h DM83Z6M TI TTVBPDM DM83Z6M TN Metabotropic glutamate receptor 1 (mGluR1) DM83Z6M MA Modulator (allosteric modulator) DM83Z6M RN Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3. DM83Z6M RU https://pubmed.ncbi.nlm.nih.gov/17929793 DM842L6 DI DM842L6 DM842L6 DN 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione DM842L6 TI TTLD29N DM842L6 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM842L6 MA Inhibitor DM842L6 RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DM842L6 RU https://pubmed.ncbi.nlm.nih.gov/8917653 DM842L6 DI DM842L6 DM842L6 DN 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione DM842L6 TI TTN9D8E DM842L6 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM842L6 MA Inhibitor DM842L6 RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DM842L6 RU https://pubmed.ncbi.nlm.nih.gov/8917653 DM842L6 DI DM842L6 DM842L6 DN 8-Chloro-3-hydroxy-1H-benzo[b]azepine-2,5-dione DM842L6 TI TTKJEMQ DM842L6 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM842L6 MA Inhibitor DM842L6 RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DM842L6 RU https://pubmed.ncbi.nlm.nih.gov/8917653 DM84CTA DI DM84CTA DM84CTA DN 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione DM84CTA TI TTKJEMQ DM84CTA TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM84CTA MA Inhibitor DM84CTA RN 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. DM84CTA RU https://pubmed.ncbi.nlm.nih.gov/9357535 DM84CTA DI DM84CTA DM84CTA DN 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione DM84CTA TI TTN9D8E DM84CTA TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM84CTA MA Inhibitor DM84CTA RN 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. DM84CTA RU https://pubmed.ncbi.nlm.nih.gov/9357535 DM84CTA DI DM84CTA DM84CTA DN 6-Nitro-1,4-dihydro-quinoxaline-2,3-dione DM84CTA TI TTLD29N DM84CTA TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM84CTA MA Inhibitor DM84CTA RN 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. DM84CTA RU https://pubmed.ncbi.nlm.nih.gov/9357535 DM84D9W DI DM84D9W DM84D9W DN 8-Amino-1,3-Dimethyl-3,7-Dihydropurine-2,6-Dione DM84D9W TI TTG9CFY DM84D9W TN Bacterial Dihydroneopterinaldolase (Bact folB) DM84D9W MA Inhibitor DM84D9W RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM84D9W RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM84DMW DI DM84DMW DM84DMW DN S3969 DM84DMW TI TTQM7TE DM84DMW TN Amiloride-sensitive sodium channel (ENaC) DM84DMW MA Activator DM84DMW RN Small molecule activator of the human epithelial sodium channel. J Biol Chem. 2008 May 2;283(18):11981-94. DM84DMW RU https://pubmed.ncbi.nlm.nih.gov/18326490 DM84GAQ DI DM84GAQ DM84GAQ DN 20-hydroxy-LTB4 DM84GAQ TI TTVJX54 DM84GAQ TN Leukotriene B4 receptor 2 (LTB4R2) DM84GAQ MA Agonist DM84GAQ RN A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997 Jun 5;387(6633):620-4. DM84GAQ RU https://pubmed.ncbi.nlm.nih.gov/9177352 DM84IW9 DI DM84IW9 DM84IW9 DN ONO-3708 DM84IW9 TI TT2O84V DM84IW9 TN Thromboxane A2 receptor (TBXA2R) DM84IW9 MA Antagonist DM84IW9 RN Characterization of U46619 binding in unactivated, intact human platelets and determination of binding site affinities of four TXA2/PGH2 receptor antagonists (13-APA, BM 13.177, ONO 3708 and SQ 29,548). Thromb Res. 1986 Feb 15;41(4):471-81. DM84IW9 RU https://pubmed.ncbi.nlm.nih.gov/3008368 DM84M20 DI DM84M20 DM84M20 DN Kuwanon V DM84M20 TI TTELIN2 DM84M20 TN PTPN1 messenger RNA (PTPN1 mRNA) DM84M20 MA Inhibitor DM84M20 RN Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61. DM84M20 RU https://pubmed.ncbi.nlm.nih.gov/19846295 DM84PWI DI DM84PWI DM84PWI DN JNJ-28318706 DM84PWI TI TTW5UDX DM84PWI TN Urotensin II receptor (UTS2R) DM84PWI MA Inhibitor DM84PWI RN Nonpeptide urotensin-II receptor antagonists: a new ligand class based on piperazino-phthalimide and piperazino-isoindolinone subunits. J Med Chem. 2009 Dec 10;52(23):7432-45. DM84PWI RU https://pubmed.ncbi.nlm.nih.gov/19731961 DM84R6C DI DM84R6C DM84R6C DN 2-thio-UDP DM84R6C TI TT72OKI DM84R6C TN P2Y purinoceptor 14 (P2RY14) DM84R6C MA Agonist DM84R6C RN Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J Med Chem. 2010 Jan 14;53(1):471-80. DM84R6C RU https://pubmed.ncbi.nlm.nih.gov/19902968 DM84TSH DI DM84TSH DM84TSH DN CGP-34938 DM84TSH TI TTDCVZW DM84TSH TN Gamma-aminobutyric acid B receptor (GABBR) DM84TSH MA Inhibitor DM84TSH RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DM84TSH RU https://pubmed.ncbi.nlm.nih.gov/7650684 DM84YCI DI DM84YCI DM84YCI DN 12-(3-Adamantan-1-yl-ureido)-dodeca noic acid DM84YCI TI TT7WVHI DM84YCI TN Soluble epoxide hydrolase (EPHX2) DM84YCI MA Inhibitor DM84YCI RN Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement. J Med Chem. 2009 Aug 27;52(16):5009-12. DM84YCI RU https://pubmed.ncbi.nlm.nih.gov/19645482 DM84ZX5 DI DM84ZX5 DM84ZX5 DN Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine DM84ZX5 TI TTJFY5U DM84ZX5 TN Adenosine A3 receptor (ADORA3) DM84ZX5 MA Inhibitor DM84ZX5 RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM84ZX5 RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM84ZX5 DI DM84ZX5 DM84ZX5 DN Cyclohexyl-(2-phenoxy-9H-purin-6-yl)-amine DM84ZX5 TI TTM2AOE DM84ZX5 TN Adenosine A2a receptor (ADORA2A) DM84ZX5 MA Inhibitor DM84ZX5 RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DM84ZX5 RU https://pubmed.ncbi.nlm.nih.gov/16033270 DM852Z6 DI DM852Z6 DM852Z6 DN (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol DM852Z6 TI TTJFY5U DM852Z6 TN Adenosine A3 receptor (ADORA3) DM852Z6 MA Inhibitor DM852Z6 RN Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem. 1995 May 12;38(10):1720-35. DM852Z6 RU https://pubmed.ncbi.nlm.nih.gov/7752196 DM852Z6 DI DM852Z6 DM852Z6 DN (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol DM852Z6 TI TTJGW1Z DM852Z6 TN Phosphodiesterase 2A (PDE2A) DM852Z6 MA Inhibitor DM852Z6 RN The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62. DM852Z6 RU https://pubmed.ncbi.nlm.nih.gov/15887951 DM852Z6 DI DM852Z6 DM852Z6 DN (2R,3S)-3-(6-Amino-purin-9-yl)-nonan-2-ol DM852Z6 TI TTM2AOE DM852Z6 TN Adenosine A2a receptor (ADORA2A) DM852Z6 MA Inhibitor DM852Z6 RN Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors. J Med Chem. 1995 May 12;38(10):1720-35. DM852Z6 RU https://pubmed.ncbi.nlm.nih.gov/7752196 DM854ED DI DM854ED DM854ED DN 2-fluorophenyl 4-(hexyloxy)phenylcarbamate DM854ED TI TTDP1UC DM854ED TN Fatty acid amide hydrolase (FAAH) DM854ED MA Inhibitor DM854ED RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM854ED RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM854IG DI DM854IG DM854IG DN 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol DM854IG TI TTHY57M DM854IG TN Matrix metalloproteinase-13 (MMP-13) DM854IG MA Inhibitor DM854IG RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DM854IG RU https://pubmed.ncbi.nlm.nih.gov/10230616 DM854IG DI DM854IG DM854IG DN 3-(4-Methoxy-benzenesulfonyl)-pentane-1-thiol DM854IG TI TTMX39J DM854IG TN Matrix metalloproteinase-1 (MMP-1) DM854IG MA Inhibitor DM854IG RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DM854IG RU https://pubmed.ncbi.nlm.nih.gov/10230616 DM856JM DI DM856JM DM856JM DN Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Phe(4-NO2) DM856JM TI TT6PKBN DM856JM TN Proto-oncogene c-Src (SRC) DM856JM MA Inhibitor DM856JM RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DM856JM RU https://pubmed.ncbi.nlm.nih.gov/16722659 DM857X2 DI DM857X2 DM857X2 DN benzyl bromide DM857X2 TI TTELV3W DM857X2 TN Transformation-sensitive protein p120 (TRPA1) DM857X2 MA Activator DM857X2 RN Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14. DM857X2 RU https://pubmed.ncbi.nlm.nih.gov/19036859 DM85AJ4 DI DM85AJ4 DM85AJ4 DN BB-PTH 1-84 DM85AJ4 TI TTEPJL5 DM85AJ4 TN Parathyroid hormone receptor (PTH2R) DM85AJ4 MA Modulator DM85AJ4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332). DM85AJ4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332 DM85EV7 DI DM85EV7 DM85EV7 DN ISIS 20994 DM85EV7 TI TTSRXJW DM85EV7 TN G-alpha-11 messenger RNA (GNA11 mRNA) DM85EV7 RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DM85EV7 RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DM85RJ1 DI DM85RJ1 DM85RJ1 DN N-arachidonoylglycine DM85RJ1 TI TTABCJ6 DM85RJ1 TN Lysophosphatidic acid receptor 5 (LPAR5) DM85RJ1 MA Agonist DM85RJ1 RN Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem. 2008 Jul 25;283(30):21054-64. DM85RJ1 RU https://pubmed.ncbi.nlm.nih.gov/18499677 DM85RJ1 DI DM85RJ1 DM85RJ1 DN N-arachidonoylglycine DM85RJ1 TI TTSLJAR DM85RJ1 TN N-arachidonyl glycine receptor (GPR18) DM85RJ1 MA Agonist DM85RJ1 RN Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun. 2006 Sep 1;347(3):827-32. DM85RJ1 RU https://pubmed.ncbi.nlm.nih.gov/16844083 DM85XP6 DI DM85XP6 DM85XP6 DN 4-(o-tolylthio)-2-(trifluoromethyl)benzonitrile DM85XP6 TI TTKPW01 DM85XP6 TN Androgen receptor messenger RNA (AR mRNA) DM85XP6 MA Inhibitor DM85XP6 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM85XP6 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM85ZCW DI DM85ZCW DM85ZCW DN 2-(N-Pyrrolidinyl)-3'-bromopropiophenone DM85ZCW TI TTAWNKZ DM85ZCW TN Norepinephrine transporter (NET) DM85ZCW MA Inhibitor DM85ZCW RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM85ZCW RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM85ZCW DI DM85ZCW DM85ZCW DN 2-(N-Pyrrolidinyl)-3'-bromopropiophenone DM85ZCW TI TTVBI8W DM85ZCW TN Dopamine transporter (DAT) DM85ZCW MA Inhibitor DM85ZCW RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DM85ZCW RU https://pubmed.ncbi.nlm.nih.gov/20158204 DM861DU DI DM861DU DM861DU DN Iso-caffeine DM861DU TI TTV5CGO DM861DU TN Phosphodiesterase 4 (PDE4) DM861DU MA Inhibitor DM861DU RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DM861DU RU https://pubmed.ncbi.nlm.nih.gov/7925603 DM862TI DI DM862TI DM862TI DN TG4-155 DM862TI TI TT1ZAVI DM862TI TN Prostaglandin E2 receptor EP2 (PTGER2) DM862TI MA Antagonist DM862TI RN Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3149-54. DM862TI RU https://pubmed.ncbi.nlm.nih.gov/22323596 DM86305 DI DM86305 DM86305 DN [[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate DM86305 TI TTHI19T DM86305 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM86305 MA Inhibitor DM86305 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM86305 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8642Z DI DM8642Z DM8642Z DN 4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one DM8642Z TI TTNE7KG DM8642Z TN Adenosine A2b receptor (ADORA2B) DM8642Z MA Antagonist DM8642Z RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM8642Z RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM8642Z DI DM8642Z DM8642Z DN 4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one DM8642Z TI TTK25J1 DM8642Z TN Adenosine A1 receptor (ADORA1) DM8642Z MA Antagonist DM8642Z RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM8642Z RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM8642Z DI DM8642Z DM8642Z DN 4-Ethoxy-7-((E)-styryl)-furo[3,2-g]chromen-5-one DM8642Z TI TTJFY5U DM8642Z TN Adenosine A3 receptor (ADORA3) DM8642Z MA Inhibitor DM8642Z RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DM8642Z RU https://pubmed.ncbi.nlm.nih.gov/8691424 DM865Y2 DI DM865Y2 DM865Y2 DN N-Hydroxy-N'-(2-methylphenyl)octanediamide DM865Y2 TI TTBH0VX DM865Y2 TN Histone deacetylase (HDAC) DM865Y2 MA Inhibitor DM865Y2 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM865Y2 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM865Y2 DI DM865Y2 DM865Y2 DN N-Hydroxy-N'-(2-methylphenyl)octanediamide DM865Y2 TI TT6R7JZ DM865Y2 TN Histone deacetylase 1 (HDAC1) DM865Y2 MA Inhibitor DM865Y2 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DM865Y2 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DM86HTZ DI DM86HTZ DM86HTZ DN 2-Hydroxycinnamic acid DM86HTZ TI TTANPDJ DM86HTZ TN Carbonic anhydrase II (CA-II) DM86HTZ MA Inhibitor DM86HTZ RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM86HTZ RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM86HTZ DI DM86HTZ DM86HTZ DN 2-Hydroxycinnamic acid DM86HTZ TI TTHQPL7 DM86HTZ TN Carbonic anhydrase I (CA-I) DM86HTZ MA Inhibitor DM86HTZ RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DM86HTZ RU https://pubmed.ncbi.nlm.nih.gov/20674354 DM86KWU DI DM86KWU DM86KWU DN ISIS 103471 DM86KWU TI TT1GV6C DM86KWU TN DUSP9 messenger RNA (DUSP9 mRNA) DM86KWU RN US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression. DM86KWU RU http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true DM86LFB DI DM86LFB DM86LFB DN Thiorphan DM86LFB TI TT5TKPM DM86LFB TN Neutral endopeptidase (MME) DM86LFB MA Inhibitor DM86LFB RN Thiorphan enhances bradykinin-induced vascular relaxation in hypoxic/hyperkalaemic porcine coronary artery. J Pharm Pharmacol. 2003 Mar;55(3):339-45. DM86LFB RU https://pubmed.ncbi.nlm.nih.gov/12724039 DM86OZD DI DM86OZD DM86OZD DN JWH-150 DM86OZD TI TTMSFAW DM86OZD TN Cannabinoid receptor 2 (CB2) DM86OZD MA Inhibitor DM86OZD RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM86OZD RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM86OZD DI DM86OZD DM86OZD DN JWH-150 DM86OZD TI TT6OEDT DM86OZD TN Cannabinoid receptor 1 (CB1) DM86OZD MA Inhibitor DM86OZD RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM86OZD RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM86WRO DI DM86WRO DM86WRO DN meso-DAP DM86WRO TI TTYSRXM DM86WRO TN Pattern recognition receptor NOD1 (NOD1) DM86WRO MA Agonist DM86WRO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1762). DM86WRO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1762 DM86XG5 DI DM86XG5 DM86XG5 DN 6-Pyridin-3-yl-1,2,3,4-tetrahydronaphthalen-2-ol DM86XG5 TI TTIQUX7 DM86XG5 TN Steroid 11-beta-hydroxylase (CYP11B1) DM86XG5 MA Inhibitor DM86XG5 RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DM86XG5 RU https://pubmed.ncbi.nlm.nih.gov/19049427 DM86Y1V DI DM86Y1V DM86Y1V DN LY456066 DM86Y1V TI TTVBPDM DM86Y1V TN Metabotropic glutamate receptor 1 (mGluR1) DM86Y1V MA Modulator (allosteric modulator) DM86Y1V RN Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one. Neuropharmacology. 2009 Sep;57(4):438-45. DM86Y1V RU https://pubmed.ncbi.nlm.nih.gov/19559036 DM86Z4H DI DM86Z4H DM86Z4H DN [4Aph(CO-(C2H4O)3-C2H4-NH-CO-NH-OCH3)5]degarelix DM86Z4H TI TT8R70G DM86Z4H TN Gonadotropin-releasing hormone receptor (GNRHR) DM86Z4H MA Inhibitor DM86Z4H RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DM86Z4H RU https://pubmed.ncbi.nlm.nih.gov/16759096 DM86ZL2 DI DM86ZL2 DM86ZL2 DN PPA DM86ZL2 TI TTUJFD0 DM86ZL2 TN Telomerase reverse transcriptase (TERT) DM86ZL2 MA Inhibitor DM86ZL2 RN Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. Gastroenterology. 2004 May;126(5):1337-46. DM86ZL2 RU https://pubmed.ncbi.nlm.nih.gov/15131795 DM870UV DI DM870UV DM870UV DN 3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one DM870UV TI TT1MPAY DM870UV TN GABA(A) receptor alpha-1 (GABRA1) DM870UV MA Inhibitor DM870UV RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DM870UV RU https://pubmed.ncbi.nlm.nih.gov/2826782 DM870UV DI DM870UV DM870UV DN 3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one DM870UV TI TTNJYV2 DM870UV TN Gamma-aminobutyric acid receptor (GAR) DM870UV MA Inhibitor DM870UV RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DM870UV RU https://pubmed.ncbi.nlm.nih.gov/2826782 DM870UV DI DM870UV DM870UV DN 3-Methyl-2-phenyl-2H-chromeno[4,3-c]pyrazol-4-one DM870UV TI TT06RH5 DM870UV TN GABA(A) receptor gamma-2 (GABRG2) DM870UV MA Inhibitor DM870UV RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DM870UV RU https://pubmed.ncbi.nlm.nih.gov/2826782 DM870W1 DI DM870W1 DM870W1 DN 3-(2-carboxy-6-mercaptohexyl)benzoic acid DM870W1 TI TT9G4N0 DM870W1 TN Glutamate carboxypeptidase II (GCPII) DM870W1 MA Inhibitor DM870W1 RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DM870W1 RU https://pubmed.ncbi.nlm.nih.gov/16686531 DM871ZE DI DM871ZE DM871ZE DN 4-Phenylbutylcarbamic Acid Biphenyl-3-yl Ester DM871ZE TI TTDP1UC DM871ZE TN Fatty acid amide hydrolase (FAAH) DM871ZE MA Inhibitor DM871ZE RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DM871ZE RU https://pubmed.ncbi.nlm.nih.gov/18507372 DM873BS DI DM873BS DM873BS DN Pervanadate DM873BS TI TTWC6MY DM873BS TN Protein tyrosine phosphatase (PTP) DM873BS MA Inhibitor DM873BS RN Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9. DM873BS RU https://pubmed.ncbi.nlm.nih.gov/9341756 DM873WR DI DM873WR DM873WR DN N-ethyl-5,6-dip-tolylpyrazine-2-carboxamide DM873WR TI TT6OEDT DM873WR TN Cannabinoid receptor 1 (CB1) DM873WR MA Inhibitor DM873WR RN Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. DM873WR RU https://pubmed.ncbi.nlm.nih.gov/17513109 DM8769D DI DM8769D DM8769D DN N,N-Dipropyl-1'H-phenothiazine-1'-carboxamide DM8769D TI TTEB0GD DM8769D TN Cholinesterase (BCHE) DM8769D MA Inhibitor DM8769D RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DM8769D RU https://pubmed.ncbi.nlm.nih.gov/20181484 DM87AYP DI DM87AYP DM87AYP DN 4-[4-(benzyloxy)piperidino]butyl-3-fluorobenzoate DM87AYP TI TTEB0GD DM87AYP TN Cholinesterase (BCHE) DM87AYP MA Inhibitor DM87AYP RN Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. DM87AYP RU https://pubmed.ncbi.nlm.nih.gov/17681794 DM87MWN DI DM87MWN DM87MWN DN 1,4-Di(berberine-9-O-yl)ethane dibromide DM87MWN TI TT1RS9F DM87MWN TN Acetylcholinesterase (AChE) DM87MWN MA Inhibitor DM87MWN RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DM87MWN RU https://pubmed.ncbi.nlm.nih.gov/20471843 DM87MWN DI DM87MWN DM87MWN DN 1,4-Di(berberine-9-O-yl)ethane dibromide DM87MWN TI TTEB0GD DM87MWN TN Cholinesterase (BCHE) DM87MWN MA Inhibitor DM87MWN RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DM87MWN RU https://pubmed.ncbi.nlm.nih.gov/20471843 DM87SOX DI DM87SOX DM87SOX DN Carbocyclic Peptidomimetic DM87SOX TI TTPT2QI DM87SOX TN Cathepsin D (CTSD) DM87SOX MA Inhibitor DM87SOX RN Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90. DM87SOX RU https://pubmed.ncbi.nlm.nih.gov/16078837 DM87SOX DI DM87SOX DM87SOX DN Carbocyclic Peptidomimetic DM87SOX TI TT8JRS7 DM87SOX TN Beta-secretase (BACE) DM87SOX MA Inhibitor DM87SOX RN Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90. DM87SOX RU https://pubmed.ncbi.nlm.nih.gov/16078837 DM87YJW DI DM87YJW DM87YJW DN N-(benzyl),N-(pyrrol-2-ylmethyl)amine DM87YJW TI TTGP7BY DM87YJW TN Monoamine oxidase type B (MAO-B) DM87YJW MA Inhibitor DM87YJW RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM87YJW RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM87YJW DI DM87YJW DM87YJW DN N-(benzyl),N-(pyrrol-2-ylmethyl)amine DM87YJW TI TT3WG5C DM87YJW TN Monoamine oxidase type A (MAO-A) DM87YJW MA Inhibitor DM87YJW RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM87YJW RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM87Z3Y DI DM87Z3Y DM87Z3Y DN RM-6427 DM87Z3Y TI TTGKNB4 DM87Z3Y TN Epidermal growth factor receptor (EGFR) DM87Z3Y MA Inhibitor DM87Z3Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM87Z3Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM87ZIH DI DM87ZIH DM87ZIH DN Tyrphostin Ag-1478 DM87ZIH TI TTGKNB4 DM87ZIH TN Epidermal growth factor receptor (EGFR) DM87ZIH MA Inhibitor DM87ZIH RN Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26. DM87ZIH RU https://pubmed.ncbi.nlm.nih.gov/10090785 DM87ZIH DI DM87ZIH DM87ZIH DN Tyrphostin Ag-1478 DM87ZIH TI TTQBR95 DM87ZIH TN Stress-activated protein kinase 2a (p38 alpha) DM87ZIH MA Inhibitor DM87ZIH RN Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5389-94. DM87ZIH RU https://pubmed.ncbi.nlm.nih.gov/15454232 DM890WJ DI DM890WJ DM890WJ DN 3-Iodoboldine DM890WJ TI TTEX248 DM890WJ TN Dopamine D2 receptor (D2R) DM890WJ MA Inhibitor DM890WJ RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DM890WJ RU https://pubmed.ncbi.nlm.nih.gov/10785418 DM890WJ DI DM890WJ DM890WJ DN 3-Iodoboldine DM890WJ TI TTZFYLI DM890WJ TN Dopamine D1 receptor (D1R) DM890WJ MA Inhibitor DM890WJ RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DM890WJ RU https://pubmed.ncbi.nlm.nih.gov/10785418 DM892JF DI DM892JF DM892JF DN Alpha-methyl-alpha-phenylsuccinimide (MPS) DM892JF TI TT729IR DM892JF TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM892JF MA Blocker DM892JF RN Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. DM892JF RU https://pubmed.ncbi.nlm.nih.gov/11641441 DM89602 DI DM89602 DM89602 DN JWH-440 DM89602 TI TT6OEDT DM89602 TN Cannabinoid receptor 1 (CB1) DM89602 MA Inhibitor DM89602 RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DM89602 RU https://pubmed.ncbi.nlm.nih.gov/20621488 DM89602 DI DM89602 DM89602 DN JWH-440 DM89602 TI TTMSFAW DM89602 TN Cannabinoid receptor 2 (CB2) DM89602 MA Inhibitor DM89602 RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DM89602 RU https://pubmed.ncbi.nlm.nih.gov/20621488 DM89CLH DI DM89CLH DM89CLH DN 2-Cyclohexyl-N-phenethyl-acetamide DM89CLH TI TT7WVHI DM89CLH TN Soluble epoxide hydrolase (EPHX2) DM89CLH MA Inhibitor DM89CLH RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DM89CLH RU https://pubmed.ncbi.nlm.nih.gov/15887969 DM89FBX DI DM89FBX DM89FBX DN LUF-5735 DM89FBX TI TTK25J1 DM89FBX TN Adenosine A1 receptor (ADORA1) DM89FBX MA Inhibitor DM89FBX RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM89FBX RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM89I0L DI DM89I0L DM89I0L DN RS67506 DM89I0L TI TT07C3Y DM89I0L TN 5-HT 4 receptor (HTR4) DM89I0L MA Agonist DM89I0L RN Peripheral 5-HT4 receptors. FASEB J. 1996 Oct;10(12):1398-407. DM89I0L RU https://pubmed.ncbi.nlm.nih.gov/8903510 DM89KNT DI DM89KNT DM89KNT DN Gue1654 DM89KNT TI TT7WBSV DM89KNT TN Oxoeicosanoid receptor 1 (OXER1) DM89KNT MA Modulator (allosteric modulator) DM89KNT RN A biased ligand for OXE-R uncouples Galpha and Gbetagamma signaling within a heterotrimer. Nat Chem Biol. 2012 Jul;8(7):631-8. DM89KNT RU https://pubmed.ncbi.nlm.nih.gov/22634634 DM89LF5 DI DM89LF5 DM89LF5 DN 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE DM89LF5 TI TT78R5H DM89LF5 TN Heat shock protein 90 alpha (HSP90A) DM89LF5 MA Inhibitor DM89LF5 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM89LF5 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM89NGE DI DM89NGE DM89NGE DN N-(2,6-diphenylpyrimidin-4-yl)propionamide DM89NGE TI TTJFY5U DM89NGE TN Adenosine A3 receptor (ADORA3) DM89NGE MA Inhibitor DM89NGE RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM89NGE RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM89NGE DI DM89NGE DM89NGE DN N-(2,6-diphenylpyrimidin-4-yl)propionamide DM89NGE TI TTM2AOE DM89NGE TN Adenosine A2a receptor (ADORA2A) DM89NGE MA Inhibitor DM89NGE RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM89NGE RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM89NGE DI DM89NGE DM89NGE DN N-(2,6-diphenylpyrimidin-4-yl)propionamide DM89NGE TI TTK25J1 DM89NGE TN Adenosine A1 receptor (ADORA1) DM89NGE MA Inhibitor DM89NGE RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DM89NGE RU https://pubmed.ncbi.nlm.nih.gov/15588088 DM89PMC DI DM89PMC DM89PMC DN VUF-10148 DM89PMC TI TTQHJ1K DM89PMC TN Histamine H2 receptor (H2R) DM89PMC MA Inhibitor DM89PMC RN Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem. 2008 Apr 24;51(8):2457-67. DM89PMC RU https://pubmed.ncbi.nlm.nih.gov/18357976 DM89PMC DI DM89PMC DM89PMC DN VUF-10148 DM89PMC TI TTTIBOJ DM89PMC TN Histamine H1 receptor (H1R) DM89PMC MA Inhibitor DM89PMC RN Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem. 2008 Apr 24;51(8):2457-67. DM89PMC RU https://pubmed.ncbi.nlm.nih.gov/18357976 DM89RN3 DI DM89RN3 DM89RN3 DN 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one DM89RN3 TI TT1RS9F DM89RN3 TN Acetylcholinesterase (AChE) DM89RN3 MA Inhibitor DM89RN3 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DM89RN3 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DM89RN3 DI DM89RN3 DM89RN3 DN 3-[6-(benzylmethylamino)hexyloxy]xanthen-9-one DM89RN3 TI TTEB0GD DM89RN3 TN Cholinesterase (BCHE) DM89RN3 MA Inhibitor DM89RN3 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DM89RN3 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DM89RYN DI DM89RYN DM89RYN DN 2-(7-phenylheptanoyl)oxazole-5-carbonitrile DM89RYN TI TTDP1UC DM89RYN TN Fatty acid amide hydrolase (FAAH) DM89RYN MA Inhibitor DM89RYN RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DM89RYN RU https://pubmed.ncbi.nlm.nih.gov/18639454 DM89WA1 DI DM89WA1 DM89WA1 DN MBX-3254 DM89WA1 TI TT7QNVC DM89WA1 TN Glucose-dependent insulinotropic receptor (GPR119) DM89WA1 MA Modulator DM89WA1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DM89WA1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DM89YV7 DI DM89YV7 DM89YV7 DN 6-hydroxymelatonin DM89YV7 TI TT0WAIE DM89YV7 TN Melatonin receptor type 1A (MTNR1A) DM89YV7 MA Agonist DM89YV7 RN Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther. 1985 Aug;234(2):395-401. DM89YV7 RU https://pubmed.ncbi.nlm.nih.gov/2991499 DM8A1HG DI DM8A1HG DM8A1HG DN (S)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide DM8A1HG TI TTCN0M9 DM8A1HG TN Sphingosine kinase 2 (SPHK2) DM8A1HG MA Inhibitor DM8A1HG RN Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21. DM8A1HG RU https://pubmed.ncbi.nlm.nih.gov/19800228 DM8A1ZU DI DM8A1ZU DM8A1ZU DN 6-bromo-5-phenylpyrimidine-2,4(1H,3H)-dione DM8A1ZU TI TTO0IB8 DM8A1ZU TN Thymidine phosphorylase (TYMP) DM8A1ZU MA Inhibitor DM8A1ZU RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DM8A1ZU RU https://pubmed.ncbi.nlm.nih.gov/17963370 DM8A23B DI DM8A23B DM8A23B DN N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8A23B TI TT1MPAY DM8A23B TN GABA(A) receptor alpha-1 (GABRA1) DM8A23B MA Inhibitor DM8A23B RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DM8A23B RU https://pubmed.ncbi.nlm.nih.gov/17335185 DM8A23B DI DM8A23B DM8A23B DN N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8A23B TI TTZA1NY DM8A23B TN GABA(A) receptor beta-2 (GABRB2) DM8A23B MA Inhibitor DM8A23B RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DM8A23B RU https://pubmed.ncbi.nlm.nih.gov/17335185 DM8A23B DI DM8A23B DM8A23B DN N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8A23B TI TT06RH5 DM8A23B TN GABA(A) receptor gamma-2 (GABRG2) DM8A23B MA Inhibitor DM8A23B RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DM8A23B RU https://pubmed.ncbi.nlm.nih.gov/17335185 DM8A23B DI DM8A23B DM8A23B DN N-Benzyl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8A23B TI TTNJYV2 DM8A23B TN Gamma-aminobutyric acid receptor (GAR) DM8A23B MA Inhibitor DM8A23B RN N'-Phenylindol-3-ylglyoxylohydrazide derivatives: synthesis, structure-activity relationships, molecular modeling studies, and pharmacological acti... J Med Chem. 1998 Sep 24;41(20):3821-30. DM8A23B RU https://pubmed.ncbi.nlm.nih.gov/9748357 DM8A2QO DI DM8A2QO DM8A2QO DN 4-Carboxyphenylboronic Acid DM8A2QO TI TTHI19T DM8A2QO TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM8A2QO MA Inhibitor DM8A2QO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8A2QO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8A3NI DI DM8A3NI DM8A3NI DN 2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine DM8A3NI TI TTXV4FI DM8A3NI TN Albendazole monooxygenase (CYP3A4) DM8A3NI MA Inhibitor DM8A3NI RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DM8A3NI RU https://pubmed.ncbi.nlm.nih.gov/14698153 DM8A3NI DI DM8A3NI DM8A3NI DN 2-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine DM8A3NI TI TTVG215 DM8A3NI TN Debrisoquine 4-hydroxylase (CYP2D6) DM8A3NI MA Inhibitor DM8A3NI RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DM8A3NI RU https://pubmed.ncbi.nlm.nih.gov/14698153 DM8A573 DI DM8A573 DM8A573 DN H-Dmt-Tic-Glu-NH2 DM8A573 TI TT27RFC DM8A573 TN Opioid receptor delta (OPRD1) DM8A573 MA Inhibitor DM8A573 RN Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6. DM8A573 RU https://pubmed.ncbi.nlm.nih.gov/15588089 DM8A573 DI DM8A573 DM8A573 DN H-Dmt-Tic-Glu-NH2 DM8A573 TI TTKWM86 DM8A573 TN Opioid receptor mu (MOP) DM8A573 MA Inhibitor DM8A573 RN Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6. DM8A573 RU https://pubmed.ncbi.nlm.nih.gov/15588089 DM8A6UH DI DM8A6UH DM8A6UH DN 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid DM8A6UH TI TTI7421 DM8A6UH TN Platelet-derived growth factor receptor beta (PDGFRB) DM8A6UH MA Inhibitor DM8A6UH RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM8A6UH RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM8A6UH DI DM8A6UH DM8A6UH DN 4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid DM8A6UH TI TT8FYO9 DM8A6UH TN Platelet-derived growth factor receptor alpha (PDGFRA) DM8A6UH MA Inhibitor DM8A6UH RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM8A6UH RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM8ABD6 DI DM8ABD6 DM8ABD6 DN Difluorobenztropine DM8ABD6 TI TTAWNKZ DM8ABD6 TN Norepinephrine transporter (NET) DM8ABD6 MA Inhibitor DM8ABD6 RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DM8ABD6 RU https://pubmed.ncbi.nlm.nih.gov/17034144 DM8ABD6 DI DM8ABD6 DM8ABD6 DN Difluorobenztropine DM8ABD6 TI TTZ9SOR DM8ABD6 TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8ABD6 MA Inhibitor DM8ABD6 RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DM8ABD6 RU https://pubmed.ncbi.nlm.nih.gov/17034144 DM8ABD6 DI DM8ABD6 DM8ABD6 DN Difluorobenztropine DM8ABD6 TI TT3ROYC DM8ABD6 TN Serotonin transporter (SERT) DM8ABD6 MA Inhibitor DM8ABD6 RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DM8ABD6 RU https://pubmed.ncbi.nlm.nih.gov/17034144 DM8ABD6 DI DM8ABD6 DM8ABD6 DN Difluorobenztropine DM8ABD6 TI TTVBI8W DM8ABD6 TN Dopamine transporter (DAT) DM8ABD6 MA Inhibitor DM8ABD6 RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DM8ABD6 RU https://pubmed.ncbi.nlm.nih.gov/17034144 DM8ACIF DI DM8ACIF DM8ACIF DN VBY- 285 DM8ACIF TI TTUMQVO DM8ACIF TN Cathepsin S (CTSS) DM8ACIF MA Inhibitor DM8ACIF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DM8ACIF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DM8AEQX DI DM8AEQX DM8AEQX DN Bmab-200 DM8AEQX TI TTGKNB4 DM8AEQX TN Epidermal growth factor receptor (EGFR) DM8AEQX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM8AEQX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM8AG5R DI DM8AG5R DM8AG5R DN HuMax-cMet DM8AG5R TI TTNDSF4 DM8AG5R TN Proto-oncogene c-Met (MET) DM8AG5R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM8AG5R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM8AHJC DI DM8AHJC DM8AHJC DN ISIS 25116 DM8AHJC TI TT8H9GB DM8AHJC TN MEK2 messenger RNA (MEK2 mRNA) DM8AHJC RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DM8AHJC RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DM8AMGF DI DM8AMGF DM8AMGF DN C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2 DM8AMGF TI TT0MV2T DM8AMGF TN Melanocortin receptor 1 (MC1R) DM8AMGF MA Inhibitor DM8AMGF RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DM8AMGF RU https://pubmed.ncbi.nlm.nih.gov/18088090 DM8AMGF DI DM8AMGF DM8AMGF DN C[CO-2,3-pyrazine-CO-D-Phe-Arg-Trp-Lys]-NH2 DM8AMGF TI TTNI91K DM8AMGF TN Melanocortin receptor 3 (MC3R) DM8AMGF MA Inhibitor DM8AMGF RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DM8AMGF RU https://pubmed.ncbi.nlm.nih.gov/18088090 DM8APLN DI DM8APLN DM8APLN DN 1-(phenylsulfonyl)-1H-pyrrolo[3,2-b]pyridine DM8APLN TI TTNDSF4 DM8APLN TN Proto-oncogene c-Met (MET) DM8APLN MA Inhibitor DM8APLN RN Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4. DM8APLN RU https://pubmed.ncbi.nlm.nih.gov/19369077 DM8AZQ3 DI DM8AZQ3 DM8AZQ3 DN difluoroagomelatine DM8AZQ3 TI TT0WAIE DM8AZQ3 TN Melatonin receptor type 1A (MTNR1A) DM8AZQ3 MA Agonist DM8AZQ3 RN Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur J Med Chem. 2012 Mar;49:310-23. DM8AZQ3 RU https://pubmed.ncbi.nlm.nih.gov/22301214 DM8B0VZ DI DM8B0VZ DM8B0VZ DN CHLOROPUUPEHENONE DM8B0VZ TI TT12ABZ DM8B0VZ TN Arachidonate 12-lipoxygenase (12-LOX) DM8B0VZ MA Inhibitor DM8B0VZ RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DM8B0VZ RU https://pubmed.ncbi.nlm.nih.gov/12608855 DM8B0VZ DI DM8B0VZ DM8B0VZ DN CHLOROPUUPEHENONE DM8B0VZ TI TTN9T81 DM8B0VZ TN Arachidonate 15-lipoxygenase (15-LOX) DM8B0VZ MA Inhibitor DM8B0VZ RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DM8B0VZ RU https://pubmed.ncbi.nlm.nih.gov/12608855 DM8BC1M DI DM8BC1M DM8BC1M DN 1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DM8BC1M TI TTZAYWL DM8BC1M TN Estrogen receptor (ESR) DM8BC1M MA Inhibitor DM8BC1M RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM8BC1M RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM8BC1M DI DM8BC1M DM8BC1M DN 1-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DM8BC1M TI TTOM3J0 DM8BC1M TN Estrogen receptor beta (ESR2) DM8BC1M MA Inhibitor DM8BC1M RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DM8BC1M RU https://pubmed.ncbi.nlm.nih.gov/15943471 DM8BJPU DI DM8BJPU DM8BJPU DN 3,4-epoxydehydroleucodin DM8BJPU TI TTSXVID DM8BJPU TN Nuclear factor NF-kappa-B (NFKB) DM8BJPU MA Inhibitor DM8BJPU RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DM8BJPU RU https://pubmed.ncbi.nlm.nih.gov/16570920 DM8BKI4 DI DM8BKI4 DM8BKI4 DN PMID16460935C28 DM8BKI4 TI TT7LRQH DM8BKI4 TN Complement C1s component (C1S) DM8BKI4 MA Inhibitor DM8BKI4 RN A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2200-4. DM8BKI4 RU https://pubmed.ncbi.nlm.nih.gov/16460935 DM8BKTV DI DM8BKTV DM8BKTV DN (10H-phenothiazin-10-yl)(o-tolyl)methanone DM8BKTV TI TTEB0GD DM8BKTV TN Cholinesterase (BCHE) DM8BKTV MA Inhibitor DM8BKTV RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DM8BKTV RU https://pubmed.ncbi.nlm.nih.gov/17681768 DM8BLK2 DI DM8BLK2 DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 TI TT8QL1J DM8BLK2 TN Protein kinase C theta (PRKCQ) DM8BLK2 MA Inhibitor DM8BLK2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8BLK2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8BLK2 DI DM8BLK2 DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 TI TTRFOXJ DM8BLK2 TN Protein kinase C gamma (PRKCG) DM8BLK2 MA Inhibitor DM8BLK2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8BLK2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8BLK2 DI DM8BLK2 DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 TI TTUWGRA DM8BLK2 TN Protein kinase C zeta (PRKCZ) DM8BLK2 MA Inhibitor DM8BLK2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8BLK2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8BLK2 DI DM8BLK2 DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 TI TTYPXQF DM8BLK2 TN Protein kinase C beta (PRKCB) DM8BLK2 MA Inhibitor DM8BLK2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8BLK2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8BLK2 DI DM8BLK2 DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 TI TTFJ8Q1 DM8BLK2 TN Protein kinase C alpha (PRKCA) DM8BLK2 MA Inhibitor DM8BLK2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8BLK2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8BLK2 DI DM8BLK2 DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 TI TT9WJ8U DM8BLK2 TN Protein kinase C delta (PRKCD) DM8BLK2 MA Inhibitor DM8BLK2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8BLK2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8BLK2 DI DM8BLK2 DM8BLK2 DN 4-cyclohexyliden(4-hydroxyphenyl)methylphenol DM8BLK2 TI TTBZ7OD DM8BLK2 TN Protein kinase C epsilon (PRKCE) DM8BLK2 MA Inhibitor DM8BLK2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8BLK2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8BLXT DI DM8BLXT DM8BLXT DN Subersic acid DM8BLXT TI TTN9T81 DM8BLXT TN Arachidonate 15-lipoxygenase (15-LOX) DM8BLXT MA Inhibitor DM8BLXT RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DM8BLXT RU https://pubmed.ncbi.nlm.nih.gov/12608855 DM8BLYO DI DM8BLYO DM8BLYO DN RO320-2947/001 DM8BLYO TI TTU3Y87 DM8BLYO TN CCR3 messenger RNA (CCR3 mRNA) DM8BLYO MA Antagonist DM8BLYO RN Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9. DM8BLYO RU https://pubmed.ncbi.nlm.nih.gov/12070060 DM8BNWH DI DM8BNWH DM8BNWH DN 6-Azido-8-(3-iodo-phenyl)-quinoline DM8BNWH TI TTZ97H5 DM8BNWH TN Phosphodiesterase 4A (PDE4A) DM8BNWH MA Inhibitor DM8BNWH RN Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3. DM8BNWH RU https://pubmed.ncbi.nlm.nih.gov/11052785 DM8BPTQ DI DM8BPTQ DM8BPTQ DN 4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine DM8BPTQ TI TTZUFI5 DM8BPTQ TN Nitric-oxide synthase brain (NOS1) DM8BPTQ MA Inhibitor DM8BPTQ RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DM8BPTQ RU https://pubmed.ncbi.nlm.nih.gov/20933416 DM8BPTQ DI DM8BPTQ DM8BPTQ DN 4-[(2-Methyl-1H-imidazol-1-yl)methyl]pyridine DM8BPTQ TI TTF10I9 DM8BPTQ TN Nitric-oxide synthase inducible (NOS2) DM8BPTQ MA Inhibitor DM8BPTQ RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DM8BPTQ RU https://pubmed.ncbi.nlm.nih.gov/20933416 DM8BS5C DI DM8BS5C DM8BS5C DN Eryvarin D DM8BS5C TI TT50QJ3 DM8BS5C TN Influenza Neuraminidase (Influ NA) DM8BS5C MA Inhibitor DM8BS5C RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DM8BS5C RU https://pubmed.ncbi.nlm.nih.gov/20363636 DM8BVJQ DI DM8BVJQ DM8BVJQ DN L-735021 DM8BVJQ TI TTFQEO5 DM8BVJQ TN Squalene synthetase (FDFT1) DM8BVJQ MA Inhibitor DM8BVJQ RN Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51. DM8BVJQ RU https://pubmed.ncbi.nlm.nih.gov/7966163 DM8BWZO DI DM8BWZO DM8BWZO DN 4-(m-tolyloxy)-2-(trifluoromethyl)benzonitrile DM8BWZO TI TTKPW01 DM8BWZO TN Androgen receptor messenger RNA (AR mRNA) DM8BWZO MA Inhibitor DM8BWZO RN Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8. DM8BWZO RU https://pubmed.ncbi.nlm.nih.gov/19286380 DM8BZQ3 DI DM8BZQ3 DM8BZQ3 DN 4-(propylthio)-2-(trifluoromethyl)benzonitrile DM8BZQ3 TI TTKPW01 DM8BZQ3 TN Androgen receptor messenger RNA (AR mRNA) DM8BZQ3 MA Inhibitor DM8BZQ3 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DM8BZQ3 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DM8BZVI DI DM8BZVI DM8BZVI DN INV-311 DM8BZVI TI TTVCZPI DM8BZVI TN Myeloperoxidase (MPO) DM8BZVI MA Inhibitor DM8BZVI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2789). DM8BZVI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2789 DM8C2Z0 DI DM8C2Z0 DM8C2Z0 DN RO-194603 DM8C2Z0 TI TT1MPAY DM8C2Z0 TN GABA(A) receptor alpha-1 (GABRA1) DM8C2Z0 MA Inhibitor DM8C2Z0 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM8C2Z0 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM8C2Z0 DI DM8C2Z0 DM8C2Z0 DN RO-194603 DM8C2Z0 TI TTZA1NY DM8C2Z0 TN GABA(A) receptor beta-2 (GABRB2) DM8C2Z0 MA Inhibitor DM8C2Z0 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM8C2Z0 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM8C2Z0 DI DM8C2Z0 DM8C2Z0 DN RO-194603 DM8C2Z0 TI TT06RH5 DM8C2Z0 TN GABA(A) receptor gamma-2 (GABRG2) DM8C2Z0 MA Inhibitor DM8C2Z0 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM8C2Z0 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM8C2Z0 DI DM8C2Z0 DM8C2Z0 DN RO-194603 DM8C2Z0 TI TTNJYV2 DM8C2Z0 TN Gamma-aminobutyric acid receptor (GAR) DM8C2Z0 MA Inhibitor DM8C2Z0 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DM8C2Z0 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DM8C43L DI DM8C43L DM8C43L DN 2,3-dioxoindoline-7-carboxylic acid DM8C43L TI TTGX0HR DM8C43L TN Bacterial DNA ligase (Bact ligA) DM8C43L MA Inhibitor DM8C43L RN Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62. DM8C43L RU https://pubmed.ncbi.nlm.nih.gov/18630893 DM8CIE4 DI DM8CIE4 DM8CIE4 DN ML233 DM8CIE4 TI TTJ8E43 DM8CIE4 TN Apelin receptor (APLNR) DM8CIE4 MA Agonist DM8CIE4 RN Functional Agonists of the Apelin (APJ) Receptor. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010. DM8CIE4 RU https://pubmed.ncbi.nlm.nih.gov/22834038 DM8CK9M DI DM8CK9M DM8CK9M DN 3-(4-Fluorophenyl)-2-nortropene DM8CK9M TI TT3ROYC DM8CK9M TN Serotonin transporter (SERT) DM8CK9M MA Inhibitor DM8CK9M RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DM8CK9M RU https://pubmed.ncbi.nlm.nih.gov/19896846 DM8CK9M DI DM8CK9M DM8CK9M DN 3-(4-Fluorophenyl)-2-nortropene DM8CK9M TI TTVBI8W DM8CK9M TN Dopamine transporter (DAT) DM8CK9M MA Inhibitor DM8CK9M RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DM8CK9M RU https://pubmed.ncbi.nlm.nih.gov/19896846 DM8CLG2 DI DM8CLG2 DM8CLG2 DN Sodium orthovanadate DM8CLG2 TI TT7YM8D DM8CLG2 TN Protein tyrosine phosphatase IVA 3 (PRL-3) DM8CLG2 MA Inhibitor DM8CLG2 RN Structure of human PRL-3, the phosphatase associated with cancer metastasis. FEBS Lett. 2004 May 7;565(1-3):181-7. DM8CLG2 RU https://pubmed.ncbi.nlm.nih.gov/15135076 DM8CN2M DI DM8CN2M DM8CN2M DN ISIS 101985 DM8CN2M TI TTON5JB DM8CN2M TN MADH6 messenger RNA (MADH6 mRNA) DM8CN2M RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DM8CN2M RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DM8CPZB DI DM8CPZB DM8CPZB DN PMID30247903-Compound-General structure24 DM8CPZB TI TTNBFWK DM8CPZB TN Programmed cell death protein 1 (PD-1) DM8CPZB MA Inhibitor DM8CPZB RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM8CPZB RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM8CYOP DI DM8CYOP DM8CYOP DN 1,3-Dihydro-naphtho[2,3-d]imidazol-2-one DM8CYOP TI TT06AWU DM8CYOP TN Phosphodiesterase 3A (PDE3A) DM8CYOP MA Inhibitor DM8CYOP RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DM8CYOP RU https://pubmed.ncbi.nlm.nih.gov/1654430 DM8D26T DI DM8D26T DM8D26T DN D-192 DM8D26T TI TTEX248 DM8D26T TN Dopamine D2 receptor (D2R) DM8D26T MA Inhibitor DM8D26T RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DM8D26T RU https://pubmed.ncbi.nlm.nih.gov/18410082 DM8D26T DI DM8D26T DM8D26T DN D-192 DM8D26T TI TT4C8EA DM8D26T TN Dopamine D3 receptor (D3R) DM8D26T MA Inhibitor DM8D26T RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DM8D26T RU https://pubmed.ncbi.nlm.nih.gov/18410082 DM8D3NY DI DM8D3NY DM8D3NY DN MERIOLIN 7 DM8D3NY TI TT1LVF2 DM8D3NY TN Cyclin-dependent kinase 9 (CDK9) DM8D3NY MA Inhibitor DM8D3NY RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM8D3NY RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM8D3NY DI DM8D3NY DM8D3NY DN MERIOLIN 7 DM8D3NY TI TTAMQ62 DM8D3NY TN Cyclin A2 (CCNA2) DM8D3NY MA Inhibitor DM8D3NY RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DM8D3NY RU https://pubmed.ncbi.nlm.nih.gov/18232649 DM8D4QT DI DM8D4QT DM8D4QT DN D[Arg4,Orn8]VP DM8D4QT TI TTK8R02 DM8D4QT TN Vasopressin V2 receptor (V2R) DM8D4QT MA Inhibitor DM8D4QT RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8D4QT RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8D4QT DI DM8D4QT DM8D4QT DN D[Arg4,Orn8]VP DM8D4QT TI TT4TFGN DM8D4QT TN Vasopressin V1a receptor (V1AR) DM8D4QT MA Inhibitor DM8D4QT RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8D4QT RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8D4QT DI DM8D4QT DM8D4QT DN D[Arg4,Orn8]VP DM8D4QT TI TTSCIUP DM8D4QT TN Oxytocin receptor (OTR) DM8D4QT MA Inhibitor DM8D4QT RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8D4QT RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8D4QT DI DM8D4QT DM8D4QT DN D[Arg4,Orn8]VP DM8D4QT TI TTL9MHW DM8D4QT TN Vasopressin V1b receptor (V1BR) DM8D4QT MA Inhibitor DM8D4QT RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8D4QT RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8D6ZL DI DM8D6ZL DM8D6ZL DN PMID26080733C7r DM8D6ZL TI TTRLW2X DM8D6ZL TN Fibroblast growth factor receptor 1 (FGFR1) DM8D6ZL MA Inhibitor DM8D6ZL RN Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold. Org Biomol Chem. 2015 Jul 28;13(28):7643-54. DM8D6ZL RU https://pubmed.ncbi.nlm.nih.gov/26080733 DM8DAGL DI DM8DAGL DM8DAGL DN N-(3,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide DM8DAGL TI TTVTX4N DM8DAGL TN Bacterial Fatty acid synthetase I (Bact inhA) DM8DAGL MA Inhibitor DM8DAGL RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DM8DAGL RU https://pubmed.ncbi.nlm.nih.gov/19428156 DM8DOBG DI DM8DOBG DM8DOBG DN APS-3010 DM8DOBG TI TTNDSF4 DM8DOBG TN Proto-oncogene c-Met (MET) DM8DOBG MA Inhibitor DM8DOBG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DM8DOBG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DM8DR1B DI DM8DR1B DM8DR1B DN 1-(3-cyano-1-methyl-1H-indol-6-yl)-3-phenylurea DM8DR1B TI TTTB4UP DM8DR1B TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM8DR1B MA Inhibitor DM8DR1B RN Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42. DM8DR1B RU https://pubmed.ncbi.nlm.nih.gov/16483773 DM8DU42 DI DM8DU42 DM8DU42 DN C(RGDfMeF) DM8DU42 TI TTT1R2L DM8DU42 TN Integrin alpha-V (ITGAV) DM8DU42 MA Inhibitor DM8DU42 RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DM8DU42 RU https://pubmed.ncbi.nlm.nih.gov/16509596 DM8DU42 DI DM8DU42 DM8DU42 DN C(RGDfMeF) DM8DU42 TI TTJA1ZO DM8DU42 TN ITGB3 messenger RNA (ITGB3 mRNA) DM8DU42 MA Inhibitor DM8DU42 RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DM8DU42 RU https://pubmed.ncbi.nlm.nih.gov/16509596 DM8DVY2 DI DM8DVY2 DM8DVY2 DN SB 221284 DM8DVY2 TI TTWJBZ5 DM8DVY2 TN 5-HT 2C receptor (HTR2C) DM8DVY2 MA Antagonist DM8DVY2 RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM8DVY2 RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM8DVY2 DI DM8DVY2 DM8DVY2 DN SB 221284 DM8DVY2 TI TTJQOD7 DM8DVY2 TN 5-HT 2A receptor (HTR2A) DM8DVY2 MA Antagonist DM8DVY2 RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM8DVY2 RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM8DVY2 DI DM8DVY2 DM8DVY2 DN SB 221284 DM8DVY2 TI TT0K1SC DM8DVY2 TN 5-HT 2B receptor (HTR2B) DM8DVY2 MA Antagonist DM8DVY2 RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM8DVY2 RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM8DYWN DI DM8DYWN DM8DYWN DN AKUAMMINE DM8DYWN TI TTKWM86 DM8DYWN TN Opioid receptor mu (MOP) DM8DYWN MA Inhibitor DM8DYWN RN Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4. DM8DYWN RU https://pubmed.ncbi.nlm.nih.gov/1317407 DM8E2L6 DI DM8E2L6 DM8E2L6 DN Isosorbide-2-benzylcarbamate-5-cyclopropanoate DM8E2L6 TI TT1RS9F DM8E2L6 TN Acetylcholinesterase (AChE) DM8E2L6 MA Inhibitor DM8E2L6 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DM8E2L6 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DM8E2L6 DI DM8E2L6 DM8E2L6 DN Isosorbide-2-benzylcarbamate-5-cyclopropanoate DM8E2L6 TI TTEB0GD DM8E2L6 TN Cholinesterase (BCHE) DM8E2L6 MA Inhibitor DM8E2L6 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DM8E2L6 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DM8E4HB DI DM8E4HB DM8E4HB DN INC-106 DM8E4HB TI TT8DBY3 DM8E4HB TN Angiotensin II receptor type-1 (AGTR1) DM8E4HB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34). DM8E4HB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34 DM8E54P DI DM8E54P DM8E54P DN BUTEIN DM8E54P TI TTL69WB DM8E54P TN Angiotensin-converting enzyme (ACE) DM8E54P MA Inhibitor DM8E54P RN The synthesis and angiotensin converting enzyme (ACE) inhibitory activity of chalcones and their pyrazole derivatives. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1990-3. DM8E54P RU https://pubmed.ncbi.nlm.nih.gov/20167484 DM8E54P DI DM8E54P DM8E54P DN BUTEIN DM8E54P TI TTNX2CS DM8E54P TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM8E54P MA Inhibitor DM8E54P RN Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR). J Med Chem. 2007 Feb 22;50(4):765-75. DM8E54P RU https://pubmed.ncbi.nlm.nih.gov/17263522 DM8E5RO DI DM8E5RO DM8E5RO DN ISIS 9063 DM8E5RO TI TT5TURO DM8E5RO TN A-Raf messenger RNA (ARAF mRNA) DM8E5RO RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DM8E5RO RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DM8E62L DI DM8E62L DM8E62L DN Sigmoidin F DM8E62L TI TTELIN2 DM8E62L TN PTPN1 messenger RNA (PTPN1 mRNA) DM8E62L MA Inhibitor DM8E62L RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DM8E62L RU https://pubmed.ncbi.nlm.nih.gov/17489632 DM8E9YS DI DM8E9YS DM8E9YS DN Trans-dimethyl gababutin DM8E9YS TI TTFK1JQ DM8E9YS TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM8E9YS MA Inhibitor DM8E9YS RN Synthesis and in vivo evaluation of bicyclic gababutins. Bioorg Med Chem Lett. 2010 Jan 15;20(2):461-4. DM8E9YS RU https://pubmed.ncbi.nlm.nih.gov/20005103 DM8EDI7 DI DM8EDI7 DM8EDI7 DN 1-Phenyl-2-pyridin-3-yl-propan-1-one DM8EDI7 TI TTIQUX7 DM8EDI7 TN Steroid 11-beta-hydroxylase (CYP11B1) DM8EDI7 MA Inhibitor DM8EDI7 RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DM8EDI7 RU https://pubmed.ncbi.nlm.nih.gov/6606707 DM8EH07 DI DM8EH07 DM8EH07 DN 3-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol DM8EH07 TI TTWHDVK DM8EH07 TN Fructose-1,6-bisphosphatase (FBP) DM8EH07 MA Inhibitor DM8EH07 RN A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22. DM8EH07 RU https://pubmed.ncbi.nlm.nih.gov/19419876 DM8EQFL DI DM8EQFL DM8EQFL DN [125I]AB-MECA DM8EQFL TI TTJFY5U DM8EQFL TN Adenosine A3 receptor (ADORA3) DM8EQFL MA Agonist DM8EQFL RN [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. DM8EQFL RU https://pubmed.ncbi.nlm.nih.gov/10779381 DM8EV4A DI DM8EV4A DM8EV4A DN 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime DM8EV4A TI TTQ3JTF DM8EV4A TN Muscarinic acetylcholine receptor M4 (CHRM4) DM8EV4A MA Inhibitor DM8EV4A RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DM8EV4A RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DM8EV4A DI DM8EV4A DM8EV4A DN 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime DM8EV4A TI TTH18TF DM8EV4A TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8EV4A MA Inhibitor DM8EV4A RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DM8EV4A RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DM8EV4A DI DM8EV4A DM8EV4A DN 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime DM8EV4A TI TTQ13Z5 DM8EV4A TN Muscarinic acetylcholine receptor M3 (CHRM3) DM8EV4A MA Inhibitor DM8EV4A RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DM8EV4A RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DM8EV4A DI DM8EV4A DM8EV4A DN 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime DM8EV4A TI TTZ9SOR DM8EV4A TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8EV4A MA Inhibitor DM8EV4A RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DM8EV4A RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DM8EV4A DI DM8EV4A DM8EV4A DN 2-Methyl-6-pyrrolidin-1-yl-hex-4-ynal oxime DM8EV4A TI TTYEG6Q DM8EV4A TN Muscarinic acetylcholine receptor M2 (CHRM2) DM8EV4A MA Inhibitor DM8EV4A RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DM8EV4A RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DM8EZTM DI DM8EZTM DM8EZTM DN RvD1-ME DM8EZTM TI TTOJ1NF DM8EZTM TN FMLP-related receptor I (FPR2) DM8EZTM MA Agonist DM8EZTM RN Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27. DM8EZTM RU https://pubmed.ncbi.nlm.nih.gov/22449948 DM8EZTM DI DM8EZTM DM8EZTM DN RvD1-ME DM8EZTM TI TT7OCUB DM8EZTM TN G-protein coupled receptor 32 (GPR32) DM8EZTM MA Agonist DM8EZTM RN Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27. DM8EZTM RU https://pubmed.ncbi.nlm.nih.gov/22449948 DM8F0N5 DI DM8F0N5 DM8F0N5 DN 4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID DM8F0N5 TI TT50QJ3 DM8F0N5 TN Influenza Neuraminidase (Influ NA) DM8F0N5 MA Inhibitor DM8F0N5 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM8F0N5 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM8F5DY DI DM8F5DY DM8F5DY DN Cyclo(-D-Tyr-D-MeArg-L-Arg-L-Nal-Gly-) DM8F5DY TI TTBID49 DM8F5DY TN C-X-C chemokine receptor type 4 (CXCR4) DM8F5DY MA Inhibitor DM8F5DY RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DM8F5DY RU https://pubmed.ncbi.nlm.nih.gov/17228861 DM8F5LR DI DM8F5LR DM8F5LR DN NAPQI DM8F5LR TI TT2AST1 DM8F5LR TN Macrophage migration inhibitory factor (MIF) DM8F5LR MA Inhibitor DM8F5LR RN MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9. DM8F5LR RU https://pubmed.ncbi.nlm.nih.gov/18721909 DM8F9KO DI DM8F9KO DM8F9KO DN 2,6-dphenyl-8-propyl-1-deazapurine DM8F9KO TI TTJFY5U DM8F9KO TN Adenosine A3 receptor (ADORA3) DM8F9KO MA Inhibitor DM8F9KO RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM8F9KO RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM8F9KO DI DM8F9KO DM8F9KO DN 2,6-dphenyl-8-propyl-1-deazapurine DM8F9KO TI TTK25J1 DM8F9KO TN Adenosine A1 receptor (ADORA1) DM8F9KO MA Inhibitor DM8F9KO RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM8F9KO RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM8F9KO DI DM8F9KO DM8F9KO DN 2,6-dphenyl-8-propyl-1-deazapurine DM8F9KO TI TTM2AOE DM8F9KO TN Adenosine A2a receptor (ADORA2A) DM8F9KO MA Inhibitor DM8F9KO RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DM8F9KO RU https://pubmed.ncbi.nlm.nih.gov/17300165 DM8FCX5 DI DM8FCX5 DM8FCX5 DN D[Cha4]AVP DM8FCX5 TI TTK8R02 DM8FCX5 TN Vasopressin V2 receptor (V2R) DM8FCX5 MA Inhibitor DM8FCX5 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8FCX5 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8FCX5 DI DM8FCX5 DM8FCX5 DN D[Cha4]AVP DM8FCX5 TI TT4TFGN DM8FCX5 TN Vasopressin V1a receptor (V1AR) DM8FCX5 MA Inhibitor DM8FCX5 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8FCX5 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8FCX5 DI DM8FCX5 DM8FCX5 DN D[Cha4]AVP DM8FCX5 TI TTL9MHW DM8FCX5 TN Vasopressin V1b receptor (V1BR) DM8FCX5 MA Inhibitor DM8FCX5 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8FCX5 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8FCX5 DI DM8FCX5 DM8FCX5 DN D[Cha4]AVP DM8FCX5 TI TTSCIUP DM8FCX5 TN Oxytocin receptor (OTR) DM8FCX5 MA Inhibitor DM8FCX5 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8FCX5 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8FD3Z DI DM8FD3Z DM8FD3Z DN HG-9-91-01 DM8FD3Z TI TTCUGZR DM8FD3Z TN Salt-inducible kinase 2 (SIK2) DM8FD3Z MA Inhibitor DM8FD3Z RN Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91. DM8FD3Z RU https://pubmed.ncbi.nlm.nih.gov/23033494 DM8FD3Z DI DM8FD3Z DM8FD3Z DN HG-9-91-01 DM8FD3Z TI TTW6L4V DM8FD3Z TN SIK family kinase 3 (SIK3) DM8FD3Z MA Inhibitor DM8FD3Z RN Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91. DM8FD3Z RU https://pubmed.ncbi.nlm.nih.gov/23033494 DM8FD3Z DI DM8FD3Z DM8FD3Z DN HG-9-91-01 DM8FD3Z TI TT1H6LC DM8FD3Z TN Salt-inducible kinase 1 (SIK1) DM8FD3Z MA Inhibitor DM8FD3Z RN Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages. Proc Natl Acad Sci U S A. 2012 Oct 16;109(42):16986-91. DM8FD3Z RU https://pubmed.ncbi.nlm.nih.gov/23033494 DM8FGMA DI DM8FGMA DM8FGMA DN C[RGDf-(R)-alpha-TfmV] DM8FGMA TI TTJA1ZO DM8FGMA TN ITGB3 messenger RNA (ITGB3 mRNA) DM8FGMA MA Inhibitor DM8FGMA RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DM8FGMA RU https://pubmed.ncbi.nlm.nih.gov/16509596 DM8FGMA DI DM8FGMA DM8FGMA DN C[RGDf-(R)-alpha-TfmV] DM8FGMA TI TTT1R2L DM8FGMA TN Integrin alpha-V (ITGAV) DM8FGMA MA Inhibitor DM8FGMA RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DM8FGMA RU https://pubmed.ncbi.nlm.nih.gov/16509596 DM8FLVH DI DM8FLVH DM8FLVH DN Human CD40 agonist ligand DM8FLVH TI TTN6Y9A DM8FLVH TN CD40L receptor (CD40) DM8FLVH MA Agonist DM8FLVH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874). DM8FLVH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874 DM8FMYL DI DM8FMYL DM8FMYL DN Decanoic Acid DM8FMYL TI TTPH97Y DM8FMYL TN Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA) DM8FMYL MA Inhibitor DM8FMYL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8FMYL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8FOSR DI DM8FOSR DM8FOSR DN N-n-dodecyl-7-methoxytacrine hydrochloride DM8FOSR TI TT1RS9F DM8FOSR TN Acetylcholinesterase (AChE) DM8FOSR MA Inhibitor DM8FOSR RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DM8FOSR RU https://pubmed.ncbi.nlm.nih.gov/20817518 DM8FTJN DI DM8FTJN DM8FTJN DN Glycyl-L-Alpha-Amino-Epsilon-Pimelyl-D-Alanine DM8FTJN TI TTLP6GN DM8FTJN TN Bacterial DD-carboxypeptidase (Bact vanYB) DM8FTJN MA Inhibitor DM8FTJN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8FTJN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8FTNC DI DM8FTNC DM8FTNC DN 6-Benzylamino-5-iodo-1H-pyrimidine-2,4-dione DM8FTNC TI TT2GPK3 DM8FTNC TN DNA topoisomerase (TOP) DM8FTNC MA Inhibitor DM8FTNC RN Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81. DM8FTNC RU https://pubmed.ncbi.nlm.nih.gov/3084785 DM8FUZL DI DM8FUZL DM8FUZL DN 6-Benzylamino-1H-pyrimidine-2,4-dione DM8FUZL TI TT2GPK3 DM8FUZL TN DNA topoisomerase (TOP) DM8FUZL MA Inhibitor DM8FUZL RN Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81. DM8FUZL RU https://pubmed.ncbi.nlm.nih.gov/3084785 DM8FXM6 DI DM8FXM6 DM8FXM6 DN Propan-2-one O-4-(heptyloxy)phenylcarbamoyl oxime DM8FXM6 TI TTDP1UC DM8FXM6 TN Fatty acid amide hydrolase (FAAH) DM8FXM6 MA Inhibitor DM8FXM6 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM8FXM6 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM8FY3H DI DM8FY3H DM8FY3H DN ISIS 105990 DM8FY3H TI TTT2SVW DM8FY3H TN PPAR-gamma messenger RNA (PPARG mRNA) DM8FY3H RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DM8FY3H RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DM8G0WX DI DM8G0WX DM8G0WX DN N,8-dihydroxy-8-(naphthalen-2-yl)octanamide DM8G0WX TI TT6R7JZ DM8G0WX TN Histone deacetylase 1 (HDAC1) DM8G0WX MA Inhibitor DM8G0WX RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DM8G0WX RU https://pubmed.ncbi.nlm.nih.gov/19136179 DM8G4HS DI DM8G4HS DM8G4HS DN BCX-1923 DM8G4HS TI TT50QJ3 DM8G4HS TN Influenza Neuraminidase (Influ NA) DM8G4HS MA Inhibitor DM8G4HS RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DM8G4HS RU https://pubmed.ncbi.nlm.nih.gov/17139286 DM8G6O4 DI DM8G6O4 DM8G6O4 DN AHPN DM8G6O4 TI TT1Q3IE DM8G6O4 TN Retinoic acid receptor gamma (RARG) DM8G6O4 MA Agonist DM8G6O4 RN Synthesis, structure-affinity relationships, and biological activities of ligands binding to retinoic acid receptor subtypes. J Med Chem. 1995 Dec 22;38(26):4993-5006. DM8G6O4 RU https://pubmed.ncbi.nlm.nih.gov/8544175 DM8G9NY DI DM8G9NY DM8G9NY DN UR-11353 DM8G9NY TI TTQL5VC DM8G9NY TN Platelet-activating factor receptor (PTAFR) DM8G9NY MA Modulator DM8G9NY RN Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents. Br J Pharmacol. 1991 Dec;104(4):990-4. DM8G9NY RU https://www.ncbi.nlm.nih.gov/pubmed/1810607 DM8GBH4 DI DM8GBH4 DM8GBH4 DN 2-(4-hydroxystyryl)quinolin-8-ol DM8GBH4 TI TT6804T DM8GBH4 TN MIF messenger RNA (MIF mRNA) DM8GBH4 MA Inhibitor DM8GBH4 RN Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24. DM8GBH4 RU https://pubmed.ncbi.nlm.nih.gov/19090668 DM8GC36 DI DM8GC36 DM8GC36 DN H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 DM8GC36 TI TT27RFC DM8GC36 TN Opioid receptor delta (OPRD1) DM8GC36 MA Inhibitor DM8GC36 RN Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80. DM8GC36 RU https://pubmed.ncbi.nlm.nih.gov/10691683 DM8GC36 DI DM8GC36 DM8GC36 DN H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 DM8GC36 TI TTKWM86 DM8GC36 TN Opioid receptor mu (MOP) DM8GC36 MA Inhibitor DM8GC36 RN Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80. DM8GC36 RU https://pubmed.ncbi.nlm.nih.gov/10691683 DM8GCHX DI DM8GCHX DM8GCHX DN PRS-060 DM8GCHX TI TTDWHC3 DM8GCHX TN Interleukin 4 receptor alpha (IL4R) DM8GCHX MA Inhibitor DM8GCHX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1697). DM8GCHX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1697 DM8GDZS DI DM8GDZS DM8GDZS DN SRI-63-675 DM8GDZS TI TTQL5VC DM8GDZS TN Platelet-activating factor receptor (PTAFR) DM8GDZS MA Modulator DM8GDZS RN The effect of SRI 63-675, a competitive platelet-activating factor receptor-antagonist, in the generalized Shwartzman reaction. J Lipid Mediat Cell Signal. 1994 Sep;10(3):229-42. DM8GDZS RU https://www.ncbi.nlm.nih.gov/pubmed/7812674 DM8GFJP DI DM8GFJP DM8GFJP DN GX-C4 DM8GFJP TI TTI2S1D DM8GFJP TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DM8GFJP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743). DM8GFJP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743 DM8GJCU DI DM8GJCU DM8GJCU DN 2-(ethylthiomethyl)-5-hydroxy-4H-pyran-4-one DM8GJCU TI TTULVH8 DM8GJCU TN Tyrosinase (TYR) DM8GJCU MA Inhibitor DM8GJCU RN Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71. DM8GJCU RU https://pubmed.ncbi.nlm.nih.gov/20934336 DM8GQ9X DI DM8GQ9X DM8GQ9X DN IKI-1 DM8GQ9X TI TTWLVKG DM8GQ9X TN Inhibitor of nuclear factor kappa-B kinase alpha (IKKA) DM8GQ9X MA Inhibitor DM8GQ9X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1989). DM8GQ9X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1989 DM8GRJK DI DM8GRJK DM8GRJK DN Rapamycin DM8GRJK TI TT7HQAF DM8GRJK TN HUMAN mammalian target of rapamycin (mTOR) DM8GRJK MA Inhibitor DM8GRJK RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DM8GRJK RU https://pubmed.ncbi.nlm.nih.gov/26868298 DM8GUN9 DI DM8GUN9 DM8GUN9 DN 1-Benzyl-5-phenyl-1H-imidazole DM8GUN9 TI TTIQUX7 DM8GUN9 TN Steroid 11-beta-hydroxylase (CYP11B1) DM8GUN9 MA Inhibitor DM8GUN9 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DM8GUN9 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DM8GZAM DI DM8GZAM DM8GZAM DN NSC-75308 DM8GZAM TI TTSZLWK DM8GZAM TN Aromatase (CYP19A1) DM8GZAM MA Inhibitor DM8GZAM RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DM8GZAM RU https://pubmed.ncbi.nlm.nih.gov/19072235 DM8H0ND DI DM8H0ND DM8H0ND DN (S)-Methyl 4-(2-oxohexadecanamido)octanoate DM8H0ND TI TTT1JVS DM8H0ND TN Cytosolic phospholipase A2 (GIVA cPLA2) DM8H0ND MA Inhibitor DM8H0ND RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DM8H0ND RU https://pubmed.ncbi.nlm.nih.gov/18993078 DM8H6AT DI DM8H6AT DM8H6AT DN Salvinorin B tert-butoxymethyl ether DM8H6AT TI TTQW87Y DM8H6AT TN Opioid receptor kappa (OPRK1) DM8H6AT MA Inhibitor DM8H6AT RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DM8H6AT RU https://pubmed.ncbi.nlm.nih.gov/17981041 DM8HALS DI DM8HALS DM8HALS DN MCL-444 DM8HALS TI TT27RFC DM8HALS TN Opioid receptor delta (OPRD1) DM8HALS MA Inhibitor DM8HALS RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM8HALS RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM8HALS DI DM8HALS DM8HALS DN MCL-444 DM8HALS TI TTQW87Y DM8HALS TN Opioid receptor kappa (OPRK1) DM8HALS MA Inhibitor DM8HALS RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM8HALS RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM8HALS DI DM8HALS DM8HALS DN MCL-444 DM8HALS TI TTKWM86 DM8HALS TN Opioid receptor mu (MOP) DM8HALS MA Inhibitor DM8HALS RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM8HALS RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM8HDW6 DI DM8HDW6 DM8HDW6 DN ISIS 103771 DM8HDW6 TI TT6TU05 DM8HDW6 TN WWP2 messenger RNA (WWP2 mRNA) DM8HDW6 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM8HDW6 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM8HG0K DI DM8HG0K DM8HG0K DN Cyclotheonamide E DM8HG0K TI TT6L509 DM8HG0K TN Coagulation factor IIa (F2) DM8HG0K MA Inhibitor DM8HG0K RN Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61. DM8HG0K RU https://pubmed.ncbi.nlm.nih.gov/11908961 DM8HK0J DI DM8HK0J DM8HK0J DN C[homoPhe-Hca-Glu-Gly-Leu-Glu-Glu]-NH2 DM8HK0J TI TT1VAUK DM8HK0J TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM8HK0J MA Inhibitor DM8HK0J RN Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor. J Med Chem. 2007 Oct 18;50(21):5135-46. DM8HK0J RU https://pubmed.ncbi.nlm.nih.gov/17900101 DM8HLEP DI DM8HLEP DM8HLEP DN 4-(2-Butyl-benzoimidazol-1-ylmethyl)-phenol DM8HLEP TI TT8DBY3 DM8HLEP TN Angiotensin II receptor type-1 (AGTR1) DM8HLEP MA Inhibitor DM8HLEP RN Discovery and development of aryl-fused imidazole-based angiotensin II antagonists, Bioorg. Med. Chem. Lett. 4(1):213-218 (1994). DM8HLEP RU http://www.sciencedirect.com/science/article/pii/S0960894X01811495 DM8HRTC DI DM8HRTC DM8HRTC DN 13-(5-n-Pentylfuran-2-yl)tridec-8(Z)-enoic acid DM8HRTC TI TT7WVHI DM8HRTC TN Soluble epoxide hydrolase (EPHX2) DM8HRTC MA Inhibitor DM8HRTC RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM8HRTC RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM8HS0B DI DM8HS0B DM8HS0B DN N-Cyclohexyl-2-(4-methoxy-phenyl)-acetamide DM8HS0B TI TT7WVHI DM8HS0B TN Soluble epoxide hydrolase (EPHX2) DM8HS0B MA Inhibitor DM8HS0B RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DM8HS0B RU https://pubmed.ncbi.nlm.nih.gov/15887969 DM8HSBT DI DM8HSBT DM8HSBT DN 2-mercaptophenylphosphonic acid DM8HSBT TI TTHI19T DM8HSBT TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DM8HSBT MA Inhibitor DM8HSBT RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DM8HSBT RU https://pubmed.ncbi.nlm.nih.gov/20527888 DM8HSMU DI DM8HSMU DM8HSMU DN 2-phenyl-2H-indazole-7-carboxamide DM8HSMU TI TTVDSZ0 DM8HSMU TN Poly [ADP-ribose] polymerase 1 (PARP1) DM8HSMU MA Inhibitor DM8HSMU RN Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85. DM8HSMU RU https://pubmed.ncbi.nlm.nih.gov/19873981 DM8HWS9 DI DM8HWS9 DM8HWS9 DN P-Anisic Acid DM8HWS9 TI TT9V5JH DM8HWS9 TN Phospholipase A2 (PLA2G1B) DM8HWS9 MA Inhibitor DM8HWS9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8HWS9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8HXYS DI DM8HXYS DM8HXYS DN 4'-(Pyridin-4-ylmethyl)biphenyl-4-amine DM8HXYS TI TTIQUX7 DM8HXYS TN Steroid 11-beta-hydroxylase (CYP11B1) DM8HXYS MA Inhibitor DM8HXYS RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM8HXYS RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM8HXYS DI DM8HXYS DM8HXYS DN 4'-(Pyridin-4-ylmethyl)biphenyl-4-amine DM8HXYS TI TTRA5BZ DM8HXYS TN Steroid 17-alpha-monooxygenase (S17AH) DM8HXYS MA Inhibitor DM8HXYS RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DM8HXYS RU https://pubmed.ncbi.nlm.nih.gov/20684610 DM8I0CZ DI DM8I0CZ DM8I0CZ DN C[Glu22-Lys26][Gly8]GLP-1(7-37)-NH2 DM8I0CZ TI TTVIMDE DM8I0CZ TN Glucagon-like peptide 1 receptor (GLP1R) DM8I0CZ MA Inhibitor DM8I0CZ RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DM8I0CZ RU https://pubmed.ncbi.nlm.nih.gov/18412318 DM8I0TY DI DM8I0TY DM8I0TY DN M8-B DM8I0TY TI TTXDKTO DM8I0TY TN Long transient receptor potential channel 8 (TRPM8) DM8I0TY MA Blocker (channel blocker) DM8I0TY RN Pharmacological blockade of the cold receptor TRPM8 attenuates autonomic and behavioral cold defenses and decreases deep body temperature. J Neurosci. 2012 Feb 8;32(6):2086-99. DM8I0TY RU https://pubmed.ncbi.nlm.nih.gov/22323721 DM8I4B9 DI DM8I4B9 DM8I4B9 DN 4-(o-tolyloxy)-2-(trifluoromethyl)benzonitrile DM8I4B9 TI TTKPW01 DM8I4B9 TN Androgen receptor messenger RNA (AR mRNA) DM8I4B9 MA Inhibitor DM8I4B9 RN Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8. DM8I4B9 RU https://pubmed.ncbi.nlm.nih.gov/19286380 DM8I6MG DI DM8I6MG DM8I6MG DN (R/R)BEFLOXATONE DM8I6MG TI TTGP7BY DM8I6MG TN Monoamine oxidase type B (MAO-B) DM8I6MG MA Inhibitor DM8I6MG RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DM8I6MG RU https://pubmed.ncbi.nlm.nih.gov/11881986 DM8I6MG DI DM8I6MG DM8I6MG DN (R/R)BEFLOXATONE DM8I6MG TI TT3WG5C DM8I6MG TN Monoamine oxidase type A (MAO-A) DM8I6MG MA Inhibitor DM8I6MG RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DM8I6MG RU https://pubmed.ncbi.nlm.nih.gov/11881986 DM8I7N2 DI DM8I7N2 DM8I7N2 DN N-benzyl,N-methyl-1H-pyrrole-2-carboxamide DM8I7N2 TI TT3WG5C DM8I7N2 TN Monoamine oxidase type A (MAO-A) DM8I7N2 MA Inhibitor DM8I7N2 RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DM8I7N2 RU https://pubmed.ncbi.nlm.nih.gov/17256833 DM8IHQP DI DM8IHQP DM8IHQP DN N-methyl-3,3-diphenylpropan-1-amine DM8IHQP TI TTJQOD7 DM8IHQP TN 5-HT 2A receptor (HTR2A) DM8IHQP MA Inhibitor DM8IHQP RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DM8IHQP RU https://pubmed.ncbi.nlm.nih.gov/19700330 DM8IHQP DI DM8IHQP DM8IHQP DN N-methyl-3,3-diphenylpropan-1-amine DM8IHQP TI TTTIBOJ DM8IHQP TN Histamine H1 receptor (H1R) DM8IHQP MA Inhibitor DM8IHQP RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DM8IHQP RU https://pubmed.ncbi.nlm.nih.gov/19700330 DM8IQX4 DI DM8IQX4 DM8IQX4 DN 5'-deoxy-5'-ureidoadenosine DM8IQX4 TI TTE2KUJ DM8IQX4 TN Adenosylhomocysteinase (AHCY) DM8IQX4 MA Inhibitor DM8IQX4 RN Design, synthesis, and molecular modeling studies of 5'-deoxy-5'-ureidoadenosine: 5'-ureido group as multiple hydrogen bonding donor in the active ... Bioorg Med Chem Lett. 2007 Aug 15;17(16):4456-9. DM8IQX4 RU https://pubmed.ncbi.nlm.nih.gov/17582766 DM8ITFJ DI DM8ITFJ DM8ITFJ DN ISIS 173813 DM8ITFJ TI TT9RTBL DM8ITFJ TN Aurora B messenger RNA (AURKB mRNA) DM8ITFJ RN US patent application no. 7,375,212, Modulation of Aurora B expression. DM8ITFJ RU http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true DM8IWUE DI DM8IWUE DM8IWUE DN A-887755 DM8IWUE TI TTE4KHA DM8IWUE TN Amyloid beta A4 protein (APP) DM8IWUE MA Inhibitor DM8IWUE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DM8IWUE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DM8IY3D DI DM8IY3D DM8IY3D DN 7-O-b-D-Glucopyranosyl-a-homonojirimycin DM8IY3D TI TTLPC70 DM8IY3D TN Lysosomal alpha-glucosidase (GAA) DM8IY3D MA Inhibitor DM8IY3D RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DM8IY3D RU https://pubmed.ncbi.nlm.nih.gov/18595718 DM8IYG1 DI DM8IYG1 DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 TI TTUWGRA DM8IYG1 TN Protein kinase C zeta (PRKCZ) DM8IYG1 MA Inhibitor DM8IYG1 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8IYG1 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8IYG1 DI DM8IYG1 DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 TI TTFJ8Q1 DM8IYG1 TN Protein kinase C alpha (PRKCA) DM8IYG1 MA Inhibitor DM8IYG1 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8IYG1 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8IYG1 DI DM8IYG1 DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 TI TTYPXQF DM8IYG1 TN Protein kinase C beta (PRKCB) DM8IYG1 MA Inhibitor DM8IYG1 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8IYG1 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8IYG1 DI DM8IYG1 DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 TI TTRFOXJ DM8IYG1 TN Protein kinase C gamma (PRKCG) DM8IYG1 MA Inhibitor DM8IYG1 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8IYG1 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8IYG1 DI DM8IYG1 DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 TI TT8QL1J DM8IYG1 TN Protein kinase C theta (PRKCQ) DM8IYG1 MA Inhibitor DM8IYG1 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8IYG1 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8IYG1 DI DM8IYG1 DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 TI TTBZ7OD DM8IYG1 TN Protein kinase C epsilon (PRKCE) DM8IYG1 MA Inhibitor DM8IYG1 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8IYG1 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8IYG1 DI DM8IYG1 DM8IYG1 DN 4-[1-(4-hydroxyphenyl)-3-methyl-1-butenyl]phenol DM8IYG1 TI TT9WJ8U DM8IYG1 TN Protein kinase C delta (PRKCD) DM8IYG1 MA Inhibitor DM8IYG1 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DM8IYG1 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DM8J24A DI DM8J24A DM8J24A DN IBC 293 DM8J24A TI TT8WFXV DM8J24A TN Hydroxycarboxylic acid receptor 3 (HCAR3) DM8J24A MA Agonist DM8J24A RN 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b. J Med Chem. 2006 Feb 23;49(4):1227-30. DM8J24A RU https://pubmed.ncbi.nlm.nih.gov/16480258 DM8J24F DI DM8J24F DM8J24F DN ISIS 134564 DM8J24F TI TTKW4ML DM8J24F TN Caspase 6 messenger RNA (CASP6 mRNA) DM8J24F RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DM8J24F RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DM8J41W DI DM8J41W DM8J41W DN UCM 793 DM8J41W TI TT0WAIE DM8J41W TN Melatonin receptor type 1A (MTNR1A) DM8J41W MA Agonist DM8J41W RN N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007 Dec 27;50(26):6618-26. DM8J41W RU https://pubmed.ncbi.nlm.nih.gov/18052314 DM8JFNU DI DM8JFNU DM8JFNU DN 2,6-DICARBOXYNAPHTHALENE DM8JFNU TI TTQO71U DM8JFNU TN Hemoglobin (HB) DM8JFNU MA Inhibitor DM8JFNU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM8JFNU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM8JHWS DI DM8JHWS DM8JHWS DN (5E,8E,11E,14E)-Icosa-5,8,11,14-tetraenal DM8JHWS TI TTMI6F5 DM8JHWS TN Transient receptor potential cation channel V1 (TRPV1) DM8JHWS MA Inhibitor DM8JHWS RN The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J Med Chem. 2005 Jul 14;48(14):4663-9. DM8JHWS RU https://pubmed.ncbi.nlm.nih.gov/16000002 DM8JLR4 DI DM8JLR4 DM8JLR4 DN N-(6-(4-hydroxyphenyl)-1H-indazol-3-yl)butyramide DM8JLR4 TI TTRSMW9 DM8JLR4 TN Glycogen synthase kinase-3 beta (GSK-3B) DM8JLR4 MA Inhibitor DM8JLR4 RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DM8JLR4 RU https://pubmed.ncbi.nlm.nih.gov/20167481 DM8JM4Q DI DM8JM4Q DM8JM4Q DN 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol DM8JM4Q TI TTLD29N DM8JM4Q TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM8JM4Q MA Inhibitor DM8JM4Q RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DM8JM4Q RU https://pubmed.ncbi.nlm.nih.gov/10425109 DM8JM4Q DI DM8JM4Q DM8JM4Q DN 4-[2-(4-Phenyl-piperidin-1-yl)-ethoxy]-phenol DM8JM4Q TI TTN9D8E DM8JM4Q TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM8JM4Q MA Inhibitor DM8JM4Q RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DM8JM4Q RU https://pubmed.ncbi.nlm.nih.gov/10425109 DM8JMBI DI DM8JMBI DM8JMBI DN NSC-745796 DM8JMBI TI TTQY2EJ DM8JMBI TN TERT messenger RNA (TERT mRNA) DM8JMBI MA Inhibitor DM8JMBI RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DM8JMBI RU https://pubmed.ncbi.nlm.nih.gov/19804981 DM8JN45 DI DM8JN45 DM8JN45 DN ZK-112993 DM8JN45 TI TTUV8G9 DM8JN45 TN Progesterone receptor (PGR) DM8JN45 MA Modulator DM8JN45 RN Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.Anticancer Res.1990 May-Jun;10(3):683-7. DM8JN45 RU https://www.ncbi.nlm.nih.gov/pubmed/2369083 DM8JQEO DI DM8JQEO DM8JQEO DN N*1*-(5-Methyl-2-nitro-phenyl)-butane-1,4-diamine DM8JQEO TI TTZUFI5 DM8JQEO TN Nitric-oxide synthase brain (NOS1) DM8JQEO MA Inhibitor DM8JQEO RN Nitroaromatic amino acids as inhibitors of neuronal nitric oxide synthase. J Med Chem. 1998 Jul 2;41(14):2636-42. DM8JQEO RU https://pubmed.ncbi.nlm.nih.gov/9651169 DM8JQL4 DI DM8JQL4 DM8JQL4 DN PMID24412111C9g DM8JQL4 TI TTHYDUM DM8JQL4 TN Bombesin receptor (BS) DM8JQL4 MA Agonist DM8JQL4 RN Discovery of novel chiral diazepines as bombesin receptor subtype-3 (BRS-3) agonists with low brain penetration. Bioorg Med Chem Lett. 2014 Feb 1;24(3):750-5. DM8JQL4 RU https://pubmed.ncbi.nlm.nih.gov/24412111 DM8JUBG DI DM8JUBG DM8JUBG DN Org 12962 DM8JUBG TI TTWJBZ5 DM8JUBG TN 5-HT 2C receptor (HTR2C) DM8JUBG MA Agonist DM8JUBG RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM8JUBG RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM8JUBG DI DM8JUBG DM8JUBG DN Org 12962 DM8JUBG TI TTJQOD7 DM8JUBG TN 5-HT 2A receptor (HTR2A) DM8JUBG MA Agonist DM8JUBG RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM8JUBG RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM8JUBG DI DM8JUBG DM8JUBG DN Org 12962 DM8JUBG TI TT0K1SC DM8JUBG TN 5-HT 2B receptor (HTR2B) DM8JUBG MA Agonist DM8JUBG RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM8JUBG RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM8K4DP DI DM8K4DP DM8K4DP DN ISIS 25126 DM8K4DP TI TT8H9GB DM8K4DP TN MEK2 messenger RNA (MEK2 mRNA) DM8K4DP RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DM8K4DP RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DM8K6VF DI DM8K6VF DM8K6VF DN [3H]mesulergine DM8K6VF TI TTWJBZ5 DM8K6VF TN 5-HT 2C receptor (HTR2C) DM8K6VF MA Antagonist DM8K6VF RN High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34. DM8K6VF RU https://pubmed.ncbi.nlm.nih.gov/10217294 DM8K6VF DI DM8K6VF DM8K6VF DN [3H]mesulergine DM8K6VF TI TT0K1SC DM8K6VF TN 5-HT 2B receptor (HTR2B) DM8K6VF MA Antagonist DM8K6VF RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DM8K6VF RU https://pubmed.ncbi.nlm.nih.gov/15322733 DM8K7C4 DI DM8K7C4 DM8K7C4 DN PBMC DM8K7C4 TI TTXDKTO DM8K7C4 TN Long transient receptor potential channel 8 (TRPM8) DM8K7C4 MA Blocker (channel blocker) DM8K7C4 RN Pharmacological blockade of TRPM8 ion channels alters cold and cold pain responses in mice. PLoS One. 2011;6(9):e25894. DM8K7C4 RU https://pubmed.ncbi.nlm.nih.gov/21984952 DM8KFZH DI DM8KFZH DM8KFZH DN CGP61594 DM8KFZH TI TTLD29N DM8KFZH TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM8KFZH MA Antagonist DM8KFZH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DM8KFZH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DM8KFZH DI DM8KFZH DM8KFZH DN CGP61594 DM8KFZH TI TTKJEMQ DM8KFZH TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM8KFZH MA Antagonist DM8KFZH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DM8KFZH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DM8KFZH DI DM8KFZH DM8KFZH DN CGP61594 DM8KFZH TI TT5POTG DM8KFZH TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DM8KFZH MA Antagonist DM8KFZH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DM8KFZH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DM8KFZH DI DM8KFZH DM8KFZH DN CGP61594 DM8KFZH TI TT1M8OW DM8KFZH TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DM8KFZH MA Antagonist DM8KFZH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DM8KFZH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DM8KFZH DI DM8KFZH DM8KFZH DN CGP61594 DM8KFZH TI TTN9D8E DM8KFZH TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM8KFZH MA Antagonist DM8KFZH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DM8KFZH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DM8KM1Q DI DM8KM1Q DM8KM1Q DN 2-(3,5-dichlorophenyl)pyrido[2,3-d]pyrimidine DM8KM1Q TI TTHS256 DM8KM1Q TN Metabotropic glutamate receptor 5 (mGluR5) DM8KM1Q MA Inhibitor DM8KM1Q RN Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9. DM8KM1Q RU https://pubmed.ncbi.nlm.nih.gov/17723296 DM8KMEG DI DM8KMEG DM8KMEG DN 6-Methyl-2-p-tolyl-chromen-4-one DM8KMEG TI TTNJYV2 DM8KMEG TN Gamma-aminobutyric acid receptor (GAR) DM8KMEG MA Inhibitor DM8KMEG RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DM8KMEG RU https://pubmed.ncbi.nlm.nih.gov/12213060 DM8KN0Q DI DM8KN0Q DM8KN0Q DN ARGENINE VASOPRESSIN DM8KN0Q TI TTK8R02 DM8KN0Q TN Vasopressin V2 receptor (V2R) DM8KN0Q MA Inhibitor DM8KN0Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8KN0Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8KN0Q DI DM8KN0Q DM8KN0Q DN ARGENINE VASOPRESSIN DM8KN0Q TI TTL9MHW DM8KN0Q TN Vasopressin V1b receptor (V1BR) DM8KN0Q MA Inhibitor DM8KN0Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8KN0Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8KN0Q DI DM8KN0Q DM8KN0Q DN ARGENINE VASOPRESSIN DM8KN0Q TI TTSCIUP DM8KN0Q TN Oxytocin receptor (OTR) DM8KN0Q MA Inhibitor DM8KN0Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8KN0Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8KN0Q DI DM8KN0Q DM8KN0Q DN ARGENINE VASOPRESSIN DM8KN0Q TI TT4TFGN DM8KN0Q TN Vasopressin V1a receptor (V1AR) DM8KN0Q MA Inhibitor DM8KN0Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DM8KN0Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DM8KON3 DI DM8KON3 DM8KON3 DN 5-hydroxy-2-(4-aminophenyl)benzofuran DM8KON3 TI TTE4KHA DM8KON3 TN Amyloid beta A4 protein (APP) DM8KON3 MA Inhibitor DM8KON3 RN Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. DM8KON3 RU https://pubmed.ncbi.nlm.nih.gov/16640332 DM8KPWM DI DM8KPWM DM8KPWM DN MTSEA DM8KPWM TI TTELV3W DM8KPWM TN Transformation-sensitive protein p120 (TRPA1) DM8KPWM MA Activator DM8KPWM RN Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 1;445(7127):541-5. DM8KPWM RU https://pubmed.ncbi.nlm.nih.gov/17237762 DM8KYUE DI DM8KYUE DM8KYUE DN SULFOARECOLINE DM8KYUE TI TTZ9SOR DM8KYUE TN Muscarinic acetylcholine receptor M1 (CHRM1) DM8KYUE MA Inhibitor DM8KYUE RN Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6. DM8KYUE RU https://pubmed.ncbi.nlm.nih.gov/3385727 DM8KYUE DI DM8KYUE DM8KYUE DN SULFOARECOLINE DM8KYUE TI TTYEG6Q DM8KYUE TN Muscarinic acetylcholine receptor M2 (CHRM2) DM8KYUE MA Inhibitor DM8KYUE RN Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6. DM8KYUE RU https://pubmed.ncbi.nlm.nih.gov/3385727 DM8KYUE DI DM8KYUE DM8KYUE DN SULFOARECOLINE DM8KYUE TI TTQ13Z5 DM8KYUE TN Muscarinic acetylcholine receptor M3 (CHRM3) DM8KYUE MA Inhibitor DM8KYUE RN Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6. DM8KYUE RU https://pubmed.ncbi.nlm.nih.gov/3385727 DM8KYUE DI DM8KYUE DM8KYUE DN SULFOARECOLINE DM8KYUE TI TTQ3JTF DM8KYUE TN Muscarinic acetylcholine receptor M4 (CHRM4) DM8KYUE MA Inhibitor DM8KYUE RN Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6. DM8KYUE RU https://pubmed.ncbi.nlm.nih.gov/3385727 DM8KYUE DI DM8KYUE DM8KYUE DN SULFOARECOLINE DM8KYUE TI TTH18TF DM8KYUE TN Muscarinic acetylcholine receptor M5 (CHRM5) DM8KYUE MA Inhibitor DM8KYUE RN Heterocyclic muscarinic agonists. Synthesis and biological activity of some bicyclic sulfonium arecoline bioisosteres. J Med Chem. 1988 Jul;31(7):1312-6. DM8KYUE RU https://pubmed.ncbi.nlm.nih.gov/3385727 DM8KZQN DI DM8KZQN DM8KZQN DN 4-Imidazol-1-ylmethyl-3-nitroxanthen-9-one DM8KZQN TI TTSZLWK DM8KZQN TN Aromatase (CYP19A1) DM8KZQN MA Inhibitor DM8KZQN RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DM8KZQN RU https://pubmed.ncbi.nlm.nih.gov/20568782 DM8L09J DI DM8L09J DM8L09J DN Gly-b7Pro-Glu DM8L09J TI TTKJEMQ DM8L09J TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM8L09J MA Inhibitor DM8L09J RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM8L09J RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM8L09J DI DM8L09J DM8L09J DN Gly-b7Pro-Glu DM8L09J TI TTN9D8E DM8L09J TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM8L09J MA Inhibitor DM8L09J RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM8L09J RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM8L09J DI DM8L09J DM8L09J DN Gly-b7Pro-Glu DM8L09J TI TTLD29N DM8L09J TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM8L09J MA Inhibitor DM8L09J RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM8L09J RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM8L1Z2 DI DM8L1Z2 DM8L1Z2 DN GR55562 DM8L1Z2 TI TTK8CXU DM8L1Z2 TN 5-HT 1B receptor (HTR1B) DM8L1Z2 MA Antagonist DM8L1Z2 RN 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol. 1999 Oct;128(3):730-4. DM8L1Z2 RU https://pubmed.ncbi.nlm.nih.gov/10516655 DM8L6WB DI DM8L6WB DM8L6WB DN IC980033 DM8L6WB TI TTGBPJE DM8L6WB TN PI3-kinase delta (PIK3CD) DM8L6WB MA Inhibitor DM8L6WB RN Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9. DM8L6WB RU https://pubmed.ncbi.nlm.nih.gov/12927784 DM8L6ZF DI DM8L6ZF DM8L6ZF DN SZ(+)-(S)-202-791 DM8L6ZF TI TTZIFHC DM8L6ZF TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DM8L6ZF MA Activator DM8L6ZF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529). DM8L6ZF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529 DM8L6ZF DI DM8L6ZF DM8L6ZF DN SZ(+)-(S)-202-791 DM8L6ZF TI TT94HRF DM8L6ZF TN Voltage-gated calcium channel alpha Cav1.1 (CACNA1S) DM8L6ZF MA Activator DM8L6ZF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528). DM8L6ZF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528 DM8LEJ4 DI DM8LEJ4 DM8LEJ4 DN Erythribyssin O DM8LEJ4 TI TT50QJ3 DM8LEJ4 TN Influenza Neuraminidase (Influ NA) DM8LEJ4 MA Inhibitor DM8LEJ4 RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DM8LEJ4 RU https://pubmed.ncbi.nlm.nih.gov/20363636 DM8LI1K DI DM8LI1K DM8LI1K DN Tert-butyl (2S)-1-cyanopyrrolidine-2-carboxylate DM8LI1K TI TTDZN01 DM8LI1K TN Cathepsin K (CTSK) DM8LI1K MA Inhibitor DM8LI1K RN Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43. DM8LI1K RU https://pubmed.ncbi.nlm.nih.gov/15896958 DM8LJ3C DI DM8LJ3C DM8LJ3C DN trimethylamine DM8LJ3C TI TTCO25G DM8LJ3C TN Trace amine receptor 5 (TAAR5) DM8LJ3C MA Agonist DM8LJ3C RN A second class of chemosensory receptors in the olfactory epithelium. Nature. 2006 Aug 10;442(7103):645-50. DM8LJ3C RU https://pubmed.ncbi.nlm.nih.gov/16878137 DM8LKED DI DM8LKED DM8LKED DN ONO-3080573 DM8LKED TI TTQ6S1K DM8LKED TN Lysophosphatidic acid receptor 1 (LPAR1) DM8LKED MA Antagonist DM8LKED RN Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. Cell. 2015 Jun 18;161(7):1633-43. DM8LKED RU https://pubmed.ncbi.nlm.nih.gov/26091040 DM8LN2X DI DM8LN2X DM8LN2X DN 5-(2-methylquinolin-7-yl)nicotinonitrile DM8LN2X TI TTHS256 DM8LN2X TN Metabotropic glutamate receptor 5 (mGluR5) DM8LN2X MA Inhibitor DM8LN2X RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DM8LN2X RU https://pubmed.ncbi.nlm.nih.gov/17590335 DM8LNMY DI DM8LNMY DM8LNMY DN N-methyl-2-(pyridin-2-yl)ethanamine DM8LNMY TI TT9JNIC DM8LNMY TN Histamine H3 receptor (H3R) DM8LNMY MA Inhibitor DM8LNMY RN 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. J Med Chem. 2009 Jul 9;52(13):3855-68. DM8LNMY RU https://pubmed.ncbi.nlm.nih.gov/19456097 DM8LOCA DI DM8LOCA DM8LOCA DN NSC-660839 DM8LOCA TI TTJLP0R DM8LOCA TN Quinone reductase 2 (NQO2) DM8LOCA MA Inhibitor DM8LOCA RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DM8LOCA RU https://pubmed.ncbi.nlm.nih.gov/20356739 DM8LODU DI DM8LODU DM8LODU DN 4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine DM8LODU TI TTUTJGQ DM8LODU TN Vascular endothelial growth factor receptor 2 (KDR) DM8LODU MA Inhibitor DM8LODU RN Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81. DM8LODU RU https://pubmed.ncbi.nlm.nih.gov/16386418 DM8LODU DI DM8LODU DM8LODU DN 4-(isoquinolin-5-yl)-N-m-tolylphthalazin-1-amine DM8LODU TI TT1VAUK DM8LODU TN VEGFR1 messenger RNA (VEGFR1 mRNA) DM8LODU MA Inhibitor DM8LODU RN Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81. DM8LODU RU https://pubmed.ncbi.nlm.nih.gov/16386418 DM8LPBF DI DM8LPBF DM8LPBF DN E5700 DM8LPBF TI TTFQEO5 DM8LPBF TN Squalene synthetase (FDFT1) DM8LPBF MA Inhibitor DM8LPBF RN Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother. 2007 Jun;51(6):2123-9. DM8LPBF RU https://pubmed.ncbi.nlm.nih.gov/17371809 DM8LR62 DI DM8LR62 DM8LR62 DN N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine DM8LR62 TI TTK25J1 DM8LR62 TN Adenosine A1 receptor (ADORA1) DM8LR62 MA Inhibitor DM8LR62 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM8LR62 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM8LR62 DI DM8LR62 DM8LR62 DN N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine DM8LR62 TI TTM2AOE DM8LR62 TN Adenosine A2a receptor (ADORA2A) DM8LR62 MA Inhibitor DM8LR62 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM8LR62 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM8LR62 DI DM8LR62 DM8LR62 DN N6-methoxy-2-[(4-methoxyphenyl)ethynyl]adenosine DM8LR62 TI TTJFY5U DM8LR62 TN Adenosine A3 receptor (ADORA3) DM8LR62 MA Inhibitor DM8LR62 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM8LR62 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM8LS3I DI DM8LS3I DM8LS3I DN PMID30247903-Compound-General structure19 DM8LS3I TI TT23XQV DM8LS3I TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM8LS3I MA Inhibitor DM8LS3I RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM8LS3I RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM8LS6H DI DM8LS6H DM8LS6H DN 2-tosylbenzene-1,4-diol DM8LS6H TI TTRVTMX DM8LS6H TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DM8LS6H MA Inhibitor DM8LS6H RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DM8LS6H RU https://pubmed.ncbi.nlm.nih.gov/18996691 DM8LSQP DI DM8LSQP DM8LSQP DN LY344864 DM8LSQP TI TT0MI3F DM8LSQP TN 5-HT 1F receptor (HTR1F) DM8LSQP MA Agonist DM8LSQP RN 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J Pharmacol Exp Ther. 1999 Sep;290(3):935-9. DM8LSQP RU https://pubmed.ncbi.nlm.nih.gov/10454462 DM8LTQ4 DI DM8LTQ4 DM8LTQ4 DN MCL-443 DM8LTQ4 TI TTKWM86 DM8LTQ4 TN Opioid receptor mu (MOP) DM8LTQ4 MA Inhibitor DM8LTQ4 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM8LTQ4 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM8LTQ4 DI DM8LTQ4 DM8LTQ4 DN MCL-443 DM8LTQ4 TI TTQW87Y DM8LTQ4 TN Opioid receptor kappa (OPRK1) DM8LTQ4 MA Inhibitor DM8LTQ4 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM8LTQ4 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM8LTQ4 DI DM8LTQ4 DM8LTQ4 DN MCL-443 DM8LTQ4 TI TT27RFC DM8LTQ4 TN Opioid receptor delta (OPRD1) DM8LTQ4 MA Inhibitor DM8LTQ4 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DM8LTQ4 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DM8LUYM DI DM8LUYM DM8LUYM DN 9-Nitropaullone DM8LUYM TI TTL4Q97 DM8LUYM TN Cyclin-dependent kinase 5 (CDK5) DM8LUYM MA Inhibitor DM8LUYM RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DM8LUYM RU https://pubmed.ncbi.nlm.nih.gov/12237154 DM8LUYM DI DM8LUYM DM8LUYM DN 9-Nitropaullone DM8LUYM TI TTH6V3D DM8LUYM TN Cyclin-dependent kinase 1 (CDK1) DM8LUYM MA Inhibitor DM8LUYM RN Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76. DM8LUYM RU https://pubmed.ncbi.nlm.nih.gov/14988404 DM8LUYM DI DM8LUYM DM8LUYM DN 9-Nitropaullone DM8LUYM TI TT7HF4W DM8LUYM TN Cyclin-dependent kinase 2 (CDK2) DM8LUYM MA Inhibitor DM8LUYM RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DM8LUYM RU https://pubmed.ncbi.nlm.nih.gov/12237154 DM8LVQF DI DM8LVQF DM8LVQF DN L-Myo-Inositol-1-Phosphate DM8LVQF TI TTXWL6D DM8LVQF TN Inositol-1(or4)-monophosphatase (IMPA2) DM8LVQF MA Inhibitor DM8LVQF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8LVQF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8LWM3 DI DM8LWM3 DM8LWM3 DN Sulfamic acid 4-(2-methoxy-benzoyl)-phenyl ester DM8LWM3 TI TTHM0R1 DM8LWM3 TN Steryl-sulfatase (STS) DM8LWM3 MA Inhibitor DM8LWM3 RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DM8LWM3 RU https://pubmed.ncbi.nlm.nih.gov/12127511 DM8LYSB DI DM8LYSB DM8LYSB DN Triazine DM8LYSB TI TT3PQ2Y DM8LYSB TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM8LYSB MA Inhibitor DM8LYSB RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DM8LYSB RU https://pubmed.ncbi.nlm.nih.gov/10658902 DM8M0N9 DI DM8M0N9 DM8M0N9 DN 4'-(p-toluenesulfonamide)-3,4-dihydroxy chalcone DM8M0N9 TI TTXWASR DM8M0N9 TN Intestinal maltase-glucoamylase (MGAM) DM8M0N9 MA Inhibitor DM8M0N9 RN Sulfonamide chalcone as a new class of alpha-glucosidase inhibitors. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5514-6. DM8M0N9 RU https://pubmed.ncbi.nlm.nih.gov/16202584 DM8MBSN DI DM8MBSN DM8MBSN DN 8-Methoxy-4,9-dihydro-3H-beta-carboline DM8MBSN TI TTJQOD7 DM8MBSN TN 5-HT 2A receptor (HTR2A) DM8MBSN MA Inhibitor DM8MBSN RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DM8MBSN RU https://pubmed.ncbi.nlm.nih.gov/14643338 DM8MBSN DI DM8MBSN DM8MBSN DN 8-Methoxy-4,9-dihydro-3H-beta-carboline DM8MBSN TI TTGP7BY DM8MBSN TN Monoamine oxidase type B (MAO-B) DM8MBSN MA Inhibitor DM8MBSN RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM8MBSN RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM8MBSN DI DM8MBSN DM8MBSN DN 8-Methoxy-4,9-dihydro-3H-beta-carboline DM8MBSN TI TT3WG5C DM8MBSN TN Monoamine oxidase type A (MAO-A) DM8MBSN MA Inhibitor DM8MBSN RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DM8MBSN RU https://pubmed.ncbi.nlm.nih.gov/15013009 DM8MD52 DI DM8MD52 DM8MD52 DN HERBACETIN DM8MD52 TI TT50QJ3 DM8MD52 TN Influenza Neuraminidase (Influ NA) DM8MD52 MA Inhibitor DM8MD52 RN Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23. DM8MD52 RU https://pubmed.ncbi.nlm.nih.gov/19729316 DM8MNZG DI DM8MNZG DM8MNZG DN 1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol DM8MNZG TI TTWJBZ5 DM8MNZG TN 5-HT 2C receptor (HTR2C) DM8MNZG MA Inhibitor DM8MNZG RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM8MNZG RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM8MNZG DI DM8MNZG DM8MNZG DN 1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol DM8MNZG TI TT0K1SC DM8MNZG TN 5-HT 2B receptor (HTR2B) DM8MNZG MA Inhibitor DM8MNZG RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM8MNZG RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM8MNZG DI DM8MNZG DM8MNZG DN 1-((S)-2-aminopropyl)-7-methyl-1H-indazol-6-ol DM8MNZG TI TTJQOD7 DM8MNZG TN 5-HT 2A receptor (HTR2A) DM8MNZG MA Inhibitor DM8MNZG RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DM8MNZG RU https://pubmed.ncbi.nlm.nih.gov/16392816 DM8MVE9 DI DM8MVE9 DM8MVE9 DN 4-[4-(benzhydryloxy)benzoyl]benzoic acid DM8MVE9 TI TTTU72V DM8MVE9 TN Steroid 5-alpha-reductase 1 (SRD5A1) DM8MVE9 MA Inhibitor DM8MVE9 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DM8MVE9 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DM8MVE9 DI DM8MVE9 DM8MVE9 DN 4-[4-(benzhydryloxy)benzoyl]benzoic acid DM8MVE9 TI TTT02K8 DM8MVE9 TN Steroid 5-alpha-reductase 2 (SRD5A2) DM8MVE9 MA Inhibitor DM8MVE9 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DM8MVE9 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DM8MVU4 DI DM8MVU4 DM8MVU4 DN 4-benzyl-2-methylphthalazin-1(2H)-one DM8MVU4 TI TT34BHT DM8MVU4 TN Adrenergic receptor alpha-1D (ADRA1D) DM8MVU4 MA Inhibitor DM8MVU4 RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DM8MVU4 RU https://pubmed.ncbi.nlm.nih.gov/16513345 DM8MVU4 DI DM8MVU4 DM8MVU4 DN 4-benzyl-2-methylphthalazin-1(2H)-one DM8MVU4 TI TTNGILX DM8MVU4 TN Adrenergic receptor alpha-1A (ADRA1A) DM8MVU4 MA Inhibitor DM8MVU4 RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DM8MVU4 RU https://pubmed.ncbi.nlm.nih.gov/16513345 DM8MXS6 DI DM8MXS6 DM8MXS6 DN ZD-6021 DM8MXS6 TI TTZPO1L DM8MXS6 TN Substance-P receptor (TACR1) DM8MXS6 MA Modulator DM8MXS6 RN Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J Pharmacol Exp Ther. 2001 Jul;298(1):307-15. DM8MXS6 RU https://www.ncbi.nlm.nih.gov/pubmed/11408556 DM8MXS6 DI DM8MXS6 DM8MXS6 DN ZD-6021 DM8MXS6 TI TTYO0A3 DM8MXS6 TN Substance-K receptor (TACR2) DM8MXS6 MA Modulator DM8MXS6 RN Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J Pharmacol Exp Ther. 2001 Jul;298(1):307-15. DM8MXS6 RU https://www.ncbi.nlm.nih.gov/pubmed/11408556 DM8MZF4 DI DM8MZF4 DM8MZF4 DN P-tolylboronic acid DM8MZF4 TI TTANPDJ DM8MZF4 TN Carbonic anhydrase II (CA-II) DM8MZF4 MA Inhibitor DM8MZF4 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DM8MZF4 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DM8MZF4 DI DM8MZF4 DM8MZF4 DN P-tolylboronic acid DM8MZF4 TI TTUNARX DM8MZF4 TN Carbonic anhydrase (CA) DM8MZF4 MA Inhibitor DM8MZF4 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DM8MZF4 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DM8N314 DI DM8N314 DM8N314 DN 8-(3-Methyl-cyclopentyloxy)-quinolin-2-ylamine DM8N314 TI TTX4RTB DM8N314 TN Melanin-concentrating hormone receptor 1 (MCHR1) DM8N314 MA Inhibitor DM8N314 RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DM8N314 RU https://pubmed.ncbi.nlm.nih.gov/15341942 DM8N3RB DI DM8N3RB DM8N3RB DN PD-136621 DM8N3RB TI TTCG0AL DM8N3RB TN Cholecystokinin receptor type A (CCKAR) DM8N3RB MA Inhibitor DM8N3RB RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DM8N3RB RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DM8N3RB DI DM8N3RB DM8N3RB DN PD-136621 DM8N3RB TI TTVFO0U DM8N3RB TN Gastrin/cholecystokinin type B receptor (CCKBR) DM8N3RB MA Inhibitor DM8N3RB RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DM8N3RB RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DM8N54C DI DM8N54C DM8N54C DN 2-methyl-3-(pyridin-4-yl)-1H-indole DM8N54C TI TTTB4UP DM8N54C TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM8N54C MA Inhibitor DM8N54C RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DM8N54C RU https://pubmed.ncbi.nlm.nih.gov/16483769 DM8N79M DI DM8N79M DM8N79M DN (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine DM8N79M TI TT34BHT DM8N79M TN Adrenergic receptor alpha-1D (ADRA1D) DM8N79M MA Inhibitor DM8N79M RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM8N79M RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM8N79M DI DM8N79M DM8N79M DN (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine DM8N79M TI TT2NUT5 DM8N79M TN Adrenergic receptor alpha-2C (ADRA2C) DM8N79M MA Inhibitor DM8N79M RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM8N79M RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM8N79M DI DM8N79M DM8N79M DN (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine DM8N79M TI TTNGILX DM8N79M TN Adrenergic receptor alpha-1A (ADRA1A) DM8N79M MA Inhibitor DM8N79M RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM8N79M RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM8N79M DI DM8N79M DM8N79M DN (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine DM8N79M TI TTWG9A4 DM8N79M TN Adrenergic receptor alpha-2A (ADRA2A) DM8N79M MA Inhibitor DM8N79M RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM8N79M RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM8N79M DI DM8N79M DM8N79M DN (2-Bromo-phenyl)-(1H-imidazol-2-yl)-amine DM8N79M TI TTBRKXS DM8N79M TN Adrenergic receptor alpha-1B (ADRA1B) DM8N79M MA Inhibitor DM8N79M RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DM8N79M RU https://pubmed.ncbi.nlm.nih.gov/9016324 DM8N7BA DI DM8N7BA DM8N7BA DN BVT 933 DM8N7BA TI TTWJBZ5 DM8N7BA TN 5-HT 2C receptor (HTR2C) DM8N7BA MA Antagonist DM8N7BA RN Obesity: pathophysiology and clinical management. Curr Med Chem. 2009;16(4):506-21. DM8N7BA RU https://pubmed.ncbi.nlm.nih.gov/19199918 DM8NARQ DI DM8NARQ DM8NARQ DN 1,3-Dibenzyl-[1,3]diazetidine-2,4-dione DM8NARQ TI TTQAJF1 DM8NARQ TN Cathepsin G (CTSG) DM8NARQ MA Inhibitor DM8NARQ RN Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4. DM8NARQ RU https://pubmed.ncbi.nlm.nih.gov/11425539 DM8NARQ DI DM8NARQ DM8NARQ DN 1,3-Dibenzyl-[1,3]diazetidine-2,4-dione DM8NARQ TI TT2WR1T DM8NARQ TN Cationic trypsinogen (PRSS1) DM8NARQ MA Inhibitor DM8NARQ RN Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4. DM8NARQ RU https://pubmed.ncbi.nlm.nih.gov/11425539 DM8NETP DI DM8NETP DM8NETP DN ARH-1029 DM8NETP TI TTF1QVM DM8NETP TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DM8NETP MA Modulator DM8NETP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DM8NETP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DM8NGEQ DI DM8NGEQ DM8NGEQ DN PMID20167483C22e DM8NGEQ TI TTHYDUM DM8NGEQ TN Bombesin receptor (BS) DM8NGEQ MA Agonist DM8NGEQ RN Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1913-7. DM8NGEQ RU https://pubmed.ncbi.nlm.nih.gov/20167483 DM8NMAV DI DM8NMAV DM8NMAV DN 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine DM8NMAV TI TT90XZ8 DM8NMAV TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM8NMAV MA Inhibitor DM8NMAV RN Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem. 2008 Jun 15;16(12):6379-86. DM8NMAV RU https://pubmed.ncbi.nlm.nih.gov/18501613 DM8NMAV DI DM8NMAV DM8NMAV DN 1-[5-(4-Chlorophenyl)-2-furoyl]piperazine DM8NMAV TI TTZOVE0 DM8NMAV TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM8NMAV MA Inhibitor DM8NMAV RN Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain. Bioorg Med Chem. 2008 Jun 15;16(12):6379-86. DM8NMAV RU https://pubmed.ncbi.nlm.nih.gov/18501613 DM8NRJQ DI DM8NRJQ DM8NRJQ DN 3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine DM8NRJQ TI TTIQUX7 DM8NRJQ TN Steroid 11-beta-hydroxylase (CYP11B1) DM8NRJQ MA Inhibitor DM8NRJQ RN Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49. DM8NRJQ RU https://pubmed.ncbi.nlm.nih.gov/18763754 DM8NRJQ DI DM8NRJQ DM8NRJQ DN 3-[3-(4-Methoxybenzyl)naphthalen-2-yl]pyridine DM8NRJQ TI TTXV4FI DM8NRJQ TN Albendazole monooxygenase (CYP3A4) DM8NRJQ MA Inhibitor DM8NRJQ RN Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49. DM8NRJQ RU https://pubmed.ncbi.nlm.nih.gov/18763754 DM8NS7U DI DM8NS7U DM8NS7U DN MRL24 DM8NS7U TI TTZMAO3 DM8NS7U TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM8NS7U MA Agonist DM8NS7U RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DM8NS7U RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DM8NV2E DI DM8NV2E DM8NV2E DN PD-161182 DM8NV2E TI TTBPGLU DM8NV2E TN Neuromedin-K receptor (TACR3) DM8NV2E MA Inhibitor DM8NV2E RN The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists, Bioorg. Med. Chem. Lett. 5(16):1773-1778 (1995). DM8NV2E RU http://www.sciencedirect.com/science/article/pii/0960894X9500313I DM8NX3Q DI DM8NX3Q DM8NX3Q DN Cis-1-adamantan-1-yl-3-(4-methoxycyclohexyl)urea DM8NX3Q TI TT7WVHI DM8NX3Q TN Soluble epoxide hydrolase (EPHX2) DM8NX3Q MA Inhibitor DM8NX3Q RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DM8NX3Q RU https://pubmed.ncbi.nlm.nih.gov/17616115 DM8O41M DI DM8O41M DM8O41M DN Prop-2-ynyl 4-sulfamoylbenzoate DM8O41M TI TTSYM0R DM8O41M TN Carbonic anhydrase XII (CA-XII) DM8O41M MA Inhibitor DM8O41M RN Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92. DM8O41M RU https://pubmed.ncbi.nlm.nih.gov/17157501 DM8O41M DI DM8O41M DM8O41M DN Prop-2-ynyl 4-sulfamoylbenzoate DM8O41M TI TTANPDJ DM8O41M TN Carbonic anhydrase II (CA-II) DM8O41M MA Inhibitor DM8O41M RN A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48. DM8O41M RU https://pubmed.ncbi.nlm.nih.gov/17064072 DM8O41M DI DM8O41M DM8O41M DN Prop-2-ynyl 4-sulfamoylbenzoate DM8O41M TI TTEYTKG DM8O41M TN Carbonic anhydrase XIV (CA-XIV) DM8O41M MA Inhibitor DM8O41M RN Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92. DM8O41M RU https://pubmed.ncbi.nlm.nih.gov/17157501 DM8O41M DI DM8O41M DM8O41M DN Prop-2-ynyl 4-sulfamoylbenzoate DM8O41M TI TT2LVK8 DM8O41M TN Carbonic anhydrase IX (CA-IX) DM8O41M MA Inhibitor DM8O41M RN A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48. DM8O41M RU https://pubmed.ncbi.nlm.nih.gov/17064072 DM8O41M DI DM8O41M DM8O41M DN Prop-2-ynyl 4-sulfamoylbenzoate DM8O41M TI TTHQPL7 DM8O41M TN Carbonic anhydrase I (CA-I) DM8O41M MA Inhibitor DM8O41M RN A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48. DM8O41M RU https://pubmed.ncbi.nlm.nih.gov/17064072 DM8O6AC DI DM8O6AC DM8O6AC DN 2-Amino-6-(2-cyano-benzenesulfinyl)-benzonitrile DM8O6AC TI TT84ETX DM8O6AC TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM8O6AC MA Inhibitor DM8O6AC RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM8O6AC RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM8O7EM DI DM8O7EM DM8O7EM DN ISIS 19651 DM8O7EM TI TTWALCO DM8O7EM TN HER4 messenger RNA (ERBB4 mRNA) DM8O7EM RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DM8O7EM RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DM8OAN9 DI DM8OAN9 DM8OAN9 DN CGK733 DM8OAN9 TI TT8ZYBQ DM8OAN9 TN Serine/threonine-protein kinase ATR (FRP1) DM8OAN9 MA Inhibitor DM8OAN9 RN Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74. DM8OAN9 RU https://pubmed.ncbi.nlm.nih.gov/16767085 DM8OAN9 DI DM8OAN9 DM8OAN9 DN CGK733 DM8OAN9 TI TTKBM7V DM8OAN9 TN ATM serine/threonine kinase (ATM) DM8OAN9 MA Inhibitor DM8OAN9 RN Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol. 2006 Jul;2(7):369-74. DM8OAN9 RU https://pubmed.ncbi.nlm.nih.gov/16767085 DM8OC9F DI DM8OC9F DM8OC9F DN Pergularinine DM8OC9F TI TT9SL3Q DM8OC9F TN Polypeptide deformylase (PDF) DM8OC9F MA Inhibitor DM8OC9F RN Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol In Vitro. 2000 Feb;14(1):53-9. DM8OC9F RU https://pubmed.ncbi.nlm.nih.gov/10699361 DM8OC9F DI DM8OC9F DM8OC9F DN Pergularinine DM8OC9F TI TTS7IR5 DM8OC9F TN c-Jun messenger RNA (c-Jun mRNA) DM8OC9F MA Inhibitor DM8OC9F RN Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42. DM8OC9F RU https://pubmed.ncbi.nlm.nih.gov/17531481 DM8ODI7 DI DM8ODI7 DM8ODI7 DN WAY-214950 DM8ODI7 TI TTXA6PH DM8ODI7 TN Oxysterols receptor LXR-beta (NR1H2) DM8ODI7 MA Inhibitor DM8ODI7 RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DM8ODI7 RU https://pubmed.ncbi.nlm.nih.gov/18973288 DM8ODI7 DI DM8ODI7 DM8ODI7 DN WAY-214950 DM8ODI7 TI TT7LCTF DM8ODI7 TN Pregnane X receptor (NR1I2) DM8ODI7 MA Inhibitor DM8ODI7 RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DM8ODI7 RU https://pubmed.ncbi.nlm.nih.gov/18973288 DM8ODI7 DI DM8ODI7 DM8ODI7 DN WAY-214950 DM8ODI7 TI TTECBXN DM8ODI7 TN Oxysterols receptor LXR-alpha (NR1H3) DM8ODI7 MA Inhibitor DM8ODI7 RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DM8ODI7 RU https://pubmed.ncbi.nlm.nih.gov/18973288 DM8ODI7 DI DM8ODI7 DM8ODI7 DN WAY-214950 DM8ODI7 TI TTOZRK6 DM8ODI7 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM8ODI7 MA Inhibitor DM8ODI7 RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DM8ODI7 RU https://pubmed.ncbi.nlm.nih.gov/18973288 DM8ORQ4 DI DM8ORQ4 DM8ORQ4 DN N-(2-iodethyl)arachidonylamide DM8ORQ4 TI TTDP1UC DM8ORQ4 TN Fatty acid amide hydrolase (FAAH) DM8ORQ4 MA Inhibitor DM8ORQ4 RN Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg Med Chem. 2009 Jan 1;17(1):49-56. DM8ORQ4 RU https://pubmed.ncbi.nlm.nih.gov/19054678 DM8OTAG DI DM8OTAG DM8OTAG DN VUF-8504 DM8OTAG TI TTJFY5U DM8OTAG TN Adenosine A3 receptor (ADORA3) DM8OTAG MA Inhibitor DM8OTAG RN Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97. DM8OTAG RU https://pubmed.ncbi.nlm.nih.gov/16821770 DM8OUHV DI DM8OUHV DM8OUHV DN H-mCpa-ser-Gly-Phe-Leu-Thr-OH DM8OUHV TI TTKWM86 DM8OUHV TN Opioid receptor mu (MOP) DM8OUHV MA Inhibitor DM8OUHV RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM8OUHV RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM8OUHV DI DM8OUHV DM8OUHV DN H-mCpa-ser-Gly-Phe-Leu-Thr-OH DM8OUHV TI TT27RFC DM8OUHV TN Opioid receptor delta (OPRD1) DM8OUHV MA Inhibitor DM8OUHV RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DM8OUHV RU https://pubmed.ncbi.nlm.nih.gov/17350835 DM8P26J DI DM8P26J DM8P26J DN 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid DM8P26J TI TT79WV3 DM8P26J TN Prostaglandin E2 receptor EP4 (PTGER4) DM8P26J MA Inhibitor DM8P26J RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM8P26J RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM8P26J DI DM8P26J DM8P26J DN 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid DM8P26J TI TTPNGDE DM8P26J TN Prostaglandin E2 receptor EP3 (PTGER3) DM8P26J MA Inhibitor DM8P26J RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM8P26J RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM8P26J DI DM8P26J DM8P26J DN 3-(2-((E)-3-phenylprop-1-enyl)phenyl)acrylic acid DM8P26J TI TT1ZAVI DM8P26J TN Prostaglandin E2 receptor EP2 (PTGER2) DM8P26J MA Inhibitor DM8P26J RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM8P26J RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM8P526 DI DM8P526 DM8P526 DN Methotrexate gamma-hydroxamic acid DM8P526 TI TTLM12X DM8P526 TN Matrix metalloproteinase-2 (MMP-2) DM8P526 MA Inhibitor DM8P526 RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DM8P526 RU https://pubmed.ncbi.nlm.nih.gov/17127067 DM8P526 DI DM8P526 DM8P526 DN Methotrexate gamma-hydroxamic acid DM8P526 TI TT6X50U DM8P526 TN Matrix metalloproteinase-9 (MMP-9) DM8P526 MA Inhibitor DM8P526 RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DM8P526 RU https://pubmed.ncbi.nlm.nih.gov/17127067 DM8PA2V DI DM8PA2V DM8PA2V DN PMID21741839C5 DM8PA2V TI TTWHYC8 DM8PA2V TN Airway trypsin-like protease (TMPRSS11D) DM8PA2V MA Inhibitor DM8PA2V RN Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4860-4. DM8PA2V RU https://pubmed.ncbi.nlm.nih.gov/21741839 DM8PA2V DI DM8PA2V DM8PA2V DN PMID21741839C5 DM8PA2V TI TT1GM2Z DM8PA2V TN Transmembrane protease serine 2 (TMPRSS2) DM8PA2V MA Inhibitor DM8PA2V RN Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4860-4. DM8PA2V RU https://pubmed.ncbi.nlm.nih.gov/21741839 DM8PA3U DI DM8PA3U DM8PA3U DN BMS-694153 DM8PA3U TI TTVG215 DM8PA3U TN Debrisoquine 4-hydroxylase (CYP2D6) DM8PA3U MA Inhibitor DM8PA3U RN Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan... J Med Chem. 2008 Aug 28;51(16):4858-61. DM8PA3U RU https://pubmed.ncbi.nlm.nih.gov/18665579 DM8PA3U DI DM8PA3U DM8PA3U DN BMS-694153 DM8PA3U TI TTY6O0Q DM8PA3U TN Calcitonin gene-related peptide receptor (CGRPR) DM8PA3U MA Inhibitor DM8PA3U RN Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1H-indazol-5-yl)-1-oxo-1-(4-(piperidin-1-yl)piperidin-1-yl)propan... J Med Chem. 2008 Aug 28;51(16):4858-61. DM8PA3U RU https://pubmed.ncbi.nlm.nih.gov/18665579 DM8PADV DI DM8PADV DM8PADV DN XCC DM8PADV TI TTNE7KG DM8PADV TN Adenosine A2b receptor (ADORA2B) DM8PADV MA Antagonist DM8PADV RN [3H]MRS 1754, a selective antagonist radioligand for A(2B) adenosine receptors. Biochem Pharmacol. 2001 Mar 15;61(6):657-63. DM8PADV RU https://pubmed.ncbi.nlm.nih.gov/11266650 DM8PB90 DI DM8PB90 DM8PB90 DN N-(2-aminophenyl)benzamide DM8PB90 TI TTSHTOI DM8PB90 TN Histone deacetylase 2 (HDAC2) DM8PB90 MA Inhibitor DM8PB90 RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DM8PB90 RU https://pubmed.ncbi.nlm.nih.gov/20392638 DM8PBCA DI DM8PBCA DM8PBCA DN ISIS 32010 DM8PBCA TI TT9H4P3 DM8PBCA TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DM8PBCA RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DM8PBCA RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DM8PBEJ DI DM8PBEJ DM8PBEJ DN 4-Hydrazinocarbonyl-benzenesulfonamide DM8PBEJ TI TT2LVK8 DM8PBEJ TN Carbonic anhydrase IX (CA-IX) DM8PBEJ MA Inhibitor DM8PBEJ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DM8PBEJ RU https://pubmed.ncbi.nlm.nih.gov/15771455 DM8PBEJ DI DM8PBEJ DM8PBEJ DN 4-Hydrazinocarbonyl-benzenesulfonamide DM8PBEJ TI TTANPDJ DM8PBEJ TN Carbonic anhydrase II (CA-II) DM8PBEJ MA Inhibitor DM8PBEJ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DM8PBEJ RU https://pubmed.ncbi.nlm.nih.gov/15771455 DM8PBEJ DI DM8PBEJ DM8PBEJ DN 4-Hydrazinocarbonyl-benzenesulfonamide DM8PBEJ TI TTHQPL7 DM8PBEJ TN Carbonic anhydrase I (CA-I) DM8PBEJ MA Inhibitor DM8PBEJ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DM8PBEJ RU https://pubmed.ncbi.nlm.nih.gov/15771455 DM8PBKQ DI DM8PBKQ DM8PBKQ DN PMID8496919C7 DM8PBKQ TI TTFQEO5 DM8PBKQ TN Squalene synthetase (FDFT1) DM8PBKQ MA Inhibitor DM8PBKQ RN N-(arylalkyl)farnesylamines: new potent squalene synthetase inhibitors. J Med Chem. 1993 May 14;36(10):1501-4. DM8PBKQ RU https://pubmed.ncbi.nlm.nih.gov/8496919 DM8PJ92 DI DM8PJ92 DM8PJ92 DN H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid DM8PJ92 TI TT27RFC DM8PJ92 TN Opioid receptor delta (OPRD1) DM8PJ92 MA Inhibitor DM8PJ92 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DM8PJ92 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DM8PJ92 DI DM8PJ92 DM8PJ92 DN H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid DM8PJ92 TI TTKWM86 DM8PJ92 TN Opioid receptor mu (MOP) DM8PJ92 MA Inhibitor DM8PJ92 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DM8PJ92 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DM8PM0E DI DM8PM0E DM8PM0E DN 3-(butylsulfinyl)-1,1,1-trifluoropropan-2-one DM8PM0E TI TTMF541 DM8PM0E TN Liver carboxylesterase (CES1) DM8PM0E MA Inhibitor DM8PM0E RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM8PM0E RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM8PNKC DI DM8PNKC DM8PNKC DN N-(5-methylthiazol-2-yl)-2-phenylacetamide DM8PNKC TI TTSJ6Q4 DM8PNKC TN LOX-5 messenger RNA (ALOX5 mRNA) DM8PNKC MA Inhibitor DM8PNKC RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DM8PNKC RU https://pubmed.ncbi.nlm.nih.gov/17461565 DM8PTNR DI DM8PTNR DM8PTNR DN 4'-(trifluoromethyl)-4-biphenylyl sulfamate DM8PTNR TI TTBGTCW DM8PTNR TN Kinesin spindle messenger RNA (KIF11 mRNA) DM8PTNR MA Inhibitor DM8PTNR RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DM8PTNR RU https://pubmed.ncbi.nlm.nih.gov/17725339 DM8PX1T DI DM8PX1T DM8PX1T DN PT-109 DM8PX1T TI TT84ETX DM8PX1T TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM8PX1T MA Inhibitor DM8PX1T RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DM8PX1T RU https://pubmed.ncbi.nlm.nih.gov/8863804 DM8PYAN DI DM8PYAN DM8PYAN DN Ro-40-0655 DM8PYAN TI TTW38KT DM8PYAN TN Retinoic acid receptor alpha (RARA) DM8PYAN MA Agonist DM8PYAN RN Tamibarotene. Drugs Today (Barc). 2007 Aug;43(8):563-8. DM8PYAN RU https://pubmed.ncbi.nlm.nih.gov/17925887 DM8Q0D9 DI DM8Q0D9 DM8Q0D9 DN 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine DM8Q0D9 TI TTQBR95 DM8Q0D9 TN Stress-activated protein kinase 2a (p38 alpha) DM8Q0D9 MA Inhibitor DM8Q0D9 RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DM8Q0D9 RU https://pubmed.ncbi.nlm.nih.gov/15689155 DM8Q267 DI DM8Q267 DM8Q267 DN 7-phenethoxy-2H-chromen-2-one DM8Q267 TI TTUNARX DM8Q267 TN Carbonic anhydrase (CA) DM8Q267 MA Inhibitor DM8Q267 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM8Q267 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM8Q267 DI DM8Q267 DM8Q267 DN 7-phenethoxy-2H-chromen-2-one DM8Q267 TI TTSYM0R DM8Q267 TN Carbonic anhydrase XII (CA-XII) DM8Q267 MA Inhibitor DM8Q267 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM8Q267 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM8Q267 DI DM8Q267 DM8Q267 DN 7-phenethoxy-2H-chromen-2-one DM8Q267 TI TT2LVK8 DM8Q267 TN Carbonic anhydrase IX (CA-IX) DM8Q267 MA Inhibitor DM8Q267 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM8Q267 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM8Q267 DI DM8Q267 DM8Q267 DN 7-phenethoxy-2H-chromen-2-one DM8Q267 TI TTEYTKG DM8Q267 TN Carbonic anhydrase XIV (CA-XIV) DM8Q267 MA Inhibitor DM8Q267 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM8Q267 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM8Q54I DI DM8Q54I DM8Q54I DN PBIT DM8Q54I TI TTCLI75 DM8Q54I TN Lysine-specific demethylase 5B (KDM5B) DM8Q54I MA Inhibitor DM8Q54I RN Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17. DM8Q54I RU https://pubmed.ncbi.nlm.nih.gov/23408432 DM8Q54I DI DM8Q54I DM8Q54I DN PBIT DM8Q54I TI TT94UCF DM8Q54I TN Lysine-specific demethylase 5C (KDM5C) DM8Q54I MA Inhibitor DM8Q54I RN Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17. DM8Q54I RU https://pubmed.ncbi.nlm.nih.gov/23408432 DM8Q54I DI DM8Q54I DM8Q54I DN PBIT DM8Q54I TI TTIG67W DM8Q54I TN Lysine-specific demethylase 5A (KDM5A) DM8Q54I MA Inhibitor DM8Q54I RN Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J Biol Chem. 2013 Mar 29;288(13):9408-17. DM8Q54I RU https://pubmed.ncbi.nlm.nih.gov/23408432 DM8Q6I0 DI DM8Q6I0 DM8Q6I0 DN (-)-cubebininolide DM8Q6I0 TI TTXV4FI DM8Q6I0 TN Albendazole monooxygenase (CYP3A4) DM8Q6I0 MA Inhibitor DM8Q6I0 RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DM8Q6I0 RU https://pubmed.ncbi.nlm.nih.gov/15679319 DM8QIB2 DI DM8QIB2 DM8QIB2 DN Anti-CD22/CD19 mab-toxin conjugate DM8QIB2 TI TTW640A DM8QIB2 TN B-lymphocyte surface antigen B4 (CD19) DM8QIB2 MA Modulator DM8QIB2 RN Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8. DM8QIB2 RU https://pubmed.ncbi.nlm.nih.gov/10803517 DM8QIB2 DI DM8QIB2 DM8QIB2 DN Anti-CD22/CD19 mab-toxin conjugate DM8QIB2 TI TTM6QSK DM8QIB2 TN B-cell receptor CD22 (CD22) DM8QIB2 MA Modulator DM8QIB2 RN Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8. DM8QIB2 RU https://pubmed.ncbi.nlm.nih.gov/10803517 DM8QJUH DI DM8QJUH DM8QJUH DN 9-Hydroxypropyladenine, S-Isomer DM8QJUH TI TTP3QRF DM8QJUH TN Thymidine kinase 1 (TK1) DM8QJUH MA Inhibitor DM8QJUH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8QJUH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8QK2O DI DM8QK2O DM8QK2O DN 5-benzyl-1,3,4-oxadiazole-2(3H)-thione DM8QK2O TI TTULVH8 DM8QK2O TN Tyrosinase (TYR) DM8QK2O MA Inhibitor DM8QK2O RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DM8QK2O RU https://pubmed.ncbi.nlm.nih.gov/20452224 DM8QMJ1 DI DM8QMJ1 DM8QMJ1 DN PD-068235 DM8QMJ1 TI TTT2SVW DM8QMJ1 TN PPAR-gamma messenger RNA (PPARG mRNA) DM8QMJ1 MA Inhibitor DM8QMJ1 RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DM8QMJ1 RU https://pubmed.ncbi.nlm.nih.gov/18329752 DM8QPTJ DI DM8QPTJ DM8QPTJ DN 4-morpholino-6-phenyl-2H-pyran-2-one DM8QPTJ TI TTK3PY9 DM8QPTJ TN DNA-dependent protein kinase catalytic (PRKDC) DM8QPTJ MA Inhibitor DM8QPTJ RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM8QPTJ RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM8QTSU DI DM8QTSU DM8QTSU DN N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2 DM8QTSU TI TT27RFC DM8QTSU TN Opioid receptor delta (OPRD1) DM8QTSU MA Inhibitor DM8QTSU RN Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. DM8QTSU RU https://pubmed.ncbi.nlm.nih.gov/17188879 DM8QTSU DI DM8QTSU DM8QTSU DN N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2 DM8QTSU TI TTKWM86 DM8QTSU TN Opioid receptor mu (MOP) DM8QTSU MA Inhibitor DM8QTSU RN Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. DM8QTSU RU https://pubmed.ncbi.nlm.nih.gov/17188879 DM8R03D DI DM8R03D DM8R03D DN 3,4-diarylpyrazoline derivative DM8R03D TI TT6OEDT DM8R03D TN Cannabinoid receptor 1 (CB1) DM8R03D MA Inhibitor DM8R03D RN Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4794-8. DM8R03D RU https://pubmed.ncbi.nlm.nih.gov/16140010 DM8R03D DI DM8R03D DM8R03D DN 3,4-diarylpyrazoline derivative DM8R03D TI TTMSFAW DM8R03D TN Cannabinoid receptor 2 (CB2) DM8R03D MA Inhibitor DM8R03D RN Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4794-8. DM8R03D RU https://pubmed.ncbi.nlm.nih.gov/16140010 DM8R12J DI DM8R12J DM8R12J DN NSC-78017 DM8R12J TI TTJLP0R DM8R12J TN Quinone reductase 2 (NQO2) DM8R12J MA Inhibitor DM8R12J RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM8R12J RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM8R16V DI DM8R16V DM8R16V DN NVP ACQ090 DM8R16V TI TTJX3UE DM8R16V TN Somatostatin receptor type 3 (SSTR3) DM8R16V MA Antagonist DM8R16V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 357). DM8R16V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=357 DM8R5AS DI DM8R5AS DM8R5AS DN Allyl 4-(2-oxohexadecanamido)butanoate DM8R5AS TI TTT1JVS DM8R5AS TN Cytosolic phospholipase A2 (GIVA cPLA2) DM8R5AS MA Inhibitor DM8R5AS RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DM8R5AS RU https://pubmed.ncbi.nlm.nih.gov/18993078 DM8RJ0V DI DM8RJ0V DM8RJ0V DN SC-50676 DM8RJ0V TI TTN53ZF DM8RJ0V TN Leukotriene B4 receptor 1 (LTB4R) DM8RJ0V MA Inhibitor DM8RJ0V RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DM8RJ0V RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DM8RKT1 DI DM8RKT1 DM8RKT1 DN Cyclo(-D-Tyr-D-Ala-L-Arg-L-Nal-Gly-) DM8RKT1 TI TTBID49 DM8RKT1 TN C-X-C chemokine receptor type 4 (CXCR4) DM8RKT1 MA Inhibitor DM8RKT1 RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DM8RKT1 RU https://pubmed.ncbi.nlm.nih.gov/17228861 DM8RSDE DI DM8RSDE DM8RSDE DN TG-3030 DM8RSDE TI TTDCVZW DM8RSDE TN Gamma-aminobutyric acid B receptor (GABBR) DM8RSDE MA Agonist DM8RSDE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241). DM8RSDE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241 DM8RTBS DI DM8RTBS DM8RTBS DN 2'-Hydroxychalcone DM8RTBS TI TTVKILB DM8RTBS TN Prostaglandin G/H synthase 2 (COX-2) DM8RTBS MA Inhibitor DM8RTBS RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DM8RTBS RU https://pubmed.ncbi.nlm.nih.gov/19233646 DM8RV5X DI DM8RV5X DM8RV5X DN 2-methyl-7-phenyl-1,8-naphthyridine DM8RV5X TI TTHS256 DM8RV5X TN Metabotropic glutamate receptor 5 (mGluR5) DM8RV5X MA Inhibitor DM8RV5X RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DM8RV5X RU https://pubmed.ncbi.nlm.nih.gov/17936624 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TTRLW2X DM8RW92 TN Fibroblast growth factor receptor 1 (FGFR1) DM8RW92 MA Inhibitor DM8RW92 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TTI7421 DM8RW92 TN Platelet-derived growth factor receptor beta (PDGFRB) DM8RW92 MA Inhibitor DM8RW92 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TTGKNB4 DM8RW92 TN Epidermal growth factor receptor (EGFR) DM8RW92 MA Inhibitor DM8RW92 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TT6PKBN DM8RW92 TN Proto-oncogene c-Src (SRC) DM8RW92 MA Inhibitor DM8RW92 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TTQBR95 DM8RW92 TN Stress-activated protein kinase 2a (p38 alpha) DM8RW92 MA Inhibitor DM8RW92 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TT3PJMV DM8RW92 TN Tyrosine-protein kinase ABL1 (ABL) DM8RW92 MA Inhibitor DM8RW92 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TT860QF DM8RW92 TN LCK tyrosine protein kinase (LCK) DM8RW92 MA Inhibitor DM8RW92 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TTX41N9 DM8RW92 TN Tyrosine-protein kinase Kit (KIT) DM8RW92 MA Inhibitor DM8RW92 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DM8RW92 DI DM8RW92 DM8RW92 DN PD-0173956 DM8RW92 TI TT8FYO9 DM8RW92 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM8RW92 MA Inhibitor DM8RW92 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DM8RW92 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DM8RY7G DI DM8RY7G DM8RY7G DN 3-formyl-4-phenyl-1,2,5-oxadiazole 2-oxide DM8RY7G TI TTR7UJ3 DM8RY7G TN Cytoplasmic thioredoxin reductase (TXNRD1) DM8RY7G MA Inhibitor DM8RY7G RN Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schis... J Med Chem. 2009 Oct 22;52(20):6474-83. DM8RY7G RU https://pubmed.ncbi.nlm.nih.gov/19761212 DM8RZE0 DI DM8RZE0 DM8RZE0 DN ibotenate DM8RZE0 TI TTVBPDM DM8RZE0 TN Metabotropic glutamate receptor 1 (mGluR1) DM8RZE0 MA Agonist DM8RZE0 RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DM8RZE0 RU https://pubmed.ncbi.nlm.nih.gov/11080213 DM8RZE0 DI DM8RZE0 DM8RZE0 DN ibotenate DM8RZE0 TI TTHS256 DM8RZE0 TN Metabotropic glutamate receptor 5 (mGluR5) DM8RZE0 MA Agonist DM8RZE0 RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DM8RZE0 RU https://pubmed.ncbi.nlm.nih.gov/11080213 DM8S7AO DI DM8S7AO DM8S7AO DN LY339434 DM8S7AO TI TT0MYE2 DM8S7AO TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM8S7AO MA Agonist DM8S7AO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM8S7AO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM8SBR2 DI DM8SBR2 DM8SBR2 DN PMID25408830C3 DM8SBR2 TI TTRA6BO DM8SBR2 TN Bromodomain-containing protein 4 (BRD4) DM8SBR2 MA Inhibitor DM8SBR2 RN 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5. DM8SBR2 RU https://pubmed.ncbi.nlm.nih.gov/25408830 DM8SBR2 DI DM8SBR2 DM8SBR2 DN PMID25408830C3 DM8SBR2 TI TTT46BN DM8SBR2 TN Bromodomain and PHD finger containing 1 (BRPF1) DM8SBR2 MA Inhibitor DM8SBR2 RN 1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain. ACS Med Chem Lett. 2014 Sep 10;5(11):1190-5. DM8SBR2 RU https://pubmed.ncbi.nlm.nih.gov/25408830 DM8SEHO DI DM8SEHO DM8SEHO DN WL-276 DM8SEHO TI TTJGNVC DM8SEHO TN Apoptosis regulator Bcl-2 (BCL-2) DM8SEHO MA Modulator DM8SEHO RN WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth. Cancer Res. 2008 Jun 1;68(11):4377-83. DM8SEHO RU https://pubmed.ncbi.nlm.nih.gov/18519699 DM8SEJP DI DM8SEJP DM8SEJP DN 1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea DM8SEJP TI TT7WVHI DM8SEJP TN Soluble epoxide hydrolase (EPHX2) DM8SEJP MA Inhibitor DM8SEJP RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DM8SEJP RU https://pubmed.ncbi.nlm.nih.gov/19216074 DM8SGTQ DI DM8SGTQ DM8SGTQ DN RS 93520 DM8SGTQ TI TTNVEIR DM8SGTQ TN Prostaglandin D2 receptor (PTGDR) DM8SGTQ MA Agonist DM8SGTQ RN Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther. 2000 May;293(2):321-8. DM8SGTQ RU https://pubmed.ncbi.nlm.nih.gov/10772998 DM8SIRL DI DM8SIRL DM8SIRL DN KNI-10368 DM8SIRL TI TTXMNHO DM8SIRL TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM8SIRL MA Inhibitor DM8SIRL RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DM8SIRL RU https://pubmed.ncbi.nlm.nih.gov/17400453 DM8SP4X DI DM8SP4X DM8SP4X DN Arteminolide DM8SP4X TI TT7WZIJ DM8SP4X TN CAAX farnesyltransferase beta (FNTB) DM8SP4X MA Inhibitor DM8SP4X RN Modeling of binding modes and inhibition mechanism of some natural ligands of farnesyl transferase using molecular docking. J Med Chem. 2002 Mar 28;45(7):1460-5. DM8SP4X RU https://pubmed.ncbi.nlm.nih.gov/11906287 DM8SRM0 DI DM8SRM0 DM8SRM0 DN 8-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one DM8SRM0 TI TTK3PY9 DM8SRM0 TN DNA-dependent protein kinase catalytic (PRKDC) DM8SRM0 MA Inhibitor DM8SRM0 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DM8SRM0 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DM8STQA DI DM8STQA DM8STQA DN N-butylresorcinol DM8STQA TI TTULVH8 DM8STQA TN Tyrosinase (TYR) DM8STQA MA Inhibitor DM8STQA RN Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1532-3. DM8STQA RU https://pubmed.ncbi.nlm.nih.gov/19181523 DM8SU6N DI DM8SU6N DM8SU6N DN LY-2183240 DM8SU6N TI TTDP1UC DM8SU6N TN Fatty acid amide hydrolase (FAAH) DM8SU6N MA Inhibitor DM8SU6N RN Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43. DM8SU6N RU https://pubmed.ncbi.nlm.nih.gov/18983142 DM8SWVN DI DM8SWVN DM8SWVN DN V-165 DM8SWVN TI TT5FH9Y DM8SWVN TN Human immunodeficiency virus Integrase (HIV IN) DM8SWVN MA Inhibitor DM8SWVN RN New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol. 2002 Jul 23;12(14):1169-77. DM8SWVN RU https://pubmed.ncbi.nlm.nih.gov/12176326 DM8SXLR DI DM8SXLR DM8SXLR DN C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 DM8SXLR TI TTD0CIQ DM8SXLR TN Melanocortin receptor 4 (MC4R) DM8SXLR MA Inhibitor DM8SXLR RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM8SXLR RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM8SXLR DI DM8SXLR DM8SXLR DN C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 DM8SXLR TI TTEOSZT DM8SXLR TN Melanocortin receptor (MCR) DM8SXLR MA Inhibitor DM8SXLR RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM8SXLR RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM8SXLR DI DM8SXLR DM8SXLR DN C[Nle-Asp-D-Nal(2')-Arg-Trp-Glu]-NH2 DM8SXLR TI TTNI91K DM8SXLR TN Melanocortin receptor 3 (MC3R) DM8SXLR MA Inhibitor DM8SXLR RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DM8SXLR RU https://pubmed.ncbi.nlm.nih.gov/16539382 DM8T1Y4 DI DM8T1Y4 DM8T1Y4 DN Salvinicin A DM8T1Y4 TI TTQW87Y DM8T1Y4 TN Opioid receptor kappa (OPRK1) DM8T1Y4 MA Inhibitor DM8T1Y4 RN Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem. 2007 Jul 26;50(15):3596-603. DM8T1Y4 RU https://pubmed.ncbi.nlm.nih.gov/17580847 DM8T1Z4 DI DM8T1Z4 DM8T1Z4 DN ISIS 5875 DM8T1Z4 TI TTHCEF6 DM8T1Z4 TN VCAM-1 messenger RNA (VCAM1 mRNA) DM8T1Z4 RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DM8T1Z4 RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DM8T2OX DI DM8T2OX DM8T2OX DN 3-(butylthio)-1,1,1-trifluoropropan-2-one DM8T2OX TI TTMF541 DM8T2OX TN Liver carboxylesterase (CES1) DM8T2OX MA Inhibitor DM8T2OX RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DM8T2OX RU https://pubmed.ncbi.nlm.nih.gov/18023188 DM8T41N DI DM8T41N DM8T41N DN PMID7966163C6g DM8T41N TI TTFQEO5 DM8T41N TN Squalene synthetase (FDFT1) DM8T41N MA Inhibitor DM8T41N RN Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51. DM8T41N RU https://pubmed.ncbi.nlm.nih.gov/7966163 DM8T6VG DI DM8T6VG DM8T6VG DN PMID19831390C22m DM8T6VG TI TTASMD8 DM8T6VG TN LIM domain kinase-2 (LIMK-2) DM8T6VG MA Inhibitor DM8T6VG RN Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12;52(21):6515-8. DM8T6VG RU https://pubmed.ncbi.nlm.nih.gov/19831390 DM8T7CG DI DM8T7CG DM8T7CG DN tetronothiodin DM8T7CG TI TTVFO0U DM8T7CG TN Gastrin/cholecystokinin type B receptor (CCKBR) DM8T7CG MA Antagonist DM8T7CG RN Species specificity of pharmacological characteristics of CCK-B receptors. Neurosci Lett. 1993 Aug 6;158(1):1-4. DM8T7CG RU https://pubmed.ncbi.nlm.nih.gov/8233061 DM8TA0M DI DM8TA0M DM8TA0M DN N,N'-Di-acenaphthen-5-yl-guanidine DM8TA0M TI TT7RGTM DM8TA0M TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DM8TA0M MA Inhibitor DM8TA0M RN Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995). DM8TA0M RU http://www.sciencedirect.com/science/article/pii/0960894X95003927 DM8TBQ9 DI DM8TBQ9 DM8TBQ9 DN Dihexan-3-yl 5-(hydroxymethyl)isophthalate DM8TBQ9 TI TT7A1BO DM8TBQ9 TN PKC-delta messenger RNA (PRKCD mRNA) DM8TBQ9 MA Inhibitor DM8TBQ9 RN Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81. DM8TBQ9 RU https://pubmed.ncbi.nlm.nih.gov/19438240 DM8TBQ9 DI DM8TBQ9 DM8TBQ9 DN Dihexan-3-yl 5-(hydroxymethyl)isophthalate DM8TBQ9 TI TTFJ8Q1 DM8TBQ9 TN Protein kinase C alpha (PRKCA) DM8TBQ9 MA Inhibitor DM8TBQ9 RN Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81. DM8TBQ9 RU https://pubmed.ncbi.nlm.nih.gov/19438240 DM8TG41 DI DM8TG41 DM8TG41 DN Difluoromethionine DM8TG41 TI TTOJ46K DM8TG41 TN Streptococcus Methionyl-tRNA synthetase (Stre-coc metG) DM8TG41 MA Inhibitor DM8TG41 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8TG41 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8TH2N DI DM8TH2N DM8TH2N DN 3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole DM8TH2N TI TTQ6VDM DM8TH2N TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM8TH2N MA Inhibitor DM8TH2N RN 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14. DM8TH2N RU https://pubmed.ncbi.nlm.nih.gov/11334570 DM8TH2N DI DM8TH2N DM8TH2N DN 3-(1-Phenethyl-piperidin-4-yl)-2-phenyl-1H-indole DM8TH2N TI TTJQOD7 DM8TH2N TN 5-HT 2A receptor (HTR2A) DM8TH2N MA Inhibitor DM8TH2N RN 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3. DM8TH2N RU https://pubmed.ncbi.nlm.nih.gov/11133072 DM8TH4B DI DM8TH4B DM8TH4B DN Bbs-Arg-(D-Pip)-Gly-(SPH(pY)EKVS)-Gly-Hir DM8TH4B TI TT6L509 DM8TH4B TN Coagulation factor IIa (F2) DM8TH4B MA Inhibitor DM8TH4B RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DM8TH4B RU https://pubmed.ncbi.nlm.nih.gov/16202582 DM8THU2 DI DM8THU2 DM8THU2 DN Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 DM8THU2 TI TT27RFC DM8THU2 TN Opioid receptor delta (OPRD1) DM8THU2 MA Inhibitor DM8THU2 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM8THU2 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM8THU2 DI DM8THU2 DM8THU2 DN Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 DM8THU2 TI TTVFO0U DM8THU2 TN Gastrin/cholecystokinin type B receptor (CCKBR) DM8THU2 MA Inhibitor DM8THU2 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DM8THU2 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DM8TJW3 DI DM8TJW3 DM8TJW3 DN CFTRinh-172 DM8TJW3 TI TTRLZHP DM8TJW3 TN cAMP-dependent chloride channel (CFTR) DM8TJW3 MA Blocker (channel blocker) DM8TJW3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DM8TJW3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DM8TQIF DI DM8TQIF DM8TQIF DN JWH-402 DM8TQIF TI TT6OEDT DM8TQIF TN Cannabinoid receptor 1 (CB1) DM8TQIF MA Inhibitor DM8TQIF RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM8TQIF RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM8TQIF DI DM8TQIF DM8TQIF DN JWH-402 DM8TQIF TI TTMSFAW DM8TQIF TN Cannabinoid receptor 2 (CB2) DM8TQIF MA Inhibitor DM8TQIF RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DM8TQIF RU https://pubmed.ncbi.nlm.nih.gov/17919913 DM8TR1Y DI DM8TR1Y DM8TR1Y DN VU0364289 DM8TR1Y TI TTHS256 DM8TR1Y TN Metabotropic glutamate receptor 5 (mGluR5) DM8TR1Y MA Modulator (allosteric modulator) DM8TR1Y RN Discovery of N-Aryl Piperazines as Selective mGlu(5) Potentiators with Efficacy in a Rodent Model Predictive of Anti-Psychotic Activity. ACS Med Chem Lett. 2010 Nov 11;1(8):433-438. DM8TR1Y RU https://pubmed.ncbi.nlm.nih.gov/23308336 DM8TWLO DI DM8TWLO DM8TWLO DN 3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine DM8TWLO TI TTIQUX7 DM8TWLO TN Steroid 11-beta-hydroxylase (CYP11B1) DM8TWLO MA Inhibitor DM8TWLO RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM8TWLO RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM8TWLO DI DM8TWLO DM8TWLO DN 3-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine DM8TWLO TI TTSZLWK DM8TWLO TN Aromatase (CYP19A1) DM8TWLO MA Inhibitor DM8TWLO RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM8TWLO RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM8TWY7 DI DM8TWY7 DM8TWY7 DN 1,1,1-Trifluoro-nonadecan-2-one DM8TWY7 TI TTDP1UC DM8TWY7 TN Fatty acid amide hydrolase (FAAH) DM8TWY7 MA Inhibitor DM8TWY7 RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DM8TWY7 RU https://pubmed.ncbi.nlm.nih.gov/15771430 DM8U1IW DI DM8U1IW DM8U1IW DN AFM-21 DM8U1IW TI TTGKNB4 DM8U1IW TN Epidermal growth factor receptor (EGFR) DM8U1IW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM8U1IW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM8U2HP DI DM8U2HP DM8U2HP DN 1-(4-nonylbenzyl)pyrrolidin-3-ylphosphonic acid DM8U2HP TI TT9JZCK DM8U2HP TN Sphingosine-1-phosphate receptor 1 (S1PR1) DM8U2HP MA Inhibitor DM8U2HP RN A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5. DM8U2HP RU https://pubmed.ncbi.nlm.nih.gov/15615513 DM8U4HE DI DM8U4HE DM8U4HE DN IATX-FVIII DM8U4HE TI TT1290U DM8U4HE TN Coagulation factor VIII (F8) DM8U4HE MA Inhibitor DM8U4HE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DM8U4HE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DM8U70E DI DM8U70E DM8U70E DN N-Butyl-N'-(4-methyl-benzoyl)-guanidine DM8U70E TI TTZOVE0 DM8U70E TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DM8U70E MA Inhibitor DM8U70E RN Solution-phase, parallel synthesis and pharmacological evaluation of acylguanidine derivatives as potential sodium channel blockers. Bioorg Med Chem Lett. 2001 Dec 17;11(24):3151-5. DM8U70E RU https://pubmed.ncbi.nlm.nih.gov/11720863 DM8UATD DI DM8UATD DM8UATD DN Salvinorin B 2-methoxyethoxymethyl ether DM8UATD TI TTQW87Y DM8UATD TN Opioid receptor kappa (OPRK1) DM8UATD MA Inhibitor DM8UATD RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DM8UATD RU https://pubmed.ncbi.nlm.nih.gov/17981041 DM8UKH7 DI DM8UKH7 DM8UKH7 DN SB-265123 DM8UKH7 TI TTT1R2L DM8UKH7 TN Integrin alpha-V (ITGAV) DM8UKH7 MA Inhibitor DM8UKH7 RN 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41. DM8UKH7 RU https://pubmed.ncbi.nlm.nih.gov/15501072 DM8UKH7 DI DM8UKH7 DM8UKH7 DN SB-265123 DM8UKH7 TI TTBVIQC DM8UKH7 TN Integrin beta-1 (ITGB1) DM8UKH7 MA Inhibitor DM8UKH7 RN Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12. DM8UKH7 RU https://pubmed.ncbi.nlm.nih.gov/10406646 DM8UKH7 DI DM8UKH7 DM8UKH7 DN SB-265123 DM8UKH7 TI TTJA1ZO DM8UKH7 TN ITGB3 messenger RNA (ITGB3 mRNA) DM8UKH7 MA Inhibitor DM8UKH7 RN 1,2,3,4-Tetrahydroquinoline-containing alphaVbeta3 integrin antagonists with enhanced oral bioavailability. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5937-41. DM8UKH7 RU https://pubmed.ncbi.nlm.nih.gov/15501072 DM8UQD5 DI DM8UQD5 DM8UQD5 DN 2-Amino-6-(2-cyano-phenylsulfanyl)-benzonitrile DM8UQD5 TI TT84ETX DM8UQD5 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM8UQD5 MA Inhibitor DM8UQD5 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM8UQD5 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM8UVI3 DI DM8UVI3 DM8UVI3 DN Erythro-3,4-dichloromethylphenidate hydrochloride DM8UVI3 TI TTVBI8W DM8UVI3 TN Dopamine transporter (DAT) DM8UVI3 MA Inhibitor DM8UVI3 RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM8UVI3 RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM8UVI3 DI DM8UVI3 DM8UVI3 DN Erythro-3,4-dichloromethylphenidate hydrochloride DM8UVI3 TI TT3ROYC DM8UVI3 TN Serotonin transporter (SERT) DM8UVI3 MA Inhibitor DM8UVI3 RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DM8UVI3 RU https://pubmed.ncbi.nlm.nih.gov/17489581 DM8UWT9 DI DM8UWT9 DM8UWT9 DN (S)-1-(3-methoxyphenethyl)-2-methylpyrrolidine DM8UWT9 TI TT9JNIC DM8UWT9 TN Histamine H3 receptor (H3R) DM8UWT9 MA Inhibitor DM8UWT9 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DM8UWT9 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DM8V5IH DI DM8V5IH DM8V5IH DN 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine DM8V5IH TI TTAWNKZ DM8V5IH TN Norepinephrine transporter (NET) DM8V5IH MA Inhibitor DM8V5IH RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM8V5IH RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM8V5IH DI DM8V5IH DM8V5IH DN 1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine DM8V5IH TI TT3ROYC DM8V5IH TN Serotonin transporter (SERT) DM8V5IH MA Inhibitor DM8V5IH RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DM8V5IH RU https://pubmed.ncbi.nlm.nih.gov/16750359 DM8VI3T DI DM8VI3T DM8VI3T DN Euro-Celtique 3 DM8VI3T TI TTXHYV6 DM8VI3T TN Voltage-gated L-type calcium channel (L-CaC) DM8VI3T MA Blocker DM8VI3T RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DM8VI3T RU https://pubmed.ncbi.nlm.nih.gov/19442208 DM8VMQ4 DI DM8VMQ4 DM8VMQ4 DN ISIS 298744 DM8VMQ4 TI TTSN6QU DM8VMQ4 TN HIF1-alpha messenger RNA (HIF1A mRNA) DM8VMQ4 RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DM8VMQ4 RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DM8VNYA DI DM8VNYA DM8VNYA DN 1-[(n-but-1-ylamino)ethyl]-1,1-bisphosphonic acid DM8VNYA TI TTIKWV4 DM8VNYA TN Geranyltranstransferase (FDPS) DM8VNYA MA Inhibitor DM8VNYA RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DM8VNYA RU https://pubmed.ncbi.nlm.nih.gov/18096393 DM8VUX3 DI DM8VUX3 DM8VUX3 DN 15-deoxy-Delta(12, 14)-prostaglandin J(2) DM8VUX3 TI TTZMAO3 DM8VUX3 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DM8VUX3 MA Agonist DM8VUX3 RN Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602. DM8VUX3 RU https://pubmed.ncbi.nlm.nih.gov/12594814 DM8VW3Z DI DM8VW3Z DM8VW3Z DN Tyr-Pro-L-Phe-Pro-NH2 DM8VW3Z TI TT27RFC DM8VW3Z TN Opioid receptor delta (OPRD1) DM8VW3Z MA Inhibitor DM8VW3Z RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DM8VW3Z RU https://pubmed.ncbi.nlm.nih.gov/8384662 DM8VW3Z DI DM8VW3Z DM8VW3Z DN Tyr-Pro-L-Phe-Pro-NH2 DM8VW3Z TI TTKWM86 DM8VW3Z TN Opioid receptor mu (MOP) DM8VW3Z MA Inhibitor DM8VW3Z RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DM8VW3Z RU https://pubmed.ncbi.nlm.nih.gov/8384662 DM8VWQ2 DI DM8VWQ2 DM8VWQ2 DN 2,7-Bis(4-chlorobutyramido)anthraquinone DM8VWQ2 TI TTQY2EJ DM8VWQ2 TN TERT messenger RNA (TERT mRNA) DM8VWQ2 MA Inhibitor DM8VWQ2 RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM8VWQ2 RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM8VZIY DI DM8VZIY DM8VZIY DN 9-Allyl-8-bromo-9H-adenine DM8VZIY TI TTM2AOE DM8VZIY TN Adenosine A2a receptor (ADORA2A) DM8VZIY MA Inhibitor DM8VZIY RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM8VZIY RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM8VZIY DI DM8VZIY DM8VZIY DN 9-Allyl-8-bromo-9H-adenine DM8VZIY TI TTNE7KG DM8VZIY TN Adenosine A2b receptor (ADORA2B) DM8VZIY MA Inhibitor DM8VZIY RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM8VZIY RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM8VZIY DI DM8VZIY DM8VZIY DN 9-Allyl-8-bromo-9H-adenine DM8VZIY TI TTK25J1 DM8VZIY TN Adenosine A1 receptor (ADORA1) DM8VZIY MA Inhibitor DM8VZIY RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DM8VZIY RU https://pubmed.ncbi.nlm.nih.gov/19282184 DM8W0J3 DI DM8W0J3 DM8W0J3 DN NSC-745884 DM8W0J3 TI TTQY2EJ DM8W0J3 TN TERT messenger RNA (TERT mRNA) DM8W0J3 MA Inhibitor DM8W0J3 RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DM8W0J3 RU https://pubmed.ncbi.nlm.nih.gov/19804981 DM8W3GC DI DM8W3GC DM8W3GC DN 3-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acrylamide DM8W3GC TI TT2J34L DM8W3GC TN Arachidonate 5-lipoxygenase (5-LOX) DM8W3GC MA Inhibitor DM8W3GC RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DM8W3GC RU https://pubmed.ncbi.nlm.nih.gov/2308149 DM8W9EO DI DM8W9EO DM8W9EO DN 3-(3,4-Dimethyl-phenyl)-1-propyl-piperidine DM8W9EO TI TTEX248 DM8W9EO TN Dopamine D2 receptor (D2R) DM8W9EO MA Inhibitor DM8W9EO RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DM8W9EO RU https://pubmed.ncbi.nlm.nih.gov/9836610 DM8WAOR DI DM8WAOR DM8WAOR DN 4-Ethoxy-3-pyridinesulfonamide DM8WAOR TI TTHQPL7 DM8WAOR TN Carbonic anhydrase I (CA-I) DM8WAOR MA Inhibitor DM8WAOR RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM8WAOR RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM8WAOR DI DM8WAOR DM8WAOR DN 4-Ethoxy-3-pyridinesulfonamide DM8WAOR TI TT2LVK8 DM8WAOR TN Carbonic anhydrase IX (CA-IX) DM8WAOR MA Inhibitor DM8WAOR RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM8WAOR RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM8WAOR DI DM8WAOR DM8WAOR DN 4-Ethoxy-3-pyridinesulfonamide DM8WAOR TI TTEYTKG DM8WAOR TN Carbonic anhydrase XIV (CA-XIV) DM8WAOR MA Inhibitor DM8WAOR RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM8WAOR RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM8WAOR DI DM8WAOR DM8WAOR DN 4-Ethoxy-3-pyridinesulfonamide DM8WAOR TI TTANPDJ DM8WAOR TN Carbonic anhydrase II (CA-II) DM8WAOR MA Inhibitor DM8WAOR RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM8WAOR RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM8WAOR DI DM8WAOR DM8WAOR DN 4-Ethoxy-3-pyridinesulfonamide DM8WAOR TI TTSYM0R DM8WAOR TN Carbonic anhydrase XII (CA-XII) DM8WAOR MA Inhibitor DM8WAOR RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DM8WAOR RU https://pubmed.ncbi.nlm.nih.gov/20202722 DM8WB96 DI DM8WB96 DM8WB96 DN 5-Benzyloxy-benzo[b]thiophene-2-carboxamidine DM8WB96 TI TTFEZ5Q DM8WB96 TN Coagulation factor IX (F9) DM8WB96 MA Inhibitor DM8WB96 RN Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72. DM8WB96 RU https://pubmed.ncbi.nlm.nih.gov/20121198 DM8WC4A DI DM8WC4A DM8WC4A DN ISIS 19658 DM8WC4A TI TTWALCO DM8WC4A TN HER4 messenger RNA (ERBB4 mRNA) DM8WC4A RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DM8WC4A RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DM8WCJK DI DM8WCJK DM8WCJK DN 4-((2S,3R)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole DM8WCJK TI TT9JNIC DM8WCJK TN Histamine H3 receptor (H3R) DM8WCJK MA Inhibitor DM8WCJK RN A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9. DM8WCJK RU https://pubmed.ncbi.nlm.nih.gov/7752184 DM8WCUY DI DM8WCUY DM8WCUY DN L-731120 DM8WCUY TI TTFQEO5 DM8WCUY TN Squalene synthetase (FDFT1) DM8WCUY MA Inhibitor DM8WCUY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645). DM8WCUY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645 DM8WJQ0 DI DM8WJQ0 DM8WJQ0 DN PNT-300 DM8WJQ0 TI TTM8FR7 DM8WJQ0 TN KRAS messenger RNA (KRAS mRNA) DM8WJQ0 MA Inhibitor DM8WJQ0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2824). DM8WJQ0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2824 DM8WL21 DI DM8WL21 DM8WL21 DN 3-(6-(phenylamino)-9H-purin-8-yl)benzonitrile DM8WL21 TI TTRSMW9 DM8WL21 TN Glycogen synthase kinase-3 beta (GSK-3B) DM8WL21 MA Inhibitor DM8WL21 RN Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93. DM8WL21 RU https://pubmed.ncbi.nlm.nih.gov/20472330 DM8WPD2 DI DM8WPD2 DM8WPD2 DN N,N-dimethylhistamine DM8WPD2 TI TTXJ178 DM8WPD2 TN Histamine H4 receptor (H4R) DM8WPD2 MA Agonist DM8WPD2 RN Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54. DM8WPD2 RU https://pubmed.ncbi.nlm.nih.gov/16432504 DM8WRAU DI DM8WRAU DM8WRAU DN ZP-2307 DM8WRAU TI TTEPJL5 DM8WRAU TN Parathyroid hormone receptor (PTH2R) DM8WRAU MA Modulator DM8WRAU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 332). DM8WRAU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=332 DM8WYEM DI DM8WYEM DM8WYEM DN Thioureido sulfonamide DM8WYEM TI TTHQPL7 DM8WYEM TN Carbonic anhydrase I (CA-I) DM8WYEM MA Inhibitor DM8WYEM RN Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowe... Bioorg Med Chem Lett. 2005 Sep 1;15(17):3821-7. DM8WYEM RU https://pubmed.ncbi.nlm.nih.gov/16039853 DM8WYEM DI DM8WYEM DM8WYEM DN Thioureido sulfonamide DM8WYEM TI TTSYM0R DM8WYEM TN Carbonic anhydrase XII (CA-XII) DM8WYEM MA Inhibitor DM8WYEM RN Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowe... Bioorg Med Chem Lett. 2005 Sep 1;15(17):3821-7. DM8WYEM RU https://pubmed.ncbi.nlm.nih.gov/16039853 DM8WYEM DI DM8WYEM DM8WYEM DN Thioureido sulfonamide DM8WYEM TI TTANPDJ DM8WYEM TN Carbonic anhydrase II (CA-II) DM8WYEM MA Inhibitor DM8WYEM RN Carbonic anhydrase inhibitors: design of thioureido sulfonamides with potent isozyme II and XII inhibitory properties and intraocular pressure lowe... Bioorg Med Chem Lett. 2005 Sep 1;15(17):3821-7. DM8WYEM RU https://pubmed.ncbi.nlm.nih.gov/16039853 DM8XAWU DI DM8XAWU DM8XAWU DN 12,13-DEHYDROMANZAMINE A DM8XAWU TI TTRSMW9 DM8XAWU TN Glycogen synthase kinase-3 beta (GSK-3B) DM8XAWU MA Inhibitor DM8XAWU RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DM8XAWU RU https://pubmed.ncbi.nlm.nih.gov/17708655 DM8XBR1 DI DM8XBR1 DM8XBR1 DN Ac-SFWKYS-NH2 DM8XBR1 TI TTW5UDX DM8XBR1 TN Urotensin II receptor (UTS2R) DM8XBR1 MA Inhibitor DM8XBR1 RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DM8XBR1 RU https://pubmed.ncbi.nlm.nih.gov/20043680 DM8XGD0 DI DM8XGD0 DM8XGD0 DN 1,2-bis(3-fluorophenyl)-2-hydroxyethanon DM8XGD0 TI TTMF541 DM8XGD0 TN Liver carboxylesterase (CES1) DM8XGD0 MA Inhibitor DM8XGD0 RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM8XGD0 RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM8XOJC DI DM8XOJC DM8XOJC DN 4-hydroxy-N-neopentyl-N-phenylbenzenesulfonamide DM8XOJC TI TTZAYWL DM8XOJC TN Estrogen receptor (ESR) DM8XOJC MA Inhibitor DM8XOJC RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DM8XOJC RU https://pubmed.ncbi.nlm.nih.gov/16300947 DM8XR4Y DI DM8XR4Y DM8XR4Y DN Gly-Hyp-Glu DM8XR4Y TI TTN9D8E DM8XR4Y TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM8XR4Y MA Inhibitor DM8XR4Y RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM8XR4Y RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM8XR4Y DI DM8XR4Y DM8XR4Y DN Gly-Hyp-Glu DM8XR4Y TI TTKJEMQ DM8XR4Y TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM8XR4Y MA Inhibitor DM8XR4Y RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM8XR4Y RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM8XR4Y DI DM8XR4Y DM8XR4Y DN Gly-Hyp-Glu DM8XR4Y TI TTLD29N DM8XR4Y TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DM8XR4Y MA Inhibitor DM8XR4Y RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DM8XR4Y RU https://pubmed.ncbi.nlm.nih.gov/16321525 DM8XRCT DI DM8XRCT DM8XRCT DN 10R-hydroxylobel-7-ene DM8XRCT TI TTVBI8W DM8XRCT TN Dopamine transporter (DAT) DM8XRCT MA Inhibitor DM8XRCT RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DM8XRCT RU https://pubmed.ncbi.nlm.nih.gov/16905316 DM8XRCT DI DM8XRCT DM8XRCT DN 10R-hydroxylobel-7-ene DM8XRCT TI TT3ROYC DM8XRCT TN Serotonin transporter (SERT) DM8XRCT MA Inhibitor DM8XRCT RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DM8XRCT RU https://pubmed.ncbi.nlm.nih.gov/16905316 DM8XSE3 DI DM8XSE3 DM8XSE3 DN 2-valproylamido-5-sulfonamidoindane DM8XSE3 TI TTANPDJ DM8XSE3 TN Carbonic anhydrase II (CA-II) DM8XSE3 MA Inhibitor DM8XSE3 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM8XSE3 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM8XSE3 DI DM8XSE3 DM8XSE3 DN 2-valproylamido-5-sulfonamidoindane DM8XSE3 TI TT2LVK8 DM8XSE3 TN Carbonic anhydrase IX (CA-IX) DM8XSE3 MA Inhibitor DM8XSE3 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM8XSE3 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM8XSE3 DI DM8XSE3 DM8XSE3 DN 2-valproylamido-5-sulfonamidoindane DM8XSE3 TI TTHQPL7 DM8XSE3 TN Carbonic anhydrase I (CA-I) DM8XSE3 MA Inhibitor DM8XSE3 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM8XSE3 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM8XT1Y DI DM8XT1Y DM8XT1Y DN ASOBAMAST DM8XT1Y TI TTMPGNS DM8XT1Y TN Leukotriene biosynthesis (LT synth) DM8XT1Y MA Modulator DM8XT1Y RN Regulation of leukotriene biosynthesis. Cancer Metastasis Rev. 1994 Dec;13(3-4):257-67. DM8XT1Y RU https://pubmed.ncbi.nlm.nih.gov/7712588 DM8XVAW DI DM8XVAW DM8XVAW DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-MeNal-Gly-) DM8XVAW TI TTBID49 DM8XVAW TN C-X-C chemokine receptor type 4 (CXCR4) DM8XVAW MA Inhibitor DM8XVAW RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DM8XVAW RU https://pubmed.ncbi.nlm.nih.gov/17228861 DM8Y1S7 DI DM8Y1S7 DM8Y1S7 DN SOPHOFLAVESCENOL DM8Y1S7 TI TTZ97H5 DM8Y1S7 TN Phosphodiesterase 4A (PDE4A) DM8Y1S7 MA Inhibitor DM8Y1S7 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DM8Y1S7 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DM8Y1S7 DI DM8Y1S7 DM8Y1S7 DN SOPHOFLAVESCENOL DM8Y1S7 TI TTJ0IQB DM8Y1S7 TN Phosphodiesterase 5A (PDE5A) DM8Y1S7 MA Inhibitor DM8Y1S7 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DM8Y1S7 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DM8Y1S7 DI DM8Y1S7 DM8Y1S7 DN SOPHOFLAVESCENOL DM8Y1S7 TI TT06AWU DM8Y1S7 TN Phosphodiesterase 3A (PDE3A) DM8Y1S7 MA Inhibitor DM8Y1S7 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DM8Y1S7 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DM8Y1S7 DI DM8Y1S7 DM8Y1S7 DN SOPHOFLAVESCENOL DM8Y1S7 TI TTVIAT9 DM8Y1S7 TN Phosphodiesterase 4B (PDE4B) DM8Y1S7 MA Inhibitor DM8Y1S7 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DM8Y1S7 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DM8Y4G5 DI DM8Y4G5 DM8Y4G5 DN 5-Ethyl-oxazolidin-(2Z)-ylideneamine DM8Y4G5 TI TTZUFI5 DM8Y4G5 TN Nitric-oxide synthase brain (NOS1) DM8Y4G5 MA Inhibitor DM8Y4G5 RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM8Y4G5 RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM8Y4G5 DI DM8Y4G5 DM8Y4G5 DN 5-Ethyl-oxazolidin-(2Z)-ylideneamine DM8Y4G5 TI TTF10I9 DM8Y4G5 TN Nitric-oxide synthase inducible (NOS2) DM8Y4G5 MA Inhibitor DM8Y4G5 RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DM8Y4G5 RU https://pubmed.ncbi.nlm.nih.gov/14698148 DM8YF3V DI DM8YF3V DM8YF3V DN [R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether DM8YF3V TI TTEX248 DM8YF3V TN Dopamine D2 receptor (D2R) DM8YF3V MA Inhibitor DM8YF3V RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DM8YF3V RU https://pubmed.ncbi.nlm.nih.gov/18313931 DM8YF3V DI DM8YF3V DM8YF3V DN [R-(-)-Apomorphine-2-yl]-(2'-hydroxy-ethyl)ether DM8YF3V TI TTZFYLI DM8YF3V TN Dopamine D1 receptor (D1R) DM8YF3V MA Inhibitor DM8YF3V RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DM8YF3V RU https://pubmed.ncbi.nlm.nih.gov/18313931 DM8YGOI DI DM8YGOI DM8YGOI DN Quinolinic Acid DM8YGOI TI TTH29K0 DM8YGOI TN Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC) DM8YGOI MA Inhibitor DM8YGOI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8YGOI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8YN42 DI DM8YN42 DM8YN42 DN TUG-469 DM8YN42 TI TTB8FUC DM8YN42 TN Free fatty acid receptor 1 (GPR40) DM8YN42 MA Agonist DM8YN42 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 225). DM8YN42 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=225 DM8YPH0 DI DM8YPH0 DM8YPH0 DN 1-Phenyl-1H-benzoimidazole DM8YPH0 TI TT8FYO9 DM8YPH0 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM8YPH0 MA Inhibitor DM8YPH0 RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DM8YPH0 RU https://pubmed.ncbi.nlm.nih.gov/9876115 DM8YPH0 DI DM8YPH0 DM8YPH0 DN 1-Phenyl-1H-benzoimidazole DM8YPH0 TI TTI7421 DM8YPH0 TN Platelet-derived growth factor receptor beta (PDGFRB) DM8YPH0 MA Inhibitor DM8YPH0 RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DM8YPH0 RU https://pubmed.ncbi.nlm.nih.gov/9876115 DM8YQ2O DI DM8YQ2O DM8YQ2O DN 1-Methoxy-6-phenyl-6H-benzo[c]chromen-8-ylamine DM8YQ2O TI TTOZRK6 DM8YQ2O TN Glucocorticoid receptor messenger RNA (GCR mRNA) DM8YQ2O MA Inhibitor DM8YQ2O RN Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2079-82. DM8YQ2O RU https://pubmed.ncbi.nlm.nih.gov/15080982 DM8YT7X DI DM8YT7X DM8YT7X DN L-817,818 DM8YT7X TI TTIND6G DM8YT7X TN Somatostatin receptor type 1 (SSTR1) DM8YT7X MA Agonist DM8YT7X RN Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40. DM8YT7X RU https://pubmed.ncbi.nlm.nih.gov/9784130 DM8YT7X DI DM8YT7X DM8YT7X DN L-817,818 DM8YT7X TI TT2BC4G DM8YT7X TN Somatostatin receptor type 5 (SSTR5) DM8YT7X MA Agonist DM8YT7X RN Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40. DM8YT7X RU https://pubmed.ncbi.nlm.nih.gov/9784130 DM8YUW6 DI DM8YUW6 DM8YUW6 DN [3H]HU-243 DM8YUW6 TI TT6OEDT DM8YUW6 TN Cannabinoid receptor 1 (CB1) DM8YUW6 MA Agonist DM8YUW6 RN A novel probe for the cannabinoid receptor. J Med Chem. 1992 May 29;35(11):2065-9. DM8YUW6 RU https://pubmed.ncbi.nlm.nih.gov/1317925 DM8YUW6 DI DM8YUW6 DM8YUW6 DN [3H]HU-243 DM8YUW6 TI TTMSFAW DM8YUW6 TN Cannabinoid receptor 2 (CB2) DM8YUW6 MA Agonist DM8YUW6 RN The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 1995 Nov 13;375(1-2):143-7. DM8YUW6 RU https://pubmed.ncbi.nlm.nih.gov/7498464 DM8Z1QU DI DM8Z1QU DM8Z1QU DN 1-(1,4-diphenylbutan-2-yl)piperazine DM8Z1QU TI TTVBI8W DM8Z1QU TN Dopamine transporter (DAT) DM8Z1QU MA Inhibitor DM8Z1QU RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DM8Z1QU RU https://pubmed.ncbi.nlm.nih.gov/16750363 DM8Z1QU DI DM8Z1QU DM8Z1QU DN 1-(1,4-diphenylbutan-2-yl)piperazine DM8Z1QU TI TT3ROYC DM8Z1QU TN Serotonin transporter (SERT) DM8Z1QU MA Inhibitor DM8Z1QU RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DM8Z1QU RU https://pubmed.ncbi.nlm.nih.gov/16750363 DM8Z1QU DI DM8Z1QU DM8Z1QU DN 1-(1,4-diphenylbutan-2-yl)piperazine DM8Z1QU TI TTAWNKZ DM8Z1QU TN Norepinephrine transporter (NET) DM8Z1QU MA Inhibitor DM8Z1QU RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DM8Z1QU RU https://pubmed.ncbi.nlm.nih.gov/16750363 DM8Z4L0 DI DM8Z4L0 DM8Z4L0 DN N-hydroxy-7-(naphthalen-2-yl)-7-oxoheptanamide DM8Z4L0 TI TT6R7JZ DM8Z4L0 TN Histone deacetylase 1 (HDAC1) DM8Z4L0 MA Inhibitor DM8Z4L0 RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DM8Z4L0 RU https://pubmed.ncbi.nlm.nih.gov/19136179 DM8ZA6K DI DM8ZA6K DM8ZA6K DN WRR-99 DM8ZA6K TI TTJOKD1 DM8ZA6K TN Cathepsin F (CTSF) DM8ZA6K MA Inhibitor DM8ZA6K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8ZA6K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8ZA6K DI DM8ZA6K DM8ZA6K DN WRR-99 DM8ZA6K TI TTEAID7 DM8ZA6K TN Trypanosoma Cruzipain (Trypano CYSP) DM8ZA6K MA Inhibitor DM8ZA6K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM8ZA6K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM8ZBHF DI DM8ZBHF DM8ZBHF DN 1-phenyl-3-(phenylsulfonyl)propan-1-one DM8ZBHF TI TTN7BL9 DM8ZBHF TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM8ZBHF MA Inhibitor DM8ZBHF RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DM8ZBHF RU https://pubmed.ncbi.nlm.nih.gov/17490884 DM8ZG2I DI DM8ZG2I DM8ZG2I DN O-DESMETHYL TRAMADOL DM8ZG2I TI TT3ROYC DM8ZG2I TN Serotonin transporter (SERT) DM8ZG2I MA Inhibitor DM8ZG2I RN Derivatives of tramadol for increased duration of effect. Bioorg Med Chem Lett. 2006 Feb;16(3):691-4. DM8ZG2I RU https://pubmed.ncbi.nlm.nih.gov/16257206 DM8ZG2I DI DM8ZG2I DM8ZG2I DN O-DESMETHYL TRAMADOL DM8ZG2I TI TTKWM86 DM8ZG2I TN Opioid receptor mu (MOP) DM8ZG2I MA Inhibitor DM8ZG2I RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DM8ZG2I RU https://pubmed.ncbi.nlm.nih.gov/19027293 DM8ZG2I DI DM8ZG2I DM8ZG2I DN O-DESMETHYL TRAMADOL DM8ZG2I TI TTQW87Y DM8ZG2I TN Opioid receptor kappa (OPRK1) DM8ZG2I MA Inhibitor DM8ZG2I RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DM8ZG2I RU https://pubmed.ncbi.nlm.nih.gov/19027293 DM8ZG2I DI DM8ZG2I DM8ZG2I DN O-DESMETHYL TRAMADOL DM8ZG2I TI TT27RFC DM8ZG2I TN Opioid receptor delta (OPRD1) DM8ZG2I MA Inhibitor DM8ZG2I RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DM8ZG2I RU https://pubmed.ncbi.nlm.nih.gov/19027293 DM8ZHYR DI DM8ZHYR DM8ZHYR DN (R)(+)-7-methyl-2-phenylchroman-4-one DM8ZHYR TI TTGP7BY DM8ZHYR TN Monoamine oxidase type B (MAO-B) DM8ZHYR MA Inhibitor DM8ZHYR RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DM8ZHYR RU https://pubmed.ncbi.nlm.nih.gov/20045650 DM8ZK12 DI DM8ZK12 DM8ZK12 DN MDP-01 DM8ZK12 TI TTGKNB4 DM8ZK12 TN Epidermal growth factor receptor (EGFR) DM8ZK12 MA Inhibitor DM8ZK12 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DM8ZK12 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DM8ZMB5 DI DM8ZMB5 DM8ZMB5 DN N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8ZMB5 TI TT06RH5 DM8ZMB5 TN GABA(A) receptor gamma-2 (GABRG2) DM8ZMB5 MA Inhibitor DM8ZMB5 RN Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97. DM8ZMB5 RU https://pubmed.ncbi.nlm.nih.gov/11428922 DM8ZMB5 DI DM8ZMB5 DM8ZMB5 DN N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8ZMB5 TI TTNJYV2 DM8ZMB5 TN Gamma-aminobutyric acid receptor (GAR) DM8ZMB5 MA Inhibitor DM8ZMB5 RN Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97. DM8ZMB5 RU https://pubmed.ncbi.nlm.nih.gov/11428922 DM8ZMB5 DI DM8ZMB5 DM8ZMB5 DN N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8ZMB5 TI TTZA1NY DM8ZMB5 TN GABA(A) receptor beta-2 (GABRB2) DM8ZMB5 MA Inhibitor DM8ZMB5 RN Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97. DM8ZMB5 RU https://pubmed.ncbi.nlm.nih.gov/11428922 DM8ZMB5 DI DM8ZMB5 DM8ZMB5 DN N-Indan-1-yl-2-(1H-indol-3-yl)-2-oxo-acetamide DM8ZMB5 TI TT1MPAY DM8ZMB5 TN GABA(A) receptor alpha-1 (GABRA1) DM8ZMB5 MA Inhibitor DM8ZMB5 RN Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands of the benzodiazepine receptor: synthesis, biological evaluation, and molecular mo... J Med Chem. 2001 Jul 5;44(14):2286-97. DM8ZMB5 RU https://pubmed.ncbi.nlm.nih.gov/11428922 DM8ZMNH DI DM8ZMNH DM8ZMNH DN naloxonazine DM8ZMNH TI TTKWM86 DM8ZMNH TN Opioid receptor mu (MOP) DM8ZMNH MA Antagonist DM8ZMNH RN Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4. DM8ZMNH RU https://pubmed.ncbi.nlm.nih.gov/8114680 DM8ZPJI DI DM8ZPJI DM8ZPJI DN 2-morpholino-6-styryl-4H-pyran-4-one DM8ZPJI TI TTK3PY9 DM8ZPJI TN DNA-dependent protein kinase catalytic (PRKDC) DM8ZPJI MA Inhibitor DM8ZPJI RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM8ZPJI RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM8ZQG3 DI DM8ZQG3 DM8ZQG3 DN Azithromycinarylalkylhydroxamic Acid DM8ZQG3 TI TT6R7JZ DM8ZQG3 TN Histone deacetylase 1 (HDAC1) DM8ZQG3 MA Inhibitor DM8ZQG3 RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DM8ZQG3 RU https://pubmed.ncbi.nlm.nih.gov/19093884 DM8ZQG3 DI DM8ZQG3 DM8ZQG3 DN Azithromycinarylalkylhydroxamic Acid DM8ZQG3 TI TTT6LFV DM8ZQG3 TN Histone deacetylase 8 (HDAC8) DM8ZQG3 MA Inhibitor DM8ZQG3 RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DM8ZQG3 RU https://pubmed.ncbi.nlm.nih.gov/19093884 DM8ZR17 DI DM8ZR17 DM8ZR17 DN LP-12 DM8ZR17 TI TTJQOD7 DM8ZR17 TN 5-HT 2A receptor (HTR2A) DM8ZR17 MA Agonist DM8ZR17 RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM8ZR17 RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM8ZR17 DI DM8ZR17 DM8ZR17 DN LP-12 DM8ZR17 TI TTSQIFT DM8ZR17 TN 5-HT 1A receptor (HTR1A) DM8ZR17 MA Agonist DM8ZR17 RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM8ZR17 RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM8ZR17 DI DM8ZR17 DM8ZR17 DN LP-12 DM8ZR17 TI TTO9X1H DM8ZR17 TN 5-HT 7 receptor (HTR7) DM8ZR17 MA Agonist DM8ZR17 RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM8ZR17 RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM8ZR17 DI DM8ZR17 DM8ZR17 DN LP-12 DM8ZR17 TI TTEX248 DM8ZR17 TN Dopamine D2 receptor (D2R) DM8ZR17 MA Agonist DM8ZR17 RN Structure-activity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a class of 5-HT7 receptor agents. 2. J Med Chem. 2007 Aug 23;50(17):4214-21. DM8ZR17 RU https://pubmed.ncbi.nlm.nih.gov/17649988 DM8ZRAE DI DM8ZRAE DM8ZRAE DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol DM8ZRAE TI TTQW87Y DM8ZRAE TN Opioid receptor kappa (OPRK1) DM8ZRAE MA Inhibitor DM8ZRAE RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DM8ZRAE RU https://pubmed.ncbi.nlm.nih.gov/18788723 DM8ZRAE DI DM8ZRAE DM8ZRAE DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol DM8ZRAE TI TT27RFC DM8ZRAE TN Opioid receptor delta (OPRD1) DM8ZRAE MA Inhibitor DM8ZRAE RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DM8ZRAE RU https://pubmed.ncbi.nlm.nih.gov/18788723 DM8ZRAE DI DM8ZRAE DM8ZRAE DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol DM8ZRAE TI TTKWM86 DM8ZRAE TN Opioid receptor mu (MOP) DM8ZRAE MA Inhibitor DM8ZRAE RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DM8ZRAE RU https://pubmed.ncbi.nlm.nih.gov/18788723 DM8ZRAE DI DM8ZRAE DM8ZRAE DN 4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol DM8ZRAE TI TTQ6VDM DM8ZRAE TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM8ZRAE MA Inhibitor DM8ZRAE RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DM8ZRAE RU https://pubmed.ncbi.nlm.nih.gov/18788723 DM8ZTPF DI DM8ZTPF DM8ZTPF DN (S)-Norfluoxetine DM8ZTPF TI TTAWNKZ DM8ZTPF TN Norepinephrine transporter (NET) DM8ZTPF MA Inhibitor DM8ZTPF RN Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43. DM8ZTPF RU https://pubmed.ncbi.nlm.nih.gov/19014888 DM8ZTPF DI DM8ZTPF DM8ZTPF DN (S)-Norfluoxetine DM8ZTPF TI TT3ROYC DM8ZTPF TN Serotonin transporter (SERT) DM8ZTPF MA Inhibitor DM8ZTPF RN Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43. DM8ZTPF RU https://pubmed.ncbi.nlm.nih.gov/19014888 DM8ZTPF DI DM8ZTPF DM8ZTPF DN (S)-Norfluoxetine DM8ZTPF TI TTVBI8W DM8ZTPF TN Dopamine transporter (DAT) DM8ZTPF MA Inhibitor DM8ZTPF RN Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43. DM8ZTPF RU https://pubmed.ncbi.nlm.nih.gov/19014888 DM8ZUBY DI DM8ZUBY DM8ZUBY DN 3-(6-phenyl-2,4'-bipyridin-4-yl)phenol DM8ZUBY TI TTGTQHC DM8ZUBY TN DNA topoisomerase I (TOP1) DM8ZUBY MA Inhibitor DM8ZUBY RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DM8ZUBY RU https://pubmed.ncbi.nlm.nih.gov/20392646 DM906JK DI DM906JK DM906JK DN Pyrrolidine-1-carbonitrile DM906JK TI TTDZN01 DM906JK TN Cathepsin K (CTSK) DM906JK MA Inhibitor DM906JK RN Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3039-43. DM906JK RU https://pubmed.ncbi.nlm.nih.gov/15896958 DM906YB DI DM906YB DM906YB DN NP-0336 DM906YB TI TTEB0GD DM906YB TN Cholinesterase (BCHE) DM906YB MA Inhibitor DM906YB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471). DM906YB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471 DM90DV6 DI DM90DV6 DM90DV6 DN 4,5-Bis(4-methoxyphenyl)isothiazole DM90DV6 TI TT8NGED DM90DV6 TN Prostaglandin G/H synthase 1 (COX-1) DM90DV6 MA Inhibitor DM90DV6 RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DM90DV6 RU https://pubmed.ncbi.nlm.nih.gov/19097798 DM90DV6 DI DM90DV6 DM90DV6 DN 4,5-Bis(4-methoxyphenyl)isothiazole DM90DV6 TI TTVKILB DM90DV6 TN Prostaglandin G/H synthase 2 (COX-2) DM90DV6 MA Inhibitor DM90DV6 RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DM90DV6 RU https://pubmed.ncbi.nlm.nih.gov/19097798 DM90GNC DI DM90GNC DM90GNC DN N-Phenylpropyl-ETAV DM90GNC TI TT9PB26 DM90GNC TN Presynaptic density protein 95 (DLG4) DM90GNC MA Inhibitor DM90GNC RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DM90GNC RU https://pubmed.ncbi.nlm.nih.gov/18811137 DM90IRW DI DM90IRW DM90IRW DN 24-thiacycloartanol DM90IRW TI TTWQ8IY DM90IRW TN Fungal Sterol 24-C-methyltransferase (Fung erg6) DM90IRW MA Inhibitor DM90IRW RN Inactivation of soybean sterol 24-C-methyltransferase by elongated sterol side chains at C26. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5902-6. DM90IRW RU https://pubmed.ncbi.nlm.nih.gov/17851075 DM90JMN DI DM90JMN DM90JMN DN 6-chloro-5-phenylpyrimidine-2,4(1H,3H)-dione DM90JMN TI TTO0IB8 DM90JMN TN Thymidine phosphorylase (TYMP) DM90JMN MA Inhibitor DM90JMN RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DM90JMN RU https://pubmed.ncbi.nlm.nih.gov/17963370 DM90KGB DI DM90KGB DM90KGB DN N-(6-ethoxypyridin-2-yl)acetamide DM90KGB TI TT0K6EO DM90KGB TN Stress-activated protein kinase JNK1 (JNK1) DM90KGB MA Inhibitor DM90KGB RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DM90KGB RU https://pubmed.ncbi.nlm.nih.gov/16759099 DM90LWT DI DM90LWT DM90LWT DN 1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione DM90LWT TI TTSKMI8 DM90LWT TN Phosphodiesterase 4D (PDE4D) DM90LWT MA Inhibitor DM90LWT RN Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44. DM90LWT RU https://pubmed.ncbi.nlm.nih.gov/1331453 DM90LWT DI DM90LWT DM90LWT DN 1-Methyl-3-propyl-3,7-dihydro-purine-2,6-dione DM90LWT TI TTZ97H5 DM90LWT TN Phosphodiesterase 4A (PDE4A) DM90LWT MA Inhibitor DM90LWT RN Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44. DM90LWT RU https://pubmed.ncbi.nlm.nih.gov/1331453 DM90TOR DI DM90TOR DM90TOR DN ISIS 134499 DM90TOR TI TTKW4ML DM90TOR TN Caspase 6 messenger RNA (CASP6 mRNA) DM90TOR RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DM90TOR RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DM90TSI DI DM90TSI DM90TSI DN 2,4-bis-docosanoylamino-benzenesulfonate DM90TSI TI TT2TDH9 DM90TSI TN Scavenger receptor A1 (MSR1) DM90TSI MA Inhibitor DM90TSI RN 2,4-Bis(octadecanoylamino)benzenesulfonic acid sodium salt as a novel scavenger receptor inhibitor with low molecular weight. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2791-5. DM90TSI RU https://pubmed.ncbi.nlm.nih.gov/15125934 DM90U5P DI DM90U5P DM90U5P DN N-{4'-[(trifluoromethyl)sulfonyl]-4-biphenyl}urea DM90U5P TI TTBGTCW DM90U5P TN Kinesin spindle messenger RNA (KIF11 mRNA) DM90U5P MA Inhibitor DM90U5P RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DM90U5P RU https://pubmed.ncbi.nlm.nih.gov/17725339 DM90ULM DI DM90ULM DM90ULM DN 1-D-glucopyranosyl uracil DM90ULM TI TTZHY6R DM90ULM TN Glycogen phosphorylase muscle form (GP) DM90ULM MA Inhibitor DM90ULM RN 1-(3-Deoxy-3-fluoro-beta-d-glucopyranosyl) pyrimidine derivatives as inhibitors of glycogen phosphorylase b: Kinetic, crystallographic and modellin... Bioorg Med Chem. 2010 May 15;18(10):3413-25. DM90ULM RU https://pubmed.ncbi.nlm.nih.gov/20430629 DM90VJ6 DI DM90VJ6 DM90VJ6 DN 6-Thiophen-3-yl-imidazo[2,1-b]thiazole DM90VJ6 TI TTTJF7V DM90VJ6 TN NADH dehydrogenase (MT-ND3) DM90VJ6 MA Inhibitor DM90VJ6 RN Thienylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH dehydrogenase. J Med Chem. 1995 Mar 31;38(7):1090-7. DM90VJ6 RU https://pubmed.ncbi.nlm.nih.gov/7707312 DM910BF DI DM910BF DM910BF DN N-(4-amino-3'-methylbiphenyl-3-yl)benzamide DM910BF TI TTSHTOI DM910BF TN Histone deacetylase 2 (HDAC2) DM910BF MA Inhibitor DM910BF RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DM910BF RU https://pubmed.ncbi.nlm.nih.gov/20392638 DM9123M DI DM9123M DM9123M DN 9-Aminomethyl-9H-fluorene-2,5,6-triol DM9123M TI TTZFYLI DM9123M TN Dopamine D1 receptor (D1R) DM9123M MA Inhibitor DM9123M RN Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12. DM9123M RU https://pubmed.ncbi.nlm.nih.gov/3761310 DM91463 DI DM91463 DM91463 DN N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine DM91463 TI TTGSEFH DM91463 TN Sodium/hydrogen exchanger 1 (SLC9A1) DM91463 MA Inhibitor DM91463 RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DM91463 RU https://pubmed.ncbi.nlm.nih.gov/9207943 DM91463 DI DM91463 DM91463 DN N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine DM91463 TI TTFZVPO DM91463 TN Sodium/hydrogen exchanger 3 (SLC9A3) DM91463 MA Inhibitor DM91463 RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DM91463 RU https://pubmed.ncbi.nlm.nih.gov/9207943 DM91PA5 DI DM91PA5 DM91PA5 DN 2-((2-ethoxyphenoxy)methyl)-4-isopropylmorpholine DM91PA5 TI TT9JNIC DM91PA5 TN Histamine H3 receptor (H3R) DM91PA5 MA Inhibitor DM91PA5 RN 2-Aryloxymethylmorpholine histamine H(3) antagonists. Bioorg Med Chem Lett. 2008 Nov 1;18(21):5796-9. DM91PA5 RU https://pubmed.ncbi.nlm.nih.gov/18922693 DM91W2K DI DM91W2K DM91W2K DN 3,4-bis(3,4-dimethoxyphenyl)furan-2(5H)-one DM91W2K TI TTSZLWK DM91W2K TN Aromatase (CYP19A1) DM91W2K MA Inhibitor DM91W2K RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DM91W2K RU https://pubmed.ncbi.nlm.nih.gov/20413308 DM920XR DI DM920XR DM920XR DN 8-(3,5-dimethoxyphenyl)-9H-purine-2,6-diamine DM920XR TI TT9SL3Q DM920XR TN Polypeptide deformylase (PDF) DM920XR MA Inhibitor DM920XR RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DM920XR RU https://pubmed.ncbi.nlm.nih.gov/20117005 DM923WK DI DM923WK DM923WK DN 2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzothiazole DM923WK TI TTXZEAJ DM923WK TN Leukotriene A-4 hydrolase (LTA4H) DM923WK MA Inhibitor DM923WK RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DM923WK RU https://pubmed.ncbi.nlm.nih.gov/18588282 DM9263J DI DM9263J DM9263J DN 5-hexyl-2-(pyrazin-2-yloxy)phenol DM9263J TI TTVTX4N DM9263J TN Bacterial Fatty acid synthetase I (Bact inhA) DM9263J MA Inhibitor DM9263J RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DM9263J RU https://pubmed.ncbi.nlm.nih.gov/18457948 DM92EG5 DI DM92EG5 DM92EG5 DN 7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DM92EG5 TI TTZAYWL DM92EG5 TN Estrogen receptor (ESR) DM92EG5 MA Inhibitor DM92EG5 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM92EG5 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM92EG5 DI DM92EG5 DM92EG5 DN 7-Ethynyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DM92EG5 TI TTOM3J0 DM92EG5 TN Estrogen receptor beta (ESR2) DM92EG5 MA Inhibitor DM92EG5 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DM92EG5 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DM92F6Z DI DM92F6Z DM92F6Z DN Isopropyl-methyl-prop-2-ynyl-amine hydrochloride DM92F6Z TI TTGP7BY DM92F6Z TN Monoamine oxidase type B (MAO-B) DM92F6Z MA Inhibitor DM92F6Z RN Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13. DM92F6Z RU https://pubmed.ncbi.nlm.nih.gov/1433183 DM92IK8 DI DM92IK8 DM92IK8 DN CRYPTADINE B DM92IK8 TI TT1RS9F DM92IK8 TN Acetylcholinesterase (AChE) DM92IK8 MA Inhibitor DM92IK8 RN Cryptadines A and B, novel C27N3-type pentacyclic alkaloids from Lycopodium cryptomerinum. Bioorg Med Chem. 2007 Dec 15;15(24):7803-8. DM92IK8 RU https://pubmed.ncbi.nlm.nih.gov/17904850 DM92QIW DI DM92QIW DM92QIW DN Iva-His-Pro-Phe-His-Sta-Leu-Phe-NH2 DM92QIW TI TTB2MXP DM92QIW TN Angiotensinogenase renin (REN) DM92QIW MA Inhibitor DM92QIW RN Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem. 1985 Dec;28(12):1779-90. DM92QIW RU https://pubmed.ncbi.nlm.nih.gov/3906131 DM92RHP DI DM92RHP DM92RHP DN KYS-05090 DM92RHP TI TT4FDG6 DM92RHP TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM92RHP MA Inhibitor DM92RHP RN Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3. DM92RHP RU https://pubmed.ncbi.nlm.nih.gov/17869104 DM92RHP DI DM92RHP DM92RHP DN KYS-05090 DM92RHP TI TT729IR DM92RHP TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DM92RHP MA Inhibitor DM92RHP RN T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. DM92RHP RU https://pubmed.ncbi.nlm.nih.gov/18585035 DM92X5T DI DM92X5T DM92X5T DN L-702-539 DM92X5T TI TTSJ6Q4 DM92X5T TN LOX-5 messenger RNA (ALOX5 mRNA) DM92X5T MA Inhibitor DM92X5T RN Substituted (pyridylmethoxy)naphthalenes as potent and orally active 5-lipoxygenase inhibitors; synthesis, biological profile, and pharmacokinetics... J Med Chem. 1997 Aug 29;40(18):2866-75. DM92X5T RU https://pubmed.ncbi.nlm.nih.gov/9288168 DM92XPO DI DM92XPO DM92XPO DN 8-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM92XPO TI TT06AWU DM92XPO TN Phosphodiesterase 3A (PDE3A) DM92XPO MA Inhibitor DM92XPO RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DM92XPO RU https://pubmed.ncbi.nlm.nih.gov/1654430 DM92ZCU DI DM92ZCU DM92ZCU DN 1-acetamido-5-sulfonamidoindane DM92ZCU TI TTHQPL7 DM92ZCU TN Carbonic anhydrase I (CA-I) DM92ZCU MA Inhibitor DM92ZCU RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DM92ZCU RU https://pubmed.ncbi.nlm.nih.gov/15501040 DM92ZCU DI DM92ZCU DM92ZCU DN 1-acetamido-5-sulfonamidoindane DM92ZCU TI TTANPDJ DM92ZCU TN Carbonic anhydrase II (CA-II) DM92ZCU MA Inhibitor DM92ZCU RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM92ZCU RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM92ZCU DI DM92ZCU DM92ZCU DN 1-acetamido-5-sulfonamidoindane DM92ZCU TI TT2LVK8 DM92ZCU TN Carbonic anhydrase IX (CA-IX) DM92ZCU MA Inhibitor DM92ZCU RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM92ZCU RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM93CA4 DI DM93CA4 DM93CA4 DN CP-376395 DM93CA4 TI TT7EFHR DM93CA4 TN Corticotropin-releasing factor receptor 1 (CRHR1) DM93CA4 MA Inhibitor DM93CA4 RN 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. J Med Chem. 2008 Mar 13;51(5):1385-92. DM93CA4 RU https://pubmed.ncbi.nlm.nih.gov/18288792 DM93CZW DI DM93CZW DM93CZW DN Naphthalen-1-yl(10H-phenothiazin-10-yl)methanone DM93CZW TI TTEB0GD DM93CZW TN Cholinesterase (BCHE) DM93CZW MA Inhibitor DM93CZW RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DM93CZW RU https://pubmed.ncbi.nlm.nih.gov/17681768 DM93DQG DI DM93DQG DM93DQG DN 4-dehydroxyriccardin C DM93DQG TI TTXA6PH DM93DQG TN Oxysterols receptor LXR-beta (NR1H2) DM93DQG MA Inhibitor DM93DQG RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DM93DQG RU https://pubmed.ncbi.nlm.nih.gov/18343126 DM93DQG DI DM93DQG DM93DQG DN 4-dehydroxyriccardin C DM93DQG TI TTECBXN DM93DQG TN Oxysterols receptor LXR-alpha (NR1H3) DM93DQG MA Inhibitor DM93DQG RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DM93DQG RU https://pubmed.ncbi.nlm.nih.gov/18343126 DM93DYT DI DM93DYT DM93DYT DN 2-methoxy-3,4-methylenedioxybenzophenone DM93DYT TI TTMF541 DM93DYT TN Liver carboxylesterase (CES1) DM93DYT MA Inhibitor DM93DYT RN Phenolic compounds from the roots of Lindera fruticosa. J Nat Prod. 2006 May;69(5):853-5. DM93DYT RU https://pubmed.ncbi.nlm.nih.gov/16724860 DM93I0B DI DM93I0B DM93I0B DN [des-His1,Tyr5,Glu9]glucagon-NH2 DM93I0B TI TT9O6WS DM93I0B TN Glucagon receptor (GCGR) DM93I0B MA Inhibitor DM93I0B RN Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55. DM93I0B RU https://pubmed.ncbi.nlm.nih.gov/8691441 DM93MAB DI DM93MAB DM93MAB DN Dioxothiomolybdenum(VI) ion DM93MAB TI TT7RJY8 DM93MAB TN Xanthine dehydrogenase/oxidase (XDH) DM93MAB MA Inhibitor DM93MAB RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DM93MAB RU https://pubmed.ncbi.nlm.nih.gov/21059682 DM93MAX DI DM93MAX DM93MAX DN 5-(pyridin-4-yl)-1,3,4-oxadiazole-2(3H)-thione DM93MAX TI TTULVH8 DM93MAX TN Tyrosinase (TYR) DM93MAX MA Inhibitor DM93MAX RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DM93MAX RU https://pubmed.ncbi.nlm.nih.gov/20452224 DM93PDA DI DM93PDA DM93PDA DN N-(4-amino-4'-methoxybiphenyl-3-yl)benzamide DM93PDA TI TTSHTOI DM93PDA TN Histone deacetylase 2 (HDAC2) DM93PDA MA Inhibitor DM93PDA RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DM93PDA RU https://pubmed.ncbi.nlm.nih.gov/20392638 DM93RKC DI DM93RKC DM93RKC DN PMID15664838C18 DM93RKC TI TTJGLZF DM93RKC TN Dipeptidyl peptidase 8 (DPP-8) DM93RKC MA Inhibitor DM93RKC RN Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 2005 Feb 1;15(3):687-91. DM93RKC RU https://pubmed.ncbi.nlm.nih.gov/15664838 DM93XJT DI DM93XJT DM93XJT DN 2-(phenylsulfonyl)-1-p-tolylethanone DM93XJT TI TTN7BL9 DM93XJT TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DM93XJT MA Inhibitor DM93XJT RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DM93XJT RU https://pubmed.ncbi.nlm.nih.gov/17490884 DM943YL DI DM943YL DM943YL DN 2-(4-Methyl-indole-1-sulfonyl)-benzoic acid DM943YL TI TTHWMFZ DM943YL TN Fatty acid-binding protein 4 (FABP4) DM943YL MA Inhibitor DM943YL RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DM943YL RU https://pubmed.ncbi.nlm.nih.gov/15357969 DM945RK DI DM945RK DM945RK DN Octanedioic acid hydroxyamide pyridin-4-ylamide DM945RK TI TTYHPU6 DM945RK TN Histone deacetylase 10 (HDAC10) DM945RK MA Inhibitor DM945RK RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM945RK RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM945RK DI DM945RK DM945RK DN Octanedioic acid hydroxyamide pyridin-4-ylamide DM945RK TI TTSHTOI DM945RK TN Histone deacetylase 2 (HDAC2) DM945RK MA Inhibitor DM945RK RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM945RK RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM945RK DI DM945RK DM945RK DN Octanedioic acid hydroxyamide pyridin-4-ylamide DM945RK TI TTT6LFV DM945RK TN Histone deacetylase 8 (HDAC8) DM945RK MA Inhibitor DM945RK RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM945RK RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM945RK DI DM945RK DM945RK DN Octanedioic acid hydroxyamide pyridin-4-ylamide DM945RK TI TTBH0VX DM945RK TN Histone deacetylase (HDAC) DM945RK MA Inhibitor DM945RK RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM945RK RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM945RK DI DM945RK DM945RK DN Octanedioic acid hydroxyamide pyridin-4-ylamide DM945RK TI TTTQGH8 DM945RK TN Histone deacetylase 4 (HDAC4) DM945RK MA Inhibitor DM945RK RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM945RK RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM945RK DI DM945RK DM945RK DN Octanedioic acid hydroxyamide pyridin-4-ylamide DM945RK TI TT5ZKDI DM945RK TN Histone deacetylase 6 (HDAC6) DM945RK MA Inhibitor DM945RK RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM945RK RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM945RK DI DM945RK DM945RK DN Octanedioic acid hydroxyamide pyridin-4-ylamide DM945RK TI TT6R7JZ DM945RK TN Histone deacetylase 1 (HDAC1) DM945RK MA Inhibitor DM945RK RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DM945RK RU https://pubmed.ncbi.nlm.nih.gov/11831887 DM946RA DI DM946RA DM946RA DN AGN-192172 DM946RA TI TTNGILX DM946RA TN Adrenergic receptor alpha-1A (ADRA1A) DM946RA MA Inhibitor DM946RA RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DM946RA RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DM946RA DI DM946RA DM946RA DN AGN-192172 DM946RA TI TT34BHT DM946RA TN Adrenergic receptor alpha-1D (ADRA1D) DM946RA MA Inhibitor DM946RA RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DM946RA RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DM946RA DI DM946RA DM946RA DN AGN-192172 DM946RA TI TTBRKXS DM946RA TN Adrenergic receptor alpha-1B (ADRA1B) DM946RA MA Inhibitor DM946RA RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DM946RA RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DM94AIL DI DM94AIL DM94AIL DN IKH-25 DM94AIL TI TT5ZKDI DM94AIL TN Histone deacetylase 6 (HDAC6) DM94AIL MA Inhibitor DM94AIL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618). DM94AIL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618 DM94B12 DI DM94B12 DM94B12 DN (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM94B12 TI TTAWNKZ DM94B12 TN Norepinephrine transporter (NET) DM94B12 MA Inhibitor DM94B12 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM94B12 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM94B12 DI DM94B12 DM94B12 DN (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM94B12 TI TT3ROYC DM94B12 TN Serotonin transporter (SERT) DM94B12 MA Inhibitor DM94B12 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM94B12 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM94B12 DI DM94B12 DM94B12 DN (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM94B12 TI TTVBI8W DM94B12 TN Dopamine transporter (DAT) DM94B12 MA Inhibitor DM94B12 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM94B12 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM94B12 DI DM94B12 DM94B12 DN (R)-3-(naphthalen-2-ylmethoxy)pyrrolidine DM94B12 TI TTQ6VDM DM94B12 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM94B12 MA Inhibitor DM94B12 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DM94B12 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DM94B7N DI DM94B7N DM94B7N DN 2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine DM94B7N TI TTJS8PY DM94B7N TN 5-HT 6 receptor (HTR6) DM94B7N MA Inhibitor DM94B7N RN Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. DM94B7N RU https://pubmed.ncbi.nlm.nih.gov/19523834 DM94IJC DI DM94IJC DM94IJC DN JNJ-19398990 DM94IJC TI TTZAYWL DM94IJC TN Estrogen receptor (ESR) DM94IJC MA Inhibitor DM94IJC RN Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69. DM94IJC RU https://pubmed.ncbi.nlm.nih.gov/19366247 DM94JXH DI DM94JXH DM94JXH DN Leucettamidine DM94JXH TI TTN53ZF DM94JXH TN Leukotriene B4 receptor 1 (LTB4R) DM94JXH MA Inhibitor DM94JXH RN New leukotriene B4 receptor antagonist: leucettamine A and related imidazole alkaloids from the marine sponge Leucetta microraphis. J Nat Prod. 1993 Jan;56(1):116-21. DM94JXH RU https://pubmed.ncbi.nlm.nih.gov/8383730 DM94K83 DI DM94K83 DM94K83 DN 3-Benzyloxy-2-phenyl-piperidine DM94K83 TI TTZPO1L DM94K83 TN Substance-P receptor (TACR1) DM94K83 MA Inhibitor DM94K83 RN 3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997). DM94K83 RU http://www.sciencedirect.com/science/article/pii/S0960894X97101184 DM94KQP DI DM94KQP DM94KQP DN Aminopyridine deriv. 2 DM94KQP TI TT0K6EO DM94KQP TN Stress-activated protein kinase JNK1 (JNK1) DM94KQP MA Inhibitor DM94KQP RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DM94KQP RU https://pubmed.ncbi.nlm.nih.gov/16759099 DM94KQP DI DM94KQP DM94KQP DN Aminopyridine deriv. 2 DM94KQP TI TT056SO DM94KQP TN Stress-activated protein kinase JNK3 (JNK3) DM94KQP MA Inhibitor DM94KQP RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DM94KQP RU https://pubmed.ncbi.nlm.nih.gov/16759099 DM94KQP DI DM94KQP DM94KQP DN Aminopyridine deriv. 2 DM94KQP TI TT3IVG2 DM94KQP TN JNK2 messenger RNA (JNK2 mRNA) DM94KQP MA Inhibitor DM94KQP RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DM94KQP RU https://pubmed.ncbi.nlm.nih.gov/16759099 DM94KWA DI DM94KWA DM94KWA DN WAY-169916 DM94KWA TI TTZAYWL DM94KWA TN Estrogen receptor (ESR) DM94KWA MA Inhibitor DM94KWA RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DM94KWA RU https://pubmed.ncbi.nlm.nih.gov/15588074 DM94KWA DI DM94KWA DM94KWA DN WAY-169916 DM94KWA TI TTOM3J0 DM94KWA TN Estrogen receptor beta (ESR2) DM94KWA MA Inhibitor DM94KWA RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DM94KWA RU https://pubmed.ncbi.nlm.nih.gov/15588074 DM94LID DI DM94LID DM94LID DN 1-(2-Fluoro-phenyl)-piperazine DM94LID TI TT6MSOK DM94LID TN 5-HT 1D receptor (HTR1D) DM94LID MA Inhibitor DM94LID RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM94LID RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM94LID DI DM94LID DM94LID DN 1-(2-Fluoro-phenyl)-piperazine DM94LID TI TTSQIFT DM94LID TN 5-HT 1A receptor (HTR1A) DM94LID MA Inhibitor DM94LID RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DM94LID RU https://pubmed.ncbi.nlm.nih.gov/2565400 DM94NM7 DI DM94NM7 DM94NM7 DN 2,4'-Dimethoxy-5,3'-dipropyl-biphenyl DM94NM7 TI TTVKILB DM94NM7 TN Prostaglandin G/H synthase 2 (COX-2) DM94NM7 MA Inhibitor DM94NM7 RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DM94NM7 RU https://pubmed.ncbi.nlm.nih.gov/19481465 DM94PBL DI DM94PBL DM94PBL DN 2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole DM94PBL TI TTRK8B9 DM94PBL TN Sodium channel unspecific (NaC) DM94PBL MA Inhibitor DM94PBL RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DM94PBL RU https://pubmed.ncbi.nlm.nih.gov/15177465 DM94PBL DI DM94PBL DM94PBL DN 2-Hexyl-4-(4-isobutyl-phenyl)-1H-imidazole DM94PBL TI TTAXZ0K DM94PBL TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DM94PBL MA Inhibitor DM94PBL RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DM94PBL RU https://pubmed.ncbi.nlm.nih.gov/15177465 DM94RJW DI DM94RJW DM94RJW DN SPT DM94RJW TI TTSLI08 DM94RJW TN Adenosine receptor (ADOR) DM94RJW MA Antagonist DM94RJW RN Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol. 1995 Mar;27(3):883-92. DM94RJW RU https://pubmed.ncbi.nlm.nih.gov/7602606 DM94V8D DI DM94V8D DM94V8D DN 5,6-dihydroxy-7-nitro-2,3-dihydroinden-1-one DM94V8D TI TTKWFB8 DM94V8D TN Catechol-O-methyl-transferase (COMT) DM94V8D MA Inhibitor DM94V8D RN Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8. DM94V8D RU https://pubmed.ncbi.nlm.nih.gov/16335931 DM94XJ2 DI DM94XJ2 DM94XJ2 DN (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone DM94XJ2 TI TTI7421 DM94XJ2 TN Platelet-derived growth factor receptor beta (PDGFRB) DM94XJ2 MA Inhibitor DM94XJ2 RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM94XJ2 RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM94XJ2 DI DM94XJ2 DM94XJ2 DN (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone DM94XJ2 TI TTGJCWZ DM94XJ2 TN Fms-like tyrosine kinase 3 (FLT-3) DM94XJ2 MA Inhibitor DM94XJ2 RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM94XJ2 RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM94XJ2 DI DM94XJ2 DM94XJ2 DN (1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone DM94XJ2 TI TT8FYO9 DM94XJ2 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM94XJ2 MA Inhibitor DM94XJ2 RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DM94XJ2 RU https://pubmed.ncbi.nlm.nih.gov/16722630 DM951PF DI DM951PF DM951PF DN Nonanoic acid biphenyl-2-ylamide DM951PF TI TTK3C21 DM951PF TN Acetoacetyl-CoA thiolase (ACAT1) DM951PF MA Inhibitor DM951PF RN Biphenyl versus phenylpyridazine derivatives: the role of the heterocycle in a series of acyl-CoA:cholesterol acyl transferase inhibitors. J Med Chem. 2008 Mar 13;51(5):1474-7. DM951PF RU https://pubmed.ncbi.nlm.nih.gov/18284184 DM953VY DI DM953VY DM953VY DN ISIS 9068 DM953VY TI TT5TURO DM953VY TN A-Raf messenger RNA (ARAF mRNA) DM953VY RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DM953VY RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DM957CK DI DM957CK DM957CK DN Nicotinaldehyde O-4-ethoxyphenylcarbamoyl oxime DM957CK TI TTDP1UC DM957CK TN Fatty acid amide hydrolase (FAAH) DM957CK MA Inhibitor DM957CK RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM957CK RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM958EN DI DM958EN DM958EN DN 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine DM958EN TI TT34BHT DM958EN TN Adrenergic receptor alpha-1D (ADRA1D) DM958EN MA Inhibitor DM958EN RN Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57. DM958EN RU https://pubmed.ncbi.nlm.nih.gov/1359141 DM958EN DI DM958EN DM958EN DN 8-Piperazin-1-yl-imidazo[1,2-a]pyrazine DM958EN TI TTNGILX DM958EN TN Adrenergic receptor alpha-1A (ADRA1A) DM958EN MA Inhibitor DM958EN RN Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57. DM958EN RU https://pubmed.ncbi.nlm.nih.gov/1359141 DM95A4Z DI DM95A4Z DM95A4Z DN [125I]APNEA DM95A4Z TI TTJFY5U DM95A4Z TN Adenosine A3 receptor (ADORA3) DM95A4Z MA Agonist DM95A4Z RN Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7432-6. DM95A4Z RU https://pubmed.ncbi.nlm.nih.gov/1323836 DM95B4J DI DM95B4J DM95B4J DN 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid DM95B4J TI TTHY57M DM95B4J TN Matrix metalloproteinase-13 (MMP-13) DM95B4J MA Inhibitor DM95B4J RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DM95B4J RU https://pubmed.ncbi.nlm.nih.gov/19703773 DM95B4J DI DM95B4J DM95B4J DN 2-(2-(biphenyl-4-yl)ethylsulfonyl)acetic acid DM95B4J TI TTXZ0KQ DM95B4J TN Matrix metalloproteinase-12 (MMP-12) DM95B4J MA Inhibitor DM95B4J RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DM95B4J RU https://pubmed.ncbi.nlm.nih.gov/19703773 DM95BL8 DI DM95BL8 DM95BL8 DN INS49266 DM95BL8 TI TTZ1DT0 DM95BL8 TN P2Y purinoceptor 12 (P2RY12) DM95BL8 MA Antagonist DM95BL8 RN Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor. J Med Chem. 2008 Feb 28;51(4):1007-25. DM95BL8 RU https://pubmed.ncbi.nlm.nih.gov/18232657 DM95JEW DI DM95JEW DM95JEW DN N-Octylcarbamic Acid Biphenyl-3-yl Ester DM95JEW TI TTDP1UC DM95JEW TN Fatty acid amide hydrolase (FAAH) DM95JEW MA Inhibitor DM95JEW RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DM95JEW RU https://pubmed.ncbi.nlm.nih.gov/18507372 DM95KRY DI DM95KRY DM95KRY DN VLI-27 DM95KRY TI TTWTSCV DM95KRY TN RAC-alpha serine/threonine-protein kinase (AKT1) DM95KRY MA Inhibitor DM95KRY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DM95KRY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DM95QEA DI DM95QEA DM95QEA DN Acetic acid 5-butyl-2-phenyl-thiazol-4-yl ester DM95QEA TI TT2J34L DM95QEA TN Arachidonate 5-lipoxygenase (5-LOX) DM95QEA MA Inhibitor DM95QEA RN 4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65. DM95QEA RU https://pubmed.ncbi.nlm.nih.gov/2066989 DM95R6O DI DM95R6O DM95R6O DN 3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane DM95R6O TI TTZUFI5 DM95R6O TN Nitric-oxide synthase brain (NOS1) DM95R6O MA Inhibitor DM95R6O RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DM95R6O RU https://pubmed.ncbi.nlm.nih.gov/11551770 DM95R6O DI DM95R6O DM95R6O DN 3-(2-Amino-ethyl)-5-imino-[1,4]oxazepane DM95R6O TI TTF10I9 DM95R6O TN Nitric-oxide synthase inducible (NOS2) DM95R6O MA Inhibitor DM95R6O RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DM95R6O RU https://pubmed.ncbi.nlm.nih.gov/11551770 DM95SJU DI DM95SJU DM95SJU DN N-(3,5-dimethoxyphenethyl)docos-13-enamide DM95SJU TI TT6OEDT DM95SJU TN Cannabinoid receptor 1 (CB1) DM95SJU MA Inhibitor DM95SJU RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM95SJU RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM95UI1 DI DM95UI1 DM95UI1 DN UVI3003 DM95UI1 TI TT6PEUO DM95UI1 TN Retinoic acid receptor RXR-alpha (RXRA) DM95UI1 MA Antagonist DM95UI1 RN Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators thro... J Biol Chem. 2005 Jan 14;280(2):1625-33. DM95UI1 RU https://pubmed.ncbi.nlm.nih.gov/15528208 DM95XWR DI DM95XWR DM95XWR DN 3-butylaminocarbonyl-6-ethyl-4-quinolone DM95XWR TI TTZA1NY DM95XWR TN GABA(A) receptor beta-2 (GABRB2) DM95XWR MA Inhibitor DM95XWR RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM95XWR RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM95XWR DI DM95XWR DM95XWR DN 3-butylaminocarbonyl-6-ethyl-4-quinolone DM95XWR TI TT06RH5 DM95XWR TN GABA(A) receptor gamma-2 (GABRG2) DM95XWR MA Inhibitor DM95XWR RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM95XWR RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM95XWR DI DM95XWR DM95XWR DN 3-butylaminocarbonyl-6-ethyl-4-quinolone DM95XWR TI TTNJYV2 DM95XWR TN Gamma-aminobutyric acid receptor (GAR) DM95XWR MA Inhibitor DM95XWR RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM95XWR RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM95XWR DI DM95XWR DM95XWR DN 3-butylaminocarbonyl-6-ethyl-4-quinolone DM95XWR TI TT1MPAY DM95XWR TN GABA(A) receptor alpha-1 (GABRA1) DM95XWR MA Inhibitor DM95XWR RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DM95XWR RU https://pubmed.ncbi.nlm.nih.gov/16610795 DM95Y82 DI DM95Y82 DM95Y82 DN AZ960 DM95Y82 TI TTRMX3V DM95Y82 TN Janus kinase 2 (JAK-2) DM95Y82 MA Inhibitor DM95Y82 RN Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43. DM95Y82 RU https://pubmed.ncbi.nlm.nih.gov/18775810 DM95Z4Q DI DM95Z4Q DM95Z4Q DN (R)-Rolipram DM95Z4Q TI TTZ97H5 DM95Z4Q TN Phosphodiesterase 4A (PDE4A) DM95Z4Q MA Inhibitor DM95Z4Q RN PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. DM95Z4Q RU https://pubmed.ncbi.nlm.nih.gov/19304913 DM95Z4Q DI DM95Z4Q DM95Z4Q DN (R)-Rolipram DM95Z4Q TI TTVIAT9 DM95Z4Q TN Phosphodiesterase 4B (PDE4B) DM95Z4Q MA Inhibitor DM95Z4Q RN PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. DM95Z4Q RU https://pubmed.ncbi.nlm.nih.gov/19304913 DM95Z4Q DI DM95Z4Q DM95Z4Q DN (R)-Rolipram DM95Z4Q TI TTV5CGO DM95Z4Q TN Phosphodiesterase 4 (PDE4) DM95Z4Q MA Inhibitor DM95Z4Q RN PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. DM95Z4Q RU https://pubmed.ncbi.nlm.nih.gov/19304913 DM960DQ DI DM960DQ DM960DQ DN MEDI-553 DM960DQ TI TTM6QSK DM960DQ TN B-cell receptor CD22 (CD22) DM960DQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2786). DM960DQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2786 DM961JG DI DM961JG DM961JG DN RAP-103 DM961JG TI TTFZYTO DM961JG TN C-C chemokine receptor type 2 (CCR2) DM961JG MA Modulator DM961JG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59). DM961JG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59 DM96ASN DI DM96ASN DM96ASN DN L-797,591 DM96ASN TI TTIND6G DM96ASN TN Somatostatin receptor type 1 (SSTR1) DM96ASN MA Agonist DM96ASN RN Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40. DM96ASN RU https://pubmed.ncbi.nlm.nih.gov/9784130 DM96ATK DI DM96ATK DM96ATK DN SC-83157 DM96ATK TI TTCIHJA DM96ATK TN Coagulation factor Xa (F10) DM96ATK MA Inhibitor DM96ATK RN Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21. DM96ATK RU https://pubmed.ncbi.nlm.nih.gov/12714830 DM96ECL DI DM96ECL DM96ECL DN CHRYSOERIOL DM96ECL TI TT7RJY8 DM96ECL TN Xanthine dehydrogenase/oxidase (XDH) DM96ECL MA Inhibitor DM96ECL RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DM96ECL RU https://pubmed.ncbi.nlm.nih.gov/3379415 DM96ECL DI DM96ECL DM96ECL DN CHRYSOERIOL DM96ECL TI TTI84H7 DM96ECL TN Cytochrome P450 1B1 (CYP1B1) DM96ECL MA Inhibitor DM96ECL RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DM96ECL RU https://pubmed.ncbi.nlm.nih.gov/20696580 DM96EJ1 DI DM96EJ1 DM96EJ1 DN alpha-conotoxin AuIB DM96EJ1 TI TTH18TF DM96EJ1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DM96EJ1 MA Antagonist DM96EJ1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DM96EJ1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DM96F8U DI DM96F8U DM96F8U DN A-867744 DM96F8U TI TTLA931 DM96F8U TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DM96F8U MA Modulator (allosteric modulator) DM96F8U RN In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methy... J Pharmacol Exp Ther. 2009 Jul;330(1):257-67. DM96F8U RU https://pubmed.ncbi.nlm.nih.gov/19389923 DM96F8U DI DM96F8U DM96F8U DN A-867744 DM96F8U TI TTH18TF DM96F8U TN Muscarinic acetylcholine receptor M5 (CHRM5) DM96F8U MA Blocker (channel blocker) DM96F8U RN In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methy... J Pharmacol Exp Ther. 2009 Jul;330(1):257-67. DM96F8U RU https://pubmed.ncbi.nlm.nih.gov/19389923 DM96F8U DI DM96F8U DM96F8U DN A-867744 DM96F8U TI TT5KPZR DM96F8U TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM96F8U MA Blocker (channel blocker) DM96F8U RN In vitro pharmacological characterization of a novel allosteric modulator of alpha 7 neuronal acetylcholine receptor, 4-(5-(4-chlorophenyl)-2-methy... J Pharmacol Exp Ther. 2009 Jul;330(1):257-67. DM96F8U RU https://pubmed.ncbi.nlm.nih.gov/19389923 DM96FQ2 DI DM96FQ2 DM96FQ2 DN VU0463597 DM96FQ2 TI TT8A9EF DM96FQ2 TN Metabotropic glutamate receptor 3 (mGluR3) DM96FQ2 MA Modulator (allosteric modulator) DM96FQ2 RN Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3921-5. DM96FQ2 RU https://pubmed.ncbi.nlm.nih.gov/22607673 DM96FTS DI DM96FTS DM96FTS DN XGP-110 DM96FTS TI TTVKILB DM96FTS TN Prostaglandin G/H synthase 2 (COX-2) DM96FTS MA Inhibitor DM96FTS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1376). DM96FTS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376 DM96LBV DI DM96LBV DM96LBV DN Adenosine-5-Diphosphoribose DM96LBV TI TTCNGJ5 DM96LBV TN Candida Elongation factor 2 (Candi EFT2) DM96LBV MA Inhibitor DM96LBV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM96LBV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM96SPJ DI DM96SPJ DM96SPJ DN L-767679 DM96SPJ TI TTJA1ZO DM96SPJ TN ITGB3 messenger RNA (ITGB3 mRNA) DM96SPJ MA Inhibitor DM96SPJ RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DM96SPJ RU https://pubmed.ncbi.nlm.nih.gov/10999999 DM96X2U DI DM96X2U DM96X2U DN NSC-99495 DM96X2U TI TTJLP0R DM96X2U TN Quinone reductase 2 (NQO2) DM96X2U MA Inhibitor DM96X2U RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM96X2U RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM96XYI DI DM96XYI DM96XYI DN (S)-2-Amino-4-methyl-pentane-1-thiol DM96XYI TI TTPHMWB DM96XYI TN Aminopeptidase N (ANPEP) DM96XYI MA Inhibitor DM96XYI RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DM96XYI RU https://pubmed.ncbi.nlm.nih.gov/10386926 DM96YR2 DI DM96YR2 DM96YR2 DN CCNCSSKWCRAHSRCC DM96YR2 TI TT84DRB DM96YR2 TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DM96YR2 MA Inhibitor DM96YR2 RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DM96YR2 RU https://pubmed.ncbi.nlm.nih.gov/17724025 DM974E5 DI DM974E5 DM974E5 DN 3-(2,5-Dimethyl-phenyl)-1-propyl-piperidine DM974E5 TI TTEX248 DM974E5 TN Dopamine D2 receptor (D2R) DM974E5 MA Inhibitor DM974E5 RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DM974E5 RU https://pubmed.ncbi.nlm.nih.gov/9836610 DM974LP DI DM974LP DM974LP DN (-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride DM974LP TI TTEX248 DM974LP TN Dopamine D2 receptor (D2R) DM974LP MA Inhibitor DM974LP RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DM974LP RU https://pubmed.ncbi.nlm.nih.gov/1431946 DM974LP DI DM974LP DM974LP DN (-)-(1S,1'R)-O,O-dimethylgrisbine hydrochloride DM974LP TI TTZFYLI DM974LP TN Dopamine D1 receptor (D1R) DM974LP MA Inhibitor DM974LP RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DM974LP RU https://pubmed.ncbi.nlm.nih.gov/1431946 DM97B2G DI DM97B2G DM97B2G DN 4-Methoxy-2-phenyl-2H-pyrazolo[4,3-c]quinoline DM97B2G TI TTJFY5U DM97B2G TN Adenosine A3 receptor (ADORA3) DM97B2G MA Inhibitor DM97B2G RN New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):5001-8. DM97B2G RU https://pubmed.ncbi.nlm.nih.gov/16033279 DM97DJL DI DM97DJL DM97DJL DN Acetic acid 2-hept-2-ynylsulfanyl-phenyl ester DM97DJL TI TT8NGED DM97DJL TN Prostaglandin G/H synthase 1 (COX-1) DM97DJL MA Inhibitor DM97DJL RN Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18. DM97DJL RU https://pubmed.ncbi.nlm.nih.gov/9822550 DM97GFB DI DM97GFB DM97GFB DN (2,5-Diphenyl-furan-3-yl)-phenyl-methanone DM97GFB TI TTZ97H5 DM97GFB TN Phosphodiesterase 4A (PDE4A) DM97GFB MA Inhibitor DM97GFB RN Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6. DM97GFB RU https://pubmed.ncbi.nlm.nih.gov/10091677 DM97H52 DI DM97H52 DM97H52 DN N5-[4-(2-Oxo-3-phenylpropoxy)phenyl]-L-glutamine DM97H52 TI TTXZEAJ DM97H52 TN Leukotriene A-4 hydrolase (LTA4H) DM97H52 MA Inhibitor DM97H52 RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DM97H52 RU https://pubmed.ncbi.nlm.nih.gov/18394906 DM97MGE DI DM97MGE DM97MGE DN N-(2-hydroxyethyl)linoleoylamide DM97MGE TI TTDP1UC DM97MGE TN Fatty acid amide hydrolase (FAAH) DM97MGE MA Inhibitor DM97MGE RN Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg Med Chem. 2009 Jan 1;17(1):49-56. DM97MGE RU https://pubmed.ncbi.nlm.nih.gov/19054678 DM97NBO DI DM97NBO DM97NBO DN LY466195 DM97NBO TI TT0MYE2 DM97NBO TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM97NBO MA Antagonist DM97NBO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DM97NBO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DM97Q6T DI DM97Q6T DM97Q6T DN N-(2-(4-chlorobenzyloxy)-5-bromobenzyl)ethanamine DM97Q6T TI TT2CEJG DM97Q6T TN C-C chemokine receptor type 5 (CCR5) DM97Q6T MA Inhibitor DM97Q6T RN CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1883-7. DM97Q6T RU https://pubmed.ncbi.nlm.nih.gov/17314043 DM97STY DI DM97STY DM97STY DN KNI-10369 DM97STY TI TTXMNHO DM97STY TN Plasmodium Plasmepsin 2 (Malaria PLA2) DM97STY MA Inhibitor DM97STY RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DM97STY RU https://pubmed.ncbi.nlm.nih.gov/18952439 DM97W5T DI DM97W5T DM97W5T DN (O10eq)-guanidino acetylryanodine DM97W5T TI TTU5CIX DM97W5T TN Ryanodine receptor 1 (RYR1) DM97W5T MA Inhibitor DM97W5T RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DM97W5T RU https://pubmed.ncbi.nlm.nih.gov/8388466 DM97XZ1 DI DM97XZ1 DM97XZ1 DN 5,6,8-Trimethoxy-4-methylquinolin-2(1H)-one DM97XZ1 TI TTJLP0R DM97XZ1 TN Quinone reductase 2 (NQO2) DM97XZ1 MA Inhibitor DM97XZ1 RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DM97XZ1 RU https://pubmed.ncbi.nlm.nih.gov/19265439 DM97ZHX DI DM97ZHX DM97ZHX DN RU85493 DM97ZHX TI TT6PKBN DM97ZHX TN Proto-oncogene c-Src (SRC) DM97ZHX MA Inhibitor DM97ZHX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM97ZHX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM983QP DI DM983QP DM983QP DN CV-4093 DM983QP TI TT7RGTM DM983QP TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DM983QP MA Inhibitor DM983QP RN Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406. DM983QP RU https://pubmed.ncbi.nlm.nih.gov/2552119 DM983QP DI DM983QP DM983QP DN CV-4093 DM983QP TI TTZIFHC DM983QP TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DM983QP MA Inhibitor DM983QP RN Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. J Med Chem. 1989 Oct;32(10):2399-406. DM983QP RU https://pubmed.ncbi.nlm.nih.gov/2552119 DM98CSW DI DM98CSW DM98CSW DN Glionitrin A DM98CSW TI TTPF2QI DM98CSW TN Caspase-3 (CASP3) DM98CSW MA Modulator DM98CSW RN Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86. DM98CSW RU https://pubmed.ncbi.nlm.nih.gov/24583858 DM98CSW DI DM98CSW DM98CSW DN Glionitrin A DM98CSW TI TTB6T7O DM98CSW TN Caspase-9 (CASP9) DM98CSW MA Modulator DM98CSW RN Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86. DM98CSW RU https://pubmed.ncbi.nlm.nih.gov/24583858 DM98CSW DI DM98CSW DM98CSW DN Glionitrin A DM98CSW TI TTEVCT0 DM98CSW TN Caspase-8 (CASP8) DM98CSW MA Modulator DM98CSW RN Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86. DM98CSW RU https://pubmed.ncbi.nlm.nih.gov/24583858 DM98EQX DI DM98EQX DM98EQX DN 5-Methoxy-N-phenylbenzo[d]oxazol-2-amine DM98EQX TI TT2J34L DM98EQX TN Arachidonate 5-lipoxygenase (5-LOX) DM98EQX MA Inhibitor DM98EQX RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DM98EQX RU https://pubmed.ncbi.nlm.nih.gov/20870413 DM98F0U DI DM98F0U DM98F0U DN 1-[2-(trityloxy)ethoxymethyl]uracil DM98F0U TI TTY8KJS DM98F0U TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DM98F0U MA Inhibitor DM98F0U RN Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95. DM98F0U RU https://pubmed.ncbi.nlm.nih.gov/16821778 DM98FQO DI DM98FQO DM98FQO DN 6-Methoxy-4,9-dihydro-3H-beta-carboline DM98FQO TI TTGP7BY DM98FQO TN Monoamine oxidase type B (MAO-B) DM98FQO MA Inhibitor DM98FQO RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM98FQO RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM98FQO DI DM98FQO DM98FQO DN 6-Methoxy-4,9-dihydro-3H-beta-carboline DM98FQO TI TT3WG5C DM98FQO TN Monoamine oxidase type A (MAO-A) DM98FQO MA Inhibitor DM98FQO RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DM98FQO RU https://pubmed.ncbi.nlm.nih.gov/15013010 DM98IOX DI DM98IOX DM98IOX DN Pterin-6-Yl-Methyl-Monophosphate DM98IOX TI TT4ILYC DM98IOX TN Bacterial Dihydropteroate synthetase (Bact folP) DM98IOX MA Inhibitor DM98IOX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM98IOX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM98L2X DI DM98L2X DM98L2X DN (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DM98L2X TI TTWG9A4 DM98L2X TN Adrenergic receptor alpha-2A (ADRA2A) DM98L2X MA Inhibitor DM98L2X RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM98L2X RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM98L2X DI DM98L2X DM98L2X DN (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DM98L2X TI TTWM4TY DM98L2X TN Adrenergic receptor alpha-2B (ADRA2B) DM98L2X MA Inhibitor DM98L2X RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM98L2X RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM98L2X DI DM98L2X DM98L2X DN (R)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DM98L2X TI TT2NUT5 DM98L2X TN Adrenergic receptor alpha-2C (ADRA2C) DM98L2X MA Inhibitor DM98L2X RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DM98L2X RU https://pubmed.ncbi.nlm.nih.gov/8784452 DM98MXT DI DM98MXT DM98MXT DN [2-(Benzoimidazol-1-yl)ethyl]-bisphosphonic acid DM98MXT TI TTIKWV4 DM98MXT TN Geranyltranstransferase (FDPS) DM98MXT MA Inhibitor DM98MXT RN Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7. DM98MXT RU https://pubmed.ncbi.nlm.nih.gov/18937434 DM98OEQ DI DM98OEQ DM98OEQ DN 5-hydroxy-1H-indole-3-acetic acid DM98OEQ TI TTGTQHC DM98OEQ TN DNA topoisomerase I (TOP1) DM98OEQ MA Binder DM98OEQ RN Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11. DM98OEQ RU https://pubmed.ncbi.nlm.nih.gov/9026436 DM98VFW DI DM98VFW DM98VFW DN A-286982 DM98VFW TI TT48WR6 DM98VFW TN Integrin alpha-L (ITGAL) DM98VFW MA Inhibitor DM98VFW RN Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. DM98VFW RU https://pubmed.ncbi.nlm.nih.gov/20655213 DM98VFW DI DM98VFW DM98VFW DN A-286982 DM98VFW TI TTIJWR7 DM98VFW TN Integrin beta-2 (ITGB2) DM98VFW MA Inhibitor DM98VFW RN Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 2. Mechanism o... J Med Chem. 2001 Apr 12;44(8):1202-10. DM98VFW RU https://pubmed.ncbi.nlm.nih.gov/11312920 DM98VFW DI DM98VFW DM98VFW DN A-286982 DM98VFW TI TTA1L39 DM98VFW TN ICAM1 messenger RNA (ICAM1 mRNA) DM98VFW MA Inhibitor DM98VFW RN Discovery of tetrahydroisoquinoline (THIQ) derivatives as potent and orally bioavailable LFA-1/ICAM-1 antagonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5269-73. DM98VFW RU https://pubmed.ncbi.nlm.nih.gov/20655213 DM98VMZ DI DM98VMZ DM98VMZ DN NS-11757 DM98VMZ TI TTP835K DM98VMZ TN ATP-binding cassette transporter C8 (ABCC8) DM98VMZ MA Modulator DM98VMZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2944). DM98VMZ RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2944 DM98WVL DI DM98WVL DM98WVL DN 2-(4-Piperidin-1-ylmethylphenoxy)benzothiazole DM98WVL TI TTXZEAJ DM98WVL TN Leukotriene A-4 hydrolase (LTA4H) DM98WVL MA Inhibitor DM98WVL RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DM98WVL RU https://pubmed.ncbi.nlm.nih.gov/18588282 DM9A1RY DI DM9A1RY DM9A1RY DN MORPHICEPTIN DM9A1RY TI TTKWM86 DM9A1RY TN Opioid receptor mu (MOP) DM9A1RY MA Inhibitor DM9A1RY RN Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600. DM9A1RY RU https://pubmed.ncbi.nlm.nih.gov/20692738 DM9AEF0 DI DM9AEF0 DM9AEF0 DN 4-(4-chlorobenzyl)phthalazin-1(2H)-one DM9AEF0 TI TT34BHT DM9AEF0 TN Adrenergic receptor alpha-1D (ADRA1D) DM9AEF0 MA Inhibitor DM9AEF0 RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DM9AEF0 RU https://pubmed.ncbi.nlm.nih.gov/16513345 DM9AEF0 DI DM9AEF0 DM9AEF0 DN 4-(4-chlorobenzyl)phthalazin-1(2H)-one DM9AEF0 TI TTNGILX DM9AEF0 TN Adrenergic receptor alpha-1A (ADRA1A) DM9AEF0 MA Inhibitor DM9AEF0 RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DM9AEF0 RU https://pubmed.ncbi.nlm.nih.gov/16513345 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TTHQPL7 DM9AFZ3 TN Carbonic anhydrase I (CA-I) DM9AFZ3 MA Inhibitor DM9AFZ3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2597). DM9AFZ3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2597 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TTUNARX DM9AFZ3 TN Carbonic anhydrase (CA) DM9AFZ3 MA Inhibitor DM9AFZ3 RN Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. DM9AFZ3 RU https://pubmed.ncbi.nlm.nih.gov/20605094 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TTZHA0O DM9AFZ3 TN Carbonic anhydrase IV (CA-IV) DM9AFZ3 MA Inhibitor DM9AFZ3 RN Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. DM9AFZ3 RU https://pubmed.ncbi.nlm.nih.gov/20605094 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TTSYM0R DM9AFZ3 TN Carbonic anhydrase XII (CA-XII) DM9AFZ3 MA Inhibitor DM9AFZ3 RN Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. DM9AFZ3 RU https://pubmed.ncbi.nlm.nih.gov/20605094 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TTANPDJ DM9AFZ3 TN Carbonic anhydrase II (CA-II) DM9AFZ3 MA Inhibitor DM9AFZ3 RN Synthesis, characterization and antiglaucoma activity of some novel pyrazole derivatives of 5-amino-1,3,4-thiadiazole-2-sulfonamide. Eur J Med Chem. 2010 Nov;45(11):4769-73. DM9AFZ3 RU https://pubmed.ncbi.nlm.nih.gov/20724038 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TTEYTKG DM9AFZ3 TN Carbonic anhydrase XIV (CA-XIV) DM9AFZ3 MA Inhibitor DM9AFZ3 RN Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. DM9AFZ3 RU https://pubmed.ncbi.nlm.nih.gov/20605094 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TT2LVK8 DM9AFZ3 TN Carbonic anhydrase IX (CA-IX) DM9AFZ3 MA Inhibitor DM9AFZ3 RN Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. DM9AFZ3 RU https://pubmed.ncbi.nlm.nih.gov/20605094 DM9AFZ3 DI DM9AFZ3 DM9AFZ3 DN CL-5343 DM9AFZ3 TI TTCFSPE DM9AFZ3 TN Carbonic anhydrase VI (CA-VI) DM9AFZ3 MA Inhibitor DM9AFZ3 RN Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a l... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. DM9AFZ3 RU https://pubmed.ncbi.nlm.nih.gov/20605094 DM9AGCV DI DM9AGCV DM9AGCV DN N-Methylleucine DM9AGCV TI TTQOVYA DM9AGCV TN C-X-C motif chemokine 10 (CXCL10) DM9AGCV MA Inhibitor DM9AGCV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9AGCV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9AJNW DI DM9AJNW DM9AJNW DN 3,3'-(1,3-Thiazol-2,4-diyl)diphenol DM9AJNW TI TTIWB6L DM9AJNW TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM9AJNW MA Inhibitor DM9AJNW RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DM9AJNW RU https://pubmed.ncbi.nlm.nih.gov/18855374 DM9AJSU DI DM9AJSU DM9AJSU DN (+/-)-3-(but-3-enyl)-1-pent-4-enoylazetidin-2-one DM9AJSU TI TTDP1UC DM9AJSU TN Fatty acid amide hydrolase (FAAH) DM9AJSU MA Inhibitor DM9AJSU RN 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7. DM9AJSU RU https://pubmed.ncbi.nlm.nih.gov/18547805 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTA76X0 DM9AKVR TN Short transient receptor potential channel 1 (TRPC1) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN TRPC1 and TRPC5 form a novel cation channel in mammalian brain. Neuron. 2001 Mar;29(3):645-55. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/11301024 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTMI6F5 DM9AKVR TN Transient receptor potential cation channel V1 (TRPV1) DM9AKVR MA Activator DM9AKVR RN 2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem. 2004 Aug 20;279(34):35741-8. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/15194687 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTRBT3W DM9AKVR TN Short transient receptor potential channel 6 (TRPC6) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491). DM9AKVR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TT32NQ1 DM9AKVR TN Short transient receptor potential channel 5 (TRPC5) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol. 2005 Jun;145(4):405-14. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/15806115 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTBECWA DM9AKVR TN Transient receptor potential cation channel V2 (TRPV2) DM9AKVR MA Activator DM9AKVR RN Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/17673572 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTNVC34 DM9AKVR TN Short transient receptor potential channel 3 (TRPC3) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN Mechanism of inhibition of TRPC cation channels by 2-aminoethoxydiphenylborane. Mol Pharmacol. 2005 Sep;68(3):758-62. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/15933213 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTV76RD DM9AKVR TN Long transient receptor potential channel 6 (TRPM6) DM9AKVR MA Activator DM9AKVR RN Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol. 2006 May;127(5):525-37. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/16636202 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTEBMN7 DM9AKVR TN Long transient receptor potential channel 2 (TRPM2) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN Inhibition of the transient receptor potential cation channel TRPM2 by 2-aminoethoxydiphenyl borate (2-APB). Br J Pharmacol. 2008 Mar;153(6):1324-30. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/18204483 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTBK14N DM9AKVR TN Transient receptor potential cation channel V6 (TRPV6) DM9AKVR MA Activator DM9AKVR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 512). DM9AKVR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=512 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TT946IA DM9AKVR TN Transient receptor potential cation channel V3 (TRPV3) DM9AKVR MA Activator DM9AKVR RN 2-aminoethoxydiphenyl borate activates and sensitizes the heat-gated ion channel TRPV3. J Neurosci. 2004 Jun 2;24(22):5177-82. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/15175387 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTO3TD8 DM9AKVR TN Long transient receptor potential channel 3 (TRPM3) DM9AKVR MA Inhibitor (gating inhibitor) DM9AKVR RN Block of TRPC5 channels by 2-aminoethoxydiphenyl borate: a differential, extracellular and voltage-dependent effect. Br J Pharmacol. 2005 Jun;145(4):405-14. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/15806115 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTXDKTO DM9AKVR TN Long transient receptor potential channel 8 (TRPM8) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN Effects of antagonists and heat on TRPM8 channel currents in dorsal root ganglion neuron activated by nociceptive cold stress and menthol. Neurochem Res. 2012 Feb;37(2):314-20. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/21964764 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTSJ9E7 DM9AKVR TN Short transient receptor potential channel 2 (TRPC2) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction. Neuron. 2003 Oct 30;40(3):551-61. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/14642279 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TT06GRA DM9AKVR TN Short transient receptor potential channel 7 (TRPC7) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 492). DM9AKVR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=492 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTFPVZO DM9AKVR TN Long transient receptor potential channel 7 (TRPM7) DM9AKVR MA Activator DM9AKVR RN LTRPC7 is a Mg.ATP-regulated divalent cation channel required for cell viability. Nature. 2001 May 31;411(6837):590-5. DM9AKVR RU https://pubmed.ncbi.nlm.nih.gov/11385574 DM9AKVR DI DM9AKVR DM9AKVR DN 2-APB DM9AKVR TI TTX0H5W DM9AKVR TN Short transient receptor potential channel 4 (TRPC4) DM9AKVR MA Blocker (channel blocker) DM9AKVR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 489). DM9AKVR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=489 DM9AL7W DI DM9AL7W DM9AL7W DN CV-1674 DM9AL7W TI TTNE7KG DM9AL7W TN Adenosine A2b receptor (ADORA2B) DM9AL7W MA Agonist DM9AL7W RN Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75. DM9AL7W RU https://pubmed.ncbi.nlm.nih.gov/9920286 DM9ATQ6 DI DM9ATQ6 DM9ATQ6 DN N-(2,6-Diflouro-Benzyl)-4-Sulfamoyl-Benzamide DM9ATQ6 TI TTANPDJ DM9ATQ6 TN Carbonic anhydrase II (CA-II) DM9ATQ6 MA Inhibitor DM9ATQ6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9ATQ6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9ATZ8 DI DM9ATZ8 DM9ATZ8 DN (N-(3-phenoxycinnamyl)-acetohydroxamic acid DM9ATZ8 TI TTSJ6Q4 DM9ATZ8 TN LOX-5 messenger RNA (ALOX5 mRNA) DM9ATZ8 MA Inhibitor DM9ATZ8 RN Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J Med Chem. 2009 Jun 11;52(11):3474-83. DM9ATZ8 RU https://pubmed.ncbi.nlm.nih.gov/19492852 DM9AW5U DI DM9AW5U DM9AW5U DN 3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine DM9AW5U TI TTSZLWK DM9AW5U TN Aromatase (CYP19A1) DM9AW5U MA Inhibitor DM9AW5U RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM9AW5U RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM9AW5U DI DM9AW5U DM9AW5U DN 3-[5-Methoxy-indan-(1E)-ylidenemethyl]-pyridine DM9AW5U TI TTIQUX7 DM9AW5U TN Steroid 11-beta-hydroxylase (CYP11B1) DM9AW5U MA Inhibitor DM9AW5U RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DM9AW5U RU https://pubmed.ncbi.nlm.nih.gov/15743198 DM9AZKE DI DM9AZKE DM9AZKE DN PFFFFF DM9AZKE TI TTFPQV7 DM9AZKE TN Galectin-3 (LGALS3) DM9AZKE MA Inhibitor DM9AZKE RN Discovery of galectin ligands in fully randomized combinatorial one-bead-one-compound (glyco)peptide libraries. Bioorg Med Chem Lett. 2007 Feb 1;17(3):793-8. DM9AZKE RU https://pubmed.ncbi.nlm.nih.gov/17095217 DM9B1ID DI DM9B1ID DM9B1ID DN N-(3,5-dichlorophenyl)-2-methyl-3-nitrobenzamide DM9B1ID TI TT3PQ2Y DM9B1ID TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM9B1ID MA Inhibitor DM9B1ID RN Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91. DM9B1ID RU https://pubmed.ncbi.nlm.nih.gov/17228860 DM9B6Y1 DI DM9B6Y1 DM9B6Y1 DN NORCANTHARIDIN DM9B6Y1 TI TTFLH0E DM9B6Y1 TN Serine/threonine PP1-alpha (PPP1CA) DM9B6Y1 MA Inhibitor DM9B6Y1 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM9B6Y1 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM9B6Y1 DI DM9B6Y1 DM9B6Y1 DN NORCANTHARIDIN DM9B6Y1 TI TTLONKX DM9B6Y1 TN PP2A B subunit isoform R5-alpha (PPP2R5A) DM9B6Y1 MA Inhibitor DM9B6Y1 RN Structure-activity relationship of cantharidin derivatives to protein phosphatases 1, 2A1, and 2B, Bioorg. Med. Chem. Lett. 7(14):1833-1836 (1997). DM9B6Y1 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003168 DM9BCDT DI DM9BCDT DM9BCDT DN 9-DEAZAINOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE DM9BCDT TI TTMCF1Y DM9BCDT TN Purine nucleoside phosphorylase (PNP) DM9BCDT MA Inhibitor DM9BCDT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9BCDT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9BDV2 DI DM9BDV2 DM9BDV2 DN 3-Phosphoglycerol DM9BDV2 TI TTNS6X4 DM9BDV2 TN Bacterial Triosephosphate isomerase (Bact TPI) DM9BDV2 MA Inhibitor DM9BDV2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9BDV2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9BDV2 DI DM9BDV2 DM9BDV2 DN 3-Phosphoglycerol DM9BDV2 TI TTHB48R DM9BDV2 TN Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ) DM9BDV2 MA Inhibitor DM9BDV2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9BDV2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9BE2S DI DM9BE2S DM9BE2S DN 2-(7-phenylheptanoyl)oxazole-4-carboxylic acid DM9BE2S TI TTDP1UC DM9BE2S TN Fatty acid amide hydrolase (FAAH) DM9BE2S MA Inhibitor DM9BE2S RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DM9BE2S RU https://pubmed.ncbi.nlm.nih.gov/18639454 DM9BIVL DI DM9BIVL DM9BIVL DN Quinoline-3-carboxylic acid adamantan-1-ylamide DM9BIVL TI TTVBPDM DM9BIVL TN Metabotropic glutamate receptor 1 (mGluR1) DM9BIVL MA Inhibitor DM9BIVL RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DM9BIVL RU https://pubmed.ncbi.nlm.nih.gov/18173231 DM9BJ27 DI DM9BJ27 DM9BJ27 DN Se-Ethyl-Isoselenourea DM9BJ27 TI TTCM4B3 DM9BJ27 TN Nitric-oxide synthase endothelial (NOS3) DM9BJ27 MA Inhibitor DM9BJ27 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9BJ27 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9BMDO DI DM9BMDO DM9BMDO DN CD154 DM9BMDO TI TTN6Y9A DM9BMDO TN CD40L receptor (CD40) DM9BMDO MA Binder DM9BMDO RN Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res. 2001 Mar;7(3):691-703. DM9BMDO RU https://pubmed.ncbi.nlm.nih.gov/11297266 DM9BPQ1 DI DM9BPQ1 DM9BPQ1 DN Methyl 6-(3-cyclohexylureido)hexanoate DM9BPQ1 TI TT7WVHI DM9BPQ1 TN Soluble epoxide hydrolase (EPHX2) DM9BPQ1 MA Inhibitor DM9BPQ1 RN Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44. DM9BPQ1 RU https://pubmed.ncbi.nlm.nih.gov/16908134 DM9BQTX DI DM9BQTX DM9BQTX DN PIK-75 DM9BQTX TI TTK3PY9 DM9BQTX TN DNA-dependent protein kinase catalytic (PRKDC) DM9BQTX MA Inhibitor DM9BQTX RN A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47. DM9BQTX RU https://pubmed.ncbi.nlm.nih.gov/16647110 DM9BQTX DI DM9BQTX DM9BQTX DN PIK-75 DM9BQTX TI TTHBTOP DM9BQTX TN PI3-kinase gamma (PIK3CG) DM9BQTX MA Inhibitor DM9BQTX RN Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. DM9BQTX RU https://pubmed.ncbi.nlm.nih.gov/17601739 DM9BQTX DI DM9BQTX DM9BQTX DN PIK-75 DM9BQTX TI TTTHBCA DM9BQTX TN PI3-kinase beta (PIK3CB) DM9BQTX MA Inhibitor DM9BQTX RN Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors. Bioorg Med Chem. 2007 Sep 1;15(17):5837-44. DM9BQTX RU https://pubmed.ncbi.nlm.nih.gov/17601739 DM9BS3W DI DM9BS3W DM9BS3W DN FR-193262 DM9BS3W TI TTOFYT1 DM9BS3W TN Prostacyclin receptor (PTGIR) DM9BS3W MA Inhibitor DM9BS3W RN Discovery of new diphenyloxazole derivatives containing a pyrrolidine ring: orally active prostacyclin mimetics. Part 2. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3279-83. DM9BS3W RU https://pubmed.ncbi.nlm.nih.gov/15935660 DM9BS50 DI DM9BS50 DM9BS50 DN Plumbagin DM9BS50 TI TT3PQ2Y DM9BS50 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM9BS50 MA Inhibitor DM9BS50 RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DM9BS50 RU https://pubmed.ncbi.nlm.nih.gov/10658902 DM9BS5L DI DM9BS5L DM9BS5L DN 7-(3,5-dihydroxyphenyl)naphthalene-1,3-diol DM9BS5L TI TTULVH8 DM9BS5L TN Tyrosinase (TYR) DM9BS5L MA Inhibitor DM9BS5L RN Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4. DM9BS5L RU https://pubmed.ncbi.nlm.nih.gov/17064896 DM9BTLC DI DM9BTLC DM9BTLC DN 3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol DM9BTLC TI TTJQOD7 DM9BTLC TN 5-HT 2A receptor (HTR2A) DM9BTLC MA Inhibitor DM9BTLC RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM9BTLC RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM9BTLC DI DM9BTLC DM9BTLC DN 3-(2-Dimethylamino-ethyl)-2-methyl-1H-indol-4-ol DM9BTLC TI TTWJBZ5 DM9BTLC TN 5-HT 2C receptor (HTR2C) DM9BTLC MA Inhibitor DM9BTLC RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DM9BTLC RU https://pubmed.ncbi.nlm.nih.gov/16061378 DM9BY8D DI DM9BY8D DM9BY8D DN 1-Oxazolo[4,5-b]pyridin-2-yl-octadec-9-yn-1-one DM9BY8D TI TTDP1UC DM9BY8D TN Fatty acid amide hydrolase (FAAH) DM9BY8D MA Inhibitor DM9BY8D RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DM9BY8D RU https://pubmed.ncbi.nlm.nih.gov/15771430 DM9BYVL DI DM9BYVL DM9BYVL DN 3-(3,4-Dimethylbenzyl)-4-hydroxy-2H-chromen-2-one DM9BYVL TI TT8XK6L DM9BYVL TN Quinone reductase 1 (NQO1) DM9BYVL MA Inhibitor DM9BYVL RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DM9BYVL RU https://pubmed.ncbi.nlm.nih.gov/19877692 DM9C0YZ DI DM9C0YZ DM9C0YZ DN 2,3-Dimethoxy-4'-amino-trans-stilbene DM9C0YZ TI TTSZLWK DM9C0YZ TN Aromatase (CYP19A1) DM9C0YZ MA Inhibitor DM9C0YZ RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DM9C0YZ RU https://pubmed.ncbi.nlm.nih.gov/20558073 DM9C7GP DI DM9C7GP DM9C7GP DN NCI-58425 DM9C7GP TI TTLUQ8E DM9C7GP TN Hormone sensitive lipase (LIPE) DM9C7GP MA Inhibitor DM9C7GP RN Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94. DM9C7GP RU https://pubmed.ncbi.nlm.nih.gov/18808096 DM9C8FP DI DM9C8FP DM9C8FP DN I-BRD9 DM9C8FP TI TTR7L5Y DM9C8FP TN Bromodomain-containing protein 9 (BRD9) DM9C8FP MA Inhibitor DM9C8FP RN Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition. J Med Chem. 2016 Feb 25;59(4):1425-39. DM9C8FP RU https://pubmed.ncbi.nlm.nih.gov/25856009 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TTISGCA DM9C8KQ TN Toll-like receptor 4 (TLR4) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TTVBE0F DM9C8KQ TN Virus Genome polyprotein (Viru POL) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TT8S9AV DM9C8KQ TN Lymphocyte antigen 96 (LY96) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TTSZDQU DM9C8KQ TN Lactotransferrin (LTF) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TTRFV0W DM9C8KQ TN Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TTO8QRU DM9C8KQ TN Group IIA phospholipase A2 (GIIA sPLA2) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TTPH97Y DM9C8KQ TN Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8KQ DI DM9C8KQ DM9C8KQ DN Lauric Acid DM9C8KQ TI TT2F3CD DM9C8KQ TN Hepatocyte nuclear factor 4-alpha (HNF4A) DM9C8KQ MA Inhibitor DM9C8KQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9C8KQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9C8NX DI DM9C8NX DM9C8NX DN Trichostatin A DM9C8NX TI TTBH0VX DM9C8NX TN Histone deacetylase (HDAC) DM9C8NX MA Inhibitor DM9C8NX RN Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Nov;168(1):7-15. DM9C8NX RU https://pubmed.ncbi.nlm.nih.gov/19538992 DM9CF45 DI DM9CF45 DM9CF45 DN thiadiazolidinone (TDZD) deriv. 6 DM9CF45 TI TTWME23 DM9CF45 TN Regulator of G-protein signaling 8 (RGS8) DM9CF45 MA Inhibitor DM9CF45 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2813). DM9CF45 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813 DM9CF45 DI DM9CF45 DM9CF45 DN thiadiazolidinone (TDZD) deriv. 6 DM9CF45 TI TTGTKX9 DM9CF45 TN Regulator of G-protein signaling 4 (RGS4) DM9CF45 MA Inhibitor DM9CF45 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2811). DM9CF45 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811 DM9CIJP DI DM9CIJP DM9CIJP DN AS70 DM9CIJP TI TTK25J1 DM9CIJP TN Adenosine A1 receptor (ADORA1) DM9CIJP MA Antagonist DM9CIJP RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DM9CIJP RU https://pubmed.ncbi.nlm.nih.gov/16219300 DM9CIJP DI DM9CIJP DM9CIJP DN AS70 DM9CIJP TI TTNE7KG DM9CIJP TN Adenosine A2b receptor (ADORA2B) DM9CIJP MA Antagonist DM9CIJP RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DM9CIJP RU https://pubmed.ncbi.nlm.nih.gov/16219300 DM9CM5V DI DM9CM5V DM9CM5V DN NSC-356820 DM9CM5V TI TTJLP0R DM9CM5V TN Quinone reductase 2 (NQO2) DM9CM5V MA Inhibitor DM9CM5V RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DM9CM5V RU https://pubmed.ncbi.nlm.nih.gov/21074425 DM9CV4P DI DM9CV4P DM9CV4P DN Sant7 DM9CV4P TI TT0E5SK DM9CV4P TN Interleukin 6 receptor (IL6R) DM9CV4P MA Antagonist DM9CV4P RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM9CV4P RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM9CV6S DI DM9CV6S DM9CV6S DN p-F-HHSiD DM9CV6S TI TTOXS3C DM9CV6S TN Muscarinic acetylcholine receptor (CHRM) DM9CV6S MA Antagonist DM9CV6S RN Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. Biochem Pharmacol. 1996 Aug 23;52(4):643-58. DM9CV6S RU https://pubmed.ncbi.nlm.nih.gov/8759038 DM9CV6S DI DM9CV6S DM9CV6S DN p-F-HHSiD DM9CV6S TI TTQ13Z5 DM9CV6S TN Muscarinic acetylcholine receptor M3 (CHRM3) DM9CV6S MA Antagonist DM9CV6S RN Stimulation of cyclic AMP accumulation and phosphoinositide hydrolysis by M3 muscarinic receptors in the rat peripheral lung. Biochem Pharmacol. 1996 Aug 23;52(4):643-58. DM9CV6S RU https://pubmed.ncbi.nlm.nih.gov/8759038 DM9CVX5 DI DM9CVX5 DM9CVX5 DN 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine DM9CVX5 TI TTAWNKZ DM9CVX5 TN Norepinephrine transporter (NET) DM9CVX5 MA Inhibitor DM9CVX5 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM9CVX5 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM9CVX5 DI DM9CVX5 DM9CVX5 DN 1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine DM9CVX5 TI TTSQIFT DM9CVX5 TN 5-HT 1A receptor (HTR1A) DM9CVX5 MA Inhibitor DM9CVX5 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DM9CVX5 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DM9D3F1 DI DM9D3F1 DM9D3F1 DN ISIS 113858 DM9D3F1 TI TTIX0ZU DM9D3F1 TN MEKK2 messenger RNA (MAP3K2 mRNA) DM9D3F1 RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DM9D3F1 RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DM9D3GM DI DM9D3GM DM9D3GM DN JWH-372 DM9D3GM TI TT6OEDT DM9D3GM TN Cannabinoid receptor 1 (CB1) DM9D3GM MA Inhibitor DM9D3GM RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM9D3GM RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM9D3GM DI DM9D3GM DM9D3GM DN JWH-372 DM9D3GM TI TTMSFAW DM9D3GM TN Cannabinoid receptor 2 (CB2) DM9D3GM MA Inhibitor DM9D3GM RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DM9D3GM RU https://pubmed.ncbi.nlm.nih.gov/16889960 DM9D805 DI DM9D805 DM9D805 DN Pyz7-D-Trp8-SRIF DM9D805 TI TTAE1BR DM9D805 TN Somatostatin receptor type 4 (SSTR4) DM9D805 MA Inhibitor DM9D805 RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DM9D805 RU https://pubmed.ncbi.nlm.nih.gov/15943475 DM9D8VH DI DM9D8VH DM9D8VH DN GFPTGG DM9D8VH TI TTPADOQ DM9D8VH TN HMG-CoA reductase (HMGCR) DM9D8VH MA Inhibitor DM9D8VH RN Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18. DM9D8VH RU https://pubmed.ncbi.nlm.nih.gov/17977732 DM9D8XC DI DM9D8XC DM9D8XC DN RS-1748 DM9D8XC TI TT7HQD0 DM9D8XC TN C-C chemokine receptor type 4 (CCR4) DM9D8XC MA Modulator DM9D8XC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61). DM9D8XC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61 DM9DA8O DI DM9DA8O DM9DA8O DN Rac-trans-N-oleoylcyclopropanolamide DM9DA8O TI TT6OEDT DM9DA8O TN Cannabinoid receptor 1 (CB1) DM9DA8O MA Inhibitor DM9DA8O RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DM9DA8O RU https://pubmed.ncbi.nlm.nih.gov/19361197 DM9DA8O DI DM9DA8O DM9DA8O DN Rac-trans-N-oleoylcyclopropanolamide DM9DA8O TI TTMSFAW DM9DA8O TN Cannabinoid receptor 2 (CB2) DM9DA8O MA Inhibitor DM9DA8O RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DM9DA8O RU https://pubmed.ncbi.nlm.nih.gov/19361197 DM9DBHU DI DM9DBHU DM9DBHU DN (R)-(+)-(4,5,6-trimethoxyindan-1-yl)methanamine DM9DBHU TI TTJQOD7 DM9DBHU TN 5-HT 2A receptor (HTR2A) DM9DBHU MA Inhibitor DM9DBHU RN C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74. DM9DBHU RU https://pubmed.ncbi.nlm.nih.gov/16821786 DM9DHNZ DI DM9DHNZ DM9DHNZ DN Cyclopentyl-(9-methyl-9H-purin-6-yl)-amine DM9DHNZ TI TTK25J1 DM9DHNZ TN Adenosine A1 receptor (ADORA1) DM9DHNZ MA Inhibitor DM9DHNZ RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DM9DHNZ RU https://pubmed.ncbi.nlm.nih.gov/1895305 DM9DURZ DI DM9DURZ DM9DURZ DN NVP-AAM077 DM9DURZ TI TTN9D8E DM9DURZ TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DM9DURZ MA Antagonist DM9DURZ RN Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006 Feb 1;26(5):1331-3. DM9DURZ RU https://pubmed.ncbi.nlm.nih.gov/16452656 DM9DURZ DI DM9DURZ DM9DURZ DN NVP-AAM077 DM9DURZ TI TTKJEMQ DM9DURZ TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DM9DURZ MA Antagonist DM9DURZ RN Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci. 2006 Feb 1;26(5):1331-3. DM9DURZ RU https://pubmed.ncbi.nlm.nih.gov/16452656 DM9DXHM DI DM9DXHM DM9DXHM DN RPR121154 DM9DXHM TI TTHXFA1 DM9DXHM TN C5a anaphylatoxin chemotactic receptor (C5AR1) DM9DXHM MA Antagonist DM9DXHM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 32). DM9DXHM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=32 DM9DXRL DI DM9DXRL DM9DXRL DN ICRF-154 DM9DXRL TI TT0IHXV DM9DXRL TN DNA topoisomerase II (TOP2) DM9DXRL MA Inhibitor DM9DXRL RN The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82. DM9DXRL RU https://pubmed.ncbi.nlm.nih.gov/12423680 DM9E2YI DI DM9E2YI DM9E2YI DN [3H]nicotine DM9E2YI TI TT5KPZR DM9E2YI TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DM9E2YI MA Agonist DM9E2YI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 465). DM9E2YI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=465 DM9E5LT DI DM9E5LT DM9E5LT DN 2-(N-tert-Butylamino)propiophenone DM9E5LT TI TTVBI8W DM9E5LT TN Dopamine transporter (DAT) DM9E5LT MA Inhibitor DM9E5LT RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DM9E5LT RU https://pubmed.ncbi.nlm.nih.gov/19821577 DM9E5LT DI DM9E5LT DM9E5LT DN 2-(N-tert-Butylamino)propiophenone DM9E5LT TI TTAWNKZ DM9E5LT TN Norepinephrine transporter (NET) DM9E5LT MA Inhibitor DM9E5LT RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DM9E5LT RU https://pubmed.ncbi.nlm.nih.gov/19821577 DM9EA3C DI DM9EA3C DM9EA3C DN 6-tert-butyl-m-cresol DM9EA3C TI TT946IA DM9EA3C TN Transient receptor potential cation channel V3 (TRPV3) DM9EA3C MA Activator DM9EA3C RN Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40. DM9EA3C RU https://pubmed.ncbi.nlm.nih.gov/17420775 DM9ECWN DI DM9ECWN DM9ECWN DN Mallotinic acid DM9ECWN TI TTE14XG DM9ECWN TN Squalene monooxygenase (SQLE) DM9ECWN MA Inhibitor DM9ECWN RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DM9ECWN RU https://pubmed.ncbi.nlm.nih.gov/11520216 DM9EK3T DI DM9EK3T DM9EK3T DN 1-(4-Cyano-thiazol-2-yl)-3-phenethyl-thiourea DM9EK3T TI TT84ETX DM9EK3T TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9EK3T MA Inhibitor DM9EK3T RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM9EK3T RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM9EN01 DI DM9EN01 DM9EN01 DN Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Ser13]SRIF DM9EN01 TI TTIND6G DM9EN01 TN Somatostatin receptor type 1 (SSTR1) DM9EN01 MA Inhibitor DM9EN01 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DM9EN01 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DM9ENXO DI DM9ENXO DM9ENXO DN 1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane DM9ENXO TI TTEX248 DM9ENXO TN Dopamine D2 receptor (D2R) DM9ENXO MA Inhibitor DM9ENXO RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DM9ENXO RU https://pubmed.ncbi.nlm.nih.gov/18313931 DM9ENXO DI DM9ENXO DM9ENXO DN 1,2-Bis-[R-(-)-apomorphine-2'-oxy]ethane DM9ENXO TI TTZFYLI DM9ENXO TN Dopamine D1 receptor (D1R) DM9ENXO MA Inhibitor DM9ENXO RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DM9ENXO RU https://pubmed.ncbi.nlm.nih.gov/18313931 DM9ERD6 DI DM9ERD6 DM9ERD6 DN ISOPILINE DM9ERD6 TI TTVBI8W DM9ERD6 TN Dopamine transporter (DAT) DM9ERD6 MA Inhibitor DM9ERD6 RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DM9ERD6 RU https://pubmed.ncbi.nlm.nih.gov/8676127 DM9ETMD DI DM9ETMD DM9ETMD DN 4-nitrophenyl-difluoromethanesulfonamide DM9ETMD TI TTANPDJ DM9ETMD TN Carbonic anhydrase II (CA-II) DM9ETMD MA Inhibitor DM9ETMD RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DM9ETMD RU https://pubmed.ncbi.nlm.nih.gov/16203142 DM9ETMD DI DM9ETMD DM9ETMD DN 4-nitrophenyl-difluoromethanesulfonamide DM9ETMD TI TT2LVK8 DM9ETMD TN Carbonic anhydrase IX (CA-IX) DM9ETMD MA Inhibitor DM9ETMD RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DM9ETMD RU https://pubmed.ncbi.nlm.nih.gov/16203142 DM9ETMD DI DM9ETMD DM9ETMD DN 4-nitrophenyl-difluoromethanesulfonamide DM9ETMD TI TTHQPL7 DM9ETMD TN Carbonic anhydrase I (CA-I) DM9ETMD MA Inhibitor DM9ETMD RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DM9ETMD RU https://pubmed.ncbi.nlm.nih.gov/16203142 DM9ETMD DI DM9ETMD DM9ETMD DN 4-nitrophenyl-difluoromethanesulfonamide DM9ETMD TI TTUNARX DM9ETMD TN Carbonic anhydrase (CA) DM9ETMD MA Inhibitor DM9ETMD RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DM9ETMD RU https://pubmed.ncbi.nlm.nih.gov/16203142 DM9EW2F DI DM9EW2F DM9EW2F DN 1,2-bis(2,5-difluorophenyl)-2-hydroxyethanone DM9EW2F TI TTMF541 DM9EW2F TN Liver carboxylesterase (CES1) DM9EW2F MA Inhibitor DM9EW2F RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM9EW2F RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM9EW7V DI DM9EW7V DM9EW7V DN Hexyl-trimethyl-ammonium DM9EW7V TI TT1RS9F DM9EW7V TN Acetylcholinesterase (AChE) DM9EW7V MA Inhibitor DM9EW7V RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DM9EW7V RU https://pubmed.ncbi.nlm.nih.gov/8978837 DM9EWN8 DI DM9EWN8 DM9EWN8 DN 1-Hydroxy-2-Amino-3-Cyclohexylpropane DM9EWN8 TI TTB2MXP DM9EWN8 TN Angiotensinogenase renin (REN) DM9EWN8 MA Inhibitor DM9EWN8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9EWN8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9FA26 DI DM9FA26 DM9FA26 DN Methyl 2-(7-phenylheptanoyl)oxazole-5-carboxylate DM9FA26 TI TTDP1UC DM9FA26 TN Fatty acid amide hydrolase (FAAH) DM9FA26 MA Inhibitor DM9FA26 RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DM9FA26 RU https://pubmed.ncbi.nlm.nih.gov/18630870 DM9FEB6 DI DM9FEB6 DM9FEB6 DN PMID30247903-Compound-General structure29 DM9FEB6 TI TT23XQV DM9FEB6 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DM9FEB6 MA Inhibitor DM9FEB6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM9FEB6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM9FEMV DI DM9FEMV DM9FEMV DN 3-cyano-N-(3-ethynylphenyl)-5-fluorobenzamide DM9FEMV TI TTHS256 DM9FEMV TN Metabotropic glutamate receptor 5 (mGluR5) DM9FEMV MA Inhibitor DM9FEMV RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DM9FEMV RU https://pubmed.ncbi.nlm.nih.gov/20598884 DM9FKSM DI DM9FKSM DM9FKSM DN 4-(1H-indol-3-yl)-1-morpholinobutan-1-one DM9FKSM TI TT2J34L DM9FKSM TN Arachidonate 5-lipoxygenase (5-LOX) DM9FKSM MA Inhibitor DM9FKSM RN Indole derivatives as potent inhibitors of 5-lipoxygenase: design, synthesis, biological evaluation, and molecular modeling. Bioorg Med Chem Lett. 2007 May 1;17(9):2414-20. DM9FKSM RU https://pubmed.ncbi.nlm.nih.gov/17336065 DM9FMUE DI DM9FMUE DM9FMUE DN 1,2-bis(2-fluorophenyl)ethane-1,2-dione DM9FMUE TI TTMF541 DM9FMUE TN Liver carboxylesterase (CES1) DM9FMUE MA Inhibitor DM9FMUE RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM9FMUE RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM9FNQ6 DI DM9FNQ6 DM9FNQ6 DN TIPPpsi DM9FNQ6 TI TT27RFC DM9FNQ6 TN Opioid receptor delta (OPRD1) DM9FNQ6 MA Antagonist DM9FNQ6 RN TIPP[psi]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity. J Med Chem. 1993 Oct 15;36(21):3182-7. DM9FNQ6 RU https://pubmed.ncbi.nlm.nih.gov/8230106 DM9FR3A DI DM9FR3A DM9FR3A DN ISIS 134565 DM9FR3A TI TTKW4ML DM9FR3A TN Caspase 6 messenger RNA (CASP6 mRNA) DM9FR3A RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DM9FR3A RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DM9FYPM DI DM9FYPM DM9FYPM DN ST-5732 DM9FYPM TI TTBH0VX DM9FYPM TN Histone deacetylase (HDAC) DM9FYPM MA Inhibitor DM9FYPM RN Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3. DM9FYPM RU https://pubmed.ncbi.nlm.nih.gov/19359173 DM9FZ0B DI DM9FZ0B DM9FZ0B DN 2-methyl-7-(pyridin-3-yl)quinoline DM9FZ0B TI TTHS256 DM9FZ0B TN Metabotropic glutamate receptor 5 (mGluR5) DM9FZ0B MA Inhibitor DM9FZ0B RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DM9FZ0B RU https://pubmed.ncbi.nlm.nih.gov/17590335 DM9G3UD DI DM9G3UD DM9G3UD DN SQ-29548 DM9G3UD TI TT2O84V DM9G3UD TN Thromboxane A2 receptor (TBXA2R) DM9G3UD MA Inhibitor DM9G3UD RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM9G3UD RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM9G7B6 DI DM9G7B6 DM9G7B6 DN 2-(3-Bromo-phenyl)-6-methyl-chromen-4-one DM9G7B6 TI TTNJYV2 DM9G7B6 TN Gamma-aminobutyric acid receptor (GAR) DM9G7B6 MA Inhibitor DM9G7B6 RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DM9G7B6 RU https://pubmed.ncbi.nlm.nih.gov/12213060 DM9G7DT DI DM9G7DT DM9G7DT DN 1,2-Dihydro-indazol-3-one DM9G7DT TI TT2J34L DM9G7DT TN Arachidonate 5-lipoxygenase (5-LOX) DM9G7DT MA Inhibitor DM9G7DT RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DM9G7DT RU https://pubmed.ncbi.nlm.nih.gov/1848292 DM9GDP5 DI DM9GDP5 DM9GDP5 DN JNJ-10198409 DM9GDP5 TI TTI7421 DM9GDP5 TN Platelet-derived growth factor receptor beta (PDGFRB) DM9GDP5 MA Inhibitor DM9GDP5 RN (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73. DM9GDP5 RU https://pubmed.ncbi.nlm.nih.gov/16366598 DM9GDP5 DI DM9GDP5 DM9GDP5 DN JNJ-10198409 DM9GDP5 TI TT2B9KF DM9GDP5 TN Fyn tyrosine protein kinase (FYN) DM9GDP5 MA Inhibitor DM9GDP5 RN (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73. DM9GDP5 RU https://pubmed.ncbi.nlm.nih.gov/16366598 DM9GDP5 DI DM9GDP5 DM9GDP5 DN JNJ-10198409 DM9GDP5 TI TT6PKBN DM9GDP5 TN Proto-oncogene c-Src (SRC) DM9GDP5 MA Inhibitor DM9GDP5 RN (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73. DM9GDP5 RU https://pubmed.ncbi.nlm.nih.gov/16366598 DM9GDP5 DI DM9GDP5 DM9GDP5 DN JNJ-10198409 DM9GDP5 TI TT3PJMV DM9GDP5 TN Tyrosine-protein kinase ABL1 (ABL) DM9GDP5 MA Inhibitor DM9GDP5 RN (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73. DM9GDP5 RU https://pubmed.ncbi.nlm.nih.gov/16366598 DM9GDP5 DI DM9GDP5 DM9GDP5 DN JNJ-10198409 DM9GDP5 TI TT860QF DM9GDP5 TN LCK tyrosine protein kinase (LCK) DM9GDP5 MA Inhibitor DM9GDP5 RN (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73. DM9GDP5 RU https://pubmed.ncbi.nlm.nih.gov/16366598 DM9GDP5 DI DM9GDP5 DM9GDP5 DN JNJ-10198409 DM9GDP5 TI TT8FYO9 DM9GDP5 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM9GDP5 MA Inhibitor DM9GDP5 RN (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73. DM9GDP5 RU https://pubmed.ncbi.nlm.nih.gov/16366598 DM9GFOM DI DM9GFOM DM9GFOM DN ProstaRex DM9GFOM TI TTS78AZ DM9GFOM TN Prostate specific antigen (KLK3) DM9GFOM MA Modulator DM9GFOM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DM9GFOM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DM9GJAY DI DM9GJAY DM9GJAY DN 6-iodo-4'-methylaminoflavone DM9GJAY TI TTE4KHA DM9GJAY TN Amyloid beta A4 protein (APP) DM9GJAY MA Inhibitor DM9GJAY RN Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60. DM9GJAY RU https://pubmed.ncbi.nlm.nih.gov/16279784 DM9GM1H DI DM9GM1H DM9GM1H DN 3-isobutyl-8-pyrrolidinoxanthine DM9GM1H TI TTNE7KG DM9GM1H TN Adenosine A2b receptor (ADORA2B) DM9GM1H MA Antagonist DM9GM1H RN Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol. 2001 Nov 1;62(9):1163-73. DM9GM1H RU https://pubmed.ncbi.nlm.nih.gov/11705449 DM9GO8Y DI DM9GO8Y DM9GO8Y DN 3,3'-(1,2,4,5-tetrazine-3,6-diyl)diphenol DM9GO8Y TI TTIWB6L DM9GO8Y TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM9GO8Y MA Inhibitor DM9GO8Y RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DM9GO8Y RU https://pubmed.ncbi.nlm.nih.gov/18855374 DM9GOAV DI DM9GOAV DM9GOAV DN U101958 DM9GOAV TI TTE0A2F DM9GOAV TN Dopamine D4 receptor (D4R) DM9GOAV MA Antagonist DM9GOAV RN Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Eur J Pharmacol. 1997 Mar 19;322(2-3):283-6. DM9GOAV RU https://pubmed.ncbi.nlm.nih.gov/9098699 DM9GOTA DI DM9GOTA DM9GOTA DN 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide DM9GOTA TI TTUNARX DM9GOTA TN Carbonic anhydrase (CA) DM9GOTA MA Inhibitor DM9GOTA RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM9GOTA RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM9GOTA DI DM9GOTA DM9GOTA DN 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide DM9GOTA TI TTHQPL7 DM9GOTA TN Carbonic anhydrase I (CA-I) DM9GOTA MA Inhibitor DM9GOTA RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM9GOTA RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM9GOTA DI DM9GOTA DM9GOTA DN 4-(2-Phenylacetamido)-3-chlorobenzenesulfonamide DM9GOTA TI TTANPDJ DM9GOTA TN Carbonic anhydrase II (CA-II) DM9GOTA MA Inhibitor DM9GOTA RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM9GOTA RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM9GPAU DI DM9GPAU DM9GPAU DN GSK2033 DM9GPAU TI TTXA6PH DM9GPAU TN Oxysterols receptor LXR-beta (NR1H2) DM9GPAU MA Antagonist DM9GPAU RN Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6. DM9GPAU RU https://pubmed.ncbi.nlm.nih.gov/20345102 DM9GPAU DI DM9GPAU DM9GPAU DN GSK2033 DM9GPAU TI TTECBXN DM9GPAU TN Oxysterols receptor LXR-alpha (NR1H3) DM9GPAU MA Antagonist DM9GPAU RN Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J Med Chem. 2010 Apr 22;53(8):3412-6. DM9GPAU RU https://pubmed.ncbi.nlm.nih.gov/20345102 DM9GQ1U DI DM9GQ1U DM9GQ1U DN 2-Amino-6-(3-cyano-benzenesulfonyl)-benzonitrile DM9GQ1U TI TT84ETX DM9GQ1U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9GQ1U MA Inhibitor DM9GQ1U RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM9GQ1U RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM9GQP0 DI DM9GQP0 DM9GQP0 DN RU79072 DM9GQP0 TI TT6PKBN DM9GQP0 TN Proto-oncogene c-Src (SRC) DM9GQP0 MA Inhibitor DM9GQP0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9GQP0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9GRN8 DI DM9GRN8 DM9GRN8 DN 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione DM9GRN8 TI TTSKMI8 DM9GRN8 TN Phosphodiesterase 4D (PDE4D) DM9GRN8 MA Inhibitor DM9GRN8 RN Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44. DM9GRN8 RU https://pubmed.ncbi.nlm.nih.gov/1331453 DM9GRN8 DI DM9GRN8 DM9GRN8 DN 1-Butyl-3-methyl-3,7-dihydro-purine-2,6-dione DM9GRN8 TI TTZ97H5 DM9GRN8 TN Phosphodiesterase 4A (PDE4A) DM9GRN8 MA Inhibitor DM9GRN8 RN Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992 Oct 30;35(22):4039-44. DM9GRN8 RU https://pubmed.ncbi.nlm.nih.gov/1331453 DM9GXFJ DI DM9GXFJ DM9GXFJ DN Alpha-Aminoisobutyric Acid DM9GXFJ TI TT64REZ DM9GXFJ TN Neuropeptide Y (NPY) DM9GXFJ MA Inhibitor DM9GXFJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9GXFJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9GXFJ DI DM9GXFJ DM9GXFJ DN Alpha-Aminoisobutyric Acid DM9GXFJ TI TTA7YIZ DM9GXFJ TN Corticoliberin (CRH) DM9GXFJ MA Inhibitor DM9GXFJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9GXFJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9GXYV DI DM9GXYV DM9GXYV DN Ro-3201195 DM9GXYV TI TTQBR95 DM9GXYV TN Stress-activated protein kinase 2a (p38 alpha) DM9GXYV MA Inhibitor DM9GXYV RN Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3745-8. DM9GXYV RU https://pubmed.ncbi.nlm.nih.gov/18539026 DM9GY7O DI DM9GY7O DM9GY7O DN [3H]DPCPX DM9GY7O TI TTNE7KG DM9GY7O TN Adenosine A2b receptor (ADORA2B) DM9GY7O MA Antagonist DM9GY7O RN [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem Pharmacol. 2004 Jul 15;68(2):305-12. DM9GY7O RU https://pubmed.ncbi.nlm.nih.gov/15194002 DM9GY7O DI DM9GY7O DM9GY7O DN [3H]DPCPX DM9GY7O TI TTK25J1 DM9GY7O TN Adenosine A1 receptor (ADORA1) DM9GY7O MA Antagonist DM9GY7O RN Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol. 2001 Nov 1;62(9):1163-73. DM9GY7O RU https://pubmed.ncbi.nlm.nih.gov/11705449 DM9H34M DI DM9H34M DM9H34M DN Benzodiazepine DM9H34M TI TTPTXIN DM9H34M TN Translocator protein (TSPO) DM9H34M MA Agonist DM9H34M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DM9H34M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DM9H3W8 DI DM9H3W8 DM9H3W8 DN N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine DM9H3W8 TI TTJFY5U DM9H3W8 TN Adenosine A3 receptor (ADORA3) DM9H3W8 MA Inhibitor DM9H3W8 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM9H3W8 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM9H3W8 DI DM9H3W8 DM9H3W8 DN N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine DM9H3W8 TI TTM2AOE DM9H3W8 TN Adenosine A2a receptor (ADORA2A) DM9H3W8 MA Inhibitor DM9H3W8 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM9H3W8 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM9H3W8 DI DM9H3W8 DM9H3W8 DN N6-methoxy-2-[(4-pyridinyl)ethynyl]adenosine DM9H3W8 TI TTK25J1 DM9H3W8 TN Adenosine A1 receptor (ADORA1) DM9H3W8 MA Inhibitor DM9H3W8 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DM9H3W8 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DM9H6LZ DI DM9H6LZ DM9H6LZ DN PMID20299227C20 DM9H6LZ TI TTFQEO5 DM9H6LZ TN Squalene synthetase (FDFT1) DM9H6LZ MA Inhibitor DM9H6LZ RN Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). Bioorg Med Chem. 2010 Apr 1;18(7):2428-38. DM9H6LZ RU https://pubmed.ncbi.nlm.nih.gov/20299227 DM9H7AZ DI DM9H7AZ DM9H7AZ DN AMG-126737 DM9H7AZ TI TTM1TDX DM9H7AZ TN Tryptase alpha/beta-1 (Tryptase) DM9H7AZ MA Inhibitor DM9H7AZ RN Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000. DM9H7AZ RU https://pubmed.ncbi.nlm.nih.gov/11823536 DM9H80P DI DM9H80P DM9H80P DN F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-CONH2 DM9H80P TI TTNT7K8 DM9H80P TN Nociceptin receptor (OPRL1) DM9H80P MA Inhibitor DM9H80P RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DM9H80P RU https://pubmed.ncbi.nlm.nih.gov/12431054 DM9HA8G DI DM9HA8G DM9HA8G DN S 0957 DM9HA8G TI TT1KPBZ DM9HA8G TN Glucose-6-phosphate translocase (SLC37A4) DM9HA8G MA Inhibitor DM9HA8G RN Identification of protein components of the microsomal glucose 6-phosphate transporter by photoaffinity labelling. Biochem J. 1999 May 1;339 ( Pt 3):629-38. DM9HA8G RU https://pubmed.ncbi.nlm.nih.gov/10215602 DM9HBY5 DI DM9HBY5 DM9HBY5 DN 6-Deoxy-Alpha-D-Glucose DM9HBY5 TI TTHCF4J DM9HBY5 TN Alpha-glucosidase (GLA) DM9HBY5 MA Inhibitor DM9HBY5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9HBY5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9HBY5 DI DM9HBY5 DM9HBY5 DN 6-Deoxy-Alpha-D-Glucose DM9HBY5 TI TTCGSZ4 DM9HBY5 TN Pancreatic alpha-amylase (AMY2A) DM9HBY5 MA Inhibitor DM9HBY5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9HBY5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9HG1Y DI DM9HG1Y DM9HG1Y DN DCG IV DM9HG1Y TI TTXJ47W DM9HG1Y TN Metabotropic glutamate receptor 2 (mGluR2) DM9HG1Y MA Agonist DM9HG1Y RN Attenuation of seizures induced by homocysteic acid in immature rats by metabotropic glutamate group II and group III receptor agonists. Brain Res. 2001 Jul 27;908(2):120-9. DM9HG1Y RU https://pubmed.ncbi.nlm.nih.gov/11454322 DM9HLXD DI DM9HLXD DM9HLXD DN Methyl 7-tert-butyl-9H-carbazole-3-carboxylate DM9HLXD TI TTBGTCW DM9HLXD TN Kinesin spindle messenger RNA (KIF11 mRNA) DM9HLXD MA Inhibitor DM9HLXD RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DM9HLXD RU https://pubmed.ncbi.nlm.nih.gov/20521839 DM9HMCS DI DM9HMCS DM9HMCS DN Ridine-5-carboxylic acid ethyl ester DM9HMCS TI TT06RH5 DM9HMCS TN GABA(A) receptor gamma-2 (GABRG2) DM9HMCS MA Inhibitor DM9HMCS RN Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73. DM9HMCS RU https://pubmed.ncbi.nlm.nih.gov/2573731 DM9HMCS DI DM9HMCS DM9HMCS DN Ridine-5-carboxylic acid ethyl ester DM9HMCS TI TTNJYV2 DM9HMCS TN Gamma-aminobutyric acid receptor (GAR) DM9HMCS MA Inhibitor DM9HMCS RN Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73. DM9HMCS RU https://pubmed.ncbi.nlm.nih.gov/2573731 DM9HMCS DI DM9HMCS DM9HMCS DN Ridine-5-carboxylic acid ethyl ester DM9HMCS TI TTZA1NY DM9HMCS TN GABA(A) receptor beta-2 (GABRB2) DM9HMCS MA Inhibitor DM9HMCS RN Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73. DM9HMCS RU https://pubmed.ncbi.nlm.nih.gov/2573731 DM9HMCS DI DM9HMCS DM9HMCS DN Ridine-5-carboxylic acid ethyl ester DM9HMCS TI TT1MPAY DM9HMCS TN GABA(A) receptor alpha-1 (GABRA1) DM9HMCS MA Inhibitor DM9HMCS RN Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents. J Med Chem. 1989 Dec;32(12):2561-73. DM9HMCS RU https://pubmed.ncbi.nlm.nih.gov/2573731 DM9HMP4 DI DM9HMP4 DM9HMP4 DN CFMTI DM9HMP4 TI TTVBPDM DM9HMP4 TN Metabotropic glutamate receptor 1 (mGluR1) DM9HMP4 MA Modulator (allosteric modulator) DM9HMP4 RN Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1,2,3-triazol-4-yl]-2,3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther. 2009 Jul;330(1):179-90. DM9HMP4 RU https://pubmed.ncbi.nlm.nih.gov/19359526 DM9HPG1 DI DM9HPG1 DM9HPG1 DN 2-N-Propargylamino-1-(4-methylthiophenyl)propane DM9HPG1 TI TT3ROYC DM9HPG1 TN Serotonin transporter (SERT) DM9HPG1 MA Inhibitor DM9HPG1 RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DM9HPG1 RU https://pubmed.ncbi.nlm.nih.gov/19717215 DM9HSQJ DI DM9HSQJ DM9HSQJ DN Prenyl pyrophosphate analogue DM9HSQJ TI TT7WZIJ DM9HSQJ TN CAAX farnesyltransferase beta (FNTB) DM9HSQJ MA Inhibitor DM9HSQJ RN Synthesis and evaluation of benzophenone-based photoaffinity labeling analogs of prenyl pyrophosphates containing stable amide linkages, Bioorg. Med. Chem. Lett. 7(16):2125-2130 (1997). DM9HSQJ RU http://www.sciencedirect.com/science/article/pii/S0960894X97003739 DM9HXPR DI DM9HXPR DM9HXPR DN 4-chloro-1H-indole-2,3-dione DM9HXPR TI TTMF541 DM9HXPR TN Liver carboxylesterase (CES1) DM9HXPR MA Inhibitor DM9HXPR RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DM9HXPR RU https://pubmed.ncbi.nlm.nih.gov/17378546 DM9I5Y0 DI DM9I5Y0 DM9I5Y0 DN Heberkinasa DM9I5Y0 TI TT2VCLI DM9I5Y0 TN Streptococcus Streptokinase (Stre-coc skc) DM9I5Y0 MA Modulator DM9I5Y0 RN Biological Activity Analysis of Native and Recombinant Streptokinase Using Clot Lysis and Chromogenic Substrate Assay DM9I5Y0 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813160 DM9IBHU DI DM9IBHU DM9IBHU DN Ado-P-Ch2-P-Ps-Ado DM9IBHU TI TTMS54D DM9IBHU TN Fragile histidine triad protein (FHIT) DM9IBHU MA Inhibitor DM9IBHU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9IBHU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9ICSA DI DM9ICSA DM9ICSA DN 1,2,3,4,6-penta-O-galloyl-D-glucopyranose DM9ICSA TI TTELIN2 DM9ICSA TN PTPN1 messenger RNA (PTPN1 mRNA) DM9ICSA MA Inhibitor DM9ICSA RN Bioactivity-guided isolation of 1,2,3,4,6-Penta-O-galloyl-D-glucopyranose from Paeonia lactiflora roots as a PTP1B inhibitor. J Nat Prod. 2010 Sep 24;73(9):1578-81. DM9ICSA RU https://pubmed.ncbi.nlm.nih.gov/20806783 DM9ID4T DI DM9ID4T DM9ID4T DN 7-((1H-imidazol-1-yl)methyl)isoquinoline DM9ID4T TI TTSZLWK DM9ID4T TN Aromatase (CYP19A1) DM9ID4T MA Inhibitor DM9ID4T RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DM9ID4T RU https://pubmed.ncbi.nlm.nih.gov/19072235 DM9IG2P DI DM9IG2P DM9IG2P DN Cantide + Cisplatin DM9IG2P TI TTQY2EJ DM9IG2P TN TERT messenger RNA (TERT mRNA) DM9IG2P RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DM9IG2P RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DM9IHFY DI DM9IHFY DM9IHFY DN 11-methyl-6,11-dihydro-5H-benzo[a]carbazol-9-ol DM9IHFY TI TTS64P2 DM9IHFY TN Androgen receptor (AR) DM9IHFY MA Inhibitor DM9IHFY RN Discovery of indole-containing tetracycles as a new scaffold for androgen receptor ligands. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3233-7. DM9IHFY RU https://pubmed.ncbi.nlm.nih.gov/16603353 DM9IHV6 DI DM9IHV6 DM9IHV6 DN 5-propyl-2'-deoxyuridine DM9IHV6 TI TTP3QRF DM9IHV6 TN Thymidine kinase 1 (TK1) DM9IHV6 MA Inhibitor DM9IHV6 RN Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. DM9IHV6 RU https://pubmed.ncbi.nlm.nih.gov/17438061 DM9IHYS DI DM9IHYS DM9IHYS DN 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine DM9IHYS TI TTAMQ62 DM9IHYS TN Cyclin A2 (CCNA2) DM9IHYS MA Inhibitor DM9IHYS RN 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22. DM9IHYS RU https://pubmed.ncbi.nlm.nih.gov/12482427 DM9IHYS DI DM9IHYS DM9IHYS DN 6-Cyclohexylmethoxy-pyrimidine-2,4,5-triamine DM9IHYS TI TT7HF4W DM9IHYS TN Cyclin-dependent kinase 2 (CDK2) DM9IHYS MA Inhibitor DM9IHYS RN 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22. DM9IHYS RU https://pubmed.ncbi.nlm.nih.gov/12482427 DM9IN0U DI DM9IN0U DM9IN0U DN BCH DM9IN0U TI TTPH2JB DM9IN0U TN Large neutral amino acids transporter 1 (SLC7A5) DM9IN0U MA Blocker DM9IN0U RN Amino acid transporter molecule as a drug target. Nippon Yakurigaku Zasshi. 1999 Oct;114 Suppl 1:11P-16P. DM9IN0U RU https://pubmed.ncbi.nlm.nih.gov/10629848 DM9IN4T DI DM9IN4T DM9IN4T DN Ac-[CFWKFC]-NH2 DM9IN4T TI TTW5UDX DM9IN4T TN Urotensin II receptor (UTS2R) DM9IN4T MA Inhibitor DM9IN4T RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DM9IN4T RU https://pubmed.ncbi.nlm.nih.gov/20043680 DM9IODG DI DM9IODG DM9IODG DN H-Phe-NH2 DM9IODG TI TTZPO1L DM9IODG TN Substance-P receptor (TACR1) DM9IODG MA Inhibitor DM9IODG RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DM9IODG RU https://pubmed.ncbi.nlm.nih.gov/20178322 DM9IPH4 DI DM9IPH4 DM9IPH4 DN CMPD-167 DM9IPH4 TI TT2CEJG DM9IPH4 TN C-C chemokine receptor type 5 (CCR5) DM9IPH4 MA Inhibitor DM9IPH4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3651). DM9IPH4 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3651 DM9IPTV DI DM9IPTV DM9IPTV DN N-Hydroxy-3-phenyl-acrylamide DM9IPTV TI TT2J34L DM9IPTV TN Arachidonate 5-lipoxygenase (5-LOX) DM9IPTV MA Inhibitor DM9IPTV RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DM9IPTV RU https://pubmed.ncbi.nlm.nih.gov/2308149 DM9IQXM DI DM9IQXM DM9IQXM DN RBI257 DM9IQXM TI TTE0A2F DM9IQXM TN Dopamine D4 receptor (D4R) DM9IQXM MA Antagonist DM9IQXM RN Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9. DM9IQXM RU https://pubmed.ncbi.nlm.nih.gov/15448188 DM9IU21 DI DM9IU21 DM9IU21 DN LY 165,163 DM9IU21 TI TTSQIFT DM9IU21 TN 5-HT 1A receptor (HTR1A) DM9IU21 MA Agonist DM9IU21 RN Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. DM9IU21 RU https://pubmed.ncbi.nlm.nih.gov/9760039 DM9IU21 DI DM9IU21 DM9IU21 DN LY 165,163 DM9IU21 TI TTJS8PY DM9IU21 TN 5-HT 6 receptor (HTR6) DM9IU21 MA Agonist DM9IU21 RN Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. DM9IU21 RU https://pubmed.ncbi.nlm.nih.gov/7680751 DM9IUSM DI DM9IUSM DM9IUSM DN AS-604850 DM9IUSM TI TTHBTOP DM9IUSM TN PI3-kinase gamma (PIK3CG) DM9IUSM MA Inhibitor DM9IUSM RN Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005 Sep;11(9):936-43. DM9IUSM RU https://pubmed.ncbi.nlm.nih.gov/16127437 DM9IZNP DI DM9IZNP DM9IZNP DN GSK-172981 DM9IZNP TI TTBPGLU DM9IZNP TN Neuromedin-K receptor (TACR3) DM9IZNP MA Antagonist DM9IZNP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 362). DM9IZNP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=362 DM9J2LT DI DM9J2LT DM9J2LT DN 8-(3-Azido-phenyl)-6-iodo-quinoline DM9J2LT TI TTZ97H5 DM9J2LT TN Phosphodiesterase 4A (PDE4A) DM9J2LT MA Inhibitor DM9J2LT RN Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3. DM9J2LT RU https://pubmed.ncbi.nlm.nih.gov/11052785 DM9J35R DI DM9J35R DM9J35R DN GNF-PF-2094 DM9J35R TI TTVG215 DM9J35R TN Debrisoquine 4-hydroxylase (CYP2D6) DM9J35R MA Inhibitor DM9J35R RN Synthesis and antiplasmodial activity of novel 2,4-diaminopyrimidines. Bioorg Med Chem Lett. 2010 Jan 1;20(1):228-31. DM9J35R RU https://pubmed.ncbi.nlm.nih.gov/19914064 DM9J4I3 DI DM9J4I3 DM9J4I3 DN ISIS 103622 DM9J4I3 TI TTBWMKT DM9J4I3 TN WWP1 messenger RNA (WWP1 mRNA) DM9J4I3 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DM9J4I3 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TTYT93M DM9J50F TN MAP kinase p38 (MAPK12) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TTFJ8Q1 DM9J50F TN Protein kinase C alpha (PRKCA) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TTQBR95 DM9J50F TN Stress-activated protein kinase 2a (p38 alpha) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TT73U6C DM9J50F TN Stress-activated protein kinase 2b (p38 beta) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TT0K6EO DM9J50F TN Stress-activated protein kinase JNK1 (JNK1) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TTZN7RP DM9J50F TN Rho-associated protein kinase 1 (ROCK1) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TTG0U4H DM9J50F TN Ribosomal protein S6 kinase beta-1 (S6K1) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J50F DI DM9J50F DM9J50F DN KT-5720 DM9J50F TI TT4TQBX DM9J50F TN Extracellular signal-regulated kinase 2 (ERK2) DM9J50F MA Inhibitor DM9J50F RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DM9J50F RU https://pubmed.ncbi.nlm.nih.gov/10998351 DM9J5IS DI DM9J5IS DM9J5IS DN Isopentyl Pyrophosphate DM9J5IS TI TTIKWV4 DM9J5IS TN Geranyltranstransferase (FDPS) DM9J5IS MA Inhibitor DM9J5IS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9J5IS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9J5Q7 DI DM9J5Q7 DM9J5Q7 DN PMID2909732C7 DM9J5Q7 TI TTPADOQ DM9J5Q7 TN HMG-CoA reductase (HMGCR) DM9J5Q7 MA Inhibitor DM9J5Q7 RN Synthesis and biological evaluation of a monocyclic, fully functional analogue of compactin. J Med Chem. 1989 Jan;32(1):197-202. DM9J5Q7 RU https://pubmed.ncbi.nlm.nih.gov/2909732 DM9J5TZ DI DM9J5TZ DM9J5TZ DN 4-phenyliminomethyl-benzenesulfonamide DM9J5TZ TI TTVKILB DM9J5TZ TN Prostaglandin G/H synthase 2 (COX-2) DM9J5TZ MA Inhibitor DM9J5TZ RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DM9J5TZ RU https://pubmed.ncbi.nlm.nih.gov/18063374 DM9JCD3 DI DM9JCD3 DM9JCD3 DN N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide DM9JCD3 TI TT7HF4W DM9JCD3 TN Cyclin-dependent kinase 2 (CDK2) DM9JCD3 MA Inhibitor DM9JCD3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9JCD3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9JECY DI DM9JECY DM9JECY DN METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID DM9JECY TI TTGA1IV DM9JECY TN Matrix metalloproteinase-8 (MMP-8) DM9JECY MA Inhibitor DM9JECY RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9JECY RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9JECY DI DM9JECY DM9JECY DN METHYLAMINO-PHENYLALANYL-LEUCYL-HYDROXAMIC ACID DM9JECY TI TTMX39J DM9JECY TN Matrix metalloproteinase-1 (MMP-1) DM9JECY MA Inhibitor DM9JECY RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9JECY RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9JG1L DI DM9JG1L DM9JG1L DN UCM 549 DM9JG1L TI TT0WAIE DM9JG1L TN Melatonin receptor type 1A (MTNR1A) DM9JG1L MA Antagonist DM9JG1L RN Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. ChemMedChem. 2007 Dec;2(12):1741-9. DM9JG1L RU https://pubmed.ncbi.nlm.nih.gov/17907131 DM9JI8C DI DM9JI8C DM9JI8C DN 12-epi LTB4 DM9JI8C TI TTVJX54 DM9JI8C TN Leukotriene B4 receptor 2 (LTB4R2) DM9JI8C MA Agonist DM9JI8C RN Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001 Apr 13;276(15):12454-9. DM9JI8C RU https://pubmed.ncbi.nlm.nih.gov/11278893 DM9JLUS DI DM9JLUS DM9JLUS DN 6,7-dihydroxy-8-nitro-1-tetralone DM9JLUS TI TTKWFB8 DM9JLUS TN Catechol-O-methyl-transferase (COMT) DM9JLUS MA Inhibitor DM9JLUS RN Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8. DM9JLUS RU https://pubmed.ncbi.nlm.nih.gov/16335931 DM9JMF2 DI DM9JMF2 DM9JMF2 DN 2-(7-phenylheptanoyl)oxazole-4-carboxamide DM9JMF2 TI TTDP1UC DM9JMF2 TN Fatty acid amide hydrolase (FAAH) DM9JMF2 MA Inhibitor DM9JMF2 RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DM9JMF2 RU https://pubmed.ncbi.nlm.nih.gov/18639454 DM9JON3 DI DM9JON3 DM9JON3 DN SU5402 DM9JON3 TI TTST7KB DM9JON3 TN Fibroblast growth factor receptor 3 (FGFR3) DM9JON3 MA Inhibitor DM9JON3 RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DM9JON3 RU https://pubmed.ncbi.nlm.nih.gov/19249983 DM9JXIZ DI DM9JXIZ DM9JXIZ DN banyu (I) DM9JXIZ TI TTU3Y87 DM9JXIZ TN CCR3 messenger RNA (CCR3 mRNA) DM9JXIZ MA Antagonist DM9JXIZ RN Identification of full, partial and inverse CC chemokine receptor 3 agonists using [35S]GTPgammaS binding. Eur J Pharmacol. 2002 Dec 5;456(1-3):1-10. DM9JXIZ RU https://pubmed.ncbi.nlm.nih.gov/12450563 DM9JYF3 DI DM9JYF3 DM9JYF3 DN PX-12 DM9JYF3 TI TTNHMO8 DM9JYF3 TN COVID-19 papain-like proteinase (PL-PRO) DM9JYF3 MA Inhibitor DM9JYF3 RN Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. DM9JYF3 RU https://pubmed.ncbi.nlm.nih.gov/32272481 DM9K27Q DI DM9K27Q DM9K27Q DN 4-tert-butyl-N-m-tolylthiazol-2-amine DM9K27Q TI TT7HQD0 DM9K27Q TN C-C chemokine receptor type 4 (CCR4) DM9K27Q MA Inhibitor DM9K27Q RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DM9K27Q RU https://pubmed.ncbi.nlm.nih.gov/16497499 DM9K2LU DI DM9K2LU DM9K2LU DN WAY-208466 DM9K2LU TI TTO9X1H DM9K2LU TN 5-HT 7 receptor (HTR7) DM9K2LU MA Inhibitor DM9K2LU RN Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. DM9K2LU RU https://pubmed.ncbi.nlm.nih.gov/19523834 DM9K2LU DI DM9K2LU DM9K2LU DN WAY-208466 DM9K2LU TI TTEX248 DM9K2LU TN Dopamine D2 receptor (D2R) DM9K2LU MA Inhibitor DM9K2LU RN Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. DM9K2LU RU https://pubmed.ncbi.nlm.nih.gov/19523834 DM9K2LU DI DM9K2LU DM9K2LU DN WAY-208466 DM9K2LU TI TTJQOD7 DM9K2LU TN 5-HT 2A receptor (HTR2A) DM9K2LU MA Inhibitor DM9K2LU RN Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. DM9K2LU RU https://pubmed.ncbi.nlm.nih.gov/19523834 DM9K2LU DI DM9K2LU DM9K2LU DN WAY-208466 DM9K2LU TI TTJS8PY DM9K2LU TN 5-HT 6 receptor (HTR6) DM9K2LU MA Inhibitor DM9K2LU RN Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. DM9K2LU RU https://pubmed.ncbi.nlm.nih.gov/19523834 DM9K2LU DI DM9K2LU DM9K2LU DN WAY-208466 DM9K2LU TI TTWJBZ5 DM9K2LU TN 5-HT 2C receptor (HTR2C) DM9K2LU MA Inhibitor DM9K2LU RN Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63. DM9K2LU RU https://pubmed.ncbi.nlm.nih.gov/19523834 DM9K4WP DI DM9K4WP DM9K4WP DN N-(6-phenethyl-1H-indazol-3-yl)butyramide DM9K4WP TI TTRSMW9 DM9K4WP TN Glycogen synthase kinase-3 beta (GSK-3B) DM9K4WP MA Inhibitor DM9K4WP RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DM9K4WP RU https://pubmed.ncbi.nlm.nih.gov/20167481 DM9K6H5 DI DM9K6H5 DM9K6H5 DN HAp-IFN DM9K6H5 TI TTSIUJ9 DM9K6H5 TN Interferon-alpha 2 (IFNA2) DM9K6H5 MA Modulator DM9K6H5 RN CN patent application no. 1921880, Protein drug sustained-release microparticle preparation for injection and process for producing the same. DM9K6H5 RU http://www.google.com/patents/CN1921880A?cl=en DM9K7CQ DI DM9K7CQ DM9K7CQ DN 4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one DM9K7CQ TI TTGP7BY DM9K7CQ TN Monoamine oxidase type B (MAO-B) DM9K7CQ MA Inhibitor DM9K7CQ RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DM9K7CQ RU https://pubmed.ncbi.nlm.nih.gov/18834112 DM9K7CQ DI DM9K7CQ DM9K7CQ DN 4-methyl-7-(2-oxocyclopentyloxy)-2H-chromen-2-one DM9K7CQ TI TT3WG5C DM9K7CQ TN Monoamine oxidase type A (MAO-A) DM9K7CQ MA Inhibitor DM9K7CQ RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DM9K7CQ RU https://pubmed.ncbi.nlm.nih.gov/18834112 DM9K834 DI DM9K834 DM9K834 DN FKB-001 DM9K834 TI TTMW94E DM9K834 TN FK506-binding protein 1A (FKBP1A) DM9K834 MA Inhibitor DM9K834 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9K834 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9K8DY DI DM9K8DY DM9K8DY DN 6-(4-Bromo-benzenesulfonyl)-2H-pyridazin-3-one DM9K8DY TI TTFBNVI DM9K8DY TN Aldose reductase (AKR1B1) DM9K8DY MA Inhibitor DM9K8DY RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DM9K8DY RU https://pubmed.ncbi.nlm.nih.gov/16190759 DM9K8HA DI DM9K8HA DM9K8HA DN 1-Cyclohexyl-3-phenyl-urea DM9K8HA TI TT7WVHI DM9K8HA TN Soluble epoxide hydrolase (EPHX2) DM9K8HA MA Inhibitor DM9K8HA RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DM9K8HA RU https://pubmed.ncbi.nlm.nih.gov/15887969 DM9KAI5 DI DM9KAI5 DM9KAI5 DN 1H-1,2,3-benzotriazol-1-amine DM9KAI5 TI TTXV4FI DM9KAI5 TN Albendazole monooxygenase (CYP3A4) DM9KAI5 MA Inhibitor DM9KAI5 RN Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):2993-5. DM9KAI5 RU https://pubmed.ncbi.nlm.nih.gov/11714595 DM9KAI5 DI DM9KAI5 DM9KAI5 DN 1H-1,2,3-benzotriazol-1-amine DM9KAI5 TI TTVG215 DM9KAI5 TN Debrisoquine 4-hydroxylase (CYP2D6) DM9KAI5 MA Inhibitor DM9KAI5 RN Discovery of a N'-hydroxyphenylformamidine derivative HET0016 as a potent and selective 20-HETE synthase inhibitor. Bioorg Med Chem Lett. 2001 Dec 3;11(23):2993-5. DM9KAI5 RU https://pubmed.ncbi.nlm.nih.gov/11714595 DM9KCXI DI DM9KCXI DM9KCXI DN 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea DM9KCXI TI TTH18TF DM9KCXI TN Muscarinic acetylcholine receptor M5 (CHRM5) DM9KCXI MA Inhibitor DM9KCXI RN Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9. DM9KCXI RU https://pubmed.ncbi.nlm.nih.gov/1507212 DM9KCXI DI DM9KCXI DM9KCXI DN 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea DM9KCXI TI TTQ3JTF DM9KCXI TN Muscarinic acetylcholine receptor M4 (CHRM4) DM9KCXI MA Inhibitor DM9KCXI RN Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9. DM9KCXI RU https://pubmed.ncbi.nlm.nih.gov/1507212 DM9KCXI DI DM9KCXI DM9KCXI DN 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea DM9KCXI TI TTYEG6Q DM9KCXI TN Muscarinic acetylcholine receptor M2 (CHRM2) DM9KCXI MA Inhibitor DM9KCXI RN Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9. DM9KCXI RU https://pubmed.ncbi.nlm.nih.gov/1507212 DM9KCXI DI DM9KCXI DM9KCXI DN 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea DM9KCXI TI TTZ9SOR DM9KCXI TN Muscarinic acetylcholine receptor M1 (CHRM1) DM9KCXI MA Inhibitor DM9KCXI RN Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9. DM9KCXI RU https://pubmed.ncbi.nlm.nih.gov/1507212 DM9KCXI DI DM9KCXI DM9KCXI DN 1-Methyl-1-(4-pyrrolidin-1-yl-but-2-ynyl)-urea DM9KCXI TI TTQ13Z5 DM9KCXI TN Muscarinic acetylcholine receptor M3 (CHRM3) DM9KCXI MA Inhibitor DM9KCXI RN Urea and 2-imidazolidone derivatives of the muscarinic agents oxotremorine and N-methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide. J Med Chem. 1992 Aug 21;35(17):3270-9. DM9KCXI RU https://pubmed.ncbi.nlm.nih.gov/1507212 DM9KCYQ DI DM9KCYQ DM9KCYQ DN L-709,587 DM9KCYQ TI TTMW94E DM9KCYQ TN FK506-binding protein 1A (FKBP1A) DM9KCYQ MA Inhibitor DM9KCYQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9KCYQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9KF0H DI DM9KF0H DM9KF0H DN Ethyl Oxo(Piperidin-1-Yl)Acetate DM9KF0H TI TTL2ADK DM9KF0H TN Rotamase A (PPIA) DM9KF0H MA Inhibitor DM9KF0H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9KF0H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9KIPU DI DM9KIPU DM9KIPU DN fluperlapine DM9KIPU TI TTO9X1H DM9KIPU TN 5-HT 7 receptor (HTR7) DM9KIPU MA Antagonist DM9KIPU RN Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. DM9KIPU RU https://pubmed.ncbi.nlm.nih.gov/7908055 DM9KIPU DI DM9KIPU DM9KIPU DN fluperlapine DM9KIPU TI TTJS8PY DM9KIPU TN 5-HT 6 receptor (HTR6) DM9KIPU MA Antagonist DM9KIPU RN Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10. DM9KIPU RU https://pubmed.ncbi.nlm.nih.gov/7908055 DM9KIS8 DI DM9KIS8 DM9KIS8 DN AG-538 DM9KIS8 TI TTGKNB4 DM9KIS8 TN Epidermal growth factor receptor (EGFR) DM9KIS8 MA Inhibitor DM9KIS8 RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DM9KIS8 RU https://pubmed.ncbi.nlm.nih.gov/1479375 DM9KLQC DI DM9KLQC DM9KLQC DN MB-03966 DM9KLQC TI TTL732K DM9KLQC TN Adenosine kinase (ADK) DM9KLQC MA Inhibitor DM9KLQC RN Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells. Neurotherapeutics. 2009 April; 6(2): 278-283. DM9KLQC RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2682344/ DM9KMEI DI DM9KMEI DM9KMEI DN Quizalofop DM9KMEI TI TTYAWV0 DM9KMEI TN Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) DM9KMEI MA Binder DM9KMEI RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DM9KMEI RU https://pubmed.ncbi.nlm.nih.gov/11768328 DM9KPHZ DI DM9KPHZ DM9KPHZ DN diBA-(5)-C4 DM9KPHZ TI TT0FC1V DM9KPHZ TN Volume regulated chloride channel (VRAC) DM9KPHZ MA Blocker (channel blocker) DM9KPHZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DM9KPHZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DM9KTH6 DI DM9KTH6 DM9KTH6 DN 1-(3-cyano-2-hydroxyphenyl)-3-phenylurea DM9KTH6 TI TT30C9G DM9KTH6 TN C-X-C chemokine receptor type 2 (CXCR2) DM9KTH6 MA Inhibitor DM9KTH6 RN Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. DM9KTH6 RU https://pubmed.ncbi.nlm.nih.gov/17236763 DM9KUQZ DI DM9KUQZ DM9KUQZ DN 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid DM9KUQZ TI TTGKIED DM9KUQZ TN Fibroblast growth factor-2 (FGF2) DM9KUQZ MA Inhibitor DM9KUQZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9KUQZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9KVBJ DI DM9KVBJ DM9KVBJ DN 1-(4-octylphenyl)prop-2-en-1-one DM9KVBJ TI TTGER3L DM9KVBJ TN Thyroid hormone receptor beta (THRB) DM9KVBJ MA Inhibitor DM9KVBJ RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DM9KVBJ RU https://pubmed.ncbi.nlm.nih.gov/17918822 DM9KVHQ DI DM9KVHQ DM9KVHQ DN 3-[12-(benzylmethylamino)dodecyloxy]xanthen-9-one DM9KVHQ TI TTEB0GD DM9KVHQ TN Cholinesterase (BCHE) DM9KVHQ MA Inhibitor DM9KVHQ RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DM9KVHQ RU https://pubmed.ncbi.nlm.nih.gov/17008100 DM9KWUR DI DM9KWUR DM9KWUR DN L023103 DM9KWUR TI TT4TFGN DM9KWUR TN Vasopressin V1a receptor (V1AR) DM9KWUR MA Antagonist DM9KWUR RN Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J Med Chem. 2005 Dec 1;48(24):7882-905. DM9KWUR RU https://pubmed.ncbi.nlm.nih.gov/16302826 DM9KWUR DI DM9KWUR DM9KWUR DN L023103 DM9KWUR TI TTSCIUP DM9KWUR TN Oxytocin receptor (OTR) DM9KWUR MA Antagonist DM9KWUR RN Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists. J Med Chem. 2005 Dec 1;48(24):7882-905. DM9KWUR RU https://pubmed.ncbi.nlm.nih.gov/16302826 DM9KXV0 DI DM9KXV0 DM9KXV0 DN RY024 DM9KXV0 TI TTNZPQ1 DM9KXV0 TN GABA(A) receptor alpha-5 (GABRA5) DM9KXV0 MA Modulator (allosteric modulator) DM9KXV0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DM9KXV0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DM9LEWH DI DM9LEWH DM9LEWH DN 3-Isothiocyanato-9H-beta-carboline DM9LEWH TI TT06RH5 DM9LEWH TN GABA(A) receptor gamma-2 (GABRG2) DM9LEWH MA Inhibitor DM9LEWH RN Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57. DM9LEWH RU https://pubmed.ncbi.nlm.nih.gov/2167977 DM9LEWH DI DM9LEWH DM9LEWH DN 3-Isothiocyanato-9H-beta-carboline DM9LEWH TI TTNJYV2 DM9LEWH TN Gamma-aminobutyric acid receptor (GAR) DM9LEWH MA Inhibitor DM9LEWH RN Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57. DM9LEWH RU https://pubmed.ncbi.nlm.nih.gov/2167977 DM9LEWH DI DM9LEWH DM9LEWH DN 3-Isothiocyanato-9H-beta-carboline DM9LEWH TI TTZA1NY DM9LEWH TN GABA(A) receptor beta-2 (GABRB2) DM9LEWH MA Inhibitor DM9LEWH RN Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57. DM9LEWH RU https://pubmed.ncbi.nlm.nih.gov/2167977 DM9LEWH DI DM9LEWH DM9LEWH DN 3-Isothiocyanato-9H-beta-carboline DM9LEWH TI TT1MPAY DM9LEWH TN GABA(A) receptor alpha-1 (GABRA1) DM9LEWH MA Inhibitor DM9LEWH RN Synthetic and computer-assisted analyses of the pharmacophore for the benzodiazepine receptor inverse agonist site. J Med Chem. 1990 Sep;33(9):2343-57. DM9LEWH RU https://pubmed.ncbi.nlm.nih.gov/2167977 DM9LI7M DI DM9LI7M DM9LI7M DN NSC-356781 DM9LI7M TI TTSZLWK DM9LI7M TN Aromatase (CYP19A1) DM9LI7M MA Inhibitor DM9LI7M RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DM9LI7M RU https://pubmed.ncbi.nlm.nih.gov/19072235 DM9LJEP DI DM9LJEP DM9LJEP DN PD-167341 DM9LJEP TI TT4FDG6 DM9LJEP TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DM9LJEP MA Inhibitor DM9LJEP RN Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic proper... J Med Chem. 1999 Oct 7;42(20):4239-49. DM9LJEP RU https://pubmed.ncbi.nlm.nih.gov/10514294 DM9LKMP DI DM9LKMP DM9LKMP DN 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide DM9LKMP TI TTANPDJ DM9LKMP TN Carbonic anhydrase II (CA-II) DM9LKMP MA Inhibitor DM9LKMP RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM9LKMP RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM9LKMP DI DM9LKMP DM9LKMP DN 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide DM9LKMP TI TTHQPL7 DM9LKMP TN Carbonic anhydrase I (CA-I) DM9LKMP MA Inhibitor DM9LKMP RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM9LKMP RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM9LKMP DI DM9LKMP DM9LKMP DN 4-(2-Pyridin-2-ylacetamido)benzenesulfonamide DM9LKMP TI TTUNARX DM9LKMP TN Carbonic anhydrase (CA) DM9LKMP MA Inhibitor DM9LKMP RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DM9LKMP RU https://pubmed.ncbi.nlm.nih.gov/19539481 DM9LKXD DI DM9LKXD DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide DM9LKXD TI TTYHPU6 DM9LKXD TN Histone deacetylase 10 (HDAC10) DM9LKXD MA Inhibitor DM9LKXD RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM9LKXD RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM9LKXD DI DM9LKXD DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide DM9LKXD TI TTSHTOI DM9LKXD TN Histone deacetylase 2 (HDAC2) DM9LKXD MA Inhibitor DM9LKXD RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM9LKXD RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM9LKXD DI DM9LKXD DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide DM9LKXD TI TTT6LFV DM9LKXD TN Histone deacetylase 8 (HDAC8) DM9LKXD MA Inhibitor DM9LKXD RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM9LKXD RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM9LKXD DI DM9LKXD DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide DM9LKXD TI TTBH0VX DM9LKXD TN Histone deacetylase (HDAC) DM9LKXD MA Inhibitor DM9LKXD RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM9LKXD RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM9LKXD DI DM9LKXD DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide DM9LKXD TI TT5ZKDI DM9LKXD TN Histone deacetylase 6 (HDAC6) DM9LKXD MA Inhibitor DM9LKXD RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM9LKXD RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM9LKXD DI DM9LKXD DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide DM9LKXD TI TT6R7JZ DM9LKXD TN Histone deacetylase 1 (HDAC1) DM9LKXD MA Inhibitor DM9LKXD RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM9LKXD RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM9LKXD DI DM9LKXD DM9LKXD DN 6-(2-Bromo-acetylamino)-hexanoic acid phenylamide DM9LKXD TI TTTQGH8 DM9LKXD TN Histone deacetylase 4 (HDAC4) DM9LKXD MA Inhibitor DM9LKXD RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DM9LKXD RU https://pubmed.ncbi.nlm.nih.gov/15715470 DM9LQH1 DI DM9LQH1 DM9LQH1 DN (2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime DM9LQH1 TI TTCEJ4F DM9LQH1 TN G1/S-specific cyclin-E1 (CCNE1) DM9LQH1 MA Inhibitor DM9LQH1 RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM9LQH1 RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM9LQH1 DI DM9LQH1 DM9LQH1 DN (2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime DM9LQH1 TI TT7HF4W DM9LQH1 TN Cyclin-dependent kinase 2 (CDK2) DM9LQH1 MA Inhibitor DM9LQH1 RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DM9LQH1 RU https://pubmed.ncbi.nlm.nih.gov/20361800 DM9LQIA DI DM9LQIA DM9LQIA DN MORPHINONE DM9LQIA TI TTKWM86 DM9LQIA TN Opioid receptor mu (MOP) DM9LQIA MA Inhibitor DM9LQIA RN Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32. DM9LQIA RU https://pubmed.ncbi.nlm.nih.gov/17616524 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTL1WGS DM9LRKB TN Estradiol 17 beta-dehydrogenase 4 (HSD17B4) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTAZHU0 DM9LRKB TN L-lactate dehydrogenase (LDH) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTIWB6L DM9LRKB TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTBO2A9 DM9LRKB TN Deoxyhypusine synthase (DHPS) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTHCF4J DM9LRKB TN Alpha-glucosidase (GLA) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTJBPN3 DM9LRKB TN Biliverdin reductase A (BLVRA) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTNX2CS DM9LRKB TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTKVNRF DM9LRKB TN Pseudomonas Nicotinate-nucleotide adenylyltransferase (Pseudo nadD) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTJS7O4 DM9LRKB TN Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTBKQL3 DM9LRKB TN Trypanosoma Dihydrolipoamide dehydrogenase (Trypano LPD) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTFLN4T DM9LRKB TN Mitochondrial aldehyde dehydrogenase (ALDH2) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTXWASR DM9LRKB TN Intestinal maltase-glucoamylase (MGAM) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TT1NFO3 DM9LRKB TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTPADOQ DM9LRKB TN HMG-CoA reductase (HMGCR) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTPS7KA DM9LRKB TN Bacterial Dehydroquinate synthase (Bact aroB) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTE2KUJ DM9LRKB TN Adenosylhomocysteinase (AHCY) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTEP6RV DM9LRKB TN Glutathione reductase (GR) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTVTX4N DM9LRKB TN Bacterial Fatty acid synthetase I (Bact inhA) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTTB4UP DM9LRKB TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TT8WCXO DM9LRKB TN Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTWUDYC DM9LRKB TN Haemophilus influenzae NadR protein (Hae-influ nadR) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTLSRBZ DM9LRKB TN Sorbitoldehydrogenase (SORD) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTNAW8S DM9LRKB TN Bacterial Flavohemoglobin (Bact hmp) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LRKB DI DM9LRKB DM9LRKB DN Nicotinamide-Adenine-Dinucleotide DM9LRKB TI TTGRHIB DM9LRKB TN UDP-glucose 4-epimerase (GALE) DM9LRKB MA Inhibitor DM9LRKB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9LRKB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9LSOW DI DM9LSOW DM9LSOW DN CLR-151 DM9LSOW TI TTEX248 DM9LSOW TN Dopamine D2 receptor (D2R) DM9LSOW MA Antagonist DM9LSOW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215). DM9LSOW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215 DM9LT60 DI DM9LT60 DM9LT60 DN Beta-Carboline-3-carboxylic acid t-butyl ester DM9LT60 TI TT06RH5 DM9LT60 TN GABA(A) receptor gamma-2 (GABRG2) DM9LT60 MA Inhibitor DM9LT60 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9LT60 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9LT60 DI DM9LT60 DM9LT60 DN Beta-Carboline-3-carboxylic acid t-butyl ester DM9LT60 TI TTNJYV2 DM9LT60 TN Gamma-aminobutyric acid receptor (GAR) DM9LT60 MA Inhibitor DM9LT60 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9LT60 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9LT60 DI DM9LT60 DM9LT60 DN Beta-Carboline-3-carboxylic acid t-butyl ester DM9LT60 TI TTNZPQ1 DM9LT60 TN GABA(A) receptor alpha-5 (GABRA5) DM9LT60 MA Inhibitor DM9LT60 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9LT60 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9LT60 DI DM9LT60 DM9LT60 DN Beta-Carboline-3-carboxylic acid t-butyl ester DM9LT60 TI TTBMV1G DM9LT60 TN GABA(A) receptor alpha-2 (GABRA2) DM9LT60 MA Inhibitor DM9LT60 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9LT60 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9LT60 DI DM9LT60 DM9LT60 DN Beta-Carboline-3-carboxylic acid t-butyl ester DM9LT60 TI TT37EDJ DM9LT60 TN GABA(A) receptor alpha-3 (GABRA3) DM9LT60 MA Inhibitor DM9LT60 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9LT60 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9LT60 DI DM9LT60 DM9LT60 DN Beta-Carboline-3-carboxylic acid t-butyl ester DM9LT60 TI TT1MPAY DM9LT60 TN GABA(A) receptor alpha-1 (GABRA1) DM9LT60 MA Inhibitor DM9LT60 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9LT60 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9LVR5 DI DM9LVR5 DM9LVR5 DN 3-(5-Thiophen-3-yl-pyridin-3-yl)-1H-indole DM9LVR5 TI TTUTJGQ DM9LVR5 TN Vascular endothelial growth factor receptor 2 (KDR) DM9LVR5 MA Inhibitor DM9LVR5 RN Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2973-6. DM9LVR5 RU https://pubmed.ncbi.nlm.nih.gov/12941314 DM9LY0Z DI DM9LY0Z DM9LY0Z DN 2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol DM9LY0Z TI TTML2WA DM9LY0Z TN Tubulin (TUB) DM9LY0Z MA Inhibitor DM9LY0Z RN The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg Med Chem Lett. 1999 Feb 8;9(3):407-12. DM9LY0Z RU https://pubmed.ncbi.nlm.nih.gov/10091693 DM9LY0Z DI DM9LY0Z DM9LY0Z DN 2-Methoxy-5-(5,6,7-trimethoxy-indan-1-yl)-phenol DM9LY0Z TI TTYFKSZ DM9LY0Z TN Tubulin beta (TUBB) DM9LY0Z MA Inhibitor DM9LY0Z RN The synthesis and evaluation of temperature sensitive tubulin toxins. Bioorg Med Chem Lett. 1999 Feb 8;9(3):407-12. DM9LY0Z RU https://pubmed.ncbi.nlm.nih.gov/10091693 DM9LYJT DI DM9LYJT DM9LYJT DN CP734432 DM9LYJT TI TT79WV3 DM9LYJT TN Prostaglandin E2 receptor EP4 (PTGER4) DM9LYJT MA Agonist DM9LYJT RN Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models. Exp Eye Res. 2009 Nov;89(5):608-17. DM9LYJT RU https://pubmed.ncbi.nlm.nih.gov/19445930 DM9M1UO DI DM9M1UO DM9M1UO DN WR-203581 DM9M1UO TI TTSFWA7 DM9M1UO TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DM9M1UO MA Inhibitor DM9M1UO RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DM9M1UO RU https://pubmed.ncbi.nlm.nih.gov/19250824 DM9M3VC DI DM9M3VC DM9M3VC DN Ki-20227 DM9M3VC TI TTX41N9 DM9M3VC TN Tyrosine-protein kinase Kit (KIT) DM9M3VC MA Inhibitor DM9M3VC RN A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43. DM9M3VC RU https://pubmed.ncbi.nlm.nih.gov/17121910 DM9M3VC DI DM9M3VC DM9M3VC DN Ki-20227 DM9M3VC TI TTUTJGQ DM9M3VC TN Vascular endothelial growth factor receptor 2 (KDR) DM9M3VC MA Inhibitor DM9M3VC RN A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43. DM9M3VC RU https://pubmed.ncbi.nlm.nih.gov/17121910 DM9M3VC DI DM9M3VC DM9M3VC DN Ki-20227 DM9M3VC TI TTVW6QL DM9M3VC TN CSF1R messenger RNA (CSF1R mRNA) DM9M3VC MA Inhibitor DM9M3VC RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DM9M3VC RU https://pubmed.ncbi.nlm.nih.gov/22037378 DM9M3VC DI DM9M3VC DM9M3VC DN Ki-20227 DM9M3VC TI TTI7421 DM9M3VC TN Platelet-derived growth factor receptor beta (PDGFRB) DM9M3VC MA Inhibitor DM9M3VC RN A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43. DM9M3VC RU https://pubmed.ncbi.nlm.nih.gov/17121910 DM9M5D1 DI DM9M5D1 DM9M5D1 DN 1-(3,4-dihydroxy-2-nitrophenyl)-2-phenylethanone DM9M5D1 TI TTKWFB8 DM9M5D1 TN Catechol-O-methyl-transferase (COMT) DM9M5D1 MA Inhibitor DM9M5D1 RN Synthesis and biological evaluation of a novel series of "ortho-nitrated" inhibitors of catechol-O-methyltransferase. J Med Chem. 2005 Dec 15;48(25):8070-8. DM9M5D1 RU https://pubmed.ncbi.nlm.nih.gov/16335931 DM9M5HC DI DM9M5HC DM9M5HC DN KNT-62 DM9M5HC TI TTQW87Y DM9M5HC TN Opioid receptor kappa (OPRK1) DM9M5HC MA Inhibitor DM9M5HC RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DM9M5HC RU https://pubmed.ncbi.nlm.nih.gov/19962305 DM9M5HC DI DM9M5HC DM9M5HC DN KNT-62 DM9M5HC TI TTKWM86 DM9M5HC TN Opioid receptor mu (MOP) DM9M5HC MA Inhibitor DM9M5HC RN Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. DM9M5HC RU https://pubmed.ncbi.nlm.nih.gov/19962305 DM9MCAU DI DM9MCAU DM9MCAU DN 1-(1H-Indazol-6-yl)-3-pyridin-2-yl-urea DM9MCAU TI TT0PG8F DM9MCAU TN Cyclin-dependent kinase 4 (CDK4) DM9MCAU MA Inhibitor DM9MCAU RN Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. DM9MCAU RU https://pubmed.ncbi.nlm.nih.gov/11741479 DM9MDBO DI DM9MDBO DM9MDBO DN AcDRGDS DM9MDBO TI TTT1R2L DM9MDBO TN Integrin alpha-V (ITGAV) DM9MDBO MA Inhibitor DM9MDBO RN Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33. DM9MDBO RU https://pubmed.ncbi.nlm.nih.gov/17289386 DM9MDBO DI DM9MDBO DM9MDBO DN AcDRGDS DM9MDBO TI TTJA1ZO DM9MDBO TN ITGB3 messenger RNA (ITGB3 mRNA) DM9MDBO MA Inhibitor DM9MDBO RN Inhibition of cancer cell adhesion by heterochiral Pro-containing RGD mimetics. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2329-33. DM9MDBO RU https://pubmed.ncbi.nlm.nih.gov/17289386 DM9MDZG DI DM9MDZG DM9MDZG DN 1-(4-chlorophenethyl)-1H-imidazole DM9MDZG TI TTRA5BZ DM9MDZG TN Steroid 17-alpha-monooxygenase (S17AH) DM9MDZG MA Inhibitor DM9MDZG RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DM9MDZG RU https://pubmed.ncbi.nlm.nih.gov/16870430 DM9MFZ1 DI DM9MFZ1 DM9MFZ1 DN 3-Thiophen-3-yl-quinoline DM9MFZ1 TI TT8FYO9 DM9MFZ1 TN Platelet-derived growth factor receptor alpha (PDGFRA) DM9MFZ1 MA Inhibitor DM9MFZ1 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM9MFZ1 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM9MFZ1 DI DM9MFZ1 DM9MFZ1 DN 3-Thiophen-3-yl-quinoline DM9MFZ1 TI TTI7421 DM9MFZ1 TN Platelet-derived growth factor receptor beta (PDGFRB) DM9MFZ1 MA Inhibitor DM9MFZ1 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM9MFZ1 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM9MIC5 DI DM9MIC5 DM9MIC5 DN 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine DM9MIC5 TI TTK25J1 DM9MIC5 TN Adenosine A1 receptor (ADORA1) DM9MIC5 MA Inhibitor DM9MIC5 RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DM9MIC5 RU https://pubmed.ncbi.nlm.nih.gov/17665891 DM9MIC5 DI DM9MIC5 DM9MIC5 DN 2-p-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine DM9MIC5 TI TTM2AOE DM9MIC5 TN Adenosine A2a receptor (ADORA2A) DM9MIC5 MA Inhibitor DM9MIC5 RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DM9MIC5 RU https://pubmed.ncbi.nlm.nih.gov/17665891 DM9MIQB DI DM9MIQB DM9MIQB DN 4-(3,5-dimethylbenzylthio)-2-aminobutanoic acid DM9MIQB TI TTFK1JQ DM9MIQB TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DM9MIQB MA Inhibitor DM9MIQB RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DM9MIQB RU https://pubmed.ncbi.nlm.nih.gov/16380257 DM9MPDK DI DM9MPDK DM9MPDK DN 6-Carboxymethyluracil DM9MPDK TI TTZPS91 DM9MPDK TN Dihydrothymine dehydrogenase (DPYD) DM9MPDK MA Inhibitor DM9MPDK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9MPDK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9MPHF DI DM9MPHF DM9MPHF DN 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine DM9MPHF TI TT9RTBL DM9MPHF TN Aurora B messenger RNA (AURKB mRNA) DM9MPHF MA Inhibitor DM9MPHF RN Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5. DM9MPHF RU https://pubmed.ncbi.nlm.nih.gov/20335034 DM9MPHF DI DM9MPHF DM9MPHF DN 4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine DM9MPHF TI TTPS3C0 DM9MPHF TN Aurora kinase A (AURKA) DM9MPHF MA Inhibitor DM9MPHF RN Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5. DM9MPHF RU https://pubmed.ncbi.nlm.nih.gov/20335034 DM9MRTW DI DM9MRTW DM9MRTW DN 3-(2-N-Pyrrolyl-propionamino)-rutaecarpine DM9MRTW TI TT1RS9F DM9MRTW TN Acetylcholinesterase (AChE) DM9MRTW MA Inhibitor DM9MRTW RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DM9MRTW RU https://pubmed.ncbi.nlm.nih.gov/20079560 DM9MRTW DI DM9MRTW DM9MRTW DN 3-(2-N-Pyrrolyl-propionamino)-rutaecarpine DM9MRTW TI TTEB0GD DM9MRTW TN Cholinesterase (BCHE) DM9MRTW MA Inhibitor DM9MRTW RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DM9MRTW RU https://pubmed.ncbi.nlm.nih.gov/20079560 DM9N0RH DI DM9N0RH DM9N0RH DN PLATENSIMYCIN DM9N0RH TI TTRFV0W DM9N0RH TN Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF) DM9N0RH MA Inhibitor DM9N0RH RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9N0RH RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9N8WM DI DM9N8WM DM9N8WM DN Ciproxifan DM9N8WM TI TTWG9A4 DM9N8WM TN Adrenergic receptor alpha-2A (ADRA2A) DM9N8WM MA Antagonist DM9N8WM RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM9N8WM RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM9N8WM DI DM9N8WM DM9N8WM DN Ciproxifan DM9N8WM TI TTNXLKE DM9N8WM TN 5-HT 3 receptor (5HT3R) DM9N8WM MA Antagonist DM9N8WM RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM9N8WM RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM9N8WM DI DM9N8WM DM9N8WM DN Ciproxifan DM9N8WM TI TT9JNIC DM9N8WM TN Histamine H3 receptor (H3R) DM9N8WM MA Antagonist DM9N8WM RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM9N8WM RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM9N8WM DI DM9N8WM DM9N8WM DN Ciproxifan DM9N8WM TI TT2NUT5 DM9N8WM TN Adrenergic receptor alpha-2C (ADRA2C) DM9N8WM MA Antagonist DM9N8WM RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DM9N8WM RU https://pubmed.ncbi.nlm.nih.gov/15665857 DM9NB1A DI DM9NB1A DM9NB1A DN ISIS 29160 DM9NB1A TI TTO6SGY DM9NB1A TN AKT3 messenger RNA (AKT3 mRNA) DM9NB1A RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DM9NB1A RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DM9NMIO DI DM9NMIO DM9NMIO DN 2-Bromo-N-(3-morpholinopropyl)nicotinamide DM9NMIO TI TTGP7BY DM9NMIO TN Monoamine oxidase type B (MAO-B) DM9NMIO MA Inhibitor DM9NMIO RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DM9NMIO RU https://pubmed.ncbi.nlm.nih.gov/20117937 DM9NMIY DI DM9NMIY DM9NMIY DN DCPIB DM9NMIY TI TT0FC1V DM9NMIY TN Volume regulated chloride channel (VRAC) DM9NMIY MA Blocker (channel blocker) DM9NMIY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DM9NMIY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DM9NO6F DI DM9NO6F DM9NO6F DN DIHYDROKAINATE DM9NO6F TI TT0MYE2 DM9NO6F TN Glutamate receptor ionotropic kainate 1 (GRIK1) DM9NO6F MA Inhibitor DM9NO6F RN Chemo-enzymatic synthesis of (2S,4R)-2-amino-4-(3-(2,2-diphenylethylamino)-3-oxopropyl)pentanedioic acid: a novel selective inhibitor of human exci... J Med Chem. 2008 Jul 24;51(14):4085-92. DM9NO6F RU https://pubmed.ncbi.nlm.nih.gov/18578477 DM9NPE4 DI DM9NPE4 DM9NPE4 DN M826 DM9NPE4 TI TTWR48J DM9NPE4 TN Caspase-5 (CASP5) DM9NPE4 MA Inhibitor DM9NPE4 RN Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80. DM9NPE4 RU https://pubmed.ncbi.nlm.nih.gov/15686936 DM9NPE4 DI DM9NPE4 DM9NPE4 DN M826 DM9NPE4 TI TTCQIBE DM9NPE4 TN Caspase-1 (CASP1) DM9NPE4 MA Inhibitor DM9NPE4 RN Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80. DM9NPE4 RU https://pubmed.ncbi.nlm.nih.gov/15686936 DM9NPE4 DI DM9NPE4 DM9NPE4 DN M826 DM9NPE4 TI TTPF2QI DM9NPE4 TN Caspase-3 (CASP3) DM9NPE4 MA Inhibitor DM9NPE4 RN Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80. DM9NPE4 RU https://pubmed.ncbi.nlm.nih.gov/15686936 DM9NPE4 DI DM9NPE4 DM9NPE4 DN M826 DM9NPE4 TI TTM7Y45 DM9NPE4 TN Caspase-7 (CASP7) DM9NPE4 MA Inhibitor DM9NPE4 RN Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80. DM9NPE4 RU https://pubmed.ncbi.nlm.nih.gov/15686936 DM9NPE4 DI DM9NPE4 DM9NPE4 DN M826 DM9NPE4 TI TT3VZ8D DM9NPE4 TN Caspase-4 (CASP4) DM9NPE4 MA Inhibitor DM9NPE4 RN Novel pyrazinone mono-amides as potent and reversible caspase-3 inhibitors. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1173-80. DM9NPE4 RU https://pubmed.ncbi.nlm.nih.gov/15686936 DM9O0AR DI DM9O0AR DM9O0AR DN SB-13 DM9O0AR TI TTE4KHA DM9O0AR TN Amyloid beta A4 protein (APP) DM9O0AR MA Inhibitor DM9O0AR RN Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. DM9O0AR RU https://pubmed.ncbi.nlm.nih.gov/16640346 DM9O5CH DI DM9O5CH DM9O5CH DN 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid DM9O5CH TI TT79WV3 DM9O5CH TN Prostaglandin E2 receptor EP4 (PTGER4) DM9O5CH MA Inhibitor DM9O5CH RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM9O5CH RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM9O5CH DI DM9O5CH DM9O5CH DN 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid DM9O5CH TI TTPNGDE DM9O5CH TN Prostaglandin E2 receptor EP3 (PTGER3) DM9O5CH MA Inhibitor DM9O5CH RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM9O5CH RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM9O5CH DI DM9O5CH DM9O5CH DN 3-(2-(naphthalen-2-ylmethyl)phenyl)acrylic acid DM9O5CH TI TT1ZAVI DM9O5CH TN Prostaglandin E2 receptor EP2 (PTGER2) DM9O5CH MA Inhibitor DM9O5CH RN Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. DM9O5CH RU https://pubmed.ncbi.nlm.nih.gov/16931013 DM9O5S6 DI DM9O5S6 DM9O5S6 DN Methyl icosylphosphonofluoridate DM9O5S6 TI TT6OEDT DM9O5S6 TN Cannabinoid receptor 1 (CB1) DM9O5S6 MA Inhibitor DM9O5S6 RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DM9O5S6 RU https://pubmed.ncbi.nlm.nih.gov/18752948 DM9O5S6 DI DM9O5S6 DM9O5S6 DN Methyl icosylphosphonofluoridate DM9O5S6 TI TTDP1UC DM9O5S6 TN Fatty acid amide hydrolase (FAAH) DM9O5S6 MA Inhibitor DM9O5S6 RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DM9O5S6 RU https://pubmed.ncbi.nlm.nih.gov/18752948 DM9O8I7 DI DM9O8I7 DM9O8I7 DN PMID23412139C16 DM9O8I7 TI TT8JRS7 DM9O8I7 TN Beta-secretase (BACE) DM9O8I7 MA Inhibitor DM9O8I7 RN Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS A Reduction. ACS Med Chem Lett. 2012 Nov 8;3(11):897-902. DM9O8I7 RU https://pubmed.ncbi.nlm.nih.gov/23412139 DM9O8UM DI DM9O8UM DM9O8UM DN 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol DM9O8UM TI TT1MPAY DM9O8UM TN GABA(A) receptor alpha-1 (GABRA1) DM9O8UM MA Inhibitor DM9O8UM RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM9O8UM RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM9O8UM DI DM9O8UM DM9O8UM DN 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol DM9O8UM TI TTZA1NY DM9O8UM TN GABA(A) receptor beta-2 (GABRB2) DM9O8UM MA Inhibitor DM9O8UM RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM9O8UM RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM9O8UM DI DM9O8UM DM9O8UM DN 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol DM9O8UM TI TT06RH5 DM9O8UM TN GABA(A) receptor gamma-2 (GABRG2) DM9O8UM MA Inhibitor DM9O8UM RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM9O8UM RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM9O8UM DI DM9O8UM DM9O8UM DN 4-Naphthalen-2-yl-5-piperidin-4-yl-isoxazol-3-ol DM9O8UM TI TTNJYV2 DM9O8UM TN Gamma-aminobutyric acid receptor (GAR) DM9O8UM MA Inhibitor DM9O8UM RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DM9O8UM RU https://pubmed.ncbi.nlm.nih.gov/15658856 DM9O8VY DI DM9O8VY DM9O8VY DN 4-(6-morpholino-4-oxo-4H-pyran-2-yl)benzonitrile DM9O8VY TI TTK3PY9 DM9O8VY TN DNA-dependent protein kinase catalytic (PRKDC) DM9O8VY MA Inhibitor DM9O8VY RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DM9O8VY RU https://pubmed.ncbi.nlm.nih.gov/17371003 DM9OD7U DI DM9OD7U DM9OD7U DN 6-ETHYL-5-PHENYLPYRIMIDINE-2,4-DIAMINE DM9OD7U TI TTU6BFZ DM9OD7U TN Candida Thymidylate synthase (Candi TMP1) DM9OD7U MA Inhibitor DM9OD7U RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9OD7U RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9ODEZ DI DM9ODEZ DM9ODEZ DN RPR-107836 DM9ODEZ TI TTVFO0U DM9ODEZ TN Gastrin/cholecystokinin type B receptor (CCKBR) DM9ODEZ MA Modulator DM9ODEZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 77). DM9ODEZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=77 DM9OEJT DI DM9OEJT DM9OEJT DN 2'-deoxythymidine triphosphate DM9OEJT TI TTIU7X1 DM9OEJT TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DM9OEJT MA Inhibitor DM9OEJT RN Inhibition of human hepatitis B virus DNA polymerase and duck hepatitis B virus DNA polymerase by triphosphates of thymidine analogs and pharmacokinetic properties of the corresponding nucleosides. JMed Virol. 1988 Dec;26(4):353-62. DM9OEJT RU https://pubmed.ncbi.nlm.nih.gov/3145322 DM9OEJT DI DM9OEJT DM9OEJT DN 2'-deoxythymidine triphosphate DM9OEJT TI TTP3QRF DM9OEJT TN Thymidine kinase 1 (TK1) DM9OEJT MA Inhibitor DM9OEJT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9OEJT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9OEJT DI DM9OEJT DM9OEJT DN 2'-deoxythymidine triphosphate DM9OEJT TI TT5B8AX DM9OEJT TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DM9OEJT MA Inhibitor DM9OEJT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9OEJT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9OEJT DI DM9OEJT DM9OEJT DN 2'-deoxythymidine triphosphate DM9OEJT TI TT84ETX DM9OEJT TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9OEJT MA Inhibitor DM9OEJT RN Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700. DM9OEJT RU https://pubmed.ncbi.nlm.nih.gov/15801860 DM9OGNE DI DM9OGNE DM9OGNE DN 3-chloro-1-(4-hydroxyphenyl)propan-1-one DM9OGNE TI TTT2LD9 DM9OGNE TN GABA transaminase (ABAT) DM9OGNE MA Inhibitor DM9OGNE RN Inactivation of GABA transaminase by 3-chloro-1-(4-hydroxyphenyl)propan-1-one. Bioorg Med Chem Lett. 2009 Feb 1;19(3):731-4. DM9OGNE RU https://pubmed.ncbi.nlm.nih.gov/19138517 DM9OI2R DI DM9OI2R DM9OI2R DN 3-[(5-ethyl-2-methyl-4-thiazolyl)ethynyl]pyridine DM9OI2R TI TTHS256 DM9OI2R TN Metabotropic glutamate receptor 5 (mGluR5) DM9OI2R MA Inhibitor DM9OI2R RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DM9OI2R RU https://pubmed.ncbi.nlm.nih.gov/16451073 DM9OJ7T DI DM9OJ7T DM9OJ7T DN 1-Octyl-3-(1-propionylpiperidin-4-yl)urea DM9OJ7T TI TT7WVHI DM9OJ7T TN Soluble epoxide hydrolase (EPHX2) DM9OJ7T MA Inhibitor DM9OJ7T RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DM9OJ7T RU https://pubmed.ncbi.nlm.nih.gov/20812725 DM9OMI3 DI DM9OMI3 DM9OMI3 DN 17-phenyl-omega-trinor-PGE2 DM9OMI3 TI TTG1QMU DM9OMI3 TN Prostaglandin E2 receptor EP1 (PTGER1) DM9OMI3 MA Agonist DM9OMI3 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM9OMI3 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM9OMI3 DI DM9OMI3 DM9OMI3 DN 17-phenyl-omega-trinor-PGE2 DM9OMI3 TI TT1ZAVI DM9OMI3 TN Prostaglandin E2 receptor EP2 (PTGER2) DM9OMI3 MA Agonist DM9OMI3 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DM9OMI3 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DM9OMI3 DI DM9OMI3 DM9OMI3 DN 17-phenyl-omega-trinor-PGE2 DM9OMI3 TI TTPNGDE DM9OMI3 TN Prostaglandin E2 receptor EP3 (PTGER3) DM9OMI3 MA Agonist DM9OMI3 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM9OMI3 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM9OPJW DI DM9OPJW DM9OPJW DN ISIS 112592 DM9OPJW TI TT6804T DM9OPJW TN MIF messenger RNA (MIF mRNA) DM9OPJW RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DM9OPJW RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DM9OWG5 DI DM9OWG5 DM9OWG5 DN CPPZ DM9OWG5 TI TTHS256 DM9OWG5 TN Metabotropic glutamate receptor 5 (mGluR5) DM9OWG5 MA Modulator (allosteric modulator) DM9OWG5 RN Preclinical profile of a novel metabotropic glutamate receptor 5 positive allosteric modulator. Eur J Pharmacol. 2011 Jun 1;659(2-3):146-54. DM9OWG5 RU https://pubmed.ncbi.nlm.nih.gov/21335002 DM9P4LB DI DM9P4LB DM9P4LB DN 6-(2-mercaptoacetamido)-N-phenylhexanamide DM9P4LB TI TTT6LFV DM9P4LB TN Histone deacetylase 8 (HDAC8) DM9P4LB MA Inhibitor DM9P4LB RN Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29. DM9P4LB RU https://pubmed.ncbi.nlm.nih.gov/18247554 DM9P62Y DI DM9P62Y DM9P62Y DN GKA1 DM9P62Y TI TTDLNGZ DM9P62Y TN Glucokinase (GCK) DM9P62Y MA Activator DM9P62Y RN Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. Diabetes. 2004 Mar;53(3):535-41. DM9P62Y RU https://pubmed.ncbi.nlm.nih.gov/14988235 DM9PDCA DI DM9PDCA DM9PDCA DN (3,5-Dibromo-4-butoxy-phenyl)-acetic acid DM9PDCA TI TTGER3L DM9PDCA TN Thyroid hormone receptor beta (THRB) DM9PDCA MA Inhibitor DM9PDCA RN Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7. DM9PDCA RU https://pubmed.ncbi.nlm.nih.gov/15857115 DM9PGQI DI DM9PGQI DM9PGQI DN MM3B6S DM9PGQI TI TTKWM86 DM9PGQI TN Opioid receptor mu (MOP) DM9PGQI MA Inhibitor DM9PGQI RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DM9PGQI RU https://pubmed.ncbi.nlm.nih.gov/16777416 DM9PK1R DI DM9PK1R DM9PK1R DN 2,5-dichloro-N-phenylthiophene-3-sulfonamide DM9PK1R TI TTSFWA7 DM9PK1R TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DM9PK1R MA Inhibitor DM9PK1R RN Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010). DM9PK1R RU http://www.sciencedirect.com/science/article/pii/S0960894X10006803 DM9PNTQ DI DM9PNTQ DM9PNTQ DN 1-pentafluorophenylamido-5-sulfonamidoindane DM9PNTQ TI TTANPDJ DM9PNTQ TN Carbonic anhydrase II (CA-II) DM9PNTQ MA Inhibitor DM9PNTQ RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM9PNTQ RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM9PNTQ DI DM9PNTQ DM9PNTQ DN 1-pentafluorophenylamido-5-sulfonamidoindane DM9PNTQ TI TT2LVK8 DM9PNTQ TN Carbonic anhydrase IX (CA-IX) DM9PNTQ MA Inhibitor DM9PNTQ RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM9PNTQ RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM9PNTQ DI DM9PNTQ DM9PNTQ DN 1-pentafluorophenylamido-5-sulfonamidoindane DM9PNTQ TI TTHQPL7 DM9PNTQ TN Carbonic anhydrase I (CA-I) DM9PNTQ MA Inhibitor DM9PNTQ RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM9PNTQ RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM9PT03 DI DM9PT03 DM9PT03 DN Equilin DM9PT03 TI TTIWB6L DM9PT03 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DM9PT03 MA Inhibitor DM9PT03 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9PT03 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9Q2PG DI DM9Q2PG DM9Q2PG DN fluprostenol DM9Q2PG TI TT2O84V DM9Q2PG TN Thromboxane A2 receptor (TBXA2R) DM9Q2PG MA Agonist DM9Q2PG RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM9Q2PG RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM9Q2PG DI DM9Q2PG DM9Q2PG DN fluprostenol DM9Q2PG TI TTPNGDE DM9Q2PG TN Prostaglandin E2 receptor EP3 (PTGER3) DM9Q2PG MA Agonist DM9Q2PG RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DM9Q2PG RU https://pubmed.ncbi.nlm.nih.gov/10634944 DM9Q2PG DI DM9Q2PG DM9Q2PG DN fluprostenol DM9Q2PG TI TTT2ZAR DM9Q2PG TN Prostaglandin F2-alpha receptor (PTGFR) DM9Q2PG MA Agonist DM9Q2PG RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DM9Q2PG RU https://pubmed.ncbi.nlm.nih.gov/9313928 DM9QA7Z DI DM9QA7Z DM9QA7Z DN N-(1-phenethylpiperidin-4-yl)-2-naphthamide DM9QA7Z TI TTJQOD7 DM9QA7Z TN 5-HT 2A receptor (HTR2A) DM9QA7Z MA Inhibitor DM9QA7Z RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9. DM9QA7Z RU https://pubmed.ncbi.nlm.nih.gov/17254782 DM9QAP4 DI DM9QAP4 DM9QAP4 DN L-750034 DM9QAP4 TI TTJA1ZO DM9QAP4 TN ITGB3 messenger RNA (ITGB3 mRNA) DM9QAP4 MA Inhibitor DM9QAP4 RN Molecular model of the alpha(IIb)beta(3) integrin. J Med Chem. 2003 Dec 4;46(25):5316-25. DM9QAP4 RU https://pubmed.ncbi.nlm.nih.gov/14640540 DM9QB0X DI DM9QB0X DM9QB0X DN 3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole DM9QB0X TI TTJS8PY DM9QB0X TN 5-HT 6 receptor (HTR6) DM9QB0X MA Inhibitor DM9QB0X RN 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60. DM9QB0X RU https://pubmed.ncbi.nlm.nih.gov/20138763 DM9QBAZ DI DM9QBAZ DM9QBAZ DN 5-chloro-2-(4-phenylbutyl)isoindoline-1,3-dione DM9QBAZ TI TTECBXN DM9QBAZ TN Oxysterols receptor LXR-alpha (NR1H3) DM9QBAZ MA Inhibitor DM9QBAZ RN Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61. DM9QBAZ RU https://pubmed.ncbi.nlm.nih.gov/17498949 DM9QIAL DI DM9QIAL DM9QIAL DN (+/-)-threo-N-(4-Methylpyridine)methylphenidate DM9QIAL TI TTVBI8W DM9QIAL TN Dopamine transporter (DAT) DM9QIAL MA Inhibitor DM9QIAL RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM9QIAL RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM9QIH4 DI DM9QIH4 DM9QIH4 DN N-(piperidin-4-yl)-N-propyl-2-naphthamide DM9QIH4 TI TT3ROYC DM9QIH4 TN Serotonin transporter (SERT) DM9QIH4 MA Inhibitor DM9QIH4 RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DM9QIH4 RU https://pubmed.ncbi.nlm.nih.gov/19740658 DM9QIH4 DI DM9QIH4 DM9QIH4 DN N-(piperidin-4-yl)-N-propyl-2-naphthamide DM9QIH4 TI TTQ6VDM DM9QIH4 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DM9QIH4 MA Inhibitor DM9QIH4 RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DM9QIH4 RU https://pubmed.ncbi.nlm.nih.gov/19740658 DM9QKLC DI DM9QKLC DM9QKLC DN 7-Methoxy-3-thiophen-3-yl-quinoline DM9QKLC TI TT8FYO9 DM9QKLC TN Platelet-derived growth factor receptor alpha (PDGFRA) DM9QKLC MA Inhibitor DM9QKLC RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM9QKLC RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM9QKLC DI DM9QKLC DM9QKLC DN 7-Methoxy-3-thiophen-3-yl-quinoline DM9QKLC TI TTI7421 DM9QKLC TN Platelet-derived growth factor receptor beta (PDGFRB) DM9QKLC MA Inhibitor DM9QKLC RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM9QKLC RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM9QMA2 DI DM9QMA2 DM9QMA2 DN PMID30247903-Compound-General structure7 DM9QMA2 TI TT8ZLTI DM9QMA2 TN Programmed cell death 1 ligand 1 (PD-L1) DM9QMA2 MA Inhibitor DM9QMA2 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DM9QMA2 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DM9QSDC DI DM9QSDC DM9QSDC DN Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate DM9QSDC TI TTNZPQ1 DM9QSDC TN GABA(A) receptor alpha-5 (GABRA5) DM9QSDC MA Inhibitor DM9QSDC RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9QSDC RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9QSDC DI DM9QSDC DM9QSDC DN Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate DM9QSDC TI TTNJYV2 DM9QSDC TN Gamma-aminobutyric acid receptor (GAR) DM9QSDC MA Inhibitor DM9QSDC RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9QSDC RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9QSDC DI DM9QSDC DM9QSDC DN Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate DM9QSDC TI TT06RH5 DM9QSDC TN GABA(A) receptor gamma-2 (GABRG2) DM9QSDC MA Inhibitor DM9QSDC RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9QSDC RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9QSDC DI DM9QSDC DM9QSDC DN Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate DM9QSDC TI TT1MPAY DM9QSDC TN GABA(A) receptor alpha-1 (GABRA1) DM9QSDC MA Inhibitor DM9QSDC RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9QSDC RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9QSDC DI DM9QSDC DM9QSDC DN Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate DM9QSDC TI TT37EDJ DM9QSDC TN GABA(A) receptor alpha-3 (GABRA3) DM9QSDC MA Inhibitor DM9QSDC RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9QSDC RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9QSDC DI DM9QSDC DM9QSDC DN Sec-butyl 9H-pyrido[3,4-b]indole-3-carboxylate DM9QSDC TI TTBMV1G DM9QSDC TN GABA(A) receptor alpha-2 (GABRA2) DM9QSDC MA Inhibitor DM9QSDC RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DM9QSDC RU https://pubmed.ncbi.nlm.nih.gov/20888240 DM9QTWB DI DM9QTWB DM9QTWB DN 1-Biphenyl-4-ylmaleimide DM9QTWB TI TTDP1UC DM9QTWB TN Fatty acid amide hydrolase (FAAH) DM9QTWB MA Inhibitor DM9QTWB RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DM9QTWB RU https://pubmed.ncbi.nlm.nih.gov/19583260 DM9QU5Y DI DM9QU5Y DM9QU5Y DN GSK343 DM9QU5Y TI TT9MZCQ DM9QU5Y TN Enhancer of zeste homolog 2 (EZH2) DM9QU5Y MA Inhibitor DM9QU5Y RN Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. DM9QU5Y RU https://pubmed.ncbi.nlm.nih.gov/24900432 DM9QU5Y DI DM9QU5Y DM9QU5Y DN GSK343 DM9QU5Y TI TTNJA0C DM9QU5Y TN Enhancer of zeste homolog 1 (EZH1) DM9QU5Y MA Inhibitor DM9QU5Y RN Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett. 2012 Oct 19;3(12):1091-6. DM9QU5Y RU https://pubmed.ncbi.nlm.nih.gov/24900432 DM9QW8N DI DM9QW8N DM9QW8N DN NSC-172033 DM9QW8N TI TTN9T81 DM9QW8N TN Arachidonate 15-lipoxygenase (15-LOX) DM9QW8N MA Inhibitor DM9QW8N RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DM9QW8N RU https://pubmed.ncbi.nlm.nih.gov/17826100 DM9QW8N DI DM9QW8N DM9QW8N DN NSC-172033 DM9QW8N TI TT12ABZ DM9QW8N TN Arachidonate 12-lipoxygenase (12-LOX) DM9QW8N MA Inhibitor DM9QW8N RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DM9QW8N RU https://pubmed.ncbi.nlm.nih.gov/17826100 DM9R3WT DI DM9R3WT DM9R3WT DN AVE 0991 DM9R3WT TI TTOISYB DM9R3WT TN Proto-oncogene Mas (MAS) DM9R3WT MA Agonist DM9R3WT RN Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension. 2004 Oct;44(4):490-6. DM9R3WT RU https://pubmed.ncbi.nlm.nih.gov/15326087 DM9R51M DI DM9R51M DM9R51M DN ISIS 116670 DM9R51M TI TTQWAU1 DM9R51M TN GSK3A messenger RNA (GSK3A mRNA) DM9R51M RN US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression. DM9R51M RU http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true DM9RAYC DI DM9RAYC DM9RAYC DN 2-(3-Bromo-phenyl)-6-nitro-chromen-4-one DM9RAYC TI TT1MPAY DM9RAYC TN GABA(A) receptor alpha-1 (GABRA1) DM9RAYC MA Inhibitor DM9RAYC RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM9RAYC RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM9RAYC DI DM9RAYC DM9RAYC DN 2-(3-Bromo-phenyl)-6-nitro-chromen-4-one DM9RAYC TI TTNJYV2 DM9RAYC TN Gamma-aminobutyric acid receptor (GAR) DM9RAYC MA Inhibitor DM9RAYC RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DM9RAYC RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DM9RC3O DI DM9RC3O DM9RC3O DN [Ncy(methyl)10]acyline DM9RC3O TI TT8R70G DM9RC3O TN Gonadotropin-releasing hormone receptor (GNRHR) DM9RC3O MA Inhibitor DM9RC3O RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM9RC3O RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM9RD0C DI DM9RD0C DM9RD0C DN GW7647 DM9RD0C TI TTJ584C DM9RD0C TN Peroxisome proliferator-activated receptor alpha (PPARA) DM9RD0C MA Agonist DM9RD0C RN Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. Bioorg Med Chem Lett. 2001 May 7;11(9):1225-7. DM9RD0C RU https://pubmed.ncbi.nlm.nih.gov/11354382 DM9RENG DI DM9RENG DM9RENG DN PMID1992149C9 DM9RENG TI TTPADOQ DM9RENG TN HMG-CoA reductase (HMGCR) DM9RENG MA Inhibitor DM9RENG RN Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted- pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones. J Med Chem. 1992 May 29;35(11):2095-103. DM9RENG RU https://pubmed.ncbi.nlm.nih.gov/1597859 DM9RF1T DI DM9RF1T DM9RF1T DN 1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol DM9RF1T TI TTOM3J0 DM9RF1T TN Estrogen receptor beta (ESR2) DM9RF1T MA Inhibitor DM9RF1T RN Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003. DM9RF1T RU https://pubmed.ncbi.nlm.nih.gov/16162002 DM9RF1T DI DM9RF1T DM9RF1T DN 1,2-Bis-(4-hydroxy-phenyl)-3H-inden-5-ol DM9RF1T TI TTZAYWL DM9RF1T TN Estrogen receptor (ESR) DM9RF1T MA Inhibitor DM9RF1T RN Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003. DM9RF1T RU https://pubmed.ncbi.nlm.nih.gov/16162002 DM9RHXC DI DM9RHXC DM9RHXC DN FGGFTGARKSARKRKNQ DM9RHXC TI TTNT7K8 DM9RHXC TN Nociceptin receptor (OPRL1) DM9RHXC MA Inhibitor DM9RHXC RN Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. DM9RHXC RU https://pubmed.ncbi.nlm.nih.gov/19577933 DM9RNUX DI DM9RNUX DM9RNUX DN 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol DM9RNUX TI TT8FYO9 DM9RNUX TN Platelet-derived growth factor receptor alpha (PDGFRA) DM9RNUX MA Inhibitor DM9RNUX RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM9RNUX RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM9RNUX DI DM9RNUX DM9RNUX DN 4-(6,7-Dimethoxy-quinolin-3-yl)-phenol DM9RNUX TI TTI7421 DM9RNUX TN Platelet-derived growth factor receptor beta (PDGFRB) DM9RNUX MA Inhibitor DM9RNUX RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DM9RNUX RU https://pubmed.ncbi.nlm.nih.gov/8035419 DM9RQ7E DI DM9RQ7E DM9RQ7E DN Ala6-SRIF-14-amide DM9RQ7E TI TTAE1BR DM9RQ7E TN Somatostatin receptor type 4 (SSTR4) DM9RQ7E MA Inhibitor DM9RQ7E RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DM9RQ7E RU https://pubmed.ncbi.nlm.nih.gov/15943475 DM9RQ7E DI DM9RQ7E DM9RQ7E DN Ala6-SRIF-14-amide DM9RQ7E TI TTZ6T9E DM9RQ7E TN Somatostatin receptor type 2 (SSTR2) DM9RQ7E MA Inhibitor DM9RQ7E RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DM9RQ7E RU https://pubmed.ncbi.nlm.nih.gov/15943475 DM9RU46 DI DM9RU46 DM9RU46 DN S24014 DM9RU46 TI TT0WAIE DM9RU46 TN Melatonin receptor type 1A (MTNR1A) DM9RU46 MA Agonist DM9RU46 RN New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. DM9RU46 RU https://pubmed.ncbi.nlm.nih.gov/12764576 DM9S210 DI DM9S210 DM9S210 DN Methyl 4-(3-cyclohexylureido)butanoate DM9S210 TI TT7WVHI DM9S210 TN Soluble epoxide hydrolase (EPHX2) DM9S210 MA Inhibitor DM9S210 RN Peptidyl-urea based inhibitors of soluble epoxide hydrolases. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5439-44. DM9S210 RU https://pubmed.ncbi.nlm.nih.gov/16908134 DM9S30P DI DM9S30P DM9S30P DN MEMOQUIN DM9S30P TI TTEB0GD DM9S30P TN Cholinesterase (BCHE) DM9S30P MA Inhibitor DM9S30P RN Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6. DM9S30P RU https://pubmed.ncbi.nlm.nih.gov/19813747 DM9S30P DI DM9S30P DM9S30P DN MEMOQUIN DM9S30P TI TT1RS9F DM9S30P TN Acetylcholinesterase (AChE) DM9S30P MA Inhibitor DM9S30P RN Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6. DM9S30P RU https://pubmed.ncbi.nlm.nih.gov/19813747 DM9S36A DI DM9S36A DM9S36A DN 3-(3-Benzylnaphthalen-2-yl)pyridine DM9S36A TI TTIQUX7 DM9S36A TN Steroid 11-beta-hydroxylase (CYP11B1) DM9S36A MA Inhibitor DM9S36A RN Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49. DM9S36A RU https://pubmed.ncbi.nlm.nih.gov/18763754 DM9S5DV DI DM9S5DV DM9S5DV DN TASPINE DM9S5DV TI TT1RS9F DM9S5DV TN Acetylcholinesterase (AChE) DM9S5DV MA Inhibitor DM9S5DV RN Taspine: bioactivity-guided isolation and molecular ligand-target insight of a potent acetylcholinesterase inhibitor from Magnolia x soulangiana. J Nat Prod. 2006 Sep;69(9):1341-6. DM9S5DV RU https://pubmed.ncbi.nlm.nih.gov/16989531 DM9S5V0 DI DM9S5V0 DM9S5V0 DN 4'-Amino-4-hydroxychalcone DM9S5V0 TI TTULVH8 DM9S5V0 TN Tyrosinase (TYR) DM9S5V0 MA Inhibitor DM9S5V0 RN Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7. DM9S5V0 RU https://pubmed.ncbi.nlm.nih.gov/20149498 DM9S8LY DI DM9S8LY DM9S8LY DN 2,7-Bis(butyramido)anthraquinone DM9S8LY TI TTQY2EJ DM9S8LY TN TERT messenger RNA (TERT mRNA) DM9S8LY MA Inhibitor DM9S8LY RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DM9S8LY RU https://pubmed.ncbi.nlm.nih.gov/18571928 DM9SF48 DI DM9SF48 DM9SF48 DN SMTP-0 DM9SF48 TI TTP86E2 DM9SF48 TN Plasminogen (PLG) DM9SF48 MA Modulator DM9SF48 RN Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. DM9SF48 RU https://pubmed.ncbi.nlm.nih.gov/23694890 DM9SFGB DI DM9SFGB DM9SFGB DN J-109,390 DM9SFGB TI TTX20QP DM9SFGB TN Geranylgeranyl transferase I (GGTase-I) DM9SFGB MA Inhibitor DM9SFGB RN Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J Bacteriol. 2000 Feb;182(3):704-13. DM9SFGB RU https://pubmed.ncbi.nlm.nih.gov/10633104 DM9SGBO DI DM9SGBO DM9SGBO DN 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide DM9SGBO TI TTVDSZ0 DM9SGBO TN Poly [ADP-ribose] polymerase 1 (PARP1) DM9SGBO MA Inhibitor DM9SGBO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9SGBO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9SGBW DI DM9SGBW DM9SGBW DN 7-phenyl-1-(5-phenyloxazol-2-yl)heptan-1-one DM9SGBW TI TTDP1UC DM9SGBW TN Fatty acid amide hydrolase (FAAH) DM9SGBW MA Inhibitor DM9SGBW RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DM9SGBW RU https://pubmed.ncbi.nlm.nih.gov/18630870 DM9SKYC DI DM9SKYC DM9SKYC DN 1-phenyl-3-(2-(pyridin-2-yl)quinazolin-4-yl)urea DM9SKYC TI TTJFY5U DM9SKYC TN Adenosine A3 receptor (ADORA3) DM9SKYC MA Inhibitor DM9SKYC RN Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97. DM9SKYC RU https://pubmed.ncbi.nlm.nih.gov/16821770 DM9SLUK DI DM9SLUK DM9SLUK DN PMID22595175C4g DM9SLUK TI TT5MLC4 DM9SLUK TN Leukocyte proteinase-3 (PRTN3) DM9SLUK MA Inhibitor DM9SLUK RN N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7. DM9SLUK RU https://pubmed.ncbi.nlm.nih.gov/22595175 DM9SLUK DI DM9SLUK DM9SLUK DN PMID22595175C4g DM9SLUK TI TTQAJF1 DM9SLUK TN Cathepsin G (CTSG) DM9SLUK MA Inhibitor DM9SLUK RN N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7. DM9SLUK RU https://pubmed.ncbi.nlm.nih.gov/22595175 DM9SLUK DI DM9SLUK DM9SLUK DN PMID22595175C4g DM9SLUK TI TTPLTSQ DM9SLUK TN Neutrophil elastase (NE) DM9SLUK MA Inhibitor DM9SLUK RN N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett. 2012 Jun 15;22(12):3993-7. DM9SLUK RU https://pubmed.ncbi.nlm.nih.gov/22595175 DM9SNFX DI DM9SNFX DM9SNFX DN p-[18F]MPPF DM9SNFX TI TTSQIFT DM9SNFX TN 5-HT 1A receptor (HTR1A) DM9SNFX MA Antagonist DM9SNFX RN A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med. 2005 Dec;46(12):1980-9. DM9SNFX RU https://pubmed.ncbi.nlm.nih.gov/16330560 DM9SP2U DI DM9SP2U DM9SP2U DN [Gly8, aib22]GLP-1(7-37)-NH2 DM9SP2U TI TTVIMDE DM9SP2U TN Glucagon-like peptide 1 receptor (GLP1R) DM9SP2U MA Inhibitor DM9SP2U RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DM9SP2U RU https://pubmed.ncbi.nlm.nih.gov/18412318 DM9SVEB DI DM9SVEB DM9SVEB DN 4-Chloro-7-methyl-2-phenyl-[1,8]naphthyridine DM9SVEB TI TTK25J1 DM9SVEB TN Adenosine A1 receptor (ADORA1) DM9SVEB MA Inhibitor DM9SVEB RN A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives. J Med Chem. 2000 Jul 27;43(15):2814-23. DM9SVEB RU https://pubmed.ncbi.nlm.nih.gov/10956189 DM9SXDI DI DM9SXDI DM9SXDI DN A-620223 DM9SXDI TI TTVDSZ0 DM9SXDI TN Poly [ADP-ribose] polymerase 1 (PARP1) DM9SXDI MA Inhibitor DM9SXDI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DM9SXDI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DM9SXMB DI DM9SXMB DM9SXMB DN Z-Arg-Leu-Val-Agly-Ile-Val-OMe DM9SXMB TI TTF2LRI DM9SXMB TN Cathepsin B (CTSB) DM9SXMB MA Inhibitor DM9SXMB RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DM9SXMB RU https://pubmed.ncbi.nlm.nih.gov/12213061 DM9SYEP DI DM9SYEP DM9SYEP DN 1'-tosylspiro[indene-1,4'-piperidine] DM9SYEP TI TT4TFGN DM9SYEP TN Vasopressin V1a receptor (V1AR) DM9SYEP MA Inhibitor DM9SYEP RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DM9SYEP RU https://pubmed.ncbi.nlm.nih.gov/20550119 DM9SYEP DI DM9SYEP DM9SYEP DN 1'-tosylspiro[indene-1,4'-piperidine] DM9SYEP TI TTSCIUP DM9SYEP TN Oxytocin receptor (OTR) DM9SYEP MA Inhibitor DM9SYEP RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DM9SYEP RU https://pubmed.ncbi.nlm.nih.gov/20550119 DM9T0OK DI DM9T0OK DM9T0OK DN N-alkyl urea hydroxamic acids DM9T0OK TI TTICO5G DM9T0OK TN Staphylococcus Peptide deformylase (Stap-coc def) DM9T0OK MA Inhibitor DM9T0OK RN N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother. 2002 Sep;46(9):2752-64. DM9T0OK RU https://pubmed.ncbi.nlm.nih.gov/12183225 DM9T2G3 DI DM9T2G3 DM9T2G3 DN pirenperone DM9T2G3 TI TTO9X1H DM9T2G3 TN 5-HT 7 receptor (HTR7) DM9T2G3 MA Antagonist DM9T2G3 RN Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol. 1997 Sep;122(1):126-32. DM9T2G3 RU https://pubmed.ncbi.nlm.nih.gov/9298538 DM9TCWA DI DM9TCWA DM9TCWA DN 2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol DM9TCWA TI TTZFYLI DM9TCWA TN Dopamine D1 receptor (D1R) DM9TCWA MA Inhibitor DM9TCWA RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DM9TCWA RU https://pubmed.ncbi.nlm.nih.gov/18313931 DM9TCWA DI DM9TCWA DM9TCWA DN 2-{[R-(-)-Apomorphine-2'-oxy]ethoxy}-ethanol DM9TCWA TI TTEX248 DM9TCWA TN Dopamine D2 receptor (D2R) DM9TCWA MA Inhibitor DM9TCWA RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DM9TCWA RU https://pubmed.ncbi.nlm.nih.gov/18313931 DM9THZE DI DM9THZE DM9THZE DN Antiproliferative Agent A771726 DM9THZE TI TT3PQ2Y DM9THZE TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DM9THZE MA Inhibitor DM9THZE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9THZE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9TN2W DI DM9TN2W DM9TN2W DN Propanoic Acid DM9TN2W TI TT6TMZU DM9TN2W TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DM9TN2W MA Inhibitor DM9TN2W RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9TN2W RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9TORW DI DM9TORW DM9TORW DN [D-Ncy(methyl)10] acyline DM9TORW TI TT8R70G DM9TORW TN Gonadotropin-releasing hormone receptor (GNRHR) DM9TORW MA Inhibitor DM9TORW RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DM9TORW RU https://pubmed.ncbi.nlm.nih.gov/17402723 DM9TSW0 DI DM9TSW0 DM9TSW0 DN (+/-)-threo-Benzylphenidate DM9TSW0 TI TTVBI8W DM9TSW0 TN Dopamine transporter (DAT) DM9TSW0 MA Inhibitor DM9TSW0 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM9TSW0 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM9TWR7 DI DM9TWR7 DM9TWR7 DN DEHYDROZINGERONE DM9TWR7 TI TTE4KHA DM9TWR7 TN Amyloid beta A4 protein (APP) DM9TWR7 MA Inhibitor DM9TWR7 RN Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9. DM9TWR7 RU https://pubmed.ncbi.nlm.nih.gov/17004725 DM9TZH4 DI DM9TZH4 DM9TZH4 DN 7-Chloro-2-phenyl-[1,8]naphthyridin-4-ol DM9TZH4 TI TTK25J1 DM9TZH4 TN Adenosine A1 receptor (ADORA1) DM9TZH4 MA Inhibitor DM9TZH4 RN Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31. DM9TZH4 RU https://pubmed.ncbi.nlm.nih.gov/15163184 DM9U1HV DI DM9U1HV DM9U1HV DN 5-fluoro-1H-indole-2-carboxylic acid DM9U1HV TI TTHGL48 DM9U1HV TN AP endonuclease 1 (APEX1) DM9U1HV MA Inhibitor DM9U1HV RN Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63. DM9U1HV RU https://pubmed.ncbi.nlm.nih.gov/21266972 DM9U8TO DI DM9U8TO DM9U8TO DN CGP-36216 DM9U8TO TI TTDCVZW DM9U8TO TN Gamma-aminobutyric acid B receptor (GABBR) DM9U8TO MA Inhibitor DM9U8TO RN Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993). DM9U8TO RU http://www.sciencedirect.com/science/article/pii/S0960894X0181218X DM9UA0N DI DM9UA0N DM9UA0N DN 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine DM9UA0N TI TTAWNKZ DM9UA0N TN Norepinephrine transporter (NET) DM9UA0N MA Inhibitor DM9UA0N RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM9UA0N RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM9UA0N DI DM9UA0N DM9UA0N DN 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine DM9UA0N TI TTVBI8W DM9UA0N TN Dopamine transporter (DAT) DM9UA0N MA Inhibitor DM9UA0N RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM9UA0N RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM9UA0N DI DM9UA0N DM9UA0N DN 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine DM9UA0N TI TT3ROYC DM9UA0N TN Serotonin transporter (SERT) DM9UA0N MA Inhibitor DM9UA0N RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM9UA0N RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM9UA0N DI DM9UA0N DM9UA0N DN 4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine DM9UA0N TI TTSQIFT DM9UA0N TN 5-HT 1A receptor (HTR1A) DM9UA0N MA Inhibitor DM9UA0N RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DM9UA0N RU https://pubmed.ncbi.nlm.nih.gov/19854053 DM9UASM DI DM9UASM DM9UASM DN HERNIARIN DM9UASM TI TTUNARX DM9UASM TN Carbonic anhydrase (CA) DM9UASM MA Inhibitor DM9UASM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM9UASM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM9UASM DI DM9UASM DM9UASM DN HERNIARIN DM9UASM TI TTZHA0O DM9UASM TN Carbonic anhydrase IV (CA-IV) DM9UASM MA Inhibitor DM9UASM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM9UASM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM9UASM DI DM9UASM DM9UASM DN HERNIARIN DM9UASM TI TTHQPL7 DM9UASM TN Carbonic anhydrase I (CA-I) DM9UASM MA Inhibitor DM9UASM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM9UASM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM9UASM DI DM9UASM DM9UASM DN HERNIARIN DM9UASM TI TTCFSPE DM9UASM TN Carbonic anhydrase VI (CA-VI) DM9UASM MA Inhibitor DM9UASM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM9UASM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM9UASM DI DM9UASM DM9UASM DN HERNIARIN DM9UASM TI TT2LVK8 DM9UASM TN Carbonic anhydrase IX (CA-IX) DM9UASM MA Inhibitor DM9UASM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM9UASM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM9UASM DI DM9UASM DM9UASM DN HERNIARIN DM9UASM TI TTEYTKG DM9UASM TN Carbonic anhydrase XIV (CA-XIV) DM9UASM MA Inhibitor DM9UASM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM9UASM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM9UASM DI DM9UASM DM9UASM DN HERNIARIN DM9UASM TI TTSYM0R DM9UASM TN Carbonic anhydrase XII (CA-XII) DM9UASM MA Inhibitor DM9UASM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DM9UASM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DM9UF02 DI DM9UF02 DM9UF02 DN Brocresine DM9UF02 TI TTV9GOF DM9UF02 TN Histidine decarboxylase (HDC) DM9UF02 MA Inhibitor DM9UF02 RN Histamine in brain--its role in regulation of seizure susceptibility. Epilepsy Res. 1991 Nov-Dec;10(2-3):111-8. DM9UF02 RU https://pubmed.ncbi.nlm.nih.gov/1817952 DM9UGFQ DI DM9UGFQ DM9UGFQ DN 1,10-bis-(Dmt-Tic-amino)decane DM9UGFQ TI TT27RFC DM9UGFQ TN Opioid receptor delta (OPRD1) DM9UGFQ MA Inhibitor DM9UGFQ RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DM9UGFQ RU https://pubmed.ncbi.nlm.nih.gov/16335927 DM9UGFQ DI DM9UGFQ DM9UGFQ DN 1,10-bis-(Dmt-Tic-amino)decane DM9UGFQ TI TTKWM86 DM9UGFQ TN Opioid receptor mu (MOP) DM9UGFQ MA Inhibitor DM9UGFQ RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DM9UGFQ RU https://pubmed.ncbi.nlm.nih.gov/16335927 DM9UGO0 DI DM9UGO0 DM9UGO0 DN 4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine DM9UGO0 TI TTXV4FI DM9UGO0 TN Albendazole monooxygenase (CYP3A4) DM9UGO0 MA Inhibitor DM9UGO0 RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DM9UGO0 RU https://pubmed.ncbi.nlm.nih.gov/14698153 DM9UGO0 DI DM9UGO0 DM9UGO0 DN 4-[2-(4-Imidazol-1-yl-phenoxy)-ethyl]-morpholine DM9UGO0 TI TTVG215 DM9UGO0 TN Debrisoquine 4-hydroxylase (CYP2D6) DM9UGO0 MA Inhibitor DM9UGO0 RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DM9UGO0 RU https://pubmed.ncbi.nlm.nih.gov/14698153 DM9UHCY DI DM9UHCY DM9UHCY DN S-tubercidinylhomocysteine DM9UHCY TI TT6VZ78 DM9UHCY TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DM9UHCY MA Inhibitor DM9UHCY RN SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg Med Chem Lett. 2009 May 15;19(10):2747-51. DM9UHCY RU https://pubmed.ncbi.nlm.nih.gov/19362833 DM9UHCY DI DM9UHCY DM9UHCY DN S-tubercidinylhomocysteine DM9UHCY TI TTHVCUP DM9UHCY TN DNA [cytosine-5]-methyltransferase (DNMT) DM9UHCY MA Inhibitor DM9UHCY RN SAR around (l)-S-adenosyl-l-homocysteine, an inhibitor of human DNA methyltransferase (DNMT) enzymes. Bioorg Med Chem Lett. 2009 May 15;19(10):2747-51. DM9UHCY RU https://pubmed.ncbi.nlm.nih.gov/19362833 DM9UK6D DI DM9UK6D DM9UK6D DN Dihydro-quinolinone DM9UK6D TI TTQBR95 DM9UK6D TN Stress-activated protein kinase 2a (p38 alpha) DM9UK6D MA Inhibitor DM9UK6D RN In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. DM9UK6D RU https://pubmed.ncbi.nlm.nih.gov/20188577 DM9UNLH DI DM9UNLH DM9UNLH DN Phenyl 4-(heptyloxy)phenylcarbamate DM9UNLH TI TTDP1UC DM9UNLH TN Fatty acid amide hydrolase (FAAH) DM9UNLH MA Inhibitor DM9UNLH RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DM9UNLH RU https://pubmed.ncbi.nlm.nih.gov/20036536 DM9UNWE DI DM9UNWE DM9UNWE DN ISIS 29224 DM9UNWE TI TTYMGWX DM9UNWE TN PDK-1 messenger RNA (PDK-1 mRNA) DM9UNWE RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DM9UNWE RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DM9UXRP DI DM9UXRP DM9UXRP DN neurokinin A DM9UXRP TI TTBPGLU DM9UXRP TN Neuromedin-K receptor (TACR3) DM9UXRP MA Agonist DM9UXRP RN Molecular and pharmacological characterization of the murine tachykinin NK(3) receptor. Eur J Pharmacol. 2001 Feb 16;413(2-3):143-50. DM9UXRP RU https://pubmed.ncbi.nlm.nih.gov/11226387 DM9UXRP DI DM9UXRP DM9UXRP DN neurokinin A DM9UXRP TI TTZPO1L DM9UXRP TN Substance-P receptor (TACR1) DM9UXRP MA Agonist DM9UXRP RN Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist. J Pharmacol Exp Ther.1997 Jun;281(3):1303-11. DM9UXRP RU https://pubmed.ncbi.nlm.nih.gov/9190866 DM9UXRP DI DM9UXRP DM9UXRP DN neurokinin A DM9UXRP TI TTYO0A3 DM9UXRP TN Substance-K receptor (TACR2) DM9UXRP MA Agonist DM9UXRP RN Structure-activity relationships of neurokinin A (4-10) at the human tachykinin NK(2) receptor: the role of natural residues and their chirality. Biochem Pharmacol. 2001 Jan 1;61(1):55-60. DM9UXRP RU https://pubmed.ncbi.nlm.nih.gov/11137709 DM9V01W DI DM9V01W DM9V01W DN VU0359516 DM9V01W TI TTICZ1O DM9V01W TN Metabotropic glutamate receptor 4 (mGluR4) DM9V01W MA Modulator (allosteric modulator) DM9V01W RN Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4. ACS Chem Neurosci. 2010 Jun 16;1(6):411-419. DM9V01W RU https://pubmed.ncbi.nlm.nih.gov/20582156 DM9V0KP DI DM9V0KP DM9V0KP DN WR85915 DM9V0KP TI TTML2WA DM9V0KP TN Tubulin (TUB) DM9V0KP MA Inhibitor DM9V0KP RN Cellular effects of leishmanial tubulin inhibitors on L. donovani. Mol Biochem Parasitol. 2000 Oct;110(2):223-36. DM9V0KP RU https://pubmed.ncbi.nlm.nih.gov/11071278 DM9V5GS DI DM9V5GS DM9V5GS DN AS604872 DM9V5GS TI TTT2ZAR DM9V5GS TN Prostaglandin F2-alpha receptor (PTGFR) DM9V5GS MA Antagonist DM9V5GS RN Arrest of preterm labor in rat and mouse by an oral and selective nonprostanoid antagonist of the prostaglandin F2alpha receptor (FP). Am J Obstet Gynecol. 2007 Jul;197(1):54.e1-9. DM9V5GS RU https://pubmed.ncbi.nlm.nih.gov/17618756 DM9V6FW DI DM9V6FW DM9V6FW DN ISIS 11159 DM9V6FW TI TTA1L39 DM9V6FW TN ICAM1 messenger RNA (ICAM1 mRNA) DM9V6FW RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DM9V6FW RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DM9V6YK DI DM9V6YK DM9V6YK DN PMID15055993C1a DM9V6YK TI TT6X50U DM9V6YK TN Matrix metalloproteinase-9 (MMP-9) DM9V6YK MA Inhibitor DM9V6YK RN Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem. 2004 Apr 8;47(8):1930-8. DM9V6YK RU https://pubmed.ncbi.nlm.nih.gov/15055993 DM9V807 DI DM9V807 DM9V807 DN PB-81 DM9V807 TI TTXQKM3 DM9V807 TN Farnesyl protein transferase (Ftase) DM9V807 MA Inhibitor DM9V807 RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DM9V807 RU https://pubmed.ncbi.nlm.nih.gov/15916422 DM9V807 DI DM9V807 DM9V807 DN PB-81 DM9V807 TI TT7WZIJ DM9V807 TN CAAX farnesyltransferase beta (FNTB) DM9V807 MA Inhibitor DM9V807 RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DM9V807 RU https://pubmed.ncbi.nlm.nih.gov/15916422 DM9VD4W DI DM9VD4W DM9VD4W DN 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide DM9VD4W TI TTKWM86 DM9VD4W TN Opioid receptor mu (MOP) DM9VD4W MA Inhibitor DM9VD4W RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DM9VD4W RU https://pubmed.ncbi.nlm.nih.gov/17980586 DM9VD4W DI DM9VD4W DM9VD4W DN 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide DM9VD4W TI TT27RFC DM9VD4W TN Opioid receptor delta (OPRD1) DM9VD4W MA Inhibitor DM9VD4W RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DM9VD4W RU https://pubmed.ncbi.nlm.nih.gov/17980586 DM9VD4W DI DM9VD4W DM9VD4W DN 6-(4-((phenethylamino)methyl)phenoxy)nicotinamide DM9VD4W TI TTQW87Y DM9VD4W TN Opioid receptor kappa (OPRK1) DM9VD4W MA Inhibitor DM9VD4W RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DM9VD4W RU https://pubmed.ncbi.nlm.nih.gov/17980586 DM9VDOG DI DM9VDOG DM9VDOG DN 13-(3-n-Pentylureido)tridec-8-ynoic acid DM9VDOG TI TT7WVHI DM9VDOG TN Soluble epoxide hydrolase (EPHX2) DM9VDOG MA Inhibitor DM9VDOG RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DM9VDOG RU https://pubmed.ncbi.nlm.nih.gov/19653681 DM9VISB DI DM9VISB DM9VISB DN O-1602 DM9VISB TI TTSLJAR DM9VISB TN N-arachidonyl glycine receptor (GPR18) DM9VISB MA Agonist DM9VISB RN Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012 Apr;165(8):2414-24. DM9VISB RU https://pubmed.ncbi.nlm.nih.gov/21595653 DM9VISB DI DM9VISB DM9VISB DN O-1602 DM9VISB TI TTNET8J DM9VISB TN G-protein coupled receptor 55 (GPR55) DM9VISB MA Agonist DM9VISB RN International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev. 2010 Dec;62(4):588-631. DM9VISB RU https://pubmed.ncbi.nlm.nih.gov/21079038 DM9VKXC DI DM9VKXC DM9VKXC DN dipropyl-5-CT DM9VKXC TI TTK8CXU DM9VKXC TN 5-HT 1B receptor (HTR1B) DM9VKXC MA Agonist DM9VKXC RN Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4. DM9VKXC RU https://pubmed.ncbi.nlm.nih.gov/1565658 DM9VKXC DI DM9VKXC DM9VKXC DN dipropyl-5-CT DM9VKXC TI TT0MI3F DM9VKXC TN 5-HT 1F receptor (HTR1F) DM9VKXC MA Agonist DM9VKXC RN Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12. DM9VKXC RU https://pubmed.ncbi.nlm.nih.gov/8380639 DM9VKXC DI DM9VKXC DM9VKXC DN dipropyl-5-CT DM9VKXC TI TT6MSOK DM9VKXC TN 5-HT 1D receptor (HTR1D) DM9VKXC MA Agonist DM9VKXC RN Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3630-4. DM9VKXC RU https://pubmed.ncbi.nlm.nih.gov/1565658 DM9VKXC DI DM9VKXC DM9VKXC DN dipropyl-5-CT DM9VKXC TI TTO9X1H DM9VKXC TN 5-HT 7 receptor (HTR7) DM9VKXC MA Agonist DM9VKXC RN Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT7 receptor (h5-HT7b). Br J Pharmacol. 1997 Sep;122(1):126-32. DM9VKXC RU https://pubmed.ncbi.nlm.nih.gov/9298538 DM9VLS2 DI DM9VLS2 DM9VLS2 DN Fumarate DM9VLS2 TI TTHDSE2 DM9VLS2 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DM9VLS2 MA Inhibitor DM9VLS2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9VLS2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9VN21 DI DM9VN21 DM9VN21 DN 4-Chloro-2,6-diisopropyl-phenol DM9VN21 TI TTNJYV2 DM9VN21 TN Gamma-aminobutyric acid receptor (GAR) DM9VN21 MA Inhibitor DM9VN21 RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DM9VN21 RU https://pubmed.ncbi.nlm.nih.gov/9599235 DM9VPFL DI DM9VPFL DM9VPFL DN 4-[4-(benzoylamino)benzoyl]benzoic acid DM9VPFL TI TTT02K8 DM9VPFL TN Steroid 5-alpha-reductase 2 (SRD5A2) DM9VPFL MA Inhibitor DM9VPFL RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DM9VPFL RU https://pubmed.ncbi.nlm.nih.gov/16420060 DM9VQ0T DI DM9VQ0T DM9VQ0T DN 4-Hydroxy-piperidine-3-carboxylic acid DM9VQ0T TI TT8RXO5 DM9VQ0T TN GABA transporter-3 (SLC6A11) DM9VQ0T MA Inhibitor DM9VQ0T RN Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62. DM9VQ0T RU https://pubmed.ncbi.nlm.nih.gov/6292417 DM9VQ0T DI DM9VQ0T DM9VQ0T DN 4-Hydroxy-piperidine-3-carboxylic acid DM9VQ0T TI TTPRKM0 DM9VQ0T TN GABA transporter GAT-1 (SLC6A1) DM9VQ0T MA Inhibitor DM9VQ0T RN Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62. DM9VQ0T RU https://pubmed.ncbi.nlm.nih.gov/6292417 DM9VYOI DI DM9VYOI DM9VYOI DN 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE DM9VYOI TI TTELIN2 DM9VYOI TN PTPN1 messenger RNA (PTPN1 mRNA) DM9VYOI MA Inhibitor DM9VYOI RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9VYOI RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9W21L DI DM9W21L DM9W21L DN Ac-WVEHRLKGELSRKGGVV[hArg]KNFVPTDVGPFAF-NH2 DM9W21L TI TTVSFJW DM9W21L TN Calcitonin gene-related peptide 1 (CALCA) DM9W21L MA Inhibitor DM9W21L RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DM9W21L RU https://pubmed.ncbi.nlm.nih.gov/19053766 DM9W2ZV DI DM9W2ZV DM9W2ZV DN Bromsulphthalein DM9W2ZV TI TTKVTQO DM9W2ZV TN Prostaglandin transporter (SLC21A2) DM9W2ZV MA Inhibitor DM9W2ZV RN Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. DM9W2ZV RU https://pubmed.ncbi.nlm.nih.gov/7754369 DM9WC1T DI DM9WC1T DM9WC1T DN NK3201 DM9WC1T TI TT8VUE0 DM9WC1T TN Chymase (CYM) DM9WC1T MA Inhibitor DM9WC1T RN Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003 Nov 1;60(2):413-20. DM9WC1T RU https://pubmed.ncbi.nlm.nih.gov/14613871 DM9WHD2 DI DM9WHD2 DM9WHD2 DN (E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide DM9WHD2 TI TTMSFAW DM9WHD2 TN Cannabinoid receptor 2 (CB2) DM9WHD2 MA Inhibitor DM9WHD2 RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM9WHD2 RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM9WHD2 DI DM9WHD2 DM9WHD2 DN (E)-N-(3,5-dimethoxyphenethyl)undec-2-enamide DM9WHD2 TI TT6OEDT DM9WHD2 TN Cannabinoid receptor 1 (CB1) DM9WHD2 MA Inhibitor DM9WHD2 RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DM9WHD2 RU https://pubmed.ncbi.nlm.nih.gov/16213718 DM9WIHJ DI DM9WIHJ DM9WIHJ DN NSC-88915 DM9WIHJ TI TT9NVXQ DM9WIHJ TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DM9WIHJ MA Inhibitor DM9WIHJ RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DM9WIHJ RU https://pubmed.ncbi.nlm.nih.gov/15615517 DM9WIHJ DI DM9WIHJ DM9WIHJ DN NSC-88915 DM9WIHJ TI TTH0KSX DM9WIHJ TN Rhodopsin (RHO) DM9WIHJ MA Inhibitor DM9WIHJ RN Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303. DM9WIHJ RU https://pubmed.ncbi.nlm.nih.gov/18707087 DM9WIHJ DI DM9WIHJ DM9WIHJ DN NSC-88915 DM9WIHJ TI TT2QM9D DM9WIHJ TN Adenylate cyclase (ADCY) DM9WIHJ MA Inhibitor DM9WIHJ RN Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64. DM9WIHJ RU https://pubmed.ncbi.nlm.nih.gov/18630896 DM9WJZK DI DM9WJZK DM9WJZK DN H-Dmt-Aba-Gly-NH-CH2-Bid DM9WJZK TI TTKWM86 DM9WJZK TN Opioid receptor mu (MOP) DM9WJZK MA Inhibitor DM9WJZK RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DM9WJZK RU https://pubmed.ncbi.nlm.nih.gov/16789756 DM9WJZK DI DM9WJZK DM9WJZK DN H-Dmt-Aba-Gly-NH-CH2-Bid DM9WJZK TI TT27RFC DM9WJZK TN Opioid receptor delta (OPRD1) DM9WJZK MA Inhibitor DM9WJZK RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DM9WJZK RU https://pubmed.ncbi.nlm.nih.gov/16789756 DM9WL6O DI DM9WL6O DM9WL6O DN (R)-2-(2-naphthamido)-5-phenylpent-4-ynoic acid DM9WL6O TI TTJNTSI DM9WL6O TN Rotamase Pin1 (PIN1) DM9WL6O MA Inhibitor DM9WL6O RN Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. DM9WL6O RU https://pubmed.ncbi.nlm.nih.gov/20207139 DM9WLN4 DI DM9WLN4 DM9WLN4 DN 10-hydroxycamptothecin DM9WLN4 TI TTGTQHC DM9WLN4 TN DNA topoisomerase I (TOP1) DM9WLN4 MA Inhibitor DM9WLN4 RN Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways. Int J Oncol. 1998 Apr;12(4):793-804. DM9WLN4 RU https://pubmed.ncbi.nlm.nih.gov/9499438 DM9WQ6V DI DM9WQ6V DM9WQ6V DN N-Acetylmethionine DM9WQ6V TI TTH0KSX DM9WQ6V TN Rhodopsin (RHO) DM9WQ6V MA Inhibitor DM9WQ6V RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9WQ6V RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9WQOJ DI DM9WQOJ DM9WQOJ DN 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine DM9WQOJ TI TT78R5H DM9WQOJ TN Heat shock protein 90 alpha (HSP90A) DM9WQOJ MA Inhibitor DM9WQOJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DM9WQOJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DM9WRUG DI DM9WRUG DM9WRUG DN BMS-344577 DM9WRUG TI TTCIHJA DM9WRUG TN Coagulation factor Xa (F10) DM9WRUG MA Inhibitor DM9WRUG RN Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. DM9WRUG RU https://pubmed.ncbi.nlm.nih.gov/19896847 DM9WRUG DI DM9WRUG DM9WRUG DN BMS-344577 DM9WRUG TI TTXAGYU DM9WRUG TN Tissue-type plasminogen activator (PLAT) DM9WRUG MA Inhibitor DM9WRUG RN Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. DM9WRUG RU https://pubmed.ncbi.nlm.nih.gov/19896847 DM9WRUG DI DM9WRUG DM9WRUG DN BMS-344577 DM9WRUG TI TT6L509 DM9WRUG TN Coagulation factor IIa (F2) DM9WRUG MA Inhibitor DM9WRUG RN Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. DM9WRUG RU https://pubmed.ncbi.nlm.nih.gov/19896847 DM9WT8M DI DM9WT8M DM9WT8M DN 4-Allyl-6-nitro-2-piperazin-1-yl-quinoline DM9WT8M TI TT3ROYC DM9WT8M TN Serotonin transporter (SERT) DM9WT8M MA Inhibitor DM9WT8M RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DM9WT8M RU https://pubmed.ncbi.nlm.nih.gov/11859009 DM9WU3R DI DM9WU3R DM9WU3R DN Dideazaacyclotetrahydrofolic acid DM9WU3R TI TTEXB9Z DM9WU3R TN Glycinamide ribonucleotide formyltransferase (GART) DM9WU3R MA Inhibitor DM9WU3R RN Asymmetric synthesis of inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 2008 Sep 11;51(17):5441-8. DM9WU3R RU https://pubmed.ncbi.nlm.nih.gov/18686942 DM9WUHD DI DM9WUHD DM9WUHD DN Clik60 DM9WUHD TI TTUMQVO DM9WUHD TN Cathepsin S (CTSS) DM9WUHD MA Inhibitor DM9WUHD RN Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest. 2002 Aug;110(3):361-9. DM9WUHD RU https://pubmed.ncbi.nlm.nih.gov/12163455 DM9WX3C DI DM9WX3C DM9WX3C DN MRS1191 DM9WX3C TI TTJFY5U DM9WX3C TN Adenosine A3 receptor (ADORA3) DM9WX3C MA Antagonist DM9WX3C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 21). DM9WX3C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21 DM9WX3C DI DM9WX3C DM9WX3C DN MRS1191 DM9WX3C TI TTNE7KG DM9WX3C TN Adenosine A2b receptor (ADORA2B) DM9WX3C MA Antagonist DM9WX3C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20). DM9WX3C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20 DM9WX3C DI DM9WX3C DM9WX3C DN MRS1191 DM9WX3C TI TTK25J1 DM9WX3C TN Adenosine A1 receptor (ADORA1) DM9WX3C MA Antagonist DM9WX3C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18). DM9WX3C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18 DM9WY1D DI DM9WY1D DM9WY1D DN GR-91272 DM9WY1D TI TTQW87Y DM9WY1D TN Opioid receptor kappa (OPRK1) DM9WY1D MA Modulator DM9WY1D RN Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist. DM9WY1D RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907793 DM9X3B7 DI DM9X3B7 DM9X3B7 DN N-omega-propargyl-L-arginine DM9X3B7 TI TTCM4B3 DM9X3B7 TN Nitric-oxide synthase endothelial (NOS3) DM9X3B7 MA Inhibitor DM9X3B7 RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM9X3B7 RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM9X3B7 DI DM9X3B7 DM9X3B7 DN N-omega-propargyl-L-arginine DM9X3B7 TI TTZUFI5 DM9X3B7 TN Nitric-oxide synthase brain (NOS1) DM9X3B7 MA Inhibitor DM9X3B7 RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM9X3B7 RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM9X3B7 DI DM9X3B7 DM9X3B7 DN N-omega-propargyl-L-arginine DM9X3B7 TI TTF10I9 DM9X3B7 TN Nitric-oxide synthase inducible (NOS2) DM9X3B7 MA Inhibitor DM9X3B7 RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DM9X3B7 RU https://pubmed.ncbi.nlm.nih.gov/19013076 DM9XC6A DI DM9XC6A DM9XC6A DN Bis(5-methoxybenzo[b]furan-2-yl)methanone DM9XC6A TI TTI7421 DM9XC6A TN Platelet-derived growth factor receptor beta (PDGFRB) DM9XC6A MA Inhibitor DM9XC6A RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DM9XC6A RU https://pubmed.ncbi.nlm.nih.gov/17210255 DM9XCZS DI DM9XCZS DM9XCZS DN N1-[4-(Phenylmethoxy)phenyl]-L-glutamine DM9XCZS TI TTXZEAJ DM9XCZS TN Leukotriene A-4 hydrolase (LTA4H) DM9XCZS MA Inhibitor DM9XCZS RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DM9XCZS RU https://pubmed.ncbi.nlm.nih.gov/18394906 DM9XFYZ DI DM9XFYZ DM9XFYZ DN ZP-G-CSF DM9XFYZ TI TTC70AJ DM9XFYZ TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DM9XFYZ MA Stimulator DM9XFYZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DM9XFYZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DM9XH18 DI DM9XH18 DM9XH18 DN N-(3-Phenyl)propyl-2,2-diphenylacetamide DM9XH18 TI TT6OEDT DM9XH18 TN Cannabinoid receptor 1 (CB1) DM9XH18 MA Inhibitor DM9XH18 RN Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5. DM9XH18 RU https://pubmed.ncbi.nlm.nih.gov/18579386 DM9XK05 DI DM9XK05 DM9XK05 DN H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 DM9XK05 TI TTW4N16 DM9XK05 TN Neuropeptide Y receptor type 4 (NPY4R) DM9XK05 MA Inhibitor DM9XK05 RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM9XK05 RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM9XK05 DI DM9XK05 DM9XK05 DN H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 DM9XK05 TI TTJ6WK9 DM9XK05 TN Neuropeptide Y receptor type 2 (NPY2R) DM9XK05 MA Inhibitor DM9XK05 RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM9XK05 RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM9XK05 DI DM9XK05 DM9XK05 DN H-[Trp-Arg-Nva-Arg-Tyr]2-NH2 DM9XK05 TI TTRK9JT DM9XK05 TN Neuropeptide Y receptor type 1 (NPY1R) DM9XK05 MA Inhibitor DM9XK05 RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DM9XK05 RU https://pubmed.ncbi.nlm.nih.gov/16610810 DM9XKJQ DI DM9XKJQ DM9XKJQ DN 2-Amino-6-(3-chloro-benzenesulfonyl)-benzonitrile DM9XKJQ TI TT84ETX DM9XKJQ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9XKJQ MA Inhibitor DM9XKJQ RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DM9XKJQ RU https://pubmed.ncbi.nlm.nih.gov/11384233 DM9XNSK DI DM9XNSK DM9XNSK DN Sulfamic acid 12-sulfamoyloxy-dodecyl ester DM9XNSK TI TTANPDJ DM9XNSK TN Carbonic anhydrase II (CA-II) DM9XNSK MA Inhibitor DM9XNSK RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DM9XNSK RU https://pubmed.ncbi.nlm.nih.gov/15664816 DM9XNSK DI DM9XNSK DM9XNSK DN Sulfamic acid 12-sulfamoyloxy-dodecyl ester DM9XNSK TI TT2LVK8 DM9XNSK TN Carbonic anhydrase IX (CA-IX) DM9XNSK MA Inhibitor DM9XNSK RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DM9XNSK RU https://pubmed.ncbi.nlm.nih.gov/15664816 DM9XNSK DI DM9XNSK DM9XNSK DN Sulfamic acid 12-sulfamoyloxy-dodecyl ester DM9XNSK TI TTHQPL7 DM9XNSK TN Carbonic anhydrase I (CA-I) DM9XNSK MA Inhibitor DM9XNSK RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DM9XNSK RU https://pubmed.ncbi.nlm.nih.gov/15664816 DM9XOE6 DI DM9XOE6 DM9XOE6 DN rawsonol DM9XOE6 TI TTPADOQ DM9XOE6 TN HMG-CoA reductase (HMGCR) DM9XOE6 MA Modulator DM9XOE6 RN Bromophenols in Marine Algae and Their Bioactivities DM9XOE6 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148503 DM9XPUN DI DM9XPUN DM9XPUN DN Furan-2-ylmethylcarbamic Acid Biphenyl-3-yl Ester DM9XPUN TI TTDP1UC DM9XPUN TN Fatty acid amide hydrolase (FAAH) DM9XPUN MA Inhibitor DM9XPUN RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DM9XPUN RU https://pubmed.ncbi.nlm.nih.gov/18507372 DM9XTY7 DI DM9XTY7 DM9XTY7 DN 1,1-Dimethyl-4-phenyl-piperazin-1-ium iodide DM9XTY7 TI TTF4E0J DM9XTY7 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DM9XTY7 MA Inhibitor DM9XTY7 RN Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8. DM9XTY7 RU https://pubmed.ncbi.nlm.nih.gov/15050613 DM9XV16 DI DM9XV16 DM9XV16 DN Sanguiin H-6 DM9XV16 TI TTE14XG DM9XV16 TN Squalene monooxygenase (SQLE) DM9XV16 MA Inhibitor DM9XV16 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DM9XV16 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DM9XZJN DI DM9XZJN DM9XZJN DN N,N-dimethyl-2,2,2-triphenylacetamide DM9XZJN TI TTMNI76 DM9XZJN TN Calcium-activated potassium channel (KCN) DM9XZJN MA Inhibitor DM9XZJN RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DM9XZJN RU https://pubmed.ncbi.nlm.nih.gov/18232633 DM9XZSC DI DM9XZSC DM9XZSC DN 2-(Biphenyl-2-ylthio)-N,N-dimethylethanamine DM9XZSC TI TTO9X1H DM9XZSC TN 5-HT 7 receptor (HTR7) DM9XZSC MA Inhibitor DM9XZSC RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DM9XZSC RU https://pubmed.ncbi.nlm.nih.gov/20138771 DM9Y3MT DI DM9Y3MT DM9Y3MT DN (+/-)-threo-N-(2-Phenylethyl)ritalinol DM9Y3MT TI TTVBI8W DM9Y3MT TN Dopamine transporter (DAT) DM9Y3MT MA Inhibitor DM9Y3MT RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DM9Y3MT RU https://pubmed.ncbi.nlm.nih.gov/20846865 DM9Y4FL DI DM9Y4FL DM9Y4FL DN Methyl-(1,2,3,4-tetrahydro-naphthalen-1-yl)-amine DM9Y4FL TI TTGP7BY DM9Y4FL TN Monoamine oxidase type B (MAO-B) DM9Y4FL MA Inhibitor DM9Y4FL RN Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site. J Med Chem. 1988 Aug;31(8):1558-66. DM9Y4FL RU https://pubmed.ncbi.nlm.nih.gov/3397993 DM9Y5NX DI DM9Y5NX DM9Y5NX DN ISIS 173831 DM9Y5NX TI TT9RTBL DM9Y5NX TN Aurora B messenger RNA (AURKB mRNA) DM9Y5NX RN US patent application no. 7,375,212, Modulation of Aurora B expression. DM9Y5NX RU http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true DM9YAPX DI DM9YAPX DM9YAPX DN NSC-745797 DM9YAPX TI TTQY2EJ DM9YAPX TN TERT messenger RNA (TERT mRNA) DM9YAPX MA Inhibitor DM9YAPX RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DM9YAPX RU https://pubmed.ncbi.nlm.nih.gov/19804981 DM9YAVX DI DM9YAVX DM9YAVX DN Abyssinone-IV DM9YAVX TI TTELIN2 DM9YAVX TN PTPN1 messenger RNA (PTPN1 mRNA) DM9YAVX MA Inhibitor DM9YAVX RN Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii. J Nat Prod. 2006 Nov;69(11):1572-6. DM9YAVX RU https://pubmed.ncbi.nlm.nih.gov/17125223 DM9YCAH DI DM9YCAH DM9YCAH DN 2-Aminothiazoline DM9YCAH TI TTCM4B3 DM9YCAH TN Nitric-oxide synthase endothelial (NOS3) DM9YCAH MA Inhibitor DM9YCAH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DM9YCAH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DM9YCAH DI DM9YCAH DM9YCAH DN 2-Aminothiazoline DM9YCAH TI TTZUFI5 DM9YCAH TN Nitric-oxide synthase brain (NOS1) DM9YCAH MA Inhibitor DM9YCAH RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM9YCAH RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM9YCAH DI DM9YCAH DM9YCAH DN 2-Aminothiazoline DM9YCAH TI TTF10I9 DM9YCAH TN Nitric-oxide synthase inducible (NOS2) DM9YCAH MA Inhibitor DM9YCAH RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DM9YCAH RU https://pubmed.ncbi.nlm.nih.gov/15357988 DM9YE6K DI DM9YE6K DM9YE6K DN METHYLHONOKIOL DM9YE6K TI TTSJ6Q4 DM9YE6K TN LOX-5 messenger RNA (ALOX5 mRNA) DM9YE6K MA Inhibitor DM9YE6K RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DM9YE6K RU https://pubmed.ncbi.nlm.nih.gov/19481465 DM9YE6K DI DM9YE6K DM9YE6K DN METHYLHONOKIOL DM9YE6K TI TTVKILB DM9YE6K TN Prostaglandin G/H synthase 2 (COX-2) DM9YE6K MA Inhibitor DM9YE6K RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DM9YE6K RU https://pubmed.ncbi.nlm.nih.gov/19481465 DM9YE6K DI DM9YE6K DM9YE6K DN METHYLHONOKIOL DM9YE6K TI TT8NGED DM9YE6K TN Prostaglandin G/H synthase 1 (COX-1) DM9YE6K MA Inhibitor DM9YE6K RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DM9YE6K RU https://pubmed.ncbi.nlm.nih.gov/19481465 DM9YHA7 DI DM9YHA7 DM9YHA7 DN [(40-OH) MeLeu]4-CsA derivatives DM9YHA7 TI TT84ETX DM9YHA7 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9YHA7 MA Inhibitor DM9YHA7 RN Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9. DM9YHA7 RU https://pubmed.ncbi.nlm.nih.gov/14643337 DM9YJI8 DI DM9YJI8 DM9YJI8 DN SCH-725737 DM9YJI8 TI TT90XZ8 DM9YJI8 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DM9YJI8 MA Inhibitor DM9YJI8 RN Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5543-7. DM9YJI8 RU https://pubmed.ncbi.nlm.nih.gov/17804230 DM9YMPI DI DM9YMPI DM9YMPI DN ISIS 298745 DM9YMPI TI TTSN6QU DM9YMPI TN HIF1-alpha messenger RNA (HIF1A mRNA) DM9YMPI RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DM9YMPI RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DM9YRCU DI DM9YRCU DM9YRCU DN ethylketocyclazocine DM9YRCU TI TTQW87Y DM9YRCU TN Opioid receptor kappa (OPRK1) DM9YRCU MA Agonist DM9YRCU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). DM9YRCU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 DM9YRCU DI DM9YRCU DM9YRCU DN ethylketocyclazocine DM9YRCU TI TT27RFC DM9YRCU TN Opioid receptor delta (OPRD1) DM9YRCU MA Agonist DM9YRCU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DM9YRCU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DM9YRCU DI DM9YRCU DM9YRCU DN ethylketocyclazocine DM9YRCU TI TTKWM86 DM9YRCU TN Opioid receptor mu (MOP) DM9YRCU MA Agonist DM9YRCU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DM9YRCU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DM9YRHW DI DM9YRHW DM9YRHW DN 4-(4-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine DM9YRHW TI TTHS256 DM9YRHW TN Metabotropic glutamate receptor 5 (mGluR5) DM9YRHW MA Inhibitor DM9YRHW RN Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9. DM9YRHW RU https://pubmed.ncbi.nlm.nih.gov/16481165 DM9YVPU DI DM9YVPU DM9YVPU DN PMID21444206C23 DM9YVPU TI TT7QNVC DM9YVPU TN Glucose-dependent insulinotropic receptor (GPR119) DM9YVPU MA Agonist DM9YVPU RN Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41. DM9YVPU RU https://pubmed.ncbi.nlm.nih.gov/21444206 DM9YWG8 DI DM9YWG8 DM9YWG8 DN Quick-acting insulin DM9YWG8 TI TTCBFJO DM9YWG8 TN Insulin receptor (INSR) DM9YWG8 MA Modulator DM9YWG8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DM9YWG8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DM9Z1NY DI DM9Z1NY DM9Z1NY DN 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione DM9Z1NY TI TTMF541 DM9Z1NY TN Liver carboxylesterase (CES1) DM9Z1NY MA Inhibitor DM9Z1NY RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM9Z1NY RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM9Z1NY DI DM9Z1NY DM9Z1NY DN 1,2-bis(2,3-fluorophenyl)ethane-1,2-dione DM9Z1NY TI TTEB0GD DM9Z1NY TN Cholinesterase (BCHE) DM9Z1NY MA Inhibitor DM9Z1NY RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DM9Z1NY RU https://pubmed.ncbi.nlm.nih.gov/17399985 DM9Z6VP DI DM9Z6VP DM9Z6VP DN N-isobutylnorlitebamine DM9Z6VP TI TT1RS9F DM9Z6VP TN Acetylcholinesterase (AChE) DM9Z6VP MA Inhibitor DM9Z6VP RN Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50. DM9Z6VP RU https://pubmed.ncbi.nlm.nih.gov/9461651 DM9Z8V5 DI DM9Z8V5 DM9Z8V5 DN 2-(2-Methoxybenzyl)-3H-benzo[f]chromen-3-one DM9Z8V5 TI TTMSFAW DM9Z8V5 TN Cannabinoid receptor 2 (CB2) DM9Z8V5 MA Inhibitor DM9Z8V5 RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DM9Z8V5 RU https://pubmed.ncbi.nlm.nih.gov/19278853 DM9ZBLE DI DM9ZBLE DM9ZBLE DN Sphinganine DM9ZBLE TI TTO3TD8 DM9ZBLE TN Long transient receptor potential channel 3 (TRPM3) DM9ZBLE MA Activator DM9ZBLE RN Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected]. Mol Pharmacol. 2005 Mar;67(3):798-805. DM9ZBLE RU https://pubmed.ncbi.nlm.nih.gov/15550678 DM9ZC7B DI DM9ZC7B DM9ZC7B DN 5-oxo-15-HETE DM9ZC7B TI TT7WBSV DM9ZC7B TN Oxoeicosanoid receptor 1 (OXER1) DM9ZC7B MA Agonist DM9ZC7B RN Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils. J Immunol. 1996 Jan 1;156(1):336-42. DM9ZC7B RU https://pubmed.ncbi.nlm.nih.gov/8598482 DM9ZCGX DI DM9ZCGX DM9ZCGX DN PT-311 DM9ZCGX TI TT84ETX DM9ZCGX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DM9ZCGX MA Inhibitor DM9ZCGX RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DM9ZCGX RU https://pubmed.ncbi.nlm.nih.gov/8523406 DM9ZCWV DI DM9ZCWV DM9ZCWV DN Cyclo[(6-bromotryptophan)arginine] DM9ZCWV TI TTWJBZ5 DM9ZCWV TN 5-HT 2C receptor (HTR2C) DM9ZCWV MA Inhibitor DM9ZCWV RN Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4. DM9ZCWV RU https://pubmed.ncbi.nlm.nih.gov/17067154 DM9ZDIK DI DM9ZDIK DM9ZDIK DN 3-(1H-inden-2-yl)pyridine DM9ZDIK TI TTIQUX7 DM9ZDIK TN Steroid 11-beta-hydroxylase (CYP11B1) DM9ZDIK MA Inhibitor DM9ZDIK RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DM9ZDIK RU https://pubmed.ncbi.nlm.nih.gov/16570918 DM9ZK0D DI DM9ZK0D DM9ZK0D DN 1-[(n-oct-1-ylamino)ethyl]-1,1-bisphosphonic acid DM9ZK0D TI TTIKWV4 DM9ZK0D TN Geranyltranstransferase (FDPS) DM9ZK0D MA Inhibitor DM9ZK0D RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DM9ZK0D RU https://pubmed.ncbi.nlm.nih.gov/18096393 DM9ZK0M DI DM9ZK0M DM9ZK0M DN 1-palmitoyl-lysophosphatidylcholine DM9ZK0M TI TT7QNVC DM9ZK0M TN Glucose-dependent insulinotropic receptor (GPR119) DM9ZK0M MA Agonist DM9ZK0M RN Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51. DM9ZK0M RU https://pubmed.ncbi.nlm.nih.gov/15607732 DM9ZK6L DI DM9ZK6L DM9ZK6L DN PD-137789 DM9ZK6L TI TTEX248 DM9ZK6L TN Dopamine D2 receptor (D2R) DM9ZK6L MA Inhibitor DM9ZK6L RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DM9ZK6L RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DM9ZOX4 DI DM9ZOX4 DM9ZOX4 DN 2-Acetylaminoethyl 18-methoxycoronaridinate DM9ZOX4 TI TTTVAFQ DM9ZOX4 TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DM9ZOX4 MA Inhibitor DM9ZOX4 RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DM9ZOX4 RU https://pubmed.ncbi.nlm.nih.gov/12801235 DM9ZRU2 DI DM9ZRU2 DM9ZRU2 DN 1-valproylamido-5-sulfonamidoindane DM9ZRU2 TI TTHQPL7 DM9ZRU2 TN Carbonic anhydrase I (CA-I) DM9ZRU2 MA Inhibitor DM9ZRU2 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM9ZRU2 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM9ZRU2 DI DM9ZRU2 DM9ZRU2 DN 1-valproylamido-5-sulfonamidoindane DM9ZRU2 TI TT2LVK8 DM9ZRU2 TN Carbonic anhydrase IX (CA-IX) DM9ZRU2 MA Inhibitor DM9ZRU2 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM9ZRU2 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM9ZRU2 DI DM9ZRU2 DM9ZRU2 DN 1-valproylamido-5-sulfonamidoindane DM9ZRU2 TI TTANPDJ DM9ZRU2 TN Carbonic anhydrase II (CA-II) DM9ZRU2 MA Inhibitor DM9ZRU2 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DM9ZRU2 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DM9ZTX4 DI DM9ZTX4 DM9ZTX4 DN MDX-1147 DM9ZTX4 TI TT9G4N0 DM9ZTX4 TN Glutamate carboxypeptidase II (GCPII) DM9ZTX4 MA Modulator DM9ZTX4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DM9ZTX4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DM9ZVHJ DI DM9ZVHJ DM9ZVHJ DN 2-m-Tolyl-1H-[1,8]naphthyridin-4-one DM9ZVHJ TI TTYFKSZ DM9ZVHJ TN Tubulin beta (TUBB) DM9ZVHJ MA Inhibitor DM9ZVHJ RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DM9ZVHJ RU https://pubmed.ncbi.nlm.nih.gov/9301667 DM9ZVHJ DI DM9ZVHJ DM9ZVHJ DN 2-m-Tolyl-1H-[1,8]naphthyridin-4-one DM9ZVHJ TI TTML2WA DM9ZVHJ TN Tubulin (TUB) DM9ZVHJ MA Inhibitor DM9ZVHJ RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DM9ZVHJ RU https://pubmed.ncbi.nlm.nih.gov/9301667 DM9ZVJ7 DI DM9ZVJ7 DM9ZVJ7 DN TENELLONE B DM9ZVJ7 TI TTZC6DR DM9ZVJ7 TN cGMP-dependent protein kinase (cGK) DM9ZVJ7 MA Inhibitor DM9ZVJ7 RN Tenellones A and B from a Diaporthe sp.: two highly substituted benzophenone inhibitors of parasite cGMP-dependent protein kinase activity. J Nat Prod. 2005 Apr;68(4):611-3. DM9ZVJ7 RU https://pubmed.ncbi.nlm.nih.gov/15844962 DM9ZWRK DI DM9ZWRK DM9ZWRK DN DELTORPHIN-II DM9ZWRK TI TT27RFC DM9ZWRK TN Opioid receptor delta (OPRD1) DM9ZWRK MA Inhibitor DM9ZWRK RN Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. DM9ZWRK RU https://pubmed.ncbi.nlm.nih.gov/20637637 DM9ZWRK DI DM9ZWRK DM9ZWRK DN DELTORPHIN-II DM9ZWRK TI TTKWM86 DM9ZWRK TN Opioid receptor mu (MOP) DM9ZWRK MA Inhibitor DM9ZWRK RN Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. DM9ZWRK RU https://pubmed.ncbi.nlm.nih.gov/20637637 DM9ZYNJ DI DM9ZYNJ DM9ZYNJ DN SB-706375 DM9ZYNJ TI TTW5UDX DM9ZYNJ TN Urotensin II receptor (UTS2R) DM9ZYNJ MA Inhibitor DM9ZYNJ RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DM9ZYNJ RU https://pubmed.ncbi.nlm.nih.gov/20043680 DMA01OF DI DMA01OF DMA01OF DN ABC-4 DMA01OF TI TT5BR7T DMA01OF TN Fibroblast growth factor receptor 4 (FGFR4) DMA01OF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811). DMA01OF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1811 DMA0D8I DI DMA0D8I DMA0D8I DN ISIS 103806 DMA0D8I TI TT6TU05 DMA0D8I TN WWP2 messenger RNA (WWP2 mRNA) DMA0D8I RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMA0D8I RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMA0E2Q DI DMA0E2Q DMA0E2Q DN ML398 DMA0E2Q TI TTE0A2F DMA0E2Q TN Dopamine D4 receptor (D4R) DMA0E2Q MA Antagonist DMA0E2Q RN Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity. ACS Med Chem Lett. 2014 Jul 9;5(9):1060-4. DMA0E2Q RU https://pubmed.ncbi.nlm.nih.gov/25221667 DMA0FO5 DI DMA0FO5 DMA0FO5 DN BW 245C DMA0FO5 TI TTNVEIR DMA0FO5 TN Prostaglandin D2 receptor (PTGDR) DMA0FO5 MA Agonist DMA0FO5 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMA0FO5 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMA0GSY DI DMA0GSY DMA0GSY DN BZYX DMA0GSY TI TT1RS9F DMA0GSY TN Acetylcholinesterase (AChE) DMA0GSY MA Inhibitor DMA0GSY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMA0GSY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMA0JZM DI DMA0JZM DMA0JZM DN SN-11 DMA0JZM TI TT27RFC DMA0JZM TN Opioid receptor delta (OPRD1) DMA0JZM MA Inhibitor DMA0JZM RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DMA0JZM RU https://pubmed.ncbi.nlm.nih.gov/19362480 DMA0JZM DI DMA0JZM DMA0JZM DN SN-11 DMA0JZM TI TTQW87Y DMA0JZM TN Opioid receptor kappa (OPRK1) DMA0JZM MA Inhibitor DMA0JZM RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DMA0JZM RU https://pubmed.ncbi.nlm.nih.gov/19362480 DMA0JZM DI DMA0JZM DMA0JZM DN SN-11 DMA0JZM TI TTKWM86 DMA0JZM TN Opioid receptor mu (MOP) DMA0JZM MA Inhibitor DMA0JZM RN Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5. DMA0JZM RU https://pubmed.ncbi.nlm.nih.gov/19362480 DMA0MEV DI DMA0MEV DMA0MEV DN Sulfamic acid 3-sulfamoyloxy-phenyl ester DMA0MEV TI TTHQPL7 DMA0MEV TN Carbonic anhydrase I (CA-I) DMA0MEV MA Inhibitor DMA0MEV RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMA0MEV RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMA0MEV DI DMA0MEV DMA0MEV DN Sulfamic acid 3-sulfamoyloxy-phenyl ester DMA0MEV TI TTANPDJ DMA0MEV TN Carbonic anhydrase II (CA-II) DMA0MEV MA Inhibitor DMA0MEV RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMA0MEV RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMA0MEV DI DMA0MEV DMA0MEV DN Sulfamic acid 3-sulfamoyloxy-phenyl ester DMA0MEV TI TT2LVK8 DMA0MEV TN Carbonic anhydrase IX (CA-IX) DMA0MEV MA Inhibitor DMA0MEV RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMA0MEV RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMA0N32 DI DMA0N32 DMA0N32 DN [Leu5]enkephalin DMA0N32 TI TT27RFC DMA0N32 TN Opioid receptor delta (OPRD1) DMA0N32 MA Inhibitor DMA0N32 RN Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81. DMA0N32 RU https://pubmed.ncbi.nlm.nih.gov/20218625 DMA0N32 DI DMA0N32 DMA0N32 DN [Leu5]enkephalin DMA0N32 TI TTQW87Y DMA0N32 TN Opioid receptor kappa (OPRK1) DMA0N32 MA Inhibitor DMA0N32 RN Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81. DMA0N32 RU https://pubmed.ncbi.nlm.nih.gov/20218625 DMA0N32 DI DMA0N32 DMA0N32 DN [Leu5]enkephalin DMA0N32 TI TTKWM86 DMA0N32 TN Opioid receptor mu (MOP) DMA0N32 MA Inhibitor DMA0N32 RN Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81. DMA0N32 RU https://pubmed.ncbi.nlm.nih.gov/20218625 DMA0YGE DI DMA0YGE DMA0YGE DN N-methyl-4-pentyl-N-(pyridin-3-yl)benzamide DMA0YGE TI TTMI6F5 DMA0YGE TN Transient receptor potential cation channel V1 (TRPV1) DMA0YGE MA Inhibitor DMA0YGE RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMA0YGE RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMA106W DI DMA106W DMA106W DN Voacangine DMA106W TI TT1RS9F DMA106W TN Acetylcholinesterase (AChE) DMA106W MA Inhibitor DMA106W RN Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6185-7. DMA106W RU https://pubmed.ncbi.nlm.nih.gov/20850311 DMA14PR DI DMA14PR DMA14PR DN TPCA-1 DMA14PR TI TTRPDBG DMA14PR TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMA14PR MA Inhibitor DMA14PR RN Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbo... J Pharmacol Exp Ther. 2005 Jan;312(1):373-81. DMA14PR RU https://pubmed.ncbi.nlm.nih.gov/15316093 DMA15WU DI DMA15WU DMA15WU DN (2-(4-chlorobenzyloxy)-5-bromophenyl)methanamine DMA15WU TI TT2CEJG DMA15WU TN C-C chemokine receptor type 5 (CCR5) DMA15WU MA Inhibitor DMA15WU RN CCR5 receptor antagonists: discovery and SAR of novel 4-hydroxypiperidine derivatives. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1883-7. DMA15WU RU https://pubmed.ncbi.nlm.nih.gov/17314043 DMA15X9 DI DMA15X9 DMA15X9 DN 1(beta)-O-galloylpedunculagin DMA15X9 TI TTE14XG DMA15X9 TN Squalene monooxygenase (SQLE) DMA15X9 MA Inhibitor DMA15X9 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMA15X9 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMA1EFL DI DMA1EFL DMA1EFL DN (R)-2-amino-4-hydroxy-N-(4-octylphenyl)butanamide DMA1EFL TI TTCN0M9 DMA1EFL TN Sphingosine kinase 2 (SPHK2) DMA1EFL MA Inhibitor DMA1EFL RN Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21. DMA1EFL RU https://pubmed.ncbi.nlm.nih.gov/19800228 DMA1FUH DI DMA1FUH DMA1FUH DN (R)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine DMA1FUH TI TT9JNIC DMA1FUH TN Histamine H3 receptor (H3R) DMA1FUH MA Inhibitor DMA1FUH RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMA1FUH RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMA1LRF DI DMA1LRF DMA1LRF DN N-(2-phenylpropyl)quinoxaline-2-carboxamide DMA1LRF TI TTVBPDM DMA1LRF TN Metabotropic glutamate receptor 1 (mGluR1) DMA1LRF MA Inhibitor DMA1LRF RN Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90. DMA1LRF RU https://pubmed.ncbi.nlm.nih.gov/17064898 DMA1N75 DI DMA1N75 DMA1N75 DN 5-(4-Chlorophenyl)-4-p-tolylisothiazole DMA1N75 TI TT8NGED DMA1N75 TN Prostaglandin G/H synthase 1 (COX-1) DMA1N75 MA Inhibitor DMA1N75 RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMA1N75 RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMA1NL9 DI DMA1NL9 DMA1NL9 DN ONO-AP-324 DMA1NL9 TI TTPNGDE DMA1NL9 TN Prostaglandin E2 receptor EP3 (PTGER3) DMA1NL9 MA Agonist DMA1NL9 RN Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324. Br J Pharmacol. 1998 Nov;125(6):1288-96. DMA1NL9 RU https://pubmed.ncbi.nlm.nih.gov/9863659 DMA1QH0 DI DMA1QH0 DMA1QH0 DN 6-Fluoro-N-(2-morpholinoethyl)nicotinamide DMA1QH0 TI TT3WG5C DMA1QH0 TN Monoamine oxidase type A (MAO-A) DMA1QH0 MA Inhibitor DMA1QH0 RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMA1QH0 RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMA1RHE DI DMA1RHE DMA1RHE DN 2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one DMA1RHE TI TT1MPAY DMA1RHE TN GABA(A) receptor alpha-1 (GABRA1) DMA1RHE MA Inhibitor DMA1RHE RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMA1RHE RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMA1RHE DI DMA1RHE DMA1RHE DN 2-Phenyl-6H-pyrazolo[1,5-c]quinazolin-5-one DMA1RHE TI TTNJYV2 DMA1RHE TN Gamma-aminobutyric acid receptor (GAR) DMA1RHE MA Inhibitor DMA1RHE RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMA1RHE RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMA20JP DI DMA20JP DMA20JP DN ASN06917370 DMA20JP TI TTMPART DMA20JP TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMA20JP MA Agonist DMA20JP RN In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52. DMA20JP RU https://pubmed.ncbi.nlm.nih.gov/21744154 DMA214F DI DMA214F DMA214F DN N-(4,6-diphenylpyrimidin-2-yl)benzamide DMA214F TI TTK25J1 DMA214F TN Adenosine A1 receptor (ADORA1) DMA214F MA Inhibitor DMA214F RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMA214F RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMA21GM DI DMA21GM DMA21GM DN 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol DMA21GM TI TTN9D8E DMA21GM TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMA21GM MA Inhibitor DMA21GM RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMA21GM RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMA21GM DI DMA21GM DMA21GM DN 4-{2-[Ethyl-(4-phenyl-butyl)-amino]-ethyl}-phenol DMA21GM TI TTLD29N DMA21GM TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMA21GM MA Inhibitor DMA21GM RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMA21GM RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMA21WB DI DMA21WB DMA21WB DN N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide DMA21WB TI TTANPDJ DMA21WB TN Carbonic anhydrase II (CA-II) DMA21WB MA Inhibitor DMA21WB RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMA21WB RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMA21WB DI DMA21WB DMA21WB DN N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide DMA21WB TI TTHQPL7 DMA21WB TN Carbonic anhydrase I (CA-I) DMA21WB MA Inhibitor DMA21WB RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMA21WB RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMA21WB DI DMA21WB DMA21WB DN N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide DMA21WB TI TTZHA0O DMA21WB TN Carbonic anhydrase IV (CA-IV) DMA21WB MA Inhibitor DMA21WB RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMA21WB RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMA21WB DI DMA21WB DMA21WB DN N-(5-phenyl-1,3,4-thiadiazol-2-yl)sulfamide DMA21WB TI TTUNARX DMA21WB TN Carbonic anhydrase (CA) DMA21WB MA Inhibitor DMA21WB RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMA21WB RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMA23LP DI DMA23LP DMA23LP DN L-652,343 DMA23LP TI TT2J34L DMA23LP TN Arachidonate 5-lipoxygenase (5-LOX) DMA23LP MA Inhibitor DMA23LP RN Pharmacology of the dual inhibitor of cyclooxygenase and 5-lipoxygenase 3-hydroxy-5-trifluoromethyl-N-(2-(2-thienyl)-2-phenyl-ethenyl)-benzo (b)thiophene-2-carboxamide. Arzneimittelforschung. 1988 Mar;38(3):372-8. DMA23LP RU https://pubmed.ncbi.nlm.nih.gov/3132928 DMA258T DI DMA258T DMA258T DN 8-Bromo-9-(3-hydroxypropyl)-9H-adenine DMA258T TI TTM2AOE DMA258T TN Adenosine A2a receptor (ADORA2A) DMA258T MA Inhibitor DMA258T RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMA258T RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMA258T DI DMA258T DMA258T DN 8-Bromo-9-(3-hydroxypropyl)-9H-adenine DMA258T TI TTNE7KG DMA258T TN Adenosine A2b receptor (ADORA2B) DMA258T MA Inhibitor DMA258T RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMA258T RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMA258T DI DMA258T DMA258T DN 8-Bromo-9-(3-hydroxypropyl)-9H-adenine DMA258T TI TTK25J1 DMA258T TN Adenosine A1 receptor (ADORA1) DMA258T MA Inhibitor DMA258T RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMA258T RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMA258T DI DMA258T DMA258T DN 8-Bromo-9-(3-hydroxypropyl)-9H-adenine DMA258T TI TTJFY5U DMA258T TN Adenosine A3 receptor (ADORA3) DMA258T MA Inhibitor DMA258T RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMA258T RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMA2607 DI DMA2607 DMA2607 DN 1-Cycloheptyl-3-(1-propionylpiperidin-4-yl)urea DMA2607 TI TT7WVHI DMA2607 TN Soluble epoxide hydrolase (EPHX2) DMA2607 MA Inhibitor DMA2607 RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DMA2607 RU https://pubmed.ncbi.nlm.nih.gov/20812725 DMA26L4 DI DMA26L4 DMA26L4 DN 8-Imidazol-1-ylmethyl-5-nitro-chromen-4-one DMA26L4 TI TTSZLWK DMA26L4 TN Aromatase (CYP19A1) DMA26L4 MA Inhibitor DMA26L4 RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMA26L4 RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMA28OL DI DMA28OL DMA28OL DN 8-methyl-4H,7H-indolo[6,5,4-cd]indol-5-one DMA28OL TI TTUTJGQ DMA28OL TN Vascular endothelial growth factor receptor 2 (KDR) DMA28OL MA Inhibitor DMA28OL RN Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33. DMA28OL RU https://pubmed.ncbi.nlm.nih.gov/17306530 DMA28ZX DI DMA28ZX DMA28ZX DN SR95531 DMA28ZX TI TTNJYV2 DMA28ZX TN Gamma-aminobutyric acid receptor (GAR) DMA28ZX MA Antagonist DMA28ZX RN GABA receptors inhibited by benzodiazepines mediate fast inhibitory transmission in the central amygdala. J Neurosci. 1999 Nov 15;19(22):9698-704. DMA28ZX RU https://pubmed.ncbi.nlm.nih.gov/10559379 DMA29SX DI DMA29SX DMA29SX DN 1-Phenethyl-3,7-dihydro-purine-2,6-dione DMA29SX TI TTJFY5U DMA29SX TN Adenosine A3 receptor (ADORA3) DMA29SX MA Inhibitor DMA29SX RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMA29SX RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMA2B1C DI DMA2B1C DMA2B1C DN BX 048 DMA2B1C TI TTZ1DT0 DMA2B1C TN P2Y purinoceptor 12 (P2RY12) DMA2B1C MA Antagonist DMA2B1C RN Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res. 2008;122(4):533-40. DMA2B1C RU https://pubmed.ncbi.nlm.nih.gov/18539312 DMA2CPG DI DMA2CPG DMA2CPG DN 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE DMA2CPG TI TT6L509 DMA2CPG TN Coagulation factor IIa (F2) DMA2CPG MA Inhibitor DMA2CPG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMA2CPG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMA2CZL DI DMA2CZL DMA2CZL DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH DMA2CZL TI TT27RFC DMA2CZL TN Opioid receptor delta (OPRD1) DMA2CZL MA Inhibitor DMA2CZL RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMA2CZL RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMA2CZL DI DMA2CZL DMA2CZL DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH DMA2CZL TI TTQW87Y DMA2CZL TN Opioid receptor kappa (OPRK1) DMA2CZL MA Inhibitor DMA2CZL RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMA2CZL RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMA2CZL DI DMA2CZL DMA2CZL DN H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH DMA2CZL TI TTKWM86 DMA2CZL TN Opioid receptor mu (MOP) DMA2CZL MA Inhibitor DMA2CZL RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMA2CZL RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMA2DQT DI DMA2DQT DMA2DQT DN OROIDIN DMA2DQT TI TTIDAPM DMA2DQT TN ERK activator kinase 1 (MEK1) DMA2DQT MA Inhibitor DMA2DQT RN Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32. DMA2DQT RU https://pubmed.ncbi.nlm.nih.gov/11784156 DMA2DQT DI DMA2DQT DMA2DQT DN OROIDIN DMA2DQT TI TTNX2CS DMA2DQT TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMA2DQT MA Inhibitor DMA2DQT RN Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tubercul... Bioorg Med Chem. 2007 Nov 1;15(21):6834-45. DMA2DQT RU https://pubmed.ncbi.nlm.nih.gov/17765547 DMA2EIK DI DMA2EIK DMA2EIK DN 12-hydroxyheptadecatrienoic acid DMA2EIK TI TTVJX54 DMA2EIK TN Leukotriene B4 receptor 2 (LTB4R2) DMA2EIK MA Agonist DMA2EIK RN 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. J Exp Med. 2008 Apr 14;205(4):759-66. DMA2EIK RU https://pubmed.ncbi.nlm.nih.gov/18378794 DMA2GIE DI DMA2GIE DMA2GIE DN 5-(2-(1H-imidazol-1-yl)ethyl)quinoline DMA2GIE TI TTSZLWK DMA2GIE TN Aromatase (CYP19A1) DMA2GIE MA Inhibitor DMA2GIE RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMA2GIE RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMA2OWK DI DMA2OWK DMA2OWK DN PMID18178086C15 DMA2OWK TI TTB7Y8I DMA2OWK TN Lysophosphatidic acid receptor 2 (LPAR2) DMA2OWK MA Antagonist DMA2OWK RN Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41. DMA2OWK RU https://pubmed.ncbi.nlm.nih.gov/18178086 DMA2RCD DI DMA2RCD DMA2RCD DN 9-(N-benzylaminomethyl)-9,10-dihydroanthracene DMA2RCD TI TTJQOD7 DMA2RCD TN 5-HT 2A receptor (HTR2A) DMA2RCD MA Inhibitor DMA2RCD RN 9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites. Bioorg Med Chem Lett. 2010 Feb 1;20(3):935-8. DMA2RCD RU https://pubmed.ncbi.nlm.nih.gov/20045641 DMA2SBL DI DMA2SBL DMA2SBL DN PRO-135 DMA2SBL TI TTZQTY2 DMA2SBL TN DMPK messenger RNA (DMPK mRNA) DMA2SBL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1505). DMA2SBL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1505 DMA2WUQ DI DMA2WUQ DMA2WUQ DN N-hydroxy-5-phenylthiophene-2-carboxamide DMA2WUQ TI TT6R7JZ DMA2WUQ TN Histone deacetylase 1 (HDAC1) DMA2WUQ MA Inhibitor DMA2WUQ RN Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. DMA2WUQ RU https://pubmed.ncbi.nlm.nih.gov/17107790 DMA2Y74 DI DMA2Y74 DMA2Y74 DN PMID20409708C34 DMA2Y74 TI TTXJ47W DMA2Y74 TN Metabotropic glutamate receptor 2 (mGluR2) DMA2Y74 MA Modulator (allosteric modulator) DMA2Y74 RN 3-Aryl-5-phenoxymethyl-1,3-oxazolidin-2-ones as positive allosteric modulators of mGluR2 for the treatment of schizophrenia: Hit-to-lead efforts. Bioorg Med Chem Lett. 2010 May 15;20(10):3129-33. DMA2Y74 RU https://pubmed.ncbi.nlm.nih.gov/20409708 DMA30RW DI DMA30RW DMA30RW DN (S,R)-(+)-fenoterol DMA30RW TI TT2CJVK DMA30RW TN Adrenergic receptor beta-2 (ADRB2) DMA30RW MA Inhibitor DMA30RW RN Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15. DMA30RW RU https://pubmed.ncbi.nlm.nih.gov/17506540 DMA318X DI DMA318X DMA318X DN Arg-Pro-Lys-Pro-Gln-Ser-Phe-Phe-Gly-Leu-Met-NH2 DMA318X TI TTZPO1L DMA318X TN Substance-P receptor (TACR1) DMA318X MA Inhibitor DMA318X RN Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6. DMA318X RU https://pubmed.ncbi.nlm.nih.gov/18067242 DMA3F7S DI DMA3F7S DMA3F7S DN CID2440433 DMA3F7S TI TTNET8J DMA3F7S TN G-protein coupled receptor 55 (GPR55) DMA3F7S MA Agonist DMA3F7S RN Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47. DMA3F7S RU https://pubmed.ncbi.nlm.nih.gov/21534610 DMA3FQP DI DMA3FQP DMA3FQP DN 6-(4-methylpiperazin-1-yl)-9Hpurine DMA3FQP TI TTXJ178 DMA3FQP TN Histamine H4 receptor (H4R) DMA3FQP MA Inhibitor DMA3FQP RN 2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96. DMA3FQP RU https://pubmed.ncbi.nlm.nih.gov/19773175 DMA3FZR DI DMA3FZR DMA3FZR DN Carbodine DMA3FZR TI TTN12BZ DMA3FZR TN CTP synthase (CTPS1) DMA3FZR MA Inhibitor DMA3FZR RN Potent activity of 5-fluoro-2'-deoxyuridine and related compounds against thymidine kinase-deficient (TK-) herpes simplex virus: targeted at thymidylate synthase. Mol Pharmacol. 1987 Aug;32(1):286-92. DMA3FZR RU https://pubmed.ncbi.nlm.nih.gov/3039343 DMA3LZ9 DI DMA3LZ9 DMA3LZ9 DN 1,1':4',1''-terphenyl-3,4''-diol DMA3LZ9 TI TTIWB6L DMA3LZ9 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMA3LZ9 MA Inhibitor DMA3LZ9 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMA3LZ9 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMA3M9H DI DMA3M9H DMA3M9H DN ZM 253270 DMA3M9H TI TTYO0A3 DMA3M9H TN Substance-K receptor (TACR2) DMA3M9H MA Antagonist DMA3M9H RN Pharmacological characterization of a new class of nonpeptide neurokinin A antagonists that demonstrate species selectivity. J Pharmacol Exp Ther. 1995 Sep;274(3):1216-21. DMA3M9H RU https://pubmed.ncbi.nlm.nih.gov/7562491 DMA3MX5 DI DMA3MX5 DMA3MX5 DN 4-heptyl-N-(pyridin-3-yl)benzamide DMA3MX5 TI TTMI6F5 DMA3MX5 TN Transient receptor potential cation channel V1 (TRPV1) DMA3MX5 MA Inhibitor DMA3MX5 RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMA3MX5 RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMA3N9R DI DMA3N9R DMA3N9R DN CIRSIMARITIN DMA3N9R TI TTJFY5U DMA3N9R TN Adenosine A3 receptor (ADORA3) DMA3N9R MA Inhibitor DMA3N9R RN Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8. DMA3N9R RU https://pubmed.ncbi.nlm.nih.gov/8576921 DMA3Y8C DI DMA3Y8C DMA3Y8C DN Fumagillin DMA3Y8C TI TTZL0OI DMA3Y8C TN Methionine aminopeptidase 2 (METAP2) DMA3Y8C MA Binder DMA3Y8C RN Homology modeling and calculation of the cobalt cluster charges of the Encephazlitozoon cuniculi methionine aminopeptidase, a potential target for drug design. Biophys Chem. 2003 Aug 1;105(1):29-43. DMA3Y8C RU https://pubmed.ncbi.nlm.nih.gov/12932577 DMA3YWU DI DMA3YWU DMA3YWU DN N-Benzyl-1H-indole-2-carboxamide DMA3YWU TI TT3WG5C DMA3YWU TN Monoamine oxidase type A (MAO-A) DMA3YWU MA Inhibitor DMA3YWU RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMA3YWU RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMA3YWU DI DMA3YWU DMA3YWU DN N-Benzyl-1H-indole-2-carboxamide DMA3YWU TI TTGP7BY DMA3YWU TN Monoamine oxidase type B (MAO-B) DMA3YWU MA Inhibitor DMA3YWU RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMA3YWU RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMA3ZGH DI DMA3ZGH DMA3ZGH DN ISIS 107773 DMA3ZGH TI TTELIN2 DMA3ZGH TN PTPN1 messenger RNA (PTPN1 mRNA) DMA3ZGH RN US patent application no. 6,261,840, Antisense modulation of PTP1B expression. DMA3ZGH RU http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true DMA3ZPH DI DMA3ZPH DMA3ZPH DN PMID30247903-Compound-General structure12 DMA3ZPH TI TT8ZLTI DMA3ZPH TN Programmed cell death 1 ligand 1 (PD-L1) DMA3ZPH MA Inhibitor DMA3ZPH RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMA3ZPH RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMA3ZRJ DI DMA3ZRJ DMA3ZRJ DN C[Glu21-Lys25][Gly8]GLP-1(7-37)-NH2 DMA3ZRJ TI TTVIMDE DMA3ZRJ TN Glucagon-like peptide 1 receptor (GLP1R) DMA3ZRJ MA Inhibitor DMA3ZRJ RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMA3ZRJ RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMA3ZXM DI DMA3ZXM DMA3ZXM DN RN1734 DMA3ZXM TI TTKP2SU DMA3ZXM TN Transient receptor potential cation channel V4 (TRPV4) DMA3ZXM MA Blocker (channel blocker) DMA3ZXM RN Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009 Nov 20;389(3):490-4. DMA3ZXM RU https://pubmed.ncbi.nlm.nih.gov/19737537 DMA43NY DI DMA43NY DMA43NY DN (S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate DMA43NY TI TTGKNB4 DMA43NY TN Epidermal growth factor receptor (EGFR) DMA43NY MA Inhibitor DMA43NY RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMA43NY RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMA4635 DI DMA4635 DMA4635 DN ISIS 112694 DMA4635 TI TT6804T DMA4635 TN MIF messenger RNA (MIF mRNA) DMA4635 RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DMA4635 RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DMA46S1 DI DMA46S1 DMA46S1 DN ISIS 183883 DMA46S1 TI TTBGTCW DMA46S1 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMA46S1 RN US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression. DMA46S1 RU http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true DMA4CZK DI DMA4CZK DMA4CZK DN 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol DMA4CZK TI TT1MPAY DMA4CZK TN GABA(A) receptor alpha-1 (GABRA1) DMA4CZK MA Inhibitor DMA4CZK RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMA4CZK RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMA4CZK DI DMA4CZK DMA4CZK DN 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol DMA4CZK TI TTZA1NY DMA4CZK TN GABA(A) receptor beta-2 (GABRB2) DMA4CZK MA Inhibitor DMA4CZK RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMA4CZK RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMA4CZK DI DMA4CZK DMA4CZK DN 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol DMA4CZK TI TTNJYV2 DMA4CZK TN Gamma-aminobutyric acid receptor (GAR) DMA4CZK MA Inhibitor DMA4CZK RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMA4CZK RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMA4CZK DI DMA4CZK DMA4CZK DN 4-Benzyl-5-piperidin-4-yl-isoxazol-3-ol DMA4CZK TI TT06RH5 DMA4CZK TN GABA(A) receptor gamma-2 (GABRG2) DMA4CZK MA Inhibitor DMA4CZK RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMA4CZK RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMA4L5P DI DMA4L5P DMA4L5P DN N-[4-(4-Phenyl-piperazin-1-yl)-butyl]-benzamide DMA4L5P TI TTSQIFT DMA4L5P TN 5-HT 1A receptor (HTR1A) DMA4L5P MA Inhibitor DMA4L5P RN Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands. J Med Chem. 1988 Oct;31(10):1968-71. DMA4L5P RU https://pubmed.ncbi.nlm.nih.gov/3172131 DMA4NI2 DI DMA4NI2 DMA4NI2 DN Dimaprit DMA4NI2 TI TTQHJ1K DMA4NI2 TN Histamine H2 receptor (H2R) DMA4NI2 MA Agonist DMA4NI2 RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMA4NI2 RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMA4SIN DI DMA4SIN DMA4SIN DN HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE DMA4SIN TI TTICO5G DMA4SIN TN Staphylococcus Peptide deformylase (Stap-coc def) DMA4SIN MA Inhibitor DMA4SIN RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMA4SIN RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMA4U2P DI DMA4U2P DMA4U2P DN ISIS 28472 DMA4U2P TI TT0J32Z DMA4U2P TN Smad7 messenger RNA (Smad7 mRNA) DMA4U2P RN US patent application no. 6,159,697, Antisense modulation of Smad7 expression. DMA4U2P RU http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true DMA4XGL DI DMA4XGL DMA4XGL DN 1-phenylbiguanide DMA4XGL TI TTR6K75 DMA4XGL TN 5-HT 3B receptor (HTR3B) DMA4XGL MA Agonist DMA4XGL RN Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4. DMA4XGL RU https://pubmed.ncbi.nlm.nih.gov/11489465 DMA4XGL DI DMA4XGL DMA4XGL DN 1-phenylbiguanide DMA4XGL TI TTPC4TU DMA4XGL TN 5-HT 3A receptor (HTR3A) DMA4XGL MA Agonist DMA4XGL RN Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors. J Neurochem. 1995 Jul;65(1):104-10. DMA4XGL RU https://pubmed.ncbi.nlm.nih.gov/7790853 DMA50BQ DI DMA50BQ DMA50BQ DN 5,7-Dibromo-1,4-dihydro-quinoxaline-2,3-dione DMA50BQ TI TTLD29N DMA50BQ TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMA50BQ MA Inhibitor DMA50BQ RN 1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996). DMA50BQ RU http://www.sciencedirect.com/science/article/pii/0960894X96000364 DMA53YD DI DMA53YD DMA53YD DN NSC-86715 DMA53YD TI TTJLP0R DMA53YD TN Quinone reductase 2 (NQO2) DMA53YD MA Inhibitor DMA53YD RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMA53YD RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMA59TP DI DMA59TP DMA59TP DN 1-(3-Bromobenzyl)-1H-imidazole DMA59TP TI TTIQUX7 DMA59TP TN Steroid 11-beta-hydroxylase (CYP11B1) DMA59TP MA Inhibitor DMA59TP RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMA59TP RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMA5DO2 DI DMA5DO2 DMA5DO2 DN (5s)-5-Iododihydro-2,4(1h,3h)-Pyrimidinedione DMA5DO2 TI TTZPS91 DMA5DO2 TN Dihydrothymine dehydrogenase (DPYD) DMA5DO2 MA Inhibitor DMA5DO2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMA5DO2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMA5EHC DI DMA5EHC DMA5EHC DN 3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one DMA5EHC TI TT8XK6L DMA5EHC TN Quinone reductase 1 (NQO1) DMA5EHC MA Inhibitor DMA5EHC RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DMA5EHC RU https://pubmed.ncbi.nlm.nih.gov/19877692 DMA5FEM DI DMA5FEM DMA5FEM DN 4-benzylphthalazin-1(2H)-one DMA5FEM TI TTVDSZ0 DMA5FEM TN Poly [ADP-ribose] polymerase 1 (PARP1) DMA5FEM MA Inhibitor DMA5FEM RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DMA5FEM RU https://pubmed.ncbi.nlm.nih.gov/19125579 DMA5FGS DI DMA5FGS DMA5FGS DN Cytidine-5'-Diphosphate DMA5FGS TI TTQ8J1V DMA5FGS TN Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) DMA5FGS MA Inhibitor DMA5FGS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMA5FGS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMA5FGS DI DMA5FGS DMA5FGS DN Cytidine-5'-Diphosphate DMA5FGS TI TTMFYEC DMA5FGS TN Streptococcus Cytidylate kinase (Stre-coc cmk) DMA5FGS MA Inhibitor DMA5FGS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMA5FGS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMA5GOX DI DMA5GOX DMA5GOX DN S 1743 DMA5GOX TI TT1KPBZ DMA5GOX TN Glucose-6-phosphate translocase (SLC37A4) DMA5GOX MA Inhibitor DMA5GOX RN Identification of protein components of the microsomal glucose 6-phosphate transporter by photoaffinity labelling. Biochem J. 1999 May 1;339 ( Pt 3):629-38. DMA5GOX RU https://pubmed.ncbi.nlm.nih.gov/10215602 DMA5K04 DI DMA5K04 DMA5K04 DN 8-(2-Methoxy-1-methyl-ethoxy)-quinolin-2-ylamine DMA5K04 TI TTX4RTB DMA5K04 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMA5K04 MA Inhibitor DMA5K04 RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMA5K04 RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMA5P9Q DI DMA5P9Q DMA5P9Q DN PMID1895299C1 DMA5P9Q TI TTPADOQ DMA5P9Q TN HMG-CoA reductase (HMGCR) DMA5P9Q MA Inhibitor DMA5P9Q RN Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety. J Med Chem. 1991 Sep;34(9):2804-15. DMA5P9Q RU https://pubmed.ncbi.nlm.nih.gov/1895299 DMA5Q4T DI DMA5Q4T DMA5Q4T DN 2-methoxy-1,4-naphthoquinone DMA5Q4T TI TTZJYKH DMA5Q4T TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMA5Q4T MA Inhibitor DMA5Q4T RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMA5Q4T RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMA5Z2G DI DMA5Z2G DMA5Z2G DN C-myb DMA5Z2G TI TTVKILB DMA5Z2G TN Prostaglandin G/H synthase 2 (COX-2) DMA5Z2G MA Regulator (upregulator) DMA5Z2G RN Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000 Apr 1;60(7):1805-9. DMA5Z2G RU https://pubmed.ncbi.nlm.nih.gov/10766162 DMA5Z7P DI DMA5Z7P DMA5Z7P DN N1,N3-bis(3-methoxybenzyl)isophthalamide DMA5Z7P TI TTHY57M DMA5Z7P TN Matrix metalloproteinase-13 (MMP-13) DMA5Z7P MA Inhibitor DMA5Z7P RN Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment ... Bioorg Med Chem Lett. 2010 Jan 15;20(2):576-80. DMA5Z7P RU https://pubmed.ncbi.nlm.nih.gov/20005097 DMA61I2 DI DMA61I2 DMA61I2 DN 5,7-dihydroxy-3-phenyl-3H-quinazolin-4-one DMA61I2 TI TTOM3J0 DMA61I2 TN Estrogen receptor beta (ESR2) DMA61I2 MA Inhibitor DMA61I2 RN Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55. DMA61I2 RU https://pubmed.ncbi.nlm.nih.gov/16610787 DMA632U DI DMA632U DMA632U DN ATLa2 DMA632U TI TTOJ1NF DMA632U TN FMLP-related receptor I (FPR2) DMA632U MA Agonist DMA632U RN Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo. J Med Chem. 2004 Apr 8;47(8):2157-65. DMA632U RU https://pubmed.ncbi.nlm.nih.gov/15056011 DMA6CLO DI DMA6CLO DMA6CLO DN VU0366058 DMA6CLO TI TTHS256 DMA6CLO TN Metabotropic glutamate receptor 5 (mGluR5) DMA6CLO MA Modulator (allosteric modulator) DMA6CLO RN Discovery of 2-(2-benzoxazoyl amino)-4-aryl-5-cyanopyrimidine as negative allosteric modulators (NAMs) of metabotropic glutamate receptor (mGlu : from an artificial neural network virtual screen to an in vivo tool compound. ChemMedChem. 2012 Mar 5;7(3):406-14. DMA6CLO RU https://pubmed.ncbi.nlm.nih.gov/22267125 DMA6E28 DI DMA6E28 DMA6E28 DN 4'-(4-Fluorobenzensulfonamide)-4-hydroxychalcone DMA6E28 TI TTULVH8 DMA6E28 TN Tyrosinase (TYR) DMA6E28 MA Inhibitor DMA6E28 RN Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7. DMA6E28 RU https://pubmed.ncbi.nlm.nih.gov/20149498 DMA6EPH DI DMA6EPH DMA6EPH DN N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) DMA6EPH TI TT6AZXG DMA6EPH TN TNF alpha converting enzyme (ADAM17) DMA6EPH MA Inhibitor DMA6EPH RN Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. DMA6EPH RU https://pubmed.ncbi.nlm.nih.gov/17936631 DMA6EPH DI DMA6EPH DMA6EPH DN N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) DMA6EPH TI TT6X50U DMA6EPH TN Matrix metalloproteinase-9 (MMP-9) DMA6EPH MA Inhibitor DMA6EPH RN Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. DMA6EPH RU https://pubmed.ncbi.nlm.nih.gov/17936631 DMA6EPH DI DMA6EPH DMA6EPH DN N-hydroxy-3-(6-methoxy-2-oxo-2H-chromen-3-yl) DMA6EPH TI TTLM12X DMA6EPH TN Matrix metalloproteinase-2 (MMP-2) DMA6EPH MA Inhibitor DMA6EPH RN Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. DMA6EPH RU https://pubmed.ncbi.nlm.nih.gov/17936631 DMA6KQU DI DMA6KQU DMA6KQU DN 2-(4-chloro-2-cyclopentylphenoxy)acetic acid DMA6KQU TI TTQDMX5 DMA6KQU TN Prostaglandin D2 receptor 2 (PTGDR2) DMA6KQU MA Inhibitor DMA6KQU RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMA6KQU RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMA6P4J DI DMA6P4J DMA6P4J DN 2-(Carbazole-9-sulfonyl)-benzoic acid DMA6P4J TI TTHWMFZ DMA6P4J TN Fatty acid-binding protein 4 (FABP4) DMA6P4J MA Inhibitor DMA6P4J RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMA6P4J RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMA6P4J DI DMA6P4J DMA6P4J DN 2-(Carbazole-9-sulfonyl)-benzoic acid DMA6P4J TI TTNT2S6 DMA6P4J TN Fatty acid-binding protein 5 (FABP5) DMA6P4J MA Inhibitor DMA6P4J RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMA6P4J RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMA6VCG DI DMA6VCG DMA6VCG DN Recombinant botulinum toxin DMA6VCG TI TTH18TF DMA6VCG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMA6VCG MA Modulator DMA6VCG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMA6VCG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMA6VNI DI DMA6VNI DMA6VNI DN [Tyr4]Bombesin DMA6VNI TI TTC1MVT DMA6VNI TN Gastrin-releasing peptide receptor (GRPR) DMA6VNI MA Inhibitor DMA6VNI RN Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10. DMA6VNI RU https://pubmed.ncbi.nlm.nih.gov/15634004 DMA6VQW DI DMA6VQW DMA6VQW DN Bicuculline DMA6VQW TI TTNJYV2 DMA6VQW TN Gamma-aminobutyric acid receptor (GAR) DMA6VQW MA Antagonist DMA6VQW RN GABA receptors inhibited by benzodiazepines mediate fast inhibitory transmission in the central amygdala. J Neurosci. 1999 Nov 15;19(22):9698-704. DMA6VQW RU https://pubmed.ncbi.nlm.nih.gov/10559379 DMA6VQW DI DMA6VQW DMA6VQW DN Bicuculline DMA6VQW TI TTAN6JD DMA6VQW TN Glutamate receptor AMPA (GRIA) DMA6VQW MA Antagonist DMA6VQW RN Effects of subcutaneous administration of the gamma-aminobutyric acid(A) receptor agonist muscimol on water intake in water-deprived rats. Physiol Behav. 2002 Nov;77(2-3):445-50. DMA6VQW RU https://pubmed.ncbi.nlm.nih.gov/12419421 DMA74PO DI DMA74PO DMA74PO DN ADX-63365 DMA74PO TI TTHS256 DMA74PO TN Metabotropic glutamate receptor 5 (mGluR5) DMA74PO MA Modulator DMA74PO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). DMA74PO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 DMA76KW DI DMA76KW DMA76KW DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) DMA76KW TI TT6R7JZ DMA76KW TN Histone deacetylase 1 (HDAC1) DMA76KW MA Inhibitor DMA76KW RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMA76KW RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMA76KW DI DMA76KW DMA76KW DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) DMA76KW TI TT5ZKDI DMA76KW TN Histone deacetylase 6 (HDAC6) DMA76KW MA Inhibitor DMA76KW RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMA76KW RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMA76KW DI DMA76KW DMA76KW DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph4-D-Pro-) DMA76KW TI TTTQGH8 DMA76KW TN Histone deacetylase 4 (HDAC4) DMA76KW MA Inhibitor DMA76KW RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMA76KW RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMA7GTH DI DMA7GTH DMA7GTH DN Threo-3,4-dichlororitalinol hydrochloride DMA7GTH TI TT3ROYC DMA7GTH TN Serotonin transporter (SERT) DMA7GTH MA Inhibitor DMA7GTH RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DMA7GTH RU https://pubmed.ncbi.nlm.nih.gov/17489581 DMA7GTH DI DMA7GTH DMA7GTH DN Threo-3,4-dichlororitalinol hydrochloride DMA7GTH TI TTVBI8W DMA7GTH TN Dopamine transporter (DAT) DMA7GTH MA Inhibitor DMA7GTH RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DMA7GTH RU https://pubmed.ncbi.nlm.nih.gov/17489581 DMA7JO4 DI DMA7JO4 DMA7JO4 DN CEP1348 DMA7JO4 TI TT9FN4J DMA7JO4 TN Mixed lineage kinase 2 (MAP3K10) DMA7JO4 MA Inhibitor DMA7JO4 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMA7JO4 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMA7KV8 DI DMA7KV8 DMA7KV8 DN ISIS 25118 DMA7KV8 TI TT8H9GB DMA7KV8 TN MEK2 messenger RNA (MEK2 mRNA) DMA7KV8 RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMA7KV8 RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMA7LEO DI DMA7LEO DMA7LEO DN 4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine DMA7LEO TI TTJS8PY DMA7LEO TN 5-HT 6 receptor (HTR6) DMA7LEO MA Inhibitor DMA7LEO RN Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3793-6. DMA7LEO RU https://pubmed.ncbi.nlm.nih.gov/16709453 DMA7LUR DI DMA7LUR DMA7LUR DN ANTAQ DMA7LUR TI TT371QC DMA7LUR TN Puromycin-sensitive aminopeptidase (NPEPPS) DMA7LUR MA Inhibitor DMA7LUR RN Fluorescent bioprobes for visualization of puromycin-sensitive aminopeptidase in living cells. Bioorg Med Chem Lett. 2003 Jan 6;13(1):83-6. DMA7LUR RU https://pubmed.ncbi.nlm.nih.gov/12467622 DMA7T0N DI DMA7T0N DMA7T0N DN Molecule 21 DMA7T0N TI TTPNGDE DMA7T0N TN Prostaglandin E2 receptor EP3 (PTGER3) DMA7T0N MA Antagonist DMA7T0N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 342). DMA7T0N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=342 DMA7URH DI DMA7URH DMA7URH DN RU26988 DMA7URH TI TTOZRK6 DMA7URH TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMA7URH MA Agonist DMA7URH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 625). DMA7URH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=625 DMA7VP5 DI DMA7VP5 DMA7VP5 DN ONO-AE-248 DMA7VP5 TI TT1ZAVI DMA7VP5 TN Prostaglandin E2 receptor EP2 (PTGER2) DMA7VP5 MA Agonist DMA7VP5 RN The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9. DMA7VP5 RU https://pubmed.ncbi.nlm.nih.gov/10746663 DMA7VP5 DI DMA7VP5 DMA7VP5 DN ONO-AE-248 DMA7VP5 TI TTPNGDE DMA7VP5 TN Prostaglandin E2 receptor EP3 (PTGER3) DMA7VP5 MA Agonist DMA7VP5 RN Selective activation of the prostanoid EP(3) receptor reduces myocardial infarct size in rodents. Arterioscler Thromb Vasc Biol. 1999 Sep;19(9):2141-7. DMA7VP5 RU https://pubmed.ncbi.nlm.nih.gov/10479656 DMA7X62 DI DMA7X62 DMA7X62 DN N-(3-Phenyl-propyl)-nicotinamide DMA7X62 TI TT7WVHI DMA7X62 TN Soluble epoxide hydrolase (EPHX2) DMA7X62 MA Inhibitor DMA7X62 RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DMA7X62 RU https://pubmed.ncbi.nlm.nih.gov/19746975 DMA7YJV DI DMA7YJV DMA7YJV DN PD-135158 DMA7YJV TI TTCG0AL DMA7YJV TN Cholecystokinin receptor type A (CCKAR) DMA7YJV MA Antagonist DMA7YJV RN Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728-32. DMA7YJV RU https://pubmed.ncbi.nlm.nih.gov/1975695 DMA7YJV DI DMA7YJV DMA7YJV DN PD-135158 DMA7YJV TI TTVFO0U DMA7YJV TN Gastrin/cholecystokinin type B receptor (CCKBR) DMA7YJV MA Antagonist DMA7YJV RN Pharmacological characterization of a Chinese hamster ovary cell line transfected with the human CCK-B receptor gene. Neuropeptides. 1996 Aug;30(4):359-63. DMA7YJV RU https://pubmed.ncbi.nlm.nih.gov/8914862 DMA7ZOW DI DMA7ZOW DMA7ZOW DN 2-Amino-5-Hydroxy-Benzimidazole DMA7ZOW TI TTGY7WI DMA7ZOW TN Urokinase-type plasminogen activator (PLAU) DMA7ZOW MA Inhibitor DMA7ZOW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMA7ZOW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMA7ZSY DI DMA7ZSY DMA7ZSY DN AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Nle-Asp-ValNH2 DMA7ZSY TI TTWXB3E DMA7ZSY TN Hepatitis C virus NS3 helicase (HCV NS3) DMA7ZSY MA Inhibitor DMA7ZSY RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMA7ZSY RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMA82IQ DI DMA82IQ DMA82IQ DN Methyl 2-(4-chloro-2-cyclohexylphenoxy)acetate DMA82IQ TI TTQDMX5 DMA82IQ TN Prostaglandin D2 receptor 2 (PTGDR2) DMA82IQ MA Inhibitor DMA82IQ RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMA82IQ RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMA8DEG DI DMA8DEG DMA8DEG DN (RS)-PPCC DMA8DEG TI TT5TPI6 DMA8DEG TN Opioid receptor sigma 1 (OPRS1) DMA8DEG MA Agonist DMA8DEG RN Novel sigma receptor ligands: synthesis and biological profile. J Med Chem. 2007 Mar 8;50(5):951-61. DMA8DEG RU https://pubmed.ncbi.nlm.nih.gov/17328523 DMA8DXG DI DMA8DXG DMA8DXG DN 7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol DMA8DXG TI TTZAYWL DMA8DXG TN Estrogen receptor (ESR) DMA8DXG MA Inhibitor DMA8DXG RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DMA8DXG RU https://pubmed.ncbi.nlm.nih.gov/15341953 DMA8DXG DI DMA8DXG DMA8DXG DN 7-Bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol DMA8DXG TI TTOM3J0 DMA8DXG TN Estrogen receptor beta (ESR2) DMA8DXG MA Inhibitor DMA8DXG RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DMA8DXG RU https://pubmed.ncbi.nlm.nih.gov/15341953 DMA8DZT DI DMA8DZT DMA8DZT DN 2-Hydroxycarbamoylmethyl-pentanedioic acid DMA8DZT TI TT9G4N0 DMA8DZT TN Glutamate carboxypeptidase II (GCPII) DMA8DZT MA Inhibitor DMA8DZT RN Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100. DMA8DZT RU https://pubmed.ncbi.nlm.nih.gov/12798312 DMA8F4N DI DMA8F4N DMA8F4N DN ITdU DMA8F4N TI TTP3QRF DMA8F4N TN Thymidine kinase 1 (TK1) DMA8F4N MA Inhibitor DMA8F4N RN Trichomonas vaginalis thymidine kinase: purification, characterization and search for inhibitors. Biochem J. 1998 Aug 15;334 ( Pt 1):15-22. DMA8F4N RU https://pubmed.ncbi.nlm.nih.gov/9693096 DMA8GI6 DI DMA8GI6 DMA8GI6 DN Primary alcohol metabolite of celecoxib DMA8GI6 TI TTVKILB DMA8GI6 TN Prostaglandin G/H synthase 2 (COX-2) DMA8GI6 MA Inhibitor DMA8GI6 RN Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole an... Bioorg Med Chem. 2008 Nov 15;16(22):9694-8. DMA8GI6 RU https://pubmed.ncbi.nlm.nih.gov/18930406 DMA8GI6 DI DMA8GI6 DMA8GI6 DN Primary alcohol metabolite of celecoxib DMA8GI6 TI TT8NGED DMA8GI6 TN Prostaglandin G/H synthase 1 (COX-1) DMA8GI6 MA Inhibitor DMA8GI6 RN Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole an... Bioorg Med Chem. 2008 Nov 15;16(22):9694-8. DMA8GI6 RU https://pubmed.ncbi.nlm.nih.gov/18930406 DMA8JH7 DI DMA8JH7 DMA8JH7 DN Ustiloxin D DMA8JH7 TI TTJ2PTI DMA8JH7 TN Tubulin beta-2 chain (TUBB2) DMA8JH7 MA Inhibitor DMA8JH7 RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMA8JH7 RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMA8JH7 DI DMA8JH7 DMA8JH7 DN Ustiloxin D DMA8JH7 TI TTYFKSZ DMA8JH7 TN Tubulin beta (TUBB) DMA8JH7 MA Inhibitor DMA8JH7 RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMA8JH7 RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMA8LFD DI DMA8LFD DMA8LFD DN KYS-05065 DMA8LFD TI TT729IR DMA8LFD TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMA8LFD MA Inhibitor DMA8LFD RN T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. DMA8LFD RU https://pubmed.ncbi.nlm.nih.gov/18585035 DMA8R47 DI DMA8R47 DMA8R47 DN N-n-heptyl-7-methoxytacrine hydrochloride DMA8R47 TI TT1RS9F DMA8R47 TN Acetylcholinesterase (AChE) DMA8R47 MA Inhibitor DMA8R47 RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMA8R47 RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMA8R47 DI DMA8R47 DMA8R47 DN N-n-heptyl-7-methoxytacrine hydrochloride DMA8R47 TI TTEB0GD DMA8R47 TN Cholinesterase (BCHE) DMA8R47 MA Inhibitor DMA8R47 RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMA8R47 RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMA8SHN DI DMA8SHN DMA8SHN DN 4-Thiomorpholin-4-yl-benzo[g]chromen-2-one DMA8SHN TI TTK3PY9 DMA8SHN TN DNA-dependent protein kinase catalytic (PRKDC) DMA8SHN MA Inhibitor DMA8SHN RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMA8SHN RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMA8TWC DI DMA8TWC DMA8TWC DN 6-(3-(pyridin-4-yl)phenyl)naphthalen-2-ol DMA8TWC TI TTRA5BZ DMA8TWC TN Steroid 17-alpha-monooxygenase (S17AH) DMA8TWC MA Inhibitor DMA8TWC RN Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17. Bioorg Med Chem Lett. 2008 Jan 1;18(1):267-73. DMA8TWC RU https://pubmed.ncbi.nlm.nih.gov/18024111 DMA8UQM DI DMA8UQM DMA8UQM DN PMID23634668C14 DMA8UQM TI TT1L79K DMA8UQM TN Methionyl aminopeptidase 1 (METAP1) DMA8UQM MA Inhibitor DMA8UQM RN Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells. J Med Chem. 2013 May 23;56(10):3996-4016. DMA8UQM RU https://pubmed.ncbi.nlm.nih.gov/23634668 DMA9104 DI DMA9104 DMA9104 DN KNI-10124 DMA9104 TI TTXMNHO DMA9104 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMA9104 MA Inhibitor DMA9104 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMA9104 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMA91T4 DI DMA91T4 DMA91T4 DN H-SMGLPCVVM-OH DMA91T4 TI TT7WZIJ DMA91T4 TN CAAX farnesyltransferase beta (FNTB) DMA91T4 MA Inhibitor DMA91T4 RN Improvement of biological activity and proteolytic stability of peptides by coupling with a cyclic peptide. Bioorg Med Chem Lett. 2003 Aug 4;13(15):2583-6. DMA91T4 RU https://pubmed.ncbi.nlm.nih.gov/12852971 DMA96KW DI DMA96KW DMA96KW DN ISIS 329956 DMA96KW TI TTWRN6M DMA96KW TN CRP messenger RNA (CRP mRNA) DMA96KW RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMA96KW RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMA96U5 DI DMA96U5 DMA96U5 DN 1-(9H-beta-Carbolin-3-yl)-butan-1-one DMA96U5 TI TT1MPAY DMA96U5 TN GABA(A) receptor alpha-1 (GABRA1) DMA96U5 MA Inhibitor DMA96U5 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMA96U5 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMA96U5 DI DMA96U5 DMA96U5 DN 1-(9H-beta-Carbolin-3-yl)-butan-1-one DMA96U5 TI TTNJYV2 DMA96U5 TN Gamma-aminobutyric acid receptor (GAR) DMA96U5 MA Inhibitor DMA96U5 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMA96U5 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMA97CS DI DMA97CS DMA97CS DN (5Z,9Z)-5,9-heptacosadienoic acid DMA97CS TI TTGTQHC DMA97CS TN DNA topoisomerase I (TOP1) DMA97CS MA Inhibitor DMA97CS RN Total synthesis and biological evaluation of (5Z,9Z)-5,9-hexadecadienoic acid, an inhibitor of human topoisomerase I. J Nat Prod. 2002 Nov;65(11):1715-8. DMA97CS RU https://pubmed.ncbi.nlm.nih.gov/12444712 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TTWG9A4 DMA9CSG TN Adrenergic receptor alpha-2A (ADRA2A) DMA9CSG MA Agonist DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TTNZRI3 DMA9CSG TN Synaptic vesicle amine transporter (SLC18A2) DMA9CSG MA Antagonist DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TT34BHT DMA9CSG TN Adrenergic receptor alpha-1D (ADRA1D) DMA9CSG MA Agonist DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TTGP7BY DMA9CSG TN Monoamine oxidase type B (MAO-B) DMA9CSG MA Antagonist DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TTVBI8W DMA9CSG TN Dopamine transporter (DAT) DMA9CSG MA Antagonist DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TTNGILX DMA9CSG TN Adrenergic receptor alpha-1A (ADRA1A) DMA9CSG MA Agonist DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TT3WG5C DMA9CSG TN Monoamine oxidase type A (MAO-A) DMA9CSG MA Inhibitor DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CSG DI DMA9CSG DMA9CSG DN Beta-methoxyamphetamine DMA9CSG TI TT3ROYC DMA9CSG TN Serotonin transporter (SERT) DMA9CSG MA Inhibitor DMA9CSG RN Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. DMA9CSG RU https://pubmed.ncbi.nlm.nih.gov/11041537 DMA9CZV DI DMA9CZV DMA9CZV DN E-003 DMA9CZV TI TTU1E82 DMA9CZV TN Apoptosis regulator Bcl-xL (BCL-xL) DMA9CZV MA Modulator DMA9CZV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2845). DMA9CZV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2845 DMA9DHE DI DMA9DHE DMA9DHE DN 4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane DMA9DHE TI TTPC4TU DMA9DHE TN 5-HT 3A receptor (HTR3A) DMA9DHE MA Inhibitor DMA9DHE RN Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor ag... J Med Chem. 2010 Feb 11;53(3):1222-37. DMA9DHE RU https://pubmed.ncbi.nlm.nih.gov/20043678 DMA9LFR DI DMA9LFR DMA9LFR DN 6-(2-acetylphenyl)-2-morpholin-4-ylchromen-4-one DMA9LFR TI TTK3PY9 DMA9LFR TN DNA-dependent protein kinase catalytic (PRKDC) DMA9LFR MA Inhibitor DMA9LFR RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMA9LFR RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMA9PW7 DI DMA9PW7 DMA9PW7 DN [6,3''']biflavone DMA9PW7 TI TTT1JVS DMA9PW7 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMA9PW7 MA Inhibitor DMA9PW7 RN Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43. DMA9PW7 RU https://pubmed.ncbi.nlm.nih.gov/17826099 DMA9RIS DI DMA9RIS DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate DMA9RIS TI TT37EDJ DMA9RIS TN GABA(A) receptor alpha-3 (GABRA3) DMA9RIS MA Inhibitor DMA9RIS RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMA9RIS RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMA9RIS DI DMA9RIS DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate DMA9RIS TI TTNJYV2 DMA9RIS TN Gamma-aminobutyric acid receptor (GAR) DMA9RIS MA Inhibitor DMA9RIS RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMA9RIS RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMA9RIS DI DMA9RIS DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate DMA9RIS TI TTBMV1G DMA9RIS TN GABA(A) receptor alpha-2 (GABRA2) DMA9RIS MA Inhibitor DMA9RIS RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMA9RIS RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMA9RIS DI DMA9RIS DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate DMA9RIS TI TT06RH5 DMA9RIS TN GABA(A) receptor gamma-2 (GABRG2) DMA9RIS MA Inhibitor DMA9RIS RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMA9RIS RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMA9RIS DI DMA9RIS DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate DMA9RIS TI TTNZPQ1 DMA9RIS TN GABA(A) receptor alpha-5 (GABRA5) DMA9RIS MA Inhibitor DMA9RIS RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMA9RIS RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMA9RIS DI DMA9RIS DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate DMA9RIS TI TT1MPAY DMA9RIS TN GABA(A) receptor alpha-1 (GABRA1) DMA9RIS MA Inhibitor DMA9RIS RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMA9RIS RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMA9RIS DI DMA9RIS DMA9RIS DN (2E,4S)-4-ammoniopent-2-enoate DMA9RIS TI TTZA1NY DMA9RIS TN GABA(A) receptor beta-2 (GABRB2) DMA9RIS MA Inhibitor DMA9RIS RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMA9RIS RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMA9TCD DI DMA9TCD DMA9TCD DN 4-(4-(4-Nitrophenyl)thiazol-2-ylamino)phenol DMA9TCD TI TTWHDVK DMA9TCD TN Fructose-1,6-bisphosphatase (FBP) DMA9TCD MA Inhibitor DMA9TCD RN A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22. DMA9TCD RU https://pubmed.ncbi.nlm.nih.gov/19419876 DMA9VBD DI DMA9VBD DMA9VBD DN KY-382 DMA9VBD TI TTMF541 DMA9VBD TN Liver carboxylesterase (CES1) DMA9VBD MA Modulator DMA9VBD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592). DMA9VBD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592 DMA9VDN DI DMA9VDN DMA9VDN DN L-760790 DMA9VDN TI TT6MSOK DMA9VDN TN 5-HT 1D receptor (HTR1D) DMA9VDN MA Inhibitor DMA9VDN RN 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1999 Feb 25;42(4):691-705. DMA9VDN RU https://pubmed.ncbi.nlm.nih.gov/10052976 DMA9YIB DI DMA9YIB DMA9YIB DN histaprodifen DMA9YIB TI TTTIBOJ DMA9YIB TN Histamine H1 receptor (H1R) DMA9YIB MA Agonist DMA9YIB RN Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. DMA9YIB RU https://pubmed.ncbi.nlm.nih.gov/15947036 DMAB1RW DI DMAB1RW DMAB1RW DN L-692289 DMAB1RW TI TTZMS1L DMAB1RW TN Fungal Papulacandin B resistance protein 1 (Fung FKS1) DMAB1RW MA Inhibitor DMAB1RW RN Antifungal lipopeptides: Structure-activity relationships of 3-hydroxyglutamine-modified pneumocandin B0 derivatives, Bioorg. Med. Chem. Lett. 5(20):2357-2362 (1995). DMAB1RW RU http://www.sciencedirect.com/science/article/pii/0960894X9500407K DMAB9KG DI DMAB9KG DMAB9KG DN Desclasinose Azithromycinarylalkyl Hydroxamate DMAB9KG TI TT6R7JZ DMAB9KG TN Histone deacetylase 1 (HDAC1) DMAB9KG MA Inhibitor DMAB9KG RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DMAB9KG RU https://pubmed.ncbi.nlm.nih.gov/19093884 DMAB9KG DI DMAB9KG DMAB9KG DN Desclasinose Azithromycinarylalkyl Hydroxamate DMAB9KG TI TTT6LFV DMAB9KG TN Histone deacetylase 8 (HDAC8) DMAB9KG MA Inhibitor DMAB9KG RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DMAB9KG RU https://pubmed.ncbi.nlm.nih.gov/19093884 DMABITD DI DMABITD DMABITD DN Tetradecyl-phosphonic acid DMABITD TI TTQ6S1K DMABITD TN Lysophosphatidic acid receptor 1 (LPAR1) DMABITD MA Inhibitor DMABITD RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMABITD RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMABIX1 DI DMABIX1 DMABIX1 DN SMOi2-17 DMABIX1 TI TT8J1S3 DMABIX1 TN Smoothened homolog (SMO) DMABIX1 MA Antagonist DMABIX1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 239). DMABIX1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=239 DMABLF7 DI DMABLF7 DMABLF7 DN PT-104 DMABLF7 TI TT84ETX DMABLF7 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMABLF7 MA Inhibitor DMABLF7 RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DMABLF7 RU https://pubmed.ncbi.nlm.nih.gov/8863804 DMABMPQ DI DMABMPQ DMABMPQ DN 4-methylhistamine DMABMPQ TI TTXJ178 DMABMPQ TN Histamine H4 receptor (H4R) DMABMPQ MA Agonist DMABMPQ RN Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54. DMABMPQ RU https://pubmed.ncbi.nlm.nih.gov/16432504 DMABSOC DI DMABSOC DMABSOC DN 5-(3-chlorophenylethynyl)-5-methyl[1,2,4]triazine DMABSOC TI TTHS256 DMABSOC TN Metabotropic glutamate receptor 5 (mGluR5) DMABSOC MA Inhibitor DMABSOC RN Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91. DMABSOC RU https://pubmed.ncbi.nlm.nih.gov/17569516 DMABZH6 DI DMABZH6 DMABZH6 DN PMID21561767C8h DMABZH6 TI TT6B75U DMABZH6 TN ABL messenger RNA (ABL mRNA) DMABZH6 MA Inhibitor DMABZH6 RN Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. DMABZH6 RU https://pubmed.ncbi.nlm.nih.gov/21561767 DMABZH6 DI DMABZH6 DMABZH6 DN PMID21561767C8h DMABZH6 TI TTRJB2G DMABZH6 TN Ephrin type-A receptor 2 (EPHA2) DMABZH6 MA Inhibitor DMABZH6 RN Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. DMABZH6 RU https://pubmed.ncbi.nlm.nih.gov/21561767 DMABZH6 DI DMABZH6 DMABZH6 DN PMID21561767C8h DMABZH6 TI TT8FYO9 DMABZH6 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMABZH6 MA Inhibitor DMABZH6 RN Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. DMABZH6 RU https://pubmed.ncbi.nlm.nih.gov/21561767 DMABZH6 DI DMABZH6 DMABZH6 DN PMID21561767C8h DMABZH6 TI TT9VGXW DMABZH6 TN Angiopoietin 1 receptor (TEK) DMABZH6 MA Inhibitor DMABZH6 RN Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. DMABZH6 RU https://pubmed.ncbi.nlm.nih.gov/21561767 DMABZH6 DI DMABZH6 DMABZH6 DN PMID21561767C8h DMABZH6 TI TT4DXQT DMABZH6 TN Proto-oncogene c-Ret (RET) DMABZH6 MA Inhibitor DMABZH6 RN Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. DMABZH6 RU https://pubmed.ncbi.nlm.nih.gov/21561767 DMABZH6 DI DMABZH6 DMABZH6 DN PMID21561767C8h DMABZH6 TI TTHS2LR DMABZH6 TN Ephrin type-A receptor 3 (EPHA3) DMABZH6 MA Inhibitor DMABZH6 RN Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. DMABZH6 RU https://pubmed.ncbi.nlm.nih.gov/21561767 DMABZH6 DI DMABZH6 DMABZH6 DN PMID21561767C8h DMABZH6 TI TTAHTVG DMABZH6 TN Ephrin type-A receptor 7 (EPHA7) DMABZH6 MA Inhibitor DMABZH6 RN Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8. DMABZH6 RU https://pubmed.ncbi.nlm.nih.gov/21561767 DMAC65P DI DMAC65P DMAC65P DN Y-c[D-Pen-(2')Nal-GSFC]KR-NH2 DMAC65P TI TT6PKBN DMAC65P TN Proto-oncogene c-Src (SRC) DMAC65P MA Inhibitor DMAC65P RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DMAC65P RU https://pubmed.ncbi.nlm.nih.gov/9632358 DMAC698 DI DMAC698 DMAC698 DN CORILAGIN DMAC698 TI TT84ETX DMAC698 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMAC698 MA Inhibitor DMAC698 RN HIV and reverse transcriptase inhibition by tanninsOriginal Research. Bioorg. Med. Chem. Lett. 2(12):1529-1534 (1992). DMAC698 RU http://www.sciencedirect.com/science/article/pii/S0960894X00804229 DMAC698 DI DMAC698 DMAC698 DN CORILAGIN DMAC698 TI TTE14XG DMAC698 TN Squalene monooxygenase (SQLE) DMAC698 MA Inhibitor DMAC698 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMAC698 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTK8CXU DMAC8TP TN 5-HT 1B receptor (HTR1B) DMAC8TP MA Agonist DMAC8TP RN Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/8863519 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTWJBZ5 DMAC8TP TN 5-HT 2C receptor (HTR2C) DMAC8TP MA Agonist DMAC8TP RN Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. 2000 Feb;35(2):144-50. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/10611640 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTCPG9S DMAC8TP TN 5-HT 1E receptor (HTR1E) DMAC8TP MA Agonist DMAC8TP RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/14744596 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TT0MI3F DMAC8TP TN 5-HT 1F receptor (HTR1F) DMAC8TP MA Agonist DMAC8TP RN Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/8380639 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTRUFDT DMAC8TP TN 5-HT 5A receptor (HTR5A) DMAC8TP MA Agonist DMAC8TP RN Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/8450829 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TT6MSOK DMAC8TP TN 5-HT 1D receptor (HTR1D) DMAC8TP MA Agonist DMAC8TP RN Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/1652050 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTO9X1H DMAC8TP TN 5-HT 7 receptor (HTR7) DMAC8TP MA Agonist DMAC8TP RN Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/8394362 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTJS8PY DMAC8TP TN 5-HT 6 receptor (HTR6) DMAC8TP MA Agonist DMAC8TP RN Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/7680751 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTJQOD7 DMAC8TP TN 5-HT 2A receptor (HTR2A) DMAC8TP MA Agonist DMAC8TP RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/15322733 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TT0K1SC DMAC8TP TN 5-HT 2B receptor (HTR2B) DMAC8TP MA Agonist DMAC8TP RN Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/8450835 DMAC8TP DI DMAC8TP DMAC8TP DN TFMPP DMAC8TP TI TTSQIFT DMAC8TP TN 5-HT 1A receptor (HTR1A) DMAC8TP MA Inhibitor DMAC8TP RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMAC8TP RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMACH7K DI DMACH7K DMACH7K DN correolide DMACH7K TI TTY3UE6 DMACH7K TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMACH7K MA Blocker (channel blocker) DMACH7K RN Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel, Kv1.3. Biochemistry. 1999 Apr 20;38(16):4922-30. DMACH7K RU https://pubmed.ncbi.nlm.nih.gov/10213593 DMACN68 DI DMACN68 DMACN68 DN (1H-pyrazol-1-yl)(o-tolyl)methanone DMACN68 TI TTPLTSQ DMACN68 TN Neutrophil elastase (NE) DMACN68 MA Inhibitor DMACN68 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMACN68 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMACRHS DI DMACRHS DMACRHS DN 4-Benzenesulfonyl-1-(3-phenyl-propyl)-piperidine DMACRHS TI TTQ6VDM DMACRHS TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMACRHS MA Inhibitor DMACRHS RN 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem. 2002 Jan 17;45(2):492-503. DMACRHS RU https://pubmed.ncbi.nlm.nih.gov/11784153 DMACT8D DI DMACT8D DMACT8D DN Gly-Arg-Gly-Asp-Ser DMACT8D TI TTT1R2L DMACT8D TN Integrin alpha-V (ITGAV) DMACT8D MA Inhibitor DMACT8D RN alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43. DMACT8D RU https://pubmed.ncbi.nlm.nih.gov/19860432 DMACT8D DI DMACT8D DMACT8D DN Gly-Arg-Gly-Asp-Ser DMACT8D TI TTJA1ZO DMACT8D TN ITGB3 messenger RNA (ITGB3 mRNA) DMACT8D MA Inhibitor DMACT8D RN alphavbeta3 Integrin-targeting Arg-Gly-Asp (RGD) peptidomimetics containing oligoethylene glycol (OEG) spacers. J Med Chem. 2009 Nov 26;52(22):7029-43. DMACT8D RU https://pubmed.ncbi.nlm.nih.gov/19860432 DMACTDZ DI DMACTDZ DMACTDZ DN 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE DMACTDZ TI TT7HF4W DMACTDZ TN Cyclin-dependent kinase 2 (CDK2) DMACTDZ MA Inhibitor DMACTDZ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMACTDZ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMACVNM DI DMACVNM DMACVNM DN (E)-6-Nitrooctadec-5-enoic Acid DMACVNM TI TTT2SVW DMACVNM TN PPAR-gamma messenger RNA (PPARG mRNA) DMACVNM MA Inhibitor DMACVNM RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMACVNM RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMACYPW DI DMACYPW DMACYPW DN ACAA DMACYPW TI TTXDKTO DMACYPW TN Long transient receptor potential channel 8 (TRPM8) DMACYPW MA Blocker (channel blocker) DMACYPW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 500). DMACYPW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=500 DMACYPW DI DMACYPW DMACYPW DN ACAA DMACYPW TI TTRBT3W DMACYPW TN Short transient receptor potential channel 6 (TRPC6) DMACYPW MA Blocker (channel blocker) DMACYPW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491). DMACYPW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491 DMACYPW DI DMACYPW DMACYPW DN ACAA DMACYPW TI TTEBMN7 DMACYPW TN Long transient receptor potential channel 2 (TRPM2) DMACYPW MA Blocker (channel blocker) DMACYPW RN Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid. Br J Pharmacol. 2006 Jun;148(3):264-73. DMACYPW RU https://pubmed.ncbi.nlm.nih.gov/16604090 DMACYPW DI DMACYPW DMACYPW DN ACAA DMACYPW TI TTNVC34 DMACYPW TN Short transient receptor potential channel 3 (TRPC3) DMACYPW MA Blocker (channel blocker) DMACYPW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 488). DMACYPW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=488 DMACYWZ DI DMACYWZ DMACYWZ DN 2-Amino-6-(3-methoxy-phenylsulfanyl)-benzonitrile DMACYWZ TI TT84ETX DMACYWZ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMACYWZ MA Inhibitor DMACYWZ RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMACYWZ RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMAD4JY DI DMAD4JY DMAD4JY DN (R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide DMAD4JY TI TTVKILB DMAD4JY TN Prostaglandin G/H synthase 2 (COX-2) DMAD4JY MA Inhibitor DMAD4JY RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMAD4JY RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMAD4JY DI DMAD4JY DMAD4JY DN (R)-2-(4-Isobutyl-phenyl)-N-phenyl-propionamide DMAD4JY TI TT8NGED DMAD4JY TN Prostaglandin G/H synthase 1 (COX-1) DMAD4JY MA Inhibitor DMAD4JY RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMAD4JY RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMADEOQ DI DMADEOQ DMADEOQ DN VUF-10214 DMADEOQ TI TT9JNIC DMADEOQ TN Histamine H3 receptor (H3R) DMADEOQ MA Inhibitor DMADEOQ RN Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem. 2008 Apr 24;51(8):2457-67. DMADEOQ RU https://pubmed.ncbi.nlm.nih.gov/18357976 DMADOK6 DI DMADOK6 DMADOK6 DN G-25 DMADOK6 TI TTCS8WB DMADOK6 TN Plasmodium Choline transporter (Malaria CT) DMADOK6 MA Blocker DMADOK6 RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMADOK6 RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMADQCW DI DMADQCW DMADQCW DN 3-(6-(furan-2-yl)-4-phenylpyridin-2-yl)-phenol DMADQCW TI TT0IHXV DMADQCW TN DNA topoisomerase II (TOP2) DMADQCW MA Inhibitor DMADQCW RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMADQCW RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMADSBT DI DMADSBT DMADSBT DN C[L-Phe-D-pro-L-Tyr-D-trp] DMADSBT TI TTQW87Y DMADSBT TN Opioid receptor kappa (OPRK1) DMADSBT MA Inhibitor DMADSBT RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMADSBT RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMADSBT DI DMADSBT DMADSBT DN C[L-Phe-D-pro-L-Tyr-D-trp] DMADSBT TI TTKWM86 DMADSBT TN Opioid receptor mu (MOP) DMADSBT MA Inhibitor DMADSBT RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMADSBT RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMADSUY DI DMADSUY DMADSUY DN 4-Oxosebacic Acid DMADSUY TI TTJHKYD DMADSUY TN Delta-aminolevulinic acid dehydratase (ALAD) DMADSUY MA Inhibitor DMADSUY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMADSUY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMADWTI DI DMADWTI DMADWTI DN 4-(N-Methyl-hydrazino)-benzenesulfonamide DMADWTI TI TTANPDJ DMADWTI TN Carbonic anhydrase II (CA-II) DMADWTI MA Inhibitor DMADWTI RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMADWTI RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMADWTI DI DMADWTI DMADWTI DN 4-(N-Methyl-hydrazino)-benzenesulfonamide DMADWTI TI TTSYM0R DMADWTI TN Carbonic anhydrase XII (CA-XII) DMADWTI MA Inhibitor DMADWTI RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMADWTI RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMADZQ9 DI DMADZQ9 DMADZQ9 DN 4-(trifluoromethyl)phenylboronic acid DMADZQ9 TI TTDP1UC DMADZQ9 TN Fatty acid amide hydrolase (FAAH) DMADZQ9 MA Inhibitor DMADZQ9 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMADZQ9 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMAE8BF DI DMAE8BF DMAE8BF DN 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea DMAE8BF TI TTCM4B3 DMAE8BF TN Nitric-oxide synthase endothelial (NOS3) DMAE8BF MA Inhibitor DMAE8BF RN Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4. DMAE8BF RU https://pubmed.ncbi.nlm.nih.gov/17317165 DMAE8BF DI DMAE8BF DMAE8BF DN 1-(2-amino-benzothiazol-5-yl)-2-ethyl-isothiourea DMAE8BF TI TTZUFI5 DMAE8BF TN Nitric-oxide synthase brain (NOS1) DMAE8BF MA Inhibitor DMAE8BF RN Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4. DMAE8BF RU https://pubmed.ncbi.nlm.nih.gov/17317165 DMAEHFT DI DMAEHFT DMAEHFT DN O-Acetylserine DMAEHFT TI TT8NGED DMAEHFT TN Prostaglandin G/H synthase 1 (COX-1) DMAEHFT MA Inhibitor DMAEHFT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAEHFT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAEL4C DI DMAEL4C DMAEL4C DN PTL-101 DMAEL4C TI TTP4520 DMAEL4C TN TGF-beta receptor type I (TGFBR1) DMAEL4C MA Modulator DMAEL4C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788). DMAEL4C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788 DMAEN9Y DI DMAEN9Y DMAEN9Y DN Adamantan-1-yl-pyrrolidin-1-yl-methanone DMAEN9Y TI TTN7BL9 DMAEN9Y TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMAEN9Y MA Inhibitor DMAEN9Y RN Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43. DMAEN9Y RU https://pubmed.ncbi.nlm.nih.gov/17350260 DMAENRQ DI DMAENRQ DMAENRQ DN 2-phenylquinoline-8-carboxamide DMAENRQ TI TTVDSZ0 DMAENRQ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMAENRQ MA Inhibitor DMAENRQ RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMAENRQ RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMAEQS9 DI DMAEQS9 DMAEQS9 DN J-104135 DMAEQS9 TI TTQ13Z5 DMAEQS9 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMAEQS9 MA Agonist DMAEQS9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15). DMAEQS9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15 DMAEW9M DI DMAEW9M DMAEW9M DN MRS1067 DMAEW9M TI TTJFY5U DMAEW9M TN Adenosine A3 receptor (ADORA3) DMAEW9M MA Antagonist DMAEW9M RN Pharmacological characterization of novel A3 adenosine receptor-selective antagonists. Neuropharmacology. 1997 Sep;36(9):1157-65. DMAEW9M RU https://pubmed.ncbi.nlm.nih.gov/9364471 DMAEWHB DI DMAEWHB DMAEWHB DN 1-Deoxy-1-Thio-Heptaethylene Glycol DMAEWHB TI TT1RS9F DMAEWHB TN Acetylcholinesterase (AChE) DMAEWHB MA Inhibitor DMAEWHB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMAEWHB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMAEWMP DI DMAEWMP DMAEWMP DN RWJ-53419 DMAEWMP TI TTJA1ZO DMAEWMP TN ITGB3 messenger RNA (ITGB3 mRNA) DMAEWMP MA Inhibitor DMAEWMP RN 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22. DMAEWMP RU https://pubmed.ncbi.nlm.nih.gov/11551763 DMAEXO3 DI DMAEXO3 DMAEXO3 DN (3S,4R)-3-butyl-1-phenylpiperidin-4-amine DMAEXO3 TI TTDIGC1 DMAEXO3 TN Dipeptidyl peptidase 4 (DPP-4) DMAEXO3 MA Inhibitor DMAEXO3 RN 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70. DMAEXO3 RU https://pubmed.ncbi.nlm.nih.gov/17418568 DMAF1W3 DI DMAF1W3 DMAF1W3 DN KNI-10759 DMAF1W3 TI TTXMNHO DMAF1W3 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMAF1W3 MA Inhibitor DMAF1W3 RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMAF1W3 RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMAF43E DI DMAF43E DMAF43E DN (3,4-dimethylphenyl)(4-phenoxyphenyl)methanone DMAF43E TI TTVBPDM DMAF43E TN Metabotropic glutamate receptor 1 (mGluR1) DMAF43E MA Inhibitor DMAF43E RN Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15. DMAF43E RU https://pubmed.ncbi.nlm.nih.gov/19574055 DMAFC3R DI DMAFC3R DMAFC3R DN isoxazole azepine compound 3 DMAFC3R TI TTRA6BO DMAFC3R TN Bromodomain-containing protein 4 (BRD4) DMAFC3R MA Inhibitor DMAFC3R RN Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors. ACS Med Chem Lett. 2013 Jul 16;4(9):835-40. DMAFC3R RU https://pubmed.ncbi.nlm.nih.gov/24900758 DMAFCZL DI DMAFCZL DMAFCZL DN 9-Cyclopropyl-9H-adenine DMAFCZL TI TTM2AOE DMAFCZL TN Adenosine A2a receptor (ADORA2A) DMAFCZL MA Inhibitor DMAFCZL RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMAFCZL RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMAFE24 DI DMAFE24 DMAFE24 DN Galanthamine derivative DMAFE24 TI TT1RS9F DMAFE24 TN Acetylcholinesterase (AChE) DMAFE24 MA Inhibitor DMAFE24 RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DMAFE24 RU https://pubmed.ncbi.nlm.nih.gov/18479118 DMAFEX8 DI DMAFEX8 DMAFEX8 DN ISIS 347573 DMAFEX8 TI TTNBTCW DMAFEX8 TN eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) DMAFEX8 RN US patent application no. 7,468,431, Modulation of eIF4E-BP2 expression. DMAFEX8 RU http://www.patentbuddy.com/Patent/7468431?ft=true&sr=true DMAFEYG DI DMAFEYG DMAFEYG DN ISIS 3224 DMAFEYG TI TTA1L39 DMAFEYG TN ICAM1 messenger RNA (ICAM1 mRNA) DMAFEYG RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DMAFEYG RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DMAFHLX DI DMAFHLX DMAFHLX DN PSB-09120 DMAFHLX TI TTM2AOE DMAFHLX TN Adenosine A2a receptor (ADORA2A) DMAFHLX MA Inhibitor DMAFHLX RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMAFHLX RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMAFHLX DI DMAFHLX DMAFHLX DN PSB-09120 DMAFHLX TI TTNE7KG DMAFHLX TN Adenosine A2b receptor (ADORA2B) DMAFHLX MA Inhibitor DMAFHLX RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMAFHLX RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMAFLCJ DI DMAFLCJ DMAFLCJ DN Isoguanosine DMAFLCJ TI TTNE7KG DMAFLCJ TN Adenosine A2b receptor (ADORA2B) DMAFLCJ MA Inhibitor DMAFLCJ RN High selectivity of novel isoguanosine analogues for the adenosine A1 receptor. Bioorg. Med. Chem. Lett. 1(9):481-486 (1991). DMAFLCJ RU http://www.sciencedirect.com/science/article/pii/S0960894X01811100 DMAFLCJ DI DMAFLCJ DMAFLCJ DN Isoguanosine DMAFLCJ TI TTK25J1 DMAFLCJ TN Adenosine A1 receptor (ADORA1) DMAFLCJ MA Inhibitor DMAFLCJ RN High selectivity of novel isoguanosine analogues for the adenosine A1 receptor. Bioorg. Med. Chem. Lett. 1(9):481-486 (1991). DMAFLCJ RU http://www.sciencedirect.com/science/article/pii/S0960894X01811100 DMAFLCJ DI DMAFLCJ DMAFLCJ DN Isoguanosine DMAFLCJ TI TTM2AOE DMAFLCJ TN Adenosine A2a receptor (ADORA2A) DMAFLCJ MA Inhibitor DMAFLCJ RN High selectivity of novel isoguanosine analogues for the adenosine A1 receptor. Bioorg. Med. Chem. Lett. 1(9):481-486 (1991). DMAFLCJ RU http://www.sciencedirect.com/science/article/pii/S0960894X01811100 DMAFNTL DI DMAFNTL DMAFNTL DN [D-Ncy(2-naphthyl)1]acyline DMAFNTL TI TT8R70G DMAFNTL TN Gonadotropin-releasing hormone receptor (GNRHR) DMAFNTL MA Inhibitor DMAFNTL RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMAFNTL RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMAFNXZ DI DMAFNXZ DMAFNXZ DN 12-(3-n-Pentylureidooxy)dodec-8(Z)-enoic acid DMAFNXZ TI TT7WVHI DMAFNXZ TN Soluble epoxide hydrolase (EPHX2) DMAFNXZ MA Inhibitor DMAFNXZ RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMAFNXZ RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMAFP18 DI DMAFP18 DMAFP18 DN 6,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one DMAFP18 TI TTJLP0R DMAFP18 TN Quinone reductase 2 (NQO2) DMAFP18 MA Inhibitor DMAFP18 RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMAFP18 RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMAFPE7 DI DMAFPE7 DMAFPE7 DN 2-methyl-4-(2-thienylethynyl)thiazole DMAFPE7 TI TTHS256 DMAFPE7 TN Metabotropic glutamate receptor 5 (mGluR5) DMAFPE7 MA Inhibitor DMAFPE7 RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMAFPE7 RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMAFQE1 DI DMAFQE1 DMAFQE1 DN UVAOL DMAFQE1 TI TTELIN2 DMAFQE1 TN PTPN1 messenger RNA (PTPN1 mRNA) DMAFQE1 MA Inhibitor DMAFQE1 RN Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8. DMAFQE1 RU https://pubmed.ncbi.nlm.nih.gov/18798681 DMAFS7J DI DMAFS7J DMAFS7J DN 1-(2-hydroxyphenyl)-3-p-tolylprop-2-en-1-one DMAFS7J TI TTVKILB DMAFS7J TN Prostaglandin G/H synthase 2 (COX-2) DMAFS7J MA Inhibitor DMAFS7J RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DMAFS7J RU https://pubmed.ncbi.nlm.nih.gov/19233646 DMAFWRT DI DMAFWRT DMAFWRT DN SB 243213 DMAFWRT TI TTWJBZ5 DMAFWRT TN 5-HT 2C receptor (HTR2C) DMAFWRT MA Agonist DMAFWRT RN SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. Neuropharmacology. 2001 Aug;41(2):186-99. DMAFWRT RU https://pubmed.ncbi.nlm.nih.gov/11489455 DMAG8QO DI DMAG8QO DMAG8QO DN ISIS 102466 DMAG8QO TI TT5U49F DMAG8QO TN PRKACA messenger RNA (PRKACA mRNA) DMAG8QO RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMAG8QO RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMAGFUH DI DMAGFUH DMAGFUH DN 2-(3'-Allyl-biphenyl-4-yl)-propionic acid DMAGFUH TI TT8NGED DMAGFUH TN Prostaglandin G/H synthase 1 (COX-1) DMAGFUH MA Inhibitor DMAGFUH RN Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12. DMAGFUH RU https://pubmed.ncbi.nlm.nih.gov/10091674 DMAGI7K DI DMAGI7K DMAGI7K DN TNFcept DMAGI7K TI TTG043C DMAGI7K TN Tumor necrosis factor receptor type I (TNF-R1) DMAGI7K MA Modulator DMAGI7K RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DMAGI7K RU https://pubmed.ncbi.nlm.nih.gov/15507622 DMAGLI8 DI DMAGLI8 DMAGLI8 DN S-(4-Methylbenzyl)isothiourea hydrochloride DMAGLI8 TI TTZJYKH DMAGLI8 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMAGLI8 MA Inhibitor DMAGLI8 RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMAGLI8 RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT57MT2 DMAGLPW TN PKC-epsilon messenger RNA (PRKCE mRNA) DMAGLPW MA Inhibitor DMAGLPW RN Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/15380221 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT8QL1J DMAGLPW TN Protein kinase C theta (PRKCQ) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT9P6OW DMAGLPW TN G2/mitotic-specific cyclin B1 (CCNB1) DMAGLPW MA Inhibitor DMAGLPW RN Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/9871700 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTFJ8Q1 DMAGLPW TN Protein kinase C alpha (PRKCA) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTYPXQF DMAGLPW TN Protein kinase C beta (PRKCB) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTUWGRA DMAGLPW TN Protein kinase C zeta (PRKCZ) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT73U6C DMAGLPW TN Stress-activated protein kinase 2b (p38 beta) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTQBR95 DMAGLPW TN Stress-activated protein kinase 2a (p38 alpha) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTWTSCV DMAGLPW TN RAC-alpha serine/threonine-protein kinase (AKT1) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT860QF DMAGLPW TN LCK tyrosine protein kinase (LCK) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTRFOXJ DMAGLPW TN Protein kinase C gamma (PRKCG) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTNAHEX DMAGLPW TN cAMP-dependent protein kinase A type I (PRKAR1A) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTH6V3D DMAGLPW TN Cyclin-dependent kinase 1 (CDK1) DMAGLPW MA Inhibitor DMAGLPW RN Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/9871700 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTUF2HO DMAGLPW TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMAGLPW MA Inhibitor DMAGLPW RN Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/17149860 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT0K6EO DMAGLPW TN Stress-activated protein kinase JNK1 (JNK1) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT9WJ8U DMAGLPW TN Protein kinase C delta (PRKCD) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTG0U4H DMAGLPW TN Ribosomal protein S6 kinase beta-1 (S6K1) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTTU902 DMAGLPW TN Checkpoint kinase-1 (CHK1) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTZN7RP DMAGLPW TN Rho-associated protein kinase 1 (ROCK1) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTBZ7OD DMAGLPW TN Protein kinase C epsilon (PRKCE) DMAGLPW MA Inhibitor DMAGLPW RN Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/1732526 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTYT93M DMAGLPW TN MAP kinase p38 (MAPK12) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TTTV8EJ DMAGLPW TN Serine/threonine-protein kinase Sgk1 (SGK1) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGLPW DI DMAGLPW DMAGLPW DN RO-316233 DMAGLPW TI TT4TQBX DMAGLPW TN Extracellular signal-regulated kinase 2 (ERK2) DMAGLPW MA Inhibitor DMAGLPW RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMAGLPW RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMAGTL1 DI DMAGTL1 DMAGTL1 DN 99mTc-EC-0652 DMAGTL1 TI TT9G4N0 DMAGTL1 TN Glutamate carboxypeptidase II (GCPII) DMAGTL1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMAGTL1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMAGVXW DI DMAGVXW DMAGVXW DN KENPAULLONE DMAGVXW TI TTH6V3D DMAGVXW TN Cyclin-dependent kinase 1 (CDK1) DMAGVXW MA Inhibitor DMAGVXW RN Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30. DMAGVXW RU https://pubmed.ncbi.nlm.nih.gov/20638755 DMAGVXW DI DMAGVXW DMAGVXW DN KENPAULLONE DMAGVXW TI TTRSMW9 DMAGVXW TN Glycogen synthase kinase-3 beta (GSK-3B) DMAGVXW MA Inhibitor DMAGVXW RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DMAGVXW RU https://pubmed.ncbi.nlm.nih.gov/14698171 DMAGVXW DI DMAGVXW DMAGVXW DN KENPAULLONE DMAGVXW TI TTSFWA7 DMAGVXW TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMAGVXW MA Inhibitor DMAGVXW RN A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26. DMAGVXW RU https://pubmed.ncbi.nlm.nih.gov/15481979 DMAGVXW DI DMAGVXW DMAGVXW DN KENPAULLONE DMAGVXW TI TT9P6OW DMAGVXW TN G2/mitotic-specific cyclin B1 (CCNB1) DMAGVXW MA Inhibitor DMAGVXW RN Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30. DMAGVXW RU https://pubmed.ncbi.nlm.nih.gov/20638755 DMAGVXW DI DMAGVXW DMAGVXW DN KENPAULLONE DMAGVXW TI TTL4Q97 DMAGVXW TN Cyclin-dependent kinase 5 (CDK5) DMAGVXW MA Inhibitor DMAGVXW RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DMAGVXW RU https://pubmed.ncbi.nlm.nih.gov/14698171 DMAGVXW DI DMAGVXW DMAGVXW DN KENPAULLONE DMAGVXW TI TTRZQE3 DMAGVXW TN Glycogen synthase kinase-3 alpha (GSK-3A) DMAGVXW MA Inhibitor DMAGVXW RN Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. DMAGVXW RU https://www.ncbi.nlm.nih.gov/pubmed/27828716 DMAGW3R DI DMAGW3R DMAGW3R DN [1-(4-p-Tolyl-butyl)-piperidin-4-yl]-methanol DMAGW3R TI TTQ6VDM DMAGW3R TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMAGW3R MA Inhibitor DMAGW3R RN Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7. DMAGW3R RU https://pubmed.ncbi.nlm.nih.gov/19660947 DMAGXMJ DI DMAGXMJ DMAGXMJ DN 3-pyridine-acetic acid DMAGXMJ TI TTWNV8U DMAGXMJ TN Nicotinic acid receptor (HCAR2) DMAGXMJ MA Agonist DMAGXMJ RN Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem. 2003 Mar 14;278(11):9869-74. DMAGXMJ RU https://pubmed.ncbi.nlm.nih.gov/12522134 DMAGZD8 DI DMAGZD8 DMAGZD8 DN Epibatidine DMAGZD8 TI TTJSZTB DMAGZD8 TN Nicotinic acetylcholine receptor (nAChR) DMAGZD8 MA Agonist DMAGZD8 RN The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents. Life Sci. 1998;62(17-18):1601-6. DMAGZD8 RU https://pubmed.ncbi.nlm.nih.gov/9585143 DMAH0RZ DI DMAH0RZ DMAH0RZ DN Long-acting Factor VII conjugate DMAH0RZ TI TTF0EGX DMAH0RZ TN Coagulation factor VII (F7) DMAH0RZ MA Modulator DMAH0RZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMAH0RZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMAH0ZG DI DMAH0ZG DMAH0ZG DN 2-(3-hydroxyphenyl)-7-methoxychroman-4-one DMAH0ZG TI TTSZLWK DMAH0ZG TN Aromatase (CYP19A1) DMAH0ZG MA Inhibitor DMAH0ZG RN New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80. DMAH0ZG RU https://pubmed.ncbi.nlm.nih.gov/18042388 DMAH4DG DI DMAH4DG DMAH4DG DN 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one DMAH4DG TI TTLD29N DMAH4DG TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMAH4DG MA Inhibitor DMAH4DG RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMAH4DG RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMAH4DG DI DMAH4DG DMAH4DG DN 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one DMAH4DG TI TTKJEMQ DMAH4DG TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMAH4DG MA Inhibitor DMAH4DG RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMAH4DG RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMAH4DG DI DMAH4DG DMAH4DG DN 3-Benzoyl-7-chloro-4-hydroxy-1H-quinolin-2-one DMAH4DG TI TTN9D8E DMAH4DG TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMAH4DG MA Inhibitor DMAH4DG RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMAH4DG RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMAHC9Z DI DMAHC9Z DMAHC9Z DN L-739750 DMAHC9Z TI TT7WZIJ DMAHC9Z TN CAAX farnesyltransferase beta (FNTB) DMAHC9Z MA Inhibitor DMAHC9Z RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DMAHC9Z RU https://pubmed.ncbi.nlm.nih.gov/9301658 DMAHG9E DI DMAHG9E DMAHG9E DN TL-1892 DMAHG9E TI TTYFKSZ DMAHG9E TN Tubulin beta (TUBB) DMAHG9E MA Inhibitor DMAHG9E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMAHG9E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMAHGBF DI DMAHGBF DMAHGBF DN M3B6S DMAHGBF TI TTKWM86 DMAHGBF TN Opioid receptor mu (MOP) DMAHGBF MA Inhibitor DMAHGBF RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMAHGBF RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMAHI7G DI DMAHI7G DMAHI7G DN 2-Phenyl-2H-pyrazolo[4,3-c]quinoline DMAHI7G TI TTJFY5U DMAHI7G TN Adenosine A3 receptor (ADORA3) DMAHI7G MA Inhibitor DMAHI7G RN New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):5001-8. DMAHI7G RU https://pubmed.ncbi.nlm.nih.gov/16033279 DMAHLF6 DI DMAHLF6 DMAHLF6 DN 4-heptyl-N-(quinolin-3-yl)benzamide DMAHLF6 TI TTMI6F5 DMAHLF6 TN Transient receptor potential cation channel V1 (TRPV1) DMAHLF6 MA Inhibitor DMAHLF6 RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMAHLF6 RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTIS03D DMAHMSV TN Alpha-galactosidase A (GLA) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTHRID2 DMAHMSV TN Insulin-like growth factor I receptor (IGF1R) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TT7LRQH DMAHMSV TN Complement C1s component (C1S) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTGY7WI DMAHMSV TN Urokinase-type plasminogen activator (PLAU) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTPLTSQ DMAHMSV TN Neutrophil elastase (NE) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TT1RS9F DMAHMSV TN Acetylcholinesterase (AChE) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTSZDQU DMAHMSV TN Lactotransferrin (LTF) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTF0EGX DMAHMSV TN Coagulation factor VII (F7) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTUMQVO DMAHMSV TN Cathepsin S (CTSS) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTAU4D6 DMAHMSV TN E-selectin (SELE) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTI2S1D DMAHMSV TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TT50QJ3 DMAHMSV TN Influenza Neuraminidase (Influ NA) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTE5VG0 DMAHMSV TN P-selectin (SELP) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTEB0GD DMAHMSV TN Cholinesterase (BCHE) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTBXIM9 DMAHMSV TN Membrane-associated lectin type-C (CD209) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTDGEC0 DMAHMSV TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTA0OSE DMAHMSV TN Lactase-phlorizin hydrolase (LCT) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHMSV DI DMAHMSV DMAHMSV DN Fucose DMAHMSV TI TTDIGC1 DMAHMSV TN Dipeptidyl peptidase 4 (DPP-4) DMAHMSV MA Inhibitor DMAHMSV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAHMSV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAHN4L DI DMAHN4L DMAHN4L DN MC-CAM DMAHN4L TI TTQW87Y DMAHN4L TN Opioid receptor kappa (OPRK1) DMAHN4L MA Inhibitor DMAHN4L RN 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30. DMAHN4L RU https://pubmed.ncbi.nlm.nih.gov/19842669 DMAHN4L DI DMAHN4L DMAHN4L DN MC-CAM DMAHN4L TI TT27RFC DMAHN4L TN Opioid receptor delta (OPRD1) DMAHN4L MA Inhibitor DMAHN4L RN 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30. DMAHN4L RU https://pubmed.ncbi.nlm.nih.gov/19842669 DMAHN4L DI DMAHN4L DMAHN4L DN MC-CAM DMAHN4L TI TTKWM86 DMAHN4L TN Opioid receptor mu (MOP) DMAHN4L MA Inhibitor DMAHN4L RN 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30. DMAHN4L RU https://pubmed.ncbi.nlm.nih.gov/19842669 DMAHO9M DI DMAHO9M DMAHO9M DN (+/-)-cis-H2-PAT DMAHO9M TI TTTIBOJ DMAHO9M TN Histamine H1 receptor (H1R) DMAHO9M MA Antagonist DMAHO9M RN A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36. DMAHO9M RU https://pubmed.ncbi.nlm.nih.gov/12065734 DMAHQIV DI DMAHQIV DMAHQIV DN Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG DMAHQIV TI TTNT7K8 DMAHQIV TN Nociceptin receptor (OPRL1) DMAHQIV MA Inhibitor DMAHQIV RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DMAHQIV RU https://pubmed.ncbi.nlm.nih.gov/16814543 DMAHQIV DI DMAHQIV DMAHQIV DN Ac-RYYRIK-GGG-K-(NH2)-YRFB-GGGGG DMAHQIV TI TTKWM86 DMAHQIV TN Opioid receptor mu (MOP) DMAHQIV MA Inhibitor DMAHQIV RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DMAHQIV RU https://pubmed.ncbi.nlm.nih.gov/16814543 DMAHZR9 DI DMAHZR9 DMAHZR9 DN 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one DMAHZR9 TI TTCJG29 DMAHZR9 TN Serine/threonine-protein kinase mTOR (mTOR) DMAHZR9 MA Inhibitor DMAHZR9 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMAHZR9 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMAHZR9 DI DMAHZR9 DMAHZR9 DN 2-(2-Methyl-morpholin-4-yl)-benzo[h]chromen-4-one DMAHZR9 TI TTK3PY9 DMAHZR9 TN DNA-dependent protein kinase catalytic (PRKDC) DMAHZR9 MA Inhibitor DMAHZR9 RN Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7. DMAHZR9 RU https://pubmed.ncbi.nlm.nih.gov/15546735 DMAI1HU DI DMAI1HU DMAI1HU DN (S)-phenylglycine DMAI1HU TI TTFK1JQ DMAI1HU TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMAI1HU MA Inhibitor DMAI1HU RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMAI1HU RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMAI3NZ DI DMAI3NZ DMAI3NZ DN 4-(mesitylthio)-2-(trifluoromethyl)benzonitrile DMAI3NZ TI TTKPW01 DMAI3NZ TN Androgen receptor messenger RNA (AR mRNA) DMAI3NZ MA Inhibitor DMAI3NZ RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMAI3NZ RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMAI43O DI DMAI43O DMAI43O DN AcGlu-Asp-Val-Val-Leu-Cys-Iqc-Nle-Thr-TyrNH2 DMAI43O TI TTWXB3E DMAI43O TN Hepatitis C virus NS3 helicase (HCV NS3) DMAI43O MA Inhibitor DMAI43O RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMAI43O RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMAI5B8 DI DMAI5B8 DMAI5B8 DN ISIS 104255 DMAI5B8 TI TTCQ2E5 DMAI5B8 TN RIP2 messenger RNA (RIP2 mRNA) DMAI5B8 RN US patent application no. 6,426,221, Antisense modulation of RIP2 expression. DMAI5B8 RU http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true DMAI6X2 DI DMAI6X2 DMAI6X2 DN 4-Benzyl-1-phenethyl-piperidine hydrochloride DMAI6X2 TI TTLD29N DMAI6X2 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMAI6X2 MA Inhibitor DMAI6X2 RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMAI6X2 RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMAI6X2 DI DMAI6X2 DMAI6X2 DN 4-Benzyl-1-phenethyl-piperidine hydrochloride DMAI6X2 TI TTN9D8E DMAI6X2 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMAI6X2 MA Inhibitor DMAI6X2 RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMAI6X2 RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMAI9Y0 DI DMAI9Y0 DMAI9Y0 DN GR 128107 DMAI9Y0 TI TT0WAIE DMAI9Y0 TN Melatonin receptor type 1A (MTNR1A) DMAI9Y0 MA Agonist DMAI9Y0 RN The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores. Br J Pharmacol. 1999 Mar;126(5):1237-45. DMAI9Y0 RU https://pubmed.ncbi.nlm.nih.gov/10205014 DMAIGM2 DI DMAIGM2 DMAIGM2 DN (RS/SR)-2-[1-(4-chlorophenyl)ethyl]piperidine DMAIGM2 TI TTVBI8W DMAIGM2 TN Dopamine transporter (DAT) DMAIGM2 MA Inhibitor DMAIGM2 RN Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. DMAIGM2 RU https://pubmed.ncbi.nlm.nih.gov/17228864 DMAILK8 DI DMAILK8 DMAILK8 DN C[RGDf-(S,R)-alpha-Dfm-F] DMAILK8 TI TTT1R2L DMAILK8 TN Integrin alpha-V (ITGAV) DMAILK8 MA Inhibitor DMAILK8 RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMAILK8 RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMAILK8 DI DMAILK8 DMAILK8 DN C[RGDf-(S,R)-alpha-Dfm-F] DMAILK8 TI TTJA1ZO DMAILK8 TN ITGB3 messenger RNA (ITGB3 mRNA) DMAILK8 MA Inhibitor DMAILK8 RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMAILK8 RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMAIOC9 DI DMAIOC9 DMAIOC9 DN Dideazafolate DMAIOC9 TI TTEXB9Z DMAIOC9 TN Glycinamide ribonucleotide formyltransferase (GART) DMAIOC9 MA Inhibitor DMAIOC9 RN N10-substituted 5,8-dideazafolate inhibitors of glycinamide ribonucleotide transformylase. J Med Chem. 1987 Jul;30(7):1254-6. DMAIOC9 RU https://pubmed.ncbi.nlm.nih.gov/3599031 DMAIOQB DI DMAIOQB DMAIOQB DN RQ-00203066 DMAIOQB TI TTAXZ0K DMAIOQB TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMAIOQB MA Antagonist DMAIOQB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580). DMAIOQB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=580 DMAIS1D DI DMAIS1D DMAIS1D DN 3-(6-Amino-purin-9-yl)-8-phenyl-octan-2-ol DMAIS1D TI TTLP57V DMAIS1D TN Adenosine deaminase (ADA) DMAIS1D MA Inhibitor DMAIS1D RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMAIS1D RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMAJ0B4 DI DMAJ0B4 DMAJ0B4 DN 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol DMAJ0B4 TI TTEX248 DMAJ0B4 TN Dopamine D2 receptor (D2R) DMAJ0B4 MA Inhibitor DMAJ0B4 RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMAJ0B4 RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMAJ0B4 DI DMAJ0B4 DMAJ0B4 DN 1,2,3,7,12,12a-hexahydro-1-aza-pleiadene-5,6-diol DMAJ0B4 TI TTZFYLI DMAJ0B4 TN Dopamine D1 receptor (D1R) DMAJ0B4 MA Inhibitor DMAJ0B4 RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMAJ0B4 RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMAJ0Q8 DI DMAJ0Q8 DMAJ0Q8 DN DM6S DMAJ0Q8 TI TTKWM86 DMAJ0Q8 TN Opioid receptor mu (MOP) DMAJ0Q8 MA Inhibitor DMAJ0Q8 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMAJ0Q8 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMAJ0Q8 DI DMAJ0Q8 DMAJ0Q8 DN DM6S DMAJ0Q8 TI TTQW87Y DMAJ0Q8 TN Opioid receptor kappa (OPRK1) DMAJ0Q8 MA Inhibitor DMAJ0Q8 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMAJ0Q8 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMAJ4LI DI DMAJ4LI DMAJ4LI DN Azithromycin-N-benzyltriazolyloctahydroxamic Acid DMAJ4LI TI TT6R7JZ DMAJ4LI TN Histone deacetylase 1 (HDAC1) DMAJ4LI MA Inhibitor DMAJ4LI RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DMAJ4LI RU https://pubmed.ncbi.nlm.nih.gov/19093884 DMAJ4LI DI DMAJ4LI DMAJ4LI DN Azithromycin-N-benzyltriazolyloctahydroxamic Acid DMAJ4LI TI TTT6LFV DMAJ4LI TN Histone deacetylase 8 (HDAC8) DMAJ4LI MA Inhibitor DMAJ4LI RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DMAJ4LI RU https://pubmed.ncbi.nlm.nih.gov/19093884 DMAJ6BW DI DMAJ6BW DMAJ6BW DN RO-145975 DMAJ6BW TI TTNJYV2 DMAJ6BW TN Gamma-aminobutyric acid receptor (GAR) DMAJ6BW MA Inhibitor DMAJ6BW RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMAJ6BW RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMAJ6BW DI DMAJ6BW DMAJ6BW DN RO-145975 DMAJ6BW TI TT06RH5 DMAJ6BW TN GABA(A) receptor gamma-2 (GABRG2) DMAJ6BW MA Inhibitor DMAJ6BW RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMAJ6BW RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMAJ6BW DI DMAJ6BW DMAJ6BW DN RO-145975 DMAJ6BW TI TTZA1NY DMAJ6BW TN GABA(A) receptor beta-2 (GABRB2) DMAJ6BW MA Inhibitor DMAJ6BW RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMAJ6BW RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMAJ6BW DI DMAJ6BW DMAJ6BW DN RO-145975 DMAJ6BW TI TT1MPAY DMAJ6BW TN GABA(A) receptor alpha-1 (GABRA1) DMAJ6BW MA Inhibitor DMAJ6BW RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMAJ6BW RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMAJ6TC DI DMAJ6TC DMAJ6TC DN Anti-VEGFR 3 mab DMAJ6TC TI TTDCBX5 DMAJ6TC TN Vascular endothelial growth factor receptor 3 (FLT-4) DMAJ6TC MA Inhibitor DMAJ6TC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814). DMAJ6TC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814 DMAJ8BS DI DMAJ8BS DMAJ8BS DN 5-chloro-2-(2-chloro-4-nitrophenoxy)phenol DMAJ8BS TI TTNX2CS DMAJ8BS TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMAJ8BS MA Inhibitor DMAJ8BS RN Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52. DMAJ8BS RU https://pubmed.ncbi.nlm.nih.gov/16198563 DMAJC42 DI DMAJC42 DMAJC42 DN 1-adamantan-1-yl-3-(1-butyl-piperidin-4-yl)-urea DMAJC42 TI TT7WVHI DMAJC42 TN Soluble epoxide hydrolase (EPHX2) DMAJC42 MA Inhibitor DMAJC42 RN Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. DMAJC42 RU https://pubmed.ncbi.nlm.nih.gov/16870439 DMAJCVL DI DMAJCVL DMAJCVL DN [2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine DMAJCVL TI TTJS8PY DMAJCVL TN 5-HT 6 receptor (HTR6) DMAJCVL MA Inhibitor DMAJCVL RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DMAJCVL RU https://pubmed.ncbi.nlm.nih.gov/15808453 DMAJDU7 DI DMAJDU7 DMAJDU7 DN Malonate sodium DMAJDU7 TI TTZHA0O DMAJDU7 TN Carbonic anhydrase IV (CA-IV) DMAJDU7 MA Inhibitor DMAJDU7 RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8. DMAJDU7 RU https://pubmed.ncbi.nlm.nih.gov/15664815 DMAJEDG DI DMAJEDG DMAJEDG DN 6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMAJEDG TI TTZAYWL DMAJEDG TN Estrogen receptor (ESR) DMAJEDG MA Inhibitor DMAJEDG RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMAJEDG RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMAJEDG DI DMAJEDG DMAJEDG DN 6-(3-Fluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMAJEDG TI TTOM3J0 DMAJEDG TN Estrogen receptor beta (ESR2) DMAJEDG MA Inhibitor DMAJEDG RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMAJEDG RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMAJHXO DI DMAJHXO DMAJHXO DN 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine DMAJHXO TI TTSZLWK DMAJHXO TN Aromatase (CYP19A1) DMAJHXO MA Inhibitor DMAJHXO RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMAJHXO RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMAJHXO DI DMAJHXO DMAJHXO DN 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine DMAJHXO TI TTIQUX7 DMAJHXO TN Steroid 11-beta-hydroxylase (CYP11B1) DMAJHXO MA Inhibitor DMAJHXO RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMAJHXO RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMAJHXO DI DMAJHXO DMAJHXO DN 3-(6-methoxy-3,4-dihydronaphthalen-2-yl)pyridine DMAJHXO TI TTRA5BZ DMAJHXO TN Steroid 17-alpha-monooxygenase (S17AH) DMAJHXO MA Inhibitor DMAJHXO RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMAJHXO RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMAJKRX DI DMAJKRX DMAJKRX DN Kodaistatin A DMAJKRX TI TT1KPBZ DMAJKRX TN Glucose-6-phosphate translocase (SLC37A4) DMAJKRX MA Inhibitor DMAJKRX RN Kodaistatins, novel inhibitors of glucose-6-phosphate translocase T1 from Aspergillus terreus thom DSM 11247. Isolation and structural elucidation. J Antibiot (Tokyo). 2000 Jul;53(7):677-86. DMAJKRX RU https://pubmed.ncbi.nlm.nih.gov/10994809 DMAJMU6 DI DMAJMU6 DMAJMU6 DN 3-Phenyl-2-nortropene DMAJMU6 TI TTVBI8W DMAJMU6 TN Dopamine transporter (DAT) DMAJMU6 MA Inhibitor DMAJMU6 RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMAJMU6 RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMAJMU6 DI DMAJMU6 DMAJMU6 DN 3-Phenyl-2-nortropene DMAJMU6 TI TT3ROYC DMAJMU6 TN Serotonin transporter (SERT) DMAJMU6 MA Inhibitor DMAJMU6 RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMAJMU6 RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMAJNPS DI DMAJNPS DMAJNPS DN Coumermycin DMAJNPS TI TTS7LWX DMAJNPS TN Bacterial DNA gyrase B (Bact gyrB) DMAJNPS MA Inhibitor DMAJNPS RN Isolation and characterization of an Escherichia coli strain exhibiting partial tolerance to quinolones. Antimicrob Agents Chemother. 1989 May;33(5):705-9. DMAJNPS RU https://pubmed.ncbi.nlm.nih.gov/2665642 DMAJNYM DI DMAJNYM DMAJNYM DN Clavulanate+Amoxicillin DMAJNYM TI TTHI19T DMAJNYM TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMAJNYM MA Inhibitor DMAJNYM RN Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. DMAJNYM RU https://pubmed.ncbi.nlm.nih.gov/16634700 DMAJVPI DI DMAJVPI DMAJVPI DN dodecyl-thiophosphate DMAJVPI TI TTB7Y8I DMAJVPI TN Lysophosphatidic acid receptor 2 (LPAR2) DMAJVPI MA Agonist DMAJVPI RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMAJVPI RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMAJVPI DI DMAJVPI DMAJVPI DN dodecyl-thiophosphate DMAJVPI TI TTE2YJR DMAJVPI TN Lysophosphatidate-3 receptor (LPAR3) DMAJVPI MA Antagonist DMAJVPI RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMAJVPI RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMAJVPI DI DMAJVPI DMAJVPI DN dodecyl-thiophosphate DMAJVPI TI TTQ6S1K DMAJVPI TN Lysophosphatidic acid receptor 1 (LPAR1) DMAJVPI MA Inhibitor DMAJVPI RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMAJVPI RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMAJXYO DI DMAJXYO DMAJXYO DN 1-(4-Cyanobenzyl)-5-(2-methylphenyl)-1H-imidazole DMAJXYO TI TTIQUX7 DMAJXYO TN Steroid 11-beta-hydroxylase (CYP11B1) DMAJXYO MA Inhibitor DMAJXYO RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMAJXYO RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMAK0P3 DI DMAK0P3 DMAK0P3 DN 8-(4-acetylphenyl)-2-morpholin-4-ylchromen-4-one DMAK0P3 TI TTK3PY9 DMAK0P3 TN DNA-dependent protein kinase catalytic (PRKDC) DMAK0P3 MA Inhibitor DMAK0P3 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMAK0P3 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMAK35M DI DMAK35M DMAK35M DN 6-hydroxy-2-methyl-9H-beta-carbolin-2-ium DMAK35M TI TT1RS9F DMAK35M TN Acetylcholinesterase (AChE) DMAK35M MA Inhibitor DMAK35M RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMAK35M RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMAK35M DI DMAK35M DMAK35M DN 6-hydroxy-2-methyl-9H-beta-carbolin-2-ium DMAK35M TI TTEB0GD DMAK35M TN Cholinesterase (BCHE) DMAK35M MA Inhibitor DMAK35M RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMAK35M RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMAK789 DI DMAK789 DMAK789 DN 4-(2,4-dichloro-phenoxy)-4'-fluoro-biphenyl-3-ol DMAK789 TI TTNX2CS DMAK789 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMAK789 MA Inhibitor DMAK789 RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DMAK789 RU https://pubmed.ncbi.nlm.nih.gov/17567585 DMAKMIJ DI DMAKMIJ DMAKMIJ DN 3-(4-bromobenzyl)-1,1-dimethylselenourea DMAKMIJ TI TTAS2UO DMAKMIJ TN Bacterial Urease (Bact ureC) DMAKMIJ MA Inhibitor DMAKMIJ RN Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91. DMAKMIJ RU https://pubmed.ncbi.nlm.nih.gov/17889535 DMAKNUH DI DMAKNUH DMAKNUH DN Acetic acid 2-hexylsulfanyl-phenyl ester DMAKNUH TI TT8NGED DMAKNUH TN Prostaglandin G/H synthase 1 (COX-1) DMAKNUH MA Inhibitor DMAKNUH RN Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18. DMAKNUH RU https://pubmed.ncbi.nlm.nih.gov/9822550 DMAKP20 DI DMAKP20 DMAKP20 DN eicosatetranoic acid DMAKP20 TI TTJ584C DMAKP20 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMAKP20 MA Agonist DMAKP20 RN PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol Chem. 1997 Jul;378(7):651-5. DMAKP20 RU https://pubmed.ncbi.nlm.nih.gov/9278144 DMAKPM1 DI DMAKPM1 DMAKPM1 DN H-Tyr-c[pen-Gly-Phe-pen]OH DMAKPM1 TI TT27RFC DMAKPM1 TN Opioid receptor delta (OPRD1) DMAKPM1 MA Inhibitor DMAKPM1 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMAKPM1 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMAKR2E DI DMAKR2E DMAKR2E DN 2-(phenylsulfonyl)naphthalene-1,4-diol DMAKR2E TI TTRVTMX DMAKR2E TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMAKR2E MA Inhibitor DMAKR2E RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DMAKR2E RU https://pubmed.ncbi.nlm.nih.gov/18996691 DMAKT65 DI DMAKT65 DMAKT65 DN Cyclopentyl-(3,4-dichloro-phenyl)-acetonitrile DMAKT65 TI TT3ROYC DMAKT65 TN Serotonin transporter (SERT) DMAKT65 MA Inhibitor DMAKT65 RN Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate. J Med Chem. 2003 Apr 10;46(8):1538-45. DMAKT65 RU https://pubmed.ncbi.nlm.nih.gov/12672255 DMAKTCH DI DMAKTCH DMAKTCH DN ISIS 25079 DMAKTCH TI TT8H9GB DMAKTCH TN MEK2 messenger RNA (MEK2 mRNA) DMAKTCH RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMAKTCH RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMAKW2S DI DMAKW2S DMAKW2S DN Thiophene sulfonamide DMAKW2S TI TTSFWA7 DMAKW2S TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMAKW2S MA Inhibitor DMAKW2S RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMAKW2S RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMAKZ43 DI DMAKZ43 DMAKZ43 DN 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one DMAKZ43 TI TTQ3JTF DMAKZ43 TN Muscarinic acetylcholine receptor M4 (CHRM4) DMAKZ43 MA Inhibitor DMAKZ43 RN Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5. DMAKZ43 RU https://pubmed.ncbi.nlm.nih.gov/9784090 DMAKZ43 DI DMAKZ43 DMAKZ43 DN 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one DMAKZ43 TI TTH18TF DMAKZ43 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMAKZ43 MA Inhibitor DMAKZ43 RN Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5. DMAKZ43 RU https://pubmed.ncbi.nlm.nih.gov/9784090 DMAKZ43 DI DMAKZ43 DMAKZ43 DN 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one DMAKZ43 TI TTYEG6Q DMAKZ43 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMAKZ43 MA Inhibitor DMAKZ43 RN Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5. DMAKZ43 RU https://pubmed.ncbi.nlm.nih.gov/9784090 DMAKZ43 DI DMAKZ43 DMAKZ43 DN 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one DMAKZ43 TI TTZ9SOR DMAKZ43 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMAKZ43 MA Inhibitor DMAKZ43 RN Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5. DMAKZ43 RU https://pubmed.ncbi.nlm.nih.gov/9784090 DMAKZ43 DI DMAKZ43 DMAKZ43 DN 2,8-Dimethyl-1-oxa-8-aza-spiro[4.5]decan-3-one DMAKZ43 TI TTQ13Z5 DMAKZ43 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMAKZ43 MA Inhibitor DMAKZ43 RN Synthesis and modeling studies of a potent conformationally rigid muscarinic agonist: 1-azabicyclo[2.2.1]heptanespirofuranone. J Med Chem. 1998 Oct 22;41(22):4181-5. DMAKZ43 RU https://pubmed.ncbi.nlm.nih.gov/9784090 DMAL1CP DI DMAL1CP DMAL1CP DN 3-methoxy-4-hydroxylonchocarpin DMAL1CP TI TTUMGNO DMAL1CP TN Ornithine decarboxylase (ODC1) DMAL1CP MA Inhibitor DMAL1CP RN New bioactive flavonoids and stilbenes in cub resin insecticide. J Nat Prod. 1999 Feb;62(2):205-10. DMAL1CP RU https://pubmed.ncbi.nlm.nih.gov/10075742 DMAL1UH DI DMAL1UH DMAL1UH DN 6-iodo-4'-dimethyaminoflavone DMAL1UH TI TTE4KHA DMAL1UH TN Amyloid beta A4 protein (APP) DMAL1UH MA Inhibitor DMAL1UH RN Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60. DMAL1UH RU https://pubmed.ncbi.nlm.nih.gov/16279784 DMALIQ8 DI DMALIQ8 DMALIQ8 DN 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol DMALIQ8 TI TTQW87Y DMALIQ8 TN Opioid receptor kappa (OPRK1) DMALIQ8 MA Inhibitor DMALIQ8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMALIQ8 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMALIQ8 DI DMALIQ8 DMALIQ8 DN 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol DMALIQ8 TI TTNT7K8 DMALIQ8 TN Nociceptin receptor (OPRL1) DMALIQ8 MA Inhibitor DMALIQ8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMALIQ8 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMALIQ8 DI DMALIQ8 DMALIQ8 DN 4-phenyl-1-(1-phenylpropyl)piperidin-4-ol DMALIQ8 TI TTKWM86 DMALIQ8 TN Opioid receptor mu (MOP) DMALIQ8 MA Inhibitor DMALIQ8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMALIQ8 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMALMGH DI DMALMGH DMALMGH DN 3-demethoxy-3-D-mannopyranosylaminothiocolchicine DMALMGH TI TT1MPAY DMALMGH TN GABA(A) receptor alpha-1 (GABRA1) DMALMGH MA Inhibitor DMALMGH RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMALMGH RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMALMGH DI DMALMGH DMALMGH DN 3-demethoxy-3-D-mannopyranosylaminothiocolchicine DMALMGH TI TTF45NW DMALMGH TN Strychnine-binding glycine receptor (GLRA1) DMALMGH MA Inhibitor DMALMGH RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMALMGH RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMALMGH DI DMALMGH DMALMGH DN 3-demethoxy-3-D-mannopyranosylaminothiocolchicine DMALMGH TI TT06RH5 DMALMGH TN GABA(A) receptor gamma-2 (GABRG2) DMALMGH MA Inhibitor DMALMGH RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMALMGH RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMALMGH DI DMALMGH DMALMGH DN 3-demethoxy-3-D-mannopyranosylaminothiocolchicine DMALMGH TI TTNJYV2 DMALMGH TN Gamma-aminobutyric acid receptor (GAR) DMALMGH MA Inhibitor DMALMGH RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMALMGH RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMALMGH DI DMALMGH DMALMGH DN 3-demethoxy-3-D-mannopyranosylaminothiocolchicine DMALMGH TI TTZ8EM9 DMALMGH TN Glycine receptor (GlyR) DMALMGH MA Inhibitor DMALMGH RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMALMGH RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMALMGH DI DMALMGH DMALMGH DN 3-demethoxy-3-D-mannopyranosylaminothiocolchicine DMALMGH TI TTZA1NY DMALMGH TN GABA(A) receptor beta-2 (GABRB2) DMALMGH MA Inhibitor DMALMGH RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMALMGH RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMALRCH DI DMALRCH DMALRCH DN Phaclofen DMALRCH TI TTDCVZW DMALRCH TN Gamma-aminobutyric acid B receptor (GABBR) DMALRCH MA Antagonist DMALRCH RN Astrocytes and interneurons in memory processing in the chick hippocampus: roles for G-coupled protein receptors, GABA(B) and mGluR1. Neurochem Res. 2009 Oct;34(10):1712-20. DMALRCH RU https://pubmed.ncbi.nlm.nih.gov/19415487 DMALRU4 DI DMALRU4 DMALRU4 DN 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMALRU4 TI TT3WG5C DMALRU4 TN Monoamine oxidase type A (MAO-A) DMALRU4 MA Inhibitor DMALRU4 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMALRU4 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMALRU4 DI DMALRU4 DMALRU4 DN 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMALRU4 TI TTJQOD7 DMALRU4 TN 5-HT 2A receptor (HTR2A) DMALRU4 MA Inhibitor DMALRU4 RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMALRU4 RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMALRU4 DI DMALRU4 DMALRU4 DN 8-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMALRU4 TI TTGP7BY DMALRU4 TN Monoamine oxidase type B (MAO-B) DMALRU4 MA Inhibitor DMALRU4 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMALRU4 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMALRU9 DI DMALRU9 DMALRU9 DN Clodinafop DMALRU9 TI TTYAWV0 DMALRU9 TN Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) DMALRU9 MA Binder DMALRU9 RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DMALRU9 RU https://pubmed.ncbi.nlm.nih.gov/11768328 DMALSIW DI DMALSIW DMALSIW DN PMID30247903-Compound-General structure28 DMALSIW TI TT23XQV DMALSIW TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMALSIW MA Inhibitor DMALSIW RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMALSIW RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMALVY7 DI DMALVY7 DMALVY7 DN CBiPES DMALVY7 TI TTXJ47W DMALVY7 TN Metabotropic glutamate receptor 2 (mGluR2) DMALVY7 MA Modulator (allosteric modulator) DMALVY7 RN Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83. DMALVY7 RU https://pubmed.ncbi.nlm.nih.gov/15717213 DMAM5WJ DI DMAM5WJ DMAM5WJ DN 10-OBn-epi-ginkgolide C DMAM5WJ TI TTQL5VC DMAM5WJ TN Platelet-activating factor receptor (PTAFR) DMAM5WJ MA Antagonist DMAM5WJ RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMAM5WJ RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMAM5ZO DI DMAM5ZO DMAM5ZO DN NOX 2137a/b DMAM5ZO TI TTNT7K8 DMAM5ZO TN Nociceptin receptor (OPRL1) DMAM5ZO RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMAM5ZO RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMAM619 DI DMAM619 DMAM619 DN Arabinose-5-Phosphate DMAM619 TI TTVNA43 DMAM619 TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DMAM619 MA Inhibitor DMAM619 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAM619 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAMCSR DI DMAMCSR DMAMCSR DN acrolein DMAMCSR TI TTELV3W DMAMCSR TN Transformation-sensitive protein p120 (TRPA1) DMAMCSR MA Activator DMAMCSR RN TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell. 2006 Mar 24;124(6):1269-82. DMAMCSR RU https://pubmed.ncbi.nlm.nih.gov/16564016 DMAMD5H DI DMAMD5H DMAMD5H DN [3H]pirenzepine DMAMD5H TI TTOXS3C DMAMD5H TN Muscarinic acetylcholine receptor (CHRM) DMAMD5H MA Antagonist DMAMD5H RN [3H]Pirenzepine identifies putative M1 muscarinic receptors in human stellate ganglia. Brain Res. 1984 Jan 2;290(1):179-82. DMAMD5H RU https://pubmed.ncbi.nlm.nih.gov/6546354 DMAMD87 DI DMAMD87 DMAMD87 DN 6,7,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one DMAMD87 TI TTJLP0R DMAMD87 TN Quinone reductase 2 (NQO2) DMAMD87 MA Inhibitor DMAMD87 RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMAMD87 RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMAMJW2 DI DMAMJW2 DMAMJW2 DN 8-Acetyl-7-hydroxy-2H-chromen-2-one DMAMJW2 TI TT2LVK8 DMAMJW2 TN Carbonic anhydrase IX (CA-IX) DMAMJW2 MA Inhibitor DMAMJW2 RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMAMJW2 RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMAMK3P DI DMAMK3P DMAMK3P DN [3H]resolvin E1 DMAMK3P TI TT4UGZL DMAMK3P TN Chemerin receptor (CMKLR1) DMAMK3P MA Agonist DMAMK3P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 79). DMAMK3P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=79 DMAMK3P DI DMAMK3P DMAMK3P DN [3H]resolvin E1 DMAMK3P TI TTHS256 DMAMK3P TN Metabotropic glutamate receptor 5 (mGluR5) DMAMK3P MA Modulator (allosteric modulator) DMAMK3P RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMAMK3P RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMAMOJE DI DMAMOJE DMAMOJE DN 3-[5-(4-Hydroxyphenyl)-2-thienyl]-5-methylphenol DMAMOJE TI TTIWB6L DMAMOJE TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMAMOJE MA Inhibitor DMAMOJE RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMAMOJE RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMAMRKS DI DMAMRKS DMAMRKS DN S-Methylcysteine DMAMRKS TI TTPT2QI DMAMRKS TN Cathepsin D (CTSD) DMAMRKS MA Inhibitor DMAMRKS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAMRKS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAMRKS DI DMAMRKS DMAMRKS DN S-Methylcysteine DMAMRKS TI TTJ8DV7 DMAMRKS TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DMAMRKS MA Inhibitor DMAMRKS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAMRKS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAMS7R DI DMAMS7R DMAMS7R DN DEMETHYLZEYLASTERONE DMAMS7R TI TT0IHXV DMAMS7R TN DNA topoisomerase II (TOP2) DMAMS7R MA Inhibitor DMAMS7R RN Catalytic inhibition of topoisomerase IIalpha by demethylzeylasterone, a 6-oxophenolic triterpenoid from Kokoona zeylanica. J Nat Prod. 2001 Oct;64(10):1294-6. DMAMS7R RU https://pubmed.ncbi.nlm.nih.gov/11678653 DMAMTLR DI DMAMTLR DMAMTLR DN ISIS 29136 DMAMTLR TI TTO6SGY DMAMTLR TN AKT3 messenger RNA (AKT3 mRNA) DMAMTLR RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMAMTLR RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMAMV6T DI DMAMV6T DMAMV6T DN Sodium sulfamate DMAMV6T TI TTZHA0O DMAMV6T TN Carbonic anhydrase IV (CA-IV) DMAMV6T MA Inhibitor DMAMV6T RN Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8. DMAMV6T RU https://pubmed.ncbi.nlm.nih.gov/19128966 DMAMYWL DI DMAMYWL DMAMYWL DN BMY-27709 DMAMYWL TI TTF4CAM DMAMYWL TN Influenza Hemagglutinin (Influ HA) DMAMYWL MA Inhibitor DMAMYWL RN Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41. DMAMYWL RU https://pubmed.ncbi.nlm.nih.gov/19004788 DMAN57F DI DMAN57F DMAN57F DN N-Hydroxy-N-methyl-3-phenanthren-2-yl-acrylamide DMAN57F TI TT2J34L DMAN57F TN Arachidonate 5-lipoxygenase (5-LOX) DMAN57F MA Inhibitor DMAN57F RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMAN57F RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMAN63P DI DMAN63P DMAN63P DN (+)-trans-H2-PAT DMAN63P TI TTTIBOJ DMAN63P TN Histamine H1 receptor (H1R) DMAN63P MA Antagonist DMAN63P RN A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36. DMAN63P RU https://pubmed.ncbi.nlm.nih.gov/12065734 DMAN7YJ DI DMAN7YJ DMAN7YJ DN (S)-2-amino-1-(4-propylthiophenyl)-propane DMAN7YJ TI TT3WG5C DMAN7YJ TN Monoamine oxidase type A (MAO-A) DMAN7YJ MA Inhibitor DMAN7YJ RN Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206. DMAN7YJ RU https://pubmed.ncbi.nlm.nih.gov/17521909 DMAN7YJ DI DMAN7YJ DMAN7YJ DN (S)-2-amino-1-(4-propylthiophenyl)-propane DMAN7YJ TI TTGP7BY DMAN7YJ TN Monoamine oxidase type B (MAO-B) DMAN7YJ MA Inhibitor DMAN7YJ RN Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206. DMAN7YJ RU https://pubmed.ncbi.nlm.nih.gov/17521909 DMAN8EH DI DMAN8EH DMAN8EH DN 2-Aminomethyl-pyrrolidine-3,4-diol DMAN8EH TI TTXWASR DMAN8EH TN Intestinal maltase-glucoamylase (MGAM) DMAN8EH MA Inhibitor DMAN8EH RN Derivatives of (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol are selective alpha-mannosidase inhibitors. Bioorg Med Chem Lett. 2001 Sep 17;11(18):2489-93. DMAN8EH RU https://pubmed.ncbi.nlm.nih.gov/11549453 DMAN94P DI DMAN94P DMAN94P DN ISIS 25117 DMAN94P TI TT8H9GB DMAN94P TN MEK2 messenger RNA (MEK2 mRNA) DMAN94P RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMAN94P RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMANEH2 DI DMANEH2 DMANEH2 DN AE-9C90CB DMANEH2 TI TTQ13Z5 DMANEH2 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMANEH2 MA Antagonist DMANEH2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 15). DMANEH2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=15 DMANHOT DI DMANHOT DMANHOT DN 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol DMANHOT TI TTZAYWL DMANHOT TN Estrogen receptor (ESR) DMANHOT MA Inhibitor DMANHOT RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMANHOT RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMANHOT DI DMANHOT DMANHOT DN 2-(6-Hydroxy-naphthalen-2-yl)-benzooxazol-6-ol DMANHOT TI TTOM3J0 DMANHOT TN Estrogen receptor beta (ESR2) DMANHOT MA Inhibitor DMANHOT RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMANHOT RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMANICH DI DMANICH DMANICH DN (S)-3-(2',2'-Dimethyl-propionyl)amino-caprolactam DMANICH TI TTFZYTO DMANICH TN C-C chemokine receptor type 2 (CCR2) DMANICH MA Inhibitor DMANICH RN Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors. J Med Chem. 2009 Jun 11;52(11):3591-5. DMANICH RU https://pubmed.ncbi.nlm.nih.gov/19425597 DMANS5X DI DMANS5X DMANS5X DN 2-(3-bromophenyl)-7-methylpyrido[2,3-d]pyrimidine DMANS5X TI TTHS256 DMANS5X TN Metabotropic glutamate receptor 5 (mGluR5) DMANS5X MA Inhibitor DMANS5X RN Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9. DMANS5X RU https://pubmed.ncbi.nlm.nih.gov/17723296 DMANSCK DI DMANSCK DMANSCK DN S-070 DMANSCK TI TTTU902 DMANSCK TN Checkpoint kinase-1 (CHK1) DMANSCK MA Inhibitor DMANSCK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987). DMANSCK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987 DMANSCK DI DMANSCK DMANSCK DN S-070 DMANSCK TI TTVDSZ0 DMANSCK TN Poly [ADP-ribose] polymerase 1 (PARP1) DMANSCK MA Inhibitor DMANSCK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMANSCK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMANTCY DI DMANTCY DMANTCY DN 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole DMANTCY TI TTECBXN DMANTCY TN Oxysterols receptor LXR-alpha (NR1H3) DMANTCY MA Inhibitor DMANTCY RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DMANTCY RU https://pubmed.ncbi.nlm.nih.gov/18973288 DMANTCY DI DMANTCY DMANTCY DN 2-Benzyl-3-phenyl-7-(trifluoromethyl)-2H-indazole DMANTCY TI TTXA6PH DMANTCY TN Oxysterols receptor LXR-beta (NR1H2) DMANTCY MA Inhibitor DMANTCY RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DMANTCY RU https://pubmed.ncbi.nlm.nih.gov/18973288 DMANTW0 DI DMANTW0 DMANTW0 DN N-Hydroxy-N-methyl-3-naphthalen-2-yl-acrylamide DMANTW0 TI TT2J34L DMANTW0 TN Arachidonate 5-lipoxygenase (5-LOX) DMANTW0 MA Inhibitor DMANTW0 RN In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J Med Chem. 1987 Nov;30(11):2121-6. DMANTW0 RU https://pubmed.ncbi.nlm.nih.gov/3669019 DMANU3W DI DMANU3W DMANU3W DN AS-602704 DMANU3W TI TTE4KHA DMANU3W TN Amyloid beta A4 protein (APP) DMANU3W MA Modulator DMANU3W RN Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa. Drug Dev Ind Pharm. 2007 Jan;33(1):71-7. DMANU3W RU https://www.ncbi.nlm.nih.gov/pubmed/17192253 DMANV7R DI DMANV7R DMANV7R DN CP-775146 DMANV7R TI TTJ584C DMANV7R TN Peroxisome proliferator-activated receptor alpha (PPARA) DMANV7R MA Agonist DMANV7R RN Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. Mol Pharmacol. 2009 Feb;75(2):296-306. DMANV7R RU https://pubmed.ncbi.nlm.nih.gov/18971326 DMANVJY DI DMANVJY DMANVJY DN Phosphoric acid monodec-9-enyl ester DMANVJY TI TTQ6S1K DMANVJY TN Lysophosphatidic acid receptor 1 (LPAR1) DMANVJY MA Inhibitor DMANVJY RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMANVJY RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMANYSO DI DMANYSO DMANYSO DN 7-Diazonium-naphthalene-1-sulfonic acid anion DMANYSO TI TTNJYV2 DMANYSO TN Gamma-aminobutyric acid receptor (GAR) DMANYSO MA Inhibitor DMANYSO RN Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor. J Med Chem. 1987 Dec;30(12):2222-7. DMANYSO RU https://pubmed.ncbi.nlm.nih.gov/2824775 DMANYU5 DI DMANYU5 DMANYU5 DN AKN-028 DMANYU5 TI TTGJCWZ DMANYU5 TN Fms-like tyrosine kinase 3 (FLT-3) DMANYU5 MA Inhibitor DMANYU5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1807). DMANYU5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1807 DMANZIE DI DMANZIE DMANZIE DN NSC-27236 DMANZIE TI TTVKILB DMANZIE TN Prostaglandin G/H synthase 2 (COX-2) DMANZIE MA Inhibitor DMANZIE RN Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4440-3. DMANZIE RU https://pubmed.ncbi.nlm.nih.gov/16814546 DMAO64J DI DMAO64J DMAO64J DN 3-((E)-Styryl)-quinoline DMAO64J TI TTI7421 DMAO64J TN Platelet-derived growth factor receptor beta (PDGFRB) DMAO64J MA Inhibitor DMAO64J RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMAO64J RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMAO64J DI DMAO64J DMAO64J DN 3-((E)-Styryl)-quinoline DMAO64J TI TT8FYO9 DMAO64J TN Platelet-derived growth factor receptor alpha (PDGFRA) DMAO64J MA Inhibitor DMAO64J RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMAO64J RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMAO6JS DI DMAO6JS DMAO6JS DN ER-23006 DMAO6JS TI TTMXGCW DMAO6JS TN Adrenergic receptor beta-3 (ADRB3) DMAO6JS MA Modulator DMAO6JS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29). DMAO6JS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29 DMAO6X9 DI DMAO6X9 DMAO6X9 DN 4-(2-(thiophen-3-yl)-9H-purin-6-yl)morpholine DMAO6X9 TI TTCJG29 DMAO6X9 TN Serine/threonine-protein kinase mTOR (mTOR) DMAO6X9 MA Inhibitor DMAO6X9 RN Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. DMAO6X9 RU https://pubmed.ncbi.nlm.nih.gov/19969455 DMAO7DS DI DMAO7DS DMAO7DS DN 2-Sulfamoyl-benzoic acid methyl ester DMAO7DS TI TT2LVK8 DMAO7DS TN Carbonic anhydrase IX (CA-IX) DMAO7DS MA Inhibitor DMAO7DS RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMAO7DS RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMAO7DS DI DMAO7DS DMAO7DS DN 2-Sulfamoyl-benzoic acid methyl ester DMAO7DS TI TTANPDJ DMAO7DS TN Carbonic anhydrase II (CA-II) DMAO7DS MA Inhibitor DMAO7DS RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMAO7DS RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMAO9SH DI DMAO9SH DMAO9SH DN [3H]NECA DMAO9SH TI TTJFY5U DMAO9SH TN Adenosine A3 receptor (ADORA3) DMAO9SH MA Agonist DMAO9SH RN Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2). Biochem Pharmacol. 2001 Nov 1;62(9):1163-73. DMAO9SH RU https://pubmed.ncbi.nlm.nih.gov/11705449 DMAO9SH DI DMAO9SH DMAO9SH DN [3H]NECA DMAO9SH TI TTNE7KG DMAO9SH TN Adenosine A2b receptor (ADORA2B) DMAO9SH MA Agonist DMAO9SH RN Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9. DMAO9SH RU https://pubmed.ncbi.nlm.nih.gov/9459566 DMAO9SH DI DMAO9SH DMAO9SH DN [3H]NECA DMAO9SH TI TTM2AOE DMAO9SH TN Adenosine A2a receptor (ADORA2A) DMAO9SH MA Inhibitor DMAO9SH RN Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83. DMAO9SH RU https://pubmed.ncbi.nlm.nih.gov/3373486 DMAO9SH DI DMAO9SH DMAO9SH DN [3H]NECA DMAO9SH TI TTK25J1 DMAO9SH TN Adenosine A1 receptor (ADORA1) DMAO9SH MA Inhibitor DMAO9SH RN Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83. DMAO9SH RU https://pubmed.ncbi.nlm.nih.gov/3373486 DMAOD0K DI DMAOD0K DMAOD0K DN 2-(3,4-Dihydroxy-benzyl)-7-hydroxy-chromen-4-one DMAOD0K TI TTFBNVI DMAOD0K TN Aldose reductase (AKR1B1) DMAOD0K MA Inhibitor DMAOD0K RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DMAOD0K RU https://pubmed.ncbi.nlm.nih.gov/10354396 DMAOGBP DI DMAOGBP DMAOGBP DN 2,4-Diamino-butyric acid(GABA) DMAOGBP TI TTNJYV2 DMAOGBP TN Gamma-aminobutyric acid receptor (GAR) DMAOGBP MA Inhibitor DMAOGBP RN Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9. DMAOGBP RU https://pubmed.ncbi.nlm.nih.gov/3005567 DMAOGBP DI DMAOGBP DMAOGBP DN 2,4-Diamino-butyric acid(GABA) DMAOGBP TI TT8RXO5 DMAOGBP TN GABA transporter-3 (SLC6A11) DMAOGBP MA Inhibitor DMAOGBP RN Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9. DMAOGBP RU https://pubmed.ncbi.nlm.nih.gov/3005567 DMAOGBP DI DMAOGBP DMAOGBP DN 2,4-Diamino-butyric acid(GABA) DMAOGBP TI TTPRKM0 DMAOGBP TN GABA transporter GAT-1 (SLC6A1) DMAOGBP MA Inhibitor DMAOGBP RN Glycine antagonists. Synthesis, structure, and biological effects of some bicyclic 5-isoxazolol zwitterions. J Med Chem. 1986 Feb;29(2):224-9. DMAOGBP RU https://pubmed.ncbi.nlm.nih.gov/3005567 DMAOI51 DI DMAOI51 DMAOI51 DN RO1138452 DMAOI51 TI TTOFYT1 DMAOI51 TN Prostacyclin receptor (PTGIR) DMAOI51 MA Antagonist DMAOI51 RN RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol. 2006 Feb;147(3):335-45. DMAOI51 RU https://pubmed.ncbi.nlm.nih.gov/16331286 DMAOIW5 DI DMAOIW5 DMAOIW5 DN PB-80 DMAOIW5 TI TT7WZIJ DMAOIW5 TN CAAX farnesyltransferase beta (FNTB) DMAOIW5 MA Inhibitor DMAOIW5 RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DMAOIW5 RU https://pubmed.ncbi.nlm.nih.gov/15916422 DMAOIW5 DI DMAOIW5 DMAOIW5 DN PB-80 DMAOIW5 TI TTXQKM3 DMAOIW5 TN Farnesyl protein transferase (Ftase) DMAOIW5 MA Inhibitor DMAOIW5 RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DMAOIW5 RU https://pubmed.ncbi.nlm.nih.gov/15916422 DMAOJ0E DI DMAOJ0E DMAOJ0E DN RU28362 DMAOJ0E TI TTOZRK6 DMAOJ0E TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMAOJ0E MA Agonist DMAOJ0E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 625). DMAOJ0E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=625 DMAOUQI DI DMAOUQI DMAOUQI DN 6-Nitro-2-piperazin-1-yl-4-vinyl-quinoline DMAOUQI TI TT3ROYC DMAOUQI TN Serotonin transporter (SERT) DMAOUQI MA Inhibitor DMAOUQI RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DMAOUQI RU https://pubmed.ncbi.nlm.nih.gov/11859009 DMAP04X DI DMAP04X DMAP04X DN PHELLIGRIDIN I DMAP04X TI TTELIN2 DMAP04X TN PTPN1 messenger RNA (PTPN1 mRNA) DMAP04X MA Inhibitor DMAP04X RN Structures, biogenesis, and biological activities of pyrano[4,3-c]isochromen-4-one derivatives from the Fungus Phellinus igniarius. J Nat Prod. 2007 Feb;70(2):296-9. DMAP04X RU https://pubmed.ncbi.nlm.nih.gov/17279797 DMAP37I DI DMAP37I DMAP37I DN 2-(3-Amino-phenyl)-6-methyl-chromen-4-one DMAP37I TI TTNJYV2 DMAP37I TN Gamma-aminobutyric acid receptor (GAR) DMAP37I MA Inhibitor DMAP37I RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMAP37I RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMAP4R8 DI DMAP4R8 DMAP4R8 DN N-(1-(4-nitrobenzyl)piperidin-4-yl)-2-naphthamide DMAP4R8 TI TTJQOD7 DMAP4R8 TN 5-HT 2A receptor (HTR2A) DMAP4R8 MA Inhibitor DMAP4R8 RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4. DMAP4R8 RU https://pubmed.ncbi.nlm.nih.gov/17251022 DMAP8VY DI DMAP8VY DMAP8VY DN FM1-43 DMAP8VY TI TTQ3JTF DMAP8VY TN Muscarinic acetylcholine receptor M4 (CHRM4) DMAP8VY MA Inhibitor DMAP8VY RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DMAP8VY RU https://pubmed.ncbi.nlm.nih.gov/18042383 DMAP8VY DI DMAP8VY DMAP8VY DN FM1-43 DMAP8VY TI TTH18TF DMAP8VY TN Muscarinic acetylcholine receptor M5 (CHRM5) DMAP8VY MA Inhibitor DMAP8VY RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DMAP8VY RU https://pubmed.ncbi.nlm.nih.gov/18042383 DMAP8VY DI DMAP8VY DMAP8VY DN FM1-43 DMAP8VY TI TTQ13Z5 DMAP8VY TN Muscarinic acetylcholine receptor M3 (CHRM3) DMAP8VY MA Inhibitor DMAP8VY RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DMAP8VY RU https://pubmed.ncbi.nlm.nih.gov/18042383 DMAP8VY DI DMAP8VY DMAP8VY DN FM1-43 DMAP8VY TI TTZ9SOR DMAP8VY TN Muscarinic acetylcholine receptor M1 (CHRM1) DMAP8VY MA Inhibitor DMAP8VY RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DMAP8VY RU https://pubmed.ncbi.nlm.nih.gov/18042383 DMAP8VY DI DMAP8VY DMAP8VY DN FM1-43 DMAP8VY TI TTYEG6Q DMAP8VY TN Muscarinic acetylcholine receptor M2 (CHRM2) DMAP8VY MA Inhibitor DMAP8VY RN Design and synthesis of a fluorescent muscarinic antagonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):825-7. DMAP8VY RU https://pubmed.ncbi.nlm.nih.gov/18042383 DMAPI2G DI DMAPI2G DMAPI2G DN 18F-AV-45 dimer DMAPI2G TI TTE4KHA DMAPI2G TN Amyloid beta A4 protein (APP) DMAPI2G MA Modulator DMAPI2G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMAPI2G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMAPRDE DI DMAPRDE DMAPRDE DN CXB-029 DMAPRDE TI TT6OEDT DMAPRDE TN Cannabinoid receptor 1 (CB1) DMAPRDE MA Antagonist DMAPRDE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56). DMAPRDE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56 DMAPRNO DI DMAPRNO DMAPRNO DN xenin DMAPRNO TI TT31Q0V DMAPRNO TN Neurotensin receptor type 2 (NTSR2) DMAPRNO MA Agonist DMAPRNO RN Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: binding properties, photoaffinity labeling, and internalization mechanism. Biochem Biophys Res Commun. 1998 Feb 13;243(2):585-90. DMAPRNO RU https://pubmed.ncbi.nlm.nih.gov/9480852 DMAPW5K DI DMAPW5K DMAPW5K DN 2-(cyclooctylamino)-5,5-diethyloxazol-4(5H)-one DMAPW5K TI TTN7BL9 DMAPW5K TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMAPW5K MA Inhibitor DMAPW5K RN Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40. DMAPW5K RU https://pubmed.ncbi.nlm.nih.gov/17600707 DMAPWC2 DI DMAPWC2 DMAPWC2 DN H-Leu-Phe-NH2 DMAPWC2 TI TTZPO1L DMAPWC2 TN Substance-P receptor (TACR1) DMAPWC2 MA Inhibitor DMAPWC2 RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMAPWC2 RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMAPWNR DI DMAPWNR DMAPWNR DN 2-(4-chlorophenyl)-6-phenyl-9H-purine DMAPWNR TI TTK25J1 DMAPWNR TN Adenosine A1 receptor (ADORA1) DMAPWNR MA Inhibitor DMAPWNR RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMAPWNR RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMAPWNR DI DMAPWNR DMAPWNR DN 2-(4-chlorophenyl)-6-phenyl-9H-purine DMAPWNR TI TTM2AOE DMAPWNR TN Adenosine A2a receptor (ADORA2A) DMAPWNR MA Inhibitor DMAPWNR RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMAPWNR RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMAPWNR DI DMAPWNR DMAPWNR DN 2-(4-chlorophenyl)-6-phenyl-9H-purine DMAPWNR TI TTJFY5U DMAPWNR TN Adenosine A3 receptor (ADORA3) DMAPWNR MA Inhibitor DMAPWNR RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMAPWNR RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMAPX9G DI DMAPX9G DMAPX9G DN Bip-tyr-thr-pro-lys-thr(obzl)-gly DMAPX9G TI TTVBI8W DMAPX9G TN Dopamine transporter (DAT) DMAPX9G MA Inhibitor DMAPX9G RN Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. DMAPX9G RU https://pubmed.ncbi.nlm.nih.gov/16821765 DMAPZKB DI DMAPZKB DMAPZKB DN D[Cha4,Dap8]VP DMAPZKB TI TT4TFGN DMAPZKB TN Vasopressin V1a receptor (V1AR) DMAPZKB MA Inhibitor DMAPZKB RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMAPZKB RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMAPZKB DI DMAPZKB DMAPZKB DN D[Cha4,Dap8]VP DMAPZKB TI TTL9MHW DMAPZKB TN Vasopressin V1b receptor (V1BR) DMAPZKB MA Inhibitor DMAPZKB RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMAPZKB RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMAPZKB DI DMAPZKB DMAPZKB DN D[Cha4,Dap8]VP DMAPZKB TI TTSCIUP DMAPZKB TN Oxytocin receptor (OTR) DMAPZKB MA Inhibitor DMAPZKB RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMAPZKB RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMAPZKB DI DMAPZKB DMAPZKB DN D[Cha4,Dap8]VP DMAPZKB TI TTK8R02 DMAPZKB TN Vasopressin V2 receptor (V2R) DMAPZKB MA Inhibitor DMAPZKB RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMAPZKB RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMAPZQW DI DMAPZQW DMAPZQW DN 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide DMAPZQW TI TT2LVK8 DMAPZQW TN Carbonic anhydrase IX (CA-IX) DMAPZQW MA Inhibitor DMAPZQW RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMAPZQW RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMAPZQW DI DMAPZQW DMAPZQW DN 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide DMAPZQW TI TTANPDJ DMAPZQW TN Carbonic anhydrase II (CA-II) DMAPZQW MA Inhibitor DMAPZQW RN Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32. DMAPZQW RU https://pubmed.ncbi.nlm.nih.gov/19651511 DMAPZQW DI DMAPZQW DMAPZQW DN 3-((4-hydroxyphenyl)diazenyl)benzenesulfonamide DMAPZQW TI TTSYM0R DMAPZQW TN Carbonic anhydrase XII (CA-XII) DMAPZQW MA Inhibitor DMAPZQW RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMAPZQW RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMAQ6OM DI DMAQ6OM DMAQ6OM DN 3,5-dimethyl-2-(phenylsulfonamido)benzoic acid DMAQ6OM TI TTZL0OI DMAQ6OM TN Methionine aminopeptidase 2 (METAP2) DMAQ6OM MA Inhibitor DMAQ6OM RN Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. DMAQ6OM RU https://pubmed.ncbi.nlm.nih.gov/16632353 DMAQ7XH DI DMAQ7XH DMAQ7XH DN ISIS 9025 DMAQ7XH TI TTBSN0L DMAQ7XH TN PKC-zeta messenger RNA (PRKCZ mRNA) DMAQ7XH RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMAQ7XH RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMAQ9EB DI DMAQ9EB DMAQ9EB DN ISIS 15998 DMAQ9EB TI TTRE6AX DMAQ9EB TN Bcl-x messenger RNA (BCL2L1 mRNA) DMAQ9EB RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMAQ9EB RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMAQBKX DI DMAQBKX DMAQBKX DN Alpha-Hydroxy-Midazolam DMAQBKX TI TTXV4FI DMAQBKX TN Albendazole monooxygenase (CYP3A4) DMAQBKX MA Inhibitor DMAQBKX RN Design and synthesis of a new fluorescent probe for cytochrome P450 3A4 (CYP 3A4). Bioorg Med Chem Lett. 2003 Nov 3;13(21):3643-5. DMAQBKX RU https://pubmed.ncbi.nlm.nih.gov/14552748 DMAQDK9 DI DMAQDK9 DMAQDK9 DN 5,10-Methylene-6-Hydrofolic Acid DMAQDK9 TI TTU6BFZ DMAQDK9 TN Candida Thymidylate synthase (Candi TMP1) DMAQDK9 MA Inhibitor DMAQDK9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAQDK9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAQGIW DI DMAQGIW DMAQGIW DN NSC-204996 DMAQGIW TI TTJLP0R DMAQGIW TN Quinone reductase 2 (NQO2) DMAQGIW MA Inhibitor DMAQGIW RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMAQGIW RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMAQGZR DI DMAQGZR DMAQGZR DN 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DMAQGZR TI TTYFKSZ DMAQGZR TN Tubulin beta (TUBB) DMAQGZR MA Inhibitor DMAQGZR RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMAQGZR RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMAQGZR DI DMAQGZR DMAQGZR DN 6-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DMAQGZR TI TTML2WA DMAQGZR TN Tubulin (TUB) DMAQGZR MA Inhibitor DMAQGZR RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMAQGZR RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMAQK0G DI DMAQK0G DMAQK0G DN Benzoic acid 2,6-diisopropyl-phenyl ester DMAQK0G TI TTNJYV2 DMAQK0G TN Gamma-aminobutyric acid receptor (GAR) DMAQK0G MA Inhibitor DMAQK0G RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DMAQK0G RU https://pubmed.ncbi.nlm.nih.gov/9599235 DMAQKO1 DI DMAQKO1 DMAQKO1 DN 1-Thiazol-2-yl-3-(2-o-tolyl-ethyl)-thiourea DMAQKO1 TI TT84ETX DMAQKO1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMAQKO1 MA Inhibitor DMAQKO1 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMAQKO1 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMAQMXJ DI DMAQMXJ DMAQMXJ DN N-(2-Propyloxy-4-nitrophenyl)methanesulfonamide DMAQMXJ TI TTSZLWK DMAQMXJ TN Aromatase (CYP19A1) DMAQMXJ MA Inhibitor DMAQMXJ RN Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9. DMAQMXJ RU https://pubmed.ncbi.nlm.nih.gov/16480277 DMAQMXT DI DMAQMXT DMAQMXT DN Ribavirin + interferon beta-1a DMAQMXT TI TTOA6YT DMAQMXT TN MERS-CoV RNA-directed RNA polymerase (RdRp) DMAQMXT MA Inhibitor DMAQMXT RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMAQMXT RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMAQOL0 DI DMAQOL0 DMAQOL0 DN 3-Imidazol-1-ylmethyl-2-isopropyl-1H-indole DMAQOL0 TI TTIQUX7 DMAQOL0 TN Steroid 11-beta-hydroxylase (CYP11B1) DMAQOL0 MA Inhibitor DMAQOL0 RN Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues. J Med Chem. 1986 Mar;29(3):342-6. DMAQOL0 RU https://pubmed.ncbi.nlm.nih.gov/3081722 DMAQR29 DI DMAQR29 DMAQR29 DN Ac-His-D-Phe-Arg-2-Nal-NHCH3 DMAQR29 TI TTD0CIQ DMAQR29 TN Melanocortin receptor 4 (MC4R) DMAQR29 MA Inhibitor DMAQR29 RN Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. DMAQR29 RU https://pubmed.ncbi.nlm.nih.gov/16766182 DMAQR29 DI DMAQR29 DMAQR29 DN Ac-His-D-Phe-Arg-2-Nal-NHCH3 DMAQR29 TI TT0MV2T DMAQR29 TN Melanocortin receptor 1 (MC1R) DMAQR29 MA Inhibitor DMAQR29 RN Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. DMAQR29 RU https://pubmed.ncbi.nlm.nih.gov/16766182 DMAQR29 DI DMAQR29 DMAQR29 DN Ac-His-D-Phe-Arg-2-Nal-NHCH3 DMAQR29 TI TTNI91K DMAQR29 TN Melanocortin receptor 3 (MC3R) DMAQR29 MA Inhibitor DMAQR29 RN Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. DMAQR29 RU https://pubmed.ncbi.nlm.nih.gov/16766182 DMAQSBV DI DMAQSBV DMAQSBV DN 1-Benzyl-4-chroman-2-ylmethyl-piperazine DMAQSBV TI TTSQIFT DMAQSBV TN 5-HT 1A receptor (HTR1A) DMAQSBV MA Inhibitor DMAQSBV RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMAQSBV RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMAQT6S DI DMAQT6S DMAQT6S DN N-Butyl 2beta-hydroxyolean-12-en-28-oate DMAQT6S TI TTZHY6R DMAQT6S TN Glycogen phosphorylase muscle form (GP) DMAQT6S MA Inhibitor DMAQT6S RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMAQT6S RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMAQTW3 DI DMAQTW3 DMAQTW3 DN NNC269100 DMAQTW3 TI TTAE1BR DMAQTW3 TN Somatostatin receptor type 4 (SSTR4) DMAQTW3 MA Agonist DMAQTW3 RN Nonpeptide somatostatin agonists with sst4 selectivity: synthesis and structure-activity relationships of thioureas. J Med Chem. 1998 Nov 19;41(24):4693-705. DMAQTW3 RU https://pubmed.ncbi.nlm.nih.gov/9822540 DMAQU71 DI DMAQU71 DMAQU71 DN Ins(3,4,5,6)P4 DMAQU71 TI TTOJI4S DMAQU71 TN Calcium-dependent chloride channel anoctamin (ANO) DMAQU71 MA Blocker (channel blocker) DMAQU71 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708). DMAQU71 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708 DMAQWM8 DI DMAQWM8 DMAQWM8 DN NSC-369087 DMAQWM8 TI TTSZLWK DMAQWM8 TN Aromatase (CYP19A1) DMAQWM8 MA Inhibitor DMAQWM8 RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMAQWM8 RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMAQX4K DI DMAQX4K DMAQX4K DN (S)-tert-butyl 1-oxohexan-2-ylcarbamate DMAQX4K TI TT36ETB DMAQX4K TN Cathepsin L (CTSL) DMAQX4K MA Inhibitor DMAQX4K RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMAQX4K RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMAQX4K DI DMAQX4K DMAQX4K DN (S)-tert-butyl 1-oxohexan-2-ylcarbamate DMAQX4K TI TTDZN01 DMAQX4K TN Cathepsin K (CTSK) DMAQX4K MA Inhibitor DMAQX4K RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMAQX4K RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMAR1D6 DI DMAR1D6 DMAR1D6 DN ISIS 29137 DMAR1D6 TI TTO6SGY DMAR1D6 TN AKT3 messenger RNA (AKT3 mRNA) DMAR1D6 RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMAR1D6 RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMAR35H DI DMAR35H DMAR35H DN KNI-10282 DMAR35H TI TTXMNHO DMAR35H TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMAR35H MA Inhibitor DMAR35H RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMAR35H RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMAR39L DI DMAR39L DMAR39L DN 1-(4-nonylbenzyl)pyrrolidine-3-carboxylic acid DMAR39L TI TT9JZCK DMAR39L TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMAR39L MA Inhibitor DMAR39L RN A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5. DMAR39L RU https://pubmed.ncbi.nlm.nih.gov/15615513 DMAR3M2 DI DMAR3M2 DMAR3M2 DN JMV1431 DMAR3M2 TI TTGY8IW DMAR3M2 TN B2 bradykinin receptor (BDKRB2) DMAR3M2 MA Antagonist DMAR3M2 RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DMAR3M2 RU https://pubmed.ncbi.nlm.nih.gov/10882364 DMAR3M2 DI DMAR3M2 DMAR3M2 DN JMV1431 DMAR3M2 TI TTG5QIA DMAR3M2 TN B1 bradykinin receptor (BDKRB1) DMAR3M2 MA Inhibitor DMAR3M2 RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DMAR3M2 RU https://pubmed.ncbi.nlm.nih.gov/10882364 DMAR4ZF DI DMAR4ZF DMAR4ZF DN 5-methyl-2-(pyridin-2-yl)-1H-benzo[d]imidazole DMAR4ZF TI TTZL0OI DMAR4ZF TN Methionine aminopeptidase 2 (METAP2) DMAR4ZF MA Inhibitor DMAR4ZF RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMAR4ZF RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMARBF9 DI DMARBF9 DMARBF9 DN Benzaldehyde O-4-propoxyphenylcarbamoyl oxime DMARBF9 TI TTDP1UC DMARBF9 TN Fatty acid amide hydrolase (FAAH) DMARBF9 MA Inhibitor DMARBF9 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMARBF9 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMARCKD DI DMARCKD DMARCKD DN 5-METHOXYTRYPTAMINE DMARCKD TI TTJS8PY DMARCKD TN 5-HT 6 receptor (HTR6) DMARCKD MA Inhibitor DMARCKD RN Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95. DMARCKD RU https://pubmed.ncbi.nlm.nih.gov/15771424 DMARCKD DI DMARCKD DMARCKD DN 5-METHOXYTRYPTAMINE DMARCKD TI TTJQOD7 DMARCKD TN 5-HT 2A receptor (HTR2A) DMARCKD MA Inhibitor DMARCKD RN Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1-12. DMARCKD RU https://pubmed.ncbi.nlm.nih.gov/3543362 DMARCKD DI DMARCKD DMARCKD DN 5-METHOXYTRYPTAMINE DMARCKD TI TTXDKTO DMARCKD TN Long transient receptor potential channel 8 (TRPM8) DMARCKD MA Inhibitor DMARCKD RN 5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9. DMARCKD RU https://pubmed.ncbi.nlm.nih.gov/20965726 DMAROTU DI DMAROTU DMAROTU DN RPKPfQwFwLL-NH2 DMAROTU TI TTWDC17 DMAROTU TN Growth hormone secretagogue receptor 1 (GHSR) DMAROTU MA Inhibitor DMAROTU RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DMAROTU RU https://pubmed.ncbi.nlm.nih.gov/17371869 DMAROW1 DI DMAROW1 DMAROW1 DN ROMe DMAROW1 TI TTCN0M9 DMAROW1 TN Sphingosine kinase 2 (SPHK2) DMAROW1 MA Inhibitor DMAROW1 RN (R)-FTY720 methyl ether is a specific sphingosine kinase 2 inhibitor: Effect on sphingosine kinase 2 expression in HEK 293 cells and actin rearrangement and survival of MCF-7 breast cancer cells. Cell Signal. 2011 Oct;23(10):1590-5. DMAROW1 RU https://pubmed.ncbi.nlm.nih.gov/21620961 DMARP3M DI DMARP3M DMARP3M DN 6-Benzyloxybenzo[b]thiophene-2-carboxamidine DMARP3M TI TTFEZ5Q DMARP3M TN Coagulation factor IX (F9) DMARP3M MA Inhibitor DMARP3M RN Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72. DMARP3M RU https://pubmed.ncbi.nlm.nih.gov/20121198 DMARTC2 DI DMARTC2 DMARTC2 DN DP-802 DMARTC2 TI TTQBR95 DMARTC2 TN Stress-activated protein kinase 2a (p38 alpha) DMARTC2 MA Inhibitor DMARTC2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499). DMARTC2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499 DMARTN3 DI DMARTN3 DMARTN3 DN JMV 1693 DMARTN3 TI TTC1MVT DMARTN3 TN Gastrin-releasing peptide receptor (GRPR) DMARTN3 MA Inhibitor DMARTN3 RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DMARTN3 RU https://pubmed.ncbi.nlm.nih.gov/10882361 DMARWG5 DI DMARWG5 DMARWG5 DN HYDRAZINECARBOXAMIDE DMARWG5 TI TT3WG5C DMARWG5 TN Monoamine oxidase type A (MAO-A) DMARWG5 MA Inhibitor DMARWG5 RN Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxi... J Med Chem. 2004 Nov 18;47(24):5860-71. DMARWG5 RU https://pubmed.ncbi.nlm.nih.gov/15537343 DMARWG5 DI DMARWG5 DMARWG5 DN HYDRAZINECARBOXAMIDE DMARWG5 TI TTGP7BY DMARWG5 TN Monoamine oxidase type B (MAO-B) DMARWG5 MA Inhibitor DMARWG5 RN Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxi... J Med Chem. 2004 Nov 18;47(24):5860-71. DMARWG5 RU https://pubmed.ncbi.nlm.nih.gov/15537343 DMARY2Z DI DMARY2Z DMARY2Z DN Human recombinant factor VIIa DMARY2Z TI TTF0EGX DMARY2Z TN Coagulation factor VII (F7) DMARY2Z MA Modulator DMARY2Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMARY2Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMARZHU DI DMARZHU DMARZHU DN N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine DMARZHU TI TTOYT5L DMARZHU TN Dipeptidyl-peptidase 7 (DPP7) DMARZHU MA Inhibitor DMARZHU RN Dipeptidyl peptidase II and leukocyte cell death. Biochem Pharmacol. 2006 Jun 28;72(1):70-9. DMARZHU RU https://pubmed.ncbi.nlm.nih.gov/16725115 DMARZHU DI DMARZHU DMARZHU DN N4-(4-chlorobenzyl)-2,4-diaminobutanoylpiperidine DMARZHU TI TTDIGC1 DMARZHU TN Dipeptidyl peptidase 4 (DPP-4) DMARZHU MA Inhibitor DMARZHU RN Synthesis and dipeptidyl peptidase inhibition of N-(4-substituted-2,4-diaminobutanoyl)piperidines. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4777-9. DMARZHU RU https://pubmed.ncbi.nlm.nih.gov/16844373 DMAS3JC DI DMAS3JC DMAS3JC DN (2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime DMAS3JC TI TT7HF4W DMAS3JC TN Cyclin-dependent kinase 2 (CDK2) DMAS3JC MA Inhibitor DMAS3JC RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMAS3JC RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMAS3JC DI DMAS3JC DMAS3JC DN (2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime DMAS3JC TI TTCEJ4F DMAS3JC TN G1/S-specific cyclin-E1 (CCNE1) DMAS3JC MA Inhibitor DMAS3JC RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMAS3JC RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMAS46B DI DMAS46B DMAS46B DN 2-Pyridin-2-ylmethyl-1,2-dihydro-indazol-3-one DMAS46B TI TT2J34L DMAS46B TN Arachidonate 5-lipoxygenase (5-LOX) DMAS46B MA Inhibitor DMAS46B RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMAS46B RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMAS5BI DI DMAS5BI DMAS5BI DN anacardic acid DMAS5BI TI TTH4VJL DMAS5BI TN Histone acetyltransferase KAT6B (KAT6B) DMAS5BI MA Inhibitor DMAS5BI RN Small molecule modulators of histone acetyltransferase p300. J Biol Chem. 2003 May 23;278(21):19134-40. DMAS5BI RU https://pubmed.ncbi.nlm.nih.gov/12624111 DMAS5BI DI DMAS5BI DMAS5BI DN anacardic acid DMAS5BI TI TTVK7SB DMAS5BI TN Histone acetyltransferase KAT2B (KAT2B) DMAS5BI MA Inhibitor DMAS5BI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2737). DMAS5BI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2737 DMAS5P8 DI DMAS5P8 DMAS5P8 DN L-366,682 DMAS5P8 TI TTSCIUP DMAS5P8 TN Oxytocin receptor (OTR) DMAS5P8 MA Antagonist DMAS5P8 RN Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61. DMAS5P8 RU https://pubmed.ncbi.nlm.nih.gov/7475979 DMASC8K DI DMASC8K DMASC8K DN 1,2-Dihydroxy-10H-anthracen-9-one DMASC8K TI TT2J34L DMASC8K TN Arachidonate 5-lipoxygenase (5-LOX) DMASC8K MA Inhibitor DMASC8K RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMASC8K RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMASE5O DI DMASE5O DMASE5O DN AS-19 DMASE5O TI TTO9X1H DMASE5O TN 5-HT 7 receptor (HTR7) DMASE5O MA Agonist DMASE5O RN Discovery of aryl-biphenyl-2-ylmethylpiperazines as novel scaffolds for 5-HT(7) ligands and role of the aromatic substituents in binding to the target receptor. Bioorg Med Chem. 2013 May 1;21(9):2568-76. DMASE5O RU https://pubmed.ncbi.nlm.nih.gov/23541835 DMASFR6 DI DMASFR6 DMASFR6 DN 6-chloro-5-heptylpyrimidine-2,4(1H,3H)-dione DMASFR6 TI TTO0IB8 DMASFR6 TN Thymidine phosphorylase (TYMP) DMASFR6 MA Inhibitor DMASFR6 RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DMASFR6 RU https://pubmed.ncbi.nlm.nih.gov/17963370 DMASH36 DI DMASH36 DMASH36 DN 2-(3-methoxyphenyl)-6-morpholino-4H-pyran-4-one DMASH36 TI TTK3PY9 DMASH36 TN DNA-dependent protein kinase catalytic (PRKDC) DMASH36 MA Inhibitor DMASH36 RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMASH36 RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMASLUF DI DMASLUF DMASLUF DN 1-(4-Chlorobenzyl)-5-phenyl-1H-imidazole DMASLUF TI TTIQUX7 DMASLUF TN Steroid 11-beta-hydroxylase (CYP11B1) DMASLUF MA Inhibitor DMASLUF RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMASLUF RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMASNGX DI DMASNGX DMASNGX DN Bis(3-bromophenyl)(5-hydroxy)thiosemicarbazone DMASNGX TI TT36ETB DMASNGX TN Cathepsin L (CTSL) DMASNGX MA Inhibitor DMASNGX RN Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. DMASNGX RU https://pubmed.ncbi.nlm.nih.gov/20933415 DMASO86 DI DMASO86 DMASO86 DN 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide DMASO86 TI TTMSFAW DMASO86 TN Cannabinoid receptor 2 (CB2) DMASO86 MA Inhibitor DMASO86 RN Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9. DMASO86 RU https://pubmed.ncbi.nlm.nih.gov/20047779 DMASO86 DI DMASO86 DMASO86 DN 4-benzhydryl-N-cyclohexylpiperazine-1-carboxamide DMASO86 TI TT6OEDT DMASO86 TN Cannabinoid receptor 1 (CB1) DMASO86 MA Inhibitor DMASO86 RN Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9. DMASO86 RU https://pubmed.ncbi.nlm.nih.gov/20047779 DMASOWP DI DMASOWP DMASOWP DN ROBINETIN DMASOWP TI TT7RJY8 DMASOWP TN Xanthine dehydrogenase/oxidase (XDH) DMASOWP MA Inhibitor DMASOWP RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DMASOWP RU https://pubmed.ncbi.nlm.nih.gov/3379415 DMASP9Z DI DMASP9Z DMASP9Z DN SU11274 DMASP9Z TI TTNDSF4 DMASP9Z TN Proto-oncogene c-Met (MET) DMASP9Z MA Inhibitor DMASP9Z RN Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. Mol Cancer Ther. 2003 Nov;2(11):1085-92. DMASP9Z RU https://pubmed.ncbi.nlm.nih.gov/14617781 DMASPV9 DI DMASPV9 DMASPV9 DN Lopinavir + ritonavir + interferon beta DMASPV9 TI TTWOH4Q DMASPV9 TN MERS-CoV 3C-like proteinase (3CLpro) DMASPV9 MA Inhibitor DMASPV9 RN Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379-381. DMASPV9 RU https://pubmed.ncbi.nlm.nih.gov/32205870 DMASQV4 DI DMASQV4 DMASQV4 DN SB-611812 DMASQV4 TI TTW5UDX DMASQV4 TN Urotensin II receptor (UTS2R) DMASQV4 MA Antagonist DMASQV4 RN A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Mol Cell Cardiol. 2005 Nov;39(5):785-91. DMASQV4 RU https://pubmed.ncbi.nlm.nih.gov/16171813 DMASQWV DI DMASQWV DMASQWV DN enantio PAF C-16 DMASQWV TI TTQL5VC DMASQWV TN Platelet-activating factor receptor (PTAFR) DMASQWV MA Agonist DMASQWV RN A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J Immunol Methods. 1995 Oct 26;186(2):225-31. DMASQWV RU https://pubmed.ncbi.nlm.nih.gov/7594622 DMASR6T DI DMASR6T DMASR6T DN GIDAZEPAM DMASR6T TI TTEX6LM DMASR6T TN GABA(A) receptor gamma-3 (GABRG3) DMASR6T MA Modulator DMASR6T RN Discriminative effects of phenazepam and gidazepam in rats: comparison with other GABA-related drugs. Pharmacol Biochem Behav. 1999 Oct;64(2):397-401. DMASR6T RU https://pubmed.ncbi.nlm.nih.gov/10515320 DMAT58Z DI DMAT58Z DMAT58Z DN (-)-Tolserine DMAT58Z TI TT1RS9F DMAT58Z TN Acetylcholinesterase (AChE) DMAT58Z MA Inhibitor DMAT58Z RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMAT58Z RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMAT58Z DI DMAT58Z DMAT58Z DN (-)-Tolserine DMAT58Z TI TTEB0GD DMAT58Z TN Cholinesterase (BCHE) DMAT58Z MA Inhibitor DMAT58Z RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMAT58Z RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMAT7VN DI DMAT7VN DMAT7VN DN 3-(4-Benzoylpiperazine-1-carbonyl)coumarin DMAT7VN TI TT1RS9F DMAT7VN TN Acetylcholinesterase (AChE) DMAT7VN MA Inhibitor DMAT7VN RN Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21. DMAT7VN RU https://pubmed.ncbi.nlm.nih.gov/18701305 DMATB8H DI DMATB8H DMATB8H DN 2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide DMATB8H TI TTSYM0R DMATB8H TN Carbonic anhydrase XII (CA-XII) DMATB8H MA Inhibitor DMATB8H RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMATB8H RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMATB8H DI DMATB8H DMATB8H DN 2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide DMATB8H TI TTANPDJ DMATB8H TN Carbonic anhydrase II (CA-II) DMATB8H MA Inhibitor DMATB8H RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMATB8H RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMATB8H DI DMATB8H DMATB8H DN 2,2-Dimethyl-N-(4-sulfamoyl-phenyl)-propionamide DMATB8H TI TT2LVK8 DMATB8H TN Carbonic anhydrase IX (CA-IX) DMATB8H MA Inhibitor DMATB8H RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMATB8H RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMATC5P DI DMATC5P DMATC5P DN AZ4800 DMATC5P TI TTE4KHA DMATC5P TN Amyloid beta A4 protein (APP) DMATC5P MA Inhibitor DMATC5P RN First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem. 2012 Apr 6;287(15):11810-9. DMATC5P RU https://pubmed.ncbi.nlm.nih.gov/22334705 DMATVZB DI DMATVZB DMATVZB DN 2-morpholino-6-(thianthren-1-yl)-4H-chromen-4-one DMATVZB TI TTK3PY9 DMATVZB TN DNA-dependent protein kinase catalytic (PRKDC) DMATVZB MA Inhibitor DMATVZB RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMATVZB RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMATWDO DI DMATWDO DMATWDO DN ISIS 32028 DMATWDO TI TT9H4P3 DMATWDO TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMATWDO RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMATWDO RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMATXHR DI DMATXHR DMATXHR DN ONO-9780307 DMATXHR TI TTQ6S1K DMATXHR TN Lysophosphatidic acid receptor 1 (LPAR1) DMATXHR MA Antagonist DMATXHR RN Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. Cell. 2015 Jun 18;161(7):1633-43. DMATXHR RU https://pubmed.ncbi.nlm.nih.gov/26091040 DMAU0SF DI DMAU0SF DMAU0SF DN 4-(1H-indol-5-ylamino)-5-styrylnicotinonitrile DMAU0SF TI TT1MS7X DMAU0SF TN PKC-theta messenger RNA (PRKCQ mRNA) DMAU0SF MA Inhibitor DMAU0SF RN First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32. DMAU0SF RU https://pubmed.ncbi.nlm.nih.gov/19762237 DMAU1M5 DI DMAU1M5 DMAU1M5 DN (R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine DMAU1M5 TI TTJQOD7 DMAU1M5 TN 5-HT 2A receptor (HTR2A) DMAU1M5 MA Inhibitor DMAU1M5 RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMAU1M5 RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMAU1M5 DI DMAU1M5 DMAU1M5 DN (R,S)-1-(5-fluoro-1H-indol-1-yl)propan-2-amine DMAU1M5 TI TTWJBZ5 DMAU1M5 TN 5-HT 2C receptor (HTR2C) DMAU1M5 MA Inhibitor DMAU1M5 RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMAU1M5 RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMAU1SZ DI DMAU1SZ DMAU1SZ DN KKHT-10318 DMAU1SZ TI TT729IR DMAU1SZ TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMAU1SZ MA Inhibitor DMAU1SZ RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DMAU1SZ RU https://pubmed.ncbi.nlm.nih.gov/17035033 DMAU2H6 DI DMAU2H6 DMAU2H6 DN H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid DMAU2H6 TI TTKWM86 DMAU2H6 TN Opioid receptor mu (MOP) DMAU2H6 MA Inhibitor DMAU2H6 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMAU2H6 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMAU2H6 DI DMAU2H6 DMAU2H6 DN H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid DMAU2H6 TI TT27RFC DMAU2H6 TN Opioid receptor delta (OPRD1) DMAU2H6 MA Inhibitor DMAU2H6 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMAU2H6 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMAU5VM DI DMAU5VM DMAU5VM DN Dichloroally-lawsone DMAU5VM TI TT3PQ2Y DMAU5VM TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMAU5VM MA Inhibitor DMAU5VM RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMAU5VM RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMAU6FN DI DMAU6FN DMAU6FN DN RwFwLL-NH2 DMAU6FN TI TTWDC17 DMAU6FN TN Growth hormone secretagogue receptor 1 (GHSR) DMAU6FN MA Inhibitor DMAU6FN RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DMAU6FN RU https://pubmed.ncbi.nlm.nih.gov/17371869 DMAU80W DI DMAU80W DMAU80W DN 3,5,6,8-Tetramethyl-N-Methyl Phenanthrolinium DMAU80W TI TTZL0OI DMAU80W TN Methionine aminopeptidase 2 (METAP2) DMAU80W MA Inhibitor DMAU80W RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAU80W RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAUB9F DI DMAUB9F DMAUB9F DN SCH-63390 DMAUB9F TI TTM2AOE DMAUB9F TN Adenosine A2a receptor (ADORA2A) DMAUB9F MA Inhibitor DMAUB9F RN Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A... J Med Chem. 1998 Jun 4;41(12):2126-33. DMAUB9F RU https://pubmed.ncbi.nlm.nih.gov/9622554 DMAUB9F DI DMAUB9F DMAUB9F DN SCH-63390 DMAUB9F TI TTK25J1 DMAUB9F TN Adenosine A1 receptor (ADORA1) DMAUB9F MA Inhibitor DMAUB9F RN Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A... J Med Chem. 1998 Jun 4;41(12):2126-33. DMAUB9F RU https://pubmed.ncbi.nlm.nih.gov/9622554 DMAUDCW DI DMAUDCW DMAUDCW DN O7-Nitrooxyethyl chrysin DMAUDCW TI TTFBNVI DMAUDCW TN Aldose reductase (AKR1B1) DMAUDCW MA Inhibitor DMAUDCW RN Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem. 2010 May 1;18(9):3020-5. DMAUDCW RU https://pubmed.ncbi.nlm.nih.gov/20395149 DMAUFLQ DI DMAUFLQ DMAUFLQ DN GENESERINE DMAUFLQ TI TT1RS9F DMAUFLQ TN Acetylcholinesterase (AChE) DMAUFLQ MA Inhibitor DMAUFLQ RN Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug g... J Med Chem. 2006 Aug 24;49(17):5051-8. DMAUFLQ RU https://pubmed.ncbi.nlm.nih.gov/16913695 DMAUH96 DI DMAUH96 DMAUH96 DN alpha-methylphenylalanine DMAUH96 TI TTGSVH2 DMAUH96 TN Phenylalanine hydroxylase (PAH) DMAUH96 MA Inhibitor DMAUH96 RN Alpha-methylphenylalanine, a new inducer of chronic hyperphenylalaninemia in sucling rats. Science. 1976 Jun 4;192(4243):1007-8. DMAUH96 RU https://pubmed.ncbi.nlm.nih.gov/944951 DMAUJOM DI DMAUJOM DMAUJOM DN agatoxin 489 DMAUJOM TI TTMI6F5 DMAUJOM TN Transient receptor potential cation channel V1 (TRPV1) DMAUJOM MA Blocker (channel blocker) DMAUJOM RN An inhibitor of TRPV1 channels isolated from funnel Web spider venom. Biochemistry. 2005 Nov 29;44(47):15544-9. DMAUJOM RU https://pubmed.ncbi.nlm.nih.gov/16300403 DMAUPQR DI DMAUPQR DMAUPQR DN 12,17-dehydroxyriccardin C DMAUPQR TI TTECBXN DMAUPQR TN Oxysterols receptor LXR-alpha (NR1H3) DMAUPQR MA Inhibitor DMAUPQR RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DMAUPQR RU https://pubmed.ncbi.nlm.nih.gov/18343126 DMAUPQR DI DMAUPQR DMAUPQR DN 12,17-dehydroxyriccardin C DMAUPQR TI TTXA6PH DMAUPQR TN Oxysterols receptor LXR-beta (NR1H2) DMAUPQR MA Inhibitor DMAUPQR RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DMAUPQR RU https://pubmed.ncbi.nlm.nih.gov/18343126 DMAURX5 DI DMAURX5 DMAURX5 DN EP-200 DMAURX5 TI TT2O4W9 DMAURX5 TN Luteinizing hormone receptor (LHCGR) DMAURX5 MA Modulator DMAURX5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 254). DMAURX5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=254 DMAUTRP DI DMAUTRP DMAUTRP DN TUPICHINOL C DMAUTRP TI TTOM3J0 DMAUTRP TN Estrogen receptor beta (ESR2) DMAUTRP MA Inhibitor DMAUTRP RN New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. DMAUTRP RU https://pubmed.ncbi.nlm.nih.gov/20493686 DMAUZHJ DI DMAUZHJ DMAUZHJ DN 1-methoxy-9-aminomethyl-9,10-dihydroanthracene DMAUZHJ TI TTJQOD7 DMAUZHJ TN 5-HT 2A receptor (HTR2A) DMAUZHJ MA Inhibitor DMAUZHJ RN Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71. DMAUZHJ RU https://pubmed.ncbi.nlm.nih.gov/18774714 DMAV0BX DI DMAV0BX DMAV0BX DN Dicaffeoyltartaric acids DMAV0BX TI TT5FH9Y DMAV0BX TN Human immunodeficiency virus Integrase (HIV IN) DMAV0BX MA Inhibitor DMAV0BX RN Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother. 1998 Jan;42(1):140-6. DMAV0BX RU https://pubmed.ncbi.nlm.nih.gov/9449274 DMAV9PS DI DMAV9PS DMAV9PS DN OVI-117 DMAV9PS TI TTU6BFZ DMAV9PS TN Candida Thymidylate synthase (Candi TMP1) DMAV9PS MA Modulator DMAV9PS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2642). DMAV9PS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2642 DMAVB0G DI DMAVB0G DMAVB0G DN N2-{4-[(4-nitrobenzyl)oxy]benzyl}glycinamide DMAVB0G TI TTGP7BY DMAVB0G TN Monoamine oxidase type B (MAO-B) DMAVB0G MA Inhibitor DMAVB0G RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMAVB0G RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMAVBKP DI DMAVBKP DMAVBKP DN SIB-1893 DMAVBKP TI TTHS256 DMAVBKP TN Metabotropic glutamate receptor 5 (mGluR5) DMAVBKP MA Inhibitor DMAVBKP RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DMAVBKP RU https://pubmed.ncbi.nlm.nih.gov/16678408 DMAVC9T DI DMAVC9T DMAVC9T DN AMBAZONE DMAVC9T TI TTUTN1I DMAVC9T TN Human Deoxyribonucleic acid (hDNA) DMAVC9T MA Binder DMAVC9T RN Ambazone as a membrane active antitumor drug. Biophys Chem. 1990 Apr;35(2-3):287-300. DMAVC9T RU https://pubmed.ncbi.nlm.nih.gov/2204445 DMAVDNU DI DMAVDNU DMAVDNU DN BVX-20-CD20 DMAVDNU TI TTUE541 DMAVDNU TN Leukocyte surface antigen Leu-16 (CD20) DMAVDNU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DMAVDNU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DMAVM94 DI DMAVM94 DMAVM94 DN Kuanoniamine D DMAVM94 TI TTK25J1 DMAVM94 TN Adenosine A1 receptor (ADORA1) DMAVM94 MA Inhibitor DMAVM94 RN Bioactive pyridoacridine alkaloids from the micronesian sponge Oceanapia sp. J Nat Prod. 1998 Feb;61(2):301-5. DMAVM94 RU https://pubmed.ncbi.nlm.nih.gov/9514015 DMAVM94 DI DMAVM94 DMAVM94 DN Kuanoniamine D DMAVM94 TI TTM2AOE DMAVM94 TN Adenosine A2a receptor (ADORA2A) DMAVM94 MA Inhibitor DMAVM94 RN Bioactive pyridoacridine alkaloids from the micronesian sponge Oceanapia sp. J Nat Prod. 1998 Feb;61(2):301-5. DMAVM94 RU https://pubmed.ncbi.nlm.nih.gov/9514015 DMAVPXL DI DMAVPXL DMAVPXL DN Ac-YCit[CEHdFRWC]-NH2 DMAVPXL TI TT0MV2T DMAVPXL TN Melanocortin receptor 1 (MC1R) DMAVPXL MA Inhibitor DMAVPXL RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMAVPXL RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMAVPXL DI DMAVPXL DMAVPXL DN Ac-YCit[CEHdFRWC]-NH2 DMAVPXL TI TTD0CIQ DMAVPXL TN Melanocortin receptor 4 (MC4R) DMAVPXL MA Inhibitor DMAVPXL RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMAVPXL RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMAVPXL DI DMAVPXL DMAVPXL DN Ac-YCit[CEHdFRWC]-NH2 DMAVPXL TI TTNI91K DMAVPXL TN Melanocortin receptor 3 (MC3R) DMAVPXL MA Inhibitor DMAVPXL RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMAVPXL RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMAVQK3 DI DMAVQK3 DMAVQK3 DN ISIS 111117 DMAVQK3 TI TTOM97J DMAVQK3 TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DMAVQK3 RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DMAVQK3 RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DMAW0R7 DI DMAW0R7 DMAW0R7 DN PELARGONIDIN CHLORIDE DMAW0R7 TI TTV9A7R DMAW0R7 TN Lactoylglutathione lyase (GLO1) DMAW0R7 MA Inhibitor DMAW0R7 RN Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I. Bioorg Med Chem. 2010 Oct 1;18(19):7029-33. DMAW0R7 RU https://pubmed.ncbi.nlm.nih.gov/20801663 DMAW40Y DI DMAW40Y DMAW40Y DN BOMA DMAW40Y TI TTHS256 DMAW40Y TN Metabotropic glutamate receptor 5 (mGluR5) DMAW40Y MA Modulator (allosteric modulator) DMAW40Y RN Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21. DMAW40Y RU https://pubmed.ncbi.nlm.nih.gov/14697765 DMAW4OE DI DMAW4OE DMAW4OE DN ISIS 19639 DMAW4OE TI TTWALCO DMAW4OE TN HER4 messenger RNA (ERBB4 mRNA) DMAW4OE RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMAW4OE RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMAW78K DI DMAW78K DMAW78K DN 1-(4-methoxyphenethyl)pyrrolidine DMAW78K TI TT9JNIC DMAW78K TN Histamine H3 receptor (H3R) DMAW78K MA Inhibitor DMAW78K RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMAW78K RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMAW86U DI DMAW86U DMAW86U DN PMID22984835C20o DMAW86U TI TTZ1DT0 DMAW86U TN P2Y purinoceptor 12 (P2RY12) DMAW86U MA Antagonist DMAW86U RN Identification of high-affinity P2Y antagonists based on a phenylpyrazole glutamic acid piperazine backbone. J Med Chem. 2012 Oct 25;55(20):8615-29. DMAW86U RU https://pubmed.ncbi.nlm.nih.gov/22984835 DMAWC7S DI DMAWC7S DMAWC7S DN 3-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide DMAWC7S TI TTK25J1 DMAWC7S TN Adenosine A1 receptor (ADORA1) DMAWC7S MA Inhibitor DMAWC7S RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMAWC7S RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMAWEQH DI DMAWEQH DMAWEQH DN 3-MeSO2-DDE DMAWEQH TI TTIQUX7 DMAWEQH TN Steroid 11-beta-hydroxylase (CYP11B1) DMAWEQH MA Inhibitor DMAWEQH RN Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In Vitro. 2002 Apr;16(2):113-21. DMAWEQH RU https://pubmed.ncbi.nlm.nih.gov/11869873 DMAWI4M DI DMAWI4M DMAWI4M DN SC-514 DMAWI4M TI TTJ3E9X DMAWI4M TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMAWI4M MA Inhibitor DMAWI4M RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMAWI4M RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMAWJPE DI DMAWJPE DMAWJPE DN AS04 DMAWJPE TI TTISGCA DMAWJPE TN Toll-like receptor 4 (TLR4) DMAWJPE MA Modulator DMAWJPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DMAWJPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DMAWMDN DI DMAWMDN DMAWMDN DN BYK-191023 DMAWMDN TI TTF10I9 DMAWMDN TN Nitric-oxide synthase inducible (NOS2) DMAWMDN MA Inhibitor DMAWMDN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1250). DMAWMDN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250 DMAWTG3 DI DMAWTG3 DMAWTG3 DN LY2109761 DMAWTG3 TI TTP4520 DMAWTG3 TN TGF-beta receptor type I (TGFBR1) DMAWTG3 MA Inhibitor DMAWTG3 RN LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr;7(4):829-40. DMAWTG3 RU https://pubmed.ncbi.nlm.nih.gov/18413796 DMAWTG3 DI DMAWTG3 DMAWTG3 DN LY2109761 DMAWTG3 TI TTZE3P7 DMAWTG3 TN TGF-beta receptor type II (TGFBR2) DMAWTG3 MA Inhibitor DMAWTG3 RN LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther. 2008 Apr;7(4):829-40. DMAWTG3 RU https://pubmed.ncbi.nlm.nih.gov/18413796 DMAWTUL DI DMAWTUL DMAWTUL DN Trifluoroethanol DMAWTUL TI TTJS7O4 DMAWTUL TN Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2) DMAWTUL MA Inhibitor DMAWTUL RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMAWTUL RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMAWXV6 DI DMAWXV6 DMAWXV6 DN 3-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylamine DMAWXV6 TI TTI7421 DMAWXV6 TN Platelet-derived growth factor receptor beta (PDGFRB) DMAWXV6 MA Inhibitor DMAWXV6 RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMAWXV6 RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMAX06G DI DMAX06G DMAX06G DN AZUMAMIDE E DMAX06G TI TT6R7JZ DMAX06G TN Histone deacetylase 1 (HDAC1) DMAX06G MA Inhibitor DMAX06G RN Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4. DMAX06G RU https://pubmed.ncbi.nlm.nih.gov/18397826 DMAX06G DI DMAX06G DMAX06G DN AZUMAMIDE E DMAX06G TI TTTQGH8 DMAX06G TN Histone deacetylase 4 (HDAC4) DMAX06G MA Inhibitor DMAX06G RN Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4. DMAX06G RU https://pubmed.ncbi.nlm.nih.gov/18397826 DMAX5TC DI DMAX5TC DMAX5TC DN 2-Benzyl-7-hydroxy-chromen-4-one DMAX5TC TI TTFBNVI DMAX5TC TN Aldose reductase (AKR1B1) DMAX5TC MA Inhibitor DMAX5TC RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DMAX5TC RU https://pubmed.ncbi.nlm.nih.gov/10354396 DMAX7LW DI DMAX7LW DMAX7LW DN d(CH2)5[D-Ile2,Ile4]AVP DMAX7LW TI TTK8R02 DMAX7LW TN Vasopressin V2 receptor (V2R) DMAX7LW MA Antagonist DMAX7LW RN Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 2000 Oct;58(4):1613-22. DMAX7LW RU https://pubmed.ncbi.nlm.nih.gov/11012895 DMAX9C3 DI DMAX9C3 DMAX9C3 DN AZD3463 DMAX9C3 TI TTQFBMY DMAX9C3 TN IGF1R messenger RNA (IGF1R mRNA) DMAX9C3 MA Inhibitor DMAX9C3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1801). DMAX9C3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1801 DMAX9C3 DI DMAX9C3 DMAX9C3 DN AZD3463 DMAX9C3 TI TTPMQSO DMAX9C3 TN ALK tyrosine kinase receptor (ALK) DMAX9C3 MA Inhibitor DMAX9C3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839). DMAX9C3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839 DMAXB8T DI DMAXB8T DMAXB8T DN ISIS 12882 DMAXB8T TI TTR5TV4 DMAXB8T TN ERBB2 messenger RNA (HER2 mRNA) DMAXB8T RN US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression. DMAXB8T RU http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true DMAXBOU DI DMAXBOU DMAXBOU DN 6-Methyl-2-phenyl-chromen-4-one DMAXBOU TI TTNJYV2 DMAXBOU TN Gamma-aminobutyric acid receptor (GAR) DMAXBOU MA Inhibitor DMAXBOU RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMAXBOU RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMAXD7P DI DMAXD7P DMAXD7P DN ISIS 29236 DMAXD7P TI TTYMGWX DMAXD7P TN PDK-1 messenger RNA (PDK-1 mRNA) DMAXD7P RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMAXD7P RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMAXEH3 DI DMAXEH3 DMAXEH3 DN Methyl arachidonyl fluorophosphonate DMAXEH3 TI TTT1JVS DMAXEH3 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMAXEH3 MA Inhibitor DMAXEH3 RN 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G586-97. DMAXEH3 RU https://pubmed.ncbi.nlm.nih.gov/11897617 DMAXESK DI DMAXESK DMAXESK DN 2-amino-6-phenyl-4-p-tolylnicotinonitrile DMAXESK TI TTM2AOE DMAXESK TN Adenosine A2a receptor (ADORA2A) DMAXESK MA Inhibitor DMAXESK RN Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7. DMAXESK RU https://pubmed.ncbi.nlm.nih.gov/16971117 DMAXESK DI DMAXESK DMAXESK DN 2-amino-6-phenyl-4-p-tolylnicotinonitrile DMAXESK TI TTK25J1 DMAXESK TN Adenosine A1 receptor (ADORA1) DMAXESK MA Inhibitor DMAXESK RN Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches. Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7. DMAXESK RU https://pubmed.ncbi.nlm.nih.gov/16971117 DMAXHEU DI DMAXHEU DMAXHEU DN 5-octyl-2-phenoxyphenol DMAXHEU TI TTVTX4N DMAXHEU TN Bacterial Fatty acid synthetase I (Bact inhA) DMAXHEU MA Inhibitor DMAXHEU RN Natural products, small molecules, and genetics in tuberculosis drug development. J Med Chem. 2008 May 8;51(9):2606-12. DMAXHEU RU https://pubmed.ncbi.nlm.nih.gov/18393405 DMAXHLK DI DMAXHLK DMAXHLK DN NQN-1 DMAXHLK TI TT5ZKDI DMAXHLK TN Histone deacetylase 6 (HDAC6) DMAXHLK MA Inhibitor DMAXHLK RN A novel class of small molecule inhibitors of HDAC6. ACS Chem Biol. 2012 Feb 17;7(2):331-9. DMAXHLK RU https://pubmed.ncbi.nlm.nih.gov/22047054 DMAXLVQ DI DMAXLVQ DMAXLVQ DN N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide DMAXLVQ TI TTMSFAW DMAXLVQ TN Cannabinoid receptor 2 (CB2) DMAXLVQ MA Inhibitor DMAXLVQ RN Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5. DMAXLVQ RU https://pubmed.ncbi.nlm.nih.gov/18579386 DMAXLVQ DI DMAXLVQ DMAXLVQ DN N-(3,3-Diphenyl)propyl-2,2-diphenylacetamide DMAXLVQ TI TT6OEDT DMAXLVQ TN Cannabinoid receptor 1 (CB1) DMAXLVQ MA Inhibitor DMAXLVQ RN Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5. DMAXLVQ RU https://pubmed.ncbi.nlm.nih.gov/18579386 DMAXOIS DI DMAXOIS DMAXOIS DN W-F-F-N--Y-Y-W DMAXOIS TI TT3ZTGU DMAXOIS TN Endothelin B receptor (EDNRB) DMAXOIS MA Inhibitor DMAXOIS RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DMAXOIS RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DMAXOIS DI DMAXOIS DMAXOIS DN W-F-F-N--Y-Y-W DMAXOIS TI TTKRD0G DMAXOIS TN Endothelin A receptor (EDNRA) DMAXOIS MA Inhibitor DMAXOIS RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DMAXOIS RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DMAXOPS DI DMAXOPS DMAXOPS DN viral macrophage inflammatory protein-II DMAXOPS TI TT8KLPT DMAXOPS TN C-C chemokine receptor (CCR) DMAXOPS MA Antagonist DMAXOPS RN A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9. DMAXOPS RU https://pubmed.ncbi.nlm.nih.gov/9287217 DMAXOPS DI DMAXOPS DMAXOPS DN viral macrophage inflammatory protein-II DMAXOPS TI TTBID49 DMAXOPS TN C-X-C chemokine receptor type 4 (CXCR4) DMAXOPS MA Antagonist DMAXOPS RN A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9. DMAXOPS RU https://pubmed.ncbi.nlm.nih.gov/9287217 DMAXOPS DI DMAXOPS DMAXOPS DN viral macrophage inflammatory protein-II DMAXOPS TI TTE836A DMAXOPS TN C-C chemokine receptor type 8 (CCR8) DMAXOPS MA Antagonist DMAXOPS RN HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J Biol Chem. 1999 Jul 30;274(31):21569-74. DMAXOPS RU https://pubmed.ncbi.nlm.nih.gov/10419462 DMAXOPS DI DMAXOPS DMAXOPS DN viral macrophage inflammatory protein-II DMAXOPS TI TTFZYTO DMAXOPS TN C-C chemokine receptor type 2 (CCR2) DMAXOPS MA Antagonist DMAXOPS RN A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9. DMAXOPS RU https://pubmed.ncbi.nlm.nih.gov/9287217 DMAXOPS DI DMAXOPS DMAXOPS DN viral macrophage inflammatory protein-II DMAXOPS TI TTJIH8Q DMAXOPS TN CCR5 messenger RNA (CCR5 mRNA) DMAXOPS MA Antagonist DMAXOPS RN A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997 Sep 12;277(5332):1656-9. DMAXOPS RU https://pubmed.ncbi.nlm.nih.gov/9287217 DMAXS9H DI DMAXS9H DMAXS9H DN (6-Benzylamino-9H-beta-carbolin-3-yl)-methanol DMAXS9H TI TT1MPAY DMAXS9H TN GABA(A) receptor alpha-1 (GABRA1) DMAXS9H MA Inhibitor DMAXS9H RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMAXS9H RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMAXS9H DI DMAXS9H DMAXS9H DN (6-Benzylamino-9H-beta-carbolin-3-yl)-methanol DMAXS9H TI TTNJYV2 DMAXS9H TN Gamma-aminobutyric acid receptor (GAR) DMAXS9H MA Inhibitor DMAXS9H RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMAXS9H RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMAY04M DI DMAY04M DMAY04M DN CEP-28122 DMAY04M TI TTPMQSO DMAY04M TN ALK tyrosine kinase receptor (ALK) DMAY04M MA Inhibitor DMAY04M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839). DMAY04M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839 DMAY2N3 DI DMAY2N3 DMAY2N3 DN Asperlicin DMAY2N3 TI TTCG0AL DMAY2N3 TN Cholecystokinin receptor type A (CCKAR) DMAY2N3 MA Antagonist DMAY2N3 RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DMAY2N3 RU https://pubmed.ncbi.nlm.nih.gov/18045214 DMAY48N DI DMAY48N DMAY48N DN GPI 18214 DMAY48N TI TT39J16 DMAY48N TN Poly [ADP-ribose] glycohydrolase (PARG) DMAY48N MA Inhibitor DMAY48N RN Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice. Crit Care Med. 2004 Jun;32(6):1365-74. DMAY48N RU https://pubmed.ncbi.nlm.nih.gov/15187521 DMAY4OZ DI DMAY4OZ DMAY4OZ DN 3-Nitro-benzenesulfonamide DMAY4OZ TI TTANPDJ DMAY4OZ TN Carbonic anhydrase II (CA-II) DMAY4OZ MA Inhibitor DMAY4OZ RN Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. DMAY4OZ RU https://pubmed.ncbi.nlm.nih.gov/15482952 DMAY4OZ DI DMAY4OZ DMAY4OZ DN 3-Nitro-benzenesulfonamide DMAY4OZ TI TTUNARX DMAY4OZ TN Carbonic anhydrase (CA) DMAY4OZ MA Inhibitor DMAY4OZ RN Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. DMAY4OZ RU https://pubmed.ncbi.nlm.nih.gov/15482952 DMAY50R DI DMAY50R DMAY50R DN Mutated growth hormone DMAY50R TI TTG4R8V DMAY50R TN Growth hormone-releasing hormone receptor (GHRHR) DMAY50R MA Agonist DMAY50R RN Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. DMAY50R RU https://pubmed.ncbi.nlm.nih.gov/16262568 DMAY9TM DI DMAY9TM DMAY9TM DN BMS-520 DMAY9TM TI TT9JZCK DMAY9TM TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMAY9TM MA Agonist DMAY9TM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275). DMAY9TM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275 DMAYCQU DI DMAYCQU DMAYCQU DN Uridine-5'-Diphosphate-Mannose DMAYCQU TI TTGRHIB DMAYCQU TN UDP-glucose 4-epimerase (GALE) DMAYCQU MA Inhibitor DMAYCQU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMAYCQU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMAYEJL DI DMAYEJL DMAYEJL DN (R)-(-)-2-Methyl-apomorphine hydrochloride DMAYEJL TI TTEX248 DMAYEJL TN Dopamine D2 receptor (D2R) DMAYEJL MA Inhibitor DMAYEJL RN Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9. DMAYEJL RU https://pubmed.ncbi.nlm.nih.gov/18289859 DMAYEJL DI DMAYEJL DMAYEJL DN (R)-(-)-2-Methyl-apomorphine hydrochloride DMAYEJL TI TT4C8EA DMAYEJL TN Dopamine D3 receptor (D3R) DMAYEJL MA Inhibitor DMAYEJL RN Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9. DMAYEJL RU https://pubmed.ncbi.nlm.nih.gov/18289859 DMAYGK9 DI DMAYGK9 DMAYGK9 DN ALD-901 DMAYGK9 TI TTEDJN4 DMAYGK9 TN Low-affinity nerve growth factor receptor (NGFR) DMAYGK9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMAYGK9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMAYLNO DI DMAYLNO DMAYLNO DN PHOSPHOGLYCOLOHYDROXAMATE DMAYLNO TI TT1FL6V DMAYLNO TN Plasmodium Fructose-bisphosphate aldolase (Malaria FBA) DMAYLNO MA Inhibitor DMAYLNO RN N-Sulfonyl hydroxamate derivatives as inhibitors of class II fructose-1,6-diphosphate aldolase. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5375-7. DMAYLNO RU https://pubmed.ncbi.nlm.nih.gov/16236509 DMAYOTF DI DMAYOTF DMAYOTF DN isothiourea-1a DMAYOTF TI TTBID49 DMAYOTF TN C-X-C chemokine receptor type 4 (CXCR4) DMAYOTF MA Antagonist DMAYOTF RN Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20. DMAYOTF RU https://pubmed.ncbi.nlm.nih.gov/19053768 DMAYPTO DI DMAYPTO DMAYPTO DN [35S]ADPbetaS DMAYPTO TI TTA93TL DMAYPTO TN P2Y purinoceptor 1 (P2RY1) DMAYPTO MA Agonist DMAYPTO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 323). DMAYPTO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=323 DMAYSGI DI DMAYSGI DMAYSGI DN Di-Benzyloxycarbonyl-guanidino acetylryanodine DMAYSGI TI TTU5CIX DMAYSGI TN Ryanodine receptor 1 (RYR1) DMAYSGI MA Inhibitor DMAYSGI RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMAYSGI RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMAYTWN DI DMAYTWN DMAYTWN DN FR122047 DMAYTWN TI TT8NGED DMAYTWN TN Prostaglandin G/H synthase 1 (COX-1) DMAYTWN MA Inhibitor DMAYTWN RN The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol. 2000 Mar 10;391(1-2):49-54. DMAYTWN RU https://pubmed.ncbi.nlm.nih.gov/10720634 DMAYUV6 DI DMAYUV6 DMAYUV6 DN Toluene-1-diazonium-3-sulfonic acid anion DMAYUV6 TI TTNJYV2 DMAYUV6 TN Gamma-aminobutyric acid receptor (GAR) DMAYUV6 MA Inhibitor DMAYUV6 RN Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor. J Med Chem. 1987 Dec;30(12):2222-7. DMAYUV6 RU https://pubmed.ncbi.nlm.nih.gov/2824775 DMAYWIN DI DMAYWIN DMAYWIN DN 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine DMAYWIN TI TT7HF4W DMAYWIN TN Cyclin-dependent kinase 2 (CDK2) DMAYWIN MA Inhibitor DMAYWIN RN Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93. DMAYWIN RU https://pubmed.ncbi.nlm.nih.gov/12139449 DMAYWIN DI DMAYWIN DMAYWIN DN 6-(Cyclohex-3-enylmethoxy)-9H-purin-2-ylamine DMAYWIN TI TTAMQ62 DMAYWIN TN Cyclin A2 (CCNA2) DMAYWIN MA Inhibitor DMAYWIN RN Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93. DMAYWIN RU https://pubmed.ncbi.nlm.nih.gov/12139449 DMAYWTI DI DMAYWTI DMAYWTI DN Boc-Tyr(SO3H)-Nle-Gly-Trp-Nle-Asp-Phe-NH2 DMAYWTI TI TTCG0AL DMAYWTI TN Cholecystokinin receptor type A (CCKAR) DMAYWTI MA Inhibitor DMAYWTI RN Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90. DMAYWTI RU https://pubmed.ncbi.nlm.nih.gov/2724293 DMAYXUR DI DMAYXUR DMAYXUR DN 2,2',4,4',6'-pentahydroxychalcone DMAYXUR TI TTULVH8 DMAYXUR TN Tyrosinase (TYR) DMAYXUR MA Inhibitor DMAYXUR RN Synthesis and evaluation of 2',4',6'-trihydroxychalcones as a new class of tyrosinase inhibitors. Bioorg Med Chem. 2007 Mar 15;15(6):2396-402. DMAYXUR RU https://pubmed.ncbi.nlm.nih.gov/17267225 DMAZ07T DI DMAZ07T DMAZ07T DN Pentanoic acid (4-sulfamoyl-phenyl)-amide DMAZ07T TI TT2LVK8 DMAZ07T TN Carbonic anhydrase IX (CA-IX) DMAZ07T MA Inhibitor DMAZ07T RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMAZ07T RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMAZ07T DI DMAZ07T DMAZ07T DN Pentanoic acid (4-sulfamoyl-phenyl)-amide DMAZ07T TI TTANPDJ DMAZ07T TN Carbonic anhydrase II (CA-II) DMAZ07T MA Inhibitor DMAZ07T RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMAZ07T RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMAZ07T DI DMAZ07T DMAZ07T DN Pentanoic acid (4-sulfamoyl-phenyl)-amide DMAZ07T TI TTSYM0R DMAZ07T TN Carbonic anhydrase XII (CA-XII) DMAZ07T MA Inhibitor DMAZ07T RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMAZ07T RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMAZ07T DI DMAZ07T DMAZ07T DN Pentanoic acid (4-sulfamoyl-phenyl)-amide DMAZ07T TI TTHQPL7 DMAZ07T TN Carbonic anhydrase I (CA-I) DMAZ07T MA Inhibitor DMAZ07T RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMAZ07T RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMAZ0EQ DI DMAZ0EQ DMAZ0EQ DN ATL-801 DMAZ0EQ TI TTNE7KG DMAZ0EQ TN Adenosine A2b receptor (ADORA2B) DMAZ0EQ MA Antagonist DMAZ0EQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20). DMAZ0EQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20 DMAZ0LV DI DMAZ0LV DMAZ0LV DN 4-(2-benzenesulfonylphenyl)piperazine DMAZ0LV TI TTJS8PY DMAZ0LV TN 5-HT 6 receptor (HTR6) DMAZ0LV MA Inhibitor DMAZ0LV RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMAZ0LV RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMAZ1NW DI DMAZ1NW DMAZ1NW DN FXI-AS1 DMAZ1NW TI TTDM4ZU DMAZ1NW TN Factor XI messenger RNA (F11 mRNA) DMAZ1NW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2360). DMAZ1NW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2360 DMAZLKX DI DMAZLKX DMAZLKX DN SC-558 DMAZLKX TI TTVKILB DMAZLKX TN Prostaglandin G/H synthase 2 (COX-2) DMAZLKX MA Inhibitor DMAZLKX RN In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. DMAZLKX RU https://pubmed.ncbi.nlm.nih.gov/20188577 DMAZLWR DI DMAZLWR DMAZLWR DN ACPC DMAZLWR TI TT9IK2Z DMAZLWR TN N-methyl-D-aspartate receptor (NMDAR) DMAZLWR MA Modulator DMAZLWR RN 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 1994;55(18):1393-8. DMAZLWR RU https://pubmed.ncbi.nlm.nih.gov/7934650 DMAZMPF DI DMAZMPF DMAZMPF DN 4-Benzyl-1-chroman-3-ylmethyl-piperidine DMAZMPF TI TTEX248 DMAZMPF TN Dopamine D2 receptor (D2R) DMAZMPF MA Inhibitor DMAZMPF RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMAZMPF RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMAZMPF DI DMAZMPF DMAZMPF DN 4-Benzyl-1-chroman-3-ylmethyl-piperidine DMAZMPF TI TTSQIFT DMAZMPF TN 5-HT 1A receptor (HTR1A) DMAZMPF MA Inhibitor DMAZMPF RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMAZMPF RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMAZR9C DI DMAZR9C DMAZR9C DN 1-(1-Propionylpiperidin-4-yl)-3-m-tolylurea DMAZR9C TI TT7WVHI DMAZR9C TN Soluble epoxide hydrolase (EPHX2) DMAZR9C MA Inhibitor DMAZR9C RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DMAZR9C RU https://pubmed.ncbi.nlm.nih.gov/20812725 DMAZV5D DI DMAZV5D DMAZV5D DN ARC-200 DMAZV5D TI TTYFKSZ DMAZV5D TN Tubulin beta (TUBB) DMAZV5D MA Modulator DMAZV5D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMAZV5D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMAZWHB DI DMAZWHB DMAZWHB DN PMID1895299C4p DMAZWHB TI TTPADOQ DMAZWHB TN HMG-CoA reductase (HMGCR) DMAZWHB MA Inhibitor DMAZWHB RN Phosphorus-containing inhibitors of HMG-CoA reductase. 2. Synthesis and biological activities of a series of substituted pyridines containing a hydroxyphosphinyl moiety. J Med Chem. 1991 Sep;34(9):2804-15. DMAZWHB RU https://pubmed.ncbi.nlm.nih.gov/1895299 DMAZYCD DI DMAZYCD DMAZYCD DN 1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea DMAZYCD TI TT7WVHI DMAZYCD TN Soluble epoxide hydrolase (EPHX2) DMAZYCD MA Inhibitor DMAZYCD RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DMAZYCD RU https://pubmed.ncbi.nlm.nih.gov/20812725 DMB06TA DI DMB06TA DMB06TA DN N-butylgalactonojirimycin DMB06TA TI TTPHEX3 DMB06TA TN Ceramide glucosyltransferase (UGCG) DMB06TA MA Inhibitor DMB06TA RN Accumulation of glucosylceramide in murine testis, caused by inhibition of beta-glucosidase 2: implications for spermatogenesis. J Biol Chem. 2007 Nov 9;282(45):32655-64. DMB06TA RU https://pubmed.ncbi.nlm.nih.gov/17848577 DMB07TU DI DMB07TU DMB07TU DN 4-(1H-indol-6-ylamino)-5-styrylnicotinonitrile DMB07TU TI TT1MS7X DMB07TU TN PKC-theta messenger RNA (PRKCQ mRNA) DMB07TU MA Inhibitor DMB07TU RN First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32. DMB07TU RU https://pubmed.ncbi.nlm.nih.gov/19762237 DMB07WE DI DMB07WE DMB07WE DN Desirudine DMB07WE TI TT6L509 DMB07WE TN Coagulation factor IIa (F2) DMB07WE MA Inhibitor DMB07WE RN New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32. DMB07WE RU https://pubmed.ncbi.nlm.nih.gov/11794963 DMB0CJ4 DI DMB0CJ4 DMB0CJ4 DN ISIS 25565 DMB0CJ4 TI TTP2U16 DMB0CJ4 TN RhoA messenger RNA (RHOA mRNA) DMB0CJ4 RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMB0CJ4 RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMB0NEL DI DMB0NEL DMB0NEL DN 2-Methyl-1,2-di-pyridin-3-yl-propan-1-one oxime DMB0NEL TI TTIQUX7 DMB0NEL TN Steroid 11-beta-hydroxylase (CYP11B1) DMB0NEL MA Inhibitor DMB0NEL RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMB0NEL RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMB0OZ3 DI DMB0OZ3 DMB0OZ3 DN PF-429242 DMB0OZ3 TI TTNSM2I DMB0OZ3 TN Endopeptidase S1P (MBTPS1) DMB0OZ3 MA Inhibitor DMB0OZ3 RN Aminopyrrolidineamide inhibitors of site-1 protease. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4411-4. DMB0OZ3 RU https://pubmed.ncbi.nlm.nih.gov/17583500 DMB10GV DI DMB10GV DMB10GV DN Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Thr12]SRIF DMB10GV TI TTIND6G DMB10GV TN Somatostatin receptor type 1 (SSTR1) DMB10GV MA Inhibitor DMB10GV RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMB10GV RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMB12M7 DI DMB12M7 DMB12M7 DN Ethyl 4-(2-oxohexadecanamido)benzoate DMB12M7 TI TTT1JVS DMB12M7 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMB12M7 MA Inhibitor DMB12M7 RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMB12M7 RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMB1NF0 DI DMB1NF0 DMB1NF0 DN 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol DMB1NF0 TI TTKWM86 DMB1NF0 TN Opioid receptor mu (MOP) DMB1NF0 MA Inhibitor DMB1NF0 RN Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7. DMB1NF0 RU https://pubmed.ncbi.nlm.nih.gov/16821764 DMB1NF0 DI DMB1NF0 DMB1NF0 DN 1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol DMB1NF0 TI TT27RFC DMB1NF0 TN Opioid receptor delta (OPRD1) DMB1NF0 MA Inhibitor DMB1NF0 RN Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7. DMB1NF0 RU https://pubmed.ncbi.nlm.nih.gov/16821764 DMB1PXR DI DMB1PXR DMB1PXR DN Methyl 2-(Benzylamino)-1H-indole-3-carboxylate DMB1PXR TI TTSJ6Q4 DMB1PXR TN LOX-5 messenger RNA (ALOX5 mRNA) DMB1PXR MA Inhibitor DMB1PXR RN Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J Med Chem. 2009 Jun 11;52(11):3474-83. DMB1PXR RU https://pubmed.ncbi.nlm.nih.gov/19492852 DMB1QCY DI DMB1QCY DMB1QCY DN 6-Phosphogluconic Acid DMB1QCY TI TTZ3IFB DMB1QCY TN Phosphogluconate dehydrogenase (PGD) DMB1QCY MA Inhibitor DMB1QCY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB1QCY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB1U8V DI DMB1U8V DMB1U8V DN CYCLORPHAN DMB1U8V TI TTKWM86 DMB1U8V TN Opioid receptor mu (MOP) DMB1U8V MA Inhibitor DMB1U8V RN Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22. DMB1U8V RU https://pubmed.ncbi.nlm.nih.gov/10633042 DMB1U8V DI DMB1U8V DMB1U8V DN CYCLORPHAN DMB1U8V TI TTQW87Y DMB1U8V TN Opioid receptor kappa (OPRK1) DMB1U8V MA Inhibitor DMB1U8V RN Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22. DMB1U8V RU https://pubmed.ncbi.nlm.nih.gov/10633042 DMB1U8V DI DMB1U8V DMB1U8V DN CYCLORPHAN DMB1U8V TI TT27RFC DMB1U8V TN Opioid receptor delta (OPRD1) DMB1U8V MA Inhibitor DMB1U8V RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMB1U8V RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMB2463 DI DMB2463 DMB2463 DN ACET DMB2463 TI TT0MYE2 DMB2463 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMB2463 MA Antagonist DMB2463 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMB2463 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMB24LJ DI DMB24LJ DMB24LJ DN 6-chloro-5-propylpyrimidine-2,4(1H,3H)-dione DMB24LJ TI TTO0IB8 DMB24LJ TN Thymidine phosphorylase (TYMP) DMB24LJ MA Inhibitor DMB24LJ RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DMB24LJ RU https://pubmed.ncbi.nlm.nih.gov/17963370 DMB26IK DI DMB26IK DMB26IK DN PACAP-27 DMB26IK TI TT4O5P0 DMB26IK TN Helodermin-preferring VIP receptor (VIPR2) DMB26IK MA Agonist DMB26IK RN A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98. DMB26IK RU https://pubmed.ncbi.nlm.nih.gov/16930633 DMB26IK DI DMB26IK DMB26IK DN PACAP-27 DMB26IK TI TTCL30I DMB26IK TN Vasoactive intestinal polypeptide receptor 1 (VIPR1) DMB26IK MA Agonist DMB26IK RN A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98. DMB26IK RU https://pubmed.ncbi.nlm.nih.gov/16930633 DMB26IK DI DMB26IK DMB26IK DN PACAP-27 DMB26IK TI TT5OREU DMB26IK TN PACAP type I receptor (PAC1R) DMB26IK MA Agonist DMB26IK RN A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98. DMB26IK RU https://pubmed.ncbi.nlm.nih.gov/16930633 DMB28D3 DI DMB28D3 DMB28D3 DN ISIS 109525 DMB28D3 TI TT3K9S2 DMB28D3 TN RANK messenger RNA (RANK mRNA) DMB28D3 RN US patent application no. 6,171,860, Antisense inhibition of rank expression. DMB28D3 RU http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true DMB28JW DI DMB28JW DMB28JW DN ISIS 298699 DMB28JW TI TTSN6QU DMB28JW TN HIF1-alpha messenger RNA (HIF1A mRNA) DMB28JW RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMB28JW RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMB2A7Q DI DMB2A7Q DMB2A7Q DN MRS2927 DMB2A7Q TI TT24DGP DMB2A7Q TN P2Y purinoceptor 4 (P2RY4) DMB2A7Q MA Agonist DMB2A7Q RN Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33. DMB2A7Q RU https://pubmed.ncbi.nlm.nih.gov/21528910 DMB2DV1 DI DMB2DV1 DMB2DV1 DN Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Phe] DMB2DV1 TI TT6PKBN DMB2DV1 TN Proto-oncogene c-Src (SRC) DMB2DV1 MA Inhibitor DMB2DV1 RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMB2DV1 RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMB2GLE DI DMB2GLE DMB2GLE DN 5-(4-hydroxyphenyl)-1,3,4-oxadiazole-2(3H)-thione DMB2GLE TI TTULVH8 DMB2GLE TN Tyrosinase (TYR) DMB2GLE MA Inhibitor DMB2GLE RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMB2GLE RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMB2HXM DI DMB2HXM DMB2HXM DN Demotensin 4 DMB2HXM TI TTTUMEP DMB2HXM TN Neurotensin receptor type 1 (NTSR1) DMB2HXM MA Inhibitor DMB2HXM RN Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76. DMB2HXM RU https://pubmed.ncbi.nlm.nih.gov/16854083 DMB2MQW DI DMB2MQW DMB2MQW DN PMID7473541C11 DMB2MQW TI TTFQEO5 DMB2MQW TN Squalene synthetase (FDFT1) DMB2MQW MA Inhibitor DMB2MQW RN Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60. DMB2MQW RU https://pubmed.ncbi.nlm.nih.gov/7473541 DMB2O1Y DI DMB2O1Y DMB2O1Y DN ISIS 112724 DMB2O1Y TI TT6804T DMB2O1Y TN MIF messenger RNA (MIF mRNA) DMB2O1Y RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DMB2O1Y RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DMB2TCF DI DMB2TCF DMB2TCF DN Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc DMB2TCF TI TTVFO0U DMB2TCF TN Gastrin/cholecystokinin type B receptor (CCKBR) DMB2TCF MA Inhibitor DMB2TCF RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMB2TCF RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMB2TCF DI DMB2TCF DMB2TCF DN Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc DMB2TCF TI TTKWM86 DMB2TCF TN Opioid receptor mu (MOP) DMB2TCF MA Inhibitor DMB2TCF RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMB2TCF RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMB2TCF DI DMB2TCF DMB2TCF DN Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc DMB2TCF TI TT27RFC DMB2TCF TN Opioid receptor delta (OPRD1) DMB2TCF MA Inhibitor DMB2TCF RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMB2TCF RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMB2TCF DI DMB2TCF DMB2TCF DN Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc DMB2TCF TI TTCG0AL DMB2TCF TN Cholecystokinin receptor type A (CCKAR) DMB2TCF MA Inhibitor DMB2TCF RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMB2TCF RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMB2YXN DI DMB2YXN DMB2YXN DN Ip5I DMB2YXN TI TTJW7B3 DMB2YXN TN P2X purinoceptor 1 (P2RX1) DMB2YXN MA Antagonist DMB2YXN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478). DMB2YXN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478 DMB31GR DI DMB31GR DMB31GR DN ISIS 11155 DMB31GR TI TTQFZWR DMB31GR TN Hepatitis C virus Core protein messenger RNA (HCV Core mRNA) DMB31GR RN US patent application no. 6,391,542, Compositions and methods for treatment of Hepatitis C virus-associated diseases. DMB31GR RU http://www.patentbuddy.com/Patent/6391542?ft=true&sr=true DMB3567 DI DMB3567 DMB3567 DN WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2 DMB3567 TI TTX3HNZ DMB3567 TN Galanin receptor type 1 (GAL1-R) DMB3567 MA Inhibitor DMB3567 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMB3567 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMB3567 DI DMB3567 DMB3567 DN WTLNSAGYLLGPHAVGNHPSFSDKNGLTS-CONH2 DMB3567 TI TTBPW3J DMB3567 TN Galanin receptor type 2 (GAL2-R) DMB3567 MA Inhibitor DMB3567 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMB3567 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMB3E7H DI DMB3E7H DMB3E7H DN N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide DMB3E7H TI TTQ3JTF DMB3E7H TN Muscarinic acetylcholine receptor M4 (CHRM4) DMB3E7H MA Inhibitor DMB3E7H RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMB3E7H RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMB3E7H DI DMB3E7H DMB3E7H DN N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide DMB3E7H TI TTH18TF DMB3E7H TN Muscarinic acetylcholine receptor M5 (CHRM5) DMB3E7H MA Inhibitor DMB3E7H RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMB3E7H RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMB3E7H DI DMB3E7H DMB3E7H DN N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide DMB3E7H TI TTZ9SOR DMB3E7H TN Muscarinic acetylcholine receptor M1 (CHRM1) DMB3E7H MA Inhibitor DMB3E7H RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMB3E7H RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMB3E7H DI DMB3E7H DMB3E7H DN N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide DMB3E7H TI TTYEG6Q DMB3E7H TN Muscarinic acetylcholine receptor M2 (CHRM2) DMB3E7H MA Inhibitor DMB3E7H RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMB3E7H RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMB3E7H DI DMB3E7H DMB3E7H DN N-(4-Dimethylamino-but-2-ynyl)-N-methyl-acetamide DMB3E7H TI TTQ13Z5 DMB3E7H TN Muscarinic acetylcholine receptor M3 (CHRM3) DMB3E7H MA Inhibitor DMB3E7H RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMB3E7H RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMB3GNC DI DMB3GNC DMB3GNC DN MANZAMINE A DMB3GNC TI TTRSMW9 DMB3GNC TN Glycogen synthase kinase-3 beta (GSK-3B) DMB3GNC MA Inhibitor DMB3GNC RN 2-N-Methyl modifications and SAR studies of manzamine A. Bioorg Med Chem. 2008 Jul 15;16(14):6702-6. DMB3GNC RU https://pubmed.ncbi.nlm.nih.gov/18595720 DMB3GNC DI DMB3GNC DMB3GNC DN MANZAMINE A DMB3GNC TI TTL4Q97 DMB3GNC TN Cyclin-dependent kinase 5 (CDK5) DMB3GNC MA Inhibitor DMB3GNC RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DMB3GNC RU https://pubmed.ncbi.nlm.nih.gov/17708655 DMB3HI4 DI DMB3HI4 DMB3HI4 DN 1-(2-(benzo[b]thiophen-4-yl)ethyl)-1H-imidazole DMB3HI4 TI TTSZLWK DMB3HI4 TN Aromatase (CYP19A1) DMB3HI4 MA Inhibitor DMB3HI4 RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMB3HI4 RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMB3JG0 DI DMB3JG0 DMB3JG0 DN 2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol DMB3JG0 TI TTOM3J0 DMB3JG0 TN Estrogen receptor beta (ESR2) DMB3JG0 MA Inhibitor DMB3JG0 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMB3JG0 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMB3JG0 DI DMB3JG0 DMB3JG0 DN 2-(5-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol DMB3JG0 TI TTZAYWL DMB3JG0 TN Estrogen receptor (ESR) DMB3JG0 MA Inhibitor DMB3JG0 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMB3JG0 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMB3JO2 DI DMB3JO2 DMB3JO2 DN 1-Methyl-5-phenyl-piperidin-2-one DMB3JO2 TI TTTU72V DMB3JO2 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMB3JO2 MA Inhibitor DMB3JO2 RN Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11. DMB3JO2 RU https://pubmed.ncbi.nlm.nih.gov/10987415 DMB3JY8 DI DMB3JY8 DMB3JY8 DN (+/-)-threo-N-(4-Nitrobenzyl)methylphenidate DMB3JY8 TI TTVBI8W DMB3JY8 TN Dopamine transporter (DAT) DMB3JY8 MA Inhibitor DMB3JY8 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMB3JY8 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMB3NZA DI DMB3NZA DMB3NZA DN PIPERNONALINE DMB3NZA TI TTA1L39 DMB3NZA TN ICAM1 messenger RNA (ICAM1 mRNA) DMB3NZA MA Inhibitor DMB3NZA RN Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6. DMB3NZA RU https://pubmed.ncbi.nlm.nih.gov/18672369 DMB3R4Z DI DMB3R4Z DMB3R4Z DN SB 216641 DMB3R4Z TI TT6MSOK DMB3R4Z TN 5-HT 1D receptor (HTR1D) DMB3R4Z MA Agonist DMB3R4Z RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMB3R4Z RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMB3R4Z DI DMB3R4Z DMB3R4Z DN SB 216641 DMB3R4Z TI TTSQIFT DMB3R4Z TN 5-HT 1A receptor (HTR1A) DMB3R4Z MA Agonist DMB3R4Z RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMB3R4Z RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMB3R4Z DI DMB3R4Z DMB3R4Z DN SB 216641 DMB3R4Z TI TTJQOD7 DMB3R4Z TN 5-HT 2A receptor (HTR2A) DMB3R4Z MA Agonist DMB3R4Z RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMB3R4Z RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMB3R4Z DI DMB3R4Z DMB3R4Z DN SB 216641 DMB3R4Z TI TT0K1SC DMB3R4Z TN 5-HT 2B receptor (HTR2B) DMB3R4Z MA Agonist DMB3R4Z RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMB3R4Z RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMB3R4Z DI DMB3R4Z DMB3R4Z DN SB 216641 DMB3R4Z TI TTK8CXU DMB3R4Z TN 5-HT 1B receptor (HTR1B) DMB3R4Z MA Agonist DMB3R4Z RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMB3R4Z RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMB3R4Z DI DMB3R4Z DMB3R4Z DN SB 216641 DMB3R4Z TI TTWJBZ5 DMB3R4Z TN 5-HT 2C receptor (HTR2C) DMB3R4Z MA Agonist DMB3R4Z RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMB3R4Z RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMB3ROZ DI DMB3ROZ DMB3ROZ DN ERK inhibitor III DMB3ROZ TI TT4TQBX DMB3ROZ TN Extracellular signal-regulated kinase 2 (ERK2) DMB3ROZ MA Inhibitor DMB3ROZ RN Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6281-7. DMB3ROZ RU https://pubmed.ncbi.nlm.nih.gov/17000106 DMB3WI8 DI DMB3WI8 DMB3WI8 DN 2,3-dihydro-1H-benzo[de]isoquinolin-1-one DMB3WI8 TI TTVDSZ0 DMB3WI8 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMB3WI8 MA Inhibitor DMB3WI8 RN Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52. DMB3WI8 RU https://pubmed.ncbi.nlm.nih.gov/20015648 DMB3XYE DI DMB3XYE DMB3XYE DN 3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine DMB3XYE TI TTIQUX7 DMB3XYE TN Steroid 11-beta-hydroxylase (CYP11B1) DMB3XYE MA Inhibitor DMB3XYE RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMB3XYE RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMB3XYE DI DMB3XYE DMB3XYE DN 3-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine DMB3XYE TI TTSZLWK DMB3XYE TN Aromatase (CYP19A1) DMB3XYE MA Inhibitor DMB3XYE RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMB3XYE RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMB3Y8H DI DMB3Y8H DMB3Y8H DN 2-Hydroxy-6-(3-phenoxy-benzoylamino)-benzoic acid DMB3Y8H TI TTRVTMX DMB3Y8H TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMB3Y8H MA Inhibitor DMB3Y8H RN Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609. DMB3Y8H RU https://pubmed.ncbi.nlm.nih.gov/15743201 DMB3YXG DI DMB3YXG DMB3YXG DN 2-(adamantan-1-ylamino)-5,5-diethyl-oxazol-4-one DMB3YXG TI TTN7BL9 DMB3YXG TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMB3YXG MA Inhibitor DMB3YXG RN Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40. DMB3YXG RU https://pubmed.ncbi.nlm.nih.gov/17600707 DMB49UP DI DMB49UP DMB49UP DN 2-(4-Bromo-phenyl)-1-methyl-ethylamine DMB49UP TI TTSQIFT DMB49UP TN 5-HT 1A receptor (HTR1A) DMB49UP MA Inhibitor DMB49UP RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMB49UP RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMB49UP DI DMB49UP DMB49UP DN 2-(4-Bromo-phenyl)-1-methyl-ethylamine DMB49UP TI TTJQOD7 DMB49UP TN 5-HT 2A receptor (HTR2A) DMB49UP MA Inhibitor DMB49UP RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMB49UP RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMB49UP DI DMB49UP DMB49UP DN 2-(4-Bromo-phenyl)-1-methyl-ethylamine DMB49UP TI TT6MSOK DMB49UP TN 5-HT 1D receptor (HTR1D) DMB49UP MA Inhibitor DMB49UP RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMB49UP RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMB4ACY DI DMB4ACY DMB4ACY DN LHRH DMB4ACY TI TT8R70G DMB4ACY TN Gonadotropin-releasing hormone receptor (GNRHR) DMB4ACY MA Inhibitor DMB4ACY RN Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor. J Med Chem. 1998 Oct 22;41(22):4190-5. DMB4ACY RU https://pubmed.ncbi.nlm.nih.gov/9784092 DMB4J3N DI DMB4J3N DMB4J3N DN [Mpa1, L-Tic7]OT DMB4J3N TI TTSCIUP DMB4J3N TN Oxytocin receptor (OTR) DMB4J3N MA Inhibitor DMB4J3N RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMB4J3N RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMB4W68 DI DMB4W68 DMB4W68 DN 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid DMB4W68 TI TT0K6EO DMB4W68 TN Stress-activated protein kinase JNK1 (JNK1) DMB4W68 MA Inhibitor DMB4W68 RN Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. DMB4W68 RU https://pubmed.ncbi.nlm.nih.gov/17107797 DMB4WP5 DI DMB4WP5 DMB4WP5 DN 3-Benzylamino-5-ethyl-6-methyl-1H-pyridin-2-one DMB4WP5 TI TT84ETX DMB4WP5 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMB4WP5 MA Inhibitor DMB4WP5 RN Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogues of 3-aminopyridin-2(1H)-one. J Med Chem. 1992 Oct 16;35(21):3792-802. DMB4WP5 RU https://pubmed.ncbi.nlm.nih.gov/1279173 DMB4ZNW DI DMB4ZNW DMB4ZNW DN Indole Naphthyridinone DMB4ZNW TI TTNX2CS DMB4ZNW TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMB4ZNW MA Inhibitor DMB4ZNW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB4ZNW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB4ZNW DI DMB4ZNW DMB4ZNW DN Indole Naphthyridinone DMB4ZNW TI TTVTX4N DMB4ZNW TN Bacterial Fatty acid synthetase I (Bact inhA) DMB4ZNW MA Inhibitor DMB4ZNW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB4ZNW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB53ML DI DMB53ML DMB53ML DN 2-(7-phenylheptanoyl)oxazole-5-carboxylic acid DMB53ML TI TTDP1UC DMB53ML TN Fatty acid amide hydrolase (FAAH) DMB53ML MA Inhibitor DMB53ML RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMB53ML RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMB5A80 DI DMB5A80 DMB5A80 DN SNX-2112 DMB5A80 TI TT78R5H DMB5A80 TN Heat shock protein 90 alpha (HSP90A) DMB5A80 MA Inhibitor DMB5A80 RN Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17. DMB5A80 RU https://pubmed.ncbi.nlm.nih.gov/20055425 DMB5F9H DI DMB5F9H DMB5F9H DN ISIS 10582 DMB5F9H TI TTS7IR5 DMB5F9H TN c-Jun messenger RNA (c-Jun mRNA) DMB5F9H RN US patent application no. 6,312,900, Antisense oligonucleotide compositions and methods for the modulation of activating protein 1. DMB5F9H RU http://www.patentbuddy.com/Patent/6312900?ft=true&sr=true DMB5I03 DI DMB5I03 DMB5I03 DN GERANIIN DMB5I03 TI TTE14XG DMB5I03 TN Squalene monooxygenase (SQLE) DMB5I03 MA Inhibitor DMB5I03 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMB5I03 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMB5IFA DI DMB5IFA DMB5IFA DN 4-(2-phenoxyphenyl)piperidine DMB5IFA TI TTAWNKZ DMB5IFA TN Norepinephrine transporter (NET) DMB5IFA MA Inhibitor DMB5IFA RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMB5IFA RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMB5IFA DI DMB5IFA DMB5IFA DN 4-(2-phenoxyphenyl)piperidine DMB5IFA TI TTVBI8W DMB5IFA TN Dopamine transporter (DAT) DMB5IFA MA Inhibitor DMB5IFA RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMB5IFA RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMB5IFA DI DMB5IFA DMB5IFA DN 4-(2-phenoxyphenyl)piperidine DMB5IFA TI TTSQIFT DMB5IFA TN 5-HT 1A receptor (HTR1A) DMB5IFA MA Inhibitor DMB5IFA RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMB5IFA RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMB5IFA DI DMB5IFA DMB5IFA DN 4-(2-phenoxyphenyl)piperidine DMB5IFA TI TT3ROYC DMB5IFA TN Serotonin transporter (SERT) DMB5IFA MA Inhibitor DMB5IFA RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMB5IFA RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMB5KQ4 DI DMB5KQ4 DMB5KQ4 DN oleoyl-lysophosphatidylcholine DMB5KQ4 TI TT7QNVC DMB5KQ4 TN Glucose-dependent insulinotropic receptor (GPR119) DMB5KQ4 MA Agonist DMB5KQ4 RN Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51. DMB5KQ4 RU https://pubmed.ncbi.nlm.nih.gov/15607732 DMB5KVZ DI DMB5KVZ DMB5KVZ DN (3,5-Dibromo-4-pentyloxy-phenyl)-acetic acid DMB5KVZ TI TTGER3L DMB5KVZ TN Thyroid hormone receptor beta (THRB) DMB5KVZ MA Inhibitor DMB5KVZ RN Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7. DMB5KVZ RU https://pubmed.ncbi.nlm.nih.gov/15857115 DMB5LHA DI DMB5LHA DMB5LHA DN 2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine DMB5LHA TI TTJS8PY DMB5LHA TN 5-HT 6 receptor (HTR6) DMB5LHA MA Inhibitor DMB5LHA RN Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87. DMB5LHA RU https://pubmed.ncbi.nlm.nih.gov/19159187 DMB5LNC DI DMB5LNC DMB5LNC DN ISIS 19675 DMB5LNC TI TTWALCO DMB5LNC TN HER4 messenger RNA (ERBB4 mRNA) DMB5LNC RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMB5LNC RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMB5OG8 DI DMB5OG8 DMB5OG8 DN modified HA14-1 compounds (cancer) DMB5OG8 TI TTJGNVC DMB5OG8 TN Apoptosis regulator Bcl-2 (BCL-2) DMB5OG8 MA Modulator DMB5OG8 RN The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther. 2004 Dec;3(12):1513-24. DMB5OG8 RU https://pubmed.ncbi.nlm.nih.gov/15634644 DMB5PLD DI DMB5PLD DMB5PLD DN NSC-660840 DMB5PLD TI TTJLP0R DMB5PLD TN Quinone reductase 2 (NQO2) DMB5PLD MA Inhibitor DMB5PLD RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMB5PLD RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMB5RJK DI DMB5RJK DMB5RJK DN 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol DMB5RJK TI TTZAYWL DMB5RJK TN Estrogen receptor (ESR) DMB5RJK MA Inhibitor DMB5RJK RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMB5RJK RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMB5RJK DI DMB5RJK DMB5RJK DN 4,10-dimethyl-6H-benzo[c]chromene-3,8-diol DMB5RJK TI TTOM3J0 DMB5RJK TN Estrogen receptor beta (ESR2) DMB5RJK MA Inhibitor DMB5RJK RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMB5RJK RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMB5U3P DI DMB5U3P DMB5U3P DN 1,1,1-trifluoroheptadecan-2-one DMB5U3P TI TTT1JVS DMB5U3P TN Cytosolic phospholipase A2 (GIVA cPLA2) DMB5U3P MA Inhibitor DMB5U3P RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMB5U3P RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMB5VQK DI DMB5VQK DMB5VQK DN 1,4-dideoxy-1,4-imino-D-arabinito DMB5VQK TI TTXWASR DMB5VQK TN Intestinal maltase-glucoamylase (MGAM) DMB5VQK MA Inhibitor DMB5VQK RN New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii. J Nat Prod. 2002 Feb;65(2):198-202. DMB5VQK RU https://pubmed.ncbi.nlm.nih.gov/11858756 DMB62OI DI DMB62OI DMB62OI DN N5-(1-iminobut-3-enyl)-L-ornithine DMB62OI TI TTCM4B3 DMB62OI TN Nitric-oxide synthase endothelial (NOS3) DMB62OI MA Inhibitor DMB62OI RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DMB62OI RU https://pubmed.ncbi.nlm.nih.gov/19013076 DMB62OI DI DMB62OI DMB62OI DN N5-(1-iminobut-3-enyl)-L-ornithine DMB62OI TI TTF10I9 DMB62OI TN Nitric-oxide synthase inducible (NOS2) DMB62OI MA Inhibitor DMB62OI RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DMB62OI RU https://pubmed.ncbi.nlm.nih.gov/19013076 DMB62OI DI DMB62OI DMB62OI DN N5-(1-iminobut-3-enyl)-L-ornithine DMB62OI TI TTZUFI5 DMB62OI TN Nitric-oxide synthase brain (NOS1) DMB62OI MA Inhibitor DMB62OI RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DMB62OI RU https://pubmed.ncbi.nlm.nih.gov/19013076 DMB6ADI DI DMB6ADI DMB6ADI DN Delta12-PGJ2 DMB6ADI TI TTQDMX5 DMB6ADI TN Prostaglandin D2 receptor 2 (PTGDR2) DMB6ADI MA Agonist DMB6ADI RN Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72. DMB6ADI RU https://pubmed.ncbi.nlm.nih.gov/12466225 DMB6ADI DI DMB6ADI DMB6ADI DN Delta12-PGJ2 DMB6ADI TI TTNVEIR DMB6ADI TN Prostaglandin D2 receptor (PTGDR) DMB6ADI MA Agonist DMB6ADI RN Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24. DMB6ADI RU https://pubmed.ncbi.nlm.nih.gov/9579725 DMB6FN7 DI DMB6FN7 DMB6FN7 DN GNF-PF-85 DMB6FN7 TI TT3PQ2Y DMB6FN7 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMB6FN7 MA Inhibitor DMB6FN7 RN Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falcipa... J Med Chem. 2008 Jun 26;51(12):3649-53. DMB6FN7 RU https://pubmed.ncbi.nlm.nih.gov/18522386 DMB6H35 DI DMB6H35 DMB6H35 DN waixenicin A DMB6H35 TI TTFPVZO DMB6H35 TN Long transient receptor potential channel 7 (TRPM7) DMB6H35 MA Blocker (channel blocker) DMB6H35 RN Waixenicin A inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels. J Biol Chem. 2011 Nov 11;286(45):39328-35. DMB6H35 RU https://pubmed.ncbi.nlm.nih.gov/21926172 DMB6SNE DI DMB6SNE DMB6SNE DN 4-(2-Imidazol-1-yl-ethoxy)-benzamide DMB6SNE TI TTIQUX7 DMB6SNE TN Steroid 11-beta-hydroxylase (CYP11B1) DMB6SNE MA Inhibitor DMB6SNE RN Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles. J Med Chem. 1985 Oct;28(10):1427-32. DMB6SNE RU https://pubmed.ncbi.nlm.nih.gov/3930740 DMB6SP8 DI DMB6SP8 DMB6SP8 DN 3-(3-aminocyclopentyl)-1H-indole-5-carbonitrile DMB6SP8 TI TT3ROYC DMB6SP8 TN Serotonin transporter (SERT) DMB6SP8 MA Inhibitor DMB6SP8 RN Conformationally restricted homotryptamines. Part 7: 3-cis-(3-aminocyclopentyl)indoles as potent selective serotonin reuptake inhibitors. J Med Chem. 2010 Nov 11;53(21):7564-72. DMB6SP8 RU https://pubmed.ncbi.nlm.nih.gov/20949929 DMB6T23 DI DMB6T23 DMB6T23 DN METAZOCINE DMB6T23 TI TT27RFC DMB6T23 TN Opioid receptor delta (OPRD1) DMB6T23 MA Inhibitor DMB6T23 RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMB6T23 RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMB6T23 DI DMB6T23 DMB6T23 DN METAZOCINE DMB6T23 TI TTQW87Y DMB6T23 TN Opioid receptor kappa (OPRK1) DMB6T23 MA Inhibitor DMB6T23 RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMB6T23 RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMB6T23 DI DMB6T23 DMB6T23 DN METAZOCINE DMB6T23 TI TTKWM86 DMB6T23 TN Opioid receptor mu (MOP) DMB6T23 MA Inhibitor DMB6T23 RN Synthesis and biological evaluation of a metazocine-containing enkephalinamide. Evidence for nonidentical roles of the tyramine moiety in opiates a... J Med Chem. 1982 Dec;25(12):1423-7. DMB6T23 RU https://pubmed.ncbi.nlm.nih.gov/7154002 DMB70NK DI DMB70NK DMB70NK DN SIGMOIDIN A DMB70NK TI TTELIN2 DMB70NK TN PTPN1 messenger RNA (PTPN1 mRNA) DMB70NK MA Inhibitor DMB70NK RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DMB70NK RU https://pubmed.ncbi.nlm.nih.gov/17489632 DMB70T3 DI DMB70T3 DMB70T3 DN SALVINICIN B DMB70T3 TI TTQW87Y DMB70T3 TN Opioid receptor kappa (OPRK1) DMB70T3 MA Inhibitor DMB70T3 RN Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem. 2007 Jul 26;50(15):3596-603. DMB70T3 RU https://pubmed.ncbi.nlm.nih.gov/17580847 DMB70WC DI DMB70WC DMB70WC DN Genz-10850 DMB70WC TI TTVTX4N DMB70WC TN Bacterial Fatty acid synthetase I (Bact inhA) DMB70WC MA Inhibitor DMB70WC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB70WC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB71FZ DI DMB71FZ DMB71FZ DN 3-(2,4-Dimethyl-phenyl)-1-propyl-piperidine DMB71FZ TI TTEX248 DMB71FZ TN Dopamine D2 receptor (D2R) DMB71FZ MA Inhibitor DMB71FZ RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DMB71FZ RU https://pubmed.ncbi.nlm.nih.gov/9836610 DMB73Y4 DI DMB73Y4 DMB73Y4 DN L 691121 DMB73Y4 TI TT1VOHK DMB73Y4 TN Potassium channel unspecific (KC) DMB73Y4 MA Modulator DMB73Y4 RN Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol. 1994;69(1):65-71. DMB73Y4 RU https://www.ncbi.nlm.nih.gov/pubmed/7717857 DMB7415 DI DMB7415 DMB7415 DN 2-Amino-6-(toluene-4-sulfonyl)-benzonitrile DMB7415 TI TT84ETX DMB7415 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMB7415 MA Inhibitor DMB7415 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMB7415 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMB74MS DI DMB74MS DMB74MS DN MM3A6S DMB74MS TI TTKWM86 DMB74MS TN Opioid receptor mu (MOP) DMB74MS MA Inhibitor DMB74MS RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMB74MS RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMB74WP DI DMB74WP DMB74WP DN Methyl 2-(Diallylamino)-1H-indole-3-carboxylate DMB74WP TI TTSJ6Q4 DMB74WP TN LOX-5 messenger RNA (ALOX5 mRNA) DMB74WP MA Inhibitor DMB74WP RN Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J Med Chem. 2009 Jun 11;52(11):3474-83. DMB74WP RU https://pubmed.ncbi.nlm.nih.gov/19492852 DMB75PV DI DMB75PV DMB75PV DN diphenyleneiodonium chloride DMB75PV TI TTHZVSK DMB75PV TN G protein-coupled receptor 3 (GPR3) DMB75PV MA Agonist DMB75PV RN Identification of a novel small-molecule agonist for human G protein-coupled receptor 3. J Pharmacol Exp Ther. 2014 Jun;349(3):437-43. DMB75PV RU https://pubmed.ncbi.nlm.nih.gov/24633425 DMB7685 DI DMB7685 DMB7685 DN EAPB0203 DMB7685 TI TTU1E82 DMB7685 TN Apoptosis regulator Bcl-xL (BCL-xL) DMB7685 MA Inhibitor DMB7685 RN EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood. 2008 Apr 1;111(7):3770-7. DMB7685 RU https://pubmed.ncbi.nlm.nih.gov/18218850 DMB7685 DI DMB7685 DMB7685 DN EAPB0203 DMB7685 TI TTQ5LRD DMB7685 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMB7685 MA Inhibitor DMB7685 RN EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood. 2008 Apr 1;111(7):3770-7. DMB7685 RU https://pubmed.ncbi.nlm.nih.gov/18218850 DMB76ZN DI DMB76ZN DMB76ZN DN 8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DMB76ZN TI TTZAYWL DMB76ZN TN Estrogen receptor (ESR) DMB76ZN MA Inhibitor DMB76ZN RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMB76ZN RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMB76ZN DI DMB76ZN DMB76ZN DN 8-Chloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DMB76ZN TI TTOM3J0 DMB76ZN TN Estrogen receptor beta (ESR2) DMB76ZN MA Inhibitor DMB76ZN RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMB76ZN RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMB78GP DI DMB78GP DMB78GP DN [Bpa1]AngII DMB78GP TI TT8DBY3 DMB78GP TN Angiotensin II receptor type-1 (AGTR1) DMB78GP MA Inhibitor DMB78GP RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMB78GP RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMB7AU5 DI DMB7AU5 DMB7AU5 DN 2-(1H-Indol-3-ylmethyl)-1,2-dihydro-indazol-3-one DMB7AU5 TI TT2J34L DMB7AU5 TN Arachidonate 5-lipoxygenase (5-LOX) DMB7AU5 MA Inhibitor DMB7AU5 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMB7AU5 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMB7DFT DI DMB7DFT DMB7DFT DN Benzaldehyde O-benzoyloxime DMB7DFT TI TTDNFMT DMB7DFT TN Platelet-activating factor acetylhydrolase (PLA2G7) DMB7DFT MA Inhibitor DMB7DFT RN Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5576-9. DMB7DFT RU https://pubmed.ncbi.nlm.nih.gov/16919943 DMB7E4X DI DMB7E4X DMB7E4X DN ISIS 138678 DMB7E4X TI TTTEOPU DMB7E4X TN Helicase-moi messenger RNA (DICER1 mRNA) DMB7E4X RN US patent application no. 7,427,470, Antisense modulation of helicase-moi expression. DMB7E4X RU http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true DMB7EGU DI DMB7EGU DMB7EGU DN RXP470.1 DMB7EGU TI TTXZ0KQ DMB7EGU TN Matrix metalloproteinase-12 (MMP-12) DMB7EGU MA Inhibitor DMB7EGU RN Molecular determinants of a selective matrix metalloprotease-12 inhibitor: insights from crystallography and thermodynamic studies. J Med Chem. 2013 Feb 14;56(3):1149-59. DMB7EGU RU https://pubmed.ncbi.nlm.nih.gov/23343195 DMB7EWZ DI DMB7EWZ DMB7EWZ DN 8-Bromo-9-phenylethyl-9H-adenine DMB7EWZ TI TTM2AOE DMB7EWZ TN Adenosine A2a receptor (ADORA2A) DMB7EWZ MA Inhibitor DMB7EWZ RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMB7EWZ RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMB7EWZ DI DMB7EWZ DMB7EWZ DN 8-Bromo-9-phenylethyl-9H-adenine DMB7EWZ TI TTK25J1 DMB7EWZ TN Adenosine A1 receptor (ADORA1) DMB7EWZ MA Inhibitor DMB7EWZ RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMB7EWZ RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMB7I0A DI DMB7I0A DMB7I0A DN VT-224 DMB7I0A TI TT8KLPT DMB7I0A TN C-C chemokine receptor (CCR) DMB7I0A MA Modulator DMB7I0A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 67). DMB7I0A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=67 DMB7R95 DI DMB7R95 DMB7R95 DN 5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide DMB7R95 TI TTGKNB4 DMB7R95 TN Epidermal growth factor receptor (EGFR) DMB7R95 MA Inhibitor DMB7R95 RN Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72. DMB7R95 RU https://pubmed.ncbi.nlm.nih.gov/16275081 DMB7TE6 DI DMB7TE6 DMB7TE6 DN PMID23589301C1 DMB7TE6 TI TT0FYAN DMB7TE6 TN Free fatty acid receptor 2 (FFAR2) DMB7TE6 MA Agonist DMB7TE6 RN Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J Biol Chem. 2013 Jun 14;288(24):17296-312. DMB7TE6 RU https://pubmed.ncbi.nlm.nih.gov/23589301 DMB813H DI DMB813H DMB813H DN GE-137 DMB813H TI TTNDSF4 DMB813H TN Proto-oncogene c-Met (MET) DMB813H MA Modulator DMB813H RN Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015 Aug;21(8):955-61. DMB813H RU https://pubmed.ncbi.nlm.nih.gov/26168295 DMB8HCW DI DMB8HCW DMB8HCW DN Galnon DMB8HCW TI TTX3HNZ DMB8HCW TN Galanin receptor type 1 (GAL1-R) DMB8HCW MA Agonist DMB8HCW RN Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A. 2002 May 14;99(10):7136-41. DMB8HCW RU https://pubmed.ncbi.nlm.nih.gov/12011470 DMB8MH0 DI DMB8MH0 DMB8MH0 DN ISIS 9066 DMB8MH0 TI TT5TURO DMB8MH0 TN A-Raf messenger RNA (ARAF mRNA) DMB8MH0 RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DMB8MH0 RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DMB8NWI DI DMB8NWI DMB8NWI DN (P-Iodophenylacetylamino)Methylphosphinic Acid DMB8NWI TI TTHI19T DMB8NWI TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMB8NWI MA Inhibitor DMB8NWI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB8NWI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB8OY6 DI DMB8OY6 DMB8OY6 DN 2-(4-Methyl-piperazin-1-yl)-quinoline DMB8OY6 TI TTPC4TU DMB8OY6 TN 5-HT 3A receptor (HTR3A) DMB8OY6 MA Inhibitor DMB8OY6 RN Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75. DMB8OY6 RU https://pubmed.ncbi.nlm.nih.gov/10229626 DMB8OY6 DI DMB8OY6 DMB8OY6 DN 2-(4-Methyl-piperazin-1-yl)-quinoline DMB8OY6 TI TTR6K75 DMB8OY6 TN 5-HT 3B receptor (HTR3B) DMB8OY6 MA Inhibitor DMB8OY6 RN Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75. DMB8OY6 RU https://pubmed.ncbi.nlm.nih.gov/10229626 DMB8OY6 DI DMB8OY6 DMB8OY6 DN 2-(4-Methyl-piperazin-1-yl)-quinoline DMB8OY6 TI TT9JNIC DMB8OY6 TN Histamine H3 receptor (H3R) DMB8OY6 MA Inhibitor DMB8OY6 RN 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11. DMB8OY6 RU https://pubmed.ncbi.nlm.nih.gov/15634025 DMB8Q7T DI DMB8Q7T DMB8Q7T DN 3-Ethyl-3-isobutyl-1-phenylazetidine-2,4-dione DMB8Q7T TI TTPLTSQ DMB8Q7T TN Neutrophil elastase (NE) DMB8Q7T MA Inhibitor DMB8Q7T RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMB8Q7T RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMB8TJC DI DMB8TJC DMB8TJC DN SN-28 DMB8TJC TI TTKWM86 DMB8TJC TN Opioid receptor mu (MOP) DMB8TJC MA Inhibitor DMB8TJC RN Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5. DMB8TJC RU https://pubmed.ncbi.nlm.nih.gov/20850307 DMB8TJC DI DMB8TJC DMB8TJC DN SN-28 DMB8TJC TI TT27RFC DMB8TJC TN Opioid receptor delta (OPRD1) DMB8TJC MA Inhibitor DMB8TJC RN Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5. DMB8TJC RU https://pubmed.ncbi.nlm.nih.gov/20850307 DMB8TJC DI DMB8TJC DMB8TJC DN SN-28 DMB8TJC TI TTQW87Y DMB8TJC TN Opioid receptor kappa (OPRK1) DMB8TJC MA Inhibitor DMB8TJC RN Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5. DMB8TJC RU https://pubmed.ncbi.nlm.nih.gov/20850307 DMB8U4F DI DMB8U4F DMB8U4F DN FPL64176 DMB8U4F TI TTZIFHC DMB8U4F TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMB8U4F MA Activator DMB8U4F RN The calcium channel ligand FPL 64176 enhances L-type but inhibits N-type neuronal calcium currents. Neuropharmacology. 2003 Aug;45(2):281-92. DMB8U4F RU https://pubmed.ncbi.nlm.nih.gov/12842134 DMB8U4F DI DMB8U4F DMB8U4F DN FPL64176 DMB8U4F TI TT94HRF DMB8U4F TN Voltage-gated calcium channel alpha Cav1.1 (CACNA1S) DMB8U4F MA Activator DMB8U4F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528). DMB8U4F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528 DMB8XZP DI DMB8XZP DMB8XZP DN SB-408124 DMB8XZP TI TT60Q8D DMB8XZP TN Orexin receptor type 1 (HCRTR1) DMB8XZP MA Antagonist DMB8XZP RN Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31. DMB8XZP RU https://pubmed.ncbi.nlm.nih.gov/19542319 DMB8XZP DI DMB8XZP DMB8XZP DN SB-408124 DMB8XZP TI TT9N02I DMB8XZP TN Orexin receptor type 2 (HCRTR2) DMB8XZP MA Antagonist DMB8XZP RN Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31. DMB8XZP RU https://pubmed.ncbi.nlm.nih.gov/19542319 DMB91UL DI DMB91UL DMB91UL DN morphanthridine DMB91UL TI TTELV3W DMB91UL TN Transformation-sensitive protein p120 (TRPA1) DMB91UL MA Activator DMB91UL RN Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6. DMB91UL RU https://pubmed.ncbi.nlm.nih.gov/18501939 DMB923H DI DMB923H DMB923H DN PRS-110 DMB923H TI TTNDSF4 DMB923H TN Proto-oncogene c-Met (MET) DMB923H MA Inhibitor DMB923H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMB923H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMB9645 DI DMB9645 DMB9645 DN 8-(3-Methylbenzyloxy)caffeine DMB9645 TI TTGP7BY DMB9645 TN Monoamine oxidase type B (MAO-B) DMB9645 MA Inhibitor DMB9645 RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMB9645 RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMB9645 DI DMB9645 DMB9645 DN 8-(3-Methylbenzyloxy)caffeine DMB9645 TI TT3WG5C DMB9645 TN Monoamine oxidase type A (MAO-A) DMB9645 MA Inhibitor DMB9645 RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMB9645 RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMB96SY DI DMB96SY DMB96SY DN 4-(2,4-dichloro-phenoxy)-biphenyl-3-ol DMB96SY TI TTNX2CS DMB96SY TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMB96SY MA Inhibitor DMB96SY RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DMB96SY RU https://pubmed.ncbi.nlm.nih.gov/17567585 DMB9A46 DI DMB9A46 DMB9A46 DN Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2 DMB9A46 TI TT27RFC DMB9A46 TN Opioid receptor delta (OPRD1) DMB9A46 MA Inhibitor DMB9A46 RN Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52. DMB9A46 RU https://pubmed.ncbi.nlm.nih.gov/9288177 DMB9A46 DI DMB9A46 DMB9A46 DN Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2 DMB9A46 TI TTKWM86 DMB9A46 TN Opioid receptor mu (MOP) DMB9A46 MA Inhibitor DMB9A46 RN Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52. DMB9A46 RU https://pubmed.ncbi.nlm.nih.gov/9288177 DMB9AIX DI DMB9AIX DMB9AIX DN Interleukin-1-alpha - Amgen/Roche DMB9AIX TI TTPM6HI DMB9AIX TN Interleukin-1 alpha (IL1A) DMB9AIX MA Modulator DMB9AIX RN Identification of regions in interleukin-1 alpha important for activity. J Biol Chem. 1993 Oct 15;268(29):22105-11. DMB9AIX RU https://www.ncbi.nlm.nih.gov/pubmed/8408069 DMB9AR7 DI DMB9AR7 DMB9AR7 DN ARTOBILOXANTHONE DMB9AR7 TI TTSXVID DMB9AR7 TN Nuclear factor NF-kappa-B (NFKB) DMB9AR7 MA Inhibitor DMB9AR7 RN Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida. J Nat Prod. 2010 May 28;73(5):949-55. DMB9AR7 RU https://pubmed.ncbi.nlm.nih.gov/20384315 DMB9CJM DI DMB9CJM DMB9CJM DN 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMB9CJM TI TTF10I9 DMB9CJM TN Nitric-oxide synthase inducible (NOS2) DMB9CJM MA Inhibitor DMB9CJM RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMB9CJM RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMB9CJM DI DMB9CJM DMB9CJM DN 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMB9CJM TI TTZUFI5 DMB9CJM TN Nitric-oxide synthase brain (NOS1) DMB9CJM MA Inhibitor DMB9CJM RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMB9CJM RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMB9CJM DI DMB9CJM DMB9CJM DN 4,5-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMB9CJM TI TTCM4B3 DMB9CJM TN Nitric-oxide synthase endothelial (NOS3) DMB9CJM MA Inhibitor DMB9CJM RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMB9CJM RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMB9CQL DI DMB9CQL DMB9CQL DN (S)-3-(azetidin-2-ylmethoxy)-2-fluoropyridine DMB9CQL TI TTF4E0J DMB9CQL TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMB9CQL MA Inhibitor DMB9CQL RN Synthesis and biological evaluation of novel carbon-11 labeled pyridyl ethers: candidate ligands for in vivo imaging of alpha4beta2 nicotinic acety... Bioorg Med Chem. 2009 Jul 1;17(13):4367-77. DMB9CQL RU https://pubmed.ncbi.nlm.nih.gov/19481945 DMB9DWH DI DMB9DWH DMB9DWH DN ISIS 25544 DMB9DWH TI TTP2U16 DMB9DWH TN RhoA messenger RNA (RHOA mRNA) DMB9DWH RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMB9DWH RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMB9F2L DI DMB9F2L DMB9F2L DN PMID19115845C89S DMB9F2L TI TTRSMW9 DMB9F2L TN Glycogen synthase kinase-3 beta (GSK-3B) DMB9F2L MA Inhibitor DMB9F2L RN First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. DMB9F2L RU https://pubmed.ncbi.nlm.nih.gov/19115845 DMB9F2L DI DMB9F2L DMB9F2L DN PMID19115845C89S DMB9F2L TI TTH6V3D DMB9F2L TN Cyclin-dependent kinase 1 (CDK1) DMB9F2L MA Inhibitor DMB9F2L RN First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. DMB9F2L RU https://pubmed.ncbi.nlm.nih.gov/19115845 DMB9F2L DI DMB9F2L DMB9F2L DN PMID19115845C89S DMB9F2L TI TTO7L0V DMB9F2L TN TAO kinase 3 (TAOK3) DMB9F2L MA Inhibitor DMB9F2L RN First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. DMB9F2L RU https://pubmed.ncbi.nlm.nih.gov/19115845 DMB9F2L DI DMB9F2L DMB9F2L DN PMID19115845C89S DMB9F2L TI TTSMTDI DMB9F2L TN CDC7-related kinase (CDC7) DMB9F2L MA Inhibitor DMB9F2L RN First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. DMB9F2L RU https://pubmed.ncbi.nlm.nih.gov/19115845 DMB9F2L DI DMB9F2L DMB9F2L DN PMID19115845C89S DMB9F2L TI TT7HF4W DMB9F2L TN Cyclin-dependent kinase 2 (CDK2) DMB9F2L MA Inhibitor DMB9F2L RN First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. DMB9F2L RU https://pubmed.ncbi.nlm.nih.gov/19115845 DMB9F2L DI DMB9F2L DMB9F2L DN PMID19115845C89S DMB9F2L TI TT1LVF2 DMB9F2L TN Cyclin-dependent kinase 9 (CDK9) DMB9F2L MA Inhibitor DMB9F2L RN First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307. DMB9F2L RU https://pubmed.ncbi.nlm.nih.gov/19115845 DMB9FCK DI DMB9FCK DMB9FCK DN 9-Hydroxypropyladenine, R-Isomer DMB9FCK TI TTP3QRF DMB9FCK TN Thymidine kinase 1 (TK1) DMB9FCK MA Inhibitor DMB9FCK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB9FCK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB9LE1 DI DMB9LE1 DMB9LE1 DN Geranyl Diphosphate DMB9LE1 TI TTIKWV4 DMB9LE1 TN Geranyltranstransferase (FDPS) DMB9LE1 MA Inhibitor DMB9LE1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMB9LE1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMB9OGI DI DMB9OGI DMB9OGI DN N-Methyl-N-Propargyl-1(R)-Aminoindan DMB9OGI TI TTGP7BY DMB9OGI TN Monoamine oxidase type B (MAO-B) DMB9OGI MA Inhibitor DMB9OGI RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMB9OGI RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMB9PDA DI DMB9PDA DMB9PDA DN arpromidine DMB9PDA TI TTTIBOJ DMB9PDA TN Histamine H1 receptor (H1R) DMB9PDA MA Antagonist DMB9PDA RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DMB9PDA RU https://pubmed.ncbi.nlm.nih.gov/12626648 DMB9PDA DI DMB9PDA DMB9PDA DN arpromidine DMB9PDA TI TTQHJ1K DMB9PDA TN Histamine H2 receptor (H2R) DMB9PDA MA Agonist DMB9PDA RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DMB9PDA RU https://pubmed.ncbi.nlm.nih.gov/16394198 DMB9SEI DI DMB9SEI DMB9SEI DN Broussoflavonol F DMB9SEI TI TTSZLWK DMB9SEI TN Aromatase (CYP19A1) DMB9SEI MA Inhibitor DMB9SEI RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DMB9SEI RU https://pubmed.ncbi.nlm.nih.gov/11678652 DMB9T6F DI DMB9T6F DMB9T6F DN 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMB9T6F TI TT3ROYC DMB9T6F TN Serotonin transporter (SERT) DMB9T6F MA Inhibitor DMB9T6F RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMB9T6F RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMB9T6F DI DMB9T6F DMB9T6F DN 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMB9T6F TI TTVBI8W DMB9T6F TN Dopamine transporter (DAT) DMB9T6F MA Inhibitor DMB9T6F RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMB9T6F RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMB9T6F DI DMB9T6F DMB9T6F DN 1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMB9T6F TI TTAWNKZ DMB9T6F TN Norepinephrine transporter (NET) DMB9T6F MA Inhibitor DMB9T6F RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMB9T6F RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMB9U17 DI DMB9U17 DMB9U17 DN JMV3008 DMB9U17 TI TTWDC17 DMB9U17 TN Growth hormone secretagogue receptor 1 (GHSR) DMB9U17 MA Antagonist DMB9U17 RN Toward potent ghrelin receptor ligands based on trisubstituted 1,2,4-triazole structure. 2. Synthesis and pharmacological in vitro and in vivo eval... J Med Chem. 2007 Nov 15;50(23):5790-806. DMB9U17 RU https://pubmed.ncbi.nlm.nih.gov/17927165 DMB9VFS DI DMB9VFS DMB9VFS DN ISIS 107681 DMB9VFS TI TT6SZNG DMB9VFS TN Caspase 8 messenger RNA (CASP8 mRNA) DMB9VFS RN US patent application no. 6,258,600, Antisense modulation of caspase 8 expression. DMB9VFS RU http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true DMB9VGW DI DMB9VGW DMB9VGW DN [3H]granisetron DMB9VGW TI TTPC4TU DMB9VGW TN 5-HT 3A receptor (HTR3A) DMB9VGW MA Antagonist DMB9VGW RN Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells. Br J Pharmacol. 1996 Jul;118(5):1237-45. DMB9VGW RU https://pubmed.ncbi.nlm.nih.gov/8818349 DMB9VGW DI DMB9VGW DMB9VGW DN [3H]granisetron DMB9VGW TI TTR6K75 DMB9VGW TN 5-HT 3B receptor (HTR3B) DMB9VGW MA Antagonist DMB9VGW RN Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4. DMB9VGW RU https://pubmed.ncbi.nlm.nih.gov/11489465 DMB9XR5 DI DMB9XR5 DMB9XR5 DN 1,3-Dihydro-imidazo[4,5-b]quinolin-2-one DMB9XR5 TI TT06AWU DMB9XR5 TN Phosphodiesterase 3A (PDE3A) DMB9XR5 MA Inhibitor DMB9XR5 RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DMB9XR5 RU https://pubmed.ncbi.nlm.nih.gov/1654430 DMB9YA8 DI DMB9YA8 DMB9YA8 DN 7-methyl-2-p-tolyl-4H-chromene-4-thione DMB9YA8 TI TTGP7BY DMB9YA8 TN Monoamine oxidase type B (MAO-B) DMB9YA8 MA Inhibitor DMB9YA8 RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMB9YA8 RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMB9YAO DI DMB9YAO DMB9YAO DN (7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile DMB9YAO TI TTGP7BY DMB9YAO TN Monoamine oxidase type B (MAO-B) DMB9YAO MA Inhibitor DMB9YAO RN Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706. DMB9YAO RU https://pubmed.ncbi.nlm.nih.gov/19810674 DMB9YAO DI DMB9YAO DMB9YAO DN (7-Benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile DMB9YAO TI TT3WG5C DMB9YAO TN Monoamine oxidase type A (MAO-A) DMB9YAO MA Inhibitor DMB9YAO RN Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706. DMB9YAO RU https://pubmed.ncbi.nlm.nih.gov/19810674 DMBA15J DI DMBA15J DMBA15J DN PD-32577 DMBA15J TI TT4FDG6 DMBA15J TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMBA15J MA Inhibitor DMBA15J RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DMBA15J RU https://pubmed.ncbi.nlm.nih.gov/10476885 DMBA15J DI DMBA15J DMBA15J DN PD-32577 DMBA15J TI TTZIFHC DMBA15J TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMBA15J MA Inhibitor DMBA15J RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DMBA15J RU https://pubmed.ncbi.nlm.nih.gov/10476885 DMBA15J DI DMBA15J DMBA15J DN PD-32577 DMBA15J TI TTIVDM3 DMBA15J TN Voltage-gated potassium channel Kv7.3 (KCNQ3) DMBA15J MA Inhibitor DMBA15J RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DMBA15J RU https://pubmed.ncbi.nlm.nih.gov/10476885 DMBA15J DI DMBA15J DMBA15J DN PD-32577 DMBA15J TI TTPXI3S DMBA15J TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DMBA15J MA Inhibitor DMBA15J RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DMBA15J RU https://pubmed.ncbi.nlm.nih.gov/10476885 DMBA15J DI DMBA15J DMBA15J DN PD-32577 DMBA15J TI TT90XZ8 DMBA15J TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMBA15J MA Inhibitor DMBA15J RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DMBA15J RU https://pubmed.ncbi.nlm.nih.gov/10476885 DMBA15J DI DMBA15J DMBA15J DN PD-32577 DMBA15J TI TT7RGTM DMBA15J TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMBA15J MA Inhibitor DMBA15J RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DMBA15J RU https://pubmed.ncbi.nlm.nih.gov/10476885 DMBA15J DI DMBA15J DMBA15J DN PD-32577 DMBA15J TI TTN9VTF DMBA15J TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMBA15J MA Inhibitor DMBA15J RN Synthesis and biological activity of substituted bis-(4-hydroxyphenyl)methanes as N-type calcium channel blockers. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2447-52. DMBA15J RU https://pubmed.ncbi.nlm.nih.gov/10476885 DMBA1LS DI DMBA1LS DMBA1LS DN Ac-I[CVWQDWGHHRC]T-NH2 DMBA1LS TI TTJGY7A DMBA1LS TN Complement C3 (CO3) DMBA1LS MA Inhibitor DMBA1LS RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMBA1LS RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMBA297 DI DMBA297 DMBA297 DN SR11254 DMBA297 TI TT1Q3IE DMBA297 TN Retinoic acid receptor gamma (RARG) DMBA297 MA Inhibitor DMBA297 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBA297 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBA4XN DI DMBA4XN DMBA4XN DN 3-cyano-5-fluoro-N-(pyridin-2-yl)benzamide DMBA4XN TI TTHS256 DMBA4XN TN Metabotropic glutamate receptor 5 (mGluR5) DMBA4XN MA Inhibitor DMBA4XN RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMBA4XN RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMBAHRJ DI DMBAHRJ DMBAHRJ DN 3-[(2,5-dimethyl-4-thiazolyl)ethynyl]pyridine DMBAHRJ TI TTHS256 DMBAHRJ TN Metabotropic glutamate receptor 5 (mGluR5) DMBAHRJ MA Inhibitor DMBAHRJ RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMBAHRJ RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMBAM5K DI DMBAM5K DMBAM5K DN ISIS 103386 DMBAM5K TI TTK0TF2 DMBAM5K TN DUSP8 messenger RNA (DUSP8 mRNA) DMBAM5K RN US patent application no. 6,482,644, Antisense modulation of dual specific phosphatase 8 expression. DMBAM5K RU http://www.patentbuddy.com/Patent/6482644?ft=true&sr=true DMBAN5P DI DMBAN5P DMBAN5P DN beta3-tetrapeptide DMBAN5P TI TTAE1BR DMBAN5P TN Somatostatin receptor type 4 (SSTR4) DMBAN5P MA Agonist DMBAN5P RN Beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Feb;367(2):95-103. DMBAN5P RU https://pubmed.ncbi.nlm.nih.gov/12595949 DMBAWDG DI DMBAWDG DMBAWDG DN Thiolactomycin DMBAWDG TI TTNX2CS DMBAWDG TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMBAWDG MA Inhibitor DMBAWDG RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMBAWDG RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMBAWDG DI DMBAWDG DMBAWDG DN Thiolactomycin DMBAWDG TI TTRVTMX DMBAWDG TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMBAWDG MA Binder DMBAWDG RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DMBAWDG RU https://pubmed.ncbi.nlm.nih.gov/11768328 DMBAWDG DI DMBAWDG DMBAWDG DN Thiolactomycin DMBAWDG TI TTRFV0W DMBAWDG TN Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF) DMBAWDG MA Binder DMBAWDG RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMBAWDG RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMBAWDG DI DMBAWDG DMBAWDG DN Thiolactomycin DMBAWDG TI TT0O4QL DMBAWDG TN Bacterial Beta-ketoacyl-ACP synthase I (Bact fabB) DMBAWDG MA Binder DMBAWDG RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMBAWDG RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMBAX2L DI DMBAX2L DMBAX2L DN 1,2-Diacetoxylycorine DMBAX2L TI TTXV4FI DMBAX2L TN Albendazole monooxygenase (CYP3A4) DMBAX2L MA Inhibitor DMBAX2L RN Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7. DMBAX2L RU https://pubmed.ncbi.nlm.nih.gov/19428250 DMBAX3P DI DMBAX3P DMBAX3P DN amthamine DMBAX3P TI TTQHJ1K DMBAX3P TN Histamine H2 receptor (H2R) DMBAX3P MA Agonist DMBAX3P RN N(G)-acylated aminothiazolylpropylguanidines as potent and selective histamine H(2) receptor agonists. ChemMedChem. 2009 Feb;4(2):232-40. DMBAX3P RU https://pubmed.ncbi.nlm.nih.gov/19072936 DMBAXDU DI DMBAXDU DMBAXDU DN Salvinorin B 2-fluoroethoxymethyl ether DMBAXDU TI TTQW87Y DMBAXDU TN Opioid receptor kappa (OPRK1) DMBAXDU MA Inhibitor DMBAXDU RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMBAXDU RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMBAY7P DI DMBAY7P DMBAY7P DN Diheptan-3-yl 5-(hydroxymethyl)isophthalate DMBAY7P TI TTFJ8Q1 DMBAY7P TN Protein kinase C alpha (PRKCA) DMBAY7P MA Inhibitor DMBAY7P RN Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81. DMBAY7P RU https://pubmed.ncbi.nlm.nih.gov/19438240 DMBAY7P DI DMBAY7P DMBAY7P DN Diheptan-3-yl 5-(hydroxymethyl)isophthalate DMBAY7P TI TT7A1BO DMBAY7P TN PKC-delta messenger RNA (PRKCD mRNA) DMBAY7P MA Inhibitor DMBAY7P RN Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81. DMBAY7P RU https://pubmed.ncbi.nlm.nih.gov/19438240 DMBAZG3 DI DMBAZG3 DMBAZG3 DN 1-benzhydryl-3-butylpiperidin-4-amine DMBAZG3 TI TTDIGC1 DMBAZG3 TN Dipeptidyl peptidase 4 (DPP-4) DMBAZG3 MA Inhibitor DMBAZG3 RN 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70. DMBAZG3 RU https://pubmed.ncbi.nlm.nih.gov/17418568 DMBCK4G DI DMBCK4G DMBCK4G DN DIECKOL DMBCK4G TI TT8JRS7 DMBCK4G TN Beta-secretase (BACE) DMBCK4G MA Inhibitor DMBCK4G RN Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5. DMBCK4G RU https://pubmed.ncbi.nlm.nih.gov/20462757 DMBCO4Q DI DMBCO4Q DMBCO4Q DN Arsenite DMBCO4Q TI TTRPDBG DMBCO4Q TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMBCO4Q MA Inhibitor DMBCO4Q RN Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem. 2000 Nov 17;275(46):36062-6. DMBCO4Q RU https://pubmed.ncbi.nlm.nih.gov/10967126 DMBCPKE DI DMBCPKE DMBCPKE DN ZK-114043 DMBCPKE TI TTUV8G9 DMBCPKE TN Progesterone receptor (PGR) DMBCPKE MA Modulator DMBCPKE RN Progesterone inhibits glucocorticoid-dependent aromatase induction in human adipose fibroblasts. J Endocrinol. 1998 Sep;158(3):401-7. DMBCPKE RU https://www.ncbi.nlm.nih.gov/pubmed/9846169 DMBCPKF DI DMBCPKF DMBCPKF DN Boc-D-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2 DMBCPKF TI TTCG0AL DMBCPKF TN Cholecystokinin receptor type A (CCKAR) DMBCPKF MA Inhibitor DMBCPKF RN Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90. DMBCPKF RU https://pubmed.ncbi.nlm.nih.gov/2724293 DMBCU6W DI DMBCU6W DMBCU6W DN 1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene DMBCU6W TI TTE4KHA DMBCU6W TN Amyloid beta A4 protein (APP) DMBCU6W MA Inhibitor DMBCU6W RN Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. DMBCU6W RU https://pubmed.ncbi.nlm.nih.gov/16640346 DMBD52I DI DMBD52I DMBD52I DN N-(9H-beta-Carbolin-3-yl)-acetamide DMBD52I TI TT1MPAY DMBD52I TN GABA(A) receptor alpha-1 (GABRA1) DMBD52I MA Inhibitor DMBD52I RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DMBD52I RU https://pubmed.ncbi.nlm.nih.gov/2989520 DMBD52I DI DMBD52I DMBD52I DN N-(9H-beta-Carbolin-3-yl)-acetamide DMBD52I TI TTNJYV2 DMBD52I TN Gamma-aminobutyric acid receptor (GAR) DMBD52I MA Inhibitor DMBD52I RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DMBD52I RU https://pubmed.ncbi.nlm.nih.gov/2989520 DMBD6TC DI DMBD6TC DMBD6TC DN slotoxin DMBD6TC TI TT1AQ50 DMBD6TC TN Charybdotoxin receptor beta-4 (BKbeta4) DMBD6TC MA Blocker (channel blocker) DMBD6TC RN Slotoxin, alphaKTx1.11, a new scorpion peptide blocker of MaxiK channels that differentiates between alpha and alpha+beta (beta1 or beta4) complexes. FEBS Lett. 2001 Sep 21;505(3):369-73. DMBD6TC RU https://pubmed.ncbi.nlm.nih.gov/11576530 DMBDFP2 DI DMBDFP2 DMBDFP2 DN 7-m-tolyl-1,6-naphthyridine DMBDFP2 TI TTHS256 DMBDFP2 TN Metabotropic glutamate receptor 5 (mGluR5) DMBDFP2 MA Inhibitor DMBDFP2 RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMBDFP2 RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMBDTFQ DI DMBDTFQ DMBDTFQ DN Cyclopentyl-(9-cyclopentyl-9H-purin-6-yl)-amine DMBDTFQ TI TTK25J1 DMBDTFQ TN Adenosine A1 receptor (ADORA1) DMBDTFQ MA Inhibitor DMBDTFQ RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMBDTFQ RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMBDVJ1 DI DMBDVJ1 DMBDVJ1 DN PSB-0963 DMBDVJ1 TI TTOZHQC DMBDVJ1 TN P2Y purinoceptor 2 (P2RY2) DMBDVJ1 MA Inhibitor DMBDVJ1 RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMBDVJ1 RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMBDVJ1 DI DMBDVJ1 DMBDVJ1 DN PSB-0963 DMBDVJ1 TI TTYM8DJ DMBDVJ1 TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DMBDVJ1 MA Inhibitor DMBDVJ1 RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMBDVJ1 RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMBDVJ1 DI DMBDVJ1 DMBDVJ1 DN PSB-0963 DMBDVJ1 TI TTK0O6Y DMBDVJ1 TN Ecto-5'-nucleotidase (CD73) DMBDVJ1 MA Inhibitor DMBDVJ1 RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMBDVJ1 RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMBDW8P DI DMBDW8P DMBDW8P DN 3-(4-sulfamoylphenyl)propanoic acid DMBDW8P TI TTHQPL7 DMBDW8P TN Carbonic anhydrase I (CA-I) DMBDW8P MA Inhibitor DMBDW8P RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMBDW8P RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMBDW8P DI DMBDW8P DMBDW8P DN 3-(4-sulfamoylphenyl)propanoic acid DMBDW8P TI TTANPDJ DMBDW8P TN Carbonic anhydrase II (CA-II) DMBDW8P MA Inhibitor DMBDW8P RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMBDW8P RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMBDW8P DI DMBDW8P DMBDW8P DN 3-(4-sulfamoylphenyl)propanoic acid DMBDW8P TI TTUNARX DMBDW8P TN Carbonic anhydrase (CA) DMBDW8P MA Inhibitor DMBDW8P RN Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. Bioorg Med Chem. 2009 Jul 1;17(13):4503-9. DMBDW8P RU https://pubmed.ncbi.nlm.nih.gov/19450983 DMBDZQA DI DMBDZQA DMBDZQA DN D[Thr4,Orn8(5/6C-Flu)]VT DMBDZQA TI TTL9MHW DMBDZQA TN Vasopressin V1b receptor (V1BR) DMBDZQA MA Inhibitor DMBDZQA RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMBDZQA RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMBDZQA DI DMBDZQA DMBDZQA DN D[Thr4,Orn8(5/6C-Flu)]VT DMBDZQA TI TTSCIUP DMBDZQA TN Oxytocin receptor (OTR) DMBDZQA MA Inhibitor DMBDZQA RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMBDZQA RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMBDZQA DI DMBDZQA DMBDZQA DN D[Thr4,Orn8(5/6C-Flu)]VT DMBDZQA TI TT4TFGN DMBDZQA TN Vasopressin V1a receptor (V1AR) DMBDZQA MA Inhibitor DMBDZQA RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMBDZQA RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMBE0CT DI DMBE0CT DMBE0CT DN Shikimate-3-Phosphate DMBE0CT TI TTB30PF DMBE0CT TN Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA) DMBE0CT MA Inhibitor DMBE0CT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBE0CT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBE0H8 DI DMBE0H8 DMBE0H8 DN ARN-2966 DMBE0H8 TI TTE4KHA DMBE0H8 TN Amyloid beta A4 protein (APP) DMBE0H8 MA Inhibitor DMBE0H8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMBE0H8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMBE1T8 DI DMBE1T8 DMBE1T8 DN ISIS 3792 DMBE1T8 TI TTHCEF6 DMBE1T8 TN VCAM-1 messenger RNA (VCAM1 mRNA) DMBE1T8 RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMBE1T8 RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMBE24Y DI DMBE24Y DMBE24Y DN PF750 DMBE24Y TI TTDP1UC DMBE24Y TN Fatty acid amide hydrolase (FAAH) DMBE24Y MA Inhibitor DMBE24Y RN Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry. 2007 Nov 13;46(45):13019-30. DMBE24Y RU https://pubmed.ncbi.nlm.nih.gov/17949010 DMBEA23 DI DMBEA23 DMBEA23 DN 4-(3,4-dichlorobenzylthio)-2-aminobutanoic acid DMBEA23 TI TTFK1JQ DMBEA23 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMBEA23 MA Inhibitor DMBEA23 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMBEA23 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMBEHA5 DI DMBEHA5 DMBEHA5 DN PMID15724976C1 DMBEHA5 TI TTVK7SB DMBEHA5 TN Histone acetyltransferase KAT2B (KAT2B) DMBEHA5 MA Inhibitor DMBEHA5 RN Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J Am Chem Soc. 2005 Mar 2;127(8):2376-7. DMBEHA5 RU https://pubmed.ncbi.nlm.nih.gov/15724976 DMBELJK DI DMBELJK DMBELJK DN Cyclo-[-Arg-Gly-Asp-Amp22-] DMBELJK TI TTT1R2L DMBELJK TN Integrin alpha-V (ITGAV) DMBELJK MA Inhibitor DMBELJK RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMBELJK RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMBELJK DI DMBELJK DMBELJK DN Cyclo-[-Arg-Gly-Asp-Amp22-] DMBELJK TI TTJA1ZO DMBELJK TN ITGB3 messenger RNA (ITGB3 mRNA) DMBELJK MA Inhibitor DMBELJK RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMBELJK RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMBEOIQ DI DMBEOIQ DMBEOIQ DN (2S,3S)-iodoreboxetine DMBEOIQ TI TTVBI8W DMBEOIQ TN Dopamine transporter (DAT) DMBEOIQ MA Inhibitor DMBEOIQ RN New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3. DMBEOIQ RU https://pubmed.ncbi.nlm.nih.gov/18762424 DMBEOIQ DI DMBEOIQ DMBEOIQ DN (2S,3S)-iodoreboxetine DMBEOIQ TI TT3ROYC DMBEOIQ TN Serotonin transporter (SERT) DMBEOIQ MA Inhibitor DMBEOIQ RN New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3. DMBEOIQ RU https://pubmed.ncbi.nlm.nih.gov/18762424 DMBEPGU DI DMBEPGU DMBEPGU DN ISIS 19649 DMBEPGU TI TTWALCO DMBEPGU TN HER4 messenger RNA (ERBB4 mRNA) DMBEPGU RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMBEPGU RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMBERSG DI DMBERSG DMBERSG DN Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG TI TTRK9JT DMBERSG TN Neuropeptide Y receptor type 1 (NPY1R) DMBERSG MA Inhibitor DMBERSG RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMBERSG RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMBERSG DI DMBERSG DMBERSG DN Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG TI TTW4N16 DMBERSG TN Neuropeptide Y receptor type 4 (NPY4R) DMBERSG MA Inhibitor DMBERSG RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMBERSG RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMBERSG DI DMBERSG DMBERSG DN Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG TI TTJ6WK9 DMBERSG TN Neuropeptide Y receptor type 2 (NPY2R) DMBERSG MA Inhibitor DMBERSG RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMBERSG RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMBEV4W DI DMBEV4W DMBEV4W DN VL-2799 DMBEV4W TI TTCG0AL DMBEV4W TN Cholecystokinin receptor type A (CCKAR) DMBEV4W MA Inhibitor DMBEV4W RN Anthranilic acid based CCK1 receptor antagonists: blocking the receptor with the same 'words' of the endogenous ligand. Bioorg Med Chem. 2009 Mar 15;17(6):2336-50. DMBEV4W RU https://pubmed.ncbi.nlm.nih.gov/19261479 DMBEZ09 DI DMBEZ09 DMBEZ09 DN 12S-HETE DMBEZ09 TI TT71ZLK DMBEZ09 TN G-protein coupled receptor 31 (GPR31) DMBEZ09 MA Agonist DMBEZ09 RN Identification of the orphan G protein-coupled receptor GPR31 as a receptor for 12-(S)-hydroxyeicosatetraenoic acid. J Biol Chem. 2011 Sep 30;286(39):33832-40. DMBEZ09 RU https://pubmed.ncbi.nlm.nih.gov/21712392 DMBEZ09 DI DMBEZ09 DMBEZ09 DN 12S-HETE DMBEZ09 TI TTVJX54 DMBEZ09 TN Leukotriene B4 receptor 2 (LTB4R2) DMBEZ09 MA Agonist DMBEZ09 RN Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001 Apr 13;276(15):12454-9. DMBEZ09 RU https://pubmed.ncbi.nlm.nih.gov/11278893 DMBF1OY DI DMBF1OY DMBF1OY DN A-935142 DMBF1OY TI TTQ6VDM DMBF1OY TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMBF1OY MA Activator DMBF1OY RN Electrophysiologic characterization of a novel hERG channel activator. Biochem Pharmacol. 2009 Apr 15;77(8):1383-90. DMBF1OY RU https://pubmed.ncbi.nlm.nih.gov/19426677 DMBF42W DI DMBF42W DMBF42W DN 5'-amino-5'-deoxy-alpha-D-thymidine DMBF42W TI TT5B8AX DMBF42W TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMBF42W MA Inhibitor DMBF42W RN Rational design of 5'-thiourea-substituted alpha-thymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacteri... J Med Chem. 2007 Nov 1;50(22):5281-92. DMBF42W RU https://pubmed.ncbi.nlm.nih.gov/17910427 DMBF5KW DI DMBF5KW DMBF5KW DN 4-nonylphenylboronic acid DMBF5KW TI TTDP1UC DMBF5KW TN Fatty acid amide hydrolase (FAAH) DMBF5KW MA Inhibitor DMBF5KW RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMBF5KW RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMBF6KS DI DMBF6KS DMBF6KS DN TPMPA DMBF6KS TI TTQMXLS DMBF6KS TN GABA(A) receptor rho2 (GABRR2) DMBF6KS MA Antagonist DMBF6KS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DMBF6KS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DMBF6KS DI DMBF6KS DMBF6KS DN TPMPA DMBF6KS TI TT4N6D8 DMBF6KS TN GABA(A) receptor rho3 (GABRR3) DMBF6KS MA Antagonist DMBF6KS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DMBF6KS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DMBF6KS DI DMBF6KS DMBF6KS DN TPMPA DMBF6KS TI TT6XFEU DMBF6KS TN GABA(A) receptor rho1 (GABRR1) DMBF6KS MA Antagonist DMBF6KS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DMBF6KS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DMBFASY DI DMBFASY DMBFASY DN N,N-Diethyl-2-(2-phenyl-1H-indol-3-yl)-acetamide DMBFASY TI TTPTXIN DMBFASY TN Translocator protein (TSPO) DMBFASY MA Inhibitor DMBFASY RN Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20. DMBFASY RU https://pubmed.ncbi.nlm.nih.gov/8411007 DMBFC1U DI DMBFC1U DMBFC1U DN N-desalkylquetiapine DMBFC1U TI TTAWNKZ DMBFC1U TN Norepinephrine transporter (NET) DMBFC1U MA Inhibitor DMBFC1U RN N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant ... Neuropsychopharmacology. 2008 Sep;33(10):2303-12. DMBFC1U RU https://pubmed.ncbi.nlm.nih.gov/18059438 DMBFCKD DI DMBFCKD DMBFCKD DN RO3244794 DMBFCKD TI TTOFYT1 DMBFCKD TN Prostacyclin receptor (PTGIR) DMBFCKD MA Antagonist DMBFCKD RN RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol. 2006 Feb;147(3):335-45. DMBFCKD RU https://pubmed.ncbi.nlm.nih.gov/16331286 DMBFCTZ DI DMBFCTZ DMBFCTZ DN 3h-Indole-5,6-Diol DMBFCTZ TI TTSZDQU DMBFCTZ TN Lactotransferrin (LTF) DMBFCTZ MA Inhibitor DMBFCTZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBFCTZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBFK8A DI DMBFK8A DMBFK8A DN ISIS 1751 DMBFK8A TI TTF3I4E DMBFK8A TN Human papillomavirus E2 region messenger RNA (HPV E2 mRNA) DMBFK8A RN US patent application no. 5,665,580, Antisense oligonucleotide inhibition of papillomavirus transformed cells. DMBFK8A RU http://www.patentbuddy.com/Patent/5665580?ft=true&sr=true DMBFLHD DI DMBFLHD DMBFLHD DN Cbz-Ile-Leu-Ala-LeuVSMe DMBFLHD TI TTF2LRI DMBFLHD TN Cathepsin B (CTSB) DMBFLHD MA Inhibitor DMBFLHD RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMBFLHD RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMBFLHD DI DMBFLHD DMBFLHD DN Cbz-Ile-Leu-Ala-LeuVSMe DMBFLHD TI TTUMQVO DMBFLHD TN Cathepsin S (CTSS) DMBFLHD MA Inhibitor DMBFLHD RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMBFLHD RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMBFLOJ DI DMBFLOJ DMBFLOJ DN LY2365109 DMBFLOJ TI TTHJTF7 DMBFLOJ TN Glycine transporter GlyT-1 (SLC6A9) DMBFLOJ MA Inhibitor DMBFLOJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DMBFLOJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DMBFUD0 DI DMBFUD0 DMBFUD0 DN Ac-R[CEHdFRWC]-NH2 DMBFUD0 TI TTNI91K DMBFUD0 TN Melanocortin receptor 3 (MC3R) DMBFUD0 MA Inhibitor DMBFUD0 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMBFUD0 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMBFUD0 DI DMBFUD0 DMBFUD0 DN Ac-R[CEHdFRWC]-NH2 DMBFUD0 TI TTD0CIQ DMBFUD0 TN Melanocortin receptor 4 (MC4R) DMBFUD0 MA Inhibitor DMBFUD0 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMBFUD0 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMBFUD0 DI DMBFUD0 DMBFUD0 DN Ac-R[CEHdFRWC]-NH2 DMBFUD0 TI TT0MV2T DMBFUD0 TN Melanocortin receptor 1 (MC1R) DMBFUD0 MA Inhibitor DMBFUD0 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMBFUD0 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMBFX5H DI DMBFX5H DMBFX5H DN IDDBCP226234 DMBFX5H TI TT69J2Z DMBFX5H TN Serine/threonine-protein kinase pim-2 (PIM2) DMBFX5H MA Inhibitor DMBFX5H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2159). DMBFX5H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2159 DMBFX7S DI DMBFX7S DMBFX7S DN TgBSSL DMBFX7S TI TTTRNQW DMBFX7S TN Bile-salt-activated lipase (CEL) DMBFX7S MA Modulator DMBFX7S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2872). DMBFX7S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2872 DMBFY4H DI DMBFY4H DMBFY4H DN 3,3,3-tris(4-chlorophenyl)propanoic acid DMBFY4H TI TT6804T DMBFY4H TN MIF messenger RNA (MIF mRNA) DMBFY4H MA Inhibitor DMBFY4H RN Classification of chemical compounds by protein-compound docking for use in designing a focused library. J Med Chem. 2006 Jan 26;49(2):523-33. DMBFY4H RU https://pubmed.ncbi.nlm.nih.gov/16420039 DMBG0H1 DI DMBG0H1 DMBG0H1 DN Sulfonylthioureas DMBG0H1 TI TTG140O DMBG0H1 TN Inward rectifier potassium channel Kir1.2 (KCNJ10) DMBG0H1 MA Blocker DMBG0H1 RN Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98. DMBG0H1 RU https://pubmed.ncbi.nlm.nih.gov/11297455 DMBG0N8 DI DMBG0N8 DMBG0N8 DN 1-benzhydryl-4-methoxy-4-phenylpiperidine DMBG0N8 TI TTNT7K8 DMBG0N8 TN Nociceptin receptor (OPRL1) DMBG0N8 MA Inhibitor DMBG0N8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMBG0N8 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMBG0N8 DI DMBG0N8 DMBG0N8 DN 1-benzhydryl-4-methoxy-4-phenylpiperidine DMBG0N8 TI TTKWM86 DMBG0N8 TN Opioid receptor mu (MOP) DMBG0N8 MA Inhibitor DMBG0N8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMBG0N8 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMBG0N8 DI DMBG0N8 DMBG0N8 DN 1-benzhydryl-4-methoxy-4-phenylpiperidine DMBG0N8 TI TT27RFC DMBG0N8 TN Opioid receptor delta (OPRD1) DMBG0N8 MA Inhibitor DMBG0N8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMBG0N8 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMBG0N8 DI DMBG0N8 DMBG0N8 DN 1-benzhydryl-4-methoxy-4-phenylpiperidine DMBG0N8 TI TTQW87Y DMBG0N8 TN Opioid receptor kappa (OPRK1) DMBG0N8 MA Inhibitor DMBG0N8 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMBG0N8 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMBG3ZF DI DMBG3ZF DMBG3ZF DN N-guanyl-1,7-diaminoheptane DMBG3ZF TI TTBO2A9 DMBG3ZF TN Deoxyhypusine synthase (DHPS) DMBG3ZF MA Inhibitor DMBG3ZF RN Modification of eukaryotic initiation factor 5A from Plasmodium vivax by a truncated deoxyhypusine synthase from Plasmodium falciparum: An enzyme w... Bioorg Med Chem. 2007 Sep 15;15(18):6200-7. DMBG3ZF RU https://pubmed.ncbi.nlm.nih.gov/17591443 DMBG4KN DI DMBG4KN DMBG4KN DN (S)(+)-7-methyl-2-phenylchroman-4-one DMBG4KN TI TTGP7BY DMBG4KN TN Monoamine oxidase type B (MAO-B) DMBG4KN MA Inhibitor DMBG4KN RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMBG4KN RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMBG5Y8 DI DMBG5Y8 DMBG5Y8 DN 6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol DMBG5Y8 TI TTOM3J0 DMBG5Y8 TN Estrogen receptor beta (ESR2) DMBG5Y8 MA Inhibitor DMBG5Y8 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMBG5Y8 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMBG5Y8 DI DMBG5Y8 DMBG5Y8 DN 6-(4-Hydroxy-phenyl)-1-methoxy-naphthalen-2-ol DMBG5Y8 TI TTZAYWL DMBG5Y8 TN Estrogen receptor (ESR) DMBG5Y8 MA Inhibitor DMBG5Y8 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMBG5Y8 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMBG7X1 DI DMBG7X1 DMBG7X1 DN Kaempferol-3-O-methyl ether DMBG7X1 TI TTVG215 DMBG7X1 TN Debrisoquine 4-hydroxylase (CYP2D6) DMBG7X1 MA Inhibitor DMBG7X1 RN Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities. J Nat Prod. 2004 Jul;67(7):1079-83. DMBG7X1 RU https://pubmed.ncbi.nlm.nih.gov/15270556 DMBG9Z3 DI DMBG9Z3 DMBG9Z3 DN 18-methoxycoronaridinate 2-Hydroxyethylamide DMBG9Z3 TI TTTVAFQ DMBG9Z3 TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMBG9Z3 MA Inhibitor DMBG9Z3 RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DMBG9Z3 RU https://pubmed.ncbi.nlm.nih.gov/12801235 DMBGAWI DI DMBGAWI DMBGAWI DN ALTANSERIN DMBGAWI TI TTJQOD7 DMBGAWI TN 5-HT 2A receptor (HTR2A) DMBGAWI MA Inhibitor DMBGAWI RN Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET. Bioorg Med Chem. 2009 Apr 15;17(8):2989-3002. DMBGAWI RU https://pubmed.ncbi.nlm.nih.gov/19329329 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTOZAFI DMBGHPE TN Gap junction delta-2 protein (Cx36) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 724). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=724 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TT7C18W DMBGHPE TN Gap junction delta-3 protein (Cx31.9) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 722). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=722 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTL9MHP DMBGHPE TN Gap junction beta-5 protein (Cx31.1) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 721). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=721 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTHWA40 DMBGHPE TN Connexin-32 (Cx32) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 723). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=723 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTFZRG0 DMBGHPE TN Gap junction alpha-3 protein (Cx46) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 730). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=730 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTZ7POK DMBGHPE TN Connexin-25 (Cx25) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 715). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=715 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTUW608 DMBGHPE TN Gap junction gamma-3 protein (Cx30.2) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 718). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=718 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTYP9NL DMBGHPE TN Connexin-59 (Cx59) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 733). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=733 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTFQKZ7 DMBGHPE TN Gap junction alpha-5 protein (Cx40) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 726). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=726 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTJ7ATH DMBGHPE TN Gap junction alpha-8 protein (Cx50) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 732). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=732 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTBRDFI DMBGHPE TN Gap junction beta-4 protein (Cx30.3) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 719). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=719 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTEP7OC DMBGHPE TN Connexin-45 (Cx45) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 729). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=729 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTQMI2N DMBGHPE TN Connexin-62 (Cx62) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 734). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=734 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTDQPXA DMBGHPE TN Connexin-23 (Cx23) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 714). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=714 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TT4F7SL DMBGHPE TN Gap junction alpha-1 protein (GJA1) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 728). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=728 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTQO1VY DMBGHPE TN Gap junction alpha-4 protein (Cx37) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 725). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=725 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTVRQ8L DMBGHPE TN Gap junction beta-3 protein (Cx31) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 720). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=720 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTRGZX3 DMBGHPE TN Gap junction beta-2 protein (Cx26) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 716). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=716 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTL07NQ DMBGHPE TN Gap junction delta-4 protein (Cx40.1) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 727). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=727 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTAU8SJ DMBGHPE TN Connexin-30 (Cx30) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 717). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=717 DMBGHPE DI DMBGHPE DMBGHPE DN Octanol DMBGHPE TI TTPOCAL DMBGHPE TN Gap junction gamma-2 protein (Cx47) DMBGHPE MA Inhibitor DMBGHPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 731). DMBGHPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=731 DMBGHTW DI DMBGHTW DMBGHTW DN CCNCSSKWCRDHSRCC DMBGHTW TI TT84DRB DMBGHTW TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMBGHTW MA Inhibitor DMBGHTW RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DMBGHTW RU https://pubmed.ncbi.nlm.nih.gov/17724025 DMBGHTW DI DMBGHTW DMBGHTW DN CCNCSSKWCRDHSRCC DMBGHTW TI TTAXZ0K DMBGHTW TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMBGHTW MA Inhibitor DMBGHTW RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DMBGHTW RU https://pubmed.ncbi.nlm.nih.gov/17724025 DMBGHX7 DI DMBGHX7 DMBGHX7 DN AcAsp-Glu-Met-Glu-Nal-Cyse DMBGHX7 TI TTWXB3E DMBGHX7 TN Hepatitis C virus NS3 helicase (HCV NS3) DMBGHX7 MA Inhibitor DMBGHX7 RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMBGHX7 RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMBGIUE DI DMBGIUE DMBGIUE DN N-phenyl-1H-pyrrole-2-carboxamide DMBGIUE TI TT3WG5C DMBGIUE TN Monoamine oxidase type A (MAO-A) DMBGIUE MA Inhibitor DMBGIUE RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMBGIUE RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMBGM1E DI DMBGM1E DMBGM1E DN PSB36 DMBGM1E TI TTK25J1 DMBGM1E TN Adenosine A1 receptor (ADORA1) DMBGM1E MA Antagonist DMBGM1E RN Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther. 2004 Jan;308(1):358-66. DMBGM1E RU https://pubmed.ncbi.nlm.nih.gov/14563788 DMBGM1E DI DMBGM1E DMBGM1E DN PSB36 DMBGM1E TI TTNE7KG DMBGM1E TN Adenosine A2b receptor (ADORA2B) DMBGM1E MA Antagonist DMBGM1E RN Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists. Bioorg Med Chem. 2006 Jun 1;14(11):3654-61. DMBGM1E RU https://pubmed.ncbi.nlm.nih.gov/16458010 DMBGM1E DI DMBGM1E DMBGM1E DN PSB36 DMBGM1E TI TTJFY5U DMBGM1E TN Adenosine A3 receptor (ADORA3) DMBGM1E MA Antagonist DMBGM1E RN Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem. 2006 Aug;1(8):891-902. DMBGM1E RU https://pubmed.ncbi.nlm.nih.gov/16902942 DMBGSHD DI DMBGSHD DMBGSHD DN 3,5-Dinitrocatechol DMBGSHD TI TTKWFB8 DMBGSHD TN Catechol-O-methyl-transferase (COMT) DMBGSHD MA Inhibitor DMBGSHD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBGSHD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBGTX9 DI DMBGTX9 DMBGTX9 DN AA-204 DMBGTX9 TI TTGKF90 DMBGTX9 TN Bone morphogenetic protein receptor (BMPR2) DMBGTX9 MA Agonist DMBGTX9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794). DMBGTX9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794 DMBGVEK DI DMBGVEK DMBGVEK DN 2-(3-Methoxy-phenyl)-6-methyl-chromen-4-one DMBGVEK TI TTNJYV2 DMBGVEK TN Gamma-aminobutyric acid receptor (GAR) DMBGVEK MA Inhibitor DMBGVEK RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMBGVEK RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMBGWEK DI DMBGWEK DMBGWEK DN GEA 3162 DMBGWEK TI TTEBMN7 DMBGWEK TN Long transient receptor potential channel 2 (TRPM2) DMBGWEK MA Activator DMBGWEK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 494). DMBGWEK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=494 DMBH18C DI DMBH18C DMBH18C DN GLP-17-(7-36) derivative DMBH18C TI TTVIMDE DMBH18C TN Glucagon-like peptide 1 receptor (GLP1R) DMBH18C MA Inhibitor DMBH18C RN Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4395-8. DMBH18C RU https://pubmed.ncbi.nlm.nih.gov/15357960 DMBHFIM DI DMBHFIM DMBHFIM DN 2-(4-chloro-2-hydroxyphenoxy)benzenaminium DMBHFIM TI TTNX2CS DMBHFIM TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMBHFIM MA Inhibitor DMBHFIM RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DMBHFIM RU https://pubmed.ncbi.nlm.nih.gov/19217192 DMBHIAK DI DMBHIAK DMBHIAK DN PD-174265 DMBHIAK TI TT6PKBN DMBHIAK TN Proto-oncogene c-Src (SRC) DMBHIAK MA Inhibitor DMBHIAK RN Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J Med Chem. 2009 Jul 9;52(13):3915-26. DMBHIAK RU https://pubmed.ncbi.nlm.nih.gov/19462975 DMBHKAV DI DMBHKAV DMBHKAV DN PHTPP DMBHKAV TI TTOM3J0 DMBHKAV TN Estrogen receptor beta (ESR2) DMBHKAV MA Antagonist DMBHKAV RN Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains. J Med Chem. 2007 Jan 25;50(2):399-403. DMBHKAV RU https://pubmed.ncbi.nlm.nih.gov/17228884 DMBHUKV DI DMBHUKV DMBHUKV DN Methyl L-phenylalaninate DMBHUKV TI TT6L509 DMBHUKV TN Coagulation factor IIa (F2) DMBHUKV MA Inhibitor DMBHUKV RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMBHUKV RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMBHUP3 DI DMBHUP3 DMBHUP3 DN 3-[10-(benzylmethylamino)decyloxy]xanthen-9-one DMBHUP3 TI TTEB0GD DMBHUP3 TN Cholinesterase (BCHE) DMBHUP3 MA Inhibitor DMBHUP3 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMBHUP3 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMBHXTL DI DMBHXTL DMBHXTL DN WAY200070 DMBHXTL TI TTOM3J0 DMBHXTL TN Estrogen receptor beta (ESR2) DMBHXTL MA Agonist DMBHXTL RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMBHXTL RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMBHXTL DI DMBHXTL DMBHXTL DN WAY200070 DMBHXTL TI TTZAYWL DMBHXTL TN Estrogen receptor (ESR) DMBHXTL MA Inhibitor DMBHXTL RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMBHXTL RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMBI2PH DI DMBI2PH DMBI2PH DN ISIS 25563 DMBI2PH TI TTP2U16 DMBI2PH TN RhoA messenger RNA (RHOA mRNA) DMBI2PH RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMBI2PH RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMBI40Y DI DMBI40Y DMBI40Y DN 6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline DMBI40Y TI TTGKNB4 DMBI40Y TN Epidermal growth factor receptor (EGFR) DMBI40Y MA Inhibitor DMBI40Y RN Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. DMBI40Y RU https://pubmed.ncbi.nlm.nih.gov/17869510 DMBI6U9 DI DMBI6U9 DMBI6U9 DN 2-Naphthalen-1-yl-benzooxazol-6-ol DMBI6U9 TI TTOM3J0 DMBI6U9 TN Estrogen receptor beta (ESR2) DMBI6U9 MA Inhibitor DMBI6U9 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMBI6U9 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMBI6U9 DI DMBI6U9 DMBI6U9 DN 2-Naphthalen-1-yl-benzooxazol-6-ol DMBI6U9 TI TTZAYWL DMBI6U9 TN Estrogen receptor (ESR) DMBI6U9 MA Inhibitor DMBI6U9 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMBI6U9 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMBI7MS DI DMBI7MS DMBI7MS DN 4-(3,4-Dimethoxyphenethyl)aniline DMBI7MS TI TTSZLWK DMBI7MS TN Aromatase (CYP19A1) DMBI7MS MA Inhibitor DMBI7MS RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMBI7MS RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMBIAGJ DI DMBIAGJ DMBIAGJ DN 8-Isopropoxy-quinolin-2-ylamine DMBIAGJ TI TTX4RTB DMBIAGJ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBIAGJ MA Inhibitor DMBIAGJ RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMBIAGJ RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMBIF42 DI DMBIF42 DMBIF42 DN SB-568849 DMBIF42 TI TTX4RTB DMBIF42 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBIF42 MA Antagonist DMBIF42 RN Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4872-8. DMBIF42 RU https://pubmed.ncbi.nlm.nih.gov/16839763 DMBIH8A DI DMBIH8A DMBIH8A DN T22 DMBIH8A TI TTBID49 DMBIH8A TN C-X-C chemokine receptor type 4 (CXCR4) DMBIH8A MA Antagonist DMBIH8A RN A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82. DMBIH8A RU https://pubmed.ncbi.nlm.nih.gov/9918823 DMBIK7D DI DMBIK7D DMBIK7D DN PSB-601 DMBIK7D TI TTK25J1 DMBIK7D TN Adenosine A1 receptor (ADORA1) DMBIK7D MA Inhibitor DMBIK7D RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMBIK7D RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMBIK7D DI DMBIK7D DMBIK7D DN PSB-601 DMBIK7D TI TTNE7KG DMBIK7D TN Adenosine A2b receptor (ADORA2B) DMBIK7D MA Inhibitor DMBIK7D RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMBIK7D RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMBIK7D DI DMBIK7D DMBIK7D DN PSB-601 DMBIK7D TI TTM2AOE DMBIK7D TN Adenosine A2a receptor (ADORA2A) DMBIK7D MA Inhibitor DMBIK7D RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMBIK7D RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMBIQV3 DI DMBIQV3 DMBIQV3 DN 4-Carboxycinnamic Acid DMBIQV3 TI TTQO71U DMBIQV3 TN Hemoglobin (HB) DMBIQV3 MA Inhibitor DMBIQV3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMBIQV3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMBIRC6 DI DMBIRC6 DMBIRC6 DN 3,7-BIS(DIMETHYLAMINO)PHENOTHIAZIN-5-IUM DMBIRC6 TI TT1RS9F DMBIRC6 TN Acetylcholinesterase (AChE) DMBIRC6 MA Inhibitor DMBIRC6 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMBIRC6 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMBIV6M DI DMBIV6M DMBIV6M DN (E,E)-5-Hydroxy-1,7-diphenyl-4,6-heptadien-3-one DMBIV6M TI TT50QJ3 DMBIV6M TN Influenza Neuraminidase (Influ NA) DMBIV6M MA Inhibitor DMBIV6M RN Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86. DMBIV6M RU https://pubmed.ncbi.nlm.nih.gov/20014777 DMBIV8F DI DMBIV8F DMBIV8F DN 2-(4-Hydroxy-phenyl)-1-p-tolyl-3H-inden-5-ol DMBIV8F TI TTOM3J0 DMBIV8F TN Estrogen receptor beta (ESR2) DMBIV8F MA Inhibitor DMBIV8F RN Differential response of estrogen receptor subtypes to 1,3-diarylindene and 2,3-diarylindene ligands. J Med Chem. 2005 Sep 22;48(19):5989-6003. DMBIV8F RU https://pubmed.ncbi.nlm.nih.gov/16162002 DMBIY98 DI DMBIY98 DMBIY98 DN 7-(2-Hydroxyethyl)-3-O-rhamnosylicariin DMBIY98 TI TTJ0IQB DMBIY98 TN Phosphodiesterase 5A (PDE5A) DMBIY98 MA Inhibitor DMBIY98 RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DMBIY98 RU https://pubmed.ncbi.nlm.nih.gov/18778098 DMBJ1E0 DI DMBJ1E0 DMBJ1E0 DN Selumetinib DMBJ1E0 TI TTAW3TO DMBJ1E0 TN HUMAN ERK activator kinase 1 (MEK1) DMBJ1E0 MA Inhibitor DMBJ1E0 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMBJ1E0 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMBJ1E0 DI DMBJ1E0 DMBJ1E0 DN Selumetinib DMBJ1E0 TI TTWX403 DMBJ1E0 TN HUMAN ERK activator kinase 2 (MEK2) DMBJ1E0 MA Inhibitor DMBJ1E0 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMBJ1E0 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMBJCGA DI DMBJCGA DMBJCGA DN 1-(4-fluorobenzyl)-1H-imidazole DMBJCGA TI TTRA5BZ DMBJCGA TN Steroid 17-alpha-monooxygenase (S17AH) DMBJCGA MA Inhibitor DMBJCGA RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DMBJCGA RU https://pubmed.ncbi.nlm.nih.gov/16870430 DMBJCGA DI DMBJCGA DMBJCGA DN 1-(4-fluorobenzyl)-1H-imidazole DMBJCGA TI TTIQUX7 DMBJCGA TN Steroid 11-beta-hydroxylase (CYP11B1) DMBJCGA MA Inhibitor DMBJCGA RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMBJCGA RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMBJFH9 DI DMBJFH9 DMBJFH9 DN MNI-135 DMBJFH9 TI TTXJ47W DMBJFH9 TN Metabotropic glutamate receptor 2 (mGluR2) DMBJFH9 MA Modulator (allosteric modulator) DMBJFH9 RN A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64. DMBJFH9 RU https://pubmed.ncbi.nlm.nih.gov/17416742 DMBJFH9 DI DMBJFH9 DMBJFH9 DN MNI-135 DMBJFH9 TI TT8A9EF DMBJFH9 TN Metabotropic glutamate receptor 3 (mGluR3) DMBJFH9 MA Modulator (allosteric modulator) DMBJFH9 RN A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64. DMBJFH9 RU https://pubmed.ncbi.nlm.nih.gov/17416742 DMBJICP DI DMBJICP DMBJICP DN 2-(4-nitro-1H-benzo[d]imidazol-2-yl)quinoxaline DMBJICP TI TTJFY5U DMBJICP TN Adenosine A3 receptor (ADORA3) DMBJICP MA Inhibitor DMBJICP RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DMBJICP RU https://pubmed.ncbi.nlm.nih.gov/16366607 DMBJKH1 DI DMBJKH1 DMBJKH1 DN N-(pyridin-3-ylmethyl) estradiol-16-carboxamide DMBJKH1 TI TTIWB6L DMBJKH1 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMBJKH1 MA Inhibitor DMBJKH1 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMBJKH1 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMBJU2X DI DMBJU2X DMBJU2X DN ISIS 116654 DMBJU2X TI TTQWAU1 DMBJU2X TN GSK3A messenger RNA (GSK3A mRNA) DMBJU2X RN US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression. DMBJU2X RU http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true DMBJUEM DI DMBJUEM DMBJUEM DN ENDOMORPHIN-1 DMBJUEM TI TTKWM86 DMBJUEM TN Opioid receptor mu (MOP) DMBJUEM MA Inhibitor DMBJUEM RN Synthesis and evaluation of new endomorphin analogues modified at the Pro(2) residue. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4115-8. DMBJUEM RU https://pubmed.ncbi.nlm.nih.gov/19560919 DMBJUEM DI DMBJUEM DMBJUEM DN ENDOMORPHIN-1 DMBJUEM TI TTQW87Y DMBJUEM TN Opioid receptor kappa (OPRK1) DMBJUEM MA Inhibitor DMBJUEM RN Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J Med Chem. 2004 Jan 29;47(3):735-43. DMBJUEM RU https://pubmed.ncbi.nlm.nih.gov/14736254 DMBJUEM DI DMBJUEM DMBJUEM DN ENDOMORPHIN-1 DMBJUEM TI TT27RFC DMBJUEM TN Opioid receptor delta (OPRD1) DMBJUEM MA Inhibitor DMBJUEM RN New endomorphin analogues containing alicyclic beta-amino acids: influence on bioactive conformation and pharmacological profile. J Med Chem. 2008 Jul 24;51(14):4270-9. DMBJUEM RU https://pubmed.ncbi.nlm.nih.gov/18572932 DMBJUP5 DI DMBJUP5 DMBJUP5 DN 2-Cyclohexyl-N-phenyl-acetamide DMBJUP5 TI TT7WVHI DMBJUP5 TN Soluble epoxide hydrolase (EPHX2) DMBJUP5 MA Inhibitor DMBJUP5 RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMBJUP5 RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMBJV90 DI DMBJV90 DMBJV90 DN Cyclopentyl-(9-phenyl-9H-purin-6-yl)-amine DMBJV90 TI TTK25J1 DMBJV90 TN Adenosine A1 receptor (ADORA1) DMBJV90 MA Inhibitor DMBJV90 RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMBJV90 RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMBJXCF DI DMBJXCF DMBJXCF DN 2pyrrolidin-1-yl-1-phenylpentan-1-one DMBJXCF TI TTAWNKZ DMBJXCF TN Norepinephrine transporter (NET) DMBJXCF MA Inhibitor DMBJXCF RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBJXCF RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBJXCF DI DMBJXCF DMBJXCF DN 2pyrrolidin-1-yl-1-phenylpentan-1-one DMBJXCF TI TTVBI8W DMBJXCF TN Dopamine transporter (DAT) DMBJXCF MA Inhibitor DMBJXCF RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBJXCF RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBJYTD DI DMBJYTD DMBJYTD DN (3-Amino-propyl)-hexyl-phosphinic acid DMBJYTD TI TTDCVZW DMBJYTD TN Gamma-aminobutyric acid B receptor (GABBR) DMBJYTD MA Inhibitor DMBJYTD RN Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993). DMBJYTD RU http://www.sciencedirect.com/science/article/pii/S0960894X0181218X DMBK2S8 DI DMBK2S8 DMBK2S8 DN Calusterone DMBK2S8 TI TTS64P2 DMBK2S8 TN Androgen receptor (AR) DMBK2S8 MA Inhibitor DMBK2S8 RN MR appearance of intra-abdominal metastatic melanoma. Magn Reson Imaging. 1992;10(4):705-8. DMBK2S8 RU https://pubmed.ncbi.nlm.nih.gov/1501542 DMBK67H DI DMBK67H DMBK67H DN 4-isothiocyanatobenzenesulfonamide DMBK67H TI TTANPDJ DMBK67H TN Carbonic anhydrase II (CA-II) DMBK67H MA Inhibitor DMBK67H RN Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. J Med Chem. 2004 Oct 7;47(21):5224-9. DMBK67H RU https://pubmed.ncbi.nlm.nih.gov/15456265 DMBK67H DI DMBK67H DMBK67H DN 4-isothiocyanatobenzenesulfonamide DMBK67H TI TTHQPL7 DMBK67H TN Carbonic anhydrase I (CA-I) DMBK67H MA Inhibitor DMBK67H RN Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library. J Med Chem. 2004 Oct 7;47(21):5224-9. DMBK67H RU https://pubmed.ncbi.nlm.nih.gov/15456265 DMBK86L DI DMBK86L DMBK86L DN chaetocin DMBK86L TI TTUWQTK DMBK86L TN Lysine N-methyltransferase 1A (SUV39H1) DMBK86L MA Inhibitor DMBK86L RN Chaetocin is a nonspecific inhibitor of histone lysine methyltransferases. Nat Chem Biol. 2013 Mar;9(3):136-7. DMBK86L RU https://pubmed.ncbi.nlm.nih.gov/23416387 DMBK9PS DI DMBK9PS DMBK9PS DN AM-404 DMBK9PS TI TTMSFAW DMBK9PS TN Cannabinoid receptor 2 (CB2) DMBK9PS MA Inhibitor DMBK9PS RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DMBK9PS RU https://pubmed.ncbi.nlm.nih.gov/19053765 DMBK9PS DI DMBK9PS DMBK9PS DN AM-404 DMBK9PS TI TT6OEDT DMBK9PS TN Cannabinoid receptor 1 (CB1) DMBK9PS MA Inhibitor DMBK9PS RN Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem. 1996 Oct 25;39(22):4515-9. DMBK9PS RU https://pubmed.ncbi.nlm.nih.gov/8893848 DMBK9PS DI DMBK9PS DMBK9PS DN AM-404 DMBK9PS TI TTDP1UC DMBK9PS TN Fatty acid amide hydrolase (FAAH) DMBK9PS MA Inhibitor DMBK9PS RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DMBK9PS RU https://pubmed.ncbi.nlm.nih.gov/19053765 DMBKDZ3 DI DMBKDZ3 DMBKDZ3 DN 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol DMBKDZ3 TI TTGA1IV DMBKDZ3 TN Matrix metalloproteinase-8 (MMP-8) DMBKDZ3 MA Inhibitor DMBKDZ3 RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DMBKDZ3 RU https://pubmed.ncbi.nlm.nih.gov/10406637 DMBKDZ3 DI DMBKDZ3 DMBKDZ3 DN 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol DMBKDZ3 TI TTHY57M DMBKDZ3 TN Matrix metalloproteinase-13 (MMP-13) DMBKDZ3 MA Inhibitor DMBKDZ3 RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DMBKDZ3 RU https://pubmed.ncbi.nlm.nih.gov/10406637 DMBKDZ3 DI DMBKDZ3 DMBKDZ3 DN 3-(4-Phenoxy-benzenesulfonyl)-cyclohexanethiol DMBKDZ3 TI TTMX39J DMBKDZ3 TN Matrix metalloproteinase-1 (MMP-1) DMBKDZ3 MA Inhibitor DMBKDZ3 RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DMBKDZ3 RU https://pubmed.ncbi.nlm.nih.gov/10406637 DMBKJL8 DI DMBKJL8 DMBKJL8 DN DIOA DMBKJL8 TI TTH6UZY DMBKJL8 TN Solute carrier family 12 member 5 (SLC12A5) DMBKJL8 MA Inhibitor DMBKJL8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 972). DMBKJL8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=972 DMBKJL8 DI DMBKJL8 DMBKJL8 DN DIOA DMBKJL8 TI TTJ8C67 DMBKJL8 TN Solute carrier family 12 member 4 (SLC12A4) DMBKJL8 MA Inhibitor DMBKJL8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 971). DMBKJL8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=971 DMBKJL8 DI DMBKJL8 DMBKJL8 DN DIOA DMBKJL8 TI TT8DFHE DMBKJL8 TN Solute carrier family 12 member 6 (SLC12A6) DMBKJL8 MA Inhibitor DMBKJL8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 973). DMBKJL8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=973 DMBKJL8 DI DMBKJL8 DMBKJL8 DN DIOA DMBKJL8 TI TTU2PCD DMBKJL8 TN Solute carrier family 12 member 7 (SLC12A7) DMBKJL8 MA Inhibitor DMBKJL8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 974). DMBKJL8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=974 DMBKL5O DI DMBKL5O DMBKL5O DN Tamoxifen butyl bromide DMBKL5O TI TTZAYWL DMBKL5O TN Estrogen receptor (ESR) DMBKL5O MA Inhibitor DMBKL5O RN Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. DMBKL5O RU https://pubmed.ncbi.nlm.nih.gov/20621492 DMBKM30 DI DMBKM30 DMBKM30 DN EX-1311 DMBKM30 TI TTWDC17 DMBKM30 TN Growth hormone secretagogue receptor 1 (GHSR) DMBKM30 MA Antagonist DMBKM30 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246). DMBKM30 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246 DMBKOJG DI DMBKOJG DMBKOJG DN H-Dmt-Tic-Asp-NH-Bzl DMBKOJG TI TTKWM86 DMBKOJG TN Opioid receptor mu (MOP) DMBKOJG MA Inhibitor DMBKOJG RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMBKOJG RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMBKOJG DI DMBKOJG DMBKOJG DN H-Dmt-Tic-Asp-NH-Bzl DMBKOJG TI TT27RFC DMBKOJG TN Opioid receptor delta (OPRD1) DMBKOJG MA Inhibitor DMBKOJG RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMBKOJG RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMBKP48 DI DMBKP48 DMBKP48 DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) DMBKP48 TI TTTQGH8 DMBKP48 TN Histone deacetylase 4 (HDAC4) DMBKP48 MA Inhibitor DMBKP48 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMBKP48 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMBKP48 DI DMBKP48 DMBKP48 DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) DMBKP48 TI TT6R7JZ DMBKP48 TN Histone deacetylase 1 (HDAC1) DMBKP48 MA Inhibitor DMBKP48 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMBKP48 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMBKP48 DI DMBKP48 DMBKP48 DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser-D-Pro-) DMBKP48 TI TT5ZKDI DMBKP48 TN Histone deacetylase 6 (HDAC6) DMBKP48 MA Inhibitor DMBKP48 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMBKP48 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMBKQ03 DI DMBKQ03 DMBKQ03 DN Carpropamid DMBKQ03 TI TT64EPS DMBKQ03 TN Fungal Scytalone dehydratase (Fung SDH1) DMBKQ03 MA Inhibitor DMBKQ03 RN Enzymatic characterization of scytalone dehydratase Val75Met variant found in melanin biosynthesis dehydratase inhibitor (MBI-D) resistant strains of the rice blast fungus. Biosci Biotechnol Biochem.2004 Mar;68(3):615-21. DMBKQ03 RU https://pubmed.ncbi.nlm.nih.gov/15056895 DMBKRQ9 DI DMBKRQ9 DMBKRQ9 DN Cyclo(-D-MeTyr-D-Arg-L-Arg-L-Nal-Gly-) DMBKRQ9 TI TTBID49 DMBKRQ9 TN C-X-C chemokine receptor type 4 (CXCR4) DMBKRQ9 MA Inhibitor DMBKRQ9 RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMBKRQ9 RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMBKTHI DI DMBKTHI DMBKTHI DN Cy3B-telenzepine DMBKTHI TI TTOXS3C DMBKTHI TN Muscarinic acetylcholine receptor (CHRM) DMBKTHI MA Antagonist DMBKTHI RN Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2693-8. DMBKTHI RU https://pubmed.ncbi.nlm.nih.gov/20133736 DMBKU9M DI DMBKU9M DMBKU9M DN Methyl 2-(2-oxo-8-phenyloctanamido)acetate DMBKU9M TI TTT1JVS DMBKU9M TN Cytosolic phospholipase A2 (GIVA cPLA2) DMBKU9M MA Inhibitor DMBKU9M RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMBKU9M RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMBKVJY DI DMBKVJY DMBKVJY DN PMEA DMBKVJY TI TTIU7X1 DMBKVJY TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMBKVJY MA Inhibitor DMBKVJY RN Herpes simplex virus-specified DNA polymerase is the target for the antiviral action of 9-(2-phosphonylmethoxyethyl)adenine. J Biol Chem. 1991 Jan 5;266(1):238-44. DMBKVJY RU https://pubmed.ncbi.nlm.nih.gov/1845964 DMBKVM4 DI DMBKVM4 DMBKVM4 DN 2-chloro-N-(6-cyanopyridin-3-yl)propanamide DMBKVM4 TI TTCJG29 DMBKVM4 TN Serine/threonine-protein kinase mTOR (mTOR) DMBKVM4 MA Inhibitor DMBKVM4 RN Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2949-52. DMBKVM4 RU https://pubmed.ncbi.nlm.nih.gov/19409777 DMBKVN9 DI DMBKVN9 DMBKVN9 DN BX 667 DMBKVN9 TI TTZ1DT0 DMBKVN9 TN P2Y purinoceptor 12 (P2RY12) DMBKVN9 MA Antagonist DMBKVN9 RN Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): pharmacodynamic and pharmacokinetic characterization. Thromb Res. 2008;122(4):533-40. DMBKVN9 RU https://pubmed.ncbi.nlm.nih.gov/18539312 DMBKWUZ DI DMBKWUZ DMBKWUZ DN Tamoxifen isopropyl bromide DMBKWUZ TI TTZAYWL DMBKWUZ TN Estrogen receptor (ESR) DMBKWUZ MA Inhibitor DMBKWUZ RN Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha. Bioorg Med Chem. 2010 Aug 1;18(15):5593-601. DMBKWUZ RU https://pubmed.ncbi.nlm.nih.gov/20621492 DMBKZDJ DI DMBKZDJ DMBKZDJ DN (5-Imino-[1,4]thiazepan-3-yl)-methanol DMBKZDJ TI TTCM4B3 DMBKZDJ TN Nitric-oxide synthase endothelial (NOS3) DMBKZDJ MA Inhibitor DMBKZDJ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMBKZDJ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMBKZDJ DI DMBKZDJ DMBKZDJ DN (5-Imino-[1,4]thiazepan-3-yl)-methanol DMBKZDJ TI TTF10I9 DMBKZDJ TN Nitric-oxide synthase inducible (NOS2) DMBKZDJ MA Inhibitor DMBKZDJ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMBKZDJ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMBKZDJ DI DMBKZDJ DMBKZDJ DN (5-Imino-[1,4]thiazepan-3-yl)-methanol DMBKZDJ TI TTZUFI5 DMBKZDJ TN Nitric-oxide synthase brain (NOS1) DMBKZDJ MA Inhibitor DMBKZDJ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMBKZDJ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMBKZOQ DI DMBKZOQ DMBKZOQ DN ISIS 24475 DMBKZOQ TI TTJMF9P DMBKZOQ TN ITGA4 messenger RNA (ITGA4 mRNA) DMBKZOQ RN US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression. DMBKZOQ RU http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true DMBL2CG DI DMBL2CG DMBL2CG DN ISIS 9003 DMBL2CG TI TTR5TV4 DMBL2CG TN ERBB2 messenger RNA (HER2 mRNA) DMBL2CG RN US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression. DMBL2CG RU http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true DMBL46A DI DMBL46A DMBL46A DN CUDRATRICUSXANTHONE DMBL46A TI TT50QJ3 DMBL46A TN Influenza Neuraminidase (Influ NA) DMBL46A MA Inhibitor DMBL46A RN Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. DMBL46A RU https://pubmed.ncbi.nlm.nih.gov/19285413 DMBL7YN DI DMBL7YN DMBL7YN DN SKA-121 DMBL7YN TI TT7M9I6 DMBL7YN TN Calcium-activated potassium channel KCa3.1 (KCNN4) DMBL7YN MA Activator DMBL7YN RN New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol. 2014 Sep;86(3):342-57. DMBL7YN RU https://pubmed.ncbi.nlm.nih.gov/24958817 DMBLAI1 DI DMBLAI1 DMBLAI1 DN 4-(2,4-diethyl-1H-pyrrol-3-yloxy)benzonitrile DMBLAI1 TI TTUV8G9 DMBLAI1 TN Progesterone receptor (PGR) DMBLAI1 MA Inhibitor DMBLAI1 RN Optimisation of a pyrazole series of progesterone antagonists; Part 1. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3384-6. DMBLAI1 RU https://pubmed.ncbi.nlm.nih.gov/20430618 DMBLAV4 DI DMBLAV4 DMBLAV4 DN PT-108 DMBLAV4 TI TT84ETX DMBLAV4 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBLAV4 MA Inhibitor DMBLAV4 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMBLAV4 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMBLAY1 DI DMBLAY1 DMBLAY1 DN (4S)-4-ammoniopentanoate DMBLAY1 TI TTZA1NY DMBLAY1 TN GABA(A) receptor beta-2 (GABRB2) DMBLAY1 MA Inhibitor DMBLAY1 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMBLAY1 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMBLAY1 DI DMBLAY1 DMBLAY1 DN (4S)-4-ammoniopentanoate DMBLAY1 TI TTNZPQ1 DMBLAY1 TN GABA(A) receptor alpha-5 (GABRA5) DMBLAY1 MA Inhibitor DMBLAY1 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMBLAY1 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMBLAY1 DI DMBLAY1 DMBLAY1 DN (4S)-4-ammoniopentanoate DMBLAY1 TI TT1MPAY DMBLAY1 TN GABA(A) receptor alpha-1 (GABRA1) DMBLAY1 MA Inhibitor DMBLAY1 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMBLAY1 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMBLAY1 DI DMBLAY1 DMBLAY1 DN (4S)-4-ammoniopentanoate DMBLAY1 TI TT06RH5 DMBLAY1 TN GABA(A) receptor gamma-2 (GABRG2) DMBLAY1 MA Inhibitor DMBLAY1 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMBLAY1 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMBLAY1 DI DMBLAY1 DMBLAY1 DN (4S)-4-ammoniopentanoate DMBLAY1 TI TTBMV1G DMBLAY1 TN GABA(A) receptor alpha-2 (GABRA2) DMBLAY1 MA Inhibitor DMBLAY1 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMBLAY1 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMBLAY1 DI DMBLAY1 DMBLAY1 DN (4S)-4-ammoniopentanoate DMBLAY1 TI TTNJYV2 DMBLAY1 TN Gamma-aminobutyric acid receptor (GAR) DMBLAY1 MA Inhibitor DMBLAY1 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMBLAY1 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMBLAY1 DI DMBLAY1 DMBLAY1 DN (4S)-4-ammoniopentanoate DMBLAY1 TI TT37EDJ DMBLAY1 TN GABA(A) receptor alpha-3 (GABRA3) DMBLAY1 MA Inhibitor DMBLAY1 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMBLAY1 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMBLEI7 DI DMBLEI7 DMBLEI7 DN 9H-beta-Carbolin-6-ylamine DMBLEI7 TI TT1MPAY DMBLEI7 TN GABA(A) receptor alpha-1 (GABRA1) DMBLEI7 MA Inhibitor DMBLEI7 RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMBLEI7 RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMBLEI7 DI DMBLEI7 DMBLEI7 DN 9H-beta-Carbolin-6-ylamine DMBLEI7 TI TTNJYV2 DMBLEI7 TN Gamma-aminobutyric acid receptor (GAR) DMBLEI7 MA Inhibitor DMBLEI7 RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMBLEI7 RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMBLGF6 DI DMBLGF6 DMBLGF6 DN (E)-octadecan-9-ynoic acid DMBLGF6 TI TTPADOQ DMBLGF6 TN HMG-CoA reductase (HMGCR) DMBLGF6 MA Inhibitor DMBLGF6 RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DMBLGF6 RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DMBLR73 DI DMBLR73 DMBLR73 DN XGP-510 DMBLR73 TI TTGKOY9 DMBLR73 TN Leukotriene CysLT1 receptor (CYSLTR1) DMBLR73 MA Antagonist DMBLR73 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 269). DMBLR73 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=269 DMBLSX3 DI DMBLSX3 DMBLSX3 DN EPB-415 DMBLSX3 TI TTCAQMW DMBLSX3 TN Inosine-5'-monophosphate dehydrogenase (IMPDH) DMBLSX3 MA Modulator DMBLSX3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2625). DMBLSX3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2625 DMBLUSA DI DMBLUSA DMBLUSA DN MF-152 DMBLUSA TI TT6RIOV DMBLUSA TN Acyl-CoA desaturase (SCD) DMBLUSA MA Inhibitor DMBLUSA RN SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1593-7. DMBLUSA RU https://pubmed.ncbi.nlm.nih.gov/20137926 DMBLW1A DI DMBLW1A DMBLW1A DN Methyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate DMBLW1A TI TTM2AOE DMBLW1A TN Adenosine A2a receptor (ADORA2A) DMBLW1A MA Inhibitor DMBLW1A RN Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1090-3. DMBLW1A RU https://pubmed.ncbi.nlm.nih.gov/20034788 DMBLWMS DI DMBLWMS DMBLWMS DN SMI-4a DMBLWMS TI TTTN5QW DMBLWMS TN Serine/threonine-protein kinase pim-1 (PIM1) DMBLWMS MA Inhibitor DMBLWMS RN Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050. DMBLWMS RU https://pubmed.ncbi.nlm.nih.gov/31114247 DMBLXOG DI DMBLXOG DMBLXOG DN 2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (DIASTEREOMERIC MIX) DMBLXOG TI TTOZRK6 DMBLXOG TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMBLXOG MA Inhibitor DMBLXOG RN 5-Functionalized indazoles as glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 May 15;20(10):3017-20. DMBLXOG RU https://pubmed.ncbi.nlm.nih.gov/20427184 DMBM7HD DI DMBM7HD DMBM7HD DN ISIS 113904 DMBM7HD TI TTIX0ZU DMBM7HD TN MEKK2 messenger RNA (MAP3K2 mRNA) DMBM7HD RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMBM7HD RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMBM7LU DI DMBM7LU DMBM7LU DN PF-0998425 DMBM7LU TI TTKPW01 DMBM7LU TN Androgen receptor messenger RNA (AR mRNA) DMBM7LU MA Inhibitor DMBM7LU RN Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen recepto... J Med Chem. 2008 Nov 13;51(21):7010-4. DMBM7LU RU https://pubmed.ncbi.nlm.nih.gov/18921992 DMBMAKG DI DMBMAKG DMBMAKG DN N-(4-tert-butylthiazol-2-yl)quinolin-5-amine DMBMAKG TI TT7HQD0 DMBMAKG TN C-C chemokine receptor type 4 (CCR4) DMBMAKG MA Inhibitor DMBMAKG RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMBMAKG RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMBMDG7 DI DMBMDG7 DMBMDG7 DN ISIS 109115 DMBMDG7 TI TTQSMFG DMBMDG7 TN Talin messenger RNA (TLN1 mRNA) DMBMDG7 RN US patent application no. 6,372,492, Antisense modulation of talin expression. DMBMDG7 RU http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true DMBMH96 DI DMBMH96 DMBMH96 DN 3-chloro-5-(2-methylquinolin-7-yl)benzonitrile DMBMH96 TI TTHS256 DMBMH96 TN Metabotropic glutamate receptor 5 (mGluR5) DMBMH96 MA Inhibitor DMBMH96 RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMBMH96 RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMBMJC5 DI DMBMJC5 DMBMJC5 DN 4-(2-oxohexadecanamido)butanoic acid DMBMJC5 TI TTT1JVS DMBMJC5 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMBMJC5 MA Inhibitor DMBMJC5 RN Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha. J Med Chem. 2007 Mar 22;50(6):1380-400. DMBMJC5 RU https://pubmed.ncbi.nlm.nih.gov/17305324 DMBMK4T DI DMBMK4T DMBMK4T DN 2-Deoxy-2-Amino Glucitol-6-Phosphate DMBMK4T TI TTC67I0 DMBMK4T TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMBMK4T MA Inhibitor DMBMK4T RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBMK4T RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBMK8S DI DMBMK8S DMBMK8S DN 2-Amino-6-(2-fluoro-benzenesulfonyl)-benzonitrile DMBMK8S TI TT84ETX DMBMK8S TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMBMK8S MA Inhibitor DMBMK8S RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMBMK8S RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMBMKV8 DI DMBMKV8 DMBMKV8 DN Disulfiram DMBMKV8 TI TTYJOLE DMBMKV8 TN MERS-CoV papain-like proteinase (PL-PRO) DMBMKV8 MA Inhibitor DMBMKV8 RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DMBMKV8 RU https://pubmed.ncbi.nlm.nih.gov/32127666 DMBMKV8 DI DMBMKV8 DMBMKV8 DN Disulfiram DMBMKV8 TI TTNHMO8 DMBMKV8 TN COVID-19 papain-like proteinase (PL-PRO) DMBMKV8 MA Inhibitor DMBMKV8 RN Structure of Mpro from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. DMBMKV8 RU https://pubmed.ncbi.nlm.nih.gov/32272481 DMBMKV8 DI DMBMKV8 DMBMKV8 DN Disulfiram DMBMKV8 TI TTRGHB2 DMBMKV8 TN SARS-CoV papain-like proteinase (PL-PRO) DMBMKV8 MA Inhibitor DMBMKV8 RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DMBMKV8 RU https://pubmed.ncbi.nlm.nih.gov/32127666 DMBMQNI DI DMBMQNI DMBMQNI DN ISIS 1931 DMBMQNI TI TTA1L39 DMBMQNI TN ICAM1 messenger RNA (ICAM1 mRNA) DMBMQNI RN US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion. DMBMQNI RU http://www.patentbuddy.com/Patent/6300491?ft=true&sr=true DMBMRUI DI DMBMRUI DMBMRUI DN 6-ethyl-2,4-diisobutylaminopyrimidine DMBMRUI TI TTZAYWL DMBMRUI TN Estrogen receptor (ESR) DMBMRUI MA Inhibitor DMBMRUI RN Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30. DMBMRUI RU https://pubmed.ncbi.nlm.nih.gov/18785725 DMBMS1U DI DMBMS1U DMBMS1U DN [3H]diprenorphine DMBMS1U TI TTQW87Y DMBMS1U TN Opioid receptor kappa (OPRK1) DMBMS1U MA Antagonist DMBMS1U RN kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci U S A.1995 Jul 18;92(15):7006-10. DMBMS1U RU https://pubmed.ncbi.nlm.nih.gov/7624359 DMBMS1U DI DMBMS1U DMBMS1U DN [3H]diprenorphine DMBMS1U TI TT27RFC DMBMS1U TN Opioid receptor delta (OPRD1) DMBMS1U MA Agonist DMBMS1U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMBMS1U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMBMS1U DI DMBMS1U DMBMS1U DN [3H]diprenorphine DMBMS1U TI TTKWM86 DMBMS1U TN Opioid receptor mu (MOP) DMBMS1U MA Antagonist DMBMS1U RN Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994 Feb;45(2):330-4. DMBMS1U RU https://pubmed.ncbi.nlm.nih.gov/8114680 DMBMTGP DI DMBMTGP DMBMTGP DN ISIS 9064 DMBMTGP TI TT5TURO DMBMTGP TN A-Raf messenger RNA (ARAF mRNA) DMBMTGP RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DMBMTGP RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DMBMY73 DI DMBMY73 DMBMY73 DN Ac-YR[CEHdFRWC]-NH2 DMBMY73 TI TTNI91K DMBMY73 TN Melanocortin receptor 3 (MC3R) DMBMY73 MA Inhibitor DMBMY73 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMBMY73 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMBMY73 DI DMBMY73 DMBMY73 DN Ac-YR[CEHdFRWC]-NH2 DMBMY73 TI TTD0CIQ DMBMY73 TN Melanocortin receptor 4 (MC4R) DMBMY73 MA Inhibitor DMBMY73 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMBMY73 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMBMY73 DI DMBMY73 DMBMY73 DN Ac-YR[CEHdFRWC]-NH2 DMBMY73 TI TT0MV2T DMBMY73 TN Melanocortin receptor 1 (MC1R) DMBMY73 MA Inhibitor DMBMY73 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMBMY73 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TTLBY21 DMBMYKQ TN Proto-oncogene c-Fes (FES) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TT3KYWB DMBMYKQ TN Ribosomal protein S6 kinase alpha-6 (RSK6) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TT0ZW9O DMBMYKQ TN Ribosomal protein S6 kinase alpha-2 (RSK2) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TT9ABMF DMBMYKQ TN Serine/threonine-protein kinase Chk2 (RAD53) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TT65FL0 DMBMYKQ TN Omphalocele kinase 1 (NUAK1) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TTUM2ZR DMBMYKQ TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TTRA9G0 DMBMYKQ TN Proto-oncogene c-Fer (FER) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBMYKQ DI DMBMYKQ DMBMYKQ DN PMID22564207C25b DMBMYKQ TI TTPMQSO DMBMYKQ TN ALK tyrosine kinase receptor (ALK) DMBMYKQ MA Inhibitor DMBMYKQ RN Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem. 2012 May 24;55(10):4580-93. DMBMYKQ RU https://pubmed.ncbi.nlm.nih.gov/22564207 DMBN3WE DI DMBN3WE DMBN3WE DN (+/-)-7-methyl-2-p-tolylchroman-4-one DMBN3WE TI TTGP7BY DMBN3WE TN Monoamine oxidase type B (MAO-B) DMBN3WE MA Inhibitor DMBN3WE RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMBN3WE RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMBN4G6 DI DMBN4G6 DMBN4G6 DN 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl DMBN4G6 TI TTS7G69 DMBN4G6 TN Fusion protein Bcr-Abl (Bcr-Abl) DMBN4G6 MA Inhibitor DMBN4G6 RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMBN4G6 RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMBN4G6 DI DMBN4G6 DMBN4G6 DN 4,3'',5''-trimethoxy-[1,1':2',1'']-terphenyl DMBN4G6 TI TT3OT40 DMBN4G6 TN Multidrug resistance protein 1 (ABCB1) DMBN4G6 MA Inhibitor DMBN4G6 RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMBN4G6 RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMBN4V6 DI DMBN4V6 DMBN4V6 DN PLSQETFSDLWKLLPEN-NH2 DMBN4V6 TI TT9TE0O DMBN4V6 TN Mdm2 messenger RNA (MDM2 mRNA) DMBN4V6 MA Inhibitor DMBN4V6 RN Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006 Jun 15;49(12):3432-5. DMBN4V6 RU https://pubmed.ncbi.nlm.nih.gov/16759082 DMBN6IE DI DMBN6IE DMBN6IE DN ADS-103274 DMBN6IE TI TT0K1SC DMBN6IE TN 5-HT 2B receptor (HTR2B) DMBN6IE MA Inhibitor DMBN6IE RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMBN6IE RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMBN6IE DI DMBN6IE DMBN6IE DN ADS-103274 DMBN6IE TI TTX4RTB DMBN6IE TN Melanin-concentrating hormone receptor 1 (MCHR1) DMBN6IE MA Inhibitor DMBN6IE RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMBN6IE RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMBN7UX DI DMBN7UX DMBN7UX DN XB-387 DMBN7UX TI TTI7421 DMBN7UX TN Platelet-derived growth factor receptor beta (PDGFRB) DMBN7UX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1804). DMBN7UX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1804 DMBNA0V DI DMBNA0V DMBNA0V DN 3-desoxy-3-carboxamidonaltrexone DMBNA0V TI TT27RFC DMBNA0V TN Opioid receptor delta (OPRD1) DMBNA0V MA Inhibitor DMBNA0V RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMBNA0V RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMBNA0V DI DMBNA0V DMBNA0V DN 3-desoxy-3-carboxamidonaltrexone DMBNA0V TI TTQW87Y DMBNA0V TN Opioid receptor kappa (OPRK1) DMBNA0V MA Inhibitor DMBNA0V RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMBNA0V RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMBNA0V DI DMBNA0V DMBNA0V DN 3-desoxy-3-carboxamidonaltrexone DMBNA0V TI TTKWM86 DMBNA0V TN Opioid receptor mu (MOP) DMBNA0V MA Inhibitor DMBNA0V RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMBNA0V RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMBNDYK DI DMBNDYK DMBNDYK DN AVP-13748 DMBNDYK TI TT2AST1 DMBNDYK TN Macrophage migration inhibitory factor (MIF) DMBNDYK MA Inhibitor DMBNDYK RN MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9. DMBNDYK RU https://pubmed.ncbi.nlm.nih.gov/18721909 DMBNFQ8 DI DMBNFQ8 DMBNFQ8 DN D-lactic acid DMBNFQ8 TI TTVK4ZO DMBNFQ8 TN G protein coupled receptor 81 (HCAR1) DMBNFQ8 MA Agonist DMBNFQ8 RN Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem Biophys Res Commun. 2008 Dec 19;377(3):987-91. DMBNFQ8 RU https://pubmed.ncbi.nlm.nih.gov/18952058 DMBNJ2L DI DMBNJ2L DMBNJ2L DN N-(6-methylpyridin-2-yl)biphenyl-3-carboxamide DMBNJ2L TI TTHS256 DMBNJ2L TN Metabotropic glutamate receptor 5 (mGluR5) DMBNJ2L MA Inhibitor DMBNJ2L RN Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75. DMBNJ2L RU https://pubmed.ncbi.nlm.nih.gov/19445453 DMBNJZ0 DI DMBNJZ0 DMBNJZ0 DN Cyclo-[-Arg-Gly-Asp-Amp27-] DMBNJZ0 TI TTJA1ZO DMBNJZ0 TN ITGB3 messenger RNA (ITGB3 mRNA) DMBNJZ0 MA Inhibitor DMBNJZ0 RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMBNJZ0 RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMBNJZ0 DI DMBNJZ0 DMBNJZ0 DN Cyclo-[-Arg-Gly-Asp-Amp27-] DMBNJZ0 TI TTT1R2L DMBNJZ0 TN Integrin alpha-V (ITGAV) DMBNJZ0 MA Inhibitor DMBNJZ0 RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMBNJZ0 RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMBNM85 DI DMBNM85 DMBNM85 DN Y-c[D-Pen-(2S,3R)-2-Me-(2')Nal-GSFC]KR-NH2 DMBNM85 TI TT6PKBN DMBNM85 TN Proto-oncogene c-Src (SRC) DMBNM85 MA Inhibitor DMBNM85 RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DMBNM85 RU https://pubmed.ncbi.nlm.nih.gov/9632358 DMBNYJW DI DMBNYJW DMBNYJW DN TEI-8362 DMBNYJW TI TTPLTSQ DMBNYJW TN Neutrophil elastase (NE) DMBNYJW MA Inhibitor DMBNYJW RN Neutrophil elastase inhibitors as treatment for COPD. Expert Opin Investig Drugs. 2002 Jul;11(7):965-80. DMBNYJW RU https://pubmed.ncbi.nlm.nih.gov/12084007 DMBNZKH DI DMBNZKH DMBNZKH DN 1-(2-Naphthyl)-2-aminopropane DMBNZKH TI TT3WG5C DMBNZKH TN Monoamine oxidase type A (MAO-A) DMBNZKH MA Inhibitor DMBNZKH RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMBNZKH RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMBO0WI DI DMBO0WI DMBO0WI DN Burnamine-17-O-3',4',5'-trimethoxybenzoate DMBO0WI TI TT2UE56 DMBO0WI TN Sodium/glucose cotransporter 1 (SGLT1) DMBO0WI MA Inhibitor DMBO0WI RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMBO0WI RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMBO0WI DI DMBO0WI DMBO0WI DN Burnamine-17-O-3',4',5'-trimethoxybenzoate DMBO0WI TI TTF8JAT DMBO0WI TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMBO0WI MA Inhibitor DMBO0WI RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMBO0WI RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMBO2DC DI DMBO2DC DMBO2DC DN 2MeSAMP DMBO2DC TI TT1FE3L DMBO2DC TN P2Y purinoceptor 13 (P2RY13) DMBO2DC MA Antagonist DMBO2DC RN Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. DMBO2DC RU https://pubmed.ncbi.nlm.nih.gov/12815166 DMBO2DC DI DMBO2DC DMBO2DC DN 2MeSAMP DMBO2DC TI TTZ1DT0 DMBO2DC TN P2Y purinoceptor 12 (P2RY12) DMBO2DC MA Antagonist DMBO2DC RN Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9. DMBO2DC RU https://pubmed.ncbi.nlm.nih.gov/11502873 DMBO3YT DI DMBO3YT DMBO3YT DN ISIS 114371 DMBO3YT TI TT8OY02 DMBO3YT TN ARA70 messenger RNA (NCOA4 mRNA) DMBO3YT RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DMBO3YT RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DMBO9J3 DI DMBO9J3 DMBO9J3 DN (-)-huperzine B DMBO9J3 TI TT1RS9F DMBO9J3 TN Acetylcholinesterase (AChE) DMBO9J3 MA Inhibitor DMBO9J3 RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DMBO9J3 RU https://pubmed.ncbi.nlm.nih.gov/18479118 DMBOE1U DI DMBOE1U DMBOE1U DN FV-Tic-TDVGPFAF DMBOE1U TI TTY6O0Q DMBOE1U TN Calcitonin gene-related peptide receptor (CGRPR) DMBOE1U MA Inhibitor DMBOE1U RN Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24. DMBOE1U RU https://pubmed.ncbi.nlm.nih.gov/16420047 DMBOKSF DI DMBOKSF DMBOKSF DN Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester DMBOKSF TI TTT6LFV DMBOKSF TN Histone deacetylase 8 (HDAC8) DMBOKSF MA Inhibitor DMBOKSF RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMBOKSF RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMBOKSF DI DMBOKSF DMBOKSF DN Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester DMBOKSF TI TT5ZKDI DMBOKSF TN Histone deacetylase 6 (HDAC6) DMBOKSF MA Inhibitor DMBOKSF RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMBOKSF RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMBOKSF DI DMBOKSF DMBOKSF DN Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester DMBOKSF TI TT6R7JZ DMBOKSF TN Histone deacetylase 1 (HDAC1) DMBOKSF MA Inhibitor DMBOKSF RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMBOKSF RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMBOKSF DI DMBOKSF DMBOKSF DN Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester DMBOKSF TI TTTQGH8 DMBOKSF TN Histone deacetylase 4 (HDAC4) DMBOKSF MA Inhibitor DMBOKSF RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMBOKSF RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMBOKSF DI DMBOKSF DMBOKSF DN Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester DMBOKSF TI TTBH0VX DMBOKSF TN Histone deacetylase (HDAC) DMBOKSF MA Inhibitor DMBOKSF RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMBOKSF RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMBOKSF DI DMBOKSF DMBOKSF DN Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester DMBOKSF TI TTSHTOI DMBOKSF TN Histone deacetylase 2 (HDAC2) DMBOKSF MA Inhibitor DMBOKSF RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMBOKSF RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMBOKSF DI DMBOKSF DMBOKSF DN Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester DMBOKSF TI TTYHPU6 DMBOKSF TN Histone deacetylase 10 (HDAC10) DMBOKSF MA Inhibitor DMBOKSF RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMBOKSF RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMBOMZE DI DMBOMZE DMBOMZE DN 5-Methoxy-4,9-dihydro-3H-beta-carboline DMBOMZE TI TT3WG5C DMBOMZE TN Monoamine oxidase type A (MAO-A) DMBOMZE MA Inhibitor DMBOMZE RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMBOMZE RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMBOMZE DI DMBOMZE DMBOMZE DN 5-Methoxy-4,9-dihydro-3H-beta-carboline DMBOMZE TI TTGP7BY DMBOMZE TN Monoamine oxidase type B (MAO-B) DMBOMZE MA Inhibitor DMBOMZE RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMBOMZE RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMBOMZE DI DMBOMZE DMBOMZE DN 5-Methoxy-4,9-dihydro-3H-beta-carboline DMBOMZE TI TTJQOD7 DMBOMZE TN 5-HT 2A receptor (HTR2A) DMBOMZE MA Inhibitor DMBOMZE RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMBOMZE RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMBONUV DI DMBONUV DMBONUV DN 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol DMBONUV TI TTZAYWL DMBONUV TN Estrogen receptor (ESR) DMBONUV MA Inhibitor DMBONUV RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMBONUV RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMBONUV DI DMBONUV DMBONUV DN 2-(3-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol DMBONUV TI TTOM3J0 DMBONUV TN Estrogen receptor beta (ESR2) DMBONUV MA Inhibitor DMBONUV RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMBONUV RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMBOQ6M DI DMBOQ6M DMBOQ6M DN INDUS-815B DMBOQ6M TI TTSLUMT DMBOQ6M TN Protein kinase D (PRKD1) DMBOQ6M MA Modulator DMBOQ6M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1489). DMBOQ6M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1489 DMBOSGN DI DMBOSGN DMBOSGN DN RWJ-49968 DMBOSGN TI TTJVCG0 DMBOSGN TN Bacterial Sporulation kinase A (Bact kinA) DMBOSGN MA Inhibitor DMBOSGN RN Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. DMBOSGN RU https://pubmed.ncbi.nlm.nih.gov/16964330 DMBOU16 DI DMBOU16 DMBOU16 DN ISIS 110065 DMBOU16 TI TTK1V5Q DMBOU16 TN Nucleolin messenger RNA (NCL mRNA) DMBOU16 RN US patent application no. 6,165,786, Antisense modulation of nucleolin expression. DMBOU16 RU http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true DMBP1TQ DI DMBP1TQ DMBP1TQ DN 2-(2-(2-chlorophenoxy)phenyl)acetic acid DMBP1TQ TI TTCTE1G DMBP1TQ TN Interleukin-8 (IL8) DMBP1TQ MA Inhibitor DMBP1TQ RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DMBP1TQ RU https://pubmed.ncbi.nlm.nih.gov/19560921 DMBP3O7 DI DMBP3O7 DMBP3O7 DN PMID17723296C18 DMBP3O7 TI TTHS256 DMBP3O7 TN Metabotropic glutamate receptor 5 (mGluR5) DMBP3O7 MA Modulator (allosteric modulator) DMBP3O7 RN Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9. DMBP3O7 RU https://pubmed.ncbi.nlm.nih.gov/17723296 DMBP5L4 DI DMBP5L4 DMBP5L4 DN Acetic acid 2,6-diisopropyl-phenyl ester DMBP5L4 TI TTNJYV2 DMBP5L4 TN Gamma-aminobutyric acid receptor (GAR) DMBP5L4 MA Inhibitor DMBP5L4 RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DMBP5L4 RU https://pubmed.ncbi.nlm.nih.gov/9599235 DMBPC0K DI DMBPC0K DMBPC0K DN N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP DMBPC0K TI TT1RS9F DMBPC0K TN Acetylcholinesterase (AChE) DMBPC0K MA Inhibitor DMBPC0K RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMBPC0K RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMBPC0K DI DMBPC0K DMBPC0K DN N,N'-(1',5'-pentylene)-bis-(-)-nor-MEP DMBPC0K TI TTEB0GD DMBPC0K TN Cholinesterase (BCHE) DMBPC0K MA Inhibitor DMBPC0K RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMBPC0K RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMBPL3J DI DMBPL3J DMBPL3J DN (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone DMBPL3J TI TT6L509 DMBPL3J TN Coagulation factor IIa (F2) DMBPL3J MA Inhibitor DMBPL3J RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMBPL3J RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMBPL3J DI DMBPL3J DMBPL3J DN (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone DMBPL3J TI TTPLTSQ DMBPL3J TN Neutrophil elastase (NE) DMBPL3J MA Inhibitor DMBPL3J RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMBPL3J RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMBPL3J DI DMBPL3J DMBPL3J DN (4-nitro-1H-pyrazol-1-yl)(o-tolyl)methanone DMBPL3J TI TTGY7WI DMBPL3J TN Urokinase-type plasminogen activator (PLAU) DMBPL3J MA Inhibitor DMBPL3J RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMBPL3J RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMBPVSD DI DMBPVSD DMBPVSD DN [Mpa1, D-Tyr(Et)2, Aib7, D-Tic9]OT DMBPVSD TI TTSCIUP DMBPVSD TN Oxytocin receptor (OTR) DMBPVSD MA Inhibitor DMBPVSD RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMBPVSD RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMBPWSJ DI DMBPWSJ DMBPWSJ DN L-747201 DMBPWSJ TI TTK8CXU DMBPWSJ TN 5-HT 1B receptor (HTR1B) DMBPWSJ MA Inhibitor DMBPWSJ RN Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1997 Oct 24;40(22):3501-3. DMBPWSJ RU https://pubmed.ncbi.nlm.nih.gov/9357515 DMBPWSJ DI DMBPWSJ DMBPWSJ DN L-747201 DMBPWSJ TI TT6MSOK DMBPWSJ TN 5-HT 1D receptor (HTR1D) DMBPWSJ MA Inhibitor DMBPWSJ RN Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem. 1997 Oct 24;40(22):3501-3. DMBPWSJ RU https://pubmed.ncbi.nlm.nih.gov/9357515 DMBQ0PR DI DMBQ0PR DMBQ0PR DN (R)-2-(4-Isobutyl-phenyl)-propionamide DMBQ0PR TI TT30C9G DMBQ0PR TN C-X-C chemokine receptor type 2 (CXCR2) DMBQ0PR MA Inhibitor DMBQ0PR RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMBQ0PR RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMBQ0PR DI DMBQ0PR DMBQ0PR DN (R)-2-(4-Isobutyl-phenyl)-propionamide DMBQ0PR TI TTMWT8Z DMBQ0PR TN C-X-C chemokine receptor type 1 (CXCR1) DMBQ0PR MA Inhibitor DMBQ0PR RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMBQ0PR RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMBQ0TY DI DMBQ0TY DMBQ0TY DN N,N-bis(cyanomethyl)-3,4-dimethoxybenzamide DMBQ0TY TI TTPLTSQ DMBQ0TY TN Neutrophil elastase (NE) DMBQ0TY MA Inhibitor DMBQ0TY RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMBQ0TY RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMBQ16F DI DMBQ16F DMBQ16F DN SC-50998 DMBQ16F TI TTCG0AL DMBQ16F TN Cholecystokinin receptor type A (CCKAR) DMBQ16F MA Antagonist DMBQ16F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 76). DMBQ16F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=76 DMBQ1VO DI DMBQ1VO DMBQ1VO DN Cudraxanthone D DMBQ1VO TI TT50QJ3 DMBQ1VO TN Influenza Neuraminidase (Influ NA) DMBQ1VO MA Inhibitor DMBQ1VO RN Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. DMBQ1VO RU https://pubmed.ncbi.nlm.nih.gov/19285413 DMBQ3HV DI DMBQ3HV DMBQ3HV DN 6-Imidazol-1-ylmethyl-8-phenyl-quinoline DMBQ3HV TI TTZ97H5 DMBQ3HV TN Phosphodiesterase 4A (PDE4A) DMBQ3HV MA Inhibitor DMBQ3HV RN Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3. DMBQ3HV RU https://pubmed.ncbi.nlm.nih.gov/11052785 DMBQ5HV DI DMBQ5HV DMBQ5HV DN 5-benzhydryl-1,3,4-thiadiazole-2(3H)-thione DMBQ5HV TI TTULVH8 DMBQ5HV TN Tyrosinase (TYR) DMBQ5HV MA Inhibitor DMBQ5HV RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMBQ5HV RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMBQ5NS DI DMBQ5NS DMBQ5NS DN N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide DMBQ5NS TI TTDZN01 DMBQ5NS TN Cathepsin K (CTSK) DMBQ5NS MA Inhibitor DMBQ5NS RN Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J Med Chem. 2006 Feb 9;49(3):1066-79. DMBQ5NS RU https://pubmed.ncbi.nlm.nih.gov/16451072 DMBQAKO DI DMBQAKO DMBQAKO DN PMID20471253C32 DMBQAKO TI TTDWFCQ DMBQAKO TN Protein kinase G2 (PRKG2) DMBQAKO MA Inhibitor DMBQAKO RN Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9. DMBQAKO RU https://pubmed.ncbi.nlm.nih.gov/20471253 DMBQAKO DI DMBQAKO DMBQAKO DN PMID20471253C32 DMBQAKO TI TTGWKQJ DMBQAKO TN Rho-associated protein kinase 2 (ROCK2) DMBQAKO MA Inhibitor DMBQAKO RN Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9. DMBQAKO RU https://pubmed.ncbi.nlm.nih.gov/20471253 DMBQAKO DI DMBQAKO DMBQAKO DN PMID20471253C32 DMBQAKO TI TTTHO0M DMBQAKO TN Protein kinase N2 (PKN2) DMBQAKO MA Inhibitor DMBQAKO RN Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3746-9. DMBQAKO RU https://pubmed.ncbi.nlm.nih.gov/20471253 DMBQCMU DI DMBQCMU DMBQCMU DN EI1 DMBQCMU TI TT9MZCQ DMBQCMU TN Enhancer of zeste homolog 2 (EZH2) DMBQCMU MA Inhibitor DMBQCMU RN Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21360-5. DMBQCMU RU https://pubmed.ncbi.nlm.nih.gov/23236167 DMBQIEF DI DMBQIEF DMBQIEF DN BX-517 DMBQIEF TI TTWTSCV DMBQIEF TN RAC-alpha serine/threonine-protein kinase (AKT1) DMBQIEF MA Inhibitor DMBQIEF RN Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. DMBQIEF RU https://pubmed.ncbi.nlm.nih.gov/17531483 DMBQIEF DI DMBQIEF DMBQIEF DN BX-517 DMBQIEF TI TTYMGWX DMBQIEF TN PDK-1 messenger RNA (PDK-1 mRNA) DMBQIEF MA Inhibitor DMBQIEF RN Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. DMBQIEF RU https://pubmed.ncbi.nlm.nih.gov/17531483 DMBQKGY DI DMBQKGY DMBQKGY DN 6-(piperidin-4-ylmethoxy)-2-naphthonitrile DMBQKGY TI TTAWNKZ DMBQKGY TN Norepinephrine transporter (NET) DMBQKGY MA Inhibitor DMBQKGY RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMBQKGY RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMBQKGY DI DMBQKGY DMBQKGY DN 6-(piperidin-4-ylmethoxy)-2-naphthonitrile DMBQKGY TI TTVBI8W DMBQKGY TN Dopamine transporter (DAT) DMBQKGY MA Inhibitor DMBQKGY RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMBQKGY RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMBQKGY DI DMBQKGY DMBQKGY DN 6-(piperidin-4-ylmethoxy)-2-naphthonitrile DMBQKGY TI TT3ROYC DMBQKGY TN Serotonin transporter (SERT) DMBQKGY MA Inhibitor DMBQKGY RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMBQKGY RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMBQLAI DI DMBQLAI DMBQLAI DN 9-Isopropyl-9H-adenine DMBQLAI TI TTK25J1 DMBQLAI TN Adenosine A1 receptor (ADORA1) DMBQLAI MA Inhibitor DMBQLAI RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMBQLAI RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMBQLAI DI DMBQLAI DMBQLAI DN 9-Isopropyl-9H-adenine DMBQLAI TI TTNE7KG DMBQLAI TN Adenosine A2b receptor (ADORA2B) DMBQLAI MA Inhibitor DMBQLAI RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMBQLAI RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMBQLAI DI DMBQLAI DMBQLAI DN 9-Isopropyl-9H-adenine DMBQLAI TI TTM2AOE DMBQLAI TN Adenosine A2a receptor (ADORA2A) DMBQLAI MA Inhibitor DMBQLAI RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMBQLAI RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TTEYTKG DMBQMGH TN Carbonic anhydrase XIV (CA-XIV) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TTCFSPE DMBQMGH TN Carbonic anhydrase VI (CA-VI) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TT2LVK8 DMBQMGH TN Carbonic anhydrase IX (CA-IX) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TTSYM0R DMBQMGH TN Carbonic anhydrase XII (CA-XII) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TTANPDJ DMBQMGH TN Carbonic anhydrase II (CA-II) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TTUNARX DMBQMGH TN Carbonic anhydrase (CA) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TTZHA0O DMBQMGH TN Carbonic anhydrase IV (CA-IV) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQMGH DI DMBQMGH DMBQMGH DN Octane-1,8-diyl disulfamate DMBQMGH TI TTHQPL7 DMBQMGH TN Carbonic anhydrase I (CA-I) DMBQMGH MA Inhibitor DMBQMGH RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMBQMGH RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMBQRA8 DI DMBQRA8 DMBQRA8 DN NVX-207 DMBQRA8 TI TTB6T7O DMBQRA8 TN Caspase-9 (CASP9) DMBQRA8 MA Modulator DMBQRA8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1625). DMBQRA8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1625 DMBQS31 DI DMBQS31 DMBQS31 DN 5-Methyl-oxazolidin-(2Z)-ylideneamine DMBQS31 TI TTF10I9 DMBQS31 TN Nitric-oxide synthase inducible (NOS2) DMBQS31 MA Inhibitor DMBQS31 RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMBQS31 RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMBQS31 DI DMBQS31 DMBQS31 DN 5-Methyl-oxazolidin-(2Z)-ylideneamine DMBQS31 TI TTZUFI5 DMBQS31 TN Nitric-oxide synthase brain (NOS1) DMBQS31 MA Inhibitor DMBQS31 RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMBQS31 RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMBQTZG DI DMBQTZG DMBQTZG DN CP-70949 DMBQTZG TI TTRSMW9 DMBQTZG TN Glycogen synthase kinase-3 beta (GSK-3B) DMBQTZG MA Inhibitor DMBQTZG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030). DMBQTZG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030 DMBQTZL DI DMBQTZL DMBQTZL DN (E)-12-Nitrooctadec-12-enoic Acid DMBQTZL TI TTJ584C DMBQTZL TN Peroxisome proliferator-activated receptor alpha (PPARA) DMBQTZL MA Inhibitor DMBQTZL RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMBQTZL RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMBQTZL DI DMBQTZL DMBQTZL DN (E)-12-Nitrooctadec-12-enoic Acid DMBQTZL TI TTT2SVW DMBQTZL TN PPAR-gamma messenger RNA (PPARG mRNA) DMBQTZL MA Inhibitor DMBQTZL RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMBQTZL RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMBQY3C DI DMBQY3C DMBQY3C DN Inhibitor Idd 384 DMBQY3C TI TTFBNVI DMBQY3C TN Aldose reductase (AKR1B1) DMBQY3C MA Inhibitor DMBQY3C RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBQY3C RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBQZ2H DI DMBQZ2H DMBQZ2H DN [3H]rauwolscine DMBQZ2H TI TTWM4TY DMBQZ2H TN Adrenergic receptor alpha-2B (ADRA2B) DMBQZ2H MA Antagonist DMBQZ2H RN Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. 1992 Jul;42(1):1-5. DMBQZ2H RU https://pubmed.ncbi.nlm.nih.gov/1353247 DMBQZ2H DI DMBQZ2H DMBQZ2H DN [3H]rauwolscine DMBQZ2H TI TT2NUT5 DMBQZ2H TN Adrenergic receptor alpha-2C (ADRA2C) DMBQZ2H MA Antagonist DMBQZ2H RN Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning. Mol Pharmacol. 1992 Jul;42(1):1-5. DMBQZ2H RU https://pubmed.ncbi.nlm.nih.gov/1353247 DMBQZ2H DI DMBQZ2H DMBQZ2H DN [3H]rauwolscine DMBQZ2H TI TT0K1SC DMBQZ2H TN 5-HT 2B receptor (HTR2B) DMBQZ2H MA Antagonist DMBQZ2H RN [3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24. DMBQZ2H RU https://pubmed.ncbi.nlm.nih.gov/9459568 DMBQZ2H DI DMBQZ2H DMBQZ2H DN [3H]rauwolscine DMBQZ2H TI TTQ8AFT DMBQZ2H TN Adrenergic receptor Alpha-2 (ADRA2) DMBQZ2H MA Antagonist DMBQZ2H RN Characterization of alpha-adrenoceptor subtypes in smooth muscle of equine ileum. Am J Vet Res. 2001 Sep;62(9):1370-4. DMBQZ2H RU https://pubmed.ncbi.nlm.nih.gov/11560262 DMBR1JS DI DMBR1JS DMBR1JS DN (S,S)-(-)-bis(10)-hupyridone DMBR1JS TI TT1RS9F DMBR1JS TN Acetylcholinesterase (AChE) DMBR1JS MA Inhibitor DMBR1JS RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DMBR1JS RU https://pubmed.ncbi.nlm.nih.gov/18479118 DMBR1MX DI DMBR1MX DMBR1MX DN N'-(2-phenylallyl)hydrazine hydrochloride DMBR1MX TI TT3WG5C DMBR1MX TN Monoamine oxidase type A (MAO-A) DMBR1MX MA Inhibitor DMBR1MX RN Design, synthesis, and biological evaluation of semicarbazide-sensitive amine oxidase (SSAO) inhibitors with anti-inflammatory activity. J Med Chem. 2006 Apr 6;49(7):2166-73. DMBR1MX RU https://pubmed.ncbi.nlm.nih.gov/16570912 DMBR7A6 DI DMBR7A6 DMBR7A6 DN PMID30247903-Compound-General structure9 DMBR7A6 TI TT8ZLTI DMBR7A6 TN Programmed cell death 1 ligand 1 (PD-L1) DMBR7A6 MA Inhibitor DMBR7A6 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMBR7A6 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMBR7O0 DI DMBR7O0 DMBR7O0 DN SALVINORIN B DMBR7O0 TI TTQW87Y DMBR7O0 TN Opioid receptor kappa (OPRK1) DMBR7O0 MA Inhibitor DMBR7O0 RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMBR7O0 RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMBR8P1 DI DMBR8P1 DMBR8P1 DN Isopropylcarbamic Acid Biphenyl-3-yl Ester DMBR8P1 TI TTDP1UC DMBR8P1 TN Fatty acid amide hydrolase (FAAH) DMBR8P1 MA Inhibitor DMBR8P1 RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMBR8P1 RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMBR9TQ DI DMBR9TQ DMBR9TQ DN 1-(4-chlorobenzyl)-1H-imidazole DMBR9TQ TI TTRA5BZ DMBR9TQ TN Steroid 17-alpha-monooxygenase (S17AH) DMBR9TQ MA Inhibitor DMBR9TQ RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DMBR9TQ RU https://pubmed.ncbi.nlm.nih.gov/16870430 DMBRAV5 DI DMBRAV5 DMBRAV5 DN Adamantan-2-yl-piperidin-1-yl-methanone DMBRAV5 TI TTN7BL9 DMBRAV5 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMBRAV5 MA Inhibitor DMBRAV5 RN Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43. DMBRAV5 RU https://pubmed.ncbi.nlm.nih.gov/17350260 DMBRETS DI DMBRETS DMBRETS DN 2-(4-methoxyphenyl)quinoline-8-carboxamide DMBRETS TI TTVDSZ0 DMBRETS TN Poly [ADP-ribose] polymerase 1 (PARP1) DMBRETS MA Inhibitor DMBRETS RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMBRETS RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMBRH0Q DI DMBRH0Q DMBRH0Q DN PMID7629799C2e DMBRH0Q TI TTFQEO5 DMBRH0Q TN Squalene synthetase (FDFT1) DMBRH0Q MA Inhibitor DMBRH0Q RN 1,1-Bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate. J Med Chem. 1995 Jul 7;38(14):2596-605. DMBRH0Q RU https://pubmed.ncbi.nlm.nih.gov/7629799 DMBRJ3C DI DMBRJ3C DMBRJ3C DN JNJ-10329670 DMBRJ3C TI TTUMQVO DMBRJ3C TN Cathepsin S (CTSS) DMBRJ3C MA Inhibitor DMBRJ3C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DMBRJ3C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DMBRJ5S DI DMBRJ5S DMBRJ5S DN 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine DMBRJ5S TI TTZFYLI DMBRJ5S TN Dopamine D1 receptor (D1R) DMBRJ5S MA Inhibitor DMBRJ5S RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMBRJ5S RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMBRJ5S DI DMBRJ5S DMBRJ5S DN 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine DMBRJ5S TI TTE0A2F DMBRJ5S TN Dopamine D4 receptor (D4R) DMBRJ5S MA Inhibitor DMBRJ5S RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMBRJ5S RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMBRJ5S DI DMBRJ5S DMBRJ5S DN 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine DMBRJ5S TI TTEX248 DMBRJ5S TN Dopamine D2 receptor (D2R) DMBRJ5S MA Inhibitor DMBRJ5S RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMBRJ5S RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMBRJ5S DI DMBRJ5S DMBRJ5S DN 1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine DMBRJ5S TI TT4C8EA DMBRJ5S TN Dopamine D3 receptor (D3R) DMBRJ5S MA Inhibitor DMBRJ5S RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMBRJ5S RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMBRKFC DI DMBRKFC DMBRKFC DN ISIS 16009 DMBRKFC TI TTRE6AX DMBRKFC TN Bcl-x messenger RNA (BCL2L1 mRNA) DMBRKFC RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMBRKFC RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMBRS3D DI DMBRS3D DMBRS3D DN 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine DMBRS3D TI TTAWNKZ DMBRS3D TN Norepinephrine transporter (NET) DMBRS3D MA Inhibitor DMBRS3D RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMBRS3D RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMBRS3D DI DMBRS3D DMBRS3D DN 1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine DMBRS3D TI TT3ROYC DMBRS3D TN Serotonin transporter (SERT) DMBRS3D MA Inhibitor DMBRS3D RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMBRS3D RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMBRVXY DI DMBRVXY DMBRVXY DN SR144528 DMBRVXY TI TTMSFAW DMBRVXY TN Cannabinoid receptor 2 (CB2) DMBRVXY MA Antagonist DMBRVXY RN Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol. 2001 May 11;419(2-3):191-8. DMBRVXY RU https://pubmed.ncbi.nlm.nih.gov/11426841 DMBRZ4P DI DMBRZ4P DMBRZ4P DN BLV-0703 DMBRZ4P TI TTS87KH DMBRZ4P TN Microtubule-associated protein tau (MAPT) DMBRZ4P MA Modulator DMBRZ4P RN Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. DMBRZ4P RU https://pubmed.ncbi.nlm.nih.gov/21902667 DMBS61O DI DMBS61O DMBS61O DN 4-methoxynaphthalen-1-amine DMBS61O TI TTZJYKH DMBS61O TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMBS61O MA Inhibitor DMBS61O RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMBS61O RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMBS8N9 DI DMBS8N9 DMBS8N9 DN BAS-0338876 DMBS8N9 TI TT3PJMV DMBS8N9 TN Tyrosine-protein kinase ABL1 (ABL) DMBS8N9 MA Inhibitor DMBS8N9 RN Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11. DMBS8N9 RU https://pubmed.ncbi.nlm.nih.gov/18078752 DMBS90M DI DMBS90M DMBS90M DN 1-(1,2,4-Oxadiazol-5-yl)-7-phenylheptan-1-one DMBS90M TI TTDP1UC DMBS90M TN Fatty acid amide hydrolase (FAAH) DMBS90M MA Inhibitor DMBS90M RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMBS90M RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMBSDIV DI DMBSDIV DMBSDIV DN 2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine DMBSDIV TI TTK25J1 DMBSDIV TN Adenosine A1 receptor (ADORA1) DMBSDIV MA Inhibitor DMBSDIV RN 2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem. 2006 Dec 14;49(25):7373-83. DMBSDIV RU https://pubmed.ncbi.nlm.nih.gov/17149867 DMBSDIV DI DMBSDIV DMBSDIV DN 2-azido-N6-methyl-9-(beta-D-ribofuranosyl)adenine DMBSDIV TI TTJFY5U DMBSDIV TN Adenosine A3 receptor (ADORA3) DMBSDIV MA Inhibitor DMBSDIV RN 2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists. J Med Chem. 2006 Dec 14;49(25):7373-83. DMBSDIV RU https://pubmed.ncbi.nlm.nih.gov/17149867 DMBSDTR DI DMBSDTR DMBSDTR DN APG-2305 DMBSDTR TI TT6H4QR DMBSDTR TN Interleukin 23 receptor (IL23R) DMBSDTR MA Inhibitor DMBSDTR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293). DMBSDTR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293 DMBSFDE DI DMBSFDE DMBSFDE DN LY-282210 DMBSFDE TI TTVJX54 DMBSFDE TN Leukotriene B4 receptor 2 (LTB4R2) DMBSFDE MA Inhibitor DMBSFDE RN Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4. DMBSFDE RU https://pubmed.ncbi.nlm.nih.gov/8254628 DMBSFDE DI DMBSFDE DMBSFDE DN LY-282210 DMBSFDE TI TTN53ZF DMBSFDE TN Leukotriene B4 receptor 1 (LTB4R) DMBSFDE MA Inhibitor DMBSFDE RN Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists. J Med Chem. 1993 Nov 26;36(24):3982-4. DMBSFDE RU https://pubmed.ncbi.nlm.nih.gov/8254628 DMBSFLW DI DMBSFLW DMBSFLW DN 5-((6-Methylpyridin-2-yl)ethynyl)nicotinonitrile DMBSFLW TI TTHS256 DMBSFLW TN Metabotropic glutamate receptor 5 (mGluR5) DMBSFLW MA Inhibitor DMBSFLW RN Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35. DMBSFLW RU https://pubmed.ncbi.nlm.nih.gov/20382541 DMBSH5L DI DMBSH5L DMBSH5L DN (+/-)-Daedalin A DMBSH5L TI TTULVH8 DMBSH5L TN Tyrosinase (TYR) DMBSH5L MA Inhibitor DMBSH5L RN Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1063-4. DMBSH5L RU https://pubmed.ncbi.nlm.nih.gov/20036119 DMBSQTR DI DMBSQTR DMBSQTR DN Borrelidin DMBSQTR TI TT75YK4 DMBSQTR TN Saccharomyces Cell division control protein 28 (Saccha CDC28) DMBSQTR MA Inhibitor DMBSQTR RN Borrelidin inhibits a cyclin-dependent kinase (CDK), Cdc28/Cln2, of Saccharomyces cerevisiae. J Antibiot (Tokyo). 2001 Jan;54(1):84-90. DMBSQTR RU https://pubmed.ncbi.nlm.nih.gov/11269718 DMBT1KS DI DMBT1KS DMBT1KS DN 7-(4-methoxyphenyl)-2-methylquinoline DMBT1KS TI TTHS256 DMBT1KS TN Metabotropic glutamate receptor 5 (mGluR5) DMBT1KS MA Inhibitor DMBT1KS RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMBT1KS RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMBT2HW DI DMBT2HW DMBT2HW DN N6-[4-(4-methylphenoxy)phenyl]-L-homoglutamine DMBT2HW TI TTXZEAJ DMBT2HW TN Leukotriene A-4 hydrolase (LTA4H) DMBT2HW MA Inhibitor DMBT2HW RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMBT2HW RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMBT2ZW DI DMBT2ZW DMBT2ZW DN cmp5 DMBT2ZW TI TTR1D7X DMBT2ZW TN Protein arginine methyltransferase 5 (PRMT5) DMBT2ZW MA Inhibitor DMBT2ZW RN Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood. 2015 Apr 16;125(16):2530-43. DMBT2ZW RU https://pubmed.ncbi.nlm.nih.gov/25742700 DMBT92F DI DMBT92F DMBT92F DN PMID23232060C5 DMBT92F TI TTPB1W3 DMBT92F TN TRAF2 and NCK interacting kinase (TNIK) DMBT92F MA Inhibitor DMBT92F RN Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors. Bioorg Med Chem Lett. 2013 Jan 15;23(2):569-73. DMBT92F RU https://pubmed.ncbi.nlm.nih.gov/23232060 DMBTC23 DI DMBTC23 DMBTC23 DN Br-5MPEPy DMBTC23 TI TTHS256 DMBTC23 TN Metabotropic glutamate receptor 5 (mGluR5) DMBTC23 MA Modulator (allosteric modulator) DMBTC23 RN A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtyp... Mol Pharmacol. 2005 Dec;68(6):1793-802. DMBTC23 RU https://pubmed.ncbi.nlm.nih.gov/16155210 DMBTDZL DI DMBTDZL DMBTDZL DN 3-Phenyl-pyrrolidine DMBTDZL TI TTEX248 DMBTDZL TN Dopamine D2 receptor (D2R) DMBTDZL MA Inhibitor DMBTDZL RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMBTDZL RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMBTLIJ DI DMBTLIJ DMBTLIJ DN 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE DMBTLIJ TI TT6L509 DMBTLIJ TN Coagulation factor IIa (F2) DMBTLIJ MA Inhibitor DMBTLIJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMBTLIJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMBTMDG DI DMBTMDG DMBTMDG DN (Z)-1,1,1-Trifluoro-nonadec-10-en-2-one DMBTMDG TI TTDP1UC DMBTMDG TN Fatty acid amide hydrolase (FAAH) DMBTMDG MA Inhibitor DMBTMDG RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DMBTMDG RU https://pubmed.ncbi.nlm.nih.gov/15771430 DMBTMN5 DI DMBTMN5 DMBTMN5 DN Sophoraflavanone G DMBTMN5 TI TTF8JAT DMBTMN5 TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMBTMN5 MA Inhibitor DMBTMN5 RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMBTMN5 RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMBTMN5 DI DMBTMN5 DMBTMN5 DN Sophoraflavanone G DMBTMN5 TI TT2UE56 DMBTMN5 TN Sodium/glucose cotransporter 1 (SGLT1) DMBTMN5 MA Inhibitor DMBTMN5 RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMBTMN5 RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMBTMO9 DI DMBTMO9 DMBTMO9 DN BMS-645737 DMBTMO9 TI TTUTJGQ DMBTMO9 TN Vascular endothelial growth factor receptor 2 (KDR) DMBTMO9 MA Inhibitor DMBTMO9 RN Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]t... Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9. DMBTMO9 RU https://pubmed.ncbi.nlm.nih.gov/18395443 DMBTMO9 DI DMBTMO9 DMBTMO9 DN BMS-645737 DMBTMO9 TI TTQ6VDM DMBTMO9 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMBTMO9 MA Inhibitor DMBTMO9 RN Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]t... Bioorg Med Chem Lett. 2008 May 1;18(9):2985-9. DMBTMO9 RU https://pubmed.ncbi.nlm.nih.gov/18395443 DMBTPDL DI DMBTPDL DMBTPDL DN MS453 DMBTPDL TI TTGC95K DMBTPDL TN SET domain containing 8 (KMT5A) DMBTPDL MA Inhibitor DMBTPDL RN Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase. J Med Chem. 2016 Nov 10;59(21):9881-9889. DMBTPDL RU https://pubmed.ncbi.nlm.nih.gov/27804297 DMBTRHG DI DMBTRHG DMBTRHG DN KNI-10106 DMBTRHG TI TTXMNHO DMBTRHG TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMBTRHG MA Inhibitor DMBTRHG RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMBTRHG RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMBTRN6 DI DMBTRN6 DMBTRN6 DN [2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine DMBTRN6 TI TTJS8PY DMBTRN6 TN 5-HT 6 receptor (HTR6) DMBTRN6 MA Inhibitor DMBTRN6 RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DMBTRN6 RU https://pubmed.ncbi.nlm.nih.gov/15808453 DMBTU7G DI DMBTU7G DMBTU7G DN Cypate-[(RGD)2-NH2]1 DMBTU7G TI TTJA1ZO DMBTU7G TN ITGB3 messenger RNA (ITGB3 mRNA) DMBTU7G MA Inhibitor DMBTU7G RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMBTU7G RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMBTU7G DI DMBTU7G DMBTU7G DN Cypate-[(RGD)2-NH2]1 DMBTU7G TI TTT1R2L DMBTU7G TN Integrin alpha-V (ITGAV) DMBTU7G MA Inhibitor DMBTU7G RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMBTU7G RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMBTV20 DI DMBTV20 DMBTV20 DN PMID19899765C22 DMBTV20 TI TTQ9RYT DMBTV20 TN Endothelin-converting enzyme 1 (ECE1) DMBTV20 MA Inhibitor DMBTV20 RN Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem. 2010 Jan 14;53(1):208-20. DMBTV20 RU https://pubmed.ncbi.nlm.nih.gov/19899765 DMBTWF0 DI DMBTWF0 DMBTWF0 DN IW-1221 DMBTWF0 TI TTQDMX5 DMBTWF0 TN Prostaglandin D2 receptor 2 (PTGDR2) DMBTWF0 MA Inhibitor DMBTWF0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339). DMBTWF0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339 DMBU0XJ DI DMBU0XJ DMBU0XJ DN PMID19433355C11s DMBU0XJ TI TTVBPDM DMBU0XJ TN Metabotropic glutamate receptor 1 (mGluR1) DMBU0XJ MA Modulator (allosteric modulator) DMBU0XJ RN Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3199-203. DMBU0XJ RU https://pubmed.ncbi.nlm.nih.gov/19433355 DMBU4KJ DI DMBU4KJ DMBU4KJ DN Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH DMBU4KJ TI TT27RFC DMBU4KJ TN Opioid receptor delta (OPRD1) DMBU4KJ MA Inhibitor DMBU4KJ RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMBU4KJ RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMBU4KJ DI DMBU4KJ DMBU4KJ DN Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH DMBU4KJ TI TTQW87Y DMBU4KJ TN Opioid receptor kappa (OPRK1) DMBU4KJ MA Inhibitor DMBU4KJ RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMBU4KJ RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMBU4KJ DI DMBU4KJ DMBU4KJ DN Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH DMBU4KJ TI TTKWM86 DMBU4KJ TN Opioid receptor mu (MOP) DMBU4KJ MA Inhibitor DMBU4KJ RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMBU4KJ RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMBU796 DI DMBU796 DMBU796 DN 1,7,8,9-tetrahydro-1,5-diaza-trindene-4,6-dione DMBU796 TI TTVDSZ0 DMBU796 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMBU796 MA Inhibitor DMBU796 RN Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42. DMBU796 RU https://pubmed.ncbi.nlm.nih.gov/16290935 DMBU942 DI DMBU942 DMBU942 DN AP-7 DMBU942 TI TTLD29N DMBU942 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMBU942 MA Inhibitor DMBU942 RN Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6. DMBU942 RU https://pubmed.ncbi.nlm.nih.gov/1361582 DMBU942 DI DMBU942 DMBU942 DN AP-7 DMBU942 TI TTN9D8E DMBU942 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMBU942 MA Inhibitor DMBU942 RN Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6. DMBU942 RU https://pubmed.ncbi.nlm.nih.gov/1361582 DMBU942 DI DMBU942 DMBU942 DN AP-7 DMBU942 TI TTKJEMQ DMBU942 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMBU942 MA Inhibitor DMBU942 RN Bioisosteric replacement of the alpha-amino carboxylic acid functionality in 2-amino-5-phosphonopentanoic acid yields unique 3,4-diamino-3-cyclobut... J Med Chem. 1992 Dec 11;35(25):4720-6. DMBU942 RU https://pubmed.ncbi.nlm.nih.gov/1361582 DMBU9E4 DI DMBU9E4 DMBU9E4 DN PMID19456099C13 DMBU9E4 TI TTFQEO5 DMBU9E4 TN Squalene synthetase (FDFT1) DMBU9E4 MA Inhibitor DMBU9E4 RN Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem. 2009 Jul 9;52(13):3869-80. DMBU9E4 RU https://pubmed.ncbi.nlm.nih.gov/19456099 DMBUD1M DI DMBUD1M DMBUD1M DN S-25585 DMBUD1M TI TTY6EWA DMBUD1M TN Neuropeptide Y receptor type 5 (NPY5R) DMBUD1M MA Antagonist DMBUD1M RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DMBUD1M RU https://pubmed.ncbi.nlm.nih.gov/16634704 DMBUD1M DI DMBUD1M DMBUD1M DN S-25585 DMBUD1M TI TTRK9JT DMBUD1M TN Neuropeptide Y receptor type 1 (NPY1R) DMBUD1M MA Antagonist DMBUD1M RN Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36. DMBUD1M RU https://pubmed.ncbi.nlm.nih.gov/16634704 DMBUH02 DI DMBUH02 DMBUH02 DN DRP-049 DMBUH02 TI TTP4520 DMBUH02 TN TGF-beta receptor type I (TGFBR1) DMBUH02 MA Inhibitor DMBUH02 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788). DMBUH02 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788 DMBULX4 DI DMBULX4 DMBULX4 DN Ethylene diamine DMBULX4 TI TT4ILYC DMBULX4 TN Bacterial Dihydropteroate synthetase (Bact folP) DMBULX4 MA Inhibitor DMBULX4 RN Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8. DMBULX4 RU https://pubmed.ncbi.nlm.nih.gov/17691942 DMBUMDG DI DMBUMDG DMBUMDG DN 1-(4-Cyanobenzyl)-5-bromo-1H-imidazole DMBUMDG TI TTIQUX7 DMBUMDG TN Steroid 11-beta-hydroxylase (CYP11B1) DMBUMDG MA Inhibitor DMBUMDG RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMBUMDG RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMBUNAP DI DMBUNAP DMBUNAP DN N-hydroxy-7-(naphthalen-2-yloxy)heptanamide DMBUNAP TI TT6R7JZ DMBUNAP TN Histone deacetylase 1 (HDAC1) DMBUNAP MA Inhibitor DMBUNAP RN Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41. DMBUNAP RU https://pubmed.ncbi.nlm.nih.gov/17046252 DMBUT8A DI DMBUT8A DMBUT8A DN 3,4-dibenzyloxy-2'-hydroxychalcone DMBUT8A TI TTVKILB DMBUT8A TN Prostaglandin G/H synthase 2 (COX-2) DMBUT8A MA Inhibitor DMBUT8A RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DMBUT8A RU https://pubmed.ncbi.nlm.nih.gov/19233646 DMBUTFN DI DMBUTFN DMBUTFN DN ISIS 102458 DMBUTFN TI TT5U49F DMBUTFN TN PRKACA messenger RNA (PRKACA mRNA) DMBUTFN RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMBUTFN RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMBUZ75 DI DMBUZ75 DMBUZ75 DN 4-tert-butyl-N-(naphthalen-1-yl)thiazol-2-amine DMBUZ75 TI TT7HQD0 DMBUZ75 TN C-C chemokine receptor type 4 (CCR4) DMBUZ75 MA Inhibitor DMBUZ75 RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMBUZ75 RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMBUZWQ DI DMBUZWQ DMBUZWQ DN 3alpha-(bis-chloro-phenylmethoxy)tropane DMBUZWQ TI TT3ROYC DMBUZWQ TN Serotonin transporter (SERT) DMBUZWQ MA Inhibitor DMBUZWQ RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DMBUZWQ RU https://pubmed.ncbi.nlm.nih.gov/17034144 DMBUZWQ DI DMBUZWQ DMBUZWQ DN 3alpha-(bis-chloro-phenylmethoxy)tropane DMBUZWQ TI TTZ9SOR DMBUZWQ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMBUZWQ MA Inhibitor DMBUZWQ RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DMBUZWQ RU https://pubmed.ncbi.nlm.nih.gov/17034144 DMBUZWQ DI DMBUZWQ DMBUZWQ DN 3alpha-(bis-chloro-phenylmethoxy)tropane DMBUZWQ TI TTVBI8W DMBUZWQ TN Dopamine transporter (DAT) DMBUZWQ MA Inhibitor DMBUZWQ RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DMBUZWQ RU https://pubmed.ncbi.nlm.nih.gov/17034144 DMBUZWQ DI DMBUZWQ DMBUZWQ DN 3alpha-(bis-chloro-phenylmethoxy)tropane DMBUZWQ TI TTAWNKZ DMBUZWQ TN Norepinephrine transporter (NET) DMBUZWQ MA Inhibitor DMBUZWQ RN Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9. DMBUZWQ RU https://pubmed.ncbi.nlm.nih.gov/17034144 DMBV19T DI DMBV19T DMBV19T DN diphenylamine-2-carboxylic acid DMBV19T TI TT30NW6 DMBV19T TN Chloride channel protein 2 (CLC-2) DMBV19T MA Blocker (channel blocker) DMBV19T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 699). DMBV19T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=699 DMBV19T DI DMBV19T DMBV19T DN diphenylamine-2-carboxylic acid DMBV19T TI TTST1AJ DMBV19T TN Chloride channel protein 7 (ClC-7) DMBV19T MA Blocker (channel blocker) DMBV19T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 709). DMBV19T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=709 DMBV79R DI DMBV79R DMBV79R DN CRTX-070 DMBV79R TI TTH18TF DMBV79R TN Muscarinic acetylcholine receptor M5 (CHRM5) DMBV79R MA Modulator DMBV79R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMBV79R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMBV8PT DI DMBV8PT DMBV8PT DN 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBV8PT TI TTVBI8W DMBV8PT TN Dopamine transporter (DAT) DMBV8PT MA Inhibitor DMBV8PT RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBV8PT RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBV8PT DI DMBV8PT DMBV8PT DN 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBV8PT TI TT3ROYC DMBV8PT TN Serotonin transporter (SERT) DMBV8PT MA Inhibitor DMBV8PT RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBV8PT RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBV8PT DI DMBV8PT DMBV8PT DN 1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBV8PT TI TTAWNKZ DMBV8PT TN Norepinephrine transporter (NET) DMBV8PT MA Inhibitor DMBV8PT RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBV8PT RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBVCLY DI DMBVCLY DMBVCLY DN 3-chloro-N-(4-(phenyldiazenyl)phenyl)benzamide DMBVCLY TI TTEAID7 DMBVCLY TN Trypanosoma Cruzipain (Trypano CYSP) DMBVCLY MA Inhibitor DMBVCLY RN Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51. DMBVCLY RU https://pubmed.ncbi.nlm.nih.gov/19908840 DMBVDY5 DI DMBVDY5 DMBVDY5 DN [2-(Imidazol-2-yl-thio)ethyl]-bisphosphonic acid DMBVDY5 TI TTIKWV4 DMBVDY5 TN Geranyltranstransferase (FDPS) DMBVDY5 MA Inhibitor DMBVDY5 RN Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7. DMBVDY5 RU https://pubmed.ncbi.nlm.nih.gov/18937434 DMBVFKR DI DMBVFKR DMBVFKR DN 8-aza-DADMe-ImmH DMBVFKR TI TTMCF1Y DMBVFKR TN Purine nucleoside phosphorylase (PNP) DMBVFKR MA Inhibitor DMBVFKR RN Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem. 2003 Aug 22;278(34):31465-8. DMBVFKR RU https://pubmed.ncbi.nlm.nih.gov/12842889 DMBVGAO DI DMBVGAO DMBVGAO DN 2-aminophenoxazine-3-one DMBVGAO TI TTF0RCZ DMBVGAO TN Apoptosis mediating surface antigen FAS (FAS) DMBVGAO MA Activator DMBVGAO RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMBVGAO RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMBVGAO DI DMBVGAO DMBVGAO DN 2-aminophenoxazine-3-one DMBVGAO TI TTZY5KP DMBVGAO TN Caspase (CASP) DMBVGAO MA Activator DMBVGAO RN Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197. DMBVGAO RU https://pubmed.ncbi.nlm.nih.gov/32389641 DMBVHLT DI DMBVHLT DMBVHLT DN ACP-106 DMBVHLT TI TTJQOD7 DMBVHLT TN 5-HT 2A receptor (HTR2A) DMBVHLT MA Agonist DMBVHLT RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMBVHLT RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMBVIKY DI DMBVIKY DMBVIKY DN Cilostamide DMBVIKY TI TTZCG4L DMBVIKY TN Phosphodiesterase 3 (PDE3) DMBVIKY MA Inhibitor DMBVIKY RN Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular gland. Anticancer Drugs. 2001 Jan;12(1):79-83. DMBVIKY RU https://pubmed.ncbi.nlm.nih.gov/11272291 DMBVLCQ DI DMBVLCQ DMBVLCQ DN RWJ-3981 DMBVLCQ TI TTICX3S DMBVLCQ TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMBVLCQ MA Inhibitor DMBVLCQ RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMBVLCQ RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMBVQI4 DI DMBVQI4 DMBVQI4 DN Sodium N-methylphenylaminomethanesulfonate DMBVQI4 TI TT2LVK8 DMBVQI4 TN Carbonic anhydrase IX (CA-IX) DMBVQI4 MA Inhibitor DMBVQI4 RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMBVQI4 RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMBVQI4 DI DMBVQI4 DMBVQI4 DN Sodium N-methylphenylaminomethanesulfonate DMBVQI4 TI TTSYM0R DMBVQI4 TN Carbonic anhydrase XII (CA-XII) DMBVQI4 MA Inhibitor DMBVQI4 RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMBVQI4 RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMBVSKZ DI DMBVSKZ DMBVSKZ DN Erythribyssin D DMBVSKZ TI TT50QJ3 DMBVSKZ TN Influenza Neuraminidase (Influ NA) DMBVSKZ MA Inhibitor DMBVSKZ RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMBVSKZ RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMBVYQR DI DMBVYQR DMBVYQR DN TCS2314 DMBVYQR TI TT6S84X DMBVYQR TN Integrin alpha-4/beta-1 (ITGA4/B1) DMBVYQR MA Inhibitor DMBVYQR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2580). DMBVYQR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2580 DMBW5DU DI DMBW5DU DMBW5DU DN homoquinolinic acid DMBW5DU TI TTKJEMQ DMBW5DU TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMBW5DU MA Agonist DMBW5DU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMBW5DU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMBW5DU DI DMBW5DU DMBW5DU DN homoquinolinic acid DMBW5DU TI TTN9D8E DMBW5DU TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMBW5DU MA Agonist DMBW5DU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMBW5DU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMBW5DU DI DMBW5DU DMBW5DU DN homoquinolinic acid DMBW5DU TI TT5POTG DMBW5DU TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMBW5DU MA Agonist DMBW5DU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMBW5DU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMBW5DU DI DMBW5DU DMBW5DU DN homoquinolinic acid DMBW5DU TI TTLD29N DMBW5DU TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMBW5DU MA Agonist DMBW5DU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMBW5DU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMBW5DU DI DMBW5DU DMBW5DU DN homoquinolinic acid DMBW5DU TI TT1M8OW DMBW5DU TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMBW5DU MA Agonist DMBW5DU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMBW5DU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMBW6GA DI DMBW6GA DMBW6GA DN 2-Propyl-beta-carboline-2-ium iodide DMBW6GA TI TTEB0GD DMBW6GA TN Cholinesterase (BCHE) DMBW6GA MA Inhibitor DMBW6GA RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DMBW6GA RU https://pubmed.ncbi.nlm.nih.gov/20361801 DMBW6GA DI DMBW6GA DMBW6GA DN 2-Propyl-beta-carboline-2-ium iodide DMBW6GA TI TT1RS9F DMBW6GA TN Acetylcholinesterase (AChE) DMBW6GA MA Inhibitor DMBW6GA RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DMBW6GA RU https://pubmed.ncbi.nlm.nih.gov/20361801 DMBW752 DI DMBW752 DMBW752 DN N-(2,6-diphenylpyrimidin-4-yl)benzamide DMBW752 TI TTJFY5U DMBW752 TN Adenosine A3 receptor (ADORA3) DMBW752 MA Inhibitor DMBW752 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMBW752 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMBW752 DI DMBW752 DMBW752 DN N-(2,6-diphenylpyrimidin-4-yl)benzamide DMBW752 TI TTK25J1 DMBW752 TN Adenosine A1 receptor (ADORA1) DMBW752 MA Inhibitor DMBW752 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMBW752 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMBW7PX DI DMBW7PX DMBW7PX DN Benzaldehyde O-4-(octyloxy)phenylcarbamoyl oxime DMBW7PX TI TTDP1UC DMBW7PX TN Fatty acid amide hydrolase (FAAH) DMBW7PX MA Inhibitor DMBW7PX RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMBW7PX RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMBWAIE DI DMBWAIE DMBWAIE DN [3H]dimethyl-W84 DMBWAIE TI TTOXS3C DMBWAIE TN Muscarinic acetylcholine receptor (CHRM) DMBWAIE MA Modulator (allosteric modulator) DMBWAIE RN Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003 Jul;64(1):180-90. DMBWAIE RU https://pubmed.ncbi.nlm.nih.gov/12815174 DMBWAMR DI DMBWAMR DMBWAMR DN 9H-beta-Carbolin-3-ol DMBWAMR TI TTNJYV2 DMBWAMR TN Gamma-aminobutyric acid receptor (GAR) DMBWAMR MA Inhibitor DMBWAMR RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMBWAMR RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMBWAMR DI DMBWAMR DMBWAMR DN 9H-beta-Carbolin-3-ol DMBWAMR TI TT1MPAY DMBWAMR TN GABA(A) receptor alpha-1 (GABRA1) DMBWAMR MA Inhibitor DMBWAMR RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMBWAMR RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMBWCOZ DI DMBWCOZ DMBWCOZ DN 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBWCOZ TI TTVBI8W DMBWCOZ TN Dopamine transporter (DAT) DMBWCOZ MA Inhibitor DMBWCOZ RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBWCOZ RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBWCOZ DI DMBWCOZ DMBWCOZ DN 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBWCOZ TI TT3ROYC DMBWCOZ TN Serotonin transporter (SERT) DMBWCOZ MA Inhibitor DMBWCOZ RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBWCOZ RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBWCOZ DI DMBWCOZ DMBWCOZ DN 1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one DMBWCOZ TI TTAWNKZ DMBWCOZ TN Norepinephrine transporter (NET) DMBWCOZ MA Inhibitor DMBWCOZ RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMBWCOZ RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMBWCZR DI DMBWCZR DMBWCZR DN ISIS 107612 DMBWCZR TI TT6SZNG DMBWCZR TN Caspase 8 messenger RNA (CASP8 mRNA) DMBWCZR RN US patent application no. 6,258,600, Antisense modulation of caspase 8 expression. DMBWCZR RU http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true DMBWDXH DI DMBWDXH DMBWDXH DN 2-m-tolyl-1,8-naphthyridine DMBWDXH TI TTHS256 DMBWDXH TN Metabotropic glutamate receptor 5 (mGluR5) DMBWDXH MA Inhibitor DMBWDXH RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMBWDXH RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMBWGCX DI DMBWGCX DMBWGCX DN 2-Allylthio-6-amino-3-benzyl-quinazolin-4(3H)-one DMBWGCX TI TT9SL3Q DMBWGCX TN Polypeptide deformylase (PDF) DMBWGCX MA Inhibitor DMBWGCX RN Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63. DMBWGCX RU https://pubmed.ncbi.nlm.nih.gov/20350811 DMBWHGP DI DMBWHGP DMBWHGP DN LSP4-2022 DMBWHGP TI TTWRP2F DMBWHGP TN Metabotropic glutamate receptor 6 (mGluR6) DMBWHGP MA Agonist DMBWHGP RN A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93. DMBWHGP RU https://pubmed.ncbi.nlm.nih.gov/22223752 DMBWHGP DI DMBWHGP DMBWHGP DN LSP4-2022 DMBWHGP TI TTICZ1O DMBWHGP TN Metabotropic glutamate receptor 4 (mGluR4) DMBWHGP MA Agonist DMBWHGP RN A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93. DMBWHGP RU https://pubmed.ncbi.nlm.nih.gov/22223752 DMBWHGP DI DMBWHGP DMBWHGP DN LSP4-2022 DMBWHGP TI TT0I76D DMBWHGP TN Metabotropic glutamate receptor 7 (mGluR7) DMBWHGP MA Agonist DMBWHGP RN A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. FASEB J. 2012 Apr;26(4):1682-93. DMBWHGP RU https://pubmed.ncbi.nlm.nih.gov/22223752 DMBWNL6 DI DMBWNL6 DMBWNL6 DN 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol DMBWNL6 TI TTZFYLI DMBWNL6 TN Dopamine D1 receptor (D1R) DMBWNL6 MA Inhibitor DMBWNL6 RN Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. J Med Chem. 1991 Oct;34(10):2946-53. DMBWNL6 RU https://pubmed.ncbi.nlm.nih.gov/1833546 DMBWNL6 DI DMBWNL6 DMBWNL6 DN 1-Aminomethyl-3-cyclohexyl-isochroman-5,6-diol DMBWNL6 TI TTEX248 DMBWNL6 TN Dopamine D2 receptor (D2R) DMBWNL6 MA Inhibitor DMBWNL6 RN Synthesis and pharmacological evaluation of 1-(aminomethyl)-3,4-dihydro-5-hydroxy-1H-2-benzopyrans as dopamine D1 selective ligands. J Med Chem. 1991 Oct;34(10):2946-53. DMBWNL6 RU https://pubmed.ncbi.nlm.nih.gov/1833546 DMBWSCR DI DMBWSCR DMBWSCR DN 1-Methyl-4-(1-phenyl-ethyl)-piperazine DMBWSCR TI TTD0CIQ DMBWSCR TN Melanocortin receptor 4 (MC4R) DMBWSCR MA Inhibitor DMBWSCR RN Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4973-8. DMBWSCR RU https://pubmed.ncbi.nlm.nih.gov/16169215 DMBWUR0 DI DMBWUR0 DMBWUR0 DN WZ-3146 DMBWUR0 TI TTGKNB4 DMBWUR0 TN Epidermal growth factor receptor (EGFR) DMBWUR0 MA Inhibitor DMBWUR0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMBWUR0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMBX0K1 DI DMBX0K1 DMBX0K1 DN N-(3,3-Diphenyl)propyl-2-phenylacetamide DMBX0K1 TI TT6OEDT DMBX0K1 TN Cannabinoid receptor 1 (CB1) DMBX0K1 MA Inhibitor DMBX0K1 RN Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5. DMBX0K1 RU https://pubmed.ncbi.nlm.nih.gov/18579386 DMBX4UJ DI DMBX4UJ DMBX4UJ DN 4-nitrophenyl phosphate DMBX4UJ TI TTHQPL7 DMBX4UJ TN Carbonic anhydrase I (CA-I) DMBX4UJ MA Inhibitor DMBX4UJ RN Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12. DMBX4UJ RU https://pubmed.ncbi.nlm.nih.gov/20833546 DMBX4UJ DI DMBX4UJ DMBX4UJ DN 4-nitrophenyl phosphate DMBX4UJ TI TTUNARX DMBX4UJ TN Carbonic anhydrase (CA) DMBX4UJ MA Inhibitor DMBX4UJ RN Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12. DMBX4UJ RU https://pubmed.ncbi.nlm.nih.gov/20833546 DMBX4UJ DI DMBX4UJ DMBX4UJ DN 4-nitrophenyl phosphate DMBX4UJ TI TTANPDJ DMBX4UJ TN Carbonic anhydrase II (CA-II) DMBX4UJ MA Inhibitor DMBX4UJ RN Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12. DMBX4UJ RU https://pubmed.ncbi.nlm.nih.gov/20833546 DMBX4WR DI DMBX4WR DMBX4WR DN isothiourea-1t DMBX4WR TI TTBID49 DMBX4WR TN C-X-C chemokine receptor type 4 (CXCR4) DMBX4WR MA Antagonist DMBX4WR RN Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo. J Med Chem. 2008 Dec 25;51(24):7915-20. DMBX4WR RU https://pubmed.ncbi.nlm.nih.gov/19053768 DMBX81R DI DMBX81R DMBX81R DN FE-203799 DMBX81R TI TT1YWO5 DMBX81R TN Glucagon-like peptide 2 receptor (GLP2R) DMBX81R MA Modulator DMBX81R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250). DMBX81R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=250 DMBXCNA DI DMBXCNA DMBXCNA DN PMID2296036C2t DMBXCNA TI TTPADOQ DMBXCNA TN HMG-CoA reductase (HMGCR) DMBXCNA MA Inhibitor DMBXCNA RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60. DMBXCNA RU https://pubmed.ncbi.nlm.nih.gov/2296036 DMBXGLA DI DMBXGLA DMBXGLA DN H-Dmt-Tic-Lys(Z)-NH-Ph DMBXGLA TI TTKWM86 DMBXGLA TN Opioid receptor mu (MOP) DMBXGLA MA Inhibitor DMBXGLA RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMBXGLA RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMBXGLA DI DMBXGLA DMBXGLA DN H-Dmt-Tic-Lys(Z)-NH-Ph DMBXGLA TI TT27RFC DMBXGLA TN Opioid receptor delta (OPRD1) DMBXGLA MA Inhibitor DMBXGLA RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMBXGLA RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMBXGVH DI DMBXGVH DMBXGVH DN Guttiferone I DMBXGVH TI TTECBXN DMBXGVH TN Oxysterols receptor LXR-alpha (NR1H3) DMBXGVH MA Inhibitor DMBXGVH RN Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand. J Nat Prod. 2005 Apr;68(4):617-9. DMBXGVH RU https://pubmed.ncbi.nlm.nih.gov/15844964 DMBXK5L DI DMBXK5L DMBXK5L DN (E)-1-(4-heptylphenyl)but-2-en-1-one DMBXK5L TI TTGER3L DMBXK5L TN Thyroid hormone receptor beta (THRB) DMBXK5L MA Inhibitor DMBXK5L RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMBXK5L RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMBXK5L DI DMBXK5L DMBXK5L DN (E)-1-(4-heptylphenyl)but-2-en-1-one DMBXK5L TI TTTSEPU DMBXK5L TN Thyroid hormone receptor alpha (THRA) DMBXK5L MA Inhibitor DMBXK5L RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMBXK5L RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMBXKYR DI DMBXKYR DMBXKYR DN MRS1041 DMBXKYR TI TTJFY5U DMBXKYR TN Adenosine A3 receptor (ADORA3) DMBXKYR MA Antagonist DMBXKYR RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMBXKYR RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMBXKYR DI DMBXKYR DMBXKYR DN MRS1041 DMBXKYR TI TTK25J1 DMBXKYR TN Adenosine A1 receptor (ADORA1) DMBXKYR MA Antagonist DMBXKYR RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMBXKYR RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMBXKYR DI DMBXKYR DMBXKYR DN MRS1041 DMBXKYR TI TTNE7KG DMBXKYR TN Adenosine A2b receptor (ADORA2B) DMBXKYR MA Antagonist DMBXKYR RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMBXKYR RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMBXRKS DI DMBXRKS DMBXRKS DN (R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol DMBXRKS TI TTAWNKZ DMBXRKS TN Norepinephrine transporter (NET) DMBXRKS MA Inhibitor DMBXRKS RN Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2022-5. DMBXRKS RU https://pubmed.ncbi.nlm.nih.gov/16413778 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TT1ZV49 DMBXT9J TN Tyrosine-protein kinase Tec (PSCTK4) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TTGM6VW DMBXT9J TN Tyrosine-protein kinase BTK (ATK) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TTNDSC3 DMBXT9J TN B lymphocyte kinase (BLK) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TT0JESD DMBXT9J TN Erbb4 tyrosine kinase receptor (Erbb-4) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TTN2I9E DMBXT9J TN Tyrosine-protein kinase BMX (BMX) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TT8M1DP DMBXT9J TN Tyrosine-protein kinase TXK (TXK) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TTR5TV4 DMBXT9J TN ERBB2 messenger RNA (HER2 mRNA) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXT9J DI DMBXT9J DMBXT9J DN PMID24915291C38 DMBXT9J TI TTGKNB4 DMBXT9J TN Epidermal growth factor receptor (EGFR) DMBXT9J MA Inhibitor DMBXT9J RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMBXT9J RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMBXTPU DI DMBXTPU DMBXTPU DN MRS1177 DMBXTPU TI TTJFY5U DMBXTPU TN Adenosine A3 receptor (ADORA3) DMBXTPU MA Antagonist DMBXTPU RN Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem. 1996 Oct 11;39(21):4142-8. DMBXTPU RU https://pubmed.ncbi.nlm.nih.gov/8863790 DMBY1RS DI DMBY1RS DMBY1RS DN ISIS 29138 DMBY1RS TI TTO6SGY DMBY1RS TN AKT3 messenger RNA (AKT3 mRNA) DMBY1RS RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMBY1RS RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMBY3T5 DI DMBY3T5 DMBY3T5 DN FR-226928 DMBY3T5 TI TTY6EWA DMBY3T5 TN Neuropeptide Y receptor type 5 (NPY5R) DMBY3T5 MA Inhibitor DMBY3T5 RN Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802. DMBY3T5 RU https://pubmed.ncbi.nlm.nih.gov/11859006 DMBY623 DI DMBY623 DMBY623 DN (11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid DMBY623 TI TT8NGED DMBY623 TN Prostaglandin G/H synthase 1 (COX-1) DMBY623 MA Inhibitor DMBY623 RN Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41. DMBY623 RU https://pubmed.ncbi.nlm.nih.gov/3488405 DMBY623 DI DMBY623 DMBY623 DN (11H-Dibenzo[b,e][1,4]dioxepin-8-yl)-acetic acid DMBY623 TI TTVKILB DMBY623 TN Prostaglandin G/H synthase 2 (COX-2) DMBY623 MA Inhibitor DMBY623 RN Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41. DMBY623 RU https://pubmed.ncbi.nlm.nih.gov/3488405 DMBYK0X DI DMBYK0X DMBYK0X DN GR94800 DMBYK0X TI TTYO0A3 DMBYK0X TN Substance-K receptor (TACR2) DMBYK0X MA Antagonist DMBYK0X RN Synthesis and characterization of selective fluorescent ligands for the neurokinin NK2 receptor. J Med Chem. 1994 Jun 24;37(13):1991-5. DMBYK0X RU https://pubmed.ncbi.nlm.nih.gov/8027981 DMBYND6 DI DMBYND6 DMBYND6 DN leucettine L41 DMBYND6 TI TTSBVFO DMBYND6 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMBYND6 MA Inhibitor DMBYND6 RN Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86. DMBYND6 RU https://pubmed.ncbi.nlm.nih.gov/21615147 DMBYND6 DI DMBYND6 DMBYND6 DN leucettine L41 DMBYND6 TI TTE6YDG DMBYND6 TN CDC-like kinase 1 (CLK1) DMBYND6 MA Inhibitor DMBYND6 RN Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86. DMBYND6 RU https://pubmed.ncbi.nlm.nih.gov/21615147 DMBYND6 DI DMBYND6 DMBYND6 DN leucettine L41 DMBYND6 TI TT84OS6 DMBYND6 TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMBYND6 MA Inhibitor DMBYND6 RN Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86. DMBYND6 RU https://pubmed.ncbi.nlm.nih.gov/21615147 DMBYND6 DI DMBYND6 DMBYND6 DN leucettine L41 DMBYND6 TI TTQPE1U DMBYND6 TN CDC-like kinase 3 (CLK3) DMBYND6 MA Inhibitor DMBYND6 RN Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86. DMBYND6 RU https://pubmed.ncbi.nlm.nih.gov/21615147 DMBYND6 DI DMBYND6 DMBYND6 DN leucettine L41 DMBYND6 TI TTTN5QW DMBYND6 TN Serine/threonine-protein kinase pim-1 (PIM1) DMBYND6 MA Inhibitor DMBYND6 RN Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing. J Med Chem. 2011 Jun 23;54(12):4172-86. DMBYND6 RU https://pubmed.ncbi.nlm.nih.gov/21615147 DMBYND6 DI DMBYND6 DMBYND6 DN leucettine L41 DMBYND6 TI TTCLIHJ DMBYND6 TN Dual-specificity tyrosine-phosphorylation regulated kinase 4 (DYRK4) DMBYND6 MA Inhibitor DMBYND6 RN Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J Med Chem. 2012 Nov 8;55(21):9312-30. DMBYND6 RU https://pubmed.ncbi.nlm.nih.gov/22998443 DMBYSEM DI DMBYSEM DMBYSEM DN SDZ-PTS-893 DMBYSEM TI TTEPJL5 DMBYSEM TN Parathyroid hormone receptor (PTH2R) DMBYSEM MA Modulator DMBYSEM RN Long-term therapy of ovariectomy-induced osteopenia with parathyroid hormone analog SDZ PTS 893 and bone maintenance in retired breeder rats. Bone. 1999 Nov;25(5):561-9. DMBYSEM RU https://www.ncbi.nlm.nih.gov/pubmed/10574576 DMBYV3M DI DMBYV3M DMBYV3M DN TRIPTOCALLINE A DMBYV3M TI TTFBNVI DMBYV3M TN Aldose reductase (AKR1B1) DMBYV3M MA Inhibitor DMBYV3M RN Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6. DMBYV3M RU https://pubmed.ncbi.nlm.nih.gov/14510595 DMBZ09U DI DMBZ09U DMBZ09U DN PD-163140 DMBZ09U TI TT3ZTGU DMBZ09U TN Endothelin B receptor (EDNRB) DMBZ09U MA Inhibitor DMBZ09U RN gamma-Carbamate butenolide analogues as potent ETA selective endothelin receptor antagonists and prodrugs, Bioorg. Med. Chem. Lett. 7(3):297-302 (1997). DMBZ09U RU http://www.sciencedirect.com/science/article/pii/S0960894X97000024 DMBZ09U DI DMBZ09U DMBZ09U DN PD-163140 DMBZ09U TI TTKRD0G DMBZ09U TN Endothelin A receptor (EDNRA) DMBZ09U MA Inhibitor DMBZ09U RN gamma-Carbamate butenolide analogues as potent ETA selective endothelin receptor antagonists and prodrugs, Bioorg. Med. Chem. Lett. 7(3):297-302 (1997). DMBZ09U RU http://www.sciencedirect.com/science/article/pii/S0960894X97000024 DMBZ0QY DI DMBZ0QY DMBZ0QY DN CHAP1 DMBZ0QY TI TTBH0VX DMBZ0QY TN Histone deacetylase (HDAC) DMBZ0QY MA Inhibitor DMBZ0QY RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMBZ0QY RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMBZ2MF DI DMBZ2MF DMBZ2MF DN THZ531 DMBZ2MF TI TTJ21A9 DMBZ2MF TN Cyclin-dependent kinase 12 (CDK12) DMBZ2MF MA Inhibitor DMBZ2MF RN Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84. DMBZ2MF RU https://pubmed.ncbi.nlm.nih.gov/27571479 DMBZ2MF DI DMBZ2MF DMBZ2MF DN THZ531 DMBZ2MF TI TTRIM0E DMBZ2MF TN Cyclin-dependent kinase 13 (CDK13) DMBZ2MF MA Inhibitor DMBZ2MF RN Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol. 2016 Oct;12(10):876-84. DMBZ2MF RU https://pubmed.ncbi.nlm.nih.gov/27571479 DMBZ5RN DI DMBZ5RN DMBZ5RN DN 1,2-bis(3,4-difluorophenyl)ethane-1,2-dione DMBZ5RN TI TTMF541 DMBZ5RN TN Liver carboxylesterase (CES1) DMBZ5RN MA Inhibitor DMBZ5RN RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMBZ5RN RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMBZ60O DI DMBZ60O DMBZ60O DN 3-Imidazol-1-ylmethyl-1H-indole DMBZ60O TI TTIQUX7 DMBZ60O TN Steroid 11-beta-hydroxylase (CYP11B1) DMBZ60O MA Inhibitor DMBZ60O RN Selective thromboxane synthetase inhibitors. 2. 3-(1H-imidazol-1-ylmethyl)-2-methyl-1H-indole-1-propanoic acid and analogues. J Med Chem. 1986 Mar;29(3):342-6. DMBZ60O RU https://pubmed.ncbi.nlm.nih.gov/3081722 DMBZ7MA DI DMBZ7MA DMBZ7MA DN JNJ-26529152 DMBZ7MA TI TTZAYWL DMBZ7MA TN Estrogen receptor (ESR) DMBZ7MA MA Inhibitor DMBZ7MA RN Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69. DMBZ7MA RU https://pubmed.ncbi.nlm.nih.gov/19366247 DMBZHUA DI DMBZHUA DMBZHUA DN 4-(4-propoxyphenoxy)phenol DMBZHUA TI TTXZEAJ DMBZHUA TN Leukotriene A-4 hydrolase (LTA4H) DMBZHUA MA Inhibitor DMBZHUA RN Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52. DMBZHUA RU https://pubmed.ncbi.nlm.nih.gov/18952425 DMBZI5F DI DMBZI5F DMBZI5F DN TrkB NAM DMBZI5F TI TTKN7QR DMBZI5F TN BDNF/NT-3 growth factors receptor (TrkB) DMBZI5F MA Modulator DMBZI5F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1818). DMBZI5F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1818 DMBZIG7 DI DMBZIG7 DMBZIG7 DN 4,6-Dideoxy-4-Amino-Alpha-D-Glucose DMBZIG7 TI TTCGSZ4 DMBZIG7 TN Pancreatic alpha-amylase (AMY2A) DMBZIG7 MA Inhibitor DMBZIG7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBZIG7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBZIUC DI DMBZIUC DMBZIUC DN 2-(2-(biphenyl-4-yl)ethylthio)acetic acid DMBZIUC TI TTXZ0KQ DMBZIUC TN Matrix metalloproteinase-12 (MMP-12) DMBZIUC MA Inhibitor DMBZIUC RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMBZIUC RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMBZJT5 DI DMBZJT5 DMBZJT5 DN (3-((1H-imidazol-1-yl)methyl)phenyl)methanol DMBZJT5 TI TTIQUX7 DMBZJT5 TN Steroid 11-beta-hydroxylase (CYP11B1) DMBZJT5 MA Inhibitor DMBZJT5 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMBZJT5 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMBZP3I DI DMBZP3I DMBZP3I DN 6,7-Dimethoxy-4-phenoxy-quinoline DMBZP3I TI TTI7421 DMBZP3I TN Platelet-derived growth factor receptor beta (PDGFRB) DMBZP3I MA Inhibitor DMBZP3I RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMBZP3I RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMBZSAO DI DMBZSAO DMBZSAO DN 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMBZSAO TI TTKJEMQ DMBZSAO TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMBZSAO MA Inhibitor DMBZSAO RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMBZSAO RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMBZSAO DI DMBZSAO DMBZSAO DN 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMBZSAO TI TTN9D8E DMBZSAO TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMBZSAO MA Inhibitor DMBZSAO RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMBZSAO RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMBZSAO DI DMBZSAO DMBZSAO DN 8-Fluoro-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMBZSAO TI TTLD29N DMBZSAO TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMBZSAO MA Inhibitor DMBZSAO RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMBZSAO RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMBZSKJ DI DMBZSKJ DMBZSKJ DN PMID15686906C29 DMBZSKJ TI TTPADOQ DMBZSKJ TN HMG-CoA reductase (HMGCR) DMBZSKJ MA Inhibitor DMBZSKJ RN Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparativemolecular similarity indices analysis (CoMSIA). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1027-32. DMBZSKJ RU https://pubmed.ncbi.nlm.nih.gov/15686906 DMBZTS5 DI DMBZTS5 DMBZTS5 DN Alpha-ketoisovalerate DMBZTS5 TI TTF9OQ6 DMBZTS5 TN Branched-chain-amino-acid transaminase 2 (BCAT2) DMBZTS5 MA Inhibitor DMBZTS5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMBZTS5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMBZVW0 DI DMBZVW0 DMBZVW0 DN ISIS 103752 DMBZVW0 TI TT6TU05 DMBZVW0 TN WWP2 messenger RNA (WWP2 mRNA) DMBZVW0 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMBZVW0 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMC013U DI DMC013U DMC013U DN 6-Thiophen-2-yl-imidazo[2,1-b]thiazole DMC013U TI TTTJF7V DMC013U TN NADH dehydrogenase (MT-ND3) DMC013U MA Inhibitor DMC013U RN Thienylimidazo[2,1-b]thiazoles as inhibitors of mitochondrial NADH dehydrogenase. J Med Chem. 1995 Mar 31;38(7):1090-7. DMC013U RU https://pubmed.ncbi.nlm.nih.gov/7707312 DMC02FP DI DMC02FP DMC02FP DN Abyssinin I DMC02FP TI TTELIN2 DMC02FP TN PTPN1 messenger RNA (PTPN1 mRNA) DMC02FP MA Inhibitor DMC02FP RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DMC02FP RU https://pubmed.ncbi.nlm.nih.gov/17489632 DMC02TI DI DMC02TI DMC02TI DN 2-methyl-7-m-tolylquinoline DMC02TI TI TTHS256 DMC02TI TN Metabotropic glutamate receptor 5 (mGluR5) DMC02TI MA Inhibitor DMC02TI RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMC02TI RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMC0FLB DI DMC0FLB DMC0FLB DN BAS-01047655 DMC0FLB TI TT6PKBN DMC0FLB TN Proto-oncogene c-Src (SRC) DMC0FLB MA Inhibitor DMC0FLB RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMC0FLB RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMC0OKA DI DMC0OKA DMC0OKA DN (+/-)-7-methoxy-2-phenylchroman-4-one DMC0OKA TI TTSZLWK DMC0OKA TN Aromatase (CYP19A1) DMC0OKA MA Inhibitor DMC0OKA RN New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80. DMC0OKA RU https://pubmed.ncbi.nlm.nih.gov/18042388 DMC0OKA DI DMC0OKA DMC0OKA DN (+/-)-7-methoxy-2-phenylchroman-4-one DMC0OKA TI TTGP7BY DMC0OKA TN Monoamine oxidase type B (MAO-B) DMC0OKA MA Inhibitor DMC0OKA RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMC0OKA RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMC0OVP DI DMC0OVP DMC0OVP DN Gamma-mangostin DMC0OVP TI TTSZLWK DMC0OVP TN Aromatase (CYP19A1) DMC0OVP MA Inhibitor DMC0OVP RN Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod. 2008 Jul;71(7):1161-6. DMC0OVP RU https://pubmed.ncbi.nlm.nih.gov/18558747 DMC0OVP DI DMC0OVP DMC0OVP DN Gamma-mangostin DMC0OVP TI TT50QJ3 DMC0OVP TN Influenza Neuraminidase (Influ NA) DMC0OVP MA Inhibitor DMC0OVP RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMC0OVP RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMC0PY5 DI DMC0PY5 DMC0PY5 DN AVE-1876 DMC0PY5 TI TTDCVZW DMC0PY5 TN Gamma-aminobutyric acid B receptor (GABBR) DMC0PY5 MA Modulator DMC0PY5 RN Company report (Sanofi) DMC0PY5 RU http://en.sanofi.com/Images/16068_AR_2004_EN.pdf DMC0TU5 DI DMC0TU5 DMC0TU5 DN Ac-YGGFL-NH2 DMC0TU5 TI TTKWM86 DMC0TU5 TN Opioid receptor mu (MOP) DMC0TU5 MA Inhibitor DMC0TU5 RN Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. DMC0TU5 RU https://pubmed.ncbi.nlm.nih.gov/18329886 DMC0V25 DI DMC0V25 DMC0V25 DN RO-4840700 DMC0V25 TI TTHJTF7 DMC0V25 TN Glycine transporter GlyT-1 (SLC6A9) DMC0V25 MA Inhibitor DMC0V25 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DMC0V25 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DMC0YOE DI DMC0YOE DMC0YOE DN AGN193109 DMC0YOE TI TT1Q3IE DMC0YOE TN Retinoic acid receptor gamma (RARG) DMC0YOE MA Antagonist DMC0YOE RN Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58. DMC0YOE RU https://pubmed.ncbi.nlm.nih.gov/10637371 DMC0YOE DI DMC0YOE DMC0YOE DN AGN193109 DMC0YOE TI TTISP28 DMC0YOE TN Retinoic acid receptor beta (RARB) DMC0YOE MA Antagonist DMC0YOE RN Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58. DMC0YOE RU https://pubmed.ncbi.nlm.nih.gov/10637371 DMC0YOE DI DMC0YOE DMC0YOE DN AGN193109 DMC0YOE TI TTW38KT DMC0YOE TN Retinoic acid receptor alpha (RARA) DMC0YOE MA Antagonist DMC0YOE RN Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des. 2000 Jan;6(1):25-58. DMC0YOE RU https://pubmed.ncbi.nlm.nih.gov/10637371 DMC10DR DI DMC10DR DMC10DR DN 2-ethylestradiol 3,17-O,O-bis-sulfamate DMC10DR TI TTHM0R1 DMC10DR TN Steryl-sulfatase (STS) DMC10DR MA Inhibitor DMC10DR RN 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96. DMC10DR RU https://pubmed.ncbi.nlm.nih.gov/17181151 DMC10HG DI DMC10HG DMC10HG DN 5-methyl-2-(phenylsulfonamido)benzoic acid DMC10HG TI TTZL0OI DMC10HG TN Methionine aminopeptidase 2 (METAP2) DMC10HG MA Inhibitor DMC10HG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMC10HG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMC153X DI DMC153X DMC153X DN 3-Methylthiofentanyl DMC153X TI TTKWM86 DMC153X TN Opioid receptor mu (MOP) DMC153X MA Agonist DMC153X RN You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. DMC153X RU https://pubmed.ncbi.nlm.nih.gov/15589524 DMC153X DI DMC153X DMC153X DN 3-Methylthiofentanyl DMC153X TI TTQW87Y DMC153X TN Opioid receptor kappa (OPRK1) DMC153X MA Agonist DMC153X RN You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. DMC153X RU https://pubmed.ncbi.nlm.nih.gov/15589524 DMC153X DI DMC153X DMC153X DN 3-Methylthiofentanyl DMC153X TI TT27RFC DMC153X TN Opioid receptor delta (OPRD1) DMC153X MA Agonist DMC153X RN You HJ, Colpaert FC, Arendt-Nielsen L: The novel analgesic and high-efficacy 5-HT1A receptor agonist F 13640 inhibits nociceptive responses, wind-up, and after-discharges in spinal neurons and withdrawal reflexes. Exp Neurol. 2005 Jan;191(1):174-83. DMC153X RU https://pubmed.ncbi.nlm.nih.gov/15589524 DMC15DM DI DMC15DM DMC15DM DN Amooranin DMC15DM TI TTEVCT0 DMC15DM TN Caspase-8 (CASP8) DMC15DM MA Inhibitor DMC15DM RN Glionitrin A, a new diketopiperazine disulfide, activates ATM-ATR-Chk1/2 via 53BP1 phosphorylation in DU145 cells and shows antitumor effect in xenograft model. Biol Pharm Bull. 2014;37(3):378-86. DMC15DM RU https://pubmed.ncbi.nlm.nih.gov/24583858 DMC1ARG DI DMC1ARG DMC1ARG DN JMV458 DMC1ARG TI TT31Q0V DMC1ARG TN Neurotensin receptor type 2 (NTSR2) DMC1ARG MA Agonist DMC1ARG RN Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol. 2001 Dec;60(6):1392-8. DMC1ARG RU https://pubmed.ncbi.nlm.nih.gov/11723247 DMC1ARG DI DMC1ARG DMC1ARG DN JMV458 DMC1ARG TI TTTUMEP DMC1ARG TN Neurotensin receptor type 1 (NTSR1) DMC1ARG MA Agonist DMC1ARG RN Agonism, inverse agonism, and neutral antagonism at the constitutively active human neurotensin receptor 2. Mol Pharmacol. 2001 Dec;60(6):1392-8. DMC1ARG RU https://pubmed.ncbi.nlm.nih.gov/11723247 DMC1F2E DI DMC1F2E DMC1F2E DN 6-ethyl-3-propylaminocarbonyl-4-quinolone DMC1F2E TI TT1MPAY DMC1F2E TN GABA(A) receptor alpha-1 (GABRA1) DMC1F2E MA Inhibitor DMC1F2E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMC1F2E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMC1F2E DI DMC1F2E DMC1F2E DN 6-ethyl-3-propylaminocarbonyl-4-quinolone DMC1F2E TI TT06RH5 DMC1F2E TN GABA(A) receptor gamma-2 (GABRG2) DMC1F2E MA Inhibitor DMC1F2E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMC1F2E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMC1F2E DI DMC1F2E DMC1F2E DN 6-ethyl-3-propylaminocarbonyl-4-quinolone DMC1F2E TI TTNJYV2 DMC1F2E TN Gamma-aminobutyric acid receptor (GAR) DMC1F2E MA Inhibitor DMC1F2E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMC1F2E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMC1F2E DI DMC1F2E DMC1F2E DN 6-ethyl-3-propylaminocarbonyl-4-quinolone DMC1F2E TI TTZA1NY DMC1F2E TN GABA(A) receptor beta-2 (GABRB2) DMC1F2E MA Inhibitor DMC1F2E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMC1F2E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMC1GYH DI DMC1GYH DMC1GYH DN N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]undecanamide DMC1GYH TI TTMI6F5 DMC1GYH TN Transient receptor potential cation channel V1 (TRPV1) DMC1GYH MA Inhibitor DMC1GYH RN New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69. DMC1GYH RU https://pubmed.ncbi.nlm.nih.gov/18027904 DMC1IKP DI DMC1IKP DMC1IKP DN 1-(2-Phenoxy-ethyl)-3-thiazol-2-yl-thiourea DMC1IKP TI TT84ETX DMC1IKP TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMC1IKP MA Inhibitor DMC1IKP RN Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8. DMC1IKP RU https://pubmed.ncbi.nlm.nih.gov/11229762 DMC1KEG DI DMC1KEG DMC1KEG DN 4-(2-nitrobenzylthio)-2-aminobutanoic acid DMC1KEG TI TTFK1JQ DMC1KEG TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMC1KEG MA Inhibitor DMC1KEG RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMC1KEG RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMC1TWI DI DMC1TWI DMC1TWI DN 2-morpholin-4-yl-8-naphthalen-2-ylchromen-4-one DMC1TWI TI TTK3PY9 DMC1TWI TN DNA-dependent protein kinase catalytic (PRKDC) DMC1TWI MA Inhibitor DMC1TWI RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMC1TWI RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMC1WHR DI DMC1WHR DMC1WHR DN [3H]QNB DMC1WHR TI TTQ13Z5 DMC1WHR TN Muscarinic acetylcholine receptor M3 (CHRM3) DMC1WHR MA Antagonist DMC1WHR RN Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors. EMBO J. 1987 Dec 20;6(13):3923-9. DMC1WHR RU https://pubmed.ncbi.nlm.nih.gov/3443095 DMC1WHR DI DMC1WHR DMC1WHR DN [3H]QNB DMC1WHR TI TTOXS3C DMC1WHR TN Muscarinic acetylcholine receptor (CHRM) DMC1WHR MA Antagonist DMC1WHR RN Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors. Brain Res. 2001 Oct 5;915(1):70-8. DMC1WHR RU https://pubmed.ncbi.nlm.nih.gov/11578621 DMC1Z0L DI DMC1Z0L DMC1Z0L DN L-370,518 DMC1Z0L TI TT6L509 DMC1Z0L TN Coagulation factor IIa (F2) DMC1Z0L MA Inhibitor DMC1Z0L RN Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost. 1998 Mar;79(3):656-62. DMC1Z0L RU https://pubmed.ncbi.nlm.nih.gov/9531058 DMC28SN DI DMC28SN DMC28SN DN N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine DMC28SN TI TTGSEFH DMC28SN TN Sodium/hydrogen exchanger 1 (SLC9A1) DMC28SN MA Inhibitor DMC28SN RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMC28SN RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMC28SN DI DMC28SN DMC28SN DN N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine DMC28SN TI TTFZVPO DMC28SN TN Sodium/hydrogen exchanger 3 (SLC9A3) DMC28SN MA Inhibitor DMC28SN RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMC28SN RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMC2EO9 DI DMC2EO9 DMC2EO9 DN VER-5384 DMC2EO9 TI TTWJBZ5 DMC2EO9 TN 5-HT 2C receptor (HTR2C) DMC2EO9 MA Inhibitor DMC2EO9 RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DMC2EO9 RU https://pubmed.ncbi.nlm.nih.gov/15081042 DMC2EO9 DI DMC2EO9 DMC2EO9 DN VER-5384 DMC2EO9 TI TTJQOD7 DMC2EO9 TN 5-HT 2A receptor (HTR2A) DMC2EO9 MA Inhibitor DMC2EO9 RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DMC2EO9 RU https://pubmed.ncbi.nlm.nih.gov/15081042 DMC2EO9 DI DMC2EO9 DMC2EO9 DN VER-5384 DMC2EO9 TI TT0K1SC DMC2EO9 TN 5-HT 2B receptor (HTR2B) DMC2EO9 MA Inhibitor DMC2EO9 RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DMC2EO9 RU https://pubmed.ncbi.nlm.nih.gov/15081042 DMC2IYH DI DMC2IYH DMC2IYH DN Conantokin-G DMC2IYH TI TTN9D8E DMC2IYH TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMC2IYH MA Inhibitor DMC2IYH RN Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13. DMC2IYH RU https://pubmed.ncbi.nlm.nih.gov/17962189 DMC2JLQ DI DMC2JLQ DMC2JLQ DN 8-n-nonylnaringenin DMC2JLQ TI TTOM3J0 DMC2JLQ TN Estrogen receptor beta (ESR2) DMC2JLQ MA Inhibitor DMC2JLQ RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMC2JLQ RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMC2JLQ DI DMC2JLQ DMC2JLQ DN 8-n-nonylnaringenin DMC2JLQ TI TTZAYWL DMC2JLQ TN Estrogen receptor (ESR) DMC2JLQ MA Inhibitor DMC2JLQ RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMC2JLQ RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMC2N80 DI DMC2N80 DMC2N80 DN 2,6-bis(4-methoxyphenyl)-9H-purine DMC2N80 TI TTJFY5U DMC2N80 TN Adenosine A3 receptor (ADORA3) DMC2N80 MA Inhibitor DMC2N80 RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMC2N80 RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMC2XSU DI DMC2XSU DMC2XSU DN JWH-201 DMC2XSU TI TTMSFAW DMC2XSU TN Cannabinoid receptor 2 (CB2) DMC2XSU MA Inhibitor DMC2XSU RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMC2XSU RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMC2ZF6 DI DMC2ZF6 DMC2ZF6 DN GSK-008A DMC2ZF6 TI TTUV8G9 DMC2ZF6 TN Progesterone receptor (PGR) DMC2ZF6 MA Agonist DMC2ZF6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627). DMC2ZF6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627 DMC34UW DI DMC34UW DMC34UW DN 3,3'-(1,2,4-thiadiazole-3,5-diyl)diphenol DMC34UW TI TTIWB6L DMC34UW TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMC34UW MA Inhibitor DMC34UW RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DMC34UW RU https://pubmed.ncbi.nlm.nih.gov/18855374 DMC3917 DI DMC3917 DMC3917 DN 3,5-Dimethoxy-4'-amino-trans-stilbene DMC3917 TI TTSZLWK DMC3917 TN Aromatase (CYP19A1) DMC3917 MA Inhibitor DMC3917 RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMC3917 RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMC3917 DI DMC3917 DMC3917 DN 3,5-Dimethoxy-4'-amino-trans-stilbene DMC3917 TI TTJLP0R DMC3917 TN Quinone reductase 2 (NQO2) DMC3917 MA Inhibitor DMC3917 RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMC3917 RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMC3APN DI DMC3APN DMC3APN DN H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH DMC3APN TI TTKWM86 DMC3APN TN Opioid receptor mu (MOP) DMC3APN MA Inhibitor DMC3APN RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMC3APN RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMC3APN DI DMC3APN DMC3APN DN H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH DMC3APN TI TT27RFC DMC3APN TN Opioid receptor delta (OPRD1) DMC3APN MA Inhibitor DMC3APN RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMC3APN RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMC3DK5 DI DMC3DK5 DMC3DK5 DN YPAA-NH2 DMC3DK5 TI TTKWM86 DMC3DK5 TN Opioid receptor mu (MOP) DMC3DK5 MA Inhibitor DMC3DK5 RN Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. DMC3DK5 RU https://pubmed.ncbi.nlm.nih.gov/18329886 DMC3ET2 DI DMC3ET2 DMC3ET2 DN 2-Methyl-1,2-di-pyridin-3-yl-propane DMC3ET2 TI TTIQUX7 DMC3ET2 TN Steroid 11-beta-hydroxylase (CYP11B1) DMC3ET2 MA Inhibitor DMC3ET2 RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMC3ET2 RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMC3GFI DI DMC3GFI DMC3GFI DN PMID30247903-Compound-General structure17 DMC3GFI TI TTNBFWK DMC3GFI TN Programmed cell death protein 1 (PD-1) DMC3GFI MA Inhibitor DMC3GFI RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMC3GFI RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMC3IGK DI DMC3IGK DMC3IGK DN 1-methyl-3-(phenylcarbamoyloxy)pyridinium bromide DMC3IGK TI TTEB0GD DMC3IGK TN Cholinesterase (BCHE) DMC3IGK MA Inhibitor DMC3IGK RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMC3IGK RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMC3PYM DI DMC3PYM DMC3PYM DN 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine DMC3PYM TI TT7SBF5 DMC3PYM TN Cellular tumor antigen p53 (TP53) DMC3PYM MA Inhibitor DMC3PYM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMC3PYM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMC3SJI DI DMC3SJI DMC3SJI DN 6-(pyridin-3-yl)-2-naphthonitrile DMC3SJI TI TTIQUX7 DMC3SJI TN Steroid 11-beta-hydroxylase (CYP11B1) DMC3SJI MA Inhibitor DMC3SJI RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMC3SJI RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMC3SJI DI DMC3SJI DMC3SJI DN 6-(pyridin-3-yl)-2-naphthonitrile DMC3SJI TI TTRA5BZ DMC3SJI TN Steroid 17-alpha-monooxygenase (S17AH) DMC3SJI MA Inhibitor DMC3SJI RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMC3SJI RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMC3UYH DI DMC3UYH DMC3UYH DN 2,3-diphenyl-1H-indole DMC3UYH TI TTOM3J0 DMC3UYH TN Estrogen receptor beta (ESR2) DMC3UYH MA Inhibitor DMC3UYH RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMC3UYH RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMC3UYH DI DMC3UYH DMC3UYH DN 2,3-diphenyl-1H-indole DMC3UYH TI TTZAYWL DMC3UYH TN Estrogen receptor (ESR) DMC3UYH MA Inhibitor DMC3UYH RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMC3UYH RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMC41UH DI DMC41UH DMC41UH DN CGS-19480A DMC41UH TI TTSQIFT DMC41UH TN 5-HT 1A receptor (HTR1A) DMC41UH MA Modulator DMC41UH RN WO patent application no. 2012,0025,83, Method for treating schizophrenia and related diseases with a combination therapy. DMC41UH RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20120105&CC=WO&NR=2012002583A1&KC=A1 DMC46RQ DI DMC46RQ DMC46RQ DN ZM 325802 DMC46RQ TI TTG1QMU DMC46RQ TN Prostaglandin E2 receptor EP1 (PTGER1) DMC46RQ MA Modulator DMC46RQ RN Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones. Br J Pharmacol. 2001 Nov;134(6):1296-302. DMC46RQ RU https://www.ncbi.nlm.nih.gov/pubmed/11704650 DMC471Z DI DMC471Z DMC471Z DN RHC80267 DMC471Z TI TTXZDEN DMC471Z TN Diacylglycerol lipase beta (DAGLB) DMC471Z MA Inhibitor DMC471Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1397). DMC471Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1397 DMC471Z DI DMC471Z DMC471Z DN RHC80267 DMC471Z TI TTRQ6UD DMC471Z TN Diacylglycerol lipase alpha (DAGLA) DMC471Z MA Inhibitor DMC471Z RN Assay and inhibition of diacylglycerol lipase activity. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4585-92. DMC471Z RU https://pubmed.ncbi.nlm.nih.gov/22738638 DMC48D9 DI DMC48D9 DMC48D9 DN NG-25 DMC48D9 TI TT6PKBN DMC48D9 TN Proto-oncogene c-Src (SRC) DMC48D9 MA Inhibitor DMC48D9 RN Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. DMC48D9 RU https://pubmed.ncbi.nlm.nih.gov/25075558 DMC48D9 DI DMC48D9 DMC48D9 DN NG-25 DMC48D9 TI TTX6F0Q DMC48D9 TN Tyrosine-protein kinase CSK (CSK) DMC48D9 MA Inhibitor DMC48D9 RN Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. DMC48D9 RU https://pubmed.ncbi.nlm.nih.gov/25075558 DMC48D9 DI DMC48D9 DMC48D9 DN NG-25 DMC48D9 TI TT1RWNJ DMC48D9 TN Tyrosine-protein kinase Lyn (JTK8) DMC48D9 MA Inhibitor DMC48D9 RN Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. DMC48D9 RU https://pubmed.ncbi.nlm.nih.gov/25075558 DMC48D9 DI DMC48D9 DMC48D9 DN NG-25 DMC48D9 TI TTJQT60 DMC48D9 TN TGF-beta-activated kinase 1 (MAP3K7) DMC48D9 MA Inhibitor DMC48D9 RN Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. DMC48D9 RU https://pubmed.ncbi.nlm.nih.gov/25075558 DMC48D9 DI DMC48D9 DMC48D9 DN NG-25 DMC48D9 TI TTQFRP0 DMC48D9 TN MEK kinase kinase 2 (MAP4K2) DMC48D9 MA Inhibitor DMC48D9 RN Discovery of type II inhibitors of TGFbeta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem. 2015 Jan 8;58(1):183-96. DMC48D9 RU https://pubmed.ncbi.nlm.nih.gov/25075558 DMC4LMT DI DMC4LMT DMC4LMT DN 1,4-bis(malimido)xylene DMC4LMT TI TTDP1UC DMC4LMT TN Fatty acid amide hydrolase (FAAH) DMC4LMT MA Inhibitor DMC4LMT RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DMC4LMT RU https://pubmed.ncbi.nlm.nih.gov/19583260 DMC4NO5 DI DMC4NO5 DMC4NO5 DN Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 DMC4NO5 TI TTKWM86 DMC4NO5 TN Opioid receptor mu (MOP) DMC4NO5 MA Inhibitor DMC4NO5 RN Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5. DMC4NO5 RU https://pubmed.ncbi.nlm.nih.gov/8289187 DMC4NO5 DI DMC4NO5 DMC4NO5 DN Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 DMC4NO5 TI TT27RFC DMC4NO5 TN Opioid receptor delta (OPRD1) DMC4NO5 MA Inhibitor DMC4NO5 RN Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5. DMC4NO5 RU https://pubmed.ncbi.nlm.nih.gov/8289187 DMC4PF0 DI DMC4PF0 DMC4PF0 DN Brolamfetamine DMC4PF0 TI TT6MSOK DMC4PF0 TN 5-HT 1D receptor (HTR1D) DMC4PF0 MA Inhibitor DMC4PF0 RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMC4PF0 RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMC4PF0 DI DMC4PF0 DMC4PF0 DN Brolamfetamine DMC4PF0 TI TTJQOD7 DMC4PF0 TN 5-HT 2A receptor (HTR2A) DMC4PF0 MA Inhibitor DMC4PF0 RN 'Hybrid' benzofuran-benzopyran congeners as rigid analogs of hallucinogenic phenethylamines. Bioorg Med Chem. 2008 Jun 1;16(11):6242-51. DMC4PF0 RU https://pubmed.ncbi.nlm.nih.gov/18467103 DMC4PF0 DI DMC4PF0 DMC4PF0 DN Brolamfetamine DMC4PF0 TI TTSQIFT DMC4PF0 TN 5-HT 1A receptor (HTR1A) DMC4PF0 MA Inhibitor DMC4PF0 RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMC4PF0 RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMC4UHD DI DMC4UHD DMC4UHD DN PF-543 DMC4UHD TI TTOHFIY DMC4UHD TN Sphingosine kinase 1 (SPHK1) DMC4UHD MA Inhibitor DMC4UHD RN Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1. Biochem J. 2012 May 15;444(1):79-88. DMC4UHD RU https://pubmed.ncbi.nlm.nih.gov/22397330 DMC4W03 DI DMC4W03 DMC4W03 DN Premafloxacin DMC4W03 TI TTIXTO3 DMC4W03 TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMC4W03 MA Inhibitor DMC4W03 RN Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7. DMC4W03 RU https://pubmed.ncbi.nlm.nih.gov/12604525 DMC4W03 DI DMC4W03 DMC4W03 DN Premafloxacin DMC4W03 TI TT1WJCI DMC4W03 TN Streptococcus Topoisomerase IV A (Stre-coc parC) DMC4W03 MA Inhibitor DMC4W03 RN Alteration of Escherichia coli topoisomerase IV to novobiocin resistance. Antimicrob Agents Chemother. 2003 Mar;47(3):941-7. DMC4W03 RU https://pubmed.ncbi.nlm.nih.gov/12604525 DMC4XJ6 DI DMC4XJ6 DMC4XJ6 DN EM-523 DMC4XJ6 TI TT953CX DMC4XJ6 TN Motilin receptor (MLNR) DMC4XJ6 MA Agonist DMC4XJ6 RN Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. DMC4XJ6 RU https://pubmed.ncbi.nlm.nih.gov/15764739 DMC4Y0R DI DMC4Y0R DMC4Y0R DN NSC-640583 DMC4Y0R TI TTJLP0R DMC4Y0R TN Quinone reductase 2 (NQO2) DMC4Y0R MA Inhibitor DMC4Y0R RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMC4Y0R RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMC4YGT DI DMC4YGT DMC4YGT DN KR-33889 DMC4YGT TI TTVDSZ0 DMC4YGT TN Poly [ADP-ribose] polymerase 1 (PARP1) DMC4YGT MA Inhibitor DMC4YGT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMC4YGT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMC520D DI DMC520D DMC520D DN Cycloguanil DMC520D TI TT9SL3Q DMC520D TN Polypeptide deformylase (PDF) DMC520D MA Inhibitor DMC520D RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMC520D RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMC537F DI DMC537F DMC537F DN 2,7-Bis[3-(ethylamino)propionamido]anthraquinone DMC537F TI TTQY2EJ DMC537F TN TERT messenger RNA (TERT mRNA) DMC537F MA Inhibitor DMC537F RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMC537F RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMC54UG DI DMC54UG DMC54UG DN G-573 DMC54UG TI TTROQ37 DMC54UG TN MAPK/ERK kinase kinase (MAP3K) DMC54UG MA Inhibitor DMC54UG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063). DMC54UG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063 DMC56YJ DI DMC56YJ DMC56YJ DN GNF-PF-2700 DMC56YJ TI TTNE7KG DMC56YJ TN Adenosine A2b receptor (ADORA2B) DMC56YJ MA Inhibitor DMC56YJ RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMC56YJ RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMC56YJ DI DMC56YJ DMC56YJ DN GNF-PF-2700 DMC56YJ TI TTM2AOE DMC56YJ TN Adenosine A2a receptor (ADORA2A) DMC56YJ MA Inhibitor DMC56YJ RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMC56YJ RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMC56YJ DI DMC56YJ DMC56YJ DN GNF-PF-2700 DMC56YJ TI TTK25J1 DMC56YJ TN Adenosine A1 receptor (ADORA1) DMC56YJ MA Inhibitor DMC56YJ RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMC56YJ RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMC5G6Y DI DMC5G6Y DMC5G6Y DN N-(3-Ethylphenyl)-N'-hydroxyoctanediamide DMC5G6Y TI TT6R7JZ DMC5G6Y TN Histone deacetylase 1 (HDAC1) DMC5G6Y MA Inhibitor DMC5G6Y RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMC5G6Y RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMC5G6Y DI DMC5G6Y DMC5G6Y DN N-(3-Ethylphenyl)-N'-hydroxyoctanediamide DMC5G6Y TI TTBH0VX DMC5G6Y TN Histone deacetylase (HDAC) DMC5G6Y MA Inhibitor DMC5G6Y RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMC5G6Y RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMC5GAW DI DMC5GAW DMC5GAW DN 4-(3-hexylureido)-N-phenylbenzenesulfonamide DMC5GAW TI TTWDC17 DMC5GAW TN Growth hormone secretagogue receptor 1 (GHSR) DMC5GAW MA Inhibitor DMC5GAW RN Discovery and optimization of novel 4-[(aminocarbonyl)amino]-N-[4-(2-aminoethyl)phenyl]benzenesulfonamide ghrelin receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6237-40. DMC5GAW RU https://pubmed.ncbi.nlm.nih.gov/19767208 DMC5H8G DI DMC5H8G DMC5H8G DN N-(4-hydroxybiphenyl-3-yl)benzamide DMC5H8G TI TTSHTOI DMC5H8G TN Histone deacetylase 2 (HDAC2) DMC5H8G MA Inhibitor DMC5H8G RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMC5H8G RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMC5H8G DI DMC5H8G DMC5H8G DN N-(4-hydroxybiphenyl-3-yl)benzamide DMC5H8G TI TT6R7JZ DMC5H8G TN Histone deacetylase 1 (HDAC1) DMC5H8G MA Inhibitor DMC5H8G RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMC5H8G RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMC5JAT DI DMC5JAT DMC5JAT DN PMID24900824C2-3-1 DMC5JAT TI TT78309 DMC5JAT TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DMC5JAT MA Inhibitor DMC5JAT RN Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1. DMC5JAT RU https://pubmed.ncbi.nlm.nih.gov/24900824 DMC5M76 DI DMC5M76 DMC5M76 DN 6-amino-4-trifluoromethylquinolin-2(1H)-one DMC5M76 TI TTKPW01 DMC5M76 TN Androgen receptor messenger RNA (AR mRNA) DMC5M76 MA Inhibitor DMC5M76 RN Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6. DMC5M76 RU https://pubmed.ncbi.nlm.nih.gov/17034117 DMC5OQ3 DI DMC5OQ3 DMC5OQ3 DN 2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine DMC5OQ3 TI TTM2AOE DMC5OQ3 TN Adenosine A2a receptor (ADORA2A) DMC5OQ3 MA Inhibitor DMC5OQ3 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMC5OQ3 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMC5OQ3 DI DMC5OQ3 DMC5OQ3 DN 2-chloro-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine DMC5OQ3 TI TTK25J1 DMC5OQ3 TN Adenosine A1 receptor (ADORA1) DMC5OQ3 MA Inhibitor DMC5OQ3 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMC5OQ3 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMC5PI4 DI DMC5PI4 DMC5PI4 DN 1-(3-Chloro-phenyl)-3-(4-hydroxy-decyl)-urea DMC5PI4 TI TT7WVHI DMC5PI4 TN Soluble epoxide hydrolase (EPHX2) DMC5PI4 MA Inhibitor DMC5PI4 RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMC5PI4 RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMC5RKY DI DMC5RKY DMC5RKY DN Concatameric CTLA4Ig DMC5RKY TI TTI2S1D DMC5RKY TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMC5RKY MA Modulator DMC5RKY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743). DMC5RKY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743 DMC5RL7 DI DMC5RL7 DMC5RL7 DN DNX-2000 DMC5RL7 TI TTOU65C DMC5RL7 TN Tyrosine-protein kinase SYK (SYK) DMC5RL7 MA Inhibitor DMC5RL7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). DMC5RL7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230 DMC5RZ9 DI DMC5RZ9 DMC5RZ9 DN JWH-245 DMC5RZ9 TI TTMSFAW DMC5RZ9 TN Cannabinoid receptor 2 (CB2) DMC5RZ9 MA Inhibitor DMC5RZ9 RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMC5RZ9 RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMC5RZ9 DI DMC5RZ9 DMC5RZ9 DN JWH-245 DMC5RZ9 TI TT6OEDT DMC5RZ9 TN Cannabinoid receptor 1 (CB1) DMC5RZ9 MA Inhibitor DMC5RZ9 RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMC5RZ9 RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMC5XQ6 DI DMC5XQ6 DMC5XQ6 DN LD201t1 DMC5XQ6 TI TT2IYXF DMC5XQ6 TN L-selectin (SELL) DMC5XQ6 RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMC5XQ6 RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMC5Z2I DI DMC5Z2I DMC5Z2I DN (S)(+)-2-(4-fluorophenyl)-7-methoxychroman-4-one DMC5Z2I TI TTGP7BY DMC5Z2I TN Monoamine oxidase type B (MAO-B) DMC5Z2I MA Inhibitor DMC5Z2I RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMC5Z2I RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMC62K1 DI DMC62K1 DMC62K1 DN N-[4-(3-pyridylethynyl)-2-thiazolyl]acetamide DMC62K1 TI TTHS256 DMC62K1 TN Metabotropic glutamate receptor 5 (mGluR5) DMC62K1 MA Inhibitor DMC62K1 RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMC62K1 RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMC64EI DI DMC64EI DMC64EI DN Beta-alanine DMC64EI TI TT8RXO5 DMC64EI TN GABA transporter-3 (SLC6A11) DMC64EI MA Blocker DMC64EI RN Stable expression of a neuronal gamma-aminobutyric acid transporter, GAT-3, in mammalian cells demonstrates unique pharmacological properties and ion dependence. Mol Pharmacol. 1994 Sep;46(3):550-7. DMC64EI RU https://pubmed.ncbi.nlm.nih.gov/7935337 DMC6DAZ DI DMC6DAZ DMC6DAZ DN CYCLAZOCINE DMC6DAZ TI TTQW87Y DMC6DAZ TN Opioid receptor kappa (OPRK1) DMC6DAZ MA Inhibitor DMC6DAZ RN Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22. DMC6DAZ RU https://pubmed.ncbi.nlm.nih.gov/10633042 DMC6DAZ DI DMC6DAZ DMC6DAZ DN CYCLAZOCINE DMC6DAZ TI TT27RFC DMC6DAZ TN Opioid receptor delta (OPRD1) DMC6DAZ MA Inhibitor DMC6DAZ RN Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants ... Bioorg Med Chem Lett. 2009 Jan 15;19(2):365-8. DMC6DAZ RU https://pubmed.ncbi.nlm.nih.gov/19091564 DMC6DAZ DI DMC6DAZ DMC6DAZ DN CYCLAZOCINE DMC6DAZ TI TTKWM86 DMC6DAZ TN Opioid receptor mu (MOP) DMC6DAZ MA Inhibitor DMC6DAZ RN Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22. DMC6DAZ RU https://pubmed.ncbi.nlm.nih.gov/10633042 DMC6E8R DI DMC6E8R DMC6E8R DN 2-(3-aminophenoxy)-5-hexylphenol DMC6E8R TI TTVTX4N DMC6E8R TN Bacterial Fatty acid synthetase I (Bact inhA) DMC6E8R MA Inhibitor DMC6E8R RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMC6E8R RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMC6GUA DI DMC6GUA DMC6GUA DN Peptide alpha-keto-beta-aldehyde-based inhibitors DMC6GUA TI TT36ETB DMC6GUA TN Cathepsin L (CTSL) DMC6GUA MA Inhibitor DMC6GUA RN Synthesis and kinetic evaluation of peptide alpha-keto-beta-aldehyde-based inhibitors of trypsin-like serine proteases. J Pharm Pharmacol. 2001 Apr;53(4):473-80. DMC6GUA RU https://pubmed.ncbi.nlm.nih.gov/11341363 DMC6HQL DI DMC6HQL DMC6HQL DN PMID2296036C4d DMC6HQL TI TTPADOQ DMC6HQL TN HMG-CoA reductase (HMGCR) DMC6HQL MA Inhibitor DMC6HQL RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60. DMC6HQL RU https://pubmed.ncbi.nlm.nih.gov/2296036 DMC6J3B DI DMC6J3B DMC6J3B DN FAUC 113 DMC6J3B TI TTE0A2F DMC6J3B TN Dopamine D4 receptor (D4R) DMC6J3B MA Antagonist DMC6J3B RN Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J Med Chem. 2001 Apr 12;44(8):1151-7. DMC6J3B RU https://pubmed.ncbi.nlm.nih.gov/11312915 DMC6KYF DI DMC6KYF DMC6KYF DN WAY 100135 DMC6KYF TI TTSQIFT DMC6KYF TN 5-HT 1A receptor (HTR1A) DMC6KYF MA Antagonist DMC6KYF RN Influence of 5-HT1A receptor antagonism on plus-maze behaviour in mice. II. WAY 100635, SDZ 216-525 and NAN-190. Pharmacol Biochem Behav. 1997 Oct;58(2):593-603. DMC6KYF RU https://pubmed.ncbi.nlm.nih.gov/9300624 DMC6U93 DI DMC6U93 DMC6U93 DN Torin2 DMC6U93 TI TTCJG29 DMC6U93 TN Serine/threonine-protein kinase mTOR (mTOR) DMC6U93 MA Inhibitor DMC6U93 RN Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin. Anticancer Res. 2016 Jan;36(1):95-102. DMC6U93 RU https://pubmed.ncbi.nlm.nih.gov/26722032 DMC70P1 DI DMC70P1 DMC70P1 DN 3-hydroxy capric acid DMC70P1 TI TTG0MQD DMC70P1 TN Inflammation-related GPCR EX33 (GPR84) DMC70P1 MA Agonist DMC70P1 RN Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. DMC70P1 RU https://pubmed.ncbi.nlm.nih.gov/23449982 DMC73DY DI DMC73DY DMC73DY DN (R)-3-(4-propylmorpholin-2-yl)phenol DMC73DY TI TTJQOD7 DMC73DY TN 5-HT 2A receptor (HTR2A) DMC73DY MA Inhibitor DMC73DY RN Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6691-6. DMC73DY RU https://pubmed.ncbi.nlm.nih.gov/17976986 DMC79YF DI DMC79YF DMC79YF DN MR-20494 DMC79YF TI TTSZLWK DMC79YF TN Aromatase (CYP19A1) DMC79YF MA Inhibitor DMC79YF RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMC79YF RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMC7ADZ DI DMC7ADZ DMC7ADZ DN Manzamine Y DMC7ADZ TI TTRSMW9 DMC7ADZ TN Glycogen synthase kinase-3 beta (GSK-3B) DMC7ADZ MA Inhibitor DMC7ADZ RN Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40. DMC7ADZ RU https://pubmed.ncbi.nlm.nih.gov/16872140 DMC7DYX DI DMC7DYX DMC7DYX DN Edoxudine DMC7DYX TI TTP3QRF DMC7DYX TN Thymidine kinase 1 (TK1) DMC7DYX MA Inhibitor DMC7DYX RN Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. DMC7DYX RU https://pubmed.ncbi.nlm.nih.gov/17438061 DMC7FLT DI DMC7FLT DMC7FLT DN 1,5-Dihydroxy-10H-anthracen-9-one DMC7FLT TI TT2J34L DMC7FLT TN Arachidonate 5-lipoxygenase (5-LOX) DMC7FLT MA Inhibitor DMC7FLT RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMC7FLT RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMC7HIS DI DMC7HIS DMC7HIS DN G749 DMC7HIS TI TTO7LKR DMC7HIS TN Tyrosine-protein kinase Mer (MERTK) DMC7HIS MA Inhibitor DMC7HIS RN G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19. DMC7HIS RU https://pubmed.ncbi.nlm.nih.gov/24532805 DMC7HIS DI DMC7HIS DMC7HIS DN G749 DMC7HIS TI TTGJCWZ DMC7HIS TN Fms-like tyrosine kinase 3 (FLT-3) DMC7HIS MA Inhibitor DMC7HIS RN G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123(14):2209-19. DMC7HIS RU https://pubmed.ncbi.nlm.nih.gov/24532805 DMC7HKA DI DMC7HKA DMC7HKA DN 4-Benzenesulfonylamino-benzenesulfonamide DMC7HKA TI TTSYM0R DMC7HKA TN Carbonic anhydrase XII (CA-XII) DMC7HKA MA Inhibitor DMC7HKA RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMC7HKA RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMC7HKA DI DMC7HKA DMC7HKA DN 4-Benzenesulfonylamino-benzenesulfonamide DMC7HKA TI TTANPDJ DMC7HKA TN Carbonic anhydrase II (CA-II) DMC7HKA MA Inhibitor DMC7HKA RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMC7HKA RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMC7HKA DI DMC7HKA DMC7HKA DN 4-Benzenesulfonylamino-benzenesulfonamide DMC7HKA TI TT2LVK8 DMC7HKA TN Carbonic anhydrase IX (CA-IX) DMC7HKA MA Inhibitor DMC7HKA RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMC7HKA RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMC7HKA DI DMC7HKA DMC7HKA DN 4-Benzenesulfonylamino-benzenesulfonamide DMC7HKA TI TTHQPL7 DMC7HKA TN Carbonic anhydrase I (CA-I) DMC7HKA MA Inhibitor DMC7HKA RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMC7HKA RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMC7LND DI DMC7LND DMC7LND DN Tyr-D-Ala-Gly-Phe-Met-NH2 DMC7LND TI TTKWM86 DMC7LND TN Opioid receptor mu (MOP) DMC7LND MA Inhibitor DMC7LND RN Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing tw... J Med Chem. 2010 Aug 12;53(15):5491-501. DMC7LND RU https://pubmed.ncbi.nlm.nih.gov/20617791 DMC7LND DI DMC7LND DMC7LND DN Tyr-D-Ala-Gly-Phe-Met-NH2 DMC7LND TI TT27RFC DMC7LND TN Opioid receptor delta (OPRD1) DMC7LND MA Inhibitor DMC7LND RN The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43. DMC7LND RU https://pubmed.ncbi.nlm.nih.gov/19762245 DMC7MLN DI DMC7MLN DMC7MLN DN Isosorbide-2-(methylcarbamate)-5-benzoate DMC7MLN TI TTEB0GD DMC7MLN TN Cholinesterase (BCHE) DMC7MLN MA Inhibitor DMC7MLN RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMC7MLN RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMC7MLN DI DMC7MLN DMC7MLN DN Isosorbide-2-(methylcarbamate)-5-benzoate DMC7MLN TI TT1RS9F DMC7MLN TN Acetylcholinesterase (AChE) DMC7MLN MA Inhibitor DMC7MLN RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMC7MLN RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMC7Q38 DI DMC7Q38 DMC7Q38 DN ISIS 13741 DMC7Q38 TI TT0EOB8 DMC7Q38 TN B-Raf messenger RNA (BRAF mRNA) DMC7Q38 RN US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression. DMC7Q38 RU http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true DMC7TNF DI DMC7TNF DMC7TNF DN Benzoyl-Arginine-Alanine-Methyl Ketone DMC7TNF TI TTEAID7 DMC7TNF TN Trypanosoma Cruzipain (Trypano CYSP) DMC7TNF MA Inhibitor DMC7TNF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMC7TNF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMC7TNF DI DMC7TNF DMC7TNF DN Benzoyl-Arginine-Alanine-Methyl Ketone DMC7TNF TI TTJOKD1 DMC7TNF TN Cathepsin F (CTSF) DMC7TNF MA Inhibitor DMC7TNF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMC7TNF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMC7XST DI DMC7XST DMC7XST DN N-Benzyl-1'H-phenothiazine-1'-carboxamide DMC7XST TI TTEB0GD DMC7XST TN Cholinesterase (BCHE) DMC7XST MA Inhibitor DMC7XST RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMC7XST RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMC7YQE DI DMC7YQE DMC7YQE DN SM-122 DMC7YQE TI TTK3WBU DMC7YQE TN XIAP messenger RNA (XIAP mRNA) DMC7YQE MA Inhibitor DMC7YQE RN Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7. DMC7YQE RU https://pubmed.ncbi.nlm.nih.gov/20684551 DMC7YQE DI DMC7YQE DMC7YQE DN SM-122 DMC7YQE TI TTAIWZN DMC7YQE TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DMC7YQE MA Inhibitor DMC7YQE RN Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7. DMC7YQE RU https://pubmed.ncbi.nlm.nih.gov/20684551 DMC80TA DI DMC80TA DMC80TA DN IRAK4 inhibitor 4b DMC80TA TI TTKFVXR DMC80TA TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMC80TA MA Inhibitor DMC80TA RN IRAK-4 inhibitors. Part 1: a series of amides. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3211-4. DMC80TA RU https://pubmed.ncbi.nlm.nih.gov/18474425 DMC82DA DI DMC82DA DMC82DA DN LY233053 DMC82DA TI TTKJEMQ DMC82DA TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMC82DA MA Antagonist DMC82DA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMC82DA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMC82DA DI DMC82DA DMC82DA DN LY233053 DMC82DA TI TTN9D8E DMC82DA TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMC82DA MA Antagonist DMC82DA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMC82DA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMC82DA DI DMC82DA DMC82DA DN LY233053 DMC82DA TI TT5POTG DMC82DA TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMC82DA MA Antagonist DMC82DA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMC82DA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMC82DA DI DMC82DA DMC82DA DN LY233053 DMC82DA TI TT1M8OW DMC82DA TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMC82DA MA Antagonist DMC82DA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMC82DA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMC82XN DI DMC82XN DMC82XN DN ASN04421891 DMC82XN TI TTMPART DMC82XN TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMC82XN MA Agonist DMC82XN RN In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52. DMC82XN RU https://pubmed.ncbi.nlm.nih.gov/21744154 DMC83HA DI DMC83HA DMC83HA DN WAY-254011 DMC83HA TI TTXA6PH DMC83HA TN Oxysterols receptor LXR-beta (NR1H2) DMC83HA MA Inhibitor DMC83HA RN Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta. Bioorg Med Chem. 2009 May 15;17(10):3519-27. DMC83HA RU https://pubmed.ncbi.nlm.nih.gov/19394832 DMC83HA DI DMC83HA DMC83HA DN WAY-254011 DMC83HA TI TTECBXN DMC83HA TN Oxysterols receptor LXR-alpha (NR1H3) DMC83HA MA Inhibitor DMC83HA RN Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta. Bioorg Med Chem. 2009 May 15;17(10):3519-27. DMC83HA RU https://pubmed.ncbi.nlm.nih.gov/19394832 DMC873V DI DMC873V DMC873V DN Phosphoric acid mono-((E)-dodec-9-enyl) ester DMC873V TI TTQ6S1K DMC873V TN Lysophosphatidic acid receptor 1 (LPAR1) DMC873V MA Inhibitor DMC873V RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMC873V RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMC89HI DI DMC89HI DMC89HI DN NM-9308 DMC89HI TI TTA0P7K DMC89HI TN Complement factor B (CFB) DMC89HI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2339). DMC89HI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2339 DMC8D4R DI DMC8D4R DMC8D4R DN 4-Iodo-6-nitro-2-piperazin-1-yl-quinoline DMC8D4R TI TT3ROYC DMC8D4R TN Serotonin transporter (SERT) DMC8D4R MA Inhibitor DMC8D4R RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DMC8D4R RU https://pubmed.ncbi.nlm.nih.gov/11859009 DMC8G4S DI DMC8G4S DMC8G4S DN PF-4181366 DMC8G4S TI TTZOEBC DMC8G4S TN Phosphodiesterase 9 (PDE9) DMC8G4S MA Inhibitor DMC8G4S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1309). DMC8G4S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1309 DMC8G7X DI DMC8G7X DMC8G7X DN fasidotrilat DMC8G7X TI TTL69WB DMC8G7X TN Angiotensin-converting enzyme (ACE) DMC8G7X MA Inhibitor DMC8G7X RN Protease inhibitors in the clinic. Med Chem. 2005 Jan;1(1):71-104. DMC8G7X RU https://pubmed.ncbi.nlm.nih.gov/16789888 DMC8G7X DI DMC8G7X DMC8G7X DN fasidotrilat DMC8G7X TI TT5TKPM DMC8G7X TN Neutral endopeptidase (MME) DMC8G7X MA Inhibitor DMC8G7X RN Modelling of aldose reductase inhibitory activity of pyrrol-1-yl-acetic acid derivatives by means of multivariate statistics. Med Chem. 2005 Jul;1(4):321-6. DMC8G7X RU https://pubmed.ncbi.nlm.nih.gov/16789889 DMC8IEM DI DMC8IEM DMC8IEM DN 2-[1,4]Oxazepan-4-yl-benzo[h]chromen-4-one DMC8IEM TI TTK3PY9 DMC8IEM TN DNA-dependent protein kinase catalytic (PRKDC) DMC8IEM MA Inhibitor DMC8IEM RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMC8IEM RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMC8L4J DI DMC8L4J DMC8L4J DN N-isopentyl-5,6-dip-tolylpyrazine-2-carboxamide DMC8L4J TI TT6OEDT DMC8L4J TN Cannabinoid receptor 1 (CB1) DMC8L4J MA Inhibitor DMC8L4J RN Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. DMC8L4J RU https://pubmed.ncbi.nlm.nih.gov/17513109 DMC8O3Z DI DMC8O3Z DMC8O3Z DN 7-AMINO-4-METHYL-CHROMEN-2-ONE DMC8O3Z TI TTL2ADK DMC8O3Z TN Rotamase A (PPIA) DMC8O3Z MA Inhibitor DMC8O3Z RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMC8O3Z RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMC8WS4 DI DMC8WS4 DMC8WS4 DN (-)-cyclorphan DMC8WS4 TI TTKWM86 DMC8WS4 TN Opioid receptor mu (MOP) DMC8WS4 MA Inhibitor DMC8WS4 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMC8WS4 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMC8WS4 DI DMC8WS4 DMC8WS4 DN (-)-cyclorphan DMC8WS4 TI TTQW87Y DMC8WS4 TN Opioid receptor kappa (OPRK1) DMC8WS4 MA Inhibitor DMC8WS4 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMC8WS4 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMC8WS4 DI DMC8WS4 DMC8WS4 DN (-)-cyclorphan DMC8WS4 TI TT27RFC DMC8WS4 TN Opioid receptor delta (OPRD1) DMC8WS4 MA Inhibitor DMC8WS4 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMC8WS4 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMC8X9Y DI DMC8X9Y DMC8X9Y DN CD666 DMC8X9Y TI TT1Q3IE DMC8X9Y TN Retinoic acid receptor gamma (RARG) DMC8X9Y MA Agonist DMC8X9Y RN Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83. DMC8X9Y RU https://pubmed.ncbi.nlm.nih.gov/1323296 DMC8X9Y DI DMC8X9Y DMC8X9Y DN CD666 DMC8X9Y TI TTISP28 DMC8X9Y TN Retinoic acid receptor beta (RARB) DMC8X9Y MA Agonist DMC8X9Y RN Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83. DMC8X9Y RU https://pubmed.ncbi.nlm.nih.gov/1323296 DMC8X9Y DI DMC8X9Y DMC8X9Y DN CD666 DMC8X9Y TI TTW38KT DMC8X9Y TN Retinoic acid receptor alpha (RARA) DMC8X9Y MA Agonist DMC8X9Y RN Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma. Biochem Biophys Res Commun. 1992 Jul 31;186(2):977-83. DMC8X9Y RU https://pubmed.ncbi.nlm.nih.gov/1323296 DMC92DQ DI DMC92DQ DMC92DQ DN TAUTOMYCIN DMC92DQ TI TTFLH0E DMC92DQ TN Serine/threonine PP1-alpha (PPP1CA) DMC92DQ MA Inhibitor DMC92DQ RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DMC92DQ RU https://pubmed.ncbi.nlm.nih.gov/11881984 DMC92ER DI DMC92ER DMC92ER DN KSG-504 DMC92ER TI TTCG0AL DMC92ER TN Cholecystokinin receptor type A (CCKAR) DMC92ER MA Antagonist DMC92ER RN Effects of KSG-504, a new CCK-A receptor antagonist, on gallbladder and gastrointestinal functions. Nihon Yakurigaku Zasshi. 1996 Jan;107(1):33-44. DMC92ER RU https://pubmed.ncbi.nlm.nih.gov/8720296 DMC958O DI DMC958O DMC958O DN TNK-651 DMC958O TI TT84ETX DMC958O TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMC958O MA Modulator DMC958O RN Synthesis and Antiviral Evaluation of 1-[(2-Phenoxyethyl)oxymethyl] and 6-(3,5-Dimethoxybenzyl) Analogues of HIV Drugs Emivirine and TNK-651.Drug Res (Stuttg).2016 Apr;66(4):181-8. DMC958O RU https://www.ncbi.nlm.nih.gov/pubmed/26313923 DMC95YB DI DMC95YB DMC95YB DN Y-39041 DMC95YB TI TTF8CQI DMC95YB TN Tumor necrosis factor (TNF) DMC95YB MA Inhibitor DMC95YB RN A novel anti-rheumatic drug suppresses tumor necrosis factor-alpha and augments interleukin-10 in adjuvant arthritic rats. Eur J Pharmacol. 2000 Dec 15;409(3):331-5. DMC95YB RU https://pubmed.ncbi.nlm.nih.gov/11108829 DMC9G2Y DI DMC9G2Y DMC9G2Y DN C[RGD-(S)-alpha-TfmfV] DMC9G2Y TI TTJA1ZO DMC9G2Y TN ITGB3 messenger RNA (ITGB3 mRNA) DMC9G2Y MA Inhibitor DMC9G2Y RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMC9G2Y RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMC9G2Y DI DMC9G2Y DMC9G2Y DN C[RGD-(S)-alpha-TfmfV] DMC9G2Y TI TTT1R2L DMC9G2Y TN Integrin alpha-V (ITGAV) DMC9G2Y MA Inhibitor DMC9G2Y RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMC9G2Y RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMC9OL7 DI DMC9OL7 DMC9OL7 DN ISIS 3067 DMC9OL7 TI TTA1L39 DMC9OL7 TN ICAM1 messenger RNA (ICAM1 mRNA) DMC9OL7 RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DMC9OL7 RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DMC9WAL DI DMC9WAL DMC9WAL DN Nicotinaldehyde O-4-propoxyphenylcarbamoyl oxime DMC9WAL TI TTDP1UC DMC9WAL TN Fatty acid amide hydrolase (FAAH) DMC9WAL MA Inhibitor DMC9WAL RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMC9WAL RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMC9XJA DI DMC9XJA DMC9XJA DN NRP290 DMC9XJA TI TTKWM86 DMC9XJA TN Opioid receptor mu (MOP) DMC9XJA MA Agonist DMC9XJA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMC9XJA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMC9XJA DI DMC9XJA DMC9XJA DN NRP290 DMC9XJA TI TT27RFC DMC9XJA TN Opioid receptor delta (OPRD1) DMC9XJA MA Agonist DMC9XJA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMC9XJA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMC9XJA DI DMC9XJA DMC9XJA DN NRP290 DMC9XJA TI TTQW87Y DMC9XJA TN Opioid receptor kappa (OPRK1) DMC9XJA MA Agonist DMC9XJA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). DMC9XJA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 DMC9Z45 DI DMC9Z45 DMC9Z45 DN 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol DMC9Z45 TI TTNGILX DMC9Z45 TN Adrenergic receptor alpha-1A (ADRA1A) DMC9Z45 MA Inhibitor DMC9Z45 RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DMC9Z45 RU https://pubmed.ncbi.nlm.nih.gov/1313109 DMC9Z45 DI DMC9Z45 DMC9Z45 DN 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol DMC9Z45 TI TT34BHT DMC9Z45 TN Adrenergic receptor alpha-1D (ADRA1D) DMC9Z45 MA Inhibitor DMC9Z45 RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DMC9Z45 RU https://pubmed.ncbi.nlm.nih.gov/1313109 DMC9Z45 DI DMC9Z45 DMC9Z45 DN 4-(4-Isopropyl-morpholin-2-yl)-benzene-1,2-diol DMC9Z45 TI TTBRKXS DMC9Z45 TN Adrenergic receptor alpha-1B (ADRA1B) DMC9Z45 MA Inhibitor DMC9Z45 RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DMC9Z45 RU https://pubmed.ncbi.nlm.nih.gov/1313109 DMCA0WJ DI DMCA0WJ DMCA0WJ DN Biliverdine Ix Alpha DMCA0WJ TI TTI6V2A DMCA0WJ TN Heme oxygenase 1 (HMOX1) DMCA0WJ MA Inhibitor DMCA0WJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCA0WJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCA2XQ DI DMCA2XQ DMCA2XQ DN 4-hydroxy-but-2-enoate DMCA2XQ TI TT6TKEN DMCA2XQ TN Gamma-hydroxybutyrate receptor (SLC52A2) DMCA2XQ MA Inhibitor DMCA2XQ RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DMCA2XQ RU https://pubmed.ncbi.nlm.nih.gov/3361576 DMCA4QR DI DMCA4QR DMCA4QR DN Ac-His-Trp-Ala-Val-Ala-His-Leu-Met-NH2 DMCA4QR TI TTC1MVT DMCA4QR TN Gastrin-releasing peptide receptor (GRPR) DMCA4QR MA Inhibitor DMCA4QR RN Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7. DMCA4QR RU https://pubmed.ncbi.nlm.nih.gov/2066982 DMCA4RM DI DMCA4RM DMCA4RM DN GW7604 DMCA4RM TI TTZAYWL DMCA4RM TN Estrogen receptor (ESR) DMCA4RM MA Antagonist DMCA4RM RN Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen. Endocrinology. 2001 Feb;142(2):838-46. DMCA4RM RU https://pubmed.ncbi.nlm.nih.gov/11159857 DMCA76M DI DMCA76M DMCA76M DN Cyclotheonamide E5 DMCA76M TI TT6L509 DMCA76M TN Coagulation factor IIa (F2) DMCA76M MA Inhibitor DMCA76M RN Cyclotheonamide E4 and E5, new potent tryptase inhibitors from an Ircinia species of sponge. J Nat Prod. 2002 Mar;65(3):259-61. DMCA76M RU https://pubmed.ncbi.nlm.nih.gov/11908961 DMCA7XU DI DMCA7XU DMCA7XU DN 3,4,5-Trimethoxy-3'-amino-trans-stilbene DMCA7XU TI TTSZLWK DMCA7XU TN Aromatase (CYP19A1) DMCA7XU MA Inhibitor DMCA7XU RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMCA7XU RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMCADRI DI DMCADRI DMCADRI DN 1-(2-Methoxy-phenyl)-4-propyl-piperazine DMCADRI TI TTJQOD7 DMCADRI TN 5-HT 2A receptor (HTR2A) DMCADRI MA Inhibitor DMCADRI RN Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60. DMCADRI RU https://pubmed.ncbi.nlm.nih.gov/8064802 DMCADRI DI DMCADRI DMCADRI DN 1-(2-Methoxy-phenyl)-4-propyl-piperazine DMCADRI TI TTSQIFT DMCADRI TN 5-HT 1A receptor (HTR1A) DMCADRI MA Inhibitor DMCADRI RN Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60. DMCADRI RU https://pubmed.ncbi.nlm.nih.gov/8064802 DMCALYO DI DMCALYO DMCALYO DN 17-desmethoxy-17-aminogeldanamycin DMCALYO TI TT78R5H DMCALYO TN Heat shock protein 90 alpha (HSP90A) DMCALYO MA Inhibitor DMCALYO RN Heat shock protein 90: inhibitors in clinical trials. J Med Chem. 2010 Jan 14;53(1):3-17. DMCALYO RU https://pubmed.ncbi.nlm.nih.gov/20055425 DMCAO3V DI DMCAO3V DMCAO3V DN C-21191 DMCAO3V TI TTEX6LM DMCAO3V TN GABA(A) receptor gamma-3 (GABRG3) DMCAO3V MA Modulator DMCAO3V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMCAO3V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMCAQ5T DI DMCAQ5T DMCAQ5T DN 1,1,1-Trifluoro-6-(4-hexyloxy-phenyl)-hexan-2-one DMCAQ5T TI TTT1JVS DMCAQ5T TN Cytosolic phospholipase A2 (GIVA cPLA2) DMCAQ5T MA Inhibitor DMCAQ5T RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMCAQ5T RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMCAR7B DI DMCAR7B DMCAR7B DN O-Sialic Acid DMCAR7B TI TTE5VG0 DMCAR7B TN P-selectin (SELP) DMCAR7B MA Inhibitor DMCAR7B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCAR7B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCAR7B DI DMCAR7B DMCAR7B DN O-Sialic Acid DMCAR7B TI TT50QJ3 DMCAR7B TN Influenza Neuraminidase (Influ NA) DMCAR7B MA Inhibitor DMCAR7B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCAR7B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCAR7B DI DMCAR7B DMCAR7B DN O-Sialic Acid DMCAR7B TI TTAU4D6 DMCAR7B TN E-selectin (SELE) DMCAR7B MA Inhibitor DMCAR7B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCAR7B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCAR7B DI DMCAR7B DMCAR7B DN O-Sialic Acid DMCAR7B TI TTMF541 DMCAR7B TN Liver carboxylesterase (CES1) DMCAR7B MA Inhibitor DMCAR7B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCAR7B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCASRD DI DMCASRD DMCASRD DN RU-5135 DMCASRD TI TTGXH6N DMCASRD TN GABA(A) receptor delta (GABRD) DMCASRD MA Modulator DMCASRD RN Complex interactions between the steroid derivative RU 5135 and the GABAA-receptor complex. Eur J Pharmacol. 1992 Oct 1;227(2):147-51. DMCASRD RU https://www.ncbi.nlm.nih.gov/pubmed/1330646 DMCAXNU DI DMCAXNU DMCAXNU DN PMID20363624C(+)17a DMCAXNU TI TTWNV8U DMCAXNU TN Nicotinic acid receptor (HCAR2) DMCAXNU MA Agonist DMCAXNU RN Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a). Bioorg Med Chem Lett. 2010 May 1;20(9):2797-800. DMCAXNU RU https://pubmed.ncbi.nlm.nih.gov/20363624 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TTCPG9S DMCAYXF TN 5-HT 1E receptor (HTR1E) DMCAYXF MA Agonist DMCAYXF RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/14744596 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TT0MI3F DMCAYXF TN 5-HT 1F receptor (HTR1F) DMCAYXF MA Agonist DMCAYXF RN Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/8380639 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TT07C3Y DMCAYXF TN 5-HT 4 receptor (HTR4) DMCAYXF MA Agonist DMCAYXF RN [3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/9225293 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TTWJBZ5 DMCAYXF TN 5-HT 2C receptor (HTR2C) DMCAYXF MA Agonist DMCAYXF RN High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/10217294 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TT0K1SC DMCAYXF TN 5-HT 2B receptor (HTR2B) DMCAYXF MA Agonist DMCAYXF RN The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/15466450 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TTJS8PY DMCAYXF TN 5-HT 6 receptor (HTR6) DMCAYXF MA Agonist DMCAYXF RN Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/9798944 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TTJQOD7 DMCAYXF TN 5-HT 2A receptor (HTR2A) DMCAYXF MA Agonist DMCAYXF RN Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 2000 Nov;58(5):877-86. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/11040033 DMCAYXF DI DMCAYXF DMCAYXF DN alpha-methyl-5-HT DMCAYXF TI TT6MSOK DMCAYXF TN 5-HT 1D receptor (HTR1D) DMCAYXF MA Agonist DMCAYXF RN Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80. DMCAYXF RU https://pubmed.ncbi.nlm.nih.gov/8967979 DMCAZ32 DI DMCAZ32 DMCAZ32 DN 2,3,4-trihydroxy-5-isopropyl-N-phenyl-benzamide DMCAZ32 TI TTJGNVC DMCAZ32 TN Apoptosis regulator Bcl-2 (BCL-2) DMCAZ32 MA Inhibitor DMCAZ32 RN Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. DMCAZ32 RU https://pubmed.ncbi.nlm.nih.gov/17034116 DMCB2IM DI DMCB2IM DMCB2IM DN 7-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one DMCB2IM TI TTFBNVI DMCB2IM TN Aldose reductase (AKR1B1) DMCB2IM MA Inhibitor DMCB2IM RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DMCB2IM RU https://pubmed.ncbi.nlm.nih.gov/10354396 DMCB2N9 DI DMCB2N9 DMCB2N9 DN Ro-4938581 DMCB2N9 TI TTBMV1G DMCB2N9 TN GABA(A) receptor alpha-2 (GABRA2) DMCB2N9 MA Inhibitor DMCB2N9 RN The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. DMCB2N9 RU https://pubmed.ncbi.nlm.nih.gov/19762240 DMCB2N9 DI DMCB2N9 DMCB2N9 DN Ro-4938581 DMCB2N9 TI TT06RH5 DMCB2N9 TN GABA(A) receptor gamma-2 (GABRG2) DMCB2N9 MA Inhibitor DMCB2N9 RN The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. DMCB2N9 RU https://pubmed.ncbi.nlm.nih.gov/19762240 DMCB2N9 DI DMCB2N9 DMCB2N9 DN Ro-4938581 DMCB2N9 TI TT37EDJ DMCB2N9 TN GABA(A) receptor alpha-3 (GABRA3) DMCB2N9 MA Inhibitor DMCB2N9 RN The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. DMCB2N9 RU https://pubmed.ncbi.nlm.nih.gov/19762240 DMCB2N9 DI DMCB2N9 DMCB2N9 DN Ro-4938581 DMCB2N9 TI TTNJYV2 DMCB2N9 TN Gamma-aminobutyric acid receptor (GAR) DMCB2N9 MA Inhibitor DMCB2N9 RN The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. DMCB2N9 RU https://pubmed.ncbi.nlm.nih.gov/19762240 DMCB2N9 DI DMCB2N9 DMCB2N9 DN Ro-4938581 DMCB2N9 TI TT1MPAY DMCB2N9 TN GABA(A) receptor alpha-1 (GABRA1) DMCB2N9 MA Inhibitor DMCB2N9 RN The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. DMCB2N9 RU https://pubmed.ncbi.nlm.nih.gov/19762240 DMCB2N9 DI DMCB2N9 DMCB2N9 DN Ro-4938581 DMCB2N9 TI TTNZPQ1 DMCB2N9 TN GABA(A) receptor alpha-5 (GABRA5) DMCB2N9 MA Inhibitor DMCB2N9 RN The discovery and unique pharmacological profile of RO4938581 and RO4882224 as potent and selective GABAA alpha5 inverse agonists for the treatment... Bioorg Med Chem Lett. 2009 Oct 15;19(20):5940-4. DMCB2N9 RU https://pubmed.ncbi.nlm.nih.gov/19762240 DMCB74T DI DMCB74T DMCB74T DN (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine DMCB74T TI TTGP7BY DMCB74T TN Monoamine oxidase type B (MAO-B) DMCB74T MA Inhibitor DMCB74T RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMCB74T RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMCB74T DI DMCB74T DMCB74T DN (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholine DMCB74T TI TT3WG5C DMCB74T TN Monoamine oxidase type A (MAO-A) DMCB74T MA Inhibitor DMCB74T RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMCB74T RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMCBFJQ DI DMCBFJQ DMCBFJQ DN [1,4]Thiazepan-(3E)-ylideneamine DMCBFJQ TI TTF10I9 DMCBFJQ TN Nitric-oxide synthase inducible (NOS2) DMCBFJQ MA Inhibitor DMCBFJQ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMCBFJQ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMCBFJQ DI DMCBFJQ DMCBFJQ DN [1,4]Thiazepan-(3E)-ylideneamine DMCBFJQ TI TTZUFI5 DMCBFJQ TN Nitric-oxide synthase brain (NOS1) DMCBFJQ MA Inhibitor DMCBFJQ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMCBFJQ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMCBFJQ DI DMCBFJQ DMCBFJQ DN [1,4]Thiazepan-(3E)-ylideneamine DMCBFJQ TI TTCM4B3 DMCBFJQ TN Nitric-oxide synthase endothelial (NOS3) DMCBFJQ MA Inhibitor DMCBFJQ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMCBFJQ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMCBV5F DI DMCBV5F DMCBV5F DN ZK-814048 DMCBV5F TI TTCIHJA DMCBV5F TN Coagulation factor Xa (F10) DMCBV5F MA Inhibitor DMCBV5F RN Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80. DMCBV5F RU https://pubmed.ncbi.nlm.nih.gov/17536795 DMCBV5F DI DMCBV5F DMCBV5F DN ZK-814048 DMCBV5F TI TTPLTSQ DMCBV5F TN Neutrophil elastase (NE) DMCBV5F MA Inhibitor DMCBV5F RN Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80. DMCBV5F RU https://pubmed.ncbi.nlm.nih.gov/17536795 DMCBV5F DI DMCBV5F DMCBV5F DN ZK-814048 DMCBV5F TI TTMF8H9 DMCBV5F TN Plasma kallikrein (KLKB1) DMCBV5F MA Inhibitor DMCBV5F RN Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80. DMCBV5F RU https://pubmed.ncbi.nlm.nih.gov/17536795 DMCBX7R DI DMCBX7R DMCBX7R DN 1-Prop-2-ynyl-3,7-dihydro-purine-2,6-dione DMCBX7R TI TTJFY5U DMCBX7R TN Adenosine A3 receptor (ADORA3) DMCBX7R MA Inhibitor DMCBX7R RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMCBX7R RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMCBXQK DI DMCBXQK DMCBXQK DN ISIS 114397 DMCBXQK TI TT8OY02 DMCBXQK TN ARA70 messenger RNA (NCOA4 mRNA) DMCBXQK RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DMCBXQK RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DMCD4GR DI DMCD4GR DMCD4GR DN 3-sal-cyclosal-d4TMP DMCD4GR TI TTEB0GD DMCD4GR TN Cholinesterase (BCHE) DMCD4GR MA Inhibitor DMCD4GR RN Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46. DMCD4GR RU https://pubmed.ncbi.nlm.nih.gov/17328534 DMCD901 DI DMCD901 DMCD901 DN 3-Chloro-9H-beta-carboline DMCD901 TI TTNJYV2 DMCD901 TN Gamma-aminobutyric acid receptor (GAR) DMCD901 MA Inhibitor DMCD901 RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMCD901 RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMCD901 DI DMCD901 DMCD901 DN 3-Chloro-9H-beta-carboline DMCD901 TI TT1MPAY DMCD901 TN GABA(A) receptor alpha-1 (GABRA1) DMCD901 MA Inhibitor DMCD901 RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMCD901 RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMCDBM5 DI DMCDBM5 DMCDBM5 DN N-cyclohexyl-4-hydroxy-N-phenylbenzenesulfonamide DMCDBM5 TI TTZAYWL DMCDBM5 TN Estrogen receptor (ESR) DMCDBM5 MA Inhibitor DMCDBM5 RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DMCDBM5 RU https://pubmed.ncbi.nlm.nih.gov/16300947 DMCDGAU DI DMCDGAU DMCDGAU DN 2-(3'-Methoxyphenyl) Benzimidazole-4-Carboxamide DMCDGAU TI TTVDSZ0 DMCDGAU TN Poly [ADP-ribose] polymerase 1 (PARP1) DMCDGAU MA Inhibitor DMCDGAU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCDGAU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCDKHJ DI DMCDKHJ DMCDKHJ DN 4-(4-Decyloxy-phenyl)-1,1,1-trifluoro-butan-2-one DMCDKHJ TI TTT1JVS DMCDKHJ TN Cytosolic phospholipase A2 (GIVA cPLA2) DMCDKHJ MA Inhibitor DMCDKHJ RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMCDKHJ RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMCDLG4 DI DMCDLG4 DMCDLG4 DN 3-MPPTS DMCDLG4 TI TTXJ47W DMCDLG4 TN Metabotropic glutamate receptor 2 (mGluR2) DMCDLG4 MA Modulator (allosteric modulator) DMCDLG4 RN Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83. DMCDLG4 RU https://pubmed.ncbi.nlm.nih.gov/15717213 DMCDLTV DI DMCDLTV DMCDLTV DN H-Cdp-ser-Gly-Phe-Leu-Thr-OH DMCDLTV TI TT27RFC DMCDLTV TN Opioid receptor delta (OPRD1) DMCDLTV MA Inhibitor DMCDLTV RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMCDLTV RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMCDLTV DI DMCDLTV DMCDLTV DN H-Cdp-ser-Gly-Phe-Leu-Thr-OH DMCDLTV TI TTKWM86 DMCDLTV TN Opioid receptor mu (MOP) DMCDLTV MA Inhibitor DMCDLTV RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMCDLTV RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMCDOHA DI DMCDOHA DMCDOHA DN PMID22464687C15a DMCDOHA TI TTFQEO5 DMCDOHA TN Squalene synthetase (FDFT1) DMCDOHA MA Inhibitor DMCDOHA RN Discovery of novel tricyclic compounds as squalene synthase inhibitors. Bioorg Med Chem. 2012 May 1;20(9):3072-93. DMCDOHA RU https://pubmed.ncbi.nlm.nih.gov/22464687 DMCDU8K DI DMCDU8K DMCDU8K DN GNF-PF-4478 DMCDU8K TI TT2EDHU DMCDU8K TN Insulin-degrading enzyme (IDE) DMCDU8K MA Inhibitor DMCDU8K RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMCDU8K RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMCDU8K DI DMCDU8K DMCDU8K DN GNF-PF-4478 DMCDU8K TI TTEAID7 DMCDU8K TN Trypanosoma Cruzipain (Trypano CYSP) DMCDU8K MA Inhibitor DMCDU8K RN Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem. 2010 Jul 8;53(13):4891-905. DMCDU8K RU https://pubmed.ncbi.nlm.nih.gov/20540517 DMCDUO1 DI DMCDUO1 DMCDUO1 DN 5-Hexyl-5-phenyl-imidazolidine-2,4-dione DMCDUO1 TI TTAXZ0K DMCDUO1 TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMCDUO1 MA Inhibitor DMCDUO1 RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DMCDUO1 RU https://pubmed.ncbi.nlm.nih.gov/10229624 DMCDUO1 DI DMCDUO1 DMCDUO1 DN 5-Hexyl-5-phenyl-imidazolidine-2,4-dione DMCDUO1 TI TTRK8B9 DMCDUO1 TN Sodium channel unspecific (NaC) DMCDUO1 MA Inhibitor DMCDUO1 RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DMCDUO1 RU https://pubmed.ncbi.nlm.nih.gov/10229624 DMCDV1O DI DMCDV1O DMCDV1O DN 1-(4-Chloro-phenyl)-2-phenyl-ethane-1,2-dione DMCDV1O TI TTMF541 DMCDV1O TN Liver carboxylesterase (CES1) DMCDV1O MA Inhibitor DMCDV1O RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMCDV1O RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMCDW4H DI DMCDW4H DMCDW4H DN ISIS 13727 DMCDW4H TI TT0EOB8 DMCDW4H TN B-Raf messenger RNA (BRAF mRNA) DMCDW4H RN US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression. DMCDW4H RU http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true DMCDWSG DI DMCDWSG DMCDWSG DN ISIS 298711 DMCDWSG TI TTSN6QU DMCDWSG TN HIF1-alpha messenger RNA (HIF1A mRNA) DMCDWSG RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMCDWSG RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMCDZ7E DI DMCDZ7E DMCDZ7E DN 4-(cyclohexyloxy)quinazoline DMCDZ7E TI TTVBPDM DMCDZ7E TN Metabotropic glutamate receptor 1 (mGluR1) DMCDZ7E MA Inhibitor DMCDZ7E RN In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. DMCDZ7E RU https://pubmed.ncbi.nlm.nih.gov/19289283 DMCDZ8A DI DMCDZ8A DMCDZ8A DN (S)-2-amino-2-p-tolylacetic acid DMCDZ8A TI TTFK1JQ DMCDZ8A TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMCDZ8A MA Inhibitor DMCDZ8A RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMCDZ8A RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMCE1SU DI DMCE1SU DMCE1SU DN (2-Chloro-9-methyl-9H-purin-6-yl)-phenyl-amine DMCE1SU TI TTK25J1 DMCE1SU TN Adenosine A1 receptor (ADORA1) DMCE1SU MA Inhibitor DMCE1SU RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMCE1SU RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMCE3NA DI DMCE3NA DMCE3NA DN CEPHARANTINE DMCE3NA TI TTRTKPV DMCE3NA TN Trypanosoma Trypanothione reductase (Trypano TPR) DMCE3NA MA Inhibitor DMCE3NA RN The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95. DMCE3NA RU https://pubmed.ncbi.nlm.nih.gov/18558492 DMCE3PJ DI DMCE3PJ DMCE3PJ DN urotensin II-related peptide DMCE3PJ TI TTW5UDX DMCE3PJ TN Urotensin II receptor (UTS2R) DMCE3PJ MA Agonist DMCE3PJ RN Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun. 2003 Oct 24;310(3):860-8. DMCE3PJ RU https://pubmed.ncbi.nlm.nih.gov/14550283 DMCE6WJ DI DMCE6WJ DMCE6WJ DN CGP-191 DMCE6WJ TI TT6PKBN DMCE6WJ TN Proto-oncogene c-Src (SRC) DMCE6WJ MA Inhibitor DMCE6WJ RN Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9. DMCE6WJ RU https://pubmed.ncbi.nlm.nih.gov/10853665 DMCE7G0 DI DMCE7G0 DMCE7G0 DN 1-(4-(methylsulfonyl)phenyl)-1H-indole DMCE7G0 TI TTVKILB DMCE7G0 TN Prostaglandin G/H synthase 2 (COX-2) DMCE7G0 MA Inhibitor DMCE7G0 RN Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71. DMCE7G0 RU https://pubmed.ncbi.nlm.nih.gov/20804197 DMCE8K1 DI DMCE8K1 DMCE8K1 DN Z-VAD-CHO DMCE8K1 TI TTCQIBE DMCE8K1 TN Caspase-1 (CASP1) DMCE8K1 MA Inhibitor DMCE8K1 RN Tethering identifies fragment that yields potent inhibitors of human caspase-1. Bioorg Med Chem Lett. 2006 Feb;16(3):559-62. DMCE8K1 RU https://pubmed.ncbi.nlm.nih.gov/16274992 DMCE8Q9 DI DMCE8Q9 DMCE8Q9 DN KH-164 DMCE8Q9 TI TT5FNQT DMCE8Q9 TN Human immunodeficiency virus Protease (HIV PR) DMCE8Q9 MA Modulator DMCE8Q9 RN Impeded progression of Friend disease in mice by an inhibitor of retroviral proteases. J Acquir Immune Defic Syndr. 1993 Jan;6(1):24-31. DMCE8Q9 RU https://www.ncbi.nlm.nih.gov/pubmed/8093263 DMCE985 DI DMCE985 DMCE985 DN Phenazone DMCE985 TI TT8NGED DMCE985 TN Prostaglandin G/H synthase 1 (COX-1) DMCE985 MA Inhibitor DMCE985 RN Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7. DMCE985 RU https://pubmed.ncbi.nlm.nih.gov/11695253 DMCEABJ DI DMCEABJ DMCEABJ DN 4-[1-(4'-Methoxybiphenyl-4-yl)propyl]pyridine DMCEABJ TI TTRA5BZ DMCEABJ TN Steroid 17-alpha-monooxygenase (S17AH) DMCEABJ MA Inhibitor DMCEABJ RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMCEABJ RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMCEFUW DI DMCEFUW DMCEFUW DN RB 2 DMCEFUW TI TTNVSKA DMCEFUW TN P2Y purinoceptor 6 (P2RY6) DMCEFUW MA Inhibitor DMCEFUW RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMCEFUW RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMCEFUW DI DMCEFUW DMCEFUW DN RB 2 DMCEFUW TI TTK0O6Y DMCEFUW TN Ecto-5'-nucleotidase (CD73) DMCEFUW MA Inhibitor DMCEFUW RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMCEFUW RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMCEFUW DI DMCEFUW DMCEFUW DN RB 2 DMCEFUW TI TTOZHQC DMCEFUW TN P2Y purinoceptor 2 (P2RY2) DMCEFUW MA Inhibitor DMCEFUW RN Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7. DMCEFUW RU https://pubmed.ncbi.nlm.nih.gov/18006312 DMCEG6V DI DMCEG6V DMCEG6V DN 6-Nitro-4-phenyl-2-piperazin-1-yl-quinoline DMCEG6V TI TT3ROYC DMCEG6V TN Serotonin transporter (SERT) DMCEG6V MA Inhibitor DMCEG6V RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DMCEG6V RU https://pubmed.ncbi.nlm.nih.gov/11859009 DMCEGZU DI DMCEGZU DMCEGZU DN 2-fluorophenyl 4-(dodecyloxy)phenylcarbamate DMCEGZU TI TTDP1UC DMCEGZU TN Fatty acid amide hydrolase (FAAH) DMCEGZU MA Inhibitor DMCEGZU RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMCEGZU RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMCEK6N DI DMCEK6N DMCEK6N DN 2-Thiomethyl-3-Phenylpropanoic Acid DMCEK6N TI TT3LJ6G DMCEK6N TN Carboxypeptidase A1 (CPA1) DMCEK6N MA Inhibitor DMCEK6N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1587). DMCEK6N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1587 DMCEK6N DI DMCEK6N DMCEK6N DN 2-Thiomethyl-3-Phenylpropanoic Acid DMCEK6N TI TTGA1IV DMCEK6N TN Matrix metalloproteinase-8 (MMP-8) DMCEK6N MA Inhibitor DMCEK6N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCEK6N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCEKNJ DI DMCEKNJ DMCEKNJ DN JWH-314 DMCEKNJ TI TTMSFAW DMCEKNJ TN Cannabinoid receptor 2 (CB2) DMCEKNJ MA Inhibitor DMCEKNJ RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMCEKNJ RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMCEY6O DI DMCEY6O DMCEY6O DN 3,5-dibromo-2-(2,4-dibromophenoxy)phenol DMCEY6O TI TTCFP0V DMCEY6O TN Glutamine amidotransferase (GMPS) DMCEY6O MA Inhibitor DMCEY6O RN Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. J Nat Prod. 1995 Sep;58(9):1384-91. DMCEY6O RU https://pubmed.ncbi.nlm.nih.gov/7494145 DMCF1ZD DI DMCF1ZD DMCF1ZD DN ISOGOIAZENSOLIDE DMCF1ZD TI TTSXVID DMCF1ZD TN Nuclear factor NF-kappa-B (NFKB) DMCF1ZD MA Inhibitor DMCF1ZD RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DMCF1ZD RU https://pubmed.ncbi.nlm.nih.gov/15537359 DMCF75U DI DMCF75U DMCF75U DN 2-(phenylsulfonyl)-1-(thiophen-3-yl)ethanone DMCF75U TI TTN7BL9 DMCF75U TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMCF75U MA Inhibitor DMCF75U RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMCF75U RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMCFEBW DI DMCFEBW DMCFEBW DN furan-1 DMCFEBW TI TT8R70G DMCFEBW TN Gonadotropin-releasing hormone receptor (GNRHR) DMCFEBW MA Antagonist DMCFEBW RN Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J Pharmacol Exp Ther. 2003 May;305(2):688-95. DMCFEBW RU https://pubmed.ncbi.nlm.nih.gov/12606616 DMCFH5W DI DMCFH5W DMCFH5W DN N-methylhistamine DMCFH5W TI TTXJ178 DMCFH5W TN Histamine H4 receptor (H4R) DMCFH5W MA Agonist DMCFH5W RN Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther. 2001 Oct;299(1):121-30. DMCFH5W RU https://pubmed.ncbi.nlm.nih.gov/11561071 DMCFH5W DI DMCFH5W DMCFH5W DN N-methylhistamine DMCFH5W TI TT9JNIC DMCFH5W TN Histamine H3 receptor (H3R) DMCFH5W MA Agonist DMCFH5W RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DMCFH5W RU https://pubmed.ncbi.nlm.nih.gov/11179434 DMCFHPD DI DMCFHPD DMCFHPD DN KUSHENOL A DMCFHPD TI TT8JRS7 DMCFHPD TN Beta-secretase (BACE) DMCFHPD MA Inhibitor DMCFHPD RN BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74. DMCFHPD RU https://pubmed.ncbi.nlm.nih.gov/18565755 DMCFIZN DI DMCFIZN DMCFIZN DN 5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol DMCFIZN TI TTZAYWL DMCFIZN TN Estrogen receptor (ESR) DMCFIZN MA Inhibitor DMCFIZN RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMCFIZN RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMCFIZN DI DMCFIZN DMCFIZN DN 5-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-6-ol DMCFIZN TI TTOM3J0 DMCFIZN TN Estrogen receptor beta (ESR2) DMCFIZN MA Inhibitor DMCFIZN RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMCFIZN RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMCFJIP DI DMCFJIP DMCFJIP DN 3,3-diethyl-1-phenylazetidine-2,4-dione DMCFJIP TI TTPLTSQ DMCFJIP TN Neutrophil elastase (NE) DMCFJIP MA Inhibitor DMCFJIP RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMCFJIP RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMCFKGW DI DMCFKGW DMCFKGW DN 5-(2-(2,5-dimethylphenyl)ethynyl)pyrimidine DMCFKGW TI TTHS256 DMCFKGW TN Metabotropic glutamate receptor 5 (mGluR5) DMCFKGW MA Inhibitor DMCFKGW RN Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. DMCFKGW RU https://pubmed.ncbi.nlm.nih.gov/18550372 DMCFKX0 DI DMCFKX0 DMCFKX0 DN 1-Adamantan-1-yl-3-phenyl-urea DMCFKX0 TI TT7WVHI DMCFKX0 TN Soluble epoxide hydrolase (EPHX2) DMCFKX0 MA Inhibitor DMCFKX0 RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMCFKX0 RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMCFM2E DI DMCFM2E DMCFM2E DN OXA-01 DMCFM2E TI TTCJG29 DMCFM2E TN Serine/threonine-protein kinase mTOR (mTOR) DMCFM2E MA Inhibitor DMCFM2E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMCFM2E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMCFNMK DI DMCFNMK DMCFNMK DN NSC-40331 DMCFNMK TI TTFQAYR DMCFNMK TN Cholesteryl ester transfer protein (CETP) DMCFNMK MA Inhibitor DMCFNMK RN Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic expl... Eur J Med Chem. 2010 Apr;45(4):1598-617. DMCFNMK RU https://pubmed.ncbi.nlm.nih.gov/20116902 DMCFR8U DI DMCFR8U DMCFR8U DN CBLB-612 DMCFR8U TI TTY7ZHS DMCFR8U TN Toll-like receptor 2 (TLR2) DMCFR8U MA Modulator DMCFR8U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1752). DMCFR8U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1752 DMCFTB8 DI DMCFTB8 DMCFTB8 DN Heptane-2,3-dione DMCFTB8 TI TTMF541 DMCFTB8 TN Liver carboxylesterase (CES1) DMCFTB8 MA Inhibitor DMCFTB8 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMCFTB8 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMCFV0X DI DMCFV0X DMCFV0X DN 7-(3-Benzoyl-ureido)-heptanoic acid hydroxyamide DMCFV0X TI TT6R7JZ DMCFV0X TN Histone deacetylase 1 (HDAC1) DMCFV0X MA Inhibitor DMCFV0X RN Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21. DMCFV0X RU https://pubmed.ncbi.nlm.nih.gov/20451378 DMCG1HE DI DMCG1HE DMCG1HE DN 2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole DMCG1HE TI TTPC4TU DMCG1HE TN 5-HT 3A receptor (HTR3A) DMCG1HE MA Inhibitor DMCG1HE RN Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists. J Med Chem. 1990 Jan;33(1):13-6. DMCG1HE RU https://pubmed.ncbi.nlm.nih.gov/2296012 DMCG1HE DI DMCG1HE DMCG1HE DN 2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole DMCG1HE TI TTR6K75 DMCG1HE TN 5-HT 3B receptor (HTR3B) DMCG1HE MA Inhibitor DMCG1HE RN Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists. J Med Chem. 1990 Jan;33(1):13-6. DMCG1HE RU https://pubmed.ncbi.nlm.nih.gov/2296012 DMCG26A DI DMCG26A DMCG26A DN N5-[4-(Phenylmethoxy)phenyl]-L-glutamine DMCG26A TI TTXZEAJ DMCG26A TN Leukotriene A-4 hydrolase (LTA4H) DMCG26A MA Inhibitor DMCG26A RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMCG26A RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMCG5V2 DI DMCG5V2 DMCG5V2 DN Deoxyuridine-5'-Triphosphate DMCG5V2 TI TTY8KJS DMCG5V2 TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMCG5V2 MA Inhibitor DMCG5V2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCG5V2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCG6EK DI DMCG6EK DMCG6EK DN 5-tert-Butyl-2-(4-ethynyl-phenyl)-[1,3]dithiane DMCG6EK TI TTNJYV2 DMCG6EK TN Gamma-aminobutyric acid receptor (GAR) DMCG6EK MA Inhibitor DMCG6EK RN Synthesis of carbon-11-, fluorine-18-, and iodine-125-labeled GABAA-gated chloride ion channel blockers: substituted 5-tert-butyl-2-phenyl-1,3-dith... J Med Chem. 1995 Jul 7;38(14):2663-71. DMCG6EK RU https://pubmed.ncbi.nlm.nih.gov/7629805 DMCG6H8 DI DMCG6H8 DMCG6H8 DN Ono 3 DMCG6H8 TI TTXHYV6 DMCG6H8 TN Voltage-gated L-type calcium channel (L-CaC) DMCG6H8 MA Blocker DMCG6H8 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMCG6H8 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMCG8BJ DI DMCG8BJ DMCG8BJ DN 6-acetyl-7-propoxy-2H-chromen-2-one DMCG8BJ TI TT2LVK8 DMCG8BJ TN Carbonic anhydrase IX (CA-IX) DMCG8BJ MA Inhibitor DMCG8BJ RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMCG8BJ RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMCGF2P DI DMCGF2P DMCGF2P DN ISIS 133211 DMCGF2P TI TTZN92A DMCGF2P TN DUSP5 messenger RNA (DUSP5 mRNA) DMCGF2P RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DMCGF2P RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DMCGF3U DI DMCGF3U DMCGF3U DN NNC052090 DMCGF3U TI TTQBMPI DMCGF3U TN Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) DMCGF3U MA Inhibitor DMCGF3U RN 1-(3-(9H-carbazol-9-yl)-1-propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol. 1997 Mar;120(6):983-5. DMCGF3U RU https://pubmed.ncbi.nlm.nih.gov/9134205 DMCGI1S DI DMCGI1S DMCGI1S DN 2-fluoro-5-(3-methylthiophen-2-yl)pyridine DMCGI1S TI TTXV4FI DMCGI1S TN Albendazole monooxygenase (CYP3A4) DMCGI1S MA Inhibitor DMCGI1S RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DMCGI1S RU https://pubmed.ncbi.nlm.nih.gov/17125252 DMCGID6 DI DMCGID6 DMCGID6 DN 2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol DMCGID6 TI TTML2WA DMCGID6 TN Tubulin (TUB) DMCGID6 MA Inhibitor DMCGID6 RN Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhance... J Med Chem. 1992 Mar 20;35(6):1058-67. DMCGID6 RU https://pubmed.ncbi.nlm.nih.gov/1552500 DMCGID6 DI DMCGID6 DMCGID6 DN 2-Methoxy-5-(3,4,5-trimethoxy-benzyl)-phenol DMCGID6 TI TTYFKSZ DMCGID6 TN Tubulin beta (TUBB) DMCGID6 MA Inhibitor DMCGID6 RN Synthesis of alkoxy-substituted diaryl compounds and correlation of ring separation with inhibition of tubulin polymerization: differential enhance... J Med Chem. 1992 Mar 20;35(6):1058-67. DMCGID6 RU https://pubmed.ncbi.nlm.nih.gov/1552500 DMCGNUO DI DMCGNUO DMCGNUO DN 7-Methyl-Guanosine-5'-Triphosphate DMCGNUO TI TTZGCP6 DMCGNUO TN EIF4E messenger RNA (EIF4E mRNA) DMCGNUO MA Inhibitor DMCGNUO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCGNUO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCGOPQ DI DMCGOPQ DMCGOPQ DN 4-(2,4-dichlorophenyl)-1-phenylpyrrolidin-3-amine DMCGOPQ TI TTDIGC1 DMCGOPQ TN Dipeptidyl peptidase 4 (DPP-4) DMCGOPQ MA Inhibitor DMCGOPQ RN Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12. DMCGOPQ RU https://pubmed.ncbi.nlm.nih.gov/17276063 DMCGRV7 DI DMCGRV7 DMCGRV7 DN 1,2-Bis-(4-methoxy-phenyl)-ethane-1,2-dione DMCGRV7 TI TTMF541 DMCGRV7 TN Liver carboxylesterase (CES1) DMCGRV7 MA Inhibitor DMCGRV7 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMCGRV7 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMCGVAB DI DMCGVAB DMCGVAB DN N/OFQ-(1-13)-NH2 DMCGVAB TI TTNT7K8 DMCGVAB TN Nociceptin receptor (OPRL1) DMCGVAB MA Agonist DMCGVAB RN Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J Med Chem. 1997 Jun 6;40(12):1789-93. DMCGVAB RU https://pubmed.ncbi.nlm.nih.gov/9191955 DMCGX9U DI DMCGX9U DMCGX9U DN PHA-665752 DMCGX9U TI TTNDSF4 DMCGX9U TN Proto-oncogene c-Met (MET) DMCGX9U MA Inhibitor DMCGX9U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMCGX9U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMCH3ZK DI DMCH3ZK DMCH3ZK DN L-689,037 DMCH3ZK TI TTDMBF5 DMCH3ZK TN Arachidonate 5-lipoxygenase activating protein (FLAP) DMCH3ZK MA Inhibitor DMCH3ZK RN 5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors. Mol Pharmacol. 1992 Feb;41(2):267-72. DMCH3ZK RU https://pubmed.ncbi.nlm.nih.gov/1538707 DMCH5M1 DI DMCH5M1 DMCH5M1 DN N-Cyclohexylethyl-ETAV DMCH5M1 TI TT9PB26 DMCH5M1 TN Presynaptic density protein 95 (DLG4) DMCH5M1 MA Inhibitor DMCH5M1 RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMCH5M1 RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMCH6R1 DI DMCH6R1 DMCH6R1 DN 1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine DMCH6R1 TI TT6MSOK DMCH6R1 TN 5-HT 1D receptor (HTR1D) DMCH6R1 MA Inhibitor DMCH6R1 RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMCH6R1 RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMCH6R1 DI DMCH6R1 DMCH6R1 DN 1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine DMCH6R1 TI TTSQIFT DMCH6R1 TN 5-HT 1A receptor (HTR1A) DMCH6R1 MA Inhibitor DMCH6R1 RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMCH6R1 RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMCH6R1 DI DMCH6R1 DMCH6R1 DN 1-(4-Bromo-2,5-dimethoxy-phenyl)-piperazine DMCH6R1 TI TTJQOD7 DMCH6R1 TN 5-HT 2A receptor (HTR2A) DMCH6R1 MA Inhibitor DMCH6R1 RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMCH6R1 RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMCH7GO DI DMCH7GO DMCH7GO DN N1-(4-bromophenyl)-N2,N2-dipentylphthalamide DMCH7GO TI TTMSFAW DMCH7GO TN Cannabinoid receptor 2 (CB2) DMCH7GO MA Inhibitor DMCH7GO RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DMCH7GO RU https://pubmed.ncbi.nlm.nih.gov/19143566 DMCHAQ7 DI DMCHAQ7 DMCHAQ7 DN 25-hydroxycholesterol DMCHAQ7 TI TTGV6LY DMCHAQ7 TN Nuclear receptor ROR-gamma (RORG) DMCHAQ7 MA Agonist DMCHAQ7 RN Structural basis for hydroxycholesterols as natural ligands of orphan nuclear receptor RORgamma. Mol Endocrinol. 2010 May;24(5):923-9. DMCHAQ7 RU https://pubmed.ncbi.nlm.nih.gov/20203100 DMCHAQ7 DI DMCHAQ7 DMCHAQ7 DN 25-hydroxycholesterol DMCHAQ7 TI TTME5YJ DMCHAQ7 TN EBV-induced G-protein coupled receptor 2 (GPR183) DMCHAQ7 MA Agonist DMCHAQ7 RN Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23. DMCHAQ7 RU https://pubmed.ncbi.nlm.nih.gov/21796211 DMCHGF1 DI DMCHGF1 DMCHGF1 DN CHLORANIL DMCHGF1 TI TTMF541 DMCHGF1 TN Liver carboxylesterase (CES1) DMCHGF1 MA Inhibitor DMCHGF1 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMCHGF1 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMCHGF1 DI DMCHGF1 DMCHGF1 DN CHLORANIL DMCHGF1 TI TT1RS9F DMCHGF1 TN Acetylcholinesterase (AChE) DMCHGF1 MA Inhibitor DMCHGF1 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMCHGF1 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMCHGF1 DI DMCHGF1 DMCHGF1 DN CHLORANIL DMCHGF1 TI TTEB0GD DMCHGF1 TN Cholinesterase (BCHE) DMCHGF1 MA Inhibitor DMCHGF1 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMCHGF1 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMCHILK DI DMCHILK DMCHILK DN 1-(3,4-Dimethyl-phenyl)-2-phenyl-ethane-1,2-dione DMCHILK TI TTMF541 DMCHILK TN Liver carboxylesterase (CES1) DMCHILK MA Inhibitor DMCHILK RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMCHILK RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMCHJL1 DI DMCHJL1 DMCHJL1 DN (2-hydroxy-3-phenoxypropyl)(propan-2-yl)amine DMCHJL1 TI TTVG215 DMCHJL1 TN Debrisoquine 4-hydroxylase (CYP2D6) DMCHJL1 MA Inhibitor DMCHJL1 RN A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3816-20. DMCHJL1 RU https://pubmed.ncbi.nlm.nih.gov/15993593 DMCHMNF DI DMCHMNF DMCHMNF DN 16-(3-Ethylureido)hexadec-11(Z)-enoic acid DMCHMNF TI TT7WVHI DMCHMNF TN Soluble epoxide hydrolase (EPHX2) DMCHMNF MA Inhibitor DMCHMNF RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMCHMNF RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMCHOFK DI DMCHOFK DMCHOFK DN 1-Phenyl-3-(1-propionylpiperidin-4-yl)urea DMCHOFK TI TT7WVHI DMCHOFK TN Soluble epoxide hydrolase (EPHX2) DMCHOFK MA Inhibitor DMCHOFK RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DMCHOFK RU https://pubmed.ncbi.nlm.nih.gov/20812725 DMCHPMA DI DMCHPMA DMCHPMA DN SNAP-8719 DMCHPMA TI TTSQIFT DMCHPMA TN 5-HT 1A receptor (HTR1A) DMCHPMA MA Inhibitor DMCHPMA RN Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9. DMCHPMA RU https://pubmed.ncbi.nlm.nih.gov/15828846 DMCHPMA DI DMCHPMA DMCHPMA DN SNAP-8719 DMCHPMA TI TTNGILX DMCHPMA TN Adrenergic receptor alpha-1A (ADRA1A) DMCHPMA MA Inhibitor DMCHPMA RN Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9. DMCHPMA RU https://pubmed.ncbi.nlm.nih.gov/15828846 DMCHPMA DI DMCHPMA DMCHPMA DN SNAP-8719 DMCHPMA TI TT34BHT DMCHPMA TN Adrenergic receptor alpha-1D (ADRA1D) DMCHPMA MA Inhibitor DMCHPMA RN Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9. DMCHPMA RU https://pubmed.ncbi.nlm.nih.gov/15828846 DMCHPMA DI DMCHPMA DMCHPMA DN SNAP-8719 DMCHPMA TI TTBRKXS DMCHPMA TN Adrenergic receptor alpha-1B (ADRA1B) DMCHPMA MA Inhibitor DMCHPMA RN Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione ... J Med Chem. 2005 Apr 21;48(8):3076-9. DMCHPMA RU https://pubmed.ncbi.nlm.nih.gov/15828846 DMCHSWQ DI DMCHSWQ DMCHSWQ DN Isosorbide-2-benzylcarbamate-5-tosylate DMCHSWQ TI TT1RS9F DMCHSWQ TN Acetylcholinesterase (AChE) DMCHSWQ MA Inhibitor DMCHSWQ RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMCHSWQ RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMCHT27 DI DMCHT27 DMCHT27 DN CGS 35066 DMCHT27 TI TTQ9RYT DMCHT27 TN Endothelin-converting enzyme 1 (ECE1) DMCHT27 MA Inhibitor DMCHT27 RN The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opin Investig Drugs. 2002 Nov;11(11):1537-52. DMCHT27 RU https://pubmed.ncbi.nlm.nih.gov/12437501 DMCHT27 DI DMCHT27 DMCHT27 DN CGS 35066 DMCHT27 TI TT5U914 DMCHT27 TN Endothelin-converting enzyme 2 (ECE2) DMCHT27 MA Inhibitor DMCHT27 RN The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system. Expert Opin Investig Drugs. 2002 Nov;11(11):1537-52. DMCHT27 RU https://pubmed.ncbi.nlm.nih.gov/12437501 DMCHTI0 DI DMCHTI0 DMCHTI0 DN 4-(2-nitroprop-1-enyl)benzene-1,2-diol DMCHTI0 TI TTGKNB4 DMCHTI0 TN Epidermal growth factor receptor (EGFR) DMCHTI0 MA Inhibitor DMCHTI0 RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMCHTI0 RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMCHVIG DI DMCHVIG DMCHVIG DN ERYSTAGALLIN A DMCHVIG TI TT50QJ3 DMCHVIG TN Influenza Neuraminidase (Influ NA) DMCHVIG MA Inhibitor DMCHVIG RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMCHVIG RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMCHZ8J DI DMCHZ8J DMCHZ8J DN 2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole DMCHZ8J TI TT9JNIC DMCHZ8J TN Histamine H3 receptor (H3R) DMCHZ8J MA Inhibitor DMCHZ8J RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMCHZ8J RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMCIA40 DI DMCIA40 DMCIA40 DN 1-Thiazol-2-yl-3-(2-p-tolyl-ethyl)-thiourea DMCIA40 TI TT84ETX DMCIA40 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMCIA40 MA Inhibitor DMCIA40 RN Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8. DMCIA40 RU https://pubmed.ncbi.nlm.nih.gov/11229762 DMCIA63 DI DMCIA63 DMCIA63 DN 6-(Naphthalene-2-sulfonyl)-2H-pyridazin-3-one DMCIA63 TI TTFBNVI DMCIA63 TN Aldose reductase (AKR1B1) DMCIA63 MA Inhibitor DMCIA63 RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMCIA63 RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMCIAJL DI DMCIAJL DMCIAJL DN N-hydroxy-nor-L-arginine DMCIAJL TI TTV1AG6 DMCIAJL TN Kidney-type arginase (ARG2) DMCIAJL MA Inhibitor DMCIAJL RN Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 2003 Oct 21;108(16):2000-6. DMCIAJL RU https://pubmed.ncbi.nlm.nih.gov/14517171 DMCIEQO DI DMCIEQO DMCIEQO DN TAD DMCIEQO TI TTL7C8Q DMCIEQO TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMCIEQO MA Inhibitor DMCIEQO RN Crystal structure of a ternary complex of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: NAD+ orients the active site loop for catalysis. Biochemistry. 2002 Nov 5;41(44):13309-17. DMCIEQO RU https://pubmed.ncbi.nlm.nih.gov/12403633 DMCIH1X DI DMCIH1X DMCIH1X DN alpha-methylserine-O-phosphate DMCIH1X TI TT0IFKL DMCIH1X TN Metabotropic glutamate receptor 8 (mGluR8) DMCIH1X MA Antagonist DMCIH1X RN The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317. DMCIH1X RU https://pubmed.ncbi.nlm.nih.gov/12769621 DMCIH1X DI DMCIH1X DMCIH1X DN alpha-methylserine-O-phosphate DMCIH1X TI TTXJ47W DMCIH1X TN Metabotropic glutamate receptor 2 (mGluR2) DMCIH1X MA Antagonist DMCIH1X RN Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br J Pharmacol. 1998 Feb;123(3):497-504. DMCIH1X RU https://pubmed.ncbi.nlm.nih.gov/9504391 DMCIH1X DI DMCIH1X DMCIH1X DN alpha-methylserine-O-phosphate DMCIH1X TI TT0I76D DMCIH1X TN Metabotropic glutamate receptor 7 (mGluR7) DMCIH1X MA Antagonist DMCIH1X RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMCIH1X RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMCIH1X DI DMCIH1X DMCIH1X DN alpha-methylserine-O-phosphate DMCIH1X TI TTWRP2F DMCIH1X TN Metabotropic glutamate receptor 6 (mGluR6) DMCIH1X MA Antagonist DMCIH1X RN The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317. DMCIH1X RU https://pubmed.ncbi.nlm.nih.gov/12769621 DMCIJ6Q DI DMCIJ6Q DMCIJ6Q DN AcAsp-Glu-Dif-Ile-Cha-Cys-Pro-Cha-Asp-ValNH2 DMCIJ6Q TI TTWXB3E DMCIJ6Q TN Hepatitis C virus NS3 helicase (HCV NS3) DMCIJ6Q MA Inhibitor DMCIJ6Q RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMCIJ6Q RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMCIJU0 DI DMCIJU0 DMCIJU0 DN N-Benzyl-4-Sulfamoyl-Benzamide DMCIJU0 TI TTANPDJ DMCIJU0 TN Carbonic anhydrase II (CA-II) DMCIJU0 MA Inhibitor DMCIJU0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCIJU0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCILV7 DI DMCILV7 DMCILV7 DN aminobenzovesamicol DMCILV7 TI TTV8KWS DMCILV7 TN Vesicular acetylcholine transporter (SLC18A3) DMCILV7 MA Inhibitor DMCILV7 RN Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. Biochem Pharmacol. 1995 Mar 15;49(6):791-7. DMCILV7 RU https://pubmed.ncbi.nlm.nih.gov/7702637 DMCIM9A DI DMCIM9A DMCIM9A DN Citraconic acid DMCIM9A TI TTHDSE2 DMCIM9A TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMCIM9A MA Inhibitor DMCIM9A RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMCIM9A RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMCIOSM DI DMCIOSM DMCIOSM DN CEP-18050 DMCIOSM TI TTPMQSO DMCIOSM TN ALK tyrosine kinase receptor (ALK) DMCIOSM MA Inhibitor DMCIOSM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839). DMCIOSM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839 DMCIRY0 DI DMCIRY0 DMCIRY0 DN Homocamptothecins (hCPTs) DMCIRY0 TI TTGTQHC DMCIRY0 TN DNA topoisomerase I (TOP1) DMCIRY0 MA Inhibitor DMCIRY0 RN Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs. Crit Rev Oncol Hematol. 2003 Jan;45(1):91-108. DMCIRY0 RU https://pubmed.ncbi.nlm.nih.gov/12482574 DMCIZ7P DI DMCIZ7P DMCIZ7P DN (S)-5-fluorowillardiine DMCIZ7P TI TTPJR0G DMCIZ7P TN Glutamate receptor AMPA 4 (GRIA4) DMCIZ7P MA Agonist DMCIZ7P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447). DMCIZ7P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447 DMCIZ7P DI DMCIZ7P DMCIZ7P DN (S)-5-fluorowillardiine DMCIZ7P TI TTVPQTF DMCIZ7P TN Glutamate receptor AMPA 1 (GRIA1) DMCIZ7P MA Agonist DMCIZ7P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444). DMCIZ7P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444 DMCIZ7P DI DMCIZ7P DMCIZ7P DN (S)-5-fluorowillardiine DMCIZ7P TI TT82EZV DMCIZ7P TN Glutamate receptor AMPA 3 (GRIA3) DMCIZ7P MA Agonist DMCIZ7P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446). DMCIZ7P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446 DMCIZ7P DI DMCIZ7P DMCIZ7P DN (S)-5-fluorowillardiine DMCIZ7P TI TT9HLZ0 DMCIZ7P TN Glutamate receptor AMPA 2 (GRIA2) DMCIZ7P MA Agonist DMCIZ7P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445). DMCIZ7P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445 DMCJ86U DI DMCJ86U DMCJ86U DN S26131 DMCJ86U TI TT0WAIE DMCJ86U TN Melatonin receptor type 1A (MTNR1A) DMCJ86U MA Antagonist DMCJ86U RN New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. DMCJ86U RU https://pubmed.ncbi.nlm.nih.gov/12764576 DMCJDLO DI DMCJDLO DMCJDLO DN PMID30247903-Compound-General structure15 DMCJDLO TI TTNBFWK DMCJDLO TN Programmed cell death protein 1 (PD-1) DMCJDLO MA antagonist DMCJDLO RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMCJDLO RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMCJED6 DI DMCJED6 DMCJED6 DN 7-benzylidenenaltrexone DMCJED6 TI TT27RFC DMCJED6 TN Opioid receptor delta (OPRD1) DMCJED6 MA Antagonist DMCJED6 RN Delta-opioid receptor antagonists as a new concept for central acting antitussive drugs. Pulm Pharmacol Ther. 2002;15(3):235-40. DMCJED6 RU https://pubmed.ncbi.nlm.nih.gov/12099770 DMCJKOQ DI DMCJKOQ DMCJKOQ DN (2-Mercapto-ethyl)-trimethyl-ammonium iodide DMCJKOQ TI TT1RS9F DMCJKOQ TN Acetylcholinesterase (AChE) DMCJKOQ MA Inhibitor DMCJKOQ RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMCJKOQ RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMCJQ0P DI DMCJQ0P DMCJQ0P DN [123I]AM251 DMCJQ0P TI TT6OEDT DMCJQ0P TN Cannabinoid receptor 1 (CB1) DMCJQ0P MA Antagonist DMCJQ0P RN Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci. 1997;61(14):PL 191-7. DMCJQ0P RU https://pubmed.ncbi.nlm.nih.gov/9335234 DMCJUWK DI DMCJUWK DMCJUWK DN 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran DMCJUWK TI TTAWNKZ DMCJUWK TN Norepinephrine transporter (NET) DMCJUWK MA Inhibitor DMCJUWK RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMCJUWK RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMCJUWK DI DMCJUWK DMCJUWK DN 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran DMCJUWK TI TTVBI8W DMCJUWK TN Dopamine transporter (DAT) DMCJUWK MA Inhibitor DMCJUWK RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMCJUWK RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMCJUWK DI DMCJUWK DMCJUWK DN 2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran DMCJUWK TI TT3ROYC DMCJUWK TN Serotonin transporter (SERT) DMCJUWK MA Inhibitor DMCJUWK RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMCJUWK RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMCJWQT DI DMCJWQT DMCJWQT DN N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide DMCJWQT TI TTEX248 DMCJWQT TN Dopamine D2 receptor (D2R) DMCJWQT MA Inhibitor DMCJWQT RN Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22. DMCJWQT RU https://pubmed.ncbi.nlm.nih.gov/18800769 DMCJWQT DI DMCJWQT DMCJWQT DN N-Benzyl-4-(2-diphenyl)-1-piperazinehexanamide DMCJWQT TI TTSQIFT DMCJWQT TN 5-HT 1A receptor (HTR1A) DMCJWQT MA Inhibitor DMCJWQT RN Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22. DMCJWQT RU https://pubmed.ncbi.nlm.nih.gov/18800769 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTK0FEA DMCJXWK TN Leucine-rich repeat kinase 2 (LRRK2) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTMO45N DMCJXWK TN Cyclin-dependent kinase-like 2 (CDKL2) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTETX6Q DMCJXWK TN Mixed lineage kinase 3 (MAP3K11) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTK1N5G DMCJXWK TN MAPK/ERK kinase kinase 2 (MAP3K2) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTERVQN DMCJXWK TN Death-associated protein kinase 3 (DAPK3) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTCZEJ9 DMCJXWK TN SRSF protein kinase 2 (SRPK2) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTUNSIX DMCJXWK TN Mixed lineage kinase 1 (MAP3K9) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TT9FN4J DMCJXWK TN Mixed lineage kinase 2 (MAP3K10) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJXWK DI DMCJXWK DMCJXWK DN URMC-099 DMCJXWK TI TTGJCWZ DMCJXWK TN Fms-like tyrosine kinase 3 (FLT-3) DMCJXWK MA Inhibitor DMCJXWK RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DMCJXWK RU https://pubmed.ncbi.nlm.nih.gov/24044867 DMCJZVA DI DMCJZVA DMCJZVA DN 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine DMCJZVA TI TT4C8EA DMCJZVA TN Dopamine D3 receptor (D3R) DMCJZVA MA Inhibitor DMCJZVA RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMCJZVA RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMCJZVA DI DMCJZVA DMCJZVA DN 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine DMCJZVA TI TTE0A2F DMCJZVA TN Dopamine D4 receptor (D4R) DMCJZVA MA Inhibitor DMCJZVA RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMCJZVA RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMCJZVA DI DMCJZVA DMCJZVA DN 1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine DMCJZVA TI TTEX248 DMCJZVA TN Dopamine D2 receptor (D2R) DMCJZVA MA Inhibitor DMCJZVA RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMCJZVA RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMCK0O1 DI DMCK0O1 DMCK0O1 DN 8-Bromo-9-cyclopentyl-9H-adenine DMCK0O1 TI TTK25J1 DMCK0O1 TN Adenosine A1 receptor (ADORA1) DMCK0O1 MA Inhibitor DMCK0O1 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMCK0O1 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMCK0O1 DI DMCK0O1 DMCK0O1 DN 8-Bromo-9-cyclopentyl-9H-adenine DMCK0O1 TI TTM2AOE DMCK0O1 TN Adenosine A2a receptor (ADORA2A) DMCK0O1 MA Inhibitor DMCK0O1 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMCK0O1 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMCK0O1 DI DMCK0O1 DMCK0O1 DN 8-Bromo-9-cyclopentyl-9H-adenine DMCK0O1 TI TTNE7KG DMCK0O1 TN Adenosine A2b receptor (ADORA2B) DMCK0O1 MA Inhibitor DMCK0O1 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMCK0O1 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMCK0O1 DI DMCK0O1 DMCK0O1 DN 8-Bromo-9-cyclopentyl-9H-adenine DMCK0O1 TI TTJFY5U DMCK0O1 TN Adenosine A3 receptor (ADORA3) DMCK0O1 MA Inhibitor DMCK0O1 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMCK0O1 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMCK1XR DI DMCK1XR DMCK1XR DN JWH-293 DMCK1XR TI TT6OEDT DMCK1XR TN Cannabinoid receptor 1 (CB1) DMCK1XR MA Inhibitor DMCK1XR RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMCK1XR RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMCK1XR DI DMCK1XR DMCK1XR DN JWH-293 DMCK1XR TI TTMSFAW DMCK1XR TN Cannabinoid receptor 2 (CB2) DMCK1XR MA Inhibitor DMCK1XR RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMCK1XR RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMCK5DG DI DMCK5DG DMCK5DG DN BADGE DMCK5DG TI TTT2SVW DMCK5DG TN PPAR-gamma messenger RNA (PPARG mRNA) DMCK5DG MA Agonist DMCK5DG RN A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem. 2000 Jan 21;275(3):1873-7. DMCK5DG RU https://pubmed.ncbi.nlm.nih.gov/10636887 DMCK7SV DI DMCK7SV DMCK7SV DN 2-(N-Isopropylamino)-3'-chloropropiophenone DMCK7SV TI TTVBI8W DMCK7SV TN Dopamine transporter (DAT) DMCK7SV MA Inhibitor DMCK7SV RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMCK7SV RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMCKAWY DI DMCKAWY DMCKAWY DN HI-172 DMCKAWY TI TT84ETX DMCKAWY TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMCKAWY MA Inhibitor DMCKAWY RN Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8. DMCKAWY RU https://pubmed.ncbi.nlm.nih.gov/10386942 DMCKBQY DI DMCKBQY DMCKBQY DN 5-phenyl-1,3,4-thiadiazole-2(3H)-thione DMCKBQY TI TTULVH8 DMCKBQY TN Tyrosinase (TYR) DMCKBQY MA Inhibitor DMCKBQY RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMCKBQY RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMCKH3P DI DMCKH3P DMCKH3P DN Anandamide DMCKH3P TI TT6OEDT DMCKH3P TN Cannabinoid receptor 1 (CB1) DMCKH3P MA Agonist DMCKH3P RN Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci. 2009 Aug 26;85(9-10):351-6. DMCKH3P RU https://pubmed.ncbi.nlm.nih.gov/19576231 DMCKJ27 DI DMCKJ27 DMCKJ27 DN 3-(1H-Pyrrol-3-yl)-propionamide DMCKJ27 TI TTG5QB7 DMCKJ27 TN Calpain-2 (CAPN2) DMCKJ27 MA Inhibitor DMCKJ27 RN Synthesis of cystamidin a (pyrrole-3-propanamide), a reported calpain inhibitor, Bioorg. Med. Chem. Lett. 6(13):1541-1542 (1996). DMCKJ27 RU http://www.sciencedirect.com/science/article/pii/S0960894X96002697 DMCKO6T DI DMCKO6T DMCKO6T DN 2,3,7-trichloro-5-nitroquinoxaline (TNQX) DMCKO6T TI TTUJFD0 DMCKO6T TN Telomerase reverse transcriptase (TERT) DMCKO6T MA Inhibitor DMCKO6T RN Identification of a quinoxaline derivative that is a potent telomerase inhibitor leading to cellular senescence of human cancer cells. Biochem J. 2003 Jul 15;373(Pt 2):523-9. DMCKO6T RU https://pubmed.ncbi.nlm.nih.gov/12689331 DMCKODQ DI DMCKODQ DMCKODQ DN 5-benzyl-6-chloropyrimidine-2,4(1H,3H)-dione DMCKODQ TI TTO0IB8 DMCKODQ TN Thymidine phosphorylase (TYMP) DMCKODQ MA Inhibitor DMCKODQ RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DMCKODQ RU https://pubmed.ncbi.nlm.nih.gov/17963370 DMCKQF7 DI DMCKQF7 DMCKQF7 DN DT-2228 DMCKQF7 TI TTXJ47W DMCKQF7 TN Metabotropic glutamate receptor 2 (mGluR2) DMCKQF7 MA Modulator DMCKQF7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 290). DMCKQF7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=290 DMCKSX7 DI DMCKSX7 DMCKSX7 DN 2-Morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one DMCKSX7 TI TTK3PY9 DMCKSX7 TN DNA-dependent protein kinase catalytic (PRKDC) DMCKSX7 MA Inhibitor DMCKSX7 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMCKSX7 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMCKSYQ DI DMCKSYQ DMCKSYQ DN UCM 724 DMCKSYQ TI TT0WAIE DMCKSYQ TN Melatonin receptor type 1A (MTNR1A) DMCKSYQ MA Antagonist DMCKSYQ RN Synthesis, enantiomeric resolution, and structure-activity relationship study of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. ChemMedChem. 2007 Dec;2(12):1741-9. DMCKSYQ RU https://pubmed.ncbi.nlm.nih.gov/17907131 DMCKT3Q DI DMCKT3Q DMCKT3Q DN 4-Benzenesulfonyl-1-phenethyl-piperidine DMCKT3Q TI TTQ6VDM DMCKT3Q TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMCKT3Q MA Inhibitor DMCKT3Q RN 4-(Phenylsulfonyl)piperidines: novel, selective, and bioavailable 5-HT(2A) receptor antagonists. J Med Chem. 2002 Jan 17;45(2):492-503. DMCKT3Q RU https://pubmed.ncbi.nlm.nih.gov/11784153 DMCL6H3 DI DMCL6H3 DMCL6H3 DN PMID24900608C1 DMCL6H3 TI TTTPCNU DMCL6H3 TN G-protein coupled receptor 39 (GPR39) DMCL6H3 MA Agonist DMCL6H3 RN Chemical Probe Identification Platform for Orphan GPCRs Using Focused Compound Screening: GPR39 as a Case Example. ACS Med Chem Lett. 2013 Sep 16;4(11):1079-84. DMCL6H3 RU https://pubmed.ncbi.nlm.nih.gov/24900608 DMCL9E6 DI DMCL9E6 DMCL9E6 DN 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid DMCL9E6 TI TT8NGED DMCL9E6 TN Prostaglandin G/H synthase 1 (COX-1) DMCL9E6 MA Inhibitor DMCL9E6 RN Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90. DMCL9E6 RU https://pubmed.ncbi.nlm.nih.gov/17517512 DMCL9E6 DI DMCL9E6 DMCL9E6 DN 2-(N-(2-fluorophenyl)pyrrol-2-yl) acetic acid DMCL9E6 TI TTVKILB DMCL9E6 TN Prostaglandin G/H synthase 2 (COX-2) DMCL9E6 MA Inhibitor DMCL9E6 RN Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90. DMCL9E6 RU https://pubmed.ncbi.nlm.nih.gov/17517512 DMCLA2D DI DMCLA2D DMCLA2D DN triazine compound PC10 DMCLA2D TI TTM67AX DMCLA2D TN Prokineticin receptor 2 (PKR2) DMCLA2D MA Antagonist DMCLA2D RN Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain. J Nucl Med. 2011 Apr;52(4):600-7. DMCLA2D RU https://pubmed.ncbi.nlm.nih.gov/21421710 DMCLA2D DI DMCLA2D DMCLA2D DN triazine compound PC10 DMCLA2D TI TTB9CIL DMCLA2D TN Prokineticin receptor-1 (PROKR1) DMCLA2D MA Antagonist DMCLA2D RN Prokineticin receptor 1 antagonist PC-10 as a biomarker for imaging inflammatory pain. J Nucl Med. 2011 Apr;52(4):600-7. DMCLA2D RU https://pubmed.ncbi.nlm.nih.gov/21421710 DMCLAHR DI DMCLAHR DMCLAHR DN JWH-303 DMCLAHR TI TTMSFAW DMCLAHR TN Cannabinoid receptor 2 (CB2) DMCLAHR MA Inhibitor DMCLAHR RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMCLAHR RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMCLAXG DI DMCLAXG DMCLAXG DN 2-benzyloxy-7,8-dihydro-6H-quinolin-5-one DMCLAXG TI TTHS256 DMCLAXG TN Metabotropic glutamate receptor 5 (mGluR5) DMCLAXG MA Inhibitor DMCLAXG RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DMCLAXG RU https://pubmed.ncbi.nlm.nih.gov/18173231 DMCLHZ5 DI DMCLHZ5 DMCLHZ5 DN splitomicin DMCLHZ5 TI TTUF2HO DMCLHZ5 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMCLHZ5 MA Inhibitor DMCLHZ5 RN Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11. DMCLHZ5 RU https://pubmed.ncbi.nlm.nih.gov/20041717 DMCLIN8 DI DMCLIN8 DMCLIN8 DN 2-(2''-indolylethyloxy)adenosine DMCLIN8 TI TTK25J1 DMCLIN8 TN Adenosine A1 receptor (ADORA1) DMCLIN8 MA Inhibitor DMCLIN8 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMCLIN8 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMCLIN8 DI DMCLIN8 DMCLIN8 DN 2-(2''-indolylethyloxy)adenosine DMCLIN8 TI TTM2AOE DMCLIN8 TN Adenosine A2a receptor (ADORA2A) DMCLIN8 MA Inhibitor DMCLIN8 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMCLIN8 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMCLIN8 DI DMCLIN8 DMCLIN8 DN 2-(2''-indolylethyloxy)adenosine DMCLIN8 TI TTJFY5U DMCLIN8 TN Adenosine A3 receptor (ADORA3) DMCLIN8 MA Inhibitor DMCLIN8 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMCLIN8 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMCLN6M DI DMCLN6M DMCLN6M DN CA-50040 DMCLN6M TI TTF1QVM DMCLN6M TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMCLN6M MA Modulator DMCLN6M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DMCLN6M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DMCLRBK DI DMCLRBK DMCLRBK DN N-(4-amino-2-propylquinolin-6-yl)cinnamamide DMCLRBK TI TTX4RTB DMCLRBK TN Melanin-concentrating hormone receptor 1 (MCHR1) DMCLRBK MA Inhibitor DMCLRBK RN 4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5275-9. DMCLRBK RU https://pubmed.ncbi.nlm.nih.gov/16919453 DMCLSE0 DI DMCLSE0 DMCLSE0 DN FUB-130 DMCLSE0 TI TT9JNIC DMCLSE0 TN Histamine H3 receptor (H3R) DMCLSE0 MA Antagonist DMCLSE0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DMCLSE0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DMCLSJZ DI DMCLSJZ DMCLSJZ DN 2-(2-aminophenyl)-6-morpholino-4H-pyran-4-one DMCLSJZ TI TTK3PY9 DMCLSJZ TN DNA-dependent protein kinase catalytic (PRKDC) DMCLSJZ MA Inhibitor DMCLSJZ RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMCLSJZ RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMCLT1V DI DMCLT1V DMCLT1V DN ME0328 DMCLT1V TI TTVDSZ0 DMCLT1V TN Poly [ADP-ribose] polymerase 1 (PARP1) DMCLT1V MA Inhibitor DMCLT1V RN Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem. 2013 Dec 12;56(23):9556-68. DMCLT1V RU https://pubmed.ncbi.nlm.nih.gov/24188023 DMCLT1V DI DMCLT1V DMCLT1V DN ME0328 DMCLT1V TI TTD8MEH DMCLT1V TN Poly [ADP-ribose] polymerase 3 (PARP3) DMCLT1V MA Inhibitor DMCLT1V RN Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3. J Med Chem. 2013 Dec 12;56(23):9556-68. DMCLT1V RU https://pubmed.ncbi.nlm.nih.gov/24188023 DMCLUXI DI DMCLUXI DMCLUXI DN D[Cha4,Dab8]VP DMCLUXI TI TTL9MHW DMCLUXI TN Vasopressin V1b receptor (V1BR) DMCLUXI MA Inhibitor DMCLUXI RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCLUXI RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCLUXI DI DMCLUXI DMCLUXI DN D[Cha4,Dab8]VP DMCLUXI TI TTSCIUP DMCLUXI TN Oxytocin receptor (OTR) DMCLUXI MA Inhibitor DMCLUXI RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCLUXI RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCLUXI DI DMCLUXI DMCLUXI DN D[Cha4,Dab8]VP DMCLUXI TI TT4TFGN DMCLUXI TN Vasopressin V1a receptor (V1AR) DMCLUXI MA Inhibitor DMCLUXI RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCLUXI RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCLUXI DI DMCLUXI DMCLUXI DN D[Cha4,Dab8]VP DMCLUXI TI TTK8R02 DMCLUXI TN Vasopressin V2 receptor (V2R) DMCLUXI MA Inhibitor DMCLUXI RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCLUXI RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCLVOZ DI DMCLVOZ DMCLVOZ DN Aminocarbonyl dihydrogen phosphate DMCLVOZ TI TTZHA0O DMCLVOZ TN Carbonic anhydrase IV (CA-IV) DMCLVOZ MA Inhibitor DMCLVOZ RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6. DMCLVOZ RU https://pubmed.ncbi.nlm.nih.gov/15745821 DMCLXO0 DI DMCLXO0 DMCLXO0 DN CENTAUREIDIN DMCLXO0 TI TTML2WA DMCLXO0 TN Tubulin (TUB) DMCLXO0 MA Inhibitor DMCLXO0 RN Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8. DMCLXO0 RU https://pubmed.ncbi.nlm.nih.gov/9632366 DMCLXO0 DI DMCLXO0 DMCLXO0 DN CENTAUREIDIN DMCLXO0 TI TTYFKSZ DMCLXO0 TN Tubulin beta (TUBB) DMCLXO0 MA Inhibitor DMCLXO0 RN Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8. DMCLXO0 RU https://pubmed.ncbi.nlm.nih.gov/9632366 DMCM01R DI DMCM01R DMCM01R DN 2-bromo-4-(3-fluorophenylethynyl)thiazole DMCM01R TI TTHS256 DMCM01R TN Metabotropic glutamate receptor 5 (mGluR5) DMCM01R MA Inhibitor DMCM01R RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMCM01R RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMCM2S4 DI DMCM2S4 DMCM2S4 DN ISIS 134566 DMCM2S4 TI TTKW4ML DMCM2S4 TN Caspase 6 messenger RNA (CASP6 mRNA) DMCM2S4 RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMCM2S4 RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMCM4LT DI DMCM4LT DMCM4LT DN SB 215505 DMCM4LT TI TTJQOD7 DMCM4LT TN 5-HT 2A receptor (HTR2A) DMCM4LT MA Antagonist DMCM4LT RN Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4. DMCM4LT RU https://pubmed.ncbi.nlm.nih.gov/10188965 DMCM4LT DI DMCM4LT DMCM4LT DN SB 215505 DMCM4LT TI TT0K1SC DMCM4LT TN 5-HT 2B receptor (HTR2B) DMCM4LT MA Antagonist DMCM4LT RN Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4. DMCM4LT RU https://pubmed.ncbi.nlm.nih.gov/10188965 DMCM4LT DI DMCM4LT DMCM4LT DN SB 215505 DMCM4LT TI TTWJBZ5 DMCM4LT TN 5-HT 2C receptor (HTR2C) DMCM4LT MA Antagonist DMCM4LT RN Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4. DMCM4LT RU https://pubmed.ncbi.nlm.nih.gov/10188965 DMCM51R DI DMCM51R DMCM51R DN N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine DMCM51R TI TTGP7BY DMCM51R TN Monoamine oxidase type B (MAO-B) DMCM51R MA Inhibitor DMCM51R RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMCM51R RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMCM51R DI DMCM51R DMCM51R DN N-(1H-Indol-2-ylmethyl)-N-methyl-N-phenylamine DMCM51R TI TT3WG5C DMCM51R TN Monoamine oxidase type A (MAO-A) DMCM51R MA Inhibitor DMCM51R RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMCM51R RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMCMH7O DI DMCMH7O DMCMH7O DN JNJ-28312141 DMCMH7O TI TTXABCW DMCMH7O TN NT-3 growth factor receptor (TrkC) DMCMH7O MA Inhibitor DMCMH7O RN JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61. DMCMH7O RU https://pubmed.ncbi.nlm.nih.gov/19887542 DMCMH7O DI DMCMH7O DMCMH7O DN JNJ-28312141 DMCMH7O TI TTX41N9 DMCMH7O TN Tyrosine-protein kinase Kit (KIT) DMCMH7O MA Inhibitor DMCMH7O RN JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61. DMCMH7O RU https://pubmed.ncbi.nlm.nih.gov/19887542 DMCMH7O DI DMCMH7O DMCMH7O DN JNJ-28312141 DMCMH7O TI TT860QF DMCMH7O TN LCK tyrosine protein kinase (LCK) DMCMH7O MA Inhibitor DMCMH7O RN JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61. DMCMH7O RU https://pubmed.ncbi.nlm.nih.gov/19887542 DMCMH7O DI DMCMH7O DMCMH7O DN JNJ-28312141 DMCMH7O TI TTVW6QL DMCMH7O TN CSF1R messenger RNA (CSF1R mRNA) DMCMH7O MA Inhibitor DMCMH7O RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DMCMH7O RU https://pubmed.ncbi.nlm.nih.gov/22037378 DMCMH7O DI DMCMH7O DMCMH7O DN JNJ-28312141 DMCMH7O TI TTGJCWZ DMCMH7O TN Fms-like tyrosine kinase 3 (FLT-3) DMCMH7O MA Inhibitor DMCMH7O RN JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009 Nov;8(11):3151-61. DMCMH7O RU https://pubmed.ncbi.nlm.nih.gov/19887542 DMCMIUG DI DMCMIUG DMCMIUG DN SITS DMCMIUG TI TTST1AJ DMCMIUG TN Chloride channel protein 7 (ClC-7) DMCMIUG MA Blocker (channel blocker) DMCMIUG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 709). DMCMIUG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=709 DMCMIUG DI DMCMIUG DMCMIUG DN SITS DMCMIUG TI TTOJI4S DMCMIUG TN Calcium-dependent chloride channel anoctamin (ANO) DMCMIUG MA Blocker (channel blocker) DMCMIUG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708). DMCMIUG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708 DMCMNKA DI DMCMNKA DMCMNKA DN 5-(4-Methoxy-phenyl)-1-phenyl-1H-benzoimidazole DMCMNKA TI TTUTJGQ DMCMNKA TN Vascular endothelial growth factor receptor 2 (KDR) DMCMNKA MA Inhibitor DMCMNKA RN Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR. Bioorg Med Chem Lett. 2003 Aug 4;13(15):2485-8. DMCMNKA RU https://pubmed.ncbi.nlm.nih.gov/12852948 DMCMP9B DI DMCMP9B DMCMP9B DN 16beta-cyano-estradiol DMCMP9B TI TTIWB6L DMCMP9B TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMCMP9B MA Inhibitor DMCMP9B RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMCMP9B RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMCMQH8 DI DMCMQH8 DMCMQH8 DN SKF-83556 DMCMQH8 TI TTS2PH3 DMCMQH8 TN Dopamine D5 receptor (D5R) DMCMQH8 MA Antagonist DMCMQH8 RN Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9. DMCMQH8 RU https://pubmed.ncbi.nlm.nih.gov/1826762 DMCMQH8 DI DMCMQH8 DMCMQH8 DN SKF-83556 DMCMQH8 TI TTZFYLI DMCMQH8 TN Dopamine D1 receptor (D1R) DMCMQH8 MA Antagonist DMCMQH8 RN Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9. DMCMQH8 RU https://pubmed.ncbi.nlm.nih.gov/1826762 DMCN2B8 DI DMCN2B8 DMCN2B8 DN TMB-8 DMCN2B8 TI TTPC4TU DMCN2B8 TN 5-HT 3A receptor (HTR3A) DMCN2B8 MA Blocker (channel blocker) DMCN2B8 RN Characterization of interaction of 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester with Torpedo californica nicotinic acetylcholine receptor and 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther. 1999 Jul;290(1):129-35. DMCN2B8 RU https://pubmed.ncbi.nlm.nih.gov/10381768 DMCN48J DI DMCN48J DMCN48J DN Bbs-Arg-(D-Pip)-Gly-S-(GS)5-Gly-Hir DMCN48J TI TT6L509 DMCN48J TN Coagulation factor IIa (F2) DMCN48J MA Inhibitor DMCN48J RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMCN48J RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMCN4ZD DI DMCN4ZD DMCN4ZD DN AA-184 DMCN4ZD TI TTGKF90 DMCN4ZD TN Bone morphogenetic protein receptor (BMPR2) DMCN4ZD MA Agonist DMCN4ZD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794). DMCN4ZD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794 DMCN56S DI DMCN56S DMCN56S DN GUANOSINE-2',3'-O-ETHYLIDENEPHOSPHONATE DMCN56S TI TTMCF1Y DMCN56S TN Purine nucleoside phosphorylase (PNP) DMCN56S MA Inhibitor DMCN56S RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCN56S RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCN6PY DI DMCN6PY DMCN6PY DN 2-cyano-3-(3,4-dihydroxyphenyl)acrylamide DMCN6PY TI TTGKNB4 DMCN6PY TN Epidermal growth factor receptor (EGFR) DMCN6PY MA Inhibitor DMCN6PY RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMCN6PY RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMCN6WR DI DMCN6WR DMCN6WR DN (RS)-tacrine(10)-hupyridone DMCN6WR TI TT1RS9F DMCN6WR TN Acetylcholinesterase (AChE) DMCN6WR MA Inhibitor DMCN6WR RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DMCN6WR RU https://pubmed.ncbi.nlm.nih.gov/18479118 DMCN6WR DI DMCN6WR DMCN6WR DN (RS)-tacrine(10)-hupyridone DMCN6WR TI TTEB0GD DMCN6WR TN Cholinesterase (BCHE) DMCN6WR MA Inhibitor DMCN6WR RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DMCN6WR RU https://pubmed.ncbi.nlm.nih.gov/18479118 DMCN78A DI DMCN78A DMCN78A DN N-n-propyl-7-methoxytacrine hydrochloride DMCN78A TI TT1RS9F DMCN78A TN Acetylcholinesterase (AChE) DMCN78A MA Inhibitor DMCN78A RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMCN78A RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMCN91A DI DMCN91A DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide DMCN91A TI TTYHPU6 DMCN91A TN Histone deacetylase 10 (HDAC10) DMCN91A MA Inhibitor DMCN91A RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCN91A RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCN91A DI DMCN91A DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide DMCN91A TI TTSHTOI DMCN91A TN Histone deacetylase 2 (HDAC2) DMCN91A MA Inhibitor DMCN91A RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCN91A RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCN91A DI DMCN91A DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide DMCN91A TI TTT6LFV DMCN91A TN Histone deacetylase 8 (HDAC8) DMCN91A MA Inhibitor DMCN91A RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCN91A RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCN91A DI DMCN91A DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide DMCN91A TI TTBH0VX DMCN91A TN Histone deacetylase (HDAC) DMCN91A MA Inhibitor DMCN91A RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCN91A RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCN91A DI DMCN91A DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide DMCN91A TI TTTQGH8 DMCN91A TN Histone deacetylase 4 (HDAC4) DMCN91A MA Inhibitor DMCN91A RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCN91A RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCN91A DI DMCN91A DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide DMCN91A TI TT5ZKDI DMCN91A TN Histone deacetylase 6 (HDAC6) DMCN91A MA Inhibitor DMCN91A RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCN91A RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCN91A DI DMCN91A DMCN91A DN N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide DMCN91A TI TT6R7JZ DMCN91A TN Histone deacetylase 1 (HDAC1) DMCN91A MA Inhibitor DMCN91A RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCN91A RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCN91V DI DMCN91V DMCN91V DN MI-1148 DMCN91V TI TTH9WF6 DMCN91V TN Dibasic-processing enzyme (Furin) DMCN91V MA Inhibitor DMCN91V RN Novel Furin Inhibitors with Potent Anti-infectious Activity. ChemMedChem. 2015 Jul;10(7):1218-31. DMCN91V RU https://pubmed.ncbi.nlm.nih.gov/25974265 DMCNBIL DI DMCNBIL DMCNBIL DN ISIS 24477 DMCNBIL TI TTJMF9P DMCNBIL TN ITGA4 messenger RNA (ITGA4 mRNA) DMCNBIL RN US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression. DMCNBIL RU http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true DMCNEXF DI DMCNEXF DMCNEXF DN CX4 DMCNEXF TI TTZ4MTQ DMCNEXF TN Voltage-gated potassium channel Kv12.2 (KCNH3) DMCNEXF MA Inhibitor (gating inhibitor) DMCNEXF RN Deletion of the potassium channel Kv12.2 causes hippocampal hyperexcitability and epilepsy. Nat Neurosci. 2010 Sep;13(9):1056-8. DMCNEXF RU https://pubmed.ncbi.nlm.nih.gov/20676103 DMCNFEL DI DMCNFEL DMCNFEL DN Dodecanesulfonate ion DMCNFEL TI TTEB0GD DMCNFEL TN Cholinesterase (BCHE) DMCNFEL MA Inhibitor DMCNFEL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCNFEL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCNG74 DI DMCNG74 DMCNG74 DN AP-21967 DMCNG74 TI TTCJG29 DMCNG74 TN Serine/threonine-protein kinase mTOR (mTOR) DMCNG74 MA Inhibitor DMCNG74 RN The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401. DMCNG74 RU https://pubmed.ncbi.nlm.nih.gov/17350953 DMCNIT2 DI DMCNIT2 DMCNIT2 DN NSC-645811 DMCNIT2 TI TTJLP0R DMCNIT2 TN Quinone reductase 2 (NQO2) DMCNIT2 MA Inhibitor DMCNIT2 RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMCNIT2 RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMCNITS DI DMCNITS DMCNITS DN 2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol DMCNITS TI TTOM3J0 DMCNITS TN Estrogen receptor beta (ESR2) DMCNITS MA Inhibitor DMCNITS RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMCNITS RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMCNITS DI DMCNITS DMCNITS DN 2-(4-Hydroxy-phenyl)-7-methoxy-benzooxazol-5-ol DMCNITS TI TTZAYWL DMCNITS TN Estrogen receptor (ESR) DMCNITS MA Inhibitor DMCNITS RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMCNITS RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMCNLBZ DI DMCNLBZ DMCNLBZ DN 4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol DMCNLBZ TI TTE4KHA DMCNLBZ TN Amyloid beta A4 protein (APP) DMCNLBZ MA Inhibitor DMCNLBZ RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DMCNLBZ RU https://pubmed.ncbi.nlm.nih.gov/16325402 DMCNOJV DI DMCNOJV DMCNOJV DN Sar-Arg-Val-Tyr-Ile-His-Pro-Ala DMCNOJV TI TTQVOEI DMCNOJV TN Angiotensin II receptor type-2 (AGTR2) DMCNOJV MA Inhibitor DMCNOJV RN Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 sub... J Med Chem. 1991 Nov;34(11):3248-60. DMCNOJV RU https://pubmed.ncbi.nlm.nih.gov/1956044 DMCNU6I DI DMCNU6I DMCNU6I DN 5-butyl-2-(2,4-dichlorophenoxy)phenol DMCNU6I TI TTNX2CS DMCNU6I TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMCNU6I MA Inhibitor DMCNU6I RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DMCNU6I RU https://pubmed.ncbi.nlm.nih.gov/19217192 DMCNV5J DI DMCNV5J DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J TI TTYRF5E DMCNV5J TN Matrix metalloproteinase-21 (MMP-21) DMCNV5J MA Inhibitor DMCNV5J RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DMCNV5J RU https://pubmed.ncbi.nlm.nih.gov/19775099 DMCNV5J DI DMCNV5J DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J TI TTJ4QE7 DMCNV5J TN Matrix metalloproteinase-14 (MMP-14) DMCNV5J MA Inhibitor DMCNV5J RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DMCNV5J RU https://pubmed.ncbi.nlm.nih.gov/19775099 DMCNV5J DI DMCNV5J DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J TI TTHY57M DMCNV5J TN Matrix metalloproteinase-13 (MMP-13) DMCNV5J MA Inhibitor DMCNV5J RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DMCNV5J RU https://pubmed.ncbi.nlm.nih.gov/19775099 DMCNV5J DI DMCNV5J DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J TI TTXZ0KQ DMCNV5J TN Matrix metalloproteinase-12 (MMP-12) DMCNV5J MA Inhibitor DMCNV5J RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DMCNV5J RU https://pubmed.ncbi.nlm.nih.gov/19775099 DMCNV5J DI DMCNV5J DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J TI TT6X50U DMCNV5J TN Matrix metalloproteinase-9 (MMP-9) DMCNV5J MA Inhibitor DMCNV5J RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DMCNV5J RU https://pubmed.ncbi.nlm.nih.gov/19775099 DMCNV5J DI DMCNV5J DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J TI TTLM12X DMCNV5J TN Matrix metalloproteinase-2 (MMP-2) DMCNV5J MA Inhibitor DMCNV5J RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DMCNV5J RU https://pubmed.ncbi.nlm.nih.gov/19775099 DMCNV5J DI DMCNV5J DMCNV5J DN 2-(Biphenyl-4-ylsulfonyl)N-hydroxybenzamide DMCNV5J TI TTGA1IV DMCNV5J TN Matrix metalloproteinase-8 (MMP-8) DMCNV5J MA Inhibitor DMCNV5J RN Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhib... J Med Chem. 2009 Oct 22;52(20):6347-61. DMCNV5J RU https://pubmed.ncbi.nlm.nih.gov/19775099 DMCNV68 DI DMCNV68 DMCNV68 DN Carboron Cluster with phenol DMCNV68 TI TTZAYWL DMCNV68 TN Estrogen receptor (ESR) DMCNV68 MA Inhibitor DMCNV68 RN Utility of boron clusters for drug design. Relation between estrogen receptor binding affinity and hydrophobicity of phenols bearing various types ... Bioorg Med Chem Lett. 2003 Nov 17;13(22):4089-92. DMCNV68 RU https://pubmed.ncbi.nlm.nih.gov/14592514 DMCNW3M DI DMCNW3M DMCNW3M DN 2-hydroxylauric acid DMCNW3M TI TTG0MQD DMCNW3M TN Inflammation-related GPCR EX33 (GPR84) DMCNW3M MA Agonist DMCNW3M RN Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. DMCNW3M RU https://pubmed.ncbi.nlm.nih.gov/23449982 DMCNX34 DI DMCNX34 DMCNX34 DN 3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane DMCNX34 TI TTPC4TU DMCNX34 TN 5-HT 3A receptor (HTR3A) DMCNX34 MA Inhibitor DMCNX34 RN Synthesis of heteroaromatic tropeines and heterogeneous binding to glycine receptors. Bioorg Med Chem. 2009 Oct 1;17(19):6872-8. DMCNX34 RU https://pubmed.ncbi.nlm.nih.gov/19726200 DMCNXKE DI DMCNXKE DMCNXKE DN PMID30247903-Compound-General structure20 DMCNXKE TI TTNBFWK DMCNXKE TN Programmed cell death protein 1 (PD-1) DMCNXKE MA Inhibitor DMCNXKE RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMCNXKE RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMCNXZM DI DMCNXZM DMCNXZM DN 2-hydrazinylbenzenesulfonamide DMCNXZM TI TTCFSPE DMCNXZM TN Carbonic anhydrase VI (CA-VI) DMCNXZM MA Inhibitor DMCNXZM RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMCNXZM RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMCNXZM DI DMCNXZM DMCNXZM DN 2-hydrazinylbenzenesulfonamide DMCNXZM TI TT2LVK8 DMCNXZM TN Carbonic anhydrase IX (CA-IX) DMCNXZM MA Inhibitor DMCNXZM RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMCNXZM RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMCNXZM DI DMCNXZM DMCNXZM DN 2-hydrazinylbenzenesulfonamide DMCNXZM TI TTANPDJ DMCNXZM TN Carbonic anhydrase II (CA-II) DMCNXZM MA Inhibitor DMCNXZM RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMCNXZM RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMCNXZM DI DMCNXZM DMCNXZM DN 2-hydrazinylbenzenesulfonamide DMCNXZM TI TTSYM0R DMCNXZM TN Carbonic anhydrase XII (CA-XII) DMCNXZM MA Inhibitor DMCNXZM RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMCNXZM RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMCNXZM DI DMCNXZM DMCNXZM DN 2-hydrazinylbenzenesulfonamide DMCNXZM TI TTUNARX DMCNXZM TN Carbonic anhydrase (CA) DMCNXZM MA Inhibitor DMCNXZM RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMCNXZM RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMCO0JU DI DMCO0JU DMCO0JU DN 1-Benzyl-4-(3-hydroxyphenyl)piperidine DMCO0JU TI TTEX248 DMCO0JU TN Dopamine D2 receptor (D2R) DMCO0JU MA Inhibitor DMCO0JU RN Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20. DMCO0JU RU https://pubmed.ncbi.nlm.nih.gov/20155917 DMCO2S4 DI DMCO2S4 DMCO2S4 DN AT-009 DMCO2S4 TI TTBID49 DMCO2S4 TN C-X-C chemokine receptor type 4 (CXCR4) DMCO2S4 MA Antagonist DMCO2S4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMCO2S4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMCOD4N DI DMCOD4N DMCOD4N DN 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide DMCOD4N TI TTANPDJ DMCOD4N TN Carbonic anhydrase II (CA-II) DMCOD4N MA Inhibitor DMCOD4N RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMCOD4N RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMCOD4N DI DMCOD4N DMCOD4N DN 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide DMCOD4N TI TTHQPL7 DMCOD4N TN Carbonic anhydrase I (CA-I) DMCOD4N MA Inhibitor DMCOD4N RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMCOD4N RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMCOD4N DI DMCOD4N DMCOD4N DN 4-(2-Phenylacetamido)-3-fluorobenzenesulfonamide DMCOD4N TI TTUNARX DMCOD4N TN Carbonic anhydrase (CA) DMCOD4N MA Inhibitor DMCOD4N RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMCOD4N RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMCOH46 DI DMCOH46 DMCOH46 DN 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMCOH46 TI TTCM4B3 DMCOH46 TN Nitric-oxide synthase endothelial (NOS3) DMCOH46 MA Inhibitor DMCOH46 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMCOH46 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMCOH46 DI DMCOH46 DMCOH46 DN 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMCOH46 TI TTZUFI5 DMCOH46 TN Nitric-oxide synthase brain (NOS1) DMCOH46 MA Inhibitor DMCOH46 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMCOH46 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMCOH46 DI DMCOH46 DMCOH46 DN 3-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMCOH46 TI TTF10I9 DMCOH46 TN Nitric-oxide synthase inducible (NOS2) DMCOH46 MA Inhibitor DMCOH46 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMCOH46 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMCOHKU DI DMCOHKU DMCOHKU DN PMID21967808CR-16 DMCOHKU TI TTBPJOK DMCOHKU TN IL-1 receptor-associated kinase 3 (IRAK3) DMCOHKU MA Inhibitor DMCOHKU RN Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84. DMCOHKU RU https://pubmed.ncbi.nlm.nih.gov/21967808 DMCOHKU DI DMCOHKU DMCOHKU DN PMID21967808CR-16 DMCOHKU TI TTYNM3X DMCOHKU TN Sugen kinase 110 (SBK3) DMCOHKU MA Inhibitor DMCOHKU RN Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84. DMCOHKU RU https://pubmed.ncbi.nlm.nih.gov/21967808 DMCOHKU DI DMCOHKU DMCOHKU DN PMID21967808CR-16 DMCOHKU TI TT4D7MJ DMCOHKU TN Serine/threonine-protein kinase ULK1 (ULK1) DMCOHKU MA Inhibitor DMCOHKU RN Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84. DMCOHKU RU https://pubmed.ncbi.nlm.nih.gov/21967808 DMCOHKU DI DMCOHKU DMCOHKU DN PMID21967808CR-16 DMCOHKU TI TTNDSF4 DMCOHKU TN Proto-oncogene c-Met (MET) DMCOHKU MA Inhibitor DMCOHKU RN Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84. DMCOHKU RU https://pubmed.ncbi.nlm.nih.gov/21967808 DMCOHKU DI DMCOHKU DMCOHKU DN PMID21967808CR-16 DMCOHKU TI TTT4236 DMCOHKU TN Tie-1 tyrosine kinase receptor (TIE1) DMCOHKU MA Inhibitor DMCOHKU RN Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group. Bioorg Med Chem. 2011 Nov 1;19(21):6274-84. DMCOHKU RU https://pubmed.ncbi.nlm.nih.gov/21967808 DMCOJIL DI DMCOJIL DMCOJIL DN 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline DMCOJIL TI TTBRKXS DMCOJIL TN Adrenergic receptor alpha-1B (ADRA1B) DMCOJIL MA Inhibitor DMCOJIL RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DMCOJIL RU https://pubmed.ncbi.nlm.nih.gov/12729659 DMCOJIL DI DMCOJIL DMCOJIL DN 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline DMCOJIL TI TT34BHT DMCOJIL TN Adrenergic receptor alpha-1D (ADRA1D) DMCOJIL MA Inhibitor DMCOJIL RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DMCOJIL RU https://pubmed.ncbi.nlm.nih.gov/12729659 DMCOJIL DI DMCOJIL DMCOJIL DN 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline DMCOJIL TI TTLD29N DMCOJIL TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMCOJIL MA Inhibitor DMCOJIL RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DMCOJIL RU https://pubmed.ncbi.nlm.nih.gov/12729659 DMCOJIL DI DMCOJIL DMCOJIL DN 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline DMCOJIL TI TTN9D8E DMCOJIL TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMCOJIL MA Inhibitor DMCOJIL RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DMCOJIL RU https://pubmed.ncbi.nlm.nih.gov/12729659 DMCOJIL DI DMCOJIL DMCOJIL DN 4-(3,4-Dihydro-1H-isoquinolin-2-yl)-quinoline DMCOJIL TI TTNGILX DMCOJIL TN Adrenergic receptor alpha-1A (ADRA1A) DMCOJIL MA Inhibitor DMCOJIL RN 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor an... Bioorg Med Chem Lett. 2003 May 19;13(10):1759-62. DMCOJIL RU https://pubmed.ncbi.nlm.nih.gov/12729659 DMCOMLS DI DMCOMLS DMCOMLS DN APY29 DMCOMLS TI TTOJ9QL DMCOMLS TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMCOMLS MA Inhibitor DMCOMLS RN Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway. Food Chem Toxicol. 2018 Apr;114:52-60. DMCOMLS RU https://pubmed.ncbi.nlm.nih.gov/29438776 DMCOPR3 DI DMCOPR3 DMCOPR3 DN N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine DMCOPR3 TI TTJFY5U DMCOPR3 TN Adenosine A3 receptor (ADORA3) DMCOPR3 MA Inhibitor DMCOPR3 RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DMCOPR3 RU https://pubmed.ncbi.nlm.nih.gov/16033270 DMCOPR3 DI DMCOPR3 DMCOPR3 DN N*6*-Cyclooctyl-N*2*-phenyl-9H-purine-2,6-diamine DMCOPR3 TI TTK25J1 DMCOPR3 TN Adenosine A1 receptor (ADORA1) DMCOPR3 MA Inhibitor DMCOPR3 RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DMCOPR3 RU https://pubmed.ncbi.nlm.nih.gov/16033270 DMCOQKH DI DMCOQKH DMCOQKH DN C646 DMCOQKH TI TTH4VJL DMCOQKH TN Histone acetyltransferase KAT6B (KAT6B) DMCOQKH MA Inhibitor DMCOQKH RN Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010 May 28;17(5):471-82. DMCOQKH RU https://pubmed.ncbi.nlm.nih.gov/20534345 DMCOYF9 DI DMCOYF9 DMCOYF9 DN GW-5823 DMCOYF9 TI TTCG0AL DMCOYF9 TN Cholecystokinin receptor type A (CCKAR) DMCOYF9 MA Agonist DMCOYF9 RN Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem. 1997 Aug 15;40(17):2706-25. DMCOYF9 RU https://pubmed.ncbi.nlm.nih.gov/9276016 DMCOYF9 DI DMCOYF9 DMCOYF9 DN GW-5823 DMCOYF9 TI TTVFO0U DMCOYF9 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMCOYF9 MA Antagonist DMCOYF9 RN Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem. 1997 Aug 15;40(17):2706-25. DMCOYF9 RU https://pubmed.ncbi.nlm.nih.gov/9276016 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TT2LVK8 DMCOYHR TN Carbonic anhydrase IX (CA-IX) DMCOYHR MA Inhibitor DMCOYHR RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TTCFSPE DMCOYHR TN Carbonic anhydrase VI (CA-VI) DMCOYHR MA Inhibitor DMCOYHR RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TTEYTKG DMCOYHR TN Carbonic anhydrase XIV (CA-XIV) DMCOYHR MA Inhibitor DMCOYHR RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TTANPDJ DMCOYHR TN Carbonic anhydrase II (CA-II) DMCOYHR MA Inhibitor DMCOYHR RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TTSYM0R DMCOYHR TN Carbonic anhydrase XII (CA-XII) DMCOYHR MA Inhibitor DMCOYHR RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TTZHA0O DMCOYHR TN Carbonic anhydrase IV (CA-IV) DMCOYHR MA Inhibitor DMCOYHR RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TTUNARX DMCOYHR TN Carbonic anhydrase (CA) DMCOYHR MA Inhibitor DMCOYHR RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMCOYHR DI DMCOYHR DMCOYHR DN 4-Amino-3-iodo-benzenesulfonamide DMCOYHR TI TTHQPL7 DMCOYHR TN Carbonic anhydrase I (CA-I) DMCOYHR MA Inhibitor DMCOYHR RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMCOYHR RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMCP089 DI DMCP089 DMCP089 DN 1-(4-Nitro-2-phenylsulfanylbenzyl)-1H-imidazole DMCP089 TI TTSZLWK DMCP089 TN Aromatase (CYP19A1) DMCP089 MA Inhibitor DMCP089 RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DMCP089 RU https://pubmed.ncbi.nlm.nih.gov/20568782 DMCP1G9 DI DMCP1G9 DMCP1G9 DN Chelerythrine DMCP1G9 TI TT473XN DMCP1G9 TN P2X purinoceptor 7 (P2RX7) DMCP1G9 MA Modulator (allosteric modulator) DMCP1G9 RN Chelerythrine and other benzophenanthridine alkaloids block the human P2X7 receptor. Br J Pharmacol. 2004 Jul;142(6):1015-9. DMCP1G9 RU https://pubmed.ncbi.nlm.nih.gov/15210579 DMCP1G9 DI DMCP1G9 DMCP1G9 DN Chelerythrine DMCP1G9 TI TT57MT2 DMCP1G9 TN PKC-epsilon messenger RNA (PRKCE mRNA) DMCP1G9 MA Inhibitor DMCP1G9 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMCP1G9 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMCP1G9 DI DMCP1G9 DMCP1G9 DN Chelerythrine DMCP1G9 TI TTYVI76 DMCP1G9 TN Fungal Protein kinase A (Fung ypkA) DMCP1G9 MA Inhibitor DMCP1G9 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMCP1G9 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMCP1I6 DI DMCP1I6 DMCP1I6 DN NSC-720622 DMCP1I6 TI TTJLP0R DMCP1I6 TN Quinone reductase 2 (NQO2) DMCP1I6 MA Inhibitor DMCP1I6 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMCP1I6 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMCP5U8 DI DMCP5U8 DMCP5U8 DN 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline DMCP5U8 TI TT8NGED DMCP5U8 TN Prostaglandin G/H synthase 1 (COX-1) DMCP5U8 MA Inhibitor DMCP5U8 RN 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51. DMCP5U8 RU https://pubmed.ncbi.nlm.nih.gov/10794700 DMCP5U8 DI DMCP5U8 DMCP5U8 DN 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline DMCP5U8 TI TTVKILB DMCP5U8 TN Prostaglandin G/H synthase 2 (COX-2) DMCP5U8 MA Inhibitor DMCP5U8 RN 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51. DMCP5U8 RU https://pubmed.ncbi.nlm.nih.gov/10794700 DMCP5U8 DI DMCP5U8 DMCP5U8 DN 5-(2-Imidazol-1-yl-ethyl)-7,8-dihydro-quinoline DMCP5U8 TI TTKNWZ4 DMCP5U8 TN Thromboxane-A synthase (TBXAS1) DMCP5U8 MA Inhibitor DMCP5U8 RN 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51. DMCP5U8 RU https://pubmed.ncbi.nlm.nih.gov/10794700 DMCPB0Q DI DMCPB0Q DMCPB0Q DN LTE4 DMCPB0Q TI TTMPART DMCPB0Q TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMCPB0Q MA Agonist DMCPB0Q RN The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair. PLoS One. 2008;3(10):e3579. DMCPB0Q RU https://pubmed.ncbi.nlm.nih.gov/18974869 DMCPB0Q DI DMCPB0Q DMCPB0Q DN LTE4 DMCPB0Q TI TTGKOY9 DMCPB0Q TN Leukotriene CysLT1 receptor (CYSLTR1) DMCPB0Q MA Agonist DMCPB0Q RN Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature. 1999 Jun 24;399(6738):789-93. DMCPB0Q RU https://pubmed.ncbi.nlm.nih.gov/10391245 DMCPB0Q DI DMCPB0Q DMCPB0Q DN LTE4 DMCPB0Q TI TT0PZR5 DMCPB0Q TN Leukotriene CysLT2 receptor (CYSLTR2) DMCPB0Q MA Agonist DMCPB0Q RN Differential signaling of cysteinyl leukotrienes and a novel cysteinyl leukotriene receptor 2 (CysLT agonist, N-methyl-leukotriene C in calcium reporter and beta arrestin assays. Mol Pharmacol. 2011 Feb;79(2):270-8. DMCPB0Q RU https://pubmed.ncbi.nlm.nih.gov/21078884 DMCPB0Q DI DMCPB0Q DMCPB0Q DN LTE4 DMCPB0Q TI TTAS1QK DMCPB0Q TN Oxoglutarate receptor (OXGR1) DMCPB0Q MA Agonist DMCPB0Q RN Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem. 2013 Apr 19;288(16):10967-72. DMCPB0Q RU https://pubmed.ncbi.nlm.nih.gov/23504326 DMCPEBF DI DMCPEBF DMCPEBF DN (RS)-5-diphosphomevalonate DMCPEBF TI TT5DFHW DMCPEBF TN Mevalonate kinase (MVK) DMCPEBF MA Inhibitor DMCPEBF RN Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6. DMCPEBF RU https://pubmed.ncbi.nlm.nih.gov/16524256 DMCPIK5 DI DMCPIK5 DMCPIK5 DN 5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole DMCPIK5 TI TT6OEDT DMCPIK5 TN Cannabinoid receptor 1 (CB1) DMCPIK5 MA Inhibitor DMCPIK5 RN New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4. DMCPIK5 RU https://pubmed.ncbi.nlm.nih.gov/18424134 DMCPIK5 DI DMCPIK5 DMCPIK5 DN 5-Biphenyl-4-ylmethyl-2-isobutyl-2H-tetrazole DMCPIK5 TI TTMSFAW DMCPIK5 TN Cannabinoid receptor 2 (CB2) DMCPIK5 MA Inhibitor DMCPIK5 RN New tetrazole-based selective anandamide uptake inhibitors. Bioorg Med Chem Lett. 2008 May 1;18(9):2820-4. DMCPIK5 RU https://pubmed.ncbi.nlm.nih.gov/18424134 DMCPIQ4 DI DMCPIQ4 DMCPIQ4 DN PMID15482908C8 DMCPIQ4 TI TTHS256 DMCPIQ4 TN Metabotropic glutamate receptor 5 (mGluR5) DMCPIQ4 MA Modulator (allosteric modulator) DMCPIQ4 RN Discovery of highly potent, selective, orally bioavailable, metabotropic glutamate subtype 5 (mGlu5) receptor antagonists devoid of cytochrome P450 1A2 inhibitory activity. Bioorg Med Chem Lett. 2004Nov 15;14(22):5481-4. DMCPIQ4 RU https://pubmed.ncbi.nlm.nih.gov/15482908 DMCPKV9 DI DMCPKV9 DMCPKV9 DN ISIS 134605 DMCPKV9 TI TTKW4ML DMCPKV9 TN Caspase 6 messenger RNA (CASP6 mRNA) DMCPKV9 RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMCPKV9 RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMCPN7V DI DMCPN7V DMCPN7V DN 2-(4-hydroxybenzylideneamino)ethanesulfonamide DMCPN7V TI TTANPDJ DMCPN7V TN Carbonic anhydrase II (CA-II) DMCPN7V MA Inhibitor DMCPN7V RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DMCPN7V RU https://pubmed.ncbi.nlm.nih.gov/19796939 DMCPOQ9 DI DMCPOQ9 DMCPOQ9 DN 3-(2,2-Diphenyl-vinyl)-pyridine DMCPOQ9 TI TTSZLWK DMCPOQ9 TN Aromatase (CYP19A1) DMCPOQ9 MA Inhibitor DMCPOQ9 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMCPOQ9 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMCPSE9 DI DMCPSE9 DMCPSE9 DN 4-(2-phenyl-1H-indol-3-yl)phenol DMCPSE9 TI TTOM3J0 DMCPSE9 TN Estrogen receptor beta (ESR2) DMCPSE9 MA Inhibitor DMCPSE9 RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMCPSE9 RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMCPSE9 DI DMCPSE9 DMCPSE9 DN 4-(2-phenyl-1H-indol-3-yl)phenol DMCPSE9 TI TTZAYWL DMCPSE9 TN Estrogen receptor (ESR) DMCPSE9 MA Inhibitor DMCPSE9 RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMCPSE9 RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMCPW5F DI DMCPW5F DMCPW5F DN MCL-153 DMCPW5F TI TTQW87Y DMCPW5F TN Opioid receptor kappa (OPRK1) DMCPW5F MA Inhibitor DMCPW5F RN Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. DMCPW5F RU https://pubmed.ncbi.nlm.nih.gov/20144870 DMCPW5F DI DMCPW5F DMCPW5F DN MCL-153 DMCPW5F TI TT27RFC DMCPW5F TN Opioid receptor delta (OPRD1) DMCPW5F MA Inhibitor DMCPW5F RN Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. DMCPW5F RU https://pubmed.ncbi.nlm.nih.gov/20144870 DMCPW5F DI DMCPW5F DMCPW5F DN MCL-153 DMCPW5F TI TTKWM86 DMCPW5F TN Opioid receptor mu (MOP) DMCPW5F MA Inhibitor DMCPW5F RN Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9. DMCPW5F RU https://pubmed.ncbi.nlm.nih.gov/20144870 DMCQ6J8 DI DMCQ6J8 DMCQ6J8 DN 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline DMCQ6J8 TI TTI7421 DMCQ6J8 TN Platelet-derived growth factor receptor beta (PDGFRB) DMCQ6J8 MA Inhibitor DMCQ6J8 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMCQ6J8 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMCQ6J8 DI DMCQ6J8 DMCQ6J8 DN 3-Cyclohexylethynyl-6,7-dimethoxy-quinoline DMCQ6J8 TI TT8FYO9 DMCQ6J8 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMCQ6J8 MA Inhibitor DMCQ6J8 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMCQ6J8 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMCQ8AL DI DMCQ8AL DMCQ8AL DN USIMINE A DMCQ8AL TI TTELIN2 DMCQ8AL TN PTPN1 messenger RNA (PTPN1 mRNA) DMCQ8AL MA Inhibitor DMCQ8AL RN Usimines A-C, bioactive usnic acid derivatives from the Antarctic lichen Stereocaulon alpinum. J Nat Prod. 2008 Apr;71(4):710-2. DMCQ8AL RU https://pubmed.ncbi.nlm.nih.gov/18288807 DMCQH23 DI DMCQH23 DMCQH23 DN H-c[Cys-Phe-DTrp-Lys-Thr-Cys]-OH DMCQH23 TI TTZ6T9E DMCQH23 TN Somatostatin receptor type 2 (SSTR2) DMCQH23 MA Inhibitor DMCQH23 RN Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96. DMCQH23 RU https://pubmed.ncbi.nlm.nih.gov/16854054 DMCQNT9 DI DMCQNT9 DMCQNT9 DN SE-ET-TP020d DMCQNT9 TI TTIHYA4 DMCQNT9 TN Thrombopoietin receptor (MPL) DMCQNT9 MA Modulator DMCQNT9 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMCQNT9 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMCQRA3 DI DMCQRA3 DMCQRA3 DN KB-9520 DMCQRA3 TI TTOM3J0 DMCQRA3 TN Estrogen receptor beta (ESR2) DMCQRA3 MA Agonist DMCQRA3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621). DMCQRA3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621 DMCQTYW DI DMCQTYW DMCQTYW DN [11C]volinanserin DMCQTYW TI TTJQOD7 DMCQTYW TN 5-HT 2A receptor (HTR2A) DMCQTYW MA Antagonist DMCQTYW RN Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse. 2000 Dec 15;38(4):421-31. DMCQTYW RU https://pubmed.ncbi.nlm.nih.gov/11044889 DMCQUWI DI DMCQUWI DMCQUWI DN PI-3065 DMCQUWI TI TTTHBCA DMCQUWI TN PI3-kinase beta (PIK3CB) DMCQUWI MA Inhibitor DMCQUWI RN Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-11. DMCQUWI RU https://pubmed.ncbi.nlm.nih.gov/24919154 DMCQUWI DI DMCQUWI DMCQUWI DN PI-3065 DMCQUWI TI TTHBTOP DMCQUWI TN PI3-kinase gamma (PIK3CG) DMCQUWI MA Inhibitor DMCQUWI RN Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature. 2014 Jun 19;510(7505):407-11. DMCQUWI RU https://pubmed.ncbi.nlm.nih.gov/24919154 DMCQYBE DI DMCQYBE DMCQYBE DN ZK-136798 DMCQYBE TI TTUV8G9 DMCQYBE TN Progesterone receptor (PGR) DMCQYBE MA Modulator DMCQYBE RN The antiovulatory activity of progesterone antagonists is not correlated to their antiprogestational potency in the rat. J Steroid Biochem Mol Biol. 1996 Sep;59(1):75-82. DMCQYBE RU https://www.ncbi.nlm.nih.gov/pubmed/9009240 DMCQYIJ DI DMCQYIJ DMCQYIJ DN H-Dmt-Aba-Gly-NH-Ph DMCQYIJ TI TTKWM86 DMCQYIJ TN Opioid receptor mu (MOP) DMCQYIJ MA Inhibitor DMCQYIJ RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DMCQYIJ RU https://pubmed.ncbi.nlm.nih.gov/16789756 DMCQYIJ DI DMCQYIJ DMCQYIJ DN H-Dmt-Aba-Gly-NH-Ph DMCQYIJ TI TT27RFC DMCQYIJ TN Opioid receptor delta (OPRD1) DMCQYIJ MA Inhibitor DMCQYIJ RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DMCQYIJ RU https://pubmed.ncbi.nlm.nih.gov/16789756 DMCQYKO DI DMCQYKO DMCQYKO DN 4-Biphenyl-4-ylethynyl-2-methyl-thiazole DMCQYKO TI TTHS256 DMCQYKO TN Metabotropic glutamate receptor 5 (mGluR5) DMCQYKO MA Inhibitor DMCQYKO RN 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6. DMCQYKO RU https://pubmed.ncbi.nlm.nih.gov/15225713 DMCR13E DI DMCR13E DMCR13E DN N4,N6-dibenzylpyrimidine-4,6-dicarboxamide DMCR13E TI TTHY57M DMCR13E TN Matrix metalloproteinase-13 (MMP-13) DMCR13E MA Inhibitor DMCR13E RN Calculation of binding free energies for non-zinc chelating pyrimidine dicarboxamide inhibitors with MMP-13. Bioorg Med Chem Lett. 2009 Jan 1;19(1):47-50. DMCR13E RU https://pubmed.ncbi.nlm.nih.gov/19042129 DMCR3VM DI DMCR3VM DMCR3VM DN 4-(2-(2-fluorobenzyloxy)phenyl)piperidine DMCR3VM TI TTVBI8W DMCR3VM TN Dopamine transporter (DAT) DMCR3VM MA Inhibitor DMCR3VM RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMCR3VM RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMCR3VM DI DMCR3VM DMCR3VM DN 4-(2-(2-fluorobenzyloxy)phenyl)piperidine DMCR3VM TI TTSQIFT DMCR3VM TN 5-HT 1A receptor (HTR1A) DMCR3VM MA Inhibitor DMCR3VM RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMCR3VM RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMCR3VM DI DMCR3VM DMCR3VM DN 4-(2-(2-fluorobenzyloxy)phenyl)piperidine DMCR3VM TI TT3ROYC DMCR3VM TN Serotonin transporter (SERT) DMCR3VM MA Inhibitor DMCR3VM RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMCR3VM RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMCR3VM DI DMCR3VM DMCR3VM DN 4-(2-(2-fluorobenzyloxy)phenyl)piperidine DMCR3VM TI TTAWNKZ DMCR3VM TN Norepinephrine transporter (NET) DMCR3VM MA Inhibitor DMCR3VM RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMCR3VM RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMCR49K DI DMCR49K DMCR49K DN 2-N-Methylamino-1-(4-methylthiophenyl)butane DMCR49K TI TT3ROYC DMCR49K TN Serotonin transporter (SERT) DMCR49K MA Inhibitor DMCR49K RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMCR49K RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMCR9KX DI DMCR9KX DMCR9KX DN 5-(3-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid DMCR9KX TI TTWNV8U DMCR9KX TN Nicotinic acid receptor (HCAR2) DMCR9KX MA Inhibitor DMCR9KX RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMCR9KX RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMCRF48 DI DMCRF48 DMCRF48 DN VU-1545 DMCRF48 TI TTHS256 DMCRF48 TN Metabotropic glutamate receptor 5 (mGluR5) DMCRF48 MA Modulator (allosteric modulator) DMCRF48 RN Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44. DMCRF48 RU https://pubmed.ncbi.nlm.nih.gov/16722652 DMCRFT5 DI DMCRFT5 DMCRFT5 DN UC-1011 DMCRFT5 TI TTEX6LM DMCRFT5 TN GABA(A) receptor gamma-3 (GABRG3) DMCRFT5 MA Antagonist DMCRFT5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMCRFT5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMCRHOA DI DMCRHOA DMCRHOA DN VER-156085 DMCRHOA TI TTMSFAW DMCRHOA TN Cannabinoid receptor 2 (CB2) DMCRHOA MA Inhibitor DMCRHOA RN Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4. DMCRHOA RU https://pubmed.ncbi.nlm.nih.gov/19515560 DMCRHOA DI DMCRHOA DMCRHOA DN VER-156085 DMCRHOA TI TT6OEDT DMCRHOA TN Cannabinoid receptor 1 (CB1) DMCRHOA MA Inhibitor DMCRHOA RN Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4. DMCRHOA RU https://pubmed.ncbi.nlm.nih.gov/19515560 DMCRHVI DI DMCRHVI DMCRHVI DN 1-[(prop-1-ylamino)ethyl]-1,1-bisphosphonic acid DMCRHVI TI TTIKWV4 DMCRHVI TN Geranyltranstransferase (FDPS) DMCRHVI MA Inhibitor DMCRHVI RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DMCRHVI RU https://pubmed.ncbi.nlm.nih.gov/18096393 DMCRJ54 DI DMCRJ54 DMCRJ54 DN 4-fluorophenyl 4-butoxybenzylcarbamate DMCRJ54 TI TTDP1UC DMCRJ54 TN Fatty acid amide hydrolase (FAAH) DMCRJ54 MA Inhibitor DMCRJ54 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMCRJ54 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMCRQ29 DI DMCRQ29 DMCRQ29 DN S-benzo[d]oxazol-2-yl O-butyl carbonothioate DMCRQ29 TI TT6804T DMCRQ29 TN MIF messenger RNA (MIF mRNA) DMCRQ29 MA Inhibitor DMCRQ29 RN An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. DMCRQ29 RU https://pubmed.ncbi.nlm.nih.gov/20639113 DMCRU17 DI DMCRU17 DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide DMCRU17 TI TTBH0VX DMCRU17 TN Histone deacetylase (HDAC) DMCRU17 MA Inhibitor DMCRU17 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCRU17 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCRU17 DI DMCRU17 DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide DMCRU17 TI TTTQGH8 DMCRU17 TN Histone deacetylase 4 (HDAC4) DMCRU17 MA Inhibitor DMCRU17 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCRU17 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCRU17 DI DMCRU17 DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide DMCRU17 TI TT6R7JZ DMCRU17 TN Histone deacetylase 1 (HDAC1) DMCRU17 MA Inhibitor DMCRU17 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCRU17 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCRU17 DI DMCRU17 DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide DMCRU17 TI TT5ZKDI DMCRU17 TN Histone deacetylase 6 (HDAC6) DMCRU17 MA Inhibitor DMCRU17 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCRU17 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCRU17 DI DMCRU17 DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide DMCRU17 TI TTT6LFV DMCRU17 TN Histone deacetylase 8 (HDAC8) DMCRU17 MA Inhibitor DMCRU17 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCRU17 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCRU17 DI DMCRU17 DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide DMCRU17 TI TTYHPU6 DMCRU17 TN Histone deacetylase 10 (HDAC10) DMCRU17 MA Inhibitor DMCRU17 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCRU17 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCRU17 DI DMCRU17 DMCRU17 DN N-Hydroxy-4-phenylacetylamino-benzamide DMCRU17 TI TTSHTOI DMCRU17 TN Histone deacetylase 2 (HDAC2) DMCRU17 MA Inhibitor DMCRU17 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMCRU17 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMCRU4H DI DMCRU4H DMCRU4H DN CYLINDROL A DMCRU4H TI TT7WZIJ DMCRU4H TN CAAX farnesyltransferase beta (FNTB) DMCRU4H MA Inhibitor DMCRU4H RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DMCRU4H RU https://pubmed.ncbi.nlm.nih.gov/9301658 DMCRVM2 DI DMCRVM2 DMCRVM2 DN SR-59026 DMCRVM2 TI TTSQIFT DMCRVM2 TN 5-HT 1A receptor (HTR1A) DMCRVM2 MA Modulator DMCRVM2 RN Effect of SR 59026A, a new 5-HT(1A) receptor agonist, on sexual activity in male rats. Behav Pharmacol. 1995 Apr;6(3):276-282. DMCRVM2 RU https://www.ncbi.nlm.nih.gov/pubmed/11224336 DMCRWTH DI DMCRWTH DMCRWTH DN 4'-((2-butylbenzofuran-3-yl)methyl)biphenyl-4-ol DMCRWTH TI TTELIN2 DMCRWTH TN PTPN1 messenger RNA (PTPN1 mRNA) DMCRWTH MA Inhibitor DMCRWTH RN Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2009 Apr 1;17(7):2658-72. DMCRWTH RU https://pubmed.ncbi.nlm.nih.gov/19297174 DMCRXAM DI DMCRXAM DMCRXAM DN PF3845 DMCRXAM TI TTDP1UC DMCRXAM TN Fatty acid amide hydrolase (FAAH) DMCRXAM MA Inhibitor DMCRXAM RN Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009 Apr 24;16(4):411-20. DMCRXAM RU https://pubmed.ncbi.nlm.nih.gov/19389627 DMCS4BL DI DMCS4BL DMCS4BL DN J-104870 DMCS4BL TI TTRK9JT DMCS4BL TN Neuropeptide Y receptor type 1 (NPY1R) DMCS4BL MA Antagonist DMCS4BL RN The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem Biophys Res Commun. 1999 Dec 9;266(1):88-91. DMCS4BL RU https://pubmed.ncbi.nlm.nih.gov/10581170 DMCS538 DI DMCS538 DMCS538 DN 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol DMCS538 TI TT1MPAY DMCS538 TN GABA(A) receptor alpha-1 (GABRA1) DMCS538 MA Inhibitor DMCS538 RN Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6. DMCS538 RU https://pubmed.ncbi.nlm.nih.gov/16821803 DMCS538 DI DMCS538 DMCS538 DN 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol DMCS538 TI TTNJYV2 DMCS538 TN Gamma-aminobutyric acid receptor (GAR) DMCS538 MA Inhibitor DMCS538 RN Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6. DMCS538 RU https://pubmed.ncbi.nlm.nih.gov/16821803 DMCS538 DI DMCS538 DMCS538 DN 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol DMCS538 TI TT06RH5 DMCS538 TN GABA(A) receptor gamma-2 (GABRG2) DMCS538 MA Inhibitor DMCS538 RN Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6. DMCS538 RU https://pubmed.ncbi.nlm.nih.gov/16821803 DMCS538 DI DMCS538 DMCS538 DN 4-(2-aminoethyl)-1,2,5-oxadiazol-3-ol DMCS538 TI TTZA1NY DMCS538 TN GABA(A) receptor beta-2 (GABRB2) DMCS538 MA Inhibitor DMCS538 RN Hydroxy-1,2,5-oxadiazolyl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and pharmacological characterization of ga... J Med Chem. 2006 Jul 13;49(14):4442-6. DMCS538 RU https://pubmed.ncbi.nlm.nih.gov/16821803 DMCS83F DI DMCS83F DMCS83F DN 4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline DMCS83F TI TTNJYV2 DMCS83F TN Gamma-aminobutyric acid receptor (GAR) DMCS83F MA Inhibitor DMCS83F RN Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52. DMCS83F RU https://pubmed.ncbi.nlm.nih.gov/9651158 DMCS83F DI DMCS83F DMCS83F DN 4-Methoxymethyl-3,6-dipropoxy-9H-beta-carboline DMCS83F TI TT1MPAY DMCS83F TN GABA(A) receptor alpha-1 (GABRA1) DMCS83F MA Inhibitor DMCS83F RN Synthesis and evaluation of analogues of the partial agonist 6-(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) a... J Med Chem. 1998 Jul 2;41(14):2537-52. DMCS83F RU https://pubmed.ncbi.nlm.nih.gov/9651158 DMCSAIJ DI DMCSAIJ DMCSAIJ DN COCHINCHINENENE B DMCSAIJ TI TT6L509 DMCSAIJ TN Coagulation factor IIa (F2) DMCSAIJ MA Inhibitor DMCSAIJ RN Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis. J Nat Prod. 2007 Oct;70(10):1570-7. DMCSAIJ RU https://pubmed.ncbi.nlm.nih.gov/17883259 DMCSHE8 DI DMCSHE8 DMCSHE8 DN visnagin DMCSHE8 TI TTNE7KG DMCSHE8 TN Adenosine A2b receptor (ADORA2B) DMCSHE8 MA Antagonist DMCSHE8 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMCSHE8 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMCSHE8 DI DMCSHE8 DMCSHE8 DN visnagin DMCSHE8 TI TTJFY5U DMCSHE8 TN Adenosine A3 receptor (ADORA3) DMCSHE8 MA Antagonist DMCSHE8 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMCSHE8 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMCSHI3 DI DMCSHI3 DMCSHI3 DN (R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate DMCSHI3 TI TT9JNIC DMCSHI3 TN Histamine H3 receptor (H3R) DMCSHI3 MA Inhibitor DMCSHI3 RN Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6682-5. DMCSHI3 RU https://pubmed.ncbi.nlm.nih.gov/19846299 DMCSHI3 DI DMCSHI3 DMCSHI3 DN (R)-3-(1H-imidazol-4-yl)propyl sec-butylcarbamate DMCSHI3 TI TTXJ178 DMCSHI3 TN Histamine H4 receptor (H4R) DMCSHI3 MA Inhibitor DMCSHI3 RN Histamine H3 and H4 receptor affinity of branched 3-(1H-imidazol-4-yl)propyl N-alkylcarbamates. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6682-5. DMCSHI3 RU https://pubmed.ncbi.nlm.nih.gov/19846299 DMCSHRL DI DMCSHRL DMCSHRL DN 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea DMCSHRL TI TTCM4B3 DMCSHRL TN Nitric-oxide synthase endothelial (NOS3) DMCSHRL MA Inhibitor DMCSHRL RN Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4. DMCSHRL RU https://pubmed.ncbi.nlm.nih.gov/17317165 DMCSHRL DI DMCSHRL DMCSHRL DN 1-(2-amino-benzothiazol-6-yl)-2-ethyl-isothiourea DMCSHRL TI TTZUFI5 DMCSHRL TN Nitric-oxide synthase brain (NOS1) DMCSHRL MA Inhibitor DMCSHRL RN Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett. 2007 May 1;17(9):2540-4. DMCSHRL RU https://pubmed.ncbi.nlm.nih.gov/17317165 DMCSMX4 DI DMCSMX4 DMCSMX4 DN Cardiolipin DMCSMX4 TI TTU5A6Q DMCSMX4 TN Adenine nucleotide translocator 1 (SLC25A4) DMCSMX4 MA Inhibitor DMCSMX4 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMCSMX4 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMCSN9M DI DMCSN9M DMCSN9M DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-COOH DMCSN9M TI TTNT7K8 DMCSN9M TN Nociceptin receptor (OPRL1) DMCSN9M MA Inhibitor DMCSN9M RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMCSN9M RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMCSOAV DI DMCSOAV DMCSOAV DN 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMCSOAV TI TTQ6VDM DMCSOAV TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMCSOAV MA Inhibitor DMCSOAV RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMCSOAV RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMCSOAV DI DMCSOAV DMCSOAV DN 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMCSOAV TI TT3ROYC DMCSOAV TN Serotonin transporter (SERT) DMCSOAV MA Inhibitor DMCSOAV RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMCSOAV RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMCSOAV DI DMCSOAV DMCSOAV DN 1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMCSOAV TI TTAWNKZ DMCSOAV TN Norepinephrine transporter (NET) DMCSOAV MA Inhibitor DMCSOAV RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMCSOAV RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMCSPU4 DI DMCSPU4 DMCSPU4 DN 1-Deoxy-D-Xylulose-5-Phosphate DMCSPU4 TI TTHB48R DMCSPU4 TN Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ) DMCSPU4 MA Inhibitor DMCSPU4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCSPU4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCSTP5 DI DMCSTP5 DMCSTP5 DN FGGFTGARKSARKLRNQ DMCSTP5 TI TTNT7K8 DMCSTP5 TN Nociceptin receptor (OPRL1) DMCSTP5 MA Inhibitor DMCSTP5 RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMCSTP5 RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMCSXNW DI DMCSXNW DMCSXNW DN CACOSPONGIONOLIDE B DMCSXNW TI TT9V5JH DMCSXNW TN Phospholipase A2 (PLA2G1B) DMCSXNW MA Inhibitor DMCSXNW RN A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5. DMCSXNW RU https://pubmed.ncbi.nlm.nih.gov/9677277 DMCSXNW DI DMCSXNW DMCSXNW DN CACOSPONGIONOLIDE B DMCSXNW TI TTO8QRU DMCSXNW TN Group IIA phospholipase A2 (GIIA sPLA2) DMCSXNW MA Inhibitor DMCSXNW RN A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5. DMCSXNW RU https://pubmed.ncbi.nlm.nih.gov/9677277 DMCSZG0 DI DMCSZG0 DMCSZG0 DN WAY-125971 DMCSZG0 TI TT1VOHK DMCSZG0 TN Potassium channel unspecific (KC) DMCSZG0 MA Modulator DMCSZG0 RN Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives. J Med Chem. 1991 Nov;34(11):3212-28. DMCSZG0 RU https://pubmed.ncbi.nlm.nih.gov/1956040 DMCT02Q DI DMCT02Q DMCT02Q DN SNG-8006 DMCT02Q TI TTZAYWL DMCT02Q TN Estrogen receptor (ESR) DMCT02Q MA Antagonist DMCT02Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMCT02Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMCT348 DI DMCT348 DMCT348 DN Ohioensin F DMCT348 TI TTELIN2 DMCT348 TN PTPN1 messenger RNA (PTPN1 mRNA) DMCT348 MA Inhibitor DMCT348 RN Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5. DMCT348 RU https://pubmed.ncbi.nlm.nih.gov/18053716 DMCTF8X DI DMCTF8X DMCTF8X DN 1-(1-Biphenyl-4-yl-2-phenyl-ethyl)-1H-imidazole DMCTF8X TI TTRA5BZ DMCTF8X TN Steroid 17-alpha-monooxygenase (S17AH) DMCTF8X MA Inhibitor DMCTF8X RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMCTF8X RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMCTFWE DI DMCTFWE DMCTFWE DN PMID18324760C28 DMCTFWE TI TTUI5H7 DMCTFWE TN Angiotensin-converting enzyme 2 (ACE2) DMCTFWE MA Inhibitor DMCTFWE RN Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2. J Med Chem. 2008 Apr 10;51(7):2216-26. DMCTFWE RU https://pubmed.ncbi.nlm.nih.gov/18324760 DMCTJAM DI DMCTJAM DMCTJAM DN PYRIPYROPENE A DMCTJAM TI TTMF541 DMCTJAM TN Liver carboxylesterase (CES1) DMCTJAM MA Inhibitor DMCTJAM RN Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4277-80. DMCTJAM RU https://pubmed.ncbi.nlm.nih.gov/15261286 DMCTJAM DI DMCTJAM DMCTJAM DN PYRIPYROPENE A DMCTJAM TI TTAK0IN DMCTJAM TN SOAT2 messenger RNA (SOAT2 mRNA) DMCTJAM MA Inhibitor DMCTJAM RN Saucerneol B derivatives as human acyl-CoA: cholesterol acyltransferase inhibitors. Bioorg Med Chem Lett. 2005 Jan 17;15(2):385-8. DMCTJAM RU https://pubmed.ncbi.nlm.nih.gov/15603959 DMCTM3L DI DMCTM3L DMCTM3L DN LUF-5978 DMCTM3L TI TTM2AOE DMCTM3L TN Adenosine A2a receptor (ADORA2A) DMCTM3L MA Inhibitor DMCTM3L RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMCTM3L RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMCTM3L DI DMCTM3L DMCTM3L DN LUF-5978 DMCTM3L TI TTNE7KG DMCTM3L TN Adenosine A2b receptor (ADORA2B) DMCTM3L MA Inhibitor DMCTM3L RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMCTM3L RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMCTM3L DI DMCTM3L DMCTM3L DN LUF-5978 DMCTM3L TI TTK25J1 DMCTM3L TN Adenosine A1 receptor (ADORA1) DMCTM3L MA Inhibitor DMCTM3L RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMCTM3L RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMCTM3L DI DMCTM3L DMCTM3L DN LUF-5978 DMCTM3L TI TTJFY5U DMCTM3L TN Adenosine A3 receptor (ADORA3) DMCTM3L MA Inhibitor DMCTM3L RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMCTM3L RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMCTSNE DI DMCTSNE DMCTSNE DN Tyr-Pro-D-Phe-Pro-NH2 DMCTSNE TI TT27RFC DMCTSNE TN Opioid receptor delta (OPRD1) DMCTSNE MA Inhibitor DMCTSNE RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMCTSNE RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMCTSNE DI DMCTSNE DMCTSNE DN Tyr-Pro-D-Phe-Pro-NH2 DMCTSNE TI TTKWM86 DMCTSNE TN Opioid receptor mu (MOP) DMCTSNE MA Inhibitor DMCTSNE RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMCTSNE RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMCTUR1 DI DMCTUR1 DMCTUR1 DN Carboxylic PRPP DMCTUR1 TI TTBL49X DMCTUR1 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMCTUR1 MA Inhibitor DMCTUR1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCTUR1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCTVMI DI DMCTVMI DMCTVMI DN PHENAZOCINE DMCTVMI TI TTQW87Y DMCTVMI TN Opioid receptor kappa (OPRK1) DMCTVMI MA Inhibitor DMCTVMI RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMCTVMI RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMCTVMI DI DMCTVMI DMCTVMI DN PHENAZOCINE DMCTVMI TI TT27RFC DMCTVMI TN Opioid receptor delta (OPRD1) DMCTVMI MA Inhibitor DMCTVMI RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMCTVMI RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMCTVMI DI DMCTVMI DMCTVMI DN PHENAZOCINE DMCTVMI TI TTKWM86 DMCTVMI TN Opioid receptor mu (MOP) DMCTVMI MA Inhibitor DMCTVMI RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMCTVMI RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMCTWBL DI DMCTWBL DMCTWBL DN 8-acetyl-7-butoxy-2H-chromen-2-one DMCTWBL TI TT2LVK8 DMCTWBL TN Carbonic anhydrase IX (CA-IX) DMCTWBL MA Inhibitor DMCTWBL RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMCTWBL RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMCTZFP DI DMCTZFP DMCTZFP DN N-[4'-(trifluoromethyl)-4-biphenylyl]sulfamide DMCTZFP TI TTBGTCW DMCTZFP TN Kinesin spindle messenger RNA (KIF11 mRNA) DMCTZFP MA Inhibitor DMCTZFP RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMCTZFP RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMCU59W DI DMCU59W DMCU59W DN UNC2025 DMCU59W TI TTO7LKR DMCU59W TN Tyrosine-protein kinase Mer (MERTK) DMCU59W MA Inhibitor DMCU59W RN MerTK as a therapeutic target in glioblastoma. Neuro Oncol. 2018 Jan 10;20(1):92-102. DMCU59W RU https://pubmed.ncbi.nlm.nih.gov/28605477 DMCU6RF DI DMCU6RF DMCU6RF DN ISIS 156452 DMCU6RF TI TTILUKB DMCU6RF TN IRAK4 messenger RNA (IRAK4 mRNA) DMCU6RF RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMCU6RF RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMCU6XV DI DMCU6XV DMCU6XV DN Acid blue 25 DMCU6XV TI TTK0O6Y DMCU6XV TN Ecto-5'-nucleotidase (CD73) DMCU6XV MA Inhibitor DMCU6XV RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMCU6XV RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMCU6XV DI DMCU6XV DMCU6XV DN Acid blue 25 DMCU6XV TI TTOZHQC DMCU6XV TN P2Y purinoceptor 2 (P2RY2) DMCU6XV MA Inhibitor DMCU6XV RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMCU6XV RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMCU8HK DI DMCU8HK DMCU8HK DN D[Arg4,Dab8]VP DMCU8HK TI TTK8R02 DMCU8HK TN Vasopressin V2 receptor (V2R) DMCU8HK MA Inhibitor DMCU8HK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCU8HK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCU8HK DI DMCU8HK DMCU8HK DN D[Arg4,Dab8]VP DMCU8HK TI TT4TFGN DMCU8HK TN Vasopressin V1a receptor (V1AR) DMCU8HK MA Inhibitor DMCU8HK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCU8HK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCU8HK DI DMCU8HK DMCU8HK DN D[Arg4,Dab8]VP DMCU8HK TI TTSCIUP DMCU8HK TN Oxytocin receptor (OTR) DMCU8HK MA Inhibitor DMCU8HK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCU8HK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCU8HK DI DMCU8HK DMCU8HK DN D[Arg4,Dab8]VP DMCU8HK TI TTL9MHW DMCU8HK TN Vasopressin V1b receptor (V1BR) DMCU8HK MA Inhibitor DMCU8HK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMCU8HK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMCUE25 DI DMCUE25 DMCUE25 DN 1-(4-Cyanobenzyl)-5-hydroxymethyl-1H-imidazole DMCUE25 TI TTIQUX7 DMCUE25 TN Steroid 11-beta-hydroxylase (CYP11B1) DMCUE25 MA Inhibitor DMCUE25 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMCUE25 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMCUJH5 DI DMCUJH5 DMCUJH5 DN Bo(15)PZ DMCUJH5 TI TTZ9SOR DMCUJH5 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMCUJH5 MA Inhibitor DMCUJH5 RN On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. J Med Chem. 2005 Dec 1;48(24):7847-59. DMCUJH5 RU https://pubmed.ncbi.nlm.nih.gov/16302823 DMCUSD4 DI DMCUSD4 DMCUSD4 DN 4-amino-N-(4-chlorophenyl)benzenesulfonamide DMCUSD4 TI TT8NGED DMCUSD4 TN Prostaglandin G/H synthase 1 (COX-1) DMCUSD4 MA Inhibitor DMCUSD4 RN Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21. DMCUSD4 RU https://pubmed.ncbi.nlm.nih.gov/17079150 DMCUSD4 DI DMCUSD4 DMCUSD4 DN 4-amino-N-(4-chlorophenyl)benzenesulfonamide DMCUSD4 TI TTVKILB DMCUSD4 TN Prostaglandin G/H synthase 2 (COX-2) DMCUSD4 MA Inhibitor DMCUSD4 RN Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21. DMCUSD4 RU https://pubmed.ncbi.nlm.nih.gov/17079150 DMCUSG3 DI DMCUSG3 DMCUSG3 DN NU6140 DMCUSG3 TI TTL4Q97 DMCUSG3 TN Cyclin-dependent kinase 5 (CDK5) DMCUSG3 MA Inhibitor DMCUSG3 RN Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. DMCUSG3 RU https://pubmed.ncbi.nlm.nih.gov/16170024 DMCUSG3 DI DMCUSG3 DMCUSG3 DN NU6140 DMCUSG3 TI TT7HF4W DMCUSG3 TN Cyclin-dependent kinase 2 (CDK2) DMCUSG3 MA Inhibitor DMCUSG3 RN Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. DMCUSG3 RU https://pubmed.ncbi.nlm.nih.gov/16170024 DMCUSG3 DI DMCUSG3 DMCUSG3 DN NU6140 DMCUSG3 TI TTQYF7G DMCUSG3 TN Cyclin-dependent kinase 7 (CDK7) DMCUSG3 MA Inhibitor DMCUSG3 RN Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. DMCUSG3 RU https://pubmed.ncbi.nlm.nih.gov/16170024 DMCUSG3 DI DMCUSG3 DMCUSG3 DN NU6140 DMCUSG3 TI TTH6V3D DMCUSG3 TN Cyclin-dependent kinase 1 (CDK1) DMCUSG3 MA Inhibitor DMCUSG3 RN Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. DMCUSG3 RU https://pubmed.ncbi.nlm.nih.gov/16170024 DMCUSG3 DI DMCUSG3 DMCUSG3 DN NU6140 DMCUSG3 TI TT0PG8F DMCUSG3 TN Cyclin-dependent kinase 4 (CDK4) DMCUSG3 MA Inhibitor DMCUSG3 RN Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37. DMCUSG3 RU https://pubmed.ncbi.nlm.nih.gov/16170024 DMCUSG3 DI DMCUSG3 DMCUSG3 DN NU6140 DMCUSG3 TI TTXEZJ4 DMCUSG3 TN Tyrosine-protein kinase EIF2AK2 (p68) DMCUSG3 MA Inhibitor DMCUSG3 RN Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4108-14. DMCUSG3 RU https://pubmed.ncbi.nlm.nih.gov/21632247 DMCUSH1 DI DMCUSH1 DMCUSH1 DN 2-Amino-indan-5-sulfonic acid DMCUSH1 TI TTUNARX DMCUSH1 TN Carbonic anhydrase (CA) DMCUSH1 MA Inhibitor DMCUSH1 RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMCUSH1 RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMCUSH1 DI DMCUSH1 DMCUSH1 DN 2-Amino-indan-5-sulfonic acid DMCUSH1 TI TTHQPL7 DMCUSH1 TN Carbonic anhydrase I (CA-I) DMCUSH1 MA Inhibitor DMCUSH1 RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DMCUSH1 RU https://pubmed.ncbi.nlm.nih.gov/15501040 DMCUSH1 DI DMCUSH1 DMCUSH1 DN 2-Amino-indan-5-sulfonic acid DMCUSH1 TI TTEYTKG DMCUSH1 TN Carbonic anhydrase XIV (CA-XIV) DMCUSH1 MA Inhibitor DMCUSH1 RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMCUSH1 RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMCUSH1 DI DMCUSH1 DMCUSH1 DN 2-Amino-indan-5-sulfonic acid DMCUSH1 TI TTANPDJ DMCUSH1 TN Carbonic anhydrase II (CA-II) DMCUSH1 MA Inhibitor DMCUSH1 RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DMCUSH1 RU https://pubmed.ncbi.nlm.nih.gov/15501040 DMCUSH1 DI DMCUSH1 DMCUSH1 DN 2-Amino-indan-5-sulfonic acid DMCUSH1 TI TTSYM0R DMCUSH1 TN Carbonic anhydrase XII (CA-XII) DMCUSH1 MA Inhibitor DMCUSH1 RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMCUSH1 RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMCUTY9 DI DMCUTY9 DMCUTY9 DN 2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran DMCUTY9 TI TTVBI8W DMCUTY9 TN Dopamine transporter (DAT) DMCUTY9 MA Inhibitor DMCUTY9 RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMCUTY9 RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMCUTY9 DI DMCUTY9 DMCUTY9 DN 2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran DMCUTY9 TI TT3ROYC DMCUTY9 TN Serotonin transporter (SERT) DMCUTY9 MA Inhibitor DMCUTY9 RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMCUTY9 RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMCUTY9 DI DMCUTY9 DMCUTY9 DN 2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran DMCUTY9 TI TTAWNKZ DMCUTY9 TN Norepinephrine transporter (NET) DMCUTY9 MA Inhibitor DMCUTY9 RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMCUTY9 RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMCV891 DI DMCV891 DMCV891 DN 7-methyl-2-m-tolylpyrido[2,3-d]pyrimidine DMCV891 TI TTHS256 DMCV891 TN Metabotropic glutamate receptor 5 (mGluR5) DMCV891 MA Inhibitor DMCV891 RN Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9. DMCV891 RU https://pubmed.ncbi.nlm.nih.gov/17723296 DMCVF7R DI DMCVF7R DMCVF7R DN 2-morpholin-4-yl-6-phenyl-4H-thiopyran-4-one DMCVF7R TI TTK3PY9 DMCVF7R TN DNA-dependent protein kinase catalytic (PRKDC) DMCVF7R MA Inhibitor DMCVF7R RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMCVF7R RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTAHTVG DMCVJK9 TN Ephrin type-A receptor 7 (EPHA7) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TT8MDAC DMCVJK9 TN Ephrin type-B receptor 1 (EPHB1) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTKPV6O DMCVJK9 TN Ephrin type-B receptor 2 (EPHB2) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTG84D3 DMCVJK9 TN Ephrin type-A receptor 4 (EPHA4) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TT5LM7U DMCVJK9 TN Ephrin type-B receptor 3 (EPHB3) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTHS2LR DMCVJK9 TN Ephrin type-A receptor 3 (EPHA3) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTV9KOD DMCVJK9 TN Ephrin type-A receptor 5 (EPHA5) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTI4ZX2 DMCVJK9 TN Ephrin type-B receptor 4 (EPHB4) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTHZ2LW DMCVJK9 TN Ephrin type-A receptor 8 (EPHA8) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTLFZVU DMCVJK9 TN Ephrin type-A receptor 1 (EPHA1) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVJK9 DI DMCVJK9 DMCVJK9 DN PMID19788238C66 DMCVJK9 TI TTRJB2G DMCVJK9 TN Ephrin type-A receptor 2 (EPHA2) DMCVJK9 MA Inhibitor DMCVJK9 RN Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009 Oct 22;52(20):6433-46. DMCVJK9 RU https://pubmed.ncbi.nlm.nih.gov/19788238 DMCVKTB DI DMCVKTB DMCVKTB DN (1R)-1,2,2-TRIMETHYLPROPYL (S)-METHYLPHOSPHINATE DMCVKTB TI TT1RS9F DMCVKTB TN Acetylcholinesterase (AChE) DMCVKTB MA Inhibitor DMCVKTB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMCVKTB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMCVP5G DI DMCVP5G DMCVP5G DN ISIS 114442 DMCVP5G TI TT8OY02 DMCVP5G TN ARA70 messenger RNA (NCOA4 mRNA) DMCVP5G RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DMCVP5G RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DMCVU1T DI DMCVU1T DMCVU1T DN UNC0321 DMCVU1T TI TTS6RZT DMCVU1T TN Histone-lysine N-methyltransferase EHMT2 (EHMT2) DMCVU1T MA Inhibitor DMCVU1T RN Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines. J Med Chem. 2010 Aug 12;53(15):5844-57. DMCVU1T RU https://pubmed.ncbi.nlm.nih.gov/20614940 DMCW5A9 DI DMCW5A9 DMCW5A9 DN (R,)-2-(2-naphthamido)-5-phenylpent-4-enoic acid DMCW5A9 TI TTJNTSI DMCW5A9 TN Rotamase Pin1 (PIN1) DMCW5A9 MA Inhibitor DMCW5A9 RN Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. DMCW5A9 RU https://pubmed.ncbi.nlm.nih.gov/20207139 DMCW65Q DI DMCW65Q DMCW65Q DN ((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine DMCW65Q TI TTZUFI5 DMCW65Q TN Nitric-oxide synthase brain (NOS1) DMCW65Q MA Inhibitor DMCW65Q RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMCW65Q RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMCW65Q DI DMCW65Q DMCW65Q DN ((E)-7-But-2-enyl)-azepan-(2Z)-ylideneamine DMCW65Q TI TTF10I9 DMCW65Q TN Nitric-oxide synthase inducible (NOS2) DMCW65Q MA Inhibitor DMCW65Q RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMCW65Q RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMCW7F5 DI DMCW7F5 DMCW7F5 DN 3-Naphthalen-1-yl-pyrrolidine DMCW7F5 TI TTEX248 DMCW7F5 TN Dopamine D2 receptor (D2R) DMCW7F5 MA Inhibitor DMCW7F5 RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMCW7F5 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMCW7F5 DI DMCW7F5 DMCW7F5 DN 3-Naphthalen-1-yl-pyrrolidine DMCW7F5 TI TTJQOD7 DMCW7F5 TN 5-HT 2A receptor (HTR2A) DMCW7F5 MA Inhibitor DMCW7F5 RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMCW7F5 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMCW7F5 DI DMCW7F5 DMCW7F5 DN 3-Naphthalen-1-yl-pyrrolidine DMCW7F5 TI TTSQIFT DMCW7F5 TN 5-HT 1A receptor (HTR1A) DMCW7F5 MA Inhibitor DMCW7F5 RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMCW7F5 RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMCW8RT DI DMCW8RT DMCW8RT DN 1-(4-Bromobenzyl)-5-phenyl-1H-imidazole DMCW8RT TI TTIQUX7 DMCW8RT TN Steroid 11-beta-hydroxylase (CYP11B1) DMCW8RT MA Inhibitor DMCW8RT RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMCW8RT RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMCWB1V DI DMCWB1V DMCWB1V DN BF/PC-21 DMCWB1V TI TTDZN01 DMCWB1V TN Cathepsin K (CTSK) DMCWB1V MA Inhibitor DMCWB1V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350). DMCWB1V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350 DMCWE90 DI DMCWE90 DMCWE90 DN T2328 DMCWE90 TI TTZPO1L DMCWE90 TN Substance-P receptor (TACR1) DMCWE90 MA Antagonist DMCWE90 RN Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile d... J Pharmacol Sci. 2008 Jan;106(1):121-7. DMCWE90 RU https://pubmed.ncbi.nlm.nih.gov/18187929 DMCWFUZ DI DMCWFUZ DMCWFUZ DN 2-(4-Hydroxy-phenyl)-quinolin-6-ol DMCWFUZ TI TTOM3J0 DMCWFUZ TN Estrogen receptor beta (ESR2) DMCWFUZ MA Inhibitor DMCWFUZ RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMCWFUZ RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMCWFUZ DI DMCWFUZ DMCWFUZ DN 2-(4-Hydroxy-phenyl)-quinolin-6-ol DMCWFUZ TI TTZAYWL DMCWFUZ TN Estrogen receptor (ESR) DMCWFUZ MA Inhibitor DMCWFUZ RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMCWFUZ RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMCWSJP DI DMCWSJP DMCWSJP DN SCH51866 DMCWSJP TI TTJ0IQB DMCWSJP TN Phosphodiesterase 5A (PDE5A) DMCWSJP MA Inhibitor DMCWSJP RN Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9. DMCWSJP RU https://pubmed.ncbi.nlm.nih.gov/8961086 DMCWSJP DI DMCWSJP DMCWSJP DN SCH51866 DMCWSJP TI TT73TEJ DMCWSJP TN Phosphodiesterase 1A (PDE1A) DMCWSJP MA Inhibitor DMCWSJP RN Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9. DMCWSJP RU https://pubmed.ncbi.nlm.nih.gov/8961086 DMCWSJP DI DMCWSJP DMCWSJP DN SCH51866 DMCWSJP TI TT3ZS42 DMCWSJP TN Phosphodiesterase 1B (PDE1B) DMCWSJP MA Inhibitor DMCWSJP RN Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9. DMCWSJP RU https://pubmed.ncbi.nlm.nih.gov/8961086 DMCWSJP DI DMCWSJP DMCWSJP DN SCH51866 DMCWSJP TI TTWIEY9 DMCWSJP TN Phosphodiesterase 7B (PDE7B) DMCWSJP MA Inhibitor DMCWSJP RN Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 2000 May 19;271(3):575-83. DMCWSJP RU https://pubmed.ncbi.nlm.nih.gov/10814504 DMCWSJP DI DMCWSJP DMCWSJP DN SCH51866 DMCWSJP TI TTW2HRK DMCWSJP TN Phosphodiesterase 1C (PDE1C) DMCWSJP MA Inhibitor DMCWSJP RN Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9. DMCWSJP RU https://pubmed.ncbi.nlm.nih.gov/8961086 DMCWSJP DI DMCWSJP DMCWSJP DN SCH51866 DMCWSJP TI TTZOEBC DMCWSJP TN Phosphodiesterase 9 (PDE9) DMCWSJP MA Inhibitor DMCWSJP RN Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998 Jun 19;273(25):15559-64. DMCWSJP RU https://pubmed.ncbi.nlm.nih.gov/9624146 DMCWT4L DI DMCWT4L DMCWT4L DN PUP-1 DMCWT4L TI TTXZ0KQ DMCWT4L TN Matrix metalloproteinase-12 (MMP-12) DMCWT4L MA Inhibitor DMCWT4L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636). DMCWT4L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636 DMCWYT7 DI DMCWYT7 DMCWYT7 DN 7-Bromo-4,9-dihydro-3H-beta-carboline DMCWYT7 TI TTGP7BY DMCWYT7 TN Monoamine oxidase type B (MAO-B) DMCWYT7 MA Inhibitor DMCWYT7 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMCWYT7 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMCWYT7 DI DMCWYT7 DMCWYT7 DN 7-Bromo-4,9-dihydro-3H-beta-carboline DMCWYT7 TI TT3WG5C DMCWYT7 TN Monoamine oxidase type A (MAO-A) DMCWYT7 MA Inhibitor DMCWYT7 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMCWYT7 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMCWZ84 DI DMCWZ84 DMCWZ84 DN SC-41661A DMCWZ84 TI TT2J34L DMCWZ84 TN Arachidonate 5-lipoxygenase (5-LOX) DMCWZ84 MA Modulator DMCWZ84 RN Induction of apoptosis in blood cells from a patient with acute myelogenous leukemia by SC41661A, a selective inhibitor of 5-lipoxygenase. Prostaglandins Leukot Essent Fatty Acids. 1993 Apr;48(4):323-6. DMCWZ84 RU https://www.ncbi.nlm.nih.gov/pubmed/8497493 DMCWZF6 DI DMCWZF6 DMCWZF6 DN 4-(2-fluorophenylethynyl)-2-methylthiazole DMCWZF6 TI TTHS256 DMCWZF6 TN Metabotropic glutamate receptor 5 (mGluR5) DMCWZF6 MA Inhibitor DMCWZF6 RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMCWZF6 RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMCX3N1 DI DMCX3N1 DMCX3N1 DN 1-Benzyl-7-chloro-4-hexyloxy-quinolinium DMCX3N1 TI TTY3UE6 DMCX3N1 TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMCX3N1 MA Inhibitor DMCX3N1 RN Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83. DMCX3N1 RU https://pubmed.ncbi.nlm.nih.gov/7540207 DMCX3TM DI DMCX3TM DMCX3TM DN 6-Bromo-2-(4-nitro-phenyl)-chromen-4-one DMCX3TM TI TTNJYV2 DMCX3TM TN Gamma-aminobutyric acid receptor (GAR) DMCX3TM MA Inhibitor DMCX3TM RN 6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997). DMCX3TM RU http://www.sciencedirect.com/science/article/pii/S0960894X97000206 DMCX3TM DI DMCX3TM DMCX3TM DN 6-Bromo-2-(4-nitro-phenyl)-chromen-4-one DMCX3TM TI TT1MPAY DMCX3TM TN GABA(A) receptor alpha-1 (GABRA1) DMCX3TM MA Inhibitor DMCX3TM RN 6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997). DMCX3TM RU http://www.sciencedirect.com/science/article/pii/S0960894X97000206 DMCX9WN DI DMCX9WN DMCX9WN DN 5-methylurapidil DMCX9WN TI TT2NUT5 DMCX9WN TN Adrenergic receptor alpha-2C (ADRA2C) DMCX9WN MA Antagonist DMCX9WN RN Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding. Imidazoline agonists bind like ant... J Biol Chem. 2001 Jul 6;276(27):25366-71. DMCX9WN RU https://pubmed.ncbi.nlm.nih.gov/11331292 DMCX9WN DI DMCX9WN DMCX9WN DN 5-methylurapidil DMCX9WN TI TTBRKXS DMCX9WN TN Adrenergic receptor alpha-1B (ADRA1B) DMCX9WN MA Antagonist DMCX9WN RN Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95. DMCX9WN RU https://pubmed.ncbi.nlm.nih.gov/11459121 DMCXA1Y DI DMCXA1Y DMCXA1Y DN 10-Isopropyl-10H-dibenzo[b,f][1,4]oxazepin-11-one DMCXA1Y TI TT84ETX DMCXA1Y TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMCXA1Y MA Inhibitor DMCXA1Y RN Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97. DMCXA1Y RU https://pubmed.ncbi.nlm.nih.gov/1375293 DMCXJLH DI DMCXJLH DMCXJLH DN neuromedin B DMCXJLH TI TTC1MVT DMCXJLH TN Gastrin-releasing peptide receptor (GRPR) DMCXJLH MA Agonist DMCXJLH RN Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20. DMCXJLH RU https://pubmed.ncbi.nlm.nih.gov/7838118 DMCXJLH DI DMCXJLH DMCXJLH DN neuromedin B DMCXJLH TI TTHYDUM DMCXJLH TN Bombesin receptor (BS) DMCXJLH MA Agonist DMCXJLH RN Insights into bombesin receptors and ligands: Highlighting recent advances. Peptides. 2015 Oct;72:128-44. DMCXJLH RU https://pubmed.ncbi.nlm.nih.gov/25976083 DMCXJOL DI DMCXJOL DMCXJOL DN C[RGDf-(S)-alpha-TfmF] DMCXJOL TI TTT1R2L DMCXJOL TN Integrin alpha-V (ITGAV) DMCXJOL MA Inhibitor DMCXJOL RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMCXJOL RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMCXJOL DI DMCXJOL DMCXJOL DN C[RGDf-(S)-alpha-TfmF] DMCXJOL TI TTJA1ZO DMCXJOL TN ITGB3 messenger RNA (ITGB3 mRNA) DMCXJOL MA Inhibitor DMCXJOL RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMCXJOL RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMCXMQJ DI DMCXMQJ DMCXMQJ DN O-1812 DMCXMQJ TI TT6OEDT DMCXMQJ TN Cannabinoid receptor 1 (CB1) DMCXMQJ MA Agonist DMCXMQJ RN Highly selective CB(1) cannabinoid receptor ligands and novel CB(1)/VR(1) vanilloid receptor "hybrid" ligands. Biochem Biophys Res Commun. 2001 Feb 23;281(2):444-51. DMCXMQJ RU https://pubmed.ncbi.nlm.nih.gov/11181068 DMCXN6R DI DMCXN6R DMCXN6R DN 9-[2-(1-Phosphonopropan-2-yloxy)ethyl]guanine DMCXN6R TI TTBL49X DMCXN6R TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMCXN6R MA Inhibitor DMCXN6R RN Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum h... Bioorg Med Chem. 2009 Sep 1;17(17):6218-32. DMCXN6R RU https://pubmed.ncbi.nlm.nih.gov/19666228 DMCXP9T DI DMCXP9T DMCXP9T DN ISIS 156474 DMCXP9T TI TTILUKB DMCXP9T TN IRAK4 messenger RNA (IRAK4 mRNA) DMCXP9T RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMCXP9T RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMCXR4M DI DMCXR4M DMCXR4M DN 2',3'-Dideoxycytidine-5'-Monophosphate DMCXR4M TI TTMFYEC DMCXR4M TN Streptococcus Cytidylate kinase (Stre-coc cmk) DMCXR4M MA Inhibitor DMCXR4M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMCXR4M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMCXSIH DI DMCXSIH DMCXSIH DN 3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine DMCXSIH TI TTSZLWK DMCXSIH TN Aromatase (CYP19A1) DMCXSIH MA Inhibitor DMCXSIH RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMCXSIH RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMCXSIH DI DMCXSIH DMCXSIH DN 3-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine DMCXSIH TI TTIQUX7 DMCXSIH TN Steroid 11-beta-hydroxylase (CYP11B1) DMCXSIH MA Inhibitor DMCXSIH RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMCXSIH RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMCXVPG DI DMCXVPG DMCXVPG DN ISIS 20995 DMCXVPG TI TTSRXJW DMCXVPG TN G-alpha-11 messenger RNA (GNA11 mRNA) DMCXVPG RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DMCXVPG RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DMCXZ9L DI DMCXZ9L DMCXZ9L DN 3-hydroxyquinazoline-2,4(1H,3H)-dione DMCXZ9L TI TT37KAF DMCXZ9L TN Human immunodeficiency virus Ribonuclease H (HIV RNH) DMCXZ9L MA Inhibitor DMCXZ9L RN RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem. 2009 Oct 8;52(19):5781-4. DMCXZ9L RU https://pubmed.ncbi.nlm.nih.gov/19791799 DMCXZGU DI DMCXZGU DMCXZGU DN VRX-03011 DMCXZGU TI TT07C3Y DMCXZGU TN 5-HT 4 receptor (HTR4) DMCXZGU MA Modulator DMCXZGU RN VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux.Neuropharmacology.2007 Sep;53(4):563-73. DMCXZGU RU https://www.ncbi.nlm.nih.gov/pubmed/17692343 DMCY4EP DI DMCY4EP DMCY4EP DN 2-morpholin-4-yl-8-thiophen-3-ylchromen-4-one DMCY4EP TI TTK3PY9 DMCY4EP TN DNA-dependent protein kinase catalytic (PRKDC) DMCY4EP MA Inhibitor DMCY4EP RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMCY4EP RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMCY4L0 DI DMCY4L0 DMCY4L0 DN C[L-Phe-D-pro-L-Phe-L-trp] DMCY4L0 TI TTKWM86 DMCY4L0 TN Opioid receptor mu (MOP) DMCY4L0 MA Inhibitor DMCY4L0 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMCY4L0 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMCY4L0 DI DMCY4L0 DMCY4L0 DN C[L-Phe-D-pro-L-Phe-L-trp] DMCY4L0 TI TTQW87Y DMCY4L0 TN Opioid receptor kappa (OPRK1) DMCY4L0 MA Inhibitor DMCY4L0 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMCY4L0 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMCY4L0 DI DMCY4L0 DMCY4L0 DN C[L-Phe-D-pro-L-Phe-L-trp] DMCY4L0 TI TT27RFC DMCY4L0 TN Opioid receptor delta (OPRD1) DMCY4L0 MA Inhibitor DMCY4L0 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMCY4L0 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMCY76E DI DMCY76E DMCY76E DN (R)-8-phenyl-N,N-dipropylchroman-3-amine DMCY76E TI TTO9X1H DMCY76E TN 5-HT 7 receptor (HTR7) DMCY76E MA Inhibitor DMCY76E RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DMCY76E RU https://pubmed.ncbi.nlm.nih.gov/20138771 DMCYD8Q DI DMCYD8Q DMCYD8Q DN (R)-ONDANSETRON DMCYD8Q TI TTQ6VDM DMCYD8Q TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMCYD8Q MA Inhibitor DMCYD8Q RN A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem. 2008 Apr 1;16(7):4107-19. DMCYD8Q RU https://pubmed.ncbi.nlm.nih.gov/18243713 DMCYOPR DI DMCYOPR DMCYOPR DN Anti-CD-20 mab DMCYOPR TI TTUE541 DMCYOPR TN Leukocyte surface antigen Leu-16 (CD20) DMCYOPR MA Inhibitor DMCYOPR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DMCYOPR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DMCYQDU DI DMCYQDU DMCYQDU DN 6-(4-Bromo-phenylamino)-1H-pyrimidine-2,4-dione DMCYQDU TI TTIU7X1 DMCYQDU TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMCYQDU MA Inhibitor DMCYQDU RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMCYQDU RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMCYQHO DI DMCYQHO DMCYQHO DN DERMORPHIN DMCYQHO TI TTKWM86 DMCYQHO TN Opioid receptor mu (MOP) DMCYQHO MA Inhibitor DMCYQHO RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DMCYQHO RU https://pubmed.ncbi.nlm.nih.gov/16814543 DMCYQHO DI DMCYQHO DMCYQHO DN DERMORPHIN DMCYQHO TI TT27RFC DMCYQHO TN Opioid receptor delta (OPRD1) DMCYQHO MA Inhibitor DMCYQHO RN Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem. 2005 Dec 29;48(26):8112-4. DMCYQHO RU https://pubmed.ncbi.nlm.nih.gov/16366592 DMCYQJF DI DMCYQJF DMCYQJF DN L-741626 DMCYQJF TI TT4C8EA DMCYQJF TN Dopamine D3 receptor (D3R) DMCYQJF MA Inhibitor DMCYQJF RN Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300. DMCYQJF RU https://pubmed.ncbi.nlm.nih.gov/20542439 DMCYQJF DI DMCYQJF DMCYQJF DN L-741626 DMCYQJF TI TTE0A2F DMCYQJF TN Dopamine D4 receptor (D4R) DMCYQJF MA Inhibitor DMCYQJF RN Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300. DMCYQJF RU https://pubmed.ncbi.nlm.nih.gov/20542439 DMCYQJF DI DMCYQJF DMCYQJF DN L-741626 DMCYQJF TI TTEX248 DMCYQJF TN Dopamine D2 receptor (D2R) DMCYQJF MA Inhibitor DMCYQJF RN Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300. DMCYQJF RU https://pubmed.ncbi.nlm.nih.gov/20542439 DMCYVS0 DI DMCYVS0 DMCYVS0 DN 2-N-Ethylamino-1-(4-ethylthiophenyl)butane DMCYVS0 TI TT3ROYC DMCYVS0 TN Serotonin transporter (SERT) DMCYVS0 MA Inhibitor DMCYVS0 RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMCYVS0 RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMCZD37 DI DMCZD37 DMCZD37 DN N-(4-Methyl-benzoyl)-N'-phenethyl-guanidine DMCZD37 TI TTZOVE0 DMCZD37 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMCZD37 MA Inhibitor DMCZD37 RN Solution-phase, parallel synthesis and pharmacological evaluation of acylguanidine derivatives as potential sodium channel blockers. Bioorg Med Chem Lett. 2001 Dec 17;11(24):3151-5. DMCZD37 RU https://pubmed.ncbi.nlm.nih.gov/11720863 DMCZHBI DI DMCZHBI DMCZHBI DN N-(Propylamide-benzophenone)-1-deoxynojirimycin DMCZHBI TI TT1B5PU DMCZHBI TN Glucosylceramidase (GBA) DMCZHBI MA Inhibitor DMCZHBI RN Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase. Bioorg Med Chem. 2010 Jan 1;18(1):267-73. DMCZHBI RU https://pubmed.ncbi.nlm.nih.gov/19931460 DMCZHEN DI DMCZHEN DMCZHEN DN 2,2,2-tris-(4-fluorophenyl)-acetamide DMCZHEN TI TTMNI76 DMCZHEN TN Calcium-activated potassium channel (KCN) DMCZHEN MA Inhibitor DMCZHEN RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMCZHEN RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMCZIFS DI DMCZIFS DMCZIFS DN TB-101 DMCZIFS TI TT6L509 DMCZIFS TN Coagulation factor IIa (F2) DMCZIFS MA Modulator DMCZIFS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMCZIFS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMCZK1U DI DMCZK1U DMCZK1U DN ISIS 4756 DMCZK1U TI TT1PL7M DMCZK1U TN E-selectin messenger RNA (SELE mRNA) DMCZK1U RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMCZK1U RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMCZKN7 DI DMCZKN7 DMCZKN7 DN 4-Phenylbutyrohydroxamic acid DMCZKN7 TI TTT6LFV DMCZKN7 TN Histone deacetylase 8 (HDAC8) DMCZKN7 MA Inhibitor DMCZKN7 RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DMCZKN7 RU https://pubmed.ncbi.nlm.nih.gov/20139990 DMCZKN7 DI DMCZKN7 DMCZKN7 DN 4-Phenylbutyrohydroxamic acid DMCZKN7 TI TTBH0VX DMCZKN7 TN Histone deacetylase (HDAC) DMCZKN7 MA Inhibitor DMCZKN7 RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DMCZKN7 RU https://pubmed.ncbi.nlm.nih.gov/20139990 DMCZKN7 DI DMCZKN7 DMCZKN7 DN 4-Phenylbutyrohydroxamic acid DMCZKN7 TI TT6R7JZ DMCZKN7 TN Histone deacetylase 1 (HDAC1) DMCZKN7 MA Inhibitor DMCZKN7 RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DMCZKN7 RU https://pubmed.ncbi.nlm.nih.gov/20139990 DMCZKN7 DI DMCZKN7 DMCZKN7 DN 4-Phenylbutyrohydroxamic acid DMCZKN7 TI TT5ZKDI DMCZKN7 TN Histone deacetylase 6 (HDAC6) DMCZKN7 MA Inhibitor DMCZKN7 RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DMCZKN7 RU https://pubmed.ncbi.nlm.nih.gov/20139990 DMCZKN7 DI DMCZKN7 DMCZKN7 DN 4-Phenylbutyrohydroxamic acid DMCZKN7 TI TTSHTOI DMCZKN7 TN Histone deacetylase 2 (HDAC2) DMCZKN7 MA Inhibitor DMCZKN7 RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DMCZKN7 RU https://pubmed.ncbi.nlm.nih.gov/20139990 DMCZLK1 DI DMCZLK1 DMCZLK1 DN ISIS 19650 DMCZLK1 TI TTWALCO DMCZLK1 TN HER4 messenger RNA (ERBB4 mRNA) DMCZLK1 RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMCZLK1 RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMCZLKA DI DMCZLKA DMCZLKA DN 7-chloro-1H-indole-2,3-dione DMCZLKA TI TTMF541 DMCZLKA TN Liver carboxylesterase (CES1) DMCZLKA MA Inhibitor DMCZLKA RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMCZLKA RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMCZNB3 DI DMCZNB3 DMCZNB3 DN VL-0699 DMCZNB3 TI TTCG0AL DMCZNB3 TN Cholecystokinin receptor type A (CCKAR) DMCZNB3 MA Inhibitor DMCZNB3 RN Anthranilic acid based CCK1 receptor antagonists and CCK-8 have a common step in their "receptor desmodynamic processes". J Med Chem. 2006 Apr 20;49(8):2456-62. DMCZNB3 RU https://pubmed.ncbi.nlm.nih.gov/16610788 DMCZOX9 DI DMCZOX9 DMCZOX9 DN KNI-10079 DMCZOX9 TI TTXMNHO DMCZOX9 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMCZOX9 MA Inhibitor DMCZOX9 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMCZOX9 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMCZPH4 DI DMCZPH4 DMCZPH4 DN K-252a analogue DMCZPH4 TI TTUTJGQ DMCZPH4 TN Vascular endothelial growth factor receptor 2 (KDR) DMCZPH4 MA Inhibitor DMCZPH4 RN Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on tr... J Med Chem. 2005 Jun 2;48(11):3776-83. DMCZPH4 RU https://pubmed.ncbi.nlm.nih.gov/15916429 DMCZPH4 DI DMCZPH4 DMCZPH4 DN K-252a analogue DMCZPH4 TI TTTDVOJ DMCZPH4 TN Tropomyosin-related kinase A (TrkA) DMCZPH4 MA Inhibitor DMCZPH4 RN Synthesis, modeling, and in vitro activity of (3'S)-epi-K-252a analogues. Elucidating the stereochemical requirements of the 3'-sugar alcohol on tr... J Med Chem. 2005 Jun 2;48(11):3776-83. DMCZPH4 RU https://pubmed.ncbi.nlm.nih.gov/15916429 DMCZSP3 DI DMCZSP3 DMCZSP3 DN 5-methoxycarbonylamino-N-acetyltryptamine DMCZSP3 TI TT32JK8 DMCZSP3 TN Melatonin receptor type 1B (MTNR1B) DMCZSP3 MA Inhibitor DMCZSP3 RN Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62. DMCZSP3 RU https://pubmed.ncbi.nlm.nih.gov/18372181 DMCZSP3 DI DMCZSP3 DMCZSP3 DN 5-methoxycarbonylamino-N-acetyltryptamine DMCZSP3 TI TT0WAIE DMCZSP3 TN Melatonin receptor type 1A (MTNR1A) DMCZSP3 MA Inhibitor DMCZSP3 RN Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. Bioorg Med Chem. 2008 May 1;16(9):4954-62. DMCZSP3 RU https://pubmed.ncbi.nlm.nih.gov/18372181 DMD04TR DI DMD04TR DMD04TR DN PMID30247903-Compound-General structure32 DMD04TR TI TT23XQV DMD04TR TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMD04TR MA Inhibitor DMD04TR RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMD04TR RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTN6GE9 DMD08RH TN Staphylococcus D-amino acid aminotransferase (Stap-coc dat) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTXZ0KQ DMD08RH TN Matrix metalloproteinase-12 (MMP-12) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT6RVLG DMD08RH TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTT2LD9 DMD08RH TN GABA transaminase (ABAT) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTL69WB DMD08RH TN Angiotensin-converting enzyme (ACE) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTC67I0 DMD08RH TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT915ZD DMD08RH TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTY8KJS DMD08RH TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTELIN2 DMD08RH TN PTPN1 messenger RNA (PTPN1 mRNA) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTZUFI5 DMD08RH TN Nitric-oxide synthase brain (NOS1) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT3PQ2Y DMD08RH TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT3NKIB DMD08RH TN Pancreatic elastase 1 (CELA1) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT6TMZU DMD08RH TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTBL49X DMD08RH TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTCM4B3 DMD08RH TN Nitric-oxide synthase endothelial (NOS3) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTANPDJ DMD08RH TN Carbonic anhydrase II (CA-II) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTOM3J0 DMD08RH TN Estrogen receptor beta (ESR2) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT8DSFC DMD08RH TN Hydroxyphenylpyruvate dioxygenase (HPD) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTZJ5U9 DMD08RH TN Thioredoxin (TXN) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT38ECI DMD08RH TN Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTXZEAJ DMD08RH TN Leukotriene A-4 hydrolase (LTA4H) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTV3NH6 DMD08RH TN Calmodulin (CALM) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT5B8AX DMD08RH TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT5ZWB6 DMD08RH TN Dihydrodiol dehydrogenase type I (AKR1C3) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TT9V5JH DMD08RH TN Phospholipase A2 (PLA2G1B) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD08RH DI DMD08RH DMD08RH DN Acetate Ion DMD08RH TI TTHI19T DMD08RH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMD08RH MA Inhibitor DMD08RH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD08RH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD09BO DI DMD09BO DMD09BO DN [3H]LTC4 DMD09BO TI TT0PZR5 DMD09BO TN Leukotriene CysLT2 receptor (CYSLTR2) DMD09BO MA Agonist DMD09BO RN The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun. 2000 Aug 2;274(2):316-22. DMD09BO RU https://pubmed.ncbi.nlm.nih.gov/10913337 DMD0K61 DI DMD0K61 DMD0K61 DN PT-102 DMD0K61 TI TT84ETX DMD0K61 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMD0K61 MA Inhibitor DMD0K61 RN Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90. DMD0K61 RU https://pubmed.ncbi.nlm.nih.gov/10636251 DMD0LCA DI DMD0LCA DMD0LCA DN Azidopine DMD0LCA TI TT7RGTM DMD0LCA TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMD0LCA MA Inhibitor (gating inhibitor) DMD0LCA RN Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. DMD0LCA RU https://pubmed.ncbi.nlm.nih.gov/19029287 DMD0LCU DI DMD0LCU DMD0LCU DN [3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol DMD0LCU TI TT1VAUK DMD0LCU TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMD0LCU MA Inhibitor DMD0LCU RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMD0LCU RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMD0LCU DI DMD0LCU DMD0LCU DN [3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol DMD0LCU TI TTUTJGQ DMD0LCU TN Vascular endothelial growth factor receptor 2 (KDR) DMD0LCU MA Inhibitor DMD0LCU RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMD0LCU RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMD0LCU DI DMD0LCU DMD0LCU DN [3-(5-Phenyl-oxazol-2-ylamino)-phenyl]-methanol DMD0LCU TI TTDCBX5 DMD0LCU TN Vascular endothelial growth factor receptor 3 (FLT-4) DMD0LCU MA Inhibitor DMD0LCU RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMD0LCU RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMD0NFL DI DMD0NFL DMD0NFL DN ZM-274773 DMD0NFL TI TTYO0A3 DMD0NFL TN Substance-K receptor (TACR2) DMD0NFL MA Antagonist DMD0NFL RN Tachykinin NK2 receptor antagonists. A patent review (2006 - 2010). Expert Opin Ther Pat. 2012 Jan;22(1):57-77. DMD0NFL RU https://pubmed.ncbi.nlm.nih.gov/22149761 DMD0OZ8 DI DMD0OZ8 DMD0OZ8 DN 3-phenyl-1,4-dihydroindeno[1,2-c]pyrazole DMD0OZ8 TI TTUTJGQ DMD0OZ8 TN Vascular endothelial growth factor receptor 2 (KDR) DMD0OZ8 MA Inhibitor DMD0OZ8 RN Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4371-5. DMD0OZ8 RU https://pubmed.ncbi.nlm.nih.gov/16750628 DMD0P4G DI DMD0P4G DMD0P4G DN (CH3)CCO-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 DMD0P4G TI TTC1MVT DMD0P4G TN Gastrin-releasing peptide receptor (GRPR) DMD0P4G MA Inhibitor DMD0P4G RN Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7. DMD0P4G RU https://pubmed.ncbi.nlm.nih.gov/2066982 DMD0Q7K DI DMD0Q7K DMD0Q7K DN PMID16242323C26a DMD0Q7K TI TTK3C21 DMD0Q7K TN Acetoacetyl-CoA thiolase (ACAT1) DMD0Q7K MA Inhibitor DMD0Q7K RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMD0Q7K RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMD0XEO DI DMD0XEO DMD0XEO DN BPH-742 DMD0XEO TI TTIKWV4 DMD0XEO TN Geranyltranstransferase (FDPS) DMD0XEO MA Inhibitor DMD0XEO RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DMD0XEO RU https://pubmed.ncbi.nlm.nih.gov/18800762 DMD0YL1 DI DMD0YL1 DMD0YL1 DN BRL-25594 DMD0YL1 TI TTEX248 DMD0YL1 TN Dopamine D2 receptor (D2R) DMD0YL1 MA Inhibitor DMD0YL1 RN Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15. DMD0YL1 RU https://pubmed.ncbi.nlm.nih.gov/12593651 DMD0Z3U DI DMD0Z3U DMD0Z3U DN 3,2'-bis-trifluoromethyl-biphenyl-4-carbonitrile DMD0Z3U TI TTKPW01 DMD0Z3U TN Androgen receptor messenger RNA (AR mRNA) DMD0Z3U MA Inhibitor DMD0Z3U RN Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5529-32. DMD0Z3U RU https://pubmed.ncbi.nlm.nih.gov/17764935 DMD1258 DI DMD1258 DMD1258 DN 10-Propyl-10H-dibenzo[b,f][1,4]oxazepin-11-one DMD1258 TI TT84ETX DMD1258 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMD1258 MA Inhibitor DMD1258 RN Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97. DMD1258 RU https://pubmed.ncbi.nlm.nih.gov/1375293 DMD16MH DI DMD16MH DMD16MH DN UCM 765 DMD16MH TI TT0WAIE DMD16MH TN Melatonin receptor type 1A (MTNR1A) DMD16MH MA Agonist DMD16MH RN N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007 Dec 27;50(26):6618-26. DMD16MH RU https://pubmed.ncbi.nlm.nih.gov/18052314 DMD18V5 DI DMD18V5 DMD18V5 DN 8-carboxamidocyclazocine DMD18V5 TI TTKWM86 DMD18V5 TN Opioid receptor mu (MOP) DMD18V5 MA Inhibitor DMD18V5 RN Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64. DMD18V5 RU https://pubmed.ncbi.nlm.nih.gov/18417347 DMD18V5 DI DMD18V5 DMD18V5 DN 8-carboxamidocyclazocine DMD18V5 TI TT27RFC DMD18V5 TN Opioid receptor delta (OPRD1) DMD18V5 MA Inhibitor DMD18V5 RN Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64. DMD18V5 RU https://pubmed.ncbi.nlm.nih.gov/18417347 DMD18V5 DI DMD18V5 DMD18V5 DN 8-carboxamidocyclazocine DMD18V5 TI TTQW87Y DMD18V5 TN Opioid receptor kappa (OPRK1) DMD18V5 MA Inhibitor DMD18V5 RN Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64. DMD18V5 RU https://pubmed.ncbi.nlm.nih.gov/18417347 DMD1C6S DI DMD1C6S DMD1C6S DN Verongamine DMD1C6S TI TT9JNIC DMD1C6S TN Histamine H3 receptor (H3R) DMD1C6S MA Inhibitor DMD1C6S RN Verongamine, a novel bromotyrosine-derived histamine H3-antagonist from the marine sponge Verongula gigantea. J Nat Prod. 1994 Jan;57(1):175-7. DMD1C6S RU https://pubmed.ncbi.nlm.nih.gov/8158162 DMD1G6R DI DMD1G6R DMD1G6R DN THPG DMD1G6R TI TTWRP2F DMD1G6R TN Metabotropic glutamate receptor 6 (mGluR6) DMD1G6R MA Antagonist DMD1G6R RN Two phenylglycine derivatives antagonize responses to L-AP4 in ON bipolar cells of the amphibian retina. Neuropharmacology. 1997 Jan;36(1):13-20. DMD1G6R RU https://pubmed.ncbi.nlm.nih.gov/9144637 DMD1JVZ DI DMD1JVZ DMD1JVZ DN ISIS 19213 DMD1JVZ TI TT1ERKL DMD1JVZ TN CD40 messenger RNA (CD40 mRNA) DMD1JVZ RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMD1JVZ RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMD1LM8 DI DMD1LM8 DMD1LM8 DN 8-Bromo-6-methyl-3-phenylcoumarin DMD1LM8 TI TTGP7BY DMD1LM8 TN Monoamine oxidase type B (MAO-B) DMD1LM8 MA Inhibitor DMD1LM8 RN New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5157-60. DMD1LM8 RU https://pubmed.ncbi.nlm.nih.gov/20659799 DMD1M24 DI DMD1M24 DMD1M24 DN SCH 206272 DMD1M24 TI TTBPGLU DMD1M24 TN Neuromedin-K receptor (TACR3) DMD1M24 MA Antagonist DMD1M24 RN SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202. DMD1M24 RU https://pubmed.ncbi.nlm.nih.gov/12206858 DMD1M24 DI DMD1M24 DMD1M24 DN SCH 206272 DMD1M24 TI TTYO0A3 DMD1M24 TN Substance-K receptor (TACR2) DMD1M24 MA Antagonist DMD1M24 RN SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202. DMD1M24 RU https://pubmed.ncbi.nlm.nih.gov/12206858 DMD1M24 DI DMD1M24 DMD1M24 DN SCH 206272 DMD1M24 TI TTZPO1L DMD1M24 TN Substance-P receptor (TACR1) DMD1M24 MA Antagonist DMD1M24 RN SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur J Pharmacol. 2002 Aug 23;450(2):191-202. DMD1M24 RU https://pubmed.ncbi.nlm.nih.gov/12206858 DMD1MEZ DI DMD1MEZ DMD1MEZ DN ISIS 9058 DMD1MEZ TI TTAN5W2 DMD1MEZ TN Raf messenger RNA (Raf mRNA) DMD1MEZ RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMD1MEZ RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMD1QOH DI DMD1QOH DMD1QOH DN GNF-PF-2812 DMD1QOH TI TT8DBY3 DMD1QOH TN Angiotensin II receptor type-1 (AGTR1) DMD1QOH MA Inhibitor DMD1QOH RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMD1QOH RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMD1SY9 DI DMD1SY9 DMD1SY9 DN bufotenine DMD1SY9 TI TT6MSOK DMD1SY9 TN 5-HT 1D receptor (HTR1D) DMD1SY9 MA Antagonist DMD1SY9 RN Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80. DMD1SY9 RU https://pubmed.ncbi.nlm.nih.gov/8967979 DMD1SY9 DI DMD1SY9 DMD1SY9 DN bufotenine DMD1SY9 TI TTJQOD7 DMD1SY9 TN 5-HT 2A receptor (HTR2A) DMD1SY9 MA Antagonist DMD1SY9 RN Mapping the binding site pocket of the serotonin 5-Hydroxytryptamine2A receptor. Ser3.36(159) provides a second interaction site for the protonated amine of serotonin but not of lysergic acid diethylamide or bufotenin. J Biol Chem. 1996 Jun 21;271(25):14672-5. DMD1SY9 RU https://pubmed.ncbi.nlm.nih.gov/8663249 DMD1SY9 DI DMD1SY9 DMD1SY9 DN bufotenine DMD1SY9 TI TTJS8PY DMD1SY9 TN 5-HT 6 receptor (HTR6) DMD1SY9 MA Antagonist DMD1SY9 RN Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology. 1997 Apr-May;36(4-5):713-20. DMD1SY9 RU https://pubmed.ncbi.nlm.nih.gov/9225298 DMD1SY9 DI DMD1SY9 DMD1SY9 DN bufotenine DMD1SY9 TI TTO9X1H DMD1SY9 TN 5-HT 7 receptor (HTR7) DMD1SY9 MA Agonist DMD1SY9 RN Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36. DMD1SY9 RU https://pubmed.ncbi.nlm.nih.gov/8394987 DMD1SY9 DI DMD1SY9 DMD1SY9 DN bufotenine DMD1SY9 TI TTRUFDT DMD1SY9 TN 5-HT 5A receptor (HTR5A) DMD1SY9 MA Antagonist DMD1SY9 RN Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett. 1995 Dec 27;377(3):451-6. DMD1SY9 RU https://pubmed.ncbi.nlm.nih.gov/8549774 DMD1XM0 DI DMD1XM0 DMD1XM0 DN NSC-613604 DMD1XM0 TI TTSZLWK DMD1XM0 TN Aromatase (CYP19A1) DMD1XM0 MA Inhibitor DMD1XM0 RN An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7. DMD1XM0 RU https://pubmed.ncbi.nlm.nih.gov/19500885 DMD24EW DI DMD24EW DMD24EW DN 3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol DMD24EW TI TTZAYWL DMD24EW TN Estrogen receptor (ESR) DMD24EW MA Inhibitor DMD24EW RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMD24EW RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMD24EW DI DMD24EW DMD24EW DN 3-(2-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol DMD24EW TI TTOM3J0 DMD24EW TN Estrogen receptor beta (ESR2) DMD24EW MA Inhibitor DMD24EW RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMD24EW RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMD25HJ DI DMD25HJ DMD25HJ DN O-Benzylsulfonyl-Serine DMD25HJ TI TT5DOVB DMD25HJ TN Cytomegalovirus Protease (CMV UL80) DMD25HJ MA Inhibitor DMD25HJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD25HJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD25I6 DI DMD25I6 DMD25I6 DN MERCK-544 DMD25I6 TI TTN7BL9 DMD25I6 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMD25I6 MA Inhibitor DMD25I6 RN Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1551-4. DMD25I6 RU https://pubmed.ncbi.nlm.nih.gov/20149650 DMD25N9 DI DMD25N9 DMD25N9 DN 1-(3-(2-methylquinolin-7-yl)phenyl)ethanone DMD25N9 TI TTHS256 DMD25N9 TN Metabotropic glutamate receptor 5 (mGluR5) DMD25N9 MA Inhibitor DMD25N9 RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMD25N9 RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMD26XN DI DMD26XN DMD26XN DN Banyu Compound-24 DMD26XN TI TTNT7K8 DMD26XN TN Nociceptin receptor (OPRL1) DMD26XN MA Antagonist DMD26XN RN Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24. Eur J Pharmacol. 2009 Jul 1;614(1-3):50-7. DMD26XN RU https://pubmed.ncbi.nlm.nih.gov/19445927 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TTX41N9 DMD2CG9 TN Tyrosine-protein kinase Kit (KIT) DMD2CG9 MA Inhibitor DMD2CG9 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TT8FYO9 DMD2CG9 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMD2CG9 MA Inhibitor DMD2CG9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TT6PKBN DMD2CG9 TN Proto-oncogene c-Src (SRC) DMD2CG9 MA Inhibitor DMD2CG9 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TT3PJMV DMD2CG9 TN Tyrosine-protein kinase ABL1 (ABL) DMD2CG9 MA Inhibitor DMD2CG9 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TTQBR95 DMD2CG9 TN Stress-activated protein kinase 2a (p38 alpha) DMD2CG9 MA Inhibitor DMD2CG9 RN Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6872-6. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/19889540 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TT860QF DMD2CG9 TN LCK tyrosine protein kinase (LCK) DMD2CG9 MA Inhibitor DMD2CG9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TTRLW2X DMD2CG9 TN Fibroblast growth factor receptor 1 (FGFR1) DMD2CG9 MA Inhibitor DMD2CG9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TTI7421 DMD2CG9 TN Platelet-derived growth factor receptor beta (PDGFRB) DMD2CG9 MA Inhibitor DMD2CG9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMD2CG9 DI DMD2CG9 DMD2CG9 DN PD-0166326 DMD2CG9 TI TTGKNB4 DMD2CG9 TN Epidermal growth factor receptor (EGFR) DMD2CG9 MA Inhibitor DMD2CG9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMD2CG9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMD2FW9 DI DMD2FW9 DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide DMD2FW9 TI TTT6LFV DMD2FW9 TN Histone deacetylase 8 (HDAC8) DMD2FW9 MA Inhibitor DMD2FW9 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD2FW9 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD2FW9 DI DMD2FW9 DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide DMD2FW9 TI TTTQGH8 DMD2FW9 TN Histone deacetylase 4 (HDAC4) DMD2FW9 MA Inhibitor DMD2FW9 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD2FW9 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD2FW9 DI DMD2FW9 DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide DMD2FW9 TI TT6R7JZ DMD2FW9 TN Histone deacetylase 1 (HDAC1) DMD2FW9 MA Inhibitor DMD2FW9 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD2FW9 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD2FW9 DI DMD2FW9 DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide DMD2FW9 TI TT5ZKDI DMD2FW9 TN Histone deacetylase 6 (HDAC6) DMD2FW9 MA Inhibitor DMD2FW9 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD2FW9 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD2FW9 DI DMD2FW9 DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide DMD2FW9 TI TTBH0VX DMD2FW9 TN Histone deacetylase (HDAC) DMD2FW9 MA Inhibitor DMD2FW9 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD2FW9 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD2FW9 DI DMD2FW9 DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide DMD2FW9 TI TTSHTOI DMD2FW9 TN Histone deacetylase 2 (HDAC2) DMD2FW9 MA Inhibitor DMD2FW9 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD2FW9 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD2FW9 DI DMD2FW9 DMD2FW9 DN 6-Mercapto-hexanoic acid phenylamide DMD2FW9 TI TTYHPU6 DMD2FW9 TN Histone deacetylase 10 (HDAC10) DMD2FW9 MA Inhibitor DMD2FW9 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD2FW9 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD2G65 DI DMD2G65 DMD2G65 DN ONO-8713 DMD2G65 TI TTPNGDE DMD2G65 TN Prostaglandin E2 receptor EP3 (PTGER3) DMD2G65 MA Agonist DMD2G65 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMD2G65 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMD2G65 DI DMD2G65 DMD2G65 DN ONO-8713 DMD2G65 TI TTG1QMU DMD2G65 TN Prostaglandin E2 receptor EP1 (PTGER1) DMD2G65 MA Antagonist DMD2G65 RN New class of biphenylene dibenzazocinones as potent ligands for the human EP1 prostanoid receptor. Bioorg Med Chem Lett. 1999 Sep 20;9(18):2699-704. DMD2G65 RU https://pubmed.ncbi.nlm.nih.gov/10509919 DMD2H7L DI DMD2H7L DMD2H7L DN BM-573 DMD2H7L TI TT2O84V DMD2H7L TN Thromboxane A2 receptor (TBXA2R) DMD2H7L MA Inhibitor DMD2H7L RN Synthesis and pharmacological evaluation of novel nitrobenzenic thromboxane modulators as antiplatelet agents acting on both the alpha and beta iso... J Med Chem. 2006 Jun 15;49(12):3701-9. DMD2H7L RU https://pubmed.ncbi.nlm.nih.gov/16759113 DMD2J3Q DI DMD2J3Q DMD2J3Q DN ISIS 114563 DMD2J3Q TI TTY3BRA DMD2J3Q TN ZNF217 messenger RNA (ZNF217 mRNA) DMD2J3Q RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DMD2J3Q RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DMD2J97 DI DMD2J97 DMD2J97 DN LY-314657 DMD2J97 TI TTAN6JD DMD2J97 TN Glutamate receptor AMPA (GRIA) DMD2J97 MA Modulator DMD2J97 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMD2J97 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMD2K4T DI DMD2K4T DMD2K4T DN N-hydroxy-8-(4-methoxyphenyl)-8-oxooctanamide DMD2K4T TI TT6R7JZ DMD2K4T TN Histone deacetylase 1 (HDAC1) DMD2K4T MA Inhibitor DMD2K4T RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMD2K4T RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMD2NXL DI DMD2NXL DMD2NXL DN 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL TI TTS2PH3 DMD2NXL TN Dopamine D5 receptor (D5R) DMD2NXL MA Inhibitor DMD2NXL RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMD2NXL RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMD2NXL DI DMD2NXL DMD2NXL DN 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL TI TT4C8EA DMD2NXL TN Dopamine D3 receptor (D3R) DMD2NXL MA Inhibitor DMD2NXL RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMD2NXL RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMD2NXL DI DMD2NXL DMD2NXL DN 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL TI TTEX248 DMD2NXL TN Dopamine D2 receptor (D2R) DMD2NXL MA Inhibitor DMD2NXL RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMD2NXL RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMD2NXL DI DMD2NXL DMD2NXL DN 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL TI TTE0A2F DMD2NXL TN Dopamine D4 receptor (D4R) DMD2NXL MA Inhibitor DMD2NXL RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMD2NXL RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMD2NXL DI DMD2NXL DMD2NXL DN 1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL TI TTZFYLI DMD2NXL TN Dopamine D1 receptor (D1R) DMD2NXL MA Inhibitor DMD2NXL RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMD2NXL RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMD2QVO DI DMD2QVO DMD2QVO DN 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine DMD2QVO TI TTXZEAJ DMD2QVO TN Leukotriene A-4 hydrolase (LTA4H) DMD2QVO MA Inhibitor DMD2QVO RN Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8. DMD2QVO RU https://pubmed.ncbi.nlm.nih.gov/19090779 DMD2QVO DI DMD2QVO DMD2QVO DN 2-(7-(benzyloxy)-1H-indol-3-yl)ethanamine DMD2QVO TI TTXDKTO DMD2QVO TN Long transient receptor potential channel 8 (TRPM8) DMD2QVO MA Inhibitor DMD2QVO RN 5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9. DMD2QVO RU https://pubmed.ncbi.nlm.nih.gov/20965726 DMD2TPA DI DMD2TPA DMD2TPA DN Alpha-D-Glucopyranosyl-2-Carboxylic Acid Amide DMD2TPA TI TTZHY6R DMD2TPA TN Glycogen phosphorylase muscle form (GP) DMD2TPA MA Inhibitor DMD2TPA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD2TPA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD2WEQ DI DMD2WEQ DMD2WEQ DN SC-0030 DMD2WEQ TI TTMI6F5 DMD2WEQ TN Transient receptor potential cation channel V1 (TRPV1) DMD2WEQ MA Inhibitor DMD2WEQ RN Silicon switch approach in TRPV1 antagonist MK-056 and its analogues. Bioorg Med Chem. 2010 Jan 1;18(1):111-6. DMD2WEQ RU https://pubmed.ncbi.nlm.nih.gov/19931463 DMD2WEQ DI DMD2WEQ DMD2WEQ DN SC-0030 DMD2WEQ TI TTKP2SU DMD2WEQ TN Transient receptor potential cation channel V4 (TRPV4) DMD2WEQ MA Inhibitor DMD2WEQ RN Novel non-vanilloid VR1 antagonist of high analgesic effects and its structural requirement for VR1 antagonistic effects. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4389-93. DMD2WEQ RU https://pubmed.ncbi.nlm.nih.gov/14643332 DMD2ZNA DI DMD2ZNA DMD2ZNA DN 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline DMD2ZNA TI TT1MPAY DMD2ZNA TN GABA(A) receptor alpha-1 (GABRA1) DMD2ZNA MA Inhibitor DMD2ZNA RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMD2ZNA RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMD2ZNA DI DMD2ZNA DMD2ZNA DN 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline DMD2ZNA TI TTZA1NY DMD2ZNA TN GABA(A) receptor beta-2 (GABRB2) DMD2ZNA MA Inhibitor DMD2ZNA RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMD2ZNA RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMD2ZNA DI DMD2ZNA DMD2ZNA DN 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline DMD2ZNA TI TT06RH5 DMD2ZNA TN GABA(A) receptor gamma-2 (GABRG2) DMD2ZNA MA Inhibitor DMD2ZNA RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMD2ZNA RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMD2ZNA DI DMD2ZNA DMD2ZNA DN 2-Isoxazol-5-yl-3H-imidazo[4,5-c]quinoline DMD2ZNA TI TTNJYV2 DMD2ZNA TN Gamma-aminobutyric acid receptor (GAR) DMD2ZNA MA Inhibitor DMD2ZNA RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMD2ZNA RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMD32IN DI DMD32IN DMD32IN DN Long-acting FSH conjugate DMD32IN TI TTZFDBT DMD32IN TN Follicle-stimulating hormone receptor (FSHR) DMD32IN MA Modulator DMD32IN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253). DMD32IN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253 DMD36WS DI DMD36WS DMD36WS DN 1,1,1,3-Tetrafluoro-heptadecan-2-one DMD36WS TI TTT1JVS DMD36WS TN Cytosolic phospholipase A2 (GIVA cPLA2) DMD36WS MA Inhibitor DMD36WS RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMD36WS RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMD3AJH DI DMD3AJH DMD3AJH DN Linear peptide of RES-701-1 DMD3AJH TI TT3ZTGU DMD3AJH TN Endothelin B receptor (EDNRB) DMD3AJH MA Inhibitor DMD3AJH RN RES-701-1/endothelin-1 hybrid peptide having a potent binding activity for type B receptor, Bioorg. Med. Chem. Lett. 7(13):1715-1720 (1997). DMD3AJH RU http://www.sciencedirect.com/science/article/pii/S0960894X97002965 DMD3BEQ DI DMD3BEQ DMD3BEQ DN ERIODICTYOL DMD3BEQ TI TTI84H7 DMD3BEQ TN Cytochrome P450 1B1 (CYP1B1) DMD3BEQ MA Inhibitor DMD3BEQ RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMD3BEQ RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMD3EUI DI DMD3EUI DMD3EUI DN 1,6-bis(4-phenylpiperazin-1-yl)hexane DMD3EUI TI TTSQIFT DMD3EUI TN 5-HT 1A receptor (HTR1A) DMD3EUI MA Inhibitor DMD3EUI RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMD3EUI RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMD3EUI DI DMD3EUI DMD3EUI DN 1,6-bis(4-phenylpiperazin-1-yl)hexane DMD3EUI TI TTJQOD7 DMD3EUI TN 5-HT 2A receptor (HTR2A) DMD3EUI MA Inhibitor DMD3EUI RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMD3EUI RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMD3EUI DI DMD3EUI DMD3EUI DN 1,6-bis(4-phenylpiperazin-1-yl)hexane DMD3EUI TI TTEX248 DMD3EUI TN Dopamine D2 receptor (D2R) DMD3EUI MA Inhibitor DMD3EUI RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMD3EUI RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMD3EUI DI DMD3EUI DMD3EUI DN 1,6-bis(4-phenylpiperazin-1-yl)hexane DMD3EUI TI TTQ6VDM DMD3EUI TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMD3EUI MA Inhibitor DMD3EUI RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMD3EUI RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMD3FWU DI DMD3FWU DMD3FWU DN 8-Mercapto-octanoic acid phenylamide DMD3FWU TI TTYHPU6 DMD3FWU TN Histone deacetylase 10 (HDAC10) DMD3FWU MA Inhibitor DMD3FWU RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD3FWU RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD3FWU DI DMD3FWU DMD3FWU DN 8-Mercapto-octanoic acid phenylamide DMD3FWU TI TTSHTOI DMD3FWU TN Histone deacetylase 2 (HDAC2) DMD3FWU MA Inhibitor DMD3FWU RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD3FWU RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD3FWU DI DMD3FWU DMD3FWU DN 8-Mercapto-octanoic acid phenylamide DMD3FWU TI TTBH0VX DMD3FWU TN Histone deacetylase (HDAC) DMD3FWU MA Inhibitor DMD3FWU RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD3FWU RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD3FWU DI DMD3FWU DMD3FWU DN 8-Mercapto-octanoic acid phenylamide DMD3FWU TI TT5ZKDI DMD3FWU TN Histone deacetylase 6 (HDAC6) DMD3FWU MA Inhibitor DMD3FWU RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD3FWU RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD3FWU DI DMD3FWU DMD3FWU DN 8-Mercapto-octanoic acid phenylamide DMD3FWU TI TT6R7JZ DMD3FWU TN Histone deacetylase 1 (HDAC1) DMD3FWU MA Inhibitor DMD3FWU RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD3FWU RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD3FWU DI DMD3FWU DMD3FWU DN 8-Mercapto-octanoic acid phenylamide DMD3FWU TI TTTQGH8 DMD3FWU TN Histone deacetylase 4 (HDAC4) DMD3FWU MA Inhibitor DMD3FWU RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD3FWU RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD3FWU DI DMD3FWU DMD3FWU DN 8-Mercapto-octanoic acid phenylamide DMD3FWU TI TTT6LFV DMD3FWU TN Histone deacetylase 8 (HDAC8) DMD3FWU MA Inhibitor DMD3FWU RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMD3FWU RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMD3M9J DI DMD3M9J DMD3M9J DN ISIS 119263 DMD3M9J TI TTKS60G DMD3M9J TN STXBP4 messenger RNA (STXBP4 mRNA) DMD3M9J RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DMD3M9J RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DMD3NSQ DI DMD3NSQ DMD3NSQ DN ISIS 298743 DMD3NSQ TI TTSN6QU DMD3NSQ TN HIF1-alpha messenger RNA (HIF1A mRNA) DMD3NSQ RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMD3NSQ RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMD3OAQ DI DMD3OAQ DMD3OAQ DN MCL-433 DMD3OAQ TI TTKWM86 DMD3OAQ TN Opioid receptor mu (MOP) DMD3OAQ MA Inhibitor DMD3OAQ RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMD3OAQ RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMD3OAQ DI DMD3OAQ DMD3OAQ DN MCL-433 DMD3OAQ TI TT27RFC DMD3OAQ TN Opioid receptor delta (OPRD1) DMD3OAQ MA Inhibitor DMD3OAQ RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMD3OAQ RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMD3OAQ DI DMD3OAQ DMD3OAQ DN MCL-433 DMD3OAQ TI TTQW87Y DMD3OAQ TN Opioid receptor kappa (OPRK1) DMD3OAQ MA Inhibitor DMD3OAQ RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMD3OAQ RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMD3OV8 DI DMD3OV8 DMD3OV8 DN 4-hydroxy-8-nitro-3-phenylquinolin-2(1H)-one DMD3OV8 TI TT7AOUD DMD3OV8 TN Fatty acid synthase (FASN) DMD3OV8 MA Inhibitor DMD3OV8 RN 3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4620-3. DMD3OV8 RU https://pubmed.ncbi.nlm.nih.gov/16784844 DMD3ST8 DI DMD3ST8 DMD3ST8 DN RTI-20 DMD3ST8 TI TT84ETX DMD3ST8 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMD3ST8 MA Inhibitor DMD3ST8 RN Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. J Med Chem. 1991 Jul;34(7):2231-41. DMD3ST8 RU https://pubmed.ncbi.nlm.nih.gov/1712395 DMD3WVO DI DMD3WVO DMD3WVO DN Pro-His-Pro-His-Phe-Phe-Val-Tyr DMD3WVO TI TTB2MXP DMD3WVO TN Angiotensinogenase renin (REN) DMD3WVO MA Inhibitor DMD3WVO RN Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61. DMD3WVO RU https://pubmed.ncbi.nlm.nih.gov/6267277 DMD3ZNP DI DMD3ZNP DMD3ZNP DN 2-chloro-2'-C-methyl-tecadenoson DMD3ZNP TI TTNE7KG DMD3ZNP TN Adenosine A2b receptor (ADORA2B) DMD3ZNP MA Inhibitor DMD3ZNP RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMD3ZNP RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMD3ZNP DI DMD3ZNP DMD3ZNP DN 2-chloro-2'-C-methyl-tecadenoson DMD3ZNP TI TTK25J1 DMD3ZNP TN Adenosine A1 receptor (ADORA1) DMD3ZNP MA Inhibitor DMD3ZNP RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMD3ZNP RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMD3ZNP DI DMD3ZNP DMD3ZNP DN 2-chloro-2'-C-methyl-tecadenoson DMD3ZNP TI TTJFY5U DMD3ZNP TN Adenosine A3 receptor (ADORA3) DMD3ZNP MA Inhibitor DMD3ZNP RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMD3ZNP RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TT48I1Y DMD45CU TN Placenta growth factor (PlGF) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TTC67I0 DMD45CU TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TT4YO0Z DMD45CU TN Phosphopantetheine adenylyltransferase (PPAT) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TTELIN2 DMD45CU TN PTPN1 messenger RNA (PTPN1 mRNA) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TTE5VG0 DMD45CU TN P-selectin (SELP) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TTN12BZ DMD45CU TN CTP synthase (CTPS1) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TTCM4B3 DMD45CU TN Nitric-oxide synthase endothelial (NOS3) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TT9PB26 DMD45CU TN Presynaptic density protein 95 (DLG4) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TT78R5H DMD45CU TN Heat shock protein 90 alpha (HSP90A) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TTV3NH6 DMD45CU TN Calmodulin (CALM) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TT5ZWB6 DMD45CU TN Dihydrodiol dehydrogenase type I (AKR1C3) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TT9V5JH DMD45CU TN Phospholipase A2 (PLA2G1B) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD45CU DI DMD45CU DMD45CU DN 2-Methyl-2,4-Pentanediol DMD45CU TI TTHI19T DMD45CU TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMD45CU MA Inhibitor DMD45CU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD45CU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD4BSJ DI DMD4BSJ DMD4BSJ DN [(N4-Bzdig)0]BB(7-14) DMD4BSJ TI TTC1MVT DMD4BSJ TN Gastrin-releasing peptide receptor (GRPR) DMD4BSJ MA Inhibitor DMD4BSJ RN Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10. DMD4BSJ RU https://pubmed.ncbi.nlm.nih.gov/15634004 DMD4BSJ DI DMD4BSJ DMD4BSJ DN [(N4-Bzdig)0]BB(7-14) DMD4BSJ TI TTHYDUM DMD4BSJ TN Bombesin receptor (BS) DMD4BSJ MA Inhibitor DMD4BSJ RN Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10. DMD4BSJ RU https://pubmed.ncbi.nlm.nih.gov/15634004 DMD4JHK DI DMD4JHK DMD4JHK DN Roche 28-2653 DMD4JHK TI TTLM12X DMD4JHK TN Matrix metalloproteinase-2 (MMP-2) DMD4JHK MA Inhibitor DMD4JHK RN The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96. DMD4JHK RU https://pubmed.ncbi.nlm.nih.gov/11960381 DMD4JHK DI DMD4JHK DMD4JHK DN Roche 28-2653 DMD4JHK TI TT6X50U DMD4JHK TN Matrix metalloproteinase-9 (MMP-9) DMD4JHK MA Inhibitor DMD4JHK RN The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96. DMD4JHK RU https://pubmed.ncbi.nlm.nih.gov/11960381 DMD4KLQ DI DMD4KLQ DMD4KLQ DN S1627 DMD4KLQ TI TTRPDBG DMD4KLQ TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMD4KLQ MA Inhibitor DMD4KLQ RN Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci. 2004 Feb 18;24(7):1637-45. DMD4KLQ RU https://pubmed.ncbi.nlm.nih.gov/14973242 DMD4LGN DI DMD4LGN DMD4LGN DN AZ-TAK1 DMD4LGN TI TTJQT60 DMD4LGN TN TGF-beta-activated kinase 1 (MAP3K7) DMD4LGN MA Inhibitor DMD4LGN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2082). DMD4LGN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2082 DMD4N2F DI DMD4N2F DMD4N2F DN Devazepide DMD4N2F TI TTCG0AL DMD4N2F TN Cholecystokinin receptor type A (CCKAR) DMD4N2F MA Antagonist DMD4N2F RN Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. DMD4N2F RU https://pubmed.ncbi.nlm.nih.gov/18045214 DMD4O6V DI DMD4O6V DMD4O6V DN 3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one DMD4O6V TI TTGKNB4 DMD4O6V TN Epidermal growth factor receptor (EGFR) DMD4O6V MA Inhibitor DMD4O6V RN Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26. DMD4O6V RU https://pubmed.ncbi.nlm.nih.gov/10090785 DMD4V6U DI DMD4V6U DMD4V6U DN D[D-3-Pal2]AVP DMD4V6U TI TT4TFGN DMD4V6U TN Vasopressin V1a receptor (V1AR) DMD4V6U MA Inhibitor DMD4V6U RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMD4V6U RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMD4V6U DI DMD4V6U DMD4V6U DN D[D-3-Pal2]AVP DMD4V6U TI TTL9MHW DMD4V6U TN Vasopressin V1b receptor (V1BR) DMD4V6U MA Inhibitor DMD4V6U RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMD4V6U RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMD4V6U DI DMD4V6U DMD4V6U DN D[D-3-Pal2]AVP DMD4V6U TI TTK8R02 DMD4V6U TN Vasopressin V2 receptor (V2R) DMD4V6U MA Inhibitor DMD4V6U RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMD4V6U RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMD4WHN DI DMD4WHN DMD4WHN DN 3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one DMD4WHN TI TTW0CMT DMD4WHN TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMD4WHN MA Inhibitor DMD4WHN RN Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4. DMD4WHN RU https://pubmed.ncbi.nlm.nih.gov/17095219 DMD4WRH DI DMD4WRH DMD4WRH DN Isosorbide-2-benzylcarbamate-5-acetate DMD4WRH TI TTEB0GD DMD4WRH TN Cholinesterase (BCHE) DMD4WRH MA Inhibitor DMD4WRH RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMD4WRH RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMD4YO9 DI DMD4YO9 DMD4YO9 DN AZD-6319 DMD4YO9 TI TTLA931 DMD4YO9 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMD4YO9 MA Agonist DMD4YO9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468). DMD4YO9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468 DMD4YPO DI DMD4YPO DMD4YPO DN (+)-(5S,8S,9R,10S)-20-methoxypuupehenone DMD4YPO TI TT12ABZ DMD4YPO TN Arachidonate 12-lipoxygenase (12-LOX) DMD4YPO MA Inhibitor DMD4YPO RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMD4YPO RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMD4YPO DI DMD4YPO DMD4YPO DN (+)-(5S,8S,9R,10S)-20-methoxypuupehenone DMD4YPO TI TTN9T81 DMD4YPO TN Arachidonate 15-lipoxygenase (15-LOX) DMD4YPO MA Inhibitor DMD4YPO RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMD4YPO RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMD4Z6H DI DMD4Z6H DMD4Z6H DN (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone DMD4Z6H TI TTPLTSQ DMD4Z6H TN Neutrophil elastase (NE) DMD4Z6H MA Inhibitor DMD4Z6H RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMD4Z6H RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMD4Z6H DI DMD4Z6H DMD4Z6H DN (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone DMD4Z6H TI TTMF8H9 DMD4Z6H TN Plasma kallikrein (KLKB1) DMD4Z6H MA Inhibitor DMD4Z6H RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMD4Z6H RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMD4Z6H DI DMD4Z6H DMD4Z6H DN (3-nitro-1H-pyrazol-1-yl)(phenyl)methanone DMD4Z6H TI TT6L509 DMD4Z6H TN Coagulation factor IIa (F2) DMD4Z6H MA Inhibitor DMD4Z6H RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMD4Z6H RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMD51I4 DI DMD51I4 DMD51I4 DN 2,6-Diisopropyl-4-nitro-phenol DMD51I4 TI TTNJYV2 DMD51I4 TN Gamma-aminobutyric acid receptor (GAR) DMD51I4 MA Inhibitor DMD51I4 RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DMD51I4 RU https://pubmed.ncbi.nlm.nih.gov/9599235 DMD524S DI DMD524S DMD524S DN PMID7966163C4e DMD524S TI TTFQEO5 DMD524S TN Squalene synthetase (FDFT1) DMD524S MA Inhibitor DMD524S RN Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51. DMD524S RU https://pubmed.ncbi.nlm.nih.gov/7966163 DMD5CB6 DI DMD5CB6 DMD5CB6 DN 7-propoxy-2H-chromen-2-one DMD5CB6 TI TTSYM0R DMD5CB6 TN Carbonic anhydrase XII (CA-XII) DMD5CB6 MA Inhibitor DMD5CB6 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMD5CB6 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMD5CB6 DI DMD5CB6 DMD5CB6 DN 7-propoxy-2H-chromen-2-one DMD5CB6 TI TTEYTKG DMD5CB6 TN Carbonic anhydrase XIV (CA-XIV) DMD5CB6 MA Inhibitor DMD5CB6 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMD5CB6 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMD5CB6 DI DMD5CB6 DMD5CB6 DN 7-propoxy-2H-chromen-2-one DMD5CB6 TI TTCFSPE DMD5CB6 TN Carbonic anhydrase VI (CA-VI) DMD5CB6 MA Inhibitor DMD5CB6 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMD5CB6 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMD5CB6 DI DMD5CB6 DMD5CB6 DN 7-propoxy-2H-chromen-2-one DMD5CB6 TI TT2LVK8 DMD5CB6 TN Carbonic anhydrase IX (CA-IX) DMD5CB6 MA Inhibitor DMD5CB6 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMD5CB6 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMD5CB6 DI DMD5CB6 DMD5CB6 DN 7-propoxy-2H-chromen-2-one DMD5CB6 TI TTUNARX DMD5CB6 TN Carbonic anhydrase (CA) DMD5CB6 MA Inhibitor DMD5CB6 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMD5CB6 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMD5E8G DI DMD5E8G DMD5E8G DN N-(5-Bromo-quinoxalin-6-yl)-guanidine DMD5E8G TI TTNGILX DMD5E8G TN Adrenergic receptor alpha-1A (ADRA1A) DMD5E8G MA Inhibitor DMD5E8G RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMD5E8G RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMD5E8G DI DMD5E8G DMD5E8G DN N-(5-Bromo-quinoxalin-6-yl)-guanidine DMD5E8G TI TT34BHT DMD5E8G TN Adrenergic receptor alpha-1D (ADRA1D) DMD5E8G MA Inhibitor DMD5E8G RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMD5E8G RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMD5E8G DI DMD5E8G DMD5E8G DN N-(5-Bromo-quinoxalin-6-yl)-guanidine DMD5E8G TI TTBRKXS DMD5E8G TN Adrenergic receptor alpha-1B (ADRA1B) DMD5E8G MA Inhibitor DMD5E8G RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMD5E8G RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMD5F6Z DI DMD5F6Z DMD5F6Z DN N-[4'-(ethylsulfonyl)-3-fluoro-4-biphenylyl]urea DMD5F6Z TI TTBGTCW DMD5F6Z TN Kinesin spindle messenger RNA (KIF11 mRNA) DMD5F6Z MA Inhibitor DMD5F6Z RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMD5F6Z RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMD5FIU DI DMD5FIU DMD5FIU DN Clorobiocin DMD5FIU TI TT0IHXV DMD5FIU TN DNA topoisomerase II (TOP2) DMD5FIU MA Inhibitor DMD5FIU RN The high-resolution crystal structure of a 24-kDa gyrase B fragment from E.coli complexed with one of the most potent coumarin inhibitors, clorobiocin. Proteins. 1997 May;28(1):41-52. DMD5FIU RU https://pubmed.ncbi.nlm.nih.gov/9144789 DMD5GO0 DI DMD5GO0 DMD5GO0 DN LD-101 DMD5GO0 TI TTWTSCV DMD5GO0 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMD5GO0 MA Inhibitor DMD5GO0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMD5GO0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMD5JYQ DI DMD5JYQ DMD5JYQ DN ZM-336372 DMD5JYQ TI TT860QF DMD5JYQ TN LCK tyrosine protein kinase (LCK) DMD5JYQ MA Inhibitor DMD5JYQ RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMD5JYQ RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMD5JYQ DI DMD5JYQ DMD5JYQ DN ZM-336372 DMD5JYQ TI TTQBR95 DMD5JYQ TN Stress-activated protein kinase 2a (p38 alpha) DMD5JYQ MA Inhibitor DMD5JYQ RN A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5383-7. DMD5JYQ RU https://pubmed.ncbi.nlm.nih.gov/15454231 DMD5JYQ DI DMD5JYQ DMD5JYQ DN ZM-336372 DMD5JYQ TI TTAN5W2 DMD5JYQ TN Raf messenger RNA (Raf mRNA) DMD5JYQ MA Inhibitor DMD5JYQ RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMD5JYQ RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMD5JYQ DI DMD5JYQ DMD5JYQ DN ZM-336372 DMD5JYQ TI TT0EOB8 DMD5JYQ TN B-Raf messenger RNA (BRAF mRNA) DMD5JYQ MA Inhibitor DMD5JYQ RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMD5JYQ RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMD5LXQ DI DMD5LXQ DMD5LXQ DN 4-fluorophenylboronic acid DMD5LXQ TI TTDP1UC DMD5LXQ TN Fatty acid amide hydrolase (FAAH) DMD5LXQ MA Inhibitor DMD5LXQ RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMD5LXQ RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMD5QOW DI DMD5QOW DMD5QOW DN 3-[5-(3-Fluorophenyl)-2-thienyl]phenol DMD5QOW TI TTIWB6L DMD5QOW TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMD5QOW MA Inhibitor DMD5QOW RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMD5QOW RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMD5TPH DI DMD5TPH DMD5TPH DN Rac-2q DMD5TPH TI TT8VUE0 DMD5TPH TN Chymase (CYM) DMD5TPH MA Inhibitor DMD5TPH RN Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4. DMD5TPH RU https://pubmed.ncbi.nlm.nih.gov/17419055 DMD5YKO DI DMD5YKO DMD5YKO DN 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione DMD5YKO TI TTSYVO6 DMD5YKO TN Cholesterol desmolase (CYP11A1) DMD5YKO MA Inhibitor DMD5YKO RN Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9. DMD5YKO RU https://pubmed.ncbi.nlm.nih.gov/3735304 DMD5YKO DI DMD5YKO DMD5YKO DN 3-(4-Amino-phenyl)-3-butyl-piperidine-2,6-dione DMD5YKO TI TTSZLWK DMD5YKO TN Aromatase (CYP19A1) DMD5YKO MA Inhibitor DMD5YKO RN Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9. DMD5YKO RU https://pubmed.ncbi.nlm.nih.gov/3735304 DMD60BA DI DMD60BA DMD60BA DN ISIS 140153 DMD60BA TI TTAK0IN DMD60BA TN SOAT2 messenger RNA (SOAT2 mRNA) DMD60BA RN US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression. DMD60BA RU http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true DMD621E DI DMD621E DMD621E DN N-methyl-5,6-dip-tolylpyrazine-2-carboxamide DMD621E TI TT6OEDT DMD621E TN Cannabinoid receptor 1 (CB1) DMD621E MA Inhibitor DMD621E RN Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. DMD621E RU https://pubmed.ncbi.nlm.nih.gov/17513109 DMD67YO DI DMD67YO DMD67YO DN ISIS 4729 DMD67YO TI TT1PL7M DMD67YO TN E-selectin messenger RNA (SELE mRNA) DMD67YO RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMD67YO RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMD6AJO DI DMD6AJO DMD6AJO DN N6-cyclopentyladenosine DMD6AJO TI TTK25J1 DMD6AJO TN Adenosine A1 receptor (ADORA1) DMD6AJO MA Inhibitor DMD6AJO RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMD6AJO RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMD6AJO DI DMD6AJO DMD6AJO DN N6-cyclopentyladenosine DMD6AJO TI TTLXAKE DMD6AJO TN Solute carrier family 29 member 1 (SLC29A1) DMD6AJO MA Inhibitor DMD6AJO RN Inhibition of nucleoside transport proteins by C8-alkylamine-substituted purines. J Med Chem. 2005 Jan 13;48(1):321-9. DMD6AJO RU https://pubmed.ncbi.nlm.nih.gov/15634027 DMD6AJO DI DMD6AJO DMD6AJO DN N6-cyclopentyladenosine DMD6AJO TI TT2QM9D DMD6AJO TN Adenylate cyclase (ADCY) DMD6AJO MA Inhibitor DMD6AJO RN Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors. J Med Chem. 1991 Dec;34(12):3388-90. DMD6AJO RU https://pubmed.ncbi.nlm.nih.gov/1766003 DMD6AJO DI DMD6AJO DMD6AJO DN N6-cyclopentyladenosine DMD6AJO TI TTM2AOE DMD6AJO TN Adenosine A2a receptor (ADORA2A) DMD6AJO MA Inhibitor DMD6AJO RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMD6AJO RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMD6AJO DI DMD6AJO DMD6AJO DN N6-cyclopentyladenosine DMD6AJO TI TTNE7KG DMD6AJO TN Adenosine A2b receptor (ADORA2B) DMD6AJO MA Inhibitor DMD6AJO RN Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives. J Med Chem. 1988 Jun;31(6):1179-83. DMD6AJO RU https://pubmed.ncbi.nlm.nih.gov/3373486 DMD6AJO DI DMD6AJO DMD6AJO DN N6-cyclopentyladenosine DMD6AJO TI TTJFY5U DMD6AJO TN Adenosine A3 receptor (ADORA3) DMD6AJO MA Inhibitor DMD6AJO RN Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprote... J Med Chem. 2005 Dec 29;48(26):8103-7. DMD6AJO RU https://pubmed.ncbi.nlm.nih.gov/16366590 DMD6AYQ DI DMD6AYQ DMD6AYQ DN 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide DMD6AYQ TI TTHQPL7 DMD6AYQ TN Carbonic anhydrase I (CA-I) DMD6AYQ MA Inhibitor DMD6AYQ RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMD6AYQ RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMD6AYQ DI DMD6AYQ DMD6AYQ DN 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide DMD6AYQ TI TTUNARX DMD6AYQ TN Carbonic anhydrase (CA) DMD6AYQ MA Inhibitor DMD6AYQ RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMD6AYQ RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMD6AYQ DI DMD6AYQ DMD6AYQ DN 4-(2-Pyridin-4-ylacetamido)benzenesulfonamide DMD6AYQ TI TTANPDJ DMD6AYQ TN Carbonic anhydrase II (CA-II) DMD6AYQ MA Inhibitor DMD6AYQ RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMD6AYQ RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMD6CHB DI DMD6CHB DMD6CHB DN 1-(trifluoromethyl)-9H-carbazole DMD6CHB TI TTBGTCW DMD6CHB TN Kinesin spindle messenger RNA (KIF11 mRNA) DMD6CHB MA Inhibitor DMD6CHB RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMD6CHB RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMD6CLG DI DMD6CLG DMD6CLG DN TZP-201 DMD6CLG TI TT953CX DMD6CLG TN Motilin receptor (MLNR) DMD6CLG MA Antagonist DMD6CLG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297). DMD6CLG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297 DMD6L7C DI DMD6L7C DMD6L7C DN 2-methoxyestrrone-3-O-sulfamate DMD6L7C TI TTANPDJ DMD6L7C TN Carbonic anhydrase II (CA-II) DMD6L7C MA Inhibitor DMD6L7C RN Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308. DMD6L7C RU https://pubmed.ncbi.nlm.nih.gov/18260615 DMD6N8V DI DMD6N8V DMD6N8V DN N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea DMD6N8V TI TTGY7WI DMD6N8V TN Urokinase-type plasminogen activator (PLAU) DMD6N8V MA Inhibitor DMD6N8V RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD6N8V RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD6NZO DI DMD6NZO DMD6NZO DN Hinokinin DMD6NZO TI TTXV4FI DMD6NZO TN Albendazole monooxygenase (CYP3A4) DMD6NZO MA Inhibitor DMD6NZO RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMD6NZO RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMD6OW4 DI DMD6OW4 DMD6OW4 DN C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMD6OW4 TI TT0MV2T DMD6OW4 TN Melanocortin receptor 1 (MC1R) DMD6OW4 MA Inhibitor DMD6OW4 RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMD6OW4 RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMD6OW4 DI DMD6OW4 DMD6OW4 DN C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMD6OW4 TI TTD0CIQ DMD6OW4 TN Melanocortin receptor 4 (MC4R) DMD6OW4 MA Inhibitor DMD6OW4 RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMD6OW4 RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMD6OW4 DI DMD6OW4 DMD6OW4 DN C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMD6OW4 TI TTNI91K DMD6OW4 TN Melanocortin receptor 3 (MC3R) DMD6OW4 MA Inhibitor DMD6OW4 RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMD6OW4 RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMD6OW4 DI DMD6OW4 DMD6OW4 DN C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMD6OW4 TI TTEOSZT DMD6OW4 TN Melanocortin receptor (MCR) DMD6OW4 MA Inhibitor DMD6OW4 RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMD6OW4 RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMD6PMZ DI DMD6PMZ DMD6PMZ DN 3-butoxycarbonyl-6-ethyl-4-quinolone DMD6PMZ TI TT1MPAY DMD6PMZ TN GABA(A) receptor alpha-1 (GABRA1) DMD6PMZ MA Inhibitor DMD6PMZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMD6PMZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMD6PMZ DI DMD6PMZ DMD6PMZ DN 3-butoxycarbonyl-6-ethyl-4-quinolone DMD6PMZ TI TT06RH5 DMD6PMZ TN GABA(A) receptor gamma-2 (GABRG2) DMD6PMZ MA Inhibitor DMD6PMZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMD6PMZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMD6PMZ DI DMD6PMZ DMD6PMZ DN 3-butoxycarbonyl-6-ethyl-4-quinolone DMD6PMZ TI TTNJYV2 DMD6PMZ TN Gamma-aminobutyric acid receptor (GAR) DMD6PMZ MA Inhibitor DMD6PMZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMD6PMZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMD6PMZ DI DMD6PMZ DMD6PMZ DN 3-butoxycarbonyl-6-ethyl-4-quinolone DMD6PMZ TI TTZA1NY DMD6PMZ TN GABA(A) receptor beta-2 (GABRB2) DMD6PMZ MA Inhibitor DMD6PMZ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMD6PMZ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMD6ROZ DI DMD6ROZ DMD6ROZ DN 4E2Rcat DMD6ROZ TI TTXQ1JS DMD6ROZ TN HUAMN eIF4E-eIF4G interaction (eIF4E-eIF4G) DMD6ROZ MA Inhibitor DMD6ROZ RN Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication. J Virol. 2011 Jul;85(13):6381-9. DMD6ROZ RU https://pubmed.ncbi.nlm.nih.gov/21507972 DMD6SJT DI DMD6SJT DMD6SJT DN Sar-Arg-Val-Tyr-Ile-His-Pro-Phe-OH DMD6SJT TI TTQVOEI DMD6SJT TN Angiotensin II receptor type-2 (AGTR2) DMD6SJT MA Inhibitor DMD6SJT RN 1-(carboxybenzyl)imidazole-5-acrylic acids: potent and selective angiotensin II receptor antagonists. J Med Chem. 1991 Apr;34(4):1514-7. DMD6SJT RU https://pubmed.ncbi.nlm.nih.gov/2016730 DMD6U4F DI DMD6U4F DMD6U4F DN ISAINDIGOTONE DMD6U4F TI TTSJ6Q4 DMD6U4F TN LOX-5 messenger RNA (ALOX5 mRNA) DMD6U4F MA Inhibitor DMD6U4F RN Inhibition of leukocyte functions by the alkaloid isaindigotone from Isatis indigotica and some new synthetic derivatives. J Nat Prod. 2001 Oct;64(10):1297-300. DMD6U4F RU https://pubmed.ncbi.nlm.nih.gov/11678654 DMD6UC9 DI DMD6UC9 DMD6UC9 DN 7alpha-Cl-ginkgolide B DMD6UC9 TI TTQL5VC DMD6UC9 TN Platelet-activating factor receptor (PTAFR) DMD6UC9 MA Antagonist DMD6UC9 RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMD6UC9 RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMD6VSY DI DMD6VSY DMD6VSY DN 8-(biphenyl-4-yl)-N-hydroxy-8-oxooctanamide DMD6VSY TI TT6R7JZ DMD6VSY TN Histone deacetylase 1 (HDAC1) DMD6VSY MA Inhibitor DMD6VSY RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMD6VSY RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMD6ZV5 DI DMD6ZV5 DMD6ZV5 DN 2,7-Bis[3-(pyrrolidino)propionamido]anthraquinone DMD6ZV5 TI TTQY2EJ DMD6ZV5 TN TERT messenger RNA (TERT mRNA) DMD6ZV5 MA Inhibitor DMD6ZV5 RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMD6ZV5 RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMD6ZWV DI DMD6ZWV DMD6ZWV DN PYY(25-36) DMD6ZWV TI TTJ6WK9 DMD6ZWV TN Neuropeptide Y receptor type 2 (NPY2R) DMD6ZWV MA Inhibitor DMD6ZWV RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DMD6ZWV RU https://pubmed.ncbi.nlm.nih.gov/17055726 DMD71VB DI DMD71VB DMD71VB DN SC-79407 DMD71VB TI TT6L509 DMD71VB TN Coagulation factor IIa (F2) DMD71VB MA Inhibitor DMD71VB RN Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21. DMD71VB RU https://pubmed.ncbi.nlm.nih.gov/12714830 DMD75MP DI DMD75MP DMD75MP DN ISIS 25237 DMD75MP TI TTJA1ZO DMD75MP TN ITGB3 messenger RNA (ITGB3 mRNA) DMD75MP RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMD75MP RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMD7HA3 DI DMD7HA3 DMD7HA3 DN ISIS 222001 DMD7HA3 TI TTWPA54 DMD7HA3 TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMD7HA3 RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMD7HA3 RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMD7HO8 DI DMD7HO8 DMD7HO8 DN F61F12 DMD7HO8 TI TTF0RCZ DMD7HO8 TN Apoptosis mediating surface antigen FAS (FAS) DMD7HO8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875). DMD7HO8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875 DMD7M9L DI DMD7M9L DMD7M9L DN VAR-10200 DMD7M9L TI TTGP7BY DMD7M9L TN Monoamine oxidase type B (MAO-B) DMD7M9L MA Modulator DMD7M9L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DMD7M9L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DMD7OQA DI DMD7OQA DMD7OQA DN C-014C DMD7OQA TI TT7HQD0 DMD7OQA TN C-C chemokine receptor type 4 (CCR4) DMD7OQA MA Inhibitor DMD7OQA RN Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines. Bioorg Med Chem. 2008 Jul 15;16(14):7021-32. DMD7OQA RU https://pubmed.ncbi.nlm.nih.gov/18539035 DMD7Q1R DI DMD7Q1R DMD7Q1R DN 7-tert-butyl-9H-carbazole-3-carboxylic acid DMD7Q1R TI TTBGTCW DMD7Q1R TN Kinesin spindle messenger RNA (KIF11 mRNA) DMD7Q1R MA Inhibitor DMD7Q1R RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMD7Q1R RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMD7VOZ DI DMD7VOZ DMD7VOZ DN PMID24999562C8d DMD7VOZ TI TTI7T1Q DMD7VOZ TN Neuromedin-U receptor 1 (NMUR1) DMD7VOZ MA Agonist DMD7VOZ RN Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. J Med Chem. 2014 Aug 14;57(15):6583-93. DMD7VOZ RU https://pubmed.ncbi.nlm.nih.gov/24999562 DMD7WGM DI DMD7WGM DMD7WGM DN (2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime DMD7WGM TI TTCEJ4F DMD7WGM TN G1/S-specific cyclin-E1 (CCNE1) DMD7WGM MA Inhibitor DMD7WGM RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMD7WGM RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMD7WGM DI DMD7WGM DMD7WGM DN (2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime DMD7WGM TI TT7HF4W DMD7WGM TN Cyclin-dependent kinase 2 (CDK2) DMD7WGM MA Inhibitor DMD7WGM RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMD7WGM RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMD7WNV DI DMD7WNV DMD7WNV DN 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane DMD7WNV TI TT04R7I DMD7WNV TN Transketolase (TK) DMD7WNV MA Inhibitor DMD7WNV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD7WNV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD7WNV DI DMD7WNV DMD7WNV DN 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane DMD7WNV TI TT2B9KF DMD7WNV TN Fyn tyrosine protein kinase (FYN) DMD7WNV MA Inhibitor DMD7WNV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMD7WNV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMD89A1 DI DMD89A1 DMD89A1 DN Acetic acid 2-hept-3-ynylsulfanyl-phenyl ester DMD89A1 TI TT8NGED DMD89A1 TN Prostaglandin G/H synthase 1 (COX-1) DMD89A1 MA Inhibitor DMD89A1 RN Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18. DMD89A1 RU https://pubmed.ncbi.nlm.nih.gov/9822550 DMD8BRG DI DMD8BRG DMD8BRG DN UFP-502 DMD8BRG TI TT27RFC DMD8BRG TN Opioid receptor delta (OPRD1) DMD8BRG MA Inhibitor DMD8BRG RN Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. DMD8BRG RU https://pubmed.ncbi.nlm.nih.gov/20637637 DMD8BRG DI DMD8BRG DMD8BRG DN UFP-502 DMD8BRG TI TTKWM86 DMD8BRG TN Opioid receptor mu (MOP) DMD8BRG MA Inhibitor DMD8BRG RN Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. DMD8BRG RU https://pubmed.ncbi.nlm.nih.gov/20637637 DMD8CQS DI DMD8CQS DMD8CQS DN 2-methylhistamine DMD8CQS TI TTXJ178 DMD8CQS TN Histamine H4 receptor (H4R) DMD8CQS MA Agonist DMD8CQS RN Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54. DMD8CQS RU https://pubmed.ncbi.nlm.nih.gov/16432504 DMD8IYZ DI DMD8IYZ DMD8IYZ DN 1-(5-fluorooxazol-2-yl)-7-phenylheptan-1-one DMD8IYZ TI TTDP1UC DMD8IYZ TN Fatty acid amide hydrolase (FAAH) DMD8IYZ MA Inhibitor DMD8IYZ RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMD8IYZ RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMD8KXB DI DMD8KXB DMD8KXB DN ISIS 29156 DMD8KXB TI TTO6SGY DMD8KXB TN AKT3 messenger RNA (AKT3 mRNA) DMD8KXB RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMD8KXB RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMD8NHB DI DMD8NHB DMD8NHB DN pentylthio-TZTP DMD8NHB TI TTQ13Z5 DMD8NHB TN Muscarinic acetylcholine receptor M3 (CHRM3) DMD8NHB MA Agonist DMD8NHB RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMD8NHB RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMD8NHB DI DMD8NHB DMD8NHB DN pentylthio-TZTP DMD8NHB TI TTOXS3C DMD8NHB TN Muscarinic acetylcholine receptor (CHRM) DMD8NHB MA Agonist DMD8NHB RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMD8NHB RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMD8O7S DI DMD8O7S DMD8O7S DN HALOXYSTEROL B DMD8O7S TI TTEB0GD DMD8O7S TN Cholinesterase (BCHE) DMD8O7S MA Inhibitor DMD8O7S RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMD8O7S RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMD8O7S DI DMD8O7S DMD8O7S DN HALOXYSTEROL B DMD8O7S TI TT1RS9F DMD8O7S TN Acetylcholinesterase (AChE) DMD8O7S MA Inhibitor DMD8O7S RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMD8O7S RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMD8Q3E DI DMD8Q3E DMD8Q3E DN 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine DMD8Q3E TI TTJFY5U DMD8Q3E TN Adenosine A3 receptor (ADORA3) DMD8Q3E MA Inhibitor DMD8Q3E RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMD8Q3E RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMD8Q3E DI DMD8Q3E DMD8Q3E DN 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine DMD8Q3E TI TTM2AOE DMD8Q3E TN Adenosine A2a receptor (ADORA2A) DMD8Q3E MA Inhibitor DMD8Q3E RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMD8Q3E RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMD8Q3E DI DMD8Q3E DMD8Q3E DN 2-(3''(5''-chloro-indolyl)ethyloxy)adenosine DMD8Q3E TI TTK25J1 DMD8Q3E TN Adenosine A1 receptor (ADORA1) DMD8Q3E MA Inhibitor DMD8Q3E RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMD8Q3E RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMD8QOZ DI DMD8QOZ DMD8QOZ DN PF-526014 DMD8QOZ TI TTAWNKZ DMD8QOZ TN Norepinephrine transporter (NET) DMD8QOZ MA Inhibitor DMD8QOZ RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMD8QOZ RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMD8QOZ DI DMD8QOZ DMD8QOZ DN PF-526014 DMD8QOZ TI TTVBI8W DMD8QOZ TN Dopamine transporter (DAT) DMD8QOZ MA Inhibitor DMD8QOZ RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMD8QOZ RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMD8QOZ DI DMD8QOZ DMD8QOZ DN PF-526014 DMD8QOZ TI TTQ6VDM DMD8QOZ TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMD8QOZ MA Inhibitor DMD8QOZ RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMD8QOZ RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMD8QOZ DI DMD8QOZ DMD8QOZ DN PF-526014 DMD8QOZ TI TT3ROYC DMD8QOZ TN Serotonin transporter (SERT) DMD8QOZ MA Inhibitor DMD8QOZ RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMD8QOZ RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMD8TWC DI DMD8TWC DMD8TWC DN dibenzoxazepine DMD8TWC TI TTELV3W DMD8TWC TN Transformation-sensitive protein p120 (TRPA1) DMD8TWC MA Activator DMD8TWC RN Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6. DMD8TWC RU https://pubmed.ncbi.nlm.nih.gov/18501939 DMD8ZUH DI DMD8ZUH DMD8ZUH DN 2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one DMD8ZUH TI TTML2WA DMD8ZUH TN Tubulin (TUB) DMD8ZUH MA Inhibitor DMD8ZUH RN Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1999 Oct 7;42(20):4081-7. DMD8ZUH RU https://pubmed.ncbi.nlm.nih.gov/10514278 DMD8ZUH DI DMD8ZUH DMD8ZUH DN 2-Furan-2-yl-7-methyl-1H-[1,8]naphthyridin-4-one DMD8ZUH TI TTYFKSZ DMD8ZUH TN Tubulin beta (TUBB) DMD8ZUH MA Inhibitor DMD8ZUH RN Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization. J Med Chem. 1999 Oct 7;42(20):4081-7. DMD8ZUH RU https://pubmed.ncbi.nlm.nih.gov/10514278 DMD91RI DI DMD91RI DMD91RI DN Lobatamide B DMD91RI TI TTTK3BH DMD91RI TN Vacuolar-type proton ATPase (v-ATPase) DMD91RI MA Inhibitor DMD91RI RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DMD91RI RU https://pubmed.ncbi.nlm.nih.gov/11259534 DMD91WS DI DMD91WS DMD91WS DN RS 57639 DMD91WS TI TT07C3Y DMD91WS TN 5-HT 4 receptor (HTR4) DMD91WS MA Agonist DMD91WS RN [3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9. DMD91WS RU https://pubmed.ncbi.nlm.nih.gov/9225293 DMD926H DI DMD926H DMD926H DN (+/-)-threo-N-(3-Phenylpropyl)methylphenidate DMD926H TI TTVBI8W DMD926H TN Dopamine transporter (DAT) DMD926H MA Inhibitor DMD926H RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMD926H RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMD93NP DI DMD93NP DMD93NP DN Ro67-4853 DMD93NP TI TTVBPDM DMD93NP TN Metabotropic glutamate receptor 1 (mGluR1) DMD93NP MA Modulator (allosteric modulator) DMD93NP RN Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7. DMD93NP RU https://pubmed.ncbi.nlm.nih.gov/11606768 DMD94OB DI DMD94OB DMD94OB DN 4-(3-nitro-benzylideneamino)-benzenesulfonamide DMD94OB TI TTVKILB DMD94OB TN Prostaglandin G/H synthase 2 (COX-2) DMD94OB MA Inhibitor DMD94OB RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMD94OB RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMD98YP DI DMD98YP DMD98YP DN Benzaldehyde O-4-ethoxyphenylcarbamoyl oxime DMD98YP TI TTDP1UC DMD98YP TN Fatty acid amide hydrolase (FAAH) DMD98YP MA Inhibitor DMD98YP RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMD98YP RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMD9A08 DI DMD9A08 DMD9A08 DN Salvinorin B 2-methoxy-2-propyl ether DMD9A08 TI TTQW87Y DMD9A08 TN Opioid receptor kappa (OPRK1) DMD9A08 MA Inhibitor DMD9A08 RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMD9A08 RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMD9FZW DI DMD9FZW DMD9FZW DN 4-butylphenylboronic acid DMD9FZW TI TTHQPL7 DMD9FZW TN Carbonic anhydrase I (CA-I) DMD9FZW MA Inhibitor DMD9FZW RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMD9FZW RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMD9FZW DI DMD9FZW DMD9FZW DN 4-butylphenylboronic acid DMD9FZW TI TTUNARX DMD9FZW TN Carbonic anhydrase (CA) DMD9FZW MA Inhibitor DMD9FZW RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMD9FZW RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMD9FZW DI DMD9FZW DMD9FZW DN 4-butylphenylboronic acid DMD9FZW TI TTANPDJ DMD9FZW TN Carbonic anhydrase II (CA-II) DMD9FZW MA Inhibitor DMD9FZW RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMD9FZW RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMD9HP8 DI DMD9HP8 DMD9HP8 DN 1,2-bis(2,3,5-trifluorophenyl)-2-hydroxyethanone DMD9HP8 TI TTMF541 DMD9HP8 TN Liver carboxylesterase (CES1) DMD9HP8 MA Inhibitor DMD9HP8 RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMD9HP8 RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMD9KEB DI DMD9KEB DMD9KEB DN Undecyl-Phosphinic Acid Butyl Ester DMD9KEB TI TTKYZA9 DMD9KEB TN Gastric triacylglycerol lipase (LIPF) DMD9KEB MA Inhibitor DMD9KEB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMD9KEB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMD9KYN DI DMD9KYN DMD9KYN DN PCCG-4 DMD9KYN TI TTXJ47W DMD9KYN TN Metabotropic glutamate receptor 2 (mGluR2) DMD9KYN MA Antagonist DMD9KYN RN Synthesis and pharmacological characterization of all sixteen stereoisomers of 2-(2'-carboxy-3'-phenylcyclopropyl)glycine. Focus on (2S,1'S,2'S,3'R)-2-(2'-carboxy-3'-phenylcyclopropyl)glycine, a novel and selective group II metabotropic glutamate receptors antagonist. J Med Chem. 1996 May 24;39(11):2259-69. DMD9KYN RU https://pubmed.ncbi.nlm.nih.gov/8667369 DMD9O2H DI DMD9O2H DMD9O2H DN ISIS 114537 DMD9O2H TI TTY3BRA DMD9O2H TN ZNF217 messenger RNA (ZNF217 mRNA) DMD9O2H RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DMD9O2H RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DMD9SCI DI DMD9SCI DMD9SCI DN RO-4920506 DMD9SCI TI TTROQ37 DMD9SCI TN MAPK/ERK kinase kinase (MAP3K) DMD9SCI MA Inhibitor DMD9SCI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063). DMD9SCI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063 DMD9SOF DI DMD9SOF DMD9SOF DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-MeA-N-Q-CONH2 DMD9SOF TI TTNT7K8 DMD9SOF TN Nociceptin receptor (OPRL1) DMD9SOF MA Inhibitor DMD9SOF RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMD9SOF RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMD9UQN DI DMD9UQN DMD9UQN DN FGGFTRKRKSARKLANQ DMD9UQN TI TTNT7K8 DMD9UQN TN Nociceptin receptor (OPRL1) DMD9UQN MA Inhibitor DMD9UQN RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMD9UQN RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMD9W0B DI DMD9W0B DMD9W0B DN JT-2724 DMD9W0B TI TTB2MXP DMD9W0B TN Angiotensinogenase renin (REN) DMD9W0B MA Modulator DMD9W0B RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMD9W0B RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMDA285 DI DMDA285 DMDA285 DN (R/S)-2-((4-phenoxyphenoxy)methyl)piperidine DMDA285 TI TTXZEAJ DMDA285 TN Leukotriene A-4 hydrolase (LTA4H) DMDA285 MA Inhibitor DMDA285 RN Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4. DMDA285 RU https://pubmed.ncbi.nlm.nih.gov/20371179 DMDA6VL DI DMDA6VL DMDA6VL DN IODOPROXYFAN DMDA6VL TI TT9JNIC DMDA6VL TN Histamine H3 receptor (H3R) DMDA6VL MA Inhibitor DMDA6VL RN Different antagonist binding properties of human and rat histamine H3 receptors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):951-4. DMDA6VL RU https://pubmed.ncbi.nlm.nih.gov/11294398 DMDA7M9 DI DMDA7M9 DMDA7M9 DN ONO-AE5-599 DMDA7M9 TI TTPNGDE DMDA7M9 TN Prostaglandin E2 receptor EP3 (PTGER3) DMDA7M9 MA Antagonist DMDA7M9 RN Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats. Life Sci. 2007 Jun 6;80(26):2446-53. DMDA7M9 RU https://pubmed.ncbi.nlm.nih.gov/17512019 DMDAN0K DI DMDAN0K DMDAN0K DN N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi) DMDAN0K TI TT2SUAQ DMDAN0K TN Cysteine protease (CYP) DMDAN0K MA Inhibitor DMDAN0K RN A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob Agents Chemother. 2007 Nov;51(11):3932-9. DMDAN0K RU https://pubmed.ncbi.nlm.nih.gov/17698625 DMDAN0K DI DMDAN0K DMDAN0K DN N-methyl-Pip-F-homoF-vinyl sulfonyl phenyl (N-methyl-Pip-F-hF-VS phi) DMDAN0K TI TTO9X1H DMDAN0K TN 5-HT 7 receptor (HTR7) DMDAN0K MA Antagonist DMDAN0K RN 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):81-90. DMDAN0K RU https://pubmed.ncbi.nlm.nih.gov/14965246 DMDAO28 DI DMDAO28 DMDAO28 DN 3-Benzyl-3-ethyl-1-phenylazetidine-2,4-dione DMDAO28 TI TTPLTSQ DMDAO28 TN Neutrophil elastase (NE) DMDAO28 MA Inhibitor DMDAO28 RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMDAO28 RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMDAO5T DI DMDAO5T DMDAO5T DN 2-(4-(benzenesulfonyl)phenyl)-1-aminoethane DMDAO5T TI TTJS8PY DMDAO5T TN 5-HT 6 receptor (HTR6) DMDAO5T MA Inhibitor DMDAO5T RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMDAO5T RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMDASC6 DI DMDASC6 DMDASC6 DN Metformin DMDASC6 TI TTKV8W5 DMDASC6 TN HUMAN mannose receptor (MRC1) DMDASC6 MA Inhibitor DMDASC6 RN A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. March 2020 DMDASC6 RU https://www.researchgate.net/publication/340097421_A_SARS-CoV-2-Human_Protein-Protein_Interaction_Map_Reveals_Drug_Targets_and_Potential_Drug-Repurposing DMDB2KJ DI DMDB2KJ DMDB2KJ DN CGS-19281A DMDB2KJ TI TTGP7BY DMDB2KJ TN Monoamine oxidase type B (MAO-B) DMDB2KJ MA Inhibitor DMDB2KJ RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DMDB2KJ RU https://pubmed.ncbi.nlm.nih.gov/15013010 DMDB2KJ DI DMDB2KJ DMDB2KJ DN CGS-19281A DMDB2KJ TI TT3WG5C DMDB2KJ TN Monoamine oxidase type A (MAO-A) DMDB2KJ MA Inhibitor DMDB2KJ RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DMDB2KJ RU https://pubmed.ncbi.nlm.nih.gov/15013010 DMDB3Q8 DI DMDB3Q8 DMDB3Q8 DN Pyz6-D-Trp8-SRIF DMDB3Q8 TI TTAE1BR DMDB3Q8 TN Somatostatin receptor type 4 (SSTR4) DMDB3Q8 MA Inhibitor DMDB3Q8 RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DMDB3Q8 RU https://pubmed.ncbi.nlm.nih.gov/15943475 DMDB3Q8 DI DMDB3Q8 DMDB3Q8 DN Pyz6-D-Trp8-SRIF DMDB3Q8 TI TTZ6T9E DMDB3Q8 TN Somatostatin receptor type 2 (SSTR2) DMDB3Q8 MA Inhibitor DMDB3Q8 RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DMDB3Q8 RU https://pubmed.ncbi.nlm.nih.gov/15943475 DMDB4LZ DI DMDB4LZ DMDB4LZ DN 2-(3-benzoyl-1H-pyrrol-1-yl)acetic acid DMDB4LZ TI TTFBNVI DMDB4LZ TN Aldose reductase (AKR1B1) DMDB4LZ MA Inhibitor DMDB4LZ RN Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisoste... Bioorg Med Chem. 2010 Mar 15;18(6):2107-2114. DMDB4LZ RU https://pubmed.ncbi.nlm.nih.gov/20189816 DMDB7ZM DI DMDB7ZM DMDB7ZM DN N-Methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide DMDB7ZM TI TTGP7BY DMDB7ZM TN Monoamine oxidase type B (MAO-B) DMDB7ZM MA Inhibitor DMDB7ZM RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMDB7ZM RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMDB9FT DI DMDB9FT DMDB9FT DN PMID30247903-Compound-General structure38 DMDB9FT TI TT23XQV DMDB9FT TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMDB9FT MA Inhibitor DMDB9FT RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMDB9FT RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMDBC1K DI DMDBC1K DMDBC1K DN 4-Propyl-1-[3-(phenylpropoxy)propyl]piperidine DMDBC1K TI TT9JNIC DMDBC1K TN Histamine H3 receptor (H3R) DMDBC1K MA Inhibitor DMDBC1K RN Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36. DMDBC1K RU https://pubmed.ncbi.nlm.nih.gov/18774720 DMDBERC DI DMDBERC DMDBERC DN KNI-10125 DMDBERC TI TTXMNHO DMDBERC TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMDBERC MA Inhibitor DMDBERC RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMDBERC RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMDBHY1 DI DMDBHY1 DMDBHY1 DN (S)-1-(4-methoxyphenethyl)-2-methylpyrrolidine DMDBHY1 TI TT9JNIC DMDBHY1 TN Histamine H3 receptor (H3R) DMDBHY1 MA Inhibitor DMDBHY1 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMDBHY1 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMDBI5S DI DMDBI5S DMDBI5S DN Octane-1-sulfonyl fluoride DMDBI5S TI TTDP1UC DMDBI5S TN Fatty acid amide hydrolase (FAAH) DMDBI5S MA Inhibitor DMDBI5S RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DMDBI5S RU https://pubmed.ncbi.nlm.nih.gov/18752948 DMDBI5S DI DMDBI5S DMDBI5S DN Octane-1-sulfonyl fluoride DMDBI5S TI TT6OEDT DMDBI5S TN Cannabinoid receptor 1 (CB1) DMDBI5S MA Inhibitor DMDBI5S RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DMDBI5S RU https://pubmed.ncbi.nlm.nih.gov/18752948 DMDBJCY DI DMDBJCY DMDBJCY DN 3-hydroxy-4-methyl-6H-benzo[c]chromen-6-one DMDBJCY TI TTOM3J0 DMDBJCY TN Estrogen receptor beta (ESR2) DMDBJCY MA Inhibitor DMDBJCY RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMDBJCY RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMDBLGQ DI DMDBLGQ DMDBLGQ DN SBTI DMDBLGQ TI TT5T3P6 DMDBLGQ TN Tissue kallikrein (KLK1) DMDBLGQ MA Inhibitor DMDBLGQ RN Expression and characterization of human tissue kallikrein variants. Protein Expr Purif. 1998 Apr;12(3):361-70. DMDBLGQ RU https://pubmed.ncbi.nlm.nih.gov/9535704 DMDBO89 DI DMDBO89 DMDBO89 DN FA-70 DMDBO89 TI TT3WG5C DMDBO89 TN Monoamine oxidase type A (MAO-A) DMDBO89 MA Inhibitor DMDBO89 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2489). DMDBO89 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2489 DMDBOJ5 DI DMDBOJ5 DMDBOJ5 DN 3,4,5-Trimethoxy-4'-amino-trans-stilbene DMDBOJ5 TI TTSZLWK DMDBOJ5 TN Aromatase (CYP19A1) DMDBOJ5 MA Inhibitor DMDBOJ5 RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMDBOJ5 RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMDBOJ5 DI DMDBOJ5 DMDBOJ5 DN 3,4,5-Trimethoxy-4'-amino-trans-stilbene DMDBOJ5 TI TTJLP0R DMDBOJ5 TN Quinone reductase 2 (NQO2) DMDBOJ5 MA Inhibitor DMDBOJ5 RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMDBOJ5 RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMDBU7Q DI DMDBU7Q DMDBU7Q DN D[Leu4,Lys8]VP DMDBU7Q TI TTK8R02 DMDBU7Q TN Vasopressin V2 receptor (V2R) DMDBU7Q MA Inhibitor DMDBU7Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMDBU7Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMDBU7Q DI DMDBU7Q DMDBU7Q DN D[Leu4,Lys8]VP DMDBU7Q TI TT4TFGN DMDBU7Q TN Vasopressin V1a receptor (V1AR) DMDBU7Q MA Inhibitor DMDBU7Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMDBU7Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMDBU7Q DI DMDBU7Q DMDBU7Q DN D[Leu4,Lys8]VP DMDBU7Q TI TTSCIUP DMDBU7Q TN Oxytocin receptor (OTR) DMDBU7Q MA Inhibitor DMDBU7Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMDBU7Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMDBU7Q DI DMDBU7Q DMDBU7Q DN D[Leu4,Lys8]VP DMDBU7Q TI TTL9MHW DMDBU7Q TN Vasopressin V1b receptor (V1BR) DMDBU7Q MA Inhibitor DMDBU7Q RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMDBU7Q RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMDBUXR DI DMDBUXR DMDBUXR DN TKP-1001 DMDBUXR TI TTE4KHA DMDBUXR TN Amyloid beta A4 protein (APP) DMDBUXR MA Modulator DMDBUXR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMDBUXR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMDBWT6 DI DMDBWT6 DMDBWT6 DN Abbott 14c DMDBWT6 TI TTWDC17 DMDBWT6 TN Growth hormone secretagogue receptor 1 (GHSR) DMDBWT6 MA Antagonist DMDBWT6 RN Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists. J Med Chem. 2006 Jul 27;49(15):4459-69. DMDBWT6 RU https://pubmed.ncbi.nlm.nih.gov/16854051 DMDBZGP DI DMDBZGP DMDBZGP DN PNRI-299 DMDBZGP TI TTN3GBV DMDBZGP TN Transcription factor AP-1 (JUN) DMDBZGP MA Inhibitor DMDBZGP RN Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1169-73. DMDBZGP RU https://pubmed.ncbi.nlm.nih.gov/12552119 DMDC1B4 DI DMDC1B4 DMDC1B4 DN RS-30199 DMDC1B4 TI TTSQIFT DMDC1B4 TN 5-HT 1A receptor (HTR1A) DMDC1B4 MA Modulator (allosteric modulator) DMDC1B4 RN Interaction of the anxiogenic agent, RS-30199, with 5-HT1A receptors: modulation of sexual activity in the male rat. Neuropharmacology. 1998 Jun;37(6):769-80. DMDC1B4 RU https://pubmed.ncbi.nlm.nih.gov/9707291 DMDC297 DI DMDC297 DMDC297 DN (R)-1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine DMDC297 TI TTJQOD7 DMDC297 TN 5-HT 2A receptor (HTR2A) DMDC297 MA Inhibitor DMDC297 RN Novel benzodifuran analogs as potent 5-HT2A receptor agonists with ocular hypotensive activity. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2998-3002. DMDC297 RU https://pubmed.ncbi.nlm.nih.gov/17419053 DMDC4HY DI DMDC4HY DMDC4HY DN Ro 28-2653 DMDC4HY TI TT6X50U DMDC4HY TN Matrix metalloproteinase-9 (MMP-9) DMDC4HY MA Inhibitor DMDC4HY RN The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene. 2002 Mar 27;21(13):2089-96. DMDC4HY RU https://pubmed.ncbi.nlm.nih.gov/11960381 DMDC6XP DI DMDC6XP DMDC6XP DN 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine DMDC6XP TI TTM2AOE DMDC6XP TN Adenosine A2a receptor (ADORA2A) DMDC6XP MA Inhibitor DMDC6XP RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMDC6XP RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMDC6XP DI DMDC6XP DMDC6XP DN 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine DMDC6XP TI TTK25J1 DMDC6XP TN Adenosine A1 receptor (ADORA1) DMDC6XP MA Inhibitor DMDC6XP RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMDC6XP RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMDC6XP DI DMDC6XP DMDC6XP DN 2-Phenyl-1H-imidazo[4,5-c]quinolin-4-ylamine DMDC6XP TI TTNE7KG DMDC6XP TN Adenosine A2b receptor (ADORA2B) DMDC6XP MA Inhibitor DMDC6XP RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMDC6XP RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMDC71B DI DMDC71B DMDC71B DN AcAsp-D-Glu-Leu-Glu-Cha-Cys DMDC71B TI TTWXB3E DMDC71B TN Hepatitis C virus NS3 helicase (HCV NS3) DMDC71B MA Inhibitor DMDC71B RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMDC71B RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMDC7MT DI DMDC7MT DMDC7MT DN Bu-RYYRIK-NH2 DMDC7MT TI TTNT7K8 DMDC7MT TN Nociceptin receptor (OPRL1) DMDC7MT MA Inhibitor DMDC7MT RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMDC7MT RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMDC7TL DI DMDC7TL DMDC7TL DN 4-benzyloxy-2'-hydroxychalcone DMDC7TL TI TTVKILB DMDC7TL TN Prostaglandin G/H synthase 2 (COX-2) DMDC7TL MA Inhibitor DMDC7TL RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DMDC7TL RU https://pubmed.ncbi.nlm.nih.gov/19233646 DMDC84U DI DMDC84U DMDC84U DN (4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine DMDC84U TI TTF10I9 DMDC84U TN Nitric-oxide synthase inducible (NOS2) DMDC84U MA Inhibitor DMDC84U RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMDC84U RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMDCE1M DI DMDCE1M DMDCE1M DN 5,6,8-trichloroquinoline-4-one-3-carboxylic acid DMDCE1M TI TTER6YH DMDCE1M TN Casein kinase II alpha (CSNK2A1) DMDCE1M MA Inhibitor DMDCE1M RN Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem. 2006 Nov 2;49(22):6443-50. DMDCE1M RU https://pubmed.ncbi.nlm.nih.gov/17064064 DMDCJWU DI DMDCJWU DMDCJWU DN Tyr-Pro-3,5Dmp-Phe-NH2 DMDCJWU TI TTKWM86 DMDCJWU TN Opioid receptor mu (MOP) DMDCJWU MA Inhibitor DMDCJWU RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMDCJWU RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMDCJWU DI DMDCJWU DMDCJWU DN Tyr-Pro-3,5Dmp-Phe-NH2 DMDCJWU TI TT27RFC DMDCJWU TN Opioid receptor delta (OPRD1) DMDCJWU MA Inhibitor DMDCJWU RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMDCJWU RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMDCNZE DI DMDCNZE DMDCNZE DN 5-(4-Chloro-benzyl)-1H-pyrazole-3-carboxylic acid DMDCNZE TI TTWNV8U DMDCNZE TN Nicotinic acid receptor (HCAR2) DMDCNZE MA Inhibitor DMDCNZE RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMDCNZE RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMDCPFJ DI DMDCPFJ DMDCPFJ DN NNC-26-0194 DMDCPFJ TI TTKMAZ6 DMDCPFJ TN Growth hormone receptor (GHR) DMDCPFJ MA Modulator DMDCPFJ RN Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica. 1998 Nov;28(11):1083-92. DMDCPFJ RU https://www.ncbi.nlm.nih.gov/pubmed/9879640 DMDCQAX DI DMDCQAX DMDCQAX DN 4-amino-3,5-dibromobenzenesulfonamide DMDCQAX TI TTUNARX DMDCQAX TN Carbonic anhydrase (CA) DMDCQAX MA Inhibitor DMDCQAX RN Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. DMDCQAX RU https://pubmed.ncbi.nlm.nih.gov/17826101 DMDCTNU DI DMDCTNU DMDCTNU DN Phenyl-(3-phenyl-1H-indazol-6-yl)-amine DMDCTNU TI TTQBR95 DMDCTNU TN Stress-activated protein kinase 2a (p38 alpha) DMDCTNU MA Inhibitor DMDCTNU RN Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9. DMDCTNU RU https://pubmed.ncbi.nlm.nih.gov/16140012 DMDCTNU DI DMDCTNU DMDCTNU DN Phenyl-(3-phenyl-1H-indazol-6-yl)-amine DMDCTNU TI TT056SO DMDCTNU TN Stress-activated protein kinase JNK3 (JNK3) DMDCTNU MA Inhibitor DMDCTNU RN Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett. 2005 Nov 15;15(22):5095-9. DMDCTNU RU https://pubmed.ncbi.nlm.nih.gov/16140012 DMDCUYB DI DMDCUYB DMDCUYB DN PMID21273063C58 DMDCUYB TI TT7QNVC DMDCUYB TN Glucose-dependent insulinotropic receptor (GPR119) DMDCUYB MA Agonist DMDCUYB RN Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9. DMDCUYB RU https://pubmed.ncbi.nlm.nih.gov/21273063 DMDCX5O DI DMDCX5O DMDCX5O DN N-(6-(2-chlorophenyl)-1H-indazol-3-yl)butyramide DMDCX5O TI TTRSMW9 DMDCX5O TN Glycogen synthase kinase-3 beta (GSK-3B) DMDCX5O MA Inhibitor DMDCX5O RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMDCX5O RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMDE3J1 DI DMDE3J1 DMDE3J1 DN ISIS 24454 DMDE3J1 TI TTJMF9P DMDE3J1 TN ITGA4 messenger RNA (ITGA4 mRNA) DMDE3J1 RN US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression. DMDE3J1 RU http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true DMDE7XJ DI DMDE7XJ DMDE7XJ DN 5,6-Cyclic-Tetrahydropteridine DMDE7XJ TI TTCM4B3 DMDE7XJ TN Nitric-oxide synthase endothelial (NOS3) DMDE7XJ MA Inhibitor DMDE7XJ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMDE7XJ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMDE8YS DI DMDE8YS DMDE8YS DN TW-37 DMDE8YS TI TTJGNVC DMDE8YS TN Apoptosis regulator Bcl-2 (BCL-2) DMDE8YS MA Inhibitor DMDE8YS RN Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. DMDE8YS RU https://pubmed.ncbi.nlm.nih.gov/17034116 DMDE8YS DI DMDE8YS DMDE8YS DN TW-37 DMDE8YS TI TTL53M6 DMDE8YS TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMDE8YS MA Inhibitor DMDE8YS RN Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. DMDE8YS RU https://pubmed.ncbi.nlm.nih.gov/17034116 DMDE8YS DI DMDE8YS DMDE8YS DN TW-37 DMDE8YS TI TTRE6AX DMDE8YS TN Bcl-x messenger RNA (BCL2L1 mRNA) DMDE8YS MA Inhibitor DMDE8YS RN Fragment-based deconstruction of Bcl-xL inhibitors. J Med Chem. 2010 Mar 25;53(6):2577-88. DMDE8YS RU https://pubmed.ncbi.nlm.nih.gov/20192224 DMDEAWS DI DMDEAWS DMDEAWS DN Gababutin DMDEAWS TI TTFK1JQ DMDEAWS TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMDEAWS MA Inhibitor DMDEAWS RN Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5. DMDEAWS RU https://pubmed.ncbi.nlm.nih.gov/19897364 DMDEFPS DI DMDEFPS DMDEFPS DN AcPYY(22-36) DMDEFPS TI TTRK9JT DMDEFPS TN Neuropeptide Y receptor type 1 (NPY1R) DMDEFPS MA Inhibitor DMDEFPS RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DMDEFPS RU https://pubmed.ncbi.nlm.nih.gov/17055726 DMDEFPS DI DMDEFPS DMDEFPS DN AcPYY(22-36) DMDEFPS TI TTJ6WK9 DMDEFPS TN Neuropeptide Y receptor type 2 (NPY2R) DMDEFPS MA Inhibitor DMDEFPS RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DMDEFPS RU https://pubmed.ncbi.nlm.nih.gov/17055726 DMDEI9X DI DMDEI9X DMDEI9X DN ISIS 104254 DMDEI9X TI TTCQ2E5 DMDEI9X TN RIP2 messenger RNA (RIP2 mRNA) DMDEI9X RN US patent application no. 6,426,221, Antisense modulation of RIP2 expression. DMDEI9X RU http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true DMDEJS6 DI DMDEJS6 DMDEJS6 DN FGGFTGARKSARKLVNQ DMDEJS6 TI TTNT7K8 DMDEJS6 TN Nociceptin receptor (OPRL1) DMDEJS6 MA Inhibitor DMDEJS6 RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMDEJS6 RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMDEMV8 DI DMDEMV8 DMDEMV8 DN 4-Hydroxy-3-nonanoyl-6-octyl-pyran-2-one DMDEMV8 TI TTPLTSQ DMDEMV8 TN Neutrophil elastase (NE) DMDEMV8 MA Inhibitor DMDEMV8 RN Inhibition of human sputum elastase by substituted 2-pyrones. J Med Chem. 1987 Jun;30(6):1017-23. DMDEMV8 RU https://pubmed.ncbi.nlm.nih.gov/3647139 DMDENVF DI DMDENVF DMDENVF DN 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline DMDENVF TI TTI7421 DMDENVF TN Platelet-derived growth factor receptor beta (PDGFRB) DMDENVF MA Inhibitor DMDENVF RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMDENVF RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMDENVF DI DMDENVF DMDENVF DN 6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline DMDENVF TI TT8FYO9 DMDENVF TN Platelet-derived growth factor receptor alpha (PDGFRA) DMDENVF MA Inhibitor DMDENVF RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMDENVF RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMDEV64 DI DMDEV64 DMDEV64 DN 3-Propoxy-9H-beta-carboline DMDEV64 TI TT1MPAY DMDEV64 TN GABA(A) receptor alpha-1 (GABRA1) DMDEV64 MA Inhibitor DMDEV64 RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMDEV64 RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMDEV64 DI DMDEV64 DMDEV64 DN 3-Propoxy-9H-beta-carboline DMDEV64 TI TTNJYV2 DMDEV64 TN Gamma-aminobutyric acid receptor (GAR) DMDEV64 MA Inhibitor DMDEV64 RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMDEV64 RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMDEV64 DI DMDEV64 DMDEV64 DN 3-Propoxy-9H-beta-carboline DMDEV64 TI TTBMV1G DMDEV64 TN GABA(A) receptor alpha-2 (GABRA2) DMDEV64 MA Inhibitor DMDEV64 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDEV64 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDEV64 DI DMDEV64 DMDEV64 DN 3-Propoxy-9H-beta-carboline DMDEV64 TI TT37EDJ DMDEV64 TN GABA(A) receptor alpha-3 (GABRA3) DMDEV64 MA Inhibitor DMDEV64 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDEV64 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDEV64 DI DMDEV64 DMDEV64 DN 3-Propoxy-9H-beta-carboline DMDEV64 TI TT06RH5 DMDEV64 TN GABA(A) receptor gamma-2 (GABRG2) DMDEV64 MA Inhibitor DMDEV64 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDEV64 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDEV64 DI DMDEV64 DMDEV64 DN 3-Propoxy-9H-beta-carboline DMDEV64 TI TTNZPQ1 DMDEV64 TN GABA(A) receptor alpha-5 (GABRA5) DMDEV64 MA Inhibitor DMDEV64 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDEV64 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDF0KZ DI DMDF0KZ DMDF0KZ DN L-659,699 DMDF0KZ TI TTQF4TK DMDF0KZ TN Hydroxymethylglutaryl-CoA synthase 1 (HMGCS1) DMDF0KZ MA Inhibitor DMDF0KZ RN Inhibition of 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis by beta-lactone inhibitors and binding of these inhibitors to the enzyme. Biochem J. 1993 Feb 1;289 ( Pt 3):889-95. DMDF0KZ RU https://pubmed.ncbi.nlm.nih.gov/8094614 DMDF26N DI DMDF26N DMDF26N DN Isoquinolin-1-yl-(3-phenyl-propyl)-amine DMDF26N TI TT64EPS DMDF26N TN Fungal Scytalone dehydratase (Fung SDH1) DMDF26N MA Inhibitor DMDF26N RN A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase, Bioorg. Med. Chem. Lett. 3(8):1605-1608 (1993). DMDF26N RU http://www.sciencedirect.com/science/article/pii/S0960894X00800268 DMDF2U3 DI DMDF2U3 DMDF2U3 DN VU0001171 DMDF2U3 TI TTICZ1O DMDF2U3 TN Metabotropic glutamate receptor 4 (mGluR4) DMDF2U3 MA Modulator (allosteric modulator) DMDF2U3 RN Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett. 2009 Feb 1;19(3):962-6. DMDF2U3 RU https://pubmed.ncbi.nlm.nih.gov/19097893 DMDF3KJ DI DMDF3KJ DMDF3KJ DN 4beta,15-epoxy-miller-9E-enolide DMDF3KJ TI TTSXVID DMDF3KJ TN Nuclear factor NF-kappa-B (NFKB) DMDF3KJ MA Inhibitor DMDF3KJ RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMDF3KJ RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMDF6WG DI DMDF6WG DMDF6WG DN MRS5698 DMDF6WG TI TTJFY5U DMDF6WG TN Adenosine A3 receptor (ADORA3) DMDF6WG MA Agonist DMDF6WG RN Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem. 2012 May 24;55(10):4847-60. DMDF6WG RU https://pubmed.ncbi.nlm.nih.gov/22559880 DMDF7M4 DI DMDF7M4 DMDF7M4 DN (E)-4-(2-(furan-2-yl)vinyl)benzenesulfonamide DMDF7M4 TI TTVKILB DMDF7M4 TN Prostaglandin G/H synthase 2 (COX-2) DMDF7M4 MA Inhibitor DMDF7M4 RN Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41. DMDF7M4 RU https://pubmed.ncbi.nlm.nih.gov/20970329 DMDF9AS DI DMDF9AS DMDF9AS DN H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 DMDF9AS TI TTKWM86 DMDF9AS TN Opioid receptor mu (MOP) DMDF9AS MA Inhibitor DMDF9AS RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMDF9AS RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMDF9AS DI DMDF9AS DMDF9AS DN H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 DMDF9AS TI TTZPO1L DMDF9AS TN Substance-P receptor (TACR1) DMDF9AS MA Inhibitor DMDF9AS RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMDF9AS RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMDF9AS DI DMDF9AS DMDF9AS DN H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 DMDF9AS TI TT27RFC DMDF9AS TN Opioid receptor delta (OPRD1) DMDF9AS MA Inhibitor DMDF9AS RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMDF9AS RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMDFBSX DI DMDFBSX DMDFBSX DN 1,8-Dihydroxy-2-propionyl-10H-anthracen-9-one DMDFBSX TI TT2J34L DMDFBSX TN Arachidonate 5-lipoxygenase (5-LOX) DMDFBSX MA Inhibitor DMDFBSX RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMDFBSX RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMDFE1R DI DMDFE1R DMDFE1R DN (E)-2-(4-(methylsulfonyl)styryl)thiophene DMDFE1R TI TTVKILB DMDFE1R TN Prostaglandin G/H synthase 2 (COX-2) DMDFE1R MA Inhibitor DMDFE1R RN Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41. DMDFE1R RU https://pubmed.ncbi.nlm.nih.gov/20970329 DMDFHCU DI DMDFHCU DMDFHCU DN 3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid DMDFHCU TI TTTSEPU DMDFHCU TN Thyroid hormone receptor alpha (THRA) DMDFHCU MA Inhibitor DMDFHCU RN Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7. DMDFHCU RU https://pubmed.ncbi.nlm.nih.gov/15857115 DMDFHCU DI DMDFHCU DMDFHCU DN 3-(3,5-Dibromo-4-hexyloxy-phenyl)-propionic acid DMDFHCU TI TTGER3L DMDFHCU TN Thyroid hormone receptor beta (THRB) DMDFHCU MA Inhibitor DMDFHCU RN Thyroid receptor ligands. 3. Design and synthesis of 3,5-dihalo-4-alkoxyphenylalkanoic acids as indirect antagonists of the thyroid hormone receptor. J Med Chem. 2005 May 5;48(9):3114-7. DMDFHCU RU https://pubmed.ncbi.nlm.nih.gov/15857115 DMDFKU3 DI DMDFKU3 DMDFKU3 DN Ac-I[CV(Bpa)QDWGAHRC]T DMDFKU3 TI TTJGY7A DMDFKU3 TN Complement C3 (CO3) DMDFKU3 MA Inhibitor DMDFKU3 RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMDFKU3 RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMDFPGB DI DMDFPGB DMDFPGB DN 2'-Me-CCPA DMDFPGB TI TTJFY5U DMDFPGB TN Adenosine A3 receptor (ADORA3) DMDFPGB MA Agonist DMDFPGB RN 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. J Med Chem. 1998 May 7;41(10):1708-15. DMDFPGB RU https://pubmed.ncbi.nlm.nih.gov/9572897 DMDFQ0Y DI DMDFQ0Y DMDFQ0Y DN bombesin DMDFQ0Y TI TTC1MVT DMDFQ0Y TN Gastrin-releasing peptide receptor (GRPR) DMDFQ0Y MA Agonist DMDFQ0Y RN Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20. DMDFQ0Y RU https://pubmed.ncbi.nlm.nih.gov/7838118 DMDFQ0Y DI DMDFQ0Y DMDFQ0Y DN bombesin DMDFQ0Y TI TTHYDUM DMDFQ0Y TN Bombesin receptor (BS) DMDFQ0Y MA Agonist DMDFQ0Y RN Expression and characterization of cloned human bombesin receptors. Mol Pharmacol. 1995 Jan;47(1):10-20. DMDFQ0Y RU https://pubmed.ncbi.nlm.nih.gov/7838118 DMDFR59 DI DMDFR59 DMDFR59 DN (+)-cis-H2-PAT DMDFR59 TI TTTIBOJ DMDFR59 TN Histamine H1 receptor (H1R) DMDFR59 MA Antagonist DMDFR59 RN A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36. DMDFR59 RU https://pubmed.ncbi.nlm.nih.gov/12065734 DMDFRTI DI DMDFRTI DMDFRTI DN Deamido-NAD DMDFRTI TI TT1NFO3 DMDFRTI TN Bacterial Nicotinate-nucleotide adenylyltransferase (Bact nadD) DMDFRTI MA Binder DMDFRTI RN Crystal structures of E. coli nicotinate mononucleotide adenylyltransferase and its complex with deamido-NAD. Structure. 2002 Jan;10(1):69-79. DMDFRTI RU https://pubmed.ncbi.nlm.nih.gov/11796112 DMDFU6S DI DMDFU6S DMDFU6S DN 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane DMDFU6S TI TTJQOD7 DMDFU6S TN 5-HT 2A receptor (HTR2A) DMDFU6S MA Inhibitor DMDFU6S RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMDFU6S RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMDFU6S DI DMDFU6S DMDFU6S DN 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane DMDFU6S TI TTSQIFT DMDFU6S TN 5-HT 1A receptor (HTR1A) DMDFU6S MA Inhibitor DMDFU6S RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMDFU6S RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMDFU6S DI DMDFU6S DMDFU6S DN 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane DMDFU6S TI TTEX248 DMDFU6S TN Dopamine D2 receptor (D2R) DMDFU6S MA Inhibitor DMDFU6S RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMDFU6S RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMDFU6S DI DMDFU6S DMDFU6S DN 1,6-bis(4-(3-chlorophenyl)piperazin-1-yl)hexane DMDFU6S TI TTQ6VDM DMDFU6S TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMDFU6S MA Inhibitor DMDFU6S RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMDFU6S RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMDFUS8 DI DMDFUS8 DMDFUS8 DN ISIS 156473 DMDFUS8 TI TTILUKB DMDFUS8 TN IRAK4 messenger RNA (IRAK4 mRNA) DMDFUS8 RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMDFUS8 RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMDFYJR DI DMDFYJR DMDFYJR DN 2-(2-Aminoethyl)anthra[1,9-cd]pyrazol-6(2H)-one DMDFYJR TI TT0IHXV DMDFYJR TN DNA topoisomerase II (TOP2) DMDFYJR MA Inhibitor DMDFYJR RN Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer... Bioorg Med Chem. 2010 Jun 1;18(11):3974-84. DMDFYJR RU https://pubmed.ncbi.nlm.nih.gov/20471276 DMDG0HK DI DMDG0HK DMDG0HK DN Tormentic acid methyl ester DMDG0HK TI TTN7BL9 DMDG0HK TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMDG0HK MA Inhibitor DMDG0HK RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DMDG0HK RU https://pubmed.ncbi.nlm.nih.gov/20100662 DMDG1ZX DI DMDG1ZX DMDG1ZX DN FVATDVGPFAF DMDG1ZX TI TTY6O0Q DMDG1ZX TN Calcitonin gene-related peptide receptor (CGRPR) DMDG1ZX MA Inhibitor DMDG1ZX RN Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24. DMDG1ZX RU https://pubmed.ncbi.nlm.nih.gov/16420047 DMDG2Y9 DI DMDG2Y9 DMDG2Y9 DN CPPHA DMDG2Y9 TI TTHS256 DMDG2Y9 TN Metabotropic glutamate receptor 5 (mGluR5) DMDG2Y9 MA Modulator (allosteric modulator) DMDG2Y9 RN A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J Pharmacol Exp Ther. 2004 May;309(2):568-77. DMDG2Y9 RU https://pubmed.ncbi.nlm.nih.gov/14747613 DMDG59X DI DMDG59X DMDG59X DN N6-methoxy-2-phenylethynyladenosine DMDG59X TI TTJFY5U DMDG59X TN Adenosine A3 receptor (ADORA3) DMDG59X MA Inhibitor DMDG59X RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMDG59X RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMDG59X DI DMDG59X DMDG59X DN N6-methoxy-2-phenylethynyladenosine DMDG59X TI TTM2AOE DMDG59X TN Adenosine A2a receptor (ADORA2A) DMDG59X MA Inhibitor DMDG59X RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMDG59X RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMDG59X DI DMDG59X DMDG59X DN N6-methoxy-2-phenylethynyladenosine DMDG59X TI TTK25J1 DMDG59X TN Adenosine A1 receptor (ADORA1) DMDG59X MA Inhibitor DMDG59X RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMDG59X RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMDG8FL DI DMDG8FL DMDG8FL DN 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran DMDG8FL TI TTAWNKZ DMDG8FL TN Norepinephrine transporter (NET) DMDG8FL MA Inhibitor DMDG8FL RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMDG8FL RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMDG8FL DI DMDG8FL DMDG8FL DN 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran DMDG8FL TI TT3ROYC DMDG8FL TN Serotonin transporter (SERT) DMDG8FL MA Inhibitor DMDG8FL RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMDG8FL RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMDG8FL DI DMDG8FL DMDG8FL DN 2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran DMDG8FL TI TTVBI8W DMDG8FL TN Dopamine transporter (DAT) DMDG8FL MA Inhibitor DMDG8FL RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMDG8FL RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMDGAHO DI DMDGAHO DMDGAHO DN 2-(phenylsulfonamido)-5-propylbenzoic acid DMDGAHO TI TTZL0OI DMDGAHO TN Methionine aminopeptidase 2 (METAP2) DMDGAHO MA Inhibitor DMDGAHO RN Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. DMDGAHO RU https://pubmed.ncbi.nlm.nih.gov/16632353 DMDGFS0 DI DMDGFS0 DMDGFS0 DN (3-Amino-phenyl)-phosphonic acid diphenyl ester DMDGFS0 TI TTDCVZW DMDGFS0 TN Gamma-aminobutyric acid B receptor (GABBR) DMDGFS0 MA Inhibitor DMDGFS0 RN Phosphorus analogues of gamma-aminobutyric acid, a new class of anticonvulsants. J Med Chem. 1984 May;27(5):654-9. DMDGFS0 RU https://pubmed.ncbi.nlm.nih.gov/6325692 DMDGIT6 DI DMDGIT6 DMDGIT6 DN Diaminopropyl sulfate DMDGIT6 TI TT6LDTK DMDGIT6 TN Bacterial Glutamate-1-semialdehyde aminomutase (Bact hemL) DMDGIT6 MA Inhibitor DMDGIT6 RN Reactions of glutamate 1-semialdehyde aminomutase with R- and S-enantiomers of a novel, mechanism-based inhibitor, 2,3-diaminopropyl sulfate. Biochemistry. 2000 Mar 21;39(11):3091-6. DMDGIT6 RU https://pubmed.ncbi.nlm.nih.gov/10715130 DMDGKFV DI DMDGKFV DMDGKFV DN 4-Hydroxy-pentanoic acid DMDGKFV TI TT6TKEN DMDGKFV TN Gamma-hydroxybutyrate receptor (SLC52A2) DMDGKFV MA Inhibitor DMDGKFV RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DMDGKFV RU https://pubmed.ncbi.nlm.nih.gov/3361576 DMDGPY9 DI DMDGPY9 DMDGPY9 DN Linoleic acid DMDGPY9 TI TTHWMFZ DMDGPY9 TN Fatty acid-binding protein 4 (FABP4) DMDGPY9 MA Inhibitor DMDGPY9 RN Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3675-9. DMDGPY9 RU https://pubmed.ncbi.nlm.nih.gov/20471252 DMDGRWM DI DMDGRWM DMDGRWM DN 2-(3,4-dimethylphenyl)-1,8-naphthyridine DMDGRWM TI TTHS256 DMDGRWM TN Metabotropic glutamate receptor 5 (mGluR5) DMDGRWM MA Inhibitor DMDGRWM RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMDGRWM RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMDGUEK DI DMDGUEK DMDGUEK DN P-tolyl 10H-phenothiazine-10-carboxylate DMDGUEK TI TTEB0GD DMDGUEK TN Cholinesterase (BCHE) DMDGUEK MA Inhibitor DMDGUEK RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMDGUEK RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMDGWAY DI DMDGWAY DMDGWAY DN 1-Cyclopentylidenethiosemicarbazide DMDGWAY TI TTULVH8 DMDGWAY TN Tyrosinase (TYR) DMDGWAY MA Inhibitor DMDGWAY RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMDGWAY RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMDH5B3 DI DMDH5B3 DMDH5B3 DN Ac-YRMEHdFRWGSPPKD-NH2 DMDH5B3 TI TT0MV2T DMDH5B3 TN Melanocortin receptor 1 (MC1R) DMDH5B3 MA Inhibitor DMDH5B3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMDH5B3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMDH5B3 DI DMDH5B3 DMDH5B3 DN Ac-YRMEHdFRWGSPPKD-NH2 DMDH5B3 TI TTD0CIQ DMDH5B3 TN Melanocortin receptor 4 (MC4R) DMDH5B3 MA Inhibitor DMDH5B3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMDH5B3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMDH5B3 DI DMDH5B3 DMDH5B3 DN Ac-YRMEHdFRWGSPPKD-NH2 DMDH5B3 TI TTNI91K DMDH5B3 TN Melanocortin receptor 3 (MC3R) DMDH5B3 MA Inhibitor DMDH5B3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMDH5B3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMDH5B3 DI DMDH5B3 DMDH5B3 DN Ac-YRMEHdFRWGSPPKD-NH2 DMDH5B3 TI TTEOSZT DMDH5B3 TN Melanocortin receptor (MCR) DMDH5B3 MA Inhibitor DMDH5B3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMDH5B3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMDH5EJ DI DMDH5EJ DMDH5EJ DN AcAsp-Glu-Cha-Val-Prb-Cys DMDH5EJ TI TTWXB3E DMDH5EJ TN Hepatitis C virus NS3 helicase (HCV NS3) DMDH5EJ MA Inhibitor DMDH5EJ RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMDH5EJ RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMDH6PJ DI DMDH6PJ DMDH6PJ DN CVT-10216 DMDH6PJ TI TTFLN4T DMDH6PJ TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMDH6PJ MA Antagonist DMDH6PJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2595). DMDH6PJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2595 DMDH943 DI DMDH943 DMDH943 DN ISIS 25115 DMDH943 TI TT8H9GB DMDH943 TN MEK2 messenger RNA (MEK2 mRNA) DMDH943 RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMDH943 RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMDHFU9 DI DMDHFU9 DMDHFU9 DN 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine DMDHFU9 TI TTJQOD7 DMDHFU9 TN 5-HT 2A receptor (HTR2A) DMDHFU9 MA Inhibitor DMDHFU9 RN 4-(3-furyl)-2-(4-methylpiperazino)pyrimidines: Potent 5-HT2A receptor antagonists, Bioorg. Med. Chem. Lett. 7(13):1635-1638 (1997). DMDHFU9 RU http://www.sciencedirect.com/science/article/pii/S0960894X97002916 DMDHFU9 DI DMDHFU9 DMDHFU9 DN 2-(4-Methyl-piperazin-1-yl)-4-phenyl-pyrimidine DMDHFU9 TI TTSQIFT DMDHFU9 TN 5-HT 1A receptor (HTR1A) DMDHFU9 MA Inhibitor DMDHFU9 RN 4-(3-furyl)-2-(4-methylpiperazino)pyrimidines: Potent 5-HT2A receptor antagonists, Bioorg. Med. Chem. Lett. 7(13):1635-1638 (1997). DMDHFU9 RU http://www.sciencedirect.com/science/article/pii/S0960894X97002916 DMDHGIR DI DMDHGIR DMDHGIR DN (-)-yatein DMDHGIR TI TTXV4FI DMDHGIR TN Albendazole monooxygenase (CYP3A4) DMDHGIR MA Inhibitor DMDHGIR RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMDHGIR RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMDHGM2 DI DMDHGM2 DMDHGM2 DN Maackiain DMDHGM2 TI TTF8JAT DMDHGM2 TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMDHGM2 MA Inhibitor DMDHGM2 RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMDHGM2 RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMDHLG3 DI DMDHLG3 DMDHLG3 DN IDD594 DMDHLG3 TI TTFBNVI DMDHLG3 TN Aldose reductase (AKR1B1) DMDHLG3 MA Inhibitor DMDHLG3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMDHLG3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMDHUL8 DI DMDHUL8 DMDHUL8 DN LUF-5833 DMDHUL8 TI TTJFY5U DMDHUL8 TN Adenosine A3 receptor (ADORA3) DMDHUL8 MA Enhancer DMDHUL8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 21). DMDHUL8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=21 DMDHV0N DI DMDHV0N DMDHV0N DN 4-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one DMDHV0N TI TTSZLWK DMDHV0N TN Aromatase (CYP19A1) DMDHV0N MA Inhibitor DMDHV0N RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMDHV0N RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMDHVY0 DI DMDHVY0 DMDHVY0 DN C-(5H-Dibenzo[a,d]cyclohepten-5-yl)-methylamine DMDHVY0 TI TTJQOD7 DMDHVY0 TN 5-HT 2A receptor (HTR2A) DMDHVY0 MA Inhibitor DMDHVY0 RN Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6. DMDHVY0 RU https://pubmed.ncbi.nlm.nih.gov/11229772 DMDHY37 DI DMDHY37 DMDHY37 DN ISIS 23544 DMDHY37 TI TT1F8OQ DMDHY37 TN IKKA messenger RNA (IKKA mRNA) DMDHY37 RN US patent application no. 6,395,545, Antisense modulation of inhibitor-kappa B kinase-alpha expression. DMDHY37 RU http://www.patentbuddy.com/Patent/6395545?ft=true&sr=true DMDHZR1 DI DMDHZR1 DMDHZR1 DN GSK1016790A DMDHZR1 TI TTKP2SU DMDHZR1 TN Transient receptor potential cation channel V4 (TRPV4) DMDHZR1 MA Activator DMDHZR1 RN N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I. J Pharmacol Exp Ther. 2008 Aug;326(2):432-42. DMDHZR1 RU https://pubmed.ncbi.nlm.nih.gov/18499743 DMDI2KH DI DMDI2KH DMDI2KH DN alsterpaullone 2-cyanoethyl DMDI2KH TI TTH6V3D DMDI2KH TN Cyclin-dependent kinase 1 (CDK1) DMDI2KH MA Inhibitor DMDI2KH RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMDI2KH RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMDI2KH DI DMDI2KH DMDI2KH DN alsterpaullone 2-cyanoethyl DMDI2KH TI TTRSMW9 DMDI2KH TN Glycogen synthase kinase-3 beta (GSK-3B) DMDI2KH MA Inhibitor DMDI2KH RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMDI2KH RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMDI32S DI DMDI32S DMDI32S DN 4-[2-(4-Benzylphenoxy)ethyl]pyridine DMDI32S TI TTXZEAJ DMDI32S TN Leukotriene A-4 hydrolase (LTA4H) DMDI32S MA Inhibitor DMDI32S RN Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85. DMDI32S RU https://pubmed.ncbi.nlm.nih.gov/19950900 DMDI98B DI DMDI98B DMDI98B DN 2-(2-Methoxy-phenyl)-1-methyl-ethylamine DMDI98B TI TT6MSOK DMDI98B TN 5-HT 1D receptor (HTR1D) DMDI98B MA Inhibitor DMDI98B RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMDI98B RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMDI98B DI DMDI98B DMDI98B DN 2-(2-Methoxy-phenyl)-1-methyl-ethylamine DMDI98B TI TTSQIFT DMDI98B TN 5-HT 1A receptor (HTR1A) DMDI98B MA Inhibitor DMDI98B RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMDI98B RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMDI98B DI DMDI98B DMDI98B DN 2-(2-Methoxy-phenyl)-1-methyl-ethylamine DMDI98B TI TTJQOD7 DMDI98B TN 5-HT 2A receptor (HTR2A) DMDI98B MA Inhibitor DMDI98B RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMDI98B RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMDIGPW DI DMDIGPW DMDIGPW DN 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid DMDIGPW TI TT6R7JZ DMDIGPW TN Histone deacetylase 1 (HDAC1) DMDIGPW MA Inhibitor DMDIGPW RN Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. DMDIGPW RU https://pubmed.ncbi.nlm.nih.gov/12951120 DMDIGPW DI DMDIGPW DMDIGPW DN 8-(Biphenyl-4-yloxy)-2-oxo-octanoic acid DMDIGPW TI TTSHTOI DMDIGPW TN Histone deacetylase 2 (HDAC2) DMDIGPW MA Inhibitor DMDIGPW RN Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. DMDIGPW RU https://pubmed.ncbi.nlm.nih.gov/12951120 DMDIH07 DI DMDIH07 DMDIH07 DN 1-methylcyclopropanecarboxylic acid DMDIH07 TI TT0FYAN DMDIH07 TN Free fatty acid receptor 2 (FFAR2) DMDIH07 MA Agonist DMDIH07 RN Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40. DMDIH07 RU https://pubmed.ncbi.nlm.nih.gov/21220428 DMDIH07 DI DMDIH07 DMDIH07 DN 1-methylcyclopropanecarboxylic acid DMDIH07 TI TTXDOHN DMDIH07 TN Free fatty acid receptor 3 (FFAR3) DMDIH07 MA Agonist DMDIH07 RN Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40. DMDIH07 RU https://pubmed.ncbi.nlm.nih.gov/21220428 DMDIH96 DI DMDIH96 DMDIH96 DN [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine DMDIH96 TI TTWJBZ5 DMDIH96 TN 5-HT 2C receptor (HTR2C) DMDIH96 MA Inhibitor DMDIH96 RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMDIH96 RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMDIH96 DI DMDIH96 DMDIH96 DN [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine DMDIH96 TI TTJQOD7 DMDIH96 TN 5-HT 2A receptor (HTR2A) DMDIH96 MA Inhibitor DMDIH96 RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMDIH96 RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMDIH96 DI DMDIH96 DMDIH96 DN [2-(4-Fluoro-1H-indol-3-yl)-ethyl]-dimethyl-amine DMDIH96 TI TT0K1SC DMDIH96 TN 5-HT 2B receptor (HTR2B) DMDIH96 MA Inhibitor DMDIH96 RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMDIH96 RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMDINX9 DI DMDINX9 DMDINX9 DN H-KPPR-OH DMDINX9 TI TTIPJCB DMDINX9 TN Neuropilin-1 (NRP1) DMDINX9 MA Inhibitor DMDINX9 RN Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. J Med Chem. 2010 Mar 11;53(5):2215-26. DMDINX9 RU https://pubmed.ncbi.nlm.nih.gov/20151671 DMDIQ7H DI DMDIQ7H DMDIQ7H DN 3-(9-Acridinylamino)-5-(hydroxymethyl)aniline (AHMA) DMDIQ7H TI TT2GPK3 DMDIQ7H TN DNA topoisomerase (TOP) DMDIQ7H MA Inhibitor DMDIQ7H RN Crystallization and preliminary X-ray analysis of anti-cancer agent 3-(9-acridinylamino)-5-(hydroxymethyl)aniline complexed with the DNA hexamer d(CGTACG)2. Biochim Biophys Acta. 2003 Jan 3;1625(1):27-9. DMDIQ7H RU https://pubmed.ncbi.nlm.nih.gov/12527422 DMDITNB DI DMDITNB DMDITNB DN BERGAPTOL DMDITNB TI TTXV4FI DMDITNB TN Albendazole monooxygenase (CYP3A4) DMDITNB MA Inhibitor DMDITNB RN Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit. Bioorg Med Chem. 2007 Jun 1;15(11):3684-91. DMDITNB RU https://pubmed.ncbi.nlm.nih.gov/17400460 DMDIUK6 DI DMDIUK6 DMDIUK6 DN Ac-I[CVWQDWGWHRC]T-NH2 DMDIUK6 TI TTJGY7A DMDIUK6 TN Complement C3 (CO3) DMDIUK6 MA Inhibitor DMDIUK6 RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMDIUK6 RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMDIW08 DI DMDIW08 DMDIW08 DN 6-O-Cyclohexylmethyl Guanine DMDIW08 TI TT7HF4W DMDIW08 TN Cyclin-dependent kinase 2 (CDK2) DMDIW08 MA Inhibitor DMDIW08 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDIW08 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDIW08 DI DMDIW08 DMDIW08 DN 6-O-Cyclohexylmethyl Guanine DMDIW08 TI TTAMQ62 DMDIW08 TN Cyclin A2 (CCNA2) DMDIW08 MA Inhibitor DMDIW08 RN N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J Med Chem. 2004 Jul 15;47(15):3710-22. DMDIW08 RU https://pubmed.ncbi.nlm.nih.gov/15239650 DMDIW1M DI DMDIW1M DMDIW1M DN CBIQ DMDIW1M TI TTRLZHP DMDIW1M TN cAMP-dependent chloride channel (CFTR) DMDIW1M MA Activator DMDIW1M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DMDIW1M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DMDIX40 DI DMDIX40 DMDIX40 DN 2,2-bis-(2-fluorophenyl)-2-phenylacetamide DMDIX40 TI TTMNI76 DMDIX40 TN Calcium-activated potassium channel (KCN) DMDIX40 MA Inhibitor DMDIX40 RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMDIX40 RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMDIYWV DI DMDIYWV DMDIYWV DN S-sulpho-L-cysteine DMDIYWV TI TTQWGU9 DMDIYWV TN Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2) DMDIYWV MA Inhibitor DMDIYWV RN Petrosamine B, an inhibitor of the Helicobacter pylori enzyme aspartyl semialdehyde dehydrogenase from the Australian sponge Oceanapia sp. J Nat Prod. 2005 May;68(5):804-6. DMDIYWV RU https://pubmed.ncbi.nlm.nih.gov/15921437 DMDIZUT DI DMDIZUT DMDIZUT DN SEM-606 DMDIZUT TI TTE4KHA DMDIZUT TN Amyloid beta A4 protein (APP) DMDIZUT MA Inhibitor DMDIZUT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMDIZUT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMDJ6RE DI DMDJ6RE DMDJ6RE DN MEDIORESINOL DMDJ6RE TI TTXV4FI DMDJ6RE TN Albendazole monooxygenase (CYP3A4) DMDJ6RE MA Inhibitor DMDJ6RE RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMDJ6RE RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMDJ9PE DI DMDJ9PE DMDJ9PE DN H-Dmt-Tic-Lys-NH-CH2-Ph DMDJ9PE TI TTKWM86 DMDJ9PE TN Opioid receptor mu (MOP) DMDJ9PE MA Inhibitor DMDJ9PE RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMDJ9PE RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMDJ9PE DI DMDJ9PE DMDJ9PE DN H-Dmt-Tic-Lys-NH-CH2-Ph DMDJ9PE TI TT27RFC DMDJ9PE TN Opioid receptor delta (OPRD1) DMDJ9PE MA Inhibitor DMDJ9PE RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMDJ9PE RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMDJ9QA DI DMDJ9QA DMDJ9QA DN Diethyl 2,2,2-trifluoro-1-phenylethyl phosphate DMDJ9QA TI TTMF541 DMDJ9QA TN Liver carboxylesterase (CES1) DMDJ9QA MA Inhibitor DMDJ9QA RN Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5528-30. DMDJ9QA RU https://pubmed.ncbi.nlm.nih.gov/19717305 DMDJCIP DI DMDJCIP DMDJCIP DN G36 DMDJCIP TI TTDSB34 DMDJCIP TN G-protein coupled estrogen receptor 1 (GPER1) DMDJCIP MA Antagonist DMDJCIP RN Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):358-66. DMDJCIP RU https://pubmed.ncbi.nlm.nih.gov/21782022 DMDJHFQ DI DMDJHFQ DMDJHFQ DN 2-Methyl-1,2-dihydro-indazol-3-one DMDJHFQ TI TTVKILB DMDJHFQ TN Prostaglandin G/H synthase 2 (COX-2) DMDJHFQ MA Inhibitor DMDJHFQ RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMDJHFQ RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMDJHFQ DI DMDJHFQ DMDJHFQ DN 2-Methyl-1,2-dihydro-indazol-3-one DMDJHFQ TI TT2J34L DMDJHFQ TN Arachidonate 5-lipoxygenase (5-LOX) DMDJHFQ MA Inhibitor DMDJHFQ RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMDJHFQ RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMDJHFQ DI DMDJHFQ DMDJHFQ DN 2-Methyl-1,2-dihydro-indazol-3-one DMDJHFQ TI TT8NGED DMDJHFQ TN Prostaglandin G/H synthase 1 (COX-1) DMDJHFQ MA Inhibitor DMDJHFQ RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMDJHFQ RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTRSMW9 DMDJLF0 TN Glycogen synthase kinase-3 beta (GSK-3B) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTUF2HO DMDJLF0 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMDJLF0 MA Inhibitor DMDJLF0 RN Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem. 2006 Dec 14;49(25):7307-16. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/17149860 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TT0K6EO DMDJLF0 TN Stress-activated protein kinase JNK1 (JNK1) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTFJ8Q1 DMDJLF0 TN Protein kinase C alpha (PRKCA) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TT73U6C DMDJLF0 TN Stress-activated protein kinase 2b (p38 beta) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTQBR95 DMDJLF0 TN Stress-activated protein kinase 2a (p38 alpha) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTWTSCV DMDJLF0 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TT860QF DMDJLF0 TN LCK tyrosine protein kinase (LCK) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TT4TQBX DMDJLF0 TN Extracellular signal-regulated kinase 2 (ERK2) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTG0U4H DMDJLF0 TN Ribosomal protein S6 kinase beta-1 (S6K1) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTZN7RP DMDJLF0 TN Rho-associated protein kinase 1 (ROCK1) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJLF0 DI DMDJLF0 DMDJLF0 DN Ro31-8220 DMDJLF0 TI TTYT93M DMDJLF0 TN MAP kinase p38 (MAPK12) DMDJLF0 MA Inhibitor DMDJLF0 RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMDJLF0 RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMDJUZX DI DMDJUZX DMDJUZX DN N7-hydroxy-N1-phenyl-2-propoxyheptanediamide DMDJUZX TI TTSHTOI DMDJUZX TN Histone deacetylase 2 (HDAC2) DMDJUZX MA Inhibitor DMDJUZX RN Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. DMDJUZX RU https://pubmed.ncbi.nlm.nih.gov/17892933 DMDJYHK DI DMDJYHK DMDJYHK DN 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane DMDJYHK TI TTS64P2 DMDJYHK TN Androgen receptor (AR) DMDJYHK MA Inhibitor DMDJYHK RN Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72. DMDJYHK RU https://pubmed.ncbi.nlm.nih.gov/17149866 DMDJYHK DI DMDJYHK DMDJYHK DN 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane DMDJYHK TI TTKPW01 DMDJYHK TN Androgen receptor messenger RNA (AR mRNA) DMDJYHK MA Inhibitor DMDJYHK RN Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist. J Med Chem. 2006 Dec 14;49(25):7366-72. DMDJYHK RU https://pubmed.ncbi.nlm.nih.gov/17149866 DMDK59X DI DMDK59X DMDK59X DN (1,1-Difluoro-pentadecyl)-phosphonic acid DMDK59X TI TTQ6S1K DMDK59X TN Lysophosphatidic acid receptor 1 (LPAR1) DMDK59X MA Inhibitor DMDK59X RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMDK59X RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMDK5BL DI DMDK5BL DMDK5BL DN CNX-010 DMDK5BL TI TTN7BL9 DMDK5BL TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMDK5BL MA Inhibitor DMDK5BL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763). DMDK5BL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763 DMDK6BP DI DMDK6BP DMDK6BP DN MT-061 DMDK6BP TI TT7AOUD DMDK6BP TN Fatty acid synthase (FASN) DMDK6BP MA Inhibitor DMDK6BP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608). DMDK6BP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608 DMDK86V DI DMDK86V DMDK86V DN UNC9994 DMDK86V TI TTEX248 DMDK86V TN Dopamine D2 receptor (D2R) DMDK86V MA Agonist DMDK86V RN Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93. DMDK86V RU https://pubmed.ncbi.nlm.nih.gov/22025698 DMDK8TR DI DMDK8TR DMDK8TR DN SCH-57726 DMDK8TR TI TTJ0IQB DMDK8TR TN Phosphodiesterase 5A (PDE5A) DMDK8TR MA Inhibitor DMDK8TR RN The Gif system as a tool in medicinal chemistry: The oxidation of Sch 57726 under GoAggIII conditions, Bioorg. Med. Chem. Lett. 7(11):1381-1386 (1997). DMDK8TR RU http://www.sciencedirect.com/science/article/pii/S0960894X97002382 DMDKB1I DI DMDKB1I DMDKB1I DN ISIS 9133 DMDKB1I TI TT53XHB DMDKB1I TN CD86 messenger RNA (CD86 mRNA) DMDKB1I RN US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein. DMDKB1I RU http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true DMDKC0J DI DMDKC0J DMDKC0J DN RS-100329 DMDKC0J TI TTNGILX DMDKC0J TN Adrenergic receptor alpha-1A (ADRA1A) DMDKC0J MA Inhibitor DMDKC0J RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMDKC0J RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMDKF03 DI DMDKF03 DMDKF03 DN 2-Hydroxyiminours-12-en-28-oic acid DMDKF03 TI TTZHY6R DMDKF03 TN Glycogen phosphorylase muscle form (GP) DMDKF03 MA Inhibitor DMDKF03 RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMDKF03 RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMDKFGX DI DMDKFGX DMDKFGX DN 15-nor-18-Methoxycornaridine DMDKFGX TI TTTVAFQ DMDKFGX TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMDKFGX MA Inhibitor DMDKFGX RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DMDKFGX RU https://pubmed.ncbi.nlm.nih.gov/12801235 DMDKFIO DI DMDKFIO DMDKFIO DN 5-iodo orotate DMDKFIO TI TT09NOX DMDKFIO TN Plasmodium Dihydroorotase (Malaria dho) DMDKFIO MA Inhibitor DMDKFIO RN Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301. DMDKFIO RU https://pubmed.ncbi.nlm.nih.gov/1348618 DMDKH8N DI DMDKH8N DMDKH8N DN AURASPERONE A DMDKH8N TI TTQY2EJ DMDKH8N TN TERT messenger RNA (TERT mRNA) DMDKH8N MA Inhibitor DMDKH8N RN New dimeric naphthopyrones from Aspergillus niger. J Nat Prod. 2003 Jan;66(1):136-9. DMDKH8N RU https://pubmed.ncbi.nlm.nih.gov/12542363 DMDKOWP DI DMDKOWP DMDKOWP DN 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide DMDKOWP TI TTKWM86 DMDKOWP TN Opioid receptor mu (MOP) DMDKOWP MA Inhibitor DMDKOWP RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DMDKOWP RU https://pubmed.ncbi.nlm.nih.gov/17980586 DMDKOWP DI DMDKOWP DMDKOWP DN 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide DMDKOWP TI TT27RFC DMDKOWP TN Opioid receptor delta (OPRD1) DMDKOWP MA Inhibitor DMDKOWP RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DMDKOWP RU https://pubmed.ncbi.nlm.nih.gov/17980586 DMDKOWP DI DMDKOWP DMDKOWP DN 6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide DMDKOWP TI TTQW87Y DMDKOWP TN Opioid receptor kappa (OPRK1) DMDKOWP MA Inhibitor DMDKOWP RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DMDKOWP RU https://pubmed.ncbi.nlm.nih.gov/17980586 DMDKSZ0 DI DMDKSZ0 DMDKSZ0 DN 2-oxo-N-m-tolyl-2H-chromene-3-carboxamide DMDKSZ0 TI TT3WG5C DMDKSZ0 TN Monoamine oxidase type A (MAO-A) DMDKSZ0 MA Inhibitor DMDKSZ0 RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMDKSZ0 RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMDKSZ0 DI DMDKSZ0 DMDKSZ0 DN 2-oxo-N-m-tolyl-2H-chromene-3-carboxamide DMDKSZ0 TI TTGP7BY DMDKSZ0 TN Monoamine oxidase type B (MAO-B) DMDKSZ0 MA Inhibitor DMDKSZ0 RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMDKSZ0 RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMDKW6G DI DMDKW6G DMDKW6G DN PMID20346665C27 DMDKW6G TI TTVBPDM DMDKW6G TN Metabotropic glutamate receptor 1 (mGluR1) DMDKW6G MA Modulator (allosteric modulator) DMDKW6G RN A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2474-7. DMDKW6G RU https://pubmed.ncbi.nlm.nih.gov/20346665 DMDKXEY DI DMDKXEY DMDKXEY DN 2,7-Bis(phenylpropionamido)anthraquinone DMDKXEY TI TTQY2EJ DMDKXEY TN TERT messenger RNA (TERT mRNA) DMDKXEY MA Inhibitor DMDKXEY RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMDKXEY RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMDL21W DI DMDL21W DMDL21W DN kisspeptin-10 DMDL21W TI TT3KBZY DMDL21W TN G-protein coupled receptor 54 (KISS1R) DMDL21W MA Agonist DMDL21W RN The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J Biol Chem. 2001 Sep 14;276(37):34631-6. DMDL21W RU https://pubmed.ncbi.nlm.nih.gov/11457843 DMDL8KY DI DMDL8KY DMDL8KY DN 2-(trifluoromethoxy)-9H-carbazole DMDL8KY TI TTBGTCW DMDL8KY TN Kinesin spindle messenger RNA (KIF11 mRNA) DMDL8KY MA Inhibitor DMDL8KY RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMDL8KY RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMDLER8 DI DMDLER8 DMDLER8 DN DEBROMOHYMENIALDISINE DMDLER8 TI TT4TQBX DMDLER8 TN Extracellular signal-regulated kinase 2 (ERK2) DMDLER8 MA Inhibitor DMDLER8 RN Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21. DMDLER8 RU https://pubmed.ncbi.nlm.nih.gov/15261294 DMDLER8 DI DMDLER8 DMDLER8 DN DEBROMOHYMENIALDISINE DMDLER8 TI TTAN5W2 DMDLER8 TN Raf messenger RNA (Raf mRNA) DMDLER8 MA Inhibitor DMDLER8 RN Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32. DMDLER8 RU https://pubmed.ncbi.nlm.nih.gov/11784156 DMDLER8 DI DMDLER8 DMDLER8 DN DEBROMOHYMENIALDISINE DMDLER8 TI TT9ABMF DMDLER8 TN Serine/threonine-protein kinase Chk2 (RAD53) DMDLER8 MA Inhibitor DMDLER8 RN Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21. DMDLER8 RU https://pubmed.ncbi.nlm.nih.gov/15261294 DMDLER8 DI DMDLER8 DMDLER8 DN DEBROMOHYMENIALDISINE DMDLER8 TI TTTU902 DMDLER8 TN Checkpoint kinase-1 (CHK1) DMDLER8 MA Inhibitor DMDLER8 RN Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21. DMDLER8 RU https://pubmed.ncbi.nlm.nih.gov/15261294 DMDLER8 DI DMDLER8 DMDLER8 DN DEBROMOHYMENIALDISINE DMDLER8 TI TTIDAPM DMDLER8 TN ERK activator kinase 1 (MEK1) DMDLER8 MA Inhibitor DMDLER8 RN Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32. DMDLER8 RU https://pubmed.ncbi.nlm.nih.gov/11784156 DMDLF0J DI DMDLF0J DMDLF0J DN Macbecin DMDLF0J TI TT78R5H DMDLF0J TN Heat shock protein 90 alpha (HSP90A) DMDLF0J MA Inhibitor DMDLF0J RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMDLF0J RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMDLHAB DI DMDLHAB DMDLHAB DN AdoC(Aun)Arg6 DMDLHAB TI TTNAHEX DMDLHAB TN cAMP-dependent protein kinase A type I (PRKAR1A) DMDLHAB MA Inhibitor DMDLHAB RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMDLHAB RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMDLHAB DI DMDLHAB DMDLHAB DN AdoC(Aun)Arg6 DMDLHAB TI TTW4Y2M DMDLHAB TN cAMP protein kinase type II-beta (PRKAR2B) DMDLHAB MA Inhibitor DMDLHAB RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMDLHAB RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMDLK9G DI DMDLK9G DMDLK9G DN C-(1H-Indol-3-yl)-methylamine DMDLK9G TI TT3WG5C DMDLK9G TN Monoamine oxidase type A (MAO-A) DMDLK9G MA Inhibitor DMDLK9G RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMDLK9G RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMDLK9G DI DMDLK9G DMDLK9G DN C-(1H-Indol-3-yl)-methylamine DMDLK9G TI TTGP7BY DMDLK9G TN Monoamine oxidase type B (MAO-B) DMDLK9G MA Inhibitor DMDLK9G RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMDLK9G RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMDLKPI DI DMDLKPI DMDLKPI DN 1-(2-p-tolyl-ethyl)-pyrrolidine DMDLKPI TI TT9JNIC DMDLKPI TN Histamine H3 receptor (H3R) DMDLKPI MA Inhibitor DMDLKPI RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMDLKPI RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMDLN9S DI DMDLN9S DMDLN9S DN ALTU-236 DMDLN9S TI TTGSVH2 DMDLN9S TN Phenylalanine hydroxylase (PAH) DMDLN9S MA Modulator DMDLN9S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240). DMDLN9S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240 DMDLVH5 DI DMDLVH5 DMDLVH5 DN ANG-2684 DMDLVH5 TI TTVDSZ0 DMDLVH5 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMDLVH5 MA Inhibitor DMDLVH5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMDLVH5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMDM0R6 DI DMDM0R6 DMDM0R6 DN 3-(2-Bromophenyl)-6-methylcoumarin DMDM0R6 TI TTGP7BY DMDM0R6 TN Monoamine oxidase type B (MAO-B) DMDM0R6 MA Inhibitor DMDM0R6 RN New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5157-60. DMDM0R6 RU https://pubmed.ncbi.nlm.nih.gov/20659799 DMDM3Y1 DI DMDM3Y1 DMDM3Y1 DN Immepip DMDM3Y1 TI TT9JNIC DMDM3Y1 TN Histamine H3 receptor (H3R) DMDM3Y1 MA Agonist DMDM3Y1 RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMDM3Y1 RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMDM50P DI DMDM50P DMDM50P DN N-(2-Ethylphenyl)-N'-hydroxyoctanediamide DMDM50P TI TT6R7JZ DMDM50P TN Histone deacetylase 1 (HDAC1) DMDM50P MA Inhibitor DMDM50P RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMDM50P RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMDM50P DI DMDM50P DMDM50P DN N-(2-Ethylphenyl)-N'-hydroxyoctanediamide DMDM50P TI TTBH0VX DMDM50P TN Histone deacetylase (HDAC) DMDM50P MA Inhibitor DMDM50P RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMDM50P RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMDM5BL DI DMDM5BL DMDM5BL DN KNI-10342 DMDM5BL TI TTXMNHO DMDM5BL TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMDM5BL MA Inhibitor DMDM5BL RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMDM5BL RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMDM7C6 DI DMDM7C6 DMDM7C6 DN TTL-1177 DMDM7C6 TI TTZPWGN DMDM7C6 TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMDM7C6 MA Inhibitor DMDM7C6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536). DMDM7C6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536 DMDM9UV DI DMDM9UV DMDM9UV DN 4,5-Dibromo-1H-pyrrole-2-carboxylic acid amide DMDM9UV TI TTIDAPM DMDM9UV TN ERK activator kinase 1 (MEK1) DMDM9UV MA Inhibitor DMDM9UV RN Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32. DMDM9UV RU https://pubmed.ncbi.nlm.nih.gov/11784156 DMDMA4Z DI DMDMA4Z DMDMA4Z DN C-(9H-Thioxanthen-9-yl)-methylamine DMDMA4Z TI TTJQOD7 DMDMA4Z TN 5-HT 2A receptor (HTR2A) DMDMA4Z MA Inhibitor DMDMA4Z RN Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6. DMDMA4Z RU https://pubmed.ncbi.nlm.nih.gov/11229772 DMDMG1O DI DMDMG1O DMDMG1O DN NIHP DMDMG1O TI TTMXGCW DMDMG1O TN Adrenergic receptor beta-3 (ADRB3) DMDMG1O MA Antagonist DMDMG1O RN LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5. DMDMG1O RU https://pubmed.ncbi.nlm.nih.gov/10079020 DMDMI7P DI DMDMI7P DMDMI7P DN N-6060 DMDMI7P TI TTEP6RV DMDMI7P TN Glutathione reductase (GR) DMDMI7P MA Inhibitor DMDMI7P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2613). DMDMI7P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2613 DMDMK5V DI DMDMK5V DMDMK5V DN 2-[4-(2-Azepan-1-ylethoxy)phenoxy]benzooxazole DMDMK5V TI TTXZEAJ DMDMK5V TN Leukotriene A-4 hydrolase (LTA4H) DMDMK5V MA Inhibitor DMDMK5V RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMDMK5V RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMDMK81 DI DMDMK81 DMDMK81 DN 2-Oxoolean-12-en-28-oic acid DMDMK81 TI TTZHY6R DMDMK81 TN Glycogen phosphorylase muscle form (GP) DMDMK81 MA Inhibitor DMDMK81 RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMDMK81 RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMDMNQV DI DMDMNQV DMDMNQV DN 6-Hydroxyuridine-5'-Phosphate DMDMNQV TI TTV7Y40 DMDMNQV TN Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF) DMDMNQV MA Inhibitor DMDMNQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDMNQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDMNQV DI DMDMNQV DMDMNQV DN 6-Hydroxyuridine-5'-Phosphate DMDMNQV TI TTAFJUD DMDMNQV TN Orotidine 5'-monophosphate decarboxylase (UMPS) DMDMNQV MA Inhibitor DMDMNQV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDMNQV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDMT5U DI DMDMT5U DMDMT5U DN FGGFTGARKSARKRRNQ DMDMT5U TI TTNT7K8 DMDMT5U TN Nociceptin receptor (OPRL1) DMDMT5U MA Inhibitor DMDMT5U RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMDMT5U RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMDMTZK DI DMDMTZK DMDMTZK DN (+/-)-threo-N-(3-Methylpyridine)methylphenidate DMDMTZK TI TTVBI8W DMDMTZK TN Dopamine transporter (DAT) DMDMTZK MA Inhibitor DMDMTZK RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMDMTZK RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMDMU01 DI DMDMU01 DMDMU01 DN PMID24775305C7u DMDMU01 TI TTPTWV5 DMDMU01 TN Legumain (LGMN) DMDMU01 MA Inhibitor DMDMU01 RN P3 SAR exploration of biphenyl carbamate based Legumain inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2521-4. DMDMU01 RU https://pubmed.ncbi.nlm.nih.gov/24775305 DMDMVA1 DI DMDMVA1 DMDMVA1 DN 2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol DMDMVA1 TI TTW0CMT DMDMVA1 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMDMVA1 MA Inhibitor DMDMVA1 RN Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. DMDMVA1 RU https://pubmed.ncbi.nlm.nih.gov/20304642 DMDN12L DI DMDN12L DMDN12L DN 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One DMDN12L TI TT0K6EO DMDN12L TN Stress-activated protein kinase JNK1 (JNK1) DMDN12L MA Inhibitor DMDN12L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDN12L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDN12L DI DMDN12L DMDN12L DN 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One DMDN12L TI TTP7EGM DMDN12L TN Dual specificity protein kinase TTK (MPS1) DMDN12L MA Inhibitor DMDN12L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDN12L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDN12L DI DMDN12L DMDN12L DN 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One DMDN12L TI TT056SO DMDN12L TN Stress-activated protein kinase JNK3 (JNK3) DMDN12L MA Inhibitor DMDN12L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDN12L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDN12L DI DMDN12L DMDN12L DN 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One DMDN12L TI TTR2TXZ DMDN12L TN Jun N terminal kinase (JNK) DMDN12L MA Inhibitor DMDN12L RN c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81. DMDN12L RU https://pubmed.ncbi.nlm.nih.gov/11435459 DMDN12L DI DMDN12L DMDN12L DN 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One DMDN12L TI TTHS0U8 DMDN12L TN Stress-activated protein kinase JNK2 (JNK2) DMDN12L MA Inhibitor DMDN12L RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMDN12L RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMDNA23 DI DMDNA23 DMDNA23 DN SU-6689 DMDNA23 TI TTYMGWX DMDNA23 TN PDK-1 messenger RNA (PDK-1 mRNA) DMDNA23 MA Inhibitor DMDNA23 RN Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. DMDNA23 RU https://pubmed.ncbi.nlm.nih.gov/17531483 DMDNEKR DI DMDNEKR DMDNEKR DN 3-(benzyloxy)-9H-pyrido[3,4-b]indole DMDNEKR TI TT1MPAY DMDNEKR TN GABA(A) receptor alpha-1 (GABRA1) DMDNEKR MA Inhibitor DMDNEKR RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDNEKR RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDNEKR DI DMDNEKR DMDNEKR DN 3-(benzyloxy)-9H-pyrido[3,4-b]indole DMDNEKR TI TT37EDJ DMDNEKR TN GABA(A) receptor alpha-3 (GABRA3) DMDNEKR MA Inhibitor DMDNEKR RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDNEKR RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDNEKR DI DMDNEKR DMDNEKR DN 3-(benzyloxy)-9H-pyrido[3,4-b]indole DMDNEKR TI TTBMV1G DMDNEKR TN GABA(A) receptor alpha-2 (GABRA2) DMDNEKR MA Inhibitor DMDNEKR RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDNEKR RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDNEKR DI DMDNEKR DMDNEKR DN 3-(benzyloxy)-9H-pyrido[3,4-b]indole DMDNEKR TI TTNZPQ1 DMDNEKR TN GABA(A) receptor alpha-5 (GABRA5) DMDNEKR MA Inhibitor DMDNEKR RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDNEKR RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDNEKR DI DMDNEKR DMDNEKR DN 3-(benzyloxy)-9H-pyrido[3,4-b]indole DMDNEKR TI TTNJYV2 DMDNEKR TN Gamma-aminobutyric acid receptor (GAR) DMDNEKR MA Inhibitor DMDNEKR RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDNEKR RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDNEKR DI DMDNEKR DMDNEKR DN 3-(benzyloxy)-9H-pyrido[3,4-b]indole DMDNEKR TI TT06RH5 DMDNEKR TN GABA(A) receptor gamma-2 (GABRG2) DMDNEKR MA Inhibitor DMDNEKR RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMDNEKR RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMDNG8F DI DMDNG8F DMDNG8F DN 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine DMDNG8F TI TTAN5W2 DMDNG8F TN Raf messenger RNA (Raf mRNA) DMDNG8F MA Inhibitor DMDNG8F RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMDNG8F RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMDNG8F DI DMDNG8F DMDNG8F DN 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine DMDNG8F TI TT1MG9E DMDNG8F TN Extracellular signal-regulated kinase 1 (ERK1) DMDNG8F MA Inhibitor DMDNG8F RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMDNG8F RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMDNHEP DI DMDNHEP DMDNHEP DN QUINPIROLE DMDNHEP TI TT4C8EA DMDNHEP TN Dopamine D3 receptor (D3R) DMDNHEP MA Inhibitor DMDNHEP RN 1,1'-Disubstituted ferrocenes as molecular hinges in mono- and bivalent dopamine receptor ligands. J Med Chem. 2009 Nov 12;52(21):6860-70. DMDNHEP RU https://pubmed.ncbi.nlm.nih.gov/19807103 DMDNHEP DI DMDNHEP DMDNHEP DN QUINPIROLE DMDNHEP TI TTEX248 DMDNHEP TN Dopamine D2 receptor (D2R) DMDNHEP MA Inhibitor DMDNHEP RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DMDNHEP RU https://pubmed.ncbi.nlm.nih.gov/9836610 DMDNHEP DI DMDNHEP DMDNHEP DN QUINPIROLE DMDNHEP TI TTE0A2F DMDNHEP TN Dopamine D4 receptor (D4R) DMDNHEP MA Inhibitor DMDNHEP RN Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of he... J Med Chem. 2005 Sep 8;48(18):5771-9. DMDNHEP RU https://pubmed.ncbi.nlm.nih.gov/16134944 DMDNHEP DI DMDNHEP DMDNHEP DN QUINPIROLE DMDNHEP TI TTZFYLI DMDNHEP TN Dopamine D1 receptor (D1R) DMDNHEP MA Inhibitor DMDNHEP RN Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of he... J Med Chem. 2005 Sep 8;48(18):5771-9. DMDNHEP RU https://pubmed.ncbi.nlm.nih.gov/16134944 DMDNM05 DI DMDNM05 DMDNM05 DN 1,3,5-tris(4-chlorophenyl)imidazolidine-2,4-dione DMDNM05 TI TT6OEDT DMDNM05 TN Cannabinoid receptor 1 (CB1) DMDNM05 MA Inhibitor DMDNM05 RN Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cann... J Med Chem. 2006 Feb 9;49(3):872-82. DMDNM05 RU https://pubmed.ncbi.nlm.nih.gov/16451053 DMDNPML DI DMDNPML DMDNPML DN BM-162115 DMDNPML TI TT9V5JH DMDNPML TN Phospholipase A2 (PLA2G1B) DMDNPML MA Inhibitor DMDNPML RN Investigation on the effect of experimental phospholipase A2 inhibitors on the formyl-methionyl-leucyl-phenylalanine-stimulated chemotaxis of human leukocytes in vitro. Arzneimittelforschung. 1998 Jan;48(1):77-81. DMDNPML RU https://pubmed.ncbi.nlm.nih.gov/9522038 DMDNRCU DI DMDNRCU DMDNRCU DN 4-Sulfamoyloxy-benzoic acid cycloheptyl ester DMDNRCU TI TTHM0R1 DMDNRCU TN Steryl-sulfatase (STS) DMDNRCU MA Inhibitor DMDNRCU RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMDNRCU RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMDNUCL DI DMDNUCL DMDNUCL DN N-(3,5-dichlorophenyl)-2-nitrobenzamide DMDNUCL TI TTVTX4N DMDNUCL TN Bacterial Fatty acid synthetase I (Bact inhA) DMDNUCL MA Inhibitor DMDNUCL RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMDNUCL RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMDNUM5 DI DMDNUM5 DMDNUM5 DN NU-7432 DMDNUM5 TI TTK3PY9 DMDNUM5 TN DNA-dependent protein kinase catalytic (PRKDC) DMDNUM5 MA Inhibitor DMDNUM5 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMDNUM5 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMDNVTF DI DMDNVTF DMDNVTF DN L-734115 DMDNVTF TI TTJA1ZO DMDNVTF TN ITGB3 messenger RNA (ITGB3 mRNA) DMDNVTF MA Inhibitor DMDNVTF RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DMDNVTF RU https://pubmed.ncbi.nlm.nih.gov/10999999 DMDO083 DI DMDO083 DMDO083 DN 6,7-dibromoquinoline-5,8-dione DMDO083 TI TTR0SWN DMDO083 TN M-phase inducer phosphatase 2 (MPIP2) DMDO083 MA Inhibitor DMDO083 RN Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9. DMDO083 RU https://pubmed.ncbi.nlm.nih.gov/18789703 DMDO13Y DI DMDO13Y DMDO13Y DN 6-Styryl-naphthalene-2-carboxamidine DMDO13Y TI TT2WR1T DMDO13Y TN Cationic trypsinogen (PRSS1) DMDO13Y MA Inhibitor DMDO13Y RN Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8. DMDO13Y RU https://pubmed.ncbi.nlm.nih.gov/15582418 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTO0FDJ DMDO175 TN Cyclin-dependent kinase 6 (CDK6) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTCEJ4F DMDO175 TN G1/S-specific cyclin-E1 (CCNE1) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTH6V3D DMDO175 TN Cyclin-dependent kinase 1 (CDK1) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTFCJ7S DMDO175 TN G1/S-specific cyclin-D1 (CCND1) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTRFOXJ DMDO175 TN Protein kinase C gamma (PRKCG) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTUTJGQ DMDO175 TN Vascular endothelial growth factor receptor 2 (KDR) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTFJ8Q1 DMDO175 TN Protein kinase C alpha (PRKCA) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TT9VGXW DMDO175 TN Angiopoietin 1 receptor (TEK) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TT0PG8F DMDO175 TN Cyclin-dependent kinase 4 (CDK4) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TT7HF4W DMDO175 TN Cyclin-dependent kinase 2 (CDK2) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTGKNB4 DMDO175 TN Epidermal growth factor receptor (EGFR) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TT9P6OW DMDO175 TN G2/mitotic-specific cyclin B1 (CCNB1) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTR5TV4 DMDO175 TN ERBB2 messenger RNA (HER2 mRNA) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO175 DI DMDO175 DMDO175 DN 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 TI TTBZ7OD DMDO175 TN Protein kinase C epsilon (PRKCE) DMDO175 MA Inhibitor DMDO175 RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMDO175 RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMDO468 DI DMDO468 DMDO468 DN Ac-YR[CEHdFRWC]SPPKD-NH2 DMDO468 TI TTD0CIQ DMDO468 TN Melanocortin receptor 4 (MC4R) DMDO468 MA Inhibitor DMDO468 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMDO468 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMDO468 DI DMDO468 DMDO468 DN Ac-YR[CEHdFRWC]SPPKD-NH2 DMDO468 TI TT0MV2T DMDO468 TN Melanocortin receptor 1 (MC1R) DMDO468 MA Inhibitor DMDO468 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMDO468 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMDO468 DI DMDO468 DMDO468 DN Ac-YR[CEHdFRWC]SPPKD-NH2 DMDO468 TI TTNI91K DMDO468 TN Melanocortin receptor 3 (MC3R) DMDO468 MA Inhibitor DMDO468 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMDO468 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMDO9AJ DI DMDO9AJ DMDO9AJ DN PMID25313322C15 DMDO9AJ TI TTTPCNU DMDO9AJ TN G-protein coupled receptor 39 (GPR39) DMDO9AJ MA Agonist DMDO9AJ RN Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists. ACS Med Chem Lett. 2014 Aug 4;5(10):1114-8. DMDO9AJ RU https://pubmed.ncbi.nlm.nih.gov/25313322 DMDO9YM DI DMDO9YM DMDO9YM DN 1-adamantan-1-yl-3-(2-hydroxyethyl)urea DMDO9YM TI TT7WVHI DMDO9YM TN Soluble epoxide hydrolase (EPHX2) DMDO9YM MA Inhibitor DMDO9YM RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMDO9YM RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMDOHRF DI DMDOHRF DMDOHRF DN 2-HYDROXY-3,5-DIIODOBENZOIC ACID DMDOHRF TI TTKRD0G DMDOHRF TN Endothelin A receptor (EDNRA) DMDOHRF MA Inhibitor DMDOHRF RN Allosteric inhibition of endothelin ETA receptors by 3, 5-dibromosalicylic acid. Mol Pharmacol. 2000 Dec;58(6):1461-9. DMDOHRF RU https://pubmed.ncbi.nlm.nih.gov/11093786 DMDOIJM DI DMDOIJM DMDOIJM DN 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol DMDOIJM TI TTWJBZ5 DMDOIJM TN 5-HT 2C receptor (HTR2C) DMDOIJM MA Inhibitor DMDOIJM RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMDOIJM RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMDOIJM DI DMDOIJM DMDOIJM DN 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol DMDOIJM TI TT0K1SC DMDOIJM TN 5-HT 2B receptor (HTR2B) DMDOIJM MA Inhibitor DMDOIJM RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMDOIJM RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMDOIJM DI DMDOIJM DMDOIJM DN 3-Dimethylaminomethyl-1-methyl-1H-indol-4-ol DMDOIJM TI TTJQOD7 DMDOIJM TN 5-HT 2A receptor (HTR2A) DMDOIJM MA Inhibitor DMDOIJM RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMDOIJM RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMDOJ4E DI DMDOJ4E DMDOJ4E DN 4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole DMDOJ4E TI TTNGILX DMDOJ4E TN Adrenergic receptor alpha-1A (ADRA1A) DMDOJ4E MA Inhibitor DMDOJ4E RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMDOJ4E RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMDOJ4E DI DMDOJ4E DMDOJ4E DN 4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole DMDOJ4E TI TT34BHT DMDOJ4E TN Adrenergic receptor alpha-1D (ADRA1D) DMDOJ4E MA Inhibitor DMDOJ4E RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMDOJ4E RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMDOJ4E DI DMDOJ4E DMDOJ4E DN 4-((E)-1-Naphthalen-1-yl-propenyl)-1H-imidazole DMDOJ4E TI TTBRKXS DMDOJ4E TN Adrenergic receptor alpha-1B (ADRA1B) DMDOJ4E MA Inhibitor DMDOJ4E RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMDOJ4E RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMDOJVX DI DMDOJVX DMDOJVX DN [3H]LTB4 DMDOJVX TI TTVJX54 DMDOJVX TN Leukotriene B4 receptor 2 (LTB4R2) DMDOJVX MA Modulator DMDOJVX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 268). DMDOJVX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=268 DMDOPVM DI DMDOPVM DMDOPVM DN 3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol DMDOPVM TI TTEX248 DMDOPVM TN Dopamine D2 receptor (D2R) DMDOPVM MA Inhibitor DMDOPVM RN 6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90. DMDOPVM RU https://pubmed.ncbi.nlm.nih.gov/1433207 DMDOPVM DI DMDOPVM DMDOPVM DN 3-Butyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol DMDOPVM TI TTSQIFT DMDOPVM TN 5-HT 1A receptor (HTR1A) DMDOPVM MA Inhibitor DMDOPVM RN 6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90. DMDOPVM RU https://pubmed.ncbi.nlm.nih.gov/1433207 DMDOR0L DI DMDOR0L DMDOR0L DN EPLIVANSERIN MESILATE DMDOR0L TI TTJQOD7 DMDOR0L TN 5-HT 2A receptor (HTR2A) DMDOR0L MA Modulator DMDOR0L RN Role of 5-HT2A receptor antagonists in the treatment of insomnia DMDOR0L RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630942 DMDOR2L DI DMDOR2L DMDOR2L DN YM44778 DMDOR2L TI TTYO0A3 DMDOR2L TN Substance-K receptor (TACR2) DMDOR2L MA Antagonist DMDOR2L RN Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model. Pharmacology. 2002 May;65(2):96-102. DMDOR2L RU https://pubmed.ncbi.nlm.nih.gov/11937780 DMDORHA DI DMDORHA DMDORHA DN ISIS 16005 DMDORHA TI TTRE6AX DMDORHA TN Bcl-x messenger RNA (BCL2L1 mRNA) DMDORHA RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMDORHA RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMDOW5S DI DMDOW5S DMDOW5S DN 8-n-propylnaringenin DMDOW5S TI TTZAYWL DMDOW5S TN Estrogen receptor (ESR) DMDOW5S MA Inhibitor DMDOW5S RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMDOW5S RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMDOW5S DI DMDOW5S DMDOW5S DN 8-n-propylnaringenin DMDOW5S TI TTOM3J0 DMDOW5S TN Estrogen receptor beta (ESR2) DMDOW5S MA Inhibitor DMDOW5S RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMDOW5S RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMDOX1Z DI DMDOX1Z DMDOX1Z DN Etoloxamine DMDOX1Z TI TT4C8EA DMDOX1Z TN Dopamine D3 receptor (D3R) DMDOX1Z MA Inhibitor DMDOX1Z RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMDOX1Z RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMDOX1Z DI DMDOX1Z DMDOX1Z DN Etoloxamine DMDOX1Z TI TTEX248 DMDOX1Z TN Dopamine D2 receptor (D2R) DMDOX1Z MA Inhibitor DMDOX1Z RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMDOX1Z RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMDOX1Z DI DMDOX1Z DMDOX1Z DN Etoloxamine DMDOX1Z TI TTZFYLI DMDOX1Z TN Dopamine D1 receptor (D1R) DMDOX1Z MA Inhibitor DMDOX1Z RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMDOX1Z RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMDOZPU DI DMDOZPU DMDOZPU DN PK 11195 DMDOZPU TI TTPTXIN DMDOZPU TN Translocator protein (TSPO) DMDOZPU MA Binder DMDOZPU RN Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001 Nov 30;85(11):1771-80. DMDOZPU RU https://pubmed.ncbi.nlm.nih.gov/11742501 DMDOZPU DI DMDOZPU DMDOZPU DN PK 11195 DMDOZPU TI TTGJVQM DMDOZPU TN Fibroblast growth factor receptor 2 (FGFR2) DMDOZPU MA Binder DMDOZPU RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMDOZPU RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMDP1QG DI DMDP1QG DMDP1QG DN N-(4,6-diphenylpyrimidin-2-yl)-2-ethylbutyramide DMDP1QG TI TTK25J1 DMDP1QG TN Adenosine A1 receptor (ADORA1) DMDP1QG MA Inhibitor DMDP1QG RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMDP1QG RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMDP7Y5 DI DMDP7Y5 DMDP7Y5 DN SIDEROXYLONAL B DMDP7Y5 TI TTTO43N DMDP7Y5 TN Endothelial plasminogen activator inhibitor (SERPINE1) DMDP7Y5 MA Inhibitor DMDP7Y5 RN Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod. 1999 Feb;62(2):324-6. DMDP7Y5 RU https://pubmed.ncbi.nlm.nih.gov/10075775 DMDP84X DI DMDP84X DMDP84X DN Methylcarbamic Acid Biphenyl-3-yl Ester DMDP84X TI TTDP1UC DMDP84X TN Fatty acid amide hydrolase (FAAH) DMDP84X MA Inhibitor DMDP84X RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMDP84X RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMDPA2T DI DMDPA2T DMDPA2T DN 6-N-propyl -4-trifluoromethylquinolin-2(1H)-one DMDPA2T TI TTKPW01 DMDPA2T TN Androgen receptor messenger RNA (AR mRNA) DMDPA2T MA Inhibitor DMDPA2T RN Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator. J Med Chem. 2006 Oct 19;49(21):6143-6. DMDPA2T RU https://pubmed.ncbi.nlm.nih.gov/17034117 DMDPBVS DI DMDPBVS DMDPBVS DN C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 DMDPBVS TI TTEOSZT DMDPBVS TN Melanocortin receptor (MCR) DMDPBVS MA Inhibitor DMDPBVS RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMDPBVS RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMDPBVS DI DMDPBVS DMDPBVS DN C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 DMDPBVS TI TTNI91K DMDPBVS TN Melanocortin receptor 3 (MC3R) DMDPBVS MA Inhibitor DMDPBVS RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMDPBVS RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMDPBVS DI DMDPBVS DMDPBVS DN C[Nle-Nle-D-Phe-Arg-Trp-Glu]-NH2 DMDPBVS TI TTD0CIQ DMDPBVS TN Melanocortin receptor 4 (MC4R) DMDPBVS MA Inhibitor DMDPBVS RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMDPBVS RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMDPH3W DI DMDPH3W DMDPH3W DN CP-394531 DMDPH3W TI TTOM3J0 DMDPH3W TN Estrogen receptor beta (ESR2) DMDPH3W MA Inhibitor DMDPH3W RN Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. DMDPH3W RU https://pubmed.ncbi.nlm.nih.gov/12036351 DMDPH3W DI DMDPH3W DMDPH3W DN CP-394531 DMDPH3W TI TTZAYWL DMDPH3W TN Estrogen receptor (ESR) DMDPH3W MA Inhibitor DMDPH3W RN Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. DMDPH3W RU https://pubmed.ncbi.nlm.nih.gov/12036351 DMDPH3W DI DMDPH3W DMDPH3W DN CP-394531 DMDPH3W TI TTKPW01 DMDPH3W TN Androgen receptor messenger RNA (AR mRNA) DMDPH3W MA Inhibitor DMDPH3W RN Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. DMDPH3W RU https://pubmed.ncbi.nlm.nih.gov/12036351 DMDPH3W DI DMDPH3W DMDPH3W DN CP-394531 DMDPH3W TI TTOZRK6 DMDPH3W TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMDPH3W MA Inhibitor DMDPH3W RN Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. J Med Chem. 2010 Apr 22;53(8):3065-74. DMDPH3W RU https://pubmed.ncbi.nlm.nih.gov/20334371 DMDPJWF DI DMDPJWF DMDPJWF DN CU201 (B9870) DMDPJWF TI TTDJ4MY DMDPJWF TN Kininogen (KNG1) DMDPJWF MA Inhibitor DMDPJWF RN Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May;8(5):1280-7. DMDPJWF RU https://pubmed.ncbi.nlm.nih.gov/12006549 DMDPKCM DI DMDPKCM DMDPKCM DN N-cyclopentyl-6-(2-phenylethynyl)nicotinamide DMDPKCM TI TTHS256 DMDPKCM TN Metabotropic glutamate receptor 5 (mGluR5) DMDPKCM MA Inhibitor DMDPKCM RN Discovery of a potent and brain penetrant mGluR5 positive allosteric modulator. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3275-8. DMDPKCM RU https://pubmed.ncbi.nlm.nih.gov/19443216 DMDPN4E DI DMDPN4E DMDPN4E DN WO2013110309CA127 DMDPN4E TI TT9U4EP DMDPN4E TN Eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4) DMDPN4E MA Inhibitor DMDPN4E RN Triazolo[4,5-d]pyrimidine Derivatives as Inhibitors of GCN2. ACS Med Chem Lett. 2014 Feb 12;5(4):282-3. DMDPN4E RU https://pubmed.ncbi.nlm.nih.gov/24900825 DMDPSBQ DI DMDPSBQ DMDPSBQ DN Ac-I[CVSQDWGHHRC]T-NH2 DMDPSBQ TI TTJGY7A DMDPSBQ TN Complement C3 (CO3) DMDPSBQ MA Inhibitor DMDPSBQ RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMDPSBQ RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMDPUC7 DI DMDPUC7 DMDPUC7 DN 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline DMDPUC7 TI TTWM4TY DMDPUC7 TN Adrenergic receptor alpha-2B (ADRA2B) DMDPUC7 MA Inhibitor DMDPUC7 RN 3-hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display re... J Med Chem. 2005 Jan 13;48(1):134-40. DMDPUC7 RU https://pubmed.ncbi.nlm.nih.gov/15634007 DMDPUC7 DI DMDPUC7 DMDPUC7 DN 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline DMDPUC7 TI TTWG9A4 DMDPUC7 TN Adrenergic receptor alpha-2A (ADRA2A) DMDPUC7 MA Inhibitor DMDPUC7 RN 3-hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display re... J Med Chem. 2005 Jan 13;48(1):134-40. DMDPUC7 RU https://pubmed.ncbi.nlm.nih.gov/15634007 DMDPUC7 DI DMDPUC7 DMDPUC7 DN 3-Fluoromethyl-1,2,3,4-tetrahydro-isoquinoline DMDPUC7 TI TT2NUT5 DMDPUC7 TN Adrenergic receptor alpha-2C (ADRA2C) DMDPUC7 MA Inhibitor DMDPUC7 RN 3-hydroxymethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline inhibitors of phenylethanolamine N-methyltransferase that display re... J Med Chem. 2005 Jan 13;48(1):134-40. DMDPUC7 RU https://pubmed.ncbi.nlm.nih.gov/15634007 DMDPXUA DI DMDPXUA DMDPXUA DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX) DMDPXUA TI TTMSFAW DMDPXUA TN Cannabinoid receptor 2 (CB2) DMDPXUA MA Inhibitor DMDPXUA RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMDPXUA RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMDPXUA DI DMDPXUA DMDPXUA DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXY-2,2-DIMETHYLPROPANAMIDE (ENANTIOMERIC MIX) DMDPXUA TI TT6OEDT DMDPXUA TN Cannabinoid receptor 1 (CB1) DMDPXUA MA Inhibitor DMDPXUA RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMDPXUA RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMDPY9N DI DMDPY9N DMDPY9N DN 3-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol DMDPY9N TI TTIWB6L DMDPY9N TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMDPY9N MA Inhibitor DMDPY9N RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMDPY9N RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMDQ2VN DI DMDQ2VN DMDQ2VN DN Azithromycin-N-benzyltriazolyldecahydroxamic Acid DMDQ2VN TI TT6R7JZ DMDQ2VN TN Histone deacetylase 1 (HDAC1) DMDQ2VN MA Inhibitor DMDQ2VN RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DMDQ2VN RU https://pubmed.ncbi.nlm.nih.gov/19093884 DMDQ7Z9 DI DMDQ7Z9 DMDQ7Z9 DN 10-EPI-8-DEOXY-CUMAMBRIN B DMDQ7Z9 TI TTSZLWK DMDQ7Z9 TN Aromatase (CYP19A1) DMDQ7Z9 MA Inhibitor DMDQ7Z9 RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMDQ7Z9 RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TTVBPDM DMDQBTX TN Metabotropic glutamate receptor 1 (mGluR1) DMDQBTX MA Agonist DMDQBTX RN Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glut... J Biol Chem. 2003 Mar 7;278(10):8340-7. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/12509432 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TT0MYE2 DMDQBTX TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMDQBTX MA Inhibitor DMDQBTX RN Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/18578478 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TT0I76D DMDQBTX TN Metabotropic glutamate receptor 7 (mGluR7) DMDQBTX MA Inhibitor DMDQBTX RN Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/9526567 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TTXJ47W DMDQBTX TN Metabotropic glutamate receptor 2 (mGluR2) DMDQBTX MA Inhibitor DMDQBTX RN Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/9526567 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TT8A9EF DMDQBTX TN Metabotropic glutamate receptor 3 (mGluR3) DMDQBTX MA Inhibitor DMDQBTX RN Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/9526567 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TT0IFKL DMDQBTX TN Metabotropic glutamate receptor 8 (mGluR8) DMDQBTX MA Inhibitor DMDQBTX RN Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/9526567 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TTHS256 DMDQBTX TN Metabotropic glutamate receptor 5 (mGluR5) DMDQBTX MA Inhibitor DMDQBTX RN Excitatory amino acid receptor ligands: resolution, absolute stereochemistry, and enantiopharmacology of 2-amino-3-(4-butyl-3-hydroxyisoxazol-5-yl)... J Med Chem. 1998 Mar 12;41(6):930-9. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/9526567 DMDQBTX DI DMDQBTX DMDQBTX DN [3H]quisqualate DMDQBTX TI TT9G4N0 DMDQBTX TN Glutamate carboxypeptidase II (GCPII) DMDQBTX MA Inhibitor DMDQBTX RN Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem. 2007 Jul 12;50(14):3267-73. DMDQBTX RU https://pubmed.ncbi.nlm.nih.gov/17567119 DMDQEZG DI DMDQEZG DMDQEZG DN N-(6-(4-aminophenyl)-1H-indazol-3-yl)butyramide DMDQEZG TI TTRSMW9 DMDQEZG TN Glycogen synthase kinase-3 beta (GSK-3B) DMDQEZG MA Inhibitor DMDQEZG RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMDQEZG RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMDQJUO DI DMDQJUO DMDQJUO DN Tyr-(R)-Aba-Gly-Phe-NH2 DMDQJUO TI TTKWM86 DMDQJUO TN Opioid receptor mu (MOP) DMDQJUO MA Inhibitor DMDQJUO RN Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. DMDQJUO RU https://pubmed.ncbi.nlm.nih.gov/18062664 DMDQJUO DI DMDQJUO DMDQJUO DN Tyr-(R)-Aba-Gly-Phe-NH2 DMDQJUO TI TT27RFC DMDQJUO TN Opioid receptor delta (OPRD1) DMDQJUO MA Inhibitor DMDQJUO RN Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. DMDQJUO RU https://pubmed.ncbi.nlm.nih.gov/18062664 DMDQKJB DI DMDQKJB DMDQKJB DN Uridine-5'-Diphosphate DMDQKJB TI TTGRHIB DMDQKJB TN UDP-glucose 4-epimerase (GALE) DMDQKJB MA Inhibitor DMDQKJB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDQKJB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDQL24 DI DMDQL24 DMDQL24 DN 4,5,6,7-Tetrahydro-1H-indazole-3-carboxylic acid DMDQL24 TI TTWNV8U DMDQL24 TN Nicotinic acid receptor (HCAR2) DMDQL24 MA Inhibitor DMDQL24 RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMDQL24 RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMDQVSU DI DMDQVSU DMDQVSU DN 1-(2-methoxyphenethyl)pyrrolidine DMDQVSU TI TT9JNIC DMDQVSU TN Histamine H3 receptor (H3R) DMDQVSU MA Inhibitor DMDQVSU RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMDQVSU RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMDQWOB DI DMDQWOB DMDQWOB DN N-Hydroxy-N-methyl-benzamide DMDQWOB TI TT2J34L DMDQWOB TN Arachidonate 5-lipoxygenase (5-LOX) DMDQWOB MA Inhibitor DMDQWOB RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMDQWOB RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMDQXJ2 DI DMDQXJ2 DMDQXJ2 DN ANNULIN B DMDQXJ2 TI TTZJYKH DMDQXJ2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMDQXJ2 MA Inhibitor DMDQXJ2 RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DMDQXJ2 RU https://pubmed.ncbi.nlm.nih.gov/17067170 DMDR1M6 DI DMDR1M6 DMDR1M6 DN 17 beta-N,N-diethylcarbamoyl-4-aza-5 alpha-androstan-3-one (4MA) DMDR1M6 TI TTZT9R2 DMDR1M6 TN Hydroxysteroid dehydrogenase 3-beta (HSD3B) DMDR1M6 MA Inhibitor DMDR1M6 RN Inhibition of 3 beta-hydroxysteroid-dehydrogenase: an approach for prostate cancer treatment Anticancer Res. 1995 Jul-Aug;15(4):1349-54. DMDR1M6 RU https://pubmed.ncbi.nlm.nih.gov/7654020 DMDR20P DI DMDR20P DMDR20P DN 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine DMDR20P TI TTIQUX7 DMDR20P TN Steroid 11-beta-hydroxylase (CYP11B1) DMDR20P MA Inhibitor DMDR20P RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMDR20P RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMDR20P DI DMDR20P DMDR20P DN 3-(4-methyl-3,4-dihydronaphthalen-2-yl)pyridine DMDR20P TI TTSZLWK DMDR20P TN Aromatase (CYP19A1) DMDR20P MA Inhibitor DMDR20P RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMDR20P RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMDR460 DI DMDR460 DMDR460 DN NSC-158324 DMDR460 TI TTHVCUP DMDR460 TN DNA [cytosine-5]-methyltransferase (DNMT) DMDR460 MA Inhibitor DMDR460 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMDR460 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMDR460 DI DMDR460 DMDR460 DN NSC-158324 DMDR460 TI TT6VZ78 DMDR460 TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMDR460 MA Inhibitor DMDR460 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMDR460 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMDR50V DI DMDR50V DMDR50V DN 2-(2-(biphenyl-4-yl)ethylsulfinyl)acetic acid DMDR50V TI TTXZ0KQ DMDR50V TN Matrix metalloproteinase-12 (MMP-12) DMDR50V MA Inhibitor DMDR50V RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMDR50V RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMDR8V9 DI DMDR8V9 DMDR8V9 DN ISIS 29202 DMDR8V9 TI TTO6SGY DMDR8V9 TN AKT3 messenger RNA (AKT3 mRNA) DMDR8V9 RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMDR8V9 RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMDR95N DI DMDR95N DMDR95N DN O-oleoyl-N-(2-hydroxyethyl)hydroxylamine DMDR95N TI TTMSFAW DMDR95N TN Cannabinoid receptor 2 (CB2) DMDR95N MA Inhibitor DMDR95N RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DMDR95N RU https://pubmed.ncbi.nlm.nih.gov/16570929 DMDRE64 DI DMDRE64 DMDRE64 DN N-benzyl-9-oxo-9,10-dihydroacridine-3-carboxamide DMDRE64 TI TTTB4UP DMDRE64 TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMDRE64 MA Inhibitor DMDRE64 RN Acridone-based inhibitors of inosine 5'-monophosphate dehydrogenase: discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1... J Med Chem. 2007 Jul 26;50(15):3730-42. DMDRE64 RU https://pubmed.ncbi.nlm.nih.gov/17585753 DMDRPLA DI DMDRPLA DMDRPLA DN 8-O-(4-bromobenzenesulfonyl)manzamine F DMDRPLA TI TTRSMW9 DMDRPLA TN Glycogen synthase kinase-3 beta (GSK-3B) DMDRPLA MA Inhibitor DMDRPLA RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DMDRPLA RU https://pubmed.ncbi.nlm.nih.gov/17708655 DMDRSFE DI DMDRSFE DMDRSFE DN Ametantrone DMDRSFE TI TT0IHXV DMDRSFE TN DNA topoisomerase II (TOP2) DMDRSFE MA Intercalator DMDRSFE RN Interactions of antitumor agents Ametantrone and Mitoxantrone (Novatrone) with double-stranded DNA. Biochem Pharmacol. 1985 Dec 15;34(24):4203-13. DMDRSFE RU https://pubmed.ncbi.nlm.nih.gov/4074383 DMDRSNH DI DMDRSNH DMDRSNH DN 6-hydroxybenzo[d][1,3]oxathiol-2-one DMDRSNH TI TTANPDJ DMDRSNH TN Carbonic anhydrase II (CA-II) DMDRSNH MA Inhibitor DMDRSNH RN Carbonic anhydrase inhibitors: thioxolone versus sulfonamides for obtaining isozyme-selective inhibitors Bioorg Med Chem Lett. 2008 Jul 15;18(14):3938-41. DMDRSNH RU https://pubmed.ncbi.nlm.nih.gov/18572406 DMDRUBL DI DMDRUBL DMDRUBL DN 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine DMDRUBL TI TTNT7K8 DMDRUBL TN Nociceptin receptor (OPRL1) DMDRUBL MA Inhibitor DMDRUBL RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMDRUBL RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMDRUBL DI DMDRUBL DMDRUBL DN 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine DMDRUBL TI TT27RFC DMDRUBL TN Opioid receptor delta (OPRD1) DMDRUBL MA Inhibitor DMDRUBL RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMDRUBL RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMDRUBL DI DMDRUBL DMDRUBL DN 1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine DMDRUBL TI TTQW87Y DMDRUBL TN Opioid receptor kappa (OPRK1) DMDRUBL MA Inhibitor DMDRUBL RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMDRUBL RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMDRWYG DI DMDRWYG DMDRWYG DN KNI-10529 DMDRWYG TI TTXMNHO DMDRWYG TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMDRWYG MA Inhibitor DMDRWYG RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMDRWYG RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMDRXCP DI DMDRXCP DMDRXCP DN AZ11645373 DMDRXCP TI TT473XN DMDRXCP TN P2X purinoceptor 7 (P2RX7) DMDRXCP MA Modulator (allosteric modulator) DMDRXCP RN Mechanism of action of species-selective P2X(7) receptor antagonists. Br J Pharmacol. 2009 Apr;156(8):1312-25. DMDRXCP RU https://pubmed.ncbi.nlm.nih.gov/19309360 DMDRYJ7 DI DMDRYJ7 DMDRYJ7 DN N4-(3-methylphenyl)-4,6-quinazolinediamine DMDRYJ7 TI TTGKNB4 DMDRYJ7 TN Epidermal growth factor receptor (EGFR) DMDRYJ7 MA Inhibitor DMDRYJ7 RN The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem. 2006 Jun 15;49(12):3544-52. DMDRYJ7 RU https://pubmed.ncbi.nlm.nih.gov/16759097 DMDS2LZ DI DMDS2LZ DMDS2LZ DN 4-(3-Chloro-phenoxy)-6,7-dimethoxy-quinazoline DMDS2LZ TI TT860QF DMDS2LZ TN LCK tyrosine protein kinase (LCK) DMDS2LZ MA Inhibitor DMDS2LZ RN he preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):417-420 (1997). DMDS2LZ RU http://www.sciencedirect.com/science/article/pii/S0960894X97000346 DMDS4BP DI DMDS4BP DMDS4BP DN ISIS 134602 DMDS4BP TI TTKW4ML DMDS4BP TN Caspase 6 messenger RNA (CASP6 mRNA) DMDS4BP RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMDS4BP RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMDS4Q0 DI DMDS4Q0 DMDS4Q0 DN 3-(2-Chloro-1,1-dimethyl-2-phenyl-ethyl)-pyridine DMDS4Q0 TI TTIQUX7 DMDS4Q0 TN Steroid 11-beta-hydroxylase (CYP11B1) DMDS4Q0 MA Inhibitor DMDS4Q0 RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMDS4Q0 RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMDS8AN DI DMDS8AN DMDS8AN DN (2R,3S,4S,5R)-2-hexylpiperidine-3,4,5-triol DMDS8AN TI TT1B5PU DMDS8AN TN Glucosylceramidase (GBA) DMDS8AN MA Inhibitor DMDS8AN RN Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors. Bioorg Med Chem. 2010 Apr 1;18(7):2645-50. DMDS8AN RU https://pubmed.ncbi.nlm.nih.gov/20231099 DMDS8UJ DI DMDS8UJ DMDS8UJ DN 3-[3-Methyl-indan-(1E)-ylidenemethyl]-pyridine DMDS8UJ TI TTSZLWK DMDS8UJ TN Aromatase (CYP19A1) DMDS8UJ MA Inhibitor DMDS8UJ RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMDS8UJ RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMDSB1F DI DMDSB1F DMDSB1F DN MRS2950 DMDSB1F TI TTA93TL DMDSB1F TN P2Y purinoceptor 1 (P2RY1) DMDSB1F MA Antagonist DMDSB1F RN Virtual screening leads to the discovery of novel non-nucleotide P2Y receptor antagonists. Bioorg Med Chem. 2012 Sep 1;20(17):5254-61. DMDSB1F RU https://pubmed.ncbi.nlm.nih.gov/22831801 DMDSJ0O DI DMDSJ0O DMDSJ0O DN 3-iodo-N-(6-methylpyridin-2-yl)benzamide DMDSJ0O TI TTHS256 DMDSJ0O TN Metabotropic glutamate receptor 5 (mGluR5) DMDSJ0O MA Inhibitor DMDSJ0O RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DMDSJ0O RU https://pubmed.ncbi.nlm.nih.gov/16678408 DMDSK9N DI DMDSK9N DMDSK9N DN GSK2801 DMDSK9N TI TT2MV0R DMDSK9N TN Bromodomain adjacent to zinc finger 2A (BAZ2A) DMDSK9N MA Inhibitor DMDSK9N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2721). DMDSK9N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2721 DMDSK9N DI DMDSK9N DMDSK9N DN GSK2801 DMDSK9N TI TT6K8YG DMDSK9N TN Bromodomain adjacent to zinc finger 2B (BAZ2B) DMDSK9N MA Inhibitor DMDSK9N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2722). DMDSK9N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2722 DMDSMJU DI DMDSMJU DMDSMJU DN ISIS 3309 DMDSMJU TI TTXAUJ8 DMDSMJU TN Influenza M messenger RNA (Influenza M mRNA) DMDSMJU RN US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides. DMDSMJU RU http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true DMDSUR2 DI DMDSUR2 DMDSUR2 DN 2-(2-(2-fluorophenoxy)phenyl)acetic acid DMDSUR2 TI TTCTE1G DMDSUR2 TN Interleukin-8 (IL8) DMDSUR2 MA Inhibitor DMDSUR2 RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DMDSUR2 RU https://pubmed.ncbi.nlm.nih.gov/19560921 DMDT42X DI DMDT42X DMDT42X DN KU-55933 DMDT42X TI TTK3PY9 DMDT42X TN DNA-dependent protein kinase catalytic (PRKDC) DMDT42X MA Inhibitor DMDT42X RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMDT42X RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMDT7SK DI DMDT7SK DMDT7SK DN 2-[(biphenyl-4-carbonyl)-amino]-benzoic acid DMDT7SK TI TT3PQ2Y DMDT7SK TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMDT7SK MA Inhibitor DMDT7SK RN The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Jan 1;16(1):88-92. DMDT7SK RU https://pubmed.ncbi.nlm.nih.gov/16236496 DMDT9KG DI DMDT9KG DMDT9KG DN 2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid DMDT9KG TI TTMWT8Z DMDT9KG TN C-X-C chemokine receptor type 1 (CXCR1) DMDT9KG MA Inhibitor DMDT9KG RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMDT9KG RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMDT9KG DI DMDT9KG DMDT9KG DN 2-[3-(1-Hydroxy-propyl)-phenyl]-propionic acid DMDT9KG TI TT30C9G DMDT9KG TN C-X-C chemokine receptor type 2 (CXCR2) DMDT9KG MA Inhibitor DMDT9KG RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMDT9KG RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMDTFKL DI DMDTFKL DMDTFKL DN 4-(3-chlorophenylethynyl)-2-methylthiazole DMDTFKL TI TTHS256 DMDTFKL TN Metabotropic glutamate receptor 5 (mGluR5) DMDTFKL MA Inhibitor DMDTFKL RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMDTFKL RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMDTILC DI DMDTILC DMDTILC DN JWH-204 DMDTILC TI TTMSFAW DMDTILC TN Cannabinoid receptor 2 (CB2) DMDTILC MA Inhibitor DMDTILC RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMDTILC RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMDTLSP DI DMDTLSP DMDTLSP DN BIBF-1202 DMDTLSP TI TTUTJGQ DMDTLSP TN Vascular endothelial growth factor receptor 2 (KDR) DMDTLSP MA Inhibitor DMDTLSP RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DMDTLSP RU https://pubmed.ncbi.nlm.nih.gov/22037378 DMDTMB7 DI DMDTMB7 DMDTMB7 DN 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide DMDTMB7 TI TT27RFC DMDTMB7 TN Opioid receptor delta (OPRD1) DMDTMB7 MA Inhibitor DMDTMB7 RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMDTMB7 RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMDTMB7 DI DMDTMB7 DMDTMB7 DN 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide DMDTMB7 TI TTQW87Y DMDTMB7 TN Opioid receptor kappa (OPRK1) DMDTMB7 MA Inhibitor DMDTMB7 RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMDTMB7 RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMDTMB7 DI DMDTMB7 DMDTMB7 DN 6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide DMDTMB7 TI TTKWM86 DMDTMB7 TN Opioid receptor mu (MOP) DMDTMB7 MA Inhibitor DMDTMB7 RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMDTMB7 RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMDTONZ DI DMDTONZ DMDTONZ DN AVP-13546 DMDTONZ TI TT2AST1 DMDTONZ TN Macrophage migration inhibitory factor (MIF) DMDTONZ MA Inhibitor DMDTONZ RN MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009 Jan;8(3):244-9. DMDTONZ RU https://pubmed.ncbi.nlm.nih.gov/18721909 DMDTP1R DI DMDTP1R DMDTP1R DN PALASONIN DMDTP1R TI TTFLH0E DMDTP1R TN Serine/threonine PP1-alpha (PPP1CA) DMDTP1R MA Inhibitor DMDTP1R RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DMDTP1R RU https://pubmed.ncbi.nlm.nih.gov/11881984 DMDTRZ2 DI DMDTRZ2 DMDTRZ2 DN 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide DMDTRZ2 TI TT2LVK8 DMDTRZ2 TN Carbonic anhydrase IX (CA-IX) DMDTRZ2 MA Inhibitor DMDTRZ2 RN Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic... Bioorg Med Chem Lett. 2005 Jan 17;15(2):367-72. DMDTRZ2 RU https://pubmed.ncbi.nlm.nih.gov/15603956 DMDTRZ2 DI DMDTRZ2 DMDTRZ2 DN 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide DMDTRZ2 TI TTANPDJ DMDTRZ2 TN Carbonic anhydrase II (CA-II) DMDTRZ2 MA Inhibitor DMDTRZ2 RN Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic... Bioorg Med Chem Lett. 2005 Jan 17;15(2):367-72. DMDTRZ2 RU https://pubmed.ncbi.nlm.nih.gov/15603956 DMDTRZ2 DI DMDTRZ2 DMDTRZ2 DN 2-Morpholin-4-yl-N-(4-sulfamoyl-phenyl)-acetamide DMDTRZ2 TI TTHQPL7 DMDTRZ2 TN Carbonic anhydrase I (CA-I) DMDTRZ2 MA Inhibitor DMDTRZ2 RN Carbonic anhydrase inhibitors. Novel sulfanilamide/acetazolamide derivatives obtained by the tail approach and their interaction with the cytosolic... Bioorg Med Chem Lett. 2005 Jan 17;15(2):367-72. DMDTRZ2 RU https://pubmed.ncbi.nlm.nih.gov/15603956 DMDTV7A DI DMDTV7A DMDTV7A DN BV-6 DMDTV7A TI TTQ5LRD DMDTV7A TN Cellular inhibitor of apoptosis 1 (BIRC2) DMDTV7A MA Inhibitor DMDTV7A RN IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81. DMDTV7A RU https://pubmed.ncbi.nlm.nih.gov/18022362 DMDTV7A DI DMDTV7A DMDTV7A DN BV-6 DMDTV7A TI TTK3WBU DMDTV7A TN XIAP messenger RNA (XIAP mRNA) DMDTV7A MA Inhibitor DMDTV7A RN IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007 Nov 16;131(4):669-81. DMDTV7A RU https://pubmed.ncbi.nlm.nih.gov/18022362 DMDTX4L DI DMDTX4L DMDTX4L DN N-Hydroxycarbamoylmethyl-4-phenoxy-benzamide DMDTX4L TI TTMX39J DMDTX4L TN Matrix metalloproteinase-1 (MMP-1) DMDTX4L MA Inhibitor DMDTX4L RN Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96. DMDTX4L RU https://pubmed.ncbi.nlm.nih.gov/16220975 DMDTYAF DI DMDTYAF DMDTYAF DN 1-(5-chloro-2-hydroxy-4-nitrophenyl)-3-phenylurea DMDTYAF TI TT30C9G DMDTYAF TN C-X-C chemokine receptor type 2 (CXCR2) DMDTYAF MA Inhibitor DMDTYAF RN Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. DMDTYAF RU https://pubmed.ncbi.nlm.nih.gov/17236763 DMDTYRV DI DMDTYRV DMDTYRV DN [3H]eletriptan DMDTYRV TI TT6MSOK DMDTYRV TN 5-HT 1D receptor (HTR1D) DMDTYRV MA Agonist DMDTYRV RN Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. DMDTYRV RU https://pubmed.ncbi.nlm.nih.gov/10193663 DMDTYRV DI DMDTYRV DMDTYRV DN [3H]eletriptan DMDTYRV TI TTK8CXU DMDTYRV TN 5-HT 1B receptor (HTR1B) DMDTYRV MA Agonist DMDTYRV RN Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol. 1999 Mar 5;368(2-3):259-68. DMDTYRV RU https://pubmed.ncbi.nlm.nih.gov/10193663 DMDU10A DI DMDU10A DMDU10A DN 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline DMDU10A TI TT8FYO9 DMDU10A TN Platelet-derived growth factor receptor alpha (PDGFRA) DMDU10A MA Inhibitor DMDU10A RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMDU10A RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMDU10A DI DMDU10A DMDU10A DN 3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline DMDU10A TI TTI7421 DMDU10A TN Platelet-derived growth factor receptor beta (PDGFRB) DMDU10A MA Inhibitor DMDU10A RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMDU10A RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMDU3X7 DI DMDU3X7 DMDU3X7 DN 1-(cyclopropyl)methyl-5'-O-tritylinosine DMDU3X7 TI TTO0IB8 DMDU3X7 TN Thymidine phosphorylase (TYMP) DMDU3X7 MA Inhibitor DMDU3X7 RN 5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70. DMDU3X7 RU https://pubmed.ncbi.nlm.nih.gov/16942029 DMDU6F4 DI DMDU6F4 DMDU6F4 DN LTERHKILHRLLQEGSPSD DMDU6F4 TI TTZAYWL DMDU6F4 TN Estrogen receptor (ESR) DMDU6F4 MA Inhibitor DMDU6F4 RN Bicyclo[2.2.2]octanes: close structural mimics of the nuclear receptor-binding motif of steroid receptor coactivators. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4118-22. DMDU6F4 RU https://pubmed.ncbi.nlm.nih.gov/17560105 DMDUB63 DI DMDUB63 DMDUB63 DN 7-amino-4-hydroxy-2-naphthalenesulfonic acid DMDUB63 TI TTGTQHC DMDUB63 TN DNA topoisomerase I (TOP1) DMDUB63 MA Binder DMDUB63 RN Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11. DMDUB63 RU https://pubmed.ncbi.nlm.nih.gov/9026436 DMDUC2X DI DMDUC2X DMDUC2X DN S-benzyl phenylmethanesulfinothioate DMDUC2X TI TT2SUAQ DMDUC2X TN Cysteine protease (CYP) DMDUC2X MA Inhibitor DMDUC2X RN Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3. DMDUC2X RU https://pubmed.ncbi.nlm.nih.gov/20692829 DMDUF21 DI DMDUF21 DMDUF21 DN 2-(2,4-dichlorophenyl)-4,5-dihydro-1H-imidazole DMDUF21 TI TTGP7BY DMDUF21 TN Monoamine oxidase type B (MAO-B) DMDUF21 MA Inhibitor DMDUF21 RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMDUF21 RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMDUG9M DI DMDUG9M DMDUG9M DN 2-(2-Fluoro-phenyl)-benzo[h]chromen-4-one DMDUG9M TI TTK3PY9 DMDUG9M TN DNA-dependent protein kinase catalytic (PRKDC) DMDUG9M MA Inhibitor DMDUG9M RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMDUG9M RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMDUGQ1 DI DMDUGQ1 DMDUGQ1 DN Trypanothione DMDUGQ1 TI TTRTKPV DMDUGQ1 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMDUGQ1 MA Inhibitor DMDUGQ1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDUGQ1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDUGZS DI DMDUGZS DMDUGZS DN (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS TI TT4H1MQ DMDUGZS TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMDUGZS MA Inhibitor DMDUGZS RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUGZS RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUGZS DI DMDUGZS DMDUGZS DN (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS TI TTVBI8W DMDUGZS TN Dopamine transporter (DAT) DMDUGZS MA Inhibitor DMDUGZS RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUGZS RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUGZS DI DMDUGZS DMDUGZS DN (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS TI TTAWNKZ DMDUGZS TN Norepinephrine transporter (NET) DMDUGZS MA Inhibitor DMDUGZS RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUGZS RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUGZS DI DMDUGZS DMDUGZS DN (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS TI TTTVAFQ DMDUGZS TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMDUGZS MA Inhibitor DMDUGZS RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUGZS RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUGZS DI DMDUGZS DMDUGZS DN (2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol DMDUGZS TI TT5KPZR DMDUGZS TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMDUGZS MA Inhibitor DMDUGZS RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUGZS RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUI8R DI DMDUI8R DMDUI8R DN (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R TI TTVBI8W DMDUI8R TN Dopamine transporter (DAT) DMDUI8R MA Inhibitor DMDUI8R RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUI8R RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUI8R DI DMDUI8R DMDUI8R DN (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R TI TT4H1MQ DMDUI8R TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMDUI8R MA Inhibitor DMDUI8R RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUI8R RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUI8R DI DMDUI8R DMDUI8R DN (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R TI TT5KPZR DMDUI8R TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMDUI8R MA Inhibitor DMDUI8R RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUI8R RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUI8R DI DMDUI8R DMDUI8R DN (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R TI TTTVAFQ DMDUI8R TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMDUI8R MA Inhibitor DMDUI8R RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUI8R RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUI8R DI DMDUI8R DMDUI8R DN (2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol DMDUI8R TI TTAWNKZ DMDUI8R TN Norepinephrine transporter (NET) DMDUI8R MA Inhibitor DMDUI8R RN Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. DMDUI8R RU https://pubmed.ncbi.nlm.nih.gov/20509659 DMDUIG3 DI DMDUIG3 DMDUIG3 DN ISIS 11221 DMDUIG3 TI TTRE6AX DMDUIG3 TN Bcl-x messenger RNA (BCL2L1 mRNA) DMDUIG3 RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMDUIG3 RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMDUN83 DI DMDUN83 DMDUN83 DN (L-)-S-adenosyl-L-homocysteine DMDUN83 TI TT2B6EV DMDUN83 TN Histamine N-methyltransferase (HNMT) DMDUN83 MA Inhibitor DMDUN83 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDUN83 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDUN83 DI DMDUN83 DMDUN83 DN (L-)-S-adenosyl-L-homocysteine DMDUN83 TI TTHVCUP DMDUN83 TN DNA [cytosine-5]-methyltransferase (DNMT) DMDUN83 MA Inhibitor DMDUN83 RN Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6. DMDUN83 RU https://pubmed.ncbi.nlm.nih.gov/19364644 DMDUN83 DI DMDUN83 DMDUN83 DN (L-)-S-adenosyl-L-homocysteine DMDUN83 TI TT6VZ78 DMDUN83 TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMDUN83 MA Inhibitor DMDUN83 RN Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009 May 15;19(10):2742-6. DMDUN83 RU https://pubmed.ncbi.nlm.nih.gov/19364644 DMDUOH4 DI DMDUOH4 DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide DMDUOH4 TI TTSHTOI DMDUOH4 TN Histone deacetylase 2 (HDAC2) DMDUOH4 MA Inhibitor DMDUOH4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMDUOH4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMDUOH4 DI DMDUOH4 DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide DMDUOH4 TI TTYHPU6 DMDUOH4 TN Histone deacetylase 10 (HDAC10) DMDUOH4 MA Inhibitor DMDUOH4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMDUOH4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMDUOH4 DI DMDUOH4 DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide DMDUOH4 TI TTTQGH8 DMDUOH4 TN Histone deacetylase 4 (HDAC4) DMDUOH4 MA Inhibitor DMDUOH4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMDUOH4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMDUOH4 DI DMDUOH4 DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide DMDUOH4 TI TT5ZKDI DMDUOH4 TN Histone deacetylase 6 (HDAC6) DMDUOH4 MA Inhibitor DMDUOH4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMDUOH4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMDUOH4 DI DMDUOH4 DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide DMDUOH4 TI TT6R7JZ DMDUOH4 TN Histone deacetylase 1 (HDAC1) DMDUOH4 MA Inhibitor DMDUOH4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMDUOH4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMDUOH4 DI DMDUOH4 DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide DMDUOH4 TI TTBH0VX DMDUOH4 TN Histone deacetylase (HDAC) DMDUOH4 MA Inhibitor DMDUOH4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMDUOH4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMDUOH4 DI DMDUOH4 DMDUOH4 DN N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide DMDUOH4 TI TTT6LFV DMDUOH4 TN Histone deacetylase 8 (HDAC8) DMDUOH4 MA Inhibitor DMDUOH4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMDUOH4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMDUR4C DI DMDUR4C DMDUR4C DN FPYVAE peptide DMDUR4C TI TTPADOQ DMDUR4C TN HMG-CoA reductase (HMGCR) DMDUR4C MA Inhibitor DMDUR4C RN Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase. Bioorg Med Chem. 2010 Jun 15;18(12):4300-9. DMDUR4C RU https://pubmed.ncbi.nlm.nih.gov/20494585 DMDUW9F DI DMDUW9F DMDUW9F DN Sulfamic acid 4-benzoyl-phenyl ester DMDUW9F TI TTHM0R1 DMDUW9F TN Steryl-sulfatase (STS) DMDUW9F MA Inhibitor DMDUW9F RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMDUW9F RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMDUWBF DI DMDUWBF DMDUWBF DN JNJ-17203212 DMDUWBF TI TTMI6F5 DMDUWBF TN Transient receptor potential cation channel V1 (TRPV1) DMDUWBF MA Inhibitor DMDUWBF RN The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J Med Chem. 2007 May 31;50(11):2589-96. DMDUWBF RU https://pubmed.ncbi.nlm.nih.gov/17489570 DMDUZ2H DI DMDUZ2H DMDUZ2H DN 2-Amino-5-(N-nitro-guanidino)-pentanoic acid DMDUZ2H TI TTZUFI5 DMDUZ2H TN Nitric-oxide synthase brain (NOS1) DMDUZ2H MA Inhibitor DMDUZ2H RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMDUZ2H RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMDUZ2H DI DMDUZ2H DMDUZ2H DN 2-Amino-5-(N-nitro-guanidino)-pentanoic acid DMDUZ2H TI TTF10I9 DMDUZ2H TN Nitric-oxide synthase inducible (NOS2) DMDUZ2H MA Inhibitor DMDUZ2H RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMDUZ2H RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMDUZ2H DI DMDUZ2H DMDUZ2H DN 2-Amino-5-(N-nitro-guanidino)-pentanoic acid DMDUZ2H TI TTCM4B3 DMDUZ2H TN Nitric-oxide synthase endothelial (NOS3) DMDUZ2H MA Inhibitor DMDUZ2H RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMDUZ2H RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMDV1SN DI DMDV1SN DMDV1SN DN Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol DMDV1SN TI TTK25J1 DMDV1SN TN Adenosine A1 receptor (ADORA1) DMDV1SN MA Inhibitor DMDV1SN RN Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. DMDV1SN RU https://pubmed.ncbi.nlm.nih.gov/18406614 DMDV1SN DI DMDV1SN DMDV1SN DN Phenyl(2-(trifluoromethyl)quinolin-4-yl)methanol DMDV1SN TI TTM2AOE DMDV1SN TN Adenosine A2a receptor (ADORA2A) DMDV1SN MA Inhibitor DMDV1SN RN Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. DMDV1SN RU https://pubmed.ncbi.nlm.nih.gov/18406614 DMDV48S DI DMDV48S DMDV48S DN 5-Fluorolevulinic Acid DMDV48S TI TTJHKYD DMDV48S TN Delta-aminolevulinic acid dehydratase (ALAD) DMDV48S MA Inhibitor DMDV48S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDV48S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDV67S DI DMDV67S DMDV67S DN lergotrile DMDV67S TI TTJS8PY DMDV67S TN 5-HT 6 receptor (HTR6) DMDV67S MA Agonist DMDV67S RN Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. DMDV67S RU https://pubmed.ncbi.nlm.nih.gov/7680751 DMDV8UT DI DMDV8UT DMDV8UT DN 8-acetyl-7-ethoxy-2H-chromen-2-one DMDV8UT TI TT2LVK8 DMDV8UT TN Carbonic anhydrase IX (CA-IX) DMDV8UT MA Inhibitor DMDV8UT RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMDV8UT RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMDVE6A DI DMDVE6A DMDVE6A DN ISIS 109490 DMDVE6A TI TT3K9S2 DMDVE6A TN RANK messenger RNA (RANK mRNA) DMDVE6A RN US patent application no. 6,171,860, Antisense inhibition of rank expression. DMDVE6A RU http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true DMDVIT1 DI DMDVIT1 DMDVIT1 DN Akt inhibitor VIII DMDVIT1 TI TTAZ05C DMDVIT1 TN RAC-gamma serine/threonine-protein kinase (AKT3) DMDVIT1 MA Inhibitor DMDVIT1 RN Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4. DMDVIT1 RU https://pubmed.ncbi.nlm.nih.gov/15664853 DMDVIT1 DI DMDVIT1 DMDVIT1 DN Akt inhibitor VIII DMDVIT1 TI TTWTSCV DMDVIT1 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMDVIT1 MA Inhibitor DMDVIT1 RN Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4. DMDVIT1 RU https://pubmed.ncbi.nlm.nih.gov/15664853 DMDVIT1 DI DMDVIT1 DMDVIT1 DN Akt inhibitor VIII DMDVIT1 TI TTH24WI DMDVIT1 TN RAC-beta serine/threonine-protein kinase (AKT2) DMDVIT1 MA Inhibitor DMDVIT1 RN Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):761-4. DMDVIT1 RU https://pubmed.ncbi.nlm.nih.gov/15664853 DMDVMSP DI DMDVMSP DMDVMSP DN (RS/SR)-2-[1-(4-chlorophenyl)hexyl]piperidine DMDVMSP TI TTVBI8W DMDVMSP TN Dopamine transporter (DAT) DMDVMSP MA Inhibitor DMDVMSP RN Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. DMDVMSP RU https://pubmed.ncbi.nlm.nih.gov/17228864 DMDVO7Z DI DMDVO7Z DMDVO7Z DN 2-methyl-6-(5-phenylpent-1-ynyl)pyridine DMDVO7Z TI TTHS256 DMDVO7Z TN Metabotropic glutamate receptor 5 (mGluR5) DMDVO7Z MA Inhibitor DMDVO7Z RN Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamate receptor 5 (mGl... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91. DMDVO7Z RU https://pubmed.ncbi.nlm.nih.gov/16837196 DMDVO9T DI DMDVO9T DMDVO9T DN N-isopropylnorlitebamineN-methoiodide DMDVO9T TI TT1RS9F DMDVO9T TN Acetylcholinesterase (AChE) DMDVO9T MA Inhibitor DMDVO9T RN Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50. DMDVO9T RU https://pubmed.ncbi.nlm.nih.gov/9461651 DMDVW4K DI DMDVW4K DMDVW4K DN PMID17929793C11c DMDVW4K TI TTVBPDM DMDVW4K TN Metabotropic glutamate receptor 1 (mGluR1) DMDVW4K MA Modulator (allosteric modulator) DMDVW4K RN Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3. DMDVW4K RU https://pubmed.ncbi.nlm.nih.gov/17929793 DMDW267 DI DMDW267 DMDW267 DN 9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazole DMDW267 TI TTX41N9 DMDW267 TN Tyrosine-protein kinase Kit (KIT) DMDW267 MA Inhibitor DMDW267 RN Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201. DMDW267 RU https://pubmed.ncbi.nlm.nih.gov/16190746 DMDW2NL DI DMDW2NL DMDW2NL DN dihydroergocryptine DMDW2NL TI TTO9X1H DMDW2NL TN 5-HT 7 receptor (HTR7) DMDW2NL MA Antagonist DMDW2NL RN Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36. DMDW2NL RU https://pubmed.ncbi.nlm.nih.gov/8394987 DMDW2NL DI DMDW2NL DMDW2NL DN dihydroergocryptine DMDW2NL TI TT0K1SC DMDW2NL TN 5-HT 2B receptor (HTR2B) DMDW2NL MA Agonist DMDW2NL RN Structural features for functional selectivity at serotonin receptors. Science. 2013 May 3;340(6132):615-9. DMDW2NL RU https://pubmed.ncbi.nlm.nih.gov/23519215 DMDW3SX DI DMDW3SX DMDW3SX DN 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine DMDW3SX TI TTH6V3D DMDW3SX TN Cyclin-dependent kinase 1 (CDK1) DMDW3SX MA Inhibitor DMDW3SX RN Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86. DMDW3SX RU https://pubmed.ncbi.nlm.nih.gov/19879023 DMDW3SX DI DMDW3SX DMDW3SX DN 4-(Quinolin-4-yl)-N-p-tolylpyrimidin-2-amine DMDW3SX TI TT9P6OW DMDW3SX TN G2/mitotic-specific cyclin B1 (CCNB1) DMDW3SX MA Inhibitor DMDW3SX RN Synthesis and cytotoxic activity of 2-methylimidazo[1,2-a]pyridine- and quinoline-substituted 2-aminopyrimidine derivatives. Eur J Med Chem. 2010 Jan;45(1):379-86. DMDW3SX RU https://pubmed.ncbi.nlm.nih.gov/19879023 DMDW8VX DI DMDW8VX DMDW8VX DN N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide DMDW8VX TI TTHS256 DMDW8VX TN Metabotropic glutamate receptor 5 (mGluR5) DMDW8VX MA Inhibitor DMDW8VX RN Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44. DMDW8VX RU https://pubmed.ncbi.nlm.nih.gov/16722652 DMDW9MS DI DMDW9MS DMDW9MS DN VU0463841 DMDW9MS TI TTHS256 DMDW9MS TN Metabotropic glutamate receptor 5 (mGluR5) DMDW9MS MA Modulator (allosteric modulator) DMDW9MS RN Substituted 1-Phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction. ACS Chem Neurosci. 2013Aug 21;4(8):1217-28. DMDW9MS RU https://pubmed.ncbi.nlm.nih.gov/23682684 DMDWCY7 DI DMDWCY7 DMDWCY7 DN AX-006 DMDWCY7 TI TTT1JVS DMDWCY7 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMDWCY7 MA Inhibitor DMDWCY7 RN 2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides. Bioorg Med Chem. 2009 Jul 1;17(13):4833-43. DMDWCY7 RU https://pubmed.ncbi.nlm.nih.gov/19443224 DMDWESP DI DMDWESP DMDWESP DN NE97220 DMDWESP TI TTIKWV4 DMDWESP TN Geranyltranstransferase (FDPS) DMDWESP MA Inhibitor DMDWESP RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMDWESP RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMDWFHV DI DMDWFHV DMDWFHV DN (S)-2-Amino-N-cyclopentyl-7-mercaptoheptanamide DMDWFHV TI TT5ZKDI DMDWFHV TN Histone deacetylase 6 (HDAC6) DMDWFHV MA Inhibitor DMDWFHV RN Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhib... J Med Chem. 2007 Nov 1;50(22):5425-38. DMDWFHV RU https://pubmed.ncbi.nlm.nih.gov/17929798 DMDWGS9 DI DMDWGS9 DMDWGS9 DN 4-Hydroxy-4-phenyl-butyric acid DMDWGS9 TI TT6TKEN DMDWGS9 TN Gamma-hydroxybutyrate receptor (SLC52A2) DMDWGS9 MA Inhibitor DMDWGS9 RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DMDWGS9 RU https://pubmed.ncbi.nlm.nih.gov/3361576 DMDWHIN DI DMDWHIN DMDWHIN DN PMID30247903-Compound-General structure37 DMDWHIN TI TT23XQV DMDWHIN TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMDWHIN MA Inhibitor DMDWHIN RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMDWHIN RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMDWRE5 DI DMDWRE5 DMDWRE5 DN 4-tert-butyl-N-(2-isopropylphenyl)thiazol-2-amine DMDWRE5 TI TT7HQD0 DMDWRE5 TN C-C chemokine receptor type 4 (CCR4) DMDWRE5 MA Inhibitor DMDWRE5 RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMDWRE5 RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMDWSH1 DI DMDWSH1 DMDWSH1 DN Factor-VIIa-XTEN DMDWSH1 TI TTF0EGX DMDWSH1 TN Coagulation factor VII (F7) DMDWSH1 MA Modulator DMDWSH1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMDWSH1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMDWUCX DI DMDWUCX DMDWUCX DN Tetragastrin DMDWUCX TI TTCG0AL DMDWUCX TN Cholecystokinin receptor type A (CCKAR) DMDWUCX MA Inhibitor DMDWUCX RN Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors. J Med Chem. 1987 Apr;30(4):729-32. DMDWUCX RU https://pubmed.ncbi.nlm.nih.gov/3560164 DMDWUCX DI DMDWUCX DMDWUCX DN Tetragastrin DMDWUCX TI TTVFO0U DMDWUCX TN Gastrin/cholecystokinin type B receptor (CCKBR) DMDWUCX MA Inhibitor DMDWUCX RN Synthesis and binding affinities of analogues of cholecystokinin-(30-33) as probes for central nervous system cholecystokinin receptors. J Med Chem. 1987 Apr;30(4):729-32. DMDWUCX RU https://pubmed.ncbi.nlm.nih.gov/3560164 DMDWZGJ DI DMDWZGJ DMDWZGJ DN 5-hydroxy-L-tryptophan DMDWZGJ TI TT5U0XA DMDWZGJ TN Solute carrier family 36 member 2 (SLC36A2) DMDWZGJ MA Inhibitor DMDWZGJ RN Amino acid derivatives are substrates or non-transported inhibitors of the amino acid transporter PAT2 (slc36a2). Biochim Biophys Acta. 2011 Jan;1808(1):260-70. DMDWZGJ RU https://pubmed.ncbi.nlm.nih.gov/20691150 DMDWZGJ DI DMDWZGJ DMDWZGJ DN 5-hydroxy-L-tryptophan DMDWZGJ TI TTUYIZW DMDWZGJ TN Solute carrier family 36 member 1 (SLC36A1) DMDWZGJ MA Inhibitor DMDWZGJ RN Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J. 2005 Sep;19(11):1468-73. DMDWZGJ RU https://pubmed.ncbi.nlm.nih.gov/16126914 DMDX0VI DI DMDX0VI DMDX0VI DN Trecadrine DMDX0VI TI TTANPDJ DMDX0VI TN Carbonic anhydrase II (CA-II) DMDX0VI MA Inhibitor DMDX0VI RN Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enzyme Inhib. 1997 Aug;12(3):175-90. DMDX0VI RU https://pubmed.ncbi.nlm.nih.gov/9314114 DMDX0VI DI DMDX0VI DMDX0VI DN Trecadrine DMDX0VI TI TTZHA0O DMDX0VI TN Carbonic anhydrase IV (CA-IV) DMDX0VI MA Inhibitor DMDX0VI RN Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enzyme Inhib. 1997 Aug;12(3):175-90. DMDX0VI RU https://pubmed.ncbi.nlm.nih.gov/9314114 DMDX0VI DI DMDX0VI DMDX0VI DN Trecadrine DMDX0VI TI TTHQPL7 DMDX0VI TN Carbonic anhydrase I (CA-I) DMDX0VI MA Inhibitor DMDX0VI RN Sulfenamido-sulfonamides as inhibitors of carbonic anhydrase isozymes I, II and IV. J Enzyme Inhib. 1997 Aug;12(3):175-90. DMDX0VI RU https://pubmed.ncbi.nlm.nih.gov/9314114 DMDX0VI DI DMDX0VI DMDX0VI DN Trecadrine DMDX0VI TI TTMXGCW DMDX0VI TN Adrenergic receptor beta-3 (ADRB3) DMDX0VI MA Agonist DMDX0VI RN Potential anti-diabetic applications of a new molecule with affinity for beta 3-adrenoceptors. Life Sci. 1996;59(11):PL141-6. DMDX0VI RU https://pubmed.ncbi.nlm.nih.gov/8795708 DMDX0VP DI DMDX0VP DMDX0VP DN 4-amino-N-[4-(benzyloxy)phenyl]butanamide DMDX0VP TI TTXZEAJ DMDX0VP TN Leukotriene A-4 hydrolase (LTA4H) DMDX0VP MA Inhibitor DMDX0VP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMDX0VP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMDX6W4 DI DMDX6W4 DMDX6W4 DN [1,3]Oxazinan-(2E)-ylideneamine DMDX6W4 TI TTZUFI5 DMDX6W4 TN Nitric-oxide synthase brain (NOS1) DMDX6W4 MA Inhibitor DMDX6W4 RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMDX6W4 RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMDX6W4 DI DMDX6W4 DMDX6W4 DN [1,3]Oxazinan-(2E)-ylideneamine DMDX6W4 TI TTF10I9 DMDX6W4 TN Nitric-oxide synthase inducible (NOS2) DMDX6W4 MA Inhibitor DMDX6W4 RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMDX6W4 RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMDX6W4 DI DMDX6W4 DMDX6W4 DN [1,3]Oxazinan-(2E)-ylideneamine DMDX6W4 TI TTCM4B3 DMDX6W4 TN Nitric-oxide synthase endothelial (NOS3) DMDX6W4 MA Inhibitor DMDX6W4 RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMDX6W4 RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMDX8M3 DI DMDX8M3 DMDX8M3 DN Boc-Agly-Val-Agly-OEt DMDX8M3 TI TTDZN01 DMDX8M3 TN Cathepsin K (CTSK) DMDX8M3 MA Inhibitor DMDX8M3 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMDX8M3 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMDXBQA DI DMDXBQA DMDXBQA DN Ac-Phe-Phe-NH2 DMDXBQA TI TTZPO1L DMDXBQA TN Substance-P receptor (TACR1) DMDXBQA MA Inhibitor DMDXBQA RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMDXBQA RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMDXCIV DI DMDXCIV DMDXCIV DN JWH-209 DMDXCIV TI TTMSFAW DMDXCIV TN Cannabinoid receptor 2 (CB2) DMDXCIV MA Inhibitor DMDXCIV RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMDXCIV RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMDXIN1 DI DMDXIN1 DMDXIN1 DN 2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline DMDXIN1 TI TTJFY5U DMDXIN1 TN Adenosine A3 receptor (ADORA3) DMDXIN1 MA Inhibitor DMDXIN1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DMDXIN1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DMDXIN1 DI DMDXIN1 DMDXIN1 DN 2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline DMDXIN1 TI TTM2AOE DMDXIN1 TN Adenosine A2a receptor (ADORA2A) DMDXIN1 MA Inhibitor DMDXIN1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DMDXIN1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DMDXIN1 DI DMDXIN1 DMDXIN1 DN 2-(4-methyl-1H-benzo[d]imidazol-2-yl)quinoxaline DMDXIN1 TI TTK25J1 DMDXIN1 TN Adenosine A1 receptor (ADORA1) DMDXIN1 MA Inhibitor DMDXIN1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DMDXIN1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DMDXIS7 DI DMDXIS7 DMDXIS7 DN H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645) DMDXIS7 TI TTG5QIA DMDXIS7 TN B1 bradykinin receptor (BDKRB1) DMDXIS7 MA Inhibitor DMDXIS7 RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DMDXIS7 RU https://pubmed.ncbi.nlm.nih.gov/10882364 DMDXIS7 DI DMDXIS7 DMDXIS7 DN H-Lys-Arg-Pro-Hyp-Gly-Igl-Ser-D-BT-OH(JMV1645) DMDXIS7 TI TTGY8IW DMDXIS7 TN B2 bradykinin receptor (BDKRB2) DMDXIS7 MA Inhibitor DMDXIS7 RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DMDXIS7 RU https://pubmed.ncbi.nlm.nih.gov/10882364 DMDXKQ6 DI DMDXKQ6 DMDXKQ6 DN (+/-)-2-(4'-Benzyloxyphenyl)thiomorpholin-5-one DMDXKQ6 TI TTGP7BY DMDXKQ6 TN Monoamine oxidase type B (MAO-B) DMDXKQ6 MA Inhibitor DMDXKQ6 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMDXKQ6 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMDXM2A DI DMDXM2A DMDXM2A DN Naphthalen-2-yl cyclohexylcarbamate DMDXM2A TI TTDP1UC DMDXM2A TN Fatty acid amide hydrolase (FAAH) DMDXM2A MA Inhibitor DMDXM2A RN Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43. DMDXM2A RU https://pubmed.ncbi.nlm.nih.gov/18983142 DMDXOBH DI DMDXOBH DMDXOBH DN 7-(3-fluorophenyl)-2-methylquinoline DMDXOBH TI TTHS256 DMDXOBH TN Metabotropic glutamate receptor 5 (mGluR5) DMDXOBH MA Inhibitor DMDXOBH RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMDXOBH RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMDXRP1 DI DMDXRP1 DMDXRP1 DN ETHISTERONE DMDXRP1 TI TTULVH8 DMDXRP1 TN Tyrosinase (TYR) DMDXRP1 MA Inhibitor DMDXRP1 RN TOMOCOMD-CARDD descriptors-based virtual screening of tyrosinase inhibitors: evaluation of different classification model combinations using bond-b... Bioorg Med Chem. 2007 Feb 1;15(3):1483-503. DMDXRP1 RU https://pubmed.ncbi.nlm.nih.gov/17110117 DMDY1M7 DI DMDY1M7 DMDY1M7 DN SRIF-14 DMDY1M7 TI TTIND6G DMDY1M7 TN Somatostatin receptor type 1 (SSTR1) DMDY1M7 MA Agonist DMDY1M7 RN Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41. DMDY1M7 RU https://pubmed.ncbi.nlm.nih.gov/9724791 DMDY1M7 DI DMDY1M7 DMDY1M7 DN SRIF-14 DMDY1M7 TI TTAE1BR DMDY1M7 TN Somatostatin receptor type 4 (SSTR4) DMDY1M7 MA Agonist DMDY1M7 RN Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41. DMDY1M7 RU https://pubmed.ncbi.nlm.nih.gov/9724791 DMDY1M7 DI DMDY1M7 DMDY1M7 DN SRIF-14 DMDY1M7 TI TTZ6T9E DMDY1M7 TN Somatostatin receptor type 2 (SSTR2) DMDY1M7 MA Agonist DMDY1M7 RN [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20. DMDY1M7 RU https://pubmed.ncbi.nlm.nih.gov/9652348 DMDY1M7 DI DMDY1M7 DMDY1M7 DN SRIF-14 DMDY1M7 TI TT2BC4G DMDY1M7 TN Somatostatin receptor type 5 (SSTR5) DMDY1M7 MA Agonist DMDY1M7 RN [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20. DMDY1M7 RU https://pubmed.ncbi.nlm.nih.gov/9652348 DMDY1M7 DI DMDY1M7 DMDY1M7 DN SRIF-14 DMDY1M7 TI TTJX3UE DMDY1M7 TN Somatostatin receptor type 3 (SSTR3) DMDY1M7 MA Agonist DMDY1M7 RN A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 1993 Apr 26;321(2-3):279-84. DMDY1M7 RU https://pubmed.ncbi.nlm.nih.gov/8097479 DMDY1MZ DI DMDY1MZ DMDY1MZ DN tetrahydrocannabivarin DMDY1MZ TI TT946IA DMDY1MZ TN Transient receptor potential cation channel V3 (TRPV3) DMDY1MZ MA Activator DMDY1MZ RN Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf). 2012 Feb;204(2):255-66. DMDY1MZ RU https://pubmed.ncbi.nlm.nih.gov/21726418 DMDY2PQ DI DMDY2PQ DMDY2PQ DN 7-Dimethylamino-3-methyl-hept-5-yn-2-one DMDY2PQ TI TTYEG6Q DMDY2PQ TN Muscarinic acetylcholine receptor M2 (CHRM2) DMDY2PQ MA Inhibitor DMDY2PQ RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMDY2PQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMDY2PQ DI DMDY2PQ DMDY2PQ DN 7-Dimethylamino-3-methyl-hept-5-yn-2-one DMDY2PQ TI TTZ9SOR DMDY2PQ TN Muscarinic acetylcholine receptor M1 (CHRM1) DMDY2PQ MA Inhibitor DMDY2PQ RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMDY2PQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMDY2PQ DI DMDY2PQ DMDY2PQ DN 7-Dimethylamino-3-methyl-hept-5-yn-2-one DMDY2PQ TI TTQ13Z5 DMDY2PQ TN Muscarinic acetylcholine receptor M3 (CHRM3) DMDY2PQ MA Inhibitor DMDY2PQ RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMDY2PQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMDY2PQ DI DMDY2PQ DMDY2PQ DN 7-Dimethylamino-3-methyl-hept-5-yn-2-one DMDY2PQ TI TTH18TF DMDY2PQ TN Muscarinic acetylcholine receptor M5 (CHRM5) DMDY2PQ MA Inhibitor DMDY2PQ RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMDY2PQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMDY2PQ DI DMDY2PQ DMDY2PQ DN 7-Dimethylamino-3-methyl-hept-5-yn-2-one DMDY2PQ TI TTQ3JTF DMDY2PQ TN Muscarinic acetylcholine receptor M4 (CHRM4) DMDY2PQ MA Inhibitor DMDY2PQ RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMDY2PQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMDY38R DI DMDY38R DMDY38R DN Org-33201 DMDY38R TI TTSZLWK DMDY38R TN Aromatase (CYP19A1) DMDY38R MA Modulator DMDY38R RN Org 33201: a new highly selective orally active aromatase inhibitor. J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):681-2. DMDY38R RU https://www.ncbi.nlm.nih.gov/pubmed/8476784 DMDY3I2 DI DMDY3I2 DMDY3I2 DN Quinoline-2-carboxylic acid adamantan-1-ylamide DMDY3I2 TI TTVBPDM DMDY3I2 TN Metabotropic glutamate receptor 1 (mGluR1) DMDY3I2 MA Inhibitor DMDY3I2 RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DMDY3I2 RU https://pubmed.ncbi.nlm.nih.gov/18173231 DMDY3JQ DI DMDY3JQ DMDY3JQ DN 2-ethylamido-5-sulfonamidoindane DMDY3JQ TI TTANPDJ DMDY3JQ TN Carbonic anhydrase II (CA-II) DMDY3JQ MA Inhibitor DMDY3JQ RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMDY3JQ RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMDY3JQ DI DMDY3JQ DMDY3JQ DN 2-ethylamido-5-sulfonamidoindane DMDY3JQ TI TT2LVK8 DMDY3JQ TN Carbonic anhydrase IX (CA-IX) DMDY3JQ MA Inhibitor DMDY3JQ RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMDY3JQ RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMDY3JQ DI DMDY3JQ DMDY3JQ DN 2-ethylamido-5-sulfonamidoindane DMDY3JQ TI TTHQPL7 DMDY3JQ TN Carbonic anhydrase I (CA-I) DMDY3JQ MA Inhibitor DMDY3JQ RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMDY3JQ RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMDY93H DI DMDY93H DMDY93H DN 1-(4-iodooxazol-2-yl)-7-phenylheptan-1-one DMDY93H TI TTDP1UC DMDY93H TN Fatty acid amide hydrolase (FAAH) DMDY93H MA Inhibitor DMDY93H RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMDY93H RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMDYBIC DI DMDYBIC DMDYBIC DN 4'-(5-Chloro-2-thienyl)biphenyl-3-ol DMDYBIC TI TTIWB6L DMDYBIC TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMDYBIC MA Inhibitor DMDYBIC RN Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505. DMDYBIC RU https://pubmed.ncbi.nlm.nih.gov/20413314 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTRJB2G DMDYC4J TN Ephrin type-A receptor 2 (EPHA2) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTZEMUY DMDYC4J TN Ephrin type-B receptor 6 (EPHB6) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTHZ2LW DMDYC4J TN Ephrin type-A receptor 8 (EPHA8) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTLFZVU DMDYC4J TN Ephrin type-A receptor 1 (EPHA1) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTFAHWI DMDYC4J TN Ephrin type-A receptor 6 (EPHA6) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTV9KOD DMDYC4J TN Ephrin type-A receptor 5 (EPHA5) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTI4ZX2 DMDYC4J TN Ephrin type-B receptor 4 (EPHB4) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTHS2LR DMDYC4J TN Ephrin type-A receptor 3 (EPHA3) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTG84D3 DMDYC4J TN Ephrin type-A receptor 4 (EPHA4) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TT5LM7U DMDYC4J TN Ephrin type-B receptor 3 (EPHB3) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTAHTVG DMDYC4J TN Ephrin type-A receptor 7 (EPHA7) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TT8MDAC DMDYC4J TN Ephrin type-B receptor 1 (EPHB1) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYC4J DI DMDYC4J DMDYC4J DN PMID23489211C20 DMDYC4J TI TTKPV6O DMDYC4J TN Ephrin type-B receptor 2 (EPHB2) DMDYC4J MA Inhibitor DMDYC4J RN Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. DMDYC4J RU https://pubmed.ncbi.nlm.nih.gov/23489211 DMDYHXE DI DMDYHXE DMDYHXE DN 4-(2-Phenylacetamidomethyl)benzenesulfonamide DMDYHXE TI TTUNARX DMDYHXE TN Carbonic anhydrase (CA) DMDYHXE MA Inhibitor DMDYHXE RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMDYHXE RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMDYHXE DI DMDYHXE DMDYHXE DN 4-(2-Phenylacetamidomethyl)benzenesulfonamide DMDYHXE TI TTHQPL7 DMDYHXE TN Carbonic anhydrase I (CA-I) DMDYHXE MA Inhibitor DMDYHXE RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMDYHXE RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMDYHXE DI DMDYHXE DMDYHXE DN 4-(2-Phenylacetamidomethyl)benzenesulfonamide DMDYHXE TI TTANPDJ DMDYHXE TN Carbonic anhydrase II (CA-II) DMDYHXE MA Inhibitor DMDYHXE RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMDYHXE RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMDYNBT DI DMDYNBT DMDYNBT DN BS 7840 DMDYNBT TI TTVG215 DMDYNBT TN Debrisoquine 4-hydroxylase (CYP2D6) DMDYNBT MA Inhibitor DMDYNBT RN Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30. DMDYNBT RU https://pubmed.ncbi.nlm.nih.gov/16610785 DMDYQE2 DI DMDYQE2 DMDYQE2 DN 6-(3-(trifluoromethyl)phenyl)picolinonitrile DMDYQE2 TI TTUMQVO DMDYQE2 TN Cathepsin S (CTSS) DMDYQE2 MA Inhibitor DMDYQE2 RN 4-(3-Trifluoromethylphenyl)-pyrimidine-2-carbonitrile as cathepsin S inhibitors: N3, not N1 is critically important. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4507-10. DMDYQE2 RU https://pubmed.ncbi.nlm.nih.gov/20580231 DMDYRNF DI DMDYRNF DMDYRNF DN 2'-Monophosphoadenosine-5'-Diphosphate DMDYRNF TI TT9SL3Q DMDYRNF TN Polypeptide deformylase (PDF) DMDYRNF MA Inhibitor DMDYRNF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMDYRNF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMDYS0L DI DMDYS0L DMDYS0L DN AG 112 DMDYS0L TI TTGKNB4 DMDYS0L TN Epidermal growth factor receptor (EGFR) DMDYS0L MA Inhibitor DMDYS0L RN Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52. DMDYS0L RU https://pubmed.ncbi.nlm.nih.gov/2552117 DMDYS7Q DI DMDYS7Q DMDYS7Q DN 3-(4-hexylthiosemicarbazono)methyl-benzoic acid DMDYS7Q TI TTHM0R1 DMDYS7Q TN Steryl-sulfatase (STS) DMDYS7Q MA Inhibitor DMDYS7Q RN Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6. DMDYS7Q RU https://pubmed.ncbi.nlm.nih.gov/17580843 DMDYT6P DI DMDYT6P DMDYT6P DN PMID25742366C14b DMDYT6P TI TTSCHFW DMDYT6P TN Peptidyl arginine deiminase type III (PADI3) DMDYT6P MA Inhibitor DMDYT6P RN Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21. DMDYT6P RU https://pubmed.ncbi.nlm.nih.gov/25742366 DMDYT6P DI DMDYT6P DMDYT6P DN PMID25742366C14b DMDYT6P TI TTQHAXM DMDYT6P TN Peptidyl arginine deiminase type IV (PADI4) DMDYT6P MA Inhibitor DMDYT6P RN Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21. DMDYT6P RU https://pubmed.ncbi.nlm.nih.gov/25742366 DMDYTSW DI DMDYTSW DMDYTSW DN W146 DMDYTSW TI TT9JZCK DMDYTSW TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMDYTSW MA Antagonist DMDYTSW RN Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat Chem Biol. 2006 Aug;2(8):434-41. DMDYTSW RU https://pubmed.ncbi.nlm.nih.gov/16829954 DMDYVA7 DI DMDYVA7 DMDYVA7 DN 3-(4-Pyridin-2-yl-imidazol-1-yl)-benzonitrile DMDYVA7 TI TTHS256 DMDYVA7 TN Metabotropic glutamate receptor 5 (mGluR5) DMDYVA7 MA Inhibitor DMDYVA7 RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMDYVA7 RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMDYW4J DI DMDYW4J DMDYW4J DN 3-(2,6-diphenylpyridin-4-yl)phenol DMDYW4J TI TT0IHXV DMDYW4J TN DNA topoisomerase II (TOP2) DMDYW4J MA Inhibitor DMDYW4J RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMDYW4J RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMDYX7P DI DMDYX7P DMDYX7P DN 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline DMDYX7P TI TTWM4TY DMDYX7P TN Adrenergic receptor alpha-2B (ADRA2B) DMDYX7P MA Inhibitor DMDYX7P RN N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70. DMDYX7P RU https://pubmed.ncbi.nlm.nih.gov/9767652 DMDYX7P DI DMDYX7P DMDYX7P DN 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline DMDYX7P TI TTWG9A4 DMDYX7P TN Adrenergic receptor alpha-2A (ADRA2A) DMDYX7P MA Inhibitor DMDYX7P RN N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70. DMDYX7P RU https://pubmed.ncbi.nlm.nih.gov/9767652 DMDYX7P DI DMDYX7P DMDYX7P DN 1,2,3,4,4a,5,10,10a-Octahydro-benzo[g]quinoline DMDYX7P TI TT2NUT5 DMDYX7P TN Adrenergic receptor alpha-2C (ADRA2C) DMDYX7P MA Inhibitor DMDYX7P RN N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70. DMDYX7P RU https://pubmed.ncbi.nlm.nih.gov/9767652 DMDYZ9K DI DMDYZ9K DMDYZ9K DN N-(3,3-diphenyl-propyl)-nicotinamide DMDYZ9K TI TT7WVHI DMDYZ9K TN Soluble epoxide hydrolase (EPHX2) DMDYZ9K MA Inhibitor DMDYZ9K RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DMDYZ9K RU https://pubmed.ncbi.nlm.nih.gov/19746975 DMDYZCH DI DMDYZCH DMDYZCH DN 9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine DMDYZCH TI TTM2AOE DMDYZCH TN Adenosine A2a receptor (ADORA2A) DMDYZCH MA Inhibitor DMDYZCH RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DMDYZCH RU https://pubmed.ncbi.nlm.nih.gov/18411049 DMDYZCH DI DMDYZCH DMDYZCH DN 9-(3-aminobenzyl)-6-(furan-2-yl)-9H-purin-2-amine DMDYZCH TI TTK25J1 DMDYZCH TN Adenosine A1 receptor (ADORA1) DMDYZCH MA Inhibitor DMDYZCH RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DMDYZCH RU https://pubmed.ncbi.nlm.nih.gov/18411049 DMDYZE5 DI DMDYZE5 DMDYZE5 DN PMID19954973C4 DMDYZE5 TI TT4UJX5 DMDYZE5 TN Carboxypeptidase B1 (CPB1) DMDYZE5 MA Inhibitor DMDYZE5 RN Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6. DMDYZE5 RU https://pubmed.ncbi.nlm.nih.gov/19954973 DMDYZE5 DI DMDYZE5 DMDYZE5 DN PMID19954973C4 DMDYZE5 TI TTP18AY DMDYZE5 TN Carboxypeptidase B2 (CPB2) DMDYZE5 MA Inhibitor DMDYZE5 RN Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. Bioorg Med Chem Lett. 2010 Jan 1;20(1):92-6. DMDYZE5 RU https://pubmed.ncbi.nlm.nih.gov/19954973 DMDZ1FR DI DMDZ1FR DMDZ1FR DN 1-methyl-1H-indole-3-carbaldehyde DMDZ1FR TI TTTB4UP DMDZ1FR TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMDZ1FR MA Inhibitor DMDZ1FR RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMDZ1FR RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMDZ3FU DI DMDZ3FU DMDZ3FU DN ISIS 133712 DMDZ3FU TI TTWRN6M DMDZ3FU TN CRP messenger RNA (CRP mRNA) DMDZ3FU RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMDZ3FU RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMDZ5XI DI DMDZ5XI DMDZ5XI DN N-Benzylmethylphenidate DMDZ5XI TI TTVBI8W DMDZ5XI TN Dopamine transporter (DAT) DMDZ5XI MA Inhibitor DMDZ5XI RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMDZ5XI RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMDZ8NA DI DMDZ8NA DMDZ8NA DN 5-chloro-2-(2-chloro-4-hydroxyphenoxy)phenol DMDZ8NA TI TTNX2CS DMDZ8NA TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMDZ8NA MA Inhibitor DMDZ8NA RN Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52. DMDZ8NA RU https://pubmed.ncbi.nlm.nih.gov/16198563 DMDZ9BY DI DMDZ9BY DMDZ9BY DN N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-benzamide DMDZ9BY TI TTZHA0O DMDZ9BY TN Carbonic anhydrase IV (CA-IV) DMDZ9BY MA Inhibitor DMDZ9BY RN Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20. DMDZ9BY RU https://pubmed.ncbi.nlm.nih.gov/11784136 DMDZ9RK DI DMDZ9RK DMDZ9RK DN 2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole DMDZ9RK TI TT3WG5C DMDZ9RK TN Monoamine oxidase type A (MAO-A) DMDZ9RK MA Inhibitor DMDZ9RK RN 3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J Med Chem. 2006 Sep 7;49(18):5578-86. DMDZ9RK RU https://pubmed.ncbi.nlm.nih.gov/16942031 DMDZ9RK DI DMDZ9RK DMDZ9RK DN 2-(5-phenyl-furan-2-yl)-4,5-dihydro-1H-imidazole DMDZ9RK TI TTGP7BY DMDZ9RK TN Monoamine oxidase type B (MAO-B) DMDZ9RK MA Inhibitor DMDZ9RK RN 3-[5-(4,5-dihydro-1H-imidazol-2-yl)-furan-2-yl]phenylamine (Amifuraline), a promising reversible and selective peripheral MAO-A inhibitor. J Med Chem. 2006 Sep 7;49(18):5578-86. DMDZ9RK RU https://pubmed.ncbi.nlm.nih.gov/16942031 DMDZA83 DI DMDZA83 DMDZA83 DN 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine DMDZA83 TI TTP3QRF DMDZA83 TN Thymidine kinase 1 (TK1) DMDZA83 MA Inhibitor DMDZA83 RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DMDZA83 RU https://pubmed.ncbi.nlm.nih.gov/17181158 DMDZAKS DI DMDZAKS DMDZAKS DN ISIS 2921 DMDZAKS TI TT4SCBE DMDZAKS TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMDZAKS RN US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections. DMDZAKS RU http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true DMDZAVU DI DMDZAVU DMDZAVU DN 1-(3-benzyloxy-pyridin-2-yl)-3-phenyl-urea DMDZAVU TI TTL2ADK DMDZAVU TN Rotamase A (PPIA) DMDZAVU MA Inhibitor DMDZAVU RN Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem. 2006 Feb 9;49(3):900-10. DMDZAVU RU https://pubmed.ncbi.nlm.nih.gov/16451056 DMDZBQH DI DMDZBQH DMDZBQH DN FTY720-phosphate DMDZBQH TI TTDZCKV DMDZBQH TN Sphingosine-1-phosphate receptor 5 (S1PR5) DMDZBQH MA Agonist DMDZBQH RN Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758-68. DMDZBQH RU https://pubmed.ncbi.nlm.nih.gov/14747617 DMDZBQH DI DMDZBQH DMDZBQH DN FTY720-phosphate DMDZBQH TI TTDYP7I DMDZBQH TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMDZBQH MA Agonist DMDZBQH RN Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004 May;309(2):758-68. DMDZBQH RU https://pubmed.ncbi.nlm.nih.gov/14747617 DMDZBQH DI DMDZBQH DMDZBQH DN FTY720-phosphate DMDZBQH TI TTZ8C5Q DMDZBQH TN Sphingosine-1-phosphate receptor 4 (S1PR4) DMDZBQH MA Agonist DMDZBQH RN The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7. DMDZBQH RU https://pubmed.ncbi.nlm.nih.gov/11967257 DMDZBQH DI DMDZBQH DMDZBQH DN FTY720-phosphate DMDZBQH TI TT9JZCK DMDZBQH TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMDZBQH MA Agonist DMDZBQH RN The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7. DMDZBQH RU https://pubmed.ncbi.nlm.nih.gov/11967257 DMDZE8N DI DMDZE8N DMDZE8N DN CAPROCTAMINE DMDZE8N TI TTEB0GD DMDZE8N TN Cholinesterase (BCHE) DMDZE8N MA Inhibitor DMDZE8N RN Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inne... J Med Chem. 2008 Nov 27;51(22):7308-12. DMDZE8N RU https://pubmed.ncbi.nlm.nih.gov/18954037 DMDZE8N DI DMDZE8N DMDZE8N DN CAPROCTAMINE DMDZE8N TI TT1RS9F DMDZE8N TN Acetylcholinesterase (AChE) DMDZE8N MA Inhibitor DMDZE8N RN Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inne... J Med Chem. 2008 Nov 27;51(22):7308-12. DMDZE8N RU https://pubmed.ncbi.nlm.nih.gov/18954037 DMDZHEO DI DMDZHEO DMDZHEO DN GALANTIDE DMDZHEO TI TTBPW3J DMDZHEO TN Galanin receptor type 2 (GAL2-R) DMDZHEO MA Inhibitor DMDZHEO RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMDZHEO RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMDZHEO DI DMDZHEO DMDZHEO DN GALANTIDE DMDZHEO TI TTX3HNZ DMDZHEO TN Galanin receptor type 1 (GAL1-R) DMDZHEO MA Inhibitor DMDZHEO RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMDZHEO RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMDZIHT DI DMDZIHT DMDZIHT DN mast cell degranulating peptide DMDZIHT TI TTS3DIK DMDZIHT TN Voltage-gated potassium channel Kv1.1 (KCNA1) DMDZIHT MA Blocker (channel blocker) DMDZIHT RN Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. DMDZIHT RU https://pubmed.ncbi.nlm.nih.gov/7517498 DMDZIHT DI DMDZIHT DMDZIHT DN mast cell degranulating peptide DMDZIHT TI TTVFB0O DMDZIHT TN Voltage-gated potassium channel Kv1.2 (KCNA2) DMDZIHT MA Blocker (channel blocker) DMDZIHT RN Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34. DMDZIHT RU https://pubmed.ncbi.nlm.nih.gov/7517498 DMDZIHT DI DMDZIHT DMDZIHT DN mast cell degranulating peptide DMDZIHT TI TTJ2W69 DMDZIHT TN Voltage-gated potassium channel Kv1.6 (KCNA6) DMDZIHT MA Blocker (channel blocker) DMDZIHT RN Cloning and expression of a human voltage-gated potassium channel. A novel member of the RCK potassium channel family. EMBO J. 1990 Jun;9(6):1749-56. DMDZIHT RU https://pubmed.ncbi.nlm.nih.gov/2347305 DMDZIV5 DI DMDZIV5 DMDZIV5 DN spiradoline DMDZIV5 TI TTQW87Y DMDZIV5 TN Opioid receptor kappa (OPRK1) DMDZIV5 MA Agonist DMDZIV5 RN Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40. DMDZIV5 RU https://pubmed.ncbi.nlm.nih.gov/8393575 DMDZKWJ DI DMDZKWJ DMDZKWJ DN SB-334867 DMDZKWJ TI TT60Q8D DMDZKWJ TN Orexin receptor type 1 (HCRTR1) DMDZKWJ MA Antagonist DMDZKWJ RN Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31. DMDZKWJ RU https://pubmed.ncbi.nlm.nih.gov/19542319 DMDZKWJ DI DMDZKWJ DMDZKWJ DN SB-334867 DMDZKWJ TI TT9N02I DMDZKWJ TN Orexin receptor type 2 (HCRTR2) DMDZKWJ MA Antagonist DMDZKWJ RN Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31. DMDZKWJ RU https://pubmed.ncbi.nlm.nih.gov/19542319 DMDZTU3 DI DMDZTU3 DMDZTU3 DN 2-MePen-RYYRIK-NH2 DMDZTU3 TI TTNT7K8 DMDZTU3 TN Nociceptin receptor (OPRL1) DMDZTU3 MA Inhibitor DMDZTU3 RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMDZTU3 RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMDZY8F DI DMDZY8F DMDZY8F DN ISIS 112005 DMDZY8F TI TTPJ9XK DMDZY8F TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMDZY8F RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMDZY8F RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DME04BH DI DME04BH DME04BH DN AMG-429 DME04BH TI TTUTJGQ DME04BH TN Vascular endothelial growth factor receptor 2 (KDR) DME04BH MA Inhibitor DME04BH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1813). DME04BH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1813 DME07AN DI DME07AN DME07AN DN RWJ-56110 DME07AN TI TTL935N DME07AN TN Proteinase activated receptor 1 (F2R) DME07AN MA Antagonist DME07AN RN Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62. DME07AN RU https://pubmed.ncbi.nlm.nih.gov/10535908 DME09J2 DI DME09J2 DME09J2 DN 2-(3-Methyl-3H-imidazol-4-yl)-ethylamine DME09J2 TI TT9JNIC DME09J2 TN Histamine H3 receptor (H3R) DME09J2 MA Inhibitor DME09J2 RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DME09J2 RU https://pubmed.ncbi.nlm.nih.gov/9871722 DME0BJD DI DME0BJD DME0BJD DN 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol DME0BJD TI TTKWM86 DME0BJD TN Opioid receptor mu (MOP) DME0BJD MA Inhibitor DME0BJD RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DME0BJD RU https://pubmed.ncbi.nlm.nih.gov/17420123 DME0BJD DI DME0BJD DME0BJD DN 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol DME0BJD TI TTNT7K8 DME0BJD TN Nociceptin receptor (OPRL1) DME0BJD MA Inhibitor DME0BJD RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DME0BJD RU https://pubmed.ncbi.nlm.nih.gov/17420123 DME0BJD DI DME0BJD DME0BJD DN 1-benzhydryl-4-(4-ethylphenyl)piperidin-4-ol DME0BJD TI TTQW87Y DME0BJD TN Opioid receptor kappa (OPRK1) DME0BJD MA Inhibitor DME0BJD RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DME0BJD RU https://pubmed.ncbi.nlm.nih.gov/17420123 DME0HPA DI DME0HPA DME0HPA DN 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid DME0HPA TI TT0K6EO DME0HPA TN Stress-activated protein kinase JNK1 (JNK1) DME0HPA MA Inhibitor DME0HPA RN Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. DME0HPA RU https://pubmed.ncbi.nlm.nih.gov/17107797 DME0I6U DI DME0I6U DME0I6U DN Aerophobin-1 DME0I6U TI TT9JNIC DME0I6U TN Histamine H3 receptor (H3R) DME0I6U MA Inhibitor DME0I6U RN Verongamine, a novel bromotyrosine-derived histamine H3-antagonist from the marine sponge Verongula gigantea. J Nat Prod. 1994 Jan;57(1):175-7. DME0I6U RU https://pubmed.ncbi.nlm.nih.gov/8158162 DME0I7O DI DME0I7O DME0I7O DN TN-14003 DME0I7O TI TTBID49 DME0I7O TN C-X-C chemokine receptor type 4 (CXCR4) DME0I7O MA Inhibitor DME0I7O RN Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50(23):5655-64. DME0I7O RU https://pubmed.ncbi.nlm.nih.gov/17958344 DME0LZ2 DI DME0LZ2 DME0LZ2 DN 2-(2,4-dichlorophenoxy)-5-isopentylphenol DME0LZ2 TI TTNX2CS DME0LZ2 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DME0LZ2 MA Inhibitor DME0LZ2 RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DME0LZ2 RU https://pubmed.ncbi.nlm.nih.gov/19217192 DME0MDL DI DME0MDL DME0MDL DN 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperidine DME0MDL TI TTEX248 DME0MDL TN Dopamine D2 receptor (D2R) DME0MDL MA Inhibitor DME0MDL RN Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20. DME0MDL RU https://pubmed.ncbi.nlm.nih.gov/20155917 DME0N2Z DI DME0N2Z DME0N2Z DN PT-306 DME0N2Z TI TT84ETX DME0N2Z TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DME0N2Z MA Inhibitor DME0N2Z RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DME0N2Z RU https://pubmed.ncbi.nlm.nih.gov/8523406 DME0NO8 DI DME0NO8 DME0NO8 DN PYZD-4409 DME0NO8 TI TTXHWA7 DME0NO8 TN Ubiquitin-activating enzyme E1 (UBAE1) DME0NO8 MA Inhibitor DME0NO8 RN The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010 Mar 18;115(11):2251-9. DME0NO8 RU https://pubmed.ncbi.nlm.nih.gov/20075161 DME0OGM DI DME0OGM DME0OGM DN 11,12-dihydro-dibenzo[a,e]cyclooctene-5,6-dione DME0OGM TI TTMF541 DME0OGM TN Liver carboxylesterase (CES1) DME0OGM MA Inhibitor DME0OGM RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DME0OGM RU https://pubmed.ncbi.nlm.nih.gov/17941623 DME0TNA DI DME0TNA DME0TNA DN 3-Amino-benzenesulfonamide DME0TNA TI TTUNARX DME0TNA TN Carbonic anhydrase (CA) DME0TNA MA Inhibitor DME0TNA RN Carbonic anhydrase inhibitors. Inhibition of the prokariotic beta and gamma-class enzymes from Archaea with sulfonamides. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6001-6. DME0TNA RU https://pubmed.ncbi.nlm.nih.gov/15546717 DME0TNA DI DME0TNA DME0TNA DN 3-Amino-benzenesulfonamide DME0TNA TI TTZHA0O DME0TNA TN Carbonic anhydrase IV (CA-IV) DME0TNA MA Inhibitor DME0TNA RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DME0TNA RU https://pubmed.ncbi.nlm.nih.gov/15686931 DME0TNA DI DME0TNA DME0TNA DN 3-Amino-benzenesulfonamide DME0TNA TI TTEYTKG DME0TNA TN Carbonic anhydrase XIV (CA-XIV) DME0TNA MA Inhibitor DME0TNA RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DME0TNA RU https://pubmed.ncbi.nlm.nih.gov/16039848 DME0TNA DI DME0TNA DME0TNA DN 3-Amino-benzenesulfonamide DME0TNA TI TT2LVK8 DME0TNA TN Carbonic anhydrase IX (CA-IX) DME0TNA MA Inhibitor DME0TNA RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DME0TNA RU https://pubmed.ncbi.nlm.nih.gov/16039848 DME0TNA DI DME0TNA DME0TNA DN 3-Amino-benzenesulfonamide DME0TNA TI TTSYM0R DME0TNA TN Carbonic anhydrase XII (CA-XII) DME0TNA MA Inhibitor DME0TNA RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DME0TNA RU https://pubmed.ncbi.nlm.nih.gov/16039848 DME0TNA DI DME0TNA DME0TNA DN 3-Amino-benzenesulfonamide DME0TNA TI TTANPDJ DME0TNA TN Carbonic anhydrase II (CA-II) DME0TNA MA Inhibitor DME0TNA RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DME0TNA RU https://pubmed.ncbi.nlm.nih.gov/15686931 DME0TZU DI DME0TZU DME0TZU DN 2,7-diaminoanthraquinone DME0TZU TI TTQY2EJ DME0TZU TN TERT messenger RNA (TERT mRNA) DME0TZU MA Inhibitor DME0TZU RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DME0TZU RU https://pubmed.ncbi.nlm.nih.gov/18571928 DME0URP DI DME0URP DME0URP DN JWH-371 DME0URP TI TT6OEDT DME0URP TN Cannabinoid receptor 1 (CB1) DME0URP MA Inhibitor DME0URP RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DME0URP RU https://pubmed.ncbi.nlm.nih.gov/16889960 DME0URP DI DME0URP DME0URP DN JWH-371 DME0URP TI TTMSFAW DME0URP TN Cannabinoid receptor 2 (CB2) DME0URP MA Inhibitor DME0URP RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DME0URP RU https://pubmed.ncbi.nlm.nih.gov/16889960 DME0XHN DI DME0XHN DME0XHN DN [3H]folinic acid DME0XHN TI TTY8Z2E DME0XHN TN Proton-coupled folate transporter (SLC46A1) DME0XHN MA Modulator DME0XHN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DME0XHN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DME0YBF DI DME0YBF DME0YBF DN N-(2,4-Dimethoxy-phenyl)-3,5-dimethoxy-benzamide DME0YBF TI TTI84H7 DME0YBF TN Cytochrome P450 1B1 (CYP1B1) DME0YBF MA Inhibitor DME0YBF RN Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. DME0YBF RU https://pubmed.ncbi.nlm.nih.gov/11754588 DME10AL DI DME10AL DME10AL DN WBZ-7 DME10AL TI TTX41N9 DME10AL TN Tyrosine-protein kinase Kit (KIT) DME10AL MA Inhibitor DME10AL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1805). DME10AL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1805 DME1304 DI DME1304 DME1304 DN 5S-HPETE DME1304 TI TT7WBSV DME1304 TN Oxoeicosanoid receptor 1 (OXER1) DME1304 MA Agonist DME1304 RN TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis. Biochem Biophys Res Commun. 2005 Sep 9;334(4):987-95. DME1304 RU https://pubmed.ncbi.nlm.nih.gov/16039985 DME1304 DI DME1304 DME1304 DN 5S-HPETE DME1304 TI TTMI6F5 DME1304 TN Transient receptor potential cation channel V1 (TRPV1) DME1304 MA Activator DME1304 RN Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6155-60. DME1304 RU https://pubmed.ncbi.nlm.nih.gov/10823958 DME13RQ DI DME13RQ DME13RQ DN hK2p01 derivative KLK2 inhibitor DME13RQ TI TTJLNAW DME13RQ TN Tissue kallikrein (KLK2) DME13RQ MA Inhibitor DME13RQ RN Novel peptide inhibitors of human kallikrein 2. J Biol Chem. 2006 May 5;281(18):12555-60. DME13RQ RU https://pubmed.ncbi.nlm.nih.gov/16527822 DME15JU DI DME15JU DME15JU DN BW723C86 DME15JU TI TTWJBZ5 DME15JU TN 5-HT 2C receptor (HTR2C) DME15JU MA Agonist DME15JU RN Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84. DME15JU RU https://pubmed.ncbi.nlm.nih.gov/12970106 DME15JU DI DME15JU DME15JU DN BW723C86 DME15JU TI TT0K1SC DME15JU TN 5-HT 2B receptor (HTR2B) DME15JU MA Agonist DME15JU RN Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br J Pharmacol. 2003 Sep;140(2):277-84. DME15JU RU https://pubmed.ncbi.nlm.nih.gov/12970106 DME15JU DI DME15JU DME15JU DN BW723C86 DME15JU TI TTJQOD7 DME15JU TN 5-HT 2A receptor (HTR2A) DME15JU MA Agonist DME15JU RN Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23. DME15JU RU https://pubmed.ncbi.nlm.nih.gov/15322733 DME15MN DI DME15MN DME15MN DN Lys-thiol DME15MN TI TTD74YX DME15MN TN Arginyl aminopeptidase (RNPEP) DME15MN MA Inhibitor DME15MN RN L-lysinethiol: a subnanomolar inhibitor of aminopeptidase B. Biochem Biophys Res Commun. 1987 Jun 30;145(3):1038-42. DME15MN RU https://pubmed.ncbi.nlm.nih.gov/3111463 DME1AGO DI DME1AGO DME1AGO DN 5-Fluoro-2'-Deoxyuridine-5'-Monophosphate DME1AGO TI TTU6BFZ DME1AGO TN Candida Thymidylate synthase (Candi TMP1) DME1AGO MA Inhibitor DME1AGO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME1AGO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME1BGO DI DME1BGO DME1BGO DN Y-c[D-Pen-(2S,3S)-2-Me-(2')Nal-GSFC]KR-NH2 DME1BGO TI TT6PKBN DME1BGO TN Proto-oncogene c-Src (SRC) DME1BGO MA Inhibitor DME1BGO RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DME1BGO RU https://pubmed.ncbi.nlm.nih.gov/9632358 DME1CT9 DI DME1CT9 DME1CT9 DN H-Poa-ser-Gly-Phe-Leu-Thr-OH DME1CT9 TI TT27RFC DME1CT9 TN Opioid receptor delta (OPRD1) DME1CT9 MA Inhibitor DME1CT9 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DME1CT9 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DME1JLM DI DME1JLM DME1JLM DN 6-(2-Fluoropropyl)-4-methylpyridin-2-amine DME1JLM TI TTZUFI5 DME1JLM TN Nitric-oxide synthase brain (NOS1) DME1JLM MA Inhibitor DME1JLM RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DME1JLM RU https://pubmed.ncbi.nlm.nih.gov/19323559 DME1JLM DI DME1JLM DME1JLM DN 6-(2-Fluoropropyl)-4-methylpyridin-2-amine DME1JLM TI TTF10I9 DME1JLM TN Nitric-oxide synthase inducible (NOS2) DME1JLM MA Inhibitor DME1JLM RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DME1JLM RU https://pubmed.ncbi.nlm.nih.gov/19323559 DME1JLM DI DME1JLM DME1JLM DN 6-(2-Fluoropropyl)-4-methylpyridin-2-amine DME1JLM TI TTCM4B3 DME1JLM TN Nitric-oxide synthase endothelial (NOS3) DME1JLM MA Inhibitor DME1JLM RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DME1JLM RU https://pubmed.ncbi.nlm.nih.gov/19323559 DME1KXM DI DME1KXM DME1KXM DN ISIS 32008 DME1KXM TI TT9H4P3 DME1KXM TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DME1KXM RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DME1KXM RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DME1R96 DI DME1R96 DME1R96 DN 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine DME1R96 TI TTGY7WI DME1R96 TN Urokinase-type plasminogen activator (PLAU) DME1R96 MA Inhibitor DME1R96 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DME1R96 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DME1SP4 DI DME1SP4 DME1SP4 DN 2-(N-tert-Butylamino)-4'-chloropropiophenone DME1SP4 TI TTVBI8W DME1SP4 TN Dopamine transporter (DAT) DME1SP4 MA Inhibitor DME1SP4 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DME1SP4 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DME1TGM DI DME1TGM DME1TGM DN EXIGUAMINE B DME1TGM TI TTZJYKH DME1TGM TN Indoleamine 2,3-dioxygenase 1 (IDO1) DME1TGM MA Inhibitor DME1TGM RN Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol. 2008 Sep;4(9):535-7. DME1TGM RU https://pubmed.ncbi.nlm.nih.gov/18677305 DME1TUK DI DME1TUK DME1TUK DN 3-Pyridin-4-yl-quinoline-6,7-diol DME1TUK TI TTGKNB4 DME1TUK TN Epidermal growth factor receptor (EGFR) DME1TUK MA Inhibitor DME1TUK RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DME1TUK RU https://pubmed.ncbi.nlm.nih.gov/8064792 DME1UNY DI DME1UNY DME1UNY DN 3-[2-(1-Benzyl-piperidin-4-yl)-ethyl]-1H-indazole DME1UNY TI TT1RS9F DME1UNY TN Acetylcholinesterase (AChE) DME1UNY MA Inhibitor DME1UNY RN A docking score function for estimating ligand-protein interactions: application to acetylcholinesterase inhibition. J Med Chem. 2004 Oct 21;47(22):5492-500. DME1UNY RU https://pubmed.ncbi.nlm.nih.gov/15481986 DME230I DI DME230I DME230I DN 6-phenyl-thieno[3,2-d]pyrimidin-4-ylamine DME230I TI TTJ3E9X DME230I TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DME230I MA Inhibitor DME230I RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DME230I RU https://pubmed.ncbi.nlm.nih.gov/16686533 DME24LV DI DME24LV DME24LV DN 4-adamantyl resorcinol DME24LV TI TTULVH8 DME24LV TN Tyrosinase (TYR) DME24LV MA Inhibitor DME24LV RN Studies on depigmenting activities of dihydroxyl benzamide derivatives containing adamantane moiety. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1532-3. DME24LV RU https://pubmed.ncbi.nlm.nih.gov/19181523 DME29PX DI DME29PX DME29PX DN 4-Hydroxy-1,2,5-Thiadiazole-3-Carboxylic Acid DME29PX TI TTAZHU0 DME29PX TN L-lactate dehydrogenase (LDH) DME29PX MA Inhibitor DME29PX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME29PX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME2PFQ DI DME2PFQ DME2PFQ DN TA-106 DME2PFQ TI TTA0P7K DME2PFQ TN Complement factor B (CFB) DME2PFQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2339). DME2PFQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2339 DME2PKB DI DME2PKB DME2PKB DN D[Lys8(5/6-Flu)]VT DME2PKB TI TT4TFGN DME2PKB TN Vasopressin V1a receptor (V1AR) DME2PKB MA Inhibitor DME2PKB RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DME2PKB RU https://pubmed.ncbi.nlm.nih.gov/12036367 DME2PKB DI DME2PKB DME2PKB DN D[Lys8(5/6-Flu)]VT DME2PKB TI TTSCIUP DME2PKB TN Oxytocin receptor (OTR) DME2PKB MA Inhibitor DME2PKB RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DME2PKB RU https://pubmed.ncbi.nlm.nih.gov/12036367 DME2PKB DI DME2PKB DME2PKB DN D[Lys8(5/6-Flu)]VT DME2PKB TI TTL9MHW DME2PKB TN Vasopressin V1b receptor (V1BR) DME2PKB MA Inhibitor DME2PKB RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DME2PKB RU https://pubmed.ncbi.nlm.nih.gov/12036367 DME2VD7 DI DME2VD7 DME2VD7 DN 7-(3-fluoro-5-methylphenyl)-1,6-naphthyridine DME2VD7 TI TTHS256 DME2VD7 TN Metabotropic glutamate receptor 5 (mGluR5) DME2VD7 MA Inhibitor DME2VD7 RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DME2VD7 RU https://pubmed.ncbi.nlm.nih.gov/17936624 DME2YL6 DI DME2YL6 DME2YL6 DN GLPTGG DME2YL6 TI TTPADOQ DME2YL6 TN HMG-CoA reductase (HMGCR) DME2YL6 MA Inhibitor DME2YL6 RN Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18. DME2YL6 RU https://pubmed.ncbi.nlm.nih.gov/17977732 DME3079 DI DME3079 DME3079 DN 3-((3-bromothiophen-2-yl)methylene)indolin-2-one DME3079 TI TTUTJGQ DME3079 TN Vascular endothelial growth factor receptor 2 (KDR) DME3079 MA Inhibitor DME3079 RN Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33. DME3079 RU https://pubmed.ncbi.nlm.nih.gov/17306530 DME32XU DI DME32XU DME32XU DN CANTHARIDIC_ACID DME32XU TI TTFLH0E DME32XU TN Serine/threonine PP1-alpha (PPP1CA) DME32XU MA Inhibitor DME32XU RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DME32XU RU https://pubmed.ncbi.nlm.nih.gov/11881984 DME35CB DI DME35CB DME35CB DN NSC-622445 DME35CB TI TTIQSC1 DME35CB TN Bacterial Lethal factor (Bact lef) DME35CB MA Inhibitor DME35CB RN Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44. DME35CB RU https://pubmed.ncbi.nlm.nih.gov/16913712 DME35CB DI DME35CB DME35CB DN NSC-622445 DME35CB TI TTHVCUP DME35CB TN DNA [cytosine-5]-methyltransferase (DNMT) DME35CB MA Inhibitor DME35CB RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DME35CB RU https://pubmed.ncbi.nlm.nih.gov/20006515 DME35CB DI DME35CB DME35CB DN NSC-622445 DME35CB TI TT6VZ78 DME35CB TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DME35CB MA Inhibitor DME35CB RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DME35CB RU https://pubmed.ncbi.nlm.nih.gov/20006515 DME39U2 DI DME39U2 DME39U2 DN 7-Methyl-Gpppa DME39U2 TI TTZGCP6 DME39U2 TN EIF4E messenger RNA (EIF4E mRNA) DME39U2 MA Inhibitor DME39U2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME39U2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME39UQ DI DME39UQ DME39UQ DN CGP 47656 DME39UQ TI TTDCVZW DME39UQ TN Gamma-aminobutyric acid B receptor (GABBR) DME39UQ MA Agonist DME39UQ RN Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46. DME39UQ RU https://pubmed.ncbi.nlm.nih.gov/9069281 DME3FUD DI DME3FUD DME3FUD DN 2-(2,4-dichlorophenoxy)-5-(3-phenylpropyl)phenol DME3FUD TI TTNX2CS DME3FUD TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DME3FUD MA Inhibitor DME3FUD RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DME3FUD RU https://pubmed.ncbi.nlm.nih.gov/17567585 DME3HK8 DI DME3HK8 DME3HK8 DN D[Leu4,Dap8]VP DME3HK8 TI TTK8R02 DME3HK8 TN Vasopressin V2 receptor (V2R) DME3HK8 MA Inhibitor DME3HK8 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DME3HK8 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DME3HK8 DI DME3HK8 DME3HK8 DN D[Leu4,Dap8]VP DME3HK8 TI TTL9MHW DME3HK8 TN Vasopressin V1b receptor (V1BR) DME3HK8 MA Inhibitor DME3HK8 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DME3HK8 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DME3HK8 DI DME3HK8 DME3HK8 DN D[Leu4,Dap8]VP DME3HK8 TI TTSCIUP DME3HK8 TN Oxytocin receptor (OTR) DME3HK8 MA Inhibitor DME3HK8 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DME3HK8 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DME3HK8 DI DME3HK8 DME3HK8 DN D[Leu4,Dap8]VP DME3HK8 TI TT4TFGN DME3HK8 TN Vasopressin V1a receptor (V1AR) DME3HK8 MA Inhibitor DME3HK8 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DME3HK8 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DME3IN1 DI DME3IN1 DME3IN1 DN 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine DME3IN1 TI TTK25J1 DME3IN1 TN Adenosine A1 receptor (ADORA1) DME3IN1 MA Inhibitor DME3IN1 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DME3IN1 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DME3IN1 DI DME3IN1 DME3IN1 DN 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine DME3IN1 TI TTM2AOE DME3IN1 TN Adenosine A2a receptor (ADORA2A) DME3IN1 MA Inhibitor DME3IN1 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DME3IN1 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DME3IN1 DI DME3IN1 DME3IN1 DN 2-(3''-(5''-fluoro-indolyl)ethyloxy)adenosine DME3IN1 TI TTJFY5U DME3IN1 TN Adenosine A3 receptor (ADORA3) DME3IN1 MA Inhibitor DME3IN1 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DME3IN1 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DME3JMH DI DME3JMH DME3JMH DN PMID21742770C1 DME3JMH TI TT9RTBL DME3JMH TN Aurora B messenger RNA (AURKB mRNA) DME3JMH MA Inhibitor DME3JMH RN A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038. DME3JMH RU https://pubmed.ncbi.nlm.nih.gov/23256033 DME3JMH DI DME3JMH DME3JMH DN PMID21742770C1 DME3JMH TI TTP34DQ DME3JMH TN Serine/threonine-protein kinase 33 (STK33) DME3JMH MA Inhibitor DME3JMH RN STK33 kinase activity is nonessential in KRAS-dependent cancer cells. Cancer Res. 2011 Sep 1;71(17):5818-26. DME3JMH RU https://pubmed.ncbi.nlm.nih.gov/21742770 DME3JMH DI DME3JMH DME3JMH DN PMID21742770C1 DME3JMH TI TTYVI76 DME3JMH TN Fungal Protein kinase A (Fung ypkA) DME3JMH MA Inhibitor DME3JMH RN A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038. DME3JMH RU https://pubmed.ncbi.nlm.nih.gov/23256033 DME3PUT DI DME3PUT DME3PUT DN 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine DME3PUT TI TT2WR1T DME3PUT TN Cationic trypsinogen (PRSS1) DME3PUT MA Inhibitor DME3PUT RN Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. DME3PUT RU https://pubmed.ncbi.nlm.nih.gov/15664864 DME3PUT DI DME3PUT DME3PUT DN 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine DME3PUT TI TT6L509 DME3PUT TN Coagulation factor IIa (F2) DME3PUT MA Inhibitor DME3PUT RN Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. DME3PUT RU https://pubmed.ncbi.nlm.nih.gov/15664864 DME3PUT DI DME3PUT DME3PUT DN 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine DME3PUT TI TTCIHJA DME3PUT TN Coagulation factor Xa (F10) DME3PUT MA Inhibitor DME3PUT RN Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. DME3PUT RU https://pubmed.ncbi.nlm.nih.gov/15664864 DME3PUT DI DME3PUT DME3PUT DN 4-(4-Benzyloxy-3-methoxy-benzylamino)-benzamidine DME3PUT TI TTF0EGX DME3PUT TN Coagulation factor VII (F7) DME3PUT MA Inhibitor DME3PUT RN Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. DME3PUT RU https://pubmed.ncbi.nlm.nih.gov/15664864 DME3WBQ DI DME3WBQ DME3WBQ DN DS-437 DME3WBQ TI TTR1D7X DME3WBQ TN Protein arginine methyltransferase 5 (PRMT5) DME3WBQ MA Inhibitor DME3WBQ RN Discovery of a Dual PRMT5-PRMT7 Inhibitor. ACS Med Chem Lett. 2015 Mar 2;6(4):408-12. DME3WBQ RU https://pubmed.ncbi.nlm.nih.gov/25893041 DME3WBQ DI DME3WBQ DME3WBQ DN DS-437 DME3WBQ TI TTAR2P0 DME3WBQ TN Protein arginine methyltransferase 7 (PRMT7) DME3WBQ MA Inhibitor DME3WBQ RN Discovery of a Dual PRMT5-PRMT7 Inhibitor. ACS Med Chem Lett. 2015 Mar 2;6(4):408-12. DME3WBQ RU https://pubmed.ncbi.nlm.nih.gov/25893041 DME3XS4 DI DME3XS4 DME3XS4 DN 16-(thiophen-2-yl)methylene-estrone DME3XS4 TI TTIWB6L DME3XS4 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DME3XS4 MA Inhibitor DME3XS4 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DME3XS4 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DME4193 DI DME4193 DME4193 DN 6,8-Dinitro-2-piperazin-1-yl-quinoline DME4193 TI TT3ROYC DME4193 TN Serotonin transporter (SERT) DME4193 MA Inhibitor DME4193 RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DME4193 RU https://pubmed.ncbi.nlm.nih.gov/10915050 DME41NR DI DME41NR DME41NR DN 2-N-Hydroxyamino-1-(4-methylthiophenyl)butane DME41NR TI TT3ROYC DME41NR TN Serotonin transporter (SERT) DME41NR MA Inhibitor DME41NR RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DME41NR RU https://pubmed.ncbi.nlm.nih.gov/19717215 DME435S DI DME435S DME435S DN 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one DME435S TI TT3ROYC DME435S TN Serotonin transporter (SERT) DME435S MA Inhibitor DME435S RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DME435S RU https://pubmed.ncbi.nlm.nih.gov/16480278 DME435S DI DME435S DME435S DN 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one DME435S TI TTVBI8W DME435S TN Dopamine transporter (DAT) DME435S MA Inhibitor DME435S RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DME435S RU https://pubmed.ncbi.nlm.nih.gov/16480278 DME435S DI DME435S DME435S DN 1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one DME435S TI TTAWNKZ DME435S TN Norepinephrine transporter (NET) DME435S MA Inhibitor DME435S RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DME435S RU https://pubmed.ncbi.nlm.nih.gov/16480278 DME45J8 DI DME45J8 DME45J8 DN N-(pentafluorophenyl)sulfamide DME45J8 TI TTHQPL7 DME45J8 TN Carbonic anhydrase I (CA-I) DME45J8 MA Inhibitor DME45J8 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DME45J8 RU https://pubmed.ncbi.nlm.nih.gov/15837324 DME45J8 DI DME45J8 DME45J8 DN N-(pentafluorophenyl)sulfamide DME45J8 TI TTSYM0R DME45J8 TN Carbonic anhydrase XII (CA-XII) DME45J8 MA Inhibitor DME45J8 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DME45J8 RU https://pubmed.ncbi.nlm.nih.gov/15837324 DME45J8 DI DME45J8 DME45J8 DN N-(pentafluorophenyl)sulfamide DME45J8 TI TTANPDJ DME45J8 TN Carbonic anhydrase II (CA-II) DME45J8 MA Inhibitor DME45J8 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DME45J8 RU https://pubmed.ncbi.nlm.nih.gov/15837324 DME45J8 DI DME45J8 DME45J8 DN N-(pentafluorophenyl)sulfamide DME45J8 TI TT2LVK8 DME45J8 TN Carbonic anhydrase IX (CA-IX) DME45J8 MA Inhibitor DME45J8 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DME45J8 RU https://pubmed.ncbi.nlm.nih.gov/15837324 DME4856 DI DME4856 DME4856 DN 2-amino-quinoline-3-carboxylic acid amide DME4856 TI TTJ3E9X DME4856 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DME4856 MA Inhibitor DME4856 RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DME4856 RU https://pubmed.ncbi.nlm.nih.gov/16686533 DME4FZD DI DME4FZD DME4FZD DN Ac-Cys-Ile-Tyr-Lys-Phe(4-N3)-Tyr DME4FZD TI TT6PKBN DME4FZD TN Proto-oncogene c-Src (SRC) DME4FZD MA Inhibitor DME4FZD RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DME4FZD RU https://pubmed.ncbi.nlm.nih.gov/16722659 DME4GBS DI DME4GBS DME4GBS DN 6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine DME4GBS TI TTK25J1 DME4GBS TN Adenosine A1 receptor (ADORA1) DME4GBS MA Inhibitor DME4GBS RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DME4GBS RU https://pubmed.ncbi.nlm.nih.gov/17378544 DME4GBS DI DME4GBS DME4GBS DN 6-ethylamino-2-(3''-indolyl)ethyloxy)adenosine DME4GBS TI TTJFY5U DME4GBS TN Adenosine A3 receptor (ADORA3) DME4GBS MA Inhibitor DME4GBS RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DME4GBS RU https://pubmed.ncbi.nlm.nih.gov/17378544 DME4JGF DI DME4JGF DME4JGF DN methyl isocyanate DME4JGF TI TTELV3W DME4JGF TN Transformation-sensitive protein p120 (TRPA1) DME4JGF MA Activator DME4JGF RN Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14. DME4JGF RU https://pubmed.ncbi.nlm.nih.gov/19036859 DME4NH1 DI DME4NH1 DME4NH1 DN Di-imidazole lexitropsin DME4NH1 TI TTOVXHF DME4NH1 TN Human Deoxyribonucleic acid minor groove (hDNA min) DME4NH1 MA Binder (minor groove binder) DME4NH1 RN Defining GC-specificity in the minor groove: side-by-side binding of the di-imidazole lexitropsin to C-A-T-G-G-C-C-A-T-G. Structure. 1997 Aug 15;5(8):1033-46. DME4NH1 RU https://pubmed.ncbi.nlm.nih.gov/9309219 DME4O5D DI DME4O5D DME4O5D DN LUF-5433 DME4O5D TI TTM2AOE DME4O5D TN Adenosine A2a receptor (ADORA2A) DME4O5D MA Inhibitor DME4O5D RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DME4O5D RU https://pubmed.ncbi.nlm.nih.gov/20188574 DME4O5D DI DME4O5D DME4O5D DN LUF-5433 DME4O5D TI TTK25J1 DME4O5D TN Adenosine A1 receptor (ADORA1) DME4O5D MA Inhibitor DME4O5D RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DME4O5D RU https://pubmed.ncbi.nlm.nih.gov/20188574 DME4O5D DI DME4O5D DME4O5D DN LUF-5433 DME4O5D TI TTJFY5U DME4O5D TN Adenosine A3 receptor (ADORA3) DME4O5D MA Inhibitor DME4O5D RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DME4O5D RU https://pubmed.ncbi.nlm.nih.gov/20188574 DME4P7K DI DME4P7K DME4P7K DN 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran DME4P7K TI TTVBI8W DME4P7K TN Dopamine transporter (DAT) DME4P7K MA Inhibitor DME4P7K RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DME4P7K RU https://pubmed.ncbi.nlm.nih.gov/19201198 DME4P7K DI DME4P7K DME4P7K DN 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran DME4P7K TI TT3ROYC DME4P7K TN Serotonin transporter (SERT) DME4P7K MA Inhibitor DME4P7K RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DME4P7K RU https://pubmed.ncbi.nlm.nih.gov/19201198 DME4P7K DI DME4P7K DME4P7K DN 2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran DME4P7K TI TTAWNKZ DME4P7K TN Norepinephrine transporter (NET) DME4P7K MA Inhibitor DME4P7K RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DME4P7K RU https://pubmed.ncbi.nlm.nih.gov/19201198 DME4SML DI DME4SML DME4SML DN HI-280 DME4SML TI TT84ETX DME4SML TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DME4SML MA Inhibitor DME4SML RN Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8. DME4SML RU https://pubmed.ncbi.nlm.nih.gov/10386942 DME4TUQ DI DME4TUQ DME4TUQ DN Lck inhibitor DME4TUQ TI TT860QF DME4TUQ TN LCK tyrosine protein kinase (LCK) DME4TUQ MA Inhibitor DME4TUQ RN Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2171-4. DME4TUQ RU https://pubmed.ncbi.nlm.nih.gov/11012022 DME4ULA DI DME4ULA DME4ULA DN A-993610 DME4ULA TI TTMI6F5 DME4ULA TN Transient receptor potential cation channel V1 (TRPV1) DME4ULA MA Blocker DME4ULA RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DME4ULA RU https://pubmed.ncbi.nlm.nih.gov/19481638 DME50RZ DI DME50RZ DME50RZ DN 2-(benzyloxy)naphthalene DME50RZ TI TTSJ6Q4 DME50RZ TN LOX-5 messenger RNA (ALOX5 mRNA) DME50RZ MA Inhibitor DME50RZ RN Bioactivity-guided mapping and navigation of chemical space. Nat Chem Biol. 2009 Aug;5(8):585-92. DME50RZ RU https://pubmed.ncbi.nlm.nih.gov/19561619 DME5238 DI DME5238 DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 TI TTUWGRA DME5238 TN Protein kinase C zeta (PRKCZ) DME5238 MA Inhibitor DME5238 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DME5238 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DME5238 DI DME5238 DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 TI TTFJ8Q1 DME5238 TN Protein kinase C alpha (PRKCA) DME5238 MA Inhibitor DME5238 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DME5238 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DME5238 DI DME5238 DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 TI TTYPXQF DME5238 TN Protein kinase C beta (PRKCB) DME5238 MA Inhibitor DME5238 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DME5238 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DME5238 DI DME5238 DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 TI TTRFOXJ DME5238 TN Protein kinase C gamma (PRKCG) DME5238 MA Inhibitor DME5238 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DME5238 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DME5238 DI DME5238 DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 TI TT8QL1J DME5238 TN Protein kinase C theta (PRKCQ) DME5238 MA Inhibitor DME5238 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DME5238 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DME5238 DI DME5238 DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 TI TTBZ7OD DME5238 TN Protein kinase C epsilon (PRKCE) DME5238 MA Inhibitor DME5238 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DME5238 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DME5238 DI DME5238 DME5238 DN 3-(4-Hydroxy-phenyl)-2,3-diphenyl-acrylonitrile DME5238 TI TT9WJ8U DME5238 TN Protein kinase C delta (PRKCD) DME5238 MA Inhibitor DME5238 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DME5238 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DME53D6 DI DME53D6 DME53D6 DN [125I]ZM-241385 DME53D6 TI TTNE7KG DME53D6 TN Adenosine A2b receptor (ADORA2B) DME53D6 MA Antagonist DME53D6 RN 125I-4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol. 1995 Dec;48(6):970-4. DME53D6 RU https://pubmed.ncbi.nlm.nih.gov/8848012 DME54M7 DI DME54M7 DME54M7 DN Melogatran DME54M7 TI TT6L509 DME54M7 TN Coagulation factor IIa (F2) DME54M7 MA Inhibitor DME54M7 RN Thrombin inhibitors in acute coronary artery disease. Eur Heart J. 2002 Aug;23(15):1142-4. DME54M7 RU https://pubmed.ncbi.nlm.nih.gov/12127916 DME5CK3 DI DME5CK3 DME5CK3 DN eucalyptol DME5CK3 TI TTXDKTO DME5CK3 TN Long transient receptor potential channel 8 (TRPM8) DME5CK3 MA Activator DME5CK3 RN Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature. 2002 Mar 7;416(6876):52-8. DME5CK3 RU https://pubmed.ncbi.nlm.nih.gov/11882888 DME5HIR DI DME5HIR DME5HIR DN S-4048 DME5HIR TI TT1KPBZ DME5HIR TN Glucose-6-phosphate translocase (SLC37A4) DME5HIR MA Inhibitor DME5HIR RN Glucose release from GLUT2-null hepatocytes: characterization of a major and a minor pathway. Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E794-801. DME5HIR RU https://pubmed.ncbi.nlm.nih.gov/11882499 DME5HIS DI DME5HIS DME5HIS DN Tyr-Pro-Hfe-Phe-NH2 DME5HIS TI TTKWM86 DME5HIS TN Opioid receptor mu (MOP) DME5HIS MA Inhibitor DME5HIS RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DME5HIS RU https://pubmed.ncbi.nlm.nih.gov/16682191 DME5HRW DI DME5HRW DME5HRW DN Cyclo-[-Arg-Gly-Asp-Amp26-] DME5HRW TI TTJA1ZO DME5HRW TN ITGB3 messenger RNA (ITGB3 mRNA) DME5HRW MA Inhibitor DME5HRW RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DME5HRW RU https://pubmed.ncbi.nlm.nih.gov/18303826 DME5HRW DI DME5HRW DME5HRW DN Cyclo-[-Arg-Gly-Asp-Amp26-] DME5HRW TI TTT1R2L DME5HRW TN Integrin alpha-V (ITGAV) DME5HRW MA Inhibitor DME5HRW RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DME5HRW RU https://pubmed.ncbi.nlm.nih.gov/18303826 DME5IJQ DI DME5IJQ DME5IJQ DN CR-5259 DME5IJQ TI TTXSU2Y DME5IJQ TN Aggrecanase (ADAMTS5) DME5IJQ MA Inhibitor DME5IJQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1677). DME5IJQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1677 DME5JBH DI DME5JBH DME5JBH DN E-3024 DME5JBH TI TTDIGC1 DME5JBH TN Dipeptidyl peptidase 4 (DPP-4) DME5JBH MA Modulator DME5JBH RN E3024, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-o ne tosylate, is a novel, selective and competitive dipeptidyl peptidase-IV inhibitor.Eur J Pharmacol.2006 Oct 24;548(1-3):181-7. DME5JBH RU https://www.ncbi.nlm.nih.gov/pubmed/16973152 DME5O17 DI DME5O17 DME5O17 DN NOSTOCARBOLINE DME5O17 TI TTEB0GD DME5O17 TN Cholinesterase (BCHE) DME5O17 MA Inhibitor DME5O17 RN Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A. J Nat Prod. 2005 Dec;68(12):1793-5. DME5O17 RU https://pubmed.ncbi.nlm.nih.gov/16378379 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TTEYTKG DME5QPX TN Carbonic anhydrase XIV (CA-XIV) DME5QPX MA Inhibitor DME5QPX RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/16039848 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TTCFSPE DME5QPX TN Carbonic anhydrase VI (CA-VI) DME5QPX MA Inhibitor DME5QPX RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/19193158 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TT2LVK8 DME5QPX TN Carbonic anhydrase IX (CA-IX) DME5QPX MA Inhibitor DME5QPX RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/19193158 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TTSYM0R DME5QPX TN Carbonic anhydrase XII (CA-XII) DME5QPX MA Inhibitor DME5QPX RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/15686894 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TTANPDJ DME5QPX TN Carbonic anhydrase II (CA-II) DME5QPX MA Inhibitor DME5QPX RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/19846301 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TTZHA0O DME5QPX TN Carbonic anhydrase IV (CA-IV) DME5QPX MA Inhibitor DME5QPX RN Carbonic anhydrase inhibitors: topically acting antiglaucoma sulfonamides incorporating esters and amides of 3- and 4-carboxybenzolamide. Bioorg Med Chem Lett. 2003 Sep 1;13(17):2867-73. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/14611846 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TTUNARX DME5QPX TN Carbonic anhydrase (CA) DME5QPX MA Inhibitor DME5QPX RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/19193158 DME5QPX DI DME5QPX DME5QPX DN BENZOLAMIDE DME5QPX TI TTHQPL7 DME5QPX TN Carbonic anhydrase I (CA-I) DME5QPX MA Inhibitor DME5QPX RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DME5QPX RU https://pubmed.ncbi.nlm.nih.gov/19520577 DME5S3C DI DME5S3C DME5S3C DN DPI-221 DME5S3C TI TT27RFC DME5S3C TN Opioid receptor delta (OPRD1) DME5S3C MA Agonist DME5S3C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DME5S3C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DME5TIR DI DME5TIR DME5TIR DN (-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile DME5TIR TI TT4C8EA DME5TIR TN Dopamine D3 receptor (D3R) DME5TIR MA Inhibitor DME5TIR RN Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J Med Chem. 1993 Oct 15;36(21):3188-96. DME5TIR RU https://pubmed.ncbi.nlm.nih.gov/8230107 DME5TIR DI DME5TIR DME5TIR DN (-)-3-(1-Propyl-piperidin-3-yl)-benzonitrile DME5TIR TI TTEX248 DME5TIR TN Dopamine D2 receptor (D2R) DME5TIR MA Inhibitor DME5TIR RN Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J Med Chem. 1993 Oct 15;36(21):3188-96. DME5TIR RU https://pubmed.ncbi.nlm.nih.gov/8230107 DME5WZQ DI DME5WZQ DME5WZQ DN 7-methoxy-2-p-tolyl-4H-chromen-4-one DME5WZQ TI TTGP7BY DME5WZQ TN Monoamine oxidase type B (MAO-B) DME5WZQ MA Inhibitor DME5WZQ RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DME5WZQ RU https://pubmed.ncbi.nlm.nih.gov/20045650 DME62OQ DI DME62OQ DME62OQ DN 5-oxo-1-2-4-oxadiazol biphenyl DME62OQ TI TT8DBY3 DME62OQ TN Angiotensin II receptor type-1 (AGTR1) DME62OQ MA Antagonist DME62OQ RN Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect. Bioorg Med Chem. 2012 Apr 15;20(8):2747-61. DME62OQ RU https://pubmed.ncbi.nlm.nih.gov/22410249 DME62U0 DI DME62U0 DME62U0 DN (R)-(-)-2-Phenyl-apomorphine hydrochloride DME62U0 TI TTEX248 DME62U0 TN Dopamine D2 receptor (D2R) DME62U0 MA Inhibitor DME62U0 RN Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9. DME62U0 RU https://pubmed.ncbi.nlm.nih.gov/18289859 DME62U0 DI DME62U0 DME62U0 DN (R)-(-)-2-Phenyl-apomorphine hydrochloride DME62U0 TI TT4C8EA DME62U0 TN Dopamine D3 receptor (D3R) DME62U0 MA Inhibitor DME62U0 RN Synthesis and neuropharmacological evaluation of 2-aryl- and alkylapomorphines. Bioorg Med Chem. 2008 Apr 1;16(7):3773-9. DME62U0 RU https://pubmed.ncbi.nlm.nih.gov/18289859 DME65H8 DI DME65H8 DME65H8 DN K185 DME65H8 TI TT0WAIE DME65H8 TN Melatonin receptor type 1A (MTNR1A) DME65H8 MA Antagonist DME65H8 RN Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.J Med Chem. 2000 Mar 23;43(6):1050-61. DME65H8 RU https://pubmed.ncbi.nlm.nih.gov/10737738 DME68VT DI DME68VT DME68VT DN RWJ-16979 DME68VT TI TTNJYV2 DME68VT TN Gamma-aminobutyric acid receptor (GAR) DME68VT MA Inhibitor DME68VT RN Potential anxiolytic agents. Pyrido[1,2-a]benzimidazoles: a new structural class of ligands for the benzodiazepine binding site on GABA-A receptors. J Med Chem. 1995 Jan 6;38(1):16-20. DME68VT RU https://pubmed.ncbi.nlm.nih.gov/7837226 DME68VT DI DME68VT DME68VT DN RWJ-16979 DME68VT TI TT1MPAY DME68VT TN GABA(A) receptor alpha-1 (GABRA1) DME68VT MA Inhibitor DME68VT RN Potential anxiolytic agents. Pyrido[1,2-a]benzimidazoles: a new structural class of ligands for the benzodiazepine binding site on GABA-A receptors. J Med Chem. 1995 Jan 6;38(1):16-20. DME68VT RU https://pubmed.ncbi.nlm.nih.gov/7837226 DME69PI DI DME69PI DME69PI DN SEA-0400 DME69PI TI TT619TC DME69PI TN Sodium/calcium exchanger (SLC) DME69PI MA Inhibitor DME69PI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4617). DME69PI RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4617 DME6BX5 DI DME6BX5 DME6BX5 DN 5-Isopropyl-1H-pyrazole-3-carboxylic acid DME6BX5 TI TTWNV8U DME6BX5 TN Nicotinic acid receptor (HCAR2) DME6BX5 MA Inhibitor DME6BX5 RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DME6BX5 RU https://pubmed.ncbi.nlm.nih.gov/12930155 DME6DHX DI DME6DHX DME6DHX DN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide DME6DHX TI TTHQPL7 DME6DHX TN Carbonic anhydrase I (CA-I) DME6DHX MA Inhibitor DME6DHX RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DME6DHX RU https://pubmed.ncbi.nlm.nih.gov/20202722 DME6DHX DI DME6DHX DME6DHX DN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide DME6DHX TI TTSYM0R DME6DHX TN Carbonic anhydrase XII (CA-XII) DME6DHX MA Inhibitor DME6DHX RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DME6DHX RU https://pubmed.ncbi.nlm.nih.gov/20202722 DME6DHX DI DME6DHX DME6DHX DN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide DME6DHX TI TTANPDJ DME6DHX TN Carbonic anhydrase II (CA-II) DME6DHX MA Inhibitor DME6DHX RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DME6DHX RU https://pubmed.ncbi.nlm.nih.gov/20202722 DME6DHX DI DME6DHX DME6DHX DN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide DME6DHX TI TTEYTKG DME6DHX TN Carbonic anhydrase XIV (CA-XIV) DME6DHX MA Inhibitor DME6DHX RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DME6DHX RU https://pubmed.ncbi.nlm.nih.gov/20202722 DME6DHX DI DME6DHX DME6DHX DN 4-(2-Methyl-8-quinolinoxy)-3-pyridinesulfonamide DME6DHX TI TT2LVK8 DME6DHX TN Carbonic anhydrase IX (CA-IX) DME6DHX MA Inhibitor DME6DHX RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DME6DHX RU https://pubmed.ncbi.nlm.nih.gov/20202722 DME6HCQ DI DME6HCQ DME6HCQ DN pyrrolidine MCHR1 antagonist 1 DME6HCQ TI TTX4RTB DME6HCQ TN Melanin-concentrating hormone receptor 1 (MCHR1) DME6HCQ MA Antagonist DME6HCQ RN Novel pyrrolidine melanin-concentrating hormone receptor 1 antagonists with reduced hERG inhibition. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2460-7. DME6HCQ RU https://pubmed.ncbi.nlm.nih.gov/21414780 DME6IKT DI DME6IKT DME6IKT DN N-(3-Chloro-phenyl)-2-cyclohexyl-acetamide DME6IKT TI TT7WVHI DME6IKT TN Soluble epoxide hydrolase (EPHX2) DME6IKT MA Inhibitor DME6IKT RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DME6IKT RU https://pubmed.ncbi.nlm.nih.gov/15887969 DME6LKY DI DME6LKY DME6LKY DN [Ncy(2-naphthyl)1]acyline DME6LKY TI TT8R70G DME6LKY TN Gonadotropin-releasing hormone receptor (GNRHR) DME6LKY MA Inhibitor DME6LKY RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DME6LKY RU https://pubmed.ncbi.nlm.nih.gov/17402723 DME6MYZ DI DME6MYZ DME6MYZ DN (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DME6MYZ TI TT2NUT5 DME6MYZ TN Adrenergic receptor alpha-2C (ADRA2C) DME6MYZ MA Inhibitor DME6MYZ RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DME6MYZ RU https://pubmed.ncbi.nlm.nih.gov/8558529 DME6MYZ DI DME6MYZ DME6MYZ DN (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DME6MYZ TI TTWM4TY DME6MYZ TN Adrenergic receptor alpha-2B (ADRA2B) DME6MYZ MA Inhibitor DME6MYZ RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DME6MYZ RU https://pubmed.ncbi.nlm.nih.gov/8558529 DME6MYZ DI DME6MYZ DME6MYZ DN (2-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DME6MYZ TI TTWG9A4 DME6MYZ TN Adrenergic receptor alpha-2A (ADRA2A) DME6MYZ MA Inhibitor DME6MYZ RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DME6MYZ RU https://pubmed.ncbi.nlm.nih.gov/8558529 DME6TNL DI DME6TNL DME6TNL DN [Tyr-Pro-Phe-Phe-NH-]2 DME6TNL TI TTKWM86 DME6TNL TN Opioid receptor mu (MOP) DME6TNL MA Inhibitor DME6TNL RN Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50. DME6TNL RU https://pubmed.ncbi.nlm.nih.gov/15780619 DME6UOM DI DME6UOM DME6UOM DN 4-Methyl-pyridine DME6UOM TI TTKNWZ4 DME6UOM TN Thromboxane-A synthase (TBXAS1) DME6UOM MA Inhibitor DME6UOM RN Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55. DME6UOM RU https://pubmed.ncbi.nlm.nih.gov/7199089 DME6VKS DI DME6VKS DME6VKS DN 2-ethynyl-4-(3-fluorophenylethynyl)thiazole DME6VKS TI TTHS256 DME6VKS TN Metabotropic glutamate receptor 5 (mGluR5) DME6VKS MA Inhibitor DME6VKS RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DME6VKS RU https://pubmed.ncbi.nlm.nih.gov/16451073 DME71ON DI DME71ON DME71ON DN VU0361737 DME71ON TI TTICZ1O DME71ON TN Metabotropic glutamate receptor 4 (mGluR4) DME71ON MA Modulator (allosteric modulator) DME71ON RN Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). J Med Chem. 2009 Jul 23;52(14):4115-8. DME71ON RU https://pubmed.ncbi.nlm.nih.gov/19469556 DME74SP DI DME74SP DME74SP DN Prostaglandin G2 DME74SP TI TTVKILB DME74SP TN Prostaglandin G/H synthase 2 (COX-2) DME74SP MA Inhibitor DME74SP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DME74SP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DME75VC DI DME75VC DME75VC DN PHENYLDIFLUOROMETHANESULFONAMIDE DME75VC TI TT2LVK8 DME75VC TN Carbonic anhydrase IX (CA-IX) DME75VC MA Inhibitor DME75VC RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DME75VC RU https://pubmed.ncbi.nlm.nih.gov/16203142 DME75VC DI DME75VC DME75VC DN PHENYLDIFLUOROMETHANESULFONAMIDE DME75VC TI TTANPDJ DME75VC TN Carbonic anhydrase II (CA-II) DME75VC MA Inhibitor DME75VC RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DME75VC RU https://pubmed.ncbi.nlm.nih.gov/16203142 DME75VC DI DME75VC DME75VC DN PHENYLDIFLUOROMETHANESULFONAMIDE DME75VC TI TTUNARX DME75VC TN Carbonic anhydrase (CA) DME75VC MA Inhibitor DME75VC RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DME75VC RU https://pubmed.ncbi.nlm.nih.gov/16203142 DME75VC DI DME75VC DME75VC DN PHENYLDIFLUOROMETHANESULFONAMIDE DME75VC TI TTHQPL7 DME75VC TN Carbonic anhydrase I (CA-I) DME75VC MA Inhibitor DME75VC RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DME75VC RU https://pubmed.ncbi.nlm.nih.gov/16203142 DME7698 DI DME7698 DME7698 DN ISIS 5884 DME7698 TI TTHCEF6 DME7698 TN VCAM-1 messenger RNA (VCAM1 mRNA) DME7698 RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DME7698 RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DME76CQ DI DME76CQ DME76CQ DN lithocholylcholine DME76CQ TI TTQ13Z5 DME76CQ TN Muscarinic acetylcholine receptor M3 (CHRM3) DME76CQ MA Antagonist DME76CQ RN Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35. DME76CQ RU https://pubmed.ncbi.nlm.nih.gov/12235229 DME76CQ DI DME76CQ DME76CQ DN lithocholylcholine DME76CQ TI TTOXS3C DME76CQ TN Muscarinic acetylcholine receptor (CHRM) DME76CQ MA Antagonist DME76CQ RN Lithocholylcholine, a bile acid/acetylcholine hybrid, is a muscarinic receptor antagonist. J Pharmacol Exp Ther. 2002 Oct;303(1):29-35. DME76CQ RU https://pubmed.ncbi.nlm.nih.gov/12235229 DME76KU DI DME76KU DME76KU DN AST-487 DME76KU TI TTGJCWZ DME76KU TN Fms-like tyrosine kinase 3 (FLT-3) DME76KU MA Inhibitor DME76KU RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DME76KU RU https://pubmed.ncbi.nlm.nih.gov/22037378 DME76KU DI DME76KU DME76KU DN AST-487 DME76KU TI TT4DXQT DME76KU TN Proto-oncogene c-Ret (RET) DME76KU MA Inhibitor DME76KU RN The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007 Jul 15;67(14):6956-64. DME76KU RU https://pubmed.ncbi.nlm.nih.gov/17638907 DME76KU DI DME76KU DME76KU DN AST-487 DME76KU TI TTUTJGQ DME76KU TN Vascular endothelial growth factor receptor 2 (KDR) DME76KU MA Inhibitor DME76KU RN The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007 Jul 15;67(14):6956-64. DME76KU RU https://pubmed.ncbi.nlm.nih.gov/17638907 DME76KU DI DME76KU DME76KU DN AST-487 DME76KU TI TTX41N9 DME76KU TN Tyrosine-protein kinase Kit (KIT) DME76KU MA Inhibitor DME76KU RN The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007 Jul 15;67(14):6956-64. DME76KU RU https://pubmed.ncbi.nlm.nih.gov/17638907 DME78MS DI DME78MS DME78MS DN O2-Sulfo-Glucuronic Acid DME78MS TI TT4V2JM DME78MS TN Hepatocyte growth factor (HGF) DME78MS MA Inhibitor DME78MS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME78MS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME78MS DI DME78MS DME78MS DN O2-Sulfo-Glucuronic Acid DME78MS TI TTMY81X DME78MS TN Heparin-binding growth factor 1 (FGF1) DME78MS MA Inhibitor DME78MS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME78MS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME7K64 DI DME7K64 DME7K64 DN 2-O-methyl-PAF C-18 DME7K64 TI TTQL5VC DME7K64 TN Platelet-activating factor receptor (PTAFR) DME7K64 MA Agonist DME7K64 RN A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J Immunol Methods. 1995 Oct 26;186(2):225-31. DME7K64 RU https://pubmed.ncbi.nlm.nih.gov/7594622 DME7ONQ DI DME7ONQ DME7ONQ DN 9-Deazainosine DME7ONQ TI TTMCF1Y DME7ONQ TN Purine nucleoside phosphorylase (PNP) DME7ONQ MA Inhibitor DME7ONQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME7ONQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME7SAV DI DME7SAV DME7SAV DN 2-benzylisoquinoline-1,3,4-trione DME7SAV TI TTPF2QI DME7SAV TN Caspase-3 (CASP3) DME7SAV MA Inhibitor DME7SAV RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DME7SAV RU https://pubmed.ncbi.nlm.nih.gov/16509578 DME7VG6 DI DME7VG6 DME7VG6 DN UK-383367 DME7VG6 TI TT0L58T DME7VG6 TN Bone morphogenetic protein 1 (BMP1) DME7VG6 MA Inhibitor DME7VG6 RN Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically a... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6562-7. DME7VG6 RU https://pubmed.ncbi.nlm.nih.gov/18945617 DME7VX6 DI DME7VX6 DME7VX6 DN ISIS 32004 DME7VX6 TI TT9H4P3 DME7VX6 TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DME7VX6 RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DME7VX6 RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DME7VZG DI DME7VZG DME7VZG DN ISIS 17152 DME7VZG TI TTHJT3X DME7VZG TN STAT3 messenger RNA (STAT3 mRNA) DME7VZG RN US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression. DME7VZG RU http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true DME7W0Q DI DME7W0Q DME7W0Q DN 4-Methyl-oxazolidin-(2Z)-ylideneamine DME7W0Q TI TTZUFI5 DME7W0Q TN Nitric-oxide synthase brain (NOS1) DME7W0Q MA Inhibitor DME7W0Q RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DME7W0Q RU https://pubmed.ncbi.nlm.nih.gov/14698148 DME7W0Q DI DME7W0Q DME7W0Q DN 4-Methyl-oxazolidin-(2Z)-ylideneamine DME7W0Q TI TTF10I9 DME7W0Q TN Nitric-oxide synthase inducible (NOS2) DME7W0Q MA Inhibitor DME7W0Q RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DME7W0Q RU https://pubmed.ncbi.nlm.nih.gov/14698148 DME80RK DI DME80RK DME80RK DN (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone DME80RK TI TTGJCWZ DME80RK TN Fms-like tyrosine kinase 3 (FLT-3) DME80RK MA Inhibitor DME80RK RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DME80RK RU https://pubmed.ncbi.nlm.nih.gov/17210255 DME80RK DI DME80RK DME80RK DN (benzo[b]furan-2-yl)-(1H-indol-2-yl)methanone DME80RK TI TTI7421 DME80RK TN Platelet-derived growth factor receptor beta (PDGFRB) DME80RK MA Inhibitor DME80RK RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DME80RK RU https://pubmed.ncbi.nlm.nih.gov/17210255 DME81U3 DI DME81U3 DME81U3 DN 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one DME81U3 TI TTYEG6Q DME81U3 TN Muscarinic acetylcholine receptor M2 (CHRM2) DME81U3 MA Inhibitor DME81U3 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DME81U3 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DME81U3 DI DME81U3 DME81U3 DN 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one DME81U3 TI TTZ9SOR DME81U3 TN Muscarinic acetylcholine receptor M1 (CHRM1) DME81U3 MA Inhibitor DME81U3 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DME81U3 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DME81U3 DI DME81U3 DME81U3 DN 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one DME81U3 TI TTQ3JTF DME81U3 TN Muscarinic acetylcholine receptor M4 (CHRM4) DME81U3 MA Inhibitor DME81U3 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DME81U3 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DME81U3 DI DME81U3 DME81U3 DN 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one DME81U3 TI TTQ13Z5 DME81U3 TN Muscarinic acetylcholine receptor M3 (CHRM3) DME81U3 MA Inhibitor DME81U3 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DME81U3 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DME81U3 DI DME81U3 DME81U3 DN 3-Methyl-7-pyrrolidin-1-yl-hept-5-yn-2-one DME81U3 TI TTH18TF DME81U3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DME81U3 MA Inhibitor DME81U3 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DME81U3 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DME8273 DI DME8273 DME8273 DN 22R-hydroxycholesterol DME8273 TI TTXA6PH DME8273 TN Oxysterols receptor LXR-beta (NR1H2) DME8273 MA Agonist DME8273 RN An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31. DME8273 RU https://pubmed.ncbi.nlm.nih.gov/8878485 DME8273 DI DME8273 DME8273 DN 22R-hydroxycholesterol DME8273 TI TTECBXN DME8273 TN Oxysterols receptor LXR-alpha (NR1H3) DME8273 MA Agonist DME8273 RN An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31. DME8273 RU https://pubmed.ncbi.nlm.nih.gov/8878485 DME8273 DI DME8273 DME8273 DN 22R-hydroxycholesterol DME8273 TI TTS4UGC DME8273 TN Farnesoid X-activated receptor (FXR) DME8273 MA Agonist DME8273 RN Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver ... J Pharmacol Exp Ther. 2006 Apr;317(1):317-25. DME8273 RU https://pubmed.ncbi.nlm.nih.gov/16371446 DME84PN DI DME84PN DME84PN DN CGNLSTCMLGTYTQDFNKPHTFPQTAIGVGAP-amide DME84PN TI TTLWS2O DME84PN TN Calcitonin receptor (CALCR) DME84PN MA Inhibitor DME84PN RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DME84PN RU https://pubmed.ncbi.nlm.nih.gov/11855991 DME85GS DI DME85GS DME85GS DN 8-(3-Fluorobenzyloxy)caffeine DME85GS TI TT3WG5C DME85GS TN Monoamine oxidase type A (MAO-A) DME85GS MA Inhibitor DME85GS RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DME85GS RU https://pubmed.ncbi.nlm.nih.gov/20093036 DME85GS DI DME85GS DME85GS DN 8-(3-Fluorobenzyloxy)caffeine DME85GS TI TTGP7BY DME85GS TN Monoamine oxidase type B (MAO-B) DME85GS MA Inhibitor DME85GS RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DME85GS RU https://pubmed.ncbi.nlm.nih.gov/20093036 DME86OK DI DME86OK DME86OK DN 3-[4-(4-Fluoro-phenoxy)-phenyl]-1H-pyrazole DME86OK TI TT84DRB DME86OK TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DME86OK MA Inhibitor DME86OK RN 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52. DME86OK RU https://pubmed.ncbi.nlm.nih.gov/14998340 DME8APC DI DME8APC DME8APC DN Phosphoric acid mono-((E)-tetradec-9-enyl) ester DME8APC TI TTQ6S1K DME8APC TN Lysophosphatidic acid receptor 1 (LPAR1) DME8APC MA Inhibitor DME8APC RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DME8APC RU https://pubmed.ncbi.nlm.nih.gov/16033271 DME8B15 DI DME8B15 DME8B15 DN 1-(4-bromophenethyl)-1H-imidazole DME8B15 TI TTRA5BZ DME8B15 TN Steroid 17-alpha-monooxygenase (S17AH) DME8B15 MA Inhibitor DME8B15 RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DME8B15 RU https://pubmed.ncbi.nlm.nih.gov/16870430 DME8BLW DI DME8BLW DME8BLW DN 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine DME8BLW TI TT7HF4W DME8BLW TN Cyclin-dependent kinase 2 (CDK2) DME8BLW MA Inhibitor DME8BLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME8BLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME8G7F DI DME8G7F DME8G7F DN AB-NECA DME8G7F TI TTNE7KG DME8G7F TN Adenosine A2b receptor (ADORA2B) DME8G7F MA Agonist DME8G7F RN Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13. DME8G7F RU https://pubmed.ncbi.nlm.nih.gov/10496952 DME8KXT DI DME8KXT DME8KXT DN N*1*-(6-Nitro-quinolin-2-yl)-ethane-1,2-diamine DME8KXT TI TT3ROYC DME8KXT TN Serotonin transporter (SERT) DME8KXT MA Inhibitor DME8KXT RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DME8KXT RU https://pubmed.ncbi.nlm.nih.gov/10915050 DME8O69 DI DME8O69 DME8O69 DN N-acetyl-phenylalanyl-glycine-nitrile DME8O69 TI TTDZN01 DME8O69 TN Cathepsin K (CTSK) DME8O69 MA Inhibitor DME8O69 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DME8O69 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DME8O69 DI DME8O69 DME8O69 DN N-acetyl-phenylalanyl-glycine-nitrile DME8O69 TI TT36ETB DME8O69 TN Cathepsin L (CTSL) DME8O69 MA Inhibitor DME8O69 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DME8O69 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DME8O69 DI DME8O69 DME8O69 DN N-acetyl-phenylalanyl-glycine-nitrile DME8O69 TI TTUMQVO DME8O69 TN Cathepsin S (CTSS) DME8O69 MA Inhibitor DME8O69 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DME8O69 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DME8RNV DI DME8RNV DME8RNV DN OM-197-MP-AC DME8RNV TI TTISGCA DME8RNV TN Toll-like receptor 4 (TLR4) DME8RNV MA Modulator DME8RNV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DME8RNV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DME8S0R DI DME8S0R DME8S0R DN 8-Pentyloxy-quinolin-2-ylamine DME8S0R TI TTX4RTB DME8S0R TN Melanin-concentrating hormone receptor 1 (MCHR1) DME8S0R MA Inhibitor DME8S0R RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DME8S0R RU https://pubmed.ncbi.nlm.nih.gov/15341942 DME8VPC DI DME8VPC DME8VPC DN 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC TI TTF45NW DME8VPC TN Strychnine-binding glycine receptor (GLRA1) DME8VPC MA Inhibitor DME8VPC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DME8VPC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DME8VPC DI DME8VPC DME8VPC DN 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC TI TT1MPAY DME8VPC TN GABA(A) receptor alpha-1 (GABRA1) DME8VPC MA Inhibitor DME8VPC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DME8VPC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DME8VPC DI DME8VPC DME8VPC DN 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC TI TTZ8EM9 DME8VPC TN Glycine receptor (GlyR) DME8VPC MA Inhibitor DME8VPC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DME8VPC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DME8VPC DI DME8VPC DME8VPC DN 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC TI TTNJYV2 DME8VPC TN Gamma-aminobutyric acid receptor (GAR) DME8VPC MA Inhibitor DME8VPC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DME8VPC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DME8VPC DI DME8VPC DME8VPC DN 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC TI TT06RH5 DME8VPC TN GABA(A) receptor gamma-2 (GABRG2) DME8VPC MA Inhibitor DME8VPC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DME8VPC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DME8VPC DI DME8VPC DME8VPC DN 3-demethoxy-3-D-lyxopyranosylaminothiocolchicine DME8VPC TI TTZA1NY DME8VPC TN GABA(A) receptor beta-2 (GABRB2) DME8VPC MA Inhibitor DME8VPC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DME8VPC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DME8W3R DI DME8W3R DME8W3R DN [D-Tic7]OT DME8W3R TI TTSCIUP DME8W3R TN Oxytocin receptor (OTR) DME8W3R MA Inhibitor DME8W3R RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DME8W3R RU https://pubmed.ncbi.nlm.nih.gov/17316912 DME91CG DI DME91CG DME91CG DN Lerdelimumab DME91CG TI TTY9TWO DME91CG TN Transforming growth factor beta 2 (TGFB2) DME91CG RN A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology. 2007 Oct;114(10):1822-30. DME91CG RU https://pubmed.ncbi.nlm.nih.gov/17908591 DME94KO DI DME94KO DME94KO DN Trecetilide fumarate DME94KO TI TT1VOHK DME94KO TN Potassium channel unspecific (KC) DME94KO MA Blocker DME94KO RN IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23. DME94KO RU https://pubmed.ncbi.nlm.nih.gov/15326913 DME96RF DI DME96RF DME96RF DN N-Hydroxy-2-methyl-3-naphthalen-2-yl-acrylamide DME96RF TI TT2J34L DME96RF TN Arachidonate 5-lipoxygenase (5-LOX) DME96RF MA Inhibitor DME96RF RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DME96RF RU https://pubmed.ncbi.nlm.nih.gov/2308149 DME9AN4 DI DME9AN4 DME9AN4 DN [D-Ncy(SO,isopropyl)7]acyline DME9AN4 TI TT8R70G DME9AN4 TN Gonadotropin-releasing hormone receptor (GNRHR) DME9AN4 MA Inhibitor DME9AN4 RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DME9AN4 RU https://pubmed.ncbi.nlm.nih.gov/17402723 DME9CGK DI DME9CGK DME9CGK DN Dodecane-1-sulfonyl fluoride DME9CGK TI TTDP1UC DME9CGK TN Fatty acid amide hydrolase (FAAH) DME9CGK MA Inhibitor DME9CGK RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DME9CGK RU https://pubmed.ncbi.nlm.nih.gov/18752948 DME9CGK DI DME9CGK DME9CGK DN Dodecane-1-sulfonyl fluoride DME9CGK TI TT6OEDT DME9CGK TN Cannabinoid receptor 1 (CB1) DME9CGK MA Inhibitor DME9CGK RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DME9CGK RU https://pubmed.ncbi.nlm.nih.gov/18752948 DME9FAV DI DME9FAV DME9FAV DN L-NIO DME9FAV TI TTCM4B3 DME9FAV TN Nitric-oxide synthase endothelial (NOS3) DME9FAV MA Inhibitor DME9FAV RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DME9FAV RU https://pubmed.ncbi.nlm.nih.gov/21059682 DME9FAV DI DME9FAV DME9FAV DN L-NIO DME9FAV TI TTF10I9 DME9FAV TN Nitric-oxide synthase inducible (NOS2) DME9FAV MA Inhibitor DME9FAV RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DME9FAV RU https://pubmed.ncbi.nlm.nih.gov/19013076 DME9FAV DI DME9FAV DME9FAV DN L-NIO DME9FAV TI TTZUFI5 DME9FAV TN Nitric-oxide synthase brain (NOS1) DME9FAV MA Inhibitor DME9FAV RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DME9FAV RU https://pubmed.ncbi.nlm.nih.gov/19013076 DME9GF8 DI DME9GF8 DME9GF8 DN JMV449 DME9GF8 TI TTTUMEP DME9GF8 TN Neurotensin receptor type 1 (NTSR1) DME9GF8 MA Agonist DME9GF8 RN Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 2003 Aug;64(2):421-9. DME9GF8 RU https://pubmed.ncbi.nlm.nih.gov/12869647 DME9HNO DI DME9HNO DME9HNO DN N-(2-Thienylmethyl)-2,5-Thiophenedisulfonamide DME9HNO TI TTANPDJ DME9HNO TN Carbonic anhydrase II (CA-II) DME9HNO MA Inhibitor DME9HNO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9HNO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9HZC DI DME9HZC DME9HZC DN KRP-110 DME9HZC TI TTKWM86 DME9HZC TN Opioid receptor mu (MOP) DME9HZC MA Modulator DME9HZC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DME9HZC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DME9LPO DI DME9LPO DME9LPO DN cyPPTS DME9LPO TI TTXJ47W DME9LPO TN Metabotropic glutamate receptor 2 (mGluR2) DME9LPO MA Modulator (allosteric modulator) DME9LPO RN Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and... Psychopharmacology (Berl). 2005 Apr;179(1):271-83. DME9LPO RU https://pubmed.ncbi.nlm.nih.gov/15717213 DME9ODX DI DME9ODX DME9ODX DN DL-3 DME9ODX TI TTS64P2 DME9ODX TN Androgen receptor (AR) DME9ODX MA Antagonist DME9ODX RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DME9ODX RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DME9Q8L DI DME9Q8L DME9Q8L DN ISIS 103582 DME9Q8L TI TTBWMKT DME9Q8L TN WWP1 messenger RNA (WWP1 mRNA) DME9Q8L RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DME9Q8L RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DME9QR0 DI DME9QR0 DME9QR0 DN S-(-)CPP DME9QR0 TI TTUYAF3 DME9QR0 TN Chloride channel protein 1 (ClC-1) DME9QR0 MA Blocker (channel blocker) DME9QR0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 698). DME9QR0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=698 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TT9SL3Q DME9S8M TN Polypeptide deformylase (PDF) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTQWGU9 DME9S8M TN Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TT5ZWB6 DME9S8M TN Dihydrodiol dehydrogenase type I (AKR1C3) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTFBNVI DME9S8M TN Aldose reductase (AKR1B1) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTKN8W0 DME9S8M TN Glucose-6-phosphate dehydrogenase (G6PD) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTN7BL9 DME9S8M TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTPADOQ DME9S8M TN HMG-CoA reductase (HMGCR) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTJS7O4 DME9S8M TN Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTZUFI5 DME9S8M TN Nitric-oxide synthase brain (NOS1) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9S8M DI DME9S8M DME9S8M DN 2'-Monophosphoadenosine 5'-Diphosphoribose DME9S8M TI TTIWB6L DME9S8M TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DME9S8M MA Inhibitor DME9S8M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DME9S8M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DME9T0A DI DME9T0A DME9T0A DN RGFP966 DME9T0A TI TT4YWTO DME9T0A TN Histone deacetylase 3 (HDAC3) DME9T0A MA Inhibitor DME9T0A RN HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2647-52. DME9T0A RU https://pubmed.ncbi.nlm.nih.gov/23297220 DME9U7Y DI DME9U7Y DME9U7Y DN N-Carboxymethyl-N-cyclopentyl-phthalamic acid DME9U7Y TI TTL69WB DME9U7Y TN Angiotensin-converting enzyme (ACE) DME9U7Y MA Inhibitor DME9U7Y RN Angiotensin converting enzyme inhibitors. (Mercaptoaroyl)amino acids. J Med Chem. 1985 Mar;28(3):328-32. DME9U7Y RU https://pubmed.ncbi.nlm.nih.gov/2983075 DME9VTX DI DME9VTX DME9VTX DN ROCAGLAMIDE DME9VTX TI TTSXVID DME9VTX TN Nuclear factor NF-kappa-B (NFKB) DME9VTX MA Inhibitor DME9VTX RN Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida. J Nat Prod. 2010 May 28;73(5):949-55. DME9VTX RU https://pubmed.ncbi.nlm.nih.gov/20384315 DME9Y8Q DI DME9Y8Q DME9Y8Q DN AFD(R) DME9Y8Q TI TTDZCKV DME9Y8Q TN Sphingosine-1-phosphate receptor 5 (S1PR5) DME9Y8Q MA Agonist DME9Y8Q RN Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48. DME9Y8Q RU https://pubmed.ncbi.nlm.nih.gov/14732717 DME9Y8Q DI DME9Y8Q DME9Y8Q DN AFD(R) DME9Y8Q TI TTDYP7I DME9Y8Q TN Sphingosine-1-phosphate receptor 3 (S1PR3) DME9Y8Q MA Agonist DME9Y8Q RN The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7. DME9Y8Q RU https://pubmed.ncbi.nlm.nih.gov/11967257 DME9Y8Q DI DME9Y8Q DME9Y8Q DN AFD(R) DME9Y8Q TI TTZ8C5Q DME9Y8Q TN Sphingosine-1-phosphate receptor 4 (S1PR4) DME9Y8Q MA Agonist DME9Y8Q RN Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48. DME9Y8Q RU https://pubmed.ncbi.nlm.nih.gov/14732717 DME9Y8Q DI DME9Y8Q DME9Y8Q DN AFD(R) DME9Y8Q TI TT9JZCK DME9Y8Q TN Sphingosine-1-phosphate receptor 1 (S1PR1) DME9Y8Q MA Agonist DME9Y8Q RN The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002 Jun 14;277(24):21453-7. DME9Y8Q RU https://pubmed.ncbi.nlm.nih.gov/11967257 DMEA2SR DI DMEA2SR DMEA2SR DN 2-[1,4]Diazepan-1-yl-6-nitro-quinoline DMEA2SR TI TT3ROYC DMEA2SR TN Serotonin transporter (SERT) DMEA2SR MA Inhibitor DMEA2SR RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DMEA2SR RU https://pubmed.ncbi.nlm.nih.gov/10915050 DMEA36L DI DMEA36L DMEA36L DN SX-ARPC DMEA36L TI TTS64P2 DMEA36L TN Androgen receptor (AR) DMEA36L MA Antagonist DMEA36L RN Clinical pipeline report, company report or official report of Progenics Pharmaceuticals Serometrix. DMEA36L RU http://www.serometrix.com/pipeline.html DMEA5BZ DI DMEA5BZ DMEA5BZ DN CGP 40336A DMEA5BZ TI TTT3ZC9 DMEA5BZ TN Human immunodeficiency virus Tat protein (HIV tat) DMEA5BZ MA Inhibitor DMEA5BZ RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMEA5BZ RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMEA8GP DI DMEA8GP DMEA8GP DN meta-chlorphenylbiguanide DMEA8GP TI TTPC4TU DMEA8GP TN 5-HT 3A receptor (HTR3A) DMEA8GP MA Agonist DMEA8GP RN Different efficacy of specific agonists at 5-HT3 receptor splice variants: the role of the extra six amino acid segment. Br J Pharmacol. 1998 Feb;123(4):661-6. DMEA8GP RU https://pubmed.ncbi.nlm.nih.gov/9517385 DMEA8GP DI DMEA8GP DMEA8GP DN meta-chlorphenylbiguanide DMEA8GP TI TTR6K75 DMEA8GP TN 5-HT 3B receptor (HTR3B) DMEA8GP MA Agonist DMEA8GP RN Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4. DMEA8GP RU https://pubmed.ncbi.nlm.nih.gov/11489465 DMEA8WP DI DMEA8WP DMEA8WP DN 5-fluoro-2-(pyridin-2-yl)-1H-benzo[d]imidazole DMEA8WP TI TTZL0OI DMEA8WP TN Methionine aminopeptidase 2 (METAP2) DMEA8WP MA Inhibitor DMEA8WP RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMEA8WP RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMEA9KH DI DMEA9KH DMEA9KH DN (-)-(S)-BayK8644 DMEA9KH TI TTJ0SO4 DMEA9KH TN Voltage-gated calcium channel alpha Cav1.4 (CACNA1F) DMEA9KH MA Activator DMEA9KH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 531). DMEA9KH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=531 DMEA9KH DI DMEA9KH DMEA9KH DN (-)-(S)-BayK8644 DMEA9KH TI TT94HRF DMEA9KH TN Voltage-gated calcium channel alpha Cav1.1 (CACNA1S) DMEA9KH MA Activator DMEA9KH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 528). DMEA9KH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=528 DMEA9KH DI DMEA9KH DMEA9KH DN (-)-(S)-BayK8644 DMEA9KH TI TT7RGTM DMEA9KH TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMEA9KH MA Activator DMEA9KH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530). DMEA9KH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530 DMEA9KH DI DMEA9KH DMEA9KH DN (-)-(S)-BayK8644 DMEA9KH TI TTZIFHC DMEA9KH TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMEA9KH MA Activator DMEA9KH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529). DMEA9KH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529 DMEAB03 DI DMEAB03 DMEAB03 DN 1,2-dioctanoyl-sn-glycerol DMEAB03 TI TTFJ8Q1 DMEAB03 TN Protein kinase C alpha (PRKCA) DMEAB03 MA Inhibitor DMEAB03 RN Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81. DMEAB03 RU https://pubmed.ncbi.nlm.nih.gov/19438240 DMEABGI DI DMEABGI DMEABGI DN 7-Phenyl-1-(2H-tetrazol-5-yl)-heptan-1-one DMEABGI TI TTDP1UC DMEABGI TN Fatty acid amide hydrolase (FAAH) DMEABGI MA Inhibitor DMEABGI RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMEABGI RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMEAGI6 DI DMEAGI6 DMEAGI6 DN 10-trifluoroacetyl-DDACTHF DMEAGI6 TI TTEXB9Z DMEAGI6 TN Glycinamide ribonucleotide formyltransferase (GART) DMEAGI6 MA Inhibitor DMEAGI6 RN Discovery of a potent, nonpolyglutamatable inhibitor of glycinamide ribonucleotide transformylase. J Med Chem. 2006 May 18;49(10):2998-3002. DMEAGI6 RU https://pubmed.ncbi.nlm.nih.gov/16686541 DMEAHFZ DI DMEAHFZ DMEAHFZ DN [3H]5-CT DMEAHFZ TI TTO9X1H DMEAHFZ TN 5-HT 7 receptor (HTR7) DMEAHFZ MA Agonist DMEAHFZ RN [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17. DMEAHFZ RU https://pubmed.ncbi.nlm.nih.gov/10807680 DMEAHFZ DI DMEAHFZ DMEAHFZ DN [3H]5-CT DMEAHFZ TI TTJS8PY DMEAHFZ TN 5-HT 6 receptor (HTR6) DMEAHFZ MA Agonist DMEAHFZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11). DMEAHFZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11 DMEAHFZ DI DMEAHFZ DMEAHFZ DN [3H]5-CT DMEAHFZ TI TT9KJ1X DMEAHFZ TN 5-HT 5B receptor (HTR5B) DMEAHFZ MA Agonist DMEAHFZ RN Putative 5-ht5 receptors: localization in the mouse CNS and lack of effect in the inhibition of dural protein extravasation. Ann N Y Acad Sci. 1998 Dec 15;861:85-90. DMEAHFZ RU https://pubmed.ncbi.nlm.nih.gov/9928243 DMEAHFZ DI DMEAHFZ DMEAHFZ DN [3H]5-CT DMEAHFZ TI TTRUFDT DMEAHFZ TN 5-HT 5A receptor (HTR5A) DMEAHFZ MA Agonist DMEAHFZ RN Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67. DMEAHFZ RU https://pubmed.ncbi.nlm.nih.gov/11343685 DMEAHFZ DI DMEAHFZ DMEAHFZ DN [3H]5-CT DMEAHFZ TI TT6MSOK DMEAHFZ TN 5-HT 1D receptor (HTR1D) DMEAHFZ MA Agonist DMEAHFZ RN Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone and heterodimers when co-expressed. FEBS Lett. 1999 Jul 30;456(1):63-7. DMEAHFZ RU https://pubmed.ncbi.nlm.nih.gov/10452531 DMEAI6V DI DMEAI6V DMEAI6V DN 1-(3,5-difluorobenzyl)-1H-imidazole DMEAI6V TI TTRA5BZ DMEAI6V TN Steroid 17-alpha-monooxygenase (S17AH) DMEAI6V MA Inhibitor DMEAI6V RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DMEAI6V RU https://pubmed.ncbi.nlm.nih.gov/16750362 DMEAIQC DI DMEAIQC DMEAIQC DN GW2433 DMEAIQC TI TT2JWF6 DMEAIQC TN Peroxisome proliferator-activated receptor delta (PPARD) DMEAIQC MA Agonist DMEAIQC RN Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library. Chem Biol. 1997 Dec;4(12):909-18. DMEAIQC RU https://pubmed.ncbi.nlm.nih.gov/9427656 DMEAUK5 DI DMEAUK5 DMEAUK5 DN CALCEOLARIOSIDE B DMEAUK5 TI TTFJ8Q1 DMEAUK5 TN Protein kinase C alpha (PRKCA) DMEAUK5 MA Inhibitor DMEAUK5 RN Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2. DMEAUK5 RU https://pubmed.ncbi.nlm.nih.gov/9834166 DMEAV9Q DI DMEAV9Q DMEAV9Q DN 4-(2-Methyl-thiazol-4-ylethynyl)-pyridine DMEAV9Q TI TTHS256 DMEAV9Q TN Metabotropic glutamate receptor 5 (mGluR5) DMEAV9Q MA Inhibitor DMEAV9Q RN 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6. DMEAV9Q RU https://pubmed.ncbi.nlm.nih.gov/15225713 DMEAVD2 DI DMEAVD2 DMEAVD2 DN 2-methoxy-4-(2-nitrovinyl)phenol DMEAVD2 TI TTGKNB4 DMEAVD2 TN Epidermal growth factor receptor (EGFR) DMEAVD2 MA Inhibitor DMEAVD2 RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMEAVD2 RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMEAVPQ DI DMEAVPQ DMEAVPQ DN ISIS 6581 DMEAVPQ TI TTONI0R DMEAVPQ TN PKC-eta messenger RNA (PRKCH mRNA) DMEAVPQ RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMEAVPQ RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMEAXV3 DI DMEAXV3 DMEAXV3 DN ISIS 32002 DMEAXV3 TI TT9H4P3 DMEAXV3 TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMEAXV3 RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMEAXV3 RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMEAZFJ DI DMEAZFJ DMEAZFJ DN 4-(propylamino)naphthalen-1-ol DMEAZFJ TI TTZJYKH DMEAZFJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMEAZFJ MA Inhibitor DMEAZFJ RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMEAZFJ RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMEB0FX DI DMEB0FX DMEB0FX DN CV-11194 DMEB0FX TI TT8DBY3 DMEB0FX TN Angiotensin II receptor type-1 (AGTR1) DMEB0FX MA Inhibitor DMEB0FX RN Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisoste... J Med Chem. 1996 Dec 20;39(26):5228-35. DMEB0FX RU https://pubmed.ncbi.nlm.nih.gov/8978851 DMEB36I DI DMEB36I DMEB36I DN ISIS 102614 DMEB36I TI TT5U49F DMEB36I TN PRKACA messenger RNA (PRKACA mRNA) DMEB36I RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMEB36I RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMEB47J DI DMEB47J DMEB47J DN 2,3-Dimethoxybenzo[i]phenanthridines DMEB47J TI TTGTQHC DMEB47J TN DNA topoisomerase I (TOP1) DMEB47J MA Activator DMEB47J RN 2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem. 2003 Feb 20;11(4):521-8. DMEB47J RU https://pubmed.ncbi.nlm.nih.gov/12538017 DMEB5XP DI DMEB5XP DMEB5XP DN 4-Methylthiopyridine-3-sulfonamide DMEB5XP TI TTEYTKG DMEB5XP TN Carbonic anhydrase XIV (CA-XIV) DMEB5XP MA Inhibitor DMEB5XP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMEB5XP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMEB5XP DI DMEB5XP DMEB5XP DN 4-Methylthiopyridine-3-sulfonamide DMEB5XP TI TT2LVK8 DMEB5XP TN Carbonic anhydrase IX (CA-IX) DMEB5XP MA Inhibitor DMEB5XP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMEB5XP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMEB5XP DI DMEB5XP DMEB5XP DN 4-Methylthiopyridine-3-sulfonamide DMEB5XP TI TTSYM0R DMEB5XP TN Carbonic anhydrase XII (CA-XII) DMEB5XP MA Inhibitor DMEB5XP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMEB5XP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMEB5XP DI DMEB5XP DMEB5XP DN 4-Methylthiopyridine-3-sulfonamide DMEB5XP TI TTANPDJ DMEB5XP TN Carbonic anhydrase II (CA-II) DMEB5XP MA Inhibitor DMEB5XP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMEB5XP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMEB5XP DI DMEB5XP DMEB5XP DN 4-Methylthiopyridine-3-sulfonamide DMEB5XP TI TTHQPL7 DMEB5XP TN Carbonic anhydrase I (CA-I) DMEB5XP MA Inhibitor DMEB5XP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMEB5XP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMEB8CG DI DMEB8CG DMEB8CG DN 1G244 DMEB8CG TI TTNDUL7 DMEB8CG TN Dipeptidyl peptidase 9 (DPP-9) DMEB8CG MA Inhibitor DMEB8CG RN Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10. DMEB8CG RU https://pubmed.ncbi.nlm.nih.gov/19439267 DMEB8CG DI DMEB8CG DMEB8CG DN 1G244 DMEB8CG TI TTJGLZF DMEB8CG TN Dipeptidyl peptidase 8 (DPP-8) DMEB8CG MA Inhibitor DMEB8CG RN Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10. DMEB8CG RU https://pubmed.ncbi.nlm.nih.gov/19439267 DMEB8UA DI DMEB8UA DMEB8UA DN AcAsp-Glu-Dif-Glu-Cha-Cys DMEB8UA TI TTWXB3E DMEB8UA TN Hepatitis C virus NS3 helicase (HCV NS3) DMEB8UA MA Inhibitor DMEB8UA RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMEB8UA RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMEB93D DI DMEB93D DMEB93D DN AGN193836 DMEB93D TI TTW38KT DMEB93D TN Retinoic acid receptor alpha (RARA) DMEB93D MA Agonist DMEB93D RN Synthesis and biological activity of retinoic acid receptor-alpha specific amides. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3145-8. DMEB93D RU https://pubmed.ncbi.nlm.nih.gov/12372520 DMEB968 DI DMEB968 DMEB968 DN 1-benzhydryl-4-phenyl-4-propoxypiperidine DMEB968 TI TTNT7K8 DMEB968 TN Nociceptin receptor (OPRL1) DMEB968 MA Inhibitor DMEB968 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMEB968 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMEB968 DI DMEB968 DMEB968 DN 1-benzhydryl-4-phenyl-4-propoxypiperidine DMEB968 TI TTKWM86 DMEB968 TN Opioid receptor mu (MOP) DMEB968 MA Inhibitor DMEB968 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMEB968 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMEB968 DI DMEB968 DMEB968 DN 1-benzhydryl-4-phenyl-4-propoxypiperidine DMEB968 TI TTQW87Y DMEB968 TN Opioid receptor kappa (OPRK1) DMEB968 MA Inhibitor DMEB968 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMEB968 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMEB968 DI DMEB968 DMEB968 DN 1-benzhydryl-4-phenyl-4-propoxypiperidine DMEB968 TI TT27RFC DMEB968 TN Opioid receptor delta (OPRD1) DMEB968 MA Inhibitor DMEB968 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMEB968 RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMEBA61 DI DMEBA61 DMEBA61 DN AZUMAMIDE C DMEBA61 TI TTTQGH8 DMEBA61 TN Histone deacetylase 4 (HDAC4) DMEBA61 MA Inhibitor DMEBA61 RN Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4. DMEBA61 RU https://pubmed.ncbi.nlm.nih.gov/18397826 DMEBA61 DI DMEBA61 DMEBA61 DN AZUMAMIDE C DMEBA61 TI TT6R7JZ DMEBA61 TN Histone deacetylase 1 (HDAC1) DMEBA61 MA Inhibitor DMEBA61 RN Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4. DMEBA61 RU https://pubmed.ncbi.nlm.nih.gov/18397826 DMEBGF1 DI DMEBGF1 DMEBGF1 DN N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide DMEBGF1 TI TTGKNB4 DMEBGF1 TN Epidermal growth factor receptor (EGFR) DMEBGF1 MA Inhibitor DMEBGF1 RN Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15. DMEBGF1 RU https://pubmed.ncbi.nlm.nih.gov/10346932 DMEBGF1 DI DMEBGF1 DMEBGF1 DN N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide DMEBGF1 TI TTR5TV4 DMEBGF1 TN ERBB2 messenger RNA (HER2 mRNA) DMEBGF1 MA Inhibitor DMEBGF1 RN Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15. DMEBGF1 RU https://pubmed.ncbi.nlm.nih.gov/10346932 DMEBHML DI DMEBHML DMEBHML DN 10-Formyl-5,8,10-Trideazafolic Acid DMEBHML TI TTEXB9Z DMEBHML TN Glycinamide ribonucleotide formyltransferase (GART) DMEBHML MA Inhibitor DMEBHML RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEBHML RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEBM19 DI DMEBM19 DMEBM19 DN PMID21688779C22a DMEBM19 TI TTICZ1O DMEBM19 TN Metabotropic glutamate receptor 4 (mGluR4) DMEBM19 MA Modulator (allosteric modulator) DMEBM19 RN Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators. J Med Chem. 2011 Jul 28;54(14):5070-81. DMEBM19 RU https://pubmed.ncbi.nlm.nih.gov/21688779 DMEBPCO DI DMEBPCO DMEBPCO DN SLG DMEBPCO TI TTRBT3W DMEBPCO TN Short transient receptor potential channel 6 (TRPC6) DMEBPCO MA Activator DMEBPCO RN Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63. DMEBPCO RU https://pubmed.ncbi.nlm.nih.gov/9930701 DMEBQLK DI DMEBQLK DMEBQLK DN MR-20492 DMEBQLK TI TTSZLWK DMEBQLK TN Aromatase (CYP19A1) DMEBQLK MA Inhibitor DMEBQLK RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMEBQLK RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMEBQUN DI DMEBQUN DMEBQUN DN ISIS 29475 DMEBQUN TI TTYMGWX DMEBQUN TN PDK-1 messenger RNA (PDK-1 mRNA) DMEBQUN RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMEBQUN RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMEBYRW DI DMEBYRW DMEBYRW DN 8-Cycloheptyloxy-quinolin-2-ylamine DMEBYRW TI TTX4RTB DMEBYRW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMEBYRW MA Inhibitor DMEBYRW RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMEBYRW RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMEC1I9 DI DMEC1I9 DMEC1I9 DN Zn2+ DMEC1I9 TI TTI0TCK DMEC1I9 TN Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA) DMEC1I9 MA Inhibitor DMEC1I9 RN Phosphatidylinositol synthesis in mycobacteria. Biochim Biophys Acta. 1999 Jan 4;1436(3):437-50. DMEC1I9 RU https://pubmed.ncbi.nlm.nih.gov/9989274 DMEC1PS DI DMEC1PS DMEC1PS DN 4-Dimethylamino-2,6-diisopropyl-phenol DMEC1PS TI TTNJYV2 DMEC1PS TN Gamma-aminobutyric acid receptor (GAR) DMEC1PS MA Inhibitor DMEC1PS RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DMEC1PS RU https://pubmed.ncbi.nlm.nih.gov/9599235 DMEC2PF DI DMEC2PF DMEC2PF DN [3H]dizocilpine DMEC2PF TI TTKJEMQ DMEC2PF TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMEC2PF MA Blocker (channel blocker) DMEC2PF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMEC2PF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMEC2PF DI DMEC2PF DMEC2PF DN [3H]dizocilpine DMEC2PF TI TT5POTG DMEC2PF TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMEC2PF MA Blocker (channel blocker) DMEC2PF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMEC2PF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMEC2PF DI DMEC2PF DMEC2PF DN [3H]dizocilpine DMEC2PF TI TTLD29N DMEC2PF TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMEC2PF MA Antagonist DMEC2PF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMEC2PF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMEC2PF DI DMEC2PF DMEC2PF DN [3H]dizocilpine DMEC2PF TI TTN9D8E DMEC2PF TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMEC2PF MA Blocker (channel blocker) DMEC2PF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMEC2PF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMEC2PF DI DMEC2PF DMEC2PF DN [3H]dizocilpine DMEC2PF TI TT1M8OW DMEC2PF TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMEC2PF MA Blocker (channel blocker) DMEC2PF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMEC2PF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMEC2PH DI DMEC2PH DMEC2PH DN C(his-L-phe-arg-trp-Aoc) DMEC2PH TI TTD0CIQ DMEC2PH TN Melanocortin receptor 4 (MC4R) DMEC2PH MA Inhibitor DMEC2PH RN Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6. DMEC2PH RU https://pubmed.ncbi.nlm.nih.gov/16678415 DMEC9YK DI DMEC9YK DMEC9YK DN 7-(3-methoxyphenyl)-2-methyl-1,6-naphthyridine DMEC9YK TI TTHS256 DMEC9YK TN Metabotropic glutamate receptor 5 (mGluR5) DMEC9YK MA Inhibitor DMEC9YK RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMEC9YK RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMECAS0 DI DMECAS0 DMECAS0 DN S-(N-phenyl-N-hydroxycarbamoyl)glutathione DMECAS0 TI TTV9A7R DMECAS0 TN Lactoylglutathione lyase (GLO1) DMECAS0 MA Inhibitor DMECAS0 RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DMECAS0 RU https://pubmed.ncbi.nlm.nih.gov/11052803 DMECBLA DI DMECBLA DMECBLA DN 3-fluorovinylglycine DMECBLA TI TT6TMZU DMECBLA TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMECBLA MA Inhibitor DMECBLA RN Mechanism-based inactivation of alanine racemase by 3-halovinylglycines. J Biol Chem. 1991 Nov 15;266(32):21657-65. DMECBLA RU https://pubmed.ncbi.nlm.nih.gov/1939194 DMECH9W DI DMECH9W DMECH9W DN (1-Phenyl-ethyl)-(2-phenyl-quinazolin-4-yl)-amine DMECH9W TI TTVBI8W DMECH9W TN Dopamine transporter (DAT) DMECH9W MA Inhibitor DMECH9W RN Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8. DMECH9W RU https://pubmed.ncbi.nlm.nih.gov/12127543 DMECHD0 DI DMECHD0 DMECHD0 DN 2-Amino-6-(indan-5-ylamino)-3H-pyrimidin-4-one DMECHD0 TI TT2GPK3 DMECHD0 TN DNA topoisomerase (TOP) DMECHD0 MA Inhibitor DMECHD0 RN Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81. DMECHD0 RU https://pubmed.ncbi.nlm.nih.gov/3084785 DMECK7H DI DMECK7H DMECK7H DN (R)-DULOXETINE DMECK7H TI TTAWNKZ DMECK7H TN Norepinephrine transporter (NET) DMECK7H MA Inhibitor DMECK7H RN Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. DMECK7H RU https://pubmed.ncbi.nlm.nih.gov/19740668 DMECK7H DI DMECK7H DMECK7H DN (R)-DULOXETINE DMECK7H TI TT3ROYC DMECK7H TN Serotonin transporter (SERT) DMECK7H MA Inhibitor DMECK7H RN 1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61. DMECK7H RU https://pubmed.ncbi.nlm.nih.gov/19038547 DMECK7H DI DMECK7H DMECK7H DN (R)-DULOXETINE DMECK7H TI TTVBI8W DMECK7H TN Dopamine transporter (DAT) DMECK7H MA Inhibitor DMECK7H RN 1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61. DMECK7H RU https://pubmed.ncbi.nlm.nih.gov/19038547 DMECMA6 DI DMECMA6 DMECMA6 DN ISIS 29112 DMECMA6 TI TTO6SGY DMECMA6 TN AKT3 messenger RNA (AKT3 mRNA) DMECMA6 RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMECMA6 RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMECQB4 DI DMECQB4 DMECQB4 DN 2-[4-(2-Morpholin-4-ylethoxy)phenoxy]benzooxazole DMECQB4 TI TTXZEAJ DMECQB4 TN Leukotriene A-4 hydrolase (LTA4H) DMECQB4 MA Inhibitor DMECQB4 RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMECQB4 RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMECWL1 DI DMECWL1 DMECWL1 DN 8-(2,6-Dichloro-phenyl)-9H-purine-2,6-diamine DMECWL1 TI TT9SL3Q DMECWL1 TN Polypeptide deformylase (PDF) DMECWL1 MA Inhibitor DMECWL1 RN Conformationally restricted analogues of trimethoprim: 2,6-diamino-8-substituted purines as potential dihydrofolate reductase inhibitors from Pneum... J Med Chem. 1997 Sep 12;40(19):3032-9. DMECWL1 RU https://pubmed.ncbi.nlm.nih.gov/9301665 DMECX8S DI DMECX8S DMECX8S DN 2-(4-fluorophenyl)-6-morpholino-4H-pyran-4-one DMECX8S TI TTK3PY9 DMECX8S TN DNA-dependent protein kinase catalytic (PRKDC) DMECX8S MA Inhibitor DMECX8S RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMECX8S RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMED9FL DI DMED9FL DMED9FL DN 2-(4-tosylpiperazin-1-yl)nicotinonitrile DMED9FL TI TTN7BL9 DMED9FL TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMED9FL MA Inhibitor DMED9FL RN Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6. DMED9FL RU https://pubmed.ncbi.nlm.nih.gov/18511278 DMEDBO2 DI DMEDBO2 DMEDBO2 DN 1,4-phenylene disulfamate DMEDBO2 TI TT2LVK8 DMEDBO2 TN Carbonic anhydrase IX (CA-IX) DMEDBO2 MA Inhibitor DMEDBO2 RN Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7. DMEDBO2 RU https://pubmed.ncbi.nlm.nih.gov/19097911 DMEDBO2 DI DMEDBO2 DMEDBO2 DN 1,4-phenylene disulfamate DMEDBO2 TI TTANPDJ DMEDBO2 TN Carbonic anhydrase II (CA-II) DMEDBO2 MA Inhibitor DMEDBO2 RN Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7. DMEDBO2 RU https://pubmed.ncbi.nlm.nih.gov/19097911 DMEDC5I DI DMEDC5I DMEDC5I DN Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine DMEDC5I TI TTAWNKZ DMEDC5I TN Norepinephrine transporter (NET) DMEDC5I MA Inhibitor DMEDC5I RN Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. DMEDC5I RU https://pubmed.ncbi.nlm.nih.gov/18550369 DMEDC5I DI DMEDC5I DMEDC5I DN Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine DMEDC5I TI TTVBI8W DMEDC5I TN Dopamine transporter (DAT) DMEDC5I MA Inhibitor DMEDC5I RN Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. DMEDC5I RU https://pubmed.ncbi.nlm.nih.gov/18550369 DMEDC5I DI DMEDC5I DMEDC5I DN Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine DMEDC5I TI TT3ROYC DMEDC5I TN Serotonin transporter (SERT) DMEDC5I MA Inhibitor DMEDC5I RN Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. DMEDC5I RU https://pubmed.ncbi.nlm.nih.gov/18550369 DMEDFLA DI DMEDFLA DMEDFLA DN ISIS 102584 DMEDFLA TI TT5U49F DMEDFLA TN PRKACA messenger RNA (PRKACA mRNA) DMEDFLA RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMEDFLA RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMEDGKO DI DMEDGKO DMEDGKO DN Dibutyl phthalate DMEDGKO TI TTELV3W DMEDGKO TN Transformation-sensitive protein p120 (TRPA1) DMEDGKO MA Activator DMEDGKO RN TRPA1 and TRPV1 activation is a novel adjuvant effect mechanism in contact hypersensitivity. J Neuroimmunol. 2009 Feb 15;207(1-2):66-74. DMEDGKO RU https://pubmed.ncbi.nlm.nih.gov/19135264 DMEDJ7X DI DMEDJ7X DMEDJ7X DN N-(1,4-diphenyl-1H-pyrazol-5-yl)benzamide DMEDJ7X TI TTHS256 DMEDJ7X TN Metabotropic glutamate receptor 5 (mGluR5) DMEDJ7X MA Inhibitor DMEDJ7X RN Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44. DMEDJ7X RU https://pubmed.ncbi.nlm.nih.gov/16722652 DMEDKA3 DI DMEDKA3 DMEDKA3 DN Dibenzothiazepines DMEDKA3 TI TT6OEDT DMEDKA3 TN Cannabinoid receptor 1 (CB1) DMEDKA3 MA Agonist DMEDKA3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56). DMEDKA3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56 DMEDMC0 DI DMEDMC0 DMEDMC0 DN (+)-AJ76 DMEDMC0 TI TT4C8EA DMEDMC0 TN Dopamine D3 receptor (D3R) DMEDMC0 MA Antagonist DMEDMC0 RN Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990 Sep 13;347(6289):146-51. DMEDMC0 RU https://pubmed.ncbi.nlm.nih.gov/1975644 DMEDOFB DI DMEDOFB DMEDOFB DN 7-phenylethoxy-2-morpholin-4-yl-chromen-4-one DMEDOFB TI TTK3PY9 DMEDOFB TN DNA-dependent protein kinase catalytic (PRKDC) DMEDOFB MA Inhibitor DMEDOFB RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMEDOFB RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMEDQVX DI DMEDQVX DMEDQVX DN 1-adamantan-1-yl-3-(5-butoxypentyl)urea DMEDQVX TI TT7WVHI DMEDQVX TN Soluble epoxide hydrolase (EPHX2) DMEDQVX MA Inhibitor DMEDQVX RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMEDQVX RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMEDRAX DI DMEDRAX DMEDRAX DN 4-Amino-3-(5-methyl-thiophen-2-yl)-butyric acid DMEDRAX TI TTDCVZW DMEDRAX TN Gamma-aminobutyric acid B receptor (GABBR) DMEDRAX MA Inhibitor DMEDRAX RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DMEDRAX RU https://pubmed.ncbi.nlm.nih.gov/1652022 DMEDSLZ DI DMEDSLZ DMEDSLZ DN 1-(3-(2-(3-methoxyphenoxy)ethoxy)propyl)azepane DMEDSLZ TI TT9JNIC DMEDSLZ TN Histamine H3 receptor (H3R) DMEDSLZ MA Inhibitor DMEDSLZ RN Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands. Bioorg Med Chem. 2009 Apr 15;17(8):3037-42. DMEDSLZ RU https://pubmed.ncbi.nlm.nih.gov/19329325 DMEDVRN DI DMEDVRN DMEDVRN DN Tyr-Pro-D-Phg-Phe-NH2 DMEDVRN TI TTKWM86 DMEDVRN TN Opioid receptor mu (MOP) DMEDVRN MA Inhibitor DMEDVRN RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DMEDVRN RU https://pubmed.ncbi.nlm.nih.gov/16682191 DMEDVRN DI DMEDVRN DMEDVRN DN Tyr-Pro-D-Phg-Phe-NH2 DMEDVRN TI TT27RFC DMEDVRN TN Opioid receptor delta (OPRD1) DMEDVRN MA Inhibitor DMEDVRN RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DMEDVRN RU https://pubmed.ncbi.nlm.nih.gov/16682191 DMEF32D DI DMEF32D DMEF32D DN TQ-1017 DMEF32D TI TTAWNKZ DMEF32D TN Norepinephrine transporter (NET) DMEF32D MA Agonist DMEF32D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMEF32D RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMEF32D DI DMEF32D DMEF32D DN TQ-1017 DMEF32D TI TTWJBZ5 DMEF32D TN 5-HT 2C receptor (HTR2C) DMEF32D MA Agonist DMEF32D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMEF32D RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMEF32D DI DMEF32D DMEF32D DN TQ-1017 DMEF32D TI TTKWM86 DMEF32D TN Opioid receptor mu (MOP) DMEF32D MA Agonist DMEF32D RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMEF32D RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMEF603 DI DMEF603 DMEF603 DN NSC-664171 DMEF603 TI TTYFKSZ DMEF603 TN Tubulin beta (TUBB) DMEF603 MA Inhibitor DMEF603 RN Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of a... J Med Chem. 1998 Mar 26;41(7):1155-62. DMEF603 RU https://pubmed.ncbi.nlm.nih.gov/9544215 DMEF603 DI DMEF603 DMEF603 DN NSC-664171 DMEF603 TI TTML2WA DMEF603 TN Tubulin (TUB) DMEF603 MA Inhibitor DMEF603 RN Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of a... J Med Chem. 1998 Mar 26;41(7):1155-62. DMEF603 RU https://pubmed.ncbi.nlm.nih.gov/9544215 DMEF8GV DI DMEF8GV DMEF8GV DN PMID21571530C5g DMEF8GV TI TT4FX9Y DMEF8GV TN Succinate receptor (SUCNR1) DMEF8GV MA Antagonist DMEF8GV RN Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3596-602. DMEF8GV RU https://pubmed.ncbi.nlm.nih.gov/21571530 DMEFHQI DI DMEFHQI DMEFHQI DN Z-LEHD-fmk DMEFHQI TI TTB6T7O DMEFHQI TN Caspase-9 (CASP9) DMEFHQI MA Inhibitor DMEFHQI RN The expression of Smac and XIAP in rat hippocampus following limbic seizure induced by kainic acid injection into amygdaloid nucleus. Sheng Li Xue Bao. 2004 Apr 25;56(2):172-7. DMEFHQI RU https://pubmed.ncbi.nlm.nih.gov/15127126 DMEFIQ9 DI DMEFIQ9 DMEFIQ9 DN [Ncy(SO,isopropyl)7]acyline DMEFIQ9 TI TT8R70G DMEFIQ9 TN Gonadotropin-releasing hormone receptor (GNRHR) DMEFIQ9 MA Inhibitor DMEFIQ9 RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMEFIQ9 RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMEFKJD DI DMEFKJD DMEFKJD DN 3-(2,3-Dimethyl-phenyl)-piperidine DMEFKJD TI TTEX248 DMEFKJD TN Dopamine D2 receptor (D2R) DMEFKJD MA Inhibitor DMEFKJD RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DMEFKJD RU https://pubmed.ncbi.nlm.nih.gov/9836610 DMEFOV6 DI DMEFOV6 DMEFOV6 DN 2-phenyl-N-(pyridin-4-yl)quinazolin-4-amine DMEFOV6 TI TTP4520 DMEFOV6 TN TGF-beta receptor type I (TGFBR1) DMEFOV6 MA Inhibitor DMEFOV6 RN Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2277-81. DMEFOV6 RU https://pubmed.ncbi.nlm.nih.gov/19285388 DMEFP15 DI DMEFP15 DMEFP15 DN 1-(1-Benzo[b]thiophen-2-yl-cyclohexyl)-azepane DMEFP15 TI TTVBI8W DMEFP15 TN Dopamine transporter (DAT) DMEFP15 MA Inhibitor DMEFP15 RN Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93. DMEFP15 RU https://pubmed.ncbi.nlm.nih.gov/8098066 DMEFUZW DI DMEFUZW DMEFUZW DN PMID21273063C1 DMEFUZW TI TT7QNVC DMEFUZW TN Glucose-dependent insulinotropic receptor (GPR119) DMEFUZW MA Agonist DMEFUZW RN Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9. DMEFUZW RU https://pubmed.ncbi.nlm.nih.gov/21273063 DMEFVPH DI DMEFVPH DMEFVPH DN Tiazofurin adenine dinucleotide DMEFVPH TI TTTB4UP DMEFVPH TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMEFVPH MA Inhibitor DMEFVPH RN Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem. 2007 Dec 27;50(26):6685-91. DMEFVPH RU https://pubmed.ncbi.nlm.nih.gov/18038969 DMEFVPH DI DMEFVPH DMEFVPH DN Tiazofurin adenine dinucleotide DMEFVPH TI TTZFTY4 DMEFVPH TN Amidophosphoribosyltransferase (PPAT) DMEFVPH MA Inhibitor DMEFVPH RN Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment. J Med Chem. 2007 Dec 27;50(26):6685-91. DMEFVPH RU https://pubmed.ncbi.nlm.nih.gov/18038969 DMEG3YX DI DMEG3YX DMEG3YX DN 3-Phenyl-1-propylquinazoline-2,4(1H,3H)-dione DMEG3YX TI TTUV8G9 DMEG3YX TN Progesterone receptor (PGR) DMEG3YX MA Inhibitor DMEG3YX RN Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54. DMEG3YX RU https://pubmed.ncbi.nlm.nih.gov/18586498 DMEGAZS DI DMEGAZS DMEGAZS DN PMID24432909C8e DMEGAZS TI TTRA9G0 DMEGAZS TN Proto-oncogene c-Fer (FER) DMEGAZS MA Inhibitor DMEGAZS RN Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. DMEGAZS RU https://pubmed.ncbi.nlm.nih.gov/24432909 DMEGAZS DI DMEGAZS DMEGAZS DN PMID24432909C8e DMEGAZS TI TTPMQSO DMEGAZS TN ALK tyrosine kinase receptor (ALK) DMEGAZS MA Inhibitor DMEGAZS RN Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. DMEGAZS RU https://pubmed.ncbi.nlm.nih.gov/24432909 DMEGAZS DI DMEGAZS DMEGAZS DN PMID24432909C8e DMEGAZS TI TT1JZG6 DMEGAZS TN Leukocyte receptor tyrosine kinase (LTK) DMEGAZS MA Inhibitor DMEGAZS RN Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. DMEGAZS RU https://pubmed.ncbi.nlm.nih.gov/24432909 DMEGAZS DI DMEGAZS DMEGAZS DN PMID24432909C8e DMEGAZS TI TTKN7QR DMEGAZS TN BDNF/NT-3 growth factors receptor (TrkB) DMEGAZS MA Inhibitor DMEGAZS RN Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. DMEGAZS RU https://pubmed.ncbi.nlm.nih.gov/24432909 DMEGAZS DI DMEGAZS DMEGAZS DN PMID24432909C8e DMEGAZS TI TTLBY21 DMEGAZS TN Proto-oncogene c-Fes (FES) DMEGAZS MA Inhibitor DMEGAZS RN Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. DMEGAZS RU https://pubmed.ncbi.nlm.nih.gov/24432909 DMEGAZS DI DMEGAZS DMEGAZS DN PMID24432909C8e DMEGAZS TI TTSZ6Y3 DMEGAZS TN Proto-oncogene c-Ros (ROS1) DMEGAZS MA Inhibitor DMEGAZS RN Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem.> 2014 Feb 27;57(4):1170-87. DMEGAZS RU https://pubmed.ncbi.nlm.nih.gov/24432909 DMEGF58 DI DMEGF58 DMEGF58 DN 3-methoxy-4-(o-tolyloxy)benzonitrile DMEGF58 TI TTKPW01 DMEGF58 TN Androgen receptor messenger RNA (AR mRNA) DMEGF58 MA Inhibitor DMEGF58 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMEGF58 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMEGL84 DI DMEGL84 DMEGL84 DN FLUPERAMIDE DMEGL84 TI TTKWM86 DMEGL84 TN Opioid receptor mu (MOP) DMEGL84 MA Inhibitor DMEGL84 RN Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9. DMEGL84 RU https://pubmed.ncbi.nlm.nih.gov/15454210 DMEGL84 DI DMEGL84 DMEGL84 DN FLUPERAMIDE DMEGL84 TI TTNT7K8 DMEGL84 TN Nociceptin receptor (OPRL1) DMEGL84 MA Inhibitor DMEGL84 RN Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5275-9. DMEGL84 RU https://pubmed.ncbi.nlm.nih.gov/15454210 DMEGNJK DI DMEGNJK DMEGNJK DN SB269652 DMEGNJK TI TTEX248 DMEGNJK TN Dopamine D2 receptor (D2R) DMEGNJK MA Modulator (allosteric modulator) DMEGNJK RN A new mechanism of allostery in a G protein-coupled receptor dimer. Nat Chem Biol. 2014 Sep;10(9):745-52. DMEGNJK RU https://pubmed.ncbi.nlm.nih.gov/25108820 DMEGNJK DI DMEGNJK DMEGNJK DN SB269652 DMEGNJK TI TT4C8EA DMEGNJK TN Dopamine D3 receptor (D3R) DMEGNJK MA Modulator (allosteric modulator) DMEGNJK RN Investigation of the binding and functional properties of extended length D3 dopamine receptor-selective antagonists. Eur Neuropsychopharmacol. 2015 Sep;25(9):1448-61. DMEGNJK RU https://pubmed.ncbi.nlm.nih.gov/25583363 DMEGPBS DI DMEGPBS DMEGPBS DN PMID19854648C27 DMEGPBS TI TTRUJBV DMEGPBS TN Eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1) DMEGPBS MA Inhibitor DMEGPBS RN Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6548-51. DMEGPBS RU https://pubmed.ncbi.nlm.nih.gov/19854648 DMEGSZD DI DMEGSZD DMEGSZD DN 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine DMEGSZD TI TT9SL3Q DMEGSZD TN Polypeptide deformylase (PDF) DMEGSZD MA Inhibitor DMEGSZD RN High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines w... J Med Chem. 1996 Feb 16;39(4):892-903. DMEGSZD RU https://pubmed.ncbi.nlm.nih.gov/8632413 DMEGU5J DI DMEGU5J DMEGU5J DN L748328 DMEGU5J TI TTMXGCW DMEGU5J TN Adrenergic receptor beta-3 (ADRB3) DMEGU5J MA Antagonist DMEGU5J RN Potent and selective human beta(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1999 Aug;290(2):649-55. DMEGU5J RU https://pubmed.ncbi.nlm.nih.gov/10411574 DMEGW7F DI DMEGW7F DMEGW7F DN FGGFTGARKSARKRWNQ DMEGW7F TI TTNT7K8 DMEGW7F TN Nociceptin receptor (OPRL1) DMEGW7F MA Inhibitor DMEGW7F RN Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. DMEGW7F RU https://pubmed.ncbi.nlm.nih.gov/19577933 DMEGX8H DI DMEGX8H DMEGX8H DN B-2-Octylglucoside DMEGX8H TI TTRAMF0 DMEGX8H TN Plasmodium Cytochrome B (Malaria MT-CYB) DMEGX8H MA Inhibitor DMEGX8H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEGX8H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEGX8H DI DMEGX8H DMEGX8H DN B-2-Octylglucoside DMEGX8H TI TTH0KSX DMEGX8H TN Rhodopsin (RHO) DMEGX8H MA Inhibitor DMEGX8H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEGX8H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEGY0T DI DMEGY0T DMEGY0T DN 2-(2-carboxy-5-mercaptopentyl)benzoic acid DMEGY0T TI TT9G4N0 DMEGY0T TN Glutamate carboxypeptidase II (GCPII) DMEGY0T MA Inhibitor DMEGY0T RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMEGY0T RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMEGY3Q DI DMEGY3Q DMEGY3Q DN GS-9256 + tegobuvir DMEGY3Q TI TTMVBWH DMEGY3Q TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMEGY3Q MA Modulator DMEGY3Q RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMEGY3Q RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMEGZHF DI DMEGZHF DMEGZHF DN CTCE-0324 DMEGZHF TI TTBID49 DMEGZHF TN C-X-C chemokine receptor type 4 (CXCR4) DMEGZHF MA Modulator DMEGZHF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMEGZHF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMEGZY7 DI DMEGZY7 DMEGZY7 DN CID1792197 DMEGZY7 TI TTNET8J DMEGZY7 TN G-protein coupled receptor 55 (GPR55) DMEGZY7 MA Agonist DMEGZY7 RN Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47. DMEGZY7 RU https://pubmed.ncbi.nlm.nih.gov/21534610 DMEH6G1 DI DMEH6G1 DMEH6G1 DN ISIS 101998 DMEH6G1 TI TTON5JB DMEH6G1 TN MADH6 messenger RNA (MADH6 mRNA) DMEH6G1 RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DMEH6G1 RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DMEH8I0 DI DMEH8I0 DMEH8I0 DN 16-(4-dimethylamino-benzylidene)-estradiol DMEH8I0 TI TTIWB6L DMEH8I0 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMEH8I0 MA Inhibitor DMEH8I0 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMEH8I0 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMEHC2I DI DMEHC2I DMEHC2I DN PMID17936624C36 DMEHC2I TI TTHS256 DMEHC2I TN Metabotropic glutamate receptor 5 (mGluR5) DMEHC2I MA Modulator (allosteric modulator) DMEHC2I RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMEHC2I RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMEHG2F DI DMEHG2F DMEHG2F DN 6-amino-N-(2,4-dichlorobenzyl)nicotinamide DMEHG2F TI TT7WVHI DMEHG2F TN Soluble epoxide hydrolase (EPHX2) DMEHG2F MA Inhibitor DMEHG2F RN Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. DMEHG2F RU https://pubmed.ncbi.nlm.nih.gov/19758802 DMEHI15 DI DMEHI15 DMEHI15 DN Indole N -acetamide DMEHI15 TI TT84ETX DMEHI15 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMEHI15 MA Inhibitor DMEHI15 RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMEHI15 RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMEHK4F DI DMEHK4F DMEHK4F DN 1-(6-Methoxy-naphthalen-2-yl)-1H-imidazole DMEHK4F TI TTIQUX7 DMEHK4F TN Steroid 11-beta-hydroxylase (CYP11B1) DMEHK4F MA Inhibitor DMEHK4F RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMEHK4F RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMEHK9M DI DMEHK9M DMEHK9M DN [125I]PD142308 DMEHK9M TI TTVFO0U DMEHK9M TN Gastrin/cholecystokinin type B receptor (CCKBR) DMEHK9M MA Antagonist DMEHK9M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 77). DMEHK9M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=77 DMEHMOK DI DMEHMOK DMEHMOK DN NU-1001-41 DMEHMOK TI TTWTSCV DMEHMOK TN RAC-alpha serine/threonine-protein kinase (AKT1) DMEHMOK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMEHMOK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMEHN2L DI DMEHN2L DMEHN2L DN RS-136270 DMEHN2L TI TTFZYTO DMEHN2L TN C-C chemokine receptor type 2 (CCR2) DMEHN2L MA Antagonist DMEHN2L RN Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within t... J Biol Chem. 2000 Aug 18;275(33):25562-71. DMEHN2L RU https://pubmed.ncbi.nlm.nih.gov/10770925 DMEHP8M DI DMEHP8M DMEHP8M DN 1-[2-(2,4,6-trimethyl-phenyl)-ethyl]-pyrrolidine DMEHP8M TI TT9JNIC DMEHP8M TN Histamine H3 receptor (H3R) DMEHP8M MA Inhibitor DMEHP8M RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMEHP8M RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMEHPVF DI DMEHPVF DMEHPVF DN KNI-10095 DMEHPVF TI TTXMNHO DMEHPVF TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMEHPVF MA Inhibitor DMEHPVF RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMEHPVF RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMEHRAJ DI DMEHRAJ DMEHRAJ DN Rutin DMEHRAJ TI TT5ZWB6 DMEHRAJ TN Dihydrodiol dehydrogenase type I (AKR1C3) DMEHRAJ MA Inhibitor DMEHRAJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEHRAJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEHRKA DI DMEHRKA DMEHRKA DN Anti-CD20 engineered toxin bodies DMEHRKA TI TTUE541 DMEHRKA TN Leukocyte surface antigen Leu-16 (CD20) DMEHRKA MA Modulator DMEHRKA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DMEHRKA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DMEHYVS DI DMEHYVS DMEHYVS DN CGP 54626A DMEHYVS TI TTDCVZW DMEHYVS TN Gamma-aminobutyric acid B receptor (GABBR) DMEHYVS MA Antagonist DMEHYVS RN GABA(B) receptors function as a heteromeric assembly of the subunits GABA(B)R1 and GABA(B)R2. Nature. 1998 Dec 17;396(6712):674-9. DMEHYVS RU https://pubmed.ncbi.nlm.nih.gov/9872315 DMEI0S7 DI DMEI0S7 DMEI0S7 DN PNU-142372 DMEI0S7 TI TTUZ2L5 DMEI0S7 TN Matrix metalloproteinase-3 (MMP-3) DMEI0S7 MA Inhibitor DMEI0S7 RN Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole ... Bioorg Med Chem Lett. 2002 Oct 7;12(19):2667-72. DMEI0S7 RU https://pubmed.ncbi.nlm.nih.gov/12217351 DMEI28S DI DMEI28S DMEI28S DN ISIS 25080 DMEI28S TI TT8H9GB DMEI28S TN MEK2 messenger RNA (MEK2 mRNA) DMEI28S RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMEI28S RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMEI890 DI DMEI890 DMEI890 DN FV-Aib-TDVGPFAF DMEI890 TI TTVSFJW DMEI890 TN Calcitonin gene-related peptide 1 (CALCA) DMEI890 MA Inhibitor DMEI890 RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMEI890 RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMEI890 DI DMEI890 DMEI890 DN FV-Aib-TDVGPFAF DMEI890 TI TTY6O0Q DMEI890 TN Calcitonin gene-related peptide receptor (CGRPR) DMEI890 MA Inhibitor DMEI890 RN Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24. DMEI890 RU https://pubmed.ncbi.nlm.nih.gov/16420047 DMEI8L2 DI DMEI8L2 DMEI8L2 DN ISIS 25124 DMEI8L2 TI TT8H9GB DMEI8L2 TN MEK2 messenger RNA (MEK2 mRNA) DMEI8L2 RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMEI8L2 RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMEIA3L DI DMEIA3L DMEIA3L DN 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol DMEIA3L TI TT06RH5 DMEIA3L TN GABA(A) receptor gamma-2 (GABRG2) DMEIA3L MA Inhibitor DMEIA3L RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMEIA3L RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMEIA3L DI DMEIA3L DMEIA3L DN 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol DMEIA3L TI TTNJYV2 DMEIA3L TN Gamma-aminobutyric acid receptor (GAR) DMEIA3L MA Inhibitor DMEIA3L RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMEIA3L RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMEIA3L DI DMEIA3L DMEIA3L DN 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol DMEIA3L TI TTZA1NY DMEIA3L TN GABA(A) receptor beta-2 (GABRB2) DMEIA3L MA Inhibitor DMEIA3L RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMEIA3L RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMEIA3L DI DMEIA3L DMEIA3L DN 4-Naphthalen-1-yl-5-piperidin-4-yl-isoxazol-3-ol DMEIA3L TI TT1MPAY DMEIA3L TN GABA(A) receptor alpha-1 (GABRA1) DMEIA3L MA Inhibitor DMEIA3L RN Potent 4-aryl- or 4-arylalkyl-substituted 3-isoxazolol GABA(A) antagonists: synthesis, pharmacology, and molecular modeling. J Med Chem. 2005 Jan 27;48(2):427-39. DMEIA3L RU https://pubmed.ncbi.nlm.nih.gov/15658856 DMEIB69 DI DMEIB69 DMEIB69 DN N-{4'-[(trifluoromethyl)thio]-4-biphenyl}urea DMEIB69 TI TTBGTCW DMEIB69 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMEIB69 MA Inhibitor DMEIB69 RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMEIB69 RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMEIB8F DI DMEIB8F DMEIB8F DN (S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine DMEIB8F TI TTJQOD7 DMEIB8F TN 5-HT 2A receptor (HTR2A) DMEIB8F MA Inhibitor DMEIB8F RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMEIB8F RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMEIB8F DI DMEIB8F DMEIB8F DN (S)-1-(5,6-difluoro-1H-indol-1-yl)propan-2-amine DMEIB8F TI TTWJBZ5 DMEIB8F TN 5-HT 2C receptor (HTR2C) DMEIB8F MA Inhibitor DMEIB8F RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMEIB8F RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMEIBTY DI DMEIBTY DMEIBTY DN SIDEROXYLONAL A DMEIBTY TI TTTO43N DMEIBTY TN Endothelial plasminogen activator inhibitor (SERPINE1) DMEIBTY MA Inhibitor DMEIBTY RN Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod. 1999 Feb;62(2):324-6. DMEIBTY RU https://pubmed.ncbi.nlm.nih.gov/10075775 DMEIH5N DI DMEIH5N DMEIH5N DN 1-(1-(4-thiophen-3-ylphenyl)ethyl)-1H-imidazole DMEIH5N TI TTRA5BZ DMEIH5N TN Steroid 17-alpha-monooxygenase (S17AH) DMEIH5N MA Inhibitor DMEIH5N RN Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxyla... Bioorg Med Chem. 2008 Feb 15;16(4):1992-2010. DMEIH5N RU https://pubmed.ncbi.nlm.nih.gov/18061460 DMEIMVW DI DMEIMVW DMEIMVW DN GTx-822 DMEIMVW TI TTOM3J0 DMEIMVW TN Estrogen receptor beta (ESR2) DMEIMVW MA Modulator DMEIMVW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621). DMEIMVW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621 DMEIP6H DI DMEIP6H DMEIP6H DN methionine benzimidazole 6 DMEIP6H TI TT5Y4EM DMEIP6H TN N-formyl peptide receptor (FPR1) DMEIP6H MA Antagonist DMEIP6H RN Discovery of small molecule human FPR1 receptor antagonists. Bioorg Med Chem Lett. 2011 May 15;21(10):2991-7. DMEIP6H RU https://pubmed.ncbi.nlm.nih.gov/21486695 DMEIRDX DI DMEIRDX DMEIRDX DN MEN-14295 DMEIRDX TI TTGTQHC DMEIRDX TN DNA topoisomerase I (TOP1) DMEIRDX MA Inhibitor DMEIRDX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMEIRDX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMEITGU DI DMEITGU DMEITGU DN PMID8410973C2 DMEITGU TI TTLXC4Q DMEITGU TN Cathepsin E (CTSE) DMEITGU MA Inhibitor DMEITGU RN Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20. DMEITGU RU https://pubmed.ncbi.nlm.nih.gov/8410973 DMEIW5T DI DMEIW5T DMEIW5T DN PT-110 DMEIW5T TI TT84ETX DMEIW5T TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMEIW5T MA Inhibitor DMEIW5T RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DMEIW5T RU https://pubmed.ncbi.nlm.nih.gov/8863804 DMEIXUQ DI DMEIXUQ DMEIXUQ DN Cyclo-[-Arg-Gly-Asp-Amp25-] DMEIXUQ TI TTT1R2L DMEIXUQ TN Integrin alpha-V (ITGAV) DMEIXUQ MA Inhibitor DMEIXUQ RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMEIXUQ RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMEIXUQ DI DMEIXUQ DMEIXUQ DN Cyclo-[-Arg-Gly-Asp-Amp25-] DMEIXUQ TI TTJA1ZO DMEIXUQ TN ITGB3 messenger RNA (ITGB3 mRNA) DMEIXUQ MA Inhibitor DMEIXUQ RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMEIXUQ RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMEIZ20 DI DMEIZ20 DMEIZ20 DN SL125 DMEIZ20 TI TTIQUX7 DMEIZ20 TN Steroid 11-beta-hydroxylase (CYP11B1) DMEIZ20 MA Inhibitor DMEIZ20 RN Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor. J Exp Clin Cancer Res. 2007 Sep;26(3):405-9. DMEIZ20 RU https://pubmed.ncbi.nlm.nih.gov/17987803 DMEJ5CP DI DMEJ5CP DMEJ5CP DN SNAP-5036 DMEJ5CP TI TTNGILX DMEJ5CP TN Adrenergic receptor alpha-1A (ADRA1A) DMEJ5CP MA Inhibitor DMEJ5CP RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMEJ5CP RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMEJ6G9 DI DMEJ6G9 DMEJ6G9 DN 4-Morpholin-4-yl-benzo[g]chromen-2-one DMEJ6G9 TI TTK3PY9 DMEJ6G9 TN DNA-dependent protein kinase catalytic (PRKDC) DMEJ6G9 MA Inhibitor DMEJ6G9 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMEJ6G9 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMEJ6SK DI DMEJ6SK DMEJ6SK DN PTAC DMEJ6SK TI TTQ13Z5 DMEJ6SK TN Muscarinic acetylcholine receptor M3 (CHRM3) DMEJ6SK MA Antagonist DMEJ6SK RN Which muscarinic receptor is important in the bladder World J Urol. 2001 Nov;19(5):299-306. DMEJ6SK RU https://pubmed.ncbi.nlm.nih.gov/11760777 DMEJ6SK DI DMEJ6SK DMEJ6SK DN PTAC DMEJ6SK TI TTQ3JTF DMEJ6SK TN Muscarinic acetylcholine receptor M4 (CHRM4) DMEJ6SK MA Agonist DMEJ6SK RN Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 May;163(6):1320-5. DMEJ6SK RU https://pubmed.ncbi.nlm.nih.gov/11371395 DMEJ6SK DI DMEJ6SK DMEJ6SK DN PTAC DMEJ6SK TI TTYEG6Q DMEJ6SK TN Muscarinic acetylcholine receptor M2 (CHRM2) DMEJ6SK MA Agonist DMEJ6SK RN Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 May;163(6):1320-5. DMEJ6SK RU https://pubmed.ncbi.nlm.nih.gov/11371395 DMEJ83H DI DMEJ83H DMEJ83H DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DMEJ83H TI TTMSFAW DMEJ83H TN Cannabinoid receptor 2 (CB2) DMEJ83H MA Inhibitor DMEJ83H RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMEJ83H RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMEJ83H DI DMEJ83H DMEJ83H DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DMEJ83H TI TTQ6VDM DMEJ83H TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMEJ83H MA Inhibitor DMEJ83H RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMEJ83H RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMEJ83H DI DMEJ83H DMEJ83H DN 6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-N-(HYDROXYMETHYL)-1,2,2-TRIMETHYL-1,2,3,4-TETRAHYDRO-1,8-NAPHTHYRIDINE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DMEJ83H TI TT6OEDT DMEJ83H TN Cannabinoid receptor 1 (CB1) DMEJ83H MA Inhibitor DMEJ83H RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMEJ83H RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMEJ8YA DI DMEJ8YA DMEJ8YA DN JWH-203 DMEJ8YA TI TTMSFAW DMEJ8YA TN Cannabinoid receptor 2 (CB2) DMEJ8YA MA Inhibitor DMEJ8YA RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMEJ8YA RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMEJF6V DI DMEJF6V DMEJF6V DN 4-(3-phenyl-1H-indol-2-yl)phenol DMEJF6V TI TTZAYWL DMEJF6V TN Estrogen receptor (ESR) DMEJF6V MA Inhibitor DMEJF6V RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMEJF6V RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMEJF6V DI DMEJF6V DMEJF6V DN 4-(3-phenyl-1H-indol-2-yl)phenol DMEJF6V TI TTOM3J0 DMEJF6V TN Estrogen receptor beta (ESR2) DMEJF6V MA Inhibitor DMEJF6V RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMEJF6V RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMEJH13 DI DMEJH13 DMEJH13 DN 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline DMEJH13 TI TTI7421 DMEJH13 TN Platelet-derived growth factor receptor beta (PDGFRB) DMEJH13 MA Inhibitor DMEJH13 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMEJH13 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMEJH13 DI DMEJH13 DMEJH13 DN 3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline DMEJH13 TI TT8FYO9 DMEJH13 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMEJH13 MA Inhibitor DMEJH13 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMEJH13 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMEJKZN DI DMEJKZN DMEJKZN DN 3-Methyl-9H-beta-carboline DMEJKZN TI TTNJYV2 DMEJKZN TN Gamma-aminobutyric acid receptor (GAR) DMEJKZN MA Inhibitor DMEJKZN RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DMEJKZN RU https://pubmed.ncbi.nlm.nih.gov/7799410 DMEJKZN DI DMEJKZN DMEJKZN DN 3-Methyl-9H-beta-carboline DMEJKZN TI TT06RH5 DMEJKZN TN GABA(A) receptor gamma-2 (GABRG2) DMEJKZN MA Inhibitor DMEJKZN RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DMEJKZN RU https://pubmed.ncbi.nlm.nih.gov/7799410 DMEJKZN DI DMEJKZN DMEJKZN DN 3-Methyl-9H-beta-carboline DMEJKZN TI TTZA1NY DMEJKZN TN GABA(A) receptor beta-2 (GABRB2) DMEJKZN MA Inhibitor DMEJKZN RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DMEJKZN RU https://pubmed.ncbi.nlm.nih.gov/7799410 DMEJKZN DI DMEJKZN DMEJKZN DN 3-Methyl-9H-beta-carboline DMEJKZN TI TT1MPAY DMEJKZN TN GABA(A) receptor alpha-1 (GABRA1) DMEJKZN MA Inhibitor DMEJKZN RN Four amino acid exchanges convert a diazepam-insensitive, inverse agonist-preferring GABAA receptor into a diazepam-preferring GABAA receptor. J Med Chem. 1994 Dec 23;37(26):4576-80. DMEJKZN RU https://pubmed.ncbi.nlm.nih.gov/7799410 DMEJNFS DI DMEJNFS DMEJNFS DN (Z)-5-Octylidene-2-thioxothiazolidin-4-one DMEJNFS TI TT1K6Q4 DMEJNFS TN Arylamine N-acetyltransferase (NAT) DMEJNFS MA Inhibitor DMEJNFS RN Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18. DMEJNFS RU https://pubmed.ncbi.nlm.nih.gov/19059786 DMEJQTA DI DMEJQTA DMEJQTA DN 3-hydroxy-4,10-dimethyl-6H-benzo[c]chromen-6-one DMEJQTA TI TTOM3J0 DMEJQTA TN Estrogen receptor beta (ESR2) DMEJQTA MA Inhibitor DMEJQTA RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMEJQTA RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMEJRVW DI DMEJRVW DMEJRVW DN ((E)-3-Amino-propenyl)-methyl-phosphinic acid DMEJRVW TI TTDCVZW DMEJRVW TN Gamma-aminobutyric acid B receptor (GABBR) DMEJRVW MA Inhibitor DMEJRVW RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DMEJRVW RU https://pubmed.ncbi.nlm.nih.gov/7650684 DMEJRVW DI DMEJRVW DMEJRVW DN ((E)-3-Amino-propenyl)-methyl-phosphinic acid DMEJRVW TI TTNJYV2 DMEJRVW TN Gamma-aminobutyric acid receptor (GAR) DMEJRVW MA Inhibitor DMEJRVW RN Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships. J Med Chem. 2008 Jul 10;51(13):3825-40. DMEJRVW RU https://pubmed.ncbi.nlm.nih.gov/18528996 DMEJXWG DI DMEJXWG DMEJXWG DN 1-(4-chlorophenylsulfonyl)-4-phenylazepan-4-ol DMEJXWG TI TTN7BL9 DMEJXWG TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMEJXWG MA Inhibitor DMEJXWG RN The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5. DMEJXWG RU https://pubmed.ncbi.nlm.nih.gov/19625185 DMEJZAC DI DMEJZAC DMEJZAC DN 1-(3-Amino-benzyl)-1H-indole-5-carboxamidine DMEJZAC TI TT2WR1T DMEJZAC TN Cationic trypsinogen (PRSS1) DMEJZAC MA Inhibitor DMEJZAC RN Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8. DMEJZAC RU https://pubmed.ncbi.nlm.nih.gov/6219223 DMEK07T DI DMEK07T DMEK07T DN (+)-Myristinin D DMEK07T TI TTIU7X1 DMEK07T TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMEK07T MA Inhibitor DMEK07T RN (+)-Myristinins A and D from Knema elegans, which inhibit DNA polymerase beta and cleave DNA. J Nat Prod. 2005 Nov;68(11):1625-8. DMEK07T RU https://pubmed.ncbi.nlm.nih.gov/16309311 DMEK2I4 DI DMEK2I4 DMEK2I4 DN GW7845 DMEK2I4 TI TTZMAO3 DMEK2I4 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMEK2I4 MA Agonist DMEK2I4 RN A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res. 1999 Nov 15;59(22):5671-3. DMEK2I4 RU https://pubmed.ncbi.nlm.nih.gov/10582681 DMEK4FY DI DMEK4FY DMEK4FY DN LG100754 DMEK4FY TI TTKLV96 DMEK4FY TN Retinoic acid receptor RXR-beta (RXRB) DMEK4FY MA Antagonist DMEK4FY RN Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3. DMEK4FY RU https://pubmed.ncbi.nlm.nih.gov/8837780 DMEK4FY DI DMEK4FY DMEK4FY DN LG100754 DMEK4FY TI TT6PEUO DMEK4FY TN Retinoic acid receptor RXR-alpha (RXRA) DMEK4FY MA Antagonist DMEK4FY RN The rexinoid LG100754 is a novel RXR:PPARgamma agonist and decreases glucose levels in vivo. Mol Endocrinol. 2001 Aug;15(8):1360-9. DMEK4FY RU https://pubmed.ncbi.nlm.nih.gov/11463859 DMEK4FY DI DMEK4FY DMEK4FY DN LG100754 DMEK4FY TI TTT2SVW DMEK4FY TN PPAR-gamma messenger RNA (PPARG mRNA) DMEK4FY MA Agonist DMEK4FY RN The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6. DMEK4FY RU https://pubmed.ncbi.nlm.nih.gov/11877384 DMEK4FY DI DMEK4FY DMEK4FY DN LG100754 DMEK4FY TI TTH029C DMEK4FY TN Retinoic acid receptor RXR-gamma (RXRG) DMEK4FY MA Antagonist DMEK4FY RN Activation of specific RXR heterodimers by an antagonist of RXR homodimers. Nature. 1996 Oct 3;383(6599):450-3. DMEK4FY RU https://pubmed.ncbi.nlm.nih.gov/8837780 DMEK4HZ DI DMEK4HZ DMEK4HZ DN C5aR pepducins DMEK4HZ TI TTHXFA1 DMEK4HZ TN C5a anaphylatoxin chemotactic receptor (C5AR1) DMEK4HZ MA Modulator DMEK4HZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 32). DMEK4HZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=32 DMEK4TJ DI DMEK4TJ DMEK4TJ DN PI-103 DMEK4TJ TI TTHBTOP DMEK4TJ TN PI3-kinase gamma (PIK3CG) DMEK4TJ MA Inhibitor DMEK4TJ RN The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. DMEK4TJ RU https://pubmed.ncbi.nlm.nih.gov/19519296 DMEK5B2 DI DMEK5B2 DMEK5B2 DN NSC-356483 DMEK5B2 TI TTSZLWK DMEK5B2 TN Aromatase (CYP19A1) DMEK5B2 MA Inhibitor DMEK5B2 RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMEK5B2 RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMEK65F DI DMEK65F DMEK65F DN L-249313 DMEK65F TI TTJFY5U DMEK65F TN Adenosine A3 receptor (ADORA3) DMEK65F MA Inhibitor DMEK65F RN The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg Med Chem Lett. 2000 Jan 3;10(1):31-4. DMEK65F RU https://pubmed.ncbi.nlm.nih.gov/10636237 DMEK65F DI DMEK65F DMEK65F DN L-249313 DMEK65F TI TTK25J1 DMEK65F TN Adenosine A1 receptor (ADORA1) DMEK65F MA Inhibitor DMEK65F RN 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9. DMEK65F RU https://pubmed.ncbi.nlm.nih.gov/11170626 DMEK6WX DI DMEK6WX DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE DMEK6WX TI TTANPDJ DMEK6WX TN Carbonic anhydrase II (CA-II) DMEK6WX MA Inhibitor DMEK6WX RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMEK6WX RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMEK6WX DI DMEK6WX DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE DMEK6WX TI TTHQPL7 DMEK6WX TN Carbonic anhydrase I (CA-I) DMEK6WX MA Inhibitor DMEK6WX RN Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-media... J Med Chem. 2005 Jul 28;48(15):4834-41. DMEK6WX RU https://pubmed.ncbi.nlm.nih.gov/16033263 DMEK6WX DI DMEK6WX DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE DMEK6WX TI TTZHA0O DMEK6WX TN Carbonic anhydrase IV (CA-IV) DMEK6WX MA Inhibitor DMEK6WX RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMEK6WX RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMEK6WX DI DMEK6WX DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE DMEK6WX TI TTUNARX DMEK6WX TN Carbonic anhydrase (CA) DMEK6WX MA Inhibitor DMEK6WX RN Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6. DMEK6WX RU https://pubmed.ncbi.nlm.nih.gov/15686895 DMEK6WX DI DMEK6WX DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE DMEK6WX TI TTSYM0R DMEK6WX TN Carbonic anhydrase XII (CA-XII) DMEK6WX MA Inhibitor DMEK6WX RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMEK6WX RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMEK6WX DI DMEK6WX DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE DMEK6WX TI TT2LVK8 DMEK6WX TN Carbonic anhydrase IX (CA-IX) DMEK6WX MA Inhibitor DMEK6WX RN Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-media... J Med Chem. 2005 Jul 28;48(15):4834-41. DMEK6WX RU https://pubmed.ncbi.nlm.nih.gov/16033263 DMEK6WX DI DMEK6WX DMEK6WX DN 4-(2-AMINOETHYL)BENZENESULFONAMIDE DMEK6WX TI TTEYTKG DMEK6WX TN Carbonic anhydrase XIV (CA-XIV) DMEK6WX MA Inhibitor DMEK6WX RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMEK6WX RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMEK9DH DI DMEK9DH DMEK9DH DN 3-hydroxy-2-propionylcyclohex-2-enone DMEK9DH TI TT8DSFC DMEK9DH TN Hydroxyphenylpyruvate dioxygenase (HPD) DMEK9DH MA Inhibitor DMEK9DH RN Enzyme inhibition potency enhancement by active site metal chelating and hydrogen bonding induced conformation-restricted cyclopropanecarbonyl deri... Bioorg Med Chem Lett. 2006 Dec 1;16(23):6024-7. DMEK9DH RU https://pubmed.ncbi.nlm.nih.gov/16979340 DMEKGIX DI DMEKGIX DMEKGIX DN (S)APOMORPHINE DMEKGIX TI TTZFYLI DMEKGIX TN Dopamine D1 receptor (D1R) DMEKGIX MA Inhibitor DMEKGIX RN Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J Med Chem. 1990 Jun;33(6):1800-5. DMEKGIX RU https://pubmed.ncbi.nlm.nih.gov/1971309 DMEKGIX DI DMEKGIX DMEKGIX DN (S)APOMORPHINE DMEKGIX TI TTEX248 DMEKGIX TN Dopamine D2 receptor (D2R) DMEKGIX MA Inhibitor DMEKGIX RN Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogues. J Med Chem. 1990 Jun;33(6):1800-5. DMEKGIX RU https://pubmed.ncbi.nlm.nih.gov/1971309 DMEKGZS DI DMEKGZS DMEKGZS DN [125I]EXP985 DMEKGZS TI TT8DBY3 DMEKGZS TN Angiotensin II receptor type-1 (AGTR1) DMEKGZS MA Antagonist DMEKGZS RN [125I]EXP985: a highly potent and specific nonpeptide radioligand antagonist for the AT1 angiotensin receptor. Biochem Biophys Res Commun. 1992 Nov 16;188(3):1030-9. DMEKGZS RU https://pubmed.ncbi.nlm.nih.gov/1445340 DMEKI1B DI DMEKI1B DMEKI1B DN 4,9-anhydro-tetrodotoxin DMEKI1B TI TT54ERL DMEKI1B TN Voltage-gated sodium channel alpha Nav1.6 (SCN8A) DMEKI1B MA Blocker (channel blocker) DMEKI1B RN The TTX metabolite 4,9-anhydro-TTX is a highly specific blocker of the Na(v1.6) voltage-dependent sodium channel. Am J Physiol Cell Physiol. 2007 Aug;293(2):C783-9. DMEKI1B RU https://pubmed.ncbi.nlm.nih.gov/17522141 DMEKI1J DI DMEKI1J DMEKI1J DN Carazolol DMEKI1J TI TTR6W5O DMEKI1J TN Adrenergic receptor beta-1 (ADRB1) DMEKI1J MA Agonist DMEKI1J RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMEKI1J RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMEKI1J DI DMEKI1J DMEKI1J DN Carazolol DMEKI1J TI TTMXGCW DMEKI1J TN Adrenergic receptor beta-3 (ADRB3) DMEKI1J MA Agonist DMEKI1J RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMEKI1J RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMEKMOF DI DMEKMOF DMEKMOF DN Isosorbide-2-(methylcarbamate)-5-mononitrate DMEKMOF TI TTEB0GD DMEKMOF TN Cholinesterase (BCHE) DMEKMOF MA Inhibitor DMEKMOF RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMEKMOF RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMEKMOF DI DMEKMOF DMEKMOF DN Isosorbide-2-(methylcarbamate)-5-mononitrate DMEKMOF TI TT1RS9F DMEKMOF TN Acetylcholinesterase (AChE) DMEKMOF MA Inhibitor DMEKMOF RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMEKMOF RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMEKNZW DI DMEKNZW DMEKNZW DN 2-(4-Butoxy-phenoxy)-N-hydroxy-N-methyl-acetamide DMEKNZW TI TT2J34L DMEKNZW TN Arachidonate 5-lipoxygenase (5-LOX) DMEKNZW MA Inhibitor DMEKNZW RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMEKNZW RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMEKSAZ DI DMEKSAZ DMEKSAZ DN 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-c]pyridine DMEKSAZ TI TT9JNIC DMEKSAZ TN Histamine H3 receptor (H3R) DMEKSAZ MA Inhibitor DMEKSAZ RN Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6176-80. DMEKSAZ RU https://pubmed.ncbi.nlm.nih.gov/19773164 DMEKSHG DI DMEKSHG DMEKSHG DN N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide DMEKSHG TI TT8JRS7 DMEKSHG TN Beta-secretase (BACE) DMEKSHG MA Inhibitor DMEKSHG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMEKSHG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMEKU71 DI DMEKU71 DMEKU71 DN Dodeca-2E,4E-dienoic acid isobutylamide DMEKU71 TI TTMSFAW DMEKU71 TN Cannabinoid receptor 2 (CB2) DMEKU71 MA Inhibitor DMEKU71 RN Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides. J Nat Prod. 2007 Jun;70(6):1010-5. DMEKU71 RU https://pubmed.ncbi.nlm.nih.gov/17497806 DMEL0SZ DI DMEL0SZ DMEL0SZ DN [des-Arg9]bradykinin DMEL0SZ TI TTGY8IW DMEL0SZ TN B2 bradykinin receptor (BDKRB2) DMEL0SZ MA Agonist DMEL0SZ RN Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization. Br J Pharmacol. 1997 Sep;122(2):393-9. DMEL0SZ RU https://pubmed.ncbi.nlm.nih.gov/9313952 DMEL2GK DI DMEL2GK DMEL2GK DN Bbs-Arg-(D-Pip)-Gly-S-(GS)3-Gly-Hir DMEL2GK TI TT6L509 DMEL2GK TN Coagulation factor IIa (F2) DMEL2GK MA Inhibitor DMEL2GK RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMEL2GK RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMEL4UN DI DMEL4UN DMEL4UN DN Y-c[D-Pen-(2R,3R)-2-Me-(2')Nal-GSFC]KR-NH2 DMEL4UN TI TT6PKBN DMEL4UN TN Proto-oncogene c-Src (SRC) DMEL4UN MA Inhibitor DMEL4UN RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DMEL4UN RU https://pubmed.ncbi.nlm.nih.gov/9632358 DMEL8S5 DI DMEL8S5 DMEL8S5 DN 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone DMEL8S5 TI TTNJYV2 DMEL8S5 TN Gamma-aminobutyric acid receptor (GAR) DMEL8S5 MA Inhibitor DMEL8S5 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMEL8S5 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMEL8S5 DI DMEL8S5 DMEL8S5 DN 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone DMEL8S5 TI TT06RH5 DMEL8S5 TN GABA(A) receptor gamma-2 (GABRG2) DMEL8S5 MA Inhibitor DMEL8S5 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMEL8S5 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMEL8S5 DI DMEL8S5 DMEL8S5 DN 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone DMEL8S5 TI TTZA1NY DMEL8S5 TN GABA(A) receptor beta-2 (GABRB2) DMEL8S5 MA Inhibitor DMEL8S5 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMEL8S5 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMEL8S5 DI DMEL8S5 DMEL8S5 DN 3-cyclopentoxycarbonyl-6-ethyl-4-quinolone DMEL8S5 TI TT1MPAY DMEL8S5 TN GABA(A) receptor alpha-1 (GABRA1) DMEL8S5 MA Inhibitor DMEL8S5 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMEL8S5 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMEL8XU DI DMEL8XU DMEL8XU DN 5-(pyridin-4-yl)-1,3,4-thiadiazole-2(3H)-thione DMEL8XU TI TTULVH8 DMEL8XU TN Tyrosinase (TYR) DMEL8XU MA Inhibitor DMEL8XU RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMEL8XU RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMELB07 DI DMELB07 DMELB07 DN N-Hydroxy-N'-(4-methoxyphenyl)octanediamide DMELB07 TI TT6R7JZ DMELB07 TN Histone deacetylase 1 (HDAC1) DMELB07 MA Inhibitor DMELB07 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMELB07 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMELB07 DI DMELB07 DMELB07 DN N-Hydroxy-N'-(4-methoxyphenyl)octanediamide DMELB07 TI TTBH0VX DMELB07 TN Histone deacetylase (HDAC) DMELB07 MA Inhibitor DMELB07 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMELB07 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMELB5S DI DMELB5S DMELB5S DN Flupentixole DMELB5S TI TTPC4TU DMELB5S TN 5-HT 3A receptor (HTR3A) DMELB5S MA Inhibitor DMELB5S RN Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. Eur J Med Chem. 2009 Jun;44(6):2667-72. DMELB5S RU https://pubmed.ncbi.nlm.nih.gov/19144451 DMELGKY DI DMELGKY DMELGKY DN 4-substituted 2,4-dioxobutanoic acids DMELGKY TI TTTG60L DMELGKY TN CAP-dependent endonuclease (CDE) DMELGKY MA Inhibitor DMELGKY RN Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother. 1996 May;40(5):1304-7. DMELGKY RU https://pubmed.ncbi.nlm.nih.gov/8723491 DMELGKY DI DMELGKY DMELGKY DN 4-substituted 2,4-dioxobutanoic acids DMELGKY TI TTV9MQG DMELGKY TN Gamma-aminobutyric acid uptake (GABAU) DMELGKY MA Inhibitor DMELGKY RN GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des. 2000 Aug;6(12):1193-209. DMELGKY RU https://pubmed.ncbi.nlm.nih.gov/10903390 DMELK2A DI DMELK2A DMELK2A DN Methotrexate gamma-L-phenylalaninehydroxamic acid DMELK2A TI TT6X50U DMELK2A TN Matrix metalloproteinase-9 (MMP-9) DMELK2A MA Inhibitor DMELK2A RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMELK2A RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMELOIQ DI DMELOIQ DMELOIQ DN Alpha-naphthoflavone DMELOIQ TI TTSZLWK DMELOIQ TN Aromatase (CYP19A1) DMELOIQ MA Inhibitor DMELOIQ RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMELOIQ RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMELOIQ DI DMELOIQ DMELOIQ DN Alpha-naphthoflavone DMELOIQ TI TTK3PY9 DMELOIQ TN DNA-dependent protein kinase catalytic (PRKDC) DMELOIQ MA Inhibitor DMELOIQ RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMELOIQ RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMELSV1 DI DMELSV1 DMELSV1 DN 1,3-bis(3,4-dihydroxyphenyl)prop-2-en-1-one DMELSV1 TI TTQY2EJ DMELSV1 TN TERT messenger RNA (TERT mRNA) DMELSV1 MA Inhibitor DMELSV1 RN Catecholic flavonoids acting as telomerase inhibitors. J Med Chem. 2004 Dec 16;47(26):6466-75. DMELSV1 RU https://pubmed.ncbi.nlm.nih.gov/15588081 DMELTM2 DI DMELTM2 DMELTM2 DN PA-10040 DMELTM2 TI TTF1QVM DMELTM2 TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMELTM2 MA Modulator DMELTM2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DMELTM2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DMELUG5 DI DMELUG5 DMELUG5 DN Crocusatin-K DMELUG5 TI TTULVH8 DMELUG5 TN Tyrosinase (TYR) DMELUG5 MA Inhibitor DMELUG5 RN Antityrosinase principles and constituents of the petals of Crocus sativus. J Nat Prod. 2004 Mar;67(3):437-40. DMELUG5 RU https://pubmed.ncbi.nlm.nih.gov/15043425 DMELYAX DI DMELYAX DMELYAX DN NU-6027 DMELYAX TI TTAMQ62 DMELYAX TN Cyclin A2 (CCNA2) DMELYAX MA Inhibitor DMELYAX RN 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22. DMELYAX RU https://pubmed.ncbi.nlm.nih.gov/12482427 DMELYAX DI DMELYAX DMELYAX DN NU-6027 DMELYAX TI TT7HF4W DMELYAX TN Cyclin-dependent kinase 2 (CDK2) DMELYAX MA Inhibitor DMELYAX RN 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg Med Chem Lett. 2003 Jan 20;13(2):217-22. DMELYAX RU https://pubmed.ncbi.nlm.nih.gov/12482427 DMEM1BA DI DMEM1BA DMEM1BA DN 6-(4-((benzylamino)methyl)phenoxy)nicotinamide DMEM1BA TI TTQW87Y DMEM1BA TN Opioid receptor kappa (OPRK1) DMEM1BA MA Inhibitor DMEM1BA RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMEM1BA RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMEM1BA DI DMEM1BA DMEM1BA DN 6-(4-((benzylamino)methyl)phenoxy)nicotinamide DMEM1BA TI TT27RFC DMEM1BA TN Opioid receptor delta (OPRD1) DMEM1BA MA Inhibitor DMEM1BA RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMEM1BA RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMEM1BA DI DMEM1BA DMEM1BA DN 6-(4-((benzylamino)methyl)phenoxy)nicotinamide DMEM1BA TI TTKWM86 DMEM1BA TN Opioid receptor mu (MOP) DMEM1BA MA Inhibitor DMEM1BA RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMEM1BA RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMEM2SW DI DMEM2SW DMEM2SW DN CYCLOPAMINE DMEM2SW TI TT8J1S3 DMEM2SW TN Smoothened homolog (SMO) DMEM2SW MA Inhibitor DMEM2SW RN Identification and structure-activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signali... Bioorg Med Chem Lett. 2009 Jan 15;19(2):328-31. DMEM2SW RU https://pubmed.ncbi.nlm.nih.gov/19091559 DMEM6Q0 DI DMEM6Q0 DMEM6Q0 DN 8-Methyl-2-phenyl-3H-quinazolin-4-one DMEM6Q0 TI TTVDSZ0 DMEM6Q0 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMEM6Q0 MA Inhibitor DMEM6Q0 RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMEM6Q0 RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMEMANH DI DMEMANH DMEMANH DN 2-Amino-benzenesulfonamide DMEMANH TI TTUNARX DMEMANH TN Carbonic anhydrase (CA) DMEMANH MA Inhibitor DMEMANH RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMEMANH RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMEMANH DI DMEMANH DMEMANH DN 2-Amino-benzenesulfonamide DMEMANH TI TTANPDJ DMEMANH TN Carbonic anhydrase II (CA-II) DMEMANH MA Inhibitor DMEMANH RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMEMANH RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMEMANH DI DMEMANH DMEMANH DN 2-Amino-benzenesulfonamide DMEMANH TI TTSYM0R DMEMANH TN Carbonic anhydrase XII (CA-XII) DMEMANH MA Inhibitor DMEMANH RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMEMANH RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMEMANH DI DMEMANH DMEMANH DN 2-Amino-benzenesulfonamide DMEMANH TI TTCFSPE DMEMANH TN Carbonic anhydrase VI (CA-VI) DMEMANH MA Inhibitor DMEMANH RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMEMANH RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMEMANH DI DMEMANH DMEMANH DN 2-Amino-benzenesulfonamide DMEMANH TI TT2LVK8 DMEMANH TN Carbonic anhydrase IX (CA-IX) DMEMANH MA Inhibitor DMEMANH RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMEMANH RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMEMANH DI DMEMANH DMEMANH DN 2-Amino-benzenesulfonamide DMEMANH TI TTEYTKG DMEMANH TN Carbonic anhydrase XIV (CA-XIV) DMEMANH MA Inhibitor DMEMANH RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMEMANH RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMEMBKW DI DMEMBKW DMEMBKW DN 5,8-Dimethoxy-4-methylquinolin-2(1H)-one DMEMBKW TI TTJLP0R DMEMBKW TN Quinone reductase 2 (NQO2) DMEMBKW MA Inhibitor DMEMBKW RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMEMBKW RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMEMGPU DI DMEMGPU DMEMGPU DN 6,7-Dimethoxy-4-m-tolyloxy-quinoline DMEMGPU TI TTI7421 DMEMGPU TN Platelet-derived growth factor receptor beta (PDGFRB) DMEMGPU MA Inhibitor DMEMGPU RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMEMGPU RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMEMHIF DI DMEMHIF DMEMHIF DN 1-(3-Oxocyclohexylidene)thiosemicarbazide DMEMHIF TI TTULVH8 DMEMHIF TN Tyrosinase (TYR) DMEMHIF MA Inhibitor DMEMHIF RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMEMHIF RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMEML8B DI DMEML8B DMEML8B DN 15-hydroxyeicosatetraenoic acid DMEML8B TI TT2J34L DMEML8B TN Arachidonate 5-lipoxygenase (5-LOX) DMEML8B MA Inhibitor DMEML8B RN Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. DMEML8B RU https://pubmed.ncbi.nlm.nih.gov/10940813 DMEMLHR DI DMEMLHR DMEMLHR DN PMID30247903-Compound-General structure25 DMEMLHR TI TTNBFWK DMEMLHR TN Programmed cell death protein 1 (PD-1) DMEMLHR MA Inhibitor DMEMLHR RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMEMLHR RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMEMN0W DI DMEMN0W DMEMN0W DN 4P-PDOT DMEMN0W TI TT0WAIE DMEMN0W TN Melatonin receptor type 1A (MTNR1A) DMEMN0W MA Antagonist DMEMN0W RN Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998 Sep;12(12):1211-20. DMEMN0W RU https://pubmed.ncbi.nlm.nih.gov/9737724 DMEMQAK DI DMEMQAK DMEMQAK DN Dmt-Pro-Tmp-Phe-NH2 DMEMQAK TI TTQW87Y DMEMQAK TN Opioid receptor kappa (OPRK1) DMEMQAK MA Inhibitor DMEMQAK RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMEMQAK RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMEMQAK DI DMEMQAK DMEMQAK DN Dmt-Pro-Tmp-Phe-NH2 DMEMQAK TI TT27RFC DMEMQAK TN Opioid receptor delta (OPRD1) DMEMQAK MA Inhibitor DMEMQAK RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMEMQAK RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMEMQAK DI DMEMQAK DMEMQAK DN Dmt-Pro-Tmp-Phe-NH2 DMEMQAK TI TTKWM86 DMEMQAK TN Opioid receptor mu (MOP) DMEMQAK MA Inhibitor DMEMQAK RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMEMQAK RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMEMQFH DI DMEMQFH DMEMQFH DN 1-Cyclopentyl-3,7-dihydro-purine-2,6-dione DMEMQFH TI TTJFY5U DMEMQFH TN Adenosine A3 receptor (ADORA3) DMEMQFH MA Inhibitor DMEMQFH RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMEMQFH RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMEMSW1 DI DMEMSW1 DMEMSW1 DN ISIS 113874 DMEMSW1 TI TTIX0ZU DMEMSW1 TN MEKK2 messenger RNA (MAP3K2 mRNA) DMEMSW1 RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMEMSW1 RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMEMVY5 DI DMEMVY5 DMEMVY5 DN [32P]MRS2500 DMEMVY5 TI TTA93TL DMEMVY5 TN P2Y purinoceptor 1 (P2RY1) DMEMVY5 MA Antagonist DMEMVY5 RN [32P]2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol. 2006 Mar;147(5):459-67. DMEMVY5 RU https://pubmed.ncbi.nlm.nih.gov/16299552 DMEMYS1 DI DMEMYS1 DMEMYS1 DN N-(3-Benzooxazol-7-yl-propyl)-propionamide DMEMYS1 TI TT32JK8 DMEMYS1 TN Melatonin receptor type 1B (MTNR1B) DMEMYS1 MA Inhibitor DMEMYS1 RN Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802. DMEMYS1 RU https://pubmed.ncbi.nlm.nih.gov/15203165 DMEMZ6Q DI DMEMZ6Q DMEMZ6Q DN BRL-55473 DMEMZ6Q TI TTQ3JTF DMEMZ6Q TN Muscarinic acetylcholine receptor M4 (CHRM4) DMEMZ6Q MA Inhibitor DMEMZ6Q RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMEMZ6Q RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMEMZ6Q DI DMEMZ6Q DMEMZ6Q DN BRL-55473 DMEMZ6Q TI TTH18TF DMEMZ6Q TN Muscarinic acetylcholine receptor M5 (CHRM5) DMEMZ6Q MA Inhibitor DMEMZ6Q RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMEMZ6Q RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMEMZ6Q DI DMEMZ6Q DMEMZ6Q DN BRL-55473 DMEMZ6Q TI TTQ13Z5 DMEMZ6Q TN Muscarinic acetylcholine receptor M3 (CHRM3) DMEMZ6Q MA Inhibitor DMEMZ6Q RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMEMZ6Q RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMEMZ6Q DI DMEMZ6Q DMEMZ6Q DN BRL-55473 DMEMZ6Q TI TTYEG6Q DMEMZ6Q TN Muscarinic acetylcholine receptor M2 (CHRM2) DMEMZ6Q MA Inhibitor DMEMZ6Q RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMEMZ6Q RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMEMZ6Q DI DMEMZ6Q DMEMZ6Q DN BRL-55473 DMEMZ6Q TI TTZ9SOR DMEMZ6Q TN Muscarinic acetylcholine receptor M1 (CHRM1) DMEMZ6Q MA Inhibitor DMEMZ6Q RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMEMZ6Q RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMEN2L3 DI DMEN2L3 DMEN2L3 DN KNI-10526 DMEN2L3 TI TTXMNHO DMEN2L3 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMEN2L3 MA Inhibitor DMEN2L3 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMEN2L3 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMEN4DZ DI DMEN4DZ DMEN4DZ DN KNI-10080 DMEN4DZ TI TTXMNHO DMEN4DZ TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMEN4DZ MA Inhibitor DMEN4DZ RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMEN4DZ RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMEN4G8 DI DMEN4G8 DMEN4G8 DN Des-AA1,2,4,5-[D-Trp8]SRIF DMEN4G8 TI TT2BC4G DMEN4G8 TN Somatostatin receptor type 5 (SSTR5) DMEN4G8 MA Inhibitor DMEN4G8 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMEN4G8 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMEN4G8 DI DMEN4G8 DMEN4G8 DN Des-AA1,2,4,5-[D-Trp8]SRIF DMEN4G8 TI TTJX3UE DMEN4G8 TN Somatostatin receptor type 3 (SSTR3) DMEN4G8 MA Inhibitor DMEN4G8 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMEN4G8 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMEN4G8 DI DMEN4G8 DMEN4G8 DN Des-AA1,2,4,5-[D-Trp8]SRIF DMEN4G8 TI TTIND6G DMEN4G8 TN Somatostatin receptor type 1 (SSTR1) DMEN4G8 MA Inhibitor DMEN4G8 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMEN4G8 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMEN4G8 DI DMEN4G8 DMEN4G8 DN Des-AA1,2,4,5-[D-Trp8]SRIF DMEN4G8 TI TTAE1BR DMEN4G8 TN Somatostatin receptor type 4 (SSTR4) DMEN4G8 MA Inhibitor DMEN4G8 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMEN4G8 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMEN4G8 DI DMEN4G8 DMEN4G8 DN Des-AA1,2,4,5-[D-Trp8]SRIF DMEN4G8 TI TTZ6T9E DMEN4G8 TN Somatostatin receptor type 2 (SSTR2) DMEN4G8 MA Inhibitor DMEN4G8 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMEN4G8 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMEN9T4 DI DMEN9T4 DMEN9T4 DN 3,4'-(thiophene-2,4-diyl)diphenol DMEN9T4 TI TTIWB6L DMEN9T4 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMEN9T4 MA Inhibitor DMEN9T4 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMEN9T4 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMENHMU DI DMENHMU DMENHMU DN IN-3 DMENHMU TI TT8R70G DMENHMU TN Gonadotropin-releasing hormone receptor (GNRHR) DMENHMU MA Antagonist DMENHMU RN Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. JClin Endocrinol Metab. 2002 Jul;87(7):3255-62. DMENHMU RU https://pubmed.ncbi.nlm.nih.gov/12107234 DMENLFY DI DMENLFY DMENLFY DN 4,5-Bis(4-chlorophenyl)isothiazole DMENLFY TI TT8NGED DMENLFY TN Prostaglandin G/H synthase 1 (COX-1) DMENLFY MA Inhibitor DMENLFY RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMENLFY RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMENLFY DI DMENLFY DMENLFY DN 4,5-Bis(4-chlorophenyl)isothiazole DMENLFY TI TTVKILB DMENLFY TN Prostaglandin G/H synthase 2 (COX-2) DMENLFY MA Inhibitor DMENLFY RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMENLFY RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMENLUP DI DMENLUP DMENLUP DN 4-(4-chlorobenzylthio)-2-aminobutanoic acid DMENLUP TI TTFK1JQ DMENLUP TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMENLUP MA Inhibitor DMENLUP RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMENLUP RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMENM1B DI DMENM1B DMENM1B DN L-beta-BA DMENM1B TI TTG2A6F DMENM1B TN Excitatory amino acid transporter 3 (SLC1A1) DMENM1B MA Inhibitor DMENM1B RN The substituted aspartate analogue L-beta-threo-benzyl-aspartate preferentially inhibits the neuronal excitatory amino acid transporter EAAT3. Neuropharmacology. 2005 Nov;49(6):850-61. DMENM1B RU https://pubmed.ncbi.nlm.nih.gov/16183084 DMENSOZ DI DMENSOZ DMENSOZ DN Monothioglycerol DMENSOZ TI TTNGKET DMENSOZ TN Prolyl endopeptidase (PREP) DMENSOZ MA Inhibitor DMENSOZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMENSOZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMENTMP DI DMENTMP DMENTMP DN UFP-112 DMENTMP TI TTNT7K8 DMENTMP TN Nociceptin receptor (OPRL1) DMENTMP MA Agonist DMENTMP RN Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein G alpha qi5. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jun;379(6):599-607. DMENTMP RU https://pubmed.ncbi.nlm.nih.gov/19183962 DMENUIH DI DMENUIH DMENUIH DN 2-(2-methylquinolin-7-yl)benzonitrile DMENUIH TI TTHS256 DMENUIH TN Metabotropic glutamate receptor 5 (mGluR5) DMENUIH MA Inhibitor DMENUIH RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMENUIH RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMENUOD DI DMENUOD DMENUOD DN L-644,698 DMENUOD TI TTNVEIR DMENUOD TN Prostaglandin D2 receptor (PTGDR) DMENUOD MA Agonist DMENUOD RN A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol. 1999 Jul 14;377(1):101-15. DMENUOD RU https://pubmed.ncbi.nlm.nih.gov/10448933 DMENVKA DI DMENVKA DMENVKA DN H-Arg-Arg-Pro-Tyr-Ile-Aac-OH DMENVKA TI TTTUMEP DMENVKA TN Neurotensin receptor type 1 (NTSR1) DMENVKA MA Inhibitor DMENVKA RN Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68. DMENVKA RU https://pubmed.ncbi.nlm.nih.gov/18809332 DMEO3Y4 DI DMEO3Y4 DMEO3Y4 DN ASN02563583 DMEO3Y4 TI TTMPART DMEO3Y4 TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMEO3Y4 MA Agonist DMEO3Y4 RN In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52. DMEO3Y4 RU https://pubmed.ncbi.nlm.nih.gov/21744154 DMEO6AH DI DMEO6AH DMEO6AH DN [3H]HEMADO DMEO6AH TI TTNE7KG DMEO6AH TN Adenosine A2b receptor (ADORA2B) DMEO6AH MA Agonist DMEO6AH RN [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol. 2007 Feb 5;556(1-3):14-8. DMEO6AH RU https://pubmed.ncbi.nlm.nih.gov/17126322 DMEO6AH DI DMEO6AH DMEO6AH DN [3H]HEMADO DMEO6AH TI TTK25J1 DMEO6AH TN Adenosine A1 receptor (ADORA1) DMEO6AH MA Agonist DMEO6AH RN [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol. 2007 Feb 5;556(1-3):14-8. DMEO6AH RU https://pubmed.ncbi.nlm.nih.gov/17126322 DMEO6AH DI DMEO6AH DMEO6AH DN [3H]HEMADO DMEO6AH TI TTJFY5U DMEO6AH TN Adenosine A3 receptor (ADORA3) DMEO6AH MA Agonist DMEO6AH RN [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol. 2007 Feb 5;556(1-3):14-8. DMEO6AH RU https://pubmed.ncbi.nlm.nih.gov/17126322 DMEO7CP DI DMEO7CP DMEO7CP DN GR-86014 DMEO7CP TI TTQW87Y DMEO7CP TN Opioid receptor kappa (OPRK1) DMEO7CP MA Modulator DMEO7CP RN Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist. DMEO7CP RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1907793 DMEO7L5 DI DMEO7L5 DMEO7L5 DN N-Hydroxy-4-iodo-benzamide DMEO7L5 TI TT2J34L DMEO7L5 TN Arachidonate 5-lipoxygenase (5-LOX) DMEO7L5 MA Inhibitor DMEO7L5 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMEO7L5 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMEO82V DI DMEO82V DMEO82V DN ARI-3531 DMEO82V TI TTNGKET DMEO82V TN Prolyl endopeptidase (PREP) DMEO82V MA Inhibitor DMEO82V RN Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77. DMEO82V RU https://pubmed.ncbi.nlm.nih.gov/23594271 DMEOBNJ DI DMEOBNJ DMEOBNJ DN 3,6-Diphenyl-1-oxa-7-aza-spiro[4.5]decane DMEOBNJ TI TTZPO1L DMEOBNJ TN Substance-P receptor (TACR1) DMEOBNJ MA Inhibitor DMEOBNJ RN Spirocyclic NK(1) antagonists II: [4.5]-spiroethers. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2719-22. DMEOBNJ RU https://pubmed.ncbi.nlm.nih.gov/12217362 DMEOCKZ DI DMEOCKZ DMEOCKZ DN JZL195 DMEOCKZ TI TT2EJXQ DMEOCKZ TN Acyloxyacyl hydrolase (neutrophil) DMEOCKZ MA Inhibitor DMEOCKZ RN A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63. DMEOCKZ RU https://pubmed.ncbi.nlm.nih.gov/24997602 DMEOHLV DI DMEOHLV DMEOHLV DN PMID18337095C27 DMEOHLV TI TTFYL58 DMEOHLV TN CaM-kinase II (CAMK2) DMEOHLV MA Inhibitor DMEOHLV RN Aryl-indolyl maleimides as inhibitors of CaMKIIdelta. Part 3: Importance of the indole orientation. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2399-403. DMEOHLV RU https://pubmed.ncbi.nlm.nih.gov/18337095 DMEOI0V DI DMEOI0V DMEOI0V DN 2-morpholino-6-(naphthalen-1-yl)-4H-pyran-4-one DMEOI0V TI TTK3PY9 DMEOI0V TN DNA-dependent protein kinase catalytic (PRKDC) DMEOI0V MA Inhibitor DMEOI0V RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMEOI0V RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMEOJ89 DI DMEOJ89 DMEOJ89 DN VAGANINE D DMEOJ89 TI TTEB0GD DMEOJ89 TN Cholinesterase (BCHE) DMEOJ89 MA Inhibitor DMEOJ89 RN Steroidal alkaloids from the leaves of Sarcococca coriacea of Nepalese origin. J Nat Prod. 2001 Jun;64(6):842-4. DMEOJ89 RU https://pubmed.ncbi.nlm.nih.gov/11421762 DMEOJ9W DI DMEOJ9W DMEOJ9W DN eledoisin DMEOJ9W TI TTZPO1L DMEOJ9W TN Substance-P receptor (TACR1) DMEOJ9W MA Agonist DMEOJ9W RN The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7. DMEOJ9W RU https://pubmed.ncbi.nlm.nih.gov/8702757 DMEOJ9W DI DMEOJ9W DMEOJ9W DN eledoisin DMEOJ9W TI TTBPGLU DMEOJ9W TN Neuromedin-K receptor (TACR3) DMEOJ9W MA Agonist DMEOJ9W RN Molecular characterisation, expression and localisation of human neurokinin-3 receptor. FEBS Lett. 1992 Mar 24;299(1):90-5. DMEOJ9W RU https://pubmed.ncbi.nlm.nih.gov/1312036 DMEOP4J DI DMEOP4J DMEOP4J DN 8-DEOXYGARTANIN DMEOP4J TI TT50QJ3 DMEOP4J TN Influenza Neuraminidase (Influ NA) DMEOP4J MA Inhibitor DMEOP4J RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMEOP4J RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMEORTQ DI DMEORTQ DMEORTQ DN Carboxyatractyloside DMEORTQ TI TTU5A6Q DMEORTQ TN Adenine nucleotide translocator 1 (SLC25A4) DMEORTQ MA Inhibitor DMEORTQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEORTQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEOS8P DI DMEOS8P DMEOS8P DN 1-(oxazol-2-yl)-4-(piperidin-4-yl)butan-1-one DMEOS8P TI TTDP1UC DMEOS8P TN Fatty acid amide hydrolase (FAAH) DMEOS8P MA Inhibitor DMEOS8P RN Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett. 2008 Mar 15;18(6):2109-13. DMEOS8P RU https://pubmed.ncbi.nlm.nih.gov/18289847 DMEP2VM DI DMEP2VM DMEP2VM DN N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide DMEP2VM TI TTBH0VX DMEP2VM TN Histone deacetylase (HDAC) DMEP2VM MA Inhibitor DMEP2VM RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMEP2VM RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMEP2VM DI DMEP2VM DMEP2VM DN N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide DMEP2VM TI TT6R7JZ DMEP2VM TN Histone deacetylase 1 (HDAC1) DMEP2VM MA Inhibitor DMEP2VM RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMEP2VM RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMEP80C DI DMEP80C DMEP80C DN 1-(piperazin-1-yl)isoquinoline DMEP80C TI TTWJBZ5 DMEP80C TN 5-HT 2C receptor (HTR2C) DMEP80C MA Inhibitor DMEP80C RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DMEP80C RU https://pubmed.ncbi.nlm.nih.gov/19914063 DMEP80Q DI DMEP80Q DMEP80Q DN 4-cyanophenyl ethyl dodecylphosphonate DMEP80Q TI TT6OEDT DMEP80Q TN Cannabinoid receptor 1 (CB1) DMEP80Q MA Inhibitor DMEP80Q RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DMEP80Q RU https://pubmed.ncbi.nlm.nih.gov/18752948 DMEP80Q DI DMEP80Q DMEP80Q DN 4-cyanophenyl ethyl dodecylphosphonate DMEP80Q TI TTDP1UC DMEP80Q TN Fatty acid amide hydrolase (FAAH) DMEP80Q MA Inhibitor DMEP80Q RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DMEP80Q RU https://pubmed.ncbi.nlm.nih.gov/18752948 DMEP903 DI DMEP903 DMEP903 DN (E)-1-(4-Nitro-phenyl)-3-pyridin-2-yl-propenone DMEP903 TI TTSFWA7 DMEP903 TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMEP903 MA Inhibitor DMEP903 RN A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26. DMEP903 RU https://pubmed.ncbi.nlm.nih.gov/15481979 DMEPB9L DI DMEPB9L DMEPB9L DN 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine DMEPB9L TI TTAWNKZ DMEPB9L TN Norepinephrine transporter (NET) DMEPB9L MA Inhibitor DMEPB9L RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMEPB9L RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMEPB9L DI DMEPB9L DMEPB9L DN 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine DMEPB9L TI TTVBI8W DMEPB9L TN Dopamine transporter (DAT) DMEPB9L MA Inhibitor DMEPB9L RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMEPB9L RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMEPB9L DI DMEPB9L DMEPB9L DN 4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine DMEPB9L TI TT3ROYC DMEPB9L TN Serotonin transporter (SERT) DMEPB9L MA Inhibitor DMEPB9L RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMEPB9L RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMEPFAB DI DMEPFAB DMEPFAB DN Trifluoromethylketone DMEPFAB TI TTBH0VX DMEPFAB TN Histone deacetylase (HDAC) DMEPFAB MA Inhibitor DMEPFAB RN Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. DMEPFAB RU https://pubmed.ncbi.nlm.nih.gov/16955068 DMEPJRD DI DMEPJRD DMEPJRD DN 1-(4-methoxyoxazol-2-yl)-7-phenylheptan-1-one DMEPJRD TI TTDP1UC DMEPJRD TN Fatty acid amide hydrolase (FAAH) DMEPJRD MA Inhibitor DMEPJRD RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMEPJRD RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMEPT8H DI DMEPT8H DMEPT8H DN [125I]DIV880 DMEPT8H TI TT0WAIE DMEPT8H TN Melatonin receptor type 1A (MTNR1A) DMEPT8H MA Agonist DMEPT8H RN New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci. 2013 Apr 25;14(5):8948-62. DMEPT8H RU https://pubmed.ncbi.nlm.nih.gov/23698757 DMEPZ2I DI DMEPZ2I DMEPZ2I DN folipastatin DMEPZ2I TI TT9V5JH DMEPZ2I TN Phospholipase A2 (PLA2G1B) DMEPZ2I MA Modulator DMEPZ2I RN Folipastatin, a new depsidone compound from Aspergillus unguis as an inhibitor of phospholipase A2.Taxonomy, fermentation, isolation, structure determination and biological properties.J Antibiot (Tokyo).1992 Aug;45(8):1195-201. DMEPZ2I RU https://www.ncbi.nlm.nih.gov/pubmed/1399838 DMEQ063 DI DMEQ063 DMEQ063 DN 2-(4-Phenyl-butyl)-1,2-dihydro-indazol-3-one DMEQ063 TI TT2J34L DMEQ063 TN Arachidonate 5-lipoxygenase (5-LOX) DMEQ063 MA Inhibitor DMEQ063 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMEQ063 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMEQ1HC DI DMEQ1HC DMEQ1HC DN 3,4-bis(indol-3-yl)maleimide derivative DMEQ1HC TI TTH6V3D DMEQ1HC TN Cyclin-dependent kinase 1 (CDK1) DMEQ1HC MA Inhibitor DMEQ1HC RN Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. DMEQ1HC RU https://pubmed.ncbi.nlm.nih.gov/9871700 DMEQ1HC DI DMEQ1HC DMEQ1HC DN 3,4-bis(indol-3-yl)maleimide derivative DMEQ1HC TI TT9P6OW DMEQ1HC TN G2/mitotic-specific cyclin B1 (CCNB1) DMEQ1HC MA Inhibitor DMEQ1HC RN Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. DMEQ1HC RU https://pubmed.ncbi.nlm.nih.gov/9871700 DMEQBS3 DI DMEQBS3 DMEQBS3 DN 3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone DMEQBS3 TI TT27RFC DMEQBS3 TN Opioid receptor delta (OPRD1) DMEQBS3 MA Inhibitor DMEQBS3 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMEQBS3 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMEQBS3 DI DMEQBS3 DMEQBS3 DN 3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone DMEQBS3 TI TTKWM86 DMEQBS3 TN Opioid receptor mu (MOP) DMEQBS3 MA Inhibitor DMEQBS3 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMEQBS3 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMEQBU2 DI DMEQBU2 DMEQBU2 DN SJ-8002 DMEQBU2 TI TTPF2QI DMEQBU2 TN Caspase-3 (CASP3) DMEQBU2 MA Inhibitor DMEQBU2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1619). DMEQBU2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1619 DMEQC4X DI DMEQC4X DMEQC4X DN 2,7-Bis(benzoamido)anthraquinone DMEQC4X TI TTQY2EJ DMEQC4X TN TERT messenger RNA (TERT mRNA) DMEQC4X MA Inhibitor DMEQC4X RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMEQC4X RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMEQH6J DI DMEQH6J DMEQH6J DN Flavone DMEQH6J TI TTJFY5U DMEQH6J TN Adenosine A3 receptor (ADORA3) DMEQH6J MA Antagonist DMEQH6J RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMEQH6J RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMEQH6J DI DMEQH6J DMEQH6J DN Flavone DMEQH6J TI TTNE7KG DMEQH6J TN Adenosine A2b receptor (ADORA2B) DMEQH6J MA Antagonist DMEQH6J RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMEQH6J RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMEQH6J DI DMEQH6J DMEQH6J DN Flavone DMEQH6J TI TTK25J1 DMEQH6J TN Adenosine A1 receptor (ADORA1) DMEQH6J MA Antagonist DMEQH6J RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMEQH6J RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMEQH6J DI DMEQH6J DMEQH6J DN Flavone DMEQH6J TI TTNJYV2 DMEQH6J TN Gamma-aminobutyric acid receptor (GAR) DMEQH6J MA Inhibitor DMEQH6J RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMEQH6J RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMEQH6J DI DMEQH6J DMEQH6J DN Flavone DMEQH6J TI TTSZLWK DMEQH6J TN Aromatase (CYP19A1) DMEQH6J MA Inhibitor DMEQH6J RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMEQH6J RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMEQH6J DI DMEQH6J DMEQH6J DN Flavone DMEQH6J TI TT1MPAY DMEQH6J TN GABA(A) receptor alpha-1 (GABRA1) DMEQH6J MA Inhibitor DMEQH6J RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMEQH6J RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMEQH6J DI DMEQH6J DMEQH6J DN Flavone DMEQH6J TI TTKPW01 DMEQH6J TN Androgen receptor messenger RNA (AR mRNA) DMEQH6J MA Inhibitor DMEQH6J RN Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. DMEQH6J RU https://pubmed.ncbi.nlm.nih.gov/19592245 DMEQKIU DI DMEQKIU DMEQKIU DN 2-Acetylamino-indan-5-sulfonic acid hydrate DMEQKIU TI TTANPDJ DMEQKIU TN Carbonic anhydrase II (CA-II) DMEQKIU MA Inhibitor DMEQKIU RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DMEQKIU RU https://pubmed.ncbi.nlm.nih.gov/15501040 DMEQKIU DI DMEQKIU DMEQKIU DN 2-Acetylamino-indan-5-sulfonic acid hydrate DMEQKIU TI TTHQPL7 DMEQKIU TN Carbonic anhydrase I (CA-I) DMEQKIU MA Inhibitor DMEQKIU RN Carbonic anhydrase inhibitors. Design of anticonvulsant sulfonamides incorporating indane moieties. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5781-6. DMEQKIU RU https://pubmed.ncbi.nlm.nih.gov/15501040 DMEQKPO DI DMEQKPO DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide DMEQKPO TI TTT6LFV DMEQKPO TN Histone deacetylase 8 (HDAC8) DMEQKPO MA Inhibitor DMEQKPO RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMEQKPO RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMEQKPO DI DMEQKPO DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide DMEQKPO TI TT6R7JZ DMEQKPO TN Histone deacetylase 1 (HDAC1) DMEQKPO MA Inhibitor DMEQKPO RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMEQKPO RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMEQKPO DI DMEQKPO DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide DMEQKPO TI TT5ZKDI DMEQKPO TN Histone deacetylase 6 (HDAC6) DMEQKPO MA Inhibitor DMEQKPO RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMEQKPO RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMEQKPO DI DMEQKPO DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide DMEQKPO TI TTTQGH8 DMEQKPO TN Histone deacetylase 4 (HDAC4) DMEQKPO MA Inhibitor DMEQKPO RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMEQKPO RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMEQKPO DI DMEQKPO DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide DMEQKPO TI TTBH0VX DMEQKPO TN Histone deacetylase (HDAC) DMEQKPO MA Inhibitor DMEQKPO RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMEQKPO RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMEQKPO DI DMEQKPO DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide DMEQKPO TI TTSHTOI DMEQKPO TN Histone deacetylase 2 (HDAC2) DMEQKPO MA Inhibitor DMEQKPO RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMEQKPO RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMEQKPO DI DMEQKPO DMEQKPO DN 7-Mercapto-heptanoic acid biphenyl-3-ylamide DMEQKPO TI TTYHPU6 DMEQKPO TN Histone deacetylase 10 (HDAC10) DMEQKPO MA Inhibitor DMEQKPO RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMEQKPO RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMEQRHY DI DMEQRHY DMEQRHY DN 2-fluoromevalonate 5-diphosphate DMEQRHY TI TTE5J6X DMEQRHY TN Diphosphomevalonate decarboxylase (MVD) DMEQRHY MA Inhibitor DMEQRHY RN Inhibition of mevalonate 5-diphosphate decarboxylase by fluorinated substrate analogs. Biochim Biophys Acta. 2006 Jul;1760(7):1080-7. DMEQRHY RU https://pubmed.ncbi.nlm.nih.gov/16626865 DMEQSTP DI DMEQSTP DMEQSTP DN Uridine-Diphosphate-N-Acetylglucosamine DMEQSTP TI TTGRHIB DMEQSTP TN UDP-glucose 4-epimerase (GALE) DMEQSTP MA Inhibitor DMEQSTP RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMEQSTP RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMEQSTP DI DMEQSTP DMEQSTP DN Uridine-Diphosphate-N-Acetylglucosamine DMEQSTP TI TTICX3S DMEQSTP TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMEQSTP MA Inhibitor DMEQSTP RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMEQSTP RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMEQWSB DI DMEQWSB DMEQWSB DN L-756568 DMEQWSB TI TTJA1ZO DMEQWSB TN ITGB3 messenger RNA (ITGB3 mRNA) DMEQWSB MA Inhibitor DMEQWSB RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DMEQWSB RU https://pubmed.ncbi.nlm.nih.gov/10999999 DMEQXUD DI DMEQXUD DMEQXUD DN 2',3'-Dideoxythymidine-5'-Monophosphate DMEQXUD TI TT5B8AX DMEQXUD TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMEQXUD MA Inhibitor DMEQXUD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEQXUD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEQZ5M DI DMEQZ5M DMEQZ5M DN (4-benzylpiperidin-1-yl)(3-chlorophenyl)methanone DMEQZ5M TI TTVTX4N DMEQZ5M TN Bacterial Fatty acid synthetase I (Bact inhA) DMEQZ5M MA Inhibitor DMEQZ5M RN Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. DMEQZ5M RU https://pubmed.ncbi.nlm.nih.gov/17723305 DMER0IY DI DMER0IY DMER0IY DN 1-(1-Phenyl-propyl)-3-thiazol-2-yl-thiourea DMER0IY TI TT84ETX DMER0IY TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMER0IY MA Inhibitor DMER0IY RN Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8. DMER0IY RU https://pubmed.ncbi.nlm.nih.gov/11229762 DMER3D9 DI DMER3D9 DMER3D9 DN 4-(3-Fluoro-phenoxy)-6,7-dimethoxy-quinoline DMER3D9 TI TTI7421 DMER3D9 TN Platelet-derived growth factor receptor beta (PDGFRB) DMER3D9 MA Inhibitor DMER3D9 RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMER3D9 RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMER4U1 DI DMER4U1 DMER4U1 DN 3-chloro-4-(4-hydroxyphenyl)salicylaldoxime DMER4U1 TI TTZAYWL DMER4U1 TN Estrogen receptor (ESR) DMER4U1 MA Inhibitor DMER4U1 RN Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem. 2008 Mar 13;51(5):1344-51. DMER4U1 RU https://pubmed.ncbi.nlm.nih.gov/18269232 DMER4U1 DI DMER4U1 DMER4U1 DN 3-chloro-4-(4-hydroxyphenyl)salicylaldoxime DMER4U1 TI TTOM3J0 DMER4U1 TN Estrogen receptor beta (ESR2) DMER4U1 MA Inhibitor DMER4U1 RN Monoaryl-substituted salicylaldoximes as ligands for estrogen receptor beta. J Med Chem. 2008 Mar 13;51(5):1344-51. DMER4U1 RU https://pubmed.ncbi.nlm.nih.gov/18269232 DMER5GT DI DMER5GT DMER5GT DN BIS(8)-HUPERZINE B DMER5GT TI TT1RS9F DMER5GT TN Acetylcholinesterase (AChE) DMER5GT MA Inhibitor DMER5GT RN Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7. DMER5GT RU https://pubmed.ncbi.nlm.nih.gov/15689148 DMERJAV DI DMERJAV DMERJAV DN ISIS 103619 DMERJAV TI TTBWMKT DMERJAV TN WWP1 messenger RNA (WWP1 mRNA) DMERJAV RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMERJAV RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMERKGH DI DMERKGH DMERKGH DN 6-Acetyl-7-ethoxy-2H-chromen-2-one DMERKGH TI TT2LVK8 DMERKGH TN Carbonic anhydrase IX (CA-IX) DMERKGH MA Inhibitor DMERKGH RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMERKGH RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMERKU2 DI DMERKU2 DMERKU2 DN CRL-37212 DMERKU2 TI TTPMQSO DMERKU2 TN ALK tyrosine kinase receptor (ALK) DMERKU2 MA Inhibitor DMERKU2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839). DMERKU2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839 DMERNSK DI DMERNSK DMERNSK DN 2-phenyl-1,1-di(pyridin-3-yl)ethanol DMERNSK TI TTW0CMT DMERNSK TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMERNSK MA Inhibitor DMERNSK RN Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. DMERNSK RU https://pubmed.ncbi.nlm.nih.gov/20304642 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TTUNARX DMERTQ4 TN Carbonic anhydrase (CA) DMERTQ4 MA Inhibitor DMERTQ4 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TTZHA0O DMERTQ4 TN Carbonic anhydrase IV (CA-IV) DMERTQ4 MA Inhibitor DMERTQ4 RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TTHQPL7 DMERTQ4 TN Carbonic anhydrase I (CA-I) DMERTQ4 MA Inhibitor DMERTQ4 RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TTEYTKG DMERTQ4 TN Carbonic anhydrase XIV (CA-XIV) DMERTQ4 MA Inhibitor DMERTQ4 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TT2LVK8 DMERTQ4 TN Carbonic anhydrase IX (CA-IX) DMERTQ4 MA Inhibitor DMERTQ4 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TTCFSPE DMERTQ4 TN Carbonic anhydrase VI (CA-VI) DMERTQ4 MA Inhibitor DMERTQ4 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TTSYM0R DMERTQ4 TN Carbonic anhydrase XII (CA-XII) DMERTQ4 MA Inhibitor DMERTQ4 RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMERTQ4 DI DMERTQ4 DMERTQ4 DN 4-Amino-3-chloro-benzenesulfonamide DMERTQ4 TI TTANPDJ DMERTQ4 TN Carbonic anhydrase II (CA-II) DMERTQ4 MA Inhibitor DMERTQ4 RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMERTQ4 RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMERZHK DI DMERZHK DMERZHK DN 3-(1H-Imidazol-4-yl)benzenethiol DMERZHK TI TTZJYKH DMERZHK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMERZHK MA Inhibitor DMERZHK RN Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77. DMERZHK RU https://pubmed.ncbi.nlm.nih.gov/18665584 DMES906 DI DMES906 DMES906 DN 3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 TI TTO0FDJ DMES906 TN Cyclin-dependent kinase 6 (CDK6) DMES906 MA Inhibitor DMES906 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMES906 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMES906 DI DMES906 DMES906 DN 3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 TI TTNX2CS DMES906 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMES906 MA Inhibitor DMES906 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMES906 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMES906 DI DMES906 DMES906 DN 3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 TI TTBE4IR DMES906 TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMES906 MA Inhibitor DMES906 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMES906 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMES906 DI DMES906 DMES906 DN 3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 TI TT7AOUD DMES906 TN Fatty acid synthase (FASN) DMES906 MA Inhibitor DMES906 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMES906 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMES906 DI DMES906 DMES906 DN 3,7,3',4'-TETRAHYDROXYFLAVONE DMES906 TI TTHPFTS DMES906 TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DMES906 MA Inhibitor DMES906 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMES906 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMES9AJ DI DMES9AJ DMES9AJ DN 4-Benzyl-1-indan-2-ylmethyl-piperidine DMES9AJ TI TTEX248 DMES9AJ TN Dopamine D2 receptor (D2R) DMES9AJ MA Inhibitor DMES9AJ RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMES9AJ RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMESFTW DI DMESFTW DMESFTW DN 2-amino-N-(quinolin-8-yl)benzenesulfonamide DMESFTW TI TTSXVID DMESFTW TN Nuclear factor NF-kappa-B (NFKB) DMESFTW MA Inhibitor DMESFTW RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DMESFTW RU https://pubmed.ncbi.nlm.nih.gov/18024113 DMESHV2 DI DMESHV2 DMESHV2 DN SODIUM PERFLUOROHEXANESULFONAMIDE DMESHV2 TI TTANPDJ DMESHV2 TN Carbonic anhydrase II (CA-II) DMESHV2 MA Inhibitor DMESHV2 RN Synthesis and investigation of inhibition effect of fluorinated sulfonamide derivatives on carbonic anhydrase. Eur J Med Chem. 2010 Mar;45(3):1225-9. DMESHV2 RU https://pubmed.ncbi.nlm.nih.gov/20036446 DMESKQX DI DMESKQX DMESKQX DN ISIS 10228 DMESKQX TI TT5TURO DMESKQX TN A-Raf messenger RNA (ARAF mRNA) DMESKQX RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMESKQX RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMESMBO DI DMESMBO DMESMBO DN 2-(2-Methoxy-benzoyl)-cyclohexane-1,3-dione DMESMBO TI TT8DSFC DMESMBO TN Hydroxyphenylpyruvate dioxygenase (HPD) DMESMBO MA Inhibitor DMESMBO RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DMESMBO RU https://pubmed.ncbi.nlm.nih.gov/10853644 DMEST0R DI DMEST0R DMEST0R DN DB-160 DMEST0R TI TTDIGC1 DMEST0R TN Dipeptidyl peptidase 4 (DPP-4) DMEST0R MA Inhibitor DMEST0R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DMEST0R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DMESU53 DI DMESU53 DMESU53 DN 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone DMESU53 TI TT1MPAY DMESU53 TN GABA(A) receptor alpha-1 (GABRA1) DMESU53 MA Inhibitor DMESU53 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMESU53 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMESU53 DI DMESU53 DMESU53 DN 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone DMESU53 TI TTNJYV2 DMESU53 TN Gamma-aminobutyric acid receptor (GAR) DMESU53 MA Inhibitor DMESU53 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMESU53 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMESU53 DI DMESU53 DMESU53 DN 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone DMESU53 TI TT06RH5 DMESU53 TN GABA(A) receptor gamma-2 (GABRG2) DMESU53 MA Inhibitor DMESU53 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMESU53 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMESU53 DI DMESU53 DMESU53 DN 6-ethyl-3-(2-methylbutoxycarbonyl)-4-quinolone DMESU53 TI TTZA1NY DMESU53 TN GABA(A) receptor beta-2 (GABRB2) DMESU53 MA Inhibitor DMESU53 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMESU53 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMESUD7 DI DMESUD7 DMESUD7 DN 1-Cyclohexyl-3-(4-methoxy-phenyl)-urea DMESUD7 TI TT7WVHI DMESUD7 TN Soluble epoxide hydrolase (EPHX2) DMESUD7 MA Inhibitor DMESUD7 RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMESUD7 RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMESVWC DI DMESVWC DMESVWC DN Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine DMESVWC TI TTVIAT9 DMESVWC TN Phosphodiesterase 4B (PDE4B) DMESVWC MA Inhibitor DMESVWC RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMESVWC RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMESVWC DI DMESVWC DMESVWC DN Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine DMESVWC TI TTJGW1Z DMESVWC TN Phosphodiesterase 2A (PDE2A) DMESVWC MA Inhibitor DMESVWC RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMESVWC RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMESVWC DI DMESVWC DMESVWC DN Benzyl-(2-pyridin-4-yl-quinazolin-4-yl)-amine DMESVWC TI TTZ97H5 DMESVWC TN Phosphodiesterase 4A (PDE4A) DMESVWC MA Inhibitor DMESVWC RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMESVWC RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMET3OJ DI DMET3OJ DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide DMET3OJ TI TTT6LFV DMET3OJ TN Histone deacetylase 8 (HDAC8) DMET3OJ MA Inhibitor DMET3OJ RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMET3OJ RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMET3OJ DI DMET3OJ DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide DMET3OJ TI TT6R7JZ DMET3OJ TN Histone deacetylase 1 (HDAC1) DMET3OJ MA Inhibitor DMET3OJ RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMET3OJ RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMET3OJ DI DMET3OJ DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide DMET3OJ TI TT5ZKDI DMET3OJ TN Histone deacetylase 6 (HDAC6) DMET3OJ MA Inhibitor DMET3OJ RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMET3OJ RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMET3OJ DI DMET3OJ DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide DMET3OJ TI TTTQGH8 DMET3OJ TN Histone deacetylase 4 (HDAC4) DMET3OJ MA Inhibitor DMET3OJ RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMET3OJ RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMET3OJ DI DMET3OJ DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide DMET3OJ TI TTBH0VX DMET3OJ TN Histone deacetylase (HDAC) DMET3OJ MA Inhibitor DMET3OJ RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMET3OJ RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMET3OJ DI DMET3OJ DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide DMET3OJ TI TTSHTOI DMET3OJ TN Histone deacetylase 2 (HDAC2) DMET3OJ MA Inhibitor DMET3OJ RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMET3OJ RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMET3OJ DI DMET3OJ DMET3OJ DN 5-Mercapto-pentanoic acid phenylamide DMET3OJ TI TTYHPU6 DMET3OJ TN Histone deacetylase 10 (HDAC10) DMET3OJ MA Inhibitor DMET3OJ RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMET3OJ RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMET46F DI DMET46F DMET46F DN 3,5-Difluorobenzenesulfonamide DMET46F TI TTANPDJ DMET46F TN Carbonic anhydrase II (CA-II) DMET46F MA Inhibitor DMET46F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMET46F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMET46L DI DMET46L DMET46L DN 2-(pyrimidin-4-ylamino)thiazole-5-carbonitrile DMET46L TI TTUTJGQ DMET46L TN Vascular endothelial growth factor receptor 2 (KDR) DMET46L MA Inhibitor DMET46L RN Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1146-50. DMET46L RU https://pubmed.ncbi.nlm.nih.gov/16368234 DMET64R DI DMET64R DMET64R DN Sucrose Octasulfate DMET64R TI TTMY81X DMET64R TN Heparin-binding growth factor 1 (FGF1) DMET64R MA Inhibitor DMET64R RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMET64R RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMET693 DI DMET693 DMET693 DN 2,7-Bis[3-(piperidino)propionamido]anthraquinone DMET693 TI TTQY2EJ DMET693 TN TERT messenger RNA (TERT mRNA) DMET693 MA Inhibitor DMET693 RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMET693 RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMET6FO DI DMET6FO DMET6FO DN 2H-chromeno[2,3-d]pyrimidine-2,4(3H)-dione DMET6FO TI TTUF2HO DMET6FO TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMET6FO MA Inhibitor DMET6FO RN Characterization of sirtuin inhibitors in nematodes expressing a muscular dystrophy protein reveals muscle cell and behavioral protection by specif... J Med Chem. 2010 Feb 11;53(3):1407-11. DMET6FO RU https://pubmed.ncbi.nlm.nih.gov/20041717 DMET6IS DI DMET6IS DMET6IS DN (3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol DMET6IS TI TTN53ZF DMET6IS TN Leukotriene B4 receptor 1 (LTB4R) DMET6IS MA Inhibitor DMET6IS RN 3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997). DMET6IS RU http://www.sciencedirect.com/science/article/pii/S0960894X97004149 DMET6IS DI DMET6IS DMET6IS DN (3S,4R)-3-Benzyl-7-isopropyl-chroman-4-ol DMET6IS TI TTVJX54 DMET6IS TN Leukotriene B4 receptor 2 (LTB4R2) DMET6IS MA Inhibitor DMET6IS RN 3-Substituted-4-hydroxy-7-chromanylacetic acid derivatives as antagonists of the leukotriene B4 (LTB4) receptor, Bioorg. Med. Chem. Lett. 7(17):2307-2312 (1997). DMET6IS RU http://www.sciencedirect.com/science/article/pii/S0960894X97004149 DMET9ZC DI DMET9ZC DMET9ZC DN Phosphoric acid mono-((E)-tetradec-11-enyl) ester DMET9ZC TI TTQ6S1K DMET9ZC TN Lysophosphatidic acid receptor 1 (LPAR1) DMET9ZC MA Inhibitor DMET9ZC RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMET9ZC RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMETAOU DI DMETAOU DMETAOU DN JWH-244 DMETAOU TI TT6OEDT DMETAOU TN Cannabinoid receptor 1 (CB1) DMETAOU MA Inhibitor DMETAOU RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMETAOU RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMETAOU DI DMETAOU DMETAOU DN JWH-244 DMETAOU TI TTMSFAW DMETAOU TN Cannabinoid receptor 2 (CB2) DMETAOU MA Inhibitor DMETAOU RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMETAOU RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMETC8A DI DMETC8A DMETC8A DN PMID8709131C4 DMETC8A TI TTFQEO5 DMETC8A TN Squalene synthetase (FDFT1) DMETC8A MA Inhibitor DMETC8A RN Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9. DMETC8A RU https://pubmed.ncbi.nlm.nih.gov/8709131 DMETDQC DI DMETDQC DMETDQC DN 1-Benzyl-4-methyl-piperazine DMETDQC TI TTD0CIQ DMETDQC TN Melanocortin receptor 4 (MC4R) DMETDQC MA Inhibitor DMETDQC RN Privileged structure based ligands for melanocortin receptors--substituted benzylic piperazine derivatives. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4973-8. DMETDQC RU https://pubmed.ncbi.nlm.nih.gov/16169215 DMETHN7 DI DMETHN7 DMETHN7 DN PMID8246233C5ab DMETHN7 TI TTPADOQ DMETHN7 TN HMG-CoA reductase (HMGCR) DMETHN7 MA Inhibitor DMETHN7 RN Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3646-57. DMETHN7 RU https://pubmed.ncbi.nlm.nih.gov/8246233 DMETK18 DI DMETK18 DMETK18 DN 4-(4,6-diphenylpyridin-2-yl)phenol DMETK18 TI TTGTQHC DMETK18 TN DNA topoisomerase I (TOP1) DMETK18 MA Inhibitor DMETK18 RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMETK18 RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMETL3Z DI DMETL3Z DMETL3Z DN P2,P3 Ketoamide derivative DMETL3Z TI TTDZN01 DMETL3Z TN Cathepsin K (CTSK) DMETL3Z MA Inhibitor DMETL3Z RN Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4897-902. DMETL3Z RU https://pubmed.ncbi.nlm.nih.gov/15341947 DMETL3Z DI DMETL3Z DMETL3Z DN P2,P3 Ketoamide derivative DMETL3Z TI TTUMQVO DMETL3Z TN Cathepsin S (CTSS) DMETL3Z MA Inhibitor DMETL3Z RN Potent and selective P2-P3 ketoamide inhibitors of cathepsin K with good pharmacokinetic properties via favorable P1', P1, and/or P3 substitutions. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4897-902. DMETL3Z RU https://pubmed.ncbi.nlm.nih.gov/15341947 DMETM3R DI DMETM3R DMETM3R DN lysophosphatidylinositol DMETM3R TI TT7QNVC DMETM3R TN Glucose-dependent insulinotropic receptor (GPR119) DMETM3R MA Agonist DMETM3R RN Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51. DMETM3R RU https://pubmed.ncbi.nlm.nih.gov/15607732 DMETM3R DI DMETM3R DMETM3R DN lysophosphatidylinositol DMETM3R TI TTBECWA DMETM3R TN Transient receptor potential cation channel V2 (TRPV2) DMETM3R MA Activator DMETM3R RN Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 2009 Mar;1793(3):528-39. DMETM3R RU https://pubmed.ncbi.nlm.nih.gov/19321128 DMETM3R DI DMETM3R DMETM3R DN lysophosphatidylinositol DMETM3R TI TTNET8J DMETM3R TN G-protein coupled receptor 55 (GPR55) DMETM3R MA Agonist DMETM3R RN Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609. DMETM3R RU https://pubmed.ncbi.nlm.nih.gov/23396314 DMETNA3 DI DMETNA3 DMETNA3 DN BMS-262084 DMETNA3 TI TTNWD8O DMETNA3 TN Delta-tryptase (TPSD1) DMETNA3 MA Inhibitor DMETNA3 RN Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33. DMETNA3 RU https://pubmed.ncbi.nlm.nih.gov/12372540 DMETNA3 DI DMETNA3 DMETNA3 DN BMS-262084 DMETNA3 TI TTM1TDX DMETNA3 TN Tryptase alpha/beta-1 (Tryptase) DMETNA3 MA Inhibitor DMETNA3 RN Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3229-33. DMETNA3 RU https://pubmed.ncbi.nlm.nih.gov/12372540 DMETQBI DI DMETQBI DMETQBI DN (R,S)-(-)-fenoterol DMETQBI TI TT2CJVK DMETQBI TN Adrenergic receptor beta-2 (ADRB2) DMETQBI MA Inhibitor DMETQBI RN Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15. DMETQBI RU https://pubmed.ncbi.nlm.nih.gov/17506540 DMETQBI DI DMETQBI DMETQBI DN (R,S)-(-)-fenoterol DMETQBI TI TTR6W5O DMETQBI TN Adrenergic receptor beta-1 (ADRB1) DMETQBI MA Inhibitor DMETQBI RN Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor. J Med Chem. 2007 Jun 14;50(12):2903-15. DMETQBI RU https://pubmed.ncbi.nlm.nih.gov/17506540 DMETRIS DI DMETRIS DMETRIS DN gemini DMETRIS TI TTK59TV DMETRIS TN Vitamin D3 receptor (VDR) DMETRIS MA Agonist DMETRIS RN Novel Gemini analogs of 1alpha,25-dihydroxyvitamin D(3) with enhanced transcriptional activity. Biochem Pharmacol. 2004 Apr 1;67(7):1327-36. DMETRIS RU https://pubmed.ncbi.nlm.nih.gov/15013848 DMETS37 DI DMETS37 DMETS37 DN HYNIC Analogue DMETS37 TI TTN53ZF DMETS37 TN Leukotriene B4 receptor 1 (LTB4R) DMETS37 MA Inhibitor DMETS37 RN Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci. J Med Chem. 2005 Oct 6;48(20):6442-53. DMETS37 RU https://pubmed.ncbi.nlm.nih.gov/16190770 DMETUHS DI DMETUHS DMETUHS DN VU0357121 DMETUHS TI TTHS256 DMETUHS TN Metabotropic glutamate receptor 5 (mGluR5) DMETUHS MA Modulator (allosteric modulator) DMETUHS RN Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology. ACS Chem Neurosci. 2010 Oct 20;1(10):702-716. DMETUHS RU https://pubmed.ncbi.nlm.nih.gov/20981342 DMETVLB DI DMETVLB DMETVLB DN Fidarestat(Stereoisomer) DMETVLB TI TTFBNVI DMETVLB TN Aldose reductase (AKR1B1) DMETVLB MA Inhibitor DMETVLB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMETVLB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMETXA8 DI DMETXA8 DMETXA8 DN AM-4768 DMETXA8 TI TT6OEDT DMETXA8 TN Cannabinoid receptor 1 (CB1) DMETXA8 MA Inhibitor DMETXA8 RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMETXA8 RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMETXA8 DI DMETXA8 DMETXA8 DN AM-4768 DMETXA8 TI TTMSFAW DMETXA8 TN Cannabinoid receptor 2 (CB2) DMETXA8 MA Inhibitor DMETXA8 RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMETXA8 RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMEU1NS DI DMEU1NS DMEU1NS DN JWH-343 DMEU1NS TI TTMSFAW DMEU1NS TN Cannabinoid receptor 2 (CB2) DMEU1NS MA Inhibitor DMEU1NS RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMEU1NS RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMEU3MN DI DMEU3MN DMEU3MN DN 1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene DMEU3MN TI TTE4KHA DMEU3MN TN Amyloid beta A4 protein (APP) DMEU3MN MA Inhibitor DMEU3MN RN Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. DMEU3MN RU https://pubmed.ncbi.nlm.nih.gov/16640346 DMEU6MH DI DMEU6MH DMEU6MH DN ADS-102550 DMEU6MH TI TT6R7JZ DMEU6MH TN Histone deacetylase 1 (HDAC1) DMEU6MH MA Inhibitor DMEU6MH RN Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. DMEU6MH RU https://pubmed.ncbi.nlm.nih.gov/17107790 DMEUBGY DI DMEUBGY DMEUBGY DN (3R)-9-amino-3-methyl-1,2,3,4-tetrahydroacridine DMEUBGY TI TT1RS9F DMEUBGY TN Acetylcholinesterase (AChE) DMEUBGY MA Inhibitor DMEUBGY RN Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones. Eur J Med Chem. 2010 Feb;45(2):526-35. DMEUBGY RU https://pubmed.ncbi.nlm.nih.gov/19954865 DMEUCI2 DI DMEUCI2 DMEUCI2 DN ISIS 6431 DMEUCI2 TI TTONI0R DMEUCI2 TN PKC-eta messenger RNA (PRKCH mRNA) DMEUCI2 RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMEUCI2 RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMEUHDL DI DMEUHDL DMEUHDL DN 1-(4-bromophenyl)-3-hydroxyurea DMEUHDL TI TTULVH8 DMEUHDL TN Tyrosinase (TYR) DMEUHDL MA Inhibitor DMEUHDL RN Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10. DMEUHDL RU https://pubmed.ncbi.nlm.nih.gov/18501598 DMEUI8C DI DMEUI8C DMEUI8C DN N-mesityl-6-methyl-3-tosylpyridin-2-amine DMEUI8C TI TT7EFHR DMEUI8C TN Corticotropin-releasing factor receptor 1 (CRHR1) DMEUI8C MA Inhibitor DMEUI8C RN Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):934-7. DMEUI8C RU https://pubmed.ncbi.nlm.nih.gov/16297619 DMEULBF DI DMEULBF DMEULBF DN 1-(But-2-enylidene)thiosemicarbazide DMEULBF TI TTULVH8 DMEULBF TN Tyrosinase (TYR) DMEULBF MA Inhibitor DMEULBF RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMEULBF RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMEUPVF DI DMEUPVF DMEUPVF DN Ocophyllals b DMEUPVF TI TTVKILB DMEUPVF TN Prostaglandin G/H synthase 2 (COX-2) DMEUPVF MA Inhibitor DMEUPVF RN COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5. DMEUPVF RU https://pubmed.ncbi.nlm.nih.gov/19880317 DMEUQFG DI DMEUQFG DMEUQFG DN PMID21939274C1 DMEUQFG TI TT7QNVC DMEUQFG TN Glucose-dependent insulinotropic receptor (GPR119) DMEUQFG MA Agonist DMEUQFG RN Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma. Chem Res Toxicol. 2011 Dec 19;24(12):2207-16. DMEUQFG RU https://pubmed.ncbi.nlm.nih.gov/21939274 DMEUT0W DI DMEUT0W DMEUT0W DN PF-06447475 DMEUT0W TI TTK0FEA DMEUT0W TN Leucine-rich repeat kinase 2 (LRRK2) DMEUT0W MA Inhibitor DMEUT0W RN Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32. DMEUT0W RU https://pubmed.ncbi.nlm.nih.gov/25353650 DMEUTXG DI DMEUTXG DMEUTXG DN SC-54750 DMEUTXG TI TT07C3Y DMEUTXG TN 5-HT 4 receptor (HTR4) DMEUTXG MA Modulator DMEUTXG RN Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12. DMEUTXG RU https://www.ncbi.nlm.nih.gov/pubmed/15482914 DMEUTXG DI DMEUTXG DMEUTXG DN SC-54750 DMEUTXG TI TTNXLKE DMEUTXG TN 5-HT 3 receptor (5HT3R) DMEUTXG MA Modulator DMEUTXG RN Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12. DMEUTXG RU https://www.ncbi.nlm.nih.gov/pubmed/15482914 DMEUV5R DI DMEUV5R DMEUV5R DN NU-8231 DMEUV5R TI TT7SBF5 DMEUV5R TN Cellular tumor antigen p53 (TP53) DMEUV5R MA Inhibitor DMEUV5R RN Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21. DMEUV5R RU https://pubmed.ncbi.nlm.nih.gov/17034127 DMEUV5R DI DMEUV5R DMEUV5R DN NU-8231 DMEUV5R TI TT9TE0O DMEUV5R TN Mdm2 messenger RNA (MDM2 mRNA) DMEUV5R MA Inhibitor DMEUV5R RN Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J Med Chem. 2006 Oct 19;49(21):6209-21. DMEUV5R RU https://pubmed.ncbi.nlm.nih.gov/17034127 DMEUVIP DI DMEUVIP DMEUVIP DN DwFwLL-NH2 DMEUVIP TI TTWDC17 DMEUVIP TN Growth hormone secretagogue receptor 1 (GHSR) DMEUVIP MA Inhibitor DMEUVIP RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DMEUVIP RU https://pubmed.ncbi.nlm.nih.gov/17371869 DMEUWB8 DI DMEUWB8 DMEUWB8 DN MDA-19 DMEUWB8 TI TTMSFAW DMEUWB8 TN Cannabinoid receptor 2 (CB2) DMEUWB8 MA Agonist DMEUWB8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DMEUWB8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DMEUXOQ DI DMEUXOQ DMEUXOQ DN N-(3,3-Dimethyl-butyl)-4-indol-1-yl-benzamide DMEUXOQ TI TT846HF DMEUXOQ TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMEUXOQ MA Inhibitor DMEUXOQ RN Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7. DMEUXOQ RU https://pubmed.ncbi.nlm.nih.gov/11689063 DMEV0GO DI DMEV0GO DMEV0GO DN 5-fluoro-6-[(2-aminoimidazol-1-yl)methyl]uracil DMEV0GO TI TTO0IB8 DMEV0GO TN Thymidine phosphorylase (TYMP) DMEV0GO MA Inhibitor DMEV0GO RN The role of phosphate in the action of thymidine phosphorylase inhibitors: Implications for the catalytic mechanism. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1648-51. DMEV0GO RU https://pubmed.ncbi.nlm.nih.gov/20138520 DMEV2AL DI DMEV2AL DMEV2AL DN KAZINOL S DMEV2AL TI TTULVH8 DMEV2AL TN Tyrosinase (TYR) DMEV2AL MA Inhibitor DMEV2AL RN Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41. DMEV2AL RU https://pubmed.ncbi.nlm.nih.gov/19046886 DMEV6Q2 DI DMEV6Q2 DMEV6Q2 DN 3-(1H-indol-3-yl)-N-methyl-3-phenylpropan-1-amine DMEV6Q2 TI TTQ6VDM DMEV6Q2 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMEV6Q2 MA Inhibitor DMEV6Q2 RN Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6. DMEV6Q2 RU https://pubmed.ncbi.nlm.nih.gov/18954985 DMEV7FY DI DMEV7FY DMEV7FY DN TINGENIN B DMEV7FY TI TTFBNVI DMEV7FY TN Aldose reductase (AKR1B1) DMEV7FY MA Inhibitor DMEV7FY RN Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6. DMEV7FY RU https://pubmed.ncbi.nlm.nih.gov/14510595 DMEV8G2 DI DMEV8G2 DMEV8G2 DN 1,3-Diallyl-3,7-dihydro-purine-2,6-dione DMEV8G2 TI TTNE7KG DMEV8G2 TN Adenosine A2b receptor (ADORA2B) DMEV8G2 MA Inhibitor DMEV8G2 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMEV8G2 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMEV8G2 DI DMEV8G2 DMEV8G2 DN 1,3-Diallyl-3,7-dihydro-purine-2,6-dione DMEV8G2 TI TTK25J1 DMEV8G2 TN Adenosine A1 receptor (ADORA1) DMEV8G2 MA Inhibitor DMEV8G2 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMEV8G2 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMEV8G2 DI DMEV8G2 DMEV8G2 DN 1,3-Diallyl-3,7-dihydro-purine-2,6-dione DMEV8G2 TI TTM2AOE DMEV8G2 TN Adenosine A2a receptor (ADORA2A) DMEV8G2 MA Inhibitor DMEV8G2 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMEV8G2 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMEV8WS DI DMEV8WS DMEV8WS DN 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole DMEV8WS TI TTVKILB DMEV8WS TN Prostaglandin G/H synthase 2 (COX-2) DMEV8WS MA Inhibitor DMEV8WS RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMEV8WS RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMEV8WS DI DMEV8WS DMEV8WS DN 5-(4-Methoxyphenyl)-4-p-tolyl-1,2-selenazole DMEV8WS TI TT8NGED DMEV8WS TN Prostaglandin G/H synthase 1 (COX-1) DMEV8WS MA Inhibitor DMEV8WS RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMEV8WS RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMEVAIF DI DMEVAIF DMEVAIF DN VTX-744 DMEVAIF TI TT8CWFK DMEVAIF TN Toll-like receptor 8 (TLR8) DMEVAIF MA Modulator DMEVAIF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1758). DMEVAIF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1758 DMEVFJW DI DMEVFJW DMEVFJW DN 2-methyl-9H-indeno[2,1-d]pyrimidin-9-one DMEVFJW TI TTGP7BY DMEVFJW TN Monoamine oxidase type B (MAO-B) DMEVFJW MA Inhibitor DMEVFJW RN Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71. DMEVFJW RU https://pubmed.ncbi.nlm.nih.gov/17910428 DMEVIBT DI DMEVIBT DMEVIBT DN 2,7-Bis(phenylacetamido)anthraquinone DMEVIBT TI TTQY2EJ DMEVIBT TN TERT messenger RNA (TERT mRNA) DMEVIBT MA Inhibitor DMEVIBT RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMEVIBT RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMEVK5F DI DMEVK5F DMEVK5F DN 4,7-dichloro-1H-indole-2,3-dione DMEVK5F TI TTMF541 DMEVK5F TN Liver carboxylesterase (CES1) DMEVK5F MA Inhibitor DMEVK5F RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMEVK5F RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMEVM0J DI DMEVM0J DMEVM0J DN CNICIN DMEVM0J TI TTICX3S DMEVM0J TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMEVM0J MA Inhibitor DMEVM0J RN Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5605-9. DMEVM0J RU https://pubmed.ncbi.nlm.nih.gov/16945528 DMEVM6G DI DMEVM6G DMEVM6G DN (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide DMEVM6G TI TTGP7BY DMEVM6G TN Monoamine oxidase type B (MAO-B) DMEVM6G MA Inhibitor DMEVM6G RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMEVM6G RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMEVNZI DI DMEVNZI DMEVNZI DN AMG-7160 DMEVNZI TI TTELV3W DMEVNZI TN Transformation-sensitive protein p120 (TRPA1) DMEVNZI MA Inhibitor DMEVNZI RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DMEVNZI RU https://pubmed.ncbi.nlm.nih.gov/20356305 DMEVO6M DI DMEVO6M DMEVO6M DN 1-Benzyl-2-methyl-1H-imidazole DMEVO6M TI TTZUFI5 DMEVO6M TN Nitric-oxide synthase brain (NOS1) DMEVO6M MA Inhibitor DMEVO6M RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DMEVO6M RU https://pubmed.ncbi.nlm.nih.gov/20933416 DMEVOD2 DI DMEVOD2 DMEVOD2 DN Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF DMEVOD2 TI TTAE1BR DMEVOD2 TN Somatostatin receptor type 4 (SSTR4) DMEVOD2 MA Inhibitor DMEVOD2 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMEVOD2 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMEVOD2 DI DMEVOD2 DMEVOD2 DN Des-AA1,2,4,5,10,12,13-[D-Trp8]SRIF DMEVOD2 TI TTJX3UE DMEVOD2 TN Somatostatin receptor type 3 (SSTR3) DMEVOD2 MA Inhibitor DMEVOD2 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMEVOD2 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMEVRH4 DI DMEVRH4 DMEVRH4 DN 5BrUTP DMEVRH4 TI TTOZHQC DMEVRH4 TN P2Y purinoceptor 2 (P2RY2) DMEVRH4 MA Agonist DMEVRH4 RN Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27. DMEVRH4 RU https://pubmed.ncbi.nlm.nih.gov/8564228 DMEVRH4 DI DMEVRH4 DMEVRH4 DN 5BrUTP DMEVRH4 TI TTNVSKA DMEVRH4 TN P2Y purinoceptor 6 (P2RY6) DMEVRH4 MA Agonist DMEVRH4 RN Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8. DMEVRH4 RU https://pubmed.ncbi.nlm.nih.gov/8670200 DMEVSFY DI DMEVSFY DMEVSFY DN 1-benzyl-1H-pyrrolo[3,2-b]pyridine DMEVSFY TI TTNDSF4 DMEVSFY TN Proto-oncogene c-Met (MET) DMEVSFY MA Inhibitor DMEVSFY RN Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4. DMEVSFY RU https://pubmed.ncbi.nlm.nih.gov/19369077 DMEVT4I DI DMEVT4I DMEVT4I DN ART-144 DMEVT4I TI TTR9XHZ DMEVT4I TN Transforming growth factor beta 1 (TGFB1) DMEVT4I MA Modulator DMEVT4I RN Pharmaceutical products of TORREYA partners. December 2011. DMEVT4I RU http://www.availablepharmaproducts.com/app_dec11.pdf DMEVT7S DI DMEVT7S DMEVT7S DN Threo-N-ethylritalinol hydrochloride DMEVT7S TI TTVBI8W DMEVT7S TN Dopamine transporter (DAT) DMEVT7S MA Inhibitor DMEVT7S RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DMEVT7S RU https://pubmed.ncbi.nlm.nih.gov/17489581 DMEW1CP DI DMEW1CP DMEW1CP DN 4'-(1-(pyridin-4-yl)propyl)biphenyl-3-ol DMEW1CP TI TTRA5BZ DMEW1CP TN Steroid 17-alpha-monooxygenase (S17AH) DMEW1CP MA Inhibitor DMEW1CP RN Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors. J Med Chem. 2010 Jul 8;53(13):5049-53. DMEW1CP RU https://pubmed.ncbi.nlm.nih.gov/20550118 DMEW37R DI DMEW37R DMEW37R DN Asp-D-Glu-Leu-Glu-Cha-Cys DMEW37R TI TTWXB3E DMEW37R TN Hepatitis C virus NS3 helicase (HCV NS3) DMEW37R MA Inhibitor DMEW37R RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMEW37R RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMEW3L0 DI DMEW3L0 DMEW3L0 DN N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE DMEW3L0 TI TTTU902 DMEW3L0 TN Checkpoint kinase-1 (CHK1) DMEW3L0 MA Inhibitor DMEW3L0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMEW3L0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMEW49T DI DMEW49T DMEW49T DN Bis(2,4-dinitrophenyl)sulfane DMEW49T TI TTR7UJ3 DMEW49T TN Cytoplasmic thioredoxin reductase (TXNRD1) DMEW49T MA Inhibitor DMEW49T RN Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92. DMEW49T RU https://pubmed.ncbi.nlm.nih.gov/16458512 DMEW7AY DI DMEW7AY DMEW7AY DN Cyclohexylmethylcarbamic Acid Biphenyl-3-yl Ester DMEW7AY TI TTDP1UC DMEW7AY TN Fatty acid amide hydrolase (FAAH) DMEW7AY MA Inhibitor DMEW7AY RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMEW7AY RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMEWAVM DI DMEWAVM DMEWAVM DN 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL DMEWAVM TI TTZAYWL DMEWAVM TN Estrogen receptor (ESR) DMEWAVM MA Inhibitor DMEWAVM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMEWAVM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMEWP9L DI DMEWP9L DMEWP9L DN N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide DMEWP9L TI TT3WG5C DMEWP9L TN Monoamine oxidase type A (MAO-A) DMEWP9L MA Inhibitor DMEWP9L RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMEWP9L RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMEWP9L DI DMEWP9L DMEWP9L DN N2-{4-[(3-fluorobenzyl)oxy]benzyl}glycinamide DMEWP9L TI TTGP7BY DMEWP9L TN Monoamine oxidase type B (MAO-B) DMEWP9L MA Inhibitor DMEWP9L RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMEWP9L RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMEWQCN DI DMEWQCN DMEWQCN DN N-(3-bromophenyl)-6-chloroquinazolin-4-amine DMEWQCN TI TTHS256 DMEWQCN TN Metabotropic glutamate receptor 5 (mGluR5) DMEWQCN MA Inhibitor DMEWQCN RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMEWQCN RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMEWQCN DI DMEWQCN DMEWQCN DN N-(3-bromophenyl)-6-chloroquinazolin-4-amine DMEWQCN TI TTVBPDM DMEWQCN TN Metabotropic glutamate receptor 1 (mGluR1) DMEWQCN MA Inhibitor DMEWQCN RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMEWQCN RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMEWQHP DI DMEWQHP DMEWQHP DN AZ-628 DMEWQHP TI TTWCGQT DMEWQHP TN Serine/threonine-protein kinase B-raf (BRAF) DMEWQHP MA Inhibitor DMEWQHP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8475). DMEWQHP RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8475 DMEWU6Z DI DMEWU6Z DMEWU6Z DN (2S)-aminobutyryl-L-proline-(2S)-methylbutylamide DMEWU6Z TI TTQ7R2V DMEWU6Z TN Tripeptidyl-peptidase II (TPP2) DMEWU6Z MA Inhibitor DMEWU6Z RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMEWU6Z RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMEWVG8 DI DMEWVG8 DMEWVG8 DN PMID24900526C1 DMEWVG8 TI TTXZ0KQ DMEWVG8 TN Matrix metalloproteinase-12 (MMP-12) DMEWVG8 MA Inhibitor DMEWVG8 RN Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. ACS Med Chem Lett. 2012 Jul 14;3(8):653-7. DMEWVG8 RU https://pubmed.ncbi.nlm.nih.gov/24900526 DMEWXR2 DI DMEWXR2 DMEWXR2 DN ISIS 101960 DMEWXR2 TI TTON5JB DMEWXR2 TN MADH6 messenger RNA (MADH6 mRNA) DMEWXR2 RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DMEWXR2 RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DMEWZ80 DI DMEWZ80 DMEWZ80 DN ICI-199441 DMEWZ80 TI TTW5UDX DMEWZ80 TN Urotensin II receptor (UTS2R) DMEWZ80 MA Inhibitor DMEWZ80 RN Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3716-9. DMEWZ80 RU https://pubmed.ncbi.nlm.nih.gov/18524591 DMEWZ80 DI DMEWZ80 DMEWZ80 DN ICI-199441 DMEWZ80 TI TT27RFC DMEWZ80 TN Opioid receptor delta (OPRD1) DMEWZ80 MA Inhibitor DMEWZ80 RN Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52. DMEWZ80 RU https://pubmed.ncbi.nlm.nih.gov/15863335 DMEWZ80 DI DMEWZ80 DMEWZ80 DN ICI-199441 DMEWZ80 TI TTQW87Y DMEWZ80 TN Opioid receptor kappa (OPRK1) DMEWZ80 MA Inhibitor DMEWZ80 RN Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse micr... J Med Chem. 1996 Apr 12;39(8):1729-35. DMEWZ80 RU https://pubmed.ncbi.nlm.nih.gov/8648612 DMEWZ80 DI DMEWZ80 DMEWZ80 DN ICI-199441 DMEWZ80 TI TTVG215 DMEWZ80 TN Debrisoquine 4-hydroxylase (CYP2D6) DMEWZ80 MA Inhibitor DMEWZ80 RN Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity. Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52. DMEWZ80 RU https://pubmed.ncbi.nlm.nih.gov/15863335 DMEWZ80 DI DMEWZ80 DMEWZ80 DN ICI-199441 DMEWZ80 TI TTKWM86 DMEWZ80 TN Opioid receptor mu (MOP) DMEWZ80 MA Inhibitor DMEWZ80 RN Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide. J Med Chem. 1994 Sep 2;37(18):2856-64. DMEWZ80 RU https://pubmed.ncbi.nlm.nih.gov/8071934 DMEX6AM DI DMEX6AM DMEX6AM DN 2-amino-2-(3-bromophenyl)acetic acid DMEX6AM TI TTFK1JQ DMEX6AM TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMEX6AM MA Inhibitor DMEX6AM RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMEX6AM RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMEX6GT DI DMEX6GT DMEX6GT DN [3H]meclinertant DMEX6GT TI TTTUMEP DMEX6GT TN Neurotensin receptor type 1 (NTSR1) DMEX6GT MA Antagonist DMEX6GT RN [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol. 1995 May;47(5):1050-6. DMEX6GT RU https://pubmed.ncbi.nlm.nih.gov/7746272 DMEX9GV DI DMEX9GV DMEX9GV DN JWH-147 DMEX9GV TI TT6OEDT DMEX9GV TN Cannabinoid receptor 1 (CB1) DMEX9GV MA Inhibitor DMEX9GV RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMEX9GV RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMEX9GV DI DMEX9GV DMEX9GV DN JWH-147 DMEX9GV TI TTMSFAW DMEX9GV TN Cannabinoid receptor 2 (CB2) DMEX9GV MA Inhibitor DMEX9GV RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMEX9GV RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMEXBUF DI DMEXBUF DMEXBUF DN 2-(naphthalen-2-ylsulfonyl)naphthalene-1,4-diol DMEXBUF TI TTRVTMX DMEXBUF TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMEXBUF MA Inhibitor DMEXBUF RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DMEXBUF RU https://pubmed.ncbi.nlm.nih.gov/18996691 DMEXLUR DI DMEXLUR DMEXLUR DN (R)-Mevalonate DMEXLUR TI TTPADOQ DMEXLUR TN HMG-CoA reductase (HMGCR) DMEXLUR MA Inhibitor DMEXLUR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMEXLUR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMEXPIJ DI DMEXPIJ DMEXPIJ DN 3,5-Diacetoxy-4'-amino-trans-stilbene DMEXPIJ TI TTSZLWK DMEXPIJ TN Aromatase (CYP19A1) DMEXPIJ MA Inhibitor DMEXPIJ RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMEXPIJ RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMEXW31 DI DMEXW31 DMEXW31 DN NSC-663284 DMEXW31 TI TTESBNC DMEXW31 TN M-phase inducer phosphatase 3 (MPIP3) DMEXW31 MA Inhibitor DMEXW31 RN Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C. Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5. DMEXW31 RU https://pubmed.ncbi.nlm.nih.gov/16216500 DMEXYSP DI DMEXYSP DMEXYSP DN 2-Phenyl-4-[1,2,4]triazol-1-yl-chroman-7-ol DMEXYSP TI TTSZLWK DMEXYSP TN Aromatase (CYP19A1) DMEXYSP MA Inhibitor DMEXYSP RN Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8. DMEXYSP RU https://pubmed.ncbi.nlm.nih.gov/15380230 DMEXZQ5 DI DMEXZQ5 DMEXZQ5 DN 2-Phenyl-3-piperidin-4-yl-1H-indole DMEXZQ5 TI TTQ6VDM DMEXZQ5 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMEXZQ5 MA Inhibitor DMEXZQ5 RN 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14. DMEXZQ5 RU https://pubmed.ncbi.nlm.nih.gov/11334570 DMEXZQ5 DI DMEXZQ5 DMEXZQ5 DN 2-Phenyl-3-piperidin-4-yl-1H-indole DMEXZQ5 TI TTJQOD7 DMEXZQ5 TN 5-HT 2A receptor (HTR2A) DMEXZQ5 MA Inhibitor DMEXZQ5 RN 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3. DMEXZQ5 RU https://pubmed.ncbi.nlm.nih.gov/11133072 DMEY7T4 DI DMEY7T4 DMEY7T4 DN ONO-AE3-208 DMEY7T4 TI TT79WV3 DMEY7T4 TN Prostaglandin E2 receptor EP4 (PTGER4) DMEY7T4 MA Antagonist DMEY7T4 RN The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93. DMEY7T4 RU https://pubmed.ncbi.nlm.nih.gov/11927615 DMEY7T4 DI DMEY7T4 DMEY7T4 DN ONO-AE3-208 DMEY7T4 TI TTPNGDE DMEY7T4 TN Prostaglandin E2 receptor EP3 (PTGER3) DMEY7T4 MA Antagonist DMEY7T4 RN The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93. DMEY7T4 RU https://pubmed.ncbi.nlm.nih.gov/11927615 DMEY9T2 DI DMEY9T2 DMEY9T2 DN 2-Thioethenamine DMEY9T2 TI TT3DQUT DMEY9T2 TN Bacterial Lantibiotic mersacidin (Bact glmM) DMEY9T2 MA Inhibitor DMEY9T2 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMEY9T2 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMEYHWN DI DMEYHWN DMEYHWN DN PMD38 DMEYHWN TI TTXDKTO DMEYHWN TN Long transient receptor potential channel 8 (TRPM8) DMEYHWN MA Activator DMEYHWN RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMEYHWN RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMEYKXL DI DMEYKXL DMEYKXL DN NSC-87877 DMEYKXL TI TT369M5 DMEYKXL TN Protein-tyrosine phosphatase SHP-1 (PTPN6) DMEYKXL MA Inhibitor DMEYKXL RN Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs. US8987474. DMEYKXL RU http://www.freepatentsonline.com/US8987474.html DMEYKXL DI DMEYKXL DMEYKXL DN NSC-87877 DMEYKXL TI TT7WUAV DMEYKXL TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMEYKXL MA Inhibitor DMEYKXL RN Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J Med Chem. 2008 Aug 28;51(16):4948-56. DMEYKXL RU https://pubmed.ncbi.nlm.nih.gov/18680359 DMEYNGP DI DMEYNGP DMEYNGP DN frescolat MGA DMEYNGP TI TTXDKTO DMEYNGP TN Long transient receptor potential channel 8 (TRPM8) DMEYNGP MA Activator DMEYNGP RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMEYNGP RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMEYOF7 DI DMEYOF7 DMEYOF7 DN 6-Phenyl-naphthalen-2-ol DMEYOF7 TI TTZAYWL DMEYOF7 TN Estrogen receptor (ESR) DMEYOF7 MA Inhibitor DMEYOF7 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMEYOF7 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMEYOF7 DI DMEYOF7 DMEYOF7 DN 6-Phenyl-naphthalen-2-ol DMEYOF7 TI TTOM3J0 DMEYOF7 TN Estrogen receptor beta (ESR2) DMEYOF7 MA Inhibitor DMEYOF7 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMEYOF7 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMEYQF9 DI DMEYQF9 DMEYQF9 DN Abyssinoflavanone VI DMEYQF9 TI TTELIN2 DMEYQF9 TN PTPN1 messenger RNA (PTPN1 mRNA) DMEYQF9 MA Inhibitor DMEYQF9 RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DMEYQF9 RU https://pubmed.ncbi.nlm.nih.gov/17489632 DMEYUH0 DI DMEYUH0 DMEYUH0 DN 4-(7-chloro-1-propyl-1H-indazol-3-yl)phenol DMEYUH0 TI TTZAYWL DMEYUH0 TN Estrogen receptor (ESR) DMEYUH0 MA Inhibitor DMEYUH0 RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DMEYUH0 RU https://pubmed.ncbi.nlm.nih.gov/15588074 DMEYV1B DI DMEYV1B DMEYV1B DN 4-(3-Pent-1-ynyl-benzyl)-1H-imidazole DMEYV1B TI TTVG215 DMEYV1B TN Debrisoquine 4-hydroxylase (CYP2D6) DMEYV1B MA Inhibitor DMEYV1B RN 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists. J Med Chem. 2008 May 22;51(10):2944-53. DMEYV1B RU https://pubmed.ncbi.nlm.nih.gov/18433114 DMEZ7O2 DI DMEZ7O2 DMEZ7O2 DN 2-(Aminomethyl)-5-phenethyltetrahydrofuran DMEZ7O2 TI TTAWNKZ DMEZ7O2 TN Norepinephrine transporter (NET) DMEZ7O2 MA Inhibitor DMEZ7O2 RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMEZ7O2 RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMEZ7O2 DI DMEZ7O2 DMEZ7O2 DN 2-(Aminomethyl)-5-phenethyltetrahydrofuran DMEZ7O2 TI TT3ROYC DMEZ7O2 TN Serotonin transporter (SERT) DMEZ7O2 MA Inhibitor DMEZ7O2 RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMEZ7O2 RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMEZ7O2 DI DMEZ7O2 DMEZ7O2 DN 2-(Aminomethyl)-5-phenethyltetrahydrofuran DMEZ7O2 TI TTVBI8W DMEZ7O2 TN Dopamine transporter (DAT) DMEZ7O2 MA Inhibitor DMEZ7O2 RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMEZ7O2 RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMEZ92A DI DMEZ92A DMEZ92A DN Hygromycin B DMEZ92A TI TTPEFM3 DMEZ92A TN Bacterial Ribosomal ATPase RbbA (Bact rbbA) DMEZ92A MA Inhibitor DMEZ92A RN A ribosomal ATPase is a target for hygromycin B inhibition on Escherichia coli ribosomes. Antimicrob Agents Chemother. 2001 Oct;45(10):2813-9. DMEZ92A RU https://pubmed.ncbi.nlm.nih.gov/11557474 DMEZ92A DI DMEZ92A DMEZ92A DN Hygromycin B DMEZ92A TI TT38DW5 DMEZ92A TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMEZ92A MA Inhibitor DMEZ92A RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMEZ92A RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMEZA0T DI DMEZA0T DMEZA0T DN PF-3409409 DMEZA0T TI TTAWNKZ DMEZA0T TN Norepinephrine transporter (NET) DMEZA0T MA Inhibitor DMEZA0T RN Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. DMEZA0T RU https://pubmed.ncbi.nlm.nih.gov/19616432 DMEZA0T DI DMEZA0T DMEZA0T DN PF-3409409 DMEZA0T TI TTH18TF DMEZA0T TN Muscarinic acetylcholine receptor M5 (CHRM5) DMEZA0T MA Inhibitor DMEZA0T RN Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. DMEZA0T RU https://pubmed.ncbi.nlm.nih.gov/19616432 DMEZA0T DI DMEZA0T DMEZA0T DN PF-3409409 DMEZA0T TI TTVBI8W DMEZA0T TN Dopamine transporter (DAT) DMEZA0T MA Inhibitor DMEZA0T RN Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. DMEZA0T RU https://pubmed.ncbi.nlm.nih.gov/19616432 DMEZA0T DI DMEZA0T DMEZA0T DN PF-3409409 DMEZA0T TI TT3ROYC DMEZA0T TN Serotonin transporter (SERT) DMEZA0T MA Inhibitor DMEZA0T RN Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. DMEZA0T RU https://pubmed.ncbi.nlm.nih.gov/19616432 DMEZA0T DI DMEZA0T DMEZA0T DN PF-3409409 DMEZA0T TI TTQ3JTF DMEZA0T TN Muscarinic acetylcholine receptor M4 (CHRM4) DMEZA0T MA Inhibitor DMEZA0T RN Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. DMEZA0T RU https://pubmed.ncbi.nlm.nih.gov/19616432 DMEZAND DI DMEZAND DMEZAND DN VVP-100X DMEZAND TI TTCBFJO DMEZAND TN Insulin receptor (INSR) DMEZAND MA Inhibitor DMEZAND RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMEZAND RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMEZAPR DI DMEZAPR DMEZAPR DN SODIUM ZINC DIHYDROLIPOYLHISTIDINATE DMEZAPR TI TTULVH8 DMEZAPR TN Tyrosinase (TYR) DMEZAPR MA Inhibitor DMEZAPR RN Modulating effects of a novel skin-lightening agent, alpha-lipoic acid derivative, on melanin production by the formation of DOPA conjugate products. Bioorg Med Chem. 2007 Mar 1;15(5):1967-75. DMEZAPR RU https://pubmed.ncbi.nlm.nih.gov/17218103 DMEZFKS DI DMEZFKS DMEZFKS DN 2-isoursolic acid DMEZFKS TI TTZHY6R DMEZFKS TN Glycogen phosphorylase muscle form (GP) DMEZFKS MA Inhibitor DMEZFKS RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMEZFKS RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMEZKX0 DI DMEZKX0 DMEZKX0 DN [D-Dab(CO-NH-OCH3)3]degarelix DMEZKX0 TI TT8R70G DMEZKX0 TN Gonadotropin-releasing hormone receptor (GNRHR) DMEZKX0 MA Inhibitor DMEZKX0 RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DMEZKX0 RU https://pubmed.ncbi.nlm.nih.gov/16759096 DMEZNXS DI DMEZNXS DMEZNXS DN (2-hydroxyphenyl)(4-hydroxyphenyl)methanone DMEZNXS TI TTGX0HR DMEZNXS TN Bacterial DNA ligase (Bact ligA) DMEZNXS MA Inhibitor DMEZNXS RN Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62. DMEZNXS RU https://pubmed.ncbi.nlm.nih.gov/18630893 DMEZO4M DI DMEZO4M DMEZO4M DN G6976 DMEZO4M TI TTSLUMT DMEZO4M TN Protein kinase D (PRKD1) DMEZO4M MA Inhibitor DMEZO4M RN Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92. DMEZO4M RU https://pubmed.ncbi.nlm.nih.gov/20580776 DMEZO4M DI DMEZO4M DMEZO4M DN G6976 DMEZO4M TI TTSXVID DMEZO4M TN Nuclear factor NF-kappa-B (NFKB) DMEZO4M MA Inhibitor DMEZO4M RN Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8542-7. DMEZO4M RU https://pubmed.ncbi.nlm.nih.gov/10900013 DMEZO4M DI DMEZO4M DMEZO4M DN G6976 DMEZO4M TI TTYVX59 DMEZO4M TN Protein kinase C (PRKC) DMEZO4M MA Inhibitor DMEZO4M RN The protein kinase C inhibitor G 6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003 Jan 1;63(1):31-5. DMEZO4M RU https://pubmed.ncbi.nlm.nih.gov/12517773 DMEZO4M DI DMEZO4M DMEZO4M DN G6976 DMEZO4M TI TTUWGRA DMEZO4M TN Protein kinase C zeta (PRKCZ) DMEZO4M MA Inhibitor DMEZO4M RN Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. DMEZO4M RU https://pubmed.ncbi.nlm.nih.gov/10982151 DMEZOT9 DI DMEZOT9 DMEZOT9 DN Kuwanon R DMEZOT9 TI TTELIN2 DMEZOT9 TN PTPN1 messenger RNA (PTPN1 mRNA) DMEZOT9 MA Inhibitor DMEZOT9 RN Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61. DMEZOT9 RU https://pubmed.ncbi.nlm.nih.gov/19846295 DMEZPC8 DI DMEZPC8 DMEZPC8 DN 1-Benzothiazol-2-yl-3-phenethyl-thiourea DMEZPC8 TI TT84ETX DMEZPC8 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMEZPC8 MA Inhibitor DMEZPC8 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMEZPC8 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMEZSHI DI DMEZSHI DMEZSHI DN PMID23374866C31 DMEZSHI TI TT4LIAC DMEZSHI TN Serine/threonine-protein kinase NIK (MAP3K14) DMEZSHI MA Inhibitor DMEZSHI RN Inhibiting NF- B-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1238-44. DMEZSHI RU https://pubmed.ncbi.nlm.nih.gov/23374866 DMEZVGK DI DMEZVGK DMEZVGK DN DAU-5884 DMEZVGK TI TTZ9SOR DMEZVGK TN Muscarinic acetylcholine receptor M1 (CHRM1) DMEZVGK MA Modulator DMEZVGK RN Doi: 10.1038/bjp.2008.208 DMEZVGK RU http://onlinelibrary.wiley.com/doi/10.1038/bjp.2008.208/pdf DMEZVGK DI DMEZVGK DMEZVGK DN DAU-5884 DMEZVGK TI TTQ13Z5 DMEZVGK TN Muscarinic acetylcholine receptor M3 (CHRM3) DMEZVGK MA Modulator DMEZVGK RN Doi: 10.1038/bjp.2008.208 DMEZVGK RU http://onlinelibrary.wiley.com/doi/10.1038/bjp.2008.208/pdf DMF04AG DI DMF04AG DMF04AG DN MR-2034 DMF04AG TI TTQW87Y DMF04AG TN Opioid receptor kappa (OPRK1) DMF04AG MA Inhibitor DMF04AG RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMF04AG RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMF04AG DI DMF04AG DMF04AG DN MR-2034 DMF04AG TI TTKWM86 DMF04AG TN Opioid receptor mu (MOP) DMF04AG MA Inhibitor DMF04AG RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMF04AG RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMF04YH DI DMF04YH DMF04YH DN 3-Benzyl-5-methoxy-7-methylchromen-2-one DMF04YH TI TT6OEDT DMF04YH TN Cannabinoid receptor 1 (CB1) DMF04YH MA Inhibitor DMF04YH RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMF04YH RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMF079L DI DMF079L DMF079L DN 4-methoxy-N'-(2-phenylacetyl)benzohydrazide DMF079L TI TTGY7WI DMF079L TN Urokinase-type plasminogen activator (PLAU) DMF079L MA Inhibitor DMF079L RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMF079L RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMF079L DI DMF079L DMF079L DN 4-methoxy-N'-(2-phenylacetyl)benzohydrazide DMF079L TI TTPLTSQ DMF079L TN Neutrophil elastase (NE) DMF079L MA Inhibitor DMF079L RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMF079L RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMF08UT DI DMF08UT DMF08UT DN 6,7-Dihydroxy-2-phenyl-chromen-4-one DMF08UT TI TTFBNVI DMF08UT TN Aldose reductase (AKR1B1) DMF08UT MA Inhibitor DMF08UT RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DMF08UT RU https://pubmed.ncbi.nlm.nih.gov/10354396 DMF091Y DI DMF091Y DMF091Y DN C[RGD-(R)-alpha-TfmfV] DMF091Y TI TTJA1ZO DMF091Y TN ITGB3 messenger RNA (ITGB3 mRNA) DMF091Y MA Inhibitor DMF091Y RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMF091Y RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMF091Y DI DMF091Y DMF091Y DN C[RGD-(R)-alpha-TfmfV] DMF091Y TI TTT1R2L DMF091Y TN Integrin alpha-V (ITGAV) DMF091Y MA Inhibitor DMF091Y RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMF091Y RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMF097H DI DMF097H DMF097H DN 3-cyano-5-fluoro-N-m-tolylbenzamide DMF097H TI TTHS256 DMF097H TN Metabotropic glutamate receptor 5 (mGluR5) DMF097H MA Inhibitor DMF097H RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMF097H RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMF0CRA DI DMF0CRA DMF0CRA DN zinc pyrithione DMF0CRA TI TTWVL5Q DMF0CRA TN Voltage-gated potassium channel Kv7.5 (KCNQ5) DMF0CRA MA Activator DMF0CRA RN Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96. DMF0CRA RU https://pubmed.ncbi.nlm.nih.gov/17435769 DMF0CRA DI DMF0CRA DMF0CRA DN zinc pyrithione DMF0CRA TI TT8HGRW DMF0CRA TN Voltage-gated potassium channel Kv7.4 (KCNQ4) DMF0CRA MA Activator DMF0CRA RN Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96. DMF0CRA RU https://pubmed.ncbi.nlm.nih.gov/17435769 DMF0CRA DI DMF0CRA DMF0CRA DN zinc pyrithione DMF0CRA TI TT846HF DMF0CRA TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMF0CRA MA Activator DMF0CRA RN Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96. DMF0CRA RU https://pubmed.ncbi.nlm.nih.gov/17435769 DMF0CRA DI DMF0CRA DMF0CRA DN zinc pyrithione DMF0CRA TI TTPXI3S DMF0CRA TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DMF0CRA MA Activator DMF0CRA RN Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. Nat Chem Biol. 2007 May;3(5):287-96. DMF0CRA RU https://pubmed.ncbi.nlm.nih.gov/17435769 DMF0GXD DI DMF0GXD DMF0GXD DN 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine DMF0GXD TI TTEX248 DMF0GXD TN Dopamine D2 receptor (D2R) DMF0GXD MA Inhibitor DMF0GXD RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMF0GXD RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMF0GXD DI DMF0GXD DMF0GXD DN 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine DMF0GXD TI TTE0A2F DMF0GXD TN Dopamine D4 receptor (D4R) DMF0GXD MA Inhibitor DMF0GXD RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMF0GXD RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMF0GXD DI DMF0GXD DMF0GXD DN 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine DMF0GXD TI TTZFYLI DMF0GXD TN Dopamine D1 receptor (D1R) DMF0GXD MA Inhibitor DMF0GXD RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMF0GXD RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMF0GXD DI DMF0GXD DMF0GXD DN 1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine DMF0GXD TI TT4C8EA DMF0GXD TN Dopamine D3 receptor (D3R) DMF0GXD MA Inhibitor DMF0GXD RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMF0GXD RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMF0IJ2 DI DMF0IJ2 DMF0IJ2 DN 5-methyl-3-phenylethynyl[1,2,4]triazine DMF0IJ2 TI TTHS256 DMF0IJ2 TN Metabotropic glutamate receptor 5 (mGluR5) DMF0IJ2 MA Inhibitor DMF0IJ2 RN Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91. DMF0IJ2 RU https://pubmed.ncbi.nlm.nih.gov/17569516 DMF0QM2 DI DMF0QM2 DMF0QM2 DN 3-[(2-methyl-4-thiazolyl)ethynyl]phenol DMF0QM2 TI TTHS256 DMF0QM2 TN Metabotropic glutamate receptor 5 (mGluR5) DMF0QM2 MA Inhibitor DMF0QM2 RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMF0QM2 RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMF0RXK DI DMF0RXK DMF0RXK DN 1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole DMF0RXK TI TT6OEDT DMF0RXK TN Cannabinoid receptor 1 (CB1) DMF0RXK MA Inhibitor DMF0RXK RN Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazoles. Bioorg Med Chem Lett. 2009 Feb 1;19(3):891-3. DMF0RXK RU https://pubmed.ncbi.nlm.nih.gov/19097888 DMF0SPB DI DMF0SPB DMF0SPB DN AG 1024 DMF0SPB TI TTQFBMY DMF0SPB TN IGF1R messenger RNA (IGF1R mRNA) DMF0SPB MA Inhibitor DMF0SPB RN Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology. 1997 Apr;138(4):1427-33. DMF0SPB RU https://pubmed.ncbi.nlm.nih.gov/9075698 DMF0VAG DI DMF0VAG DMF0VAG DN indole-3-propionic acid DMF0VAG TI TTUYIZW DMF0VAG TN Solute carrier family 36 member 1 (SLC36A1) DMF0VAG MA Inhibitor DMF0VAG RN Serotonin, L-tryptophan, and tryptamine are effective inhibitors of the amino acid transport system PAT1. FASEB J. 2005 Sep;19(11):1468-73. DMF0VAG RU https://pubmed.ncbi.nlm.nih.gov/16126914 DMF0VLX DI DMF0VLX DMF0VLX DN PMID16242323C26b DMF0VLX TI TTK3C21 DMF0VLX TN Acetoacetyl-CoA thiolase (ACAT1) DMF0VLX MA Inhibitor DMF0VLX RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMF0VLX RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMF0X2S DI DMF0X2S DMF0X2S DN SSR126768A DMF0X2S TI TT4TFGN DMF0X2S TN Vasopressin V1a receptor (V1AR) DMF0X2S MA Antagonist DMF0X2S RN SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, ... J Pharmacol Exp Ther. 2004 Apr;309(1):414-24. DMF0X2S RU https://pubmed.ncbi.nlm.nih.gov/14722330 DMF0X2S DI DMF0X2S DMF0X2S DN SSR126768A DMF0X2S TI TTSCIUP DMF0X2S TN Oxytocin receptor (OTR) DMF0X2S MA Antagonist DMF0X2S RN SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, ... J Pharmacol Exp Ther. 2004 Apr;309(1):414-24. DMF0X2S RU https://pubmed.ncbi.nlm.nih.gov/14722330 DMF0YJ3 DI DMF0YJ3 DMF0YJ3 DN (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone DMF0YJ3 TI TTQBR95 DMF0YJ3 TN Stress-activated protein kinase 2a (p38 alpha) DMF0YJ3 MA Inhibitor DMF0YJ3 RN Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highl... J Med Chem. 2006 Mar 9;49(5):1562-75. DMF0YJ3 RU https://pubmed.ncbi.nlm.nih.gov/16509574 DMF0ZXU DI DMF0ZXU DMF0ZXU DN PMID15955699C24 DMF0ZXU TI TTYXEPL DMF0ZXU TN Ribosomal protein S6 kinase alpha-5 (RSK5) DMF0ZXU MA Inhibitor DMF0ZXU RN (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors. Bioorg Med Chem Lett. 2005 Jul 15;15(14):3407-11. DMF0ZXU RU https://pubmed.ncbi.nlm.nih.gov/15955699 DMF10WT DI DMF10WT DMF10WT DN Cis-2-aminocyclohexylcarbamoylphosphonic acid DMF10WT TI TTLM12X DMF10WT TN Matrix metalloproteinase-2 (MMP-2) DMF10WT MA Inhibitor DMF10WT RN Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic mat... J Med Chem. 2008 Mar 13;51(5):1406-14. DMF10WT RU https://pubmed.ncbi.nlm.nih.gov/18257543 DMF1264 DI DMF1264 DMF1264 DN Aptiganel HCl DMF1264 TI TT9IK2Z DMF1264 TN N-methyl-D-aspartate receptor (NMDAR) DMF1264 MA Antagonist DMF1264 RN Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 2003 Jan;3(1):9-20. DMF1264 RU https://pubmed.ncbi.nlm.nih.gov/12507405 DMF1589 DI DMF1589 DMF1589 DN SULFAMATE DMF1589 TI TTZHA0O DMF1589 TN Carbonic anhydrase IV (CA-IV) DMF1589 MA Inhibitor DMF1589 RN Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73. DMF1589 RU https://pubmed.ncbi.nlm.nih.gov/15501038 DMF1589 DI DMF1589 DMF1589 DN SULFAMATE DMF1589 TI TTUNARX DMF1589 TN Carbonic anhydrase (CA) DMF1589 MA Inhibitor DMF1589 RN Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43. DMF1589 RU https://pubmed.ncbi.nlm.nih.gov/16621537 DMF1589 DI DMF1589 DMF1589 DN SULFAMATE DMF1589 TI TTHQPL7 DMF1589 TN Carbonic anhydrase I (CA-I) DMF1589 MA Inhibitor DMF1589 RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMF1589 RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMF1589 DI DMF1589 DMF1589 DN SULFAMATE DMF1589 TI TT2LVK8 DMF1589 TN Carbonic anhydrase IX (CA-IX) DMF1589 MA Inhibitor DMF1589 RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71. DMF1589 RU https://pubmed.ncbi.nlm.nih.gov/15664814 DMF1589 DI DMF1589 DMF1589 DN SULFAMATE DMF1589 TI TTANPDJ DMF1589 TN Carbonic anhydrase II (CA-II) DMF1589 MA Inhibitor DMF1589 RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMF1589 RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMF1KDX DI DMF1KDX DMF1KDX DN VER-49009 DMF1KDX TI TT78R5H DMF1KDX TN Heat shock protein 90 alpha (HSP90A) DMF1KDX MA Inhibitor DMF1KDX RN Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem. 2005 Jun 30;48(13):4212-5. DMF1KDX RU https://pubmed.ncbi.nlm.nih.gov/15974572 DMF1MJ2 DI DMF1MJ2 DMF1MJ2 DN ISIS 29256 DMF1MJ2 TI TTYMGWX DMF1MJ2 TN PDK-1 messenger RNA (PDK-1 mRNA) DMF1MJ2 RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMF1MJ2 RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMF1O0Z DI DMF1O0Z DMF1O0Z DN VUF5391 DMF1O0Z TI TT9JNIC DMF1O0Z TN Histamine H3 receptor (H3R) DMF1O0Z MA Antagonist DMF1O0Z RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMF1O0Z RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMF1P6W DI DMF1P6W DMF1P6W DN SU 6656 DMF1P6W TI TTLYXIT DMF1P6W TN Aurora kinase C (AURKC) DMF1P6W MA Inhibitor DMF1P6W RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMF1P6W RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMF1P6W DI DMF1P6W DMF1P6W DN SU 6656 DMF1P6W TI TT6PKBN DMF1P6W TN Proto-oncogene c-Src (SRC) DMF1P6W MA Inhibitor DMF1P6W RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMF1P6W RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMF1P6W DI DMF1P6W DMF1P6W DN SU 6656 DMF1P6W TI TT860QF DMF1P6W TN LCK tyrosine protein kinase (LCK) DMF1P6W MA Inhibitor DMF1P6W RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMF1P6W RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMF1P6W DI DMF1P6W DMF1P6W DN SU 6656 DMF1P6W TI TTLAFZV DMF1P6W TN AMP-activated protein kinase (AMPK) DMF1P6W MA Inhibitor DMF1P6W RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMF1P6W RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMF1P6W DI DMF1P6W DMF1P6W DN SU 6656 DMF1P6W TI TT9RTBL DMF1P6W TN Aurora B messenger RNA (AURKB mRNA) DMF1P6W MA Inhibitor DMF1P6W RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMF1P6W RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMF1PIW DI DMF1PIW DMF1PIW DN 3-cyano-5-fluoro-N-(3-fluorophenyl)benzamide DMF1PIW TI TTHS256 DMF1PIW TN Metabotropic glutamate receptor 5 (mGluR5) DMF1PIW MA Inhibitor DMF1PIW RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMF1PIW RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMF1VS9 DI DMF1VS9 DMF1VS9 DN AV-370 DMF1VS9 TI TTST7KB DMF1VS9 TN Fibroblast growth factor receptor 3 (FGFR3) DMF1VS9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810). DMF1VS9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1810 DMF1WA6 DI DMF1WA6 DMF1WA6 DN 1-Iodyl-4-nitro-benzene DMF1WA6 TI TTELIN2 DMF1WA6 TN PTPN1 messenger RNA (PTPN1 mRNA) DMF1WA6 MA Inhibitor DMF1WA6 RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DMF1WA6 RU https://pubmed.ncbi.nlm.nih.gov/10091683 DMF1XLZ DI DMF1XLZ DMF1XLZ DN 9H-purine derivative DMF1XLZ TI TTJFY5U DMF1XLZ TN Adenosine A3 receptor (ADORA3) DMF1XLZ MA Inhibitor DMF1XLZ RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMF1XLZ RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMF1ZE6 DI DMF1ZE6 DMF1ZE6 DN Benzofuran-2-yl(indolin-1-yl)methanone DMF1ZE6 TI TT6804T DMF1ZE6 TN MIF messenger RNA (MIF mRNA) DMF1ZE6 MA Inhibitor DMF1ZE6 RN Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24. DMF1ZE6 RU https://pubmed.ncbi.nlm.nih.gov/19090668 DMF27YT DI DMF27YT DMF27YT DN 3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one DMF27YT TI TTMF541 DMF27YT TN Liver carboxylesterase (CES1) DMF27YT MA Inhibitor DMF27YT RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMF27YT RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMF27YT DI DMF27YT DMF27YT DN 3-(decylsulfonyl)-1,1,1-trifluoropropan-2-one DMF27YT TI TTDP1UC DMF27YT TN Fatty acid amide hydrolase (FAAH) DMF27YT MA Inhibitor DMF27YT RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMF27YT RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMF28IU DI DMF28IU DMF28IU DN PUUPEHEDIONE DMF28IU TI TTSJ6Q4 DMF28IU TN LOX-5 messenger RNA (ALOX5 mRNA) DMF28IU MA Inhibitor DMF28IU RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMF28IU RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMF28IU DI DMF28IU DMF28IU DN PUUPEHEDIONE DMF28IU TI TTN9T81 DMF28IU TN Arachidonate 15-lipoxygenase (15-LOX) DMF28IU MA Inhibitor DMF28IU RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMF28IU RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMF28IU DI DMF28IU DMF28IU DN PUUPEHEDIONE DMF28IU TI TT12ABZ DMF28IU TN Arachidonate 12-lipoxygenase (12-LOX) DMF28IU MA Inhibitor DMF28IU RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMF28IU RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMF2D4O DI DMF2D4O DMF2D4O DN N-(3,4-Difluorophenyl)propyl-ETAV DMF2D4O TI TT9PB26 DMF2D4O TN Presynaptic density protein 95 (DLG4) DMF2D4O MA Inhibitor DMF2D4O RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMF2D4O RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMF2IW8 DI DMF2IW8 DMF2IW8 DN 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine DMF2IW8 TI TTIQUX7 DMF2IW8 TN Steroid 11-beta-hydroxylase (CYP11B1) DMF2IW8 MA Inhibitor DMF2IW8 RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMF2IW8 RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMF2IW8 DI DMF2IW8 DMF2IW8 DN 3-methoxy-5-(6-methoxynaphthalen-2-yl)pyridine DMF2IW8 TI TTXV4FI DMF2IW8 TN Albendazole monooxygenase (CYP3A4) DMF2IW8 MA Inhibitor DMF2IW8 RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMF2IW8 RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMF2IY8 DI DMF2IY8 DMF2IY8 DN (S)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea DMF2IY8 TI TTMI6F5 DMF2IY8 TN Transient receptor potential cation channel V1 (TRPV1) DMF2IY8 MA Inhibitor DMF2IY8 RN Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9. DMF2IY8 RU https://pubmed.ncbi.nlm.nih.gov/17507218 DMF2RGY DI DMF2RGY DMF2RGY DN 6-fluoro-noradrenaline DMF2RGY TI TT2NUT5 DMF2RGY TN Adrenergic receptor alpha-2C (ADRA2C) DMF2RGY MA Agonist DMF2RGY RN Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. DMF2RGY RU https://pubmed.ncbi.nlm.nih.gov/7969082 DMF2XHZ DI DMF2XHZ DMF2XHZ DN 2-(1-dodecyl-1H-indol-3-yl)acetic acid DMF2XHZ TI TTLZS4Q DMF2XHZ TN M-phase inducer phosphatase 1 (MPIP1) DMF2XHZ MA Inhibitor DMF2XHZ RN Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3. DMF2XHZ RU https://pubmed.ncbi.nlm.nih.gov/18442908 DMF369N DI DMF369N DMF369N DN 3-(2-phenyl-6-(thiophen-3-yl)pyridin-4-yl)-phenol DMF369N TI TT0IHXV DMF369N TN DNA topoisomerase II (TOP2) DMF369N MA Inhibitor DMF369N RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMF369N RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMF375O DI DMF375O DMF375O DN Piperidine-1-carboxylic acid adamantan-2-yl ester DMF375O TI TTN7BL9 DMF375O TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMF375O MA Inhibitor DMF375O RN Discovery and optimization of adamantyl carbamate inhibitors of 11-HSD1. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6725-9. DMF375O RU https://pubmed.ncbi.nlm.nih.gov/20864344 DMF38M5 DI DMF38M5 DMF38M5 DN 4-Bromo-N-hydroxy-benzamide DMF38M5 TI TT2J34L DMF38M5 TN Arachidonate 5-lipoxygenase (5-LOX) DMF38M5 MA Inhibitor DMF38M5 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMF38M5 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMF3BCK DI DMF3BCK DMF3BCK DN PUUPEHENONE DMF3BCK TI TTSJ6Q4 DMF3BCK TN LOX-5 messenger RNA (ALOX5 mRNA) DMF3BCK MA Inhibitor DMF3BCK RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMF3BCK RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMF3BCK DI DMF3BCK DMF3BCK DN PUUPEHENONE DMF3BCK TI TTN9T81 DMF3BCK TN Arachidonate 15-lipoxygenase (15-LOX) DMF3BCK MA Inhibitor DMF3BCK RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMF3BCK RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMF3BCK DI DMF3BCK DMF3BCK DN PUUPEHENONE DMF3BCK TI TT12ABZ DMF3BCK TN Arachidonate 12-lipoxygenase (12-LOX) DMF3BCK MA Inhibitor DMF3BCK RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMF3BCK RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMF3C71 DI DMF3C71 DMF3C71 DN 4-Sulfamoyloxy-benzoic acid cyclopentyl ester DMF3C71 TI TTHM0R1 DMF3C71 TN Steryl-sulfatase (STS) DMF3C71 MA Inhibitor DMF3C71 RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMF3C71 RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMF3CLX DI DMF3CLX DMF3CLX DN 4-Iodopyrazole DMF3CLX TI TTBK0PU DMF3CLX TN Mycobacterium Cytochrome p450 121 (MycB cyp121) DMF3CLX MA Inhibitor DMF3CLX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF3CLX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF3D5R DI DMF3D5R DMF3D5R DN 1-(Bis-biphenyl-4-yl-methyl)-1H-imidazole DMF3D5R TI TTRA5BZ DMF3D5R TN Steroid 17-alpha-monooxygenase (S17AH) DMF3D5R MA Inhibitor DMF3D5R RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMF3D5R RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMF3DBE DI DMF3DBE DMF3DBE DN 3-amino-2-(benzylideneamino)-5-mercaptophenol DMF3DBE TI TTGX0HR DMF3DBE TN Bacterial DNA ligase (Bact ligA) DMF3DBE MA Inhibitor DMF3DBE RN Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62. DMF3DBE RU https://pubmed.ncbi.nlm.nih.gov/18630893 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTQBCEJ DMF3DZX TN MAPK/ERK kinase kinase 1 (MAP3K1) DMF3DZX MA Inhibitor DMF3DZX RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTK1N5G DMF3DZX TN MAPK/ERK kinase kinase 2 (MAP3K2) DMF3DZX MA Inhibitor DMF3DZX RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTTV8EJ DMF3DZX TN Serine/threonine-protein kinase Sgk1 (SGK1) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TT4TQBX DMF3DZX TN Extracellular signal-regulated kinase 2 (ERK2) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTG0U4H DMF3DZX TN Ribosomal protein S6 kinase beta-1 (S6K1) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTZN7RP DMF3DZX TN Rho-associated protein kinase 1 (ROCK1) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TT0K6EO DMF3DZX TN Stress-activated protein kinase JNK1 (JNK1) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTFJ8Q1 DMF3DZX TN Protein kinase C alpha (PRKCA) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TT73U6C DMF3DZX TN Stress-activated protein kinase 2b (p38 beta) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTQBR95 DMF3DZX TN Stress-activated protein kinase 2a (p38 alpha) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TT860QF DMF3DZX TN LCK tyrosine protein kinase (LCK) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTTU902 DMF3DZX TN Checkpoint kinase-1 (CHK1) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTYT93M DMF3DZX TN MAP kinase p38 (MAPK12) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTRSMW9 DMF3DZX TN Glycogen synthase kinase-3 beta (GSK-3B) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3DZX DI DMF3DZX DMF3DZX DN CI-1040 DMF3DZX TI TTWTSCV DMF3DZX TN RAC-alpha serine/threonine-protein kinase (AKT1) DMF3DZX MA Inhibitor DMF3DZX RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMF3DZX RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMF3G06 DI DMF3G06 DMF3G06 DN NSC-319745 DMF3G06 TI TT6VZ78 DMF3G06 TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMF3G06 MA Inhibitor DMF3G06 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMF3G06 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMF3G06 DI DMF3G06 DMF3G06 DN NSC-319745 DMF3G06 TI TTHVCUP DMF3G06 TN DNA [cytosine-5]-methyltransferase (DNMT) DMF3G06 MA Inhibitor DMF3G06 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMF3G06 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMF3JHM DI DMF3JHM DMF3JHM DN 3-Methylpyridine DMF3JHM TI TTUZ2L5 DMF3JHM TN Matrix metalloproteinase-3 (MMP-3) DMF3JHM MA Inhibitor DMF3JHM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF3JHM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF3JHM DI DMF3JHM DMF3JHM DN 3-Methylpyridine DMF3JHM TI TTHY57M DMF3JHM TN Matrix metalloproteinase-13 (MMP-13) DMF3JHM MA Inhibitor DMF3JHM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF3JHM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF3NPW DI DMF3NPW DMF3NPW DN 2-morpholino-6-(thiophen-3-yl)-4H-pyran-4-one DMF3NPW TI TTK3PY9 DMF3NPW TN DNA-dependent protein kinase catalytic (PRKDC) DMF3NPW MA Inhibitor DMF3NPW RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMF3NPW RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMF3O10 DI DMF3O10 DMF3O10 DN 4-(methylamino)naphthalen-1-ol DMF3O10 TI TTZJYKH DMF3O10 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMF3O10 MA Inhibitor DMF3O10 RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMF3O10 RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMF3S50 DI DMF3S50 DMF3S50 DN 4-(2-(benzyloxy)-6-fluorophenyl)piperidine DMF3S50 TI TTVBI8W DMF3S50 TN Dopamine transporter (DAT) DMF3S50 MA Inhibitor DMF3S50 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMF3S50 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMF3S50 DI DMF3S50 DMF3S50 DN 4-(2-(benzyloxy)-6-fluorophenyl)piperidine DMF3S50 TI TT3ROYC DMF3S50 TN Serotonin transporter (SERT) DMF3S50 MA Inhibitor DMF3S50 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMF3S50 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMF3S50 DI DMF3S50 DMF3S50 DN 4-(2-(benzyloxy)-6-fluorophenyl)piperidine DMF3S50 TI TTSQIFT DMF3S50 TN 5-HT 1A receptor (HTR1A) DMF3S50 MA Inhibitor DMF3S50 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMF3S50 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMF3S50 DI DMF3S50 DMF3S50 DN 4-(2-(benzyloxy)-6-fluorophenyl)piperidine DMF3S50 TI TTAWNKZ DMF3S50 TN Norepinephrine transporter (NET) DMF3S50 MA Inhibitor DMF3S50 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMF3S50 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMF3W15 DI DMF3W15 DMF3W15 DN 6-Heptyl-4-hydroxy-3-octanoyl-pyran-2-one DMF3W15 TI TTPLTSQ DMF3W15 TN Neutrophil elastase (NE) DMF3W15 MA Inhibitor DMF3W15 RN Inhibition of human sputum elastase by substituted 2-pyrones. J Med Chem. 1987 Jun;30(6):1017-23. DMF3W15 RU https://pubmed.ncbi.nlm.nih.gov/3647139 DMF4AHD DI DMF4AHD DMF4AHD DN Bis-cyclosal-d4TMP DMF4AHD TI TTEB0GD DMF4AHD TN Cholinesterase (BCHE) DMF4AHD MA Inhibitor DMF4AHD RN Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46. DMF4AHD RU https://pubmed.ncbi.nlm.nih.gov/17328534 DMF4BCP DI DMF4BCP DMF4BCP DN 1-Furan-2-ylmethyl-3-thiazol-2-yl-thiourea DMF4BCP TI TT84ETX DMF4BCP TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMF4BCP MA Inhibitor DMF4BCP RN Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8. DMF4BCP RU https://pubmed.ncbi.nlm.nih.gov/11229762 DMF4RGW DI DMF4RGW DMF4RGW DN 5-thia-8,11,14,17-eicosatetraenoic acid DMF4RGW TI TTVKILB DMF4RGW TN Prostaglandin G/H synthase 2 (COX-2) DMF4RGW MA Inhibitor DMF4RGW RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMF4RGW RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMF4TWE DI DMF4TWE DMF4TWE DN [3H]pentazocine DMF4TWE TI TT5TPI6 DMF4TWE TN Opioid receptor sigma 1 (OPRS1) DMF4TWE MA Agonist DMF4TWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2552). DMF4TWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2552 DMF4V58 DI DMF4V58 DMF4V58 DN ISIS 111084 DMF4V58 TI TTOM97J DMF4V58 TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DMF4V58 RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DMF4V58 RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DMF50YH DI DMF50YH DMF50YH DN 2-Dipropylamino-1,2,3,4-tetrahydro-anthracen-9-ol DMF50YH TI TTSQIFT DMF50YH TN 5-HT 1A receptor (HTR1A) DMF50YH MA Inhibitor DMF50YH RN Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993). DMF50YH RU http://www.sciencedirect.com/science/article/pii/S0960894X0181009X DMF52SH DI DMF52SH DMF52SH DN H-Dmt-Tic-Glu-NH-(CH2)5-NH2 DMF52SH TI TTKWM86 DMF52SH TN Opioid receptor mu (MOP) DMF52SH MA Inhibitor DMF52SH RN Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6. DMF52SH RU https://pubmed.ncbi.nlm.nih.gov/15588089 DMF52SH DI DMF52SH DMF52SH DN H-Dmt-Tic-Glu-NH-(CH2)5-NH2 DMF52SH TI TT27RFC DMF52SH TN Opioid receptor delta (OPRD1) DMF52SH MA Inhibitor DMF52SH RN Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6. DMF52SH RU https://pubmed.ncbi.nlm.nih.gov/15588089 DMF5D1N DI DMF5D1N DMF5D1N DN Butylphosphonate DMF5D1N TI TT3GKN5 DMF5D1N TN Lipase unspecific (LIP) DMF5D1N MA Inhibitor DMF5D1N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5D1N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTQICM2 DMF5DLW TN ADAM metallopeptidase 33 (ADAM33) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTMF541 DMF5DLW TN Liver carboxylesterase (CES1) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTSZDQU DMF5DLW TN Lactotransferrin (LTF) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTVRZUO DMF5DLW TN Reticulon-4 receptor (RTN4R) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TT50QJ3 DMF5DLW TN Influenza Neuraminidase (Influ NA) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTI2S1D DMF5DLW TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TT4QPUL DMF5DLW TN Antithrombin-III (ATIII) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTFC29G DMF5DLW TN Glycoprotein hormones alpha (CGA) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TT9V5JH DMF5DLW TN Phospholipase A2 (PLA2G1B) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTH0KSX DMF5DLW TN Rhodopsin (RHO) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTHRID2 DMF5DLW TN Insulin-like growth factor I receptor (IGF1R) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTIS03D DMF5DLW TN Alpha-galactosidase A (GLA) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TT8NGED DMF5DLW TN Prostaglandin G/H synthase 1 (COX-1) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TT0E5SK DMF5DLW TN Interleukin 6 receptor (IL6R) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTH0DUS DMF5DLW TN Low-density lipoprotein receptor (LDL-R) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TT8XSKJ DMF5DLW TN Heparin cofactor II (SERPIND1) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTF4CAM DMF5DLW TN Influenza Hemagglutinin (Influ HA) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TT2OUI9 DMF5DLW TN Beta-2-glycoprotein 1 (APOH) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTPT2QI DMF5DLW TN Cathepsin D (CTSD) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTDIGC1 DMF5DLW TN Dipeptidyl peptidase 4 (DPP-4) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTA0OSE DMF5DLW TN Lactase-phlorizin hydrolase (LCT) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTJDUNO DMF5DLW TN T-cell surface antigen CD2 (CD2) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTEB0GD DMF5DLW TN Cholinesterase (BCHE) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTZUFI5 DMF5DLW TN Nitric-oxide synthase brain (NOS1) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTYWGOJ DMF5DLW TN Deoxyribonuclease I (DNASE1) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTDGEC0 DMF5DLW TN Immunoglobulin epsilon Fc receptor gamma (FCERG) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5DLW DI DMF5DLW DMF5DLW DN Alpha-D-Mannose DMF5DLW TI TTBXIM9 DMF5DLW TN Membrane-associated lectin type-C (CD209) DMF5DLW MA Inhibitor DMF5DLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF5DLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF5MGQ DI DMF5MGQ DMF5MGQ DN 2-benzyl-N1-hydroxy-N3-(3-phenylpropyl)malonamide DMF5MGQ TI TTPHMWB DMF5MGQ TN Aminopeptidase N (ANPEP) DMF5MGQ MA Inhibitor DMF5MGQ RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMF5MGQ RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMF5N4O DI DMF5N4O DMF5N4O DN N-(2-naphthylsulfonyl)-glycyl-glycine-nitrile DMF5N4O TI TTUMQVO DMF5N4O TN Cathepsin S (CTSS) DMF5N4O MA Inhibitor DMF5N4O RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMF5N4O RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMF5SK8 DI DMF5SK8 DMF5SK8 DN ISIS 32014 DMF5SK8 TI TT9H4P3 DMF5SK8 TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMF5SK8 RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMF5SK8 RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMF62GN DI DMF62GN DMF62GN DN (+)-(1R,1'S)-berbamunine hydrochloride DMF62GN TI TTZFYLI DMF62GN TN Dopamine D1 receptor (D1R) DMF62GN MA Inhibitor DMF62GN RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMF62GN RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMF62GN DI DMF62GN DMF62GN DN (+)-(1R,1'S)-berbamunine hydrochloride DMF62GN TI TTEX248 DMF62GN TN Dopamine D2 receptor (D2R) DMF62GN MA Inhibitor DMF62GN RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMF62GN RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMF62JR DI DMF62JR DMF62JR DN [1,5]Thiazocan-(4E)-ylideneamine DMF62JR TI TTF10I9 DMF62JR TN Nitric-oxide synthase inducible (NOS2) DMF62JR MA Inhibitor DMF62JR RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMF62JR RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMF6MRS DI DMF6MRS DMF6MRS DN Methyl 2-(naphthalen-2-yl)benzoate DMF6MRS TI TTVBI8W DMF6MRS TN Dopamine transporter (DAT) DMF6MRS MA Inhibitor DMF6MRS RN Synthesis, inhibition and binding of simple non-nitrogen inhibitors of monoamine transporters. Bioorg Med Chem. 2007 Jun 15;15(12):4159-74. DMF6MRS RU https://pubmed.ncbi.nlm.nih.gov/17446076 DMF6PMU DI DMF6PMU DMF6PMU DN 2-Cyclohexyl-N-(4-methoxy-phenyl)-acetamide DMF6PMU TI TT7WVHI DMF6PMU TN Soluble epoxide hydrolase (EPHX2) DMF6PMU MA Inhibitor DMF6PMU RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMF6PMU RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMF6RVS DI DMF6RVS DMF6RVS DN N1-hydroxy-2-isobutyl-N3-phenethylmalonamide DMF6RVS TI TTPHMWB DMF6RVS TN Aminopeptidase N (ANPEP) DMF6RVS MA Inhibitor DMF6RVS RN A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening. Bioorg Med Chem. 2007 Jan 1;15(1):63-76. DMF6RVS RU https://pubmed.ncbi.nlm.nih.gov/17070058 DMF6S3X DI DMF6S3X DMF6S3X DN 4-(Benzylamino)-1-naphthol DMF6S3X TI TTZJYKH DMF6S3X TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMF6S3X MA Inhibitor DMF6S3X RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMF6S3X RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMF6V8W DI DMF6V8W DMF6V8W DN HALOPEMIDE DMF6V8W TI TT3T17P DMF6V8W TN Phospholipase D1 (PLD1) DMF6V8W MA Inhibitor DMF6V8W RN Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. DMF6V8W RU https://pubmed.ncbi.nlm.nih.gov/19136975 DMF6V8W DI DMF6V8W DMF6V8W DN HALOPEMIDE DMF6V8W TI TTQW170 DMF6V8W TN Phospholipase D (PLD) DMF6V8W MA Inhibitor DMF6V8W RN Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17. DMF6V8W RU https://pubmed.ncbi.nlm.nih.gov/19136975 DMF6VGK DI DMF6VGK DMF6VGK DN 3beta-hydroxyolean-12-en-27-oic acid DMF6VGK TI TTELIN2 DMF6VGK TN PTPN1 messenger RNA (PTPN1 mRNA) DMF6VGK MA Inhibitor DMF6VGK RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DMF6VGK RU https://pubmed.ncbi.nlm.nih.gov/16580200 DMF6WHC DI DMF6WHC DMF6WHC DN (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol DMF6WHC TI TT2NUT5 DMF6WHC TN Adrenergic receptor alpha-2C (ADRA2C) DMF6WHC MA Inhibitor DMF6WHC RN 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90. DMF6WHC RU https://pubmed.ncbi.nlm.nih.gov/10354406 DMF6WHC DI DMF6WHC DMF6WHC DN (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol DMF6WHC TI TTWM4TY DMF6WHC TN Adrenergic receptor alpha-2B (ADRA2B) DMF6WHC MA Inhibitor DMF6WHC RN 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90. DMF6WHC RU https://pubmed.ncbi.nlm.nih.gov/10354406 DMF6WHC DI DMF6WHC DMF6WHC DN (1,2,3,4-Tetrahydro-isoquinolin-3-yl)-methanol DMF6WHC TI TTWG9A4 DMF6WHC TN Adrenergic receptor alpha-2A (ADRA2A) DMF6WHC MA Inhibitor DMF6WHC RN 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90. DMF6WHC RU https://pubmed.ncbi.nlm.nih.gov/10354406 DMF70IM DI DMF70IM DMF70IM DN JWH-207 DMF70IM TI TTMSFAW DMF70IM TN Cannabinoid receptor 2 (CB2) DMF70IM MA Inhibitor DMF70IM RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMF70IM RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMF71B3 DI DMF71B3 DMF71B3 DN RS-102895 DMF71B3 TI TTFZYTO DMF71B3 TN C-C chemokine receptor type 2 (CCR2) DMF71B3 MA Antagonist DMF71B3 RN Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within t... J Biol Chem. 2000 Aug 18;275(33):25562-71. DMF71B3 RU https://pubmed.ncbi.nlm.nih.gov/10770925 DMF74GJ DI DMF74GJ DMF74GJ DN (E)-13-Nitrooctadec-12-enoic Acid DMF74GJ TI TTJ584C DMF74GJ TN Peroxisome proliferator-activated receptor alpha (PPARA) DMF74GJ MA Inhibitor DMF74GJ RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMF74GJ RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMF74GJ DI DMF74GJ DMF74GJ DN (E)-13-Nitrooctadec-12-enoic Acid DMF74GJ TI TTT2SVW DMF74GJ TN PPAR-gamma messenger RNA (PPARG mRNA) DMF74GJ MA Inhibitor DMF74GJ RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMF74GJ RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMF76M8 DI DMF76M8 DMF76M8 DN MDL-28618 DMF76M8 TI TTAWNKZ DMF76M8 TN Norepinephrine transporter (NET) DMF76M8 MA Inhibitor DMF76M8 RN Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8. DMF76M8 RU https://pubmed.ncbi.nlm.nih.gov/18667309 DMF76M8 DI DMF76M8 DMF76M8 DN MDL-28618 DMF76M8 TI TT3ROYC DMF76M8 TN Serotonin transporter (SERT) DMF76M8 MA Inhibitor DMF76M8 RN Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8. DMF76M8 RU https://pubmed.ncbi.nlm.nih.gov/18667309 DMF7JPO DI DMF7JPO DMF7JPO DN 5'-Deoxy-5'-(N,N-dimethylamino)adenosine DMF7JPO TI TTBFROQ DMF7JPO TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMF7JPO MA Inhibitor DMF7JPO RN New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407. DMF7JPO RU https://pubmed.ncbi.nlm.nih.gov/19209891 DMF7LST DI DMF7LST DMF7LST DN (6-Benzyloxy-2-naphthyl)-2-aminopropane DMF7LST TI TT3WG5C DMF7LST TN Monoamine oxidase type A (MAO-A) DMF7LST MA Inhibitor DMF7LST RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMF7LST RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMF7LST DI DMF7LST DMF7LST DN (6-Benzyloxy-2-naphthyl)-2-aminopropane DMF7LST TI TTGP7BY DMF7LST TN Monoamine oxidase type B (MAO-B) DMF7LST MA Inhibitor DMF7LST RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMF7LST RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMF7QS5 DI DMF7QS5 DMF7QS5 DN 9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline DMF7QS5 TI TT3WG5C DMF7QS5 TN Monoamine oxidase type A (MAO-A) DMF7QS5 MA Inhibitor DMF7QS5 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMF7QS5 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMF7QS5 DI DMF7QS5 DMF7QS5 DN 9-Methyl-2,3,4,9-tetrahydro-1H-beta-carboline DMF7QS5 TI TTGP7BY DMF7QS5 TN Monoamine oxidase type B (MAO-B) DMF7QS5 MA Inhibitor DMF7QS5 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMF7QS5 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMF7S54 DI DMF7S54 DMF7S54 DN Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2 DMF7S54 TI TT860QF DMF7S54 TN LCK tyrosine protein kinase (LCK) DMF7S54 MA Inhibitor DMF7S54 RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DMF7S54 RU https://pubmed.ncbi.nlm.nih.gov/9632358 DMF7S54 DI DMF7S54 DMF7S54 DN Y-c[D-Pen-(3,5-diI)Tyr-GSFC]KR-NH2 DMF7S54 TI TT6PKBN DMF7S54 TN Proto-oncogene c-Src (SRC) DMF7S54 MA Inhibitor DMF7S54 RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DMF7S54 RU https://pubmed.ncbi.nlm.nih.gov/9632358 DMF7TBW DI DMF7TBW DMF7TBW DN CATPB DMF7TBW TI TT0FYAN DMF7TBW TN Free fatty acid receptor 2 (FFAR2) DMF7TBW MA Antagonist DMF7TBW RN Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 2012 Nov 30;287(49):41195-209. DMF7TBW RU https://pubmed.ncbi.nlm.nih.gov/23066016 DMF7VZO DI DMF7VZO DMF7VZO DN PMID18754614C18 DMF7VZO TI TTFQEO5 DMF7VZO TN Squalene synthetase (FDFT1) DMF7VZO MA Inhibitor DMF7VZO RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DMF7VZO RU https://pubmed.ncbi.nlm.nih.gov/18754614 DMF7X31 DI DMF7X31 DMF7X31 DN Hemoparatide DMF7X31 TI TTEPJL5 DMF7X31 TN Parathyroid hormone receptor (PTH2R) DMF7X31 MA Modulator DMF7X31 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMF7X31 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMF7ZYQ DI DMF7ZYQ DMF7ZYQ DN AH 11110 DMF7ZYQ TI TTBRKXS DMF7ZYQ TN Adrenergic receptor alpha-1B (ADRA1B) DMF7ZYQ MA Antagonist DMF7ZYQ RN Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. J Pharmacol Exp Ther. 1996 Jul;278(1):136-44. DMF7ZYQ RU https://pubmed.ncbi.nlm.nih.gov/8764344 DMF82C1 DI DMF82C1 DMF82C1 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H DMF82C1 TI TTVFO0U DMF82C1 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMF82C1 MA Inhibitor DMF82C1 RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMF82C1 RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMF82C1 DI DMF82C1 DMF82C1 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H DMF82C1 TI TTKWM86 DMF82C1 TN Opioid receptor mu (MOP) DMF82C1 MA Inhibitor DMF82C1 RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMF82C1 RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMF82C1 DI DMF82C1 DMF82C1 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H DMF82C1 TI TTCG0AL DMF82C1 TN Cholecystokinin receptor type A (CCKAR) DMF82C1 MA Inhibitor DMF82C1 RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMF82C1 RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMF82C1 DI DMF82C1 DMF82C1 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H DMF82C1 TI TT27RFC DMF82C1 TN Opioid receptor delta (OPRD1) DMF82C1 MA Inhibitor DMF82C1 RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMF82C1 RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMF86P3 DI DMF86P3 DMF86P3 DN PD-140547 DMF86P3 TI TTVFO0U DMF86P3 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMF86P3 MA Inhibitor DMF86P3 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMF86P3 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMF86P3 DI DMF86P3 DMF86P3 DN PD-140547 DMF86P3 TI TTCG0AL DMF86P3 TN Cholecystokinin receptor type A (CCKAR) DMF86P3 MA Inhibitor DMF86P3 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMF86P3 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMF87Z5 DI DMF87Z5 DMF87Z5 DN 1-N-Acetyl-Beta-D-Glucosamine DMF87Z5 TI TTZHY6R DMF87Z5 TN Glycogen phosphorylase muscle form (GP) DMF87Z5 MA Inhibitor DMF87Z5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF87Z5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF8C50 DI DMF8C50 DMF8C50 DN (+)-5-deoxyadeenophorine DMF8C50 TI TTIS03D DMF8C50 TN Alpha-galactosidase A (GLA) DMF8C50 MA Inhibitor DMF8C50 RN Flexible synthesis and biological evaluation of novel 5-deoxyadenophorine analogues. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3262-7. DMF8C50 RU https://pubmed.ncbi.nlm.nih.gov/16603357 DMF8D5S DI DMF8D5S DMF8D5S DN 4-(2-aminoethyl)-2-ethylphenol DMF8D5S TI TT8JRS7 DMF8D5S TN Beta-secretase (BACE) DMF8D5S MA Inhibitor DMF8D5S RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMF8D5S RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMF8E5L DI DMF8E5L DMF8E5L DN 2-methoxy-4-(2-methoxyphenylthio)benzonitrile DMF8E5L TI TTKPW01 DMF8E5L TN Androgen receptor messenger RNA (AR mRNA) DMF8E5L MA Inhibitor DMF8E5L RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMF8E5L RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMF8EJ6 DI DMF8EJ6 DMF8EJ6 DN Iodo-Phenylalanine DMF8EJ6 TI TTDIGC1 DMF8EJ6 TN Dipeptidyl peptidase 4 (DPP-4) DMF8EJ6 MA Inhibitor DMF8EJ6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF8EJ6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF8GAX DI DMF8GAX DMF8GAX DN sergliflozin DMF8GAX TI TTLWPVF DMF8GAX TN Sodium/glucose cotransporter 2 (SGLT2) DMF8GAX MA Inhibitor DMF8GAX RN Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal gluco... J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. DMF8GAX RU https://pubmed.ncbi.nlm.nih.gov/17050778 DMF8GAX DI DMF8GAX DMF8GAX DN sergliflozin DMF8GAX TI TT2UE56 DMF8GAX TN Sodium/glucose cotransporter 1 (SGLT1) DMF8GAX MA Inhibitor DMF8GAX RN Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal gluco... J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. DMF8GAX RU https://pubmed.ncbi.nlm.nih.gov/17050778 DMF8I2W DI DMF8I2W DMF8I2W DN (S)-2-amino-4-(benzylthio)butanoic acid DMF8I2W TI TTFK1JQ DMF8I2W TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMF8I2W MA Inhibitor DMF8I2W RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMF8I2W RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMF8IA6 DI DMF8IA6 DMF8IA6 DN N-methoxyquinuclidine-3-carboximidoyl fluoride DMF8IA6 TI TTH18TF DMF8IA6 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMF8IA6 MA Inhibitor DMF8IA6 RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMF8IA6 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMF8IA6 DI DMF8IA6 DMF8IA6 DN N-methoxyquinuclidine-3-carboximidoyl fluoride DMF8IA6 TI TTQ3JTF DMF8IA6 TN Muscarinic acetylcholine receptor M4 (CHRM4) DMF8IA6 MA Inhibitor DMF8IA6 RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMF8IA6 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMF8IA6 DI DMF8IA6 DMF8IA6 DN N-methoxyquinuclidine-3-carboximidoyl fluoride DMF8IA6 TI TTQ13Z5 DMF8IA6 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMF8IA6 MA Inhibitor DMF8IA6 RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMF8IA6 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMF8IA6 DI DMF8IA6 DMF8IA6 DN N-methoxyquinuclidine-3-carboximidoyl fluoride DMF8IA6 TI TTYEG6Q DMF8IA6 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMF8IA6 MA Inhibitor DMF8IA6 RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMF8IA6 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMF8IA6 DI DMF8IA6 DMF8IA6 DN N-methoxyquinuclidine-3-carboximidoyl fluoride DMF8IA6 TI TTZ9SOR DMF8IA6 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMF8IA6 MA Inhibitor DMF8IA6 RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMF8IA6 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMF8M0W DI DMF8M0W DMF8M0W DN tetrahydrodeoxycorticosterone DMF8M0W TI TTBMV1G DMF8M0W TN GABA(A) receptor alpha-2 (GABRA2) DMF8M0W MA Modulator (allosteric modulator) DMF8M0W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMF8M0W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMF8M0W DI DMF8M0W DMF8M0W DN tetrahydrodeoxycorticosterone DMF8M0W TI TT37EDJ DMF8M0W TN GABA(A) receptor alpha-3 (GABRA3) DMF8M0W MA Modulator (allosteric modulator) DMF8M0W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMF8M0W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMF8M0W DI DMF8M0W DMF8M0W DN tetrahydrodeoxycorticosterone DMF8M0W TI TTEX6LM DMF8M0W TN GABA(A) receptor gamma-3 (GABRG3) DMF8M0W MA Modulator (allosteric modulator) DMF8M0W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMF8M0W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMF8M0W DI DMF8M0W DMF8M0W DN tetrahydrodeoxycorticosterone DMF8M0W TI TTNZPQ1 DMF8M0W TN GABA(A) receptor alpha-5 (GABRA5) DMF8M0W MA Modulator (allosteric modulator) DMF8M0W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMF8M0W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMF8O62 DI DMF8O62 DMF8O62 DN SAVX-1 DMF8O62 TI TT2JWF6 DMF8O62 TN Peroxisome proliferator-activated receptor delta (PPARD) DMF8O62 MA Modulator DMF8O62 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 594). DMF8O62 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=594 DMF8QR6 DI DMF8QR6 DMF8QR6 DN TRIPHLOROETHOL A DMF8QR6 TI TT8JRS7 DMF8QR6 TN Beta-secretase (BACE) DMF8QR6 MA Inhibitor DMF8QR6 RN Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5. DMF8QR6 RU https://pubmed.ncbi.nlm.nih.gov/20462757 DMF8UWE DI DMF8UWE DMF8UWE DN BZ6 DMF8UWE TI TTVDSZ0 DMF8UWE TN Poly [ADP-ribose] polymerase 1 (PARP1) DMF8UWE MA Inhibitor DMF8UWE RN Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8. DMF8UWE RU https://pubmed.ncbi.nlm.nih.gov/12855651 DMF8VX3 DI DMF8VX3 DMF8VX3 DN MDL-74156 DMF8VX3 TI TTQ6VDM DMF8VX3 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMF8VX3 MA Inhibitor DMF8VX3 RN Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg Med Chem Lett. 2003 Aug 18;13(16):2773-5. DMF8VX3 RU https://pubmed.ncbi.nlm.nih.gov/12873512 DMF9HIJ DI DMF9HIJ DMF9HIJ DN PMID30247903-Compound-General structure35 DMF9HIJ TI TT23XQV DMF9HIJ TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMF9HIJ MA Inhibitor DMF9HIJ RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMF9HIJ RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMF9HYI DI DMF9HYI DMF9HYI DN MSX-3 DMF9HYI TI TTM2AOE DMF9HYI TN Adenosine A2a receptor (ADORA2A) DMF9HYI MA Modulator DMF9HYI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5610). DMF9HYI RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5610 DMF9JAH DI DMF9JAH DMF9JAH DN ISIS 103671 DMF9JAH TI TT6TU05 DMF9JAH TN WWP2 messenger RNA (WWP2 mRNA) DMF9JAH RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMF9JAH RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMF9M06 DI DMF9M06 DMF9M06 DN DX-2400 DMF9M06 TI TTJ4QE7 DMF9M06 TN Matrix metalloproteinase-14 (MMP-14) DMF9M06 MA Inhibitor DMF9M06 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1638). DMF9M06 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1638 DMF9P25 DI DMF9P25 DMF9P25 DN KNI-10341 DMF9P25 TI TTXMNHO DMF9P25 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMF9P25 MA Inhibitor DMF9P25 RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMF9P25 RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMF9SOV DI DMF9SOV DMF9SOV DN WTLNSAGYLL-CONH2 DMF9SOV TI TTBPW3J DMF9SOV TN Galanin receptor type 2 (GAL2-R) DMF9SOV MA Inhibitor DMF9SOV RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMF9SOV RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMF9SOV DI DMF9SOV DMF9SOV DN WTLNSAGYLL-CONH2 DMF9SOV TI TTX3HNZ DMF9SOV TN Galanin receptor type 1 (GAL1-R) DMF9SOV MA Inhibitor DMF9SOV RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMF9SOV RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMF9T64 DI DMF9T64 DMF9T64 DN Phthalic Acid DMF9T64 TI TTH29K0 DMF9T64 TN Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC) DMF9T64 MA Inhibitor DMF9T64 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMF9T64 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMF9U2O DI DMF9U2O DMF9U2O DN N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine DMF9U2O TI TT6OEDT DMF9U2O TN Cannabinoid receptor 1 (CB1) DMF9U2O MA Inhibitor DMF9U2O RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DMF9U2O RU https://pubmed.ncbi.nlm.nih.gov/16570929 DMF9U2O DI DMF9U2O DMF9U2O DN N-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine DMF9U2O TI TTMSFAW DMF9U2O TN Cannabinoid receptor 2 (CB2) DMF9U2O MA Inhibitor DMF9U2O RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DMF9U2O RU https://pubmed.ncbi.nlm.nih.gov/16570929 DMF9W41 DI DMF9W41 DMF9W41 DN example 20 (WO2010128058) DMF9W41 TI TT69DB8 DMF9W41 TN Beta-site APP-cleaving enzyme 2 (BACE2) DMF9W41 MA Inhibitor DMF9W41 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2331). DMF9W41 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2331 DMF9X2T DI DMF9X2T DMF9X2T DN 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one DMF9X2T TI TTWN3F4 DMF9X2T TN Presenilin 2 (PSEN2) DMF9X2T MA Inhibitor DMF9X2T RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMF9X2T RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMF9X2T DI DMF9X2T DMF9X2T DN 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one DMF9X2T TI TTZ3S8C DMF9X2T TN Presenilin 1 (PSEN1) DMF9X2T MA Inhibitor DMF9X2T RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMF9X2T RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMF9X2T DI DMF9X2T DMF9X2T DN 1-benzoyl-2-benzyl-1,2-dihydropyridin-3(6H)-one DMF9X2T TI TT9W8GU DMF9X2T TN Gamma-secretase (GS) DMF9X2T MA Inhibitor DMF9X2T RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMF9X2T RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMF9YLR DI DMF9YLR DMF9YLR DN (S)-1-(2-methoxyphenethyl)-2-methylpyrrolidine DMF9YLR TI TT9JNIC DMF9YLR TN Histamine H3 receptor (H3R) DMF9YLR MA Inhibitor DMF9YLR RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMF9YLR RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMFA8CW DI DMFA8CW DMFA8CW DN 1,3,7-trihydroxyacridone DMFA8CW TI TT0IHXV DMFA8CW TN DNA topoisomerase II (TOP2) DMFA8CW MA Inhibitor DMFA8CW RN 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34. DMFA8CW RU https://pubmed.ncbi.nlm.nih.gov/10809021 DMFACRH DI DMFACRH DMFACRH DN PMID30247903-Compound-General structure21 DMFACRH TI TTNBFWK DMFACRH TN Programmed cell death protein 1 (PD-1) DMFACRH MA Inhibitor DMFACRH RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMFACRH RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMFAITE DI DMFAITE DMFAITE DN 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione DMFAITE TI TT6X50U DMFAITE TN Matrix metalloproteinase-9 (MMP-9) DMFAITE MA Inhibitor DMFAITE RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DMFAITE RU https://pubmed.ncbi.nlm.nih.gov/11327602 DMFAITE DI DMFAITE DMFAITE DN 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione DMFAITE TI TTUZ2L5 DMFAITE TN Matrix metalloproteinase-3 (MMP-3) DMFAITE MA Inhibitor DMFAITE RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DMFAITE RU https://pubmed.ncbi.nlm.nih.gov/11327602 DMFAITE DI DMFAITE DMFAITE DN 5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione DMFAITE TI TTLM12X DMFAITE TN Matrix metalloproteinase-2 (MMP-2) DMFAITE MA Inhibitor DMFAITE RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DMFAITE RU https://pubmed.ncbi.nlm.nih.gov/11327602 DMFAL2E DI DMFAL2E DMFAL2E DN ISIS 9061 DMFAL2E TI TT5TURO DMFAL2E TN A-Raf messenger RNA (ARAF mRNA) DMFAL2E RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DMFAL2E RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DMFALTY DI DMFALTY DMFALTY DN 6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMFALTY TI TTZAYWL DMFALTY TN Estrogen receptor (ESR) DMFALTY MA Inhibitor DMFALTY RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMFALTY RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMFALTY DI DMFALTY DMFALTY DN 6-(2,6-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMFALTY TI TTOM3J0 DMFALTY TN Estrogen receptor beta (ESR2) DMFALTY MA Inhibitor DMFALTY RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMFALTY RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMFAM7P DI DMFAM7P DMFAM7P DN santacruzamate A DMFAM7P TI TTSHTOI DMFAM7P TN Histone deacetylase 2 (HDAC2) DMFAM7P MA Inhibitor DMFAM7P RN Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. DMFAM7P RU https://pubmed.ncbi.nlm.nih.gov/24164245 DMFAM7P DI DMFAM7P DMFAM7P DN santacruzamate A DMFAM7P TI TTTQGH8 DMFAM7P TN Histone deacetylase 4 (HDAC4) DMFAM7P MA Inhibitor DMFAM7P RN Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. DMFAM7P RU https://pubmed.ncbi.nlm.nih.gov/24164245 DMFAM7P DI DMFAM7P DMFAM7P DN santacruzamate A DMFAM7P TI TT5ZKDI DMFAM7P TN Histone deacetylase 6 (HDAC6) DMFAM7P MA Inhibitor DMFAM7P RN Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp. J Nat Prod. 2013 Nov 22;76(11):2026-33. DMFAM7P RU https://pubmed.ncbi.nlm.nih.gov/24164245 DMFAME4 DI DMFAME4 DMFAME4 DN 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide DMFAME4 TI TT06RH5 DMFAME4 TN GABA(A) receptor gamma-2 (GABRG2) DMFAME4 MA Inhibitor DMFAME4 RN Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20. DMFAME4 RU https://pubmed.ncbi.nlm.nih.gov/1319492 DMFAME4 DI DMFAME4 DMFAME4 DN 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide DMFAME4 TI TTNJYV2 DMFAME4 TN Gamma-aminobutyric acid receptor (GAR) DMFAME4 MA Inhibitor DMFAME4 RN Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20. DMFAME4 RU https://pubmed.ncbi.nlm.nih.gov/1319492 DMFAME4 DI DMFAME4 DMFAME4 DN 2-(1H-Indol-3-yl)-2-oxo-N-phenethyl-acetamide DMFAME4 TI TT1MPAY DMFAME4 TN GABA(A) receptor alpha-1 (GABRA1) DMFAME4 MA Inhibitor DMFAME4 RN Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20. DMFAME4 RU https://pubmed.ncbi.nlm.nih.gov/1319492 DMFASRB DI DMFASRB DMFASRB DN RGD DMFASRB TI TT38RM1 DMFASRB TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DMFASRB MA Binder DMFASRB RN AlphaIIbbeta3 and its antagonism at the new millennium. Thromb Haemost. 2001 Jul;86(1):34-40. DMFASRB RU https://pubmed.ncbi.nlm.nih.gov/11487023 DMFAST4 DI DMFAST4 DMFAST4 DN Recombinant coagulation factors DMFAST4 TI TTCIHJA DMFAST4 TN Coagulation factor Xa (F10) DMFAST4 MA Modulator DMFAST4 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMFAST4 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMFAUGP DI DMFAUGP DMFAUGP DN ML213 DMFAUGP TI TT8HGRW DMFAUGP TN Voltage-gated potassium channel Kv7.4 (KCNQ4) DMFAUGP MA Activator DMFAUGP RN Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS Chem Neurosci. 2011 Oct 19;2(10):572-577. DMFAUGP RU https://pubmed.ncbi.nlm.nih.gov/22125664 DMFAV5R DI DMFAV5R DMFAV5R DN 2-tert-Butyldimethylsilyloxylycorine DMFAV5R TI TTXV4FI DMFAV5R TN Albendazole monooxygenase (CYP3A4) DMFAV5R MA Inhibitor DMFAV5R RN Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7. DMFAV5R RU https://pubmed.ncbi.nlm.nih.gov/19428250 DMFAVB5 DI DMFAVB5 DMFAVB5 DN BRD9539 DMFAVB5 TI TTS6RZT DMFAVB5 TN Histone-lysine N-methyltransferase EHMT2 (EHMT2) DMFAVB5 MA Inhibitor DMFAVB5 RN A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012 Jul 20;7(7):1152-7. DMFAVB5 RU https://pubmed.ncbi.nlm.nih.gov/22536950 DMFAW4R DI DMFAW4R DMFAW4R DN 2-BFi DMFAW4R TI TTWG9A4 DMFAW4R TN Adrenergic receptor alpha-2A (ADRA2A) DMFAW4R MA Inhibitor DMFAW4R RN Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7. DMFAW4R RU https://pubmed.ncbi.nlm.nih.gov/10741563 DMFAW4R DI DMFAW4R DMFAW4R DN 2-BFi DMFAW4R TI TTGP7BY DMFAW4R TN Monoamine oxidase type B (MAO-B) DMFAW4R MA Inhibitor DMFAW4R RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMFAW4R RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMFAW4R DI DMFAW4R DMFAW4R DN 2-BFi DMFAW4R TI TTWM4TY DMFAW4R TN Adrenergic receptor alpha-2B (ADRA2B) DMFAW4R MA Inhibitor DMFAW4R RN Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7. DMFAW4R RU https://pubmed.ncbi.nlm.nih.gov/10741563 DMFAW4R DI DMFAW4R DMFAW4R DN 2-BFi DMFAW4R TI TT3WG5C DMFAW4R TN Monoamine oxidase type A (MAO-A) DMFAW4R MA Inhibitor DMFAW4R RN Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7. DMFAW4R RU https://pubmed.ncbi.nlm.nih.gov/10741563 DMFAW4R DI DMFAW4R DMFAW4R DN 2-BFi DMFAW4R TI TT2NUT5 DMFAW4R TN Adrenergic receptor alpha-2C (ADRA2C) DMFAW4R MA Inhibitor DMFAW4R RN Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I2 ligand. Bioorg Med Chem Lett. 2000 Mar 20;10(6):605-7. DMFAW4R RU https://pubmed.ncbi.nlm.nih.gov/10741563 DMFAWGX DI DMFAWGX DMFAWGX DN ISIS 19219 DMFAWGX TI TT1ERKL DMFAWGX TN CD40 messenger RNA (CD40 mRNA) DMFAWGX RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMFAWGX RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMFAX1Q DI DMFAX1Q DMFAX1Q DN [D-Gln3,D-Ncy(SO,isopropyl)7]acyline DMFAX1Q TI TT8R70G DMFAX1Q TN Gonadotropin-releasing hormone receptor (GNRHR) DMFAX1Q MA Inhibitor DMFAX1Q RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMFAX1Q RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMFB4M5 DI DMFB4M5 DMFB4M5 DN Benzyl-biphenyl-4-ylmethyl-imidazol-1-yl-amine DMFB4M5 TI TTSZLWK DMFB4M5 TN Aromatase (CYP19A1) DMFB4M5 MA Inhibitor DMFB4M5 RN CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. Bioorg Med Chem. 2008 Sep 15;16(18):8349-58. DMFB4M5 RU https://pubmed.ncbi.nlm.nih.gov/18782670 DMFBD3K DI DMFBD3K DMFBD3K DN 2-cyclohexylamido-5-sulfonamidoindane DMFBD3K TI TTANPDJ DMFBD3K TN Carbonic anhydrase II (CA-II) DMFBD3K MA Inhibitor DMFBD3K RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMFBD3K RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMFBD3K DI DMFBD3K DMFBD3K DN 2-cyclohexylamido-5-sulfonamidoindane DMFBD3K TI TT2LVK8 DMFBD3K TN Carbonic anhydrase IX (CA-IX) DMFBD3K MA Inhibitor DMFBD3K RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMFBD3K RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMFBD3K DI DMFBD3K DMFBD3K DN 2-cyclohexylamido-5-sulfonamidoindane DMFBD3K TI TTHQPL7 DMFBD3K TN Carbonic anhydrase I (CA-I) DMFBD3K MA Inhibitor DMFBD3K RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMFBD3K RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMFBMYG DI DMFBMYG DMFBMYG DN KF-A5 DMFBMYG TI TT3ROYC DMFBMYG TN Serotonin transporter (SERT) DMFBMYG MA Inhibitor DMFBMYG RN Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. DMFBMYG RU https://pubmed.ncbi.nlm.nih.gov/17846138 DMFBMYG DI DMFBMYG DMFBMYG DN KF-A5 DMFBMYG TI TTAWNKZ DMFBMYG TN Norepinephrine transporter (NET) DMFBMYG MA Inhibitor DMFBMYG RN Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. DMFBMYG RU https://pubmed.ncbi.nlm.nih.gov/17846138 DMFBN9O DI DMFBN9O DMFBN9O DN BB-78484 DMFBN9O TI TT0OFWN DMFBN9O TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DMFBN9O MA Inhibitor DMFBN9O RN Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother. 2002 Jun;46(6):1793-9. DMFBN9O RU https://pubmed.ncbi.nlm.nih.gov/12019092 DMFBP7C DI DMFBP7C DMFBP7C DN FUTOENONE DMFBP7C TI TTUZ2L5 DMFBP7C TN Matrix metalloproteinase-3 (MMP-3) DMFBP7C MA Inhibitor DMFBP7C RN Inhibition of metalloproteinase by futoenone derivatives, Bioorg. Med. Chem. Lett. 5(15):1637-1642 (1995). DMFBP7C RU http://www.sciencedirect.com/science/article/pii/0960894X9500282X DMFBTM2 DI DMFBTM2 DMFBTM2 DN 2-(phenylsulfonamido)-1-naphthoic acid DMFBTM2 TI TTZL0OI DMFBTM2 TN Methionine aminopeptidase 2 (METAP2) DMFBTM2 MA Inhibitor DMFBTM2 RN Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. DMFBTM2 RU https://pubmed.ncbi.nlm.nih.gov/16632353 DMFBW1H DI DMFBW1H DMFBW1H DN CHIR-98023 DMFBW1H TI TTRSMW9 DMFBW1H TN Glycogen synthase kinase-3 beta (GSK-3B) DMFBW1H MA Inhibitor DMFBW1H RN Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. DMFBW1H RU https://pubmed.ncbi.nlm.nih.gov/18929433 DMFBZEI DI DMFBZEI DMFBZEI DN NSC-30171 DMFBZEI TI TT9NVXQ DMFBZEI TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMFBZEI MA Inhibitor DMFBZEI RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMFBZEI RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMFC0H5 DI DMFC0H5 DMFC0H5 DN 3-Methyl-2H-benzo[f]quinazolin-1-one DMFC0H5 TI TTU6BFZ DMFC0H5 TN Candida Thymidylate synthase (Candi TMP1) DMFC0H5 MA Inhibitor DMFC0H5 RN Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoylglutamate and related de... J Med Chem. 1993 Oct 29;36(22):3464-71. DMFC0H5 RU https://pubmed.ncbi.nlm.nih.gov/8230138 DMFC3B5 DI DMFC3B5 DMFC3B5 DN 2-phenyl-N-(1,3,4-thiadiazol-2-yl)acetamide DMFC3B5 TI TTSJ6Q4 DMFC3B5 TN LOX-5 messenger RNA (ALOX5 mRNA) DMFC3B5 MA Inhibitor DMFC3B5 RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMFC3B5 RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMFC3XI DI DMFC3XI DMFC3XI DN N-(quinolin-6-yl)-6-(sulfamoylamino)hexanamide DMFC3XI TI TT5ZKDI DMFC3XI TN Histone deacetylase 6 (HDAC6) DMFC3XI MA Inhibitor DMFC3XI RN Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. DMFC3XI RU https://pubmed.ncbi.nlm.nih.gov/19084395 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TT4N6D8 DMFC3XP TN GABA(A) receptor rho3 (GABRR3) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TT6XFEU DMFC3XP TN GABA(A) receptor rho1 (GABRR1) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TT37EDJ DMFC3XP TN GABA(A) receptor alpha-3 (GABRA3) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTBY4OD DMFC3XP TN GABA(A) receptor epsilon (GABRE) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 417). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=417 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTQMXLS DMFC3XP TN GABA(A) receptor rho2 (GABRR2) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTGXH6N DMFC3XP TN GABA(A) receptor delta (GABRD) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 416). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=416 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTXDUR9 DMFC3XP TN GABA(A) receptor theta (GABRQ) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 418). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=418 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTBMV1G DMFC3XP TN GABA(A) receptor alpha-2 (GABRA2) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TT06RH5 DMFC3XP TN GABA(A) receptor gamma-2 (GABRG2) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 414). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=414 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TT3E0DI DMFC3XP TN GABA(A) receptor pi (GABRP) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 419). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=419 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTEX6LM DMFC3XP TN GABA(A) receptor gamma-3 (GABRG3) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTNZPQ1 DMFC3XP TN GABA(A) receptor alpha-5 (GABRA5) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMFC3XP DI DMFC3XP DMFC3XP DN TBPS DMFC3XP TI TTZA1NY DMFC3XP TN GABA(A) receptor beta-2 (GABRB2) DMFC3XP MA Blocker (channel blocker) DMFC3XP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 411). DMFC3XP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=411 DMFC430 DI DMFC430 DMFC430 DN S-41744 DMFC430 TI TTZPO1L DMFC430 TN Substance-P receptor (TACR1) DMFC430 MA Antagonist DMFC430 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360). DMFC430 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360 DMFC564 DI DMFC564 DMFC564 DN N-(2-bromobenzoyloxy)-4-chlorobenzamide DMFC564 TI TT6804T DMFC564 TN MIF messenger RNA (MIF mRNA) DMFC564 MA Inhibitor DMFC564 RN An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. DMFC564 RU https://pubmed.ncbi.nlm.nih.gov/20639113 DMFC8Q4 DI DMFC8Q4 DMFC8Q4 DN 4-Pyridin-2-yl-piperazine-1-carboxylic acid amide DMFC8Q4 TI TTMI6F5 DMFC8Q4 TN Transient receptor potential cation channel V1 (TRPV1) DMFC8Q4 MA Inhibitor DMFC8Q4 RN N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6. DMFC8Q4 RU https://pubmed.ncbi.nlm.nih.gov/15026052 DMFC8Q4 DI DMFC8Q4 DMFC8Q4 DN 4-Pyridin-2-yl-piperazine-1-carboxylic acid amide DMFC8Q4 TI TTKP2SU DMFC8Q4 TN Transient receptor potential cation channel V4 (TRPV4) DMFC8Q4 MA Inhibitor DMFC8Q4 RN N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6. DMFC8Q4 RU https://pubmed.ncbi.nlm.nih.gov/15026052 DMFCA05 DI DMFCA05 DMFCA05 DN Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF DMFCA05 TI TTIND6G DMFCA05 TN Somatostatin receptor type 1 (SSTR1) DMFCA05 MA Inhibitor DMFCA05 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMFCA05 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMFCA05 DI DMFCA05 DMFCA05 DN Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]Cbm-SRIF DMFCA05 TI TTAE1BR DMFCA05 TN Somatostatin receptor type 4 (SSTR4) DMFCA05 MA Inhibitor DMFCA05 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMFCA05 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMFCB7L DI DMFCB7L DMFCB7L DN 4-Butoxy-N-hydroxy-N-methyl-benzamide DMFCB7L TI TT2J34L DMFCB7L TN Arachidonate 5-lipoxygenase (5-LOX) DMFCB7L MA Inhibitor DMFCB7L RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMFCB7L RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMFCOA5 DI DMFCOA5 DMFCOA5 DN ISIS 134524 DMFCOA5 TI TTKW4ML DMFCOA5 TN Caspase 6 messenger RNA (CASP6 mRNA) DMFCOA5 RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMFCOA5 RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMFCS8G DI DMFCS8G DMFCS8G DN 4-(2-(4-Methoxyphenylamino)ethyl)-1H-imidazole DMFCS8G TI TT9JNIC DMFCS8G TN Histamine H3 receptor (H3R) DMFCS8G MA Inhibitor DMFCS8G RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMFCS8G RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMFCUN4 DI DMFCUN4 DMFCUN4 DN M6S DMFCUN4 TI TTKWM86 DMFCUN4 TN Opioid receptor mu (MOP) DMFCUN4 MA Inhibitor DMFCUN4 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMFCUN4 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMFCUN4 DI DMFCUN4 DMFCUN4 DN M6S DMFCUN4 TI TTQW87Y DMFCUN4 TN Opioid receptor kappa (OPRK1) DMFCUN4 MA Inhibitor DMFCUN4 RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMFCUN4 RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMFDCJK DI DMFDCJK DMFDCJK DN [3H]PSB-11 DMFDCJK TI TTJFY5U DMFDCJK TN Adenosine A3 receptor (ADORA3) DMFDCJK MA Antagonist DMFDCJK RN [(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):501-3. DMFDCJK RU https://pubmed.ncbi.nlm.nih.gov/11814828 DMFDK4N DI DMFDK4N DMFDK4N DN 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl DMFDK4N TI TTNGILX DMFDK4N TN Adrenergic receptor alpha-1A (ADRA1A) DMFDK4N MA Inhibitor DMFDK4N RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMFDK4N RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMFDK4N DI DMFDK4N DMFDK4N DN 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl DMFDK4N TI TT34BHT DMFDK4N TN Adrenergic receptor alpha-1D (ADRA1D) DMFDK4N MA Inhibitor DMFDK4N RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMFDK4N RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMFDK4N DI DMFDK4N DMFDK4N DN 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl DMFDK4N TI TTWM4TY DMFDK4N TN Adrenergic receptor alpha-2B (ADRA2B) DMFDK4N MA Inhibitor DMFDK4N RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMFDK4N RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMFDK4N DI DMFDK4N DMFDK4N DN 1',2',3',6'-Tetrahydro-[2,4']bipyridinyl DMFDK4N TI TTWG9A4 DMFDK4N TN Adrenergic receptor alpha-2A (ADRA2A) DMFDK4N MA Inhibitor DMFDK4N RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMFDK4N RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMFDRMH DI DMFDRMH DMFDRMH DN PMID16242323C22c DMFDRMH TI TTK3C21 DMFDRMH TN Acetoacetyl-CoA thiolase (ACAT1) DMFDRMH MA Inhibitor DMFDRMH RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMFDRMH RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMFDROW DI DMFDROW DMFDROW DN Thieno-phenanthridin-6-one DMFDROW TI TTVDSZ0 DMFDROW TN Poly [ADP-ribose] polymerase 1 (PARP1) DMFDROW MA Inhibitor DMFDROW RN Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005 May;4(5):421-40. DMFDROW RU https://pubmed.ncbi.nlm.nih.gov/15864271 DMFDW4C DI DMFDW4C DMFDW4C DN (R)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol DMFDW4C TI TT9JNIC DMFDW4C TN Histamine H3 receptor (H3R) DMFDW4C MA Inhibitor DMFDW4C RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMFDW4C RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMFDXLB DI DMFDXLB DMFDXLB DN N,N'-Bis-(4-sec-butyl-phenyl)-guanidine DMFDXLB TI TTLD29N DMFDXLB TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMFDXLB MA Inhibitor DMFDXLB RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMFDXLB RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMFDXLB DI DMFDXLB DMFDXLB DN N,N'-Bis-(4-sec-butyl-phenyl)-guanidine DMFDXLB TI TTN9D8E DMFDXLB TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMFDXLB MA Inhibitor DMFDXLB RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMFDXLB RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMFDXLB DI DMFDXLB DMFDXLB DN N,N'-Bis-(4-sec-butyl-phenyl)-guanidine DMFDXLB TI TTKJEMQ DMFDXLB TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMFDXLB MA Inhibitor DMFDXLB RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMFDXLB RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMFE2R1 DI DMFE2R1 DMFE2R1 DN 2-phenyl-2H-pyrazolo[3,4-c]quinolin-4(5H)-one DMFE2R1 TI TTK25J1 DMFE2R1 TN Adenosine A1 receptor (ADORA1) DMFE2R1 MA Inhibitor DMFE2R1 RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DMFE2R1 RU https://pubmed.ncbi.nlm.nih.gov/17665891 DMFE3J4 DI DMFE3J4 DMFE3J4 DN H-Aba-ser-Gly-Phe-Leu-Thr-OH DMFE3J4 TI TTKWM86 DMFE3J4 TN Opioid receptor mu (MOP) DMFE3J4 MA Inhibitor DMFE3J4 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMFE3J4 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMFE3J4 DI DMFE3J4 DMFE3J4 DN H-Aba-ser-Gly-Phe-Leu-Thr-OH DMFE3J4 TI TT27RFC DMFE3J4 TN Opioid receptor delta (OPRD1) DMFE3J4 MA Inhibitor DMFE3J4 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMFE3J4 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMFE3YK DI DMFE3YK DMFE3YK DN (-)-SNAP-5399 DMFE3YK TI TTNGILX DMFE3YK TN Adrenergic receptor alpha-1A (ADRA1A) DMFE3YK MA Inhibitor DMFE3YK RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMFE3YK RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMFE5GX DI DMFE5GX DMFE5GX DN CPFPX DMFE5GX TI TTNE7KG DMFE5GX TN Adenosine A2b receptor (ADORA2B) DMFE5GX MA Antagonist DMFE5GX RN Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002 Nov 7;45(23):5150-6. DMFE5GX RU https://pubmed.ncbi.nlm.nih.gov/12408725 DMFE5GX DI DMFE5GX DMFE5GX DN CPFPX DMFE5GX TI TTK25J1 DMFE5GX TN Adenosine A1 receptor (ADORA1) DMFE5GX MA Antagonist DMFE5GX RN Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. J Med Chem. 2002 Nov 7;45(23):5150-6. DMFE5GX RU https://pubmed.ncbi.nlm.nih.gov/12408725 DMFE93N DI DMFE93N DMFE93N DN 2-(4-chlorobenzylidene)cyclopentyl ethyl ether DMFE93N TI TT5ZWB6 DMFE93N TN Dihydrodiol dehydrogenase type I (AKR1C3) DMFE93N MA Inhibitor DMFE93N RN New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71. DMFE93N RU https://pubmed.ncbi.nlm.nih.gov/19237229 DMFEBCO DI DMFEBCO DMFEBCO DN 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole DMFEBCO TI TTR5TV4 DMFEBCO TN ERBB2 messenger RNA (HER2 mRNA) DMFEBCO MA Inhibitor DMFEBCO RN Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. DMFEBCO RU https://pubmed.ncbi.nlm.nih.gov/17174554 DMFECXI DI DMFECXI DMFECXI DN 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol DMFECXI TI TTOM3J0 DMFECXI TN Estrogen receptor beta (ESR2) DMFECXI MA Inhibitor DMFECXI RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMFECXI RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMFECXI DI DMFECXI DMFECXI DN 4,6,7-trimethyl-6H-benzo[c]chromene-3,8-diol DMFECXI TI TTZAYWL DMFECXI TN Estrogen receptor (ESR) DMFECXI MA Inhibitor DMFECXI RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMFECXI RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMFEGPX DI DMFEGPX DMFEGPX DN (S)-2-Amino-2-phenyl-ethanethiol DMFEGPX TI TTPHMWB DMFEGPX TN Aminopeptidase N (ANPEP) DMFEGPX MA Inhibitor DMFEGPX RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMFEGPX RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMFEGYB DI DMFEGYB DMFEGYB DN NSC-65069 DMFEGYB TI TT8XK6L DMFEGYB TN Quinone reductase 1 (NQO1) DMFEGYB MA Inhibitor DMFEGYB RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMFEGYB RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMFEHDY DI DMFEHDY DMFEHDY DN 3-(2-N-Piperidyl-propionamino)-rutaecarpine DMFEHDY TI TTEB0GD DMFEHDY TN Cholinesterase (BCHE) DMFEHDY MA Inhibitor DMFEHDY RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DMFEHDY RU https://pubmed.ncbi.nlm.nih.gov/20079560 DMFEHDY DI DMFEHDY DMFEHDY DN 3-(2-N-Piperidyl-propionamino)-rutaecarpine DMFEHDY TI TT1RS9F DMFEHDY TN Acetylcholinesterase (AChE) DMFEHDY MA Inhibitor DMFEHDY RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DMFEHDY RU https://pubmed.ncbi.nlm.nih.gov/20079560 DMFEL39 DI DMFEL39 DMFEL39 DN 3-methoxy-N-(1,3,4-thiadiazol-2-yl)benzamide DMFEL39 TI TTSJ6Q4 DMFEL39 TN LOX-5 messenger RNA (ALOX5 mRNA) DMFEL39 MA Inhibitor DMFEL39 RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMFEL39 RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMFEQ6S DI DMFEQ6S DMFEQ6S DN 3,5-DHPG DMFEQ6S TI TTHS256 DMFEQ6S TN Metabotropic glutamate receptor 5 (mGluR5) DMFEQ6S MA Agonist DMFEQ6S RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMFEQ6S RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMFEQ6S DI DMFEQ6S DMFEQ6S DN 3,5-DHPG DMFEQ6S TI TTVBPDM DMFEQ6S TN Metabotropic glutamate receptor 1 (mGluR1) DMFEQ6S MA Agonist DMFEQ6S RN [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93. DMFEQ6S RU https://pubmed.ncbi.nlm.nih.gov/12695537 DMFETRH DI DMFETRH DMFETRH DN 2-(3-Bromophenylthio)-N,N-dimethylethanamine DMFETRH TI TTSQIFT DMFETRH TN 5-HT 1A receptor (HTR1A) DMFETRH MA Inhibitor DMFETRH RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DMFETRH RU https://pubmed.ncbi.nlm.nih.gov/20138771 DMFEYLS DI DMFEYLS DMFEYLS DN [3H]GlySar DMFEYLS TI TT5LF3C DMFEYLS TN Solute carrier family 15 member 1 (SLC15A1) DMFEYLS MA Modulator DMFEYLS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 984). DMFEYLS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=984 DMFEYLS DI DMFEYLS DMFEYLS DN [3H]GlySar DMFEYLS TI TT27Q3A DMFEYLS TN Solute carrier family 15 member 2 (SLC15A2) DMFEYLS MA Modulator DMFEYLS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985). DMFEYLS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985 DMFEZHM DI DMFEZHM DMFEZHM DN ISIS 116360 DMFEZHM TI TTGECUM DMFEZHM TN Cot oncogene messenger RNA (MAP3K8 mRNA) DMFEZHM RN US patent application no. 6,265,216, Antisense modulation of cot oncogene expression. DMFEZHM RU http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true DMFG0XS DI DMFG0XS DMFG0XS DN CR-2345 DMFG0XS TI TTCG0AL DMFG0XS TN Cholecystokinin receptor type A (CCKAR) DMFG0XS MA Inhibitor DMFG0XS RN Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists, Bioorg. Med. Chem. Lett. 3(5):861-866 (1993). DMFG0XS RU http://www.sciencedirect.com/science/article/pii/S0960894X00806812 DMFG2S5 DI DMFG2S5 DMFG2S5 DN 2-(2-chlorophenyl)-2-morpholinoethanamine DMFG2S5 TI TTDIGC1 DMFG2S5 TN Dipeptidyl peptidase 4 (DPP-4) DMFG2S5 MA Inhibitor DMFG2S5 RN In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9. DMFG2S5 RU https://pubmed.ncbi.nlm.nih.gov/16321524 DMFG6MU DI DMFG6MU DMFG6MU DN N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine DMFG6MU TI TTFZVPO DMFG6MU TN Sodium/hydrogen exchanger 3 (SLC9A3) DMFG6MU MA Inhibitor DMFG6MU RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMFG6MU RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMFG6MU DI DMFG6MU DMFG6MU DN N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine DMFG6MU TI TTGSEFH DMFG6MU TN Sodium/hydrogen exchanger 1 (SLC9A1) DMFG6MU MA Inhibitor DMFG6MU RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMFG6MU RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMFGCS1 DI DMFGCS1 DMFGCS1 DN 2-(4-benzyl-piperidin-1-ylmethyl)-1H-indol-6-ol DMFGCS1 TI TTN9D8E DMFGCS1 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMFGCS1 MA Inhibitor DMFGCS1 RN Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem. 2007 Mar 8;50(5):901-14. DMFGCS1 RU https://pubmed.ncbi.nlm.nih.gov/17290978 DMFGO4W DI DMFGO4W DMFGO4W DN [Tyr-Pro-Phe-Phe-NH-CH2-]2 DMFGO4W TI TTKWM86 DMFGO4W TN Opioid receptor mu (MOP) DMFGO4W MA Inhibitor DMFGO4W RN Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50. DMFGO4W RU https://pubmed.ncbi.nlm.nih.gov/15780619 DMFGOW0 DI DMFGOW0 DMFGOW0 DN NAAG DMFGOW0 TI TT8A9EF DMFGOW0 TN Metabotropic glutamate receptor 3 (mGluR3) DMFGOW0 MA Agonist DMFGOW0 RN Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6. DMFGOW0 RU https://pubmed.ncbi.nlm.nih.gov/10884552 DMFGQ02 DI DMFGQ02 DMFGQ02 DN 4,4'-Biphenyldiboronic Acid DMFGQ02 TI TTHI19T DMFGQ02 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMFGQ02 MA Inhibitor DMFGQ02 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFGQ02 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFGQ7K DI DMFGQ7K DMFGQ7K DN 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide DMFGQ7K TI TTHQPL7 DMFGQ7K TN Carbonic anhydrase I (CA-I) DMFGQ7K MA Inhibitor DMFGQ7K RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMFGQ7K RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMFGQ7K DI DMFGQ7K DMFGQ7K DN 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide DMFGQ7K TI TT2LVK8 DMFGQ7K TN Carbonic anhydrase IX (CA-IX) DMFGQ7K MA Inhibitor DMFGQ7K RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMFGQ7K RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMFGQ7K DI DMFGQ7K DMFGQ7K DN 2-(4-chlorobenzyloxyamino)-N-hydroxyhexanamide DMFGQ7K TI TTANPDJ DMFGQ7K TN Carbonic anhydrase II (CA-II) DMFGQ7K MA Inhibitor DMFGQ7K RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMFGQ7K RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMFGSLO DI DMFGSLO DMFGSLO DN N-(Chlorophenyl)-N'-Hydroxyguanidine DMFGSLO TI TTCM4B3 DMFGSLO TN Nitric-oxide synthase endothelial (NOS3) DMFGSLO MA Inhibitor DMFGSLO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMFGSLO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMFGUCY DI DMFGUCY DMFGUCY DN 8-PHENYL THEOPHYLLINE DMFGUCY TI TTM2AOE DMFGUCY TN Adenosine A2a receptor (ADORA2A) DMFGUCY MA Inhibitor DMFGUCY RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMFGUCY RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMFGUCY DI DMFGUCY DMFGUCY DN 8-PHENYL THEOPHYLLINE DMFGUCY TI TTNE7KG DMFGUCY TN Adenosine A2b receptor (ADORA2B) DMFGUCY MA Inhibitor DMFGUCY RN 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9. DMFGUCY RU https://pubmed.ncbi.nlm.nih.gov/11170626 DMFGUCY DI DMFGUCY DMFGUCY DN 8-PHENYL THEOPHYLLINE DMFGUCY TI TTK25J1 DMFGUCY TN Adenosine A1 receptor (ADORA1) DMFGUCY MA Inhibitor DMFGUCY RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMFGUCY RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMFGUCY DI DMFGUCY DMFGUCY DN 8-PHENYL THEOPHYLLINE DMFGUCY TI TTJFY5U DMFGUCY TN Adenosine A3 receptor (ADORA3) DMFGUCY MA Inhibitor DMFGUCY RN Adenosine receptors: targets for future drugs. J Med Chem. 1982 Mar;25(3):197-207. DMFGUCY RU https://pubmed.ncbi.nlm.nih.gov/6279840 DMFGUXZ DI DMFGUXZ DMFGUXZ DN 1-(oxazolo[4,5-b]pyridin-2-yl)octan-1-one DMFGUXZ TI TTDP1UC DMFGUXZ TN Fatty acid amide hydrolase (FAAH) DMFGUXZ MA Inhibitor DMFGUXZ RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMFGUXZ RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMFH5J9 DI DMFH5J9 DMFH5J9 DN cooling agent 10 DMFH5J9 TI TTXDKTO DMFH5J9 TN Long transient receptor potential channel 8 (TRPM8) DMFH5J9 MA Activator DMFH5J9 RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMFH5J9 RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMFH79T DI DMFH79T DMFH79T DN UNIFLORINE B DMFH79T TI TTLPC70 DMFH79T TN Lysosomal alpha-glucosidase (GAA) DMFH79T MA Inhibitor DMFH79T RN Total synthesis of (-)-uniflorine A. J Nat Prod. 2009 Nov;72(11):2058-60. DMFH79T RU https://pubmed.ncbi.nlm.nih.gov/19835391 DMFHBJM DI DMFHBJM DMFHBJM DN 1-[5-(triphenylmethoxy)pentyl]thymine DMFHBJM TI TT7KNZQ DMFHBJM TN Thymidine kinase 2 (Mt-TK2) DMFHBJM MA Inhibitor DMFHBJM RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DMFHBJM RU https://pubmed.ncbi.nlm.nih.gov/17181158 DMFHBJM DI DMFHBJM DMFHBJM DN 1-[5-(triphenylmethoxy)pentyl]thymine DMFHBJM TI TTP3QRF DMFHBJM TN Thymidine kinase 1 (TK1) DMFHBJM MA Inhibitor DMFHBJM RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DMFHBJM RU https://pubmed.ncbi.nlm.nih.gov/17181158 DMFHCV9 DI DMFHCV9 DMFHCV9 DN hydroxycitronellal DMFHCV9 TI TTXDKTO DMFHCV9 TN Long transient receptor potential channel 8 (TRPM8) DMFHCV9 MA Activator DMFHCV9 RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMFHCV9 RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMFHDWG DI DMFHDWG DMFHDWG DN 5,7-dichloro-1H-indole-2,3-dione DMFHDWG TI TTMF541 DMFHDWG TN Liver carboxylesterase (CES1) DMFHDWG MA Inhibitor DMFHDWG RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMFHDWG RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMFHS4V DI DMFHS4V DMFHS4V DN PMID20638279C11 DMFHS4V TI TTICZ1O DMFHS4V TN Metabotropic glutamate receptor 4 (mGluR4) DMFHS4V MA Modulator (allosteric modulator) DMFHS4V RN An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4901-5. DMFHS4V RU https://pubmed.ncbi.nlm.nih.gov/20638279 DMFHT3U DI DMFHT3U DMFHT3U DN LY334362 DMFHT3U TI TTWJBZ5 DMFHT3U TN 5-HT 2C receptor (HTR2C) DMFHT3U MA Antagonist DMFHT3U RN A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68. DMFHT3U RU https://pubmed.ncbi.nlm.nih.gov/8845011 DMFHTEG DI DMFHTEG DMFHTEG DN 2-morpholino-1,1,2-triphenylethanol DMFHTEG TI TTW0CMT DMFHTEG TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMFHTEG MA Inhibitor DMFHTEG RN Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. DMFHTEG RU https://pubmed.ncbi.nlm.nih.gov/20304642 DMFHUGC DI DMFHUGC DMFHUGC DN SB 269970-A DMFHUGC TI TTO9X1H DMFHUGC TN 5-HT 7 receptor (HTR7) DMFHUGC MA Antagonist DMFHUGC RN 5-HT7 receptors. Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):81-90. DMFHUGC RU https://pubmed.ncbi.nlm.nih.gov/14965246 DMFHY04 DI DMFHY04 DMFHY04 DN BIX 02188 DMFHY04 TI TTV3O87 DMFHY04 TN ERK activator kinase 5 (MAP2K5) DMFHY04 MA Inhibitor DMFHY04 RN Identification of pharmacological inhibitors of the MEK5/ERK5 pathway. Biochem Biophys Res Commun. 2008 Dec 5;377(1):120-5. DMFHY04 RU https://pubmed.ncbi.nlm.nih.gov/18834865 DMFHYAE DI DMFHYAE DMFHYAE DN 3-noradamantyl-1,3-dipropylxanthine DMFHYAE TI TTK25J1 DMFHYAE TN Adenosine A1 receptor (ADORA1) DMFHYAE MA Inhibitor DMFHYAE RN Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. DMFHYAE RU https://pubmed.ncbi.nlm.nih.gov/17125264 DMFHYAE DI DMFHYAE DMFHYAE DN 3-noradamantyl-1,3-dipropylxanthine DMFHYAE TI TTNE7KG DMFHYAE TN Adenosine A2b receptor (ADORA2B) DMFHYAE MA Inhibitor DMFHYAE RN Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. DMFHYAE RU https://pubmed.ncbi.nlm.nih.gov/17125264 DMFHYAE DI DMFHYAE DMFHYAE DN 3-noradamantyl-1,3-dipropylxanthine DMFHYAE TI TTM2AOE DMFHYAE TN Adenosine A2a receptor (ADORA2A) DMFHYAE MA Inhibitor DMFHYAE RN Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. DMFHYAE RU https://pubmed.ncbi.nlm.nih.gov/17125264 DMFHYAE DI DMFHYAE DMFHYAE DN 3-noradamantyl-1,3-dipropylxanthine DMFHYAE TI TTJFY5U DMFHYAE TN Adenosine A3 receptor (ADORA3) DMFHYAE MA Inhibitor DMFHYAE RN Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem. 2006 Nov 30;49(24):7119-31. DMFHYAE RU https://pubmed.ncbi.nlm.nih.gov/17125264 DMFI057 DI DMFI057 DMFI057 DN N-(5-methylthiazol-2-yl)benzamide DMFI057 TI TTSJ6Q4 DMFI057 TN LOX-5 messenger RNA (ALOX5 mRNA) DMFI057 MA Inhibitor DMFI057 RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMFI057 RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMFI4J6 DI DMFI4J6 DMFI4J6 DN PMID15261275C1 DMFI4J6 TI TT60Q8D DMFI4J6 TN Orexin receptor type 1 (HCRTR1) DMFI4J6 MA Antagonist DMFI4J6 RN Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4225-9. DMFI4J6 RU https://pubmed.ncbi.nlm.nih.gov/15261275 DMFI4J6 DI DMFI4J6 DMFI4J6 DN PMID15261275C1 DMFI4J6 TI TT9N02I DMFI4J6 TN Orexin receptor type 2 (HCRTR2) DMFI4J6 MA Antagonist DMFI4J6 RN Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4225-9. DMFI4J6 RU https://pubmed.ncbi.nlm.nih.gov/15261275 DMFI7A8 DI DMFI7A8 DMFI7A8 DN 6-Benzyloxy-9H-purin-2-ylamine DMFI7A8 TI TTJ8DV7 DMFI7A8 TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DMFI7A8 MA Inhibitor DMFI7A8 RN Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8. DMFI7A8 RU https://pubmed.ncbi.nlm.nih.gov/9484500 DMFIDA0 DI DMFIDA0 DMFIDA0 DN BD-1047 DMFIDA0 TI TT5TPI6 DMFIDA0 TN Opioid receptor sigma 1 (OPRS1) DMFIDA0 MA Antagonist DMFIDA0 RN Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol. 1995 Jul 14;280(3):301-10. DMFIDA0 RU https://pubmed.ncbi.nlm.nih.gov/8566098 DMFIDJS DI DMFIDJS DMFIDJS DN Lobatamide C DMFIDJS TI TTTK3BH DMFIDJS TN Vacuolar-type proton ATPase (v-ATPase) DMFIDJS MA Inhibitor DMFIDJS RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DMFIDJS RU https://pubmed.ncbi.nlm.nih.gov/11259534 DMFIE0U DI DMFIE0U DMFIE0U DN NTE-1 DMFIE0U TI TT2EDHU DMFIE0U TN Insulin-degrading enzyme (IDE) DMFIE0U MA Inhibitor DMFIE0U RN Dual Exosite-binding Inhibitors of Insulin-degrading Enzyme Challenge Its Role as the Primary Mediator of Insulin Clearance in Vivo. J Biol Chem. 2015 Aug 14;290(33):20044-59. DMFIE0U RU https://pubmed.ncbi.nlm.nih.gov/26085101 DMFIPXA DI DMFIPXA DMFIPXA DN Tyr-Pro-Trp-D-Ala-Bn DMFIPXA TI TTKWM86 DMFIPXA TN Opioid receptor mu (MOP) DMFIPXA MA Inhibitor DMFIPXA RN Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. DMFIPXA RU https://pubmed.ncbi.nlm.nih.gov/19679474 DMFIQGW DI DMFIQGW DMFIQGW DN ISIS 109355 DMFIQGW TI TT1MS7X DMFIQGW TN PKC-theta messenger RNA (PRKCQ mRNA) DMFIQGW RN US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression. DMFIQGW RU http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true DMFIWAN DI DMFIWAN DMFIWAN DN NPPB DMFIWAN TI TTST1AJ DMFIWAN TN Chloride channel protein 7 (ClC-7) DMFIWAN MA Blocker (channel blocker) DMFIWAN RN The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One. 2010 Sep 7;5(9):e12585. DMFIWAN RU https://pubmed.ncbi.nlm.nih.gov/20830208 DMFIWAN DI DMFIWAN DMFIWAN DN NPPB DMFIWAN TI TT30NW6 DMFIWAN TN Chloride channel protein 2 (CLC-2) DMFIWAN MA Blocker (channel blocker) DMFIWAN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 699). DMFIWAN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=699 DMFIWAN DI DMFIWAN DMFIWAN DN NPPB DMFIWAN TI TTELV3W DMFIWAN TN Transformation-sensitive protein p120 (TRPA1) DMFIWAN MA Activator DMFIWAN RN NPPB structure-specifically activates TRPA1 channels. Biochem Pharmacol. 2010 Jul 1;80(1):113-21. DMFIWAN RU https://pubmed.ncbi.nlm.nih.gov/20226176 DMFIWAN DI DMFIWAN DMFIWAN DN NPPB DMFIWAN TI TT0FC1V DMFIWAN TN Volume regulated chloride channel (VRAC) DMFIWAN MA Blocker (channel blocker) DMFIWAN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DMFIWAN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DMFIWAN DI DMFIWAN DMFIWAN DN NPPB DMFIWAN TI TTOJI4S DMFIWAN TN Calcium-dependent chloride channel anoctamin (ANO) DMFIWAN MA Blocker (channel blocker) DMFIWAN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708). DMFIWAN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708 DMFIWAN DI DMFIWAN DMFIWAN DN NPPB DMFIWAN TI TTT1MCF DMFIWAN TN Permeability pathway (NP pathway) DMFIWAN MA Inhibitor DMFIWAN RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMFIWAN RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMFJ1EI DI DMFJ1EI DMFJ1EI DN G3139 + Dacarbazine DMFJ1EI TI TTFOUV4 DMFJ1EI TN BCL-2 messenger RNA (BCL2 mRNA) DMFJ1EI RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMFJ1EI RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMFJ3VC DI DMFJ3VC DMFJ3VC DN DY131 DMFJ3VC TI TT9ZRHB DMFJ3VC TN Estrogen-related receptor-gamma (ESRRG) DMFJ3VC MA Agonist DMFJ3VC RN Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. J Med Chem. 2005 May 5;48(9):3107-9. DMFJ3VC RU https://pubmed.ncbi.nlm.nih.gov/15857113 DMFJ3VC DI DMFJ3VC DMFJ3VC DN DY131 DMFJ3VC TI TTKF0XS DMFJ3VC TN Estrogen-related receptor-beta (ESRRB) DMFJ3VC MA Agonist DMFJ3VC RN Identification of an agonist ligand for estrogen-related receptors ERRbeta/gamma. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1311-3. DMFJ3VC RU https://pubmed.ncbi.nlm.nih.gov/15713377 DMFJ9N0 DI DMFJ9N0 DMFJ9N0 DN 3,3-Diethyl-dihydro-furan-2-one DMFJ9N0 TI TT1MPAY DMFJ9N0 TN GABA(A) receptor alpha-1 (GABRA1) DMFJ9N0 MA Inhibitor DMFJ9N0 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMFJ9N0 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMFJ9N0 DI DMFJ9N0 DMFJ9N0 DN 3,3-Diethyl-dihydro-furan-2-one DMFJ9N0 TI TTZA1NY DMFJ9N0 TN GABA(A) receptor beta-2 (GABRB2) DMFJ9N0 MA Inhibitor DMFJ9N0 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMFJ9N0 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMFJ9N0 DI DMFJ9N0 DMFJ9N0 DN 3,3-Diethyl-dihydro-furan-2-one DMFJ9N0 TI TTNJYV2 DMFJ9N0 TN Gamma-aminobutyric acid receptor (GAR) DMFJ9N0 MA Inhibitor DMFJ9N0 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMFJ9N0 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMFJ9N0 DI DMFJ9N0 DMFJ9N0 DN 3,3-Diethyl-dihydro-furan-2-one DMFJ9N0 TI TT06RH5 DMFJ9N0 TN GABA(A) receptor gamma-2 (GABRG2) DMFJ9N0 MA Inhibitor DMFJ9N0 RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMFJ9N0 RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMFJES5 DI DMFJES5 DMFJES5 DN ISIS 100750 DMFJES5 TI TTVXEGU DMFJES5 TN ADAM10 messenger RNA (ADAM10 mRNA) DMFJES5 RN US patent application no. 6,228,648, Antisense modulation of ADAM10 expression. DMFJES5 RU http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true DMFJHMQ DI DMFJHMQ DMFJHMQ DN MRS1486 DMFJHMQ TI TTJFY5U DMFJHMQ TN Adenosine A3 receptor (ADORA3) DMFJHMQ MA Antagonist DMFJHMQ RN Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201. DMFJHMQ RU https://pubmed.ncbi.nlm.nih.gov/9703464 DMFJLWO DI DMFJLWO DMFJLWO DN 3-Hydroxy-Myristic Acid DMFJLWO TI TT8S9AV DMFJLWO TN Lymphocyte antigen 96 (LY96) DMFJLWO MA Inhibitor DMFJLWO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFJLWO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFJLWO DI DMFJLWO DMFJLWO DN 3-Hydroxy-Myristic Acid DMFJLWO TI TTISGCA DMFJLWO TN Toll-like receptor 4 (TLR4) DMFJLWO MA Inhibitor DMFJLWO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFJLWO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFJOHG DI DMFJOHG DMFJOHG DN 2-[125I]melatonin DMFJOHG TI TT0WAIE DMFJOHG TN Melatonin receptor type 1A (MTNR1A) DMFJOHG MA Agonist DMFJOHG RN Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75. DMFJOHG RU https://pubmed.ncbi.nlm.nih.gov/9089668 DMFJR0S DI DMFJR0S DMFJR0S DN Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester DMFJR0S TI TT2LVK8 DMFJR0S TN Carbonic anhydrase IX (CA-IX) DMFJR0S MA Inhibitor DMFJR0S RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMFJR0S RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMFJR0S DI DMFJR0S DMFJR0S DN Sulfamic acid 4-sulfamoyloxymethyl-benzyl ester DMFJR0S TI TTANPDJ DMFJR0S TN Carbonic anhydrase II (CA-II) DMFJR0S MA Inhibitor DMFJR0S RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMFJR0S RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMFJW2E DI DMFJW2E DMFJW2E DN 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine DMFJW2E TI TTQBR95 DMFJW2E TN Stress-activated protein kinase 2a (p38 alpha) DMFJW2E MA Inhibitor DMFJW2E RN Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (T... J Med Chem. 2005 Sep 22;48(19):5966-79. DMFJW2E RU https://pubmed.ncbi.nlm.nih.gov/16162000 DMFK0GM DI DMFK0GM DMFK0GM DN 2-(2-bromo-2-naphthamido)benzoic acid DMFK0GM TI TT3PQ2Y DMFK0GM TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMFK0GM MA Inhibitor DMFK0GM RN The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Jan 1;16(1):88-92. DMFK0GM RU https://pubmed.ncbi.nlm.nih.gov/16236496 DMFK7O1 DI DMFK7O1 DMFK7O1 DN (S)-2-amino-1-(4-ethylthiophenyl)-propane DMFK7O1 TI TT3WG5C DMFK7O1 TN Monoamine oxidase type A (MAO-A) DMFK7O1 MA Inhibitor DMFK7O1 RN Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206. DMFK7O1 RU https://pubmed.ncbi.nlm.nih.gov/17521909 DMFK9GA DI DMFK9GA DMFK9GA DN 2-(1H-Imidazol-1-yl)-1-(4-nitrophenyl)ethanone DMFK9GA TI TTSZLWK DMFK9GA TN Aromatase (CYP19A1) DMFK9GA MA Inhibitor DMFK9GA RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMFK9GA RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMFK9V5 DI DMFK9V5 DMFK9V5 DN [HO1][Orn8(5/6C-Flu)]VT DMFK9V5 TI TT4TFGN DMFK9V5 TN Vasopressin V1a receptor (V1AR) DMFK9V5 MA Inhibitor DMFK9V5 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMFK9V5 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMFK9V5 DI DMFK9V5 DMFK9V5 DN [HO1][Orn8(5/6C-Flu)]VT DMFK9V5 TI TTL9MHW DMFK9V5 TN Vasopressin V1b receptor (V1BR) DMFK9V5 MA Inhibitor DMFK9V5 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMFK9V5 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMFK9V5 DI DMFK9V5 DMFK9V5 DN [HO1][Orn8(5/6C-Flu)]VT DMFK9V5 TI TTSCIUP DMFK9V5 TN Oxytocin receptor (OTR) DMFK9V5 MA Inhibitor DMFK9V5 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMFK9V5 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMFKE6C DI DMFKE6C DMFKE6C DN SEL-73 DMFKE6C TI TTO9X1H DMFKE6C TN 5-HT 7 receptor (HTR7) DMFKE6C MA Modulator DMFKE6C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 12). DMFKE6C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=12 DMFKE6C DI DMFKE6C DMFKE6C DN SEL-73 DMFKE6C TI TTEX248 DMFKE6C TN Dopamine D2 receptor (D2R) DMFKE6C MA Modulator DMFKE6C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 215). DMFKE6C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215 DMFKE6C DI DMFKE6C DMFKE6C DN SEL-73 DMFKE6C TI TTSQIFT DMFKE6C TN 5-HT 1A receptor (HTR1A) DMFKE6C MA Modulator DMFKE6C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1). DMFKE6C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1 DMFKE6C DI DMFKE6C DMFKE6C DN SEL-73 DMFKE6C TI TTJQOD7 DMFKE6C TN 5-HT 2A receptor (HTR2A) DMFKE6C MA Modulator DMFKE6C RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMFKE6C RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMFKE6C DI DMFKE6C DMFKE6C DN SEL-73 DMFKE6C TI TTJS8PY DMFKE6C TN 5-HT 6 receptor (HTR6) DMFKE6C MA Modulator DMFKE6C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11). DMFKE6C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11 DMFKG7C DI DMFKG7C DMFKG7C DN MP-RM-1 DMFKG7C TI TTDC8N2 DMFKG7C TN Erbb3 tyrosine kinase receptor (Erbb-3) DMFKG7C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). DMFKG7C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798 DMFKLUS DI DMFKLUS DMFKLUS DN ISIS 32006 DMFKLUS TI TT9H4P3 DMFKLUS TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMFKLUS RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMFKLUS RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMFKMYV DI DMFKMYV DMFKMYV DN 5-butyl-6-chloropyrimidine-2,4(1H,3H)-dione DMFKMYV TI TTO0IB8 DMFKMYV TN Thymidine phosphorylase (TYMP) DMFKMYV MA Inhibitor DMFKMYV RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DMFKMYV RU https://pubmed.ncbi.nlm.nih.gov/17963370 DMFKN1M DI DMFKN1M DMFKN1M DN 4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide DMFKN1M TI TTJFY5U DMFKN1M TN Adenosine A3 receptor (ADORA3) DMFKN1M MA Inhibitor DMFKN1M RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMFKN1M RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMFKN1M DI DMFKN1M DMFKN1M DN 4-Methoxy-N-(3-phenyl-isoquinolin-1-yl)-benzamide DMFKN1M TI TTK25J1 DMFKN1M TN Adenosine A1 receptor (ADORA1) DMFKN1M MA Inhibitor DMFKN1M RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMFKN1M RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMFKQ0B DI DMFKQ0B DMFKQ0B DN Isorhamnetin 3,7-disulfate DMFKQ0B TI TTFBNVI DMFKQ0B TN Aldose reductase (AKR1B1) DMFKQ0B MA Inhibitor DMFKQ0B RN Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5. DMFKQ0B RU https://pubmed.ncbi.nlm.nih.gov/8699190 DMFKQ1W DI DMFKQ1W DMFKQ1W DN T-98475 DMFKQ1W TI TT8R70G DMFKQ1W TN Gonadotropin-releasing hormone receptor (GNRHR) DMFKQ1W MA Inhibitor DMFKQ1W RN Non-peptide gonadotropin-releasing hormone receptor antagonists. J Med Chem. 2008 Jun 26;51(12):3331-48. DMFKQ1W RU https://pubmed.ncbi.nlm.nih.gov/18419112 DMFKRIH DI DMFKRIH DMFKRIH DN Acetic acid 2-pentylsulfanyl-phenyl ester DMFKRIH TI TT8NGED DMFKRIH TN Prostaglandin G/H synthase 1 (COX-1) DMFKRIH MA Inhibitor DMFKRIH RN Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18. DMFKRIH RU https://pubmed.ncbi.nlm.nih.gov/9822550 DMFKRMG DI DMFKRMG DMFKRMG DN 4-[3-(4-Butyl-phenoxy)-propyl]-1H-imidazole DMFKRMG TI TT9JNIC DMFKRMG TN Histamine H3 receptor (H3R) DMFKRMG MA Inhibitor DMFKRMG RN Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists. Bioorg Med Chem Lett. 2000 Oct 16;10(20):2379-82. DMFKRMG RU https://pubmed.ncbi.nlm.nih.gov/11055360 DMFKSMW DI DMFKSMW DMFKSMW DN 7-hydroxy-8-propionyl-2H-chromen-2-one DMFKSMW TI TT2LVK8 DMFKSMW TN Carbonic anhydrase IX (CA-IX) DMFKSMW MA Inhibitor DMFKSMW RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMFKSMW RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMFKTJ8 DI DMFKTJ8 DMFKTJ8 DN [D-4Aph(CO-NH-(C2H4O)2-C2H5)6]degarelix DMFKTJ8 TI TT8R70G DMFKTJ8 TN Gonadotropin-releasing hormone receptor (GNRHR) DMFKTJ8 MA Inhibitor DMFKTJ8 RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DMFKTJ8 RU https://pubmed.ncbi.nlm.nih.gov/16759096 DMFKTPO DI DMFKTPO DMFKTPO DN VAR-10300 DMFKTPO TI TTGP7BY DMFKTPO TN Monoamine oxidase type B (MAO-B) DMFKTPO MA Inhibitor DMFKTPO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DMFKTPO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DMFKV97 DI DMFKV97 DMFKV97 DN AC1LG8KT DMFKV97 TI TT056SO DMFKV97 TN Stress-activated protein kinase JNK3 (JNK3) DMFKV97 MA Inhibitor DMFKV97 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1498). DMFKV97 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1498 DMFKV97 DI DMFKV97 DMFKV97 DN AC1LG8KT DMFKV97 TI TT3IVG2 DMFKV97 TN JNK2 messenger RNA (JNK2 mRNA) DMFKV97 MA Inhibitor DMFKV97 RN N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301. DMFKV97 RU https://pubmed.ncbi.nlm.nih.gov/17194588 DMFKVPA DI DMFKVPA DMFKVPA DN 9-(sec-Butyl)-9H-adenine DMFKVPA TI TTM2AOE DMFKVPA TN Adenosine A2a receptor (ADORA2A) DMFKVPA MA Inhibitor DMFKVPA RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMFKVPA RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMFKVPA DI DMFKVPA DMFKVPA DN 9-(sec-Butyl)-9H-adenine DMFKVPA TI TTNE7KG DMFKVPA TN Adenosine A2b receptor (ADORA2B) DMFKVPA MA Inhibitor DMFKVPA RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMFKVPA RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMFKWRM DI DMFKWRM DMFKWRM DN DIHYDROXANTHOHUMOL DMFKWRM TI TTG5QB7 DMFKWRM TN Calpain-2 (CAPN2) DMFKWRM MA Inhibitor DMFKWRM RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMFKWRM RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMFKX7Z DI DMFKX7Z DMFKX7Z DN NDT9520492 DMFKX7Z TI TTHXFA1 DMFKX7Z TN C5a anaphylatoxin chemotactic receptor (C5AR1) DMFKX7Z MA Antagonist DMFKX7Z RN Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule ... J Biol Chem. 2005 Dec 9;280(49):40617-23. DMFKX7Z RU https://pubmed.ncbi.nlm.nih.gov/16230349 DMFKXMT DI DMFKXMT DMFKXMT DN BW-202W92 DMFKXMT TI TTAXZ0K DMFKXMT TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMFKXMT MA Inhibitor DMFKXMT RN Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707. DMFKXMT RU https://pubmed.ncbi.nlm.nih.gov/19341281 DMFKXMT DI DMFKXMT DMFKXMT DN BW-202W92 DMFKXMT TI TT84DRB DMFKXMT TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMFKXMT MA Inhibitor DMFKXMT RN Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707. DMFKXMT RU https://pubmed.ncbi.nlm.nih.gov/19341281 DMFKXMT DI DMFKXMT DMFKXMT DN BW-202W92 DMFKXMT TI TTRK8B9 DMFKXMT TN Sodium channel unspecific (NaC) DMFKXMT MA Inhibitor DMFKXMT RN Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707. DMFKXMT RU https://pubmed.ncbi.nlm.nih.gov/19341281 DMFKXMT DI DMFKXMT DMFKXMT DN BW-202W92 DMFKXMT TI TT90XZ8 DMFKXMT TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMFKXMT MA Inhibitor DMFKXMT RN Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. J Med Chem. 2009 May 14;52(9):2694-707. DMFKXMT RU https://pubmed.ncbi.nlm.nih.gov/19341281 DMFL46R DI DMFL46R DMFL46R DN 8-Hydroxy-7,9-dimethyl-delta-carboline DMFL46R TI TTJFY5U DMFL46R TN Adenosine A3 receptor (ADORA3) DMFL46R MA Inhibitor DMFL46R RN Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30. DMFL46R RU https://pubmed.ncbi.nlm.nih.gov/18262425 DMFL5XU DI DMFL5XU DMFL5XU DN TPO gene plasmid DMFL5XU TI TT52XDZ DMFL5XU TN Thyroid peroxidase (TPO) DMFL5XU MA Modulator DMFL5XU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2526). DMFL5XU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2526 DMFL6B9 DI DMFL6B9 DMFL6B9 DN JWH-401 DMFL6B9 TI TT6OEDT DMFL6B9 TN Cannabinoid receptor 1 (CB1) DMFL6B9 MA Inhibitor DMFL6B9 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMFL6B9 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMFL6B9 DI DMFL6B9 DMFL6B9 DN JWH-401 DMFL6B9 TI TTMSFAW DMFL6B9 TN Cannabinoid receptor 2 (CB2) DMFL6B9 MA Inhibitor DMFL6B9 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMFL6B9 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMFLA5T DI DMFLA5T DMFLA5T DN Ac-I[CV(Bta)QDWGAHRC]T-NH2 DMFLA5T TI TTJGY7A DMFLA5T TN Complement C3 (CO3) DMFLA5T MA Inhibitor DMFLA5T RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMFLA5T RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMFLB1Z DI DMFLB1Z DMFLB1Z DN JWH-363 DMFLB1Z TI TTMSFAW DMFLB1Z TN Cannabinoid receptor 2 (CB2) DMFLB1Z MA Inhibitor DMFLB1Z RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMFLB1Z RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMFLB1Z DI DMFLB1Z DMFLB1Z DN JWH-363 DMFLB1Z TI TT6OEDT DMFLB1Z TN Cannabinoid receptor 1 (CB1) DMFLB1Z MA Inhibitor DMFLB1Z RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMFLB1Z RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMFLDPU DI DMFLDPU DMFLDPU DN (Z)-2,6-diisopropyl-N-phenyloctadec-9-enamide DMFLDPU TI TTK3C21 DMFLDPU TN Acetoacetyl-CoA thiolase (ACAT1) DMFLDPU MA Inhibitor DMFLDPU RN Biphenyl versus phenylpyridazine derivatives: the role of the heterocycle in a series of acyl-CoA:cholesterol acyl transferase inhibitors. J Med Chem. 2008 Mar 13;51(5):1474-7. DMFLDPU RU https://pubmed.ncbi.nlm.nih.gov/18284184 DMFLH2G DI DMFLH2G DMFLH2G DN 4-(4-tert-butylbenzylideneamino)benzoic acid DMFLH2G TI TTANPDJ DMFLH2G TN Carbonic anhydrase II (CA-II) DMFLH2G MA Inhibitor DMFLH2G RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DMFLH2G RU https://pubmed.ncbi.nlm.nih.gov/19796939 DMFLQ96 DI DMFLQ96 DMFLQ96 DN PMID30247903-Compound-General structure33 DMFLQ96 TI TT23XQV DMFLQ96 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMFLQ96 MA Inhibitor DMFLQ96 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMFLQ96 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMFLVED DI DMFLVED DMFLVED DN [des-His1,Tyr5,Glu9,D-Tyr10]glucagon-NH2 DMFLVED TI TT9O6WS DMFLVED TN Glucagon receptor (GCGR) DMFLVED MA Inhibitor DMFLVED RN Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences. J Med Chem. 1996 Jun 21;39(13):2449-55. DMFLVED RU https://pubmed.ncbi.nlm.nih.gov/8691441 DMFM19S DI DMFM19S DMFM19S DN SNAP-5114 DMFM19S TI TTHVBOC DMFM19S TN Gamma-aminobutyric acid transporter 4 (SLC6A11) DMFM19S MA Blocker DMFM19S RN GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology. 2000 Sep;39(12):2399-407. DMFM19S RU https://pubmed.ncbi.nlm.nih.gov/10974324 DMFM60H DI DMFM60H DMFM60H DN 3,4'-(Ethane-1,2-diyl)dibenzenamine DMFM60H TI TTSZLWK DMFM60H TN Aromatase (CYP19A1) DMFM60H MA Inhibitor DMFM60H RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMFM60H RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMFM9SH DI DMFM9SH DMFM9SH DN 4-(3-Ethyl-phenoxy)-6,7-dimethoxy-quinoline DMFM9SH TI TTI7421 DMFM9SH TN Platelet-derived growth factor receptor beta (PDGFRB) DMFM9SH MA Inhibitor DMFM9SH RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMFM9SH RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMFMB31 DI DMFMB31 DMFMB31 DN [4Aph(CO-NH-OH)5]degarelix DMFMB31 TI TT8R70G DMFMB31 TN Gonadotropin-releasing hormone receptor (GNRHR) DMFMB31 MA Inhibitor DMFMB31 RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DMFMB31 RU https://pubmed.ncbi.nlm.nih.gov/16759096 DMFMBPT DI DMFMBPT DMFMBPT DN (3-Tetradecylamino-cyclopentyl)-phosphonic acid DMFMBPT TI TT9JZCK DMFMBPT TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMFMBPT MA Inhibitor DMFMBPT RN Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6. DMFMBPT RU https://pubmed.ncbi.nlm.nih.gov/15341940 DMFMBZ9 DI DMFMBZ9 DMFMBZ9 DN BAS-09534324 DMFMBZ9 TI TT3PJMV DMFMBZ9 TN Tyrosine-protein kinase ABL1 (ABL) DMFMBZ9 MA Inhibitor DMFMBZ9 RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMFMBZ9 RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMFMBZ9 DI DMFMBZ9 DMFMBZ9 DN BAS-09534324 DMFMBZ9 TI TT6PKBN DMFMBZ9 TN Proto-oncogene c-Src (SRC) DMFMBZ9 MA Inhibitor DMFMBZ9 RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMFMBZ9 RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMFMK6Y DI DMFMK6Y DMFMK6Y DN 6-Methyl-2-pyridin-3-yl-chromen-4-one DMFMK6Y TI TTNJYV2 DMFMK6Y TN Gamma-aminobutyric acid receptor (GAR) DMFMK6Y MA Inhibitor DMFMK6Y RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMFMK6Y RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMFMK89 DI DMFMK89 DMFMK89 DN SB399885 DMFMK89 TI TTJS8PY DMFMK89 TN 5-HT 6 receptor (HTR6) DMFMK89 MA Antagonist DMFMK89 RN SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition ... Eur J Pharmacol. 2006 Dec 28;553(1-3):109-19. DMFMK89 RU https://pubmed.ncbi.nlm.nih.gov/17069795 DMFMOX5 DI DMFMOX5 DMFMOX5 DN Miller-9Z-enolide DMFMOX5 TI TTSXVID DMFMOX5 TN Nuclear factor NF-kappa-B (NFKB) DMFMOX5 MA Inhibitor DMFMOX5 RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMFMOX5 RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMFMR2N DI DMFMR2N DMFMR2N DN 1-[bis(4-chlorophenyl)methyl]-3-phenylthiourea DMFMR2N TI TT6OEDT DMFMR2N TN Cannabinoid receptor 1 (CB1) DMFMR2N MA Inhibitor DMFMR2N RN 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90. DMFMR2N RU https://pubmed.ncbi.nlm.nih.gov/16279809 DMFMRN8 DI DMFMRN8 DMFMRN8 DN 18beta-Glycyrrhetic acid DMFMRN8 TI TTELIN2 DMFMRN8 TN PTPN1 messenger RNA (PTPN1 mRNA) DMFMRN8 MA Inhibitor DMFMRN8 RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DMFMRN8 RU https://pubmed.ncbi.nlm.nih.gov/16580200 DMFMWA7 DI DMFMWA7 DMFMWA7 DN EpiCept DMFMWA7 TI TT85JO3 DMFMWA7 TN 5-HT receptor (5HTR) DMFMWA7 MA Antagonist DMFMWA7 RN Emerging therapies for neuropathic pain. Expert Opin Emerg Drugs. 2005 Feb;10(1):95-108. DMFMWA7 RU https://pubmed.ncbi.nlm.nih.gov/15757406 DMFMY1L DI DMFMY1L DMFMY1L DN IGERNELLIN DMFMY1L TI TTN9T81 DMFMY1L TN Arachidonate 15-lipoxygenase (15-LOX) DMFMY1L MA Inhibitor DMFMY1L RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMFMY1L RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMFMYIH DI DMFMYIH DMFMYIH DN Iva-His-Pro-Phe-His-ACHPA-Leu-Phe-NH2 DMFMYIH TI TTB2MXP DMFMYIH TN Angiotensinogenase renin (REN) DMFMYIH MA Inhibitor DMFMYIH RN Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem. 1985 Dec;28(12):1779-90. DMFMYIH RU https://pubmed.ncbi.nlm.nih.gov/3906131 DMFMZRB DI DMFMZRB DMFMZRB DN 2-cyclohexylamino-pyridine-2-carbonitrile DMFMZRB TI TTDZN01 DMFMZRB TN Cathepsin K (CTSK) DMFMZRB MA Inhibitor DMFMZRB RN 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem. 2007 Feb 22;50(4):591-4. DMFMZRB RU https://pubmed.ncbi.nlm.nih.gov/17256925 DMFN58T DI DMFN58T DMFN58T DN Ginsenoside RG3 DMFN58T TI TTQ6VDM DMFN58T TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMFN58T MA Activator DMFN58T RN Ginsenoside Rg(3) decelerates hERG K(+) channel deactivation through Ser631 residue interaction. Eur J Pharmacol. 2011 Aug 1;663(1-3):59-67. DMFN58T RU https://pubmed.ncbi.nlm.nih.gov/21586280 DMFN769 DI DMFN769 DMFN769 DN 2-oxo-2H-chromene-3-carboxylic acid DMFN769 TI TTUNARX DMFN769 TN Carbonic anhydrase (CA) DMFN769 MA Inhibitor DMFN769 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMFN769 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMFN769 DI DMFN769 DMFN769 DN 2-oxo-2H-chromene-3-carboxylic acid DMFN769 TI TTZHA0O DMFN769 TN Carbonic anhydrase IV (CA-IV) DMFN769 MA Inhibitor DMFN769 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMFN769 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMFN769 DI DMFN769 DMFN769 DN 2-oxo-2H-chromene-3-carboxylic acid DMFN769 TI TTHQPL7 DMFN769 TN Carbonic anhydrase I (CA-I) DMFN769 MA Inhibitor DMFN769 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMFN769 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMFN769 DI DMFN769 DMFN769 DN 2-oxo-2H-chromene-3-carboxylic acid DMFN769 TI TT2LVK8 DMFN769 TN Carbonic anhydrase IX (CA-IX) DMFN769 MA Inhibitor DMFN769 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMFN769 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMFN769 DI DMFN769 DMFN769 DN 2-oxo-2H-chromene-3-carboxylic acid DMFN769 TI TTEYTKG DMFN769 TN Carbonic anhydrase XIV (CA-XIV) DMFN769 MA Inhibitor DMFN769 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMFN769 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMFN769 DI DMFN769 DMFN769 DN 2-oxo-2H-chromene-3-carboxylic acid DMFN769 TI TTSYM0R DMFN769 TN Carbonic anhydrase XII (CA-XII) DMFN769 MA Inhibitor DMFN769 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMFN769 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMFN8T6 DI DMFN8T6 DMFN8T6 DN 1-(4-hexylphenyl)-3-morpholinopropan-1-one DMFN8T6 TI TTTSEPU DMFN8T6 TN Thyroid hormone receptor alpha (THRA) DMFN8T6 MA Inhibitor DMFN8T6 RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMFN8T6 RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMFN8T6 DI DMFN8T6 DMFN8T6 DN 1-(4-hexylphenyl)-3-morpholinopropan-1-one DMFN8T6 TI TTGER3L DMFN8T6 TN Thyroid hormone receptor beta (THRB) DMFN8T6 MA Inhibitor DMFN8T6 RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMFN8T6 RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMFNAKU DI DMFNAKU DMFNAKU DN BAS-4844343 DMFNAKU TI TT6PKBN DMFNAKU TN Proto-oncogene c-Src (SRC) DMFNAKU MA Inhibitor DMFNAKU RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMFNAKU RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMFNB40 DI DMFNB40 DMFNB40 DN Noradrenalone (arterenone) DMFNB40 TI TTN451K DMFNB40 TN Aromatic-L-amino-acid decarboxylase (DDC) DMFNB40 MA Activator DMFNB40 RN Activation of an adrenergic pro-drug through sequential stereoselective action of tandem target enzymes. Biochem Biophys Res Commun. 1992 Nov 30;189(1):33-9. DMFNB40 RU https://pubmed.ncbi.nlm.nih.gov/1449487 DMFNCG8 DI DMFNCG8 DMFNCG8 DN 8-Furan-3-yl-6-styryl-naphthalene-2-carboxamidine DMFNCG8 TI TT2WR1T DMFNCG8 TN Cationic trypsinogen (PRSS1) DMFNCG8 MA Inhibitor DMFNCG8 RN Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8. DMFNCG8 RU https://pubmed.ncbi.nlm.nih.gov/15582418 DMFNCQ1 DI DMFNCQ1 DMFNCQ1 DN N-alpha-amidino-Tyr(Me)-D-Pro-Gly-Trp-Phe-NH2 DMFNCQ1 TI TTKWM86 DMFNCQ1 TN Opioid receptor mu (MOP) DMFNCQ1 MA Inhibitor DMFNCQ1 RN Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. DMFNCQ1 RU https://pubmed.ncbi.nlm.nih.gov/17188879 DMFNEZW DI DMFNEZW DMFNEZW DN 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE DMFNEZW TI TT7HF4W DMFNEZW TN Cyclin-dependent kinase 2 (CDK2) DMFNEZW MA Inhibitor DMFNEZW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMFNEZW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMFNQEA DI DMFNQEA DMFNQEA DN PD 168368 DMFNQEA TI TTC1MVT DMFNQEA TN Gastrin-releasing peptide receptor (GRPR) DMFNQEA MA Antagonist DMFNQEA RN Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368. J Pharmacol Exp Ther. 1999 Sep;290(3):1202-11. DMFNQEA RU https://pubmed.ncbi.nlm.nih.gov/10454496 DMFNQEA DI DMFNQEA DMFNQEA DN PD 168368 DMFNQEA TI TTHYDUM DMFNQEA TN Bombesin receptor (BS) DMFNQEA MA Antagonist DMFNQEA RN Characterization of putative GRP- and NMB-receptor antagonist's interaction with human receptors. Peptides. 2009 Aug;30(8):1473-86. DMFNQEA RU https://pubmed.ncbi.nlm.nih.gov/19463875 DMFNQZS DI DMFNQZS DMFNQZS DN 2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol DMFNQZS TI TTE4KHA DMFNQZS TN Amyloid beta A4 protein (APP) DMFNQZS MA Inhibitor DMFNQZS RN Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. DMFNQZS RU https://pubmed.ncbi.nlm.nih.gov/16640346 DMFNR3Y DI DMFNR3Y DMFNR3Y DN A35566-A DMFNR3Y TI TTGTQHC DMFNR3Y TN DNA topoisomerase I (TOP1) DMFNR3Y MA Inhibitor DMFNR3Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMFNR3Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMFNR75 DI DMFNR75 DMFNR75 DN SYN-1327 DMFNR75 TI TTKLPHO DMFNR75 TN Neonatal Fc receptor (FCGRT) DMFNR75 MA Inhibitor DMFNR75 RN Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction. Bioorg Med Chem. 2008 Jun 15;16(12):6394-405. DMFNR75 RU https://pubmed.ncbi.nlm.nih.gov/18501614 DMFNTMY DI DMFNTMY DMFNTMY DN Fibrates DMFNTMY TI TTJ584C DMFNTMY TN Peroxisome proliferator-activated receptor alpha (PPARA) DMFNTMY MA Agonist DMFNTMY RN Emerging antidyslipidemic drugs. Expert Opin Emerg Drugs. 2008 Jun;13(2):363-81. DMFNTMY RU https://pubmed.ncbi.nlm.nih.gov/18537526 DMFNUHQ DI DMFNUHQ DMFNUHQ DN 8-chloro-quinoline-3-carbonitrile DMFNUHQ TI TTUZ2L5 DMFNUHQ TN Matrix metalloproteinase-3 (MMP-3) DMFNUHQ MA Inhibitor DMFNUHQ RN Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007 Nov 16;282(46):33295-304. DMFNUHQ RU https://pubmed.ncbi.nlm.nih.gov/17848581 DMFNUHQ DI DMFNUHQ DMFNUHQ DN 8-chloro-quinoline-3-carbonitrile DMFNUHQ TI TTGECUM DMFNUHQ TN Cot oncogene messenger RNA (MAP3K8 mRNA) DMFNUHQ MA Inhibitor DMFNUHQ RN Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007 Nov 16;282(46):33295-304. DMFNUHQ RU https://pubmed.ncbi.nlm.nih.gov/17848581 DMFNZOI DI DMFNZOI DMFNZOI DN ASN-11124542 DMFNZOI TI TTXEZJ4 DMFNZOI TN Tyrosine-protein kinase EIF2AK2 (p68) DMFNZOI MA Inhibitor DMFNZOI RN Small molecule inhibitors of the RNA-dependent protein kinase. Biochem Biophys Res Commun. 2003 Aug 15;308(1):50-7. DMFNZOI RU https://pubmed.ncbi.nlm.nih.gov/12890478 DMFNZSL DI DMFNZSL DMFNZSL DN N-(5-o-Tolyl-furan-2-carbonyl)-guanidine DMFNZSL TI TTGSEFH DMFNZSL TN Sodium/hydrogen exchanger 1 (SLC9A1) DMFNZSL MA Inhibitor DMFNZSL RN (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. DMFNZSL RU https://pubmed.ncbi.nlm.nih.gov/15828827 DMFO19B DI DMFO19B DMFO19B DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol DMFO19B TI TTN9D8E DMFO19B TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMFO19B MA Inhibitor DMFO19B RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMFO19B RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMFO19B DI DMFO19B DMFO19B DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ol DMFO19B TI TTLD29N DMFO19B TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMFO19B MA Inhibitor DMFO19B RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMFO19B RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMFO1H2 DI DMFO1H2 DMFO1H2 DN 2,6-di-tert-butyl-4-methoxyphenol DMFO1H2 TI TTANPDJ DMFO1H2 TN Carbonic anhydrase II (CA-II) DMFO1H2 MA Inhibitor DMFO1H2 RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMFO1H2 RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMFO7CH DI DMFO7CH DMFO7CH DN 2-(butylthiomethyl)-5-hydroxy-4H-pyran-4-one DMFO7CH TI TTULVH8 DMFO7CH TN Tyrosinase (TYR) DMFO7CH MA Inhibitor DMFO7CH RN Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71. DMFO7CH RU https://pubmed.ncbi.nlm.nih.gov/20934336 DMFO7UC DI DMFO7UC DMFO7UC DN PMID12014956C12 DMFO7UC TI TTIKWV4 DMFO7UC TN Geranyltranstransferase (FDPS) DMFO7UC MA Inhibitor DMFO7UC RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem. 2002 May 23;45(11):2185-96. DMFO7UC RU https://pubmed.ncbi.nlm.nih.gov/12014956 DMFO8DR DI DMFO8DR DMFO8DR DN (4-Phenoxy-phenyl)-quinazolin-4-yl-amine DMFO8DR TI TT9VGXW DMFO8DR TN Angiopoietin 1 receptor (TEK) DMFO8DR MA Inhibitor DMFO8DR RN Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70. DMFO8DR RU https://pubmed.ncbi.nlm.nih.gov/11012021 DMFO8DR DI DMFO8DR DMFO8DR DN (4-Phenoxy-phenyl)-quinazolin-4-yl-amine DMFO8DR TI TTUTJGQ DMFO8DR TN Vascular endothelial growth factor receptor 2 (KDR) DMFO8DR MA Inhibitor DMFO8DR RN Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70. DMFO8DR RU https://pubmed.ncbi.nlm.nih.gov/11012021 DMFO8DR DI DMFO8DR DMFO8DR DN (4-Phenoxy-phenyl)-quinazolin-4-yl-amine DMFO8DR TI TT860QF DMFO8DR TN LCK tyrosine protein kinase (LCK) DMFO8DR MA Inhibitor DMFO8DR RN Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I. Bioorg Med Chem Lett. 2000 Oct 2;10(19):2167-70. DMFO8DR RU https://pubmed.ncbi.nlm.nih.gov/11012021 DMFOA6R DI DMFOA6R DMFOA6R DN 2-(3-Methyl-indole-1-sulfonyl)-benzoic acid DMFOA6R TI TTHWMFZ DMFOA6R TN Fatty acid-binding protein 4 (FABP4) DMFOA6R MA Inhibitor DMFOA6R RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMFOA6R RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMFOD2L DI DMFOD2L DMFOD2L DN 1-(9H-beta-Carbolin-3-yl)-ethanone DMFOD2L TI TT1MPAY DMFOD2L TN GABA(A) receptor alpha-1 (GABRA1) DMFOD2L MA Inhibitor DMFOD2L RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMFOD2L RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMFOD2L DI DMFOD2L DMFOD2L DN 1-(9H-beta-Carbolin-3-yl)-ethanone DMFOD2L TI TTNJYV2 DMFOD2L TN Gamma-aminobutyric acid receptor (GAR) DMFOD2L MA Inhibitor DMFOD2L RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMFOD2L RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMFODQV DI DMFODQV DMFODQV DN BMS-739562 DMFODQV TI TTLYXIT DMFODQV TN Aurora kinase C (AURKC) DMFODQV MA Inhibitor DMFODQV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DMFODQV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DMFOGE2 DI DMFOGE2 DMFOGE2 DN SIB-1757 DMFOGE2 TI TTHS256 DMFOGE2 TN Metabotropic glutamate receptor 5 (mGluR5) DMFOGE2 MA Inhibitor DMFOGE2 RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DMFOGE2 RU https://pubmed.ncbi.nlm.nih.gov/16678408 DMFOIPL DI DMFOIPL DMFOIPL DN undecanoic acid DMFOIPL TI TTG0MQD DMFOIPL TN Inflammation-related GPCR EX33 (GPR84) DMFOIPL MA Agonist DMFOIPL RN Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J Biol Chem. 2006 Nov 10;281(45):34457-64. DMFOIPL RU https://pubmed.ncbi.nlm.nih.gov/16966319 DMFOM10 DI DMFOM10 DMFOM10 DN 8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-ylamine DMFOM10 TI TTSQIFT DMFOM10 TN 5-HT 1A receptor (HTR1A) DMFOM10 MA Inhibitor DMFOM10 RN Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993). DMFOM10 RU http://www.sciencedirect.com/science/article/pii/S0960894X0181009X DMFONC1 DI DMFONC1 DMFONC1 DN N-(Adamant-1-yl)-1'H-phenothiazine-1'-carboxamide DMFONC1 TI TTEB0GD DMFONC1 TN Cholinesterase (BCHE) DMFONC1 MA Inhibitor DMFONC1 RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMFONC1 RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMFOSYU DI DMFOSYU DMFOSYU DN ISIS 105989 DMFOSYU TI TTT2SVW DMFOSYU TN PPAR-gamma messenger RNA (PPARG mRNA) DMFOSYU RN US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression. DMFOSYU RU http://www.patentbuddy.com/Patent/6159734?ft=true&sr=true DMFOTQY DI DMFOTQY DMFOTQY DN ISIS 107774 DMFOTQY TI TTELIN2 DMFOTQY TN PTPN1 messenger RNA (PTPN1 mRNA) DMFOTQY RN US patent application no. 6,261,840, Antisense modulation of PTP1B expression. DMFOTQY RU http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true DMFOTYQ DI DMFOTYQ DMFOTYQ DN Ac-I[CVFQDWGHHRC]T-NH2 DMFOTYQ TI TTJGY7A DMFOTYQ TN Complement C3 (CO3) DMFOTYQ MA Inhibitor DMFOTYQ RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMFOTYQ RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMFOU8G DI DMFOU8G DMFOU8G DN 7-fluoro-2-p-tolyl-4H-chromen-4-one DMFOU8G TI TTGP7BY DMFOU8G TN Monoamine oxidase type B (MAO-B) DMFOU8G MA Inhibitor DMFOU8G RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMFOU8G RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMFOU92 DI DMFOU92 DMFOU92 DN FORMYLCHROMONE DMFOU92 TI TTELIN2 DMFOU92 TN PTPN1 messenger RNA (PTPN1 mRNA) DMFOU92 MA Inhibitor DMFOU92 RN Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18. DMFOU92 RU https://pubmed.ncbi.nlm.nih.gov/20627471 DMFOZ60 DI DMFOZ60 DMFOZ60 DN aconitine DMFOZ60 TI TTLJTUF DMFOZ60 TN Voltage-gated sodium channel alpha Nav1.2 (SCN2A) DMFOZ60 MA Activator DMFOZ60 RN Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem. 1981 Sep 10;256(17):8922-7. DMFOZ60 RU https://pubmed.ncbi.nlm.nih.gov/6114956 DMFOZ60 DI DMFOZ60 DMFOZ60 DN aconitine DMFOZ60 TI TTZOVE0 DMFOZ60 TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMFOZ60 MA Activator DMFOZ60 RN Properties of aconitine-modified sodium channels in single cells of mouse ventricular myocardium. Gen Physiol Biophys. 1986 Oct;5(5):473-84. DMFOZ60 RU https://pubmed.ncbi.nlm.nih.gov/2433183 DMFP0IW DI DMFP0IW DMFP0IW DN 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine DMFP0IW TI TTJFY5U DMFP0IW TN Adenosine A3 receptor (ADORA3) DMFP0IW MA Inhibitor DMFP0IW RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMFP0IW RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMFP0IW DI DMFP0IW DMFP0IW DN 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine DMFP0IW TI TTM2AOE DMFP0IW TN Adenosine A2a receptor (ADORA2A) DMFP0IW MA Inhibitor DMFP0IW RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMFP0IW RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMFP0IW DI DMFP0IW DMFP0IW DN 2-(3''-(5''-iodo-indolyl)ethyloxy)adenosine DMFP0IW TI TTK25J1 DMFP0IW TN Adenosine A1 receptor (ADORA1) DMFP0IW MA Inhibitor DMFP0IW RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMFP0IW RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMFP1C5 DI DMFP1C5 DMFP1C5 DN indirubin derivative E804 DMFP1C5 TI TTXEZJ4 DMFP1C5 TN Tyrosine-protein kinase EIF2AK2 (p68) DMFP1C5 MA Inhibitor DMFP1C5 RN Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett. 2011 Jul 1;21(13):4108-14. DMFP1C5 RU https://pubmed.ncbi.nlm.nih.gov/21632247 DMFP598 DI DMFP598 DMFP598 DN ISIS 102676 DMFP598 TI TT5U49F DMFP598 TN PRKACA messenger RNA (PRKACA mRNA) DMFP598 RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMFP598 RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMFP8WE DI DMFP8WE DMFP8WE DN ZM-447439 DMFP8WE TI TTPS3C0 DMFP8WE TN Aurora kinase A (AURKA) DMFP8WE MA Inhibitor DMFP8WE RN Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring. J Med Chem. 2006 Aug 10;49(16):4805-8. DMFP8WE RU https://pubmed.ncbi.nlm.nih.gov/16884290 DMFPCSJ DI DMFPCSJ DMFPCSJ DN 6-amino-5-chlorouracil hydrochloride DMFPCSJ TI TTO0IB8 DMFPCSJ TN Thymidine phosphorylase (TYMP) DMFPCSJ MA Inhibitor DMFPCSJ RN Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7. DMFPCSJ RU https://pubmed.ncbi.nlm.nih.gov/16337119 DMFPM5S DI DMFPM5S DMFPM5S DN ISIS 119281 DMFPM5S TI TTKS60G DMFPM5S TN STXBP4 messenger RNA (STXBP4 mRNA) DMFPM5S RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DMFPM5S RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DMFPNQ9 DI DMFPNQ9 DMFPNQ9 DN 4-(2-Oxo-2-phenyl-acetyl)-benzoic acid DMFPNQ9 TI TTMF541 DMFPNQ9 TN Liver carboxylesterase (CES1) DMFPNQ9 MA Inhibitor DMFPNQ9 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMFPNQ9 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMFPNRD DI DMFPNRD DMFPNRD DN VUF 4904 DMFPNRD TI TT9JNIC DMFPNRD TN Histamine H3 receptor (H3R) DMFPNRD MA Antagonist DMFPNRD RN Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001 Dec;299(3):908-14. DMFPNRD RU https://pubmed.ncbi.nlm.nih.gov/11714875 DMFPO16 DI DMFPO16 DMFPO16 DN 4',4-Dihydroxychalcone DMFPO16 TI TTULVH8 DMFPO16 TN Tyrosinase (TYR) DMFPO16 MA Inhibitor DMFPO16 RN Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7. DMFPO16 RU https://pubmed.ncbi.nlm.nih.gov/20149498 DMFPOUC DI DMFPOUC DMFPOUC DN CGP-57380 DMFPOUC TI TT9RTBL DMFPOUC TN Aurora B messenger RNA (AURKB mRNA) DMFPOUC MA Inhibitor DMFPOUC RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMFPOUC RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMFPOUC DI DMFPOUC DMFPOUC DN CGP-57380 DMFPOUC TI TTTV8EJ DMFPOUC TN Serine/threonine-protein kinase Sgk1 (SGK1) DMFPOUC MA Inhibitor DMFPOUC RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMFPOUC RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMFPOUC DI DMFPOUC DMFPOUC DN CGP-57380 DMFPOUC TI TT860QF DMFPOUC TN LCK tyrosine protein kinase (LCK) DMFPOUC MA Inhibitor DMFPOUC RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMFPOUC RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMFPQME DI DMFPQME DMFPQME DN 1-cyclohexylamido-5-sulfonamidoindane DMFPQME TI TTHQPL7 DMFPQME TN Carbonic anhydrase I (CA-I) DMFPQME MA Inhibitor DMFPQME RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMFPQME RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMFPQME DI DMFPQME DMFPQME DN 1-cyclohexylamido-5-sulfonamidoindane DMFPQME TI TT2LVK8 DMFPQME TN Carbonic anhydrase IX (CA-IX) DMFPQME MA Inhibitor DMFPQME RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMFPQME RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMFPQME DI DMFPQME DMFPQME DN 1-cyclohexylamido-5-sulfonamidoindane DMFPQME TI TTANPDJ DMFPQME TN Carbonic anhydrase II (CA-II) DMFPQME MA Inhibitor DMFPQME RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMFPQME RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMFPSOQ DI DMFPSOQ DMFPSOQ DN Benzaldehyde O-4-(decyloxy)phenylcarbamoyl oxime DMFPSOQ TI TTDP1UC DMFPSOQ TN Fatty acid amide hydrolase (FAAH) DMFPSOQ MA Inhibitor DMFPSOQ RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMFPSOQ RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMFPTXO DI DMFPTXO DMFPTXO DN 3-(3-bromophenylethynyl)-5-methyl[1,2,4]triazine DMFPTXO TI TTHS256 DMFPTXO TN Metabotropic glutamate receptor 5 (mGluR5) DMFPTXO MA Inhibitor DMFPTXO RN Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91. DMFPTXO RU https://pubmed.ncbi.nlm.nih.gov/17569516 DMFPUGV DI DMFPUGV DMFPUGV DN 1-(3-Phenylallylidene)thiosemicarbazide DMFPUGV TI TTULVH8 DMFPUGV TN Tyrosinase (TYR) DMFPUGV MA Inhibitor DMFPUGV RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMFPUGV RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMFPWJL DI DMFPWJL DMFPWJL DN 8-sec-Butoxy-quinolin-2-ylamine DMFPWJL TI TTX4RTB DMFPWJL TN Melanin-concentrating hormone receptor 1 (MCHR1) DMFPWJL MA Inhibitor DMFPWJL RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMFPWJL RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMFPYU8 DI DMFPYU8 DMFPYU8 DN 2,2-Dibenzylcyclopentanol DMFPYU8 TI TT5ZWB6 DMFPYU8 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMFPYU8 MA Inhibitor DMFPYU8 RN New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71. DMFPYU8 RU https://pubmed.ncbi.nlm.nih.gov/19237229 DMFQ0Z4 DI DMFQ0Z4 DMFQ0Z4 DN [1,4]Thiazepan-(5E)-ylideneamine DMFQ0Z4 TI TTZUFI5 DMFQ0Z4 TN Nitric-oxide synthase brain (NOS1) DMFQ0Z4 MA Inhibitor DMFQ0Z4 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMFQ0Z4 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMFQ0Z4 DI DMFQ0Z4 DMFQ0Z4 DN [1,4]Thiazepan-(5E)-ylideneamine DMFQ0Z4 TI TTF10I9 DMFQ0Z4 TN Nitric-oxide synthase inducible (NOS2) DMFQ0Z4 MA Inhibitor DMFQ0Z4 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMFQ0Z4 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMFQ0Z4 DI DMFQ0Z4 DMFQ0Z4 DN [1,4]Thiazepan-(5E)-ylideneamine DMFQ0Z4 TI TTCM4B3 DMFQ0Z4 TN Nitric-oxide synthase endothelial (NOS3) DMFQ0Z4 MA Inhibitor DMFQ0Z4 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMFQ0Z4 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMFQ10R DI DMFQ10R DMFQ10R DN ISIS 103819 DMFQ10R TI TT6TU05 DMFQ10R TN WWP2 messenger RNA (WWP2 mRNA) DMFQ10R RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMFQ10R RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMFQE1C DI DMFQE1C DMFQE1C DN Acetic acid 2-hex-2-ynylsulfanyl-phenyl ester DMFQE1C TI TT8NGED DMFQE1C TN Prostaglandin G/H synthase 1 (COX-1) DMFQE1C MA Inhibitor DMFQE1C RN Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18. DMFQE1C RU https://pubmed.ncbi.nlm.nih.gov/9822550 DMFQEWM DI DMFQEWM DMFQEWM DN LEUCETTAMINE B DMFQEWM TI TTRSMW9 DMFQEWM TN Glycogen synthase kinase-3 beta (GSK-3B) DMFQEWM MA Inhibitor DMFQEWM RN Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10. DMFQEWM RU https://pubmed.ncbi.nlm.nih.gov/19879673 DMFQEWM DI DMFQEWM DMFQEWM DN LEUCETTAMINE B DMFQEWM TI TTQWAU1 DMFQEWM TN GSK3A messenger RNA (GSK3A mRNA) DMFQEWM MA Inhibitor DMFQEWM RN Synthesis and preliminary biological evaluation of new derivatives of the marine alkaloid leucettamine B as kinase inhibitors. Eur J Med Chem. 2010 Feb;45(2):805-10. DMFQEWM RU https://pubmed.ncbi.nlm.nih.gov/19879673 DMFQHVL DI DMFQHVL DMFQHVL DN PMID22266036C9a DMFQHVL TI TTVBPDM DMFQHVL TN Metabotropic glutamate receptor 1 (mGluR1) DMFQHVL MA Modulator (allosteric modulator) DMFQHVL RN Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1575-8. DMFQHVL RU https://pubmed.ncbi.nlm.nih.gov/22266036 DMFQI4C DI DMFQI4C DMFQI4C DN 2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole DMFQI4C TI TTGP7BY DMFQI4C TN Monoamine oxidase type B (MAO-B) DMFQI4C MA Inhibitor DMFQI4C RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMFQI4C RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMFQMHK DI DMFQMHK DMFQMHK DN Phenethyl-(4-phenyl-butyl)-amine DMFQMHK TI TTN9D8E DMFQMHK TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMFQMHK MA Inhibitor DMFQMHK RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMFQMHK RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMFQMHK DI DMFQMHK DMFQMHK DN Phenethyl-(4-phenyl-butyl)-amine DMFQMHK TI TTLD29N DMFQMHK TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMFQMHK MA Inhibitor DMFQMHK RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMFQMHK RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMFQO21 DI DMFQO21 DMFQO21 DN ISIS 25123 DMFQO21 TI TT8H9GB DMFQO21 TN MEK2 messenger RNA (MEK2 mRNA) DMFQO21 RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMFQO21 RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMFQT9O DI DMFQT9O DMFQT9O DN 4-(2-(4-fluorophenoxy)phenyl)piperidine DMFQT9O TI TTSQIFT DMFQT9O TN 5-HT 1A receptor (HTR1A) DMFQT9O MA Inhibitor DMFQT9O RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMFQT9O RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMFQT9O DI DMFQT9O DMFQT9O DN 4-(2-(4-fluorophenoxy)phenyl)piperidine DMFQT9O TI TT3ROYC DMFQT9O TN Serotonin transporter (SERT) DMFQT9O MA Inhibitor DMFQT9O RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMFQT9O RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMFQT9O DI DMFQT9O DMFQT9O DN 4-(2-(4-fluorophenoxy)phenyl)piperidine DMFQT9O TI TTVBI8W DMFQT9O TN Dopamine transporter (DAT) DMFQT9O MA Inhibitor DMFQT9O RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMFQT9O RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMFQT9O DI DMFQT9O DMFQT9O DN 4-(2-(4-fluorophenoxy)phenyl)piperidine DMFQT9O TI TTAWNKZ DMFQT9O TN Norepinephrine transporter (NET) DMFQT9O MA Inhibitor DMFQT9O RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMFQT9O RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMFQUGE DI DMFQUGE DMFQUGE DN 3-Deoxyguanosine DMFQUGE TI TTMCF1Y DMFQUGE TN Purine nucleoside phosphorylase (PNP) DMFQUGE MA Inhibitor DMFQUGE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFQUGE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFQVLW DI DMFQVLW DMFQVLW DN CD45RB DMFQVLW TI TTE4KHA DMFQVLW TN Amyloid beta A4 protein (APP) DMFQVLW MA Agonist DMFQVLW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMFQVLW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMFQVNL DI DMFQVNL DMFQVNL DN PMID23517011C9 DMFQVNL TI TTRA6BO DMFQVNL TN Bromodomain-containing protein 4 (BRD4) DMFQVNL MA Inhibitor DMFQVNL RN Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J Med Chem. 2013 Apr 25;56(8):3217-27. DMFQVNL RU https://pubmed.ncbi.nlm.nih.gov/23517011 DMFQX1U DI DMFQX1U DMFQX1U DN EMATE DMFQX1U TI TTANPDJ DMFQX1U TN Carbonic anhydrase II (CA-II) DMFQX1U MA Inhibitor DMFQX1U RN 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96. DMFQX1U RU https://pubmed.ncbi.nlm.nih.gov/17181151 DMFQX1U DI DMFQX1U DMFQX1U DN EMATE DMFQX1U TI TTHM0R1 DMFQX1U TN Steryl-sulfatase (STS) DMFQX1U MA Inhibitor DMFQX1U RN Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6. DMFQX1U RU https://pubmed.ncbi.nlm.nih.gov/17580843 DMFQZOI DI DMFQZOI DMFQZOI DN 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol DMFQZOI TI TTZAYWL DMFQZOI TN Estrogen receptor (ESR) DMFQZOI MA Inhibitor DMFQZOI RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMFQZOI RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMFQZOI DI DMFQZOI DMFQZOI DN 4-(2-phenyl-1H-benzo[d]imidazol-1-yl)phenol DMFQZOI TI TTOM3J0 DMFQZOI TN Estrogen receptor beta (ESR2) DMFQZOI MA Inhibitor DMFQZOI RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMFQZOI RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMFR1SE DI DMFR1SE DMFR1SE DN ETONITAZENE DMFR1SE TI TTQW87Y DMFR1SE TN Opioid receptor kappa (OPRK1) DMFR1SE MA Inhibitor DMFR1SE RN Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. J Med Chem. 1990 Sep;33(9):2456-64. DMFR1SE RU https://pubmed.ncbi.nlm.nih.gov/2167979 DMFR1SE DI DMFR1SE DMFR1SE DN ETONITAZENE DMFR1SE TI TT27RFC DMFR1SE TN Opioid receptor delta (OPRD1) DMFR1SE MA Inhibitor DMFR1SE RN Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. J Med Chem. 1990 Sep;33(9):2456-64. DMFR1SE RU https://pubmed.ncbi.nlm.nih.gov/2167979 DMFR1SE DI DMFR1SE DMFR1SE DN ETONITAZENE DMFR1SE TI TTKWM86 DMFR1SE TN Opioid receptor mu (MOP) DMFR1SE MA Inhibitor DMFR1SE RN Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15. DMFR1SE RU https://pubmed.ncbi.nlm.nih.gov/18403056 DMFR3SD DI DMFR3SD DMFR3SD DN 9-[5-(beta-Carboline-9-yl)pentyl]-beta-carboline DMFR3SD TI TTEB0GD DMFR3SD TN Cholinesterase (BCHE) DMFR3SD MA Inhibitor DMFR3SD RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DMFR3SD RU https://pubmed.ncbi.nlm.nih.gov/20361801 DMFR7JW DI DMFR7JW DMFR7JW DN 1-Methyloxy-4-Sulfone-Benzene DMFR7JW TI TTHY57M DMFR7JW TN Matrix metalloproteinase-13 (MMP-13) DMFR7JW MA Inhibitor DMFR7JW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFR7JW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFR7JW DI DMFR7JW DMFR7JW DN 1-Methyloxy-4-Sulfone-Benzene DMFR7JW TI TTUZ2L5 DMFR7JW TN Matrix metalloproteinase-3 (MMP-3) DMFR7JW MA Inhibitor DMFR7JW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFR7JW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFRA1Y DI DMFRA1Y DMFRA1Y DN Phenylarsonic acid DMFRA1Y TI TTZHA0O DMFRA1Y TN Carbonic anhydrase IV (CA-IV) DMFRA1Y MA Inhibitor DMFRA1Y RN Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73. DMFRA1Y RU https://pubmed.ncbi.nlm.nih.gov/15501038 DMFRA1Y DI DMFRA1Y DMFRA1Y DN Phenylarsonic acid DMFRA1Y TI TTUNARX DMFRA1Y TN Carbonic anhydrase (CA) DMFRA1Y MA Inhibitor DMFRA1Y RN Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43. DMFRA1Y RU https://pubmed.ncbi.nlm.nih.gov/16621537 DMFRASQ DI DMFRASQ DMFRASQ DN 4-methyl-N-(naphthalen-1-yl)thiazol-2-amine DMFRASQ TI TT7HQD0 DMFRASQ TN C-C chemokine receptor type 4 (CCR4) DMFRASQ MA Inhibitor DMFRASQ RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMFRASQ RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMFRCQS DI DMFRCQS DMFRCQS DN 4-Indan-(1E)-ylidenemethyl-pyridine DMFRCQS TI TTSZLWK DMFRCQS TN Aromatase (CYP19A1) DMFRCQS MA Inhibitor DMFRCQS RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMFRCQS RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMFRD09 DI DMFRD09 DMFRD09 DN N-3-(4-bromophenyl)propyl imidazole DMFRD09 TI TTRA5BZ DMFRD09 TN Steroid 17-alpha-monooxygenase (S17AH) DMFRD09 MA Inhibitor DMFRD09 RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DMFRD09 RU https://pubmed.ncbi.nlm.nih.gov/16870430 DMFRP7H DI DMFRP7H DMFRP7H DN GW4065 DMFRP7H TI TTS4UGC DMFRP7H TN Farnesoid X-activated receptor (FXR) DMFRP7H MA Agonist DMFRP7H RN Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7. DMFRP7H RU https://pubmed.ncbi.nlm.nih.gov/12052824 DMFRPGX DI DMFRPGX DMFRPGX DN (2-Benzyl-phenyl)-(2-pyrrolidin-1-yl-ethyl)-amine DMFRPGX TI TT4C8EA DMFRPGX TN Dopamine D3 receptor (D3R) DMFRPGX MA Inhibitor DMFRPGX RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMFRPGX RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMFRQ2U DI DMFRQ2U DMFRQ2U DN N-(17-Methylmorphinan-3-yl)-N'-phenylurea DMFRQ2U TI TTQW87Y DMFRQ2U TN Opioid receptor kappa (OPRK1) DMFRQ2U MA Inhibitor DMFRQ2U RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMFRQ2U RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMFRQ2U DI DMFRQ2U DMFRQ2U DN N-(17-Methylmorphinan-3-yl)-N'-phenylurea DMFRQ2U TI TT27RFC DMFRQ2U TN Opioid receptor delta (OPRD1) DMFRQ2U MA Inhibitor DMFRQ2U RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMFRQ2U RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMFRQ2U DI DMFRQ2U DMFRQ2U DN N-(17-Methylmorphinan-3-yl)-N'-phenylurea DMFRQ2U TI TTKWM86 DMFRQ2U TN Opioid receptor mu (MOP) DMFRQ2U MA Inhibitor DMFRQ2U RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMFRQ2U RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMFRQJ3 DI DMFRQJ3 DMFRQJ3 DN 2-phenylethynyl-7,8-dihydro-6H-quinolin-5-one DMFRQJ3 TI TTHS256 DMFRQJ3 TN Metabotropic glutamate receptor 5 (mGluR5) DMFRQJ3 MA Inhibitor DMFRQJ3 RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DMFRQJ3 RU https://pubmed.ncbi.nlm.nih.gov/18173231 DMFRXDT DI DMFRXDT DMFRXDT DN 6,7-Dimethoxy-3-phenylethynyl-quinoline DMFRXDT TI TTI7421 DMFRXDT TN Platelet-derived growth factor receptor beta (PDGFRB) DMFRXDT MA Inhibitor DMFRXDT RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMFRXDT RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMFRXDT DI DMFRXDT DMFRXDT DN 6,7-Dimethoxy-3-phenylethynyl-quinoline DMFRXDT TI TT8FYO9 DMFRXDT TN Platelet-derived growth factor receptor alpha (PDGFRA) DMFRXDT MA Inhibitor DMFRXDT RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMFRXDT RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMFRZGS DI DMFRZGS DMFRZGS DN 3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one DMFRZGS TI TTW0CMT DMFRZGS TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMFRZGS MA Inhibitor DMFRZGS RN Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4. DMFRZGS RU https://pubmed.ncbi.nlm.nih.gov/17095219 DMFS2V9 DI DMFS2V9 DMFS2V9 DN BIC1 DMFS2V9 TI TTDP48B DMFS2V9 TN Bromodomain-containing protein 2 (BRD2) DMFS2V9 MA Inhibitor DMFS2V9 RN Real-time imaging of histone H4K12-specific acetylation determines the modes of action of histone deacetylase and bromodomain inhibitors. Chem Biol. 2011 Apr 22;18(4):495-507. DMFS2V9 RU https://pubmed.ncbi.nlm.nih.gov/21513886 DMFS4RD DI DMFS4RD DMFS4RD DN Autoantibody LKM-3 DMFS4RD TI TTO69J7 DMFS4RD TN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMFS4RD MA Inhibitor DMFS4RD RN Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases. Hepatology. 2001 May;33(5):1053-9. DMFS4RD RU https://pubmed.ncbi.nlm.nih.gov/11343231 DMFS7QK DI DMFS7QK DMFS7QK DN M-5MPEP DMFS7QK TI TTHS256 DMFS7QK TN Metabotropic glutamate receptor 5 (mGluR5) DMFS7QK MA Modulator (allosteric modulator) DMFS7QK RN A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtyp... Mol Pharmacol. 2005 Dec;68(6):1793-802. DMFS7QK RU https://pubmed.ncbi.nlm.nih.gov/16155210 DMFSAK3 DI DMFSAK3 DMFSAK3 DN IAA-94 DMFSAK3 TI TT0FC1V DMFSAK3 TN Volume regulated chloride channel (VRAC) DMFSAK3 MA Blocker (channel blocker) DMFSAK3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DMFSAK3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DMFSH2I DI DMFSH2I DMFSH2I DN 4-iodo-acetamido phenylboronic acid DMFSH2I TI TTHI19T DMFSH2I TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMFSH2I MA Inhibitor DMFSH2I RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFSH2I RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFSHXW DI DMFSHXW DMFSHXW DN example 8 [WO1999033801A1] DMFSHXW TI TTQ7R2V DMFSHXW TN Tripeptidyl-peptidase II (TPP2) DMFSHXW MA Inhibitor DMFSHXW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2423). DMFSHXW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2423 DMFSJQC DI DMFSJQC DMFSJQC DN PMID24793884C74 DMFSJQC TI TT4D2GZ DMFSJQC TN Yet another novel kinase 2 (STK32B) DMFSJQC MA Inhibitor DMFSJQC RN Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82. DMFSJQC RU https://pubmed.ncbi.nlm.nih.gov/24793884 DMFSJQC DI DMFSJQC DMFSJQC DN PMID24793884C74 DMFSJQC TI TT7ZY03 DMFSJQC TN Oxidative stress responsive 1 (OXSR1) DMFSJQC MA Inhibitor DMFSJQC RN Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82. DMFSJQC RU https://pubmed.ncbi.nlm.nih.gov/24793884 DMFSJQC DI DMFSJQC DMFSJQC DN PMID24793884C74 DMFSJQC TI TTSMTDI DMFSJQC TN CDC7-related kinase (CDC7) DMFSJQC MA Inhibitor DMFSJQC RN Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82. DMFSJQC RU https://pubmed.ncbi.nlm.nih.gov/24793884 DMFSKDM DI DMFSKDM DMFSKDM DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H DMFSKDM TI TTKWM86 DMFSKDM TN Opioid receptor mu (MOP) DMFSKDM MA Inhibitor DMFSKDM RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMFSKDM RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMFSKDM DI DMFSKDM DMFSKDM DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H DMFSKDM TI TT27RFC DMFSKDM TN Opioid receptor delta (OPRD1) DMFSKDM MA Inhibitor DMFSKDM RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMFSKDM RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMFSKDM DI DMFSKDM DMFSKDM DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H DMFSKDM TI TTCG0AL DMFSKDM TN Cholecystokinin receptor type A (CCKAR) DMFSKDM MA Inhibitor DMFSKDM RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMFSKDM RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMFSPHE DI DMFSPHE DMFSPHE DN Cis-2-fluoro-2-phenylcyclopropanamine DMFSPHE TI TTGP7BY DMFSPHE TN Monoamine oxidase type B (MAO-B) DMFSPHE MA Inhibitor DMFSPHE RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMFSPHE RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMFSUJB DI DMFSUJB DMFSUJB DN Kuwanon J DMFSUJB TI TTELIN2 DMFSUJB TN PTPN1 messenger RNA (PTPN1 mRNA) DMFSUJB MA Inhibitor DMFSUJB RN Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61. DMFSUJB RU https://pubmed.ncbi.nlm.nih.gov/19846295 DMFSW5M DI DMFSW5M DMFSW5M DN N-isopropyl estradiol-16-carboxamide DMFSW5M TI TTIWB6L DMFSW5M TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMFSW5M MA Inhibitor DMFSW5M RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMFSW5M RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMFSXOM DI DMFSXOM DMFSXOM DN Gamma-acetylenic GABA DMFSXOM TI TTT2LD9 DMFSXOM TN GABA transaminase (ABAT) DMFSXOM MA Inhibitor DMFSXOM RN Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration. Neurology. 1981 Feb;31(2):207-11. DMFSXOM RU https://pubmed.ncbi.nlm.nih.gov/6258106 DMFSXTJ DI DMFSXTJ DMFSXTJ DN (S)-Ethyl 6-(2-oxohexadecanamido)decanoate DMFSXTJ TI TTT1JVS DMFSXTJ TN Cytosolic phospholipase A2 (GIVA cPLA2) DMFSXTJ MA Inhibitor DMFSXTJ RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMFSXTJ RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMFSZ8H DI DMFSZ8H DMFSZ8H DN (+/-)-threo-3',4'-Dichloromethylphenidate amide DMFSZ8H TI TTVBI8W DMFSZ8H TN Dopamine transporter (DAT) DMFSZ8H MA Inhibitor DMFSZ8H RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMFSZ8H RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMFT0HU DI DMFT0HU DMFT0HU DN [3H]resolvin D1 DMFT0HU TI TTELV3W DMFT0HU TN Transformation-sensitive protein p120 (TRPA1) DMFT0HU MA Inhibitor (gating inhibitor) DMFT0HU RN Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception. Br J Pharmacol. 2010 Oct;161(3):707-20. DMFT0HU RU https://pubmed.ncbi.nlm.nih.gov/20880407 DMFT0HU DI DMFT0HU DMFT0HU DN [3H]resolvin D1 DMFT0HU TI TTOJ1NF DMFT0HU TN FMLP-related receptor I (FPR2) DMFT0HU MA Agonist DMFT0HU RN Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5. DMFT0HU RU https://pubmed.ncbi.nlm.nih.gov/20080636 DMFT0HU DI DMFT0HU DMFT0HU DN [3H]resolvin D1 DMFT0HU TI TT7OCUB DMFT0HU TN G-protein coupled receptor 32 (GPR32) DMFT0HU MA Agonist DMFT0HU RN Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5. DMFT0HU RU https://pubmed.ncbi.nlm.nih.gov/20080636 DMFT1DO DI DMFT1DO DMFT1DO DN PMID14697765C16a DMFT1DO TI TTHS256 DMFT1DO TN Metabotropic glutamate receptor 5 (mGluR5) DMFT1DO MA Modulator (allosteric modulator) DMFT1DO RN Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21. DMFT1DO RU https://pubmed.ncbi.nlm.nih.gov/14697765 DMFT3J2 DI DMFT3J2 DMFT3J2 DN Decyl-phosphonic acid DMFT3J2 TI TTQ6S1K DMFT3J2 TN Lysophosphatidic acid receptor 1 (LPAR1) DMFT3J2 MA Inhibitor DMFT3J2 RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMFT3J2 RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMFT49S DI DMFT49S DMFT49S DN VRT-750018 DMFT49S TI TTOU65C DMFT49S TN Tyrosine-protein kinase SYK (SYK) DMFT49S MA Inhibitor DMFT49S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). DMFT49S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230 DMFT4GU DI DMFT4GU DMFT4GU DN GANSTIGMINE DMFT4GU TI TT1RS9F DMFT4GU TN Acetylcholinesterase (AChE) DMFT4GU MA Inhibitor DMFT4GU RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DMFT4GU RU https://pubmed.ncbi.nlm.nih.gov/18479118 DMFT51X DI DMFT51X DMFT51X DN Z 944 DMFT51X TI TTZPWGN DMFT51X TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMFT51X MA Modulator DMFT51X RN Z944, a Novel Selective T-Type Calcium Channel Antagonist Delays the Progression of Seizures in the Amygdala Kindling Model.PLoS One.2015 Aug 14;10(8):e0130012. DMFT51X RU https://www.ncbi.nlm.nih.gov/pubmed/26274319 DMFT5N9 DI DMFT5N9 DMFT5N9 DN [125I]7-azido-8-iodoketanserine DMFT5N9 TI TTNZRI3 DMFT5N9 TN Synaptic vesicle amine transporter (SLC18A2) DMFT5N9 MA Inhibitor DMFT5N9 RN Peptide mapping of the [125I]Iodoazidoketanserin and [125I]2-N-[(3'-iodo-4'-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. J Biol Chem. 1997 Oct 10;272(41):26049-55. DMFT5N9 RU https://pubmed.ncbi.nlm.nih.gov/9325342 DMFTBPI DI DMFTBPI DMFTBPI DN Z-YVAD-FMK DMFTBPI TI TTCQIBE DMFTBPI TN Caspase-1 (CASP1) DMFTBPI MA Inhibitor DMFTBPI RN Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines. J Nutr. 2002 Jul;132(7):1812-8. DMFTBPI RU https://pubmed.ncbi.nlm.nih.gov/12097652 DMFTDPQ DI DMFTDPQ DMFTDPQ DN Cyclostellettamine derivative DMFTDPQ TI TTYHPU6 DMFTDPQ TN Histone deacetylase 10 (HDAC10) DMFTDPQ MA Inhibitor DMFTDPQ RN Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. DMFTDPQ RU https://pubmed.ncbi.nlm.nih.gov/15109664 DMFTDPQ DI DMFTDPQ DMFTDPQ DN Cyclostellettamine derivative DMFTDPQ TI TTSHTOI DMFTDPQ TN Histone deacetylase 2 (HDAC2) DMFTDPQ MA Inhibitor DMFTDPQ RN Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. DMFTDPQ RU https://pubmed.ncbi.nlm.nih.gov/15109664 DMFTDPQ DI DMFTDPQ DMFTDPQ DN Cyclostellettamine derivative DMFTDPQ TI TTBH0VX DMFTDPQ TN Histone deacetylase (HDAC) DMFTDPQ MA Inhibitor DMFTDPQ RN Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. DMFTDPQ RU https://pubmed.ncbi.nlm.nih.gov/15109664 DMFTDPQ DI DMFTDPQ DMFTDPQ DN Cyclostellettamine derivative DMFTDPQ TI TTTQGH8 DMFTDPQ TN Histone deacetylase 4 (HDAC4) DMFTDPQ MA Inhibitor DMFTDPQ RN Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. DMFTDPQ RU https://pubmed.ncbi.nlm.nih.gov/15109664 DMFTDPQ DI DMFTDPQ DMFTDPQ DN Cyclostellettamine derivative DMFTDPQ TI TT5ZKDI DMFTDPQ TN Histone deacetylase 6 (HDAC6) DMFTDPQ MA Inhibitor DMFTDPQ RN Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. DMFTDPQ RU https://pubmed.ncbi.nlm.nih.gov/15109664 DMFTDPQ DI DMFTDPQ DMFTDPQ DN Cyclostellettamine derivative DMFTDPQ TI TT6R7JZ DMFTDPQ TN Histone deacetylase 1 (HDAC1) DMFTDPQ MA Inhibitor DMFTDPQ RN Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. DMFTDPQ RU https://pubmed.ncbi.nlm.nih.gov/15109664 DMFTDPQ DI DMFTDPQ DMFTDPQ DN Cyclostellettamine derivative DMFTDPQ TI TTT6LFV DMFTDPQ TN Histone deacetylase 8 (HDAC8) DMFTDPQ MA Inhibitor DMFTDPQ RN Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia. Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20. DMFTDPQ RU https://pubmed.ncbi.nlm.nih.gov/15109664 DMFTIMS DI DMFTIMS DMFTIMS DN Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine DMFTIMS TI TTI7421 DMFTIMS TN Platelet-derived growth factor receptor beta (PDGFRB) DMFTIMS MA Inhibitor DMFTIMS RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMFTIMS RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMFTIMS DI DMFTIMS DMFTIMS DN Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine DMFTIMS TI TT8FYO9 DMFTIMS TN Platelet-derived growth factor receptor alpha (PDGFRA) DMFTIMS MA Inhibitor DMFTIMS RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMFTIMS RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMFTJD5 DI DMFTJD5 DMFTJD5 DN ISIS 188757 DMFTJD5 TI TTLRVIA DMFTJD5 TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DMFTJD5 RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DMFTJD5 RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DMFTLY9 DI DMFTLY9 DMFTLY9 DN S-propyl propane-1-sulfinothioate DMFTLY9 TI TT2SUAQ DMFTLY9 TN Cysteine protease (CYP) DMFTLY9 MA Inhibitor DMFTLY9 RN Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3. DMFTLY9 RU https://pubmed.ncbi.nlm.nih.gov/20692829 DMFTNAP DI DMFTNAP DMFTNAP DN Debio-0930 DMFTNAP TI TTLAFZV DMFTNAP TN AMP-activated protein kinase (AMPK) DMFTNAP MA Stimulator DMFTNAP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1540). DMFTNAP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1540 DMFTO8R DI DMFTO8R DMFTO8R DN SB-357134 DMFTO8R TI TTJS8PY DMFTO8R TN 5-HT 6 receptor (HTR6) DMFTO8R MA Inhibitor DMFTO8R RN Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43. DMFTO8R RU https://pubmed.ncbi.nlm.nih.gov/18053713 DMFTPMX DI DMFTPMX DMFTPMX DN MCL0129 DMFTPMX TI TTD0CIQ DMFTPMX TN Melanocortin receptor 4 (MC4R) DMFTPMX MA Antagonist DMFTPMX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285). DMFTPMX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285 DMFTW0U DI DMFTW0U DMFTW0U DN RO116-4875/608 DMFTW0U TI TTU3Y87 DMFTW0U TN CCR3 messenger RNA (CCR3 mRNA) DMFTW0U MA Antagonist DMFTW0U RN Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9. DMFTW0U RU https://pubmed.ncbi.nlm.nih.gov/12070060 DMFU1PK DI DMFU1PK DMFU1PK DN 2-(2,3,4-trimethoxyphenyl)-1H-indene DMFU1PK TI TTVKILB DMFU1PK TN Prostaglandin G/H synthase 2 (COX-2) DMFU1PK MA Inhibitor DMFU1PK RN 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18. DMFU1PK RU https://pubmed.ncbi.nlm.nih.gov/17604631 DMFU1PK DI DMFU1PK DMFU1PK DN 2-(2,3,4-trimethoxyphenyl)-1H-indene DMFU1PK TI TT8NGED DMFU1PK TN Prostaglandin G/H synthase 1 (COX-1) DMFU1PK MA Inhibitor DMFU1PK RN 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18. DMFU1PK RU https://pubmed.ncbi.nlm.nih.gov/17604631 DMFU6AI DI DMFU6AI DMFU6AI DN PMID18986805C9b DMFU6AI TI TT7HF4W DMFU6AI TN Cyclin-dependent kinase 2 (CDK2) DMFU6AI MA Inhibitor DMFU6AI RN Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. DMFU6AI RU https://pubmed.ncbi.nlm.nih.gov/18986805 DMFU6AI DI DMFU6AI DMFU6AI DN PMID18986805C9b DMFU6AI TI TTBTI6P DMFU6AI TN Cyclin-dependent kinase-like 1 (CDKL1) DMFU6AI MA Inhibitor DMFU6AI RN Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. DMFU6AI RU https://pubmed.ncbi.nlm.nih.gov/18986805 DMFU6AI DI DMFU6AI DMFU6AI DN PMID18986805C9b DMFU6AI TI TTH6V3D DMFU6AI TN Cyclin-dependent kinase 1 (CDK1) DMFU6AI MA Inhibitor DMFU6AI RN Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. DMFU6AI RU https://pubmed.ncbi.nlm.nih.gov/18986805 DMFU6AI DI DMFU6AI DMFU6AI DN PMID18986805C9b DMFU6AI TI TT0PG8F DMFU6AI TN Cyclin-dependent kinase 4 (CDK4) DMFU6AI MA Inhibitor DMFU6AI RN Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6486-9. DMFU6AI RU https://pubmed.ncbi.nlm.nih.gov/18986805 DMFU76I DI DMFU76I DMFU76I DN JN-711 DMFU76I TI TTLA931 DMFU76I TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMFU76I MA Agonist DMFU76I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468). DMFU76I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468 DMFU92Z DI DMFU92Z DMFU92Z DN Insulin molecules, Novo DMFU92Z TI TTZOPHG DMFU92Z TN Insulin (INS) DMFU92Z MA Modulator DMFU92Z RN Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 1995 May;38(5):592-8. DMFU92Z RU https://www.ncbi.nlm.nih.gov/pubmed/7489843 DMFU9VH DI DMFU9VH DMFU9VH DN GR-113808 DMFU9VH TI TT07C3Y DMFU9VH TN 5-HT 4 receptor (HTR4) DMFU9VH MA Inhibitor DMFU9VH RN Synthesis of specific bivalent probes that functionally interact with 5-HT(4) receptor dimers. J Med Chem. 2007 Sep 6;50(18):4482-92. DMFU9VH RU https://pubmed.ncbi.nlm.nih.gov/17676726 DMFUABI DI DMFUABI DMFUABI DN 1-aminohexylphosphonic acid DMFUABI TI TTPHMWB DMFUABI TN Aminopeptidase N (ANPEP) DMFUABI MA Inhibitor DMFUABI RN New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6. DMFUABI RU https://pubmed.ncbi.nlm.nih.gov/20347318 DMFUBQ8 DI DMFUBQ8 DMFUBQ8 DN N-(4-tert-butylthiazol-2-yl)-1H-indol-4-amine DMFUBQ8 TI TT7HQD0 DMFUBQ8 TN C-C chemokine receptor type 4 (CCR4) DMFUBQ8 MA Inhibitor DMFUBQ8 RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMFUBQ8 RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMFUBRC DI DMFUBRC DMFUBRC DN 4-((1H-imidazol-1-yl)methyl)benzonitrile DMFUBRC TI TTSZLWK DMFUBRC TN Aromatase (CYP19A1) DMFUBRC MA Inhibitor DMFUBRC RN Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36. DMFUBRC RU https://pubmed.ncbi.nlm.nih.gov/1825337 DMFUBRC DI DMFUBRC DMFUBRC DN 4-((1H-imidazol-1-yl)methyl)benzonitrile DMFUBRC TI TTRA5BZ DMFUBRC TN Steroid 17-alpha-monooxygenase (S17AH) DMFUBRC MA Inhibitor DMFUBRC RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DMFUBRC RU https://pubmed.ncbi.nlm.nih.gov/16750362 DMFUBRC DI DMFUBRC DMFUBRC DN 4-((1H-imidazol-1-yl)methyl)benzonitrile DMFUBRC TI TTIQUX7 DMFUBRC TN Steroid 11-beta-hydroxylase (CYP11B1) DMFUBRC MA Inhibitor DMFUBRC RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMFUBRC RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMFUE43 DI DMFUE43 DMFUE43 DN UCB-1277763 DMFUE43 TI TTQBR95 DMFUE43 TN Stress-activated protein kinase 2a (p38 alpha) DMFUE43 MA Inhibitor DMFUE43 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499). DMFUE43 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499 DMFUG05 DI DMFUG05 DMFUG05 DN Cyclo(1,10)EIYDPGDDIK DMFUG05 TI TTJDUNO DMFUG05 TN T-cell surface antigen CD2 (CD2) DMFUG05 MA Inhibitor DMFUG05 RN Design of beta-hairpin peptides for modulation of cell adhesion by beta-turn constraint. J Med Chem. 2009 Feb 12;52(3):726-36. DMFUG05 RU https://pubmed.ncbi.nlm.nih.gov/19123855 DMFUHKP DI DMFUHKP DMFUHKP DN adenosine diphosphate DMFUHKP TI TT1FE3L DMFUHKP TN P2Y purinoceptor 13 (P2RY13) DMFUHKP MA Agonist DMFUHKP RN Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. DMFUHKP RU https://pubmed.ncbi.nlm.nih.gov/12815166 DMFUHKP DI DMFUHKP DMFUHKP DN adenosine diphosphate DMFUHKP TI TTA93TL DMFUHKP TN P2Y purinoceptor 1 (P2RY1) DMFUHKP MA Agonist DMFUHKP RN Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57. DMFUHKP RU https://pubmed.ncbi.nlm.nih.gov/12391289 DMFUHKP DI DMFUHKP DMFUHKP DN adenosine diphosphate DMFUHKP TI TTNVSKA DMFUHKP TN P2Y purinoceptor 6 (P2RY6) DMFUHKP MA Agonist DMFUHKP RN Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8. DMFUHKP RU https://pubmed.ncbi.nlm.nih.gov/8670200 DMFUHKP DI DMFUHKP DMFUHKP DN adenosine diphosphate DMFUHKP TI TTJ2HKA DMFUHKP TN Long transient receptor potential channel 4 (TRPM4) DMFUHKP MA Inhibitor (gating inhibitor) DMFUHKP RN Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5. DMFUHKP RU https://pubmed.ncbi.nlm.nih.gov/14758478 DMFUHKP DI DMFUHKP DMFUHKP DN adenosine diphosphate DMFUHKP TI TTZ1DT0 DMFUHKP TN P2Y purinoceptor 12 (P2RY12) DMFUHKP MA Agonist DMFUHKP RN P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. DMFUHKP RU https://pubmed.ncbi.nlm.nih.gov/15199474 DMFULZO DI DMFULZO DMFULZO DN Macrocyclic tripeptide motif DMFULZO TI TT6L509 DMFULZO TN Coagulation factor IIa (F2) DMFULZO MA Inhibitor DMFULZO RN Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif, Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996). DMFULZO RU http://www.sciencedirect.com/science/article/pii/S0960894X96005549 DMFULZO DI DMFULZO DMFULZO DN Macrocyclic tripeptide motif DMFULZO TI TT2WR1T DMFULZO TN Cationic trypsinogen (PRSS1) DMFULZO MA Inhibitor DMFULZO RN Novel thrombin inhibitors that are based on a macrocyclic tripeptide motif, Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996). DMFULZO RU http://www.sciencedirect.com/science/article/pii/S0960894X96005549 DMFUM62 DI DMFUM62 DMFUM62 DN ISIS 150463 DMFUM62 TI TTP9K3Q DMFUM62 TN SOD1 messenger RNA (SOD1 mRNA) DMFUM62 RN US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. DMFUM62 RU http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true DMFUNL1 DI DMFUNL1 DMFUNL1 DN Pyridoxine-5'-phosphate DMFUNL1 TI TTUMGNO DMFUNL1 TN Ornithine decarboxylase (ODC1) DMFUNL1 MA Inhibitor DMFUNL1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFUNL1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFUNL1 DI DMFUNL1 DMFUNL1 DN Pyridoxine-5'-phosphate DMFUNL1 TI TTHB48R DMFUNL1 TN Bacterial Pyridoxal phosphate biosynthetic pdxJ (Bact pdxJ) DMFUNL1 MA Inhibitor DMFUNL1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMFUNL1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMFUQIT DI DMFUQIT DMFUQIT DN PMID21493067C1d DMFUQIT TI TT6SA0X DMFUQIT TN Muscle-specific kinase receptor (MUSK) DMFUQIT MA Inhibitor DMFUQIT RN In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. DMFUQIT RU https://pubmed.ncbi.nlm.nih.gov/21493067 DMFUQIT DI DMFUQIT DMFUQIT DN PMID21493067C1d DMFUQIT TI TTRMX3V DMFUQIT TN Janus kinase 2 (JAK-2) DMFUQIT MA Inhibitor DMFUQIT RN In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. DMFUQIT RU https://pubmed.ncbi.nlm.nih.gov/21493067 DMFUQIT DI DMFUQIT DMFUQIT DN PMID21493067C1d DMFUQIT TI TTST7KB DMFUQIT TN Fibroblast growth factor receptor 3 (FGFR3) DMFUQIT MA Inhibitor DMFUQIT RN In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. DMFUQIT RU https://pubmed.ncbi.nlm.nih.gov/21493067 DMFUQIT DI DMFUQIT DMFUQIT DN PMID21493067C1d DMFUQIT TI TTXABCW DMFUQIT TN NT-3 growth factor receptor (TrkC) DMFUQIT MA Inhibitor DMFUQIT RN In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. DMFUQIT RU https://pubmed.ncbi.nlm.nih.gov/21493067 DMFUQIT DI DMFUQIT DMFUQIT DN PMID21493067C1d DMFUQIT TI TTT7PJU DMFUQIT TN Janus kinase 3 (JAK-3) DMFUQIT MA Inhibitor DMFUQIT RN In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. DMFUQIT RU https://pubmed.ncbi.nlm.nih.gov/21493067 DMFUQIT DI DMFUQIT DMFUQIT DN PMID21493067C1d DMFUQIT TI TT4DXQT DMFUQIT TN Proto-oncogene c-Ret (RET) DMFUQIT MA Inhibitor DMFUQIT RN In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. DMFUQIT RU https://pubmed.ncbi.nlm.nih.gov/21493067 DMFUT57 DI DMFUT57 DMFUT57 DN 3-cyano-N-(3-ethylphenyl)-5-fluorobenzamide DMFUT57 TI TTHS256 DMFUT57 TN Metabotropic glutamate receptor 5 (mGluR5) DMFUT57 MA Inhibitor DMFUT57 RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMFUT57 RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMFUYR1 DI DMFUYR1 DMFUYR1 DN Pyz11-D-Trp8-SRIF DMFUYR1 TI TTZ6T9E DMFUYR1 TN Somatostatin receptor type 2 (SSTR2) DMFUYR1 MA Inhibitor DMFUYR1 RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DMFUYR1 RU https://pubmed.ncbi.nlm.nih.gov/15943475 DMFUYR1 DI DMFUYR1 DMFUYR1 DN Pyz11-D-Trp8-SRIF DMFUYR1 TI TTAE1BR DMFUYR1 TN Somatostatin receptor type 4 (SSTR4) DMFUYR1 MA Inhibitor DMFUYR1 RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DMFUYR1 RU https://pubmed.ncbi.nlm.nih.gov/15943475 DMFV0JC DI DMFV0JC DMFV0JC DN 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol DMFV0JC TI TTKWM86 DMFV0JC TN Opioid receptor mu (MOP) DMFV0JC MA Inhibitor DMFV0JC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMFV0JC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMFV0JC DI DMFV0JC DMFV0JC DN 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol DMFV0JC TI TTNT7K8 DMFV0JC TN Nociceptin receptor (OPRL1) DMFV0JC MA Inhibitor DMFV0JC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMFV0JC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMFV0JC DI DMFV0JC DMFV0JC DN 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol DMFV0JC TI TT27RFC DMFV0JC TN Opioid receptor delta (OPRD1) DMFV0JC MA Inhibitor DMFV0JC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMFV0JC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMFV0JC DI DMFV0JC DMFV0JC DN 4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol DMFV0JC TI TTQW87Y DMFV0JC TN Opioid receptor kappa (OPRK1) DMFV0JC MA Inhibitor DMFV0JC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMFV0JC RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMFV3Y9 DI DMFV3Y9 DMFV3Y9 DN 3,4-difluorobenzaldehyde O-benzoyloxime DMFV3Y9 TI TTDNFMT DMFV3Y9 TN Platelet-activating factor acetylhydrolase (PLA2G7) DMFV3Y9 MA Inhibitor DMFV3Y9 RN Potent inhibitors of lipoprotein-associated phospholipase A(2): benzaldehyde O-heterocycle-4-carbonyloxime. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5576-9. DMFV3Y9 RU https://pubmed.ncbi.nlm.nih.gov/16919943 DMFV5UL DI DMFV5UL DMFV5UL DN human monoclonal antibodies (GM-CSF) DMFV5UL TI TTNYZG2 DMFV5UL TN Granulocyte-macrophage colony-stimulating factor (CSF2) DMFV5UL MA Modulator DMFV5UL RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMFV5UL RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMFV76H DI DMFV76H DMFV76H DN (2-fluorophenyl)-(4-fluorophenyl)phenylacetamide DMFV76H TI TTMNI76 DMFV76H TN Calcium-activated potassium channel (KCN) DMFV76H MA Inhibitor DMFV76H RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMFV76H RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMFV7NI DI DMFV7NI DMFV7NI DN Tyr-Pro-Phe-Phe-OCH2OH DMFV7NI TI TTKWM86 DMFV7NI TN Opioid receptor mu (MOP) DMFV7NI MA Inhibitor DMFV7NI RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMFV7NI RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMFV7NI DI DMFV7NI DMFV7NI DN Tyr-Pro-Phe-Phe-OCH2OH DMFV7NI TI TT27RFC DMFV7NI TN Opioid receptor delta (OPRD1) DMFV7NI MA Inhibitor DMFV7NI RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMFV7NI RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMFVCOP DI DMFVCOP DMFVCOP DN 3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one DMFVCOP TI TTSQIFT DMFVCOP TN 5-HT 1A receptor (HTR1A) DMFVCOP MA Inhibitor DMFVCOP RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMFVCOP RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMFVCOP DI DMFVCOP DMFVCOP DN 3-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one DMFVCOP TI TTEX248 DMFVCOP TN Dopamine D2 receptor (D2R) DMFVCOP MA Inhibitor DMFVCOP RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMFVCOP RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMFVE3N DI DMFVE3N DMFVE3N DN Sulfamic acid 3-(4-methoxy-benzoyl)-phenyl ester DMFVE3N TI TTHM0R1 DMFVE3N TN Steryl-sulfatase (STS) DMFVE3N MA Inhibitor DMFVE3N RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMFVE3N RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMFVGXW DI DMFVGXW DMFVGXW DN AM-1241 DMFVGXW TI TTMSFAW DMFVGXW TN Cannabinoid receptor 2 (CB2) DMFVGXW MA Inhibitor DMFVGXW RN Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315. DMFVGXW RU https://pubmed.ncbi.nlm.nih.gov/19921781 DMFVGXW DI DMFVGXW DMFVGXW DN AM-1241 DMFVGXW TI TT6OEDT DMFVGXW TN Cannabinoid receptor 1 (CB1) DMFVGXW MA Inhibitor DMFVGXW RN Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315. DMFVGXW RU https://pubmed.ncbi.nlm.nih.gov/19921781 DMFVITM DI DMFVITM DMFVITM DN 2-(3-Hydroxycarbamoyl-propyl)-pentanedioic acid DMFVITM TI TT9G4N0 DMFVITM TN Glutamate carboxypeptidase II (GCPII) DMFVITM MA Inhibitor DMFVITM RN Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100. DMFVITM RU https://pubmed.ncbi.nlm.nih.gov/12798312 DMFVN71 DI DMFVN71 DMFVN71 DN Isosorbide-di-(benzylcarbamate) DMFVN71 TI TT1RS9F DMFVN71 TN Acetylcholinesterase (AChE) DMFVN71 MA Inhibitor DMFVN71 RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMFVN71 RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMFVN71 DI DMFVN71 DMFVN71 DN Isosorbide-di-(benzylcarbamate) DMFVN71 TI TTEB0GD DMFVN71 TN Cholinesterase (BCHE) DMFVN71 MA Inhibitor DMFVN71 RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMFVN71 RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMFVP6K DI DMFVP6K DMFVP6K DN 11A1 DMFVP6K TI TTE4KHA DMFVP6K TN Amyloid beta A4 protein (APP) DMFVP6K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMFVP6K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMFVQYI DI DMFVQYI DMFVQYI DN Sulfamic acid benzo[1,3]dioxol-2-ylmethyl ester DMFVQYI TI TTANPDJ DMFVQYI TN Carbonic anhydrase II (CA-II) DMFVQYI MA Inhibitor DMFVQYI RN Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005 Mar 24;48(6):1941-7. DMFVQYI RU https://pubmed.ncbi.nlm.nih.gov/15771438 DMFVS16 DI DMFVS16 DMFVS16 DN KML110 DMFVS16 TI TT6A5ZL DMFVS16 TN Nucleobindin-1 (NUCB1) DMFVS16 MA Antagonist DMFVS16 RN A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell. 2015 Jun 18;161(7):1668-80. DMFVS16 RU https://pubmed.ncbi.nlm.nih.gov/26091042 DMFVSBK DI DMFVSBK DMFVSBK DN 1-Methoxy-3-(oxiran-2-ylmethoxy)-9H-xanthen-9-one DMFVSBK TI TT0IHXV DMFVSBK TN DNA topoisomerase II (TOP2) DMFVSBK MA Inhibitor DMFVSBK RN Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues. Eur J Med Chem. 2010 Sep;45(9):4221-8. DMFVSBK RU https://pubmed.ncbi.nlm.nih.gov/20619511 DMFVT81 DI DMFVT81 DMFVT81 DN Kazinol F DMFVT81 TI TTULVH8 DMFVT81 TN Tyrosinase (TYR) DMFVT81 MA Inhibitor DMFVT81 RN Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41. DMFVT81 RU https://pubmed.ncbi.nlm.nih.gov/19046886 DMFVT8A DI DMFVT8A DMFVT8A DN 6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline DMFVT8A TI TTGKNB4 DMFVT8A TN Epidermal growth factor receptor (EGFR) DMFVT8A MA Inhibitor DMFVT8A RN Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. DMFVT8A RU https://pubmed.ncbi.nlm.nih.gov/17869510 DMFVYHI DI DMFVYHI DMFVYHI DN 4-(2-methoxyphenylethynyl)-2-methylthiazole DMFVYHI TI TTHS256 DMFVYHI TN Metabotropic glutamate receptor 5 (mGluR5) DMFVYHI MA Inhibitor DMFVYHI RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMFVYHI RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMFW1JC DI DMFW1JC DMFW1JC DN C-Naphthalen-1-yl-methylamine DMFW1JC TI TTWG9A4 DMFW1JC TN Adrenergic receptor alpha-2A (ADRA2A) DMFW1JC MA Inhibitor DMFW1JC RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMFW1JC RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMFW1JC DI DMFW1JC DMFW1JC DN C-Naphthalen-1-yl-methylamine DMFW1JC TI TTWM4TY DMFW1JC TN Adrenergic receptor alpha-2B (ADRA2B) DMFW1JC MA Inhibitor DMFW1JC RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMFW1JC RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMFW1JC DI DMFW1JC DMFW1JC DN C-Naphthalen-1-yl-methylamine DMFW1JC TI TT2NUT5 DMFW1JC TN Adrenergic receptor alpha-2C (ADRA2C) DMFW1JC MA Inhibitor DMFW1JC RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMFW1JC RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMFW5VK DI DMFW5VK DMFW5VK DN ISIS 100748 DMFW5VK TI TTVXEGU DMFW5VK TN ADAM10 messenger RNA (ADAM10 mRNA) DMFW5VK RN US patent application no. 6,228,648, Antisense modulation of ADAM10 expression. DMFW5VK RU http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true DMFW6Q0 DI DMFW6Q0 DMFW6Q0 DN 8-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole DMFW6Q0 TI TTJQOD7 DMFW6Q0 TN 5-HT 2A receptor (HTR2A) DMFW6Q0 MA Inhibitor DMFW6Q0 RN Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8. DMFW6Q0 RU https://pubmed.ncbi.nlm.nih.gov/11755343 DMFW8O5 DI DMFW8O5 DMFW8O5 DN NOX-B11 DMFW8O5 TI TTWDC17 DMFW8O5 TN Growth hormone secretagogue receptor 1 (GHSR) DMFW8O5 MA Antagonist DMFW8O5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246). DMFW8O5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246 DMFW9D3 DI DMFW9D3 DMFW9D3 DN 2-Amino-6-(2-chloro-benzenesulfonyl)-benzonitrile DMFW9D3 TI TT84ETX DMFW9D3 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMFW9D3 MA Inhibitor DMFW9D3 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMFW9D3 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMFWA9Y DI DMFWA9Y DMFWA9Y DN 2-p-tolyl-4H-chromen-4-one DMFWA9Y TI TTGP7BY DMFWA9Y TN Monoamine oxidase type B (MAO-B) DMFWA9Y MA Inhibitor DMFWA9Y RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMFWA9Y RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMFWCAJ DI DMFWCAJ DMFWCAJ DN PMID14697765C11a DMFWCAJ TI TTHS256 DMFWCAJ TN Metabotropic glutamate receptor 5 (mGluR5) DMFWCAJ MA Modulator (allosteric modulator) DMFWCAJ RN Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21. DMFWCAJ RU https://pubmed.ncbi.nlm.nih.gov/14697765 DMFWDNJ DI DMFWDNJ DMFWDNJ DN detirelix DMFWDNJ TI TT8R70G DMFWDNJ TN Gonadotropin-releasing hormone receptor (GNRHR) DMFWDNJ MA Modulator DMFWDNJ RN Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix). J Clin Endocrinol Metab. 1991 Apr;72(4):927-33. DMFWDNJ RU https://www.ncbi.nlm.nih.gov/pubmed/2005220 DMFWE4H DI DMFWE4H DMFWE4H DN [125I]GR231118 DMFWE4H TI TTRK9JT DMFWE4H TN Neuropeptide Y receptor type 1 (NPY1R) DMFWE4H MA Antagonist DMFWE4H RN [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46. DMFWE4H RU https://pubmed.ncbi.nlm.nih.gov/10694200 DMFWE4H DI DMFWE4H DMFWE4H DN [125I]GR231118 DMFWE4H TI TTW4N16 DMFWE4H TN Neuropeptide Y receptor type 4 (NPY4R) DMFWE4H MA Agonist DMFWE4H RN [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors. Br J Pharmacol. 2000 Jan;129(1):37-46. DMFWE4H RU https://pubmed.ncbi.nlm.nih.gov/10694200 DMFWJC2 DI DMFWJC2 DMFWJC2 DN Boceprevir DMFWJC2 TI TT1D53B DMFWJC2 TN COVID-19 3C-like protease (3CLpro) DMFWJC2 MA Inhibitor DMFWJC2 RN Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. 2020. April 20. doi: https://doi.org/10.1101/2020.04.20.051581 DMFWJC2 RU https://www.biorxiv.org/content/10.1101/2020.04.20.051581v1 DMFWN5U DI DMFWN5U DMFWN5U DN N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine DMFWN5U TI TTGKNB4 DMFWN5U TN Epidermal growth factor receptor (EGFR) DMFWN5U MA Inhibitor DMFWN5U RN Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28. DMFWN5U RU https://pubmed.ncbi.nlm.nih.gov/8632415 DMFWOMY DI DMFWOMY DMFWOMY DN 2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol DMFWOMY TI TTZAYWL DMFWOMY TN Estrogen receptor (ESR) DMFWOMY MA Inhibitor DMFWOMY RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMFWOMY RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMFWOMY DI DMFWOMY DMFWOMY DN 2-(4-Hydroxy-phenyl)-7-isopropyl-benzooxazol-5-ol DMFWOMY TI TTOM3J0 DMFWOMY TN Estrogen receptor beta (ESR2) DMFWOMY MA Inhibitor DMFWOMY RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMFWOMY RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMFWTOP DI DMFWTOP DMFWTOP DN ASP-8370 DMFWTOP TI TTMI6F5 DMFWTOP TN Transient receptor potential cation channel V1 (TRPV1) DMFWTOP MA Antagonist DMFWTOP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DMFWTOP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DMFWVJI DI DMFWVJI DMFWVJI DN 4-(1H-1,2,3-triazol-5-yl)pyridine DMFWVJI TI TTZJYKH DMFWVJI TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMFWVJI MA Inhibitor DMFWVJI RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMFWVJI RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMFX16H DI DMFX16H DMFX16H DN Iso-OMPA DMFX16H TI TTEB0GD DMFX16H TN Cholinesterase (BCHE) DMFX16H MA Inhibitor DMFX16H RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMFX16H RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMFX16H DI DMFX16H DMFX16H DN Iso-OMPA DMFX16H TI TT1RS9F DMFX16H TN Acetylcholinesterase (AChE) DMFX16H MA Inhibitor DMFX16H RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMFX16H RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMFX9H8 DI DMFX9H8 DMFX9H8 DN (2-bromophenyl)difluoromethanesulfonamide DMFX9H8 TI TTUNARX DMFX9H8 TN Carbonic anhydrase (CA) DMFX9H8 MA Inhibitor DMFX9H8 RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMFX9H8 RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMFX9H8 DI DMFX9H8 DMFX9H8 DN (2-bromophenyl)difluoromethanesulfonamide DMFX9H8 TI TTHQPL7 DMFX9H8 TN Carbonic anhydrase I (CA-I) DMFX9H8 MA Inhibitor DMFX9H8 RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMFX9H8 RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMFX9H8 DI DMFX9H8 DMFX9H8 DN (2-bromophenyl)difluoromethanesulfonamide DMFX9H8 TI TT2LVK8 DMFX9H8 TN Carbonic anhydrase IX (CA-IX) DMFX9H8 MA Inhibitor DMFX9H8 RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMFX9H8 RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMFX9H8 DI DMFX9H8 DMFX9H8 DN (2-bromophenyl)difluoromethanesulfonamide DMFX9H8 TI TTANPDJ DMFX9H8 TN Carbonic anhydrase II (CA-II) DMFX9H8 MA Inhibitor DMFX9H8 RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMFX9H8 RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMFXA8P DI DMFXA8P DMFXA8P DN [1,1':2',1'']Terphenyl-4'-carbaldehyde oxime DMFXA8P TI TTZAYWL DMFXA8P TN Estrogen receptor (ESR) DMFXA8P MA Inhibitor DMFXA8P RN Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J Med Chem. 2003 Sep 11;46(19):4032-42. DMFXA8P RU https://pubmed.ncbi.nlm.nih.gov/12954056 DMFXA8P DI DMFXA8P DMFXA8P DN [1,1':2',1'']Terphenyl-4'-carbaldehyde oxime DMFXA8P TI TTOM3J0 DMFXA8P TN Estrogen receptor beta (ESR2) DMFXA8P MA Inhibitor DMFXA8P RN Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process. J Med Chem. 2003 Sep 11;46(19):4032-42. DMFXA8P RU https://pubmed.ncbi.nlm.nih.gov/12954056 DMFXB21 DI DMFXB21 DMFXB21 DN 1,2-Di-p-tolyl-ethane-1,2-dione DMFXB21 TI TTMF541 DMFXB21 TN Liver carboxylesterase (CES1) DMFXB21 MA Inhibitor DMFXB21 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMFXB21 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMFXDY3 DI DMFXDY3 DMFXDY3 DN 2-(1-(aminomethyl)-3-butylcyclopentyl)acetic acid DMFXDY3 TI TTFK1JQ DMFXDY3 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMFXDY3 MA Inhibitor DMFXDY3 RN Synthesis and in vivo evaluation of 3-substituted gababutins. Bioorg Med Chem Lett. 2010 Jan 1;20(1):362-5. DMFXDY3 RU https://pubmed.ncbi.nlm.nih.gov/19897364 DMFXEIK DI DMFXEIK DMFXEIK DN NSC-621351 DMFXEIK TI TT8XK6L DMFXEIK TN Quinone reductase 1 (NQO1) DMFXEIK MA Inhibitor DMFXEIK RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMFXEIK RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMFXG2E DI DMFXG2E DMFXG2E DN 2-thiomorpholino-4H-benzo[h]chromen-4-one DMFXG2E TI TTK3PY9 DMFXG2E TN DNA-dependent protein kinase catalytic (PRKDC) DMFXG2E MA Inhibitor DMFXG2E RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMFXG2E RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMFXJKB DI DMFXJKB DMFXJKB DN S-p-bromobenzyl glutatione DMFXJKB TI TTV9A7R DMFXJKB TN Lactoylglutathione lyase (GLO1) DMFXJKB MA Inhibitor DMFXJKB RN Inhibition of glyoxalase I: the first low-nanomolar tight-binding inhibitors. J Med Chem. 2009 Aug 13;52(15):4650-6. DMFXJKB RU https://pubmed.ncbi.nlm.nih.gov/19610604 DMFXKN1 DI DMFXKN1 DMFXKN1 DN 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine DMFXKN1 TI TT6L509 DMFXKN1 TN Coagulation factor IIa (F2) DMFXKN1 MA Inhibitor DMFXKN1 RN Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26. DMFXKN1 RU https://pubmed.ncbi.nlm.nih.gov/16821772 DMFXKN1 DI DMFXKN1 DMFXKN1 DN 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine DMFXKN1 TI TTPRO7W DMFXKN1 TN Suppressor of tumorigenicity 14 protein (ST14) DMFXKN1 MA Inhibitor DMFXKN1 RN Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26. DMFXKN1 RU https://pubmed.ncbi.nlm.nih.gov/16821772 DMFXKN1 DI DMFXKN1 DMFXKN1 DN 2-nas-phe(3-am)-4-(2-guanidinoethyl)piperidine DMFXKN1 TI TTGY7WI DMFXKN1 TN Urokinase-type plasminogen activator (PLAU) DMFXKN1 MA Inhibitor DMFXKN1 RN Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26. DMFXKN1 RU https://pubmed.ncbi.nlm.nih.gov/16821772 DMFXKRO DI DMFXKRO DMFXKRO DN Des-AA1,2,5-[D-Trp8,IAmp9,(NalphaMe)Cys14]SRIF DMFXKRO TI TTIND6G DMFXKRO TN Somatostatin receptor type 1 (SSTR1) DMFXKRO MA Inhibitor DMFXKRO RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMFXKRO RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMFY3VS DI DMFY3VS DMFY3VS DN 1,4-diphenyl-(1E,3E)-1,3-butadiene DMFY3VS TI TTGP7BY DMFY3VS TN Monoamine oxidase type B (MAO-B) DMFY3VS MA Inhibitor DMFY3VS RN Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4438-46. DMFY3VS RU https://pubmed.ncbi.nlm.nih.gov/16137882 DMFYBLH DI DMFYBLH DMFYBLH DN 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole DMFYBLH TI TTNGILX DMFYBLH TN Adrenergic receptor alpha-1A (ADRA1A) DMFYBLH MA Inhibitor DMFYBLH RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMFYBLH RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMFYBLH DI DMFYBLH DMFYBLH DN 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole DMFYBLH TI TTWM4TY DMFYBLH TN Adrenergic receptor alpha-2B (ADRA2B) DMFYBLH MA Inhibitor DMFYBLH RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMFYBLH RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMFYBLH DI DMFYBLH DMFYBLH DN 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole DMFYBLH TI TT2NUT5 DMFYBLH TN Adrenergic receptor alpha-2C (ADRA2C) DMFYBLH MA Inhibitor DMFYBLH RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMFYBLH RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMFYBLH DI DMFYBLH DMFYBLH DN 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole DMFYBLH TI TT34BHT DMFYBLH TN Adrenergic receptor alpha-1D (ADRA1D) DMFYBLH MA Inhibitor DMFYBLH RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMFYBLH RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMFYBLH DI DMFYBLH DMFYBLH DN 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole DMFYBLH TI TTBRKXS DMFYBLH TN Adrenergic receptor alpha-1B (ADRA1B) DMFYBLH MA Inhibitor DMFYBLH RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMFYBLH RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMFYBLH DI DMFYBLH DMFYBLH DN 4-(1-Naphthalen-1-yl-ethyl)-1H-imidazole DMFYBLH TI TTWG9A4 DMFYBLH TN Adrenergic receptor alpha-2A (ADRA2A) DMFYBLH MA Inhibitor DMFYBLH RN A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33. DMFYBLH RU https://pubmed.ncbi.nlm.nih.gov/7914537 DMFYCQ1 DI DMFYCQ1 DMFYCQ1 DN DBT-066 DMFYCQ1 TI TTMO9HF DMFYCQ1 TN Advanced glycosylation end product receptor (AGER) DMFYCQ1 MA Modulator DMFYCQ1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2843). DMFYCQ1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2843 DMFYDE4 DI DMFYDE4 DMFYDE4 DN ISIS 20993 DMFYDE4 TI TTSRXJW DMFYDE4 TN G-alpha-11 messenger RNA (GNA11 mRNA) DMFYDE4 RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DMFYDE4 RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DMFYEL8 DI DMFYEL8 DMFYEL8 DN 5-(4-Chlorophenyl)-4-p-tolyl-3H-1,2-dithiol-3-one DMFYEL8 TI TT8NGED DMFYEL8 TN Prostaglandin G/H synthase 1 (COX-1) DMFYEL8 MA Inhibitor DMFYEL8 RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMFYEL8 RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMFYG79 DI DMFYG79 DMFYG79 DN N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide DMFYG79 TI TTSHTOI DMFYG79 TN Histone deacetylase 2 (HDAC2) DMFYG79 MA Inhibitor DMFYG79 RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMFYG79 RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMFYG79 DI DMFYG79 DMFYG79 DN N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide DMFYG79 TI TTBH0VX DMFYG79 TN Histone deacetylase (HDAC) DMFYG79 MA Inhibitor DMFYG79 RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMFYG79 RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMFYG79 DI DMFYG79 DMFYG79 DN N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide DMFYG79 TI TT6R7JZ DMFYG79 TN Histone deacetylase 1 (HDAC1) DMFYG79 MA Inhibitor DMFYG79 RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMFYG79 RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMFYJ5V DI DMFYJ5V DMFYJ5V DN 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one DMFYJ5V TI TTVBI8W DMFYJ5V TN Dopamine transporter (DAT) DMFYJ5V MA Inhibitor DMFYJ5V RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMFYJ5V RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMFYJ5V DI DMFYJ5V DMFYJ5V DN 1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one DMFYJ5V TI TTAWNKZ DMFYJ5V TN Norepinephrine transporter (NET) DMFYJ5V MA Inhibitor DMFYJ5V RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMFYJ5V RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMFYJ6O DI DMFYJ6O DMFYJ6O DN PMID21273063C36 DMFYJ6O TI TT7QNVC DMFYJ6O TN Glucose-dependent insulinotropic receptor (GPR119) DMFYJ6O MA Agonist DMFYJ6O RN Design of potent and selective GPR119 agonists for type II diabetes. Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9. DMFYJ6O RU https://pubmed.ncbi.nlm.nih.gov/21273063 DMFYK6T DI DMFYK6T DMFYK6T DN 1-(4-p-Tolyl-butyl)-piperidine DMFYK6T TI TTTIBOJ DMFYK6T TN Histamine H1 receptor (H1R) DMFYK6T MA Inhibitor DMFYK6T RN Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7. DMFYK6T RU https://pubmed.ncbi.nlm.nih.gov/19660947 DMFYK6T DI DMFYK6T DMFYK6T DN 1-(4-p-Tolyl-butyl)-piperidine DMFYK6T TI TTQ6VDM DMFYK6T TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMFYK6T MA Inhibitor DMFYK6T RN Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7. DMFYK6T RU https://pubmed.ncbi.nlm.nih.gov/19660947 DMFYR6H DI DMFYR6H DMFYR6H DN 4-(2-Phenylacetamido)benzenesulfonamide DMFYR6H TI TTUNARX DMFYR6H TN Carbonic anhydrase (CA) DMFYR6H MA Inhibitor DMFYR6H RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMFYR6H RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMFYR6H DI DMFYR6H DMFYR6H DN 4-(2-Phenylacetamido)benzenesulfonamide DMFYR6H TI TTHQPL7 DMFYR6H TN Carbonic anhydrase I (CA-I) DMFYR6H MA Inhibitor DMFYR6H RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMFYR6H RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMFYR6H DI DMFYR6H DMFYR6H DN 4-(2-Phenylacetamido)benzenesulfonamide DMFYR6H TI TTANPDJ DMFYR6H TN Carbonic anhydrase II (CA-II) DMFYR6H MA Inhibitor DMFYR6H RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMFYR6H RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMFYUMX DI DMFYUMX DMFYUMX DN UCL-67022 DMFYUMX TI TT5ZKDI DMFYUMX TN Histone deacetylase 6 (HDAC6) DMFYUMX MA Inhibitor DMFYUMX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2618). DMFYUMX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2618 DMFYWE3 DI DMFYWE3 DMFYWE3 DN CD-832.HCL DMFYWE3 TI TT5HONZ DMFYWE3 TN Calcium channel unspecific (CaC) DMFYWE3 MA Modulator DMFYWE3 RN Actions of a new Ca2+ channel antagonist, CD832, on two types of Ca2+ channels in smooth muscle. Eur J Pharmacol. 1994 Feb 11;252(3):267-74. DMFYWE3 RU https://www.ncbi.nlm.nih.gov/pubmed/8162949 DMFZ2PI DI DMFZ2PI DMFZ2PI DN 6-bromo-5-methyl-1H-indole-2,3-dione DMFZ2PI TI TTMF541 DMFZ2PI TN Liver carboxylesterase (CES1) DMFZ2PI MA Inhibitor DMFZ2PI RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMFZ2PI RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMFZAS9 DI DMFZAS9 DMFZAS9 DN N-(2,4-dimethylphenyl)-2-nitrobenzamide DMFZAS9 TI TTVTX4N DMFZAS9 TN Bacterial Fatty acid synthetase I (Bact inhA) DMFZAS9 MA Inhibitor DMFZAS9 RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMFZAS9 RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMFZH49 DI DMFZH49 DMFZH49 DN Phenyl Boronic acid DMFZH49 TI TTLP6GN DMFZH49 TN Bacterial DD-carboxypeptidase (Bact vanYB) DMFZH49 MA Inhibitor DMFZH49 RN Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106. DMFZH49 RU https://pubmed.ncbi.nlm.nih.gov/19731939 DMFZH49 DI DMFZH49 DMFZH49 DN Phenyl Boronic acid DMFZH49 TI TTANPDJ DMFZH49 TN Carbonic anhydrase II (CA-II) DMFZH49 MA Inhibitor DMFZH49 RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMFZH49 RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMFZH49 DI DMFZH49 DMFZH49 DN Phenyl Boronic acid DMFZH49 TI TTZHA0O DMFZH49 TN Carbonic anhydrase IV (CA-IV) DMFZH49 MA Inhibitor DMFZH49 RN Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8. DMFZH49 RU https://pubmed.ncbi.nlm.nih.gov/19128966 DMFZH49 DI DMFZH49 DMFZH49 DN Phenyl Boronic acid DMFZH49 TI TTUNARX DMFZH49 TN Carbonic anhydrase (CA) DMFZH49 MA Inhibitor DMFZH49 RN Carbonic anhydrase inhibitors: inhibition of the cytosolic human isozyme VII with anions. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3139-43. DMFZH49 RU https://pubmed.ncbi.nlm.nih.gov/16621537 DMFZH49 DI DMFZH49 DMFZH49 DN Phenyl Boronic acid DMFZH49 TI TTDP1UC DMFZH49 TN Fatty acid amide hydrolase (FAAH) DMFZH49 MA Inhibitor DMFZH49 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMFZH49 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMFZH49 DI DMFZH49 DMFZH49 DN Phenyl Boronic acid DMFZH49 TI TTHQPL7 DMFZH49 TN Carbonic anhydrase I (CA-I) DMFZH49 MA Inhibitor DMFZH49 RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMFZH49 RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMFZJRN DI DMFZJRN DMFZJRN DN Acetyl-Ala-Ala-Pro-Ala-trifluromethane DMFZJRN TI TT3NKIB DMFZJRN TN Pancreatic elastase 1 (CELA1) DMFZJRN MA Inhibitor DMFZJRN RN Synthesis of peptidyl fluoromethyl ketones and peptidyl alpha-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase, ... J Med Chem. 1990 Jan;33(1):394-407. DMFZJRN RU https://pubmed.ncbi.nlm.nih.gov/2296031 DMFZMA2 DI DMFZMA2 DMFZMA2 DN VER-156084 DMFZMA2 TI TTMSFAW DMFZMA2 TN Cannabinoid receptor 2 (CB2) DMFZMA2 MA Inhibitor DMFZMA2 RN Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4. DMFZMA2 RU https://pubmed.ncbi.nlm.nih.gov/19515560 DMFZMA2 DI DMFZMA2 DMFZMA2 DN VER-156084 DMFZMA2 TI TT6OEDT DMFZMA2 TN Cannabinoid receptor 1 (CB1) DMFZMA2 MA Inhibitor DMFZMA2 RN Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4. DMFZMA2 RU https://pubmed.ncbi.nlm.nih.gov/19515560 DMFZMA2 DI DMFZMA2 DMFZMA2 DN VER-156084 DMFZMA2 TI TTDP1UC DMFZMA2 TN Fatty acid amide hydrolase (FAAH) DMFZMA2 MA Inhibitor DMFZMA2 RN Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4241-4. DMFZMA2 RU https://pubmed.ncbi.nlm.nih.gov/19515560 DMFZML9 DI DMFZML9 DMFZML9 DN DP-3590 DMFZML9 TI TTNDSF4 DMFZML9 TN Proto-oncogene c-Met (MET) DMFZML9 MA Inhibitor DMFZML9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMFZML9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMFZN7J DI DMFZN7J DMFZN7J DN 5-Me-IAA DMFZN7J TI TTQMXLS DMFZN7J TN GABA(A) receptor rho2 (GABRR2) DMFZN7J MA Agonist DMFZN7J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DMFZN7J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DMFZN7J DI DMFZN7J DMFZN7J DN 5-Me-IAA DMFZN7J TI TT4N6D8 DMFZN7J TN GABA(A) receptor rho3 (GABRR3) DMFZN7J MA Agonist DMFZN7J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DMFZN7J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DMFZN7J DI DMFZN7J DMFZN7J DN 5-Me-IAA DMFZN7J TI TT6XFEU DMFZN7J TN GABA(A) receptor rho1 (GABRR1) DMFZN7J MA Agonist DMFZN7J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DMFZN7J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DMFZPCD DI DMFZPCD DMFZPCD DN N-(naphthalen-1-yl)-4-phenylthiazol-2-amine DMFZPCD TI TT7HQD0 DMFZPCD TN C-C chemokine receptor type 4 (CCR4) DMFZPCD MA Inhibitor DMFZPCD RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMFZPCD RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMFZXI2 DI DMFZXI2 DMFZXI2 DN NVP-TAE684 DMFZXI2 TI TTCBFJO DMFZXI2 TN Insulin receptor (INSR) DMFZXI2 MA Inhibitor DMFZXI2 RN Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5. DMFZXI2 RU https://pubmed.ncbi.nlm.nih.gov/17185414 DMG05V1 DI DMG05V1 DMG05V1 DN 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone DMG05V1 TI TTNJYV2 DMG05V1 TN Gamma-aminobutyric acid receptor (GAR) DMG05V1 MA Inhibitor DMG05V1 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMG05V1 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMG05V1 DI DMG05V1 DMG05V1 DN 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone DMG05V1 TI TT06RH5 DMG05V1 TN GABA(A) receptor gamma-2 (GABRG2) DMG05V1 MA Inhibitor DMG05V1 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMG05V1 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMG05V1 DI DMG05V1 DMG05V1 DN 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone DMG05V1 TI TTZA1NY DMG05V1 TN GABA(A) receptor beta-2 (GABRB2) DMG05V1 MA Inhibitor DMG05V1 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMG05V1 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMG05V1 DI DMG05V1 DMG05V1 DN 6-ethyl-3-(3-pentoxycarbonyl)-4-quinolone DMG05V1 TI TT1MPAY DMG05V1 TN GABA(A) receptor alpha-1 (GABRA1) DMG05V1 MA Inhibitor DMG05V1 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMG05V1 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMG0B4N DI DMG0B4N DMG0B4N DN PMID23434029C53 DMG0B4N TI TTHS256 DMG0B4N TN Metabotropic glutamate receptor 5 (mGluR5) DMG0B4N MA Modulator (allosteric modulator) DMG0B4N RN Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett. 2013 Apr 1;23(7):2134-9. DMG0B4N RU https://pubmed.ncbi.nlm.nih.gov/23434029 DMG0CSZ DI DMG0CSZ DMG0CSZ DN (S)-2-amino-6-hydroxy-N-(4-octylphenyl)hexanamide DMG0CSZ TI TTCN0M9 DMG0CSZ TN Sphingosine kinase 2 (SPHK2) DMG0CSZ MA Inhibitor DMG0CSZ RN Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21. DMG0CSZ RU https://pubmed.ncbi.nlm.nih.gov/19800228 DMG0EL7 DI DMG0EL7 DMG0EL7 DN 5-MEO-DMT DMG0EL7 TI TTJQOD7 DMG0EL7 TN 5-HT 2A receptor (HTR2A) DMG0EL7 MA Inhibitor DMG0EL7 RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMG0EL7 RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMG0EL7 DI DMG0EL7 DMG0EL7 DN 5-MEO-DMT DMG0EL7 TI TTJS8PY DMG0EL7 TN 5-HT 6 receptor (HTR6) DMG0EL7 MA Inhibitor DMG0EL7 RN Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5832-5. DMG0EL7 RU https://pubmed.ncbi.nlm.nih.gov/16945532 DMG0EL7 DI DMG0EL7 DMG0EL7 DN 5-MEO-DMT DMG0EL7 TI TT0K1SC DMG0EL7 TN 5-HT 2B receptor (HTR2B) DMG0EL7 MA Inhibitor DMG0EL7 RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMG0EL7 RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMG0EL7 DI DMG0EL7 DMG0EL7 DN 5-MEO-DMT DMG0EL7 TI TTWJBZ5 DMG0EL7 TN 5-HT 2C receptor (HTR2C) DMG0EL7 MA Inhibitor DMG0EL7 RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMG0EL7 RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMG0I25 DI DMG0I25 DMG0I25 DN 2-propylamido-5-sulfonamidoindane DMG0I25 TI TTHQPL7 DMG0I25 TN Carbonic anhydrase I (CA-I) DMG0I25 MA Inhibitor DMG0I25 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMG0I25 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMG0I25 DI DMG0I25 DMG0I25 DN 2-propylamido-5-sulfonamidoindane DMG0I25 TI TT2LVK8 DMG0I25 TN Carbonic anhydrase IX (CA-IX) DMG0I25 MA Inhibitor DMG0I25 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMG0I25 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMG0I25 DI DMG0I25 DMG0I25 DN 2-propylamido-5-sulfonamidoindane DMG0I25 TI TTANPDJ DMG0I25 TN Carbonic anhydrase II (CA-II) DMG0I25 MA Inhibitor DMG0I25 RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMG0I25 RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMG0OUD DI DMG0OUD DMG0OUD DN GS4071 DMG0OUD TI TT50QJ3 DMG0OUD TN Influenza Neuraminidase (Influ NA) DMG0OUD MA Inhibitor DMG0OUD RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMG0OUD RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMG0PHU DI DMG0PHU DMG0PHU DN CYNAROPICRIN DMG0PHU TI TTICX3S DMG0PHU TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMG0PHU MA Inhibitor DMG0PHU RN Sesquiterpene lactones are potent and irreversible inhibitors of the antibacterial target enzyme MurA. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5605-9. DMG0PHU RU https://pubmed.ncbi.nlm.nih.gov/16945528 DMG0QKL DI DMG0QKL DMG0QKL DN (2S)-aminobutyryl-L-prolinamide DMG0QKL TI TTQ7R2V DMG0QKL TN Tripeptidyl-peptidase II (TPP2) DMG0QKL MA Inhibitor DMG0QKL RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMG0QKL RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMG0S9B DI DMG0S9B DMG0S9B DN Rp-cAMPS DMG0S9B TI TTYVI76 DMG0S9B TN Fungal Protein kinase A (Fung ypkA) DMG0S9B MA Inhibitor DMG0S9B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694). DMG0S9B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1694 DMG0TW2 DI DMG0TW2 DMG0TW2 DN Isosorbide-2-(benzylcarbamate)-5-mononitrate DMG0TW2 TI TTEB0GD DMG0TW2 TN Cholinesterase (BCHE) DMG0TW2 MA Inhibitor DMG0TW2 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMG0TW2 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMG0UVT DI DMG0UVT DMG0UVT DN Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine DMG0UVT TI TTCM4B3 DMG0UVT TN Nitric-oxide synthase endothelial (NOS3) DMG0UVT MA Inhibitor DMG0UVT RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMG0UVT RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMG0UVT DI DMG0UVT DMG0UVT DN Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine DMG0UVT TI TTF10I9 DMG0UVT TN Nitric-oxide synthase inducible (NOS2) DMG0UVT MA Inhibitor DMG0UVT RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMG0UVT RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMG0UVT DI DMG0UVT DMG0UVT DN Hexahydro-cyclopenta[c]pyrrol-(1Z)-ylideneamine DMG0UVT TI TTZUFI5 DMG0UVT TN Nitric-oxide synthase brain (NOS1) DMG0UVT MA Inhibitor DMG0UVT RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMG0UVT RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMG0VN6 DI DMG0VN6 DMG0VN6 DN 1-Deaza-Adenosine DMG0VN6 TI TTLP57V DMG0VN6 TN Adenosine deaminase (ADA) DMG0VN6 MA Inhibitor DMG0VN6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMG0VN6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMG0XC7 DI DMG0XC7 DMG0XC7 DN PMID23434029C41 DMG0XC7 TI TTHS256 DMG0XC7 TN Metabotropic glutamate receptor 5 (mGluR5) DMG0XC7 MA Modulator (allosteric modulator) DMG0XC7 RN Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. Bioorg Med Chem Lett. 2013 Apr 1;23(7):2134-9. DMG0XC7 RU https://pubmed.ncbi.nlm.nih.gov/23434029 DMG0Y3W DI DMG0Y3W DMG0Y3W DN 4-Ethyl-oxazolidin-(2Z)-ylideneamine DMG0Y3W TI TTZUFI5 DMG0Y3W TN Nitric-oxide synthase brain (NOS1) DMG0Y3W MA Inhibitor DMG0Y3W RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMG0Y3W RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMG0Y3W DI DMG0Y3W DMG0Y3W DN 4-Ethyl-oxazolidin-(2Z)-ylideneamine DMG0Y3W TI TTF10I9 DMG0Y3W TN Nitric-oxide synthase inducible (NOS2) DMG0Y3W MA Inhibitor DMG0Y3W RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMG0Y3W RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMG12AE DI DMG12AE DMG12AE DN Ajinomoto 3 DMG12AE TI TTXHYV6 DMG12AE TN Voltage-gated L-type calcium channel (L-CaC) DMG12AE MA Blocker DMG12AE RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMG12AE RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMG17IU DI DMG17IU DMG17IU DN [14C]MTEP DMG17IU TI TTHS256 DMG17IU TN Metabotropic glutamate receptor 5 (mGluR5) DMG17IU MA Modulator (allosteric modulator) DMG17IU RN [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1044-51. DMG17IU RU https://pubmed.ncbi.nlm.nih.gov/12438526 DMG19LW DI DMG19LW DMG19LW DN Ac-Cys-Ile-Phe(4-NO2)-Lys-Phe(4-NO2)-Tyr DMG19LW TI TT6PKBN DMG19LW TN Proto-oncogene c-Src (SRC) DMG19LW MA Inhibitor DMG19LW RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMG19LW RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMG1ATX DI DMG1ATX DMG1ATX DN [(1e)-4-Phenylbut-1-Enyl]Benzene DMG1ATX TI TTGP7BY DMG1ATX TN Monoamine oxidase type B (MAO-B) DMG1ATX MA Inhibitor DMG1ATX RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMG1ATX RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMG1BYH DI DMG1BYH DMG1BYH DN Human recombinant factor VIII DMG1BYH TI TT1290U DMG1BYH TN Coagulation factor VIII (F8) DMG1BYH MA Modulator DMG1BYH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMG1BYH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMG1CD5 DI DMG1CD5 DMG1CD5 DN D-315 DMG1CD5 TI TTEX248 DMG1CD5 TN Dopamine D2 receptor (D2R) DMG1CD5 MA Inhibitor DMG1CD5 RN Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template... Bioorg Med Chem. 2010 Aug 1;18(15):5661-74. DMG1CD5 RU https://pubmed.ncbi.nlm.nih.gov/20605099 DMG1CD5 DI DMG1CD5 DMG1CD5 DN D-315 DMG1CD5 TI TT4C8EA DMG1CD5 TN Dopamine D3 receptor (D3R) DMG1CD5 MA Inhibitor DMG1CD5 RN Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template... Bioorg Med Chem. 2010 Aug 1;18(15):5661-74. DMG1CD5 RU https://pubmed.ncbi.nlm.nih.gov/20605099 DMG1K5H DI DMG1K5H DMG1K5H DN (+/-)-threo-N-(6-Phenylhexyl)methylphenidate DMG1K5H TI TTVBI8W DMG1K5H TN Dopamine transporter (DAT) DMG1K5H MA Inhibitor DMG1K5H RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMG1K5H RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMG1KIJ DI DMG1KIJ DMG1KIJ DN (3-Ethoxy-pyridin-2-yl)-pyridin-2-yl-amine DMG1KIJ TI TTHS256 DMG1KIJ TN Metabotropic glutamate receptor 5 (mGluR5) DMG1KIJ MA Inhibitor DMG1KIJ RN Dipyridyl amines: potent metabotropic glutamate subtype 5 receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4350-3. DMG1KIJ RU https://pubmed.ncbi.nlm.nih.gov/16039855 DMG1NM7 DI DMG1NM7 DMG1NM7 DN Uridine-5'-Monophosphate DMG1NM7 TI TTU6BFZ DMG1NM7 TN Candida Thymidylate synthase (Candi TMP1) DMG1NM7 MA Inhibitor DMG1NM7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMG1NM7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMG1NM7 DI DMG1NM7 DMG1NM7 DN Uridine-5'-Monophosphate DMG1NM7 TI TTV7Y40 DMG1NM7 TN Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF) DMG1NM7 MA Inhibitor DMG1NM7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMG1NM7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMG1PNX DI DMG1PNX DMG1PNX DN 7-Phenyl-1-(pyridazin-3-yl)-heptan-1-one DMG1PNX TI TTDP1UC DMG1PNX TN Fatty acid amide hydrolase (FAAH) DMG1PNX MA Inhibitor DMG1PNX RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMG1PNX RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMG1Q0W DI DMG1Q0W DMG1Q0W DN VT-362 DMG1Q0W TI TT2GM5R DMG1Q0W TN Lymphocyte activation antigen CD30 (TNFRSF8) DMG1Q0W MA Modulator DMG1Q0W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1877). DMG1Q0W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1877 DMG1SXD DI DMG1SXD DMG1SXD DN CXCL8 DMG1SXD TI TT30C9G DMG1SXD TN C-X-C chemokine receptor type 2 (CXCR2) DMG1SXD MA Agonist DMG1SXD RN Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. DMG1SXD RU https://pubmed.ncbi.nlm.nih.gov/15282370 DMG1SXD DI DMG1SXD DMG1SXD DN CXCL8 DMG1SXD TI TTBID49 DMG1SXD TN C-X-C chemokine receptor type 4 (CXCR4) DMG1SXD MA Agonist DMG1SXD RN Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. DMG1SXD RU https://pubmed.ncbi.nlm.nih.gov/15282370 DMG1T6H DI DMG1T6H DMG1T6H DN 3'-Methoxy-4'Hydroxyclomiphene DMG1T6H TI TTOM3J0 DMG1T6H TN Estrogen receptor beta (ESR2) DMG1T6H MA Inhibitor DMG1T6H RN Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects ... J Med Chem. 1989 Jan;32(1):192-7. DMG1T6H RU https://pubmed.ncbi.nlm.nih.gov/2909731 DMG1T6H DI DMG1T6H DMG1T6H DN 3'-Methoxy-4'Hydroxyclomiphene DMG1T6H TI TTZAYWL DMG1T6H TN Estrogen receptor (ESR) DMG1T6H MA Inhibitor DMG1T6H RN Phenolic metabolites of clomiphene: [(E,Z)-2-[4-(1,2-diphenyl-2-chlorovinyl)phenoxy]ethyl]diethylamine. Preparation, electrophilicity, and effects ... J Med Chem. 1989 Jan;32(1):192-7. DMG1T6H RU https://pubmed.ncbi.nlm.nih.gov/2909731 DMG1TIV DI DMG1TIV DMG1TIV DN [3H]NLX-112 DMG1TIV TI TTSQIFT DMG1TIV TN 5-HT 1A receptor (HTR1A) DMG1TIV MA Agonist DMG1TIV RN [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand. Naunyn Schmiedebergs Arch Pharmacol. 2010 Oct;382(4):321-30. DMG1TIV RU https://pubmed.ncbi.nlm.nih.gov/20799027 DMG1UOR DI DMG1UOR DMG1UOR DN LG-120838 DMG1UOR TI TT26PHO DMG1UOR TN Mineralocorticoid receptor (MR) DMG1UOR MA Inhibitor DMG1UOR RN 5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9. DMG1UOR RU https://pubmed.ncbi.nlm.nih.gov/9784110 DMG1UOR DI DMG1UOR DMG1UOR DN LG-120838 DMG1UOR TI TTKPW01 DMG1UOR TN Androgen receptor messenger RNA (AR mRNA) DMG1UOR MA Inhibitor DMG1UOR RN 5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9. DMG1UOR RU https://pubmed.ncbi.nlm.nih.gov/9784110 DMG1UOR DI DMG1UOR DMG1UOR DN LG-120838 DMG1UOR TI TTOZRK6 DMG1UOR TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMG1UOR MA Inhibitor DMG1UOR RN 5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists. J Med Chem. 1998 Oct 22;41(22):4354-9. DMG1UOR RU https://pubmed.ncbi.nlm.nih.gov/9784110 DMG1YZQ DI DMG1YZQ DMG1YZQ DN VCP-28 DMG1YZQ TI TTK25J1 DMG1YZQ TN Adenosine A1 receptor (ADORA1) DMG1YZQ MA Inhibitor DMG1YZQ RN Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists. Bioorg Med Chem. 2010 May 1;18(9):3078-87. DMG1YZQ RU https://pubmed.ncbi.nlm.nih.gov/20385496 DMG21PZ DI DMG21PZ DMG21PZ DN Di(2,6-diisopropylphenol) DMG21PZ TI TTANPDJ DMG21PZ TN Carbonic anhydrase II (CA-II) DMG21PZ MA Inhibitor DMG21PZ RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMG21PZ RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMG273T DI DMG273T DMG273T DN 15(S)-15-methyl-PGD2 DMG273T TI TTQDMX5 DMG273T TN Prostaglandin D2 receptor 2 (PTGDR2) DMG273T MA Agonist DMG273T RN Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72. DMG273T RU https://pubmed.ncbi.nlm.nih.gov/12466225 DMG27K1 DI DMG27K1 DMG27K1 DN (4e)-4-Aminohex-4-Enoic Acid DMG27K1 TI TTT2LD9 DMG27K1 TN GABA transaminase (ABAT) DMG27K1 MA Inhibitor DMG27K1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMG27K1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMG2D4S DI DMG2D4S DMG2D4S DN AL7182 DMG2D4S TI TTANPDJ DMG2D4S TN Carbonic anhydrase II (CA-II) DMG2D4S MA Inhibitor DMG2D4S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMG2D4S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMG2HSU DI DMG2HSU DMG2HSU DN 5-methoxy-2-(4-(methylsulfonyl)phenyl)-1H-indole DMG2HSU TI TTVKILB DMG2HSU TN Prostaglandin G/H synthase 2 (COX-2) DMG2HSU MA Inhibitor DMG2HSU RN Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2009 Jul 15;17(14):5312-7. DMG2HSU RU https://pubmed.ncbi.nlm.nih.gov/19560931 DMG2LVM DI DMG2LVM DMG2LVM DN WR-289012 DMG2LVM TI TTSFWA7 DMG2LVM TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMG2LVM MA Inhibitor DMG2LVM RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DMG2LVM RU https://pubmed.ncbi.nlm.nih.gov/19250824 DMG2MSX DI DMG2MSX DMG2MSX DN N-(2-aminoethyl)isoquinoline-5-sulfonamide DMG2MSX TI TTSFWA7 DMG2MSX TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMG2MSX MA Inhibitor DMG2MSX RN Evaluation of broad spectrum protein kinase inhibitors to probe the architecture of the malarial cyclin dependent protein kinase Pfmrk. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4961-6. DMG2MSX RU https://pubmed.ncbi.nlm.nih.gov/17588749 DMG2NI9 DI DMG2NI9 DMG2NI9 DN CPS125 DMG2NI9 TI TTXDKTO DMG2NI9 TN Long transient receptor potential channel 8 (TRPM8) DMG2NI9 MA Activator DMG2NI9 RN Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship. J Pharm Pharm Sci. 2010;13(2):242-53. DMG2NI9 RU https://pubmed.ncbi.nlm.nih.gov/20816009 DMG2P7B DI DMG2P7B DMG2P7B DN ISIS 140157 DMG2P7B TI TTAK0IN DMG2P7B TN SOAT2 messenger RNA (SOAT2 mRNA) DMG2P7B RN US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression. DMG2P7B RU http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true DMG2VQB DI DMG2VQB DMG2VQB DN 5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-ol DMG2VQB TI TT30C9G DMG2VQB TN C-X-C chemokine receptor type 2 (CXCR2) DMG2VQB MA Inhibitor DMG2VQB RN Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):960-3. DMG2VQB RU https://pubmed.ncbi.nlm.nih.gov/16297626 DMG2ZFV DI DMG2ZFV DMG2ZFV DN Guanosine-5',3'-Tetraphosphate DMG2ZFV TI TTBL49X DMG2ZFV TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMG2ZFV MA Inhibitor DMG2ZFV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMG2ZFV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMG32HQ DI DMG32HQ DMG32HQ DN 2-(4-Butoxy-phenoxy)-N-hydroxy-acetamide DMG32HQ TI TT2J34L DMG32HQ TN Arachidonate 5-lipoxygenase (5-LOX) DMG32HQ MA Inhibitor DMG32HQ RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMG32HQ RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMG35MJ DI DMG35MJ DMG35MJ DN Boc-Ile-Leu-L-(difluoro)aminobutyric aid DMG35MJ TI TTWXB3E DMG35MJ TN Hepatitis C virus NS3 helicase (HCV NS3) DMG35MJ MA Inhibitor DMG35MJ RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMG35MJ RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMG362U DI DMG362U DMG362U DN 1,1-bisphosphonate esters DMG362U TI TTS4UGC DMG362U TN Farnesoid X-activated receptor (FXR) DMG362U MA Agonist DMG362U RN The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59. DMG362U RU https://pubmed.ncbi.nlm.nih.gov/11254888 DMG36BD DI DMG36BD DMG36BD DN HI-244 DMG36BD TI TT84ETX DMG36BD TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG36BD MA Inhibitor DMG36BD RN Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea compounds. Bioorg Med Chem Lett. 2001 Feb 26;11(4):523-8. DMG36BD RU https://pubmed.ncbi.nlm.nih.gov/11229762 DMG3A4Z DI DMG3A4Z DMG3A4Z DN 3-(1-benzylpiperidin-4-yloxy)benzamide DMG3A4Z TI TTQW87Y DMG3A4Z TN Opioid receptor kappa (OPRK1) DMG3A4Z MA Inhibitor DMG3A4Z RN Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5847-52. DMG3A4Z RU https://pubmed.ncbi.nlm.nih.gov/20727752 DMG3DUE DI DMG3DUE DMG3DUE DN MANGOSTANOL DMG3DUE TI TT50QJ3 DMG3DUE TN Influenza Neuraminidase (Influ NA) DMG3DUE MA Inhibitor DMG3DUE RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMG3DUE RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMG3F7D DI DMG3F7D DMG3F7D DN 6-methoxy-2,9-dimethyl-9H-beta-carbolin-2-ium DMG3F7D TI TT1RS9F DMG3F7D TN Acetylcholinesterase (AChE) DMG3F7D MA Inhibitor DMG3F7D RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMG3F7D RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMG3FA1 DI DMG3FA1 DMG3FA1 DN (+/-)-threo-N-(4-Phenylbutyl)ritalinol DMG3FA1 TI TTVBI8W DMG3FA1 TN Dopamine transporter (DAT) DMG3FA1 MA Inhibitor DMG3FA1 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMG3FA1 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMG3FDE DI DMG3FDE DMG3FDE DN KL044 DMG3FDE TI TT5MLZR DMG3FDE TN Cryptochrome circadian clock 1 (CRY1) DMG3FDE MA Modulator DMG3FDE RN Development of Small-Molecule Cryptochrome Stabilizer Derivatives as Modulators of the Circadian Clock. ChemMedChem. 2015 Sep;10(9):1489-97. DMG3FDE RU https://pubmed.ncbi.nlm.nih.gov/26174033 DMG3FPJ DI DMG3FPJ DMG3FPJ DN 3-(aminomethyl)-4-(furan-3-yl)butanoic acid DMG3FPJ TI TTFK1JQ DMG3FPJ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMG3FPJ MA Inhibitor DMG3FPJ RN Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32. DMG3FPJ RU https://pubmed.ncbi.nlm.nih.gov/16099652 DMG3MF2 DI DMG3MF2 DMG3MF2 DN (+/-)-2-(4'-Butoxyphenyl)thiomorpholine DMG3MF2 TI TTGP7BY DMG3MF2 TN Monoamine oxidase type B (MAO-B) DMG3MF2 MA Inhibitor DMG3MF2 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMG3MF2 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMG3MF2 DI DMG3MF2 DMG3MF2 DN (+/-)-2-(4'-Butoxyphenyl)thiomorpholine DMG3MF2 TI TT3WG5C DMG3MF2 TN Monoamine oxidase type A (MAO-A) DMG3MF2 MA Inhibitor DMG3MF2 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMG3MF2 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMG3WTE DI DMG3WTE DMG3WTE DN Dimethylnordihydroguarierate acid DMG3WTE TI TTN9T81 DMG3WTE TN Arachidonate 15-lipoxygenase (15-LOX) DMG3WTE MA Inhibitor DMG3WTE RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMG3WTE RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMG3WTE DI DMG3WTE DMG3WTE DN Dimethylnordihydroguarierate acid DMG3WTE TI TT12ABZ DMG3WTE TN Arachidonate 12-lipoxygenase (12-LOX) DMG3WTE MA Inhibitor DMG3WTE RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMG3WTE RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMG3ZD1 DI DMG3ZD1 DMG3ZD1 DN PMID8568816C56 DMG3ZD1 TI TTGKNB4 DMG3ZD1 TN Epidermal growth factor receptor (EGFR) DMG3ZD1 MA Inhibitor DMG3ZD1 RN Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. DMG3ZD1 RU https://pubmed.ncbi.nlm.nih.gov/8568816 DMG418C DI DMG418C DMG418C DN AC-Nle-c[Asp-His-DPhe-Pro-Trp-Lys]-NH2 DMG418C TI TTD0CIQ DMG418C TN Melanocortin receptor 4 (MC4R) DMG418C MA Inhibitor DMG418C RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMG418C RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMG47QU DI DMG47QU DMG47QU DN (E)-6-Styrylisatin DMG47QU TI TTGP7BY DMG47QU TN Monoamine oxidase type B (MAO-B) DMG47QU MA Inhibitor DMG47QU RN Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. DMG47QU RU https://pubmed.ncbi.nlm.nih.gov/19342233 DMG49N2 DI DMG49N2 DMG49N2 DN 2-(2,4-diphenylthiazol-5-yl)acetic acid DMG49N2 TI TTQDMX5 DMG49N2 TN Prostaglandin D2 receptor 2 (PTGDR2) DMG49N2 MA Inhibitor DMG49N2 RN Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 1. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1177-80. DMG49N2 RU https://pubmed.ncbi.nlm.nih.gov/20031403 DMG4HO3 DI DMG4HO3 DMG4HO3 DN 4-(1,2,3-thiadiazol-4-yl)phenyl butylcarbamate DMG4HO3 TI TTDP1UC DMG4HO3 TN Fatty acid amide hydrolase (FAAH) DMG4HO3 MA Inhibitor DMG4HO3 RN The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008. DMG4HO3 RU https://pubmed.ncbi.nlm.nih.gov/19232787 DMG4ITB DI DMG4ITB DMG4ITB DN 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide DMG4ITB TI TTHQPL7 DMG4ITB TN Carbonic anhydrase I (CA-I) DMG4ITB MA Inhibitor DMG4ITB RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMG4ITB RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMG4ITB DI DMG4ITB DMG4ITB DN 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide DMG4ITB TI TTANPDJ DMG4ITB TN Carbonic anhydrase II (CA-II) DMG4ITB MA Inhibitor DMG4ITB RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMG4ITB RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMG4ITB DI DMG4ITB DMG4ITB DN 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide DMG4ITB TI TTSYM0R DMG4ITB TN Carbonic anhydrase XII (CA-XII) DMG4ITB MA Inhibitor DMG4ITB RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMG4ITB RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMG4ITB DI DMG4ITB DMG4ITB DN 2,2,2-Trifluoro-N-(4-sulfamoyl-phenyl)-acetamide DMG4ITB TI TT2LVK8 DMG4ITB TN Carbonic anhydrase IX (CA-IX) DMG4ITB MA Inhibitor DMG4ITB RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMG4ITB RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMG4KIU DI DMG4KIU DMG4KIU DN (S)-secoantioquine hydrochloride DMG4KIU TI TTEX248 DMG4KIU TN Dopamine D2 receptor (D2R) DMG4KIU MA Inhibitor DMG4KIU RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMG4KIU RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMG4LD9 DI DMG4LD9 DMG4LD9 DN 4-Sulfamoyloxy-benzoic acid cyclooctyl ester DMG4LD9 TI TTHM0R1 DMG4LD9 TN Steryl-sulfatase (STS) DMG4LD9 MA Inhibitor DMG4LD9 RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMG4LD9 RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMG4MLA DI DMG4MLA DMG4MLA DN PMID23441572C24 DMG4MLA TI TT1A6HL DMG4MLA TN Tyrosine-protein kinase ABL2 (ABL2) DMG4MLA MA Inhibitor DMG4MLA RN Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47. DMG4MLA RU https://pubmed.ncbi.nlm.nih.gov/23441572 DMG4MLA DI DMG4MLA DMG4MLA DN PMID23441572C24 DMG4MLA TI TT6B75U DMG4MLA TN ABL messenger RNA (ABL mRNA) DMG4MLA MA Inhibitor DMG4MLA RN Rapid discovery of a novel series of Abl kinase inhibitors by application of an integrated microfluidic synthesis and screening platform. J Med Chem. 2013 Apr 11;56(7):3033-47. DMG4MLA RU https://pubmed.ncbi.nlm.nih.gov/23441572 DMG4NQV DI DMG4NQV DMG4NQV DN PMID24418773C37 DMG4NQV TI TTZUXYS DMG4NQV TN Vitamin K-dependent protein C (PROC) DMG4NQV MA Inhibitor DMG4NQV RN Design, synthesis, and SAR of a series of activated protein C (APC) inhibitors with selectivity against thrombin for the treatment of haemophilia. Bioorg Med Chem Lett. 2014 Feb 1;24(3):821-7. DMG4NQV RU https://pubmed.ncbi.nlm.nih.gov/24418773 DMG4NR3 DI DMG4NR3 DMG4NR3 DN 3,4-Dihydroxy-10H-anthracen-9-one DMG4NR3 TI TT2J34L DMG4NR3 TN Arachidonate 5-lipoxygenase (5-LOX) DMG4NR3 MA Inhibitor DMG4NR3 RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMG4NR3 RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMG4RMZ DI DMG4RMZ DMG4RMZ DN ISIS 29471 DMG4RMZ TI TTYMGWX DMG4RMZ TN PDK-1 messenger RNA (PDK-1 mRNA) DMG4RMZ RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMG4RMZ RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMG4UCX DI DMG4UCX DMG4UCX DN 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione DMG4UCX TI TTN9D8E DMG4UCX TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMG4UCX MA Inhibitor DMG4UCX RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMG4UCX RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMG4UCX DI DMG4UCX DMG4UCX DN 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione DMG4UCX TI TTKJEMQ DMG4UCX TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMG4UCX MA Inhibitor DMG4UCX RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMG4UCX RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMG4UCX DI DMG4UCX DMG4UCX DN 5,7-Dinitro-1,4-dihydro-quinoxaline-2,3-dione DMG4UCX TI TTLD29N DMG4UCX TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMG4UCX MA Inhibitor DMG4UCX RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMG4UCX RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMG4W2C DI DMG4W2C DMG4W2C DN 8-Hydroxy-5,7,9-trimethyl-delta-carboline DMG4W2C TI TTJFY5U DMG4W2C TN Adenosine A3 receptor (ADORA3) DMG4W2C MA Inhibitor DMG4W2C RN Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30. DMG4W2C RU https://pubmed.ncbi.nlm.nih.gov/18262425 DMG4X13 DI DMG4X13 DMG4X13 DN 4-(3-benzenesulfonylphenyl)piperazine DMG4X13 TI TTJS8PY DMG4X13 TN 5-HT 6 receptor (HTR6) DMG4X13 MA Inhibitor DMG4X13 RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMG4X13 RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMG4YWM DI DMG4YWM DMG4YWM DN LUF-5956 DMG4YWM TI TTM2AOE DMG4YWM TN Adenosine A2a receptor (ADORA2A) DMG4YWM MA Inhibitor DMG4YWM RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMG4YWM RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMG4YWM DI DMG4YWM DMG4YWM DN LUF-5956 DMG4YWM TI TTK25J1 DMG4YWM TN Adenosine A1 receptor (ADORA1) DMG4YWM MA Inhibitor DMG4YWM RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMG4YWM RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMG4YWM DI DMG4YWM DMG4YWM DN LUF-5956 DMG4YWM TI TTJFY5U DMG4YWM TN Adenosine A3 receptor (ADORA3) DMG4YWM MA Inhibitor DMG4YWM RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMG4YWM RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMG53XV DI DMG53XV DMG53XV DN VA-119930 DMG53XV TI TTGPQ0F DMG53XV TN Prolyl endopeptidase FAP (FAP) DMG53XV MA Inhibitor DMG53XV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365). DMG53XV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2365 DMG56EU DI DMG56EU DMG56EU DN MG-111 DMG56EU TI TTGKNB4 DMG56EU TN Epidermal growth factor receptor (EGFR) DMG56EU MA Modulator DMG56EU RN Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201. DMG56EU RU https://www.ncbi.nlm.nih.gov/pubmed/2595297 DMG58HM DI DMG58HM DMG58HM DN (S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid DMG58HM TI TTCM4B3 DMG58HM TN Nitric-oxide synthase endothelial (NOS3) DMG58HM MA Inhibitor DMG58HM RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMG58HM RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMG58HM DI DMG58HM DMG58HM DN (S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid DMG58HM TI TTF10I9 DMG58HM TN Nitric-oxide synthase inducible (NOS2) DMG58HM MA Inhibitor DMG58HM RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMG58HM RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMG58HM DI DMG58HM DMG58HM DN (S)-6-Amino-2-(2-imino-ethylamino)-hexanoic acid DMG58HM TI TTZUFI5 DMG58HM TN Nitric-oxide synthase brain (NOS1) DMG58HM MA Inhibitor DMG58HM RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMG58HM RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMG594K DI DMG594K DMG594K DN KM-01221 DMG594K TI TT8VUE0 DMG594K TN Chymase (CYM) DMG594K MA Inhibitor DMG594K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2340). DMG594K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2340 DMG5ABT DI DMG5ABT DMG5ABT DN 6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one DMG5ABT TI TT06AWU DMG5ABT TN Phosphodiesterase 3A (PDE3A) DMG5ABT MA Inhibitor DMG5ABT RN 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8. DMG5ABT RU https://pubmed.ncbi.nlm.nih.gov/1311763 DMG5ABT DI DMG5ABT DMG5ABT DN 6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one DMG5ABT TI TTIQUX7 DMG5ABT TN Steroid 11-beta-hydroxylase (CYP11B1) DMG5ABT MA Inhibitor DMG5ABT RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMG5ABT RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMG5BUA DI DMG5BUA DMG5BUA DN (S)-3,4-DCPG DMG5BUA TI TTICZ1O DMG5BUA TN Metabotropic glutamate receptor 4 (mGluR4) DMG5BUA MA Agonist DMG5BUA RN (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8. DMG5BUA RU https://pubmed.ncbi.nlm.nih.gov/11166323 DMG5BUA DI DMG5BUA DMG5BUA DN (S)-3,4-DCPG DMG5BUA TI TTWRP2F DMG5BUA TN Metabotropic glutamate receptor 6 (mGluR6) DMG5BUA MA Agonist DMG5BUA RN (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8. DMG5BUA RU https://pubmed.ncbi.nlm.nih.gov/11166323 DMG5BUA DI DMG5BUA DMG5BUA DN (S)-3,4-DCPG DMG5BUA TI TT0IFKL DMG5BUA TN Metabotropic glutamate receptor 8 (mGluR8) DMG5BUA MA Agonist DMG5BUA RN (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology. 2001 Mar;40(3):311-8. DMG5BUA RU https://pubmed.ncbi.nlm.nih.gov/11166323 DMG5D6B DI DMG5D6B DMG5D6B DN CI-1044 DMG5D6B TI TTVIAT9 DMG5D6B TN Phosphodiesterase 4B (PDE4B) DMG5D6B MA Inhibitor DMG5D6B RN Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indol... J Med Chem. 2000 Dec 14;43(25):4850-67. DMG5D6B RU https://pubmed.ncbi.nlm.nih.gov/11123995 DMG5D6B DI DMG5D6B DMG5D6B DN CI-1044 DMG5D6B TI TTZ97H5 DMG5D6B TN Phosphodiesterase 4A (PDE4A) DMG5D6B MA Inhibitor DMG5D6B RN Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indol... J Med Chem. 2000 Dec 14;43(25):4850-67. DMG5D6B RU https://pubmed.ncbi.nlm.nih.gov/11123995 DMG5KDY DI DMG5KDY DMG5KDY DN Pyrogallol DMG5KDY TI TT2J34L DMG5KDY TN Arachidonate 5-lipoxygenase (5-LOX) DMG5KDY MA Inhibitor DMG5KDY RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMG5KDY RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMG5KVS DI DMG5KVS DMG5KVS DN L-764406 DMG5KVS TI TTT2SVW DMG5KVS TN PPAR-gamma messenger RNA (PPARG mRNA) DMG5KVS MA Agonist DMG5KVS RN L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem. 1999 Mar 19;274(12):7913-22. DMG5KVS RU https://pubmed.ncbi.nlm.nih.gov/10075686 DMG5LXT DI DMG5LXT DMG5LXT DN FGGFTGARKSARKLYNQ DMG5LXT TI TTNT7K8 DMG5LXT TN Nociceptin receptor (OPRL1) DMG5LXT MA Inhibitor DMG5LXT RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMG5LXT RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMG5MJL DI DMG5MJL DMG5MJL DN Phosphoric acid monotetradecyl ester DMG5MJL TI TTQ6S1K DMG5MJL TN Lysophosphatidic acid receptor 1 (LPAR1) DMG5MJL MA Inhibitor DMG5MJL RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMG5MJL RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMG5MNZ DI DMG5MNZ DMG5MNZ DN 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide DMG5MNZ TI TTGY7WI DMG5MNZ TN Urokinase-type plasminogen activator (PLAU) DMG5MNZ MA Inhibitor DMG5MNZ RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMG5MNZ RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMG5MNZ DI DMG5MNZ DMG5MNZ DN 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide DMG5MNZ TI TTPLTSQ DMG5MNZ TN Neutrophil elastase (NE) DMG5MNZ MA Inhibitor DMG5MNZ RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMG5MNZ RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMG5MNZ DI DMG5MNZ DMG5MNZ DN 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide DMG5MNZ TI TTMF8H9 DMG5MNZ TN Plasma kallikrein (KLKB1) DMG5MNZ MA Inhibitor DMG5MNZ RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMG5MNZ RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMG5MNZ DI DMG5MNZ DMG5MNZ DN 1-benzoyl-N-phenyl-1H-pyrazole-3-carboxamide DMG5MNZ TI TT6L509 DMG5MNZ TN Coagulation factor IIa (F2) DMG5MNZ MA Inhibitor DMG5MNZ RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMG5MNZ RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMG5OZP DI DMG5OZP DMG5OZP DN Fascaplysin DMG5OZP TI TT0PG8F DMG5OZP TN Cyclin-dependent kinase 4 (CDK4) DMG5OZP MA Inhibitor DMG5OZP RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMG5OZP RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMG5OZP DI DMG5OZP DMG5OZP DN Fascaplysin DMG5OZP TI TTO0FDJ DMG5OZP TN Cyclin-dependent kinase 6 (CDK6) DMG5OZP MA Inhibitor DMG5OZP RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMG5OZP RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMG5PL7 DI DMG5PL7 DMG5PL7 DN N-[2-(5-hydroxy-1H-indol-3-yl)ethyl]linoleamide DMG5PL7 TI TTMI6F5 DMG5PL7 TN Transient receptor potential cation channel V1 (TRPV1) DMG5PL7 MA Inhibitor DMG5PL7 RN New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J Med Chem. 2007 Dec 27;50(26):6554-69. DMG5PL7 RU https://pubmed.ncbi.nlm.nih.gov/18027904 DMG5QJB DI DMG5QJB DMG5QJB DN (+)-MCPG DMG5QJB TI TTXJ47W DMG5QJB TN Metabotropic glutamate receptor 2 (mGluR2) DMG5QJB MA Antagonist DMG5QJB RN Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br J Pharmacol. 1998 Feb;123(3):497-504. DMG5QJB RU https://pubmed.ncbi.nlm.nih.gov/9504391 DMG5QJB DI DMG5QJB DMG5QJB DN (+)-MCPG DMG5QJB TI TTHS256 DMG5QJB TN Metabotropic glutamate receptor 5 (mGluR5) DMG5QJB MA Antagonist DMG5QJB RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMG5QJB RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMG5QJB DI DMG5QJB DMG5QJB DN (+)-MCPG DMG5QJB TI TT8A9EF DMG5QJB TN Metabotropic glutamate receptor 3 (mGluR3) DMG5QJB MA Antagonist DMG5QJB RN [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. DMG5QJB RU https://pubmed.ncbi.nlm.nih.gov/10530814 DMG5QJB DI DMG5QJB DMG5QJB DN (+)-MCPG DMG5QJB TI TT0I76D DMG5QJB TN Metabotropic glutamate receptor 7 (mGluR7) DMG5QJB MA Antagonist DMG5QJB RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMG5QJB RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMG5QJB DI DMG5QJB DMG5QJB DN (+)-MCPG DMG5QJB TI TTVBPDM DMG5QJB TN Metabotropic glutamate receptor 1 (mGluR1) DMG5QJB MA Antagonist DMG5QJB RN [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93. DMG5QJB RU https://pubmed.ncbi.nlm.nih.gov/12695537 DMG5R0N DI DMG5R0N DMG5R0N DN 3-(2-carboxy-3-phosphonopropyl)benzoic acid DMG5R0N TI TT9G4N0 DMG5R0N TN Glutamate carboxypeptidase II (GCPII) DMG5R0N MA Inhibitor DMG5R0N RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMG5R0N RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMG5SAQ DI DMG5SAQ DMG5SAQ DN 2-chloro-1-(5-(pyridin-2-yl)oxazol-2-yl)ethanone DMG5SAQ TI TTDP1UC DMG5SAQ TN Fatty acid amide hydrolase (FAAH) DMG5SAQ MA Inhibitor DMG5SAQ RN Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2007 Jul 12;50(14):3359-68. DMG5SAQ RU https://pubmed.ncbi.nlm.nih.gov/17559203 DMG5VMH DI DMG5VMH DMG5VMH DN 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one DMG5VMH TI TTGER3L DMG5VMH TN Thyroid hormone receptor beta (THRB) DMG5VMH MA Inhibitor DMG5VMH RN Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901. DMG5VMH RU https://pubmed.ncbi.nlm.nih.gov/19469546 DMG5VMH DI DMG5VMH DMG5VMH DN 3-(dimethylamino)-1-(4-heptylphenyl)propan-1-one DMG5VMH TI TTQ6VDM DMG5VMH TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMG5VMH MA Inhibitor DMG5VMH RN Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901. DMG5VMH RU https://pubmed.ncbi.nlm.nih.gov/19469546 DMG60ET DI DMG60ET DMG60ET DN GW-3965 DMG60ET TI TTXA6PH DMG60ET TN Oxysterols receptor LXR-beta (NR1H2) DMG60ET MA Inhibitor DMG60ET RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DMG60ET RU https://pubmed.ncbi.nlm.nih.gov/18973288 DMG60ET DI DMG60ET DMG60ET DN GW-3965 DMG60ET TI TTECBXN DMG60ET TN Oxysterols receptor LXR-alpha (NR1H3) DMG60ET MA Inhibitor DMG60ET RN Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8. DMG60ET RU https://pubmed.ncbi.nlm.nih.gov/18973288 DMG69IX DI DMG69IX DMG69IX DN Isosorbide-2-benzylcarbamate-5-triflate DMG69IX TI TTEB0GD DMG69IX TN Cholinesterase (BCHE) DMG69IX MA Inhibitor DMG69IX RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMG69IX RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMG6ABE DI DMG6ABE DMG6ABE DN 2-(2-Chloro-benzoyl)-cyclohexane-1,3-dione DMG6ABE TI TT8DSFC DMG6ABE TN Hydroxyphenylpyruvate dioxygenase (HPD) DMG6ABE MA Inhibitor DMG6ABE RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DMG6ABE RU https://pubmed.ncbi.nlm.nih.gov/10853644 DMG6DV9 DI DMG6DV9 DMG6DV9 DN 4-(4-tert-butylbenzylthio)-2-aminobutanoic acid DMG6DV9 TI TTFK1JQ DMG6DV9 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMG6DV9 MA Inhibitor DMG6DV9 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMG6DV9 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMG6LJ8 DI DMG6LJ8 DMG6LJ8 DN AW-00430 DMG6LJ8 TI TTG5QB7 DMG6LJ8 TN Calpain-2 (CAPN2) DMG6LJ8 MA Inhibitor DMG6LJ8 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMG6LJ8 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMG6NDA DI DMG6NDA DMG6NDA DN Tyr-Gly-Gly-Phe-leu-c(Cys-Arg-Ile-Arg-Cys)-lys DMG6NDA TI TT27RFC DMG6NDA TN Opioid receptor delta (OPRD1) DMG6NDA MA Inhibitor DMG6NDA RN Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7. DMG6NDA RU https://pubmed.ncbi.nlm.nih.gov/8096246 DMG6O0L DI DMG6O0L DMG6O0L DN Oximidine I DMG6O0L TI TTTK3BH DMG6O0L TN Vacuolar-type proton ATPase (v-ATPase) DMG6O0L MA Inhibitor DMG6O0L RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DMG6O0L RU https://pubmed.ncbi.nlm.nih.gov/11259534 DMG6PZT DI DMG6PZT DMG6PZT DN 6-Phenylaminomethyl-quinazoline-2,4-diamine DMG6PZT TI TT9SL3Q DMG6PZT TN Polypeptide deformylase (PDF) DMG6PZT MA Inhibitor DMG6PZT RN Design and synthesis of dihydrofolate reductase inhibitors encompassing a bridging ester group. Evaluation in a mouse colitis model. J Med Chem. 2003 Jul 31;46(16):3455-62. DMG6PZT RU https://pubmed.ncbi.nlm.nih.gov/12877583 DMG6RTJ DI DMG6RTJ DMG6RTJ DN N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide DMG6RTJ TI TTGKNB4 DMG6RTJ TN Epidermal growth factor receptor (EGFR) DMG6RTJ MA Inhibitor DMG6RTJ RN Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15. DMG6RTJ RU https://pubmed.ncbi.nlm.nih.gov/10346932 DMG6S2V DI DMG6S2V DMG6S2V DN THEASINENSIN A DMG6S2V TI TTE14XG DMG6S2V TN Squalene monooxygenase (SQLE) DMG6S2V MA Inhibitor DMG6S2V RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMG6S2V RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMG6SYP DI DMG6SYP DMG6SYP DN ISIS 25114 DMG6SYP TI TT8H9GB DMG6SYP TN MEK2 messenger RNA (MEK2 mRNA) DMG6SYP RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMG6SYP RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMG6TL7 DI DMG6TL7 DMG6TL7 DN GSK1614343 DMG6TL7 TI TTWDC17 DMG6TL7 TN Growth hormone secretagogue receptor 1 (GHSR) DMG6TL7 MA Antagonist DMG6TL7 RN Discovery process and characterization of novel carbohydrazide derivatives as potent and selective GHSR1a antagonists. ChemMedChem. 2010 Sep 3;5(9):1450-5. DMG6TL7 RU https://pubmed.ncbi.nlm.nih.gov/20593439 DMG6TOA DI DMG6TOA DMG6TOA DN RTI-4229-982 DMG6TOA TI TTHS256 DMG6TOA TN Metabotropic glutamate receptor 5 (mGluR5) DMG6TOA MA Antagonist DMG6TOA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). DMG6TOA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 DMG6ZHO DI DMG6ZHO DMG6ZHO DN A778317 DMG6ZHO TI TTMI6F5 DMG6ZHO TN Transient receptor potential cation channel V1 (TRPV1) DMG6ZHO MA Blocker (channel blocker) DMG6ZHO RN [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand ... J Pharmacol Exp Ther. 2007 Oct;323(1):285-93. DMG6ZHO RU https://pubmed.ncbi.nlm.nih.gov/17660385 DMG706J DI DMG706J DMG706J DN Lobatamide D DMG706J TI TTTK3BH DMG706J TN Vacuolar-type proton ATPase (v-ATPase) DMG706J MA Inhibitor DMG706J RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DMG706J RU https://pubmed.ncbi.nlm.nih.gov/11259534 DMG76LS DI DMG76LS DMG76LS DN 3-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine DMG76LS TI TTSZLWK DMG76LS TN Aromatase (CYP19A1) DMG76LS MA Inhibitor DMG76LS RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMG76LS RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMG78U2 DI DMG78U2 DMG78U2 DN 2-Hydrazinocarbonyl-benzenesulfonamide DMG78U2 TI TTANPDJ DMG78U2 TN Carbonic anhydrase II (CA-II) DMG78U2 MA Inhibitor DMG78U2 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMG78U2 RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMG78U2 DI DMG78U2 DMG78U2 DN 2-Hydrazinocarbonyl-benzenesulfonamide DMG78U2 TI TT2LVK8 DMG78U2 TN Carbonic anhydrase IX (CA-IX) DMG78U2 MA Inhibitor DMG78U2 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMG78U2 RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMG7CAU DI DMG7CAU DMG7CAU DN 2'-Deoxycytidine-5'-Monophosphate DMG7CAU TI TTU6BFZ DMG7CAU TN Candida Thymidylate synthase (Candi TMP1) DMG7CAU MA Inhibitor DMG7CAU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMG7CAU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMG7D3I DI DMG7D3I DMG7D3I DN PMID19191557C14 DMG7D3I TI TTFQEO5 DMG7D3I TN Squalene synthetase (FDFT1) DMG7D3I MA Inhibitor DMG7D3I RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DMG7D3I RU https://pubmed.ncbi.nlm.nih.gov/19191557 DMG7EPF DI DMG7EPF DMG7EPF DN 2,2',3-Tribromo-4,4',5,5'-tetrahydroxybibenzyl DMG7EPF TI TT58ZYW DMG7EPF TN Mycobacterium Isocitrate lyase (MycB icl) DMG7EPF MA Inhibitor DMG7EPF RN Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8. DMG7EPF RU https://pubmed.ncbi.nlm.nih.gov/20888765 DMG7HP2 DI DMG7HP2 DMG7HP2 DN 2-Amino-6-(3-fluoro-phenylsulfanyl)-benzonitrile DMG7HP2 TI TT84ETX DMG7HP2 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMG7HP2 MA Inhibitor DMG7HP2 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMG7HP2 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMG7K84 DI DMG7K84 DMG7K84 DN Polybrominated diphenyl ether derivative DMG7K84 TI TT12ABZ DMG7K84 TN Arachidonate 12-lipoxygenase (12-LOX) DMG7K84 MA Inhibitor DMG7K84 RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMG7K84 RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMG7K84 DI DMG7K84 DMG7K84 DN Polybrominated diphenyl ether derivative DMG7K84 TI TTN9T81 DMG7K84 TN Arachidonate 15-lipoxygenase (15-LOX) DMG7K84 MA Inhibitor DMG7K84 RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMG7K84 RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMG7PC0 DI DMG7PC0 DMG7PC0 DN Anti-D DMG7PC0 TI TTEX248 DMG7PC0 TN Dopamine D2 receptor (D2R) DMG7PC0 MA Antagonist DMG7PC0 RN Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. DMG7PC0 RU https://pubmed.ncbi.nlm.nih.gov/18537519 DMG7PKA DI DMG7PKA DMG7PKA DN 1-(4-methoxyphenylsulfonyl)-4-phenylazepan-4-ol DMG7PKA TI TTN7BL9 DMG7PKA TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMG7PKA MA Inhibitor DMG7PKA RN The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5. DMG7PKA RU https://pubmed.ncbi.nlm.nih.gov/19625185 DMG7UPR DI DMG7UPR DMG7UPR DN Gamma-secretase modulators DMG7UPR TI TTE4KHA DMG7UPR TN Amyloid beta A4 protein (APP) DMG7UPR MA Modulator DMG7UPR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMG7UPR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMG7XL5 DI DMG7XL5 DMG7XL5 DN (S)-1-(4-nitrophenethyl)-2-methylpyrrolidine DMG7XL5 TI TT9JNIC DMG7XL5 TN Histamine H3 receptor (H3R) DMG7XL5 MA Inhibitor DMG7XL5 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMG7XL5 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMG87RK DI DMG87RK DMG87RK DN 2-(N-Cyclopentylamino)-3'-methylpropiophenone DMG87RK TI TTVBI8W DMG87RK TN Dopamine transporter (DAT) DMG87RK MA Inhibitor DMG87RK RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMG87RK RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMG87RK DI DMG87RK DMG87RK DN 2-(N-Cyclopentylamino)-3'-methylpropiophenone DMG87RK TI TTAWNKZ DMG87RK TN Norepinephrine transporter (NET) DMG87RK MA Inhibitor DMG87RK RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMG87RK RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMG8A74 DI DMG8A74 DMG8A74 DN Naphthalene-2-carboxylic acid hydroxyamide DMG8A74 TI TT2J34L DMG8A74 TN Arachidonate 5-lipoxygenase (5-LOX) DMG8A74 MA Inhibitor DMG8A74 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMG8A74 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMG8DLM DI DMG8DLM DMG8DLM DN 1-(3-phenoxypropyl)-4-(piperidin-1-yl)piperidine DMG8DLM TI TTULVH8 DMG8DLM TN Tyrosinase (TYR) DMG8DLM MA Inhibitor DMG8DLM RN Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur J Med Chem. 2007 Nov-Dec;42(11-12):1370-81. DMG8DLM RU https://pubmed.ncbi.nlm.nih.gov/17637486 DMG8KRN DI DMG8KRN DMG8KRN DN 4,5-Dihydroxy-10H-anthracen-9-one DMG8KRN TI TT2J34L DMG8KRN TN Arachidonate 5-lipoxygenase (5-LOX) DMG8KRN MA Inhibitor DMG8KRN RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMG8KRN RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMG8KS9 DI DMG8KS9 DMG8KS9 DN Phenanthrene-9,10-dione DMG8KS9 TI TTEB0GD DMG8KS9 TN Cholinesterase (BCHE) DMG8KS9 MA Inhibitor DMG8KS9 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMG8KS9 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMG8KS9 DI DMG8KS9 DMG8KS9 DN Phenanthrene-9,10-dione DMG8KS9 TI TTMF541 DMG8KS9 TN Liver carboxylesterase (CES1) DMG8KS9 MA Inhibitor DMG8KS9 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMG8KS9 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMG8KXR DI DMG8KXR DMG8KXR DN N-(Naphthalene-2-yl)ethyl-ETAV DMG8KXR TI TT9PB26 DMG8KXR TN Presynaptic density protein 95 (DLG4) DMG8KXR MA Inhibitor DMG8KXR RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMG8KXR RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMG8NB0 DI DMG8NB0 DMG8NB0 DN N-isopropylnorlitebamine DMG8NB0 TI TT1RS9F DMG8NB0 TN Acetylcholinesterase (AChE) DMG8NB0 MA Inhibitor DMG8NB0 RN Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50. DMG8NB0 RU https://pubmed.ncbi.nlm.nih.gov/9461651 DMG8P24 DI DMG8P24 DMG8P24 DN ACETYLSULFANILAMIDE DMG8P24 TI TT2LVK8 DMG8P24 TN Carbonic anhydrase IX (CA-IX) DMG8P24 MA Inhibitor DMG8P24 RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMG8P24 RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMG8P24 DI DMG8P24 DMG8P24 DN ACETYLSULFANILAMIDE DMG8P24 TI TTSYM0R DMG8P24 TN Carbonic anhydrase XII (CA-XII) DMG8P24 MA Inhibitor DMG8P24 RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMG8P24 RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMG8P24 DI DMG8P24 DMG8P24 DN ACETYLSULFANILAMIDE DMG8P24 TI TTANPDJ DMG8P24 TN Carbonic anhydrase II (CA-II) DMG8P24 MA Inhibitor DMG8P24 RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMG8P24 RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMG8T3W DI DMG8T3W DMG8T3W DN [3H]BQ123 DMG8T3W TI TTKRD0G DMG8T3W TN Endothelin A receptor (EDNRA) DMG8T3W MA Antagonist DMG8T3W RN [3H]BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype. Eur J Pharmacol. 1995 Feb 14;274(1-3):1-6. DMG8T3W RU https://pubmed.ncbi.nlm.nih.gov/7768260 DMG8XD1 DI DMG8XD1 DMG8XD1 DN Methyl estradiol-16-beta-carboxylate DMG8XD1 TI TTIWB6L DMG8XD1 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMG8XD1 MA Inhibitor DMG8XD1 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMG8XD1 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMG8ZJA DI DMG8ZJA DMG8ZJA DN 7-Bromo-2-phenyl-[1,8]naphthyridin-4-ol DMG8ZJA TI TTK25J1 DMG8ZJA TN Adenosine A1 receptor (ADORA1) DMG8ZJA MA Inhibitor DMG8ZJA RN Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31. DMG8ZJA RU https://pubmed.ncbi.nlm.nih.gov/15163184 DMG9BFR DI DMG9BFR DMG9BFR DN DCDPC DMG9BFR TI TTOJI4S DMG9BFR TN Calcium-dependent chloride channel anoctamin (ANO) DMG9BFR MA Blocker (channel blocker) DMG9BFR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708). DMG9BFR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708 DMG9BWY DI DMG9BWY DMG9BWY DN NSC-745887 DMG9BWY TI TTQY2EJ DMG9BWY TN TERT messenger RNA (TERT mRNA) DMG9BWY MA Inhibitor DMG9BWY RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMG9BWY RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMG9D7A DI DMG9D7A DMG9D7A DN N-(4-Propylaminobutyl)-4-biphenylcarboxamide DMG9D7A TI TT4C8EA DMG9D7A TN Dopamine D3 receptor (D3R) DMG9D7A MA Inhibitor DMG9D7A RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMG9D7A RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMG9D7A DI DMG9D7A DMG9D7A DN N-(4-Propylaminobutyl)-4-biphenylcarboxamide DMG9D7A TI TTZFYLI DMG9D7A TN Dopamine D1 receptor (D1R) DMG9D7A MA Inhibitor DMG9D7A RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMG9D7A RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMG9D7A DI DMG9D7A DMG9D7A DN N-(4-Propylaminobutyl)-4-biphenylcarboxamide DMG9D7A TI TTE0A2F DMG9D7A TN Dopamine D4 receptor (D4R) DMG9D7A MA Inhibitor DMG9D7A RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMG9D7A RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMG9JSK DI DMG9JSK DMG9JSK DN 4-Indol-1-ylmethyl-benzamidine DMG9JSK TI TT2WR1T DMG9JSK TN Cationic trypsinogen (PRSS1) DMG9JSK MA Inhibitor DMG9JSK RN Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8. DMG9JSK RU https://pubmed.ncbi.nlm.nih.gov/6219223 DMG9KMN DI DMG9KMN DMG9KMN DN (S)-2-amino-2-o-tolylacetic acid DMG9KMN TI TTFK1JQ DMG9KMN TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMG9KMN MA Inhibitor DMG9KMN RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMG9KMN RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMG9OBA DI DMG9OBA DMG9OBA DN NI-1401 DMG9OBA TI TT69OHW DMG9OBA TN Interleukin 17 receptor (IL17R) DMG9OBA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294). DMG9OBA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2294 DMG9ZYP DI DMG9ZYP DMG9ZYP DN PMID17189691C42 DMG9ZYP TI TTHS256 DMG9ZYP TN Metabotropic glutamate receptor 5 (mGluR5) DMG9ZYP MA Modulator (allosteric modulator) DMG9ZYP RN Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam struc... Bioorg Med Chem Lett. 2007 Mar 1;17(5):1302-6. DMG9ZYP RU https://pubmed.ncbi.nlm.nih.gov/17189691 DMGA47N DI DMGA47N DMGA47N DN 5-Amino-[1,3,4]thiadiazole-2-thiol DMGA47N TI TTHQPL7 DMGA47N TN Carbonic anhydrase I (CA-I) DMGA47N MA Inhibitor DMGA47N RN Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52. DMGA47N RU https://pubmed.ncbi.nlm.nih.gov/15837323 DMGA47N DI DMGA47N DMGA47N DN 5-Amino-[1,3,4]thiadiazole-2-thiol DMGA47N TI TT2LVK8 DMGA47N TN Carbonic anhydrase IX (CA-IX) DMGA47N MA Inhibitor DMGA47N RN Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52. DMGA47N RU https://pubmed.ncbi.nlm.nih.gov/15837323 DMGA47N DI DMGA47N DMGA47N DN 5-Amino-[1,3,4]thiadiazole-2-thiol DMGA47N TI TTANPDJ DMGA47N TN Carbonic anhydrase II (CA-II) DMGA47N MA Inhibitor DMGA47N RN Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52. DMGA47N RU https://pubmed.ncbi.nlm.nih.gov/15837323 DMGA48T DI DMGA48T DMGA48T DN D-237 DMGA48T TI TTEX248 DMGA48T TN Dopamine D2 receptor (D2R) DMGA48T MA Inhibitor DMGA48T RN Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19. DMGA48T RU https://pubmed.ncbi.nlm.nih.gov/19053758 DMGA48T DI DMGA48T DMGA48T DN D-237 DMGA48T TI TT4C8EA DMGA48T TN Dopamine D3 receptor (D3R) DMGA48T MA Inhibitor DMGA48T RN Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding character... J Med Chem. 2008 Dec 25;51(24):7806-19. DMGA48T RU https://pubmed.ncbi.nlm.nih.gov/19053758 DMGA4W5 DI DMGA4W5 DMGA4W5 DN ONO-AE3-237 DMGA4W5 TI TTNVEIR DMGA4W5 TN Prostaglandin D2 receptor (PTGDR) DMGA4W5 MA Antagonist DMGA4W5 RN Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. J Immunol. 2008 Jan 15;180(2):783-92. DMGA4W5 RU https://pubmed.ncbi.nlm.nih.gov/18178816 DMGA9U7 DI DMGA9U7 DMGA9U7 DN C4-MAD DMGA9U7 TI TTTB4UP DMGA9U7 TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMGA9U7 MA Inhibitor DMGA9U7 RN Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J Med Chem. 2002 Jan 31;45(3):703-12. DMGA9U7 RU https://pubmed.ncbi.nlm.nih.gov/11806722 DMGADQ1 DI DMGADQ1 DMGADQ1 DN 2MeSADP DMGADQ1 TI TTA93TL DMGADQ1 TN P2Y purinoceptor 1 (P2RY1) DMGADQ1 MA Agonist DMGADQ1 RN Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9. DMGADQ1 RU https://pubmed.ncbi.nlm.nih.gov/11502873 DMGADQ1 DI DMGADQ1 DMGADQ1 DN 2MeSADP DMGADQ1 TI TTZ1DT0 DMGADQ1 TN P2Y purinoceptor 12 (P2RY12) DMGADQ1 MA Agonist DMGADQ1 RN Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol. 2001 Sep;60(3):432-9. DMGADQ1 RU https://pubmed.ncbi.nlm.nih.gov/11502873 DMGADQ1 DI DMGADQ1 DMGADQ1 DN 2MeSADP DMGADQ1 TI TT1FE3L DMGADQ1 TN P2Y purinoceptor 13 (P2RY13) DMGADQ1 MA Agonist DMGADQ1 RN Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. DMGADQ1 RU https://pubmed.ncbi.nlm.nih.gov/12815166 DMGAE9Z DI DMGAE9Z DMGAE9Z DN 9-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one DMGAE9Z TI TTVDSZ0 DMGAE9Z TN Poly [ADP-ribose] polymerase 1 (PARP1) DMGAE9Z MA Inhibitor DMGAE9Z RN Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3. DMGAE9Z RU https://pubmed.ncbi.nlm.nih.gov/16078828 DMGAITY DI DMGAITY DMGAITY DN N-(5-Benzyloxy-isoquinolin-1-yl)-guanidine DMGAITY TI TTXAGYU DMGAITY TN Tissue-type plasminogen activator (PLAT) DMGAITY MA Inhibitor DMGAITY RN Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. DMGAITY RU https://pubmed.ncbi.nlm.nih.gov/15149680 DMGAJYW DI DMGAJYW DMGAJYW DN (1R)-MENTHYL HEXYL PHOSPHONATE GROUP DMGAJYW TI TTEB0GD DMGAJYW TN Cholinesterase (BCHE) DMGAJYW MA Inhibitor DMGAJYW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGAJYW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGAPCD DI DMGAPCD DMGAPCD DN 7alpha-OCOCH2Ph-ginkgolide B DMGAPCD TI TTQL5VC DMGAPCD TN Platelet-activating factor receptor (PTAFR) DMGAPCD MA Antagonist DMGAPCD RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMGAPCD RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMGAY4M DI DMGAY4M DMGAY4M DN PMID2153213C2d DMGAY4M TI TTPADOQ DMGAY4M TN HMG-CoA reductase (HMGCR) DMGAY4M MA Inhibitor DMGAY4M RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DMGAY4M RU https://pubmed.ncbi.nlm.nih.gov/2153213 DMGB1QU DI DMGB1QU DMGB1QU DN 2-Pyridin-4-ylmethyl-1,2-dihydro-indazol-3-one DMGB1QU TI TT2J34L DMGB1QU TN Arachidonate 5-lipoxygenase (5-LOX) DMGB1QU MA Inhibitor DMGB1QU RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMGB1QU RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMGB90V DI DMGB90V DMGB90V DN Aspartate Semialdehyde DMGB90V TI TTQWGU9 DMGB90V TN Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2) DMGB90V MA Inhibitor DMGB90V RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGB90V RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGB97I DI DMGB97I DMGB97I DN (biphenyl-3-ylamino)methylenediphosphonic acid DMGB97I TI TTIKWV4 DMGB97I TN Geranyltranstransferase (FDPS) DMGB97I MA Inhibitor DMGB97I RN Bisphosphonate inhibitors of ATP-mediated HIV-1 reverse transcriptase catalyzed excision of chain-terminating 3'-azido, 3'-deoxythymidine: a QSAR i... Bioorg Med Chem. 2008 Oct 1;16(19):8959-67. DMGB97I RU https://pubmed.ncbi.nlm.nih.gov/18789701 DMGB9IE DI DMGB9IE DMGB9IE DN 7-Methyl-2-propyl-[1,8]naphthyridin-4-ol DMGB9IE TI TTK25J1 DMGB9IE TN Adenosine A1 receptor (ADORA1) DMGB9IE MA Inhibitor DMGB9IE RN Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31. DMGB9IE RU https://pubmed.ncbi.nlm.nih.gov/15163184 DMGB9PN DI DMGB9PN DMGB9PN DN BLV-0801 DMGB9PN TI TTZJYKH DMGB9PN TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMGB9PN MA Inhibitor DMGB9PN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2829). DMGB9PN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2829 DMGBCP0 DI DMGBCP0 DMGBCP0 DN DIPROTIN A DMGBCP0 TI TTDIGC1 DMGBCP0 TN Dipeptidyl peptidase 4 (DPP-4) DMGBCP0 MA Inhibitor DMGBCP0 RN Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin. Bioorg Med Chem Lett. 2008 Jan 15;18(2):479-84. DMGBCP0 RU https://pubmed.ncbi.nlm.nih.gov/18068977 DMGBEFY DI DMGBEFY DMGBEFY DN 2-Fluoro-4-[5-(3-hydroxyphenyl)-3-thienyl]phenol DMGBEFY TI TTIWB6L DMGBEFY TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMGBEFY MA Inhibitor DMGBEFY RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMGBEFY RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMGBKN7 DI DMGBKN7 DMGBKN7 DN 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide DMGBKN7 TI TTANPDJ DMGBKN7 TN Carbonic anhydrase II (CA-II) DMGBKN7 MA Inhibitor DMGBKN7 RN Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7. DMGBKN7 RU https://pubmed.ncbi.nlm.nih.gov/19097911 DMGBKN7 DI DMGBKN7 DMGBKN7 DN 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide DMGBKN7 TI TT2LVK8 DMGBKN7 TN Carbonic anhydrase IX (CA-IX) DMGBKN7 MA Inhibitor DMGBKN7 RN Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7. DMGBKN7 RU https://pubmed.ncbi.nlm.nih.gov/19097911 DMGBKN7 DI DMGBKN7 DMGBKN7 DN 4-fluoro-N-(4-sulfamoylbenzyl)benzenesulfonamide DMGBKN7 TI TTHQPL7 DMGBKN7 TN Carbonic anhydrase I (CA-I) DMGBKN7 MA Inhibitor DMGBKN7 RN Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7. DMGBKN7 RU https://pubmed.ncbi.nlm.nih.gov/19097911 DMGBSWP DI DMGBSWP DMGBSWP DN 1-hydroxy-2-dodecyl-4(1H)quinolone DMGBSWP TI TT3PQ2Y DMGBSWP TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMGBSWP MA Inhibitor DMGBSWP RN Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):972-5. DMGBSWP RU https://pubmed.ncbi.nlm.nih.gov/19097788 DMGBT68 DI DMGBT68 DMGBT68 DN Chlorphrifos oxon DMGBT68 TI TT1RS9F DMGBT68 TN Acetylcholinesterase (AChE) DMGBT68 MA Inhibitor DMGBT68 RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DMGBT68 RU https://pubmed.ncbi.nlm.nih.gov/18438404 DMGBT68 DI DMGBT68 DMGBT68 DN Chlorphrifos oxon DMGBT68 TI TTDP1UC DMGBT68 TN Fatty acid amide hydrolase (FAAH) DMGBT68 MA Inhibitor DMGBT68 RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DMGBT68 RU https://pubmed.ncbi.nlm.nih.gov/18438404 DMGBT68 DI DMGBT68 DMGBT68 DN Chlorphrifos oxon DMGBT68 TI TT6OEDT DMGBT68 TN Cannabinoid receptor 1 (CB1) DMGBT68 MA Inhibitor DMGBT68 RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DMGBT68 RU https://pubmed.ncbi.nlm.nih.gov/18752948 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTNAW8S DMGC287 TN Bacterial Flavohemoglobin (Bact hmp) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTI6V2A DMGC287 TN Heme oxygenase 1 (HMOX1) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TT8NGED DMGC287 TN Prostaglandin G/H synthase 1 (COX-1) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTHDSE2 DMGC287 TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTVKILB DMGC287 TN Prostaglandin G/H synthase 2 (COX-2) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTBK0PU DMGC287 TN Mycobacterium Cytochrome p450 121 (MycB cyp121) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTVZJ7G DMGC287 TN Cystathionine beta-synthase (CBS) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TT2J34L DMGC287 TN Arachidonate 5-lipoxygenase (5-LOX) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTCM4B3 DMGC287 TN Nitric-oxide synthase endothelial (NOS3) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTQO71U DMGC287 TN Hemoglobin (HB) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTZUFI5 DMGC287 TN Nitric-oxide synthase brain (NOS1) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTXV4FI DMGC287 TN Albendazole monooxygenase (CYP3A4) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC287 DI DMGC287 DMGC287 DN Heme DMGC287 TI TTF10I9 DMGC287 TN Nitric-oxide synthase inducible (NOS2) DMGC287 MA Inhibitor DMGC287 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGC287 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGC7F5 DI DMGC7F5 DMGC7F5 DN (-)-3,3'-bisdemethylpinoresinol DMGC7F5 TI TTSJ6Q4 DMGC7F5 TN LOX-5 messenger RNA (ALOX5 mRNA) DMGC7F5 MA Inhibitor DMGC7F5 RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DMGC7F5 RU https://pubmed.ncbi.nlm.nih.gov/17378609 DMGC7F5 DI DMGC7F5 DMGC7F5 DN (-)-3,3'-bisdemethylpinoresinol DMGC7F5 TI TTN9T81 DMGC7F5 TN Arachidonate 15-lipoxygenase (15-LOX) DMGC7F5 MA Inhibitor DMGC7F5 RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DMGC7F5 RU https://pubmed.ncbi.nlm.nih.gov/17378609 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TT9VGXW DMGC7RY TN Angiopoietin 1 receptor (TEK) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TT0PG8F DMGC7RY TN Cyclin-dependent kinase 4 (CDK4) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTUTJGQ DMGC7RY TN Vascular endothelial growth factor receptor 2 (KDR) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TT7HF4W DMGC7RY TN Cyclin-dependent kinase 2 (CDK2) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTGKNB4 DMGC7RY TN Epidermal growth factor receptor (EGFR) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TT9P6OW DMGC7RY TN G2/mitotic-specific cyclin B1 (CCNB1) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTR5TV4 DMGC7RY TN ERBB2 messenger RNA (HER2 mRNA) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTBZ7OD DMGC7RY TN Protein kinase C epsilon (PRKCE) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTRFOXJ DMGC7RY TN Protein kinase C gamma (PRKCG) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTCEJ4F DMGC7RY TN G1/S-specific cyclin-E1 (CCNE1) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTO0FDJ DMGC7RY TN Cyclin-dependent kinase 6 (CDK6) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTH6V3D DMGC7RY TN Cyclin-dependent kinase 1 (CDK1) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTFCJ7S DMGC7RY TN G1/S-specific cyclin-D1 (CCND1) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC7RY DI DMGC7RY DMGC7RY DN 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY TI TTFJ8Q1 DMGC7RY TN Protein kinase C alpha (PRKCA) DMGC7RY MA Inhibitor DMGC7RY RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMGC7RY RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMGC84U DI DMGC84U DMGC84U DN 6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol DMGC84U TI TTOM3J0 DMGC84U TN Estrogen receptor beta (ESR2) DMGC84U MA Inhibitor DMGC84U RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMGC84U RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMGC84U DI DMGC84U DMGC84U DN 6-(4-Hydroxy-phenyl)-1-nitro-naphthalen-2-ol DMGC84U TI TTZAYWL DMGC84U TN Estrogen receptor (ESR) DMGC84U MA Inhibitor DMGC84U RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMGC84U RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMGCAIO DI DMGCAIO DMGCAIO DN PMID25719566C7 DMGCAIO TI TT6K8YG DMGCAIO TN Bromodomain adjacent to zinc finger 2B (BAZ2B) DMGCAIO MA Inhibitor DMGCAIO RN Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9. DMGCAIO RU https://pubmed.ncbi.nlm.nih.gov/25719566 DMGCF51 DI DMGCF51 DMGCF51 DN Wogonin DMGCF51 TI TT7RJY8 DMGCF51 TN Xanthine dehydrogenase/oxidase (XDH) DMGCF51 MA Inhibitor DMGCF51 RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DMGCF51 RU https://pubmed.ncbi.nlm.nih.gov/3379415 DMGCF51 DI DMGCF51 DMGCF51 DN Wogonin DMGCF51 TI TTVKILB DMGCF51 TN Prostaglandin G/H synthase 2 (COX-2) DMGCF51 MA Inhibitor DMGCF51 RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DMGCF51 RU https://pubmed.ncbi.nlm.nih.gov/19233646 DMGCOQF DI DMGCOQF DMGCOQF DN AM-156 DMGCOQF TI TTQDMX5 DMGCOQF TN Prostaglandin D2 receptor 2 (PTGDR2) DMGCOQF MA Antagonist DMGCOQF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339). DMGCOQF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339 DMGCPHO DI DMGCPHO DMGCPHO DN MRS2905 DMGCPHO TI TT72OKI DMGCPHO TN P2Y purinoceptor 14 (P2RY14) DMGCPHO MA Agonist DMGCPHO RN Pharmacochemistry of the platelet purinergic receptors. Purinergic Signal. 2011 Sep;7(3):305-24. DMGCPHO RU https://pubmed.ncbi.nlm.nih.gov/21484092 DMGCPKU DI DMGCPKU DMGCPKU DN 4-(3-methoxyphenylethynyl)-2-methylthiazole DMGCPKU TI TTHS256 DMGCPKU TN Metabotropic glutamate receptor 5 (mGluR5) DMGCPKU MA Inhibitor DMGCPKU RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMGCPKU RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMGCVT2 DI DMGCVT2 DMGCVT2 DN 9-anthroic acid DMGCVT2 TI TT0FC1V DMGCVT2 TN Volume regulated chloride channel (VRAC) DMGCVT2 MA Blocker (channel blocker) DMGCVT2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DMGCVT2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DMGCVT2 DI DMGCVT2 DMGCVT2 DN 9-anthroic acid DMGCVT2 TI TTOJI4S DMGCVT2 TN Calcium-dependent chloride channel anoctamin (ANO) DMGCVT2 MA Blocker (channel blocker) DMGCVT2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708). DMGCVT2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708 DMGCVT2 DI DMGCVT2 DMGCVT2 DN 9-anthroic acid DMGCVT2 TI TTUYAF3 DMGCVT2 TN Chloride channel protein 1 (ClC-1) DMGCVT2 MA Blocker (channel blocker) DMGCVT2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 698). DMGCVT2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=698 DMGCX7E DI DMGCX7E DMGCX7E DN 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione DMGCX7E TI TTTU902 DMGCX7E TN Checkpoint kinase-1 (CHK1) DMGCX7E MA Inhibitor DMGCX7E RN 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modific... J Med Chem. 2006 Aug 10;49(16):4896-911. DMGCX7E RU https://pubmed.ncbi.nlm.nih.gov/16884302 DMGCX7E DI DMGCX7E DMGCX7E DN 9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione DMGCX7E TI TTJFOAL DMGCX7E TN Wee1-like protein kinase (WEE1) DMGCX7E MA Inhibitor DMGCX7E RN Receptor-based 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur J Med Chem. 2009 Apr;44(4):1383-95. DMGCX7E RU https://pubmed.ncbi.nlm.nih.gov/18976834 DMGCYS1 DI DMGCYS1 DMGCYS1 DN 4-TERT-BUTYLBENZENESULFONIC ACID DMGCYS1 TI TT6L509 DMGCYS1 TN Coagulation factor IIa (F2) DMGCYS1 MA Inhibitor DMGCYS1 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGCYS1 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGCZOI DI DMGCZOI DMGCZOI DN (4-sulfamoylphenylethylthioureido)fluorescein DMGCZOI TI TT2LVK8 DMGCZOI TN Carbonic anhydrase IX (CA-IX) DMGCZOI MA Inhibitor DMGCZOI RN Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6. DMGCZOI RU https://pubmed.ncbi.nlm.nih.gov/18348513 DMGD026 DI DMGD026 DMGD026 DN (R)-1-(2-aminoacetyl)pyrrolidin-2-ylboronic acid DMGD026 TI TTDIGC1 DMGD026 TN Dipeptidyl peptidase 4 (DPP-4) DMGD026 MA Inhibitor DMGD026 RN Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13. DMGD026 RU https://pubmed.ncbi.nlm.nih.gov/18783201 DMGD0HT DI DMGD0HT DMGD0HT DN Tellurium DMGD0HT TI TTE14XG DMGD0HT TN Squalene monooxygenase (SQLE) DMGD0HT MA Inhibitor DMGD0HT RN Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50. DMGD0HT RU https://pubmed.ncbi.nlm.nih.gov/12467639 DMGD487 DI DMGD487 DMGD487 DN [3-(4-Nonyl-benzylamino)-propyl]-phosphonic acid DMGD487 TI TT9JZCK DMGD487 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMGD487 MA Inhibitor DMGD487 RN Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6. DMGD487 RU https://pubmed.ncbi.nlm.nih.gov/15341940 DMGD73A DI DMGD73A DMGD73A DN JWH-243 DMGD73A TI TTMSFAW DMGD73A TN Cannabinoid receptor 2 (CB2) DMGD73A MA Inhibitor DMGD73A RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMGD73A RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMGD73A DI DMGD73A DMGD73A DN JWH-243 DMGD73A TI TT6OEDT DMGD73A TN Cannabinoid receptor 1 (CB1) DMGD73A MA Inhibitor DMGD73A RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMGD73A RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMGD7JM DI DMGD7JM DMGD7JM DN D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide DMGD7JM TI TT6L509 DMGD7JM TN Coagulation factor IIa (F2) DMGD7JM MA Inhibitor DMGD7JM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGD7JM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGDN93 DI DMGDN93 DMGDN93 DN 3-(1-Benzyl-piperidin-3-yl)-2-phenyl-1H-indole DMGDN93 TI TTQ6VDM DMGDN93 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMGDN93 MA Inhibitor DMGDN93 RN 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14. DMGDN93 RU https://pubmed.ncbi.nlm.nih.gov/11334570 DMGDT8V DI DMGDT8V DMGDT8V DN 3-tert-Butyl-3-ethyl-dihydro-furan-2-one DMGDT8V TI TT1MPAY DMGDT8V TN GABA(A) receptor alpha-1 (GABRA1) DMGDT8V MA Inhibitor DMGDT8V RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMGDT8V RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMGDT8V DI DMGDT8V DMGDT8V DN 3-tert-Butyl-3-ethyl-dihydro-furan-2-one DMGDT8V TI TT06RH5 DMGDT8V TN GABA(A) receptor gamma-2 (GABRG2) DMGDT8V MA Inhibitor DMGDT8V RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMGDT8V RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMGDT8V DI DMGDT8V DMGDT8V DN 3-tert-Butyl-3-ethyl-dihydro-furan-2-one DMGDT8V TI TTNJYV2 DMGDT8V TN Gamma-aminobutyric acid receptor (GAR) DMGDT8V MA Inhibitor DMGDT8V RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMGDT8V RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMGDT8V DI DMGDT8V DMGDT8V DN 3-tert-Butyl-3-ethyl-dihydro-furan-2-one DMGDT8V TI TTZA1NY DMGDT8V TN GABA(A) receptor beta-2 (GABRB2) DMGDT8V MA Inhibitor DMGDT8V RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMGDT8V RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMGDTNI DI DMGDTNI DMGDTNI DN 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine DMGDTNI TI TTWJBZ5 DMGDTNI TN 5-HT 2C receptor (HTR2C) DMGDTNI MA Inhibitor DMGDTNI RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMGDTNI RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMGDTNI DI DMGDTNI DMGDTNI DN 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine DMGDTNI TI TTRUFDT DMGDTNI TN 5-HT 5A receptor (HTR5A) DMGDTNI MA Inhibitor DMGDTNI RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMGDTNI RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMGDTNI DI DMGDTNI DMGDTNI DN 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine DMGDTNI TI TTSQIFT DMGDTNI TN 5-HT 1A receptor (HTR1A) DMGDTNI MA Inhibitor DMGDTNI RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMGDTNI RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMGDTNI DI DMGDTNI DMGDTNI DN 5-chloro-4-ethyl-3,4-dihydroquinazolin-2-amine DMGDTNI TI TTO9X1H DMGDTNI TN 5-HT 7 receptor (HTR7) DMGDTNI MA Inhibitor DMGDTNI RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMGDTNI RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMGDY4X DI DMGDY4X DMGDY4X DN 1-benzyl-4-(2,4-dichlorophenyl)pyrrolidin-3-amine DMGDY4X TI TTDIGC1 DMGDY4X TN Dipeptidyl peptidase 4 (DPP-4) DMGDY4X MA Inhibitor DMGDY4X RN Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12. DMGDY4X RU https://pubmed.ncbi.nlm.nih.gov/17276063 DMGDZ6Q DI DMGDZ6Q DMGDZ6Q DN Antanal 1 DMGDZ6Q TI TT27RFC DMGDZ6Q TN Opioid receptor delta (OPRD1) DMGDZ6Q MA Inhibitor DMGDZ6Q RN Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70. DMGDZ6Q RU https://pubmed.ncbi.nlm.nih.gov/18800771 DMGDZ6Q DI DMGDZ6Q DMGDZ6Q DN Antanal 1 DMGDZ6Q TI TTKWM86 DMGDZ6Q TN Opioid receptor mu (MOP) DMGDZ6Q MA Inhibitor DMGDZ6Q RN Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70. DMGDZ6Q RU https://pubmed.ncbi.nlm.nih.gov/18800771 DMGE82R DI DMGE82R DMGE82R DN BMS184394 DMGE82R TI TT1Q3IE DMGE82R TN Retinoic acid receptor gamma (RARG) DMGE82R MA Inhibitor DMGE82R RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGE82R RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGEDQJ DI DMGEDQJ DMGEDQJ DN R-L3 DMGEDQJ TI TT846HF DMGEDQJ TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMGEDQJ MA Activator DMGEDQJ RN A novel benzodiazepine that activates cardiac slow delayed rectifier K+ currents. Mol Pharmacol. 1998 Jul;54(1):220-30. DMGEDQJ RU https://pubmed.ncbi.nlm.nih.gov/9658209 DMGEFQP DI DMGEFQP DMGEFQP DN 2-benzoylaminoquinazoline-4-carboxyanilide DMGEFQP TI TTJFY5U DMGEFQP TN Adenosine A3 receptor (ADORA3) DMGEFQP MA Inhibitor DMGEFQP RN Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606. DMGEFQP RU https://pubmed.ncbi.nlm.nih.gov/18047262 DMGEHNX DI DMGEHNX DMGEHNX DN S 202 791 DMGEHNX TI TTXHYV6 DMGEHNX TN Voltage-gated L-type calcium channel (L-CaC) DMGEHNX MA Activator DMGEHNX RN Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96. DMGEHNX RU https://pubmed.ncbi.nlm.nih.gov/9131258 DMGELY0 DI DMGELY0 DMGELY0 DN 2-(2-Mercapto-ethyl)-pentanedioic acid DMGELY0 TI TT9G4N0 DMGELY0 TN Glutamate carboxypeptidase II (GCPII) DMGELY0 MA Inhibitor DMGELY0 RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DMGELY0 RU https://pubmed.ncbi.nlm.nih.gov/12723961 DMGEMQX DI DMGEMQX DMGEMQX DN Anthracen-10-yl(10H-phenothiazin-10-yl)methanone DMGEMQX TI TTEB0GD DMGEMQX TN Cholinesterase (BCHE) DMGEMQX MA Inhibitor DMGEMQX RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMGEMQX RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMGEO8N DI DMGEO8N DMGEO8N DN HEPTANOATE DMGEO8N TI TTTQR47 DMGEO8N TN Solute carrier family 22 member 8 (SLC22A8) DMGEO8N MA Inhibitor DMGEO8N RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DMGEO8N RU https://pubmed.ncbi.nlm.nih.gov/17553798 DMGESUH DI DMGESUH DMGESUH DN ETHIONINE DMGESUH TI TTFK1JQ DMGESUH TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMGESUH MA Inhibitor DMGESUH RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMGESUH RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMGEVBH DI DMGEVBH DMGEVBH DN Aminothiazoline DMGEVBH TI TTF10I9 DMGEVBH TN Nitric-oxide synthase inducible (NOS2) DMGEVBH MA Inhibitor DMGEVBH RN The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6206-9. DMGEVBH RU https://pubmed.ncbi.nlm.nih.gov/18930653 DMGEXOZ DI DMGEXOZ DMGEXOZ DN 1-adamantan-1-yl-3-(3-hexyloxypropyl)urea DMGEXOZ TI TT7WVHI DMGEXOZ TN Soluble epoxide hydrolase (EPHX2) DMGEXOZ MA Inhibitor DMGEXOZ RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMGEXOZ RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMGEYAK DI DMGEYAK DMGEYAK DN 2,6-Difluorobenzenesulfonamide DMGEYAK TI TTANPDJ DMGEYAK TN Carbonic anhydrase II (CA-II) DMGEYAK MA Inhibitor DMGEYAK RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMGEYAK RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMGEYFB DI DMGEYFB DMGEYFB DN BP-100-1.02 DMGEYFB TI TTFOUV4 DMGEYFB TN BCL-2 messenger RNA (BCL2 mRNA) DMGEYFB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2844). DMGEYFB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2844 DMGF4XC DI DMGF4XC DMGF4XC DN N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile DMGF4XC TI TT36ETB DMGF4XC TN Cathepsin L (CTSL) DMGF4XC MA Inhibitor DMGF4XC RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMGF4XC RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMGF4XC DI DMGF4XC DMGF4XC DN N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile DMGF4XC TI TTUMQVO DMGF4XC TN Cathepsin S (CTSS) DMGF4XC MA Inhibitor DMGF4XC RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMGF4XC RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMGF4XC DI DMGF4XC DMGF4XC DN N-(tert-butoxycarbonyl)-norleucyl-glycine-nitrile DMGF4XC TI TTDZN01 DMGF4XC TN Cathepsin K (CTSK) DMGF4XC MA Inhibitor DMGF4XC RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMGF4XC RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMGF7XC DI DMGF7XC DMGF7XC DN MAR--99 DMGF7XC TI TTTWGIX DMGF7XC TN Leukotriene receptor (LTR) DMGF7XC MA Modulator DMGF7XC RN Effect of 1,6-dihydro-2[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidineca rboxyli c acid on ethanol-induced microvascular injury in rats. Arzneimittelforschung. 1996 Aug;46(8):779-83. DMGF7XC RU https://pubmed.ncbi.nlm.nih.gov/9125278 DMGFC8D DI DMGFC8D DMGFC8D DN Spiro[cyclopropane-1,2-adamantan]-2-amine DMGFC8D TI TTXT3PU DMGFC8D TN Influenza M2 protein (Influ M) DMGFC8D MA Inhibitor DMGFC8D RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMGFC8D RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMGFEPJ DI DMGFEPJ DMGFEPJ DN Cyclopropyl DMGFEPJ TI TTJS7O4 DMGFEPJ TN Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2) DMGFEPJ MA Inhibitor DMGFEPJ RN Entamoeba histolytica alcohol dehydrogenase 2 (EhADH2) as a target for anti-amoebic agents. J Antimicrob Chemother. 2004 Jul;54(1):56-9. DMGFEPJ RU https://pubmed.ncbi.nlm.nih.gov/15150165 DMGFIJV DI DMGFIJV DMGFIJV DN (3-Amino-propyl)-hydroxymethyl-phosphinic acid DMGFIJV TI TTDCVZW DMGFIJV TN Gamma-aminobutyric acid B receptor (GABBR) DMGFIJV MA Inhibitor DMGFIJV RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DMGFIJV RU https://pubmed.ncbi.nlm.nih.gov/7650684 DMGFLI7 DI DMGFLI7 DMGFLI7 DN Carbaphosphonate DMGFLI7 TI TTPS7KA DMGFLI7 TN Bacterial Dehydroquinate synthase (Bact aroB) DMGFLI7 MA Inhibitor DMGFLI7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGFLI7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGFOQJ DI DMGFOQJ DMGFOQJ DN (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide DMGFOQJ TI TT8HGRW DMGFOQJ TN Voltage-gated potassium channel Kv7.4 (KCNQ4) DMGFOQJ MA Activator DMGFOQJ RN The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77. DMGFOQJ RU https://pubmed.ncbi.nlm.nih.gov/16904708 DMGFOQJ DI DMGFOQJ DMGFOQJ DN (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide DMGFOQJ TI TTWVL5Q DMGFOQJ TN Voltage-gated potassium channel Kv7.5 (KCNQ5) DMGFOQJ MA Activator DMGFOQJ RN The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77. DMGFOQJ RU https://pubmed.ncbi.nlm.nih.gov/16904708 DMGFOQJ DI DMGFOQJ DMGFOQJ DN (S)-N-[1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-acrylamide DMGFOQJ TI TTPXI3S DMGFOQJ TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DMGFOQJ MA Activator DMGFOQJ RN The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels. Neuropharmacology. 2006 Nov;51(6):1068-77. DMGFOQJ RU https://pubmed.ncbi.nlm.nih.gov/16904708 DMGFQLE DI DMGFQLE DMGFQLE DN 9-(5,5-Difluoro-5-Phosphonopentyl)Guanine DMGFQLE TI TTMCF1Y DMGFQLE TN Purine nucleoside phosphorylase (PNP) DMGFQLE MA Inhibitor DMGFQLE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGFQLE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGFRSY DI DMGFRSY DMGFRSY DN OMPT DMGFRSY TI TTE2YJR DMGFRSY TN Lysophosphatidate-3 receptor (LPAR3) DMGFRSY MA Agonist DMGFRSY RN Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem. 2003 Apr 4;278(14):11962-9. DMGFRSY RU https://pubmed.ncbi.nlm.nih.gov/12554733 DMGFSQB DI DMGFSQB DMGFSQB DN JWH-206 DMGFSQB TI TTMSFAW DMGFSQB TN Cannabinoid receptor 2 (CB2) DMGFSQB MA Inhibitor DMGFSQB RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMGFSQB RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMGFTVI DI DMGFTVI DMGFTVI DN VU0090157 DMGFTVI TI TTOXS3C DMGFTVI TN Muscarinic acetylcholine receptor (CHRM) DMGFTVI MA Modulator (allosteric modulator) DMGFTVI RN Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol. 2009 Mar;75(3):577-88. DMGFTVI RU https://pubmed.ncbi.nlm.nih.gov/19047481 DMGFY4X DI DMGFY4X DMGFY4X DN BUDDLEDIN A DMGFY4X TI TT2J34L DMGFY4X TN Arachidonate 5-lipoxygenase (5-LOX) DMGFY4X MA Inhibitor DMGFY4X RN Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J Nat Prod. 1999 Sep;62(9):1241-5. DMGFY4X RU https://pubmed.ncbi.nlm.nih.gov/10514305 DMGH1LX DI DMGH1LX DMGH1LX DN BMS-509744 DMGH1LX TI TT3C80U DMGH1LX TN T-cell-specific kinase (ITK) DMGH1LX MA Inhibitor DMGH1LX RN Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacol. 1990 Jun;10(3):200-3. DMGH1LX RU https://pubmed.ncbi.nlm.nih.gov/2115893 DMGH8WV DI DMGH8WV DMGH8WV DN MeTRH DMGH8WV TI TT4J8MF DMGH8WV TN Thyrotropin-releasing hormone receptor (TRHR) DMGH8WV MA Agonist DMGH8WV RN Thyrotropin-releasing hormone receptor type 1 (TRH-R1), not TRH-R2, primarily mediates taltirelin actions in the CNS of mice. Neuropsychopharmacology. 2013 May;38(6):950-6. DMGH8WV RU https://pubmed.ncbi.nlm.nih.gov/23303050 DMGHAC7 DI DMGHAC7 DMGHAC7 DN 1,1':4',1''-terphenyl-3,3''-diol DMGHAC7 TI TTXV4FI DMGHAC7 TN Albendazole monooxygenase (CYP3A4) DMGHAC7 MA Inhibitor DMGHAC7 RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DMGHAC7 RU https://pubmed.ncbi.nlm.nih.gov/18855374 DMGHAC7 DI DMGHAC7 DMGHAC7 DN 1,1':4',1''-terphenyl-3,3''-diol DMGHAC7 TI TTIWB6L DMGHAC7 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMGHAC7 MA Inhibitor DMGHAC7 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMGHAC7 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMGHEQV DI DMGHEQV DMGHEQV DN Butyl 10H-phenothiazine-10-carboxylate DMGHEQV TI TTEB0GD DMGHEQV TN Cholinesterase (BCHE) DMGHEQV MA Inhibitor DMGHEQV RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMGHEQV RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMGHM1L DI DMGHM1L DMGHM1L DN Dephospho Coenzyme A DMGHM1L TI TT4YO0Z DMGHM1L TN Phosphopantetheine adenylyltransferase (PPAT) DMGHM1L MA Inhibitor DMGHM1L RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMGHM1L RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMGHQJ8 DI DMGHQJ8 DMGHQJ8 DN N-(phosphonacetyl)-L-aspartate DMGHQJ8 TI TT2YT1K DMGHQJ8 TN Aspartate carbamoyltransferase (CAD) DMGHQJ8 MA Inhibitor DMGHQJ8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGHQJ8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGHQJ8 DI DMGHQJ8 DMGHQJ8 DN N-(phosphonacetyl)-L-aspartate DMGHQJ8 TI TTDRBPW DMGHQJ8 TN Pseudomonas Aspartate carbamoyltransferase (Pseudo pyrB) DMGHQJ8 MA Inhibitor DMGHQJ8 RN Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Mar;41(3):894-904. DMGHQJ8 RU https://pubmed.ncbi.nlm.nih.gov/7459875 DMGHQJ8 DI DMGHQJ8 DMGHQJ8 DN N-(phosphonacetyl)-L-aspartate DMGHQJ8 TI TTZHA0O DMGHQJ8 TN Carbonic anhydrase IV (CA-IV) DMGHQJ8 MA Inhibitor DMGHQJ8 RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6. DMGHQJ8 RU https://pubmed.ncbi.nlm.nih.gov/15745821 DMGHQJ8 DI DMGHQJ8 DMGHQJ8 DN N-(phosphonacetyl)-L-aspartate DMGHQJ8 TI TTANPDJ DMGHQJ8 TN Carbonic anhydrase II (CA-II) DMGHQJ8 MA Inhibitor DMGHQJ8 RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6. DMGHQJ8 RU https://pubmed.ncbi.nlm.nih.gov/15745821 DMGHRY0 DI DMGHRY0 DMGHRY0 DN SB 714786 DMGHRY0 TI TTK8CXU DMGHRY0 TN 5-HT 1B receptor (HTR1B) DMGHRY0 MA Antagonist DMGHRY0 RN Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80. DMGHRY0 RU https://pubmed.ncbi.nlm.nih.gov/15887956 DMGHRY0 DI DMGHRY0 DMGHRY0 DN SB 714786 DMGHRY0 TI TT6MSOK DMGHRY0 TN 5-HT 1D receptor (HTR1D) DMGHRY0 MA Antagonist DMGHRY0 RN Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80. DMGHRY0 RU https://pubmed.ncbi.nlm.nih.gov/15887956 DMGHRY0 DI DMGHRY0 DMGHRY0 DN SB 714786 DMGHRY0 TI TTSQIFT DMGHRY0 TN 5-HT 1A receptor (HTR1A) DMGHRY0 MA Antagonist DMGHRY0 RN Discovery of the first potent, selective 5-hydroxytryptamine1D receptor antagonist. J Med Chem. 2005 May 19;48(10):3478-80. DMGHRY0 RU https://pubmed.ncbi.nlm.nih.gov/15887956 DMGHVW7 DI DMGHVW7 DMGHVW7 DN 4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol DMGHVW7 TI TTE4KHA DMGHVW7 TN Amyloid beta A4 protein (APP) DMGHVW7 MA Inhibitor DMGHVW7 RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DMGHVW7 RU https://pubmed.ncbi.nlm.nih.gov/16325402 DMGHWJ5 DI DMGHWJ5 DMGHWJ5 DN (RS/SR)-2-[1-(4-chlorophenyl)butyl]piperidine DMGHWJ5 TI TTVBI8W DMGHWJ5 TN Dopamine transporter (DAT) DMGHWJ5 MA Inhibitor DMGHWJ5 RN Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. DMGHWJ5 RU https://pubmed.ncbi.nlm.nih.gov/17228864 DMGHXQE DI DMGHXQE DMGHXQE DN AMX-256 DMGHXQE TI TT1YWO5 DMGHXQE TN Glucagon-like peptide 2 receptor (GLP2R) DMGHXQE MA Modulator DMGHXQE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 250). DMGHXQE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=250 DMGI0YV DI DMGI0YV DMGI0YV DN 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid DMGI0YV TI TT6X50U DMGI0YV TN Matrix metalloproteinase-9 (MMP-9) DMGI0YV MA Inhibitor DMGI0YV RN Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. DMGI0YV RU https://pubmed.ncbi.nlm.nih.gov/18364257 DMGI0YV DI DMGI0YV DMGI0YV DN 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid DMGI0YV TI TTGA1IV DMGI0YV TN Matrix metalloproteinase-8 (MMP-8) DMGI0YV MA Inhibitor DMGI0YV RN Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. DMGI0YV RU https://pubmed.ncbi.nlm.nih.gov/18364257 DMGI0YV DI DMGI0YV DMGI0YV DN 4-amino-3-(4-(hexyloxy)phenyl)-4-oxobutanoic acid DMGI0YV TI TTHY57M DMGI0YV TN Matrix metalloproteinase-13 (MMP-13) DMGI0YV MA Inhibitor DMGI0YV RN Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. DMGI0YV RU https://pubmed.ncbi.nlm.nih.gov/18364257 DMGI4ZW DI DMGI4ZW DMGI4ZW DN norfenfluramine DMGI4ZW TI TT0K1SC DMGI4ZW TN 5-HT 2B receptor (HTR2B) DMGI4ZW MA Agonist DMGI4ZW RN Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. DMGI4ZW RU https://pubmed.ncbi.nlm.nih.gov/11104741 DMGI9EA DI DMGI9EA DMGI9EA DN N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine DMGI9EA TI TTGSEFH DMGI9EA TN Sodium/hydrogen exchanger 1 (SLC9A1) DMGI9EA MA Inhibitor DMGI9EA RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMGI9EA RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMGI9EA DI DMGI9EA DMGI9EA DN N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine DMGI9EA TI TTFZVPO DMGI9EA TN Sodium/hydrogen exchanger 3 (SLC9A3) DMGI9EA MA Inhibitor DMGI9EA RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMGI9EA RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMGI9SM DI DMGI9SM DMGI9SM DN Alpha-monofluoromethyl-3,4-dehydroornithine methyl ester DMGI9SM TI TTUMGNO DMGI9SM TN Ornithine decarboxylase (ODC1) DMGI9SM MA Inhibitor DMGI9SM RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DMGI9SM RU https://pubmed.ncbi.nlm.nih.gov/3115816 DMGID4T DI DMGID4T DMGID4T DN FP-1102 DMGID4T TI TT7HC21 DMGID4T TN Membrane copper amine oxidase (AOC3) DMGID4T MA Inhibitor DMGID4T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767). DMGID4T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767 DMGIF1L DI DMGIF1L DMGIF1L DN Prodipine DMGIF1L TI TTVG215 DMGIF1L TN Debrisoquine 4-hydroxylase (CYP2D6) DMGIF1L MA Inhibitor DMGIF1L RN Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. 1993 Apr 30;36(9):1136-45. DMGIF1L RU https://pubmed.ncbi.nlm.nih.gov/8487254 DMGIKWA DI DMGIKWA DMGIKWA DN 2-fluorophenyl 4'-ethylbiphenyl-4-ylcarbamate DMGIKWA TI TTDP1UC DMGIKWA TN Fatty acid amide hydrolase (FAAH) DMGIKWA MA Inhibitor DMGIKWA RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMGIKWA RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMGIMH8 DI DMGIMH8 DMGIMH8 DN ISIS 19657 DMGIMH8 TI TTWALCO DMGIMH8 TN HER4 messenger RNA (ERBB4 mRNA) DMGIMH8 RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMGIMH8 RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMGINBT DI DMGINBT DMGINBT DN SGC707 DMGINBT TI TTL4XSQ DMGINBT TN Protein arginine methyltransferase 3 (PRMT3) DMGINBT MA Modulator (allosteric modulator) DMGINBT RN A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70. DMGINBT RU https://pubmed.ncbi.nlm.nih.gov/25728001 DMGIO3R DI DMGIO3R DMGIO3R DN 5-(azepan-1-ylsulfonyl)indoline-2,3-dione DMGIO3R TI TTPF2QI DMGIO3R TN Caspase-3 (CASP3) DMGIO3R MA Inhibitor DMGIO3R RN Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7. DMGIO3R RU https://pubmed.ncbi.nlm.nih.gov/19631549 DMGIS5Q DI DMGIS5Q DMGIS5Q DN pCMPS DMGIS5Q TI TTZ1DT0 DMGIS5Q TN P2Y purinoceptor 12 (P2RY12) DMGIS5Q MA Antagonist DMGIS5Q RN P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med. 2003 May;3(2):113-22. DMGIS5Q RU https://pubmed.ncbi.nlm.nih.gov/15199474 DMGIZ5U DI DMGIZ5U DMGIZ5U DN carveol DMGIZ5U TI TT946IA DMGIZ5U TN Transient receptor potential cation channel V3 (TRPV3) DMGIZ5U MA Activator DMGIZ5U RN Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40. DMGIZ5U RU https://pubmed.ncbi.nlm.nih.gov/17420775 DMGJ0IE DI DMGJ0IE DMGJ0IE DN MRS1186 DMGJ0IE TI TTJFY5U DMGJ0IE TN Adenosine A3 receptor (ADORA3) DMGJ0IE MA Antagonist DMGJ0IE RN Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J Med Chem. 1996 Oct 11;39(21):4142-8. DMGJ0IE RU https://pubmed.ncbi.nlm.nih.gov/8863790 DMGJ3L6 DI DMGJ3L6 DMGJ3L6 DN 8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DMGJ3L6 TI TTZAYWL DMGJ3L6 TN Estrogen receptor (ESR) DMGJ3L6 MA Inhibitor DMGJ3L6 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMGJ3L6 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMGJ3L6 DI DMGJ3L6 DMGJ3L6 DN 8-Fluoro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DMGJ3L6 TI TTOM3J0 DMGJ3L6 TN Estrogen receptor beta (ESR2) DMGJ3L6 MA Inhibitor DMGJ3L6 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMGJ3L6 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMGJ4AO DI DMGJ4AO DMGJ4AO DN ISIS 298712 DMGJ4AO TI TTSN6QU DMGJ4AO TN HIF1-alpha messenger RNA (HIF1A mRNA) DMGJ4AO RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMGJ4AO RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMGJEH9 DI DMGJEH9 DMGJEH9 DN N2-(3-trifluoromethylphenyl)guanine DMGJEH9 TI TTP3QRF DMGJEH9 TN Thymidine kinase 1 (TK1) DMGJEH9 MA Inhibitor DMGJEH9 RN Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. DMGJEH9 RU https://pubmed.ncbi.nlm.nih.gov/17438061 DMGJPYO DI DMGJPYO DMGJPYO DN 2-(3,5-difluorophenyl)-7-methyl-1,8-naphthyridine DMGJPYO TI TTHS256 DMGJPYO TN Metabotropic glutamate receptor 5 (mGluR5) DMGJPYO MA Inhibitor DMGJPYO RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMGJPYO RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMGJS9N DI DMGJS9N DMGJS9N DN 3-(3-cyano-1H-indol-6-yl)-1-methyl-1-phenylurea DMGJS9N TI TTTB4UP DMGJS9N TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMGJS9N MA Inhibitor DMGJS9N RN Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42. DMGJS9N RU https://pubmed.ncbi.nlm.nih.gov/16483773 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TTSYM0R DMGJSVD TN Carbonic anhydrase XII (CA-XII) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TTANPDJ DMGJSVD TN Carbonic anhydrase II (CA-II) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TTEYTKG DMGJSVD TN Carbonic anhydrase XIV (CA-XIV) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TT2LVK8 DMGJSVD TN Carbonic anhydrase IX (CA-IX) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TTCFSPE DMGJSVD TN Carbonic anhydrase VI (CA-VI) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TTHQPL7 DMGJSVD TN Carbonic anhydrase I (CA-I) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TTZHA0O DMGJSVD TN Carbonic anhydrase IV (CA-IV) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJSVD DI DMGJSVD DMGJSVD DN P-Coumaric Acid DMGJSVD TI TTUNARX DMGJSVD TN Carbonic anhydrase (CA) DMGJSVD MA Inhibitor DMGJSVD RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMGJSVD RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMGJTL3 DI DMGJTL3 DMGJTL3 DN SMaRT FVIII DMGJTL3 TI TT1290U DMGJTL3 TN Coagulation factor VIII (F8) DMGJTL3 MA Modulator DMGJTL3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMGJTL3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMGJURC DI DMGJURC DMGJURC DN ISIS 29135 DMGJURC TI TTO6SGY DMGJURC TN AKT3 messenger RNA (AKT3 mRNA) DMGJURC RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMGJURC RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMGJYIZ DI DMGJYIZ DMGJYIZ DN MystiLol DMGJYIZ TI TTMXGCW DMGJYIZ TN Adrenergic receptor beta-3 (ADRB3) DMGJYIZ MA Blocker DMGJYIZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 29). DMGJYIZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=29 DMGJYWF DI DMGJYWF DMGJYWF DN 6-Benzylamino-5-bromo-1H-pyrimidine-2,4-dione DMGJYWF TI TT2GPK3 DMGJYWF TN DNA topoisomerase (TOP) DMGJYWF MA Inhibitor DMGJYWF RN Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81. DMGJYWF RU https://pubmed.ncbi.nlm.nih.gov/3084785 DMGK05W DI DMGK05W DMGK05W DN 5-Phosphoribosyl-1-(Beta-Methylene) Pyrophosphate DMGK05W TI TTH29K0 DMGK05W TN Mycobacterium Nicotinate-nucleotide pyrophosphorylase (MycB nadC) DMGK05W MA Inhibitor DMGK05W RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGK05W RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGK2PC DI DMGK2PC DMGK2PC DN PSB-11 DMGK2PC TI TTK25J1 DMGK2PC TN Adenosine A1 receptor (ADORA1) DMGK2PC MA Antagonist DMGK2PC RN 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. Bioorg Med Chem. 2003 Feb 6;11(3):347-56. DMGK2PC RU https://pubmed.ncbi.nlm.nih.gov/12517430 DMGK2PC DI DMGK2PC DMGK2PC DN PSB-11 DMGK2PC TI TTNE7KG DMGK2PC TN Adenosine A2b receptor (ADORA2B) DMGK2PC MA Antagonist DMGK2PC RN Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3440-50. DMGK2PC RU https://pubmed.ncbi.nlm.nih.gov/12139454 DMGK2PC DI DMGK2PC DMGK2PC DN PSB-11 DMGK2PC TI TTJFY5U DMGK2PC TN Adenosine A3 receptor (ADORA3) DMGK2PC MA Antagonist DMGK2PC RN [(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. Bioorg Med Chem Lett. 2002 Feb 11;12(3):501-3. DMGK2PC RU https://pubmed.ncbi.nlm.nih.gov/11814828 DMGK2TQ DI DMGK2TQ DMGK2TQ DN ISIS 9007 DMGK2TQ TI TTBSN0L DMGK2TQ TN PKC-zeta messenger RNA (PRKCZ mRNA) DMGK2TQ RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMGK2TQ RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMGK7U5 DI DMGK7U5 DMGK7U5 DN BX-201 DMGK7U5 TI TTYMGWX DMGK7U5 TN PDK-1 messenger RNA (PDK-1 mRNA) DMGK7U5 MA Inhibitor DMGK7U5 RN Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3814-8. DMGK7U5 RU https://pubmed.ncbi.nlm.nih.gov/17531483 DMGKEO5 DI DMGKEO5 DMGKEO5 DN GW0742X DMGKEO5 TI TT2JWF6 DMGKEO5 TN Peroxisome proliferator-activated receptor delta (PPARD) DMGKEO5 MA Agonist DMGKEO5 RN Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity. Bioorg Med Chem Lett. 2003 May 5;13(9):1517-21. DMGKEO5 RU https://pubmed.ncbi.nlm.nih.gov/12699745 DMGKIYE DI DMGKIYE DMGKIYE DN EPIDEPRIDE DMGKIYE TI TTEX248 DMGKIYE TN Dopamine D2 receptor (D2R) DMGKIYE MA Inhibitor DMGKIYE RN Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8. DMGKIYE RU https://pubmed.ncbi.nlm.nih.gov/8093734 DMGKP9Y DI DMGKP9Y DMGKP9Y DN 1-Ethyl-4-(2-methoxy-phenyl)-piperazine DMGKP9Y TI TTSQIFT DMGKP9Y TN 5-HT 1A receptor (HTR1A) DMGKP9Y MA Inhibitor DMGKP9Y RN Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60. DMGKP9Y RU https://pubmed.ncbi.nlm.nih.gov/8064802 DMGKP9Y DI DMGKP9Y DMGKP9Y DN 1-Ethyl-4-(2-methoxy-phenyl)-piperazine DMGKP9Y TI TTJQOD7 DMGKP9Y TN 5-HT 2A receptor (HTR2A) DMGKP9Y MA Inhibitor DMGKP9Y RN Structure-activity relationship studies of central nervous system agents. 13. 4-[3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new ... J Med Chem. 1994 Aug 19;37(17):2754-60. DMGKP9Y RU https://pubmed.ncbi.nlm.nih.gov/8064802 DMGKSVF DI DMGKSVF DMGKSVF DN carbocyclic thromboxane A2 DMGKSVF TI TT2O84V DMGKSVF TN Thromboxane A2 receptor (TBXA2R) DMGKSVF MA Agonist DMGKSVF RN Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64. DMGKSVF RU https://pubmed.ncbi.nlm.nih.gov/1434130 DMGKXOI DI DMGKXOI DMGKXOI DN 2-(N-Pyrrolidinyl)-3'-methylpropiophenone DMGKXOI TI TTVBI8W DMGKXOI TN Dopamine transporter (DAT) DMGKXOI MA Inhibitor DMGKXOI RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMGKXOI RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMGKXOI DI DMGKXOI DMGKXOI DN 2-(N-Pyrrolidinyl)-3'-methylpropiophenone DMGKXOI TI TTAWNKZ DMGKXOI TN Norepinephrine transporter (NET) DMGKXOI MA Inhibitor DMGKXOI RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMGKXOI RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMGL4MJ DI DMGL4MJ DMGL4MJ DN 1-Bromo-4-imidazol-1-ylmethyl-xanthen-9-one DMGL4MJ TI TTSZLWK DMGL4MJ TN Aromatase (CYP19A1) DMGL4MJ MA Inhibitor DMGL4MJ RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMGL4MJ RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMGL7TM DI DMGL7TM DMGL7TM DN Ro26-4550 DMGL7TM TI TTAJU0S DMGL7TM TN Interleukin 2 receptor (IL2R) DMGL7TM MA Antagonist DMGL7TM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2297). DMGL7TM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2297 DMGLDFI DI DMGLDFI DMGLDFI DN PHENYLMETHANESULFONAMIDE DMGLDFI TI TT2LVK8 DMGLDFI TN Carbonic anhydrase IX (CA-IX) DMGLDFI MA Inhibitor DMGLDFI RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMGLDFI RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMGLDFI DI DMGLDFI DMGLDFI DN PHENYLMETHANESULFONAMIDE DMGLDFI TI TTANPDJ DMGLDFI TN Carbonic anhydrase II (CA-II) DMGLDFI MA Inhibitor DMGLDFI RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMGLDFI RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMGLDFI DI DMGLDFI DMGLDFI DN PHENYLMETHANESULFONAMIDE DMGLDFI TI TTUNARX DMGLDFI TN Carbonic anhydrase (CA) DMGLDFI MA Inhibitor DMGLDFI RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMGLDFI RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMGLDFI DI DMGLDFI DMGLDFI DN PHENYLMETHANESULFONAMIDE DMGLDFI TI TTHQPL7 DMGLDFI TN Carbonic anhydrase I (CA-I) DMGLDFI MA Inhibitor DMGLDFI RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMGLDFI RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMGLEX5 DI DMGLEX5 DMGLEX5 DN 2-(4-Fluoro-3-phenoxy-benzoylamino)-benzoic acid DMGLEX5 TI TTRVTMX DMGLEX5 TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMGLEX5 MA Inhibitor DMGLEX5 RN Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609. DMGLEX5 RU https://pubmed.ncbi.nlm.nih.gov/15743201 DMGLIPV DI DMGLIPV DMGLIPV DN GNF-5 DMGLIPV TI TT6B75U DMGLIPV TN ABL messenger RNA (ABL mRNA) DMGLIPV MA Inhibitor DMGLIPV RN Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6. DMGLIPV RU https://pubmed.ncbi.nlm.nih.gov/20072125 DMGLO2X DI DMGLO2X DMGLO2X DN CP-226269 DMGLO2X TI TTE0A2F DMGLO2X TN Dopamine D4 receptor (D4R) DMGLO2X MA Agonist DMGLO2X RN Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9. DMGLO2X RU https://pubmed.ncbi.nlm.nih.gov/15448188 DMGLQ72 DI DMGLQ72 DMGLQ72 DN [14C]GlySar DMGLQ72 TI TT5LF3C DMGLQ72 TN Solute carrier family 15 member 1 (SLC15A1) DMGLQ72 MA Modulator DMGLQ72 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 984). DMGLQ72 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=984 DMGLQ72 DI DMGLQ72 DMGLQ72 DN [14C]GlySar DMGLQ72 TI TT27Q3A DMGLQ72 TN Solute carrier family 15 member 2 (SLC15A2) DMGLQ72 MA Modulator DMGLQ72 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985). DMGLQ72 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985 DMGLSPC DI DMGLSPC DMGLSPC DN Salicylhydroxamic acid DMGLSPC TI TT3PQ2Y DMGLSPC TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMGLSPC MA Inhibitor DMGLSPC RN Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8. DMGLSPC RU https://pubmed.ncbi.nlm.nih.gov/7726490 DMGLT0N DI DMGLT0N DMGLT0N DN 6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol DMGLT0N TI TTZAYWL DMGLT0N TN Estrogen receptor (ESR) DMGLT0N MA Inhibitor DMGLT0N RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMGLT0N RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMGLT0N DI DMGLT0N DMGLT0N DN 6-(4-Hydroxy-phenyl)-1-methyl-naphthalen-2-ol DMGLT0N TI TTOM3J0 DMGLT0N TN Estrogen receptor beta (ESR2) DMGLT0N MA Inhibitor DMGLT0N RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMGLT0N RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMGLWOM DI DMGLWOM DMGLWOM DN 7-Nitroindazole-2-Carboxamidine DMGLWOM TI TTCM4B3 DMGLWOM TN Nitric-oxide synthase endothelial (NOS3) DMGLWOM MA Inhibitor DMGLWOM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGLWOM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGMAPB DI DMGMAPB DMGMAPB DN (S)-N2-[4-(benzyloxy)benzyl]alaninamide DMGMAPB TI TTGP7BY DMGMAPB TN Monoamine oxidase type B (MAO-B) DMGMAPB MA Inhibitor DMGMAPB RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMGMAPB RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMGMD1K DI DMGMD1K DMGMD1K DN 9-N-Phenylmethylamino-Tacrine DMGMD1K TI TTEB0GD DMGMD1K TN Cholinesterase (BCHE) DMGMD1K MA Inhibitor DMGMD1K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGMD1K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGMH8T DI DMGMH8T DMGMH8T DN NF157 DMGMH8T TI TTYXPCO DMGMH8T TN P2Y purinoceptor 11 (P2RY11) DMGMH8T MA Antagonist DMGMH8T RN Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem. 2005 Nov 3;48(22):7040-8. DMGMH8T RU https://pubmed.ncbi.nlm.nih.gov/16250663 DMGMIX3 DI DMGMIX3 DMGMIX3 DN omega-chloroacetophenone DMGMIX3 TI TTELV3W DMGMIX3 TN Transformation-sensitive protein p120 (TRPA1) DMGMIX3 MA Activator DMGMIX3 RN Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6. DMGMIX3 RU https://pubmed.ncbi.nlm.nih.gov/18501939 DMGMJWL DI DMGMJWL DMGMJWL DN 3,3'-difluorobenzaldazine DMGMJWL TI TTHS256 DMGMJWL TN Metabotropic glutamate receptor 5 (mGluR5) DMGMJWL MA Modulator (allosteric modulator) DMGMJWL RN A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol. 2003 Sep;64(3):731-40. DMGMJWL RU https://pubmed.ncbi.nlm.nih.gov/12920211 DMGMKH3 DI DMGMKH3 DMGMKH3 DN ISIS 28405 DMGMKH3 TI TT9GR53 DMGMKH3 TN Smad1 messenger RNA (SMAD1 mRNA) DMGMKH3 RN US patent application no. 6,159,697, Antisense modulation of Smad7 expression. DMGMKH3 RU http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true DMGMO3Q DI DMGMO3Q DMGMO3Q DN LP-661438 DMGMO3Q TI TTJOCE4 DMGMO3Q TN Deoxycytidine kinase (DCK) DMGMO3Q MA Modulator DMGMO3Q RN 236th ACS National Meeting DMGMO3Q RU http://www.amriglobal.com/img/document_files/TR_aug08a.pdf DMGMWA6 DI DMGMWA6 DMGMWA6 DN 24(S)-hydroxycholesterol DMGMWA6 TI TTXA6PH DMGMWA6 TN Oxysterols receptor LXR-beta (NR1H2) DMGMWA6 MA Agonist DMGMWA6 RN Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997 Feb 7;272(6):3137-40. DMGMWA6 RU https://pubmed.ncbi.nlm.nih.gov/9013544 DMGMWA6 DI DMGMWA6 DMGMWA6 DN 24(S)-hydroxycholesterol DMGMWA6 TI TTECBXN DMGMWA6 TN Oxysterols receptor LXR-alpha (NR1H3) DMGMWA6 MA Agonist DMGMWA6 RN Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997 Feb 7;272(6):3137-40. DMGMWA6 RU https://pubmed.ncbi.nlm.nih.gov/9013544 DMGMXQC DI DMGMXQC DMGMXQC DN STEPHOLIDINE DMGMXQC TI TTS2PH3 DMGMXQC TN Dopamine D5 receptor (D5R) DMGMXQC MA Inhibitor DMGMXQC RN Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. DMGMXQC RU https://pubmed.ncbi.nlm.nih.gov/19744859 DMGMXQC DI DMGMXQC DMGMXQC DN STEPHOLIDINE DMGMXQC TI TT4C8EA DMGMXQC TN Dopamine D3 receptor (D3R) DMGMXQC MA Inhibitor DMGMXQC RN Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. DMGMXQC RU https://pubmed.ncbi.nlm.nih.gov/19744859 DMGMXQC DI DMGMXQC DMGMXQC DN STEPHOLIDINE DMGMXQC TI TTEX248 DMGMXQC TN Dopamine D2 receptor (D2R) DMGMXQC MA Inhibitor DMGMXQC RN Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. DMGMXQC RU https://pubmed.ncbi.nlm.nih.gov/19744859 DMGMXQC DI DMGMXQC DMGMXQC DN STEPHOLIDINE DMGMXQC TI TTE0A2F DMGMXQC TN Dopamine D4 receptor (D4R) DMGMXQC MA Inhibitor DMGMXQC RN Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. DMGMXQC RU https://pubmed.ncbi.nlm.nih.gov/19744859 DMGMXQC DI DMGMXQC DMGMXQC DN STEPHOLIDINE DMGMXQC TI TTZFYLI DMGMXQC TN Dopamine D1 receptor (D1R) DMGMXQC MA Inhibitor DMGMXQC RN Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907. DMGMXQC RU https://pubmed.ncbi.nlm.nih.gov/19744859 DMGMZV9 DI DMGMZV9 DMGMZV9 DN 2-(4-benzoylpiperidine-1-carbonyl)benzoic acid DMGMZV9 TI TTP18AY DMGMZV9 TN Carboxypeptidase B2 (CPB2) DMGMZV9 MA Inhibitor DMGMZV9 RN A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71. DMGMZV9 RU https://pubmed.ncbi.nlm.nih.gov/19386397 DMGN051 DI DMGN051 DMGN051 DN ISIS 6443 DMGN051 TI TTONI0R DMGN051 TN PKC-eta messenger RNA (PRKCH mRNA) DMGN051 RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMGN051 RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMGN38F DI DMGN38F DMGN38F DN CP-271485 DMGN38F TI TTXZ0KQ DMGN38F TN Matrix metalloproteinase-12 (MMP-12) DMGN38F MA Inhibitor DMGN38F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGN38F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGN4OQ DI DMGN4OQ DMGN4OQ DN ISIS-1939 DMGN4OQ TI TTCT6F7 DMGN4OQ TN Intercellular adhesion molecule ICAM-1 (ICAM1) DMGN4OQ MA Modulator DMGN4OQ RN Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162-71. DMGN4OQ RU https://www.ncbi.nlm.nih.gov/pubmed/1680858 DMGNFXY DI DMGNFXY DMGNFXY DN isoamyl-agomelatine DMGNFXY TI TT0WAIE DMGNFXY TN Melatonin receptor type 1A (MTNR1A) DMGNFXY MA Agonist DMGNFXY RN Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur J Med Chem. 2012 Mar;49:310-23. DMGNFXY RU https://pubmed.ncbi.nlm.nih.gov/22301214 DMGNL2A DI DMGNL2A DMGNL2A DN 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane DMGNL2A TI TT3ROYC DMGNL2A TN Serotonin transporter (SERT) DMGNL2A MA Inhibitor DMGNL2A RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMGNL2A RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMGNL2A DI DMGNL2A DMGNL2A DN 1-(benzofuran-2-yl)-3-aza-bicyclo[3.1.0]hexane DMGNL2A TI TTVBI8W DMGNL2A TN Dopamine transporter (DAT) DMGNL2A MA Inhibitor DMGNL2A RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMGNL2A RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMGNVEF DI DMGNVEF DMGNVEF DN 1-hydroxy-3-(4-(trifluoromethyl)phenyl)urea DMGNVEF TI TTULVH8 DMGNVEF TN Tyrosinase (TYR) DMGNVEF MA Inhibitor DMGNVEF RN Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10. DMGNVEF RU https://pubmed.ncbi.nlm.nih.gov/18501598 DMGNWBV DI DMGNWBV DMGNWBV DN 7alpha-N3-ginkgolide B DMGNWBV TI TTQL5VC DMGNWBV TN Platelet-activating factor receptor (PTAFR) DMGNWBV MA Antagonist DMGNWBV RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMGNWBV RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMGNX6M DI DMGNX6M DMGNX6M DN MOLEPHANTININ DMGNX6M TI TTSXVID DMGNX6M TN Nuclear factor NF-kappa-B (NFKB) DMGNX6M MA Inhibitor DMGNX6M RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DMGNX6M RU https://pubmed.ncbi.nlm.nih.gov/15537359 DMGO2D7 DI DMGO2D7 DMGO2D7 DN 3-acetyl-11-keto-beta-boswellic acid DMGO2D7 TI TT9H85R DMGO2D7 TN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DMGO2D7 MA Inhibitor DMGO2D7 RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DMGO2D7 RU https://pubmed.ncbi.nlm.nih.gov/20100662 DMGO2D7 DI DMGO2D7 DMGO2D7 DN 3-acetyl-11-keto-beta-boswellic acid DMGO2D7 TI TTN7BL9 DMGO2D7 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMGO2D7 MA Inhibitor DMGO2D7 RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DMGO2D7 RU https://pubmed.ncbi.nlm.nih.gov/20100662 DMGO4TZ DI DMGO4TZ DMGO4TZ DN ISIS 102624 DMGO4TZ TI TT5U49F DMGO4TZ TN PRKACA messenger RNA (PRKACA mRNA) DMGO4TZ RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMGO4TZ RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMGOHSF DI DMGOHSF DMGOHSF DN 4-(2,3-dichlorobenzylthio)-2-aminobutanoic acid DMGOHSF TI TTFK1JQ DMGOHSF TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMGOHSF MA Inhibitor DMGOHSF RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMGOHSF RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMGOIF5 DI DMGOIF5 DMGOIF5 DN LUF-5980 DMGOIF5 TI TTJFY5U DMGOIF5 TN Adenosine A3 receptor (ADORA3) DMGOIF5 MA Inhibitor DMGOIF5 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMGOIF5 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMGOIF5 DI DMGOIF5 DMGOIF5 DN LUF-5980 DMGOIF5 TI TTK25J1 DMGOIF5 TN Adenosine A1 receptor (ADORA1) DMGOIF5 MA Inhibitor DMGOIF5 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMGOIF5 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMGOIF5 DI DMGOIF5 DMGOIF5 DN LUF-5980 DMGOIF5 TI TTNE7KG DMGOIF5 TN Adenosine A2b receptor (ADORA2B) DMGOIF5 MA Inhibitor DMGOIF5 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMGOIF5 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMGOIF5 DI DMGOIF5 DMGOIF5 DN LUF-5980 DMGOIF5 TI TTM2AOE DMGOIF5 TN Adenosine A2a receptor (ADORA2A) DMGOIF5 MA Inhibitor DMGOIF5 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMGOIF5 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMGOIME DI DMGOIME DMGOIME DN Gly-Arg-Gly-Asp-Ser-Pro-Lys DMGOIME TI TTT1R2L DMGOIME TN Integrin alpha-V (ITGAV) DMGOIME MA Inhibitor DMGOIME RN N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40. DMGOIME RU https://pubmed.ncbi.nlm.nih.gov/10447947 DMGOIME DI DMGOIME DMGOIME DN Gly-Arg-Gly-Asp-Ser-Pro-Lys DMGOIME TI TTJA1ZO DMGOIME TN ITGB3 messenger RNA (ITGB3 mRNA) DMGOIME MA Inhibitor DMGOIME RN N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999 Aug 12;42(16):3033-40. DMGOIME RU https://pubmed.ncbi.nlm.nih.gov/10447947 DMGOMYN DI DMGOMYN DMGOMYN DN XP-21510 DMGOMYN TI TTP86E2 DMGOMYN TN Plasminogen (PLG) DMGOMYN MA Inhibitor DMGOMYN RN Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. DMGOMYN RU https://pubmed.ncbi.nlm.nih.gov/23694890 DMGOPHN DI DMGOPHN DMGOPHN DN ISIS 9139 DMGOPHN TI TT53XHB DMGOPHN TN CD86 messenger RNA (CD86 mRNA) DMGOPHN RN US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein. DMGOPHN RU http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true DMGOPY1 DI DMGOPY1 DMGOPY1 DN RO330-0802/001 DMGOPY1 TI TTU3Y87 DMGOPY1 TN CCR3 messenger RNA (CCR3 mRNA) DMGOPY1 MA Antagonist DMGOPY1 RN Responses of leukocytes to chemokines in whole blood and their antagonism by novel CC-chemokine receptor 3 antagonists. Am J Respir Crit Care Med. 2002 Jun 15;165(12):1602-9. DMGOPY1 RU https://pubmed.ncbi.nlm.nih.gov/12070060 DMGOQY2 DI DMGOQY2 DMGOQY2 DN WIN 62,577 DMGOQY2 TI TTQ13Z5 DMGOQY2 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMGOQY2 MA Modulator (allosteric modulator) DMGOQY2 RN Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505. DMGOQY2 RU https://pubmed.ncbi.nlm.nih.gov/12435818 DMGOQY2 DI DMGOQY2 DMGOQY2 DN WIN 62,577 DMGOQY2 TI TTOXS3C DMGOQY2 TN Muscarinic acetylcholine receptor (CHRM) DMGOQY2 MA Modulator (allosteric modulator) DMGOQY2 RN Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505. DMGOQY2 RU https://pubmed.ncbi.nlm.nih.gov/12435818 DMGORXQ DI DMGORXQ DMGORXQ DN 9-OH-risperidone DMGORXQ TI TTJQOD7 DMGORXQ TN 5-HT 2A receptor (HTR2A) DMGORXQ MA Antagonist DMGORXQ RN Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. DMGORXQ RU https://pubmed.ncbi.nlm.nih.gov/8935801 DMGORXQ DI DMGORXQ DMGORXQ DN 9-OH-risperidone DMGORXQ TI TTSQIFT DMGORXQ TN 5-HT 1A receptor (HTR1A) DMGORXQ MA Antagonist DMGORXQ RN Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. DMGORXQ RU https://pubmed.ncbi.nlm.nih.gov/8935801 DMGORXQ DI DMGORXQ DMGORXQ DN 9-OH-risperidone DMGORXQ TI TT6MSOK DMGORXQ TN 5-HT 1D receptor (HTR1D) DMGORXQ MA Antagonist DMGORXQ RN Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. DMGORXQ RU https://pubmed.ncbi.nlm.nih.gov/8935801 DMGORXQ DI DMGORXQ DMGORXQ DN 9-OH-risperidone DMGORXQ TI TTCPG9S DMGORXQ TN 5-HT 1E receptor (HTR1E) DMGORXQ MA Antagonist DMGORXQ RN Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. DMGORXQ RU https://pubmed.ncbi.nlm.nih.gov/8935801 DMGORXQ DI DMGORXQ DMGORXQ DN 9-OH-risperidone DMGORXQ TI TTTIBOJ DMGORXQ TN Histamine H1 receptor (H1R) DMGORXQ MA Antagonist DMGORXQ RN Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. DMGORXQ RU https://pubmed.ncbi.nlm.nih.gov/8935801 DMGORXQ DI DMGORXQ DMGORXQ DN 9-OH-risperidone DMGORXQ TI TTK8CXU DMGORXQ TN 5-HT 1B receptor (HTR1B) DMGORXQ MA Antagonist DMGORXQ RN Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996 Mar;124(1-2):57-73. DMGORXQ RU https://pubmed.ncbi.nlm.nih.gov/8935801 DMGOTYC DI DMGOTYC DMGOTYC DN 4'-(4-Aminobenzensulfonamide)-4-hydroxychalcone DMGOTYC TI TTULVH8 DMGOTYC TN Tyrosinase (TYR) DMGOTYC MA Inhibitor DMGOTYC RN Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7. DMGOTYC RU https://pubmed.ncbi.nlm.nih.gov/20149498 DMGOURX DI DMGOURX DMGOURX DN USNIC ACID DMGOURX TI TTELIN2 DMGOURX TN PTPN1 messenger RNA (PTPN1 mRNA) DMGOURX MA Inhibitor DMGOURX RN Usimines A-C, bioactive usnic acid derivatives from the Antarctic lichen Stereocaulon alpinum. J Nat Prod. 2008 Apr;71(4):710-2. DMGOURX RU https://pubmed.ncbi.nlm.nih.gov/18288807 DMGOW1E DI DMGOW1E DMGOW1E DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-Gly-) DMGOW1E TI TTBID49 DMGOW1E TN C-X-C chemokine receptor type 4 (CXCR4) DMGOW1E MA Inhibitor DMGOW1E RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMGOW1E RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMGP4M3 DI DMGP4M3 DMGP4M3 DN Carba-Nicotinamide-Adenine-Dinucleotide DMGP4M3 TI TTVDSZ0 DMGP4M3 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMGP4M3 MA Inhibitor DMGP4M3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMGP4M3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMGP9MN DI DMGP9MN DMGP9MN DN BETA-HYDROXYETHYL THEOPHYLLINE DMGP9MN TI TTNE7KG DMGP9MN TN Adenosine A2b receptor (ADORA2B) DMGP9MN MA Inhibitor DMGP9MN RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMGP9MN RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMGPAM0 DI DMGPAM0 DMGPAM0 DN H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH DMGPAM0 TI TTKWM86 DMGPAM0 TN Opioid receptor mu (MOP) DMGPAM0 MA Inhibitor DMGPAM0 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMGPAM0 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMGPAM0 DI DMGPAM0 DMGPAM0 DN H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH DMGPAM0 TI TT27RFC DMGPAM0 TN Opioid receptor delta (OPRD1) DMGPAM0 MA Inhibitor DMGPAM0 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMGPAM0 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMGPDYE DI DMGPDYE DMGPDYE DN 2-methyl-6-(3-(p-tolyloxy)prop-1-ynyl)pyridine DMGPDYE TI TTHS256 DMGPDYE TN Metabotropic glutamate receptor 5 (mGluR5) DMGPDYE MA Inhibitor DMGPDYE RN A new series of pyridinyl-alkynes as antagonists of the metabotropic glutamate receptor 5 (mGluR5). Bioorg Med Chem Lett. 2006 Sep 15;16(18):4792-5. DMGPDYE RU https://pubmed.ncbi.nlm.nih.gov/16839764 DMGPF0N DI DMGPF0N DMGPF0N DN [3H]estrone-3-sulphate DMGPF0N TI TT340CE DMGPF0N TN Organic anion transporter F (SLCO1C1) DMGPF0N MA Modulator DMGPF0N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1222). DMGPF0N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1222 DMGPF0N DI DMGPF0N DMGPF0N DN [3H]estrone-3-sulphate DMGPF0N TI TTUGD21 DMGPF0N TN Sodium-independent organic anion transporter (SLCO1A2) DMGPF0N MA Modulator DMGPF0N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1219). DMGPF0N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1219 DMGPF0N DI DMGPF0N DMGPF0N DN [3H]estrone-3-sulphate DMGPF0N TI TT5CE6L DMGPF0N TN Organic anion transporter D (SLCO3A1) DMGPF0N MA Modulator DMGPF0N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1225). DMGPF0N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1225 DMGPF0N DI DMGPF0N DMGPF0N DN [3H]estrone-3-sulphate DMGPF0N TI TTV1YIE DMGPF0N TN Organic anion transporter E (SLCO4A1) DMGPF0N MA Modulator DMGPF0N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1226). DMGPF0N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1226 DMGPF0N DI DMGPF0N DMGPF0N DN [3H]estrone-3-sulphate DMGPF0N TI TTDL3UZ DMGPF0N TN Organic anion transporter B (SLCO2B1) DMGPF0N MA Modulator DMGPF0N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1224). DMGPF0N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1224 DMGPF0N DI DMGPF0N DMGPF0N DN [3H]estrone-3-sulphate DMGPF0N TI TTFGXEB DMGPF0N TN Liver organic anion transporter 1 (SLCO1B1) DMGPF0N MA Modulator DMGPF0N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1220). DMGPF0N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1220 DMGPI0C DI DMGPI0C DMGPI0C DN 2-Pyrrolidin-1-yl-benzo[h]chromen-4-one DMGPI0C TI TTK3PY9 DMGPI0C TN DNA-dependent protein kinase catalytic (PRKDC) DMGPI0C MA Inhibitor DMGPI0C RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMGPI0C RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMGPIL0 DI DMGPIL0 DMGPIL0 DN 1-adamantan-1-yl-3-piperidin-4-ylmethyl-urea DMGPIL0 TI TT7WVHI DMGPIL0 TN Soluble epoxide hydrolase (EPHX2) DMGPIL0 MA Inhibitor DMGPIL0 RN Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. DMGPIL0 RU https://pubmed.ncbi.nlm.nih.gov/16870439 DMGPKIY DI DMGPKIY DMGPKIY DN 3-benzyl-6-methylbenzo[d]oxazol-2(3H)-one DMGPKIY TI TT6804T DMGPKIY TN MIF messenger RNA (MIF mRNA) DMGPKIY MA Inhibitor DMGPKIY RN Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4. DMGPKIY RU https://pubmed.ncbi.nlm.nih.gov/20728358 DMGPN61 DI DMGPN61 DMGPN61 DN JWH-151 DMGPN61 TI TTMSFAW DMGPN61 TN Cannabinoid receptor 2 (CB2) DMGPN61 MA Inhibitor DMGPN61 RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DMGPN61 RU https://pubmed.ncbi.nlm.nih.gov/19143566 DMGPOZE DI DMGPOZE DMGPOZE DN 3-Phenyl-1-(2-methylthiazol-4-ylethynyl)benzene DMGPOZE TI TTHS256 DMGPOZE TN Metabotropic glutamate receptor 5 (mGluR5) DMGPOZE MA Inhibitor DMGPOZE RN Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75. DMGPOZE RU https://pubmed.ncbi.nlm.nih.gov/19445453 DMGPQ0Y DI DMGPQ0Y DMGPQ0Y DN T-1105 DMGPQ0Y TI TTSUKYD DMGPQ0Y TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMGPQ0Y MA Inhibitor DMGPQ0Y RN Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9. DMGPQ0Y RU https://pubmed.ncbi.nlm.nih.gov/18955536 DMGPRBE DI DMGPRBE DMGPRBE DN 3-Ethylquinoline-8-carboxamide DMGPRBE TI TTVDSZ0 DMGPRBE TN Poly [ADP-ribose] polymerase 1 (PARP1) DMGPRBE MA Inhibitor DMGPRBE RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMGPRBE RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMGPRT7 DI DMGPRT7 DMGPRT7 DN E339-3D6 DMGPRT7 TI TTJ8E43 DMGPRT7 TN Apelin receptor (APLNR) DMGPRT7 MA Agonist DMGPRT7 RN Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J. 2010 May;24(5):1506-17. DMGPRT7 RU https://pubmed.ncbi.nlm.nih.gov/20040517 DMGQ9Z5 DI DMGQ9Z5 DMGQ9Z5 DN SKS-927 DMGQ9Z5 TI TT6PKBN DMGQ9Z5 TN Proto-oncogene c-Src (SRC) DMGQ9Z5 MA Inhibitor DMGQ9Z5 RN Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1358-61. DMGQ9Z5 RU https://pubmed.ncbi.nlm.nih.gov/17188862 DMGQC2F DI DMGQC2F DMGQC2F DN 2-(2-(pyrrolidin-1-yl)ethyl)pyridine DMGQC2F TI TT9JNIC DMGQC2F TN Histamine H3 receptor (H3R) DMGQC2F MA Inhibitor DMGQC2F RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMGQC2F RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMGQDLU DI DMGQDLU DMGQDLU DN [3H]GBR12935 DMGQDLU TI TTVBI8W DMGQDLU TN Dopamine transporter (DAT) DMGQDLU MA Inhibitor DMGQDLU RN Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994 Jan;45(1):125-35. DMGQDLU RU https://pubmed.ncbi.nlm.nih.gov/8302271 DMGQDLU DI DMGQDLU DMGQDLU DN [3H]GBR12935 DMGQDLU TI TT8DBY3 DMGQDLU TN Angiotensin II receptor type-1 (AGTR1) DMGQDLU MA Antagonist DMGQDLU RN Specific binding of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenyl propyl) piperazine (GBR-12935), an inhibitor of the dopamine transporter, to human CYP2D6. Biochem Pharmacol. 1997 Jun 15;53(12):1937-9. DMGQDLU RU https://pubmed.ncbi.nlm.nih.gov/9256169 DMGQE1B DI DMGQE1B DMGQE1B DN L-366,509 DMGQE1B TI TTSCIUP DMGQE1B TN Oxytocin receptor (OTR) DMGQE1B MA Antagonist DMGQE1B RN Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61. DMGQE1B RU https://pubmed.ncbi.nlm.nih.gov/7475979 DMGQE4B DI DMGQE4B DMGQE4B DN 2,3,4,5-Tetrafluoro-6-pentafluorophenylazo-phenol DMGQE4B TI TTRA5BZ DMGQE4B TN Steroid 17-alpha-monooxygenase (S17AH) DMGQE4B MA Inhibitor DMGQE4B RN Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5. DMGQE4B RU https://pubmed.ncbi.nlm.nih.gov/2391687 DMGQE8D DI DMGQE8D DMGQE8D DN 3-(4-cyclohexylthiosemicarbazono)methyl-phenol DMGQE8D TI TTHM0R1 DMGQE8D TN Steryl-sulfatase (STS) DMGQE8D MA Inhibitor DMGQE8D RN Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6. DMGQE8D RU https://pubmed.ncbi.nlm.nih.gov/17580843 DMGQHBU DI DMGQHBU DMGQHBU DN 2-(4-Amino-phenyl)-6-methyl-chromen-4-one DMGQHBU TI TTNJYV2 DMGQHBU TN Gamma-aminobutyric acid receptor (GAR) DMGQHBU MA Inhibitor DMGQHBU RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMGQHBU RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMGQLYR DI DMGQLYR DMGQLYR DN TEI-9063 DMGQLYR TI TTOFYT1 DMGQLYR TN Prostacyclin receptor (PTGIR) DMGQLYR MA Agonist DMGQLYR RN Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35. DMGQLYR RU https://pubmed.ncbi.nlm.nih.gov/9156364 DMGQRON DI DMGQRON DMGQRON DN BETULIN DMGQRON TI TTZHY6R DMGQRON TN Glycogen phosphorylase muscle form (GP) DMGQRON MA Inhibitor DMGQRON RN Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54. DMGQRON RU https://pubmed.ncbi.nlm.nih.gov/18517260 DMGQTF9 DI DMGQTF9 DMGQTF9 DN 4-decyl-N-(pyridin-3-yl)benzamide DMGQTF9 TI TTMI6F5 DMGQTF9 TN Transient receptor potential cation channel V1 (TRPV1) DMGQTF9 MA Inhibitor DMGQTF9 RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMGQTF9 RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMGQVF5 DI DMGQVF5 DMGQVF5 DN 2,5-Dideoxy-2,5-imino-D-mannitol DMGQVF5 TI TTXWASR DMGQVF5 TN Intestinal maltase-glucoamylase (MGAM) DMGQVF5 MA Inhibitor DMGQVF5 RN New sugar-mimic alkaloids from the pods of Angylocalyx pynaertii. J Nat Prod. 2002 Feb;65(2):198-202. DMGQVF5 RU https://pubmed.ncbi.nlm.nih.gov/11858756 DMGQX1I DI DMGQX1I DMGQX1I DN 2-(piperidin-1-yl)-4H-benzo[h]chromen-4-one DMGQX1I TI TTK3PY9 DMGQX1I TN DNA-dependent protein kinase catalytic (PRKDC) DMGQX1I MA Inhibitor DMGQX1I RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMGQX1I RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMGQXN7 DI DMGQXN7 DMGQXN7 DN SU-11652 DMGQXN7 TI TTI7421 DMGQXN7 TN Platelet-derived growth factor receptor beta (PDGFRB) DMGQXN7 MA Inhibitor DMGQXN7 RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DMGQXN7 RU https://pubmed.ncbi.nlm.nih.gov/12646019 DMGQXN7 DI DMGQXN7 DMGQXN7 DN SU-11652 DMGQXN7 TI TT8FYO9 DMGQXN7 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMGQXN7 MA Inhibitor DMGQXN7 RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DMGQXN7 RU https://pubmed.ncbi.nlm.nih.gov/12646019 DMGQXN7 DI DMGQXN7 DMGQXN7 DN SU-11652 DMGQXN7 TI TT2Q6G1 DMGQXN7 TN Vascular endothelial growth factor receptor 1 (FLT-1) DMGQXN7 MA Inhibitor DMGQXN7 RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DMGQXN7 RU https://pubmed.ncbi.nlm.nih.gov/12646019 DMGQXN7 DI DMGQXN7 DMGQXN7 DN SU-11652 DMGQXN7 TI TTUTJGQ DMGQXN7 TN Vascular endothelial growth factor receptor 2 (KDR) DMGQXN7 MA Inhibitor DMGQXN7 RN Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. DMGQXN7 RU https://pubmed.ncbi.nlm.nih.gov/12646019 DMGQXTR DI DMGQXTR DMGQXTR DN BPI-704001 DMGQXTR TI TTVDSZ0 DMGQXTR TN Poly [ADP-ribose] polymerase 1 (PARP1) DMGQXTR MA Inhibitor DMGQXTR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMGQXTR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMGRA3T DI DMGRA3T DMGRA3T DN 2-ethoxy-5-(m-tolylethynyl)pyrimidine DMGRA3T TI TTHS256 DMGRA3T TN Metabotropic glutamate receptor 5 (mGluR5) DMGRA3T MA Inhibitor DMGRA3T RN Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a... J Med Chem. 2009 Jul 23;52(14):4103-6. DMGRA3T RU https://pubmed.ncbi.nlm.nih.gov/19537763 DMGRC24 DI DMGRC24 DMGRC24 DN 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine DMGRC24 TI TTJFY5U DMGRC24 TN Adenosine A3 receptor (ADORA3) DMGRC24 MA Inhibitor DMGRC24 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMGRC24 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMGRC24 DI DMGRC24 DMGRC24 DN 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine DMGRC24 TI TTK25J1 DMGRC24 TN Adenosine A1 receptor (ADORA1) DMGRC24 MA Inhibitor DMGRC24 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMGRC24 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMGRC24 DI DMGRC24 DMGRC24 DN 2-(3''-(6''-bromo-indolyl)ethyloxy)adenosine DMGRC24 TI TTM2AOE DMGRC24 TN Adenosine A2a receptor (ADORA2A) DMGRC24 MA Inhibitor DMGRC24 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMGRC24 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMGRFYV DI DMGRFYV DMGRFYV DN N-(4-morpholinophenyl)docos-13-enamide DMGRFYV TI TT6OEDT DMGRFYV TN Cannabinoid receptor 1 (CB1) DMGRFYV MA Inhibitor DMGRFYV RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DMGRFYV RU https://pubmed.ncbi.nlm.nih.gov/16213718 DMGRK3V DI DMGRK3V DMGRK3V DN 8-acetyl-7-propoxy-2H-chromen-2-one DMGRK3V TI TT2LVK8 DMGRK3V TN Carbonic anhydrase IX (CA-IX) DMGRK3V MA Inhibitor DMGRK3V RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMGRK3V RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMGRKDP DI DMGRKDP DMGRKDP DN Bis(5-hydroxybenzo[b]furan-2-yl)methanone DMGRKDP TI TTI7421 DMGRKDP TN Platelet-derived growth factor receptor beta (PDGFRB) DMGRKDP MA Inhibitor DMGRKDP RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMGRKDP RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMGRKDP DI DMGRKDP DMGRKDP DN Bis(5-hydroxybenzo[b]furan-2-yl)methanone DMGRKDP TI TTGJCWZ DMGRKDP TN Fms-like tyrosine kinase 3 (FLT-3) DMGRKDP MA Inhibitor DMGRKDP RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMGRKDP RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMGRKT4 DI DMGRKT4 DMGRKT4 DN GW-559768X DMGRKT4 TI TT4DXQT DMGRKT4 TN Proto-oncogene c-Ret (RET) DMGRKT4 MA Inhibitor DMGRKT4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185). DMGRKT4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185 DMGRPK8 DI DMGRPK8 DMGRPK8 DN PONKORANOL DMGRPK8 TI TTXWASR DMGRPK8 TN Intestinal maltase-glucoamylase (MGAM) DMGRPK8 MA Inhibitor DMGRPK8 RN Probing the active-site requirements of human intestinal N-terminal maltase glucoamylase: the effect of replacing the sulfate moiety by a methyl et... Bioorg Med Chem Lett. 2010 Oct 1;20(19):5686-9. DMGRPK8 RU https://pubmed.ncbi.nlm.nih.gov/20801033 DMGRUN1 DI DMGRUN1 DMGRUN1 DN DB-900 DMGRUN1 TI TTJ584C DMGRUN1 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMGRUN1 MA Agonist DMGRUN1 RN CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof. DMGRUN1 RU http://www.google.com/patents/CN102459215A?cl=en DMGRUN1 DI DMGRUN1 DMGRUN1 DN DB-900 DMGRUN1 TI TT2JWF6 DMGRUN1 TN Peroxisome proliferator-activated receptor delta (PPARD) DMGRUN1 MA Agonist DMGRUN1 RN CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof. DMGRUN1 RU http://www.google.com/patents/CN102459215A?cl=en DMGRUN1 DI DMGRUN1 DMGRUN1 DN DB-900 DMGRUN1 TI TTZMAO3 DMGRUN1 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMGRUN1 MA Agonist DMGRUN1 RN CN patent application no. 102459215, 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof. DMGRUN1 RU http://www.google.com/patents/CN102459215A?cl=en DMGRV8U DI DMGRV8U DMGRV8U DN 1-((9H-Fluoren-2-yl)ethyl)-1H-imidazole DMGRV8U TI TTRA5BZ DMGRV8U TN Steroid 17-alpha-monooxygenase (S17AH) DMGRV8U MA Inhibitor DMGRV8U RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMGRV8U RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMGRWA3 DI DMGRWA3 DMGRWA3 DN ANHYDRORYANIDINE DMGRWA3 TI TTU5CIX DMGRWA3 TN Ryanodine receptor 1 (RYR1) DMGRWA3 MA Inhibitor DMGRWA3 RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMGRWA3 RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMGRWEU DI DMGRWEU DMGRWEU DN 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide DMGRWEU TI TT7HF4W DMGRWEU TN Cyclin-dependent kinase 2 (CDK2) DMGRWEU MA Inhibitor DMGRWEU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGRWEU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGRXD4 DI DMGRXD4 DMGRXD4 DN Orthovanadate DMGRXD4 TI TTCWXFA DMGRXD4 TN Protein-tyrosine phosphatase sigma (R-PTP-sigma) DMGRXD4 MA Inhibitor DMGRXD4 RN Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43. DMGRXD4 RU https://pubmed.ncbi.nlm.nih.gov/8992885 DMGS2X7 DI DMGS2X7 DMGS2X7 DN 3-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate DMGS2X7 TI TTHM0R1 DMGS2X7 TN Steryl-sulfatase (STS) DMGS2X7 MA Inhibitor DMGS2X7 RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMGS2X7 RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMGS3FI DI DMGS3FI DMGS3FI DN CHLORODYSINOSIN A DMGS3FI TI TT6L509 DMGS3FI TN Coagulation factor IIa (F2) DMGS3FI MA Inhibitor DMGS3FI RN From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32. DMGS3FI RU https://pubmed.ncbi.nlm.nih.gov/19674897 DMGS6HB DI DMGS6HB DMGS6HB DN NSC-89508 DMGS6HB TI TTFQAYR DMGS6HB TN Cholesteryl ester transfer protein (CETP) DMGS6HB MA Inhibitor DMGS6HB RN Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic expl... Eur J Med Chem. 2010 Apr;45(4):1598-617. DMGS6HB RU https://pubmed.ncbi.nlm.nih.gov/20116902 DMGS6YH DI DMGS6YH DMGS6YH DN PCNOTAXIME GROUP DMGS6YH TI TTHI19T DMGS6YH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMGS6YH MA Inhibitor DMGS6YH RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGS6YH RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGS6YH DI DMGS6YH DMGS6YH DN PCNOTAXIME GROUP DMGS6YH TI TT85JMW DMGS6YH TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMGS6YH MA Inhibitor DMGS6YH RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGS6YH RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGS7CE DI DMGS7CE DMGS7CE DN 8-(1,3,3-Trimethyl-butoxy)-quinolin-2-ylamine DMGS7CE TI TTX4RTB DMGS7CE TN Melanin-concentrating hormone receptor 1 (MCHR1) DMGS7CE MA Inhibitor DMGS7CE RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 2. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4879-82. DMGS7CE RU https://pubmed.ncbi.nlm.nih.gov/15341943 DMGSKAO DI DMGSKAO DMGSKAO DN 1-(2-chlorophenyl)-3-(pyridin-2-yl)thiourea DMGSKAO TI TT6804T DMGSKAO TN MIF messenger RNA (MIF mRNA) DMGSKAO MA Inhibitor DMGSKAO RN An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. DMGSKAO RU https://pubmed.ncbi.nlm.nih.gov/20639113 DMGSNU4 DI DMGSNU4 DMGSNU4 DN NE-10575 DMGSNU4 TI TTIKWV4 DMGSNU4 TN Geranyltranstransferase (FDPS) DMGSNU4 MA Inhibitor DMGSNU4 RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMGSNU4 RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMGSOZ7 DI DMGSOZ7 DMGSOZ7 DN UC-2029 DMGSOZ7 TI TTEX6LM DMGSOZ7 TN GABA(A) receptor gamma-3 (GABRG3) DMGSOZ7 MA Modulator DMGSOZ7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMGSOZ7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMGSQTK DI DMGSQTK DMGSQTK DN 1D05 DMGSQTK TI TTBRG7E DMGSQTK TN Proprotein convertase subtilisin/kexin type 9 (PCSK9) DMGSQTK RN A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011 Jan;52(1):78-86. DMGSQTK RU https://pubmed.ncbi.nlm.nih.gov/20959675 DMGSRLA DI DMGSRLA DMGSRLA DN GNF-PF-1967 DMGSRLA TI TTZPWGN DMGSRLA TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMGSRLA MA Inhibitor DMGSRLA RN 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105. DMGSRLA RU https://pubmed.ncbi.nlm.nih.gov/17074493 DMGSTKZ DI DMGSTKZ DMGSTKZ DN 1,2-Bis-(3-nitro-phenyl)-ethane-1,2-dione DMGSTKZ TI TTMF541 DMGSTKZ TN Liver carboxylesterase (CES1) DMGSTKZ MA Inhibitor DMGSTKZ RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMGSTKZ RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMGSVL0 DI DMGSVL0 DMGSVL0 DN LXA4 DMGSVL0 TI TTOJ1NF DMGSVL0 TN FMLP-related receptor I (FPR2) DMGSVL0 MA Agonist DMGSVL0 RN Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5. DMGSVL0 RU https://pubmed.ncbi.nlm.nih.gov/20080636 DMGSVL0 DI DMGSVL0 DMGSVL0 DN LXA4 DMGSVL0 TI TT7OCUB DMGSVL0 TN G-protein coupled receptor 32 (GPR32) DMGSVL0 MA Agonist DMGSVL0 RN Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5. DMGSVL0 RU https://pubmed.ncbi.nlm.nih.gov/20080636 DMGSVL0 DI DMGSVL0 DMGSVL0 DN LXA4 DMGSVL0 TI TT16TM5 DMGSVL0 TN N-formyl peptide receptor 3 (FPR3) DMGSVL0 MA Agonist DMGSVL0 RN Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J Exp Med. 1997 May 5;185(9):1693-704. DMGSVL0 RU https://pubmed.ncbi.nlm.nih.gov/9151906 DMGSZB2 DI DMGSZB2 DMGSZB2 DN 4-(isopentylthio)-2-(trifluoromethyl)benzonitrile DMGSZB2 TI TTKPW01 DMGSZB2 TN Androgen receptor messenger RNA (AR mRNA) DMGSZB2 MA Inhibitor DMGSZB2 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMGSZB2 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMGT6DN DI DMGT6DN DMGT6DN DN JMV 1802 DMGT6DN TI TTC1MVT DMGT6DN TN Gastrin-releasing peptide receptor (GRPR) DMGT6DN MA Inhibitor DMGT6DN RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DMGT6DN RU https://pubmed.ncbi.nlm.nih.gov/10882361 DMGT82V DI DMGT82V DMGT82V DN 10-Ethyl-10H-dibenzo[b,f][1,4]oxazepin-11-one DMGT82V TI TT84ETX DMGT82V TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMGT82V MA Inhibitor DMGT82V RN Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97. DMGT82V RU https://pubmed.ncbi.nlm.nih.gov/1375293 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TT18ETS DMGTAWC TN Myosin light kinase (MYLK) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TTZQTY2 DMGTAWC TN DMPK messenger RNA (DMPK mRNA) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TTFN95D DMGTAWC TN PAK-1 protein kinase (PAK1) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TT5Z0EF DMGTAWC TN CDC42 binding protein kinase alpha (DMPK-like alpha) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TTWL9TY DMGTAWC TN LIM domain kinase-1 (LIMK-1) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TTSL41O DMGTAWC TN Protein kinase N1 (PKN1) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TTGWKQJ DMGTAWC TN Rho-associated protein kinase 2 (ROCK2) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAWC DI DMGTAWC DMGTAWC DN RKI-1447 DMGTAWC TI TTZN7RP DMGTAWC TN Rho-associated protein kinase 1 (ROCK1) DMGTAWC MA Inhibitor DMGTAWC RN Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). Medchemcomm. 2012 Jun 1;3(6):699-709. DMGTAWC RU https://pubmed.ncbi.nlm.nih.gov/23275831 DMGTAZ4 DI DMGTAZ4 DMGTAZ4 DN Des-His1[Glu9]glucagon-NH2 DMGTAZ4 TI TT9O6WS DMGTAZ4 TN Glucagon receptor (GCGR) DMGTAZ4 MA Inhibitor DMGTAZ4 RN Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1401-5. DMGTAZ4 RU https://pubmed.ncbi.nlm.nih.gov/15713396 DMGTB95 DI DMGTB95 DMGTB95 DN VTX-763 DMGTB95 TI TT8CWFK DMGTB95 TN Toll-like receptor 8 (TLR8) DMGTB95 MA Antagonist DMGTB95 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1758). DMGTB95 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1758 DMGTEXD DI DMGTEXD DMGTEXD DN AP-24226 DMGTEXD TI TT6PKBN DMGTEXD TN Proto-oncogene c-Src (SRC) DMGTEXD MA Inhibitor DMGTEXD RN 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56. DMGTEXD RU https://pubmed.ncbi.nlm.nih.gov/19572547 DMGTEXD DI DMGTEXD DMGTEXD DN AP-24226 DMGTEXD TI TT3PJMV DMGTEXD TN Tyrosine-protein kinase ABL1 (ABL) DMGTEXD MA Inhibitor DMGTEXD RN Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP2453... J Med Chem. 2010 Jun 24;53(12):4701-19. DMGTEXD RU https://pubmed.ncbi.nlm.nih.gov/20513156 DMGTEYB DI DMGTEYB DMGTEYB DN JWH-246 DMGTEYB TI TT6OEDT DMGTEYB TN Cannabinoid receptor 1 (CB1) DMGTEYB MA Inhibitor DMGTEYB RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMGTEYB RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMGTEYB DI DMGTEYB DMGTEYB DN JWH-246 DMGTEYB TI TTMSFAW DMGTEYB TN Cannabinoid receptor 2 (CB2) DMGTEYB MA Inhibitor DMGTEYB RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMGTEYB RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMGTFON DI DMGTFON DMGTFON DN Cbz-Ile-t-ButylGln-Ala-LeuVSMe DMGTFON TI TTUMQVO DMGTFON TN Cathepsin S (CTSS) DMGTFON MA Inhibitor DMGTFON RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMGTFON RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMGTNQY DI DMGTNQY DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide DMGTNQY TI TTSHTOI DMGTNQY TN Histone deacetylase 2 (HDAC2) DMGTNQY MA Inhibitor DMGTNQY RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMGTNQY RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMGTNQY DI DMGTNQY DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide DMGTNQY TI TTYHPU6 DMGTNQY TN Histone deacetylase 10 (HDAC10) DMGTNQY MA Inhibitor DMGTNQY RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMGTNQY RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMGTNQY DI DMGTNQY DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide DMGTNQY TI TTT6LFV DMGTNQY TN Histone deacetylase 8 (HDAC8) DMGTNQY MA Inhibitor DMGTNQY RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMGTNQY RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMGTNQY DI DMGTNQY DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide DMGTNQY TI TT5ZKDI DMGTNQY TN Histone deacetylase 6 (HDAC6) DMGTNQY MA Inhibitor DMGTNQY RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMGTNQY RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMGTNQY DI DMGTNQY DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide DMGTNQY TI TT6R7JZ DMGTNQY TN Histone deacetylase 1 (HDAC1) DMGTNQY MA Inhibitor DMGTNQY RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMGTNQY RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMGTNQY DI DMGTNQY DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide DMGTNQY TI TTTQGH8 DMGTNQY TN Histone deacetylase 4 (HDAC4) DMGTNQY MA Inhibitor DMGTNQY RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMGTNQY RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMGTNQY DI DMGTNQY DMGTNQY DN N-Hydroxy-4-(pentanoylamino-methyl)-benzamide DMGTNQY TI TTBH0VX DMGTNQY TN Histone deacetylase (HDAC) DMGTNQY MA Inhibitor DMGTNQY RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMGTNQY RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMGTPDA DI DMGTPDA DMGTPDA DN GLPDGG peptide DMGTPDA TI TTPADOQ DMGTPDA TN HMG-CoA reductase (HMGCR) DMGTPDA MA Inhibitor DMGTPDA RN Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase. Bioorg Med Chem. 2010 Jun 15;18(12):4300-9. DMGTPDA RU https://pubmed.ncbi.nlm.nih.gov/20494585 DMGTPFY DI DMGTPFY DMGTPFY DN acetyl-podocarpic dimer DMGTPFY TI TTECBXN DMGTPFY TN Oxysterols receptor LXR-alpha (NR1H3) DMGTPFY MA Agonist DMGTPFY RN A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem. 2002 Mar 22;277(12):10021-7. DMGTPFY RU https://pubmed.ncbi.nlm.nih.gov/11790770 DMGTPFY DI DMGTPFY DMGTPFY DN acetyl-podocarpic dimer DMGTPFY TI TTXA6PH DMGTPFY TN Oxysterols receptor LXR-beta (NR1H2) DMGTPFY MA Agonist DMGTPFY RN A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J Biol Chem. 2002 Mar 22;277(12):10021-7. DMGTPFY RU https://pubmed.ncbi.nlm.nih.gov/11790770 DMGTRZE DI DMGTRZE DMGTRZE DN grifolic acid DMGTRZE TI TT08JVB DMGTRZE TN G-protein coupled receptor 120 (GPR120) DMGTRZE MA Agonist DMGTRZE RN Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol. 2009 Sep;380(3):247-55. DMGTRZE RU https://pubmed.ncbi.nlm.nih.gov/19471906 DMGTX6O DI DMGTX6O DMGTX6O DN ISIS 103615 DMGTX6O TI TTBWMKT DMGTX6O TN WWP1 messenger RNA (WWP1 mRNA) DMGTX6O RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMGTX6O RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMGTZ9Q DI DMGTZ9Q DMGTZ9Q DN CYM5181 DMGTZ9Q TI TT9JZCK DMGTZ9Q TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMGTZ9Q MA Agonist DMGTZ9Q RN Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol. 2008 Nov;74(5):1308-18. DMGTZ9Q RU https://pubmed.ncbi.nlm.nih.gov/18708635 DMGU76I DI DMGU76I DMGU76I DN 1-aminoanthracene-9,10-dione DMGU76I TI TTM2AOE DMGU76I TN Adenosine A2a receptor (ADORA2A) DMGU76I MA Inhibitor DMGU76I RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DMGU76I RU https://pubmed.ncbi.nlm.nih.gov/20095623 DMGU7MO DI DMGU7MO DMGU7MO DN 1-(3-methoxyphenethyl)pyrrolidine DMGU7MO TI TT9JNIC DMGU7MO TN Histamine H3 receptor (H3R) DMGU7MO MA Inhibitor DMGU7MO RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMGU7MO RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMGU97P DI DMGU97P DMGU97P DN Cyclopentane amide derivatives 2 DMGU97P TI TT50QJ3 DMGU97P TN Influenza Neuraminidase (Influ NA) DMGU97P MA Inhibitor DMGU97P RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMGU97P RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMGUABP DI DMGUABP DMGUABP DN KNI-10737 DMGUABP TI TTXMNHO DMGUABP TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMGUABP MA Inhibitor DMGUABP RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMGUABP RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMGUIR1 DI DMGUIR1 DMGUIR1 DN Dmt-Pro-Dmp-Phe-NH2 DMGUIR1 TI TTQW87Y DMGUIR1 TN Opioid receptor kappa (OPRK1) DMGUIR1 MA Inhibitor DMGUIR1 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMGUIR1 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMGUIR1 DI DMGUIR1 DMGUIR1 DN Dmt-Pro-Dmp-Phe-NH2 DMGUIR1 TI TT27RFC DMGUIR1 TN Opioid receptor delta (OPRD1) DMGUIR1 MA Inhibitor DMGUIR1 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMGUIR1 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMGUIR1 DI DMGUIR1 DMGUIR1 DN Dmt-Pro-Dmp-Phe-NH2 DMGUIR1 TI TTKWM86 DMGUIR1 TN Opioid receptor mu (MOP) DMGUIR1 MA Inhibitor DMGUIR1 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMGUIR1 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMGUKCF DI DMGUKCF DMGUKCF DN 19(R)-OH-PGE2 DMGUKCF TI TT79WV3 DMGUKCF TN Prostaglandin E2 receptor EP4 (PTGER4) DMGUKCF MA Agonist DMGUKCF RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMGUKCF RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMGUKCF DI DMGUKCF DMGUKCF DN 19(R)-OH-PGE2 DMGUKCF TI TT1ZAVI DMGUKCF TN Prostaglandin E2 receptor EP2 (PTGER2) DMGUKCF MA Agonist DMGUKCF RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMGUKCF RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMGULNZ DI DMGULNZ DMGULNZ DN BL-5040 DMGULNZ TI TT0HD6V DMGULNZ TN Leptin receptor (LEPR) DMGULNZ MA Antagonist DMGULNZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DMGULNZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DMGUWFJ DI DMGUWFJ DMGUWFJ DN RWJ-61907 DMGUWFJ TI TTJVCG0 DMGUWFJ TN Bacterial Sporulation kinase A (Bact kinA) DMGUWFJ MA Inhibitor DMGUWFJ RN Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. DMGUWFJ RU https://pubmed.ncbi.nlm.nih.gov/16964330 DMGUX16 DI DMGUX16 DMGUX16 DN RY-066 DMGUX16 TI TT37EDJ DMGUX16 TN GABA(A) receptor alpha-3 (GABRA3) DMGUX16 MA Inhibitor DMGUX16 RN Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42. DMGUX16 RU https://pubmed.ncbi.nlm.nih.gov/9767648 DMGUX16 DI DMGUX16 DMGUX16 DN RY-066 DMGUX16 TI TTNJYV2 DMGUX16 TN Gamma-aminobutyric acid receptor (GAR) DMGUX16 MA Inhibitor DMGUX16 RN Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42. DMGUX16 RU https://pubmed.ncbi.nlm.nih.gov/9767648 DMGUX16 DI DMGUX16 DMGUX16 DN RY-066 DMGUX16 TI TT06RH5 DMGUX16 TN GABA(A) receptor gamma-2 (GABRG2) DMGUX16 MA Inhibitor DMGUX16 RN Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42. DMGUX16 RU https://pubmed.ncbi.nlm.nih.gov/9767648 DMGUX16 DI DMGUX16 DMGUX16 DN RY-066 DMGUX16 TI TTBMV1G DMGUX16 TN GABA(A) receptor alpha-2 (GABRA2) DMGUX16 MA Inhibitor DMGUX16 RN Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42. DMGUX16 RU https://pubmed.ncbi.nlm.nih.gov/9767648 DMGUX16 DI DMGUX16 DMGUX16 DN RY-066 DMGUX16 TI TT1MPAY DMGUX16 TN GABA(A) receptor alpha-1 (GABRA1) DMGUX16 MA Inhibitor DMGUX16 RN Predictive models for GABAA/benzodiazepine receptor subtypes: studies of quantitative structure-activity relationships for imidazobenzodiazepines a... J Med Chem. 1998 Oct 8;41(21):4130-42. DMGUX16 RU https://pubmed.ncbi.nlm.nih.gov/9767648 DMGV4DS DI DMGV4DS DMGV4DS DN R-norduloxetine DMGV4DS TI TTAWNKZ DMGV4DS TN Norepinephrine transporter (NET) DMGV4DS MA Inhibitor DMGV4DS RN Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. DMGV4DS RU https://pubmed.ncbi.nlm.nih.gov/19740668 DMGV4DS DI DMGV4DS DMGV4DS DN R-norduloxetine DMGV4DS TI TT3ROYC DMGV4DS TN Serotonin transporter (SERT) DMGV4DS MA Inhibitor DMGV4DS RN Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. DMGV4DS RU https://pubmed.ncbi.nlm.nih.gov/19740668 DMGV4DS DI DMGV4DS DMGV4DS DN R-norduloxetine DMGV4DS TI TTVBI8W DMGV4DS TN Dopamine transporter (DAT) DMGV4DS MA Inhibitor DMGV4DS RN Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. DMGV4DS RU https://pubmed.ncbi.nlm.nih.gov/19740668 DMGV4O7 DI DMGV4O7 DMGV4O7 DN ISIS 29233 DMGV4O7 TI TTYMGWX DMGV4O7 TN PDK-1 messenger RNA (PDK-1 mRNA) DMGV4O7 RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMGV4O7 RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMGV6BI DI DMGV6BI DMGV6BI DN 1-Phenyl-1H-benzoimidazol-5-ol DMGV6BI TI TTI7421 DMGV6BI TN Platelet-derived growth factor receptor beta (PDGFRB) DMGV6BI MA Inhibitor DMGV6BI RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DMGV6BI RU https://pubmed.ncbi.nlm.nih.gov/9876115 DMGV6BI DI DMGV6BI DMGV6BI DN 1-Phenyl-1H-benzoimidazol-5-ol DMGV6BI TI TT8FYO9 DMGV6BI TN Platelet-derived growth factor receptor alpha (PDGFRA) DMGV6BI MA Inhibitor DMGV6BI RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DMGV6BI RU https://pubmed.ncbi.nlm.nih.gov/9876115 DMGVBIT DI DMGVBIT DMGVBIT DN KNI-10283 DMGVBIT TI TTXMNHO DMGVBIT TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMGVBIT MA Inhibitor DMGVBIT RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMGVBIT RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMGVCKZ DI DMGVCKZ DMGVCKZ DN 2-(2-propoxypyrimidin-4-ylamino)benzoic acid DMGVCKZ TI TT0K6EO DMGVCKZ TN Stress-activated protein kinase JNK1 (JNK1) DMGVCKZ MA Inhibitor DMGVCKZ RN Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. DMGVCKZ RU https://pubmed.ncbi.nlm.nih.gov/17107797 DMGVDEL DI DMGVDEL DMGVDEL DN (4-benzylpiperidin-1-yl)(2-fluorophenyl)methanone DMGVDEL TI TTVTX4N DMGVDEL TN Bacterial Fatty acid synthetase I (Bact inhA) DMGVDEL MA Inhibitor DMGVDEL RN Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. DMGVDEL RU https://pubmed.ncbi.nlm.nih.gov/17723305 DMGVDR6 DI DMGVDR6 DMGVDR6 DN Ochnaflavone DMGVDR6 TI TTO8QRU DMGVDR6 TN Group IIA phospholipase A2 (GIIA sPLA2) DMGVDR6 MA Inhibitor DMGVDR6 RN Synthesis of phospholipase A2 inhibitory biflavonoids. Bioorg Med Chem Lett. 2006 May 1;16(9):2373-5. DMGVDR6 RU https://pubmed.ncbi.nlm.nih.gov/16504502 DMGVE3F DI DMGVE3F DMGVE3F DN 1-(1-Biphenyl-4-yl-propyl)-1H-imidazole DMGVE3F TI TTRA5BZ DMGVE3F TN Steroid 17-alpha-monooxygenase (S17AH) DMGVE3F MA Inhibitor DMGVE3F RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMGVE3F RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMGVELK DI DMGVELK DMGVELK DN L-Tyrosinamide DMGVELK TI TT64REZ DMGVELK TN Neuropeptide Y (NPY) DMGVELK MA Inhibitor DMGVELK RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGVELK RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGVELK DI DMGVELK DMGVELK DN L-Tyrosinamide DMGVELK TI TTTZ3EU DMGVELK TN Valacyclovir hydrolase (BPHL) DMGVELK MA Inhibitor DMGVELK RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGVELK RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGVI08 DI DMGVI08 DMGVI08 DN 6-ethyl-3-propoxycarbonyl-4-quinolone DMGVI08 TI TTNJYV2 DMGVI08 TN Gamma-aminobutyric acid receptor (GAR) DMGVI08 MA Inhibitor DMGVI08 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMGVI08 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMGVI08 DI DMGVI08 DMGVI08 DN 6-ethyl-3-propoxycarbonyl-4-quinolone DMGVI08 TI TT06RH5 DMGVI08 TN GABA(A) receptor gamma-2 (GABRG2) DMGVI08 MA Inhibitor DMGVI08 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMGVI08 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMGVI08 DI DMGVI08 DMGVI08 DN 6-ethyl-3-propoxycarbonyl-4-quinolone DMGVI08 TI TTZA1NY DMGVI08 TN GABA(A) receptor beta-2 (GABRB2) DMGVI08 MA Inhibitor DMGVI08 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMGVI08 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMGVI08 DI DMGVI08 DMGVI08 DN 6-ethyl-3-propoxycarbonyl-4-quinolone DMGVI08 TI TT1MPAY DMGVI08 TN GABA(A) receptor alpha-1 (GABRA1) DMGVI08 MA Inhibitor DMGVI08 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMGVI08 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMGVIXW DI DMGVIXW DMGVIXW DN 4-cyclohexylamino-pyrimidine-2-carbonitrile DMGVIXW TI TTDZN01 DMGVIXW TN Cathepsin K (CTSK) DMGVIXW MA Inhibitor DMGVIXW RN 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem. 2007 Feb 22;50(4):591-4. DMGVIXW RU https://pubmed.ncbi.nlm.nih.gov/17256925 DMGVJBD DI DMGVJBD DMGVJBD DN N-Phenyl-5-phenylimidazo[1,5-a]pyrazin-8-amine DMGVJBD TI TT6PKBN DMGVJBD TN Proto-oncogene c-Src (SRC) DMGVJBD MA Inhibitor DMGVJBD RN Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Bioorg Med Chem. 2007 Jan 15;15(2):868-85. DMGVJBD RU https://pubmed.ncbi.nlm.nih.gov/17095233 DMGVLR0 DI DMGVLR0 DMGVLR0 DN MERIOLIN 5 DMGVLR0 TI TT1LVF2 DMGVLR0 TN Cyclin-dependent kinase 9 (CDK9) DMGVLR0 MA Inhibitor DMGVLR0 RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMGVLR0 RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMGVLR0 DI DMGVLR0 DMGVLR0 DN MERIOLIN 5 DMGVLR0 TI TT7HF4W DMGVLR0 TN Cyclin-dependent kinase 2 (CDK2) DMGVLR0 MA Inhibitor DMGVLR0 RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMGVLR0 RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMGVLR0 DI DMGVLR0 DMGVLR0 DN MERIOLIN 5 DMGVLR0 TI TTAMQ62 DMGVLR0 TN Cyclin A2 (CCNA2) DMGVLR0 MA Inhibitor DMGVLR0 RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMGVLR0 RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMGVN7A DI DMGVN7A DMGVN7A DN ISIS 113209 DMGVN7A TI TTHJT3X DMGVN7A TN STAT3 messenger RNA (STAT3 mRNA) DMGVN7A RN US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression. DMGVN7A RU http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true DMGVNE3 DI DMGVNE3 DMGVNE3 DN 4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide DMGVNE3 TI TTSYM0R DMGVNE3 TN Carbonic anhydrase XII (CA-XII) DMGVNE3 MA Inhibitor DMGVNE3 RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMGVNE3 RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMGVNE3 DI DMGVNE3 DMGVNE3 DN 4-(4'-N-Methylphenyl)diazenylbenzenesulfonamide DMGVNE3 TI TT2LVK8 DMGVNE3 TN Carbonic anhydrase IX (CA-IX) DMGVNE3 MA Inhibitor DMGVNE3 RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMGVNE3 RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMGVPMT DI DMGVPMT DMGVPMT DN 1-(biphenyl-3-ylmethyl)-1H-1,2,4-triazole DMGVPMT TI TTSZLWK DMGVPMT TN Aromatase (CYP19A1) DMGVPMT MA Inhibitor DMGVPMT RN Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70. DMGVPMT RU https://pubmed.ncbi.nlm.nih.gov/20148564 DMGW42V DI DMGW42V DMGW42V DN GSK-8062 DMGW42V TI TTXV4FI DMGW42V TN Albendazole monooxygenase (CYP3A4) DMGW42V MA Inhibitor DMGW42V RN Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4339-43. DMGW42V RU https://pubmed.ncbi.nlm.nih.gov/18621523 DMGW9QL DI DMGW9QL DMGW9QL DN CG-103065 DMGW9QL TI TTOU65C DMGW9QL TN Tyrosine-protein kinase SYK (SYK) DMGW9QL MA Inhibitor DMGW9QL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). DMGW9QL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230 DMGW9XJ DI DMGW9XJ DMGW9XJ DN 4-butyl-N-(pyridin-3-yl)benzamide DMGW9XJ TI TTMI6F5 DMGW9XJ TN Transient receptor potential cation channel V1 (TRPV1) DMGW9XJ MA Inhibitor DMGW9XJ RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMGW9XJ RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMGWH0E DI DMGWH0E DMGWH0E DN 3-morpholino-1H-benzo[f]chromen-1-one DMGWH0E TI TTK3PY9 DMGWH0E TN DNA-dependent protein kinase catalytic (PRKDC) DMGWH0E MA Inhibitor DMGWH0E RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMGWH0E RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMGWNDB DI DMGWNDB DMGWNDB DN 6-Pyridin-3-yl-naphthalen-2-ol DMGWNDB TI TTIQUX7 DMGWNDB TN Steroid 11-beta-hydroxylase (CYP11B1) DMGWNDB MA Inhibitor DMGWNDB RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMGWNDB RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMGWNDB DI DMGWNDB DMGWNDB DN 6-Pyridin-3-yl-naphthalen-2-ol DMGWNDB TI TTRA5BZ DMGWNDB TN Steroid 17-alpha-monooxygenase (S17AH) DMGWNDB MA Inhibitor DMGWNDB RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMGWNDB RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMGWO9J DI DMGWO9J DMGWO9J DN A-317567 DMGWO9J TI TTVMWLP DMGWO9J TN Acid-sensing ion channel 2 (ASIC2) DMGWO9J MA Blocker (channel blocker) DMGWO9J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 685). DMGWO9J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=685 DMGWO9J DI DMGWO9J DMGWO9J DN A-317567 DMGWO9J TI TTLGDIS DMGWO9J TN Acid-sensing ion channel 3 (ASIC3) DMGWO9J MA Blocker (channel blocker) DMGWO9J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686). DMGWO9J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686 DMGWRID DI DMGWRID DMGWRID DN 2-Benzyl-6-methoxy-5-oxazol-5-yl-1H-indole DMGWRID TI TTTB4UP DMGWRID TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMGWRID MA Inhibitor DMGWRID RN Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1273-6. DMGWRID RU https://pubmed.ncbi.nlm.nih.gov/12657262 DMGWSCI DI DMGWSCI DMGWSCI DN LC34AD3 DMGWSCI TI TT7QNVC DMGWSCI TN Glucose-dependent insulinotropic receptor (GPR119) DMGWSCI MA Agonist DMGWSCI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DMGWSCI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DMGWZA3 DI DMGWZA3 DMGWZA3 DN PMID25974391C34 DMGWZA3 TI TTT46BN DMGWZA3 TN Bromodomain and PHD finger containing 1 (BRPF1) DMGWZA3 MA Inhibitor DMGWZA3 RN Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J Med Chem. 2016 Feb 25;59(4):1642-7. DMGWZA3 RU https://pubmed.ncbi.nlm.nih.gov/25974391 DMGWZA3 DI DMGWZA3 DMGWZA3 DN PMID25974391C34 DMGWZA3 TI TT9Q7AE DMGWZA3 TN Tripartite motif-containing 24 (TRIM24) DMGWZA3 MA Inhibitor DMGWZA3 RN Discovery of a Chemical Tool Inhibitor Targeting the Bromodomains of TRIM24 and BRPF. J Med Chem. 2016 Feb 25;59(4):1642-7. DMGWZA3 RU https://pubmed.ncbi.nlm.nih.gov/25974391 DMGX0Y8 DI DMGX0Y8 DMGX0Y8 DN [3H]LY341495 DMGX0Y8 TI TT0I76D DMGX0Y8 TN Metabotropic glutamate receptor 7 (mGluR7) DMGX0Y8 MA Antagonist DMGX0Y8 RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMGX0Y8 RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMGX0Y8 DI DMGX0Y8 DMGX0Y8 DN [3H]LY341495 DMGX0Y8 TI TTWRP2F DMGX0Y8 TN Metabotropic glutamate receptor 6 (mGluR6) DMGX0Y8 MA Antagonist DMGX0Y8 RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMGX0Y8 RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMGX0Y8 DI DMGX0Y8 DMGX0Y8 DN [3H]LY341495 DMGX0Y8 TI TT8A9EF DMGX0Y8 TN Metabotropic glutamate receptor 3 (mGluR3) DMGX0Y8 MA Agonist DMGX0Y8 RN Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6. DMGX0Y8 RU https://pubmed.ncbi.nlm.nih.gov/10884552 DMGX0Y8 DI DMGX0Y8 DMGX0Y8 DN [3H]LY341495 DMGX0Y8 TI TTXJ47W DMGX0Y8 TN Metabotropic glutamate receptor 2 (mGluR2) DMGX0Y8 MA Antagonist DMGX0Y8 RN [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. DMGX0Y8 RU https://pubmed.ncbi.nlm.nih.gov/10530814 DMGX6UH DI DMGX6UH DMGX6UH DN GalB2 DMGX6UH TI TTBPW3J DMGX6UH TN Galanin receptor type 2 (GAL2-R) DMGX6UH MA Inhibitor DMGX6UH RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMGX6UH RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMGX6UH DI DMGX6UH DMGX6UH DN GalB2 DMGX6UH TI TTX3HNZ DMGX6UH TN Galanin receptor type 1 (GAL1-R) DMGX6UH MA Inhibitor DMGX6UH RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMGX6UH RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMGXM9C DI DMGXM9C DMGXM9C DN 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide DMGXM9C TI TT2LVK8 DMGXM9C TN Carbonic anhydrase IX (CA-IX) DMGXM9C MA Inhibitor DMGXM9C RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMGXM9C RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMGXM9C DI DMGXM9C DMGXM9C DN 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide DMGXM9C TI TTANPDJ DMGXM9C TN Carbonic anhydrase II (CA-II) DMGXM9C MA Inhibitor DMGXM9C RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMGXM9C RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMGXM9C DI DMGXM9C DMGXM9C DN 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide DMGXM9C TI TTSYM0R DMGXM9C TN Carbonic anhydrase XII (CA-XII) DMGXM9C MA Inhibitor DMGXM9C RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMGXM9C RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMGXM9C DI DMGXM9C DMGXM9C DN 4-[2-(3-Phenyl-ureido)-ethyl]-benzenesulfonamide DMGXM9C TI TTHQPL7 DMGXM9C TN Carbonic anhydrase I (CA-I) DMGXM9C MA Inhibitor DMGXM9C RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMGXM9C RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMGXMF0 DI DMGXMF0 DMGXMF0 DN 1,2-Di-naphthalen-2-yl-ethane-1,2-dione DMGXMF0 TI TTMF541 DMGXMF0 TN Liver carboxylesterase (CES1) DMGXMF0 MA Inhibitor DMGXMF0 RN Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and t... J Med Chem. 2005 Aug 25;48(17):5543-50. DMGXMF0 RU https://pubmed.ncbi.nlm.nih.gov/16107154 DMGXMZL DI DMGXMZL DMGXMZL DN 6-isopropyl-2-morpholin-4-yl-4H-thiopyran-4-one DMGXMZL TI TTK3PY9 DMGXMZL TN DNA-dependent protein kinase catalytic (PRKDC) DMGXMZL MA Inhibitor DMGXMZL RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMGXMZL RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMGXPJV DI DMGXPJV DMGXPJV DN 3-(4,5-Bis-biphenyl-4-yl-1H-imidazol-2-yl)-phenol DMGXPJV TI TTELIN2 DMGXPJV TN PTPN1 messenger RNA (PTPN1 mRNA) DMGXPJV MA Inhibitor DMGXPJV RN Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem. 2002 May 23;45(11):2213-21. DMGXPJV RU https://pubmed.ncbi.nlm.nih.gov/12014959 DMGXRSZ DI DMGXRSZ DMGXRSZ DN (2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime DMGXRSZ TI TTCEJ4F DMGXRSZ TN G1/S-specific cyclin-E1 (CCNE1) DMGXRSZ MA Inhibitor DMGXRSZ RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMGXRSZ RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMGXRSZ DI DMGXRSZ DMGXRSZ DN (2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime DMGXRSZ TI TT7HF4W DMGXRSZ TN Cyclin-dependent kinase 2 (CDK2) DMGXRSZ MA Inhibitor DMGXRSZ RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMGXRSZ RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMGXSTB DI DMGXSTB DMGXSTB DN TI3 DMGXSTB TI TTVDSZ0 DMGXSTB TN Poly [ADP-ribose] polymerase 1 (PARP1) DMGXSTB MA Inhibitor DMGXSTB RN Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8. DMGXSTB RU https://pubmed.ncbi.nlm.nih.gov/12855651 DMGXTSB DI DMGXTSB DMGXTSB DN (D)-Ala-Pro-Glu DMGXTSB TI TTLD29N DMGXTSB TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMGXTSB MA Inhibitor DMGXTSB RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMGXTSB RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMGXTSB DI DMGXTSB DMGXTSB DN (D)-Ala-Pro-Glu DMGXTSB TI TTN9D8E DMGXTSB TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMGXTSB MA Inhibitor DMGXTSB RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMGXTSB RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMGXTSB DI DMGXTSB DMGXTSB DN (D)-Ala-Pro-Glu DMGXTSB TI TTKJEMQ DMGXTSB TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMGXTSB MA Inhibitor DMGXTSB RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMGXTSB RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMGXVBA DI DMGXVBA DMGXVBA DN 2,3-DIMETHYL-1,4-NAPHTHOQUINONE DMGXVBA TI TTHDSE2 DMGXVBA TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMGXVBA MA Inhibitor DMGXVBA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMGXVBA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMGY32O DI DMGY32O DMGY32O DN 1-(10H-phenothiazin-10-yl)-4-phenylbutan-1-one DMGY32O TI TTEB0GD DMGY32O TN Cholinesterase (BCHE) DMGY32O MA Inhibitor DMGY32O RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMGY32O RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMGY5WB DI DMGY5WB DMGY5WB DN (+/-)-2-(4-fluorophenyl)-7-methoxychroman-4-one DMGY5WB TI TTGP7BY DMGY5WB TN Monoamine oxidase type B (MAO-B) DMGY5WB MA Inhibitor DMGY5WB RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMGY5WB RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMGY5Z0 DI DMGY5Z0 DMGY5Z0 DN KNI-10093 DMGY5Z0 TI TTXMNHO DMGY5Z0 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMGY5Z0 MA Inhibitor DMGY5Z0 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMGY5Z0 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMGYAP7 DI DMGYAP7 DMGYAP7 DN (3-Phenoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine DMGYAP7 TI TTUTJGQ DMGYAP7 TN Vascular endothelial growth factor receptor 2 (KDR) DMGYAP7 MA Inhibitor DMGYAP7 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMGYAP7 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMGYBSC DI DMGYBSC DMGYBSC DN LU-53439 DMGYBSC TI TTGP7BY DMGYBSC TN Monoamine oxidase type B (MAO-B) DMGYBSC MA Modulator DMGYBSC RN Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy. J Pharmacol Exp Ther. 1999 Mar;288(3):984-92. DMGYBSC RU https://www.ncbi.nlm.nih.gov/pubmed/10027835 DMGYCQ3 DI DMGYCQ3 DMGYCQ3 DN 1-benzhydryl-4-isopropylpiperidin-4-ol DMGYCQ3 TI TTNT7K8 DMGYCQ3 TN Nociceptin receptor (OPRL1) DMGYCQ3 MA Inhibitor DMGYCQ3 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMGYCQ3 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMGYCQ3 DI DMGYCQ3 DMGYCQ3 DN 1-benzhydryl-4-isopropylpiperidin-4-ol DMGYCQ3 TI TTKWM86 DMGYCQ3 TN Opioid receptor mu (MOP) DMGYCQ3 MA Inhibitor DMGYCQ3 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMGYCQ3 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMGYCQ3 DI DMGYCQ3 DMGYCQ3 DN 1-benzhydryl-4-isopropylpiperidin-4-ol DMGYCQ3 TI TTQW87Y DMGYCQ3 TN Opioid receptor kappa (OPRK1) DMGYCQ3 MA Inhibitor DMGYCQ3 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMGYCQ3 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMGYDEK DI DMGYDEK DMGYDEK DN 3-(1-Benzyl-1H-imidazol-5-yl)-1-propanol DMGYDEK TI TTIQUX7 DMGYDEK TN Steroid 11-beta-hydroxylase (CYP11B1) DMGYDEK MA Inhibitor DMGYDEK RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMGYDEK RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMGYK25 DI DMGYK25 DMGYK25 DN 4ALPHA-(HYDROXYMETHYL)-4ALPHA-DEMETHYLTERRITREM B DMGYK25 TI TT1RS9F DMGYK25 TN Acetylcholinesterase (AChE) DMGYK25 MA Inhibitor DMGYK25 RN Structure and anti-acetylcholinesterase activity of 4 alpha-(hydroxymethyl)-4 alpha-demethylterritrem B. J Nat Prod. 1997 Aug;60(8):842-3. DMGYK25 RU https://pubmed.ncbi.nlm.nih.gov/9287420 DMGYLC1 DI DMGYLC1 DMGYLC1 DN N-(1-(3-bromobenzyl)piperidin-4-yl)-1-naphthamide DMGYLC1 TI TTJQOD7 DMGYLC1 TN 5-HT 2A receptor (HTR2A) DMGYLC1 MA Inhibitor DMGYLC1 RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4. DMGYLC1 RU https://pubmed.ncbi.nlm.nih.gov/17251022 DMGYVFD DI DMGYVFD DMGYVFD DN xanthine amine congener DMGYVFD TI TTJFY5U DMGYVFD TN Adenosine A3 receptor (ADORA3) DMGYVFD MA Antagonist DMGYVFD RN [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. DMGYVFD RU https://pubmed.ncbi.nlm.nih.gov/10779381 DMGYVFD DI DMGYVFD DMGYVFD DN xanthine amine congener DMGYVFD TI TTNE7KG DMGYVFD TN Adenosine A2b receptor (ADORA2B) DMGYVFD MA Antagonist DMGYVFD RN Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov. 1999 Nov;16(3):217-26. DMGYVFD RU https://pubmed.ncbi.nlm.nih.gov/10624567 DMGYVFD DI DMGYVFD DMGYVFD DN xanthine amine congener DMGYVFD TI TTK25J1 DMGYVFD TN Adenosine A1 receptor (ADORA1) DMGYVFD MA Antagonist DMGYVFD RN Species difference in the G protein selectivity of the human and bovine A1-adenosine receptor. J Biol Chem. 1994 Dec 23;269(51):32077-84. DMGYVFD RU https://pubmed.ncbi.nlm.nih.gov/7798201 DMGYWIK DI DMGYWIK DMGYWIK DN RG6046 DMGYWIK TI TTZAYWL DMGYWIK TN Estrogen receptor (ESR) DMGYWIK MA Modulator DMGYWIK RN Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 DMGYWIK RU https://www.accessdata.fda.gov/scripts/cder/drugsatfda/ DMGYZ8D DI DMGYZ8D DMGYZ8D DN 2-(4-chloro-2-cyclohexylphenoxy)acetic acid DMGYZ8D TI TTQDMX5 DMGYZ8D TN Prostaglandin D2 receptor 2 (PTGDR2) DMGYZ8D MA Inhibitor DMGYZ8D RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMGYZ8D RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMGYZHU DI DMGYZHU DMGYZHU DN Methyl 10H-phenothiazine-10-carboxylate DMGYZHU TI TTEB0GD DMGYZHU TN Cholinesterase (BCHE) DMGYZHU MA Inhibitor DMGYZHU RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMGYZHU RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMGZ0KM DI DMGZ0KM DMGZ0KM DN Cyclorgdfv DMGZ0KM TI TTJA1ZO DMGZ0KM TN ITGB3 messenger RNA (ITGB3 mRNA) DMGZ0KM MA Inhibitor DMGZ0KM RN Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetr... J Med Chem. 2010 Jan 14;53(1):106-18. DMGZ0KM RU https://pubmed.ncbi.nlm.nih.gov/20055426 DMGZ0KM DI DMGZ0KM DMGZ0KM DN Cyclorgdfv DMGZ0KM TI TTT1R2L DMGZ0KM TN Integrin alpha-V (ITGAV) DMGZ0KM MA Inhibitor DMGZ0KM RN Antiangiogenic effect of dual/selective alpha(5)beta(1)/alpha(v)beta(3) integrin antagonists designed on partially modified retro-inverso cyclotetr... J Med Chem. 2010 Jan 14;53(1):106-18. DMGZ0KM RU https://pubmed.ncbi.nlm.nih.gov/20055426 DMGZ2H5 DI DMGZ2H5 DMGZ2H5 DN Del 60 tetramer DMGZ2H5 TI TTI2S1D DMGZ2H5 TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMGZ2H5 RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMGZ2H5 RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMGZKCT DI DMGZKCT DMGZKCT DN 2-(2-((benzylamino)methyl)phenoxy)-5-chlorophenol DMGZKCT TI TTNX2CS DMGZKCT TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMGZKCT MA Inhibitor DMGZKCT RN Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2'-substituted triclosan der... Bioorg Med Chem Lett. 2006 Apr 15;16(8):2163-9. DMGZKCT RU https://pubmed.ncbi.nlm.nih.gov/16466916 DMGZM6V DI DMGZM6V DMGZM6V DN Anti-CD40-XTEN DMGZM6V TI TTN6Y9A DMGZM6V TN CD40L receptor (CD40) DMGZM6V MA Antagonist DMGZM6V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874). DMGZM6V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874 DMGZQ5P DI DMGZQ5P DMGZQ5P DN Linalool DMGZQ5P TI TTXDKTO DMGZQ5P TN Long transient receptor potential channel 8 (TRPM8) DMGZQ5P MA Activator DMGZQ5P RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMGZQ5P RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMGZQNS DI DMGZQNS DMGZQNS DN 6-desoxonaltrexone DMGZQNS TI TTKWM86 DMGZQNS TN Opioid receptor mu (MOP) DMGZQNS MA Inhibitor DMGZQNS RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMGZQNS RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMGZQNS DI DMGZQNS DMGZQNS DN 6-desoxonaltrexone DMGZQNS TI TT27RFC DMGZQNS TN Opioid receptor delta (OPRD1) DMGZQNS MA Inhibitor DMGZQNS RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMGZQNS RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMGZQNS DI DMGZQNS DMGZQNS DN 6-desoxonaltrexone DMGZQNS TI TTQW87Y DMGZQNS TN Opioid receptor kappa (OPRK1) DMGZQNS MA Inhibitor DMGZQNS RN Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94. DMGZQNS RU https://pubmed.ncbi.nlm.nih.gov/19282177 DMGZTQW DI DMGZTQW DMGZTQW DN GFPEGG DMGZTQW TI TTPADOQ DMGZTQW TN HMG-CoA reductase (HMGCR) DMGZTQW MA Inhibitor DMGZTQW RN Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18. DMGZTQW RU https://pubmed.ncbi.nlm.nih.gov/17977732 DMGZY1Q DI DMGZY1Q DMGZY1Q DN N-hydroxy-8-(naphthalen-2-yl)oct-7-enamide DMGZY1Q TI TT6R7JZ DMGZY1Q TN Histone deacetylase 1 (HDAC1) DMGZY1Q MA Inhibitor DMGZY1Q RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMGZY1Q RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMH01JV DI DMH01JV DMH01JV DN cloprostenol DMH01JV TI TTG1QMU DMH01JV TN Prostaglandin E2 receptor EP1 (PTGER1) DMH01JV MA Agonist DMH01JV RN Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47. DMH01JV RU https://pubmed.ncbi.nlm.nih.gov/11999132 DMH01JV DI DMH01JV DMH01JV DN cloprostenol DMH01JV TI TTT2ZAR DMH01JV TN Prostaglandin F2-alpha receptor (PTGFR) DMH01JV MA Agonist DMH01JV RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMH01JV RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMH01JV DI DMH01JV DMH01JV DN cloprostenol DMH01JV TI TTPNGDE DMH01JV TN Prostaglandin E2 receptor EP3 (PTGER3) DMH01JV MA Agonist DMH01JV RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMH01JV RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMH01JV DI DMH01JV DMH01JV DN cloprostenol DMH01JV TI TT2O84V DMH01JV TN Thromboxane A2 receptor (TBXA2R) DMH01JV MA Agonist DMH01JV RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMH01JV RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMH01JV DI DMH01JV DMH01JV DN cloprostenol DMH01JV TI TTNVEIR DMH01JV TN Prostaglandin D2 receptor (PTGDR) DMH01JV MA Agonist DMH01JV RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMH01JV RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMH04P7 DI DMH04P7 DMH04P7 DN 3,7-dihydroxy-flavone DMH04P7 TI TTNX2CS DMH04P7 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMH04P7 MA Inhibitor DMH04P7 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMH04P7 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMH08O3 DI DMH08O3 DMH08O3 DN Tyr-Pro-D-(NMe)Phe-D-Pro-NH2 DMH08O3 TI TTKWM86 DMH08O3 TN Opioid receptor mu (MOP) DMH08O3 MA Inhibitor DMH08O3 RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMH08O3 RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMH0DLZ DI DMH0DLZ DMH0DLZ DN Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF DMH0DLZ TI TTJX3UE DMH0DLZ TN Somatostatin receptor type 3 (SSTR3) DMH0DLZ MA Inhibitor DMH0DLZ RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMH0DLZ RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMH0DLZ DI DMH0DLZ DMH0DLZ DN Des-AA1,2,5-[D-Trp8,IAmp9,m-I-Tyr11]Cbm-SRIF DMH0DLZ TI TTIND6G DMH0DLZ TN Somatostatin receptor type 1 (SSTR1) DMH0DLZ MA Inhibitor DMH0DLZ RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMH0DLZ RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMH0EAI DI DMH0EAI DMH0EAI DN Ac-YR[CEHFRWC]-NH2 DMH0EAI TI TT0MV2T DMH0EAI TN Melanocortin receptor 1 (MC1R) DMH0EAI MA Inhibitor DMH0EAI RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMH0EAI RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMH0EAI DI DMH0EAI DMH0EAI DN Ac-YR[CEHFRWC]-NH2 DMH0EAI TI TTD0CIQ DMH0EAI TN Melanocortin receptor 4 (MC4R) DMH0EAI MA Inhibitor DMH0EAI RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMH0EAI RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMH0G8W DI DMH0G8W DMH0G8W DN Kurarinone DMH0G8W TI TT8JRS7 DMH0G8W TN Beta-secretase (BACE) DMH0G8W MA Inhibitor DMH0G8W RN BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74. DMH0G8W RU https://pubmed.ncbi.nlm.nih.gov/18565755 DMH0G8W DI DMH0G8W DMH0G8W DN Kurarinone DMH0G8W TI TTF8JAT DMH0G8W TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMH0G8W MA Inhibitor DMH0G8W RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMH0G8W RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMH0G8W DI DMH0G8W DMH0G8W DN Kurarinone DMH0G8W TI TT2UE56 DMH0G8W TN Sodium/glucose cotransporter 1 (SGLT1) DMH0G8W MA Inhibitor DMH0G8W RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMH0G8W RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMH0LOT DI DMH0LOT DMH0LOT DN N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide DMH0LOT TI TT0WAIE DMH0LOT TN Melatonin receptor type 1A (MTNR1A) DMH0LOT MA Inhibitor DMH0LOT RN 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33. DMH0LOT RU https://pubmed.ncbi.nlm.nih.gov/19193160 DMH0LOT DI DMH0LOT DMH0LOT DN N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamide DMH0LOT TI TT32JK8 DMH0LOT TN Melatonin receptor type 1B (MTNR1B) DMH0LOT MA Inhibitor DMH0LOT RN 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33. DMH0LOT RU https://pubmed.ncbi.nlm.nih.gov/19193160 DMH0Q9V DI DMH0Q9V DMH0Q9V DN Lys[Z(NO2)]-Lys[Z(NO2)] DMH0Q9V TI TT27Q3A DMH0Q9V TN Solute carrier family 15 member 2 (SLC15A2) DMH0Q9V MA Inhibitor DMH0Q9V RN Defining minimal structural features in substrates of the H(+)/peptide cotransporter PEPT2 using novel amino acid and dipeptide derivatives. Mol Pharmacol. 2002 Jan;61(1):214-21. DMH0Q9V RU https://pubmed.ncbi.nlm.nih.gov/11752223 DMH0QA7 DI DMH0QA7 DMH0QA7 DN 5-((E)-Styryl)-quinazoline-2,4-diamine DMH0QA7 TI TT9SL3Q DMH0QA7 TN Polypeptide deformylase (PDF) DMH0QA7 MA Inhibitor DMH0QA7 RN 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dih... J Med Chem. 1995 Mar 3;38(5):745-52. DMH0QA7 RU https://pubmed.ncbi.nlm.nih.gov/7877140 DMH0SQC DI DMH0SQC DMH0SQC DN Ac-Cys-Ile-cyclo[Phe-Lys]-Tyr-Tyr DMH0SQC TI TT6PKBN DMH0SQC TN Proto-oncogene c-Src (SRC) DMH0SQC MA Inhibitor DMH0SQC RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMH0SQC RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMH0TUZ DI DMH0TUZ DMH0TUZ DN L-765314 DMH0TUZ TI TTNGILX DMH0TUZ TN Adrenergic receptor alpha-1A (ADRA1A) DMH0TUZ MA Inhibitor DMH0TUZ RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMH0TUZ RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMH0UVE DI DMH0UVE DMH0UVE DN 7-methoxy-8-propionyl-2H-chromen-2-one DMH0UVE TI TT2LVK8 DMH0UVE TN Carbonic anhydrase IX (CA-IX) DMH0UVE MA Inhibitor DMH0UVE RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMH0UVE RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMH0ZVR DI DMH0ZVR DMH0ZVR DN 1-benzyl-5'-O-tritylinosine DMH0ZVR TI TTO0IB8 DMH0ZVR TN Thymidine phosphorylase (TYMP) DMH0ZVR MA Inhibitor DMH0ZVR RN 5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70. DMH0ZVR RU https://pubmed.ncbi.nlm.nih.gov/16942029 DMH106Y DI DMH106Y DMH106Y DN LONGANINE DMH106Y TI TT27RFC DMH106Y TN Opioid receptor delta (OPRD1) DMH106Y MA Inhibitor DMH106Y RN Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91. DMH106Y RU https://pubmed.ncbi.nlm.nih.gov/20426456 DMH17MU DI DMH17MU DMH17MU DN Gabaculine DMH17MU TI TT6LDTK DMH17MU TN Bacterial Glutamate-1-semialdehyde aminomutase (Bact hemL) DMH17MU MA Inhibitor DMH17MU RN A suicide vector for allelic recombination involving the gene for glutamate 1-semialdehyde aminotransferase in the cyanobacterium Synechococcus PCC 7942. Mol Gen Genet. 1997 Jul;255(4):392-9. DMH17MU RU https://pubmed.ncbi.nlm.nih.gov/9267435 DMH1AZV DI DMH1AZV DMH1AZV DN 4-(butylthio)-2-methoxybenzonitrile DMH1AZV TI TTKPW01 DMH1AZV TN Androgen receptor messenger RNA (AR mRNA) DMH1AZV MA Inhibitor DMH1AZV RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMH1AZV RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TT4C8EA DMH1BN4 TN Dopamine D3 receptor (D3R) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTQ13Z5 DMH1BN4 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTS2PH3 DMH1BN4 TN Dopamine D5 receptor (D5R) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTYEG6Q DMH1BN4 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTZ9SOR DMH1BN4 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTH18TF DMH1BN4 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTE0A2F DMH1BN4 TN Dopamine D4 receptor (D4R) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTEX248 DMH1BN4 TN Dopamine D2 receptor (D2R) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTZFYLI DMH1BN4 TN Dopamine D1 receptor (D1R) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BN4 DI DMH1BN4 DMH1BN4 DN ISOLOXAPINE DMH1BN4 TI TTQ3JTF DMH1BN4 TN Muscarinic acetylcholine receptor M4 (CHRM4) DMH1BN4 MA Inhibitor DMH1BN4 RN Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6. DMH1BN4 RU https://pubmed.ncbi.nlm.nih.gov/7288815 DMH1BVG DI DMH1BVG DMH1BVG DN NCL-1 DMH1BVG TI TTNR0UQ DMH1BVG TN Lysine-specific histone demethylase 1 (LSD) DMH1BVG MA Inhibitor DMH1BVG RN Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorg Med Chem. 2011 Jun 15;19(12):3702-8. DMH1BVG RU https://pubmed.ncbi.nlm.nih.gov/21227703 DMH1CFX DI DMH1CFX DMH1CFX DN SB-214111 DMH1CFX TI TTJS8PY DMH1CFX TN 5-HT 6 receptor (HTR6) DMH1CFX MA Modulator DMH1CFX RN The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]S... Brain Res. 2002 Apr 26;934(1):49-57. DMH1CFX RU https://www.ncbi.nlm.nih.gov/pubmed/11937069 DMH1I32 DI DMH1I32 DMH1I32 DN 4-[1-(4-hydroxyphenyl)-2-phenylprop-1-enyl]phenol DMH1I32 TI TTZAYWL DMH1I32 TN Estrogen receptor (ESR) DMH1I32 MA Inhibitor DMH1I32 RN Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64. DMH1I32 RU https://pubmed.ncbi.nlm.nih.gov/12431063 DMH1IVN DI DMH1IVN DMH1IVN DN 5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DMH1IVN TI TTML2WA DMH1IVN TN Tubulin (TUB) DMH1IVN MA Inhibitor DMH1IVN RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMH1IVN RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMH1IVN DI DMH1IVN DMH1IVN DN 5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DMH1IVN TI TTYFKSZ DMH1IVN TN Tubulin beta (TUBB) DMH1IVN MA Inhibitor DMH1IVN RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMH1IVN RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMH1L3P DI DMH1L3P DMH1L3P DN H-Aba-Gly-Gly-Phe-Leu-OH DMH1L3P TI TTKWM86 DMH1L3P TN Opioid receptor mu (MOP) DMH1L3P MA Inhibitor DMH1L3P RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMH1L3P RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMH1L3P DI DMH1L3P DMH1L3P DN H-Aba-Gly-Gly-Phe-Leu-OH DMH1L3P TI TT27RFC DMH1L3P TN Opioid receptor delta (OPRD1) DMH1L3P MA Inhibitor DMH1L3P RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMH1L3P RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMH1M6N DI DMH1M6N DMH1M6N DN ORG2058 DMH1M6N TI TTUV8G9 DMH1M6N TN Progesterone receptor (PGR) DMH1M6N MA Agonist DMH1M6N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 627). DMH1M6N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=627 DMH1RX6 DI DMH1RX6 DMH1RX6 DN 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline DMH1RX6 TI TTWG9A4 DMH1RX6 TN Adrenergic receptor alpha-2A (ADRA2A) DMH1RX6 MA Inhibitor DMH1RX6 RN 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90. DMH1RX6 RU https://pubmed.ncbi.nlm.nih.gov/10354406 DMH1RX6 DI DMH1RX6 DMH1RX6 DN 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline DMH1RX6 TI TTWM4TY DMH1RX6 TN Adrenergic receptor alpha-2B (ADRA2B) DMH1RX6 MA Inhibitor DMH1RX6 RN 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90. DMH1RX6 RU https://pubmed.ncbi.nlm.nih.gov/10354406 DMH1RX6 DI DMH1RX6 DMH1RX6 DN 3-Methoxymethyl-1,2,3,4-tetrahydro-isoquinoline DMH1RX6 TI TT2NUT5 DMH1RX6 TN Adrenergic receptor alpha-2C (ADRA2C) DMH1RX6 MA Inhibitor DMH1RX6 RN 3,7-Disubstituted-1,2,3,4-tetrahydroisoquinolines display remarkable potency and selectivity as inhibitors of phenylethanolamine N-methyltransferas... J Med Chem. 1999 Jun 3;42(11):1982-90. DMH1RX6 RU https://pubmed.ncbi.nlm.nih.gov/10354406 DMH1S57 DI DMH1S57 DMH1S57 DN Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine DMH1S57 TI TT3WG5C DMH1S57 TN Monoamine oxidase type A (MAO-A) DMH1S57 MA Inhibitor DMH1S57 RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMH1S57 RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMH1S57 DI DMH1S57 DMH1S57 DN Trans-2-(4-chlorophenyl)-2-fluorocyclopropanamine DMH1S57 TI TTGP7BY DMH1S57 TN Monoamine oxidase type B (MAO-B) DMH1S57 MA Inhibitor DMH1S57 RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMH1S57 RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMH1VCE DI DMH1VCE DMH1VCE DN 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole DMH1VCE TI TTGP7BY DMH1VCE TN Monoamine oxidase type B (MAO-B) DMH1VCE MA Inhibitor DMH1VCE RN Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. DMH1VCE RU https://pubmed.ncbi.nlm.nih.gov/20579890 DMH1VCE DI DMH1VCE DMH1VCE DN 2-(2-cyclopentylidenehydrazinyl)-4-phenylthiazole DMH1VCE TI TT3WG5C DMH1VCE TN Monoamine oxidase type A (MAO-A) DMH1VCE MA Inhibitor DMH1VCE RN Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. DMH1VCE RU https://pubmed.ncbi.nlm.nih.gov/20579890 DMH1YN6 DI DMH1YN6 DMH1YN6 DN MMI-175 DMH1YN6 TI TT8JRS7 DMH1YN6 TN Beta-secretase (BACE) DMH1YN6 MA Inhibitor DMH1YN6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMH1YN6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMH204Y DI DMH204Y DMH204Y DN CKD-533 DMH204Y TI TTJ0IQB DMH204Y TN Phosphodiesterase 5A (PDE5A) DMH204Y MA Inhibitor DMH204Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304). DMH204Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304 DMH25OD DI DMH25OD DMH25OD DN hexahydrodifenidol DMH25OD TI TTQ13Z5 DMH25OD TN Muscarinic acetylcholine receptor M3 (CHRM3) DMH25OD MA Antagonist DMH25OD RN Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. DMH25OD RU https://pubmed.ncbi.nlm.nih.gov/2704370 DMH25OD DI DMH25OD DMH25OD DN hexahydrodifenidol DMH25OD TI TTOXS3C DMH25OD TN Muscarinic acetylcholine receptor (CHRM) DMH25OD MA Antagonist DMH25OD RN Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol. 1989 Apr;35(4):469-76. DMH25OD RU https://pubmed.ncbi.nlm.nih.gov/2704370 DMH27E0 DI DMH27E0 DMH27E0 DN 3-(4-Phenylpiperazin-1-carbonyl)coumarin DMH27E0 TI TT1RS9F DMH27E0 TN Acetylcholinesterase (AChE) DMH27E0 MA Inhibitor DMH27E0 RN Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21. DMH27E0 RU https://pubmed.ncbi.nlm.nih.gov/18701305 DMH2CKX DI DMH2CKX DMH2CKX DN METHOCTRAMINE DMH2CKX TI TTJFY5U DMH2CKX TN Adenosine A3 receptor (ADORA3) DMH2CKX MA Inhibitor DMH2CKX RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMH2CKX RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMH2CKX DI DMH2CKX DMH2CKX DN METHOCTRAMINE DMH2CKX TI TTYEG6Q DMH2CKX TN Muscarinic acetylcholine receptor M2 (CHRM2) DMH2CKX MA Inhibitor DMH2CKX RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMH2CKX RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMH2CX5 DI DMH2CX5 DMH2CX5 DN Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3-ol DMH2CX5 TI TTRA5BZ DMH2CX5 TN Steroid 17-alpha-monooxygenase (S17AH) DMH2CX5 MA Inhibitor DMH2CX5 RN Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75. DMH2CX5 RU https://pubmed.ncbi.nlm.nih.gov/19211174 DMH2G13 DI DMH2G13 DMH2G13 DN 1-(oxazolo[4,5-b]pyridin-2-yl)pentan-1-one DMH2G13 TI TTDP1UC DMH2G13 TN Fatty acid amide hydrolase (FAAH) DMH2G13 MA Inhibitor DMH2G13 RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMH2G13 RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMH2OV9 DI DMH2OV9 DMH2OV9 DN PD-137342 DMH2OV9 TI TTCG0AL DMH2OV9 TN Cholecystokinin receptor type A (CCKAR) DMH2OV9 MA Inhibitor DMH2OV9 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMH2OV9 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMH2OV9 DI DMH2OV9 DMH2OV9 DN PD-137342 DMH2OV9 TI TTVFO0U DMH2OV9 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMH2OV9 MA Inhibitor DMH2OV9 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMH2OV9 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMH2SU4 DI DMH2SU4 DMH2SU4 DN Ac-hPhe-Leu-Gly-LeuVSMe DMH2SU4 TI TTUMQVO DMH2SU4 TN Cathepsin S (CTSS) DMH2SU4 MA Inhibitor DMH2SU4 RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMH2SU4 RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMH2U4Z DI DMH2U4Z DMH2U4Z DN (E)-2-(4-(methylsulfonyl)styryl)furan DMH2U4Z TI TTVKILB DMH2U4Z TN Prostaglandin G/H synthase 2 (COX-2) DMH2U4Z MA Inhibitor DMH2U4Z RN Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41. DMH2U4Z RU https://pubmed.ncbi.nlm.nih.gov/20970329 DMH318X DI DMH318X DMH318X DN Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine DMH318X TI TTZ97H5 DMH318X TN Phosphodiesterase 4A (PDE4A) DMH318X MA Inhibitor DMH318X RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMH318X RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMH318X DI DMH318X DMH318X DN Benzyl-(2-thiophen-2-yl-quinazolin-4-yl)-amine DMH318X TI TTVIAT9 DMH318X TN Phosphodiesterase 4B (PDE4B) DMH318X MA Inhibitor DMH318X RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMH318X RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMH340E DI DMH340E DMH340E DN Deprotected cogener of M6G DMH340E TI TT27RFC DMH340E TN Opioid receptor delta (OPRD1) DMH340E MA Inhibitor DMH340E RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMH340E RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMH340E DI DMH340E DMH340E DN Deprotected cogener of M6G DMH340E TI TTQW87Y DMH340E TN Opioid receptor kappa (OPRK1) DMH340E MA Inhibitor DMH340E RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMH340E RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMH340E DI DMH340E DMH340E DN Deprotected cogener of M6G DMH340E TI TTKWM86 DMH340E TN Opioid receptor mu (MOP) DMH340E MA Inhibitor DMH340E RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMH340E RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMH360U DI DMH360U DMH360U DN 4-(1H-indol-5-yloxy)-5-styrylnicotinonitrile DMH360U TI TT1MS7X DMH360U TN PKC-theta messenger RNA (PRKCQ mRNA) DMH360U MA Inhibitor DMH360U RN First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32. DMH360U RU https://pubmed.ncbi.nlm.nih.gov/19762237 DMH36A9 DI DMH36A9 DMH36A9 DN SF303 DMH36A9 TI TTCIHJA DMH36A9 TN Coagulation factor Xa (F10) DMH36A9 MA Inhibitor DMH36A9 RN The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem. 2001 Jun;1(2):137-49. DMH36A9 RU https://pubmed.ncbi.nlm.nih.gov/11899249 DMH397E DI DMH397E DMH397E DN 5-Chlorosalicylic Acid DMH397E TI TTANPDJ DMH397E TN Carbonic anhydrase II (CA-II) DMH397E MA Inhibitor DMH397E RN In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5. DMH397E RU https://pubmed.ncbi.nlm.nih.gov/18819808 DMH397E DI DMH397E DMH397E DN 5-Chlorosalicylic Acid DMH397E TI TTHQPL7 DMH397E TN Carbonic anhydrase I (CA-I) DMH397E MA Inhibitor DMH397E RN In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5. DMH397E RU https://pubmed.ncbi.nlm.nih.gov/18819808 DMH3BG5 DI DMH3BG5 DMH3BG5 DN [1-Benzyl-1H-quinolin-(4E)-ylidene]-hexyl-amine DMH3BG5 TI TTY3UE6 DMH3BG5 TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMH3BG5 MA Inhibitor DMH3BG5 RN Novel inhibitors of potassium ion channels on human T lymphocytes. J Med Chem. 1995 May 26;38(11):1877-83. DMH3BG5 RU https://pubmed.ncbi.nlm.nih.gov/7540207 DMH3C01 DI DMH3C01 DMH3C01 DN ISIS 25128 DMH3C01 TI TT8H9GB DMH3C01 TN MEK2 messenger RNA (MEK2 mRNA) DMH3C01 RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMH3C01 RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMH3CK2 DI DMH3CK2 DMH3CK2 DN ABYSSINONE V DMH3CK2 TI TT9V5JH DMH3CK2 TN Phospholipase A2 (PLA2G1B) DMH3CK2 MA Inhibitor DMH3CK2 RN Phospholipase A2 Inhibitors from an Erythrina Species from Samoa J. Nat. Prod. 60(6):537-539 (1997). DMH3CK2 RU http://pubs.acs.org/doi/abs/10.1021/np960533e DMH3NTP DI DMH3NTP DMH3NTP DN TINGENONE DMH3NTP TI TTFBNVI DMH3NTP TN Aldose reductase (AKR1B1) DMH3NTP MA Inhibitor DMH3NTP RN Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6. DMH3NTP RU https://pubmed.ncbi.nlm.nih.gov/14510595 DMH3PDG DI DMH3PDG DMH3PDG DN GT2394 DMH3PDG TI TT9JNIC DMH3PDG TN Histamine H3 receptor (H3R) DMH3PDG MA Antagonist DMH3PDG RN Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur J Pharmacol. 2002 Oct 18;453(1):33-41. DMH3PDG RU https://pubmed.ncbi.nlm.nih.gov/12393057 DMH3QLF DI DMH3QLF DMH3QLF DN 2-(tert-Butylamino)-3',5'-difluoropropiophenone DMH3QLF TI TTVBI8W DMH3QLF TN Dopamine transporter (DAT) DMH3QLF MA Inhibitor DMH3QLF RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMH3QLF RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMH3R21 DI DMH3R21 DMH3R21 DN N-(3-acetamidophenyl)-3-chlorobenzamide DMH3R21 TI TTHS256 DMH3R21 TN Metabotropic glutamate receptor 5 (mGluR5) DMH3R21 MA Inhibitor DMH3R21 RN Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6. DMH3R21 RU https://pubmed.ncbi.nlm.nih.gov/19875287 DMH3SDO DI DMH3SDO DMH3SDO DN 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one DMH3SDO TI TTSHTOI DMH3SDO TN Histone deacetylase 2 (HDAC2) DMH3SDO MA Inhibitor DMH3SDO RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DMH3SDO RU https://pubmed.ncbi.nlm.nih.gov/12419380 DMH3SDO DI DMH3SDO DMH3SDO DN 8-(Biphenyl-3-yloxy)-1,1,1-trifluoro-octan-2-one DMH3SDO TI TT6R7JZ DMH3SDO TN Histone deacetylase 1 (HDAC1) DMH3SDO MA Inhibitor DMH3SDO RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DMH3SDO RU https://pubmed.ncbi.nlm.nih.gov/12419380 DMH3TBQ DI DMH3TBQ DMH3TBQ DN 4-(2,6-diamino-9H-purin-8-yl)-2,6-dimethoxyphenol DMH3TBQ TI TT9SL3Q DMH3TBQ TN Polypeptide deformylase (PDF) DMH3TBQ MA Inhibitor DMH3TBQ RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DMH3TBQ RU https://pubmed.ncbi.nlm.nih.gov/20117005 DMH3UPO DI DMH3UPO DMH3UPO DN 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide DMH3UPO TI TTHQPL7 DMH3UPO TN Carbonic anhydrase I (CA-I) DMH3UPO MA Inhibitor DMH3UPO RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMH3UPO RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMH3UPO DI DMH3UPO DMH3UPO DN 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide DMH3UPO TI TTUNARX DMH3UPO TN Carbonic anhydrase (CA) DMH3UPO MA Inhibitor DMH3UPO RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMH3UPO RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMH3UPO DI DMH3UPO DMH3UPO DN 4-[2-(2-Thienyl)acetamidoethyl]benzenesulfonamide DMH3UPO TI TTANPDJ DMH3UPO TN Carbonic anhydrase II (CA-II) DMH3UPO MA Inhibitor DMH3UPO RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMH3UPO RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMH3X06 DI DMH3X06 DMH3X06 DN LAVENDUSTIN A DMH3X06 TI TTGKNB4 DMH3X06 TN Epidermal growth factor receptor (EGFR) DMH3X06 MA Inhibitor DMH3X06 RN Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84. DMH3X06 RU https://pubmed.ncbi.nlm.nih.gov/7990108 DMH3X06 DI DMH3X06 DMH3X06 DN LAVENDUSTIN A DMH3X06 TI TT860QF DMH3X06 TN LCK tyrosine protein kinase (LCK) DMH3X06 MA Inhibitor DMH3X06 RN Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors. J Med Chem. 1993 Oct 1;36(20):3010-4. DMH3X06 RU https://pubmed.ncbi.nlm.nih.gov/8105084 DMH3YBR DI DMH3YBR DMH3YBR DN 2-(biphenyl-4-ylsulfonamido)pentanedioic acid DMH3YBR TI TTGA1IV DMH3YBR TN Matrix metalloproteinase-8 (MMP-8) DMH3YBR MA Inhibitor DMH3YBR RN Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. DMH3YBR RU https://pubmed.ncbi.nlm.nih.gov/18364257 DMH3YBR DI DMH3YBR DMH3YBR DN 2-(biphenyl-4-ylsulfonamido)pentanedioic acid DMH3YBR TI TT6X50U DMH3YBR TN Matrix metalloproteinase-9 (MMP-9) DMH3YBR MA Inhibitor DMH3YBR RN Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. DMH3YBR RU https://pubmed.ncbi.nlm.nih.gov/18364257 DMH3YBR DI DMH3YBR DMH3YBR DN 2-(biphenyl-4-ylsulfonamido)pentanedioic acid DMH3YBR TI TTHY57M DMH3YBR TN Matrix metalloproteinase-13 (MMP-13) DMH3YBR MA Inhibitor DMH3YBR RN Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. DMH3YBR RU https://pubmed.ncbi.nlm.nih.gov/18364257 DMH3YKR DI DMH3YKR DMH3YKR DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl DMH3YKR TI TT27RFC DMH3YKR TN Opioid receptor delta (OPRD1) DMH3YKR MA Inhibitor DMH3YKR RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMH3YKR RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMH3YKR DI DMH3YKR DMH3YKR DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl DMH3YKR TI TTZPO1L DMH3YKR TN Substance-P receptor (TACR1) DMH3YKR MA Inhibitor DMH3YKR RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMH3YKR RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMH3YKR DI DMH3YKR DMH3YKR DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl DMH3YKR TI TTKWM86 DMH3YKR TN Opioid receptor mu (MOP) DMH3YKR MA Inhibitor DMH3YKR RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMH3YKR RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMH42L8 DI DMH42L8 DMH42L8 DN N-(7-methoxy-4-phenylbenzofuran-2-yl)acetamide DMH42L8 TI TTM2AOE DMH42L8 TN Adenosine A2a receptor (ADORA2A) DMH42L8 MA Inhibitor DMH42L8 RN Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1090-3. DMH42L8 RU https://pubmed.ncbi.nlm.nih.gov/20034788 DMH42YF DI DMH42YF DMH42YF DN N-(2-Methyl-1H-indol-5-yl)benzamide DMH42YF TI TTGP7BY DMH42YF TN Monoamine oxidase type B (MAO-B) DMH42YF MA Inhibitor DMH42YF RN Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66. DMH42YF RU https://pubmed.ncbi.nlm.nih.gov/20674099 DMH49OD DI DMH49OD DMH49OD DN 1-(9H-fluoren-9-yl)-1H-imidazole DMH49OD TI TTSZLWK DMH49OD TN Aromatase (CYP19A1) DMH49OD MA Inhibitor DMH49OD RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMH49OD RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMH4AGL DI DMH4AGL DMH4AGL DN Tetraethylene Glycol DMH4AGL TI TT1RS9F DMH4AGL TN Acetylcholinesterase (AChE) DMH4AGL MA Inhibitor DMH4AGL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMH4AGL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMH4AKG DI DMH4AKG DMH4AKG DN PG-1014491 DMH4AKG TI TTIKWV4 DMH4AKG TN Geranyltranstransferase (FDPS) DMH4AKG MA Inhibitor DMH4AKG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 643). DMH4AKG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=643 DMH4IRP DI DMH4IRP DMH4IRP DN 2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine DMH4IRP TI TTZL0OI DMH4IRP TN Methionine aminopeptidase 2 (METAP2) DMH4IRP MA Inhibitor DMH4IRP RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMH4IRP RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMH4KGX DI DMH4KGX DMH4KGX DN ICR 62 DMH4KGX TI TTGKNB4 DMH4KGX TN Epidermal growth factor receptor (EGFR) DMH4KGX RN Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611. DMH4KGX RU https://pubmed.ncbi.nlm.nih.gov/11920518 DMH4MBW DI DMH4MBW DMH4MBW DN ET bromodomain inhibitor DMH4MBW TI TTDP48B DMH4MBW TN Bromodomain-containing protein 2 (BRD2) DMH4MBW MA Inhibitor DMH4MBW RN Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014 Oct 31;346(6209):638-41. DMH4MBW RU https://pubmed.ncbi.nlm.nih.gov/25323695 DMH4SLZ DI DMH4SLZ DMH4SLZ DN 5-Chloro-2-(2-methylquinolin-7-yl)benzonitrile DMH4SLZ TI TTHS256 DMH4SLZ TN Metabotropic glutamate receptor 5 (mGluR5) DMH4SLZ MA Inhibitor DMH4SLZ RN Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35. DMH4SLZ RU https://pubmed.ncbi.nlm.nih.gov/20382541 DMH4TRD DI DMH4TRD DMH4TRD DN 2-Amino-6-(3-bromo-phenylsulfanyl)-benzonitrile DMH4TRD TI TT84ETX DMH4TRD TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMH4TRD MA Inhibitor DMH4TRD RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMH4TRD RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMH50RX DI DMH50RX DMH50RX DN ISIS 9065 DMH50RX TI TT5TURO DMH50RX TN A-Raf messenger RNA (ARAF mRNA) DMH50RX RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DMH50RX RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DMH5329 DI DMH5329 DMH5329 DN 3-[(6-Methylpyridin-2-yl)ethynyl]benzonitrile DMH5329 TI TTHS256 DMH5329 TN Metabotropic glutamate receptor 5 (mGluR5) DMH5329 MA Inhibitor DMH5329 RN Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75. DMH5329 RU https://pubmed.ncbi.nlm.nih.gov/19445453 DMH5CAQ DI DMH5CAQ DMH5CAQ DN 4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ TI TTXZEAJ DMH5CAQ TN Leukotriene A-4 hydrolase (LTA4H) DMH5CAQ MA Inhibitor DMH5CAQ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMH5CAQ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMH5CAQ DI DMH5CAQ DMH5CAQ DN 4-(2-amino-1,3-thiazol-4-yl)phenol DMH5CAQ TI TTWHDVK DMH5CAQ TN Fructose-1,6-bisphosphatase (FBP) DMH5CAQ MA Inhibitor DMH5CAQ RN A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22. DMH5CAQ RU https://pubmed.ncbi.nlm.nih.gov/19419876 DMH5GW6 DI DMH5GW6 DMH5GW6 DN N-butyl-4-hydroxy-N-phenylbenzenesulfonamide DMH5GW6 TI TTZAYWL DMH5GW6 TN Estrogen receptor (ESR) DMH5GW6 MA Inhibitor DMH5GW6 RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DMH5GW6 RU https://pubmed.ncbi.nlm.nih.gov/16300947 DMH5QEA DI DMH5QEA DMH5QEA DN 11-Butyryloxy-N-n-propylnoraporphine DMH5QEA TI TTZFYLI DMH5QEA TN Dopamine D1 receptor (D1R) DMH5QEA MA Inhibitor DMH5QEA RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMH5QEA RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMH5QEA DI DMH5QEA DMH5QEA DN 11-Butyryloxy-N-n-propylnoraporphine DMH5QEA TI TTJQOD7 DMH5QEA TN 5-HT 2A receptor (HTR2A) DMH5QEA MA Inhibitor DMH5QEA RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMH5QEA RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTGJCWZ DMH5RFU TN Fms-like tyrosine kinase 3 (FLT-3) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTDCBX5 DMH5RFU TN Vascular endothelial growth factor receptor 3 (FLT-4) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTI7421 DMH5RFU TN Platelet-derived growth factor receptor beta (PDGFRB) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTRLW2X DMH5RFU TN Fibroblast growth factor receptor 1 (FGFR1) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTUM2ZR DMH5RFU TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTI0AHJ DMH5RFU TN MEK kinase kinase 3 (MAP4K3) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TT8FYO9 DMH5RFU TN Platelet-derived growth factor receptor alpha (PDGFRA) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTX41N9 DMH5RFU TN Tyrosine-protein kinase Kit (KIT) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TTUTJGQ DMH5RFU TN Vascular endothelial growth factor receptor 2 (KDR) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TT1VAUK DMH5RFU TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5RFU DI DMH5RFU DMH5RFU DN PMID22765894C8h DMH5RFU TI TT6PKBN DMH5RFU TN Proto-oncogene c-Src (SRC) DMH5RFU MA Inhibitor DMH5RFU RN The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85. DMH5RFU RU https://pubmed.ncbi.nlm.nih.gov/22765894 DMH5SMT DI DMH5SMT DMH5SMT DN MCL-147 DMH5SMT TI TT27RFC DMH5SMT TN Opioid receptor delta (OPRD1) DMH5SMT MA Inhibitor DMH5SMT RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMH5SMT RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMH5SMT DI DMH5SMT DMH5SMT DN MCL-147 DMH5SMT TI TTQW87Y DMH5SMT TN Opioid receptor kappa (OPRK1) DMH5SMT MA Inhibitor DMH5SMT RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMH5SMT RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMH5SMT DI DMH5SMT DMH5SMT DN MCL-147 DMH5SMT TI TTKWM86 DMH5SMT TN Opioid receptor mu (MOP) DMH5SMT MA Inhibitor DMH5SMT RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMH5SMT RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMH5SQV DI DMH5SQV DMH5SQV DN Folate gamma-L-proline-hydroxamic acid DMH5SQV TI TTMTWOS DMH5SQV TN Matrix metalloproteinase-7 (MMP-7) DMH5SQV MA Inhibitor DMH5SQV RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMH5SQV RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMH5SQV DI DMH5SQV DMH5SQV DN Folate gamma-L-proline-hydroxamic acid DMH5SQV TI TTLM12X DMH5SQV TN Matrix metalloproteinase-2 (MMP-2) DMH5SQV MA Inhibitor DMH5SQV RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMH5SQV RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMH67J2 DI DMH67J2 DMH67J2 DN Isopropyl 10H-phenothiazine-10-carboxylate DMH67J2 TI TTEB0GD DMH67J2 TN Cholinesterase (BCHE) DMH67J2 MA Inhibitor DMH67J2 RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMH67J2 RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMH684Q DI DMH684Q DMH684Q DN NSC-138419 DMH684Q TI TT6VZ78 DMH684Q TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMH684Q MA Inhibitor DMH684Q RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMH684Q RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMH684Q DI DMH684Q DMH684Q DN NSC-138419 DMH684Q TI TTHVCUP DMH684Q TN DNA [cytosine-5]-methyltransferase (DNMT) DMH684Q MA Inhibitor DMH684Q RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMH684Q RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMH693E DI DMH693E DMH693E DN Lu AF21934 DMH693E TI TTICZ1O DMH693E TN Metabotropic glutamate receptor 4 (mGluR4) DMH693E MA Modulator (allosteric modulator) DMH693E RN Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology. 2013 Mar;66:158-69. DMH693E RU https://pubmed.ncbi.nlm.nih.gov/22491024 DMH6EVM DI DMH6EVM DMH6EVM DN (-)-Ro 363 DMH6EVM TI TTMXGCW DMH6EVM TN Adrenergic receptor beta-3 (ADRB3) DMH6EVM MA Agonist DMH6EVM RN Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors. Br J Pharmacol. 1997 Jan;120(2):165-76. DMH6EVM RU https://pubmed.ncbi.nlm.nih.gov/9117106 DMH6FKX DI DMH6FKX DMH6FKX DN 2-(N-Cyclopentylamino)-3'-fluoropropiophenone DMH6FKX TI TTVBI8W DMH6FKX TN Dopamine transporter (DAT) DMH6FKX MA Inhibitor DMH6FKX RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMH6FKX RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMH6FKX DI DMH6FKX DMH6FKX DN 2-(N-Cyclopentylamino)-3'-fluoropropiophenone DMH6FKX TI TTAWNKZ DMH6FKX TN Norepinephrine transporter (NET) DMH6FKX MA Inhibitor DMH6FKX RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMH6FKX RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMH6I4E DI DMH6I4E DMH6I4E DN 3-(2-Bromophenyl)-2-thioxo-(1H )-quinazolin-4-one DMH6I4E TI TTVIAT9 DMH6I4E TN Phosphodiesterase 4B (PDE4B) DMH6I4E MA Inhibitor DMH6I4E RN CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem. 2008 Jul;43(7):1349-59. DMH6I4E RU https://pubmed.ncbi.nlm.nih.gov/18082290 DMH6JI8 DI DMH6JI8 DMH6JI8 DN S-OOPP DMH6JI8 TI TTMN4HY DMH6JI8 TN N-acylethanolamine-hydrolyzing acidamidase (NAAA) DMH6JI8 MA Inhibitor DMH6JI8 RN Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20966-71. DMH6JI8 RU https://pubmed.ncbi.nlm.nih.gov/19926854 DMH6JOU DI DMH6JOU DMH6JOU DN H-Dmt-Tic-Gly-NH-CH2-Bid DMH6JOU TI TTKWM86 DMH6JOU TN Opioid receptor mu (MOP) DMH6JOU MA Inhibitor DMH6JOU RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DMH6JOU RU https://pubmed.ncbi.nlm.nih.gov/16789756 DMH6JOU DI DMH6JOU DMH6JOU DN H-Dmt-Tic-Gly-NH-CH2-Bid DMH6JOU TI TT27RFC DMH6JOU TN Opioid receptor delta (OPRD1) DMH6JOU MA Inhibitor DMH6JOU RN New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3. DMH6JOU RU https://pubmed.ncbi.nlm.nih.gov/16789756 DMH6LD0 DI DMH6LD0 DMH6LD0 DN 7alpha-hydroxycholesterol DMH6LD0 TI TTME5YJ DMH6LD0 TN EBV-induced G-protein coupled receptor 2 (GPR183) DMH6LD0 MA Agonist DMH6LD0 RN Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23. DMH6LD0 RU https://pubmed.ncbi.nlm.nih.gov/21796211 DMH6MVJ DI DMH6MVJ DMH6MVJ DN NIBR-0213 DMH6MVJ TI TT9JZCK DMH6MVJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMH6MVJ MA Antagonist DMH6MVJ RN A potent and selective S1P(1) antagonist with efficacy in experimental autoimmune encephalomyelitis. Chem Biol. 2012 Sep 21;19(9):1142-51. DMH6MVJ RU https://pubmed.ncbi.nlm.nih.gov/22999882 DMH6O4G DI DMH6O4G DMH6O4G DN N5-[4-Benzylphenyl]-L-glutamamide DMH6O4G TI TTXZEAJ DMH6O4G TN Leukotriene A-4 hydrolase (LTA4H) DMH6O4G MA Inhibitor DMH6O4G RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMH6O4G RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMH6OPI DI DMH6OPI DMH6OPI DN 4-Bromo-6-nitro-2-piperazin-1-yl-quinoline DMH6OPI TI TT3ROYC DMH6OPI TN Serotonin transporter (SERT) DMH6OPI MA Inhibitor DMH6OPI RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DMH6OPI RU https://pubmed.ncbi.nlm.nih.gov/11859009 DMH6QZO DI DMH6QZO DMH6QZO DN 4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid DMH6QZO TI TTHI19T DMH6QZO TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMH6QZO MA Inhibitor DMH6QZO RN N-aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of beta-lactamases. J Med Chem. 1988 Feb;31(2):370-4. DMH6QZO RU https://pubmed.ncbi.nlm.nih.gov/3257523 DMH6RDL DI DMH6RDL DMH6RDL DN 2,5-Bis-(3,4-dimethoxy-phenyl)-furan DMH6RDL TI TTZ97H5 DMH6RDL TN Phosphodiesterase 4A (PDE4A) DMH6RDL MA Inhibitor DMH6RDL RN Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6. DMH6RDL RU https://pubmed.ncbi.nlm.nih.gov/10091677 DMH6UN8 DI DMH6UN8 DMH6UN8 DN TCS-359 DMH6UN8 TI TTGJCWZ DMH6UN8 TN Fms-like tyrosine kinase 3 (FLT-3) DMH6UN8 MA Inhibitor DMH6UN8 RN Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3282-6. DMH6UN8 RU https://pubmed.ncbi.nlm.nih.gov/16580199 DMH6UOL DI DMH6UOL DMH6UOL DN G3139 + G-CSF DMH6UOL TI TTFOUV4 DMH6UOL TN BCL-2 messenger RNA (BCL2 mRNA) DMH6UOL RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMH6UOL RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMH6XTP DI DMH6XTP DMH6XTP DN L-Ala-L-boroPro DMH6XTP TI TTDIGC1 DMH6XTP TN Dipeptidyl peptidase 4 (DPP-4) DMH6XTP MA Inhibitor DMH6XTP RN Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8. DMH6XTP RU https://pubmed.ncbi.nlm.nih.gov/17458948 DMH6YVD DI DMH6YVD DMH6YVD DN ISC-4 DMH6YVD TI TTAZ05C DMH6YVD TN RAC-gamma serine/threonine-protein kinase (AKT3) DMH6YVD MA Inhibitor DMH6YVD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2286). DMH6YVD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2286 DMH70UC DI DMH70UC DMH70UC DN PMID19097784C2 DMH70UC TI TTIYVQP DMH70UC TN Polo-like kinase 1 (PLK1) DMH70UC MA Inhibitor DMH70UC RN Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21. DMH70UC RU https://pubmed.ncbi.nlm.nih.gov/19097784 DMH71N6 DI DMH71N6 DMH71N6 DN Sulfamic acid 3-(4-hydroxy-benzoyl)-phenyl ester DMH71N6 TI TTHM0R1 DMH71N6 TN Steryl-sulfatase (STS) DMH71N6 MA Inhibitor DMH71N6 RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMH71N6 RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMH720P DI DMH720P DMH720P DN VU0240382 DMH720P TI TTHS256 DMH720P TN Metabotropic glutamate receptor 5 (mGluR5) DMH720P MA Modulator (allosteric modulator) DMH720P RN Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol.2012 Feb;81(2):120-33. DMH720P RU https://pubmed.ncbi.nlm.nih.gov/22021324 DMH72MU DI DMH72MU DMH72MU DN 9-Hydroxy-7,8-benzoflavone DMH72MU TI TTSZLWK DMH72MU TN Aromatase (CYP19A1) DMH72MU MA Inhibitor DMH72MU RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMH72MU RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMH75AO DI DMH75AO DMH75AO DN 3-(4-Hydroxyphenyl)-7-isopropoxychromen-4-one DMH75AO TI TTZAYWL DMH75AO TN Estrogen receptor (ESR) DMH75AO MA Inhibitor DMH75AO RN Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26;53(16):6153-63. DMH75AO RU https://pubmed.ncbi.nlm.nih.gov/20669983 DMH76C5 DI DMH76C5 DMH76C5 DN 2-methoxy-1-naphthaldehyde thiosemicarbazone DMH76C5 TI TTEAID7 DMH76C5 TN Trypanosoma Cruzipain (Trypano CYSP) DMH76C5 MA Inhibitor DMH76C5 RN Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707. DMH76C5 RU https://pubmed.ncbi.nlm.nih.gov/12061873 DMH76SO DI DMH76SO DMH76SO DN 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione DMH76SO TI TTECBXN DMH76SO TN Oxysterols receptor LXR-alpha (NR1H3) DMH76SO MA Inhibitor DMH76SO RN Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61. DMH76SO RU https://pubmed.ncbi.nlm.nih.gov/17498949 DMH76SO DI DMH76SO DMH76SO DN 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione DMH76SO TI TTXA6PH DMH76SO TN Oxysterols receptor LXR-beta (NR1H2) DMH76SO MA Inhibitor DMH76SO RN Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61. DMH76SO RU https://pubmed.ncbi.nlm.nih.gov/17498949 DMH782V DI DMH782V DMH782V DN 7-Dimethylamino-hept-5-yn-2-one DMH782V TI TTQ3JTF DMH782V TN Muscarinic acetylcholine receptor M4 (CHRM4) DMH782V MA Inhibitor DMH782V RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMH782V RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMH782V DI DMH782V DMH782V DN 7-Dimethylamino-hept-5-yn-2-one DMH782V TI TTH18TF DMH782V TN Muscarinic acetylcholine receptor M5 (CHRM5) DMH782V MA Inhibitor DMH782V RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMH782V RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMH782V DI DMH782V DMH782V DN 7-Dimethylamino-hept-5-yn-2-one DMH782V TI TTYEG6Q DMH782V TN Muscarinic acetylcholine receptor M2 (CHRM2) DMH782V MA Inhibitor DMH782V RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMH782V RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMH782V DI DMH782V DMH782V DN 7-Dimethylamino-hept-5-yn-2-one DMH782V TI TTZ9SOR DMH782V TN Muscarinic acetylcholine receptor M1 (CHRM1) DMH782V MA Inhibitor DMH782V RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMH782V RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMH782V DI DMH782V DMH782V DN 7-Dimethylamino-hept-5-yn-2-one DMH782V TI TTQ13Z5 DMH782V TN Muscarinic acetylcholine receptor M3 (CHRM3) DMH782V MA Inhibitor DMH782V RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMH782V RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMH78QU DI DMH78QU DMH78QU DN 4-hydroxy-6-nitro-3-phenylquinolin-2(1H)-one DMH78QU TI TT7AOUD DMH78QU TN Fatty acid synthase (FASN) DMH78QU MA Inhibitor DMH78QU RN 3-Aryl-4-hydroxyquinolin-2(1H)-one derivatives as type I fatty acid synthase inhibitors. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4620-3. DMH78QU RU https://pubmed.ncbi.nlm.nih.gov/16784844 DMH791N DI DMH791N DMH791N DN D[Orn8(5/6C-Flu)]VT DMH791N TI TT4TFGN DMH791N TN Vasopressin V1a receptor (V1AR) DMH791N MA Inhibitor DMH791N RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMH791N RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMH791N DI DMH791N DMH791N DN D[Orn8(5/6C-Flu)]VT DMH791N TI TTSCIUP DMH791N TN Oxytocin receptor (OTR) DMH791N MA Inhibitor DMH791N RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMH791N RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMH791N DI DMH791N DMH791N DN D[Orn8(5/6C-Flu)]VT DMH791N TI TTL9MHW DMH791N TN Vasopressin V1b receptor (V1BR) DMH791N MA Inhibitor DMH791N RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMH791N RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMH798G DI DMH798G DMH798G DN 3-nitropropionate DMH798G TI TT58ZYW DMH798G TN Mycobacterium Isocitrate lyase (MycB icl) DMH798G MA Inhibitor DMH798G RN Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol. 2000 Aug;7(8):663-8. DMH798G RU https://pubmed.ncbi.nlm.nih.gov/10932251 DMH7A32 DI DMH7A32 DMH7A32 DN 3,3',3''-Thiene-2,3,5-triyltriphenol DMH7A32 TI TTIWB6L DMH7A32 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMH7A32 MA Inhibitor DMH7A32 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMH7A32 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMH7EWZ DI DMH7EWZ DMH7EWZ DN SCH-225336 DMH7EWZ TI TTMSFAW DMH7EWZ TN Cannabinoid receptor 2 (CB2) DMH7EWZ MA Inhibitor DMH7EWZ RN Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1565-8. DMH7EWZ RU https://pubmed.ncbi.nlm.nih.gov/20137936 DMH7FC9 DI DMH7FC9 DMH7FC9 DN 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide DMH7FC9 TI TTHS256 DMH7FC9 TN Metabotropic glutamate receptor 5 (mGluR5) DMH7FC9 MA Inhibitor DMH7FC9 RN Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. JMed Chem. 2004 Nov 18;47(24):5825-8. DMH7FC9 RU https://pubmed.ncbi.nlm.nih.gov/15537338 DMH7GLE DI DMH7GLE DMH7GLE DN ND-2158 DMH7GLE TI TTKFVXR DMH7GLE TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMH7GLE MA Inhibitor DMH7GLE RN Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015 Jan 8;58(1):96-110. DMH7GLE RU https://pubmed.ncbi.nlm.nih.gov/25479567 DMH7K0N DI DMH7K0N DMH7K0N DN 3-(trifluoromethyl)phenyl 4-butoxybenzylcarbamate DMH7K0N TI TTDP1UC DMH7K0N TN Fatty acid amide hydrolase (FAAH) DMH7K0N MA Inhibitor DMH7K0N RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMH7K0N RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMH7LDX DI DMH7LDX DMH7LDX DN FHT-2107 DMH7LDX TI TTGKNB4 DMH7LDX TN Epidermal growth factor receptor (EGFR) DMH7LDX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMH7LDX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMH7LPO DI DMH7LPO DMH7LPO DN ISIS 6186 DMH7LPO TI TT28ZON DMH7LPO TN H-ras messenger RNA (HRAS mRNA) DMH7LPO RN US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides. DMH7LPO RU http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true DMH7QOF DI DMH7QOF DMH7QOF DN N-[5-(Formyl-hydroxy-amino)-pentyl]-benzamide DMH7QOF TI TT5ZKDI DMH7QOF TN Histone deacetylase 6 (HDAC6) DMH7QOF MA Inhibitor DMH7QOF RN Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg Med Chem Lett. 2004 Jan 19;14(2):449-53. DMH7QOF RU https://pubmed.ncbi.nlm.nih.gov/14698179 DMH7QZ2 DI DMH7QZ2 DMH7QZ2 DN (S)-tacrine(10)-hupyridone DMH7QZ2 TI TT1RS9F DMH7QZ2 TN Acetylcholinesterase (AChE) DMH7QZ2 MA Inhibitor DMH7QZ2 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMH7QZ2 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMH7R6L DI DMH7R6L DMH7R6L DN LDC1267 DMH7R6L TI TTZPY6J DMH7R6L TN Tyrosine-protein kinase UFO (AXL) DMH7R6L MA Inhibitor DMH7R6L RN The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12. DMH7R6L RU https://pubmed.ncbi.nlm.nih.gov/24553136 DMH7R6L DI DMH7R6L DMH7R6L DN LDC1267 DMH7R6L TI TTIEMFN DMH7R6L TN TYRO3 tyrosine kinase receptor (TYRO3) DMH7R6L MA Inhibitor DMH7R6L RN The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12. DMH7R6L RU https://pubmed.ncbi.nlm.nih.gov/24553136 DMH7R6L DI DMH7R6L DMH7R6L DN LDC1267 DMH7R6L TI TTO7LKR DMH7R6L TN Tyrosine-protein kinase Mer (MERTK) DMH7R6L MA Inhibitor DMH7R6L RN The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014 Mar 27;507(7493):508-12. DMH7R6L RU https://pubmed.ncbi.nlm.nih.gov/24553136 DMH7RY0 DI DMH7RY0 DMH7RY0 DN 1-(4-(methylsulfonyl)phenyl)-3-phenylurea DMH7RY0 TI TT8NGED DMH7RY0 TN Prostaglandin G/H synthase 1 (COX-1) DMH7RY0 MA Inhibitor DMH7RY0 RN Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9. DMH7RY0 RU https://pubmed.ncbi.nlm.nih.gov/18226898 DMH7RY0 DI DMH7RY0 DMH7RY0 DN 1-(4-(methylsulfonyl)phenyl)-3-phenylurea DMH7RY0 TI TTVKILB DMH7RY0 TN Prostaglandin G/H synthase 2 (COX-2) DMH7RY0 MA Inhibitor DMH7RY0 RN Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9. DMH7RY0 RU https://pubmed.ncbi.nlm.nih.gov/18226898 DMH7SIX DI DMH7SIX DMH7SIX DN 5-Nitroindazole DMH7SIX TI TTF10I9 DMH7SIX TN Nitric-oxide synthase inducible (NOS2) DMH7SIX MA Inhibitor DMH7SIX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMH7SIX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMH7SIX DI DMH7SIX DMH7SIX DN 5-Nitroindazole DMH7SIX TI TTCM4B3 DMH7SIX TN Nitric-oxide synthase endothelial (NOS3) DMH7SIX MA Inhibitor DMH7SIX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMH7SIX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMH7TNA DI DMH7TNA DMH7TNA DN L-valyl-L-prolinamide DMH7TNA TI TTQ7R2V DMH7TNA TN Tripeptidyl-peptidase II (TPP2) DMH7TNA MA Inhibitor DMH7TNA RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMH7TNA RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMH7Z4L DI DMH7Z4L DMH7Z4L DN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide DMH7Z4L TI TT1MPAY DMH7Z4L TN GABA(A) receptor alpha-1 (GABRA1) DMH7Z4L MA Inhibitor DMH7Z4L RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMH7Z4L RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMH7Z4L DI DMH7Z4L DMH7Z4L DN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide DMH7Z4L TI TTZA1NY DMH7Z4L TN GABA(A) receptor beta-2 (GABRB2) DMH7Z4L MA Inhibitor DMH7Z4L RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMH7Z4L RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMH7Z4L DI DMH7Z4L DMH7Z4L DN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide DMH7Z4L TI TTNJYV2 DMH7Z4L TN Gamma-aminobutyric acid receptor (GAR) DMH7Z4L MA Inhibitor DMH7Z4L RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMH7Z4L RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMH7Z4L DI DMH7Z4L DMH7Z4L DN N-butyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide DMH7Z4L TI TT06RH5 DMH7Z4L TN GABA(A) receptor gamma-2 (GABRG2) DMH7Z4L MA Inhibitor DMH7Z4L RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMH7Z4L RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMH89O5 DI DMH89O5 DMH89O5 DN 2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol DMH89O5 TI TTW0CMT DMH89O5 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMH89O5 MA Inhibitor DMH89O5 RN Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. DMH89O5 RU https://pubmed.ncbi.nlm.nih.gov/20304642 DMH89TO DI DMH89TO DMH89TO DN 2,7-Bis[2-(propylamino)acetamido]anthraquinone DMH89TO TI TTQY2EJ DMH89TO TN TERT messenger RNA (TERT mRNA) DMH89TO MA Inhibitor DMH89TO RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMH89TO RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMH8QRI DI DMH8QRI DMH8QRI DN PMID19191557C32 DMH8QRI TI TTFQEO5 DMH8QRI TN Squalene synthetase (FDFT1) DMH8QRI MA Inhibitor DMH8QRI RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DMH8QRI RU https://pubmed.ncbi.nlm.nih.gov/19191557 DMH8QWY DI DMH8QWY DMH8QWY DN 2-oxo-N-phenyl-2H-chromene-3-carboxamide DMH8QWY TI TTGP7BY DMH8QWY TN Monoamine oxidase type B (MAO-B) DMH8QWY MA Inhibitor DMH8QWY RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMH8QWY RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMH8QWY DI DMH8QWY DMH8QWY DN 2-oxo-N-phenyl-2H-chromene-3-carboxamide DMH8QWY TI TT3WG5C DMH8QWY TN Monoamine oxidase type A (MAO-A) DMH8QWY MA Inhibitor DMH8QWY RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMH8QWY RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMH8VYM DI DMH8VYM DMH8VYM DN N5-[4-(N-Phenylamino)phenyl]-L-glutamine DMH8VYM TI TTXZEAJ DMH8VYM TN Leukotriene A-4 hydrolase (LTA4H) DMH8VYM MA Inhibitor DMH8VYM RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMH8VYM RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMH8WA2 DI DMH8WA2 DMH8WA2 DN 6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 TI TTZAYWL DMH8WA2 TN Estrogen receptor (ESR) DMH8WA2 MA Inhibitor DMH8WA2 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMH8WA2 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMH8WA2 DI DMH8WA2 DMH8WA2 DN 6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 TI TTXV4FI DMH8WA2 TN Albendazole monooxygenase (CYP3A4) DMH8WA2 MA Inhibitor DMH8WA2 RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DMH8WA2 RU https://pubmed.ncbi.nlm.nih.gov/18324762 DMH8WA2 DI DMH8WA2 DMH8WA2 DN 6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 TI TTIWB6L DMH8WA2 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMH8WA2 MA Inhibitor DMH8WA2 RN Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98. DMH8WA2 RU https://pubmed.ncbi.nlm.nih.gov/18630892 DMH8WA2 DI DMH8WA2 DMH8WA2 DN 6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 TI TTULVH8 DMH8WA2 TN Tyrosinase (TYR) DMH8WA2 MA Inhibitor DMH8WA2 RN Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4. DMH8WA2 RU https://pubmed.ncbi.nlm.nih.gov/17064896 DMH8WA2 DI DMH8WA2 DMH8WA2 DN 6-(3-Hydroxy-phenyl)-naphthalen-2-ol DMH8WA2 TI TTOM3J0 DMH8WA2 TN Estrogen receptor beta (ESR2) DMH8WA2 MA Inhibitor DMH8WA2 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMH8WA2 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMH8YMP DI DMH8YMP DMH8YMP DN PS-444035 DMH8YMP TI TTXMNHO DMH8YMP TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMH8YMP MA Inhibitor DMH8YMP RN Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20. DMH8YMP RU https://pubmed.ncbi.nlm.nih.gov/9873534 DMH908V DI DMH908V DMH908V DN 5-Bromomethyl-oxazolidin-(2Z)-ylideneamine DMH908V TI TTF10I9 DMH908V TN Nitric-oxide synthase inducible (NOS2) DMH908V MA Inhibitor DMH908V RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMH908V RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMH908V DI DMH908V DMH908V DN 5-Bromomethyl-oxazolidin-(2Z)-ylideneamine DMH908V TI TTZUFI5 DMH908V TN Nitric-oxide synthase brain (NOS1) DMH908V MA Inhibitor DMH908V RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMH908V RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMH96AI DI DMH96AI DMH96AI DN homo-AMPA DMH96AI TI TTWRP2F DMH96AI TN Metabotropic glutamate receptor 6 (mGluR6) DMH96AI MA Agonist DMH96AI RN A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl)butyric acid. J Med Chem. 1996 Aug 2;39(16):3188-94. DMH96AI RU https://pubmed.ncbi.nlm.nih.gov/8759641 DMH96UP DI DMH96UP DMH96UP DN ISIS 28466 DMH96UP TI TT0J32Z DMH96UP TN Smad7 messenger RNA (Smad7 mRNA) DMH96UP RN US patent application no. 6,159,697, Antisense modulation of Smad7 expression. DMH96UP RU http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true DMH971B DI DMH971B DMH971B DN V1A F/U DMH971B TI TT4TFGN DMH971B TN Vasopressin V1a receptor (V1AR) DMH971B MA Antagonist DMH971B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 366). DMH971B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=366 DMH9A4S DI DMH9A4S DMH9A4S DN ADS-103253 DMH9A4S TI TTX4RTB DMH9A4S TN Melanin-concentrating hormone receptor 1 (MCHR1) DMH9A4S MA Inhibitor DMH9A4S RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMH9A4S RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMH9A4S DI DMH9A4S DMH9A4S DN ADS-103253 DMH9A4S TI TTQ6VDM DMH9A4S TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMH9A4S MA Inhibitor DMH9A4S RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMH9A4S RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMH9A4S DI DMH9A4S DMH9A4S DN ADS-103253 DMH9A4S TI TT0K1SC DMH9A4S TN 5-HT 2B receptor (HTR2B) DMH9A4S MA Inhibitor DMH9A4S RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMH9A4S RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMH9O6V DI DMH9O6V DMH9O6V DN 1-Cyclohexyl-3-phenethyl-urea DMH9O6V TI TT7WVHI DMH9O6V TN Soluble epoxide hydrolase (EPHX2) DMH9O6V MA Inhibitor DMH9O6V RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMH9O6V RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMH9QAF DI DMH9QAF DMH9QAF DN RHODIOLININ DMH9QAF TI TT50QJ3 DMH9QAF TN Influenza Neuraminidase (Influ NA) DMH9QAF MA Inhibitor DMH9QAF RN Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23. DMH9QAF RU https://pubmed.ncbi.nlm.nih.gov/19729316 DMH9VLF DI DMH9VLF DMH9VLF DN 3-fluoro-5-(1,6-naphthyridin-7-yl)benzonitrile DMH9VLF TI TTHS256 DMH9VLF TN Metabotropic glutamate receptor 5 (mGluR5) DMH9VLF MA Inhibitor DMH9VLF RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMH9VLF RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMH9VMO DI DMH9VMO DMH9VMO DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-Gly-) DMH9VMO TI TTBID49 DMH9VMO TN C-X-C chemokine receptor type 4 (CXCR4) DMH9VMO MA Inhibitor DMH9VMO RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMH9VMO RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMH9WFD DI DMH9WFD DMH9WFD DN 1-Deoxy-Ribofuranose-5'-Phosphate DMH9WFD TI TTVNA43 DMH9WFD TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DMH9WFD MA Inhibitor DMH9WFD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMH9WFD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHA9S3 DI DMHA9S3 DMHA9S3 DN ANISOCOUMARIN H DMHA9S3 TI TTQW87Y DMHA9S3 TN Opioid receptor kappa (OPRK1) DMHA9S3 MA Inhibitor DMHA9S3 RN Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. DMHA9S3 RU https://pubmed.ncbi.nlm.nih.gov/18166466 DMHAE31 DI DMHAE31 DMHAE31 DN 2-(4-methoxy-benzyl)isoquinoline-1,3,4-trione DMHAE31 TI TTPF2QI DMHAE31 TN Caspase-3 (CASP3) DMHAE31 MA Inhibitor DMHAE31 RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMHAE31 RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMHAGSW DI DMHAGSW DMHAGSW DN N-(1H-Indol-2-ylmethyl)-N-(4-phenylbutyl)amine DMHAGSW TI TT3WG5C DMHAGSW TN Monoamine oxidase type A (MAO-A) DMHAGSW MA Inhibitor DMHAGSW RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMHAGSW RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMHAJ6W DI DMHAJ6W DMHAJ6W DN 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione DMHAJ6W TI TTLZS4Q DMHAJ6W TN M-phase inducer phosphatase 1 (MPIP1) DMHAJ6W MA Inhibitor DMHAJ6W RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMHAJ6W RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMHAJ6W DI DMHAJ6W DMHAJ6W DN 3-isopropyl-4-(phenylamino)naphthalene-1,2-dione DMHAJ6W TI TTR0SWN DMHAJ6W TN M-phase inducer phosphatase 2 (MPIP2) DMHAJ6W MA Inhibitor DMHAJ6W RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMHAJ6W RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMHAJC1 DI DMHAJC1 DMHAJC1 DN PU24S DMHAJC1 TI TT78R5H DMHAJC1 TN Heat shock protein 90 alpha (HSP90A) DMHAJC1 MA Inhibitor DMHAJC1 RN Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. DMHAJC1 RU https://pubmed.ncbi.nlm.nih.gov/18855578 DMHANU5 DI DMHANU5 DMHANU5 DN N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea DMHANU5 TI TTQW87Y DMHANU5 TN Opioid receptor kappa (OPRK1) DMHANU5 MA Inhibitor DMHANU5 RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMHANU5 RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMHANU5 DI DMHANU5 DMHANU5 DN N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea DMHANU5 TI TT27RFC DMHANU5 TN Opioid receptor delta (OPRD1) DMHANU5 MA Inhibitor DMHANU5 RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMHANU5 RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMHANU5 DI DMHANU5 DMHANU5 DN N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea DMHANU5 TI TTKWM86 DMHANU5 TN Opioid receptor mu (MOP) DMHANU5 MA Inhibitor DMHANU5 RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMHANU5 RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMHANXD DI DMHANXD DMHANXD DN 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine DMHANXD TI TTQBR95 DMHANXD TN Stress-activated protein kinase 2a (p38 alpha) DMHANXD MA Inhibitor DMHANXD RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMHANXD RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMHANXD DI DMHANXD DMHANXD DN 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine DMHANXD TI TT860QF DMHANXD TN LCK tyrosine protein kinase (LCK) DMHANXD MA Inhibitor DMHANXD RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMHANXD RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMHARQX DI DMHARQX DMHARQX DN C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 DMHARQX TI TTEOSZT DMHARQX TN Melanocortin receptor (MCR) DMHARQX MA Inhibitor DMHARQX RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMHARQX RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMHARQX DI DMHARQX DMHARQX DN C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 DMHARQX TI TTNI91K DMHARQX TN Melanocortin receptor 3 (MC3R) DMHARQX MA Inhibitor DMHARQX RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMHARQX RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMHARQX DI DMHARQX DMHARQX DN C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 DMHARQX TI TTD0CIQ DMHARQX TN Melanocortin receptor 4 (MC4R) DMHARQX MA Inhibitor DMHARQX RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMHARQX RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMHARQX DI DMHARQX DMHARQX DN C[CO-(CH2)2-CO-Nle-D-Nal(2)-Arg-Trp-Lys]-NH2 DMHARQX TI TT0MV2T DMHARQX TN Melanocortin receptor 1 (MC1R) DMHARQX MA Inhibitor DMHARQX RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMHARQX RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMHAS2B DI DMHAS2B DMHAS2B DN 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione DMHAS2B TI TTRA5BZ DMHAS2B TN Steroid 17-alpha-monooxygenase (S17AH) DMHAS2B MA Inhibitor DMHAS2B RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMHAS2B RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMHAS2B DI DMHAS2B DMHAS2B DN 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione DMHAS2B TI TTIQUX7 DMHAS2B TN Steroid 11-beta-hydroxylase (CYP11B1) DMHAS2B MA Inhibitor DMHAS2B RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMHAS2B RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMHAS3G DI DMHAS3G DMHAS3G DN 1-Adamantan-1-yl-3-(3-methoxy-phenyl)-urea DMHAS3G TI TT7WVHI DMHAS3G TN Soluble epoxide hydrolase (EPHX2) DMHAS3G MA Inhibitor DMHAS3G RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMHAS3G RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMHATCZ DI DMHATCZ DMHATCZ DN Tpl2 kinase inhibitor DMHATCZ TI TTGECUM DMHATCZ TN Cot oncogene messenger RNA (MAP3K8 mRNA) DMHATCZ MA Inhibitor DMHATCZ RN Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5288-92. DMHATCZ RU https://pubmed.ncbi.nlm.nih.gov/16165349 DMHAWMV DI DMHAWMV DMHAWMV DN ISIS 122991 DMHAWMV TI TTJZNIG DMHAWMV TN MEKK3 messenger RNA (MAP3K3 mRNA) DMHAWMV RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DMHAWMV RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DMHAWYJ DI DMHAWYJ DMHAWYJ DN GR 196429 DMHAWYJ TI TT0WAIE DMHAWYJ TN Melatonin receptor type 1A (MTNR1A) DMHAWYJ MA Agonist DMHAWYJ RN GR196429: a nonindolic agonist at high-affinity melatonin receptors. J Pharmacol Exp Ther. 1998 Jun;285(3):1239-45. DMHAWYJ RU https://pubmed.ncbi.nlm.nih.gov/9618428 DMHB1N6 DI DMHB1N6 DMHB1N6 DN 4'-(4-Nitrobenzensulfonamide)-4-hydroxychalcone DMHB1N6 TI TTULVH8 DMHB1N6 TN Tyrosinase (TYR) DMHB1N6 MA Inhibitor DMHB1N6 RN Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7. DMHB1N6 RU https://pubmed.ncbi.nlm.nih.gov/20149498 DMHB4PA DI DMHB4PA DMHB4PA DN 3-(1,2-dihydroacenaphthylen-5-yl)pyridine DMHB4PA TI TTIQUX7 DMHB4PA TN Steroid 11-beta-hydroxylase (CYP11B1) DMHB4PA MA Inhibitor DMHB4PA RN Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg Med Chem Lett. 2006 Jan 1;16(1):25-30. DMHB4PA RU https://pubmed.ncbi.nlm.nih.gov/16246562 DMHB6UY DI DMHB6UY DMHB6UY DN S-9947 DMHB6UY TI TTW0CMT DMHB6UY TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMHB6UY MA Blocker DMHB6UY RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMHB6UY RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMHBD1T DI DMHBD1T DMHBD1T DN 5-(2-hydroxyethyl)nonane-1,9-diol DMHBD1T TI TTQ9RYT DMHBD1T TN Endothelin-converting enzyme 1 (ECE1) DMHBD1T MA Inhibitor DMHBD1T RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHBD1T RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHBE0X DI DMHBE0X DMHBE0X DN 2-(2-Bromophenoxy)-N,N-dimethylethanamine DMHBE0X TI TTO9X1H DMHBE0X TN 5-HT 7 receptor (HTR7) DMHBE0X MA Inhibitor DMHBE0X RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DMHBE0X RU https://pubmed.ncbi.nlm.nih.gov/20138771 DMHBMJZ DI DMHBMJZ DMHBMJZ DN Textilinin DMHBMJZ TI TTP86E2 DMHBMJZ TN Plasminogen (PLG) DMHBMJZ MA Inhibitor DMHBMJZ RN Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86. DMHBMJZ RU https://pubmed.ncbi.nlm.nih.gov/23694890 DMHBO17 DI DMHBO17 DMHBO17 DN 4,6-dichloro-1H-indole-2,3-dione DMHBO17 TI TTMF541 DMHBO17 TN Liver carboxylesterase (CES1) DMHBO17 MA Inhibitor DMHBO17 RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMHBO17 RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMHBUG5 DI DMHBUG5 DMHBUG5 DN GSK-1344386B DMHBUG5 TI TTFZYTO DMHBUG5 TN C-C chemokine receptor type 2 (CCR2) DMHBUG5 MA Antagonist DMHBUG5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59). DMHBUG5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59 DMHBWM9 DI DMHBWM9 DMHBWM9 DN N-(4-Pyridin-2-yl-thiazol-2-yl)-benzamide DMHBWM9 TI TTM2AOE DMHBWM9 TN Adenosine A2a receptor (ADORA2A) DMHBWM9 MA Inhibitor DMHBWM9 RN Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62. DMHBWM9 RU https://pubmed.ncbi.nlm.nih.gov/11262085 DMHBYN5 DI DMHBYN5 DMHBYN5 DN NSC-745886 DMHBYN5 TI TTQY2EJ DMHBYN5 TN TERT messenger RNA (TERT mRNA) DMHBYN5 MA Inhibitor DMHBYN5 RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMHBYN5 RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMHBZ0N DI DMHBZ0N DMHBZ0N DN PMID23639540C13r DMHBZ0N TI TTP4520 DMHBZ0N TN TGF-beta receptor type I (TGFBR1) DMHBZ0N MA Inhibitor DMHBZ0N RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMHBZ0N RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMHBZ0N DI DMHBZ0N DMHBZ0N DN PMID23639540C13r DMHBZ0N TI TTJNBQA DMHBZ0N TN Activin receptor-like kinase 2 (ALK-2) DMHBZ0N MA Inhibitor DMHBZ0N RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMHBZ0N RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMHBZ0N DI DMHBZ0N DMHBZ0N DN PMID23639540C13r DMHBZ0N TI TTGKF90 DMHBZ0N TN Bone morphogenetic protein receptor (BMPR2) DMHBZ0N MA Inhibitor DMHBZ0N RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMHBZ0N RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMHBZ0N DI DMHBZ0N DMHBZ0N DN PMID23639540C13r DMHBZ0N TI TTGYPTC DMHBZ0N TN Activin receptor-like kinase-1 (ACVRL1) DMHBZ0N MA Inhibitor DMHBZ0N RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMHBZ0N RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMHBZ0N DI DMHBZ0N DMHBZ0N DN PMID23639540C13r DMHBZ0N TI TTPKHTZ DMHBZ0N TN Activin receptor type IB (ACVR1B) DMHBZ0N MA Inhibitor DMHBZ0N RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMHBZ0N RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMHC32M DI DMHC32M DMHC32M DN N8,2-dihydroxy-N1-phenyloctanediamide DMHC32M TI TTSHTOI DMHC32M TN Histone deacetylase 2 (HDAC2) DMHC32M MA Inhibitor DMHC32M RN Omega-alkoxy analogues of SAHA (vorinostat) as inhibitors of HDAC: a study of chain-length and stereochemical dependence. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6261-5. DMHC32M RU https://pubmed.ncbi.nlm.nih.gov/17892933 DMHC6KX DI DMHC6KX DMHC6KX DN [125I]S70254 DMHC6KX TI TT0WAIE DMHC6KX TN Melatonin receptor type 1A (MTNR1A) DMHC6KX MA Agonist DMHC6KX RN New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors. Int J Mol Sci. 2013 Apr 25;14(5):8948-62. DMHC6KX RU https://pubmed.ncbi.nlm.nih.gov/23698757 DMHC853 DI DMHC853 DMHC853 DN LY266500 DMHC853 TI TTYX5QR DMHC853 TN Pseudomonas Histidine kinase AlgR2 (Pseudo algQ) DMHC853 MA Inhibitor DMHC853 RN Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem. 2002 Apr;10(4):855-67. DMHC853 RU https://pubmed.ncbi.nlm.nih.gov/11836091 DMHCEOU DI DMHCEOU DMHCEOU DN PXS-4159 DMHCEOU TI TT7HC21 DMHCEOU TN Membrane copper amine oxidase (AOC3) DMHCEOU MA Inhibitor DMHCEOU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767). DMHCEOU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767 DMHCGBZ DI DMHCGBZ DMHCGBZ DN GNF-PF-1591 DMHCGBZ TI TTL53M6 DMHCGBZ TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMHCGBZ MA Inhibitor DMHCGBZ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMHCGBZ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMHCGIS DI DMHCGIS DMHCGIS DN EDN-OL1 DMHCGIS TI TTE4KHA DMHCGIS TN Amyloid beta A4 protein (APP) DMHCGIS MA Modulator DMHCGIS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMHCGIS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMHCVKJ DI DMHCVKJ DMHCVKJ DN 2-N-Methoxyamino-1-(4-methylthiophenyl)propane DMHCVKJ TI TT3ROYC DMHCVKJ TN Serotonin transporter (SERT) DMHCVKJ MA Inhibitor DMHCVKJ RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMHCVKJ RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMHCWY8 DI DMHCWY8 DMHCWY8 DN 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid DMHCWY8 TI TT2LVK8 DMHCWY8 TN Carbonic anhydrase IX (CA-IX) DMHCWY8 MA Inhibitor DMHCWY8 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMHCWY8 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMHCWY8 DI DMHCWY8 DMHCWY8 DN 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid DMHCWY8 TI TTEYTKG DMHCWY8 TN Carbonic anhydrase XIV (CA-XIV) DMHCWY8 MA Inhibitor DMHCWY8 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMHCWY8 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMHCWY8 DI DMHCWY8 DMHCWY8 DN 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid DMHCWY8 TI TTSYM0R DMHCWY8 TN Carbonic anhydrase XII (CA-XII) DMHCWY8 MA Inhibitor DMHCWY8 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMHCWY8 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMHCWY8 DI DMHCWY8 DMHCWY8 DN 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid DMHCWY8 TI TTUNARX DMHCWY8 TN Carbonic anhydrase (CA) DMHCWY8 MA Inhibitor DMHCWY8 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMHCWY8 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMHCWY8 DI DMHCWY8 DMHCWY8 DN 8-methoxy-2-oxo-2H-chromene-3-carboxylic acid DMHCWY8 TI TTHQPL7 DMHCWY8 TN Carbonic anhydrase I (CA-I) DMHCWY8 MA Inhibitor DMHCWY8 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMHCWY8 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMHCZP0 DI DMHCZP0 DMHCZP0 DN DPO-1 DMHCZP0 TI TTW0CMT DMHCZP0 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMHCZP0 MA Antagonist DMHCZP0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542). DMHCZP0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=542 DMHD1XM DI DMHD1XM DMHD1XM DN Trans,trans-1,3-bis-(4-hydroxycyclohexyl)urea DMHD1XM TI TT7WVHI DMHD1XM TN Soluble epoxide hydrolase (EPHX2) DMHD1XM MA Inhibitor DMHD1XM RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DMHD1XM RU https://pubmed.ncbi.nlm.nih.gov/17616115 DMHD6N7 DI DMHD6N7 DMHD6N7 DN FGGFTGARKSARKKWNQ DMHD6N7 TI TTNT7K8 DMHD6N7 TN Nociceptin receptor (OPRL1) DMHD6N7 MA Inhibitor DMHD6N7 RN Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. DMHD6N7 RU https://pubmed.ncbi.nlm.nih.gov/19577933 DMHD8UL DI DMHD8UL DMHD8UL DN PD-151307 DMHD8UL TI TT4FDG6 DMHD8UL TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMHD8UL MA Inhibitor DMHD8UL RN Synthesis of a series of 4-benzyloxyaniline analogues as neuronal N-type calcium channel blockers with improved anticonvulsant and analgesic proper... J Med Chem. 1999 Oct 7;42(20):4239-49. DMHD8UL RU https://pubmed.ncbi.nlm.nih.gov/10514294 DMHDB70 DI DMHDB70 DMHDB70 DN 4-amino-biphenyl-3-carboxylic acid amide DMHDB70 TI TTJ3E9X DMHDB70 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMHDB70 MA Inhibitor DMHDB70 RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DMHDB70 RU https://pubmed.ncbi.nlm.nih.gov/16686533 DMHDFZE DI DMHDFZE DMHDFZE DN 3-Amino-5-Phenylpentane DMHDFZE TI TTDZN01 DMHDFZE TN Cathepsin K (CTSK) DMHDFZE MA Inhibitor DMHDFZE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHDFZE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHDGB3 DI DMHDGB3 DMHDGB3 DN [3H]CCPA DMHDGB3 TI TTK25J1 DMHDGB3 TN Adenosine A1 receptor (ADORA1) DMHDGB3 MA Agonist DMHDGB3 RN Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9. DMHDGB3 RU https://pubmed.ncbi.nlm.nih.gov/9459566 DMHDGB3 DI DMHDGB3 DMHDGB3 DN [3H]CCPA DMHDGB3 TI TTNE7KG DMHDGB3 TN Adenosine A2b receptor (ADORA2B) DMHDGB3 MA Inhibitor DMHDGB3 RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMHDGB3 RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMHDGB3 DI DMHDGB3 DMHDGB3 DN [3H]CCPA DMHDGB3 TI TTM2AOE DMHDGB3 TN Adenosine A2a receptor (ADORA2A) DMHDGB3 MA Inhibitor DMHDGB3 RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMHDGB3 RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMHDGB3 DI DMHDGB3 DMHDGB3 DN [3H]CCPA DMHDGB3 TI TTJFY5U DMHDGB3 TN Adenosine A3 receptor (ADORA3) DMHDGB3 MA Inhibitor DMHDGB3 RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMHDGB3 RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMHDN25 DI DMHDN25 DMHDN25 DN 4-ethyl-3,4-dihydroquinazolin-2-amine DMHDN25 TI TTRUFDT DMHDN25 TN 5-HT 5A receptor (HTR5A) DMHDN25 MA Inhibitor DMHDN25 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMHDN25 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMHDWTS DI DMHDWTS DMHDWTS DN Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate DMHDWTS TI TTGP7BY DMHDWTS TN Monoamine oxidase type B (MAO-B) DMHDWTS MA Inhibitor DMHDWTS RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMHDWTS RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMHDWTS DI DMHDWTS DMHDWTS DN Phenyl 4-(4,5-dihydro-1H-imidazol-2-yl)benzoate DMHDWTS TI TT3WG5C DMHDWTS TN Monoamine oxidase type A (MAO-A) DMHDWTS MA Inhibitor DMHDWTS RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMHDWTS RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMHDYBN DI DMHDYBN DMHDYBN DN RS-102,221 DMHDYBN TI TTWJBZ5 DMHDYBN TN 5-HT 2C receptor (HTR2C) DMHDYBN MA Inhibitor DMHDYBN RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMHDYBN RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMHDZUO DI DMHDZUO DMHDZUO DN 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMHDZUO TI TTSZLWK DMHDZUO TN Aromatase (CYP19A1) DMHDZUO MA Inhibitor DMHDZUO RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMHDZUO RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMHDZUO DI DMHDZUO DMHDZUO DN 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMHDZUO TI TTIQUX7 DMHDZUO TN Steroid 11-beta-hydroxylase (CYP11B1) DMHDZUO MA Inhibitor DMHDZUO RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMHDZUO RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMHDZUO DI DMHDZUO DMHDZUO DN 4-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMHDZUO TI TTRA5BZ DMHDZUO TN Steroid 17-alpha-monooxygenase (S17AH) DMHDZUO MA Inhibitor DMHDZUO RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMHDZUO RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMHE7J5 DI DMHE7J5 DMHE7J5 DN 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMHE7J5 TI TTJQOD7 DMHE7J5 TN 5-HT 2A receptor (HTR2A) DMHE7J5 MA Inhibitor DMHE7J5 RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMHE7J5 RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMHE7J5 DI DMHE7J5 DMHE7J5 DN 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMHE7J5 TI TTGP7BY DMHE7J5 TN Monoamine oxidase type B (MAO-B) DMHE7J5 MA Inhibitor DMHE7J5 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMHE7J5 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMHE7J5 DI DMHE7J5 DMHE7J5 DN 8-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMHE7J5 TI TT3WG5C DMHE7J5 TN Monoamine oxidase type A (MAO-A) DMHE7J5 MA Inhibitor DMHE7J5 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMHE7J5 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMHED9G DI DMHED9G DMHED9G DN (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DMHED9G TI TT2NUT5 DMHED9G TN Adrenergic receptor alpha-2C (ADRA2C) DMHED9G MA Inhibitor DMHED9G RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMHED9G RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMHED9G DI DMHED9G DMHED9G DN (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DMHED9G TI TTWG9A4 DMHED9G TN Adrenergic receptor alpha-2A (ADRA2A) DMHED9G MA Inhibitor DMHED9G RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMHED9G RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMHED9G DI DMHED9G DMHED9G DN (3-Methyl-indol-1-yl)-propyl-pyridin-4-yl-amine DMHED9G TI TTWM4TY DMHED9G TN Adrenergic receptor alpha-2B (ADRA2B) DMHED9G MA Inhibitor DMHED9G RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMHED9G RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMHEIKQ DI DMHEIKQ DMHEIKQ DN 1-(3-(4-(2-fluoroethyl)phenoxy)propyl)piperidine DMHEIKQ TI TT9JNIC DMHEIKQ TN Histamine H3 receptor (H3R) DMHEIKQ MA Inhibitor DMHEIKQ RN Fluorinated non-imidazole histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2172-5. DMHEIKQ RU https://pubmed.ncbi.nlm.nih.gov/19286376 DMHEK4U DI DMHEK4U DMHEK4U DN ATS-907 DMHEK4U TI TTZN7RP DMHEK4U TN Rho-associated protein kinase 1 (ROCK1) DMHEK4U MA Inhibitor DMHEK4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503). DMHEK4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503 DMHEK4U DI DMHEK4U DMHEK4U DN ATS-907 DMHEK4U TI TTGWKQJ DMHEK4U TN Rho-associated protein kinase 2 (ROCK2) DMHEK4U MA Inhibitor DMHEK4U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504). DMHEK4U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TT50QJ3 DMHEMUB TN Influenza Neuraminidase (Influ NA) DMHEMUB MA Inhibitor DMHEMUB RN Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/19729316 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTSJ6Q4 DMHEMUB TN LOX-5 messenger RNA (ALOX5 mRNA) DMHEMUB MA Inhibitor DMHEMUB RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/17378609 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTN9T81 DMHEMUB TN Arachidonate 15-lipoxygenase (15-LOX) DMHEMUB MA Inhibitor DMHEMUB RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/17378609 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTFBNVI DMHEMUB TN Aldose reductase (AKR1B1) DMHEMUB MA Inhibitor DMHEMUB RN Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/18298080 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTV9A7R DMHEMUB TN Lactoylglutathione lyase (GLO1) DMHEMUB MA Inhibitor DMHEMUB RN Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects. Bioorg Med Chem. 2008 Apr 1;16(7):3969-75. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/18258440 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTBE4IR DMHEMUB TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMHEMUB MA Inhibitor DMHEMUB RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTI84H7 DMHEMUB TN Cytochrome P450 1B1 (CYP1B1) DMHEMUB MA Inhibitor DMHEMUB RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTIWB6L DMHEMUB TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMHEMUB MA Inhibitor DMHEMUB RN Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/18533708 DMHEMUB DI DMHEMUB DMHEMUB DN Kaempferol DMHEMUB TI TTKPW01 DMHEMUB TN Androgen receptor messenger RNA (AR mRNA) DMHEMUB MA Inhibitor DMHEMUB RN Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. DMHEMUB RU https://pubmed.ncbi.nlm.nih.gov/19592245 DMHEOBY DI DMHEOBY DMHEOBY DN KIN-3031 DMHEOBY TI TTKWM86 DMHEOBY TN Opioid receptor mu (MOP) DMHEOBY MA Modulator DMHEOBY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMHEOBY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMHEQ41 DI DMHEQ41 DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide DMHEQ41 TI TTBH0VX DMHEQ41 TN Histone deacetylase (HDAC) DMHEQ41 MA Inhibitor DMHEQ41 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMHEQ41 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMHEQ41 DI DMHEQ41 DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide DMHEQ41 TI TTTQGH8 DMHEQ41 TN Histone deacetylase 4 (HDAC4) DMHEQ41 MA Inhibitor DMHEQ41 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMHEQ41 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMHEQ41 DI DMHEQ41 DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide DMHEQ41 TI TT6R7JZ DMHEQ41 TN Histone deacetylase 1 (HDAC1) DMHEQ41 MA Inhibitor DMHEQ41 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMHEQ41 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMHEQ41 DI DMHEQ41 DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide DMHEQ41 TI TT5ZKDI DMHEQ41 TN Histone deacetylase 6 (HDAC6) DMHEQ41 MA Inhibitor DMHEQ41 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMHEQ41 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMHEQ41 DI DMHEQ41 DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide DMHEQ41 TI TTT6LFV DMHEQ41 TN Histone deacetylase 8 (HDAC8) DMHEQ41 MA Inhibitor DMHEQ41 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMHEQ41 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMHEQ41 DI DMHEQ41 DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide DMHEQ41 TI TTYHPU6 DMHEQ41 TN Histone deacetylase 10 (HDAC10) DMHEQ41 MA Inhibitor DMHEQ41 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMHEQ41 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMHEQ41 DI DMHEQ41 DMHEQ41 DN N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide DMHEQ41 TI TTSHTOI DMHEQ41 TN Histone deacetylase 2 (HDAC2) DMHEQ41 MA Inhibitor DMHEQ41 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMHEQ41 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMHETY7 DI DMHETY7 DMHETY7 DN SK&F-106686 DMHETY7 TI TT34BHT DMHETY7 TN Adrenergic receptor alpha-1D (ADRA1D) DMHETY7 MA Inhibitor DMHETY7 RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMHETY7 RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMHETY7 DI DMHETY7 DMHETY7 DN SK&F-106686 DMHETY7 TI TTNGILX DMHETY7 TN Adrenergic receptor alpha-1A (ADRA1A) DMHETY7 MA Inhibitor DMHETY7 RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMHETY7 RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMHETY7 DI DMHETY7 DMHETY7 DN SK&F-106686 DMHETY7 TI TTBRKXS DMHETY7 TN Adrenergic receptor alpha-1B (ADRA1B) DMHETY7 MA Inhibitor DMHETY7 RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMHETY7 RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMHETZN DI DMHETZN DMHETZN DN F-18 exendin-4 derivative PET tracers DMHETZN TI TTVIMDE DMHETZN TN Glucagon-like peptide 1 receptor (GLP1R) DMHETZN MA Modulator DMHETZN RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DMHETZN RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DMHEV75 DI DMHEV75 DMHEV75 DN Preclamol DMHEV75 TI TTEX248 DMHEV75 TN Dopamine D2 receptor (D2R) DMHEV75 MA Inhibitor DMHEV75 RN Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22. DMHEV75 RU https://pubmed.ncbi.nlm.nih.gov/1968512 DMHEYOK DI DMHEYOK DMHEYOK DN (1'H-Phenothiazin-1'-yl)(piperidin-1-yl)methanone DMHEYOK TI TTEB0GD DMHEYOK TN Cholinesterase (BCHE) DMHEYOK MA Inhibitor DMHEYOK RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMHEYOK RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMHF01G DI DMHF01G DMHF01G DN (3-Bromobenzoylpyridine)thiosemicarbazone DMHF01G TI TT36ETB DMHF01G TN Cathepsin L (CTSL) DMHF01G MA Inhibitor DMHF01G RN Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5. DMHF01G RU https://pubmed.ncbi.nlm.nih.gov/20933415 DMHFCZA DI DMHFCZA DMHFCZA DN Tylophorinidine DMHFCZA TI TT9SL3Q DMHFCZA TN Polypeptide deformylase (PDF) DMHFCZA MA Inhibitor DMHFCZA RN Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol In Vitro. 2000 Feb;14(1):53-9. DMHFCZA RU https://pubmed.ncbi.nlm.nih.gov/10699361 DMHFGMQ DI DMHFGMQ DMHFGMQ DN 2-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridine DMHFGMQ TI TTZL0OI DMHFGMQ TN Methionine aminopeptidase 2 (METAP2) DMHFGMQ MA Inhibitor DMHFGMQ RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMHFGMQ RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMHFKUC DI DMHFKUC DMHFKUC DN RU90395 DMHFKUC TI TT6PKBN DMHFKUC TN Proto-oncogene c-Src (SRC) DMHFKUC MA Inhibitor DMHFKUC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHFKUC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHFPE3 DI DMHFPE3 DMHFPE3 DN N-(8-(3-cyanophenyl)-9H-purin-6-yl)pentanamide DMHFPE3 TI TTRSMW9 DMHFPE3 TN Glycogen synthase kinase-3 beta (GSK-3B) DMHFPE3 MA Inhibitor DMHFPE3 RN Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93. DMHFPE3 RU https://pubmed.ncbi.nlm.nih.gov/20472330 DMHFPRJ DI DMHFPRJ DMHFPRJ DN A-796260 DMHFPRJ TI TT6OEDT DMHFPRJ TN Cannabinoid receptor 1 (CB1) DMHFPRJ MA Inhibitor DMHFPRJ RN Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315. DMHFPRJ RU https://pubmed.ncbi.nlm.nih.gov/19921781 DMHFPRJ DI DMHFPRJ DMHFPRJ DN A-796260 DMHFPRJ TI TTMSFAW DMHFPRJ TN Cannabinoid receptor 2 (CB2) DMHFPRJ MA Inhibitor DMHFPRJ RN Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315. DMHFPRJ RU https://pubmed.ncbi.nlm.nih.gov/19921781 DMHFYK2 DI DMHFYK2 DMHFYK2 DN N,N'-(1',8'-octylene)-bis-(-)-nor-MEP DMHFYK2 TI TT1RS9F DMHFYK2 TN Acetylcholinesterase (AChE) DMHFYK2 MA Inhibitor DMHFYK2 RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMHFYK2 RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMHFYK2 DI DMHFYK2 DMHFYK2 DN N,N'-(1',8'-octylene)-bis-(-)-nor-MEP DMHFYK2 TI TTEB0GD DMHFYK2 TN Cholinesterase (BCHE) DMHFYK2 MA Inhibitor DMHFYK2 RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMHFYK2 RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMHFYNE DI DMHFYNE DMHFYNE DN AG-014376 DMHFYNE TI TTVDSZ0 DMHFYNE TN Poly [ADP-ribose] polymerase 1 (PARP1) DMHFYNE MA Inhibitor DMHFYNE RN Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem. 2004 Oct 21;47(22):5467-81. DMHFYNE RU https://pubmed.ncbi.nlm.nih.gov/15481984 DMHG2TB DI DMHG2TB DMHG2TB DN FGGFTGARKSARKKANQ DMHG2TB TI TTNT7K8 DMHG2TB TN Nociceptin receptor (OPRL1) DMHG2TB MA Inhibitor DMHG2TB RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMHG2TB RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMHG54F DI DMHG54F DMHG54F DN AL4623 DMHG54F TI TTANPDJ DMHG54F TN Carbonic anhydrase II (CA-II) DMHG54F MA Inhibitor DMHG54F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHG54F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHG7MU DI DMHG7MU DMHG7MU DN (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone DMHG7MU TI TTWN3F4 DMHG7MU TN Presenilin 2 (PSEN2) DMHG7MU MA Inhibitor DMHG7MU RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMHG7MU RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMHG7MU DI DMHG7MU DMHG7MU DN (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone DMHG7MU TI TTZ3S8C DMHG7MU TN Presenilin 1 (PSEN1) DMHG7MU MA Inhibitor DMHG7MU RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMHG7MU RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMHG7MU DI DMHG7MU DMHG7MU DN (5R,6S)-6-(benzyloxy)-5-methoxycyclohex-2-enone DMHG7MU TI TT9W8GU DMHG7MU TN Gamma-secretase (GS) DMHG7MU MA Inhibitor DMHG7MU RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMHG7MU RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMHGIB1 DI DMHGIB1 DMHGIB1 DN NSC-126445 DMHGIB1 TI TT9NVXQ DMHGIB1 TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMHGIB1 MA Inhibitor DMHGIB1 RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMHGIB1 RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMHGQRF DI DMHGQRF DMHGQRF DN 5-Hex-5-enyl-2-nonyl-3,4-dihydro-2H-pyrrole DMHGQRF TI TT1RS9F DMHGQRF TN Acetylcholinesterase (AChE) DMHGQRF MA Inhibitor DMHGQRF RN Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995). DMHGQRF RU http://www.sciencedirect.com/science/article/pii/0960894X9500179W DMHGRPB DI DMHGRPB DMHGRPB DN 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL DMHGRPB TI TTZAYWL DMHGRPB TN Estrogen receptor (ESR) DMHGRPB MA Inhibitor DMHGRPB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHGRPB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHGX1N DI DMHGX1N DMHGX1N DN C75 DMHGX1N TI TT7AOUD DMHGX1N TN Fatty acid synthase (FASN) DMHGX1N MA Inhibitor DMHGX1N RN C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. DMHGX1N RU https://pubmed.ncbi.nlm.nih.gov/12060712 DMHGX1N DI DMHGX1N DMHGX1N DN C75 DMHGX1N TI TTDL0NY DMHGX1N TN Carnitine O-palmitoyltransferase I (CPT1B) DMHGX1N MA Activator DMHGX1N RN C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity. Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9498-502. DMHGX1N RU https://pubmed.ncbi.nlm.nih.gov/12060712 DMHGXPY DI DMHGXPY DMHGXPY DN N-(6-chloro-1H-indazol-3-yl)butyramide DMHGXPY TI TTRSMW9 DMHGXPY TN Glycogen synthase kinase-3 beta (GSK-3B) DMHGXPY MA Inhibitor DMHGXPY RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMHGXPY RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMHI0UL DI DMHI0UL DMHI0UL DN Cyclo(-D-MeTyr-L-Arg-L-Arg-L-Nal-Gly-) DMHI0UL TI TTBID49 DMHI0UL TN C-X-C chemokine receptor type 4 (CXCR4) DMHI0UL MA Inhibitor DMHI0UL RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMHI0UL RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMHI4Y6 DI DMHI4Y6 DMHI4Y6 DN N-(2,4-Dichloro-benzoyl)-benzenesulfonamide DMHI4Y6 TI TTDCBX5 DMHI4Y6 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMHI4Y6 MA Inhibitor DMHI4Y6 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMHI4Y6 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMHI4Y6 DI DMHI4Y6 DMHI4Y6 DN N-(2,4-Dichloro-benzoyl)-benzenesulfonamide DMHI4Y6 TI TT1VAUK DMHI4Y6 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMHI4Y6 MA Inhibitor DMHI4Y6 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMHI4Y6 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMHI4Y6 DI DMHI4Y6 DMHI4Y6 DN N-(2,4-Dichloro-benzoyl)-benzenesulfonamide DMHI4Y6 TI TTUTJGQ DMHI4Y6 TN Vascular endothelial growth factor receptor 2 (KDR) DMHI4Y6 MA Inhibitor DMHI4Y6 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMHI4Y6 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMHI50W DI DMHI50W DMHI50W DN 4-(Indan-1-ylsulfanyl)-phenylamine DMHI50W TI TTJS8PY DMHI50W TN 5-HT 6 receptor (HTR6) DMHI50W MA Inhibitor DMHI50W RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DMHI50W RU https://pubmed.ncbi.nlm.nih.gov/15808453 DMHI7Y2 DI DMHI7Y2 DMHI7Y2 DN 5alpha-Androstan-3,17-Dione DMHI7Y2 TI TTZT9R2 DMHI7Y2 TN Hydroxysteroid dehydrogenase 3-beta (HSD3B) DMHI7Y2 MA Inhibitor DMHI7Y2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHI7Y2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHI7Y2 DI DMHI7Y2 DMHI7Y2 DN 5alpha-Androstan-3,17-Dione DMHI7Y2 TI TTIWB6L DMHI7Y2 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMHI7Y2 MA Inhibitor DMHI7Y2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHI7Y2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHI8C9 DI DMHI8C9 DMHI8C9 DN PD-157672 DMHI8C9 TI TTBPGLU DMHI8C9 TN Neuromedin-K receptor (TACR3) DMHI8C9 MA Inhibitor DMHI8C9 RN The rational development of small molecule tachykinin NK3 receptor selective antagonists - the utilisation of a dipeptide chemical library in drug design, Bioorg. Med. Chem. Lett. 4(14):1679-1684 (1994). DMHI8C9 RU http://www.sciencedirect.com/science/article/pii/S0960894X00803601 DMHI9ZJ DI DMHI9ZJ DMHI9ZJ DN DL-benzylsuccinic acid DMHI9ZJ TI TT3LJ6G DMHI9ZJ TN Carboxypeptidase A1 (CPA1) DMHI9ZJ MA Inhibitor DMHI9ZJ RN A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71. DMHI9ZJ RU https://pubmed.ncbi.nlm.nih.gov/19386397 DMHI9ZJ DI DMHI9ZJ DMHI9ZJ DN DL-benzylsuccinic acid DMHI9ZJ TI TTP18AY DMHI9ZJ TN Carboxypeptidase B2 (CPB2) DMHI9ZJ MA Inhibitor DMHI9ZJ RN A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71. DMHI9ZJ RU https://pubmed.ncbi.nlm.nih.gov/19386397 DMHIDY6 DI DMHIDY6 DMHIDY6 DN 4-(Pent-3-ylamino)-1-naphthol DMHIDY6 TI TTZJYKH DMHIDY6 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMHIDY6 MA Inhibitor DMHIDY6 RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMHIDY6 RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMHIG9K DI DMHIG9K DMHIG9K DN Beta-D-Mannose DMHIG9K TI TTEB0GD DMHIG9K TN Cholinesterase (BCHE) DMHIG9K MA Inhibitor DMHIG9K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHIG9K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHIG9K DI DMHIG9K DMHIG9K DN Beta-D-Mannose DMHIG9K TI TTEYTKG DMHIG9K TN Carbonic anhydrase XIV (CA-XIV) DMHIG9K MA Inhibitor DMHIG9K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHIG9K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHIG9K DI DMHIG9K DMHIG9K DN Beta-D-Mannose DMHIG9K TI TT8NGED DMHIG9K TN Prostaglandin G/H synthase 1 (COX-1) DMHIG9K MA Inhibitor DMHIG9K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHIG9K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHIG9K DI DMHIG9K DMHIG9K DN Beta-D-Mannose DMHIG9K TI TTH0KSX DMHIG9K TN Rhodopsin (RHO) DMHIG9K MA Inhibitor DMHIG9K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHIG9K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHIG9K DI DMHIG9K DMHIG9K DN Beta-D-Mannose DMHIG9K TI TT50QJ3 DMHIG9K TN Influenza Neuraminidase (Influ NA) DMHIG9K MA Inhibitor DMHIG9K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHIG9K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHIGDM DI DMHIGDM DMHIGDM DN Benzylserine DMHIGDM TI TTF7WRM DMHIGDM TN Alanine/serine/cysteine transporter 2 (SLC1A5) DMHIGDM MA Inhibitor DMHIGDM RN New inhibitors for the neutral amino acid transporter ASCT2 reveal its Na+-dependent anion leak. J Physiol. 2004 Jun 15;557(Pt 3):747-59. DMHIGDM RU https://pubmed.ncbi.nlm.nih.gov/15107471 DMHIKD2 DI DMHIKD2 DMHIKD2 DN (+/-)-threo-N-(4-Methoxybenzyl)methylphenidate DMHIKD2 TI TTVBI8W DMHIKD2 TN Dopamine transporter (DAT) DMHIKD2 MA Inhibitor DMHIKD2 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMHIKD2 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMHIM6N DI DMHIM6N DMHIM6N DN NE58062 DMHIM6N TI TTIKWV4 DMHIM6N TN Geranyltranstransferase (FDPS) DMHIM6N MA Inhibitor DMHIM6N RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMHIM6N RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMHINE0 DI DMHINE0 DMHINE0 DN N(6)-cyclohexyladenosine DMHINE0 TI TTK25J1 DMHINE0 TN Adenosine A1 receptor (ADORA1) DMHINE0 MA Agonist DMHINE0 RN Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology. 1993;46(2):91-100. DMHINE0 RU https://pubmed.ncbi.nlm.nih.gov/8441759 DMHINE0 DI DMHINE0 DMHINE0 DN N(6)-cyclohexyladenosine DMHINE0 TI TTNE7KG DMHINE0 TN Adenosine A2b receptor (ADORA2B) DMHINE0 MA Agonist DMHINE0 RN Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91. DMHINE0 RU https://pubmed.ncbi.nlm.nih.gov/6253037 DMHINE0 DI DMHINE0 DMHINE0 DN N(6)-cyclohexyladenosine DMHINE0 TI TTJFY5U DMHINE0 TN Adenosine A3 receptor (ADORA3) DMHINE0 MA Agonist DMHINE0 RN Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol. 1996 May 1;156(9):3435-42. DMHINE0 RU https://pubmed.ncbi.nlm.nih.gov/8617970 DMHINWF DI DMHINWF DMHINWF DN 3-Benzyl-3-methyl-1-phenylazetidine-2,4-dione DMHINWF TI TTPLTSQ DMHINWF TN Neutrophil elastase (NE) DMHINWF MA Inhibitor DMHINWF RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMHINWF RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMHISM2 DI DMHISM2 DMHISM2 DN 3-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMHISM2 TI TTRA5BZ DMHISM2 TN Steroid 17-alpha-monooxygenase (S17AH) DMHISM2 MA Inhibitor DMHISM2 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMHISM2 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMHITF8 DI DMHITF8 DMHITF8 DN 6-methoxy-2-methyl-9H-beta-carbolin-2-ium DMHITF8 TI TT1RS9F DMHITF8 TN Acetylcholinesterase (AChE) DMHITF8 MA Inhibitor DMHITF8 RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMHITF8 RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMHITF8 DI DMHITF8 DMHITF8 DN 6-methoxy-2-methyl-9H-beta-carbolin-2-ium DMHITF8 TI TTEB0GD DMHITF8 TN Cholinesterase (BCHE) DMHITF8 MA Inhibitor DMHITF8 RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMHITF8 RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMHIW2L DI DMHIW2L DMHIW2L DN ALBANOL A DMHIW2L TI TTSZLWK DMHIW2L TN Aromatase (CYP19A1) DMHIW2L MA Inhibitor DMHIW2L RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DMHIW2L RU https://pubmed.ncbi.nlm.nih.gov/11678652 DMHIYB3 DI DMHIYB3 DMHIYB3 DN 1-(1,3,4-Oxadiazol-2-yl)-7-phenylheptan-1-one DMHIYB3 TI TTDP1UC DMHIYB3 TN Fatty acid amide hydrolase (FAAH) DMHIYB3 MA Inhibitor DMHIYB3 RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMHIYB3 RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMHJ0SV DI DMHJ0SV DMHJ0SV DN 3-(6-fluoroquinazolin-4-ylamino)benzonitrile DMHJ0SV TI TTHS256 DMHJ0SV TN Metabotropic glutamate receptor 5 (mGluR5) DMHJ0SV MA Inhibitor DMHJ0SV RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMHJ0SV RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMHJ2IP DI DMHJ2IP DMHJ2IP DN N2-{4-[(3-chlorobenzyl)oxy]benzyl}glycinamide DMHJ2IP TI TTGP7BY DMHJ2IP TN Monoamine oxidase type B (MAO-B) DMHJ2IP MA Inhibitor DMHJ2IP RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMHJ2IP RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMHJ47A DI DMHJ47A DMHJ47A DN MRS-2160 DMHJ47A TI TT1NLOA DMHJ47A TN P2X purinoceptor 4 (P2RX4) DMHJ47A MA Inhibitor DMHJ47A RN Purine and pyrimidine (P2) receptors as drug targets. J Med Chem. 2002 Sep 12;45(19):4057-93. DMHJ47A RU https://pubmed.ncbi.nlm.nih.gov/12213051 DMHJ6TU DI DMHJ6TU DMHJ6TU DN 7-Allyl-1,3-dipropyl-3,7-dihydro-purine-2,6-dione DMHJ6TU TI TTM2AOE DMHJ6TU TN Adenosine A2a receptor (ADORA2A) DMHJ6TU MA Inhibitor DMHJ6TU RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DMHJ6TU RU https://pubmed.ncbi.nlm.nih.gov/3806581 DMHJCN6 DI DMHJCN6 DMHJCN6 DN ML-18 DMHJCN6 TI TTHYDUM DMHJCN6 TN Bombesin receptor (BS) DMHJCN6 MA Antagonist DMHJCN6 RN ML-18 is a non-peptide bombesin receptor subtype-3 antagonist which inhibits lung cancer growth. Peptides. 2015 Feb;64:55-61. DMHJCN6 RU https://pubmed.ncbi.nlm.nih.gov/25554218 DMHJEQL DI DMHJEQL DMHJEQL DN [Asp6,Lys10]N/OFQ(1-13)NH2 DMHJEQL TI TTNT7K8 DMHJEQL TN Nociceptin receptor (OPRL1) DMHJEQL MA Inhibitor DMHJEQL RN High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7. DMHJEQL RU https://pubmed.ncbi.nlm.nih.gov/18624395 DMHJG5N DI DMHJG5N DMHJG5N DN (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine DMHJG5N TI TT1MPAY DMHJG5N TN GABA(A) receptor alpha-1 (GABRA1) DMHJG5N MA Inhibitor DMHJG5N RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMHJG5N RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMHJG5N DI DMHJG5N DMHJG5N DN (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine DMHJG5N TI TTNJYV2 DMHJG5N TN Gamma-aminobutyric acid receptor (GAR) DMHJG5N MA Inhibitor DMHJG5N RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMHJG5N RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMHJG5N DI DMHJG5N DMHJG5N DN (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine DMHJG5N TI TT06RH5 DMHJG5N TN GABA(A) receptor gamma-2 (GABRG2) DMHJG5N MA Inhibitor DMHJG5N RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMHJG5N RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMHJG5N DI DMHJG5N DMHJG5N DN (9-Benzyl-9H-purin-6-yl)-cyclopropyl-amine DMHJG5N TI TTZA1NY DMHJG5N TN GABA(A) receptor beta-2 (GABRB2) DMHJG5N MA Inhibitor DMHJG5N RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMHJG5N RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMHJIN0 DI DMHJIN0 DMHJIN0 DN 6-Chloro-4-morpholin-4-yl-chromen-2-one DMHJIN0 TI TTK3PY9 DMHJIN0 TN DNA-dependent protein kinase catalytic (PRKDC) DMHJIN0 MA Inhibitor DMHJIN0 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMHJIN0 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMHJL58 DI DMHJL58 DMHJL58 DN [125I]iodoaminopotentidine DMHJL58 TI TTQHJ1K DMHJL58 TN Histamine H2 receptor (H2R) DMHJL58 MA Antagonist DMHJL58 RN G proteins of the Gq family couple the H2 histamine receptor to phospholipase C. Mol Endocrinol. 1996 Dec;10(12):1697-707. DMHJL58 RU https://pubmed.ncbi.nlm.nih.gov/8961278 DMHJM0B DI DMHJM0B DMHJM0B DN trans-2-methylcrotonic acid DMHJM0B TI TT0FYAN DMHJM0B TN Free fatty acid receptor 2 (FFAR2) DMHJM0B MA Agonist DMHJM0B RN Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. J Biol Chem. 2011 Mar 25;286(12):10628-40. DMHJM0B RU https://pubmed.ncbi.nlm.nih.gov/21220428 DMHJM0F DI DMHJM0F DMHJM0F DN 227Th-rituximab DMHJM0F TI TTUE541 DMHJM0F TN Leukocyte surface antigen Leu-16 (CD20) DMHJM0F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DMHJM0F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DMHJMTI DI DMHJMTI DMHJMTI DN N-isopropyl estradiol-16-methyl carboxamide DMHJMTI TI TTIWB6L DMHJMTI TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMHJMTI MA Inhibitor DMHJMTI RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMHJMTI RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMHJMUX DI DMHJMUX DMHJMUX DN 2-(2-Bromophenylthio)-N,N-dimethylethanamine DMHJMUX TI TTO9X1H DMHJMUX TN 5-HT 7 receptor (HTR7) DMHJMUX MA Inhibitor DMHJMUX RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DMHJMUX RU https://pubmed.ncbi.nlm.nih.gov/20138771 DMHJOBQ DI DMHJOBQ DMHJOBQ DN N-(2,4-dichlorophenyl)-4-methyl-3-nitrobenzamide DMHJOBQ TI TTVTX4N DMHJOBQ TN Bacterial Fatty acid synthetase I (Bact inhA) DMHJOBQ MA Inhibitor DMHJOBQ RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMHJOBQ RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMHJTLW DI DMHJTLW DMHJTLW DN 3-methoxyphenylboronic acid DMHJTLW TI TTDP1UC DMHJTLW TN Fatty acid amide hydrolase (FAAH) DMHJTLW MA Inhibitor DMHJTLW RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMHJTLW RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMHJU7A DI DMHJU7A DMHJU7A DN GSK-LSD1 DMHJU7A TI TTNR0UQ DMHJU7A TN Lysine-specific histone demethylase 1 (LSD) DMHJU7A MA Inhibitor DMHJU7A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2669). DMHJU7A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2669 DMHK0F6 DI DMHK0F6 DMHK0F6 DN NSC-106970 DMHK0F6 TI TTML2WA DMHK0F6 TN Tubulin (TUB) DMHK0F6 MA Inhibitor DMHK0F6 RN Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8. DMHK0F6 RU https://pubmed.ncbi.nlm.nih.gov/9632366 DMHK0F6 DI DMHK0F6 DMHK0F6 DN NSC-106970 DMHK0F6 TI TTYFKSZ DMHK0F6 TN Tubulin beta (TUBB) DMHK0F6 MA Inhibitor DMHK0F6 RN Structure-activity requirements for flavone cytotoxicity and binding to tubulin. J Med Chem. 1998 Jun 18;41(13):2333-8. DMHK0F6 RU https://pubmed.ncbi.nlm.nih.gov/9632366 DMHK25N DI DMHK25N DMHK25N DN 2-Mercaptomethyl-pentanedioic acid DMHK25N TI TT9G4N0 DMHK25N TN Glutamate carboxypeptidase II (GCPII) DMHK25N MA Inhibitor DMHK25N RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DMHK25N RU https://pubmed.ncbi.nlm.nih.gov/12723961 DMHK2NQ DI DMHK2NQ DMHK2NQ DN 2-hydroxyphenethyl 3,4,5-trihydroxybenzoate DMHK2NQ TI TTULVH8 DMHK2NQ TN Tyrosinase (TYR) DMHK2NQ MA Inhibitor DMHK2NQ RN Synthetic tyrosyl gallate derivatives as potent melanin formation inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5462-4. DMHK2NQ RU https://pubmed.ncbi.nlm.nih.gov/17693086 DMHK70B DI DMHK70B DMHK70B DN H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2 DMHK70B TI TTKWM86 DMHK70B TN Opioid receptor mu (MOP) DMHK70B MA Inhibitor DMHK70B RN From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11. DMHK70B RU https://pubmed.ncbi.nlm.nih.gov/16107162 DMHK70B DI DMHK70B DMHK70B DN H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2 DMHK70B TI TT27RFC DMHK70B TN Opioid receptor delta (OPRD1) DMHK70B MA Inhibitor DMHK70B RN From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11. DMHK70B RU https://pubmed.ncbi.nlm.nih.gov/16107162 DMHKANE DI DMHKANE DMHKANE DN 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol DMHKANE TI TTWM4TY DMHKANE TN Adrenergic receptor alpha-2B (ADRA2B) DMHKANE MA Inhibitor DMHKANE RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMHKANE RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMHKANE DI DMHKANE DMHKANE DN 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol DMHKANE TI TTWG9A4 DMHKANE TN Adrenergic receptor alpha-2A (ADRA2A) DMHKANE MA Inhibitor DMHKANE RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMHKANE RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMHKANE DI DMHKANE DMHKANE DN 1,2,3,4-Tetrahydro-benzo[h]isoquinolin-8-ol DMHKANE TI TT2NUT5 DMHKANE TN Adrenergic receptor alpha-2C (ADRA2C) DMHKANE MA Inhibitor DMHKANE RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMHKANE RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMHKE3M DI DMHKE3M DMHKE3M DN Diisopropyl mercapto(phenyl)methylphosphonate DMHKE3M TI TTHI19T DMHKE3M TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMHKE3M MA Inhibitor DMHKE3M RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMHKE3M RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMHKETG DI DMHKETG DMHKETG DN CGP-35024 DMHKETG TI TTDCVZW DMHKETG TN Gamma-aminobutyric acid B receptor (GABBR) DMHKETG MA Inhibitor DMHKETG RN Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. Am J Physiol. 1999 Oct;277(4 Pt 1):G867-74. DMHKETG RU https://pubmed.ncbi.nlm.nih.gov/10516154 DMHKG89 DI DMHKG89 DMHKG89 DN 1-Adamantan-1-yl-3-(4-hydroxy-decyl)-urea DMHKG89 TI TT7WVHI DMHKG89 TN Soluble epoxide hydrolase (EPHX2) DMHKG89 MA Inhibitor DMHKG89 RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMHKG89 RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMHKGCM DI DMHKGCM DMHKGCM DN L-Ornithine DMHKGCM TI TTI1PRE DMHKGCM TN G-protein coupled receptor GPCR33 (GPRC6A) DMHKGCM MA Agonist DMHKGCM RN Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97. DMHKGCM RU https://pubmed.ncbi.nlm.nih.gov/15576628 DMHKMU1 DI DMHKMU1 DMHKMU1 DN 7-Methoxy-9H-beta-carboline DMHKMU1 TI TT3WG5C DMHKMU1 TN Monoamine oxidase type A (MAO-A) DMHKMU1 MA Inhibitor DMHKMU1 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMHKMU1 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMHKMU1 DI DMHKMU1 DMHKMU1 DN 7-Methoxy-9H-beta-carboline DMHKMU1 TI TTGP7BY DMHKMU1 TN Monoamine oxidase type B (MAO-B) DMHKMU1 MA Inhibitor DMHKMU1 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMHKMU1 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMHKQ1L DI DMHKQ1L DMHKQ1L DN 5,7-Dichlorokynurenic Acid DMHKQ1L TI TTLD29N DMHKQ1L TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMHKQ1L MA Inhibitor DMHKQ1L RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHKQ1L RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHKUBG DI DMHKUBG DMHKUBG DN Vesamicol DMHKUBG TI TTV8KWS DMHKUBG TN Vesicular acetylcholine transporter (SLC18A3) DMHKUBG MA Inhibitor DMHKUBG RN Vesamicol analogues as sigma ligands. Molecular determinants of selectivity at the vesamicol receptor. Biochem Pharmacol. 1995 Mar 15;49(6):791-7. DMHKUBG RU https://pubmed.ncbi.nlm.nih.gov/7702637 DMHKUO9 DI DMHKUO9 DMHKUO9 DN 9-Ethyl-beta-carboline DMHKUO9 TI TT1RS9F DMHKUO9 TN Acetylcholinesterase (AChE) DMHKUO9 MA Inhibitor DMHKUO9 RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DMHKUO9 RU https://pubmed.ncbi.nlm.nih.gov/20361801 DMHKXPM DI DMHKXPM DMHKXPM DN (E)-N-(6-(prop-1-enyl)-1H-indazol-3-yl)butyramide DMHKXPM TI TTRSMW9 DMHKXPM TN Glycogen synthase kinase-3 beta (GSK-3B) DMHKXPM MA Inhibitor DMHKXPM RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMHKXPM RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMHL0ID DI DMHL0ID DMHL0ID DN Andromustine DMHL0ID TI TTS64P2 DMHL0ID TN Androgen receptor (AR) DMHL0ID MA Modulator DMHL0ID RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMHL0ID RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMHL3YV DI DMHL3YV DMHL3YV DN WEDELOLACTONE DMHL3YV TI TTNJYV2 DMHL3YV TN Gamma-aminobutyric acid receptor (GAR) DMHL3YV MA Inhibitor DMHL3YV RN Synthesis and preliminary pharmacological evaluation of coumestans with different patterns of oxygenation. Bioorg Med Chem Lett. 2001 Feb 12;11(3):283-6. DMHL3YV RU https://pubmed.ncbi.nlm.nih.gov/11212092 DMHL48F DI DMHL48F DMHL48F DN ARACHIDONYL TRIFLUOROMETHYLKETONE DMHL48F TI TTT1JVS DMHL48F TN Cytosolic phospholipase A2 (GIVA cPLA2) DMHL48F MA Inhibitor DMHL48F RN 85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G586-97. DMHL48F RU https://pubmed.ncbi.nlm.nih.gov/11897617 DMHL48F DI DMHL48F DMHL48F DN ARACHIDONYL TRIFLUOROMETHYLKETONE DMHL48F TI TTDP1UC DMHL48F TN Fatty acid amide hydrolase (FAAH) DMHL48F MA Inhibitor DMHL48F RN 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52. DMHL48F RU https://pubmed.ncbi.nlm.nih.gov/20005725 DMHL7BC DI DMHL7BC DMHL7BC DN (+/-)-2-(4-fluorophenyl)-7-methylchroman-4-one DMHL7BC TI TTGP7BY DMHL7BC TN Monoamine oxidase type B (MAO-B) DMHL7BC MA Inhibitor DMHL7BC RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMHL7BC RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMHL901 DI DMHL901 DMHL901 DN L-5-(bromovinyl)deoxyuridine DMHL901 TI TTP3QRF DMHL901 TN Thymidine kinase 1 (TK1) DMHL901 MA Inhibitor DMHL901 RN Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. DMHL901 RU https://pubmed.ncbi.nlm.nih.gov/17438061 DMHL9V3 DI DMHL9V3 DMHL9V3 DN 4-chloro-N-(2,5-dichlorophenyl)-3-nitrobenzamide DMHL9V3 TI TTVTX4N DMHL9V3 TN Bacterial Fatty acid synthetase I (Bact inhA) DMHL9V3 MA Inhibitor DMHL9V3 RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMHL9V3 RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMHL9Y6 DI DMHL9Y6 DMHL9Y6 DN HINOKITIOL DMHL9Y6 TI TTULVH8 DMHL9Y6 TN Tyrosinase (TYR) DMHL9Y6 MA Inhibitor DMHL9Y6 RN Structural insights into the hot spot amino acid residues of mushroom tyrosinase for the bindings of thujaplicins. Bioorg Med Chem. 2010 Nov 15;18(22):8112-8. DMHL9Y6 RU https://pubmed.ncbi.nlm.nih.gov/20947360 DMHLBZR DI DMHLBZR DMHLBZR DN P-IODOAMPHETAMINE DMHLBZR TI TTK25J1 DMHLBZR TN Adenosine A1 receptor (ADORA1) DMHLBZR MA Inhibitor DMHLBZR RN Synthesis and biological activity of N6-(p-sulfophenyl)alkyl and N6-sulfoalkyl derivatives of adenosine: water-soluble and peripherally selective a... J Med Chem. 1992 Oct 30;35(22):4143-9. DMHLBZR RU https://pubmed.ncbi.nlm.nih.gov/1433217 DMHLEGT DI DMHLEGT DMHLEGT DN ON-123 DMHLEGT TI TT976FS DMHLEGT TN Polo-like kinase 2 (PLK2) DMHLEGT MA Inhibitor DMHLEGT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2169). DMHLEGT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2169 DMHLF2S DI DMHLF2S DMHLF2S DN (3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine DMHLF2S TI TTGKNB4 DMHLF2S TN Epidermal growth factor receptor (EGFR) DMHLF2S MA Inhibitor DMHLF2S RN Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7. DMHLF2S RU https://pubmed.ncbi.nlm.nih.gov/7658435 DMHLFAE DI DMHLFAE DMHLFAE DN KNI-10217 DMHLFAE TI TTXMNHO DMHLFAE TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMHLFAE MA Inhibitor DMHLFAE RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMHLFAE RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMHLKAE DI DMHLKAE DMHLKAE DN 8-Methoxy-4-morpholin-4-yl-chromen-2-one DMHLKAE TI TTK3PY9 DMHLKAE TN DNA-dependent protein kinase catalytic (PRKDC) DMHLKAE MA Inhibitor DMHLKAE RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMHLKAE RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMHLNA2 DI DMHLNA2 DMHLNA2 DN DdCTP SODIUM DMHLNA2 TI TTIU7X1 DMHLNA2 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMHLNA2 MA Inhibitor DMHLNA2 RN Acylphloroglucinol derivatives from Mahurea palustris. J Nat Prod. 2005 Jul;68(7):979-84. DMHLNA2 RU https://pubmed.ncbi.nlm.nih.gov/16038535 DMHLQSE DI DMHLQSE DMHLQSE DN 4-butyl-N-(isoquinolin-5-yl)benzamide DMHLQSE TI TTMI6F5 DMHLQSE TN Transient receptor potential cation channel V1 (TRPV1) DMHLQSE MA Inhibitor DMHLQSE RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMHLQSE RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMHLYUM DI DMHLYUM DMHLYUM DN Formycin B DMHLYUM TI TTBL49X DMHLYUM TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMHLYUM MA Inhibitor DMHLYUM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHLYUM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHM0RW DI DMHM0RW DMHM0RW DN 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine DMHM0RW TI TTGY7WI DMHM0RW TN Urokinase-type plasminogen activator (PLAU) DMHM0RW MA Inhibitor DMHM0RW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHM0RW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHM0WI DI DMHM0WI DMHM0WI DN N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide DMHM0WI TI TT32JK8 DMHM0WI TN Melatonin receptor type 1B (MTNR1B) DMHM0WI MA Inhibitor DMHM0WI RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMHM0WI RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMHM0WI DI DMHM0WI DMHM0WI DN N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamide DMHM0WI TI TT0WAIE DMHM0WI TN Melatonin receptor type 1A (MTNR1A) DMHM0WI MA Inhibitor DMHM0WI RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMHM0WI RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMHM3LC DI DMHM3LC DMHM3LC DN N-(4-methoxybenzyl)oleamide DMHM3LC TI TT6OEDT DMHM3LC TN Cannabinoid receptor 1 (CB1) DMHM3LC MA Inhibitor DMHM3LC RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DMHM3LC RU https://pubmed.ncbi.nlm.nih.gov/16213718 DMHM5GJ DI DMHM5GJ DMHM5GJ DN 2-Methyl-2-Propanol DMHM5GJ TI TTV3NH6 DMHM5GJ TN Calmodulin (CALM) DMHM5GJ MA Inhibitor DMHM5GJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHM5GJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHM5GJ DI DMHM5GJ DMHM5GJ DN 2-Methyl-2-Propanol DMHM5GJ TI TTZL0OI DMHM5GJ TN Methionine aminopeptidase 2 (METAP2) DMHM5GJ MA Inhibitor DMHM5GJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHM5GJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHMFKE DI DMHMFKE DMHMFKE DN EVP-4473 DMHMFKE TI TTLA931 DMHMFKE TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMHMFKE MA Agonist DMHMFKE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468). DMHMFKE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468 DMHMUNB DI DMHMUNB DMHMUNB DN PMID30247903-Compound-General structure45 DMHMUNB TI TT23XQV DMHMUNB TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMHMUNB MA Inhibitor DMHMUNB RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMHMUNB RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMHMVOI DI DMHMVOI DMHMVOI DN Ajinomoto 1 DMHMVOI TI TTXHYV6 DMHMVOI TN Voltage-gated L-type calcium channel (L-CaC) DMHMVOI MA Blocker DMHMVOI RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMHMVOI RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMHN2LT DI DMHN2LT DMHN2LT DN CP-94,253 DMHN2LT TI TTK8CXU DMHN2LT TN 5-HT 1B receptor (HTR1B) DMHN2LT MA Agonist DMHN2LT RN Anxiogenic-like effect of serotonin(1B) receptor stimulation in the rat elevated plus-maze. Pharmacol Biochem Behav. 2002 Apr;71(4):581-7. DMHN2LT RU https://pubmed.ncbi.nlm.nih.gov/11888549 DMHN5OL DI DMHN5OL DMHN5OL DN 4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine DMHN5OL TI TTIQUX7 DMHN5OL TN Steroid 11-beta-hydroxylase (CYP11B1) DMHN5OL MA Inhibitor DMHN5OL RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMHN5OL RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMHN5OL DI DMHN5OL DMHN5OL DN 4-((3',4'-Difluorobiphenyl-4-yl)methyl)pyridine DMHN5OL TI TTRA5BZ DMHN5OL TN Steroid 17-alpha-monooxygenase (S17AH) DMHN5OL MA Inhibitor DMHN5OL RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMHN5OL RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMHN74V DI DMHN74V DMHN74V DN Lanosterol DMHN74V TI TT7O8ZA DMHN74V TN Lanosterol synthase (LSS) DMHN74V MA Inhibitor DMHN74V RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHN74V RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHN7CB DI DMHN7CB DMHN7CB DN Tributylstannanyl DMHN7CB TI TT6PEUO DMHN7CB TN Retinoic acid receptor RXR-alpha (RXRA) DMHN7CB MA Inhibitor DMHN7CB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHN7CB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHN82B DI DMHN82B DMHN82B DN EP-37 DMHN82B TI TTCIHJA DMHN82B TN Coagulation factor Xa (F10) DMHN82B MA Antagonist DMHN82B RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMHN82B RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMHNCAG DI DMHNCAG DMHNCAG DN C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 DMHNCAG TI TTNI91K DMHNCAG TN Melanocortin receptor 3 (MC3R) DMHNCAG MA Inhibitor DMHNCAG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMHNCAG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMHNCAG DI DMHNCAG DMHNCAG DN C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 DMHNCAG TI TTEOSZT DMHNCAG TN Melanocortin receptor (MCR) DMHNCAG MA Inhibitor DMHNCAG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMHNCAG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMHNCAG DI DMHNCAG DMHNCAG DN C[Nle-Glu-D-Nal(2')-Arg-Trp-Glu]-NH2 DMHNCAG TI TTD0CIQ DMHNCAG TN Melanocortin receptor 4 (MC4R) DMHNCAG MA Inhibitor DMHNCAG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMHNCAG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMHNDTW DI DMHNDTW DMHNDTW DN aminooxyacetic acid DMHNDTW TI TTVZJ7G DMHNDTW TN Cystathionine beta-synthase (CBS) DMHNDTW MA Inhibitor DMHNDTW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1443). DMHNDTW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1443 DMHNDTW DI DMHNDTW DMHNDTW DN aminooxyacetic acid DMHNDTW TI TTU507L DMHNDTW TN Cytoplasmic aspartate aminotransferase (GOT1) DMHNDTW MA Inhibitor DMHNDTW RN Aspartate aminotransferase isotope exchange reactions: implications for glutamate/glutamine shuttle hypothesis. Am J Physiol Cell Physiol. 2002 Jun;282(6):C1404-13. DMHNDTW RU https://pubmed.ncbi.nlm.nih.gov/11997255 DMHNILP DI DMHNILP DMHNILP DN JWH-346 DMHNILP TI TTMSFAW DMHNILP TN Cannabinoid receptor 2 (CB2) DMHNILP MA Inhibitor DMHNILP RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMHNILP RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMHNILP DI DMHNILP DMHNILP DN JWH-346 DMHNILP TI TT6OEDT DMHNILP TN Cannabinoid receptor 1 (CB1) DMHNILP MA Inhibitor DMHNILP RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMHNILP RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMHNJDE DI DMHNJDE DMHNJDE DN Gamma-Glutamyl[S-(2-Iodobenzyl)Cysteinyl]Glycine DMHNJDE TI TTJ0IQB DMHNJDE TN Phosphodiesterase 5A (PDE5A) DMHNJDE MA Inhibitor DMHNJDE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHNJDE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHNKWR DI DMHNKWR DMHNKWR DN (R)(+)-7-fluoro-2-p-tolylchroman-4-one DMHNKWR TI TTGP7BY DMHNKWR TN Monoamine oxidase type B (MAO-B) DMHNKWR MA Inhibitor DMHNKWR RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMHNKWR RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMHNM3K DI DMHNM3K DMHNM3K DN Tyr-(R)-spiro-Aba-Gly-Phe-NH2 DMHNM3K TI TTKWM86 DMHNM3K TN Opioid receptor mu (MOP) DMHNM3K MA Inhibitor DMHNM3K RN Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. DMHNM3K RU https://pubmed.ncbi.nlm.nih.gov/18062664 DMHNOLA DI DMHNOLA DMHNOLA DN 1-(1,4-diacetylphenyl)dithiosemicarbazide DMHNOLA TI TTULVH8 DMHNOLA TN Tyrosinase (TYR) DMHNOLA MA Inhibitor DMHNOLA RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DMHNOLA RU https://pubmed.ncbi.nlm.nih.gov/18326070 DMHNQO9 DI DMHNQO9 DMHNQO9 DN (+/-)-threo-N-(5-Phenylpentyl)methylphenidate DMHNQO9 TI TTVBI8W DMHNQO9 TN Dopamine transporter (DAT) DMHNQO9 MA Inhibitor DMHNQO9 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMHNQO9 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMHNR36 DI DMHNR36 DMHNR36 DN N-[(CYCLOHEXYLAMINO)CARBONYL]GLYCINE DMHNR36 TI TT7WVHI DMHNR36 TN Soluble epoxide hydrolase (EPHX2) DMHNR36 MA Inhibitor DMHNR36 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHNR36 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHNR63 DI DMHNR63 DMHNR63 DN D-phenylalanyl-N-benzyl-L-prolinamide DMHNR63 TI TT6L509 DMHNR63 TN Coagulation factor IIa (F2) DMHNR63 MA Inhibitor DMHNR63 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHNR63 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHNRXT DI DMHNRXT DMHNRXT DN 5-hexyl-2-phenoxyphenol DMHNRXT TI TTVTX4N DMHNRXT TN Bacterial Fatty acid synthetase I (Bact inhA) DMHNRXT MA Inhibitor DMHNRXT RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMHNRXT RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMHNS0V DI DMHNS0V DMHNS0V DN Purine Riboside DMHNS0V TI TTLP57V DMHNS0V TN Adenosine deaminase (ADA) DMHNS0V MA Inhibitor DMHNS0V RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHNS0V RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHNSXP DI DMHNSXP DMHNSXP DN 4-chloro-1H-indazole DMHNSXP TI TTZUFI5 DMHNSXP TN Nitric-oxide synthase brain (NOS1) DMHNSXP MA Inhibitor DMHNSXP RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DMHNSXP RU https://pubmed.ncbi.nlm.nih.gov/17395463 DMHNTZ8 DI DMHNTZ8 DMHNTZ8 DN JWH-325 DMHNTZ8 TI TT6OEDT DMHNTZ8 TN Cannabinoid receptor 1 (CB1) DMHNTZ8 MA Inhibitor DMHNTZ8 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMHNTZ8 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMHNTZ8 DI DMHNTZ8 DMHNTZ8 DN JWH-325 DMHNTZ8 TI TTMSFAW DMHNTZ8 TN Cannabinoid receptor 2 (CB2) DMHNTZ8 MA Inhibitor DMHNTZ8 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMHNTZ8 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMHNUWG DI DMHNUWG DMHNUWG DN 1,3-Di-p-tolyl-[1,3]diazetidine-2,4-dione DMHNUWG TI TT2WR1T DMHNUWG TN Cationic trypsinogen (PRSS1) DMHNUWG MA Inhibitor DMHNUWG RN Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4. DMHNUWG RU https://pubmed.ncbi.nlm.nih.gov/11425539 DMHNWS1 DI DMHNWS1 DMHNWS1 DN Octanedioic acid hydroxyamide pyridin-2-ylamide DMHNWS1 TI TT5ZKDI DMHNWS1 TN Histone deacetylase 6 (HDAC6) DMHNWS1 MA Inhibitor DMHNWS1 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMHNWS1 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMHNWS1 DI DMHNWS1 DMHNWS1 DN Octanedioic acid hydroxyamide pyridin-2-ylamide DMHNWS1 TI TT6R7JZ DMHNWS1 TN Histone deacetylase 1 (HDAC1) DMHNWS1 MA Inhibitor DMHNWS1 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMHNWS1 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMHNWS1 DI DMHNWS1 DMHNWS1 DN Octanedioic acid hydroxyamide pyridin-2-ylamide DMHNWS1 TI TTTQGH8 DMHNWS1 TN Histone deacetylase 4 (HDAC4) DMHNWS1 MA Inhibitor DMHNWS1 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMHNWS1 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMHNWS1 DI DMHNWS1 DMHNWS1 DN Octanedioic acid hydroxyamide pyridin-2-ylamide DMHNWS1 TI TTBH0VX DMHNWS1 TN Histone deacetylase (HDAC) DMHNWS1 MA Inhibitor DMHNWS1 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMHNWS1 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMHNWS1 DI DMHNWS1 DMHNWS1 DN Octanedioic acid hydroxyamide pyridin-2-ylamide DMHNWS1 TI TTT6LFV DMHNWS1 TN Histone deacetylase 8 (HDAC8) DMHNWS1 MA Inhibitor DMHNWS1 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMHNWS1 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMHNWS1 DI DMHNWS1 DMHNWS1 DN Octanedioic acid hydroxyamide pyridin-2-ylamide DMHNWS1 TI TTSHTOI DMHNWS1 TN Histone deacetylase 2 (HDAC2) DMHNWS1 MA Inhibitor DMHNWS1 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMHNWS1 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMHNWS1 DI DMHNWS1 DMHNWS1 DN Octanedioic acid hydroxyamide pyridin-2-ylamide DMHNWS1 TI TTYHPU6 DMHNWS1 TN Histone deacetylase 10 (HDAC10) DMHNWS1 MA Inhibitor DMHNWS1 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMHNWS1 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMHNZGP DI DMHNZGP DMHNZGP DN C(Arg-Gly-Asp-D-Phe-Val) DMHNZGP TI TTJA1ZO DMHNZGP TN ITGB3 messenger RNA (ITGB3 mRNA) DMHNZGP MA Inhibitor DMHNZGP RN Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20. DMHNZGP RU https://pubmed.ncbi.nlm.nih.gov/16722662 DMHNZGP DI DMHNZGP DMHNZGP DN C(Arg-Gly-Asp-D-Phe-Val) DMHNZGP TI TTT1R2L DMHNZGP TN Integrin alpha-V (ITGAV) DMHNZGP MA Inhibitor DMHNZGP RN Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20. DMHNZGP RU https://pubmed.ncbi.nlm.nih.gov/16722662 DMHO29Y DI DMHO29Y DMHO29Y DN T83193 DMHO29Y TI TTT2LD9 DMHO29Y TN GABA transaminase (ABAT) DMHO29Y MA Inhibitor DMHO29Y RN Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5. DMHO29Y RU https://pubmed.ncbi.nlm.nih.gov/16290145 DMHO29Y DI DMHO29Y DMHO29Y DN T83193 DMHO29Y TI TTJUWVB DMHO29Y TN Succinate-semialdehyde dehydrogenase (ALDH5A1) DMHO29Y MA Inhibitor DMHO29Y RN Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5. DMHO29Y RU https://pubmed.ncbi.nlm.nih.gov/16290145 DMHO29Y DI DMHO29Y DMHO29Y DN T83193 DMHO29Y TI TTGP7BY DMHO29Y TN Monoamine oxidase type B (MAO-B) DMHO29Y MA Inhibitor DMHO29Y RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMHO29Y RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMHO3N1 DI DMHO3N1 DMHO3N1 DN Decoyinine DMHO3N1 TI TTCFP0V DMHO3N1 TN Glutamine amidotransferase (GMPS) DMHO3N1 MA Inhibitor DMHO3N1 RN High-level production from a baculovirus expression system and biochemical characterization of human GMP synthetase. Protein Expr Purif. 1995 Aug;6(4):487-95. DMHO3N1 RU https://pubmed.ncbi.nlm.nih.gov/8527935 DMHO3XL DI DMHO3XL DMHO3XL DN LUF-5981 DMHO3XL TI TTJFY5U DMHO3XL TN Adenosine A3 receptor (ADORA3) DMHO3XL MA Inhibitor DMHO3XL RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMHO3XL RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMHO3XL DI DMHO3XL DMHO3XL DN LUF-5981 DMHO3XL TI TTM2AOE DMHO3XL TN Adenosine A2a receptor (ADORA2A) DMHO3XL MA Inhibitor DMHO3XL RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMHO3XL RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMHO3XL DI DMHO3XL DMHO3XL DN LUF-5981 DMHO3XL TI TTNE7KG DMHO3XL TN Adenosine A2b receptor (ADORA2B) DMHO3XL MA Inhibitor DMHO3XL RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMHO3XL RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMHO3XL DI DMHO3XL DMHO3XL DN LUF-5981 DMHO3XL TI TTK25J1 DMHO3XL TN Adenosine A1 receptor (ADORA1) DMHO3XL MA Inhibitor DMHO3XL RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMHO3XL RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMHO40Q DI DMHO40Q DMHO40Q DN NSC-380292 DMHO40Q TI TT84ETX DMHO40Q TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMHO40Q MA Inhibitor DMHO40Q RN New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity. Bioorg Med Chem Lett. 2006 Jun 1;16(11):3034-8. DMHO40Q RU https://pubmed.ncbi.nlm.nih.gov/16527484 DMHO56W DI DMHO56W DMHO56W DN Equilenin DMHO56W TI TTZT9R2 DMHO56W TN Hydroxysteroid dehydrogenase 3-beta (HSD3B) DMHO56W MA Inhibitor DMHO56W RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHO56W RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHO634 DI DMHO634 DMHO634 DN alpha-conotoxin GI DMHO634 TI TTH18TF DMHO634 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMHO634 MA Antagonist DMHO634 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMHO634 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMHO7TZ DI DMHO7TZ DMHO7TZ DN 6-Methoxy-5-oxazol-5-yl-2-phenyl-1H-indole DMHO7TZ TI TTTB4UP DMHO7TZ TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMHO7TZ MA Inhibitor DMHO7TZ RN Novel indole-based inhibitors of IMPDH: introduction of hydrogen bond acceptors at indole C-3. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1273-6. DMHO7TZ RU https://pubmed.ncbi.nlm.nih.gov/12657262 DMHO8KQ DI DMHO8KQ DMHO8KQ DN 2-hydroxy-saclofen DMHO8KQ TI TTDCVZW DMHO8KQ TN Gamma-aminobutyric acid B receptor (GABBR) DMHO8KQ MA Antagonist DMHO8KQ RN Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46. DMHO8KQ RU https://pubmed.ncbi.nlm.nih.gov/9069281 DMHODXG DI DMHODXG DMHODXG DN (3-Chloro-4-Propoxy-Phenyl)-Acetic Acid DMHODXG TI TT8NGED DMHODXG TN Prostaglandin G/H synthase 1 (COX-1) DMHODXG MA Inhibitor DMHODXG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHODXG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHOG7W DI DMHOG7W DMHOG7W DN SAG DMHOG7W TI TTSJ9E7 DMHOG7W TN Short transient receptor potential channel 2 (TRPC2) DMHOG7W MA Activator DMHOG7W RN A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction. Neuron. 2003 Oct 30;40(3):551-61. DMHOG7W RU https://pubmed.ncbi.nlm.nih.gov/14642279 DMHOG7W DI DMHOG7W DMHOG7W DN SAG DMHOG7W TI TTRBT3W DMHOG7W TN Short transient receptor potential channel 6 (TRPC6) DMHOG7W MA Activator DMHOG7W RN Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63. DMHOG7W RU https://pubmed.ncbi.nlm.nih.gov/9930701 DMHOJ0Z DI DMHOJ0Z DMHOJ0Z DN ISIS 298746 DMHOJ0Z TI TTSN6QU DMHOJ0Z TN HIF1-alpha messenger RNA (HIF1A mRNA) DMHOJ0Z RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMHOJ0Z RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMHOT9P DI DMHOT9P DMHOT9P DN DELTORPHIN DMHOT9P TI TT27RFC DMHOT9P TN Opioid receptor delta (OPRD1) DMHOT9P MA Inhibitor DMHOT9P RN Cyclic enkephalin analogs with exceptional potency at peripheral delta opioid receptors. J Med Chem. 1994 Jan 7;37(1):146-50. DMHOT9P RU https://pubmed.ncbi.nlm.nih.gov/8289188 DMHOT9P DI DMHOT9P DMHOT9P DN DELTORPHIN DMHOT9P TI TTKWM86 DMHOT9P TN Opioid receptor mu (MOP) DMHOT9P MA Inhibitor DMHOT9P RN Synthesis and structure-activity relationships of deltorphin analogues. J Med Chem. 1991 May;34(5):1656-61. DMHOT9P RU https://pubmed.ncbi.nlm.nih.gov/1851843 DMHOUSR DI DMHOUSR DMHOUSR DN SCH-221510 DMHOUSR TI TTNT7K8 DMHOUSR TN Nociceptin receptor (OPRL1) DMHOUSR MA Agonist DMHOUSR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). DMHOUSR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 DMHPBQC DI DMHPBQC DMHPBQC DN [2-(6-Methoxy-indol-1-yl)-ethyl]-dimethyl-amine DMHPBQC TI TTJQOD7 DMHPBQC TN 5-HT 2A receptor (HTR2A) DMHPBQC MA Inhibitor DMHPBQC RN Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8. DMHPBQC RU https://pubmed.ncbi.nlm.nih.gov/11755343 DMHPD2Y DI DMHPD2Y DMHPD2Y DN SODIUM CITRATE DMHPD2Y TI TTZHA0O DMHPD2Y TN Carbonic anhydrase IV (CA-IV) DMHPD2Y MA Inhibitor DMHPD2Y RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with carboxylates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):573-8. DMHPD2Y RU https://pubmed.ncbi.nlm.nih.gov/15664815 DMHPE4L DI DMHPE4L DMHPE4L DN (+/-)-threo-N-(3-Methylfuran)methylphenidate DMHPE4L TI TTVBI8W DMHPE4L TN Dopamine transporter (DAT) DMHPE4L MA Inhibitor DMHPE4L RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMHPE4L RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMHPENR DI DMHPENR DMHPENR DN ISIS 191759 DMHPENR TI TT0GV3R DMHPENR TN DGAT1 messenger RNA (DGAT1 mRNA) DMHPENR RN US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression. DMHPENR RU http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true DMHPFMV DI DMHPFMV DMHPFMV DN E-1455 DMHPFMV TI TTE0A2F DMHPFMV TN Dopamine D4 receptor (D4R) DMHPFMV MA Modulator DMHPFMV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 217). DMHPFMV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=217 DMHPITZ DI DMHPITZ DMHPITZ DN N-(biphenyl-4-ylsulfonyl)-D-leucine DMHPITZ TI TTXZ0KQ DMHPITZ TN Matrix metalloproteinase-12 (MMP-12) DMHPITZ MA Inhibitor DMHPITZ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHPITZ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHPV8A DI DMHPV8A DMHPV8A DN GALANIN DMHPV8A TI TTX3HNZ DMHPV8A TN Galanin receptor type 1 (GAL1-R) DMHPV8A MA Inhibitor DMHPV8A RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMHPV8A RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMHPV8A DI DMHPV8A DMHPV8A DN GALANIN DMHPV8A TI TTBPW3J DMHPV8A TN Galanin receptor type 2 (GAL2-R) DMHPV8A MA Inhibitor DMHPV8A RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMHPV8A RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMHPYSM DI DMHPYSM DMHPYSM DN Ellipticine DMHPYSM TI TT0IHXV DMHPYSM TN DNA topoisomerase II (TOP2) DMHPYSM MA Inhibitor DMHPYSM RN In vitro sensitivity of Trichomonas vaginalis to DNA topoisomerase II inhibitors. Southeast Asian J Trop Med Public Health. 2000 Mar;31(1):118-22. DMHPYSM RU https://pubmed.ncbi.nlm.nih.gov/11023077 DMHPYWM DI DMHPYWM DMHPYWM DN 3-(1-carboxy-4-mercaptobutoxy)benzoic acid DMHPYWM TI TT9G4N0 DMHPYWM TN Glutamate carboxypeptidase II (GCPII) DMHPYWM MA Inhibitor DMHPYWM RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMHPYWM RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMHQ0T2 DI DMHQ0T2 DMHQ0T2 DN LY433221 DMHQ0T2 TI TTSQIFT DMHQ0T2 TN 5-HT 1A receptor (HTR1A) DMHQ0T2 MA Antagonist DMHQ0T2 RN Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. DMHQ0T2 RU https://pubmed.ncbi.nlm.nih.gov/17017959 DMHQ1ZD DI DMHQ1ZD DMHQ1ZD DN PMID30247903-Compound-General structure30 DMHQ1ZD TI TT23XQV DMHQ1ZD TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMHQ1ZD MA Inhibitor DMHQ1ZD RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMHQ1ZD RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMHQ467 DI DMHQ467 DMHQ467 DN 3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol DMHQ467 TI TTK25J1 DMHQ467 TN Adenosine A1 receptor (ADORA1) DMHQ467 MA Inhibitor DMHQ467 RN 1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10. DMHQ467 RU https://pubmed.ncbi.nlm.nih.gov/16099648 DMHQ467 DI DMHQ467 DMHQ467 DN 3-Benzyl-7-methyl-[1,8]naphthyridin-4-ol DMHQ467 TI TTM2AOE DMHQ467 TN Adenosine A2a receptor (ADORA2A) DMHQ467 MA Inhibitor DMHQ467 RN 1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10. DMHQ467 RU https://pubmed.ncbi.nlm.nih.gov/16099648 DMHQ6C3 DI DMHQ6C3 DMHQ6C3 DN PMID30247903-Compound-General structure6 DMHQ6C3 TI TT8ZLTI DMHQ6C3 TN Programmed cell death 1 ligand 1 (PD-L1) DMHQ6C3 MA Inhibitor DMHQ6C3 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMHQ6C3 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMHQ6KT DI DMHQ6KT DMHQ6KT DN PHA-666859 DMHQ6KT TI TTQBR95 DMHQ6KT TN Stress-activated protein kinase 2a (p38 alpha) DMHQ6KT MA Inhibitor DMHQ6KT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1499). DMHQ6KT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1499 DMHQCRU DI DMHQCRU DMHQCRU DN (4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine DMHQCRU TI TT4C8EA DMHQCRU TN Dopamine D3 receptor (D3R) DMHQCRU MA Inhibitor DMHQCRU RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMHQCRU RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMHQCRU DI DMHQCRU DMHQCRU DN (4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine DMHQCRU TI TTEX248 DMHQCRU TN Dopamine D2 receptor (D2R) DMHQCRU MA Inhibitor DMHQCRU RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMHQCRU RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMHQCRU DI DMHQCRU DMHQCRU DN (4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine DMHQCRU TI TTE0A2F DMHQCRU TN Dopamine D4 receptor (D4R) DMHQCRU MA Inhibitor DMHQCRU RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMHQCRU RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMHQD76 DI DMHQD76 DMHQD76 DN ISIS 23416 DMHQD76 TI TTAIWZN DMHQD76 TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DMHQD76 RN US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression. DMHQD76 RU http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true DMHQDLX DI DMHQDLX DMHQDLX DN EPO-derived peptide DMHQDLX TI TTAUX24 DMHQDLX TN Erythropoietin Receptor (EPOR) DMHQDLX MA Modulator DMHQDLX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DMHQDLX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DMHQF1J DI DMHQF1J DMHQF1J DN ISIS 29239 DMHQF1J TI TTYMGWX DMHQF1J TN PDK-1 messenger RNA (PDK-1 mRNA) DMHQF1J RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMHQF1J RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMHQGOC DI DMHQGOC DMHQGOC DN 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione DMHQGOC TI TTNE7KG DMHQGOC TN Adenosine A2b receptor (ADORA2B) DMHQGOC MA Inhibitor DMHQGOC RN Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43. DMHQGOC RU https://pubmed.ncbi.nlm.nih.gov/14761205 DMHQGOC DI DMHQGOC DMHQGOC DN 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione DMHQGOC TI TTM2AOE DMHQGOC TN Adenosine A2a receptor (ADORA2A) DMHQGOC MA Inhibitor DMHQGOC RN Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43. DMHQGOC RU https://pubmed.ncbi.nlm.nih.gov/14761205 DMHQGOC DI DMHQGOC DMHQGOC DN 8-Phenyl-1-propyl-3,7-dihydro-purine-2,6-dione DMHQGOC TI TTK25J1 DMHQGOC TN Adenosine A1 receptor (ADORA1) DMHQGOC MA Inhibitor DMHQGOC RN Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationshi... J Med Chem. 1993 Oct 29;36(22):3341-9. DMHQGOC RU https://pubmed.ncbi.nlm.nih.gov/8230124 DMHQK54 DI DMHQK54 DMHQK54 DN PMID24440480C3 DMHQK54 TI TTSCHFW DMHQK54 TN Peptidyl arginine deiminase type III (PADI3) DMHQK54 MA Inhibitor DMHQK54 RN Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem. 2014 Feb 15;22(4):1362-9. DMHQK54 RU https://pubmed.ncbi.nlm.nih.gov/24440480 DMHQK54 DI DMHQK54 DMHQK54 DN PMID24440480C3 DMHQK54 TI TTQHAXM DMHQK54 TN Peptidyl arginine deiminase type IV (PADI4) DMHQK54 MA Inhibitor DMHQK54 RN Insights into the mechanism of streptonigrin-induced protein arginine deiminase inactivation. Bioorg Med Chem. 2014 Feb 15;22(4):1362-9. DMHQK54 RU https://pubmed.ncbi.nlm.nih.gov/24440480 DMHQKCJ DI DMHQKCJ DMHQKCJ DN BIS(20)-HUPERZINE B DMHQKCJ TI TT1RS9F DMHQKCJ TN Acetylcholinesterase (AChE) DMHQKCJ MA Inhibitor DMHQKCJ RN Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7. DMHQKCJ RU https://pubmed.ncbi.nlm.nih.gov/15689148 DMHQNZD DI DMHQNZD DMHQNZD DN 2-amino-2-(thiophen-2-yl)acetic acid DMHQNZD TI TTFK1JQ DMHQNZD TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMHQNZD MA Inhibitor DMHQNZD RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMHQNZD RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMHQP84 DI DMHQP84 DMHQP84 DN BW B218C DMHQP84 TI TT2J34L DMHQP84 TN Arachidonate 5-lipoxygenase (5-LOX) DMHQP84 MA Inhibitor DMHQP84 RN Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99. DMHQP84 RU https://pubmed.ncbi.nlm.nih.gov/1793063 DMHR1GX DI DMHR1GX DMHR1GX DN MG-1104 DMHR1GX TI TTFEZ5Q DMHR1GX TN Coagulation factor IX (F9) DMHR1GX MA Modulator DMHR1GX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364). DMHR1GX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364 DMHR1IB DI DMHR1IB DMHR1IB DN (S)(+)-7-fluoro-2-phenylchroman-4-one DMHR1IB TI TTGP7BY DMHR1IB TN Monoamine oxidase type B (MAO-B) DMHR1IB MA Inhibitor DMHR1IB RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMHR1IB RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMHR1UE DI DMHR1UE DMHR1UE DN 2H-Isoquinolin-1-one DMHR1UE TI TTVDSZ0 DMHR1UE TN Poly [ADP-ribose] polymerase 1 (PARP1) DMHR1UE MA Inhibitor DMHR1UE RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMHR1UE RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMHR3ZG DI DMHR3ZG DMHR3ZG DN AP-101 DMHR3ZG TI TT9VGXW DMHR3ZG TN Angiopoietin 1 receptor (TEK) DMHR3ZG MA Modulator DMHR3ZG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1842). DMHR3ZG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1842 DMHR90S DI DMHR90S DMHR90S DN 1beta-methoxy-miller-9Z-enolide DMHR90S TI TTSXVID DMHR90S TN Nuclear factor NF-kappa-B (NFKB) DMHR90S MA Inhibitor DMHR90S RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMHR90S RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMHRGTY DI DMHRGTY DMHRGTY DN Bis(5-aminobenzo[b]furan-2-yl)methanone DMHRGTY TI TTGJCWZ DMHRGTY TN Fms-like tyrosine kinase 3 (FLT-3) DMHRGTY MA Inhibitor DMHRGTY RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMHRGTY RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMHRGTY DI DMHRGTY DMHRGTY DN Bis(5-aminobenzo[b]furan-2-yl)methanone DMHRGTY TI TTI7421 DMHRGTY TN Platelet-derived growth factor receptor beta (PDGFRB) DMHRGTY MA Inhibitor DMHRGTY RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMHRGTY RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMHRLYJ DI DMHRLYJ DMHRLYJ DN ISIS 112003 DMHRLYJ TI TTPJ9XK DMHRLYJ TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMHRLYJ RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMHRLYJ RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMHRME4 DI DMHRME4 DMHRME4 DN Alpha,beta-methylene-dATP DMHRME4 TI TTIU7X1 DMHRME4 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMHRME4 MA Inhibitor DMHRME4 RN Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70. DMHRME4 RU https://pubmed.ncbi.nlm.nih.gov/18811136 DMHRPAM DI DMHRPAM DMHRPAM DN ABBV-744 DMHRPAM TI TTNISW6 DMHRPAM TN HUMAN bromodomain-containing protein 2 (BRD2) DMHRPAM MA Inhibitor DMHRPAM RN Uncovering the Role of BRD2 in COVID-19. 2020-03-19 DMHRPAM RU https://www.caymanchem.com/news/uncovering-the-role-of-brd2-in-covid-19 DMHRT0F DI DMHRT0F DMHRT0F DN Dmt-Sar-Phe-D-2-Nal-NH DMHRT0F TI TTKWM86 DMHRT0F TN Opioid receptor mu (MOP) DMHRT0F MA Inhibitor DMHRT0F RN Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. DMHRT0F RU https://pubmed.ncbi.nlm.nih.gov/18207400 DMHRV2A DI DMHRV2A DMHRV2A DN 9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide DMHRV2A TI TTEB0GD DMHRV2A TN Cholinesterase (BCHE) DMHRV2A MA Inhibitor DMHRV2A RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMHRV2A RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMHRV2A DI DMHRV2A DMHRV2A DN 9-O-[3-(2-Pyridinoxyl)butyl]-berberine bromide DMHRV2A TI TT1RS9F DMHRV2A TN Acetylcholinesterase (AChE) DMHRV2A MA Inhibitor DMHRV2A RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMHRV2A RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMHRZ2V DI DMHRZ2V DMHRZ2V DN 3-acetyl-11-keto-ursolic acid DMHRZ2V TI TTN7BL9 DMHRZ2V TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMHRZ2V MA Inhibitor DMHRZ2V RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DMHRZ2V RU https://pubmed.ncbi.nlm.nih.gov/20100662 DMHS3N6 DI DMHS3N6 DMHS3N6 DN 2-biphenyl-4-yl-1-phenothiazin-10-yl-ethanone DMHS3N6 TI TTEB0GD DMHS3N6 TN Cholinesterase (BCHE) DMHS3N6 MA Inhibitor DMHS3N6 RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMHS3N6 RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMHSAOQ DI DMHSAOQ DMHSAOQ DN 3-Biphenyl-3-yl-N-hydroxy-N-methyl-acrylamide DMHSAOQ TI TT2J34L DMHSAOQ TN Arachidonate 5-lipoxygenase (5-LOX) DMHSAOQ MA Inhibitor DMHSAOQ RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMHSAOQ RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMHSE96 DI DMHSE96 DMHSE96 DN PMID18754614C19 DMHSE96 TI TTFQEO5 DMHSE96 TN Squalene synthetase (FDFT1) DMHSE96 MA Inhibitor DMHSE96 RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DMHSE96 RU https://pubmed.ncbi.nlm.nih.gov/18754614 DMHSJAT DI DMHSJAT DMHSJAT DN (E)-(thiophen-2-ylmethylidene)amino benzoate DMHSJAT TI TTDNFMT DMHSJAT TN Platelet-activating factor acetylhydrolase (PLA2G7) DMHSJAT MA Inhibitor DMHSJAT RN (E)-Phenyl- and -heteroaryl-substituted O-benzoyl-(or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors. Bioorg Med Chem Lett. 2005 Mar 1;15(5):1525-7. DMHSJAT RU https://pubmed.ncbi.nlm.nih.gov/15713421 DMHSLXI DI DMHSLXI DMHSLXI DN 2,4-Dimethoxy-3'-amino-trans-stilbene DMHSLXI TI TTSZLWK DMHSLXI TN Aromatase (CYP19A1) DMHSLXI MA Inhibitor DMHSLXI RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMHSLXI RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMHSORL DI DMHSORL DMHSORL DN 2-(1H-pyrazol-3-yl)-1H-benzimidazole DMHSORL TI TTPS3C0 DMHSORL TN Aurora kinase A (AURKA) DMHSORL MA Inhibitor DMHSORL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHSORL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHSPRE DI DMHSPRE DMHSPRE DN A-058 DMHSPRE TI TTMVBWH DMHSPRE TN Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) DMHSPRE MA Modulator DMHSPRE RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMHSPRE RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMHSWT6 DI DMHSWT6 DMHSWT6 DN P-MPPI DMHSWT6 TI TTSQIFT DMHSWT6 TN 5-HT 1A receptor (HTR1A) DMHSWT6 MA Antagonist DMHSWT6 RN p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90. DMHSWT6 RU https://pubmed.ncbi.nlm.nih.gov/9832390 DMHT61V DI DMHT61V DMHT61V DN TETRAHYDROQUINOLINE B DMHT61V TI TTFQAYR DMHT61V TN Cholesteryl ester transfer protein (CETP) DMHT61V MA Inhibitor DMHT61V RN Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett. 2009 May 1;19(9):2456-60. DMHT61V RU https://pubmed.ncbi.nlm.nih.gov/19339179 DMHT6FX DI DMHT6FX DMHT6FX DN 3-[6-Methoxy-indan-(1E)-ylidenemethyl]-pyridine DMHT6FX TI TTSZLWK DMHT6FX TN Aromatase (CYP19A1) DMHT6FX MA Inhibitor DMHT6FX RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMHT6FX RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMHT80R DI DMHT80R DMHT80R DN 2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one DMHT80R TI TTNJYV2 DMHT80R TN Gamma-aminobutyric acid receptor (GAR) DMHT80R MA Inhibitor DMHT80R RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMHT80R RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMHT80R DI DMHT80R DMHT80R DN 2-Furan-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one DMHT80R TI TT1MPAY DMHT80R TN GABA(A) receptor alpha-1 (GABRA1) DMHT80R MA Inhibitor DMHT80R RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMHT80R RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMHT9AR DI DMHT9AR DMHT9AR DN phenylglycine-01 DMHT9AR TI TTRLZHP DMHT9AR TN cAMP-dependent chloride channel (CFTR) DMHT9AR MA Activator DMHT9AR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DMHT9AR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DMHTBDN DI DMHTBDN DMHTBDN DN Isojaspic acid DMHTBDN TI TTSJ6Q4 DMHTBDN TN LOX-5 messenger RNA (ALOX5 mRNA) DMHTBDN MA Inhibitor DMHTBDN RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMHTBDN RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMHTBDN DI DMHTBDN DMHTBDN DN Isojaspic acid DMHTBDN TI TT12ABZ DMHTBDN TN Arachidonate 12-lipoxygenase (12-LOX) DMHTBDN MA Inhibitor DMHTBDN RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMHTBDN RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMHTBDN DI DMHTBDN DMHTBDN DN Isojaspic acid DMHTBDN TI TTN9T81 DMHTBDN TN Arachidonate 15-lipoxygenase (15-LOX) DMHTBDN MA Inhibitor DMHTBDN RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMHTBDN RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMHTEMP DI DMHTEMP DMHTEMP DN TG-3003 DMHTEMP TI TTC70AJ DMHTEMP TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMHTEMP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMHTEMP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMHTGCR DI DMHTGCR DMHTGCR DN METYRAPOL DMHTGCR TI TTIQUX7 DMHTGCR TN Steroid 11-beta-hydroxylase (CYP11B1) DMHTGCR MA Inhibitor DMHTGCR RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMHTGCR RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMHTI5X DI DMHTI5X DMHTI5X DN N-oxo-2-[(4-phenylphenyl)sulfonylamino]ethanamide DMHTI5X TI TTXZ0KQ DMHTI5X TN Matrix metalloproteinase-12 (MMP-12) DMHTI5X MA Inhibitor DMHTI5X RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHTI5X RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHTPSF DI DMHTPSF DMHTPSF DN PNU-22394 DMHTPSF TI TTGP7BY DMHTPSF TN Monoamine oxidase type B (MAO-B) DMHTPSF MA Inhibitor DMHTPSF RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMHTPSF RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMHTPSF DI DMHTPSF DMHTPSF DN PNU-22394 DMHTPSF TI TT3WG5C DMHTPSF TN Monoamine oxidase type A (MAO-A) DMHTPSF MA Inhibitor DMHTPSF RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMHTPSF RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMHTSAX DI DMHTSAX DMHTSAX DN d(CH2)5[Tyr(Me)2]AVP DMHTSAX TI TTK8R02 DMHTSAX TN Vasopressin V2 receptor (V2R) DMHTSAX MA Antagonist DMHTSAX RN Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 2000 Oct;58(4):1613-22. DMHTSAX RU https://pubmed.ncbi.nlm.nih.gov/11012895 DMHTSAX DI DMHTSAX DMHTSAX DN d(CH2)5[Tyr(Me)2]AVP DMHTSAX TI TTL9MHW DMHTSAX TN Vasopressin V1b receptor (V1BR) DMHTSAX MA Antagonist DMHTSAX RN 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol. 1997 Jun 1;53(11):1711-7. DMHTSAX RU https://pubmed.ncbi.nlm.nih.gov/9264324 DMHTSAX DI DMHTSAX DMHTSAX DN d(CH2)5[Tyr(Me)2]AVP DMHTSAX TI TTSCIUP DMHTSAX TN Oxytocin receptor (OTR) DMHTSAX MA Antagonist DMHTSAX RN Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61. DMHTSAX RU https://pubmed.ncbi.nlm.nih.gov/7475979 DMHTSAX DI DMHTSAX DMHTSAX DN d(CH2)5[Tyr(Me)2]AVP DMHTSAX TI TT4TFGN DMHTSAX TN Vasopressin V1a receptor (V1AR) DMHTSAX MA Antagonist DMHTSAX RN Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur J Biochem. 2000 Jul;267(13):4253-63. DMHTSAX RU https://pubmed.ncbi.nlm.nih.gov/10866830 DMHTVRL DI DMHTVRL DMHTVRL DN Cyclopentane amide derivatives 3 DMHTVRL TI TT50QJ3 DMHTVRL TN Influenza Neuraminidase (Influ NA) DMHTVRL MA Inhibitor DMHTVRL RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMHTVRL RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMHTWN9 DI DMHTWN9 DMHTWN9 DN Hex-RYYRIK-NH2 DMHTWN9 TI TTNT7K8 DMHTWN9 TN Nociceptin receptor (OPRL1) DMHTWN9 MA Inhibitor DMHTWN9 RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMHTWN9 RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMHTYBS DI DMHTYBS DMHTYBS DN JNJ-7706621 DMHTYBS TI TTH6V3D DMHTYBS TN Cyclin-dependent kinase 1 (CDK1) DMHTYBS MA Inhibitor DMHTYBS RN Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. DMHTYBS RU https://pubmed.ncbi.nlm.nih.gov/16682186 DMHTYBS DI DMHTYBS DMHTYBS DN JNJ-7706621 DMHTYBS TI TT7HF4W DMHTYBS TN Cyclin-dependent kinase 2 (CDK2) DMHTYBS MA Inhibitor DMHTYBS RN Synthesis and evaluation of N-acyl sulfonamides as potential prodrugs of cyclin-dependent kinase inhibitor JNJ-7706621. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41. DMHTYBS RU https://pubmed.ncbi.nlm.nih.gov/16682186 DMHU4NS DI DMHU4NS DMHU4NS DN [3,4''']biflavone DMHU4NS TI TTT1JVS DMHU4NS TN Cytosolic phospholipase A2 (GIVA cPLA2) DMHU4NS MA Inhibitor DMHU4NS RN Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43. DMHU4NS RU https://pubmed.ncbi.nlm.nih.gov/17826099 DMHU78R DI DMHU78R DMHU78R DN 6-m-Tolyl-pteridine-2,4,7-triamine DMHU78R TI TT9SL3Q DMHU78R TN Polypeptide deformylase (PDF) DMHU78R MA Inhibitor DMHU78R RN Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three ... J Med Chem. 2003 Apr 24;46(9):1726-36. DMHU78R RU https://pubmed.ncbi.nlm.nih.gov/12699390 DMHU9V5 DI DMHU9V5 DMHU9V5 DN 3-(3-methylthiophen-2-yl)pyridine DMHU9V5 TI TTXV4FI DMHU9V5 TN Albendazole monooxygenase (CYP3A4) DMHU9V5 MA Inhibitor DMHU9V5 RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DMHU9V5 RU https://pubmed.ncbi.nlm.nih.gov/17125252 DMHUBT5 DI DMHUBT5 DMHUBT5 DN 3-Carbazol-9-yl-propionic acid DMHUBT5 TI TTHWMFZ DMHUBT5 TN Fatty acid-binding protein 4 (FABP4) DMHUBT5 MA Inhibitor DMHUBT5 RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMHUBT5 RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMHUC1X DI DMHUC1X DMHUC1X DN ISIS 100935 DMHUC1X TI TTW8TJI DMHUC1X TN MEKK1 messenger RNA (MAP3K1 mRNA) DMHUC1X RN US patent application no. 6,168,950, Antisense modulation of MEKK1 expression. DMHUC1X RU http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true DMHUC3Q DI DMHUC3Q DMHUC3Q DN ISIS 113873 DMHUC3Q TI TTIX0ZU DMHUC3Q TN MEKK2 messenger RNA (MAP3K2 mRNA) DMHUC3Q RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMHUC3Q RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMHUG1W DI DMHUG1W DMHUG1W DN NSC-359466 DMHUG1W TI TTJLP0R DMHUG1W TN Quinone reductase 2 (NQO2) DMHUG1W MA Inhibitor DMHUG1W RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMHUG1W RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMHUMDR DI DMHUMDR DMHUMDR DN [L-Tic7]OT DMHUMDR TI TTSCIUP DMHUMDR TN Oxytocin receptor (OTR) DMHUMDR MA Inhibitor DMHUMDR RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMHUMDR RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMHUMP9 DI DMHUMP9 DMHUMP9 DN GSK4716 DMHUMP9 TI TT9ZRHB DMHUMP9 TN Estrogen-related receptor-gamma (ESRRG) DMHUMP9 MA Agonist DMHUMP9 RN Identification and structure-activity relationship of phenolic acyl hydrazones as selective agonists for the estrogen-related orphan nuclear receptors ERRbeta and ERRgamma. J Med Chem. 2005 May 5;48(9):3107-9. DMHUMP9 RU https://pubmed.ncbi.nlm.nih.gov/15857113 DMHUQWN DI DMHUQWN DMHUQWN DN Benzaldehyde O-4-butoxyphenylcarbamoyl oxime DMHUQWN TI TTDP1UC DMHUQWN TN Fatty acid amide hydrolase (FAAH) DMHUQWN MA Inhibitor DMHUQWN RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMHUQWN RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMHURXY DI DMHURXY DMHURXY DN 4,5-dibenzylbenzene-1,2-diol DMHURXY TI TTRE6AX DMHURXY TN Bcl-x messenger RNA (BCL2L1 mRNA) DMHURXY MA Inhibitor DMHURXY RN Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906. DMHURXY RU https://pubmed.ncbi.nlm.nih.gov/20441222 DMHURXY DI DMHURXY DMHURXY DN 4,5-dibenzylbenzene-1,2-diol DMHURXY TI TTJGNVC DMHURXY TN Apoptosis regulator Bcl-2 (BCL-2) DMHURXY MA Inhibitor DMHURXY RN Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention. J Med Chem. 2010 May 27;53(10):3899-906. DMHURXY RU https://pubmed.ncbi.nlm.nih.gov/20441222 DMHUWZS DI DMHUWZS DMHUWZS DN PMID24000170C36 DMHUWZS TI TTHE657 DMHUWZS TN Bromodomain-containing protein 3 (BRD3) DMHUWZS MA Inhibitor DMHUWZS RN Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. DMHUWZS RU https://pubmed.ncbi.nlm.nih.gov/24000170 DMHUWZS DI DMHUWZS DMHUWZS DN PMID24000170C36 DMHUWZS TI TTRA6BO DMHUWZS TN Bromodomain-containing protein 4 (BRD4) DMHUWZS MA Inhibitor DMHUWZS RN Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. DMHUWZS RU https://pubmed.ncbi.nlm.nih.gov/24000170 DMHUWZS DI DMHUWZS DMHUWZS DN PMID24000170C36 DMHUWZS TI TTDP48B DMHUWZS TN Bromodomain-containing protein 2 (BRD2) DMHUWZS MA Inhibitor DMHUWZS RN Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. DMHUWZS RU https://pubmed.ncbi.nlm.nih.gov/24000170 DMHUX9A DI DMHUX9A DMHUX9A DN ISIS 104256 DMHUX9A TI TTCQ2E5 DMHUX9A TN RIP2 messenger RNA (RIP2 mRNA) DMHUX9A RN US patent application no. 6,426,221, Antisense modulation of RIP2 expression. DMHUX9A RU http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true DMHUXRP DI DMHUXRP DMHUXRP DN ARTORIGIDIN A DMHUXRP TI TTSXVID DMHUXRP TN Nuclear factor NF-kappa-B (NFKB) DMHUXRP MA Inhibitor DMHUXRP RN Cytotoxic and NF-kappaB inhibitory constituents of Artocarpus rigida. J Nat Prod. 2010 May 28;73(5):949-55. DMHUXRP RU https://pubmed.ncbi.nlm.nih.gov/20384315 DMHV14R DI DMHV14R DMHV14R DN Alpha-acarviosinyl-(1-->7)-3-alpha-D-glucopyranosylpropen DMHV14R TI TTCGSZ4 DMHV14R TN Pancreatic alpha-amylase (AMY2A) DMHV14R MA Inhibitor DMHV14R RN Enzymatic synthesis of a selective inhibitor for alpha-glucosidases: alpha-acarviosinyl-(1-->9)-3-alpha-D-glucopyranosylpropen. J Agric Food Chem. 2008 Jul 9;56(13):5324-30. DMHV14R RU https://pubmed.ncbi.nlm.nih.gov/18553919 DMHV5NK DI DMHV5NK DMHV5NK DN TOLOXATONE DMHV5NK TI TT3WG5C DMHV5NK TN Monoamine oxidase type A (MAO-A) DMHV5NK MA Inhibitor DMHV5NK RN Quercetin as the active principle of Hypericum hircinum exerts a selective inhibitory activity against MAO-A: extraction, biological analysis, and ... J Nat Prod. 2006 Jun;69(6):945-9. DMHV5NK RU https://pubmed.ncbi.nlm.nih.gov/16792415 DMHV5NK DI DMHV5NK DMHV5NK DN TOLOXATONE DMHV5NK TI TTGP7BY DMHV5NK TN Monoamine oxidase type B (MAO-B) DMHV5NK MA Inhibitor DMHV5NK RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DMHV5NK RU https://pubmed.ncbi.nlm.nih.gov/11881986 DMHVEJF DI DMHVEJF DMHVEJF DN S-14671 DMHVEJF TI TTSQIFT DMHVEJF TN 5-HT 1A receptor (HTR1A) DMHVEJF MA Agonist DMHVEJF RN Labelling of recombinant human and native rat serotonin 5-HT1A receptors by a novel, selective radioligand, [3H]-S 15535: definition of its binding profile using agonists, antagonists and inverse agonists. Naunyn Schmiedebergs Arch Pharmacol. 1998 Mar;357(3):205-17. DMHVEJF RU https://pubmed.ncbi.nlm.nih.gov/9550290 DMHVIK3 DI DMHVIK3 DMHVIK3 DN 3-methoxydesaminokynurenine DMHVIK3 TI TTWQM3J DMHVIK3 TN Kynureninase (KYNU) DMHVIK3 MA Inhibitor DMHVIK3 RN Comparative inhibition by substrate analogues 3-methoxy- and 3-hydroxydesaminokynurenine and an improved 3 step purification of recombinant human kynureninase. BMC Biochem. 2003 Sep 24;4:13. DMHVIK3 RU https://pubmed.ncbi.nlm.nih.gov/14505498 DMHVKIJ DI DMHVKIJ DMHVKIJ DN 2,7-Bis[2-(pyrrolidino)acetamido]anthraquinone DMHVKIJ TI TTQY2EJ DMHVKIJ TN TERT messenger RNA (TERT mRNA) DMHVKIJ MA Inhibitor DMHVKIJ RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMHVKIJ RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMHVNQM DI DMHVNQM DMHVNQM DN 3-methyl-2(1H)-thioxo-4(3H)-quinazolinone DMHVNQM TI TT3WG5C DMHVNQM TN Monoamine oxidase type A (MAO-A) DMHVNQM MA Inhibitor DMHVNQM RN New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A ... Bioorg Med Chem. 2009 Jan 15;17(2):675-89. DMHVNQM RU https://pubmed.ncbi.nlm.nih.gov/19091581 DMHVQ0S DI DMHVQ0S DMHVQ0S DN ISIS 20586 DMHVQ0S TI TTSRXJW DMHVQ0S TN G-alpha-11 messenger RNA (GNA11 mRNA) DMHVQ0S RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DMHVQ0S RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DMHVRFM DI DMHVRFM DMHVRFM DN N-Benzyl,N-methyl-1H-indole-2-carboxamide DMHVRFM TI TTGP7BY DMHVRFM TN Monoamine oxidase type B (MAO-B) DMHVRFM MA Inhibitor DMHVRFM RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMHVRFM RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMHVRFM DI DMHVRFM DMHVRFM DN N-Benzyl,N-methyl-1H-indole-2-carboxamide DMHVRFM TI TT3WG5C DMHVRFM TN Monoamine oxidase type A (MAO-A) DMHVRFM MA Inhibitor DMHVRFM RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMHVRFM RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMHVUF8 DI DMHVUF8 DMHVUF8 DN 3-Methyl-pyrrolidin-(2Z)-ylideneamine DMHVUF8 TI TTCM4B3 DMHVUF8 TN Nitric-oxide synthase endothelial (NOS3) DMHVUF8 MA Inhibitor DMHVUF8 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMHVUF8 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMHVUF8 DI DMHVUF8 DMHVUF8 DN 3-Methyl-pyrrolidin-(2Z)-ylideneamine DMHVUF8 TI TTF10I9 DMHVUF8 TN Nitric-oxide synthase inducible (NOS2) DMHVUF8 MA Inhibitor DMHVUF8 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMHVUF8 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMHVUF8 DI DMHVUF8 DMHVUF8 DN 3-Methyl-pyrrolidin-(2Z)-ylideneamine DMHVUF8 TI TTZUFI5 DMHVUF8 TN Nitric-oxide synthase brain (NOS1) DMHVUF8 MA Inhibitor DMHVUF8 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMHVUF8 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMHVW61 DI DMHVW61 DMHVW61 DN PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE DMHVW61 TI TT7HF4W DMHVW61 TN Cyclin-dependent kinase 2 (CDK2) DMHVW61 MA Inhibitor DMHVW61 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHVW61 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHW2DU DI DMHW2DU DMHW2DU DN Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2 DMHW2DU TI TTYO0A3 DMHW2DU TN Substance-K receptor (TACR2) DMHW2DU MA Inhibitor DMHW2DU RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMHW2DU RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMHW2DU DI DMHW2DU DMHW2DU DN Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2 DMHW2DU TI TT4TFGN DMHW2DU TN Vasopressin V1a receptor (V1AR) DMHW2DU MA Inhibitor DMHW2DU RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMHW2DU RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMHW2DU DI DMHW2DU DMHW2DU DN Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2 DMHW2DU TI TTD0CIQ DMHW2DU TN Melanocortin receptor 4 (MC4R) DMHW2DU MA Inhibitor DMHW2DU RN Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92. DMHW2DU RU https://pubmed.ncbi.nlm.nih.gov/16876401 DMHW40F DI DMHW40F DMHW40F DN KYS-05077 DMHW40F TI TT729IR DMHW40F TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMHW40F MA Inhibitor DMHW40F RN Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. DMHW40F RU https://pubmed.ncbi.nlm.nih.gov/17064894 DMHW40F DI DMHW40F DMHW40F DN KYS-05077 DMHW40F TI TTZPWGN DMHW40F TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMHW40F MA Inhibitor DMHW40F RN Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. DMHW40F RU https://pubmed.ncbi.nlm.nih.gov/17064894 DMHW5FT DI DMHW5FT DMHW5FT DN 2-(5-fluoro-1H-indol-3-yl)ethanamine DMHW5FT TI TTCPG9S DMHW5FT TN 5-HT 1E receptor (HTR1E) DMHW5FT MA Agonist DMHW5FT RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DMHW5FT RU https://pubmed.ncbi.nlm.nih.gov/14744596 DMHW5FT DI DMHW5FT DMHW5FT DN 2-(5-fluoro-1H-indol-3-yl)ethanamine DMHW5FT TI TTXDKTO DMHW5FT TN Long transient receptor potential channel 8 (TRPM8) DMHW5FT MA Inhibitor DMHW5FT RN 5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9. DMHW5FT RU https://pubmed.ncbi.nlm.nih.gov/20965726 DMHW9GL DI DMHW9GL DMHW9GL DN 2-methylisoquinoline-1,3,4-trione DMHW9GL TI TTPF2QI DMHW9GL TN Caspase-3 (CASP3) DMHW9GL MA Inhibitor DMHW9GL RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMHW9GL RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMHWCFJ DI DMHWCFJ DMHWCFJ DN SEMIPLENAMIDE B DMHWCFJ TI TT6OEDT DMHWCFJ TN Cannabinoid receptor 1 (CB1) DMHWCFJ MA Inhibitor DMHWCFJ RN Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Nat Prod. 2003 Oct;66(10):1364-8. DMHWCFJ RU https://pubmed.ncbi.nlm.nih.gov/14575438 DMHWD2C DI DMHWD2C DMHWD2C DN 4-(2-(pyrrolidin-1-yl)ethyl)pyridine DMHWD2C TI TT9JNIC DMHWD2C TN Histamine H3 receptor (H3R) DMHWD2C MA Inhibitor DMHWD2C RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMHWD2C RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMHWGL0 DI DMHWGL0 DMHWGL0 DN ISIS 14548 DMHWGL0 TI TTY3BRA DMHWGL0 TN ZNF217 messenger RNA (ZNF217 mRNA) DMHWGL0 RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DMHWGL0 RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DMHWIG6 DI DMHWIG6 DMHWIG6 DN Ginkgolide M DMHWIG6 TI TTZ8EM9 DMHWIG6 TN Glycine receptor (GlyR) DMHWIG6 MA Inhibitor DMHWIG6 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMHWIG6 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMHWIG6 DI DMHWIG6 DMHWIG6 DN Ginkgolide M DMHWIG6 TI TTF45NW DMHWIG6 TN Strychnine-binding glycine receptor (GLRA1) DMHWIG6 MA Inhibitor DMHWIG6 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMHWIG6 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMHWIMO DI DMHWIMO DMHWIMO DN 4-(4-bromobenzylthio)-2-aminobutanoic acid DMHWIMO TI TTFK1JQ DMHWIMO TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMHWIMO MA Inhibitor DMHWIMO RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMHWIMO RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMHWITR DI DMHWITR DMHWITR DN 1-(isoquinolin-5-yl)-3-(4-morpholinobenzyl)urea DMHWITR TI TTMI6F5 DMHWITR TN Transient receptor potential cation channel V1 (TRPV1) DMHWITR MA Inhibitor DMHWITR RN In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 ... J Med Chem. 2007 Jul 26;50(15):3651-60. DMHWITR RU https://pubmed.ncbi.nlm.nih.gov/17583335 DMHWMFP DI DMHWMFP DMHWMFP DN ISIS 191755 DMHWMFP TI TT0GV3R DMHWMFP TN DGAT1 messenger RNA (DGAT1 mRNA) DMHWMFP RN US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression. DMHWMFP RU http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true DMHWNOS DI DMHWNOS DMHWNOS DN [123I] iodobenzoyl 12-Ex4 DMHWNOS TI TTVIMDE DMHWNOS TN Glucagon-like peptide 1 receptor (GLP1R) DMHWNOS MA Modulator DMHWNOS RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DMHWNOS RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DMHWTCY DI DMHWTCY DMHWTCY DN XMetD DMHWTCY TI TTCBFJO DMHWTCY TN Insulin receptor (INSR) DMHWTCY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMHWTCY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMHWX2O DI DMHWX2O DMHWX2O DN PMID21536438C20f DMHWX2O TI TT7QNVC DMHWX2O TN Glucose-dependent insulinotropic receptor (GPR119) DMHWX2O MA Agonist DMHWX2O RN Discovery of a nortropanol derivative as a potent and orally active GPR119 agonist for type 2 diabetes. Bioorg Med Chem Lett. 2011 Jun 1;21(11):3290-6. DMHWX2O RU https://pubmed.ncbi.nlm.nih.gov/21536438 DMHX1KJ DI DMHX1KJ DMHX1KJ DN VU-71 DMHX1KJ TI TTVBPDM DMHX1KJ TN Metabotropic glutamate receptor 1 (mGluR1) DMHX1KJ MA Modulator (allosteric modulator) DMHX1KJ RN 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4628-31. DMHX1KJ RU https://pubmed.ncbi.nlm.nih.gov/16099654 DMHX4F2 DI DMHX4F2 DMHX4F2 DN N-(4'-t-butyl-4-biphenylyl)urea DMHX4F2 TI TTBGTCW DMHX4F2 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMHX4F2 MA Inhibitor DMHX4F2 RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMHX4F2 RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMHX704 DI DMHX704 DMHX704 DN PMI-008 DMHX704 TI TTLUQ8E DMHX704 TN Hormone sensitive lipase (LIPE) DMHX704 MA Modulator DMHX704 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2593). DMHX704 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2593 DMHX9CT DI DMHX9CT DMHX9CT DN R-820 DMHX9CT TI TTBPGLU DMHX9CT TN Neuromedin-K receptor (TACR3) DMHX9CT MA Antagonist DMHX9CT RN Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br J Pharmacol. 2003 Feb;138(4):554-63. DMHX9CT RU https://pubmed.ncbi.nlm.nih.gov/12598409 DMHX9P8 DI DMHX9P8 DMHX9P8 DN Mallotusinic acid DMHX9P8 TI TTE14XG DMHX9P8 TN Squalene monooxygenase (SQLE) DMHX9P8 MA Inhibitor DMHX9P8 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMHX9P8 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMHXAMR DI DMHXAMR DMHXAMR DN 1-[4-hydroxy-3-(tritylaminomethyl)butyl]uracil DMHXAMR TI TTY8KJS DMHXAMR TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMHXAMR MA Inhibitor DMHXAMR RN Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95. DMHXAMR RU https://pubmed.ncbi.nlm.nih.gov/16821778 DMHXGCO DI DMHXGCO DMHXGCO DN RO5488608 DMHXGCO TI TTXJ47W DMHXGCO TN Metabotropic glutamate receptor 2 (mGluR2) DMHXGCO MA Modulator (allosteric modulator) DMHXGCO RN Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol. 2011 Sep;164(2b):521-37. DMHXGCO RU https://pubmed.ncbi.nlm.nih.gov/21470207 DMHXI21 DI DMHXI21 DMHXI21 DN 3-(6-Amino-purin-9-yl)-5-m-tolyl-pentan-2-ol DMHXI21 TI TTLP57V DMHXI21 TN Adenosine deaminase (ADA) DMHXI21 MA Inhibitor DMHXI21 RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMHXI21 RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMHXMY5 DI DMHXMY5 DMHXMY5 DN 7-(4,6-dimethoxypyrimidin-2-yl)-2-methylquinoline DMHXMY5 TI TTHS256 DMHXMY5 TN Metabotropic glutamate receptor 5 (mGluR5) DMHXMY5 MA Inhibitor DMHXMY5 RN Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91. DMHXMY5 RU https://pubmed.ncbi.nlm.nih.gov/17446071 DMHXRQL DI DMHXRQL DMHXRQL DN 3-benzoyl-1-pentyl-1,4-dihydroquinolin-4-one DMHXRQL TI TTMSFAW DMHXRQL TN Cannabinoid receptor 2 (CB2) DMHXRQL MA Inhibitor DMHXRQL RN Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequence... J Med Chem. 2007 Nov 1;50(22):5471-84. DMHXRQL RU https://pubmed.ncbi.nlm.nih.gov/17915849 DMHXTWK DI DMHXTWK DMHXTWK DN C[L-Ala-D-pro-L-Phe-D-trp] DMHXTWK TI TTQW87Y DMHXTWK TN Opioid receptor kappa (OPRK1) DMHXTWK MA Inhibitor DMHXTWK RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMHXTWK RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMHXTWK DI DMHXTWK DMHXTWK DN C[L-Ala-D-pro-L-Phe-D-trp] DMHXTWK TI TTKWM86 DMHXTWK TN Opioid receptor mu (MOP) DMHXTWK MA Inhibitor DMHXTWK RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMHXTWK RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMHXVNZ DI DMHXVNZ DMHXVNZ DN 2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid DMHXVNZ TI TT9G4N0 DMHXVNZ TN Glutamate carboxypeptidase II (GCPII) DMHXVNZ MA Inhibitor DMHXVNZ RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMHXVNZ RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMHY2RA DI DMHY2RA DMHY2RA DN 2alpha-Hydroxyolean-12-en-28-oic acid DMHY2RA TI TTZHY6R DMHY2RA TN Glycogen phosphorylase muscle form (GP) DMHY2RA MA Inhibitor DMHY2RA RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMHY2RA RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMHY30B DI DMHY30B DMHY30B DN Diphosphate DMHY30B TI TTYQ4AE DMHY30B TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DMHY30B MA Inhibitor DMHY30B RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHY30B RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHY30B DI DMHY30B DMHY30B DN Diphosphate DMHY30B TI TT5B8AX DMHY30B TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMHY30B MA Inhibitor DMHY30B RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHY30B RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHY30B DI DMHY30B DMHY30B DN Diphosphate DMHY30B TI TT8WCXO DMHY30B TN Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE) DMHY30B MA Inhibitor DMHY30B RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMHY30B RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMHY35A DI DMHY35A DMHY35A DN N-ethyl-4-hydroxy-N-phenylbenzenesulfonamide DMHY35A TI TTZAYWL DMHY35A TN Estrogen receptor (ESR) DMHY35A MA Inhibitor DMHY35A RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DMHY35A RU https://pubmed.ncbi.nlm.nih.gov/16300947 DMHY95J DI DMHY95J DMHY95J DN PMID15925511C13 DMHY95J TI TTU3WV6 DMHY95J TN SRSF protein kinase 1 (SRPK1) DMHY95J MA Inhibitor DMHY95J RN Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6. DMHY95J RU https://pubmed.ncbi.nlm.nih.gov/15925511 DMHYA7G DI DMHYA7G DMHYA7G DN 2-methyl-3-phenethyl-3H-pyrimidin-4-one DMHYA7G TI TTBUYHA DMHYA7G TN Extracellular calcium-sensing receptor (CASR) DMHYA7G MA Antagonist DMHYA7G RN Design, new synthesis, and calcilytic activity of substituted 3H-pyrimidin-4-ones. Bioorg Med Chem Lett. 2005 May 16;15(10):2537-40. DMHYA7G RU https://pubmed.ncbi.nlm.nih.gov/15863312 DMHYKBC DI DMHYKBC DMHYKBC DN H-Dmt-Tic-Gly-N(Me)-Ph DMHYKBC TI TT27RFC DMHYKBC TN Opioid receptor delta (OPRD1) DMHYKBC MA Inhibitor DMHYKBC RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMHYKBC RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMHYKBC DI DMHYKBC DMHYKBC DN H-Dmt-Tic-Gly-N(Me)-Ph DMHYKBC TI TTKWM86 DMHYKBC TN Opioid receptor mu (MOP) DMHYKBC MA Inhibitor DMHYKBC RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMHYKBC RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMHYKR8 DI DMHYKR8 DMHYKR8 DN 2-(N''-Acetyl-hydrazino)-benzenesulfonamide DMHYKR8 TI TT2LVK8 DMHYKR8 TN Carbonic anhydrase IX (CA-IX) DMHYKR8 MA Inhibitor DMHYKR8 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMHYKR8 RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMHYKR8 DI DMHYKR8 DMHYKR8 DN 2-(N''-Acetyl-hydrazino)-benzenesulfonamide DMHYKR8 TI TTANPDJ DMHYKR8 TN Carbonic anhydrase II (CA-II) DMHYKR8 MA Inhibitor DMHYKR8 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMHYKR8 RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMHYLQ2 DI DMHYLQ2 DMHYLQ2 DN Lithium chloride DMHYLQ2 TI TTRZQE3 DMHYLQ2 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMHYLQ2 MA Inhibitor DMHYLQ2 RN Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS. J Neuroimmune Pharmacol. 2007 Mar;2(1):93-6. DMHYLQ2 RU https://pubmed.ncbi.nlm.nih.gov/18040831 DMHYORU DI DMHYORU DMHYORU DN UCB-101333-3 DMHYORU TI TTVIAT9 DMHYORU TN Phosphodiesterase 4B (PDE4B) DMHYORU MA Inhibitor DMHYORU RN First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9. DMHYORU RU https://pubmed.ncbi.nlm.nih.gov/16439121 DMHYORU DI DMHYORU DMHYORU DN UCB-101333-3 DMHYORU TI TTZ97H5 DMHYORU TN Phosphodiesterase 4A (PDE4A) DMHYORU MA Inhibitor DMHYORU RN First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9. DMHYORU RU https://pubmed.ncbi.nlm.nih.gov/16439121 DMHYORU DI DMHYORU DMHYORU DN UCB-101333-3 DMHYORU TI TTQ13Z5 DMHYORU TN Muscarinic acetylcholine receptor M3 (CHRM3) DMHYORU MA Inhibitor DMHYORU RN Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3077-80. DMHYORU RU https://pubmed.ncbi.nlm.nih.gov/17398090 DMHYORU DI DMHYORU DMHYORU DN UCB-101333-3 DMHYORU TI TTSKMI8 DMHYORU TN Phosphodiesterase 4D (PDE4D) DMHYORU MA Inhibitor DMHYORU RN First dual M3 antagonists-PDE4 inhibitors: synthesis and SAR of 4,6-diaminopyrimidine derivatives. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1834-9. DMHYORU RU https://pubmed.ncbi.nlm.nih.gov/16439121 DMHYQ3Z DI DMHYQ3Z DMHYQ3Z DN 3-benzyl-5-methylbenzo[d]oxazol-2(3H)-one DMHYQ3Z TI TT6804T DMHYQ3Z TN MIF messenger RNA (MIF mRNA) DMHYQ3Z MA Inhibitor DMHYQ3Z RN Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4. DMHYQ3Z RU https://pubmed.ncbi.nlm.nih.gov/20728358 DMHYRES DI DMHYRES DMHYRES DN 3-methoxy-5-(1,5-naphthyridin-3-yl)benzonitrile DMHYRES TI TTHS256 DMHYRES TN Metabotropic glutamate receptor 5 (mGluR5) DMHYRES MA Inhibitor DMHYRES RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMHYRES RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMHZ256 DI DMHZ256 DMHZ256 DN N-(5-chloro-2-(phenylthio)phenyl)butyramide DMHZ256 TI TTRTKPV DMHZ256 TN Trypanosoma Trypanothione reductase (Trypano TPR) DMHZ256 MA Inhibitor DMHZ256 RN Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class ... J Med Chem. 2005 Dec 15;48(25):8087-97. DMHZ256 RU https://pubmed.ncbi.nlm.nih.gov/16335933 DMHZ5SB DI DMHZ5SB DMHZ5SB DN 8-Methoxy-quinolin-2-ylamine DMHZ5SB TI TT6MSOK DMHZ5SB TN 5-HT 1D receptor (HTR1D) DMHZ5SB MA Inhibitor DMHZ5SB RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMHZ5SB RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMHZ5SB DI DMHZ5SB DMHZ5SB DN 8-Methoxy-quinolin-2-ylamine DMHZ5SB TI TTSQIFT DMHZ5SB TN 5-HT 1A receptor (HTR1A) DMHZ5SB MA Inhibitor DMHZ5SB RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMHZ5SB RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMHZ5SB DI DMHZ5SB DMHZ5SB DN 8-Methoxy-quinolin-2-ylamine DMHZ5SB TI TTX4RTB DMHZ5SB TN Melanin-concentrating hormone receptor 1 (MCHR1) DMHZ5SB MA Inhibitor DMHZ5SB RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMHZ5SB RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMHZ5W3 DI DMHZ5W3 DMHZ5W3 DN AcAsp-Glu-Cha-Val-Prb-Cpg DMHZ5W3 TI TTWXB3E DMHZ5W3 TN Hepatitis C virus NS3 helicase (HCV NS3) DMHZ5W3 MA Inhibitor DMHZ5W3 RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMHZ5W3 RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMHZCLV DI DMHZCLV DMHZCLV DN N-Propargyl-1(S)-Aminoindan DMHZCLV TI TTGP7BY DMHZCLV TN Monoamine oxidase type B (MAO-B) DMHZCLV MA Inhibitor DMHZCLV RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMHZCLV RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMHZFK1 DI DMHZFK1 DMHZFK1 DN Piperidine-1-carboxylic acid adamantan-2-ylamide DMHZFK1 TI TTN7BL9 DMHZFK1 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMHZFK1 MA Inhibitor DMHZFK1 RN Discovery and optimization of adamantyl carbamate inhibitors of 11-HSD1. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6725-9. DMHZFK1 RU https://pubmed.ncbi.nlm.nih.gov/20864344 DMHZJXG DI DMHZJXG DMHZJXG DN 2-(benzyloxyamino)-N-hydroxyacetamide DMHZJXG TI TT2LVK8 DMHZJXG TN Carbonic anhydrase IX (CA-IX) DMHZJXG MA Inhibitor DMHZJXG RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMHZJXG RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMHZKMG DI DMHZKMG DMHZKMG DN DABCO DMHZKMG TI TTODZF1 DMHZKMG TN Voltage-gated potassium channel Kv3.4 (KCNC4) DMHZKMG MA Blocker (channel blocker) DMHZKMG RN 1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers. Mol Pharmacol. 2006 Mar;69(3):718-26. DMHZKMG RU https://pubmed.ncbi.nlm.nih.gov/16317109 DMHZOIU DI DMHZOIU DMHZOIU DN PMID26061392C2 DMHZOIU TI TT0EOB8 DMHZOIU TN B-Raf messenger RNA (BRAF mRNA) DMHZOIU MA Inhibitor DMHZOIU RN Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib. ACS Chem Biol. 2015 Sep 18;10(9):2099-107. DMHZOIU RU https://pubmed.ncbi.nlm.nih.gov/26061392 DMHZPJ0 DI DMHZPJ0 DMHZPJ0 DN ISIS 18078 DMHZPJ0 TI TT3IVG2 DMHZPJ0 TN JNK2 messenger RNA (JNK2 mRNA) DMHZPJ0 RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMHZPJ0 RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMHZT1S DI DMHZT1S DMHZT1S DN 5-hexyl-2-(pyridin-3-yloxy)phenol DMHZT1S TI TTVTX4N DMHZT1S TN Bacterial Fatty acid synthetase I (Bact inhA) DMHZT1S MA Inhibitor DMHZT1S RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMHZT1S RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMHZU8K DI DMHZU8K DMHZU8K DN N-(3-phenethoxybenzyl)-4-hydroxybenzamide DMHZU8K TI TTN9D8E DMHZU8K TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMHZU8K MA Inhibitor DMHZU8K RN Structure-activity relationship study of novel NR2B-selective antagonists with arylamides to avoid reactive metabolites formation. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5537-42. DMHZU8K RU https://pubmed.ncbi.nlm.nih.gov/17766107 DMI01YM DI DMI01YM DMI01YM DN LY178002 DMI01YM TI TT9V5JH DMI01YM TN Phospholipase A2 (PLA2G1B) DMI01YM MA Inhibitor DMI01YM RN The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. DMI01YM RU https://pubmed.ncbi.nlm.nih.gov/2508442 DMI03KV DI DMI03KV DMI03KV DN 4-fluorophenyl-2,2-diphenylacetamide DMI03KV TI TTMNI76 DMI03KV TN Calcium-activated potassium channel (KCN) DMI03KV MA Inhibitor DMI03KV RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMI03KV RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMI065U DI DMI065U DMI065U DN N-mesityl-4,6-dimethyl-3-tosylpyridin-2-amine DMI065U TI TT7EFHR DMI065U TN Corticotropin-releasing factor receptor 1 (CRHR1) DMI065U MA Inhibitor DMI065U RN Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):934-7. DMI065U RU https://pubmed.ncbi.nlm.nih.gov/16297619 DMI0GMB DI DMI0GMB DMI0GMB DN 5-hydroxyindole DMI0GMB TI TTPC4TU DMI0GMB TN 5-HT 3A receptor (HTR3A) DMI0GMB MA Modulator (allosteric modulator) DMI0GMB RN The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor. J Biol Chem. 2008 Mar 14;283(11):6826-31. DMI0GMB RU https://pubmed.ncbi.nlm.nih.gov/18187416 DMI0U87 DI DMI0U87 DMI0U87 DN H-Tyr-Tic-Phe-Phe-OH DMI0U87 TI TT27RFC DMI0U87 TN Opioid receptor delta (OPRD1) DMI0U87 MA Inhibitor DMI0U87 RN The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers. 1999;51(6):411-25. DMI0U87 RU https://pubmed.ncbi.nlm.nih.gov/10797230 DMI0U87 DI DMI0U87 DMI0U87 DN H-Tyr-Tic-Phe-Phe-OH DMI0U87 TI TTKWM86 DMI0U87 TN Opioid receptor mu (MOP) DMI0U87 MA Inhibitor DMI0U87 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMI0U87 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMI12X9 DI DMI12X9 DMI12X9 DN (S)-4-CMTB DMI12X9 TI TTXDOHN DMI12X9 TN Free fatty acid receptor 3 (FFAR3) DMI12X9 MA Agonist DMI12X9 RN Identification and functional characterization of allosteric agonists for the G protein-coupled receptor FFA2. Mol Pharmacol. 2008 Dec;74(6):1599-609. DMI12X9 RU https://pubmed.ncbi.nlm.nih.gov/18818303 DMI12X9 DI DMI12X9 DMI12X9 DN (S)-4-CMTB DMI12X9 TI TT0FYAN DMI12X9 TN Free fatty acid receptor 2 (FFAR2) DMI12X9 MA Agonist DMI12X9 RN Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J Biol Chem. 2012 Nov 30;287(49):41195-209. DMI12X9 RU https://pubmed.ncbi.nlm.nih.gov/23066016 DMI12Y8 DI DMI12Y8 DMI12Y8 DN Nickel chloride DMI12Y8 TI TT729IR DMI12Y8 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMI12Y8 MA Blocker DMI12Y8 RN T-type calcium channels facilitate insulin secretion by enhancing general excitability in the insulin-secreting beta-cell line, INS-1. Endocrinology. 1997 Sep;138(9):3735-40. DMI12Y8 RU https://pubmed.ncbi.nlm.nih.gov/9275059 DMI146O DI DMI146O DMI146O DN (E)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid DMI146O TI TTLZS4Q DMI146O TN M-phase inducer phosphatase 1 (MPIP1) DMI146O MA Inhibitor DMI146O RN Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3. DMI146O RU https://pubmed.ncbi.nlm.nih.gov/18442908 DMI1598 DI DMI1598 DMI1598 DN 4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine DMI1598 TI TTJS8PY DMI1598 TN 5-HT 6 receptor (HTR6) DMI1598 MA Inhibitor DMI1598 RN Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302. DMI1598 RU https://pubmed.ncbi.nlm.nih.gov/16183286 DMI15LJ DI DMI15LJ DMI15LJ DN 1-(3-Methylbutylidene)thiosemicarbazide DMI15LJ TI TTULVH8 DMI15LJ TN Tyrosinase (TYR) DMI15LJ MA Inhibitor DMI15LJ RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMI15LJ RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMI15VQ DI DMI15VQ DMI15VQ DN 4-((+/-)-(1H-imidazol-1-yl)-(E)-methylretinoate DMI15VQ TI TTD7Q0R DMI15VQ TN Cytochrome P450 26 (CYP26A1) DMI15VQ MA Inhibitor DMI15VQ RN Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and pros... J Med Chem. 2004 Dec 30;47(27):6716-29. DMI15VQ RU https://pubmed.ncbi.nlm.nih.gov/15615521 DMI16MD DI DMI16MD DMI16MD DN 7-Ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DMI16MD TI TT06AWU DMI16MD TN Phosphodiesterase 3A (PDE3A) DMI16MD MA Inhibitor DMI16MD RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DMI16MD RU https://pubmed.ncbi.nlm.nih.gov/1654430 DMI1CAJ DI DMI1CAJ DMI1CAJ DN oleocanthal DMI1CAJ TI TTELV3W DMI1CAJ TN Transformation-sensitive protein p120 (TRPA1) DMI1CAJ MA Activator DMI1CAJ RN Unusual pungency from extra-virgin olive oil is attributable to restricted spatial expression of the receptor of oleocanthal. J Neurosci. 2011 Jan 19;31(3):999-1009. DMI1CAJ RU https://pubmed.ncbi.nlm.nih.gov/21248124 DMI1EFY DI DMI1EFY DMI1EFY DN 4-Benzythiopyridine-3-sulfonamide DMI1EFY TI TT2LVK8 DMI1EFY TN Carbonic anhydrase IX (CA-IX) DMI1EFY MA Inhibitor DMI1EFY RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMI1EFY RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMI1EFY DI DMI1EFY DMI1EFY DN 4-Benzythiopyridine-3-sulfonamide DMI1EFY TI TTEYTKG DMI1EFY TN Carbonic anhydrase XIV (CA-XIV) DMI1EFY MA Inhibitor DMI1EFY RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMI1EFY RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMI1EFY DI DMI1EFY DMI1EFY DN 4-Benzythiopyridine-3-sulfonamide DMI1EFY TI TTANPDJ DMI1EFY TN Carbonic anhydrase II (CA-II) DMI1EFY MA Inhibitor DMI1EFY RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMI1EFY RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMI1EFY DI DMI1EFY DMI1EFY DN 4-Benzythiopyridine-3-sulfonamide DMI1EFY TI TTSYM0R DMI1EFY TN Carbonic anhydrase XII (CA-XII) DMI1EFY MA Inhibitor DMI1EFY RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMI1EFY RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMI1EFY DI DMI1EFY DMI1EFY DN 4-Benzythiopyridine-3-sulfonamide DMI1EFY TI TTHQPL7 DMI1EFY TN Carbonic anhydrase I (CA-I) DMI1EFY MA Inhibitor DMI1EFY RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMI1EFY RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMI1FGV DI DMI1FGV DMI1FGV DN PMID21851057C4d DMI1FGV TI TTRA6BO DMI1FGV TN Bromodomain-containing protein 4 (BRD4) DMI1FGV MA Inhibitor DMI1FGV RN 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011 Oct 13;54(19):6761-70. DMI1FGV RU https://pubmed.ncbi.nlm.nih.gov/21851057 DMI1FGV DI DMI1FGV DMI1FGV DN PMID21851057C4d DMI1FGV TI TTDP48B DMI1FGV TN Bromodomain-containing protein 2 (BRD2) DMI1FGV MA Inhibitor DMI1FGV RN 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011 Oct 13;54(19):6761-70. DMI1FGV RU https://pubmed.ncbi.nlm.nih.gov/21851057 DMI1H3Y DI DMI1H3Y DMI1H3Y DN BVDU-MP DMI1H3Y TI TTP3QRF DMI1H3Y TN Thymidine kinase 1 (TK1) DMI1H3Y MA Inhibitor DMI1H3Y RN Crystal structure of varicella zoster virus thymidine kinase. J Biol Chem. 2003 Jul 4;278(27):24680-7. DMI1H3Y RU https://pubmed.ncbi.nlm.nih.gov/12686543 DMI1HBR DI DMI1HBR DMI1HBR DN N-(1-oxobutan-2-yl)-3-(trifluoromethyl)benzamide DMI1HBR TI TTUMQVO DMI1HBR TN Cathepsin S (CTSS) DMI1HBR MA Inhibitor DMI1HBR RN Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6890-4. DMI1HBR RU https://pubmed.ncbi.nlm.nih.gov/21030256 DMI1L6Q DI DMI1L6Q DMI1L6Q DN 4-methylaminomethyl-7-methoxycoumarin DMI1L6Q TI TTVG215 DMI1L6Q TN Debrisoquine 4-hydroxylase (CYP2D6) DMI1L6Q MA Inhibitor DMI1L6Q RN Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. J Med Chem. 2010 Oct 14;53(19):7129-39. DMI1L6Q RU https://pubmed.ncbi.nlm.nih.gov/20839775 DMI1O54 DI DMI1O54 DMI1O54 DN 2,5-dideoxy-2,5-imino-D-altritol DMI1O54 TI TTA0OSE DMI1O54 TN Lactase-phlorizin hydrolase (LCT) DMI1O54 MA Inhibitor DMI1O54 RN 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4. DMI1O54 RU https://pubmed.ncbi.nlm.nih.gov/20457528 DMI1O54 DI DMI1O54 DMI1O54 DN 2,5-dideoxy-2,5-imino-D-altritol DMI1O54 TI TTIS03D DMI1O54 TN Alpha-galactosidase A (GLA) DMI1O54 MA Inhibitor DMI1O54 RN 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4. DMI1O54 RU https://pubmed.ncbi.nlm.nih.gov/20457528 DMI245K DI DMI245K DMI245K DN N-(dibenzo[b,d]thiophen-3-ylsulfonyl)-L-valine DMI245K TI TTXZ0KQ DMI245K TN Matrix metalloproteinase-12 (MMP-12) DMI245K MA Inhibitor DMI245K RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMI245K RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMI29ED DI DMI29ED DMI29ED DN PF-4840154 DMI29ED TI TTELV3W DMI29ED TN Transformation-sensitive protein p120 (TRPA1) DMI29ED MA Activator DMI29ED RN Design and pharmacological evaluation of PF-4840154, a non-electrophilic reference agonist of the TrpA1 channel. Bioorg Med Chem Lett. 2011 Aug 15;21(16):4857-9. DMI29ED RU https://pubmed.ncbi.nlm.nih.gov/21741838 DMI2EM5 DI DMI2EM5 DMI2EM5 DN 4-(4-butoxyphenoxy)phenol DMI2EM5 TI TTXZEAJ DMI2EM5 TN Leukotriene A-4 hydrolase (LTA4H) DMI2EM5 MA Inhibitor DMI2EM5 RN Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52. DMI2EM5 RU https://pubmed.ncbi.nlm.nih.gov/18952425 DMI2GFM DI DMI2GFM DMI2GFM DN NSC-745795 DMI2GFM TI TTQY2EJ DMI2GFM TN TERT messenger RNA (TERT mRNA) DMI2GFM MA Inhibitor DMI2GFM RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMI2GFM RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMI2KE7 DI DMI2KE7 DMI2KE7 DN SC-50135 DMI2KE7 TI TTN53ZF DMI2KE7 TN Leukotriene B4 receptor 1 (LTB4R) DMI2KE7 MA Inhibitor DMI2KE7 RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DMI2KE7 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DMI2PXO DI DMI2PXO DMI2PXO DN 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione DMI2PXO TI TTLM12X DMI2PXO TN Matrix metalloproteinase-2 (MMP-2) DMI2PXO MA Inhibitor DMI2PXO RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DMI2PXO RU https://pubmed.ncbi.nlm.nih.gov/11327602 DMI2PXO DI DMI2PXO DMI2PXO DN 5-Biphenyl-4-yl-5-hexyl-pyrimidine-2,4,6-trione DMI2PXO TI TT6X50U DMI2PXO TN Matrix metalloproteinase-9 (MMP-9) DMI2PXO MA Inhibitor DMI2PXO RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DMI2PXO RU https://pubmed.ncbi.nlm.nih.gov/11327602 DMI2PY7 DI DMI2PY7 DMI2PY7 DN 2,4,3',5'-tetrahydroxybibenzyl DMI2PY7 TI TTULVH8 DMI2PY7 TN Tyrosinase (TYR) DMI2PY7 MA Inhibitor DMI2PY7 RN Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5650-3. DMI2PY7 RU https://pubmed.ncbi.nlm.nih.gov/16919455 DMI2RH1 DI DMI2RH1 DMI2RH1 DN 3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one DMI2RH1 TI TTJFY5U DMI2RH1 TN Adenosine A3 receptor (ADORA3) DMI2RH1 MA Inhibitor DMI2RH1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DMI2RH1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DMI2RH1 DI DMI2RH1 DMI2RH1 DN 3-(3-chloro-1H-pyrazol-5-yl)quinoxalin-2(1H)-one DMI2RH1 TI TTK25J1 DMI2RH1 TN Adenosine A1 receptor (ADORA1) DMI2RH1 MA Inhibitor DMI2RH1 RN Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J Med Chem. 2008 Mar 27;51(6):1764-70. DMI2RH1 RU https://pubmed.ncbi.nlm.nih.gov/18269230 DMI2RQS DI DMI2RQS DMI2RQS DN Endomorphins DMI2RQS TI TTKWM86 DMI2RQS TN Opioid receptor mu (MOP) DMI2RQS MA Modulator DMI2RQS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMI2RQS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMI2XUQ DI DMI2XUQ DMI2XUQ DN 6-Allyloxy-9H-purin-2-ylamine DMI2XUQ TI TTJ8DV7 DMI2XUQ TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DMI2XUQ MA Inhibitor DMI2XUQ RN Resistance-modifying agents. 8. Inhibition of O(6)-alkylguanine-DNA alkyltransferase by O(6)-alkenyl-, O(6)-cycloalkenyl-, and O(6)-(2-oxoalkyl)gua... J Med Chem. 2000 Nov 2;43(22):4071-83. DMI2XUQ RU https://pubmed.ncbi.nlm.nih.gov/11063604 DMI2XWY DI DMI2XWY DMI2XWY DN 1,1,1-Trifluoro-5-(4-octylphenoxy)pentan-2-one DMI2XWY TI TTT1JVS DMI2XWY TN Cytosolic phospholipase A2 (GIVA cPLA2) DMI2XWY MA Inhibitor DMI2XWY RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DMI2XWY RU https://pubmed.ncbi.nlm.nih.gov/20369880 DMI30V7 DI DMI30V7 DMI30V7 DN PMID20527968-compound-6577871 DMI30V7 TI TTRGHB2 DMI30V7 TN SARS-CoV papain-like proteinase (PL-PRO) DMI30V7 MA Inhibitor DMI30V7 RN Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biologic... J Med Chem. 2010 Jul 8;53(13):4968-79. DMI30V7 RU https://pubmed.ncbi.nlm.nih.gov/20527968 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TT50QJ3 DMI3491 TN Influenza Neuraminidase (Influ NA) DMI3491 MA Inhibitor DMI3491 RN Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/19729316 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTER6YH DMI3491 TN Casein kinase II alpha (CSNK2A1) DMI3491 MA Inhibitor DMI3491 RN Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/19414254 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTFBNVI DMI3491 TN Aldose reductase (AKR1B1) DMI3491 MA Inhibitor DMI3491 RN Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/18298080 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTI84H7 DMI3491 TN Cytochrome P450 1B1 (CYP1B1) DMI3491 MA Inhibitor DMI3491 RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTSZLWK DMI3491 TN Aromatase (CYP19A1) DMI3491 MA Inhibitor DMI3491 RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTKPW01 DMI3491 TN Androgen receptor messenger RNA (AR mRNA) DMI3491 MA Inhibitor DMI3491 RN Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/19592245 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTSFWA7 DMI3491 TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMI3491 MA Inhibitor DMI3491 RN A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/15481979 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTO0FDJ DMI3491 TN Cyclin-dependent kinase 6 (CDK6) DMI3491 MA Inhibitor DMI3491 RN Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem. 2005 Feb 10;48(3):737-43. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/15689157 DMI3491 DI DMI3491 DMI3491 DN Apigenin DMI3491 TI TTIWB6L DMI3491 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMI3491 MA Inhibitor DMI3491 RN Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem. 2008 Jul 24;51(14):4188-99. DMI3491 RU https://pubmed.ncbi.nlm.nih.gov/18533708 DMI36WC DI DMI36WC DMI36WC DN 1,4-Diethylene Dioxide DMI36WC TI TTWMIDN DMI36WC TN B-cell-activating factor (TNFSF13B) DMI36WC MA Inhibitor DMI36WC RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMI36WC RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMI39LV DI DMI39LV DMI39LV DN (D-Arg)(9)-p19(ARF) 26-44 peptide DMI39LV TI TTD3KOX DMI39LV TN Forkhead box protein M1 (FOXM1) DMI39LV MA Inhibitor DMI39LV RN Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor. Genes Dev. 2004 Apr 1;18(7):830-50. DMI39LV RU https://pubmed.ncbi.nlm.nih.gov/15082532 DMI39QT DI DMI39QT DMI39QT DN 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one DMI39QT TI TTVKILB DMI39QT TN Prostaglandin G/H synthase 2 (COX-2) DMI39QT MA Inhibitor DMI39QT RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMI39QT RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMI39QT DI DMI39QT DMI39QT DN 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiol-3-one DMI39QT TI TT8NGED DMI39QT TN Prostaglandin G/H synthase 1 (COX-1) DMI39QT MA Inhibitor DMI39QT RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMI39QT RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMI39YX DI DMI39YX DMI39YX DN AMG-628 DMI39YX TI TTMI6F5 DMI39YX TN Transient receptor potential cation channel V1 (TRPV1) DMI39YX MA Inhibitor DMI39YX RN Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacok... J Med Chem. 2007 Jul 26;50(15):3528-39. DMI39YX RU https://pubmed.ncbi.nlm.nih.gov/17585751 DMI3ANC DI DMI3ANC DMI3ANC DN BI 7273 DMI3ANC TI TTR7L5Y DMI3ANC TN Bromodomain-containing protein 9 (BRD9) DMI3ANC MA Inhibitor DMI3ANC RN Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 2016 May 26;59(10):4462-75. DMI3ANC RU https://pubmed.ncbi.nlm.nih.gov/26914985 DMI3CSJ DI DMI3CSJ DMI3CSJ DN C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 DMI3CSJ TI TTNI91K DMI3CSJ TN Melanocortin receptor 3 (MC3R) DMI3CSJ MA Inhibitor DMI3CSJ RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMI3CSJ RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMI3CSJ DI DMI3CSJ DMI3CSJ DN C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 DMI3CSJ TI TTEOSZT DMI3CSJ TN Melanocortin receptor (MCR) DMI3CSJ MA Inhibitor DMI3CSJ RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMI3CSJ RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMI3CSJ DI DMI3CSJ DMI3CSJ DN C[CO-(CH2)2-CO-Nle-D-Phe-Arg-Trp-Lys]-NH2 DMI3CSJ TI TTD0CIQ DMI3CSJ TN Melanocortin receptor 4 (MC4R) DMI3CSJ MA Inhibitor DMI3CSJ RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMI3CSJ RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMI3CUZ DI DMI3CUZ DMI3CUZ DN N,N-dimethyl-3,4-dihydroquinazolin-2-amine DMI3CUZ TI TTRUFDT DMI3CUZ TN 5-HT 5A receptor (HTR5A) DMI3CUZ MA Inhibitor DMI3CUZ RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMI3CUZ RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMI3OR9 DI DMI3OR9 DMI3OR9 DN 4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide DMI3OR9 TI TTDCBX5 DMI3OR9 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMI3OR9 MA Inhibitor DMI3OR9 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMI3OR9 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMI3OR9 DI DMI3OR9 DMI3OR9 DN 4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide DMI3OR9 TI TT1VAUK DMI3OR9 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMI3OR9 MA Inhibitor DMI3OR9 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMI3OR9 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMI3OR9 DI DMI3OR9 DMI3OR9 DN 4-Chloro-N-(3-chloro-benzoyl)-benzenesulfonamide DMI3OR9 TI TTUTJGQ DMI3OR9 TN Vascular endothelial growth factor receptor 2 (KDR) DMI3OR9 MA Inhibitor DMI3OR9 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMI3OR9 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMI3PCZ DI DMI3PCZ DMI3PCZ DN PMID1992138C8b DMI3PCZ TI TTPADOQ DMI3PCZ TN HMG-CoA reductase (HMGCR) DMI3PCZ MA Inhibitor DMI3PCZ RN Inhibitors of cholesterol biosynthesis. 4. trans-6-[2-(substituted-quinolinyl)ethenyl/ethyl]tetrahydro-4-hydroxy-2 H-pyran-2-ones, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1991 Jan;34(1):367-73. DMI3PCZ RU https://pubmed.ncbi.nlm.nih.gov/1992138 DMI3URD DI DMI3URD DMI3URD DN (+/-)-7-methyl-2-phenylchroman-4-one DMI3URD TI TTGP7BY DMI3URD TN Monoamine oxidase type B (MAO-B) DMI3URD MA Inhibitor DMI3URD RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMI3URD RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMI452E DI DMI452E DMI452E DN N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide DMI452E TI TT32JK8 DMI452E TN Melatonin receptor type 1B (MTNR1B) DMI452E MA Inhibitor DMI452E RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMI452E RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMI452E DI DMI452E DMI452E DN N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamide DMI452E TI TT0WAIE DMI452E TN Melatonin receptor type 1A (MTNR1A) DMI452E MA Inhibitor DMI452E RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMI452E RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMI457Y DI DMI457Y DMI457Y DN 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one DMI457Y TI TTVBI8W DMI457Y TN Dopamine transporter (DAT) DMI457Y MA Inhibitor DMI457Y RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMI457Y RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMI457Y DI DMI457Y DMI457Y DN 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one DMI457Y TI TT3ROYC DMI457Y TN Serotonin transporter (SERT) DMI457Y MA Inhibitor DMI457Y RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMI457Y RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMI457Y DI DMI457Y DMI457Y DN 2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one DMI457Y TI TTAWNKZ DMI457Y TN Norepinephrine transporter (NET) DMI457Y MA Inhibitor DMI457Y RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMI457Y RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMI479T DI DMI479T DMI479T DN 1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) DMI479T TI TTXV4FI DMI479T TN Albendazole monooxygenase (CYP3A4) DMI479T MA Inhibitor DMI479T RN 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001. DMI479T RU https://pubmed.ncbi.nlm.nih.gov/20527970 DMI479T DI DMI479T DMI479T DN 1-(METHOXYMETHYL)-6-(NAPHTHALEN-2-YL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) DMI479T TI TTVG215 DMI479T TN Debrisoquine 4-hydroxylase (CYP2D6) DMI479T MA Inhibitor DMI479T RN 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001. DMI479T RU https://pubmed.ncbi.nlm.nih.gov/20527970 DMI49D0 DI DMI49D0 DMI49D0 DN 16-alphaH,17-isovaleryloxy-ent-kauran-19-oic acid DMI49D0 TI TTELIN2 DMI49D0 TN PTPN1 messenger RNA (PTPN1 mRNA) DMI49D0 MA Inhibitor DMI49D0 RN Inhibition of protein tyrosine phosphatase 1B by diterpenoids isolated from Acanthopanax koreanum. Bioorg Med Chem Lett. 2006 Jun 1;16(11):3061-4. DMI49D0 RU https://pubmed.ncbi.nlm.nih.gov/16545563 DMI4EU5 DI DMI4EU5 DMI4EU5 DN PMID30247903-Compound-General structure36 DMI4EU5 TI TT23XQV DMI4EU5 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMI4EU5 MA Inhibitor DMI4EU5 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMI4EU5 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMI4FKH DI DMI4FKH DMI4FKH DN lysophosphatidylethanolamine DMI4FKH TI TT7QNVC DMI4FKH TN Glucose-dependent insulinotropic receptor (GPR119) DMI4FKH MA Agonist DMI4FKH RN Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51. DMI4FKH RU https://pubmed.ncbi.nlm.nih.gov/15607732 DMI4H05 DI DMI4H05 DMI4H05 DN 1,3-DIPHENYLUREA DMI4H05 TI TT7WVHI DMI4H05 TN Soluble epoxide hydrolase (EPHX2) DMI4H05 MA Inhibitor DMI4H05 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMI4H05 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMI4KNB DI DMI4KNB DMI4KNB DN N-(2-morpholinophenyl)-5-nitrofuran-2-carboxamide DMI4KNB TI TTC70AJ DMI4KNB TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMI4KNB MA Inhibitor DMI4KNB RN Potent 2'-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6070-4. DMI4KNB RU https://pubmed.ncbi.nlm.nih.gov/17904845 DMI4MPZ DI DMI4MPZ DMI4MPZ DN PD-135540 DMI4MPZ TI TTEX248 DMI4MPZ TN Dopamine D2 receptor (D2R) DMI4MPZ MA Inhibitor DMI4MPZ RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DMI4MPZ RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DMI4OTW DI DMI4OTW DMI4OTW DN ALFAXALONE DMI4OTW TI TTNJYV2 DMI4OTW TN Gamma-aminobutyric acid receptor (GAR) DMI4OTW MA Inhibitor DMI4OTW RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DMI4OTW RU https://pubmed.ncbi.nlm.nih.gov/9599235 DMI4TVB DI DMI4TVB DMI4TVB DN A-381393 DMI4TVB TI TTE0A2F DMI4TVB TN Dopamine D4 receptor (D4R) DMI4TVB MA Antagonist DMI4TVB RN Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77. DMI4TVB RU https://pubmed.ncbi.nlm.nih.gov/18604600 DMI4WCQ DI DMI4WCQ DMI4WCQ DN 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate DMI4WCQ TI TT27RFC DMI4WCQ TN Opioid receptor delta (OPRD1) DMI4WCQ MA Inhibitor DMI4WCQ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMI4WCQ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMI4WCQ DI DMI4WCQ DMI4WCQ DN 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate DMI4WCQ TI TTQW87Y DMI4WCQ TN Opioid receptor kappa (OPRK1) DMI4WCQ MA Inhibitor DMI4WCQ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMI4WCQ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMI4WCQ DI DMI4WCQ DMI4WCQ DN 17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate DMI4WCQ TI TTKWM86 DMI4WCQ TN Opioid receptor mu (MOP) DMI4WCQ MA Inhibitor DMI4WCQ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMI4WCQ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMI4WVE DI DMI4WVE DMI4WVE DN CPCCOEt DMI4WVE TI TTVBPDM DMI4WVE TN Metabotropic glutamate receptor 1 (mGluR1) DMI4WVE MA Modulator (allosteric modulator) DMI4WVE RN [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93. DMI4WVE RU https://pubmed.ncbi.nlm.nih.gov/12695537 DMI53WR DI DMI53WR DMI53WR DN Cbz-Ile-Leu-L-(difluoro)aminobutyric acid DMI53WR TI TTWXB3E DMI53WR TN Hepatitis C virus NS3 helicase (HCV NS3) DMI53WR MA Inhibitor DMI53WR RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMI53WR RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMI580M DI DMI580M DMI580M DN 4-Chloro-5,7-diphenyl-7H-pyrrolo[2,3-d]pyrimidine DMI580M TI TT6PKBN DMI580M TN Proto-oncogene c-Src (SRC) DMI580M MA Inhibitor DMI580M RN Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9. DMI580M RU https://pubmed.ncbi.nlm.nih.gov/10853665 DMI59T7 DI DMI59T7 DMI59T7 DN AA-29504 DMI59T7 TI TTEX6LM DMI59T7 TN GABA(A) receptor gamma-3 (GABRG3) DMI59T7 MA Modulator DMI59T7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMI59T7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMI5N23 DI DMI5N23 DMI5N23 DN IN-N01 DMI5N23 TI TTE4KHA DMI5N23 TN Amyloid beta A4 protein (APP) DMI5N23 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMI5N23 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMI5R3E DI DMI5R3E DMI5R3E DN (+/-)-oxiran-2-ylmethyl (9Z)-octadec-9-enoate DMI5R3E TI TTDP1UC DMI5R3E TN Fatty acid amide hydrolase (FAAH) DMI5R3E MA Inhibitor DMI5R3E RN Structure-activity relationship of a series of inhibitors of monoacylglycerol hydrolysis--comparison with effects upon fatty acid amide hydrolase. J Med Chem. 2007 Oct 4;50(20):5012-23. DMI5R3E RU https://pubmed.ncbi.nlm.nih.gov/17764163 DMI5RNJ DI DMI5RNJ DMI5RNJ DN 6-Benzyl-2-isobutylsulfanyl-3H-pyrimidin-4-one DMI5RNJ TI TT84ETX DMI5RNJ TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMI5RNJ MA Inhibitor DMI5RNJ RN Synthesis and anti-HIV-1 activity of thio analogues of dihydroalkoxybenzyloxopyrimidines. J Med Chem. 1995 Aug 18;38(17):3258-63. DMI5RNJ RU https://pubmed.ncbi.nlm.nih.gov/7650679 DMI5WF1 DI DMI5WF1 DMI5WF1 DN ZEARALANONE DMI5WF1 TI TT78R5H DMI5WF1 TN Heat shock protein 90 alpha (HSP90A) DMI5WF1 MA Inhibitor DMI5WF1 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMI5WF1 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMI5WPQ DI DMI5WPQ DMI5WPQ DN PMID16242323C18a DMI5WPQ TI TTK3C21 DMI5WPQ TN Acetoacetyl-CoA thiolase (ACAT1) DMI5WPQ MA Inhibitor DMI5WPQ RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMI5WPQ RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMI5XB1 DI DMI5XB1 DMI5XB1 DN 4-(Naphthalene-1-sulfonyl)-phenylamine DMI5XB1 TI TTJS8PY DMI5XB1 TN 5-HT 6 receptor (HTR6) DMI5XB1 MA Inhibitor DMI5XB1 RN 1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11. DMI5XB1 RU https://pubmed.ncbi.nlm.nih.gov/15745826 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TT9JZCK DMI5XR1 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMI5XR1 MA Agonist DMI5XR1 RN Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem. 1998 Aug 21;273(34):22105-12. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/9705355 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TTABCJ6 DMI5XR1 TN Lysophosphatidic acid receptor 5 (LPAR5) DMI5XR1 MA Agonist DMI5XR1 RN Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/23396314 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TTE2YJR DMI5XR1 TN Lysophosphatidate-3 receptor (LPAR3) DMI5XR1 MA Agonist DMI5XR1 RN Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999 Sep 24;274(39):27776-85. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/10488122 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TTB7Y8I DMI5XR1 TN Lysophosphatidic acid receptor 2 (LPAR2) DMI5XR1 MA Agonist DMI5XR1 RN Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3473-6. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/15177455 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TTZDAGB DMI5XR1 TN Lysophosphatidic acid receptor 6 (LPAR6) DMI5XR1 MA Agonist DMI5XR1 RN G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008 Mar;40(3):329-34. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/18297070 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TTMFOU6 DMI5XR1 TN P2Y purinoceptor 10 (P2RY10) DMI5XR1 MA Agonist DMI5XR1 RN Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/18466763 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TTO897C DMI5XR1 TN G protein coupled receptor 87 (GPR87) DMI5XR1 MA Agonist DMI5XR1 RN Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/18466763 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TTQ6S1K DMI5XR1 TN Lysophosphatidic acid receptor 1 (LPAR1) DMI5XR1 MA Agonist DMI5XR1 RN Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci. 2010 May 26;30(21):7300-9. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/20505096 DMI5XR1 DI DMI5XR1 DMI5XR1 DN LPA DMI5XR1 TI TT7ZMY4 DMI5XR1 TN Lysophosphatidic acid receptor 4 (LPAR4) DMI5XR1 MA Agonist DMI5XR1 RN Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem. 2003 Jul 11;278(28):25600-6. DMI5XR1 RU https://pubmed.ncbi.nlm.nih.gov/12724320 DMI638K DI DMI638K DMI638K DN 4-(2,2-Diphenyl-vinyl)-pyridine DMI638K TI TTSZLWK DMI638K TN Aromatase (CYP19A1) DMI638K MA Inhibitor DMI638K RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMI638K RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMI65GV DI DMI65GV DMI65GV DN Tyr-Pro-L-(NMe)Phe-D-Pro-NH2 DMI65GV TI TT27RFC DMI65GV TN Opioid receptor delta (OPRD1) DMI65GV MA Inhibitor DMI65GV RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMI65GV RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMI65GV DI DMI65GV DMI65GV DN Tyr-Pro-L-(NMe)Phe-D-Pro-NH2 DMI65GV TI TTKWM86 DMI65GV TN Opioid receptor mu (MOP) DMI65GV MA Inhibitor DMI65GV RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMI65GV RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMI6AZ5 DI DMI6AZ5 DMI6AZ5 DN 2-(3-carboxybenzyl)succinic acid DMI6AZ5 TI TT9G4N0 DMI6AZ5 TN Glutamate carboxypeptidase II (GCPII) DMI6AZ5 MA Inhibitor DMI6AZ5 RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMI6AZ5 RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMI6FZN DI DMI6FZN DMI6FZN DN 2-Cinnamamido-N1-hydroxy-N4-pentylsuccinamide DMI6FZN TI TTPHMWB DMI6FZN TN Aminopeptidase N (ANPEP) DMI6FZN MA Inhibitor DMI6FZN RN Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404. DMI6FZN RU https://pubmed.ncbi.nlm.nih.gov/19782572 DMI6GD0 DI DMI6GD0 DMI6GD0 DN VUF 8328 DMI6GD0 TI TT9JNIC DMI6GD0 TN Histamine H3 receptor (H3R) DMI6GD0 MA Agonist DMI6GD0 RN Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001 Dec;299(3):908-14. DMI6GD0 RU https://pubmed.ncbi.nlm.nih.gov/11714875 DMI6NJ1 DI DMI6NJ1 DMI6NJ1 DN Isogranulatimide DMI6NJ1 TI TTTU902 DMI6NJ1 TN Checkpoint kinase-1 (CHK1) DMI6NJ1 MA Inhibitor DMI6NJ1 RN Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolo[3,4-a]carbazole-1,3-diones, pyrrolo[3,4-c]carbazole-1,3... Eur J Med Chem. 2008 Feb;43(2):282-92. DMI6NJ1 RU https://pubmed.ncbi.nlm.nih.gov/17502122 DMI6P91 DI DMI6P91 DMI6P91 DN 1-Methyl-1,2,3,4-tetrahydro-isoquinoline-6,7-diol DMI6P91 TI TTEX248 DMI6P91 TN Dopamine D2 receptor (D2R) DMI6P91 MA Inhibitor DMI6P91 RN D4 dopamine receptor-selective compounds from the Chinese plant Phoebe chekiangensis, Bioorg. Med. Chem. Lett. 7(9):1207-1212 (1997). DMI6P91 RU http://www.sciencedirect.com/science/article/pii/S0960894X97001947 DMI6SNQ DI DMI6SNQ DMI6SNQ DN SF-21 DMI6SNQ TI TT0NLAQ DMI6SNQ TN Mucolipin-3 (TRPML3) DMI6SNQ MA Activator DMI6SNQ RN Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48. DMI6SNQ RU https://pubmed.ncbi.nlm.nih.gov/20189104 DMI6TKU DI DMI6TKU DMI6TKU DN PROTOSTEMODIOL DMI6TKU TI TTJSZTB DMI6TKU TN Nicotinic acetylcholine receptor (nAChR) DMI6TKU MA Inhibitor DMI6TKU RN Alkaloids from stems and leaves of Stemona japonica and their insecticidal activities. J Nat Prod. 2008 Jan;71(1):112-6. DMI6TKU RU https://pubmed.ncbi.nlm.nih.gov/18163592 DMI6UVN DI DMI6UVN DMI6UVN DN 6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol DMI6UVN TI TTZAYWL DMI6UVN TN Estrogen receptor (ESR) DMI6UVN MA Inhibitor DMI6UVN RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMI6UVN RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMI6UVN DI DMI6UVN DMI6UVN DN 6-(4-Hydroxy-phenyl)-1-phenyl-naphthalen-2-ol DMI6UVN TI TTOM3J0 DMI6UVN TN Estrogen receptor beta (ESR2) DMI6UVN MA Inhibitor DMI6UVN RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMI6UVN RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMI6VAX DI DMI6VAX DMI6VAX DN U-89854 DMI6VAX TI TTPTXIN DMI6VAX TN Translocator protein (TSPO) DMI6VAX MA Modulator DMI6VAX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMI6VAX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMI6WA7 DI DMI6WA7 DMI6WA7 DN NSC-58046 DMI6WA7 TI TT9NVXQ DMI6WA7 TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMI6WA7 MA Inhibitor DMI6WA7 RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMI6WA7 RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMI7258 DI DMI7258 DMI7258 DN Homspera DMI7258 TI TTZPO1L DMI7258 TN Substance-P receptor (TACR1) DMI7258 MA Agonist DMI7258 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360). DMI7258 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360 DMI74KM DI DMI74KM DMI74KM DN N-(4-(phenylamino)quinazolin-6-yl)acrylamide DMI74KM TI TT6PKBN DMI74KM TN Proto-oncogene c-Src (SRC) DMI74KM MA Inhibitor DMI74KM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMI74KM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMI74KM DI DMI74KM DMI74KM DN N-(4-(phenylamino)quinazolin-6-yl)acrylamide DMI74KM TI TTGKNB4 DMI74KM TN Epidermal growth factor receptor (EGFR) DMI74KM MA Inhibitor DMI74KM RN Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38. DMI74KM RU https://pubmed.ncbi.nlm.nih.gov/17334377 DMI75A3 DI DMI75A3 DMI75A3 DN BOMPPA DMI75A3 TI TT0WAIE DMI75A3 TN Melatonin receptor type 1A (MTNR1A) DMI75A3 MA Agonist DMI75A3 RN Development of substituted N-[3-(3-methoxylphenyl)propyl] amides as MT(2)-selective melatonin agonists: improving metabolic stability. Bioorg Med Chem. 2013 Jan 15;21(2):547-52. DMI75A3 RU https://pubmed.ncbi.nlm.nih.gov/23228808 DMI7859 DI DMI7859 DMI7859 DN MK-10 DMI7859 TI TTEOSZT DMI7859 TN Melanocortin receptor (MCR) DMI7859 MA Inhibitor DMI7859 RN Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50. DMI7859 RU https://pubmed.ncbi.nlm.nih.gov/12036373 DMI7859 DI DMI7859 DMI7859 DN MK-10 DMI7859 TI TTNI91K DMI7859 TN Melanocortin receptor 3 (MC3R) DMI7859 MA Inhibitor DMI7859 RN Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50. DMI7859 RU https://pubmed.ncbi.nlm.nih.gov/12036373 DMI7859 DI DMI7859 DMI7859 DN MK-10 DMI7859 TI TTD0CIQ DMI7859 TN Melanocortin receptor 4 (MC4R) DMI7859 MA Inhibitor DMI7859 RN Novel cyclic templates of alpha-MSH give highly selective and potent antagonists/agonists for human melanocortin-3/4 receptors. J Med Chem. 2002 Jun 6;45(12):2644-50. DMI7859 RU https://pubmed.ncbi.nlm.nih.gov/12036373 DMI785L DI DMI785L DMI785L DN 3-hydroxy-2-methoxybenzaldehyde DMI785L TI TTANPDJ DMI785L TN Carbonic anhydrase II (CA-II) DMI785L MA Inhibitor DMI785L RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMI785L RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMI796T DI DMI796T DMI796T DN BMS-A DMI796T TI TTFZYTO DMI796T TN C-C chemokine receptor type 2 (CCR2) DMI796T MA Antagonist DMI796T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59). DMI796T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59 DMI79FV DI DMI79FV DMI79FV DN 2,6-diphenyl-8-methyl-1-deazapurine DMI79FV TI TTJFY5U DMI79FV TN Adenosine A3 receptor (ADORA3) DMI79FV MA Inhibitor DMI79FV RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMI79FV RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMI79FV DI DMI79FV DMI79FV DN 2,6-diphenyl-8-methyl-1-deazapurine DMI79FV TI TTM2AOE DMI79FV TN Adenosine A2a receptor (ADORA2A) DMI79FV MA Inhibitor DMI79FV RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMI79FV RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMI79FV DI DMI79FV DMI79FV DN 2,6-diphenyl-8-methyl-1-deazapurine DMI79FV TI TTK25J1 DMI79FV TN Adenosine A1 receptor (ADORA1) DMI79FV MA Inhibitor DMI79FV RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMI79FV RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMI7A6R DI DMI7A6R DMI7A6R DN Narciclasine DMI7A6R TI TT8R0BZ DMI7A6R TN Elongation factor 1A (EF1A) DMI7A6R MA Inhibitor DMI7A6R RN Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 2010 Nov;24(11):4575-84. DMI7A6R RU https://pubmed.ncbi.nlm.nih.gov/20643906 DMI7AUJ DI DMI7AUJ DMI7AUJ DN PYRAZOLOPYRIDAZINE 2 DMI7AUJ TI TT7HF4W DMI7AUJ TN Cyclin-dependent kinase 2 (CDK2) DMI7AUJ MA Inhibitor DMI7AUJ RN N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30. DMI7AUJ RU https://pubmed.ncbi.nlm.nih.gov/15341487 DMI7AUJ DI DMI7AUJ DMI7AUJ DN PYRAZOLOPYRIDAZINE 2 DMI7AUJ TI TT0PG8F DMI7AUJ TN Cyclin-dependent kinase 4 (CDK4) DMI7AUJ MA Inhibitor DMI7AUJ RN N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30. DMI7AUJ RU https://pubmed.ncbi.nlm.nih.gov/15341487 DMI7AUJ DI DMI7AUJ DMI7AUJ DN PYRAZOLOPYRIDAZINE 2 DMI7AUJ TI TTRSMW9 DMI7AUJ TN Glycogen synthase kinase-3 beta (GSK-3B) DMI7AUJ MA Inhibitor DMI7AUJ RN N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30. DMI7AUJ RU https://pubmed.ncbi.nlm.nih.gov/15341487 DMI7CR9 DI DMI7CR9 DMI7CR9 DN H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2 DMI7CR9 TI TTKWM86 DMI7CR9 TN Opioid receptor mu (MOP) DMI7CR9 MA Inhibitor DMI7CR9 RN Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32. DMI7CR9 RU https://pubmed.ncbi.nlm.nih.gov/1656045 DMI7CR9 DI DMI7CR9 DMI7CR9 DN H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2 DMI7CR9 TI TT27RFC DMI7CR9 TN Opioid receptor delta (OPRD1) DMI7CR9 MA Inhibitor DMI7CR9 RN Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32. DMI7CR9 RU https://pubmed.ncbi.nlm.nih.gov/1656045 DMI7DSM DI DMI7DSM DMI7DSM DN 5-butyl-2-(phenylsulfonamido)benzoic acid DMI7DSM TI TTZL0OI DMI7DSM TN Methionine aminopeptidase 2 (METAP2) DMI7DSM MA Inhibitor DMI7DSM RN Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7. DMI7DSM RU https://pubmed.ncbi.nlm.nih.gov/16632353 DMI7FNZ DI DMI7FNZ DMI7FNZ DN 6-Benzylsulfanyl-9H-purine DMI7FNZ TI TTAN5W2 DMI7FNZ TN Raf messenger RNA (Raf mRNA) DMI7FNZ MA Inhibitor DMI7FNZ RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMI7FNZ RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMI7FNZ DI DMI7FNZ DMI7FNZ DN 6-Benzylsulfanyl-9H-purine DMI7FNZ TI TTQBR95 DMI7FNZ TN Stress-activated protein kinase 2a (p38 alpha) DMI7FNZ MA Inhibitor DMI7FNZ RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMI7FNZ RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMI7FVJ DI DMI7FVJ DMI7FVJ DN 6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline DMI7FVJ TI TTGKNB4 DMI7FVJ TN Epidermal growth factor receptor (EGFR) DMI7FVJ MA Inhibitor DMI7FVJ RN Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. DMI7FVJ RU https://pubmed.ncbi.nlm.nih.gov/17869510 DMI7J1L DI DMI7J1L DMI7J1L DN A-740003 DMI7J1L TI TT473XN DMI7J1L TN P2X purinoceptor 7 (P2RX7) DMI7J1L MA Inhibitor DMI7J1L RN Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem. 2009 Jul 15;17(14):4861-5. DMI7J1L RU https://pubmed.ncbi.nlm.nih.gov/19540765 DMI7JQG DI DMI7JQG DMI7JQG DN ISIS 6435 DMI7JQG TI TTONI0R DMI7JQG TN PKC-eta messenger RNA (PRKCH mRNA) DMI7JQG RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMI7JQG RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMI7LF1 DI DMI7LF1 DMI7LF1 DN JWH-302 DMI7LF1 TI TTMSFAW DMI7LF1 TN Cannabinoid receptor 2 (CB2) DMI7LF1 MA Inhibitor DMI7LF1 RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMI7LF1 RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMI7LXH DI DMI7LXH DMI7LXH DN 14-O-phenylpropylnaltrexone DMI7LXH TI TTKWM86 DMI7LXH TN Opioid receptor mu (MOP) DMI7LXH MA Inhibitor DMI7LXH RN 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7. DMI7LXH RU https://pubmed.ncbi.nlm.nih.gov/19253983 DMI7LXH DI DMI7LXH DMI7LXH DN 14-O-phenylpropylnaltrexone DMI7LXH TI TT27RFC DMI7LXH TN Opioid receptor delta (OPRD1) DMI7LXH MA Inhibitor DMI7LXH RN 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7. DMI7LXH RU https://pubmed.ncbi.nlm.nih.gov/19253983 DMI7LXH DI DMI7LXH DMI7LXH DN 14-O-phenylpropylnaltrexone DMI7LXH TI TTQW87Y DMI7LXH TN Opioid receptor kappa (OPRK1) DMI7LXH MA Inhibitor DMI7LXH RN 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7. DMI7LXH RU https://pubmed.ncbi.nlm.nih.gov/19253983 DMI7NAF DI DMI7NAF DMI7NAF DN ranatensin DMI7NAF TI TTC1MVT DMI7NAF TN Gastrin-releasing peptide receptor (GRPR) DMI7NAF MA Agonist DMI7NAF RN Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R). Biochemistry. 1999 Jun 1;38(22):7307-20. DMI7NAF RU https://pubmed.ncbi.nlm.nih.gov/10353842 DMI7NAF DI DMI7NAF DMI7NAF DN ranatensin DMI7NAF TI TTHYDUM DMI7NAF TN Bombesin receptor (BS) DMI7NAF MA Agonist DMI7NAF RN Pharmacology and cell biology of the bombesin receptor subtype 4 (BB4-R). Biochemistry. 1999 Jun 1;38(22):7307-20. DMI7NAF RU https://pubmed.ncbi.nlm.nih.gov/10353842 DMI7PGZ DI DMI7PGZ DMI7PGZ DN ISIS 100743 DMI7PGZ TI TTVXEGU DMI7PGZ TN ADAM10 messenger RNA (ADAM10 mRNA) DMI7PGZ RN US patent application no. 6,228,648, Antisense modulation of ADAM10 expression. DMI7PGZ RU http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true DMI7Q61 DI DMI7Q61 DMI7Q61 DN CARBOXYFENTANYL DMI7Q61 TI TT27RFC DMI7Q61 TN Opioid receptor delta (OPRD1) DMI7Q61 MA Inhibitor DMI7Q61 RN Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem. 2007 Nov 1;50(22):5528-32. DMI7Q61 RU https://pubmed.ncbi.nlm.nih.gov/17927164 DMI7Q61 DI DMI7Q61 DMI7Q61 DN CARBOXYFENTANYL DMI7Q61 TI TTKWM86 DMI7Q61 TN Opioid receptor mu (MOP) DMI7Q61 MA Inhibitor DMI7Q61 RN Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem. 2007 Nov 1;50(22):5528-32. DMI7Q61 RU https://pubmed.ncbi.nlm.nih.gov/17927164 DMI7RPT DI DMI7RPT DMI7RPT DN GalR3ant DMI7RPT TI TTOPAY7 DMI7RPT TN Galanin receptor (GAL-R) DMI7RPT MA Antagonist DMI7RPT RN Galanin (2-11) binds to GalR3 in transfected cell lines: limitations for pharmacological definition of receptor subtypes. Neuropeptides. 2005 Jun;39(3):165-7. DMI7RPT RU https://pubmed.ncbi.nlm.nih.gov/15944007 DMI7W9N DI DMI7W9N DMI7W9N DN N-(2-amino-5-(furan-3-yl)phenyl)benzamide DMI7W9N TI TTSHTOI DMI7W9N TN Histone deacetylase 2 (HDAC2) DMI7W9N MA Inhibitor DMI7W9N RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMI7W9N RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMI7YAQ DI DMI7YAQ DMI7YAQ DN 4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine DMI7YAQ TI TTRA5BZ DMI7YAQ TN Steroid 17-alpha-monooxygenase (S17AH) DMI7YAQ MA Inhibitor DMI7YAQ RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMI7YAQ RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMI7YAQ DI DMI7YAQ DMI7YAQ DN 4-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine DMI7YAQ TI TTIQUX7 DMI7YAQ TN Steroid 11-beta-hydroxylase (CYP11B1) DMI7YAQ MA Inhibitor DMI7YAQ RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMI7YAQ RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMI8217 DI DMI8217 DMI8217 DN PMID22136433C20 DMI8217 TI TTV298Y DMI8217 TN Calmodulin-dependent kinase II (CAMKK2) DMI8217 MA Inhibitor DMI8217 RN 7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13. DMI8217 RU https://pubmed.ncbi.nlm.nih.gov/22136433 DMI8217 DI DMI8217 DMI8217 DN PMID22136433C20 DMI8217 TI TTCGOIN DMI8217 TN PIM-3 protein kinase (PIM3) DMI8217 MA Inhibitor DMI8217 RN 7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13. DMI8217 RU https://pubmed.ncbi.nlm.nih.gov/22136433 DMI8217 DI DMI8217 DMI8217 DN PMID22136433C20 DMI8217 TI TTTN5QW DMI8217 TN Serine/threonine-protein kinase pim-1 (PIM1) DMI8217 MA Inhibitor DMI8217 RN 7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13. DMI8217 RU https://pubmed.ncbi.nlm.nih.gov/22136433 DMI8217 DI DMI8217 DMI8217 DN PMID22136433C20 DMI8217 TI TTSL41O DMI8217 TN Protein kinase N1 (PKN1) DMI8217 MA Inhibitor DMI8217 RN 7,8-dichloro-1-oxo-beta-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes. J Med Chem. 2012 Jan 12;55(1):403-13. DMI8217 RU https://pubmed.ncbi.nlm.nih.gov/22136433 DMI87UE DI DMI87UE DMI87UE DN Ac-RYYRIK-NH2 DMI87UE TI TTNT7K8 DMI87UE TN Nociceptin receptor (OPRL1) DMI87UE MA Inhibitor DMI87UE RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DMI87UE RU https://pubmed.ncbi.nlm.nih.gov/16814543 DMI89RL DI DMI89RL DMI89RL DN 2-Chlorobenzenemethanethiol DMI89RL TI TTZJYKH DMI89RL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMI89RL MA Inhibitor DMI89RL RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMI89RL RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMI8HAV DI DMI8HAV DMI8HAV DN PMID16439120C20 DMI8HAV TI TTHS256 DMI8HAV TN Metabotropic glutamate receptor 5 (mGluR5) DMI8HAV MA Modulator (allosteric modulator) DMI8HAV RN Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. DMI8HAV RU https://pubmed.ncbi.nlm.nih.gov/16439120 DMI8JTE DI DMI8JTE DMI8JTE DN PD-172939 DMI8JTE TI TTEX248 DMI8JTE TN Dopamine D2 receptor (D2R) DMI8JTE MA Inhibitor DMI8JTE RN Isoindolinone enantiomers having affinity for the dopamine D4 receptor. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1499-502. DMI8JTE RU https://pubmed.ncbi.nlm.nih.gov/9873377 DMI8KOF DI DMI8KOF DMI8KOF DN 6-(2-Amino-ethyl)-biphenyl-2,3-diol DMI8KOF TI TTZFYLI DMI8KOF TN Dopamine D1 receptor (D1R) DMI8KOF MA Inhibitor DMI8KOF RN Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12. DMI8KOF RU https://pubmed.ncbi.nlm.nih.gov/3761310 DMI8NYF DI DMI8NYF DMI8NYF DN ISIS 113902 DMI8NYF TI TTIX0ZU DMI8NYF TN MEKK2 messenger RNA (MAP3K2 mRNA) DMI8NYF RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMI8NYF RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMI8RU0 DI DMI8RU0 DMI8RU0 DN [3H]WIN35428 DMI8RU0 TI TTVBI8W DMI8RU0 TN Dopamine transporter (DAT) DMI8RU0 MA Inhibitor DMI8RU0 RN Pharmacological heterogeneity of the cloned and native human dopamine transporter: disassociation of [3H]WIN 35,428 and [3H]GBR 12,935 binding. Mol Pharmacol. 1994 Jan;45(1):125-35. DMI8RU0 RU https://pubmed.ncbi.nlm.nih.gov/8302271 DMI8RU0 DI DMI8RU0 DMI8RU0 DN [3H]WIN35428 DMI8RU0 TI TTAWNKZ DMI8RU0 TN Norepinephrine transporter (NET) DMI8RU0 MA Inhibitor DMI8RU0 RN 3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41. DMI8RU0 RU https://pubmed.ncbi.nlm.nih.gov/8863789 DMI8RU0 DI DMI8RU0 DMI8RU0 DN [3H]WIN35428 DMI8RU0 TI TT3ROYC DMI8RU0 TN Serotonin transporter (SERT) DMI8RU0 MA Inhibitor DMI8RU0 RN 3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41. DMI8RU0 RU https://pubmed.ncbi.nlm.nih.gov/8863789 DMI8SH2 DI DMI8SH2 DMI8SH2 DN PROSTEPHABYSSINE DMI8SH2 TI TT27RFC DMI8SH2 TN Opioid receptor delta (OPRD1) DMI8SH2 MA Inhibitor DMI8SH2 RN Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91. DMI8SH2 RU https://pubmed.ncbi.nlm.nih.gov/20426456 DMI8T1Y DI DMI8T1Y DMI8T1Y DN PMID24809814C31 DMI8T1Y TI TT618Q2 DMI8T1Y TN Sphingosine-1-phosphate lyase 1 (SGPL1) DMI8T1Y MA Inhibitor DMI8T1Y RN Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis. J MedChem. 2014 Jun 26;57(12):5074-84. DMI8T1Y RU https://pubmed.ncbi.nlm.nih.gov/24809814 DMI8UC7 DI DMI8UC7 DMI8UC7 DN 1-(4-Cyanobenzyl)-5-(3-methylphenyl)-1H-imidazole DMI8UC7 TI TTIQUX7 DMI8UC7 TN Steroid 11-beta-hydroxylase (CYP11B1) DMI8UC7 MA Inhibitor DMI8UC7 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMI8UC7 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMI95DP DI DMI95DP DMI95DP DN Ro67-7476 DMI95DP TI TTVBPDM DMI95DP TN Metabotropic glutamate receptor 1 (mGluR1) DMI95DP MA Modulator (allosteric modulator) DMI95DP RN Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13402-7. DMI95DP RU https://pubmed.ncbi.nlm.nih.gov/11606768 DMI96Y3 DI DMI96Y3 DMI96Y3 DN PHT-427 DMI96Y3 TI TT9QBI6 DMI96Y3 TN Phosphoinositide dependent protein kinase-1 (PDPK1) DMI96Y3 MA Inhibitor DMI96Y3 RN Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17. DMI96Y3 RU https://pubmed.ncbi.nlm.nih.gov/20197390 DMI96Y3 DI DMI96Y3 DMI96Y3 DN PHT-427 DMI96Y3 TI TTH24WI DMI96Y3 TN RAC-beta serine/threonine-protein kinase (AKT2) DMI96Y3 MA Inhibitor DMI96Y3 RN Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther. 2010 Mar;9(3):706-17. DMI96Y3 RU https://pubmed.ncbi.nlm.nih.gov/20197390 DMI9C57 DI DMI9C57 DMI9C57 DN Cyclo[Cys7,Cys10]N/OFQ(1-13)NH2 DMI9C57 TI TTNT7K8 DMI9C57 TN Nociceptin receptor (OPRL1) DMI9C57 MA Inhibitor DMI9C57 RN High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7. DMI9C57 RU https://pubmed.ncbi.nlm.nih.gov/18624395 DMI9GQV DI DMI9GQV DMI9GQV DN N-[2-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine DMI9GQV TI TTGSEFH DMI9GQV TN Sodium/hydrogen exchanger 1 (SLC9A1) DMI9GQV MA Inhibitor DMI9GQV RN Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-... Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3. DMI9GQV RU https://pubmed.ncbi.nlm.nih.gov/17346962 DMI9MBO DI DMI9MBO DMI9MBO DN [Mpa1, D-Tyr(Et)2, D-Tic7, D-Tic9]OT DMI9MBO TI TTSCIUP DMI9MBO TN Oxytocin receptor (OTR) DMI9MBO MA Inhibitor DMI9MBO RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMI9MBO RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMI9N8G DI DMI9N8G DMI9N8G DN (3Z)-1H-indole-2,3-dione 3-thiosemicarbazone DMI9N8G TI TTEAID7 DMI9N8G TN Trypanosoma Cruzipain (Trypano CYSP) DMI9N8G MA Inhibitor DMI9N8G RN Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30. DMI9N8G RU https://pubmed.ncbi.nlm.nih.gov/14505663 DMI9QRO DI DMI9QRO DMI9QRO DN N-methoxyethyl estrone-16-methyl carboxamide DMI9QRO TI TTIWB6L DMI9QRO TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMI9QRO MA Inhibitor DMI9QRO RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMI9QRO RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMI9RLZ DI DMI9RLZ DMI9RLZ DN [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala DMI9RLZ TI TT5TKPM DMI9RLZ TN Neutral endopeptidase (MME) DMI9RLZ MA Inhibitor DMI9RLZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMI9RLZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMI9RLZ DI DMI9RLZ DMI9RLZ DN [2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala DMI9RLZ TI TTVDSZ0 DMI9RLZ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMI9RLZ MA Inhibitor DMI9RLZ RN Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8. DMI9RLZ RU https://pubmed.ncbi.nlm.nih.gov/12855651 DMI9VNO DI DMI9VNO DMI9VNO DN LUDARTIN DMI9VNO TI TTSZLWK DMI9VNO TN Aromatase (CYP19A1) DMI9VNO MA Inhibitor DMI9VNO RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMI9VNO RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMI9YGU DI DMI9YGU DMI9YGU DN 2-Amino-4,6-diphenyl-pyrimidine DMI9YGU TI TTK25J1 DMI9YGU TN Adenosine A1 receptor (ADORA1) DMI9YGU MA Inhibitor DMI9YGU RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DMI9YGU RU https://pubmed.ncbi.nlm.nih.gov/18258439 DMI9YGU DI DMI9YGU DMI9YGU DN 2-Amino-4,6-diphenyl-pyrimidine DMI9YGU TI TTM2AOE DMI9YGU TN Adenosine A2a receptor (ADORA2A) DMI9YGU MA Inhibitor DMI9YGU RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DMI9YGU RU https://pubmed.ncbi.nlm.nih.gov/18258439 DMIA2F1 DI DMIA2F1 DMIA2F1 DN ATC-120 DMIA2F1 TI TTMI6F5 DMIA2F1 TN Transient receptor potential cation channel V1 (TRPV1) DMIA2F1 MA Inhibitor DMIA2F1 RN Silicon switch approach in TRPV1 antagonist MK-056 and its analogues. Bioorg Med Chem. 2010 Jan 1;18(1):111-6. DMIA2F1 RU https://pubmed.ncbi.nlm.nih.gov/19931463 DMIA2XJ DI DMIA2XJ DMIA2XJ DN FGGFTGARKSARKLKNQ DMIA2XJ TI TTNT7K8 DMIA2XJ TN Nociceptin receptor (OPRL1) DMIA2XJ MA Inhibitor DMIA2XJ RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMIA2XJ RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMIA7ND DI DMIA7ND DMIA7ND DN 6s-5,6,7,8-Tetrahydrobiopterin DMIA7ND TI TTCM4B3 DMIA7ND TN Nitric-oxide synthase endothelial (NOS3) DMIA7ND MA Inhibitor DMIA7ND RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIA7ND RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIAFN5 DI DMIAFN5 DMIAFN5 DN PD-138916 DMIAFN5 TI TTCG0AL DMIAFN5 TN Cholecystokinin receptor type A (CCKAR) DMIAFN5 MA Inhibitor DMIAFN5 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMIAFN5 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMIAFN5 DI DMIAFN5 DMIAFN5 DN PD-138916 DMIAFN5 TI TTVFO0U DMIAFN5 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMIAFN5 MA Inhibitor DMIAFN5 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMIAFN5 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMIAGS8 DI DMIAGS8 DMIAGS8 DN N-(4-amino-4'-bromobiphenyl-3-yl)benzamide DMIAGS8 TI TTSHTOI DMIAGS8 TN Histone deacetylase 2 (HDAC2) DMIAGS8 MA Inhibitor DMIAGS8 RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMIAGS8 RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMIAM5L DI DMIAM5L DMIAM5L DN 2-Deoxy-2,3-Dehydro-N-Acetyl-Neuraminic Acid DMIAM5L TI TT50QJ3 DMIAM5L TN Influenza Neuraminidase (Influ NA) DMIAM5L MA Inhibitor DMIAM5L RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIAM5L RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIAO4V DI DMIAO4V DMIAO4V DN [125I]CGP 64213 DMIAO4V TI TTDCVZW DMIAO4V TN Gamma-aminobutyric acid B receptor (GABBR) DMIAO4V MA Antagonist DMIAO4V RN Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. Mol Pharmacol. 2000 Mar;57(3):419-26. DMIAO4V RU https://pubmed.ncbi.nlm.nih.gov/10692480 DMIAQUC DI DMIAQUC DMIAQUC DN 6-p-Tolylamino-1H-pyrimidine-2,4-dione DMIAQUC TI TT2GPK3 DMIAQUC TN DNA topoisomerase (TOP) DMIAQUC MA Inhibitor DMIAQUC RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMIAQUC RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMIAQX4 DI DMIAQX4 DMIAQX4 DN Heptulose-2-Phosphate DMIAQX4 TI TTZHY6R DMIAQX4 TN Glycogen phosphorylase muscle form (GP) DMIAQX4 MA Inhibitor DMIAQX4 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIAQX4 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIARG7 DI DMIARG7 DMIARG7 DN 5'-Guanosine-Diphosphate-Monothiophosphate DMIARG7 TI TT4W1VJ DMIARG7 TN Bacterial Celldivision protein FtsZ (Bact ftsZ) DMIARG7 MA Inhibitor DMIARG7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIARG7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIAUB1 DI DMIAUB1 DMIAUB1 DN Biphenyl-3-ylboronic acid DMIAUB1 TI TTDP1UC DMIAUB1 TN Fatty acid amide hydrolase (FAAH) DMIAUB1 MA Inhibitor DMIAUB1 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMIAUB1 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMIAYTP DI DMIAYTP DMIAYTP DN Ac-Lys-[Leu(8)]-des-Arg(9)-BK DMIAYTP TI TTG5QIA DMIAYTP TN B1 bradykinin receptor (BDKRB1) DMIAYTP MA Antagonist DMIAYTP RN Non-competitive pharmacological antagonism at the rabbit B(1) receptor. Br J Pharmacol. 2000 Nov;131(5):885-92. DMIAYTP RU https://pubmed.ncbi.nlm.nih.gov/11053207 DMIB3J2 DI DMIB3J2 DMIB3J2 DN Hexahydro-pyrrolizin-(3E)-ylideneamine DMIB3J2 TI TTZUFI5 DMIB3J2 TN Nitric-oxide synthase brain (NOS1) DMIB3J2 MA Inhibitor DMIB3J2 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMIB3J2 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMIB5O3 DI DMIB5O3 DMIB5O3 DN Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe DMIB5O3 TI TTF2LRI DMIB5O3 TN Cathepsin B (CTSB) DMIB5O3 MA Inhibitor DMIB5O3 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMIB5O3 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMIB5O3 DI DMIB5O3 DMIB5O3 DN Z-Ala-Leu-Tyr(Me)-Agly-Ile-Val-OMe DMIB5O3 TI TTDZN01 DMIB5O3 TN Cathepsin K (CTSK) DMIB5O3 MA Inhibitor DMIB5O3 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMIB5O3 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMIB6JL DI DMIB6JL DMIB6JL DN ISIS 100742 DMIB6JL TI TTVXEGU DMIB6JL TN ADAM10 messenger RNA (ADAM10 mRNA) DMIB6JL RN US patent application no. 6,228,648, Antisense modulation of ADAM10 expression. DMIB6JL RU http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true DMIB9AX DI DMIB9AX DMIB9AX DN 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol DMIB9AX TI TTULVH8 DMIB9AX TN Tyrosinase (TYR) DMIB9AX MA Inhibitor DMIB9AX RN A newly synthesized, potent tyrosinase inhibitor: 5-(6-hydroxy-2-naphthyl)-1,2,3-benzenetriol. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4882-4. DMIB9AX RU https://pubmed.ncbi.nlm.nih.gov/20619644 DMIBAM2 DI DMIBAM2 DMIBAM2 DN 3-(4-o-Tolylpiperazine-1-carbonyl)coumarin DMIBAM2 TI TT1RS9F DMIBAM2 TN Acetylcholinesterase (AChE) DMIBAM2 MA Inhibitor DMIBAM2 RN Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21. DMIBAM2 RU https://pubmed.ncbi.nlm.nih.gov/18701305 DMIBCZJ DI DMIBCZJ DMIBCZJ DN frescolat ML DMIBCZJ TI TTXDKTO DMIBCZJ TN Long transient receptor potential channel 8 (TRPM8) DMIBCZJ MA Activator DMIBCZJ RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMIBCZJ RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMIBGWO DI DMIBGWO DMIBGWO DN C-[-Arg-Gly-Asp-Acpca33-] DMIBGWO TI TTT1R2L DMIBGWO TN Integrin alpha-V (ITGAV) DMIBGWO MA Inhibitor DMIBGWO RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMIBGWO RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMIBGWO DI DMIBGWO DMIBGWO DN C-[-Arg-Gly-Asp-Acpca33-] DMIBGWO TI TTJA1ZO DMIBGWO TN ITGB3 messenger RNA (ITGB3 mRNA) DMIBGWO MA Inhibitor DMIBGWO RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMIBGWO RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMIBHP5 DI DMIBHP5 DMIBHP5 DN 5-aminoquinolin-8-ol DMIBHP5 TI TTZJYKH DMIBHP5 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMIBHP5 MA Inhibitor DMIBHP5 RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMIBHP5 RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMIBKNZ DI DMIBKNZ DMIBKNZ DN 2-methoxyestradiol-17-O-sulfamate DMIBKNZ TI TTANPDJ DMIBKNZ TN Carbonic anhydrase II (CA-II) DMIBKNZ MA Inhibitor DMIBKNZ RN Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308. DMIBKNZ RU https://pubmed.ncbi.nlm.nih.gov/18260615 DMIBLGH DI DMIBLGH DMIBLGH DN Cyanopindolol DMIBLGH TI TTWT5K7 DMIBLGH TN 5-HT 1 receptor (5HT1R) DMIBLGH MA Antagonist DMIBLGH RN The inhibitory effect of serotonin on the spontaneous discharge of suprachiasmatic neurons in hypothalamic slice is mediated by 5-HT(7) receptor. Brain Res Bull. 2001 Mar 1;54(4):395-8. DMIBLGH RU https://pubmed.ncbi.nlm.nih.gov/11306191 DMIBOAK DI DMIBOAK DMIBOAK DN D-211A DMIBOAK TI TT3ROYC DMIBOAK TN Serotonin transporter (SERT) DMIBOAK MA Inhibitor DMIBOAK RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMIBOAK RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMIBOAK DI DMIBOAK DMIBOAK DN D-211A DMIBOAK TI TTVBI8W DMIBOAK TN Dopamine transporter (DAT) DMIBOAK MA Inhibitor DMIBOAK RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMIBOAK RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMIBOAK DI DMIBOAK DMIBOAK DN D-211A DMIBOAK TI TTAWNKZ DMIBOAK TN Norepinephrine transporter (NET) DMIBOAK MA Inhibitor DMIBOAK RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMIBOAK RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMIBRYM DI DMIBRYM DMIBRYM DN 2-Hex-5-enyl-5-nonyl-pyrrolidine DMIBRYM TI TT1RS9F DMIBRYM TN Acetylcholinesterase (AChE) DMIBRYM MA Inhibitor DMIBRYM RN Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995). DMIBRYM RU http://www.sciencedirect.com/science/article/pii/0960894X9500179W DMIBS95 DI DMIBS95 DMIBS95 DN SB-2280 DMIBS95 TI TTCJG29 DMIBS95 TN Serine/threonine-protein kinase mTOR (mTOR) DMIBS95 MA Inhibitor DMIBS95 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMIBS95 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMIBUW5 DI DMIBUW5 DMIBUW5 DN GW-788388 DMIBUW5 TI TT860QF DMIBUW5 TN LCK tyrosine protein kinase (LCK) DMIBUW5 MA Inhibitor DMIBUW5 RN Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21. DMIBUW5 RU https://pubmed.ncbi.nlm.nih.gov/16570917 DMIBUW5 DI DMIBUW5 DMIBUW5 DN GW-788388 DMIBUW5 TI TTQBR95 DMIBUW5 TN Stress-activated protein kinase 2a (p38 alpha) DMIBUW5 MA Inhibitor DMIBUW5 RN Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21. DMIBUW5 RU https://pubmed.ncbi.nlm.nih.gov/16570917 DMIBUW5 DI DMIBUW5 DMIBUW5 DN GW-788388 DMIBUW5 TI TTP4520 DMIBUW5 TN TGF-beta receptor type I (TGFBR1) DMIBUW5 MA Inhibitor DMIBUW5 RN Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21. DMIBUW5 RU https://pubmed.ncbi.nlm.nih.gov/16570917 DMIBZJC DI DMIBZJC DMIBZJC DN 4-[6-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine DMIBZJC TI TTSZLWK DMIBZJC TN Aromatase (CYP19A1) DMIBZJC MA Inhibitor DMIBZJC RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMIBZJC RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMIC0OU DI DMIC0OU DMIC0OU DN 16-(pyridin-2-yl)methylene-estradiol DMIC0OU TI TTIWB6L DMIC0OU TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMIC0OU MA Inhibitor DMIC0OU RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMIC0OU RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMIC2A8 DI DMIC2A8 DMIC2A8 DN N-hydroxy-9-oxo-9-phenylnonanamide DMIC2A8 TI TT6R7JZ DMIC2A8 TN Histone deacetylase 1 (HDAC1) DMIC2A8 MA Inhibitor DMIC2A8 RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMIC2A8 RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMIC372 DI DMIC372 DMIC372 DN EC-0565 DMIC372 TI TTCJG29 DMIC372 TN Serine/threonine-protein kinase mTOR (mTOR) DMIC372 MA Inhibitor DMIC372 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMIC372 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMIC4HJ DI DMIC4HJ DMIC4HJ DN ZK-813039 DMIC4HJ TI TTCIHJA DMIC4HJ TN Coagulation factor Xa (F10) DMIC4HJ MA Modulator DMIC4HJ RN Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80. DMIC4HJ RU https://pubmed.ncbi.nlm.nih.gov/17536795 DMIC8Z6 DI DMIC8Z6 DMIC8Z6 DN N-Cyclohexylmethyl-ETAV DMIC8Z6 TI TT9PB26 DMIC8Z6 TN Presynaptic density protein 95 (DLG4) DMIC8Z6 MA Inhibitor DMIC8Z6 RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMIC8Z6 RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMICKOU DI DMICKOU DMICKOU DN 5-Heptyl-5-phenyl-imidazolidine-2,4-dione DMICKOU TI TTAXZ0K DMICKOU TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMICKOU MA Inhibitor DMICKOU RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DMICKOU RU https://pubmed.ncbi.nlm.nih.gov/10229624 DMICKOU DI DMICKOU DMICKOU DN 5-Heptyl-5-phenyl-imidazolidine-2,4-dione DMICKOU TI TTRK8B9 DMICKOU TN Sodium channel unspecific (NaC) DMICKOU MA Inhibitor DMICKOU RN Comparative molecular field analysis of hydantoin binding to the neuronal voltage-dependent sodium channel. J Med Chem. 1999 May 6;42(9):1537-45. DMICKOU RU https://pubmed.ncbi.nlm.nih.gov/10229624 DMICOL3 DI DMICOL3 DMICOL3 DN 2-arachidonoylglycerolphosphoinositol DMICOL3 TI TTNET8J DMICOL3 TN G-protein coupled receptor 55 (GPR55) DMICOL3 MA Agonist DMICOL3 RN 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem. 2009 Jan;145(1):13-20. DMICOL3 RU https://pubmed.ncbi.nlm.nih.gov/18845565 DMICQWN DI DMICQWN DMICQWN DN 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID DMICQWN TI TTELIN2 DMICQWN TN PTPN1 messenger RNA (PTPN1 mRNA) DMICQWN MA Inhibitor DMICQWN RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMICQWN RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMICRFQ DI DMICRFQ DMICRFQ DN 6-benzyl-3-ethoxycarbonyl-4-quinolone DMICRFQ TI TT1MPAY DMICRFQ TN GABA(A) receptor alpha-1 (GABRA1) DMICRFQ MA Inhibitor DMICRFQ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMICRFQ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMICRFQ DI DMICRFQ DMICRFQ DN 6-benzyl-3-ethoxycarbonyl-4-quinolone DMICRFQ TI TTZA1NY DMICRFQ TN GABA(A) receptor beta-2 (GABRB2) DMICRFQ MA Inhibitor DMICRFQ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMICRFQ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMICRFQ DI DMICRFQ DMICRFQ DN 6-benzyl-3-ethoxycarbonyl-4-quinolone DMICRFQ TI TT06RH5 DMICRFQ TN GABA(A) receptor gamma-2 (GABRG2) DMICRFQ MA Inhibitor DMICRFQ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMICRFQ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMICRFQ DI DMICRFQ DMICRFQ DN 6-benzyl-3-ethoxycarbonyl-4-quinolone DMICRFQ TI TTNJYV2 DMICRFQ TN Gamma-aminobutyric acid receptor (GAR) DMICRFQ MA Inhibitor DMICRFQ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMICRFQ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMICRFQ DI DMICRFQ DMICRFQ DN 6-benzyl-3-ethoxycarbonyl-4-quinolone DMICRFQ TI TT37EDJ DMICRFQ TN GABA(A) receptor alpha-3 (GABRA3) DMICRFQ MA Inhibitor DMICRFQ RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMICRFQ RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMICUQK DI DMICUQK DMICUQK DN (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate DMICUQK TI TTF2LRI DMICUQK TN Cathepsin B (CTSB) DMICUQK MA Inhibitor DMICUQK RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMICUQK RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMICUQK DI DMICUQK DMICUQK DN (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate DMICUQK TI TT36ETB DMICUQK TN Cathepsin L (CTSL) DMICUQK MA Inhibitor DMICUQK RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMICUQK RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMICUQK DI DMICUQK DMICUQK DN (S)-1-benzylcyclopentyl 1-oxohexan-2-ylcarbamate DMICUQK TI TTDZN01 DMICUQK TN Cathepsin K (CTSK) DMICUQK MA Inhibitor DMICUQK RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMICUQK RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMICVXN DI DMICVXN DMICVXN DN PL017 DMICVXN TI TTKWM86 DMICVXN TN Opioid receptor mu (MOP) DMICVXN MA Agonist DMICVXN RN Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403-8. DMICVXN RU https://pubmed.ncbi.nlm.nih.gov/6313901 DMICZK0 DI DMICZK0 DMICZK0 DN 1-(5-(pyridin-2-yl)oxazol-2-yl)octadec-9-en-1-one DMICZK0 TI TTDP1UC DMICZK0 TN Fatty acid amide hydrolase (FAAH) DMICZK0 MA Inhibitor DMICZK0 RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMICZK0 RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMID3BF DI DMID3BF DMID3BF DN N-hydroxy-9,10-dihydroanthracene-9-carboxamide DMID3BF TI TTTQGH8 DMID3BF TN Histone deacetylase 4 (HDAC4) DMID3BF MA Inhibitor DMID3BF RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DMID3BF RU https://pubmed.ncbi.nlm.nih.gov/19699639 DMID3BF DI DMID3BF DMID3BF DN N-hydroxy-9,10-dihydroanthracene-9-carboxamide DMID3BF TI TTBH0VX DMID3BF TN Histone deacetylase (HDAC) DMID3BF MA Inhibitor DMID3BF RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DMID3BF RU https://pubmed.ncbi.nlm.nih.gov/19699639 DMID3F7 DI DMID3F7 DMID3F7 DN NNC55-0396 DMID3F7 TI TTP52ZV DMID3F7 TN Cation channel sperm-associated protein 3 (CatSper3) DMID3F7 MA Blocker (channel blocker) DMID3F7 RN The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6. DMID3F7 RU https://pubmed.ncbi.nlm.nih.gov/21412338 DMID3F7 DI DMID3F7 DMID3F7 DN NNC55-0396 DMID3F7 TI TT5CISB DMID3F7 TN Cation channel sperm-associated protein 1 (CatSper1) DMID3F7 MA Blocker (channel blocker) DMID3F7 RN The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6. DMID3F7 RU https://pubmed.ncbi.nlm.nih.gov/21412338 DMID3F7 DI DMID3F7 DMID3F7 DN NNC55-0396 DMID3F7 TI TTWOCZI DMID3F7 TN Cation channel sperm-associated protein (CatSper) DMID3F7 MA Blocker (channel blocker) DMID3F7 RN The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6. DMID3F7 RU https://pubmed.ncbi.nlm.nih.gov/21412338 DMID3F7 DI DMID3F7 DMID3F7 DN NNC55-0396 DMID3F7 TI TTOEGC4 DMID3F7 TN Cation channel sperm-associated protein 2 (CatSper2) DMID3F7 MA Blocker (channel blocker) DMID3F7 RN The CatSper channel mediates progesterone-induced Ca2+ influx in human sperm. Nature. 2011 Mar 17;471(7338):382-6. DMID3F7 RU https://pubmed.ncbi.nlm.nih.gov/21412338 DMID40H DI DMID40H DMID40H DN 4-Methoxy-5-phenyl-6-thia-10b-aza-benzo[e]azulene DMID40H TI TTPTXIN DMID40H TN Translocator protein (TSPO) DMID40H MA Inhibitor DMID40H RN A concerted study using binding measurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affi... J Med Chem. 1995 Nov 10;38(23):4730-8. DMID40H RU https://pubmed.ncbi.nlm.nih.gov/7473601 DMID7TC DI DMID7TC DMID7TC DN 3-demethoxy-3D-glucopyranosylaminothiocolchicine DMID7TC TI TT06RH5 DMID7TC TN GABA(A) receptor gamma-2 (GABRG2) DMID7TC MA Inhibitor DMID7TC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMID7TC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMID7TC DI DMID7TC DMID7TC DN 3-demethoxy-3D-glucopyranosylaminothiocolchicine DMID7TC TI TTNJYV2 DMID7TC TN Gamma-aminobutyric acid receptor (GAR) DMID7TC MA Inhibitor DMID7TC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMID7TC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMID7TC DI DMID7TC DMID7TC DN 3-demethoxy-3D-glucopyranosylaminothiocolchicine DMID7TC TI TTZ8EM9 DMID7TC TN Glycine receptor (GlyR) DMID7TC MA Inhibitor DMID7TC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMID7TC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMID7TC DI DMID7TC DMID7TC DN 3-demethoxy-3D-glucopyranosylaminothiocolchicine DMID7TC TI TTZA1NY DMID7TC TN GABA(A) receptor beta-2 (GABRB2) DMID7TC MA Inhibitor DMID7TC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMID7TC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMID7TC DI DMID7TC DMID7TC DN 3-demethoxy-3D-glucopyranosylaminothiocolchicine DMID7TC TI TT1MPAY DMID7TC TN GABA(A) receptor alpha-1 (GABRA1) DMID7TC MA Inhibitor DMID7TC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMID7TC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMID7TC DI DMID7TC DMID7TC DN 3-demethoxy-3D-glucopyranosylaminothiocolchicine DMID7TC TI TTF45NW DMID7TC TN Strychnine-binding glycine receptor (GLRA1) DMID7TC MA Inhibitor DMID7TC RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMID7TC RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMID9YA DI DMID9YA DMID9YA DN 2-(4-Benzyl-piperidin-1-ylmethyl)-chroman-4-one DMID9YA TI TTSQIFT DMID9YA TN 5-HT 1A receptor (HTR1A) DMID9YA MA Inhibitor DMID9YA RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMID9YA RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMIDGNB DI DMIDGNB DMIDGNB DN 2-Naphthalen-1-ylmethyl-1,2-dihydro-indazol-3-one DMIDGNB TI TT2J34L DMIDGNB TN Arachidonate 5-lipoxygenase (5-LOX) DMIDGNB MA Inhibitor DMIDGNB RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMIDGNB RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMIDLPT DI DMIDLPT DMIDLPT DN H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me) DMIDLPT TI TTKWM86 DMIDLPT TN Opioid receptor mu (MOP) DMIDLPT MA Inhibitor DMIDLPT RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMIDLPT RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMIDLPT DI DMIDLPT DMIDLPT DN H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid(N1-Me) DMIDLPT TI TT27RFC DMIDLPT TN Opioid receptor delta (OPRD1) DMIDLPT MA Inhibitor DMIDLPT RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMIDLPT RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMIDP1R DI DMIDP1R DMIDP1R DN peptide 18 DMIDP1R TI TTH9WF6 DMIDP1R TN Dibasic-processing enzyme (Furin) DMIDP1R MA Inhibitor DMIDP1R RN Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109. DMIDP1R RU https://pubmed.ncbi.nlm.nih.gov/24350995 DMIDP1R DI DMIDP1R DMIDP1R DN peptide 18 DMIDP1R TI TT75LN9 DMIDP1R TN Proprotein convertase subtilisin/kexin type 6 (PCSK6) DMIDP1R MA Inhibitor DMIDP1R RN Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109. DMIDP1R RU https://pubmed.ncbi.nlm.nih.gov/24350995 DMIDP1R DI DMIDP1R DMIDP1R DN peptide 18 DMIDP1R TI TT46F0P DMIDP1R TN Neuroendocrine convertase 2 (PCSK2) DMIDP1R MA Inhibitor DMIDP1R RN Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109. DMIDP1R RU https://pubmed.ncbi.nlm.nih.gov/24350995 DMIDP1R DI DMIDP1R DMIDP1R DN peptide 18 DMIDP1R TI TTD30LY DMIDP1R TN Proprotein convertase subtilisin/kexin type 7 (PCSK7) DMIDP1R MA Inhibitor DMIDP1R RN Design, synthesis, and structure-activity relationship studies of a potent PACE4 inhibitor. J Med Chem. 2014 Jan 9;57(1):98-109. DMIDP1R RU https://pubmed.ncbi.nlm.nih.gov/24350995 DMIDQ8B DI DMIDQ8B DMIDQ8B DN GSK931145 DMIDQ8B TI TTHJTF7 DMIDQ8B TN Glycine transporter GlyT-1 (SLC6A9) DMIDQ8B MA Inhibitor DMIDQ8B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DMIDQ8B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DMIDSJ9 DI DMIDSJ9 DMIDSJ9 DN PENECA DMIDSJ9 TI TTK25J1 DMIDSJ9 TN Adenosine A1 receptor (ADORA1) DMIDSJ9 MA Agonist DMIDSJ9 RN N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9. DMIDSJ9 RU https://pubmed.ncbi.nlm.nih.gov/12109910 DMIDSJ9 DI DMIDSJ9 DMIDSJ9 DN PENECA DMIDSJ9 TI TTNE7KG DMIDSJ9 TN Adenosine A2b receptor (ADORA2B) DMIDSJ9 MA Agonist DMIDSJ9 RN N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9. DMIDSJ9 RU https://pubmed.ncbi.nlm.nih.gov/12109910 DMIDSJ9 DI DMIDSJ9 DMIDSJ9 DN PENECA DMIDSJ9 TI TTJFY5U DMIDSJ9 TN Adenosine A3 receptor (ADORA3) DMIDSJ9 MA Agonist DMIDSJ9 RN N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9. DMIDSJ9 RU https://pubmed.ncbi.nlm.nih.gov/12109910 DMIDUO9 DI DMIDUO9 DMIDUO9 DN (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone DMIDUO9 TI TT6L509 DMIDUO9 TN Coagulation factor IIa (F2) DMIDUO9 MA Inhibitor DMIDUO9 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMIDUO9 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMIDUO9 DI DMIDUO9 DMIDUO9 DN (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone DMIDUO9 TI TTGY7WI DMIDUO9 TN Urokinase-type plasminogen activator (PLAU) DMIDUO9 MA Inhibitor DMIDUO9 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMIDUO9 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMIDUO9 DI DMIDUO9 DMIDUO9 DN (4-nitro-1H-pyrazol-1-yl)(phenyl)methanone DMIDUO9 TI TTPLTSQ DMIDUO9 TN Neutrophil elastase (NE) DMIDUO9 MA Inhibitor DMIDUO9 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMIDUO9 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMIDX7P DI DMIDX7P DMIDX7P DN 1-Imidazol-1-ylmethylxanthen-9-one DMIDX7P TI TTRA5BZ DMIDX7P TN Steroid 17-alpha-monooxygenase (S17AH) DMIDX7P MA Inhibitor DMIDX7P RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DMIDX7P RU https://pubmed.ncbi.nlm.nih.gov/20568782 DMIDX7P DI DMIDX7P DMIDX7P DN 1-Imidazol-1-ylmethylxanthen-9-one DMIDX7P TI TTSZLWK DMIDX7P TN Aromatase (CYP19A1) DMIDX7P MA Inhibitor DMIDX7P RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DMIDX7P RU https://pubmed.ncbi.nlm.nih.gov/20568782 DMIDXSN DI DMIDXSN DMIDXSN DN AX-048 DMIDXSN TI TTT1JVS DMIDXSN TN Cytosolic phospholipase A2 (GIVA cPLA2) DMIDXSN MA Inhibitor DMIDXSN RN 2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides. Bioorg Med Chem. 2009 Jul 1;17(13):4833-43. DMIDXSN RU https://pubmed.ncbi.nlm.nih.gov/19443224 DMIDXTR DI DMIDXTR DMIDXTR DN 2-(4-methoxyphenyl)-4H-chromene-4-thione DMIDXTR TI TTGP7BY DMIDXTR TN Monoamine oxidase type B (MAO-B) DMIDXTR MA Inhibitor DMIDXTR RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMIDXTR RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMIE0GJ DI DMIE0GJ DMIE0GJ DN ISIS 112699 DMIE0GJ TI TT6804T DMIE0GJ TN MIF messenger RNA (MIF mRNA) DMIE0GJ RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DMIE0GJ RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DMIE4U5 DI DMIE4U5 DMIE4U5 DN Tyr-Pro-Phe-Ala-Bn DMIE4U5 TI TTKWM86 DMIE4U5 TN Opioid receptor mu (MOP) DMIE4U5 MA Inhibitor DMIE4U5 RN Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. DMIE4U5 RU https://pubmed.ncbi.nlm.nih.gov/19679474 DMIE9BG DI DMIE9BG DMIE9BG DN 5-Methyl-2-p-tolyl-thiazol-4-ol DMIE9BG TI TT2J34L DMIE9BG TN Arachidonate 5-lipoxygenase (5-LOX) DMIE9BG MA Inhibitor DMIE9BG RN 4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65. DMIE9BG RU https://pubmed.ncbi.nlm.nih.gov/2066989 DMIEB8R DI DMIEB8R DMIEB8R DN 2-(3,5-dimethoxy-4-phenethoxyphenyl)ethanamine DMIEB8R TI TTJQOD7 DMIEB8R TN 5-HT 2A receptor (HTR2A) DMIEB8R MA Inhibitor DMIEB8R RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DMIEB8R RU https://pubmed.ncbi.nlm.nih.gov/18296055 DMIECOF DI DMIECOF DMIECOF DN PMID19831390C14 DMIECOF TI TTASMD8 DMIECOF TN LIM domain kinase-2 (LIMK-2) DMIECOF MA Inhibitor DMIECOF RN Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12;52(21):6515-8. DMIECOF RU https://pubmed.ncbi.nlm.nih.gov/19831390 DMIECOF DI DMIECOF DMIECOF DN PMID19831390C14 DMIECOF TI TTWL9TY DMIECOF TN LIM domain kinase-1 (LIMK-1) DMIECOF MA Inhibitor DMIECOF RN Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12;52(21):6515-8. DMIECOF RU https://pubmed.ncbi.nlm.nih.gov/19831390 DMIEGF4 DI DMIEGF4 DMIEGF4 DN 2-THIOSALVINORIN B DMIEGF4 TI TTQW87Y DMIEGF4 TN Opioid receptor kappa (OPRK1) DMIEGF4 MA Inhibitor DMIEGF4 RN Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32. DMIEGF4 RU https://pubmed.ncbi.nlm.nih.gov/17303418 DMIEKJ4 DI DMIEKJ4 DMIEKJ4 DN KR61639 DMIEKJ4 TI TTELIN2 DMIEKJ4 TN PTPN1 messenger RNA (PTPN1 mRNA) DMIEKJ4 MA Inhibitor DMIEKJ4 RN Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. Eur J Pharmacol. 2004 Feb 6;485(1-3):333-9. DMIEKJ4 RU https://pubmed.ncbi.nlm.nih.gov/14757158 DMIEKVB DI DMIEKVB DMIEKVB DN PNT-500 DMIEKVB TI TTR5TV4 DMIEKVB TN ERBB2 messenger RNA (HER2 mRNA) DMIEKVB MA Inhibitor DMIEKVB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2019). DMIEKVB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2019 DMIEMWA DI DMIEMWA DMIEMWA DN 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA TI TTRA5BZ DMIEMWA TN Steroid 17-alpha-monooxygenase (S17AH) DMIEMWA MA Inhibitor DMIEMWA RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMIEMWA RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMIEMWA DI DMIEMWA DMIEMWA DN 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA TI TTIQUX7 DMIEMWA TN Steroid 11-beta-hydroxylase (CYP11B1) DMIEMWA MA Inhibitor DMIEMWA RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMIEMWA RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMIEMWA DI DMIEMWA DMIEMWA DN 4-[(4'-Hydroxybiphenyl-4-yl)methyl]pyridine DMIEMWA TI TTSZLWK DMIEMWA TN Aromatase (CYP19A1) DMIEMWA MA Inhibitor DMIEMWA RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMIEMWA RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMIENSW DI DMIENSW DMIENSW DN GKA-23 DMIENSW TI TTDLNGZ DMIENSW TN Glucokinase (GCK) DMIENSW MA Activator DMIENSW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2798). DMIENSW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2798 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TTEYTKG DMIERWO TN Carbonic anhydrase XIV (CA-XIV) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TTCFSPE DMIERWO TN Carbonic anhydrase VI (CA-VI) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TT2LVK8 DMIERWO TN Carbonic anhydrase IX (CA-IX) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TTSYM0R DMIERWO TN Carbonic anhydrase XII (CA-XII) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TTANPDJ DMIERWO TN Carbonic anhydrase II (CA-II) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TTUNARX DMIERWO TN Carbonic anhydrase (CA) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TTZHA0O DMIERWO TN Carbonic anhydrase IV (CA-IV) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIERWO DI DMIERWO DMIERWO DN Decyl sulfamate DMIERWO TI TTHQPL7 DMIERWO TN Carbonic anhydrase I (CA-I) DMIERWO MA Inhibitor DMIERWO RN Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-bi... J Med Chem. 2009 Oct 8;52(19):5990-8. DMIERWO RU https://pubmed.ncbi.nlm.nih.gov/19731956 DMIESYM DI DMIESYM DMIESYM DN Desmethylclomipramine DMIESYM TI TTJXYQ6 DMIESYM TN Monoamine uptake (MA uptake) DMIESYM MA Inhibitor DMIESYM RN Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds Eur J Pharmacol. 1999 Aug 6;378(2):161-8. DMIESYM RU https://pubmed.ncbi.nlm.nih.gov/10478628 DMIEZGD DI DMIEZGD DMIEZGD DN 3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide DMIEZGD TI TT3WG5C DMIEZGD TN Monoamine oxidase type A (MAO-A) DMIEZGD MA Inhibitor DMIEZGD RN Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66. DMIEZGD RU https://pubmed.ncbi.nlm.nih.gov/20674099 DMIEZGD DI DMIEZGD DMIEZGD DN 3-Chloro-N-(2-methyl-1H-indol-5-yl)benzamide DMIEZGD TI TTGP7BY DMIEZGD TN Monoamine oxidase type B (MAO-B) DMIEZGD MA Inhibitor DMIEZGD RN Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66. DMIEZGD RU https://pubmed.ncbi.nlm.nih.gov/20674099 DMIF1D6 DI DMIF1D6 DMIF1D6 DN 4-ethynyl benzene sulfonamide DMIF1D6 TI TTHQPL7 DMIF1D6 TN Carbonic anhydrase I (CA-I) DMIF1D6 MA Inhibitor DMIF1D6 RN Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem. 2008 Mar 27;51(6):1945-53. DMIF1D6 RU https://pubmed.ncbi.nlm.nih.gov/18307288 DMIF1D6 DI DMIF1D6 DMIF1D6 DN 4-ethynyl benzene sulfonamide DMIF1D6 TI TTANPDJ DMIF1D6 TN Carbonic anhydrase II (CA-II) DMIF1D6 MA Inhibitor DMIF1D6 RN Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem. 2008 Mar 27;51(6):1945-53. DMIF1D6 RU https://pubmed.ncbi.nlm.nih.gov/18307288 DMIF1D6 DI DMIF1D6 DMIF1D6 DN 4-ethynyl benzene sulfonamide DMIF1D6 TI TT2LVK8 DMIF1D6 TN Carbonic anhydrase IX (CA-IX) DMIF1D6 MA Inhibitor DMIF1D6 RN Inhibition of carbonic anhydrases with glycosyltriazole benzene sulfonamides. J Med Chem. 2008 Mar 27;51(6):1945-53. DMIF1D6 RU https://pubmed.ncbi.nlm.nih.gov/18307288 DMIF6NS DI DMIF6NS DMIF6NS DN TROX-1 DMIF6NS TI TT4FDG6 DMIF6NS TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMIF6NS MA Inhibitor (gating inhibitor) DMIF6NS RN Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther. 2010 Aug;334(2):545-55. DMIF6NS RU https://pubmed.ncbi.nlm.nih.gov/20439438 DMIFARP DI DMIFARP DMIFARP DN 1-(3-(4-chlorophenyl)propyl)-1H-imidazole DMIFARP TI TTRA5BZ DMIFARP TN Steroid 17-alpha-monooxygenase (S17AH) DMIFARP MA Inhibitor DMIFARP RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DMIFARP RU https://pubmed.ncbi.nlm.nih.gov/16870430 DMIFCHL DI DMIFCHL DMIFCHL DN D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide DMIFCHL TI TT6L509 DMIFCHL TN Coagulation factor IIa (F2) DMIFCHL MA Inhibitor DMIFCHL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIFCHL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMIFCMW DI DMIFCMW DMIFCMW DN K-777 DMIFCMW TI TTEAID7 DMIFCMW TN Trypanosoma Cruzipain (Trypano CYSP) DMIFCMW MA Inhibitor DMIFCMW RN Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6218-21. DMIFCMW RU https://pubmed.ncbi.nlm.nih.gov/19773167 DMIFCMW DI DMIFCMW DMIFCMW DN K-777 DMIFCMW TI TT2SUAQ DMIFCMW TN Cysteine protease (CYP) DMIFCMW MA Inhibitor DMIFCMW RN Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6218-21. DMIFCMW RU https://pubmed.ncbi.nlm.nih.gov/19773167 DMIFD35 DI DMIFD35 DMIFD35 DN Inositol 1,3,4,5-tetrakisphosphate DMIFD35 TI TTWTSCV DMIFD35 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMIFD35 MA Inhibitor DMIFD35 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIFD35 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIFD35 DI DMIFD35 DMIFD35 DN Inositol 1,3,4,5-tetrakisphosphate DMIFD35 TI TTGM6VW DMIFD35 TN Tyrosine-protein kinase BTK (ATK) DMIFD35 MA Inhibitor DMIFD35 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIFD35 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIFJRS DI DMIFJRS DMIFJRS DN 3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one DMIFJRS TI TTOM3J0 DMIFJRS TN Estrogen receptor beta (ESR2) DMIFJRS MA Inhibitor DMIFJRS RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMIFJRS RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMIFJRS DI DMIFJRS DMIFJRS DN 3,8-dihydroxy-4-methyl-6H-benzo[c]chromen-6-one DMIFJRS TI TTZAYWL DMIFJRS TN Estrogen receptor (ESR) DMIFJRS MA Inhibitor DMIFJRS RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMIFJRS RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMIFKPE DI DMIFKPE DMIFKPE DN FGGFTGARKRKRKLANQ DMIFKPE TI TTNT7K8 DMIFKPE TN Nociceptin receptor (OPRL1) DMIFKPE MA Inhibitor DMIFKPE RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMIFKPE RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMIFKUX DI DMIFKUX DMIFKUX DN [3H]CNQX DMIFKUX TI TTVPQTF DMIFKUX TN Glutamate receptor AMPA 1 (GRIA1) DMIFKUX MA Antagonist DMIFKUX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444). DMIFKUX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444 DMIFKUX DI DMIFKUX DMIFKUX DN [3H]CNQX DMIFKUX TI TT82EZV DMIFKUX TN Glutamate receptor AMPA 3 (GRIA3) DMIFKUX MA Modulator DMIFKUX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446). DMIFKUX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446 DMIFKUX DI DMIFKUX DMIFKUX DN [3H]CNQX DMIFKUX TI TTPJR0G DMIFKUX TN Glutamate receptor AMPA 4 (GRIA4) DMIFKUX MA Modulator DMIFKUX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447). DMIFKUX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447 DMIFKUX DI DMIFKUX DMIFKUX DN [3H]CNQX DMIFKUX TI TT9HLZ0 DMIFKUX TN Glutamate receptor AMPA 2 (GRIA2) DMIFKUX MA Antagonist DMIFKUX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445). DMIFKUX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445 DMIFKUX DI DMIFKUX DMIFKUX DN [3H]CNQX DMIFKUX TI TTAN6JD DMIFKUX TN Glutamate receptor AMPA (GRIA) DMIFKUX MA Inhibitor DMIFKUX RN Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists. J Med Chem. 2006 Apr 20;49(8):2579-92. DMIFKUX RU https://pubmed.ncbi.nlm.nih.gov/16610801 DMIFL3V DI DMIFL3V DMIFL3V DN (6-Propoxy-2-naphthyl)-2-aminopropane DMIFL3V TI TTGP7BY DMIFL3V TN Monoamine oxidase type B (MAO-B) DMIFL3V MA Inhibitor DMIFL3V RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMIFL3V RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMIFL3V DI DMIFL3V DMIFL3V DN (6-Propoxy-2-naphthyl)-2-aminopropane DMIFL3V TI TT3WG5C DMIFL3V TN Monoamine oxidase type A (MAO-A) DMIFL3V MA Inhibitor DMIFL3V RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMIFL3V RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMIFMDC DI DMIFMDC DMIFMDC DN Deoxyuridine-5'-Diphosphate DMIFMDC TI TTY8KJS DMIFMDC TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMIFMDC MA Inhibitor DMIFMDC RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMIFMDC RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMIFOXE DI DMIFOXE DMIFOXE DN 1,4-Dithiothreitol DMIFOXE TI TTU6BFZ DMIFOXE TN Candida Thymidylate synthase (Candi TMP1) DMIFOXE MA Inhibitor DMIFOXE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIFOXE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIFOXE DI DMIFOXE DMIFOXE DN 1,4-Dithiothreitol DMIFOXE TI TT6ZFQ4 DMIFOXE TN Rotamase B (PPIB) DMIFOXE MA Inhibitor DMIFOXE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIFOXE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIFOXE DI DMIFOXE DMIFOXE DN 1,4-Dithiothreitol DMIFOXE TI TTPADOQ DMIFOXE TN HMG-CoA reductase (HMGCR) DMIFOXE MA Inhibitor DMIFOXE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIFOXE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIFUDG DI DMIFUDG DMIFUDG DN 3,3-Diisopropyl-dihydro-furan-2-one DMIFUDG TI TTZA1NY DMIFUDG TN GABA(A) receptor beta-2 (GABRB2) DMIFUDG MA Inhibitor DMIFUDG RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMIFUDG RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMIFUDG DI DMIFUDG DMIFUDG DN 3,3-Diisopropyl-dihydro-furan-2-one DMIFUDG TI TTNJYV2 DMIFUDG TN Gamma-aminobutyric acid receptor (GAR) DMIFUDG MA Inhibitor DMIFUDG RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMIFUDG RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMIFUDG DI DMIFUDG DMIFUDG DN 3,3-Diisopropyl-dihydro-furan-2-one DMIFUDG TI TT06RH5 DMIFUDG TN GABA(A) receptor gamma-2 (GABRG2) DMIFUDG MA Inhibitor DMIFUDG RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMIFUDG RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMIFUDG DI DMIFUDG DMIFUDG DN 3,3-Diisopropyl-dihydro-furan-2-one DMIFUDG TI TT1MPAY DMIFUDG TN GABA(A) receptor alpha-1 (GABRA1) DMIFUDG MA Inhibitor DMIFUDG RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMIFUDG RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMIG308 DI DMIG308 DMIG308 DN PMID17929793C23c DMIG308 TI TTVBPDM DMIG308 TN Metabotropic glutamate receptor 1 (mGluR1) DMIG308 MA Modulator (allosteric modulator) DMIG308 RN Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3. DMIG308 RU https://pubmed.ncbi.nlm.nih.gov/17929793 DMIG3FX DI DMIG3FX DMIG3FX DN Lysophosphotidylserine DMIG3FX TI TT6L509 DMIG3FX TN Coagulation factor IIa (F2) DMIG3FX MA Inhibitor DMIG3FX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIG3FX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIG82P DI DMIG82P DMIG82P DN 4-aminonaphthalen-1-ol DMIG82P TI TTZJYKH DMIG82P TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMIG82P MA Inhibitor DMIG82P RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMIG82P RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMIG9H3 DI DMIG9H3 DMIG9H3 DN (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DMIG9H3 TI TTZUFI5 DMIG9H3 TN Nitric-oxide synthase brain (NOS1) DMIG9H3 MA Inhibitor DMIG9H3 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMIG9H3 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMIG9H3 DI DMIG9H3 DMIG9H3 DN (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DMIG9H3 TI TTF10I9 DMIG9H3 TN Nitric-oxide synthase inducible (NOS2) DMIG9H3 MA Inhibitor DMIG9H3 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMIG9H3 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMIG9H3 DI DMIG9H3 DMIG9H3 DN (S)-3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DMIG9H3 TI TTCM4B3 DMIG9H3 TN Nitric-oxide synthase endothelial (NOS3) DMIG9H3 MA Inhibitor DMIG9H3 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMIG9H3 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMIGB7N DI DMIGB7N DMIGB7N DN COCHINCHINENIN B DMIGB7N TI TT6L509 DMIGB7N TN Coagulation factor IIa (F2) DMIGB7N MA Inhibitor DMIGB7N RN Anti-Helicobacter pylori and thrombin inhibitory components from Chinese dragon's blood, Dracaena cochinchinensis. J Nat Prod. 2007 Oct;70(10):1570-7. DMIGB7N RU https://pubmed.ncbi.nlm.nih.gov/17883259 DMIGDCK DI DMIGDCK DMIGDCK DN 1-(4-Butyl-thiazol-2-yl)-3-phenethyl-thiourea DMIGDCK TI TT84ETX DMIGDCK TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMIGDCK MA Inhibitor DMIGDCK RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMIGDCK RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMIGFX6 DI DMIGFX6 DMIGFX6 DN 2,5-difluorophenol DMIGFX6 TI TTUNARX DMIGFX6 TN Carbonic anhydrase (CA) DMIGFX6 MA Inhibitor DMIGFX6 RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMIGFX6 RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMIGRMV DI DMIGRMV DMIGRMV DN 2-(1-adamantyl)-2-methyl-pyrrolidine DMIGRMV TI TTXT3PU DMIGRMV TN Influenza M2 protein (Influ M) DMIGRMV MA Inhibitor DMIGRMV RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMIGRMV RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMIGV0H DI DMIGV0H DMIGV0H DN ISIS 105987 DMIGV0H TI TTT2SVW DMIGV0H TN PPAR-gamma messenger RNA (PPARG mRNA) DMIGV0H RN US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression. DMIGV0H RU http://www.patentbuddy.com/Patent/6159734?ft=true&sr=true DMIGXRJ DI DMIGXRJ DMIGXRJ DN 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol DMIGXRJ TI TTOM3J0 DMIGXRJ TN Estrogen receptor beta (ESR2) DMIGXRJ MA Inhibitor DMIGXRJ RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMIGXRJ RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMIGXRJ DI DMIGXRJ DMIGXRJ DN 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-6-ol DMIGXRJ TI TTZAYWL DMIGXRJ TN Estrogen receptor (ESR) DMIGXRJ MA Inhibitor DMIGXRJ RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMIGXRJ RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMIH38V DI DMIH38V DMIH38V DN ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID DMIH38V TI TTXQKM3 DMIH38V TN Farnesyl protein transferase (Ftase) DMIH38V MA Inhibitor DMIH38V RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIH38V RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMIH38V DI DMIH38V DMIH38V DN ALPHA-HYDROXYFARNESYLPHOSPHONIC ACID DMIH38V TI TT7WZIJ DMIH38V TN CAAX farnesyltransferase beta (FNTB) DMIH38V MA Inhibitor DMIH38V RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIH38V RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMIH5CD DI DMIH5CD DMIH5CD DN Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 DMIH5CD TI TT0MV2T DMIH5CD TN Melanocortin receptor 1 (MC1R) DMIH5CD MA Inhibitor DMIH5CD RN Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. DMIH5CD RU https://pubmed.ncbi.nlm.nih.gov/16766182 DMIH5CD DI DMIH5CD DMIH5CD DN Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 DMIH5CD TI TTD0CIQ DMIH5CD TN Melanocortin receptor 4 (MC4R) DMIH5CD MA Inhibitor DMIH5CD RN Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. DMIH5CD RU https://pubmed.ncbi.nlm.nih.gov/16766182 DMIH5CD DI DMIH5CD DMIH5CD DN Ac-Tyr-D-Phe-Arg-2-Nal-NHCH3 DMIH5CD TI TTNI91K DMIH5CD TN Melanocortin receptor 3 (MC3R) DMIH5CD MA Inhibitor DMIH5CD RN Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4668-73. DMIH5CD RU https://pubmed.ncbi.nlm.nih.gov/16766182 DMIH6JU DI DMIH6JU DMIH6JU DN 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane DMIH6JU TI TTQ3JTF DMIH6JU TN Muscarinic acetylcholine receptor M4 (CHRM4) DMIH6JU MA Inhibitor DMIH6JU RN Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90. DMIH6JU RU https://pubmed.ncbi.nlm.nih.gov/1560440 DMIH6JU DI DMIH6JU DMIH6JU DN 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane DMIH6JU TI TTH18TF DMIH6JU TN Muscarinic acetylcholine receptor M5 (CHRM5) DMIH6JU MA Inhibitor DMIH6JU RN Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90. DMIH6JU RU https://pubmed.ncbi.nlm.nih.gov/1560440 DMIH6JU DI DMIH6JU DMIH6JU DN 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane DMIH6JU TI TTQ13Z5 DMIH6JU TN Muscarinic acetylcholine receptor M3 (CHRM3) DMIH6JU MA Inhibitor DMIH6JU RN Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90. DMIH6JU RU https://pubmed.ncbi.nlm.nih.gov/1560440 DMIH6JU DI DMIH6JU DMIH6JU DN 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane DMIH6JU TI TTYEG6Q DMIH6JU TN Muscarinic acetylcholine receptor M2 (CHRM2) DMIH6JU MA Inhibitor DMIH6JU RN Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90. DMIH6JU RU https://pubmed.ncbi.nlm.nih.gov/1560440 DMIH6JU DI DMIH6JU DMIH6JU DN 3-Tetrazol-2-yl-1-aza-bicyclo[2.2.2]octane DMIH6JU TI TTZ9SOR DMIH6JU TN Muscarinic acetylcholine receptor M1 (CHRM1) DMIH6JU MA Inhibitor DMIH6JU RN Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives. J Med Chem. 1992 Apr 3;35(7):1280-90. DMIH6JU RU https://pubmed.ncbi.nlm.nih.gov/1560440 DMIH7W1 DI DMIH7W1 DMIH7W1 DN 5-Chloro-1-(4-chloro-benzyl)-1H-indole-2,3-dione DMIH7W1 TI TTEAID7 DMIH7W1 TN Trypanosoma Cruzipain (Trypano CYSP) DMIH7W1 MA Inhibitor DMIH7W1 RN Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30. DMIH7W1 RU https://pubmed.ncbi.nlm.nih.gov/14505663 DMIHBC5 DI DMIHBC5 DMIHBC5 DN T140 DMIHBC5 TI TTBID49 DMIHBC5 TN C-X-C chemokine receptor type 4 (CXCR4) DMIHBC5 MA Antagonist DMIHBC5 RN A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998 Dec 30;253(3):877-82. DMIHBC5 RU https://pubmed.ncbi.nlm.nih.gov/9918823 DMIHBFO DI DMIHBFO DMIHBFO DN 1-[(Z)-4-trityloxy-2-butenyl]uracil DMIHBFO TI TTY8KJS DMIHBFO TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMIHBFO MA Inhibitor DMIHBFO RN Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95. DMIHBFO RU https://pubmed.ncbi.nlm.nih.gov/16821778 DMIHDEB DI DMIHDEB DMIHDEB DN LG-889 DMIHDEB TI TT1290U DMIHDEB TN Coagulation factor VIII (F8) DMIHDEB MA Modulator DMIHDEB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMIHDEB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMIHFQY DI DMIHFQY DMIHFQY DN HOMOAROMOLINE DMIHFQY TI TTVBI8W DMIHFQY TN Dopamine transporter (DAT) DMIHFQY MA Inhibitor DMIHFQY RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DMIHFQY RU https://pubmed.ncbi.nlm.nih.gov/8676127 DMIHJSA DI DMIHJSA DMIHJSA DN 2-Bromoacetyl Group DMIHJSA TI TT8NGED DMIHJSA TN Prostaglandin G/H synthase 1 (COX-1) DMIHJSA MA Inhibitor DMIHJSA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIHJSA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIHMP5 DI DMIHMP5 DMIHMP5 DN Biphenyl-4-ylboronic acid DMIHMP5 TI TTHQPL7 DMIHMP5 TN Carbonic anhydrase I (CA-I) DMIHMP5 MA Inhibitor DMIHMP5 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMIHMP5 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMIHMP5 DI DMIHMP5 DMIHMP5 DN Biphenyl-4-ylboronic acid DMIHMP5 TI TTUNARX DMIHMP5 TN Carbonic anhydrase (CA) DMIHMP5 MA Inhibitor DMIHMP5 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMIHMP5 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMIHMP5 DI DMIHMP5 DMIHMP5 DN Biphenyl-4-ylboronic acid DMIHMP5 TI TTDP1UC DMIHMP5 TN Fatty acid amide hydrolase (FAAH) DMIHMP5 MA Inhibitor DMIHMP5 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMIHMP5 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMIHMP5 DI DMIHMP5 DMIHMP5 DN Biphenyl-4-ylboronic acid DMIHMP5 TI TTANPDJ DMIHMP5 TN Carbonic anhydrase II (CA-II) DMIHMP5 MA Inhibitor DMIHMP5 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMIHMP5 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMIHO0P DI DMIHO0P DMIHO0P DN PIPEROXAN DMIHO0P TI TT2NUT5 DMIHO0P TN Adrenergic receptor alpha-2C (ADRA2C) DMIHO0P MA Inhibitor DMIHO0P RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMIHO0P RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMIHO0P DI DMIHO0P DMIHO0P DN PIPEROXAN DMIHO0P TI TTWM4TY DMIHO0P TN Adrenergic receptor alpha-2B (ADRA2B) DMIHO0P MA Inhibitor DMIHO0P RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMIHO0P RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMIHO0P DI DMIHO0P DMIHO0P DN PIPEROXAN DMIHO0P TI TTWG9A4 DMIHO0P TN Adrenergic receptor alpha-2A (ADRA2A) DMIHO0P MA Inhibitor DMIHO0P RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMIHO0P RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMIHOYF DI DMIHOYF DMIHOYF DN GW-5074 DMIHOYF TI TTAN5W2 DMIHOYF TN Raf messenger RNA (Raf mRNA) DMIHOYF MA Inhibitor DMIHOYF RN Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7. DMIHOYF RU https://pubmed.ncbi.nlm.nih.gov/15013000 DMIHOYF DI DMIHOYF DMIHOYF DN GW-5074 DMIHOYF TI TTTDVOJ DMIHOYF TN Tropomyosin-related kinase A (TrkA) DMIHOYF MA Inhibitor DMIHOYF RN Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7. DMIHOYF RU https://pubmed.ncbi.nlm.nih.gov/15013000 DMIHR14 DI DMIHR14 DMIHR14 DN (R)-N-oleoyltyrosinol DMIHR14 TI TT7QNVC DMIHR14 TN Glucose-dependent insulinotropic receptor (GPR119) DMIHR14 MA Agonist DMIHR14 RN N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol. 2010 Jan;24(1):161-70. DMIHR14 RU https://pubmed.ncbi.nlm.nih.gov/19901198 DMIHSEV DI DMIHSEV DMIHSEV DN PT-322 DMIHSEV TI TT84ETX DMIHSEV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMIHSEV MA Inhibitor DMIHSEV RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMIHSEV RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMIHTL0 DI DMIHTL0 DMIHTL0 DN 2-(2-Methyl-thiazol-4-ylethynyl)-pyridine DMIHTL0 TI TTHS256 DMIHTL0 TN Metabotropic glutamate receptor 5 (mGluR5) DMIHTL0 MA Inhibitor DMIHTL0 RN 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6. DMIHTL0 RU https://pubmed.ncbi.nlm.nih.gov/15225713 DMIHTPC DI DMIHTPC DMIHTPC DN ISIS 111121 DMIHTPC TI TTOM97J DMIHTPC TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DMIHTPC RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DMIHTPC RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DMIHWAJ DI DMIHWAJ DMIHWAJ DN 3-[1'-{4'-(Benzyloxy)-phenyl}]-quinuclidine-2-ene DMIHWAJ TI TTFQEO5 DMIHWAJ TN Squalene synthetase (FDFT1) DMIHWAJ MA Inhibitor DMIHWAJ RN Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61. DMIHWAJ RU https://pubmed.ncbi.nlm.nih.gov/17709461 DMIHYKG DI DMIHYKG DMIHYKG DN 1,4-diaminoanthracene-9,10-dione DMIHYKG TI TTM2AOE DMIHYKG TN Adenosine A2a receptor (ADORA2A) DMIHYKG MA Inhibitor DMIHYKG RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DMIHYKG RU https://pubmed.ncbi.nlm.nih.gov/20095623 DMIJ2GV DI DMIJ2GV DMIJ2GV DN I-ABA DMIJ2GV TI TTJFY5U DMIJ2GV TN Adenosine A3 receptor (ADORA3) DMIJ2GV MA Agonist DMIJ2GV RN Molecular cloning and characterization of the human A3 adenosine receptor. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10365-9. DMIJ2GV RU https://pubmed.ncbi.nlm.nih.gov/8234299 DMIJ4VZ DI DMIJ4VZ DMIJ4VZ DN 4,6-Dinitro salicylic acid DMIJ4VZ TI TTANPDJ DMIJ4VZ TN Carbonic anhydrase II (CA-II) DMIJ4VZ MA Inhibitor DMIJ4VZ RN In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5. DMIJ4VZ RU https://pubmed.ncbi.nlm.nih.gov/18819808 DMIJ4VZ DI DMIJ4VZ DMIJ4VZ DN 4,6-Dinitro salicylic acid DMIJ4VZ TI TTHQPL7 DMIJ4VZ TN Carbonic anhydrase I (CA-I) DMIJ4VZ MA Inhibitor DMIJ4VZ RN In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorg Med Chem. 2008 Oct 15;16(20):9101-5. DMIJ4VZ RU https://pubmed.ncbi.nlm.nih.gov/18819808 DMIJ7PC DI DMIJ7PC DMIJ7PC DN (+/-)-threo-N-(3-Methylthiopene)methylphenidate DMIJ7PC TI TTVBI8W DMIJ7PC TN Dopamine transporter (DAT) DMIJ7PC MA Inhibitor DMIJ7PC RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMIJ7PC RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMIJES1 DI DMIJES1 DMIJES1 DN ISIS 116625 DMIJES1 TI TTQWAU1 DMIJES1 TN GSK3A messenger RNA (GSK3A mRNA) DMIJES1 RN US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression. DMIJES1 RU http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true DMIJH7W DI DMIJH7W DMIJH7W DN (3-bromophenyl)(10H-phenothiazin-10-yl)methanone DMIJH7W TI TTEB0GD DMIJH7W TN Cholinesterase (BCHE) DMIJH7W MA Inhibitor DMIJH7W RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMIJH7W RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMIJLX6 DI DMIJLX6 DMIJLX6 DN N-(4'-acetyl-4-aminobiphenyl-3-yl)benzamide DMIJLX6 TI TTSHTOI DMIJLX6 TN Histone deacetylase 2 (HDAC2) DMIJLX6 MA Inhibitor DMIJLX6 RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMIJLX6 RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMIJMZQ DI DMIJMZQ DMIJMZQ DN MERIOLIN 4 DMIJMZQ TI TT1LVF2 DMIJMZQ TN Cyclin-dependent kinase 9 (CDK9) DMIJMZQ MA Inhibitor DMIJMZQ RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMIJMZQ RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMIJMZQ DI DMIJMZQ DMIJMZQ DN MERIOLIN 4 DMIJMZQ TI TTAMQ62 DMIJMZQ TN Cyclin A2 (CCNA2) DMIJMZQ MA Inhibitor DMIJMZQ RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMIJMZQ RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMIJMZQ DI DMIJMZQ DMIJMZQ DN MERIOLIN 4 DMIJMZQ TI TT7HF4W DMIJMZQ TN Cyclin-dependent kinase 2 (CDK2) DMIJMZQ MA Inhibitor DMIJMZQ RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMIJMZQ RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMIJN9E DI DMIJN9E DMIJN9E DN 3-phenylprop-1-enylboronic acid DMIJN9E TI TTHQPL7 DMIJN9E TN Carbonic anhydrase I (CA-I) DMIJN9E MA Inhibitor DMIJN9E RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMIJN9E RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMIJN9E DI DMIJN9E DMIJN9E DN 3-phenylprop-1-enylboronic acid DMIJN9E TI TTANPDJ DMIJN9E TN Carbonic anhydrase II (CA-II) DMIJN9E MA Inhibitor DMIJN9E RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMIJN9E RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMIK0GR DI DMIK0GR DMIK0GR DN ISIS 23707 DMIK0GR TI TTEWOHV DMIK0GR TN Survivin messenger RNA (Survivin mRNA) DMIK0GR RN US patent application no. 6,165,788, Antisense modulation of Survivin expression. DMIK0GR RU http://www.patentbuddy.com/Patent/6165788?ft=true&sr=true DMIK40C DI DMIK40C DMIK40C DN Nifeviroc DMIK40C TI TT2CEJG DMIK40C TN C-C chemokine receptor type 5 (CCR5) DMIK40C MA Modulator DMIK40C RN Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study. J Pharm Biomed Anal. 2011 Nov 1;56(3):637-40. DMIK40C RU https://pubmed.ncbi.nlm.nih.gov/21802236 DMIK7XV DI DMIK7XV DMIK7XV DN 1,3-bis(nitrooxy)propan-2-yl 2-acetoxybenzoate DMIK7XV TI TTVKILB DMIK7XV TN Prostaglandin G/H synthase 2 (COX-2) DMIK7XV MA Inhibitor DMIK7XV RN Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evalu... Bioorg Med Chem Lett. 2009 Jun 1;19(11):3014-8. DMIK7XV RU https://pubmed.ncbi.nlm.nih.gov/19419861 DMIK9VO DI DMIK9VO DMIK9VO DN 3-Phosphoglyceric Acid DMIK9VO TI TTHJWVK DMIK9VO TN Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI) DMIK9VO MA Inhibitor DMIK9VO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIK9VO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIK9VO DI DMIK9VO DMIK9VO DN 3-Phosphoglyceric Acid DMIK9VO TI TTNS6X4 DMIK9VO TN Bacterial Triosephosphate isomerase (Bact TPI) DMIK9VO MA Inhibitor DMIK9VO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIK9VO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIKD8X DI DMIKD8X DMIKD8X DN COMBETASTATIN DMIKD8X TI TTYFKSZ DMIKD8X TN Tubulin beta (TUBB) DMIKD8X MA Inhibitor DMIKD8X RN Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 1998 Aug 4;8(15):1997-2000. DMIKD8X RU https://pubmed.ncbi.nlm.nih.gov/9873473 DMIKD8X DI DMIKD8X DMIKD8X DN COMBETASTATIN DMIKD8X TI TTML2WA DMIKD8X TN Tubulin (TUB) DMIKD8X MA Inhibitor DMIKD8X RN Asymmetric synthesis of antimitotic combretadioxolane with potent antitumor activity against multi-drug resistant cells. Bioorg Med Chem Lett. 1998 Aug 4;8(15):1997-2000. DMIKD8X RU https://pubmed.ncbi.nlm.nih.gov/9873473 DMIKDAR DI DMIKDAR DMIKDAR DN AGN-190744 DMIKDAR TI TT5HONZ DMIKDAR TN Calcium channel unspecific (CaC) DMIKDAR MA Modulator DMIKDAR RN The antiinflammatory activity of topically applied novel calcium-channel antagonists. Inflammation. 1995 Apr;19(2):261-75. DMIKDAR RU https://www.ncbi.nlm.nih.gov/pubmed/7601508 DMIKEXD DI DMIKEXD DMIKEXD DN ISIS 19220 DMIKEXD TI TT1ERKL DMIKEXD TN CD40 messenger RNA (CD40 mRNA) DMIKEXD RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMIKEXD RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMIKJLP DI DMIKJLP DMIKJLP DN Sch-036 DMIKJLP TI TTMSFAW DMIKJLP TN Cannabinoid receptor 2 (CB2) DMIKJLP MA Agonist DMIKJLP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DMIKJLP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DMIKJNL DI DMIKJNL DMIKJNL DN S6-nitrobenzyl mercaptopurine riboside DMIKJNL TI TTLXAKE DMIKJNL TN Solute carrier family 29 member 1 (SLC29A1) DMIKJNL MA Inhibitor DMIKJNL RN Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):917-21. DMIKJNL RU https://pubmed.ncbi.nlm.nih.gov/19097778 DMIKP5Y DI DMIKP5Y DMIKP5Y DN N-(3-chlorophenyl)-6-nitroquinazolin-4-amine DMIKP5Y TI TTHS256 DMIKP5Y TN Metabotropic glutamate receptor 5 (mGluR5) DMIKP5Y MA Inhibitor DMIKP5Y RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMIKP5Y RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMIKRP6 DI DMIKRP6 DMIKRP6 DN 6-phenylethynyl-nicotinic acid methyl ester DMIKRP6 TI TTHS256 DMIKRP6 TN Metabotropic glutamate receptor 5 (mGluR5) DMIKRP6 MA Inhibitor DMIKRP6 RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DMIKRP6 RU https://pubmed.ncbi.nlm.nih.gov/18173231 DMIKSTL DI DMIKSTL DMIKSTL DN 7-hydroxy-2-(morpholin-4-yl)chromen-4-one DMIKSTL TI TTK3PY9 DMIKSTL TN DNA-dependent protein kinase catalytic (PRKDC) DMIKSTL MA Inhibitor DMIKSTL RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMIKSTL RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMIKT7W DI DMIKT7W DMIKT7W DN SER-203 DMIKT7W TI TTGTQHC DMIKT7W TN DNA topoisomerase I (TOP1) DMIKT7W MA Stimulator DMIKT7W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMIKT7W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMIKUBY DI DMIKUBY DMIKUBY DN Des-bromoaplysamine-1 DMIKUBY TI TT9JNIC DMIKUBY TN Histamine H3 receptor (H3R) DMIKUBY MA Inhibitor DMIKUBY RN Aplysamine-1 and related analogs as histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2006 Feb 15;16(4):897-900. DMIKUBY RU https://pubmed.ncbi.nlm.nih.gov/16300945 DMIL45X DI DMIL45X DMIL45X DN 4-(2'-(trifluoromethoxy)biphenyl-3-yl)oxazole DMIL45X TI TT4G2JS DMIL45X TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMIL45X MA Inhibitor DMIL45X RN Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40. DMIL45X RU https://pubmed.ncbi.nlm.nih.gov/20709552 DMILA4P DI DMILA4P DMILA4P DN AP811 DMILA4P TI TTWVLS6 DMILA4P TN Natriuretic peptide receptor (NPR3) DMILA4P MA Antagonist DMILA4P RN The discovery of non-basic atrial natriuretic peptide clearance receptor antagonists. Part 1. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1949-52. DMILA4P RU https://pubmed.ncbi.nlm.nih.gov/10987424 DMILBO9 DI DMILBO9 DMILBO9 DN SARMs DMILBO9 TI TTS64P2 DMILBO9 TN Androgen receptor (AR) DMILBO9 MA Modulator DMILBO9 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMILBO9 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMILJUE DI DMILJUE DMILJUE DN N,N-dibenzyl[D-Pro-10]Dyn A-(1-11) DMILJUE TI TTQW87Y DMILJUE TN Opioid receptor kappa (OPRK1) DMILJUE MA Inhibitor DMILJUE RN Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9. DMILJUE RU https://pubmed.ncbi.nlm.nih.gov/9276018 DMILMHZ DI DMILMHZ DMILMHZ DN BMS-564929 DMILMHZ TI TTKPW01 DMILMHZ TN Androgen receptor messenger RNA (AR mRNA) DMILMHZ MA Inhibitor DMILMHZ RN N-aryl-oxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation. J Med Chem. 2009 May 14;52(9):2794-8. DMILMHZ RU https://pubmed.ncbi.nlm.nih.gov/19351168 DMILP0F DI DMILP0F DMILP0F DN NE-2 DMILP0F TI TTKWM86 DMILP0F TN Opioid receptor mu (MOP) DMILP0F MA Agonist DMILP0F RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMILP0F RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMILTRN DI DMILTRN DMILTRN DN 3-Sulfinoalanine DMILTRN TI TTS0EZJ DMILTRN TN Hydroxymethylglutaryl-CoA synthase 2 (HMGCS2) DMILTRN MA Inhibitor DMILTRN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMILTRN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMILTRN DI DMILTRN DMILTRN DN 3-Sulfinoalanine DMILTRN TI TTICO5G DMILTRN TN Staphylococcus Peptide deformylase (Stap-coc def) DMILTRN MA Inhibitor DMILTRN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMILTRN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMILTRN DI DMILTRN DMILTRN DN 3-Sulfinoalanine DMILTRN TI TTEP6RV DMILTRN TN Glutathione reductase (GR) DMILTRN MA Inhibitor DMILTRN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMILTRN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMILWE7 DI DMILWE7 DMILWE7 DN (S)(+)-7-fluoro-2-(4-fluorophenyl)chroman-4-one DMILWE7 TI TTGP7BY DMILWE7 TN Monoamine oxidase type B (MAO-B) DMILWE7 MA Inhibitor DMILWE7 RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMILWE7 RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMILWPS DI DMILWPS DMILWPS DN N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide DMILWPS TI TT32JK8 DMILWPS TN Melatonin receptor type 1B (MTNR1B) DMILWPS MA Inhibitor DMILWPS RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMILWPS RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMILWPS DI DMILWPS DMILWPS DN N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamide DMILWPS TI TT0WAIE DMILWPS TN Melatonin receptor type 1A (MTNR1A) DMILWPS MA Inhibitor DMILWPS RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMILWPS RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMIM5DL DI DMIM5DL DMIM5DL DN 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one DMIM5DL TI TTIQUX7 DMIM5DL TN Steroid 11-beta-hydroxylase (CYP11B1) DMIM5DL MA Inhibitor DMIM5DL RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMIM5DL RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMIM5DL DI DMIM5DL DMIM5DL DN 6-Pyridin-3-yl-3,4-dihydronaphthalen-2(1H)-one DMIM5DL TI TTXV4FI DMIM5DL TN Albendazole monooxygenase (CYP3A4) DMIM5DL MA Inhibitor DMIM5DL RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMIM5DL RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMIM5WE DI DMIM5WE DMIM5WE DN 3-[4-(4-Hydroxyphenyl)-1,3-oxazol-2-yl]phenol DMIM5WE TI TTIWB6L DMIM5WE TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMIM5WE MA Inhibitor DMIM5WE RN Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid ... Bioorg Med Chem. 2008 Jun 15;16(12):6423-35. DMIM5WE RU https://pubmed.ncbi.nlm.nih.gov/18514529 DMIMD0T DI DMIMD0T DMIMD0T DN ARI-3099 DMIMD0T TI TTYWEDQ DMIMD0T TN Acylamino-acid-releasing enzyme (APEH) DMIMD0T MA Inhibitor DMIMD0T RN A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63. DMIMD0T RU https://pubmed.ncbi.nlm.nih.gov/24997602 DMIMD0T DI DMIMD0T DMIMD0T DN ARI-3099 DMIMD0T TI TTGPQ0F DMIMD0T TN Prolyl endopeptidase FAP (FAP) DMIMD0T MA Inhibitor DMIMD0T RN Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77. DMIMD0T RU https://pubmed.ncbi.nlm.nih.gov/23594271 DMIMJNU DI DMIMJNU DMIMJNU DN N-(1H-indazol-5-yl)acetamide DMIMJNU TI TTVKILB DMIMJNU TN Prostaglandin G/H synthase 2 (COX-2) DMIMJNU MA Inhibitor DMIMJNU RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DMIMJNU RU https://pubmed.ncbi.nlm.nih.gov/19053765 DMIMJNU DI DMIMJNU DMIMJNU DN N-(1H-indazol-5-yl)acetamide DMIMJNU TI TT8NGED DMIMJNU TN Prostaglandin G/H synthase 1 (COX-1) DMIMJNU MA Inhibitor DMIMJNU RN New analgesics synthetically derived from the paracetamol metabolite N-(4-hydroxyphenyl)-(5Z,8Z,11Z,14Z)-icosatetra-5,8,11,14-enamide. J Med Chem. 2008 Dec 25;51(24):7800-5. DMIMJNU RU https://pubmed.ncbi.nlm.nih.gov/19053765 DMIMKFZ DI DMIMKFZ DMIMKFZ DN MGS0028 DMIMKFZ TI TTXJ47W DMIMKFZ TN Metabotropic glutamate receptor 2 (mGluR2) DMIMKFZ MA Agonist DMIMKFZ RN Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem. 2000 Dec 14;43(25):4893-909. DMIMKFZ RU https://pubmed.ncbi.nlm.nih.gov/11123999 DMIMLUO DI DMIMLUO DMIMLUO DN 7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine DMIMLUO TI TTWJBZ5 DMIMLUO TN 5-HT 2C receptor (HTR2C) DMIMLUO MA Inhibitor DMIMLUO RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DMIMLUO RU https://pubmed.ncbi.nlm.nih.gov/18083579 DMIMLUO DI DMIMLUO DMIMLUO DN 7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine DMIMLUO TI TT0K1SC DMIMLUO TN 5-HT 2B receptor (HTR2B) DMIMLUO MA Inhibitor DMIMLUO RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DMIMLUO RU https://pubmed.ncbi.nlm.nih.gov/18083579 DMIMLUO DI DMIMLUO DMIMLUO DN 7,8,9,10-tetrahydro-6H-furo-[2,3-g][3]benzazepine DMIMLUO TI TTJQOD7 DMIMLUO TN 5-HT 2A receptor (HTR2A) DMIMLUO MA Inhibitor DMIMLUO RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DMIMLUO RU https://pubmed.ncbi.nlm.nih.gov/18083579 DMIMPDL DI DMIMPDL DMIMPDL DN PCI-34051 DMIMPDL TI TTT6LFV DMIMPDL TN Histone deacetylase 8 (HDAC8) DMIMPDL MA Inhibitor DMIMPDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2619). DMIMPDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2619 DMIMRCH DI DMIMRCH DMIMRCH DN 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine DMIMRCH TI TTK25J1 DMIMRCH TN Adenosine A1 receptor (ADORA1) DMIMRCH MA Inhibitor DMIMRCH RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DMIMRCH RU https://pubmed.ncbi.nlm.nih.gov/17665891 DMIMRCH DI DMIMRCH DMIMRCH DN 2-m-tolyl-2H-pyrazolo[3,4-c]quinolin-4-amine DMIMRCH TI TTM2AOE DMIMRCH TN Adenosine A2a receptor (ADORA2A) DMIMRCH MA Inhibitor DMIMRCH RN New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluati... J Med Chem. 2007 Aug 23;50(17):4061-74. DMIMRCH RU https://pubmed.ncbi.nlm.nih.gov/17665891 DMIMW1E DI DMIMW1E DMIMW1E DN 4-butyl-N-phenylbenzamide DMIMW1E TI TTMI6F5 DMIMW1E TN Transient receptor potential cation channel V1 (TRPV1) DMIMW1E MA Inhibitor DMIMW1E RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMIMW1E RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMIMZ21 DI DMIMZ21 DMIMZ21 DN 16-(pyridin-3-yl)methylene-estradiol DMIMZ21 TI TTIWB6L DMIMZ21 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMIMZ21 MA Inhibitor DMIMZ21 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMIMZ21 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMIN128 DI DMIN128 DMIN128 DN N-(6-chloro-5-p-tolyl-1H-indazol-3-yl)butyramide DMIN128 TI TTRSMW9 DMIN128 TN Glycogen synthase kinase-3 beta (GSK-3B) DMIN128 MA Inhibitor DMIN128 RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMIN128 RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMIN60B DI DMIN60B DMIN60B DN N-(pyridin-3-ylmethyl)aniline DMIN60B TI TTXZEAJ DMIN60B TN Leukotriene A-4 hydrolase (LTA4H) DMIN60B MA Inhibitor DMIN60B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIN60B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMIN9HC DI DMIN9HC DMIN9HC DN 8-Bromo-9-isopropyl-9H-adenine DMIN9HC TI TTK25J1 DMIN9HC TN Adenosine A1 receptor (ADORA1) DMIN9HC MA Inhibitor DMIN9HC RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMIN9HC RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMIN9HC DI DMIN9HC DMIN9HC DN 8-Bromo-9-isopropyl-9H-adenine DMIN9HC TI TTM2AOE DMIN9HC TN Adenosine A2a receptor (ADORA2A) DMIN9HC MA Inhibitor DMIN9HC RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMIN9HC RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMIN9HC DI DMIN9HC DMIN9HC DN 8-Bromo-9-isopropyl-9H-adenine DMIN9HC TI TTNE7KG DMIN9HC TN Adenosine A2b receptor (ADORA2B) DMIN9HC MA Inhibitor DMIN9HC RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMIN9HC RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMIN9HC DI DMIN9HC DMIN9HC DN 8-Bromo-9-isopropyl-9H-adenine DMIN9HC TI TTJFY5U DMIN9HC TN Adenosine A3 receptor (ADORA3) DMIN9HC MA Inhibitor DMIN9HC RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMIN9HC RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMINK9Q DI DMINK9Q DMINK9Q DN N5-[4-(3-Phenylpropoxy)phenyl]-L-glutamine DMINK9Q TI TTXZEAJ DMINK9Q TN Leukotriene A-4 hydrolase (LTA4H) DMINK9Q MA Inhibitor DMINK9Q RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMINK9Q RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMINLCJ DI DMINLCJ DMINLCJ DN (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}serinamide DMINLCJ TI TTGP7BY DMINLCJ TN Monoamine oxidase type B (MAO-B) DMINLCJ MA Inhibitor DMINLCJ RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMINLCJ RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMINM2D DI DMINM2D DMINM2D DN carvacrol DMINM2D TI TTFPVZO DMINM2D TN Long transient receptor potential channel 7 (TRPM7) DMINM2D MA Blocker (channel blocker) DMINM2D RN Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channels. Cell Calcium. 2009 Mar;45(3):300-9. DMINM2D RU https://pubmed.ncbi.nlm.nih.gov/19135721 DMINM2D DI DMINM2D DMINM2D DN carvacrol DMINM2D TI TT946IA DMINM2D TN Transient receptor potential cation channel V3 (TRPV3) DMINM2D MA Activator DMINM2D RN Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci. 2006 May;9(5):628-35. DMINM2D RU https://pubmed.ncbi.nlm.nih.gov/16617338 DMINOFE DI DMINOFE DMINOFE DN L-796,778 DMINOFE TI TTJX3UE DMINOFE TN Somatostatin receptor type 3 (SSTR3) DMINOFE MA Agonist DMINOFE RN Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40. DMINOFE RU https://pubmed.ncbi.nlm.nih.gov/9784130 DMINUHD DI DMINUHD DMINUHD DN 4-Amino-2-Deoxy-2,3-Dehydro-N-Neuraminic Acid DMINUHD TI TT50QJ3 DMINUHD TN Influenza Neuraminidase (Influ NA) DMINUHD MA Inhibitor DMINUHD RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMINUHD RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMIO254 DI DMIO254 DMIO254 DN 4,5-Bis(4-chlorophenyl)-1,2-selenazole DMIO254 TI TTVKILB DMIO254 TN Prostaglandin G/H synthase 2 (COX-2) DMIO254 MA Inhibitor DMIO254 RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMIO254 RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMIO254 DI DMIO254 DMIO254 DN 4,5-Bis(4-chlorophenyl)-1,2-selenazole DMIO254 TI TT8NGED DMIO254 TN Prostaglandin G/H synthase 1 (COX-1) DMIO254 MA Inhibitor DMIO254 RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMIO254 RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMIO405 DI DMIO405 DMIO405 DN LVAYPWT DMIO405 TI TT2THBD DMIO405 TN P2X purinoceptor 3 (P2RX3) DMIO405 MA Inhibitor DMIO405 RN Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7. DMIO405 RU https://pubmed.ncbi.nlm.nih.gov/17676725 DMIOA9M DI DMIOA9M DMIOA9M DN Dehydropipernonaline DMIOA9M TI TTA1L39 DMIOA9M TN ICAM1 messenger RNA (ICAM1 mRNA) DMIOA9M MA Inhibitor DMIOA9M RN Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6. DMIOA9M RU https://pubmed.ncbi.nlm.nih.gov/18672369 DMIOFQE DI DMIOFQE DMIOFQE DN SOMATOSTATIN DMIOFQE TI TTKWM86 DMIOFQE TN Opioid receptor mu (MOP) DMIOFQE MA Inhibitor DMIOFQE RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMIOFQE RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMIOFQE DI DMIOFQE DMIOFQE DN SOMATOSTATIN DMIOFQE TI TTZ6T9E DMIOFQE TN Somatostatin receptor type 2 (SSTR2) DMIOFQE MA Inhibitor DMIOFQE RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DMIOFQE RU https://pubmed.ncbi.nlm.nih.gov/16220980 DMIOFQE DI DMIOFQE DMIOFQE DN SOMATOSTATIN DMIOFQE TI TTAE1BR DMIOFQE TN Somatostatin receptor type 4 (SSTR4) DMIOFQE MA Inhibitor DMIOFQE RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DMIOFQE RU https://pubmed.ncbi.nlm.nih.gov/16220980 DMIOFQE DI DMIOFQE DMIOFQE DN SOMATOSTATIN DMIOFQE TI TTIND6G DMIOFQE TN Somatostatin receptor type 1 (SSTR1) DMIOFQE MA Inhibitor DMIOFQE RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DMIOFQE RU https://pubmed.ncbi.nlm.nih.gov/16220980 DMIOFQE DI DMIOFQE DMIOFQE DN SOMATOSTATIN DMIOFQE TI TTJX3UE DMIOFQE TN Somatostatin receptor type 3 (SSTR3) DMIOFQE MA Inhibitor DMIOFQE RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DMIOFQE RU https://pubmed.ncbi.nlm.nih.gov/16220980 DMIOFQE DI DMIOFQE DMIOFQE DN SOMATOSTATIN DMIOFQE TI TT2BC4G DMIOFQE TN Somatostatin receptor type 5 (SSTR5) DMIOFQE MA Inhibitor DMIOFQE RN Discovery of iodinated somatostatin analogues selective for hsst2 and hsst5 with excellent inhibition of growth hormone and prolactin release from ... J Med Chem. 2005 Oct 20;48(21):6643-52. DMIOFQE RU https://pubmed.ncbi.nlm.nih.gov/16220980 DMIOFQE DI DMIOFQE DMIOFQE DN SOMATOSTATIN DMIOFQE TI TT27RFC DMIOFQE TN Opioid receptor delta (OPRD1) DMIOFQE MA Inhibitor DMIOFQE RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMIOFQE RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMIOHMZ DI DMIOHMZ DMIOHMZ DN BNV-222 DMIOHMZ TI TTFBNVI DMIOHMZ TN Aldose reductase (AKR1B1) DMIOHMZ MA Modulator DMIOHMZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768). DMIOHMZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2768 DMIOQFU DI DMIOQFU DMIOQFU DN Nitrilotriacetic Acid DMIOQFU TI TTSZDQU DMIOQFU TN Lactotransferrin (LTF) DMIOQFU MA Inhibitor DMIOQFU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIOQFU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIOQJD DI DMIOQJD DMIOQJD DN 4-(p-Tolyl)spiro[chromene-2,4'-piperidine] DMIOQJD TI TTQW87Y DMIOQJD TN Opioid receptor kappa (OPRK1) DMIOQJD MA Inhibitor DMIOQJD RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DMIOQJD RU https://pubmed.ncbi.nlm.nih.gov/18788723 DMIOQJD DI DMIOQJD DMIOQJD DN 4-(p-Tolyl)spiro[chromene-2,4'-piperidine] DMIOQJD TI TT27RFC DMIOQJD TN Opioid receptor delta (OPRD1) DMIOQJD MA Inhibitor DMIOQJD RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DMIOQJD RU https://pubmed.ncbi.nlm.nih.gov/18788723 DMIOQJD DI DMIOQJD DMIOQJD DN 4-(p-Tolyl)spiro[chromene-2,4'-piperidine] DMIOQJD TI TTQ6VDM DMIOQJD TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMIOQJD MA Inhibitor DMIOQJD RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DMIOQJD RU https://pubmed.ncbi.nlm.nih.gov/18788723 DMIORW9 DI DMIORW9 DMIORW9 DN L902688 DMIORW9 TI TT79WV3 DMIORW9 TN Prostaglandin E2 receptor EP4 (PTGER4) DMIORW9 MA Agonist DMIORW9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). DMIORW9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343 DMIOTHG DI DMIOTHG DMIOTHG DN Thieno analogue of kenpaullone DMIOTHG TI TTL4Q97 DMIOTHG TN Cyclin-dependent kinase 5 (CDK5) DMIOTHG MA Inhibitor DMIOTHG RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DMIOTHG RU https://pubmed.ncbi.nlm.nih.gov/14698171 DMIOTHG DI DMIOTHG DMIOTHG DN Thieno analogue of kenpaullone DMIOTHG TI TT9P6OW DMIOTHG TN G2/mitotic-specific cyclin B1 (CCNB1) DMIOTHG MA Inhibitor DMIOTHG RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DMIOTHG RU https://pubmed.ncbi.nlm.nih.gov/14698171 DMIOTHG DI DMIOTHG DMIOTHG DN Thieno analogue of kenpaullone DMIOTHG TI TTRSMW9 DMIOTHG TN Glycogen synthase kinase-3 beta (GSK-3B) DMIOTHG MA Inhibitor DMIOTHG RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DMIOTHG RU https://pubmed.ncbi.nlm.nih.gov/14698171 DMIOTHG DI DMIOTHG DMIOTHG DN Thieno analogue of kenpaullone DMIOTHG TI TTH6V3D DMIOTHG TN Cyclin-dependent kinase 1 (CDK1) DMIOTHG MA Inhibitor DMIOTHG RN 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6. DMIOTHG RU https://pubmed.ncbi.nlm.nih.gov/14698171 DMIOTQ8 DI DMIOTQ8 DMIOTQ8 DN 1-Hydroxy-1-Thio-Glycerol DMIOTQ8 TI TTNGKET DMIOTQ8 TN Prolyl endopeptidase (PREP) DMIOTQ8 MA Inhibitor DMIOTQ8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIOTQ8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIOW3D DI DMIOW3D DMIOW3D DN 2-(4-tert-butylbenzylideneamino)ethanesulfonamide DMIOW3D TI TTANPDJ DMIOW3D TN Carbonic anhydrase II (CA-II) DMIOW3D MA Inhibitor DMIOW3D RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DMIOW3D RU https://pubmed.ncbi.nlm.nih.gov/19796939 DMIOWBH DI DMIOWBH DMIOWBH DN ISIS 114404 DMIOWBH TI TT8OY02 DMIOWBH TN ARA70 messenger RNA (NCOA4 mRNA) DMIOWBH RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DMIOWBH RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DMIP5K7 DI DMIP5K7 DMIP5K7 DN N,N-Dimethyl-3,3-diphenylpropan-1-amine DMIP5K7 TI TTTIBOJ DMIP5K7 TN Histamine H1 receptor (H1R) DMIP5K7 MA Inhibitor DMIP5K7 RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMIP5K7 RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMIP5K7 DI DMIP5K7 DMIP5K7 DN N,N-Dimethyl-3,3-diphenylpropan-1-amine DMIP5K7 TI TTJQOD7 DMIP5K7 TN 5-HT 2A receptor (HTR2A) DMIP5K7 MA Inhibitor DMIP5K7 RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMIP5K7 RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMIP8AK DI DMIP8AK DMIP8AK DN N-[3,3-Bis-(4-fluorophenyl)-propyl]-nicotinamide DMIP8AK TI TT7WVHI DMIP8AK TN Soluble epoxide hydrolase (EPHX2) DMIP8AK MA Inhibitor DMIP8AK RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DMIP8AK RU https://pubmed.ncbi.nlm.nih.gov/19746975 DMIP9DN DI DMIP9DN DMIP9DN DN Indatraline DMIP9DN TI TTVBI8W DMIP9DN TN Dopamine transporter (DAT) DMIP9DN MA Inhibitor DMIP9DN RN Effects of indatraline and buprenorphine on self-administration of speedball combinations of cocaine and heroin by rhesus monkeys. Neuropsychopharmacology. 2001 Jul;25(1):104-17. DMIP9DN RU https://pubmed.ncbi.nlm.nih.gov/11377924 DMIPAMW DI DMIPAMW DMIPAMW DN 1-(2-mercaptoethyl)-3-(m-tolylsulfonyl)urea DMIPAMW TI TTWHDVK DMIPAMW TN Fructose-1,6-bisphosphatase (FBP) DMIPAMW MA Inhibitor DMIPAMW RN Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12. DMIPAMW RU https://pubmed.ncbi.nlm.nih.gov/18650089 DMIPENJ DI DMIPENJ DMIPENJ DN 4-Iodo-2,6-diisopropyl-phenol DMIPENJ TI TTNJYV2 DMIPENJ TN Gamma-aminobutyric acid receptor (GAR) DMIPENJ MA Inhibitor DMIPENJ RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DMIPENJ RU https://pubmed.ncbi.nlm.nih.gov/9599235 DMIPJUS DI DMIPJUS DMIPJUS DN CACOSPONGIONOLIDE DMIPJUS TI TTO8QRU DMIPJUS TN Group IIA phospholipase A2 (GIIA sPLA2) DMIPJUS MA Inhibitor DMIPJUS RN A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5. DMIPJUS RU https://pubmed.ncbi.nlm.nih.gov/9677277 DMIPJUS DI DMIPJUS DMIPJUS DN CACOSPONGIONOLIDE DMIPJUS TI TT9V5JH DMIPJUS TN Phospholipase A2 (PLA2G1B) DMIPJUS MA Inhibitor DMIPJUS RN A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5. DMIPJUS RU https://pubmed.ncbi.nlm.nih.gov/9677277 DMIPKNQ DI DMIPKNQ DMIPKNQ DN N-(4-(benzyloxy)phenethyl)pyridin-4-amine DMIPKNQ TI TTQ6VDM DMIPKNQ TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMIPKNQ MA Inhibitor DMIPKNQ RN Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetr... J Med Chem. 2007 Feb 22;50(4):807-19. DMIPKNQ RU https://pubmed.ncbi.nlm.nih.gov/17249648 DMIPKNQ DI DMIPKNQ DMIPKNQ DN N-(4-(benzyloxy)phenethyl)pyridin-4-amine DMIPKNQ TI TTN9D8E DMIPKNQ TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMIPKNQ MA Inhibitor DMIPKNQ RN Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetr... J Med Chem. 2007 Feb 22;50(4):807-19. DMIPKNQ RU https://pubmed.ncbi.nlm.nih.gov/17249648 DMIPQTW DI DMIPQTW DMIPQTW DN 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE DMIPQTW TI TTQBR95 DMIPQTW TN Stress-activated protein kinase 2a (p38 alpha) DMIPQTW MA Inhibitor DMIPQTW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIPQTW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMIPXCZ DI DMIPXCZ DMIPXCZ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc DMIPXCZ TI TTCG0AL DMIPXCZ TN Cholecystokinin receptor type A (CCKAR) DMIPXCZ MA Inhibitor DMIPXCZ RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMIPXCZ RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMIPXCZ DI DMIPXCZ DMIPXCZ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc DMIPXCZ TI TT27RFC DMIPXCZ TN Opioid receptor delta (OPRD1) DMIPXCZ MA Inhibitor DMIPXCZ RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMIPXCZ RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMIPXCZ DI DMIPXCZ DMIPXCZ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc DMIPXCZ TI TTVFO0U DMIPXCZ TN Gastrin/cholecystokinin type B receptor (CCKBR) DMIPXCZ MA Inhibitor DMIPXCZ RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMIPXCZ RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMIPXCZ DI DMIPXCZ DMIPXCZ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc DMIPXCZ TI TTKWM86 DMIPXCZ TN Opioid receptor mu (MOP) DMIPXCZ MA Inhibitor DMIPXCZ RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMIPXCZ RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMIPY3W DI DMIPY3W DMIPY3W DN (E)-5-octadecen-7,9-diynoic acid DMIPY3W TI TTPADOQ DMIPY3W TN HMG-CoA reductase (HMGCR) DMIPY3W MA Inhibitor DMIPY3W RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DMIPY3W RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DMIPZTM DI DMIPZTM DMIPZTM DN RN1747 DMIPZTM TI TTKP2SU DMIPZTM TN Transient receptor potential cation channel V4 (TRPV4) DMIPZTM MA Activator DMIPZTM RN Identification and characterization of novel TRPV4 modulators. Biochem Biophys Res Commun. 2009 Nov 20;389(3):490-4. DMIPZTM RU https://pubmed.ncbi.nlm.nih.gov/19737537 DMIQ0DF DI DMIQ0DF DMIQ0DF DN Propan-2-one O-4-(decyloxy)phenylcarbamoyl oxime DMIQ0DF TI TTDP1UC DMIQ0DF TN Fatty acid amide hydrolase (FAAH) DMIQ0DF MA Inhibitor DMIQ0DF RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMIQ0DF RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMIQ0VA DI DMIQ0VA DMIQ0VA DN 1-(4-heptylphenyl)prop-2-en-1-one DMIQ0VA TI TTGER3L DMIQ0VA TN Thyroid hormone receptor beta (THRB) DMIQ0VA MA Inhibitor DMIQ0VA RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMIQ0VA RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMIQ14F DI DMIQ14F DMIQ14F DN (Z)-3-[2-(9H-fluoren-2-yloxy)ethylidene]-quinuclidine hydrochloride 31 DMIQ14F TI TTFQEO5 DMIQ14F TN Squalene synthetase (FDFT1) DMIQ14F MA Inhibitor DMIQ14F RN Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Bioorg Med Chem. 2003 May 29;11(11):2403-14. DMIQ14F RU https://pubmed.ncbi.nlm.nih.gov/12735986 DMIQ18W DI DMIQ18W DMIQ18W DN Phenyl-(9-phenyl-9H-purin-6-yl)-amine DMIQ18W TI TTK25J1 DMIQ18W TN Adenosine A1 receptor (ADORA1) DMIQ18W MA Inhibitor DMIQ18W RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMIQ18W RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMIQ1X3 DI DMIQ1X3 DMIQ1X3 DN 5-methylenearisteromycin DMIQ1X3 TI TTE2KUJ DMIQ1X3 TN Adenosylhomocysteinase (AHCY) DMIQ1X3 MA Inhibitor DMIQ1X3 RN Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. Bioorg Med Chem. 2008 Apr 1;16(7):3809-15. DMIQ1X3 RU https://pubmed.ncbi.nlm.nih.gov/18295495 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TTHQPL7 DMIQ3VR TN Carbonic anhydrase I (CA-I) DMIQ3VR MA Inhibitor DMIQ3VR RN Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/20624682 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TTUNARX DMIQ3VR TN Carbonic anhydrase (CA) DMIQ3VR MA Inhibitor DMIQ3VR RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TTZHA0O DMIQ3VR TN Carbonic anhydrase IV (CA-IV) DMIQ3VR MA Inhibitor DMIQ3VR RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TTSYM0R DMIQ3VR TN Carbonic anhydrase XII (CA-XII) DMIQ3VR MA Inhibitor DMIQ3VR RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TTANPDJ DMIQ3VR TN Carbonic anhydrase II (CA-II) DMIQ3VR MA Inhibitor DMIQ3VR RN Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/20624682 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TTEYTKG DMIQ3VR TN Carbonic anhydrase XIV (CA-XIV) DMIQ3VR MA Inhibitor DMIQ3VR RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TT2LVK8 DMIQ3VR TN Carbonic anhydrase IX (CA-IX) DMIQ3VR MA Inhibitor DMIQ3VR RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIQ3VR DI DMIQ3VR DMIQ3VR DN 4-Amino-3-fluoro-benzenesulfonamide DMIQ3VR TI TTCFSPE DMIQ3VR TN Carbonic anhydrase VI (CA-VI) DMIQ3VR MA Inhibitor DMIQ3VR RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIQ3VR RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIQ801 DI DMIQ801 DMIQ801 DN ER-119884 DMIQ801 TI TTFQEO5 DMIQ801 TN Squalene synthetase (FDFT1) DMIQ801 MA Inhibitor DMIQ801 RN Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother. 2007 Jun;51(6):2123-9. DMIQ801 RU https://pubmed.ncbi.nlm.nih.gov/17371809 DMIQ8GL DI DMIQ8GL DMIQ8GL DN MR-22388 DMIQ8GL TI TTYFKSZ DMIQ8GL TN Tubulin beta (TUBB) DMIQ8GL MA Inhibitor DMIQ8GL RN Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem. 2004 Mar 11;47(6):1448-64. DMIQ8GL RU https://pubmed.ncbi.nlm.nih.gov/14998333 DMIQ8GL DI DMIQ8GL DMIQ8GL DN MR-22388 DMIQ8GL TI TTML2WA DMIQ8GL TN Tubulin (TUB) DMIQ8GL MA Inhibitor DMIQ8GL RN Design, synthesis, and evaluation of novel thienopyrrolizinones as antitubulin agents. J Med Chem. 2004 Mar 11;47(6):1448-64. DMIQ8GL RU https://pubmed.ncbi.nlm.nih.gov/14998333 DMIQAO9 DI DMIQAO9 DMIQAO9 DN 5,6,7,8-tetrahydroanthracene-1,4-dione DMIQAO9 TI TTR0SWN DMIQAO9 TN M-phase inducer phosphatase 2 (MPIP2) DMIQAO9 MA Inhibitor DMIQAO9 RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMIQAO9 RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMIQBXD DI DMIQBXD DMIQBXD DN 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one DMIQBXD TI TTVKILB DMIQBXD TN Prostaglandin G/H synthase 2 (COX-2) DMIQBXD MA Inhibitor DMIQBXD RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMIQBXD RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMIQBXD DI DMIQBXD DMIQBXD DN 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one DMIQBXD TI TT8NGED DMIQBXD TN Prostaglandin G/H synthase 1 (COX-1) DMIQBXD MA Inhibitor DMIQBXD RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMIQBXD RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMIQBXD DI DMIQBXD DMIQBXD DN 2-(3-Phenyl-propyl)-1,2-dihydro-indazol-3-one DMIQBXD TI TT2J34L DMIQBXD TN Arachidonate 5-lipoxygenase (5-LOX) DMIQBXD MA Inhibitor DMIQBXD RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMIQBXD RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMIQFAU DI DMIQFAU DMIQFAU DN Cudraxanthone M DMIQFAU TI TT50QJ3 DMIQFAU TN Influenza Neuraminidase (Influ NA) DMIQFAU MA Inhibitor DMIQFAU RN Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. DMIQFAU RU https://pubmed.ncbi.nlm.nih.gov/19285413 DMIQGWK DI DMIQGWK DMIQGWK DN 2-N-Hydroxyamino-1-(4-ethylthiophenyl)propane DMIQGWK TI TT3ROYC DMIQGWK TN Serotonin transporter (SERT) DMIQGWK MA Inhibitor DMIQGWK RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMIQGWK RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMIQHYZ DI DMIQHYZ DMIQHYZ DN 4-((naphthalen-2-yloxy)methyl)piperidine DMIQHYZ TI TTQ6VDM DMIQHYZ TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMIQHYZ MA Inhibitor DMIQHYZ RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMIQHYZ RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMIQHYZ DI DMIQHYZ DMIQHYZ DN 4-((naphthalen-2-yloxy)methyl)piperidine DMIQHYZ TI TT3ROYC DMIQHYZ TN Serotonin transporter (SERT) DMIQHYZ MA Inhibitor DMIQHYZ RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMIQHYZ RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMIQHYZ DI DMIQHYZ DMIQHYZ DN 4-((naphthalen-2-yloxy)methyl)piperidine DMIQHYZ TI TTPC4TU DMIQHYZ TN 5-HT 3A receptor (HTR3A) DMIQHYZ MA Inhibitor DMIQHYZ RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMIQHYZ RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMIQHYZ DI DMIQHYZ DMIQHYZ DN 4-((naphthalen-2-yloxy)methyl)piperidine DMIQHYZ TI TTAWNKZ DMIQHYZ TN Norepinephrine transporter (NET) DMIQHYZ MA Inhibitor DMIQHYZ RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMIQHYZ RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMIQJM4 DI DMIQJM4 DMIQJM4 DN 5-(2-Methylquinolin-7-yl)-2-phenylbenzonitrile DMIQJM4 TI TTHS256 DMIQJM4 TN Metabotropic glutamate receptor 5 (mGluR5) DMIQJM4 MA Inhibitor DMIQJM4 RN Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35. DMIQJM4 RU https://pubmed.ncbi.nlm.nih.gov/20382541 DMIQM4O DI DMIQM4O DMIQM4O DN 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid DMIQM4O TI TTUNARX DMIQM4O TN Carbonic anhydrase (CA) DMIQM4O MA Inhibitor DMIQM4O RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMIQM4O RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMIQM4O DI DMIQM4O DMIQM4O DN 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid DMIQM4O TI TTEYTKG DMIQM4O TN Carbonic anhydrase XIV (CA-XIV) DMIQM4O MA Inhibitor DMIQM4O RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMIQM4O RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMIQM4O DI DMIQM4O DMIQM4O DN 2-acetamido-2,3-dihydro-1H-indene-5-sulfonic acid DMIQM4O TI TTSYM0R DMIQM4O TN Carbonic anhydrase XII (CA-XII) DMIQM4O MA Inhibitor DMIQM4O RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMIQM4O RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMIQNX9 DI DMIQNX9 DMIQNX9 DN (2R,3S,4S,5R)-2-nonylpiperidine-3,4,5-triol DMIQNX9 TI TT1B5PU DMIQNX9 TN Glucosylceramidase (GBA) DMIQNX9 MA Inhibitor DMIQNX9 RN Synthesis of new beta-1-C-alkylated imino-L-iditols: A comparative study of their activity as beta-glucocerebrosidase inhibitors. Bioorg Med Chem. 2010 Apr 1;18(7):2645-50. DMIQNX9 RU https://pubmed.ncbi.nlm.nih.gov/20231099 DMIQOXH DI DMIQOXH DMIQOXH DN Apigenin-7-O-beta-D-glucuronide DMIQOXH TI TTFBNVI DMIQOXH TN Aldose reductase (AKR1B1) DMIQOXH MA Inhibitor DMIQOXH RN Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5. DMIQOXH RU https://pubmed.ncbi.nlm.nih.gov/18298080 DMIQP69 DI DMIQP69 DMIQP69 DN XR-9504 DMIQP69 TI TTOI92F DMIQP69 TN Multidrug resistance-associated protein 1 (ABCC1) DMIQP69 MA Inhibitor DMIQP69 RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DMIQP69 RU https://pubmed.ncbi.nlm.nih.gov/18083034 DMIQP69 DI DMIQP69 DMIQP69 DN XR-9504 DMIQP69 TI TT3OT40 DMIQP69 TN Multidrug resistance protein 1 (ABCB1) DMIQP69 MA Inhibitor DMIQP69 RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DMIQP69 RU https://pubmed.ncbi.nlm.nih.gov/18083034 DMIQU8D DI DMIQU8D DMIQU8D DN S-Benzyl-Glutathione DMIQU8D TI TTV9A7R DMIQU8D TN Lactoylglutathione lyase (GLO1) DMIQU8D MA Inhibitor DMIQU8D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIQU8D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIQWAH DI DMIQWAH DMIQWAH DN Sulfamic acid 3-(3-methoxy-benzoyl)-phenyl ester DMIQWAH TI TTHM0R1 DMIQWAH TN Steryl-sulfatase (STS) DMIQWAH MA Inhibitor DMIQWAH RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMIQWAH RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMIQYWM DI DMIQYWM DMIQYWM DN 2-morpholino-N-phenethylpyrimidin-4-amine DMIQYWM TI TT1RS9F DMIQYWM TN Acetylcholinesterase (AChE) DMIQYWM MA Inhibitor DMIQYWM RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMIQYWM RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TTGJVQM DMIR3X2 TN Fibroblast growth factor receptor 2 (FGFR2) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TTI4ZX2 DMIR3X2 TN Ephrin type-B receptor 4 (EPHB4) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TTUTJGQ DMIR3X2 TN Vascular endothelial growth factor receptor 2 (KDR) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TT860QF DMIR3X2 TN LCK tyrosine protein kinase (LCK) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TT3PJMV DMIR3X2 TN Tyrosine-protein kinase ABL1 (ABL) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TT4DXQT DMIR3X2 TN Proto-oncogene c-Ret (RET) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TT6PKBN DMIR3X2 TN Proto-oncogene c-Src (SRC) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TT0SQ8J DMIR3X2 TN Yes tyrosine kinase (YES) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIR3X2 DI DMIR3X2 DMIR3X2 DN TG-100435 DMIR3X2 TI TTI7421 DMIR3X2 TN Platelet-derived growth factor receptor beta (PDGFRB) DMIR3X2 MA Inhibitor DMIR3X2 RN Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinas... Bioorg Med Chem Lett. 2007 Feb 1;17(3):602-8. DMIR3X2 RU https://pubmed.ncbi.nlm.nih.gov/17113292 DMIRBYE DI DMIRBYE DMIRBYE DN Fluoro-Phosphite Ion DMIRBYE TI TTZHY6R DMIRBYE TN Glycogen phosphorylase muscle form (GP) DMIRBYE MA Inhibitor DMIRBYE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIRBYE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIRD8S DI DMIRD8S DMIRD8S DN BENZOYL-TYROSINE-ALANINE-METHYL KETONE DMIRD8S TI TTJOKD1 DMIRD8S TN Cathepsin F (CTSF) DMIRD8S MA Inhibitor DMIRD8S RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMIRD8S RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMIRK41 DI DMIRK41 DMIRK41 DN NSC-57893 DMIRK41 TI TT6VZ78 DMIRK41 TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMIRK41 MA Inhibitor DMIRK41 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMIRK41 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMIRK41 DI DMIRK41 DMIRK41 DN NSC-57893 DMIRK41 TI TTHVCUP DMIRK41 TN DNA [cytosine-5]-methyltransferase (DNMT) DMIRK41 MA Inhibitor DMIRK41 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMIRK41 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMIRQ65 DI DMIRQ65 DMIRQ65 DN Tumor vascular thrombogen DMIRQ65 TI TT6L509 DMIRQ65 TN Coagulation factor IIa (F2) DMIRQ65 MA Modulator DMIRQ65 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMIRQ65 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMIRSA5 DI DMIRSA5 DMIRSA5 DN 10Z-Hymenialdisine DMIRSA5 TI TTH6V3D DMIRSA5 TN Cyclin-dependent kinase 1 (CDK1) DMIRSA5 MA Binder DMIRSA5 RN DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. DMIRSA5 RU https://pubmed.ncbi.nlm.nih.gov/18048412 DMIRSA5 DI DMIRSA5 DMIRSA5 DN 10Z-Hymenialdisine DMIRSA5 TI TT7HF4W DMIRSA5 TN Cyclin-dependent kinase 2 (CDK2) DMIRSA5 MA Inhibitor DMIRSA5 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMIRSA5 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMIRSA5 DI DMIRSA5 DMIRSA5 DN 10Z-Hymenialdisine DMIRSA5 TI TTL4Q97 DMIRSA5 TN Cyclin-dependent kinase 5 (CDK5) DMIRSA5 MA Inhibitor DMIRSA5 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMIRSA5 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMIRSNA DI DMIRSNA DMIRSNA DN DPDPE DMIRSNA TI TTKWM86 DMIRSNA TN Opioid receptor mu (MOP) DMIRSNA MA Inhibitor DMIRSNA RN Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. DMIRSNA RU https://pubmed.ncbi.nlm.nih.gov/20599386 DMIRSNA DI DMIRSNA DMIRSNA DN DPDPE DMIRSNA TI TT27RFC DMIRSNA TN Opioid receptor delta (OPRD1) DMIRSNA MA Inhibitor DMIRSNA RN Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. DMIRSNA RU https://pubmed.ncbi.nlm.nih.gov/20599386 DMIRSNA DI DMIRSNA DMIRSNA DN DPDPE DMIRSNA TI TTQW87Y DMIRSNA TN Opioid receptor kappa (OPRK1) DMIRSNA MA Inhibitor DMIRSNA RN Opioid agonist and antagonist activities of morphindoles related to naltrindole. J Med Chem. 1992 Nov 13;35(23):4325-9. DMIRSNA RU https://pubmed.ncbi.nlm.nih.gov/1333013 DMIRSQO DI DMIRSQO DMIRSQO DN 2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine DMIRSQO TI TTK25J1 DMIRSQO TN Adenosine A1 receptor (ADORA1) DMIRSQO MA Inhibitor DMIRSQO RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMIRSQO RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMIRSQO DI DMIRSQO DMIRSQO DN 2-ethyl-4-(thiophen-2-yl)thieno[3,2-d]pyrimidine DMIRSQO TI TTM2AOE DMIRSQO TN Adenosine A2a receptor (ADORA2A) DMIRSQO MA Inhibitor DMIRSQO RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMIRSQO RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMIRSWL DI DMIRSWL DMIRSWL DN PMID16099654C3a DMIRSWL TI TTVBPDM DMIRSWL TN Metabotropic glutamate receptor 1 (mGluR1) DMIRSWL MA Modulator (allosteric modulator) DMIRSWL RN 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4628-31. DMIRSWL RU https://pubmed.ncbi.nlm.nih.gov/16099654 DMIRTF5 DI DMIRTF5 DMIRTF5 DN ARRY-575 DMIRTF5 TI TTTU902 DMIRTF5 TN Checkpoint kinase-1 (CHK1) DMIRTF5 MA Inhibitor DMIRTF5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987). DMIRTF5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987 DMIS39C DI DMIS39C DMIS39C DN (2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine DMIS39C TI TTJQOD7 DMIS39C TN 5-HT 2A receptor (HTR2A) DMIS39C MA Inhibitor DMIS39C RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DMIS39C RU https://pubmed.ncbi.nlm.nih.gov/18035544 DMIS39C DI DMIS39C DMIS39C DN (2S)-1-(1H-furo[2,3-g]indazol-1-yl)propan-2-amine DMIS39C TI TTWJBZ5 DMIS39C TN 5-HT 2C receptor (HTR2C) DMIS39C MA Inhibitor DMIS39C RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DMIS39C RU https://pubmed.ncbi.nlm.nih.gov/18035544 DMIS3LN DI DMIS3LN DMIS3LN DN 3-Amino-4'-amino-trans-stilbene DMIS3LN TI TTSZLWK DMIS3LN TN Aromatase (CYP19A1) DMIS3LN MA Inhibitor DMIS3LN RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMIS3LN RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMIS715 DI DMIS715 DMIS715 DN ISIS 119262 DMIS715 TI TTKS60G DMIS715 TN STXBP4 messenger RNA (STXBP4 mRNA) DMIS715 RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DMIS715 RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DMIS7NT DI DMIS7NT DMIS7NT DN PMID16242323C18b DMIS7NT TI TTK3C21 DMIS7NT TN Acetoacetyl-CoA thiolase (ACAT1) DMIS7NT MA Inhibitor DMIS7NT RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMIS7NT RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMIS82X DI DMIS82X DMIS82X DN LY2087101 DMIS82X TI TT5KPZR DMIS82X TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMIS82X MA Modulator (allosteric modulator) DMIS82X RN Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17. DMIS82X RU https://pubmed.ncbi.nlm.nih.gov/16738207 DMIS82X DI DMIS82X DMIS82X DN LY2087101 DMIS82X TI TTF4E0J DMIS82X TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMIS82X MA Modulator (allosteric modulator) DMIS82X RN Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17. DMIS82X RU https://pubmed.ncbi.nlm.nih.gov/16738207 DMIS82X DI DMIS82X DMIS82X DN LY2087101 DMIS82X TI TTLA931 DMIS82X TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMIS82X MA Modulator (allosteric modulator) DMIS82X RN Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17. DMIS82X RU https://pubmed.ncbi.nlm.nih.gov/16738207 DMIS8JQ DI DMIS8JQ DMIS8JQ DN SB 224289 DMIS8JQ TI TTK8CXU DMIS8JQ TN 5-HT 1B receptor (HTR1B) DMIS8JQ MA Antagonist DMIS8JQ RN 5-hydroxytryptamine receptors mediating contraction in human small muscular pulmonary arteries: importance of the 5-HT1B receptor. Br J Pharmacol. 1999 Oct;128(3):730-4. DMIS8JQ RU https://pubmed.ncbi.nlm.nih.gov/10516655 DMISB5V DI DMISB5V DMISB5V DN ISIS 32021 DMISB5V TI TT9H4P3 DMISB5V TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMISB5V RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMISB5V RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMISBDC DI DMISBDC DMISBDC DN SB 242084 DMISBDC TI TTWJBZ5 DMISBDC TN 5-HT 2C receptor (HTR2C) DMISBDC MA Antagonist DMISBDC RN SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20. DMISBDC RU https://pubmed.ncbi.nlm.nih.gov/9225286 DMISBDC DI DMISBDC DMISBDC DN SB 242084 DMISBDC TI TTJQOD7 DMISBDC TN 5-HT 2A receptor (HTR2A) DMISBDC MA Antagonist DMISBDC RN SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20. DMISBDC RU https://pubmed.ncbi.nlm.nih.gov/9225286 DMISBDC DI DMISBDC DMISBDC DN SB 242084 DMISBDC TI TT0K1SC DMISBDC TN 5-HT 2B receptor (HTR2B) DMISBDC MA Antagonist DMISBDC RN SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):609-20. DMISBDC RU https://pubmed.ncbi.nlm.nih.gov/9225286 DMISHCW DI DMISHCW DMISHCW DN MCL-431 DMISHCW TI TTQW87Y DMISHCW TN Opioid receptor kappa (OPRK1) DMISHCW MA Inhibitor DMISHCW RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMISHCW RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMISHCW DI DMISHCW DMISHCW DN MCL-431 DMISHCW TI TT27RFC DMISHCW TN Opioid receptor delta (OPRD1) DMISHCW MA Inhibitor DMISHCW RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMISHCW RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMISHCW DI DMISHCW DMISHCW DN MCL-431 DMISHCW TI TTKWM86 DMISHCW TN Opioid receptor mu (MOP) DMISHCW MA Inhibitor DMISHCW RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMISHCW RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMISHTB DI DMISHTB DMISHTB DN Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine DMISHTB TI TTGKNB4 DMISHTB TN Epidermal growth factor receptor (EGFR) DMISHTB MA Inhibitor DMISHTB RN Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28. DMISHTB RU https://pubmed.ncbi.nlm.nih.gov/8632415 DMISJXB DI DMISJXB DMISJXB DN AGN192093 DMISJXB TI TT2O84V DMISJXB TN Thromboxane A2 receptor (TBXA2R) DMISJXB MA Agonist DMISJXB RN Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br J Pharmacol. 1996 Mar;117(6):1171-80. DMISJXB RU https://pubmed.ncbi.nlm.nih.gov/8882612 DMISL9R DI DMISL9R DMISL9R DN 3-(6-Amino-purin-9-yl)-4-butoxy-butan-2-ol DMISL9R TI TTLP57V DMISL9R TN Adenosine deaminase (ADA) DMISL9R MA Inhibitor DMISL9R RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMISL9R RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMISLV4 DI DMISLV4 DMISLV4 DN 3-(6-Methoxy-3-methylnaphthalen-2-yl)pyridine DMISLV4 TI TTIQUX7 DMISLV4 TN Steroid 11-beta-hydroxylase (CYP11B1) DMISLV4 MA Inhibitor DMISLV4 RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMISLV4 RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMISNWV DI DMISNWV DMISNWV DN ISIS 109491 DMISNWV TI TT3K9S2 DMISNWV TN RANK messenger RNA (RANK mRNA) DMISNWV RN US patent application no. 6,171,860, Antisense inhibition of rank expression. DMISNWV RU http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true DMISOLU DI DMISOLU DMISOLU DN 5-(4-hydroxy-2,6-dimethylstyryl)nicotinic acid DMISOLU TI TTAN5W2 DMISOLU TN Raf messenger RNA (Raf mRNA) DMISOLU MA Inhibitor DMISOLU RN Aza-stilbenes as potent and selective c-RAF inhibitors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5378-83. DMISOLU RU https://pubmed.ncbi.nlm.nih.gov/16890436 DMISP20 DI DMISP20 DMISP20 DN C[Asp22-Lys26][Gly8]GLP-1(7-37)-NH2 DMISP20 TI TTVIMDE DMISP20 TN Glucagon-like peptide 1 receptor (GLP1R) DMISP20 MA Inhibitor DMISP20 RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMISP20 RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMISP7G DI DMISP7G DMISP7G DN FR194921 DMISP7G TI TTK25J1 DMISP7G TN Adenosine A1 receptor (ADORA1) DMISP7G MA Antagonist DMISP7G RN Pharmacological characterization of FR194921, a new potent, selective, and orally active antagonist for central adenosine A1 receptors. J Pharmacol Sci. 2004 Sep;96(1):42-52. DMISP7G RU https://pubmed.ncbi.nlm.nih.gov/15351792 DMISRMT DI DMISRMT DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide DMISRMT TI TTSHTOI DMISRMT TN Histone deacetylase 2 (HDAC2) DMISRMT MA Inhibitor DMISRMT RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMISRMT RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMISRMT DI DMISRMT DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide DMISRMT TI TTYHPU6 DMISRMT TN Histone deacetylase 10 (HDAC10) DMISRMT MA Inhibitor DMISRMT RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMISRMT RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMISRMT DI DMISRMT DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide DMISRMT TI TT6R7JZ DMISRMT TN Histone deacetylase 1 (HDAC1) DMISRMT MA Inhibitor DMISRMT RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMISRMT RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMISRMT DI DMISRMT DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide DMISRMT TI TT5ZKDI DMISRMT TN Histone deacetylase 6 (HDAC6) DMISRMT MA Inhibitor DMISRMT RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMISRMT RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMISRMT DI DMISRMT DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide DMISRMT TI TTTQGH8 DMISRMT TN Histone deacetylase 4 (HDAC4) DMISRMT MA Inhibitor DMISRMT RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMISRMT RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMISRMT DI DMISRMT DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide DMISRMT TI TTBH0VX DMISRMT TN Histone deacetylase (HDAC) DMISRMT MA Inhibitor DMISRMT RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMISRMT RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMISRMT DI DMISRMT DMISRMT DN N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide DMISRMT TI TTT6LFV DMISRMT TN Histone deacetylase 8 (HDAC8) DMISRMT MA Inhibitor DMISRMT RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMISRMT RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMISTXQ DI DMISTXQ DMISTXQ DN 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol DMISTXQ TI TTKWM86 DMISTXQ TN Opioid receptor mu (MOP) DMISTXQ MA Inhibitor DMISTXQ RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMISTXQ RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMISTXQ DI DMISTXQ DMISTXQ DN 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol DMISTXQ TI TTNT7K8 DMISTXQ TN Nociceptin receptor (OPRL1) DMISTXQ MA Inhibitor DMISTXQ RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMISTXQ RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMISTXQ DI DMISTXQ DMISTXQ DN 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol DMISTXQ TI TTQW87Y DMISTXQ TN Opioid receptor kappa (OPRK1) DMISTXQ MA Inhibitor DMISTXQ RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMISTXQ RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMISTXQ DI DMISTXQ DMISTXQ DN 4-phenyl-1-(1-phenylheptyl)piperidin-4-ol DMISTXQ TI TT27RFC DMISTXQ TN Opioid receptor delta (OPRD1) DMISTXQ MA Inhibitor DMISTXQ RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMISTXQ RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMISV5A DI DMISV5A DMISV5A DN 6-(3-Iodo-phenylamino)-1H-pyrimidine-2,4-dione DMISV5A TI TT2GPK3 DMISV5A TN DNA topoisomerase (TOP) DMISV5A MA Inhibitor DMISV5A RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMISV5A RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMISXUM DI DMISXUM DMISXUM DN N-Hydroxy-2-(naphthalen-2-ylsulfanyl)-acetamide DMISXUM TI TTPHMWB DMISXUM TN Aminopeptidase N (ANPEP) DMISXUM MA Inhibitor DMISXUM RN N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity. Bioorg Med Chem Lett. 2005 Jan 3;15(1):181-3. DMISXUM RU https://pubmed.ncbi.nlm.nih.gov/15582436 DMIT4UN DI DMIT4UN DMIT4UN DN PMID16250654C37 DMIT4UN TI TTSCIUP DMIT4UN TN Oxytocin receptor (OTR) DMIT4UN MA Antagonist DMIT4UN RN 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics. J Med Chem. 2005 Nov 3;48(22):6956-69. DMIT4UN RU https://pubmed.ncbi.nlm.nih.gov/16250654 DMIT7SH DI DMIT7SH DMIT7SH DN 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol DMIT7SH TI TTQW87Y DMIT7SH TN Opioid receptor kappa (OPRK1) DMIT7SH MA Inhibitor DMIT7SH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMIT7SH RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMIT7SH DI DMIT7SH DMIT7SH DN 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol DMIT7SH TI TT27RFC DMIT7SH TN Opioid receptor delta (OPRD1) DMIT7SH MA Inhibitor DMIT7SH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMIT7SH RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMIT7SH DI DMIT7SH DMIT7SH DN 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol DMIT7SH TI TTKWM86 DMIT7SH TN Opioid receptor mu (MOP) DMIT7SH MA Inhibitor DMIT7SH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMIT7SH RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMIT7SH DI DMIT7SH DMIT7SH DN 1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol DMIT7SH TI TTNT7K8 DMIT7SH TN Nociceptin receptor (OPRL1) DMIT7SH MA Inhibitor DMIT7SH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMIT7SH RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMITDEB DI DMITDEB DMITDEB DN PMID17064898C29 DMITDEB TI TTVBPDM DMITDEB TN Metabotropic glutamate receptor 1 (mGluR1) DMITDEB MA Modulator (allosteric modulator) DMITDEB RN Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90. DMITDEB RU https://pubmed.ncbi.nlm.nih.gov/17064898 DMITE1A DI DMITE1A DMITE1A DN NSC-339583 DMITE1A TI TT8XK6L DMITE1A TN Quinone reductase 1 (NQO1) DMITE1A MA Inhibitor DMITE1A RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMITE1A RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMITEND DI DMITEND DMITEND DN 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine DMITEND TI TTM2AOE DMITEND TN Adenosine A2a receptor (ADORA2A) DMITEND MA Inhibitor DMITEND RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMITEND RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMITEND DI DMITEND DMITEND DN 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine DMITEND TI TTK25J1 DMITEND TN Adenosine A1 receptor (ADORA1) DMITEND MA Inhibitor DMITEND RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMITEND RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMITEND DI DMITEND DMITEND DN 2-(3''(7''-bromo-indolyl)ethyloxy)adenosine DMITEND TI TTJFY5U DMITEND TN Adenosine A3 receptor (ADORA3) DMITEND MA Inhibitor DMITEND RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMITEND RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMITF0P DI DMITF0P DMITF0P DN 2,7-Bis[2-(piperidino)acetamido]anthraquinone DMITF0P TI TTQY2EJ DMITF0P TN TERT messenger RNA (TERT mRNA) DMITF0P MA Inhibitor DMITF0P RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMITF0P RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMITHX5 DI DMITHX5 DMITHX5 DN 3-(4-Amino-phenyl)-3-methyl-pyrrolidine-2,5-dione DMITHX5 TI TTSZLWK DMITHX5 TN Aromatase (CYP19A1) DMITHX5 MA Inhibitor DMITHX5 RN Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3. DMITHX5 RU https://pubmed.ncbi.nlm.nih.gov/3754286 DMITKX8 DI DMITKX8 DMITKX8 DN GW853606 DMITKX8 TI TTIYVQP DMITKX8 TN Polo-like kinase 1 (PLK1) DMITKX8 MA Inhibitor DMITKX8 RN Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009 Feb 1;19(3):1018-21. DMITKX8 RU https://pubmed.ncbi.nlm.nih.gov/19097784 DMITKZY DI DMITKZY DMITKZY DN 2-(2-acetyl-4-bromophenoxy)acetic acid DMITKZY TI TTQDMX5 DMITKZY TN Prostaglandin D2 receptor 2 (PTGDR2) DMITKZY MA Inhibitor DMITKZY RN Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41. DMITKZY RU https://pubmed.ncbi.nlm.nih.gov/17154491 DMITMN9 DI DMITMN9 DMITMN9 DN Meta-Nitro-Tyrosine DMITMN9 TI TTEP6RV DMITMN9 TN Glutathione reductase (GR) DMITMN9 MA Inhibitor DMITMN9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMITMN9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMITN82 DI DMITN82 DMITN82 DN N-[4-(1,3-benzodioxol-5-yl)phenyl]sulfamide DMITN82 TI TTBGTCW DMITN82 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMITN82 MA Inhibitor DMITN82 RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMITN82 RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMITR7A DI DMITR7A DMITR7A DN [3H]CGP39653 DMITR7A TI TT1M8OW DMITR7A TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMITR7A MA Antagonist DMITR7A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMITR7A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMITR7A DI DMITR7A DMITR7A DN [3H]CGP39653 DMITR7A TI TTN9D8E DMITR7A TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMITR7A MA Antagonist DMITR7A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMITR7A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMITR7A DI DMITR7A DMITR7A DN [3H]CGP39653 DMITR7A TI TTKJEMQ DMITR7A TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMITR7A MA Antagonist DMITR7A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMITR7A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMITR7A DI DMITR7A DMITR7A DN [3H]CGP39653 DMITR7A TI TT5POTG DMITR7A TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMITR7A MA Antagonist DMITR7A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMITR7A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMITR7A DI DMITR7A DMITR7A DN [3H]CGP39653 DMITR7A TI TTLD29N DMITR7A TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMITR7A MA Antagonist DMITR7A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMITR7A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMITW5P DI DMITW5P DMITW5P DN (1R,2S)-N-Oleoylcyclopropanolamide DMITW5P TI TT6OEDT DMITW5P TN Cannabinoid receptor 1 (CB1) DMITW5P MA Inhibitor DMITW5P RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMITW5P RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMITW5P DI DMITW5P DMITW5P DN (1R,2S)-N-Oleoylcyclopropanolamide DMITW5P TI TTMSFAW DMITW5P TN Cannabinoid receptor 2 (CB2) DMITW5P MA Inhibitor DMITW5P RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMITW5P RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMITWZ7 DI DMITWZ7 DMITWZ7 DN (-)-trans-H2-PAT DMITWZ7 TI TTTIBOJ DMITWZ7 TN Histamine H1 receptor (H1R) DMITWZ7 MA Antagonist DMITWZ7 RN A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther. 2002 Jul;302(1):328-36. DMITWZ7 RU https://pubmed.ncbi.nlm.nih.gov/12065734 DMITXKJ DI DMITXKJ DMITXKJ DN (E)-3-[2-(2-methyl-4-thiazolyl)vinyl]pyridine DMITXKJ TI TTHS256 DMITXKJ TN Metabotropic glutamate receptor 5 (mGluR5) DMITXKJ MA Inhibitor DMITXKJ RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMITXKJ RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMITY0H DI DMITY0H DMITY0H DN CBOBNEA DMITY0H TI TT0WAIE DMITY0H TN Melatonin receptor type 1A (MTNR1A) DMITY0H MA Agonist DMITY0H RN Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT(1) melatoninergic ligands. Bioorg Med Chem. 2010 May 15;18(10):3426-36. DMITY0H RU https://pubmed.ncbi.nlm.nih.gov/20444610 DMIU0QJ DI DMIU0QJ DMIU0QJ DN ISIS 173840 DMIU0QJ TI TT9RTBL DMIU0QJ TN Aurora B messenger RNA (AURKB mRNA) DMIU0QJ RN US patent application no. 7,375,212, Modulation of Aurora B expression. DMIU0QJ RU http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true DMIU3C8 DI DMIU3C8 DMIU3C8 DN 1-(4-cyano-2-hydroxyphenyl)-3-phenylurea DMIU3C8 TI TT30C9G DMIU3C8 TN C-X-C chemokine receptor type 2 (CXCR2) DMIU3C8 MA Inhibitor DMIU3C8 RN Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. DMIU3C8 RU https://pubmed.ncbi.nlm.nih.gov/17236763 DMIU52O DI DMIU52O DMIU52O DN H-Tyr-Tic-OH DMIU52O TI TT27RFC DMIU52O TN Opioid receptor delta (OPRD1) DMIU52O MA Inhibitor DMIU52O RN Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5. DMIU52O RU https://pubmed.ncbi.nlm.nih.gov/19827750 DMIUABO DI DMIUABO DMIUABO DN helodermin DMIUABO TI TT4O5P0 DMIUABO TN Helodermin-preferring VIP receptor (VIPR2) DMIUABO MA Agonist DMIUABO RN Analogues of VIP, helodermin, and PACAP discriminate between rat and human VIP1 and VIP2 receptors. Ann N Y Acad Sci. 1998 Dec 11;865:247-52. DMIUABO RU https://pubmed.ncbi.nlm.nih.gov/9928018 DMIUABO DI DMIUABO DMIUABO DN helodermin DMIUABO TI TTCL30I DMIUABO TN Vasoactive intestinal polypeptide receptor 1 (VIPR1) DMIUABO MA Agonist DMIUABO RN Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. Eur J Pharmacol. 1996 Apr 29;302(1-3):207-14. DMIUABO RU https://pubmed.ncbi.nlm.nih.gov/8791009 DMIUCSW DI DMIUCSW DMIUCSW DN Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine DMIUCSW TI TTK25J1 DMIUCSW TN Adenosine A1 receptor (ADORA1) DMIUCSW MA Inhibitor DMIUCSW RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMIUCSW RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMIUD0L DI DMIUD0L DMIUD0L DN B-623 DMIUD0L TI TTGY7WI DMIUD0L TN Urokinase-type plasminogen activator (PLAU) DMIUD0L MA Modulator DMIUD0L RN Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncol Rep. 1999 May-Jun;6(3):523-6. DMIUD0L RU https://www.ncbi.nlm.nih.gov/pubmed/10203585 DMIUV25 DI DMIUV25 DMIUV25 DN PRONTOCIL DMIUV25 TI TTUNARX DMIUV25 TN Carbonic anhydrase (CA) DMIUV25 MA Inhibitor DMIUV25 RN Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. DMIUV25 RU https://pubmed.ncbi.nlm.nih.gov/17826101 DMIUV25 DI DMIUV25 DMIUV25 DN PRONTOCIL DMIUV25 TI TTANPDJ DMIUV25 TN Carbonic anhydrase II (CA-II) DMIUV25 MA Inhibitor DMIUV25 RN Carbonic anhydrase inhibitors. Inhibition of the Rv1284 and Rv3273 beta-carbonic anhydrases from Mycobacterium tuberculosis with diazenylbenzenesul... Bioorg Med Chem Lett. 2009 Sep 1;19(17):4929-32. DMIUV25 RU https://pubmed.ncbi.nlm.nih.gov/19651511 DMIUVQ6 DI DMIUVQ6 DMIUVQ6 DN Cyclo(-D-Tyr-L-MeArg-L-Arg-L-Nal-Gly-) DMIUVQ6 TI TTBID49 DMIUVQ6 TN C-X-C chemokine receptor type 4 (CXCR4) DMIUVQ6 MA Inhibitor DMIUVQ6 RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMIUVQ6 RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMIUZGY DI DMIUZGY DMIUZGY DN PK68 DMIUZGY TI TTAIQSN DMIUZGY TN Receptor-interacting protein 1 (RIPK1) DMIUZGY MA Inhibitor DMIUZGY RN Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis. Cell Death Dis. 2019 Jun 24;10(7):493. DMIUZGY RU https://pubmed.ncbi.nlm.nih.gov/31235688 DMIUZSR DI DMIUZSR DMIUZSR DN PF-956980 DMIUZSR TI TTT7PJU DMIUZSR TN Janus kinase 3 (JAK-3) DMIUZSR MA Inhibitor DMIUZSR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). DMIUZSR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049 DMIUZX3 DI DMIUZX3 DMIUZX3 DN LTD4 DMIUZX3 TI TTGKOY9 DMIUZX3 TN Leukotriene CysLT1 receptor (CYSLTR1) DMIUZX3 MA Agonist DMIUZX3 RN Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999 Sep;56(3):657-63. DMIUZX3 RU https://pubmed.ncbi.nlm.nih.gov/10462554 DMIUZX3 DI DMIUZX3 DMIUZX3 DN LTD4 DMIUZX3 TI TTMPART DMIUZX3 TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMIUZX3 MA Agonist DMIUZX3 RN The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27. DMIUZX3 RU https://pubmed.ncbi.nlm.nih.gov/16990797 DMIUZX3 DI DMIUZX3 DMIUZX3 DN LTD4 DMIUZX3 TI TT0PZR5 DMIUZX3 TN Leukotriene CysLT2 receptor (CYSLTR2) DMIUZX3 MA Agonist DMIUZX3 RN Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8. DMIUZX3 RU https://pubmed.ncbi.nlm.nih.gov/11093801 DMIV0MT DI DMIV0MT DMIV0MT DN (S,R)-antioquine hydrochloride DMIV0MT TI TTEX248 DMIV0MT TN Dopamine D2 receptor (D2R) DMIV0MT MA Inhibitor DMIV0MT RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMIV0MT RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMIV2OY DI DMIV2OY DMIV2OY DN (1S,2S)-N-Oleoylcyclopropanolamide DMIV2OY TI TT6OEDT DMIV2OY TN Cannabinoid receptor 1 (CB1) DMIV2OY MA Inhibitor DMIV2OY RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMIV2OY RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMIV2OY DI DMIV2OY DMIV2OY DN (1S,2S)-N-Oleoylcyclopropanolamide DMIV2OY TI TTMSFAW DMIV2OY TN Cannabinoid receptor 2 (CB2) DMIV2OY MA Inhibitor DMIV2OY RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMIV2OY RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMIV3S8 DI DMIV3S8 DMIV3S8 DN Benzaldehyde O-4-(nonyloxy)phenylcarbamoyl oxime DMIV3S8 TI TTDP1UC DMIV3S8 TN Fatty acid amide hydrolase (FAAH) DMIV3S8 MA Inhibitor DMIV3S8 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMIV3S8 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMIV4BU DI DMIV4BU DMIV4BU DN (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone DMIV4BU TI TTGJCWZ DMIV4BU TN Fms-like tyrosine kinase 3 (FLT-3) DMIV4BU MA Inhibitor DMIV4BU RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMIV4BU RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMIV4BU DI DMIV4BU DMIV4BU DN (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone DMIV4BU TI TTI7421 DMIV4BU TN Platelet-derived growth factor receptor beta (PDGFRB) DMIV4BU MA Inhibitor DMIV4BU RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMIV4BU RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMIV4BU DI DMIV4BU DMIV4BU DN (5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone DMIV4BU TI TT8FYO9 DMIV4BU TN Platelet-derived growth factor receptor alpha (PDGFRA) DMIV4BU MA Inhibitor DMIV4BU RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMIV4BU RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMIV75Q DI DMIV75Q DMIV75Q DN TS antisense + raltitrexed DMIV75Q TI TTP1UKZ DMIV75Q TN Thymidylate synthase messenger RNA (TYMS mRNA) DMIV75Q RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMIV75Q RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMIV82T DI DMIV82T DMIV82T DN CD4 red blood cell electroinsertion DMIV82T TI TTBYP1X DMIV82T TN Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120) DMIV82T MA Modulator DMIV82T RN Red blood cells bearing CD4 bind to gp120 covered plates and aggregate with cells expressing gp120. J Acquir Immune Defic Syndr. 1990;3(11):1041-5. DMIV82T RU https://www.ncbi.nlm.nih.gov/pubmed/1698964 DMIVDFW DI DMIVDFW DMIVDFW DN 3-hydroxy-2-phenylquinoline-4-carboxylic acid DMIVDFW TI TT3PQ2Y DMIVDFW TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMIVDFW MA Inhibitor DMIVDFW RN Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. J Med Chem. 2007 Jan 11;50(1):21-39. DMIVDFW RU https://pubmed.ncbi.nlm.nih.gov/17201408 DMIVFZE DI DMIVFZE DMIVFZE DN AcAsp-Glu-Met-Glu-Glu-Cys DMIVFZE TI TTWXB3E DMIVFZE TN Hepatitis C virus NS3 helicase (HCV NS3) DMIVFZE MA Inhibitor DMIVFZE RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMIVFZE RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMIVGHB DI DMIVGHB DMIVGHB DN MRS-2179 DMIVGHB TI TTA93TL DMIVGHB TN P2Y purinoceptor 1 (P2RY1) DMIVGHB MA Antagonist DMIVGHB RN The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev. 2003 Spring;21(1):67-76. DMIVGHB RU https://pubmed.ncbi.nlm.nih.gov/12595918 DMIVNMJ DI DMIVNMJ DMIVNMJ DN CT-10 DMIVNMJ TI TTIKWV4 DMIVNMJ TN Geranyltranstransferase (FDPS) DMIVNMJ MA Inhibitor DMIVNMJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 643). DMIVNMJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=643 DMIVO8P DI DMIVO8P DMIVO8P DN N-Isopropyl-N'-Hydroxyguanidine DMIVO8P TI TTZUFI5 DMIVO8P TN Nitric-oxide synthase brain (NOS1) DMIVO8P MA Inhibitor DMIVO8P RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIVO8P RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIVQGW DI DMIVQGW DMIVQGW DN 4-Hydroxy-4-phenyl-but-2-enoic acid DMIVQGW TI TT6TKEN DMIVQGW TN Gamma-hydroxybutyrate receptor (SLC52A2) DMIVQGW MA Inhibitor DMIVQGW RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DMIVQGW RU https://pubmed.ncbi.nlm.nih.gov/3361576 DMIVREK DI DMIVREK DMIVREK DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) DMIVREK TI TT5ZKDI DMIVREK TN Histone deacetylase 6 (HDAC6) DMIVREK MA Inhibitor DMIVREK RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMIVREK RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMIVREK DI DMIVREK DMIVREK DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) DMIVREK TI TT6R7JZ DMIVREK TN Histone deacetylase 1 (HDAC1) DMIVREK MA Inhibitor DMIVREK RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMIVREK RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMIVREK DI DMIVREK DMIVREK DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Pro-) DMIVREK TI TTTQGH8 DMIVREK TN Histone deacetylase 4 (HDAC4) DMIVREK MA Inhibitor DMIVREK RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMIVREK RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMIVY0Q DI DMIVY0Q DMIVY0Q DN Eckol DMIVY0Q TI TT8JRS7 DMIVY0Q TN Beta-secretase (BACE) DMIVY0Q MA Inhibitor DMIVY0Q RN Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5. DMIVY0Q RU https://pubmed.ncbi.nlm.nih.gov/20462757 DMIVZ3W DI DMIVZ3W DMIVZ3W DN ES-936 DMIVZ3W TI TT8XK6L DMIVZ3W TN Quinone reductase 1 (NQO1) DMIVZ3W MA Inhibitor DMIVZ3W RN Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) ... J Med Chem. 2007 Nov 15;50(23):5780-9. DMIVZ3W RU https://pubmed.ncbi.nlm.nih.gov/17944451 DMIW5TY DI DMIW5TY DMIW5TY DN PMID12372533C20 DMIW5TY TI TT3RMNA DMIW5TY TN Chymotrypsin-C (CLCR) DMIW5TY MA Inhibitor DMIW5TY RN P1 Phenethyl peptide boronic acid inhibitors of HCV NS3 protease. Bioorg Med Chem Lett. 2002 Nov 4;12(21):3199-202. DMIW5TY RU https://pubmed.ncbi.nlm.nih.gov/12372533 DMIWF7U DI DMIWF7U DMIWF7U DN N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP DMIWF7U TI TTEB0GD DMIWF7U TN Cholinesterase (BCHE) DMIWF7U MA Inhibitor DMIWF7U RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMIWF7U RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMIWF7U DI DMIWF7U DMIWF7U DN N,N'-(1',9'-nonylene)-bis-(-)-nor-MEP DMIWF7U TI TT1RS9F DMIWF7U TN Acetylcholinesterase (AChE) DMIWF7U MA Inhibitor DMIWF7U RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMIWF7U RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMIWGZS DI DMIWGZS DMIWGZS DN 4-amino-6-chlorobenzene-1,3-disulfonamide DMIWGZS TI TTUNARX DMIWGZS TN Carbonic anhydrase (CA) DMIWGZS MA Inhibitor DMIWGZS RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIWGZS RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIWGZS DI DMIWGZS DMIWGZS DN 4-amino-6-chlorobenzene-1,3-disulfonamide DMIWGZS TI TTHQPL7 DMIWGZS TN Carbonic anhydrase I (CA-I) DMIWGZS MA Inhibitor DMIWGZS RN Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503. DMIWGZS RU https://pubmed.ncbi.nlm.nih.gov/20624682 DMIWGZS DI DMIWGZS DMIWGZS DN 4-amino-6-chlorobenzene-1,3-disulfonamide DMIWGZS TI TTCFSPE DMIWGZS TN Carbonic anhydrase VI (CA-VI) DMIWGZS MA Inhibitor DMIWGZS RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIWGZS RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIWGZS DI DMIWGZS DMIWGZS DN 4-amino-6-chlorobenzene-1,3-disulfonamide DMIWGZS TI TT2LVK8 DMIWGZS TN Carbonic anhydrase IX (CA-IX) DMIWGZS MA Inhibitor DMIWGZS RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMIWGZS RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMIWGZS DI DMIWGZS DMIWGZS DN 4-amino-6-chlorobenzene-1,3-disulfonamide DMIWGZS TI TTANPDJ DMIWGZS TN Carbonic anhydrase II (CA-II) DMIWGZS MA Inhibitor DMIWGZS RN Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503. DMIWGZS RU https://pubmed.ncbi.nlm.nih.gov/20624682 DMIWMJP DI DMIWMJP DMIWMJP DN AwFwLL-NH2 DMIWMJP TI TTWDC17 DMIWMJP TN Growth hormone secretagogue receptor 1 (GHSR) DMIWMJP MA Inhibitor DMIWMJP RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DMIWMJP RU https://pubmed.ncbi.nlm.nih.gov/17371869 DMIWMN6 DI DMIWMN6 DMIWMN6 DN Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 DMIWMN6 TI TTVFO0U DMIWMN6 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMIWMN6 MA Inhibitor DMIWMN6 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMIWMN6 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMIWMN6 DI DMIWMN6 DMIWMN6 DN Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 DMIWMN6 TI TTKWM86 DMIWMN6 TN Opioid receptor mu (MOP) DMIWMN6 MA Inhibitor DMIWMN6 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMIWMN6 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMIWMN6 DI DMIWMN6 DMIWMN6 DN Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 DMIWMN6 TI TT27RFC DMIWMN6 TN Opioid receptor delta (OPRD1) DMIWMN6 MA Inhibitor DMIWMN6 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMIWMN6 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMIWMN6 DI DMIWMN6 DMIWMN6 DN Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 DMIWMN6 TI TTCG0AL DMIWMN6 TN Cholecystokinin receptor type A (CCKAR) DMIWMN6 MA Inhibitor DMIWMN6 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMIWMN6 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMIWMZY DI DMIWMZY DMIWMZY DN LP-403812 DMIWMZY TI TT9LGO5 DMIWMZY TN Sodium-dependent proline transporter (SLC6A7) DMIWMZY MA Inhibitor DMIWMZY RN Discovery and characterization of potent small molecule inhibitors of the high affinity proline transporter. Neurosci Lett. 2009 Feb 27;451(3):212-6. DMIWMZY RU https://pubmed.ncbi.nlm.nih.gov/19159658 DMIWNAY DI DMIWNAY DMIWNAY DN N-(4-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine DMIWNAY TI TT2J34L DMIWNAY TN Arachidonate 5-lipoxygenase (5-LOX) DMIWNAY MA Inhibitor DMIWNAY RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DMIWNAY RU https://pubmed.ncbi.nlm.nih.gov/20870413 DMIWPKB DI DMIWPKB DMIWPKB DN Tyr-(NMe)Ala-L-Phe-D-Pro-NH2 DMIWPKB TI TTKWM86 DMIWPKB TN Opioid receptor mu (MOP) DMIWPKB MA Inhibitor DMIWPKB RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMIWPKB RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMIWPKB DI DMIWPKB DMIWPKB DN Tyr-(NMe)Ala-L-Phe-D-Pro-NH2 DMIWPKB TI TT27RFC DMIWPKB TN Opioid receptor delta (OPRD1) DMIWPKB MA Inhibitor DMIWPKB RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMIWPKB RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMIWQ7G DI DMIWQ7G DMIWQ7G DN 3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMIWQ7G TI TT2NUT5 DMIWQ7G TN Adrenergic receptor alpha-2C (ADRA2C) DMIWQ7G MA Inhibitor DMIWQ7G RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMIWQ7G RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMIWQ7G DI DMIWQ7G DMIWQ7G DN 3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMIWQ7G TI TTWM4TY DMIWQ7G TN Adrenergic receptor alpha-2B (ADRA2B) DMIWQ7G MA Inhibitor DMIWQ7G RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMIWQ7G RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMIWQ7G DI DMIWQ7G DMIWQ7G DN 3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMIWQ7G TI TTWG9A4 DMIWQ7G TN Adrenergic receptor alpha-2A (ADRA2A) DMIWQ7G MA Inhibitor DMIWQ7G RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMIWQ7G RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMIWT60 DI DMIWT60 DMIWT60 DN 4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine DMIWT60 TI TT8FYO9 DMIWT60 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMIWT60 MA Inhibitor DMIWT60 RN Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1999 Jul 1;42(13):2373-82. DMIWT60 RU https://pubmed.ncbi.nlm.nih.gov/10395478 DMIWT60 DI DMIWT60 DMIWT60 DN 4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine DMIWT60 TI TTI7421 DMIWT60 TN Platelet-derived growth factor receptor beta (PDGFRB) DMIWT60 MA Inhibitor DMIWT60 RN Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1999 Jul 1;42(13):2373-82. DMIWT60 RU https://pubmed.ncbi.nlm.nih.gov/10395478 DMIWX21 DI DMIWX21 DMIWX21 DN 2-Methyl-1,2-di-pyridin-3-yl-1-methoxypropane DMIWX21 TI TTIQUX7 DMIWX21 TN Steroid 11-beta-hydroxylase (CYP11B1) DMIWX21 MA Inhibitor DMIWX21 RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMIWX21 RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMIWX3B DI DMIWX3B DMIWX3B DN 4'-Demethyl-epipodophyllotoxin DMIWX3B TI TT0IHXV DMIWX3B TN DNA topoisomerase II (TOP2) DMIWX3B MA Inhibitor DMIWX3B RN Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod. 1989 May-Jun;52(3):606-13. DMIWX3B RU https://pubmed.ncbi.nlm.nih.gov/2550587 DMIWY7Q DI DMIWY7Q DMIWY7Q DN GSK1331268 DMIWY7Q TI TTXJ47W DMIWY7Q TN Metabotropic glutamate receptor 2 (mGluR2) DMIWY7Q MA Modulator (allosteric modulator) DMIWY7Q RN The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2. Bioorg Med Chem Lett. 2010 Jan 15;20(2):759-62. DMIWY7Q RU https://pubmed.ncbi.nlm.nih.gov/20005096 DMIX0CT DI DMIX0CT DMIX0CT DN N,N'-(1',10'-decylene)-bis-(-)-nor-MEP DMIX0CT TI TT1RS9F DMIX0CT TN Acetylcholinesterase (AChE) DMIX0CT MA Inhibitor DMIX0CT RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMIX0CT RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMIX0CT DI DMIX0CT DMIX0CT DN N,N'-(1',10'-decylene)-bis-(-)-nor-MEP DMIX0CT TI TTEB0GD DMIX0CT TN Cholinesterase (BCHE) DMIX0CT MA Inhibitor DMIX0CT RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMIX0CT RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMIX0UN DI DMIX0UN DMIX0UN DN 4-Sulfamoyloxy-benzoic acid cyclohexyl ester DMIX0UN TI TTHM0R1 DMIX0UN TN Steryl-sulfatase (STS) DMIX0UN MA Inhibitor DMIX0UN RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMIX0UN RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMIX347 DI DMIX347 DMIX347 DN CLAVARINONE DMIX347 TI TT7WZIJ DMIX347 TN CAAX farnesyltransferase beta (FNTB) DMIX347 MA Inhibitor DMIX347 RN Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase. J Med Chem. 1998 Nov 5;41(23):4492-501. DMIX347 RU https://pubmed.ncbi.nlm.nih.gov/9804689 DMIX347 DI DMIX347 DMIX347 DN CLAVARINONE DMIX347 TI TTXQKM3 DMIX347 TN Farnesyl protein transferase (Ftase) DMIX347 MA Inhibitor DMIX347 RN Clavaric acid and steroidal analogues as Ras- and FPP-directed inhibitors of human farnesyl-protein transferase. J Med Chem. 1998 Nov 5;41(23):4492-501. DMIX347 RU https://pubmed.ncbi.nlm.nih.gov/9804689 DMIX6RG DI DMIX6RG DMIX6RG DN 4-Benzyl-1-[3-phenylpropoxy)propyl]piperidine DMIX6RG TI TT9JNIC DMIX6RG TN Histamine H3 receptor (H3R) DMIX6RG MA Inhibitor DMIX6RG RN Piperidine variations in search for non-imidazole histamine H(3) receptor ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8729-36. DMIX6RG RU https://pubmed.ncbi.nlm.nih.gov/18774720 DMIX7CP DI DMIX7CP DMIX7CP DN IP-1200 DMIX7CP TI TT9B4N3 DMIX7CP TN Prostaglandin receptor (PTGR) DMIX7CP MA Modulator DMIX7CP RN Clinical pipeline report, company report or official report of Immunologic. DMIX7CP RU http://www.immunologic.nl/products/antibodies/i/ DMIX81A DI DMIX81A DMIX81A DN 4-Amino-3-(2-chloro-phenyl)-butyric acid DMIX81A TI TTDCVZW DMIX81A TN Gamma-aminobutyric acid B receptor (GABBR) DMIX81A MA Inhibitor DMIX81A RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DMIX81A RU https://pubmed.ncbi.nlm.nih.gov/1652022 DMIXFGC DI DMIXFGC DMIXFGC DN L-norvalyl-L-prolinamide DMIXFGC TI TTQ7R2V DMIXFGC TN Tripeptidyl-peptidase II (TPP2) DMIXFGC MA Inhibitor DMIXFGC RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMIXFGC RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMIXPU6 DI DMIXPU6 DMIXPU6 DN Diprenorphine DMIXPU6 TI TTKWM86 DMIXPU6 TN Opioid receptor mu (MOP) DMIXPU6 MA Antagonist DMIXPU6 RN [6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. DMIXPU6 RU https://pubmed.ncbi.nlm.nih.gov/20641600 DMIXPU6 DI DMIXPU6 DMIXPU6 DN Diprenorphine DMIXPU6 TI TTQW87Y DMIXPU6 TN Opioid receptor kappa (OPRK1) DMIXPU6 MA Antagonist DMIXPU6 RN [6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. DMIXPU6 RU https://pubmed.ncbi.nlm.nih.gov/20641600 DMIXPU6 DI DMIXPU6 DMIXPU6 DN Diprenorphine DMIXPU6 TI TT27RFC DMIXPU6 TN Opioid receptor delta (OPRD1) DMIXPU6 MA Antagonist DMIXPU6 RN [6-O-methyl-11C]Diprenorphine Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. DMIXPU6 RU https://pubmed.ncbi.nlm.nih.gov/20641600 DMIXQG6 DI DMIXQG6 DMIXQG6 DN 5-hydroxyvaleric acid DMIXQG6 TI TTJHKYD DMIXQG6 TN Delta-aminolevulinic acid dehydratase (ALAD) DMIXQG6 MA Inhibitor DMIXQG6 RN Structure of yeast 5-aminolaevulinic acid dehydratase complexed with the inhibitor 5-hydroxylaevulinic acid. Acta Crystallogr D Biol Crystallogr. 2005 Sep;61(Pt 9):1222-6. DMIXQG6 RU https://pubmed.ncbi.nlm.nih.gov/16131755 DMIXRCS DI DMIXRCS DMIXRCS DN 4-[4-(benzyloxy)piperidino]butyl-3-chlorobenzoate DMIXRCS TI TTEB0GD DMIXRCS TN Cholinesterase (BCHE) DMIXRCS MA Inhibitor DMIXRCS RN Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. DMIXRCS RU https://pubmed.ncbi.nlm.nih.gov/17681794 DMIXT2L DI DMIXT2L DMIXT2L DN 6-(3,5-dimethoxy-phenyl)-naphthalen-2-ol DMIXT2L TI TT3OT40 DMIXT2L TN Multidrug resistance protein 1 (ABCB1) DMIXT2L MA Inhibitor DMIXT2L RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMIXT2L RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMIXUM3 DI DMIXUM3 DMIXUM3 DN VPC03090-P DMIXUM3 TI TT9JZCK DMIXUM3 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMIXUM3 MA Antagonist DMIXUM3 RN Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89. DMIXUM3 RU https://pubmed.ncbi.nlm.nih.gov/21632869 DMIXUM3 DI DMIXUM3 DMIXUM3 DN VPC03090-P DMIXUM3 TI TTZ8C5Q DMIXUM3 TN Sphingosine-1-phosphate receptor 4 (S1PR4) DMIXUM3 MA Agonist DMIXUM3 RN Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89. DMIXUM3 RU https://pubmed.ncbi.nlm.nih.gov/21632869 DMIXUM3 DI DMIXUM3 DMIXUM3 DN VPC03090-P DMIXUM3 TI TTDYP7I DMIXUM3 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMIXUM3 MA Antagonist DMIXUM3 RN Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89. DMIXUM3 RU https://pubmed.ncbi.nlm.nih.gov/21632869 DMIXUM3 DI DMIXUM3 DMIXUM3 DN VPC03090-P DMIXUM3 TI TTDZCKV DMIXUM3 TN Sphingosine-1-phosphate receptor 5 (S1PR5) DMIXUM3 MA Agonist DMIXUM3 RN Characterization of a sphingosine 1-phosphate receptor antagonist prodrug. J Pharmacol Exp Ther. 2011 Sep;338(3):879-89. DMIXUM3 RU https://pubmed.ncbi.nlm.nih.gov/21632869 DMIXUNB DI DMIXUNB DMIXUNB DN JNJ-17156516 DMIXUNB TI TTCG0AL DMIXUNB TN Cholecystokinin receptor type A (CCKAR) DMIXUNB MA Antagonist DMIXUNB RN 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokini... J Pharmacol Exp Ther. 2007 Nov;323(2):562-9. DMIXUNB RU https://pubmed.ncbi.nlm.nih.gov/17684117 DMIXY1O DI DMIXY1O DMIXY1O DN HC067047 DMIXY1O TI TTKP2SU DMIXY1O TN Transient receptor potential cation channel V4 (TRPV4) DMIXY1O MA Blocker (channel blocker) DMIXY1O RN Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19084-9. DMIXY1O RU https://pubmed.ncbi.nlm.nih.gov/20956320 DMIY134 DI DMIY134 DMIY134 DN ANA-04 DMIY134 TI TT69OHW DMIY134 TN Interleukin 17 receptor (IL17R) DMIY134 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294). DMIY134 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2294 DMIY2HW DI DMIY2HW DMIY2HW DN Bile acid DMIY2HW TI TTSDVTR DMIY2HW TN G-protein coupled bile acid receptor 1 (GPBAR1) DMIY2HW MA Inhibitor DMIY2HW RN Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5718-21. DMIY2HW RU https://pubmed.ncbi.nlm.nih.gov/20801037 DMIY3D6 DI DMIY3D6 DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one DMIY3D6 TI TTYHPU6 DMIY3D6 TN Histone deacetylase 10 (HDAC10) DMIY3D6 MA Inhibitor DMIY3D6 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMIY3D6 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMIY3D6 DI DMIY3D6 DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one DMIY3D6 TI TTSHTOI DMIY3D6 TN Histone deacetylase 2 (HDAC2) DMIY3D6 MA Inhibitor DMIY3D6 RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DMIY3D6 RU https://pubmed.ncbi.nlm.nih.gov/12419380 DMIY3D6 DI DMIY3D6 DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one DMIY3D6 TI TTBH0VX DMIY3D6 TN Histone deacetylase (HDAC) DMIY3D6 MA Inhibitor DMIY3D6 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMIY3D6 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMIY3D6 DI DMIY3D6 DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one DMIY3D6 TI TT5ZKDI DMIY3D6 TN Histone deacetylase 6 (HDAC6) DMIY3D6 MA Inhibitor DMIY3D6 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMIY3D6 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMIY3D6 DI DMIY3D6 DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one DMIY3D6 TI TT6R7JZ DMIY3D6 TN Histone deacetylase 1 (HDAC1) DMIY3D6 MA Inhibitor DMIY3D6 RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DMIY3D6 RU https://pubmed.ncbi.nlm.nih.gov/12419380 DMIY3D6 DI DMIY3D6 DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one DMIY3D6 TI TTTQGH8 DMIY3D6 TN Histone deacetylase 4 (HDAC4) DMIY3D6 MA Inhibitor DMIY3D6 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMIY3D6 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMIY3D6 DI DMIY3D6 DMIY3D6 DN 9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one DMIY3D6 TI TTT6LFV DMIY3D6 TN Histone deacetylase 8 (HDAC8) DMIY3D6 MA Inhibitor DMIY3D6 RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMIY3D6 RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMIY5QU DI DMIY5QU DMIY5QU DN 4-(7,7-Dimethyl-oct-3-ynyl)-1H-imidazole DMIY5QU TI TT9JNIC DMIY5QU TN Histamine H3 receptor (H3R) DMIY5QU MA Inhibitor DMIY5QU RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DMIY5QU RU https://pubmed.ncbi.nlm.nih.gov/9871722 DMIY79U DI DMIY79U DMIY79U DN GNF-PF-3832 DMIY79U TI TT8DBY3 DMIY79U TN Angiotensin II receptor type-1 (AGTR1) DMIY79U MA Inhibitor DMIY79U RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMIY79U RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMIY9DB DI DMIY9DB DMIY9DB DN 13-(3-n-Pentylthioureido)tridec-8(Z)-enoic Acid DMIY9DB TI TT7WVHI DMIY9DB TN Soluble epoxide hydrolase (EPHX2) DMIY9DB MA Inhibitor DMIY9DB RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMIY9DB RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMIY9UF DI DMIY9UF DMIY9UF DN GR-38414 DMIY9UF TI TTQW87Y DMIY9UF TN Opioid receptor kappa (OPRK1) DMIY9UF MA Modulator DMIY9UF RN A series of novel, highly potent and selective agonists for the kappa-opioid receptor. Br J Pharmacol. 1990 Dec;101(4):944-8. DMIY9UF RU https://www.ncbi.nlm.nih.gov/pubmed/1964823 DMIYCMF DI DMIYCMF DMIYCMF DN ISIS 112599 DMIYCMF TI TT6804T DMIYCMF TN MIF messenger RNA (MIF mRNA) DMIYCMF RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DMIYCMF RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DMIYFQ5 DI DMIYFQ5 DMIYFQ5 DN SB216763 DMIYFQ5 TI TTRZQE3 DMIYFQ5 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMIYFQ5 MA Inhibitor DMIYFQ5 RN Intracellular protein phosphorylation in eosinophils and the functional relevance in cytokine production. Int Arch Allergy Immunol. 2009;149 Suppl 1:45-50. DMIYFQ5 RU https://pubmed.ncbi.nlm.nih.gov/19494504 DMIYJ2M DI DMIYJ2M DMIYJ2M DN STA2 DMIYJ2M TI TT2O84V DMIYJ2M TN Thromboxane A2 receptor (TBXA2R) DMIYJ2M MA Agonist DMIYJ2M RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMIYJ2M RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMIYJ2M DI DMIYJ2M DMIYJ2M DN STA2 DMIYJ2M TI TTPNGDE DMIYJ2M TN Prostaglandin E2 receptor EP3 (PTGER3) DMIYJ2M MA Agonist DMIYJ2M RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMIYJ2M RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMIYLXU DI DMIYLXU DMIYLXU DN 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine DMIYLXU TI TTJQOD7 DMIYLXU TN 5-HT 2A receptor (HTR2A) DMIYLXU MA Inhibitor DMIYLXU RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DMIYLXU RU https://pubmed.ncbi.nlm.nih.gov/18296055 DMIYVJX DI DMIYVJX DMIYVJX DN 4-CHLORO-3',3''-DIBROMOPHENOL-1,8-NAPHTHALEIN DMIYVJX TI TTU6BFZ DMIYVJX TN Candida Thymidylate synthase (Candi TMP1) DMIYVJX MA Inhibitor DMIYVJX RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMIYVJX RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMIZ0GO DI DMIZ0GO DMIZ0GO DN 4,17-dehydroxyriccardin C DMIZ0GO TI TTECBXN DMIZ0GO TN Oxysterols receptor LXR-alpha (NR1H3) DMIZ0GO MA Inhibitor DMIZ0GO RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DMIZ0GO RU https://pubmed.ncbi.nlm.nih.gov/18343126 DMIZ0GO DI DMIZ0GO DMIZ0GO DN 4,17-dehydroxyriccardin C DMIZ0GO TI TTXA6PH DMIZ0GO TN Oxysterols receptor LXR-beta (NR1H2) DMIZ0GO MA Inhibitor DMIZ0GO RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DMIZ0GO RU https://pubmed.ncbi.nlm.nih.gov/18343126 DMIZ28H DI DMIZ28H DMIZ28H DN H-Dmt-Tic-Gly-NH-Ph DMIZ28H TI TT27RFC DMIZ28H TN Opioid receptor delta (OPRD1) DMIZ28H MA Inhibitor DMIZ28H RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMIZ28H RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMIZ28H DI DMIZ28H DMIZ28H DN H-Dmt-Tic-Gly-NH-Ph DMIZ28H TI TTKWM86 DMIZ28H TN Opioid receptor mu (MOP) DMIZ28H MA Inhibitor DMIZ28H RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMIZ28H RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMIZ5VO DI DMIZ5VO DMIZ5VO DN Acylated Ceftazidime DMIZ5VO TI TTHI19T DMIZ5VO TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMIZ5VO MA Inhibitor DMIZ5VO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIZ5VO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIZ8RC DI DMIZ8RC DMIZ8RC DN 3-cyano-5-fluoro-N-phenylbenzamide DMIZ8RC TI TTHS256 DMIZ8RC TN Metabotropic glutamate receptor 5 (mGluR5) DMIZ8RC MA Inhibitor DMIZ8RC RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMIZ8RC RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMIZ9ON DI DMIZ9ON DMIZ9ON DN BRD1240 DMIZ9ON TI TTTK3BH DMIZ9ON TN Vacuolar-type proton ATPase (v-ATPase) DMIZ9ON MA Inhibitor DMIZ9ON RN Lysosomes as a therapeutic target. Nat Rev Drug Discov. 2019 Dec;18(12):923-948. DMIZ9ON RU https://pubmed.ncbi.nlm.nih.gov/31477883 DMIZB25 DI DMIZB25 DMIZB25 DN Tyr-Sar-Phe-D-2-Nal-NH2 DMIZB25 TI TTKWM86 DMIZB25 TN Opioid receptor mu (MOP) DMIZB25 MA Inhibitor DMIZB25 RN Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. DMIZB25 RU https://pubmed.ncbi.nlm.nih.gov/18207400 DMIZB81 DI DMIZB81 DMIZB81 DN Pyrazine-2-carboxylic acid adamantan-1-ylamide DMIZB81 TI TTVBPDM DMIZB81 TN Metabotropic glutamate receptor 1 (mGluR1) DMIZB81 MA Inhibitor DMIZB81 RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DMIZB81 RU https://pubmed.ncbi.nlm.nih.gov/18173231 DMIZBP6 DI DMIZBP6 DMIZBP6 DN 1-(1-phenyl-2-(pyridin-2-yl)ethyl)piperazine DMIZBP6 TI TT3ROYC DMIZBP6 TN Serotonin transporter (SERT) DMIZBP6 MA Inhibitor DMIZBP6 RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DMIZBP6 RU https://pubmed.ncbi.nlm.nih.gov/16750363 DMIZESL DI DMIZESL DMIZESL DN Stachyflin DMIZESL TI TTF4CAM DMIZESL TN Influenza Hemagglutinin (Influ HA) DMIZESL MA Inhibitor DMIZESL RN Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41. DMIZESL RU https://pubmed.ncbi.nlm.nih.gov/19004788 DMIZH16 DI DMIZH16 DMIZH16 DN ISIS 114388 DMIZH16 TI TT8OY02 DMIZH16 TN ARA70 messenger RNA (NCOA4 mRNA) DMIZH16 RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DMIZH16 RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DMIZJ9G DI DMIZJ9G DMIZJ9G DN 3-nitro-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide DMIZJ9G TI TTHS256 DMIZJ9G TN Metabotropic glutamate receptor 5 (mGluR5) DMIZJ9G MA Inhibitor DMIZJ9G RN Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44. DMIZJ9G RU https://pubmed.ncbi.nlm.nih.gov/16722652 DMIZLVW DI DMIZLVW DMIZLVW DN Phosphocholine DMIZLVW TI TTWRN6M DMIZLVW TN CRP messenger RNA (CRP mRNA) DMIZLVW MA Inhibitor DMIZLVW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMIZLVW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMIZQOG DI DMIZQOG DMIZQOG DN AMA37 DMIZQOG TI TTK3PY9 DMIZQOG TN DNA-dependent protein kinase catalytic (PRKDC) DMIZQOG MA Inhibitor DMIZQOG RN Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl)pyrimido[2,1-alpha]isoquinolin-4-one. J Biol Chem. 2007 Aug 17;282(33):24463-70. DMIZQOG RU https://pubmed.ncbi.nlm.nih.gov/17562705 DMIZQTX DI DMIZQTX DMIZQTX DN DYSIDENIN DMIZQTX TI TTN9T81 DMIZQTX TN Arachidonate 15-lipoxygenase (15-LOX) DMIZQTX MA Inhibitor DMIZQTX RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DMIZQTX RU https://pubmed.ncbi.nlm.nih.gov/17826100 DMIZQTX DI DMIZQTX DMIZQTX DN DYSIDENIN DMIZQTX TI TT12ABZ DMIZQTX TN Arachidonate 12-lipoxygenase (12-LOX) DMIZQTX MA Inhibitor DMIZQTX RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DMIZQTX RU https://pubmed.ncbi.nlm.nih.gov/17826100 DMIZQW6 DI DMIZQW6 DMIZQW6 DN LYSICAMINE DMIZQW6 TI TT1RS9F DMIZQW6 TN Acetylcholinesterase (AChE) DMIZQW6 MA Inhibitor DMIZQW6 RN Characterization of Acetylcholinesterase Inhibitory Constituents from Annona glabra Assisted by HPLC Microfractionation. J Nat Prod. 2010 Oct 22;73(10):1632-5. DMIZQW6 RU https://pubmed.ncbi.nlm.nih.gov/20828184 DMIZV6T DI DMIZV6T DMIZV6T DN XR-9577 DMIZV6T TI TT3OT40 DMIZV6T TN Multidrug resistance protein 1 (ABCB1) DMIZV6T MA Inhibitor DMIZV6T RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DMIZV6T RU https://pubmed.ncbi.nlm.nih.gov/18083034 DMIZV6T DI DMIZV6T DMIZV6T DN XR-9577 DMIZV6T TI TTOI92F DMIZV6T TN Multidrug resistance-associated protein 1 (ABCC1) DMIZV6T MA Inhibitor DMIZV6T RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DMIZV6T RU https://pubmed.ncbi.nlm.nih.gov/18083034 DMIZVA6 DI DMIZVA6 DMIZVA6 DN LEUCETTAMINE A DMIZVA6 TI TTN53ZF DMIZVA6 TN Leukotriene B4 receptor 1 (LTB4R) DMIZVA6 MA Inhibitor DMIZVA6 RN New leukotriene B4 receptor antagonist: leucettamine A and related imidazole alkaloids from the marine sponge Leucetta microraphis. J Nat Prod. 1993 Jan;56(1):116-21. DMIZVA6 RU https://pubmed.ncbi.nlm.nih.gov/8383730 DMIZVMT DI DMIZVMT DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide DMIZVMT TI TTYHPU6 DMIZVMT TN Histone deacetylase 10 (HDAC10) DMIZVMT MA Inhibitor DMIZVMT RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMIZVMT RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMIZVMT DI DMIZVMT DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide DMIZVMT TI TTSHTOI DMIZVMT TN Histone deacetylase 2 (HDAC2) DMIZVMT MA Inhibitor DMIZVMT RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMIZVMT RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMIZVMT DI DMIZVMT DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide DMIZVMT TI TTT6LFV DMIZVMT TN Histone deacetylase 8 (HDAC8) DMIZVMT MA Inhibitor DMIZVMT RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMIZVMT RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMIZVMT DI DMIZVMT DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide DMIZVMT TI TTBH0VX DMIZVMT TN Histone deacetylase (HDAC) DMIZVMT MA Inhibitor DMIZVMT RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMIZVMT RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMIZVMT DI DMIZVMT DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide DMIZVMT TI TTTQGH8 DMIZVMT TN Histone deacetylase 4 (HDAC4) DMIZVMT MA Inhibitor DMIZVMT RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMIZVMT RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMIZVMT DI DMIZVMT DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide DMIZVMT TI TT5ZKDI DMIZVMT TN Histone deacetylase 6 (HDAC6) DMIZVMT MA Inhibitor DMIZVMT RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMIZVMT RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMIZVMT DI DMIZVMT DMIZVMT DN N-(6-Hydroxycarbamoyl-hexyl)-benzamide DMIZVMT TI TT6R7JZ DMIZVMT TN Histone deacetylase 1 (HDAC1) DMIZVMT MA Inhibitor DMIZVMT RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMIZVMT RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMIZX8P DI DMIZX8P DMIZX8P DN Triflupromazine DMIZX8P TI TTAIY2U DMIZX8P TN HUMAN clathrin-mediated endocytosis (RME) DMIZX8P MA Inhibitor DMIZX8P RN Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. DMIZX8P RU https://pubmed.ncbi.nlm.nih.gov/24841273 DMIZXYM DI DMIZXYM DMIZXYM DN 4-(3,4-Diethoxy-benzylamino)-benzamidine DMIZXYM TI TT6L509 DMIZXYM TN Coagulation factor IIa (F2) DMIZXYM MA Inhibitor DMIZXYM RN Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. DMIZXYM RU https://pubmed.ncbi.nlm.nih.gov/15664864 DMIZXYM DI DMIZXYM DMIZXYM DN 4-(3,4-Diethoxy-benzylamino)-benzamidine DMIZXYM TI TT2WR1T DMIZXYM TN Cationic trypsinogen (PRSS1) DMIZXYM MA Inhibitor DMIZXYM RN Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. DMIZXYM RU https://pubmed.ncbi.nlm.nih.gov/15664864 DMIZXYM DI DMIZXYM DMIZXYM DN 4-(3,4-Diethoxy-benzylamino)-benzamidine DMIZXYM TI TTF0EGX DMIZXYM TN Coagulation factor VII (F7) DMIZXYM MA Inhibitor DMIZXYM RN Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22. DMIZXYM RU https://pubmed.ncbi.nlm.nih.gov/15664864 DMJ025O DI DMJ025O DMJ025O DN N1-(4-chlorobenzyl)-2-amino-N3-hydroxymalonamide DMJ025O TI TTPHMWB DMJ025O TN Aminopeptidase N (ANPEP) DMJ025O MA Inhibitor DMJ025O RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMJ025O RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMJ0368 DI DMJ0368 DMJ0368 DN 2-bromo-4-methylphenyl 2-nitrobenzoate DMJ0368 TI TTVTX4N DMJ0368 TN Bacterial Fatty acid synthetase I (Bact inhA) DMJ0368 MA Inhibitor DMJ0368 RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMJ0368 RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMJ03UM DI DMJ03UM DMJ03UM DN ROLIPRAM DMJ03UM TI TTVIAT9 DMJ03UM TN Phosphodiesterase 4B (PDE4B) DMJ03UM MA Inhibitor DMJ03UM RN Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997 May 9;40(10):1417-21. DMJ03UM RU https://pubmed.ncbi.nlm.nih.gov/9154964 DMJ03UM DI DMJ03UM DMJ03UM DN ROLIPRAM DMJ03UM TI TTSKMI8 DMJ03UM TN Phosphodiesterase 4D (PDE4D) DMJ03UM MA Inhibitor DMJ03UM RN In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. DMJ03UM RU https://pubmed.ncbi.nlm.nih.gov/20188577 DMJ03UM DI DMJ03UM DMJ03UM DN ROLIPRAM DMJ03UM TI TTJ0IQB DMJ03UM TN Phosphodiesterase 5A (PDE5A) DMJ03UM MA Inhibitor DMJ03UM RN Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J Med Chem. 1994 Jun 24;37(13):2106-11. DMJ03UM RU https://pubmed.ncbi.nlm.nih.gov/8027992 DMJ03UM DI DMJ03UM DMJ03UM DN ROLIPRAM DMJ03UM TI TTZ97H5 DMJ03UM TN Phosphodiesterase 4A (PDE4A) DMJ03UM MA Inhibitor DMJ03UM RN Discovery of micromolar PDE IV inhibitors that exhibit much reduced affinity for the [3H]rolipram binding site: 3-norbornyloxy-4-methoxyphenylmethylene oxindoles, Bioorg. Med. Chem. Lett. 5(17):1965-1968 (1995). DMJ03UM RU http://www.sciencedirect.com/science/article/pii/0960894X9500333O DMJ0654 DI DMJ0654 DMJ0654 DN 3,7-DIHYDROXYNAPHTHALENE-2-CARBOXYLIC ACID DMJ0654 TI TTAZHU0 DMJ0654 TN L-lactate dehydrogenase (LDH) DMJ0654 MA Inhibitor DMJ0654 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMJ0654 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMJ0936 DI DMJ0936 DMJ0936 DN PF-03772304 DMJ0936 TI TTHBTOP DMJ0936 TN PI3-kinase gamma (PIK3CG) DMJ0936 MA Inhibitor DMJ0936 RN Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7. DMJ0936 RU https://pubmed.ncbi.nlm.nih.gov/24900568 DMJ0936 DI DMJ0936 DMJ0936 DN PF-03772304 DMJ0936 TI TTCJG29 DMJ0936 TN Serine/threonine-protein kinase mTOR (mTOR) DMJ0936 MA Inhibitor DMJ0936 RN Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Med Chem Lett. 2012 Nov 7;4(1):91-7. DMJ0936 RU https://pubmed.ncbi.nlm.nih.gov/24900568 DMJ0A4Z DI DMJ0A4Z DMJ0A4Z DN 4'-Phosphopantetheine DMJ0A4Z TI TT4YO0Z DMJ0A4Z TN Phosphopantetheine adenylyltransferase (PPAT) DMJ0A4Z MA Inhibitor DMJ0A4Z RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJ0A4Z RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJ0BEG DI DMJ0BEG DMJ0BEG DN AMIFLAMINE DMJ0BEG TI TTAWNKZ DMJ0BEG TN Norepinephrine transporter (NET) DMJ0BEG MA Inhibitor DMJ0BEG RN Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12. DMJ0BEG RU https://pubmed.ncbi.nlm.nih.gov/3735309 DMJ0FCG DI DMJ0FCG DMJ0FCG DN REC2615 DMJ0FCG TI TTNGILX DMJ0FCG TN Adrenergic receptor alpha-1A (ADRA1A) DMJ0FCG MA Antagonist DMJ0FCG RN Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. DMJ0FCG RU https://pubmed.ncbi.nlm.nih.gov/17826689 DMJ0ICN DI DMJ0ICN DMJ0ICN DN GCCSNPVCHLEHSNLC* DMJ0ICN TI TTLA931 DMJ0ICN TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMJ0ICN MA Inhibitor DMJ0ICN RN Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45. DMJ0ICN RU https://pubmed.ncbi.nlm.nih.gov/16033252 DMJ0ICN DI DMJ0ICN DMJ0ICN DN GCCSNPVCHLEHSNLC* DMJ0ICN TI TT5KPZR DMJ0ICN TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMJ0ICN MA Inhibitor DMJ0ICN RN Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45. DMJ0ICN RU https://pubmed.ncbi.nlm.nih.gov/16033252 DMJ0ICN DI DMJ0ICN DMJ0ICN DN GCCSNPVCHLEHSNLC* DMJ0ICN TI TTTVAFQ DMJ0ICN TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMJ0ICN MA Inhibitor DMJ0ICN RN Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations. J Med Chem. 2005 Jul 28;48(15):4705-45. DMJ0ICN RU https://pubmed.ncbi.nlm.nih.gov/16033252 DMJ0LB1 DI DMJ0LB1 DMJ0LB1 DN ISIS 23412 DMJ0LB1 TI TTAIWZN DMJ0LB1 TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DMJ0LB1 RN US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression. DMJ0LB1 RU http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true DMJ0S5C DI DMJ0S5C DMJ0S5C DN N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile DMJ0S5C TI TTDZN01 DMJ0S5C TN Cathepsin K (CTSK) DMJ0S5C MA Inhibitor DMJ0S5C RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMJ0S5C RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMJ0S5C DI DMJ0S5C DMJ0S5C DN N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile DMJ0S5C TI TTUMQVO DMJ0S5C TN Cathepsin S (CTSS) DMJ0S5C MA Inhibitor DMJ0S5C RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMJ0S5C RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMJ0S5C DI DMJ0S5C DMJ0S5C DN N-(tert-butoxycarbonyl)-isoleucyl-glycine-nitrile DMJ0S5C TI TT36ETB DMJ0S5C TN Cathepsin L (CTSL) DMJ0S5C MA Inhibitor DMJ0S5C RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMJ0S5C RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMJ0SVB DI DMJ0SVB DMJ0SVB DN 3-Phenyl-1-propyl-pyrrolidine DMJ0SVB TI TTSQIFT DMJ0SVB TN 5-HT 1A receptor (HTR1A) DMJ0SVB MA Inhibitor DMJ0SVB RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMJ0SVB RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMJ0SVB DI DMJ0SVB DMJ0SVB DN 3-Phenyl-1-propyl-pyrrolidine DMJ0SVB TI TTEX248 DMJ0SVB TN Dopamine D2 receptor (D2R) DMJ0SVB MA Inhibitor DMJ0SVB RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMJ0SVB RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMJ0T3W DI DMJ0T3W DMJ0T3W DN N-cyclohexylquinazolin-4-amine DMJ0T3W TI TTVBPDM DMJ0T3W TN Metabotropic glutamate receptor 1 (mGluR1) DMJ0T3W MA Inhibitor DMJ0T3W RN In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. DMJ0T3W RU https://pubmed.ncbi.nlm.nih.gov/19289283 DMJ0W43 DI DMJ0W43 DMJ0W43 DN P-(2'-Iodo-5'-Thenoyl)Hydrotropic Acid DMJ0W43 TI TT8NGED DMJ0W43 TN Prostaglandin G/H synthase 1 (COX-1) DMJ0W43 MA Inhibitor DMJ0W43 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJ0W43 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJ0YZA DI DMJ0YZA DMJ0YZA DN PMID30247903-Compound-General structure13 DMJ0YZA TI TTNBFWK DMJ0YZA TN Programmed cell death protein 1 (PD-1) DMJ0YZA MA antagonist DMJ0YZA RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMJ0YZA RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMJ0ZMT DI DMJ0ZMT DMJ0ZMT DN 1,1,1-trifluoro-3-(hexylsulfinyl)propan-2-one DMJ0ZMT TI TTMF541 DMJ0ZMT TN Liver carboxylesterase (CES1) DMJ0ZMT MA Inhibitor DMJ0ZMT RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMJ0ZMT RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMJ108U DI DMJ108U DMJ108U DN LJP-1207 DMJ108U TI TT7HC21 DMJ108U TN Membrane copper amine oxidase (AOC3) DMJ108U MA Inhibitor DMJ108U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767). DMJ108U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767 DMJ10WH DI DMJ10WH DMJ10WH DN N-1,3,4-thiadiazol-2-ylsulfamide DMJ10WH TI TTZHA0O DMJ10WH TN Carbonic anhydrase IV (CA-IV) DMJ10WH MA Inhibitor DMJ10WH RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMJ10WH RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMJ10WH DI DMJ10WH DMJ10WH DN N-1,3,4-thiadiazol-2-ylsulfamide DMJ10WH TI TTHQPL7 DMJ10WH TN Carbonic anhydrase I (CA-I) DMJ10WH MA Inhibitor DMJ10WH RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMJ10WH RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMJ10WH DI DMJ10WH DMJ10WH DN N-1,3,4-thiadiazol-2-ylsulfamide DMJ10WH TI TTANPDJ DMJ10WH TN Carbonic anhydrase II (CA-II) DMJ10WH MA Inhibitor DMJ10WH RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMJ10WH RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMJ13TR DI DMJ13TR DMJ13TR DN N-Carbamoyl-L-Aspartate DMJ13TR TI TT09NOX DMJ13TR TN Plasmodium Dihydroorotase (Malaria dho) DMJ13TR MA Inhibitor DMJ13TR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJ13TR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJ14NE DI DMJ14NE DMJ14NE DN WAY-207024 DMJ14NE TI TTQHJ1K DMJ14NE TN Histamine H2 receptor (H2R) DMJ14NE MA Inhibitor DMJ14NE RN Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the ... J Med Chem. 2009 Apr 9;52(7):2148-52. DMJ14NE RU https://pubmed.ncbi.nlm.nih.gov/19271735 DMJ14NE DI DMJ14NE DMJ14NE DN WAY-207024 DMJ14NE TI TTYO0A3 DMJ14NE TN Substance-K receptor (TACR2) DMJ14NE MA Inhibitor DMJ14NE RN Discovery of 6-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): an orally active antagonist of the ... J Med Chem. 2009 Apr 9;52(7):2148-52. DMJ14NE RU https://pubmed.ncbi.nlm.nih.gov/19271735 DMJ14NE DI DMJ14NE DMJ14NE DN WAY-207024 DMJ14NE TI TT8R70G DMJ14NE TN Gonadotropin-releasing hormone receptor (GNRHR) DMJ14NE MA Inhibitor DMJ14NE RN Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2512-5. DMJ14NE RU https://pubmed.ncbi.nlm.nih.gov/20236823 DMJ14OV DI DMJ14OV DMJ14OV DN R-116712 DMJ14OV TI TT07C3Y DMJ14OV TN 5-HT 4 receptor (HTR4) DMJ14OV MA Antagonist DMJ14OV RN Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse. 2000 Apr;36(1):35-46. DMJ14OV RU https://pubmed.ncbi.nlm.nih.gov/10700024 DMJ16AD DI DMJ16AD DMJ16AD DN ZP-3022 DMJ16AD TI TTVIMDE DMJ16AD TN Glucagon-like peptide 1 receptor (GLP1R) DMJ16AD MA Agonist DMJ16AD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMJ16AD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMJ1DE9 DI DMJ1DE9 DMJ1DE9 DN JNJ-17148066 DMJ1DE9 TI TTZAYWL DMJ1DE9 TN Estrogen receptor (ESR) DMJ1DE9 MA Inhibitor DMJ1DE9 RN Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69. DMJ1DE9 RU https://pubmed.ncbi.nlm.nih.gov/19366247 DMJ1HX2 DI DMJ1HX2 DMJ1HX2 DN 5-Methoxymethyl-3-pyrrol-1-yl-oxazolidin-2-one DMJ1HX2 TI TT3WG5C DMJ1HX2 TN Monoamine oxidase type A (MAO-A) DMJ1HX2 MA Inhibitor DMJ1HX2 RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DMJ1HX2 RU https://pubmed.ncbi.nlm.nih.gov/11881986 DMJ1IRO DI DMJ1IRO DMJ1IRO DN 5,8-dimethoxy-1,4-dimethylquinolin-2(1H)-one DMJ1IRO TI TTJLP0R DMJ1IRO TN Quinone reductase 2 (NQO2) DMJ1IRO MA Inhibitor DMJ1IRO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJ1IRO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJ1VAE DI DMJ1VAE DMJ1VAE DN 98mTc-CIM-ANT DMJ1VAE TI TTZ6T9E DMJ1VAE TN Somatostatin receptor type 2 (SSTR2) DMJ1VAE MA Antagonist DMJ1VAE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356). DMJ1VAE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356 DMJ1VRU DI DMJ1VRU DMJ1VRU DN oleoyl-CoA DMJ1VRU TI TTH7UO3 DMJ1VRU TN Inward rectifier potassium channel Kir2.1 (KCNJ2) DMJ1VRU MA Inhibitor (gating inhibitor) DMJ1VRU RN Cytoplasmic accumulation of long-chain coenzyme A esters activates KATP and inhibits Kir2.1 channels. J Physiol. 2006 Sep 1;575(Pt 2):433-42. DMJ1VRU RU https://pubmed.ncbi.nlm.nih.gov/16777940 DMJ218E DI DMJ218E DMJ218E DN BMS-187308 DMJ218E TI TTKRD0G DMJ218E TN Endothelin A receptor (EDNRA) DMJ218E MA Modulator DMJ218E RN Biphenylsulfonamide endothelin antagonists: structure-activity relationships of a series of mono- and disubstituted analogues and pharmacology of t... J Med Chem. 1998 Dec 17;41(26):5198-218. DMJ218E RU https://www.ncbi.nlm.nih.gov/pubmed/9857090 DMJ21XT DI DMJ21XT DMJ21XT DN 1-(1-(pyridin-3-yl)ethylidene)thiosemicarbazide DMJ21XT TI TTULVH8 DMJ21XT TN Tyrosinase (TYR) DMJ21XT MA Inhibitor DMJ21XT RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DMJ21XT RU https://pubmed.ncbi.nlm.nih.gov/18326070 DMJ249P DI DMJ249P DMJ249P DN (-)-Cercosporamide DMJ249P TI TTYPXQF DMJ249P TN Protein kinase C beta (PRKCB) DMJ249P MA Inhibitor DMJ249P RN (-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6. DMJ249P RU https://pubmed.ncbi.nlm.nih.gov/19109017 DMJ249P DI DMJ249P DMJ249P DN (-)-Cercosporamide DMJ249P TI TTFJ8Q1 DMJ249P TN Protein kinase C alpha (PRKCA) DMJ249P MA Inhibitor DMJ249P RN (-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6. DMJ249P RU https://pubmed.ncbi.nlm.nih.gov/19109017 DMJ249P DI DMJ249P DMJ249P DN (-)-Cercosporamide DMJ249P TI TTRFOXJ DMJ249P TN Protein kinase C gamma (PRKCG) DMJ249P MA Inhibitor DMJ249P RN (-)-Cercosporamide derivatives as novel antihyperglycemic agents. Bioorg Med Chem Lett. 2009 Feb 1;19(3):724-6. DMJ249P RU https://pubmed.ncbi.nlm.nih.gov/19109017 DMJ27QT DI DMJ27QT DMJ27QT DN 15-deoxy-Delta12,14-PGD2 DMJ27QT TI TTQDMX5 DMJ27QT TN Prostaglandin D2 receptor 2 (PTGDR2) DMJ27QT MA Agonist DMJ27QT RN Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. DMJ27QT RU https://pubmed.ncbi.nlm.nih.gov/12721327 DMJ29MN DI DMJ29MN DMJ29MN DN N-benzyl-2-oxo-2H-chromene-3-carboxamide DMJ29MN TI TTGP7BY DMJ29MN TN Monoamine oxidase type B (MAO-B) DMJ29MN MA Inhibitor DMJ29MN RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMJ29MN RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMJ2DE4 DI DMJ2DE4 DMJ2DE4 DN 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid DMJ2DE4 TI TT8NGED DMJ2DE4 TN Prostaglandin G/H synthase 1 (COX-1) DMJ2DE4 MA Inhibitor DMJ2DE4 RN Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90. DMJ2DE4 RU https://pubmed.ncbi.nlm.nih.gov/17434872 DMJ2DE4 DI DMJ2DE4 DMJ2DE4 DN 2-(2-(2,6-dimethylphenylamino)phenyl)acetic acid DMJ2DE4 TI TTVKILB DMJ2DE4 TN Prostaglandin G/H synthase 2 (COX-2) DMJ2DE4 MA Inhibitor DMJ2DE4 RN Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. J Biol Chem. 2007 Jun 1;282(22):16379-90. DMJ2DE4 RU https://pubmed.ncbi.nlm.nih.gov/17434872 DMJ2EI9 DI DMJ2EI9 DMJ2EI9 DN JWH-324 DMJ2EI9 TI TT6OEDT DMJ2EI9 TN Cannabinoid receptor 1 (CB1) DMJ2EI9 MA Inhibitor DMJ2EI9 RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DMJ2EI9 RU https://pubmed.ncbi.nlm.nih.gov/20621488 DMJ2EI9 DI DMJ2EI9 DMJ2EI9 DN JWH-324 DMJ2EI9 TI TTMSFAW DMJ2EI9 TN Cannabinoid receptor 2 (CB2) DMJ2EI9 MA Inhibitor DMJ2EI9 RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DMJ2EI9 RU https://pubmed.ncbi.nlm.nih.gov/20621488 DMJ2F8M DI DMJ2F8M DMJ2F8M DN H-Dmt-Tic-NH-CH2-Imid DMJ2F8M TI TTKWM86 DMJ2F8M TN Opioid receptor mu (MOP) DMJ2F8M MA Inhibitor DMJ2F8M RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMJ2F8M RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMJ2F8M DI DMJ2F8M DMJ2F8M DN H-Dmt-Tic-NH-CH2-Imid DMJ2F8M TI TT27RFC DMJ2F8M TN Opioid receptor delta (OPRD1) DMJ2F8M MA Inhibitor DMJ2F8M RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMJ2F8M RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMJ2FQA DI DMJ2FQA DMJ2FQA DN I-SAP DMJ2FQA TI TT2O84V DMJ2FQA TN Thromboxane A2 receptor (TBXA2R) DMJ2FQA MA Antagonist DMJ2FQA RN 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors. J Pharmacol Exp Ther. 1992 Aug;262(2):632-7. DMJ2FQA RU https://pubmed.ncbi.nlm.nih.gov/1386885 DMJ2GW0 DI DMJ2GW0 DMJ2GW0 DN 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine DMJ2GW0 TI TTAWNKZ DMJ2GW0 TN Norepinephrine transporter (NET) DMJ2GW0 MA Inhibitor DMJ2GW0 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJ2GW0 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJ2GW0 DI DMJ2GW0 DMJ2GW0 DN 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine DMJ2GW0 TI TT3ROYC DMJ2GW0 TN Serotonin transporter (SERT) DMJ2GW0 MA Inhibitor DMJ2GW0 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJ2GW0 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJ2GW0 DI DMJ2GW0 DMJ2GW0 DN 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine DMJ2GW0 TI TTSQIFT DMJ2GW0 TN 5-HT 1A receptor (HTR1A) DMJ2GW0 MA Inhibitor DMJ2GW0 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJ2GW0 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJ2GW0 DI DMJ2GW0 DMJ2GW0 DN 4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine DMJ2GW0 TI TTVBI8W DMJ2GW0 TN Dopamine transporter (DAT) DMJ2GW0 MA Inhibitor DMJ2GW0 RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJ2GW0 RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJ2NPY DI DMJ2NPY DMJ2NPY DN 2-(3-acetylphenyl)-6-morpholino-4H-pyran-4-one DMJ2NPY TI TTK3PY9 DMJ2NPY TN DNA-dependent protein kinase catalytic (PRKDC) DMJ2NPY MA Inhibitor DMJ2NPY RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMJ2NPY RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMJ2P0N DI DMJ2P0N DMJ2P0N DN E-6837 DMJ2P0N TI TTJS8PY DMJ2P0N TN 5-HT 6 receptor (HTR6) DMJ2P0N MA Inhibitor DMJ2P0N RN Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87. DMJ2P0N RU https://pubmed.ncbi.nlm.nih.gov/19159187 DMJ2PG1 DI DMJ2PG1 DMJ2PG1 DN VTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2 DMJ2PG1 TI TTVSFJW DMJ2PG1 TN Calcitonin gene-related peptide 1 (CALCA) DMJ2PG1 MA Inhibitor DMJ2PG1 RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMJ2PG1 RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMJ2SZ1 DI DMJ2SZ1 DMJ2SZ1 DN 3-chlorophenyl 4-butoxybenzylcarbamate DMJ2SZ1 TI TTDP1UC DMJ2SZ1 TN Fatty acid amide hydrolase (FAAH) DMJ2SZ1 MA Inhibitor DMJ2SZ1 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMJ2SZ1 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMJ2T7P DI DMJ2T7P DMJ2T7P DN 13-Acetylphorbol DMJ2T7P TI TT9WJ8U DMJ2T7P TN Protein kinase C delta (PRKCD) DMJ2T7P MA Inhibitor DMJ2T7P RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJ2T7P RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJ2WD5 DI DMJ2WD5 DMJ2WD5 DN (1S)-MENTHYL HEXYL PHOSPHONATE GROUP DMJ2WD5 TI TTEB0GD DMJ2WD5 TN Cholinesterase (BCHE) DMJ2WD5 MA Inhibitor DMJ2WD5 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJ2WD5 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJ2X64 DI DMJ2X64 DMJ2X64 DN KD-7332 DMJ2X64 TI TTF10I9 DMJ2X64 TN Nitric-oxide synthase inducible (NOS2) DMJ2X64 MA Inhibitor DMJ2X64 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1250). DMJ2X64 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250 DMJ2Z9G DI DMJ2Z9G DMJ2Z9G DN 2-Amino-1-(4-methylthiophenyl)propane DMJ2Z9G TI TTAWNKZ DMJ2Z9G TN Norepinephrine transporter (NET) DMJ2Z9G MA Inhibitor DMJ2Z9G RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMJ2Z9G RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMJ2Z9G DI DMJ2Z9G DMJ2Z9G DN 2-Amino-1-(4-methylthiophenyl)propane DMJ2Z9G TI TT3ROYC DMJ2Z9G TN Serotonin transporter (SERT) DMJ2Z9G MA Inhibitor DMJ2Z9G RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMJ2Z9G RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMJ2Z9G DI DMJ2Z9G DMJ2Z9G DN 2-Amino-1-(4-methylthiophenyl)propane DMJ2Z9G TI TTVBI8W DMJ2Z9G TN Dopamine transporter (DAT) DMJ2Z9G MA Inhibitor DMJ2Z9G RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMJ2Z9G RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMJ2Z9G DI DMJ2Z9G DMJ2Z9G DN 2-Amino-1-(4-methylthiophenyl)propane DMJ2Z9G TI TT3WG5C DMJ2Z9G TN Monoamine oxidase type A (MAO-A) DMJ2Z9G MA Inhibitor DMJ2Z9G RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMJ2Z9G RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMJ38LE DI DMJ38LE DMJ38LE DN 2-(2-chlorophenylamino)-5-methylthiazol-4(5H)-one DMJ38LE TI TTN7BL9 DMJ38LE TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMJ38LE MA Inhibitor DMJ38LE RN The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6056-61. DMJ38LE RU https://pubmed.ncbi.nlm.nih.gov/17919905 DMJ38YV DI DMJ38YV DMJ38YV DN QEDIIRNIARHLAQVGDSMDR DMJ38YV TI TTL53M6 DMJ38YV TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMJ38YV MA Inhibitor DMJ38YV RN Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. DMJ38YV RU https://pubmed.ncbi.nlm.nih.gov/17034116 DMJ38YV DI DMJ38YV DMJ38YV DN QEDIIRNIARHLAQVGDSMDR DMJ38YV TI TTJGNVC DMJ38YV TN Apoptosis regulator Bcl-2 (BCL-2) DMJ38YV MA Inhibitor DMJ38YV RN Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. DMJ38YV RU https://pubmed.ncbi.nlm.nih.gov/17034116 DMJ38YV DI DMJ38YV DMJ38YV DN QEDIIRNIARHLAQVGDSMDR DMJ38YV TI TTRE6AX DMJ38YV TN Bcl-x messenger RNA (BCL2L1 mRNA) DMJ38YV MA Inhibitor DMJ38YV RN Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006 Oct 19;49(21):6139-42. DMJ38YV RU https://pubmed.ncbi.nlm.nih.gov/17034116 DMJ3ATL DI DMJ3ATL DMJ3ATL DN 2-HEPTYL-4-HYDROXY QUINOLINE N-OXIDE DMJ3ATL TI TTHDSE2 DMJ3ATL TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMJ3ATL MA Inhibitor DMJ3ATL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJ3ATL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJ3C20 DI DMJ3C20 DMJ3C20 DN Ac-Ala-Pro-Val-(2-benzoxazole) DMJ3C20 TI TTPLTSQ DMJ3C20 TN Neutrophil elastase (NE) DMJ3C20 MA Inhibitor DMJ3C20 RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMJ3C20 RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMJ3DOI DI DMJ3DOI DMJ3DOI DN PD-171729 DMJ3DOI TI TT7EFHR DMJ3DOI TN Corticotropin-releasing factor receptor 1 (CRHR1) DMJ3DOI MA Inhibitor DMJ3DOI RN Pyrazolo[1,5-a]pyrimidine CRF-1 receptor antagonists. Bioorg Med Chem Lett. 1998 Aug 18;8(16):2067-70. DMJ3DOI RU https://pubmed.ncbi.nlm.nih.gov/9873487 DMJ3HG9 DI DMJ3HG9 DMJ3HG9 DN Cis-2,6-dimethyl-1-methyl sulfonyl piperidine DMJ3HG9 TI TT1RS9F DMJ3HG9 TN Acetylcholinesterase (AChE) DMJ3HG9 MA Inhibitor DMJ3HG9 RN Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylc... Eur J Med Chem. 2009 Oct;44(10):4057-62. DMJ3HG9 RU https://pubmed.ncbi.nlm.nih.gov/19493592 DMJ3WNP DI DMJ3WNP DMJ3WNP DN 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol DMJ3WNP TI TTSZLWK DMJ3WNP TN Aromatase (CYP19A1) DMJ3WNP MA Inhibitor DMJ3WNP RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMJ3WNP RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMJ3WNP DI DMJ3WNP DMJ3WNP DN 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol DMJ3WNP TI TTRA5BZ DMJ3WNP TN Steroid 17-alpha-monooxygenase (S17AH) DMJ3WNP MA Inhibitor DMJ3WNP RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMJ3WNP RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMJ3WNP DI DMJ3WNP DMJ3WNP DN 3-Fluoro-4'-(pyridin-4-ylmethyl)biphenyl-4-ol DMJ3WNP TI TTIQUX7 DMJ3WNP TN Steroid 11-beta-hydroxylase (CYP11B1) DMJ3WNP MA Inhibitor DMJ3WNP RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMJ3WNP RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMJ4126 DI DMJ4126 DMJ4126 DN PMID2153213C2c DMJ4126 TI TTPADOQ DMJ4126 TN HMG-CoA reductase (HMGCR) DMJ4126 MA Inhibitor DMJ4126 RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DMJ4126 RU https://pubmed.ncbi.nlm.nih.gov/2153213 DMJ46CB DI DMJ46CB DMJ46CB DN Buthionine sulfoximine DMJ46CB TI TTNFESW DMJ46CB TN Glutamate--cysteine ligase modifier (GCLM) DMJ46CB MA Inhibitor DMJ46CB RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DMJ46CB RU https://pubmed.ncbi.nlm.nih.gov/17339102 DMJ47DM DI DMJ47DM DMJ47DM DN GRN-529 DMJ47DM TI TTHS256 DMJ47DM TN Metabotropic glutamate receptor 5 (mGluR5) DMJ47DM MA Modulator DMJ47DM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). DMJ47DM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 DMJ4ABD DI DMJ4ABD DMJ4ABD DN (2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime DMJ4ABD TI TTCEJ4F DMJ4ABD TN G1/S-specific cyclin-E1 (CCNE1) DMJ4ABD MA Inhibitor DMJ4ABD RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMJ4ABD RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMJ4ABD DI DMJ4ABD DMJ4ABD DN (2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime DMJ4ABD TI TT7HF4W DMJ4ABD TN Cyclin-dependent kinase 2 (CDK2) DMJ4ABD MA Inhibitor DMJ4ABD RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMJ4ABD RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMJ4D1P DI DMJ4D1P DMJ4D1P DN Micrococcin DMJ4D1P TI TTLFGBV DMJ4D1P TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DMJ4D1P MA Binder DMJ4D1P RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DMJ4D1P RU https://pubmed.ncbi.nlm.nih.gov/11768328 DMJ4F3Q DI DMJ4F3Q DMJ4F3Q DN Folate gamma-hydroxamic acid DMJ4F3Q TI TTMTWOS DMJ4F3Q TN Matrix metalloproteinase-7 (MMP-7) DMJ4F3Q MA Inhibitor DMJ4F3Q RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMJ4F3Q RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMJ4F3Q DI DMJ4F3Q DMJ4F3Q DN Folate gamma-hydroxamic acid DMJ4F3Q TI TTLM12X DMJ4F3Q TN Matrix metalloproteinase-2 (MMP-2) DMJ4F3Q MA Inhibitor DMJ4F3Q RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMJ4F3Q RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMJ4F3Q DI DMJ4F3Q DMJ4F3Q DN Folate gamma-hydroxamic acid DMJ4F3Q TI TT6X50U DMJ4F3Q TN Matrix metalloproteinase-9 (MMP-9) DMJ4F3Q MA Inhibitor DMJ4F3Q RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMJ4F3Q RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMJ4G27 DI DMJ4G27 DMJ4G27 DN 7-methyl-2-phenylpyrido[2,3-d]pyrimidine DMJ4G27 TI TTHS256 DMJ4G27 TN Metabotropic glutamate receptor 5 (mGluR5) DMJ4G27 MA Inhibitor DMJ4G27 RN Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9. DMJ4G27 RU https://pubmed.ncbi.nlm.nih.gov/17723296 DMJ4GO9 DI DMJ4GO9 DMJ4GO9 DN NF023 DMJ4GO9 TI TTJW7B3 DMJ4GO9 TN P2X purinoceptor 1 (P2RX1) DMJ4GO9 MA Antagonist DMJ4GO9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478). DMJ4GO9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478 DMJ4H9F DI DMJ4H9F DMJ4H9F DN 2-Amino-6-benzenesulfonyl-benzonitrile DMJ4H9F TI TT84ETX DMJ4H9F TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJ4H9F MA Inhibitor DMJ4H9F RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMJ4H9F RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMJ4I98 DI DMJ4I98 DMJ4I98 DN Trimethyl-(4-oxo-pentyl)-ammonium iodide DMJ4I98 TI TT1RS9F DMJ4I98 TN Acetylcholinesterase (AChE) DMJ4I98 MA Inhibitor DMJ4I98 RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMJ4I98 RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMJ4ME7 DI DMJ4ME7 DMJ4ME7 DN Huprine-Tacrine Heterodimer DMJ4ME7 TI TTEB0GD DMJ4ME7 TN Cholinesterase (BCHE) DMJ4ME7 MA Inhibitor DMJ4ME7 RN Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem. 2005 Mar 24;48(6):1701-4. DMJ4ME7 RU https://pubmed.ncbi.nlm.nih.gov/15771413 DMJ4ME7 DI DMJ4ME7 DMJ4ME7 DN Huprine-Tacrine Heterodimer DMJ4ME7 TI TT1RS9F DMJ4ME7 TN Acetylcholinesterase (AChE) DMJ4ME7 MA Inhibitor DMJ4ME7 RN Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors. J Med Chem. 2005 Mar 24;48(6):1701-4. DMJ4ME7 RU https://pubmed.ncbi.nlm.nih.gov/15771413 DMJ4SBM DI DMJ4SBM DMJ4SBM DN N-acetylserotonin DMJ4SBM TI TT0WAIE DMJ4SBM TN Melatonin receptor type 1A (MTNR1A) DMJ4SBM MA Inhibitor DMJ4SBM RN Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. J Med Chem. 1996 Aug 2;39(16):3089-95. DMJ4SBM RU https://pubmed.ncbi.nlm.nih.gov/8759629 DMJ4SDM DI DMJ4SDM DMJ4SDM DN 3-chlorotyrosine DMJ4SDM TI TTUHP71 DMJ4SDM TN Tyrosine 3-monooxygenase (TH) DMJ4SDM MA Inhibitor DMJ4SDM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243). DMJ4SDM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243 DMJ4SIA DI DMJ4SIA DMJ4SIA DN P'-geranyl 3,5,7-trihydroxy-3-methylheptanate 7-diphosphate DMJ4SIA TI TTE5J6X DMJ4SIA TN Diphosphomevalonate decarboxylase (MVD) DMJ4SIA MA Inhibitor DMJ4SIA RN Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6. DMJ4SIA RU https://pubmed.ncbi.nlm.nih.gov/16524256 DMJ4Z7W DI DMJ4Z7W DMJ4Z7W DN Styrylboronic acid DMJ4Z7W TI TTHQPL7 DMJ4Z7W TN Carbonic anhydrase I (CA-I) DMJ4Z7W MA Inhibitor DMJ4Z7W RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMJ4Z7W RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMJ504Y DI DMJ504Y DMJ504Y DN PMID2231594C3u DMJ504Y TI TTPADOQ DMJ504Y TN HMG-CoA reductase (HMGCR) DMJ504Y MA Inhibitor DMJ504Y RN Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6. DMJ504Y RU https://pubmed.ncbi.nlm.nih.gov/2231594 DMJ56XU DI DMJ56XU DMJ56XU DN ISIS 133726 DMJ56XU TI TTWRN6M DMJ56XU TN CRP messenger RNA (CRP mRNA) DMJ56XU RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMJ56XU RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMJ576C DI DMJ576C DMJ576C DN SC-52491 DMJ576C TI TT07C3Y DMJ576C TN 5-HT 4 receptor (HTR4) DMJ576C MA Modulator DMJ576C RN Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12. DMJ576C RU https://www.ncbi.nlm.nih.gov/pubmed/15482914 DMJ576C DI DMJ576C DMJ576C DN SC-52491 DMJ576C TI TTNXLKE DMJ576C TN 5-HT 3 receptor (5HT3R) DMJ576C MA Modulator DMJ576C RN Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5509-12. DMJ576C RU https://www.ncbi.nlm.nih.gov/pubmed/15482914 DMJ5BDQ DI DMJ5BDQ DMJ5BDQ DN [3H]histidine DMJ5BDQ TI TTC8YPT DMJ5BDQ TN Solute carrier family 38 member 5 (SLC38A5) DMJ5BDQ MA Modulator DMJ5BDQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1173). DMJ5BDQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1173 DMJ5BDQ DI DMJ5BDQ DMJ5BDQ DN [3H]histidine DMJ5BDQ TI TTAYPWS DMJ5BDQ TN Solute carrier family 15 member 3 (SLC15A3) DMJ5BDQ MA Modulator DMJ5BDQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 986). DMJ5BDQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=986 DMJ5BDQ DI DMJ5BDQ DMJ5BDQ DN [3H]histidine DMJ5BDQ TI TTG2XRE DMJ5BDQ TN Solute carrier family 15 member 4 (SLC15A4) DMJ5BDQ MA Modulator DMJ5BDQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 987). DMJ5BDQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=987 DMJ5GY7 DI DMJ5GY7 DMJ5GY7 DN PHENSTATIN DMJ5GY7 TI TTYFKSZ DMJ5GY7 TN Tubulin beta (TUBB) DMJ5GY7 MA Inhibitor DMJ5GY7 RN Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 2002 Jun 6;45(12):2534-42. DMJ5GY7 RU https://pubmed.ncbi.nlm.nih.gov/12036362 DMJ5GY7 DI DMJ5GY7 DMJ5GY7 DN PHENSTATIN DMJ5GY7 TI TTML2WA DMJ5GY7 TN Tubulin (TUB) DMJ5GY7 MA Inhibitor DMJ5GY7 RN Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate. J Med Chem. 2002 Jun 6;45(12):2534-42. DMJ5GY7 RU https://pubmed.ncbi.nlm.nih.gov/12036362 DMJ5TAU DI DMJ5TAU DMJ5TAU DN Paeoniflorin DMJ5TAU TI TTK25J1 DMJ5TAU TN Adenosine A1 receptor (ADORA1) DMJ5TAU MA Modulator DMJ5TAU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18). DMJ5TAU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18 DMJ5U8C DI DMJ5U8C DMJ5U8C DN Aconitate Ion DMJ5U8C TI TTMTF2P DMJ5U8C TN Citrate hydro-lyase (ACO2) DMJ5U8C MA Inhibitor DMJ5U8C RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJ5U8C RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJ610E DI DMJ610E DMJ610E DN 4-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide DMJ610E TI TTHS256 DMJ610E TN Metabotropic glutamate receptor 5 (mGluR5) DMJ610E MA Inhibitor DMJ610E RN Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44. DMJ610E RU https://pubmed.ncbi.nlm.nih.gov/16722652 DMJ6FP7 DI DMJ6FP7 DMJ6FP7 DN N-(3-aminophenyl)benzenesulfonamide DMJ6FP7 TI TTJS8PY DMJ6FP7 TN 5-HT 6 receptor (HTR6) DMJ6FP7 MA Inhibitor DMJ6FP7 RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMJ6FP7 RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMJ6IMZ DI DMJ6IMZ DMJ6IMZ DN A-62824 DMJ6IMZ TI TTFK8YB DMJ6IMZ TN Bacterial DNA topoisomerase 4A (Bact parC) DMJ6IMZ MA Inhibitor DMJ6IMZ RN Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent anti... Bioorg Med Chem Lett. 2006 Mar 1;16(5):1272-6. DMJ6IMZ RU https://pubmed.ncbi.nlm.nih.gov/16337791 DMJ6L9U DI DMJ6L9U DMJ6L9U DN AMG7703 DMJ6L9U TI TT0FYAN DMJ6L9U TN Free fatty acid receptor 2 (FFAR2) DMJ6L9U MA Modulator (allosteric modulator) DMJ6L9U RN Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol. 2011 Jul;80(1):163-73. DMJ6L9U RU https://pubmed.ncbi.nlm.nih.gov/21498659 DMJ6LI8 DI DMJ6LI8 DMJ6LI8 DN N-(2,3-dihydro-1H-inden-2-yl)quinazolin-4-amine DMJ6LI8 TI TTVBPDM DMJ6LI8 TN Metabotropic glutamate receptor 1 (mGluR1) DMJ6LI8 MA Inhibitor DMJ6LI8 RN In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. DMJ6LI8 RU https://pubmed.ncbi.nlm.nih.gov/19289283 DMJ6MPO DI DMJ6MPO DMJ6MPO DN (+/-)-2-Methyl-1-(1-phenylethyl)-1H-imidazole DMJ6MPO TI TTZUFI5 DMJ6MPO TN Nitric-oxide synthase brain (NOS1) DMJ6MPO MA Inhibitor DMJ6MPO RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DMJ6MPO RU https://pubmed.ncbi.nlm.nih.gov/20933416 DMJ6MUE DI DMJ6MUE DMJ6MUE DN ABT-116 DMJ6MUE TI TTMI6F5 DMJ6MUE TN Transient receptor potential cation channel V1 (TRPV1) DMJ6MUE MA Antagonist DMJ6MUE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DMJ6MUE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DMJ6N1X DI DMJ6N1X DMJ6N1X DN H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH DMJ6N1X TI TTZPO1L DMJ6N1X TN Substance-P receptor (TACR1) DMJ6N1X MA Inhibitor DMJ6N1X RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMJ6N1X RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMJ6O43 DI DMJ6O43 DMJ6O43 DN 3-((1H-imidazol-4-yl)methyl)pyridine DMJ6O43 TI TT9JNIC DMJ6O43 TN Histamine H3 receptor (H3R) DMJ6O43 MA Inhibitor DMJ6O43 RN Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem. 2010 Sep 9;53(17):6445-56. DMJ6O43 RU https://pubmed.ncbi.nlm.nih.gov/20690643 DMJ6PB8 DI DMJ6PB8 DMJ6PB8 DN Ethylgallate DMJ6PB8 TI TTE14XG DMJ6PB8 TN Squalene monooxygenase (SQLE) DMJ6PB8 MA Inhibitor DMJ6PB8 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMJ6PB8 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMJ6RZI DI DMJ6RZI DMJ6RZI DN RPR-108518A DMJ6RZI TI TT860QF DMJ6RZI TN LCK tyrosine protein kinase (LCK) DMJ6RZI MA Inhibitor DMJ6RZI RN he preparation and sar of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56lck and EGF-R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):417-420 (1997). DMJ6RZI RU http://www.sciencedirect.com/science/article/pii/S0960894X97000346 DMJ6SYI DI DMJ6SYI DMJ6SYI DN C-(6-Methoxy-naphthalen-1-yl)-methylamine DMJ6SYI TI TTWM4TY DMJ6SYI TN Adrenergic receptor alpha-2B (ADRA2B) DMJ6SYI MA Inhibitor DMJ6SYI RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMJ6SYI RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMJ6SYI DI DMJ6SYI DMJ6SYI DN C-(6-Methoxy-naphthalen-1-yl)-methylamine DMJ6SYI TI TTWG9A4 DMJ6SYI TN Adrenergic receptor alpha-2A (ADRA2A) DMJ6SYI MA Inhibitor DMJ6SYI RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMJ6SYI RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMJ6SYI DI DMJ6SYI DMJ6SYI DN C-(6-Methoxy-naphthalen-1-yl)-methylamine DMJ6SYI TI TT2NUT5 DMJ6SYI TN Adrenergic receptor alpha-2C (ADRA2C) DMJ6SYI MA Inhibitor DMJ6SYI RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMJ6SYI RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMJ6U4H DI DMJ6U4H DMJ6U4H DN N-(Ethylphosphoryl)-L-isoleucyl-L-Trp-NHCH3 DMJ6U4H TI TTMX39J DMJ6U4H TN Matrix metalloproteinase-1 (MMP-1) DMJ6U4H MA Inhibitor DMJ6U4H RN Phosphoramidate peptide inhibitors of human skin fibroblast collagenase. J Med Chem. 1990 Jan;33(1):263-73. DMJ6U4H RU https://pubmed.ncbi.nlm.nih.gov/2153207 DMJ6WNK DI DMJ6WNK DMJ6WNK DN Spathodic acid DMJ6WNK TI TTELIN2 DMJ6WNK TN PTPN1 messenger RNA (PTPN1 mRNA) DMJ6WNK MA Inhibitor DMJ6WNK RN Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8. DMJ6WNK RU https://pubmed.ncbi.nlm.nih.gov/18798681 DMJ723D DI DMJ723D DMJ723D DN 1-Phenyl-3-(4-pyridin-2-yl-thiazol-2-yl)-urea DMJ723D TI TTM2AOE DMJ723D TN Adenosine A2a receptor (ADORA2A) DMJ723D MA Inhibitor DMJ723D RN Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. J Med Chem. 2001 Mar 1;44(5):749-62. DMJ723D RU https://pubmed.ncbi.nlm.nih.gov/11262085 DMJ73T6 DI DMJ73T6 DMJ73T6 DN N-(4-Ethylphenyl)benzo[d]oxazol-2-amine DMJ73T6 TI TT2J34L DMJ73T6 TN Arachidonate 5-lipoxygenase (5-LOX) DMJ73T6 MA Inhibitor DMJ73T6 RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DMJ73T6 RU https://pubmed.ncbi.nlm.nih.gov/20870413 DMJ7BOL DI DMJ7BOL DMJ7BOL DN ISIS 114532 DMJ7BOL TI TTY3BRA DMJ7BOL TN ZNF217 messenger RNA (ZNF217 mRNA) DMJ7BOL RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DMJ7BOL RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DMJ7EDV DI DMJ7EDV DMJ7EDV DN ISIS 109524 DMJ7EDV TI TT3K9S2 DMJ7EDV TN RANK messenger RNA (RANK mRNA) DMJ7EDV RN US patent application no. 6,171,860, Antisense inhibition of rank expression. DMJ7EDV RU http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true DMJ7G0E DI DMJ7G0E DMJ7G0E DN 4-hydroxyphenethyl 3,4,5-trihydroxybenzoate DMJ7G0E TI TTULVH8 DMJ7G0E TN Tyrosinase (TYR) DMJ7G0E MA Inhibitor DMJ7G0E RN Synthetic tyrosyl gallate derivatives as potent melanin formation inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5462-4. DMJ7G0E RU https://pubmed.ncbi.nlm.nih.gov/17693086 DMJ7I4U DI DMJ7I4U DMJ7I4U DN Sodium phenylaminomethanesulfonate DMJ7I4U TI TT2LVK8 DMJ7I4U TN Carbonic anhydrase IX (CA-IX) DMJ7I4U MA Inhibitor DMJ7I4U RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMJ7I4U RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMJ7I4U DI DMJ7I4U DMJ7I4U DN Sodium phenylaminomethanesulfonate DMJ7I4U TI TTSYM0R DMJ7I4U TN Carbonic anhydrase XII (CA-XII) DMJ7I4U MA Inhibitor DMJ7I4U RN Carbonic anhydrase inhibitors. Diazenylbenzenesulfonamides are potent and selective inhibitors of the tumor-associated isozymes IX and XII over the... Bioorg Med Chem. 2009 Oct 15;17(20):7093-9. DMJ7I4U RU https://pubmed.ncbi.nlm.nih.gov/19773173 DMJ7Y3H DI DMJ7Y3H DMJ7Y3H DN 3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol DMJ7Y3H TI TTMSFAW DMJ7Y3H TN Cannabinoid receptor 2 (CB2) DMJ7Y3H MA Inhibitor DMJ7Y3H RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMJ7Y3H RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMJ7Y3H DI DMJ7Y3H DMJ7Y3H DN 3'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol DMJ7Y3H TI TT6OEDT DMJ7Y3H TN Cannabinoid receptor 1 (CB1) DMJ7Y3H MA Inhibitor DMJ7Y3H RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMJ7Y3H RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMJ81IL DI DMJ81IL DMJ81IL DN 4-(6-phenyl-2,4'-bipyridin-4-yl)phenol DMJ81IL TI TTGTQHC DMJ81IL TN DNA topoisomerase I (TOP1) DMJ81IL MA Inhibitor DMJ81IL RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMJ81IL RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMJ81M3 DI DMJ81M3 DMJ81M3 DN (4-benzylpiperidin-1-yl)(p-tolyl)methanone DMJ81M3 TI TTVTX4N DMJ81M3 TN Bacterial Fatty acid synthetase I (Bact inhA) DMJ81M3 MA Inhibitor DMJ81M3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJ81M3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJ82TO DI DMJ82TO DMJ82TO DN 8R-hydroxylobelane DMJ82TO TI TTVBI8W DMJ82TO TN Dopamine transporter (DAT) DMJ82TO MA Inhibitor DMJ82TO RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMJ82TO RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMJ82TO DI DMJ82TO DMJ82TO DN 8R-hydroxylobelane DMJ82TO TI TT3ROYC DMJ82TO TN Serotonin transporter (SERT) DMJ82TO MA Inhibitor DMJ82TO RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMJ82TO RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMJ83LK DI DMJ83LK DMJ83LK DN A-674563 DMJ83LK TI TTWTSCV DMJ83LK TN RAC-alpha serine/threonine-protein kinase (AKT1) DMJ83LK MA Inhibitor DMJ83LK RN Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51. DMJ83LK RU https://pubmed.ncbi.nlm.nih.gov/22037378 DMJ86OS DI DMJ86OS DMJ86OS DN 4-(7-Methyl-oct-3-ynyl)-1H-imidazole DMJ86OS TI TT9JNIC DMJ86OS TN Histamine H3 receptor (H3R) DMJ86OS MA Inhibitor DMJ86OS RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DMJ86OS RU https://pubmed.ncbi.nlm.nih.gov/9871722 DMJ86U4 DI DMJ86U4 DMJ86U4 DN ISIS 111086 DMJ86U4 TI TTOM97J DMJ86U4 TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DMJ86U4 RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DMJ86U4 RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DMJ8A4I DI DMJ8A4I DMJ8A4I DN PMID1656041C11dd DMJ8A4I TI TTPADOQ DMJ8A4I TN HMG-CoA reductase (HMGCR) DMJ8A4I MA Inhibitor DMJ8A4I RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83. DMJ8A4I RU https://pubmed.ncbi.nlm.nih.gov/1656041 DMJ8F60 DI DMJ8F60 DMJ8F60 DN 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol DMJ8F60 TI TTQW87Y DMJ8F60 TN Opioid receptor kappa (OPRK1) DMJ8F60 MA Inhibitor DMJ8F60 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMJ8F60 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMJ8F60 DI DMJ8F60 DMJ8F60 DN 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol DMJ8F60 TI TTNT7K8 DMJ8F60 TN Nociceptin receptor (OPRL1) DMJ8F60 MA Inhibitor DMJ8F60 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMJ8F60 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMJ8F60 DI DMJ8F60 DMJ8F60 DN 1-benzhydryl-4-(pyridin-2-yl)piperidin-4-ol DMJ8F60 TI TTKWM86 DMJ8F60 TN Opioid receptor mu (MOP) DMJ8F60 MA Inhibitor DMJ8F60 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMJ8F60 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMJ8TP3 DI DMJ8TP3 DMJ8TP3 DN Protoporphyrin Ix Containing Co DMJ8TP3 TI TT8NGED DMJ8TP3 TN Prostaglandin G/H synthase 1 (COX-1) DMJ8TP3 MA Inhibitor DMJ8TP3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJ8TP3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJ8W6F DI DMJ8W6F DMJ8W6F DN N-[2-(Indol-3-yl)ethyl]-S-benzyl-dithiocarbamate DMJ8W6F TI TTZJYKH DMJ8W6F TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJ8W6F MA Inhibitor DMJ8W6F RN Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2006 Jan 26;49(2):684-92. DMJ8W6F RU https://pubmed.ncbi.nlm.nih.gov/16420054 DMJ8ZS6 DI DMJ8ZS6 DMJ8ZS6 DN 1-Adamantan-1-yl-3-(2-hydroxy-phenyl)-urea DMJ8ZS6 TI TT7WVHI DMJ8ZS6 TN Soluble epoxide hydrolase (EPHX2) DMJ8ZS6 MA Inhibitor DMJ8ZS6 RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMJ8ZS6 RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMJ91Y7 DI DMJ91Y7 DMJ91Y7 DN NSC-23180 DMJ91Y7 TI TT1RS9F DMJ91Y7 TN Acetylcholinesterase (AChE) DMJ91Y7 MA Inhibitor DMJ91Y7 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMJ91Y7 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMJ91Y7 DI DMJ91Y7 DMJ91Y7 DN NSC-23180 DMJ91Y7 TI TTMF541 DMJ91Y7 TN Liver carboxylesterase (CES1) DMJ91Y7 MA Inhibitor DMJ91Y7 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMJ91Y7 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMJ91Y7 DI DMJ91Y7 DMJ91Y7 DN NSC-23180 DMJ91Y7 TI TTEB0GD DMJ91Y7 TN Cholinesterase (BCHE) DMJ91Y7 MA Inhibitor DMJ91Y7 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMJ91Y7 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMJ92W0 DI DMJ92W0 DMJ92W0 DN 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine DMJ92W0 TI TTAMQ62 DMJ92W0 TN Cyclin A2 (CCNA2) DMJ92W0 MA Inhibitor DMJ92W0 RN Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93. DMJ92W0 RU https://pubmed.ncbi.nlm.nih.gov/12139449 DMJ92W0 DI DMJ92W0 DMJ92W0 DN 6-(3-Amino-benzyloxy)-9H-purin-2-ylamine DMJ92W0 TI TT7HF4W DMJ92W0 TN Cyclin-dependent kinase 2 (CDK2) DMJ92W0 MA Inhibitor DMJ92W0 RN Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93. DMJ92W0 RU https://pubmed.ncbi.nlm.nih.gov/12139449 DMJ9CNA DI DMJ9CNA DMJ9CNA DN 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine DMJ9CNA TI TTVBI8W DMJ9CNA TN Dopamine transporter (DAT) DMJ9CNA MA Inhibitor DMJ9CNA RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJ9CNA RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJ9CNA DI DMJ9CNA DMJ9CNA DN 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine DMJ9CNA TI TT3ROYC DMJ9CNA TN Serotonin transporter (SERT) DMJ9CNA MA Inhibitor DMJ9CNA RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJ9CNA RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJ9CNA DI DMJ9CNA DMJ9CNA DN 4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine DMJ9CNA TI TTAWNKZ DMJ9CNA TN Norepinephrine transporter (NET) DMJ9CNA MA Inhibitor DMJ9CNA RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJ9CNA RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJ9DN3 DI DMJ9DN3 DMJ9DN3 DN G3139 + Dexamethasone DMJ9DN3 TI TTFOUV4 DMJ9DN3 TN BCL-2 messenger RNA (BCL2 mRNA) DMJ9DN3 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMJ9DN3 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMJ9KNU DI DMJ9KNU DMJ9KNU DN Hyacinthacine B3 DMJ9KNU TI TTA0OSE DMJ9KNU TN Lactase-phlorizin hydrolase (LCT) DMJ9KNU MA Inhibitor DMJ9KNU RN New polyhydroxylated pyrrolidine, piperidine, and pyrrolizidine alkaloids from Scilla sibirica. J Nat Prod. 2002 Dec;65(12):1875-81. DMJ9KNU RU https://pubmed.ncbi.nlm.nih.gov/12502331 DMJ9LRE DI DMJ9LRE DMJ9LRE DN 3-(1-Pyridin-2-yl-1H-pyrrol-3-yl)-benzonitrile DMJ9LRE TI TTHS256 DMJ9LRE TN Metabotropic glutamate receptor 5 (mGluR5) DMJ9LRE MA Inhibitor DMJ9LRE RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMJ9LRE RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMJ9ML8 DI DMJ9ML8 DMJ9ML8 DN PSB-6426 DMJ9ML8 TI TTYM8DJ DMJ9ML8 TN Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) DMJ9ML8 MA Inhibitor DMJ9ML8 RN Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. J Med Chem. 2008 Aug 14;51(15):4518-28. DMJ9ML8 RU https://pubmed.ncbi.nlm.nih.gov/18630897 DMJ9Z31 DI DMJ9Z31 DMJ9Z31 DN CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-amide DMJ9Z31 TI TTLWS2O DMJ9Z31 TN Calcitonin receptor (CALCR) DMJ9Z31 MA Inhibitor DMJ9Z31 RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMJ9Z31 RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTQICM2 DMJA4UE TN ADAM metallopeptidase 33 (ADAM33) DMJA4UE MA Inhibitor DMJA4UE RN Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/18790648 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TT6AZXG DMJA4UE TN TNF alpha converting enzyme (ADAM17) DMJA4UE MA Inhibitor DMJA4UE RN Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge. Bioorg Med Chem. 2008 Oct 1;16(19):8781-94. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/18790648 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTYRF5E DMJA4UE TN Matrix metalloproteinase-21 (MMP-21) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTJ4QE7 DMJA4UE TN Matrix metalloproteinase-14 (MMP-14) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TT6X50U DMJA4UE TN Matrix metalloproteinase-9 (MMP-9) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTLM12X DMJA4UE TN Matrix metalloproteinase-2 (MMP-2) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTUZ2L5 DMJA4UE TN Matrix metalloproteinase-3 (MMP-3) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTGA1IV DMJA4UE TN Matrix metalloproteinase-8 (MMP-8) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTF8CQI DMJA4UE TN Tumor necrosis factor (TNF) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTMTWOS DMJA4UE TN Matrix metalloproteinase-7 (MMP-7) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA4UE DI DMJA4UE DMJA4UE DN IK-862 DMJA4UE TI TTHY57M DMJA4UE TN Matrix metalloproteinase-13 (MMP-13) DMJA4UE MA Inhibitor DMJA4UE RN Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structu... J Med Chem. 2002 Nov 7;45(23):4954-7. DMJA4UE RU https://pubmed.ncbi.nlm.nih.gov/12408705 DMJA5Y4 DI DMJA5Y4 DMJA5Y4 DN 2-(4-benzoylpiperazin-1-yl)thiazole-5-carboxamide DMJA5Y4 TI TT6RIOV DMJA5Y4 TN Acyl-CoA desaturase (SCD) DMJA5Y4 MA Inhibitor DMJA5Y4 RN Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5214-7. DMJA5Y4 RU https://pubmed.ncbi.nlm.nih.gov/19632834 DMJA8I4 DI DMJA8I4 DMJA8I4 DN CN-2097 DMJA8I4 TI TTN9D8E DMJA8I4 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMJA8I4 MA Modulator DMJA8I4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMJA8I4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMJAEMT DI DMJAEMT DMJAEMT DN JASPAQUINOL DMJAEMT TI TTSJ6Q4 DMJAEMT TN LOX-5 messenger RNA (ALOX5 mRNA) DMJAEMT MA Inhibitor DMJAEMT RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMJAEMT RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMJAEMT DI DMJAEMT DMJAEMT DN JASPAQUINOL DMJAEMT TI TTN9T81 DMJAEMT TN Arachidonate 15-lipoxygenase (15-LOX) DMJAEMT MA Inhibitor DMJAEMT RN Using enzyme assays to evaluate the structure and bioactivity of sponge-derived meroterpenes. J Nat Prod. 2009 Oct;72(10):1857-63. DMJAEMT RU https://pubmed.ncbi.nlm.nih.gov/19848434 DMJAEZ8 DI DMJAEZ8 DMJAEZ8 DN 2-(7-phenylheptanoyl)oxazole-4-carbaldehyde DMJAEZ8 TI TTDP1UC DMJAEZ8 TN Fatty acid amide hydrolase (FAAH) DMJAEZ8 MA Inhibitor DMJAEZ8 RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMJAEZ8 RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMJAG7M DI DMJAG7M DMJAG7M DN 5-(biphenyl-4-yl)-3-methoxypentanoic acid DMJAG7M TI TTXZ0KQ DMJAG7M TN Matrix metalloproteinase-12 (MMP-12) DMJAG7M MA Inhibitor DMJAG7M RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMJAG7M RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMJAK0E DI DMJAK0E DMJAK0E DN 1,2-di(10H-phenothiazin-10-yl)ethane-1,2-dione DMJAK0E TI TTEB0GD DMJAK0E TN Cholinesterase (BCHE) DMJAK0E MA Inhibitor DMJAK0E RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMJAK0E RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMJAN52 DI DMJAN52 DMJAN52 DN 2-hydroxy capric acid DMJAN52 TI TTG0MQD DMJAN52 TN Inflammation-related GPCR EX33 (GPR84) DMJAN52 MA Agonist DMJAN52 RN Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. DMJAN52 RU https://pubmed.ncbi.nlm.nih.gov/23449982 DMJAO6Z DI DMJAO6Z DMJAO6Z DN NSC-12999 DMJAO6Z TI TTSZLWK DMJAO6Z TN Aromatase (CYP19A1) DMJAO6Z MA Inhibitor DMJAO6Z RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMJAO6Z RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMJAPFH DI DMJAPFH DMJAPFH DN Asterric acid DMJAPFH TI TTKRD0G DMJAPFH TN Endothelin A receptor (EDNRA) DMJAPFH MA Inhibitor DMJAPFH RN New chlorinated diphenyl ethers from an Aspergillus species. J Nat Prod. 2002 Jan;65(1):7-10. DMJAPFH RU https://pubmed.ncbi.nlm.nih.gov/11809055 DMJAPML DI DMJAPML DMJAPML DN I-BOP DMJAPML TI TT2O84V DMJAPML TN Thromboxane A2 receptor (TBXA2R) DMJAPML MA Agonist DMJAPML RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMJAPML RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMJAPML DI DMJAPML DMJAPML DN I-BOP DMJAPML TI TTT2ZAR DMJAPML TN Prostaglandin F2-alpha receptor (PTGFR) DMJAPML MA Agonist DMJAPML RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMJAPML RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMJAPML DI DMJAPML DMJAPML DN I-BOP DMJAPML TI TTPNGDE DMJAPML TN Prostaglandin E2 receptor EP3 (PTGER3) DMJAPML MA Agonist DMJAPML RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMJAPML RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMJAQ41 DI DMJAQ41 DMJAQ41 DN 5,7-Dimethoxy-3-thiophen-3-yl-quinoline DMJAQ41 TI TT8FYO9 DMJAQ41 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMJAQ41 MA Inhibitor DMJAQ41 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMJAQ41 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMJAQ41 DI DMJAQ41 DMJAQ41 DN 5,7-Dimethoxy-3-thiophen-3-yl-quinoline DMJAQ41 TI TTI7421 DMJAQ41 TN Platelet-derived growth factor receptor beta (PDGFRB) DMJAQ41 MA Inhibitor DMJAQ41 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMJAQ41 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMJATBL DI DMJATBL DMJATBL DN Chimeric small nucleolar RNA-TAR decoy DMJATBL TI TTNSXG2 DMJATBL TN Human immunodeficiency virus TAR RNA (HIV TAR-RNA) DMJATBL MA Inhibitor DMJATBL RN A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14047-52. DMJATBL RU https://pubmed.ncbi.nlm.nih.gov/12376617 DMJAUH0 DI DMJAUH0 DMJAUH0 DN 2-Adamantan-1-yl-N-decyl-acetamide DMJAUH0 TI TT7WVHI DMJAUH0 TN Soluble epoxide hydrolase (EPHX2) DMJAUH0 MA Inhibitor DMJAUH0 RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMJAUH0 RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMJB1KL DI DMJB1KL DMJB1KL DN 3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine DMJB1KL TI TT5KPZR DMJB1KL TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMJB1KL MA Inhibitor DMJB1KL RN Aryloxyethylamines: binding at alpha7 nicotinic acetylcholine receptors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4283-6. DMJB1KL RU https://pubmed.ncbi.nlm.nih.gov/16765047 DMJB1KL DI DMJB1KL DMJB1KL DN 3-[2-(N,N,N-trimethylammonium)ethoxy]pyridine DMJB1KL TI TT4H1MQ DMJB1KL TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMJB1KL MA Inhibitor DMJB1KL RN Aryloxyethylamines: binding at alpha7 nicotinic acetylcholine receptors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4283-6. DMJB1KL RU https://pubmed.ncbi.nlm.nih.gov/16765047 DMJB1NI DI DMJB1NI DMJB1NI DN 8-Phenyl-3,7-dihydro-purine-2,6-dione DMJB1NI TI TTK25J1 DMJB1NI TN Adenosine A1 receptor (ADORA1) DMJB1NI MA Inhibitor DMJB1NI RN Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationshi... J Med Chem. 1993 Oct 29;36(22):3341-9. DMJB1NI RU https://pubmed.ncbi.nlm.nih.gov/8230124 DMJB3E1 DI DMJB3E1 DMJB3E1 DN VITAMIN K2 DMJB3E1 TI TTEAID7 DMJB3E1 TN Trypanosoma Cruzipain (Trypano CYSP) DMJB3E1 MA Inhibitor DMJB3E1 RN Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65. DMJB3E1 RU https://pubmed.ncbi.nlm.nih.gov/20426472 DMJB7SE DI DMJB7SE DMJB7SE DN N-(3-phenylamino-4-pyridinyl)methanesulfonamide DMJB7SE TI TT8NGED DMJB7SE TN Prostaglandin G/H synthase 1 (COX-1) DMJB7SE MA Inhibitor DMJB7SE RN Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71. DMJB7SE RU https://pubmed.ncbi.nlm.nih.gov/19791801 DMJB7SE DI DMJB7SE DMJB7SE DN N-(3-phenylamino-4-pyridinyl)methanesulfonamide DMJB7SE TI TTVKILB DMJB7SE TN Prostaglandin G/H synthase 2 (COX-2) DMJB7SE MA Inhibitor DMJB7SE RN Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71. DMJB7SE RU https://pubmed.ncbi.nlm.nih.gov/19791801 DMJB7W1 DI DMJB7W1 DMJB7W1 DN 2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide DMJB7W1 TI TTOPAY7 DMJB7W1 TN Galanin receptor (GAL-R) DMJB7W1 MA Antagonist DMJB7W1 RN 2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor. Bioorg Med Chem. 2000 Jun;8(6):1383-91. DMJB7W1 RU https://pubmed.ncbi.nlm.nih.gov/10896115 DMJB876 DI DMJB876 DMJB876 DN Indol-1-yl-methyl-pyridin-4-yl-amine DMJB876 TI TT2NUT5 DMJB876 TN Adrenergic receptor alpha-2C (ADRA2C) DMJB876 MA Inhibitor DMJB876 RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMJB876 RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMJB876 DI DMJB876 DMJB876 DN Indol-1-yl-methyl-pyridin-4-yl-amine DMJB876 TI TTWM4TY DMJB876 TN Adrenergic receptor alpha-2B (ADRA2B) DMJB876 MA Inhibitor DMJB876 RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMJB876 RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMJB876 DI DMJB876 DMJB876 DN Indol-1-yl-methyl-pyridin-4-yl-amine DMJB876 TI TTWG9A4 DMJB876 TN Adrenergic receptor alpha-2A (ADRA2A) DMJB876 MA Inhibitor DMJB876 RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMJB876 RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMJB87Q DI DMJB87Q DMJB87Q DN Halisulfate 1 DMJB87Q TI TTN9T81 DMJB87Q TN Arachidonate 15-lipoxygenase (15-LOX) DMJB87Q MA Inhibitor DMJB87Q RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMJB87Q RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMJB87Q DI DMJB87Q DMJB87Q DN Halisulfate 1 DMJB87Q TI TT58ZYW DMJB87Q TN Mycobacterium Isocitrate lyase (MycB icl) DMJB87Q MA Inhibitor DMJB87Q RN Sesterterpene sulfates as isocitrate lyase inhibitors from tropical sponge Hippospongia sp. Bioorg Med Chem Lett. 2007 May 1;17(9):2483-6. DMJB87Q RU https://pubmed.ncbi.nlm.nih.gov/17317180 DMJBAEP DI DMJBAEP DMJBAEP DN DEMETHYLDEBROMOFLUSTRAMINE B DMJBAEP TI TTEB0GD DMJBAEP TN Cholinesterase (BCHE) DMJBAEP MA Inhibitor DMJBAEP RN Synthesis and biological evaluation of (-)- and (+)-debromoflustramine B and its analogues as selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Sep 11;51(17):5271-84. DMJBAEP RU https://pubmed.ncbi.nlm.nih.gov/18686941 DMJBC03 DI DMJBC03 DMJBC03 DN N-hydroxysulfonamides DMJBC03 TI TTHQPL7 DMJBC03 TN Carbonic anhydrase I (CA-I) DMJBC03 MA Inhibitor DMJBC03 RN Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. J Enzyme Inhib. 1998 Jul;13(4):267-84. DMJBC03 RU https://pubmed.ncbi.nlm.nih.gov/9795865 DMJBC03 DI DMJBC03 DMJBC03 DN N-hydroxysulfonamides DMJBC03 TI TTZHA0O DMJBC03 TN Carbonic anhydrase IV (CA-IV) DMJBC03 MA Inhibitor DMJBC03 RN Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. J Enzyme Inhib. 1998 Jul;13(4):267-84. DMJBC03 RU https://pubmed.ncbi.nlm.nih.gov/9795865 DMJBC03 DI DMJBC03 DMJBC03 DN N-hydroxysulfonamides DMJBC03 TI TTANPDJ DMJBC03 TN Carbonic anhydrase II (CA-II) DMJBC03 MA Inhibitor DMJBC03 RN Carbonic anhydrase inhibitors: inhibition of isozymes I, II and IV with N-hydroxysulfonamides--a novel class of intraocular pressure lowering agents. J Enzyme Inhib. 1998 Jul;13(4):267-84. DMJBC03 RU https://pubmed.ncbi.nlm.nih.gov/9795865 DMJBEIF DI DMJBEIF DMJBEIF DN 5-phenyl-1H-indazol-3-amine DMJBEIF TI TTRMX3V DMJBEIF TN Janus kinase 2 (JAK-2) DMJBEIF MA Inhibitor DMJBEIF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJBEIF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJBFN0 DI DMJBFN0 DMJBFN0 DN 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE DMJBFN0 TI TTFGVKC DMJBFN0 TN Bacterial Phosphoenolpyruvate transferase (Bact ptsI) DMJBFN0 MA Inhibitor DMJBFN0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJBFN0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJBFN0 DI DMJBFN0 DMJBFN0 DN 1-ETHOXY-2-(2-ETHOXYETHOXY)ETHANE DMJBFN0 TI TT1RS9F DMJBFN0 TN Acetylcholinesterase (AChE) DMJBFN0 MA Inhibitor DMJBFN0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJBFN0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJBHR9 DI DMJBHR9 DMJBHR9 DN 5-chloro-2-(pyridin-2-yl)-1H-benzo[d]imidazole DMJBHR9 TI TTZL0OI DMJBHR9 TN Methionine aminopeptidase 2 (METAP2) DMJBHR9 MA Inhibitor DMJBHR9 RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMJBHR9 RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMJBK7F DI DMJBK7F DMJBK7F DN 5-(pyrrolidin-1-ylsulfonyl)indoline-2,3-dione DMJBK7F TI TTPF2QI DMJBK7F TN Caspase-3 (CASP3) DMJBK7F MA Inhibitor DMJBK7F RN Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7. DMJBK7F RU https://pubmed.ncbi.nlm.nih.gov/19631549 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTV9A7R DMJBO3D TN Lactoylglutathione lyase (GLO1) DMJBO3D MA Inhibitor DMJBO3D RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTA7UJC DMJBO3D TN Alpha-1-antitrypsin (SERPINA1) DMJBO3D MA Inhibitor DMJBO3D RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTZT9R2 DMJBO3D TN Hydroxysteroid dehydrogenase 3-beta (HSD3B) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTU6BFZ DMJBO3D TN Candida Thymidylate synthase (Candi TMP1) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTGKIED DMJBO3D TN Fibroblast growth factor-2 (FGF2) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTR0SWN DMJBO3D TN M-phase inducer phosphatase 2 (MPIP2) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTWQYB7 DMJBO3D TN High mobility group protein B1 (HMGB1) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTYQ4AE DMJBO3D TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTANPDJ DMJBO3D TN Carbonic anhydrase II (CA-II) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTJHKYD DMJBO3D TN Delta-aminolevulinic acid dehydratase (ALAD) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TTUNARX DMJBO3D TN Carbonic anhydrase (CA) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBO3D DI DMJBO3D DMJBO3D DN 2-Sulfhydryl-Ethanol DMJBO3D TI TT9SL3Q DMJBO3D TN Polypeptide deformylase (PDF) DMJBO3D MA Inhibitor DMJBO3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJBO3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJBPR3 DI DMJBPR3 DMJBPR3 DN A-849531 DMJBPR3 TI TTN7BL9 DMJBPR3 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMJBPR3 MA Inhibitor DMJBPR3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763). DMJBPR3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763 DMJBQD8 DI DMJBQD8 DMJBQD8 DN 2-tert-butyl-7-(trifluoromethyl)-9H-carbazole DMJBQD8 TI TTBGTCW DMJBQD8 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMJBQD8 MA Inhibitor DMJBQD8 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMJBQD8 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMJBR75 DI DMJBR75 DMJBR75 DN Tyr-Pro-Hfe-Pro-NH2 DMJBR75 TI TTKWM86 DMJBR75 TN Opioid receptor mu (MOP) DMJBR75 MA Inhibitor DMJBR75 RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DMJBR75 RU https://pubmed.ncbi.nlm.nih.gov/16682191 DMJBW7X DI DMJBW7X DMJBW7X DN SEW2871 DMJBW7X TI TT9JZCK DMJBW7X TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMJBW7X MA Agonist DMJBW7X RN Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004 Apr 2;279(14):13839-48. DMJBW7X RU https://pubmed.ncbi.nlm.nih.gov/14732717 DMJC0NQ DI DMJC0NQ DMJC0NQ DN 15-DEOXYBUDLEIN A DMJC0NQ TI TTSXVID DMJC0NQ TN Nuclear factor NF-kappa-B (NFKB) DMJC0NQ MA Inhibitor DMJC0NQ RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DMJC0NQ RU https://pubmed.ncbi.nlm.nih.gov/15537359 DMJC0UH DI DMJC0UH DMJC0UH DN VUF 8430 DMJC0UH TI TTXJ178 DMJC0UH TN Histamine H4 receptor (H4R) DMJC0UH MA Agonist DMJC0UH RN Discovery of S-(2-guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem. 2006 Nov 16;49(23):6650-1. DMJC0UH RU https://pubmed.ncbi.nlm.nih.gov/17154494 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTSYM0R DMJC7NF TN Carbonic anhydrase XII (CA-XII) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTANPDJ DMJC7NF TN Carbonic anhydrase II (CA-II) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTEYTKG DMJC7NF TN Carbonic anhydrase XIV (CA-XIV) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TT2LVK8 DMJC7NF TN Carbonic anhydrase IX (CA-IX) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTCFSPE DMJC7NF TN Carbonic anhydrase VI (CA-VI) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTHQPL7 DMJC7NF TN Carbonic anhydrase I (CA-I) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTZHA0O DMJC7NF TN Carbonic anhydrase IV (CA-IV) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTUNARX DMJC7NF TN Carbonic anhydrase (CA) DMJC7NF MA Inhibitor DMJC7NF RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMJC7NF RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMJC7NF DI DMJC7NF DMJC7NF DN Ferulic Acid DMJC7NF TI TTGP7BY DMJC7NF TN Monoamine oxidase type B (MAO-B) DMJC7NF MA Inhibitor DMJC7NF RN Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110. DMJC7NF RU https://www.ncbi.nlm.nih.gov/pubmed/25399762 DMJCHE1 DI DMJCHE1 DMJCHE1 DN Hexadecanal DMJCHE1 TI TTH0KSX DMJCHE1 TN Rhodopsin (RHO) DMJCHE1 MA Inhibitor DMJCHE1 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMJCHE1 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMJCI2A DI DMJCI2A DMJCI2A DN [3H]JB-93182 DMJCI2A TI TTVFO0U DMJCI2A TN Gastrin/cholecystokinin type B receptor (CCKBR) DMJCI2A MA Antagonist DMJCI2A RN Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex. Br J Pharmacol. 1999 Mar;126(6):1504-12. DMJCI2A RU https://pubmed.ncbi.nlm.nih.gov/10217546 DMJCN0Y DI DMJCN0Y DMJCN0Y DN (R)(+)-7-fluoro-2-phenylchroman-4-one DMJCN0Y TI TTGP7BY DMJCN0Y TN Monoamine oxidase type B (MAO-B) DMJCN0Y MA Inhibitor DMJCN0Y RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMJCN0Y RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMJCO7F DI DMJCO7F DMJCO7F DN N-(2-Phenylethyl)-1H-indole-2-carboxamide DMJCO7F TI TTGP7BY DMJCO7F TN Monoamine oxidase type B (MAO-B) DMJCO7F MA Inhibitor DMJCO7F RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMJCO7F RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMJCO7F DI DMJCO7F DMJCO7F DN N-(2-Phenylethyl)-1H-indole-2-carboxamide DMJCO7F TI TT3WG5C DMJCO7F TN Monoamine oxidase type A (MAO-A) DMJCO7F MA Inhibitor DMJCO7F RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMJCO7F RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMJCOKV DI DMJCOKV DMJCOKV DN PALMATINE DMJCOKV TI TTXV4FI DMJCOKV TN Albendazole monooxygenase (CYP3A4) DMJCOKV MA Inhibitor DMJCOKV RN Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. J Nat Prod. 2007 Dec;70(12):1930-3. DMJCOKV RU https://pubmed.ncbi.nlm.nih.gov/17994701 DMJCPSD DI DMJCPSD DMJCPSD DN A-850002 DMJCPSD TI TTVBPDM DMJCPSD TN Metabotropic glutamate receptor 1 (mGluR1) DMJCPSD MA Modulator (allosteric modulator) DMJCPSD RN Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem. 2005 Nov 17;48(23):7374-88. DMJCPSD RU https://pubmed.ncbi.nlm.nih.gov/16279797 DMJCTWO DI DMJCTWO DMJCTWO DN L-888607 DMJCTWO TI TTQDMX5 DMJCTWO TN Prostaglandin D2 receptor 2 (PTGDR2) DMJCTWO MA Inhibitor DMJCTWO RN Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2. J Med Chem. 2005 Oct 6;48(20):6174-7. DMJCTWO RU https://pubmed.ncbi.nlm.nih.gov/16190744 DMJCVQN DI DMJCVQN DMJCVQN DN 1-(3-benzylquinoxalin-2-yl)hydrazine DMJCVQN TI TT3WG5C DMJCVQN TN Monoamine oxidase type A (MAO-A) DMJCVQN MA Inhibitor DMJCVQN RN Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6. DMJCVQN RU https://pubmed.ncbi.nlm.nih.gov/16356714 DMJCW8Y DI DMJCW8Y DMJCW8Y DN D[Leu4,Orn8]VP DMJCW8Y TI TTSCIUP DMJCW8Y TN Oxytocin receptor (OTR) DMJCW8Y MA Inhibitor DMJCW8Y RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJCW8Y RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJCW8Y DI DMJCW8Y DMJCW8Y DN D[Leu4,Orn8]VP DMJCW8Y TI TTL9MHW DMJCW8Y TN Vasopressin V1b receptor (V1BR) DMJCW8Y MA Inhibitor DMJCW8Y RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJCW8Y RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJCW8Y DI DMJCW8Y DMJCW8Y DN D[Leu4,Orn8]VP DMJCW8Y TI TT4TFGN DMJCW8Y TN Vasopressin V1a receptor (V1AR) DMJCW8Y MA Inhibitor DMJCW8Y RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJCW8Y RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJCW8Y DI DMJCW8Y DMJCW8Y DN D[Leu4,Orn8]VP DMJCW8Y TI TTK8R02 DMJCW8Y TN Vasopressin V2 receptor (V2R) DMJCW8Y MA Inhibitor DMJCW8Y RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJCW8Y RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJCWXK DI DMJCWXK DMJCWXK DN Anidulafungin DMJCWXK TI TTV1095 DMJCWXK TN COVID-19 RNA-directed RNA polymerase (RdRp) DMJCWXK MA Inhibitor DMJCWXK RN Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh DMJCWXK RU https://osf.io/urxwh DMJCXHM DI DMJCXHM DMJCXHM DN ISIS 15770 DMJCXHM TI TTAN5W2 DMJCXHM TN Raf messenger RNA (Raf mRNA) DMJCXHM RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMJCXHM RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMJCXYQ DI DMJCXYQ DMJCXYQ DN N-(4-Sulfamoyl-phenyl)-isobutyramide DMJCXYQ TI TT2LVK8 DMJCXYQ TN Carbonic anhydrase IX (CA-IX) DMJCXYQ MA Inhibitor DMJCXYQ RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMJCXYQ RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMJCXYQ DI DMJCXYQ DMJCXYQ DN N-(4-Sulfamoyl-phenyl)-isobutyramide DMJCXYQ TI TTANPDJ DMJCXYQ TN Carbonic anhydrase II (CA-II) DMJCXYQ MA Inhibitor DMJCXYQ RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMJCXYQ RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMJCXYQ DI DMJCXYQ DMJCXYQ DN N-(4-Sulfamoyl-phenyl)-isobutyramide DMJCXYQ TI TTSYM0R DMJCXYQ TN Carbonic anhydrase XII (CA-XII) DMJCXYQ MA Inhibitor DMJCXYQ RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMJCXYQ RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMJCYMW DI DMJCYMW DMJCYMW DN NC00075159 DMJCYMW TI TT8HGRW DMJCYMW TN Voltage-gated potassium channel Kv7.4 (KCNQ4) DMJCYMW MA Activator DMJCYMW RN Identification of novel KCNQ4 openers by a high-throughput fluorescence-based thallium flux assay. Anal Biochem. 2011 Nov 1;418(1):66-72. DMJCYMW RU https://pubmed.ncbi.nlm.nih.gov/21782781 DMJD03I DI DMJD03I DMJD03I DN SCUTELLAREIN DMJD03I TI TT7RJY8 DMJD03I TN Xanthine dehydrogenase/oxidase (XDH) DMJD03I MA Inhibitor DMJD03I RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DMJD03I RU https://pubmed.ncbi.nlm.nih.gov/3379415 DMJD0UV DI DMJD0UV DMJD0UV DN 3-Hydroxy-3-Methyl-Glutaric Acid DMJD0UV TI TTPADOQ DMJD0UV TN HMG-CoA reductase (HMGCR) DMJD0UV MA Inhibitor DMJD0UV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJD0UV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJD1QF DI DMJD1QF DMJD1QF DN 1-arylmethylpyrrolidin-2-yl ethanol amine DMJD1QF TI TTBUYHA DMJD1QF TN Extracellular calcium-sensing receptor (CASR) DMJD1QF MA Antagonist DMJD1QF RN Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5478-82. DMJD1QF RU https://pubmed.ncbi.nlm.nih.gov/16216508 DMJD34Q DI DMJD34Q DMJD34Q DN (-)-eseroline DMJD34Q TI TT27RFC DMJD34Q TN Opioid receptor delta (OPRD1) DMJD34Q MA Inhibitor DMJD34Q RN Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4. DMJD34Q RU https://pubmed.ncbi.nlm.nih.gov/1317407 DMJD34Q DI DMJD34Q DMJD34Q DN (-)-eseroline DMJD34Q TI TTKWM86 DMJD34Q TN Opioid receptor mu (MOP) DMJD34Q MA Inhibitor DMJD34Q RN Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4. DMJD34Q RU https://pubmed.ncbi.nlm.nih.gov/1317407 DMJD3WY DI DMJD3WY DMJD3WY DN RI-TPO DMJD3WY TI TTIHYA4 DMJD3WY TN Thrombopoietin receptor (MPL) DMJD3WY MA Modulator DMJD3WY RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMJD3WY RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMJD479 DI DMJD479 DMJD479 DN THPO DMJD479 TI TTV9MQG DMJD479 TN Gamma-aminobutyric acid uptake (GABAU) DMJD479 MA Inhibitor DMJD479 RN Anticonvulsant activity of intracerebroventricularly administered glial GABA uptake inhibitors and other GABAmimetics in chemical seizure models. Epilepsy Res. 1989 Jul-Aug;4(1):34-41. DMJD479 RU https://pubmed.ncbi.nlm.nih.gov/2526732 DMJD8XN DI DMJD8XN DMJD8XN DN PHENIDONE DMJD8XN TI TT2J34L DMJD8XN TN Arachidonate 5-lipoxygenase (5-LOX) DMJD8XN MA Inhibitor DMJD8XN RN Cylindol A, a novel biphenyl ether with 5-lipoxygenase inhibitory activity, and a related compound from Imperata Cylindrica. J Nat Prod. 1994 Sep;57(9):1290-3. DMJD8XN RU https://pubmed.ncbi.nlm.nih.gov/7798964 DMJD8XN DI DMJD8XN DMJD8XN DN PHENIDONE DMJD8XN TI TT8NGED DMJD8XN TN Prostaglandin G/H synthase 1 (COX-1) DMJD8XN MA Inhibitor DMJD8XN RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMJD8XN RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMJD8XN DI DMJD8XN DMJD8XN DN PHENIDONE DMJD8XN TI TTVKILB DMJD8XN TN Prostaglandin G/H synthase 2 (COX-2) DMJD8XN MA Inhibitor DMJD8XN RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMJD8XN RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMJDE6Y DI DMJDE6Y DMJDE6Y DN RB-400 DMJDE6Y TI TTVFO0U DMJDE6Y TN Gastrin/cholecystokinin type B receptor (CCKBR) DMJDE6Y MA Agonist DMJDE6Y RN Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties. Bioorg Med Chem Lett. 2004 Jan 19;14(2):369-72. DMJDE6Y RU https://pubmed.ncbi.nlm.nih.gov/14698161 DMJDG9C DI DMJDG9C DMJDG9C DN 3-(N-alkylamino) propylphosphonic acid derivative DMJDG9C TI TT9JZCK DMJDG9C TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMJDG9C MA Inhibitor DMJDG9C RN Design and synthesis of conformationally constrained 3-(N-alkylamino)propylphosphonic acids as potent agonists of sphingosine-1-phosphate (S1P) rec... Bioorg Med Chem Lett. 2004 Oct 4;14(19):4861-6. DMJDG9C RU https://pubmed.ncbi.nlm.nih.gov/15341940 DMJDI7O DI DMJDI7O DMJDI7O DN P-6915 DMJDI7O TI TTCJG29 DMJDI7O TN Serine/threonine-protein kinase mTOR (mTOR) DMJDI7O MA Inhibitor DMJDI7O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMJDI7O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMJDI7O DI DMJDI7O DMJDI7O DN P-6915 DMJDI7O TI TTHBTOP DMJDI7O TN PI3-kinase gamma (PIK3CG) DMJDI7O MA Inhibitor DMJDI7O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMJDI7O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMJDK7Z DI DMJDK7Z DMJDK7Z DN 1-(3,3-diphenylpropyl)-4-phenylpiperidin-4-ol DMJDK7Z TI TTNT7K8 DMJDK7Z TN Nociceptin receptor (OPRL1) DMJDK7Z MA Inhibitor DMJDK7Z RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMJDK7Z RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMJDO2F DI DMJDO2F DMJDO2F DN Adenosine-5'-O-(2-thiodiphosphate) DMJDO2F TI TTQD1SA DMJDO2F TN P2Y purinoceptor (P2RY) DMJDO2F MA Agonist DMJDO2F RN Stimulation of insulin secretion and improvement of glucose tolerance in rat and dog by the P2y-purinoceptor agonist, adenosine-5'-O-(2-thiodiphosphate). Br J Pharmacol. 1993 May;109(1):183-7. DMJDO2F RU https://pubmed.ncbi.nlm.nih.gov/8495239 DMJDQGR DI DMJDQGR DMJDQGR DN N,N-dimethyl-2,2-diphenylethanamine DMJDQGR TI TTJQOD7 DMJDQGR TN 5-HT 2A receptor (HTR2A) DMJDQGR MA Inhibitor DMJDQGR RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMJDQGR RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMJDQGR DI DMJDQGR DMJDQGR DN N,N-dimethyl-2,2-diphenylethanamine DMJDQGR TI TTTIBOJ DMJDQGR TN Histamine H1 receptor (H1R) DMJDQGR MA Inhibitor DMJDQGR RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMJDQGR RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMJDU5S DI DMJDU5S DMJDU5S DN quinazoline deriv. 1 DMJDU5S TI TT9RTBL DMJDU5S TN Aurora B messenger RNA (AURKB mRNA) DMJDU5S MA Inhibitor DMJDU5S RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMJDU5S RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMJDU5S DI DMJDU5S DMJDU5S DN quinazoline deriv. 1 DMJDU5S TI TTLYXIT DMJDU5S TN Aurora kinase C (AURKC) DMJDU5S MA Inhibitor DMJDU5S RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMJDU5S RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMJDUM5 DI DMJDUM5 DMJDUM5 DN 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol DMJDUM5 TI TTNT7K8 DMJDUM5 TN Nociceptin receptor (OPRL1) DMJDUM5 MA Inhibitor DMJDUM5 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMJDUM5 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMJDUM5 DI DMJDUM5 DMJDUM5 DN 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol DMJDUM5 TI TTKWM86 DMJDUM5 TN Opioid receptor mu (MOP) DMJDUM5 MA Inhibitor DMJDUM5 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMJDUM5 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMJDUM5 DI DMJDUM5 DMJDUM5 DN 1-benzhydryl-4-(4-propylphenyl)piperidin-4-ol DMJDUM5 TI TTQW87Y DMJDUM5 TN Opioid receptor kappa (OPRK1) DMJDUM5 MA Inhibitor DMJDUM5 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMJDUM5 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMJDW50 DI DMJDW50 DMJDW50 DN 4-(1,2-Diphenyl-but-1-enyl)-phenol DMJDW50 TI TTZAYWL DMJDW50 TN Estrogen receptor (ESR) DMJDW50 MA Inhibitor DMJDW50 RN Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64. DMJDW50 RU https://pubmed.ncbi.nlm.nih.gov/12431063 DMJDWX5 DI DMJDWX5 DMJDWX5 DN ISIS 3801 DMJDWX5 TI TTHCEF6 DMJDWX5 TN VCAM-1 messenger RNA (VCAM1 mRNA) DMJDWX5 RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMJDWX5 RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMJE4HK DI DMJE4HK DMJE4HK DN Cyanide DMJE4HK TI TT3PQ2Y DMJE4HK TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMJE4HK MA Inhibitor DMJE4HK RN Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob Agents Chemother. 1995 Feb;39(2):325-8. DMJE4HK RU https://pubmed.ncbi.nlm.nih.gov/7726490 DMJE83O DI DMJE83O DMJE83O DN (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone DMJE83O TI TTWN3F4 DMJE83O TN Presenilin 2 (PSEN2) DMJE83O MA Inhibitor DMJE83O RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMJE83O RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMJE83O DI DMJE83O DMJE83O DN (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone DMJE83O TI TTZ3S8C DMJE83O TN Presenilin 1 (PSEN1) DMJE83O MA Inhibitor DMJE83O RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMJE83O RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMJE83O DI DMJE83O DMJE83O DN (2S,3R)-2-(benzyloxy)-3-methoxycyclohexanone DMJE83O TI TT9W8GU DMJE83O TN Gamma-secretase (GS) DMJE83O MA Inhibitor DMJE83O RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMJE83O RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMJEBXA DI DMJEBXA DMJEBXA DN (+/-)-7-fluoro-2-phenylchroman-4-one DMJEBXA TI TTGP7BY DMJEBXA TN Monoamine oxidase type B (MAO-B) DMJEBXA MA Inhibitor DMJEBXA RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMJEBXA RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMJEGMI DI DMJEGMI DMJEGMI DN (S)-2-Amino-4-phenyl-butane-1-thiol DMJEGMI TI TTPHMWB DMJEGMI TN Aminopeptidase N (ANPEP) DMJEGMI MA Inhibitor DMJEGMI RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMJEGMI RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMJEN45 DI DMJEN45 DMJEN45 DN Cyclohexyl-(3,4-dichloro-phenyl)-acetonitrile DMJEN45 TI TT3ROYC DMJEN45 TN Serotonin transporter (SERT) DMJEN45 MA Inhibitor DMJEN45 RN Synthesis and evaluation of dopamine and serotonin transporter inhibition by oxacyclic and carbacyclic analogues of methylphenidate. J Med Chem. 2003 Apr 10;46(8):1538-45. DMJEN45 RU https://pubmed.ncbi.nlm.nih.gov/12672255 DMJEZ62 DI DMJEZ62 DMJEZ62 DN Asp-BrPmp-Leu DMJEZ62 TI TTUS45N DMJEZ62 TN Leukocyte common antigen (PTPRC) DMJEZ62 MA Inhibitor DMJEZ62 RN A protected l-bromophosphonomethylphenylalanine amino acid derivative (BrPmp) for synthesis of irreversible protein tyrosine phosphatase inhibitors. Bioorg Med Chem. 2010 Dec 15;18(24):8679-86. DMJEZ62 RU https://pubmed.ncbi.nlm.nih.gov/21055952 DMJF6AQ DI DMJF6AQ DMJF6AQ DN Doxorubicin-Formaldehyde Conjugate DMJF6AQ TI TTOM3J0 DMJF6AQ TN Estrogen receptor beta (ESR2) DMJF6AQ MA Inhibitor DMJF6AQ RN Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem. 2004 Feb 26;47(5):1193-206. DMJF6AQ RU https://pubmed.ncbi.nlm.nih.gov/14971899 DMJF6AQ DI DMJF6AQ DMJF6AQ DN Doxorubicin-Formaldehyde Conjugate DMJF6AQ TI TTZAYWL DMJF6AQ TN Estrogen receptor (ESR) DMJF6AQ MA Inhibitor DMJF6AQ RN Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells. J Med Chem. 2004 Feb 26;47(5):1193-206. DMJF6AQ RU https://pubmed.ncbi.nlm.nih.gov/14971899 DMJF7OC DI DMJF7OC DMJF7OC DN PMID7966163C3f DMJF7OC TI TTFQEO5 DMJF7OC TN Squalene synthetase (FDFT1) DMJF7OC MA Inhibitor DMJF7OC RN Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51. DMJF7OC RU https://pubmed.ncbi.nlm.nih.gov/7966163 DMJF9VA DI DMJF9VA DMJF9VA DN N-biphenyl-3-ylmethyl-N'-hydroxy-malonamide DMJF9VA TI TTPHMWB DMJF9VA TN Aminopeptidase N (ANPEP) DMJF9VA MA Inhibitor DMJF9VA RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMJF9VA RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMJFBQ1 DI DMJFBQ1 DMJFBQ1 DN 9-phenanthrol DMJFBQ1 TI TTJ2HKA DMJFBQ1 TN Long transient receptor potential channel 4 (TRPM4) DMJFBQ1 MA Blocker (channel blocker) DMJFBQ1 RN 9-phenanthrol inhibits human TRPM4 but not TRPM5 cationic channels. Br J Pharmacol. 2008 Apr;153(8):1697-705. DMJFBQ1 RU https://pubmed.ncbi.nlm.nih.gov/18297105 DMJFH97 DI DMJFH97 DMJFH97 DN (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMJFH97 TI TT3ROYC DMJFH97 TN Serotonin transporter (SERT) DMJFH97 MA Inhibitor DMJFH97 RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMJFH97 RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMJFH97 DI DMJFH97 DMJFH97 DN (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMJFH97 TI TTQ6VDM DMJFH97 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMJFH97 MA Inhibitor DMJFH97 RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMJFH97 RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMJFH97 DI DMJFH97 DMJFH97 DN (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMJFH97 TI TTVBI8W DMJFH97 TN Dopamine transporter (DAT) DMJFH97 MA Inhibitor DMJFH97 RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMJFH97 RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMJFH97 DI DMJFH97 DMJFH97 DN (R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMJFH97 TI TTAWNKZ DMJFH97 TN Norepinephrine transporter (NET) DMJFH97 MA Inhibitor DMJFH97 RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMJFH97 RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMJFI75 DI DMJFI75 DMJFI75 DN (S)-2-methyl-1-(2-p-tolyl-ethyl)-pyrrolidine DMJFI75 TI TT9JNIC DMJFI75 TN Histamine H3 receptor (H3R) DMJFI75 MA Inhibitor DMJFI75 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMJFI75 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMJFKG4 DI DMJFKG4 DMJFKG4 DN Acetaldehyde DMJFKG4 TI TTELV3W DMJFKG4 TN Transformation-sensitive protein p120 (TRPA1) DMJFKG4 MA Activator DMJFKG4 RN Transient receptor potential A1 mediates acetaldehyde-evoked pain sensation. Eur J Neurosci. 2007 Nov;26(9):2516-23. DMJFKG4 RU https://pubmed.ncbi.nlm.nih.gov/17970723 DMJFKSU DI DMJFKSU DMJFKSU DN FAICAR DMJFKSU TI TT9NVXQ DMJFKSU TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMJFKSU MA Inhibitor DMJFKSU RN Structure-based design, synthesis, evaluation, and crystal structures of transition state analogue inhibitors of inosine monophosphate cyclohydrolase. J Biol Chem. 2007 Apr 27;282(17):13033-46. DMJFKSU RU https://pubmed.ncbi.nlm.nih.gov/17324932 DMJFLK0 DI DMJFLK0 DMJFLK0 DN ISIS 2920 DMJFLK0 TI TT4SCBE DMJFLK0 TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMJFLK0 RN US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections. DMJFLK0 RU http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true DMJFMH9 DI DMJFMH9 DMJFMH9 DN LUF-5957 DMJFMH9 TI TTM2AOE DMJFMH9 TN Adenosine A2a receptor (ADORA2A) DMJFMH9 MA Inhibitor DMJFMH9 RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMJFMH9 RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMJFMH9 DI DMJFMH9 DMJFMH9 DN LUF-5957 DMJFMH9 TI TTK25J1 DMJFMH9 TN Adenosine A1 receptor (ADORA1) DMJFMH9 MA Inhibitor DMJFMH9 RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMJFMH9 RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMJFMH9 DI DMJFMH9 DMJFMH9 DN LUF-5957 DMJFMH9 TI TTJFY5U DMJFMH9 TN Adenosine A3 receptor (ADORA3) DMJFMH9 MA Inhibitor DMJFMH9 RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMJFMH9 RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMJFOGW DI DMJFOGW DMJFOGW DN PMID17600705C23 DMJFOGW TI TT8M1DP DMJFOGW TN Tyrosine-protein kinase TXK (TXK) DMJFOGW MA Inhibitor DMJFOGW RN N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8. DMJFOGW RU https://pubmed.ncbi.nlm.nih.gov/17600705 DMJFOGW DI DMJFOGW DMJFOGW DN PMID17600705C23 DMJFOGW TI TTOU65C DMJFOGW TN Tyrosine-protein kinase SYK (SYK) DMJFOGW MA Inhibitor DMJFOGW RN N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8. DMJFOGW RU https://pubmed.ncbi.nlm.nih.gov/17600705 DMJFOGW DI DMJFOGW DMJFOGW DN PMID17600705C23 DMJFOGW TI TT1RWNJ DMJFOGW TN Tyrosine-protein kinase Lyn (JTK8) DMJFOGW MA Inhibitor DMJFOGW RN N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8. DMJFOGW RU https://pubmed.ncbi.nlm.nih.gov/17600705 DMJFOGW DI DMJFOGW DMJFOGW DN PMID17600705C23 DMJFOGW TI TT860QF DMJFOGW TN LCK tyrosine protein kinase (LCK) DMJFOGW MA Inhibitor DMJFOGW RN N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8. DMJFOGW RU https://pubmed.ncbi.nlm.nih.gov/17600705 DMJFPA9 DI DMJFPA9 DMJFPA9 DN CARAMIPEN DMJFPA9 TI TTYEG6Q DMJFPA9 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMJFPA9 MA Inhibitor DMJFPA9 RN Muscarinic receptor binding profile of para-substituted caramiphen analogues. J Med Chem. 1991 Oct;34(10):2984-9. DMJFPA9 RU https://pubmed.ncbi.nlm.nih.gov/1920350 DMJFPA9 DI DMJFPA9 DMJFPA9 DN CARAMIPEN DMJFPA9 TI TTZ9SOR DMJFPA9 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMJFPA9 MA Inhibitor DMJFPA9 RN Muscarinic receptor binding profile of para-substituted caramiphen analogues. J Med Chem. 1991 Oct;34(10):2984-9. DMJFPA9 RU https://pubmed.ncbi.nlm.nih.gov/1920350 DMJFSTX DI DMJFSTX DMJFSTX DN 4-(Isopropylamino)-1-naphthol DMJFSTX TI TTZJYKH DMJFSTX TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMJFSTX MA Inhibitor DMJFSTX RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMJFSTX RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMJFXKA DI DMJFXKA DMJFXKA DN 7-fluoro-2-p-tolyl-4H-chromene-4-thione DMJFXKA TI TTGP7BY DMJFXKA TN Monoamine oxidase type B (MAO-B) DMJFXKA MA Inhibitor DMJFXKA RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMJFXKA RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMJFY9Z DI DMJFY9Z DMJFY9Z DN 4-Bromo-N-(4-phenyl-thiazol-2-yl)-benzamide DMJFY9Z TI TTK25J1 DMJFY9Z TN Adenosine A1 receptor (ADORA1) DMJFY9Z MA Inhibitor DMJFY9Z RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMJFY9Z RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMJG4RC DI DMJG4RC DMJG4RC DN RU82197 DMJG4RC TI TT6PKBN DMJG4RC TN Proto-oncogene c-Src (SRC) DMJG4RC MA Inhibitor DMJG4RC RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMJG4RC RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMJG4U0 DI DMJG4U0 DMJG4U0 DN R-fadrozole DMJG4U0 TI TTIQUX7 DMJG4U0 TN Steroid 11-beta-hydroxylase (CYP11B1) DMJG4U0 MA Inhibitor DMJG4U0 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMJG4U0 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMJGAFV DI DMJGAFV DMJGAFV DN (E)-4,4-Dimethyl-1-quinolin-3-yl-pent-1-en-3-one DMJGAFV TI TTVBPDM DMJGAFV TN Metabotropic glutamate receptor 1 (mGluR1) DMJGAFV MA Inhibitor DMJGAFV RN Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15. DMJGAFV RU https://pubmed.ncbi.nlm.nih.gov/19574055 DMJGKND DI DMJGKND DMJGKND DN DIMS-9054 DMJGKND TI TTSHG0T DMJGKND TN Toll-like receptor 9 (TLR9) DMJGKND MA Modulator DMJGKND RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1759). DMJGKND RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1759 DMJGTS7 DI DMJGTS7 DMJGTS7 DN 4-(piperazin-1-yl)thieno[3,2-c]pyridine DMJGTS7 TI TTWJBZ5 DMJGTS7 TN 5-HT 2C receptor (HTR2C) DMJGTS7 MA Inhibitor DMJGTS7 RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DMJGTS7 RU https://pubmed.ncbi.nlm.nih.gov/19914063 DMJGZ79 DI DMJGZ79 DMJGZ79 DN SX-MTR1 DMJGZ79 TI TTCJG29 DMJGZ79 TN Serine/threonine-protein kinase mTOR (mTOR) DMJGZ79 MA Modulator DMJGZ79 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMJGZ79 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMJH2OE DI DMJH2OE DMJH2OE DN 4-(3-chlorophenylthio)-2-(pyridin-2-yl)pyrimidine DMJH2OE TI TTHS256 DMJH2OE TN Metabotropic glutamate receptor 5 (mGluR5) DMJH2OE MA Inhibitor DMJH2OE RN Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9. DMJH2OE RU https://pubmed.ncbi.nlm.nih.gov/16481165 DMJH4BF DI DMJH4BF DMJH4BF DN Euro-Celtique 2 DMJH4BF TI TTXHYV6 DMJH4BF TN Voltage-gated L-type calcium channel (L-CaC) DMJH4BF MA Blocker DMJH4BF RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMJH4BF RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMJHG1O DI DMJHG1O DMJHG1O DN WIN-68577 DMJHG1O TI TTZPO1L DMJHG1O TN Substance-P receptor (TACR1) DMJHG1O MA Modulator DMJHG1O RN WIN 66306, a new neurokinin antagonist produced by an Aspergillus species: fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 1994 Nov;47(11):1182-7. DMJHG1O RU https://www.ncbi.nlm.nih.gov/pubmed/7528191 DMJHQ9T DI DMJHQ9T DMJHQ9T DN MPPG DMJHQ9T TI TTWRP2F DMJHQ9T TN Metabotropic glutamate receptor 6 (mGluR6) DMJHQ9T MA Antagonist DMJHQ9T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294). DMJHQ9T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294 DMJHQ9T DI DMJHQ9T DMJHQ9T DN MPPG DMJHQ9T TI TTICZ1O DMJHQ9T TN Metabotropic glutamate receptor 4 (mGluR4) DMJHQ9T MA Antagonist DMJHQ9T RN Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13. DMJHQ9T RU https://pubmed.ncbi.nlm.nih.gov/10187777 DMJHQ9T DI DMJHQ9T DMJHQ9T DN MPPG DMJHQ9T TI TT0I76D DMJHQ9T TN Metabotropic glutamate receptor 7 (mGluR7) DMJHQ9T MA Antagonist DMJHQ9T RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMJHQ9T RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMJHQ9T DI DMJHQ9T DMJHQ9T DN MPPG DMJHQ9T TI TT0IFKL DMJHQ9T TN Metabotropic glutamate receptor 8 (mGluR8) DMJHQ9T MA Antagonist DMJHQ9T RN Group III human metabotropic glutamate receptors 4, 7 and 8: molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells. Brain Res Mol Brain Res. 1998 Jan;53(1-2):88-97. DMJHQ9T RU https://pubmed.ncbi.nlm.nih.gov/9473604 DMJHTQK DI DMJHTQK DMJHTQK DN TOXIFERINE DMJHTQK TI TTLA931 DMJHTQK TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMJHTQK MA Inhibitor DMJHTQK RN Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29. DMJHTQK RU https://pubmed.ncbi.nlm.nih.gov/17722904 DMJHTUG DI DMJHTUG DMJHTUG DN QSPac DMJHTUG TI TT2UE56 DMJHTUG TN Sodium/glucose cotransporter 1 (SGLT1) DMJHTUG MA Inhibitor DMJHTUG RN Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13. DMJHTUG RU https://pubmed.ncbi.nlm.nih.gov/17686765 DMJHWGS DI DMJHWGS DMJHWGS DN NB3322 DMJHWGS TI TT9SL3Q DMJHWGS TN Polypeptide deformylase (PDF) DMJHWGS MA Inhibitor DMJHWGS RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMJHWGS RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMJHXMY DI DMJHXMY DMJHXMY DN 1-benzyl-APDC DMJHXMY TI TTWRP2F DMJHXMY TN Metabotropic glutamate receptor 6 (mGluR6) DMJHXMY MA Agonist DMJHXMY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 294). DMJHXMY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=294 DMJI1EA DI DMJI1EA DMJI1EA DN BND-001 DMJI1EA TI TTNT7K8 DMJI1EA TN Nociceptin receptor (OPRL1) DMJI1EA MA Antagonist DMJI1EA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). DMJI1EA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 DMJI5H0 DI DMJI5H0 DMJI5H0 DN SNC-80 DMJI5H0 TI TT27RFC DMJI5H0 TN Opioid receptor delta (OPRD1) DMJI5H0 MA Agonist DMJI5H0 RN Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats. Neuropsychopharmacology. 2002 Jun;26(6):744-55. DMJI5H0 RU https://pubmed.ncbi.nlm.nih.gov/12007745 DMJI6AM DI DMJI6AM DMJI6AM DN 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE DMJI6AM TI TT6L509 DMJI6AM TN Coagulation factor IIa (F2) DMJI6AM MA Inhibitor DMJI6AM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJI6AM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJI6BK DI DMJI6BK DMJI6BK DN Des-AA1,2,4,5,11,12,13-[D-Trp8]SRIF DMJI6BK TI TTZ6T9E DMJI6BK TN Somatostatin receptor type 2 (SSTR2) DMJI6BK MA Inhibitor DMJI6BK RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMJI6BK RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMJI6QH DI DMJI6QH DMJI6QH DN 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole DMJI6QH TI TT1MPAY DMJI6QH TN GABA(A) receptor alpha-1 (GABRA1) DMJI6QH MA Inhibitor DMJI6QH RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMJI6QH RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMJI6QH DI DMJI6QH DMJI6QH DN 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole DMJI6QH TI TTZA1NY DMJI6QH TN GABA(A) receptor beta-2 (GABRB2) DMJI6QH MA Inhibitor DMJI6QH RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMJI6QH RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMJI6QH DI DMJI6QH DMJI6QH DN 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole DMJI6QH TI TT06RH5 DMJI6QH TN GABA(A) receptor gamma-2 (GABRG2) DMJI6QH MA Inhibitor DMJI6QH RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMJI6QH RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMJI6QH DI DMJI6QH DMJI6QH DN 4-(4-chlorophenyl)-1-pyrid-2-yl-pyrazole DMJI6QH TI TTNJYV2 DMJI6QH TN Gamma-aminobutyric acid receptor (GAR) DMJI6QH MA Inhibitor DMJI6QH RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMJI6QH RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMJI8TX DI DMJI8TX DMJI8TX DN Alpha,beta-methylene-dCTP DMJI8TX TI TTIU7X1 DMJI8TX TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMJI8TX MA Inhibitor DMJI8TX RN Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70. DMJI8TX RU https://pubmed.ncbi.nlm.nih.gov/18811136 DMJIB8N DI DMJIB8N DMJIB8N DN PSN632408 DMJIB8N TI TT7QNVC DMJIB8N TN Glucose-dependent insulinotropic receptor (GPR119) DMJIB8N MA Agonist DMJIB8N RN Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 2006 Mar;3(3):167-75. DMJIB8N RU https://pubmed.ncbi.nlm.nih.gov/16517404 DMJICNL DI DMJICNL DMJICNL DN PMID16242323C22d DMJICNL TI TTK3C21 DMJICNL TN Acetoacetyl-CoA thiolase (ACAT1) DMJICNL MA Inhibitor DMJICNL RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMJICNL RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMJIFY3 DI DMJIFY3 DMJIFY3 DN DADMe-ImmG DMJIFY3 TI TTMCF1Y DMJIFY3 TN Purine nucleoside phosphorylase (PNP) DMJIFY3 MA Inhibitor DMJIFY3 RN Achieving the ultimate physiological goal in transition state analogue inhibitors for purine nucleoside phosphorylase. J Biol Chem. 2003 Aug 22;278(34):31465-8. DMJIFY3 RU https://pubmed.ncbi.nlm.nih.gov/12842889 DMJIKHQ DI DMJIKHQ DMJIKHQ DN BsAb cG7-MICA DMJIKHQ TI TTCTYNP DMJIKHQ TN Small cell lung carcinoma cluster 4 antigen (CD24) DMJIKHQ RN Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008 Apr 15;68(8):2803-12. DMJIKHQ RU https://pubmed.ncbi.nlm.nih.gov/217546303 DMJIQG2 DI DMJIQG2 DMJIQG2 DN KNI-10094 DMJIQG2 TI TTXMNHO DMJIQG2 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMJIQG2 MA Inhibitor DMJIQG2 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMJIQG2 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMJITU0 DI DMJITU0 DMJITU0 DN 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid DMJITU0 TI TTUNARX DMJITU0 TN Carbonic anhydrase (CA) DMJITU0 MA Inhibitor DMJITU0 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJITU0 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJITU0 DI DMJITU0 DMJITU0 DN 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid DMJITU0 TI TTHQPL7 DMJITU0 TN Carbonic anhydrase I (CA-I) DMJITU0 MA Inhibitor DMJITU0 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJITU0 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJITU0 DI DMJITU0 DMJITU0 DN 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid DMJITU0 TI TT2LVK8 DMJITU0 TN Carbonic anhydrase IX (CA-IX) DMJITU0 MA Inhibitor DMJITU0 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJITU0 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJITU0 DI DMJITU0 DMJITU0 DN 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid DMJITU0 TI TTEYTKG DMJITU0 TN Carbonic anhydrase XIV (CA-XIV) DMJITU0 MA Inhibitor DMJITU0 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJITU0 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJITU0 DI DMJITU0 DMJITU0 DN 7-methoxy-2-oxo-2H-chromene-4-carboxylic acid DMJITU0 TI TTSYM0R DMJITU0 TN Carbonic anhydrase XII (CA-XII) DMJITU0 MA Inhibitor DMJITU0 RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJITU0 RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJIU3Y DI DMJIU3Y DMJIU3Y DN Lactoferrin DMJIU3Y TI TTM1TDX DMJIU3Y TN Tryptase alpha/beta-1 (Tryptase) DMJIU3Y MA Inhibitor DMJIU3Y RN Inhibitors of tryptase for the treatment of mast cell-mediated diseases. Curr Pharm Des. 1998 Oct;4(5):381-96. DMJIU3Y RU https://pubmed.ncbi.nlm.nih.gov/10197050 DMJIVL3 DI DMJIVL3 DMJIVL3 DN 2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one DMJIVL3 TI TTNJYV2 DMJIVL3 TN Gamma-aminobutyric acid receptor (GAR) DMJIVL3 MA Inhibitor DMJIVL3 RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMJIVL3 RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMJIVL3 DI DMJIVL3 DMJIVL3 DN 2-p-Tolyl-6H-pyrazolo[1,5-c]quinazolin-5-one DMJIVL3 TI TT1MPAY DMJIVL3 TN GABA(A) receptor alpha-1 (GABRA1) DMJIVL3 MA Inhibitor DMJIVL3 RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMJIVL3 RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMJIVLY DI DMJIVLY DMJIVLY DN 5-(azetidin-1-ylsulfonyl)indoline-2,3-dione DMJIVLY TI TTPF2QI DMJIVLY TN Caspase-3 (CASP3) DMJIVLY MA Inhibitor DMJIVLY RN Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7. DMJIVLY RU https://pubmed.ncbi.nlm.nih.gov/19631549 DMJIX7H DI DMJIX7H DMJIX7H DN 4-Methoxy-3-pyridinesulfonamide DMJIX7H TI TT2LVK8 DMJIX7H TN Carbonic anhydrase IX (CA-IX) DMJIX7H MA Inhibitor DMJIX7H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMJIX7H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMJIX7H DI DMJIX7H DMJIX7H DN 4-Methoxy-3-pyridinesulfonamide DMJIX7H TI TTSYM0R DMJIX7H TN Carbonic anhydrase XII (CA-XII) DMJIX7H MA Inhibitor DMJIX7H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMJIX7H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMJIX7H DI DMJIX7H DMJIX7H DN 4-Methoxy-3-pyridinesulfonamide DMJIX7H TI TTANPDJ DMJIX7H TN Carbonic anhydrase II (CA-II) DMJIX7H MA Inhibitor DMJIX7H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMJIX7H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMJIX7H DI DMJIX7H DMJIX7H DN 4-Methoxy-3-pyridinesulfonamide DMJIX7H TI TTHQPL7 DMJIX7H TN Carbonic anhydrase I (CA-I) DMJIX7H MA Inhibitor DMJIX7H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMJIX7H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMJK0H5 DI DMJK0H5 DMJK0H5 DN DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT DMJK0H5 TI TT4TFGN DMJK0H5 TN Vasopressin V1a receptor (V1AR) DMJK0H5 MA Inhibitor DMJK0H5 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMJK0H5 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMJK0H5 DI DMJK0H5 DMJK0H5 DN DesGly-NH2,d(CH2)5[D-Tyr2,Thr4,Orn8(5/6C-Flu)]VT DMJK0H5 TI TTSCIUP DMJK0H5 TN Oxytocin receptor (OTR) DMJK0H5 MA Inhibitor DMJK0H5 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMJK0H5 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMJK0MF DI DMJK0MF DMJK0MF DN 1-Naphthalen-2-yl-piperazine DMJK0MF TI TTK8CXU DMJK0MF TN 5-HT 1B receptor (HTR1B) DMJK0MF MA Inhibitor DMJK0MF RN 5-HT1B receptor antagonist properties of novel arylpiperazide derivatives of 1-naphthylpiperazine. J Med Chem. 1997 Nov 21;40(24):3974-8. DMJK0MF RU https://pubmed.ncbi.nlm.nih.gov/9397179 DMJK0MF DI DMJK0MF DMJK0MF DN 1-Naphthalen-2-yl-piperazine DMJK0MF TI TTJQOD7 DMJK0MF TN 5-HT 2A receptor (HTR2A) DMJK0MF MA Inhibitor DMJK0MF RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMJK0MF RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMJK0MF DI DMJK0MF DMJK0MF DN 1-Naphthalen-2-yl-piperazine DMJK0MF TI TTSQIFT DMJK0MF TN 5-HT 1A receptor (HTR1A) DMJK0MF MA Inhibitor DMJK0MF RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMJK0MF RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMJK0MF DI DMJK0MF DMJK0MF DN 1-Naphthalen-2-yl-piperazine DMJK0MF TI TT6MSOK DMJK0MF TN 5-HT 1D receptor (HTR1D) DMJK0MF MA Inhibitor DMJK0MF RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMJK0MF RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMJK1RE DI DMJK1RE DMJK1RE DN M3A6S DMJK1RE TI TTQW87Y DMJK1RE TN Opioid receptor kappa (OPRK1) DMJK1RE MA Inhibitor DMJK1RE RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMJK1RE RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMJK1RE DI DMJK1RE DMJK1RE DN M3A6S DMJK1RE TI TTKWM86 DMJK1RE TN Opioid receptor mu (MOP) DMJK1RE MA Inhibitor DMJK1RE RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMJK1RE RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMJK8QZ DI DMJK8QZ DMJK8QZ DN Ac-YR[CE(1-Me-H)dFRWC]-NH2 DMJK8QZ TI TTD0CIQ DMJK8QZ TN Melanocortin receptor 4 (MC4R) DMJK8QZ MA Inhibitor DMJK8QZ RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMJK8QZ RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMJKA3F DI DMJKA3F DMJKA3F DN BB-78485 DMJKA3F TI TT0OFWN DMJKA3F TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DMJKA3F MA Inhibitor DMJKA3F RN Antibacterial activities and characterization of novel inhibitors of LpxC. Antimicrob Agents Chemother. 2002 Jun;46(6):1793-9. DMJKA3F RU https://pubmed.ncbi.nlm.nih.gov/12019092 DMJKAF0 DI DMJKAF0 DMJKAF0 DN 5-(4-Chloro-phenyl)-1-methyl-piperidin-2-one DMJKAF0 TI TTTU72V DMJKAF0 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMJKAF0 MA Inhibitor DMJKAF0 RN Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11. DMJKAF0 RU https://pubmed.ncbi.nlm.nih.gov/10987415 DMJKAQR DI DMJKAQR DMJKAQR DN L-790070 DMJKAQR TI TTAN5W2 DMJKAQR TN Raf messenger RNA (Raf mRNA) DMJKAQR MA Inhibitor DMJKAQR RN Design, synthesis, and biological evaluation of novel Tri- and tetrasubstituted imidazoles as highly potent and specific ATP-mimetic inhibitors of ... J Med Chem. 2008 Jul 24;51(14):4122-49. DMJKAQR RU https://pubmed.ncbi.nlm.nih.gov/18578517 DMJKC45 DI DMJKC45 DMJKC45 DN ISIS 7851 DMJKC45 TI TTAN5W2 DMJKC45 TN Raf messenger RNA (Raf mRNA) DMJKC45 RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMJKC45 RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMJKE4M DI DMJKE4M DMJKE4M DN SB-218655 DMJKE4M TI TTQBR95 DMJKE4M TN Stress-activated protein kinase 2a (p38 alpha) DMJKE4M MA Inhibitor DMJKE4M RN In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. DMJKE4M RU https://pubmed.ncbi.nlm.nih.gov/20188577 DMJKF17 DI DMJKF17 DMJKF17 DN 4-Imidazol-1-yl-2-phenyl-chroman-7-ol DMJKF17 TI TTSZLWK DMJKF17 TN Aromatase (CYP19A1) DMJKF17 MA Inhibitor DMJKF17 RN Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8. DMJKF17 RU https://pubmed.ncbi.nlm.nih.gov/15380230 DMJKH28 DI DMJKH28 DMJKH28 DN PD-144418 DMJKH28 TI TTTPE1L DMJKH28 TN HUMAN opioid receptor sigma 1 (OPRS1) DMJKH28 MA Antagonist DMJKH28 RN A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DMJKH28 RU https://www.nature.com/articles/s41586-020-2286-9 DMJKHAB DI DMJKHAB DMJKHAB DN C(his-D-phe-arg-trp-Ahx) DMJKHAB TI TTD0CIQ DMJKHAB TN Melanocortin receptor 4 (MC4R) DMJKHAB MA Inhibitor DMJKHAB RN Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6. DMJKHAB RU https://pubmed.ncbi.nlm.nih.gov/16678415 DMJKIUX DI DMJKIUX DMJKIUX DN hypoglaucin A DMJKIUX TI TT1UCIJ DMJKIUX TN C-X-C chemokine receptor type 3 (CXCR3) DMJKIUX MA Antagonist DMJKIUX RN Discovery of structurally diverse natural product antagonists of chemokine receptor CXCR3. Mol Divers. 2005;9(1-3):123-9. DMJKIUX RU https://pubmed.ncbi.nlm.nih.gov/15789559 DMJKL3Z DI DMJKL3Z DMJKL3Z DN 8-(2-Cyclopropyl-ethoxy)-quinolin-2-ylamine DMJKL3Z TI TTX4RTB DMJKL3Z TN Melanin-concentrating hormone receptor 1 (MCHR1) DMJKL3Z MA Inhibitor DMJKL3Z RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMJKL3Z RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMJKOFW DI DMJKOFW DMJKOFW DN (E)-5-Nitrooctadec-5-enoic Acid DMJKOFW TI TTT2SVW DMJKOFW TN PPAR-gamma messenger RNA (PPARG mRNA) DMJKOFW MA Inhibitor DMJKOFW RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMJKOFW RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMJKQ5I DI DMJKQ5I DMJKQ5I DN 5-amino-3-(N-methylpiperidin-4-yl)-1H-indole DMJKQ5I TI TT6MSOK DMJKQ5I TN 5-HT 1D receptor (HTR1D) DMJKQ5I MA Inhibitor DMJKQ5I RN Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16. DMJKQ5I RU https://pubmed.ncbi.nlm.nih.gov/18507369 DMJKQ5I DI DMJKQ5I DMJKQ5I DN 5-amino-3-(N-methylpiperidin-4-yl)-1H-indole DMJKQ5I TI TTK8CXU DMJKQ5I TN 5-HT 1B receptor (HTR1B) DMJKQ5I MA Inhibitor DMJKQ5I RN Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16. DMJKQ5I RU https://pubmed.ncbi.nlm.nih.gov/18507369 DMJKUQI DI DMJKUQI DMJKUQI DN 4-(5-bromo-1H-indol-3-yl)pyrimidin-2-amine DMJKUQI TI TTRSMW9 DMJKUQI TN Glycogen synthase kinase-3 beta (GSK-3B) DMJKUQI MA Inhibitor DMJKUQI RN Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. DMJKUQI RU https://pubmed.ncbi.nlm.nih.gov/18929433 DMJKVZ3 DI DMJKVZ3 DMJKVZ3 DN 2-(3,4-Difluorophenyl)-2,2-diphenylacetamide DMJKVZ3 TI TTMNI76 DMJKVZ3 TN Calcium-activated potassium channel (KCN) DMJKVZ3 MA Inhibitor DMJKVZ3 RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMJKVZ3 RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMJKW4S DI DMJKW4S DMJKW4S DN Isocitric Acid DMJKW4S TI TTMTF2P DMJKW4S TN Citrate hydro-lyase (ACO2) DMJKW4S MA Inhibitor DMJKW4S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJKW4S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJKWFI DI DMJKWFI DMJKWFI DN 4,4'-(4-phenylpyridine-2,6-diyl)diphenol DMJKWFI TI TT0IHXV DMJKWFI TN DNA topoisomerase II (TOP2) DMJKWFI MA Inhibitor DMJKWFI RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMJKWFI RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMJKWNY DI DMJKWNY DMJKWNY DN [3H]RY80 DMJKWNY TI TTNZPQ1 DMJKWNY TN GABA(A) receptor alpha-5 (GABRA5) DMJKWNY MA Modulator DMJKWNY RN [3H]RY 80: A high-affinity, selective ligand for gamma-aminobutyric acidA receptors containing alpha-5 subunits. J Pharmacol Exp Ther. 1997 Nov;283(2):488-93. DMJKWNY RU https://pubmed.ncbi.nlm.nih.gov/9353361 DMJKZUC DI DMJKZUC DMJKZUC DN NC-2100 DMJKZUC TI TTSC2YM DMJKZUC TN Mitochondrial uncoupling protein 2 (UCP2) DMJKZUC MA Inducer DMJKZUC RN A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes. 2000 May;49(5):759-67. DMJKZUC RU https://pubmed.ncbi.nlm.nih.gov/10905484 DMJKZUC DI DMJKZUC DMJKZUC DN NC-2100 DMJKZUC TI TTI12YJ DMJKZUC TN Mitochondrial uncoupling protein 1 (UCP1) DMJKZUC MA Inducer DMJKZUC RN A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes. 2000 May;49(5):759-67. DMJKZUC RU https://pubmed.ncbi.nlm.nih.gov/10905484 DMJL6HX DI DMJL6HX DMJL6HX DN SKI-2852 DMJL6HX TI TTN7BL9 DMJL6HX TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMJL6HX MA Inhibitor DMJL6HX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2763). DMJL6HX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2763 DMJL6ZM DI DMJL6ZM DMJL6ZM DN UNC569 DMJL6ZM TI TTO7LKR DMJL6ZM TN Tyrosine-protein kinase Mer (MERTK) DMJL6ZM MA Inhibitor DMJL6ZM RN UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77. DMJL6ZM RU https://pubmed.ncbi.nlm.nih.gov/23997116 DMJL8QZ DI DMJL8QZ DMJL8QZ DN (1-Amino-3-methylsulfanyl-propyl)-phosphinic acid DMJL8QZ TI TTPHMWB DMJL8QZ TN Aminopeptidase N (ANPEP) DMJL8QZ MA Inhibitor DMJL8QZ RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMJL8QZ RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMJL8SE DI DMJL8SE DMJL8SE DN (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K DMJL8SE TI TTX3HNZ DMJL8SE TN Galanin receptor type 1 (GAL1-R) DMJL8SE MA Inhibitor DMJL8SE RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMJL8SE RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMJL8SE DI DMJL8SE DMJL8SE DN (Sar)WTLNSAGYLLGPKK(Lys-decanoyl)K DMJL8SE TI TTBPW3J DMJL8SE TN Galanin receptor type 2 (GAL2-R) DMJL8SE MA Inhibitor DMJL8SE RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMJL8SE RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMJLFOQ DI DMJLFOQ DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide DMJLFOQ TI TTYHPU6 DMJLFOQ TN Histone deacetylase 10 (HDAC10) DMJLFOQ MA Inhibitor DMJLFOQ RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DMJLFOQ RU https://pubmed.ncbi.nlm.nih.gov/15808449 DMJLFOQ DI DMJLFOQ DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide DMJLFOQ TI TTSHTOI DMJLFOQ TN Histone deacetylase 2 (HDAC2) DMJLFOQ MA Inhibitor DMJLFOQ RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DMJLFOQ RU https://pubmed.ncbi.nlm.nih.gov/15808449 DMJLFOQ DI DMJLFOQ DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide DMJLFOQ TI TTBH0VX DMJLFOQ TN Histone deacetylase (HDAC) DMJLFOQ MA Inhibitor DMJLFOQ RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DMJLFOQ RU https://pubmed.ncbi.nlm.nih.gov/15808449 DMJLFOQ DI DMJLFOQ DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide DMJLFOQ TI TTTQGH8 DMJLFOQ TN Histone deacetylase 4 (HDAC4) DMJLFOQ MA Inhibitor DMJLFOQ RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DMJLFOQ RU https://pubmed.ncbi.nlm.nih.gov/15808449 DMJLFOQ DI DMJLFOQ DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide DMJLFOQ TI TT5ZKDI DMJLFOQ TN Histone deacetylase 6 (HDAC6) DMJLFOQ MA Inhibitor DMJLFOQ RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DMJLFOQ RU https://pubmed.ncbi.nlm.nih.gov/15808449 DMJLFOQ DI DMJLFOQ DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide DMJLFOQ TI TT6R7JZ DMJLFOQ TN Histone deacetylase 1 (HDAC1) DMJLFOQ MA Inhibitor DMJLFOQ RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DMJLFOQ RU https://pubmed.ncbi.nlm.nih.gov/15808449 DMJLFOQ DI DMJLFOQ DMJLFOQ DN N-(2-Mercapto-ethyl)-N'-phenyl-succinamide DMJLFOQ TI TTT6LFV DMJLFOQ TN Histone deacetylase 8 (HDAC8) DMJLFOQ MA Inhibitor DMJLFOQ RN Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72. DMJLFOQ RU https://pubmed.ncbi.nlm.nih.gov/15808449 DMJLHE7 DI DMJLHE7 DMJLHE7 DN ISIS 103629 DMJLHE7 TI TTBWMKT DMJLHE7 TN WWP1 messenger RNA (WWP1 mRNA) DMJLHE7 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMJLHE7 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMJLSX0 DI DMJLSX0 DMJLSX0 DN Ro4491533 DMJLSX0 TI TT8A9EF DMJLSX0 TN Metabotropic glutamate receptor 3 (mGluR3) DMJLSX0 MA Modulator (allosteric modulator) DMJLSX0 RN Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6969-74. DMJLSX0 RU https://pubmed.ncbi.nlm.nih.gov/20971004 DMJLSX0 DI DMJLSX0 DMJLSX0 DN Ro4491533 DMJLSX0 TI TTXJ47W DMJLSX0 TN Metabotropic glutamate receptor 2 (mGluR2) DMJLSX0 MA Modulator (allosteric modulator) DMJLSX0 RN Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet. 2011 Dec;25(4):152-66. DMJLSX0 RU https://pubmed.ncbi.nlm.nih.gov/22091727 DMJLUFM DI DMJLUFM DMJLUFM DN phenamil DMJLUFM TI TTAHD89 DMJLUFM TN Polycystic kidney disease 2-like 1 (TRPP2) DMJLUFM MA Blocker (channel blocker) DMJLUFM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505). DMJLUFM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=505 DMJM2H1 DI DMJM2H1 DMJM2H1 DN 4-(benzylideneamino)benzoic acid DMJM2H1 TI TTANPDJ DMJM2H1 TN Carbonic anhydrase II (CA-II) DMJM2H1 MA Inhibitor DMJM2H1 RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DMJM2H1 RU https://pubmed.ncbi.nlm.nih.gov/19796939 DMJM5VW DI DMJM5VW DMJM5VW DN 2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol DMJM5VW TI TTZAYWL DMJM5VW TN Estrogen receptor (ESR) DMJM5VW MA Inhibitor DMJM5VW RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMJM5VW RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMJM5VW DI DMJM5VW DMJM5VW DN 2-(3-Butoxy-4-hydroxy-phenyl)-benzooxazol-6-ol DMJM5VW TI TTOM3J0 DMJM5VW TN Estrogen receptor beta (ESR2) DMJM5VW MA Inhibitor DMJM5VW RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMJM5VW RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMJM8OQ DI DMJM8OQ DMJM8OQ DN BMS pyrazole inhibitor 7f DMJM8OQ TI TTIZQFJ DMJM8OQ TN Histone-arginine methyltransferase CARM1 (CARM1) DMJM8OQ MA Inhibitor DMJM8OQ RN Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1). Bioorg Med Chem Lett. 2009 Jun 1;19(11):2924-7. DMJM8OQ RU https://pubmed.ncbi.nlm.nih.gov/19419866 DMJMC43 DI DMJMC43 DMJMC43 DN Rp-8-CPT-cGMPS DMJMC43 TI TT7IZSA DMJMC43 TN Protein kinase G1 (PRKG1) DMJMC43 MA Inhibitor DMJMC43 RN (Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor. Eur J Pharmacol. 1994 Oct 14;269(2):265-8. DMJMC43 RU https://pubmed.ncbi.nlm.nih.gov/7851503 DMJMCDP DI DMJMCDP DMJMCDP DN AD-412 DMJMCDP TI TTT7PJU DMJMCDP TN Janus kinase 3 (JAK-3) DMJMCDP MA Inhibitor DMJMCDP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049). DMJMCDP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2049 DMJMDNX DI DMJMDNX DMJMDNX DN 1-amino-4-chloroanthracene-9,10-dione DMJMDNX TI TTM2AOE DMJMDNX TN Adenosine A2a receptor (ADORA2A) DMJMDNX MA Inhibitor DMJMDNX RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DMJMDNX RU https://pubmed.ncbi.nlm.nih.gov/20095623 DMJMHAV DI DMJMHAV DMJMHAV DN Cyclo-[-Arg-Gly-Asp-Amp28-] DMJMHAV TI TTT1R2L DMJMHAV TN Integrin alpha-V (ITGAV) DMJMHAV MA Inhibitor DMJMHAV RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMJMHAV RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMJMHAV DI DMJMHAV DMJMHAV DN Cyclo-[-Arg-Gly-Asp-Amp28-] DMJMHAV TI TTJA1ZO DMJMHAV TN ITGB3 messenger RNA (ITGB3 mRNA) DMJMHAV MA Inhibitor DMJMHAV RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMJMHAV RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMJMLKA DI DMJMLKA DMJMLKA DN Phe-Pro-Glu DMJMLKA TI TTLD29N DMJMLKA TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMJMLKA MA Inhibitor DMJMLKA RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMJMLKA RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMJMLKA DI DMJMLKA DMJMLKA DN Phe-Pro-Glu DMJMLKA TI TTKJEMQ DMJMLKA TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMJMLKA MA Inhibitor DMJMLKA RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMJMLKA RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMJMLKA DI DMJMLKA DMJMLKA DN Phe-Pro-Glu DMJMLKA TI TTN9D8E DMJMLKA TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMJMLKA MA Inhibitor DMJMLKA RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMJMLKA RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMJMOAI DI DMJMOAI DMJMOAI DN 4-iodophenyl-alaninyl-(S)-2-cyano-pyrrolidine DMJMOAI TI TTDIGC1 DMJMOAI TN Dipeptidyl peptidase 4 (DPP-4) DMJMOAI MA Inhibitor DMJMOAI RN Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2006 Jan 1;16(1):123-8. DMJMOAI RU https://pubmed.ncbi.nlm.nih.gov/16236500 DMJMOUK DI DMJMOUK DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide DMJMOUK TI TT5ZKDI DMJMOUK TN Histone deacetylase 6 (HDAC6) DMJMOUK MA Inhibitor DMJMOUK RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMJMOUK RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMJMOUK DI DMJMOUK DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide DMJMOUK TI TT6R7JZ DMJMOUK TN Histone deacetylase 1 (HDAC1) DMJMOUK MA Inhibitor DMJMOUK RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMJMOUK RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMJMOUK DI DMJMOUK DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide DMJMOUK TI TTTQGH8 DMJMOUK TN Histone deacetylase 4 (HDAC4) DMJMOUK MA Inhibitor DMJMOUK RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMJMOUK RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMJMOUK DI DMJMOUK DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide DMJMOUK TI TTBH0VX DMJMOUK TN Histone deacetylase (HDAC) DMJMOUK MA Inhibitor DMJMOUK RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMJMOUK RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMJMOUK DI DMJMOUK DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide DMJMOUK TI TTT6LFV DMJMOUK TN Histone deacetylase 8 (HDAC8) DMJMOUK MA Inhibitor DMJMOUK RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMJMOUK RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMJMOUK DI DMJMOUK DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide DMJMOUK TI TTSHTOI DMJMOUK TN Histone deacetylase 2 (HDAC2) DMJMOUK MA Inhibitor DMJMOUK RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMJMOUK RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMJMOUK DI DMJMOUK DMJMOUK DN 7-Mercapto-heptanoic acid biphenyl-4-ylamide DMJMOUK TI TTYHPU6 DMJMOUK TN Histone deacetylase 10 (HDAC10) DMJMOUK MA Inhibitor DMJMOUK RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMJMOUK RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMJMTVQ DI DMJMTVQ DMJMTVQ DN (+/-)-7-methoxy-2-p-tolylchroman-4-one DMJMTVQ TI TTGP7BY DMJMTVQ TN Monoamine oxidase type B (MAO-B) DMJMTVQ MA Inhibitor DMJMTVQ RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMJMTVQ RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMJMU09 DI DMJMU09 DMJMU09 DN PF-18298 DMJMU09 TI TTAWNKZ DMJMU09 TN Norepinephrine transporter (NET) DMJMU09 MA Inhibitor DMJMU09 RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMJMU09 RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMJMU09 DI DMJMU09 DMJMU09 DN PF-18298 DMJMU09 TI TTVBI8W DMJMU09 TN Dopamine transporter (DAT) DMJMU09 MA Inhibitor DMJMU09 RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMJMU09 RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMJMU09 DI DMJMU09 DMJMU09 DN PF-18298 DMJMU09 TI TT3ROYC DMJMU09 TN Serotonin transporter (SERT) DMJMU09 MA Inhibitor DMJMU09 RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMJMU09 RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMJMWOE DI DMJMWOE DMJMWOE DN 8-Phenyl-2-thiomorpholin-4-yl-chromen-4-one DMJMWOE TI TTK3PY9 DMJMWOE TN DNA-dependent protein kinase catalytic (PRKDC) DMJMWOE MA Inhibitor DMJMWOE RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMJMWOE RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMJN0BL DI DMJN0BL DMJN0BL DN HAMI3379 DMJN0BL TI TT0PZR5 DMJN0BL TN Leukotriene CysLT2 receptor (CYSLTR2) DMJN0BL MA Antagonist DMJN0BL RN Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409. DMJN0BL RU https://pubmed.ncbi.nlm.nih.gov/20423349 DMJN2OW DI DMJN2OW DMJN2OW DN 4-((2R,3S)-2-Methyl-pyrrolidin-3-yl)-1H-imidazole DMJN2OW TI TT9JNIC DMJN2OW TN Histamine H3 receptor (H3R) DMJN2OW MA Inhibitor DMJN2OW RN A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9. DMJN2OW RU https://pubmed.ncbi.nlm.nih.gov/7752184 DMJN659 DI DMJN659 DMJN659 DN (S)-cetirizine DMJN659 TI TTTIBOJ DMJN659 TN Histamine H1 receptor (H1R) DMJN659 MA Antagonist DMJN659 RN Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur J Biochem. 2004 Jul;271(13):2636-46. DMJN659 RU https://pubmed.ncbi.nlm.nih.gov/15206929 DMJN8XK DI DMJN8XK DMJN8XK DN [2-(Pyrazol-1-yl)ethyl]-bisphosphonic acid DMJN8XK TI TTIKWV4 DMJN8XK TN Geranyltranstransferase (FDPS) DMJN8XK MA Inhibitor DMJN8XK RN Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7. DMJN8XK RU https://pubmed.ncbi.nlm.nih.gov/18937434 DMJN93U DI DMJN93U DMJN93U DN 3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine DMJN93U TI TTIQUX7 DMJN93U TN Steroid 11-beta-hydroxylase (CYP11B1) DMJN93U MA Inhibitor DMJN93U RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMJN93U RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMJN93U DI DMJN93U DMJN93U DN 3-[4-Methyl-indan-(1E)-ylidenemethyl]-pyridine DMJN93U TI TTSZLWK DMJN93U TN Aromatase (CYP19A1) DMJN93U MA Inhibitor DMJN93U RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMJN93U RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMJNAX5 DI DMJNAX5 DMJNAX5 DN 1-phenyl-3-(3-(pyridin-2-yl)isoquinolin-1-yl)urea DMJNAX5 TI TTJFY5U DMJNAX5 TN Adenosine A3 receptor (ADORA3) DMJNAX5 MA Inhibitor DMJNAX5 RN Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97. DMJNAX5 RU https://pubmed.ncbi.nlm.nih.gov/16821770 DMJNB8C DI DMJNB8C DMJNB8C DN 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine DMJNB8C TI TTVBI8W DMJNB8C TN Dopamine transporter (DAT) DMJNB8C MA Inhibitor DMJNB8C RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJNB8C RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJNB8C DI DMJNB8C DMJNB8C DN 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine DMJNB8C TI TT3ROYC DMJNB8C TN Serotonin transporter (SERT) DMJNB8C MA Inhibitor DMJNB8C RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJNB8C RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJNB8C DI DMJNB8C DMJNB8C DN 4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine DMJNB8C TI TTAWNKZ DMJNB8C TN Norepinephrine transporter (NET) DMJNB8C MA Inhibitor DMJNB8C RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJNB8C RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJNG8A DI DMJNG8A DMJNG8A DN 1-Aminomethyl-3-phenyl-isochroman-5,6-diol DMJNG8A TI TTZFYLI DMJNG8A TN Dopamine D1 receptor (D1R) DMJNG8A MA Inhibitor DMJNG8A RN (1R,3S)-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran: a potent and selective D1 agonist. J Med Chem. 1990 Nov;33(11):2948-50. DMJNG8A RU https://pubmed.ncbi.nlm.nih.gov/1977907 DMJNHSL DI DMJNHSL DMJNHSL DN 6,7-Dichloro-3-thiophen-3-yl-quinoline DMJNHSL TI TT8FYO9 DMJNHSL TN Platelet-derived growth factor receptor alpha (PDGFRA) DMJNHSL MA Inhibitor DMJNHSL RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMJNHSL RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMJNHSL DI DMJNHSL DMJNHSL DN 6,7-Dichloro-3-thiophen-3-yl-quinoline DMJNHSL TI TTI7421 DMJNHSL TN Platelet-derived growth factor receptor beta (PDGFRB) DMJNHSL MA Inhibitor DMJNHSL RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMJNHSL RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMJNLQ5 DI DMJNLQ5 DMJNLQ5 DN (12E,20Z,18S)-8-hydroxyvariabilin DMJNLQ5 TI TTZ8EM9 DMJNLQ5 TN Glycine receptor (GlyR) DMJNLQ5 MA Inhibitor DMJNLQ5 RN Ircinialactams: subunit-selective glycine receptor modulators from Australian sponges of the family Irciniidae. Bioorg Med Chem. 2010 Apr 15;18(8):2912-9. DMJNLQ5 RU https://pubmed.ncbi.nlm.nih.gov/20346682 DMJNLSI DI DMJNLSI DMJNLSI DN L-736281 DMJNLSI TI TTZPO1L DMJNLSI TN Substance-P receptor (TACR1) DMJNLSI MA Inhibitor DMJNLSI RN N-heteroaryl-2-phenyl-3-(benzyloxy)piperidines: a novel class of potent orally active human NK1 antagonists. J Med Chem. 1996 Jul 19;39(15):2907-14. DMJNLSI RU https://pubmed.ncbi.nlm.nih.gov/8709125 DMJNQ5G DI DMJNQ5G DMJNQ5G DN ATC0065 DMJNQ5G TI TTX4RTB DMJNQ5G TN Melanin-concentrating hormone receptor 1 (MCHR1) DMJNQ5G MA Antagonist DMJNQ5G RN Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagoni... J Pharmacol Exp Ther. 2005 May;313(2):831-9. DMJNQ5G RU https://pubmed.ncbi.nlm.nih.gov/15677346 DMJNQ5G DI DMJNQ5G DMJNQ5G DN ATC0065 DMJNQ5G TI TTS17MG DMJNQ5G TN Melanin-concentrating hormone receptor 2 (MCHR2) DMJNQ5G MA Antagonist DMJNQ5G RN Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagoni... J Pharmacol Exp Ther. 2005 May;313(2):831-9. DMJNQ5G RU https://pubmed.ncbi.nlm.nih.gov/15677346 DMJNQ9K DI DMJNQ9K DMJNQ9K DN Octanedioic acid bis-hydroxyamide DMJNQ9K TI TTSHTOI DMJNQ9K TN Histone deacetylase 2 (HDAC2) DMJNQ9K MA Inhibitor DMJNQ9K RN Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309. DMJNQ9K RU https://pubmed.ncbi.nlm.nih.gov/12109913 DMJNQ9K DI DMJNQ9K DMJNQ9K DN Octanedioic acid bis-hydroxyamide DMJNQ9K TI TTT6LFV DMJNQ9K TN Histone deacetylase 8 (HDAC8) DMJNQ9K MA Inhibitor DMJNQ9K RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DMJNQ9K RU https://pubmed.ncbi.nlm.nih.gov/20139990 DMJNQ9K DI DMJNQ9K DMJNQ9K DN Octanedioic acid bis-hydroxyamide DMJNQ9K TI TTBH0VX DMJNQ9K TN Histone deacetylase (HDAC) DMJNQ9K MA Inhibitor DMJNQ9K RN Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243. DMJNQ9K RU https://pubmed.ncbi.nlm.nih.gov/20139990 DMJNQ9K DI DMJNQ9K DMJNQ9K DN Octanedioic acid bis-hydroxyamide DMJNQ9K TI TT5ZKDI DMJNQ9K TN Histone deacetylase 6 (HDAC6) DMJNQ9K MA Inhibitor DMJNQ9K RN Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309. DMJNQ9K RU https://pubmed.ncbi.nlm.nih.gov/12109913 DMJNQ9K DI DMJNQ9K DMJNQ9K DN Octanedioic acid bis-hydroxyamide DMJNQ9K TI TT6R7JZ DMJNQ9K TN Histone deacetylase 1 (HDAC1) DMJNQ9K MA Inhibitor DMJNQ9K RN Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309. DMJNQ9K RU https://pubmed.ncbi.nlm.nih.gov/12109913 DMJNQ9K DI DMJNQ9K DMJNQ9K DN Octanedioic acid bis-hydroxyamide DMJNQ9K TI TTTQGH8 DMJNQ9K TN Histone deacetylase 4 (HDAC4) DMJNQ9K MA Inhibitor DMJNQ9K RN Structure-activity relationships on phenylalanine-containing inhibitors of histone deacetylase: in vitro enzyme inhibition, induction of differenti... J Med Chem. 2002 Jul 18;45(15):3296-309. DMJNQ9K RU https://pubmed.ncbi.nlm.nih.gov/12109913 DMJNQE1 DI DMJNQE1 DMJNQE1 DN PMID24749861C34 DMJNQE1 TI TTOJ9QL DMJNQE1 TN Endoplasmic reticulum to nucleus signaling 1 (ERN1) DMJNQE1 MA Inhibitor DMJNQE1 RN Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301. DMJNQE1 RU https://pubmed.ncbi.nlm.nih.gov/24749861 DMJNT95 DI DMJNT95 DMJNT95 DN D[Orn4]AVP DMJNT95 TI TTK8R02 DMJNT95 TN Vasopressin V2 receptor (V2R) DMJNT95 MA Inhibitor DMJNT95 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJNT95 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJNT95 DI DMJNT95 DMJNT95 DN D[Orn4]AVP DMJNT95 TI TT4TFGN DMJNT95 TN Vasopressin V1a receptor (V1AR) DMJNT95 MA Inhibitor DMJNT95 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJNT95 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJNT95 DI DMJNT95 DMJNT95 DN D[Orn4]AVP DMJNT95 TI TTSCIUP DMJNT95 TN Oxytocin receptor (OTR) DMJNT95 MA Inhibitor DMJNT95 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJNT95 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJNT95 DI DMJNT95 DMJNT95 DN D[Orn4]AVP DMJNT95 TI TTL9MHW DMJNT95 TN Vasopressin V1b receptor (V1BR) DMJNT95 MA Inhibitor DMJNT95 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMJNT95 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMJNW9P DI DMJNW9P DMJNW9P DN Cypate-[(RGD)2-NH2]2 DMJNW9P TI TTJA1ZO DMJNW9P TN ITGB3 messenger RNA (ITGB3 mRNA) DMJNW9P MA Inhibitor DMJNW9P RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMJNW9P RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMJNW9P DI DMJNW9P DMJNW9P DN Cypate-[(RGD)2-NH2]2 DMJNW9P TI TTT1R2L DMJNW9P TN Integrin alpha-V (ITGAV) DMJNW9P MA Inhibitor DMJNW9P RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMJNW9P RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMJO3B1 DI DMJO3B1 DMJO3B1 DN N'-(phenylsulfonyl)benzofuran-2-carbohydrazide DMJO3B1 TI TTF9OQ6 DMJO3B1 TN Branched-chain-amino-acid transaminase 2 (BCAT2) DMJO3B1 MA Inhibitor DMJO3B1 RN The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases. Bioorg Med Chem Lett. 2006 May 1;16(9):2337-40. DMJO3B1 RU https://pubmed.ncbi.nlm.nih.gov/16143519 DMJO4I7 DI DMJO4I7 DMJO4I7 DN 6-(3-Chloro-benzenesulfonyl)-2H-pyridazin-3-one DMJO4I7 TI TTFBNVI DMJO4I7 TN Aldose reductase (AKR1B1) DMJO4I7 MA Inhibitor DMJO4I7 RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMJO4I7 RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMJOD1T DI DMJOD1T DMJOD1T DN 3-Phenylcyclopentanecarboxylic acid DMJOD1T TI TT5ZWB6 DMJOD1T TN Dihydrodiol dehydrogenase type I (AKR1C3) DMJOD1T MA Inhibitor DMJOD1T RN New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71. DMJOD1T RU https://pubmed.ncbi.nlm.nih.gov/19237229 DMJORCV DI DMJORCV DMJORCV DN 2-(4-chlorophenylsulfonyl)naphthalene-1,4-diol DMJORCV TI TTRVTMX DMJORCV TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMJORCV MA Inhibitor DMJORCV RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DMJORCV RU https://pubmed.ncbi.nlm.nih.gov/18996691 DMJORFK DI DMJORFK DMJORFK DN Beta-funaltrexamine DMJORFK TI TTKWM86 DMJORFK TN Opioid receptor mu (MOP) DMJORFK MA Inhibitor DMJORFK RN Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors. J Med Chem. 2009 Dec 10;52(23):7372-5. DMJORFK RU https://pubmed.ncbi.nlm.nih.gov/19621878 DMJOZYG DI DMJOZYG DMJOZYG DN Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide DMJOZYG TI TTJFY5U DMJOZYG TN Adenosine A3 receptor (ADORA3) DMJOZYG MA Inhibitor DMJOZYG RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMJOZYG RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMJOZYG DI DMJOZYG DMJOZYG DN Hexanoic Acid (2,6-diphenylpyrimidin-4-yl)amide DMJOZYG TI TTK25J1 DMJOZYG TN Adenosine A1 receptor (ADORA1) DMJOZYG MA Inhibitor DMJOZYG RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMJOZYG RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMJP0QT DI DMJP0QT DMJP0QT DN BURTTINONE DMJP0QT TI TTELIN2 DMJP0QT TN PTPN1 messenger RNA (PTPN1 mRNA) DMJP0QT MA Inhibitor DMJP0QT RN Flavanones from the stem bark of Erythrina abyssinica. Bioorg Med Chem. 2008 Dec 15;16(24):10356-62. DMJP0QT RU https://pubmed.ncbi.nlm.nih.gov/19008110 DMJP5YH DI DMJP5YH DMJP5YH DN 4-(dimethylamino)-N-(thiazol-2-yl)benzamide DMJP5YH TI TTSJ6Q4 DMJP5YH TN LOX-5 messenger RNA (ALOX5 mRNA) DMJP5YH MA Inhibitor DMJP5YH RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMJP5YH RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMJPBAX DI DMJPBAX DMJPBAX DN Oxybutynine DMJPBAX TI TTQ13Z5 DMJPBAX TN Muscarinic acetylcholine receptor M3 (CHRM3) DMJPBAX MA Antagonist DMJPBAX RN Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor. Biochem J. 2008 May 15;412(1):103-12. DMJPBAX RU https://pubmed.ncbi.nlm.nih.gov/18237275 DMJPL7E DI DMJPL7E DMJPL7E DN N-(6-bromo-1H-indazol-3-yl)butyramide DMJPL7E TI TTRSMW9 DMJPL7E TN Glycogen synthase kinase-3 beta (GSK-3B) DMJPL7E MA Inhibitor DMJPL7E RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMJPL7E RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMJPN8Z DI DMJPN8Z DMJPN8Z DN BPR1K-0224 DMJPN8Z TI TTLYXIT DMJPN8Z TN Aurora kinase C (AURKC) DMJPN8Z MA Inhibitor DMJPN8Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DMJPN8Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DMJPR8M DI DMJPR8M DMJPR8M DN PMID25037917C58 DMJPR8M TI TTVBI8W DMJPR8M TN Dopamine transporter (DAT) DMJPR8M MA Inhibitor DMJPR8M RN Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3886-90. DMJPR8M RU https://pubmed.ncbi.nlm.nih.gov/25037917 DMJPR8M DI DMJPR8M DMJPR8M DN PMID25037917C58 DMJPR8M TI TT9LGO5 DMJPR8M TN Sodium-dependent proline transporter (SLC6A7) DMJPR8M MA Inhibitor DMJPR8M RN Novel inhibitors of the high-affinity L-proline transporter as potential therapeutic agents for the treatment of cognitive disorders. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3886-90. DMJPR8M RU https://pubmed.ncbi.nlm.nih.gov/25037917 DMJPYIZ DI DMJPYIZ DMJPYIZ DN 8-(2,4-dimethoxyphenyl)-9H-purine-2,6-diamine DMJPYIZ TI TT9SL3Q DMJPYIZ TN Polypeptide deformylase (PDF) DMJPYIZ MA Inhibitor DMJPYIZ RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DMJPYIZ RU https://pubmed.ncbi.nlm.nih.gov/20117005 DMJQ3LN DI DMJQ3LN DMJQ3LN DN Carbamic Acid DMJQ3LN TI TTHI19T DMJQ3LN TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMJQ3LN MA Inhibitor DMJQ3LN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJQ3LN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJQ4L7 DI DMJQ4L7 DMJQ4L7 DN N-oleoylethanolamide DMJQ4L7 TI TTJ584C DMJQ4L7 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMJQ4L7 MA Agonist DMJQ4L7 RN Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005 Jun;48(8):1147-53. DMJQ4L7 RU https://pubmed.ncbi.nlm.nih.gov/15910890 DMJQ4L7 DI DMJQ4L7 DMJQ4L7 DN N-oleoylethanolamide DMJQ4L7 TI TTNET8J DMJQ4L7 TN G-protein coupled receptor 55 (GPR55) DMJQ4L7 MA Agonist DMJQ4L7 RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DMJQ4L7 RU https://pubmed.ncbi.nlm.nih.gov/17876302 DMJQ4L7 DI DMJQ4L7 DMJQ4L7 DN N-oleoylethanolamide DMJQ4L7 TI TT7QNVC DMJQ4L7 TN Glucose-dependent insulinotropic receptor (GPR119) DMJQ4L7 MA Agonist DMJQ4L7 RN Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609. DMJQ4L7 RU https://pubmed.ncbi.nlm.nih.gov/23396314 DMJQ4L7 DI DMJQ4L7 DMJQ4L7 DN N-oleoylethanolamide DMJQ4L7 TI TT6OEDT DMJQ4L7 TN Cannabinoid receptor 1 (CB1) DMJQ4L7 MA Inhibitor DMJQ4L7 RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMJQ4L7 RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMJQ5B0 DI DMJQ5B0 DMJQ5B0 DN PMID2231594C3q DMJQ5B0 TI TTPADOQ DMJQ5B0 TN HMG-CoA reductase (HMGCR) DMJQ5B0 MA Inhibitor DMJQ5B0 RN Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6. DMJQ5B0 RU https://pubmed.ncbi.nlm.nih.gov/2231594 DMJQ7T0 DI DMJQ7T0 DMJQ7T0 DN 1-(pentyloxy)-4-phenoxybenzene DMJQ7T0 TI TTXZEAJ DMJQ7T0 TN Leukotriene A-4 hydrolase (LTA4H) DMJQ7T0 MA Inhibitor DMJQ7T0 RN Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52. DMJQ7T0 RU https://pubmed.ncbi.nlm.nih.gov/18952425 DMJQ7XD DI DMJQ7XD DMJQ7XD DN Recombinant TSH superagonists DMJQ7XD TI TT6NYJA DMJQ7XD TN Thyrotropin receptor (TSHR) DMJQ7XD MA Agonist DMJQ7XD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 255). DMJQ7XD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=255 DMJQ8AP DI DMJQ8AP DMJQ8AP DN 8-Benzyloxycaffeine DMJQ8AP TI TTGP7BY DMJQ8AP TN Monoamine oxidase type B (MAO-B) DMJQ8AP MA Inhibitor DMJQ8AP RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMJQ8AP RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMJQ8AP DI DMJQ8AP DMJQ8AP DN 8-Benzyloxycaffeine DMJQ8AP TI TT3WG5C DMJQ8AP TN Monoamine oxidase type A (MAO-A) DMJQ8AP MA Inhibitor DMJQ8AP RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMJQ8AP RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMJQFD5 DI DMJQFD5 DMJQFD5 DN 4-tert-butyl-N-o-tolylthiazol-2-amine DMJQFD5 TI TT7HQD0 DMJQFD5 TN C-C chemokine receptor type 4 (CCR4) DMJQFD5 MA Inhibitor DMJQFD5 RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMJQFD5 RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMJQFZH DI DMJQFZH DMJQFZH DN 5-hydroxy-pentanoate DMJQFZH TI TT6TKEN DMJQFZH TN Gamma-hydroxybutyrate receptor (SLC52A2) DMJQFZH MA Inhibitor DMJQFZH RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DMJQFZH RU https://pubmed.ncbi.nlm.nih.gov/3361576 DMJQG82 DI DMJQG82 DMJQG82 DN M&B 28767 DMJQG82 TI TT2O84V DMJQG82 TN Thromboxane A2 receptor (TBXA2R) DMJQG82 MA Agonist DMJQG82 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMJQG82 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMJQG82 DI DMJQG82 DMJQG82 DN M&B 28767 DMJQG82 TI TT79WV3 DMJQG82 TN Prostaglandin E2 receptor EP4 (PTGER4) DMJQG82 MA Agonist DMJQG82 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMJQG82 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMJQG82 DI DMJQG82 DMJQG82 DN M&B 28767 DMJQG82 TI TTT2ZAR DMJQG82 TN Prostaglandin F2-alpha receptor (PTGFR) DMJQG82 MA Agonist DMJQG82 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMJQG82 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMJQG82 DI DMJQG82 DMJQG82 DN M&B 28767 DMJQG82 TI TTG1QMU DMJQG82 TN Prostaglandin E2 receptor EP1 (PTGER1) DMJQG82 MA Agonist DMJQG82 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMJQG82 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMJQG82 DI DMJQG82 DMJQG82 DN M&B 28767 DMJQG82 TI TTPNGDE DMJQG82 TN Prostaglandin E2 receptor EP3 (PTGER3) DMJQG82 MA Agonist DMJQG82 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMJQG82 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMJQG82 DI DMJQG82 DMJQG82 DN M&B 28767 DMJQG82 TI TT1ZAVI DMJQG82 TN Prostaglandin E2 receptor EP2 (PTGER2) DMJQG82 MA Agonist DMJQG82 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMJQG82 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMJQI7A DI DMJQI7A DMJQI7A DN HO-LVA DMJQI7A TI TT4TFGN DMJQI7A TN Vasopressin V1a receptor (V1AR) DMJQI7A MA Inhibitor DMJQI7A RN Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J Med Chem. 2007 Oct 4;50(20):4976-85. DMJQI7A RU https://pubmed.ncbi.nlm.nih.gov/17850055 DMJQM7H DI DMJQM7H DMJQM7H DN ADC-1012 DMJQM7H TI TT6H4QR DMJQM7H TN Interleukin 23 receptor (IL23R) DMJQM7H MA Antagonist DMJQM7H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293). DMJQM7H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293 DMJQNLR DI DMJQNLR DMJQNLR DN 1-(10H-phenothiazin-10-yl)-3-phenylpropan-1-one DMJQNLR TI TTEB0GD DMJQNLR TN Cholinesterase (BCHE) DMJQNLR MA Inhibitor DMJQNLR RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMJQNLR RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMJQS5O DI DMJQS5O DMJQS5O DN ISIS 111085 DMJQS5O TI TTOM97J DMJQS5O TN Cytohesin-2 messenger RNA (CYTH2 mRNA) DMJQS5O RN US patent application no. 6,271,029, Antisense inhibition of cytohesin-2 expression. DMJQS5O RU http://www.patentbuddy.com/Patent/6271029?ft=true&sr=true DMJQSLW DI DMJQSLW DMJQSLW DN Benzo[b]thiophen-2-ylboronic acid DMJQSLW TI TTHI19T DMJQSLW TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMJQSLW MA Inhibitor DMJQSLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJQSLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJQSLW DI DMJQSLW DMJQSLW DN Benzo[b]thiophen-2-ylboronic acid DMJQSLW TI TTDP1UC DMJQSLW TN Fatty acid amide hydrolase (FAAH) DMJQSLW MA Inhibitor DMJQSLW RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMJQSLW RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMJQTIK DI DMJQTIK DMJQTIK DN Ethyl Bis(4-hydroxy-2-oxo-2H-chromen-3-yl)acetate DMJQTIK TI TT8XK6L DMJQTIK TN Quinone reductase 1 (NQO1) DMJQTIK MA Inhibitor DMJQTIK RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DMJQTIK RU https://pubmed.ncbi.nlm.nih.gov/19877692 DMJQVAG DI DMJQVAG DMJQVAG DN S-ATPO DMJQVAG TI TT0MYE2 DMJQVAG TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMJQVAG MA Inhibitor DMJQVAG RN 3-Substituted phenylalanines as selective AMPA- and kainate receptor ligands. Bioorg Med Chem. 2009 Sep 1;17(17):6390-401. DMJQVAG RU https://pubmed.ncbi.nlm.nih.gov/19656686 DMJQZMH DI DMJQZMH DMJQZMH DN N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine DMJQZMH TI TT1RS9F DMJQZMH TN Acetylcholinesterase (AChE) DMJQZMH MA Inhibitor DMJQZMH RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMJQZMH RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMJQZMH DI DMJQZMH DMJQZMH DN N-phenethyl-2-(pyrrolidin-1-yl)pyrimidin-4-amine DMJQZMH TI TTEB0GD DMJQZMH TN Cholinesterase (BCHE) DMJQZMH MA Inhibitor DMJQZMH RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMJQZMH RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMJR5UD DI DMJR5UD DMJR5UD DN C[Glu18-Lys22][Gly8]GLP-1(7-37)-NH2 DMJR5UD TI TTVIMDE DMJR5UD TN Glucagon-like peptide 1 receptor (GLP1R) DMJR5UD MA Inhibitor DMJR5UD RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMJR5UD RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMJR983 DI DMJR983 DMJR983 DN 3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone DMJR983 TI TT27RFC DMJR983 TN Opioid receptor delta (OPRD1) DMJR983 MA Inhibitor DMJR983 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMJR983 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMJR983 DI DMJR983 DMJR983 DN 3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone DMJR983 TI TTKWM86 DMJR983 TN Opioid receptor mu (MOP) DMJR983 MA Inhibitor DMJR983 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMJR983 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMJRBKO DI DMJRBKO DMJRBKO DN 5-(6-hydroxynaphthalen-2-yl)benzene-1,3-diol DMJRBKO TI TTULVH8 DMJRBKO TN Tyrosinase (TYR) DMJRBKO MA Inhibitor DMJRBKO RN Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Jan 15;17(2):461-4. DMJRBKO RU https://pubmed.ncbi.nlm.nih.gov/17064896 DMJRBT1 DI DMJRBT1 DMJRBT1 DN 3-(naphthalen-2-yl)pyridine DMJRBT1 TI TTSZLWK DMJRBT1 TN Aromatase (CYP19A1) DMJRBT1 MA Inhibitor DMJRBT1 RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMJRBT1 RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMJRBT1 DI DMJRBT1 DMJRBT1 DN 3-(naphthalen-2-yl)pyridine DMJRBT1 TI TTIQUX7 DMJRBT1 TN Steroid 11-beta-hydroxylase (CYP11B1) DMJRBT1 MA Inhibitor DMJRBT1 RN Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49. DMJRBT1 RU https://pubmed.ncbi.nlm.nih.gov/18763754 DMJRDAQ DI DMJRDAQ DMJRDAQ DN 2-(4-Amino-phenyl)-8-methyl-3H-quinazolin-4-one DMJRDAQ TI TTVDSZ0 DMJRDAQ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMJRDAQ MA Inhibitor DMJRDAQ RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMJRDAQ RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMJRGZT DI DMJRGZT DMJRGZT DN TUG-891 DMJRGZT TI TT08JVB DMJRGZT TN G-protein coupled receptor 120 (GPR120) DMJRGZT MA Agonist DMJRGZT RN Discovery of a potent and selective GPR120 agonist. J Med Chem. 2012 May 10;55(9):4511-5. DMJRGZT RU https://pubmed.ncbi.nlm.nih.gov/22519963 DMJRI6A DI DMJRI6A DMJRI6A DN VN/107-1 DMJRI6A TI TTRA5BZ DMJRI6A TN Steroid 17-alpha-monooxygenase (S17AH) DMJRI6A MA Inhibitor DMJRI6A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1361). DMJRI6A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1361 DMJRK47 DI DMJRK47 DMJRK47 DN M-Phenoxybenzoic Acid For Cis-Isomer DMJRK47 TI TT5ZWB6 DMJRK47 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMJRK47 MA Inhibitor DMJRK47 RN Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of ant... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5170-5. DMJRK47 RU https://pubmed.ncbi.nlm.nih.gov/16183274 DMJRLB5 DI DMJRLB5 DMJRLB5 DN PMID19289283C22 DMJRLB5 TI TTVBPDM DMJRLB5 TN Metabotropic glutamate receptor 1 (mGluR1) DMJRLB5 MA Modulator (allosteric modulator) DMJRLB5 RN In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. DMJRLB5 RU https://pubmed.ncbi.nlm.nih.gov/19289283 DMJRNI7 DI DMJRNI7 DMJRNI7 DN 3-(Octahydro-indolizin-8-yl)-phenol DMJRNI7 TI TTEX248 DMJRNI7 TN Dopamine D2 receptor (D2R) DMJRNI7 MA Inhibitor DMJRNI7 RN Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22. DMJRNI7 RU https://pubmed.ncbi.nlm.nih.gov/1968512 DMJRNWK DI DMJRNWK DMJRNWK DN ISIS 20585 DMJRNWK TI TTSRXJW DMJRNWK TN G-alpha-11 messenger RNA (GNA11 mRNA) DMJRNWK RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DMJRNWK RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DMJRSIF DI DMJRSIF DMJRSIF DN COCAINE.HCL DMJRSIF TI TTVBI8W DMJRSIF TN Dopamine transporter (DAT) DMJRSIF MA Inhibitor DMJRSIF RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DMJRSIF RU https://pubmed.ncbi.nlm.nih.gov/17489581 DMJRSIF DI DMJRSIF DMJRSIF DN COCAINE.HCL DMJRSIF TI TT3ROYC DMJRSIF TN Serotonin transporter (SERT) DMJRSIF MA Inhibitor DMJRSIF RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DMJRSIF RU https://pubmed.ncbi.nlm.nih.gov/17489581 DMJRVBS DI DMJRVBS DMJRVBS DN VERAGUENSIN DMJRVBS TI TTQL5VC DMJRVBS TN Platelet-activating factor receptor (PTAFR) DMJRVBS MA Inhibitor DMJRVBS RN Development, synthesis, and biological evaluation of (-)-trans-(2S,5S)-2-[3-[(2-oxopropyl)sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy)-phenyl]-5-(3,... J Med Chem. 1992 Sep 18;35(19):3474-82. DMJRVBS RU https://pubmed.ncbi.nlm.nih.gov/1404229 DMJRXLD DI DMJRXLD DMJRXLD DN 5,3'-Dipropyl-biphenyl-2,4'-diol DMJRXLD TI TT8NGED DMJRXLD TN Prostaglandin G/H synthase 1 (COX-1) DMJRXLD MA Inhibitor DMJRXLD RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMJRXLD RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMJRXLD DI DMJRXLD DMJRXLD DN 5,3'-Dipropyl-biphenyl-2,4'-diol DMJRXLD TI TTVKILB DMJRXLD TN Prostaglandin G/H synthase 2 (COX-2) DMJRXLD MA Inhibitor DMJRXLD RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMJRXLD RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMJRXLD DI DMJRXLD DMJRXLD DN 5,3'-Dipropyl-biphenyl-2,4'-diol DMJRXLD TI TTSJ6Q4 DMJRXLD TN LOX-5 messenger RNA (ALOX5 mRNA) DMJRXLD MA Inhibitor DMJRXLD RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMJRXLD RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMJS0F5 DI DMJS0F5 DMJS0F5 DN PMID24900311C1a DMJS0F5 TI TTOL9B0 DMJS0F5 TN G-protein-coupled receptor PGR3 (GPR139) DMJS0F5 MA Agonist DMJS0F5 RN Discovery and SAR of a Series of Agonists at Orphan G Protein-Coupled Receptor 139. ACS Med Chem Lett. 2011 Feb 28;2(4):303-6. DMJS0F5 RU https://pubmed.ncbi.nlm.nih.gov/24900311 DMJS62X DI DMJS62X DMJS62X DN Fluoro loxoprofen DMJS62X TI TTVKILB DMJS62X TN Prostaglandin G/H synthase 2 (COX-2) DMJS62X MA Inhibitor DMJS62X RN Properties and synthesis of 2-{2-fluoro (or bromo)-4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid: nonsteroidal anti-inflammatory drugs with low... J Med Chem. 2010 Nov 11;53(21):7879-82. DMJS62X RU https://pubmed.ncbi.nlm.nih.gov/20954731 DMJS6B0 DI DMJS6B0 DMJS6B0 DN ISIS 6720 DMJS6B0 TI TTAN5W2 DMJS6B0 TN Raf messenger RNA (Raf mRNA) DMJS6B0 RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMJS6B0 RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMJS6IZ DI DMJS6IZ DMJS6IZ DN (-)-isoelaeocarpiline DMJS6IZ TI TT27RFC DMJS6IZ TN Opioid receptor delta (OPRD1) DMJS6IZ MA Inhibitor DMJS6IZ RN Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9. DMJS6IZ RU https://pubmed.ncbi.nlm.nih.gov/16989522 DMJS7MV DI DMJS7MV DMJS7MV DN ISOSAKUTANETIN DMJS7MV TI TTI84H7 DMJS7MV TN Cytochrome P450 1B1 (CYP1B1) DMJS7MV MA Inhibitor DMJS7MV RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMJS7MV RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMJS8VQ DI DMJS8VQ DMJS8VQ DN WH-4-023 DMJS8VQ TI TT6PKBN DMJS8VQ TN Proto-oncogene c-Src (SRC) DMJS8VQ MA Inhibitor DMJS8VQ RN Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem. 2006 Aug 10;49(16):4981-91. DMJS8VQ RU https://pubmed.ncbi.nlm.nih.gov/16884310 DMJS8VQ DI DMJS8VQ DMJS8VQ DN WH-4-023 DMJS8VQ TI TT860QF DMJS8VQ TN LCK tyrosine protein kinase (LCK) DMJS8VQ MA Inhibitor DMJS8VQ RN Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem. 2006 Aug 10;49(16):4981-91. DMJS8VQ RU https://pubmed.ncbi.nlm.nih.gov/16884310 DMJSBFU DI DMJSBFU DMJSBFU DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine DMJSBFU TI TTN9D8E DMJSBFU TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMJSBFU MA Inhibitor DMJSBFU RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMJSBFU RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMJSBFU DI DMJSBFU DMJSBFU DN 2-(4-Phenoxy-benzyl)-3H-benzoimidazol-5-ylamine DMJSBFU TI TTLD29N DMJSBFU TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMJSBFU MA Inhibitor DMJSBFU RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMJSBFU RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMJSCO7 DI DMJSCO7 DMJSCO7 DN [D-Gln3,Ncy(SO2,isopropyl)7]acyline DMJSCO7 TI TT8R70G DMJSCO7 TN Gonadotropin-releasing hormone receptor (GNRHR) DMJSCO7 MA Inhibitor DMJSCO7 RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMJSCO7 RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMJSKIP DI DMJSKIP DMJSKIP DN Thiocolchicine DMJSKIP TI TTYFKSZ DMJSKIP TN Tubulin beta (TUBB) DMJSKIP MA Inhibitor DMJSKIP RN Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)me... J Med Chem. 1993 Mar 5;36(5):544-51. DMJSKIP RU https://pubmed.ncbi.nlm.nih.gov/8496935 DMJSKIP DI DMJSKIP DMJSKIP DN Thiocolchicine DMJSKIP TI TTML2WA DMJSKIP TN Tubulin (TUB) DMJSKIP MA Inhibitor DMJSKIP RN Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)me... J Med Chem. 1993 Mar 5;36(5):544-51. DMJSKIP RU https://pubmed.ncbi.nlm.nih.gov/8496935 DMJSLVT DI DMJSLVT DMJSLVT DN 3-Iodyl-benzoic acid DMJSLVT TI TTELIN2 DMJSLVT TN PTPN1 messenger RNA (PTPN1 mRNA) DMJSLVT MA Inhibitor DMJSLVT RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DMJSLVT RU https://pubmed.ncbi.nlm.nih.gov/10091683 DMJSOTE DI DMJSOTE DMJSOTE DN 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide DMJSOTE TI TTXZ0KQ DMJSOTE TN Matrix metalloproteinase-12 (MMP-12) DMJSOTE MA Inhibitor DMJSOTE RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DMJSOTE RU https://pubmed.ncbi.nlm.nih.gov/10882358 DMJSOTE DI DMJSOTE DMJSOTE DN 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide DMJSOTE TI TTHY57M DMJSOTE TN Matrix metalloproteinase-13 (MMP-13) DMJSOTE MA Inhibitor DMJSOTE RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DMJSOTE RU https://pubmed.ncbi.nlm.nih.gov/10882358 DMJSOTE DI DMJSOTE DMJSOTE DN 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide DMJSOTE TI TTMTWOS DMJSOTE TN Matrix metalloproteinase-7 (MMP-7) DMJSOTE MA Inhibitor DMJSOTE RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DMJSOTE RU https://pubmed.ncbi.nlm.nih.gov/10882358 DMJSOTE DI DMJSOTE DMJSOTE DN 3-Cyclohexanesulfonyl-heptanoic acid hydroxyamide DMJSOTE TI TTMX39J DMJSOTE TN Matrix metalloproteinase-1 (MMP-1) DMJSOTE MA Inhibitor DMJSOTE RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DMJSOTE RU https://pubmed.ncbi.nlm.nih.gov/10882358 DMJSTCK DI DMJSTCK DMJSTCK DN 5-(4-Methoxyphenyl)-4-p-tolylisothiazole DMJSTCK TI TT8NGED DMJSTCK TN Prostaglandin G/H synthase 1 (COX-1) DMJSTCK MA Inhibitor DMJSTCK RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMJSTCK RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMJT4UR DI DMJT4UR DMJT4UR DN N5-[4-(1H-pyrrol-1-yl)phenyl]-L-glutamamide DMJT4UR TI TTXZEAJ DMJT4UR TN Leukotriene A-4 hydrolase (LTA4H) DMJT4UR MA Inhibitor DMJT4UR RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMJT4UR RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMJT6D3 DI DMJT6D3 DMJT6D3 DN [3H]GW2331 DMJT6D3 TI TTT2SVW DMJT6D3 TN PPAR-gamma messenger RNA (PPARG mRNA) DMJT6D3 MA Agonist DMJT6D3 RN Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4318-23. DMJT6D3 RU https://pubmed.ncbi.nlm.nih.gov/9113987 DMJT7VI DI DMJT7VI DMJT7VI DN 1-[bis(4-iodophenyl)methyl]-3-(4-bromophenyl)urea DMJT7VI TI TT6OEDT DMJT7VI TN Cannabinoid receptor 1 (CB1) DMJT7VI MA Inhibitor DMJT7VI RN 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90. DMJT7VI RU https://pubmed.ncbi.nlm.nih.gov/16279809 DMJT93H DI DMJT93H DMJT93H DN MERIOLIN 1 DMJT93H TI TT7HF4W DMJT93H TN Cyclin-dependent kinase 2 (CDK2) DMJT93H MA Inhibitor DMJT93H RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMJT93H RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMJT93H DI DMJT93H DMJT93H DN MERIOLIN 1 DMJT93H TI TTAMQ62 DMJT93H TN Cyclin A2 (CCNA2) DMJT93H MA Inhibitor DMJT93H RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMJT93H RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMJT93H DI DMJT93H DMJT93H DN MERIOLIN 1 DMJT93H TI TT1LVF2 DMJT93H TN Cyclin-dependent kinase 9 (CDK9) DMJT93H MA Inhibitor DMJT93H RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMJT93H RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMJTC2B DI DMJTC2B DMJTC2B DN Phenylmercury DMJTC2B TI TT1O264 DMJTC2B TN Coagulation factor Va (F5) DMJTC2B MA Inhibitor DMJTC2B RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJTC2B RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJTDK9 DI DMJTDK9 DMJTDK9 DN Ki16425 DMJTDK9 TI TTQ6S1K DMJTDK9 TN Lysophosphatidic acid receptor 1 (LPAR1) DMJTDK9 MA Antagonist DMJTDK9 RN Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012 Apr;40(4):1133-41. DMJTDK9 RU https://pubmed.ncbi.nlm.nih.gov/22200658 DMJTDK9 DI DMJTDK9 DMJTDK9 DN Ki16425 DMJTDK9 TI TTO897C DMJTDK9 TN G protein coupled receptor 87 (GPR87) DMJTDK9 MA Antagonist DMJTDK9 RN The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2007 Nov 23;363(3):861-6. DMJTDK9 RU https://pubmed.ncbi.nlm.nih.gov/17905198 DMJTDK9 DI DMJTDK9 DMJTDK9 DN Ki16425 DMJTDK9 TI TTB7Y8I DMJTDK9 TN Lysophosphatidic acid receptor 2 (LPAR2) DMJTDK9 MA Antagonist DMJTDK9 RN Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005. DMJTDK9 RU https://pubmed.ncbi.nlm.nih.gov/14500756 DMJTDK9 DI DMJTDK9 DMJTDK9 DN Ki16425 DMJTDK9 TI TTE2YJR DMJTDK9 TN Lysophosphatidate-3 receptor (LPAR3) DMJTDK9 MA Antagonist DMJTDK9 RN Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005. DMJTDK9 RU https://pubmed.ncbi.nlm.nih.gov/14500756 DMJTGZV DI DMJTGZV DMJTGZV DN Alpha-monofluoromethyl-3,4-dehydroornithine ethyl ester DMJTGZV TI TTUMGNO DMJTGZV TN Ornithine decarboxylase (ODC1) DMJTGZV MA Inhibitor DMJTGZV RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DMJTGZV RU https://pubmed.ncbi.nlm.nih.gov/3115816 DMJTHXY DI DMJTHXY DMJTHXY DN ISIS 2918 DMJTHXY TI TT4SCBE DMJTHXY TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMJTHXY RN US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections. DMJTHXY RU http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true DMJU4AM DI DMJU4AM DMJU4AM DN Ac-WVTH[Cit]LAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2 DMJU4AM TI TTVSFJW DMJU4AM TN Calcitonin gene-related peptide 1 (CALCA) DMJU4AM MA Inhibitor DMJU4AM RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMJU4AM RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMJU5A9 DI DMJU5A9 DMJU5A9 DN RM65 DMJU5A9 TI TTVOJAI DMJU5A9 TN Protein arginine methyltransferase 1 (PRMT1) DMJU5A9 MA Inhibitor DMJU5A9 RN A novel arginine methyltransferase inhibitor with cellular activity. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4150-3. DMJU5A9 RU https://pubmed.ncbi.nlm.nih.gov/17570663 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TTSYM0R DMJU9TG TN Carbonic anhydrase XII (CA-XII) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TTANPDJ DMJU9TG TN Carbonic anhydrase II (CA-II) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TTEYTKG DMJU9TG TN Carbonic anhydrase XIV (CA-XIV) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TTCFSPE DMJU9TG TN Carbonic anhydrase VI (CA-VI) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TT2LVK8 DMJU9TG TN Carbonic anhydrase IX (CA-IX) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TTHQPL7 DMJU9TG TN Carbonic anhydrase I (CA-I) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TTZHA0O DMJU9TG TN Carbonic anhydrase IV (CA-IV) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJU9TG DI DMJU9TG DMJU9TG DN 6-(aminomethyl)-2H-chromen-2-one DMJU9TG TI TTUNARX DMJU9TG TN Carbonic anhydrase (CA) DMJU9TG MA Inhibitor DMJU9TG RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMJU9TG RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMJUQT1 DI DMJUQT1 DMJUQT1 DN L-685,818 DMJUQT1 TI TTA4LDE DMJUQT1 TN Calcineurin (PPP3CA) DMJUQT1 MA Inhibitor DMJUQT1 RN Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob Agents Chemother. 2000 Mar;44(3):739-46. DMJUQT1 RU https://pubmed.ncbi.nlm.nih.gov/10681348 DMJUQT1 DI DMJUQT1 DMJUQT1 DN L-685,818 DMJUQT1 TI TTQW87Y DMJUQT1 TN Opioid receptor kappa (OPRK1) DMJUQT1 MA Antagonist DMJUQT1 RN FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9. DMJUQT1 RU https://pubmed.ncbi.nlm.nih.gov/7684380 DMJUT70 DI DMJUT70 DMJUT70 DN 6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium DMJUT70 TI TTEB0GD DMJUT70 TN Cholinesterase (BCHE) DMJUT70 MA Inhibitor DMJUT70 RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMJUT70 RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMJUT70 DI DMJUT70 DMJUT70 DN 6-methoxy-1,2-dimethyl-9H-beta-carbolin-2-ium DMJUT70 TI TT1RS9F DMJUT70 TN Acetylcholinesterase (AChE) DMJUT70 MA Inhibitor DMJUT70 RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMJUT70 RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMJUTWG DI DMJUTWG DMJUTWG DN Butyl-methyl-prop-2-ynyl-amine hydrochloride DMJUTWG TI TTGP7BY DMJUTWG TN Monoamine oxidase type B (MAO-B) DMJUTWG MA Inhibitor DMJUTWG RN Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13. DMJUTWG RU https://pubmed.ncbi.nlm.nih.gov/1433183 DMJUXKY DI DMJUXKY DMJUXKY DN GTPgammaS DMJUXKY TI TTST1AJ DMJUXKY TN Chloride channel protein 7 (ClC-7) DMJUXKY MA Activator DMJUXKY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 709). DMJUXKY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=709 DMJUXKY DI DMJUXKY DMJUXKY DN GTPgammaS DMJUXKY TI TT0FC1V DMJUXKY TN Volume regulated chloride channel (VRAC) DMJUXKY MA Activator DMJUXKY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DMJUXKY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DMJV3R7 DI DMJV3R7 DMJV3R7 DN KSP-BCS-1-alpha-CHF2-20-epi-22-oxabishomo-26-OH DMJV3R7 TI TTK59TV DMJV3R7 TN Vitamin D3 receptor (VDR) DMJV3R7 MA Inhibitor DMJV3R7 RN Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, an... J Med Chem. 2006 Dec 14;49(25):7513-7. DMJV3R7 RU https://pubmed.ncbi.nlm.nih.gov/17149880 DMJV3UO DI DMJV3UO DMJV3UO DN N-(6-chloro-5-phenyl-1H-indazol-3-yl)butyramide DMJV3UO TI TTRSMW9 DMJV3UO TN Glycogen synthase kinase-3 beta (GSK-3B) DMJV3UO MA Inhibitor DMJV3UO RN Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9. DMJV3UO RU https://pubmed.ncbi.nlm.nih.gov/20189807 DMJVG30 DI DMJVG30 DMJVG30 DN 2-Amino-6-Chloropyrazine DMJVG30 TI TT7HF4W DMJVG30 TN Cyclin-dependent kinase 2 (CDK2) DMJVG30 MA Inhibitor DMJVG30 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJVG30 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJVGUZ DI DMJVGUZ DMJVGUZ DN 5-Benzyl-1H-pyrazole-3-carboxylic acid DMJVGUZ TI TTWNV8U DMJVGUZ TN Nicotinic acid receptor (HCAR2) DMJVGUZ MA Inhibitor DMJVGUZ RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMJVGUZ RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMJVITG DI DMJVITG DMJVITG DN 1-phenyl-3-(2-(pyridin-4-yl)thiazol-4-yl)urea DMJVITG TI TTL4Q97 DMJVITG TN Cyclin-dependent kinase 5 (CDK5) DMJVITG MA Inhibitor DMJVITG RN Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors. Bioorg Med Chem. 2007 Oct 15;15(20):6574-95. DMJVITG RU https://pubmed.ncbi.nlm.nih.gov/17697781 DMJVKMO DI DMJVKMO DMJVKMO DN 3,3'-(4-phenylpyridine-2,6-diyl)diphenol DMJVKMO TI TT0IHXV DMJVKMO TN DNA topoisomerase II (TOP2) DMJVKMO MA Inhibitor DMJVKMO RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMJVKMO RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMJVKMO DI DMJVKMO DMJVKMO DN 3,3'-(4-phenylpyridine-2,6-diyl)diphenol DMJVKMO TI TTGTQHC DMJVKMO TN DNA topoisomerase I (TOP1) DMJVKMO MA Inhibitor DMJVKMO RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMJVKMO RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMJVNQB DI DMJVNQB DMJVNQB DN (-)-hydroxycitrate DMJVNQB TI TT0Z6Y2 DMJVNQB TN ATP-citrate synthase (ACLY) DMJVNQB MA Inhibitor DMJVNQB RN 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11. DMJVNQB RU https://pubmed.ncbi.nlm.nih.gov/17383874 DMJVPF0 DI DMJVPF0 DMJVPF0 DN 4-hydroxybenzylamine DMJVPF0 TI TTT2LD9 DMJVPF0 TN GABA transaminase (ABAT) DMJVPF0 MA Inhibitor DMJVPF0 RN Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5. DMJVPF0 RU https://pubmed.ncbi.nlm.nih.gov/16290145 DMJVPK6 DI DMJVPK6 DMJVPK6 DN N-(4-methoxyphenyl)oleamide DMJVPK6 TI TT6OEDT DMJVPK6 TN Cannabinoid receptor 1 (CB1) DMJVPK6 MA Inhibitor DMJVPK6 RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DMJVPK6 RU https://pubmed.ncbi.nlm.nih.gov/16213718 DMJVQN8 DI DMJVQN8 DMJVQN8 DN (R)-2-(Benzylamino-methyl)-chroman-7-ol DMJVQN8 TI TT4C8EA DMJVQN8 TN Dopamine D3 receptor (D3R) DMJVQN8 MA Inhibitor DMJVQN8 RN Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybri... J Med Chem. 2003 Oct 9;46(21):4377-92. DMJVQN8 RU https://pubmed.ncbi.nlm.nih.gov/14521403 DMJVRPD DI DMJVRPD DMJVRPD DN Ac-I[CV(1Nal)QDWGAHRC]T DMJVRPD TI TTJGY7A DMJVRPD TN Complement C3 (CO3) DMJVRPD MA Inhibitor DMJVRPD RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMJVRPD RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMJVT4K DI DMJVT4K DMJVT4K DN UC-2024 DMJVT4K TI TTEX6LM DMJVT4K TN GABA(A) receptor gamma-3 (GABRG3) DMJVT4K MA Modulator DMJVT4K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMJVT4K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMJVW1N DI DMJVW1N DMJVW1N DN C[-Arg-Gly-Asp-Acpca20-] DMJVW1N TI TTT1R2L DMJVW1N TN Integrin alpha-V (ITGAV) DMJVW1N MA Inhibitor DMJVW1N RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMJVW1N RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMJVW1N DI DMJVW1N DMJVW1N DN C[-Arg-Gly-Asp-Acpca20-] DMJVW1N TI TTJA1ZO DMJVW1N TN ITGB3 messenger RNA (ITGB3 mRNA) DMJVW1N MA Inhibitor DMJVW1N RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMJVW1N RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMJW25X DI DMJW25X DMJW25X DN 10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X TI TTF8JAT DMJW25X TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMJW25X MA Inhibitor DMJW25X RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMJW25X RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMJW25X DI DMJW25X DMJW25X DN 10-methoxy-N(1)-methylburnamine-17-O-veratrate DMJW25X TI TT2UE56 DMJW25X TN Sodium/glucose cotransporter 1 (SGLT1) DMJW25X MA Inhibitor DMJW25X RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMJW25X RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMJW4C5 DI DMJW4C5 DMJW4C5 DN ISIS 144368 DMJW4C5 TI TT5S8DR DMJW4C5 TN APOA1 messenger RNA (APOA1 mRNA) DMJW4C5 RN US patent application no. 7,259,150, Modulation of apolipoprotein (a) expression. DMJW4C5 RU http://www.patentbuddy.com/Patent/7259150?ft=true&sr=true DMJW4CS DI DMJW4CS DMJW4CS DN 2-aminoquinazoline-4-carboxy-(4-bromophenyl)amide DMJW4CS TI TTJFY5U DMJW4CS TN Adenosine A3 receptor (ADORA3) DMJW4CS MA Inhibitor DMJW4CS RN Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606. DMJW4CS RU https://pubmed.ncbi.nlm.nih.gov/18047262 DMJW4I5 DI DMJW4I5 DMJW4I5 DN AKUAMMIGINE DMJW4I5 TI TTWG9A4 DMJW4I5 TN Adrenergic receptor alpha-2A (ADRA2A) DMJW4I5 MA Inhibitor DMJW4I5 RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMJW4I5 RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMJW72O DI DMJW72O DMJW72O DN SB-416 DMJW72O TI TTOZHQC DMJW72O TN P2Y purinoceptor 2 (P2RY2) DMJW72O MA Inhibitor DMJW72O RN Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7. DMJW72O RU https://pubmed.ncbi.nlm.nih.gov/18006312 DMJW8NV DI DMJW8NV DMJW8NV DN SQ-14603 DMJW8NV TI TT3LJ6G DMJW8NV TN Carboxypeptidase A1 (CPA1) DMJW8NV MA Inhibitor DMJW8NV RN Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem. 2007 Nov 29;50(24):6095-103. DMJW8NV RU https://pubmed.ncbi.nlm.nih.gov/17990866 DMJWCAH DI DMJWCAH DMJWCAH DN 7-ethynyl-6H-chromeno[4,3-b]quinoline-3,9-diol DMJWCAH TI TTPNQAC DMJWCAH TN Estrogen-related receptor-alpha (ESRRA) DMJWCAH MA Inhibitor DMJWCAH RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMJWCAH RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMJWED7 DI DMJWED7 DMJWED7 DN CGP 71872 DMJWED7 TI TTDCVZW DMJWED7 TN Gamma-aminobutyric acid B receptor (GABBR) DMJWED7 MA Antagonist DMJWED7 RN Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46. DMJWED7 RU https://pubmed.ncbi.nlm.nih.gov/9069281 DMJWEXQ DI DMJWEXQ DMJWEXQ DN PMID8246234C3h DMJWEXQ TI TTPADOQ DMJWEXQ TN HMG-CoA reductase (HMGCR) DMJWEXQ MA Inhibitor DMJWEXQ RN Inhibitors of cholesterol biosynthesis. 2. 3,5-Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3658-62. DMJWEXQ RU https://pubmed.ncbi.nlm.nih.gov/8246234 DMJWIPS DI DMJWIPS DMJWIPS DN 5-(6-hydroxy-2-naphthyl)pyridin-3-ol DMJWIPS TI TTIWB6L DMJWIPS TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMJWIPS MA Inhibitor DMJWIPS RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DMJWIPS RU https://pubmed.ncbi.nlm.nih.gov/18324762 DMJWK0T DI DMJWK0T DMJWK0T DN PD-137337 DMJWK0T TI TTVFO0U DMJWK0T TN Gastrin/cholecystokinin type B receptor (CCKBR) DMJWK0T MA Inhibitor DMJWK0T RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMJWK0T RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMJWK0T DI DMJWK0T DMJWK0T DN PD-137337 DMJWK0T TI TTCG0AL DMJWK0T TN Cholecystokinin receptor type A (CCKAR) DMJWK0T MA Inhibitor DMJWK0T RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMJWK0T RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMJWT3X DI DMJWT3X DMJWT3X DN HONOKIOL DMJWT3X TI TTSJ6Q4 DMJWT3X TN LOX-5 messenger RNA (ALOX5 mRNA) DMJWT3X MA Inhibitor DMJWT3X RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMJWT3X RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMJWT3X DI DMJWT3X DMJWT3X DN HONOKIOL DMJWT3X TI TT8NGED DMJWT3X TN Prostaglandin G/H synthase 1 (COX-1) DMJWT3X MA Inhibitor DMJWT3X RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMJWT3X RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMJWT3X DI DMJWT3X DMJWT3X DN HONOKIOL DMJWT3X TI TTVKILB DMJWT3X TN Prostaglandin G/H synthase 2 (COX-2) DMJWT3X MA Inhibitor DMJWT3X RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMJWT3X RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMJWTH9 DI DMJWTH9 DMJWTH9 DN N-(1-(1-phenylethyl)piperidin-4-yl)-1-naphthamide DMJWTH9 TI TTJQOD7 DMJWTH9 TN 5-HT 2A receptor (HTR2A) DMJWTH9 MA Inhibitor DMJWTH9 RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9. DMJWTH9 RU https://pubmed.ncbi.nlm.nih.gov/17254782 DMJWZB3 DI DMJWZB3 DMJWZB3 DN Allylcarbamic Acid Biphenyl-3-yl Ester DMJWZB3 TI TTDP1UC DMJWZB3 TN Fatty acid amide hydrolase (FAAH) DMJWZB3 MA Inhibitor DMJWZB3 RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMJWZB3 RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMJX1G9 DI DMJX1G9 DMJX1G9 DN ANIBAMINE DMJX1G9 TI TT2CEJG DMJX1G9 TN C-C chemokine receptor type 5 (CCR5) DMJX1G9 MA Inhibitor DMJX1G9 RN Isolation and structure of antagonists of chemokine receptor (CCR5). J Nat Prod. 2004 Jun;67(6):1036-8. DMJX1G9 RU https://pubmed.ncbi.nlm.nih.gov/15217290 DMJX2CS DI DMJX2CS DMJX2CS DN mabionHER2 DMJX2CS TI TTGKNB4 DMJX2CS TN Epidermal growth factor receptor (EGFR) DMJX2CS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMJX2CS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMJX39N DI DMJX39N DMJX39N DN PIP3 DMJX39N TI TT8SJGB DMJX39N TN Cyclic nucleotide-gated channel alpha-2 (CNGA2) DMJX39N MA Inhibitor (gating inhibitor) DMJX39N RN Interplay between PIP3 and calmodulin regulation of olfactory cyclic nucleotide-gated channels. Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15635-40. DMJX39N RU https://pubmed.ncbi.nlm.nih.gov/17032767 DMJX4GA DI DMJX4GA DMJX4GA DN Lys[Z(NO2)]-Pro DMJX4GA TI TT5LF3C DMJX4GA TN Solute carrier family 15 member 1 (SLC15A1) DMJX4GA MA Inhibitor DMJX4GA RN A novel inhibitor of the mammalian peptide transporter PEPT1. Biochemistry. 2001 Apr 10;40(14):4454-8. DMJX4GA RU https://pubmed.ncbi.nlm.nih.gov/11284702 DMJX4GA DI DMJX4GA DMJX4GA DN Lys[Z(NO2)]-Pro DMJX4GA TI TT27Q3A DMJX4GA TN Solute carrier family 15 member 2 (SLC15A2) DMJX4GA MA Inhibitor DMJX4GA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 985). DMJX4GA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=985 DMJX9E1 DI DMJX9E1 DMJX9E1 DN KRP-100 DMJX9E1 TI TTKWM86 DMJX9E1 TN Opioid receptor mu (MOP) DMJX9E1 MA Antagonist DMJX9E1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMJX9E1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMJX9NQ DI DMJX9NQ DMJX9NQ DN 6,7,8-Trimethoxy-4-methylquinolin-2(1H)-one DMJX9NQ TI TTJLP0R DMJX9NQ TN Quinone reductase 2 (NQO2) DMJX9NQ MA Inhibitor DMJX9NQ RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMJX9NQ RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMJXAF7 DI DMJXAF7 DMJXAF7 DN 2,2,2-tris-(3-fluorophenyl)-acetamide DMJXAF7 TI TTMNI76 DMJXAF7 TN Calcium-activated potassium channel (KCN) DMJXAF7 MA Inhibitor DMJXAF7 RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMJXAF7 RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMJXBWV DI DMJXBWV DMJXBWV DN HERKINORIN DMJXBWV TI TTKWM86 DMJXBWV TN Opioid receptor mu (MOP) DMJXBWV MA Inhibitor DMJXBWV RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMJXBWV RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMJXBWV DI DMJXBWV DMJXBWV DN HERKINORIN DMJXBWV TI TTQW87Y DMJXBWV TN Opioid receptor kappa (OPRK1) DMJXBWV MA Inhibitor DMJXBWV RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMJXBWV RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMJXBWV DI DMJXBWV DMJXBWV DN HERKINORIN DMJXBWV TI TT27RFC DMJXBWV TN Opioid receptor delta (OPRD1) DMJXBWV MA Inhibitor DMJXBWV RN Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31. DMJXBWV RU https://pubmed.ncbi.nlm.nih.gov/18380425 DMJXCVA DI DMJXCVA DMJXCVA DN CYPRODIME DMJXCVA TI TTKWM86 DMJXCVA TN Opioid receptor mu (MOP) DMJXCVA MA Inhibitor DMJXCVA RN Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonis... J Med Chem. 2004 Jun 3;47(12):3242-7. DMJXCVA RU https://pubmed.ncbi.nlm.nih.gov/15163203 DMJXE6K DI DMJXE6K DMJXE6K DN GNF-PF-607 DMJXE6K TI TT9SL3Q DMJXE6K TN Polypeptide deformylase (PDF) DMJXE6K MA Inhibitor DMJXE6K RN CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate r... J Med Chem. 2005 Mar 10;48(5):1448-69. DMJXE6K RU https://pubmed.ncbi.nlm.nih.gov/15743188 DMJXHU8 DI DMJXHU8 DMJXHU8 DN GSK579289A DMJXHU8 TI TTIYVQP DMJXHU8 TN Polo-like kinase 1 (PLK1) DMJXHU8 MA Inhibitor DMJXHU8 RN Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7. DMJXHU8 RU https://pubmed.ncbi.nlm.nih.gov/19237286 DMJXHU8 DI DMJXHU8 DMJXHU8 DN GSK579289A DMJXHU8 TI TT3VZ24 DMJXHU8 TN NIMA-related kinase 2 (NEK2) DMJXHU8 MA Inhibitor DMJXHU8 RN Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1694-7. DMJXHU8 RU https://pubmed.ncbi.nlm.nih.gov/19237286 DMJXI65 DI DMJXI65 DMJXI65 DN 5-(2-Amino-ethyl)-2-chloro-phenol hydrobromide DMJXI65 TI TTZFYLI DMJXI65 TN Dopamine D1 receptor (D1R) DMJXI65 MA Inhibitor DMJXI65 RN Synthesis and pharmacological characterization of 2-(4-chloro-3-hydroxyphenyl)ethylamine and N,N-dialkyl derivatives as dopamine receptor ligands. J Med Chem. 1992 Nov 13;35(23):4408-14. DMJXI65 RU https://pubmed.ncbi.nlm.nih.gov/1360027 DMJXKOF DI DMJXKOF DMJXKOF DN 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine DMJXKOF TI TTAWNKZ DMJXKOF TN Norepinephrine transporter (NET) DMJXKOF MA Inhibitor DMJXKOF RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJXKOF RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJXKOF DI DMJXKOF DMJXKOF DN 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine DMJXKOF TI TTSQIFT DMJXKOF TN 5-HT 1A receptor (HTR1A) DMJXKOF MA Inhibitor DMJXKOF RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJXKOF RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJXKOF DI DMJXKOF DMJXKOF DN 1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine DMJXKOF TI TT3ROYC DMJXKOF TN Serotonin transporter (SERT) DMJXKOF MA Inhibitor DMJXKOF RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMJXKOF RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMJXN1G DI DMJXN1G DMJXN1G DN Soluble ErbB3 theragnostics DMJXN1G TI TTDC8N2 DMJXN1G TN Erbb3 tyrosine kinase receptor (Erbb-3) DMJXN1G MA Inhibitor DMJXN1G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). DMJXN1G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798 DMJXOUK DI DMJXOUK DMJXOUK DN 1-(3-CHLORO-4-FLUOROPHENYL)-2,2,2-TRIFLUORO-1-(1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)ETHANOL (ENANTIOMERIC MIX) DMJXOUK TI TTOZRK6 DMJXOUK TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMJXOUK MA Inhibitor DMJXOUK RN 5-Functionalized indazoles as glucocorticoid receptor agonists. Bioorg Med Chem Lett. 2010 May 15;20(10):3017-20. DMJXOUK RU https://pubmed.ncbi.nlm.nih.gov/20427184 DMJXU67 DI DMJXU67 DMJXU67 DN MCL-145 DMJXU67 TI TTQW87Y DMJXU67 TN Opioid receptor kappa (OPRK1) DMJXU67 MA Inhibitor DMJXU67 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMJXU67 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMJXU67 DI DMJXU67 DMJXU67 DN MCL-145 DMJXU67 TI TT27RFC DMJXU67 TN Opioid receptor delta (OPRD1) DMJXU67 MA Inhibitor DMJXU67 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMJXU67 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMJXU67 DI DMJXU67 DMJXU67 DN MCL-145 DMJXU67 TI TTKWM86 DMJXU67 TN Opioid receptor mu (MOP) DMJXU67 MA Inhibitor DMJXU67 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMJXU67 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMJXV7C DI DMJXV7C DMJXV7C DN N-(2-aminophenyl)quinoxaline-6-carboxamide DMJXV7C TI TTSHTOI DMJXV7C TN Histone deacetylase 2 (HDAC2) DMJXV7C MA Inhibitor DMJXV7C RN Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. DMJXV7C RU https://pubmed.ncbi.nlm.nih.gov/17941625 DMJXV7C DI DMJXV7C DMJXV7C DN N-(2-aminophenyl)quinoxaline-6-carboxamide DMJXV7C TI TT6R7JZ DMJXV7C TN Histone deacetylase 1 (HDAC1) DMJXV7C MA Inhibitor DMJXV7C RN Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. DMJXV7C RU https://pubmed.ncbi.nlm.nih.gov/17941625 DMJXWH0 DI DMJXWH0 DMJXWH0 DN 2-Amino-6-(toluene-3-sulfinyl)-benzonitrile DMJXWH0 TI TT84ETX DMJXWH0 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMJXWH0 MA Inhibitor DMJXWH0 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMJXWH0 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMJXZD5 DI DMJXZD5 DMJXZD5 DN calhex 231 DMJXZD5 TI TTBUYHA DMJXZD5 TN Extracellular calcium-sensing receptor (CASR) DMJXZD5 MA Modulator (allosteric modulator) DMJXZD5 RN Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem. 2003 Dec 5;278(49):49487-94. DMJXZD5 RU https://pubmed.ncbi.nlm.nih.gov/14506236 DMJY1KR DI DMJY1KR DMJY1KR DN BNP-FIX DMJY1KR TI TTFEZ5Q DMJY1KR TN Coagulation factor IX (F9) DMJY1KR MA Modulator DMJY1KR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364). DMJY1KR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364 DMJY2PA DI DMJY2PA DMJY2PA DN N-cyclohexylquinolin-4-amine DMJY2PA TI TTVBPDM DMJY2PA TN Metabotropic glutamate receptor 1 (mGluR1) DMJY2PA MA Inhibitor DMJY2PA RN In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. DMJY2PA RU https://pubmed.ncbi.nlm.nih.gov/19289283 DMJYCHG DI DMJYCHG DMJYCHG DN 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one DMJYCHG TI TTTSEPU DMJYCHG TN Thyroid hormone receptor alpha (THRA) DMJYCHG MA Inhibitor DMJYCHG RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMJYCHG RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMJYCHG DI DMJYCHG DMJYCHG DN 3-(dimethylamino)-1-(4-hexylphenyl)propan-1-one DMJYCHG TI TTGER3L DMJYCHG TN Thyroid hormone receptor beta (THRB) DMJYCHG MA Inhibitor DMJYCHG RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMJYCHG RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMJYHIM DI DMJYHIM DMJYHIM DN PMID2231594C3k DMJYHIM TI TTPADOQ DMJYHIM TN HMG-CoA reductase (HMGCR) DMJYHIM MA Inhibitor DMJYHIM RN Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6. DMJYHIM RU https://pubmed.ncbi.nlm.nih.gov/2231594 DMJYI0P DI DMJYI0P DMJYI0P DN 2-Pyridin-3-ylmethyl-1,2-dihydro-indazol-3-one DMJYI0P TI TT2J34L DMJYI0P TN Arachidonate 5-lipoxygenase (5-LOX) DMJYI0P MA Inhibitor DMJYI0P RN Tumour necrosis factor production in a rat airpouch model of inflammation: role of eicosanoids. Agents Actions. 1991 Mar;32(3-4):289-94. DMJYI0P RU https://pubmed.ncbi.nlm.nih.gov/1650523 DMJYMFE DI DMJYMFE DMJYMFE DN 9-(3-n-Pentylureido)non-4-ynoic acid DMJYMFE TI TT7WVHI DMJYMFE TN Soluble epoxide hydrolase (EPHX2) DMJYMFE MA Inhibitor DMJYMFE RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMJYMFE RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMJYNMC DI DMJYNMC DMJYNMC DN FAMOXADONE DMJYNMC TI TTRAMF0 DMJYNMC TN Plasmodium Cytochrome B (Malaria MT-CYB) DMJYNMC MA Inhibitor DMJYNMC RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJYNMC RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJYSF3 DI DMJYSF3 DMJYSF3 DN 2-methyl-6-(trifluoromethyl)-9H-carbazole DMJYSF3 TI TTBGTCW DMJYSF3 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMJYSF3 MA Inhibitor DMJYSF3 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMJYSF3 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMJZ0AM DI DMJZ0AM DMJZ0AM DN GERANYLGERANYL DIPHOSPHATE DMJZ0AM TI TT7WZIJ DMJZ0AM TN CAAX farnesyltransferase beta (FNTB) DMJZ0AM MA Inhibitor DMJZ0AM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJZ0AM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJZ0AM DI DMJZ0AM DMJZ0AM DN GERANYLGERANYL DIPHOSPHATE DMJZ0AM TI TTIKWV4 DMJZ0AM TN Geranyltranstransferase (FDPS) DMJZ0AM MA Inhibitor DMJZ0AM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJZ0AM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJZ0AM DI DMJZ0AM DMJZ0AM DN GERANYLGERANYL DIPHOSPHATE DMJZ0AM TI TTXQKM3 DMJZ0AM TN Farnesyl protein transferase (Ftase) DMJZ0AM MA Inhibitor DMJZ0AM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMJZ0AM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMJZ2IP DI DMJZ2IP DMJZ2IP DN N-(4,6-diphenylpyrimidin-2-yl)propionamide DMJZ2IP TI TTK25J1 DMJZ2IP TN Adenosine A1 receptor (ADORA1) DMJZ2IP MA Inhibitor DMJZ2IP RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMJZ2IP RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMJZ2IP DI DMJZ2IP DMJZ2IP DN N-(4,6-diphenylpyrimidin-2-yl)propionamide DMJZ2IP TI TTM2AOE DMJZ2IP TN Adenosine A2a receptor (ADORA2A) DMJZ2IP MA Inhibitor DMJZ2IP RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMJZ2IP RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMJZ2IP DI DMJZ2IP DMJZ2IP DN N-(4,6-diphenylpyrimidin-2-yl)propionamide DMJZ2IP TI TTJFY5U DMJZ2IP TN Adenosine A3 receptor (ADORA3) DMJZ2IP MA Inhibitor DMJZ2IP RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMJZ2IP RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMJZ5V0 DI DMJZ5V0 DMJZ5V0 DN 2-thioUTP DMJZ5V0 TI TTOZHQC DMJZ5V0 TN P2Y purinoceptor 2 (P2RY2) DMJZ5V0 MA Agonist DMJZ5V0 RN Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87. DMJZ5V0 RU https://pubmed.ncbi.nlm.nih.gov/17125260 DMJZEMB DI DMJZEMB DMJZEMB DN 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione DMJZEMB TI TTR0SWN DMJZEMB TN M-phase inducer phosphatase 2 (MPIP2) DMJZEMB MA Inhibitor DMJZEMB RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMJZEMB RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMJZEMB DI DMJZEMB DMJZEMB DN 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione DMJZEMB TI TTLZS4Q DMJZEMB TN M-phase inducer phosphatase 1 (MPIP1) DMJZEMB MA Inhibitor DMJZEMB RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMJZEMB RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMJZEMB DI DMJZEMB DMJZEMB DN 3-isopropyl-4-(phenylthio)naphthalene-1,2-dione DMJZEMB TI TTELIN2 DMJZEMB TN PTPN1 messenger RNA (PTPN1 mRNA) DMJZEMB MA Inhibitor DMJZEMB RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMJZEMB RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMJZK40 DI DMJZK40 DMJZK40 DN 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 TI TT1LVF2 DMJZK40 TN Cyclin-dependent kinase 9 (CDK9) DMJZK40 MA Inhibitor DMJZK40 RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMJZK40 RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMJZK40 DI DMJZK40 DMJZK40 DN 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 TI TT7HF4W DMJZK40 TN Cyclin-dependent kinase 2 (CDK2) DMJZK40 MA Inhibitor DMJZK40 RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMJZK40 RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMJZK40 DI DMJZK40 DMJZK40 DN 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 TI TTAMQ62 DMJZK40 TN Cyclin A2 (CCNA2) DMJZK40 MA Inhibitor DMJZK40 RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMJZK40 RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMJZK40 DI DMJZK40 DMJZK40 DN 3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 TI TTCEJ4F DMJZK40 TN G1/S-specific cyclin-E1 (CCNE1) DMJZK40 MA Inhibitor DMJZK40 RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMJZK40 RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMJZKEH DI DMJZKEH DMJZKEH DN Sp-876 DMJZKEH TI TTU6BFZ DMJZKEH TN Candida Thymidylate synthase (Candi TMP1) DMJZKEH MA Inhibitor DMJZKEH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJZKEH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJZNX6 DI DMJZNX6 DMJZNX6 DN 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide DMJZNX6 TI TTCFSPE DMJZNX6 TN Carbonic anhydrase VI (CA-VI) DMJZNX6 MA Inhibitor DMJZNX6 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMJZNX6 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMJZNX6 DI DMJZNX6 DMJZNX6 DN 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide DMJZNX6 TI TT2LVK8 DMJZNX6 TN Carbonic anhydrase IX (CA-IX) DMJZNX6 MA Inhibitor DMJZNX6 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMJZNX6 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMJZNX6 DI DMJZNX6 DMJZNX6 DN 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide DMJZNX6 TI TTANPDJ DMJZNX6 TN Carbonic anhydrase II (CA-II) DMJZNX6 MA Inhibitor DMJZNX6 RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMJZNX6 RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMJZNX6 DI DMJZNX6 DMJZNX6 DN 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide DMJZNX6 TI TTUNARX DMJZNX6 TN Carbonic anhydrase (CA) DMJZNX6 MA Inhibitor DMJZNX6 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMJZNX6 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMJZNX6 DI DMJZNX6 DMJZNX6 DN 4-amino-N-(4-sulfamoylbenzyl)benzenesulfonamide DMJZNX6 TI TTHQPL7 DMJZNX6 TN Carbonic anhydrase I (CA-I) DMJZNX6 MA Inhibitor DMJZNX6 RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMJZNX6 RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMJZPSX DI DMJZPSX DMJZPSX DN Adenosine Monotungstate DMJZPSX TI TTMS54D DMJZPSX TN Fragile histidine triad protein (FHIT) DMJZPSX MA Inhibitor DMJZPSX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMJZPSX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMJZR0A DI DMJZR0A DMJZR0A DN 7-Oxo-7H-dibenzo[de,g]quinoline DMJZR0A TI TTEB0GD DMJZR0A TN Cholinesterase (BCHE) DMJZR0A MA Inhibitor DMJZR0A RN Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32. DMJZR0A RU https://pubmed.ncbi.nlm.nih.gov/19243862 DMJZR0A DI DMJZR0A DMJZR0A DN 7-Oxo-7H-dibenzo[de,g]quinoline DMJZR0A TI TT1RS9F DMJZR0A TN Acetylcholinesterase (AChE) DMJZR0A MA Inhibitor DMJZR0A RN Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32. DMJZR0A RU https://pubmed.ncbi.nlm.nih.gov/19243862 DMJZXAF DI DMJZXAF DMJZXAF DN L-748780 DMJZXAF TI TTVKILB DMJZXAF TN Prostaglandin G/H synthase 2 (COX-2) DMJZXAF MA Inhibitor DMJZXAF RN From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors, Bioorg. Med. Chem. Lett. 6(6):725-730 (1996). DMJZXAF RU http://www.sciencedirect.com/science/article/pii/0960894X9600100X DMK02YC DI DMK02YC DMK02YC DN Nocardimicin F DMK02YC TI TTQ13Z5 DMK02YC TN Muscarinic acetylcholine receptor M3 (CHRM3) DMK02YC MA Inhibitor DMK02YC RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMK02YC RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMK07MI DI DMK07MI DMK07MI DN L-(cis)-diltiazem DMK07MI TI TTHIQMC DMK07MI TN Cyclic nucleotide-gated channel alpha-1 (CNGA1) DMK07MI MA Blocker (channel blocker) DMK07MI RN A new subunit of the cyclic nucleotide-gated cation channel in retinal rods. Nature. 1993 Apr 22;362(6422):764-7. DMK07MI RU https://pubmed.ncbi.nlm.nih.gov/7682292 DMK07MI DI DMK07MI DMK07MI DN L-(cis)-diltiazem DMK07MI TI TTJ0SO4 DMK07MI TN Voltage-gated calcium channel alpha Cav1.4 (CACNA1F) DMK07MI MA Inhibitor (gating inhibitor) DMK07MI RN Functional characterization of the L-type Ca2+ channel Cav1.4alpha1 from mouse retina. Invest Ophthalmol Vis Sci. 2004 Feb;45(2):708-13. DMK07MI RU https://pubmed.ncbi.nlm.nih.gov/14744918 DMK07MI DI DMK07MI DMK07MI DN L-(cis)-diltiazem DMK07MI TI TT8SJGB DMK07MI TN Cyclic nucleotide-gated channel alpha-2 (CNGA2) DMK07MI MA Blocker (channel blocker) DMK07MI RN Primary structure and functional expression of a cyclic nucleotide-activated channel from olfactory neurons. Nature. 1990 Sep 13;347(6289):184-7. DMK07MI RU https://pubmed.ncbi.nlm.nih.gov/1697649 DMK07MI DI DMK07MI DMK07MI DN L-(cis)-diltiazem DMK07MI TI TTW0QOV DMK07MI TN Cyclic nucleotide-gated channel alpha-3 (CNGA3) DMK07MI MA Inhibitor DMK07MI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 396). DMK07MI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=396 DMK07MI DI DMK07MI DMK07MI DN L-(cis)-diltiazem DMK07MI TI TT0LJCG DMK07MI TN Cyclic nucleotide-gated channel beta-3 (CNGB3) DMK07MI MA Blocker (channel blocker) DMK07MI RN Molecular cloning and functional characterization of a new modulatory cyclic nucleotide-gated channel subunit from mouse retina. J Neurosci. 2000 Feb 15;20(4):1324-32. DMK07MI RU https://pubmed.ncbi.nlm.nih.gov/10662822 DMK0FNX DI DMK0FNX DMK0FNX DN JWH-368 DMK0FNX TI TT6OEDT DMK0FNX TN Cannabinoid receptor 1 (CB1) DMK0FNX MA Inhibitor DMK0FNX RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMK0FNX RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMK0FNX DI DMK0FNX DMK0FNX DN JWH-368 DMK0FNX TI TTMSFAW DMK0FNX TN Cannabinoid receptor 2 (CB2) DMK0FNX MA Inhibitor DMK0FNX RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMK0FNX RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMK0GJ3 DI DMK0GJ3 DMK0GJ3 DN 12R-HETE DMK0GJ3 TI TTVJX54 DMK0GJ3 TN Leukotriene B4 receptor 2 (LTB4R2) DMK0GJ3 MA Agonist DMK0GJ3 RN A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997 Jun 5;387(6633):620-4. DMK0GJ3 RU https://pubmed.ncbi.nlm.nih.gov/9177352 DMK0H2P DI DMK0H2P DMK0H2P DN NSC-339580 DMK0H2P TI TT8XK6L DMK0H2P TN Quinone reductase 1 (NQO1) DMK0H2P MA Inhibitor DMK0H2P RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMK0H2P RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMK0OVE DI DMK0OVE DMK0OVE DN WEHI-0103122 DMK0OVE TI TTU1E82 DMK0OVE TN Apoptosis regulator Bcl-xL (BCL-xL) DMK0OVE MA Inhibitor DMK0OVE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2845). DMK0OVE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2845 DMK0PAL DI DMK0PAL DMK0PAL DN 5-Naphthalen-2-yl-1H-imidazole DMK0PAL TI TTIQUX7 DMK0PAL TN Steroid 11-beta-hydroxylase (CYP11B1) DMK0PAL MA Inhibitor DMK0PAL RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMK0PAL RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMK0VFS DI DMK0VFS DMK0VFS DN dithiipin-1,1,4,4-tetroxide analogue 7 DMK0VFS TI TTOPAY7 DMK0VFS TN Galanin receptor (GAL-R) DMK0VFS MA Antagonist DMK0VFS RN 2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule non-peptide antagonists of the human galanin hGAL-1 receptor. Bioorg Med Chem. 2000 Jun;8(6):1383-91. DMK0VFS RU https://pubmed.ncbi.nlm.nih.gov/10896115 DMK0YP7 DI DMK0YP7 DMK0YP7 DN R-1 DMK0YP7 TI TT0K1SC DMK0YP7 TN 5-HT 2B receptor (HTR2B) DMK0YP7 MA Antagonist DMK0YP7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7). DMK0YP7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7 DMK10WX DI DMK10WX DMK10WX DN N1-[4-(Phenylmethoxy)phenyl]-D-glutamine DMK10WX TI TTXZEAJ DMK10WX TN Leukotriene A-4 hydrolase (LTA4H) DMK10WX MA Inhibitor DMK10WX RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMK10WX RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMK12C0 DI DMK12C0 DMK12C0 DN L-mannitol derivative DMK12C0 TI TTH9VL3 DMK12C0 TN Plasmodium Plasmepsin 1 (Malaria PLA1) DMK12C0 MA Inhibitor DMK12C0 RN Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J Med Chem. 2005 Sep 22;48(19):6090-106. DMK12C0 RU https://pubmed.ncbi.nlm.nih.gov/16162010 DMK17GN DI DMK17GN DMK17GN DN KM-4056 DMK17GN TI TTTSGRH DMK17GN TN Leucine-rich repeat-containing GPCR 5 (LGR5) DMK17GN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 148). DMK17GN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=148 DMK18CS DI DMK18CS DMK18CS DN [Phe3]OT DMK18CS TI TTK8R02 DMK18CS TN Vasopressin V2 receptor (V2R) DMK18CS MA Agonist DMK18CS RN Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 1995 May 15;14(10):2176-82. DMK18CS RU https://pubmed.ncbi.nlm.nih.gov/7774575 DMK18CS DI DMK18CS DMK18CS DN [Phe3]OT DMK18CS TI TT4TFGN DMK18CS TN Vasopressin V1a receptor (V1AR) DMK18CS MA Agonist DMK18CS RN Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. EMBO J. 1995 May 15;14(10):2176-82. DMK18CS RU https://pubmed.ncbi.nlm.nih.gov/7774575 DMK18CS DI DMK18CS DMK18CS DN [Phe3]OT DMK18CS TI TTSCIUP DMK18CS TN Oxytocin receptor (OTR) DMK18CS MA Agonist DMK18CS RN Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. FEBS Lett. 1996 Nov 18;397(2-3):201-6. DMK18CS RU https://pubmed.ncbi.nlm.nih.gov/8955347 DMK1IMC DI DMK1IMC DMK1IMC DN ANG-2004 DMK1IMC TI TT0HD6V DMK1IMC TN Leptin receptor (LEPR) DMK1IMC MA Modulator DMK1IMC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DMK1IMC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DMK1IWD DI DMK1IWD DMK1IWD DN 4-(4-aminophenyl)-1H-indazol-3yl-amine DMK1IWD TI TTGJCWZ DMK1IWD TN Fms-like tyrosine kinase 3 (FLT-3) DMK1IWD MA Inhibitor DMK1IWD RN Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97. DMK1IWD RU https://pubmed.ncbi.nlm.nih.gov/17343372 DMK1IWD DI DMK1IWD DMK1IWD DN 4-(4-aminophenyl)-1H-indazol-3yl-amine DMK1IWD TI TTX41N9 DMK1IWD TN Tyrosine-protein kinase Kit (KIT) DMK1IWD MA Inhibitor DMK1IWD RN Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97. DMK1IWD RU https://pubmed.ncbi.nlm.nih.gov/17343372 DMK1IWD DI DMK1IWD DMK1IWD DN 4-(4-aminophenyl)-1H-indazol-3yl-amine DMK1IWD TI TTUTJGQ DMK1IWD TN Vascular endothelial growth factor receptor 2 (KDR) DMK1IWD MA Inhibitor DMK1IWD RN Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97. DMK1IWD RU https://pubmed.ncbi.nlm.nih.gov/17343372 DMK1OP2 DI DMK1OP2 DMK1OP2 DN SK549 DMK1OP2 TI TTCIHJA DMK1OP2 TN Coagulation factor Xa (F10) DMK1OP2 MA Inhibitor DMK1OP2 RN Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2. J Med Chem. 1999 Jul 29;42(15):2760-73. DMK1OP2 RU https://pubmed.ncbi.nlm.nih.gov/10425087 DMK1TRG DI DMK1TRG DMK1TRG DN [3H]robalzotan DMK1TRG TI TTSQIFT DMK1TRG TN 5-HT 1A receptor (HTR1A) DMK1TRG MA Antagonist DMK1TRG RN Receptor binding characteristics of [3H]NAD-299, a new selective 5-HT1A receptor antagonist. Eur J Pharmacol. 1998 Nov 6;360(2-3):219-25. DMK1TRG RU https://pubmed.ncbi.nlm.nih.gov/9851589 DMK1ZF2 DI DMK1ZF2 DMK1ZF2 DN 4-(5-(4-Hydroxyphenyl)isothiazol-4-yl)phenol DMK1ZF2 TI TT8NGED DMK1ZF2 TN Prostaglandin G/H synthase 1 (COX-1) DMK1ZF2 MA Inhibitor DMK1ZF2 RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMK1ZF2 RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMK209P DI DMK209P DMK209P DN 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol DMK209P TI TTR6W5O DMK209P TN Adrenergic receptor beta-1 (ADRB1) DMK209P MA Inhibitor DMK209P RN A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. DMK209P RU https://pubmed.ncbi.nlm.nih.gov/20434333 DMK209P DI DMK209P DMK209P DN 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol DMK209P TI TTMXGCW DMK209P TN Adrenergic receptor beta-3 (ADRB3) DMK209P MA Inhibitor DMK209P RN A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. DMK209P RU https://pubmed.ncbi.nlm.nih.gov/20434333 DMK209P DI DMK209P DMK209P DN 1-(2-isopropylphenoxy)-3-morpholinopropan-2-ol DMK209P TI TT2CJVK DMK209P TN Adrenergic receptor beta-2 (ADRB2) DMK209P MA Inhibitor DMK209P RN A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. DMK209P RU https://pubmed.ncbi.nlm.nih.gov/20434333 DMK28IS DI DMK28IS DMK28IS DN 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine DMK28IS TI TTCM4B3 DMK28IS TN Nitric-oxide synthase endothelial (NOS3) DMK28IS MA Inhibitor DMK28IS RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMK28IS RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMK28IS DI DMK28IS DMK28IS DN 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine DMK28IS TI TTF10I9 DMK28IS TN Nitric-oxide synthase inducible (NOS2) DMK28IS MA Inhibitor DMK28IS RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMK28IS RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMK28IS DI DMK28IS DMK28IS DN 7-(2-Nitro-ethyl)-azepan-(2Z)-ylideneamine DMK28IS TI TTZUFI5 DMK28IS TN Nitric-oxide synthase brain (NOS1) DMK28IS MA Inhibitor DMK28IS RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMK28IS RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMK2FOX DI DMK2FOX DMK2FOX DN MT-Immucillin-H DMK2FOX TI TTMCF1Y DMK2FOX TN Purine nucleoside phosphorylase (PNP) DMK2FOX MA Inhibitor DMK2FOX RN Plasmodium falciparum purine nucleoside phosphorylase: crystal structures, immucillin inhibitors, and dual catalytic function. J Biol Chem. 2004 Apr 30;279(18):18103-6. DMK2FOX RU https://pubmed.ncbi.nlm.nih.gov/14982926 DMK2J5L DI DMK2J5L DMK2J5L DN THIOGENISTEIN DMK2J5L TI TTOM3J0 DMK2J5L TN Estrogen receptor beta (ESR2) DMK2J5L MA Inhibitor DMK2J5L RN Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators. J Med Chem. 2006 Apr 20;49(8):2440-55. DMK2J5L RU https://pubmed.ncbi.nlm.nih.gov/16610787 DMK2NQ1 DI DMK2NQ1 DMK2NQ1 DN JWH-347 DMK2NQ1 TI TT6OEDT DMK2NQ1 TN Cannabinoid receptor 1 (CB1) DMK2NQ1 MA Inhibitor DMK2NQ1 RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMK2NQ1 RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMK2NQ1 DI DMK2NQ1 DMK2NQ1 DN JWH-347 DMK2NQ1 TI TTMSFAW DMK2NQ1 TN Cannabinoid receptor 2 (CB2) DMK2NQ1 MA Inhibitor DMK2NQ1 RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMK2NQ1 RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMK2PBJ DI DMK2PBJ DMK2PBJ DN 4'-bromo-3-(imidazolylmethyl)-7-methoxyflavone DMK2PBJ TI TTSZLWK DMK2PBJ TN Aromatase (CYP19A1) DMK2PBJ MA Inhibitor DMK2PBJ RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DMK2PBJ RU https://pubmed.ncbi.nlm.nih.gov/16854084 DMK2QPU DI DMK2QPU DMK2QPU DN ISIS 29255 DMK2QPU TI TTYMGWX DMK2QPU TN PDK-1 messenger RNA (PDK-1 mRNA) DMK2QPU RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMK2QPU RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMK2XB7 DI DMK2XB7 DMK2XB7 DN AR-00341677 DMK2XB7 TI TTWCGQT DMK2XB7 TN Serine/threonine-protein kinase B-raf (BRAF) DMK2XB7 MA Inhibitor DMK2XB7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5681). DMK2XB7 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5681 DMK2ZG4 DI DMK2ZG4 DMK2ZG4 DN Bis(benzo[b]furan-2-yl)methanone DMK2ZG4 TI TTI7421 DMK2ZG4 TN Platelet-derived growth factor receptor beta (PDGFRB) DMK2ZG4 MA Inhibitor DMK2ZG4 RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMK2ZG4 RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMK2ZG4 DI DMK2ZG4 DMK2ZG4 DN Bis(benzo[b]furan-2-yl)methanone DMK2ZG4 TI TTGJCWZ DMK2ZG4 TN Fms-like tyrosine kinase 3 (FLT-3) DMK2ZG4 MA Inhibitor DMK2ZG4 RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMK2ZG4 RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMK3DUZ DI DMK3DUZ DMK3DUZ DN JWH-337 DMK3DUZ TI TTMSFAW DMK3DUZ TN Cannabinoid receptor 2 (CB2) DMK3DUZ MA Inhibitor DMK3DUZ RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMK3DUZ RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMK3DUZ DI DMK3DUZ DMK3DUZ DN JWH-337 DMK3DUZ TI TT6OEDT DMK3DUZ TN Cannabinoid receptor 1 (CB1) DMK3DUZ MA Inhibitor DMK3DUZ RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMK3DUZ RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMK3J8Q DI DMK3J8Q DMK3J8Q DN 4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine DMK3J8Q TI TTM2AOE DMK3J8Q TN Adenosine A2a receptor (ADORA2A) DMK3J8Q MA Inhibitor DMK3J8Q RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMK3J8Q RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMK3J8Q DI DMK3J8Q DMK3J8Q DN 4-(thiazol-2-yl)thieno[3,2-d]pyrimidin-2-amine DMK3J8Q TI TTK25J1 DMK3J8Q TN Adenosine A1 receptor (ADORA1) DMK3J8Q MA Inhibitor DMK3J8Q RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMK3J8Q RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMK3JZS DI DMK3JZS DMK3JZS DN (3-Amino-propyl)-phosphonic acid DMK3JZS TI TTDCVZW DMK3JZS TN Gamma-aminobutyric acid B receptor (GABBR) DMK3JZS MA Inhibitor DMK3JZS RN Phosphorus analogues of gamma-aminobutyric acid, a new class of anticonvulsants. J Med Chem. 1984 May;27(5):654-9. DMK3JZS RU https://pubmed.ncbi.nlm.nih.gov/6325692 DMK3TEV DI DMK3TEV DMK3TEV DN 5-(trifluoromethoxy)-1H-indole-2,3-dione DMK3TEV TI TTMF541 DMK3TEV TN Liver carboxylesterase (CES1) DMK3TEV MA Inhibitor DMK3TEV RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMK3TEV RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMK3VID DI DMK3VID DMK3VID DN EPPTB DMK3VID TI TTIU98M DMK3VID TN Trace amine-associated receptor-1 (TAAR1) DMK3VID MA Antagonist DMK3VID RN The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20081-6. DMK3VID RU https://pubmed.ncbi.nlm.nih.gov/19892733 DMK3WY4 DI DMK3WY4 DMK3WY4 DN DMCM DMK3WY4 TI TTBMV1G DMK3WY4 TN GABA(A) receptor alpha-2 (GABRA2) DMK3WY4 MA Modulator (allosteric modulator) DMK3WY4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMK3WY4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMK3WY4 DI DMK3WY4 DMK3WY4 DN DMCM DMK3WY4 TI TT37EDJ DMK3WY4 TN GABA(A) receptor alpha-3 (GABRA3) DMK3WY4 MA Modulator (allosteric modulator) DMK3WY4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMK3WY4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMK3WY4 DI DMK3WY4 DMK3WY4 DN DMCM DMK3WY4 TI TTNZPQ1 DMK3WY4 TN GABA(A) receptor alpha-5 (GABRA5) DMK3WY4 MA Modulator (allosteric modulator) DMK3WY4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMK3WY4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMK3WY4 DI DMK3WY4 DMK3WY4 DN DMCM DMK3WY4 TI TTEX6LM DMK3WY4 TN GABA(A) receptor gamma-3 (GABRG3) DMK3WY4 MA Modulator (allosteric modulator) DMK3WY4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMK3WY4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMK3Y5U DI DMK3Y5U DMK3Y5U DN LY320135 DMK3Y5U TI TT6OEDT DMK3Y5U TN Cannabinoid receptor 1 (CB1) DMK3Y5U MA Antagonist DMK3Y5U RN LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther. 1998 Jan;284(1):291-7. DMK3Y5U RU https://pubmed.ncbi.nlm.nih.gov/9435190 DMK41DJ DI DMK41DJ DMK41DJ DN 11H-benzo[a]carbazole DMK41DJ TI TTBGTCW DMK41DJ TN Kinesin spindle messenger RNA (KIF11 mRNA) DMK41DJ MA Inhibitor DMK41DJ RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMK41DJ RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMK42RU DI DMK42RU DMK42RU DN (+/-)-3-allylazetidin-2-one DMK42RU TI TTDP1UC DMK42RU TN Fatty acid amide hydrolase (FAAH) DMK42RU MA Inhibitor DMK42RU RN 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7. DMK42RU RU https://pubmed.ncbi.nlm.nih.gov/18547805 DMK459I DI DMK459I DMK459I DN 9H-beta-Carboline-3-carboxylic acid ethyl ester DMK459I TI TT37EDJ DMK459I TN GABA(A) receptor alpha-3 (GABRA3) DMK459I MA Inhibitor DMK459I RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMK459I RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMK459I DI DMK459I DMK459I DN 9H-beta-Carboline-3-carboxylic acid ethyl ester DMK459I TI TTBMV1G DMK459I TN GABA(A) receptor alpha-2 (GABRA2) DMK459I MA Inhibitor DMK459I RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMK459I RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMK459I DI DMK459I DMK459I DN 9H-beta-Carboline-3-carboxylic acid ethyl ester DMK459I TI TT1MPAY DMK459I TN GABA(A) receptor alpha-1 (GABRA1) DMK459I MA Inhibitor DMK459I RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMK459I RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMK459I DI DMK459I DMK459I DN 9H-beta-Carboline-3-carboxylic acid ethyl ester DMK459I TI TTNJYV2 DMK459I TN Gamma-aminobutyric acid receptor (GAR) DMK459I MA Inhibitor DMK459I RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMK459I RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMK459I DI DMK459I DMK459I DN 9H-beta-Carboline-3-carboxylic acid ethyl ester DMK459I TI TT06RH5 DMK459I TN GABA(A) receptor gamma-2 (GABRG2) DMK459I MA Inhibitor DMK459I RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMK459I RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMK459I DI DMK459I DMK459I DN 9H-beta-Carboline-3-carboxylic acid ethyl ester DMK459I TI TTNZPQ1 DMK459I TN GABA(A) receptor alpha-5 (GABRA5) DMK459I MA Inhibitor DMK459I RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMK459I RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMK46C7 DI DMK46C7 DMK46C7 DN [3H]PBC-264 DMK46C7 TI TTVFO0U DMK46C7 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMK46C7 MA Agonist DMK46C7 RN [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702. Mol Pharmacol. 1992 Jun;41(6):1089-95. DMK46C7 RU https://pubmed.ncbi.nlm.nih.gov/1614411 DMK4A0J DI DMK4A0J DMK4A0J DN 2-methyl-4-(3-thienylethynyl)thiazole DMK4A0J TI TTHS256 DMK4A0J TN Metabotropic glutamate receptor 5 (mGluR5) DMK4A0J MA Inhibitor DMK4A0J RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMK4A0J RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMK4IBO DI DMK4IBO DMK4IBO DN KM-233-M DMK4IBO TI TT6OEDT DMK4IBO TN Cannabinoid receptor 1 (CB1) DMK4IBO MA Inhibitor DMK4IBO RN Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500. DMK4IBO RU https://pubmed.ncbi.nlm.nih.gov/18524604 DMK4IBO DI DMK4IBO DMK4IBO DN KM-233-M DMK4IBO TI TTMSFAW DMK4IBO TN Cannabinoid receptor 2 (CB2) DMK4IBO MA Inhibitor DMK4IBO RN Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500. DMK4IBO RU https://pubmed.ncbi.nlm.nih.gov/18524604 DMK4ICB DI DMK4ICB DMK4ICB DN 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol DMK4ICB TI TTVG215 DMK4ICB TN Debrisoquine 4-hydroxylase (CYP2D6) DMK4ICB MA Inhibitor DMK4ICB RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMK4ICB RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMK4ICB DI DMK4ICB DMK4ICB DN 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol DMK4ICB TI TTIWB6L DMK4ICB TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMK4ICB MA Inhibitor DMK4ICB RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMK4ICB RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMK4ICB DI DMK4ICB DMK4ICB DN 4-[5-(3-Hydroxyphenyl)-2-thienyl)-2-methyl]phenol DMK4ICB TI TTXV4FI DMK4ICB TN Albendazole monooxygenase (CYP3A4) DMK4ICB MA Inhibitor DMK4ICB RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMK4ICB RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMK4LTB DI DMK4LTB DMK4LTB DN 2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol DMK4LTB TI TTN9T81 DMK4LTB TN Arachidonate 15-lipoxygenase (15-LOX) DMK4LTB MA Inhibitor DMK4LTB RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMK4LTB RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMK4LTB DI DMK4LTB DMK4LTB DN 2,3,4,5-Tetrabromo-6-(2,4-dibromo-phenoxy)-phenol DMK4LTB TI TT12ABZ DMK4LTB TN Arachidonate 12-lipoxygenase (12-LOX) DMK4LTB MA Inhibitor DMK4LTB RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMK4LTB RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMK4N2F DI DMK4N2F DMK4N2F DN 16-(2',2'-Dimethyl)-propylidene-estradiol DMK4N2F TI TTIWB6L DMK4N2F TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMK4N2F MA Inhibitor DMK4N2F RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMK4N2F RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMK4OD7 DI DMK4OD7 DMK4OD7 DN A2P5P DMK4OD7 TI TTA93TL DMK4OD7 TN P2Y purinoceptor 1 (P2RY1) DMK4OD7 MA Antagonist DMK4OD7 RN Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol. 1996 Nov;50(5):1323-9. DMK4OD7 RU https://pubmed.ncbi.nlm.nih.gov/8913364 DMK4T5Y DI DMK4T5Y DMK4T5Y DN Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate DMK4T5Y TI TTJFY5U DMK4T5Y TN Adenosine A3 receptor (ADORA3) DMK4T5Y MA Inhibitor DMK4T5Y RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMK4T5Y RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMK4T5Y DI DMK4T5Y DMK4T5Y DN Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate DMK4T5Y TI TTK25J1 DMK4T5Y TN Adenosine A1 receptor (ADORA1) DMK4T5Y MA Inhibitor DMK4T5Y RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMK4T5Y RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMK4T5Y DI DMK4T5Y DMK4T5Y DN Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate DMK4T5Y TI TTNE7KG DMK4T5Y TN Adenosine A2b receptor (ADORA2B) DMK4T5Y MA Inhibitor DMK4T5Y RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMK4T5Y RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMK4T5Y DI DMK4T5Y DMK4T5Y DN Ethyl 5-benzoyl-4-phenylthiazol-2-ylcarbamate DMK4T5Y TI TTM2AOE DMK4T5Y TN Adenosine A2a receptor (ADORA2A) DMK4T5Y MA Inhibitor DMK4T5Y RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMK4T5Y RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMK4XLD DI DMK4XLD DMK4XLD DN Cacodylate Ion DMK4XLD TI TTGER3L DMK4XLD TN Thyroid hormone receptor beta (THRB) DMK4XLD MA Inhibitor DMK4XLD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMK4XLD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMK4XLD DI DMK4XLD DMK4XLD DN Cacodylate Ion DMK4XLD TI TT0OFWN DMK4XLD TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DMK4XLD MA Inhibitor DMK4XLD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMK4XLD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMK4XLD DI DMK4XLD DMK4XLD DN Cacodylate Ion DMK4XLD TI TTCM4B3 DMK4XLD TN Nitric-oxide synthase endothelial (NOS3) DMK4XLD MA Inhibitor DMK4XLD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMK4XLD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMK4XLD DI DMK4XLD DMK4XLD DN Cacodylate Ion DMK4XLD TI TTQWGU9 DMK4XLD TN Bacterial Aspartate-semialdehyde dehydrogenase (Bact asd2) DMK4XLD MA Inhibitor DMK4XLD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMK4XLD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMK4XLD DI DMK4XLD DMK4XLD DN Cacodylate Ion DMK4XLD TI TTZJ5U9 DMK4XLD TN Thioredoxin (TXN) DMK4XLD MA Inhibitor DMK4XLD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMK4XLD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMK4XLD DI DMK4XLD DMK4XLD DN Cacodylate Ion DMK4XLD TI TTV3NH6 DMK4XLD TN Calmodulin (CALM) DMK4XLD MA Inhibitor DMK4XLD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMK4XLD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMK52UH DI DMK52UH DMK52UH DN 5'-methylthio-immucillin-H DMK52UH TI TTMCF1Y DMK52UH TN Purine nucleoside phosphorylase (PNP) DMK52UH MA Inhibitor DMK52UH RN Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase. Eur J Med Chem. 2010 Nov;45(11):5140-9. DMK52UH RU https://pubmed.ncbi.nlm.nih.gov/20817362 DMK53AT DI DMK53AT DMK53AT DN 3,9-Dihydroxy-4-prenyl-[6aR,11aR]pterocarpan DMK53AT TI TTELIN2 DMK53AT TN PTPN1 messenger RNA (PTPN1 mRNA) DMK53AT MA Inhibitor DMK53AT RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DMK53AT RU https://pubmed.ncbi.nlm.nih.gov/19836230 DMK543E DI DMK543E DMK543E DN ginkgolide X DMK543E TI TTZ8EM9 DMK543E TN Glycine receptor (GlyR) DMK543E MA Antagonist DMK543E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 427). DMK543E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=427 DMK54RM DI DMK54RM DMK54RM DN CRA_1144 DMK54RM TI TT25MVL DMK54RM TN Serine protease hepsin (HPN) DMK54RM MA Inhibitor DMK54RM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMK54RM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMK57W2 DI DMK57W2 DMK57W2 DN 5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole DMK57W2 TI TTK8CXU DMK57W2 TN 5-HT 1B receptor (HTR1B) DMK57W2 MA Inhibitor DMK57W2 RN 5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9. DMK57W2 RU https://pubmed.ncbi.nlm.nih.gov/10937729 DMK57W2 DI DMK57W2 DMK57W2 DN 5-Ethyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole DMK57W2 TI TT6MSOK DMK57W2 TN 5-HT 1D receptor (HTR1D) DMK57W2 MA Inhibitor DMK57W2 RN 5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9. DMK57W2 RU https://pubmed.ncbi.nlm.nih.gov/10937729 DMK5AU4 DI DMK5AU4 DMK5AU4 DN N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide DMK5AU4 TI TTM2AOE DMK5AU4 TN Adenosine A2a receptor (ADORA2A) DMK5AU4 MA Inhibitor DMK5AU4 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMK5AU4 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMK5AU4 DI DMK5AU4 DMK5AU4 DN N-(2,6-diphenylpyrimidin-4-yl)-2-ethylbutyramide DMK5AU4 TI TTK25J1 DMK5AU4 TN Adenosine A1 receptor (ADORA1) DMK5AU4 MA Inhibitor DMK5AU4 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMK5AU4 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMK5CJO DI DMK5CJO DMK5CJO DN 4-(1H-Indol-3-ylmethyl)-phenylamine DMK5CJO TI TTJS8PY DMK5CJO TN 5-HT 6 receptor (HTR6) DMK5CJO MA Inhibitor DMK5CJO RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DMK5CJO RU https://pubmed.ncbi.nlm.nih.gov/15808453 DMK5DUA DI DMK5DUA DMK5DUA DN 9-chloro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide DMK5DUA TI TTSXVID DMK5DUA TN Nuclear factor NF-kappa-B (NFKB) DMK5DUA MA Inhibitor DMK5DUA RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DMK5DUA RU https://pubmed.ncbi.nlm.nih.gov/18024113 DMK5JB8 DI DMK5JB8 DMK5JB8 DN PMID19524438C6o DMK5JB8 TI TT8WFXV DMK5JB8 TN Hydroxycarboxylic acid receptor 3 (HCAR3) DMK5JB8 MA Agonist DMK5JB8 RN 5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4207-9. DMK5JB8 RU https://pubmed.ncbi.nlm.nih.gov/19524438 DMK5PO8 DI DMK5PO8 DMK5PO8 DN PMID18072721C50 DMK5PO8 TI TTPADOQ DMK5PO8 TN HMG-CoA reductase (HMGCR) DMK5PO8 MA Inhibitor DMK5PO8 RN Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylca... J Med Chem. 2008 Jan 10;51(1):31-45. DMK5PO8 RU https://pubmed.ncbi.nlm.nih.gov/18072721 DMK5QYW DI DMK5QYW DMK5QYW DN BENZENEMETHANETHIOL DMK5QYW TI TTZJYKH DMK5QYW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMK5QYW MA Inhibitor DMK5QYW RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMK5QYW RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMK5VYG DI DMK5VYG DMK5VYG DN Biphenyl-4-carboxylic acid hydroxyamide DMK5VYG TI TT2J34L DMK5VYG TN Arachidonate 5-lipoxygenase (5-LOX) DMK5VYG MA Inhibitor DMK5VYG RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMK5VYG RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMK63P2 DI DMK63P2 DMK63P2 DN 8-methylnaringenin DMK63P2 TI TTOM3J0 DMK63P2 TN Estrogen receptor beta (ESR2) DMK63P2 MA Inhibitor DMK63P2 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMK63P2 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMK63P2 DI DMK63P2 DMK63P2 DN 8-methylnaringenin DMK63P2 TI TTZAYWL DMK63P2 TN Estrogen receptor (ESR) DMK63P2 MA Inhibitor DMK63P2 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMK63P2 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMK64AZ DI DMK64AZ DMK64AZ DN LY-465608 DMK64AZ TI TTT2SVW DMK64AZ TN PPAR-gamma messenger RNA (PPARG mRNA) DMK64AZ MA Agonist DMK64AZ RN Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J Med Chem. 2001 Jun 21;44(13):2061-4. DMK64AZ RU https://pubmed.ncbi.nlm.nih.gov/11405642 DMK64AZ DI DMK64AZ DMK64AZ DN LY-465608 DMK64AZ TI TTJ584C DMK64AZ TN Peroxisome proliferator-activated receptor alpha (PPARA) DMK64AZ MA Agonist DMK64AZ RN Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists. J Med Chem. 2004 May 6;47(10):2422-5. DMK64AZ RU https://pubmed.ncbi.nlm.nih.gov/15115385 DMK674I DI DMK674I DMK674I DN N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine DMK674I TI TTGKNB4 DMK674I TN Epidermal growth factor receptor (EGFR) DMK674I MA Inhibitor DMK674I RN Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35. DMK674I RU https://pubmed.ncbi.nlm.nih.gov/8627606 DMK69ZR DI DMK69ZR DMK69ZR DN ISIS 16507 DMK69ZR TI TT9TE0O DMK69ZR TN Mdm2 messenger RNA (MDM2 mRNA) DMK69ZR RN US patent application no. 6,238,921, Antisense oligonucleotide modulation of human mdm2 expression. DMK69ZR RU http://www.patentbuddy.com/Patent/6238921?ft=true&sr=true DMK6BWV DI DMK6BWV DMK6BWV DN 1-dodecyl-1H-indole-2,3-dione DMK6BWV TI TTMF541 DMK6BWV TN Liver carboxylesterase (CES1) DMK6BWV MA Inhibitor DMK6BWV RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMK6BWV RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMK6BWV DI DMK6BWV DMK6BWV DN 1-dodecyl-1H-indole-2,3-dione DMK6BWV TI TTLZS4Q DMK6BWV TN M-phase inducer phosphatase 1 (MPIP1) DMK6BWV MA Inhibitor DMK6BWV RN Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3. DMK6BWV RU https://pubmed.ncbi.nlm.nih.gov/18442908 DMK6CD9 DI DMK6CD9 DMK6CD9 DN 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one DMK6CD9 TI TTML2WA DMK6CD9 TN Tubulin (TUB) DMK6CD9 MA Inhibitor DMK6CD9 RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMK6CD9 RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMK6CD9 DI DMK6CD9 DMK6CD9 DN 2-(3-Chloro-phenyl)-1H-[1,8]naphthyridin-4-one DMK6CD9 TI TTYFKSZ DMK6CD9 TN Tubulin beta (TUBB) DMK6CD9 MA Inhibitor DMK6CD9 RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMK6CD9 RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMK6E10 DI DMK6E10 DMK6E10 DN EC-0845 DMK6E10 TI TTCJG29 DMK6E10 TN Serine/threonine-protein kinase mTOR (mTOR) DMK6E10 MA Modulator DMK6E10 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMK6E10 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMK6GAU DI DMK6GAU DMK6GAU DN PMID24556381C10f DMK6GAU TI TTTRNQW DMK6GAU TN Bile-salt-activated lipase (CEL) DMK6GAU MA Inhibitor DMK6GAU RN Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9. DMK6GAU RU https://pubmed.ncbi.nlm.nih.gov/24556381 DMK6GAU DI DMK6GAU DMK6GAU DN PMID24556381C10f DMK6GAU TI TTPLTSQ DMK6GAU TN Neutrophil elastase (NE) DMK6GAU MA Inhibitor DMK6GAU RN Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9. DMK6GAU RU https://pubmed.ncbi.nlm.nih.gov/24556381 DMK6HGI DI DMK6HGI DMK6HGI DN AcGlu-Dif-Ile-Cha-Cys DMK6HGI TI TTWXB3E DMK6HGI TN Hepatitis C virus NS3 helicase (HCV NS3) DMK6HGI MA Inhibitor DMK6HGI RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMK6HGI RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMK6HMS DI DMK6HMS DMK6HMS DN PS020990 DMK6HMS TI TTGY8IW DMK6HMS TN B2 bradykinin receptor (BDKRB2) DMK6HMS MA Antagonist DMK6HMS RN Small molecule antagonists of the bradykinin B1 receptor. Immunopharmacology. 1999 Sep;43(2-3):169-77. DMK6HMS RU https://pubmed.ncbi.nlm.nih.gov/10596850 DMK6IJW DI DMK6IJW DMK6IJW DN (+/-)-threo-N-(4-Phenylbutyl)methylphenidate DMK6IJW TI TTVBI8W DMK6IJW TN Dopamine transporter (DAT) DMK6IJW MA Inhibitor DMK6IJW RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMK6IJW RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMK6JV7 DI DMK6JV7 DMK6JV7 DN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline DMK6JV7 TI TTI7421 DMK6JV7 TN Platelet-derived growth factor receptor beta (PDGFRB) DMK6JV7 MA Inhibitor DMK6JV7 RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMK6JV7 RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMK6JV7 DI DMK6JV7 DMK6JV7 DN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline DMK6JV7 TI TTGKNB4 DMK6JV7 TN Epidermal growth factor receptor (EGFR) DMK6JV7 MA Inhibitor DMK6JV7 RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMK6JV7 RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMK6SMW DI DMK6SMW DMK6SMW DN KF24345 DMK6SMW TI TTLXAKE DMK6SMW TN Solute carrier family 29 member 1 (SLC29A1) DMK6SMW MA Inhibitor DMK6SMW RN Interaction of the novel adenosine uptake inhibitor 3-[1-(6,7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1,6-dimethyl-2,4(1H,3H)-quinazol... J Pharmacol Exp Ther. 2004 Mar;308(3):1083-93. DMK6SMW RU https://pubmed.ncbi.nlm.nih.gov/14634039 DMK6TVN DI DMK6TVN DMK6TVN DN JNJ-26529126 DMK6TVN TI TTZAYWL DMK6TVN TN Estrogen receptor (ESR) DMK6TVN MA Inhibitor DMK6TVN RN Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symp... J Med Chem. 2009 Dec 10;52(23):7544-69. DMK6TVN RU https://pubmed.ncbi.nlm.nih.gov/19366247 DMK6U2V DI DMK6U2V DMK6U2V DN 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine DMK6U2V TI TT6MSOK DMK6U2V TN 5-HT 1D receptor (HTR1D) DMK6U2V MA Inhibitor DMK6U2V RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMK6U2V RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMK6U2V DI DMK6U2V DMK6U2V DN 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine DMK6U2V TI TTO9X1H DMK6U2V TN 5-HT 7 receptor (HTR7) DMK6U2V MA Inhibitor DMK6U2V RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMK6U2V RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMK6U2V DI DMK6U2V DMK6U2V DN 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine DMK6U2V TI TTSQIFT DMK6U2V TN 5-HT 1A receptor (HTR1A) DMK6U2V MA Inhibitor DMK6U2V RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMK6U2V RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMK6U2V DI DMK6U2V DMK6U2V DN 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine DMK6U2V TI TTWJBZ5 DMK6U2V TN 5-HT 2C receptor (HTR2C) DMK6U2V MA Inhibitor DMK6U2V RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMK6U2V RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMK6U2V DI DMK6U2V DMK6U2V DN 8-methoxy-4-methyl-3,4-dihydroquinazolin-2-amine DMK6U2V TI TTRUFDT DMK6U2V TN 5-HT 5A receptor (HTR5A) DMK6U2V MA Inhibitor DMK6U2V RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMK6U2V RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMK6X5P DI DMK6X5P DMK6X5P DN OSCILLARIN DMK6X5P TI TT6L509 DMK6X5P TN Coagulation factor IIa (F2) DMK6X5P MA Inhibitor DMK6X5P RN From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32. DMK6X5P RU https://pubmed.ncbi.nlm.nih.gov/19674897 DMK6YC1 DI DMK6YC1 DMK6YC1 DN ML-253764 DMK6YC1 TI TTD0CIQ DMK6YC1 TN Melanocortin receptor 4 (MC4R) DMK6YC1 MA Inhibitor DMK6YC1 RN Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22. DMK6YC1 RU https://pubmed.ncbi.nlm.nih.gov/16451057 DMK6YOP DI DMK6YOP DMK6YOP DN CID1172084 DMK6YOP TI TTNET8J DMK6YOP TN G-protein coupled receptor 55 (GPR55) DMK6YOP MA Agonist DMK6YOP RN Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47. DMK6YOP RU https://pubmed.ncbi.nlm.nih.gov/21534610 DMK79U1 DI DMK79U1 DMK79U1 DN 3-(4-Methoxy-benzenesulfonyl)-cyclopentanethiol DMK79U1 TI TTHY57M DMK79U1 TN Matrix metalloproteinase-13 (MMP-13) DMK79U1 MA Inhibitor DMK79U1 RN Synthesis and identification of conformationally constrained selective MMP inhibitors. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1757-60. DMK79U1 RU https://pubmed.ncbi.nlm.nih.gov/10406637 DMK7D8N DI DMK7D8N DMK7D8N DN 3'-bromopropiophenonethiosemicarbazone DMK7D8N TI TTEAID7 DMK7D8N TN Trypanosoma Cruzipain (Trypano CYSP) DMK7D8N MA Inhibitor DMK7D8N RN Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. Bioorg Med Chem. 2010 Nov 15;18(22):7826-35. DMK7D8N RU https://pubmed.ncbi.nlm.nih.gov/20961766 DMK7QXA DI DMK7QXA DMK7QXA DN DIETHOXYFLOURESCEIN DMK7QXA TI TTXV4FI DMK7QXA TN Albendazole monooxygenase (CYP3A4) DMK7QXA MA Inhibitor DMK7QXA RN Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists. J Med Chem. 2010 Oct 14;53(19):7129-39. DMK7QXA RU https://pubmed.ncbi.nlm.nih.gov/20839775 DMK7VS1 DI DMK7VS1 DMK7VS1 DN CHLOROCYCLINONE D DMK7VS1 TI TTT2SVW DMK7VS1 TN PPAR-gamma messenger RNA (PPARG mRNA) DMK7VS1 MA Inhibitor DMK7VS1 RN Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8. DMK7VS1 RU https://pubmed.ncbi.nlm.nih.gov/18044841 DMK7WON DI DMK7WON DMK7WON DN 2-morpholino-7-phenyl-4H-chromen-4-one DMK7WON TI TT06AWU DMK7WON TN Phosphodiesterase 3A (PDE3A) DMK7WON MA Inhibitor DMK7WON RN Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73. DMK7WON RU https://pubmed.ncbi.nlm.nih.gov/16290931 DMK7YIG DI DMK7YIG DMK7YIG DN Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Tyr DMK7YIG TI TT6PKBN DMK7YIG TN Proto-oncogene c-Src (SRC) DMK7YIG MA Inhibitor DMK7YIG RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMK7YIG RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMK846H DI DMK846H DMK846H DN HEPT DMK846H TI TT84ETX DMK846H TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMK846H MA Inhibitor DMK846H RN 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S... Bioorg Med Chem Lett. 2004 Jun 21;14(12):3173-6. DMK846H RU https://pubmed.ncbi.nlm.nih.gov/15149669 DMK8AGF DI DMK8AGF DMK8AGF DN O-2442 DMK8AGF TI TTVBI8W DMK8AGF TN Dopamine transporter (DAT) DMK8AGF MA Inhibitor DMK8AGF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927). DMK8AGF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=927 DMK8DCF DI DMK8DCF DMK8DCF DN 4-(4-fluoro-phenyliminomethyl)-benzenesulfonamide DMK8DCF TI TTVKILB DMK8DCF TN Prostaglandin G/H synthase 2 (COX-2) DMK8DCF MA Inhibitor DMK8DCF RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMK8DCF RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMK8FPR DI DMK8FPR DMK8FPR DN ISIS 2922 + foscarnet 3' -azido-3'-deoxythymidine 2'-3'-dideoxycytidine DMK8FPR TI TT4SCBE DMK8FPR TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMK8FPR RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMK8FPR RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMK8LEC DI DMK8LEC DMK8LEC DN OF-1 DMK8LEC TI TTT46BN DMK8LEC TN Bromodomain and PHD finger containing 1 (BRPF1) DMK8LEC MA Inhibitor DMK8LEC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2730). DMK8LEC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2730 DMK8LEC DI DMK8LEC DMK8LEC DN OF-1 DMK8LEC TI TTT09OB DMK8LEC TN Bromodomain-containing protein 1 (BRD1) DMK8LEC MA Inhibitor DMK8LEC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2724). DMK8LEC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2724 DMK8LHB DI DMK8LHB DMK8LHB DN 3-(1-Methyl-piperidin-2-yl)-2-phenyl-1H-indole DMK8LHB TI TTQ6VDM DMK8LHB TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMK8LHB MA Inhibitor DMK8LHB RN 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14. DMK8LHB RU https://pubmed.ncbi.nlm.nih.gov/11334570 DMK8P61 DI DMK8P61 DMK8P61 DN Tetradecane DMK8P61 TI TT7O8ZA DMK8P61 TN Lanosterol synthase (LSS) DMK8P61 MA Inhibitor DMK8P61 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMK8P61 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMK8ROX DI DMK8ROX DMK8ROX DN 4-(2-(4-tert-Butylphenylamino)ethyl)-1H-imidazole DMK8ROX TI TT9JNIC DMK8ROX TN Histamine H3 receptor (H3R) DMK8ROX MA Inhibitor DMK8ROX RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMK8ROX RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMK8T61 DI DMK8T61 DMK8T61 DN diphenyltetrahydrofuran DMK8T61 TI TT946IA DMK8T61 TN Transient receptor potential cation channel V3 (TRPV3) DMK8T61 MA Blocker (channel blocker) DMK8T61 RN Biphasic currents evoked by chemical or thermal activation of the heat-gated ion channel, TRPV3. J Biol Chem. 2005 Apr 22;280(16):15928-41. DMK8T61 RU https://pubmed.ncbi.nlm.nih.gov/15722340 DMK8VZM DI DMK8VZM DMK8VZM DN N-Methyl-1'H-phenothiazine-1'-carboxamide DMK8VZM TI TT1RS9F DMK8VZM TN Acetylcholinesterase (AChE) DMK8VZM MA Inhibitor DMK8VZM RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMK8VZM RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMK8VZM DI DMK8VZM DMK8VZM DN N-Methyl-1'H-phenothiazine-1'-carboxamide DMK8VZM TI TTEB0GD DMK8VZM TN Cholinesterase (BCHE) DMK8VZM MA Inhibitor DMK8VZM RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMK8VZM RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMK8WUR DI DMK8WUR DMK8WUR DN 2-hydroxy-3-isopropyl-2,4,6-cycloheptatrien-1-one DMK8WUR TI TTULVH8 DMK8WUR TN Tyrosinase (TYR) DMK8WUR MA Inhibitor DMK8WUR RN Structural insights into the hot spot amino acid residues of mushroom tyrosinase for the bindings of thujaplicins. Bioorg Med Chem. 2010 Nov 15;18(22):8112-8. DMK8WUR RU https://pubmed.ncbi.nlm.nih.gov/20947360 DMK8XIO DI DMK8XIO DMK8XIO DN 6-Benzyloxy-5-nitro-pyrimidine-2,4-diamine DMK8XIO TI TTJ8DV7 DMK8XIO TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DMK8XIO MA Inhibitor DMK8XIO RN Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8. DMK8XIO RU https://pubmed.ncbi.nlm.nih.gov/9484500 DMK96BL DI DMK96BL DMK96BL DN 2-HYDROXYGARVIN A DMK96BL TI TTZJYKH DMK96BL TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMK96BL MA Inhibitor DMK96BL RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DMK96BL RU https://pubmed.ncbi.nlm.nih.gov/17067170 DMK9743 DI DMK9743 DMK9743 DN Trimetoquinol DMK9743 TI TTMXGCW DMK9743 TN Adrenergic receptor beta-3 (ADRB3) DMK9743 MA Agonist DMK9743 RN Synthesis and human beta-adrenoceptor activity of 1-(3,5-diiodo-4- methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-6-ol derivatives in vitro. J Med Chem. 2000 Feb 24;43(4):591-8. DMK9743 RU https://pubmed.ncbi.nlm.nih.gov/10691685 DMK97WC DI DMK97WC DMK97WC DN Sulfamic acid 4-(3-methoxy-benzoyl)-phenyl ester DMK97WC TI TTHM0R1 DMK97WC TN Steryl-sulfatase (STS) DMK97WC MA Inhibitor DMK97WC RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMK97WC RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMK98LE DI DMK98LE DMK98LE DN N-hydroxy-5-(pyridin-3-yl)thiophene-2-carboxamide DMK98LE TI TT6R7JZ DMK98LE TN Histone deacetylase 1 (HDAC1) DMK98LE MA Inhibitor DMK98LE RN Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. DMK98LE RU https://pubmed.ncbi.nlm.nih.gov/17107790 DMK9BMQ DI DMK9BMQ DMK9BMQ DN AVVYPWT DMK9BMQ TI TT2THBD DMK9BMQ TN P2X purinoceptor 3 (P2RX3) DMK9BMQ MA Inhibitor DMK9BMQ RN Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7. DMK9BMQ RU https://pubmed.ncbi.nlm.nih.gov/17676725 DMK9BN0 DI DMK9BN0 DMK9BN0 DN 3,3-di(pent-4-enyl)azetidin-2-one DMK9BN0 TI TTDP1UC DMK9BN0 TN Fatty acid amide hydrolase (FAAH) DMK9BN0 MA Inhibitor DMK9BN0 RN 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7. DMK9BN0 RU https://pubmed.ncbi.nlm.nih.gov/18547805 DMK9FQG DI DMK9FQG DMK9FQG DN N-(4-iodophenyl)-4-(trifluoromethyl)benzamide DMK9FQG TI TTMI6F5 DMK9FQG TN Transient receptor potential cation channel V1 (TRPV1) DMK9FQG MA Inhibitor DMK9FQG RN Synthesis of benzamide derivatives as TRPV1 antagonists. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1072-8. DMK9FQG RU https://pubmed.ncbi.nlm.nih.gov/18155908 DMK9JCA DI DMK9JCA DMK9JCA DN 3,5-Diamino-4'-amino-trans-stilbene DMK9JCA TI TTSZLWK DMK9JCA TN Aromatase (CYP19A1) DMK9JCA MA Inhibitor DMK9JCA RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMK9JCA RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMK9OYM DI DMK9OYM DMK9OYM DN 2-tosylnaphthalene-1,4-dione DMK9OYM TI TTRVTMX DMK9OYM TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMK9OYM MA Inhibitor DMK9OYM RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DMK9OYM RU https://pubmed.ncbi.nlm.nih.gov/18996691 DMKA0ON DI DMKA0ON DMKA0ON DN (1S,2S)-N-Arachidonoylcyclopropanolamide DMKA0ON TI TTMSFAW DMKA0ON TN Cannabinoid receptor 2 (CB2) DMKA0ON MA Inhibitor DMKA0ON RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMKA0ON RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMKA0ON DI DMKA0ON DMKA0ON DN (1S,2S)-N-Arachidonoylcyclopropanolamide DMKA0ON TI TT6OEDT DMKA0ON TN Cannabinoid receptor 1 (CB1) DMKA0ON MA Inhibitor DMKA0ON RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMKA0ON RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMKA3V2 DI DMKA3V2 DMKA3V2 DN 2-N-Ethylamino-1-(4-methylthiophenyl)butane DMKA3V2 TI TT3ROYC DMKA3V2 TN Serotonin transporter (SERT) DMKA3V2 MA Inhibitor DMKA3V2 RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMKA3V2 RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMKA8R4 DI DMKA8R4 DMKA8R4 DN SB 228357 DMKA8R4 TI TT0K1SC DMKA8R4 TN 5-HT 2B receptor (HTR2B) DMKA8R4 MA Antagonist DMKA8R4 RN Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34. DMKA8R4 RU https://pubmed.ncbi.nlm.nih.gov/10737744 DMKA8R4 DI DMKA8R4 DMKA8R4 DN SB 228357 DMKA8R4 TI TTJQOD7 DMKA8R4 TN 5-HT 2A receptor (HTR2A) DMKA8R4 MA Antagonist DMKA8R4 RN Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34. DMKA8R4 RU https://pubmed.ncbi.nlm.nih.gov/10737744 DMKA8R4 DI DMKA8R4 DMKA8R4 DN SB 228357 DMKA8R4 TI TTWJBZ5 DMKA8R4 TN 5-HT 2C receptor (HTR2C) DMKA8R4 MA Antagonist DMKA8R4 RN Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent. J Med Chem. 2000 Mar 23;43(6):1123-34. DMKA8R4 RU https://pubmed.ncbi.nlm.nih.gov/10737744 DMKA8YT DI DMKA8YT DMKA8YT DN NSC-637994 DMKA8YT TI TTJLP0R DMKA8YT TN Quinone reductase 2 (NQO2) DMKA8YT MA Inhibitor DMKA8YT RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMKA8YT RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMKAEQP DI DMKAEQP DMKAEQP DN H-mCpa-Gly-Gly-Phe-Leu-OH DMKAEQP TI TT27RFC DMKAEQP TN Opioid receptor delta (OPRD1) DMKAEQP MA Inhibitor DMKAEQP RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMKAEQP RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMKAEUD DI DMKAEUD DMKAEUD DN 3-(3-(3-chlorobenzyloxy)-5-methylphenyl)pyridine DMKAEUD TI TTHS256 DMKAEUD TN Metabotropic glutamate receptor 5 (mGluR5) DMKAEUD MA Inhibitor DMKAEUD RN Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. DMKAEUD RU https://pubmed.ncbi.nlm.nih.gov/16439120 DMKAHYQ DI DMKAHYQ DMKAHYQ DN Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe DMKAHYQ TI TTCG0AL DMKAHYQ TN Cholecystokinin receptor type A (CCKAR) DMKAHYQ MA Inhibitor DMKAHYQ RN Toward developing peptidomimetics: Successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists, Bioorg. Med. Chem. Lett. 3(5):855-860 (1993). DMKAHYQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00806800 DMKAHYQ DI DMKAHYQ DMKAHYQ DN Asp-Tyr(OSO3H)-Met-Gly-Trp-Met-Asp-Phe DMKAHYQ TI TTVFO0U DMKAHYQ TN Gastrin/cholecystokinin type B receptor (CCKBR) DMKAHYQ MA Inhibitor DMKAHYQ RN The rational design and synthesis of non-peptide hegnylogues of CCK-26-33 - a novel series of CCK-A selective ligands, Bioorg. Med. Chem. Lett. 3(5):889-894 (1993). DMKAHYQ RU http://www.sciencedirect.com/science/article/pii/S0960894X00806873 DMKANOH DI DMKANOH DMKANOH DN Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH TI TTY6EWA DMKANOH TN Neuropeptide Y receptor type 5 (NPY5R) DMKANOH MA Agonist DMKANOH RN Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90. DMKANOH RU https://pubmed.ncbi.nlm.nih.gov/12182951 DMKANOH DI DMKANOH DMKANOH DN Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH TI TTKAPQ1 DMKANOH TN Cholecystokinin receptor (CCKR) DMKANOH MA Antagonist DMKANOH RN Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines. FEBS Lett. 1996 Apr 1;383(3):241-4. DMKANOH RU https://pubmed.ncbi.nlm.nih.gov/8925905 DMKANOH DI DMKANOH DMKANOH DN Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH TI TTCG0AL DMKANOH TN Cholecystokinin receptor type A (CCKAR) DMKANOH MA Antagonist DMKANOH RN Role of CCK(A) receptors in postprandial lower esophageal sphincter function in morbidly obese subjects. Dig Dis Sci. 2002 Nov;47(11):2531-7. DMKANOH RU https://pubmed.ncbi.nlm.nih.gov/12452391 DMKAQ6U DI DMKAQ6U DMKAQ6U DN ISIS 7855 DMKAQ6U TI TTAN5W2 DMKAQ6U TN Raf messenger RNA (Raf mRNA) DMKAQ6U RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMKAQ6U RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMKATOJ DI DMKATOJ DMKATOJ DN 1-(4-fluorophenyl)-3-(phenylsulfonyl)propan-1-one DMKATOJ TI TTN7BL9 DMKATOJ TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMKATOJ MA Inhibitor DMKATOJ RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMKATOJ RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMKAW4P DI DMKAW4P DMKAW4P DN (R)-alpha-methylhistamine DMKAW4P TI TT9JNIC DMKAW4P TN Histamine H3 receptor (H3R) DMKAW4P MA Agonist DMKAW4P RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMKAW4P RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMKAW4P DI DMKAW4P DMKAW4P DN (R)-alpha-methylhistamine DMKAW4P TI TTXJ178 DMKAW4P TN Histamine H4 receptor (H4R) DMKAW4P MA Agonist DMKAW4P RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DMKAW4P RU https://pubmed.ncbi.nlm.nih.gov/11179434 DMKAX3Q DI DMKAX3Q DMKAX3Q DN N-(3-Phenylpropyl)-1H-indole-2-carboxamide DMKAX3Q TI TT3WG5C DMKAX3Q TN Monoamine oxidase type A (MAO-A) DMKAX3Q MA Inhibitor DMKAX3Q RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMKAX3Q RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMKAX3Q DI DMKAX3Q DMKAX3Q DN N-(3-Phenylpropyl)-1H-indole-2-carboxamide DMKAX3Q TI TTGP7BY DMKAX3Q TN Monoamine oxidase type B (MAO-B) DMKAX3Q MA Inhibitor DMKAX3Q RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMKAX3Q RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMKAX76 DI DMKAX76 DMKAX76 DN T-BuAc-RYYRIK-NH2 DMKAX76 TI TTNT7K8 DMKAX76 TN Nociceptin receptor (OPRL1) DMKAX76 MA Inhibitor DMKAX76 RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMKAX76 RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMKAY5G DI DMKAY5G DMKAY5G DN KNI-10763 DMKAY5G TI TTXMNHO DMKAY5G TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMKAY5G MA Inhibitor DMKAY5G RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMKAY5G RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMKAZ1O DI DMKAZ1O DMKAZ1O DN PMID20299227C12 DMKAZ1O TI TTFQEO5 DMKAZ1O TN Squalene synthetase (FDFT1) DMKAZ1O MA Inhibitor DMKAZ1O RN Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). Bioorg Med Chem. 2010 Apr 1;18(7):2428-38. DMKAZ1O RU https://pubmed.ncbi.nlm.nih.gov/20299227 DMKB2IJ DI DMKB2IJ DMKB2IJ DN SEN-1500 DMKB2IJ TI TTE4KHA DMKB2IJ TN Amyloid beta A4 protein (APP) DMKB2IJ MA Inhibitor DMKB2IJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMKB2IJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMKB2P8 DI DMKB2P8 DMKB2P8 DN 2-methylbut-3-yn-2-yl 4-methoxybenzoate DMKB2P8 TI TTPLTSQ DMKB2P8 TN Neutrophil elastase (NE) DMKB2P8 MA Inhibitor DMKB2P8 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMKB2P8 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMKB621 DI DMKB621 DMKB621 DN (R)-(-)-11-hydroxy-N-n-propylnoraporphine DMKB621 TI TTZFYLI DMKB621 TN Dopamine D1 receptor (D1R) DMKB621 MA Inhibitor DMKB621 RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMKB621 RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMKB621 DI DMKB621 DMKB621 DN (R)-(-)-11-hydroxy-N-n-propylnoraporphine DMKB621 TI TTJQOD7 DMKB621 TN 5-HT 2A receptor (HTR2A) DMKB621 MA Inhibitor DMKB621 RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMKB621 RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMKB621 DI DMKB621 DMKB621 DN (R)-(-)-11-hydroxy-N-n-propylnoraporphine DMKB621 TI TTEX248 DMKB621 TN Dopamine D2 receptor (D2R) DMKB621 MA Inhibitor DMKB621 RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMKB621 RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMKBACJ DI DMKBACJ DMKBACJ DN N-Hydroxy-3-naphthalen-2-yl-N-p-tolyl-acrylamide DMKBACJ TI TT2J34L DMKBACJ TN Arachidonate 5-lipoxygenase (5-LOX) DMKBACJ MA Inhibitor DMKBACJ RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMKBACJ RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMKBCS2 DI DMKBCS2 DMKBCS2 DN PNU 101017 DMKBCS2 TI TTEX6LM DMKBCS2 TN GABA(A) receptor gamma-3 (GABRG3) DMKBCS2 MA Modulator DMKBCS2 RN Neuroprotective effects of the GABA(A) receptor partial agonist U-101017 in 3-acetylpyridine-treated rats. Neurosci Lett. 1997 May 30;228(1):45-9. DMKBCS2 RU https://www.ncbi.nlm.nih.gov/pubmed/9197284 DMKBG1F DI DMKBG1F DMKBG1F DN N-Propyl-2-methylnorapomorphine hydrochloride DMKBG1F TI TTEX248 DMKBG1F TN Dopamine D2 receptor (D2R) DMKBG1F MA Inhibitor DMKBG1F RN N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62. DMKBG1F RU https://pubmed.ncbi.nlm.nih.gov/19454369 DMKBRIM DI DMKBRIM DMKBRIM DN 3-Biphenyl-4-yl-N-hydroxy-N-methyl-acrylamide DMKBRIM TI TT2J34L DMKBRIM TN Arachidonate 5-lipoxygenase (5-LOX) DMKBRIM MA Inhibitor DMKBRIM RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMKBRIM RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMKBSGN DI DMKBSGN DMKBSGN DN L-165461 DMKBSGN TI TTT2SVW DMKBSGN TN PPAR-gamma messenger RNA (PPARG mRNA) DMKBSGN MA Inhibitor DMKBSGN RN Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80. DMKBSGN RU https://pubmed.ncbi.nlm.nih.gov/12657263 DMKBSGN DI DMKBSGN DMKBSGN DN L-165461 DMKBSGN TI TTJ584C DMKBSGN TN Peroxisome proliferator-activated receptor alpha (PPARA) DMKBSGN MA Inhibitor DMKBSGN RN Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80. DMKBSGN RU https://pubmed.ncbi.nlm.nih.gov/12657263 DMKBSGN DI DMKBSGN DMKBSGN DN L-165461 DMKBSGN TI TT2JWF6 DMKBSGN TN Peroxisome proliferator-activated receptor delta (PPARD) DMKBSGN MA Inhibitor DMKBSGN RN Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80. DMKBSGN RU https://pubmed.ncbi.nlm.nih.gov/12657263 DMKC1GI DI DMKC1GI DMKC1GI DN 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine DMKC1GI TI TTK25J1 DMKC1GI TN Adenosine A1 receptor (ADORA1) DMKC1GI MA Inhibitor DMKC1GI RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMKC1GI RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMKC1GI DI DMKC1GI DMKC1GI DN 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine DMKC1GI TI TTM2AOE DMKC1GI TN Adenosine A2a receptor (ADORA2A) DMKC1GI MA Inhibitor DMKC1GI RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMKC1GI RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMKC1GI DI DMKC1GI DMKC1GI DN 2-[(4-acetylphenyl)ethynyl]-N6-methoxyadenosine DMKC1GI TI TTJFY5U DMKC1GI TN Adenosine A3 receptor (ADORA3) DMKC1GI MA Inhibitor DMKC1GI RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMKC1GI RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMKC2BE DI DMKC2BE DMKC2BE DN (5-pyridin-3-yl-furan-2-yl)methanethiol DMKC2BE TI TTXV4FI DMKC2BE TN Albendazole monooxygenase (CYP3A4) DMKC2BE MA Inhibitor DMKC2BE RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DMKC2BE RU https://pubmed.ncbi.nlm.nih.gov/17125252 DMKC2BE DI DMKC2BE DMKC2BE DN (5-pyridin-3-yl-furan-2-yl)methanethiol DMKC2BE TI TTVG215 DMKC2BE TN Debrisoquine 4-hydroxylase (CYP2D6) DMKC2BE MA Inhibitor DMKC2BE RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DMKC2BE RU https://pubmed.ncbi.nlm.nih.gov/17125252 DMKC52N DI DMKC52N DMKC52N DN 1-(4-Cyanobenzyl)-5-methyl-1H-imidazole DMKC52N TI TTIQUX7 DMKC52N TN Steroid 11-beta-hydroxylase (CYP11B1) DMKC52N MA Inhibitor DMKC52N RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMKC52N RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMKC52N DI DMKC52N DMKC52N DN 1-(4-Cyanobenzyl)-5-methyl-1H-imidazole DMKC52N TI TTSZLWK DMKC52N TN Aromatase (CYP19A1) DMKC52N MA Inhibitor DMKC52N RN Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36. DMKC52N RU https://pubmed.ncbi.nlm.nih.gov/1825337 DMKC6IX DI DMKC6IX DMKC6IX DN spantide II DMKC6IX TI TTZPO1L DMKC6IX TN Substance-P receptor (TACR1) DMKC6IX MA Antagonist DMKC6IX RN Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4833-5. DMKC6IX RU https://pubmed.ncbi.nlm.nih.gov/1693780 DMKC6L8 DI DMKC6L8 DMKC6L8 DN 3,4-Benzo-7-acetonyloxy-8-methylcoumarin DMKC6L8 TI TT3WG5C DMKC6L8 TN Monoamine oxidase type A (MAO-A) DMKC6L8 MA Inhibitor DMKC6L8 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMKC6L8 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMKCBIL DI DMKCBIL DMKCBIL DN 6-chloro-1H-indazole DMKCBIL TI TTZUFI5 DMKCBIL TN Nitric-oxide synthase brain (NOS1) DMKCBIL MA Inhibitor DMKCBIL RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DMKCBIL RU https://pubmed.ncbi.nlm.nih.gov/17395463 DMKCG41 DI DMKCG41 DMKCG41 DN ISIS 150453 DMKCG41 TI TTP9K3Q DMKCG41 TN SOD1 messenger RNA (SOD1 mRNA) DMKCG41 RN US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. DMKCG41 RU http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true DMKCG8H DI DMKCG8H DMKCG8H DN methyl salicylate DMKCG8H TI TTELV3W DMKCG8H TN Transformation-sensitive protein p120 (TRPA1) DMKCG8H MA Activator DMKCG8H RN Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004 Mar 25;41(6):849-57. DMKCG8H RU https://pubmed.ncbi.nlm.nih.gov/15046718 DMKCIP0 DI DMKCIP0 DMKCIP0 DN ML381 DMKCIP0 TI TTQ13Z5 DMKCIP0 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMKCIP0 MA Antagonist DMKCIP0 RN Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. ChemMedChem. 2014 Aug;9(8):1677-82. DMKCIP0 RU https://pubmed.ncbi.nlm.nih.gov/24692176 DMKCIP0 DI DMKCIP0 DMKCIP0 DN ML381 DMKCIP0 TI TTOXS3C DMKCIP0 TN Muscarinic acetylcholine receptor (CHRM) DMKCIP0 MA Antagonist DMKCIP0 RN Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe. ChemMedChem. 2014 Aug;9(8):1677-82. DMKCIP0 RU https://pubmed.ncbi.nlm.nih.gov/24692176 DMKCJQW DI DMKCJQW DMKCJQW DN SP-SAP DMKCJQW TI TTZPO1L DMKCJQW TN Substance-P receptor (TACR1) DMKCJQW MA Inhibitor DMKCJQW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360). DMKCJQW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360 DMKCOS2 DI DMKCOS2 DMKCOS2 DN 2-Phenyl-3-pyridin-4-ylmethylene-chroman-4-one DMKCOS2 TI TTSZLWK DMKCOS2 TN Aromatase (CYP19A1) DMKCOS2 MA Inhibitor DMKCOS2 RN New aromatase inhibitors. Synthesis and inhibitory activity of pyridinyl-substituted flavanone derivatives. Bioorg Med Chem Lett. 2002 Apr 8;12(7):1059-61. DMKCOS2 RU https://pubmed.ncbi.nlm.nih.gov/11909717 DMKCOYE DI DMKCOYE DMKCOYE DN ADS-103316 DMKCOYE TI TTX4RTB DMKCOYE TN Melanin-concentrating hormone receptor 1 (MCHR1) DMKCOYE MA Inhibitor DMKCOYE RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMKCOYE RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMKCT0M DI DMKCT0M DMKCT0M DN AX-9657 DMKCT0M TI TTPLTSQ DMKCT0M TN Neutrophil elastase (NE) DMKCT0M MA Inhibitor DMKCT0M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2358). DMKCT0M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2358 DMKCUY6 DI DMKCUY6 DMKCUY6 DN Salvinorin B propoxymethyl ether DMKCUY6 TI TTQW87Y DMKCUY6 TN Opioid receptor kappa (OPRK1) DMKCUY6 MA Inhibitor DMKCUY6 RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMKCUY6 RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMKCX5N DI DMKCX5N DMKCX5N DN N-Butyl-N'-Hydroxyguanidine DMKCX5N TI TTZUFI5 DMKCX5N TN Nitric-oxide synthase brain (NOS1) DMKCX5N MA Inhibitor DMKCX5N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKCX5N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKCY0X DI DMKCY0X DMKCY0X DN THA-902 DMKCY0X TI TTLGDIS DMKCY0X TN Acid-sensing ion channel 3 (ASIC3) DMKCY0X MA Antagonist DMKCY0X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686). DMKCY0X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686 DMKD0ZP DI DMKD0ZP DMKD0ZP DN 9-methyl-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide DMKD0ZP TI TTSXVID DMKD0ZP TN Nuclear factor NF-kappa-B (NFKB) DMKD0ZP MA Inhibitor DMKD0ZP RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DMKD0ZP RU https://pubmed.ncbi.nlm.nih.gov/18024113 DMKD2Q4 DI DMKD2Q4 DMKD2Q4 DN 8-Hydroxy-2-phenyl-3H-quinazolin-4-one DMKD2Q4 TI TTVDSZ0 DMKD2Q4 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMKD2Q4 MA Inhibitor DMKD2Q4 RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMKD2Q4 RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMKD6GA DI DMKD6GA DMKD6GA DN Toremifene DMKD6GA TI TTZ3COY DMKD6GA TN COVID-19 spike glycoprotein (S) DMKD6GA MA Inhibitor DMKD6GA RN Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020. DMKD6GA RU https://chemrxiv.org/articles/Repurposing_of_FDA-Approved_Toremifene_to_Treat_COVID-19_by_Blocking_the_Spike_Glycoprotein_and_NSP14_of_SARS-CoV-2/12431966/1 DMKD6GA DI DMKD6GA DMKD6GA DN Toremifene DMKD6GA TI TTC2DS7 DMKD6GA TN COVID-19 non-structural protein 14 (nsp14) DMKD6GA MA Inhibitor DMKD6GA RN Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020. DMKD6GA RU https://chemrxiv.org/articles/Repurposing_of_FDA-Approved_Toremifene_to_Treat_COVID-19_by_Blocking_the_Spike_Glycoprotein_and_NSP14_of_SARS-CoV-2/12431966/1 DMKD874 DI DMKD874 DMKD874 DN 3-benzyloxy-4-methoxy-2'-hydroxychalcone DMKD874 TI TTVKILB DMKD874 TN Prostaglandin G/H synthase 2 (COX-2) DMKD874 MA Inhibitor DMKD874 RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DMKD874 RU https://pubmed.ncbi.nlm.nih.gov/19233646 DMKD94Q DI DMKD94Q DMKD94Q DN H-Aba-ala-Gly-Phe-Met-OH DMKD94Q TI TTKWM86 DMKD94Q TN Opioid receptor mu (MOP) DMKD94Q MA Inhibitor DMKD94Q RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMKD94Q RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMKD94Q DI DMKD94Q DMKD94Q DN H-Aba-ala-Gly-Phe-Met-OH DMKD94Q TI TT27RFC DMKD94Q TN Opioid receptor delta (OPRD1) DMKD94Q MA Inhibitor DMKD94Q RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMKD94Q RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMKDAJ2 DI DMKDAJ2 DMKDAJ2 DN 1-(4-Cyanobenzyl)-5-(2-fluorophenyl)-1H-imidazole DMKDAJ2 TI TTIQUX7 DMKDAJ2 TN Steroid 11-beta-hydroxylase (CYP11B1) DMKDAJ2 MA Inhibitor DMKDAJ2 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMKDAJ2 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMKDBFL DI DMKDBFL DMKDBFL DN HBR-985 DMKDBFL TI TTP835K DMKDBFL TN ATP-binding cassette transporter C8 (ABCC8) DMKDBFL MA Inhibitor DMKDBFL RN Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98. DMKDBFL RU https://pubmed.ncbi.nlm.nih.gov/11297455 DMKDBFL DI DMKDBFL DMKDBFL DN HBR-985 DMKDBFL TI TT329V4 DMKDBFL TN Inward rectifier potassium channel Kir6.2 (KCNJ11) DMKDBFL MA Inhibitor DMKDBFL RN Cardioselective K(ATP) channel blockers derived from a new series of m-anisamidoethylbenzenesulfonylthioureas. J Med Chem. 2001 Mar 29;44(7):1085-98. DMKDBFL RU https://pubmed.ncbi.nlm.nih.gov/11297455 DMKDBHN DI DMKDBHN DMKDBHN DN 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol DMKDBHN TI TTLD29N DMKDBHN TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMKDBHN MA Inhibitor DMKDBHN RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMKDBHN RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMKDBHN DI DMKDBHN DMKDBHN DN 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol DMKDBHN TI TTN9D8E DMKDBHN TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMKDBHN MA Inhibitor DMKDBHN RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMKDBHN RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMKDBHN DI DMKDBHN DMKDBHN DN 4-[3-(5-Phenyl-pentylamino)-propyl]-phenol DMKDBHN TI TTKJEMQ DMKDBHN TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMKDBHN MA Inhibitor DMKDBHN RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMKDBHN RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMKDEWH DI DMKDEWH DMKDEWH DN AcDif-Glu-Cha-Cys DMKDEWH TI TTWXB3E DMKDEWH TN Hepatitis C virus NS3 helicase (HCV NS3) DMKDEWH MA Inhibitor DMKDEWH RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMKDEWH RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMKDGLA DI DMKDGLA DMKDGLA DN LP-211 DMKDGLA TI TTO9X1H DMKDGLA TN 5-HT 7 receptor (HTR7) DMKDGLA MA Agonist DMKDGLA RN Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22. DMKDGLA RU https://pubmed.ncbi.nlm.nih.gov/18800769 DMKDGLA DI DMKDGLA DMKDGLA DN LP-211 DMKDGLA TI TTEX248 DMKDGLA TN Dopamine D2 receptor (D2R) DMKDGLA MA Agonist DMKDGLA RN Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22. DMKDGLA RU https://pubmed.ncbi.nlm.nih.gov/18800769 DMKDGLA DI DMKDGLA DMKDGLA DN LP-211 DMKDGLA TI TTSQIFT DMKDGLA TN 5-HT 1A receptor (HTR1A) DMKDGLA MA Agonist DMKDGLA RN Structural modifications of N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides: influence on lipophilicity and 5-HT7 receptor act... J Med Chem. 2008 Sep 25;51(18):5813-22. DMKDGLA RU https://pubmed.ncbi.nlm.nih.gov/18800769 DMKDLB7 DI DMKDLB7 DMKDLB7 DN GSK-3787 DMKDLB7 TI TT2JWF6 DMKDLB7 TN Peroxisome proliferator-activated receptor delta (PPARD) DMKDLB7 MA Inhibitor DMKDLB7 RN Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversibl... J Med Chem. 2010 Feb 25;53(4):1857-61. DMKDLB7 RU https://pubmed.ncbi.nlm.nih.gov/20128594 DMKDMPL DI DMKDMPL DMKDMPL DN Salvinorin B methylthiomethyl ether DMKDMPL TI TTQW87Y DMKDMPL TN Opioid receptor kappa (OPRK1) DMKDMPL MA Inhibitor DMKDMPL RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMKDMPL RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMKDRVZ DI DMKDRVZ DMKDRVZ DN Adamant-1-ylcarbamic Acid Biphenyl-3-yl Ester DMKDRVZ TI TTDP1UC DMKDRVZ TN Fatty acid amide hydrolase (FAAH) DMKDRVZ MA Inhibitor DMKDRVZ RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMKDRVZ RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMKDSGE DI DMKDSGE DMKDSGE DN 2,7-Bis[2-(diethylamino)acetamido]anthraquinone DMKDSGE TI TTQY2EJ DMKDSGE TN TERT messenger RNA (TERT mRNA) DMKDSGE MA Inhibitor DMKDSGE RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMKDSGE RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMKDVP7 DI DMKDVP7 DMKDVP7 DN NSC-645835 DMKDVP7 TI TTJLP0R DMKDVP7 TN Quinone reductase 2 (NQO2) DMKDVP7 MA Inhibitor DMKDVP7 RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMKDVP7 RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMKDZH4 DI DMKDZH4 DMKDZH4 DN AcAsp-Glu-Leu-Glu-Cha-Cys DMKDZH4 TI TTWXB3E DMKDZH4 TN Hepatitis C virus NS3 helicase (HCV NS3) DMKDZH4 MA Inhibitor DMKDZH4 RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMKDZH4 RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMKDZLG DI DMKDZLG DMKDZLG DN BAZ2-ICR DMKDZLG TI TT2MV0R DMKDZLG TN Bromodomain adjacent to zinc finger 2A (BAZ2A) DMKDZLG MA Inhibitor DMKDZLG RN Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9. DMKDZLG RU https://pubmed.ncbi.nlm.nih.gov/25719566 DMKDZLG DI DMKDZLG DMKDZLG DN BAZ2-ICR DMKDZLG TI TT6K8YG DMKDZLG TN Bromodomain adjacent to zinc finger 2B (BAZ2B) DMKDZLG MA Inhibitor DMKDZLG RN Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015 Mar 12;58(5):2553-9. DMKDZLG RU https://pubmed.ncbi.nlm.nih.gov/25719566 DMKE03Q DI DMKE03Q DMKE03Q DN Makaluvamine N DMKE03Q TI TT0IHXV DMKE03Q TN DNA topoisomerase II (TOP2) DMKE03Q MA Inhibitor DMKE03Q RN Makaluvamine N: a new pyrroloiminoquinone from Zyzzya fuliginosa. J Nat Prod. 1997 Apr;60(4):408-10. DMKE03Q RU https://pubmed.ncbi.nlm.nih.gov/9134749 DMKE18W DI DMKE18W DMKE18W DN Methionine Sulfoxide DMKE18W TI TTU6BFZ DMKE18W TN Candida Thymidylate synthase (Candi TMP1) DMKE18W MA Inhibitor DMKE18W RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKE18W RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKE18W DI DMKE18W DMKE18W DN Methionine Sulfoxide DMKE18W TI TTE4KHA DMKE18W TN Amyloid beta A4 protein (APP) DMKE18W MA Inhibitor DMKE18W RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKE18W RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKE7FG DI DMKE7FG DMKE7FG DN 1-(pyridin-2-yl)piperazine DMKE7FG TI TT3T17P DMKE7FG TN Phospholipase D1 (PLD1) DMKE7FG MA Inhibitor DMKE7FG RN Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privil... Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3. DMKE7FG RU https://pubmed.ncbi.nlm.nih.gov/19299128 DMKE7FG DI DMKE7FG DMKE7FG DN 1-(pyridin-2-yl)piperazine DMKE7FG TI TTWG9A4 DMKE7FG TN Adrenergic receptor alpha-2A (ADRA2A) DMKE7FG MA Inhibitor DMKE7FG RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMKE7FG RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMKE7FG DI DMKE7FG DMKE7FG DN 1-(pyridin-2-yl)piperazine DMKE7FG TI TT34BHT DMKE7FG TN Adrenergic receptor alpha-1D (ADRA1D) DMKE7FG MA Inhibitor DMKE7FG RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMKE7FG RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMKE7FG DI DMKE7FG DMKE7FG DN 1-(pyridin-2-yl)piperazine DMKE7FG TI TTNGILX DMKE7FG TN Adrenergic receptor alpha-1A (ADRA1A) DMKE7FG MA Inhibitor DMKE7FG RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMKE7FG RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMKE7FG DI DMKE7FG DMKE7FG DN 1-(pyridin-2-yl)piperazine DMKE7FG TI TTWM4TY DMKE7FG TN Adrenergic receptor alpha-2B (ADRA2B) DMKE7FG MA Inhibitor DMKE7FG RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMKE7FG RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMKEDU6 DI DMKEDU6 DMKEDU6 DN L-869298 DMKEDU6 TI TTVIAT9 DMKEDU6 TN Phosphodiesterase 4B (PDE4B) DMKEDU6 MA Inhibitor DMKEDU6 RN Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73. DMKEDU6 RU https://pubmed.ncbi.nlm.nih.gov/16539372 DMKEDU6 DI DMKEDU6 DMKEDU6 DN L-869298 DMKEDU6 TI TTSKMI8 DMKEDU6 TN Phosphodiesterase 4D (PDE4D) DMKEDU6 MA Inhibitor DMKEDU6 RN Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73. DMKEDU6 RU https://pubmed.ncbi.nlm.nih.gov/16539372 DMKEDU6 DI DMKEDU6 DMKEDU6 DN L-869298 DMKEDU6 TI TTZ97H5 DMKEDU6 TN Phosphodiesterase 4A (PDE4A) DMKEDU6 MA Inhibitor DMKEDU6 RN Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase. J Med Chem. 2006 Mar 23;49(6):1867-73. DMKEDU6 RU https://pubmed.ncbi.nlm.nih.gov/16539372 DMKEFJ0 DI DMKEFJ0 DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 TI TTO9X1H DMKEFJ0 TN 5-HT 7 receptor (HTR7) DMKEFJ0 MA Inhibitor DMKEFJ0 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMKEFJ0 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMKEFJ0 DI DMKEFJ0 DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 TI TTSQIFT DMKEFJ0 TN 5-HT 1A receptor (HTR1A) DMKEFJ0 MA Inhibitor DMKEFJ0 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMKEFJ0 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMKEFJ0 DI DMKEFJ0 DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 TI TTJQOD7 DMKEFJ0 TN 5-HT 2A receptor (HTR2A) DMKEFJ0 MA Inhibitor DMKEFJ0 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMKEFJ0 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMKEFJ0 DI DMKEFJ0 DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 TI TTPC4TU DMKEFJ0 TN 5-HT 3A receptor (HTR3A) DMKEFJ0 MA Inhibitor DMKEFJ0 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMKEFJ0 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMKEFJ0 DI DMKEFJ0 DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 TI TT6MSOK DMKEFJ0 TN 5-HT 1D receptor (HTR1D) DMKEFJ0 MA Inhibitor DMKEFJ0 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMKEFJ0 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMKEFJ0 DI DMKEFJ0 DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 TI TTRUFDT DMKEFJ0 TN 5-HT 5A receptor (HTR5A) DMKEFJ0 MA Inhibitor DMKEFJ0 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMKEFJ0 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMKEFJ0 DI DMKEFJ0 DMKEFJ0 DN 5-chloro-3,4-dihydroquinazolin-2-amine DMKEFJ0 TI TTWJBZ5 DMKEFJ0 TN 5-HT 2C receptor (HTR2C) DMKEFJ0 MA Inhibitor DMKEFJ0 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMKEFJ0 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMKEG2B DI DMKEG2B DMKEG2B DN MK-9 DMKEG2B TI TTNI91K DMKEG2B TN Melanocortin receptor 3 (MC3R) DMKEG2B MA Inhibitor DMKEG2B RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMKEG2B RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMKEHLD DI DMKEHLD DMKEHLD DN 4-Dipropylamino-cyclohex-1-enecarbonitrile DMKEHLD TI TT4C8EA DMKEHLD TN Dopamine D3 receptor (D3R) DMKEHLD MA Inhibitor DMKEHLD RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMKEHLD RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMKEIAS DI DMKEIAS DMKEIAS DN CTLA-4-XTEN DMKEIAS TI TTI2S1D DMKEIAS TN Cytotoxic T-lymphocyte protein 4 (CTLA-4) DMKEIAS MA Modulator DMKEIAS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743). DMKEIAS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2743 DMKELRB DI DMKELRB DMKELRB DN N-hydroxy-4-(2-oleamidoethyl)benzamide DMKELRB TI TTIQSC1 DMKELRB TN Bacterial Lethal factor (Bact lef) DMKELRB MA Inhibitor DMKELRB RN Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8. DMKELRB RU https://pubmed.ncbi.nlm.nih.gov/17574849 DMKELWG DI DMKELWG DMKELWG DN MRS1084 DMKELWG TI TTNE7KG DMKELWG TN Adenosine A2b receptor (ADORA2B) DMKELWG MA Antagonist DMKELWG RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMKELWG RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMKELWG DI DMKELWG DMKELWG DN MRS1084 DMKELWG TI TTK25J1 DMKELWG TN Adenosine A1 receptor (ADORA1) DMKELWG MA Antagonist DMKELWG RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMKELWG RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMKENFU DI DMKENFU DMKENFU DN C-[-Arg-Gly-Asp-Acpca31-] DMKENFU TI TTT1R2L DMKENFU TN Integrin alpha-V (ITGAV) DMKENFU MA Inhibitor DMKENFU RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMKENFU RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMKENFU DI DMKENFU DMKENFU DN C-[-Arg-Gly-Asp-Acpca31-] DMKENFU TI TTJA1ZO DMKENFU TN ITGB3 messenger RNA (ITGB3 mRNA) DMKENFU MA Inhibitor DMKENFU RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMKENFU RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMKEPGN DI DMKEPGN DMKEPGN DN PT-319 DMKEPGN TI TT84ETX DMKEPGN TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMKEPGN MA Inhibitor DMKEPGN RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMKEPGN RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMKETL5 DI DMKETL5 DMKETL5 DN zinterol DMKETL5 TI TTMXGCW DMKETL5 TN Adrenergic receptor beta-3 (ADRB3) DMKETL5 MA Agonist DMKETL5 RN The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol. 2010 Jul;160(5):1048-61. DMKETL5 RU https://pubmed.ncbi.nlm.nih.gov/20590599 DMKEV5U DI DMKEV5U DMKEV5U DN Dmt-Pro-Trp-D-2-Nal-NH2 DMKEV5U TI TT27RFC DMKEV5U TN Opioid receptor delta (OPRD1) DMKEV5U MA Inhibitor DMKEV5U RN Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20. DMKEV5U RU https://pubmed.ncbi.nlm.nih.gov/17266203 DMKEV5U DI DMKEV5U DMKEV5U DN Dmt-Pro-Trp-D-2-Nal-NH2 DMKEV5U TI TTKWM86 DMKEV5U TN Opioid receptor mu (MOP) DMKEV5U MA Inhibitor DMKEV5U RN Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20. DMKEV5U RU https://pubmed.ncbi.nlm.nih.gov/17266203 DMKEY9V DI DMKEY9V DMKEY9V DN 2-(3-(naphthalen-2-yl)propanamido)benzoic acid DMKEY9V TI TTWNV8U DMKEY9V TN Nicotinic acid receptor (HCAR2) DMKEY9V MA Inhibitor DMKEY9V RN Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4963-7. DMKEY9V RU https://pubmed.ncbi.nlm.nih.gov/18760600 DMKEZ5G DI DMKEZ5G DMKEZ5G DN 2-[2-(1H-Imidazol-4-yl)-cyclopropyl]-ethylamine DMKEZ5G TI TT9JNIC DMKEZ5G TN Histamine H3 receptor (H3R) DMKEZ5G MA Inhibitor DMKEZ5G RN Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist f... J Med Chem. 2003 May 8;46(10):1980-8. DMKEZ5G RU https://pubmed.ncbi.nlm.nih.gov/12723960 DMKF0GH DI DMKF0GH DMKF0GH DN CGP-44532 DMKF0GH TI TTDCVZW DMKF0GH TN Gamma-aminobutyric acid B receptor (GABBR) DMKF0GH MA Agonist DMKF0GH RN Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17. DMKF0GH RU https://pubmed.ncbi.nlm.nih.gov/16377242 DMKF3U6 DI DMKF3U6 DMKF3U6 DN (4-Quinolin-2-ylpiperazin-1-yl)acetic Acid DMKF3U6 TI TTEX248 DMKF3U6 TN Dopamine D2 receptor (D2R) DMKF3U6 MA Inhibitor DMKF3U6 RN Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships. J Med Chem. 2009 Jun 11;52(11):3548-62. DMKF3U6 RU https://pubmed.ncbi.nlm.nih.gov/19425598 DMKF3U6 DI DMKF3U6 DMKF3U6 DN (4-Quinolin-2-ylpiperazin-1-yl)acetic Acid DMKF3U6 TI TTPC4TU DMKF3U6 TN 5-HT 3A receptor (HTR3A) DMKF3U6 MA Inhibitor DMKF3U6 RN Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships. J Med Chem. 2009 Jun 11;52(11):3548-62. DMKF3U6 RU https://pubmed.ncbi.nlm.nih.gov/19425598 DMKF762 DI DMKF762 DMKF762 DN Heptyl 1-Thiohexopyranoside DMKF762 TI TTH0KSX DMKF762 TN Rhodopsin (RHO) DMKF762 MA Inhibitor DMKF762 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKF762 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKFBVS DI DMKFBVS DMKFBVS DN 2-Methyl-4-o-tolylethynyl-thiazole DMKFBVS TI TTHS256 DMKFBVS TN Metabotropic glutamate receptor 5 (mGluR5) DMKFBVS MA Inhibitor DMKFBVS RN 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6. DMKFBVS RU https://pubmed.ncbi.nlm.nih.gov/15225713 DMKFCD5 DI DMKFCD5 DMKFCD5 DN ISIS 19211 DMKFCD5 TI TT1ERKL DMKFCD5 TN CD40 messenger RNA (CD40 mRNA) DMKFCD5 RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMKFCD5 RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMKFDQ7 DI DMKFDQ7 DMKFDQ7 DN 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline DMKFDQ7 TI TT3ROYC DMKFDQ7 TN Serotonin transporter (SERT) DMKFDQ7 MA Inhibitor DMKFDQ7 RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMKFDQ7 RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMKFDQ7 DI DMKFDQ7 DMKFDQ7 DN 6-(3-aza-bicyclo[3.1.0]hexan-1-yl)quinoline DMKFDQ7 TI TTVBI8W DMKFDQ7 TN Dopamine transporter (DAT) DMKFDQ7 MA Inhibitor DMKFDQ7 RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMKFDQ7 RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMKFE6X DI DMKFE6X DMKFE6X DN IN1535 DMKFE6X TI TTH6V3D DMKFE6X TN Cyclin-dependent kinase 1 (CDK1) DMKFE6X MA Binder DMKFE6X RN M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol. Biochem Biophys Res Commun. 2003 Jul 11;306(4):880-6. DMKFE6X RU https://pubmed.ncbi.nlm.nih.gov/12821124 DMKFGDI DI DMKFGDI DMKFGDI DN 3-(1H-pyrazol-3-yl)benzoic acid DMKFGDI TI TT6804T DMKFGDI TN MIF messenger RNA (MIF mRNA) DMKFGDI MA Inhibitor DMKFGDI RN Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening. J Med Chem. 2009 Jan 22;52(2):416-24. DMKFGDI RU https://pubmed.ncbi.nlm.nih.gov/19090668 DMKFIEY DI DMKFIEY DMKFIEY DN 2-(4-Fluoro-indole-1-sulfonyl)-benzoic acid DMKFIEY TI TTHWMFZ DMKFIEY TN Fatty acid-binding protein 4 (FABP4) DMKFIEY MA Inhibitor DMKFIEY RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMKFIEY RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMKFJP2 DI DMKFJP2 DMKFJP2 DN PMID20638279C7 DMKFJP2 TI TTICZ1O DMKFJP2 TN Metabotropic glutamate receptor 4 (mGluR4) DMKFJP2 MA Modulator (allosteric modulator) DMKFJP2 RN An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4901-5. DMKFJP2 RU https://pubmed.ncbi.nlm.nih.gov/20638279 DMKFMQ5 DI DMKFMQ5 DMKFMQ5 DN GWTLNSAGYLLGPPPALALA-CONH2 DMKFMQ5 TI TTBPW3J DMKFMQ5 TN Galanin receptor type 2 (GAL2-R) DMKFMQ5 MA Inhibitor DMKFMQ5 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMKFMQ5 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMKFMQ5 DI DMKFMQ5 DMKFMQ5 DN GWTLNSAGYLLGPPPALALA-CONH2 DMKFMQ5 TI TTX3HNZ DMKFMQ5 TN Galanin receptor type 1 (GAL1-R) DMKFMQ5 MA Inhibitor DMKFMQ5 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMKFMQ5 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMKFMRY DI DMKFMRY DMKFMRY DN Deoxyfluorothymidine DMKFMRY TI TT84ETX DMKFMRY TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMKFMRY MA Inhibitor DMKFMRY RN Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother. 1993 Jul;32 Suppl A:133-8. DMKFMRY RU https://pubmed.ncbi.nlm.nih.gov/8407695 DMKFPA9 DI DMKFPA9 DMKFPA9 DN NEOLIGNAN 9-NOR-7,8-DEHYDRO-ISOLICARIN B DMKFPA9 TI TTVKILB DMKFPA9 TN Prostaglandin G/H synthase 2 (COX-2) DMKFPA9 MA Inhibitor DMKFPA9 RN COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5. DMKFPA9 RU https://pubmed.ncbi.nlm.nih.gov/19880317 DMKFPMC DI DMKFPMC DMKFPMC DN (R)-Indan-1-yl-methyl-prop-2-ynyl-amine DMKFPMC TI TTGP7BY DMKFPMC TN Monoamine oxidase type B (MAO-B) DMKFPMC MA Inhibitor DMKFPMC RN Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4438-46. DMKFPMC RU https://pubmed.ncbi.nlm.nih.gov/16137882 DMKFPMC DI DMKFPMC DMKFPMC DN (R)-Indan-1-yl-methyl-prop-2-ynyl-amine DMKFPMC TI TT3WG5C DMKFPMC TN Monoamine oxidase type A (MAO-A) DMKFPMC MA Inhibitor DMKFPMC RN Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem. 2002 Nov 21;45(24):5260-79. DMKFPMC RU https://pubmed.ncbi.nlm.nih.gov/12431053 DMKFSQ8 DI DMKFSQ8 DMKFSQ8 DN (+/-)-2-(4'-Methoxyphenyl)thiomorpholine DMKFSQ8 TI TT3WG5C DMKFSQ8 TN Monoamine oxidase type A (MAO-A) DMKFSQ8 MA Inhibitor DMKFSQ8 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMKFSQ8 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMKFSQ8 DI DMKFSQ8 DMKFSQ8 DN (+/-)-2-(4'-Methoxyphenyl)thiomorpholine DMKFSQ8 TI TTGP7BY DMKFSQ8 TN Monoamine oxidase type B (MAO-B) DMKFSQ8 MA Inhibitor DMKFSQ8 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMKFSQ8 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMKFTW8 DI DMKFTW8 DMKFTW8 DN Bromo-WR99210 DMKFTW8 TI TT9SL3Q DMKFTW8 TN Polypeptide deformylase (PDF) DMKFTW8 MA Inhibitor DMKFTW8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKFTW8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKFTZA DI DMKFTZA DMKFTZA DN BayCysLT2 DMKFTZA TI TT0PZR5 DMKFTZA TN Leukotriene CysLT2 receptor (CYSLTR2) DMKFTZA MA Antagonist DMKFTZA RN Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J. 2011 Oct;25(10):3519-28. DMKFTZA RU https://pubmed.ncbi.nlm.nih.gov/21753081 DMKFTZA DI DMKFTZA DMKFTZA DN BayCysLT2 DMKFTZA TI TTGKOY9 DMKFTZA TN Leukotriene CysLT1 receptor (CYSLTR1) DMKFTZA MA Antagonist DMKFTZA RN Synthesis of cysteinyl leukotrienes in human endothelial cells: subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J. 2011 Oct;25(10):3519-28. DMKFTZA RU https://pubmed.ncbi.nlm.nih.gov/21753081 DMKFUO0 DI DMKFUO0 DMKFUO0 DN 6-Fluoromelatonin DMKFUO0 TI TT0K1SC DMKFUO0 TN 5-HT 2B receptor (HTR2B) DMKFUO0 MA Inhibitor DMKFUO0 RN Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86. DMKFUO0 RU https://pubmed.ncbi.nlm.nih.gov/20958049 DMKG7J2 DI DMKG7J2 DMKG7J2 DN lysophosphatidylserine DMKG7J2 TI TTVXSTQ DMKG7J2 TN G-protein coupled receptor 34 (GPR34) DMKG7J2 MA Agonist DMKG7J2 RN GPR34 is a receptor for lysophosphatidylserine with a fatty acid at the sn-2 position. J Biochem. 2012 May;151(5):511-8. DMKG7J2 RU https://pubmed.ncbi.nlm.nih.gov/22343749 DMKG7J2 DI DMKG7J2 DMKG7J2 DN lysophosphatidylserine DMKG7J2 TI TTYUB4M DMKG7J2 TN G-protein coupled receptor 174 (GPR174) DMKG7J2 MA Agonist DMKG7J2 RN TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat Methods. 2012 Oct;9(10):1021-9. DMKG7J2 RU https://pubmed.ncbi.nlm.nih.gov/22983457 DMKGBZA DI DMKGBZA DMKGBZA DN N-(6-(3-hydroxyphenyl)-1H-indazol-3-yl)butyramide DMKGBZA TI TTRSMW9 DMKGBZA TN Glycogen synthase kinase-3 beta (GSK-3B) DMKGBZA MA Inhibitor DMKGBZA RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMKGBZA RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMKGIQ1 DI DMKGIQ1 DMKGIQ1 DN 3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one DMKGIQ1 TI TT6MSOK DMKGIQ1 TN 5-HT 1D receptor (HTR1D) DMKGIQ1 MA Inhibitor DMKGIQ1 RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMKGIQ1 RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMKGIQ1 DI DMKGIQ1 DMKGIQ1 DN 3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one DMKGIQ1 TI TTJQOD7 DMKGIQ1 TN 5-HT 2A receptor (HTR2A) DMKGIQ1 MA Inhibitor DMKGIQ1 RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMKGIQ1 RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMKGIQ1 DI DMKGIQ1 DMKGIQ1 DN 3-Amino-1-(2-amino-5-methoxy-phenyl)-propan-1-one DMKGIQ1 TI TTSQIFT DMKGIQ1 TN 5-HT 1A receptor (HTR1A) DMKGIQ1 MA Inhibitor DMKGIQ1 RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMKGIQ1 RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMKGIQJ DI DMKGIQJ DMKGIQJ DN H-Dmt-Tic-NH-CH2-ImidPh DMKGIQJ TI TTKWM86 DMKGIQJ TN Opioid receptor mu (MOP) DMKGIQJ MA Inhibitor DMKGIQJ RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMKGIQJ RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMKGIQJ DI DMKGIQJ DMKGIQJ DN H-Dmt-Tic-NH-CH2-ImidPh DMKGIQJ TI TT27RFC DMKGIQJ TN Opioid receptor delta (OPRD1) DMKGIQJ MA Inhibitor DMKGIQJ RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMKGIQJ RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMKGSRZ DI DMKGSRZ DMKGSRZ DN C-176 DMKGSRZ TI TTT402Y DMKGSRZ TN Stimulator of interferon genes protein (TMEM173) DMKGSRZ MA Agonist DMKGSRZ RN Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165. DMKGSRZ RU https://pubmed.ncbi.nlm.nih.gov/32450897 DMKGTRF DI DMKGTRF DMKGTRF DN 6-(4-fluorostyryl)-2-morpholino-4H-chromen-4-one DMKGTRF TI TTK3PY9 DMKGTRF TN DNA-dependent protein kinase catalytic (PRKDC) DMKGTRF MA Inhibitor DMKGTRF RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMKGTRF RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMKGWAH DI DMKGWAH DMKGWAH DN MESULERGINE DMKGWAH TI TTO9X1H DMKGWAH TN 5-HT 7 receptor (HTR7) DMKGWAH MA Inhibitor DMKGWAH RN Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem. 2009 Apr 23;52(8):2384-92. DMKGWAH RU https://pubmed.ncbi.nlm.nih.gov/19326916 DMKGWAH DI DMKGWAH DMKGWAH DN MESULERGINE DMKGWAH TI TTR6K75 DMKGWAH TN 5-HT 3B receptor (HTR3B) DMKGWAH MA Inhibitor DMKGWAH RN Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8. DMKGWAH RU https://pubmed.ncbi.nlm.nih.gov/9357534 DMKGWAH DI DMKGWAH DMKGWAH DN MESULERGINE DMKGWAH TI TTJFY5U DMKGWAH TN Adenosine A3 receptor (ADORA3) DMKGWAH MA Inhibitor DMKGWAH RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMKGWAH RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMKGWAH DI DMKGWAH DMKGWAH DN MESULERGINE DMKGWAH TI TTPC4TU DMKGWAH TN 5-HT 3A receptor (HTR3A) DMKGWAH MA Inhibitor DMKGWAH RN Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8. DMKGWAH RU https://pubmed.ncbi.nlm.nih.gov/9357534 DMKGXB9 DI DMKGXB9 DMKGXB9 DN Thymine DMKGXB9 TI TTO0IB8 DMKGXB9 TN Thymidine phosphorylase (TYMP) DMKGXB9 MA Inhibitor DMKGXB9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKGXB9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKH0OC DI DMKH0OC DMKH0OC DN 12-O-deacetyl-12-epi-19-deoxy-21-hydroxyscalarin DMKH0OC TI TTS4UGC DMKH0OC TN Farnesoid X-activated receptor (FXR) DMKH0OC MA Inhibitor DMKH0OC RN Scalarane sesterterpenes from a marine sponge of the genus Spongia and their FXR antagonistic activity. J Nat Prod. 2007 Nov;70(11):1691-5. DMKH0OC RU https://pubmed.ncbi.nlm.nih.gov/17988093 DMKH32S DI DMKH32S DMKH32S DN Beta-methylmelatonin DMKH32S TI TT0WAIE DMKH32S TN Melatonin receptor type 1A (MTNR1A) DMKH32S MA Inhibitor DMKH32S RN Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19. DMKH32S RU https://pubmed.ncbi.nlm.nih.gov/16759094 DMKH32S DI DMKH32S DMKH32S DN Beta-methylmelatonin DMKH32S TI TT32JK8 DMKH32S TN Melatonin receptor type 1B (MTNR1B) DMKH32S MA Inhibitor DMKH32S RN Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-me... J Med Chem. 2006 Jun 15;49(12):3509-19. DMKH32S RU https://pubmed.ncbi.nlm.nih.gov/16759094 DMKH8PF DI DMKH8PF DMKH8PF DN H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF TI TTRK9JT DMKH8PF TN Neuropeptide Y receptor type 1 (NPY1R) DMKH8PF MA Inhibitor DMKH8PF RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMKH8PF RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMKH8PF DI DMKH8PF DMKH8PF DN H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF TI TTW4N16 DMKH8PF TN Neuropeptide Y receptor type 4 (NPY4R) DMKH8PF MA Inhibitor DMKH8PF RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMKH8PF RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMKH8PF DI DMKH8PF DMKH8PF DN H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF TI TTJ6WK9 DMKH8PF TN Neuropeptide Y receptor type 2 (NPY2R) DMKH8PF MA Inhibitor DMKH8PF RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMKH8PF RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMKH8TC DI DMKH8TC DMKH8TC DN Etisulergine DMKH8TC TI TTSQIFT DMKH8TC TN 5-HT 1A receptor (HTR1A) DMKH8TC MA Inhibitor DMKH8TC RN Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-... J Med Chem. 1985 Oct;28(10):1540-2. DMKH8TC RU https://pubmed.ncbi.nlm.nih.gov/4045929 DMKH8TC DI DMKH8TC DMKH8TC DN Etisulergine DMKH8TC TI TTJQOD7 DMKH8TC TN 5-HT 2A receptor (HTR2A) DMKH8TC MA Inhibitor DMKH8TC RN Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-... J Med Chem. 1985 Oct;28(10):1540-2. DMKH8TC RU https://pubmed.ncbi.nlm.nih.gov/4045929 DMKH8TC DI DMKH8TC DMKH8TC DN Etisulergine DMKH8TC TI TT6MSOK DMKH8TC TN 5-HT 1D receptor (HTR1D) DMKH8TC MA Inhibitor DMKH8TC RN Resolution and absolute configuration of the potent dopamine agonist N,N-diethyl-N'-[(3 alpha, 4a alpha, 10a beta)-1,2,3,4,4a,5,10,10a- -octahydro-... J Med Chem. 1985 Oct;28(10):1540-2. DMKH8TC RU https://pubmed.ncbi.nlm.nih.gov/4045929 DMKH9IE DI DMKH9IE DMKH9IE DN subalin DMKH9IE TI TTSIUJ9 DMKH9IE TN Interferon-alpha 2 (IFNA2) DMKH9IE MA Modulator DMKH9IE RN [Adjuvant properties of subalin, a recombinant interferon-producing probiotic].Zh Mikrobiol Epidemiol Immunobiol.2001 Nov-Dec;(6):77-82. DMKH9IE RU https://www.ncbi.nlm.nih.gov/pubmed/11881504 DMKH9O7 DI DMKH9O7 DMKH9O7 DN JNJ-1930942 DMKH9O7 TI TTLA931 DMKH9O7 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMKH9O7 MA Modulator DMKH9O7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468). DMKH9O7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468 DMKHD1M DI DMKHD1M DMKHD1M DN 4,5-Bis(4-methoxyphenyl)-1,2-selenazole DMKHD1M TI TTVKILB DMKHD1M TN Prostaglandin G/H synthase 2 (COX-2) DMKHD1M MA Inhibitor DMKHD1M RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMKHD1M RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMKHD1M DI DMKHD1M DMKHD1M DN 4,5-Bis(4-methoxyphenyl)-1,2-selenazole DMKHD1M TI TT8NGED DMKHD1M TN Prostaglandin G/H synthase 1 (COX-1) DMKHD1M MA Inhibitor DMKHD1M RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMKHD1M RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMKHF87 DI DMKHF87 DMKHF87 DN 8-benzylnaringenin DMKHF87 TI TTZAYWL DMKHF87 TN Estrogen receptor (ESR) DMKHF87 MA Inhibitor DMKHF87 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMKHF87 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMKHF87 DI DMKHF87 DMKHF87 DN 8-benzylnaringenin DMKHF87 TI TTOM3J0 DMKHF87 TN Estrogen receptor beta (ESR2) DMKHF87 MA Inhibitor DMKHF87 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMKHF87 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMKHFV4 DI DMKHFV4 DMKHFV4 DN 5-PENTYL-2-PHENOXYPHENOL DMKHFV4 TI TTVTX4N DMKHFV4 TN Bacterial Fatty acid synthetase I (Bact inhA) DMKHFV4 MA Inhibitor DMKHFV4 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKHFV4 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKHJ8G DI DMKHJ8G DMKHJ8G DN 3-methoxy-5-(1,6-naphthyridin-7-yl)benzonitrile DMKHJ8G TI TTHS256 DMKHJ8G TN Metabotropic glutamate receptor 5 (mGluR5) DMKHJ8G MA Inhibitor DMKHJ8G RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMKHJ8G RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMKHJBI DI DMKHJBI DMKHJBI DN 1-(7-methyl-9H-carbazol-3-yl)ethanone DMKHJBI TI TTBGTCW DMKHJBI TN Kinesin spindle messenger RNA (KIF11 mRNA) DMKHJBI MA Inhibitor DMKHJBI RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMKHJBI RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMKHMS4 DI DMKHMS4 DMKHMS4 DN NSC-119910 DMKHMS4 TI TTHYBIX DMKHMS4 TN Heat shock protein 70 (HSP70) DMKHMS4 MA Inhibitor DMKHMS4 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMKHMS4 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMKHNTY DI DMKHNTY DMKHNTY DN 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole DMKHNTY TI TTBMV1G DMKHNTY TN GABA(A) receptor alpha-2 (GABRA2) DMKHNTY MA Inhibitor DMKHNTY RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMKHNTY RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMKHNTY DI DMKHNTY DMKHNTY DN 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole DMKHNTY TI TT37EDJ DMKHNTY TN GABA(A) receptor alpha-3 (GABRA3) DMKHNTY MA Inhibitor DMKHNTY RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMKHNTY RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMKHNTY DI DMKHNTY DMKHNTY DN 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole DMKHNTY TI TT1MPAY DMKHNTY TN GABA(A) receptor alpha-1 (GABRA1) DMKHNTY MA Inhibitor DMKHNTY RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMKHNTY RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMKHNTY DI DMKHNTY DMKHNTY DN 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole DMKHNTY TI TT06RH5 DMKHNTY TN GABA(A) receptor gamma-2 (GABRG2) DMKHNTY MA Inhibitor DMKHNTY RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMKHNTY RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMKHNTY DI DMKHNTY DMKHNTY DN 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole DMKHNTY TI TTNJYV2 DMKHNTY TN Gamma-aminobutyric acid receptor (GAR) DMKHNTY MA Inhibitor DMKHNTY RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMKHNTY RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMKHNTY DI DMKHNTY DMKHNTY DN 3-(hexa-1,3-dienyloxy)-9H-pyrido[3,4-b]indole DMKHNTY TI TTNZPQ1 DMKHNTY TN GABA(A) receptor alpha-5 (GABRA5) DMKHNTY MA Inhibitor DMKHNTY RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMKHNTY RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMKHPAE DI DMKHPAE DMKHPAE DN 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine DMKHPAE TI TT78R5H DMKHPAE TN Heat shock protein 90 alpha (HSP90A) DMKHPAE MA Inhibitor DMKHPAE RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKHPAE RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKHSAV DI DMKHSAV DMKHSAV DN C[-Arg-Gly-Asp-Acpca34-] DMKHSAV TI TTT1R2L DMKHSAV TN Integrin alpha-V (ITGAV) DMKHSAV MA Inhibitor DMKHSAV RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMKHSAV RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMKHSAV DI DMKHSAV DMKHSAV DN C[-Arg-Gly-Asp-Acpca34-] DMKHSAV TI TTJA1ZO DMKHSAV TN ITGB3 messenger RNA (ITGB3 mRNA) DMKHSAV MA Inhibitor DMKHSAV RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMKHSAV RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMKHVGJ DI DMKHVGJ DMKHVGJ DN 3-methoxyphenyl 10H-phenothiazine-10-carboxylate DMKHVGJ TI TTEB0GD DMKHVGJ TN Cholinesterase (BCHE) DMKHVGJ MA Inhibitor DMKHVGJ RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMKHVGJ RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMKHVUE DI DMKHVUE DMKHVUE DN HM-5016699 DMKHVUE TI TTHBTOP DMKHVUE TN PI3-kinase gamma (PIK3CG) DMKHVUE MA Inhibitor DMKHVUE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMKHVUE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMKHVUE DI DMKHVUE DMKHVUE DN HM-5016699 DMKHVUE TI TTCJG29 DMKHVUE TN Serine/threonine-protein kinase mTOR (mTOR) DMKHVUE MA Inhibitor DMKHVUE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMKHVUE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMKHXT9 DI DMKHXT9 DMKHXT9 DN 9-[2-(1-Phosphonobutan-2-yloxy)ethyl]hypoxanthine DMKHXT9 TI TTBL49X DMKHXT9 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMKHXT9 MA Inhibitor DMKHXT9 RN Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum h... Bioorg Med Chem. 2009 Sep 1;17(17):6218-32. DMKHXT9 RU https://pubmed.ncbi.nlm.nih.gov/19666228 DMKHZQW DI DMKHZQW DMKHZQW DN Pitrazepine DMKHZQW TI TTNJYV2 DMKHZQW TN Gamma-aminobutyric acid receptor (GAR) DMKHZQW MA Inhibitor DMKHZQW RN Structure and molecular modeling of GABAA receptor antagonists. J Med Chem. 1992 May 29;35(11):1969-77. DMKHZQW RU https://pubmed.ncbi.nlm.nih.gov/1317920 DMKI2GJ DI DMKI2GJ DMKI2GJ DN Azaperone DMKI2GJ TI TT4C8EA DMKI2GJ TN Dopamine D3 receptor (D3R) DMKI2GJ MA Inhibitor DMKI2GJ RN Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem. 1993 Nov 26;36(24):3929-36. DMKI2GJ RU https://pubmed.ncbi.nlm.nih.gov/7902870 DMKI2GJ DI DMKI2GJ DMKI2GJ DN Azaperone DMKI2GJ TI TTEX248 DMKI2GJ TN Dopamine D2 receptor (D2R) DMKI2GJ MA Inhibitor DMKI2GJ RN Evaluation of the effects of the enantiomers of reduced haloperidol, azaperol, and related 4-amino-1-arylbutanols on dopamine and sigma receptors. J Med Chem. 1993 Nov 26;36(24):3929-36. DMKI2GJ RU https://pubmed.ncbi.nlm.nih.gov/7902870 DMKI2Y9 DI DMKI2Y9 DMKI2Y9 DN (9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester DMKI2Y9 TI TTNJYV2 DMKI2Y9 TN Gamma-aminobutyric acid receptor (GAR) DMKI2Y9 MA Inhibitor DMKI2Y9 RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DMKI2Y9 RU https://pubmed.ncbi.nlm.nih.gov/2989520 DMKI2Y9 DI DMKI2Y9 DMKI2Y9 DN (9H-beta-Carbolin-3-yl)-carbamic acid ethyl ester DMKI2Y9 TI TT1MPAY DMKI2Y9 TN GABA(A) receptor alpha-1 (GABRA1) DMKI2Y9 MA Inhibitor DMKI2Y9 RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DMKI2Y9 RU https://pubmed.ncbi.nlm.nih.gov/2989520 DMKI6GQ DI DMKI6GQ DMKI6GQ DN 2-(6-Imidazol-1-yl-hexyl)-isoindole-1,3-dione DMKI6GQ TI TTKNWZ4 DMKI6GQ TN Thromboxane-A synthase (TBXAS1) DMKI6GQ MA Inhibitor DMKI6GQ RN Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-... J Med Chem. 1986 May;29(5):816-9. DMKI6GQ RU https://pubmed.ncbi.nlm.nih.gov/3517332 DMKI6JF DI DMKI6JF DMKI6JF DN ISIS 103736 DMKI6JF TI TT6TU05 DMKI6JF TN WWP2 messenger RNA (WWP2 mRNA) DMKI6JF RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMKI6JF RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMKI6L5 DI DMKI6L5 DMKI6L5 DN ISIS 102664 DMKI6L5 TI TT5U49F DMKI6L5 TN PRKACA messenger RNA (PRKACA mRNA) DMKI6L5 RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMKI6L5 RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMKI70D DI DMKI70D DMKI70D DN LHD-4 DMKI70D TI TT4QPUL DMKI70D TN Antithrombin-III (ATIII) DMKI70D MA Modulator DMKI70D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2632). DMKI70D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2632 DMKI719 DI DMKI719 DMKI719 DN 1-(3,4-dihydroxy-5-nitrophenyl)-2-phenoxyethanone DMKI719 TI TTKWFB8 DMKI719 TN Catechol-O-methyl-transferase (COMT) DMKI719 MA Inhibitor DMKI719 RN Synthesis, biological evaluation, and molecular modeling studies of a novel, peripherally selective inhibitor of catechol-O-methyltransferase. J Med Chem. 2004 Dec 2;47(25):6207-17. DMKI719 RU https://pubmed.ncbi.nlm.nih.gov/15566291 DMKIDRY DI DMKIDRY DMKIDRY DN SYM-011 DMKIDRY TI TTGKNB4 DMKIDRY TN Epidermal growth factor receptor (EGFR) DMKIDRY MA Modulator DMKIDRY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMKIDRY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMKIDRY DI DMKIDRY DMKIDRY DN SYM-011 DMKIDRY TI TTDC8N2 DMKIDRY TN Erbb3 tyrosine kinase receptor (Erbb-3) DMKIDRY MA Modulator DMKIDRY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1798). DMKIDRY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798 DMKIEVP DI DMKIEVP DMKIEVP DN 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone DMKIEVP TI TTAWNKZ DMKIEVP TN Norepinephrine transporter (NET) DMKIEVP MA Inhibitor DMKIEVP RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMKIEVP RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMKIEVP DI DMKIEVP DMKIEVP DN 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone DMKIEVP TI TT3ROYC DMKIEVP TN Serotonin transporter (SERT) DMKIEVP MA Inhibitor DMKIEVP RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMKIEVP RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMKIEVP DI DMKIEVP DMKIEVP DN 2-(N-tert-Butylamino)-3',4'-dichloropropiophenone DMKIEVP TI TTVBI8W DMKIEVP TN Dopamine transporter (DAT) DMKIEVP MA Inhibitor DMKIEVP RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMKIEVP RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMKIML1 DI DMKIML1 DMKIML1 DN D-tryptophan DMKIML1 TI TT8WFXV DMKIML1 TN Hydroxycarboxylic acid receptor 3 (HCAR3) DMKIML1 MA Agonist DMKIML1 RN Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3930-4. DMKIML1 RU https://pubmed.ncbi.nlm.nih.gov/19237584 DMKIR63 DI DMKIR63 DMKIR63 DN JWH-205 DMKIR63 TI TTMSFAW DMKIR63 TN Cannabinoid receptor 2 (CB2) DMKIR63 MA Inhibitor DMKIR63 RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMKIR63 RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMKITY6 DI DMKITY6 DMKITY6 DN 1-(2-m-tolyl-ethyl)-pyrrolidine DMKITY6 TI TT9JNIC DMKITY6 TN Histamine H3 receptor (H3R) DMKITY6 MA Inhibitor DMKITY6 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMKITY6 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMKIWBT DI DMKIWBT DMKIWBT DN 1-(10H-phenothiazin-10-yl)-2-phenylbutan-1-one DMKIWBT TI TTEB0GD DMKIWBT TN Cholinesterase (BCHE) DMKIWBT MA Inhibitor DMKIWBT RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMKIWBT RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMKJ18X DI DMKJ18X DMKJ18X DN 4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol DMKJ18X TI TTPNQAC DMKJ18X TN Estrogen-related receptor-alpha (ESRRA) DMKJ18X MA Inhibitor DMKJ18X RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMKJ18X RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMKJ18X DI DMKJ18X DMKJ18X DN 4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol DMKJ18X TI TTOM3J0 DMKJ18X TN Estrogen receptor beta (ESR2) DMKJ18X MA Inhibitor DMKJ18X RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMKJ18X RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMKJ18X DI DMKJ18X DMKJ18X DN 4-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol DMKJ18X TI TTZAYWL DMKJ18X TN Estrogen receptor (ESR) DMKJ18X MA Inhibitor DMKJ18X RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMKJ18X RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMKJ57H DI DMKJ57H DMKJ57H DN ISIS 119283 DMKJ57H TI TTKS60G DMKJ57H TN STXBP4 messenger RNA (STXBP4 mRNA) DMKJ57H RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DMKJ57H RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DMKJ6F8 DI DMKJ6F8 DMKJ6F8 DN N-Benzyl-(6-methoxy-2-naphthyl)-2-aminopropane DMKJ6F8 TI TT3WG5C DMKJ6F8 TN Monoamine oxidase type A (MAO-A) DMKJ6F8 MA Inhibitor DMKJ6F8 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMKJ6F8 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMKJ9WM DI DMKJ9WM DMKJ9WM DN MRS928 DMKJ9WM TI TTJFY5U DMKJ9WM TN Adenosine A3 receptor (ADORA3) DMKJ9WM MA Antagonist DMKJ9WM RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMKJ9WM RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMKJ9WM DI DMKJ9WM DMKJ9WM DN MRS928 DMKJ9WM TI TTNE7KG DMKJ9WM TN Adenosine A2b receptor (ADORA2B) DMKJ9WM MA Antagonist DMKJ9WM RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMKJ9WM RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMKJ9WM DI DMKJ9WM DMKJ9WM DN MRS928 DMKJ9WM TI TTK25J1 DMKJ9WM TN Adenosine A1 receptor (ADORA1) DMKJ9WM MA Antagonist DMKJ9WM RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMKJ9WM RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMKJBRZ DI DMKJBRZ DMKJBRZ DN 1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DMKJBRZ TI TTZAYWL DMKJBRZ TN Estrogen receptor (ESR) DMKJBRZ MA Inhibitor DMKJBRZ RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMKJBRZ RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMKJBRZ DI DMKJBRZ DMKJBRZ DN 1,8-Dichloro-6-(4-hydroxy-phenyl)-naphthalen-2-ol DMKJBRZ TI TTOM3J0 DMKJBRZ TN Estrogen receptor beta (ESR2) DMKJBRZ MA Inhibitor DMKJBRZ RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMKJBRZ RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMKJGLO DI DMKJGLO DMKJGLO DN ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE DMKJGLO TI TTANPDJ DMKJGLO TN Carbonic anhydrase II (CA-II) DMKJGLO MA Inhibitor DMKJGLO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKJGLO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKJGLO DI DMKJGLO DMKJGLO DN ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE DMKJGLO TI TTHQPL7 DMKJGLO TN Carbonic anhydrase I (CA-I) DMKJGLO MA Inhibitor DMKJGLO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKJGLO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKJGTH DI DMKJGTH DMKJGTH DN 1,8-bis-maleimidodiethyleneglycol DMKJGTH TI TTDP1UC DMKJGTH TN Fatty acid amide hydrolase (FAAH) DMKJGTH MA Inhibitor DMKJGTH RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DMKJGTH RU https://pubmed.ncbi.nlm.nih.gov/19583260 DMKJOL6 DI DMKJOL6 DMKJOL6 DN 6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMKJOL6 TI TTOM3J0 DMKJOL6 TN Estrogen receptor beta (ESR2) DMKJOL6 MA Inhibitor DMKJOL6 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMKJOL6 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMKJOL6 DI DMKJOL6 DMKJOL6 DN 6-(3,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMKJOL6 TI TTZAYWL DMKJOL6 TN Estrogen receptor (ESR) DMKJOL6 MA Inhibitor DMKJOL6 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMKJOL6 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMKJQWR DI DMKJQWR DMKJQWR DN FR-230481 DMKJQWR TI TTY6EWA DMKJQWR TN Neuropeptide Y receptor type 5 (NPY5R) DMKJQWR MA Inhibitor DMKJQWR RN Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802. DMKJQWR RU https://pubmed.ncbi.nlm.nih.gov/11859006 DMKJQZ4 DI DMKJQZ4 DMKJQZ4 DN AM-1715 DMKJQZ4 TI TT6OEDT DMKJQZ4 TN Cannabinoid receptor 1 (CB1) DMKJQZ4 MA Inhibitor DMKJQZ4 RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMKJQZ4 RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMKJQZ4 DI DMKJQZ4 DMKJQZ4 DN AM-1715 DMKJQZ4 TI TTMSFAW DMKJQZ4 TN Cannabinoid receptor 2 (CB2) DMKJQZ4 MA Inhibitor DMKJQZ4 RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMKJQZ4 RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMKJWGP DI DMKJWGP DMKJWGP DN NSC-407228 DMKJWGP TI TTJFY5U DMKJWGP TN Adenosine A3 receptor (ADORA3) DMKJWGP MA Inhibitor DMKJWGP RN Interactions of flavonoids and other phytochemicals with adenosine receptors. J Med Chem. 1996 Feb 2;39(3):781-8. DMKJWGP RU https://pubmed.ncbi.nlm.nih.gov/8576921 DMKJWMC DI DMKJWMC DMKJWMC DN (R)-11-Amino-2-methoxyaporphine DMKJWMC TI TTZFYLI DMKJWMC TN Dopamine D1 receptor (D1R) DMKJWMC MA Inhibitor DMKJWMC RN Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. DMKJWMC RU https://pubmed.ncbi.nlm.nih.gov/18562201 DMKJWMC DI DMKJWMC DMKJWMC DN (R)-11-Amino-2-methoxyaporphine DMKJWMC TI TTSQIFT DMKJWMC TN 5-HT 1A receptor (HTR1A) DMKJWMC MA Inhibitor DMKJWMC RN Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. DMKJWMC RU https://pubmed.ncbi.nlm.nih.gov/18562201 DMKJY3U DI DMKJY3U DMKJY3U DN parathyroid hormone DMKJY3U TI TT6F7GZ DMKJY3U TN Parathyroid hormone (PTH) DMKJY3U MA Modulator DMKJY3U RN Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.J Bone Miner Res.2012 Aug;27(8):1811-20. DMKJY3U RU https://www.ncbi.nlm.nih.gov/pubmed/22492501 DMKJYCU DI DMKJYCU DMKJYCU DN 1-biphenyl-2-ylmethanamine DMKJYCU TI TTDIGC1 DMKJYCU TN Dipeptidyl peptidase 4 (DPP-4) DMKJYCU MA Inhibitor DMKJYCU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKJYCU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKL201 DI DMKL201 DMKL201 DN 1-Biphenyl-4-ylmethylmaleimide DMKL201 TI TTDP1UC DMKL201 TN Fatty acid amide hydrolase (FAAH) DMKL201 MA Inhibitor DMKL201 RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DMKL201 RU https://pubmed.ncbi.nlm.nih.gov/19583260 DMKL59W DI DMKL59W DMKL59W DN 3beta-hydroxyrus-18,20(30)-dien-28-oic acid DMKL59W TI TTIU7X1 DMKL59W TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMKL59W MA Inhibitor DMKL59W RN DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6. DMKL59W RU https://pubmed.ncbi.nlm.nih.gov/10654412 DMKL6IC DI DMKL6IC DMKL6IC DN PAC-10649 DMKL6IC TI TTVKILB DMKL6IC TN Prostaglandin G/H synthase 2 (COX-2) DMKL6IC MA Inhibitor DMKL6IC RN PAC 10649 Pacific licensing offer, Worldwide excluding South Korea. R & D Focus Drug News. September 22, 2003. DMKL6IC RU http://business.highbeam.com/436989/article-1G1-107911540/pac-10649-pacific-licensing-offer-worldwide-excluding DMKL9X7 DI DMKL9X7 DMKL9X7 DN [3H]bag-2 DMKL9X7 TI TTHYDUM DMKL9X7 TN Bombesin receptor (BS) DMKL9X7 MA Agonist DMKL9X7 RN Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab. 2010 Feb 3;11(2):101-12. DMKL9X7 RU https://pubmed.ncbi.nlm.nih.gov/20096642 DMKLATO DI DMKLATO DMKLATO DN PMID30247903-Compound-General structure39 DMKLATO TI TT23XQV DMKLATO TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMKLATO MA Inhibitor DMKLATO RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMKLATO RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMKLB4O DI DMKLB4O DMKLB4O DN UTPgammaS DMKLB4O TI TTOZHQC DMKLB4O TN P2Y purinoceptor 2 (P2RY2) DMKLB4O MA Agonist DMKLB4O RN Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27. DMKLB4O RU https://pubmed.ncbi.nlm.nih.gov/8564228 DMKLB4O DI DMKLB4O DMKLB4O DN UTPgammaS DMKLB4O TI TT24DGP DMKLB4O TN P2Y purinoceptor 4 (P2RY4) DMKLB4O MA Agonist DMKLB4O RN Enzymatic synthesis of UTP gamma S, a potent hydrolysis resistant agonist of P2U-purinoceptors. Br J Pharmacol. 1996 Jan;117(1):203-9. DMKLB4O RU https://pubmed.ncbi.nlm.nih.gov/8825364 DMKLC3O DI DMKLC3O DMKLC3O DN aminopurvalanol A DMKLC3O TI TTL4Q97 DMKLC3O TN Cyclin-dependent kinase 5 (CDK5) DMKLC3O MA Inhibitor DMKLC3O RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMKLC3O RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMKLC3O DI DMKLC3O DMKLC3O DN aminopurvalanol A DMKLC3O TI TT7HF4W DMKLC3O TN Cyclin-dependent kinase 2 (CDK2) DMKLC3O MA Inhibitor DMKLC3O RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMKLC3O RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMKLC3O DI DMKLC3O DMKLC3O DN aminopurvalanol A DMKLC3O TI TTH6V3D DMKLC3O TN Cyclin-dependent kinase 1 (CDK1) DMKLC3O MA Inhibitor DMKLC3O RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMKLC3O RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMKLDWF DI DMKLDWF DMKLDWF DN Tyr-Pro-Trp-Gly-Bn DMKLDWF TI TTKWM86 DMKLDWF TN Opioid receptor mu (MOP) DMKLDWF MA Inhibitor DMKLDWF RN Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. DMKLDWF RU https://pubmed.ncbi.nlm.nih.gov/19679474 DMKLIXZ DI DMKLIXZ DMKLIXZ DN Tetrabromocinnamic acid DMKLIXZ TI TTZ5NI7 DMKLIXZ TN Casein kinase II (CSNK2) DMKLIXZ MA Inhibitor DMKLIXZ RN Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39. DMKLIXZ RU https://pubmed.ncbi.nlm.nih.gov/17133643 DMKLRCX DI DMKLRCX DMKLRCX DN Pedunculagin DMKLRCX TI TT6L509 DMKLRCX TN Coagulation factor IIa (F2) DMKLRCX MA Inhibitor DMKLRCX RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DMKLRCX RU https://pubmed.ncbi.nlm.nih.gov/9834152 DMKLRCX DI DMKLRCX DMKLRCX DN Pedunculagin DMKLRCX TI TTCIHJA DMKLRCX TN Coagulation factor Xa (F10) DMKLRCX MA Inhibitor DMKLRCX RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DMKLRCX RU https://pubmed.ncbi.nlm.nih.gov/9834152 DMKLRCX DI DMKLRCX DMKLRCX DN Pedunculagin DMKLRCX TI TTE14XG DMKLRCX TN Squalene monooxygenase (SQLE) DMKLRCX MA Inhibitor DMKLRCX RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMKLRCX RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMKLSBN DI DMKLSBN DMKLSBN DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-CONH2 DMKLSBN TI TTNT7K8 DMKLSBN TN Nociceptin receptor (OPRL1) DMKLSBN MA Inhibitor DMKLSBN RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMKLSBN RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMKLTD5 DI DMKLTD5 DMKLTD5 DN 9-methyl-2-(trifluoromethyl)-9H-carbazole DMKLTD5 TI TTBGTCW DMKLTD5 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMKLTD5 MA Inhibitor DMKLTD5 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMKLTD5 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMKLVSO DI DMKLVSO DMKLVSO DN Palodesangren C DMKLVSO TI TTS64P2 DMKLVSO TN Androgen receptor (AR) DMKLVSO MA Inhibitor DMKLVSO RN Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002. DMKLVSO RU https://pubmed.ncbi.nlm.nih.gov/9358642 DMKLWSG DI DMKLWSG DMKLWSG DN SB-201076 DMKLWSG TI TT0Z6Y2 DMKLWSG TN ATP-citrate synthase (ACLY) DMKLWSG MA Inhibitor DMKLWSG RN The biology and chemistry of hyperlipidemia. Bioorg Med Chem. 2007 Jul 15;15(14):4674-99. DMKLWSG RU https://pubmed.ncbi.nlm.nih.gov/17521912 DMKLY20 DI DMKLY20 DMKLY20 DN 5-Indan-(1Z)-ylidenemethyl-1H-imidazole DMKLY20 TI TTIQUX7 DMKLY20 TN Steroid 11-beta-hydroxylase (CYP11B1) DMKLY20 MA Inhibitor DMKLY20 RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMKLY20 RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMKLY20 DI DMKLY20 DMKLY20 DN 5-Indan-(1Z)-ylidenemethyl-1H-imidazole DMKLY20 TI TTSZLWK DMKLY20 TN Aromatase (CYP19A1) DMKLY20 MA Inhibitor DMKLY20 RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMKLY20 RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMKLZ2H DI DMKLZ2H DMKLZ2H DN ISIS 113908 DMKLZ2H TI TTIX0ZU DMKLZ2H TN MEKK2 messenger RNA (MAP3K2 mRNA) DMKLZ2H RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMKLZ2H RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMKLZXV DI DMKLZXV DMKLZXV DN 3-Hydroxyisoxazole-4-Carboxylic Acid DMKLZXV TI TTAZHU0 DMKLZXV TN L-lactate dehydrogenase (LDH) DMKLZXV MA Inhibitor DMKLZXV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKLZXV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKM3WJ DI DMKM3WJ DMKM3WJ DN cholesten DMKM3WJ TI TTS4UGC DMKM3WJ TN Farnesoid X-activated receptor (FXR) DMKM3WJ MA Agonist DMKM3WJ RN Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol. 2003 Feb;23(3):864-72. DMKM3WJ RU https://pubmed.ncbi.nlm.nih.gov/12529392 DMKM6NQ DI DMKM6NQ DMKM6NQ DN Thymidine-5'-Phosphate DMKM6NQ TI TTU6BFZ DMKM6NQ TN Candida Thymidylate synthase (Candi TMP1) DMKM6NQ MA Inhibitor DMKM6NQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKM6NQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKM6NQ DI DMKM6NQ DMKM6NQ DN Thymidine-5'-Phosphate DMKM6NQ TI TT5B8AX DMKM6NQ TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMKM6NQ MA Inhibitor DMKM6NQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKM6NQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKM6NQ DI DMKM6NQ DMKM6NQ DN Thymidine-5'-Phosphate DMKM6NQ TI TTP3QRF DMKM6NQ TN Thymidine kinase 1 (TK1) DMKM6NQ MA Inhibitor DMKM6NQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKM6NQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKM81A DI DMKM81A DMKM81A DN Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 DMKM81A TI TT27RFC DMKM81A TN Opioid receptor delta (OPRD1) DMKM81A MA Inhibitor DMKM81A RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMKM81A RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMKM81A DI DMKM81A DMKM81A DN Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 DMKM81A TI TTCG0AL DMKM81A TN Cholecystokinin receptor type A (CCKAR) DMKM81A MA Inhibitor DMKM81A RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMKM81A RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMKM81A DI DMKM81A DMKM81A DN Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 DMKM81A TI TTKWM86 DMKM81A TN Opioid receptor mu (MOP) DMKM81A MA Inhibitor DMKM81A RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMKM81A RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMKM81A DI DMKM81A DMKM81A DN Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 DMKM81A TI TTVFO0U DMKM81A TN Gastrin/cholecystokinin type B receptor (CCKBR) DMKM81A MA Inhibitor DMKM81A RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMKM81A RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMKM8E2 DI DMKM8E2 DMKM8E2 DN (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine DMKM8E2 TI TTVBI8W DMKM8E2 TN Dopamine transporter (DAT) DMKM8E2 MA Inhibitor DMKM8E2 RN Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. DMKM8E2 RU https://pubmed.ncbi.nlm.nih.gov/19640707 DMKM8E2 DI DMKM8E2 DMKM8E2 DN (2R,3S)-2-[(4-Iodophenoxy)phenylmethyl]morpholine DMKM8E2 TI TT3ROYC DMKM8E2 TN Serotonin transporter (SERT) DMKM8E2 MA Inhibitor DMKM8E2 RN Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. DMKM8E2 RU https://pubmed.ncbi.nlm.nih.gov/19640707 DMKM9F0 DI DMKM9F0 DMKM9F0 DN Broussonin C DMKM9F0 TI TTULVH8 DMKM9F0 TN Tyrosinase (TYR) DMKM9F0 MA Inhibitor DMKM9F0 RN Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41. DMKM9F0 RU https://pubmed.ncbi.nlm.nih.gov/19046886 DMKMBSJ DI DMKMBSJ DMKMBSJ DN NM-9405 DMKMBSJ TI TTG043C DMKMBSJ TN Tumor necrosis factor receptor type I (TNF-R1) DMKMBSJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870). DMKMBSJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870 DMKMESD DI DMKMESD DMKMESD DN N-(3-Benzooxazol-7-yl-propyl)-butyramide DMKMESD TI TT32JK8 DMKMESD TN Melatonin receptor type 1B (MTNR1B) DMKMESD MA Inhibitor DMKMESD RN Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802. DMKMESD RU https://pubmed.ncbi.nlm.nih.gov/15203165 DMKMH2X DI DMKMH2X DMKMH2X DN O5-Acetyl-O7-nitrooxyethyl chrysin DMKMH2X TI TTFBNVI DMKMH2X TN Aldose reductase (AKR1B1) DMKMH2X MA Inhibitor DMKMH2X RN Synthesis, characterization and vasculoprotective effects of nitric oxide-donating derivatives of chrysin. Bioorg Med Chem. 2010 May 1;18(9):3020-5. DMKMH2X RU https://pubmed.ncbi.nlm.nih.gov/20395149 DMKMH5L DI DMKMH5L DMKMH5L DN 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L TI TTY3UE6 DMKMH5L TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMKMH5L MA Inhibitor DMKMH5L RN Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70. DMKMH5L RU https://pubmed.ncbi.nlm.nih.gov/16099841 DMKMH5L DI DMKMH5L DMKMH5L DN 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L TI TTMNI76 DMKMH5L TN Calcium-activated potassium channel (KCN) DMKMH5L MA Inhibitor DMKMH5L RN Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304. DMKMH5L RU https://pubmed.ncbi.nlm.nih.gov/19282171 DMKMH5L DI DMKMH5L DMKMH5L DN 4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L TI TTW0CMT DMKMH5L TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMKMH5L MA Inhibitor DMKMH5L RN Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92. DMKMH5L RU https://pubmed.ncbi.nlm.nih.gov/20974533 DMKMJBL DI DMKMJBL DMKMJBL DN (S)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide DMKMJBL TI TTGP7BY DMKMJBL TN Monoamine oxidase type B (MAO-B) DMKMJBL MA Inhibitor DMKMJBL RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMKMJBL RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMKMPS6 DI DMKMPS6 DMKMPS6 DN MRS2578 DMKMPS6 TI TTNVSKA DMKMPS6 TN P2Y purinoceptor 6 (P2RY6) DMKMPS6 MA Antagonist DMKMPS6 RN Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70. DMKMPS6 RU https://pubmed.ncbi.nlm.nih.gov/15081875 DMKMTJ9 DI DMKMTJ9 DMKMTJ9 DN NSC-693571 DMKMTJ9 TI TTJLP0R DMKMTJ9 TN Quinone reductase 2 (NQO2) DMKMTJ9 MA Inhibitor DMKMTJ9 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMKMTJ9 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMKMYAJ DI DMKMYAJ DMKMYAJ DN 6-oxo-estrone DMKMYAJ TI TTIWB6L DMKMYAJ TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMKMYAJ MA Inhibitor DMKMYAJ RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMKMYAJ RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMKN10X DI DMKN10X DMKN10X DN Abloid DMKN10X TI TTE4KHA DMKN10X TN Amyloid beta A4 protein (APP) DMKN10X MA Inhibitor DMKN10X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMKN10X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMKN3R9 DI DMKN3R9 DMKN3R9 DN AH6809 DMKN3R9 TI TTG1QMU DMKN3R9 TN Prostaglandin E2 receptor EP1 (PTGER1) DMKN3R9 MA Antagonist DMKN3R9 RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMKN3R9 RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMKN3R9 DI DMKN3R9 DMKN3R9 DN AH6809 DMKN3R9 TI TTPNGDE DMKN3R9 TN Prostaglandin E2 receptor EP3 (PTGER3) DMKN3R9 MA Antagonist DMKN3R9 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMKN3R9 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMKN3R9 DI DMKN3R9 DMKN3R9 DN AH6809 DMKN3R9 TI TT1ZAVI DMKN3R9 TN Prostaglandin E2 receptor EP2 (PTGER2) DMKN3R9 MA Antagonist DMKN3R9 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMKN3R9 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMKN3R9 DI DMKN3R9 DMKN3R9 DN AH6809 DMKN3R9 TI TTNVEIR DMKN3R9 TN Prostaglandin D2 receptor (PTGDR) DMKN3R9 MA Antagonist DMKN3R9 RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMKN3R9 RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMKN76P DI DMKN76P DMKN76P DN GSK-1564023A DMKN76P TI TTUV8G9 DMKN76P TN Progesterone receptor (PGR) DMKN76P MA Inhibitor DMKN76P RN The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2340-3. DMKN76P RU https://pubmed.ncbi.nlm.nih.gov/20202837 DMKN8U6 DI DMKN8U6 DMKN8U6 DN N-(4-Ethylphenyl)-N'-hydroxyoctanediamide DMKN8U6 TI TTBH0VX DMKN8U6 TN Histone deacetylase (HDAC) DMKN8U6 MA Inhibitor DMKN8U6 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMKN8U6 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMKN8U6 DI DMKN8U6 DMKN8U6 DN N-(4-Ethylphenyl)-N'-hydroxyoctanediamide DMKN8U6 TI TT6R7JZ DMKN8U6 TN Histone deacetylase 1 (HDAC1) DMKN8U6 MA Inhibitor DMKN8U6 RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMKN8U6 RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMKNA5U DI DMKNA5U DMKNA5U DN 1-(4-propoxyphenyl)propan-2-amine DMKNA5U TI TT3WG5C DMKNA5U TN Monoamine oxidase type A (MAO-A) DMKNA5U MA Inhibitor DMKNA5U RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMKNA5U RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMKND0T DI DMKND0T DMKND0T DN 2-(3,5-dimethoxyphenyl)-1,8-naphthyridine DMKND0T TI TTHS256 DMKND0T TN Metabotropic glutamate receptor 5 (mGluR5) DMKND0T MA Inhibitor DMKND0T RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMKND0T RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMKND2R DI DMKND2R DMKND2R DN Tyr-Gly-Gly-Phe-c(Cys-Arg-Arg-Ile-Cys)-Arg-lys DMKND2R TI TT27RFC DMKND2R TN Opioid receptor delta (OPRD1) DMKND2R MA Inhibitor DMKND2R RN Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7. DMKND2R RU https://pubmed.ncbi.nlm.nih.gov/8096246 DMKNOLV DI DMKNOLV DMKNOLV DN 6-Cl-MLT DMKNOLV TI TT0WAIE DMKNOLV TN Melatonin receptor type 1A (MTNR1A) DMKNOLV MA Agonist DMKNOLV RN Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther. 1985 Aug;234(2):395-401. DMKNOLV RU https://pubmed.ncbi.nlm.nih.gov/2991499 DMKNQW4 DI DMKNQW4 DMKNQW4 DN 7,8-dichloroquinoline-4-one-3-carboxylic acid DMKNQW4 TI TTER6YH DMKNQW4 TN Casein kinase II alpha (CSNK2A1) DMKNQW4 MA Inhibitor DMKNQW4 RN Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem. 2006 Nov 2;49(22):6443-50. DMKNQW4 RU https://pubmed.ncbi.nlm.nih.gov/17064064 DMKNUP3 DI DMKNUP3 DMKNUP3 DN norfluoxetine DMKNUP3 TI TT0K1SC DMKNUP3 TN 5-HT 2B receptor (HTR2B) DMKNUP3 MA Antagonist DMKNUP3 RN Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. DMKNUP3 RU https://pubmed.ncbi.nlm.nih.gov/11104741 DMKNUP3 DI DMKNUP3 DMKNUP3 DN norfluoxetine DMKNUP3 TI TTJQOD7 DMKNUP3 TN 5-HT 2A receptor (HTR2A) DMKNUP3 MA Antagonist DMKNUP3 RN Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. DMKNUP3 RU https://pubmed.ncbi.nlm.nih.gov/11104741 DMKNUP3 DI DMKNUP3 DMKNUP3 DN norfluoxetine DMKNUP3 TI TTWJBZ5 DMKNUP3 TN 5-HT 2C receptor (HTR2C) DMKNUP3 MA Antagonist DMKNUP3 RN Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. DMKNUP3 RU https://pubmed.ncbi.nlm.nih.gov/11104741 DMKNUP3 DI DMKNUP3 DMKNUP3 DN norfluoxetine DMKNUP3 TI TTVUWHQ DMKNUP3 TN Voltage-gated potassium channel Kv3.1 (KCNC1) DMKNUP3 MA Inhibitor (gating inhibitor) DMKNUP3 RN Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1. Neuropharmacology. 2001 Sep;41(4):443-53. DMKNUP3 RU https://pubmed.ncbi.nlm.nih.gov/11543764 DMKNUYF DI DMKNUYF DMKNUYF DN CMPD1 DMKNUYF TI TTMUG9D DMKNUYF TN MAPK-activated protein kinase 2 (MAPKAPK2) DMKNUYF MA Inhibitor DMKNUYF RN Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6832-5. DMKNUYF RU https://pubmed.ncbi.nlm.nih.gov/17964780 DMKO8LE DI DMKO8LE DMKO8LE DN PD-0179483 DMKO8LE TI TTI7421 DMKO8LE TN Platelet-derived growth factor receptor beta (PDGFRB) DMKO8LE MA Inhibitor DMKO8LE RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMKO8LE RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMKO8LE DI DMKO8LE DMKO8LE DN PD-0179483 DMKO8LE TI TTRLW2X DMKO8LE TN Fibroblast growth factor receptor 1 (FGFR1) DMKO8LE MA Inhibitor DMKO8LE RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMKO8LE RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMKO8LE DI DMKO8LE DMKO8LE DN PD-0179483 DMKO8LE TI TT8FYO9 DMKO8LE TN Platelet-derived growth factor receptor alpha (PDGFRA) DMKO8LE MA Inhibitor DMKO8LE RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMKO8LE RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMKO8LE DI DMKO8LE DMKO8LE DN PD-0179483 DMKO8LE TI TT6PKBN DMKO8LE TN Proto-oncogene c-Src (SRC) DMKO8LE MA Inhibitor DMKO8LE RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMKO8LE RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMKO8LE DI DMKO8LE DMKO8LE DN PD-0179483 DMKO8LE TI TT860QF DMKO8LE TN LCK tyrosine protein kinase (LCK) DMKO8LE MA Inhibitor DMKO8LE RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMKO8LE RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMKO8QT DI DMKO8QT DMKO8QT DN 6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline DMKO8QT TI TTGKNB4 DMKO8QT TN Epidermal growth factor receptor (EGFR) DMKO8QT MA Inhibitor DMKO8QT RN Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. DMKO8QT RU https://pubmed.ncbi.nlm.nih.gov/17869510 DMKO982 DI DMKO982 DMKO982 DN Ac-WVTHRLAGLLS[Cit]SGGVVRKNFVPTDVGPFAF-NH2 DMKO982 TI TTVSFJW DMKO982 TN Calcitonin gene-related peptide 1 (CALCA) DMKO982 MA Inhibitor DMKO982 RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMKO982 RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMKOB2T DI DMKOB2T DMKOB2T DN 3-[6-Methyl-indan-(1Z)-ylidenemethyl]-pyridine DMKOB2T TI TTSZLWK DMKOB2T TN Aromatase (CYP19A1) DMKOB2T MA Inhibitor DMKOB2T RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMKOB2T RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMKOE9I DI DMKOE9I DMKOE9I DN 3,4,5,6-Tetrahydrobenzo[c]quinolizin-3-(4aH)-one DMKOE9I TI TTTU72V DMKOE9I TN Steroid 5-alpha-reductase 1 (SRD5A1) DMKOE9I MA Inhibitor DMKOE9I RN Benzo[c]quinolizin-3-ones: a novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem. 2000 Oct 5;43(20):3718-35. DMKOE9I RU https://pubmed.ncbi.nlm.nih.gov/11020287 DMKOFNX DI DMKOFNX DMKOFNX DN ISIS 19221 DMKOFNX TI TT1ERKL DMKOFNX TN CD40 messenger RNA (CD40 mRNA) DMKOFNX RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMKOFNX RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMKOFRE DI DMKOFRE DMKOFRE DN 2-(2,4-dichlorophenoxy)-5-isobutylphenol DMKOFRE TI TTNX2CS DMKOFRE TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMKOFRE MA Inhibitor DMKOFRE RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DMKOFRE RU https://pubmed.ncbi.nlm.nih.gov/19217192 DMKOMP2 DI DMKOMP2 DMKOMP2 DN HOE-33258 DMKOMP2 TI TTQY2EJ DMKOMP2 TN TERT messenger RNA (TERT mRNA) DMKOMP2 MA Inhibitor DMKOMP2 RN Nucleic acid-binding ligands identify new mechanisms to inhibit telomerase. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3467-71. DMKOMP2 RU https://pubmed.ncbi.nlm.nih.gov/15177454 DMKORTS DI DMKORTS DMKORTS DN 2-Hexyloxy-5-imidazol-1-yl-pyridine DMKORTS TI TTVG215 DMKORTS TN Debrisoquine 4-hydroxylase (CYP2D6) DMKORTS MA Inhibitor DMKORTS RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DMKORTS RU https://pubmed.ncbi.nlm.nih.gov/14698153 DMKOUCM DI DMKOUCM DMKOUCM DN 2-Fluoro-5-[5-(4-hydroxyphenyl)-2-thienyl]phenol DMKOUCM TI TTIWB6L DMKOUCM TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMKOUCM MA Inhibitor DMKOUCM RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMKOUCM RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMKOX0N DI DMKOX0N DMKOX0N DN 3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxamide DMKOX0N TI TTUTJGQ DMKOX0N TN Vascular endothelial growth factor receptor 2 (KDR) DMKOX0N MA Inhibitor DMKOX0N RN Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors. Bioorg Med Chem Lett. 2006 Jan 1;16(1):96-9. DMKOX0N RU https://pubmed.ncbi.nlm.nih.gov/16216502 DMKP6BM DI DMKP6BM DMKP6BM DN 2-Methylamino-succinic acid(NMDA) DMKP6BM TI TT1M8OW DMKP6BM TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMKP6BM MA Agonist DMKP6BM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMKP6BM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMKP6BM DI DMKP6BM DMKP6BM DN 2-Methylamino-succinic acid(NMDA) DMKP6BM TI TT5POTG DMKP6BM TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMKP6BM MA Agonist DMKP6BM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMKP6BM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMKP6BM DI DMKP6BM DMKP6BM DN 2-Methylamino-succinic acid(NMDA) DMKP6BM TI TTLD29N DMKP6BM TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMKP6BM MA Inhibitor DMKP6BM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMKP6BM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMKP6BM DI DMKP6BM DMKP6BM DN 2-Methylamino-succinic acid(NMDA) DMKP6BM TI TTN9D8E DMKP6BM TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMKP6BM MA Inhibitor DMKP6BM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMKP6BM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMKP6BM DI DMKP6BM DMKP6BM DN 2-Methylamino-succinic acid(NMDA) DMKP6BM TI TTKJEMQ DMKP6BM TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMKP6BM MA Inhibitor DMKP6BM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMKP6BM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMKP7O0 DI DMKP7O0 DMKP7O0 DN 2,5-dideoxy-2,5-imino-dl-glycero-D-manno-heptitol DMKP7O0 TI TTA0OSE DMKP7O0 TN Lactase-phlorizin hydrolase (LCT) DMKP7O0 MA Inhibitor DMKP7O0 RN Nitrogen-containing furanose and pyranose analogues from Hyacinthus orientalis. J Nat Prod. 1998 May;61(5):625-8. DMKP7O0 RU https://pubmed.ncbi.nlm.nih.gov/9599261 DMKP8L9 DI DMKP8L9 DMKP8L9 DN AMG-889436 DMKP8L9 TI TTPJR0G DMKP8L9 TN Glutamate receptor AMPA 4 (GRIA4) DMKP8L9 MA Agonist DMKP8L9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447). DMKP8L9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447 DMKP974 DI DMKP974 DMKP974 DN 2-(2,4-dichlorophenoxy)-5-propylphenol DMKP974 TI TTNX2CS DMKP974 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMKP974 MA Inhibitor DMKP974 RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DMKP974 RU https://pubmed.ncbi.nlm.nih.gov/17567585 DMKPIH0 DI DMKPIH0 DMKPIH0 DN D-203 DMKPIH0 TI TT4C8EA DMKPIH0 TN Dopamine D3 receptor (D3R) DMKPIH0 MA Inhibitor DMKPIH0 RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMKPIH0 RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMKPIH0 DI DMKPIH0 DMKPIH0 DN D-203 DMKPIH0 TI TTEX248 DMKPIH0 TN Dopamine D2 receptor (D2R) DMKPIH0 MA Inhibitor DMKPIH0 RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMKPIH0 RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMKPMFJ DI DMKPMFJ DMKPMFJ DN 8-Fluoro-6H,11H-indeno[1,2-c]isoquinolin-5-one DMKPMFJ TI TTVDSZ0 DMKPMFJ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMKPMFJ MA Inhibitor DMKPMFJ RN Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3. DMKPMFJ RU https://pubmed.ncbi.nlm.nih.gov/16078828 DMKPNSH DI DMKPNSH DMKPNSH DN 4-Naphthalen-2-yl-phenol DMKPNSH TI TTZAYWL DMKPNSH TN Estrogen receptor (ESR) DMKPNSH MA Inhibitor DMKPNSH RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMKPNSH RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMKPNSH DI DMKPNSH DMKPNSH DN 4-Naphthalen-2-yl-phenol DMKPNSH TI TTOM3J0 DMKPNSH TN Estrogen receptor beta (ESR2) DMKPNSH MA Inhibitor DMKPNSH RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMKPNSH RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMKPUI6 DI DMKPUI6 DMKPUI6 DN Chlorpyrifos DMKPUI6 TI TT1RS9F DMKPUI6 TN Acetylcholinesterase (AChE) DMKPUI6 MA Inhibitor DMKPUI6 RN Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpy... Bioorg Med Chem Lett. 2006 Feb;16(3):622-7. DMKPUI6 RU https://pubmed.ncbi.nlm.nih.gov/16288867 DMKPUWX DI DMKPUWX DMKPUWX DN 9-O-[3-(Phenylamino)propyl]-berberine bromide DMKPUWX TI TTEB0GD DMKPUWX TN Cholinesterase (BCHE) DMKPUWX MA Inhibitor DMKPUWX RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMKPUWX RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMKPUWX DI DMKPUWX DMKPUWX DN 9-O-[3-(Phenylamino)propyl]-berberine bromide DMKPUWX TI TT1RS9F DMKPUWX TN Acetylcholinesterase (AChE) DMKPUWX MA Inhibitor DMKPUWX RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMKPUWX RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMKPWN0 DI DMKPWN0 DMKPWN0 DN 6-deoxymanzamine X DMKPWN0 TI TTRSMW9 DMKPWN0 TN Glycogen synthase kinase-3 beta (GSK-3B) DMKPWN0 MA Inhibitor DMKPWN0 RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DMKPWN0 RU https://pubmed.ncbi.nlm.nih.gov/17708655 DMKPX7W DI DMKPX7W DMKPX7W DN (+/-)-2-(4'-Ethoxyphenyl)thiomorpholine DMKPX7W TI TTGP7BY DMKPX7W TN Monoamine oxidase type B (MAO-B) DMKPX7W MA Inhibitor DMKPX7W RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMKPX7W RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMKPX7W DI DMKPX7W DMKPX7W DN (+/-)-2-(4'-Ethoxyphenyl)thiomorpholine DMKPX7W TI TT3WG5C DMKPX7W TN Monoamine oxidase type A (MAO-A) DMKPX7W MA Inhibitor DMKPX7W RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMKPX7W RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMKPYEU DI DMKPYEU DMKPYEU DN N-[3,3-Bis-(4-fluorophenyl)-propyl]-benzamide DMKPYEU TI TT7WVHI DMKPYEU TN Soluble epoxide hydrolase (EPHX2) DMKPYEU MA Inhibitor DMKPYEU RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DMKPYEU RU https://pubmed.ncbi.nlm.nih.gov/19746975 DMKQ0CA DI DMKQ0CA DMKQ0CA DN bromoenol lactone DMKQ0CA TI TT32NQ1 DMKQ0CA TN Short transient receptor potential channel 5 (TRPC5) DMKQ0CA MA Blocker (channel blocker) DMKQ0CA RN Bromoenol lactone inhibits voltage-gated Ca2+ and transient receptor potential canonical channels. J Pharmacol Exp Ther. 2011 Nov;339(2):329-40. DMKQ0CA RU https://pubmed.ncbi.nlm.nih.gov/21795434 DMKQ0CA DI DMKQ0CA DMKQ0CA DN bromoenol lactone DMKQ0CA TI TTDP1UC DMKQ0CA TN Fatty acid amide hydrolase (FAAH) DMKQ0CA MA Inhibitor DMKQ0CA RN Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43. DMKQ0CA RU https://pubmed.ncbi.nlm.nih.gov/18983142 DMKQ679 DI DMKQ679 DMKQ679 DN (Z)-2-(1-decyl-2-oxoindolin-3-ylidene)acetic acid DMKQ679 TI TTLZS4Q DMKQ679 TN M-phase inducer phosphatase 1 (MPIP1) DMKQ679 MA Inhibitor DMKQ679 RN Design and synthesis of N-alkyl oxindolylidene acetic acids as a new class of potent Cdc25A inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3350-3. DMKQ679 RU https://pubmed.ncbi.nlm.nih.gov/18442908 DMKQMXV DI DMKQMXV DMKQMXV DN ISIS 29477 DMKQMXV TI TTYMGWX DMKQMXV TN PDK-1 messenger RNA (PDK-1 mRNA) DMKQMXV RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMKQMXV RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMKQT1Y DI DMKQT1Y DMKQT1Y DN RS-1636 DMKQT1Y TI TTGP7BY DMKQT1Y TN Monoamine oxidase type B (MAO-B) DMKQT1Y MA Inhibitor DMKQT1Y RN Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82. DMKQT1Y RU https://pubmed.ncbi.nlm.nih.gov/11928718 DMKQWSB DI DMKQWSB DMKQWSB DN Up3U DMKQWSB TI TTNVSKA DMKQWSB TN P2Y purinoceptor 6 (P2RY6) DMKQWSB MA Agonist DMKQWSB RN P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312. DMKQWSB RU https://pubmed.ncbi.nlm.nih.gov/16475938 DMKQYMX DI DMKQYMX DMKQYMX DN NSC-137546 DMKQYMX TI TT6VZ78 DMKQYMX TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMKQYMX MA Inhibitor DMKQYMX RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMKQYMX RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMKQYMX DI DMKQYMX DMKQYMX DN NSC-137546 DMKQYMX TI TTHVCUP DMKQYMX TN DNA [cytosine-5]-methyltransferase (DNMT) DMKQYMX MA Inhibitor DMKQYMX RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMKQYMX RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMKQZB7 DI DMKQZB7 DMKQZB7 DN 1-(piperidin-4-ylmethyl)pyridin-2(1H)-one DMKQZB7 TI TTF4E0J DMKQZB7 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMKQZB7 MA Inhibitor DMKQZB7 RN Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6. DMKQZB7 RU https://pubmed.ncbi.nlm.nih.gov/16640326 DMKR47X DI DMKR47X DMKR47X DN 2-ethylquinoline-8-carboxamide DMKR47X TI TTVDSZ0 DMKR47X TN Poly [ADP-ribose] polymerase 1 (PARP1) DMKR47X MA Inhibitor DMKR47X RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMKR47X RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMKR69T DI DMKR69T DMKR69T DN ASN04450772 DMKR69T TI TTMPART DMKR69T TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMKR69T MA Agonist DMKR69T RN In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52. DMKR69T RU https://pubmed.ncbi.nlm.nih.gov/21744154 DMKR8BI DI DMKR8BI DMKR8BI DN 1-(4-nitrophenethyl)pyrrolidine DMKR8BI TI TT9JNIC DMKR8BI TN Histamine H3 receptor (H3R) DMKR8BI MA Inhibitor DMKR8BI RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMKR8BI RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMKRAEW DI DMKRAEW DMKRAEW DN Alstiphyllanine F DMKRAEW TI TT2UE56 DMKRAEW TN Sodium/glucose cotransporter 1 (SGLT1) DMKRAEW MA Inhibitor DMKRAEW RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMKRAEW RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMKRAEW DI DMKRAEW DMKRAEW DN Alstiphyllanine F DMKRAEW TI TTF8JAT DMKRAEW TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMKRAEW MA Inhibitor DMKRAEW RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMKRAEW RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMKRG2C DI DMKRG2C DMKRG2C DN Thiadiazolo[2,3-a]pyrimidine DMKRG2C TI TTSUKYD DMKRG2C TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMKRG2C MA Inhibitor DMKRG2C RN Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9. DMKRG2C RU https://pubmed.ncbi.nlm.nih.gov/18955536 DMKRHQ3 DI DMKRHQ3 DMKRHQ3 DN 4-methyl-2H-benzofuro[3,2-g]chromen-2-one DMKRHQ3 TI TT3WG5C DMKRHQ3 TN Monoamine oxidase type A (MAO-A) DMKRHQ3 MA Inhibitor DMKRHQ3 RN A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56. DMKRHQ3 RU https://pubmed.ncbi.nlm.nih.gov/16451079 DMKRI1J DI DMKRI1J DMKRI1J DN MNI-137 DMKRI1J TI TTXJ47W DMKRI1J TN Metabotropic glutamate receptor 2 (mGluR2) DMKRI1J MA Modulator (allosteric modulator) DMKRI1J RN A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64. DMKRI1J RU https://pubmed.ncbi.nlm.nih.gov/17416742 DMKRI1J DI DMKRI1J DMKRI1J DN MNI-137 DMKRI1J TI TT8A9EF DMKRI1J TN Metabotropic glutamate receptor 3 (mGluR3) DMKRI1J MA Modulator (allosteric modulator) DMKRI1J RN A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther. 2007 Jul;322(1):254-64. DMKRI1J RU https://pubmed.ncbi.nlm.nih.gov/17416742 DMKRMSP DI DMKRMSP DMKRMSP DN Pr-RYYRIK-NH2 DMKRMSP TI TTNT7K8 DMKRMSP TN Nociceptin receptor (OPRL1) DMKRMSP MA Inhibitor DMKRMSP RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMKRMSP RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMKRSZY DI DMKRSZY DMKRSZY DN LGD-2226 DMKRSZY TI TTKPW01 DMKRSZY TN Androgen receptor messenger RNA (AR mRNA) DMKRSZY MA Inhibitor DMKRSZY RN Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1527-31. DMKRSZY RU https://pubmed.ncbi.nlm.nih.gov/17267219 DMKRT20 DI DMKRT20 DMKRT20 DN Degraded Cephaloridine DMKRT20 TI TTHI19T DMKRT20 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMKRT20 MA Inhibitor DMKRT20 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKRT20 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKRTBM DI DMKRTBM DMKRTBM DN (-)-3-O-acetylspectaline DMKRTBM TI TT8NGED DMKRTBM TN Prostaglandin G/H synthase 1 (COX-1) DMKRTBM MA Inhibitor DMKRTBM RN Lipoperoxidation and cyclooxygenase enzyme inhibitory piperidine alkaloids from Cassia spectabilis green fruits. J Nat Prod. 2007 Dec;70(12):2026-8. DMKRTBM RU https://pubmed.ncbi.nlm.nih.gov/18047293 DMKSDT4 DI DMKSDT4 DMKSDT4 DN 2-[3-(2-Methyl-butyl)-phenyl]-propionic acid DMKSDT4 TI TTMWT8Z DMKSDT4 TN C-X-C chemokine receptor type 1 (CXCR1) DMKSDT4 MA Inhibitor DMKSDT4 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMKSDT4 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMKSDT4 DI DMKSDT4 DMKSDT4 DN 2-[3-(2-Methyl-butyl)-phenyl]-propionic acid DMKSDT4 TI TT30C9G DMKSDT4 TN C-X-C chemokine receptor type 2 (CXCR2) DMKSDT4 MA Inhibitor DMKSDT4 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMKSDT4 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMKSI80 DI DMKSI80 DMKSI80 DN [125I]L703,606 DMKSI80 TI TTZPO1L DMKSI80 TN Substance-P receptor (TACR1) DMKSI80 MA Antagonist DMKSI80 RN Radioiodinated L-703,606: a potent, selective antagonist to the human NK1 receptor. Appl Radiat Isot. 1994 Jan;45(1):97-103. DMKSI80 RU https://pubmed.ncbi.nlm.nih.gov/8287060 DMKSIVL DI DMKSIVL DMKSIVL DN Selenazofurin DMKSIVL TI TTL7C8Q DMKSIVL TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMKSIVL MA Inhibitor DMKSIVL RN In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. Anticancer Res. 1998 Jul-Aug;18(4A):2623-30. DMKSIVL RU https://pubmed.ncbi.nlm.nih.gov/9703919 DMKSJE3 DI DMKSJE3 DMKSJE3 DN 7-hydroxy-1,2,9,9a-tetrahydrofluoren-3-one DMKSJE3 TI TTOM3J0 DMKSJE3 TN Estrogen receptor beta (ESR2) DMKSJE3 MA Inhibitor DMKSJE3 RN The discovery of tetrahydrofluorenones as a new class of estrogen receptor beta-subtype selective ligands. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3489-94. DMKSJE3 RU https://pubmed.ncbi.nlm.nih.gov/16632357 DMKSM5A DI DMKSM5A DMKSM5A DN N-(3-(3-methoxyphenyl)propyl)propionamide DMKSM5A TI TT32JK8 DMKSM5A TN Melatonin receptor type 1B (MTNR1B) DMKSM5A MA Inhibitor DMKSM5A RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMKSM5A RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMKSM5A DI DMKSM5A DMKSM5A DN N-(3-(3-methoxyphenyl)propyl)propionamide DMKSM5A TI TT0WAIE DMKSM5A TN Melatonin receptor type 1A (MTNR1A) DMKSM5A MA Inhibitor DMKSM5A RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMKSM5A RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMKSQUB DI DMKSQUB DMKSQUB DN DIDS DMKSQUB TI TTR68GQ DMKSQUB TN Chloride channel protein ClC-Kb (ClC-K2) DMKSQUB MA Blocker (channel blocker) DMKSQUB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 701). DMKSQUB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=701 DMKSQUB DI DMKSQUB DMKSQUB DN DIDS DMKSQUB TI TTST1AJ DMKSQUB TN Chloride channel protein 7 (ClC-7) DMKSQUB MA Blocker (channel blocker) DMKSQUB RN The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect. PLoS One. 2010 Sep 7;5(9):e12585. DMKSQUB RU https://pubmed.ncbi.nlm.nih.gov/20830208 DMKSQUB DI DMKSQUB DMKSQUB DN DIDS DMKSQUB TI TT823N1 DMKSQUB TN Chloride channel protein ClC-Ka (ClC-K1) DMKSQUB MA Blocker (channel blocker) DMKSQUB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 700). DMKSQUB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=700 DMKSQUB DI DMKSQUB DMKSQUB DN DIDS DMKSQUB TI TTCJRDO DMKSQUB TN Chloride channel protein 6 (ClC-6) DMKSQUB MA Blocker (channel blocker) DMKSQUB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 705). DMKSQUB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=705 DMKSQUB DI DMKSQUB DMKSQUB DN DIDS DMKSQUB TI TT0FC1V DMKSQUB TN Volume regulated chloride channel (VRAC) DMKSQUB MA Blocker (channel blocker) DMKSQUB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DMKSQUB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DMKSQUB DI DMKSQUB DMKSQUB DN DIDS DMKSQUB TI TTOJI4S DMKSQUB TN Calcium-dependent chloride channel anoctamin (ANO) DMKSQUB MA Blocker (channel blocker) DMKSQUB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 708). DMKSQUB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=708 DMKSQY1 DI DMKSQY1 DMKSQY1 DN Azelaic bishydroxamic acid DMKSQY1 TI TTBH0VX DMKSQY1 TN Histone deacetylase (HDAC) DMKSQY1 MA Inhibitor DMKSQY1 RN Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. DMKSQY1 RU https://pubmed.ncbi.nlm.nih.gov/16955068 DMKSUV9 DI DMKSUV9 DMKSUV9 DN 3-tapap DMKSUV9 TI TTPRO7W DMKSUV9 TN Suppressor of tumorigenicity 14 protein (ST14) DMKSUV9 MA Inhibitor DMKSUV9 RN Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem. 2006 Jul 13;49(14):4116-26. DMKSUV9 RU https://pubmed.ncbi.nlm.nih.gov/16821772 DMKSUVH DI DMKSUVH DMKSUVH DN 2-N,N-Dimethylamino-1-(4-methylthiophenyl)propane DMKSUVH TI TT3ROYC DMKSUVH TN Serotonin transporter (SERT) DMKSUVH MA Inhibitor DMKSUVH RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMKSUVH RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMKT0YQ DI DMKT0YQ DMKT0YQ DN 8-Cyclohexyloxy-quinolin-2-ylamine DMKT0YQ TI TTX4RTB DMKT0YQ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMKT0YQ MA Inhibitor DMKT0YQ RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMKT0YQ RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMKT1DA DI DMKT1DA DMKT1DA DN MT-II DMKT1DA TI TTD0CIQ DMKT1DA TN Melanocortin receptor 4 (MC4R) DMKT1DA MA Agonist DMKT1DA RN Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry. 2000 Dec 5;39(48):14900-11. DMKT1DA RU https://pubmed.ncbi.nlm.nih.gov/11101306 DMKT1DA DI DMKT1DA DMKT1DA DN MT-II DMKT1DA TI TT6QAJ3 DMKT1DA TN Melanocortin receptor 5 (MC5R) DMKT1DA MA Agonist DMKT1DA RN The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur J Pharmacol. 2002 Apr 12;440(2-3):141-57. DMKT1DA RU https://pubmed.ncbi.nlm.nih.gov/12007532 DMKT1DA DI DMKT1DA DMKT1DA DN MT-II DMKT1DA TI TT0MV2T DMKT1DA TN Melanocortin receptor 1 (MC1R) DMKT1DA MA Agonist DMKT1DA RN Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9. DMKT1DA RU https://pubmed.ncbi.nlm.nih.gov/2535874 DMKT1DA DI DMKT1DA DMKT1DA DN MT-II DMKT1DA TI TTNI91K DMKT1DA TN Melanocortin receptor 3 (MC3R) DMKT1DA MA Agonist DMKT1DA RN Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):249-58. DMKT1DA RU https://pubmed.ncbi.nlm.nih.gov/10493100 DMKT1DA DI DMKT1DA DMKT1DA DN MT-II DMKT1DA TI TTEOSZT DMKT1DA TN Melanocortin receptor (MCR) DMKT1DA MA Inhibitor DMKT1DA RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMKT1DA RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMKT20Q DI DMKT20Q DMKT20Q DN 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide DMKT20Q TI TTSYM0R DMKT20Q TN Carbonic anhydrase XII (CA-XII) DMKT20Q MA Inhibitor DMKT20Q RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMKT20Q RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMKT20Q DI DMKT20Q DMKT20Q DN 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide DMKT20Q TI TTANPDJ DMKT20Q TN Carbonic anhydrase II (CA-II) DMKT20Q MA Inhibitor DMKT20Q RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMKT20Q RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMKT20Q DI DMKT20Q DMKT20Q DN 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide DMKT20Q TI TTEYTKG DMKT20Q TN Carbonic anhydrase XIV (CA-XIV) DMKT20Q MA Inhibitor DMKT20Q RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMKT20Q RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMKT20Q DI DMKT20Q DMKT20Q DN 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide DMKT20Q TI TT2LVK8 DMKT20Q TN Carbonic anhydrase IX (CA-IX) DMKT20Q MA Inhibitor DMKT20Q RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMKT20Q RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMKT20Q DI DMKT20Q DMKT20Q DN 4-(5-Methyl-2-pirazolino)-3-pyridinesulfonamide DMKT20Q TI TTHQPL7 DMKT20Q TN Carbonic anhydrase I (CA-I) DMKT20Q MA Inhibitor DMKT20Q RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMKT20Q RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMKT21X DI DMKT21X DMKT21X DN MAR-531 DMKT21X TI TT9O6WS DMKT21X TN Glucagon receptor (GCGR) DMKT21X MA Modulator DMKT21X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 251). DMKT21X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=251 DMKT2MB DI DMKT2MB DMKT2MB DN 1-(4-nitrobenzyl)-1H-imidazole DMKT2MB TI TTRA5BZ DMKT2MB TN Steroid 17-alpha-monooxygenase (S17AH) DMKT2MB MA Inhibitor DMKT2MB RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DMKT2MB RU https://pubmed.ncbi.nlm.nih.gov/16750362 DMKT51Z DI DMKT51Z DMKT51Z DN 2-(2-(4-tert-butylphenoxy)acetamido)benzoic acid DMKT51Z TI TTWNV8U DMKT51Z TN Nicotinic acid receptor (HCAR2) DMKT51Z MA Inhibitor DMKT51Z RN Molecular modeling aided design of nicotinic acid receptor GPR109A agonists. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4963-7. DMKT51Z RU https://pubmed.ncbi.nlm.nih.gov/18760600 DMKT915 DI DMKT915 DMKT915 DN 4-Furan-2-yl-6-nitro-2-piperazin-1-yl-quinoline DMKT915 TI TT3ROYC DMKT915 TN Serotonin transporter (SERT) DMKT915 MA Inhibitor DMKT915 RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DMKT915 RU https://pubmed.ncbi.nlm.nih.gov/11859009 DMKTA5R DI DMKTA5R DMKTA5R DN O-methyldauricine DMKTA5R TI TTVBI8W DMKTA5R TN Dopamine transporter (DAT) DMKTA5R MA Inhibitor DMKTA5R RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DMKTA5R RU https://pubmed.ncbi.nlm.nih.gov/8676127 DMKTB5U DI DMKTB5U DMKTB5U DN PYRAZOLOPYRIDAZINE 1 DMKTB5U TI TT0PG8F DMKTB5U TN Cyclin-dependent kinase 4 (CDK4) DMKTB5U MA Inhibitor DMKTB5U RN N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30. DMKTB5U RU https://pubmed.ncbi.nlm.nih.gov/15341487 DMKTB5U DI DMKTB5U DMKTB5U DN PYRAZOLOPYRIDAZINE 1 DMKTB5U TI TTRSMW9 DMKTB5U TN Glycogen synthase kinase-3 beta (GSK-3B) DMKTB5U MA Inhibitor DMKTB5U RN N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30. DMKTB5U RU https://pubmed.ncbi.nlm.nih.gov/15341487 DMKTB5U DI DMKTB5U DMKTB5U DN PYRAZOLOPYRIDAZINE 1 DMKTB5U TI TT7HF4W DMKTB5U TN Cyclin-dependent kinase 2 (CDK2) DMKTB5U MA Inhibitor DMKTB5U RN N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular effi... J Med Chem. 2004 Sep 9;47(19):4716-30. DMKTB5U RU https://pubmed.ncbi.nlm.nih.gov/15341487 DMKTBCM DI DMKTBCM DMKTBCM DN PMID24900526C5 DMKTBCM TI TTXZ0KQ DMKTBCM TN Matrix metalloproteinase-12 (MMP-12) DMKTBCM MA Inhibitor DMKTBCM RN Target-Activated Prodrugs (TAPs) for the Autoregulated Inhibition of MMP12. ACS Med Chem Lett. 2012 Jul 14;3(8):653-7. DMKTBCM RU https://pubmed.ncbi.nlm.nih.gov/24900526 DMKTBEH DI DMKTBEH DMKTBEH DN ISOTHIAZOLIDINONE ANALOG DMKTBEH TI TTELIN2 DMKTBEH TN PTPN1 messenger RNA (PTPN1 mRNA) DMKTBEH MA Inhibitor DMKTBEH RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKTBEH RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKTE5V DI DMKTE5V DMKTE5V DN N-octadecyl-N'-propylsulfamide DMKTE5V TI TT6OEDT DMKTE5V TN Cannabinoid receptor 1 (CB1) DMKTE5V MA Inhibitor DMKTE5V RN Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95. DMKTE5V RU https://pubmed.ncbi.nlm.nih.gov/19762126 DMKTJBU DI DMKTJBU DMKTJBU DN G418 DMKTJBU TI TTUMGNO DMKTJBU TN Ornithine decarboxylase (ODC1) DMKTJBU MA Inhibitor DMKTJBU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKTJBU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKTJBU DI DMKTJBU DMKTJBU DN G418 DMKTJBU TI TT38DW5 DMKTJBU TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMKTJBU MA Inhibitor DMKTJBU RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMKTJBU RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMKTNVJ DI DMKTNVJ DMKTNVJ DN ISIS 113048 DMKTNVJ TI TTASI04 DMKTNVJ TN E2F1 messenger RNA (E2F1 mRNA) DMKTNVJ RN US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression. DMKTNVJ RU http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true DMKTOPJ DI DMKTOPJ DMKTOPJ DN methyl-piperidino-pyrazole DMKTOPJ TI TTZAYWL DMKTOPJ TN Estrogen receptor (ESR) DMKTOPJ MA Antagonist DMKTOPJ RN Antagonists selective for estrogen receptor alpha. Endocrinology. 2002 Mar;143(3):941-7. DMKTOPJ RU https://pubmed.ncbi.nlm.nih.gov/11861516 DMKTQB2 DI DMKTQB2 DMKTQB2 DN 2-Methyl-1(3)H-anthrasimidazole-6,11-dione DMKTQB2 TI TTQY2EJ DMKTQB2 TN TERT messenger RNA (TERT mRNA) DMKTQB2 MA Inhibitor DMKTQB2 RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMKTQB2 RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMKTSPM DI DMKTSPM DMKTSPM DN 4-Chlorobenzenemethanethiol DMKTSPM TI TTZJYKH DMKTSPM TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMKTSPM MA Inhibitor DMKTSPM RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMKTSPM RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMKTX1A DI DMKTX1A DMKTX1A DN MCCG DMKTX1A TI TT0I76D DMKTX1A TN Metabotropic glutamate receptor 7 (mGluR7) DMKTX1A MA Antagonist DMKTX1A RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMKTX1A RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMKTZSY DI DMKTZSY DMKTZSY DN 1-(2'-chlorophenyl)penta-1,4-dien-3-one DMKTZSY TI TTRTKPV DMKTZSY TN Trypanosoma Trypanothione reductase (Trypano TPR) DMKTZSY MA Inhibitor DMKTZSY RN Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem. 2005 Nov 17;48(23):7400-10. DMKTZSY RU https://pubmed.ncbi.nlm.nih.gov/16279799 DMKTZSY DI DMKTZSY DMKTZSY DN 1-(2'-chlorophenyl)penta-1,4-dien-3-one DMKTZSY TI TTEP6RV DMKTZSY TN Glutathione reductase (GR) DMKTZSY MA Inhibitor DMKTZSY RN Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate. J Med Chem. 2005 Nov 17;48(23):7400-10. DMKTZSY RU https://pubmed.ncbi.nlm.nih.gov/16279799 DMKU06T DI DMKU06T DMKU06T DN 8-Bromo-6-styryl-naphthalene-2-carboxamidine DMKU06T TI TT2WR1T DMKU06T TN Cationic trypsinogen (PRSS1) DMKU06T MA Inhibitor DMKU06T RN Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8. DMKU06T RU https://pubmed.ncbi.nlm.nih.gov/15582418 DMKU1PN DI DMKU1PN DMKU1PN DN ISIS 4730 DMKU1PN TI TT1PL7M DMKU1PN TN E-selectin messenger RNA (SELE mRNA) DMKU1PN RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMKU1PN RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMKU4TR DI DMKU4TR DMKU4TR DN 4-Butyl-thiazolidin-(2E)-ylideneamine DMKU4TR TI TTZUFI5 DMKU4TR TN Nitric-oxide synthase brain (NOS1) DMKU4TR MA Inhibitor DMKU4TR RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMKU4TR RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMKU4TR DI DMKU4TR DMKU4TR DN 4-Butyl-thiazolidin-(2E)-ylideneamine DMKU4TR TI TTF10I9 DMKU4TR TN Nitric-oxide synthase inducible (NOS2) DMKU4TR MA Inhibitor DMKU4TR RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMKU4TR RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMKU4YQ DI DMKU4YQ DMKU4YQ DN [3H]ZM 241385 DMKU4YQ TI TTNE7KG DMKU4YQ TN Adenosine A2b receptor (ADORA2B) DMKU4YQ MA Antagonist DMKU4YQ RN Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des Discov. 1999 Nov;16(3):217-26. DMKU4YQ RU https://pubmed.ncbi.nlm.nih.gov/10624567 DMKUAEY DI DMKUAEY DMKUAEY DN 4-(3-Adamantan-1-yl-ureido)-benzoic acid DMKUAEY TI TT7WVHI DMKUAEY TN Soluble epoxide hydrolase (EPHX2) DMKUAEY MA Inhibitor DMKUAEY RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMKUAEY RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMKUGH1 DI DMKUGH1 DMKUGH1 DN 17-METHYL-17-ALPHA-DIHYDROEQUILENIN DMKUGH1 TI TTZAYWL DMKUGH1 TN Estrogen receptor (ESR) DMKUGH1 MA Inhibitor DMKUGH1 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKUGH1 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKUHN9 DI DMKUHN9 DMKUHN9 DN 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione DMKUHN9 TI TT2GPK3 DMKUHN9 TN DNA topoisomerase (TOP) DMKUHN9 MA Inhibitor DMKUHN9 RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMKUHN9 RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMKUHN9 DI DMKUHN9 DMKUHN9 DN 6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione DMKUHN9 TI TTIU7X1 DMKUHN9 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMKUHN9 MA Inhibitor DMKUHN9 RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMKUHN9 RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMKUM4L DI DMKUM4L DMKUM4L DN 3-methoxy-4-(oxazol-5-yl)aniline DMKUM4L TI TTTB4UP DMKUM4L TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMKUM4L MA Inhibitor DMKUM4L RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMKUM4L RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMKUT6A DI DMKUT6A DMKUT6A DN 5-HEAT DMKUT6A TI TT0WAIE DMKUT6A TN Melatonin receptor type 1A (MTNR1A) DMKUT6A MA Agonist DMKUT6A RN A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties. J Pineal Res. 2000 Nov;29(4):234-40. DMKUT6A RU https://pubmed.ncbi.nlm.nih.gov/11068946 DMKV17L DI DMKV17L DMKV17L DN 1-phenyl-4-(1-phenyl-1H-tetrazol-5-yl)butan-2-one DMKV17L TI TTN7BL9 DMKV17L TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMKV17L MA Inhibitor DMKV17L RN Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3265-71. DMKV17L RU https://pubmed.ncbi.nlm.nih.gov/20452767 DMKV52P DI DMKV52P DMKV52P DN TK-112690 DMKV52P TI TT9TQRP DMKV52P TN Uridine phosphorylase (UPP) DMKV52P MA Modulator DMKV52P RN CN patent application no. 102014919, Methotrexate adjuvants to reduce toxicity and methods for using the same. DMKV52P RU http://www.google.com/patents/CN102014919B?cl=en DMKV9EZ DI DMKV9EZ DMKV9EZ DN 2,3-Dimethylnaphtho[2,3-f]quinoxaline-7,12-dione DMKV9EZ TI TTQY2EJ DMKV9EZ TN TERT messenger RNA (TERT mRNA) DMKV9EZ MA Inhibitor DMKV9EZ RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMKV9EZ RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMKVA6Z DI DMKVA6Z DMKVA6Z DN FE 999011 DMKVA6Z TI TTDIGC1 DMKVA6Z TN Dipeptidyl peptidase 4 (DPP-4) DMKVA6Z MA Inhibitor DMKVA6Z RN Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes. 2002 May;51(5):1461-9. DMKVA6Z RU https://pubmed.ncbi.nlm.nih.gov/11978643 DMKVDAN DI DMKVDAN DMKVDAN DN Augustic acid DMKVDAN TI TTELIN2 DMKVDAN TN PTPN1 messenger RNA (PTPN1 mRNA) DMKVDAN MA Inhibitor DMKVDAN RN Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6618-22. DMKVDAN RU https://pubmed.ncbi.nlm.nih.gov/19846303 DMKVF5Q DI DMKVF5Q DMKVF5Q DN TCPOBOP DMKVF5Q TI TTRANFM DMKVF5Q TN Orphan nuclear receptor NR1I3 (NR1I3) DMKVF5Q MA Agonist DMKVF5Q RN The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction. J Biol Chem. 2004 May 7;279(19):19832-8. DMKVF5Q RU https://pubmed.ncbi.nlm.nih.gov/15004031 DMKVH90 DI DMKVH90 DMKVH90 DN 4-(2,5-dichlorobenzylthio)-2-aminobutanoic acid DMKVH90 TI TTFK1JQ DMKVH90 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMKVH90 MA Inhibitor DMKVH90 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMKVH90 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMKVONZ DI DMKVONZ DMKVONZ DN PMID20690647C4b DMKVONZ TI TTG5QB7 DMKVONZ TN Calpain-2 (CAPN2) DMKVONZ MA Inhibitor DMKVONZ RN Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. J Med Chem. 2010 Sep 9;53(17):6326-36. DMKVONZ RU https://pubmed.ncbi.nlm.nih.gov/20690647 DMKVPMS DI DMKVPMS DMKVPMS DN KNI-10332 DMKVPMS TI TTXMNHO DMKVPMS TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMKVPMS MA Inhibitor DMKVPMS RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMKVPMS RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMKVTZN DI DMKVTZN DMKVTZN DN Go 6983 DMKVTZN TI TTRFOXJ DMKVTZN TN Protein kinase C gamma (PRKCG) DMKVTZN MA Inhibitor DMKVTZN RN Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80. DMKVTZN RU https://pubmed.ncbi.nlm.nih.gov/8772178 DMKVTZN DI DMKVTZN DMKVTZN DN Go 6983 DMKVTZN TI TTFJ8Q1 DMKVTZN TN Protein kinase C alpha (PRKCA) DMKVTZN MA Inhibitor DMKVTZN RN Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80. DMKVTZN RU https://pubmed.ncbi.nlm.nih.gov/8772178 DMKVTZN DI DMKVTZN DMKVTZN DN Go 6983 DMKVTZN TI TTYPXQF DMKVTZN TN Protein kinase C beta (PRKCB) DMKVTZN MA Inhibitor DMKVTZN RN Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80. DMKVTZN RU https://pubmed.ncbi.nlm.nih.gov/8772178 DMKVTZN DI DMKVTZN DMKVTZN DN Go 6983 DMKVTZN TI TT7A1BO DMKVTZN TN PKC-delta messenger RNA (PRKCD mRNA) DMKVTZN MA Inhibitor DMKVTZN RN Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80. DMKVTZN RU https://pubmed.ncbi.nlm.nih.gov/8772178 DMKVTZN DI DMKVTZN DMKVTZN DN Go 6983 DMKVTZN TI TTBSN0L DMKVTZN TN PKC-zeta messenger RNA (PRKCZ mRNA) DMKVTZN MA Inhibitor DMKVTZN RN Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80. DMKVTZN RU https://pubmed.ncbi.nlm.nih.gov/8772178 DMKVU8P DI DMKVU8P DMKVU8P DN Ac-L-Phe-D-trp-L-Phe-D-pro-NH2 DMKVU8P TI TTKWM86 DMKVU8P TN Opioid receptor mu (MOP) DMKVU8P MA Inhibitor DMKVU8P RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMKVU8P RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMKW0Q3 DI DMKW0Q3 DMKW0Q3 DN eGlu DMKW0Q3 TI TT8A9EF DMKW0Q3 TN Metabotropic glutamate receptor 3 (mGluR3) DMKW0Q3 MA Antagonist DMKW0Q3 RN Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6. DMKW0Q3 RU https://pubmed.ncbi.nlm.nih.gov/10884552 DMKW0Q3 DI DMKW0Q3 DMKW0Q3 DN eGlu DMKW0Q3 TI TTXJ47W DMKW0Q3 TN Metabotropic glutamate receptor 2 (mGluR2) DMKW0Q3 MA Antagonist DMKW0Q3 RN Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6. DMKW0Q3 RU https://pubmed.ncbi.nlm.nih.gov/10884552 DMKW2PE DI DMKW2PE DMKW2PE DN 8-Bromo-9-(2-hydroxypropyl)-9H-adenine DMKW2PE TI TTNE7KG DMKW2PE TN Adenosine A2b receptor (ADORA2B) DMKW2PE MA Inhibitor DMKW2PE RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMKW2PE RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMKW2PE DI DMKW2PE DMKW2PE DN 8-Bromo-9-(2-hydroxypropyl)-9H-adenine DMKW2PE TI TTM2AOE DMKW2PE TN Adenosine A2a receptor (ADORA2A) DMKW2PE MA Inhibitor DMKW2PE RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMKW2PE RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMKW2PE DI DMKW2PE DMKW2PE DN 8-Bromo-9-(2-hydroxypropyl)-9H-adenine DMKW2PE TI TTK25J1 DMKW2PE TN Adenosine A1 receptor (ADORA1) DMKW2PE MA Inhibitor DMKW2PE RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMKW2PE RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMKW5YL DI DMKW5YL DMKW5YL DN VL-0395 DMKW5YL TI TTCG0AL DMKW5YL TN Cholecystokinin receptor type A (CCKAR) DMKW5YL MA Inhibitor DMKW5YL RN 2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'. Bioorg Med Chem. 2009 Jul 15;17(14):5198-206. DMKW5YL RU https://pubmed.ncbi.nlm.nih.gov/19523833 DMKWAV6 DI DMKWAV6 DMKWAV6 DN 3-methyl-2-morpholino-1,1-diphenylbutan-1-ol DMKWAV6 TI TTW0CMT DMKWAV6 TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMKWAV6 MA Inhibitor DMKWAV6 RN Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. DMKWAV6 RU https://pubmed.ncbi.nlm.nih.gov/20304642 DMKWB31 DI DMKWB31 DMKWB31 DN CP55,244 DMKWB31 TI TTNET8J DMKWB31 TN G-protein coupled receptor 55 (GPR55) DMKWB31 MA Agonist DMKWB31 RN Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46. DMKWB31 RU https://pubmed.ncbi.nlm.nih.gov/21233197 DMKWBNA DI DMKWBNA DMKWBNA DN MOD-5023 DMKWBNA TI TTF0EGX DMKWBNA TN Coagulation factor VII (F7) DMKWBNA MA Modulator DMKWBNA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2363). DMKWBNA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2363 DMKWBY8 DI DMKWBY8 DMKWBY8 DN (+/-)-7-fluoro-2-(4-fluorophenyl)chroman-4-one DMKWBY8 TI TTGP7BY DMKWBY8 TN Monoamine oxidase type B (MAO-B) DMKWBY8 MA Inhibitor DMKWBY8 RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMKWBY8 RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMKWEAJ DI DMKWEAJ DMKWEAJ DN (+)-HA966 DMKWEAJ TI TTN9D8E DMKWEAJ TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMKWEAJ MA Agonist DMKWEAJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMKWEAJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMKWEAJ DI DMKWEAJ DMKWEAJ DN (+)-HA966 DMKWEAJ TI TTLD29N DMKWEAJ TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMKWEAJ MA Agonist DMKWEAJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMKWEAJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMKWEAJ DI DMKWEAJ DMKWEAJ DN (+)-HA966 DMKWEAJ TI TTKJEMQ DMKWEAJ TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMKWEAJ MA Agonist DMKWEAJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMKWEAJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMKWIYP DI DMKWIYP DMKWIYP DN (-)-thujaplicatintrimethyl ether DMKWIYP TI TTXV4FI DMKWIYP TN Albendazole monooxygenase (CYP3A4) DMKWIYP MA Inhibitor DMKWIYP RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMKWIYP RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMKWLSB DI DMKWLSB DMKWLSB DN (Z)-7-octedecan-9-ynoic acid DMKWLSB TI TTPADOQ DMKWLSB TN HMG-CoA reductase (HMGCR) DMKWLSB MA Inhibitor DMKWLSB RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DMKWLSB RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DMKWO6A DI DMKWO6A DMKWO6A DN 1-(2-aminoethyl)-1H-indazol-6-ol DMKWO6A TI TTWJBZ5 DMKWO6A TN 5-HT 2C receptor (HTR2C) DMKWO6A MA Inhibitor DMKWO6A RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMKWO6A RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMKWO6A DI DMKWO6A DMKWO6A DN 1-(2-aminoethyl)-1H-indazol-6-ol DMKWO6A TI TTJQOD7 DMKWO6A TN 5-HT 2A receptor (HTR2A) DMKWO6A MA Inhibitor DMKWO6A RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMKWO6A RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMKWO6A DI DMKWO6A DMKWO6A DN 1-(2-aminoethyl)-1H-indazol-6-ol DMKWO6A TI TT0K1SC DMKWO6A TN 5-HT 2B receptor (HTR2B) DMKWO6A MA Inhibitor DMKWO6A RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMKWO6A RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMKWQ52 DI DMKWQ52 DMKWQ52 DN MA-2029 DMKWQ52 TI TT953CX DMKWQ52 TN Motilin receptor (MLNR) DMKWQ52 MA Antagonist DMKWQ52 RN Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits. Eur J Pharmacol. 2008 Mar10;581(3):296-305. DMKWQ52 RU https://pubmed.ncbi.nlm.nih.gov/18164286 DMKWRCD DI DMKWRCD DMKWRCD DN 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine DMKWRCD TI TTAWNKZ DMKWRCD TN Norepinephrine transporter (NET) DMKWRCD MA Inhibitor DMKWRCD RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMKWRCD RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMKWRCD DI DMKWRCD DMKWRCD DN 1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine DMKWRCD TI TT3ROYC DMKWRCD TN Serotonin transporter (SERT) DMKWRCD MA Inhibitor DMKWRCD RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMKWRCD RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMKWRFA DI DMKWRFA DMKWRFA DN (2E)-3-(2-OCT-1-YN-1-YLPHENYL)ACRYLIC ACID DMKWRFA TI TTN9T81 DMKWRFA TN Arachidonate 15-lipoxygenase (15-LOX) DMKWRFA MA Inhibitor DMKWRFA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMKWRFA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMKWT6F DI DMKWT6F DMKWT6F DN ISIS 1753 DMKWT6F TI TTF3I4E DMKWT6F TN Human papillomavirus E2 region messenger RNA (HPV E2 mRNA) DMKWT6F RN US patent application no. 5,665,580, Antisense oligonucleotide inhibition of papillomavirus transformed cells. DMKWT6F RU http://www.patentbuddy.com/Patent/5665580?ft=true&sr=true DMKWYJX DI DMKWYJX DMKWYJX DN 8-Propionyl-7-propoxy-2H-chromen-2-one DMKWYJX TI TT2LVK8 DMKWYJX TN Carbonic anhydrase IX (CA-IX) DMKWYJX MA Inhibitor DMKWYJX RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMKWYJX RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMKWYMP DI DMKWYMP DMKWYMP DN N-(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate DMKWYMP TI TTA93TL DMKWYMP TN P2Y purinoceptor 1 (P2RY1) DMKWYMP MA Antagonist DMKWYMP RN Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation. 2001 Feb 6;103(5):718-23. DMKWYMP RU https://pubmed.ncbi.nlm.nih.gov/11156884 DMKX6LY DI DMKX6LY DMKX6LY DN BPL-001 DMKX6LY TI TTPADOQ DMKX6LY TN HMG-CoA reductase (HMGCR) DMKX6LY MA Inhibitor DMKX6LY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639). DMKX6LY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639 DMKXEQ6 DI DMKXEQ6 DMKXEQ6 DN Salvinorin B benzyloxymethyl ether DMKXEQ6 TI TTQW87Y DMKXEQ6 TN Opioid receptor kappa (OPRK1) DMKXEQ6 MA Inhibitor DMKXEQ6 RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMKXEQ6 RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMKXFDA DI DMKXFDA DMKXFDA DN 2,2-difluoromevalonate 5-diphosphate DMKXFDA TI TTE5J6X DMKXFDA TN Diphosphomevalonate decarboxylase (MVD) DMKXFDA MA Inhibitor DMKXFDA RN Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6164-8. DMKXFDA RU https://pubmed.ncbi.nlm.nih.gov/17888661 DMKXG3V DI DMKXG3V DMKXG3V DN MESUAGENIN B DMKXG3V TI TT1RS9F DMKXG3V TN Acetylcholinesterase (AChE) DMKXG3V MA Inhibitor DMKXG3V RN 4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg Med Chem. 2010 Nov 15;18(22):7873-7. DMKXG3V RU https://pubmed.ncbi.nlm.nih.gov/20943395 DMKXIWQ DI DMKXIWQ DMKXIWQ DN 5,7-Diphenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ol DMKXIWQ TI TT6PKBN DMKXIWQ TN Proto-oncogene c-Src (SRC) DMKXIWQ MA Inhibitor DMKXIWQ RN Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9. DMKXIWQ RU https://pubmed.ncbi.nlm.nih.gov/10853665 DMKXNP0 DI DMKXNP0 DMKXNP0 DN 6-(2-Phenylsulfanyl-ethyl)-pteridine-2,4-diamine DMKXNP0 TI TT9SL3Q DMKXNP0 TN Polypeptide deformylase (PDF) DMKXNP0 MA Inhibitor DMKXNP0 RN Further studies on 2,4-diamino-5-(2',5'-disubstituted benzyl)pyrimidines as potent and selective inhibitors of dihydrofolate reductases from three ... J Med Chem. 2003 Apr 24;46(9):1726-36. DMKXNP0 RU https://pubmed.ncbi.nlm.nih.gov/12699390 DMKXPOL DI DMKXPOL DMKXPOL DN GSK189254A DMKXPOL TI TT9JNIC DMKXPOL TN Histamine H3 receptor (H3R) DMKXPOL MA Antagonist DMKXPOL RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMKXPOL RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMKY5LI DI DMKY5LI DMKY5LI DN ISIS 133206 DMKY5LI TI TTZN92A DMKY5LI TN DUSP5 messenger RNA (DUSP5 mRNA) DMKY5LI RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DMKY5LI RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DMKY6CU DI DMKY6CU DMKY6CU DN CGS-9895 DMKY6CU TI TT06RH5 DMKY6CU TN GABA(A) receptor gamma-2 (GABRG2) DMKY6CU MA Inhibitor DMKY6CU RN 1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. J Med Chem. 1987 Oct;30(10):1737-42. DMKY6CU RU https://pubmed.ncbi.nlm.nih.gov/2821257 DMKY6CU DI DMKY6CU DMKY6CU DN CGS-9895 DMKY6CU TI TTNJYV2 DMKY6CU TN Gamma-aminobutyric acid receptor (GAR) DMKY6CU MA Inhibitor DMKY6CU RN 1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. J Med Chem. 1987 Oct;30(10):1737-42. DMKY6CU RU https://pubmed.ncbi.nlm.nih.gov/2821257 DMKY6CU DI DMKY6CU DMKY6CU DN CGS-9895 DMKY6CU TI TT1MPAY DMKY6CU TN GABA(A) receptor alpha-1 (GABRA1) DMKY6CU MA Inhibitor DMKY6CU RN 1,3-Diarylpyrazolo[4,5-c]- and -[5,4-c]quinolin-4-ones. 4. Synthesis and specific inhibition of benzodiazepine receptor binding. J Med Chem. 1987 Oct;30(10):1737-42. DMKY6CU RU https://pubmed.ncbi.nlm.nih.gov/2821257 DMKY71Z DI DMKY71Z DMKY71Z DN 2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole DMKY71Z TI TTGP7BY DMKY71Z TN Monoamine oxidase type B (MAO-B) DMKY71Z MA Inhibitor DMKY71Z RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMKY71Z RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMKY71Z DI DMKY71Z DMKY71Z DN 2-(naphthalen-2-yl)-4,5-dihydro-1H-imidazole DMKY71Z TI TT3WG5C DMKY71Z TN Monoamine oxidase type A (MAO-A) DMKY71Z MA Inhibitor DMKY71Z RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMKY71Z RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMKY7T8 DI DMKY7T8 DMKY7T8 DN Adenosine-5'-Rp-Alpha-Thio-Triphosphate DMKY7T8 TI TT2QM9D DMKY7T8 TN Adenylate cyclase (ADCY) DMKY7T8 MA Inhibitor DMKY7T8 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMKY7T8 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMKY9G5 DI DMKY9G5 DMKY9G5 DN A412997 DMKY9G5 TI TTE0A2F DMKY9G5 TN Dopamine D4 receptor (D4R) DMKY9G5 MA Agonist DMKY9G5 RN A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol Biochem Behav. 2005 Sep;82(1):140-7. DMKY9G5 RU https://pubmed.ncbi.nlm.nih.gov/16153699 DMKYB4D DI DMKYB4D DMKYB4D DN 4-((+/-)-(1H-imidazol-1-yl)-(E)-retinoic acid DMKYB4D TI TTD7Q0R DMKYB4D TN Cytochrome P450 26 (CYP26A1) DMKYB4D MA Inhibitor DMKYB4D RN Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and pros... J Med Chem. 2004 Dec 30;47(27):6716-29. DMKYB4D RU https://pubmed.ncbi.nlm.nih.gov/15615521 DMKYE16 DI DMKYE16 DMKYE16 DN 1,3-Diethyl-3,7-dihydro-purine-2,6-dione DMKYE16 TI TTK25J1 DMKYE16 TN Adenosine A1 receptor (ADORA1) DMKYE16 MA Inhibitor DMKYE16 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMKYE16 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMKYE16 DI DMKYE16 DMKYE16 DN 1,3-Diethyl-3,7-dihydro-purine-2,6-dione DMKYE16 TI TTNE7KG DMKYE16 TN Adenosine A2b receptor (ADORA2B) DMKYE16 MA Inhibitor DMKYE16 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMKYE16 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMKYE16 DI DMKYE16 DMKYE16 DN 1,3-Diethyl-3,7-dihydro-purine-2,6-dione DMKYE16 TI TTM2AOE DMKYE16 TN Adenosine A2a receptor (ADORA2A) DMKYE16 MA Inhibitor DMKYE16 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMKYE16 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMKYF5U DI DMKYF5U DMKYF5U DN Piperidine-1-carboxamidine DMKYF5U TI TT2WR1T DMKYF5U TN Cationic trypsinogen (PRSS1) DMKYF5U MA Inhibitor DMKYF5U RN GRID/CPCA: a new computational tool to design selective ligands. J Med Chem. 2000 Aug 10;43(16):3033-44. DMKYF5U RU https://pubmed.ncbi.nlm.nih.gov/10956211 DMKYNGE DI DMKYNGE DMKYNGE DN RX-1792 DMKYNGE TI TTGKNB4 DMKYNGE TN Epidermal growth factor receptor (EGFR) DMKYNGE MA Antagonist DMKYNGE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMKYNGE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMKYPUW DI DMKYPUW DMKYPUW DN 3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione DMKYPUW TI TTJFY5U DMKYPUW TN Adenosine A3 receptor (ADORA3) DMKYPUW MA Inhibitor DMKYPUW RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMKYPUW RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMKYPUW DI DMKYPUW DMKYPUW DN 3-Methyl-1-phenethyl-3,7-dihydro-purine-2,6-dione DMKYPUW TI TTNE7KG DMKYPUW TN Adenosine A2b receptor (ADORA2B) DMKYPUW MA Inhibitor DMKYPUW RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMKYPUW RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMKYQWG DI DMKYQWG DMKYQWG DN NORHARMANE DMKYQWG TI TT1MPAY DMKYQWG TN GABA(A) receptor alpha-1 (GABRA1) DMKYQWG MA Inhibitor DMKYQWG RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMKYQWG RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMKYQWG DI DMKYQWG DMKYQWG DN NORHARMANE DMKYQWG TI TTNJYV2 DMKYQWG TN Gamma-aminobutyric acid receptor (GAR) DMKYQWG MA Inhibitor DMKYQWG RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMKYQWG RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMKYWQ2 DI DMKYWQ2 DMKYWQ2 DN ISIS 140148 DMKYWQ2 TI TTAK0IN DMKYWQ2 TN SOAT2 messenger RNA (SOAT2 mRNA) DMKYWQ2 RN US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression. DMKYWQ2 RU http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true DMKYXJW DI DMKYXJW DMKYXJW DN Dorsomorphin DMKYXJW TI TTLAFZV DMKYXJW TN AMP-activated protein kinase (AMPK) DMKYXJW MA Inhibitor DMKYXJW RN The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular a... Bioorg Med Chem Lett. 2010 Nov 15;20(22):6394-9. DMKYXJW RU https://pubmed.ncbi.nlm.nih.gov/20932747 DMKYZGD DI DMKYZGD DMKYZGD DN 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol DMKYZGD TI TTJQOD7 DMKYZGD TN 5-HT 2A receptor (HTR2A) DMKYZGD MA Inhibitor DMKYZGD RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMKYZGD RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMKYZGD DI DMKYZGD DMKYZGD DN 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol DMKYZGD TI TT0K1SC DMKYZGD TN 5-HT 2B receptor (HTR2B) DMKYZGD MA Inhibitor DMKYZGD RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMKYZGD RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMKYZGD DI DMKYZGD DMKYZGD DN 3-(2-Dimethylamino-ethyl)-1-methyl-1H-indol-4-ol DMKYZGD TI TTWJBZ5 DMKYZGD TN 5-HT 2C receptor (HTR2C) DMKYZGD MA Inhibitor DMKYZGD RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMKYZGD RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMKZ32J DI DMKZ32J DMKZ32J DN Cis-2-phenylcyclopropylamine DMKZ32J TI TT3WG5C DMKZ32J TN Monoamine oxidase type A (MAO-A) DMKZ32J MA Inhibitor DMKZ32J RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMKZ32J RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMKZ32J DI DMKZ32J DMKZ32J DN Cis-2-phenylcyclopropylamine DMKZ32J TI TTGP7BY DMKZ32J TN Monoamine oxidase type B (MAO-B) DMKZ32J MA Inhibitor DMKZ32J RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMKZ32J RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMKZ4C6 DI DMKZ4C6 DMKZ4C6 DN (R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine DMKZ4C6 TI TTWJBZ5 DMKZ4C6 TN 5-HT 2C receptor (HTR2C) DMKZ4C6 MA Inhibitor DMKZ4C6 RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMKZ4C6 RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMKZ4C6 DI DMKZ4C6 DMKZ4C6 DN (R,S)-1-(5-bromo-1H-indol-1-yl)propan-2-amine DMKZ4C6 TI TTJQOD7 DMKZ4C6 TN 5-HT 2A receptor (HTR2A) DMKZ4C6 MA Inhibitor DMKZ4C6 RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMKZ4C6 RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMKZ6JW DI DMKZ6JW DMKZ6JW DN 4-(2-(3,4-Dimethylphenylamino)ethyl)-1H-imidazole DMKZ6JW TI TT9JNIC DMKZ6JW TN Histamine H3 receptor (H3R) DMKZ6JW MA Inhibitor DMKZ6JW RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMKZ6JW RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMKZDYP DI DMKZDYP DMKZDYP DN 3-Benzyl-5-isopropyl-8-methylchromen-2-one DMKZDYP TI TT6OEDT DMKZDYP TN Cannabinoid receptor 1 (CB1) DMKZDYP MA Inhibitor DMKZDYP RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMKZDYP RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMKZDYP DI DMKZDYP DMKZDYP DN 3-Benzyl-5-isopropyl-8-methylchromen-2-one DMKZDYP TI TTMSFAW DMKZDYP TN Cannabinoid receptor 2 (CB2) DMKZDYP MA Inhibitor DMKZDYP RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMKZDYP RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMKZF01 DI DMKZF01 DMKZF01 DN UFP-101 DMKZF01 TI TTNT7K8 DMKZF01 TN Nociceptin receptor (OPRL1) DMKZF01 MA Antagonist DMKZF01 RN Nphe1,Arg14,Lys15nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. Br J Pharmacol. 2002 May;136(2):303-11. DMKZF01 RU https://pubmed.ncbi.nlm.nih.gov/12010780 DMKZIES DI DMKZIES DMKZIES DN Chloroethylclonidine DMKZIES TI TTWG9A4 DMKZIES TN Adrenergic receptor alpha-2A (ADRA2A) DMKZIES MA Agonist DMKZIES RN Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165-70. DMKZIES RU https://pubmed.ncbi.nlm.nih.gov/8264553 DMKZIES DI DMKZIES DMKZIES DN Chloroethylclonidine DMKZIES TI TT2NUT5 DMKZIES TN Adrenergic receptor alpha-2C (ADRA2C) DMKZIES MA Agonist DMKZIES RN Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165-70. DMKZIES RU https://pubmed.ncbi.nlm.nih.gov/8264553 DMKZJ1V DI DMKZJ1V DMKZJ1V DN 4-nitrobenzo[c][1,2,5]thiadiazole DMKZJ1V TI TTEP6RV DMKZJ1V TN Glutathione reductase (GR) DMKZJ1V MA Inhibitor DMKZJ1V RN Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92. DMKZJ1V RU https://pubmed.ncbi.nlm.nih.gov/16458512 DMKZJ7T DI DMKZJ7T DMKZJ7T DN GINKGOLIDE A DMKZJ7T TI TTZ8EM9 DMKZJ7T TN Glycine receptor (GlyR) DMKZJ7T MA Inhibitor DMKZJ7T RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMKZJ7T RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMKZJ7T DI DMKZJ7T DMKZJ7T DN GINKGOLIDE A DMKZJ7T TI TTF45NW DMKZJ7T TN Strychnine-binding glycine receptor (GLRA1) DMKZJ7T MA Inhibitor DMKZJ7T RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMKZJ7T RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMKZJVA DI DMKZJVA DMKZJVA DN LY214352 DMKZJVA TI TT3PQ2Y DMKZJVA TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMKZJVA MA Inhibitor DMKZJVA RN Identification of a new antifungal target site through a dual biochemical and molecular-genetics approach. Curr Genet. 1996 Jul 31;30(2):159-65. DMKZJVA RU https://pubmed.ncbi.nlm.nih.gov/8660469 DMKZJWV DI DMKZJWV DMKZJWV DN ST-1093 DMKZJWV TI TT9JNIC DMKZJWV TN Histamine H3 receptor (H3R) DMKZJWV MA Inhibitor DMKZJWV RN Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5883-6. DMKZJWV RU https://pubmed.ncbi.nlm.nih.gov/20727744 DMKZL5H DI DMKZL5H DMKZL5H DN N-Methylmesoporphyrin Containing Copper DMKZL5H TI TTQ6VF4 DMKZL5H TN Ferrochelatase (FECH) DMKZL5H MA Inhibitor DMKZL5H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMKZL5H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMKZM1L DI DMKZM1L DMKZM1L DN Brutieridin DMKZM1L TI TTPADOQ DMKZM1L TN HMG-CoA reductase (HMGCR) DMKZM1L MA Inhibitor DMKZM1L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639). DMKZM1L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639 DMKZQ3I DI DMKZQ3I DMKZQ3I DN 4-iodo-1H-indazole DMKZQ3I TI TTZUFI5 DMKZQ3I TN Nitric-oxide synthase brain (NOS1) DMKZQ3I MA Inhibitor DMKZQ3I RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DMKZQ3I RU https://pubmed.ncbi.nlm.nih.gov/17395463 DMKZUWY DI DMKZUWY DMKZUWY DN 4-Nitro-N-(4-phenyl-thiazol-2-yl)-benzamide DMKZUWY TI TTK25J1 DMKZUWY TN Adenosine A1 receptor (ADORA1) DMKZUWY MA Inhibitor DMKZUWY RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMKZUWY RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMKZVEQ DI DMKZVEQ DMKZVEQ DN SM-130,686 DMKZVEQ TI TTWDC17 DMKZVEQ TN Growth hormone secretagogue receptor 1 (GHSR) DMKZVEQ MA Agonist DMKZVEQ RN Oxindole derivatives as orally active potent growth hormone secretagogues. J Med Chem. 2001 Dec 20;44(26):4641-9. DMKZVEQ RU https://pubmed.ncbi.nlm.nih.gov/11741481 DMKZXV3 DI DMKZXV3 DMKZXV3 DN C[Glu24-Lys28][Gly8]GLP-1(7-37)-NH2 DMKZXV3 TI TTVIMDE DMKZXV3 TN Glucagon-like peptide 1 receptor (GLP1R) DMKZXV3 MA Inhibitor DMKZXV3 RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMKZXV3 RU https://pubmed.ncbi.nlm.nih.gov/18412318 DML01Y7 DI DML01Y7 DML01Y7 DN TAT-120 DML01Y7 TI TTCPLVN DML01Y7 TN MST-1 protein kinase (STK4) DML01Y7 MA Inhibitor DML01Y7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2225). DML01Y7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2225 DML09OS DI DML09OS DML09OS DN GRL-0667 DML09OS TI TTRGHB2 DML09OS TN SARS-CoV papain-like proteinase (PL-PRO) DML09OS MA Inhibitor DML09OS RN Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biologic... J Med Chem. 2010 Jul 8;53(13):4968-79. DML09OS RU https://pubmed.ncbi.nlm.nih.gov/20527968 DML0GZ2 DI DML0GZ2 DML0GZ2 DN Lead acetate DML0GZ2 TI TTQ6VF4 DML0GZ2 TN Ferrochelatase (FECH) DML0GZ2 MA Inhibitor DML0GZ2 RN Ferrochelatase, a novel target for photodynamic therapy of cancer. Oncol Rep. 1999 Nov-Dec;6(6):1439-42. DML0GZ2 RU https://pubmed.ncbi.nlm.nih.gov/10523727 DML0ME9 DI DML0ME9 DML0ME9 DN 3-Benzyl-4-hydroxy-6,7-dimethyl-2H-chromen-2-one DML0ME9 TI TT8XK6L DML0ME9 TN Quinone reductase 1 (NQO1) DML0ME9 MA Inhibitor DML0ME9 RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DML0ME9 RU https://pubmed.ncbi.nlm.nih.gov/19877692 DML0N7D DI DML0N7D DML0N7D DN NS 2028 DML0N7D TI TTWNFC2 DML0N7D TN Soluble guanylyl cyclase (GUCY2D) DML0N7D MA Inhibitor DML0N7D RN Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase. Br J Pharmacol. 1998 Jan;123(2):299-309. DML0N7D RU https://pubmed.ncbi.nlm.nih.gov/9489619 DML0OUY DI DML0OUY DML0OUY DN Gelsolin DML0OUY TI TTE4KHA DML0OUY TN Amyloid beta A4 protein (APP) DML0OUY RN Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003 Jan 1;23(1):29-33. DML0OUY RU https://pubmed.ncbi.nlm.nih.gov/12514198 DML0P72 DI DML0P72 DML0P72 DN O-arachidonoyl ethanolamine DML0P72 TI TTNET8J DML0P72 TN G-protein coupled receptor 55 (GPR55) DML0P72 MA Agonist DML0P72 RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DML0P72 RU https://pubmed.ncbi.nlm.nih.gov/17876302 DML0PFU DI DML0PFU DML0PFU DN PMID24997608CA DML0PFU TI TT08JVB DML0PFU TN G-protein coupled receptor 120 (GPR120) DML0PFU MA Agonist DML0PFU RN A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. 2014 Aug;20(8):942-7. DML0PFU RU https://pubmed.ncbi.nlm.nih.gov/24997608 DML0S7V DI DML0S7V DML0S7V DN IRL-1841 DML0S7V TI TT3ZTGU DML0S7V TN Endothelin B receptor (EDNRB) DML0S7V MA Inhibitor DML0S7V RN IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996). DML0S7V RU http://www.sciencedirect.com/science/article/pii/0960894X96004210 DML0S8M DI DML0S8M DML0S8M DN 2-chloro-6(methylamino)purine DML0S8M TI TT7RJY8 DML0S8M TN Xanthine dehydrogenase/oxidase (XDH) DML0S8M MA Inhibitor DML0S8M RN The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors. Bioorg Med Chem. 2007 May 15;15(10):3450-6. DML0S8M RU https://pubmed.ncbi.nlm.nih.gov/17379526 DML0U8B DI DML0U8B DML0U8B DN C-[-Arg-Gly-Asp-Acpca30-] DML0U8B TI TTT1R2L DML0U8B TN Integrin alpha-V (ITGAV) DML0U8B MA Inhibitor DML0U8B RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DML0U8B RU https://pubmed.ncbi.nlm.nih.gov/16302808 DML0U8B DI DML0U8B DML0U8B DN C-[-Arg-Gly-Asp-Acpca30-] DML0U8B TI TTJA1ZO DML0U8B TN ITGB3 messenger RNA (ITGB3 mRNA) DML0U8B MA Inhibitor DML0U8B RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DML0U8B RU https://pubmed.ncbi.nlm.nih.gov/16302808 DML0YEK DI DML0YEK DML0YEK DN Catechol DML0YEK TI TTUNARX DML0YEK TN Carbonic anhydrase (CA) DML0YEK MA Inhibitor DML0YEK RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DML0YEK RU https://pubmed.ncbi.nlm.nih.gov/20185318 DML0YEK DI DML0YEK DML0YEK DN Catechol DML0YEK TI TTZHA0O DML0YEK TN Carbonic anhydrase IV (CA-IV) DML0YEK MA Inhibitor DML0YEK RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DML0YEK RU https://pubmed.ncbi.nlm.nih.gov/20185318 DML0YEK DI DML0YEK DML0YEK DN Catechol DML0YEK TI TTANPDJ DML0YEK TN Carbonic anhydrase II (CA-II) DML0YEK MA Inhibitor DML0YEK RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DML0YEK RU https://pubmed.ncbi.nlm.nih.gov/20185318 DML0YEK DI DML0YEK DML0YEK DN Catechol DML0YEK TI TTSYM0R DML0YEK TN Carbonic anhydrase XII (CA-XII) DML0YEK MA Inhibitor DML0YEK RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DML0YEK RU https://pubmed.ncbi.nlm.nih.gov/20185318 DML10NT DI DML10NT DML10NT DN N-(biphenyl-4-yl)benzo[d]isoxazol-3-amine DML10NT TI TT7WVHI DML10NT TN Soluble epoxide hydrolase (EPHX2) DML10NT MA Inhibitor DML10NT RN A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21. DML10NT RU https://pubmed.ncbi.nlm.nih.gov/19700315 DML16BT DI DML16BT DML16BT DN Z-Ala-Leu-Phe-Agly-Ile-Val-OMe DML16BT TI TTDZN01 DML16BT TN Cathepsin K (CTSK) DML16BT MA Inhibitor DML16BT RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DML16BT RU https://pubmed.ncbi.nlm.nih.gov/12213061 DML16BT DI DML16BT DML16BT DN Z-Ala-Leu-Phe-Agly-Ile-Val-OMe DML16BT TI TTF2LRI DML16BT TN Cathepsin B (CTSB) DML16BT MA Inhibitor DML16BT RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DML16BT RU https://pubmed.ncbi.nlm.nih.gov/12213061 DML1G9S DI DML1G9S DML1G9S DN 4-(isopentylthio)-2-methoxybenzonitrile DML1G9S TI TTKPW01 DML1G9S TN Androgen receptor messenger RNA (AR mRNA) DML1G9S MA Inhibitor DML1G9S RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DML1G9S RU https://pubmed.ncbi.nlm.nih.gov/19201190 DML1GP5 DI DML1GP5 DML1GP5 DN (S-(2-oxo)pentadecyl-CoA) DML1GP5 TI TTBAF05 DML1GP5 TN Candida Peptide N-myristoyltransferase (Candi NMT1) DML1GP5 MA Inhibitor DML1GP5 RN Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-... J Biol Chem. 2007 Jul 27;282(30):22185-94. DML1GP5 RU https://pubmed.ncbi.nlm.nih.gov/17513302 DML1JY4 DI DML1JY4 DML1JY4 DN YIL781 DML1JY4 TI TTWDC17 DML1JY4 TN Growth hormone secretagogue receptor 1 (GHSR) DML1JY4 MA Antagonist DML1JY4 RN Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss. Endocrinology. 2007 Nov;148(11):5175-85. DML1JY4 RU https://pubmed.ncbi.nlm.nih.gov/17656463 DML1K07 DI DML1K07 DML1K07 DN XV454 DML1K07 TI TT38RM1 DML1K07 TN Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DML1K07 MA Antagonist DML1K07 RN Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003 Sep;90(3):549-54. DML1K07 RU https://pubmed.ncbi.nlm.nih.gov/12958625 DML1PV3 DI DML1PV3 DML1PV3 DN Aom-0763 DML1PV3 TI TT7RJY8 DML1PV3 TN Xanthine dehydrogenase/oxidase (XDH) DML1PV3 MA Inhibitor DML1PV3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2646). DML1PV3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2646 DML1UMX DI DML1UMX DML1UMX DN JWH-253 DML1UMX TI TTMSFAW DML1UMX TN Cannabinoid receptor 2 (CB2) DML1UMX MA Inhibitor DML1UMX RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DML1UMX RU https://pubmed.ncbi.nlm.nih.gov/16005223 DML1W5Z DI DML1W5Z DML1W5Z DN 2-biphenyl-4-yl-6-morpholin-4-yl-pyran-4-one DML1W5Z TI TTK3PY9 DML1W5Z TN DNA-dependent protein kinase catalytic (PRKDC) DML1W5Z MA Inhibitor DML1W5Z RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DML1W5Z RU https://pubmed.ncbi.nlm.nih.gov/17371003 DML20N9 DI DML20N9 DML20N9 DN A-80040 DML20N9 TI TTYAWV0 DML20N9 TN Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) DML20N9 MA Inhibitor DML20N9 RN Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acet... J Med Chem. 2006 Jun 29;49(13):3770-3. DML20N9 RU https://pubmed.ncbi.nlm.nih.gov/16789734 DML20N9 DI DML20N9 DML20N9 DN A-80040 DML20N9 TI TTY84UG DML20N9 TN Acetyl-CoA carboxylase 2 (ACACB) DML20N9 MA Inhibitor DML20N9 RN Synthesis and structure-activity relationships of N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1- methylprop-2-ynyl}carboxy derivatives as selective acet... J Med Chem. 2006 Jun 29;49(13):3770-3. DML20N9 RU https://pubmed.ncbi.nlm.nih.gov/16789734 DML27CG DI DML27CG DML27CG DN N-Hexylcarbamic Acid Biphenyl-3-yl Ester DML27CG TI TTDP1UC DML27CG TN Fatty acid amide hydrolase (FAAH) DML27CG MA Inhibitor DML27CG RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DML27CG RU https://pubmed.ncbi.nlm.nih.gov/18507372 DML2AC1 DI DML2AC1 DML2AC1 DN 6-Dimethylamino-2-methyl-hex-4-ynal oxime DML2AC1 TI TTQ3JTF DML2AC1 TN Muscarinic acetylcholine receptor M4 (CHRM4) DML2AC1 MA Inhibitor DML2AC1 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DML2AC1 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DML2AC1 DI DML2AC1 DML2AC1 DN 6-Dimethylamino-2-methyl-hex-4-ynal oxime DML2AC1 TI TTH18TF DML2AC1 TN Muscarinic acetylcholine receptor M5 (CHRM5) DML2AC1 MA Inhibitor DML2AC1 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DML2AC1 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DML2AC1 DI DML2AC1 DML2AC1 DN 6-Dimethylamino-2-methyl-hex-4-ynal oxime DML2AC1 TI TTYEG6Q DML2AC1 TN Muscarinic acetylcholine receptor M2 (CHRM2) DML2AC1 MA Inhibitor DML2AC1 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DML2AC1 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DML2AC1 DI DML2AC1 DML2AC1 DN 6-Dimethylamino-2-methyl-hex-4-ynal oxime DML2AC1 TI TTZ9SOR DML2AC1 TN Muscarinic acetylcholine receptor M1 (CHRM1) DML2AC1 MA Inhibitor DML2AC1 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DML2AC1 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DML2AC1 DI DML2AC1 DML2AC1 DN 6-Dimethylamino-2-methyl-hex-4-ynal oxime DML2AC1 TI TTQ13Z5 DML2AC1 TN Muscarinic acetylcholine receptor M3 (CHRM3) DML2AC1 MA Inhibitor DML2AC1 RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DML2AC1 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DML2B04 DI DML2B04 DML2B04 DN DIOXINODEHYDROECKOL DML2B04 TI TT8JRS7 DML2B04 TN Beta-secretase (BACE) DML2B04 MA Inhibitor DML2B04 RN Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5. DML2B04 RU https://pubmed.ncbi.nlm.nih.gov/20462757 DML2EF4 DI DML2EF4 DML2EF4 DN 4'-(Benzensulfonamide)-4-hydroxychalcone DML2EF4 TI TTULVH8 DML2EF4 TN Tyrosinase (TYR) DML2EF4 MA Inhibitor DML2EF4 RN Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7. DML2EF4 RU https://pubmed.ncbi.nlm.nih.gov/20149498 DML2F3N DI DML2F3N DML2F3N DN ISIS 25125 DML2F3N TI TT8H9GB DML2F3N TN MEK2 messenger RNA (MEK2 mRNA) DML2F3N RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DML2F3N RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DML2GFB DI DML2GFB DML2GFB DN medica 16 DML2GFB TI TTB8FUC DML2GFB TN Free fatty acid receptor 1 (GPR40) DML2GFB MA Agonist DML2GFB RN A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun. 2003 Feb 7;301(2):406-10. DML2GFB RU https://pubmed.ncbi.nlm.nih.gov/12565875 DML2MAI DI DML2MAI DML2MAI DN ATRIPLICIOLIDTIGLATE DML2MAI TI TTSXVID DML2MAI TN Nuclear factor NF-kappa-B (NFKB) DML2MAI MA Inhibitor DML2MAI RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DML2MAI RU https://pubmed.ncbi.nlm.nih.gov/15537359 DML2UCP DI DML2UCP DML2UCP DN 3-aminobenzo[c][1,5]naphthyridin-6(5H)-one DML2UCP TI TTVDSZ0 DML2UCP TN Poly [ADP-ribose] polymerase 1 (PARP1) DML2UCP MA Inhibitor DML2UCP RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DML2UCP RU https://pubmed.ncbi.nlm.nih.gov/19125579 DML2V1I DI DML2V1I DML2V1I DN Sp7343-Sp7964 DML2V1I TI TTELIN2 DML2V1I TN PTPN1 messenger RNA (PTPN1 mRNA) DML2V1I MA Inhibitor DML2V1I RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML2V1I RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML357W DI DML357W DML357W DN 4-(4-hydroxybenzylideneamino)benzoic acid DML357W TI TTANPDJ DML357W TN Carbonic anhydrase II (CA-II) DML357W MA Inhibitor DML357W RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DML357W RU https://pubmed.ncbi.nlm.nih.gov/19796939 DML35GB DI DML35GB DML35GB DN N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE DML35GB TI TT8JRS7 DML35GB TN Beta-secretase (BACE) DML35GB MA Inhibitor DML35GB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DML35GB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DML36ZE DI DML36ZE DML36ZE DN LY-292223 DML36ZE TI TTL69WB DML36ZE TN Angiotensin-converting enzyme (ACE) DML36ZE MA Inhibitor DML36ZE RN Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem. 2005 Jan 27;48(2):483-98. DML36ZE RU https://pubmed.ncbi.nlm.nih.gov/15658862 DML36ZE DI DML36ZE DML36ZE DN LY-292223 DML36ZE TI TTGBPJE DML36ZE TN PI3-kinase delta (PIK3CD) DML36ZE MA Inhibitor DML36ZE RN LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. DML36ZE RU https://pubmed.ncbi.nlm.nih.gov/11294389 DML36ZE DI DML36ZE DML36ZE DN LY-292223 DML36ZE TI TTQ9RYT DML36ZE TN Endothelin-converting enzyme 1 (ECE1) DML36ZE MA Inhibitor DML36ZE RN Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem. 2005 Jan 27;48(2):483-98. DML36ZE RU https://pubmed.ncbi.nlm.nih.gov/15658862 DML36ZE DI DML36ZE DML36ZE DN LY-292223 DML36ZE TI TTHBTOP DML36ZE TN PI3-kinase gamma (PIK3CG) DML36ZE MA Inhibitor DML36ZE RN LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. DML36ZE RU https://pubmed.ncbi.nlm.nih.gov/11294389 DML36ZE DI DML36ZE DML36ZE DN LY-292223 DML36ZE TI TTK3PY9 DML36ZE TN DNA-dependent protein kinase catalytic (PRKDC) DML36ZE MA Inhibitor DML36ZE RN Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6083-7. DML36ZE RU https://pubmed.ncbi.nlm.nih.gov/15546735 DML36ZE DI DML36ZE DML36ZE DN LY-292223 DML36ZE TI TT9H4P3 DML36ZE TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DML36ZE MA Inhibitor DML36ZE RN LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg Med Chem Lett. 2001 Apr 9;11(7):909-13. DML36ZE RU https://pubmed.ncbi.nlm.nih.gov/11294389 DML39UW DI DML39UW DML39UW DN 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine DML39UW TI TTM2AOE DML39UW TN Adenosine A2a receptor (ADORA2A) DML39UW MA Inhibitor DML39UW RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DML39UW RU https://pubmed.ncbi.nlm.nih.gov/17378544 DML39UW DI DML39UW DML39UW DN 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine DML39UW TI TTK25J1 DML39UW TN Adenosine A1 receptor (ADORA1) DML39UW MA Inhibitor DML39UW RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DML39UW RU https://pubmed.ncbi.nlm.nih.gov/17378544 DML39UW DI DML39UW DML39UW DN 2-(3''-(6''-chloro-indolyl)ethyloxy)adenosine DML39UW TI TTJFY5U DML39UW TN Adenosine A3 receptor (ADORA3) DML39UW MA Inhibitor DML39UW RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DML39UW RU https://pubmed.ncbi.nlm.nih.gov/17378544 DML3AZG DI DML3AZG DML3AZG DN McN-A-343 DML3AZG TI TTQ13Z5 DML3AZG TN Muscarinic acetylcholine receptor M3 (CHRM3) DML3AZG MA Agonist DML3AZG RN Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists. Br J Pharmacol. 1995 Mar;114(6):1241-9. DML3AZG RU https://pubmed.ncbi.nlm.nih.gov/7620715 DML3AZG DI DML3AZG DML3AZG DN McN-A-343 DML3AZG TI TTOXS3C DML3AZG TN Muscarinic acetylcholine receptor (CHRM) DML3AZG MA Agonist DML3AZG RN Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells. J Pharmacol Exp Ther. 1989 Feb;248(2):661-70. DML3AZG RU https://pubmed.ncbi.nlm.nih.gov/2537406 DML3OHW DI DML3OHW DML3OHW DN Thiophene-2-ylboronic acid DML3OHW TI TTHI19T DML3OHW TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DML3OHW MA Inhibitor DML3OHW RN Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54. DML3OHW RU https://pubmed.ncbi.nlm.nih.gov/17956081 DML3OYH DI DML3OYH DML3OYH DN TriMixDC DML3OYH TI TTIJP3Q DML3OYH TN TNF related activation protein (CD40LG) DML3OYH RN Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383. DML3OYH RU https://pubmed.ncbi.nlm.nih.gov/23509826 DML3OYH DI DML3OYH DML3OYH DN TriMixDC DML3OYH TI TTISGCA DML3OYH TN Toll-like receptor 4 (TLR4) DML3OYH RN Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383. DML3OYH RU https://pubmed.ncbi.nlm.nih.gov/23509826 DML3OYH DI DML3OYH DML3OYH DN TriMixDC DML3OYH TI TTNCIE0 DML3OYH TN CD70 antigen (CD27-L) DML3OYH RN Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383. DML3OYH RU https://pubmed.ncbi.nlm.nih.gov/23509826 DML3R5Z DI DML3R5Z DML3R5Z DN Atropisomer 1 DML3R5Z TI TTT7PJU DML3R5Z TN Janus kinase 3 (JAK-3) DML3R5Z MA Inhibitor DML3R5Z RN Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41. DML3R5Z RU https://pubmed.ncbi.nlm.nih.gov/20014869 DML3R5Z DI DML3R5Z DML3R5Z DN Atropisomer 1 DML3R5Z TI TTRMX3V DML3R5Z TN Janus kinase 2 (JAK-2) DML3R5Z MA Inhibitor DML3R5Z RN Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41. DML3R5Z RU https://pubmed.ncbi.nlm.nih.gov/20014869 DML3VB7 DI DML3VB7 DML3VB7 DN 4-(3-bromobenzylthio)-2-aminobutanoic acid DML3VB7 TI TTFK1JQ DML3VB7 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DML3VB7 MA Inhibitor DML3VB7 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DML3VB7 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DML40N3 DI DML40N3 DML40N3 DN ISIS 102450 DML40N3 TI TT5U49F DML40N3 TN PRKACA messenger RNA (PRKACA mRNA) DML40N3 RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DML40N3 RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DML49FI DI DML49FI DML49FI DN R-138727 DML49FI TI TTZ1DT0 DML49FI TN P2Y purinoceptor 12 (P2RY12) DML49FI MA Antagonist DML49FI RN Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost. 2005 Sep;94(3):593-8. DML49FI RU https://pubmed.ncbi.nlm.nih.gov/16268477 DML4DPV DI DML4DPV DML4DPV DN ONO-9910539 DML4DPV TI TTQ6S1K DML4DPV TN Lysophosphatidic acid receptor 1 (LPAR1) DML4DPV MA Antagonist DML4DPV RN Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1. Cell. 2015 Jun 18;161(7):1633-43. DML4DPV RU https://pubmed.ncbi.nlm.nih.gov/26091040 DML4DQ3 DI DML4DQ3 DML4DQ3 DN BIIB-513 DML4DQ3 TI TTGSEFH DML4DQ3 TN Sodium/hydrogen exchanger 1 (SLC9A1) DML4DQ3 MA Inhibitor DML4DQ3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 948). DML4DQ3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=948 DML4DSG DI DML4DSG DML4DSG DN 5-((1H-imidazol-1-yl)methyl)-7,8-dihydroquinoline DML4DSG TI TTSZLWK DML4DSG TN Aromatase (CYP19A1) DML4DSG MA Inhibitor DML4DSG RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DML4DSG RU https://pubmed.ncbi.nlm.nih.gov/19072235 DML4G6K DI DML4G6K DML4G6K DN D-Val-L-boroPro DML4G6K TI TTDIGC1 DML4G6K TN Dipeptidyl peptidase 4 (DPP-4) DML4G6K MA Inhibitor DML4G6K RN Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8. DML4G6K RU https://pubmed.ncbi.nlm.nih.gov/17458948 DML4GHA DI DML4GHA DML4GHA DN 2-(N-Cyclopentylamino)-3'-bromopropiophenone DML4GHA TI TTVBI8W DML4GHA TN Dopamine transporter (DAT) DML4GHA MA Inhibitor DML4GHA RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DML4GHA RU https://pubmed.ncbi.nlm.nih.gov/20158204 DML4GHA DI DML4GHA DML4GHA DN 2-(N-Cyclopentylamino)-3'-bromopropiophenone DML4GHA TI TTAWNKZ DML4GHA TN Norepinephrine transporter (NET) DML4GHA MA Inhibitor DML4GHA RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DML4GHA RU https://pubmed.ncbi.nlm.nih.gov/20158204 DML4KMP DI DML4KMP DML4KMP DN PMID24044867C8 DML4KMP TI TTETX6Q DML4KMP TN Mixed lineage kinase 3 (MAP3K11) DML4KMP MA Inhibitor DML4KMP RN Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3. J Med Chem. 2013 Oct 24;56(20):8032-48. DML4KMP RU https://pubmed.ncbi.nlm.nih.gov/24044867 DML4NJU DI DML4NJU DML4NJU DN 4-(3-thienyl)benzene-1,2-diamine) DML4NJU TI TTQ6VDM DML4NJU TN Voltage-gated potassium channel Kv11.1 (KCNH2) DML4NJU MA Inhibitor DML4NJU RN Parallel medicinal chemistry approaches to selective HDAC1/HDAC2 inhibitor (SHI-1:2) optimization. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1168-72. DML4NJU RU https://pubmed.ncbi.nlm.nih.gov/19138845 DML4P6O DI DML4P6O DML4P6O DN A-313326 DML4P6O TI TT7WZIJ DML4P6O TN CAAX farnesyltransferase beta (FNTB) DML4P6O MA Inhibitor DML4P6O RN Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8. DML4P6O RU https://pubmed.ncbi.nlm.nih.gov/15582430 DML4P6O DI DML4P6O DML4P6O DN A-313326 DML4P6O TI TTX20QP DML4P6O TN Geranylgeranyl transferase I (GGTase-I) DML4P6O MA Inhibitor DML4P6O RN Design and synthesis of o-trifluoromethylbiphenyl substituted 2-amino-nicotinonitriles as inhibitors of farnesyltransferase. Bioorg Med Chem Lett. 2005 Jan 3;15(1):153-8. DML4P6O RU https://pubmed.ncbi.nlm.nih.gov/15582430 DML4TQ5 DI DML4TQ5 DML4TQ5 DN thiochrome DML4TQ5 TI TTOXS3C DML4TQ5 TN Muscarinic acetylcholine receptor (CHRM) DML4TQ5 MA Modulator (allosteric modulator) DML4TQ5 RN Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66. DML4TQ5 RU https://pubmed.ncbi.nlm.nih.gov/14722259 DML4TQ5 DI DML4TQ5 DML4TQ5 DN thiochrome DML4TQ5 TI TTQ13Z5 DML4TQ5 TN Muscarinic acetylcholine receptor M3 (CHRM3) DML4TQ5 MA Modulator (allosteric modulator) DML4TQ5 RN Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol Pharmacol. 2004 Jan;65(1):257-66. DML4TQ5 RU https://pubmed.ncbi.nlm.nih.gov/14722259 DML4UMT DI DML4UMT DML4UMT DN GW-8510 DML4UMT TI TT7HF4W DML4UMT TN Cyclin-dependent kinase 2 (CDK2) DML4UMT MA Inhibitor DML4UMT RN Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7. DML4UMT RU https://pubmed.ncbi.nlm.nih.gov/15013000 DML4UMT DI DML4UMT DML4UMT DN GW-8510 DML4UMT TI TTAMQ62 DML4UMT TN Cyclin A2 (CCNA2) DML4UMT MA Inhibitor DML4UMT RN Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg Med Chem Lett. 2004 Feb 23;14(4):953-7. DML4UMT RU https://pubmed.ncbi.nlm.nih.gov/15013000 DML4V73 DI DML4V73 DML4V73 DN Drug 7684380 DML4V73 TI TTQW87Y DML4V73 TN Opioid receptor kappa (OPRK1) DML4V73 MA Antagonist DML4V73 RN FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J Biol Chem. 1993 May 25;268(15):11335-9. DML4V73 RU https://pubmed.ncbi.nlm.nih.gov/7684380 DML4WQJ DI DML4WQJ DML4WQJ DN Zaragozic Acid D2 DML4WQJ TI TTFQEO5 DML4WQJ TN Squalene synthetase (FDFT1) DML4WQJ MA Inhibitor DML4WQJ RN Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9. DML4WQJ RU https://pubmed.ncbi.nlm.nih.gov/8289063 DML5302 DI DML5302 DML5302 DN 4,7-Dioxosebacic Acid DML5302 TI TTJHKYD DML5302 TN Delta-aminolevulinic acid dehydratase (ALAD) DML5302 MA Inhibitor DML5302 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML5302 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML53GP DI DML53GP DML53GP DN Tendamistat DML53GP TI TTHCF4J DML53GP TN Alpha-glucosidase (GLA) DML53GP MA Inhibitor DML53GP RN Influence of Specific Signal Peptide Mutations on the Expression and Secretion of the alpha -Amylase Inhibitor Tendamistat in Streptomyces lividans. J Biol Chem. 1996 Jun 21;271(25):15244-52. DML53GP RU https://pubmed.ncbi.nlm.nih.gov/8662986 DML53SK DI DML53SK DML53SK DN JWH-345 DML53SK TI TT6OEDT DML53SK TN Cannabinoid receptor 1 (CB1) DML53SK MA Inhibitor DML53SK RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DML53SK RU https://pubmed.ncbi.nlm.nih.gov/17919913 DML53SK DI DML53SK DML53SK DN JWH-345 DML53SK TI TTMSFAW DML53SK TN Cannabinoid receptor 2 (CB2) DML53SK MA Inhibitor DML53SK RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DML53SK RU https://pubmed.ncbi.nlm.nih.gov/17919913 DML54EA DI DML54EA DML54EA DN Isopropyl dodecylfluorophosphonate DML54EA TI TTDP1UC DML54EA TN Fatty acid amide hydrolase (FAAH) DML54EA MA Inhibitor DML54EA RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DML54EA RU https://pubmed.ncbi.nlm.nih.gov/18438404 DML54EA DI DML54EA DML54EA DN Isopropyl dodecylfluorophosphonate DML54EA TI TT6OEDT DML54EA TN Cannabinoid receptor 1 (CB1) DML54EA MA Inhibitor DML54EA RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DML54EA RU https://pubmed.ncbi.nlm.nih.gov/18438404 DML54EA DI DML54EA DML54EA DN Isopropyl dodecylfluorophosphonate DML54EA TI TT1RS9F DML54EA TN Acetylcholinesterase (AChE) DML54EA MA Inhibitor DML54EA RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DML54EA RU https://pubmed.ncbi.nlm.nih.gov/18438404 DML54H2 DI DML54H2 DML54H2 DN 1-Allyl-3,7-dihydro-purine-2,6-dione DML54H2 TI TTJFY5U DML54H2 TN Adenosine A3 receptor (ADORA3) DML54H2 MA Inhibitor DML54H2 RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DML54H2 RU https://pubmed.ncbi.nlm.nih.gov/12014951 DML562D DI DML562D DML562D DN Calcineurin DML562D TI TTHT87J DML562D TN TWIK-related spinal cord potassium channel (TRESK) DML562D MA Activator DML562D RN TRESK channel as a potential target to treat T-cell mediated immune dysfunction. Biochem Biophys Res Commun. 2009 Dec 25;390(4):1102-5. DML562D RU https://pubmed.ncbi.nlm.nih.gov/19852929 DML5AWQ DI DML5AWQ DML5AWQ DN OM-294-DP DML5AWQ TI TTISGCA DML5AWQ TN Toll-like receptor 4 (TLR4) DML5AWQ MA Modulator DML5AWQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DML5AWQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DML5DU0 DI DML5DU0 DML5DU0 DN YM90709 DML5DU0 TI TTXH9AD DML5DU0 TN Interleukin 5 receptor alpha (IL5RA) DML5DU0 MA Antagonist DML5DU0 RN Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int Immunopharmacol. 2002 Nov;2(12):1693-702. DML5DU0 RU https://pubmed.ncbi.nlm.nih.gov/12469943 DML5ECR DI DML5ECR DML5ECR DN 1,2-bis(2,3,4-trifluorophenyl)ethane-1,2-dione DML5ECR TI TTMF541 DML5ECR TN Liver carboxylesterase (CES1) DML5ECR MA Inhibitor DML5ECR RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DML5ECR RU https://pubmed.ncbi.nlm.nih.gov/17399985 DML5FQT DI DML5FQT DML5FQT DN 1-methyl-1H-indole-3-carbonitrile DML5FQT TI TTTB4UP DML5FQT TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DML5FQT MA Inhibitor DML5FQT RN Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42. DML5FQT RU https://pubmed.ncbi.nlm.nih.gov/16483773 DML5J94 DI DML5J94 DML5J94 DN 1-Propyl-3,7-dihydro-purine-2,6-dione DML5J94 TI TTJFY5U DML5J94 TN Adenosine A3 receptor (ADORA3) DML5J94 MA Inhibitor DML5J94 RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DML5J94 RU https://pubmed.ncbi.nlm.nih.gov/12014951 DML5J94 DI DML5J94 DML5J94 DN 1-Propyl-3,7-dihydro-purine-2,6-dione DML5J94 TI TTNE7KG DML5J94 TN Adenosine A2b receptor (ADORA2B) DML5J94 MA Inhibitor DML5J94 RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DML5J94 RU https://pubmed.ncbi.nlm.nih.gov/12014951 DML5J94 DI DML5J94 DML5J94 DN 1-Propyl-3,7-dihydro-purine-2,6-dione DML5J94 TI TTK25J1 DML5J94 TN Adenosine A1 receptor (ADORA1) DML5J94 MA Inhibitor DML5J94 RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DML5J94 RU https://pubmed.ncbi.nlm.nih.gov/12014951 DML5NF6 DI DML5NF6 DML5NF6 DN 4-(3-bromopyrazolo[1,5-a]pyrimidin-6-yl)phenol DML5NF6 TI TTLAFZV DML5NF6 TN AMP-activated protein kinase (AMPK) DML5NF6 MA Inhibitor DML5NF6 RN The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular a... Bioorg Med Chem Lett. 2010 Nov 15;20(22):6394-9. DML5NF6 RU https://pubmed.ncbi.nlm.nih.gov/20932747 DML5O0H DI DML5O0H DML5O0H DN 2-Propanol, Isopropanol DML5O0H TI TTCM4B3 DML5O0H TN Nitric-oxide synthase endothelial (NOS3) DML5O0H MA Inhibitor DML5O0H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML5O0H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML5O0H DI DML5O0H DML5O0H DN 2-Propanol, Isopropanol DML5O0H TI TTXA6PH DML5O0H TN Oxysterols receptor LXR-beta (NR1H2) DML5O0H MA Inhibitor DML5O0H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML5O0H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML5O0H DI DML5O0H DML5O0H DN 2-Propanol, Isopropanol DML5O0H TI TTI6V2A DML5O0H TN Heme oxygenase 1 (HMOX1) DML5O0H MA Inhibitor DML5O0H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML5O0H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML5O0H DI DML5O0H DML5O0H DN 2-Propanol, Isopropanol DML5O0H TI TTLSWP6 DML5O0H TN GTP cyclohydrolase-I (GCH1) DML5O0H MA Inhibitor DML5O0H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DML5O0H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DML5O0H DI DML5O0H DML5O0H DN 2-Propanol, Isopropanol DML5O0H TI TTO8QRU DML5O0H TN Group IIA phospholipase A2 (GIIA sPLA2) DML5O0H MA Inhibitor DML5O0H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DML5O0H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DML5O0H DI DML5O0H DML5O0H DN 2-Propanol, Isopropanol DML5O0H TI TTF8CQI DML5O0H TN Tumor necrosis factor (TNF) DML5O0H MA Inhibitor DML5O0H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DML5O0H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DML5O0H DI DML5O0H DML5O0H DN 2-Propanol, Isopropanol DML5O0H TI TTE2KUJ DML5O0H TN Adenosylhomocysteinase (AHCY) DML5O0H MA Inhibitor DML5O0H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DML5O0H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DML5PE9 DI DML5PE9 DML5PE9 DN 2-methoxyphenylboronic acid DML5PE9 TI TTDP1UC DML5PE9 TN Fatty acid amide hydrolase (FAAH) DML5PE9 MA Inhibitor DML5PE9 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DML5PE9 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DML5QFZ DI DML5QFZ DML5QFZ DN GNF-PF-2857 DML5QFZ TI TTWG9A4 DML5QFZ TN Adrenergic receptor alpha-2A (ADRA2A) DML5QFZ MA Inhibitor DML5QFZ RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DML5QFZ RU https://pubmed.ncbi.nlm.nih.gov/17034141 DML5QFZ DI DML5QFZ DML5QFZ DN GNF-PF-2857 DML5QFZ TI TTWM4TY DML5QFZ TN Adrenergic receptor alpha-2B (ADRA2B) DML5QFZ MA Inhibitor DML5QFZ RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DML5QFZ RU https://pubmed.ncbi.nlm.nih.gov/17034141 DML5QFZ DI DML5QFZ DML5QFZ DN GNF-PF-2857 DML5QFZ TI TT2NUT5 DML5QFZ TN Adrenergic receptor alpha-2C (ADRA2C) DML5QFZ MA Inhibitor DML5QFZ RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DML5QFZ RU https://pubmed.ncbi.nlm.nih.gov/17034141 DML5URN DI DML5URN DML5URN DN (+/-)-2-Aminoindane-2-carboxylic acid DML5URN TI TTPH2JB DML5URN TN Large neutral amino acids transporter 1 (SLC7A5) DML5URN MA Inhibitor DML5URN RN Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3688-91. DML5URN RU https://pubmed.ncbi.nlm.nih.gov/20466543 DML5Y1Q DI DML5Y1Q DML5Y1Q DN AIKO-152 DML5Y1Q TI TTKWM86 DML5Y1Q TN Opioid receptor mu (MOP) DML5Y1Q MA Modulator DML5Y1Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DML5Y1Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DML5ZEJ DI DML5ZEJ DML5ZEJ DN 5'-iodotubercidin DML5ZEJ TI TTL732K DML5ZEJ TN Adenosine kinase (ADK) DML5ZEJ MA Inhibitor DML5ZEJ RN Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage. 2005 Mar;13(3):250-7. DML5ZEJ RU https://pubmed.ncbi.nlm.nih.gov/15727892 DML5ZSJ DI DML5ZSJ DML5ZSJ DN Ac-I[CVWQDWGAHRC]dT DML5ZSJ TI TTJGY7A DML5ZSJ TN Complement C3 (CO3) DML5ZSJ MA Inhibitor DML5ZSJ RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DML5ZSJ RU https://pubmed.ncbi.nlm.nih.gov/15634022 DML63MX DI DML63MX DML63MX DN 3-(imidazolylmethyl)-7-methoxy-4'-nitroflavone DML63MX TI TTSZLWK DML63MX TN Aromatase (CYP19A1) DML63MX MA Inhibitor DML63MX RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DML63MX RU https://pubmed.ncbi.nlm.nih.gov/16854084 DML68KX DI DML68KX DML68KX DN (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine DML68KX TI TTVBI8W DML68KX TN Dopamine transporter (DAT) DML68KX MA Inhibitor DML68KX RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DML68KX RU https://pubmed.ncbi.nlm.nih.gov/19282174 DML68KX DI DML68KX DML68KX DN (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine DML68KX TI TT3ROYC DML68KX TN Serotonin transporter (SERT) DML68KX MA Inhibitor DML68KX RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DML68KX RU https://pubmed.ncbi.nlm.nih.gov/19282174 DML68KX DI DML68KX DML68KX DN (+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine DML68KX TI TTAWNKZ DML68KX TN Norepinephrine transporter (NET) DML68KX MA Inhibitor DML68KX RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DML68KX RU https://pubmed.ncbi.nlm.nih.gov/19282174 DML68UF DI DML68UF DML68UF DN DM3B6S DML68UF TI TTKWM86 DML68UF TN Opioid receptor mu (MOP) DML68UF MA Inhibitor DML68UF RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DML68UF RU https://pubmed.ncbi.nlm.nih.gov/16777416 DML6EFV DI DML6EFV DML6EFV DN 2-Amino-6-(4-chloro-phenylsulfanyl)-benzonitrile DML6EFV TI TT84ETX DML6EFV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DML6EFV MA Inhibitor DML6EFV RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DML6EFV RU https://pubmed.ncbi.nlm.nih.gov/11384233 DML6FI3 DI DML6FI3 DML6FI3 DN Naphthalene Trisulfonate DML6FI3 TI TTMY81X DML6FI3 TN Heparin-binding growth factor 1 (FGF1) DML6FI3 MA Inhibitor DML6FI3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML6FI3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML6HSE DI DML6HSE DML6HSE DN 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline DML6HSE TI TTWJBZ5 DML6HSE TN 5-HT 2C receptor (HTR2C) DML6HSE MA Inhibitor DML6HSE RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DML6HSE RU https://pubmed.ncbi.nlm.nih.gov/19914063 DML6HSE DI DML6HSE DML6HSE DN 2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline DML6HSE TI TTJQOD7 DML6HSE TN 5-HT 2A receptor (HTR2A) DML6HSE MA Inhibitor DML6HSE RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DML6HSE RU https://pubmed.ncbi.nlm.nih.gov/19914063 DML6I8J DI DML6I8J DML6I8J DN AS96 DML6I8J TI TTNE7KG DML6I8J TN Adenosine A2b receptor (ADORA2B) DML6I8J MA Antagonist DML6I8J RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DML6I8J RU https://pubmed.ncbi.nlm.nih.gov/16219300 DML6MVH DI DML6MVH DML6MVH DN Delta1-dihydrotestosterone DML6MVH TI TTS64P2 DML6MVH TN Androgen receptor (AR) DML6MVH MA Agonist DML6MVH RN 17beta-hydroxy-5alpha-androst-1-en-3-one (1-testosterone) is a potent androgen with anabolic properties. Toxicol Lett. 2006 Aug 20;165(2):149-55. DML6MVH RU https://pubmed.ncbi.nlm.nih.gov/16621347 DML6O4N DI DML6O4N DML6O4N DN Dimethylformamide DML6O4N TI TTB2MXP DML6O4N TN Angiotensinogenase renin (REN) DML6O4N MA Inhibitor DML6O4N RN Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6. DML6O4N RU https://pubmed.ncbi.nlm.nih.gov/3358569 DML6O4N DI DML6O4N DML6O4N DN Dimethylformamide DML6O4N TI TT3NKIB DML6O4N TN Pancreatic elastase 1 (CELA1) DML6O4N MA Inhibitor DML6O4N RN Liver disease associated with occupational exposure to the solvent dimethylformamide. Ann Intern Med. 1988 May;108(5):680-6. DML6O4N RU https://pubmed.ncbi.nlm.nih.gov/3358569 DML6OMH DI DML6OMH DML6OMH DN NSC-745799 DML6OMH TI TTQY2EJ DML6OMH TN TERT messenger RNA (TERT mRNA) DML6OMH MA Inhibitor DML6OMH RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DML6OMH RU https://pubmed.ncbi.nlm.nih.gov/19804981 DML6OZR DI DML6OZR DML6OZR DN PMID20483621C5m DML6OZR TI TT32VXH DML6OZR TN BMP-2-inducible protein kinase (BMP2K) DML6OZR MA Inhibitor DML6OZR RN Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. DML6OZR RU https://pubmed.ncbi.nlm.nih.gov/20483621 DML6OZR DI DML6OZR DML6OZR DN PMID20483621C5m DML6OZR TI TTPMQSO DML6OZR TN ALK tyrosine kinase receptor (ALK) DML6OZR MA Inhibitor DML6OZR RN Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. DML6OZR RU https://pubmed.ncbi.nlm.nih.gov/20483621 DML6PJD DI DML6PJD DML6PJD DN (E)-N-(4-methoxyphenethyl)undec-2-enamide DML6PJD TI TT6OEDT DML6PJD TN Cannabinoid receptor 1 (CB1) DML6PJD MA Inhibitor DML6PJD RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DML6PJD RU https://pubmed.ncbi.nlm.nih.gov/16213718 DML6PJD DI DML6PJD DML6PJD DN (E)-N-(4-methoxyphenethyl)undec-2-enamide DML6PJD TI TTMSFAW DML6PJD TN Cannabinoid receptor 2 (CB2) DML6PJD MA Inhibitor DML6PJD RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DML6PJD RU https://pubmed.ncbi.nlm.nih.gov/16213718 DML6PTX DI DML6PTX DML6PTX DN 4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole DML6PTX TI TTRK8B9 DML6PTX TN Sodium channel unspecific (NaC) DML6PTX MA Inhibitor DML6PTX RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DML6PTX RU https://pubmed.ncbi.nlm.nih.gov/15177465 DML6PTX DI DML6PTX DML6PTX DN 4-Biphenyl-4-yl-2-(1-pentyl-hexyl)-1H-imidazole DML6PTX TI TTAXZ0K DML6PTX TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DML6PTX MA Inhibitor DML6PTX RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DML6PTX RU https://pubmed.ncbi.nlm.nih.gov/15177465 DML6SAG DI DML6SAG DML6SAG DN N-Propyl-2-phenylnorapomorphine hydrochloride DML6SAG TI TTEX248 DML6SAG TN Dopamine D2 receptor (D2R) DML6SAG MA Inhibitor DML6SAG RN N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62. DML6SAG RU https://pubmed.ncbi.nlm.nih.gov/19454369 DML6SIE DI DML6SIE DML6SIE DN SQ32,910 DML6SIE TI TTXHYV6 DML6SIE TN Voltage-gated L-type calcium channel (L-CaC) DML6SIE MA Blocker DML6SIE RN Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96. DML6SIE RU https://pubmed.ncbi.nlm.nih.gov/9131258 DML6UJM DI DML6UJM DML6UJM DN 1-aminohexylphosphonic acid monophenyl ester DML6UJM TI TTPHMWB DML6UJM TN Aminopeptidase N (ANPEP) DML6UJM MA Inhibitor DML6UJM RN New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6. DML6UJM RU https://pubmed.ncbi.nlm.nih.gov/20347318 DML70NC DI DML70NC DML70NC DN aza-THIP DML70NC TI TT6XFEU DML70NC TN GABA(A) receptor rho1 (GABRR1) DML70NC MA Antagonist DML70NC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DML70NC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DML70NC DI DML70NC DML70NC DN aza-THIP DML70NC TI TT4N6D8 DML70NC TN GABA(A) receptor rho3 (GABRR3) DML70NC MA Antagonist DML70NC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DML70NC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DML70NC DI DML70NC DML70NC DN aza-THIP DML70NC TI TTQMXLS DML70NC TN GABA(A) receptor rho2 (GABRR2) DML70NC MA Antagonist DML70NC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DML70NC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DML72JT DI DML72JT DML72JT DN PPTN DML72JT TI TT72OKI DML72JT TN P2Y purinoceptor 14 (P2RY14) DML72JT MA Antagonist DML72JT RN A selective high-affinity antagonist of the P2Y14 receptor inhibits UDP-glucose-stimulated chemotaxis of human neutrophils. Mol Pharmacol. 2013 Jul;84(1):41-9. DML72JT RU https://pubmed.ncbi.nlm.nih.gov/23592514 DML745Y DI DML745Y DML745Y DN 10,10-difluoro TXA2 DML745Y TI TT2O84V DML745Y TN Thromboxane A2 receptor (TBXA2R) DML745Y MA Agonist DML745Y RN Difluorothromboxane A2 and stereoisomers: stable derivatives of thromboxane A2 with differential effects on platelets and blood vessels. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5600-4. DML745Y RU https://pubmed.ncbi.nlm.nih.gov/2748606 DML79NU DI DML79NU DML79NU DN CGP 20712A DML79NU TI TTR6W5O DML79NU TN Adrenergic receptor beta-1 (ADRB1) DML79NU MA Antagonist DML79NU RN Distribution of beta 1- and beta 2-adrenoceptor subtypes in various mouse tissues. Neurosci Lett. 1993 Sep 17;160(1):96-100. DML79NU RU https://pubmed.ncbi.nlm.nih.gov/7902545 DML7HFP DI DML7HFP DML7HFP DN BIBO3304 DML7HFP TI TTRK9JT DML7HFP TN Neuropeptide Y receptor type 1 (NPY1R) DML7HFP MA Antagonist DML7HFP RN Neuropeptide Y induced modulation of dopamine synthesis in the striatum. Regul Pept. 2005 Jul 15;129(1-3):73-8. DML7HFP RU https://pubmed.ncbi.nlm.nih.gov/15927700 DML7SQH DI DML7SQH DML7SQH DN RN486 DML7SQH TI TTGM6VW DML7SQH TN Tyrosine-protein kinase BTK (ATK) DML7SQH MA Inhibitor DML7SQH RN RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012 Apr;341(1):90-103. DML7SQH RU https://pubmed.ncbi.nlm.nih.gov/22228807 DML7SQH DI DML7SQH DML7SQH DN RN486 DML7SQH TI TT8K4DE DML7SQH TN STE20-related serine/threonine-protein kinase (SLK) DML7SQH MA Inhibitor DML7SQH RN RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther. 2012 Apr;341(1):90-103. DML7SQH RU https://pubmed.ncbi.nlm.nih.gov/22228807 DML7SU3 DI DML7SU3 DML7SU3 DN Alpha-monofluoromethyl-3,4-dehydroornithine DML7SU3 TI TTUMGNO DML7SU3 TN Ornithine decarboxylase (ODC1) DML7SU3 MA Inhibitor DML7SU3 RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DML7SU3 RU https://pubmed.ncbi.nlm.nih.gov/3115816 DML7UQ1 DI DML7UQ1 DML7UQ1 DN 4-[4-(benzyloxy)piperidino]butyl-4-fluorobenzoate DML7UQ1 TI TTEB0GD DML7UQ1 TN Cholinesterase (BCHE) DML7UQ1 MA Inhibitor DML7UQ1 RN Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. DML7UQ1 RU https://pubmed.ncbi.nlm.nih.gov/17681794 DML7Y1R DI DML7Y1R DML7Y1R DN Thiostrepton DML7Y1R TI TTLFGBV DML7Y1R TN Bacterial 23S ribosomal RNA (Bact 23S rRNA) DML7Y1R MA Binder DML7Y1R RN The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51. DML7Y1R RU https://pubmed.ncbi.nlm.nih.gov/11768328 DML7YPS DI DML7YPS DML7YPS DN Duroquinone DML7YPS TI TT8XK6L DML7YPS TN Quinone reductase 1 (NQO1) DML7YPS MA Inhibitor DML7YPS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML7YPS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML7Z1H DI DML7Z1H DML7Z1H DN ACVR2B DML7Z1H TI TTLFRKS DML7Z1H TN Activin receptor type IIB (ACVR2B) DML7Z1H MA Antagonist DML7Z1H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1792). DML7Z1H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1792 DML83DM DI DML83DM DML83DM DN 2-(3-Chloro-phenyl)-chromen-4-one DML83DM TI TT1MPAY DML83DM TN GABA(A) receptor alpha-1 (GABRA1) DML83DM MA Inhibitor DML83DM RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DML83DM RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DML83DM DI DML83DM DML83DM DN 2-(3-Chloro-phenyl)-chromen-4-one DML83DM TI TTNJYV2 DML83DM TN Gamma-aminobutyric acid receptor (GAR) DML83DM MA Inhibitor DML83DM RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DML83DM RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DML83XP DI DML83XP DML83XP DN L-homoarginine DML83XP TI TTCM4B3 DML83XP TN Nitric-oxide synthase endothelial (NOS3) DML83XP MA Inhibitor DML83XP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DML83XP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DML8B3T DI DML8B3T DML8B3T DN 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol DML8B3T TI TTN9D8E DML8B3T TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DML8B3T MA Inhibitor DML8B3T RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DML8B3T RU https://pubmed.ncbi.nlm.nih.gov/9719603 DML8B3T DI DML8B3T DML8B3T DN 4-[2-(4-Phenyl-butoxy)-ethyl]-phenol DML8B3T TI TTLD29N DML8B3T TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DML8B3T MA Inhibitor DML8B3T RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DML8B3T RU https://pubmed.ncbi.nlm.nih.gov/9719603 DML8BT7 DI DML8BT7 DML8BT7 DN PAS219 DML8BT7 TI TT6PKBN DML8BT7 TN Proto-oncogene c-Src (SRC) DML8BT7 MA Inhibitor DML8BT7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DML8BT7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DML8EVA DI DML8EVA DML8EVA DN N-(quinolin-8-yl)-6-(sulfamoylamino)hexanamide DML8EVA TI TT5ZKDI DML8EVA TN Histone deacetylase 6 (HDAC6) DML8EVA MA Inhibitor DML8EVA RN Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. DML8EVA RU https://pubmed.ncbi.nlm.nih.gov/19084395 DML8HCZ DI DML8HCZ DML8HCZ DN ISIS 9067 DML8HCZ TI TT5TURO DML8HCZ TN A-Raf messenger RNA (ARAF mRNA) DML8HCZ RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DML8HCZ RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DML8MSC DI DML8MSC DML8MSC DN CL 385319 DML8MSC TI TTF4CAM DML8MSC TN Influenza Hemagglutinin (Influ HA) DML8MSC MA Inhibitor DML8MSC RN Structure of influenza hemagglutinin in complex with an inhibitor of membrane fusion. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17736-41. DML8MSC RU https://pubmed.ncbi.nlm.nih.gov/19004788 DML8NY0 DI DML8NY0 DML8NY0 DN 3beta-hydroxyrus-12,19(29)-dien-28-oic acid DML8NY0 TI TTIU7X1 DML8NY0 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DML8NY0 MA Inhibitor DML8NY0 RN DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6. DML8NY0 RU https://pubmed.ncbi.nlm.nih.gov/10654412 DML8PH7 DI DML8PH7 DML8PH7 DN 7-bromo-N-(3-bromophenyl)isoquinolin-1-amine DML8PH7 TI TTHS256 DML8PH7 TN Metabotropic glutamate receptor 5 (mGluR5) DML8PH7 MA Inhibitor DML8PH7 RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DML8PH7 RU https://pubmed.ncbi.nlm.nih.gov/19854049 DML8RTO DI DML8RTO DML8RTO DN TCS-OX2-29 DML8RTO TI TT9N02I DML8RTO TN Orexin receptor type 2 (HCRTR2) DML8RTO MA Antagonist DML8RTO RN N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4497-9. DML8RTO RU https://pubmed.ncbi.nlm.nih.gov/14643355 DML8S7J DI DML8S7J DML8S7J DN H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2 DML8S7J TI TTZ6T9E DML8S7J TN Somatostatin receptor type 2 (SSTR2) DML8S7J MA Inhibitor DML8S7J RN Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96. DML8S7J RU https://pubmed.ncbi.nlm.nih.gov/16854054 DML8S7J DI DML8S7J DML8S7J DN H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2 DML8S7J TI TT2BC4G DML8S7J TN Somatostatin receptor type 5 (SSTR5) DML8S7J MA Inhibitor DML8S7J RN Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96. DML8S7J RU https://pubmed.ncbi.nlm.nih.gov/16854054 DML8S7J DI DML8S7J DML8S7J DN H-D-Phe-c[Cys-Ala-D-Trp-Lys-Thr-Cys]-Thr-NH2 DML8S7J TI TTJX3UE DML8S7J TN Somatostatin receptor type 3 (SSTR3) DML8S7J MA Inhibitor DML8S7J RN Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96. DML8S7J RU https://pubmed.ncbi.nlm.nih.gov/16854054 DML8V4F DI DML8V4F DML8V4F DN [Mpa1, D-Tyr(Et)2, Gly(But)3, Gly(But)7]OT DML8V4F TI TTSCIUP DML8V4F TN Oxytocin receptor (OTR) DML8V4F MA Inhibitor DML8V4F RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DML8V4F RU https://pubmed.ncbi.nlm.nih.gov/17316912 DML8ZBR DI DML8ZBR DML8ZBR DN PMID17935989C25 DML8ZBR TI TT1VAUK DML8ZBR TN VEGFR1 messenger RNA (VEGFR1 mRNA) DML8ZBR MA Inhibitor DML8ZBR RN Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601. DML8ZBR RU https://pubmed.ncbi.nlm.nih.gov/17935989 DML8ZBR DI DML8ZBR DML8ZBR DN PMID17935989C25 DML8ZBR TI TT6SA0X DML8ZBR TN Muscle-specific kinase receptor (MUSK) DML8ZBR MA Inhibitor DML8ZBR RN Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601. DML8ZBR RU https://pubmed.ncbi.nlm.nih.gov/17935989 DML8ZBR DI DML8ZBR DML8ZBR DN PMID17935989C25 DML8ZBR TI TTTU902 DML8ZBR TN Checkpoint kinase-1 (CHK1) DML8ZBR MA Inhibitor DML8ZBR RN Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and prelimina... Bioorg Med Chem Lett. 2007 Dec 1;17(23):6593-601. DML8ZBR RU https://pubmed.ncbi.nlm.nih.gov/17935989 DML92OK DI DML92OK DML92OK DN 2,3-dimethoxy-2'-hydroxychalcone DML92OK TI TTVKILB DML92OK TN Prostaglandin G/H synthase 2 (COX-2) DML92OK MA Inhibitor DML92OK RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DML92OK RU https://pubmed.ncbi.nlm.nih.gov/19233646 DML9DH8 DI DML9DH8 DML9DH8 DN galmic DML9DH8 TI TTOPAY7 DML9DH8 TN Galanin receptor (GAL-R) DML9DH8 MA Agonist DML9DH8 RN Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10470-5. DML9DH8 RU https://pubmed.ncbi.nlm.nih.gov/15240875 DML9DJP DI DML9DJP DML9DJP DN 2-Phenyl-3H-imidazo[4,5-c]quinoline DML9DJP TI TT1MPAY DML9DJP TN GABA(A) receptor alpha-1 (GABRA1) DML9DJP MA Inhibitor DML9DJP RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DML9DJP RU https://pubmed.ncbi.nlm.nih.gov/8709114 DML9DJP DI DML9DJP DML9DJP DN 2-Phenyl-3H-imidazo[4,5-c]quinoline DML9DJP TI TTNJYV2 DML9DJP TN Gamma-aminobutyric acid receptor (GAR) DML9DJP MA Inhibitor DML9DJP RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DML9DJP RU https://pubmed.ncbi.nlm.nih.gov/8709114 DML9EU7 DI DML9EU7 DML9EU7 DN 6-ethyl-3-i-propoxycarbonyl-4-quinolone DML9EU7 TI TTZA1NY DML9EU7 TN GABA(A) receptor beta-2 (GABRB2) DML9EU7 MA Inhibitor DML9EU7 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DML9EU7 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DML9EU7 DI DML9EU7 DML9EU7 DN 6-ethyl-3-i-propoxycarbonyl-4-quinolone DML9EU7 TI TTNJYV2 DML9EU7 TN Gamma-aminobutyric acid receptor (GAR) DML9EU7 MA Inhibitor DML9EU7 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DML9EU7 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DML9EU7 DI DML9EU7 DML9EU7 DN 6-ethyl-3-i-propoxycarbonyl-4-quinolone DML9EU7 TI TT06RH5 DML9EU7 TN GABA(A) receptor gamma-2 (GABRG2) DML9EU7 MA Inhibitor DML9EU7 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DML9EU7 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DML9EU7 DI DML9EU7 DML9EU7 DN 6-ethyl-3-i-propoxycarbonyl-4-quinolone DML9EU7 TI TT1MPAY DML9EU7 TN GABA(A) receptor alpha-1 (GABRA1) DML9EU7 MA Inhibitor DML9EU7 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DML9EU7 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DML9HDA DI DML9HDA DML9HDA DN 8R-hydroxylobel-9-ene DML9HDA TI TT3ROYC DML9HDA TN Serotonin transporter (SERT) DML9HDA MA Inhibitor DML9HDA RN Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg Med Chem. 2010 Jan 15;18(2):640-9. DML9HDA RU https://pubmed.ncbi.nlm.nih.gov/20036131 DML9HDA DI DML9HDA DML9HDA DN 8R-hydroxylobel-9-ene DML9HDA TI TTVBI8W DML9HDA TN Dopamine transporter (DAT) DML9HDA MA Inhibitor DML9HDA RN Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters. Bioorg Med Chem. 2010 Jan 15;18(2):640-9. DML9HDA RU https://pubmed.ncbi.nlm.nih.gov/20036131 DML9IGY DI DML9IGY DML9IGY DN FGGFTCARKCARK DML9IGY TI TTNT7K8 DML9IGY TN Nociceptin receptor (OPRL1) DML9IGY MA Inhibitor DML9IGY RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DML9IGY RU https://pubmed.ncbi.nlm.nih.gov/11689089 DML9MCU DI DML9MCU DML9MCU DN 2-butylamido-5-sulfonamidoindane DML9MCU TI TT2LVK8 DML9MCU TN Carbonic anhydrase IX (CA-IX) DML9MCU MA Inhibitor DML9MCU RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DML9MCU RU https://pubmed.ncbi.nlm.nih.gov/16640335 DML9MCU DI DML9MCU DML9MCU DN 2-butylamido-5-sulfonamidoindane DML9MCU TI TTANPDJ DML9MCU TN Carbonic anhydrase II (CA-II) DML9MCU MA Inhibitor DML9MCU RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DML9MCU RU https://pubmed.ncbi.nlm.nih.gov/16640335 DML9MCU DI DML9MCU DML9MCU DN 2-butylamido-5-sulfonamidoindane DML9MCU TI TTHQPL7 DML9MCU TN Carbonic anhydrase I (CA-I) DML9MCU MA Inhibitor DML9MCU RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DML9MCU RU https://pubmed.ncbi.nlm.nih.gov/16640335 DML9W2V DI DML9W2V DML9W2V DN Amarylline DML9W2V TI TTOA6YT DML9W2V TN MERS-CoV RNA-directed RNA polymerase (RdRp) DML9W2V MA Inhibitor DML9W2V RN Lycorine: A prospective natural lead for anticancer drug discovery. Biomed Pharmacother. 2018 Nov;107:615-624. DML9W2V RU https://pubmed.ncbi.nlm.nih.gov/30114645 DMLA384 DI DMLA384 DMLA384 DN CGNLSTCBLGTYTQDFNKFHZYPQTAIGVGAP-amide DMLA384 TI TTLWS2O DMLA384 TN Calcitonin receptor (CALCR) DMLA384 MA Inhibitor DMLA384 RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMLA384 RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMLA3WY DI DMLA3WY DMLA3WY DN SP4160 DMLA3WY TI TTF89GD DMLA3WY TN Interleukin-2 (IL2) DMLA3WY MA Inhibitor DMLA3WY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLA3WY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLA5I9 DI DMLA5I9 DMLA5I9 DN ISIS 4764 DMLA5I9 TI TT1PL7M DMLA5I9 TN E-selectin messenger RNA (SELE mRNA) DMLA5I9 RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DMLA5I9 RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DMLA92O DI DMLA92O DMLA92O DN N-(4-aminobiphenyl-3-yl)benzamide DMLA92O TI TTSHTOI DMLA92O TN Histone deacetylase 2 (HDAC2) DMLA92O MA Inhibitor DMLA92O RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMLA92O RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMLABGW DI DMLABGW DMLABGW DN JWH-311 DMLABGW TI TTMSFAW DMLABGW TN Cannabinoid receptor 2 (CB2) DMLABGW MA Inhibitor DMLABGW RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMLABGW RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMLABR9 DI DMLABR9 DMLABR9 DN 5-oxo-12-HETE DMLABR9 TI TT7WBSV DMLABR9 TN Oxoeicosanoid receptor 1 (OXER1) DMLABR9 MA Antagonist DMLABR9 RN Biological inactivation of 5-oxo-6,8,11,14-eicosatetraenoic acid by human platelets. Blood. 1999 Feb 1;93(3):1086-96. DMLABR9 RU https://pubmed.ncbi.nlm.nih.gov/9920859 DMLAEPF DI DMLAEPF DMLAEPF DN (4-bromophenyl)(10H-phenothiazin-10-yl)methanone DMLAEPF TI TTEB0GD DMLAEPF TN Cholinesterase (BCHE) DMLAEPF MA Inhibitor DMLAEPF RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMLAEPF RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMLAFJE DI DMLAFJE DMLAFJE DN PSB-0702 DMLAFJE TI TTZ1DT0 DMLAFJE TN P2Y purinoceptor 12 (P2RY12) DMLAFJE MA Inhibitor DMLAFJE RN High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem. 2009 Jun 25;52(12):3784-93. DMLAFJE RU https://pubmed.ncbi.nlm.nih.gov/19463000 DMLANGY DI DMLANGY DMLANGY DN 8-(4-hydroxyphenyl)-2-morpholin-4-ylchromen-4-one DMLANGY TI TTK3PY9 DMLANGY TN DNA-dependent protein kinase catalytic (PRKDC) DMLANGY MA Inhibitor DMLANGY RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMLANGY RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMLASOF DI DMLASOF DMLASOF DN GSK2606414 DMLASOF TI TTHLGB2 DMLASOF TN Myosin light chain kinase 2 (MYLK2) DMLASOF MA Inhibitor DMLASOF RN Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012 Aug 23;55(16):7193-207. DMLASOF RU https://pubmed.ncbi.nlm.nih.gov/22827572 DMLASOF DI DMLASOF DMLASOF DN GSK2606414 DMLASOF TI TT5OU0D DMLASOF TN PRKR-like endoplasmic reticulum kinase (PERK) DMLASOF MA Inhibitor DMLASOF RN Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012 Aug 23;55(16):7193-207. DMLASOF RU https://pubmed.ncbi.nlm.nih.gov/22827572 DMLB2W5 DI DMLB2W5 DMLB2W5 DN 3h-Pyrazolo[4,3-D]Pyrimidin-7-Ol DMLB2W5 TI TTBL49X DMLB2W5 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMLB2W5 MA Inhibitor DMLB2W5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLB2W5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLB3RT DI DMLB3RT DMLB3RT DN 1,6-hexamethylene diisocyanate DMLB3RT TI TTELV3W DMLB3RT TN Transformation-sensitive protein p120 (TRPA1) DMLB3RT MA Activator DMLB3RT RN Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14. DMLB3RT RU https://pubmed.ncbi.nlm.nih.gov/19036859 DMLB4TU DI DMLB4TU DMLB4TU DN KKHT-20718 DMLB4TU TI TT729IR DMLB4TU TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMLB4TU MA Inhibitor DMLB4TU RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DMLB4TU RU https://pubmed.ncbi.nlm.nih.gov/17035033 DMLB6UA DI DMLB6UA DMLB6UA DN C[L-Tyr(OMe)-D-pro-L-Phe-D-trp] DMLB6UA TI TTKWM86 DMLB6UA TN Opioid receptor mu (MOP) DMLB6UA MA Inhibitor DMLB6UA RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMLB6UA RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMLB6UA DI DMLB6UA DMLB6UA DN C[L-Tyr(OMe)-D-pro-L-Phe-D-trp] DMLB6UA TI TTQW87Y DMLB6UA TN Opioid receptor kappa (OPRK1) DMLB6UA MA Inhibitor DMLB6UA RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMLB6UA RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMLBCE5 DI DMLBCE5 DMLBCE5 DN 1-(1-Benzyl-2-biphenyl-4-yl-ethyl)-1H-imidazole DMLBCE5 TI TTSZLWK DMLBCE5 TN Aromatase (CYP19A1) DMLBCE5 MA Inhibitor DMLBCE5 RN CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. Bioorg Med Chem. 2008 Sep 15;16(18):8349-58. DMLBCE5 RU https://pubmed.ncbi.nlm.nih.gov/18782670 DMLBECR DI DMLBECR DMLBECR DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) DMLBECR TI TT6R7JZ DMLBECR TN Histone deacetylase 1 (HDAC1) DMLBECR MA Inhibitor DMLBECR RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMLBECR RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMLBECR DI DMLBECR DMLBECR DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) DMLBECR TI TT5ZKDI DMLBECR TN Histone deacetylase 6 (HDAC6) DMLBECR MA Inhibitor DMLBECR RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMLBECR RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMLBECR DI DMLBECR DMLBECR DN Cyclo(-L-Am7(S2Py)-Aib-L-Ala-D-Tic-) DMLBECR TI TTTQGH8 DMLBECR TN Histone deacetylase 4 (HDAC4) DMLBECR MA Inhibitor DMLBECR RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMLBECR RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMLBHXN DI DMLBHXN DMLBHXN DN 1,4-bis-(Dmt-Tic-amino)butane DMLBHXN TI TTKWM86 DMLBHXN TN Opioid receptor mu (MOP) DMLBHXN MA Inhibitor DMLBHXN RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMLBHXN RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMLBHXN DI DMLBHXN DMLBHXN DN 1,4-bis-(Dmt-Tic-amino)butane DMLBHXN TI TT27RFC DMLBHXN TN Opioid receptor delta (OPRD1) DMLBHXN MA Inhibitor DMLBHXN RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMLBHXN RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMLBP3F DI DMLBP3F DMLBP3F DN Rapamycin complexed with immunophilin FKBP12 DMLBP3F TI TTCJG29 DMLBP3F TN Serine/threonine-protein kinase mTOR (mTOR) DMLBP3F MA Inhibitor DMLBP3F RN Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37. DMLBP3F RU https://pubmed.ncbi.nlm.nih.gov/11743214 DMLBSNP DI DMLBSNP DMLBSNP DN aspirin triggered lipoxin A4 DMLBSNP TI TTOJ1NF DMLBSNP TN FMLP-related receptor I (FPR2) DMLBSNP MA Agonist DMLBSNP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 223). DMLBSNP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=223 DMLBT0E DI DMLBT0E DMLBT0E DN 1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one DMLBT0E TI TTDP1UC DMLBT0E TN Fatty acid amide hydrolase (FAAH) DMLBT0E MA Inhibitor DMLBT0E RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMLBT0E RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMLBT0E DI DMLBT0E DMLBT0E DN 1,1,1-trifluoro-3-(octylsulfinyl)propan-2-one DMLBT0E TI TTMF541 DMLBT0E TN Liver carboxylesterase (CES1) DMLBT0E MA Inhibitor DMLBT0E RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMLBT0E RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMLBX3Q DI DMLBX3Q DMLBX3Q DN JD-0100 DMLBX3Q TI TTGP7BY DMLBX3Q TN Monoamine oxidase type B (MAO-B) DMLBX3Q MA Inhibitor DMLBX3Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DMLBX3Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DMLBX4Q DI DMLBX4Q DMLBX4Q DN 4-[5-Methoxy-indan-(1Z)-ylidenemethyl]-pyridine DMLBX4Q TI TTSZLWK DMLBX4Q TN Aromatase (CYP19A1) DMLBX4Q MA Inhibitor DMLBX4Q RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMLBX4Q RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMLBX9Z DI DMLBX9Z DMLBX9Z DN ISIS 107775 DMLBX9Z TI TTELIN2 DMLBX9Z TN PTPN1 messenger RNA (PTPN1 mRNA) DMLBX9Z RN US patent application no. 6,261,840, Antisense modulation of PTP1B expression. DMLBX9Z RU http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true DMLBYFG DI DMLBYFG DMLBYFG DN CZC 24832 DMLBYFG TI TTHBTOP DMLBYFG TN PI3-kinase gamma (PIK3CG) DMLBYFG MA Inhibitor DMLBYFG RN A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation. Nat Chem Biol. 2012 Apr 29;8(6):576-82. DMLBYFG RU https://pubmed.ncbi.nlm.nih.gov/22544264 DMLC041 DI DMLC041 DMLC041 DN Cyclosal-d4TMP DMLC041 TI TTEB0GD DMLC041 TN Cholinesterase (BCHE) DMLC041 MA Inhibitor DMLC041 RN Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46. DMLC041 RU https://pubmed.ncbi.nlm.nih.gov/17328534 DMLC0NW DI DMLC0NW DMLC0NW DN Tyr-D-Ala-Phe-Thr[-D-Glc(OAc)4]-Tyr-Pro-Ser-NH2 DMLC0NW TI TTKWM86 DMLC0NW TN Opioid receptor mu (MOP) DMLC0NW MA Inhibitor DMLC0NW RN Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52. DMLC0NW RU https://pubmed.ncbi.nlm.nih.gov/9288177 DMLC257 DI DMLC257 DMLC257 DN N-n-octyl-7-methoxytacrine hydrochloride DMLC257 TI TTEB0GD DMLC257 TN Cholinesterase (BCHE) DMLC257 MA Inhibitor DMLC257 RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMLC257 RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMLC257 DI DMLC257 DMLC257 DN N-n-octyl-7-methoxytacrine hydrochloride DMLC257 TI TT1RS9F DMLC257 TN Acetylcholinesterase (AChE) DMLC257 MA Inhibitor DMLC257 RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMLC257 RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMLC2I6 DI DMLC2I6 DMLC2I6 DN 3-chloro-N-(6-chloropyridin-2-yl)benzamide DMLC2I6 TI TTHS256 DMLC2I6 TN Metabotropic glutamate receptor 5 (mGluR5) DMLC2I6 MA Inhibitor DMLC2I6 RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DMLC2I6 RU https://pubmed.ncbi.nlm.nih.gov/16678408 DMLC2VE DI DMLC2VE DMLC2VE DN 177Lu-labelled RM2 DMLC2VE TI TTC1MVT DMLC2VE TN Gastrin-releasing peptide receptor (GRPR) DMLC2VE MA Antagonist DMLC2VE RN Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608. DMLC2VE RU https://pubmed.ncbi.nlm.nih.gov/32728208 DMLC7HE DI DMLC7HE DMLC7HE DN A804598 DMLC7HE TI TT473XN DMLC7HE TN P2X purinoceptor 7 (P2RX7) DMLC7HE MA Antagonist DMLC7HE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484). DMLC7HE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484 DMLC8OB DI DMLC8OB DMLC8OB DN 2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole DMLC8OB TI TTJS8PY DMLC8OB TN 5-HT 6 receptor (HTR6) DMLC8OB MA Inhibitor DMLC8OB RN 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4230-4. DMLC8OB RU https://pubmed.ncbi.nlm.nih.gov/16055331 DMLC8PX DI DMLC8PX DMLC8PX DN TH-1320 DMLC8PX TI TTGTQHC DMLC8PX TN DNA topoisomerase I (TOP1) DMLC8PX MA Modulator DMLC8PX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMLC8PX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMLCDZN DI DMLCDZN DMLCDZN DN 2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one DMLCDZN TI TTNJYV2 DMLCDZN TN Gamma-aminobutyric acid receptor (GAR) DMLCDZN MA Inhibitor DMLCDZN RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMLCDZN RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMLCDZN DI DMLCDZN DMLCDZN DN 2-Pyridin-2-yl-6H-pyrazolo[1,5-c]quinazolin-5-one DMLCDZN TI TT1MPAY DMLCDZN TN GABA(A) receptor alpha-1 (GABRA1) DMLCDZN MA Inhibitor DMLCDZN RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMLCDZN RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMLCGSY DI DMLCGSY DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one DMLCGSY TI TTSHTOI DMLCGSY TN Histone deacetylase 2 (HDAC2) DMLCGSY MA Inhibitor DMLCGSY RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMLCGSY RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMLCGSY DI DMLCGSY DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one DMLCGSY TI TTYHPU6 DMLCGSY TN Histone deacetylase 10 (HDAC10) DMLCGSY MA Inhibitor DMLCGSY RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMLCGSY RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMLCGSY DI DMLCGSY DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one DMLCGSY TI TT5ZKDI DMLCGSY TN Histone deacetylase 6 (HDAC6) DMLCGSY MA Inhibitor DMLCGSY RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMLCGSY RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMLCGSY DI DMLCGSY DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one DMLCGSY TI TT6R7JZ DMLCGSY TN Histone deacetylase 1 (HDAC1) DMLCGSY MA Inhibitor DMLCGSY RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMLCGSY RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMLCGSY DI DMLCGSY DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one DMLCGSY TI TTTQGH8 DMLCGSY TN Histone deacetylase 4 (HDAC4) DMLCGSY MA Inhibitor DMLCGSY RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMLCGSY RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMLCGSY DI DMLCGSY DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one DMLCGSY TI TTBH0VX DMLCGSY TN Histone deacetylase (HDAC) DMLCGSY MA Inhibitor DMLCGSY RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMLCGSY RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMLCGSY DI DMLCGSY DMLCGSY DN 7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one DMLCGSY TI TTT6LFV DMLCGSY TN Histone deacetylase 8 (HDAC8) DMLCGSY MA Inhibitor DMLCGSY RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMLCGSY RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMLCIJX DI DMLCIJX DMLCIJX DN 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol DMLCIJX TI TTLD29N DMLCIJX TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMLCIJX MA Inhibitor DMLCIJX RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMLCIJX RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMLCIJX DI DMLCIJX DMLCIJX DN 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol DMLCIJX TI TTKJEMQ DMLCIJX TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMLCIJX MA Inhibitor DMLCIJX RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMLCIJX RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMLCIJX DI DMLCIJX DMLCIJX DN 4-[2-(6-Phenyl-hexylamino)-ethyl]-phenol DMLCIJX TI TTN9D8E DMLCIJX TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMLCIJX MA Inhibitor DMLCIJX RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMLCIJX RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMLCIZ8 DI DMLCIZ8 DMLCIZ8 DN H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2 DMLCIZ8 TI TTZ6T9E DMLCIZ8 TN Somatostatin receptor type 2 (SSTR2) DMLCIZ8 MA Inhibitor DMLCIZ8 RN Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96. DMLCIZ8 RU https://pubmed.ncbi.nlm.nih.gov/16854054 DMLCIZ8 DI DMLCIZ8 DMLCIZ8 DN H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2 DMLCIZ8 TI TT2BC4G DMLCIZ8 TN Somatostatin receptor type 5 (SSTR5) DMLCIZ8 MA Inhibitor DMLCIZ8 RN Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96. DMLCIZ8 RU https://pubmed.ncbi.nlm.nih.gov/16854054 DMLCIZ8 DI DMLCIZ8 DMLCIZ8 DN H-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-NH2 DMLCIZ8 TI TTJX3UE DMLCIZ8 TN Somatostatin receptor type 3 (SSTR3) DMLCIZ8 MA Inhibitor DMLCIZ8 RN Novel sst2-selective somatostatin agonists. Three-dimensional consensus structure by NMR. J Med Chem. 2006 Jul 27;49(15):4487-96. DMLCIZ8 RU https://pubmed.ncbi.nlm.nih.gov/16854054 DMLCMA3 DI DMLCMA3 DMLCMA3 DN BOHEMINE DMLCMA3 TI TT7HF4W DMLCMA3 TN Cyclin-dependent kinase 2 (CDK2) DMLCMA3 MA Inhibitor DMLCMA3 RN Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem. 2000 Jun 29;43(13):2506-13. DMLCMA3 RU https://pubmed.ncbi.nlm.nih.gov/10891109 DMLCZ3D DI DMLCZ3D DMLCZ3D DN Chk1-A DMLCZ3D TI TTTU902 DMLCZ3D TN Checkpoint kinase-1 (CHK1) DMLCZ3D MA Inhibitor DMLCZ3D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987). DMLCZ3D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987 DMLD1IU DI DMLD1IU DMLD1IU DN PMID30247903-Compound-General structure22 DMLD1IU TI TTNBFWK DMLD1IU TN Programmed cell death protein 1 (PD-1) DMLD1IU MA Inhibitor DMLD1IU RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMLD1IU RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMLD2G3 DI DMLD2G3 DMLD2G3 DN 1-Adamantan-1-yl-3-decyl-urea DMLD2G3 TI TT7WVHI DMLD2G3 TN Soluble epoxide hydrolase (EPHX2) DMLD2G3 MA Inhibitor DMLD2G3 RN Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. J Med Chem. 2005 May 19;48(10):3621-9. DMLD2G3 RU https://pubmed.ncbi.nlm.nih.gov/15887969 DMLDAR4 DI DMLDAR4 DMLDAR4 DN TEI-9647 DMLDAR4 TI TTK59TV DMLDAR4 TN Vitamin D3 receptor (VDR) DMLDAR4 MA Antagonist DMLDAR4 RN Further synthetic and biological studies on vitamin D hormone antagonists based on C24-alkylation and C2alpha-functionalization of 25-dehydro-1alpha-hydroxyvitamin D(3)-26,23-lactones. J Med Chem. 2006 Nov 30;49(24):7063-75. DMLDAR4 RU https://pubmed.ncbi.nlm.nih.gov/17125259 DMLDH4Z DI DMLDH4Z DMLDH4Z DN 1,1,1,3-Tetrafluoro-6-phenylhexan-2-one DMLDH4Z TI TTT1JVS DMLDH4Z TN Cytosolic phospholipase A2 (GIVA cPLA2) DMLDH4Z MA Inhibitor DMLDH4Z RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DMLDH4Z RU https://pubmed.ncbi.nlm.nih.gov/20369880 DMLDHMB DI DMLDHMB DMLDHMB DN 2,5-Anhydroglucitol-1,6-Biphosphate DMLDHMB TI TTWHDVK DMLDHMB TN Fructose-1,6-bisphosphatase (FBP) DMLDHMB MA Inhibitor DMLDHMB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLDHMB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLDOH6 DI DMLDOH6 DMLDOH6 DN 2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine DMLDOH6 TI TTJFY5U DMLDOH6 TN Adenosine A3 receptor (ADORA3) DMLDOH6 MA Inhibitor DMLDOH6 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMLDOH6 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMLDOH6 DI DMLDOH6 DMLDOH6 DN 2-(3''-(benzoimidazole-1''-yl)ethyloxy)adenosine DMLDOH6 TI TTM2AOE DMLDOH6 TN Adenosine A2a receptor (ADORA2A) DMLDOH6 MA Inhibitor DMLDOH6 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMLDOH6 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMLDOYV DI DMLDOYV DMLDOYV DN JWH-167 DMLDOYV TI TTMSFAW DMLDOYV TN Cannabinoid receptor 2 (CB2) DMLDOYV MA Inhibitor DMLDOYV RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMLDOYV RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMLDQ6I DI DMLDQ6I DMLDQ6I DN 2-chloro-N-(o-tolylcarbamoyl)benzamide DMLDQ6I TI TTSFWA7 DMLDQ6I TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMLDQ6I MA Inhibitor DMLDQ6I RN Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010). DMLDQ6I RU http://www.sciencedirect.com/science/article/pii/S0960894X10006803 DMLDQWT DI DMLDQWT DMLDQWT DN (+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol DMLDQWT TI TTN9T81 DMLDQWT TN Arachidonate 15-lipoxygenase (15-LOX) DMLDQWT MA Inhibitor DMLDQWT RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMLDQWT RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMLDQWT DI DMLDQWT DMLDQWT DN (+)-(5S,8S,10S)-20-methoxy-9,15-ene-puupehenol DMLDQWT TI TT12ABZ DMLDQWT TN Arachidonate 12-lipoxygenase (12-LOX) DMLDQWT MA Inhibitor DMLDQWT RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMLDQWT RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMLDUJ1 DI DMLDUJ1 DMLDUJ1 DN Kuraidin DMLDUJ1 TI TTZ97H5 DMLDUJ1 TN Phosphodiesterase 4A (PDE4A) DMLDUJ1 MA Inhibitor DMLDUJ1 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMLDUJ1 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMLDUJ1 DI DMLDUJ1 DMLDUJ1 DN Kuraidin DMLDUJ1 TI TT2UE56 DMLDUJ1 TN Sodium/glucose cotransporter 1 (SGLT1) DMLDUJ1 MA Inhibitor DMLDUJ1 RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMLDUJ1 RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMLDUJ1 DI DMLDUJ1 DMLDUJ1 DN Kuraidin DMLDUJ1 TI TTJ0IQB DMLDUJ1 TN Phosphodiesterase 5A (PDE5A) DMLDUJ1 MA Inhibitor DMLDUJ1 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMLDUJ1 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMLDUJ1 DI DMLDUJ1 DMLDUJ1 DN Kuraidin DMLDUJ1 TI TT06AWU DMLDUJ1 TN Phosphodiesterase 3A (PDE3A) DMLDUJ1 MA Inhibitor DMLDUJ1 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMLDUJ1 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMLDUJ1 DI DMLDUJ1 DMLDUJ1 DN Kuraidin DMLDUJ1 TI TTVIAT9 DMLDUJ1 TN Phosphodiesterase 4B (PDE4B) DMLDUJ1 MA Inhibitor DMLDUJ1 RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMLDUJ1 RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMLDUJ1 DI DMLDUJ1 DMLDUJ1 DN Kuraidin DMLDUJ1 TI TTF8JAT DMLDUJ1 TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMLDUJ1 MA Inhibitor DMLDUJ1 RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMLDUJ1 RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMLDVFM DI DMLDVFM DMLDVFM DN GB88 DMLDVFM TI TTQR74A DMLDVFM TN Proteinase activated receptor 2 (PAR2) DMLDVFM MA Antagonist DMLDVFM RN Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br J Pharmacol. 2012 Mar;165(5):1413-23. DMLDVFM RU https://pubmed.ncbi.nlm.nih.gov/21806599 DMLDWCB DI DMLDWCB DMLDWCB DN RPR-118723 DMLDWCB TI TTVPQTF DMLDWCB TN Glutamate receptor AMPA 1 (GRIA1) DMLDWCB MA Inhibitor DMLDWCB RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DMLDWCB RU https://pubmed.ncbi.nlm.nih.gov/10882363 DMLDWCB DI DMLDWCB DMLDWCB DN RPR-118723 DMLDWCB TI TTLD29N DMLDWCB TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMLDWCB MA Inhibitor DMLDWCB RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DMLDWCB RU https://pubmed.ncbi.nlm.nih.gov/10882363 DMLDWCB DI DMLDWCB DMLDWCB DN RPR-118723 DMLDWCB TI TTN9D8E DMLDWCB TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMLDWCB MA Inhibitor DMLDWCB RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DMLDWCB RU https://pubmed.ncbi.nlm.nih.gov/10882363 DMLDWCB DI DMLDWCB DMLDWCB DN RPR-118723 DMLDWCB TI TTKJEMQ DMLDWCB TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMLDWCB MA Inhibitor DMLDWCB RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DMLDWCB RU https://pubmed.ncbi.nlm.nih.gov/10882363 DMLDWCB DI DMLDWCB DMLDWCB DN RPR-118723 DMLDWCB TI TTAN6JD DMLDWCB TN Glutamate receptor AMPA (GRIA) DMLDWCB MA Inhibitor DMLDWCB RN Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81. DMLDWCB RU https://pubmed.ncbi.nlm.nih.gov/10882363 DMLDWFE DI DMLDWFE DMLDWFE DN FGGFTGARKSARKLFNQ DMLDWFE TI TTNT7K8 DMLDWFE TN Nociceptin receptor (OPRL1) DMLDWFE MA Inhibitor DMLDWFE RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMLDWFE RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMLDWHP DI DMLDWHP DMLDWHP DN ATI-2341 DMLDWHP TI TTBID49 DMLDWHP TN C-X-C chemokine receptor type 4 (CXCR4) DMLDWHP MA Agonist DMLDWHP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMLDWHP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMLDY3H DI DMLDY3H DMLDY3H DN 1-[(tert-butylamino)ethyl]-1,1-bisphosphonicacid DMLDY3H TI TTIKWV4 DMLDY3H TN Geranyltranstransferase (FDPS) DMLDY3H MA Inhibitor DMLDY3H RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DMLDY3H RU https://pubmed.ncbi.nlm.nih.gov/18096393 DMLDYVB DI DMLDYVB DMLDYVB DN TURBINATINE DMLDYVB TI TT1RS9F DMLDYVB TN Acetylcholinesterase (AChE) DMLDYVB MA Inhibitor DMLDYVB RN Indole glucoalkaloids from Chimarrhis turbinata and their evaluation as antioxidant agents and acetylcholinesterase inhibitors. J Nat Prod. 2004 Nov;67(11):1882-5. DMLDYVB RU https://pubmed.ncbi.nlm.nih.gov/15568781 DMLE0I7 DI DMLE0I7 DMLE0I7 DN 4557W DMLE0I7 TI TTGKNB4 DMLE0I7 TN Epidermal growth factor receptor (EGFR) DMLE0I7 MA Inhibitor DMLE0I7 RN Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5. DMLE0I7 RU https://pubmed.ncbi.nlm.nih.gov/11378364 DMLE0I7 DI DMLE0I7 DMLE0I7 DN 4557W DMLE0I7 TI TTR5TV4 DMLE0I7 TN ERBB2 messenger RNA (HER2 mRNA) DMLE0I7 MA Inhibitor DMLE0I7 RN Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5. DMLE0I7 RU https://pubmed.ncbi.nlm.nih.gov/11378364 DMLE1IJ DI DMLE1IJ DMLE1IJ DN ISIS 29159 DMLE1IJ TI TTO6SGY DMLE1IJ TN AKT3 messenger RNA (AKT3 mRNA) DMLE1IJ RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMLE1IJ RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMLE7YQ DI DMLE7YQ DMLE7YQ DN ISIS 138612 DMLE7YQ TI TTTEOPU DMLE7YQ TN Helicase-moi messenger RNA (DICER1 mRNA) DMLE7YQ RN US patent application no. 7,427,470, Antisense modulation of helicase-moi expression. DMLE7YQ RU http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true DMLEDHR DI DMLEDHR DMLEDHR DN AL-43 DMLEDHR TI TTOZRK6 DMLEDHR TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMLEDHR MA Inhibitor DMLEDHR RN Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1721-7. DMLEDHR RU https://pubmed.ncbi.nlm.nih.gov/15026058 DMLEDHR DI DMLEDHR DMLEDHR DN AL-43 DMLEDHR TI TTKPW01 DMLEDHR TN Androgen receptor messenger RNA (AR mRNA) DMLEDHR MA Inhibitor DMLEDHR RN Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30. DMLEDHR RU https://pubmed.ncbi.nlm.nih.gov/12620078 DMLEDHR DI DMLEDHR DMLEDHR DN AL-43 DMLEDHR TI TTUV8G9 DMLEDHR TN Progesterone receptor (PGR) DMLEDHR MA Inhibitor DMLEDHR RN Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30. DMLEDHR RU https://pubmed.ncbi.nlm.nih.gov/12620078 DMLEDHR DI DMLEDHR DMLEDHR DN AL-43 DMLEDHR TI TT26PHO DMLEDHR TN Mineralocorticoid receptor (MR) DMLEDHR MA Inhibitor DMLEDHR RN Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dih... J Med Chem. 2003 Mar 13;46(6):1016-30. DMLEDHR RU https://pubmed.ncbi.nlm.nih.gov/12620078 DMLEMUX DI DMLEMUX DMLEMUX DN N1-[4-(Phenylmethoxy)phenyl]-L-aspartamine DMLEMUX TI TTXZEAJ DMLEMUX TN Leukotriene A-4 hydrolase (LTA4H) DMLEMUX MA Inhibitor DMLEMUX RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMLEMUX RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMLEN4X DI DMLEN4X DMLEN4X DN NSC-56071 DMLEN4X TI TTHVCUP DMLEN4X TN DNA [cytosine-5]-methyltransferase (DNMT) DMLEN4X MA Inhibitor DMLEN4X RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMLEN4X RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMLEN4X DI DMLEN4X DMLEN4X DN NSC-56071 DMLEN4X TI TT6VZ78 DMLEN4X TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMLEN4X MA Inhibitor DMLEN4X RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMLEN4X RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMLEPYN DI DMLEPYN DMLEPYN DN Tetramethylammonium Ion DMLEPYN TI TTGRHIB DMLEPYN TN UDP-glucose 4-epimerase (GALE) DMLEPYN MA Inhibitor DMLEPYN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLEPYN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLES7J DI DMLES7J DMLES7J DN ISIS 29232 DMLES7J TI TTYMGWX DMLES7J TN PDK-1 messenger RNA (PDK-1 mRNA) DMLES7J RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMLES7J RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMLEUF6 DI DMLEUF6 DMLEUF6 DN Tyr-Pro-Phe-D-Ala-Bn DMLEUF6 TI TTKWM86 DMLEUF6 TN Opioid receptor mu (MOP) DMLEUF6 MA Inhibitor DMLEUF6 RN Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. DMLEUF6 RU https://pubmed.ncbi.nlm.nih.gov/19679474 DMLEUP2 DI DMLEUP2 DMLEUP2 DN 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone DMLEUP2 TI TTNJYV2 DMLEUP2 TN Gamma-aminobutyric acid receptor (GAR) DMLEUP2 MA Inhibitor DMLEUP2 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMLEUP2 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMLEUP2 DI DMLEUP2 DMLEUP2 DN 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone DMLEUP2 TI TT06RH5 DMLEUP2 TN GABA(A) receptor gamma-2 (GABRG2) DMLEUP2 MA Inhibitor DMLEUP2 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMLEUP2 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMLEUP2 DI DMLEUP2 DMLEUP2 DN 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone DMLEUP2 TI TTZA1NY DMLEUP2 TN GABA(A) receptor beta-2 (GABRB2) DMLEUP2 MA Inhibitor DMLEUP2 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMLEUP2 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMLEUP2 DI DMLEUP2 DMLEUP2 DN 6-ethyl-3-(2-ethylbutoxycarbonyl)-4-quinolone DMLEUP2 TI TT1MPAY DMLEUP2 TN GABA(A) receptor alpha-1 (GABRA1) DMLEUP2 MA Inhibitor DMLEUP2 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMLEUP2 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMLEXN0 DI DMLEXN0 DMLEXN0 DN Chrysamine -G DMLEXN0 TI TTE4KHA DMLEXN0 TN Amyloid beta A4 protein (APP) DMLEXN0 MA Inhibitor DMLEXN0 RN Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9. DMLEXN0 RU https://pubmed.ncbi.nlm.nih.gov/17004725 DMLEXWC DI DMLEXWC DMLEXWC DN 3beta,6beta-dihydroxyolean-12-en-27-oic acid DMLEXWC TI TTELIN2 DMLEXWC TN PTPN1 messenger RNA (PTPN1 mRNA) DMLEXWC MA Inhibitor DMLEXWC RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DMLEXWC RU https://pubmed.ncbi.nlm.nih.gov/16580200 DMLEZKJ DI DMLEZKJ DMLEZKJ DN (2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid DMLEZKJ TI TT1MPAY DMLEZKJ TN GABA(A) receptor alpha-1 (GABRA1) DMLEZKJ MA Inhibitor DMLEZKJ RN ( )-2-amino-2-thiazoline-4-ethanoic acid; a novel, specific GABAA receptor agonist. Bioorg. Med. Chem. Lett. 1(5):247-248 (1991). DMLEZKJ RU http://www.sciencedirect.com/science/article/pii/S0960894X01810350 DMLEZKJ DI DMLEZKJ DMLEZKJ DN (2-Amino-4,5-dihydro-thiazol-4-yl)-acetic acid DMLEZKJ TI TTNJYV2 DMLEZKJ TN Gamma-aminobutyric acid receptor (GAR) DMLEZKJ MA Inhibitor DMLEZKJ RN ( )-2-amino-2-thiazoline-4-ethanoic acid; a novel, specific GABAA receptor agonist. Bioorg. Med. Chem. Lett. 1(5):247-248 (1991). DMLEZKJ RU http://www.sciencedirect.com/science/article/pii/S0960894X01810350 DMLF7MK DI DMLF7MK DMLF7MK DN chlorobenzylidene malononitrile DMLF7MK TI TTELV3W DMLF7MK TN Transformation-sensitive protein p120 (TRPA1) DMLF7MK MA Activator DMLF7MK RN Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. 2008 Sep 1;231(2):150-6. DMLF7MK RU https://pubmed.ncbi.nlm.nih.gov/18501939 DMLF7SG DI DMLF7SG DMLF7SG DN [3H]AMPA DMLF7SG TI TTPJR0G DMLF7SG TN Glutamate receptor AMPA 4 (GRIA4) DMLF7SG MA Agonist DMLF7SG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447). DMLF7SG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447 DMLF7SG DI DMLF7SG DMLF7SG DN [3H]AMPA DMLF7SG TI TTVPQTF DMLF7SG TN Glutamate receptor AMPA 1 (GRIA1) DMLF7SG MA Agonist DMLF7SG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444). DMLF7SG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444 DMLF7SG DI DMLF7SG DMLF7SG DN [3H]AMPA DMLF7SG TI TT82EZV DMLF7SG TN Glutamate receptor AMPA 3 (GRIA3) DMLF7SG MA Modulator DMLF7SG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446). DMLF7SG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446 DMLF7SG DI DMLF7SG DMLF7SG DN [3H]AMPA DMLF7SG TI TT9HLZ0 DMLF7SG TN Glutamate receptor AMPA 2 (GRIA2) DMLF7SG MA Agonist DMLF7SG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445). DMLF7SG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445 DMLFJHE DI DMLFJHE DMLFJHE DN Pycnogenol DMLFJHE TI TTSXVID DMLFJHE TN Nuclear factor NF-kappa-B (NFKB) DMLFJHE MA Inhibitor DMLFJHE RN Inhibition mechanisms of bioflavonoids extracted from the bark of Pinus maritima on the expression of proinflammatory cytokines. Ann N Y Acad Sci. 2001 Apr;928:141-56. DMLFJHE RU https://pubmed.ncbi.nlm.nih.gov/11795505 DMLFNTH DI DMLFNTH DMLFNTH DN CP-100263 DMLFNTH TI TTZPO1L DMLFNTH TN Substance-P receptor (TACR1) DMLFNTH MA Antagonist DMLFNTH RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMLFNTH RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMLFOPV DI DMLFOPV DMLFOPV DN (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}serinamide DMLFOPV TI TTGP7BY DMLFOPV TN Monoamine oxidase type B (MAO-B) DMLFOPV MA Inhibitor DMLFOPV RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMLFOPV RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMLFQKU DI DMLFQKU DMLFQKU DN pyrazolone, 1 DMLFQKU TI TTOJ1NF DMLFQKU TN FMLP-related receptor I (FPR2) DMLFQKU MA Agonist DMLFQKU RN Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3713-8. DMLFQKU RU https://pubmed.ncbi.nlm.nih.gov/16697190 DMLFQKU DI DMLFQKU DMLFQKU DN pyrazolone, 1 DMLFQKU TI TT5Y4EM DMLFQKU TN N-formyl peptide receptor (FPR1) DMLFQKU MA Agonist DMLFQKU RN Functional characterization of three mouse formyl peptide receptors. Mol Pharmacol. 2013 Feb;83(2):389-98. DMLFQKU RU https://pubmed.ncbi.nlm.nih.gov/23160941 DMLFY2T DI DMLFY2T DMLFY2T DN 5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole DMLFY2T TI TTXZEAJ DMLFY2T TN Leukotriene A-4 hydrolase (LTA4H) DMLFY2T MA Inhibitor DMLFY2T RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLFY2T RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLFZ6Q DI DMLFZ6Q DMLFZ6Q DN 4-tert-Butyl-N-(4-phenyl-thiazol-2-yl)-benzamide DMLFZ6Q TI TTK25J1 DMLFZ6Q TN Adenosine A1 receptor (ADORA1) DMLFZ6Q MA Inhibitor DMLFZ6Q RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMLFZ6Q RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMLG05U DI DMLG05U DMLG05U DN NSC-625987 DMLG05U TI TT0PG8F DMLG05U TN Cyclin-dependent kinase 4 (CDK4) DMLG05U MA Inhibitor DMLG05U RN The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86. DMLG05U RU https://pubmed.ncbi.nlm.nih.gov/10632371 DMLG05U DI DMLG05U DMLG05U DN NSC-625987 DMLG05U TI TT7HF4W DMLG05U TN Cyclin-dependent kinase 2 (CDK2) DMLG05U MA Inhibitor DMLG05U RN The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. Clin Cancer Res. 1999 Dec;5(12):4279-86. DMLG05U RU https://pubmed.ncbi.nlm.nih.gov/10632371 DMLG2EA DI DMLG2EA DMLG2EA DN Ki-11502 DMLG2EA TI TTI7421 DMLG2EA TN Platelet-derived growth factor receptor beta (PDGFRB) DMLG2EA MA Inhibitor DMLG2EA RN Identification of potent and selective inhibitors of PDGF receptor autophosphorylation. J Med Chem. 2006 Apr 6;49(7):2186-92. DMLG2EA RU https://pubmed.ncbi.nlm.nih.gov/16570914 DMLG69R DI DMLG69R DMLG69R DN 3-Fluoro-4-hydrazino-benzenesulfonamide DMLG69R TI TTHQPL7 DMLG69R TN Carbonic anhydrase I (CA-I) DMLG69R MA Inhibitor DMLG69R RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMLG69R RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMLG69R DI DMLG69R DMLG69R DN 3-Fluoro-4-hydrazino-benzenesulfonamide DMLG69R TI TTANPDJ DMLG69R TN Carbonic anhydrase II (CA-II) DMLG69R MA Inhibitor DMLG69R RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMLG69R RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMLG69R DI DMLG69R DMLG69R DN 3-Fluoro-4-hydrazino-benzenesulfonamide DMLG69R TI TT2LVK8 DMLG69R TN Carbonic anhydrase IX (CA-IX) DMLG69R MA Inhibitor DMLG69R RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMLG69R RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMLG8Q2 DI DMLG8Q2 DMLG8Q2 DN (S)-tert-Butyl 4-(2-oxohexadecanamido)pentanoate DMLG8Q2 TI TTT1JVS DMLG8Q2 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMLG8Q2 MA Inhibitor DMLG8Q2 RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMLG8Q2 RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMLGK27 DI DMLGK27 DMLGK27 DN LA-N8 DMLGK27 TI TT1290U DMLGK27 TN Coagulation factor VIII (F8) DMLGK27 MA Modulator DMLGK27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMLGK27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMLGKD3 DI DMLGKD3 DMLGKD3 DN PMID21927650C18 DMLGKD3 TI TTHS256 DMLGKD3 TN Metabotropic glutamate receptor 5 (mGluR5) DMLGKD3 MA Modulator (allosteric modulator) DMLGKD3 RN (3-Cyano-5-fluorophenyl)biaryl negative allosteric modulators of mGlu(5): Discovery of a new tool compound with activity in the OSS mouse model of addiction. ACS Chem Neurosci. 2011 Aug 17;2(8):471-482. DMLGKD3 RU https://pubmed.ncbi.nlm.nih.gov/21927650 DMLGMTQ DI DMLGMTQ DMLGMTQ DN alpha.beta-methylene-2-thio-UDP DMLGMTQ TI TT72OKI DMLGMTQ TN P2Y purinoceptor 14 (P2RY14) DMLGMTQ MA Agonist DMLGMTQ RN Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J Med Chem. 2010 Jan 14;53(1):471-80. DMLGMTQ RU https://pubmed.ncbi.nlm.nih.gov/19902968 DMLGS82 DI DMLGS82 DMLGS82 DN Caprylic acid DMLGS82 TI TTPH97Y DMLGS82 TN Mycobacterium 3-oxoacyl-[acyl-carrier-protein] synthase 1 (MycB kasA) DMLGS82 MA Inhibitor DMLGS82 RN Characterization of ochratoxin A transport by human organic anion transporters. Life Sci. 2001 Sep 21;69(18):2123-35. DMLGS82 RU https://pubmed.ncbi.nlm.nih.gov/11669456 DMLGWHM DI DMLGWHM DMLGWHM DN NSC-381864 DMLGWHM TI TTJLP0R DMLGWHM TN Quinone reductase 2 (NQO2) DMLGWHM MA Inhibitor DMLGWHM RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMLGWHM RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMLH1PK DI DMLH1PK DMLH1PK DN XE991 DMLH1PK TI TTWVL5Q DMLH1PK TN Voltage-gated potassium channel Kv7.5 (KCNQ5) DMLH1PK MA Blocker (channel blocker) DMLH1PK RN KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. J Biol Chem. 2000 Aug 4;275(31):24089-95. DMLH1PK RU https://pubmed.ncbi.nlm.nih.gov/10816588 DMLH1PK DI DMLH1PK DMLH1PK DN XE991 DMLH1PK TI TT8HGRW DMLH1PK TN Voltage-gated potassium channel Kv7.4 (KCNQ4) DMLH1PK MA Blocker (channel blocker) DMLH1PK RN KCNQ4 channels expressed in mammalian cells: functional characteristics and pharmacology. Am J Physiol Cell Physiol. 2001 Apr;280(4):C859-66. DMLH1PK RU https://pubmed.ncbi.nlm.nih.gov/11245603 DMLH1PK DI DMLH1PK DMLH1PK DN XE991 DMLH1PK TI TT846HF DMLH1PK TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMLH1PK MA Blocker (channel blocker) DMLH1PK RN Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol Pharmacol. 2000 Jun;57(6):1218-23. DMLH1PK RU https://pubmed.ncbi.nlm.nih.gov/10825393 DMLH1PK DI DMLH1PK DMLH1PK DN XE991 DMLH1PK TI TTPXI3S DMLH1PK TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DMLH1PK MA Blocker (channel blocker) DMLH1PK RN KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998 Dec 4;282(5395):1890-3. DMLH1PK RU https://pubmed.ncbi.nlm.nih.gov/9836639 DMLH23M DI DMLH23M DMLH23M DN N-n-nonyl-7-methoxytacrine hydrochloride DMLH23M TI TT1RS9F DMLH23M TN Acetylcholinesterase (AChE) DMLH23M MA Inhibitor DMLH23M RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMLH23M RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMLH23M DI DMLH23M DMLH23M DN N-n-nonyl-7-methoxytacrine hydrochloride DMLH23M TI TTEB0GD DMLH23M TN Cholinesterase (BCHE) DMLH23M MA Inhibitor DMLH23M RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMLH23M RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMLH546 DI DMLH546 DMLH546 DN FR236913 DMLH546 TI TTLP57V DMLH546 TN Adenosine deaminase (ADA) DMLH546 MA Inhibitor DMLH546 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLH546 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLH73O DI DMLH73O DMLH73O DN PMID10602705C40 DMLH73O TI TT9PBIL DMLH73O TN Glutamyl aminopeptidase (ENPEP) DMLH73O MA Inhibitor DMLH73O RN Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme. J Med Chem. 1999 Dec 16;42(25):5197-211. DMLH73O RU https://pubmed.ncbi.nlm.nih.gov/10602705 DMLH7YI DI DMLH7YI DMLH7YI DN 3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine DMLH7YI TI TTRA5BZ DMLH7YI TN Steroid 17-alpha-monooxygenase (S17AH) DMLH7YI MA Inhibitor DMLH7YI RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMLH7YI RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMLH7YI DI DMLH7YI DMLH7YI DN 3-(1-Chloro-7-methoxy-naphthalen-2-yl)-pyridine DMLH7YI TI TTIQUX7 DMLH7YI TN Steroid 11-beta-hydroxylase (CYP11B1) DMLH7YI MA Inhibitor DMLH7YI RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMLH7YI RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMLHA6K DI DMLHA6K DMLHA6K DN ISIS 122974 DMLHA6K TI TTJZNIG DMLHA6K TN MEKK3 messenger RNA (MAP3K3 mRNA) DMLHA6K RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DMLHA6K RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DMLHDE3 DI DMLHDE3 DMLHDE3 DN 1-(7-Methoxy-2-phenyl-chroman-4-yl)-1H-imidazole DMLHDE3 TI TTSZLWK DMLHDE3 TN Aromatase (CYP19A1) DMLHDE3 MA Inhibitor DMLHDE3 RN Synthesis and evaluation of 4-triazolylflavans as new aromatase inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5215-8. DMLHDE3 RU https://pubmed.ncbi.nlm.nih.gov/15380230 DMLHF3E DI DMLHF3E DMLHF3E DN Conantokins G DMLHF3E TI TTN9D8E DMLHF3E TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMLHF3E MA Antagonist DMLHF3E RN Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16. DMLHF3E RU https://pubmed.ncbi.nlm.nih.gov/12507705 DMLHI5T DI DMLHI5T DMLHI5T DN 7-Phenyl-1-(thiazol-2-yl)-heptan-1-one DMLHI5T TI TTDP1UC DMLHI5T TN Fatty acid amide hydrolase (FAAH) DMLHI5T MA Inhibitor DMLHI5T RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMLHI5T RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMLHKI9 DI DMLHKI9 DMLHKI9 DN Dodecyl-phosphonic acid DMLHKI9 TI TTQ6S1K DMLHKI9 TN Lysophosphatidic acid receptor 1 (LPAR1) DMLHKI9 MA Inhibitor DMLHKI9 RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMLHKI9 RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMLHKQS DI DMLHKQS DMLHKQS DN Benzaldehyde O-4-methoxyphenylcarbamoyl oxime DMLHKQS TI TTDP1UC DMLHKQS TN Fatty acid amide hydrolase (FAAH) DMLHKQS MA Inhibitor DMLHKQS RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMLHKQS RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMLHQ2J DI DMLHQ2J DMLHQ2J DN ISIS 24448 DMLHQ2J TI TTJMF9P DMLHQ2J TN ITGA4 messenger RNA (ITGA4 mRNA) DMLHQ2J RN US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression. DMLHQ2J RU http://www.patentbuddy.com/Patent/6258790?ft=true&sr=true DMLHUPY DI DMLHUPY DMLHUPY DN Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9,Tyr11]SRIF DMLHUPY TI TTIND6G DMLHUPY TN Somatostatin receptor type 1 (SSTR1) DMLHUPY MA Inhibitor DMLHUPY RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMLHUPY RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMLHVWP DI DMLHVWP DMLHVWP DN 1,1,1-Trifluoro-7-phenylheptan-2-one DMLHVWP TI TTT1JVS DMLHVWP TN Cytosolic phospholipase A2 (GIVA cPLA2) DMLHVWP MA Inhibitor DMLHVWP RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMLHVWP RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMLHVWP DI DMLHVWP DMLHVWP DN 1,1,1-Trifluoro-7-phenylheptan-2-one DMLHVWP TI TTDP1UC DMLHVWP TN Fatty acid amide hydrolase (FAAH) DMLHVWP MA Inhibitor DMLHVWP RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DMLHVWP RU https://pubmed.ncbi.nlm.nih.gov/15771430 DMLHWNG DI DMLHWNG DMLHWNG DN Naphthalene-2,6-disulfonic acid DMLHWNG TI TTAZHU0 DMLHWNG TN L-lactate dehydrogenase (LDH) DMLHWNG MA Inhibitor DMLHWNG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLHWNG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLI4RF DI DMLI4RF DMLI4RF DN Prifelone DMLI4RF TI TTVKILB DMLI4RF TN Prostaglandin G/H synthase 2 (COX-2) DMLI4RF MA Inhibitor DMLI4RF RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMLI4RF RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMLI4RF DI DMLI4RF DMLI4RF DN Prifelone DMLI4RF TI TT8NGED DMLI4RF TN Prostaglandin G/H synthase 1 (COX-1) DMLI4RF MA Inhibitor DMLI4RF RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMLI4RF RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMLI5U2 DI DMLI5U2 DMLI5U2 DN RS-513815 DMLI5U2 TI TTNGILX DMLI5U2 TN Adrenergic receptor alpha-1A (ADRA1A) DMLI5U2 MA Inhibitor DMLI5U2 RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMLI5U2 RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMLI5UT DI DMLI5UT DMLI5UT DN 2,3,5-Trimethoxy-4'-amino-trans-stilbene DMLI5UT TI TTSZLWK DMLI5UT TN Aromatase (CYP19A1) DMLI5UT MA Inhibitor DMLI5UT RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMLI5UT RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMLI5VH DI DMLI5VH DMLI5VH DN MDL 100,453 DMLI5VH TI TTKJEMQ DMLI5VH TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMLI5VH MA Antagonist DMLI5VH RN Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther. 1999 Sep;290(3):1034-40. DMLI5VH RU https://pubmed.ncbi.nlm.nih.gov/10454475 DMLI7F4 DI DMLI7F4 DMLI7F4 DN 3-(imidazolylmethyl)flavone DMLI7F4 TI TTSZLWK DMLI7F4 TN Aromatase (CYP19A1) DMLI7F4 MA Inhibitor DMLI7F4 RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DMLI7F4 RU https://pubmed.ncbi.nlm.nih.gov/16854084 DMLI8GZ DI DMLI8GZ DMLI8GZ DN ZD1604 DMLI8GZ TI TTU6BFZ DMLI8GZ TN Candida Thymidylate synthase (Candi TMP1) DMLI8GZ MA Inhibitor DMLI8GZ RN Acquisition of resistance to anticancer agents by overproduction of target enzymes. Nippon Rinsho. 1997 May;55(5):1030-7. DMLI8GZ RU https://pubmed.ncbi.nlm.nih.gov/9155148 DMLIG3X DI DMLIG3X DMLIG3X DN 3,5 DIBROMOTYROSINE DMLIG3X TI TTAUX24 DMLIG3X TN Erythropoietin Receptor (EPOR) DMLIG3X MA Inhibitor DMLIG3X RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLIG3X RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLIJYS DI DMLIJYS DMLIJYS DN 1-(9-Phenyl-9H-fluoren-9-yl)1H-imidazole DMLIJYS TI TTSZLWK DMLIJYS TN Aromatase (CYP19A1) DMLIJYS MA Inhibitor DMLIJYS RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMLIJYS RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMLIK7X DI DMLIK7X DMLIK7X DN KRP 203-phosphate DMLIK7X TI TTZ8C5Q DMLIK7X TN Sphingosine-1-phosphate receptor 4 (S1PR4) DMLIK7X MA Agonist DMLIK7X RN A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-d... J Pharmacol Exp Ther. 2008 Jan;324(1):276-83. DMLIK7X RU https://pubmed.ncbi.nlm.nih.gov/17898319 DMLIK7X DI DMLIK7X DMLIK7X DN KRP 203-phosphate DMLIK7X TI TT9JZCK DMLIK7X TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMLIK7X MA Agonist DMLIK7X RN A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-d... J Pharmacol Exp Ther. 2008 Jan;324(1):276-83. DMLIK7X RU https://pubmed.ncbi.nlm.nih.gov/17898319 DMLIMOP DI DMLIMOP DMLIMOP DN 5-hexyl-2-(pyridin-2-yloxy)phenol DMLIMOP TI TTVTX4N DMLIMOP TN Bacterial Fatty acid synthetase I (Bact inhA) DMLIMOP MA Inhibitor DMLIMOP RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMLIMOP RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMLIOV2 DI DMLIOV2 DMLIOV2 DN ADS-103254 DMLIOV2 TI TTX4RTB DMLIOV2 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMLIOV2 MA Inhibitor DMLIOV2 RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMLIOV2 RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMLIQUA DI DMLIQUA DMLIQUA DN (E)-5-(3-Chlorostyryl)isatin DMLIQUA TI TT3WG5C DMLIQUA TN Monoamine oxidase type A (MAO-A) DMLIQUA MA Inhibitor DMLIQUA RN Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. DMLIQUA RU https://pubmed.ncbi.nlm.nih.gov/19342233 DMLIQUA DI DMLIQUA DMLIQUA DN (E)-5-(3-Chlorostyryl)isatin DMLIQUA TI TTGP7BY DMLIQUA TN Monoamine oxidase type B (MAO-B) DMLIQUA MA Inhibitor DMLIQUA RN Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. DMLIQUA RU https://pubmed.ncbi.nlm.nih.gov/19342233 DMLIRKY DI DMLIRKY DMLIRKY DN ISIS 9002 DMLIRKY TI TTR5TV4 DMLIRKY TN ERBB2 messenger RNA (HER2 mRNA) DMLIRKY RN US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression. DMLIRKY RU http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true DMLISP2 DI DMLISP2 DMLISP2 DN Glucose analogue DMLISP2 TI TTYXA6Z DMLISP2 TN Plasmodium Hexose transporter 1 (Malaria ht1) DMLISP2 MA Binder DMLISP2 RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMLISP2 RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMLIT84 DI DMLIT84 DMLIT84 DN BBT-021 DMLIT84 TI TTAUX24 DMLIT84 TN Erythropoietin Receptor (EPOR) DMLIT84 MA Stimulator DMLIT84 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DMLIT84 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DMLIXJW DI DMLIXJW DMLIXJW DN PMID1656041C11jj DMLIXJW TI TTPADOQ DMLIXJW TN HMG-CoA reductase (HMGCR) DMLIXJW MA Inhibitor DMLIXJW RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83. DMLIXJW RU https://pubmed.ncbi.nlm.nih.gov/1656041 DMLIYUJ DI DMLIYUJ DMLIYUJ DN 7-(4-methoxyphenyl)pteridine-2,4-diol DMLIYUJ TI TTGX0HR DMLIYUJ TN Bacterial DNA ligase (Bact ligA) DMLIYUJ MA Inhibitor DMLIYUJ RN Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62. DMLIYUJ RU https://pubmed.ncbi.nlm.nih.gov/18630893 DMLJ30O DI DMLJ30O DMLJ30O DN 2-N-(n-Propyl)amino-1-(4-methylthiophenyl)butane DMLJ30O TI TT3ROYC DMLJ30O TN Serotonin transporter (SERT) DMLJ30O MA Inhibitor DMLJ30O RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMLJ30O RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMLJ645 DI DMLJ645 DMLJ645 DN INDUS-815C DMLJ645 TI TTLKF5M DMLJ645 TN NAD-dependent deacetylase sirtuin-2 (SIRT2) DMLJ645 MA Inhibitor DMLJ645 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2708). DMLJ645 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2708 DMLJ7WA DI DMLJ7WA DMLJ7WA DN 1-(1-(Biphenyl-4-yl)allyl)-1H-imidazole DMLJ7WA TI TTRA5BZ DMLJ7WA TN Steroid 17-alpha-monooxygenase (S17AH) DMLJ7WA MA Inhibitor DMLJ7WA RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMLJ7WA RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMLJ8T7 DI DMLJ8T7 DMLJ8T7 DN SC-55634 DMLJ8T7 TI TTQVOEI DMLJ8T7 TN Angiotensin II receptor type-2 (AGTR2) DMLJ8T7 MA Inhibitor DMLJ8T7 RN N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993). DMLJ8T7 RU http://www.sciencedirect.com/science/article/pii/S0960894X00802863 DMLJBU8 DI DMLJBU8 DMLJBU8 DN ISIS 1822 DMLJBU8 TI TTSJ6Q4 DMLJBU8 TN LOX-5 messenger RNA (ALOX5 mRNA) DMLJBU8 RN US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism. DMLJBU8 RU http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true DMLJBVP DI DMLJBVP DMLJBVP DN Ohioensin G DMLJBVP TI TTELIN2 DMLJBVP TN PTPN1 messenger RNA (PTPN1 mRNA) DMLJBVP MA Inhibitor DMLJBVP RN Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5. DMLJBVP RU https://pubmed.ncbi.nlm.nih.gov/18053716 DMLJDU5 DI DMLJDU5 DMLJDU5 DN 4-nitro-N-(quinolin-8-yl)benzenesulfonamide DMLJDU5 TI TTSXVID DMLJDU5 TN Nuclear factor NF-kappa-B (NFKB) DMLJDU5 MA Inhibitor DMLJDU5 RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DMLJDU5 RU https://pubmed.ncbi.nlm.nih.gov/18024113 DMLJGF1 DI DMLJGF1 DMLJGF1 DN 3-chloro-N-(6-methylpyridin-2-yl)benzamide DMLJGF1 TI TTHS256 DMLJGF1 TN Metabotropic glutamate receptor 5 (mGluR5) DMLJGF1 MA Inhibitor DMLJGF1 RN Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75. DMLJGF1 RU https://pubmed.ncbi.nlm.nih.gov/19445453 DMLJGVX DI DMLJGVX DMLJGVX DN CHF-2819 DMLJGVX TI TT1RS9F DMLJGVX TN Acetylcholinesterase (AChE) DMLJGVX MA Inhibitor DMLJGVX RN Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug g... J Med Chem. 2006 Aug 24;49(17):5051-8. DMLJGVX RU https://pubmed.ncbi.nlm.nih.gov/16913695 DMLJGVX DI DMLJGVX DMLJGVX DN CHF-2819 DMLJGVX TI TTEB0GD DMLJGVX TN Cholinesterase (BCHE) DMLJGVX MA Inhibitor DMLJGVX RN Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. J Med Chem. 2005 Feb 24;48(4):986-94. DMLJGVX RU https://pubmed.ncbi.nlm.nih.gov/15715468 DMLJH92 DI DMLJH92 DMLJH92 DN 2-(3-(2-methylquinolin-7-yl)phenyl)acetonitrile DMLJH92 TI TTHS256 DMLJH92 TN Metabotropic glutamate receptor 5 (mGluR5) DMLJH92 MA Inhibitor DMLJH92 RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMLJH92 RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMLJITC DI DMLJITC DMLJITC DN S26284 DMLJITC TI TT0WAIE DMLJITC TN Melatonin receptor type 1A (MTNR1A) DMLJITC MA Agonist DMLJITC RN New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003 Jun;367(6):553-61. DMLJITC RU https://pubmed.ncbi.nlm.nih.gov/12764576 DMLJMOD DI DMLJMOD DMLJMOD DN Benzyloxycarbonyl-glycylryanodine DMLJMOD TI TTU5CIX DMLJMOD TN Ryanodine receptor 1 (RYR1) DMLJMOD MA Inhibitor DMLJMOD RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMLJMOD RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMLJN8Z DI DMLJN8Z DMLJN8Z DN 6-Phenylhexylcarbamic Acid Biphenyl-3-yl Ester DMLJN8Z TI TTDP1UC DMLJN8Z TN Fatty acid amide hydrolase (FAAH) DMLJN8Z MA Inhibitor DMLJN8Z RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMLJN8Z RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMLJOGK DI DMLJOGK DMLJOGK DN Cremastrine DMLJOGK TI TTQ3JTF DMLJOGK TN Muscarinic acetylcholine receptor M4 (CHRM4) DMLJOGK MA Inhibitor DMLJOGK RN Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3. DMLJOGK RU https://pubmed.ncbi.nlm.nih.gov/15844951 DMLJOGK DI DMLJOGK DMLJOGK DN Cremastrine DMLJOGK TI TTH18TF DMLJOGK TN Muscarinic acetylcholine receptor M5 (CHRM5) DMLJOGK MA Inhibitor DMLJOGK RN Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3. DMLJOGK RU https://pubmed.ncbi.nlm.nih.gov/15844951 DMLJOGK DI DMLJOGK DMLJOGK DN Cremastrine DMLJOGK TI TTQ13Z5 DMLJOGK TN Muscarinic acetylcholine receptor M3 (CHRM3) DMLJOGK MA Inhibitor DMLJOGK RN Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3. DMLJOGK RU https://pubmed.ncbi.nlm.nih.gov/15844951 DMLJOGK DI DMLJOGK DMLJOGK DN Cremastrine DMLJOGK TI TTZ9SOR DMLJOGK TN Muscarinic acetylcholine receptor M1 (CHRM1) DMLJOGK MA Inhibitor DMLJOGK RN Cremastrine, a pyrrolizidine alkaloid from Cremastra appendiculata. J Nat Prod. 2005 Apr;68(4):572-3. DMLJOGK RU https://pubmed.ncbi.nlm.nih.gov/15844951 DMLJPDW DI DMLJPDW DMLJPDW DN AZD-7507 DMLJPDW TI TTC70AJ DMLJPDW TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMLJPDW MA Inhibitor DMLJPDW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMLJPDW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMLJQZS DI DMLJQZS DMLJQZS DN 3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine DMLJQZS TI TTIQUX7 DMLJQZS TN Steroid 11-beta-hydroxylase (CYP11B1) DMLJQZS MA Inhibitor DMLJQZS RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMLJQZS RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMLJQZS DI DMLJQZS DMLJQZS DN 3-[5-Ethoxy-indan-(1E)-ylidenemethyl]-pyridine DMLJQZS TI TTSZLWK DMLJQZS TN Aromatase (CYP19A1) DMLJQZS MA Inhibitor DMLJQZS RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMLJQZS RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMLJVB7 DI DMLJVB7 DMLJVB7 DN 5-methyl-benzo[b]thiophen-2-ylboronic acid DMLJVB7 TI TTHI19T DMLJVB7 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMLJVB7 MA Inhibitor DMLJVB7 RN Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54. DMLJVB7 RU https://pubmed.ncbi.nlm.nih.gov/17956081 DMLJZGD DI DMLJZGD DMLJZGD DN N-(furan-2-ylmethyl)estradiol-16-carboxamide DMLJZGD TI TTIWB6L DMLJZGD TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMLJZGD MA Inhibitor DMLJZGD RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMLJZGD RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMLK0J8 DI DMLK0J8 DMLK0J8 DN N-2-Thiophen-2-Yl-Acetamide Boronic Acid DMLK0J8 TI TTHI19T DMLK0J8 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMLK0J8 MA Inhibitor DMLK0J8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLK0J8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLK0TX DI DMLK0TX DMLK0TX DN 9-fluoro-5H-6-thia-4,5-diaza-chrysene 6,6-dioxide DMLK0TX TI TTSXVID DMLK0TX TN Nuclear factor NF-kappa-B (NFKB) DMLK0TX MA Inhibitor DMLK0TX RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DMLK0TX RU https://pubmed.ncbi.nlm.nih.gov/18024113 DMLK2VT DI DMLK2VT DMLK2VT DN 5-Phenyl-6-thia-10b-aza-benzo[e]azulen-4-one DMLK2VT TI TTPTXIN DMLK2VT TN Translocator protein (TSPO) DMLK2VT MA Inhibitor DMLK2VT RN Novel ligands specific for mitochondrial benzodiazepine receptors: 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives. Synthesis, structure-activ... J Med Chem. 1994 May 13;37(10):1427-38. DMLK2VT RU https://pubmed.ncbi.nlm.nih.gov/8182701 DMLK3I9 DI DMLK3I9 DMLK3I9 DN VPC32183 DMLK3I9 TI TTE2YJR DMLK3I9 TN Lysophosphatidate-3 receptor (LPAR3) DMLK3I9 MA Antagonist DMLK3I9 RN Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40. DMLK3I9 RU https://pubmed.ncbi.nlm.nih.gov/15125924 DMLK3I9 DI DMLK3I9 DMLK3I9 DN VPC32183 DMLK3I9 TI TTQ6S1K DMLK3I9 TN Lysophosphatidic acid receptor 1 (LPAR1) DMLK3I9 MA Antagonist DMLK3I9 RN Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40. DMLK3I9 RU https://pubmed.ncbi.nlm.nih.gov/15125924 DMLK428 DI DMLK428 DMLK428 DN D-Phe-Arg-2-Nal-NHCH3 DMLK428 TI TTD0CIQ DMLK428 TN Melanocortin receptor 4 (MC4R) DMLK428 MA Inhibitor DMLK428 RN Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic ap... J Med Chem. 2006 Jul 27;49(15):4745-61. DMLK428 RU https://pubmed.ncbi.nlm.nih.gov/16854081 DMLK428 DI DMLK428 DMLK428 DN D-Phe-Arg-2-Nal-NHCH3 DMLK428 TI TT0MV2T DMLK428 TN Melanocortin receptor 1 (MC1R) DMLK428 MA Inhibitor DMLK428 RN Design, synthesis, and evaluation of proline and pyrrolidine based melanocortin receptor agonists. A conformationally restricted dipeptide mimic ap... J Med Chem. 2006 Jul 27;49(15):4745-61. DMLK428 RU https://pubmed.ncbi.nlm.nih.gov/16854081 DMLK4WO DI DMLK4WO DMLK4WO DN 8R-Lisuride DMLK4WO TI TTTIBOJ DMLK4WO TN Histamine H1 receptor (H1R) DMLK4WO MA Agonist DMLK4WO RN 8R-lisuride is a potent stereospecific histamine H1-receptor partial agonist. Mol Pharmacol. 2004 Mar;65(3):538-49. DMLK4WO RU https://pubmed.ncbi.nlm.nih.gov/14978232 DMLK4X5 DI DMLK4X5 DMLK4X5 DN EGIS-7625 DMLK4X5 TI TTWJBZ5 DMLK4X5 TN 5-HT 2C receptor (HTR2C) DMLK4X5 MA Antagonist DMLK4X5 RN Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34. DMLK4X5 RU https://pubmed.ncbi.nlm.nih.gov/15107597 DMLK4X5 DI DMLK4X5 DMLK4X5 DN EGIS-7625 DMLK4X5 TI TT0K1SC DMLK4X5 TN 5-HT 2B receptor (HTR2B) DMLK4X5 MA Antagonist DMLK4X5 RN Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34. DMLK4X5 RU https://pubmed.ncbi.nlm.nih.gov/15107597 DMLK4X5 DI DMLK4X5 DMLK4X5 DN EGIS-7625 DMLK4X5 TI TTJQOD7 DMLK4X5 TN 5-HT 2A receptor (HTR2A) DMLK4X5 MA Antagonist DMLK4X5 RN Effects of EGIS-7625, a selective and competitive 5-HT2B receptor antagonist. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):427-34. DMLK4X5 RU https://pubmed.ncbi.nlm.nih.gov/15107597 DMLK5I0 DI DMLK5I0 DMLK5I0 DN Bbs-Arg-(D-Pip)-Gly-S-(GS)7-Gly-Hir DMLK5I0 TI TT6L509 DMLK5I0 TN Coagulation factor IIa (F2) DMLK5I0 MA Inhibitor DMLK5I0 RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMLK5I0 RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMLK8YQ DI DMLK8YQ DMLK8YQ DN [Ncy(methyl)4]acyline DMLK8YQ TI TT8R70G DMLK8YQ TN Gonadotropin-releasing hormone receptor (GNRHR) DMLK8YQ MA Inhibitor DMLK8YQ RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMLK8YQ RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMLKA5O DI DMLKA5O DMLKA5O DN 1-(oxazol-2-yl)-7-phenylheptan-1-one DMLKA5O TI TTDP1UC DMLKA5O TN Fatty acid amide hydrolase (FAAH) DMLKA5O MA Inhibitor DMLKA5O RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMLKA5O RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMLKBNR DI DMLKBNR DMLKBNR DN DESMETHYLOLANZAPINE DMLKBNR TI TTQ6VDM DMLKBNR TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMLKBNR MA Inhibitor DMLKBNR RN Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new ... J Med Chem. 2009 Jul 23;52(14):4266-76. DMLKBNR RU https://pubmed.ncbi.nlm.nih.gov/19534531 DMLKFTE DI DMLKFTE DMLKFTE DN PMID20346665C24 DMLKFTE TI TTVBPDM DMLKFTE TN Metabotropic glutamate receptor 1 (mGluR1) DMLKFTE MA Modulator (allosteric modulator) DMLKFTE RN A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2474-7. DMLKFTE RU https://pubmed.ncbi.nlm.nih.gov/20346665 DMLKFZC DI DMLKFZC DMLKFZC DN CL-387785 DMLKFZC TI TTR5TV4 DMLKFZC TN ERBB2 messenger RNA (HER2 mRNA) DMLKFZC MA Inhibitor DMLKFZC RN Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85. DMLKFZC RU https://pubmed.ncbi.nlm.nih.gov/16480284 DMLKFZC DI DMLKFZC DMLKFZC DN CL-387785 DMLKFZC TI TTGKNB4 DMLKFZC TN Epidermal growth factor receptor (EGFR) DMLKFZC MA Inhibitor DMLKFZC RN Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75. DMLKFZC RU https://pubmed.ncbi.nlm.nih.gov/19170633 DMLKFZC DI DMLKFZC DMLKFZC DN CL-387785 DMLKFZC TI TTWALCO DMLKFZC TN HER4 messenger RNA (ERBB4 mRNA) DMLKFZC MA Inhibitor DMLKFZC RN Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85. DMLKFZC RU https://pubmed.ncbi.nlm.nih.gov/16480284 DMLKJD9 DI DMLKJD9 DMLKJD9 DN 9-(4-Hydroxybutyl)-N2-Phenylguanine DMLKJD9 TI TTP3QRF DMLKJD9 TN Thymidine kinase 1 (TK1) DMLKJD9 MA Inhibitor DMLKJD9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLKJD9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLKPZ6 DI DMLKPZ6 DMLKPZ6 DN RP73870 DMLKPZ6 TI TTVFO0U DMLKPZ6 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMLKPZ6 MA Antagonist DMLKPZ6 RN Pharmacological analysis of CCK2 receptor antagonists using isolated rat stomach ECL cells. Br J Pharmacol. 1999 May;127(2):530-6. DMLKPZ6 RU https://pubmed.ncbi.nlm.nih.gov/10385255 DMLKWTG DI DMLKWTG DMLKWTG DN Tricarballylic Acid DMLKWTG TI TTMTF2P DMLKWTG TN Citrate hydro-lyase (ACO2) DMLKWTG MA Inhibitor DMLKWTG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLKWTG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLKZQH DI DMLKZQH DMLKZQH DN cADPR DMLKZQH TI TTEBMN7 DMLKZQH TN Long transient receptor potential channel 2 (TRPM2) DMLKZQH MA Activator DMLKZQH RN Nicotinic acid adenine dinucleotide phosphate and cyclic ADP-ribose regulate TRPM2 channels in T lymphocytes. FASEB J. 2006 May;20(7):962-4. DMLKZQH RU https://pubmed.ncbi.nlm.nih.gov/16585058 DMLM02I DI DMLM02I DMLM02I DN GFPDGG DMLM02I TI TTPADOQ DMLM02I TN HMG-CoA reductase (HMGCR) DMLM02I MA Inhibitor DMLM02I RN Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18. DMLM02I RU https://pubmed.ncbi.nlm.nih.gov/17977732 DMLM2WU DI DMLM2WU DMLM2WU DN 2-fluorophenyl 4-(heptyloxy)phenylcarbamate DMLM2WU TI TTDP1UC DMLM2WU TN Fatty acid amide hydrolase (FAAH) DMLM2WU MA Inhibitor DMLM2WU RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMLM2WU RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMLMCBW DI DMLMCBW DMLMCBW DN 1,2-bis(2,4-difluorophenyl)-2-hydroxyethanone DMLMCBW TI TTMF541 DMLMCBW TN Liver carboxylesterase (CES1) DMLMCBW MA Inhibitor DMLMCBW RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMLMCBW RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMLMOC0 DI DMLMOC0 DMLMOC0 DN 6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMLMOC0 TI TTZAYWL DMLMOC0 TN Estrogen receptor (ESR) DMLMOC0 MA Inhibitor DMLMOC0 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMLMOC0 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMLMOC0 DI DMLMOC0 DMLMOC0 DN 6-Chloro-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMLMOC0 TI TTOM3J0 DMLMOC0 TN Estrogen receptor beta (ESR2) DMLMOC0 MA Inhibitor DMLMOC0 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMLMOC0 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMLMTIY DI DMLMTIY DMLMTIY DN PGlu-His-Trp-Ser-His-D-Tyr-Leu-Arg-Pro-Gly-NH2 DMLMTIY TI TT8R70G DMLMTIY TN Gonadotropin-releasing hormone receptor (GNRHR) DMLMTIY MA Inhibitor DMLMTIY RN Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J Med Chem. 2006 Jan 26;49(2):637-47. DMLMTIY RU https://pubmed.ncbi.nlm.nih.gov/16420049 DMLMU63 DI DMLMU63 DMLMU63 DN A-443654 DMLMU63 TI TTWTSCV DMLMU63 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMLMU63 MA Inhibitor DMLMU63 RN Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J Med Chem. 2007 Jun 28;50(13):2990-3003. DMLMU63 RU https://pubmed.ncbi.nlm.nih.gov/17523610 DMLMV9P DI DMLMV9P DMLMV9P DN L-708568 DMLMV9P TI TTZPO1L DMLMV9P TN Substance-P receptor (TACR1) DMLMV9P MA Inhibitor DMLMV9P RN N-acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists. J Med Chem. 1993 Jul 9;36(14):2044-5. DMLMV9P RU https://pubmed.ncbi.nlm.nih.gov/8393115 DMLMYE0 DI DMLMYE0 DMLMYE0 DN PMID30247903-Compound-General structure8 DMLMYE0 TI TT8ZLTI DMLMYE0 TN Programmed cell death 1 ligand 1 (PD-L1) DMLMYE0 MA Inhibitor DMLMYE0 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMLMYE0 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMLN280 DI DMLN280 DMLN280 DN RQ-00000010 DMLN280 TI TT07C3Y DMLN280 TN 5-HT 4 receptor (HTR4) DMLN280 MA Agonist DMLN280 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMLN280 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMLN2GQ DI DMLN2GQ DMLN2GQ DN Oxalic Acid DMLN2GQ TI TT6PKBN DMLN2GQ TN Proto-oncogene c-Src (SRC) DMLN2GQ MA Inhibitor DMLN2GQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLN2GQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLN4V5 DI DMLN4V5 DMLN4V5 DN EPZ-004777 DMLN4V5 TI TTSZ8T1 DMLN4V5 TN Histone-lysine N-methyltransferase (HLNM) DMLN4V5 MA Inhibitor DMLN4V5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7377). DMLN4V5 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7377 DMLN8XS DI DMLN8XS DMLN8XS DN ISIS 122990 DMLN8XS TI TTJZNIG DMLN8XS TN MEKK3 messenger RNA (MAP3K3 mRNA) DMLN8XS RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DMLN8XS RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DMLND5S DI DMLND5S DMLND5S DN ISIS 119282 DMLND5S TI TTKS60G DMLND5S TN STXBP4 messenger RNA (STXBP4 mRNA) DMLND5S RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DMLND5S RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DMLNJ0O DI DMLNJ0O DMLNJ0O DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) DMLNJ0O TI TT6R7JZ DMLNJ0O TN Histone deacetylase 1 (HDAC1) DMLNJ0O MA Inhibitor DMLNJ0O RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMLNJ0O RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMLNJ0O DI DMLNJ0O DMLNJ0O DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) DMLNJ0O TI TT5ZKDI DMLNJ0O TN Histone deacetylase 6 (HDAC6) DMLNJ0O MA Inhibitor DMLNJ0O RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMLNJ0O RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMLNJ0O DI DMLNJ0O DMLNJ0O DN Cyclo(-L-Am7(S2Py)-Aib-L-Ph5-D-Pro-) DMLNJ0O TI TTTQGH8 DMLNJ0O TN Histone deacetylase 4 (HDAC4) DMLNJ0O MA Inhibitor DMLNJ0O RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMLNJ0O RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMLNQ2F DI DMLNQ2F DMLNQ2F DN Biopterin DMLNQ2F TI TT9SL3Q DMLNQ2F TN Polypeptide deformylase (PDF) DMLNQ2F MA Inhibitor DMLNQ2F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLNQ2F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLNTB5 DI DMLNTB5 DMLNTB5 DN TILIROSIDE DMLNTB5 TI TTXV4FI DMLNTB5 TN Albendazole monooxygenase (CYP3A4) DMLNTB5 MA Inhibitor DMLNTB5 RN Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa. J Nat Prod. 2004 Nov;67(11):1839-41. DMLNTB5 RU https://pubmed.ncbi.nlm.nih.gov/15568772 DMLNVH8 DI DMLNVH8 DMLNVH8 DN TC-2559 DMLNVH8 TI TT5KPZR DMLNVH8 TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMLNVH8 MA Agonist DMLNVH8 RN The nicotinic alpha 4 beta 2 receptor selective agonist, TC-2559, increases dopamine neuronal activity in the ventral tegmental area of rat midbrain slices. Neuropharmacology. 2003 Sep;45(3):334-44. DMLNVH8 RU https://pubmed.ncbi.nlm.nih.gov/12871651 DMLOAZB DI DMLOAZB DMLOAZB DN TAK-075 DMLOAZB TI TTBUYHA DMLOAZB TN Extracellular calcium-sensing receptor (CASR) DMLOAZB MA Antagonist DMLOAZB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 54). DMLOAZB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=54 DMLOD2Y DI DMLOD2Y DMLOD2Y DN 2-(2-benzoyl-4-bromophenoxy)acetic acid DMLOD2Y TI TTQDMX5 DMLOD2Y TN Prostaglandin D2 receptor 2 (PTGDR2) DMLOD2Y MA Inhibitor DMLOD2Y RN Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41. DMLOD2Y RU https://pubmed.ncbi.nlm.nih.gov/17154491 DMLODAM DI DMLODAM DMLODAM DN 1-(4-(Hexyloxy)phenyl)-3-morpholinopropan-1-one DMLODAM TI TTGER3L DMLODAM TN Thyroid hormone receptor beta (THRB) DMLODAM MA Inhibitor DMLODAM RN Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901. DMLODAM RU https://pubmed.ncbi.nlm.nih.gov/19469546 DMLOHAZ DI DMLOHAZ DMLOHAZ DN MRS1097 DMLOHAZ TI TTJFY5U DMLOHAZ TN Adenosine A3 receptor (ADORA3) DMLOHAZ MA Antagonist DMLOHAZ RN Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors. J Med Chem. 1996 Jul 19;39(15):2980-9. DMLOHAZ RU https://pubmed.ncbi.nlm.nih.gov/8709132 DMLOIUK DI DMLOIUK DMLOIUK DN (2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime DMLOIUK TI TTCEJ4F DMLOIUK TN G1/S-specific cyclin-E1 (CCNE1) DMLOIUK MA Inhibitor DMLOIUK RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMLOIUK RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMLOIUK DI DMLOIUK DMLOIUK DN (2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime DMLOIUK TI TT7HF4W DMLOIUK TN Cyclin-dependent kinase 2 (CDK2) DMLOIUK MA Inhibitor DMLOIUK RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMLOIUK RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMLOJ42 DI DMLOJ42 DMLOJ42 DN SC-52569 DMLOJ42 TI TTN53ZF DMLOJ42 TN Leukotriene B4 receptor 1 (LTB4R) DMLOJ42 MA Inhibitor DMLOJ42 RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DMLOJ42 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DMLON9K DI DMLON9K DMLON9K DN CTAP DMLON9K TI TT27RFC DMLON9K TN Opioid receptor delta (OPRD1) DMLON9K MA Antagonist DMLON9K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMLON9K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMLON9K DI DMLON9K DMLON9K DN CTAP DMLON9K TI TTKWM86 DMLON9K TN Opioid receptor mu (MOP) DMLON9K MA Antagonist DMLON9K RN Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403-8. DMLON9K RU https://pubmed.ncbi.nlm.nih.gov/6313901 DMLONTS DI DMLONTS DMLONTS DN 8S-hydroxylobelane DMLONTS TI TTVBI8W DMLONTS TN Dopamine transporter (DAT) DMLONTS MA Inhibitor DMLONTS RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMLONTS RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMLONTS DI DMLONTS DMLONTS DN 8S-hydroxylobelane DMLONTS TI TT3ROYC DMLONTS TN Serotonin transporter (SERT) DMLONTS MA Inhibitor DMLONTS RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMLONTS RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMLOP2B DI DMLOP2B DMLOP2B DN N,N'-Bis-(4-butoxy-phenyl)-guanidine DMLOP2B TI TTLD29N DMLOP2B TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMLOP2B MA Inhibitor DMLOP2B RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMLOP2B RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMLOP2B DI DMLOP2B DMLOP2B DN N,N'-Bis-(4-butoxy-phenyl)-guanidine DMLOP2B TI TTN9D8E DMLOP2B TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMLOP2B MA Inhibitor DMLOP2B RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMLOP2B RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMLOP2B DI DMLOP2B DMLOP2B DN N,N'-Bis-(4-butoxy-phenyl)-guanidine DMLOP2B TI TTKJEMQ DMLOP2B TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMLOP2B MA Inhibitor DMLOP2B RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMLOP2B RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMLOQ92 DI DMLOQ92 DMLOQ92 DN JNJ-42153605 DMLOQ92 TI TTXJ47W DMLOQ92 TN Metabotropic glutamate receptor 2 (mGluR2) DMLOQ92 MA Modulator (allosteric modulator) DMLOQ92 RN Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. JMed Chem. 2012 Oct 25;55(20):8770-89. DMLOQ92 RU https://pubmed.ncbi.nlm.nih.gov/23072213 DMLOR6F DI DMLOR6F DMLOR6F DN PMID8246237C18t DMLOR6F TI TTPADOQ DMLOR6F TN HMG-CoA reductase (HMGCR) DMLOR6F MA Inhibitor DMLOR6F RN HMG-CoA reductase inhibitors: design, synthesis, and biological activity of tetrahydroindazole-substituted 3,5-dihydroxy-6-heptenoic acid sodium salts. J Med Chem. 1993 Nov 12;36(23):3674-85. DMLOR6F RU https://pubmed.ncbi.nlm.nih.gov/8246237 DMLOV18 DI DMLOV18 DMLOV18 DN FALCARINDIOL DMLOV18 TI TTKWM86 DMLOV18 TN Opioid receptor mu (MOP) DMLOV18 MA Inhibitor DMLOV18 RN Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. DMLOV18 RU https://pubmed.ncbi.nlm.nih.gov/18166466 DMLOV18 DI DMLOV18 DMLOV18 DN FALCARINDIOL DMLOV18 TI TTZFYLI DMLOV18 TN Dopamine D1 receptor (D1R) DMLOV18 MA Inhibitor DMLOV18 RN Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. DMLOV18 RU https://pubmed.ncbi.nlm.nih.gov/18166466 DMLOV18 DI DMLOV18 DMLOV18 DN FALCARINDIOL DMLOV18 TI TTO9X1H DMLOV18 TN 5-HT 7 receptor (HTR7) DMLOV18 MA Inhibitor DMLOV18 RN Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod. 2006 Apr;69(4):536-41. DMLOV18 RU https://pubmed.ncbi.nlm.nih.gov/16643021 DMLOV18 DI DMLOV18 DMLOV18 DN FALCARINDIOL DMLOV18 TI TTQW87Y DMLOV18 TN Opioid receptor kappa (OPRK1) DMLOV18 MA Inhibitor DMLOV18 RN Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. DMLOV18 RU https://pubmed.ncbi.nlm.nih.gov/18166466 DMLOV18 DI DMLOV18 DMLOV18 DN FALCARINDIOL DMLOV18 TI TT27RFC DMLOV18 TN Opioid receptor delta (OPRD1) DMLOV18 MA Inhibitor DMLOV18 RN Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23. DMLOV18 RU https://pubmed.ncbi.nlm.nih.gov/18166466 DMLOX0Y DI DMLOX0Y DMLOX0Y DN 2-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-imidazole DMLOX0Y TI TT3WG5C DMLOX0Y TN Monoamine oxidase type A (MAO-A) DMLOX0Y MA Inhibitor DMLOX0Y RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMLOX0Y RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMLOXMQ DI DMLOXMQ DMLOXMQ DN KNI-10033 DMLOXMQ TI TTXMNHO DMLOXMQ TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMLOXMQ MA Inhibitor DMLOXMQ RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMLOXMQ RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMLP241 DI DMLP241 DMLP241 DN GNF-PF-2893 DMLP241 TI TTT2SVW DMLP241 TN PPAR-gamma messenger RNA (PPARG mRNA) DMLP241 MA Inhibitor DMLP241 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMLP241 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMLP63J DI DMLP63J DMLP63J DN (S)-N2-{4-[(4-nitrobenzyl)oxy]benzyl}serinamide DMLP63J TI TTGP7BY DMLP63J TN Monoamine oxidase type B (MAO-B) DMLP63J MA Inhibitor DMLP63J RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMLP63J RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMLP67R DI DMLP67R DMLP67R DN 4'-(trifluoromethyl)-4-biphenylsulfonamide DMLP67R TI TTBGTCW DMLP67R TN Kinesin spindle messenger RNA (KIF11 mRNA) DMLP67R MA Inhibitor DMLP67R RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMLP67R RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TTNZPQ1 DMLP68J TN GABA(A) receptor alpha-5 (GABRA5) DMLP68J MA Modulator (allosteric modulator) DMLP68J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMLP68J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TTBMV1G DMLP68J TN GABA(A) receptor alpha-2 (GABRA2) DMLP68J MA Modulator (allosteric modulator) DMLP68J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMLP68J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TTEX6LM DMLP68J TN GABA(A) receptor gamma-3 (GABRG3) DMLP68J MA Modulator (allosteric modulator) DMLP68J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMLP68J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TT37EDJ DMLP68J TN GABA(A) receptor alpha-3 (GABRA3) DMLP68J MA Modulator (allosteric modulator) DMLP68J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMLP68J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TT1MPAY DMLP68J TN GABA(A) receptor alpha-1 (GABRA1) DMLP68J MA Inhibitor DMLP68J RN Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90. DMLP68J RU https://pubmed.ncbi.nlm.nih.gov/1846920 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TTZA1NY DMLP68J TN GABA(A) receptor beta-2 (GABRB2) DMLP68J MA Inhibitor DMLP68J RN Substituted 3-(2-benzoxazyl)-benzimidazol-2-(1H)-ones: a new class of GABA(A) brain receptor ligands. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2723-6. DMLP68J RU https://pubmed.ncbi.nlm.nih.gov/11133077 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TT06RH5 DMLP68J TN GABA(A) receptor gamma-2 (GABRG2) DMLP68J MA Inhibitor DMLP68J RN Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90. DMLP68J RU https://pubmed.ncbi.nlm.nih.gov/1846920 DMLP68J DI DMLP68J DMLP68J DN [3H]CGS8216 DMLP68J TI TTNJYV2 DMLP68J TN Gamma-aminobutyric acid receptor (GAR) DMLP68J MA Inhibitor DMLP68J RN Synthesis and benzodiazepine binding activity of a series of novel [1,2,4]triazolo[1,5-c]quinazolin-5(6H)-ones. J Med Chem. 1991 Jan;34(1):281-90. DMLP68J RU https://pubmed.ncbi.nlm.nih.gov/1846920 DMLP9VM DI DMLP9VM DMLP9VM DN N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine DMLP9VM TI TT27RFC DMLP9VM TN Opioid receptor delta (OPRD1) DMLP9VM MA Inhibitor DMLP9VM RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMLP9VM RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMLP9VM DI DMLP9VM DMLP9VM DN N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine DMLP9VM TI TTQW87Y DMLP9VM TN Opioid receptor kappa (OPRK1) DMLP9VM MA Inhibitor DMLP9VM RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMLP9VM RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMLP9VM DI DMLP9VM DMLP9VM DN N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine DMLP9VM TI TTKWM86 DMLP9VM TN Opioid receptor mu (MOP) DMLP9VM MA Inhibitor DMLP9VM RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMLP9VM RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMLPAD8 DI DMLPAD8 DMLPAD8 DN S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 TI TTU6BFZ DMLPAD8 TN Candida Thymidylate synthase (Candi TMP1) DMLPAD8 MA Inhibitor DMLPAD8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLPAD8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLPAD8 DI DMLPAD8 DMLPAD8 DN S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 TI TTKGY3F DMLPAD8 TN Mycobacterium DTDP-dehydrorhamnose epimerase rmlC (MycB rmlC) DMLPAD8 MA Inhibitor DMLPAD8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLPAD8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLPAD8 DI DMLPAD8 DMLPAD8 DN S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 TI TTVIAT9 DMLPAD8 TN Phosphodiesterase 4B (PDE4B) DMLPAD8 MA Inhibitor DMLPAD8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLPAD8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLPAD8 DI DMLPAD8 DMLPAD8 DN S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 TI TT1KW50 DMLPAD8 TN Maspin (SERPINB5) DMLPAD8 MA Inhibitor DMLPAD8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLPAD8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLPAD8 DI DMLPAD8 DMLPAD8 DN S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 TI TTHQENC DMLPAD8 TN Phosphodiesterase 1 (PDE1) DMLPAD8 MA Inhibitor DMLPAD8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLPAD8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLPAD8 DI DMLPAD8 DMLPAD8 DN S,S-(2-Hydroxyethyl)Thiocysteine DMLPAD8 TI TTJHKYD DMLPAD8 TN Delta-aminolevulinic acid dehydratase (ALAD) DMLPAD8 MA Inhibitor DMLPAD8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLPAD8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLPC17 DI DMLPC17 DMLPC17 DN PMID17888661C18 DMLPC17 TI TTE5J6X DMLPC17 TN Diphosphomevalonate decarboxylase (MVD) DMLPC17 MA Inhibitor DMLPC17 RN Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6164-8. DMLPC17 RU https://pubmed.ncbi.nlm.nih.gov/17888661 DMLPJGX DI DMLPJGX DMLPJGX DN N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide DMLPJGX TI TT3WG5C DMLPJGX TN Monoamine oxidase type A (MAO-A) DMLPJGX MA Inhibitor DMLPJGX RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMLPJGX RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMLPJGX DI DMLPJGX DMLPJGX DN N2-{4-[(4-chlorobenzyl)oxy]benzyl}glycinamide DMLPJGX TI TTGP7BY DMLPJGX TN Monoamine oxidase type B (MAO-B) DMLPJGX MA Inhibitor DMLPJGX RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMLPJGX RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMLPMAY DI DMLPMAY DMLPMAY DN VU0405601 DMLPMAY TI TTQ6VDM DMLPMAY TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMLPMAY MA Activator DMLPMAY RN Identification and characterization of a compound that protects cardiac tissue from human Ether- -go-go-related gene (hERG)-related drug-induced arrhythmias. J Biol Chem. 2012 Nov 16;287(47):39613-25. DMLPMAY RU https://pubmed.ncbi.nlm.nih.gov/23033485 DMLPN95 DI DMLPN95 DMLPN95 DN SQ-27986 DMLPN95 TI TTNVEIR DMLPN95 TN Prostaglandin D2 receptor (PTGDR) DMLPN95 MA Agonist DMLPN95 RN Affinities, selectivities, potencies, and intrinsic activities of natural and synthetic prostanoids using endogenous receptors: focus on DP class prostanoids. J Pharmacol Exp Ther. 2000 May;293(2):321-8. DMLPN95 RU https://pubmed.ncbi.nlm.nih.gov/10772998 DMLPRIG DI DMLPRIG DMLPRIG DN Acetic acid 2-heptylsulfanyl-phenyl ester DMLPRIG TI TT8NGED DMLPRIG TN Prostaglandin G/H synthase 1 (COX-1) DMLPRIG MA Inhibitor DMLPRIG RN Covalent modification of cyclooxygenase-2 (COX-2) by 2-acetoxyphenyl alkyl sulfides, a new class of selective COX-2 inactivators. J Med Chem. 1998 Nov 19;41(24):4800-18. DMLPRIG RU https://pubmed.ncbi.nlm.nih.gov/9822550 DMLPRU4 DI DMLPRU4 DMLPRU4 DN SDZ-208911 DMLPRU4 TI TTEX248 DMLPRU4 TN Dopamine D2 receptor (D2R) DMLPRU4 MA Modulator DMLPRU4 RN Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study. Naunyn SchmiedebergsArch Pharmacol. 1991 Sep;344(3):263-74. DMLPRU4 RU https://pubmed.ncbi.nlm.nih.gov/1683686 DMLPZ3N DI DMLPZ3N DMLPZ3N DN ICI 200,355 DMLPZ3N TI TTPLTSQ DMLPZ3N TN Neutrophil elastase (NE) DMLPZ3N MA Inhibitor DMLPZ3N RN Role of neutrophil elastase in hypersecretion in asthma. Eur Respir J. 1999 Jan;13(1):190-6. DMLPZ3N RU https://pubmed.ncbi.nlm.nih.gov/10836347 DMLQ3PR DI DMLQ3PR DMLQ3PR DN Tyr-Pro-Phe-D-2-Nal-NH2 DMLQ3PR TI TTKWM86 DMLQ3PR TN Opioid receptor mu (MOP) DMLQ3PR MA Inhibitor DMLQ3PR RN Novel highly potent mu-opioid receptor antagonist based on endomorphin-2 structure. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1350-3. DMLQ3PR RU https://pubmed.ncbi.nlm.nih.gov/18207400 DMLQ90D DI DMLQ90D DMLQ90D DN 8-Methyl-2-morpholin-4-yl-chromen-4-one DMLQ90D TI TTK3PY9 DMLQ90D TN DNA-dependent protein kinase catalytic (PRKDC) DMLQ90D MA Inhibitor DMLQ90D RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMLQ90D RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMLQ9WD DI DMLQ9WD DMLQ9WD DN 2-(8-Imidazol-1-yl-octyl)-isoindole-1,3-dione DMLQ9WD TI TTKNWZ4 DMLQ9WD TN Thromboxane-A synthase (TBXAS1) DMLQ9WD MA Inhibitor DMLQ9WD RN Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-... J Med Chem. 1986 May;29(5):816-9. DMLQ9WD RU https://pubmed.ncbi.nlm.nih.gov/3517332 DMLQJ64 DI DMLQJ64 DMLQJ64 DN 3-Decanoyl-4-hydroxy-6-nonyl-pyran-2-one DMLQJ64 TI TTPLTSQ DMLQJ64 TN Neutrophil elastase (NE) DMLQJ64 MA Inhibitor DMLQJ64 RN Inhibition of human sputum elastase by substituted 2-pyrones. J Med Chem. 1987 Jun;30(6):1017-23. DMLQJ64 RU https://pubmed.ncbi.nlm.nih.gov/3647139 DMLQPVH DI DMLQPVH DMLQPVH DN 8-(3-Fluoro-phenyl)-9-methyl-9H-purin-6-ylamine DMLQPVH TI TTNE7KG DMLQPVH TN Adenosine A2b receptor (ADORA2B) DMLQPVH MA Inhibitor DMLQPVH RN 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic gluc... J Med Chem. 2001 Jan 18;44(2):170-9. DMLQPVH RU https://pubmed.ncbi.nlm.nih.gov/11170626 DMLQT5F DI DMLQT5F DMLQT5F DN ISIS 19212 DMLQT5F TI TT1ERKL DMLQT5F TN CD40 messenger RNA (CD40 mRNA) DMLQT5F RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMLQT5F RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMLQYN7 DI DMLQYN7 DMLQYN7 DN MRS1476 DMLQYN7 TI TTJFY5U DMLQYN7 TN Adenosine A3 receptor (ADORA3) DMLQYN7 MA Antagonist DMLQYN7 RN Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. J Med Chem. 1998 Aug 13;41(17):3186-201. DMLQYN7 RU https://pubmed.ncbi.nlm.nih.gov/9703464 DMLQZGJ DI DMLQZGJ DMLQZGJ DN CL-385004 DMLQZGJ TI TTK8R02 DMLQZGJ TN Vasopressin V2 receptor (V2R) DMLQZGJ MA Antagonist DMLQZGJ RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DMLQZGJ RU https://pubmed.ncbi.nlm.nih.gov/12436936 DMLQZGJ DI DMLQZGJ DMLQZGJ DN CL-385004 DMLQZGJ TI TT4TFGN DMLQZGJ TN Vasopressin V1a receptor (V1AR) DMLQZGJ MA Antagonist DMLQZGJ RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DMLQZGJ RU https://pubmed.ncbi.nlm.nih.gov/12436936 DMLR0N3 DI DMLR0N3 DMLR0N3 DN (S)-N-(1-phenylethyl)acetimidamide hydrobromide DMLR0N3 TI TTF10I9 DMLR0N3 TN Nitric-oxide synthase inducible (NOS2) DMLR0N3 MA Inhibitor DMLR0N3 RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DMLR0N3 RU https://pubmed.ncbi.nlm.nih.gov/20933416 DMLR2FB DI DMLR2FB DMLR2FB DN 12-Phenylheme DMLR2FB TI TTI6V2A DMLR2FB TN Heme oxygenase 1 (HMOX1) DMLR2FB MA Inhibitor DMLR2FB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLR2FB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLR86H DI DMLR86H DMLR86H DN Inosinic Acid DMLR86H TI TTTB4UP DMLR86H TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMLR86H MA Inhibitor DMLR86H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLR86H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLR86H DI DMLR86H DMLR86H DN Inosinic Acid DMLR86H TI TTL7C8Q DMLR86H TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMLR86H MA Inhibitor DMLR86H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLR86H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLR86H DI DMLR86H DMLR86H DN Inosinic Acid DMLR86H TI TTZHY6R DMLR86H TN Glycogen phosphorylase muscle form (GP) DMLR86H MA Inhibitor DMLR86H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLR86H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLR86H DI DMLR86H DMLR86H DN Inosinic Acid DMLR86H TI TTBL49X DMLR86H TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMLR86H MA Inhibitor DMLR86H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLR86H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLR86H DI DMLR86H DMLR86H DN Inosinic Acid DMLR86H TI TTYQ4AE DMLR86H TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DMLR86H MA Inhibitor DMLR86H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLR86H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLREDJ DI DMLREDJ DMLREDJ DN Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine DMLREDJ TI TTM2AOE DMLREDJ TN Adenosine A2a receptor (ADORA2A) DMLREDJ MA Inhibitor DMLREDJ RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DMLREDJ RU https://pubmed.ncbi.nlm.nih.gov/16033270 DMLREDJ DI DMLREDJ DMLREDJ DN Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine DMLREDJ TI TTK25J1 DMLREDJ TN Adenosine A1 receptor (ADORA1) DMLREDJ MA Inhibitor DMLREDJ RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DMLREDJ RU https://pubmed.ncbi.nlm.nih.gov/16033270 DMLREDJ DI DMLREDJ DMLREDJ DN Cyclohexyl-(2-phenylsulfanyl-9H-purin-6-yl)-amine DMLREDJ TI TTJFY5U DMLREDJ TN Adenosine A3 receptor (ADORA3) DMLREDJ MA Inhibitor DMLREDJ RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DMLREDJ RU https://pubmed.ncbi.nlm.nih.gov/16033270 DMLRM9Z DI DMLRM9Z DMLRM9Z DN 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one DMLRM9Z TI TTSZLWK DMLRM9Z TN Aromatase (CYP19A1) DMLRM9Z MA Inhibitor DMLRM9Z RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMLRM9Z RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMLRM9Z DI DMLRM9Z DMLRM9Z DN 5-Pyridin-3-yl-1,3-dihydro-2H-indol-2-one DMLRM9Z TI TTIQUX7 DMLRM9Z TN Steroid 11-beta-hydroxylase (CYP11B1) DMLRM9Z MA Inhibitor DMLRM9Z RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMLRM9Z RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TTZA1NY DMLRNV2 TN GABA(A) receptor beta-2 (GABRB2) DMLRNV2 MA Inhibitor DMLRNV2 RN Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/12824018 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TTL53M6 DMLRNV2 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMLRNV2 MA Inhibitor DMLRNV2 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TTNZPQ1 DMLRNV2 TN GABA(A) receptor alpha-5 (GABRA5) DMLRNV2 MA Inhibitor DMLRNV2 RN Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/12824018 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TT1MPAY DMLRNV2 TN GABA(A) receptor alpha-1 (GABRA1) DMLRNV2 MA Inhibitor DMLRNV2 RN Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/12824018 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TT06RH5 DMLRNV2 TN GABA(A) receptor gamma-2 (GABRG2) DMLRNV2 MA Inhibitor DMLRNV2 RN Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/12824018 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TTBMV1G DMLRNV2 TN GABA(A) receptor alpha-2 (GABRA2) DMLRNV2 MA Inhibitor DMLRNV2 RN Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/12824018 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TT37EDJ DMLRNV2 TN GABA(A) receptor alpha-3 (GABRA3) DMLRNV2 MA Inhibitor DMLRNV2 RN Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/12824018 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TT7RJY8 DMLRNV2 TN Xanthine dehydrogenase/oxidase (XDH) DMLRNV2 MA Inhibitor DMLRNV2 RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/3379415 DMLRNV2 DI DMLRNV2 DMLRNV2 DN AMENTOFLAVONE DMLRNV2 TI TTNJYV2 DMLRNV2 TN Gamma-aminobutyric acid receptor (GAR) DMLRNV2 MA Inhibitor DMLRNV2 RN Semisynthetic preparation of amentoflavone: A negative modulator at GABA(A) receptors. Bioorg Med Chem Lett. 2003 Jul 21;13(14):2281-4. DMLRNV2 RU https://pubmed.ncbi.nlm.nih.gov/12824018 DMLRQH0 DI DMLRQH0 DMLRQH0 DN Indirubin-3'-monoxime DMLRQH0 TI TTH6V3D DMLRQH0 TN Cyclin-dependent kinase 1 (CDK1) DMLRQH0 MA Binder DMLRQH0 RN The kinase inhibitor indirubin-3'-oxime prevents germinal vesicle breakdown and reduces parthenogenetic development of pig oocytes. Theriogenology. 2006 Mar 1;65(4):744-56. DMLRQH0 RU https://pubmed.ncbi.nlm.nih.gov/16105677 DMLRQH0 DI DMLRQH0 DMLRQH0 DN Indirubin-3'-monoxime DMLRQH0 TI TT7HF4W DMLRQH0 TN Cyclin-dependent kinase 2 (CDK2) DMLRQH0 MA Inhibitor DMLRQH0 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMLRQH0 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMLRQH0 DI DMLRQH0 DMLRQH0 DN Indirubin-3'-monoxime DMLRQH0 TI TTL4Q97 DMLRQH0 TN Cyclin-dependent kinase 5 (CDK5) DMLRQH0 MA Inhibitor DMLRQH0 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMLRQH0 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMLRQH0 DI DMLRQH0 DMLRQH0 DN Indirubin-3'-monoxime DMLRQH0 TI TT9RTBL DMLRQH0 TN Aurora B messenger RNA (AURKB mRNA) DMLRQH0 MA Inhibitor DMLRQH0 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMLRQH0 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMLRQH0 DI DMLRQH0 DMLRQH0 DN Indirubin-3'-monoxime DMLRQH0 TI TTPS3C0 DMLRQH0 TN Aurora kinase A (AURKA) DMLRQH0 MA Inhibitor DMLRQH0 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMLRQH0 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMLRQH0 DI DMLRQH0 DMLRQH0 DN Indirubin-3'-monoxime DMLRQH0 TI TTLYXIT DMLRQH0 TN Aurora kinase C (AURKC) DMLRQH0 MA Inhibitor DMLRQH0 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMLRQH0 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMLRS8I DI DMLRS8I DMLRS8I DN 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol DMLRS8I TI TT27RFC DMLRS8I TN Opioid receptor delta (OPRD1) DMLRS8I MA Inhibitor DMLRS8I RN Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7. DMLRS8I RU https://pubmed.ncbi.nlm.nih.gov/16821764 DMLRS8I DI DMLRS8I DMLRS8I DN 1-[3-(3-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol DMLRS8I TI TTKWM86 DMLRS8I TN Opioid receptor mu (MOP) DMLRS8I MA Inhibitor DMLRS8I RN Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7. DMLRS8I RU https://pubmed.ncbi.nlm.nih.gov/16821764 DMLRTPH DI DMLRTPH DMLRTPH DN GPYRMEHFRWGSPPKD-NH2 DMLRTPH TI TTD0CIQ DMLRTPH TN Melanocortin receptor 4 (MC4R) DMLRTPH MA Inhibitor DMLRTPH RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMLRTPH RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMLRTPH DI DMLRTPH DMLRTPH DN GPYRMEHFRWGSPPKD-NH2 DMLRTPH TI TT0MV2T DMLRTPH TN Melanocortin receptor 1 (MC1R) DMLRTPH MA Inhibitor DMLRTPH RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMLRTPH RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMLRTPH DI DMLRTPH DMLRTPH DN GPYRMEHFRWGSPPKD-NH2 DMLRTPH TI TTEOSZT DMLRTPH TN Melanocortin receptor (MCR) DMLRTPH MA Inhibitor DMLRTPH RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMLRTPH RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMLRTPH DI DMLRTPH DMLRTPH DN GPYRMEHFRWGSPPKD-NH2 DMLRTPH TI TTNI91K DMLRTPH TN Melanocortin receptor 3 (MC3R) DMLRTPH MA Inhibitor DMLRTPH RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMLRTPH RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMLRUVA DI DMLRUVA DMLRUVA DN HDS-029 DMLRUVA TI TT0JESD DMLRUVA TN Erbb4 tyrosine kinase receptor (Erbb-4) DMLRUVA MA Inhibitor DMLRUVA RN Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85. DMLRUVA RU https://pubmed.ncbi.nlm.nih.gov/16480284 DMLRUVA DI DMLRUVA DMLRUVA DN HDS-029 DMLRUVA TI TTR5TV4 DMLRUVA TN ERBB2 messenger RNA (HER2 mRNA) DMLRUVA MA Inhibitor DMLRUVA RN Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85. DMLRUVA RU https://pubmed.ncbi.nlm.nih.gov/16480284 DMLRUVA DI DMLRUVA DMLRUVA DN HDS-029 DMLRUVA TI TTGKNB4 DMLRUVA TN Epidermal growth factor receptor (EGFR) DMLRUVA MA Inhibitor DMLRUVA RN Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85. DMLRUVA RU https://pubmed.ncbi.nlm.nih.gov/16480284 DMLRVEJ DI DMLRVEJ DMLRVEJ DN KMI-172 DMLRVEJ TI TT8JRS7 DMLRVEJ TN Beta-secretase (BACE) DMLRVEJ MA Inhibitor DMLRVEJ RN Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1629-33. DMLRVEJ RU https://pubmed.ncbi.nlm.nih.gov/17251016 DMLRWAF DI DMLRWAF DMLRWAF DN (Z)-5-Butylidene-2-thioxothiazolidin-4-one DMLRWAF TI TT1K6Q4 DMLRWAF TN Arylamine N-acetyltransferase (NAT) DMLRWAF MA Inhibitor DMLRWAF RN Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18. DMLRWAF RU https://pubmed.ncbi.nlm.nih.gov/19059786 DMLRYXK DI DMLRYXK DMLRYXK DN C[RGDf-(S)-alpha-TfmV] DMLRYXK TI TTJA1ZO DMLRYXK TN ITGB3 messenger RNA (ITGB3 mRNA) DMLRYXK MA Inhibitor DMLRYXK RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMLRYXK RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMLRYXK DI DMLRYXK DMLRYXK DN C[RGDf-(S)-alpha-TfmV] DMLRYXK TI TTT1R2L DMLRYXK TN Integrin alpha-V (ITGAV) DMLRYXK MA Inhibitor DMLRYXK RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMLRYXK RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMLS29E DI DMLS29E DMLS29E DN (2S,1'R,2'S)-2-(2'-phosphonocyclopropyl)glycine DMLS29E TI TTICZ1O DMLS29E TN Metabotropic glutamate receptor 4 (mGluR4) DMLS29E MA Inhibitor DMLS29E RN Synthesis and preliminary pharmacological evaluation of the four stereoisomers of (2S)-2-(2'-phosphono-3'-phenylcyclopropyl)glycine, the first clas... Bioorg Med Chem. 2007 May 1;15(9):3161-70. DMLS29E RU https://pubmed.ncbi.nlm.nih.gov/17350267 DMLSABI DI DMLSABI DMLSABI DN Hypoxanthine DMLSABI TI TTMCF1Y DMLSABI TN Purine nucleoside phosphorylase (PNP) DMLSABI MA Inhibitor DMLSABI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLSABI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLSC10 DI DMLSC10 DMLSC10 DN 5-Fluoro orotate DMLSC10 TI TT09NOX DMLSC10 TN Plasmodium Dihydroorotase (Malaria dho) DMLSC10 MA Inhibitor DMLSC10 RN Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301. DMLSC10 RU https://pubmed.ncbi.nlm.nih.gov/1348618 DMLSC10 DI DMLSC10 DMLSC10 DN 5-Fluoro orotate DMLSC10 TI TT3PQ2Y DMLSC10 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMLSC10 MA Inhibitor DMLSC10 RN Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301. DMLSC10 RU https://pubmed.ncbi.nlm.nih.gov/1348618 DMLSEJN DI DMLSEJN DMLSEJN DN Monastrol DMLSEJN TI TTTRP0H DMLSEJN TN Kinesin-like protein KIF11 (KIF11) DMLSEJN MA Inhibitor DMLSEJN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLSEJN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLSET4 DI DMLSET4 DMLSET4 DN 3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid DMLSET4 TI TT9G4N0 DMLSET4 TN Glutamate carboxypeptidase II (GCPII) DMLSET4 MA Inhibitor DMLSET4 RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMLSET4 RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMLSFQI DI DMLSFQI DMLSFQI DN N-(2-aminoethyl)-p-chlorobenzamide DMLSFQI TI TTGP7BY DMLSFQI TN Monoamine oxidase type B (MAO-B) DMLSFQI MA Inhibitor DMLSFQI RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLSFQI RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLSGU1 DI DMLSGU1 DMLSGU1 DN 4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline DMLSGU1 TI TTGKNB4 DMLSGU1 TN Epidermal growth factor receptor (EGFR) DMLSGU1 MA Inhibitor DMLSGU1 RN Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88. DMLSGU1 RU https://pubmed.ncbi.nlm.nih.gov/17981366 DMLSJKM DI DMLSJKM DMLSJKM DN (D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Aoc-Arg DMLSJKM TI TTGY8IW DMLSJKM TN B2 bradykinin receptor (BDKRB2) DMLSJKM MA Inhibitor DMLSJKM RN Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3. DMLSJKM RU https://pubmed.ncbi.nlm.nih.gov/1848297 DMLSMBI DI DMLSMBI DMLSMBI DN EDP-13 DMLSMBI TI TTGKNB4 DMLSMBI TN Epidermal growth factor receptor (EGFR) DMLSMBI MA Antagonist DMLSMBI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMLSMBI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMLSU30 DI DMLSU30 DMLSU30 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine DMLSU30 TI TT4C8EA DMLSU30 TN Dopamine D3 receptor (D3R) DMLSU30 MA Inhibitor DMLSU30 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMLSU30 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMLSU30 DI DMLSU30 DMLSU30 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine DMLSU30 TI TTS2PH3 DMLSU30 TN Dopamine D5 receptor (D5R) DMLSU30 MA Inhibitor DMLSU30 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMLSU30 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMLSU30 DI DMLSU30 DMLSU30 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine DMLSU30 TI TTZFYLI DMLSU30 TN Dopamine D1 receptor (D1R) DMLSU30 MA Inhibitor DMLSU30 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMLSU30 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMLSU30 DI DMLSU30 DMLSU30 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine DMLSU30 TI TTE0A2F DMLSU30 TN Dopamine D4 receptor (D4R) DMLSU30 MA Inhibitor DMLSU30 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMLSU30 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMLSUXD DI DMLSUXD DMLSUXD DN 4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole DMLSUXD TI TTAXZ0K DMLSUXD TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMLSUXD MA Inhibitor DMLSUXD RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMLSUXD RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMLSUXD DI DMLSUXD DMLSUXD DN 4-Biphenyl-4-yl-2-cyclohexylmethyl-1H-imidazole DMLSUXD TI TTRK8B9 DMLSUXD TN Sodium channel unspecific (NaC) DMLSUXD MA Inhibitor DMLSUXD RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMLSUXD RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMLSWHP DI DMLSWHP DMLSWHP DN 1-(3,5-dichlorobenzyl)-1H-imidazole DMLSWHP TI TTRA5BZ DMLSWHP TN Steroid 17-alpha-monooxygenase (S17AH) DMLSWHP MA Inhibitor DMLSWHP RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DMLSWHP RU https://pubmed.ncbi.nlm.nih.gov/16750362 DMLSYD9 DI DMLSYD9 DMLSYD9 DN MCL-435 DMLSYD9 TI TTKWM86 DMLSYD9 TN Opioid receptor mu (MOP) DMLSYD9 MA Inhibitor DMLSYD9 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMLSYD9 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMLSYD9 DI DMLSYD9 DMLSYD9 DN MCL-435 DMLSYD9 TI TTQW87Y DMLSYD9 TN Opioid receptor kappa (OPRK1) DMLSYD9 MA Inhibitor DMLSYD9 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMLSYD9 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMLSYD9 DI DMLSYD9 DMLSYD9 DN MCL-435 DMLSYD9 TI TT27RFC DMLSYD9 TN Opioid receptor delta (OPRD1) DMLSYD9 MA Inhibitor DMLSYD9 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMLSYD9 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMLSZW2 DI DMLSZW2 DMLSZW2 DN 15-ACETOXY-EREMANTHOLIDE B DMLSZW2 TI TTSXVID DMLSZW2 TN Nuclear factor NF-kappa-B (NFKB) DMLSZW2 MA Inhibitor DMLSZW2 RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DMLSZW2 RU https://pubmed.ncbi.nlm.nih.gov/15537359 DMLT01H DI DMLT01H DMLT01H DN 6-Bromo-2-piperazin-1-yl-quinoline DMLT01H TI TT3ROYC DMLT01H TN Serotonin transporter (SERT) DMLT01H MA Inhibitor DMLT01H RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DMLT01H RU https://pubmed.ncbi.nlm.nih.gov/10915050 DMLT1N3 DI DMLT1N3 DMLT1N3 DN decavanadate DMLT1N3 TI TT473XN DMLT1N3 TN P2X purinoceptor 7 (P2RX7) DMLT1N3 MA Antagonist DMLT1N3 RN Decavanadate, a P2X receptor antagonist, and its use to study ligand interactions with P2X7 receptors. Eur J Pharmacol. 2006 Mar 18;534(1-3):19-29. DMLT1N3 RU https://pubmed.ncbi.nlm.nih.gov/16487507 DMLT1N3 DI DMLT1N3 DMLT1N3 DN decavanadate DMLT1N3 TI TTJ2HKA DMLT1N3 TN Long transient receptor potential channel 4 (TRPM4) DMLT1N3 MA Activator DMLT1N3 RN Decavanadate modulates gating of TRPM4 cation channels. J Physiol. 2004 Nov 1;560(Pt 3):753-65. DMLT1N3 RU https://pubmed.ncbi.nlm.nih.gov/15331675 DMLT1N3 DI DMLT1N3 DMLT1N3 DN decavanadate DMLT1N3 TI TTH1769 DMLT1N3 TN IP3 receptor isoform 3 (ITPR3) DMLT1N3 MA Antagonist DMLT1N3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 745). DMLT1N3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=745 DMLT1N3 DI DMLT1N3 DMLT1N3 DN decavanadate DMLT1N3 TI TTK9OV3 DMLT1N3 TN IP3 receptor isoform 2 (IP3R2) DMLT1N3 MA Antagonist DMLT1N3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 744). DMLT1N3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=744 DMLT1N3 DI DMLT1N3 DMLT1N3 DN decavanadate DMLT1N3 TI TT5HWAT DMLT1N3 TN IP3 receptor isoform 1 (ITPR1) DMLT1N3 MA Antagonist DMLT1N3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743). DMLT1N3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743 DMLT4JA DI DMLT4JA DMLT4JA DN UDP-glucose DMLT4JA TI TTMPART DMLT4JA TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMLT4JA MA Agonist DMLT4JA RN The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J. 2006 Oct 4;25(19):4615-27. DMLT4JA RU https://pubmed.ncbi.nlm.nih.gov/16990797 DMLT4JA DI DMLT4JA DMLT4JA DN UDP-glucose DMLT4JA TI TT72OKI DMLT4JA TN P2Y purinoceptor 14 (P2RY14) DMLT4JA MA Agonist DMLT4JA RN Cloning, pharmacology, and tissue distribution of G-protein-coupled receptor GPR105 (KIAA0001) rodent orthologs. Genomics. 2001 Dec;78(3):124-8. DMLT4JA RU https://pubmed.ncbi.nlm.nih.gov/11735218 DMLT4JA DI DMLT4JA DMLT4JA DN UDP-glucose DMLT4JA TI TTGRHIB DMLT4JA TN UDP-glucose 4-epimerase (GALE) DMLT4JA MA Inhibitor DMLT4JA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLT4JA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLT635 DI DMLT635 DMLT635 DN 2-(p-Methylsulfonylbenzoyl)furan DMLT635 TI TTVKILB DMLT635 TN Prostaglandin G/H synthase 2 (COX-2) DMLT635 MA Inhibitor DMLT635 RN Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71. DMLT635 RU https://pubmed.ncbi.nlm.nih.gov/20804197 DMLT635 DI DMLT635 DMLT635 DN 2-(p-Methylsulfonylbenzoyl)furan DMLT635 TI TT8NGED DMLT635 TN Prostaglandin G/H synthase 1 (COX-1) DMLT635 MA Inhibitor DMLT635 RN Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71. DMLT635 RU https://pubmed.ncbi.nlm.nih.gov/20804197 DMLT7FQ DI DMLT7FQ DMLT7FQ DN Erythose-4-Phosphate DMLT7FQ TI TTVNA43 DMLT7FQ TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DMLT7FQ MA Inhibitor DMLT7FQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLT7FQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLT8G9 DI DMLT8G9 DMLT8G9 DN NSC 19630 DMLT8G9 TI TT2H5WQ DMLT8G9 TN Werner syndrome ATP-dependent helicase (WRN) DMLT8G9 MA Inhibitor DMLT8G9 RN WRN-targeted therapy using inhibitors NSC 19630 and NSC 617145 induce apoptosis in HTLV-1-transformed adult T-cell leukemia cells. J Hematol Oncol. 2016 Nov 9;9(1):121. DMLT8G9 RU https://pubmed.ncbi.nlm.nih.gov/27829440 DMLTJDR DI DMLTJDR DMLTJDR DN 2-methyl-1-(thiophen-2-yl)pent-1-en-3-one oxime DMLTJDR TI TTELV3W DMLTJDR TN Transformation-sensitive protein p120 (TRPA1) DMLTJDR MA Inhibitor DMLTJDR RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DMLTJDR RU https://pubmed.ncbi.nlm.nih.gov/20356305 DMLTMPC DI DMLTMPC DMLTMPC DN (2-Butyryloxy-ethyl)-trimethyl-ammonium iodide DMLTMPC TI TT1RS9F DMLTMPC TN Acetylcholinesterase (AChE) DMLTMPC MA Inhibitor DMLTMPC RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMLTMPC RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMLTNHY DI DMLTNHY DMLTNHY DN Acetic Acid Salicyloyl-Amino-Ester DMLTNHY TI TT8NGED DMLTNHY TN Prostaglandin G/H synthase 1 (COX-1) DMLTNHY MA Inhibitor DMLTNHY RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLTNHY RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLTROU DI DMLTROU DMLTROU DN N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide DMLTROU TI TTK25J1 DMLTROU TN Adenosine A1 receptor (ADORA1) DMLTROU MA Inhibitor DMLTROU RN Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700. DMLTROU RU https://pubmed.ncbi.nlm.nih.gov/20137946 DMLTROU DI DMLTROU DMLTROU DN N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide DMLTROU TI TTNE7KG DMLTROU TN Adenosine A2b receptor (ADORA2B) DMLTROU MA Inhibitor DMLTROU RN Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700. DMLTROU RU https://pubmed.ncbi.nlm.nih.gov/20137946 DMLTROU DI DMLTROU DMLTROU DN N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide DMLTROU TI TTM2AOE DMLTROU TN Adenosine A2a receptor (ADORA2A) DMLTROU MA Inhibitor DMLTROU RN Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700. DMLTROU RU https://pubmed.ncbi.nlm.nih.gov/20137946 DMLTROU DI DMLTROU DMLTROU DN N-(2-(furan-2-yl)-3,4'-bipyridin-6-yl)acetamide DMLTROU TI TTJFY5U DMLTROU TN Adenosine A3 receptor (ADORA3) DMLTROU MA Inhibitor DMLTROU RN Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1697-700. DMLTROU RU https://pubmed.ncbi.nlm.nih.gov/20137946 DMLTU3J DI DMLTU3J DMLTU3J DN 2-(2-butoxypyrimidin-4-ylamino)benzoic acid DMLTU3J TI TT0K6EO DMLTU3J TN Stress-activated protein kinase JNK1 (JNK1) DMLTU3J MA Inhibitor DMLTU3J RN Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. DMLTU3J RU https://pubmed.ncbi.nlm.nih.gov/17107797 DMLTVI6 DI DMLTVI6 DMLTVI6 DN XAP044 DMLTVI6 TI TT0I76D DMLTVI6 TN Metabotropic glutamate receptor 7 (mGluR7) DMLTVI6 MA Modulator (allosteric modulator) DMLTVI6 RN Blocking metabotropic glutamate receptor subtype 7 (mGlu7) via the Venus flytrap domain (VFTD) inhibits amygdala plasticity, stress, and anxiety-related behavior. J Biol Chem. 2014 Apr 18;289(16):10975-87. DMLTVI6 RU https://pubmed.ncbi.nlm.nih.gov/24596089 DMLTXHJ DI DMLTXHJ DMLTXHJ DN PMID17125263C17 DMLTXHJ TI TTX4RTB DMLTXHJ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMLTXHJ MA Antagonist DMLTXHJ RN 6-(4-chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3H)-one-based melanin-concentrating hormone receptor 1 antagonist. J Med Chem. 2006 Nov 30;49(24):7108-18. DMLTXHJ RU https://pubmed.ncbi.nlm.nih.gov/17125263 DMLTYPS DI DMLTYPS DMLTYPS DN N-[(4-bromo-1-benzothien-3-yl)methyl]sulfamide DMLTYPS TI TTANPDJ DMLTYPS TN Carbonic anhydrase II (CA-II) DMLTYPS MA Inhibitor DMLTYPS RN Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into huma... J Med Chem. 2009 Dec 10;52(23):7528-36. DMLTYPS RU https://pubmed.ncbi.nlm.nih.gov/19388676 DMLTZ5F DI DMLTZ5F DMLTZ5F DN 3-[6-(5-Chloro-2-thienyl)pyridin-2-yl]phenol DMLTZ5F TI TTIWB6L DMLTZ5F TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMLTZ5F MA Inhibitor DMLTZ5F RN Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505. DMLTZ5F RU https://pubmed.ncbi.nlm.nih.gov/20413314 DMLU27Y DI DMLU27Y DMLU27Y DN N,N,N-Triisobutyl-pyrimidine-2,4,6-triamine DMLU27Y TI TTZAYWL DMLU27Y TN Estrogen receptor (ESR) DMLU27Y MA Inhibitor DMLU27Y RN Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30. DMLU27Y RU https://pubmed.ncbi.nlm.nih.gov/18785725 DMLU3PZ DI DMLU3PZ DMLU3PZ DN Ac-I[CVHQDWGHHRC]T-NH2 DMLU3PZ TI TTJGY7A DMLU3PZ TN Complement C3 (CO3) DMLU3PZ MA Inhibitor DMLU3PZ RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMLU3PZ RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMLU6J0 DI DMLU6J0 DMLU6J0 DN SAIT301 DMLU6J0 TI TTKA5LP DMLU6J0 TN HGF/Met signaling pathway (HGF/Met pathway) DMLU6J0 RN Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16. DMLU6J0 RU http://journalofnasopharyngealcarcinoma.org/JNPC/article/view/30/227 DMLU6VM DI DMLU6VM DMLU6VM DN HZ-166 DMLU6VM TI TTEX6LM DMLU6VM TN GABA(A) receptor gamma-3 (GABRG3) DMLU6VM MA Modulator DMLU6VM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMLU6VM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMLU9P6 DI DMLU9P6 DMLU9P6 DN PD-307243 DMLU9P6 TI TTQ6VDM DMLU9P6 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMLU9P6 MA Activator DMLU9P6 RN 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-r... Mol Pharmacol. 2008 Mar;73(3):639-51. DMLU9P6 RU https://pubmed.ncbi.nlm.nih.gov/18042732 DMLUCSB DI DMLUCSB DMLUCSB DN PMID22873688C3a DMLUCSB TI TTA93TL DMLUCSB TN P2Y purinoceptor 1 (P2RY1) DMLUCSB MA Agonist DMLUCSB RN Identification of a promising drug candidate for the treatment of type 2 diabetes based on a P2Y(1) receptor agonist. J Med Chem. 2012 Sep 13;55(17):7623-35. DMLUCSB RU https://pubmed.ncbi.nlm.nih.gov/22873688 DMLUP30 DI DMLUP30 DMLUP30 DN UBIQUINONE-2 DMLUP30 TI TTRAMF0 DMLUP30 TN Plasmodium Cytochrome B (Malaria MT-CYB) DMLUP30 MA Inhibitor DMLUP30 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLUP30 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLV0PQ DI DMLV0PQ DMLV0PQ DN 1-(2-allylphenoxy)-3-morpholinopropan-2-ol DMLV0PQ TI TT2CJVK DMLV0PQ TN Adrenergic receptor beta-2 (ADRB2) DMLV0PQ MA Inhibitor DMLV0PQ RN A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. DMLV0PQ RU https://pubmed.ncbi.nlm.nih.gov/20434333 DMLV0PQ DI DMLV0PQ DMLV0PQ DN 1-(2-allylphenoxy)-3-morpholinopropan-2-ol DMLV0PQ TI TTR6W5O DMLV0PQ TN Adrenergic receptor beta-1 (ADRB1) DMLV0PQ MA Inhibitor DMLV0PQ RN A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. DMLV0PQ RU https://pubmed.ncbi.nlm.nih.gov/20434333 DMLV0PQ DI DMLV0PQ DMLV0PQ DN 1-(2-allylphenoxy)-3-morpholinopropan-2-ol DMLV0PQ TI TTMXGCW DMLV0PQ TN Adrenergic receptor beta-3 (ADRB3) DMLV0PQ MA Inhibitor DMLV0PQ RN A vHTS approach for the identification of beta-adrenoceptor ligands. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3399-404. DMLV0PQ RU https://pubmed.ncbi.nlm.nih.gov/20434333 DMLV18K DI DMLV18K DMLV18K DN N-[4-(3-amino-1H-indazol-4-yl)phenyl]benzamide DMLV18K TI TTGJCWZ DMLV18K TN Fms-like tyrosine kinase 3 (FLT-3) DMLV18K MA Inhibitor DMLV18K RN Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted ... J Med Chem. 2007 Apr 5;50(7):1584-97. DMLV18K RU https://pubmed.ncbi.nlm.nih.gov/17343372 DMLV59R DI DMLV59R DMLV59R DN 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol DMLV59R TI TTCBFJO DMLV59R TN Insulin receptor (INSR) DMLV59R MA Inhibitor DMLV59R RN ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11. DMLV59R RU https://pubmed.ncbi.nlm.nih.gov/17376430 DMLV59R DI DMLV59R DMLV59R DN 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol DMLV59R TI TTHRID2 DMLV59R TN Insulin-like growth factor I receptor (IGF1R) DMLV59R MA Inhibitor DMLV59R RN ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents. Eur J Pharmacol. 2007 May 7;562(1-2):1-11. DMLV59R RU https://pubmed.ncbi.nlm.nih.gov/17376430 DMLV80B DI DMLV80B DMLV80B DN 3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine DMLV80B TI TTAWNKZ DMLV80B TN Norepinephrine transporter (NET) DMLV80B MA Inhibitor DMLV80B RN Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70. DMLV80B RU https://pubmed.ncbi.nlm.nih.gov/18951020 DMLV80B DI DMLV80B DMLV80B DN 3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine DMLV80B TI TT3ROYC DMLV80B TN Serotonin transporter (SERT) DMLV80B MA Inhibitor DMLV80B RN Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70. DMLV80B RU https://pubmed.ncbi.nlm.nih.gov/18951020 DMLVCON DI DMLVCON DMLVCON DN 8-Bromo-9-cyclohexyl-9H-adenine DMLVCON TI TTM2AOE DMLVCON TN Adenosine A2a receptor (ADORA2A) DMLVCON MA Inhibitor DMLVCON RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMLVCON RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMLVCON DI DMLVCON DMLVCON DN 8-Bromo-9-cyclohexyl-9H-adenine DMLVCON TI TTK25J1 DMLVCON TN Adenosine A1 receptor (ADORA1) DMLVCON MA Inhibitor DMLVCON RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMLVCON RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMLVCON DI DMLVCON DMLVCON DN 8-Bromo-9-cyclohexyl-9H-adenine DMLVCON TI TTJFY5U DMLVCON TN Adenosine A3 receptor (ADORA3) DMLVCON MA Inhibitor DMLVCON RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMLVCON RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMLVERQ DI DMLVERQ DMLVERQ DN Ro-0505124 DMLVERQ TI TT0PG8F DMLVERQ TN Cyclin-dependent kinase 4 (CDK4) DMLVERQ MA Inhibitor DMLVERQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1976). DMLVERQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1976 DMLVERQ DI DMLVERQ DMLVERQ DN Ro-0505124 DMLVERQ TI TTX5KEQ DMLVERQ TN Fused homolog (STK36) DMLVERQ MA Inhibitor DMLVERQ RN Inhibition of S/G2 phase CDK4 reduces mitotic fidelity. J Biol Chem. 2006 Apr 14;281(15):9987-95. DMLVERQ RU https://pubmed.ncbi.nlm.nih.gov/16476733 DMLVFUY DI DMLVFUY DMLVFUY DN N-o-Tolyl-1'H-phenothiazine-1'-carboxamide DMLVFUY TI TTEB0GD DMLVFUY TN Cholinesterase (BCHE) DMLVFUY MA Inhibitor DMLVFUY RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMLVFUY RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMLVGT8 DI DMLVGT8 DMLVGT8 DN N-arachidonylmaleimide DMLVGT8 TI TTDP1UC DMLVGT8 TN Fatty acid amide hydrolase (FAAH) DMLVGT8 MA Inhibitor DMLVGT8 RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DMLVGT8 RU https://pubmed.ncbi.nlm.nih.gov/19583260 DMLVKPD DI DMLVKPD DMLVKPD DN ISIS 13805 DMLVKPD TI TT89Z17 DMLVKPD TN B7 translation initiation codon region messenger RNA (CD80 mRNA) DMLVKPD RN US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein. DMLVKPD RU http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true DMLVKPG DI DMLVKPG DMLVKPG DN PMID22902653C35 DMLVKPG TI TTRMD8U DMLVKPG TN Testis-specific kinase 2 (TESK2) DMLVKPG MA Inhibitor DMLVKPG RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMLVKPG RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMLVKPG DI DMLVKPG DMLVKPG DN PMID22902653C35 DMLVKPG TI TTWL9TY DMLVKPG TN LIM domain kinase-1 (LIMK-1) DMLVKPG MA Inhibitor DMLVKPG RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMLVKPG RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMLVKPG DI DMLVKPG DMLVKPG DN PMID22902653C35 DMLVKPG TI TTASMD8 DMLVKPG TN LIM domain kinase-2 (LIMK-2) DMLVKPG MA Inhibitor DMLVKPG RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMLVKPG RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMLVKPG DI DMLVKPG DMLVKPG DN PMID22902653C35 DMLVKPG TI TTWKT3Y DMLVKPG TN Testis-specific kinase 1 (TESK1) DMLVKPG MA Inhibitor DMLVKPG RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMLVKPG RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMLVMJH DI DMLVMJH DMLVMJH DN N,N'-dicyclohexyl-urea DMLVMJH TI TT7WVHI DMLVMJH TN Soluble epoxide hydrolase (EPHX2) DMLVMJH MA Inhibitor DMLVMJH RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DMLVMJH RU https://pubmed.ncbi.nlm.nih.gov/17616115 DMLVPOA DI DMLVPOA DMLVPOA DN ISIS 103708 DMLVPOA TI TT6TU05 DMLVPOA TN WWP2 messenger RNA (WWP2 mRNA) DMLVPOA RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMLVPOA RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMLVRU7 DI DMLVRU7 DMLVRU7 DN PD-138915 DMLVRU7 TI TTCG0AL DMLVRU7 TN Cholecystokinin receptor type A (CCKAR) DMLVRU7 MA Inhibitor DMLVRU7 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMLVRU7 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMLVRU7 DI DMLVRU7 DMLVRU7 DN PD-138915 DMLVRU7 TI TTVFO0U DMLVRU7 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMLVRU7 MA Inhibitor DMLVRU7 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMLVRU7 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMLVTXM DI DMLVTXM DMLVTXM DN LK 204-545 DMLVTXM TI TTMXGCW DMLVTXM TN Adrenergic receptor beta-3 (ADRB3) DMLVTXM MA Antagonist DMLVTXM RN LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors. Eur J Pharmacol. 1999 Feb 19;367(2-3):431-5. DMLVTXM RU https://pubmed.ncbi.nlm.nih.gov/10079020 DMLVU6H DI DMLVU6H DMLVU6H DN resolvin D2 DMLVU6H TI TTELV3W DMLVU6H TN Transformation-sensitive protein p120 (TRPA1) DMLVU6H MA Inhibitor (gating inhibitor) DMLVU6H RN Resolvin D2 is a potent endogenous inhibitor for transient receptor potential subtype V1/A1, inflammatory pain, and spinal cord synaptic plasticity in mice: distinct roles of resolvin D1, D2, and E1.J Neurosci. 2011 Dec 14;31(50):18433-8. DMLVU6H RU https://pubmed.ncbi.nlm.nih.gov/22171045 DMLVZ6O DI DMLVZ6O DMLVZ6O DN 4-(3-benzenesulfonamidophenyl)piperazine DMLVZ6O TI TTJS8PY DMLVZ6O TN 5-HT 6 receptor (HTR6) DMLVZ6O MA Inhibitor DMLVZ6O RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMLVZ6O RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMLW651 DI DMLW651 DMLW651 DN 4-amino-N-p-tolylbenzenesulfonamide DMLW651 TI TT8NGED DMLW651 TN Prostaglandin G/H synthase 1 (COX-1) DMLW651 MA Inhibitor DMLW651 RN Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21. DMLW651 RU https://pubmed.ncbi.nlm.nih.gov/17079150 DMLW7TV DI DMLW7TV DMLW7TV DN (Tert-Butyloxycarbonyl)-Alanyl-Alanyl-Amine DMLW7TV TI TT3NKIB DMLW7TV TN Pancreatic elastase 1 (CELA1) DMLW7TV MA Inhibitor DMLW7TV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMLW7TV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMLW8BI DI DMLW8BI DMLW8BI DN SB-699551-A DMLW8BI TI TTRUFDT DMLW8BI TN 5-HT 5A receptor (HTR5A) DMLW8BI MA Antagonist DMLW8BI RN 5-ht5A receptors as a therapeutic target. Pharmacol Ther. 2006 Sep;111(3):707-14. DMLW8BI RU https://pubmed.ncbi.nlm.nih.gov/16516972 DMLWGPC DI DMLWGPC DMLWGPC DN N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide DMLWGPC TI TT32JK8 DMLWGPC TN Melatonin receptor type 1B (MTNR1B) DMLWGPC MA Inhibitor DMLWGPC RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMLWGPC RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMLWGPC DI DMLWGPC DMLWGPC DN N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamide DMLWGPC TI TT0WAIE DMLWGPC TN Melatonin receptor type 1A (MTNR1A) DMLWGPC MA Inhibitor DMLWGPC RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMLWGPC RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMLWMZ4 DI DMLWMZ4 DMLWMZ4 DN MK-5596 DMLWMZ4 TI TT6OEDT DMLWMZ4 TN Cannabinoid receptor 1 (CB1) DMLWMZ4 MA Agonist DMLWMZ4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 56). DMLWMZ4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56 DMLWO70 DI DMLWO70 DMLWO70 DN ISIS 20990 DMLWO70 TI TTSRXJW DMLWO70 TN G-alpha-11 messenger RNA (GNA11 mRNA) DMLWO70 RN US patent application no. 5,951,455, Antisense modulation of G-alpha-11 expression. DMLWO70 RU http://www.patentbuddy.com/Patent/5951455?ft=true&sr=true DMLWOFY DI DMLWOFY DMLWOFY DN KNI-10539 DMLWOFY TI TTXMNHO DMLWOFY TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMLWOFY MA Inhibitor DMLWOFY RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMLWOFY RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMLWYJB DI DMLWYJB DMLWYJB DN JNK-IN-8 DMLWYJB TI TT3IVG2 DMLWYJB TN JNK2 messenger RNA (JNK2 mRNA) DMLWYJB MA Inhibitor DMLWYJB RN Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. DMLWYJB RU https://pubmed.ncbi.nlm.nih.gov/22284361 DMLWYJB DI DMLWYJB DMLWYJB DN JNK-IN-8 DMLWYJB TI TT056SO DMLWYJB TN Stress-activated protein kinase JNK3 (JNK3) DMLWYJB MA Inhibitor DMLWYJB RN Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. DMLWYJB RU https://pubmed.ncbi.nlm.nih.gov/22284361 DMLWYJB DI DMLWYJB DMLWYJB DN JNK-IN-8 DMLWYJB TI TT0K6EO DMLWYJB TN Stress-activated protein kinase JNK1 (JNK1) DMLWYJB MA Inhibitor DMLWYJB RN Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. DMLWYJB RU https://pubmed.ncbi.nlm.nih.gov/22284361 DMLWZRT DI DMLWZRT DMLWZRT DN CID16020046 DMLWZRT TI TTNET8J DMLWZRT TN G-protein coupled receptor 55 (GPR55) DMLWZRT MA Antagonist DMLWZRT RN A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther. 2013 Jul;346(1):54-66. DMLWZRT RU https://pubmed.ncbi.nlm.nih.gov/23639801 DMLX0PI DI DMLX0PI DMLX0PI DN N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine DMLX0PI TI TT4H1MQ DMLX0PI TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMLX0PI MA Inhibitor DMLX0PI RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMLX0PI RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMLX0PI DI DMLX0PI DMLX0PI DN N,N-dimethyl-4-(pyridin-3-yl)but-3-yn-1-amine DMLX0PI TI TT5KPZR DMLX0PI TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMLX0PI MA Inhibitor DMLX0PI RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMLX0PI RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMLX87P DI DMLX87P DMLX87P DN PMID17560788C29f DMLX87P TI TTPADOQ DMLX87P TN HMG-CoA reductase (HMGCR) DMLX87P MA Inhibitor DMLX87P RN Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase. Bioorg Med Chem. 2007 Aug 15;15(16):5576-89. DMLX87P RU https://pubmed.ncbi.nlm.nih.gov/17560788 DMLX8RW DI DMLX8RW DMLX8RW DN Saxitoxin DMLX8RW TI TTRK8B9 DMLX8RW TN Sodium channel unspecific (NaC) DMLX8RW MA Blocker DMLX8RW RN Effect of neurotoxins on the electrical activity and contraction of the heart muscle. C R Seances Soc Biol Fil. 1997;191(3):451-71. DMLX8RW RU https://pubmed.ncbi.nlm.nih.gov/9295968 DMLX9RG DI DMLX9RG DMLX9RG DN 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-ol DMLX9RG TI TTIQUX7 DMLX9RG TN Steroid 11-beta-hydroxylase (CYP11B1) DMLX9RG MA Inhibitor DMLX9RG RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMLX9RG RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMLX9SI DI DMLX9SI DMLX9SI DN 3-[3-(2-Hydroxy-ethoxy)-phenyl]-1H-quinolin-2-one DMLX9SI TI TTSFWA7 DMLX9SI TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMLX9SI MA Inhibitor DMLX9SI RN A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26. DMLX9SI RU https://pubmed.ncbi.nlm.nih.gov/15481979 DMLXB62 DI DMLXB62 DMLXB62 DN (R)-(-)-2-methoxy-N-npropylnorapomorphine DMLXB62 TI TTZFYLI DMLXB62 TN Dopamine D1 receptor (D1R) DMLXB62 MA Inhibitor DMLXB62 RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMLXB62 RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMLXB62 DI DMLXB62 DMLXB62 DN (R)-(-)-2-methoxy-N-npropylnorapomorphine DMLXB62 TI TTEX248 DMLXB62 TN Dopamine D2 receptor (D2R) DMLXB62 MA Inhibitor DMLXB62 RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMLXB62 RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMLXFHD DI DMLXFHD DMLXFHD DN BS-194 DMLXFHD TI TTMBO1Z DMLXFHD TN Cyclin-dependent kinase (CDK) DMLXFHD MA Inhibitor DMLXFHD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8176). DMLXFHD RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8176 DMLXHAI DI DMLXHAI DMLXHAI DN Sulfamic acid 3-benzoyl-phenyl ester DMLXHAI TI TTHM0R1 DMLXHAI TN Steryl-sulfatase (STS) DMLXHAI MA Inhibitor DMLXHAI RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMLXHAI RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMLXKZH DI DMLXKZH DMLXKZH DN EUPAFOLIN DMLXKZH TI TT86VZE DMLXKZH TN Plasmodium M1-family aminopeptidase (Malaria MFA) DMLXKZH MA Inhibitor DMLXKZH RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMLXKZH RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMLXOAQ DI DMLXOAQ DMLXOAQ DN PMID23639540C13a DMLXOAQ TI TTUTJGQ DMLXOAQ TN Vascular endothelial growth factor receptor 2 (KDR) DMLXOAQ MA Inhibitor DMLXOAQ RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMLXOAQ RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMLXOAQ DI DMLXOAQ DMLXOAQ DN PMID23639540C13a DMLXOAQ TI TTZE3P7 DMLXOAQ TN TGF-beta receptor type II (TGFBR2) DMLXOAQ MA Inhibitor DMLXOAQ RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMLXOAQ RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMLXOAQ DI DMLXOAQ DMLXOAQ DN PMID23639540C13a DMLXOAQ TI TTJNBQA DMLXOAQ TN Activin receptor-like kinase 2 (ALK-2) DMLXOAQ MA Inhibitor DMLXOAQ RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMLXOAQ RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMLXOAQ DI DMLXOAQ DMLXOAQ DN PMID23639540C13a DMLXOAQ TI TTLAFZV DMLXOAQ TN AMP-activated protein kinase (AMPK) DMLXOAQ MA Inhibitor DMLXOAQ RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMLXOAQ RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMLXOAQ DI DMLXOAQ DMLXOAQ DN PMID23639540C13a DMLXOAQ TI TTGYPTC DMLXOAQ TN Activin receptor-like kinase-1 (ACVRL1) DMLXOAQ MA Inhibitor DMLXOAQ RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMLXOAQ RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMLXOAQ DI DMLXOAQ DMLXOAQ DN PMID23639540C13a DMLXOAQ TI TTGKF90 DMLXOAQ TN Bone morphogenetic protein receptor (BMPR2) DMLXOAQ MA Inhibitor DMLXOAQ RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMLXOAQ RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMLXOHE DI DMLXOHE DMLXOHE DN 2-amino-2-(2-fluorophenyl)acetic acid DMLXOHE TI TTFK1JQ DMLXOHE TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMLXOHE MA Inhibitor DMLXOHE RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMLXOHE RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMLXR90 DI DMLXR90 DMLXR90 DN GNE-9605 DMLXR90 TI TTK0FEA DMLXR90 TN Leucine-rich repeat kinase 2 (LRRK2) DMLXR90 MA Inhibitor DMLXR90 RN Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36. DMLXR90 RU https://pubmed.ncbi.nlm.nih.gov/24354345 DMLY46X DI DMLY46X DMLY46X DN 8-(3-Methoxybenzyloxy)caffeine DMLY46X TI TTGP7BY DMLY46X TN Monoamine oxidase type B (MAO-B) DMLY46X MA Inhibitor DMLY46X RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMLY46X RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMLY46X DI DMLY46X DMLY46X DN 8-(3-Methoxybenzyloxy)caffeine DMLY46X TI TT3WG5C DMLY46X TN Monoamine oxidase type A (MAO-A) DMLY46X MA Inhibitor DMLY46X RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMLY46X RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMLY4C9 DI DMLY4C9 DMLY4C9 DN RTA-301 DMLY4C9 TI TTYFKSZ DMLY4C9 TN Tubulin beta (TUBB) DMLY4C9 MA Inhibitor DMLY4C9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMLY4C9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMLY4ER DI DMLY4ER DMLY4ER DN 1-(2-phenoxybenzyl)-1H-imidazole DMLY4ER TI TTSZLWK DMLY4ER TN Aromatase (CYP19A1) DMLY4ER MA Inhibitor DMLY4ER RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DMLY4ER RU https://pubmed.ncbi.nlm.nih.gov/20568782 DMLY5IF DI DMLY5IF DMLY5IF DN IKs124 DMLY5IF TI TT846HF DMLY5IF TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMLY5IF MA Blocker (channel blocker) DMLY5IF RN Heteromeric KCNE2/KCNQ1 potassium channels in the luminal membrane of gastric parietal cells. J Physiol. 2004 Dec 1;561(Pt 2):547-57. DMLY5IF RU https://pubmed.ncbi.nlm.nih.gov/15579540 DMLY6WX DI DMLY6WX DMLY6WX DN NSC-37031 DMLY6WX TI TT9NVXQ DMLY6WX TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMLY6WX MA Inhibitor DMLY6WX RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMLY6WX RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMLY7DC DI DMLY7DC DMLY7DC DN Des-AA1,5-[Tyr2,D-Trp8,IAmp9]SRIF CH-288 DMLY7DC TI TTIND6G DMLY7DC TN Somatostatin receptor type 1 (SSTR1) DMLY7DC MA Inhibitor DMLY7DC RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMLY7DC RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMLY8CU DI DMLY8CU DMLY8CU DN Cyclo(-D-Ala-D-Arg-L-Arg-L-Nal-Gly-) DMLY8CU TI TTBID49 DMLY8CU TN C-X-C chemokine receptor type 4 (CXCR4) DMLY8CU MA Inhibitor DMLY8CU RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMLY8CU RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMLYGPW DI DMLYGPW DMLYGPW DN Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2 DMLYGPW TI TTD0CIQ DMLYGPW TN Melanocortin receptor 4 (MC4R) DMLYGPW MA Inhibitor DMLYGPW RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMLYGPW RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMLYGPW DI DMLYGPW DMLYGPW DN Ac-Nle-c[Asp-His-DNaI(2')-Pro-Trp-Lys]-NH2 DMLYGPW TI TT0MV2T DMLYGPW TN Melanocortin receptor 1 (MC1R) DMLYGPW MA Inhibitor DMLYGPW RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMLYGPW RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMLYHUN DI DMLYHUN DMLYHUN DN JWH-208 DMLYHUN TI TTMSFAW DMLYHUN TN Cannabinoid receptor 2 (CB2) DMLYHUN MA Inhibitor DMLYHUN RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMLYHUN RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMLYIBO DI DMLYIBO DMLYIBO DN IIK7 DMLYIBO TI TT0WAIE DMLYIBO TN Melatonin receptor type 1A (MTNR1A) DMLYIBO MA Agonist DMLYIBO RN Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles.J Med Chem. 2000 Mar 23;43(6):1050-61. DMLYIBO RU https://pubmed.ncbi.nlm.nih.gov/10737738 DMLYO8P DI DMLYO8P DMLYO8P DN 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol DMLYO8P TI TT27RFC DMLYO8P TN Opioid receptor delta (OPRD1) DMLYO8P MA Inhibitor DMLYO8P RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMLYO8P RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMLYO8P DI DMLYO8P DMLYO8P DN 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol DMLYO8P TI TTQW87Y DMLYO8P TN Opioid receptor kappa (OPRK1) DMLYO8P MA Inhibitor DMLYO8P RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMLYO8P RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMLYO8P DI DMLYO8P DMLYO8P DN 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol DMLYO8P TI TTKWM86 DMLYO8P TN Opioid receptor mu (MOP) DMLYO8P MA Inhibitor DMLYO8P RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMLYO8P RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMLYO8P DI DMLYO8P DMLYO8P DN 1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol DMLYO8P TI TTNT7K8 DMLYO8P TN Nociceptin receptor (OPRL1) DMLYO8P MA Inhibitor DMLYO8P RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMLYO8P RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMLYQWV DI DMLYQWV DMLYQWV DN Recombinant human TNF receptor DMLYQWV TI TTG043C DMLYQWV TN Tumor necrosis factor receptor type I (TNF-R1) DMLYQWV MA Modulator DMLYQWV RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DMLYQWV RU https://pubmed.ncbi.nlm.nih.gov/15507622 DMLYVPH DI DMLYVPH DMLYVPH DN 3-(3-aminobenzo[e][1,2,4]triazin-7-yl)phenol DMLYVPH TI TT6PKBN DMLYVPH TN Proto-oncogene c-Src (SRC) DMLYVPH MA Inhibitor DMLYVPH RN Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50. DMLYVPH RU https://pubmed.ncbi.nlm.nih.gov/16931012 DMLYVQB DI DMLYVQB DMLYVQB DN MOD-3012 DMLYVQB TI TTFEZ5Q DMLYVQB TN Coagulation factor IX (F9) DMLYVQB MA Modulator DMLYVQB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364). DMLYVQB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364 DMLYZOG DI DMLYZOG DMLYZOG DN NORBINALTORPHIMINE DMLYZOG TI TTKWM86 DMLYZOG TN Opioid receptor mu (MOP) DMLYZOG MA Inhibitor DMLYZOG RN Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8. DMLYZOG RU https://pubmed.ncbi.nlm.nih.gov/20685120 DMLYZOG DI DMLYZOG DMLYZOG DN NORBINALTORPHIMINE DMLYZOG TI TT27RFC DMLYZOG TN Opioid receptor delta (OPRD1) DMLYZOG MA Inhibitor DMLYZOG RN Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-... J Med Chem. 2003 Jul 3;46(14):3127-37. DMLYZOG RU https://pubmed.ncbi.nlm.nih.gov/12825951 DMLYZOG DI DMLYZOG DMLYZOG DN NORBINALTORPHIMINE DMLYZOG TI TTQW87Y DMLYZOG TN Opioid receptor kappa (OPRK1) DMLYZOG MA Inhibitor DMLYZOG RN Synthesis of pyrrolomorphinan derivatives as kappa opioid agonists. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5035-8. DMLYZOG RU https://pubmed.ncbi.nlm.nih.gov/20685120 DMLZ5F1 DI DMLZ5F1 DMLZ5F1 DN 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine DMLZ5F1 TI TTSQIFT DMLZ5F1 TN 5-HT 1A receptor (HTR1A) DMLZ5F1 MA Inhibitor DMLZ5F1 RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DMLZ5F1 RU https://pubmed.ncbi.nlm.nih.gov/17064079 DMLZ5F1 DI DMLZ5F1 DMLZ5F1 DN 3-{[2-(2-phenylethyl)phenoxy]methyl}pyridine DMLZ5F1 TI TTEX248 DMLZ5F1 TN Dopamine D2 receptor (D2R) DMLZ5F1 MA Inhibitor DMLZ5F1 RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DMLZ5F1 RU https://pubmed.ncbi.nlm.nih.gov/17064079 DMLZ5R6 DI DMLZ5R6 DMLZ5R6 DN Bbs-Arg-(D-Pip)-Gly-S-(GS)9-Gly-Hir DMLZ5R6 TI TT6L509 DMLZ5R6 TN Coagulation factor IIa (F2) DMLZ5R6 MA Inhibitor DMLZ5R6 RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMLZ5R6 RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTG0U4H DMLZ89P TN Ribosomal protein S6 kinase beta-1 (S6K1) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTTU902 DMLZ89P TN Checkpoint kinase-1 (CHK1) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTZN7RP DMLZ89P TN Rho-associated protein kinase 1 (ROCK1) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTYT93M DMLZ89P TN MAP kinase p38 (MAPK12) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TT4TQBX DMLZ89P TN Extracellular signal-regulated kinase 2 (ERK2) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTTV8EJ DMLZ89P TN Serine/threonine-protein kinase Sgk1 (SGK1) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTFJ8Q1 DMLZ89P TN Protein kinase C alpha (PRKCA) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TT73U6C DMLZ89P TN Stress-activated protein kinase 2b (p38 beta) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TT473XN DMLZ89P TN P2X purinoceptor 7 (P2RX7) DMLZ89P MA Inhibitor DMLZ89P RN Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6053-8. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/19800793 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTQBR95 DMLZ89P TN Stress-activated protein kinase 2a (p38 alpha) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TTWTSCV DMLZ89P TN RAC-alpha serine/threonine-protein kinase (AKT1) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TT860QF DMLZ89P TN LCK tyrosine protein kinase (LCK) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZ89P DI DMLZ89P DMLZ89P DN KN-62 DMLZ89P TI TT0K6EO DMLZ89P TN Stress-activated protein kinase JNK1 (JNK1) DMLZ89P MA Inhibitor DMLZ89P RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMLZ89P RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMLZBJT DI DMLZBJT DMLZBJT DN (S)-4-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine DMLZBJT TI TT9JNIC DMLZBJT TN Histamine H3 receptor (H3R) DMLZBJT MA Inhibitor DMLZBJT RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMLZBJT RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMLZCOU DI DMLZCOU DMLZCOU DN 2-N-Propargylamino-1-(4-methylthiophenyl)butane DMLZCOU TI TT3ROYC DMLZCOU TN Serotonin transporter (SERT) DMLZCOU MA Inhibitor DMLZCOU RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMLZCOU RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMLZDK6 DI DMLZDK6 DMLZDK6 DN SB251023 DMLZDK6 TI TTMXGCW DMLZDK6 TN Adrenergic receptor beta-3 (ADRB3) DMLZDK6 MA Agonist DMLZDK6 RN Mouse beta 3a- and beta 3b-adrenoceptors expressed in Chinese hamster ovary cells display identical pharmacology but utilize distinct signalling pathways. Br J Pharmacol. 2002 Apr;135(8):1903-14. DMLZDK6 RU https://pubmed.ncbi.nlm.nih.gov/11959793 DMLZFTH DI DMLZFTH DMLZFTH DN INS48823 DMLZFTH TI TTNVSKA DMLZFTH TN P2Y purinoceptor 6 (P2RY6) DMLZFTH MA Agonist DMLZFTH RN P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312. DMLZFTH RU https://pubmed.ncbi.nlm.nih.gov/16475938 DMLZGO7 DI DMLZGO7 DMLZGO7 DN Mesuagenin D DMLZGO7 TI TT1RS9F DMLZGO7 TN Acetylcholinesterase (AChE) DMLZGO7 MA Inhibitor DMLZGO7 RN 4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg Med Chem. 2010 Nov 15;18(22):7873-7. DMLZGO7 RU https://pubmed.ncbi.nlm.nih.gov/20943395 DMLZKNF DI DMLZKNF DMLZKNF DN 5-hydroxy-2-phenylisoindoline-1,3-dione DMLZKNF TI TTZAYWL DMLZKNF TN Estrogen receptor (ESR) DMLZKNF MA Inhibitor DMLZKNF RN Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones. Bioorg Med Chem Lett. 2007 Jan 1;17(1):118-22. DMLZKNF RU https://pubmed.ncbi.nlm.nih.gov/17049855 DMLZNK6 DI DMLZNK6 DMLZNK6 DN [HO1][Lys8(5/6C-Flu)]VT DMLZNK6 TI TT4TFGN DMLZNK6 TN Vasopressin V1a receptor (V1AR) DMLZNK6 MA Inhibitor DMLZNK6 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMLZNK6 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMLZNK6 DI DMLZNK6 DMLZNK6 DN [HO1][Lys8(5/6C-Flu)]VT DMLZNK6 TI TTSCIUP DMLZNK6 TN Oxytocin receptor (OTR) DMLZNK6 MA Inhibitor DMLZNK6 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMLZNK6 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMLZNK6 DI DMLZNK6 DMLZNK6 DN [HO1][Lys8(5/6C-Flu)]VT DMLZNK6 TI TTL9MHW DMLZNK6 TN Vasopressin V1b receptor (V1BR) DMLZNK6 MA Inhibitor DMLZNK6 RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMLZNK6 RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMLZSH1 DI DMLZSH1 DMLZSH1 DN 4-Phenyl-benzo[b]thiophene-2-carboxamidine DMLZSH1 TI TTFEZ5Q DMLZSH1 TN Coagulation factor IX (F9) DMLZSH1 MA Inhibitor DMLZSH1 RN Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72. DMLZSH1 RU https://pubmed.ncbi.nlm.nih.gov/20121198 DMLZT64 DI DMLZT64 DMLZT64 DN 1400W DMLZT64 TI TTF10I9 DMLZT64 TN Nitric-oxide synthase inducible (NOS2) DMLZT64 MA Inhibitor DMLZT64 RN 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem. 1997 Feb 21;272(8):4959-63. DMLZT64 RU https://pubmed.ncbi.nlm.nih.gov/9030556 DMLZT64 DI DMLZT64 DMLZT64 DN 1400W DMLZT64 TI TTCM4B3 DMLZT64 TN Nitric-oxide synthase endothelial (NOS3) DMLZT64 MA Inhibitor DMLZT64 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLZT64 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLZT64 DI DMLZT64 DMLZT64 DN 1400W DMLZT64 TI TTZUFI5 DMLZT64 TN Nitric-oxide synthase brain (NOS1) DMLZT64 MA Inhibitor DMLZT64 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMLZT64 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMLZU09 DI DMLZU09 DMLZU09 DN E-52862 DMLZU09 TI TTTPE1L DMLZU09 TN HUMAN opioid receptor sigma 1 (OPRS1) DMLZU09 MA Antagonist DMLZU09 RN A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DMLZU09 RU https://www.nature.com/articles/s41586-020-2286-9 DMM05AO DI DMM05AO DMM05AO DN 2-Phosphonooxy-pentanedioic acid DMM05AO TI TT9G4N0 DMM05AO TN Glutamate carboxypeptidase II (GCPII) DMM05AO MA Inhibitor DMM05AO RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DMM05AO RU https://pubmed.ncbi.nlm.nih.gov/12723961 DMM05G2 DI DMM05G2 DMM05G2 DN 3-(dimethylamino)phenyl phenylcarbamate DMM05G2 TI TTEB0GD DMM05G2 TN Cholinesterase (BCHE) DMM05G2 MA Inhibitor DMM05G2 RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMM05G2 RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMM05G2 DI DMM05G2 DMM05G2 DN 3-(dimethylamino)phenyl phenylcarbamate DMM05G2 TI TT1RS9F DMM05G2 TN Acetylcholinesterase (AChE) DMM05G2 MA Inhibitor DMM05G2 RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMM05G2 RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMM08LV DI DMM08LV DMM08LV DN PMID8831774C19 DMM08LV TI TTG5QB7 DMM08LV TN Calpain-2 (CAPN2) DMM08LV MA Inhibitor DMM08LV RN Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases. J Med Chem. 1996 Sep 27;39(20):4089-98. DMM08LV RU https://pubmed.ncbi.nlm.nih.gov/8831774 DMM0EYR DI DMM0EYR DMM0EYR DN PNU177836 DMM0EYR TI TTELIN2 DMM0EYR TN PTPN1 messenger RNA (PTPN1 mRNA) DMM0EYR MA Inhibitor DMM0EYR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM0EYR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM0F2G DI DMM0F2G DMM0F2G DN N-Hexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide DMM0F2G TI TTPTXIN DMM0F2G TN Translocator protein (TSPO) DMM0F2G MA Inhibitor DMM0F2G RN Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20. DMM0F2G RU https://pubmed.ncbi.nlm.nih.gov/8411007 DMM0GUN DI DMM0GUN DMM0GUN DN ISIS 25074 DMM0GUN TI TT8H9GB DMM0GUN TN MEK2 messenger RNA (MEK2 mRNA) DMM0GUN RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMM0GUN RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMM0H9Y DI DMM0H9Y DMM0H9Y DN 4,4-Diphenyl-N-(pyridin-3-yl)-butyramide DMM0H9Y TI TT7WVHI DMM0H9Y TN Soluble epoxide hydrolase (EPHX2) DMM0H9Y MA Inhibitor DMM0H9Y RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DMM0H9Y RU https://pubmed.ncbi.nlm.nih.gov/19746975 DMM0JA4 DI DMM0JA4 DMM0JA4 DN Gly-Pip-Glu DMM0JA4 TI TTKJEMQ DMM0JA4 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMM0JA4 MA Inhibitor DMM0JA4 RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMM0JA4 RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMM0JA4 DI DMM0JA4 DMM0JA4 DN Gly-Pip-Glu DMM0JA4 TI TTN9D8E DMM0JA4 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMM0JA4 MA Inhibitor DMM0JA4 RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMM0JA4 RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMM0JA4 DI DMM0JA4 DMM0JA4 DN Gly-Pip-Glu DMM0JA4 TI TTLD29N DMM0JA4 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMM0JA4 MA Inhibitor DMM0JA4 RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMM0JA4 RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMM0KOJ DI DMM0KOJ DMM0KOJ DN 2-arachidonoylglycerol DMM0KOJ TI TTDP1UC DMM0KOJ TN Fatty acid amide hydrolase (FAAH) DMM0KOJ MA Inhibitor DMM0KOJ RN Conformationally constrained analogues of 2-arachidonoylglycerol. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5959-63. DMM0KOJ RU https://pubmed.ncbi.nlm.nih.gov/17826996 DMM0LRE DI DMM0LRE DMM0LRE DN TGX-221 DMM0LRE TI TTHBTOP DMM0LRE TN PI3-kinase gamma (PIK3CG) DMM0LRE MA Inhibitor DMM0LRE RN PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14. DMM0LRE RU https://pubmed.ncbi.nlm.nih.gov/15834429 DMM0LRE DI DMM0LRE DMM0LRE DN TGX-221 DMM0LRE TI TTTHBCA DMM0LRE TN PI3-kinase beta (PIK3CB) DMM0LRE MA Inhibitor DMM0LRE RN PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med. 2005 May;11(5):507-14. DMM0LRE RU https://pubmed.ncbi.nlm.nih.gov/15834429 DMM0TL6 DI DMM0TL6 DMM0TL6 DN 4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide DMM0TL6 TI TT1VAUK DMM0TL6 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMM0TL6 MA Inhibitor DMM0TL6 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMM0TL6 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMM0TL6 DI DMM0TL6 DMM0TL6 DN 4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide DMM0TL6 TI TTUTJGQ DMM0TL6 TN Vascular endothelial growth factor receptor 2 (KDR) DMM0TL6 MA Inhibitor DMM0TL6 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMM0TL6 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMM0TL6 DI DMM0TL6 DMM0TL6 DN 4-Chloro-N-(4-nitro-benzoyl)-benzenesulfonamide DMM0TL6 TI TTDCBX5 DMM0TL6 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMM0TL6 MA Inhibitor DMM0TL6 RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMM0TL6 RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMM0VDK DI DMM0VDK DMM0VDK DN DM-1451 DMM0VDK TI TTJS8PY DMM0VDK TN 5-HT 6 receptor (HTR6) DMM0VDK MA Agonist DMM0VDK RN Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27. DMM0VDK RU https://pubmed.ncbi.nlm.nih.gov/10327430 DMM0VDK DI DMM0VDK DMM0VDK DN DM-1451 DMM0VDK TI TTO9X1H DMM0VDK TN 5-HT 7 receptor (HTR7) DMM0VDK MA Agonist DMM0VDK RN Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27. DMM0VDK RU https://pubmed.ncbi.nlm.nih.gov/10327430 DMM0WGI DI DMM0WGI DMM0WGI DN 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole DMM0WGI TI TTE0A2F DMM0WGI TN Dopamine D4 receptor (D4R) DMM0WGI MA Inhibitor DMM0WGI RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DMM0WGI RU https://pubmed.ncbi.nlm.nih.gov/8642550 DMM0WGI DI DMM0WGI DMM0WGI DN 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole DMM0WGI TI TTEX248 DMM0WGI TN Dopamine D2 receptor (D2R) DMM0WGI MA Inhibitor DMM0WGI RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DMM0WGI RU https://pubmed.ncbi.nlm.nih.gov/8642550 DMM0WGI DI DMM0WGI DMM0WGI DN 3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole DMM0WGI TI TT4C8EA DMM0WGI TN Dopamine D3 receptor (D3R) DMM0WGI MA Inhibitor DMM0WGI RN 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2. DMM0WGI RU https://pubmed.ncbi.nlm.nih.gov/8642550 DMM0Z6Y DI DMM0Z6Y DMM0Z6Y DN Lactose DMM0Z6Y TI TT50QJ3 DMM0Z6Y TN Influenza Neuraminidase (Influ NA) DMM0Z6Y MA Inhibitor DMM0Z6Y RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM0Z6Y RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM0ZKQ DI DMM0ZKQ DMM0ZKQ DN GMQ DMM0ZKQ TI TTLGDIS DMM0ZKQ TN Acid-sensing ion channel 3 (ASIC3) DMM0ZKQ MA Activator DMM0ZKQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686). DMM0ZKQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686 DMM10TG DI DMM10TG DMM10TG DN Cirsimarin DMM10TG TI TTK25J1 DMM10TG TN Adenosine A1 receptor (ADORA1) DMM10TG MA Inhibitor DMM10TG RN Adenosine-1 active ligands: cirsimarin, a flavone glycoside from Microtea debilis. J Nat Prod. 1997 Jun;60(6):638-41. DMM10TG RU https://pubmed.ncbi.nlm.nih.gov/9214739 DMM17AO DI DMM17AO DMM17AO DN FGGFTGARKSARKWANQ DMM17AO TI TTNT7K8 DMM17AO TN Nociceptin receptor (OPRL1) DMM17AO MA Inhibitor DMM17AO RN Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. DMM17AO RU https://pubmed.ncbi.nlm.nih.gov/19577933 DMM17I0 DI DMM17I0 DMM17I0 DN 1-(4-iodobenzyl)-1H-imidazole DMM17I0 TI TTRA5BZ DMM17I0 TN Steroid 17-alpha-monooxygenase (S17AH) DMM17I0 MA Inhibitor DMM17I0 RN Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as pote... Bioorg Med Chem Lett. 2010 Sep 1;20(17):5345-8. DMM17I0 RU https://pubmed.ncbi.nlm.nih.gov/20675132 DMM18AQ DI DMM18AQ DMM18AQ DN 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one DMM18AQ TI TT4C8EA DMM18AQ TN Dopamine D3 receptor (D3R) DMM18AQ MA Inhibitor DMM18AQ RN Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Bioorg Med Chem. 2007 Sep 1;15(17):5811-8. DMM18AQ RU https://pubmed.ncbi.nlm.nih.gov/17576067 DMM18AQ DI DMM18AQ DMM18AQ DN 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one DMM18AQ TI TTS2PH3 DMM18AQ TN Dopamine D5 receptor (D5R) DMM18AQ MA Inhibitor DMM18AQ RN Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Bioorg Med Chem. 2007 Sep 1;15(17):5811-8. DMM18AQ RU https://pubmed.ncbi.nlm.nih.gov/17576067 DMM18AQ DI DMM18AQ DMM18AQ DN 1-(4-(4-phenyl-1-piperazinyl)butyl)indolin-2-one DMM18AQ TI TTEX248 DMM18AQ TN Dopamine D2 receptor (D2R) DMM18AQ MA Inhibitor DMM18AQ RN Synthesis of novel lactam derivatives and their evaluation as ligands for the dopamine receptors, leading to a D(4)-selective ligand. Bioorg Med Chem. 2007 Sep 1;15(17):5811-8. DMM18AQ RU https://pubmed.ncbi.nlm.nih.gov/17576067 DMM19AO DI DMM19AO DMM19AO DN alkyl OMPT DMM19AO TI TTE2YJR DMM19AO TN Lysophosphatidate-3 receptor (LPAR3) DMM19AO MA Agonist DMM19AO RN Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. ChemMedChem. 2006 Mar;1(3):376-83. DMM19AO RU https://pubmed.ncbi.nlm.nih.gov/16892372 DMM19AO DI DMM19AO DMM19AO DN alkyl OMPT DMM19AO TI TTQ6S1K DMM19AO TN Lysophosphatidic acid receptor 1 (LPAR1) DMM19AO MA Agonist DMM19AO RN Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists. ChemMedChem. 2006 Mar;1(3):376-83. DMM19AO RU https://pubmed.ncbi.nlm.nih.gov/16892372 DMM19SJ DI DMM19SJ DMM19SJ DN C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ TI TTEOSZT DMM19SJ TN Melanocortin receptor (MCR) DMM19SJ MA Inhibitor DMM19SJ RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMM19SJ RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMM19SJ DI DMM19SJ DMM19SJ DN C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ TI TTNI91K DMM19SJ TN Melanocortin receptor 3 (MC3R) DMM19SJ MA Inhibitor DMM19SJ RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMM19SJ RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMM19SJ DI DMM19SJ DMM19SJ DN C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ TI TTD0CIQ DMM19SJ TN Melanocortin receptor 4 (MC4R) DMM19SJ MA Inhibitor DMM19SJ RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMM19SJ RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMM19SJ DI DMM19SJ DMM19SJ DN C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2 DMM19SJ TI TT0MV2T DMM19SJ TN Melanocortin receptor 1 (MC1R) DMM19SJ MA Inhibitor DMM19SJ RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMM19SJ RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMM1CKZ DI DMM1CKZ DMM1CKZ DN 3-(5-Pyridin-2-yl-tetrazol-2-yl)-benzonitrile DMM1CKZ TI TTHS256 DMM1CKZ TN Metabotropic glutamate receptor 5 (mGluR5) DMM1CKZ MA Inhibitor DMM1CKZ RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMM1CKZ RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMM1GXI DI DMM1GXI DMM1GXI DN DL-guanidinoethylmercaptosuccinic acid DMM1GXI TI TTP18AY DMM1GXI TN Carboxypeptidase B2 (CPB2) DMM1GXI MA Inhibitor DMM1GXI RN A new type of five-membered heterocyclic inhibitors of basic metallocarboxypeptidases. Eur J Med Chem. 2009 Aug;44(8):3266-71. DMM1GXI RU https://pubmed.ncbi.nlm.nih.gov/19386397 DMM1IAU DI DMM1IAU DMM1IAU DN PHENYLTHIOUREA DMM1IAU TI TTULVH8 DMM1IAU TN Tyrosinase (TYR) DMM1IAU MA Inhibitor DMM1IAU RN Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10. DMM1IAU RU https://pubmed.ncbi.nlm.nih.gov/18501598 DMM1J2D DI DMM1J2D DMM1J2D DN m-chlorophenylpiperazine DMM1J2D TI TTCPG9S DMM1J2D TN 5-HT 1E receptor (HTR1E) DMM1J2D MA Agonist DMM1J2D RN Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. DMM1J2D RU https://pubmed.ncbi.nlm.nih.gov/14744596 DMM1J2D DI DMM1J2D DMM1J2D DN m-chlorophenylpiperazine DMM1J2D TI TTWJBZ5 DMM1J2D TN 5-HT 2C receptor (HTR2C) DMM1J2D MA Agonist DMM1J2D RN Pharmacological profile of YM348, a novel, potent and orally active 5-HT2C receptor agonist. Eur J Pharmacol. 2004 Jan 1;483(1):37-43. DMM1J2D RU https://pubmed.ncbi.nlm.nih.gov/14709324 DMM1J2D DI DMM1J2D DMM1J2D DN m-chlorophenylpiperazine DMM1J2D TI TTO9X1H DMM1J2D TN 5-HT 7 receptor (HTR7) DMM1J2D MA Agonist DMM1J2D RN Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem. 1993 Aug 25;268(24):18200-4. DMM1J2D RU https://pubmed.ncbi.nlm.nih.gov/8394362 DMM1J2D DI DMM1J2D DMM1J2D DN m-chlorophenylpiperazine DMM1J2D TI TTJS8PY DMM1J2D TN 5-HT 6 receptor (HTR6) DMM1J2D MA Agonist DMM1J2D RN Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. DMM1J2D RU https://pubmed.ncbi.nlm.nih.gov/7680751 DMM1J2D DI DMM1J2D DMM1J2D DN m-chlorophenylpiperazine DMM1J2D TI TTJQOD7 DMM1J2D TN 5-HT 2A receptor (HTR2A) DMM1J2D MA Agonist DMM1J2D RN Comparisons of hallucinogenic phenylisopropylamine binding affinities at cloned human 5-HT2A, -HT(2B) and 5-HT2C receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jan;359(1):1-6. DMM1J2D RU https://pubmed.ncbi.nlm.nih.gov/9933142 DMM1J2D DI DMM1J2D DMM1J2D DN m-chlorophenylpiperazine DMM1J2D TI TT0K1SC DMM1J2D TN 5-HT 2B receptor (HTR2B) DMM1J2D MA Agonist DMM1J2D RN Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. DMM1J2D RU https://pubmed.ncbi.nlm.nih.gov/8450835 DMM1J2D DI DMM1J2D DMM1J2D DN m-chlorophenylpiperazine DMM1J2D TI TT6MSOK DMM1J2D TN 5-HT 1D receptor (HTR1D) DMM1J2D MA Antagonist DMM1J2D RN Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8. DMM1J2D RU https://pubmed.ncbi.nlm.nih.gov/1652050 DMM1KBW DI DMM1KBW DMM1KBW DN [3H]EM-TBPC DMM1KBW TI TTVBPDM DMM1KBW TN Metabotropic glutamate receptor 1 (mGluR1) DMM1KBW MA Modulator (allosteric modulator) DMM1KBW RN Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glut... J Biol Chem. 2003 Mar 7;278(10):8340-7. DMM1KBW RU https://pubmed.ncbi.nlm.nih.gov/12509432 DMM1RCS DI DMM1RCS DMM1RCS DN 4-(piperazin-1-yl)-1H-indole DMM1RCS TI TTJS8PY DMM1RCS TN 5-HT 6 receptor (HTR6) DMM1RCS MA Inhibitor DMM1RCS RN Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302. DMM1RCS RU https://pubmed.ncbi.nlm.nih.gov/16183286 DMM1YBE DI DMM1YBE DMM1YBE DN PMID21444206C3j DMM1YBE TI TT7QNVC DMM1YBE TN Glucose-dependent insulinotropic receptor (GPR119) DMM1YBE MA Agonist DMM1YBE RN Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41. DMM1YBE RU https://pubmed.ncbi.nlm.nih.gov/21444206 DMM2A5Q DI DMM2A5Q DMM2A5Q DN KNI-10758 DMM2A5Q TI TTXMNHO DMM2A5Q TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMM2A5Q MA Inhibitor DMM2A5Q RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMM2A5Q RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMM2AR3 DI DMM2AR3 DMM2AR3 DN 3-(furan-3-yl)-1H-indole DMM2AR3 TI TTTB4UP DMM2AR3 TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMM2AR3 MA Inhibitor DMM2AR3 RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMM2AR3 RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMM2EX6 DI DMM2EX6 DMM2EX6 DN (6-Ethoxy-2-naphthyl)-2-aminopropane DMM2EX6 TI TT3WG5C DMM2EX6 TN Monoamine oxidase type A (MAO-A) DMM2EX6 MA Inhibitor DMM2EX6 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMM2EX6 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMM2EX6 DI DMM2EX6 DMM2EX6 DN (6-Ethoxy-2-naphthyl)-2-aminopropane DMM2EX6 TI TTGP7BY DMM2EX6 TN Monoamine oxidase type B (MAO-B) DMM2EX6 MA Inhibitor DMM2EX6 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMM2EX6 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMM2GQC DI DMM2GQC DMM2GQC DN 9-Mercaptomethyl-10-oxo-azecane-2-carboxylic acid DMM2GQC TI TT5TKPM DMM2GQC TN Neutral endopeptidase (MME) DMM2GQC MA Inhibitor DMM2GQC RN Design and synthesis of an orally active macrocyclic neutral endopeptidase 24.11 inhibitor. J Med Chem. 1993 Nov 26;36(24):3821-8. DMM2GQC RU https://pubmed.ncbi.nlm.nih.gov/8254611 DMM2I9G DI DMM2I9G DMM2I9G DN ischemin DMM2I9G TI TTFRCTK DMM2I9G TN CREB-binding protein (CREBBP) DMM2I9G MA Inhibitor DMM2I9G RN A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol. 2011 Apr 22;18(4):531-41. DMM2I9G RU https://pubmed.ncbi.nlm.nih.gov/21513889 DMM2NHZ DI DMM2NHZ DMM2NHZ DN 4-(2-(benzyloxy)-3-fluorophenyl)piperidine DMM2NHZ TI TTAWNKZ DMM2NHZ TN Norepinephrine transporter (NET) DMM2NHZ MA Inhibitor DMM2NHZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMM2NHZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMM2NHZ DI DMM2NHZ DMM2NHZ DN 4-(2-(benzyloxy)-3-fluorophenyl)piperidine DMM2NHZ TI TTVBI8W DMM2NHZ TN Dopamine transporter (DAT) DMM2NHZ MA Inhibitor DMM2NHZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMM2NHZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMM2NHZ DI DMM2NHZ DMM2NHZ DN 4-(2-(benzyloxy)-3-fluorophenyl)piperidine DMM2NHZ TI TTSQIFT DMM2NHZ TN 5-HT 1A receptor (HTR1A) DMM2NHZ MA Inhibitor DMM2NHZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMM2NHZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMM2NHZ DI DMM2NHZ DMM2NHZ DN 4-(2-(benzyloxy)-3-fluorophenyl)piperidine DMM2NHZ TI TT3ROYC DMM2NHZ TN Serotonin transporter (SERT) DMM2NHZ MA Inhibitor DMM2NHZ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMM2NHZ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMM2Q9L DI DMM2Q9L DMM2Q9L DN ADS-103294 DMM2Q9L TI TTX4RTB DMM2Q9L TN Melanin-concentrating hormone receptor 1 (MCHR1) DMM2Q9L MA Inhibitor DMM2Q9L RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMM2Q9L RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMM2QOX DI DMM2QOX DMM2QOX DN (+/-)-TRANS-U-50488 METHANESULFONATE DMM2QOX TI TTKWM86 DMM2QOX TN Opioid receptor mu (MOP) DMM2QOX MA Inhibitor DMM2QOX RN Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4. DMM2QOX RU https://pubmed.ncbi.nlm.nih.gov/1317407 DMM2R1N DI DMM2R1N DMM2R1N DN all-trans-4-oxo-retinoic acid DMM2R1N TI TTGB2LZ DMM2R1N TN RAR-related orphan receptor-beta (RORB) DMM2R1N MA Antagonist DMM2R1N RN All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta. Nat Struct Biol. 2003 Oct;10(10):820-5. DMM2R1N RU https://pubmed.ncbi.nlm.nih.gov/12958591 DMM2R1N DI DMM2R1N DMM2R1N DN all-trans-4-oxo-retinoic acid DMM2R1N TI TT2NUT5 DMM2R1N TN Adrenergic receptor alpha-2C (ADRA2C) DMM2R1N MA Antagonist DMM2R1N RN Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. DMM2R1N RU https://pubmed.ncbi.nlm.nih.gov/15771415 DMM2TFX DI DMM2TFX DMM2TFX DN 6-(Naphthalen-2-ylamino)-1H-pyrimidine-2,4-dione DMM2TFX TI TT2GPK3 DMM2TFX TN DNA topoisomerase (TOP) DMM2TFX MA Inhibitor DMM2TFX RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMM2TFX RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMM2WG7 DI DMM2WG7 DMM2WG7 DN MR-16089 DMM2WG7 TI TTSZLWK DMM2WG7 TN Aromatase (CYP19A1) DMM2WG7 MA Inhibitor DMM2WG7 RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMM2WG7 RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMM2WPH DI DMM2WPH DMM2WPH DN BW-858C DMM2WPH TI TT2J34L DMM2WPH TN Arachidonate 5-lipoxygenase (5-LOX) DMM2WPH MA Modulator DMM2WPH RN Effect of BW B70C, a novel inhibitor of arachidonic acid 5-lipoxygenase, on allergen-induced bronchoconstriction and late-phase lung eosinophil accumulation in sensitised guinea-pigs. Agents Actions.1993 Jan;38(1-2):8-18. DMM2WPH RU https://pubmed.ncbi.nlm.nih.gov/8480540 DMM2YU9 DI DMM2YU9 DMM2YU9 DN [18F]FP-TZTP DMM2YU9 TI TTOXS3C DMM2YU9 TN Muscarinic acetylcholine receptor (CHRM) DMM2YU9 MA Agonist DMM2YU9 RN Regional brain uptake of the muscarinic ligand, [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology. 2003 Apr;44(5):653-61. DMM2YU9 RU https://pubmed.ncbi.nlm.nih.gov/12668051 DMM32CF DI DMM32CF DMM32CF DN SK-683 DMM32CF TI TT6R7JZ DMM32CF TN Histone deacetylase 1 (HDAC1) DMM32CF MA Inhibitor DMM32CF RN On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors. J Med Chem. 2004 Jun 17;47(13):3409-17. DMM32CF RU https://pubmed.ncbi.nlm.nih.gov/15189037 DMM3465 DI DMM3465 DMM3465 DN Recombinant human butyrylcholinesterase DMM3465 TI TTEB0GD DMM3465 TN Cholinesterase (BCHE) DMM3465 MA Modulator DMM3465 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471). DMM3465 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471 DMM36DE DI DMM36DE DMM36DE DN 1-(3-(4-chlorobenzyl)quinoxalin-2-yl)hydrazine DMM36DE TI TT3WG5C DMM36DE TN Monoamine oxidase type A (MAO-A) DMM36DE MA Inhibitor DMM36DE RN Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6. DMM36DE RU https://pubmed.ncbi.nlm.nih.gov/16356714 DMM3798 DI DMM3798 DMM3798 DN 6-(2-Hydroxy-phenyl)-naphthalen-2-ol DMM3798 TI TTOM3J0 DMM3798 TN Estrogen receptor beta (ESR2) DMM3798 MA Inhibitor DMM3798 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMM3798 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMM37C0 DI DMM37C0 DMM37C0 DN Resorcinol DMM37C0 TI TTSYM0R DMM37C0 TN Carbonic anhydrase XII (CA-XII) DMM37C0 MA Inhibitor DMM37C0 RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMM37C0 RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMM37C0 DI DMM37C0 DMM37C0 DN Resorcinol DMM37C0 TI TTANPDJ DMM37C0 TN Carbonic anhydrase II (CA-II) DMM37C0 MA Inhibitor DMM37C0 RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMM37C0 RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMM37C0 DI DMM37C0 DMM37C0 DN Resorcinol DMM37C0 TI TTEYTKG DMM37C0 TN Carbonic anhydrase XIV (CA-XIV) DMM37C0 MA Inhibitor DMM37C0 RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMM37C0 RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMM37C0 DI DMM37C0 DMM37C0 DN Resorcinol DMM37C0 TI TTUNARX DMM37C0 TN Carbonic anhydrase (CA) DMM37C0 MA Inhibitor DMM37C0 RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMM37C0 RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMM37C0 DI DMM37C0 DMM37C0 DN Resorcinol DMM37C0 TI TT8NGED DMM37C0 TN Prostaglandin G/H synthase 1 (COX-1) DMM37C0 MA Inhibitor DMM37C0 RN Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82. DMM37C0 RU https://pubmed.ncbi.nlm.nih.gov/15568761 DMM38BC DI DMM38BC DMM38BC DN N,N'-Bis-(4-isopropyl-phenyl)-guanidine DMM38BC TI TTKJEMQ DMM38BC TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMM38BC MA Inhibitor DMM38BC RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMM38BC RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMM38BC DI DMM38BC DMM38BC DN N,N'-Bis-(4-isopropyl-phenyl)-guanidine DMM38BC TI TTN9D8E DMM38BC TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMM38BC MA Inhibitor DMM38BC RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMM38BC RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMM38BC DI DMM38BC DMM38BC DN N,N'-Bis-(4-isopropyl-phenyl)-guanidine DMM38BC TI TTLD29N DMM38BC TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMM38BC MA Inhibitor DMM38BC RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMM38BC RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMM39YW DI DMM39YW DMM39YW DN H-Dmt-Tic-Gly-NH-Bzl DMM39YW TI TTKWM86 DMM39YW TN Opioid receptor mu (MOP) DMM39YW MA Inhibitor DMM39YW RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMM39YW RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMM39YW DI DMM39YW DMM39YW DN H-Dmt-Tic-Gly-NH-Bzl DMM39YW TI TT27RFC DMM39YW TN Opioid receptor delta (OPRD1) DMM39YW MA Inhibitor DMM39YW RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMM39YW RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMM3B21 DI DMM3B21 DMM3B21 DN N-Methyl,N-phenyl-1H-indole-2-carboxamide DMM3B21 TI TT3WG5C DMM3B21 TN Monoamine oxidase type A (MAO-A) DMM3B21 MA Inhibitor DMM3B21 RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMM3B21 RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMM3B21 DI DMM3B21 DMM3B21 DN N-Methyl,N-phenyl-1H-indole-2-carboxamide DMM3B21 TI TTGP7BY DMM3B21 TN Monoamine oxidase type B (MAO-B) DMM3B21 MA Inhibitor DMM3B21 RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMM3B21 RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMM3F9K DI DMM3F9K DMM3F9K DN 4-(3,5-dichlorobenzylthio)-2-aminobutanoic acid DMM3F9K TI TTFK1JQ DMM3F9K TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMM3F9K MA Inhibitor DMM3F9K RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMM3F9K RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMM3FD2 DI DMM3FD2 DMM3FD2 DN HS014 DMM3FD2 TI TTD0CIQ DMM3FD2 TN Melanocortin receptor 4 (MC4R) DMM3FD2 MA Antagonist DMM3FD2 RN Long-term administration of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport. 1999 Mar 17;10(4):707-11. DMM3FD2 RU https://pubmed.ncbi.nlm.nih.gov/10208535 DMM3I1P DI DMM3I1P DMM3I1P DN 1,2-bis(3-fluorophenyl)ethane-1,2-dione DMM3I1P TI TTMF541 DMM3I1P TN Liver carboxylesterase (CES1) DMM3I1P MA Inhibitor DMM3I1P RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMM3I1P RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMM3LET DI DMM3LET DMM3LET DN 1-(2-Dimethylamino-ethyl)-1H-indol-4-ol DMM3LET TI TTWJBZ5 DMM3LET TN 5-HT 2C receptor (HTR2C) DMM3LET MA Inhibitor DMM3LET RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMM3LET RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMM3QPL DI DMM3QPL DMM3QPL DN 4-Hydroxy-3-(2-naphthylmethyl)-2H-chromen-2-one DMM3QPL TI TT8XK6L DMM3QPL TN Quinone reductase 1 (NQO1) DMM3QPL MA Inhibitor DMM3QPL RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DMM3QPL RU https://pubmed.ncbi.nlm.nih.gov/19877692 DMM3RNV DI DMM3RNV DMM3RNV DN 3-methyl-5-(2-methylquinolin-7-yl)benzonitrile DMM3RNV TI TTHS256 DMM3RNV TN Metabotropic glutamate receptor 5 (mGluR5) DMM3RNV MA Inhibitor DMM3RNV RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMM3RNV RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMM41AQ DI DMM41AQ DMM41AQ DN 6-Chloro-2-piperazin-1-yl-quinoline DMM41AQ TI TT3ROYC DMM41AQ TN Serotonin transporter (SERT) DMM41AQ MA Inhibitor DMM41AQ RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DMM41AQ RU https://pubmed.ncbi.nlm.nih.gov/10915050 DMM41O9 DI DMM41O9 DMM41O9 DN TP-680 DMM41O9 TI TTVFO0U DMM41O9 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMM41O9 MA Antagonist DMM41O9 RN Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol. 1996 Apr;117(7):1558-64. DMM41O9 RU https://pubmed.ncbi.nlm.nih.gov/8730754 DMM41O9 DI DMM41O9 DMM41O9 DN TP-680 DMM41O9 TI TTCG0AL DMM41O9 TN Cholecystokinin receptor type A (CCKAR) DMM41O9 MA Antagonist DMM41O9 RN Pharmacological profile of TP-680, a new cholecystokininA receptor antagonist. Br J Pharmacol. 1996 Apr;117(7):1558-64. DMM41O9 RU https://pubmed.ncbi.nlm.nih.gov/8730754 DMM48L6 DI DMM48L6 DMM48L6 DN 2-Benzylbenzo[f]chromen-3-one DMM48L6 TI TT6OEDT DMM48L6 TN Cannabinoid receptor 1 (CB1) DMM48L6 MA Inhibitor DMM48L6 RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMM48L6 RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMM49JO DI DMM49JO DMM49JO DN PMID20121197C57 DMM49JO TI TTFEZ5Q DMM49JO TN Coagulation factor IX (F9) DMM49JO MA Inhibitor DMM49JO RN Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors. J Med Chem. 2010 Feb 25;53(4):1473-82. DMM49JO RU https://pubmed.ncbi.nlm.nih.gov/20121197 DMM4A7P DI DMM4A7P DMM4A7P DN PMID16242323C15a DMM4A7P TI TTK3C21 DMM4A7P TN Acetoacetyl-CoA thiolase (ACAT1) DMM4A7P MA Inhibitor DMM4A7P RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMM4A7P RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMM4CE7 DI DMM4CE7 DMM4CE7 DN Ovalicin DMM4CE7 TI TTZL0OI DMM4CE7 TN Methionine aminopeptidase 2 (METAP2) DMM4CE7 MA Inhibitor DMM4CE7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM4CE7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM4CU9 DI DMM4CU9 DMM4CU9 DN Pyrrolo[3,4-e]indole-1,3(2H,6H)-dione DMM4CU9 TI TTVDSZ0 DMM4CU9 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMM4CU9 MA Inhibitor DMM4CU9 RN Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42. DMM4CU9 RU https://pubmed.ncbi.nlm.nih.gov/16290935 DMM4HF8 DI DMM4HF8 DMM4HF8 DN 3'-(5-Chloro-2-thienyl)biphenyl-3-ol DMM4HF8 TI TTIWB6L DMM4HF8 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMM4HF8 MA Inhibitor DMM4HF8 RN Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505. DMM4HF8 RU https://pubmed.ncbi.nlm.nih.gov/20413314 DMM4HXK DI DMM4HXK DMM4HXK DN 2-methylsulfanylestradiol 3,17-O,O-bis-sulfamate DMM4HXK TI TTHM0R1 DMM4HXK TN Steryl-sulfatase (STS) DMM4HXK MA Inhibitor DMM4HXK RN 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96. DMM4HXK RU https://pubmed.ncbi.nlm.nih.gov/17181151 DMM4JCA DI DMM4JCA DMM4JCA DN HG-1051 DMM4JCA TI TTPW9LJ DMM4JCA TN Co-stimulatory molecule 4-1BB (CD137) DMM4JCA MA Modulator DMM4JCA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1878). DMM4JCA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878 DMM4QFL DI DMM4QFL DMM4QFL DN Diethylphosphono Group DMM4QFL TI TTEB0GD DMM4QFL TN Cholinesterase (BCHE) DMM4QFL MA Inhibitor DMM4QFL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM4QFL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM4S1R DI DMM4S1R DMM4S1R DN 2-(4-hydroxylphenyl)-3-(3,5-dihydroxylphenyl) propenoic acid (NNU-hdpa) DMM4S1R TI TT2J34L DMM4S1R TN Arachidonate 5-lipoxygenase (5-LOX) DMM4S1R MA Inhibitor DMM4S1R RN Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor. Eur J Pharmacol. 2009 Jun 2;611(1-3):100-6. DMM4S1R RU https://pubmed.ncbi.nlm.nih.gov/19345206 DMM4T1Q DI DMM4T1Q DMM4T1Q DN 2,7-Bis[2-(isobutylamino)acetamido]anthraquinone DMM4T1Q TI TTQY2EJ DMM4T1Q TN TERT messenger RNA (TERT mRNA) DMM4T1Q MA Inhibitor DMM4T1Q RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMM4T1Q RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMM4VWD DI DMM4VWD DMM4VWD DN P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate DMM4VWD TI TT5B8AX DMM4VWD TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMM4VWD MA Inhibitor DMM4VWD RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMM4VWD RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMM4VWD DI DMM4VWD DMM4VWD DN P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate DMM4VWD TI TTP3QRF DMM4VWD TN Thymidine kinase 1 (TK1) DMM4VWD MA Inhibitor DMM4VWD RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMM4VWD RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMM4XVL DI DMM4XVL DMM4XVL DN Iodoacetamide DMM4XVL TI TT9INHD DMM4XVL TN Creatine kinase (CK) DMM4XVL MA Inhibitor DMM4XVL RN Creatine kinase inhibitor iodoacetamide antagonizes calcium-stimulated inotropy in cardiomyocytes. Clin Exp Pharmacol Physiol. 2009 Feb;36(2):141-5. DMM4XVL RU https://pubmed.ncbi.nlm.nih.gov/18761665 DMM4ZKU DI DMM4ZKU DMM4ZKU DN ZAPOTIN DMM4ZKU TI TTUMGNO DMM4ZKU TN Ornithine decarboxylase (ODC1) DMM4ZKU MA Inhibitor DMM4ZKU RN Synthesis and cancer chemopreventive activity of zapotin, a natural product from Casimiroa edulis. J Med Chem. 2007 Jan 25;50(2):350-5. DMM4ZKU RU https://pubmed.ncbi.nlm.nih.gov/17228877 DMM50ED DI DMM50ED DMM50ED DN IC87114 DMM50ED TI TTGBPJE DMM50ED TN PI3-kinase delta (PIK3CD) DMM50ED MA Inhibitor DMM50ED RN Selective role of PI3K delta in neutrophil inflammatory responses. Biochem Biophys Res Commun. 2003 Sep 5;308(4):764-9. DMM50ED RU https://pubmed.ncbi.nlm.nih.gov/12927784 DMM5208 DI DMM5208 DMM5208 DN Oxindole 16 (compound 3) DMM5208 TI TTBJR4L DMM5208 TN Cyclin-dependent kinase 8 (CDK8) DMM5208 MA Inhibitor DMM5208 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMM5208 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMM5208 DI DMM5208 DMM5208 DN Oxindole 16 (compound 3) DMM5208 TI TTL4Q97 DMM5208 TN Cyclin-dependent kinase 5 (CDK5) DMM5208 MA Inhibitor DMM5208 RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMM5208 RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMM52D3 DI DMM52D3 DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate DMM52D3 TI TTTQGH8 DMM52D3 TN Histone deacetylase 4 (HDAC4) DMM52D3 MA Inhibitor DMM52D3 RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DMM52D3 RU https://pubmed.ncbi.nlm.nih.gov/18294844 DMM52D3 DI DMM52D3 DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate DMM52D3 TI TT5ZKDI DMM52D3 TN Histone deacetylase 6 (HDAC6) DMM52D3 MA Inhibitor DMM52D3 RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DMM52D3 RU https://pubmed.ncbi.nlm.nih.gov/18294844 DMM52D3 DI DMM52D3 DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate DMM52D3 TI TT6R7JZ DMM52D3 TN Histone deacetylase 1 (HDAC1) DMM52D3 MA Inhibitor DMM52D3 RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DMM52D3 RU https://pubmed.ncbi.nlm.nih.gov/18294844 DMM52D3 DI DMM52D3 DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate DMM52D3 TI TTBH0VX DMM52D3 TN Histone deacetylase (HDAC) DMM52D3 MA Inhibitor DMM52D3 RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DMM52D3 RU https://pubmed.ncbi.nlm.nih.gov/18294844 DMM52D3 DI DMM52D3 DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate DMM52D3 TI TTT6LFV DMM52D3 TN Histone deacetylase 8 (HDAC8) DMM52D3 MA Inhibitor DMM52D3 RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DMM52D3 RU https://pubmed.ncbi.nlm.nih.gov/18294844 DMM52D3 DI DMM52D3 DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate DMM52D3 TI TTSHTOI DMM52D3 TN Histone deacetylase 2 (HDAC2) DMM52D3 MA Inhibitor DMM52D3 RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DMM52D3 RU https://pubmed.ncbi.nlm.nih.gov/18294844 DMM52D3 DI DMM52D3 DMM52D3 DN 2-(methylsulfonylthio)ethyl 2-propylpentanoate DMM52D3 TI TTYHPU6 DMM52D3 TN Histone deacetylase 10 (HDAC10) DMM52D3 MA Inhibitor DMM52D3 RN New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. DMM52D3 RU https://pubmed.ncbi.nlm.nih.gov/18294844 DMM52FD DI DMM52FD DMM52FD DN AEZS-126 DMM52FD TI TTHBTOP DMM52FD TN PI3-kinase gamma (PIK3CG) DMM52FD MA Inhibitor DMM52FD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMM52FD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMM52LC DI DMM52LC DMM52LC DN 3-(imidazolylmethyl)-4'-methoxyflavone DMM52LC TI TTSZLWK DMM52LC TN Aromatase (CYP19A1) DMM52LC MA Inhibitor DMM52LC RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DMM52LC RU https://pubmed.ncbi.nlm.nih.gov/16854084 DMM59IS DI DMM59IS DMM59IS DN N1,2-dibenzyl-N3-hydroxymalonamide DMM59IS TI TTPHMWB DMM59IS TN Aminopeptidase N (ANPEP) DMM59IS MA Inhibitor DMM59IS RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMM59IS RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMM5AYL DI DMM5AYL DMM5AYL DN L-736380 DMM5AYL TI TTCG0AL DMM5AYL TN Cholecystokinin receptor type A (CCKAR) DMM5AYL MA Antagonist DMM5AYL RN Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas. J Med Chem. 1996 Feb 16;39(4):842-9. DMM5AYL RU https://pubmed.ncbi.nlm.nih.gov/8632408 DMM5DTF DI DMM5DTF DMM5DTF DN 1-benzhydryl-4-tert-butylpiperidin-4-ol DMM5DTF TI TTQW87Y DMM5DTF TN Opioid receptor kappa (OPRK1) DMM5DTF MA Inhibitor DMM5DTF RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMM5DTF RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMM5DTF DI DMM5DTF DMM5DTF DN 1-benzhydryl-4-tert-butylpiperidin-4-ol DMM5DTF TI TTKWM86 DMM5DTF TN Opioid receptor mu (MOP) DMM5DTF MA Inhibitor DMM5DTF RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMM5DTF RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMM5DTF DI DMM5DTF DMM5DTF DN 1-benzhydryl-4-tert-butylpiperidin-4-ol DMM5DTF TI TTNT7K8 DMM5DTF TN Nociceptin receptor (OPRL1) DMM5DTF MA Inhibitor DMM5DTF RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMM5DTF RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMM5O2V DI DMM5O2V DMM5O2V DN Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2 DMM5O2V TI TTF2LRI DMM5O2V TN Cathepsin B (CTSB) DMM5O2V MA Inhibitor DMM5O2V RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMM5O2V RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMM5O2V DI DMM5O2V DMM5O2V DN Z-Arg-Leu-Val-Agly-Trp-Val-Ala-NH2 DMM5O2V TI TTDZN01 DMM5O2V TN Cathepsin K (CTSK) DMM5O2V MA Inhibitor DMM5O2V RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMM5O2V RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMM5O30 DI DMM5O30 DMM5O30 DN RXP-407 DMM5O30 TI TTL69WB DMM5O30 TN Angiotensin-converting enzyme (ACE) DMM5O30 MA Inhibitor DMM5O30 RN New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme. Biol Chem. 2012 May;393(6):485-93. DMM5O30 RU https://pubmed.ncbi.nlm.nih.gov/22628311 DMM5P8Q DI DMM5P8Q DMM5P8Q DN ML-10302 DMM5P8Q TI TT07C3Y DMM5P8Q TN 5-HT 4 receptor (HTR4) DMM5P8Q MA Modulator DMM5P8Q RN Intestinal motor stimulation by the 5-HT4 receptor agonist ML10302: differential involvement of tachykininergic pathways in the canine small bowel ... Neurogastroenterol Motil. 2001 Dec;13(6):543-53. DMM5P8Q RU https://www.ncbi.nlm.nih.gov/pubmed/11903915 DMM5PEV DI DMM5PEV DMM5PEV DN ANONAINE DMM5PEV TI TTEX248 DMM5PEV TN Dopamine D2 receptor (D2R) DMM5PEV MA Inhibitor DMM5PEV RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMM5PEV RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMM5PEV DI DMM5PEV DMM5PEV DN ANONAINE DMM5PEV TI TTVBI8W DMM5PEV TN Dopamine transporter (DAT) DMM5PEV MA Inhibitor DMM5PEV RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DMM5PEV RU https://pubmed.ncbi.nlm.nih.gov/8676127 DMM5PVL DI DMM5PVL DMM5PVL DN syn-BrP-LPA DMM5PVL TI TTQ6S1K DMM5PVL TN Lysophosphatidic acid receptor 1 (LPAR1) DMM5PVL MA Antagonist DMM5PVL RN Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9. DMM5PVL RU https://pubmed.ncbi.nlm.nih.gov/19509223 DMM5QXL DI DMM5QXL DMM5QXL DN Malonic acid DMM5QXL TI TTZFUY6 DMM5QXL TN Serine Racemase (SRR) DMM5QXL MA Inhibitor DMM5QXL RN Inhibition of human serine racemase, an emerging target for medicinal chemistry. Curr Drug Targets. 2011 Jun;12(7):1037-55. DMM5QXL RU https://pubmed.ncbi.nlm.nih.gov/21291385 DMM5SDT DI DMM5SDT DMM5SDT DN KNI-10074 DMM5SDT TI TTXMNHO DMM5SDT TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMM5SDT MA Inhibitor DMM5SDT RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMM5SDT RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMM5SI1 DI DMM5SI1 DMM5SI1 DN DAU-6202 DMM5SI1 TI TTZ9SOR DMM5SI1 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMM5SI1 MA Modulator DMM5SI1 RN Characterization of muscarinic receptors in guinea-pig uterus. Eur J Pharmacol. 1993 Dec 7;250(2):223-30. DMM5SI1 RU https://www.ncbi.nlm.nih.gov/pubmed/8112383 DMM5SI4 DI DMM5SI4 DMM5SI4 DN PMID26155854C60 DMM5SI4 TI TT9A0HI DMM5SI4 TN ATPase family AAA domain containing 2 (ATAD2) DMM5SI4 MA Inhibitor DMM5SI4 RN Fragment-Based Discovery of Low-Micromolar ATAD2 Bromodomain Inhibitors. J Med Chem. 2015 Jul 23;58(14):5649-73. DMM5SI4 RU https://pubmed.ncbi.nlm.nih.gov/26155854 DMM5UT9 DI DMM5UT9 DMM5UT9 DN NSC-622444 DMM5UT9 TI TT6VZ78 DMM5UT9 TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMM5UT9 MA Inhibitor DMM5UT9 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMM5UT9 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMM5UT9 DI DMM5UT9 DMM5UT9 DN NSC-622444 DMM5UT9 TI TTHVCUP DMM5UT9 TN DNA [cytosine-5]-methyltransferase (DNMT) DMM5UT9 MA Inhibitor DMM5UT9 RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMM5UT9 RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMM5X8Z DI DMM5X8Z DMM5X8Z DN M55113 DMM5X8Z TI TTCIHJA DMM5X8Z TN Coagulation factor Xa (F10) DMM5X8Z MA Inhibitor DMM5X8Z RN Synthesis and evaluation of 1-arylsulfonyl-3-piperazinone derivatives as factor Xa inhibitor. Chem Pharm Bull (Tokyo). 2001 Oct;49(10):1237-44. DMM5X8Z RU https://pubmed.ncbi.nlm.nih.gov/11605647 DMM5XD6 DI DMM5XD6 DMM5XD6 DN A-425444 DMM5XD6 TI TTE0A2F DMM5XD6 TN Dopamine D4 receptor (D4R) DMM5XD6 MA Inhibitor DMM5XD6 RN Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 ago... J Med Chem. 2006 Dec 14;49(25):7450-65. DMM5XD6 RU https://pubmed.ncbi.nlm.nih.gov/17149874 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TT0MI3F DMM61Y2 TN 5-HT 1F receptor (HTR1F) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TTCPG9S DMM61Y2 TN 5-HT 1E receptor (HTR1E) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TTWJBZ5 DMM61Y2 TN 5-HT 2C receptor (HTR2C) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TTK8CXU DMM61Y2 TN 5-HT 1B receptor (HTR1B) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TT0K1SC DMM61Y2 TN 5-HT 2B receptor (HTR2B) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TTJS8PY DMM61Y2 TN 5-HT 6 receptor (HTR6) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TTJQOD7 DMM61Y2 TN 5-HT 2A receptor (HTR2A) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TTSQIFT DMM61Y2 TN 5-HT 1A receptor (HTR1A) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM61Y2 DI DMM61Y2 DMM61Y2 DN BRL-15572 DMM61Y2 TI TT6MSOK DMM61Y2 TN 5-HT 1D receptor (HTR1D) DMM61Y2 MA Agonist DMM61Y2 RN SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20. DMM61Y2 RU https://pubmed.ncbi.nlm.nih.gov/9303567 DMM632N DI DMM632N DMM632N DN 3,6,8-Tribromo-dibenzo[1,4]dioxin-1-ol DMM632N TI TTN9T81 DMM632N TN Arachidonate 15-lipoxygenase (15-LOX) DMM632N MA Inhibitor DMM632N RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMM632N RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMM635K DI DMM635K DMM635K DN 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one DMM635K TI TT1MPAY DMM635K TN GABA(A) receptor alpha-1 (GABRA1) DMM635K MA Inhibitor DMM635K RN 6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995). DMM635K RU http://www.sciencedirect.com/science/article/pii/0960894X95004645 DMM635K DI DMM635K DMM635K DN 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one DMM635K TI TT06RH5 DMM635K TN GABA(A) receptor gamma-2 (GABRG2) DMM635K MA Inhibitor DMM635K RN 6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995). DMM635K RU http://www.sciencedirect.com/science/article/pii/0960894X95004645 DMM635K DI DMM635K DMM635K DN 6-Nitro-2-(4-nitro-phenyl)-chromen-4-one DMM635K TI TTNJYV2 DMM635K TN Gamma-aminobutyric acid receptor (GAR) DMM635K MA Inhibitor DMM635K RN 6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995). DMM635K RU http://www.sciencedirect.com/science/article/pii/0960894X95004645 DMM678B DI DMM678B DMM678B DN N,N-bis(tosylmethyl)hexan-1-amine DMM678B TI TTX4RTB DMM678B TN Melanin-concentrating hormone receptor 1 (MCHR1) DMM678B MA Inhibitor DMM678B RN Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem. 2008 Feb 14;51(3):581-8. DMM678B RU https://pubmed.ncbi.nlm.nih.gov/18198821 DMM6A7P DI DMM6A7P DMM6A7P DN cannabinol DMM6A7P TI TTBECWA DMM6A7P TN Transient receptor potential cation channel V2 (TRPV2) DMM6A7P MA Activator DMM6A7P RN TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008 Jun 11;28(24):6231-8. DMM6A7P RU https://pubmed.ncbi.nlm.nih.gov/18550765 DMM6A7P DI DMM6A7P DMM6A7P DN cannabinol DMM6A7P TI TT6OEDT DMM6A7P TN Cannabinoid receptor 1 (CB1) DMM6A7P MA Agonist DMM6A7P RN Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther. 1996 Sep;278(3):989-99. DMM6A7P RU https://pubmed.ncbi.nlm.nih.gov/8819477 DMM6CJI DI DMM6CJI DMM6CJI DN 11-keto-beta-boswellicacid DMM6CJI TI TTN7BL9 DMM6CJI TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMM6CJI MA Inhibitor DMM6CJI RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DMM6CJI RU https://pubmed.ncbi.nlm.nih.gov/20100662 DMM6CJI DI DMM6CJI DMM6CJI DN 11-keto-beta-boswellicacid DMM6CJI TI TT9H85R DMM6CJI TN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DMM6CJI MA Inhibitor DMM6CJI RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DMM6CJI RU https://pubmed.ncbi.nlm.nih.gov/20100662 DMM6G4H DI DMM6G4H DMM6G4H DN KYS-05042 DMM6G4H TI TT729IR DMM6G4H TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMM6G4H MA Inhibitor DMM6G4H RN T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. DMM6G4H RU https://pubmed.ncbi.nlm.nih.gov/18585035 DMM6G4H DI DMM6G4H DMM6G4H DN KYS-05042 DMM6G4H TI TTZPWGN DMM6G4H TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMM6G4H MA Inhibitor DMM6G4H RN 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84. DMM6G4H RU https://pubmed.ncbi.nlm.nih.gov/15177437 DMM6KBD DI DMM6KBD DMM6KBD DN 2,2',4,4'-tetrahydroxychalcone DMM6KBD TI TTULVH8 DMM6KBD TN Tyrosinase (TYR) DMM6KBD MA Inhibitor DMM6KBD RN Synthesis and evaluation of 2',4',6'-trihydroxychalcones as a new class of tyrosinase inhibitors. Bioorg Med Chem. 2007 Mar 15;15(6):2396-402. DMM6KBD RU https://pubmed.ncbi.nlm.nih.gov/17267225 DMM6QV5 DI DMM6QV5 DMM6QV5 DN (4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine DMM6QV5 TI TTZUFI5 DMM6QV5 TN Nitric-oxide synthase brain (NOS1) DMM6QV5 MA Inhibitor DMM6QV5 RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMM6QV5 RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMM6QV5 DI DMM6QV5 DMM6QV5 DN (4S,5R)-4,5-Diethyl-oxazolidin-(2Z)-ylideneamine DMM6QV5 TI TTF10I9 DMM6QV5 TN Nitric-oxide synthase inducible (NOS2) DMM6QV5 MA Inhibitor DMM6QV5 RN 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. DMM6QV5 RU https://pubmed.ncbi.nlm.nih.gov/14698148 DMM6UPD DI DMM6UPD DMM6UPD DN 4-Benzenesulfonylamino-N-hydroxy-benzamide DMM6UPD TI TT6R7JZ DMM6UPD TN Histone deacetylase 1 (HDAC1) DMM6UPD MA Inhibitor DMM6UPD RN Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg Med Chem Lett. 2001 Nov 5;11(21):2847-50. DMM6UPD RU https://pubmed.ncbi.nlm.nih.gov/11597413 DMM70K1 DI DMM70K1 DMM70K1 DN Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester DMM70K1 TI TTHM0R1 DMM70K1 TN Steryl-sulfatase (STS) DMM70K1 MA Inhibitor DMM70K1 RN Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J Med Chem. 2003 Nov 6;46(23):5091-4. DMM70K1 RU https://pubmed.ncbi.nlm.nih.gov/14584960 DMM731A DI DMM731A DMM731A DN N-Me-aminopyrimidinone 9 DMM731A TI TT4G2JS DMM731A TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMM731A MA Inhibitor (gating inhibitor) DMM731A RN Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists. Bioorg Med Chem Lett. 2012 Jan 15;22(2):1055-60. DMM731A RU https://pubmed.ncbi.nlm.nih.gov/22209205 DMM7BQP DI DMM7BQP DMM7BQP DN 3-(4-ethyl-3,4-dihydronaphthalen-2-yl)pyridine DMM7BQP TI TTIQUX7 DMM7BQP TN Steroid 11-beta-hydroxylase (CYP11B1) DMM7BQP MA Inhibitor DMM7BQP RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMM7BQP RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMM7DHB DI DMM7DHB DMM7DHB DN 3-bromo-7-nitro-1H-indazole DMM7DHB TI TTCM4B3 DMM7DHB TN Nitric-oxide synthase endothelial (NOS3) DMM7DHB MA Inhibitor DMM7DHB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM7DHB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM7DHB DI DMM7DHB DMM7DHB DN 3-bromo-7-nitro-1H-indazole DMM7DHB TI TTZUFI5 DMM7DHB TN Nitric-oxide synthase brain (NOS1) DMM7DHB MA Inhibitor DMM7DHB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM7DHB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM7DHB DI DMM7DHB DMM7DHB DN 3-bromo-7-nitro-1H-indazole DMM7DHB TI TTF10I9 DMM7DHB TN Nitric-oxide synthase inducible (NOS2) DMM7DHB MA Inhibitor DMM7DHB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM7DHB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM7IAK DI DMM7IAK DMM7IAK DN 6,7-Dimethoxy-3-p-tolyl-quinoline DMM7IAK TI TT8FYO9 DMM7IAK TN Platelet-derived growth factor receptor alpha (PDGFRA) DMM7IAK MA Inhibitor DMM7IAK RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMM7IAK RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMM7IAK DI DMM7IAK DMM7IAK DN 6,7-Dimethoxy-3-p-tolyl-quinoline DMM7IAK TI TTI7421 DMM7IAK TN Platelet-derived growth factor receptor beta (PDGFRB) DMM7IAK MA Inhibitor DMM7IAK RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMM7IAK RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMM7IJZ DI DMM7IJZ DMM7IJZ DN 1-(4-tert-butylphenylsulfonyl)-4-methoxyazepane DMM7IJZ TI TTN7BL9 DMM7IJZ TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMM7IJZ MA Inhibitor DMM7IJZ RN The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5. DMM7IJZ RU https://pubmed.ncbi.nlm.nih.gov/19625185 DMM7N6K DI DMM7N6K DMM7N6K DN 5,10-Dioxy-2-phenyl-benzo[g]pteridin-4-ylamine DMM7N6K TI TTJGNVC DMM7N6K TN Apoptosis regulator Bcl-2 (BCL-2) DMM7N6K MA Inhibitor DMM7N6K RN Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001 Dec 6;44(25):4313-24. DMM7N6K RU https://pubmed.ncbi.nlm.nih.gov/11728179 DMM7NHI DI DMM7NHI DMM7NHI DN 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline DMM7NHI TI TT8FYO9 DMM7NHI TN Platelet-derived growth factor receptor alpha (PDGFRA) DMM7NHI MA Inhibitor DMM7NHI RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMM7NHI RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMM7NHI DI DMM7NHI DMM7NHI DN 6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline DMM7NHI TI TTI7421 DMM7NHI TN Platelet-derived growth factor receptor beta (PDGFRB) DMM7NHI MA Inhibitor DMM7NHI RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMM7NHI RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMM7RAD DI DMM7RAD DMM7RAD DN CV-3988 DMM7RAD TI TTQL5VC DMM7RAD TN Platelet-activating factor receptor (PTAFR) DMM7RAD MA Antagonist DMM7RAD RN Inhibition by CV-3988 of the binding of [3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol. 1985 May 1;34(9):1491-5. DMM7RAD RU https://pubmed.ncbi.nlm.nih.gov/2986648 DMM7T13 DI DMM7T13 DMM7T13 DN N-[2-(1h-Indol-5-Yl)-Butyl]-4-Sulfamoyl-Benzamide DMM7T13 TI TTANPDJ DMM7T13 TN Carbonic anhydrase II (CA-II) DMM7T13 MA Inhibitor DMM7T13 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM7T13 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM86PK DI DMM86PK DMM86PK DN 6-guanidino-2-(3''-indolylethyloxy)adenosine DMM86PK TI TTJFY5U DMM86PK TN Adenosine A3 receptor (ADORA3) DMM86PK MA Inhibitor DMM86PK RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMM86PK RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMM86PK DI DMM86PK DMM86PK DN 6-guanidino-2-(3''-indolylethyloxy)adenosine DMM86PK TI TTM2AOE DMM86PK TN Adenosine A2a receptor (ADORA2A) DMM86PK MA Inhibitor DMM86PK RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMM86PK RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMM86PK DI DMM86PK DMM86PK DN 6-guanidino-2-(3''-indolylethyloxy)adenosine DMM86PK TI TTK25J1 DMM86PK TN Adenosine A1 receptor (ADORA1) DMM86PK MA Inhibitor DMM86PK RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMM86PK RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMM86YK DI DMM86YK DMM86YK DN 4-(4-nitro-benzylideneamino)-benzenesulfonamide DMM86YK TI TTVKILB DMM86YK TN Prostaglandin G/H synthase 2 (COX-2) DMM86YK MA Inhibitor DMM86YK RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMM86YK RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMM8AY5 DI DMM8AY5 DMM8AY5 DN 4-(3H-indol-4-ylamino)-5-styrylnicotinonitrile DMM8AY5 TI TT1MS7X DMM8AY5 TN PKC-theta messenger RNA (PRKCQ mRNA) DMM8AY5 MA Inhibitor DMM8AY5 RN First generation 5-vinyl-3-pyridinecarbonitrile PKCtheta inhibitors. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5829-32. DMM8AY5 RU https://pubmed.ncbi.nlm.nih.gov/19762237 DMM8BIE DI DMM8BIE DMM8BIE DN Dmt-Pro-Phe-Phe-NH2 DMM8BIE TI TTKWM86 DMM8BIE TN Opioid receptor mu (MOP) DMM8BIE MA Inhibitor DMM8BIE RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMM8BIE RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMM8BIE DI DMM8BIE DMM8BIE DN Dmt-Pro-Phe-Phe-NH2 DMM8BIE TI TT27RFC DMM8BIE TN Opioid receptor delta (OPRD1) DMM8BIE MA Inhibitor DMM8BIE RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMM8BIE RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMM8BIE DI DMM8BIE DMM8BIE DN Dmt-Pro-Phe-Phe-NH2 DMM8BIE TI TTQW87Y DMM8BIE TN Opioid receptor kappa (OPRK1) DMM8BIE MA Inhibitor DMM8BIE RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMM8BIE RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMM8CU2 DI DMM8CU2 DMM8CU2 DN 4-(2-(4-Cyclohexylphenylamino)ethyl)-1H-imidazole DMM8CU2 TI TT9JNIC DMM8CU2 TN Histamine H3 receptor (H3R) DMM8CU2 MA Inhibitor DMM8CU2 RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMM8CU2 RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMM8FUT DI DMM8FUT DMM8FUT DN CPU-228 DMM8FUT TI TTZIFHC DMM8FUT TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMM8FUT MA Modulator DMM8FUT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 529). DMM8FUT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=529 DMM8FUT DI DMM8FUT DMM8FUT DN CPU-228 DMM8FUT TI TTX4QDJ DMM8FUT TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMM8FUT MA Modulator DMM8FUT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 532). DMM8FUT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=532 DMM8FUT DI DMM8FUT DMM8FUT DN CPU-228 DMM8FUT TI TT7RGTM DMM8FUT TN Voltage-gated calcium channel alpha Cav1.3 (CACNA1D) DMM8FUT MA Modulator DMM8FUT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 530). DMM8FUT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=530 DMM8FUT DI DMM8FUT DMM8FUT DN CPU-228 DMM8FUT TI TTYRP0M DMM8FUT TN Voltage-gated calcium channel alpha Cav2.3 (CACNA1E) DMM8FUT MA Modulator DMM8FUT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 534). DMM8FUT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=534 DMM8FUT DI DMM8FUT DMM8FUT DN CPU-228 DMM8FUT TI TT4FDG6 DMM8FUT TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMM8FUT MA Modulator DMM8FUT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 533). DMM8FUT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=533 DMM8G03 DI DMM8G03 DMM8G03 DN ISIS 188759 DMM8G03 TI TTLRVIA DMM8G03 TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DMM8G03 RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DMM8G03 RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DMM8G6H DI DMM8G6H DMM8G6H DN 4-Chloro-N-(3-morpholinopropyl)nicotinamide DMM8G6H TI TT3WG5C DMM8G6H TN Monoamine oxidase type A (MAO-A) DMM8G6H MA Inhibitor DMM8G6H RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMM8G6H RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMM8HK0 DI DMM8HK0 DMM8HK0 DN 4-Imidazol-1-ylmethylxanthen-9-one DMM8HK0 TI TTSZLWK DMM8HK0 TN Aromatase (CYP19A1) DMM8HK0 MA Inhibitor DMM8HK0 RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DMM8HK0 RU https://pubmed.ncbi.nlm.nih.gov/20568782 DMM8O1X DI DMM8O1X DMM8O1X DN 4-phenyl-1-(3-phenylpropyl)piperidin-4-ol DMM8O1X TI TTNT7K8 DMM8O1X TN Nociceptin receptor (OPRL1) DMM8O1X MA Inhibitor DMM8O1X RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMM8O1X RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMM8TE0 DI DMM8TE0 DMM8TE0 DN (R)-N-benzyl-4-(pyrrolidin-2-ylmethoxy)aniline DMM8TE0 TI TTXZEAJ DMM8TE0 TN Leukotriene A-4 hydrolase (LTA4H) DMM8TE0 MA Inhibitor DMM8TE0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMM8TE0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMM8V9E DI DMM8V9E DMM8V9E DN GW-2331 DMM8V9E TI TTZMAO3 DMM8V9E TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMM8V9E MA Modulator DMM8V9E RN PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71. DMM8V9E RU https://www.ncbi.nlm.nih.gov/pubmed/12746235 DMM8V9E DI DMM8V9E DMM8V9E DN GW-2331 DMM8V9E TI TTJ584C DMM8V9E TN Peroxisome proliferator-activated receptor alpha (PPARA) DMM8V9E MA Modulator DMM8V9E RN PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independe... Br J Pharmacol. 2003 May;139(1):163-71. DMM8V9E RU https://www.ncbi.nlm.nih.gov/pubmed/12746235 DMM91WE DI DMM91WE DMM91WE DN 11-valeryloxynoraporphine DMM91WE TI TTZFYLI DMM91WE TN Dopamine D1 receptor (D1R) DMM91WE MA Inhibitor DMM91WE RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMM91WE RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMM91WE DI DMM91WE DMM91WE DN 11-valeryloxynoraporphine DMM91WE TI TTJQOD7 DMM91WE TN 5-HT 2A receptor (HTR2A) DMM91WE MA Inhibitor DMM91WE RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMM91WE RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMM92IB DI DMM92IB DMM92IB DN PMID23631440C29e DMM92IB TI TT6X50U DMM92IB TN Matrix metalloproteinase-9 (MMP-9) DMM92IB MA Inhibitor DMM92IB RN Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73. DMM92IB RU https://pubmed.ncbi.nlm.nih.gov/23631440 DMM92IB DI DMM92IB DMM92IB DN PMID23631440C29e DMM92IB TI TTJ4QE7 DMM92IB TN Matrix metalloproteinase-14 (MMP-14) DMM92IB MA Inhibitor DMM92IB RN Matrix metalloproteinase inhibitors based on the 3-mercaptopyrrolidine core. J Med Chem. 2013 Jun 13;56(11):4357-73. DMM92IB RU https://pubmed.ncbi.nlm.nih.gov/23631440 DMM92LG DI DMM92LG DMM92LG DN Dynorphin(1-8) DMM92LG TI TTKWM86 DMM92LG TN Opioid receptor mu (MOP) DMM92LG MA Inhibitor DMM92LG RN Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5. DMM92LG RU https://pubmed.ncbi.nlm.nih.gov/2879914 DMM92LG DI DMM92LG DMM92LG DN Dynorphin(1-8) DMM92LG TI TTQW87Y DMM92LG TN Opioid receptor kappa (OPRK1) DMM92LG MA Inhibitor DMM92LG RN Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5. DMM92LG RU https://pubmed.ncbi.nlm.nih.gov/2879914 DMM94Y2 DI DMM94Y2 DMM94Y2 DN 1-benzhydryl-4-cyclopropylpiperidin-4-ol DMM94Y2 TI TTNT7K8 DMM94Y2 TN Nociceptin receptor (OPRL1) DMM94Y2 MA Inhibitor DMM94Y2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMM94Y2 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMM94Y2 DI DMM94Y2 DMM94Y2 DN 1-benzhydryl-4-cyclopropylpiperidin-4-ol DMM94Y2 TI TTKWM86 DMM94Y2 TN Opioid receptor mu (MOP) DMM94Y2 MA Inhibitor DMM94Y2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMM94Y2 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMM9526 DI DMM9526 DMM9526 DN N-ethyl estrone-16-methyl carboxamide DMM9526 TI TTIWB6L DMM9526 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMM9526 MA Inhibitor DMM9526 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMM9526 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMM98BC DI DMM98BC DMM98BC DN OBIDOXIME DMM98BC TI TT1RS9F DMM98BC TN Acetylcholinesterase (AChE) DMM98BC MA Inhibitor DMM98BC RN Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpy... Bioorg Med Chem Lett. 2006 Feb;16(3):622-7. DMM98BC RU https://pubmed.ncbi.nlm.nih.gov/16288867 DMM9A5N DI DMM9A5N DMM9A5N DN AGL 2043 DMM9A5N TI TTI7421 DMM9A5N TN Platelet-derived growth factor receptor beta (PDGFRB) DMM9A5N MA Inhibitor DMM9A5N RN Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem. 2003 May 1;11(9):2007-18. DMM9A5N RU https://pubmed.ncbi.nlm.nih.gov/12670652 DMM9A8G DI DMM9A8G DMM9A8G DN 2-(2-aminophenoxy)-5-hexylphenol DMM9A8G TI TTVTX4N DMM9A8G TN Bacterial Fatty acid synthetase I (Bact inhA) DMM9A8G MA Inhibitor DMM9A8G RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMM9A8G RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMM9ARP DI DMM9ARP DMM9ARP DN ISIS 156471 DMM9ARP TI TTILUKB DMM9ARP TN IRAK4 messenger RNA (IRAK4 mRNA) DMM9ARP RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMM9ARP RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMM9EPQ DI DMM9EPQ DMM9EPQ DN H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH DMM9EPQ TI TTKWM86 DMM9EPQ TN Opioid receptor mu (MOP) DMM9EPQ MA Inhibitor DMM9EPQ RN From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11. DMM9EPQ RU https://pubmed.ncbi.nlm.nih.gov/16107162 DMM9EPQ DI DMM9EPQ DMM9EPQ DN H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH DMM9EPQ TI TT27RFC DMM9EPQ TN Opioid receptor delta (OPRD1) DMM9EPQ MA Inhibitor DMM9EPQ RN From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11. DMM9EPQ RU https://pubmed.ncbi.nlm.nih.gov/16107162 DMM9G0J DI DMM9G0J DMM9G0J DN 6-(piperazin-1-yl)-3-tosyl-1H-indazole DMM9G0J TI TTJS8PY DMM9G0J TN 5-HT 6 receptor (HTR6) DMM9G0J MA Inhibitor DMM9G0J RN 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46. DMM9G0J RU https://pubmed.ncbi.nlm.nih.gov/20932009 DMM9GCA DI DMM9GCA DMM9GCA DN 5-[(2-methyl-4-thiazolyl)ethynyl]pyrimidine DMM9GCA TI TTHS256 DMM9GCA TN Metabotropic glutamate receptor 5 (mGluR5) DMM9GCA MA Inhibitor DMM9GCA RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMM9GCA RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMM9GEA DI DMM9GEA DMM9GEA DN 10-OBn-7alpha-F-gingkolide B DMM9GEA TI TTQL5VC DMM9GEA TN Platelet-activating factor receptor (PTAFR) DMM9GEA MA Antagonist DMM9GEA RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMM9GEA RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMM9GOR DI DMM9GOR DMM9GOR DN 6-bromo-1-methyl-3-(pyridin-4-yl)-1H-indole DMM9GOR TI TTTB4UP DMM9GOR TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMM9GOR MA Inhibitor DMM9GOR RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMM9GOR RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMM9H07 DI DMM9H07 DMM9H07 DN Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 DMM9H07 TI TTKWM86 DMM9H07 TN Opioid receptor mu (MOP) DMM9H07 MA Inhibitor DMM9H07 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMM9H07 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMM9H07 DI DMM9H07 DMM9H07 DN Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 DMM9H07 TI TTVFO0U DMM9H07 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMM9H07 MA Inhibitor DMM9H07 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMM9H07 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMM9H07 DI DMM9H07 DMM9H07 DN Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 DMM9H07 TI TT27RFC DMM9H07 TN Opioid receptor delta (OPRD1) DMM9H07 MA Inhibitor DMM9H07 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMM9H07 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMM9IXB DI DMM9IXB DMM9IXB DN 7-(4-Hydroxy-phenyl)-naphthalen-2-ol DMM9IXB TI TTZAYWL DMM9IXB TN Estrogen receptor (ESR) DMM9IXB MA Inhibitor DMM9IXB RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMM9IXB RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMM9IXB DI DMM9IXB DMM9IXB DN 7-(4-Hydroxy-phenyl)-naphthalen-2-ol DMM9IXB TI TTOM3J0 DMM9IXB TN Estrogen receptor beta (ESR2) DMM9IXB MA Inhibitor DMM9IXB RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMM9IXB RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMM9K5S DI DMM9K5S DMM9K5S DN Cmp-2-Keto-3-Deoxy-Octulosonic Acid DMM9K5S TI TTQ8J1V DMM9K5S TN Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB) DMM9K5S MA Inhibitor DMM9K5S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMM9K5S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMM9PDR DI DMM9PDR DMM9PDR DN NSC-224124 DMM9PDR TI TT8XK6L DMM9PDR TN Quinone reductase 1 (NQO1) DMM9PDR MA Inhibitor DMM9PDR RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMM9PDR RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMM9TUR DI DMM9TUR DMM9TUR DN H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH DMM9TUR TI TTKWM86 DMM9TUR TN Opioid receptor mu (MOP) DMM9TUR MA Inhibitor DMM9TUR RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMM9TUR RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMM9TUR DI DMM9TUR DMM9TUR DN H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH DMM9TUR TI TT27RFC DMM9TUR TN Opioid receptor delta (OPRD1) DMM9TUR MA Inhibitor DMM9TUR RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMM9TUR RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMM9WB0 DI DMM9WB0 DMM9WB0 DN 2-(3-(3,5-dichlorophenyl)ureido)benzoic acid DMM9WB0 TI TT3PQ2Y DMM9WB0 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMM9WB0 MA Inhibitor DMM9WB0 RN Discovery of novel inhibitors for DHODH via virtual screening and X-ray crystallographic structures. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1981-4. DMM9WB0 RU https://pubmed.ncbi.nlm.nih.gov/20153645 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTKWM86 DMM9X0G TN Opioid receptor mu (MOP) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT9JNIC DMM9X0G TN Histamine H3 receptor (H3R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTQ13Z5 DMM9X0G TN Muscarinic acetylcholine receptor M3 (CHRM3) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT4C8EA DMM9X0G TN Dopamine D3 receptor (D3R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT1RS9F DMM9X0G TN Acetylcholinesterase (AChE) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTTUMEP DMM9X0G TN Neurotensin receptor type 1 (NTSR1) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTD0CIQ DMM9X0G TN Melanocortin receptor 4 (MC4R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT4H1MQ DMM9X0G TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTPC4TU DMM9X0G TN 5-HT 3A receptor (HTR3A) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT0K1SC DMM9X0G TN 5-HT 2B receptor (HTR2B) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT3ROYC DMM9X0G TN Serotonin transporter (SERT) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTNGILX DMM9X0G TN Adrenergic receptor alpha-1A (ADRA1A) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTKRD0G DMM9X0G TN Endothelin A receptor (EDNRA) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTZ9SOR DMM9X0G TN Muscarinic acetylcholine receptor M1 (CHRM1) DMM9X0G MA Inhibitor DMM9X0G RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTTIBOJ DMM9X0G TN Histamine H1 receptor (H1R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTYEG6Q DMM9X0G TN Muscarinic acetylcholine receptor M2 (CHRM2) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTK25J1 DMM9X0G TN Adenosine A1 receptor (ADORA1) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT07C3Y DMM9X0G TN 5-HT 4 receptor (HTR4) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTQHJ1K DMM9X0G TN Histamine H2 receptor (H2R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTVBI8W DMM9X0G TN Dopamine transporter (DAT) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTH18TF DMM9X0G TN Muscarinic acetylcholine receptor M5 (CHRM5) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT6OEDT DMM9X0G TN Cannabinoid receptor 1 (CB1) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT34BHT DMM9X0G TN Adrenergic receptor alpha-1D (ADRA1D) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTZFYLI DMM9X0G TN Dopamine D1 receptor (D1R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTQ3JTF DMM9X0G TN Muscarinic acetylcholine receptor M4 (CHRM4) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTJQOD7 DMM9X0G TN 5-HT 2A receptor (HTR2A) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTSQIFT DMM9X0G TN 5-HT 1A receptor (HTR1A) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTVFO0U DMM9X0G TN Gastrin/cholecystokinin type B receptor (CCKBR) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTJFY5U DMM9X0G TN Adenosine A3 receptor (ADORA3) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTO9X1H DMM9X0G TN 5-HT 7 receptor (HTR7) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT0WAIE DMM9X0G TN Melatonin receptor type 1A (MTNR1A) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTEX248 DMM9X0G TN Dopamine D2 receptor (D2R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTWG9A4 DMM9X0G TN Adrenergic receptor alpha-2A (ADRA2A) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTRK9JT DMM9X0G TN Neuropeptide Y receptor type 1 (NPY1R) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTWJBZ5 DMM9X0G TN 5-HT 2C receptor (HTR2C) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTR6W5O DMM9X0G TN Adrenergic receptor beta-1 (ADRB1) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TT5KPZR DMM9X0G TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTYO0A3 DMM9X0G TN Substance-K receptor (TACR2) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTBRKXS DMM9X0G TN Adrenergic receptor alpha-1B (ADRA1B) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTZPO1L DMM9X0G TN Substance-P receptor (TACR1) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTM2AOE DMM9X0G TN Adenosine A2a receptor (ADORA2A) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTAWNKZ DMM9X0G TN Norepinephrine transporter (NET) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9X0G DI DMM9X0G DMM9X0G DN 4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G TI TTOZRK6 DMM9X0G TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMM9X0G MA Inhibitor DMM9X0G RN Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97. DMM9X0G RU https://pubmed.ncbi.nlm.nih.gov/20684563 DMM9Z0B DI DMM9Z0B DMM9Z0B DN 2-hydroxy-17beta-estradiol DMM9Z0B TI TT2QM9D DMM9Z0B TN Adenylate cyclase (ADCY) DMM9Z0B MA Inhibitor DMM9Z0B RN Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64. DMM9Z0B RU https://pubmed.ncbi.nlm.nih.gov/18630896 DMMA9GE DI DMMA9GE DMMA9GE DN C[Glu22-Orn26][Gly8]GLP-1(7-37)-NH2 DMMA9GE TI TTVIMDE DMMA9GE TN Glucagon-like peptide 1 receptor (GLP1R) DMMA9GE MA Inhibitor DMMA9GE RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMMA9GE RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMMAIQ2 DI DMMAIQ2 DMMAIQ2 DN L-888,291 DMMAIQ2 TI TTNVEIR DMMAIQ2 TN Prostaglandin D2 receptor (PTGDR) DMMAIQ2 MA Agonist DMMAIQ2 RN Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9. DMMAIQ2 RU https://pubmed.ncbi.nlm.nih.gov/15755909 DMMAIQ2 DI DMMAIQ2 DMMAIQ2 DN L-888,291 DMMAIQ2 TI TTQDMX5 DMMAIQ2 TN Prostaglandin D2 receptor 2 (PTGDR2) DMMAIQ2 MA Agonist DMMAIQ2 RN Identification of a potent and selective synthetic agonist at the CRTH2 receptor. Mol Pharmacol. 2005 Jun;67(6):1834-9. DMMAIQ2 RU https://pubmed.ncbi.nlm.nih.gov/15755909 DMMAJW9 DI DMMAJW9 DMMAJW9 DN 1-benzhydryl-4-(4-butylphenyl)piperidin-4-ol DMMAJW9 TI TTNT7K8 DMMAJW9 TN Nociceptin receptor (OPRL1) DMMAJW9 MA Inhibitor DMMAJW9 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMMAJW9 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMMAK83 DI DMMAK83 DMMAK83 DN 3-hydroxyphenethyl 3,4,5-trihydroxybenzoate DMMAK83 TI TTULVH8 DMMAK83 TN Tyrosinase (TYR) DMMAK83 MA Inhibitor DMMAK83 RN Synthetic tyrosyl gallate derivatives as potent melanin formation inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5462-4. DMMAK83 RU https://pubmed.ncbi.nlm.nih.gov/17693086 DMMAL3I DI DMMAL3I DMMAL3I DN SB-415286 DMMAL3I TI TTRSMW9 DMMAL3I TN Glycogen synthase kinase-3 beta (GSK-3B) DMMAL3I MA Inhibitor DMMAL3I RN Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71. DMMAL3I RU https://pubmed.ncbi.nlm.nih.gov/18929433 DMMAL3I DI DMMAL3I DMMAL3I DN SB-415286 DMMAL3I TI TTG0U4H DMMAL3I TN Ribosomal protein S6 kinase beta-1 (S6K1) DMMAL3I MA Inhibitor DMMAL3I RN 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg Med Chem Lett. 2001 Mar 12;11(5):635-9. DMMAL3I RU https://pubmed.ncbi.nlm.nih.gov/11266159 DMMALY3 DI DMMALY3 DMMALY3 DN 4-Chloro-3-hydroxy-1H-quinolin-2-one DMMALY3 TI TTLD29N DMMALY3 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMMALY3 MA Inhibitor DMMALY3 RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMMALY3 RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMMALY3 DI DMMALY3 DMMALY3 DN 4-Chloro-3-hydroxy-1H-quinolin-2-one DMMALY3 TI TTKJEMQ DMMALY3 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMMALY3 MA Inhibitor DMMALY3 RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMMALY3 RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMMALY3 DI DMMALY3 DMMALY3 DN 4-Chloro-3-hydroxy-1H-quinolin-2-one DMMALY3 TI TTN9D8E DMMALY3 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMMALY3 MA Inhibitor DMMALY3 RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMMALY3 RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMMAUKO DI DMMAUKO DMMAUKO DN (S)-2-Amino-3-phenyl-propane-1-thiol DMMAUKO TI TTPHMWB DMMAUKO TN Aminopeptidase N (ANPEP) DMMAUKO MA Inhibitor DMMAUKO RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMMAUKO RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMMB29S DI DMMB29S DMMB29S DN Orotate DMMB29S TI TT3PQ2Y DMMB29S TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMMB29S MA Inhibitor DMMB29S RN Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301. DMMB29S RU https://pubmed.ncbi.nlm.nih.gov/1348618 DMMB29S DI DMMB29S DMMB29S DN Orotate DMMB29S TI TT09NOX DMMB29S TN Plasmodium Dihydroorotase (Malaria dho) DMMB29S MA Inhibitor DMMB29S RN Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301. DMMB29S RU https://pubmed.ncbi.nlm.nih.gov/1348618 DMMB2GV DI DMMB2GV DMMB2GV DN 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol DMMB2GV TI TTNT7K8 DMMB2GV TN Nociceptin receptor (OPRL1) DMMB2GV MA Inhibitor DMMB2GV RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMMB2GV RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMMB2GV DI DMMB2GV DMMB2GV DN 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol DMMB2GV TI TTKWM86 DMMB2GV TN Opioid receptor mu (MOP) DMMB2GV MA Inhibitor DMMB2GV RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMMB2GV RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMMB2GV DI DMMB2GV DMMB2GV DN 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol DMMB2GV TI TT27RFC DMMB2GV TN Opioid receptor delta (OPRD1) DMMB2GV MA Inhibitor DMMB2GV RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMMB2GV RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMMB2GV DI DMMB2GV DMMB2GV DN 1-benzhydryl-4-(furan-2-yl)piperidin-4-ol DMMB2GV TI TTQW87Y DMMB2GV TN Opioid receptor kappa (OPRK1) DMMB2GV MA Inhibitor DMMB2GV RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMMB2GV RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMMB3PG DI DMMB3PG DMMB3PG DN N-methoxyquinuclidine-3-carboximidoyl chloride DMMB3PG TI TTQ13Z5 DMMB3PG TN Muscarinic acetylcholine receptor M3 (CHRM3) DMMB3PG MA Inhibitor DMMB3PG RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMMB3PG RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMMB3PG DI DMMB3PG DMMB3PG DN N-methoxyquinuclidine-3-carboximidoyl chloride DMMB3PG TI TTZ9SOR DMMB3PG TN Muscarinic acetylcholine receptor M1 (CHRM1) DMMB3PG MA Inhibitor DMMB3PG RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMMB3PG RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMMB3PG DI DMMB3PG DMMB3PG DN N-methoxyquinuclidine-3-carboximidoyl chloride DMMB3PG TI TTYEG6Q DMMB3PG TN Muscarinic acetylcholine receptor M2 (CHRM2) DMMB3PG MA Inhibitor DMMB3PG RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMMB3PG RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMMB3PG DI DMMB3PG DMMB3PG DN N-methoxyquinuclidine-3-carboximidoyl chloride DMMB3PG TI TTH18TF DMMB3PG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMMB3PG MA Inhibitor DMMB3PG RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMMB3PG RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMMB3PG DI DMMB3PG DMMB3PG DN N-methoxyquinuclidine-3-carboximidoyl chloride DMMB3PG TI TTQ3JTF DMMB3PG TN Muscarinic acetylcholine receptor M4 (CHRM4) DMMB3PG MA Inhibitor DMMB3PG RN A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Bioorg. Med. Chem. Lett. 2(8):791-796 (1992). DMMB3PG RU http://www.sciencedirect.com/science/article/pii/S0960894X00805338 DMMB4US DI DMMB4US DMMB4US DN {[(9Z)-octadec-9-en-1-yl]sulfamoyl}amine DMMB4US TI TT6OEDT DMMB4US TN Cannabinoid receptor 1 (CB1) DMMB4US MA Inhibitor DMMB4US RN Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide. Eur J Med Chem. 2009 Dec;44(12):4889-95. DMMB4US RU https://pubmed.ncbi.nlm.nih.gov/19762126 DMMB6NU DI DMMB6NU DMMB6NU DN PMID17709461C4g DMMB6NU TI TTFQEO5 DMMB6NU TN Squalene synthetase (FDFT1) DMMB6NU MA Inhibitor DMMB6NU RN Quinuclidine derivatives as potential antiparasitics. Antimicrob Agents Chemother. 2007 Nov;51(11):4049-61. DMMB6NU RU https://pubmed.ncbi.nlm.nih.gov/17709461 DMMBA70 DI DMMBA70 DMMBA70 DN CALYSTEGINE B2 DMMBA70 TI TTIS03D DMMBA70 TN Alpha-galactosidase A (GLA) DMMBA70 MA Inhibitor DMMBA70 RN Identification of the glycosidase inhibitors swainsonine and calystegine B2 in Weir vine (Ipomoea sp. Q6 [aff. calobra]) and correlation with toxicity. J Nat Prod. 1995 Jun;58(6):878-86. DMMBA70 RU https://pubmed.ncbi.nlm.nih.gov/7673932 DMMBAR3 DI DMMBAR3 DMMBAR3 DN NSC-645808 DMMBAR3 TI TT8XK6L DMMBAR3 TN Quinone reductase 1 (NQO1) DMMBAR3 MA Inhibitor DMMBAR3 RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMMBAR3 RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMMBAR3 DI DMMBAR3 DMMBAR3 DN NSC-645808 DMMBAR3 TI TTJLP0R DMMBAR3 TN Quinone reductase 2 (NQO2) DMMBAR3 MA Inhibitor DMMBAR3 RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMMBAR3 RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMMBESU DI DMMBESU DMMBESU DN C(RGDfF) DMMBESU TI TTT1R2L DMMBESU TN Integrin alpha-V (ITGAV) DMMBESU MA Inhibitor DMMBESU RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMMBESU RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMMBESU DI DMMBESU DMMBESU DN C(RGDfF) DMMBESU TI TTJA1ZO DMMBESU TN ITGB3 messenger RNA (ITGB3 mRNA) DMMBESU MA Inhibitor DMMBESU RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMMBESU RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMMBGK0 DI DMMBGK0 DMMBGK0 DN 2-Amino-6-phenylsulfanyl-benzonitrile DMMBGK0 TI TT84ETX DMMBGK0 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMBGK0 MA Inhibitor DMMBGK0 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMMBGK0 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMMBH9N DI DMMBH9N DMMBH9N DN 8-(1H-indol-5-yl)-2-morpholin-4-ylchromen-4-one DMMBH9N TI TTK3PY9 DMMBH9N TN DNA-dependent protein kinase catalytic (PRKDC) DMMBH9N MA Inhibitor DMMBH9N RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMMBH9N RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMMBI9Y DI DMMBI9Y DMMBI9Y DN W-84 DMMBI9Y TI TTOXS3C DMMBI9Y TN Muscarinic acetylcholine receptor (CHRM) DMMBI9Y MA Modulator (allosteric modulator) DMMBI9Y RN Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003 Jul;64(1):180-90. DMMBI9Y RU https://pubmed.ncbi.nlm.nih.gov/12815174 DMMBJWK DI DMMBJWK DMMBJWK DN ISIS 102482 DMMBJWK TI TT5U49F DMMBJWK TN PRKACA messenger RNA (PRKACA mRNA) DMMBJWK RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMMBJWK RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TT2O84V DMMBQYE TN Thromboxane A2 receptor (TBXA2R) DMMBQYE MA Agonist DMMBQYE RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TT79WV3 DMMBQYE TN Prostaglandin E2 receptor EP4 (PTGER4) DMMBQYE MA Agonist DMMBQYE RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TTNVEIR DMMBQYE TN Prostaglandin D2 receptor (PTGDR) DMMBQYE MA Agonist DMMBQYE RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TTG1QMU DMMBQYE TN Prostaglandin E2 receptor EP1 (PTGER1) DMMBQYE MA Agonist DMMBQYE RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TTOFYT1 DMMBQYE TN Prostacyclin receptor (PTGIR) DMMBQYE MA Agonist DMMBQYE RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TTT2ZAR DMMBQYE TN Prostaglandin F2-alpha receptor (PTGFR) DMMBQYE MA Agonist DMMBQYE RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TT1ZAVI DMMBQYE TN Prostaglandin E2 receptor EP2 (PTGER2) DMMBQYE MA Agonist DMMBQYE RN The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/10634944 DMMBQYE DI DMMBQYE DMMBQYE DN carbacyclin DMMBQYE TI TTPNGDE DMMBQYE TN Prostaglandin E2 receptor EP3 (PTGER3) DMMBQYE MA Agonist DMMBQYE RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMMBQYE RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMMBW13 DI DMMBW13 DMMBW13 DN ISIS 150450 DMMBW13 TI TTP9K3Q DMMBW13 TN SOD1 messenger RNA (SOD1 mRNA) DMMBW13 RN US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. DMMBW13 RU http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TTEX6LM DMMBWKL TN GABA(A) receptor gamma-3 (GABRG3) DMMBWKL MA Modulator (allosteric modulator) DMMBWKL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMMBWKL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TTZA1NY DMMBWKL TN GABA(A) receptor beta-2 (GABRB2) DMMBWKL MA Inhibitor DMMBWKL RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMMBWKL RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TTNZPQ1 DMMBWKL TN GABA(A) receptor alpha-5 (GABRA5) DMMBWKL MA Inhibitor DMMBWKL RN Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34. DMMBWKL RU https://pubmed.ncbi.nlm.nih.gov/8627617 DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TT1MPAY DMMBWKL TN GABA(A) receptor alpha-1 (GABRA1) DMMBWKL MA Inhibitor DMMBWKL RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMMBWKL RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TT06RH5 DMMBWKL TN GABA(A) receptor gamma-2 (GABRG2) DMMBWKL MA Inhibitor DMMBWKL RN Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68. DMMBWKL RU https://pubmed.ncbi.nlm.nih.gov/8145225 DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TTBMV1G DMMBWKL TN GABA(A) receptor alpha-2 (GABRA2) DMMBWKL MA Inhibitor DMMBWKL RN Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34. DMMBWKL RU https://pubmed.ncbi.nlm.nih.gov/8627617 DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TTNJYV2 DMMBWKL TN Gamma-aminobutyric acid receptor (GAR) DMMBWKL MA Inhibitor DMMBWKL RN Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34. DMMBWKL RU https://pubmed.ncbi.nlm.nih.gov/8627617 DMMBWKL DI DMMBWKL DMMBWKL DN [3H]Ro154513 DMMBWKL TI TT37EDJ DMMBWKL TN GABA(A) receptor alpha-3 (GABRA3) DMMBWKL MA Inhibitor DMMBWKL RN Synthesis and pharmacological properties of novel 8-substituted imidazobenzodiazepines: high-affinity, selective probes for alpha 5-containing GABA... J Med Chem. 1996 Apr 26;39(9):1928-34. DMMBWKL RU https://pubmed.ncbi.nlm.nih.gov/8627617 DMMBYGE DI DMMBYGE DMMBYGE DN Benzenesulfonyl DMMBYGE TI TTXA6PH DMMBYGE TN Oxysterols receptor LXR-beta (NR1H2) DMMBYGE MA Inhibitor DMMBYGE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMBYGE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMBYOD DI DMMBYOD DMMBYOD DN 1-Adamantan-1-yl-3-(4-methoxy-phenyl)-urea DMMBYOD TI TT7WVHI DMMBYOD TN Soluble epoxide hydrolase (EPHX2) DMMBYOD MA Inhibitor DMMBYOD RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMMBYOD RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMMC0I7 DI DMMC0I7 DMMC0I7 DN METHIOTHEPIN DMMC0I7 TI TTO9X1H DMMC0I7 TN 5-HT 7 receptor (HTR7) DMMC0I7 MA Inhibitor DMMC0I7 RN Novel quinazolinone derivatives as 5-HT7 receptor ligands. Bioorg Med Chem. 2008 Mar 1;16(5):2570-8. DMMC0I7 RU https://pubmed.ncbi.nlm.nih.gov/18083580 DMMC0I7 DI DMMC0I7 DMMC0I7 DN METHIOTHEPIN DMMC0I7 TI TTJS8PY DMMC0I7 TN 5-HT 6 receptor (HTR6) DMMC0I7 MA Inhibitor DMMC0I7 RN 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7. DMMC0I7 RU https://pubmed.ncbi.nlm.nih.gov/20170099 DMMC0I7 DI DMMC0I7 DMMC0I7 DN METHIOTHEPIN DMMC0I7 TI TTRUFDT DMMC0I7 TN 5-HT 5A receptor (HTR5A) DMMC0I7 MA Inhibitor DMMC0I7 RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMMC0I7 RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMMC0ZP DI DMMC0ZP DMMC0ZP DN 2-morpholino-6-phenyl-4H-pyran-4-one DMMC0ZP TI TTK3PY9 DMMC0ZP TN DNA-dependent protein kinase catalytic (PRKDC) DMMC0ZP MA Inhibitor DMMC0ZP RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMMC0ZP RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMMC139 DI DMMC139 DMMC139 DN (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane DMMC139 TI TT3ROYC DMMC139 TN Serotonin transporter (SERT) DMMC139 MA Inhibitor DMMC139 RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMMC139 RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMMC139 DI DMMC139 DMMC139 DN (cis)-1,6-diphenyl-3-aza-bicyclo[3.1.0]hexane DMMC139 TI TTVBI8W DMMC139 TN Dopamine transporter (DAT) DMMC139 MA Inhibitor DMMC139 RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMMC139 RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMMC2Q9 DI DMMC2Q9 DMMC2Q9 DN 3-biphenyl-4-ylethynyl-5-methyl-[1,2,4]triazine DMMC2Q9 TI TTHS256 DMMC2Q9 TN Metabotropic glutamate receptor 5 (mGluR5) DMMC2Q9 MA Inhibitor DMMC2Q9 RN Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91. DMMC2Q9 RU https://pubmed.ncbi.nlm.nih.gov/17569516 DMMC42Z DI DMMC42Z DMMC42Z DN NGB 2904 DMMC42Z TI TT4C8EA DMMC42Z TN Dopamine D3 receptor (D3R) DMMC42Z MA Antagonist DMMC42Z RN Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction. CNS Drug Rev. 2007 Summer;13(2):240-59. DMMC42Z RU https://pubmed.ncbi.nlm.nih.gov/17627675 DMMC4BY DI DMMC4BY DMMC4BY DN Brominide tartrate DMMC4BY TI TTQ8AFT DMMC4BY TN Adrenergic receptor Alpha-2 (ADRA2) DMMC4BY MA Agonist DMMC4BY RN Alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8. DMMC4BY RU https://pubmed.ncbi.nlm.nih.gov/10799649 DMMC8IG DI DMMC8IG DMMC8IG DN 2-Deoxy-2fluoro-Glucose DMMC8IG TI TTA0OSE DMMC8IG TN Lactase-phlorizin hydrolase (LCT) DMMC8IG MA Inhibitor DMMC8IG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMC8IG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMC8RN DI DMMC8RN DMMC8RN DN M3Pr6S DMMC8RN TI TTQW87Y DMMC8RN TN Opioid receptor kappa (OPRK1) DMMC8RN MA Inhibitor DMMC8RN RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMMC8RN RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMMC8RN DI DMMC8RN DMMC8RN DN M3Pr6S DMMC8RN TI TTKWM86 DMMC8RN TN Opioid receptor mu (MOP) DMMC8RN MA Inhibitor DMMC8RN RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMMC8RN RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMMCAZG DI DMMCAZG DMMCAZG DN 8-biphenyl-2-yl-2-morpholin-4-ylchromen-4-one DMMCAZG TI TTK3PY9 DMMCAZG TN DNA-dependent protein kinase catalytic (PRKDC) DMMCAZG MA Inhibitor DMMCAZG RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMMCAZG RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMMCFEX DI DMMCFEX DMMCFEX DN ARN34 DMMCFEX TI TTS64P2 DMMCFEX TN Androgen receptor (AR) DMMCFEX MA Antagonist DMMCFEX RN Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol. 2004 Feb 12;214(1-2):175-87. DMMCFEX RU https://pubmed.ncbi.nlm.nih.gov/15062556 DMMCGL3 DI DMMCGL3 DMMCGL3 DN N-(1-(1-phenylethyl)piperidin-4-yl)-2-naphthamide DMMCGL3 TI TTJQOD7 DMMCGL3 TN 5-HT 2A receptor (HTR2A) DMMCGL3 MA Inhibitor DMMCGL3 RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9. DMMCGL3 RU https://pubmed.ncbi.nlm.nih.gov/17254782 DMMCNQI DI DMMCNQI DMMCNQI DN 6-Bromo-2-phenyl-chromen-4-one DMMCNQI TI TTNJYV2 DMMCNQI TN Gamma-aminobutyric acid receptor (GAR) DMMCNQI MA Inhibitor DMMCNQI RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMMCNQI RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMMCNQI DI DMMCNQI DMMCNQI DN 6-Bromo-2-phenyl-chromen-4-one DMMCNQI TI TT1MPAY DMMCNQI TN GABA(A) receptor alpha-1 (GABRA1) DMMCNQI MA Inhibitor DMMCNQI RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMMCNQI RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMMCXWQ DI DMMCXWQ DMMCXWQ DN YM-75440 DMMCXWQ TI TTFQEO5 DMMCXWQ TN Squalene synthetase (FDFT1) DMMCXWQ MA Inhibitor DMMCXWQ RN Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg Med Chem. 2004 Nov 15;12(22):5899-908. DMMCXWQ RU https://pubmed.ncbi.nlm.nih.gov/15498666 DMMD3G6 DI DMMD3G6 DMMD3G6 DN 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one DMMD3G6 TI TT1RS9F DMMD3G6 TN Acetylcholinesterase (AChE) DMMD3G6 MA Inhibitor DMMD3G6 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMMD3G6 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMMD3G6 DI DMMD3G6 DMMD3G6 DN 3-[7-(benzylmethylamino)-heptyloxy]xanthen-9-one DMMD3G6 TI TTEB0GD DMMD3G6 TN Cholinesterase (BCHE) DMMD3G6 MA Inhibitor DMMD3G6 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMMD3G6 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMMD5W3 DI DMMD5W3 DMMD5W3 DN KB-R7943 DMMD5W3 TI TTRBT3W DMMD5W3 TN Short transient receptor potential channel 6 (TRPC6) DMMD5W3 MA Blocker (channel blocker) DMMD5W3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491). DMMD5W3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491 DMMD5W3 DI DMMD5W3 DMMD5W3 DN KB-R7943 DMMD5W3 TI TT32NQ1 DMMD5W3 TN Short transient receptor potential channel 5 (TRPC5) DMMD5W3 MA Blocker (channel blocker) DMMD5W3 RN The Na+/Ca2+ exchange inhibitor KB-R7943 potently blocks TRPC channels. Biochem Biophys Res Commun. 2007 Sep 14;361(1):230-6. DMMD5W3 RU https://pubmed.ncbi.nlm.nih.gov/17658472 DMMD5W3 DI DMMD5W3 DMMD5W3 DN KB-R7943 DMMD5W3 TI TTNVC34 DMMD5W3 TN Short transient receptor potential channel 3 (TRPC3) DMMD5W3 MA Blocker (channel blocker) DMMD5W3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 488). DMMD5W3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=488 DMMD9A0 DI DMMD9A0 DMMD9A0 DN N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine DMMD9A0 TI TT4H1MQ DMMD9A0 TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMMD9A0 MA Inhibitor DMMD9A0 RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMMD9A0 RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMMD9A0 DI DMMD9A0 DMMD9A0 DN N,N-dimethyl-2-(pyridin-3-yloxy)ethanamine DMMD9A0 TI TT5KPZR DMMD9A0 TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMMD9A0 MA Inhibitor DMMD9A0 RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMMD9A0 RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMMDG92 DI DMMDG92 DMMDG92 DN Dodecyl-Alpha-D-Maltoside DMMDG92 TI TT1Q3IE DMMDG92 TN Retinoic acid receptor gamma (RARG) DMMDG92 MA Inhibitor DMMDG92 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMMDG92 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMMDGR2 DI DMMDGR2 DMMDGR2 DN 4-ISOPROPYLPHENSERINE DMMDGR2 TI TTEB0GD DMMDGR2 TN Cholinesterase (BCHE) DMMDGR2 MA Inhibitor DMMDGR2 RN A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17(3):159-65. DMMDGR2 RU https://pubmed.ncbi.nlm.nih.gov/11900310 DMMDGR2 DI DMMDGR2 DMMDGR2 DN 4-ISOPROPYLPHENSERINE DMMDGR2 TI TT1RS9F DMMDGR2 TN Acetylcholinesterase (AChE) DMMDGR2 MA Inhibitor DMMDGR2 RN Design, synthesis, evaluation and QSAR analysis of N(1)-substituted norcymserine derivatives as selective butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1718-20. DMMDGR2 RU https://pubmed.ncbi.nlm.nih.gov/20137934 DMMDIB9 DI DMMDIB9 DMMDIB9 DN 3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine DMMDIB9 TI TTSZLWK DMMDIB9 TN Aromatase (CYP19A1) DMMDIB9 MA Inhibitor DMMDIB9 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMMDIB9 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMMDIB9 DI DMMDIB9 DMMDIB9 DN 3-[4-Chloro-indan-(1Z)-ylidenemethyl]-pyridine DMMDIB9 TI TTIQUX7 DMMDIB9 TN Steroid 11-beta-hydroxylase (CYP11B1) DMMDIB9 MA Inhibitor DMMDIB9 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMMDIB9 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMMDJPC DI DMMDJPC DMMDJPC DN Ac-hPhe-Leu-Phe-LeuVSMe DMMDJPC TI TTF2LRI DMMDJPC TN Cathepsin B (CTSB) DMMDJPC MA Inhibitor DMMDJPC RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMMDJPC RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMMDJPC DI DMMDJPC DMMDJPC DN Ac-hPhe-Leu-Phe-LeuVSMe DMMDJPC TI TTUMQVO DMMDJPC TN Cathepsin S (CTSS) DMMDJPC MA Inhibitor DMMDJPC RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMMDJPC RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMMDNA8 DI DMMDNA8 DMMDNA8 DN 2-(3-Mercapto-propyl)-pentanedioic acid DMMDNA8 TI TT9G4N0 DMMDNA8 TN Glutamate carboxypeptidase II (GCPII) DMMDNA8 MA Inhibitor DMMDNA8 RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DMMDNA8 RU https://pubmed.ncbi.nlm.nih.gov/12723961 DMMDOI4 DI DMMDOI4 DMMDOI4 DN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone DMMDOI4 TI TT1MPAY DMMDOI4 TN GABA(A) receptor alpha-1 (GABRA1) DMMDOI4 MA Inhibitor DMMDOI4 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMMDOI4 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMMDOI4 DI DMMDOI4 DMMDOI4 DN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone DMMDOI4 TI TTZA1NY DMMDOI4 TN GABA(A) receptor beta-2 (GABRB2) DMMDOI4 MA Inhibitor DMMDOI4 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMMDOI4 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMMDOI4 DI DMMDOI4 DMMDOI4 DN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone DMMDOI4 TI TT06RH5 DMMDOI4 TN GABA(A) receptor gamma-2 (GABRG2) DMMDOI4 MA Inhibitor DMMDOI4 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMMDOI4 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMMDOI4 DI DMMDOI4 DMMDOI4 DN 3-ethoxycarbonyl-6-ethyl-2-methyl-4-quinolone DMMDOI4 TI TTNJYV2 DMMDOI4 TN Gamma-aminobutyric acid receptor (GAR) DMMDOI4 MA Inhibitor DMMDOI4 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMMDOI4 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMMDS2T DI DMMDS2T DMMDS2T DN 2-phenyl-5H-indeno[1,2-d]pyrimidine DMMDS2T TI TT3WG5C DMMDS2T TN Monoamine oxidase type A (MAO-A) DMMDS2T MA Inhibitor DMMDS2T RN Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71. DMMDS2T RU https://pubmed.ncbi.nlm.nih.gov/17910428 DMMDU0K DI DMMDU0K DMMDU0K DN GM-109 DMMDU0K TI TT953CX DMMDU0K TN Motilin receptor (MLNR) DMMDU0K MA Antagonist DMMDU0K RN Design and synthesis of motilin antagonists derived from the [1-4] fragment of porcine motilin. J Med Chem. 2002 Jan 31;45(3):670-5. DMMDU0K RU https://pubmed.ncbi.nlm.nih.gov/11806718 DMMDXEO DI DMMDXEO DMMDXEO DN N-(2-Ethylphenyl)-5-methylbenzo[d]oxazol-2-amine DMMDXEO TI TT2J34L DMMDXEO TN Arachidonate 5-lipoxygenase (5-LOX) DMMDXEO MA Inhibitor DMMDXEO RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DMMDXEO RU https://pubmed.ncbi.nlm.nih.gov/20870413 DMMDZ4B DI DMMDZ4B DMMDZ4B DN LAU-0901 DMMDZ4B TI TTQL5VC DMMDZ4B TN Platelet-activating factor receptor (PTAFR) DMMDZ4B MA Antagonist DMMDZ4B RN Superior Neuroprotective Efficacy of LAU-0901, a Novel Platelet-Activating Factor Antagonist, in Experimental Stroke. Transl Stroke Res. 2012 Mar;3(1):154-63. DMMDZ4B RU https://pubmed.ncbi.nlm.nih.gov/22408693 DMME09C DI DMME09C DMME09C DN 1H-Imidazo[4,5-c]quinolin-4-ylamine HCl DMME09C TI TTK25J1 DMME09C TN Adenosine A1 receptor (ADORA1) DMME09C MA Inhibitor DMME09C RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMME09C RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMME09C DI DMME09C DMME09C DN 1H-Imidazo[4,5-c]quinolin-4-ylamine HCl DMME09C TI TTNE7KG DMME09C TN Adenosine A2b receptor (ADORA2B) DMME09C MA Inhibitor DMME09C RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMME09C RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMME09C DI DMME09C DMME09C DN 1H-Imidazo[4,5-c]quinolin-4-ylamine HCl DMME09C TI TTM2AOE DMME09C TN Adenosine A2a receptor (ADORA2A) DMME09C MA Inhibitor DMME09C RN 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem. 1991 Mar;34(3):1202-6. DMME09C RU https://pubmed.ncbi.nlm.nih.gov/2002461 DMME0VN DI DMME0VN DMME0VN DN Phosphoric acid monododecyl ester DMME0VN TI TTQ6S1K DMME0VN TN Lysophosphatidic acid receptor 1 (LPAR1) DMME0VN MA Inhibitor DMME0VN RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMME0VN RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMME40U DI DMME40U DMME40U DN LY-379268 DMME40U TI TT8A9EF DMME40U TN Metabotropic glutamate receptor 3 (mGluR3) DMME40U MA Inhibitor DMME40U RN Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40. DMME40U RU https://pubmed.ncbi.nlm.nih.gov/17228865 DMME40U DI DMME40U DMME40U DN LY-379268 DMME40U TI TTXJ47W DMME40U TN Metabotropic glutamate receptor 2 (mGluR2) DMME40U MA Inhibitor DMME40U RN Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (-)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate: identif... J Med Chem. 2007 Jan 25;50(2):233-40. DMME40U RU https://pubmed.ncbi.nlm.nih.gov/17228865 DMME6K2 DI DMME6K2 DMME6K2 DN CP-305202 DMME6K2 TI TTB2MXP DMME6K2 TN Angiotensinogenase renin (REN) DMME6K2 MA Inhibitor DMME6K2 RN Direct renin inhibitors as a new therapy for hypertension. J Med Chem. 2010 Nov 11;53(21):7490-520. DMME6K2 RU https://pubmed.ncbi.nlm.nih.gov/20731374 DMME8JP DI DMME8JP DMME8JP DN ISIS 104253 DMME8JP TI TTCQ2E5 DMME8JP TN RIP2 messenger RNA (RIP2 mRNA) DMME8JP RN US patent application no. 6,426,221, Antisense modulation of RIP2 expression. DMME8JP RU http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true DMMEB64 DI DMMEB64 DMMEB64 DN 17-methyl-4'-methyldihydromorphinone DMMEB64 TI TTKWM86 DMMEB64 TN Opioid receptor mu (MOP) DMMEB64 MA Inhibitor DMMEB64 RN Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8. DMMEB64 RU https://pubmed.ncbi.nlm.nih.gov/16913723 DMMEB64 DI DMMEB64 DMMEB64 DN 17-methyl-4'-methyldihydromorphinone DMMEB64 TI TTQW87Y DMMEB64 TN Opioid receptor kappa (OPRK1) DMMEB64 MA Inhibitor DMMEB64 RN Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8. DMMEB64 RU https://pubmed.ncbi.nlm.nih.gov/16913723 DMMEB64 DI DMMEB64 DMMEB64 DN 17-methyl-4'-methyldihydromorphinone DMMEB64 TI TT27RFC DMMEB64 TN Opioid receptor delta (OPRD1) DMMEB64 MA Inhibitor DMMEB64 RN Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8. DMMEB64 RU https://pubmed.ncbi.nlm.nih.gov/16913723 DMMEBH3 DI DMMEBH3 DMMEBH3 DN 2-(2-formylphenoxy)acetic acid DMMEBH3 TI TTQDMX5 DMMEBH3 TN Prostaglandin D2 receptor 2 (PTGDR2) DMMEBH3 MA Inhibitor DMMEBH3 RN Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41. DMMEBH3 RU https://pubmed.ncbi.nlm.nih.gov/17154491 DMMEC9D DI DMMEC9D DMMEC9D DN G15 DMMEC9D TI TTDSB34 DMMEC9D TN G-protein coupled estrogen receptor 1 (GPER1) DMMEC9D MA Antagonist DMMEC9D RN In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009 Jun;5(6):421-7. DMMEC9D RU https://pubmed.ncbi.nlm.nih.gov/19430488 DMMEDJT DI DMMEDJT DMMEDJT DN OXDEX DMMEDJT TI TTOZRK6 DMMEDJT TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMMEDJT MA Inhibitor DMMEDJT RN Investigation of the relative cellular permeability of DNA-binding pyrrole-imidazole polyamides. J Med Chem. 2009 Aug 13;52(15):4604-12. DMMEDJT RU https://pubmed.ncbi.nlm.nih.gov/19610652 DMMEL39 DI DMMEL39 DMMEL39 DN 2-(2-Hydroxycarbamoyl-ethyl)-pentanedioic acid DMMEL39 TI TT9G4N0 DMMEL39 TN Glutamate carboxypeptidase II (GCPII) DMMEL39 MA Inhibitor DMMEL39 RN Synthesis and biological evaluation of hydroxamate-Based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2097-100. DMMEL39 RU https://pubmed.ncbi.nlm.nih.gov/12798312 DMMENDC DI DMMENDC DMMENDC DN 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (3,5-BIS-TRIFLUOROMETHYL-BENZYL)-METHYL-AMIDE (STRUCTURAL MIX) DMMENDC TI TTZPO1L DMMENDC TN Substance-P receptor (TACR1) DMMENDC MA Inhibitor DMMENDC RN Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of... J Med Chem. 1998 Oct 22;41(22):4232-9. DMMENDC RU https://pubmed.ncbi.nlm.nih.gov/9784098 DMMEP6J DI DMMEP6J DMMEP6J DN ISIS 15999 DMMEP6J TI TTRE6AX DMMEP6J TN Bcl-x messenger RNA (BCL2L1 mRNA) DMMEP6J RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMMEP6J RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMMEQ3R DI DMMEQ3R DMMEQ3R DN [D-Gln3,Ncy(isopropyl)7]acyline DMMEQ3R TI TT8R70G DMMEQ3R TN Gonadotropin-releasing hormone receptor (GNRHR) DMMEQ3R MA Inhibitor DMMEQ3R RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMMEQ3R RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMMEQUR DI DMMEQUR DMMEQUR DN Ethidium DMMEQUR TI TTUTN1I DMMEQUR TN Human Deoxyribonucleic acid (hDNA) DMMEQUR MA Intercalator DMMEQUR RN 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12. DMMEQUR RU https://pubmed.ncbi.nlm.nih.gov/2472832 DMMESBW DI DMMESBW DMMESBW DN PMID20005102C1 DMMESBW TI TTFN95D DMMESBW TN PAK-1 protein kinase (PAK1) DMMESBW MA Inhibitor DMMESBW RN 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. DMMESBW RU https://pubmed.ncbi.nlm.nih.gov/20005102 DMMESBW DI DMMESBW DMMESBW DN PMID20005102C1 DMMESBW TI TT9QBI6 DMMESBW TN Phosphoinositide dependent protein kinase-1 (PDPK1) DMMESBW MA Inhibitor DMMESBW RN 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. DMMESBW RU https://pubmed.ncbi.nlm.nih.gov/20005102 DMMESBW DI DMMESBW DMMESBW DN PMID20005102C1 DMMESBW TI TTAZ05C DMMESBW TN RAC-gamma serine/threonine-protein kinase (AKT3) DMMESBW MA Inhibitor DMMESBW RN 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. DMMESBW RU https://pubmed.ncbi.nlm.nih.gov/20005102 DMMESBW DI DMMESBW DMMESBW DN PMID20005102C1 DMMESBW TI TTH24WI DMMESBW TN RAC-beta serine/threonine-protein kinase (AKT2) DMMESBW MA Inhibitor DMMESBW RN 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. DMMESBW RU https://pubmed.ncbi.nlm.nih.gov/20005102 DMMESBW DI DMMESBW DMMESBW DN PMID20005102C1 DMMESBW TI TTWTSCV DMMESBW TN RAC-alpha serine/threonine-protein kinase (AKT1) DMMESBW MA Inhibitor DMMESBW RN 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. DMMESBW RU https://pubmed.ncbi.nlm.nih.gov/20005102 DMMESBW DI DMMESBW DMMESBW DN PMID20005102C1 DMMESBW TI TTG0U4H DMMESBW TN Ribosomal protein S6 kinase beta-1 (S6K1) DMMESBW MA Inhibitor DMMESBW RN 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. DMMESBW RU https://pubmed.ncbi.nlm.nih.gov/20005102 DMMESBW DI DMMESBW DMMESBW DN PMID20005102C1 DMMESBW TI TTYVI76 DMMESBW TN Fungal Protein kinase A (Fung ypkA) DMMESBW MA Inhibitor DMMESBW RN 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83. DMMESBW RU https://pubmed.ncbi.nlm.nih.gov/20005102 DMMESIU DI DMMESIU DMMESIU DN 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine DMMESIU TI TTJFY5U DMMESIU TN Adenosine A3 receptor (ADORA3) DMMESIU MA Inhibitor DMMESIU RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DMMESIU RU https://pubmed.ncbi.nlm.nih.gov/19317449 DMMESIU DI DMMESIU DMMESIU DN 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine DMMESIU TI TTK25J1 DMMESIU TN Adenosine A1 receptor (ADORA1) DMMESIU MA Inhibitor DMMESIU RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DMMESIU RU https://pubmed.ncbi.nlm.nih.gov/19317449 DMMESIU DI DMMESIU DMMESIU DN 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine DMMESIU TI TTNE7KG DMMESIU TN Adenosine A2b receptor (ADORA2B) DMMESIU MA Inhibitor DMMESIU RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DMMESIU RU https://pubmed.ncbi.nlm.nih.gov/19317449 DMMESIU DI DMMESIU DMMESIU DN 2,5'-dichloro-5'-deoxy-N6-cyclopentyladenosine DMMESIU TI TTM2AOE DMMESIU TN Adenosine A2a receptor (ADORA2A) DMMESIU MA Inhibitor DMMESIU RN N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine recept... J Med Chem. 2009 Apr 23;52(8):2393-406. DMMESIU RU https://pubmed.ncbi.nlm.nih.gov/19317449 DMMETC2 DI DMMETC2 DMMETC2 DN S-(N-ethyl-N-hydroxycarbamoyl)glutathione DMMETC2 TI TTV9A7R DMMETC2 TN Lactoylglutathione lyase (GLO1) DMMETC2 MA Inhibitor DMMETC2 RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DMMETC2 RU https://pubmed.ncbi.nlm.nih.gov/11052803 DMMF1HX DI DMMF1HX DMMF1HX DN ISOCONAZOLE DMMF1HX TI TTRA5BZ DMMF1HX TN Steroid 17-alpha-monooxygenase (S17AH) DMMF1HX MA Inhibitor DMMF1HX RN Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J Med Chem. 2003 Jun 5;46(12):2345-51. DMMF1HX RU https://pubmed.ncbi.nlm.nih.gov/12773039 DMMF57V DI DMMF57V DMMF57V DN 5-hydroxynaphthalene-1-sulfonamide DMMF57V TI TT7HF4W DMMF57V TN Cyclin-dependent kinase 2 (CDK2) DMMF57V MA Inhibitor DMMF57V RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMMF57V RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMMFA4N DI DMMFA4N DMMFA4N DN 3-m-tolyl-1,5-naphthyridine DMMFA4N TI TTHS256 DMMFA4N TN Metabotropic glutamate receptor 5 (mGluR5) DMMFA4N MA Inhibitor DMMFA4N RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMMFA4N RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMMFCHU DI DMMFCHU DMMFCHU DN Tic-D-Phe-Arg-2-Nal-NHCH3 DMMFCHU TI TT0MV2T DMMFCHU TN Melanocortin receptor 1 (MC1R) DMMFCHU MA Inhibitor DMMFCHU RN Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5. DMMFCHU RU https://pubmed.ncbi.nlm.nih.gov/16376076 DMMFCHU DI DMMFCHU DMMFCHU DN Tic-D-Phe-Arg-2-Nal-NHCH3 DMMFCHU TI TTD0CIQ DMMFCHU TN Melanocortin receptor 4 (MC4R) DMMFCHU MA Inhibitor DMMFCHU RN Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5. DMMFCHU RU https://pubmed.ncbi.nlm.nih.gov/16376076 DMMFCHU DI DMMFCHU DMMFCHU DN Tic-D-Phe-Arg-2-Nal-NHCH3 DMMFCHU TI TTNI91K DMMFCHU TN Melanocortin receptor 3 (MC3R) DMMFCHU MA Inhibitor DMMFCHU RN Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1721-5. DMMFCHU RU https://pubmed.ncbi.nlm.nih.gov/16376076 DMMFJA8 DI DMMFJA8 DMMFJA8 DN MRE 3010F20 DMMFJA8 TI TTJFY5U DMMFJA8 TN Adenosine A3 receptor (ADORA3) DMMFJA8 MA Antagonist DMMFJA8 RN [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. DMMFJA8 RU https://pubmed.ncbi.nlm.nih.gov/10779381 DMMFKOH DI DMMFKOH DMMFKOH DN 2-methyl-7-m-tolyl-1,6-naphthyridine DMMFKOH TI TTHS256 DMMFKOH TN Metabotropic glutamate receptor 5 (mGluR5) DMMFKOH MA Inhibitor DMMFKOH RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMMFKOH RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMMFP57 DI DMMFP57 DMMFP57 DN Resveratrol Potassium4,-Sulfate DMMFP57 TI TTF10I9 DMMFP57 TN Nitric-oxide synthase inducible (NOS2) DMMFP57 MA Inhibitor DMMFP57 RN Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43. DMMFP57 RU https://pubmed.ncbi.nlm.nih.gov/20527891 DMMFP57 DI DMMFP57 DMMFP57 DN Resveratrol Potassium4,-Sulfate DMMFP57 TI TT8NGED DMMFP57 TN Prostaglandin G/H synthase 1 (COX-1) DMMFP57 MA Inhibitor DMMFP57 RN Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43. DMMFP57 RU https://pubmed.ncbi.nlm.nih.gov/20527891 DMMFP57 DI DMMFP57 DMMFP57 DN Resveratrol Potassium4,-Sulfate DMMFP57 TI TTVKILB DMMFP57 TN Prostaglandin G/H synthase 2 (COX-2) DMMFP57 MA Inhibitor DMMFP57 RN Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43. DMMFP57 RU https://pubmed.ncbi.nlm.nih.gov/20527891 DMMFQR2 DI DMMFQR2 DMMFQR2 DN AG-26 DMMFQR2 TI TTOJ1NF DMMFQR2 TN FMLP-related receptor I (FPR2) DMMFQR2 MA Agonist DMMFQR2 RN Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol. 2010 Feb;77(2):159-70. DMMFQR2 RU https://pubmed.ncbi.nlm.nih.gov/19903830 DMMFWYX DI DMMFWYX DMMFWYX DN 6-(3-Bromo-phenylamino)-1H-pyrimidine-2,4-dione DMMFWYX TI TT2GPK3 DMMFWYX TN DNA topoisomerase (TOP) DMMFWYX MA Inhibitor DMMFWYX RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMMFWYX RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMMFYP9 DI DMMFYP9 DMMFYP9 DN ME bromodomain inhibitor DMMFYP9 TI TTDP48B DMMFYP9 TN Bromodomain-containing protein 2 (BRD2) DMMFYP9 MA Inhibitor DMMFYP9 RN Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science. 2014 Oct 31;346(6209):638-41. DMMFYP9 RU https://pubmed.ncbi.nlm.nih.gov/25323695 DMMG1TA DI DMMG1TA DMMG1TA DN [123I]SB 207710 DMMG1TA TI TT07C3Y DMMG1TA TN 5-HT 4 receptor (HTR4) DMMG1TA MA Antagonist DMMG1TA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMMG1TA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMMG9PV DI DMMG9PV DMMG9PV DN 5-Biphenyl-4-ylethynyl-pyrimidine DMMG9PV TI TTHS256 DMMG9PV TN Metabotropic glutamate receptor 5 (mGluR5) DMMG9PV MA Inhibitor DMMG9PV RN Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. DMMG9PV RU https://pubmed.ncbi.nlm.nih.gov/18550372 DMMGA6K DI DMMGA6K DMMGA6K DN ISIS 11224 DMMGA6K TI TTRE6AX DMMGA6K TN Bcl-x messenger RNA (BCL2L1 mRNA) DMMGA6K RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMMGA6K RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMMGHNA DI DMMGHNA DMMGHNA DN 4-{2-[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic Acid DMMGHNA TI TTZHY6R DMMGHNA TN Glycogen phosphorylase muscle form (GP) DMMGHNA MA Inhibitor DMMGHNA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMMGHNA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMMGK2B DI DMMGK2B DMMGK2B DN 4-Butoxy-N-hydroxycarbamoylmethyl-benzamide DMMGK2B TI TTMX39J DMMGK2B TN Matrix metalloproteinase-1 (MMP-1) DMMGK2B MA Inhibitor DMMGK2B RN Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96. DMMGK2B RU https://pubmed.ncbi.nlm.nih.gov/16220975 DMMGP9X DI DMMGP9X DMMGP9X DN 1,4-dihydroindeno[1,2-c]-pyrazole DMMGP9X TI TT6OEDT DMMGP9X TN Cannabinoid receptor 1 (CB1) DMMGP9X MA Inhibitor DMMGP9X RN Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichl... J Med Chem. 2005 Nov 17;48(23):7351-62. DMMGP9X RU https://pubmed.ncbi.nlm.nih.gov/16279795 DMMGP9X DI DMMGP9X DMMGP9X DN 1,4-dihydroindeno[1,2-c]-pyrazole DMMGP9X TI TTMSFAW DMMGP9X TN Cannabinoid receptor 2 (CB2) DMMGP9X MA Inhibitor DMMGP9X RN Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichl... J Med Chem. 2005 Nov 17;48(23):7351-62. DMMGP9X RU https://pubmed.ncbi.nlm.nih.gov/16279795 DMMGQZ8 DI DMMGQZ8 DMMGQZ8 DN IRL-1722 DMMGQZ8 TI TT3ZTGU DMMGQZ8 TN Endothelin B receptor (EDNRB) DMMGQZ8 MA Inhibitor DMMGQZ8 RN IRL 2500: A potent ETB selective endothelin antagonist, Bioorg. Med. Chem. Lett. 6(19):2323-2328 (1996). DMMGQZ8 RU http://www.sciencedirect.com/science/article/pii/0960894X96004210 DMMGWXQ DI DMMGWXQ DMMGWXQ DN FR-900452 DMMGWXQ TI TTQL5VC DMMGWXQ TN Platelet-activating factor receptor (PTAFR) DMMGWXQ MA Modulator DMMGWXQ RN FR-900452, a specific antagonist of platelet activating factor (PAF) produced by Streptomyces phaeofaciens. I. Taxonomy, fermentation, isolation, a... J Antibiot (Tokyo). 1986 Feb;39(2):198-204. DMMGWXQ RU https://www.ncbi.nlm.nih.gov/pubmed/3082838 DMMH179 DI DMMH179 DMMH179 DN (C8-S)-Hydantocidin 5'-Phosphate DMMH179 TI TTYQ4AE DMMH179 TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DMMH179 MA Inhibitor DMMH179 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMH179 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMH70I DI DMMH70I DMMH70I DN Isosorbide-2-(ethylcarbamate)-5-mononitrate DMMH70I TI TTEB0GD DMMH70I TN Cholinesterase (BCHE) DMMH70I MA Inhibitor DMMH70I RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMMH70I RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMMHD9Z DI DMMHD9Z DMMHD9Z DN N-(6-(trifluoromethyl)-1H-indazol-3-yl)butyramide DMMHD9Z TI TTRSMW9 DMMHD9Z TN Glycogen synthase kinase-3 beta (GSK-3B) DMMHD9Z MA Inhibitor DMMHD9Z RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMMHD9Z RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMMHGIN DI DMMHGIN DMMHGIN DN But-3-enyl-trimethyl-ammonium bromide DMMHGIN TI TT1RS9F DMMHGIN TN Acetylcholinesterase (AChE) DMMHGIN MA Inhibitor DMMHGIN RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMMHGIN RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMMHQDX DI DMMHQDX DMMHQDX DN SNAP-94847 DMMHQDX TI TTNGILX DMMHQDX TN Adrenergic receptor alpha-1A (ADRA1A) DMMHQDX MA Inhibitor DMMHQDX RN Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key frag... J Med Chem. 2007 Aug 9;50(16):3883-90. DMMHQDX RU https://pubmed.ncbi.nlm.nih.gov/17668922 DMMHQDX DI DMMHQDX DMMHQDX DN SNAP-94847 DMMHQDX TI TTEX248 DMMHQDX TN Dopamine D2 receptor (D2R) DMMHQDX MA Inhibitor DMMHQDX RN Synthesis and SAR investigations for novel melanin-concentrating hormone 1 receptor (MCH1) antagonists part 2: A hybrid strategy combining key frag... J Med Chem. 2007 Aug 9;50(16):3883-90. DMMHQDX RU https://pubmed.ncbi.nlm.nih.gov/17668922 DMMHQE8 DI DMMHQE8 DMMHQE8 DN N-Hydroxy-4-naphthalen-2-yl-benzamide DMMHQE8 TI TT2J34L DMMHQE8 TN Arachidonate 5-lipoxygenase (5-LOX) DMMHQE8 MA Inhibitor DMMHQE8 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMMHQE8 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMMHQL4 DI DMMHQL4 DMMHQL4 DN PF-04475270 DMMHQL4 TI TT79WV3 DMMHQL4 TN Prostaglandin E2 receptor EP4 (PTGER4) DMMHQL4 MA Agonist DMMHQL4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). DMMHQL4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343 DMMHQRT DI DMMHQRT DMMHQRT DN N-[4'-(trifluoromethyl)-4-biphenylyl]urea DMMHQRT TI TTBGTCW DMMHQRT TN Kinesin spindle messenger RNA (KIF11 mRNA) DMMHQRT MA Inhibitor DMMHQRT RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMMHQRT RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMMHQYB DI DMMHQYB DMMHQYB DN phosphatidyl (3,5) inositol biphosphate DMMHQYB TI TTZWC8B DMMHQYB TN Two pore calcium channel protein 2 (TPC2) DMMHQYB MA Activator DMMHQYB RN TPC proteins are phosphoinositide- activated sodium-selective ion channels in endosomes and lysosomes. Cell. 2012 Oct 12;151(2):372-83. DMMHQYB RU https://pubmed.ncbi.nlm.nih.gov/23063126 DMMHQYB DI DMMHQYB DMMHQYB DN phosphatidyl (3,5) inositol biphosphate DMMHQYB TI TT9XBVO DMMHQYB TN Mucolipin-1 (TRPML1) DMMHQYB MA Activator DMMHQYB RN PI(3,5)P(2) controls membrane trafficking by direct activation of mucolipin Ca(2+) release channels in the endolysosome. Nat Commun. 2010 Jul 13;1:38. DMMHQYB RU https://pubmed.ncbi.nlm.nih.gov/20802798 DMMHQYB DI DMMHQYB DMMHQYB DN phosphatidyl (3,5) inositol biphosphate DMMHQYB TI TTODQE2 DMMHQYB TN Two pore calcium channel protein 1 (TPC1) DMMHQYB MA Activator DMMHQYB RN The voltage-gated sodium channel TPC1 confers endolysosomal excitability. Nat Chem Biol. 2014 Jun;10(6):463-9. DMMHQYB RU https://pubmed.ncbi.nlm.nih.gov/24776928 DMMHRVO DI DMMHRVO DMMHRVO DN 6-(3-Hydroxy-phenyl)-naphthalen-1-ol DMMHRVO TI TTOM3J0 DMMHRVO TN Estrogen receptor beta (ESR2) DMMHRVO MA Inhibitor DMMHRVO RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMMHRVO RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMMHRVO DI DMMHRVO DMMHRVO DN 6-(3-Hydroxy-phenyl)-naphthalen-1-ol DMMHRVO TI TTZAYWL DMMHRVO TN Estrogen receptor (ESR) DMMHRVO MA Inhibitor DMMHRVO RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMMHRVO RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMMHSYA DI DMMHSYA DMMHSYA DN [3H]GR65630 DMMHSYA TI TTPC4TU DMMHSYA TN 5-HT 3A receptor (HTR3A) DMMHSYA MA Antagonist DMMHSYA RN Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci. 2007 Jul;104(3):263-73. DMMHSYA RU https://pubmed.ncbi.nlm.nih.gov/17652911 DMMHSYV DI DMMHSYV DMMHSYV DN 2-phenyl-9H-indeno[2,1-d]pyrimidine DMMHSYV TI TTGP7BY DMMHSYV TN Monoamine oxidase type B (MAO-B) DMMHSYV MA Inhibitor DMMHSYV RN Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71. DMMHSYV RU https://pubmed.ncbi.nlm.nih.gov/17910428 DMMHSYV DI DMMHSYV DMMHSYV DN 2-phenyl-9H-indeno[2,1-d]pyrimidine DMMHSYV TI TT3WG5C DMMHSYV TN Monoamine oxidase type A (MAO-A) DMMHSYV MA Inhibitor DMMHSYV RN Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71. DMMHSYV RU https://pubmed.ncbi.nlm.nih.gov/17910428 DMMHU8G DI DMMHU8G DMMHU8G DN chlordane DMMHU8G TI TTPNQAC DMMHU8G TN Estrogen-related receptor-alpha (ESRRA) DMMHU8G MA Antagonist DMMHU8G RN Two organochlorine pesticides, toxaphene and chlordane, are antagonists for estrogen-related receptor alpha-1 orphan receptor. Cancer Res. 1999 Sep 15;59(18):4519-24. DMMHU8G RU https://pubmed.ncbi.nlm.nih.gov/10493499 DMMHYQ4 DI DMMHYQ4 DMMHYQ4 DN LG-121071 DMMHYQ4 TI TTKPW01 DMMHYQ4 TN Androgen receptor messenger RNA (AR mRNA) DMMHYQ4 MA Inhibitor DMMHYQ4 RN Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem. 2007 May 17;50(10):2486-96. DMMHYQ4 RU https://pubmed.ncbi.nlm.nih.gov/17439112 DMMI0UC DI DMMI0UC DMMI0UC DN 3-(thiophen-3-yl)-1H-indol-6-amine DMMI0UC TI TTTB4UP DMMI0UC TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMMI0UC MA Inhibitor DMMI0UC RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMMI0UC RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMMI1H0 DI DMMI1H0 DMMI1H0 DN KKHT-10609 DMMI1H0 TI TT729IR DMMI1H0 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMMI1H0 MA Inhibitor DMMI1H0 RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DMMI1H0 RU https://pubmed.ncbi.nlm.nih.gov/17035033 DMMI4H3 DI DMMI4H3 DMMI4H3 DN 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMMI4H3 TI TTJQOD7 DMMI4H3 TN 5-HT 2A receptor (HTR2A) DMMI4H3 MA Inhibitor DMMI4H3 RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMMI4H3 RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMMI4H3 DI DMMI4H3 DMMI4H3 DN 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMMI4H3 TI TTGP7BY DMMI4H3 TN Monoamine oxidase type B (MAO-B) DMMI4H3 MA Inhibitor DMMI4H3 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMMI4H3 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMMI4H3 DI DMMI4H3 DMMI4H3 DN 5-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMMI4H3 TI TT3WG5C DMMI4H3 TN Monoamine oxidase type A (MAO-A) DMMI4H3 MA Inhibitor DMMI4H3 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMMI4H3 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMMI8X4 DI DMMI8X4 DMMI8X4 DN N-butyl-4-methyl-3,4-dihydroquinazolin-2-amine DMMI8X4 TI TTRUFDT DMMI8X4 TN 5-HT 5A receptor (HTR5A) DMMI8X4 MA Inhibitor DMMI8X4 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration. Bioorg Med Chem Lett. 2008 Jan 1;18(1):262-6. DMMI8X4 RU https://pubmed.ncbi.nlm.nih.gov/18023344 DMMI9JE DI DMMI9JE DMMI9JE DN PMID22984835C4 DMMI9JE TI TTZ1DT0 DMMI9JE TN P2Y purinoceptor 12 (P2RY12) DMMI9JE MA Antagonist DMMI9JE RN Identification of high-affinity P2Y antagonists based on a phenylpyrazole glutamic acid piperazine backbone. J Med Chem. 2012 Oct 25;55(20):8615-29. DMMI9JE RU https://pubmed.ncbi.nlm.nih.gov/22984835 DMMIA36 DI DMMIA36 DMMIA36 DN 4-chloro-1-guanidino-7-isoquinolinesulphonamide DMMIA36 TI TTGY7WI DMMIA36 TN Urokinase-type plasminogen activator (PLAU) DMMIA36 MA Inhibitor DMMIA36 RN Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. DMMIA36 RU https://pubmed.ncbi.nlm.nih.gov/17447747 DMMIA38 DI DMMIA38 DMMIA38 DN kassinin DMMIA38 TI TTZPO1L DMMIA38 TN Substance-P receptor (TACR1) DMMIA38 MA Agonist DMMIA38 RN The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7. DMMIA38 RU https://pubmed.ncbi.nlm.nih.gov/8702757 DMMIA38 DI DMMIA38 DMMIA38 DN kassinin DMMIA38 TI TTBPGLU DMMIA38 TN Neuromedin-K receptor (TACR3) DMMIA38 MA Agonist DMMIA38 RN The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7. DMMIA38 RU https://pubmed.ncbi.nlm.nih.gov/8702757 DMMIB0R DI DMMIB0R DMMIB0R DN 4-phenyl-6-propylpyrimidine-2-carbonitrile DMMIB0R TI TTDZN01 DMMIB0R TN Cathepsin K (CTSK) DMMIB0R MA Inhibitor DMMIB0R RN 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4447-50. DMMIB0R RU https://pubmed.ncbi.nlm.nih.gov/20594841 DMMIDCG DI DMMIDCG DMMIDCG DN KNI-10316 DMMIDCG TI TTXMNHO DMMIDCG TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMMIDCG MA Inhibitor DMMIDCG RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMMIDCG RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMMIGXO DI DMMIGXO DMMIGXO DN 2-cyclohexylamino-pyrimidine-4-carbonitrile DMMIGXO TI TTDZN01 DMMIGXO TN Cathepsin K (CTSK) DMMIGXO MA Inhibitor DMMIGXO RN 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. J Med Chem. 2007 Feb 22;50(4):591-4. DMMIGXO RU https://pubmed.ncbi.nlm.nih.gov/17256925 DMMILJS DI DMMILJS DMMILJS DN 2-hydroxyoctanoic acid DMMILJS TI TT8WFXV DMMILJS TN Hydroxycarboxylic acid receptor 3 (HCAR3) DMMILJS MA Agonist DMMILJS RN Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J Biol Chem. 2009 Aug 14;284(33):21928-33. DMMILJS RU https://pubmed.ncbi.nlm.nih.gov/19561068 DMMIPZ8 DI DMMIPZ8 DMMIPZ8 DN (3-Bromo-phenyl)-quinazolin-4-yl-amine DMMIPZ8 TI TTGKNB4 DMMIPZ8 TN Epidermal growth factor receptor (EGFR) DMMIPZ8 MA Inhibitor DMMIPZ8 RN Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28. DMMIPZ8 RU https://pubmed.ncbi.nlm.nih.gov/8632415 DMMISH6 DI DMMISH6 DMMISH6 DN KNI-10006 DMMISH6 TI TTH9VL3 DMMISH6 TN Plasmodium Plasmepsin 1 (Malaria PLA1) DMMISH6 MA Inhibitor DMMISH6 RN alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49. DMMISH6 RU https://pubmed.ncbi.nlm.nih.gov/19635672 DMMISH6 DI DMMISH6 DMMISH6 DN KNI-10006 DMMISH6 TI TTPT2QI DMMISH6 TN Cathepsin D (CTSD) DMMISH6 MA Inhibitor DMMISH6 RN alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49. DMMISH6 RU https://pubmed.ncbi.nlm.nih.gov/19635672 DMMISH6 DI DMMISH6 DMMISH6 DN KNI-10006 DMMISH6 TI TTXMNHO DMMISH6 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMMISH6 MA Inhibitor DMMISH6 RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMMISH6 RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMMITAJ DI DMMITAJ DMMITAJ DN 8-cyclopentyltheophylline DMMITAJ TI TTK25J1 DMMITAJ TN Adenosine A1 receptor (ADORA1) DMMITAJ MA Antagonist DMMITAJ RN Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. Biochem Pharmacol. 1998 Dec 1;56(11):1437-45. DMMITAJ RU https://pubmed.ncbi.nlm.nih.gov/9827575 DMMIWHV DI DMMIWHV DMMIWHV DN GSK494581A DMMIWHV TI TTNET8J DMMIWHV TN G-protein coupled receptor 55 (GPR55) DMMIWHV MA Agonist DMMIWHV RN Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46. DMMIWHV RU https://pubmed.ncbi.nlm.nih.gov/21233197 DMMIZWE DI DMMIZWE DMMIZWE DN piperidine-4-sulphonic acid DMMIZWE TI TTQMXLS DMMIZWE TN GABA(A) receptor rho2 (GABRR2) DMMIZWE MA Antagonist DMMIZWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DMMIZWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DMMIZWE DI DMMIZWE DMMIZWE DN piperidine-4-sulphonic acid DMMIZWE TI TTBMV1G DMMIZWE TN GABA(A) receptor alpha-2 (GABRA2) DMMIZWE MA Agonist DMMIZWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMMIZWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMMIZWE DI DMMIZWE DMMIZWE DN piperidine-4-sulphonic acid DMMIZWE TI TT4N6D8 DMMIZWE TN GABA(A) receptor rho3 (GABRR3) DMMIZWE MA Antagonist DMMIZWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DMMIZWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DMMIZWE DI DMMIZWE DMMIZWE DN piperidine-4-sulphonic acid DMMIZWE TI TT37EDJ DMMIZWE TN GABA(A) receptor alpha-3 (GABRA3) DMMIZWE MA Agonist DMMIZWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMMIZWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMMIZWE DI DMMIZWE DMMIZWE DN piperidine-4-sulphonic acid DMMIZWE TI TT6XFEU DMMIZWE TN GABA(A) receptor rho1 (GABRR1) DMMIZWE MA Antagonist DMMIZWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DMMIZWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DMMIZWE DI DMMIZWE DMMIZWE DN piperidine-4-sulphonic acid DMMIZWE TI TTEX6LM DMMIZWE TN GABA(A) receptor gamma-3 (GABRG3) DMMIZWE MA Agonist DMMIZWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMMIZWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMMIZWE DI DMMIZWE DMMIZWE DN piperidine-4-sulphonic acid DMMIZWE TI TTNZPQ1 DMMIZWE TN GABA(A) receptor alpha-5 (GABRA5) DMMIZWE MA Agonist DMMIZWE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMMIZWE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMMJ4I5 DI DMMJ4I5 DMMJ4I5 DN Bbs-Arg-(D-Pip)-Gly-(EQKLISEEDL)-Gly-Hir DMMJ4I5 TI TT6L509 DMMJ4I5 TN Coagulation factor IIa (F2) DMMJ4I5 MA Inhibitor DMMJ4I5 RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMMJ4I5 RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMMJ613 DI DMMJ613 DMMJ613 DN 2,2',4,4'-tetrahydroxy-6'-methoxychalcone DMMJ613 TI TTULVH8 DMMJ613 TN Tyrosinase (TYR) DMMJ613 MA Inhibitor DMMJ613 RN Synthesis and evaluation of 2',4',6'-trihydroxychalcones as a new class of tyrosinase inhibitors. Bioorg Med Chem. 2007 Mar 15;15(6):2396-402. DMMJ613 RU https://pubmed.ncbi.nlm.nih.gov/17267225 DMMJ635 DI DMMJ635 DMMJ635 DN Bis(3-Fluorophenyl)-ketone]thiosemicarbazone DMMJ635 TI TT36ETB DMMJ635 TN Cathepsin L (CTSL) DMMJ635 MA Inhibitor DMMJ635 RN Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9. DMMJ635 RU https://pubmed.ncbi.nlm.nih.gov/20089402 DMMJ6NS DI DMMJ6NS DMMJ6NS DN Imetit DMMJ6NS TI TT9JNIC DMMJ6NS TN Histamine H3 receptor (H3R) DMMJ6NS MA Agonist DMMJ6NS RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMMJ6NS RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMMJ6NS DI DMMJ6NS DMMJ6NS DN Imetit DMMJ6NS TI TTXJ178 DMMJ6NS TN Histamine H4 receptor (H4R) DMMJ6NS MA Agonist DMMJ6NS RN Histamine excites neonatal rat sympathetic preganglionic neurons in vitro via activation of H1 receptors. J Neurophysiol. 2006 Apr;95(4):2492-500. DMMJ6NS RU https://pubmed.ncbi.nlm.nih.gov/16354729 DMMJ9YN DI DMMJ9YN DMMJ9YN DN H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H DMMJ9YN TI TTKWM86 DMMJ9YN TN Opioid receptor mu (MOP) DMMJ9YN MA Inhibitor DMMJ9YN RN New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. DMMJ9YN RU https://pubmed.ncbi.nlm.nih.gov/16183273 DMMJ9YN DI DMMJ9YN DMMJ9YN DN H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H DMMJ9YN TI TT27RFC DMMJ9YN TN Opioid receptor delta (OPRD1) DMMJ9YN MA Inhibitor DMMJ9YN RN New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. DMMJ9YN RU https://pubmed.ncbi.nlm.nih.gov/16183273 DMMJC5E DI DMMJC5E DMMJC5E DN 1-(3-Nitro-phenyl)-piperazine DMMJC5E TI TT6MSOK DMMJC5E TN 5-HT 1D receptor (HTR1D) DMMJC5E MA Inhibitor DMMJC5E RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DMMJC5E RU https://pubmed.ncbi.nlm.nih.gov/2565400 DMMJC5E DI DMMJC5E DMMJC5E DN 1-(3-Nitro-phenyl)-piperazine DMMJC5E TI TTSQIFT DMMJC5E TN 5-HT 1A receptor (HTR1A) DMMJC5E MA Inhibitor DMMJC5E RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DMMJC5E RU https://pubmed.ncbi.nlm.nih.gov/2565400 DMMJDXT DI DMMJDXT DMMJDXT DN FR239087 DMMJDXT TI TTLP57V DMMJDXT TN Adenosine deaminase (ADA) DMMJDXT MA Inhibitor DMMJDXT RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMMJDXT RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMMJENF DI DMMJENF DMMJENF DN 2-phenyl-N,N-bis(o-tolylthiomethyl)ethanamine DMMJENF TI TTX4RTB DMMJENF TN Melanin-concentrating hormone receptor 1 (MCHR1) DMMJENF MA Inhibitor DMMJENF RN Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem. 2008 Feb 14;51(3):581-8. DMMJENF RU https://pubmed.ncbi.nlm.nih.gov/18198821 DMMJFTR DI DMMJFTR DMMJFTR DN Non-PEGylated butyrylcholinesterase DMMJFTR TI TTEB0GD DMMJFTR TN Cholinesterase (BCHE) DMMJFTR MA Modulator DMMJFTR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2471). DMMJFTR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2471 DMMJI4R DI DMMJI4R DMMJI4R DN 4-(1H-Inden-1-ylmethyl)-phenylamine DMMJI4R TI TTJS8PY DMMJI4R TN 5-HT 6 receptor (HTR6) DMMJI4R MA Inhibitor DMMJI4R RN Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91. DMMJI4R RU https://pubmed.ncbi.nlm.nih.gov/15808453 DMMJP9D DI DMMJP9D DMMJP9D DN 3-(2-Dimethylamino-propyl)-1H-indol-4-ol DMMJP9D TI TTWJBZ5 DMMJP9D TN 5-HT 2C receptor (HTR2C) DMMJP9D MA Inhibitor DMMJP9D RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMMJP9D RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMMJP9D DI DMMJP9D DMMJP9D DN 3-(2-Dimethylamino-propyl)-1H-indol-4-ol DMMJP9D TI TTJQOD7 DMMJP9D TN 5-HT 2A receptor (HTR2A) DMMJP9D MA Inhibitor DMMJP9D RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMMJP9D RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMMJP9D DI DMMJP9D DMMJP9D DN 3-(2-Dimethylamino-propyl)-1H-indol-4-ol DMMJP9D TI TT0K1SC DMMJP9D TN 5-HT 2B receptor (HTR2B) DMMJP9D MA Inhibitor DMMJP9D RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMMJP9D RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMMJZYC DI DMMJZYC DMMJZYC DN CH-223191 DMMJZYC TI TT037IE DMMJZYC TN Aryl hydrocarbon receptor (AHR) DMMJZYC MA Antagonist DMMJZYC RN Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol. 2006 Jun;69(6):1871-8. DMMJZYC RU https://pubmed.ncbi.nlm.nih.gov/16540597 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TTO6LI7 DMMK7XU TN Glutamate receptor ionotropic kainate 5 (GRIK5) DMMK7XU MA Agonist DMMK7XU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454). DMMK7XU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TTNP6O2 DMMK7XU TN Glutamate receptor ionotropic kainate 3 (GluK3) DMMK7XU MA Agonist DMMK7XU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 452). DMMK7XU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=452 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TTQV6BO DMMK7XU TN Glutamate receptor ionotropic kainate 4 (GluK4) DMMK7XU MA Agonist DMMK7XU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453). DMMK7XU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TT0K5RG DMMK7XU TN Glutamate receptor ionotropic kainate 2 (GRIK2) DMMK7XU MA Agonist DMMK7XU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451). DMMK7XU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TT0MYE2 DMMK7XU TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMMK7XU MA Agonist DMMK7XU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMMK7XU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TTVPQTF DMMK7XU TN Glutamate receptor AMPA 1 (GRIA1) DMMK7XU MA Inhibitor DMMK7XU RN 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8. DMMK7XU RU https://pubmed.ncbi.nlm.nih.gov/18811139 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TTAN6JD DMMK7XU TN Glutamate receptor AMPA (GRIA) DMMK7XU MA Inhibitor DMMK7XU RN 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8. DMMK7XU RU https://pubmed.ncbi.nlm.nih.gov/18811139 DMMK7XU DI DMMK7XU DMMK7XU DN [3H]kainate DMMK7XU TI TTJFY5U DMMK7XU TN Adenosine A3 receptor (ADORA3) DMMK7XU MA Inhibitor DMMK7XU RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMMK7XU RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMMK9RC DI DMMK9RC DMMK9RC DN 4-(4-Chlorophenyl)-5-p-tolylisothiazole DMMK9RC TI TT8NGED DMMK9RC TN Prostaglandin G/H synthase 1 (COX-1) DMMK9RC MA Inhibitor DMMK9RC RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMMK9RC RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMMKBFN DI DMMKBFN DMMKBFN DN benzoquinazolinone 12 DMMKBFN TI TTOXS3C DMMKBFN TN Muscarinic acetylcholine receptor (CHRM) DMMKBFN MA Modulator (allosteric modulator) DMMKBFN RN Mechanistic insights into allosteric structure-function relationships at the M1 muscarinic acetylcholine receptor. J Biol Chem. 2014 Nov 28;289(48):33701-11. DMMKBFN RU https://pubmed.ncbi.nlm.nih.gov/25326383 DMMKDEZ DI DMMKDEZ DMMKDEZ DN Beta-1-C-Butyl-1-deoxygalactonojirimycin DMMKDEZ TI TTIS03D DMMKDEZ TN Alpha-galactosidase A (GLA) DMMKDEZ MA Inhibitor DMMKDEZ RN 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem. 2010 Jun 1;18(11):3790-4. DMMKDEZ RU https://pubmed.ncbi.nlm.nih.gov/20457528 DMMKGT4 DI DMMKGT4 DMMKGT4 DN analog 3 (Vlattas et al., 1996) DMMKGT4 TI TTE5J6X DMMKGT4 TN Diphosphomevalonate decarboxylase (MVD) DMMKGT4 MA Inhibitor DMMKGT4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 642). DMMKGT4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642 DMMKH72 DI DMMKH72 DMMKH72 DN Mulberrofuran D DMMKH72 TI TTELIN2 DMMKH72 TN PTPN1 messenger RNA (PTPN1 mRNA) DMMKH72 MA Inhibitor DMMKH72 RN Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61. DMMKH72 RU https://pubmed.ncbi.nlm.nih.gov/19846295 DMMKJYG DI DMMKJYG DMMKJYG DN 2-Amino-6-(naphthalene-2-sulfonyl)-benzonitrile DMMKJYG TI TT84ETX DMMKJYG TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMMKJYG MA Inhibitor DMMKJYG RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMMKJYG RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMMKSGL DI DMMKSGL DMMKSGL DN N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine DMMKSGL TI TT5KPZR DMMKSGL TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMMKSGL MA Inhibitor DMMKSGL RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMMKSGL RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMMKSGL DI DMMKSGL DMMKSGL DN N-ethyl-N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine DMMKSGL TI TT4H1MQ DMMKSGL TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMMKSGL MA Inhibitor DMMKSGL RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMMKSGL RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMMKYGP DI DMMKYGP DMMKYGP DN JWH-229 DMMKYGP TI TT6OEDT DMMKYGP TN Cannabinoid receptor 1 (CB1) DMMKYGP MA Inhibitor DMMKYGP RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DMMKYGP RU https://pubmed.ncbi.nlm.nih.gov/19143566 DMMKYGP DI DMMKYGP DMMKYGP DN JWH-229 DMMKYGP TI TTMSFAW DMMKYGP TN Cannabinoid receptor 2 (CB2) DMMKYGP MA Inhibitor DMMKYGP RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DMMKYGP RU https://pubmed.ncbi.nlm.nih.gov/19143566 DMML0VP DI DMML0VP DMML0VP DN 2-(3-iodophenyl)histamine DMML0VP TI TTTIBOJ DMML0VP TN Histamine H1 receptor (H1R) DMML0VP MA Agonist DMML0VP RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DMML0VP RU https://pubmed.ncbi.nlm.nih.gov/12626648 DMML1HC DI DMML1HC DMML1HC DN S6716 DMML1HC TI TTW5UDX DMML1HC TN Urotensin II receptor (UTS2R) DMML1HC MA Antagonist DMML1HC RN Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem. 2002 Apr 25;45(9):1799-805. DMML1HC RU https://pubmed.ncbi.nlm.nih.gov/11960491 DMML1J4 DI DMML1J4 DMML1J4 DN N-9xxx DMML1J4 TI TTEP6RV DMML1J4 TN Glutathione reductase (GR) DMML1J4 MA Modulator DMML1J4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2613). DMML1J4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2613 DMML3XI DI DMML3XI DMML3XI DN 2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine DMML3XI TI TTJS8PY DMML3XI TN 5-HT 6 receptor (HTR6) DMML3XI MA Inhibitor DMML3XI RN Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87. DMML3XI RU https://pubmed.ncbi.nlm.nih.gov/19159187 DMML9AY DI DMML9AY DMML9AY DN Indolin-2-one deriv. 4b DMML9AY TI TTUTJGQ DMML9AY TN Vascular endothelial growth factor receptor 2 (KDR) DMML9AY MA Inhibitor DMML9AY RN Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. J Med Chem. 2000 Jul 13;43(14):2655-63. DMML9AY RU https://pubmed.ncbi.nlm.nih.gov/10893303 DMMLCSG DI DMMLCSG DMMLCSG DN 1-(4-Bromo-2,5-difluorophenyl)-2-aminopropane DMMLCSG TI TTJQOD7 DMMLCSG TN 5-HT 2A receptor (HTR2A) DMMLCSG MA Inhibitor DMMLCSG RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DMMLCSG RU https://pubmed.ncbi.nlm.nih.gov/18296055 DMMLDOZ DI DMMLDOZ DMMLDOZ DN 3-[(2-methyl-4-thiazolyl)ethynyl]benzamide DMMLDOZ TI TTHS256 DMMLDOZ TN Metabotropic glutamate receptor 5 (mGluR5) DMMLDOZ MA Inhibitor DMMLDOZ RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMMLDOZ RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMMLSZ4 DI DMMLSZ4 DMMLSZ4 DN TENOSAL DMMLSZ4 TI TTVKILB DMMLSZ4 TN Prostaglandin G/H synthase 2 (COX-2) DMMLSZ4 MA Inhibitor DMMLSZ4 RN US patent application no. 6,274,627, Conjugates of dithiocarbamate disulfides with pharmacologically active agents and uses therefor. DMMLSZ4 RU http://www.google.com/patents/US6274627 DMMN0GO DI DMMN0GO DMMN0GO DN EDP-21 DMMN0GO TI TT0HD6V DMMN0GO TN Leptin receptor (LEPR) DMMN0GO MA Agonist DMMN0GO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DMMN0GO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DMMN42V DI DMMN42V DMMN42V DN MRS923 DMMN42V TI TTNE7KG DMMN42V TN Adenosine A2b receptor (ADORA2B) DMMN42V MA Antagonist DMMN42V RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMMN42V RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMMN42V DI DMMN42V DMMN42V DN MRS923 DMMN42V TI TTK25J1 DMMN42V TN Adenosine A1 receptor (ADORA1) DMMN42V MA Antagonist DMMN42V RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMMN42V RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMMN5TA DI DMMN5TA DMMN5TA DN 1-Benzo[b]thiophen-2-yl-cycloheptylamine DMMN5TA TI TTVBI8W DMMN5TA TN Dopamine transporter (DAT) DMMN5TA MA Inhibitor DMMN5TA RN Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93. DMMN5TA RU https://pubmed.ncbi.nlm.nih.gov/8098066 DMMNEJB DI DMMNEJB DMMNEJB DN PF-454583 DMMNEJB TI TTNT7K8 DMMNEJB TN Nociceptin receptor (OPRL1) DMMNEJB MA Antagonist DMMNEJB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). DMMNEJB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 DMMNH4K DI DMMNH4K DMMNH4K DN 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione DMMNH4K TI TTQ13Z5 DMMNH4K TN Muscarinic acetylcholine receptor M3 (CHRM3) DMMNH4K MA Inhibitor DMMNH4K RN Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62. DMMNH4K RU https://pubmed.ncbi.nlm.nih.gov/2785211 DMMNH4K DI DMMNH4K DMMNH4K DN 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione DMMNH4K TI TTYEG6Q DMMNH4K TN Muscarinic acetylcholine receptor M2 (CHRM2) DMMNH4K MA Inhibitor DMMNH4K RN Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62. DMMNH4K RU https://pubmed.ncbi.nlm.nih.gov/2785211 DMMNH4K DI DMMNH4K DMMNH4K DN 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione DMMNH4K TI TTZ9SOR DMMNH4K TN Muscarinic acetylcholine receptor M1 (CHRM1) DMMNH4K MA Inhibitor DMMNH4K RN Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62. DMMNH4K RU https://pubmed.ncbi.nlm.nih.gov/2785211 DMMNH4K DI DMMNH4K DMMNH4K DN 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione DMMNH4K TI TTH18TF DMMNH4K TN Muscarinic acetylcholine receptor M5 (CHRM5) DMMNH4K MA Inhibitor DMMNH4K RN Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62. DMMNH4K RU https://pubmed.ncbi.nlm.nih.gov/2785211 DMMNH4K DI DMMNH4K DMMNH4K DN 1'-Benzyl-3-phenyl-[3,4']bipiperidinyl-2,6-dione DMMNH4K TI TTQ3JTF DMMNH4K TN Muscarinic acetylcholine receptor M4 (CHRM4) DMMNH4K MA Inhibitor DMMNH4K RN Synthesis and biological evaluation of [125I]- and [123I]-4-iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem. 1989 May;32(5):1057-62. DMMNH4K RU https://pubmed.ncbi.nlm.nih.gov/2785211 DMMNIRC DI DMMNIRC DMMNIRC DN N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine DMMNIRC TI TT5KPZR DMMNIRC TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMMNIRC MA Inhibitor DMMNIRC RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMMNIRC RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMMNIRC DI DMMNIRC DMMNIRC DN N-methyl-4-(pyridin-3-yl)but-3-yn-1-amine DMMNIRC TI TT4H1MQ DMMNIRC TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMMNIRC MA Inhibitor DMMNIRC RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMMNIRC RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMMNQ1B DI DMMNQ1B DMMNQ1B DN PB28 DMMNQ1B TI TTTPE1L DMMNQ1B TN HUMAN opioid receptor sigma 1 (OPRS1) DMMNQ1B MA Modulator DMMNQ1B RN A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DMMNQ1B RU https://www.nature.com/articles/s41586-020-2286-9 DMMNQ1B DI DMMNQ1B DMMNQ1B DN PB28 DMMNQ1B TI TTIS0R2 DMMNQ1B TN HUMAN sigma intracellular receptor 2 (TMEM97) DMMNQ1B MA Modulator DMMNQ1B RN A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DMMNQ1B RU https://www.nature.com/articles/s41586-020-2286-9 DMMNQE3 DI DMMNQE3 DMMNQE3 DN ACH-702 DMMNQE3 TI TTE72ID DMMNQE3 TN Haemophilus influenzae DNA gyrase A (Hae-influ gyrA) DMMNQE3 MA Inhibitor DMMNQE3 RN In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrob Agents Chemother. 2010 Aug;54(8):3478-80. DMMNQE3 RU https://pubmed.ncbi.nlm.nih.gov/20516287 DMMNVGJ DI DMMNVGJ DMMNVGJ DN VUF 5207 DMMNVGJ TI TT9JNIC DMMNVGJ TN Histamine H3 receptor (H3R) DMMNVGJ MA Agonist DMMNVGJ RN Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J Pharmacol Exp Ther. 2001 Dec;299(3):908-14. DMMNVGJ RU https://pubmed.ncbi.nlm.nih.gov/11714875 DMMNYXK DI DMMNYXK DMMNYXK DN Phenylcarbamic Acid Biphenyl-3-yl Ester DMMNYXK TI TTDP1UC DMMNYXK TN Fatty acid amide hydrolase (FAAH) DMMNYXK MA Inhibitor DMMNYXK RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMMNYXK RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMMO6PH DI DMMO6PH DMMO6PH DN RO 116 1148 DMMO6PH TI TT07C3Y DMMO6PH TN 5-HT 4 receptor (HTR4) DMMO6PH MA Antagonist DMMO6PH RN A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J Biol Chem. 2002 Jul 12;277(28):25502-11. DMMO6PH RU https://pubmed.ncbi.nlm.nih.gov/11976337 DMMO6QI DI DMMO6QI DMMO6QI DN 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMMO6QI TI TTCM4B3 DMMO6QI TN Nitric-oxide synthase endothelial (NOS3) DMMO6QI MA Inhibitor DMMO6QI RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMMO6QI RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMMO6QI DI DMMO6QI DMMO6QI DN 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMMO6QI TI TTZUFI5 DMMO6QI TN Nitric-oxide synthase brain (NOS1) DMMO6QI MA Inhibitor DMMO6QI RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMMO6QI RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMMO6QI DI DMMO6QI DMMO6QI DN 3,4-Dimethyl-pyrrolidin-(2Z)-ylideneamine DMMO6QI TI TTF10I9 DMMO6QI TN Nitric-oxide synthase inducible (NOS2) DMMO6QI MA Inhibitor DMMO6QI RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMMO6QI RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTKYZA9 DMMO75G TN Gastric triacylglycerol lipase (LIPF) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TT26PHO DMMO75G TN Mineralocorticoid receptor (MR) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTXMY0J DMMO75G TN Pancreatic triacylglycerol lipase (PNLIP) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TT7O8ZA DMMO75G TN Lanosterol synthase (LSS) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TT8NGED DMMO75G TN Prostaglandin G/H synthase 1 (COX-1) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTH0KSX DMMO75G TN Rhodopsin (RHO) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTVKILB DMMO75G TN Prostaglandin G/H synthase 2 (COX-2) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTGQA9W DMMO75G TN Apolipoprotein A-II (APOA2) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTRAMF0 DMMO75G TN Plasmodium Cytochrome B (Malaria MT-CYB) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTYRL6O DMMO75G TN Glucocorticoid receptor (NR3C1) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TT3PQ2Y DMMO75G TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTHM0R1 DMMO75G TN Steryl-sulfatase (STS) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTQBR95 DMMO75G TN Stress-activated protein kinase 2a (p38 alpha) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTO8QRU DMMO75G TN Group IIA phospholipase A2 (GIIA sPLA2) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTELIN2 DMMO75G TN PTPN1 messenger RNA (PTPN1 mRNA) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTXT3PU DMMO75G TN Influenza M2 protein (Influ M) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO75G DI DMMO75G DMMO75G DN B-Octylglucoside DMMO75G TI TTF10I9 DMMO75G TN Nitric-oxide synthase inducible (NOS2) DMMO75G MA Inhibitor DMMO75G RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMO75G RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMO8A2 DI DMMO8A2 DMMO8A2 DN CGNLSTCMLGTYTQDFNPKHTFPQTAIGVGAP-amide DMMO8A2 TI TTLWS2O DMMO8A2 TN Calcitonin receptor (CALCR) DMMO8A2 MA Inhibitor DMMO8A2 RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMMO8A2 RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMMO9YR DI DMMO9YR DMMO9YR DN AGTAD[CFWKYC]V DMMO9YR TI TTW5UDX DMMO9YR TN Urotensin II receptor (UTS2R) DMMO9YR MA Inhibitor DMMO9YR RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DMMO9YR RU https://pubmed.ncbi.nlm.nih.gov/20043680 DMMOBPN DI DMMOBPN DMMOBPN DN 1,3-dibenzyl urea DMMOBPN TI TTMI6F5 DMMOBPN TN Transient receptor potential cation channel V1 (TRPV1) DMMOBPN MA Inhibitor DMMOBPN RN Rare dipeptide and urea derivatives from roots of Moringa oleifera as potential anti-inflammatory and antinociceptive agents. Eur J Med Chem. 2009 Jan;44(1):432-6. DMMOBPN RU https://pubmed.ncbi.nlm.nih.gov/18243423 DMMODRE DI DMMODRE DMMODRE DN ND-2110 DMMODRE TI TTKFVXR DMMODRE TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMMODRE MA Inhibitor DMMODRE RN Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. J Med Chem. 2015 Jan 8;58(1):96-110. DMMODRE RU https://pubmed.ncbi.nlm.nih.gov/25479567 DMMOE40 DI DMMOE40 DMMOE40 DN 3-(Prop-2-Ene-1-Sulfinyl)-Propene-1-Thiol DMMOE40 TI TTEP6RV DMMOE40 TN Glutathione reductase (GR) DMMOE40 MA Inhibitor DMMOE40 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMOE40 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMOFKD DI DMMOFKD DMMOFKD DN NU-6102 DMMOFKD TI TT7HF4W DMMOFKD TN Cyclin-dependent kinase 2 (CDK2) DMMOFKD MA Inhibitor DMMOFKD RN Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7. DMMOFKD RU https://pubmed.ncbi.nlm.nih.gov/16942020 DMMOFKD DI DMMOFKD DMMOFKD DN NU-6102 DMMOFKD TI TTTU902 DMMOFKD TN Checkpoint kinase-1 (CHK1) DMMOFKD MA Inhibitor DMMOFKD RN Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7. DMMOFKD RU https://pubmed.ncbi.nlm.nih.gov/16325401 DMMOFKD DI DMMOFKD DMMOFKD DN NU-6102 DMMOFKD TI TTYMGWX DMMOFKD TN PDK-1 messenger RNA (PDK-1 mRNA) DMMOFKD MA Inhibitor DMMOFKD RN Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7. DMMOFKD RU https://pubmed.ncbi.nlm.nih.gov/16325401 DMMOFKD DI DMMOFKD DMMOFKD DN NU-6102 DMMOFKD TI TTRSMW9 DMMOFKD TN Glycogen synthase kinase-3 beta (GSK-3B) DMMOFKD MA Inhibitor DMMOFKD RN Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1353-7. DMMOFKD RU https://pubmed.ncbi.nlm.nih.gov/16325401 DMMOFKD DI DMMOFKD DMMOFKD DN NU-6102 DMMOFKD TI TT0PG8F DMMOFKD TN Cyclin-dependent kinase 4 (CDK4) DMMOFKD MA Inhibitor DMMOFKD RN Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J Med Chem. 2006 Sep 7;49(18):5470-7. DMMOFKD RU https://pubmed.ncbi.nlm.nih.gov/16942020 DMMOH51 DI DMMOH51 DMMOH51 DN WAY-466 DMMOH51 TI TT0MI3F DMMOH51 TN 5-HT 1F receptor (HTR1F) DMMOH51 MA Inhibitor DMMOH51 RN Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. DMMOH51 RU https://pubmed.ncbi.nlm.nih.gov/15658848 DMMOH51 DI DMMOH51 DMMOH51 DN WAY-466 DMMOH51 TI TTK8CXU DMMOH51 TN 5-HT 1B receptor (HTR1B) DMMOH51 MA Inhibitor DMMOH51 RN Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. DMMOH51 RU https://pubmed.ncbi.nlm.nih.gov/15658848 DMMOH51 DI DMMOH51 DMMOH51 DN WAY-466 DMMOH51 TI TTWJBZ5 DMMOH51 TN 5-HT 2C receptor (HTR2C) DMMOH51 MA Inhibitor DMMOH51 RN Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. DMMOH51 RU https://pubmed.ncbi.nlm.nih.gov/15658848 DMMOH51 DI DMMOH51 DMMOH51 DN WAY-466 DMMOH51 TI TTO9X1H DMMOH51 TN 5-HT 7 receptor (HTR7) DMMOH51 MA Inhibitor DMMOH51 RN Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. DMMOH51 RU https://pubmed.ncbi.nlm.nih.gov/15658848 DMMOH51 DI DMMOH51 DMMOH51 DN WAY-466 DMMOH51 TI TTSQIFT DMMOH51 TN 5-HT 1A receptor (HTR1A) DMMOH51 MA Inhibitor DMMOH51 RN Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. DMMOH51 RU https://pubmed.ncbi.nlm.nih.gov/15658848 DMMOH51 DI DMMOH51 DMMOH51 DN WAY-466 DMMOH51 TI TTJS8PY DMMOH51 TN 5-HT 6 receptor (HTR6) DMMOH51 MA Inhibitor DMMOH51 RN Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. DMMOH51 RU https://pubmed.ncbi.nlm.nih.gov/15658848 DMMOH51 DI DMMOH51 DMMOH51 DN WAY-466 DMMOH51 TI TT6MSOK DMMOH51 TN 5-HT 1D receptor (HTR1D) DMMOH51 MA Inhibitor DMMOH51 RN Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6. DMMOH51 RU https://pubmed.ncbi.nlm.nih.gov/15658848 DMMOPAK DI DMMOPAK DMMOPAK DN E-64 DMMOPAK TI TTXMNHO DMMOPAK TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMMOPAK MA Inhibitor DMMOPAK RN Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother. 1998 Sep;42(9):2254-8. DMMOPAK RU https://pubmed.ncbi.nlm.nih.gov/9736544 DMMOPAK DI DMMOPAK DMMOPAK DN E-64 DMMOPAK TI TTUMQVO DMMOPAK TN Cathepsin S (CTSS) DMMOPAK MA Inhibitor DMMOPAK RN Baculoviral expression and characterization of rodent cathepsin S. Protein Expr Purif. 2001 Oct;23(1):45-54. DMMOPAK RU https://pubmed.ncbi.nlm.nih.gov/11570845 DMMOPAK DI DMMOPAK DMMOPAK DN E-64 DMMOPAK TI TTREV7X DMMOPAK TN Virus Cysteine proteinase (Viru VCATH) DMMOPAK MA Inhibitor DMMOPAK RN Characterization of a cysteine proteinase from Taenia crassiceps cysts. Mol Biochem Parasitol. 1997 Apr;85(2):243-53. DMMOPAK RU https://pubmed.ncbi.nlm.nih.gov/9106197 DMMOPAK DI DMMOPAK DMMOPAK DN E-64 DMMOPAK TI TTH9VL3 DMMOPAK TN Plasmodium Plasmepsin 1 (Malaria PLA1) DMMOPAK MA Inhibitor DMMOPAK RN Antimalarial synergy of cysteine and aspartic protease inhibitors. Antimicrob Agents Chemother. 1998 Sep;42(9):2254-8. DMMOPAK RU https://pubmed.ncbi.nlm.nih.gov/9736544 DMMOPUK DI DMMOPUK DMMOPUK DN ISIS 114559 DMMOPUK TI TTY3BRA DMMOPUK TN ZNF217 messenger RNA (ZNF217 mRNA) DMMOPUK RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DMMOPUK RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DMMOV9U DI DMMOV9U DMMOV9U DN ISIS 28477 DMMOV9U TI TT0J32Z DMMOV9U TN Smad7 messenger RNA (Smad7 mRNA) DMMOV9U RN US patent application no. 6,159,697, Antisense modulation of Smad7 expression. DMMOV9U RU http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true DMMP0D8 DI DMMP0D8 DMMP0D8 DN Ac-His-DPhe-Arg-Trp-NH2 DMMP0D8 TI TT0MV2T DMMP0D8 TN Melanocortin receptor 1 (MC1R) DMMP0D8 MA Inhibitor DMMP0D8 RN Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 1997 Jul 4;40(14):2133-9. DMMP0D8 RU https://pubmed.ncbi.nlm.nih.gov/9216831 DMMP0D8 DI DMMP0D8 DMMP0D8 DN Ac-His-DPhe-Arg-Trp-NH2 DMMP0D8 TI TTD0CIQ DMMP0D8 TN Melanocortin receptor 4 (MC4R) DMMP0D8 MA Inhibitor DMMP0D8 RN Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R. J Med Chem. 1997 Jul 4;40(14):2133-9. DMMP0D8 RU https://pubmed.ncbi.nlm.nih.gov/9216831 DMMP0DT DI DMMP0DT DMMP0DT DN Z-Ala-Leu-His-Agly-Ile-Val-OMe DMMP0DT TI TTF2LRI DMMP0DT TN Cathepsin B (CTSB) DMMP0DT MA Inhibitor DMMP0DT RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMMP0DT RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMMP0DT DI DMMP0DT DMMP0DT DN Z-Ala-Leu-His-Agly-Ile-Val-OMe DMMP0DT TI TTDZN01 DMMP0DT TN Cathepsin K (CTSK) DMMP0DT MA Inhibitor DMMP0DT RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMMP0DT RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMMP6YH DI DMMP6YH DMMP6YH DN MJ-451 DMMP6YH TI TT1VOHK DMMP6YH TN Potassium channel unspecific (KC) DMMP6YH MA Modulator DMMP6YH RN Pharmacological characteristics of MJ-451, a new benzopyran- derived ATP-sensitive potassium channel opener, in guinea pig isolated trachea. Pharmacology. 1998 Dec;57(6):314-22. DMMP6YH RU https://www.ncbi.nlm.nih.gov/pubmed/9792972 DMMP7HU DI DMMP7HU DMMP7HU DN 1'-acetoxychavicol acetate DMMP7HU TI TTELV3W DMMP7HU TN Transformation-sensitive protein p120 (TRPA1) DMMP7HU MA Activator DMMP7HU RN Galangal pungent component, 1'-acetoxychavicol acetate, activates TRPA1. Biosci Biotechnol Biochem. 2010;74(8):1694-6. DMMP7HU RU https://pubmed.ncbi.nlm.nih.gov/20699565 DMMP8TR DI DMMP8TR DMMP8TR DN (2S)-2-(BUTYRYLOXY)-3-HYDROXYPROPYL NONANOATE DMMP8TR TI TTYOMFZ DMMP8TR TN Voltage-gated potassium channel (VGKC) DMMP8TR MA Inhibitor DMMP8TR RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMMP8TR RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMMPAWD DI DMMPAWD DMMPAWD DN 5-(6-Methoxynaphthalen-2-yl)pyridin-3-ol DMMPAWD TI TTIQUX7 DMMPAWD TN Steroid 11-beta-hydroxylase (CYP11B1) DMMPAWD MA Inhibitor DMMPAWD RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMMPAWD RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMMPL3D DI DMMPL3D DMMPL3D DN 2-Deoxy-Glucose-6-Phosphate DMMPL3D TI TTZHY6R DMMPL3D TN Glycogen phosphorylase muscle form (GP) DMMPL3D MA Inhibitor DMMPL3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMPL3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMPOEK DI DMMPOEK DMMPOEK DN alpha-ergocryptine DMMPOEK TI TTJS8PY DMMPOEK TN 5-HT 6 receptor (HTR6) DMMPOEK MA Antagonist DMMPOEK RN Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77. DMMPOEK RU https://pubmed.ncbi.nlm.nih.gov/9798944 DMMPXHQ DI DMMPXHQ DMMPXHQ DN C-(1-Azido-Alpha-D-Glucopyranosyl) Formamide DMMPXHQ TI TTZHY6R DMMPXHQ TN Glycogen phosphorylase muscle form (GP) DMMPXHQ MA Inhibitor DMMPXHQ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMMPXHQ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMMQ2L7 DI DMMQ2L7 DMMQ2L7 DN ISIS 183910 DMMQ2L7 TI TTBGTCW DMMQ2L7 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMMQ2L7 RN US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression. DMMQ2L7 RU http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true DMMQ3WX DI DMMQ3WX DMMQ3WX DN Anti-FGFR2 humanized mab DMMQ3WX TI TTGJVQM DMMQ3WX TN Fibroblast growth factor receptor 2 (FGFR2) DMMQ3WX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1809). DMMQ3WX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1809 DMMQ79W DI DMMQ79W DMMQ79W DN 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine DMMQ79W TI TTNE7KG DMMQ79W TN Adenosine A2b receptor (ADORA2B) DMMQ79W MA Inhibitor DMMQ79W RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMMQ79W RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMMQ79W DI DMMQ79W DMMQ79W DN 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine DMMQ79W TI TTM2AOE DMMQ79W TN Adenosine A2a receptor (ADORA2A) DMMQ79W MA Inhibitor DMMQ79W RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMMQ79W RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMMQ79W DI DMMQ79W DMMQ79W DN 8-Bromo-9-(2,3-dihydroxypropyl)-9H-adenine DMMQ79W TI TTK25J1 DMMQ79W TN Adenosine A1 receptor (ADORA1) DMMQ79W MA Inhibitor DMMQ79W RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMMQ79W RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMMQKCV DI DMMQKCV DMMQKCV DN Acurea DMMQKCV TI TTZHY6R DMMQKCV TN Glycogen phosphorylase muscle form (GP) DMMQKCV MA Inhibitor DMMQKCV RN Binding of N-acetyl-N '-beta-D-glucopyranosyl urea and N-benzoyl-N '-beta-D-glucopyranosyl urea to glycogen phosphorylase b: kinetic and crystallographic studies. Eur J Biochem. 2002 Mar;269(6):1684-96. DMMQKCV RU https://pubmed.ncbi.nlm.nih.gov/11895439 DMMQPFE DI DMMQPFE DMMQPFE DN ISIS 29223 DMMQPFE TI TTYMGWX DMMQPFE TN PDK-1 messenger RNA (PDK-1 mRNA) DMMQPFE RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMMQPFE RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMMQXON DI DMMQXON DMMQXON DN N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide DMMQXON TI TT6R7JZ DMMQXON TN Histone deacetylase 1 (HDAC1) DMMQXON MA Inhibitor DMMQXON RN Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. DMMQXON RU https://pubmed.ncbi.nlm.nih.gov/19084395 DMMQXON DI DMMQXON DMMQXON DN N1-(biphenyl-3-yl)-N8-hydroxyoctanediamide DMMQXON TI TT5ZKDI DMMQXON TN Histone deacetylase 6 (HDAC6) DMMQXON MA Inhibitor DMMQXON RN Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. DMMQXON RU https://pubmed.ncbi.nlm.nih.gov/19084395 DMMQY42 DI DMMQY42 DMMQY42 DN Parke-Davis 9 DMMQY42 TI TTXHYV6 DMMQY42 TN Voltage-gated L-type calcium channel (L-CaC) DMMQY42 MA Blocker DMMQY42 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMMQY42 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMMR7DI DI DMMR7DI DMMR7DI DN N-p-Tolyl-1'H-phenothiazine-1'-carboxamide DMMR7DI TI TTEB0GD DMMR7DI TN Cholinesterase (BCHE) DMMR7DI MA Inhibitor DMMR7DI RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMMR7DI RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMMRSZB DI DMMRSZB DMMRSZB DN PMID7473541C21 DMMRSZB TI TTFQEO5 DMMRSZB TN Squalene synthetase (FDFT1) DMMRSZB MA Inhibitor DMMRSZB RN Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60. DMMRSZB RU https://pubmed.ncbi.nlm.nih.gov/7473541 DMMRUVF DI DMMRUVF DMMRUVF DN (S,R)-pseudoxandrine hydrochloride DMMRUVF TI TTEX248 DMMRUVF TN Dopamine D2 receptor (D2R) DMMRUVF MA Inhibitor DMMRUVF RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMMRUVF RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMMRV1N DI DMMRV1N DMMRV1N DN 3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid DMMRV1N TI TTELIN2 DMMRV1N TN PTPN1 messenger RNA (PTPN1 mRNA) DMMRV1N MA Inhibitor DMMRV1N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMRV1N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMRV21 DI DMMRV21 DMMRV21 DN 1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione DMMRV21 TI TTJFY5U DMMRV21 TN Adenosine A3 receptor (ADORA3) DMMRV21 MA Inhibitor DMMRV21 RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMMRV21 RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMMRV21 DI DMMRV21 DMMRV21 DN 1-Benzyl-3-methyl-3,7-dihydro-purine-2,6-dione DMMRV21 TI TTNE7KG DMMRV21 TN Adenosine A2b receptor (ADORA2B) DMMRV21 MA Inhibitor DMMRV21 RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMMRV21 RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMMRWJG DI DMMRWJG DMMRWJG DN NCG21 DMMRWJG TI TT08JVB DMMRWJG TN G-protein coupled receptor 120 (GPR120) DMMRWJG MA Agonist DMMRWJG RN Identification of G protein-coupled receptor 120-selective agonists derived from PPARgamma agonists. J Med Chem. 2008 Dec 11;51(23):7640-4. DMMRWJG RU https://pubmed.ncbi.nlm.nih.gov/19007110 DMMS6D3 DI DMMS6D3 DMMS6D3 DN IN-1166 DMMS6D3 TI TTP4520 DMMS6D3 TN TGF-beta receptor type I (TGFBR1) DMMS6D3 MA Inhibitor DMMS6D3 RN Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7. DMMS6D3 RU https://pubmed.ncbi.nlm.nih.gov/17552507 DMMS6D3 DI DMMS6D3 DMMS6D3 DN IN-1166 DMMS6D3 TI TTQBR95 DMMS6D3 TN Stress-activated protein kinase 2a (p38 alpha) DMMS6D3 MA Inhibitor DMMS6D3 RN Synthesis and biological evaluation of trisubstituted imidazole derivatives as inhibitors of p38alpha mitogen-activated protein kinase. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4006-10. DMMS6D3 RU https://pubmed.ncbi.nlm.nih.gov/18571921 DMMS6D3 DI DMMS6D3 DMMS6D3 DN IN-1166 DMMS6D3 TI TT3IVG2 DMMS6D3 TN JNK2 messenger RNA (JNK2 mRNA) DMMS6D3 MA Inhibitor DMMS6D3 RN Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7. DMMS6D3 RU https://pubmed.ncbi.nlm.nih.gov/17552507 DMMSFEU DI DMMSFEU DMMSFEU DN 2-(1-adamantyl) pyrrolidine DMMSFEU TI TTXT3PU DMMSFEU TN Influenza M2 protein (Influ M) DMMSFEU MA Inhibitor DMMSFEU RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMMSFEU RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMMSI67 DI DMMSI67 DMMSI67 DN 2-(Phenylsulfonamido)acetic Acid DMMSI67 TI TTFBNVI DMMSI67 TN Aldose reductase (AKR1B1) DMMSI67 MA Inhibitor DMMSI67 RN A diverse series of substituted benzenesulfonamides as aldose reductase inhibitors with antioxidant activity: design, synthesis, and in vitro activ... J Med Chem. 2010 Nov 11;53(21):7756-66. DMMSI67 RU https://pubmed.ncbi.nlm.nih.gov/20936791 DMMSK9W DI DMMSK9W DMMSK9W DN 5-(1-Methyl-pyrrolidin-2-yl)-2-phenethyl-pyridine DMMSK9W TI TTF4E0J DMMSK9W TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMMSK9W MA Inhibitor DMMSK9W RN 6-(2-Phenylethyl)nicotine: a novel nicotinic cholinergic receptor ligand. Bioorg Med Chem Lett. 2005 Jul 1;15(13):3237-40. DMMSK9W RU https://pubmed.ncbi.nlm.nih.gov/15925512 DMMSQLC DI DMMSQLC DMMSQLC DN 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea DMMSQLC TI TT8NGED DMMSQLC TN Prostaglandin G/H synthase 1 (COX-1) DMMSQLC MA Inhibitor DMMSQLC RN Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9. DMMSQLC RU https://pubmed.ncbi.nlm.nih.gov/18226898 DMMSQLC DI DMMSQLC DMMSQLC DN 1-(4-(methylsulfonyl)phenyl)-3-p-tolylurea DMMSQLC TI TTVKILB DMMSQLC TN Prostaglandin G/H synthase 2 (COX-2) DMMSQLC MA Inhibitor DMMSQLC RN Design and synthesis of 1,3-diarylurea derivatives as selective cyclooxygenase (COX-2) inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1336-9. DMMSQLC RU https://pubmed.ncbi.nlm.nih.gov/18226898 DMMT05U DI DMMT05U DMMT05U DN GOSSYPETIN DMMT05U TI TT50QJ3 DMMT05U TN Influenza Neuraminidase (Influ NA) DMMT05U MA Inhibitor DMMT05U RN Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorg Med Chem. 2009 Oct 1;17(19):6816-23. DMMT05U RU https://pubmed.ncbi.nlm.nih.gov/19729316 DMMT05U DI DMMT05U DMMT05U DN GOSSYPETIN DMMT05U TI TTSZLWK DMMT05U TN Aromatase (CYP19A1) DMMT05U MA Inhibitor DMMT05U RN Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70. DMMT05U RU https://pubmed.ncbi.nlm.nih.gov/18778944 DMMT2GP DI DMMT2GP DMMT2GP DN TCN-201 DMMT2GP TI TTKJEMQ DMMT2GP TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMMT2GP MA Modulator (allosteric modulator) DMMT2GP RN Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. J Neurosci. 2012 May 2;32(18):6197-208. DMMT2GP RU https://pubmed.ncbi.nlm.nih.gov/22553026 DMMT65J DI DMMT65J DMMT65J DN N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide DMMT65J TI TT1MPAY DMMT65J TN GABA(A) receptor alpha-1 (GABRA1) DMMT65J MA Inhibitor DMMT65J RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMMT65J RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMMT65J DI DMMT65J DMMT65J DN N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide DMMT65J TI TT06RH5 DMMT65J TN GABA(A) receptor gamma-2 (GABRG2) DMMT65J MA Inhibitor DMMT65J RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMMT65J RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMMT65J DI DMMT65J DMMT65J DN N-benzyl-2-(5-nitro-1H-indol-3-yl)-2-oxoacetamide DMMT65J TI TTZA1NY DMMT65J TN GABA(A) receptor beta-2 (GABRB2) DMMT65J MA Inhibitor DMMT65J RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMMT65J RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMMT73G DI DMMT73G DMMT73G DN NSC-640559 DMMT73G TI TTJLP0R DMMT73G TN Quinone reductase 2 (NQO2) DMMT73G MA Inhibitor DMMT73G RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMMT73G RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMMT7WO DI DMMT7WO DMMT7WO DN 5-chloro-6-hydrazinouracil hydrochloride DMMT7WO TI TTO0IB8 DMMT7WO TN Thymidine phosphorylase (TYMP) DMMT7WO MA Inhibitor DMMT7WO RN Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7. DMMT7WO RU https://pubmed.ncbi.nlm.nih.gov/16337119 DMMTG7L DI DMMTG7L DMMTG7L DN 6-(4-chlorophenyl)-4-morpholino-2H-pyran-2-one DMMTG7L TI TTK3PY9 DMMTG7L TN DNA-dependent protein kinase catalytic (PRKDC) DMMTG7L MA Inhibitor DMMTG7L RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMMTG7L RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMMTJE3 DI DMMTJE3 DMMTJE3 DN Zaragozic Acid D DMMTJE3 TI TTFQEO5 DMMTJE3 TN Squalene synthetase (FDFT1) DMMTJE3 MA Inhibitor DMMTJE3 RN Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9. DMMTJE3 RU https://pubmed.ncbi.nlm.nih.gov/8289063 DMMTPK3 DI DMMTPK3 DMMTPK3 DN 135PAM1 DMMTPK3 TI TT64ZVP DMMTPK3 TN Relaxin-3 receptor 1 (RXFP3) DMMTPK3 MA Modulator (allosteric modulator) DMMTPK3 RN In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependency. PLoS One. 2012;7(2):e30792. DMMTPK3 RU https://pubmed.ncbi.nlm.nih.gov/22347403 DMMTQ3N DI DMMTQ3N DMMTQ3N DN N,4-dimethyl-3,4-dihydroquinazolin-2-amine DMMTQ3N TI TTRUFDT DMMTQ3N TN 5-HT 5A receptor (HTR5A) DMMTQ3N MA Inhibitor DMMTQ3N RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration. Bioorg Med Chem Lett. 2008 Jan 1;18(1):262-6. DMMTQ3N RU https://pubmed.ncbi.nlm.nih.gov/18023344 DMMTSL2 DI DMMTSL2 DMMTSL2 DN Talmapimod DMMTSL2 TI TTQBR95 DMMTSL2 TN Stress-activated protein kinase 2a (p38 alpha) DMMTSL2 MA Modulator DMMTSL2 RN Mitogen-activated protein kinases in innate immunity.Nat Rev Immunol.2013 Sep;13(9):679-92. DMMTSL2 RU https://www.ncbi.nlm.nih.gov/pubmed/23954936 DMMTU78 DI DMMTU78 DMMTU78 DN 3-(6-Amino-purin-9-yl)-4-phenethyloxy-butan-2-ol DMMTU78 TI TTLP57V DMMTU78 TN Adenosine deaminase (ADA) DMMTU78 MA Inhibitor DMMTU78 RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMMTU78 RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMMTUON DI DMMTUON DMMTUON DN 3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine DMMTUON TI TTIQUX7 DMMTUON TN Steroid 11-beta-hydroxylase (CYP11B1) DMMTUON MA Inhibitor DMMTUON RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMMTUON RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMMTUON DI DMMTUON DMMTUON DN 3-[5-Ethoxy-indan-(1Z)-ylidenemethyl]-pyridine DMMTUON TI TTSZLWK DMMTUON TN Aromatase (CYP19A1) DMMTUON MA Inhibitor DMMTUON RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMMTUON RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMMTXKO DI DMMTXKO DMMTXKO DN (Z)-1-(pyridazin-3-yl)octadec-9-en-1-one DMMTXKO TI TTDP1UC DMMTXKO TN Fatty acid amide hydrolase (FAAH) DMMTXKO MA Inhibitor DMMTXKO RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMMTXKO RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMMU1CQ DI DMMU1CQ DMMU1CQ DN 2-amino-2-(3-chloro-4-fluorophenyl)acetic acid DMMU1CQ TI TTFK1JQ DMMU1CQ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMMU1CQ MA Inhibitor DMMU1CQ RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMMU1CQ RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMMU2BZ DI DMMU2BZ DMMU2BZ DN 2-(4-aminophenylsulfonamido)acetic acid DMMU2BZ TI TTFBNVI DMMU2BZ TN Aldose reductase (AKR1B1) DMMU2BZ MA Inhibitor DMMU2BZ RN Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors. Bioorg Med Chem. 2008 Apr 1;16(7):3926-32. DMMU2BZ RU https://pubmed.ncbi.nlm.nih.gov/18267362 DMMU5SO DI DMMU5SO DMMU5SO DN 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline DMMU5SO TI TTI7421 DMMU5SO TN Platelet-derived growth factor receptor beta (PDGFRB) DMMU5SO MA Inhibitor DMMU5SO RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMMU5SO RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMMU5SO DI DMMU5SO DMMU5SO DN 7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline DMMU5SO TI TT8FYO9 DMMU5SO TN Platelet-derived growth factor receptor alpha (PDGFRA) DMMU5SO MA Inhibitor DMMU5SO RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMMU5SO RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMMU6WQ DI DMMU6WQ DMMU6WQ DN Tetrahydro-pyrimidin-2-ylideneamine DMMU6WQ TI TTZUFI5 DMMU6WQ TN Nitric-oxide synthase brain (NOS1) DMMU6WQ MA Inhibitor DMMU6WQ RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMMU6WQ RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMMUAW5 DI DMMUAW5 DMMUAW5 DN L-779,976 DMMUAW5 TI TTZ6T9E DMMUAW5 TN Somatostatin receptor type 2 (SSTR2) DMMUAW5 MA Agonist DMMUAW5 RN Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40. DMMUAW5 RU https://pubmed.ncbi.nlm.nih.gov/9784130 DMMUBIF DI DMMUBIF DMMUBIF DN JWH-392 DMMUBIF TI TT6OEDT DMMUBIF TN Cannabinoid receptor 1 (CB1) DMMUBIF MA Inhibitor DMMUBIF RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMMUBIF RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMMUBIF DI DMMUBIF DMMUBIF DN JWH-392 DMMUBIF TI TTMSFAW DMMUBIF TN Cannabinoid receptor 2 (CB2) DMMUBIF MA Inhibitor DMMUBIF RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMMUBIF RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMMUDQ7 DI DMMUDQ7 DMMUDQ7 DN 2-(tert-Butylamino)-3',4'-dichloropentanophenone DMMUDQ7 TI TTVBI8W DMMUDQ7 TN Dopamine transporter (DAT) DMMUDQ7 MA Inhibitor DMMUDQ7 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMMUDQ7 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMMUDQ7 DI DMMUDQ7 DMMUDQ7 DN 2-(tert-Butylamino)-3',4'-dichloropentanophenone DMMUDQ7 TI TT3ROYC DMMUDQ7 TN Serotonin transporter (SERT) DMMUDQ7 MA Inhibitor DMMUDQ7 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMMUDQ7 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMMUDQ7 DI DMMUDQ7 DMMUDQ7 DN 2-(tert-Butylamino)-3',4'-dichloropentanophenone DMMUDQ7 TI TTAWNKZ DMMUDQ7 TN Norepinephrine transporter (NET) DMMUDQ7 MA Inhibitor DMMUDQ7 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMMUDQ7 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMMUE05 DI DMMUE05 DMMUE05 DN 6-Amino-2-(1H-imidazol-4-yl)-hexanoic acid DMMUE05 TI TTP18AY DMMUE05 TN Carboxypeptidase B2 (CPB2) DMMUE05 MA Inhibitor DMMUE05 RN Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P(1)(') group. Bioorg Med Chem Lett. 2004 May 3;14(9):2141-5. DMMUE05 RU https://pubmed.ncbi.nlm.nih.gov/15080996 DMMUFSQ DI DMMUFSQ DMMUFSQ DN TCS 5861528 DMMUFSQ TI TTELV3W DMMUFSQ TN Transformation-sensitive protein p120 (TRPA1) DMMUFSQ MA Inhibitor (gating inhibitor) DMMUFSQ RN Attenuation of mechanical hypersensitivity by an antagonist of the TRPA1 ion channel in diabetic animals. Anesthesiology. 2009 Jul;111(1):147-54. DMMUFSQ RU https://pubmed.ncbi.nlm.nih.gov/19512877 DMMUH98 DI DMMUH98 DMMUH98 DN 9H-beta-Carboline-3-carboxylic acid propyl ester DMMUH98 TI TT1MPAY DMMUH98 TN GABA(A) receptor alpha-1 (GABRA1) DMMUH98 MA Inhibitor DMMUH98 RN beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503. DMMUH98 RU https://pubmed.ncbi.nlm.nih.gov/6300400 DMMUH98 DI DMMUH98 DMMUH98 DN 9H-beta-Carboline-3-carboxylic acid propyl ester DMMUH98 TI TTNJYV2 DMMUH98 TN Gamma-aminobutyric acid receptor (GAR) DMMUH98 MA Inhibitor DMMUH98 RN beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503. DMMUH98 RU https://pubmed.ncbi.nlm.nih.gov/6300400 DMMUH98 DI DMMUH98 DMMUH98 DN 9H-beta-Carboline-3-carboxylic acid propyl ester DMMUH98 TI TT06RH5 DMMUH98 TN GABA(A) receptor gamma-2 (GABRG2) DMMUH98 MA Inhibitor DMMUH98 RN beta-Carbolines as benzodiazepine receptor ligands. 1. Synthesis and benzodiazepine receptor interaction of esters of beta-carboline-3-carboxylic a... J Med Chem. 1983 Apr;26(4):499-503. DMMUH98 RU https://pubmed.ncbi.nlm.nih.gov/6300400 DMMUIQ6 DI DMMUIQ6 DMMUIQ6 DN BBI-11008 DMMUIQ6 TI TT27RFC DMMUIQ6 TN Opioid receptor delta (OPRD1) DMMUIQ6 MA Agonist DMMUIQ6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMMUIQ6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMMUNA7 DI DMMUNA7 DMMUNA7 DN 2-(4-Hydroxy-phenyl)-benzooxazol-5-ol DMMUNA7 TI TTOM3J0 DMMUNA7 TN Estrogen receptor beta (ESR2) DMMUNA7 MA Inhibitor DMMUNA7 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMMUNA7 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMMUNA7 DI DMMUNA7 DMMUNA7 DN 2-(4-Hydroxy-phenyl)-benzooxazol-5-ol DMMUNA7 TI TTZAYWL DMMUNA7 TN Estrogen receptor (ESR) DMMUNA7 MA Inhibitor DMMUNA7 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMMUNA7 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMMUV7R DI DMMUV7R DMMUV7R DN (RS/SR)-2-[1-(4-chlorophenyl)pentyl]piperidine DMMUV7R TI TTVBI8W DMMUV7R TN Dopamine transporter (DAT) DMMUV7R MA Inhibitor DMMUV7R RN Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. DMMUV7R RU https://pubmed.ncbi.nlm.nih.gov/17228864 DMMUX86 DI DMMUX86 DMMUX86 DN N-(4-tert-butylthiazol-2-yl)isoquinolin-5-amine DMMUX86 TI TT7HQD0 DMMUX86 TN C-C chemokine receptor type 4 (CCR4) DMMUX86 MA Inhibitor DMMUX86 RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMMUX86 RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMMUY73 DI DMMUY73 DMMUY73 DN NPT-500 DMMUY73 TI TTSQIFT DMMUY73 TN 5-HT 1A receptor (HTR1A) DMMUY73 MA Modulator DMMUY73 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1). DMMUY73 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1 DMMUYHX DI DMMUYHX DMMUYHX DN L-693612 DMMUYHX TI TTHQPL7 DMMUYHX TN Carbonic anhydrase I (CA-I) DMMUYHX MA Modulator DMMUYHX RN Dose-dependent pharmacokinetics of L-693,612, a carbonic anhydrase inhibitor, following oral administration in rats. Pharm Res. 1994 Mar;11(3):438-41. DMMUYHX RU https://pubmed.ncbi.nlm.nih.gov/8008713 DMMUZK9 DI DMMUZK9 DMMUZK9 DN 1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane DMMUZK9 TI TTKWM86 DMMUZK9 TN Opioid receptor mu (MOP) DMMUZK9 MA Inhibitor DMMUZK9 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMMUZK9 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMMUZK9 DI DMMUZK9 DMMUZK9 DN 1,6-bis-(N,N-dimethyl-Dmt-Tic-NH)hexane DMMUZK9 TI TT27RFC DMMUZK9 TN Opioid receptor delta (OPRD1) DMMUZK9 MA Inhibitor DMMUZK9 RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMMUZK9 RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMMUZVS DI DMMUZVS DMMUZVS DN [1,4]Oxazepan-(5E)-ylideneamine DMMUZVS TI TTZUFI5 DMMUZVS TN Nitric-oxide synthase brain (NOS1) DMMUZVS MA Inhibitor DMMUZVS RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMMUZVS RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMMUZVS DI DMMUZVS DMMUZVS DN [1,4]Oxazepan-(5E)-ylideneamine DMMUZVS TI TTF10I9 DMMUZVS TN Nitric-oxide synthase inducible (NOS2) DMMUZVS MA Inhibitor DMMUZVS RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMMUZVS RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMMV061 DI DMMV061 DMMV061 DN F-G-G-F-T-G-Aib-R-K-S-Aib-R-K-L-A-N-Q-CONH2 DMMV061 TI TTNT7K8 DMMV061 TN Nociceptin receptor (OPRL1) DMMV061 MA Inhibitor DMMV061 RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMMV061 RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMMV1CB DI DMMV1CB DMMV1CB DN N5-[4-(4-methylphenoxy)phenyl]-L-glutamamide DMMV1CB TI TTXZEAJ DMMV1CB TN Leukotriene A-4 hydrolase (LTA4H) DMMV1CB MA Inhibitor DMMV1CB RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMMV1CB RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMMV1YN DI DMMV1YN DMMV1YN DN N-Pyridoxyl-Glycine-5-Monophosphate DMMV1YN TI TTUMGNO DMMV1YN TN Ornithine decarboxylase (ODC1) DMMV1YN MA Inhibitor DMMV1YN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMV1YN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMV2LN DI DMMV2LN DMMV2LN DN Cyclopentyl 10H-phenothiazine-10-carboxylate DMMV2LN TI TTEB0GD DMMV2LN TN Cholinesterase (BCHE) DMMV2LN MA Inhibitor DMMV2LN RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMMV2LN RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMMV30B DI DMMV30B DMMV30B DN 1-aminopentylphosphonic acid monophenyl ester DMMV30B TI TTPHMWB DMMV30B TN Aminopeptidase N (ANPEP) DMMV30B MA Inhibitor DMMV30B RN New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2010 Apr 15;18(8):2930-6. DMMV30B RU https://pubmed.ncbi.nlm.nih.gov/20347318 DMMV4WX DI DMMV4WX DMMV4WX DN ISIS 32015 DMMV4WX TI TT9H4P3 DMMV4WX TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMMV4WX RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMMV4WX RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMMV931 DI DMMV931 DMMV931 DN 5-chloro-N-(quinolin-8-yl)thiophene-2-sulfonamide DMMV931 TI TTSXVID DMMV931 TN Nuclear factor NF-kappa-B (NFKB) DMMV931 MA Inhibitor DMMV931 RN Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput s... Bioorg Med Chem Lett. 2008 Jan 1;18(1):329-35. DMMV931 RU https://pubmed.ncbi.nlm.nih.gov/18024113 DMMVASI DI DMMVASI DMMVASI DN 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one DMMVASI TI TTSZLWK DMMVASI TN Aromatase (CYP19A1) DMMVASI MA Inhibitor DMMVASI RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMMVASI RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMMVASI DI DMMVASI DMMVASI DN 4-Bromo-1-imidazol-1-ylmethyl-xanthen-9-one DMMVASI TI TTRA5BZ DMMVASI TN Steroid 17-alpha-monooxygenase (S17AH) DMMVASI MA Inhibitor DMMVASI RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMMVASI RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMMVB5P DI DMMVB5P DMMVB5P DN BOLDINE DMMVB5P TI TT5KPZR DMMVB5P TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMMVB5P MA Inhibitor DMMVB5P RN Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72. DMMVB5P RU https://pubmed.ncbi.nlm.nih.gov/17391965 DMMVB5P DI DMMVB5P DMMVB5P DN BOLDINE DMMVB5P TI TTEX248 DMMVB5P TN Dopamine D2 receptor (D2R) DMMVB5P MA Inhibitor DMMVB5P RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DMMVB5P RU https://pubmed.ncbi.nlm.nih.gov/10785418 DMMVB5P DI DMMVB5P DMMVB5P DN BOLDINE DMMVB5P TI TTZFYLI DMMVB5P TN Dopamine D1 receptor (D1R) DMMVB5P MA Inhibitor DMMVB5P RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DMMVB5P RU https://pubmed.ncbi.nlm.nih.gov/10785418 DMMVB5P DI DMMVB5P DMMVB5P DN BOLDINE DMMVB5P TI TT4H1MQ DMMVB5P TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMMVB5P MA Inhibitor DMMVB5P RN Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72. DMMVB5P RU https://pubmed.ncbi.nlm.nih.gov/17391965 DMMVBK6 DI DMMVBK6 DMMVBK6 DN JP1302 DMMVBK6 TI TT2NUT5 DMMVBK6 TN Adrenergic receptor alpha-2C (ADRA2C) DMMVBK6 MA Antagonist DMMVBK6 RN Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Br J Pharmacol. 2007 Feb;150(4):391-402. DMMVBK6 RU https://pubmed.ncbi.nlm.nih.gov/17220913 DMMVBK6 DI DMMVBK6 DMMVBK6 DN JP1302 DMMVBK6 TI TTWM4TY DMMVBK6 TN Adrenergic receptor alpha-2B (ADRA2B) DMMVBK6 MA Inhibitor DMMVBK6 RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DMMVBK6 RU https://pubmed.ncbi.nlm.nih.gov/17034141 DMMVBK6 DI DMMVBK6 DMMVBK6 DN JP1302 DMMVBK6 TI TTWG9A4 DMMVBK6 TN Adrenergic receptor alpha-2A (ADRA2A) DMMVBK6 MA Inhibitor DMMVBK6 RN Structure-activity relationship of quinoline derivatives as potent and selective alpha(2C)-adrenoceptor antagonists. J Med Chem. 2006 Oct 19;49(21):6351-63. DMMVBK6 RU https://pubmed.ncbi.nlm.nih.gov/17034141 DMMVIX7 DI DMMVIX7 DMMVIX7 DN [D-4Aph(CO-NH-OH)6]degarelix DMMVIX7 TI TT8R70G DMMVIX7 TN Gonadotropin-releasing hormone receptor (GNRHR) DMMVIX7 MA Inhibitor DMMVIX7 RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DMMVIX7 RU https://pubmed.ncbi.nlm.nih.gov/16759096 DMMVL5P DI DMMVL5P DMMVL5P DN 3,6,9,12,15-PENTAOXATRICOSAN-1-OL DMMVL5P TI TT3PQ2Y DMMVL5P TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMMVL5P MA Inhibitor DMMVL5P RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMMVL5P RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMMVZFN DI DMMVZFN DMMVZFN DN Petrosaspongiolide P DMMVZFN TI TT9V5JH DMMVZFN TN Phospholipase A2 (PLA2G1B) DMMVZFN MA Inhibitor DMMVZFN RN Petrosaspongiolides M-R: new potent and selective phospholipase A2 inhibitors from the New Caledonian marine sponge Petrosaspongia nigra. J Nat Prod. 1998 May;61(5):571-5. DMMVZFN RU https://pubmed.ncbi.nlm.nih.gov/9599251 DMMVZU0 DI DMMVZU0 DMMVZU0 DN Eleutherobin DMMVZU0 TI TTML2WA DMMVZU0 TN Tubulin (TUB) DMMVZU0 MA Inducer DMMVZU0 RN Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res. 1998 Mar 15;58(6):1111-5. DMMVZU0 RU https://pubmed.ncbi.nlm.nih.gov/9515790 DMMW0OF DI DMMW0OF DMMW0OF DN HL-034 DMMW0OF TI TTIHYA4 DMMW0OF TN Thrombopoietin receptor (MPL) DMMW0OF MA Antagonist DMMW0OF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DMMW0OF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DMMW3L1 DI DMMW3L1 DMMW3L1 DN YM-175735 DMMW3L1 TI TTKPW01 DMMW3L1 TN Androgen receptor messenger RNA (AR mRNA) DMMW3L1 MA Inhibitor DMMW3L1 RN (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally po... J Med Chem. 2006 Jan 26;49(2):716-26. DMMW3L1 RU https://pubmed.ncbi.nlm.nih.gov/16420057 DMMW8J1 DI DMMW8J1 DMMW8J1 DN N-Cyclohexyl-1'H-phenothiazine-1'-carboxamide DMMW8J1 TI TTEB0GD DMMW8J1 TN Cholinesterase (BCHE) DMMW8J1 MA Inhibitor DMMW8J1 RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMMW8J1 RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMMWBU6 DI DMMWBU6 DMMWBU6 DN GSK-188909 DMMWBU6 TI TT8JRS7 DMMWBU6 TN Beta-secretase (BACE) DMMWBU6 MA Inhibitor DMMWBU6 RN Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3664-8. DMMWBU6 RU https://pubmed.ncbi.nlm.nih.gov/19428244 DMMWCLV DI DMMWCLV DMMWCLV DN SB-221420-A DMMWCLV TI TTN9VTF DMMWCLV TN Voltage-gated sodium channel alpha Nav1.9 (SCN11A) DMMWCLV MA Blocker DMMWCLV RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMMWCLV RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMMWDC5 DI DMMWDC5 DMMWDC5 DN Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 TI TTJX3UE DMMWDC5 TN Somatostatin receptor type 3 (SSTR3) DMMWDC5 MA Inhibitor DMMWDC5 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMMWDC5 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMMWDC5 DI DMMWDC5 DMMWDC5 DN Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 TI TT2BC4G DMMWDC5 TN Somatostatin receptor type 5 (SSTR5) DMMWDC5 MA Inhibitor DMMWDC5 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMMWDC5 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMMWDC5 DI DMMWDC5 DMMWDC5 DN Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 TI TTZ6T9E DMMWDC5 TN Somatostatin receptor type 2 (SSTR2) DMMWDC5 MA Inhibitor DMMWDC5 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMMWDC5 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMMWDC5 DI DMMWDC5 DMMWDC5 DN Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 TI TTAE1BR DMMWDC5 TN Somatostatin receptor type 4 (SSTR4) DMMWDC5 MA Inhibitor DMMWDC5 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMMWDC5 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMMWDC5 DI DMMWDC5 DMMWDC5 DN Des-AA1,2,4,12,13-[D-Trp8]SRIF DMMWDC5 TI TTIND6G DMMWDC5 TN Somatostatin receptor type 1 (SSTR1) DMMWDC5 MA Inhibitor DMMWDC5 RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMMWDC5 RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMMWGVI DI DMMWGVI DMMWGVI DN 9-Benzyl-8-bromo-9H-adenine DMMWGVI TI TTM2AOE DMMWGVI TN Adenosine A2a receptor (ADORA2A) DMMWGVI MA Inhibitor DMMWGVI RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMMWGVI RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMMWGVI DI DMMWGVI DMMWGVI DN 9-Benzyl-8-bromo-9H-adenine DMMWGVI TI TTK25J1 DMMWGVI TN Adenosine A1 receptor (ADORA1) DMMWGVI MA Inhibitor DMMWGVI RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMMWGVI RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMMWHAV DI DMMWHAV DMMWHAV DN UDP-beta-S DMMWHAV TI TTNVSKA DMMWHAV TN P2Y purinoceptor 6 (P2RY6) DMMWHAV MA Agonist DMMWHAV RN P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312. DMMWHAV RU https://pubmed.ncbi.nlm.nih.gov/16475938 DMMWNPT DI DMMWNPT DMMWNPT DN AdoC(GABA)Arg6 DMMWNPT TI TTW4Y2M DMMWNPT TN cAMP protein kinase type II-beta (PRKAR2B) DMMWNPT MA Inhibitor DMMWNPT RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMMWNPT RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMMWNPT DI DMMWNPT DMMWNPT DN AdoC(GABA)Arg6 DMMWNPT TI TTNAHEX DMMWNPT TN cAMP-dependent protein kinase A type I (PRKAR1A) DMMWNPT MA Inhibitor DMMWNPT RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMMWNPT RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMMWVCH DI DMMWVCH DMMWVCH DN ISIS 102490 DMMWVCH TI TT5U49F DMMWVCH TN PRKACA messenger RNA (PRKACA mRNA) DMMWVCH RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMMWVCH RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMMWYFR DI DMMWYFR DMMWYFR DN 5-Phenylsulfanyl-2,4-Quinazolinediamine DMMWYFR TI TT9SL3Q DMMWYFR TN Polypeptide deformylase (PDF) DMMWYFR MA Inhibitor DMMWYFR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMWYFR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMWYI9 DI DMMWYI9 DMMWYI9 DN 4-phenoxyphenylboronic acid DMMWYI9 TI TTANPDJ DMMWYI9 TN Carbonic anhydrase II (CA-II) DMMWYI9 MA Inhibitor DMMWYI9 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMMWYI9 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMMWYI9 DI DMMWYI9 DMMWYI9 DN 4-phenoxyphenylboronic acid DMMWYI9 TI TTHQPL7 DMMWYI9 TN Carbonic anhydrase I (CA-I) DMMWYI9 MA Inhibitor DMMWYI9 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMMWYI9 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMMWYI9 DI DMMWYI9 DMMWYI9 DN 4-phenoxyphenylboronic acid DMMWYI9 TI TTUNARX DMMWYI9 TN Carbonic anhydrase (CA) DMMWYI9 MA Inhibitor DMMWYI9 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMMWYI9 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMMWZLC DI DMMWZLC DMMWZLC DN 4'-(trifluoromethyl)-4-biphenylol DMMWZLC TI TTBGTCW DMMWZLC TN Kinesin spindle messenger RNA (KIF11 mRNA) DMMWZLC MA Inhibitor DMMWZLC RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMMWZLC RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMMX19B DI DMMX19B DMMX19B DN NNC 11-1585 DMMX19B TI TTOXS3C DMMX19B TN Muscarinic acetylcholine receptor (CHRM) DMMX19B MA Agonist DMMX19B RN Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8. DMMX19B RU https://pubmed.ncbi.nlm.nih.gov/11504829 DMMX19B DI DMMX19B DMMX19B DN NNC 11-1585 DMMX19B TI TTQ13Z5 DMMX19B TN Muscarinic acetylcholine receptor M3 (CHRM3) DMMX19B MA Agonist DMMX19B RN Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8. DMMX19B RU https://pubmed.ncbi.nlm.nih.gov/11504829 DMMX1QJ DI DMMX1QJ DMMX1QJ DN 6,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione DMMX1QJ TI TTLD29N DMMX1QJ TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMMX1QJ MA Inhibitor DMMX1QJ RN 1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996). DMMX1QJ RU http://www.sciencedirect.com/science/article/pii/0960894X96000364 DMMX65T DI DMMX65T DMMX65T DN N-[4-(trifluoromethyl)phenyl]sulfamide DMMX65T TI TTANPDJ DMMX65T TN Carbonic anhydrase II (CA-II) DMMX65T MA Inhibitor DMMX65T RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DMMX65T RU https://pubmed.ncbi.nlm.nih.gov/15837324 DMMX65T DI DMMX65T DMMX65T DN N-[4-(trifluoromethyl)phenyl]sulfamide DMMX65T TI TTHQPL7 DMMX65T TN Carbonic anhydrase I (CA-I) DMMX65T MA Inhibitor DMMX65T RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DMMX65T RU https://pubmed.ncbi.nlm.nih.gov/15837324 DMMX69H DI DMMX69H DMMX69H DN 5-(2-methylquinolin-7-yl)isophthalonitrile DMMX69H TI TTHS256 DMMX69H TN Metabotropic glutamate receptor 5 (mGluR5) DMMX69H MA Inhibitor DMMX69H RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMMX69H RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMMX7KL DI DMMX7KL DMMX7KL DN GR 125,743 DMMX7KL TI TTSQIFT DMMX7KL TN 5-HT 1A receptor (HTR1A) DMMX7KL MA Antagonist DMMX7KL RN Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8. DMMX7KL RU https://pubmed.ncbi.nlm.nih.gov/9205951 DMMX7V8 DI DMMX7V8 DMMX7V8 DN 1-Methyl-1,3-dihydro-indol-2-one DMMX7V8 TI TTSQIFT DMMX7V8 TN 5-HT 1A receptor (HTR1A) DMMX7V8 MA Inhibitor DMMX7V8 RN Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity. Bioorg Med Chem Lett. 2001 May 7;11(9):1229-31. DMMX7V8 RU https://pubmed.ncbi.nlm.nih.gov/11354383 DMMX7V8 DI DMMX7V8 DMMX7V8 DN 1-Methyl-1,3-dihydro-indol-2-one DMMX7V8 TI TTJQOD7 DMMX7V8 TN 5-HT 2A receptor (HTR2A) DMMX7V8 MA Inhibitor DMMX7V8 RN Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity. Bioorg Med Chem Lett. 2001 May 7;11(9):1229-31. DMMX7V8 RU https://pubmed.ncbi.nlm.nih.gov/11354383 DMMXA5K DI DMMXA5K DMMXA5K DN D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 DMMXA5K TI TT27RFC DMMXA5K TN Opioid receptor delta (OPRD1) DMMXA5K MA Inhibitor DMMXA5K RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMMXA5K RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMMXA5K DI DMMXA5K DMMXA5K DN D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 DMMXA5K TI TTKWM86 DMMXA5K TN Opioid receptor mu (MOP) DMMXA5K MA Inhibitor DMMXA5K RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMMXA5K RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMMXAEN DI DMMXAEN DMMXAEN DN 7-benzyloxy-2-(morpholin-4-yl)-chromen-4-one DMMXAEN TI TTK3PY9 DMMXAEN TN DNA-dependent protein kinase catalytic (PRKDC) DMMXAEN MA Inhibitor DMMXAEN RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMMXAEN RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMMXFBJ DI DMMXFBJ DMMXFBJ DN dATP DMMXFBJ TI TTYXPCO DMMXFBJ TN P2Y purinoceptor 11 (P2RY11) DMMXFBJ MA Agonist DMMXFBJ RN Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206. DMMXFBJ RU https://pubmed.ncbi.nlm.nih.gov/10578132 DMMXIB4 DI DMMXIB4 DMMXIB4 DN SCH-546909 DMMXIB4 TI TT7HF4W DMMXIB4 TN Cyclin-dependent kinase 2 (CDK2) DMMXIB4 MA Inhibitor DMMXIB4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973). DMMXIB4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1973 DMMXL4E DI DMMXL4E DMMXL4E DN WAY-213613 DMMXL4E TI TT2F078 DMMXL4E TN Excitatory amino acid transporter 2 (SLC1A2) DMMXL4E MA Inhibitor DMMXL4E RN Characterization of novel aryl-ether, biaryl, and fluorene aspartic acid and diaminopropionic acid analogs as potent inhibitors of the high-affinit... Mol Pharmacol. 2005 Oct;68(4):974-82. DMMXL4E RU https://pubmed.ncbi.nlm.nih.gov/16014807 DMMXLHW DI DMMXLHW DMMXLHW DN PMID30247903-Compound-General structure23 DMMXLHW TI TTNBFWK DMMXLHW TN Programmed cell death protein 1 (PD-1) DMMXLHW MA Inhibitor DMMXLHW RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMMXLHW RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMMXU6R DI DMMXU6R DMMXU6R DN SR142948A DMMXU6R TI TTTUMEP DMMXU6R TN Neurotensin receptor type 1 (NTSR1) DMMXU6R MA Antagonist DMMXU6R RN Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J Pharmacol Exp Ther. 1997 Feb;280(2):802-12. DMMXU6R RU https://pubmed.ncbi.nlm.nih.gov/9023294 DMMY0NF DI DMMY0NF DMMY0NF DN (R)-1-(2-methoxyphenethyl)-2-methylpyrrolidine DMMY0NF TI TT9JNIC DMMY0NF TN Histamine H3 receptor (H3R) DMMY0NF MA Inhibitor DMMY0NF RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMMY0NF RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMMY542 DI DMMY542 DMMY542 DN Maltosyl-Alpha (1,4)-D-Gluconhydroximo-1,5-Lactam DMMY542 TI TTCGSZ4 DMMY542 TN Pancreatic alpha-amylase (AMY2A) DMMY542 MA Inhibitor DMMY542 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMMY542 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMMYENH DI DMMYENH DMMYENH DN 5-cyclohexyl-1,3,4-oxadiazole-2(3H)-thione DMMYENH TI TTULVH8 DMMYENH TN Tyrosinase (TYR) DMMYENH MA Inhibitor DMMYENH RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMMYENH RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMMYGB9 DI DMMYGB9 DMMYGB9 DN Benzo[c][1,5]naphthyridin-6(5H)-one DMMYGB9 TI TTVDSZ0 DMMYGB9 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMMYGB9 MA Inhibitor DMMYGB9 RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DMMYGB9 RU https://pubmed.ncbi.nlm.nih.gov/19125579 DMMYIJ0 DI DMMYIJ0 DMMYIJ0 DN N5-[4-(Phenylmethoxy)phenyl]-L-glutamamide DMMYIJ0 TI TTXZEAJ DMMYIJ0 TN Leukotriene A-4 hydrolase (LTA4H) DMMYIJ0 MA Inhibitor DMMYIJ0 RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMMYIJ0 RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMMYJ3R DI DMMYJ3R DMMYJ3R DN 2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole DMMYJ3R TI TTQ6VDM DMMYJ3R TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMMYJ3R MA Inhibitor DMMYJ3R RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMMYJ3R RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMMYJ3R DI DMMYJ3R DMMYJ3R DN 2-[4-(2-Piperidin-1-ylethyl)phenoxy]benzothiazole DMMYJ3R TI TTXZEAJ DMMYJ3R TN Leukotriene A-4 hydrolase (LTA4H) DMMYJ3R MA Inhibitor DMMYJ3R RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMMYJ3R RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMMYQ9R DI DMMYQ9R DMMYQ9R DN 2-(3-nitrophenyl)-4,5-dihydro-1H-imidazole DMMYQ9R TI TTGP7BY DMMYQ9R TN Monoamine oxidase type B (MAO-B) DMMYQ9R MA Inhibitor DMMYQ9R RN Ultrasound promoted synthesis of 2-imidazolines in water: a greener approach toward monoamine oxidase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):546-9. DMMYQ9R RU https://pubmed.ncbi.nlm.nih.gov/19064321 DMMYT4W DI DMMYT4W DMMYT4W DN 1-(4-Aminophenyl)-2-(1H-imidazol-1-yl)ethanone DMMYT4W TI TTSZLWK DMMYT4W TN Aromatase (CYP19A1) DMMYT4W MA Inhibitor DMMYT4W RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMMYT4W RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMMYUB9 DI DMMYUB9 DMMYUB9 DN ADS-103168 DMMYUB9 TI TTX4RTB DMMYUB9 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMMYUB9 MA Inhibitor DMMYUB9 RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMMYUB9 RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMMYV34 DI DMMYV34 DMMYV34 DN N-Hydroxy-N-methyl-3-naphthalen-2-yl-propionamide DMMYV34 TI TT2J34L DMMYV34 TN Arachidonate 5-lipoxygenase (5-LOX) DMMYV34 MA Inhibitor DMMYV34 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMMYV34 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMMYX7C DI DMMYX7C DMMYX7C DN SK1-I DMMYX7C TI TTOHFIY DMMYX7C TN Sphingosine kinase 1 (SPHK1) DMMYX7C MA Inhibitor DMMYX7C RN A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood. 2008 Aug 15;112(4):1382-91. DMMYX7C RU https://pubmed.ncbi.nlm.nih.gov/18511810 DMMZ1LR DI DMMZ1LR DMMZ1LR DN PMID7473541C20 DMMZ1LR TI TTFQEO5 DMMZ1LR TN Squalene synthetase (FDFT1) DMMZ1LR MA Inhibitor DMMZ1LR RN Phenoxypropylamines: a new series of squalene synthase inhibitors. J Med Chem. 1995 Oct 13;38(21):4157-60. DMMZ1LR RU https://pubmed.ncbi.nlm.nih.gov/7473541 DMMZ2LI DI DMMZ2LI DMMZ2LI DN 2-amino-3,4',5-trimethoxy-(Z)-stillbene DMMZ2LI TI TTJ2PTI DMMZ2LI TN Tubulin beta-2 chain (TUBB2) DMMZ2LI MA Inhibitor DMMZ2LI RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMMZ2LI RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMMZ2LI DI DMMZ2LI DMMZ2LI DN 2-amino-3,4',5-trimethoxy-(Z)-stillbene DMMZ2LI TI TTYFKSZ DMMZ2LI TN Tubulin beta (TUBB) DMMZ2LI MA Inhibitor DMMZ2LI RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMMZ2LI RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMMZ643 DI DMMZ643 DMMZ643 DN 2,4-Dimethoxy-4'-amino-trans-stilbene DMMZ643 TI TTSZLWK DMMZ643 TN Aromatase (CYP19A1) DMMZ643 MA Inhibitor DMMZ643 RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMMZ643 RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMMZ6AO DI DMMZ6AO DMMZ6AO DN KNI-10061 DMMZ6AO TI TTXMNHO DMMZ6AO TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMMZ6AO MA Inhibitor DMMZ6AO RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMMZ6AO RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMMZENV DI DMMZENV DMMZENV DN 6-(3-Hydroxyphenyl)-1-phenyl-2-naphthol DMMZENV TI TTIWB6L DMMZENV TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMMZENV MA Inhibitor DMMZENV RN Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98. DMMZENV RU https://pubmed.ncbi.nlm.nih.gov/18630892 DMMZH3Q DI DMMZH3Q DMMZH3Q DN Exiguamine A DMMZH3Q TI TTZJYKH DMMZH3Q TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMMZH3Q MA Inhibitor DMMZH3Q RN Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem. 2008 May 8;51(9):2634-7. DMMZH3Q RU https://pubmed.ncbi.nlm.nih.gov/18393489 DMMZK89 DI DMMZK89 DMMZK89 DN CSNLSTCVLGKLSQELc[DKLQK]YPRTNTGSGTP-amide DMMZK89 TI TTLWS2O DMMZK89 TN Calcitonin receptor (CALCR) DMMZK89 MA Inhibitor DMMZK89 RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMMZK89 RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMMZQB5 DI DMMZQB5 DMMZQB5 DN S-(2-boronoethyl)-L-cysteine DMMZQB5 TI TTV1AG6 DMMZQB5 TN Kidney-type arginase (ARG2) DMMZQB5 MA Inhibitor DMMZQB5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMMZQB5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMMZTE3 DI DMMZTE3 DMMZTE3 DN 6,6-dimethyl-1-phenyl-3-aza-bicyclo[3.1.0]hexane DMMZTE3 TI TT3ROYC DMMZTE3 TN Serotonin transporter (SERT) DMMZTE3 MA Inhibitor DMMZTE3 RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMMZTE3 RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMMZUPX DI DMMZUPX DMMZUPX DN [11C]AZ10419369 DMMZUPX TI TTK8CXU DMMZUPX TN 5-HT 1B receptor (HTR1B) DMMZUPX MA Agonist DMMZUPX RN Quantitative analysis of [11C]AZ10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011 Jan;31(1):113-23. DMMZUPX RU https://pubmed.ncbi.nlm.nih.gov/20424633 DMMZURL DI DMMZURL DMMZURL DN 3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide DMMZURL TI TT3WG5C DMMZURL TN Monoamine oxidase type A (MAO-A) DMMZURL MA Inhibitor DMMZURL RN Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66. DMMZURL RU https://pubmed.ncbi.nlm.nih.gov/20674099 DMMZURL DI DMMZURL DMMZURL DN 3,4-Dichloro-N-(2-methyl-1H-indol-5-yl)benzamide DMMZURL TI TTGP7BY DMMZURL TN Monoamine oxidase type B (MAO-B) DMMZURL MA Inhibitor DMMZURL RN Inhibition of monoamine oxidase by indole and benzofuran derivatives. Eur J Med Chem. 2010 Oct;45(10):4458-66. DMMZURL RU https://pubmed.ncbi.nlm.nih.gov/20674099 DMMZW8J DI DMMZW8J DMMZW8J DN ISIS 25564 DMMZW8J TI TTP2U16 DMMZW8J TN RhoA messenger RNA (RHOA mRNA) DMMZW8J RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMMZW8J RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMMZXRT DI DMMZXRT DMMZXRT DN NP93-31 DMMZXRT TI TTN9D8E DMMZXRT TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMMZXRT MA Antagonist DMMZXRT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMMZXRT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMMZYX6 DI DMMZYX6 DMMZYX6 DN OXYBENZONE DMMZYX6 TI TTLUQ8E DMMZYX6 TN Hormone sensitive lipase (LIPE) DMMZYX6 MA Inhibitor DMMZYX6 RN Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94. DMMZYX6 RU https://pubmed.ncbi.nlm.nih.gov/18808096 DMN01PI DI DMN01PI DMN01PI DN 3-(4-Hydroxy-phenyl)-4H-chromen-7-ol DMN01PI TI TTOM3J0 DMN01PI TN Estrogen receptor beta (ESR2) DMN01PI MA Inhibitor DMN01PI RN Structure-based virtual screening for plant-based ERbeta-selective ligands as potential preventative therapy against age-related neurodegenerative ... J Med Chem. 2005 May 19;48(10):3463-6. DMN01PI RU https://pubmed.ncbi.nlm.nih.gov/15887952 DMN049T DI DMN049T DMN049T DN RU28318 DMN049T TI TT26PHO DMN049T TN Mineralocorticoid receptor (MR) DMN049T MA Antagonist DMN049T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626). DMN049T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626 DMN052T DI DMN052T DMN052T DN BI-32169 DMN052T TI TT9O6WS DMN052T TN Glucagon receptor (GCGR) DMN052T MA Inhibitor DMN052T RN BI-32169, a bicyclic 19-peptide with strong glucagon receptor antagonist activity from Streptomyces sp. J Nat Prod. 2004 Sep;67(9):1528-31. DMN052T RU https://pubmed.ncbi.nlm.nih.gov/15387654 DMN0A1R DI DMN0A1R DMN0A1R DN ISIS 7942 DMN0A1R TI TT57MT2 DMN0A1R TN PKC-epsilon messenger RNA (PRKCE mRNA) DMN0A1R RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMN0A1R RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMN0BT3 DI DMN0BT3 DMN0BT3 DN [Tdf1]AngII DMN0BT3 TI TT8DBY3 DMN0BT3 TN Angiotensin II receptor type-1 (AGTR1) DMN0BT3 MA Inhibitor DMN0BT3 RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMN0BT3 RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMN0D14 DI DMN0D14 DMN0D14 DN PhSO2-Gly-(Me-Gly)-Arg-(2-thiazole) DMN0D14 TI TTCIHJA DMN0D14 TN Coagulation factor Xa (F10) DMN0D14 MA Inhibitor DMN0D14 RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMN0D14 RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMN0DR2 DI DMN0DR2 DMN0DR2 DN ISIS 19677 DMN0DR2 TI TTWALCO DMN0DR2 TN HER4 messenger RNA (ERBB4 mRNA) DMN0DR2 RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMN0DR2 RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMN0J4W DI DMN0J4W DMN0J4W DN CCK-8 DMN0J4W TI TTCG0AL DMN0J4W TN Cholecystokinin receptor type A (CCKAR) DMN0J4W MA Agonist DMN0J4W RN Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728-32. DMN0J4W RU https://pubmed.ncbi.nlm.nih.gov/1975695 DMN0J4W DI DMN0J4W DMN0J4W DN CCK-8 DMN0J4W TI TTVFO0U DMN0J4W TN Gastrin/cholecystokinin type B receptor (CCKBR) DMN0J4W MA Agonist DMN0J4W RN Functional characterization of a human brain cholecystokinin-B receptor. A trophic effect of cholecystokinin and gastrin. J Biol Chem. 1993 Aug 25;268(24):18300-5. DMN0J4W RU https://pubmed.ncbi.nlm.nih.gov/8349705 DMN0Q71 DI DMN0Q71 DMN0Q71 DN Sulfamic acid chroman-2-ylmethyl ester DMN0Q71 TI TTANPDJ DMN0Q71 TN Carbonic anhydrase II (CA-II) DMN0Q71 MA Inhibitor DMN0Q71 RN Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform. J Med Chem. 2005 Mar 24;48(6):1941-7. DMN0Q71 RU https://pubmed.ncbi.nlm.nih.gov/15771438 DMN0SYW DI DMN0SYW DMN0SYW DN 6-Methyl-4-(4-o-tolylpiperazin-1-yl)coumarin DMN0SYW TI TT1RS9F DMN0SYW TN Acetylcholinesterase (AChE) DMN0SYW MA Inhibitor DMN0SYW RN Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21. DMN0SYW RU https://pubmed.ncbi.nlm.nih.gov/18701305 DMN12EX DI DMN12EX DMN12EX DN 4-CYANOPHENOL DMN12EX TI TTCFSPE DMN12EX TN Carbonic anhydrase VI (CA-VI) DMN12EX MA Inhibitor DMN12EX RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMN12EX RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMN12EX DI DMN12EX DMN12EX DN 4-CYANOPHENOL DMN12EX TI TTSYM0R DMN12EX TN Carbonic anhydrase XII (CA-XII) DMN12EX MA Inhibitor DMN12EX RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMN12EX RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMN12EX DI DMN12EX DMN12EX DN 4-CYANOPHENOL DMN12EX TI TTANPDJ DMN12EX TN Carbonic anhydrase II (CA-II) DMN12EX MA Inhibitor DMN12EX RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMN12EX RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMN12EX DI DMN12EX DMN12EX DN 4-CYANOPHENOL DMN12EX TI TTUNARX DMN12EX TN Carbonic anhydrase (CA) DMN12EX MA Inhibitor DMN12EX RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMN12EX RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMN1579 DI DMN1579 DMN1579 DN Fedratinib DMN1579 TI TT0F5HE DMN1579 TN HUMAN janus kinase 2 (JAK-2) DMN1579 MA Inhibitor DMN1579 RN TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7. DMN1579 RU https://pubmed.ncbi.nlm.nih.gov/32205092 DMN176Y DI DMN176Y DMN176Y DN 2-(2-naphthamido)benzoic acid DMN176Y TI TT3PQ2Y DMN176Y TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMN176Y MA Inhibitor DMN176Y RN The first de novo designed inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. Bioorg Med Chem Lett. 2006 Jan 1;16(1):88-92. DMN176Y RU https://pubmed.ncbi.nlm.nih.gov/16236496 DMN19QP DI DMN19QP DMN19QP DN 4-amino-N-(4-iodophenyl)benzenesulfonamide DMN19QP TI TTVKILB DMN19QP TN Prostaglandin G/H synthase 2 (COX-2) DMN19QP MA Inhibitor DMN19QP RN Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors. Bioorg Med Chem. 2007 Jan 15;15(2):1014-21. DMN19QP RU https://pubmed.ncbi.nlm.nih.gov/17079150 DMN1DPJ DI DMN1DPJ DMN1DPJ DN N-(3-phenoxy-4-pyridinyl)propanesulfonamide DMN1DPJ TI TT8NGED DMN1DPJ TN Prostaglandin G/H synthase 1 (COX-1) DMN1DPJ MA Inhibitor DMN1DPJ RN Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59. DMN1DPJ RU https://pubmed.ncbi.nlm.nih.gov/15615524 DMN1DWF DI DMN1DWF DMN1DWF DN 3-(phenylsulfonyl)-1H-pyrrolo[2,3-b]pyridine DMN1DWF TI TTNDSF4 DMN1DWF TN Proto-oncogene c-Met (MET) DMN1DWF MA Inhibitor DMN1DWF RN Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4. DMN1DWF RU https://pubmed.ncbi.nlm.nih.gov/19369077 DMN1F7Z DI DMN1F7Z DMN1F7Z DN MG-28 DMN1F7Z TI TT7AOUD DMN1F7Z TN Fatty acid synthase (FASN) DMN1F7Z MA Inhibitor DMN1F7Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608). DMN1F7Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608 DMN1FIU DI DMN1FIU DMN1FIU DN N-isobutylnoroxymorphone DMN1FIU TI TTKWM86 DMN1FIU TN Opioid receptor mu (MOP) DMN1FIU MA Inhibitor DMN1FIU RN Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81. DMN1FIU RU https://pubmed.ncbi.nlm.nih.gov/18755589 DMN1FIU DI DMN1FIU DMN1FIU DN N-isobutylnoroxymorphone DMN1FIU TI TTQW87Y DMN1FIU TN Opioid receptor kappa (OPRK1) DMN1FIU MA Inhibitor DMN1FIU RN Synthesis of N-isobutylnoroxymorphone from naltrexone by a selective cyclopropane ring opening reaction. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4978-81. DMN1FIU RU https://pubmed.ncbi.nlm.nih.gov/18755589 DMN1G5S DI DMN1G5S DMN1G5S DN SB 218078 DMN1G5S TI TTTU902 DMN1G5S TN Checkpoint kinase-1 (CHK1) DMN1G5S MA Inhibitor DMN1G5S RN An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res. 2000 Feb 1;60(3):566-72. DMN1G5S RU https://pubmed.ncbi.nlm.nih.gov/10676638 DMN1G8L DI DMN1G8L DMN1G8L DN (S)-2-amino-N-(1-cyano-2-phenylethyl)acetamide DMN1G8L TI TT4H0V2 DMN1G8L TN Dipeptidyl peptidase I (CTSC) DMN1G8L MA Inhibitor DMN1G8L RN Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3614-7. DMN1G8L RU https://pubmed.ncbi.nlm.nih.gov/16647256 DMN1LHI DI DMN1LHI DMN1LHI DN ISIS 29200 DMN1LHI TI TTO6SGY DMN1LHI TN AKT3 messenger RNA (AKT3 mRNA) DMN1LHI RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMN1LHI RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMN1RLA DI DMN1RLA DMN1RLA DN Resveratrol Potassium3-Sulfate DMN1RLA TI TTVKILB DMN1RLA TN Prostaglandin G/H synthase 2 (COX-2) DMN1RLA MA Inhibitor DMN1RLA RN Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43. DMN1RLA RU https://pubmed.ncbi.nlm.nih.gov/20527891 DMN1RLA DI DMN1RLA DMN1RLA DN Resveratrol Potassium3-Sulfate DMN1RLA TI TT8NGED DMN1RLA TN Prostaglandin G/H synthase 1 (COX-1) DMN1RLA MA Inhibitor DMN1RLA RN Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J Med Chem. 2010 Jul 8;53(13):5033-43. DMN1RLA RU https://pubmed.ncbi.nlm.nih.gov/20527891 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TT6MSOK DMN1S35 TN 5-HT 1D receptor (HTR1D) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TTO9X1H DMN1S35 TN 5-HT 7 receptor (HTR7) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TTPC4TU DMN1S35 TN 5-HT 3A receptor (HTR3A) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TTJS8PY DMN1S35 TN 5-HT 6 receptor (HTR6) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TTJQOD7 DMN1S35 TN 5-HT 2A receptor (HTR2A) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TTSQIFT DMN1S35 TN 5-HT 1A receptor (HTR1A) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TTWJBZ5 DMN1S35 TN 5-HT 2C receptor (HTR2C) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1S35 DI DMN1S35 DMN1S35 DN 5,6-dichloro-3,4-dihydroquinazolin-2-amine DMN1S35 TI TTRUFDT DMN1S35 TN 5-HT 5A receptor (HTR5A) DMN1S35 MA Inhibitor DMN1S35 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMN1S35 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMN1U56 DI DMN1U56 DMN1U56 DN 7alpha-OAc-ginkgolide B DMN1U56 TI TTQL5VC DMN1U56 TN Platelet-activating factor receptor (PTAFR) DMN1U56 MA Antagonist DMN1U56 RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMN1U56 RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMN1XMK DI DMN1XMK DMN1XMK DN 4-Pentadeca-1,3,6-trienylsulfanyl-butyric acid DMN1XMK TI TT2J34L DMN1XMK TN Arachidonate 5-lipoxygenase (5-LOX) DMN1XMK MA Inhibitor DMN1XMK RN Design, synthesis, and 5-lipoxygenase-inhibiting properties of 1-thio-substituted butadienes. J Med Chem. 1990 Apr;33(4):1163-70. DMN1XMK RU https://pubmed.ncbi.nlm.nih.gov/2319562 DMN1YQ6 DI DMN1YQ6 DMN1YQ6 DN 10S-hydroxylobel-7-ene DMN1YQ6 TI TT3ROYC DMN1YQ6 TN Serotonin transporter (SERT) DMN1YQ6 MA Inhibitor DMN1YQ6 RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMN1YQ6 RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMN1YQ6 DI DMN1YQ6 DMN1YQ6 DN 10S-hydroxylobel-7-ene DMN1YQ6 TI TTVBI8W DMN1YQ6 TN Dopamine transporter (DAT) DMN1YQ6 MA Inhibitor DMN1YQ6 RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMN1YQ6 RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMN23KT DI DMN23KT DMN23KT DN isoferulic acid DMN23KT TI TTXMI0C DMN23KT TN Phosphomevalonate kinase (PMVK) DMN23KT MA Inhibitor DMN23KT RN Inhibition of rat liver mevalonate pyrophosphate decarboxylase and mevalonate phosphate kinase by phenyl and phenolic compounds. Biochem J. 1979 Jul 1;181(1):143-51. DMN23KT RU https://pubmed.ncbi.nlm.nih.gov/226078 DMN2AQO DI DMN2AQO DMN2AQO DN H-Tyr-D-Ala-(R or S)Atc-Asp-Val-Val-Gly-NH2 DMN2AQO TI TTKWM86 DMN2AQO TN Opioid receptor mu (MOP) DMN2AQO MA Inhibitor DMN2AQO RN Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56. DMN2AQO RU https://pubmed.ncbi.nlm.nih.gov/8254604 DMN2HXL DI DMN2HXL DMN2HXL DN PMID20615702C8f DMN2HXL TI TTWNV8U DMN2HXL TN Nicotinic acid receptor (HCAR2) DMN2HXL MA Agonist DMN2HXL RN GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4. DMN2HXL RU https://pubmed.ncbi.nlm.nih.gov/20615702 DMN2LHM DI DMN2LHM DMN2LHM DN 1-[bis(4-chlorophenyl)methyl]-3-(4-chlorophenyl)- DMN2LHM TI TT6OEDT DMN2LHM TN Cannabinoid receptor 1 (CB1) DMN2LHM MA Inhibitor DMN2LHM RN 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90. DMN2LHM RU https://pubmed.ncbi.nlm.nih.gov/16279809 DMN2Q7Y DI DMN2Q7Y DMN2Q7Y DN FTI 276 DMN2Q7Y TI TT7WZIJ DMN2Q7Y TN CAAX farnesyltransferase beta (FNTB) DMN2Q7Y MA Inhibitor DMN2Q7Y RN Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem. 1995 Nov 10;270(45):26802-6. DMN2Q7Y RU https://pubmed.ncbi.nlm.nih.gov/7592920 DMN2TMS DI DMN2TMS DMN2TMS DN 4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide DMN2TMS TI TTGKNB4 DMN2TMS TN Epidermal growth factor receptor (EGFR) DMN2TMS MA Inhibitor DMN2TMS RN Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72. DMN2TMS RU https://pubmed.ncbi.nlm.nih.gov/16275081 DMN2UKC DI DMN2UKC DMN2UKC DN Ac-YRMEHdFRWG-NH2 DMN2UKC TI TTD0CIQ DMN2UKC TN Melanocortin receptor 4 (MC4R) DMN2UKC MA Inhibitor DMN2UKC RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMN2UKC RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMN2UKC DI DMN2UKC DMN2UKC DN Ac-YRMEHdFRWG-NH2 DMN2UKC TI TT0MV2T DMN2UKC TN Melanocortin receptor 1 (MC1R) DMN2UKC MA Inhibitor DMN2UKC RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMN2UKC RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMN2UKC DI DMN2UKC DMN2UKC DN Ac-YRMEHdFRWG-NH2 DMN2UKC TI TTEOSZT DMN2UKC TN Melanocortin receptor (MCR) DMN2UKC MA Inhibitor DMN2UKC RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMN2UKC RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMN2UKC DI DMN2UKC DMN2UKC DN Ac-YRMEHdFRWG-NH2 DMN2UKC TI TTNI91K DMN2UKC TN Melanocortin receptor 3 (MC3R) DMN2UKC MA Inhibitor DMN2UKC RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMN2UKC RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMN2XTQ DI DMN2XTQ DMN2XTQ DN B173 DMN2XTQ TI TTCPG9S DMN2XTQ TN 5-HT 1E receptor (HTR1E) DMN2XTQ MA Agonist DMN2XTQ RN The gamma-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res. 2007 Jan;31(1):11-8. DMN2XTQ RU https://pubmed.ncbi.nlm.nih.gov/17207096 DMN320E DI DMN320E DMN320E DN A-558693 DMN320E TI TTG5QB7 DMN320E TN Calpain-2 (CAPN2) DMN320E MA Inhibitor DMN320E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336). DMN320E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2336 DMN35BY DI DMN35BY DMN35BY DN [3H](-)CGP 12177 DMN35BY TI TTMXGCW DMN35BY TN Adrenergic receptor beta-3 (ADRB3) DMN35BY MA Agonist DMN35BY RN Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. DMN35BY RU https://pubmed.ncbi.nlm.nih.gov/15060759 DMN37KO DI DMN37KO DMN37KO DN o-hydroxyatorvastatin DMN37KO TI TTPADOQ DMN37KO TN HMG-CoA reductase (HMGCR) DMN37KO MA Inhibitor DMN37KO RN Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Med Chem. 2008 Jul 10;51(13):3804-13. DMN37KO RU https://pubmed.ncbi.nlm.nih.gov/18540668 DMN38JC DI DMN38JC DMN38JC DN Bip-tyr-thr-pro-ala-thr(obzl)-gly DMN38JC TI TTVBI8W DMN38JC TN Dopamine transporter (DAT) DMN38JC MA Inhibitor DMN38JC RN Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. DMN38JC RU https://pubmed.ncbi.nlm.nih.gov/16821765 DMN39V6 DI DMN39V6 DMN39V6 DN PMID32321856-compound-11a DMN39V6 TI TTNHMO8 DMN39V6 TN COVID-19 papain-like proteinase (PL-PRO) DMN39V6 MA Inhibitor DMN39V6 RN Structure-based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science. 2020 Apr 22;eabb4489. DMN39V6 RU https://pubmed.ncbi.nlm.nih.gov/32321856 DMN3E9Q DI DMN3E9Q DMN3E9Q DN AS95 DMN3E9Q TI TTNE7KG DMN3E9Q TN Adenosine A2b receptor (ADORA2B) DMN3E9Q MA Antagonist DMN3E9Q RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DMN3E9Q RU https://pubmed.ncbi.nlm.nih.gov/16219300 DMN3EU9 DI DMN3EU9 DMN3EU9 DN Boc-Glu-Tyr(SO3H)-Nle-D-Lys-Trp-Nle-Asp-Phe-NH2 DMN3EU9 TI TTCG0AL DMN3EU9 TN Cholecystokinin receptor type A (CCKAR) DMN3EU9 MA Inhibitor DMN3EU9 RN Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90. DMN3EU9 RU https://pubmed.ncbi.nlm.nih.gov/2724293 DMN3GTF DI DMN3GTF DMN3GTF DN DABCO-C16 DMN3GTF TI TT5OEKU DMN3GTF TN Voltage-gated potassium channel Kv2.1 (KCNB1) DMN3GTF MA Blocker (channel blocker) DMN3GTF RN 1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers. Mol Pharmacol. 2006 Mar;69(3):718-26. DMN3GTF RU https://pubmed.ncbi.nlm.nih.gov/16317109 DMN3GTF DI DMN3GTF DMN3GTF DN DABCO-C16 DMN3GTF TI TTODZF1 DMN3GTF TN Voltage-gated potassium channel Kv3.4 (KCNC4) DMN3GTF MA Blocker (channel blocker) DMN3GTF RN 1,4-Diazabicyclo[2.2.2]octane derivatives: a novel class of voltage-gated potassium channel blockers. Mol Pharmacol. 2006 Mar;69(3):718-26. DMN3GTF RU https://pubmed.ncbi.nlm.nih.gov/16317109 DMN3L0Y DI DMN3L0Y DMN3L0Y DN ISIS 138613 DMN3L0Y TI TTTEOPU DMN3L0Y TN Helicase-moi messenger RNA (DICER1 mRNA) DMN3L0Y RN US patent application no. 7,427,470, Antisense modulation of helicase-moi expression. DMN3L0Y RU http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true DMN3OWP DI DMN3OWP DMN3OWP DN ONO-AE3-240 DMN3OWP TI TT79WV3 DMN3OWP TN Prostaglandin E2 receptor EP4 (PTGER4) DMN3OWP MA Antagonist DMN3OWP RN Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003 Jan 20;197(2):221-32. DMN3OWP RU https://pubmed.ncbi.nlm.nih.gov/12538661 DMN3OWP DI DMN3OWP DMN3OWP DN ONO-AE3-240 DMN3OWP TI TTPNGDE DMN3OWP TN Prostaglandin E2 receptor EP3 (PTGER3) DMN3OWP MA Antagonist DMN3OWP RN Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003 Jan 20;197(2):221-32. DMN3OWP RU https://pubmed.ncbi.nlm.nih.gov/12538661 DMN3YEQ DI DMN3YEQ DMN3YEQ DN CG-1521 DMN3YEQ TI TTBH0VX DMN3YEQ TN Histone deacetylase (HDAC) DMN3YEQ MA Inhibitor DMN3YEQ RN Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. DMN3YEQ RU https://pubmed.ncbi.nlm.nih.gov/16955068 DMN3ZOD DI DMN3ZOD DMN3ZOD DN RS-PPCC DMN3ZOD TI TTTPE1L DMN3ZOD TN HUMAN opioid receptor sigma 1 (OPRS1) DMN3ZOD MA Agonist DMN3ZOD RN A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DMN3ZOD RU https://www.nature.com/articles/s41586-020-2286-9 DMN42I5 DI DMN42I5 DMN42I5 DN 3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMN42I5 TI TTIQUX7 DMN42I5 TN Steroid 11-beta-hydroxylase (CYP11B1) DMN42I5 MA Inhibitor DMN42I5 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMN42I5 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMN42I5 DI DMN42I5 DMN42I5 DN 3-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMN42I5 TI TTSZLWK DMN42I5 TN Aromatase (CYP19A1) DMN42I5 MA Inhibitor DMN42I5 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMN42I5 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMN45EH DI DMN45EH DMN45EH DN 4-methyl-N-propyl-3,4-dihydroquinazolin-2-amine DMN45EH TI TTRUFDT DMN45EH TN 5-HT 5A receptor (HTR5A) DMN45EH MA Inhibitor DMN45EH RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration. Bioorg Med Chem Lett. 2008 Jan 1;18(1):262-6. DMN45EH RU https://pubmed.ncbi.nlm.nih.gov/18023344 DMN493F DI DMN493F DMN493F DN N-[Tosyl-D-Prolinyl]Amino-Ethanethiol DMN493F TI TTU6BFZ DMN493F TN Candida Thymidylate synthase (Candi TMP1) DMN493F MA Inhibitor DMN493F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMN493F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMN4ABU DI DMN4ABU DMN4ABU DN [125I]iodophenpropit DMN4ABU TI TT9JNIC DMN4ABU TN Histamine H3 receptor (H3R) DMN4ABU MA Antagonist DMN4ABU RN Characterization of the binding of the first selective radiolabelled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain. Br J Pharmacol. 1994 Oct;113(2):355-62. DMN4ABU RU https://pubmed.ncbi.nlm.nih.gov/7834183 DMN4ABU DI DMN4ABU DMN4ABU DN [125I]iodophenpropit DMN4ABU TI TTXJ178 DMN4ABU TN Histamine H4 receptor (H4R) DMN4ABU MA Inhibitor DMN4ABU RN Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. J Med Chem. 2008 Jun 12;51(11):3145-53. DMN4ABU RU https://pubmed.ncbi.nlm.nih.gov/18459760 DMN4EUB DI DMN4EUB DMN4EUB DN KAG-308 DMN4EUB TI TT79WV3 DMN4EUB TN Prostaglandin E2 receptor EP4 (PTGER4) DMN4EUB MA Agonist DMN4EUB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). DMN4EUB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343 DMN4G7U DI DMN4G7U DMN4G7U DN 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea DMN4G7U TI TT30C9G DMN4G7U TN C-X-C chemokine receptor type 2 (CXCR2) DMN4G7U MA Inhibitor DMN4G7U RN Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem. 1998 Apr 24;273(17):10095-8. DMN4G7U RU https://pubmed.ncbi.nlm.nih.gov/9553055 DMN4G7U DI DMN4G7U DMN4G7U DN 1-(2-hydroxy-4-nitrophenyl)-3-phenylurea DMN4G7U TI TTMWT8Z DMN4G7U TN C-X-C chemokine receptor type 1 (CXCR1) DMN4G7U MA Inhibitor DMN4G7U RN Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem. 2004 Mar 11;47(6):1319-21. DMN4G7U RU https://pubmed.ncbi.nlm.nih.gov/14998320 DMN4IW5 DI DMN4IW5 DMN4IW5 DN Suramin DMN4IW5 TI TTV1095 DMN4IW5 TN COVID-19 RNA-directed RNA polymerase (RdRp) DMN4IW5 MA Inhibitor DMN4IW5 RN Suramin, Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection. April.21.2020. Doi: 10.31219/osf.io/urxwh DMN4IW5 RU https://osf.io/urxwh DMN4JU0 DI DMN4JU0 DMN4JU0 DN 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol DMN4JU0 TI TTAWNKZ DMN4JU0 TN Norepinephrine transporter (NET) DMN4JU0 MA Inhibitor DMN4JU0 RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DMN4JU0 RU https://pubmed.ncbi.nlm.nih.gov/15115403 DMN4JU0 DI DMN4JU0 DMN4JU0 DN 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol DMN4JU0 TI TTVBI8W DMN4JU0 TN Dopamine transporter (DAT) DMN4JU0 MA Inhibitor DMN4JU0 RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DMN4JU0 RU https://pubmed.ncbi.nlm.nih.gov/15115403 DMN4JU0 DI DMN4JU0 DMN4JU0 DN 1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol DMN4JU0 TI TT3ROYC DMN4JU0 TN Serotonin transporter (SERT) DMN4JU0 MA Inhibitor DMN4JU0 RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DMN4JU0 RU https://pubmed.ncbi.nlm.nih.gov/15115403 DMN4KJI DI DMN4KJI DMN4KJI DN Conantokin-R DMN4KJI TI TTN9D8E DMN4KJI TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMN4KJI MA Inhibitor DMN4KJI RN Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13. DMN4KJI RU https://pubmed.ncbi.nlm.nih.gov/17962189 DMN4KJI DI DMN4KJI DMN4KJI DN Conantokin-R DMN4KJI TI TTKJEMQ DMN4KJI TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMN4KJI MA Inhibitor DMN4KJI RN Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem. 2007 Dec 21;282(51):36905-13. DMN4KJI RU https://pubmed.ncbi.nlm.nih.gov/17962189 DMN4Z27 DI DMN4Z27 DMN4Z27 DN 3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin DMN4Z27 TI TT3WG5C DMN4Z27 TN Monoamine oxidase type A (MAO-A) DMN4Z27 MA Inhibitor DMN4Z27 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMN4Z27 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMN4Z27 DI DMN4Z27 DMN4Z27 DN 3,4-Benzo-7-(beta-bromoallyloxy)-8-methylcoumarin DMN4Z27 TI TTGP7BY DMN4Z27 TN Monoamine oxidase type B (MAO-B) DMN4Z27 MA Inhibitor DMN4Z27 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMN4Z27 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMN4ZKC DI DMN4ZKC DMN4ZKC DN Paraoxon DMN4ZKC TI TTUNARX DMN4ZKC TN Carbonic anhydrase (CA) DMN4ZKC MA Inhibitor DMN4ZKC RN Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12. DMN4ZKC RU https://pubmed.ncbi.nlm.nih.gov/20833546 DMN4ZKC DI DMN4ZKC DMN4ZKC DN Paraoxon DMN4ZKC TI TTDP1UC DMN4ZKC TN Fatty acid amide hydrolase (FAAH) DMN4ZKC MA Inhibitor DMN4ZKC RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DMN4ZKC RU https://pubmed.ncbi.nlm.nih.gov/18438404 DMN4ZKC DI DMN4ZKC DMN4ZKC DN Paraoxon DMN4ZKC TI TTHQPL7 DMN4ZKC TN Carbonic anhydrase I (CA-I) DMN4ZKC MA Inhibitor DMN4ZKC RN Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12. DMN4ZKC RU https://pubmed.ncbi.nlm.nih.gov/20833546 DMN4ZKC DI DMN4ZKC DMN4ZKC DN Paraoxon DMN4ZKC TI TT6OEDT DMN4ZKC TN Cannabinoid receptor 1 (CB1) DMN4ZKC MA Inhibitor DMN4ZKC RN Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5875-8. DMN4ZKC RU https://pubmed.ncbi.nlm.nih.gov/18752948 DMN4ZKC DI DMN4ZKC DMN4ZKC DN Paraoxon DMN4ZKC TI TT1RS9F DMN4ZKC TN Acetylcholinesterase (AChE) DMN4ZKC MA Inhibitor DMN4ZKC RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DMN4ZKC RU https://pubmed.ncbi.nlm.nih.gov/18438404 DMN4ZKC DI DMN4ZKC DMN4ZKC DN Paraoxon DMN4ZKC TI TTANPDJ DMN4ZKC TN Carbonic anhydrase II (CA-II) DMN4ZKC MA Inhibitor DMN4ZKC RN Paraoxon, 4-nitrophenyl phosphate and acetate are substrates of - but not of -, - and -carbonic anhydrases. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6208-12. DMN4ZKC RU https://pubmed.ncbi.nlm.nih.gov/20833546 DMN4ZYO DI DMN4ZYO DMN4ZYO DN Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9]SRIF DMN4ZYO TI TTIND6G DMN4ZYO TN Somatostatin receptor type 1 (SSTR1) DMN4ZYO MA Inhibitor DMN4ZYO RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMN4ZYO RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMN50B9 DI DMN50B9 DMN50B9 DN PMID21444206C3a DMN50B9 TI TT7QNVC DMN50B9 TN Glucose-dependent insulinotropic receptor (GPR119) DMN50B9 MA Agonist DMN50B9 RN Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41. DMN50B9 RU https://pubmed.ncbi.nlm.nih.gov/21444206 DMN50OT DI DMN50OT DMN50OT DN NSC-324572 DMN50OT TI TT9NVXQ DMN50OT TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMN50OT MA Inhibitor DMN50OT RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMN50OT RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMN516S DI DMN516S DMN516S DN 2-pyridylethylamine DMN516S TI TTTIBOJ DMN516S TN Histamine H1 receptor (H1R) DMN516S MA Agonist DMN516S RN Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur J Biochem. 2004 Jul;271(13):2636-46. DMN516S RU https://pubmed.ncbi.nlm.nih.gov/15206929 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TT8QL1J DMN53M4 TN Protein kinase C theta (PRKCQ) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TTBSN0L DMN53M4 TN PKC-zeta messenger RNA (PRKCZ mRNA) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TTBZ7OD DMN53M4 TN Protein kinase C epsilon (PRKCE) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TT7A1BO DMN53M4 TN PKC-delta messenger RNA (PRKCD mRNA) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TT9WJ8U DMN53M4 TN Protein kinase C delta (PRKCD) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TTRFOXJ DMN53M4 TN Protein kinase C gamma (PRKCG) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TTONI0R DMN53M4 TN PKC-eta messenger RNA (PRKCH mRNA) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TTFJ8Q1 DMN53M4 TN Protein kinase C alpha (PRKCA) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TTYPXQF DMN53M4 TN Protein kinase C beta (PRKCB) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN53M4 DI DMN53M4 DMN53M4 DN LY-326449 DMN53M4 TI TTUWGRA DMN53M4 TN Protein kinase C zeta (PRKCZ) DMN53M4 MA Inhibitor DMN53M4 RN (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71. DMN53M4 RU https://pubmed.ncbi.nlm.nih.gov/8709095 DMN54LS DI DMN54LS DMN54LS DN HAEGTFTSDVSSYLEGQAAKEIFAWLVKGR DMN54LS TI TTVIMDE DMN54LS TN Glucagon-like peptide 1 receptor (GLP1R) DMN54LS MA Inhibitor DMN54LS RN Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1. Bioorg Med Chem. 2008 Dec 1;16(23):10106-12. DMN54LS RU https://pubmed.ncbi.nlm.nih.gov/18952440 DMN56VM DI DMN56VM DMN56VM DN 2,7-Dinitroantraquinone DMN56VM TI TTQY2EJ DMN56VM TN TERT messenger RNA (TERT mRNA) DMN56VM MA Inhibitor DMN56VM RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMN56VM RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMN5AE8 DI DMN5AE8 DMN5AE8 DN PSEUDOCOCAINE DMN5AE8 TI TTVBI8W DMN5AE8 TN Dopamine transporter (DAT) DMN5AE8 MA Inhibitor DMN5AE8 RN Synthesis of 8-Oxa analogues of norcocaine endowed with interesting cocaine-like activity. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1831-6. DMN5AE8 RU https://pubmed.ncbi.nlm.nih.gov/10406650 DMN5LZQ DI DMN5LZQ DMN5LZQ DN PMID15603962Crac-16 DMN5LZQ TI TT7M9I6 DMN5LZQ TN Calcium-activated potassium channel KCa3.1 (KCNN4) DMN5LZQ MA Blocker (channel blocker) DMN5LZQ RN IKCa-channel blockers. Part 2: discovery of cyclohexadienes. Bioorg Med Chem Lett. 2005 Jan 17;15(2):401-4. DMN5LZQ RU https://pubmed.ncbi.nlm.nih.gov/15603962 DMN5SL6 DI DMN5SL6 DMN5SL6 DN 1-(1-phenylethylidene)thiosemicarbazide DMN5SL6 TI TTULVH8 DMN5SL6 TN Tyrosinase (TYR) DMN5SL6 MA Inhibitor DMN5SL6 RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DMN5SL6 RU https://pubmed.ncbi.nlm.nih.gov/18326070 DMN5VDB DI DMN5VDB DMN5VDB DN ATI-1150 DMN5VDB TI TTGTQHC DMN5VDB TN DNA topoisomerase I (TOP1) DMN5VDB MA Inhibitor DMN5VDB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMN5VDB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMN5X17 DI DMN5X17 DMN5X17 DN BZ3 DMN5X17 TI TTVDSZ0 DMN5X17 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMN5X17 MA Inhibitor DMN5X17 RN Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8. DMN5X17 RU https://pubmed.ncbi.nlm.nih.gov/12855651 DMN5YOR DI DMN5YOR DMN5YOR DN C-(9H-Xanthen-9-yl)-methylamine DMN5YOR TI TTJQOD7 DMN5YOR TN 5-HT 2A receptor (HTR2A) DMN5YOR MA Inhibitor DMN5YOR RN Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6. DMN5YOR RU https://pubmed.ncbi.nlm.nih.gov/11229772 DMN5Z0F DI DMN5Z0F DMN5Z0F DN Acetyl-Pro-Ala-Pro-Ala-trifluoro methane DMN5Z0F TI TT3NKIB DMN5Z0F TN Pancreatic elastase 1 (CELA1) DMN5Z0F MA Inhibitor DMN5Z0F RN Synthesis of peptidyl fluoromethyl ketones and peptidyl alpha-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase, ... J Med Chem. 1990 Jan;33(1):394-407. DMN5Z0F RU https://pubmed.ncbi.nlm.nih.gov/2296031 DMN60YG DI DMN60YG DMN60YG DN 3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine DMN60YG TI TTIQUX7 DMN60YG TN Steroid 11-beta-hydroxylase (CYP11B1) DMN60YG MA Inhibitor DMN60YG RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMN60YG RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMN60YG DI DMN60YG DMN60YG DN 3-[5-Chloro-indan-(1Z)-ylidenemethyl]-pyridine DMN60YG TI TTSZLWK DMN60YG TN Aromatase (CYP19A1) DMN60YG MA Inhibitor DMN60YG RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMN60YG RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMN61Q5 DI DMN61Q5 DMN61Q5 DN 3,4-Dichlorobenzenemethanethiol DMN61Q5 TI TTZJYKH DMN61Q5 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMN61Q5 MA Inhibitor DMN61Q5 RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMN61Q5 RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMN62KP DI DMN62KP DMN62KP DN S-(2-Chlorobenzyl)isothiourea hydrochloride DMN62KP TI TTZJYKH DMN62KP TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMN62KP MA Inhibitor DMN62KP RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMN62KP RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMN62VE DI DMN62VE DMN62VE DN VDA-1124 DMN62VE TI TTKEPHX DMN62VE TN Granzyme B (GZMB) DMN62VE MA Inhibitor DMN62VE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2369). DMN62VE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2369 DMN68K4 DI DMN68K4 DMN68K4 DN 1,1,1,2,2,4-hexafluoro-7-phenylheptan-3-one DMN68K4 TI TTT1JVS DMN68K4 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMN68K4 MA Inhibitor DMN68K4 RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DMN68K4 RU https://pubmed.ncbi.nlm.nih.gov/20369880 DMN6DAZ DI DMN6DAZ DMN6DAZ DN N-(4-tert-butylphenyl)-4-(pyridin-2-yl)benzamide DMN6DAZ TI TTMI6F5 DMN6DAZ TN Transient receptor potential cation channel V1 (TRPV1) DMN6DAZ MA Inhibitor DMN6DAZ RN From arylureas to biarylamides to aminoquinazolines: discovery of a novel, potent TRPV1 antagonist. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5217-21. DMN6DAZ RU https://pubmed.ncbi.nlm.nih.gov/16870426 DMN6EZY DI DMN6EZY DMN6EZY DN Vitamin K DMN6EZY TI TT6L509 DMN6EZY TN Coagulation factor IIa (F2) DMN6EZY MA Cofactor DMN6EZY RN Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy. Tohoku J Exp Med. 1986 Aug;149(4):351-7. DMN6EZY RU https://pubmed.ncbi.nlm.nih.gov/3775760 DMN6HE3 DI DMN6HE3 DMN6HE3 DN S136492 DMN6HE3 TI TT5U914 DMN6HE3 TN Endothelin-converting enzyme 2 (ECE2) DMN6HE3 MA Inhibitor DMN6HE3 RN Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2. J Med Chem. 2008 Jun 26;51(12):3378-87. DMN6HE3 RU https://pubmed.ncbi.nlm.nih.gov/18507370 DMN6IBS DI DMN6IBS DMN6IBS DN ISIS 112019 DMN6IBS TI TTPJ9XK DMN6IBS TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMN6IBS RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMN6IBS RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMN6IDK DI DMN6IDK DMN6IDK DN 6-Methylamino-5-Nitroisocytosine DMN6IDK TI TT4ILYC DMN6IDK TN Bacterial Dihydropteroate synthetase (Bact folP) DMN6IDK MA Inhibitor DMN6IDK RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMN6IDK RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMN6IV2 DI DMN6IV2 DMN6IV2 DN 2-(2-benzhydryl-4-phenylthiazol-5-yl)acetic acid DMN6IV2 TI TTQDMX5 DMN6IV2 TN Prostaglandin D2 receptor 2 (PTGDR2) DMN6IV2 MA Inhibitor DMN6IV2 RN Novel selective thiazoleacetic acids as CRTH2 antagonists developed from in silico derived hits. Part 2. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1181-5. DMN6IV2 RU https://pubmed.ncbi.nlm.nih.gov/20022749 DMN6Q4E DI DMN6Q4E DMN6Q4E DN Polyporic acid DMN6Q4E TI TT3PQ2Y DMN6Q4E TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMN6Q4E MA Inhibitor DMN6Q4E RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMN6Q4E RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMN6S3F DI DMN6S3F DMN6S3F DN 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL DMN6S3F TI TTOM3J0 DMN6S3F TN Estrogen receptor beta (ESR2) DMN6S3F MA Inhibitor DMN6S3F RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMN6S3F RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMN6S3F DI DMN6S3F DMN6S3F DN 2-(4-HYDROXY-PHENYL)BENZOFURAN-5-OL DMN6S3F TI TTZAYWL DMN6S3F TN Estrogen receptor (ESR) DMN6S3F MA Inhibitor DMN6S3F RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMN6S3F RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMN6UET DI DMN6UET DMN6UET DN ICI 154129 DMN6UET TI TT27RFC DMN6UET TN Opioid receptor delta (OPRD1) DMN6UET MA Antagonist DMN6UET RN In vivo evidence for the selectivity of ICI 154129 for the delta-opioid receptor. Neuropharmacology. 1985 Feb;24(2):107-10. DMN6UET RU https://pubmed.ncbi.nlm.nih.gov/2986029 DMN6ZX9 DI DMN6ZX9 DMN6ZX9 DN (+/-)-threo-N-(2-Methylpyridine)methylphenidate DMN6ZX9 TI TTVBI8W DMN6ZX9 TN Dopamine transporter (DAT) DMN6ZX9 MA Inhibitor DMN6ZX9 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMN6ZX9 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMN70VT DI DMN70VT DMN70VT DN [Au(CN)2]- DMN70VT TI TTHQPL7 DMN70VT TN Carbonic anhydrase I (CA-I) DMN70VT MA Inhibitor DMN70VT RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13. DMN70VT RU https://pubmed.ncbi.nlm.nih.gov/15780631 DMN7290 DI DMN7290 DMN7290 DN Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 DMN7290 TI TTKWM86 DMN7290 TN Opioid receptor mu (MOP) DMN7290 MA Inhibitor DMN7290 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMN7290 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMN7290 DI DMN7290 DMN7290 DN Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 DMN7290 TI TTVFO0U DMN7290 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMN7290 MA Inhibitor DMN7290 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMN7290 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMN7290 DI DMN7290 DMN7290 DN Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 DMN7290 TI TT27RFC DMN7290 TN Opioid receptor delta (OPRD1) DMN7290 MA Inhibitor DMN7290 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMN7290 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMN7501 DI DMN7501 DMN7501 DN F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-CONH2 DMN7501 TI TTNT7K8 DMN7501 TN Nociceptin receptor (OPRL1) DMN7501 MA Inhibitor DMN7501 RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMN7501 RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMN75RD DI DMN75RD DMN75RD DN 3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine DMN75RD TI TTVG215 DMN75RD TN Debrisoquine 4-hydroxylase (CYP2D6) DMN75RD MA Inhibitor DMN75RD RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMN75RD RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMN75RD DI DMN75RD DMN75RD DN 3-(6-Methoxynaphthalen-2-yl)pyridin-4-amine DMN75RD TI TTIQUX7 DMN75RD TN Steroid 11-beta-hydroxylase (CYP11B1) DMN75RD MA Inhibitor DMN75RD RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMN75RD RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMN76A4 DI DMN76A4 DMN76A4 DN Anti-TLR3 mabs DMN76A4 TI TTD24Y0 DMN76A4 TN Toll-like receptor 3 (TLR3) DMN76A4 MA Modulator DMN76A4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753). DMN76A4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753 DMN7DJ5 DI DMN7DJ5 DMN7DJ5 DN BetaARKct DMN7DJ5 TI TTAZ3MN DMN7DJ5 TN Beta-adrenergic receptor kinase 1 (ADRBK1) DMN7DJ5 MA Inhibitor DMN7DJ5 RN Gene-mediated inhibition of the b-adrenergic receptor kinase: a new therapeutic strategy for heart failure. Minerva Cardioangiol. 2001 Dec;49(6):389-94. DMN7DJ5 RU https://pubmed.ncbi.nlm.nih.gov/11733734 DMN7E6Y DI DMN7E6Y DMN7E6Y DN D-257A DMN7E6Y TI TTVBI8W DMN7E6Y TN Dopamine transporter (DAT) DMN7E6Y MA Inhibitor DMN7E6Y RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMN7E6Y RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMN7E6Y DI DMN7E6Y DMN7E6Y DN D-257A DMN7E6Y TI TTAWNKZ DMN7E6Y TN Norepinephrine transporter (NET) DMN7E6Y MA Inhibitor DMN7E6Y RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMN7E6Y RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMN7E6Y DI DMN7E6Y DMN7E6Y DN D-257A DMN7E6Y TI TT3ROYC DMN7E6Y TN Serotonin transporter (SERT) DMN7E6Y MA Inhibitor DMN7E6Y RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMN7E6Y RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMN7GO8 DI DMN7GO8 DMN7GO8 DN NOCARDIMICIN A DMN7GO8 TI TTQ13Z5 DMN7GO8 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMN7GO8 MA Inhibitor DMN7GO8 RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMN7GO8 RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMN7KHS DI DMN7KHS DMN7KHS DN 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one DMN7KHS TI TTSZLWK DMN7KHS TN Aromatase (CYP19A1) DMN7KHS MA Inhibitor DMN7KHS RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMN7KHS RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMN7KHS DI DMN7KHS DMN7KHS DN 1-Imidazol-1-ylmethyl-4-nitro-xanthen-9-one DMN7KHS TI TTRA5BZ DMN7KHS TN Steroid 17-alpha-monooxygenase (S17AH) DMN7KHS MA Inhibitor DMN7KHS RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMN7KHS RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMN7KPQ DI DMN7KPQ DMN7KPQ DN OICR-9429 DMN7KPQ TI TT7OFWB DMN7KPQ TN WD repeat-containing protein 5 (WDR5) DMN7KPQ MA Antagonist DMN7KPQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2831). DMN7KPQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2831 DMN7QB8 DI DMN7QB8 DMN7QB8 DN PMID24915291C31 DMN7QB8 TI TT1ZV49 DMN7QB8 TN Tyrosine-protein kinase Tec (PSCTK4) DMN7QB8 MA Inhibitor DMN7QB8 RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMN7QB8 RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMN7QB8 DI DMN7QB8 DMN7QB8 DN PMID24915291C31 DMN7QB8 TI TTNDSC3 DMN7QB8 TN B lymphocyte kinase (BLK) DMN7QB8 MA Inhibitor DMN7QB8 RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMN7QB8 RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMN7QB8 DI DMN7QB8 DMN7QB8 DN PMID24915291C31 DMN7QB8 TI TTGM6VW DMN7QB8 TN Tyrosine-protein kinase BTK (ATK) DMN7QB8 MA Inhibitor DMN7QB8 RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMN7QB8 RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMN7QB8 DI DMN7QB8 DMN7QB8 DN PMID24915291C31 DMN7QB8 TI TTN2I9E DMN7QB8 TN Tyrosine-protein kinase BMX (BMX) DMN7QB8 MA Inhibitor DMN7QB8 RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMN7QB8 RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMN7QB8 DI DMN7QB8 DMN7QB8 DN PMID24915291C31 DMN7QB8 TI TT8M1DP DMN7QB8 TN Tyrosine-protein kinase TXK (TXK) DMN7QB8 MA Inhibitor DMN7QB8 RN Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. DMN7QB8 RU https://pubmed.ncbi.nlm.nih.gov/24915291 DMN7S4L DI DMN7S4L DMN7S4L DN OXYRESVERATROL DMN7S4L TI TTULVH8 DMN7S4L TN Tyrosinase (TYR) DMN7S4L MA Inhibitor DMN7S4L RN Chemical transformations of oxyresveratrol (trans-2,4,3',5'-tetrahydroxystilbene) into a potent tyrosinase inhibitor and a strong cytotoxic agent. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5650-3. DMN7S4L RU https://pubmed.ncbi.nlm.nih.gov/16919455 DMN7XT9 DI DMN7XT9 DMN7XT9 DN (2-Ethoxy-ethyl)-trimethyl-ammonium iodide DMN7XT9 TI TT1RS9F DMN7XT9 TN Acetylcholinesterase (AChE) DMN7XT9 MA Inhibitor DMN7XT9 RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMN7XT9 RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMN802V DI DMN802V DMN802V DN ROSETTACIN DMN802V TI TTGTQHC DMN802V TN DNA topoisomerase I (TOP1) DMN802V MA Inhibitor DMN802V RN Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of share... Bioorg Med Chem. 2009 Oct 15;17(20):7145-55. DMN802V RU https://pubmed.ncbi.nlm.nih.gov/19783447 DMN80XD DI DMN80XD DMN80XD DN PT-313 DMN80XD TI TT84ETX DMN80XD TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMN80XD MA Inhibitor DMN80XD RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMN80XD RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMN84RM DI DMN84RM DMN84RM DN 6-Formylindolo[3,2-b]carbazole DMN84RM TI TT037IE DMN84RM TN Aryl hydrocarbon receptor (AHR) DMN84RM MA Agonist DMN84RM RN 6-Formylindolo(3,2-b)carbazole induced aryl hydrocarbon receptor activation prevents intestinal barrier dysfunction through regulation of claudin-2 expression. Chem Biol Interact. 2018 May 25;288:83-90. DMN84RM RU https://pubmed.ncbi.nlm.nih.gov/29680209 DMN861Q DI DMN861Q DMN861Q DN AZALINE B DMN861Q TI TT8R70G DMN861Q TN Gonadotropin-releasing hormone receptor (GNRHR) DMN861Q MA Inhibitor DMN861Q RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMN861Q RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMN8AP0 DI DMN8AP0 DMN8AP0 DN flufenamate DMN8AP0 TI TTAHD89 DMN8AP0 TN Polycystic kidney disease 2-like 1 (TRPP2) DMN8AP0 MA Blocker (channel blocker) DMN8AP0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505). DMN8AP0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=505 DMN8AP0 DI DMN8AP0 DMN8AP0 DN flufenamate DMN8AP0 TI TTRBT3W DMN8AP0 TN Short transient receptor potential channel 6 (TRPC6) DMN8AP0 MA Activator DMN8AP0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491). DMN8AP0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491 DMN8B1S DI DMN8B1S DMN8B1S DN CFMMC DMN8B1S TI TTVBPDM DMN8B1S TN Metabotropic glutamate receptor 1 (mGluR1) DMN8B1S MA Modulator (allosteric modulator) DMN8B1S RN Identification of a novel transmembrane domain involved in the negative modulation of mGluR1 using a newly discovered allosteric mGluR1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one. Neuropharmacology. 2009 Sep;57(4):438-45. DMN8B1S RU https://pubmed.ncbi.nlm.nih.gov/19559036 DMN8C93 DI DMN8C93 DMN8C93 DN 3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol DMN8C93 TI TTSQIFT DMN8C93 TN 5-HT 1A receptor (HTR1A) DMN8C93 MA Inhibitor DMN8C93 RN 6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90. DMN8C93 RU https://pubmed.ncbi.nlm.nih.gov/1433207 DMN8C93 DI DMN8C93 DMN8C93 DN 3-Ethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-6-ol DMN8C93 TI TTEX248 DMN8C93 TN Dopamine D2 receptor (D2R) DMN8C93 MA Inhibitor DMN8C93 RN 6-Hydroxy-3-n-propyl-2,3,4,5-tetrahydro-1H-3-benzazepine and analogs: new centrally acting 5-HT1A receptor agonists. J Med Chem. 1992 Oct 30;35(22):3984-90. DMN8C93 RU https://pubmed.ncbi.nlm.nih.gov/1433207 DMN8JKX DI DMN8JKX DMN8JKX DN E-EBU-dM DMN8JKX TI TT84ETX DMN8JKX TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMN8JKX MA Modulator DMN8JKX RN Construction of the chimeric reverse transcriptase of simian immunodeficiency virus sensitive to nonnucleoside reverse transcriptase inhibitor. Microbiol Immunol. 1998;42(3):195-202. DMN8JKX RU https://www.ncbi.nlm.nih.gov/pubmed/9570285 DMN8M5P DI DMN8M5P DMN8M5P DN PD-168393 DMN8M5P TI TTGKNB4 DMN8M5P TN Epidermal growth factor receptor (EGFR) DMN8M5P MA Inhibitor DMN8M5P RN Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38. DMN8M5P RU https://pubmed.ncbi.nlm.nih.gov/17334377 DMN8M5P DI DMN8M5P DMN8M5P DN PD-168393 DMN8M5P TI TTR5TV4 DMN8M5P TN ERBB2 messenger RNA (HER2 mRNA) DMN8M5P MA Inhibitor DMN8M5P RN Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15. DMN8M5P RU https://pubmed.ncbi.nlm.nih.gov/10346932 DMN8OHG DI DMN8OHG DMN8OHG DN ISIS 4189 DMN8OHG TI TT2MI95 DMN8OHG TN PKC-alpha messenger RNA (PRKCA mRNA) DMN8OHG RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMN8OHG RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMN8OR2 DI DMN8OR2 DMN8OR2 DN Piperidin-(2E)-ylideneamine DMN8OR2 TI TTCM4B3 DMN8OR2 TN Nitric-oxide synthase endothelial (NOS3) DMN8OR2 MA Inhibitor DMN8OR2 RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMN8OR2 RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMN8OR2 DI DMN8OR2 DMN8OR2 DN Piperidin-(2E)-ylideneamine DMN8OR2 TI TTF10I9 DMN8OR2 TN Nitric-oxide synthase inducible (NOS2) DMN8OR2 MA Inhibitor DMN8OR2 RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMN8OR2 RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMN8OR2 DI DMN8OR2 DMN8OR2 DN Piperidin-(2E)-ylideneamine DMN8OR2 TI TTZUFI5 DMN8OR2 TN Nitric-oxide synthase brain (NOS1) DMN8OR2 MA Inhibitor DMN8OR2 RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMN8OR2 RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMN8QAF DI DMN8QAF DMN8QAF DN 8-aminoquinolines DMN8QAF TI TT3PQ2Y DMN8QAF TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMN8QAF MA Inhibitor DMN8QAF RN The effects of antimalarials on the Plasmodium falciparum dihydroorotate dehydrogenase. Exp Parasitol. 1994 Aug;79(1):50-6. DMN8QAF RU https://pubmed.ncbi.nlm.nih.gov/8050525 DMN8QAF DI DMN8QAF DMN8QAF DN 8-aminoquinolines DMN8QAF TI TTJSZTB DMN8QAF TN Nicotinic acetylcholine receptor (nAChR) DMN8QAF MA Antagonist DMN8QAF RN Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994 Oct;5(10):1033-40. DMN8QAF RU https://pubmed.ncbi.nlm.nih.gov/7848904 DMN8TVB DI DMN8TVB DMN8TVB DN 2-Acetyl-cyclohexane-1,3-dione DMN8TVB TI TT8DSFC DMN8TVB TN Hydroxyphenylpyruvate dioxygenase (HPD) DMN8TVB MA Inhibitor DMN8TVB RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DMN8TVB RU https://pubmed.ncbi.nlm.nih.gov/10853644 DMN8W1H DI DMN8W1H DMN8W1H DN 2-ethyl-9H-carbazole DMN8W1H TI TTBGTCW DMN8W1H TN Kinesin spindle messenger RNA (KIF11 mRNA) DMN8W1H MA Inhibitor DMN8W1H RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMN8W1H RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMN8W46 DI DMN8W46 DMN8W46 DN AR231453 DMN8W46 TI TT7QNVC DMN8W46 TN Glucose-dependent insulinotropic receptor (GPR119) DMN8W46 MA Agonist DMN8W46 RN A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology. 2007 Jun;148(6):2601-9. DMN8W46 RU https://pubmed.ncbi.nlm.nih.gov/17289847 DMN8Z3C DI DMN8Z3C DMN8Z3C DN 4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine DMN8Z3C TI TTZUFI5 DMN8Z3C TN Nitric-oxide synthase brain (NOS1) DMN8Z3C MA Inhibitor DMN8Z3C RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMN8Z3C RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMN8Z3C DI DMN8Z3C DMN8Z3C DN 4-Methyl-5-propyl-pyrrolidin-(2Z)-ylideneamine DMN8Z3C TI TTF10I9 DMN8Z3C TN Nitric-oxide synthase inducible (NOS2) DMN8Z3C MA Inhibitor DMN8Z3C RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMN8Z3C RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMN90R6 DI DMN90R6 DMN90R6 DN NVP-SAA164 DMN90R6 TI TTG5QIA DMN90R6 TN B1 bradykinin receptor (BDKRB1) DMN90R6 MA Antagonist DMN90R6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 659). DMN90R6 RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=659 DMN93QT DI DMN93QT DMN93QT DN 10R-hydroxylobelane DMN93QT TI TTVBI8W DMN93QT TN Dopamine transporter (DAT) DMN93QT MA Inhibitor DMN93QT RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMN93QT RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMN93QT DI DMN93QT DMN93QT DN 10R-hydroxylobelane DMN93QT TI TT3ROYC DMN93QT TN Serotonin transporter (SERT) DMN93QT MA Inhibitor DMN93QT RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMN93QT RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMN97BF DI DMN97BF DMN97BF DN PALBINONE DMN97BF TI TTFBNVI DMN97BF TN Aldose reductase (AKR1B1) DMN97BF MA Inhibitor DMN97BF RN Inhibitors of aldose reductase and formation of advanced glycation end-products in moutan cortex (Paeonia suffruticosa). J Nat Prod. 2009 Aug;72(8):1465-70. DMN97BF RU https://pubmed.ncbi.nlm.nih.gov/19670875 DMN97TC DI DMN97TC DMN97TC DN 4-(2-(4-chlorobenzyloxy)-5-bromobenzyl)morpholine DMN97TC TI TT2CEJG DMN97TC TN C-C chemokine receptor type 5 (CCR5) DMN97TC MA Inhibitor DMN97TC RN CCR5 receptor antagonists: discovery and SAR study of guanylhydrazone derivatives. Bioorg Med Chem Lett. 2007 Jan 1;17(1):231-4. DMN97TC RU https://pubmed.ncbi.nlm.nih.gov/17081751 DMN98U1 DI DMN98U1 DMN98U1 DN Rimantadine isomer 1 DMN98U1 TI TTXT3PU DMN98U1 TN Influenza M2 protein (Influ M) DMN98U1 MA Inhibitor DMN98U1 RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMN98U1 RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMN9FPV DI DMN9FPV DMN9FPV DN 5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid DMN9FPV TI TTHI19T DMN9FPV TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMN9FPV MA Inhibitor DMN9FPV RN Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54. DMN9FPV RU https://pubmed.ncbi.nlm.nih.gov/17956081 DMN9OS1 DI DMN9OS1 DMN9OS1 DN 2-oleoyl-LPA DMN9OS1 TI TTQ6S1K DMN9OS1 TN Lysophosphatidic acid receptor 1 (LPAR1) DMN9OS1 MA Agonist DMN9OS1 RN Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65. DMN9OS1 RU https://pubmed.ncbi.nlm.nih.gov/10922489 DMN9OS1 DI DMN9OS1 DMN9OS1 DN 2-oleoyl-LPA DMN9OS1 TI TTE2YJR DMN9OS1 TN Lysophosphatidate-3 receptor (LPAR3) DMN9OS1 MA Agonist DMN9OS1 RN Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65. DMN9OS1 RU https://pubmed.ncbi.nlm.nih.gov/10922489 DMN9OS1 DI DMN9OS1 DMN9OS1 DN 2-oleoyl-LPA DMN9OS1 TI TTB7Y8I DMN9OS1 TN Lysophosphatidic acid receptor 2 (LPAR2) DMN9OS1 MA Agonist DMN9OS1 RN Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65. DMN9OS1 RU https://pubmed.ncbi.nlm.nih.gov/10922489 DMN9OS1 DI DMN9OS1 DMN9OS1 DN 2-oleoyl-LPA DMN9OS1 TI TT254XD DMN9OS1 TN Kynurenic acid receptor (GPR35) DMN9OS1 MA Agonist DMN9OS1 RN GPR35 is a novel lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2010 Apr 30;395(2):232-7. DMN9OS1 RU https://pubmed.ncbi.nlm.nih.gov/20361937 DMN9QO4 DI DMN9QO4 DMN9QO4 DN UCCF-853 DMN9QO4 TI TTRLZHP DMN9QO4 TN cAMP-dependent chloride channel (CFTR) DMN9QO4 MA Activator DMN9QO4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DMN9QO4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DMN9RE5 DI DMN9RE5 DMN9RE5 DN AEZS-131 DMN9RE5 TI TT4TQBX DMN9RE5 TN Extracellular signal-regulated kinase 2 (ERK2) DMN9RE5 MA Inhibitor DMN9RE5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1495). DMN9RE5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1495 DMN9UCI DI DMN9UCI DMN9UCI DN ZY H2 DMN9UCI TI TTZMAO3 DMN9UCI TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMN9UCI MA Modulator DMN9UCI RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMN9UCI RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMN9UCI DI DMN9UCI DMN9UCI DN ZY H2 DMN9UCI TI TTJ584C DMN9UCI TN Peroxisome proliferator-activated receptor alpha (PPARA) DMN9UCI MA Modulator DMN9UCI RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMN9UCI RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMN9UX3 DI DMN9UX3 DMN9UX3 DN MASLINIC ACID DMN9UX3 TI TTELIN2 DMN9UX3 TN PTPN1 messenger RNA (PTPN1 mRNA) DMN9UX3 MA Inhibitor DMN9UX3 RN Synthesis and biological evaluation of heterocyclic ring-substituted maslinic acid derivatives as novel inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6618-22. DMN9UX3 RU https://pubmed.ncbi.nlm.nih.gov/19846303 DMN9W56 DI DMN9W56 DMN9W56 DN PERIPENTADENINE DMN9W56 TI TT27RFC DMN9W56 TN Opioid receptor delta (OPRD1) DMN9W56 MA Inhibitor DMN9W56 RN Alkaloids with human delta-opioid receptor binding affinity from the Australian rainforest tree Peripentadenia mearsii. J Nat Prod. 2007 Dec;70(12):1946-50. DMN9W56 RU https://pubmed.ncbi.nlm.nih.gov/18039010 DMN9WZ3 DI DMN9WZ3 DMN9WZ3 DN N-Benzyl-(6-butoxy-2-naphthyl)-2-aminopropane DMN9WZ3 TI TT3WG5C DMN9WZ3 TN Monoamine oxidase type A (MAO-A) DMN9WZ3 MA Inhibitor DMN9WZ3 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMN9WZ3 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTQBR95 DMN9YOB TN Stress-activated protein kinase 2a (p38 alpha) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TT73U6C DMN9YOB TN Stress-activated protein kinase 2b (p38 beta) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTIDAPM DMN9YOB TN ERK activator kinase 1 (MEK1) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TT860QF DMN9YOB TN LCK tyrosine protein kinase (LCK) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTWTSCV DMN9YOB TN RAC-alpha serine/threonine-protein kinase (AKT1) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTFJ8Q1 DMN9YOB TN Protein kinase C alpha (PRKCA) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TT0K6EO DMN9YOB TN Stress-activated protein kinase JNK1 (JNK1) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTRSMW9 DMN9YOB TN Glycogen synthase kinase-3 beta (GSK-3B) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTYT93M DMN9YOB TN MAP kinase p38 (MAPK12) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTZN7RP DMN9YOB TN Rho-associated protein kinase 1 (ROCK1) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTG0U4H DMN9YOB TN Ribosomal protein S6 kinase beta-1 (S6K1) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTTU902 DMN9YOB TN Checkpoint kinase-1 (CHK1) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTLAFZV DMN9YOB TN AMP-activated protein kinase (AMPK) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTTV8EJ DMN9YOB TN Serine/threonine-protein kinase Sgk1 (SGK1) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TT4TQBX DMN9YOB TN Extracellular signal-regulated kinase 2 (ERK2) DMN9YOB MA Inhibitor DMN9YOB RN Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/15566294 DMN9YOB DI DMN9YOB DMN9YOB DN 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB TI TTER6YH DMN9YOB TN Casein kinase II alpha (CSNK2A1) DMN9YOB MA Inhibitor DMN9YOB RN Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. DMN9YOB RU https://pubmed.ncbi.nlm.nih.gov/19414254 DMN9YXL DI DMN9YXL DMN9YXL DN (S)-4-AHCP DMN9YXL TI TT0MYE2 DMN9YXL TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMN9YXL MA Agonist DMN9YXL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMN9YXL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMNA2M6 DI DMNA2M6 DMNA2M6 DN 6-hydroxy-2,9-dimethyl-9H-beta-carbolin-2-ium DMNA2M6 TI TT1RS9F DMNA2M6 TN Acetylcholinesterase (AChE) DMNA2M6 MA Inhibitor DMNA2M6 RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMNA2M6 RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMNA3F4 DI DMNA3F4 DMNA3F4 DN Ac-RYYRIK-K-(NH2)-YRFB DMNA3F4 TI TTNT7K8 DMNA3F4 TN Nociceptin receptor (OPRL1) DMNA3F4 MA Inhibitor DMNA3F4 RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DMNA3F4 RU https://pubmed.ncbi.nlm.nih.gov/16814543 DMNA3F4 DI DMNA3F4 DMNA3F4 DN Ac-RYYRIK-K-(NH2)-YRFB DMNA3F4 TI TTKWM86 DMNA3F4 TN Opioid receptor mu (MOP) DMNA3F4 MA Inhibitor DMNA3F4 RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DMNA3F4 RU https://pubmed.ncbi.nlm.nih.gov/16814543 DMNA6LF DI DMNA6LF DMNA6LF DN 3-(tetradecylamino)propylphosphonic acid DMNA6LF TI TT9JZCK DMNA6LF TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMNA6LF MA Inhibitor DMNA6LF RN A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5. DMNA6LF RU https://pubmed.ncbi.nlm.nih.gov/15615513 DMNA8RS DI DMNA8RS DMNA8RS DN ICI-204448 DMNA8RS TI TTQW87Y DMNA8RS TN Opioid receptor kappa (OPRK1) DMNA8RS MA Modulator DMNA8RS RN ICI 204448: a kappa-opioid agonist with limited access to the CNS. DMNA8RS RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1854424 DMNAE6J DI DMNAE6J DMNAE6J DN H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 DMNAE6J TI TT27RFC DMNAE6J TN Opioid receptor delta (OPRD1) DMNAE6J MA Inhibitor DMNAE6J RN Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80. DMNAE6J RU https://pubmed.ncbi.nlm.nih.gov/10691683 DMNAE6J DI DMNAE6J DMNAE6J DN H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 DMNAE6J TI TTKWM86 DMNAE6J TN Opioid receptor mu (MOP) DMNAE6J MA Inhibitor DMNAE6J RN Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80. DMNAE6J RU https://pubmed.ncbi.nlm.nih.gov/10691683 DMNAHVB DI DMNAHVB DMNAHVB DN 6-(4-Chloro-benzenesulfonyl)-2H-pyridazin-3-one DMNAHVB TI TTFBNVI DMNAHVB TN Aldose reductase (AKR1B1) DMNAHVB MA Inhibitor DMNAHVB RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMNAHVB RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMNAJQY DI DMNAJQY DMNAJQY DN ARO 087 DMNAJQY TI TT0LF7H DMNAJQY TN Fibroblast growth factor receptor (FGFR) DMNAJQY MA Modulator DMNAJQY RN J Clin Oncol 33, 2015 (suppl; abstr 2545). DMNAJQY RU http://meetinglibrary.asco.org/content/149025-156 DMNALMF DI DMNALMF DMNALMF DN trichloroethanol DMNALMF TI TTR6K75 DMNALMF TN 5-HT 3B receptor (HTR3B) DMNALMF MA Modulator (allosteric modulator) DMNALMF RN Co-expression of the 5-HT(3B) subunit with the 5-HT(3A) receptor reduces alcohol sensitivity. Brain Res Mol Brain Res. 2005 Dec 14;142(2):146-50. DMNALMF RU https://pubmed.ncbi.nlm.nih.gov/16257471 DMNALMF DI DMNALMF DMNALMF DN trichloroethanol DMNALMF TI TTPC4TU DMNALMF TN 5-HT 3A receptor (HTR3A) DMNALMF MA Modulator (allosteric modulator) DMNALMF RN Arginine 246 of the pretransmembrane domain 1 region alters 2,2,2-trichloroethanol action in the 5-hydroxytryptamine3A receptor. J Pharmacol Exp Ther. 2008 Mar;324(3):1011-8. DMNALMF RU https://pubmed.ncbi.nlm.nih.gov/18094321 DMNARGO DI DMNARGO DMNARGO DN Phlorizin DMNARGO TI TT2UE56 DMNARGO TN Sodium/glucose cotransporter 1 (SGLT1) DMNARGO MA Inhibitor DMNARGO RN J Biol Chem. 1988 Jan 5;263(1):187-92.High affinity phlorizin binding to the LLC-PK1 cells exhibits a sodium:phlorizin stoichiometry of 2:1. DMNARGO RU https://pubmed.ncbi.nlm.nih.gov/3335496 DMNAT1D DI DMNAT1D DMNAT1D DN 4-((4-methoxyphenyl)diazenyl)benzenesulfonamide DMNAT1D TI TTVKILB DMNAT1D TN Prostaglandin G/H synthase 2 (COX-2) DMNAT1D MA Inhibitor DMNAT1D RN Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4440-3. DMNAT1D RU https://pubmed.ncbi.nlm.nih.gov/16814546 DMNAX1Q DI DMNAX1Q DMNAX1Q DN BIX 02565 DMNAX1Q TI TTUM2ZR DMNAX1Q TN Ribosomal protein S6 kinase alpha-3 (RSK3) DMNAX1Q MA Inhibitor DMNAX1Q RN Indole RSK inhibitors. Part 2: optimization of cell potency and kinase selectivity. Bioorg Med Chem Lett. 2012 Jan 1;22(1):738-42. DMNAX1Q RU https://pubmed.ncbi.nlm.nih.gov/22056746 DMNAYEP DI DMNAYEP DMNAYEP DN STYLISSADINE B DMNAYEP TI TT473XN DMNAYEP TN P2X purinoceptor 7 (P2RX7) DMNAYEP MA Inhibitor DMNAYEP RN Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem. 2009 Jul 15;17(14):4861-5. DMNAYEP RU https://pubmed.ncbi.nlm.nih.gov/19540765 DMNB4UJ DI DMNB4UJ DMNB4UJ DN ISIS 156475 DMNB4UJ TI TTILUKB DMNB4UJ TN IRAK4 messenger RNA (IRAK4 mRNA) DMNB4UJ RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMNB4UJ RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMNB7CW DI DMNB7CW DMNB7CW DN BAS-01047341 DMNB7CW TI TT6PKBN DMNB7CW TN Proto-oncogene c-Src (SRC) DMNB7CW MA Inhibitor DMNB7CW RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMNB7CW RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMNB82L DI DMNB82L DMNB82L DN LY063518 DMNB82L TI TTJQOD7 DMNB82L TN 5-HT 2A receptor (HTR2A) DMNB82L MA Antagonist DMNB82L RN A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68. DMNB82L RU https://pubmed.ncbi.nlm.nih.gov/8845011 DMNBA0G DI DMNBA0G DMNBA0G DN Benzoquinone DMNBA0G TI TT1RS9F DMNBA0G TN Acetylcholinesterase (AChE) DMNBA0G MA Inhibitor DMNBA0G RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMNBA0G RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMNBA0G DI DMNBA0G DMNBA0G DN Benzoquinone DMNBA0G TI TTEB0GD DMNBA0G TN Cholinesterase (BCHE) DMNBA0G MA Inhibitor DMNBA0G RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMNBA0G RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMNBDGH DI DMNBDGH DMNBDGH DN (Z)-1-(benzo[d]oxazol-2-yl)octadec-9-en-1-one DMNBDGH TI TTDP1UC DMNBDGH TN Fatty acid amide hydrolase (FAAH) DMNBDGH MA Inhibitor DMNBDGH RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMNBDGH RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMNBFX0 DI DMNBFX0 DMNBFX0 DN MS436 DMNBFX0 TI TTRA6BO DMNBFX0 TN Bromodomain-containing protein 4 (BRD4) DMNBFX0 MA Inhibitor DMNBFX0 RN Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J Med Chem. 2013 Nov 27;56(22):9251-64. DMNBFX0 RU https://pubmed.ncbi.nlm.nih.gov/24144283 DMNBLPA DI DMNBLPA DMNBLPA DN 5-hexyl-2-(4-nitrophenoxy)phenol DMNBLPA TI TTVTX4N DMNBLPA TN Bacterial Fatty acid synthetase I (Bact inhA) DMNBLPA MA Inhibitor DMNBLPA RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMNBLPA RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMNBLQ8 DI DMNBLQ8 DMNBLQ8 DN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline DMNBLQ8 TI TTI7421 DMNBLQ8 TN Platelet-derived growth factor receptor beta (PDGFRB) DMNBLQ8 MA Inhibitor DMNBLQ8 RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMNBLQ8 RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMNBLQ8 DI DMNBLQ8 DMNBLQ8 DN 4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline DMNBLQ8 TI TTGKNB4 DMNBLQ8 TN Epidermal growth factor receptor (EGFR) DMNBLQ8 MA Inhibitor DMNBLQ8 RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMNBLQ8 RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMNBUS4 DI DMNBUS4 DMNBUS4 DN KNI-10152 DMNBUS4 TI TTXMNHO DMNBUS4 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMNBUS4 MA Inhibitor DMNBUS4 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMNBUS4 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMNC2A5 DI DMNC2A5 DMNC2A5 DN Tosyl-D-Proline DMNC2A5 TI TTU6BFZ DMNC2A5 TN Candida Thymidylate synthase (Candi TMP1) DMNC2A5 MA Inhibitor DMNC2A5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNC2A5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNC6W9 DI DMNC6W9 DMNC6W9 DN 3-[3-(4-hydroxyphenyl)isoxazol-5-yl]phenol DMNC6W9 TI TTIWB6L DMNC6W9 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMNC6W9 MA Inhibitor DMNC6W9 RN Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid ... Bioorg Med Chem. 2008 Jun 15;16(12):6423-35. DMNC6W9 RU https://pubmed.ncbi.nlm.nih.gov/18514529 DMNCAE9 DI DMNCAE9 DMNCAE9 DN [4-(3-Adamantan-1-yl-ureido)-phenyl]-acetic acid DMNCAE9 TI TT7WVHI DMNCAE9 TN Soluble epoxide hydrolase (EPHX2) DMNCAE9 MA Inhibitor DMNCAE9 RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMNCAE9 RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMNCJ5R DI DMNCJ5R DMNCJ5R DN 1,3,7-Tripropyl-3,7-dihydro-purine-2,6-dione DMNCJ5R TI TTM2AOE DMNCJ5R TN Adenosine A2a receptor (ADORA2A) DMNCJ5R MA Inhibitor DMNCJ5R RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DMNCJ5R RU https://pubmed.ncbi.nlm.nih.gov/3806581 DMNCL5G DI DMNCL5G DMNCL5G DN 9-Benzyl-6-phenylsulfanyl-9H-purine DMNCL5G TI TTQBR95 DMNCL5G TN Stress-activated protein kinase 2a (p38 alpha) DMNCL5G MA Inhibitor DMNCL5G RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMNCL5G RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMNCP8Y DI DMNCP8Y DMNCP8Y DN 2-(3''-pyrrolylethyloxy)adenosine DMNCP8Y TI TTJFY5U DMNCP8Y TN Adenosine A3 receptor (ADORA3) DMNCP8Y MA Inhibitor DMNCP8Y RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMNCP8Y RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMNCP8Y DI DMNCP8Y DMNCP8Y DN 2-(3''-pyrrolylethyloxy)adenosine DMNCP8Y TI TTK25J1 DMNCP8Y TN Adenosine A1 receptor (ADORA1) DMNCP8Y MA Inhibitor DMNCP8Y RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMNCP8Y RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMNCP8Y DI DMNCP8Y DMNCP8Y DN 2-(3''-pyrrolylethyloxy)adenosine DMNCP8Y TI TTM2AOE DMNCP8Y TN Adenosine A2a receptor (ADORA2A) DMNCP8Y MA Inhibitor DMNCP8Y RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMNCP8Y RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMNCU6H DI DMNCU6H DMNCU6H DN Neamine DMNCU6H TI TT38DW5 DMNCU6H TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMNCU6H MA Inhibitor DMNCU6H RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMNCU6H RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMNCVIP DI DMNCVIP DMNCVIP DN 4-MA DMNCVIP TI TTZT9R2 DMNCVIP TN Hydroxysteroid dehydrogenase 3-beta (HSD3B) DMNCVIP MA Inhibitor DMNCVIP RN Activity and inhibition of 3-beta-hydroxysteroid dehydrogenase/delta-5-4-isomerase in human skin. Skin Pharmacol. 1997;10(3):160-8. DMNCVIP RU https://pubmed.ncbi.nlm.nih.gov/9287397 DMNCWXZ DI DMNCWXZ DMNCWXZ DN 1,3,5-BENZENETRICARBOXYLIC ACID DMNCWXZ TI TTQO71U DMNCWXZ TN Hemoglobin (HB) DMNCWXZ MA Inhibitor DMNCWXZ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNCWXZ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNCZEQ DI DMNCZEQ DMNCZEQ DN WAY-644 DMNCZEQ TI TTXZ0KQ DMNCZEQ TN Matrix metalloproteinase-12 (MMP-12) DMNCZEQ MA Inhibitor DMNCZEQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636). DMNCZEQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636 DMND0JL DI DMND0JL DMND0JL DN ISIS 12883 DMND0JL TI TTR5TV4 DMND0JL TN ERBB2 messenger RNA (HER2 mRNA) DMND0JL RN US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression. DMND0JL RU http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true DMND2AS DI DMND2AS DMND2AS DN Diisopropylphosphono Group DMND2AS TI TTDIGC1 DMND2AS TN Dipeptidyl peptidase 4 (DPP-4) DMND2AS MA Inhibitor DMND2AS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMND2AS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMND2QG DI DMND2QG DMND2QG DN PICROTIN DMND2QG TI TTZ8EM9 DMND2QG TN Glycine receptor (GlyR) DMND2QG MA Inhibitor DMND2QG RN Mechanisms for picrotoxinin and picrotin blocks of alpha2 homomeric glycine receptors. J Biol Chem. 2007 Jun 1;282(22):16016-35. DMND2QG RU https://pubmed.ncbi.nlm.nih.gov/17405877 DMND39P DI DMND39P DMND39P DN 9-(2-aminopropyl)-9,10-dihydroanthracene DMND39P TI TTTIBOJ DMND39P TN Histamine H1 receptor (H1R) DMND39P MA Inhibitor DMND39P RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMND39P RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMND39P DI DMND39P DMND39P DN 9-(2-aminopropyl)-9,10-dihydroanthracene DMND39P TI TTJQOD7 DMND39P TN 5-HT 2A receptor (HTR2A) DMND39P MA Inhibitor DMND39P RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMND39P RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMND5EU DI DMND5EU DMND5EU DN Alpha-7-Deoxyhomonojirimycin DMND5EU TI TTLPC70 DMND5EU TN Lysosomal alpha-glucosidase (GAA) DMND5EU MA Inhibitor DMND5EU RN New polyhydroxylated pyrrolidine, piperidine, and pyrrolizidine alkaloids from Scilla sibirica. J Nat Prod. 2002 Dec;65(12):1875-81. DMND5EU RU https://pubmed.ncbi.nlm.nih.gov/12502331 DMND63Z DI DMND63Z DMND63Z DN 2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol DMND63Z TI TTZAYWL DMND63Z TN Estrogen receptor (ESR) DMND63Z MA Inhibitor DMND63Z RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMND63Z RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMND63Z DI DMND63Z DMND63Z DN 2-(4-Hydroxy-phenyl)-7-propenyl-benzooxazol-5-ol DMND63Z TI TTOM3J0 DMND63Z TN Estrogen receptor beta (ESR2) DMND63Z MA Inhibitor DMND63Z RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMND63Z RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMNDECA DI DMNDECA DMNDECA DN 15-deoxy-Delta12,14-PGJ2 DMNDECA TI TTQDMX5 DMNDECA TN Prostaglandin D2 receptor 2 (PTGDR2) DMNDECA MA Agonist DMNDECA RN Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. DMNDECA RU https://pubmed.ncbi.nlm.nih.gov/12721327 DMNDECA DI DMNDECA DMNDECA DN 15-deoxy-Delta12,14-PGJ2 DMNDECA TI TTNVEIR DMNDECA TN Prostaglandin D2 receptor (PTGDR) DMNDECA MA Agonist DMNDECA RN Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24. DMNDECA RU https://pubmed.ncbi.nlm.nih.gov/9579725 DMNDJTL DI DMNDJTL DMNDJTL DN 1'-(4-Methyl-benzyl)-[1,4']bipiperidinyl DMNDJTL TI TTULVH8 DMNDJTL TN Tyrosinase (TYR) DMNDJTL MA Inhibitor DMNDJTL RN Dragon method for finding novel tyrosinase inhibitors: Biosilico identification and experimental in vitro assays. Eur J Med Chem. 2007 Nov-Dec;42(11-12):1370-81. DMNDJTL RU https://pubmed.ncbi.nlm.nih.gov/17637486 DMNDLAS DI DMNDLAS DMNDLAS DN PKF-242-484 DMNDLAS TI TT6AZXG DMNDLAS TN TNF alpha converting enzyme (ADAM17) DMNDLAS MA Inhibitor DMNDLAS RN Current perspective of TACE inhibitors: a review. Bioorg Med Chem. 2009 Jan 15;17(2):444-59. DMNDLAS RU https://pubmed.ncbi.nlm.nih.gov/19095454 DMNDLAS DI DMNDLAS DMNDLAS DN PKF-242-484 DMNDLAS TI TTHY57M DMNDLAS TN Matrix metalloproteinase-13 (MMP-13) DMNDLAS MA Inhibitor DMNDLAS RN A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6. DMNDLAS RU https://pubmed.ncbi.nlm.nih.gov/16516469 DMNDLAS DI DMNDLAS DMNDLAS DN PKF-242-484 DMNDLAS TI TTUZ2L5 DMNDLAS TN Matrix metalloproteinase-3 (MMP-3) DMNDLAS MA Inhibitor DMNDLAS RN A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6. DMNDLAS RU https://pubmed.ncbi.nlm.nih.gov/16516469 DMNDLAS DI DMNDLAS DMNDLAS DN PKF-242-484 DMNDLAS TI TTF8CQI DMNDLAS TN Tumor necrosis factor (TNF) DMNDLAS MA Inhibitor DMNDLAS RN Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme. J Med Chem. 2002 May 23;45(11):2289-93. DMNDLAS RU https://pubmed.ncbi.nlm.nih.gov/12014967 DMNDLAS DI DMNDLAS DMNDLAS DN PKF-242-484 DMNDLAS TI TTMX39J DMNDLAS TN Matrix metalloproteinase-1 (MMP-1) DMNDLAS MA Inhibitor DMNDLAS RN A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2632-6. DMNDLAS RU https://pubmed.ncbi.nlm.nih.gov/16516469 DMNDOLZ DI DMNDOLZ DMNDOLZ DN naltriben DMNDOLZ TI TTKWM86 DMNDOLZ TN Opioid receptor mu (MOP) DMNDOLZ MA Antagonist DMNDOLZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMNDOLZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMNDOLZ DI DMNDOLZ DMNDOLZ DN naltriben DMNDOLZ TI TT27RFC DMNDOLZ TN Opioid receptor delta (OPRD1) DMNDOLZ MA Antagonist DMNDOLZ RN Differential antagonism of delta opioid agonists by naltrindole and its benzofuran analog (NTB) in mice: evidence for delta opioid receptor subtypes. J Pharmacol Exp Ther. 1991 May;257(2):676-80. DMNDOLZ RU https://pubmed.ncbi.nlm.nih.gov/1851833 DMNDOLZ DI DMNDOLZ DMNDOLZ DN naltriben DMNDOLZ TI TTQW87Y DMNDOLZ TN Opioid receptor kappa (OPRK1) DMNDOLZ MA Antagonist DMNDOLZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). DMNDOLZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 DMNDS19 DI DMNDS19 DMNDS19 DN 4-Flourobenzenesulfonamide DMNDS19 TI TTANPDJ DMNDS19 TN Carbonic anhydrase II (CA-II) DMNDS19 MA Inhibitor DMNDS19 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNDS19 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNDUI3 DI DMNDUI3 DMNDUI3 DN Pro-His-Pro-His-Phe-Phe-Val-Tyr-Lys DMNDUI3 TI TTB2MXP DMNDUI3 TN Angiotensinogenase renin (REN) DMNDUI3 MA Inhibitor DMNDUI3 RN Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61. DMNDUI3 RU https://pubmed.ncbi.nlm.nih.gov/6267277 DMNDUJ5 DI DMNDUJ5 DMNDUJ5 DN Muscarine DMNDUJ5 TI TTH18TF DMNDUJ5 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMNDUJ5 MA Agonist DMNDUJ5 RN The effects of the antagonists of muscarinic acetylcholine receptor subtypes in rat brain on urinary bladder contraction. Nippon Hinyokika Gakkai Zasshi. 2002 Mar;93(3):427-34. DMNDUJ5 RU https://pubmed.ncbi.nlm.nih.gov/11968796 DMNDVMH DI DMNDVMH DMNDVMH DN 1H-indole-4,7-dione DMNDVMH TI TTZJYKH DMNDVMH TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMNDVMH MA Inhibitor DMNDVMH RN Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J Med Chem. 2008 May 8;51(9):2634-7. DMNDVMH RU https://pubmed.ncbi.nlm.nih.gov/18393489 DMNDW4J DI DMNDW4J DMNDW4J DN 1-allyl-2-[3-(isopropylamino)propoxy]-9H-xanthen-9-one DMNDW4J TI TTFQEO5 DMNDW4J TN Squalene synthetase (FDFT1) DMNDW4J MA Inhibitor DMNDW4J RN Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg Med Chem. 2004 Nov 15;12(22):5899-908. DMNDW4J RU https://pubmed.ncbi.nlm.nih.gov/15498666 DMNE1M3 DI DMNE1M3 DMNE1M3 DN Benzyl-(9-isopropyl-9H-purin-6-yl)-amine DMNE1M3 TI TT7HF4W DMNE1M3 TN Cyclin-dependent kinase 2 (CDK2) DMNE1M3 MA Inhibitor DMNE1M3 RN Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2. J Med Chem. 2000 Jun 29;43(13):2506-13. DMNE1M3 RU https://pubmed.ncbi.nlm.nih.gov/10891109 DMNE4C6 DI DMNE4C6 DMNE4C6 DN beta-D-hydroxybutyric acid DMNE4C6 TI TTWNV8U DMNE4C6 TN Nicotinic acid receptor (HCAR2) DMNE4C6 MA Agonist DMNE4C6 RN (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem. 2005 Jul 22;280(29):26649-52. DMNE4C6 RU https://pubmed.ncbi.nlm.nih.gov/15929991 DMNE52B DI DMNE52B DMNE52B DN 8-Hydroxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one DMNE52B TI TTVDSZ0 DMNE52B TN Poly [ADP-ribose] polymerase 1 (PARP1) DMNE52B MA Inhibitor DMNE52B RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMNE52B RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMNE5H7 DI DMNE5H7 DMNE5H7 DN 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide DMNE5H7 TI TTR5TV4 DMNE5H7 TN ERBB2 messenger RNA (HER2 mRNA) DMNE5H7 MA Inhibitor DMNE5H7 RN Synthesis, biological evaluation and molecular docking studies of amide-coupled benzoic nitrogen mustard derivatives as potential antitumor agents. Bioorg Med Chem. 2010 Jan 15;18(2):880-6. DMNE5H7 RU https://pubmed.ncbi.nlm.nih.gov/20005116 DMNEAJH DI DMNEAJH DMNEAJH DN 4-(4-Cyanophenoxy)-3-pyridinesulfonamide DMNEAJH TI TTHQPL7 DMNEAJH TN Carbonic anhydrase I (CA-I) DMNEAJH MA Inhibitor DMNEAJH RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMNEAJH RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMNEAJH DI DMNEAJH DMNEAJH DN 4-(4-Cyanophenoxy)-3-pyridinesulfonamide DMNEAJH TI TTANPDJ DMNEAJH TN Carbonic anhydrase II (CA-II) DMNEAJH MA Inhibitor DMNEAJH RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMNEAJH RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMNEAJH DI DMNEAJH DMNEAJH DN 4-(4-Cyanophenoxy)-3-pyridinesulfonamide DMNEAJH TI TTSYM0R DMNEAJH TN Carbonic anhydrase XII (CA-XII) DMNEAJH MA Inhibitor DMNEAJH RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMNEAJH RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMNEAJH DI DMNEAJH DMNEAJH DN 4-(4-Cyanophenoxy)-3-pyridinesulfonamide DMNEAJH TI TT2LVK8 DMNEAJH TN Carbonic anhydrase IX (CA-IX) DMNEAJH MA Inhibitor DMNEAJH RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMNEAJH RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMNEAQ9 DI DMNEAQ9 DMNEAQ9 DN H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me) DMNEAQ9 TI TTKWM86 DMNEAQ9 TN Opioid receptor mu (MOP) DMNEAQ9 MA Inhibitor DMNEAQ9 RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMNEAQ9 RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMNEAQ9 DI DMNEAQ9 DMNEAQ9 DN H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me) DMNEAQ9 TI TT27RFC DMNEAQ9 TN Opioid receptor delta (OPRD1) DMNEAQ9 MA Inhibitor DMNEAQ9 RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMNEAQ9 RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMNEAU0 DI DMNEAU0 DMNEAU0 DN 7-Dimethylamino-2-phenyl-[1,8]naphthyridin-4-ol DMNEAU0 TI TTK25J1 DMNEAU0 TN Adenosine A1 receptor (ADORA1) DMNEAU0 MA Inhibitor DMNEAU0 RN Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives. J Med Chem. 2004 Jun 3;47(12):3019-31. DMNEAU0 RU https://pubmed.ncbi.nlm.nih.gov/15163184 DMNEB6J DI DMNEB6J DMNEB6J DN PMID20855207C25 DMNEB6J TI TTLYXIT DMNEB6J TN Aurora kinase C (AURKC) DMNEB6J MA Inhibitor DMNEB6J RN Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43. DMNEB6J RU https://pubmed.ncbi.nlm.nih.gov/20855207 DMNEB6J DI DMNEB6J DMNEB6J DN PMID20855207C25 DMNEB6J TI TTTU902 DMNEB6J TN Checkpoint kinase-1 (CHK1) DMNEB6J MA Inhibitor DMNEB6J RN Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43. DMNEB6J RU https://pubmed.ncbi.nlm.nih.gov/20855207 DMNEB6J DI DMNEB6J DMNEB6J DN PMID20855207C25 DMNEB6J TI TT9RTBL DMNEB6J TN Aurora B messenger RNA (AURKB mRNA) DMNEB6J MA Inhibitor DMNEB6J RN Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43. DMNEB6J RU https://pubmed.ncbi.nlm.nih.gov/20855207 DMNEGHJ DI DMNEGHJ DMNEGHJ DN Anthramycin DMNEGHJ TI TTJP4SM DMNEGHJ TN Bacterial Penicillin binding protein (Bact PBP) DMNEGHJ RN Crystal structure of a covalent DNA-drug adduct: anthramycin bound to C-C-A-A-C-G-T-T-G-G and a molecular explanation of specificity. Biochemistry. 1994 Nov 22;33(46):13593-610. DMNEGHJ RU https://pubmed.ncbi.nlm.nih.gov/7947769 DMNEJ8W DI DMNEJ8W DMNEJ8W DN 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione DMNEJ8W TI TTN9D8E DMNEJ8W TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMNEJ8W MA Inhibitor DMNEJ8W RN 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. DMNEJ8W RU https://pubmed.ncbi.nlm.nih.gov/15081038 DMNEJ8W DI DMNEJ8W DMNEJ8W DN 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione DMNEJ8W TI TTKJEMQ DMNEJ8W TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMNEJ8W MA Inhibitor DMNEJ8W RN 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. DMNEJ8W RU https://pubmed.ncbi.nlm.nih.gov/15081038 DMNEJ8W DI DMNEJ8W DMNEJ8W DN 6,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione DMNEJ8W TI TTLD29N DMNEJ8W TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMNEJ8W MA Inhibitor DMNEJ8W RN 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. DMNEJ8W RU https://pubmed.ncbi.nlm.nih.gov/15081038 DMNEK79 DI DMNEK79 DMNEK79 DN RBx-343E48F0 DMNEK79 TI TTOXS3C DMNEK79 TN Muscarinic acetylcholine receptor (CHRM) DMNEK79 MA Modulator DMNEK79 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 17). DMNEK79 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=17 DMNEML0 DI DMNEML0 DMNEML0 DN GlaxoSmithKline compound 5h DMNEML0 TI TTA93TL DMNEML0 TN P2Y purinoceptor 1 (P2RY1) DMNEML0 MA Antagonist DMNEML0 RN Benzofuran-substituted urea derivatives as novel P2Y(1) receptor antagonists. Bioorg Med Chem Lett. 2010 Jul 15;20(14):4104-7. DMNEML0 RU https://pubmed.ncbi.nlm.nih.gov/20542694 DMNERM6 DI DMNERM6 DMNERM6 DN ST-2986 DMNERM6 TI TTBH0VX DMNERM6 TN Histone deacetylase (HDAC) DMNERM6 MA Inhibitor DMNERM6 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMNERM6 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMNERM6 DI DMNERM6 DMNERM6 DN ST-2986 DMNERM6 TI TT6R7JZ DMNERM6 TN Histone deacetylase 1 (HDAC1) DMNERM6 MA Inhibitor DMNERM6 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMNERM6 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMNERM6 DI DMNERM6 DMNERM6 DN ST-2986 DMNERM6 TI TT5ZKDI DMNERM6 TN Histone deacetylase 6 (HDAC6) DMNERM6 MA Inhibitor DMNERM6 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMNERM6 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMNERM6 DI DMNERM6 DMNERM6 DN ST-2986 DMNERM6 TI TTT6LFV DMNERM6 TN Histone deacetylase 8 (HDAC8) DMNERM6 MA Inhibitor DMNERM6 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMNERM6 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMNERM6 DI DMNERM6 DMNERM6 DN ST-2986 DMNERM6 TI TTYHPU6 DMNERM6 TN Histone deacetylase 10 (HDAC10) DMNERM6 MA Inhibitor DMNERM6 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMNERM6 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMNERM6 DI DMNERM6 DMNERM6 DN ST-2986 DMNERM6 TI TTSHTOI DMNERM6 TN Histone deacetylase 2 (HDAC2) DMNERM6 MA Inhibitor DMNERM6 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMNERM6 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMNETHQ DI DMNETHQ DMNETHQ DN 1-(2,5-Dimethoxy-phenyl)-piperazine DMNETHQ TI TT6MSOK DMNETHQ TN 5-HT 1D receptor (HTR1D) DMNETHQ MA Inhibitor DMNETHQ RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMNETHQ RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMNETHQ DI DMNETHQ DMNETHQ DN 1-(2,5-Dimethoxy-phenyl)-piperazine DMNETHQ TI TTSQIFT DMNETHQ TN 5-HT 1A receptor (HTR1A) DMNETHQ MA Inhibitor DMNETHQ RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMNETHQ RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMNETHQ DI DMNETHQ DMNETHQ DN 1-(2,5-Dimethoxy-phenyl)-piperazine DMNETHQ TI TTJQOD7 DMNETHQ TN 5-HT 2A receptor (HTR2A) DMNETHQ MA Inhibitor DMNETHQ RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMNETHQ RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMNETSX DI DMNETSX DMNETSX DN Acerogenin C DMNETSX TI TTF8JAT DMNETSX TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMNETSX MA Inhibitor DMNETSX RN Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4. DMNETSX RU https://pubmed.ncbi.nlm.nih.gov/20036535 DMNEVXT DI DMNEVXT DMNEVXT DN AMG-5445 DMNEVXT TI TTELV3W DMNEVXT TN Transformation-sensitive protein p120 (TRPA1) DMNEVXT MA Inhibitor DMNEVXT RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DMNEVXT RU https://pubmed.ncbi.nlm.nih.gov/20356305 DMNF70P DI DMNF70P DMNF70P DN IS1 DMNF70P TI TTB9CIL DMNF70P TN Prokineticin receptor-1 (PROKR1) DMNF70P MA Agonist DMNF70P RN Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS One. 2015 Apr 1;10(4):e0121027. DMNF70P RU https://pubmed.ncbi.nlm.nih.gov/25831128 DMNFCXW DI DMNFCXW DMNFCXW DN THIOCTIC ACID DMNFCXW TI TTVKILB DMNFCXW TN Prostaglandin G/H synthase 2 (COX-2) DMNFCXW MA Inhibitor DMNFCXW RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMNFCXW RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMNFCXW DI DMNFCXW DMNFCXW DN THIOCTIC ACID DMNFCXW TI TT1RS9F DMNFCXW TN Acetylcholinesterase (AChE) DMNFCXW MA Inhibitor DMNFCXW RN Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem. 2008 Feb 14;51(3):347-72. DMNFCXW RU https://pubmed.ncbi.nlm.nih.gov/18181565 DMNFGRV DI DMNFGRV DMNFGRV DN Allylamines DMNFGRV TI TTE14XG DMNFGRV TN Squalene monooxygenase (SQLE) DMNFGRV MA Inhibitor DMNFGRV RN Differential inhibition of fungal amd mammalian squalene epoxidases by the benzylamine SDZ SBA 586 in comparison with the allylamine terbinafine. Arch Biochem Biophys. 1997 Apr 15;340(2):265-9. DMNFGRV RU https://pubmed.ncbi.nlm.nih.gov/9143330 DMNFI02 DI DMNFI02 DMNFI02 DN 7-iodoindirubin-3-oxime DMNFI02 TI TTLYXIT DMNFI02 TN Aurora kinase C (AURKC) DMNFI02 MA Inhibitor DMNFI02 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMNFI02 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMNFI02 DI DMNFI02 DMNFI02 DN 7-iodoindirubin-3-oxime DMNFI02 TI TT9RTBL DMNFI02 TN Aurora B messenger RNA (AURKB mRNA) DMNFI02 MA Inhibitor DMNFI02 RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMNFI02 RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMNFIZD DI DMNFIZD DMNFIZD DN 7-Methoxy-4-morpholin-4-yl-chromen-2-one DMNFIZD TI TTK3PY9 DMNFIZD TN DNA-dependent protein kinase catalytic (PRKDC) DMNFIZD MA Inhibitor DMNFIZD RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMNFIZD RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMNFTO6 DI DMNFTO6 DMNFTO6 DN N-butylnorlitebamine DMNFTO6 TI TT1RS9F DMNFTO6 TN Acetylcholinesterase (AChE) DMNFTO6 MA Inhibitor DMNFTO6 RN Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50. DMNFTO6 RU https://pubmed.ncbi.nlm.nih.gov/9461651 DMNFVO7 DI DMNFVO7 DMNFVO7 DN Vinylsulphones DMNFVO7 TI TTEAID7 DMNFVO7 TN Trypanosoma Cruzipain (Trypano CYSP) DMNFVO7 MA Binder DMNFVO7 RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMNFVO7 RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMNFVO7 DI DMNFVO7 DMNFVO7 DN Vinylsulphones DMNFVO7 TI TT7EASG DMNFVO7 TN Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) DMNFVO7 MA Binder DMNFVO7 RN Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. DMNFVO7 RU https://pubmed.ncbi.nlm.nih.gov/16138106 DMNFYZL DI DMNFYZL DMNFYZL DN ISIS 138649 DMNFYZL TI TTTEOPU DMNFYZL TN Helicase-moi messenger RNA (DICER1 mRNA) DMNFYZL RN US patent application no. 7,427,470, Antisense modulation of helicase-moi expression. DMNFYZL RU http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTB30PF DMNFZC6 TN Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TT915ZD DMNFZC6 TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTZUFI5 DMNFZC6 TN Nitric-oxide synthase brain (NOS1) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTBL49X DMNFZC6 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTANPDJ DMNFZC6 TN Carbonic anhydrase II (CA-II) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTJHKYD DMNFZC6 TN Delta-aminolevulinic acid dehydratase (ALAD) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTICO5G DMNFZC6 TN Staphylococcus Peptide deformylase (Stap-coc def) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTI6V2A DMNFZC6 TN Heme oxygenase 1 (HMOX1) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTCYE56 DMNFZC6 TN Glutathione-dependent PGD synthase (HPGDS) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNFZC6 DI DMNFZC6 DMNFZC6 DN Formic Acid DMNFZC6 TI TTMY81X DMNFZC6 TN Heparin-binding growth factor 1 (FGF1) DMNFZC6 MA Inhibitor DMNFZC6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNFZC6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNG0TY DI DMNG0TY DMNG0TY DN 3-benzyl-1-cyclohexylpyrrolidin-2-one DMNG0TY TI TTN7BL9 DMNG0TY TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMNG0TY MA Inhibitor DMNG0TY RN Discovery of orally active butyrolactam 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5555-60. DMNG0TY RU https://pubmed.ncbi.nlm.nih.gov/16931002 DMNG4B1 DI DMNG4B1 DMNG4B1 DN Cyclohexylglycine-(2S)-cyanopyrrolidine DMNG4B1 TI TTDIGC1 DMNG4B1 TN Dipeptidyl peptidase 4 (DPP-4) DMNG4B1 MA Inhibitor DMNG4B1 RN 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1-oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: a potent, selective, and orally bioava... J Med Chem. 2006 Jan 12;49(1):373-80. DMNG4B1 RU https://pubmed.ncbi.nlm.nih.gov/16392822 DMNG6JB DI DMNG6JB DMNG6JB DN S-(3-Chlorobenzyl)isothiourea hydrochloride DMNG6JB TI TTZJYKH DMNG6JB TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMNG6JB MA Inhibitor DMNG6JB RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMNG6JB RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMNG6O7 DI DMNG6O7 DMNG6O7 DN 9-Aminomethyl-9H-fluorene-3,4-diol DMNG6O7 TI TTZFYLI DMNG6O7 TN Dopamine D1 receptor (D1R) DMNG6O7 MA Inhibitor DMNG6O7 RN Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12. DMNG6O7 RU https://pubmed.ncbi.nlm.nih.gov/3761310 DMNG9B2 DI DMNG9B2 DMNG9B2 DN Cis-2-Fluoro-2-(4-methoxyphenyl)cyclopropylamine DMNG9B2 TI TTGP7BY DMNG9B2 TN Monoamine oxidase type B (MAO-B) DMNG9B2 MA Inhibitor DMNG9B2 RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMNG9B2 RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMNGC79 DI DMNGC79 DMNGC79 DN MRS2603 DMNGC79 TI TT1FE3L DMNGC79 TN P2Y purinoceptor 13 (P2RY13) DMNGC79 MA Antagonist DMNGC79 RN Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochem Pharmacol. 2005 Jul 15;70(2):266-74. DMNGC79 RU https://pubmed.ncbi.nlm.nih.gov/15913566 DMNGDOM DI DMNGDOM DMNGDOM DN 4-(4-Butoxy-phenyl)-N-hydroxy-4-oxo-butyramide DMNGDOM TI TTMX39J DMNGDOM TN Matrix metalloproteinase-1 (MMP-1) DMNGDOM MA Inhibitor DMNGDOM RN Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96. DMNGDOM RU https://pubmed.ncbi.nlm.nih.gov/16220975 DMNGEAY DI DMNGEAY DMNGEAY DN GSK-5182 DMNGEAY TI TTZAYWL DMNGEAY TN Estrogen receptor (ESR) DMNGEAY MA Inhibitor DMNGEAY RN Structure-guided synthesis of tamoxifen analogs with improved selectivity for the orphan ERRgamma. Bioorg Med Chem Lett. 2006 Feb 15;16(4):821-4. DMNGEAY RU https://pubmed.ncbi.nlm.nih.gov/16307879 DMNGEFS DI DMNGEFS DMNGEFS DN (2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine DMNGEFS TI TTI7421 DMNGEFS TN Platelet-derived growth factor receptor beta (PDGFRB) DMNGEFS MA Inhibitor DMNGEFS RN (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73. DMNGEFS RU https://pubmed.ncbi.nlm.nih.gov/16366598 DMNGKYF DI DMNGKYF DMNGKYF DN RU83876 DMNGKYF TI TT6PKBN DMNGKYF TN Proto-oncogene c-Src (SRC) DMNGKYF MA Inhibitor DMNGKYF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNGKYF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNGLM1 DI DMNGLM1 DMNGLM1 DN 7-[1,2,4]Triazol-4-ylmethyl-chromen-4-one DMNGLM1 TI TTSZLWK DMNGLM1 TN Aromatase (CYP19A1) DMNGLM1 MA Inhibitor DMNGLM1 RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMNGLM1 RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMNGQ3I DI DMNGQ3I DMNGQ3I DN MRL20 DMNGQ3I TI TTZMAO3 DMNGQ3I TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMNGQ3I MA Agonist DMNGQ3I RN PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91. DMNGQ3I RU https://www.ncbi.nlm.nih.gov/pubmed/25416646 DMNGSQK DI DMNGSQK DMNGSQK DN N*4*-Benzyl-6-chloro-pyrimidine-2,4-diamine DMNGSQK TI TT2GPK3 DMNGSQK TN DNA topoisomerase (TOP) DMNGSQK MA Inhibitor DMNGSQK RN Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81. DMNGSQK RU https://pubmed.ncbi.nlm.nih.gov/3084785 DMNGTOY DI DMNGTOY DMNGTOY DN MRS2500 DMNGTOY TI TTA93TL DMNGTOY TN P2Y purinoceptor 1 (P2RY1) DMNGTOY MA Antagonist DMNGTOY RN 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem. 2003 Nov 6;46(23):4974-87. DMNGTOY RU https://pubmed.ncbi.nlm.nih.gov/14584948 DMNGW1A DI DMNGW1A DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A TI TT9WJ8U DMNGW1A TN Protein kinase C delta (PRKCD) DMNGW1A MA Inhibitor DMNGW1A RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMNGW1A RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMNGW1A DI DMNGW1A DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A TI TTBZ7OD DMNGW1A TN Protein kinase C epsilon (PRKCE) DMNGW1A MA Inhibitor DMNGW1A RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMNGW1A RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMNGW1A DI DMNGW1A DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A TI TTYPXQF DMNGW1A TN Protein kinase C beta (PRKCB) DMNGW1A MA Inhibitor DMNGW1A RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMNGW1A RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMNGW1A DI DMNGW1A DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A TI TTFJ8Q1 DMNGW1A TN Protein kinase C alpha (PRKCA) DMNGW1A MA Inhibitor DMNGW1A RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMNGW1A RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMNGW1A DI DMNGW1A DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A TI TTUWGRA DMNGW1A TN Protein kinase C zeta (PRKCZ) DMNGW1A MA Inhibitor DMNGW1A RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMNGW1A RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMNGW1A DI DMNGW1A DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A TI TTRFOXJ DMNGW1A TN Protein kinase C gamma (PRKCG) DMNGW1A MA Inhibitor DMNGW1A RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMNGW1A RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMNGW1A DI DMNGW1A DMNGW1A DN 2-(4-Hydroxy-phenyl)-3,3-diphenyl-acrylonitrile DMNGW1A TI TT8QL1J DMNGW1A TN Protein kinase C theta (PRKCQ) DMNGW1A MA Inhibitor DMNGW1A RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMNGW1A RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMNGY0E DI DMNGY0E DMNGY0E DN 1-anilinonaphthalene-8-sulfonic acid DMNGY0E TI TTIV96N DMNGY0E TN Fatty acid-binding protein 1 (FABP1) DMNGY0E MA Inhibitor DMNGY0E RN Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64. DMNGY0E RU https://pubmed.ncbi.nlm.nih.gov/18533710 DMNH0CM DI DMNH0CM DMNH0CM DN WAY-196025 DMNH0CM TI TTT1JVS DMNH0CM TN Cytosolic phospholipase A2 (GIVA cPLA2) DMNH0CM MA Inhibitor DMNH0CM RN Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71. DMNH0CM RU https://pubmed.ncbi.nlm.nih.gov/19178292 DMNH3ST DI DMNH3ST DMNH3ST DN Tetrahydroimidazo[4,5,1-jk]-[1,4]benzodiazepin-2(1H)-one DMNH3ST TI TT84ETX DMNH3ST TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMNH3ST MA Inhibitor DMNH3ST RN Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9878-82. DMNH3ST RU https://pubmed.ncbi.nlm.nih.gov/1719542 DMNHBGJ DI DMNHBGJ DMNHBGJ DN ISIS 107776 DMNHBGJ TI TTELIN2 DMNHBGJ TN PTPN1 messenger RNA (PTPN1 mRNA) DMNHBGJ RN US patent application no. 6,261,840, Antisense modulation of PTP1B expression. DMNHBGJ RU http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true DMNHEUT DI DMNHEUT DMNHEUT DN BPIQ-I DMNHEUT TI TTGKNB4 DMNHEUT TN Epidermal growth factor receptor (EGFR) DMNHEUT MA Inhibitor DMNHEUT RN Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28. DMNHEUT RU https://pubmed.ncbi.nlm.nih.gov/8632415 DMNHGVD DI DMNHGVD DMNHGVD DN 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide DMNHGVD TI TT2LVK8 DMNHGVD TN Carbonic anhydrase IX (CA-IX) DMNHGVD MA Inhibitor DMNHGVD RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMNHGVD RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMNHGVD DI DMNHGVD DMNHGVD DN 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide DMNHGVD TI TTHQPL7 DMNHGVD TN Carbonic anhydrase I (CA-I) DMNHGVD MA Inhibitor DMNHGVD RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMNHGVD RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMNHGVD DI DMNHGVD DMNHGVD DN 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide DMNHGVD TI TTSYM0R DMNHGVD TN Carbonic anhydrase XII (CA-XII) DMNHGVD MA Inhibitor DMNHGVD RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMNHGVD RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMNHGVD DI DMNHGVD DMNHGVD DN 1,4-Dihydro-1-methyl-4-oxo-3-pyridinesulfonamide DMNHGVD TI TTANPDJ DMNHGVD TN Carbonic anhydrase II (CA-II) DMNHGVD MA Inhibitor DMNHGVD RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMNHGVD RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMNHM1B DI DMNHM1B DMNHM1B DN AMG-837 DMNHM1B TI TTB8FUC DMNHM1B TN Free fatty acid receptor 1 (GPR40) DMNHM1B MA Agonist DMNHM1B RN Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012 Nov;82(5):843-59. DMNHM1B RU https://pubmed.ncbi.nlm.nih.gov/22859723 DMNHOI3 DI DMNHOI3 DMNHOI3 DN Recombinant follicle stimulating hormone DMNHOI3 TI TTZFDBT DMNHOI3 TN Follicle-stimulating hormone receptor (FSHR) DMNHOI3 MA Modulator DMNHOI3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253). DMNHOI3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253 DMNHSR0 DI DMNHSR0 DMNHSR0 DN C[L-mTyr-D-pro-L-Phe-D-trp] DMNHSR0 TI TTKWM86 DMNHSR0 TN Opioid receptor mu (MOP) DMNHSR0 MA Inhibitor DMNHSR0 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMNHSR0 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMNHSR0 DI DMNHSR0 DMNHSR0 DN C[L-mTyr-D-pro-L-Phe-D-trp] DMNHSR0 TI TT27RFC DMNHSR0 TN Opioid receptor delta (OPRD1) DMNHSR0 MA Inhibitor DMNHSR0 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMNHSR0 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMNHSR0 DI DMNHSR0 DMNHSR0 DN C[L-mTyr-D-pro-L-Phe-D-trp] DMNHSR0 TI TTQW87Y DMNHSR0 TN Opioid receptor kappa (OPRK1) DMNHSR0 MA Inhibitor DMNHSR0 RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMNHSR0 RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMNHT7Q DI DMNHT7Q DMNHT7Q DN 5,6,8-Trimethoxy-1,4-dimethylquinolin-2(1H)-one DMNHT7Q TI TTJLP0R DMNHT7Q TN Quinone reductase 2 (NQO2) DMNHT7Q MA Inhibitor DMNHT7Q RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMNHT7Q RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMNHU4M DI DMNHU4M DMNHU4M DN TRIM DMNHU4M TI TTBECWA DMNHU4M TN Transient receptor potential cation channel V2 (TRPV2) DMNHU4M MA Blocker (channel blocker) DMNHU4M RN Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68. DMNHU4M RU https://pubmed.ncbi.nlm.nih.gov/17673572 DMNHUOD DI DMNHUOD DMNHUOD DN Sanggenon G DMNHUOD TI TTELIN2 DMNHUOD TN PTPN1 messenger RNA (PTPN1 mRNA) DMNHUOD MA Inhibitor DMNHUOD RN Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9. DMNHUOD RU https://pubmed.ncbi.nlm.nih.gov/16356713 DMNHYQ0 DI DMNHYQ0 DMNHYQ0 DN 2-morpholin-4-yl-8-styrylchromen-4-one DMNHYQ0 TI TTK3PY9 DMNHYQ0 TN DNA-dependent protein kinase catalytic (PRKDC) DMNHYQ0 MA Inhibitor DMNHYQ0 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMNHYQ0 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMNHZFG DI DMNHZFG DMNHZFG DN 9-Amino-1,2,3,4-tetrahydro-acridine-1,7-diol DMNHZFG TI TT1RS9F DMNHZFG TN Acetylcholinesterase (AChE) DMNHZFG MA Inhibitor DMNHZFG RN Synthesis and biological activity of putative mono-hydroxylated metabolites of velnacrine, Bioorg. Med. Chem. Lett. 2(8):865-870 (1992). DMNHZFG RU http://www.sciencedirect.com/science/article/pii/S0960894X00805466 DMNI5FW DI DMNI5FW DMNI5FW DN HJC 0350 DMNI5FW TI TTOS63B DMNI5FW TN Rap guanine nucleotide exchange factor 4 (EPAC2) DMNI5FW MA Inhibitor DMNI5FW RN Identification and characterization of small molecules as potent and specific EPAC2 antagonists. J Med Chem. 2013 Feb 14;56(3):952-62. DMNI5FW RU https://pubmed.ncbi.nlm.nih.gov/23286832 DMNI6YU DI DMNI6YU DMNI6YU DN EX5 DMNI6YU TI TTQWOU1 DMNI6YU TN MTHFR messenger RNA (MTHFR mRNA) DMNI6YU RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMNI6YU RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMNI91Z DI DMNI91Z DMNI91Z DN SC-74020 DMNI91Z TI TTLM12X DMNI91Z TN Matrix metalloproteinase-2 (MMP-2) DMNI91Z MA Inhibitor DMNI91Z RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNI91Z RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNIBTG DI DMNIBTG DMNIBTG DN ISIS 111992 DMNIBTG TI TTPJ9XK DMNIBTG TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMNIBTG RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMNIBTG RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMNIEHV DI DMNIEHV DMNIEHV DN APC-300 DMNIEHV TI TTW2R9X DMNIEHV TN GTPase NRas (NRAS) DMNIEHV MA Inhibitor DMNIEHV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2823). DMNIEHV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2823 DMNILXG DI DMNILXG DMNILXG DN 3-[4-Methyl-indan-(1Z)-ylidenemethyl]-pyridine DMNILXG TI TTSZLWK DMNILXG TN Aromatase (CYP19A1) DMNILXG MA Inhibitor DMNILXG RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMNILXG RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMNIP7J DI DMNIP7J DMNIP7J DN (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine DMNIP7J TI TT6EO5L DMNIP7J TN Erbb2 tyrosine kinase receptor (HER2) DMNIP7J MA Inhibitor DMNIP7J RN Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5. DMNIP7J RU https://pubmed.ncbi.nlm.nih.gov/11378364 DMNIVOX DI DMNIVOX DMNIVOX DN GSK-0660 DMNIVOX TI TT2JWF6 DMNIVOX TN Peroxisome proliferator-activated receptor delta (PPARD) DMNIVOX MA Inhibitor DMNIVOX RN Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversibl... J Med Chem. 2010 Feb 25;53(4):1857-61. DMNIVOX RU https://pubmed.ncbi.nlm.nih.gov/20128594 DMNJ0XZ DI DMNJ0XZ DMNJ0XZ DN 5-Methyl-N-phenylbenzo[d]oxazol-2-amine DMNJ0XZ TI TT2J34L DMNJ0XZ TN Arachidonate 5-lipoxygenase (5-LOX) DMNJ0XZ MA Inhibitor DMNJ0XZ RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DMNJ0XZ RU https://pubmed.ncbi.nlm.nih.gov/20870413 DMNJ2CS DI DMNJ2CS DMNJ2CS DN 1-(4-methoxyphenyl)-3-(1,3,4-thiadiazol-2-yl)urea DMNJ2CS TI TTSJ6Q4 DMNJ2CS TN LOX-5 messenger RNA (ALOX5 mRNA) DMNJ2CS MA Inhibitor DMNJ2CS RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMNJ2CS RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMNJ632 DI DMNJ632 DMNJ632 DN AR-534 DMNJ632 TI TTRZQE3 DMNJ632 TN Glycogen synthase kinase-3 alpha (GSK-3A) DMNJ632 MA Inhibitor DMNJ632 RN A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J Clin Invest. 2009 May;119(5):1382-95. DMNJ632 RU https://pubmed.ncbi.nlm.nih.gov/19363289 DMNJA3C DI DMNJA3C DMNJA3C DN N',2-diphenylquinoline-4-carbohydrazide 8m DMNJA3C TI TTBPGLU DMNJA3C TN Neuromedin-K receptor (TACR3) DMNJA3C MA Antagonist DMNJA3C RN N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists II. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5752-6. DMNJA3C RU https://pubmed.ncbi.nlm.nih.gov/16950617 DMNJAV1 DI DMNJAV1 DMNJAV1 DN 2-(4-phenylbutyl)pyrido[2,3-d]pyrimidin-4(3H)-one DMNJAV1 TI TTWNV8U DMNJAV1 TN Nicotinic acid receptor (HCAR2) DMNJAV1 MA Inhibitor DMNJAV1 RN Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5426-30. DMNJAV1 RU https://pubmed.ncbi.nlm.nih.gov/20724150 DMNJBF8 DI DMNJBF8 DMNJBF8 DN doxorubicin-LL2 conjugate DMNJBF8 TI TTUTN1I DMNJBF8 TN Human Deoxyribonucleic acid (hDNA) DMNJBF8 MA Modulator DMNJBF8 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMNJBF8 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMNJBF8 DI DMNJBF8 DMNJBF8 DN doxorubicin-LL2 conjugate DMNJBF8 TI TT0IHXV DMNJBF8 TN DNA topoisomerase II (TOP2) DMNJBF8 MA Modulator DMNJBF8 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMNJBF8 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMNJLW2 DI DMNJLW2 DMNJLW2 DN NSC-645827 DMNJLW2 TI TT8XK6L DMNJLW2 TN Quinone reductase 1 (NQO1) DMNJLW2 MA Inhibitor DMNJLW2 RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMNJLW2 RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMNJMGK DI DMNJMGK DMNJMGK DN 1-[(7-Fluoronaphth-2-yl)methyl]-1H-imidazole DMNJMGK TI TTSZLWK DMNJMGK TN Aromatase (CYP19A1) DMNJMGK MA Inhibitor DMNJMGK RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMNJMGK RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMNJPCD DI DMNJPCD DMNJPCD DN 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE DMNJPCD TI TT8JRS7 DMNJPCD TN Beta-secretase (BACE) DMNJPCD MA Inhibitor DMNJPCD RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNJPCD RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNJRFP DI DMNJRFP DMNJRFP DN 6-Methyl-2-oxa-spiro[4.4]nonan-1-one DMNJRFP TI TT06RH5 DMNJRFP TN GABA(A) receptor gamma-2 (GABRG2) DMNJRFP MA Inhibitor DMNJRFP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMNJRFP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMNJRFP DI DMNJRFP DMNJRFP DN 6-Methyl-2-oxa-spiro[4.4]nonan-1-one DMNJRFP TI TTNJYV2 DMNJRFP TN Gamma-aminobutyric acid receptor (GAR) DMNJRFP MA Inhibitor DMNJRFP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMNJRFP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMNJRFP DI DMNJRFP DMNJRFP DN 6-Methyl-2-oxa-spiro[4.4]nonan-1-one DMNJRFP TI TTZA1NY DMNJRFP TN GABA(A) receptor beta-2 (GABRB2) DMNJRFP MA Inhibitor DMNJRFP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMNJRFP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMNJRFP DI DMNJRFP DMNJRFP DN 6-Methyl-2-oxa-spiro[4.4]nonan-1-one DMNJRFP TI TT1MPAY DMNJRFP TN GABA(A) receptor alpha-1 (GABRA1) DMNJRFP MA Inhibitor DMNJRFP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMNJRFP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMNJS0K DI DMNJS0K DMNJS0K DN ISIS 11220 DMNJS0K TI TTRE6AX DMNJS0K TN Bcl-x messenger RNA (BCL2L1 mRNA) DMNJS0K RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMNJS0K RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMNJSTM DI DMNJSTM DMNJSTM DN (S)-AMPA DMNJSTM TI TTAN6JD DMNJSTM TN Glutamate receptor AMPA (GRIA) DMNJSTM MA Inhibitor DMNJSTM RN Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem. 2005 Dec 1;48(24):7867-81. DMNJSTM RU https://pubmed.ncbi.nlm.nih.gov/16302825 DMNJSTM DI DMNJSTM DMNJSTM DN (S)-AMPA DMNJSTM TI TTVPQTF DMNJSTM TN Glutamate receptor AMPA 1 (GRIA1) DMNJSTM MA Inhibitor DMNJSTM RN Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. J Med Chem. 2005 Dec 1;48(24):7867-81. DMNJSTM RU https://pubmed.ncbi.nlm.nih.gov/16302825 DMNJVZU DI DMNJVZU DMNJVZU DN SPIROINDANYLOXYMORPHONE DMNJVZU TI TTKWM86 DMNJVZU TN Opioid receptor mu (MOP) DMNJVZU MA Inhibitor DMNJVZU RN Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normo... Bioorg Med Chem. 2009 Aug 15;17(16):5983-8. DMNJVZU RU https://pubmed.ncbi.nlm.nih.gov/19620007 DMNJVZU DI DMNJVZU DMNJVZU DN SPIROINDANYLOXYMORPHONE DMNJVZU TI TTQW87Y DMNJVZU TN Opioid receptor kappa (OPRK1) DMNJVZU MA Inhibitor DMNJVZU RN Aerobic oxidation of indolomorphinan without the 4,5-epoxy bridge and subsequent rearrangement of the oxidation product to spiroindolinonyl-C-normo... Bioorg Med Chem. 2009 Aug 15;17(16):5983-8. DMNJVZU RU https://pubmed.ncbi.nlm.nih.gov/19620007 DMNJXHF DI DMNJXHF DMNJXHF DN Monoisopropyl Ester Phosphonic Acid Group DMNJXHF TI TTEB0GD DMNJXHF TN Cholinesterase (BCHE) DMNJXHF MA Inhibitor DMNJXHF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNJXHF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNJXHF DI DMNJXHF DMNJXHF DN Monoisopropyl Ester Phosphonic Acid Group DMNJXHF TI TT5DOVB DMNJXHF TN Cytomegalovirus Protease (CMV UL80) DMNJXHF MA Inhibitor DMNJXHF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNJXHF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNJY79 DI DMNJY79 DMNJY79 DN PHCCC DMNJY79 TI TTVBPDM DMNJY79 TN Metabotropic glutamate receptor 1 (mGluR1) DMNJY79 MA Modulator (allosteric modulator) DMNJY79 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 289). DMNJY79 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=289 DMNJY79 DI DMNJY79 DMNJY79 DN PHCCC DMNJY79 TI TTICZ1O DMNJY79 TN Metabotropic glutamate receptor 4 (mGluR4) DMNJY79 MA Modulator (allosteric modulator) DMNJY79 RN (-)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology. 2003 Dec;45(7):895-906. DMNJY79 RU https://pubmed.ncbi.nlm.nih.gov/14573382 DMNJY79 DI DMNJY79 DMNJY79 DN PHCCC DMNJY79 TI TTWRP2F DMNJY79 TN Metabotropic glutamate receptor 6 (mGluR6) DMNJY79 MA Modulator (allosteric modulator) DMNJY79 RN The mGlu(4) receptor allosteric modulator N-phenyl-7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxamide acts as a direct agonist at mGlu(6) receptors. Eur J Pharmacol. 2008 Jul 28;589(1-3):49-52. DMNJY79 RU https://pubmed.ncbi.nlm.nih.gov/18593581 DMNKC9J DI DMNKC9J DMNKC9J DN Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe DMNKC9J TI TTF2LRI DMNKC9J TN Cathepsin B (CTSB) DMNKC9J MA Inhibitor DMNKC9J RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMNKC9J RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMNKC9J DI DMNKC9J DMNKC9J DN Cbz-Ile-t-ButylhomoGlu-Ala-LeuVSMe DMNKC9J TI TTUMQVO DMNKC9J TN Cathepsin S (CTSS) DMNKC9J MA Inhibitor DMNKC9J RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMNKC9J RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMNKDT5 DI DMNKDT5 DMNKDT5 DN decyl dihydrogen phosphate DMNKDT5 TI TTB7Y8I DMNKDT5 TN Lysophosphatidic acid receptor 2 (LPAR2) DMNKDT5 MA Agonist DMNKDT5 RN Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42. DMNKDT5 RU https://pubmed.ncbi.nlm.nih.gov/12695531 DMNKEUG DI DMNKEUG DMNKEUG DN (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid DMNKEUG TI TTZMAO3 DMNKEUG TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMNKEUG MA Inhibitor DMNKEUG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNKEUG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNKHOI DI DMNKHOI DMNKHOI DN 2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one DMNKHOI TI TT06AWU DMNKHOI TN Phosphodiesterase 3A (PDE3A) DMNKHOI MA Inhibitor DMNKHOI RN Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73. DMNKHOI RU https://pubmed.ncbi.nlm.nih.gov/16290931 DMNKHOI DI DMNKHOI DMNKHOI DN 2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one DMNKHOI TI TTJGW1Z DMNKHOI TN Phosphodiesterase 2A (PDE2A) DMNKHOI MA Inhibitor DMNKHOI RN PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2847-51. DMNKHOI RU https://pubmed.ncbi.nlm.nih.gov/15125945 DMNKT8J DI DMNKT8J DMNKT8J DN C[CO-o-C6H4-CO-Pro-D-Phe-Arg-Trp-Lys]-NH2 DMNKT8J TI TTD0CIQ DMNKT8J TN Melanocortin receptor 4 (MC4R) DMNKT8J MA Inhibitor DMNKT8J RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMNKT8J RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMNKY2R DI DMNKY2R DMNKY2R DN ISIS 11061 DMNKY2R TI TTAN5W2 DMNKY2R TN Raf messenger RNA (Raf mRNA) DMNKY2R RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMNKY2R RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMNL0BK DI DMNL0BK DMNL0BK DN IsoVa-RYYRIK-NH2 DMNL0BK TI TTNT7K8 DMNL0BK TN Nociceptin receptor (OPRL1) DMNL0BK MA Inhibitor DMNL0BK RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMNL0BK RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMNLC2Y DI DMNLC2Y DMNLC2Y DN 4-Biphenyl-4-yl-2-methyl-1H-imidazole DMNLC2Y TI TTRK8B9 DMNLC2Y TN Sodium channel unspecific (NaC) DMNLC2Y MA Inhibitor DMNLC2Y RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMNLC2Y RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMNLC2Y DI DMNLC2Y DMNLC2Y DN 4-Biphenyl-4-yl-2-methyl-1H-imidazole DMNLC2Y TI TTAXZ0K DMNLC2Y TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMNLC2Y MA Inhibitor DMNLC2Y RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMNLC2Y RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMNLCUH DI DMNLCUH DMNLCUH DN Racemic DOTFM DMNLCUH TI TTJQOD7 DMNLCUH TN 5-HT 2A receptor (HTR2A) DMNLCUH MA Inhibitor DMNLCUH RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DMNLCUH RU https://pubmed.ncbi.nlm.nih.gov/18296055 DMNLD6E DI DMNLD6E DMNLD6E DN CP55,667 DMNLD6E TI TTNET8J DMNLD6E TN G-protein coupled receptor 55 (GPR55) DMNLD6E MA Antagonist DMNLD6E RN Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther. 2011 Apr;337(1):236-46. DMNLD6E RU https://pubmed.ncbi.nlm.nih.gov/21233197 DMNLD6W DI DMNLD6W DMNLD6W DN SCH 44643 DMNLD6W TI TT27K59 DMNLD6W TN Platelet activating factor (PAF) DMNLD6W MA Inhibitor DMNLD6W RN Determination of plasma concentrations of SCH 44643 by a GC method and correlation of plasma concentration and anti-PAF activity in cynomolgus monkeys. J Pharm Biomed Anal. 1996 Dec;15(3):343-7. DMNLD6W RU https://pubmed.ncbi.nlm.nih.gov/8951694 DMNLE4S DI DMNLE4S DMNLE4S DN D-210 DMNLE4S TI TT4C8EA DMNLE4S TN Dopamine D3 receptor (D3R) DMNLE4S MA Inhibitor DMNLE4S RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMNLE4S RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMNLE4S DI DMNLE4S DMNLE4S DN D-210 DMNLE4S TI TTEX248 DMNLE4S TN Dopamine D2 receptor (D2R) DMNLE4S MA Inhibitor DMNLE4S RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMNLE4S RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMNLTGF DI DMNLTGF DMNLTGF DN Canaline DMNLTGF TI TTTSCQ2 DMNLTGF TN Ornithine delta-aminotransferase (OAT) DMNLTGF MA Inhibitor DMNLTGF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNLTGF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNLUKS DI DMNLUKS DMNLUKS DN 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane DMNLUKS TI TTQ6VDM DMNLUKS TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMNLUKS MA Inhibitor DMNLUKS RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMNLUKS RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMNLUKS DI DMNLUKS DMNLUKS DN 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane DMNLUKS TI TTJQOD7 DMNLUKS TN 5-HT 2A receptor (HTR2A) DMNLUKS MA Inhibitor DMNLUKS RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMNLUKS RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMNLUKS DI DMNLUKS DMNLUKS DN 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane DMNLUKS TI TTSQIFT DMNLUKS TN 5-HT 1A receptor (HTR1A) DMNLUKS MA Inhibitor DMNLUKS RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMNLUKS RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMNLUKS DI DMNLUKS DMNLUKS DN 1,6-bis(4-(3-methoxyphenyl)piperazin-1-yl)hexane DMNLUKS TI TTEX248 DMNLUKS TN Dopamine D2 receptor (D2R) DMNLUKS MA Inhibitor DMNLUKS RN Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. J Med Chem. 2010 Jun 24;53(12):4803-7. DMNLUKS RU https://pubmed.ncbi.nlm.nih.gov/20481570 DMNLVRS DI DMNLVRS DMNLVRS DN RWJ-68354 DMNLVRS TI TT73U6C DMNLVRS TN Stress-activated protein kinase 2b (p38 beta) DMNLVRS MA Inhibitor DMNLVRS RN Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50. DMNLVRS RU https://pubmed.ncbi.nlm.nih.gov/12565927 DMNLVRS DI DMNLVRS DMNLVRS DN RWJ-68354 DMNLVRS TI TTQBR95 DMNLVRS TN Stress-activated protein kinase 2a (p38 alpha) DMNLVRS MA Inhibitor DMNLVRS RN Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50. DMNLVRS RU https://pubmed.ncbi.nlm.nih.gov/12565927 DMNLVRS DI DMNLVRS DMNLVRS DN RWJ-68354 DMNLVRS TI TTYT93M DMNLVRS TN MAP kinase p38 (MAPK12) DMNLVRS MA Inhibitor DMNLVRS RN Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50. DMNLVRS RU https://pubmed.ncbi.nlm.nih.gov/12565927 DMNM1EZ DI DMNM1EZ DMNM1EZ DN 6-Hydroxy-7,8-Dihydro Purine Nucleoside DMNM1EZ TI TTLP57V DMNM1EZ TN Adenosine deaminase (ADA) DMNM1EZ MA Inhibitor DMNM1EZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNM1EZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNM2SQ DI DMNM2SQ DMNM2SQ DN ISOSCOPOLETIN DMNM2SQ TI TTN9T81 DMNM2SQ TN Arachidonate 15-lipoxygenase (15-LOX) DMNM2SQ MA Inhibitor DMNM2SQ RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DMNM2SQ RU https://pubmed.ncbi.nlm.nih.gov/17378609 DMNM4GE DI DMNM4GE DMNM4GE DN 4-propyl-6-m-tolylpyrimidine-2-carbonitrile DMNM4GE TI TTDZN01 DMNM4GE TN Cathepsin K (CTSK) DMNM4GE MA Inhibitor DMNM4GE RN 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4447-50. DMNM4GE RU https://pubmed.ncbi.nlm.nih.gov/20594841 DMNM4GE DI DMNM4GE DMNM4GE DN 4-propyl-6-m-tolylpyrimidine-2-carbonitrile DMNM4GE TI TTUMQVO DMNM4GE TN Cathepsin S (CTSS) DMNM4GE MA Inhibitor DMNM4GE RN 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4447-50. DMNM4GE RU https://pubmed.ncbi.nlm.nih.gov/20594841 DMNM50K DI DMNM50K DMNM50K DN WIN-63395 DMNM50K TI TTPLTSQ DMNM50K TN Neutrophil elastase (NE) DMNM50K MA Inhibitor DMNM50K RN A comparative SAR and computer modeling study of benzisothiazolone, mechanism-based inhibitors with porcine pancreatic and human leukocyte elastase, Bioorg. Med. Chem. Lett. 6(24):2941-2946 (1996). DMNM50K RU http://www.sciencedirect.com/science/article/pii/S0960894X96005537 DMNM63G DI DMNM63G DMNM63G DN BTP2 DMNM63G TI TTNVC34 DMNM63G TN Short transient receptor potential channel 3 (TRPC3) DMNM63G MA Blocker (channel blocker) DMNM63G RN A functional link between store-operated and TRPC channels revealed by the 3,5-bis(trifluoromethyl)pyrazole derivative, BTP2. J Biol Chem. 2005 Mar 25;280(12):10997-1006. DMNM63G RU https://pubmed.ncbi.nlm.nih.gov/15647288 DMNM63G DI DMNM63G DMNM63G DN BTP2 DMNM63G TI TTJ2HKA DMNM63G TN Long transient receptor potential channel 4 (TRPM4) DMNM63G MA Activator DMNM63G RN A pyrazole derivative potently inhibits lymphocyte Ca2+ influx and cytokine production by facilitating transient receptor potential melastatin 4 ch... Mol Pharmacol. 2006 Apr;69(4):1413-20. DMNM63G RU https://pubmed.ncbi.nlm.nih.gov/16407466 DMNM63G DI DMNM63G DMNM63G DN BTP2 DMNM63G TI TT32NQ1 DMNM63G TN Short transient receptor potential channel 5 (TRPC5) DMNM63G MA Blocker (channel blocker) DMNM63G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490). DMNM63G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=490 DMNM6GQ DI DMNM6GQ DMNM6GQ DN NB3178 DMNM6GQ TI TT9SL3Q DMNM6GQ TN Polypeptide deformylase (PDF) DMNM6GQ MA Inhibitor DMNM6GQ RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMNM6GQ RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMNM8VY DI DMNM8VY DMNM8VY DN 4-(piperazin-1-yl)furo[3,2-c]pyridine DMNM8VY TI TTWJBZ5 DMNM8VY TN 5-HT 2C receptor (HTR2C) DMNM8VY MA Inhibitor DMNM8VY RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DMNM8VY RU https://pubmed.ncbi.nlm.nih.gov/19914063 DMNMB6V DI DMNMB6V DMNMB6V DN 3-hydroxylauric acid DMNMB6V TI TTG0MQD DMNMB6V TN Inflammation-related GPCR EX33 (GPR84) DMNMB6V MA Agonist DMNMB6V RN Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. DMNMB6V RU https://pubmed.ncbi.nlm.nih.gov/23449982 DMNMC9O DI DMNMC9O DMNMC9O DN 4-[(5-methoxy-2-methylphenoxy)methyl]pyridine DMNMC9O TI TTQO71U DMNMC9O TN Hemoglobin (HB) DMNMC9O MA Inhibitor DMNMC9O RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNMC9O RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNMCQJ DI DMNMCQJ DMNMCQJ DN S-(3,4-Dichlorobenzyl)isothiourea hydrochloride DMNMCQJ TI TTZJYKH DMNMCQJ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMNMCQJ MA Inhibitor DMNMCQJ RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMNMCQJ RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMNMD0J DI DMNMD0J DMNMD0J DN ZK-158252 DMNMD0J TI TTVJX54 DMNMD0J TN Leukotriene B4 receptor 2 (LTB4R2) DMNMD0J MA Antagonist DMNMD0J RN Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2. J Biol Chem. 2001 Apr 13;276(15):12454-9. DMNMD0J RU https://pubmed.ncbi.nlm.nih.gov/11278893 DMNMEAW DI DMNMEAW DMNMEAW DN Evatak DMNMEAW TI TTMSB0A DMNMEAW TN Integrin alpha-2/beta-1 (ITGA2/B1) DMNMEAW MA Modulator DMNMEAW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2578). DMNMEAW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2578 DMNMEPB DI DMNMEPB DMNMEPB DN 2-Naphthalen-2-ylmethyl-4,5-dihydro-1H-imidazole DMNMEPB TI TT3ROYC DMNMEPB TN Serotonin transporter (SERT) DMNMEPB MA Inhibitor DMNMEPB RN Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamine s possessing dual 5-HT upt... J Med Chem. 1997 Mar 28;40(7):1049-62. DMNMEPB RU https://pubmed.ncbi.nlm.nih.gov/9089327 DMNMES3 DI DMNMES3 DMNMES3 DN 2-(N-Cyclopropylamino)-3-chloropropiophenone DMNMES3 TI TTVBI8W DMNMES3 TN Dopamine transporter (DAT) DMNMES3 MA Inhibitor DMNMES3 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMNMES3 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMNMES3 DI DMNMES3 DMNMES3 DN 2-(N-Cyclopropylamino)-3-chloropropiophenone DMNMES3 TI TT3ROYC DMNMES3 TN Serotonin transporter (SERT) DMNMES3 MA Inhibitor DMNMES3 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMNMES3 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMNMES3 DI DMNMES3 DMNMES3 DN 2-(N-Cyclopropylamino)-3-chloropropiophenone DMNMES3 TI TTAWNKZ DMNMES3 TN Norepinephrine transporter (NET) DMNMES3 MA Inhibitor DMNMES3 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMNMES3 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMNMF0C DI DMNMF0C DMNMF0C DN NSC-666292 DMNMF0C TI TTSZLWK DMNMF0C TN Aromatase (CYP19A1) DMNMF0C MA Inhibitor DMNMF0C RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMNMF0C RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMNMG0I DI DMNMG0I DMNMG0I DN CGP 55845 DMNMG0I TI TTDCVZW DMNMG0I TN Gamma-aminobutyric acid B receptor (GABBR) DMNMG0I MA Antagonist DMNMG0I RN The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Br J Pharmacol. 2000 Nov;131(6):1050-4. DMNMG0I RU https://pubmed.ncbi.nlm.nih.gov/11082110 DMNMITH DI DMNMITH DMNMITH DN GT-1282 DMNMITH TI TT2CEJG DMNMITH TN C-C chemokine receptor type 5 (CCR5) DMNMITH MA Inhibitor DMNMITH RN Reduced cardiac side-effect potential by introduction of polar groups: discovery of NIBR-1282, an orally bioavailable CCR5 antagonist which is acti... Bioorg Med Chem Lett. 2008 Mar 15;18(6):2000-5. DMNMITH RU https://pubmed.ncbi.nlm.nih.gov/18267361 DMNMJDL DI DMNMJDL DMNMJDL DN 4-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN DMNMJDL TI TTGP7BY DMNMJDL TN Monoamine oxidase type B (MAO-B) DMNMJDL MA Inhibitor DMNMJDL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNMJDL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNMO4Q DI DMNMO4Q DMNMO4Q DN WAY-163909 DMNMO4Q TI TTWJBZ5 DMNMO4Q TN 5-HT 2C receptor (HTR2C) DMNMO4Q MA Agonist DMNMO4Q RN WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-sele... J Pharmacol Exp Ther. 2005 May;313(2):862-9. DMNMO4Q RU https://pubmed.ncbi.nlm.nih.gov/15705738 DMNMO83 DI DMNMO83 DMNMO83 DN FR-122788 DMNMO83 TI TT2J34L DMNMO83 TN Arachidonate 5-lipoxygenase (5-LOX) DMNMO83 MA Modulator DMNMO83 RN Studies on 5-lipoxygenase inhibitors. I. Synthesis and 5-lipoxygenase-inhibitory activity of novel hydroxamic acid derivatives. Chem Pharm Bull (Tokyo). 1998 Jun;46(6):966-72. DMNMO83 RU https://www.ncbi.nlm.nih.gov/pubmed/9658575 DMNMRHX DI DMNMRHX DMNMRHX DN L-Tryptophan-L-glutamine DMNMRHX TI TTT2SVW DMNMRHX TN PPAR-gamma messenger RNA (PPARG mRNA) DMNMRHX MA Inhibitor DMNMRHX RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DMNMRHX RU https://pubmed.ncbi.nlm.nih.gov/18329752 DMNMVCZ DI DMNMVCZ DMNMVCZ DN 9-amino-7H-dibenzo[de,h]quinolin-7-one DMNMVCZ TI TT1RS9F DMNMVCZ TN Acetylcholinesterase (AChE) DMNMVCZ MA Inhibitor DMNMVCZ RN Synthesis, biological evaluation and molecular modeling of oxoisoaporphine and oxoaporphine derivatives as new dual inhibitors of acetylcholinester... Eur J Med Chem. 2009 Jun;44(6):2523-32. DMNMVCZ RU https://pubmed.ncbi.nlm.nih.gov/19243862 DMNMXCE DI DMNMXCE DMNMXCE DN 4-Methyl-piperidin-(2E)-ylideneamine DMNMXCE TI TTCM4B3 DMNMXCE TN Nitric-oxide synthase endothelial (NOS3) DMNMXCE MA Inhibitor DMNMXCE RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMNMXCE RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMNMXCE DI DMNMXCE DMNMXCE DN 4-Methyl-piperidin-(2E)-ylideneamine DMNMXCE TI TTZUFI5 DMNMXCE TN Nitric-oxide synthase brain (NOS1) DMNMXCE MA Inhibitor DMNMXCE RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMNMXCE RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMNMXCE DI DMNMXCE DMNMXCE DN 4-Methyl-piperidin-(2E)-ylideneamine DMNMXCE TI TTF10I9 DMNMXCE TN Nitric-oxide synthase inducible (NOS2) DMNMXCE MA Inhibitor DMNMXCE RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMNMXCE RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMNMXKC DI DMNMXKC DMNMXKC DN ISIS 147483 DMNMXKC TI TTN1IE2 DMNMXKC TN APOB messenger RNA (APOB mRNA) DMNMXKC RN US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression. DMNMXKC RU http://www.patentbuddy.com/Patent/7407943?ft=true&sr=true DMNMYWI DI DMNMYWI DMNMYWI DN C-(2'-Chloro-biphenyl-2-yl)-methylamine DMNMYWI TI TTDIGC1 DMNMYWI TN Dipeptidyl peptidase 4 (DPP-4) DMNMYWI MA Inhibitor DMNMYWI RN In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9. DMNMYWI RU https://pubmed.ncbi.nlm.nih.gov/16321524 DMNO2EP DI DMNO2EP DMNO2EP DN PD-140548 DMNO2EP TI TTCG0AL DMNO2EP TN Cholecystokinin receptor type A (CCKAR) DMNO2EP MA Inhibitor DMNO2EP RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMNO2EP RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMNO2EP DI DMNO2EP DMNO2EP DN PD-140548 DMNO2EP TI TTVFO0U DMNO2EP TN Gastrin/cholecystokinin type B receptor (CCKBR) DMNO2EP MA Inhibitor DMNO2EP RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMNO2EP RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMNO46U DI DMNO46U DMNO46U DN N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine DMNO46U TI TTXAGYU DMNO46U TN Tissue-type plasminogen activator (PLAT) DMNO46U MA Inhibitor DMNO46U RN Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. DMNO46U RU https://pubmed.ncbi.nlm.nih.gov/15149680 DMNO46U DI DMNO46U DMNO46U DN N-(4-Chloro-7-p-tolyl-isoquinolin-1-yl)-guanidine DMNO46U TI TTP86E2 DMNO46U TN Plasminogen (PLG) DMNO46U MA Inhibitor DMNO46U RN Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. DMNO46U RU https://pubmed.ncbi.nlm.nih.gov/15149680 DMNO51B DI DMNO51B DMNO51B DN AAE-M-PBP-amine DMNO51B TI TT0WAIE DMNO51B TN Melatonin receptor type 1A (MTNR1A) DMNO51B MA Agonist DMNO51B RN MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. ChemMedChem. 2012 Nov;7(11):1954-64. DMNO51B RU https://pubmed.ncbi.nlm.nih.gov/22927210 DMNO6PL DI DMNO6PL DMNO6PL DN AZ10417808 DMNO6PL TI TTPF2QI DMNO6PL TN Caspase-3 (CASP3) DMNO6PL MA Inhibitor DMNO6PL RN Novel small molecule inhibitors of caspase-3 block cellular and biochemical features of apoptosis. J Pharmacol Exp Ther. 2003 Jan;304(1):433-40. DMNO6PL RU https://pubmed.ncbi.nlm.nih.gov/12490620 DMNOAJG DI DMNOAJG DMNOAJG DN 2ewy DMNOAJG TI TT69DB8 DMNOAJG TN Beta-site APP-cleaving enzyme 2 (BACE2) DMNOAJG MA Inhibitor DMNOAJG RN Crystal structure of human BACE2 in complex with a hydroxyethylamine transition-state inhibitor. J Mol Biol. 2006 Jan 13;355(2):249-61. DMNOAJG RU https://pubmed.ncbi.nlm.nih.gov/16305800 DMNOD2Q DI DMNOD2Q DMNOD2Q DN 4-[4-(benzyloxy)piperidino]butyl-4-nitrobenzoate DMNOD2Q TI TTEB0GD DMNOD2Q TN Cholinesterase (BCHE) DMNOD2Q MA Inhibitor DMNOD2Q RN Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. DMNOD2Q RU https://pubmed.ncbi.nlm.nih.gov/17681794 DMNOE0V DI DMNOE0V DMNOE0V DN 2-phenyl-N-(1-phenylethyl)quinoline-4-carboxamide DMNOE0V TI TTBPGLU DMNOE0V TN Neuromedin-K receptor (TACR3) DMNOE0V MA Inhibitor DMNOE0V RN Virtual screening to identify novel antagonists for the G protein-coupled NK3 receptor. J Med Chem. 2010 Nov 25;53(22):8080-8. DMNOE0V RU https://pubmed.ncbi.nlm.nih.gov/21047106 DMNOFTX DI DMNOFTX DMNOFTX DN HM-61713B DMNOFTX TI TTGKNB4 DMNOFTX TN Epidermal growth factor receptor (EGFR) DMNOFTX MA Inhibitor DMNOFTX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMNOFTX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMNOI7B DI DMNOI7B DMNOI7B DN 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene DMNOI7B TI TT2NUT5 DMNOI7B TN Adrenergic receptor alpha-2C (ADRA2C) DMNOI7B MA Inhibitor DMNOI7B RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMNOI7B RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMNOI7B DI DMNOI7B DMNOI7B DN 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene DMNOI7B TI TTWG9A4 DMNOI7B TN Adrenergic receptor alpha-2A (ADRA2A) DMNOI7B MA Inhibitor DMNOI7B RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMNOI7B RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMNOI7B DI DMNOI7B DMNOI7B DN 6,7,8,9-Tetrahydro-5-thia-8-aza-benzocycloheptene DMNOI7B TI TTWM4TY DMNOI7B TN Adrenergic receptor alpha-2B (ADRA2B) DMNOI7B MA Inhibitor DMNOI7B RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMNOI7B RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMNOKR3 DI DMNOKR3 DMNOKR3 DN 3-(2-carbamoyl-5-mercaptopentyl)benzoic acid DMNOKR3 TI TT9G4N0 DMNOKR3 TN Glutamate carboxypeptidase II (GCPII) DMNOKR3 MA Inhibitor DMNOKR3 RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMNOKR3 RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMNOMCT DI DMNOMCT DMNOMCT DN PMID1656041C11nn DMNOMCT TI TTPADOQ DMNOMCT TN HMG-CoA reductase (HMGCR) DMNOMCT MA Inhibitor DMNOMCT RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83. DMNOMCT RU https://pubmed.ncbi.nlm.nih.gov/1656041 DMNOPWB DI DMNOPWB DMNOPWB DN ISIS 12660 DMNOPWB TI TT4SCBE DMNOPWB TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMNOPWB RN US patent application no. 5,767,102, Antisense composition and method for treatment of CMV infection. DMNOPWB RU http://www.patentbuddy.com/Patent/5767102?ft=true&sr=true DMNOQ49 DI DMNOQ49 DMNOQ49 DN 1-(3,4-dichlorophenyl)-3-(3,5-dichlorophenyl)urea DMNOQ49 TI TTA93TL DMNOQ49 TN P2Y purinoceptor 1 (P2RY1) DMNOQ49 MA Inhibitor DMNOQ49 RN P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3338-43. DMNOQ49 RU https://pubmed.ncbi.nlm.nih.gov/18445527 DMNOREK DI DMNOREK DMNOREK DN ML315 DMNOREK TI TT1RFQP DMNOREK TN CDC-like kinase 4 (CLK4) DMNOREK MA Inhibitor DMNOREK RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DMNOREK RU https://pubmed.ncbi.nlm.nih.gov/23642479 DMNOREK DI DMNOREK DMNOREK DN ML315 DMNOREK TI TTSBVFO DMNOREK TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMNOREK MA Inhibitor DMNOREK RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DMNOREK RU https://pubmed.ncbi.nlm.nih.gov/23642479 DMNOREK DI DMNOREK DMNOREK DN ML315 DMNOREK TI TT85TPS DMNOREK TN CDC-like kinase 2 (CLK2) DMNOREK MA Inhibitor DMNOREK RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DMNOREK RU https://pubmed.ncbi.nlm.nih.gov/23642479 DMNOREK DI DMNOREK DMNOREK DN ML315 DMNOREK TI TTE6YDG DMNOREK TN CDC-like kinase 1 (CLK1) DMNOREK MA Inhibitor DMNOREK RN Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorg Med Chem Lett. 2013 Jun15;23(12):3654-61. DMNOREK RU https://pubmed.ncbi.nlm.nih.gov/23642479 DMNOTH5 DI DMNOTH5 DMNOTH5 DN ETHOXY-IDAZOXAN DMNOTH5 TI TT2NUT5 DMNOTH5 TN Adrenergic receptor alpha-2C (ADRA2C) DMNOTH5 MA Modulator DMNOTH5 RN Discriminative stimulus properties of ethoxy idazoxan. J Psychopharmacol. 1995 Jan;9(3):228-33. DMNOTH5 RU https://pubmed.ncbi.nlm.nih.gov/22297762 DMNOU59 DI DMNOU59 DMNOU59 DN GSK'963 DMNOU59 TI TTAIQSN DMNOU59 TN Receptor-interacting protein 1 (RIPK1) DMNOU59 MA Inhibitor DMNOU59 RN Characterization of GSK'963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015 Jul 27;1:15009. DMNOU59 RU https://pubmed.ncbi.nlm.nih.gov/27551444 DMNOUSV DI DMNOUSV DMNOUSV DN 3,3-diphenylpropan-1-amine DMNOUSV TI TTTIBOJ DMNOUSV TN Histamine H1 receptor (H1R) DMNOUSV MA Inhibitor DMNOUSV RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMNOUSV RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMNOWAQ DI DMNOWAQ DMNOWAQ DN ZK-810388 DMNOWAQ TI TTMF8H9 DMNOWAQ TN Plasma kallikrein (KLKB1) DMNOWAQ MA Inhibitor DMNOWAQ RN Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80. DMNOWAQ RU https://pubmed.ncbi.nlm.nih.gov/17536795 DMNOWAQ DI DMNOWAQ DMNOWAQ DN ZK-810388 DMNOWAQ TI TTCIHJA DMNOWAQ TN Coagulation factor Xa (F10) DMNOWAQ MA Inhibitor DMNOWAQ RN Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors. J Med Chem. 2007 Jun 28;50(13):2967-80. DMNOWAQ RU https://pubmed.ncbi.nlm.nih.gov/17536795 DMNOWZ2 DI DMNOWZ2 DMNOWZ2 DN (S)-N-oleoyltyrosinol DMNOWZ2 TI TT7QNVC DMNOWZ2 TN Glucose-dependent insulinotropic receptor (GPR119) DMNOWZ2 MA Agonist DMNOWZ2 RN N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119. Mol Endocrinol. 2010 Jan;24(1):161-70. DMNOWZ2 RU https://pubmed.ncbi.nlm.nih.gov/19901198 DMNOZR2 DI DMNOZR2 DMNOZR2 DN 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol DMNOZR2 TI TT27RFC DMNOZR2 TN Opioid receptor delta (OPRD1) DMNOZR2 MA Inhibitor DMNOZR2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMNOZR2 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMNOZR2 DI DMNOZR2 DMNOZR2 DN 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol DMNOZR2 TI TTQW87Y DMNOZR2 TN Opioid receptor kappa (OPRK1) DMNOZR2 MA Inhibitor DMNOZR2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMNOZR2 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMNOZR2 DI DMNOZR2 DMNOZR2 DN 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol DMNOZR2 TI TTNT7K8 DMNOZR2 TN Nociceptin receptor (OPRL1) DMNOZR2 MA Inhibitor DMNOZR2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMNOZR2 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMNOZR2 DI DMNOZR2 DMNOZR2 DN 1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol DMNOZR2 TI TTKWM86 DMNOZR2 TN Opioid receptor mu (MOP) DMNOZR2 MA Inhibitor DMNOZR2 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMNOZR2 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMNP6QD DI DMNP6QD DMNP6QD DN piribedil DMNP6QD TI TT4C8EA DMNP6QD TN Dopamine D3 receptor (D3R) DMNP6QD MA Agonist DMNP6QD RN Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. DMNP6QD RU https://pubmed.ncbi.nlm.nih.gov/12388666 DMNP6QD DI DMNP6QD DMNP6QD DN piribedil DMNP6QD TI TT0K1SC DMNP6QD TN 5-HT 2B receptor (HTR2B) DMNP6QD MA Antagonist DMNP6QD RN Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. DMNP6QD RU https://pubmed.ncbi.nlm.nih.gov/12388666 DMNP6QD DI DMNP6QD DMNP6QD DN piribedil DMNP6QD TI TTSQIFT DMNP6QD TN 5-HT 1A receptor (HTR1A) DMNP6QD MA Agonist DMNP6QD RN Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. DMNP6QD RU https://pubmed.ncbi.nlm.nih.gov/12388666 DMNP6QD DI DMNP6QD DMNP6QD DN piribedil DMNP6QD TI TTE0A2F DMNP6QD TN Dopamine D4 receptor (D4R) DMNP6QD MA Antagonist DMNP6QD RN Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. DMNP6QD RU https://pubmed.ncbi.nlm.nih.gov/12388666 DMNP6QD DI DMNP6QD DMNP6QD DN piribedil DMNP6QD TI TTEX248 DMNP6QD TN Dopamine D2 receptor (D2R) DMNP6QD MA Agonist DMNP6QD RN Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. DMNP6QD RU https://pubmed.ncbi.nlm.nih.gov/12388666 DMNP6QD DI DMNP6QD DMNP6QD DN piribedil DMNP6QD TI TT2NUT5 DMNP6QD TN Adrenergic receptor alpha-2C (ADRA2C) DMNP6QD MA Antagonist DMNP6QD RN Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804. DMNP6QD RU https://pubmed.ncbi.nlm.nih.gov/12388666 DMNP7GD DI DMNP7GD DMNP7GD DN JWH-406 DMNP7GD TI TTMSFAW DMNP7GD TN Cannabinoid receptor 2 (CB2) DMNP7GD MA Inhibitor DMNP7GD RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMNP7GD RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMNP7GD DI DMNP7GD DMNP7GD DN JWH-406 DMNP7GD TI TT6OEDT DMNP7GD TN Cannabinoid receptor 1 (CB1) DMNP7GD MA Inhibitor DMNP7GD RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMNP7GD RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMNP8DQ DI DMNP8DQ DMNP8DQ DN 3-sec-Butoxy-9H-beta-carboline DMNP8DQ TI TT1MPAY DMNP8DQ TN GABA(A) receptor alpha-1 (GABRA1) DMNP8DQ MA Inhibitor DMNP8DQ RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMNP8DQ RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMNP8DQ DI DMNP8DQ DMNP8DQ DN 3-sec-Butoxy-9H-beta-carboline DMNP8DQ TI TTNJYV2 DMNP8DQ TN Gamma-aminobutyric acid receptor (GAR) DMNP8DQ MA Inhibitor DMNP8DQ RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMNP8DQ RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMNP8HG DI DMNP8HG DMNP8HG DN ISIS 134601 DMNP8HG TI TTKW4ML DMNP8HG TN Caspase 6 messenger RNA (CASP6 mRNA) DMNP8HG RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMNP8HG RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMNPA2C DI DMNPA2C DMNPA2C DN PMID24946214C3b DMNPA2C TI TT68GPI DMNPA2C TN Proteasome beta-5 (PS beta-5) DMNPA2C MA Inhibitor DMNPA2C RN Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors. Eur J Med Chem. 2014 Aug 18;83:1-14. DMNPA2C RU https://pubmed.ncbi.nlm.nih.gov/24946214 DMNPEM4 DI DMNPEM4 DMNPEM4 DN ARL66096 DMNPEM4 TI TTZ1DT0 DMNPEM4 TN P2Y purinoceptor 12 (P2RY12) DMNPEM4 MA Antagonist DMNPEM4 RN FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol. 1994 Nov;113(3):1057-63. DMNPEM4 RU https://pubmed.ncbi.nlm.nih.gov/7858849 DMNPGXA DI DMNPGXA DMNPGXA DN 2-fluorophenyl-2,2-diphenylacetamide DMNPGXA TI TTMNI76 DMNPGXA TN Calcium-activated potassium channel (KCN) DMNPGXA MA Inhibitor DMNPGXA RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMNPGXA RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMNPKZ6 DI DMNPKZ6 DMNPKZ6 DN 3-[(Z)-2-phenylvinyl]pyridine DMNPKZ6 TI TTIQUX7 DMNPKZ6 TN Steroid 11-beta-hydroxylase (CYP11B1) DMNPKZ6 MA Inhibitor DMNPKZ6 RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMNPKZ6 RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMNPMW4 DI DMNPMW4 DMNPMW4 DN ISIS 103613 DMNPMW4 TI TTBWMKT DMNPMW4 TN WWP1 messenger RNA (WWP1 mRNA) DMNPMW4 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMNPMW4 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMNPO9Q DI DMNPO9Q DMNPO9Q DN Uracil DMNPO9Q TI TTZPS91 DMNPO9Q TN Dihydrothymine dehydrogenase (DPYD) DMNPO9Q MA Modulator DMNPO9Q RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMNPO9Q RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMNPS4R DI DMNPS4R DMNPS4R DN N-Benzyl-ETAV DMNPS4R TI TT9PB26 DMNPS4R TN Presynaptic density protein 95 (DLG4) DMNPS4R MA Inhibitor DMNPS4R RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMNPS4R RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMNQ3HV DI DMNQ3HV DMNQ3HV DN AZ20 DMNQ3HV TI TT8ZYBQ DMNQ3HV TN Serine/threonine-protein kinase ATR (FRP1) DMNQ3HV MA Inhibitor DMNQ3HV RN Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. J Med Chem. 2013 Mar 14;56(5):2125-38. DMNQ3HV RU https://pubmed.ncbi.nlm.nih.gov/23394205 DMNQ7TM DI DMNQ7TM DMNQ7TM DN Purvalanol A DMNQ7TM TI TTH6V3D DMNQ7TM TN Cyclin-dependent kinase 1 (CDK1) DMNQ7TM MA Inhibitor DMNQ7TM RN Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J Biol Chem. 2004 May 7;279(19):20267-76. DMNQ7TM RU https://pubmed.ncbi.nlm.nih.gov/14988404 DMNQ7TM DI DMNQ7TM DMNQ7TM DN Purvalanol A DMNQ7TM TI TT7HF4W DMNQ7TM TN Cyclin-dependent kinase 2 (CDK2) DMNQ7TM MA Inhibitor DMNQ7TM RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMNQ7TM RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMNQ7TM DI DMNQ7TM DMNQ7TM DN Purvalanol A DMNQ7TM TI TTAMQ62 DMNQ7TM TN Cyclin A2 (CCNA2) DMNQ7TM MA Inhibitor DMNQ7TM RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMNQ7TM RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMNQ9M1 DI DMNQ9M1 DMNQ9M1 DN APCK-110 DMNQ9M1 TI TTX41N9 DMNQ9M1 TN Tyrosine-protein kinase Kit (KIT) DMNQ9M1 MA Inhibitor DMNQ9M1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1805). DMNQ9M1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1805 DMNQ9R4 DI DMNQ9R4 DMNQ9R4 DN AVPIAQKSEK-FAM DMNQ9R4 TI TTK3WBU DMNQ9R4 TN XIAP messenger RNA (XIAP mRNA) DMNQ9R4 MA Inhibitor DMNQ9R4 RN Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40. DMNQ9R4 RU https://pubmed.ncbi.nlm.nih.gov/15115387 DMNQDLC DI DMNQDLC DMNQDLC DN N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide DMNQDLC TI TTZHA0O DMNQDLC TN Carbonic anhydrase IV (CA-IV) DMNQDLC MA Inhibitor DMNQDLC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMNQDLC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMNQDLC DI DMNQDLC DMNQDLC DN N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide DMNQDLC TI TTUNARX DMNQDLC TN Carbonic anhydrase (CA) DMNQDLC MA Inhibitor DMNQDLC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMNQDLC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMNQDLC DI DMNQDLC DMNQDLC DN N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide DMNQDLC TI TTHQPL7 DMNQDLC TN Carbonic anhydrase I (CA-I) DMNQDLC MA Inhibitor DMNQDLC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMNQDLC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMNQDLC DI DMNQDLC DMNQDLC DN N-(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamide DMNQDLC TI TTANPDJ DMNQDLC TN Carbonic anhydrase II (CA-II) DMNQDLC MA Inhibitor DMNQDLC RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMNQDLC RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMNQF03 DI DMNQF03 DMNQF03 DN 3-chloro-4-(o-tolyloxy)benzonitrile DMNQF03 TI TTKPW01 DMNQF03 TN Androgen receptor messenger RNA (AR mRNA) DMNQF03 MA Inhibitor DMNQF03 RN Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8. DMNQF03 RU https://pubmed.ncbi.nlm.nih.gov/19286380 DMNQIGZ DI DMNQIGZ DMNQIGZ DN 2,5-bis(4-Hydroxyphenyl)thiophene DMNQIGZ TI TTE4KHA DMNQIGZ TN Amyloid beta A4 protein (APP) DMNQIGZ MA Inhibitor DMNQIGZ RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DMNQIGZ RU https://pubmed.ncbi.nlm.nih.gov/16325402 DMNQL17 DI DMNQL17 DMNQL17 DN 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE DMNQL17 TI TTZAYWL DMNQL17 TN Estrogen receptor (ESR) DMNQL17 MA Inhibitor DMNQL17 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNQL17 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNQTBU DI DMNQTBU DMNQTBU DN D[Orn4,Lys8]VP DMNQTBU TI TTL9MHW DMNQTBU TN Vasopressin V1b receptor (V1BR) DMNQTBU MA Inhibitor DMNQTBU RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNQTBU RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNQTBU DI DMNQTBU DMNQTBU DN D[Orn4,Lys8]VP DMNQTBU TI TTSCIUP DMNQTBU TN Oxytocin receptor (OTR) DMNQTBU MA Inhibitor DMNQTBU RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNQTBU RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNQTBU DI DMNQTBU DMNQTBU DN D[Orn4,Lys8]VP DMNQTBU TI TT4TFGN DMNQTBU TN Vasopressin V1a receptor (V1AR) DMNQTBU MA Inhibitor DMNQTBU RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNQTBU RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNQTBU DI DMNQTBU DMNQTBU DN D[Orn4,Lys8]VP DMNQTBU TI TTK8R02 DMNQTBU TN Vasopressin V2 receptor (V2R) DMNQTBU MA Inhibitor DMNQTBU RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNQTBU RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNQW2B DI DMNQW2B DMNQW2B DN 7-(3,6,9,12-tetraoxatricos-22-enyl)theophylline DMNQW2B TI TTK25J1 DMNQW2B TN Adenosine A1 receptor (ADORA1) DMNQW2B MA Inhibitor DMNQW2B RN Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors. Bioorg Med Chem. 2010 Mar 15;18(6):2081-2088. DMNQW2B RU https://pubmed.ncbi.nlm.nih.gov/20202853 DMNQWBS DI DMNQWBS DMNQWBS DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-beta-Ala-) DMNQWBS TI TTBID49 DMNQWBS TN C-X-C chemokine receptor type 4 (CXCR4) DMNQWBS MA Inhibitor DMNQWBS RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMNQWBS RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMNQWZO DI DMNQWZO DMNQWZO DN 6-(2-Dipropylamino-ethyl)-biphenyl-2,3-diol DMNQWZO TI TTZFYLI DMNQWZO TN Dopamine D1 receptor (D1R) DMNQWZO MA Inhibitor DMNQWZO RN Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12. DMNQWZO RU https://pubmed.ncbi.nlm.nih.gov/3761310 DMNQXE0 DI DMNQXE0 DMNQXE0 DN NSC-665126 DMNQXE0 TI TTJLP0R DMNQXE0 TN Quinone reductase 2 (NQO2) DMNQXE0 MA Inhibitor DMNQXE0 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMNQXE0 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMNR3YL DI DMNR3YL DMNR3YL DN (+/-)-2-Phenylthiomorpholine DMNR3YL TI TTGP7BY DMNR3YL TN Monoamine oxidase type B (MAO-B) DMNR3YL MA Inhibitor DMNR3YL RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMNR3YL RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMNR3YL DI DMNR3YL DMNR3YL DN (+/-)-2-Phenylthiomorpholine DMNR3YL TI TT3WG5C DMNR3YL TN Monoamine oxidase type A (MAO-A) DMNR3YL MA Inhibitor DMNR3YL RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMNR3YL RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMNR439 DI DMNR439 DMNR439 DN Diisopropyl 1-mercaptopropylphosphonate DMNR439 TI TTHI19T DMNR439 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMNR439 MA Inhibitor DMNR439 RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMNR439 RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMNRBDP DI DMNRBDP DMNRBDP DN WA-8242-A1 DMNRBDP TI TT9V5JH DMNRBDP TN Phospholipase A2 (PLA2G1B) DMNRBDP MA Modulator DMNRBDP RN WA8242A1, A2 and B, novel secretary phospholipase A2 inhibitors produced by Streptomyces violaceusniger. III. Structure elucidation and total synth... J Antibiot (Tokyo). 1998 Jul;51(7):655-64. DMNRBDP RU https://www.ncbi.nlm.nih.gov/pubmed/9727392 DMNRCDI DI DMNRCDI DMNRCDI DN 7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DMNRCDI TI TT06AWU DMNRCDI TN Phosphodiesterase 3A (PDE3A) DMNRCDI MA Inhibitor DMNRCDI RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DMNRCDI RU https://pubmed.ncbi.nlm.nih.gov/1654430 DMNRCM0 DI DMNRCM0 DMNRCM0 DN 1-(3,5-dibromobenzyl)-1H-imidazole DMNRCM0 TI TTRA5BZ DMNRCM0 TN Steroid 17-alpha-monooxygenase (S17AH) DMNRCM0 MA Inhibitor DMNRCM0 RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DMNRCM0 RU https://pubmed.ncbi.nlm.nih.gov/16750362 DMNRHSO DI DMNRHSO DMNRHSO DN BENZYLIMIDAZOLE DMNRHSO TI TTIQUX7 DMNRHSO TN Steroid 11-beta-hydroxylase (CYP11B1) DMNRHSO MA Inhibitor DMNRHSO RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMNRHSO RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMNRLA7 DI DMNRLA7 DMNRLA7 DN DMP-695/696 DMNRLA7 TI TT7EFHR DMNRLA7 TN Corticotropin-releasing factor receptor 1 (CRHR1) DMNRLA7 MA Antagonist DMNRLA7 RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DMNRLA7 RU https://pubmed.ncbi.nlm.nih.gov/17109611 DMNRMKA DI DMNRMKA DMNRMKA DN MB-3 DMNRMKA TI TTVK7SB DMNRMKA TN Histone acetyltransferase KAT2B (KAT2B) DMNRMKA MA Inhibitor DMNRMKA RN Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew Chem Int Ed Engl. 2004 Jul 26;43(30):3974-6. DMNRMKA RU https://pubmed.ncbi.nlm.nih.gov/15274229 DMNRMTX DI DMNRMTX DMNRMTX DN 13,14-dihydro-16-m-chlorophenoxy-w-tetranor-PGF1alpha DMNRMTX TI TTT2ZAR DMNRMTX TN Prostaglandin F2-alpha receptor (PTGFR) DMNRMTX MA Agonist DMNRMTX RN Design and synthesis of 13,14-dihydro prostaglandin F(1alpha) analogues as potent and selective ligands for the human FP receptor. J Med Chem. 2000 Mar 9;43(5):945-52. DMNRMTX RU https://pubmed.ncbi.nlm.nih.gov/10715159 DMNROUV DI DMNROUV DMNROUV DN (R)-1-(4-nitrophenethyl)-2-methylpyrrolidine DMNROUV TI TT9JNIC DMNROUV TN Histamine H3 receptor (H3R) DMNROUV MA Inhibitor DMNROUV RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMNROUV RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMNRP2L DI DMNRP2L DMNRP2L DN GSK-650394 DMNRP2L TI TTTV8EJ DMNRP2L TN Serine/threonine-protein kinase Sgk1 (SGK1) DMNRP2L MA Inhibitor DMNRP2L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8040). DMNRP2L RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8040 DMNRSYA DI DMNRSYA DMNRSYA DN 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMNRSYA TI TT3WG5C DMNRSYA TN Monoamine oxidase type A (MAO-A) DMNRSYA MA Inhibitor DMNRSYA RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMNRSYA RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMNRSYA DI DMNRSYA DMNRSYA DN 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMNRSYA TI TTGP7BY DMNRSYA TN Monoamine oxidase type B (MAO-B) DMNRSYA MA Inhibitor DMNRSYA RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMNRSYA RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMNRSYA DI DMNRSYA DMNRSYA DN 5-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMNRSYA TI TTJQOD7 DMNRSYA TN 5-HT 2A receptor (HTR2A) DMNRSYA MA Inhibitor DMNRSYA RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMNRSYA RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMNRSYP DI DMNRSYP DMNRSYP DN N-(6-(thiophen-3-yl)-1H-indazol-3-yl)butyramide DMNRSYP TI TTRSMW9 DMNRSYP TN Glycogen synthase kinase-3 beta (GSK-3B) DMNRSYP MA Inhibitor DMNRSYP RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMNRSYP RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMNRWEV DI DMNRWEV DMNRWEV DN 5-{8(Z),-pentadecenyl}resorcinol DMNRWEV TI TTULVH8 DMNRWEV TN Tyrosinase (TYR) DMNRWEV MA Inhibitor DMNRWEV RN Tyrosinase inhibitors from Anacardium occidentale fruits. J Nat Prod. 1994 Apr;57(4):545-51. DMNRWEV RU https://pubmed.ncbi.nlm.nih.gov/8021657 DMNRXJU DI DMNRXJU DMNRXJU DN JWH-296 DMNRXJU TI TTMSFAW DMNRXJU TN Cannabinoid receptor 2 (CB2) DMNRXJU MA Inhibitor DMNRXJU RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMNRXJU RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMNRZ3S DI DMNRZ3S DMNRZ3S DN MANGOSTENONE F DMNRZ3S TI TT50QJ3 DMNRZ3S TN Influenza Neuraminidase (Influ NA) DMNRZ3S MA Inhibitor DMNRZ3S RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMNRZ3S RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMNS1GX DI DMNS1GX DMNS1GX DN H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2 DMNS1GX TI TT27RFC DMNS1GX TN Opioid receptor delta (OPRD1) DMNS1GX MA Inhibitor DMNS1GX RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMNS1GX RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMNS1GX DI DMNS1GX DMNS1GX DN H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2 DMNS1GX TI TTKWM86 DMNS1GX TN Opioid receptor mu (MOP) DMNS1GX MA Inhibitor DMNS1GX RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMNS1GX RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMNS265 DI DMNS265 DMNS265 DN DTPA Conjugate DMNS265 TI TTN53ZF DMNS265 TN Leukotriene B4 receptor 1 (LTB4R) DMNS265 MA Inhibitor DMNS265 RN Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci. J Med Chem. 2005 Oct 6;48(20):6442-53. DMNS265 RU https://pubmed.ncbi.nlm.nih.gov/16190770 DMNS3HC DI DMNS3HC DMNS3HC DN C[RGDf-(S)-N-Me-alpha-TfmF] DMNS3HC TI TTJA1ZO DMNS3HC TN ITGB3 messenger RNA (ITGB3 mRNA) DMNS3HC MA Inhibitor DMNS3HC RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMNS3HC RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMNS3HC DI DMNS3HC DMNS3HC DN C[RGDf-(S)-N-Me-alpha-TfmF] DMNS3HC TI TTT1R2L DMNS3HC TN Integrin alpha-V (ITGAV) DMNS3HC MA Inhibitor DMNS3HC RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMNS3HC RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMNS3RT DI DMNS3RT DMNS3RT DN MRS2690 DMNS3RT TI TT72OKI DMNS3RT TN P2Y purinoceptor 14 (P2RY14) DMNS3RT MA Agonist DMNS3RT RN The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells. Purinergic Signal. 2013 Mar;9(1):31-40. DMNS3RT RU https://pubmed.ncbi.nlm.nih.gov/22825617 DMNS70E DI DMNS70E DMNS70E DN PHA-690509 DMNS70E TI TT7HF4W DMNS70E TN Cyclin-dependent kinase 2 (CDK2) DMNS70E MA Inhibitor DMNS70E RN Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14621-6. DMNS70E RU https://pubmed.ncbi.nlm.nih.gov/20679242 DMNS976 DI DMNS976 DMNS976 DN Erybreadin C DMNS976 TI TTELIN2 DMNS976 TN PTPN1 messenger RNA (PTPN1 mRNA) DMNS976 MA Inhibitor DMNS976 RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DMNS976 RU https://pubmed.ncbi.nlm.nih.gov/19836230 DMNS9KW DI DMNS9KW DMNS9KW DN IDN-5174 DMNS9KW TI TTGTQHC DMNS9KW TN DNA topoisomerase I (TOP1) DMNS9KW MA Inhibitor DMNS9KW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2636). DMNS9KW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2636 DMNSEH1 DI DMNSEH1 DMNSEH1 DN ISIS 102454 DMNSEH1 TI TT5U49F DMNSEH1 TN PRKACA messenger RNA (PRKACA mRNA) DMNSEH1 RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMNSEH1 RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMNSIF2 DI DMNSIF2 DMNSIF2 DN 5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole DMNSIF2 TI TTJS8PY DMNSIF2 TN 5-HT 6 receptor (HTR6) DMNSIF2 MA Inhibitor DMNSIF2 RN 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46. DMNSIF2 RU https://pubmed.ncbi.nlm.nih.gov/20932009 DMNSKXR DI DMNSKXR DMNSKXR DN 4-(2-methoxybenzylthio)-2-aminobutanoic acid DMNSKXR TI TTFK1JQ DMNSKXR TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMNSKXR MA Inhibitor DMNSKXR RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMNSKXR RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMNSLGC DI DMNSLGC DMNSLGC DN BW A360C DMNSLGC TI TT2J34L DMNSLGC TN Arachidonate 5-lipoxygenase (5-LOX) DMNSLGC MA Inhibitor DMNSLGC RN Hydroxamic acids and hydroxyureas as novel, selective 5-lipoxygenase inhibitors for possible use in asthma. Agents Actions Suppl. 1991;34:189-99. DMNSLGC RU https://pubmed.ncbi.nlm.nih.gov/1793063 DMNSPFG DI DMNSPFG DMNSPFG DN Chk2 inhibitor II DMNSPFG TI TT9ABMF DMNSPFG TN Serine/threonine-protein kinase Chk2 (RAD53) DMNSPFG MA Inhibitor DMNSPFG RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMNSPFG RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMNSTKD DI DMNSTKD DMNSTKD DN Isosorbide-di-(butylcarbamate) DMNSTKD TI TTEB0GD DMNSTKD TN Cholinesterase (BCHE) DMNSTKD MA Inhibitor DMNSTKD RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMNSTKD RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMNSU1H DI DMNSU1H DMNSU1H DN 4-octyl-N-(pyridin-3-yl)benzamide DMNSU1H TI TTMI6F5 DMNSU1H TN Transient receptor potential cation channel V1 (TRPV1) DMNSU1H MA Inhibitor DMNSU1H RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMNSU1H RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMNSUD9 DI DMNSUD9 DMNSUD9 DN CXCR4 gene disrupted T cells DMNSUD9 TI TTBID49 DMNSUD9 TN C-X-C chemokine receptor type 4 (CXCR4) DMNSUD9 MA Modulator DMNSUD9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMNSUD9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMNSXG9 DI DMNSXG9 DMNSXG9 DN D[Leu4,Dab8]VP DMNSXG9 TI TT4TFGN DMNSXG9 TN Vasopressin V1a receptor (V1AR) DMNSXG9 MA Inhibitor DMNSXG9 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNSXG9 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNSXG9 DI DMNSXG9 DMNSXG9 DN D[Leu4,Dab8]VP DMNSXG9 TI TTSCIUP DMNSXG9 TN Oxytocin receptor (OTR) DMNSXG9 MA Inhibitor DMNSXG9 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNSXG9 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNSXG9 DI DMNSXG9 DMNSXG9 DN D[Leu4,Dab8]VP DMNSXG9 TI TTL9MHW DMNSXG9 TN Vasopressin V1b receptor (V1BR) DMNSXG9 MA Inhibitor DMNSXG9 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNSXG9 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNSXG9 DI DMNSXG9 DMNSXG9 DN D[Leu4,Dab8]VP DMNSXG9 TI TTK8R02 DMNSXG9 TN Vasopressin V2 receptor (V2R) DMNSXG9 MA Inhibitor DMNSXG9 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMNSXG9 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMNSZPX DI DMNSZPX DMNSZPX DN ISIS 102629 DMNSZPX TI TT5U49F DMNSZPX TN PRKACA messenger RNA (PRKACA mRNA) DMNSZPX RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMNSZPX RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMNT1XI DI DMNT1XI DMNT1XI DN 13,14-dihydro-15-keto-PGF2alpha DMNT1XI TI TTQDMX5 DMNT1XI TN Prostaglandin D2 receptor 2 (PTGDR2) DMNT1XI MA Agonist DMNT1XI RN Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72. DMNT1XI RU https://pubmed.ncbi.nlm.nih.gov/12466225 DMNT3JV DI DMNT3JV DMNT3JV DN N-(2,4-dihydroxybenzyl)-3,4,5-trihydroxybenzamide DMNT3JV TI TTULVH8 DMNT3JV TN Tyrosinase (TYR) DMNT3JV MA Inhibitor DMNT3JV RN N-Benzylbenzamides: a new class of potent tyrosinase inhibitors. Bioorg Med Chem Lett. 2006 May 15;16(10):2682-4. DMNT3JV RU https://pubmed.ncbi.nlm.nih.gov/16513349 DMNT5BF DI DMNT5BF DMNT5BF DN 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile DMNT5BF TI TTUMQVO DMNT5BF TN Cathepsin S (CTSS) DMNT5BF MA Inhibitor DMNT5BF RN Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. DMNT5BF RU https://pubmed.ncbi.nlm.nih.gov/20149657 DMNT5BF DI DMNT5BF DMNT5BF DN 4-cycloheptyl-6-propylpyrimidine-2-carbonitrile DMNT5BF TI TTDZN01 DMNT5BF TN Cathepsin K (CTSK) DMNT5BF MA Inhibitor DMNT5BF RN Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. DMNT5BF RU https://pubmed.ncbi.nlm.nih.gov/20149657 DMNTAV8 DI DMNTAV8 DMNTAV8 DN CX-7000 DMNTAV8 TI TTER6YH DMNTAV8 TN Casein kinase II alpha (CSNK2A1) DMNTAV8 MA Inhibitor DMNTAV8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1549). DMNTAV8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1549 DMNTDFV DI DMNTDFV DMNTDFV DN 6-Cl-IMP DMNTDFV TI TTL7C8Q DMNTDFV TN Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) DMNTDFV MA Inhibitor DMNTDFV RN Identification of the IMP binding site in the IMP dehydrogenase from Tritrichomonas foetus. Biochemistry. 1995 Oct 24;34(42):13889-94. DMNTDFV RU https://pubmed.ncbi.nlm.nih.gov/7577983 DMNTDFV DI DMNTDFV DMNTDFV DN 6-Cl-IMP DMNTDFV TI TTYQ4AE DMNTDFV TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DMNTDFV MA Inhibitor DMNTDFV RN High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants. Biol Reprod. 1994 Jun;50(6):1403-12. DMNTDFV RU https://pubmed.ncbi.nlm.nih.gov/8080928 DMNTELW DI DMNTELW DMNTELW DN 1-benzyl-4-phenylpiperidin-4-ol DMNTELW TI TTNT7K8 DMNTELW TN Nociceptin receptor (OPRL1) DMNTELW MA Inhibitor DMNTELW RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMNTELW RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMNTF2O DI DMNTF2O DMNTF2O DN Muscimol DMNTF2O TI TTNJYV2 DMNTF2O TN Gamma-aminobutyric acid receptor (GAR) DMNTF2O MA Agonist DMNTF2O RN THIP treatment of Huntington's disease. Neurology. 1983 May;33(5):637-9. DMNTF2O RU https://pubmed.ncbi.nlm.nih.gov/6221200 DMNTF2O DI DMNTF2O DMNTF2O DN Muscimol DMNTF2O TI TTAN6JD DMNTF2O TN Glutamate receptor AMPA (GRIA) DMNTF2O MA Agonist DMNTF2O RN GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32. DMNTF2O RU https://pubmed.ncbi.nlm.nih.gov/12171573 DMNTHK5 DI DMNTHK5 DMNTHK5 DN 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol DMNTHK5 TI TTOM3J0 DMNTHK5 TN Estrogen receptor beta (ESR2) DMNTHK5 MA Inhibitor DMNTHK5 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMNTHK5 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMNTHK5 DI DMNTHK5 DMNTHK5 DN 2-(3-Fluoro-4-hydroxy-phenyl)-benzooxazol-5-ol DMNTHK5 TI TTZAYWL DMNTHK5 TN Estrogen receptor (ESR) DMNTHK5 MA Inhibitor DMNTHK5 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMNTHK5 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMNTRKI DI DMNTRKI DMNTRKI DN ISIS 114372 DMNTRKI TI TT8OY02 DMNTRKI TN ARA70 messenger RNA (NCOA4 mRNA) DMNTRKI RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DMNTRKI RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DMNU1YR DI DMNU1YR DMNU1YR DN 2S,4R-4-METHYLGLUTAMATE DMNU1YR TI TT0MYE2 DMNU1YR TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMNU1YR MA Inhibitor DMNU1YR RN Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103. DMNU1YR RU https://pubmed.ncbi.nlm.nih.gov/18578478 DMNU2RM DI DMNU2RM DMNU2RM DN 4-(piperazin-1-yl)thieno[2,3-d]pyrimidine DMNU2RM TI TTWJBZ5 DMNU2RM TN 5-HT 2C receptor (HTR2C) DMNU2RM MA Inhibitor DMNU2RM RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DMNU2RM RU https://pubmed.ncbi.nlm.nih.gov/19914063 DMNU68D DI DMNU68D DMNU68D DN N-(5-Phenyl-furan-2-carbonyl)-guanidine DMNU68D TI TTGSEFH DMNU68D TN Sodium/hydrogen exchanger 1 (SLC9A1) DMNU68D MA Inhibitor DMNU68D RN (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. DMNU68D RU https://pubmed.ncbi.nlm.nih.gov/15828827 DMNU9WV DI DMNU9WV DMNU9WV DN Tert-Butyl 3-(2-oxo-8-phenyloctanamido)propanoate DMNU9WV TI TTT1JVS DMNU9WV TN Cytosolic phospholipase A2 (GIVA cPLA2) DMNU9WV MA Inhibitor DMNU9WV RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMNU9WV RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMNUAB9 DI DMNUAB9 DMNUAB9 DN 1-pentenyl-4-(aminosulfonyl)benzoate DMNUAB9 TI TTANPDJ DMNUAB9 TN Carbonic anhydrase II (CA-II) DMNUAB9 MA Inhibitor DMNUAB9 RN Synthesis and structure-activity relationships of novel benzene sulfonamides with potent binding affinity for bovine carbonic anhydrase II. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5429-33. DMNUAB9 RU https://pubmed.ncbi.nlm.nih.gov/16213706 DMNUE4H DI DMNUE4H DMNUE4H DN AC-3174 DMNUE4H TI TTVIMDE DMNUE4H TN Glucagon-like peptide 1 receptor (GLP1R) DMNUE4H MA Agonist DMNUE4H RN 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). DMNUE4H RU http://www.nature.com/nrd/journal/v11/n1/full/nrd3645.html DMNUGTL DI DMNUGTL DMNUGTL DN Ohioensin C DMNUGTL TI TTELIN2 DMNUGTL TN PTPN1 messenger RNA (PTPN1 mRNA) DMNUGTL MA Inhibitor DMNUGTL RN Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5. DMNUGTL RU https://pubmed.ncbi.nlm.nih.gov/18053716 DMNUKIX DI DMNUKIX DMNUKIX DN D-myo-inositol 1,4,5-trisphosphate DMNUKIX TI TTC9IZL DMNUKIX TN Inositol 1,4,5-trisphosphate receptor (ITPR) DMNUKIX MA Inhibitor DMNUKIX RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMNUKIX RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMNUM4K DI DMNUM4K DMNUM4K DN 3-hydroxybenzylhydrazine DMNUM4K TI TTN451K DMNUM4K TN Aromatic-L-amino-acid decarboxylase (DDC) DMNUM4K MA Inhibitor DMNUM4K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1271). DMNUM4K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1271 DMNUO79 DI DMNUO79 DMNUO79 DN (1-Amino-3-methyl-butyl)-phosphinic acid DMNUO79 TI TTPHMWB DMNUO79 TN Aminopeptidase N (ANPEP) DMNUO79 MA Inhibitor DMNUO79 RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMNUO79 RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMNUQ9P DI DMNUQ9P DMNUQ9P DN SKF-89124A DMNUQ9P TI TTEX248 DMNUQ9P TN Dopamine D2 receptor (D2R) DMNUQ9P MA Inhibitor DMNUQ9P RN Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzot... J Med Chem. 1987 Jul;30(7):1166-76. DMNUQ9P RU https://pubmed.ncbi.nlm.nih.gov/2955118 DMNUQAG DI DMNUQAG DMNUQAG DN CGP-029482 DMNUQAG TI TTER6YH DMNUQAG TN Casein kinase II alpha (CSNK2A1) DMNUQAG MA Inhibitor DMNUQAG RN Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. DMNUQAG RU https://pubmed.ncbi.nlm.nih.gov/19414254 DMNURE0 DI DMNURE0 DMNURE0 DN TETRAHYDROBENXIMIDAZOLE DMNURE0 TI TT06AWU DMNURE0 TN Phosphodiesterase 3A (PDE3A) DMNURE0 MA Inhibitor DMNURE0 RN Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50. DMNURE0 RU https://pubmed.ncbi.nlm.nih.gov/2536438 DMNUSKT DI DMNUSKT DMNUSKT DN NSC-292213 DMNUSKT TI TT12ABZ DMNUSKT TN Arachidonate 12-lipoxygenase (12-LOX) DMNUSKT MA Inhibitor DMNUSKT RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DMNUSKT RU https://pubmed.ncbi.nlm.nih.gov/17826100 DMNUSKT DI DMNUSKT DMNUSKT DN NSC-292213 DMNUSKT TI TT9NVXQ DMNUSKT TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMNUSKT MA Inhibitor DMNUSKT RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMNUSKT RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMNUWK2 DI DMNUWK2 DMNUWK2 DN 4-(3,4,5-Trimethoxyphenethyl)aniline DMNUWK2 TI TTSZLWK DMNUWK2 TN Aromatase (CYP19A1) DMNUWK2 MA Inhibitor DMNUWK2 RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMNUWK2 RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMNUWVB DI DMNUWVB DMNUWVB DN (+)-3,3'-bisdemethyltanegool DMNUWVB TI TTN9T81 DMNUWVB TN Arachidonate 15-lipoxygenase (15-LOX) DMNUWVB MA Inhibitor DMNUWVB RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DMNUWVB RU https://pubmed.ncbi.nlm.nih.gov/17378609 DMNUWVB DI DMNUWVB DMNUWVB DN (+)-3,3'-bisdemethyltanegool DMNUWVB TI TTSJ6Q4 DMNUWVB TN LOX-5 messenger RNA (ALOX5 mRNA) DMNUWVB MA Inhibitor DMNUWVB RN Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J Nat Prod. 2007 May;70(5):859-62. DMNUWVB RU https://pubmed.ncbi.nlm.nih.gov/17378609 DMNV0EZ DI DMNV0EZ DMNV0EZ DN 3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine DMNV0EZ TI TTUTJGQ DMNV0EZ TN Vascular endothelial growth factor receptor 2 (KDR) DMNV0EZ MA Inhibitor DMNV0EZ RN Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharm... Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41. DMNV0EZ RU https://pubmed.ncbi.nlm.nih.gov/12443771 DMNV0EZ DI DMNV0EZ DMNV0EZ DN 3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine DMNV0EZ TI TT1VAUK DMNV0EZ TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMNV0EZ MA Inhibitor DMNV0EZ RN Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70. DMNV0EZ RU https://pubmed.ncbi.nlm.nih.gov/12217372 DMNV0EZ DI DMNV0EZ DMNV0EZ DN 3,6-Di-pyridin-4-yl-pyrazolo[1,5-a]pyrimidine DMNV0EZ TI TTDCBX5 DMNV0EZ TN Vascular endothelial growth factor receptor 3 (FLT-4) DMNV0EZ MA Inhibitor DMNV0EZ RN Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2002 Oct 7;12(19):2767-70. DMNV0EZ RU https://pubmed.ncbi.nlm.nih.gov/12217372 DMNV1P3 DI DMNV1P3 DMNV1P3 DN 3-Hydroxy-benzamide DMNV1P3 TI TTVDSZ0 DMNV1P3 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMNV1P3 MA Inhibitor DMNV1P3 RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMNV1P3 RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMNV1ST DI DMNV1ST DMNV1ST DN C-10068 DMNV1ST TI TT5TPI6 DMNV1ST TN Opioid receptor sigma 1 (OPRS1) DMNV1ST MA Agonist DMNV1ST RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMNV1ST RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMNV9H5 DI DMNV9H5 DMNV9H5 DN 4-(1-benzyl-7-chloro-1H-indazol-3-yl)phenol DMNV9H5 TI TTZAYWL DMNV9H5 TN Estrogen receptor (ESR) DMNV9H5 MA Inhibitor DMNV9H5 RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DMNV9H5 RU https://pubmed.ncbi.nlm.nih.gov/15588074 DMNVD8I DI DMNVD8I DMNVD8I DN N-Hydroxy-N-methyl-2-naphthalen-2-yl-propionamide DMNVD8I TI TT2J34L DMNVD8I TN Arachidonate 5-lipoxygenase (5-LOX) DMNVD8I MA Inhibitor DMNVD8I RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMNVD8I RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMNVDLI DI DMNVDLI DMNVDLI DN (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone DMNVDLI TI TTPLTSQ DMNVDLI TN Neutrophil elastase (NE) DMNVDLI MA Inhibitor DMNVDLI RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMNVDLI RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMNVDLI DI DMNVDLI DMNVDLI DN (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone DMNVDLI TI TTGY7WI DMNVDLI TN Urokinase-type plasminogen activator (PLAU) DMNVDLI MA Inhibitor DMNVDLI RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMNVDLI RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMNVDLI DI DMNVDLI DMNVDLI DN (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone DMNVDLI TI TT6L509 DMNVDLI TN Coagulation factor IIa (F2) DMNVDLI MA Inhibitor DMNVDLI RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMNVDLI RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMNVDLI DI DMNVDLI DMNVDLI DN (3,4-dichlorophenyl)(1H-pyrazol-1-yl)methanone DMNVDLI TI TTMF8H9 DMNVDLI TN Plasma kallikrein (KLKB1) DMNVDLI MA Inhibitor DMNVDLI RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMNVDLI RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMNVG1M DI DMNVG1M DMNVG1M DN Benzofuran-3-yl-(indol-3-yl)maleimides DMNVG1M TI TTRZQE3 DMNVG1M TN Glycogen synthase kinase-3 alpha (GSK-3A) DMNVG1M MA Inhibitor DMNVG1M RN From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells. J Med Chem. 2009 Apr 9;52(7):1853-63. DMNVG1M RU https://pubmed.ncbi.nlm.nih.gov/19338355 DMNVJY0 DI DMNVJY0 DMNVJY0 DN 2'-epi-guianin DMNVJY0 TI TT8NGED DMNVJY0 TN Prostaglandin G/H synthase 1 (COX-1) DMNVJY0 MA Inhibitor DMNVJY0 RN COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5. DMNVJY0 RU https://pubmed.ncbi.nlm.nih.gov/19880317 DMNVK6T DI DMNVK6T DMNVK6T DN N5-(4-Phenoxyphenyl)-L-glutamine DMNVK6T TI TTXZEAJ DMNVK6T TN Leukotriene A-4 hydrolase (LTA4H) DMNVK6T MA Inhibitor DMNVK6T RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMNVK6T RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMNVLE2 DI DMNVLE2 DMNVLE2 DN ISIS 6434 DMNVLE2 TI TTONI0R DMNVLE2 TN PKC-eta messenger RNA (PRKCH mRNA) DMNVLE2 RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMNVLE2 RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMNVMB5 DI DMNVMB5 DMNVMB5 DN Ac-I[CVTQDWGHHRC]T-NH2 DMNVMB5 TI TTJGY7A DMNVMB5 TN Complement C3 (CO3) DMNVMB5 MA Inhibitor DMNVMB5 RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMNVMB5 RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMNVQ29 DI DMNVQ29 DMNVQ29 DN PMID23414845C30 DMNVQ29 TI TTON5IT DMNVQ29 TN Focal adhesion kinase 1 (FAK) DMNVQ29 MA Inhibitor DMNVQ29 RN Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1779-85. DMNVQ29 RU https://pubmed.ncbi.nlm.nih.gov/23414845 DMNW12R DI DMNW12R DMNW12R DN Cdk1 inhibitor DMNW12R TI TTH6V3D DMNW12R TN Cyclin-dependent kinase 1 (CDK1) DMNW12R MA Inhibitor DMNW12R RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMNW12R RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMNW5PL DI DMNW5PL DMNW5PL DN 2,7-Bis[2-(dimethylamino)acetamido]anthraquinone DMNW5PL TI TTQY2EJ DMNW5PL TN TERT messenger RNA (TERT mRNA) DMNW5PL MA Inhibitor DMNW5PL RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMNW5PL RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMNW7GR DI DMNW7GR DMNW7GR DN Ac-Cys-Ile-Tyr-Lys-Phe(4-CN)-Tyr DMNW7GR TI TT6PKBN DMNW7GR TN Proto-oncogene c-Src (SRC) DMNW7GR MA Inhibitor DMNW7GR RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMNW7GR RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMNWC29 DI DMNWC29 DMNWC29 DN 8-Methoxy-2-piperazin-1-yl-quinoline DMNWC29 TI TT6MSOK DMNWC29 TN 5-HT 1D receptor (HTR1D) DMNWC29 MA Inhibitor DMNWC29 RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMNWC29 RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMNWC29 DI DMNWC29 DMNWC29 DN 8-Methoxy-2-piperazin-1-yl-quinoline DMNWC29 TI TTSQIFT DMNWC29 TN 5-HT 1A receptor (HTR1A) DMNWC29 MA Inhibitor DMNWC29 RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMNWC29 RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMNWC29 DI DMNWC29 DMNWC29 DN 8-Methoxy-2-piperazin-1-yl-quinoline DMNWC29 TI TTJQOD7 DMNWC29 TN 5-HT 2A receptor (HTR2A) DMNWC29 MA Inhibitor DMNWC29 RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMNWC29 RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMNWEC9 DI DMNWEC9 DMNWEC9 DN 1-Benzyl-4-pyrrol-1-yl-piperidine DMNWEC9 TI TTEX248 DMNWEC9 TN Dopamine D2 receptor (D2R) DMNWEC9 MA Inhibitor DMNWEC9 RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMNWEC9 RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMNWEC9 DI DMNWEC9 DMNWEC9 DN 1-Benzyl-4-pyrrol-1-yl-piperidine DMNWEC9 TI TTE0A2F DMNWEC9 TN Dopamine D4 receptor (D4R) DMNWEC9 MA Inhibitor DMNWEC9 RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMNWEC9 RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMNWEC9 DI DMNWEC9 DMNWEC9 DN 1-Benzyl-4-pyrrol-1-yl-piperidine DMNWEC9 TI TT4C8EA DMNWEC9 TN Dopamine D3 receptor (D3R) DMNWEC9 MA Inhibitor DMNWEC9 RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMNWEC9 RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMNWGOE DI DMNWGOE DMNWGOE DN 1-Benzyl-3-thiazol-2-yl-thiourea DMNWGOE TI TT84ETX DMNWGOE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMNWGOE MA Inhibitor DMNWGOE RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMNWGOE RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMNWIYM DI DMNWIYM DMNWIYM DN Flavanone DMNWIYM TI TTN7BL9 DMNWIYM TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMNWIYM MA Inhibitor DMNWIYM RN A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol. 2003 Dec 30;212(1-2):41-9. DMNWIYM RU https://pubmed.ncbi.nlm.nih.gov/14654249 DMNWIYM DI DMNWIYM DMNWIYM DN Flavanone DMNWIYM TI TTGP7BY DMNWIYM TN Monoamine oxidase type B (MAO-B) DMNWIYM MA Inhibitor DMNWIYM RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMNWIYM RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMNWM5S DI DMNWM5S DMNWM5S DN 1,2-bis(2-fluorophenyl)-2-hydroxyethanone DMNWM5S TI TTMF541 DMNWM5S TN Liver carboxylesterase (CES1) DMNWM5S MA Inhibitor DMNWM5S RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMNWM5S RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMNWM8H DI DMNWM8H DMNWM8H DN Sinefungin DMNWM8H TI TTFHEWL DMNWM8H TN Streptomyces RNA methyltransferase (Stre-myc carB) DMNWM8H MA Inhibitor DMNWM8H RN The effect of sinefungin and synthetic analogues on RNA and DNA methyltransferases from Streptomyces. J Antibiot (Tokyo). 1991 Oct;44(10):1141-7. DMNWM8H RU https://pubmed.ncbi.nlm.nih.gov/1720117 DMNWP02 DI DMNWP02 DMNWP02 DN S-hexylglutathione DMNWP02 TI TTCYE56 DMNWP02 TN Glutathione-dependent PGD synthase (HPGDS) DMNWP02 MA Inhibitor DMNWP02 RN Purification and catalytic properties of glutathione transferase from the hepatopancreas of crayfish macrobrachium vollenhovenii (herklots). J Biochem Mol Toxicol. 2004;18(6):332-44. DMNWP02 RU https://pubmed.ncbi.nlm.nih.gov/15674845 DMNWRV9 DI DMNWRV9 DMNWRV9 DN De-O-sulfonated kotalanol DMNWRV9 TI TTXWASR DMNWRV9 TN Intestinal maltase-glucoamylase (MGAM) DMNWRV9 MA Inhibitor DMNWRV9 RN Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8. DMNWRV9 RU https://pubmed.ncbi.nlm.nih.gov/20970346 DMNWU83 DI DMNWU83 DMNWU83 DN Gallic acid 5,6-dihydroxy-3-carboxyphenylester DMNWU83 TI TTIU7X1 DMNWU83 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMNWU83 MA Inhibitor DMNWU83 RN Differential inhibition of reverse transcriptase and various DNA polymerases by digallic acid and its derivatives. J Nat Prod. 1990 Sep-Oct;53(5):1234-40. DMNWU83 RU https://pubmed.ncbi.nlm.nih.gov/1705574 DMNWXCA DI DMNWXCA DMNWXCA DN KNX-Monoclonal204 DMNWXCA TI TTE4KHA DMNWXCA TN Amyloid beta A4 protein (APP) DMNWXCA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMNWXCA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMNWXOC DI DMNWXOC DMNWXOC DN CLEMATOMANDSHURICA SAPONIN B DMNWXOC TI TTVKILB DMNWXOC TN Prostaglandin G/H synthase 2 (COX-2) DMNWXOC MA Inhibitor DMNWXOC RN Triterpene saponins from clematis mandshurica. J Nat Prod. 2006 Nov;69(11):1591-5. DMNWXOC RU https://pubmed.ncbi.nlm.nih.gov/17125227 DMNX245 DI DMNX245 DMNX245 DN NSC-26745 DMNX245 TI TTKPW01 DMNX245 TN Androgen receptor messenger RNA (AR mRNA) DMNX245 MA Inhibitor DMNX245 RN Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. DMNX245 RU https://pubmed.ncbi.nlm.nih.gov/19592245 DMNX6CE DI DMNX6CE DMNX6CE DN 1-(2,2'-bithiophen-5-yl)methanamine DMNX6CE TI TTXZEAJ DMNX6CE TN Leukotriene A-4 hydrolase (LTA4H) DMNX6CE MA Inhibitor DMNX6CE RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNX6CE RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNX9FC DI DMNX9FC DMNX9FC DN Aminomethylcyclohexane DMNX9FC TI TTICX3S DMNX9FC TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMNX9FC MA Inhibitor DMNX9FC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNX9FC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNXBTD DI DMNXBTD DMNXBTD DN CEP-6331 DMNXBTD TI TTETX6Q DMNXBTD TN Mixed lineage kinase 3 (MAP3K11) DMNXBTD MA Inhibitor DMNXBTD RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMNXBTD RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMNXBTD DI DMNXBTD DMNXBTD DN CEP-6331 DMNXBTD TI TT9FN4J DMNXBTD TN Mixed lineage kinase 2 (MAP3K10) DMNXBTD MA Inhibitor DMNXBTD RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMNXBTD RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMNXBTD DI DMNXBTD DMNXBTD DN CEP-6331 DMNXBTD TI TTUNSIX DMNXBTD TN Mixed lineage kinase 1 (MAP3K9) DMNXBTD MA Inhibitor DMNXBTD RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMNXBTD RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMNXBTD DI DMNXBTD DMNXBTD DN CEP-6331 DMNXBTD TI TTDCBX5 DMNXBTD TN Vascular endothelial growth factor receptor 3 (FLT-4) DMNXBTD MA Inhibitor DMNXBTD RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMNXBTD RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMNXBTD DI DMNXBTD DMNXBTD DN CEP-6331 DMNXBTD TI TT2B9KF DMNXBTD TN Fyn tyrosine protein kinase (FYN) DMNXBTD MA Inhibitor DMNXBTD RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMNXBTD RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMNXBTD DI DMNXBTD DMNXBTD DN CEP-6331 DMNXBTD TI TTTDVOJ DMNXBTD TN Tropomyosin-related kinase A (TrkA) DMNXBTD MA Inhibitor DMNXBTD RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMNXBTD RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMNXCHT DI DMNXCHT DMNXCHT DN Tyr-Pro-Dmp-Phe-NH2 DMNXCHT TI TT27RFC DMNXCHT TN Opioid receptor delta (OPRD1) DMNXCHT MA Inhibitor DMNXCHT RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMNXCHT RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMNXCHT DI DMNXCHT DMNXCHT DN Tyr-Pro-Dmp-Phe-NH2 DMNXCHT TI TTKWM86 DMNXCHT TN Opioid receptor mu (MOP) DMNXCHT MA Inhibitor DMNXCHT RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMNXCHT RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMNXDGQ DI DMNXDGQ DMNXDGQ DN NSC-1771 DMNXDGQ TI TTRMX3V DMNXDGQ TN Janus kinase 2 (JAK-2) DMNXDGQ MA Inhibitor DMNXDGQ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMNXDGQ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMNXDWV DI DMNXDWV DMNXDWV DN S-(4-Ethylbenzyl)isothiourea hydrochloride DMNXDWV TI TTZJYKH DMNXDWV TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMNXDWV MA Inhibitor DMNXDWV RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMNXDWV RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMNXGZP DI DMNXGZP DMNXGZP DN 6-Benzylthioinosine DMNXGZP TI TTL732K DMNXGZP TN Adenosine kinase (ADK) DMNXGZP MA Inhibitor DMNXGZP RN Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. Bioorg Med Chem. 2010 May 15;18(10):3403-12. DMNXGZP RU https://pubmed.ncbi.nlm.nih.gov/20456959 DMNXI1E DI DMNXI1E DMNXI1E DN 2-tert-butylbenzene-1,4-diol DMNXI1E TI TTF4CAM DMNXI1E TN Influenza Hemagglutinin (Influ HA) DMNXI1E MA Inhibitor DMNXI1E RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNXI1E RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNXI6D DI DMNXI6D DMNXI6D DN 2-Phenyl-3-(1-phenyl-ethoxy)-piperidine DMNXI6D TI TTZPO1L DMNXI6D TN Substance-P receptor (TACR1) DMNXI6D MA Inhibitor DMNXI6D RN 3-Benzyloxy-2-phenylpiperidine NK1 antagonists: the influence of alpha methyl substitution, Bioorg. Med. Chem. Lett. 7(23):2959-2962 (1997). DMNXI6D RU http://www.sciencedirect.com/science/article/pii/S0960894X97101184 DMNXO9C DI DMNXO9C DMNXO9C DN Estriol E3 DMNXO9C TI TTZAYWL DMNXO9C TN Estrogen receptor (ESR) DMNXO9C MA Modulator DMNXO9C RN Estrogen: estrone (E1), estradiol (E2), estriol (E3) and estetrol (E4). Nihon Rinsho. 2010 Jul;68 Suppl 7:448-61. DMNXO9C RU https://pubmed.ncbi.nlm.nih.gov/20960812 DMNXQ7Z DI DMNXQ7Z DMNXQ7Z DN 1,2,3,4-Tetrahydro-naphthalen-1-ylamine DMNXQ7Z TI TTGP7BY DMNXQ7Z TN Monoamine oxidase type B (MAO-B) DMNXQ7Z MA Inhibitor DMNXQ7Z RN Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site. J Med Chem. 1988 Aug;31(8):1558-66. DMNXQ7Z RU https://pubmed.ncbi.nlm.nih.gov/3397993 DMNXR17 DI DMNXR17 DMNXR17 DN HMR1883 DMNXR17 TI TT1VOHK DMNXR17 TN Potassium channel unspecific (KC) DMNXR17 MA Modulator DMNXR17 RN Clamikalant (Aventis). IDrugs. 2000 Nov;3(11):1353-7. DMNXR17 RU https://www.ncbi.nlm.nih.gov/pubmed/16047257 DMNXSM2 DI DMNXSM2 DMNXSM2 DN 4-amino-1,2,5-oxadiazole-3-carboximidamide DMNXSM2 TI TTZJYKH DMNXSM2 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMNXSM2 MA Inhibitor DMNXSM2 RN Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma mo... J Med Chem. 2009 Dec 10;52(23):7364-7. DMNXSM2 RU https://pubmed.ncbi.nlm.nih.gov/19507862 DMNXU1O DI DMNXU1O DMNXU1O DN 1-adamantan-1-yl-3-(1-benzyl-piperidin-4-yl)-urea DMNXU1O TI TT7WVHI DMNXU1O TN Soluble epoxide hydrolase (EPHX2) DMNXU1O MA Inhibitor DMNXU1O RN Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. DMNXU1O RU https://pubmed.ncbi.nlm.nih.gov/16870439 DMNXV2I DI DMNXV2I DMNXV2I DN 2-Hydroxyiminoolean-12-en-28-oic acid DMNXV2I TI TTZHY6R DMNXV2I TN Glycogen phosphorylase muscle form (GP) DMNXV2I MA Inhibitor DMNXV2I RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMNXV2I RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMNXYSM DI DMNXYSM DMNXYSM DN gingerol DMNXYSM TI TTELV3W DMNXYSM TN Transformation-sensitive protein p120 (TRPA1) DMNXYSM MA Activator DMNXYSM RN Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004 Mar 25;41(6):849-57. DMNXYSM RU https://pubmed.ncbi.nlm.nih.gov/15046718 DMNY0I5 DI DMNY0I5 DMNY0I5 DN 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide DMNY0I5 TI TTANPDJ DMNY0I5 TN Carbonic anhydrase II (CA-II) DMNY0I5 MA Inhibitor DMNY0I5 RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DMNY0I5 RU https://pubmed.ncbi.nlm.nih.gov/19796939 DMNY0I5 DI DMNY0I5 DMNY0I5 DN 4-(4-hydroxy-benzylideneamino)-benzenesulfonamide DMNY0I5 TI TTVKILB DMNY0I5 TN Prostaglandin G/H synthase 2 (COX-2) DMNY0I5 MA Inhibitor DMNY0I5 RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMNY0I5 RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMNY187 DI DMNY187 DMNY187 DN P'-geranyl 2-fluoromevalonate 5-diphosphate DMNY187 TI TTE5J6X DMNY187 TN Diphosphomevalonate decarboxylase (MVD) DMNY187 MA Inhibitor DMNY187 RN Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure. Arch Biochem Biophys. 2008 Dec 1;480(1):58-67. DMNY187 RU https://pubmed.ncbi.nlm.nih.gov/18823933 DMNY3A1 DI DMNY3A1 DMNY3A1 DN H-Dmt-Tic-NH-CH2-Indl DMNY3A1 TI TT27RFC DMNY3A1 TN Opioid receptor delta (OPRD1) DMNY3A1 MA Inhibitor DMNY3A1 RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMNY3A1 RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMNY3A1 DI DMNY3A1 DMNY3A1 DN H-Dmt-Tic-NH-CH2-Indl DMNY3A1 TI TTKWM86 DMNY3A1 TN Opioid receptor mu (MOP) DMNY3A1 MA Inhibitor DMNY3A1 RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMNY3A1 RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMNY5P1 DI DMNY5P1 DMNY5P1 DN 9-Benzyl-6-(4-nitro-benzylsulfanyl)-9H-purine DMNY5P1 TI TTLXAKE DMNY5P1 TN Solute carrier family 29 member 1 (SLC29A1) DMNY5P1 MA Inhibitor DMNY5P1 RN Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups. J Med Chem. 2004 Oct 21;47(22):5441-50. DMNY5P1 RU https://pubmed.ncbi.nlm.nih.gov/15481982 DMNY8H7 DI DMNY8H7 DMNY8H7 DN AF-DX-384 DMNY8H7 TI TTOXS3C DMNY8H7 TN Muscarinic acetylcholine receptor (CHRM) DMNY8H7 MA Antagonist DMNY8H7 RN Binding of [3H]AF-DX 384 to cloned and native muscarinic receptors. J Pharmacol Exp Ther. 1991 Nov;259(2):601-7. DMNY8H7 RU https://pubmed.ncbi.nlm.nih.gov/1941609 DMNY8H7 DI DMNY8H7 DMNY8H7 DN AF-DX-384 DMNY8H7 TI TTQ3JTF DMNY8H7 TN Muscarinic acetylcholine receptor M4 (CHRM4) DMNY8H7 MA Modulator DMNY8H7 RN M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull. 2005 May 15;65(5):397-403. DMNY8H7 RU https://www.ncbi.nlm.nih.gov/pubmed/15833594 DMNY8H7 DI DMNY8H7 DMNY8H7 DN AF-DX-384 DMNY8H7 TI TTYEG6Q DMNY8H7 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMNY8H7 MA Modulator DMNY8H7 RN M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull. 2005 May 15;65(5):397-403. DMNY8H7 RU https://www.ncbi.nlm.nih.gov/pubmed/15833594 DMNYH3X DI DMNYH3X DMNYH3X DN (-)-dihydroclusin DMNYH3X TI TTXV4FI DMNYH3X TN Albendazole monooxygenase (CYP3A4) DMNYH3X MA Inhibitor DMNYH3X RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMNYH3X RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMNYOH5 DI DMNYOH5 DMNYOH5 DN 2-phenylethynyl-5,6,7,8-tetrahydro-quinolin-5-ol DMNYOH5 TI TTHS256 DMNYOH5 TN Metabotropic glutamate receptor 5 (mGluR5) DMNYOH5 MA Inhibitor DMNYOH5 RN Positive and negative modulation of group I metabotropic glutamate receptors. J Med Chem. 2008 Feb 14;51(3):634-47. DMNYOH5 RU https://pubmed.ncbi.nlm.nih.gov/18173231 DMNYOV3 DI DMNYOV3 DMNYOV3 DN 5-hexyl-2-(pyrimidin-2-yloxy)phenol DMNYOV3 TI TTVTX4N DMNYOV3 TN Bacterial Fatty acid synthetase I (Bact inhA) DMNYOV3 MA Inhibitor DMNYOV3 RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMNYOV3 RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMNYPCQ DI DMNYPCQ DMNYPCQ DN 8-(3-Methyl-butoxy)-quinolin-2-ylamine DMNYPCQ TI TTX4RTB DMNYPCQ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMNYPCQ MA Inhibitor DMNYPCQ RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMNYPCQ RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMNYQ28 DI DMNYQ28 DMNYQ28 DN N-propargyl-1H-pyrrole-2-carboxamide DMNYQ28 TI TT3WG5C DMNYQ28 TN Monoamine oxidase type A (MAO-A) DMNYQ28 MA Inhibitor DMNYQ28 RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMNYQ28 RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMNYQGS DI DMNYQGS DMNYQGS DN 5''-Quinolin-4-yl-[2,4'']bithiazolyl-2''-ylamine DMNYQGS TI TTP4520 DMNYQGS TN TGF-beta receptor type I (TGFBR1) DMNYQGS MA Inhibitor DMNYQGS RN Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506. DMNYQGS RU https://pubmed.ncbi.nlm.nih.gov/15317461 DMNYQGV DI DMNYQGV DMNYQGV DN 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one DMNYQGV TI TTNGILX DMNYQGV TN Adrenergic receptor alpha-1A (ADRA1A) DMNYQGV MA Inhibitor DMNYQGV RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DMNYQGV RU https://pubmed.ncbi.nlm.nih.gov/16513345 DMNYQGV DI DMNYQGV DMNYQGV DN 4-(4-chlorobenzyl)-2-methylphthalazin-1(2H)-one DMNYQGV TI TT34BHT DMNYQGV TN Adrenergic receptor alpha-1D (ADRA1D) DMNYQGV MA Inhibitor DMNYQGV RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DMNYQGV RU https://pubmed.ncbi.nlm.nih.gov/16513345 DMNYQL9 DI DMNYQL9 DMNYQL9 DN DYSIDINE DMNYQL9 TI TTELIN2 DMNYQL9 TN PTPN1 messenger RNA (PTPN1 mRNA) DMNYQL9 MA Inhibitor DMNYQL9 RN A novel sesquiterpene quinone from Hainan sponge Dysidea villosa. Bioorg Med Chem Lett. 2009 Jan 15;19(2):390-2. DMNYQL9 RU https://pubmed.ncbi.nlm.nih.gov/19091557 DMNYQL9 DI DMNYQL9 DMNYQL9 DN DYSIDINE DMNYQL9 TI TTO8QRU DMNYQL9 TN Group IIA phospholipase A2 (GIIA sPLA2) DMNYQL9 MA Inhibitor DMNYQL9 RN New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5. DMNYQL9 RU https://pubmed.ncbi.nlm.nih.gov/11374954 DMNYWAT DI DMNYWAT DMNYWAT DN 2-(3-Fluoro-phenyl)-benzo[h]chromen-4-one DMNYWAT TI TTK3PY9 DMNYWAT TN DNA-dependent protein kinase catalytic (PRKDC) DMNYWAT MA Inhibitor DMNYWAT RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMNYWAT RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMNZ37C DI DMNZ37C DMNZ37C DN N-Tridecanoic Acid DMNZ37C TI TT9V5JH DMNZ37C TN Phospholipase A2 (PLA2G1B) DMNZ37C MA Inhibitor DMNZ37C RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNZ37C RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNZ37C DI DMNZ37C DMNZ37C DN N-Tridecanoic Acid DMNZ37C TI TTO8QRU DMNZ37C TN Group IIA phospholipase A2 (GIIA sPLA2) DMNZ37C MA Inhibitor DMNZ37C RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMNZ37C RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMNZAVE DI DMNZAVE DMNZAVE DN 1h-Benoximidazole-2-Carboxylic Acid DMNZAVE TI TTPT2QI DMNZAVE TN Cathepsin D (CTSD) DMNZAVE MA Inhibitor DMNZAVE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMNZAVE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMNZI9R DI DMNZI9R DMNZI9R DN 3-Naphthalen-1-yl-1-propyl-pyrrolidine DMNZI9R TI TTSQIFT DMNZI9R TN 5-HT 1A receptor (HTR1A) DMNZI9R MA Inhibitor DMNZI9R RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMNZI9R RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMNZI9R DI DMNZI9R DMNZI9R DN 3-Naphthalen-1-yl-1-propyl-pyrrolidine DMNZI9R TI TTJQOD7 DMNZI9R TN 5-HT 2A receptor (HTR2A) DMNZI9R MA Inhibitor DMNZI9R RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMNZI9R RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMNZI9R DI DMNZI9R DMNZI9R DN 3-Naphthalen-1-yl-1-propyl-pyrrolidine DMNZI9R TI TTEX248 DMNZI9R TN Dopamine D2 receptor (D2R) DMNZI9R MA Inhibitor DMNZI9R RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMNZI9R RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMNZJAX DI DMNZJAX DMNZJAX DN Cdk4 inhibitor III DMNZJAX TI TT7HF4W DMNZJAX TN Cyclin-dependent kinase 2 (CDK2) DMNZJAX MA Inhibitor DMNZJAX RN 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4. DMNZJAX RU https://pubmed.ncbi.nlm.nih.gov/10743948 DMNZJAX DI DMNZJAX DMNZJAX DN Cdk4 inhibitor III DMNZJAX TI TT0PG8F DMNZJAX TN Cyclin-dependent kinase 4 (CDK4) DMNZJAX MA Inhibitor DMNZJAX RN 5-Arylamino-2-methyl-4,7-dioxobenzothiazoles as inhibitors of cyclin-dependent kinase 4 and cytotoxic agents. Bioorg Med Chem Lett. 2000 Mar 6;10(5):461-4. DMNZJAX RU https://pubmed.ncbi.nlm.nih.gov/10743948 DMNZKCL DI DMNZKCL DMNZKCL DN N,N`-bis-alkyl butylimmidazole 12b DMNZKCL TI TT8DBY3 DMNZKCL TN Angiotensin II receptor type-1 (AGTR1) DMNZKCL MA Antagonist DMNZKCL RN Rational design, efficient syntheses and biological evaluation of N,N'-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers. Eur J Med Chem. 2013 Apr;62:352-70. DMNZKCL RU https://pubmed.ncbi.nlm.nih.gov/23376252 DMNZLD6 DI DMNZLD6 DMNZLD6 DN Hexahydro-cyclopenta[b]pyrrol-(2Z)-ylideneamine DMNZLD6 TI TTZUFI5 DMNZLD6 TN Nitric-oxide synthase brain (NOS1) DMNZLD6 MA Inhibitor DMNZLD6 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMNZLD6 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMNZMH6 DI DMNZMH6 DMNZMH6 DN 3-iodotyrosine DMNZMH6 TI TTUHP71 DMNZMH6 TN Tyrosine 3-monooxygenase (TH) DMNZMH6 MA Inhibitor DMNZMH6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243). DMNZMH6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243 DMNZO7M DI DMNZO7M DMNZO7M DN GS-441524 DMNZO7M TI TTS824E DMNZO7M TN COVID-19 replicase polyprotein 1ab (pp1ab) DMNZO7M MA Inhibitor DMNZO7M RN Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Mar 27;9:100128. DMNZO7M RU https://pubmed.ncbi.nlm.nih.gov/32258351 DMNZQO9 DI DMNZQO9 DMNZQO9 DN TOPOSTATIN DMNZQO9 TI TT0IHXV DMNZQO9 TN DNA topoisomerase II (TOP2) DMNZQO9 MA Inhibitor DMNZQO9 RN Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7. DMNZQO9 RU https://pubmed.ncbi.nlm.nih.gov/11430001 DMNZQO9 DI DMNZQO9 DMNZQO9 DN TOPOSTATIN DMNZQO9 TI TTGTQHC DMNZQO9 TN DNA topoisomerase I (TOP1) DMNZQO9 MA Inhibitor DMNZQO9 RN Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7. DMNZQO9 RU https://pubmed.ncbi.nlm.nih.gov/11430001 DMNZQO9 DI DMNZQO9 DMNZQO9 DN TOPOSTATIN DMNZQO9 TI TT2GPK3 DMNZQO9 TN DNA topoisomerase (TOP) DMNZQO9 MA Inhibitor DMNZQO9 RN Isoaurostatin, a novel topoisomerase inhibitor produced by Thermomonospora alba. J Nat Prod. 2001 Feb;64(2):204-7. DMNZQO9 RU https://pubmed.ncbi.nlm.nih.gov/11430001 DMNZS94 DI DMNZS94 DMNZS94 DN Radicicol DMNZS94 TI TT78R5H DMNZS94 TN Heat shock protein 90 alpha (HSP90A) DMNZS94 MA Inhibitor DMNZS94 RN High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem. 2004 Apr 15;327(2):176-83. DMNZS94 RU https://pubmed.ncbi.nlm.nih.gov/15051534 DMNZYWR DI DMNZYWR DMNZYWR DN 1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione DMNZYWR TI TTPLTSQ DMNZYWR TN Neutrophil elastase (NE) DMNZYWR MA Inhibitor DMNZYWR RN Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4. DMNZYWR RU https://pubmed.ncbi.nlm.nih.gov/11086715 DMNZYWR DI DMNZYWR DMNZYWR DN 1-(3,3-Dimethyl-2-oxo-butyl)-1H-indole-2,3-dione DMNZYWR TI TTP86E2 DMNZYWR TN Plasminogen (PLG) DMNZYWR MA Inhibitor DMNZYWR RN Parallel synthesis of isatin-based serine protease inhibitors. Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4. DMNZYWR RU https://pubmed.ncbi.nlm.nih.gov/11086715 DMO01AG DI DMO01AG DMO01AG DN SB-258719 DMO01AG TI TTEX248 DMO01AG TN Dopamine D2 receptor (D2R) DMO01AG MA Inhibitor DMO01AG RN Atropisomeric derivatives of 2',6'-disubstituted (R)-11-phenylaporphine: selective serotonin 5-HT(7) receptor antagonists. J Med Chem. 2001 Apr 26;44(9):1337-40. DMO01AG RU https://pubmed.ncbi.nlm.nih.gov/11311055 DMO01AG DI DMO01AG DMO01AG DN SB-258719 DMO01AG TI TTO9X1H DMO01AG TN 5-HT 7 receptor (HTR7) DMO01AG MA Inhibitor DMO01AG RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMO01AG RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMO01T8 DI DMO01T8 DMO01T8 DN Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine DMO01T8 TI TTGP7BY DMO01T8 TN Monoamine oxidase type B (MAO-B) DMO01T8 MA Inhibitor DMO01T8 RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMO01T8 RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMO01T8 DI DMO01T8 DMO01T8 DN Trans-2-fluoro-2-(4-fluorophenyl)cyclopropanamine DMO01T8 TI TT3WG5C DMO01T8 TN Monoamine oxidase type A (MAO-A) DMO01T8 MA Inhibitor DMO01T8 RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMO01T8 RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMO071E DI DMO071E DMO071E DN Gluconolactone DMO071E TI TTA0OSE DMO071E TN Lactase-phlorizin hydrolase (LCT) DMO071E MA Inhibitor DMO071E RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMO071E RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMO09DU DI DMO09DU DMO09DU DN ISIS 133245 DMO09DU TI TTZN92A DMO09DU TN DUSP5 messenger RNA (DUSP5 mRNA) DMO09DU RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DMO09DU RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DMO0N3Q DI DMO0N3Q DMO0N3Q DN ICA-27243 DMO0N3Q TI TTPXI3S DMO0N3Q TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DMO0N3Q MA Activator DMO0N3Q RN The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site. Neurosci Lett. 2009 Nov 13;465(2):138-42. DMO0N3Q RU https://pubmed.ncbi.nlm.nih.gov/19733209 DMO0PS9 DI DMO0PS9 DMO0PS9 DN CP-640186 DMO0PS9 TI TTY84UG DMO0PS9 TN Acetyl-CoA carboxylase 2 (ACACB) DMO0PS9 MA Inhibitor DMO0PS9 RN (4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6645-8. DMO0PS9 RU https://pubmed.ncbi.nlm.nih.gov/19853443 DMO0PS9 DI DMO0PS9 DMO0PS9 DN CP-640186 DMO0PS9 TI TTYAWV0 DMO0PS9 TN Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1) DMO0PS9 MA Inhibitor DMO0PS9 RN Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2383-8. DMO0PS9 RU https://pubmed.ncbi.nlm.nih.gov/20219367 DMO0Q1F DI DMO0Q1F DMO0Q1F DN Nectamazin C DMO0Q1F TI TTVKILB DMO0Q1F TN Prostaglandin G/H synthase 2 (COX-2) DMO0Q1F MA Inhibitor DMO0Q1F RN COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5. DMO0Q1F RU https://pubmed.ncbi.nlm.nih.gov/19880317 DMO0RGL DI DMO0RGL DMO0RGL DN 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(R)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX) DMO0RGL TI TTZPO1L DMO0RGL TN Substance-P receptor (TACR1) DMO0RGL MA Inhibitor DMO0RGL RN Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of... J Med Chem. 1998 Oct 22;41(22):4232-9. DMO0RGL RU https://pubmed.ncbi.nlm.nih.gov/9784098 DMO0UI8 DI DMO0UI8 DMO0UI8 DN Dimethyl-pent-4-enyl-ammonium bromide DMO0UI8 TI TT1RS9F DMO0UI8 TN Acetylcholinesterase (AChE) DMO0UI8 MA Inhibitor DMO0UI8 RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMO0UI8 RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMO0W9V DI DMO0W9V DMO0W9V DN Ac-VTHRLAGLLSRSGGVVKNNFVPTDVGPFAF-NH2 DMO0W9V TI TTVSFJW DMO0W9V TN Calcitonin gene-related peptide 1 (CALCA) DMO0W9V MA Inhibitor DMO0W9V RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMO0W9V RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMO0Y79 DI DMO0Y79 DMO0Y79 DN 2-(3-chlorophenyl)histamine DMO0Y79 TI TTTIBOJ DMO0Y79 TN Histamine H1 receptor (H1R) DMO0Y79 MA Agonist DMO0Y79 RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DMO0Y79 RU https://pubmed.ncbi.nlm.nih.gov/12626648 DMO10FD DI DMO10FD DMO10FD DN 1-(Propan-2-ylidene)thiosemicarbazide DMO10FD TI TTULVH8 DMO10FD TN Tyrosinase (TYR) DMO10FD MA Inhibitor DMO10FD RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMO10FD RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMO14NH DI DMO14NH DMO14NH DN 2-Phosphoglycolic Acid DMO14NH TI TTNS6X4 DMO14NH TN Bacterial Triosephosphate isomerase (Bact TPI) DMO14NH MA Inhibitor DMO14NH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMO14NH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMO17J0 DI DMO17J0 DMO17J0 DN 9-Phenylethyl-9H-adenine DMO17J0 TI TTM2AOE DMO17J0 TN Adenosine A2a receptor (ADORA2A) DMO17J0 MA Inhibitor DMO17J0 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMO17J0 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMO18YN DI DMO18YN DMO18YN DN IM-094882 DMO18YN TI TTUTJGQ DMO18YN TN Vascular endothelial growth factor receptor 2 (KDR) DMO18YN MA Inhibitor DMO18YN RN Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81. DMO18YN RU https://pubmed.ncbi.nlm.nih.gov/16386418 DMO18YN DI DMO18YN DMO18YN DN IM-094882 DMO18YN TI TT1VAUK DMO18YN TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMO18YN MA Inhibitor DMO18YN RN Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81. DMO18YN RU https://pubmed.ncbi.nlm.nih.gov/16386418 DMO1FCU DI DMO1FCU DMO1FCU DN LG190178 DMO1FCU TI TTK59TV DMO1FCU TN Vitamin D3 receptor (VDR) DMO1FCU MA Agonist DMO1FCU RN Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem Biol. 1999 May;6(5):265-75. DMO1FCU RU https://pubmed.ncbi.nlm.nih.gov/10322128 DMO1I6G DI DMO1I6G DMO1I6G DN PHLOROFUCOFUROECKOL A DMO1I6G TI TT8JRS7 DMO1I6G TN Beta-secretase (BACE) DMO1I6G MA Inhibitor DMO1I6G RN Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3211-5. DMO1I6G RU https://pubmed.ncbi.nlm.nih.gov/20462757 DMO1L3I DI DMO1L3I DMO1L3I DN 1-adamantan-1-yl-3-(6-propyloxyhexyl)urea DMO1L3I TI TT7WVHI DMO1L3I TN Soluble epoxide hydrolase (EPHX2) DMO1L3I MA Inhibitor DMO1L3I RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMO1L3I RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMO1N2T DI DMO1N2T DMO1N2T DN FETAV DMO1N2T TI TT9PB26 DMO1N2T TN Presynaptic density protein 95 (DLG4) DMO1N2T MA Inhibitor DMO1N2T RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMO1N2T RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMO1R69 DI DMO1R69 DMO1R69 DN S-(2,4-Dichlorobenzyl)isothiourea hydrobromide DMO1R69 TI TTZJYKH DMO1R69 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMO1R69 MA Inhibitor DMO1R69 RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMO1R69 RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMO1WI8 DI DMO1WI8 DMO1WI8 DN SB-227931 DMO1WI8 TI TTQBR95 DMO1WI8 TN Stress-activated protein kinase 2a (p38 alpha) DMO1WI8 MA Inhibitor DMO1WI8 RN The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4666-70. DMO1WI8 RU https://pubmed.ncbi.nlm.nih.gov/16153829 DMO1Z5Q DI DMO1Z5Q DMO1Z5Q DN L-lactic acid DMO1Z5Q TI TTVK4ZO DMO1Z5Q TN G protein coupled receptor 81 (HCAR1) DMO1Z5Q MA Agonist DMO1Z5Q RN Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609. DMO1Z5Q RU https://pubmed.ncbi.nlm.nih.gov/23396314 DMO1ZC2 DI DMO1ZC2 DMO1ZC2 DN ALBAFURAN A DMO1ZC2 TI TTELIN2 DMO1ZC2 TN PTPN1 messenger RNA (PTPN1 mRNA) DMO1ZC2 MA Inhibitor DMO1ZC2 RN Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61. DMO1ZC2 RU https://pubmed.ncbi.nlm.nih.gov/19846295 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TTBMV1G DMO1ZHE TN GABA(A) receptor alpha-2 (GABRA2) DMO1ZHE MA Agonist DMO1ZHE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMO1ZHE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TTQMXLS DMO1ZHE TN GABA(A) receptor rho2 (GABRR2) DMO1ZHE MA Antagonist DMO1ZHE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DMO1ZHE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TT4N6D8 DMO1ZHE TN GABA(A) receptor rho3 (GABRR3) DMO1ZHE MA Antagonist DMO1ZHE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DMO1ZHE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TT37EDJ DMO1ZHE TN GABA(A) receptor alpha-3 (GABRA3) DMO1ZHE MA Agonist DMO1ZHE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMO1ZHE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TT6XFEU DMO1ZHE TN GABA(A) receptor rho1 (GABRR1) DMO1ZHE MA Antagonist DMO1ZHE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DMO1ZHE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TTNZPQ1 DMO1ZHE TN GABA(A) receptor alpha-5 (GABRA5) DMO1ZHE MA Agonist DMO1ZHE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMO1ZHE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TTEX6LM DMO1ZHE TN GABA(A) receptor gamma-3 (GABRG3) DMO1ZHE MA Agonist DMO1ZHE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMO1ZHE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMO1ZHE DI DMO1ZHE DMO1ZHE DN Isonipecotic acid DMO1ZHE TI TTNJYV2 DMO1ZHE TN Gamma-aminobutyric acid receptor (GAR) DMO1ZHE MA Inhibitor DMO1ZHE RN Hydroxy- and amino-substituted piperidinecarboxylic acids as gamma-aminobutyric acid agonists and uptake inhibitors. J Med Chem. 1982 Oct;25(10):1157-62. DMO1ZHE RU https://pubmed.ncbi.nlm.nih.gov/6292417 DMO21H5 DI DMO21H5 DMO21H5 DN PMID18078750C1b DMO21H5 TI TT5TKPM DMO21H5 TN Neutral endopeptidase (MME) DMO21H5 MA Inhibitor DMO21H5 RN Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. Bioorg Med Chem Lett. 2008 Jan 15;18(2):732-7. DMO21H5 RU https://pubmed.ncbi.nlm.nih.gov/18078750 DMO21H5 DI DMO21H5 DMO21H5 DN PMID18078750C1b DMO21H5 TI TT3LJ6G DMO21H5 TN Carboxypeptidase A1 (CPA1) DMO21H5 MA Inhibitor DMO21H5 RN Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite. Bioorg Med Chem Lett. 2008 Jan 15;18(2):732-7. DMO21H5 RU https://pubmed.ncbi.nlm.nih.gov/18078750 DMO21T7 DI DMO21T7 DMO21T7 DN Anti-PSA mabs DMO21T7 TI TTS78AZ DMO21T7 TN Prostate specific antigen (KLK3) DMO21T7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DMO21T7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DMO2EXW DI DMO2EXW DMO2EXW DN SB-731489 DMO2EXW TI TTBGTCW DMO2EXW TN Kinesin spindle messenger RNA (KIF11 mRNA) DMO2EXW MA Inhibitor DMO2EXW RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMO2EXW RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMO2F8L DI DMO2F8L DMO2F8L DN 6-Isopropyl-2-phenyl-chromen-4-one DMO2F8L TI TTNJYV2 DMO2F8L TN Gamma-aminobutyric acid receptor (GAR) DMO2F8L MA Inhibitor DMO2F8L RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMO2F8L RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMO2FY8 DI DMO2FY8 DMO2FY8 DN ISIS 112020 DMO2FY8 TI TTPJ9XK DMO2FY8 TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMO2FY8 RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMO2FY8 RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMO2N56 DI DMO2N56 DMO2N56 DN 3-methoxy-9-aminomethyl-9,10-dihydroanthracene DMO2N56 TI TTJQOD7 DMO2N56 TN 5-HT 2A receptor (HTR2A) DMO2N56 MA Inhibitor DMO2N56 RN Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71. DMO2N56 RU https://pubmed.ncbi.nlm.nih.gov/18774714 DMO2PY8 DI DMO2PY8 DMO2PY8 DN ETP-46321 DMO2PY8 TI TTGBPJE DMO2PY8 TN PI3-kinase delta (PIK3CD) DMO2PY8 MA Inhibitor DMO2PY8 RN ETP-46321, a dual p110alpha/ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem Pharmacol. 2016 Apr 15;106:56-69. DMO2PY8 RU https://pubmed.ncbi.nlm.nih.gov/26883061 DMO2PY8 DI DMO2PY8 DMO2PY8 DN ETP-46321 DMO2PY8 TI TTEUNMR DMO2PY8 TN PI3-kinase alpha (PIK3CA) DMO2PY8 MA Inhibitor DMO2PY8 RN ETP-46321, a dual p110alpha/ class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. Biochem Pharmacol. 2016 Apr 15;106:56-69. DMO2PY8 RU https://pubmed.ncbi.nlm.nih.gov/26883061 DMO2V5C DI DMO2V5C DMO2V5C DN ISIS 9023 DMO2V5C TI TTBSN0L DMO2V5C TN PKC-zeta messenger RNA (PRKCZ mRNA) DMO2V5C RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMO2V5C RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMO325J DI DMO325J DMO325J DN Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMO325J TI TTQ3JTF DMO325J TN Muscarinic acetylcholine receptor M4 (CHRM4) DMO325J MA Inhibitor DMO325J RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DMO325J RU https://pubmed.ncbi.nlm.nih.gov/10891110 DMO325J DI DMO325J DMO325J DN Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMO325J TI TTQ13Z5 DMO325J TN Muscarinic acetylcholine receptor M3 (CHRM3) DMO325J MA Inhibitor DMO325J RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DMO325J RU https://pubmed.ncbi.nlm.nih.gov/10891110 DMO325J DI DMO325J DMO325J DN Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMO325J TI TTZ9SOR DMO325J TN Muscarinic acetylcholine receptor M1 (CHRM1) DMO325J MA Inhibitor DMO325J RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DMO325J RU https://pubmed.ncbi.nlm.nih.gov/10891110 DMO325J DI DMO325J DMO325J DN Propionic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMO325J TI TTYEG6Q DMO325J TN Muscarinic acetylcholine receptor M2 (CHRM2) DMO325J MA Inhibitor DMO325J RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DMO325J RU https://pubmed.ncbi.nlm.nih.gov/10891110 DMO32HN DI DMO32HN DMO32HN DN HYDROSULFIDE DMO32HN TI TT2LVK8 DMO32HN TN Carbonic anhydrase IX (CA-IX) DMO32HN MA Inhibitor DMO32HN RN Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73. DMO32HN RU https://pubmed.ncbi.nlm.nih.gov/15501038 DMO32HN DI DMO32HN DMO32HN DN HYDROSULFIDE DMO32HN TI TTANPDJ DMO32HN TN Carbonic anhydrase II (CA-II) DMO32HN MA Inhibitor DMO32HN RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMO32HN RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMO32HN DI DMO32HN DMO32HN DN HYDROSULFIDE DMO32HN TI TTHQPL7 DMO32HN TN Carbonic anhydrase I (CA-I) DMO32HN MA Inhibitor DMO32HN RN Carbonic anhydrase inhibitors: inhibition of the membrane-bound human isozyme IV with anions. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5769-73. DMO32HN RU https://pubmed.ncbi.nlm.nih.gov/15501038 DMO34LJ DI DMO34LJ DMO34LJ DN 3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol DMO34LJ TI TT12ABZ DMO34LJ TN Arachidonate 12-lipoxygenase (12-LOX) DMO34LJ MA Inhibitor DMO34LJ RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMO34LJ RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMO34LJ DI DMO34LJ DMO34LJ DN 3,4,6-Tribromo-2-(2,4-dibromo-phenoxy)-phenol DMO34LJ TI TTN9T81 DMO34LJ TN Arachidonate 15-lipoxygenase (15-LOX) DMO34LJ MA Inhibitor DMO34LJ RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMO34LJ RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMO37W4 DI DMO37W4 DMO37W4 DN 5-methyl-5-(5-methylthiophen-3-yl)-4-oxo-4,5-dihydrofuran-2-carboxylic acid DMO37W4 TI TT8WFXV DMO37W4 TN Hydroxycarboxylic acid receptor 3 (HCAR3) DMO37W4 MA Agonist DMO37W4 RN Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J Med Chem. 2007 Apr 5;50(7):1445-8. DMO37W4 RU https://pubmed.ncbi.nlm.nih.gov/17358052 DMO38CP DI DMO38CP DMO38CP DN (E)-10-Nitrohexadec-9-enoic Acid DMO38CP TI TTT2SVW DMO38CP TN PPAR-gamma messenger RNA (PPARG mRNA) DMO38CP MA Inhibitor DMO38CP RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMO38CP RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMO3AZ6 DI DMO3AZ6 DMO3AZ6 DN Euro-Celtique 1 DMO3AZ6 TI TTXHYV6 DMO3AZ6 TN Voltage-gated L-type calcium channel (L-CaC) DMO3AZ6 MA Blocker DMO3AZ6 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMO3AZ6 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMO3CFV DI DMO3CFV DMO3CFV DN Des-AA5-[D-Trp8]SRIF DMO3CFV TI TTIND6G DMO3CFV TN Somatostatin receptor type 1 (SSTR1) DMO3CFV MA Inhibitor DMO3CFV RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMO3CFV RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMO3CFV DI DMO3CFV DMO3CFV DN Des-AA5-[D-Trp8]SRIF DMO3CFV TI TTZ6T9E DMO3CFV TN Somatostatin receptor type 2 (SSTR2) DMO3CFV MA Inhibitor DMO3CFV RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMO3CFV RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMO3CFV DI DMO3CFV DMO3CFV DN Des-AA5-[D-Trp8]SRIF DMO3CFV TI TTAE1BR DMO3CFV TN Somatostatin receptor type 4 (SSTR4) DMO3CFV MA Inhibitor DMO3CFV RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMO3CFV RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMO3CFV DI DMO3CFV DMO3CFV DN Des-AA5-[D-Trp8]SRIF DMO3CFV TI TT2BC4G DMO3CFV TN Somatostatin receptor type 5 (SSTR5) DMO3CFV MA Inhibitor DMO3CFV RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMO3CFV RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMO3CFV DI DMO3CFV DMO3CFV DN Des-AA5-[D-Trp8]SRIF DMO3CFV TI TTJX3UE DMO3CFV TN Somatostatin receptor type 3 (SSTR3) DMO3CFV MA Inhibitor DMO3CFV RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMO3CFV RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMO3G6Q DI DMO3G6Q DMO3G6Q DN 2-(benzofuran-2-yl)-6-morpholino-4H-pyran-4-one DMO3G6Q TI TTK3PY9 DMO3G6Q TN DNA-dependent protein kinase catalytic (PRKDC) DMO3G6Q MA Inhibitor DMO3G6Q RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMO3G6Q RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMO3KU5 DI DMO3KU5 DMO3KU5 DN Diclosan DMO3KU5 TI TTVTX4N DMO3KU5 TN Bacterial Fatty acid synthetase I (Bact inhA) DMO3KU5 MA Inhibitor DMO3KU5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMO3KU5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMO3PNF DI DMO3PNF DMO3PNF DN N-methyl-4,4-diphenylbutan-1-amine DMO3PNF TI TTTIBOJ DMO3PNF TN Histamine H1 receptor (H1R) DMO3PNF MA Inhibitor DMO3PNF RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMO3PNF RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMO3PNF DI DMO3PNF DMO3PNF DN N-methyl-4,4-diphenylbutan-1-amine DMO3PNF TI TTJQOD7 DMO3PNF TN 5-HT 2A receptor (HTR2A) DMO3PNF MA Inhibitor DMO3PNF RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMO3PNF RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMO3VLJ DI DMO3VLJ DMO3VLJ DN N-{4-[2-(3-Hydroxyphenyl)ethyl]phenyl}phthalimide DMO3VLJ TI TTECBXN DMO3VLJ TN Oxysterols receptor LXR-alpha (NR1H3) DMO3VLJ MA Inhibitor DMO3VLJ RN Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. DMO3VLJ RU https://pubmed.ncbi.nlm.nih.gov/19539483 DMO3WEG DI DMO3WEG DMO3WEG DN RU-56187 DMO3WEG TI TTKPW01 DMO3WEG TN Androgen receptor messenger RNA (AR mRNA) DMO3WEG MA Inhibitor DMO3WEG RN Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists. Bioorg Med Chem. 2010 May 1;18(9):3159-68. DMO3WEG RU https://pubmed.ncbi.nlm.nih.gov/20381361 DMO3Y0B DI DMO3Y0B DMO3Y0B DN N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) DMO3Y0B TI TTMSFAW DMO3Y0B TN Cannabinoid receptor 2 (CB2) DMO3Y0B MA Inhibitor DMO3Y0B RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMO3Y0B RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMO3Y0B DI DMO3Y0B DMO3Y0B DN N-(7-(2-CHLOROPHENYL)-6-(4-CHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) DMO3Y0B TI TT6OEDT DMO3Y0B TN Cannabinoid receptor 1 (CB1) DMO3Y0B MA Inhibitor DMO3Y0B RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMO3Y0B RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMO41UZ DI DMO41UZ DMO41UZ DN Anti-miR-191 modified oligonucleotide DMO41UZ TI TT3ULBR DMO41UZ TN microRNA hsa-miR-191 (MIR191) DMO41UZ RN hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res. 2010 Oct 15;70(20):8077-87. DMO41UZ RU https://pubmed.ncbi.nlm.nih.gov/20924108 DMO4CEL DI DMO4CEL DMO4CEL DN Euro-Celtique 4 DMO4CEL TI TTXHYV6 DMO4CEL TN Voltage-gated L-type calcium channel (L-CaC) DMO4CEL MA Blocker DMO4CEL RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMO4CEL RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMO4CR7 DI DMO4CR7 DMO4CR7 DN N-hydroxy-8-oxo-8-(pyridin-3-yl)octanamide DMO4CR7 TI TT6R7JZ DMO4CR7 TN Histone deacetylase 1 (HDAC1) DMO4CR7 MA Inhibitor DMO4CR7 RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMO4CR7 RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMO4CSP DI DMO4CSP DMO4CSP DN 9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine DMO4CSP TI TTM2AOE DMO4CSP TN Adenosine A2a receptor (ADORA2A) DMO4CSP MA Inhibitor DMO4CSP RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMO4CSP RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMO4CSP DI DMO4CSP DMO4CSP DN 9-Methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine DMO4CSP TI TTK25J1 DMO4CSP TN Adenosine A1 receptor (ADORA1) DMO4CSP MA Inhibitor DMO4CSP RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMO4CSP RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMO4E9U DI DMO4E9U DMO4E9U DN N-isobutyl-2-oxo-2H-chromene-3-carboxamide DMO4E9U TI TTGP7BY DMO4E9U TN Monoamine oxidase type B (MAO-B) DMO4E9U MA Inhibitor DMO4E9U RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMO4E9U RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMO4FSH DI DMO4FSH DMO4FSH DN 2,4-Dichloro-N-(4-phenyl-thiazol-2-yl)-benzamide DMO4FSH TI TTK25J1 DMO4FSH TN Adenosine A1 receptor (ADORA1) DMO4FSH MA Inhibitor DMO4FSH RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMO4FSH RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMO4GBK DI DMO4GBK DMO4GBK DN vinburnine DMO4GBK TI TTOXS3C DMO4GBK TN Muscarinic acetylcholine receptor (CHRM) DMO4GBK MA Modulator (allosteric modulator) DMO4GBK RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMO4GBK RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMO4GBK DI DMO4GBK DMO4GBK DN vinburnine DMO4GBK TI TTQ13Z5 DMO4GBK TN Muscarinic acetylcholine receptor M3 (CHRM3) DMO4GBK MA Modulator (allosteric modulator) DMO4GBK RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMO4GBK RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMO4MYI DI DMO4MYI DMO4MYI DN Ac-Cys-Ile-Tyr-Lys-Phe(4-I)-Tyr DMO4MYI TI TT6PKBN DMO4MYI TN Proto-oncogene c-Src (SRC) DMO4MYI MA Inhibitor DMO4MYI RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMO4MYI RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMO4WH9 DI DMO4WH9 DMO4WH9 DN OPC-22575 DMO4WH9 TI TTF1QVM DMO4WH9 TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMO4WH9 MA Modulator DMO4WH9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DMO4WH9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DMO4XUC DI DMO4XUC DMO4XUC DN Diphenyl(piperidin-4-yl)methanol DMO4XUC TI TTTIBOJ DMO4XUC TN Histamine H1 receptor (H1R) DMO4XUC MA Inhibitor DMO4XUC RN Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5043-7. DMO4XUC RU https://pubmed.ncbi.nlm.nih.gov/19660947 DMO4YLA DI DMO4YLA DMO4YLA DN 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide DMO4YLA TI TT6R7JZ DMO4YLA TN Histone deacetylase 1 (HDAC1) DMO4YLA MA Inhibitor DMO4YLA RN Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. DMO4YLA RU https://pubmed.ncbi.nlm.nih.gov/12951120 DMO4YLA DI DMO4YLA DMO4YLA DN 7-(Biphenyl-4-yloxy)-heptanoic acid hydroxyamide DMO4YLA TI TTSHTOI DMO4YLA TN Histone deacetylase 2 (HDAC2) DMO4YLA MA Inhibitor DMO4YLA RN Alpha-keto amides as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Oct 6;13(19):3331-5. DMO4YLA RU https://pubmed.ncbi.nlm.nih.gov/12951120 DMO51QG DI DMO51QG DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG TI TT8QL1J DMO51QG TN Protein kinase C theta (PRKCQ) DMO51QG MA Inhibitor DMO51QG RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMO51QG RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMO51QG DI DMO51QG DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG TI TTRFOXJ DMO51QG TN Protein kinase C gamma (PRKCG) DMO51QG MA Inhibitor DMO51QG RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMO51QG RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMO51QG DI DMO51QG DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG TI TTUWGRA DMO51QG TN Protein kinase C zeta (PRKCZ) DMO51QG MA Inhibitor DMO51QG RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMO51QG RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMO51QG DI DMO51QG DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG TI TTYPXQF DMO51QG TN Protein kinase C beta (PRKCB) DMO51QG MA Inhibitor DMO51QG RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMO51QG RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMO51QG DI DMO51QG DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG TI TTFJ8Q1 DMO51QG TN Protein kinase C alpha (PRKCA) DMO51QG MA Inhibitor DMO51QG RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMO51QG RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMO51QG DI DMO51QG DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG TI TTBZ7OD DMO51QG TN Protein kinase C epsilon (PRKCE) DMO51QG MA Inhibitor DMO51QG RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMO51QG RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMO51QG DI DMO51QG DMO51QG DN 3,3-Bis-(4-hydroxy-phenyl)-2-phenyl-acrylonitrile DMO51QG TI TT9WJ8U DMO51QG TN Protein kinase C delta (PRKCD) DMO51QG MA Inhibitor DMO51QG RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMO51QG RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMO56XY DI DMO56XY DMO56XY DN N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine DMO56XY TI TTGKNB4 DMO56XY TN Epidermal growth factor receptor (EGFR) DMO56XY MA Inhibitor DMO56XY RN Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7. DMO56XY RU https://pubmed.ncbi.nlm.nih.gov/7658435 DMO58UW DI DMO58UW DMO58UW DN methyl p-hydroxybenzoate DMO58UW TI TTELV3W DMO58UW TN Transformation-sensitive protein p120 (TRPA1) DMO58UW MA Activator DMO58UW RN Methyl p-hydroxybenzoate causes pain sensation through activation of TRPA1 channels. Br J Pharmacol. 2007 May;151(1):153-60. DMO58UW RU https://pubmed.ncbi.nlm.nih.gov/17351650 DMO5E2L DI DMO5E2L DMO5E2L DN ME4 DMO5E2L TI TT953CX DMO5E2L TN Motilin receptor (MLNR) DMO5E2L MA Agonist DMO5E2L RN Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. DMO5E2L RU https://pubmed.ncbi.nlm.nih.gov/15764739 DMO5EBI DI DMO5EBI DMO5EBI DN 3-dodecyl-1,1-dimethylthiourea DMO5EBI TI TTAS2UO DMO5EBI TN Bacterial Urease (Bact ureC) DMO5EBI MA Inhibitor DMO5EBI RN Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91. DMO5EBI RU https://pubmed.ncbi.nlm.nih.gov/17889535 DMO5IJA DI DMO5IJA DMO5IJA DN 3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane DMO5IJA TI TT3ROYC DMO5IJA TN Serotonin transporter (SERT) DMO5IJA MA Inhibitor DMO5IJA RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMO5IJA RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMO5IJA DI DMO5IJA DMO5IJA DN 3-alpha-Phenylmethoxy-3-beta-phenyl-nortropane DMO5IJA TI TTVBI8W DMO5IJA TN Dopamine transporter (DAT) DMO5IJA MA Inhibitor DMO5IJA RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMO5IJA RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMO5IM0 DI DMO5IM0 DMO5IM0 DN 2-(4-Butoxy-phenoxy)-N-hydroxy-propionamide DMO5IM0 TI TT2J34L DMO5IM0 TN Arachidonate 5-lipoxygenase (5-LOX) DMO5IM0 MA Inhibitor DMO5IM0 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMO5IM0 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMO5J39 DI DMO5J39 DMO5J39 DN MRS2768 DMO5J39 TI TTOZHQC DMO5J39 TN P2Y purinoceptor 2 (P2RY2) DMO5J39 MA Agonist DMO5J39 RN Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32. DMO5J39 RU https://pubmed.ncbi.nlm.nih.gov/18514530 DMO5J8N DI DMO5J8N DMO5J8N DN PMID12238936C3f DMO5J8N TI TTFQEO5 DMO5J8N TN Squalene synthetase (FDFT1) DMO5J8N MA Inhibitor DMO5J8N RN Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J Med Chem. 2002 Sep 26;45(20):4571-80. DMO5J8N RU https://pubmed.ncbi.nlm.nih.gov/12238936 DMO5LUF DI DMO5LUF DMO5LUF DN arvanil DMO5LUF TI TTMI6F5 DMO5LUF TN Transient receptor potential cation channel V1 (TRPV1) DMO5LUF MA Activator DMO5LUF RN Cloning and pharmacological characterization of mouse TRPV1. Neurosci Lett. 2004 Nov 3;370(1):55-60. DMO5LUF RU https://pubmed.ncbi.nlm.nih.gov/15489017 DMO5UGV DI DMO5UGV DMO5UGV DN DEMETHOXYCURCUMIN DMO5UGV TI TT8NGED DMO5UGV TN Prostaglandin G/H synthase 1 (COX-1) DMO5UGV MA Inhibitor DMO5UGV RN Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammator... Bioorg Med Chem Lett. 2005 Apr 1;15(7):1793-7. DMO5UGV RU https://pubmed.ncbi.nlm.nih.gov/15780608 DMO5V9M DI DMO5V9M DMO5V9M DN Cyclo[Ac-Cys-Ile-Tyr-Lys-Tyr-Tyr] DMO5V9M TI TT6PKBN DMO5V9M TN Proto-oncogene c-Src (SRC) DMO5V9M MA Inhibitor DMO5V9M RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMO5V9M RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMO5WG8 DI DMO5WG8 DMO5WG8 DN 5-(2-m-tolylethynyl)pyrimidine DMO5WG8 TI TTHS256 DMO5WG8 TN Metabotropic glutamate receptor 5 (mGluR5) DMO5WG8 MA Inhibitor DMO5WG8 RN Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. DMO5WG8 RU https://pubmed.ncbi.nlm.nih.gov/18550372 DMO5ZEK DI DMO5ZEK DMO5ZEK DN (2S)-aminobutyryl-L-proline isobutylamide DMO5ZEK TI TTQ7R2V DMO5ZEK TN Tripeptidyl-peptidase II (TPP2) DMO5ZEK MA Inhibitor DMO5ZEK RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMO5ZEK RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMO648T DI DMO648T DMO648T DN Carbenoxolone DMO648T TI TTN7BL9 DMO648T TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMO648T MA Inhibitor DMO648T RN Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid. J Steroid Biochem Mol Biol. 2009 Feb;113(3-5):248-52. DMO648T RU https://pubmed.ncbi.nlm.nih.gov/19429429 DMO69TS DI DMO69TS DMO69TS DN 2-Amino-4,6-diphenyl-nicotinonitrile DMO69TS TI TTK25J1 DMO69TS TN Adenosine A1 receptor (ADORA1) DMO69TS MA Inhibitor DMO69TS RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMO69TS RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMO69TS DI DMO69TS DMO69TS DN 2-Amino-4,6-diphenyl-nicotinonitrile DMO69TS TI TTM2AOE DMO69TS TN Adenosine A2a receptor (ADORA2A) DMO69TS MA Inhibitor DMO69TS RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMO69TS RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMO6CB7 DI DMO6CB7 DMO6CB7 DN 9-benzyl-6-(furan-2-yl)-9H-purin-2-amine DMO6CB7 TI TTK25J1 DMO6CB7 TN Adenosine A1 receptor (ADORA1) DMO6CB7 MA Inhibitor DMO6CB7 RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DMO6CB7 RU https://pubmed.ncbi.nlm.nih.gov/18411049 DMO6CB7 DI DMO6CB7 DMO6CB7 DN 9-benzyl-6-(furan-2-yl)-9H-purin-2-amine DMO6CB7 TI TTM2AOE DMO6CB7 TN Adenosine A2a receptor (ADORA2A) DMO6CB7 MA Inhibitor DMO6CB7 RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DMO6CB7 RU https://pubmed.ncbi.nlm.nih.gov/18411049 DMO6HWJ DI DMO6HWJ DMO6HWJ DN Bis(4-fluorophenyl)-2-fluorophenylacetamide DMO6HWJ TI TTMNI76 DMO6HWJ TN Calcium-activated potassium channel (KCN) DMO6HWJ MA Inhibitor DMO6HWJ RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMO6HWJ RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMO6IM1 DI DMO6IM1 DMO6IM1 DN group E 1682-2106 DMO6IM1 TI TT5Y4EM DMO6IM1 TN N-formyl peptide receptor (FPR1) DMO6IM1 MA Antagonist DMO6IM1 RN Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists. Mol Pharmacol. 2005 Nov;68(5):1301-10. DMO6IM1 RU https://pubmed.ncbi.nlm.nih.gov/16118363 DMO6JRW DI DMO6JRW DMO6JRW DN 2'-O-Methyl G-Clamp Containing Oligonucleotides DMO6JRW TI TT8Z1FE DMO6JRW TN Human immunodeficiency virus Tat-TAR RNA interaction (HIV Tat-TAR PPI) DMO6JRW MA Inhibitor DMO6JRW RN The synthesis of 2'-O-methyl G-clamp containing oligonucleotides and their inhibition of the HIV-1 Tat-TAR interaction. Nucleosides Nucleotides Nucleic Acids. 2003 May-Aug;22(5-8):1259-62. DMO6JRW RU https://pubmed.ncbi.nlm.nih.gov/14565394 DMO6LID DI DMO6LID DMO6LID DN 3-(4-Phenoxy-phenyl)-1H-pyrazole DMO6LID TI TT84DRB DMO6LID TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMO6LID MA Inhibitor DMO6LID RN 3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers. J Med Chem. 2004 Mar 11;47(6):1547-52. DMO6LID RU https://pubmed.ncbi.nlm.nih.gov/14998340 DMO6MGJ DI DMO6MGJ DMO6MGJ DN Haempatch DMO6MGJ TI TT6L509 DMO6MGJ TN Coagulation factor IIa (F2) DMO6MGJ MA Inhibitor DMO6MGJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMO6MGJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMO6N7C DI DMO6N7C DMO6N7C DN (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K DMO6N7C TI TTBPW3J DMO6N7C TN Galanin receptor type 2 (GAL2-R) DMO6N7C MA Inhibitor DMO6N7C RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMO6N7C RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMO6N7C DI DMO6N7C DMO6N7C DN (Sar)WTLNSAGYLLGPKK(Lys-stearoyl)K DMO6N7C TI TTX3HNZ DMO6N7C TN Galanin receptor type 1 (GAL1-R) DMO6N7C MA Inhibitor DMO6N7C RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMO6N7C RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMO6NEX DI DMO6NEX DMO6NEX DN PMID25497965C17c DMO6NEX TI TTHYDUM DMO6NEX TN Bombesin receptor (BS) DMO6NEX MA Agonist DMO6NEX RN Synthesis and biological evaluation of novel chiral diazepine derivatives as bombesin receptor subtype-3 (BRS-3) agonists incorporating an antedrug approach. Bioorg Med Chem. 2015 Jan 1;23(1):89-104. DMO6NEX RU https://pubmed.ncbi.nlm.nih.gov/25497965 DMO6R1I DI DMO6R1I DMO6R1I DN ISIS 13743 DMO6R1I TI TT0EOB8 DMO6R1I TN B-Raf messenger RNA (BRAF mRNA) DMO6R1I RN US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression. DMO6R1I RU http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true DMO6T9C DI DMO6T9C DMO6T9C DN NAX-5055 DMO6T9C TI TTX3HNZ DMO6T9C TN Galanin receptor type 1 (GAL1-R) DMO6T9C MA Agonist DMO6T9C RN Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43. DMO6T9C RU https://pubmed.ncbi.nlm.nih.gov/19008076 DMO6XK2 DI DMO6XK2 DMO6XK2 DN 4-nitrophenylboronic acid DMO6XK2 TI TTDP1UC DMO6XK2 TN Fatty acid amide hydrolase (FAAH) DMO6XK2 MA Inhibitor DMO6XK2 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMO6XK2 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMO6Z02 DI DMO6Z02 DMO6Z02 DN Di(2,6-di-t-butylphenol) DMO6Z02 TI TTANPDJ DMO6Z02 TN Carbonic anhydrase II (CA-II) DMO6Z02 MA Inhibitor DMO6Z02 RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMO6Z02 RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMO724D DI DMO724D DMO724D DN 6-(2-Amino-ethyl)-biphenyl-2,3,4'-triol DMO724D TI TTZFYLI DMO724D TN Dopamine D1 receptor (D1R) DMO724D MA Inhibitor DMO724D RN Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes. J Med Chem. 1986 Oct;29(10):1904-12. DMO724D RU https://pubmed.ncbi.nlm.nih.gov/3761310 DMO72XF DI DMO72XF DMO72XF DN KB-130015 DMO72XF TI TTQ6VDM DMO72XF TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMO72XF MA Activator DMO72XF RN The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism. Eur J Pharmacol. 2010 Apr 25;632(1-3):52-9. DMO72XF RU https://pubmed.ncbi.nlm.nih.gov/20097192 DMO73M9 DI DMO73M9 DMO73M9 DN Iodyl-benzene DMO73M9 TI TTELIN2 DMO73M9 TN PTPN1 messenger RNA (PTPN1 mRNA) DMO73M9 MA Inhibitor DMO73M9 RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DMO73M9 RU https://pubmed.ncbi.nlm.nih.gov/10091683 DMO7492 DI DMO7492 DMO7492 DN ISIS 343867 DMO7492 TI TTEWOHV DMO7492 TN Survivin messenger RNA (Survivin mRNA) DMO7492 RN US patent application no. 7,541,344, Modulation of survivin expression. DMO7492 RU http://www.patentbuddy.com/Patent/7541344?ft=true&sr=true DMO74HX DI DMO74HX DMO74HX DN 5-(2-Methylquinolin-7-yl)-2-phenylnicotinonitrile DMO74HX TI TTHS256 DMO74HX TN Metabotropic glutamate receptor 5 (mGluR5) DMO74HX MA Inhibitor DMO74HX RN Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35. DMO74HX RU https://pubmed.ncbi.nlm.nih.gov/20382541 DMO78QB DI DMO78QB DMO78QB DN CHLOROCYCLINONE B DMO78QB TI TTT2SVW DMO78QB TN PPAR-gamma messenger RNA (PPARG mRNA) DMO78QB MA Inhibitor DMO78QB RN Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8. DMO78QB RU https://pubmed.ncbi.nlm.nih.gov/18044841 DMO792L DI DMO792L DMO792L DN 2-amino-uridine-5'-monophosphate DMO792L TI TT24DGP DMO792L TN P2Y purinoceptor 4 (P2RY4) DMO792L MA Agonist DMO792L RN Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2011 Apr 28;54(8):2878-90. DMO792L RU https://pubmed.ncbi.nlm.nih.gov/21417463 DMO7BMZ DI DMO7BMZ DMO7BMZ DN C[Ser-Tyr-Thr-His-Dphe-Arg-Trp-Thr-Ile-Pro] DMO7BMZ TI TTD0CIQ DMO7BMZ TN Melanocortin receptor 4 (MC4R) DMO7BMZ MA Inhibitor DMO7BMZ RN Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22. DMO7BMZ RU https://pubmed.ncbi.nlm.nih.gov/16451057 DMO7EBX DI DMO7EBX DMO7EBX DN AMSH DMO7EBX TI TTD0CIQ DMO7EBX TN Melanocortin receptor 4 (MC4R) DMO7EBX MA Agonist DMO7EBX RN Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66. DMO7EBX RU https://pubmed.ncbi.nlm.nih.gov/17826689 DMO7G94 DI DMO7G94 DMO7G94 DN RS 67333 DMO7G94 TI TT07C3Y DMO7G94 TN 5-HT 4 receptor (HTR4) DMO7G94 MA Agonist DMO7G94 RN Pharmacological characterization of the human 5-HT(4(d)) receptor splice variant stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 2000 Oct;131(4):827-35. DMO7G94 RU https://pubmed.ncbi.nlm.nih.gov/11030734 DMO7JGS DI DMO7JGS DMO7JGS DN Metiamide DMO7JGS TI TTQHJ1K DMO7JGS TN Histamine H2 receptor (H2R) DMO7JGS MA Antagonist DMO7JGS RN Metiamide--an orally active histamine H2-receptor antagonist. 1973. Agents Actions. 1994 Dec;43(3-4):91-5; discussion 96. DMO7JGS RU https://pubmed.ncbi.nlm.nih.gov/7725982 DMO7MTX DI DMO7MTX DMO7MTX DN N-propylnorapomorphine DMO7MTX TI TT4C8EA DMO7MTX TN Dopamine D3 receptor (D3R) DMO7MTX MA Agonist DMO7MTX RN A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport. 1995 Jan 26;6(2):329-32. DMO7MTX RU https://pubmed.ncbi.nlm.nih.gov/7756621 DMO7MTX DI DMO7MTX DMO7MTX DN N-propylnorapomorphine DMO7MTX TI TTEX248 DMO7MTX TN Dopamine D2 receptor (D2R) DMO7MTX MA Inhibitor DMO7MTX RN A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport. 1995 Jan 26;6(2):329-32. DMO7MTX RU https://pubmed.ncbi.nlm.nih.gov/7756621 DMO7MTX DI DMO7MTX DMO7MTX DN N-propylnorapomorphine DMO7MTX TI TTS2PH3 DMO7MTX TN Dopamine D5 receptor (D5R) DMO7MTX MA Agonist DMO7MTX RN Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9. DMO7MTX RU https://pubmed.ncbi.nlm.nih.gov/1826762 DMO7MTX DI DMO7MTX DMO7MTX DN N-propylnorapomorphine DMO7MTX TI TTZFYLI DMO7MTX TN Dopamine D1 receptor (D1R) DMO7MTX MA Agonist DMO7MTX RN Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9. DMO7MTX RU https://pubmed.ncbi.nlm.nih.gov/1826762 DMO7NXE DI DMO7NXE DMO7NXE DN 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol DMO7NXE TI TTWJBZ5 DMO7NXE TN 5-HT 2C receptor (HTR2C) DMO7NXE MA Inhibitor DMO7NXE RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMO7NXE RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMO7NXE DI DMO7NXE DMO7NXE DN 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol DMO7NXE TI TTJQOD7 DMO7NXE TN 5-HT 2A receptor (HTR2A) DMO7NXE MA Inhibitor DMO7NXE RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMO7NXE RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMO7NXE DI DMO7NXE DMO7NXE DN 1-Butyl-3-(2-dimethylamino-ethyl)-1H-indol-4-ol DMO7NXE TI TT0K1SC DMO7NXE TN 5-HT 2B receptor (HTR2B) DMO7NXE MA Inhibitor DMO7NXE RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMO7NXE RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMO7QCN DI DMO7QCN DMO7QCN DN 2-morpholino-6-(naphthalen-2-yl)-4H-pyran-4-one DMO7QCN TI TTK3PY9 DMO7QCN TN DNA-dependent protein kinase catalytic (PRKDC) DMO7QCN MA Inhibitor DMO7QCN RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMO7QCN RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMO7QUP DI DMO7QUP DMO7QUP DN AM-1710 DMO7QUP TI TTMSFAW DMO7QUP TN Cannabinoid receptor 2 (CB2) DMO7QUP MA Inhibitor DMO7QUP RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMO7QUP RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMO7QUP DI DMO7QUP DMO7QUP DN AM-1710 DMO7QUP TI TT6OEDT DMO7QUP TN Cannabinoid receptor 1 (CB1) DMO7QUP MA Inhibitor DMO7QUP RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMO7QUP RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMO7RFL DI DMO7RFL DMO7RFL DN (2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime DMO7RFL TI TTCEJ4F DMO7RFL TN G1/S-specific cyclin-E1 (CCNE1) DMO7RFL MA Inhibitor DMO7RFL RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMO7RFL RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMO7RFL DI DMO7RFL DMO7RFL DN (2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime DMO7RFL TI TT7HF4W DMO7RFL TN Cyclin-dependent kinase 2 (CDK2) DMO7RFL MA Inhibitor DMO7RFL RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMO7RFL RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMO7RPW DI DMO7RPW DMO7RPW DN 6-Methyl-4-morpholin-4-yl-chromen-2-one DMO7RPW TI TTK3PY9 DMO7RPW TN DNA-dependent protein kinase catalytic (PRKDC) DMO7RPW MA Inhibitor DMO7RPW RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMO7RPW RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMO7U62 DI DMO7U62 DMO7U62 DN FL104 DMO7U62 TI TTW5UDX DMO7U62 TN Urotensin II receptor (UTS2R) DMO7U62 MA Agonist DMO7U62 RN Novel and potent small-molecule urotensin II receptor agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4657-65. DMO7U62 RU https://pubmed.ncbi.nlm.nih.gov/19481466 DMO7VRJ DI DMO7VRJ DMO7VRJ DN [125I]L750667 DMO7VRJ TI TTE0A2F DMO7VRJ TN Dopamine D4 receptor (D4R) DMO7VRJ MA Antagonist DMO7VRJ RN Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol. 1996 Dec;50(6):1658-64. DMO7VRJ RU https://pubmed.ncbi.nlm.nih.gov/8967990 DMO7WRU DI DMO7WRU DMO7WRU DN ST074946 DMO7WRU TI TTMBUHI DMO7WRU TN Deneddylase-1 (SENP8) DMO7WRU MA Inhibitor DMO7WRU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2417). DMO7WRU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2417 DMO87PG DI DMO87PG DMO87PG DN ISIS 140158 DMO87PG TI TTAK0IN DMO87PG TN SOAT2 messenger RNA (SOAT2 mRNA) DMO87PG RN US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression. DMO87PG RU http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true DMO89N0 DI DMO89N0 DMO89N0 DN [3H]MK-912 DMO89N0 TI TTWM4TY DMO89N0 TN Adrenergic receptor alpha-2B (ADRA2B) DMO89N0 MA Antagonist DMO89N0 RN The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65. DMO89N0 RU https://pubmed.ncbi.nlm.nih.gov/7996470 DMO89N0 DI DMO89N0 DMO89N0 DN [3H]MK-912 DMO89N0 TI TT2NUT5 DMO89N0 TN Adrenergic receptor alpha-2C (ADRA2C) DMO89N0 MA Antagonist DMO89N0 RN The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65. DMO89N0 RU https://pubmed.ncbi.nlm.nih.gov/7996470 DMO8D4V DI DMO8D4V DMO8D4V DN AdoC(beta-Ala)Arg6 DMO8D4V TI TTNAHEX DMO8D4V TN cAMP-dependent protein kinase A type I (PRKAR1A) DMO8D4V MA Inhibitor DMO8D4V RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMO8D4V RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMO8D4V DI DMO8D4V DMO8D4V DN AdoC(beta-Ala)Arg6 DMO8D4V TI TTW4Y2M DMO8D4V TN cAMP protein kinase type II-beta (PRKAR2B) DMO8D4V MA Inhibitor DMO8D4V RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMO8D4V RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMO8DYW DI DMO8DYW DMO8DYW DN 7-(2-methoxyphenyl)-2-methylquinoline DMO8DYW TI TTHS256 DMO8DYW TN Metabotropic glutamate receptor 5 (mGluR5) DMO8DYW MA Inhibitor DMO8DYW RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMO8DYW RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMO8GEI DI DMO8GEI DMO8GEI DN 7,9-octadecadiynoic acid DMO8GEI TI TTPADOQ DMO8GEI TN HMG-CoA reductase (HMGCR) DMO8GEI MA Inhibitor DMO8GEI RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DMO8GEI RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DMO8IVA DI DMO8IVA DMO8IVA DN ISIS 25552 DMO8IVA TI TTP2U16 DMO8IVA TN RhoA messenger RNA (RHOA mRNA) DMO8IVA RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMO8IVA RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMO8JQM DI DMO8JQM DMO8JQM DN KIN-4044 DMO8JQM TI TTKWM86 DMO8JQM TN Opioid receptor mu (MOP) DMO8JQM MA Antagonist DMO8JQM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMO8JQM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMO8L57 DI DMO8L57 DMO8L57 DN N-(4'-methyl-4-biphenylyl)urea DMO8L57 TI TTBGTCW DMO8L57 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMO8L57 MA Inhibitor DMO8L57 RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMO8L57 RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMO8LAC DI DMO8LAC DMO8LAC DN Gly-Amp-Glu DMO8LAC TI TTKJEMQ DMO8LAC TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMO8LAC MA Inhibitor DMO8LAC RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMO8LAC RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMO8LAC DI DMO8LAC DMO8LAC DN Gly-Amp-Glu DMO8LAC TI TTN9D8E DMO8LAC TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMO8LAC MA Inhibitor DMO8LAC RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMO8LAC RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMO8LAC DI DMO8LAC DMO8LAC DN Gly-Amp-Glu DMO8LAC TI TTLD29N DMO8LAC TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMO8LAC MA Inhibitor DMO8LAC RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMO8LAC RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMO8LPZ DI DMO8LPZ DMO8LPZ DN Beta-Hydroxy Aspartic Acid DMO8LPZ TI TTCIHJA DMO8LPZ TN Coagulation factor Xa (F10) DMO8LPZ MA Inhibitor DMO8LPZ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMO8LPZ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMO8SQA DI DMO8SQA DMO8SQA DN 4-(3-methoxy-benzylideneamino)-benzenesulfonamide DMO8SQA TI TTVKILB DMO8SQA TN Prostaglandin G/H synthase 2 (COX-2) DMO8SQA MA Inhibitor DMO8SQA RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMO8SQA RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMO8U3S DI DMO8U3S DMO8U3S DN [Gly8,Glu22]GLP-1(7,37)-NH2 DMO8U3S TI TTVIMDE DMO8U3S TN Glucagon-like peptide 1 receptor (GLP1R) DMO8U3S MA Inhibitor DMO8U3S RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMO8U3S RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMO8WB2 DI DMO8WB2 DMO8WB2 DN 7-propoxy-2-(morpholin-4-yl)-chromen-4-one DMO8WB2 TI TTK3PY9 DMO8WB2 TN DNA-dependent protein kinase catalytic (PRKDC) DMO8WB2 MA Inhibitor DMO8WB2 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMO8WB2 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMO91EH DI DMO91EH DMO91EH DN 4,5,6,7-tetrahydroisoxazolo-[5,4-c]-pyridin-3-ol DMO91EH TI TTAN6JD DMO91EH TN Glutamate receptor AMPA (GRIA) DMO91EH MA Agonist DMO91EH RN Reduction in potency of selective gamma-aminobutyric acidA agonists and diazepam in CA1 region of in vitro hippocampal slices from chronic flurazepam-treated rats. J Pharmacol Exp Ther. 1992 Jul;262(1):204-11. DMO91EH RU https://pubmed.ncbi.nlm.nih.gov/1320683 DMO97FR DI DMO97FR DMO97FR DN 2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile DMO97FR TI TTGKNB4 DMO97FR TN Epidermal growth factor receptor (EGFR) DMO97FR MA Inhibitor DMO97FR RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMO97FR RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMO9BUR DI DMO9BUR DMO9BUR DN P'-geranyl 3,5,8-trihydroxy-3-methyloctanate 8-diphosphate DMO9BUR TI TTE5J6X DMO9BUR TN Diphosphomevalonate decarboxylase (MVD) DMO9BUR MA Inhibitor DMO9BUR RN Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase. Org Lett. 2006 Mar 16;8(6):1013-6. DMO9BUR RU https://pubmed.ncbi.nlm.nih.gov/16524256 DMO9L38 DI DMO9L38 DMO9L38 DN [3H]SB-674042 DMO9L38 TI TT9N02I DMO9L38 TN Orexin receptor type 2 (HCRTR2) DMO9L38 MA Antagonist DMO9L38 RN Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison ... Mol Pharmacol. 2009 Sep;76(3):618-31. DMO9L38 RU https://pubmed.ncbi.nlm.nih.gov/19542319 DMO9L38 DI DMO9L38 DMO9L38 DN [3H]SB-674042 DMO9L38 TI TT60Q8D DMO9L38 TN Orexin receptor type 1 (HCRTR1) DMO9L38 MA Antagonist DMO9L38 RN Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol. 2010 Jul;78(1):81-93. DMO9L38 RU https://pubmed.ncbi.nlm.nih.gov/20404073 DMO9R6T DI DMO9R6T DMO9R6T DN 9alpha-acetoxy-miller-1(10)Z-enolide DMO9R6T TI TTSXVID DMO9R6T TN Nuclear factor NF-kappa-B (NFKB) DMO9R6T MA Inhibitor DMO9R6T RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMO9R6T RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMO9S5P DI DMO9S5P DMO9S5P DN UCCF-029 DMO9S5P TI TTRLZHP DMO9S5P TN cAMP-dependent chloride channel (CFTR) DMO9S5P MA Activator DMO9S5P RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DMO9S5P RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DMO9SP1 DI DMO9SP1 DMO9SP1 DN 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile DMO9SP1 TI TTAWNKZ DMO9SP1 TN Norepinephrine transporter (NET) DMO9SP1 MA Inhibitor DMO9SP1 RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMO9SP1 RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMO9SP1 DI DMO9SP1 DMO9SP1 DN 2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile DMO9SP1 TI TT3ROYC DMO9SP1 TN Serotonin transporter (SERT) DMO9SP1 MA Inhibitor DMO9SP1 RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMO9SP1 RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMO9UMK DI DMO9UMK DMO9UMK DN CVS-1578 DMO9UMK TI TT6L509 DMO9UMK TN Coagulation factor IIa (F2) DMO9UMK MA Modulator DMO9UMK RN Design and construction of novel thrombin inhibitors featuring P3-P4 quaternary lactam dipeptide surrogates. Bioorg Med Chem Lett. 1998 Sep 22;8(18):2501-6. DMO9UMK RU https://www.ncbi.nlm.nih.gov/pubmed/9873569 DMO9VWH DI DMO9VWH DMO9VWH DN Ac-I[CV(Dht)QDWGAHRC]T DMO9VWH TI TTJGY7A DMO9VWH TN Complement C3 (CO3) DMO9VWH MA Inhibitor DMO9VWH RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMO9VWH RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMO9VWJ DI DMO9VWJ DMO9VWJ DN STYLISSADINE A DMO9VWJ TI TT473XN DMO9VWJ TN P2X purinoceptor 7 (P2RX7) DMO9VWJ MA Inhibitor DMO9VWJ RN Purinergic P2X(7) receptor antagonists: Chemistry and fundamentals of biological screening. Bioorg Med Chem. 2009 Jul 15;17(14):4861-5. DMO9VWJ RU https://pubmed.ncbi.nlm.nih.gov/19540765 DMO9WZN DI DMO9WZN DMO9WZN DN CV-6504.HCL DMO9WZN TI TTKNWZ4 DMO9WZN TN Thromboxane-A synthase (TBXAS1) DMO9WZN MA Modulator DMO9WZN RN Involvement of thromboxane A2, leukotrienes and free radicals in puromycin nephrosis in rats. Kidney Int. 1991 May;39(5):920-9. DMO9WZN RU https://pubmed.ncbi.nlm.nih.gov/2067208 DMO9YH0 DI DMO9YH0 DMO9YH0 DN 4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine DMO9YH0 TI TTE4KHA DMO9YH0 TN Amyloid beta A4 protein (APP) DMO9YH0 MA Inhibitor DMO9YH0 RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DMO9YH0 RU https://pubmed.ncbi.nlm.nih.gov/16325402 DMOA1Y7 DI DMOA1Y7 DMOA1Y7 DN PMID30247903-Compound-General structure10 DMOA1Y7 TI TT8ZLTI DMOA1Y7 TN Programmed cell death 1 ligand 1 (PD-L1) DMOA1Y7 MA Inhibitor DMOA1Y7 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMOA1Y7 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMOA2J8 DI DMOA2J8 DMOA2J8 DN iodocyanopindolol DMOA2J8 TI TTMXGCW DMOA2J8 TN Adrenergic receptor beta-3 (ADRB3) DMOA2J8 MA Antagonist DMOA2J8 RN Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared... Br J Pharmacol. 2004 May;142(1):51-6. DMOA2J8 RU https://pubmed.ncbi.nlm.nih.gov/15037517 DMOA54M DI DMOA54M DMOA54M DN Methyl3beta-hydroxyolean-12-en-27-oate DMOA54M TI TTELIN2 DMOA54M TN PTPN1 messenger RNA (PTPN1 mRNA) DMOA54M MA Inhibitor DMOA54M RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DMOA54M RU https://pubmed.ncbi.nlm.nih.gov/16580200 DMOA7EP DI DMOA7EP DMOA7EP DN Cyclopentane amide derivatives 4 DMOA7EP TI TT50QJ3 DMOA7EP TN Influenza Neuraminidase (Influ NA) DMOA7EP MA Inhibitor DMOA7EP RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMOA7EP RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMOA8FK DI DMOA8FK DMOA8FK DN RU85053 DMOA8FK TI TT6PKBN DMOA8FK TN Proto-oncogene c-Src (SRC) DMOA8FK MA Inhibitor DMOA8FK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOA8FK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOA8L2 DI DMOA8L2 DMOA8L2 DN Chlorophenylpiperazine DMOA8L2 TI TT6MSOK DMOA8L2 TN 5-HT 1D receptor (HTR1D) DMOA8L2 MA Inhibitor DMOA8L2 RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DMOA8L2 RU https://pubmed.ncbi.nlm.nih.gov/2565400 DMOA8L2 DI DMOA8L2 DMOA8L2 DN Chlorophenylpiperazine DMOA8L2 TI TT0K1SC DMOA8L2 TN 5-HT 2B receptor (HTR2B) DMOA8L2 MA Inhibitor DMOA8L2 RN Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33. DMOA8L2 RU https://pubmed.ncbi.nlm.nih.gov/20022752 DMOA8L2 DI DMOA8L2 DMOA8L2 DN Chlorophenylpiperazine DMOA8L2 TI TTJS8PY DMOA8L2 TN 5-HT 6 receptor (HTR6) DMOA8L2 MA Inhibitor DMOA8L2 RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMOA8L2 RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMOA8L2 DI DMOA8L2 DMOA8L2 DN Chlorophenylpiperazine DMOA8L2 TI TTJQOD7 DMOA8L2 TN 5-HT 2A receptor (HTR2A) DMOA8L2 MA Inhibitor DMOA8L2 RN Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33. DMOA8L2 RU https://pubmed.ncbi.nlm.nih.gov/20022752 DMOA8L2 DI DMOA8L2 DMOA8L2 DN Chlorophenylpiperazine DMOA8L2 TI TTSQIFT DMOA8L2 TN 5-HT 1A receptor (HTR1A) DMOA8L2 MA Inhibitor DMOA8L2 RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DMOA8L2 RU https://pubmed.ncbi.nlm.nih.gov/2565400 DMOA8L2 DI DMOA8L2 DMOA8L2 DN Chlorophenylpiperazine DMOA8L2 TI TTWJBZ5 DMOA8L2 TN 5-HT 2C receptor (HTR2C) DMOA8L2 MA Inhibitor DMOA8L2 RN Tricyclic dihydroquinazolinones as novel 5-HT2C selective and orally efficacious anti-obesity agents. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1128-33. DMOA8L2 RU https://pubmed.ncbi.nlm.nih.gov/20022752 DMOAJ0E DI DMOAJ0E DMOAJ0E DN 7-METHYL-8-OXO-5-P-TOLYL-7,8-DIHYDRO-[1,7]NAPHTHYRIDINE-6-CARBOXYLIC ACID (S)-[(S)-1-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL]-METHYL-AMIDE (ENANTIOMERIC MIX) DMOAJ0E TI TTZPO1L DMOAJ0E TN Substance-P receptor (TACR1) DMOAJ0E MA Inhibitor DMOAJ0E RN Axially chiral N-benzyl-N,7-dimethyl-5-phenyl-1, 7-naphthyridine-6-carboxamide derivatives as tachykinin NK1 receptor antagonists: determination of... J Med Chem. 1998 Oct 22;41(22):4232-9. DMOAJ0E RU https://pubmed.ncbi.nlm.nih.gov/9784098 DMOANXP DI DMOANXP DMOANXP DN 2-(2-Hydroxy-phenyl)-6-methyl-chromen-4-one DMOANXP TI TTNJYV2 DMOANXP TN Gamma-aminobutyric acid receptor (GAR) DMOANXP MA Inhibitor DMOANXP RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMOANXP RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMOAPJ1 DI DMOAPJ1 DMOAPJ1 DN N-(4,6-diphenylpyrimidin-2-yl)-3-methylbutyramide DMOAPJ1 TI TTK25J1 DMOAPJ1 TN Adenosine A1 receptor (ADORA1) DMOAPJ1 MA Inhibitor DMOAPJ1 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMOAPJ1 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMOAQ1E DI DMOAQ1E DMOAQ1E DN 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine DMOAQ1E TI TTCM4B3 DMOAQ1E TN Nitric-oxide synthase endothelial (NOS3) DMOAQ1E MA Inhibitor DMOAQ1E RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMOAQ1E RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMOAQ1E DI DMOAQ1E DMOAQ1E DN 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine DMOAQ1E TI TTZUFI5 DMOAQ1E TN Nitric-oxide synthase brain (NOS1) DMOAQ1E MA Inhibitor DMOAQ1E RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMOAQ1E RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMOAQ1E DI DMOAQ1E DMOAQ1E DN 4-Ethyl-5-methyl-pyrrolidin-(2Z)-ylideneamine DMOAQ1E TI TTF10I9 DMOAQ1E TN Nitric-oxide synthase inducible (NOS2) DMOAQ1E MA Inhibitor DMOAQ1E RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMOAQ1E RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMOAQC4 DI DMOAQC4 DMOAQC4 DN 1-Amino-3-(aminoxy)-2-propanol Dihydrochloride DMOAQC4 TI TTUMGNO DMOAQC4 TN Ornithine decarboxylase (ODC1) DMOAQC4 MA Inhibitor DMOAQC4 RN Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4364-6. DMOAQC4 RU https://pubmed.ncbi.nlm.nih.gov/20615694 DMOAY8R DI DMOAY8R DMOAY8R DN 3 9-DIHYDRO-N-DESMETHYL-N-ISOPROPYLERYTHROMYCIN A DMOAY8R TI TTQ6VDM DMOAY8R TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMOAY8R MA Inhibitor DMOAY8R RN 9-Dihydroerythromycin ethers as motilin agonists--developing structure-activity relationships for potency and safety. Bioorg Med Chem. 2010 Nov 1;18(21):7651-8. DMOAY8R RU https://pubmed.ncbi.nlm.nih.gov/20869254 DMOAZX5 DI DMOAZX5 DMOAZX5 DN CEP1349 DMOAZX5 TI TTETX6Q DMOAZX5 TN Mixed lineage kinase 3 (MAP3K11) DMOAZX5 MA Inhibitor DMOAZX5 RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMOAZX5 RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMOB07W DI DMOB07W DMOB07W DN PMID17929793C23e DMOB07W TI TTVBPDM DMOB07W TN Metabotropic glutamate receptor 1 (mGluR1) DMOB07W MA Modulator (allosteric modulator) DMOB07W RN Discovery of orally efficacious tetracyclic metabotropic glutamate receptor 1 (mGluR1) antagonists for the treatment of chronic pain. J Med Chem. 2007 Nov 15;50(23):5550-3. DMOB07W RU https://pubmed.ncbi.nlm.nih.gov/17929793 DMOB7P6 DI DMOB7P6 DMOB7P6 DN 2',3'-ddATP DMOB7P6 TI TTA93TL DMOB7P6 TN P2Y purinoceptor 1 (P2RY1) DMOB7P6 MA Agonist DMOB7P6 RN An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997 May;121(2):338-44. DMOB7P6 RU https://pubmed.ncbi.nlm.nih.gov/9154346 DMOB7P6 DI DMOB7P6 DMOB7P6 DN 2',3'-ddATP DMOB7P6 TI TT84ETX DMOB7P6 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMOB7P6 MA Inhibitor DMOB7P6 RN Synthesis of 2',3'-dideoxynucleoside 5'-alpha-P-borano-beta,gamma-(difluoromethylene)triphosphates and their inhibition of HIV-1 reverse transcript... J Med Chem. 2005 Apr 7;48(7):2695-700. DMOB7P6 RU https://pubmed.ncbi.nlm.nih.gov/15801860 DMOB8XT DI DMOB8XT DMOB8XT DN 8-(2-Ethoxy-1-methyl-ethoxy)-quinolin-2-ylamine DMOB8XT TI TTX4RTB DMOB8XT TN Melanin-concentrating hormone receptor 1 (MCHR1) DMOB8XT MA Inhibitor DMOB8XT RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMOB8XT RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMOB9E4 DI DMOB9E4 DMOB9E4 DN (Z)-8-(3-chlorostyryl)caffeine DMOB9E4 TI TTM2AOE DMOB9E4 TN Adenosine A2a receptor (ADORA2A) DMOB9E4 MA Inhibitor DMOB9E4 RN Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84. DMOB9E4 RU https://pubmed.ncbi.nlm.nih.gov/18723354 DMOBC0F DI DMOBC0F DMOBC0F DN 4-Benzyl-6-nitro-2-piperazin-1-yl-quinoline DMOBC0F TI TT3ROYC DMOBC0F TN Serotonin transporter (SERT) DMOBC0F MA Inhibitor DMOBC0F RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):811-5. DMOBC0F RU https://pubmed.ncbi.nlm.nih.gov/11859009 DMOBEL9 DI DMOBEL9 DMOBEL9 DN 7,8,3',4'-tetrahydroxyflavone DMOBEL9 TI TTQY2EJ DMOBEL9 TN TERT messenger RNA (TERT mRNA) DMOBEL9 MA Inhibitor DMOBEL9 RN Catecholic flavonoids acting as telomerase inhibitors. J Med Chem. 2004 Dec 16;47(26):6466-75. DMOBEL9 RU https://pubmed.ncbi.nlm.nih.gov/15588081 DMOBU62 DI DMOBU62 DMOBU62 DN Neurotensin(8-13) DMOBU62 TI TTTUMEP DMOBU62 TN Neurotensin receptor type 1 (NTSR1) DMOBU62 MA Inhibitor DMOBU62 RN Comparison of N-terminal modifications on neurotensin(8-13) analogues correlates peptide stability but not binding affinity with in vivo efficacy. J Med Chem. 2009 Apr 9;52(7):1803-13. DMOBU62 RU https://pubmed.ncbi.nlm.nih.gov/19290594 DMOBXVL DI DMOBXVL DMOBXVL DN WFwLL-NH2 DMOBXVL TI TTWDC17 DMOBXVL TN Growth hormone secretagogue receptor 1 (GHSR) DMOBXVL MA Inhibitor DMOBXVL RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DMOBXVL RU https://pubmed.ncbi.nlm.nih.gov/17371869 DMOBYU3 DI DMOBYU3 DMOBYU3 DN KT 5823 DMOBYU3 TI TTOXS3C DMOBYU3 TN Muscarinic acetylcholine receptor (CHRM) DMOBYU3 MA Modulator (allosteric modulator) DMOBYU3 RN Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207. DMOBYU3 RU https://pubmed.ncbi.nlm.nih.gov/10860942 DMOBYVL DI DMOBYVL DMOBYVL DN Butyrylthiocholine DMOBYVL TI TTEB0GD DMOBYVL TN Cholinesterase (BCHE) DMOBYVL MA Inhibitor DMOBYVL RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMOBYVL RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMOC0DT DI DMOC0DT DMOC0DT DN ISIS 23414 DMOC0DT TI TTAIWZN DMOC0DT TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DMOC0DT RN US patent application no. 5,958,771, Antisense modulation of cellular inhibitor of Apoptosis-2 expression. DMOC0DT RU http://www.patentbuddy.com/Patent/5958771?ft=true&sr=true DMOC67J DI DMOC67J DMOC67J DN 1-(4-Nitro-phenyl)-2-phenyl-ethane-1,2-dione DMOC67J TI TTMF541 DMOC67J TN Liver carboxylesterase (CES1) DMOC67J MA Inhibitor DMOC67J RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMOC67J RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMOC7PY DI DMOC7PY DMOC7PY DN 4-(2-(benzyloxy)phenyl)piperidine DMOC7PY TI TTVBI8W DMOC7PY TN Dopamine transporter (DAT) DMOC7PY MA Inhibitor DMOC7PY RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMOC7PY RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMOC7PY DI DMOC7PY DMOC7PY DN 4-(2-(benzyloxy)phenyl)piperidine DMOC7PY TI TT3ROYC DMOC7PY TN Serotonin transporter (SERT) DMOC7PY MA Inhibitor DMOC7PY RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMOC7PY RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMOC7PY DI DMOC7PY DMOC7PY DN 4-(2-(benzyloxy)phenyl)piperidine DMOC7PY TI TTSQIFT DMOC7PY TN 5-HT 1A receptor (HTR1A) DMOC7PY MA Inhibitor DMOC7PY RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMOC7PY RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMOC7PY DI DMOC7PY DMOC7PY DN 4-(2-(benzyloxy)phenyl)piperidine DMOC7PY TI TTAWNKZ DMOC7PY TN Norepinephrine transporter (NET) DMOC7PY MA Inhibitor DMOC7PY RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMOC7PY RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMOCAUL DI DMOCAUL DMOCAUL DN 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine DMOCAUL TI TTEX248 DMOCAUL TN Dopamine D2 receptor (D2R) DMOCAUL MA Inhibitor DMOCAUL RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMOCAUL RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMOCAUL DI DMOCAUL DMOCAUL DN 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine DMOCAUL TI TTSQIFT DMOCAUL TN 5-HT 1A receptor (HTR1A) DMOCAUL MA Inhibitor DMOCAUL RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMOCAUL RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMOCAUL DI DMOCAUL DMOCAUL DN 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine DMOCAUL TI TTJQOD7 DMOCAUL TN 5-HT 2A receptor (HTR2A) DMOCAUL MA Inhibitor DMOCAUL RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMOCAUL RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMOCAUL DI DMOCAUL DMOCAUL DN 1-Propyl-3-(3-trifluoromethyl-phenyl)-pyrrolidine DMOCAUL TI TT4C8EA DMOCAUL TN Dopamine D3 receptor (D3R) DMOCAUL MA Inhibitor DMOCAUL RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMOCAUL RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMOCEPA DI DMOCEPA DMOCEPA DN 5,8-Dihydroxy-1,4-naphthoquinone DMOCEPA TI TTR7UJ3 DMOCEPA TN Cytoplasmic thioredoxin reductase (TXNRD1) DMOCEPA MA Inhibitor DMOCEPA RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DMOCEPA RU https://pubmed.ncbi.nlm.nih.gov/17339102 DMOCEPA DI DMOCEPA DMOCEPA DN 5,8-Dihydroxy-1,4-naphthoquinone DMOCEPA TI TT2J34L DMOCEPA TN Arachidonate 5-lipoxygenase (5-LOX) DMOCEPA MA Inhibitor DMOCEPA RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMOCEPA RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMOCG6M DI DMOCG6M DMOCG6M DN Pyridin-3-yl 4-butoxybenzylcarbamate DMOCG6M TI TTDP1UC DMOCG6M TN Fatty acid amide hydrolase (FAAH) DMOCG6M MA Inhibitor DMOCG6M RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMOCG6M RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMOCKMZ DI DMOCKMZ DMOCKMZ DN CVT-12012 DMOCKMZ TI TT6RIOV DMOCKMZ TN Acyl-CoA desaturase (SCD) DMOCKMZ MA Inhibitor DMOCKMZ RN Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4070-4. DMOCKMZ RU https://pubmed.ncbi.nlm.nih.gov/19577469 DMOCQ9I DI DMOCQ9I DMOCQ9I DN N~3~-BENZYLPYRIDINE-2,3-DIAMINE DMOCQ9I TI TT8JRS7 DMOCQ9I TN Beta-secretase (BACE) DMOCQ9I MA Inhibitor DMOCQ9I RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOCQ9I RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMOCQ9J DI DMOCQ9J DMOCQ9J DN Diamide DMOCQ9J TI TTWC6MY DMOCQ9J TN Protein tyrosine phosphatase (PTP) DMOCQ9J MA Inhibitor DMOCQ9J RN Induction of endothelial cell surface adhesion molecules by tumor necrosis factor is blocked by protein tyrosine phosphatase inhibitors: role of the nuclear transcription factor NF-kappa B. Eur J Immunol. 1997 Sep;27(9):2172-9. DMOCQ9J RU https://pubmed.ncbi.nlm.nih.gov/9341756 DMOCXLW DI DMOCXLW DMOCXLW DN Methyl Methylsulfinylmethyl Sulfide DMOCXLW TI TTMW94E DMOCXLW TN FK506-binding protein 1A (FKBP1A) DMOCXLW MA Inhibitor DMOCXLW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOCXLW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOCYDU DI DMOCYDU DMOCYDU DN 5-chloro-1H-indazole DMOCYDU TI TTZUFI5 DMOCYDU TN Nitric-oxide synthase brain (NOS1) DMOCYDU MA Inhibitor DMOCYDU RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DMOCYDU RU https://pubmed.ncbi.nlm.nih.gov/17395463 DMOCYZJ DI DMOCYZJ DMOCYZJ DN (4-bromophenyl)difluoromethanesulfonamide DMOCYZJ TI TTUNARX DMOCYZJ TN Carbonic anhydrase (CA) DMOCYZJ MA Inhibitor DMOCYZJ RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMOCYZJ RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMOCYZJ DI DMOCYZJ DMOCYZJ DN (4-bromophenyl)difluoromethanesulfonamide DMOCYZJ TI TTHQPL7 DMOCYZJ TN Carbonic anhydrase I (CA-I) DMOCYZJ MA Inhibitor DMOCYZJ RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMOCYZJ RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMOCYZJ DI DMOCYZJ DMOCYZJ DN (4-bromophenyl)difluoromethanesulfonamide DMOCYZJ TI TT2LVK8 DMOCYZJ TN Carbonic anhydrase IX (CA-IX) DMOCYZJ MA Inhibitor DMOCYZJ RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMOCYZJ RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMOCYZJ DI DMOCYZJ DMOCYZJ DN (4-bromophenyl)difluoromethanesulfonamide DMOCYZJ TI TTANPDJ DMOCYZJ TN Carbonic anhydrase II (CA-II) DMOCYZJ MA Inhibitor DMOCYZJ RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMOCYZJ RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMOCZVB DI DMOCZVB DMOCZVB DN N-(3-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide DMOCZVB TI TTVTX4N DMOCZVB TN Bacterial Fatty acid synthetase I (Bact inhA) DMOCZVB MA Inhibitor DMOCZVB RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMOCZVB RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMOD5CK DI DMOD5CK DMOD5CK DN L-lysine DMOD5CK TI TTI1PRE DMOD5CK TN G-protein coupled receptor GPCR33 (GPRC6A) DMOD5CK MA Agonist DMOD5CK RN Deorphanization of GPRC6A: a promiscuous L-alpha-amino acid receptor with preference for basic amino acids. Mol Pharmacol. 2005 Mar;67(3):589-97. DMOD5CK RU https://pubmed.ncbi.nlm.nih.gov/15576628 DMOD5Y0 DI DMOD5Y0 DMOD5Y0 DN Dilazep DMOD5Y0 TI TTLXAKE DMOD5Y0 TN Solute carrier family 29 member 1 (SLC29A1) DMOD5Y0 MA Inhibitor DMOD5Y0 RN Residues Met89 and Ser160 in the human equilibrative nucleoside transporter 1 affect its affinity for adenosine, guanosine, S6-(4-nitrobenzyl)-merc... Mol Pharmacol. 2005 Mar;67(3):837-44. DMOD5Y0 RU https://pubmed.ncbi.nlm.nih.gov/15557207 DMOD9R7 DI DMOD9R7 DMOD9R7 DN (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin DMOD9R7 TI TTZUFI5 DMOD9R7 TN Nitric-oxide synthase brain (NOS1) DMOD9R7 MA Inhibitor DMOD9R7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOD9R7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOD9R7 DI DMOD9R7 DMOD9R7 DN (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin DMOD9R7 TI TTF10I9 DMOD9R7 TN Nitric-oxide synthase inducible (NOS2) DMOD9R7 MA Inhibitor DMOD9R7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOD9R7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOD9R7 DI DMOD9R7 DMOD9R7 DN (6r,1'r,2's)-5,6,7,8 Tetrahydrobiopterin DMOD9R7 TI TTCM4B3 DMOD9R7 TN Nitric-oxide synthase endothelial (NOS3) DMOD9R7 MA Inhibitor DMOD9R7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOD9R7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMODCAM DI DMODCAM DMODCAM DN 1,1,1-Trifluoro-4-(4-hexyloxy-phenyl)-butan-2-one DMODCAM TI TTT1JVS DMODCAM TN Cytosolic phospholipase A2 (GIVA cPLA2) DMODCAM MA Inhibitor DMODCAM RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMODCAM RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMODLPS DI DMODLPS DMODLPS DN AT-008 DMODLPS TI TT7HQD0 DMODLPS TN C-C chemokine receptor type 4 (CCR4) DMODLPS MA Antagonist DMODLPS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 61). DMODLPS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=61 DMODS9A DI DMODS9A DMODS9A DN S-hexyl hexane-1-sulfinothioate DMODS9A TI TT2SUAQ DMODS9A TN Cysteine protease (CYP) DMODS9A MA Inhibitor DMODS9A RN Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3. DMODS9A RU https://pubmed.ncbi.nlm.nih.gov/20692829 DMODVGN DI DMODVGN DMODVGN DN 4-(4-Chlorophenyl)-5-(4-methoxyphenyl)isothiazole DMODVGN TI TT8NGED DMODVGN TN Prostaglandin G/H synthase 1 (COX-1) DMODVGN MA Inhibitor DMODVGN RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMODVGN RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMOE0JX DI DMOE0JX DMOE0JX DN Ro-21-7767 DMOE0JX TI TTZFYLI DMOE0JX TN Dopamine D1 receptor (D1R) DMOE0JX MA Inhibitor DMOE0JX RN Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine recepto... J Med Chem. 1995 Jan 20;38(2):318-27. DMOE0JX RU https://pubmed.ncbi.nlm.nih.gov/7830274 DMOE0JX DI DMOE0JX DMOE0JX DN Ro-21-7767 DMOE0JX TI TTEX248 DMOE0JX TN Dopamine D2 receptor (D2R) DMOE0JX MA Inhibitor DMOE0JX RN Evaluation of cis- and trans-9- and 11-hydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridines as structurally rigid, selective D1 dopamine recepto... J Med Chem. 1995 Jan 20;38(2):318-27. DMOE0JX RU https://pubmed.ncbi.nlm.nih.gov/7830274 DMOE2ZV DI DMOE2ZV DMOE2ZV DN 1-Butyl-3,7-dihydro-purine-2,6-dione DMOE2ZV TI TTJFY5U DMOE2ZV TN Adenosine A3 receptor (ADORA3) DMOE2ZV MA Inhibitor DMOE2ZV RN Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem. 2002 May 23;45(11):2131-8. DMOE2ZV RU https://pubmed.ncbi.nlm.nih.gov/12014951 DMOE39X DI DMOE39X DMOE39X DN Piragliatin DMOE39X TI TTDLNGZ DMOE39X TN Glucokinase (GCK) DMOE39X MA Modulator DMOE39X RN Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.J Clin Endocrinol Metab.2010 Nov;95(11):5028-36. DMOE39X RU https://www.ncbi.nlm.nih.gov/pubmed/20739378 DMOE3IJ DI DMOE3IJ DMOE3IJ DN Threo-3-methylglutamate DMOE3IJ TI TT2F078 DMOE3IJ TN Excitatory amino acid transporter 2 (SLC1A2) DMOE3IJ MA Inhibitor DMOE3IJ RN Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2. Mol Pharmacol. 1997 May;51(5):809-15. DMOE3IJ RU https://pubmed.ncbi.nlm.nih.gov/9145919 DMOE3IJ DI DMOE3IJ DMOE3IJ DN Threo-3-methylglutamate DMOE3IJ TI TT6KMPN DMOE3IJ TN Excitatory amino acid transporter 4 (SLC1A6) DMOE3IJ MA Inhibitor DMOE3IJ RN Pharmacological characterization of threo-3-methylglutamic acid with excitatory amino acid transporters in native and recombinant systems. J Neurochem. 2001 Apr;77(2):550-7. DMOE3IJ RU https://pubmed.ncbi.nlm.nih.gov/11299317 DMOE8LT DI DMOE8LT DMOE8LT DN IODOSUPROFEN DMOE8LT TI TT8NGED DMOE8LT TN Prostaglandin G/H synthase 1 (COX-1) DMOE8LT MA Inhibitor DMOE8LT RN In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. DMOE8LT RU https://pubmed.ncbi.nlm.nih.gov/20188577 DMOEB8M DI DMOEB8M DMOEB8M DN SCH-356036 DMOEB8M TI TTMSFAW DMOEB8M TN Cannabinoid receptor 2 (CB2) DMOEB8M MA Inhibitor DMOEB8M RN Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1084-9. DMOEB8M RU https://pubmed.ncbi.nlm.nih.gov/20031412 DMOEB8M DI DMOEB8M DMOEB8M DN SCH-356036 DMOEB8M TI TT6OEDT DMOEB8M TN Cannabinoid receptor 1 (CB1) DMOEB8M MA Inhibitor DMOEB8M RN Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1084-9. DMOEB8M RU https://pubmed.ncbi.nlm.nih.gov/20031412 DMOEGZV DI DMOEGZV DMOEGZV DN 1-(4-Butoxy-phenyl)-1H-imidazole DMOEGZV TI TTVG215 DMOEGZV TN Debrisoquine 4-hydroxylase (CYP2D6) DMOEGZV MA Inhibitor DMOEGZV RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DMOEGZV RU https://pubmed.ncbi.nlm.nih.gov/14698153 DMOEGZV DI DMOEGZV DMOEGZV DN 1-(4-Butoxy-phenyl)-1H-imidazole DMOEGZV TI TTXV4FI DMOEGZV TN Albendazole monooxygenase (CYP3A4) DMOEGZV MA Inhibitor DMOEGZV RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DMOEGZV RU https://pubmed.ncbi.nlm.nih.gov/14698153 DMOEIHC DI DMOEIHC DMOEIHC DN [1,3]Thiazinan-(2E)-ylideneamine DMOEIHC TI TTZUFI5 DMOEIHC TN Nitric-oxide synthase brain (NOS1) DMOEIHC MA Inhibitor DMOEIHC RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMOEIHC RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMOEIHC DI DMOEIHC DMOEIHC DN [1,3]Thiazinan-(2E)-ylideneamine DMOEIHC TI TTF10I9 DMOEIHC TN Nitric-oxide synthase inducible (NOS2) DMOEIHC MA Inhibitor DMOEIHC RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMOEIHC RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMOEIHC DI DMOEIHC DMOEIHC DN [1,3]Thiazinan-(2E)-ylideneamine DMOEIHC TI TTCM4B3 DMOEIHC TN Nitric-oxide synthase endothelial (NOS3) DMOEIHC MA Inhibitor DMOEIHC RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMOEIHC RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMOEIYQ DI DMOEIYQ DMOEIYQ DN Endothelin-2 DMOEIYQ TI TTKRD0G DMOEIYQ TN Endothelin A receptor (EDNRA) DMOEIYQ MA Inhibitor DMOEIYQ RN 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6. DMOEIYQ RU https://pubmed.ncbi.nlm.nih.gov/19916528 DMOEQDP DI DMOEQDP DMOEQDP DN 1-Deoxy-1-Methoxycarbamido-Beta-D-Glucopyranose DMOEQDP TI TTZHY6R DMOEQDP TN Glycogen phosphorylase muscle form (GP) DMOEQDP MA Inhibitor DMOEQDP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOEQDP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOEQTN DI DMOEQTN DMOEQTN DN LF-160335 DMOEQTN TI TTGY8IW DMOEQTN TN B2 bradykinin receptor (BDKRB2) DMOEQTN MA Modulator DMOEQTN RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMOEQTN RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMOESL1 DI DMOESL1 DMOESL1 DN (R)-5-diphosphomevalonate DMOESL1 TI TTXMI0C DMOESL1 TN Phosphomevalonate kinase (PMVK) DMOESL1 MA Inhibitor DMOESL1 RN Functional evaluation of conserved basic residues in human phosphomevalonate kinase. Biochemistry. 2007 Oct 23;46(42):11780-8. DMOESL1 RU https://pubmed.ncbi.nlm.nih.gov/17902708 DMOF07G DI DMOF07G DMOF07G DN 1-Benzyl-4-[3-(methylsulfonyl)phenyl]piperazine DMOF07G TI TTEX248 DMOF07G TN Dopamine D2 receptor (D2R) DMOF07G MA Inhibitor DMOF07G RN Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20. DMOF07G RU https://pubmed.ncbi.nlm.nih.gov/20155917 DMOF0J1 DI DMOF0J1 DMOF0J1 DN 4-(4,5-dihydrothiazol-2-yl)phenyl butylcarbamate DMOF0J1 TI TTDP1UC DMOF0J1 TN Fatty acid amide hydrolase (FAAH) DMOF0J1 MA Inhibitor DMOF0J1 RN The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008. DMOF0J1 RU https://pubmed.ncbi.nlm.nih.gov/19232787 DMOF0TB DI DMOF0TB DMOF0TB DN Jaspic acid DMOF0TB TI TTN9T81 DMOF0TB TN Arachidonate 15-lipoxygenase (15-LOX) DMOF0TB MA Inhibitor DMOF0TB RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMOF0TB RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMOF0TB DI DMOF0TB DMOF0TB DN Jaspic acid DMOF0TB TI TT12ABZ DMOF0TB TN Arachidonate 12-lipoxygenase (12-LOX) DMOF0TB MA Inhibitor DMOF0TB RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMOF0TB RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMOF7JL DI DMOF7JL DMOF7JL DN GABA-B receptor PAM DMOF7JL TI TTDCVZW DMOF7JL TN Gamma-aminobutyric acid B receptor (GABBR) DMOF7JL MA Modulator DMOF7JL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241). DMOF7JL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241 DMOF9YN DI DMOF9YN DMOF9YN DN 4-[3-(4-Phenyl-butylamino)-propyl]-phenol DMOF9YN TI TTLD29N DMOF9YN TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMOF9YN MA Inhibitor DMOF9YN RN Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24. DMOF9YN RU https://pubmed.ncbi.nlm.nih.gov/10386947 DMOF9YN DI DMOF9YN DMOF9YN DN 4-[3-(4-Phenyl-butylamino)-propyl]-phenol DMOF9YN TI TTKJEMQ DMOF9YN TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMOF9YN MA Inhibitor DMOF9YN RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMOF9YN RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMOF9YN DI DMOF9YN DMOF9YN DN 4-[3-(4-Phenyl-butylamino)-propyl]-phenol DMOF9YN TI TTN9D8E DMOF9YN TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMOF9YN MA Inhibitor DMOF9YN RN Structure-activity relationship for a series of 2-substituted 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indoles: potent subtype-selective inhibitors of N-... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1619-24. DMOF9YN RU https://pubmed.ncbi.nlm.nih.gov/10386947 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTK8CXU DMOFCRY TN 5-HT 1B receptor (HTR1B) DMOFCRY MA Inhibitor DMOFCRY RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTWJBZ5 DMOFCRY TN 5-HT 2C receptor (HTR2C) DMOFCRY MA Inhibitor DMOFCRY RN Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/17067154 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TT07C3Y DMOFCRY TN 5-HT 4 receptor (HTR4) DMOFCRY MA Inhibitor DMOFCRY RN Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/17067154 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTRUFDT DMOFCRY TN 5-HT 5A receptor (HTR5A) DMOFCRY MA Inhibitor DMOFCRY RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TT6MSOK DMOFCRY TN 5-HT 1D receptor (HTR1D) DMOFCRY MA Inhibitor DMOFCRY RN Designing selective, high affinity ligands of 5-HT1D receptor by covalent dimerization of 5-HT1F ligands derived from 4-fluoro-N-[3-(1-methyl-4-pip... J Med Chem. 2008 Jun 26;51(12):3609-16. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/18507369 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTJS8PY DMOFCRY TN 5-HT 6 receptor (HTR6) DMOFCRY MA Inhibitor DMOFCRY RN 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/20170099 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTJQOD7 DMOFCRY TN 5-HT 2A receptor (HTR2A) DMOFCRY MA Inhibitor DMOFCRY RN Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/19831400 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTSQIFT DMOFCRY TN 5-HT 1A receptor (HTR1A) DMOFCRY MA Inhibitor DMOFCRY RN Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/19831400 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTPC4TU DMOFCRY TN 5-HT 3A receptor (HTR3A) DMOFCRY MA Inhibitor DMOFCRY RN Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/10229626 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TT0K1SC DMOFCRY TN 5-HT 2B receptor (HTR2B) DMOFCRY MA Inhibitor DMOFCRY RN Pyrrolo(iso)quinoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2006 Feb;16(3):677-80. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/16257207 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTJFY5U DMOFCRY TN Adenosine A3 receptor (ADORA3) DMOFCRY MA Inhibitor DMOFCRY RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTR6K75 DMOFCRY TN 5-HT 3B receptor (HTR3B) DMOFCRY MA Inhibitor DMOFCRY RN Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/10229626 DMOFCRY DI DMOFCRY DMOFCRY DN Serotonin DMOFCRY TI TTO9X1H DMOFCRY TN 5-HT 7 receptor (HTR7) DMOFCRY MA Inhibitor DMOFCRY RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMOFCRY RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMOFDVE DI DMOFDVE DMOFDVE DN 2-tosylanthracene-1,4-diol DMOFDVE TI TTRVTMX DMOFDVE TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMOFDVE MA Inhibitor DMOFDVE RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DMOFDVE RU https://pubmed.ncbi.nlm.nih.gov/18996691 DMOFG4M DI DMOFG4M DMOFG4M DN 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine DMOFG4M TI TT2NUT5 DMOFG4M TN Adrenergic receptor alpha-2C (ADRA2C) DMOFG4M MA Inhibitor DMOFG4M RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMOFG4M RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMOFG4M DI DMOFG4M DMOFG4M DN 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine DMOFG4M TI TTWM4TY DMOFG4M TN Adrenergic receptor alpha-2B (ADRA2B) DMOFG4M MA Inhibitor DMOFG4M RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMOFG4M RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMOFG4M DI DMOFG4M DMOFG4M DN 2,3,4,5-Tetrahydro-benzo[f][1,4]oxazepine DMOFG4M TI TTWG9A4 DMOFG4M TN Adrenergic receptor alpha-2A (ADRA2A) DMOFG4M MA Inhibitor DMOFG4M RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMOFG4M RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMOG1Q4 DI DMOG1Q4 DMOG1Q4 DN HC-056456 DMOG1Q4 TI TT5CISB DMOG1Q4 TN Cation channel sperm-associated protein 1 (CatSper1) DMOG1Q4 MA Blocker (channel blocker) DMOG1Q4 RN Pharmacological targeting of native CatSper channels reveals a required role in maintenance of sperm hyperactivation. PLoS One. 2009 Aug 31;4(8):e6844. DMOG1Q4 RU https://pubmed.ncbi.nlm.nih.gov/19718436 DMOG37L DI DMOG37L DMOG37L DN N,4-dibenzhydrylpiperazine-1-carboxamide DMOG37L TI TTFK1JQ DMOG37L TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMOG37L MA Inhibitor DMOG37L RN Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. DMOG37L RU https://pubmed.ncbi.nlm.nih.gov/19815411 DMOGD42 DI DMOGD42 DMOGD42 DN 9-[2-(1-Phosphonobutan-2-yloxy)ethyl]guanine DMOGD42 TI TTBL49X DMOGD42 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMOGD42 MA Inhibitor DMOGD42 RN Synthesis of branched 9-[2-(2-phosphonoethoxy)ethyl]purines as a new class of acyclic nucleoside phosphonates which inhibit Plasmodium falciparum h... Bioorg Med Chem. 2009 Sep 1;17(17):6218-32. DMOGD42 RU https://pubmed.ncbi.nlm.nih.gov/19666228 DMOGETD DI DMOGETD DMOGETD DN 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol DMOGETD TI TTZAYWL DMOGETD TN Estrogen receptor (ESR) DMOGETD MA Inhibitor DMOGETD RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMOGETD RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMOGETD DI DMOGETD DMOGETD DN 6-ethyl-4,7-dimethyl-6H-benzo[c]chromene-3,8-diol DMOGETD TI TTOM3J0 DMOGETD TN Estrogen receptor beta (ESR2) DMOGETD MA Inhibitor DMOGETD RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMOGETD RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMOGFVH DI DMOGFVH DMOGFVH DN Lysophosphatidylcholine DMOGFVH TI TTBECWA DMOGFVH TN Transient receptor potential cation channel V2 (TRPV2) DMOGFVH MA Activator DMOGFVH RN Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta. 2009 Mar;1793(3):528-39. DMOGFVH RU https://pubmed.ncbi.nlm.nih.gov/19321128 DMOGFVH DI DMOGFVH DMOGFVH DN Lysophosphatidylcholine DMOGFVH TI TTRBT3W DMOGFVH TN Short transient receptor potential channel 6 (TRPC6) DMOGFVH MA Activator DMOGFVH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491). DMOGFVH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491 DMOGFVH DI DMOGFVH DMOGFVH DN Lysophosphatidylcholine DMOGFVH TI TT32NQ1 DMOGFVH TN Short transient receptor potential channel 5 (TRPC5) DMOGFVH MA Activator DMOGFVH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490). DMOGFVH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=490 DMOGHRS DI DMOGHRS DMOGHRS DN 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one DMOGHRS TI TT1MPAY DMOGHRS TN GABA(A) receptor alpha-1 (GABRA1) DMOGHRS MA Inhibitor DMOGHRS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOGHRS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOGHRS DI DMOGHRS DMOGHRS DN 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one DMOGHRS TI TTNJYV2 DMOGHRS TN Gamma-aminobutyric acid receptor (GAR) DMOGHRS MA Inhibitor DMOGHRS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOGHRS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOGHRS DI DMOGHRS DMOGHRS DN 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one DMOGHRS TI TT06RH5 DMOGHRS TN GABA(A) receptor gamma-2 (GABRG2) DMOGHRS MA Inhibitor DMOGHRS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOGHRS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOGHRS DI DMOGHRS DMOGHRS DN 1,1-Dimethyl-5-oxa-spiro[2.4]heptan-4-one DMOGHRS TI TTZA1NY DMOGHRS TN GABA(A) receptor beta-2 (GABRB2) DMOGHRS MA Inhibitor DMOGHRS RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOGHRS RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOGM3H DI DMOGM3H DMOGM3H DN 4-octyl-N-(quinolin-3-yl)benzamide DMOGM3H TI TTMI6F5 DMOGM3H TN Transient receptor potential cation channel V1 (TRPV1) DMOGM3H MA Inhibitor DMOGM3H RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMOGM3H RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMOGMJ9 DI DMOGMJ9 DMOGMJ9 DN 4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine DMOGMJ9 TI TTE4KHA DMOGMJ9 TN Amyloid beta A4 protein (APP) DMOGMJ9 MA Inhibitor DMOGMJ9 RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DMOGMJ9 RU https://pubmed.ncbi.nlm.nih.gov/16325402 DMOGV9F DI DMOGV9F DMOGV9F DN NSC-2113 DMOGV9F TI TT8XK6L DMOGV9F TN Quinone reductase 1 (NQO1) DMOGV9F MA Inhibitor DMOGV9F RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMOGV9F RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMOGVZ2 DI DMOGVZ2 DMOGVZ2 DN 1-(4-Chloro-phenyl)-2-p-tolyl-ethane-1,2-dione DMOGVZ2 TI TTMF541 DMOGVZ2 TN Liver carboxylesterase (CES1) DMOGVZ2 MA Inhibitor DMOGVZ2 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMOGVZ2 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMOGWIK DI DMOGWIK DMOGWIK DN 2-nonylamido-5-sulfonamidoindane DMOGWIK TI TTHQPL7 DMOGWIK TN Carbonic anhydrase I (CA-I) DMOGWIK MA Inhibitor DMOGWIK RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMOGWIK RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMOGWIK DI DMOGWIK DMOGWIK DN 2-nonylamido-5-sulfonamidoindane DMOGWIK TI TTANPDJ DMOGWIK TN Carbonic anhydrase II (CA-II) DMOGWIK MA Inhibitor DMOGWIK RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMOGWIK RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMOGWIK DI DMOGWIK DMOGWIK DN 2-nonylamido-5-sulfonamidoindane DMOGWIK TI TT2LVK8 DMOGWIK TN Carbonic anhydrase IX (CA-IX) DMOGWIK MA Inhibitor DMOGWIK RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMOGWIK RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMOGZLU DI DMOGZLU DMOGZLU DN LLZ16406 DMOGZLU TI TTQBCEJ DMOGZLU TN MAPK/ERK kinase kinase 1 (MAP3K1) DMOGZLU MA Inhibitor DMOGZLU RN Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. DMOGZLU RU https://pubmed.ncbi.nlm.nih.gov/11804650 DMOGZUK DI DMOGZUK DMOGZUK DN 3-butyl-3-ethyl-1-phenylazetidine-2,4-dione DMOGZUK TI TTPLTSQ DMOGZUK TN Neutrophil elastase (NE) DMOGZUK MA Inhibitor DMOGZUK RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMOGZUK RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMOH2VC DI DMOH2VC DMOH2VC DN PSB-1115 DMOH2VC TI TTNE7KG DMOH2VC TN Adenosine A2b receptor (ADORA2B) DMOH2VC MA Inhibitor DMOH2VC RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMOH2VC RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMOH2VC DI DMOH2VC DMOH2VC DN PSB-1115 DMOH2VC TI TTK25J1 DMOH2VC TN Adenosine A1 receptor (ADORA1) DMOH2VC MA Inhibitor DMOH2VC RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMOH2VC RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMOH2YC DI DMOH2YC DMOH2YC DN 2-(4-Chlorobenzylidene)cyclopentanone DMOH2YC TI TT5ZWB6 DMOH2YC TN Dihydrodiol dehydrogenase type I (AKR1C3) DMOH2YC MA Inhibitor DMOH2YC RN New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71. DMOH2YC RU https://pubmed.ncbi.nlm.nih.gov/19237229 DMOH45T DI DMOH45T DMOH45T DN PMID24556381C10l DMOH45T TI TTTRNQW DMOH45T TN Bile-salt-activated lipase (CEL) DMOH45T MA Inhibitor DMOH45T RN Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9. DMOH45T RU https://pubmed.ncbi.nlm.nih.gov/24556381 DMOH45T DI DMOH45T DMOH45T DN PMID24556381C10l DMOH45T TI TTPLTSQ DMOH45T TN Neutrophil elastase (NE) DMOH45T MA Inhibitor DMOH45T RN Synthesis and evaluation of 2-(1H-indol-3-yl)-4-phenylquinolines as inhibitors of cholesterol esterase. Bioorg Med Chem Lett. 2014 Mar 15;24(6):1545-9. DMOH45T RU https://pubmed.ncbi.nlm.nih.gov/24556381 DMOH46C DI DMOH46C DMOH46C DN 2-(4-cyclohexylthiosemicarbazono)methyl-phenol DMOH46C TI TTHM0R1 DMOH46C TN Steryl-sulfatase (STS) DMOH46C MA Inhibitor DMOH46C RN Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6. DMOH46C RU https://pubmed.ncbi.nlm.nih.gov/17580843 DMOH75D DI DMOH75D DMOH75D DN Para-chloroamphetamine DMOH75D TI TT3ROYC DMOH75D TN Serotonin transporter (SERT) DMOH75D MA Inhibitor DMOH75D RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMOH75D RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMOH75D DI DMOH75D DMOH75D DN Para-chloroamphetamine DMOH75D TI TTVBI8W DMOH75D TN Dopamine transporter (DAT) DMOH75D MA Inhibitor DMOH75D RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMOH75D RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMOH75D DI DMOH75D DMOH75D DN Para-chloroamphetamine DMOH75D TI TTAWNKZ DMOH75D TN Norepinephrine transporter (NET) DMOH75D MA Inhibitor DMOH75D RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMOH75D RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMOH9TA DI DMOH9TA DMOH9TA DN SB-216995 DMOH9TA TI TTQBR95 DMOH9TA TN Stress-activated protein kinase 2a (p38 alpha) DMOH9TA MA Inhibitor DMOH9TA RN In silico search for multi-target anti-inflammatories in Chinese herbs and formulas. Bioorg Med Chem. 2010 Mar 15;18(6):2204-2218. DMOH9TA RU https://pubmed.ncbi.nlm.nih.gov/20188577 DMOHABR DI DMOHABR DMOHABR DN 2'-Deoxyuridine 5'-Alpha,Beta-Imido-Triphosphate DMOHABR TI TTY8KJS DMOHABR TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMOHABR MA Inhibitor DMOHABR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOHABR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOHB3Z DI DMOHB3Z DMOHB3Z DN 8-sulfophenyl theophylline DMOHB3Z TI TTSLI08 DMOHB3Z TN Adenosine receptor (ADOR) DMOHB3Z MA Antagonist DMOHB3Z RN Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. J Invest Dermatol. 2001 Dec;117(6):1594-600. DMOHB3Z RU https://pubmed.ncbi.nlm.nih.gov/11886528 DMOHB6U DI DMOHB6U DMOHB6U DN 4-(4-phenoxybenzoyl)benzoic acid DMOHB6U TI TTTU72V DMOHB6U TN Steroid 5-alpha-reductase 1 (SRD5A1) DMOHB6U MA Inhibitor DMOHB6U RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMOHB6U RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMOHB6U DI DMOHB6U DMOHB6U DN 4-(4-phenoxybenzoyl)benzoic acid DMOHB6U TI TTT02K8 DMOHB6U TN Steroid 5-alpha-reductase 2 (SRD5A2) DMOHB6U MA Inhibitor DMOHB6U RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMOHB6U RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMOHDRS DI DMOHDRS DMOHDRS DN 4-Piperidin-1-yl-chromen-2-one DMOHDRS TI TTK3PY9 DMOHDRS TN DNA-dependent protein kinase catalytic (PRKDC) DMOHDRS MA Inhibitor DMOHDRS RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMOHDRS RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMOHELX DI DMOHELX DMOHELX DN Centratherin DMOHELX TI TTSXVID DMOHELX TN Nuclear factor NF-kappa-B (NFKB) DMOHELX MA Inhibitor DMOHELX RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMOHELX RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMOHSY0 DI DMOHSY0 DMOHSY0 DN 5'-Deoxy-5'-(N,N-dimethylamino)-8-methyladenosine DMOHSY0 TI TTBFROQ DMOHSY0 TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMOHSY0 MA Inhibitor DMOHSY0 RN New insights into the design of inhibitors of human S-adenosylmethionine decarboxylase: studies of adenine C8 substitution in structural analogues ... J Med Chem. 2009 Mar 12;52(5):1388-407. DMOHSY0 RU https://pubmed.ncbi.nlm.nih.gov/19209891 DMOHTC6 DI DMOHTC6 DMOHTC6 DN Ruthenium red DMOHTC6 TI TTU5CIX DMOHTC6 TN Ryanodine receptor 1 (RYR1) DMOHTC6 MA Antagonist DMOHTC6 RN Role of ryanodine receptor channels in Ca2+ oscillations of porcine tracheal smooth muscle. Am J Physiol. 1997 Apr;272(4 Pt 1):L659-64. DMOHTC6 RU https://pubmed.ncbi.nlm.nih.gov/9142939 DMOHWPD DI DMOHWPD DMOHWPD DN 6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole DMOHWPD TI TTEB0GD DMOHWPD TN Cholinesterase (BCHE) DMOHWPD MA Inhibitor DMOHWPD RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMOHWPD RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMOHWPD DI DMOHWPD DMOHWPD DN 6-methoxy-1,9-dimethyl-9H-pyrido[3,4-b]indole DMOHWPD TI TT1RS9F DMOHWPD TN Acetylcholinesterase (AChE) DMOHWPD MA Inhibitor DMOHWPD RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMOHWPD RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMOHZKW DI DMOHZKW DMOHZKW DN ISIS 31963 DMOHZKW TI TT9H4P3 DMOHZKW TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMOHZKW RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMOHZKW RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMOI1U5 DI DMOI1U5 DMOI1U5 DN H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2 DMOI1U5 TI TT27RFC DMOI1U5 TN Opioid receptor delta (OPRD1) DMOI1U5 MA Inhibitor DMOI1U5 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMOI1U5 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMOI1U5 DI DMOI1U5 DMOI1U5 DN H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2 DMOI1U5 TI TTKWM86 DMOI1U5 TN Opioid receptor mu (MOP) DMOI1U5 MA Inhibitor DMOI1U5 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMOI1U5 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMOI7ME DI DMOI7ME DMOI7ME DN 5-Fluoro-2-hydroxy-N-isopropyl-benzamide DMOI7ME TI TT64EPS DMOI7ME TN Fungal Scytalone dehydratase (Fung SDH1) DMOI7ME MA Inhibitor DMOI7ME RN Binding dynamics of two water molecules constrained within the scytalone dehydratase binding pocket. Bioorg Med Chem Lett. 2000 Jan 3;10(1):23-6. DMOI7ME RU https://pubmed.ncbi.nlm.nih.gov/10636235 DMOI9RT DI DMOI9RT DMOI9RT DN Manzamine E DMOI9RT TI TTRSMW9 DMOI9RT TN Glycogen synthase kinase-3 beta (GSK-3B) DMOI9RT MA Inhibitor DMOI9RT RN Manzamine B and E and ircinal A related alkaloids from an Indonesian Acanthostrongylophora sponge and their activity against infectious, tropical p... J Nat Prod. 2006 Jul;69(7):1034-40. DMOI9RT RU https://pubmed.ncbi.nlm.nih.gov/16872140 DMOIC64 DI DMOIC64 DMOIC64 DN 6-Methyl-[1,3]dioxolo[4,5-h]quinolin-8(9H)-one DMOIC64 TI TTJLP0R DMOIC64 TN Quinone reductase 2 (NQO2) DMOIC64 MA Inhibitor DMOIC64 RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMOIC64 RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMOIFAP DI DMOIFAP DMOIFAP DN 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DMOIFAP TI TT1MPAY DMOIFAP TN GABA(A) receptor alpha-1 (GABRA1) DMOIFAP MA Inhibitor DMOIFAP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOIFAP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOIFAP DI DMOIFAP DMOIFAP DN 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DMOIFAP TI TTZA1NY DMOIFAP TN GABA(A) receptor beta-2 (GABRB2) DMOIFAP MA Inhibitor DMOIFAP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOIFAP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOIFAP DI DMOIFAP DMOIFAP DN 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DMOIFAP TI TTNJYV2 DMOIFAP TN Gamma-aminobutyric acid receptor (GAR) DMOIFAP MA Inhibitor DMOIFAP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOIFAP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOIFAP DI DMOIFAP DMOIFAP DN 6,6-Dimethyl-2-oxa-spiro[4.4]nonan-1-one DMOIFAP TI TT06RH5 DMOIFAP TN GABA(A) receptor gamma-2 (GABRG2) DMOIFAP MA Inhibitor DMOIFAP RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMOIFAP RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMOIFBK DI DMOIFBK DMOIFBK DN Drug 311440 DMOIFBK TI TTWN3F4 DMOIFBK TN Presenilin 2 (PSEN2) DMOIFBK MA Inhibitor DMOIFBK RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DMOIFBK RU https://pubmed.ncbi.nlm.nih.gov/15267231 DMOIFBK DI DMOIFBK DMOIFBK DN Drug 311440 DMOIFBK TI TTZ3S8C DMOIFBK TN Presenilin 1 (PSEN1) DMOIFBK MA Inhibitor DMOIFBK RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DMOIFBK RU https://pubmed.ncbi.nlm.nih.gov/15267231 DMOIFBK DI DMOIFBK DMOIFBK DN Drug 311440 DMOIFBK TI TT9W8GU DMOIFBK TN Gamma-secretase (GS) DMOIFBK MA Inhibitor DMOIFBK RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DMOIFBK RU https://pubmed.ncbi.nlm.nih.gov/15267231 DMOIPYD DI DMOIPYD DMOIPYD DN hGCGR antagonist DMOIPYD TI TT9O6WS DMOIPYD TN Glucagon receptor (GCGR) DMOIPYD MA Antagonist DMOIPYD RN A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes. 2004 Dec;53(12):3267-73. DMOIPYD RU https://pubmed.ncbi.nlm.nih.gov/15561959 DMOIQ4K DI DMOIQ4K DMOIQ4K DN Auryntricarboxylic acid (ATA) DMOIQ4K TI TT3SZBT DMOIQ4K TN von Willebrand factor (VWF) DMOIQ4K MA Inhibitor DMOIQ4K RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DMOIQ4K RU https://pubmed.ncbi.nlm.nih.gov/11804648 DMOIZY1 DI DMOIZY1 DMOIZY1 DN 2-Amino-4-phosphono-butyric acid DMOIZY1 TI TT0IFKL DMOIZY1 TN Metabotropic glutamate receptor 8 (mGluR8) DMOIZY1 MA Inhibitor DMOIZY1 RN (2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic ... Bioorg Med Chem Lett. 2005 Jan 17;15(2):349-51. DMOIZY1 RU https://pubmed.ncbi.nlm.nih.gov/15603952 DMOJ3CW DI DMOJ3CW DMOJ3CW DN AGELADINE A DMOJ3CW TI TTXZ0KQ DMOJ3CW TN Matrix metalloproteinase-12 (MMP-12) DMOJ3CW MA Inhibitor DMOJ3CW RN Synthesis of novel ageladine A analogs showing more potent matrix metalloproteinase (MMP)-12 inhibitory activity than the natural product. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5461-3. DMOJ3CW RU https://pubmed.ncbi.nlm.nih.gov/19665375 DMOJ4TG DI DMOJ4TG DMOJ4TG DN UCM-5600 DMOJ4TG TI TTO9X1H DMOJ4TG TN 5-HT 7 receptor (HTR7) DMOJ4TG MA Inhibitor DMOJ4TG RN Synthesis of new serotonin 5-HT7 receptor ligands. Determinants of 5-HT7/5-HT1A receptor selectivity. J Med Chem. 2009 Apr 23;52(8):2384-92. DMOJ4TG RU https://pubmed.ncbi.nlm.nih.gov/19326916 DMOJ52F DI DMOJ52F DMOJ52F DN ISOMER A DMOJ52F TI TTY6O0Q DMOJ52F TN Calcitonin gene-related peptide receptor (CGRPR) DMOJ52F MA Inhibitor DMOJ52F RN The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4740-2. DMOJ52F RU https://pubmed.ncbi.nlm.nih.gov/19577468 DMOJ57D DI DMOJ57D DMOJ57D DN PMID7629799C2d DMOJ57D TI TTFQEO5 DMOJ57D TN Squalene synthetase (FDFT1) DMOJ57D MA Inhibitor DMOJ57D RN 1,1-Bisphosphonate squalene synthase inhibitors: interplay between the isoprenoid subunit and the diphosphate surrogate. J Med Chem. 1995 Jul 7;38(14):2596-605. DMOJ57D RU https://pubmed.ncbi.nlm.nih.gov/7629799 DMOJ5LM DI DMOJ5LM DMOJ5LM DN 5,7-Dichloro-1,4-dihydro-quinoxaline-2,3-dione DMOJ5LM TI TTLD29N DMOJ5LM TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMOJ5LM MA Inhibitor DMOJ5LM RN 1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996). DMOJ5LM RU http://www.sciencedirect.com/science/article/pii/0960894X96000364 DMOJ8QR DI DMOJ8QR DMOJ8QR DN PMID23312943C21 DMOJ8QR TI TT6NI13 DMOJ8QR TN MEK kinase kinase 4 (MAP4K4) DMOJ8QR MA Inhibitor DMOJ8QR RN Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5. DMOJ8QR RU https://pubmed.ncbi.nlm.nih.gov/23312943 DMOJ8QR DI DMOJ8QR DMOJ8QR DN PMID23312943C21 DMOJ8QR TI TTOU65C DMOJ8QR TN Tyrosine-protein kinase SYK (SYK) DMOJ8QR MA Inhibitor DMOJ8QR RN Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. Bioorg Med Chem Lett. 2013 Feb 15;23(4):1051-5. DMOJ8QR RU https://pubmed.ncbi.nlm.nih.gov/23312943 DMOJ917 DI DMOJ917 DMOJ917 DN Cinchoninic acid DMOJ917 TI TT3PQ2Y DMOJ917 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMOJ917 MA Inhibitor DMOJ917 RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMOJ917 RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMOJ9N6 DI DMOJ9N6 DMOJ9N6 DN S-21007 DMOJ9N6 TI TTNXLKE DMOJ9N6 TN 5-HT 3 receptor (5HT3R) DMOJ9N6 MA Modulator DMOJ9N6 RN Effects of S-21007, a potent 5-HT3 partial agonist, in mouse anxiety. Zhongguo Yao Li Xue Bao. 1999 Sep;20(9):805-12. DMOJ9N6 RU https://www.ncbi.nlm.nih.gov/pubmed/11245088 DMOJAUI DI DMOJAUI DMOJAUI DN JWH-251 DMOJAUI TI TTMSFAW DMOJAUI TN Cannabinoid receptor 2 (CB2) DMOJAUI MA Inhibitor DMOJAUI RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMOJAUI RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMOJBHC DI DMOJBHC DMOJBHC DN ISIS 188763 DMOJBHC TI TTLRVIA DMOJBHC TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DMOJBHC RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DMOJBHC RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DMOJC9Z DI DMOJC9Z DMOJC9Z DN 1-(Benzhydrylamino)ethaniminium bromide DMOJC9Z TI TTZUFI5 DMOJC9Z TN Nitric-oxide synthase brain (NOS1) DMOJC9Z MA Inhibitor DMOJC9Z RN N-Substituted acetamidines and 2-methylimidazole derivatives as selective inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6495-9. DMOJC9Z RU https://pubmed.ncbi.nlm.nih.gov/20933416 DMOJF6D DI DMOJF6D DMOJF6D DN Domoric acid DMOJF6D TI TT0MYE2 DMOJF6D TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMOJF6D MA Inhibitor DMOJF6D RN Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103. DMOJF6D RU https://pubmed.ncbi.nlm.nih.gov/18578478 DMOJGF3 DI DMOJGF3 DMOJGF3 DN ACE-435 DMOJGF3 TI TTP4520 DMOJGF3 TN TGF-beta receptor type I (TGFBR1) DMOJGF3 MA Inhibitor DMOJGF3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788). DMOJGF3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788 DMOJI0N DI DMOJI0N DMOJI0N DN H22xKi-4 DMOJI0N TI TT2GM5R DMOJI0N TN Lymphocyte activation antigen CD30 (TNFRSF8) DMOJI0N RN Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002 Nov 1;100(9):3101-7. DMOJI0N RU https://pubmed.ncbi.nlm.nih.gov/12384405 DMOJK8Y DI DMOJK8Y DMOJK8Y DN 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone DMOJK8Y TI TTAWNKZ DMOJK8Y TN Norepinephrine transporter (NET) DMOJK8Y MA Inhibitor DMOJK8Y RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMOJK8Y RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMOJK8Y DI DMOJK8Y DMOJK8Y DN 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone DMOJK8Y TI TTVBI8W DMOJK8Y TN Dopamine transporter (DAT) DMOJK8Y MA Inhibitor DMOJK8Y RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMOJK8Y RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMOJK8Y DI DMOJK8Y DMOJK8Y DN 2-(tert-Butylamino)-3',4'-dichlorobutyrophenone DMOJK8Y TI TT3ROYC DMOJK8Y TN Serotonin transporter (SERT) DMOJK8Y MA Inhibitor DMOJK8Y RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMOJK8Y RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMOJL61 DI DMOJL61 DMOJL61 DN GNF-PF-3955 DMOJL61 TI TTL53M6 DMOJL61 TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMOJL61 MA Inhibitor DMOJL61 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMOJL61 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMOJTZD DI DMOJTZD DMOJTZD DN 4-amino-2-p-tolylisoindoline-1,3-dione DMOJTZD TI TTM2AOE DMOJTZD TN Adenosine A2a receptor (ADORA2A) DMOJTZD MA Inhibitor DMOJTZD RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DMOJTZD RU https://pubmed.ncbi.nlm.nih.gov/20095623 DMOJUEC DI DMOJUEC DMOJUEC DN (hydroxymethylphenyl)agomelatine DMOJUEC TI TT0WAIE DMOJUEC TN Melatonin receptor type 1A (MTNR1A) DMOJUEC MA Antagonist DMOJUEC RN Synthesis of 3-phenylnaphthalenic derivatives as new selective MT(2) melatoninergic ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8339-48. DMOJUEC RU https://pubmed.ncbi.nlm.nih.gov/18778943 DMOJXCK DI DMOJXCK DMOJXCK DN (+/-)-threo-N-Benzyl-3',4'-dichlororitalinol DMOJXCK TI TTVBI8W DMOJXCK TN Dopamine transporter (DAT) DMOJXCK MA Inhibitor DMOJXCK RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMOJXCK RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMOK0U8 DI DMOK0U8 DMOK0U8 DN Benzaldehyde O-4-(hexyloxy)phenylcarbamoyl oxime DMOK0U8 TI TTDP1UC DMOK0U8 TN Fatty acid amide hydrolase (FAAH) DMOK0U8 MA Inhibitor DMOK0U8 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMOK0U8 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMOK6IP DI DMOK6IP DMOK6IP DN LAVYPWT DMOK6IP TI TT2THBD DMOK6IP TN P2X purinoceptor 3 (P2RX3) DMOK6IP MA Inhibitor DMOK6IP RN Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7. DMOK6IP RU https://pubmed.ncbi.nlm.nih.gov/17676725 DMOK9FA DI DMOK9FA DMOK9FA DN ISIS 103631 DMOK9FA TI TTBWMKT DMOK9FA TN WWP1 messenger RNA (WWP1 mRNA) DMOK9FA RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMOK9FA RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMOKN27 DI DMOKN27 DMOKN27 DN AM-281 DMOKN27 TI TTMSFAW DMOKN27 TN Cannabinoid receptor 2 (CB2) DMOKN27 MA Inhibitor DMOKN27 RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMOKN27 RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMOKN27 DI DMOKN27 DMOKN27 DN AM-281 DMOKN27 TI TT6OEDT DMOKN27 TN Cannabinoid receptor 1 (CB1) DMOKN27 MA Inhibitor DMOKN27 RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMOKN27 RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMOKNXE DI DMOKNXE DMOKNXE DN Dibenzo-p-dioxin-2-carboxylic acid DMOKNXE TI TTGTQHC DMOKNXE TN DNA topoisomerase I (TOP1) DMOKNXE MA Binder DMOKNXE RN Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11. DMOKNXE RU https://pubmed.ncbi.nlm.nih.gov/9026436 DMOKVAT DI DMOKVAT DMOKVAT DN Benzyl 4-aminobutyl(3-aminopropyl)carbamate DMOKVAT TI TTLD29N DMOKVAT TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMOKVAT MA Inhibitor DMOKVAT RN Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41. DMOKVAT RU https://pubmed.ncbi.nlm.nih.gov/16563762 DMOKVAT DI DMOKVAT DMOKVAT DN Benzyl 4-aminobutyl(3-aminopropyl)carbamate DMOKVAT TI TTKJEMQ DMOKVAT TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMOKVAT MA Inhibitor DMOKVAT RN Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41. DMOKVAT RU https://pubmed.ncbi.nlm.nih.gov/16563762 DMOKVAT DI DMOKVAT DMOKVAT DN Benzyl 4-aminobutyl(3-aminopropyl)carbamate DMOKVAT TI TTN9D8E DMOKVAT TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMOKVAT MA Inhibitor DMOKVAT RN Polyamines and the NMDA receptor: modifying intrinsic activities with aromatic substituents. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2837-41. DMOKVAT RU https://pubmed.ncbi.nlm.nih.gov/16563762 DMOKX76 DI DMOKX76 DMOKX76 DN Efomycine M DMOKX76 TI TTE5VG0 DMOKX76 TN P-selectin (SELP) DMOKX76 MA Inhibitor DMOKX76 RN Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52. DMOKX76 RU https://pubmed.ncbi.nlm.nih.gov/12559762 DMOKX76 DI DMOKX76 DMOKX76 DN Efomycine M DMOKX76 TI TTAU4D6 DMOKX76 TN E-selectin (SELE) DMOKX76 MA Inhibitor DMOKX76 RN Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52. DMOKX76 RU https://pubmed.ncbi.nlm.nih.gov/12559762 DMOKZ3R DI DMOKZ3R DMOKZ3R DN PMID2296027C25 DMOKZ3R TI TTPADOQ DMOKZ3R TN HMG-CoA reductase (HMGCR) DMOKZ3R MA Inhibitor DMOKZ3R RN Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles. J Med Chem. 1990 Jan;33(1):31-8. DMOKZ3R RU https://pubmed.ncbi.nlm.nih.gov/2296027 DMOL01E DI DMOL01E DMOL01E DN 9-(4-Hydroxyphenyl)-2,7-Phenanthroline DMOL01E TI TT056SO DMOL01E TN Stress-activated protein kinase JNK3 (JNK3) DMOL01E MA Inhibitor DMOL01E RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOL01E RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOL2Y0 DI DMOL2Y0 DMOL2Y0 DN 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 TI TTS2PH3 DMOL2Y0 TN Dopamine D5 receptor (D5R) DMOL2Y0 MA Inhibitor DMOL2Y0 RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DMOL2Y0 RU https://pubmed.ncbi.nlm.nih.gov/7108902 DMOL2Y0 DI DMOL2Y0 DMOL2Y0 DN 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 TI TT4C8EA DMOL2Y0 TN Dopamine D3 receptor (D3R) DMOL2Y0 MA Inhibitor DMOL2Y0 RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DMOL2Y0 RU https://pubmed.ncbi.nlm.nih.gov/7108902 DMOL2Y0 DI DMOL2Y0 DMOL2Y0 DN 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 TI TTEX248 DMOL2Y0 TN Dopamine D2 receptor (D2R) DMOL2Y0 MA Inhibitor DMOL2Y0 RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DMOL2Y0 RU https://pubmed.ncbi.nlm.nih.gov/7108902 DMOL2Y0 DI DMOL2Y0 DMOL2Y0 DN 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 TI TTE0A2F DMOL2Y0 TN Dopamine D4 receptor (D4R) DMOL2Y0 MA Inhibitor DMOL2Y0 RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DMOL2Y0 RU https://pubmed.ncbi.nlm.nih.gov/7108902 DMOL2Y0 DI DMOL2Y0 DMOL2Y0 DN 1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 TI TTZFYLI DMOL2Y0 TN Dopamine D1 receptor (D1R) DMOL2Y0 MA Inhibitor DMOL2Y0 RN Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8. DMOL2Y0 RU https://pubmed.ncbi.nlm.nih.gov/7108902 DMOL79W DI DMOL79W DMOL79W DN N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide DMOL79W TI TTBH0VX DMOL79W TN Histone deacetylase (HDAC) DMOL79W MA Inhibitor DMOL79W RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMOL79W RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMOL79W DI DMOL79W DMOL79W DN N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide DMOL79W TI TT6R7JZ DMOL79W TN Histone deacetylase 1 (HDAC1) DMOL79W MA Inhibitor DMOL79W RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMOL79W RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMOLCFQ DI DMOLCFQ DMOLCFQ DN BMS-279700 DMOLCFQ TI TT6PKBN DMOLCFQ TN Proto-oncogene c-Src (SRC) DMOLCFQ MA Inhibitor DMOLCFQ RN Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke. Bioorg Med Chem. 2007 Jan 15;15(2):868-85. DMOLCFQ RU https://pubmed.ncbi.nlm.nih.gov/17095233 DMOLFHZ DI DMOLFHZ DMOLFHZ DN 4-cyanophenylboronic acid DMOLFHZ TI TTDP1UC DMOLFHZ TN Fatty acid amide hydrolase (FAAH) DMOLFHZ MA Inhibitor DMOLFHZ RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMOLFHZ RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMOLI1E DI DMOLI1E DMOLI1E DN PF-05313261 DMOLI1E TI TTKFVXR DMOLI1E TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMOLI1E MA Inhibitor DMOLI1E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045). DMOLI1E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045 DMOLIE1 DI DMOLIE1 DMOLIE1 DN PMID2153213C1f DMOLIE1 TI TTPADOQ DMOLIE1 TN HMG-CoA reductase (HMGCR) DMOLIE1 MA Inhibitor DMOLIE1 RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DMOLIE1 RU https://pubmed.ncbi.nlm.nih.gov/2153213 DMOLIW4 DI DMOLIW4 DMOLIW4 DN 6-Furan-2-yl-9-phenethyl-9H-purin-2-ylamine DMOLIW4 TI TTM2AOE DMOLIW4 TN Adenosine A2a receptor (ADORA2A) DMOLIW4 MA Inhibitor DMOLIW4 RN 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2119-22. DMOLIW4 RU https://pubmed.ncbi.nlm.nih.gov/15808481 DMOLJRH DI DMOLJRH DMOLJRH DN TCS 2510 DMOLJRH TI TT79WV3 DMOLJRH TN Prostaglandin E2 receptor EP4 (PTGER4) DMOLJRH MA Agonist DMOLJRH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). DMOLJRH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343 DMOLNQX DI DMOLNQX DMOLNQX DN SB 272183 DMOLNQX TI TTK8CXU DMOLNQX TN 5-HT 1B receptor (HTR1B) DMOLNQX MA Antagonist DMOLNQX RN SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol. 2001 Jul;133(6):797-806. DMOLNQX RU https://pubmed.ncbi.nlm.nih.gov/11454652 DMOLNQX DI DMOLNQX DMOLNQX DN SB 272183 DMOLNQX TI TT6MSOK DMOLNQX TN 5-HT 1D receptor (HTR1D) DMOLNQX MA Antagonist DMOLNQX RN SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol. 2001 Jul;133(6):797-806. DMOLNQX RU https://pubmed.ncbi.nlm.nih.gov/11454652 DMOLNQX DI DMOLNQX DMOLNQX DN SB 272183 DMOLNQX TI TTSQIFT DMOLNQX TN 5-HT 1A receptor (HTR1A) DMOLNQX MA Antagonist DMOLNQX RN SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue. Br J Pharmacol. 2001 Jul;133(6):797-806. DMOLNQX RU https://pubmed.ncbi.nlm.nih.gov/11454652 DMOLQNK DI DMOLQNK DMOLQNK DN SNG-163 DMOLQNK TI TTZAYWL DMOLQNK TN Estrogen receptor (ESR) DMOLQNK MA Inhibitor DMOLQNK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620). DMOLQNK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=620 DMOLRIY DI DMOLRIY DMOLRIY DN PMID24000170C38 DMOLRIY TI TTHE657 DMOLRIY TN Bromodomain-containing protein 3 (BRD3) DMOLRIY MA Inhibitor DMOLRIY RN Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. DMOLRIY RU https://pubmed.ncbi.nlm.nih.gov/24000170 DMOLRIY DI DMOLRIY DMOLRIY DN PMID24000170C38 DMOLRIY TI TTDP48B DMOLRIY TN Bromodomain-containing protein 2 (BRD2) DMOLRIY MA Inhibitor DMOLRIY RN Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. DMOLRIY RU https://pubmed.ncbi.nlm.nih.gov/24000170 DMOLRIY DI DMOLRIY DMOLRIY DN PMID24000170C38 DMOLRIY TI TTRA6BO DMOLRIY TN Bromodomain-containing protein 4 (BRD4) DMOLRIY MA Inhibitor DMOLRIY RN Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem. 2014 Mar;9(3):580-9. DMOLRIY RU https://pubmed.ncbi.nlm.nih.gov/24000170 DMOLZ65 DI DMOLZ65 DMOLZ65 DN 3-phenacyl-UDP DMOLZ65 TI TTNVSKA DMOLZ65 TN P2Y purinoceptor 6 (P2RY6) DMOLZ65 MA Agonist DMOLZ65 RN Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87. DMOLZ65 RU https://pubmed.ncbi.nlm.nih.gov/17125260 DMOM35G DI DMOM35G DMOM35G DN 5-Benzyloxytryptamine DMOM35G TI TTXDKTO DMOM35G TN Long transient receptor potential channel 8 (TRPM8) DMOM35G MA Inhibitor DMOM35G RN 5-benzyloxytryptamine as an antagonist of TRPM8. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7076-9. DMOM35G RU https://pubmed.ncbi.nlm.nih.gov/20965726 DMOM4VS DI DMOM4VS DMOM4VS DN 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane DMOM4VS TI TT3ROYC DMOM4VS TN Serotonin transporter (SERT) DMOM4VS MA Inhibitor DMOM4VS RN 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7. DMOM4VS RU https://pubmed.ncbi.nlm.nih.gov/11078197 DMOM4VS DI DMOM4VS DMOM4VS DN 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane DMOM4VS TI TTAWNKZ DMOM4VS TN Norepinephrine transporter (NET) DMOM4VS MA Inhibitor DMOM4VS RN 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7. DMOM4VS RU https://pubmed.ncbi.nlm.nih.gov/11078197 DMOM4VS DI DMOM4VS DMOM4VS DN 8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane DMOM4VS TI TTVBI8W DMOM4VS TN Dopamine transporter (DAT) DMOM4VS MA Inhibitor DMOM4VS RN 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7. DMOM4VS RU https://pubmed.ncbi.nlm.nih.gov/11078197 DMOMAXJ DI DMOMAXJ DMOMAXJ DN 1-(2-Phenoxy-ethyl)-1H-imidazole DMOMAXJ TI TTIQUX7 DMOMAXJ TN Steroid 11-beta-hydroxylase (CYP11B1) DMOMAXJ MA Inhibitor DMOMAXJ RN Selective thromboxane synthetase inhibitors. 1. 1-[(Aryloxy)alkyl]-1H-imidazoles. J Med Chem. 1985 Oct;28(10):1427-32. DMOMAXJ RU https://pubmed.ncbi.nlm.nih.gov/3930740 DMOMG7S DI DMOMG7S DMOMG7S DN MACLURAXANTHONE DMOMG7S TI TT50QJ3 DMOMG7S TN Influenza Neuraminidase (Influ NA) DMOMG7S MA Inhibitor DMOMG7S RN Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. DMOMG7S RU https://pubmed.ncbi.nlm.nih.gov/19285413 DMOMI91 DI DMOMI91 DMOMI91 DN AcAsp-Glu-Met-Glu-Cha-Cys DMOMI91 TI TTWXB3E DMOMI91 TN Hepatitis C virus NS3 helicase (HCV NS3) DMOMI91 MA Inhibitor DMOMI91 RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMOMI91 RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMOMSTN DI DMOMSTN DMOMSTN DN 3-(1-carbamoyl-1,1-diphenylmethyl)-1-(4-methoxyphenylethyl)pyrrolidine (APP) DMOMSTN TI TTQ13Z5 DMOMSTN TN Muscarinic acetylcholine receptor M3 (CHRM3) DMOMSTN MA Antagonist DMOMSTN RN Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. DMOMSTN RU https://pubmed.ncbi.nlm.nih.gov/14769832 DMOMXP7 DI DMOMXP7 DMOMXP7 DN TROPOLONE DMOMXP7 TI TTULVH8 DMOMXP7 TN Tyrosinase (TYR) DMOMXP7 MA Inhibitor DMOMXP7 RN Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6157-60. DMOMXP7 RU https://pubmed.ncbi.nlm.nih.gov/19800229 DMOMYDV DI DMOMYDV DMOMYDV DN N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide DMOMYDV TI TT7HF4W DMOMYDV TN Cyclin-dependent kinase 2 (CDK2) DMOMYDV MA Inhibitor DMOMYDV RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOMYDV RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMON1A5 DI DMON1A5 DMON1A5 DN 2-(p-tolylthio)naphthalene-1,4-dione DMON1A5 TI TTRVTMX DMON1A5 TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMON1A5 MA Inhibitor DMON1A5 RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DMON1A5 RU https://pubmed.ncbi.nlm.nih.gov/18996691 DMON7RZ DI DMON7RZ DMON7RZ DN 8-(3-Azido-phenyl)-6-pyridin-4-ylmethyl-quinoline DMON7RZ TI TTZ97H5 DMON7RZ TN Phosphodiesterase 4A (PDE4A) DMON7RZ MA Inhibitor DMON7RZ RN Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl... J Med Chem. 2000 Oct 19;43(21):3820-3. DMON7RZ RU https://pubmed.ncbi.nlm.nih.gov/11052785 DMONCUL DI DMONCUL DMONCUL DN 9-BENZYL-9H-ADENINE DMONCUL TI TTM2AOE DMONCUL TN Adenosine A2a receptor (ADORA2A) DMONCUL MA Inhibitor DMONCUL RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMONCUL RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMONDP1 DI DMONDP1 DMONDP1 DN MPC-MECA DMONDP1 TI TTJFY5U DMONDP1 TN Adenosine A3 receptor (ADORA3) DMONDP1 MA Agonist DMONDP1 RN [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. DMONDP1 RU https://pubmed.ncbi.nlm.nih.gov/10779381 DMONGDX DI DMONGDX DMONGDX DN 4-Piperidino-Piperidine DMONGDX TI TTMF541 DMONGDX TN Liver carboxylesterase (CES1) DMONGDX MA Inhibitor DMONGDX RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMONGDX RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMONHFR DI DMONHFR DMONHFR DN 3-amino-5-(4-octylphenyl)pentanoic acid DMONHFR TI TT9JZCK DMONHFR TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMONHFR MA Inhibitor DMONHFR RN S1P receptor mediated activity of FTY720 phosphate mimics. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1485-7. DMONHFR RU https://pubmed.ncbi.nlm.nih.gov/20153186 DMONI13 DI DMONI13 DMONI13 DN [3H]methoxymethyl-MTEP DMONI13 TI TTHS256 DMONI13 TN Metabotropic glutamate receptor 5 (mGluR5) DMONI13 MA Modulator (allosteric modulator) DMONI13 RN [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J Pharmacol Exp Ther. 2002 Dec;303(3):1044-51. DMONI13 RU https://pubmed.ncbi.nlm.nih.gov/12438526 DMONK0F DI DMONK0F DMONK0F DN GNF-PF-2272 DMONK0F TI TTHQZV7 DMONK0F TN Mothers against decapentaplegic homolog 3 (SMAD3) DMONK0F MA Inhibitor DMONK0F RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMONK0F RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMONK0F DI DMONK0F DMONK0F DN GNF-PF-2272 DMONK0F TI TT915ZD DMONK0F TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMONK0F MA Inhibitor DMONK0F RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMONK0F RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMONKDQ DI DMONKDQ DMONKDQ DN 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile DMONKDQ TI TTUTJGQ DMONKDQ TN Vascular endothelial growth factor receptor 2 (KDR) DMONKDQ MA Inhibitor DMONKDQ RN 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. DMONKDQ RU https://pubmed.ncbi.nlm.nih.gov/17481894 DMONKDQ DI DMONKDQ DMONKDQ DN 4-phenyl-2-(phenylamino)pyrimidine-5-carbonitrile DMONKDQ TI TTH6V3D DMONKDQ TN Cyclin-dependent kinase 1 (CDK1) DMONKDQ MA Inhibitor DMONKDQ RN 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. DMONKDQ RU https://pubmed.ncbi.nlm.nih.gov/17481894 DMONMHK DI DMONMHK DMONMHK DN incensole acetate DMONMHK TI TT946IA DMONMHK TN Transient receptor potential cation channel V3 (TRPV3) DMONMHK MA Activator DMONMHK RN Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J. 2008 Aug;22(8):3024-34. DMONMHK RU https://pubmed.ncbi.nlm.nih.gov/18492727 DMONSM1 DI DMONSM1 DMONSM1 DN 3-(4,5-Dihydrooxazol-2-yl)phenyl propylcarbamate DMONSM1 TI TTDP1UC DMONSM1 TN Fatty acid amide hydrolase (FAAH) DMONSM1 MA Inhibitor DMONSM1 RN Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and int... Eur J Med Chem. 2009 Oct;44(10):4179-91. DMONSM1 RU https://pubmed.ncbi.nlm.nih.gov/19539407 DMONT2D DI DMONT2D DMONT2D DN 2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol DMONT2D TI TTZAYWL DMONT2D TN Estrogen receptor (ESR) DMONT2D MA Inhibitor DMONT2D RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMONT2D RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMONT2D DI DMONT2D DMONT2D DN 2-(4-Hydroxy-phenyl)-7-propyl-benzooxazol-5-ol DMONT2D TI TTOM3J0 DMONT2D TN Estrogen receptor beta (ESR2) DMONT2D MA Inhibitor DMONT2D RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMONT2D RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMONV0M DI DMONV0M DMONV0M DN D[Orn4,Orn8]VP DMONV0M TI TTK8R02 DMONV0M TN Vasopressin V2 receptor (V2R) DMONV0M MA Inhibitor DMONV0M RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMONV0M RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMONV0M DI DMONV0M DMONV0M DN D[Orn4,Orn8]VP DMONV0M TI TTL9MHW DMONV0M TN Vasopressin V1b receptor (V1BR) DMONV0M MA Inhibitor DMONV0M RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMONV0M RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMONV0M DI DMONV0M DMONV0M DN D[Orn4,Orn8]VP DMONV0M TI TTSCIUP DMONV0M TN Oxytocin receptor (OTR) DMONV0M MA Inhibitor DMONV0M RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMONV0M RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMONV0M DI DMONV0M DMONV0M DN D[Orn4,Orn8]VP DMONV0M TI TT4TFGN DMONV0M TN Vasopressin V1a receptor (V1AR) DMONV0M MA Inhibitor DMONV0M RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMONV0M RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMONZ0Y DI DMONZ0Y DMONZ0Y DN 4-hexylphenyl propiolate DMONZ0Y TI TTGER3L DMONZ0Y TN Thyroid hormone receptor beta (THRB) DMONZ0Y MA Inhibitor DMONZ0Y RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMONZ0Y RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMONZ0Y DI DMONZ0Y DMONZ0Y DN 4-hexylphenyl propiolate DMONZ0Y TI TTTSEPU DMONZ0Y TN Thyroid hormone receptor alpha (THRA) DMONZ0Y MA Inhibitor DMONZ0Y RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMONZ0Y RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMOP128 DI DMOP128 DMOP128 DN N-methyl-N-(pyridin-3-ylmethyl)ethanamine DMOP128 TI TT5KPZR DMOP128 TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMOP128 MA Inhibitor DMOP128 RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMOP128 RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMOP128 DI DMOP128 DMOP128 DN N-methyl-N-(pyridin-3-ylmethyl)ethanamine DMOP128 TI TT4H1MQ DMOP128 TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMOP128 MA Inhibitor DMOP128 RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMOP128 RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMOP5AJ DI DMOP5AJ DMOP5AJ DN 9-(3-IODOBENZYLAMINO)-1,2,3,4-TETRAHYDROACRIDINE DMOP5AJ TI TTEB0GD DMOP5AJ TN Cholinesterase (BCHE) DMOP5AJ MA Inhibitor DMOP5AJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOP5AJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMOP5N7 DI DMOP5N7 DMOP5N7 DN N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile DMOP5N7 TI TTUMQVO DMOP5N7 TN Cathepsin S (CTSS) DMOP5N7 MA Inhibitor DMOP5N7 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMOP5N7 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMOP5N7 DI DMOP5N7 DMOP5N7 DN N-(tert-butoxycarbonyl)-norvalyl-glycine-nitrile DMOP5N7 TI TTDZN01 DMOP5N7 TN Cathepsin K (CTSK) DMOP5N7 MA Inhibitor DMOP5N7 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMOP5N7 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMOP8IJ DI DMOP8IJ DMOP8IJ DN OAG DMOP8IJ TI TTNVC34 DMOP8IJ TN Short transient receptor potential channel 3 (TRPC3) DMOP8IJ MA Activator DMOP8IJ RN Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63. DMOP8IJ RU https://pubmed.ncbi.nlm.nih.gov/9930701 DMOP8IJ DI DMOP8IJ DMOP8IJ DN OAG DMOP8IJ TI TTRBT3W DMOP8IJ TN Short transient receptor potential channel 6 (TRPC6) DMOP8IJ MA Activator DMOP8IJ RN Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999 Jan 21;397(6716):259-63. DMOP8IJ RU https://pubmed.ncbi.nlm.nih.gov/9930701 DMOP8IJ DI DMOP8IJ DMOP8IJ DN OAG DMOP8IJ TI TTSJ9E7 DMOP8IJ TN Short transient receptor potential channel 2 (TRPC2) DMOP8IJ MA Activator DMOP8IJ RN A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction. Neuron. 2003 Oct 30;40(3):551-61. DMOP8IJ RU https://pubmed.ncbi.nlm.nih.gov/14642279 DMOP8IJ DI DMOP8IJ DMOP8IJ DN OAG DMOP8IJ TI TT06GRA DMOP8IJ TN Short transient receptor potential channel 7 (TRPC7) DMOP8IJ MA Activator DMOP8IJ RN Molecular and functional characterization of a novel mouse transient receptor potential protein homologue TRP7. Ca(2+)-permeable cation channel that is constitutively activated and enhanced by stimulation of G protein-coupled receptor. J Biol Chem. 1999 Sep 24;274(39):27359-70. DMOP8IJ RU https://pubmed.ncbi.nlm.nih.gov/10488066 DMOP8YM DI DMOP8YM DMOP8YM DN PMID16290936C1b DMOP8YM TI TT3G406 DMOP8YM TN Cathepsin H (CTSH) DMOP8YM MA Inhibitor DMOP8YM RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMOP8YM RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMOP8YM DI DMOP8YM DMOP8YM DN PMID16290936C1b DMOP8YM TI TTDZN01 DMOP8YM TN Cathepsin K (CTSK) DMOP8YM MA Inhibitor DMOP8YM RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMOP8YM RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMOP941 DI DMOP941 DMOP941 DN aspirin-triggered resolvin D1 DMOP941 TI TTOJ1NF DMOP941 TN FMLP-related receptor I (FPR2) DMOP941 MA Agonist DMOP941 RN Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012 May;180(5):2018-27. DMOP941 RU https://pubmed.ncbi.nlm.nih.gov/22449948 DMOP941 DI DMOP941 DMOP941 DN aspirin-triggered resolvin D1 DMOP941 TI TT946IA DMOP941 TN Transient receptor potential cation channel V3 (TRPV3) DMOP941 MA Blocker (channel blocker) DMOP941 RN 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. Br J Pharmacol. 2012 Feb;165(3):683-92. DMOP941 RU https://pubmed.ncbi.nlm.nih.gov/21718307 DMOPCBD DI DMOPCBD DMOPCBD DN UNC1999 DMOPCBD TI TT9MZCQ DMOPCBD TN Enhancer of zeste homolog 2 (EZH2) DMOPCBD MA Inhibitor DMOPCBD RN An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-34. DMOPCBD RU https://pubmed.ncbi.nlm.nih.gov/23614352 DMOPLQI DI DMOPLQI DMOPLQI DN VU0238429 DMOPLQI TI TTH18TF DMOPLQI TN Muscarinic acetylcholine receptor M5 (CHRM5) DMOPLQI MA Inhibitor DMOPLQI RN Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of ... J Med Chem. 2009 Jun 11;52(11):3445-8. DMOPLQI RU https://pubmed.ncbi.nlm.nih.gov/19438238 DMOPMNC DI DMOPMNC DMOPMNC DN (5-methoxy-1H-indol-3-yl)methanamine DMOPMNC TI TT0K1SC DMOPMNC TN 5-HT 2B receptor (HTR2B) DMOPMNC MA Inhibitor DMOPMNC RN Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86. DMOPMNC RU https://pubmed.ncbi.nlm.nih.gov/20958049 DMOPN4K DI DMOPN4K DMOPN4K DN 8-Methoxy-2-methyl-3H-quinazolin-4-one DMOPN4K TI TTVDSZ0 DMOPN4K TN Poly [ADP-ribose] polymerase 1 (PARP1) DMOPN4K MA Inhibitor DMOPN4K RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMOPN4K RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMOPRQ7 DI DMOPRQ7 DMOPRQ7 DN 4-[3-(3-benzyloxy-pyridin-2-yl)-ureido]-benzamide DMOPRQ7 TI TTL2ADK DMOPRQ7 TN Rotamase A (PPIA) DMOPRQ7 MA Inhibitor DMOPRQ7 RN Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A. J Med Chem. 2006 Feb 9;49(3):900-10. DMOPRQ7 RU https://pubmed.ncbi.nlm.nih.gov/16451056 DMOPSJU DI DMOPSJU DMOPSJU DN N-tert-Butyl-1'H-phenothiazine-1'-carboxamide DMOPSJU TI TTEB0GD DMOPSJU TN Cholinesterase (BCHE) DMOPSJU MA Inhibitor DMOPSJU RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMOPSJU RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMOPUIH DI DMOPUIH DMOPUIH DN PMID15546730C2 DMOPUIH TI TT42OGM DMOPUIH TN Hematopoietic cell kinase (HCK) DMOPUIH MA Inhibitor DMOPUIH RN Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. DMOPUIH RU https://pubmed.ncbi.nlm.nih.gov/15546730 DMOPUIH DI DMOPUIH DMOPUIH DN PMID15546730C2 DMOPUIH TI TT2B9KF DMOPUIH TN Fyn tyrosine protein kinase (FYN) DMOPUIH MA Inhibitor DMOPUIH RN Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. DMOPUIH RU https://pubmed.ncbi.nlm.nih.gov/15546730 DMOPUIH DI DMOPUIH DMOPUIH DN PMID15546730C2 DMOPUIH TI TTPOGS1 DMOPUIH TN Tyrosine-protein kinase Fgr (FGR) DMOPUIH MA Inhibitor DMOPUIH RN Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. DMOPUIH RU https://pubmed.ncbi.nlm.nih.gov/15546730 DMOPUIH DI DMOPUIH DMOPUIH DN PMID15546730C2 DMOPUIH TI TTNDSC3 DMOPUIH TN B lymphocyte kinase (BLK) DMOPUIH MA Inhibitor DMOPUIH RN Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. DMOPUIH RU https://pubmed.ncbi.nlm.nih.gov/15546730 DMOPUIH DI DMOPUIH DMOPUIH DN PMID15546730C2 DMOPUIH TI TT860QF DMOPUIH TN LCK tyrosine protein kinase (LCK) DMOPUIH MA Inhibitor DMOPUIH RN Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. DMOPUIH RU https://pubmed.ncbi.nlm.nih.gov/15546730 DMOPUIH DI DMOPUIH DMOPUIH DN PMID15546730C2 DMOPUIH TI TT6PKBN DMOPUIH TN Proto-oncogene c-Src (SRC) DMOPUIH MA Inhibitor DMOPUIH RN Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. DMOPUIH RU https://pubmed.ncbi.nlm.nih.gov/15546730 DMOPUIH DI DMOPUIH DMOPUIH DN PMID15546730C2 DMOPUIH TI TTT7PJU DMOPUIH TN Janus kinase 3 (JAK-3) DMOPUIH MA Inhibitor DMOPUIH RN Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6061-6. DMOPUIH RU https://pubmed.ncbi.nlm.nih.gov/15546730 DMOQ08F DI DMOQ08F DMOQ08F DN N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide DMOQ08F TI TT1VAUK DMOQ08F TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMOQ08F MA Inhibitor DMOQ08F RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMOQ08F RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMOQ08F DI DMOQ08F DMOQ08F DN N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide DMOQ08F TI TTUTJGQ DMOQ08F TN Vascular endothelial growth factor receptor 2 (KDR) DMOQ08F MA Inhibitor DMOQ08F RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMOQ08F RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMOQ08F DI DMOQ08F DMOQ08F DN N-(3-Bromo-benzoyl)-4-chloro-benzenesulfonamide DMOQ08F TI TTDCBX5 DMOQ08F TN Vascular endothelial growth factor receptor 3 (FLT-4) DMOQ08F MA Inhibitor DMOQ08F RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMOQ08F RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMOQ0CE DI DMOQ0CE DMOQ0CE DN Ro-11-04253 DMOQ0CE TI TTNGILX DMOQ0CE TN Adrenergic receptor alpha-1A (ADRA1A) DMOQ0CE MA Inhibitor DMOQ0CE RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMOQ0CE RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMOQ0XD DI DMOQ0XD DMOQ0XD DN ISIS 113022 DMOQ0XD TI TTASI04 DMOQ0XD TN E2F1 messenger RNA (E2F1 mRNA) DMOQ0XD RN US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression. DMOQ0XD RU http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true DMOQ27M DI DMOQ27M DMOQ27M DN ISIS 191729 DMOQ27M TI TT0GV3R DMOQ27M TN DGAT1 messenger RNA (DGAT1 mRNA) DMOQ27M RN US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression. DMOQ27M RU http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true DMOQ2R8 DI DMOQ2R8 DMOQ2R8 DN 2-amino-5-phenylthiophene-3-carboxamide DMOQ2R8 TI TTJ3E9X DMOQ2R8 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMOQ2R8 MA Inhibitor DMOQ2R8 RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DMOQ2R8 RU https://pubmed.ncbi.nlm.nih.gov/16686533 DMOQ43W DI DMOQ43W DMOQ43W DN Naphthalene-1,4-diol DMOQ43W TI TTZJYKH DMOQ43W TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMOQ43W MA Inhibitor DMOQ43W RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMOQ43W RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMOQ4ER DI DMOQ4ER DMOQ4ER DN 3-(1-Phenethyl-piperidin-3-yl)-2-phenyl-1H-indole DMOQ4ER TI TTQ6VDM DMOQ4ER TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMOQ4ER MA Inhibitor DMOQ4ER RN 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14. DMOQ4ER RU https://pubmed.ncbi.nlm.nih.gov/11334570 DMOQ8PF DI DMOQ8PF DMOQ8PF DN PMID15027864C8d DMOQ8PF TI TT9G4N0 DMOQ8PF TN Glutamate carboxypeptidase II (GCPII) DMOQ8PF MA Inhibitor DMOQ8PF RN Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004 Mar 25;47(7):1729-38. DMOQ8PF RU https://pubmed.ncbi.nlm.nih.gov/15027864 DMOQBGP DI DMOQBGP DMOQBGP DN IRAK-1/4 inhibitor DMOQBGP TI TTXAJWN DMOQBGP TN IL-1 receptor-associated kinase 1 (IRAK1) DMOQBGP MA Inhibitor DMOQBGP RN Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5. DMOQBGP RU https://pubmed.ncbi.nlm.nih.gov/16563752 DMOQBGP DI DMOQBGP DMOQBGP DN IRAK-1/4 inhibitor DMOQBGP TI TTKFVXR DMOQBGP TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMOQBGP MA Inhibitor DMOQBGP RN Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5. DMOQBGP RU https://pubmed.ncbi.nlm.nih.gov/16563752 DMOQDBA DI DMOQDBA DMOQDBA DN 2,2'-pyridylisatogen tosylate DMOQDBA TI TTA93TL DMOQDBA TN P2Y purinoceptor 1 (P2RY1) DMOQDBA MA Modulator (allosteric modulator) DMOQDBA RN 2,2'-Pyridylisatogen tosylate antagonizes P2Y1 receptor signaling without affecting nucleotide binding. Biochem Pharmacol. 2004 Jul 15;68(2):231-7. DMOQDBA RU https://pubmed.ncbi.nlm.nih.gov/15193995 DMOQE5W DI DMOQE5W DMOQE5W DN 4-(3-Ethoxy-phenoxy)-6,7-dimethoxy-quinoline DMOQE5W TI TTI7421 DMOQE5W TN Platelet-derived growth factor receptor beta (PDGFRB) DMOQE5W MA Inhibitor DMOQE5W RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMOQE5W RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMOQE91 DI DMOQE91 DMOQE91 DN RU78191 DMOQE91 TI TT6PKBN DMOQE91 TN Proto-oncogene c-Src (SRC) DMOQE91 MA Inhibitor DMOQE91 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOQE91 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMOQEZK DI DMOQEZK DMOQEZK DN BF/PC-18 DMOQEZK TI TTUMQVO DMOQEZK TN Cathepsin S (CTSS) DMOQEZK MA Inhibitor DMOQEZK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353). DMOQEZK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2353 DMOQIDG DI DMOQIDG DMOQIDG DN IAI-100 DMOQIDG TI TTOMWSY DMOQIDG TN Mammalian disintegrin-metalloprotease (ADAM10) DMOQIDG MA Inhibitor DMOQIDG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8679). DMOQIDG RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=8679 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTYVX59 DMOQJZC TN Protein kinase C (PRKC) DMOQJZC MA Inhibitor DMOQJZC RN Protein kinase epsilon dampens the secretory response of model intestinal epithelia during ischemia. Surgery. 2001 Aug;130(2):310-8. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/11490365 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTUWGRA DMOQJZC TN Protein kinase C zeta (PRKCZ) DMOQJZC MA Inhibitor DMOQJZC RN Protein kinase C zeta isoform is critical for proliferation in human glioblastoma cell lines. J Neurooncol. 2000 Apr;47(2):109-15. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10982151 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TT0K6EO DMOQJZC TN Stress-activated protein kinase JNK1 (JNK1) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTH6V3D DMOQJZC TN Cyclin-dependent kinase 1 (CDK1) DMOQJZC MA Inhibitor DMOQJZC RN Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/9871700 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTRFOXJ DMOQJZC TN Protein kinase C gamma (PRKCG) DMOQJZC MA Inhibitor DMOQJZC RN Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/17875639 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTRSMW9 DMOQJZC TN Glycogen synthase kinase-3 beta (GSK-3B) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTQBR95 DMOQJZC TN Stress-activated protein kinase 2a (p38 alpha) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TT73U6C DMOQJZC TN Stress-activated protein kinase 2b (p38 beta) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TT860QF DMOQJZC TN LCK tyrosine protein kinase (LCK) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTWTSCV DMOQJZC TN RAC-alpha serine/threonine-protein kinase (AKT1) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TT9P6OW DMOQJZC TN G2/mitotic-specific cyclin B1 (CCNB1) DMOQJZC MA Inhibitor DMOQJZC RN Design of new inhibitors for cdc2 kinase based on a multiple pseudosubstrate structure. Bioorg Med Chem Lett. 1998 May 5;8(9):1019-22. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/9871700 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TT4TQBX DMOQJZC TN Extracellular signal-regulated kinase 2 (ERK2) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTTV8EJ DMOQJZC TN Serine/threonine-protein kinase Sgk1 (SGK1) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TT57MT2 DMOQJZC TN PKC-epsilon messenger RNA (PRKCE mRNA) DMOQJZC MA Inhibitor DMOQJZC RN Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/17875639 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTYT93M DMOQJZC TN MAP kinase p38 (MAPK12) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TT7A1BO DMOQJZC TN PKC-delta messenger RNA (PRKCD mRNA) DMOQJZC MA Inhibitor DMOQJZC RN Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/17875639 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTIQSC1 DMOQJZC TN Bacterial Lethal factor (Bact lef) DMOQJZC MA Inhibitor DMOQJZC RN Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob Agents Chemother. 2007 Jul;51(7):2403-11. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/17485504 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTZN7RP DMOQJZC TN Rho-associated protein kinase 1 (ROCK1) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQJZC DI DMOQJZC DMOQJZC DN Bisindolylmaleimide-I DMOQJZC TI TTTU902 DMOQJZC TN Checkpoint kinase-1 (CHK1) DMOQJZC MA Inhibitor DMOQJZC RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMOQJZC RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMOQMA0 DI DMOQMA0 DMOQMA0 DN 7-trans-OH-PIPAT DMOQMA0 TI TTEX248 DMOQMA0 TN Dopamine D2 receptor (D2R) DMOQMA0 MA Agonist DMOQMA0 RN Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem. 1994 Nov 25;37(24):4245-50. DMOQMA0 RU https://pubmed.ncbi.nlm.nih.gov/7990123 DMOQMA0 DI DMOQMA0 DMOQMA0 DN 7-trans-OH-PIPAT DMOQMA0 TI TT4C8EA DMOQMA0 TN Dopamine D3 receptor (D3R) DMOQMA0 MA Agonist DMOQMA0 RN Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem. 1994 Nov 25;37(24):4245-50. DMOQMA0 RU https://pubmed.ncbi.nlm.nih.gov/7990123 DMOQMEU DI DMOQMEU DMOQMEU DN N-benzyl brucine DMOQMEU TI TTOXS3C DMOQMEU TN Muscarinic acetylcholine receptor (CHRM) DMOQMEU MA Modulator (allosteric modulator) DMOQMEU RN Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89. DMOQMEU RU https://pubmed.ncbi.nlm.nih.gov/9495826 DMOQMEU DI DMOQMEU DMOQMEU DN N-benzyl brucine DMOQMEU TI TTQ13Z5 DMOQMEU TN Muscarinic acetylcholine receptor M3 (CHRM3) DMOQMEU MA Modulator (allosteric modulator) DMOQMEU RN Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies. Mol Pharmacol. 1998 Mar;53(3):573-89. DMOQMEU RU https://pubmed.ncbi.nlm.nih.gov/9495826 DMOQPHK DI DMOQPHK DMOQPHK DN 2,5-bis(4-hydroxybenzylidene)cyclopentanone DMOQPHK TI TTXV4FI DMOQPHK TN Albendazole monooxygenase (CYP3A4) DMOQPHK MA Inhibitor DMOQPHK RN Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31. DMOQPHK RU https://pubmed.ncbi.nlm.nih.gov/18249473 DMOQPKT DI DMOQPKT DMOQPKT DN 1-(1-(4'-Ethylbiphenyl-4-yl)propyl)-1H-imidazole DMOQPKT TI TTRA5BZ DMOQPKT TN Steroid 17-alpha-monooxygenase (S17AH) DMOQPKT MA Inhibitor DMOQPKT RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMOQPKT RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMOQWBU DI DMOQWBU DMOQWBU DN ENDOMORPHIN 2 DMOQWBU TI TTKWM86 DMOQWBU TN Opioid receptor mu (MOP) DMOQWBU MA Inhibitor DMOQWBU RN Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600. DMOQWBU RU https://pubmed.ncbi.nlm.nih.gov/20692738 DMOQWBU DI DMOQWBU DMOQWBU DN ENDOMORPHIN 2 DMOQWBU TI TT27RFC DMOQWBU TN Opioid receptor delta (OPRD1) DMOQWBU MA Inhibitor DMOQWBU RN Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600. DMOQWBU RU https://pubmed.ncbi.nlm.nih.gov/20692738 DMOQWBU DI DMOQWBU DMOQWBU DN ENDOMORPHIN 2 DMOQWBU TI TTZPO1L DMOQWBU TN Substance-P receptor (TACR1) DMOQWBU MA Inhibitor DMOQWBU RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMOQWBU RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMOQWBU DI DMOQWBU DMOQWBU DN ENDOMORPHIN 2 DMOQWBU TI TTQW87Y DMOQWBU TN Opioid receptor kappa (OPRK1) DMOQWBU MA Inhibitor DMOQWBU RN Structure-activity study on the Phe side chain arrangement of endomorphins using conformationally constrained analogues. J Med Chem. 2004 Jan 29;47(3):735-43. DMOQWBU RU https://pubmed.ncbi.nlm.nih.gov/14736254 DMOQWDS DI DMOQWDS DMOQWDS DN 3-trans-p-coumaroyl maslinic acid DMOQWDS TI TTIU7X1 DMOQWDS TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMOQWDS MA Inhibitor DMOQWDS RN DNA polymerase beta inhibitors from Tetracera boiviniana. J Nat Prod. 1999 Dec;62(12):1660-3. DMOQWDS RU https://pubmed.ncbi.nlm.nih.gov/10654414 DMOR04W DI DMOR04W DMOR04W DN 6-((1H-imidazol-1-yl)methyl)-2H-chromene-2-thione DMOR04W TI TTSZLWK DMOR04W TN Aromatase (CYP19A1) DMOR04W MA Inhibitor DMOR04W RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMOR04W RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMOR9EK DI DMOR9EK DMOR9EK DN 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol DMOR9EK TI TTKWM86 DMOR9EK TN Opioid receptor mu (MOP) DMOR9EK MA Inhibitor DMOR9EK RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMOR9EK RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMOR9EK DI DMOR9EK DMOR9EK DN 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol DMOR9EK TI TTNT7K8 DMOR9EK TN Nociceptin receptor (OPRL1) DMOR9EK MA Inhibitor DMOR9EK RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMOR9EK RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMOR9EK DI DMOR9EK DMOR9EK DN 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol DMOR9EK TI TTQW87Y DMOR9EK TN Opioid receptor kappa (OPRK1) DMOR9EK MA Inhibitor DMOR9EK RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMOR9EK RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMOR9EK DI DMOR9EK DMOR9EK DN 1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol DMOR9EK TI TT27RFC DMOR9EK TN Opioid receptor delta (OPRD1) DMOR9EK MA Inhibitor DMOR9EK RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMOR9EK RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMORD8S DI DMORD8S DMORD8S DN (5-phenylfuran-2-yl)methanamine DMORD8S TI TTVG215 DMORD8S TN Debrisoquine 4-hydroxylase (CYP2D6) DMORD8S MA Inhibitor DMORD8S RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DMORD8S RU https://pubmed.ncbi.nlm.nih.gov/17125252 DMORFZE DI DMORFZE DMORFZE DN (S)-2-Amino-1-thiazolidin-3-yl-propane-1-thione DMORFZE TI TTDIGC1 DMORFZE TN Dipeptidyl peptidase 4 (DPP-4) DMORFZE MA Inhibitor DMORFZE RN Development of potent and selective dipeptidyl peptidase II inhibitors. Bioorg Med Chem Lett. 2002 Oct 21;12(20):2825-8. DMORFZE RU https://pubmed.ncbi.nlm.nih.gov/12270155 DMORG3D DI DMORG3D DMORG3D DN 2-Propionyl-1H-indole-6-carboxamidine DMORG3D TI TT2WR1T DMORG3D TN Cationic trypsinogen (PRSS1) DMORG3D MA Inhibitor DMORG3D RN Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8. DMORG3D RU https://pubmed.ncbi.nlm.nih.gov/6219223 DMORLTH DI DMORLTH DMORLTH DN PDGF receptor tyrosine kinase inhibitor III DMORLTH TI TTI7421 DMORLTH TN Platelet-derived growth factor receptor beta (PDGFRB) DMORLTH MA Inhibitor DMORLTH RN Potent and selective inhibitors of platelet-derived growth factor receptor phosphorylation. 3. Replacement of quinazoline moiety and improvement of metabolic polymorphism of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives. J Med Chem. 2003 Nov 6;46(23):4910-25. DMORLTH RU https://pubmed.ncbi.nlm.nih.gov/14584942 DMORMGU DI DMORMGU DMORMGU DN MCL-457 DMORMGU TI TTKWM86 DMORMGU TN Opioid receptor mu (MOP) DMORMGU MA Inhibitor DMORMGU RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMORMGU RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMORMGU DI DMORMGU DMORMGU DN MCL-457 DMORMGU TI TTQW87Y DMORMGU TN Opioid receptor kappa (OPRK1) DMORMGU MA Inhibitor DMORMGU RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMORMGU RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMORPDV DI DMORPDV DMORPDV DN Ac-Cys-Ile-Phe(4-NO2)-Lys-Tyr-Phe(4-NO2) DMORPDV TI TT6PKBN DMORPDV TN Proto-oncogene c-Src (SRC) DMORPDV MA Inhibitor DMORPDV RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMORPDV RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMOS2GH DI DMOS2GH DMOS2GH DN N,N'-Bis-(4-butyl-phenyl)-guanidine DMOS2GH TI TTN9D8E DMOS2GH TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMOS2GH MA Inhibitor DMOS2GH RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMOS2GH RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMOS2GH DI DMOS2GH DMOS2GH DN N,N'-Bis-(4-butyl-phenyl)-guanidine DMOS2GH TI TTKJEMQ DMOS2GH TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMOS2GH MA Inhibitor DMOS2GH RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMOS2GH RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMOS2GH DI DMOS2GH DMOS2GH DN N,N'-Bis-(4-butyl-phenyl)-guanidine DMOS2GH TI TTLD29N DMOS2GH TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMOS2GH MA Inhibitor DMOS2GH RN Synthesis and pharmacological evaluation of N,N'-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J Med Chem. 1998 Aug 13;41(17):3298-302. DMOS2GH RU https://pubmed.ncbi.nlm.nih.gov/9703475 DMOS4ZQ DI DMOS4ZQ DMOS4ZQ DN 7-((1H-imidazol-1-yl)methyl)-4H-chromen-4-one DMOS4ZQ TI TTSZLWK DMOS4ZQ TN Aromatase (CYP19A1) DMOS4ZQ MA Inhibitor DMOS4ZQ RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMOS4ZQ RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMOS68D DI DMOS68D DMOS68D DN (4-fluorophenyl)(pyridin-4-yl)methanone DMOS68D TI TTXZEAJ DMOS68D TN Leukotriene A-4 hydrolase (LTA4H) DMOS68D MA Inhibitor DMOS68D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOS68D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMOS864 DI DMOS864 DMOS864 DN (2-chloro-6-phenoxyphenyl)methanamine DMOS864 TI TTDIGC1 DMOS864 TN Dipeptidyl peptidase 4 (DPP-4) DMOS864 MA Inhibitor DMOS864 RN In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9. DMOS864 RU https://pubmed.ncbi.nlm.nih.gov/16321524 DMOSDAN DI DMOSDAN DMOSDAN DN 4-(2-pyrrolidin-1-yl-pentanoyl)benzonitrile DMOSDAN TI TTVBI8W DMOSDAN TN Dopamine transporter (DAT) DMOSDAN MA Inhibitor DMOSDAN RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMOSDAN RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMOSDM2 DI DMOSDM2 DMOSDM2 DN 6-(4-(2-(benzylamino)ethyl)phenoxy)picolinamide DMOSDM2 TI TTKWM86 DMOSDM2 TN Opioid receptor mu (MOP) DMOSDM2 MA Inhibitor DMOSDM2 RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMOSDM2 RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMOSG0Q DI DMOSG0Q DMOSG0Q DN BPI-711001 DMOSG0Q TI TTDIGC1 DMOSG0Q TN Dipeptidyl peptidase 4 (DPP-4) DMOSG0Q MA Inhibitor DMOSG0Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DMOSG0Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DMOSI4U DI DMOSI4U DMOSI4U DN Aza-C-nucleosides DMOSI4U TI TTMCF1Y DMOSI4U TN Purine nucleoside phosphorylase (PNP) DMOSI4U MA Inhibitor DMOSI4U RN Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. J Med Chem. 2003 Jul 17;46(15):3412-23. DMOSI4U RU https://pubmed.ncbi.nlm.nih.gov/12852771 DMOSKJ8 DI DMOSKJ8 DMOSKJ8 DN 5-N-Allyl-Arginine DMOSKJ8 TI TTZUFI5 DMOSKJ8 TN Nitric-oxide synthase brain (NOS1) DMOSKJ8 MA Inhibitor DMOSKJ8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOSKJ8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOSMBZ DI DMOSMBZ DMOSMBZ DN PMID24900824C2-1-1 DMOSMBZ TI TT78309 DMOSMBZ TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DMOSMBZ MA Inhibitor DMOSMBZ RN Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1. DMOSMBZ RU https://pubmed.ncbi.nlm.nih.gov/24900824 DMOSRET DI DMOSRET DMOSRET DN 1DMe DMOSRET TI TTXYNDJ DMOSRET TN Neuropeptide FF receptor 2 (NPFFR2) DMOSRET MA Agonist DMOSRET RN Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience. 2002;115(2):349-61. DMOSRET RU https://pubmed.ncbi.nlm.nih.gov/12421602 DMOSRET DI DMOSRET DMOSRET DN 1DMe DMOSRET TI TTEP027 DMOSRET TN Neuropeptide FF receptor 1 (NPFFR1) DMOSRET MA Agonist DMOSRET RN Quantitative autoradiographic distribution of NPFF1 neuropeptide FF receptor in the rat brain and comparison with NPFF2 receptor by using [125I]YVP and [(125I]EYF as selective radioligands. Neuroscience. 2002;115(2):349-61. DMOSRET RU https://pubmed.ncbi.nlm.nih.gov/12421602 DMOSTP9 DI DMOSTP9 DMOSTP9 DN SM-337 DMOSTP9 TI TTK3WBU DMOSTP9 TN XIAP messenger RNA (XIAP mRNA) DMOSTP9 MA Inhibitor DMOSTP9 RN Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7. DMOSTP9 RU https://pubmed.ncbi.nlm.nih.gov/20684551 DMOSTP9 DI DMOSTP9 DMOSTP9 DN SM-337 DMOSTP9 TI TTAIWZN DMOSTP9 TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DMOSTP9 MA Inhibitor DMOSTP9 RN Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J Med Chem. 2010 Sep 9;53(17):6361-7. DMOSTP9 RU https://pubmed.ncbi.nlm.nih.gov/20684551 DMOT1LQ DI DMOT1LQ DMOT1LQ DN 2-Hydrazino-3-methyl-4(3H)-quinazolinone DMOT1LQ TI TTGP7BY DMOT1LQ TN Monoamine oxidase type B (MAO-B) DMOT1LQ MA Inhibitor DMOT1LQ RN New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A ... Bioorg Med Chem. 2009 Jan 15;17(2):675-89. DMOT1LQ RU https://pubmed.ncbi.nlm.nih.gov/19091581 DMOT6V7 DI DMOT6V7 DMOT6V7 DN 2-HYDROXYCARBAMOYL-4-METHYL-PENTANOIC ACID DMOT6V7 TI TTGA1IV DMOT6V7 TN Matrix metalloproteinase-8 (MMP-8) DMOT6V7 MA Inhibitor DMOT6V7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOT6V7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMOTHAC DI DMOTHAC DMOTHAC DN YPWA-NH2 DMOTHAC TI TTKWM86 DMOTHAC TN Opioid receptor mu (MOP) DMOTHAC MA Inhibitor DMOTHAC RN Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. DMOTHAC RU https://pubmed.ncbi.nlm.nih.gov/18329886 DMOTI0P DI DMOTI0P DMOTI0P DN H-Tyr-c[D-Orn-Aic-Glu]-NH2 DMOTI0P TI TTKWM86 DMOTI0P TN Opioid receptor mu (MOP) DMOTI0P MA Inhibitor DMOTI0P RN Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32. DMOTI0P RU https://pubmed.ncbi.nlm.nih.gov/1656045 DMOTI0P DI DMOTI0P DMOTI0P DN H-Tyr-c[D-Orn-Aic-Glu]-NH2 DMOTI0P TI TT27RFC DMOTI0P TN Opioid receptor delta (OPRD1) DMOTI0P MA Inhibitor DMOTI0P RN Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32. DMOTI0P RU https://pubmed.ncbi.nlm.nih.gov/1656045 DMOTICP DI DMOTICP DMOTICP DN 1-(isoquinolin-5-yl)-3-(1-phenylpropyl)urea DMOTICP TI TTMI6F5 DMOTICP TN Transient receptor potential cation channel V1 (TRPV1) DMOTICP MA Inhibitor DMOTICP RN Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9. DMOTICP RU https://pubmed.ncbi.nlm.nih.gov/17507218 DMOTJWZ DI DMOTJWZ DMOTJWZ DN 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone DMOTJWZ TI TTI6V2A DMOTJWZ TN Heme oxygenase 1 (HMOX1) DMOTJWZ MA Inhibitor DMOTJWZ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOTJWZ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMOTMVP DI DMOTMVP DMOTMVP DN ISIS 16179 DMOTMVP TI TTO7014 DMOTMVP TN FasL messenger RNA (FASLG mRNA) DMOTMVP RN US patent application no. 6,204,055, Antisense inhibition of Fas mediated signaling. DMOTMVP RU http://www.patentbuddy.com/Patent/6204055?ft=true&sr=true DMOTNPC DI DMOTNPC DMOTNPC DN 16-(pyridin-4-yl)methylene-estradiol DMOTNPC TI TTIWB6L DMOTNPC TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMOTNPC MA Inhibitor DMOTNPC RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMOTNPC RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMOTPJD DI DMOTPJD DMOTPJD DN Rockout DMOTPJD TI TTTB4UP DMOTPJD TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMOTPJD MA Inhibitor DMOTPJD RN Novel indole inhibitors of IMPDH from fragments: synthesis and initial structure-activity relationships. Bioorg Med Chem Lett. 2006 May 1;16(9):2539-42. DMOTPJD RU https://pubmed.ncbi.nlm.nih.gov/16483773 DMOTXE3 DI DMOTXE3 DMOTXE3 DN Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2 DMOTXE3 TI TTZPO1L DMOTXE3 TN Substance-P receptor (TACR1) DMOTXE3 MA Inhibitor DMOTXE3 RN Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6. DMOTXE3 RU https://pubmed.ncbi.nlm.nih.gov/18067242 DMOTXP1 DI DMOTXP1 DMOTXP1 DN Hydantocidin-5'-Monophosphate DMOTXP1 TI TTYQ4AE DMOTXP1 TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DMOTXP1 MA Inhibitor DMOTXP1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOTXP1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOU234 DI DMOU234 DMOU234 DN IGEL1.2 DMOU234 TI TTYJQTF DMOU234 TN Immunoglobulin E (IgE) DMOU234 RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMOU234 RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMOU43H DI DMOU43H DMOU43H DN Tyr-Pro-Dmt-Phe-NH2 DMOU43H TI TTKWM86 DMOU43H TN Opioid receptor mu (MOP) DMOU43H MA Inhibitor DMOU43H RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMOU43H RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMOU43H DI DMOU43H DMOU43H DN Tyr-Pro-Dmt-Phe-NH2 DMOU43H TI TT27RFC DMOU43H TN Opioid receptor delta (OPRD1) DMOU43H MA Inhibitor DMOU43H RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMOU43H RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMOU93V DI DMOU93V DMOU93V DN Cyclic guanosine monophosphate DMOU93V TI TTJGW1Z DMOU93V TN Phosphodiesterase 2A (PDE2A) DMOU93V MA Inhibitor DMOU93V RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOU93V RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOU93V DI DMOU93V DMOU93V DN Cyclic guanosine monophosphate DMOU93V TI TTNAHEX DMOU93V TN cAMP-dependent protein kinase A type I (PRKAR1A) DMOU93V MA Inhibitor DMOU93V RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOU93V RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOU9EP DI DMOU9EP DMOU9EP DN ISIS 183881 DMOU9EP TI TTBGTCW DMOU9EP TN Kinesin spindle messenger RNA (KIF11 mRNA) DMOU9EP RN US patent application no. 7,407,943, Antisense modulation of apolipoprotein B expression. DMOU9EP RU http://www.patentbuddy.com/Patent/7407943?ft=true&sr=true DMOUG6Y DI DMOUG6Y DMOUG6Y DN 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose DMOUG6Y TI TTL69WB DMOUG6Y TN Angiotensin-converting enzyme (ACE) DMOUG6Y MA Inhibitor DMOUG6Y RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOUG6Y RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOUG6Y DI DMOUG6Y DMOUG6Y DN 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose DMOUG6Y TI TT1RS9F DMOUG6Y TN Acetylcholinesterase (AChE) DMOUG6Y MA Inhibitor DMOUG6Y RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOUG6Y RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOUG6Y DI DMOUG6Y DMOUG6Y DN 2-(Acetylamino)-2-Deoxy-a-D-Glucopyranose DMOUG6Y TI TT1B5PU DMOUG6Y TN Glucosylceramidase (GBA) DMOUG6Y MA Inhibitor DMOUG6Y RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOUG6Y RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOUKTH DI DMOUKTH DMOUKTH DN 2-(benzyloxyamino)-N-hydroxyhexanamide DMOUKTH TI TT2LVK8 DMOUKTH TN Carbonic anhydrase IX (CA-IX) DMOUKTH MA Inhibitor DMOUKTH RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMOUKTH RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMOUKTH DI DMOUKTH DMOUKTH DN 2-(benzyloxyamino)-N-hydroxyhexanamide DMOUKTH TI TTANPDJ DMOUKTH TN Carbonic anhydrase II (CA-II) DMOUKTH MA Inhibitor DMOUKTH RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMOUKTH RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMOUNPH DI DMOUNPH DMOUNPH DN 3-(5-[1,3]dithiolan-2-yl-furan-2-yl)pyridine DMOUNPH TI TTXV4FI DMOUNPH TN Albendazole monooxygenase (CYP3A4) DMOUNPH MA Inhibitor DMOUNPH RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DMOUNPH RU https://pubmed.ncbi.nlm.nih.gov/17125252 DMOUPNT DI DMOUPNT DMOUPNT DN 1-(4-chlorobenzyl)-1H-indole-2,3-dione DMOUPNT TI TTMF541 DMOUPNT TN Liver carboxylesterase (CES1) DMOUPNT MA Inhibitor DMOUPNT RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMOUPNT RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMOUQLB DI DMOUQLB DMOUQLB DN guanylpirenzepine DMOUQLB TI TTOXS3C DMOUQLB TN Muscarinic acetylcholine receptor (CHRM) DMOUQLB MA Antagonist DMOUQLB RN Subtypes of muscarinic receptors in rat duodenum: a comparison with rabbit vas deferens, rat atria, guinea-pig ileum and gallbladder by using imperialine. Gen Pharmacol. 1999 Apr;32(4):505-11. DMOUQLB RU https://pubmed.ncbi.nlm.nih.gov/10323493 DMOUQLB DI DMOUQLB DMOUQLB DN guanylpirenzepine DMOUQLB TI TTQ13Z5 DMOUQLB TN Muscarinic acetylcholine receptor M3 (CHRM3) DMOUQLB MA Antagonist DMOUQLB RN Binding of the labelled muscarinic toxin 125I-MT1 to rat brain muscarinic M1 receptors. Eur J Pharmacol. 1996 Jun 3;305(1-3):187-92. DMOUQLB RU https://pubmed.ncbi.nlm.nih.gov/8813552 DMOUSWN DI DMOUSWN DMOUSWN DN Cochliobolic acid DMOUSWN TI TTGKNB4 DMOUSWN TN Epidermal growth factor receptor (EGFR) DMOUSWN MA Inhibitor DMOUSWN RN Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. J Nat Prod. 1997 Jan;60(1):6-8. DMOUSWN RU https://pubmed.ncbi.nlm.nih.gov/9014347 DMOUTNA DI DMOUTNA DMOUTNA DN Methionine Phosphonate DMOUTNA TI TTOJ46K DMOUTNA TN Streptococcus Methionyl-tRNA synthetase (Stre-coc metG) DMOUTNA MA Inhibitor DMOUTNA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOUTNA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOUW0A DI DMOUW0A DMOUW0A DN KF-66490 DMOUW0A TI TTZ97H5 DMOUW0A TN Phosphodiesterase 4A (PDE4A) DMOUW0A MA Inhibitor DMOUW0A RN Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62. DMOUW0A RU https://pubmed.ncbi.nlm.nih.gov/18854230 DMOUW0A DI DMOUW0A DMOUW0A DN KF-66490 DMOUW0A TI TTVIAT9 DMOUW0A TN Phosphodiesterase 4B (PDE4B) DMOUW0A MA Inhibitor DMOUW0A RN Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62. DMOUW0A RU https://pubmed.ncbi.nlm.nih.gov/18854230 DMOUW0A DI DMOUW0A DMOUW0A DN KF-66490 DMOUW0A TI TTSKMI8 DMOUW0A TN Phosphodiesterase 4D (PDE4D) DMOUW0A MA Inhibitor DMOUW0A RN Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models. Int Immunopharmacol. 2009 Jan;9(1):55-62. DMOUW0A RU https://pubmed.ncbi.nlm.nih.gov/18854230 DMOV0QT DI DMOV0QT DMOV0QT DN NVP-PDF386 DMOV0QT TI TTICO5G DMOV0QT TN Staphylococcus Peptide deformylase (Stap-coc def) DMOV0QT MA Inhibitor DMOV0QT RN Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother. 2003 Jan;51(1):157-61. DMOV0QT RU https://pubmed.ncbi.nlm.nih.gov/12493802 DMOV980 DI DMOV980 DMOV980 DN GW1929 DMOV980 TI TTT2SVW DMOV980 TN PPAR-gamma messenger RNA (PPARG mRNA) DMOV980 MA Agonist DMOV980 RN A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48(7):1415-24. DMOV980 RU https://pubmed.ncbi.nlm.nih.gov/10389847 DMOVE31 DI DMOVE31 DMOVE31 DN PRT-064445 DMOVE31 TI TTCIHJA DMOVE31 TN Coagulation factor Xa (F10) DMOVE31 MA Inhibitor DMOVE31 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMOVE31 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMOVI7Y DI DMOVI7Y DMOVI7Y DN Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 DMOVI7Y TI TTNI91K DMOVI7Y TN Melanocortin receptor 3 (MC3R) DMOVI7Y MA Inhibitor DMOVI7Y RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMOVI7Y RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMOVI7Y DI DMOVI7Y DMOVI7Y DN Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 DMOVI7Y TI TTEOSZT DMOVI7Y TN Melanocortin receptor (MCR) DMOVI7Y MA Inhibitor DMOVI7Y RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMOVI7Y RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMOVI7Y DI DMOVI7Y DMOVI7Y DN Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 DMOVI7Y TI TT0MV2T DMOVI7Y TN Melanocortin receptor 1 (MC1R) DMOVI7Y MA Inhibitor DMOVI7Y RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMOVI7Y RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMOVI7Y DI DMOVI7Y DMOVI7Y DN Ac-Nle-c[Asp-His-DNal(2')-Pro-Trp-Lys]-NH2 DMOVI7Y TI TTD0CIQ DMOVI7Y TN Melanocortin receptor 4 (MC4R) DMOVI7Y MA Inhibitor DMOVI7Y RN Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35. DMOVI7Y RU https://pubmed.ncbi.nlm.nih.gov/19473029 DMOVJP3 DI DMOVJP3 DMOVJP3 DN xamoterol DMOVJP3 TI TTMXGCW DMOVJP3 TN Adrenergic receptor beta-3 (ADRB3) DMOVJP3 MA Agonist DMOVJP3 RN Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists. Mol Pharmacol. 1999 Nov;56(5):875-85. DMOVJP3 RU https://pubmed.ncbi.nlm.nih.gov/10531390 DMOVQ1T DI DMOVQ1T DMOVQ1T DN (S)-2-Amino-4-methylsulfanyl-butane-1-thiol DMOVQ1T TI TTPHMWB DMOVQ1T TN Aminopeptidase N (ANPEP) DMOVQ1T MA Inhibitor DMOVQ1T RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMOVQ1T RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMOVRX7 DI DMOVRX7 DMOVRX7 DN 2-isooleanolic acid DMOVRX7 TI TTZHY6R DMOVRX7 TN Glycogen phosphorylase muscle form (GP) DMOVRX7 MA Inhibitor DMOVRX7 RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMOVRX7 RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMOVUP2 DI DMOVUP2 DMOVUP2 DN 6-Methyl-4-(4-benzoylpiperazin-1-yl)coumarin DMOVUP2 TI TT1RS9F DMOVUP2 TN Acetylcholinesterase (AChE) DMOVUP2 MA Inhibitor DMOVUP2 RN Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21. DMOVUP2 RU https://pubmed.ncbi.nlm.nih.gov/18701305 DMOVY6L DI DMOVY6L DMOVY6L DN Uinagolide DMOVY6L TI TTEX248 DMOVY6L TN Dopamine D2 receptor (D2R) DMOVY6L MA Agonist DMOVY6L RN Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol. 2002 Jun;136(4):620-8. DMOVY6L RU https://pubmed.ncbi.nlm.nih.gov/12055141 DMOVYXT DI DMOVYXT DMOVYXT DN 2-(indolin-1yl)-melatonin DMOVYXT TI TT0WAIE DMOVYXT TN Melatonin receptor type 1A (MTNR1A) DMOVYXT MA Antagonist DMOVYXT RN 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33. DMOVYXT RU https://pubmed.ncbi.nlm.nih.gov/19193160 DMOW0L9 DI DMOW0L9 DMOW0L9 DN 3-(3,4-Dimethyl-phenyl)-piperidine DMOW0L9 TI TTEX248 DMOW0L9 TN Dopamine D2 receptor (D2R) DMOW0L9 MA Inhibitor DMOW0L9 RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DMOW0L9 RU https://pubmed.ncbi.nlm.nih.gov/9836610 DMOW2QS DI DMOW2QS DMOW2QS DN Netropsin DMOW2QS TI TTOVXHF DMOW2QS TN Human Deoxyribonucleic acid minor groove (hDNA min) DMOW2QS MA Binder (minor groove binder) DMOW2QS RN Drug-DNA binding specificity: binding of netropsin and distamycin to poly(d2NH2A-dT). Biopolymers. 1990;30(1-2):223-7. DMOW2QS RU https://pubmed.ncbi.nlm.nih.gov/2171689 DMOW8TM DI DMOW8TM DMOW8TM DN 4-nonyl-N-(quinolin-3-yl)benzamide DMOW8TM TI TTMI6F5 DMOW8TM TN Transient receptor potential cation channel V1 (TRPV1) DMOW8TM MA Inhibitor DMOW8TM RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMOW8TM RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMOWFE5 DI DMOWFE5 DMOWFE5 DN (4-Iodo-butyl)-trimethyl-ammonium iodide DMOWFE5 TI TT1RS9F DMOWFE5 TN Acetylcholinesterase (AChE) DMOWFE5 MA Inhibitor DMOWFE5 RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMOWFE5 RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMOWGT3 DI DMOWGT3 DMOWGT3 DN (E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid DMOWGT3 TI TTT02K8 DMOWGT3 TN Steroid 5-alpha-reductase 2 (SRD5A2) DMOWGT3 MA Inhibitor DMOWGT3 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMOWGT3 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMOWGT3 DI DMOWGT3 DMOWGT3 DN (E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid DMOWGT3 TI TTTU72V DMOWGT3 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMOWGT3 MA Inhibitor DMOWGT3 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMOWGT3 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMOWHER DI DMOWHER DMOWHER DN TACRINE(8)-4-AMINOQUINOLINE DMOWHER TI TT1RS9F DMOWHER TN Acetylcholinesterase (AChE) DMOWHER MA Inhibitor DMOWHER RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMOWHER RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMOWMPL DI DMOWMPL DMOWMPL DN METHYLNORADRENALINE DMOWMPL TI TTWG9A4 DMOWMPL TN Adrenergic receptor alpha-2A (ADRA2A) DMOWMPL MA Inhibitor DMOWMPL RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMOWMPL RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMOWMPL DI DMOWMPL DMOWMPL DN METHYLNORADRENALINE DMOWMPL TI TTWM4TY DMOWMPL TN Adrenergic receptor alpha-2B (ADRA2B) DMOWMPL MA Inhibitor DMOWMPL RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMOWMPL RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMOWMPL DI DMOWMPL DMOWMPL DN METHYLNORADRENALINE DMOWMPL TI TT2NUT5 DMOWMPL TN Adrenergic receptor alpha-2C (ADRA2C) DMOWMPL MA Inhibitor DMOWMPL RN alpha 2 adrenoceptors: classification, localization, mechanisms, and targets for drugs. J Med Chem. 1982 Dec;25(12):1389-401. DMOWMPL RU https://pubmed.ncbi.nlm.nih.gov/6296387 DMOWNB4 DI DMOWNB4 DMOWNB4 DN 2,3-dihydroxypropanal DMOWNB4 TI TTFBNVI DMOWNB4 TN Aldose reductase (AKR1B1) DMOWNB4 MA Inhibitor DMOWNB4 RN Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20764-9. DMOWNB4 RU https://pubmed.ncbi.nlm.nih.gov/18087047 DMOWT4H DI DMOWT4H DMOWT4H DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Ala-Sar-) DMOWT4H TI TTBID49 DMOWT4H TN C-X-C chemokine receptor type 4 (CXCR4) DMOWT4H MA Inhibitor DMOWT4H RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMOWT4H RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMOWZUB DI DMOWZUB DMOWZUB DN MANGOSTANIN DMOWZUB TI TT50QJ3 DMOWZUB TN Influenza Neuraminidase (Influ NA) DMOWZUB MA Inhibitor DMOWZUB RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMOWZUB RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMOX1S0 DI DMOX1S0 DMOX1S0 DN WIN-35066-2 DMOX1S0 TI TT3ROYC DMOX1S0 TN Serotonin transporter (SERT) DMOX1S0 MA Inhibitor DMOX1S0 RN Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9. DMOX1S0 RU https://pubmed.ncbi.nlm.nih.gov/15566309 DMOX1S0 DI DMOX1S0 DMOX1S0 DN WIN-35066-2 DMOX1S0 TI TTVBI8W DMOX1S0 TN Dopamine transporter (DAT) DMOX1S0 MA Inhibitor DMOX1S0 RN Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9. DMOX1S0 RU https://pubmed.ncbi.nlm.nih.gov/15566309 DMOX1S0 DI DMOX1S0 DMOX1S0 DN WIN-35066-2 DMOX1S0 TI TTAWNKZ DMOX1S0 TN Norepinephrine transporter (NET) DMOX1S0 MA Inhibitor DMOX1S0 RN Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9. DMOX1S0 RU https://pubmed.ncbi.nlm.nih.gov/15566309 DMOX21P DI DMOX21P DMOX21P DN 9-hydrazino-1,2,3,4-tetrahydroacridine DMOX21P TI TT1RS9F DMOX21P TN Acetylcholinesterase (AChE) DMOX21P MA Inhibitor DMOX21P RN Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. J Med Chem. 2006 Dec 14;49(25):7540-4. DMOX21P RU https://pubmed.ncbi.nlm.nih.gov/17149883 DMOX3AH DI DMOX3AH DMOX3AH DN TGF alpha DMOX3AH TI TTGKNB4 DMOX3AH TN Epidermal growth factor receptor (EGFR) DMOX3AH MA Modulator DMOX3AH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMOX3AH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMOX40J DI DMOX40J DMOX40J DN 4-(2-(4-fluorophenyl)ethynyl)-2-methylthiazole DMOX40J TI TTHS256 DMOX40J TN Metabotropic glutamate receptor 5 (mGluR5) DMOX40J MA Inhibitor DMOX40J RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMOX40J RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMOX5MC DI DMOX5MC DMOX5MC DN 1-adamantan-1-yl-3-(6-hydroxyhexyl)urea DMOX5MC TI TT7WVHI DMOX5MC TN Soluble epoxide hydrolase (EPHX2) DMOX5MC MA Inhibitor DMOX5MC RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMOX5MC RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMOX7FJ DI DMOX7FJ DMOX7FJ DN ISIS 7453 DMOX7FJ TI TTM8FR7 DMOX7FJ TN KRAS messenger RNA (KRAS mRNA) DMOX7FJ RN US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides. DMOX7FJ RU http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true DMOX8FD DI DMOX8FD DMOX8FD DN KELATORPHAN DMOX8FD TI TTPHMWB DMOX8FD TN Aminopeptidase N (ANPEP) DMOX8FD MA Inhibitor DMOX8FD RN Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. J Med Chem. 1988 Sep;31(9):1825-31. DMOX8FD RU https://pubmed.ncbi.nlm.nih.gov/2900898 DMOX8FD DI DMOX8FD DMOX8FD DN KELATORPHAN DMOX8FD TI TT9PBIL DMOX8FD TN Glutamyl aminopeptidase (ENPEP) DMOX8FD MA Inhibitor DMOX8FD RN Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes. J Med Chem. 1988 Sep;31(9):1825-31. DMOX8FD RU https://pubmed.ncbi.nlm.nih.gov/2900898 DMOX8JE DI DMOX8JE DMOX8JE DN L-159093 DMOX8JE TI TT8DBY3 DMOX8JE TN Angiotensin II receptor type-1 (AGTR1) DMOX8JE MA Inhibitor DMOX8JE RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMOX8JE RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMOX8JE DI DMOX8JE DMOX8JE DN L-159093 DMOX8JE TI TTQVOEI DMOX8JE TN Angiotensin II receptor type-2 (AGTR2) DMOX8JE MA Inhibitor DMOX8JE RN A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor. J Med Chem. 1993 Oct 15;36(21):3207-10. DMOX8JE RU https://pubmed.ncbi.nlm.nih.gov/8230109 DMOX8JF DI DMOX8JF DMOX8JF DN ISIS 107652 DMOX8JF TI TT6SZNG DMOX8JF TN Caspase 8 messenger RNA (CASP8 mRNA) DMOX8JF RN US patent application no. 6,258,600, Antisense modulation of caspase 8 expression. DMOX8JF RU http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true DMOXBDT DI DMOXBDT DMOXBDT DN ISIS 7848 DMOXBDT TI TTAN5W2 DMOXBDT TN Raf messenger RNA (Raf mRNA) DMOXBDT RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMOXBDT RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMOXINT DI DMOXINT DMOXINT DN TI4 DMOXINT TI TTVDSZ0 DMOXINT TN Poly [ADP-ribose] polymerase 1 (PARP1) DMOXINT MA Inhibitor DMOXINT RN Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8. DMOXINT RU https://pubmed.ncbi.nlm.nih.gov/12855651 DMOXKLH DI DMOXKLH DMOXKLH DN 10-OBn-ginkgolide C DMOXKLH TI TTQL5VC DMOXKLH TN Platelet-activating factor receptor (PTAFR) DMOXKLH MA Antagonist DMOXKLH RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMOXKLH RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMOXLHT DI DMOXLHT DMOXLHT DN 1,2,4-Triazole-Carboxamidine DMOXLHT TI TTCM4B3 DMOXLHT TN Nitric-oxide synthase endothelial (NOS3) DMOXLHT MA Inhibitor DMOXLHT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOXLHT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOXNYQ DI DMOXNYQ DMOXNYQ DN Patuletin 3-O-beta-D-galactoside DMOXNYQ TI TTFBNVI DMOXNYQ TN Aldose reductase (AKR1B1) DMOXNYQ MA Inhibitor DMOXNYQ RN Flavonoids with anti-cataract activity from Brickellia arguta. J Nat Prod. 1984 Mar-Apr;47(2):316-9. DMOXNYQ RU https://pubmed.ncbi.nlm.nih.gov/6429283 DMOXQ3N DI DMOXQ3N DMOXQ3N DN N-Omega-Hydroxy-L-Arginine DMOXQ3N TI TTCM4B3 DMOXQ3N TN Nitric-oxide synthase endothelial (NOS3) DMOXQ3N MA Inhibitor DMOXQ3N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOXQ3N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOXQ3N DI DMOXQ3N DMOXQ3N DN N-Omega-Hydroxy-L-Arginine DMOXQ3N TI TTF10I9 DMOXQ3N TN Nitric-oxide synthase inducible (NOS2) DMOXQ3N MA Inhibitor DMOXQ3N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOXQ3N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOXQ3N DI DMOXQ3N DMOXQ3N DN N-Omega-Hydroxy-L-Arginine DMOXQ3N TI TTZUFI5 DMOXQ3N TN Nitric-oxide synthase brain (NOS1) DMOXQ3N MA Inhibitor DMOXQ3N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMOXQ3N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMOXR4K DI DMOXR4K DMOXR4K DN N-(3,3-Diphenyl-propyl)-isonicotinamide DMOXR4K TI TT7WVHI DMOXR4K TN Soluble epoxide hydrolase (EPHX2) DMOXR4K MA Inhibitor DMOXR4K RN Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95. DMOXR4K RU https://pubmed.ncbi.nlm.nih.gov/19746975 DMOXRID DI DMOXRID DMOXRID DN CHAP31 DMOXRID TI TTBH0VX DMOXRID TN Histone deacetylase (HDAC) DMOXRID MA Inhibitor DMOXRID RN Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92. DMOXRID RU https://pubmed.ncbi.nlm.nih.gov/17896917 DMOXY78 DI DMOXY78 DMOXY78 DN 3-bromo-5-[(2-methyl-4-thiazolyl)ethynyl]pyridine DMOXY78 TI TTHS256 DMOXY78 TN Metabotropic glutamate receptor 5 (mGluR5) DMOXY78 MA Inhibitor DMOXY78 RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMOXY78 RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMOY2AI DI DMOY2AI DMOY2AI DN HC-030031 DMOY2AI TI TT79AOF DMOY2AI TN Transient receptor potential channel (TRP channel) DMOY2AI MA Inhibitor DMOY2AI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4211). DMOY2AI RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=4211 DMOY627 DI DMOY627 DMOY627 DN P(1)-(6-Hydroxymethylpterin)-P(4)-(5'-adenosyl)tetraphosphate DMOY627 TI TT38ECI DMOY627 TN Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) DMOY627 MA Inhibitor DMOY627 RN Bisubstrate analogue inhibitors of 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase: synthesis and biochemical and crystallographic studies. J Med Chem. 2001 Apr 26;44(9):1364-71. DMOY627 RU https://pubmed.ncbi.nlm.nih.gov/11311059 DMOY7TF DI DMOY7TF DMOY7TF DN A-967079 DMOY7TF TI TTELV3W DMOY7TF TN Transformation-sensitive protein p120 (TRPA1) DMOY7TF MA Antagonist DMOY7TF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 485). DMOY7TF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=485 DMOY9J8 DI DMOY9J8 DMOY9J8 DN (-)-norfenfluramine DMOY9J8 TI TT0K1SC DMOY9J8 TN 5-HT 2B receptor (HTR2B) DMOY9J8 MA Agonist DMOY9J8 RN Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. DMOY9J8 RU https://pubmed.ncbi.nlm.nih.gov/11104741 DMOYADT DI DMOYADT DMOYADT DN AF150(S) DMOYADT TI TTZ9SOR DMOYADT TN Muscarinic acetylcholine receptor M1 (CHRM1) DMOYADT MA Agonist DMOYADT RN M1 muscarinic agonists target major hallmarks of Alzheimer's disease--an update. Curr Alzheimer Res. 2007 Dec;4(5):577-80. DMOYADT RU https://pubmed.ncbi.nlm.nih.gov/18220527 DMOYBFQ DI DMOYBFQ DMOYBFQ DN ISIS 341881 DMOYBFQ TI TTEWOHV DMOYBFQ TN Survivin messenger RNA (Survivin mRNA) DMOYBFQ RN US patent application no. 7,541,344, Modulation of survivin expression. DMOYBFQ RU http://www.patentbuddy.com/Patent/7541344?ft=true&sr=true DMOYC0U DI DMOYC0U DMOYC0U DN 18-Methylaminocoronaridine DMOYC0U TI TTTVAFQ DMOYC0U TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMOYC0U MA Inhibitor DMOYC0U RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DMOYC0U RU https://pubmed.ncbi.nlm.nih.gov/12801235 DMOYCBH DI DMOYCBH DMOYCBH DN 6-(furan-2-yl)-9H-purin-2-amine DMOYCBH TI TTM2AOE DMOYCBH TN Adenosine A2a receptor (ADORA2A) DMOYCBH MA Inhibitor DMOYCBH RN Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47. DMOYCBH RU https://pubmed.ncbi.nlm.nih.gov/19072055 DMOYCBH DI DMOYCBH DMOYCBH DN 6-(furan-2-yl)-9H-purin-2-amine DMOYCBH TI TTK25J1 DMOYCBH TN Adenosine A1 receptor (ADORA1) DMOYCBH MA Inhibitor DMOYCBH RN Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47. DMOYCBH RU https://pubmed.ncbi.nlm.nih.gov/19072055 DMOYCWU DI DMOYCWU DMOYCWU DN 2-bromo-LSD DMOYCWU TI TTO9X1H DMOYCWU TN 5-HT 7 receptor (HTR7) DMOYCWU MA Antagonist DMOYCWU RN Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. Mol Pharmacol. 1993 Aug;44(2):229-36. DMOYCWU RU https://pubmed.ncbi.nlm.nih.gov/8394987 DMOYCWU DI DMOYCWU DMOYCWU DN 2-bromo-LSD DMOYCWU TI TTJS8PY DMOYCWU TN 5-HT 6 receptor (HTR6) DMOYCWU MA Antagonist DMOYCWU RN Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7. DMOYCWU RU https://pubmed.ncbi.nlm.nih.gov/7680751 DMOYINM DI DMOYINM DMOYINM DN ISIS 188781 DMOYINM TI TTLRVIA DMOYINM TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DMOYINM RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DMOYINM RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DMOYL71 DI DMOYL71 DMOYL71 DN 6-Methoxy-3-thiophen-3-yl-quinoline DMOYL71 TI TTI7421 DMOYL71 TN Platelet-derived growth factor receptor beta (PDGFRB) DMOYL71 MA Inhibitor DMOYL71 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMOYL71 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMOYL71 DI DMOYL71 DMOYL71 DN 6-Methoxy-3-thiophen-3-yl-quinoline DMOYL71 TI TT8FYO9 DMOYL71 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMOYL71 MA Inhibitor DMOYL71 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMOYL71 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMOYQPM DI DMOYQPM DMOYQPM DN H-Gly-dmP-Glu-OH DMOYQPM TI TTN9D8E DMOYQPM TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMOYQPM MA Inhibitor DMOYQPM RN The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. DMOYQPM RU https://pubmed.ncbi.nlm.nih.gov/16650992 DMOYQPM DI DMOYQPM DMOYQPM DN H-Gly-dmP-Glu-OH DMOYQPM TI TTKJEMQ DMOYQPM TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMOYQPM MA Inhibitor DMOYQPM RN The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. DMOYQPM RU https://pubmed.ncbi.nlm.nih.gov/16650992 DMOYQPM DI DMOYQPM DMOYQPM DN H-Gly-dmP-Glu-OH DMOYQPM TI TTLD29N DMOYQPM TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMOYQPM MA Inhibitor DMOYQPM RN The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. DMOYQPM RU https://pubmed.ncbi.nlm.nih.gov/16650992 DMOYT8I DI DMOYT8I DMOYT8I DN 2-(4-(4-Hydroxyphenyl)thiazol-2-ylamino)phenol DMOYT8I TI TTWHDVK DMOYT8I TN Fructose-1,6-bisphosphatase (FBP) DMOYT8I MA Inhibitor DMOYT8I RN A library of novel allosteric inhibitors against fructose 1,6-bisphosphatase. Bioorg Med Chem. 2009 Jun 1;17(11):3916-22. DMOYT8I RU https://pubmed.ncbi.nlm.nih.gov/19419876 DMOZ1IY DI DMOZ1IY DMOZ1IY DN N2-[4-(benzyloxy)benzyl]glycinamide DMOZ1IY TI TTGP7BY DMOZ1IY TN Monoamine oxidase type B (MAO-B) DMOZ1IY MA Inhibitor DMOZ1IY RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMOZ1IY RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMOZ1IY DI DMOZ1IY DMOZ1IY DN N2-[4-(benzyloxy)benzyl]glycinamide DMOZ1IY TI TT3WG5C DMOZ1IY TN Monoamine oxidase type A (MAO-A) DMOZ1IY MA Inhibitor DMOZ1IY RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMOZ1IY RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMOZ73L DI DMOZ73L DMOZ73L DN [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine DMOZ73L TI TT6MSOK DMOZ73L TN 5-HT 1D receptor (HTR1D) DMOZ73L MA Inhibitor DMOZ73L RN 5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9. DMOZ73L RU https://pubmed.ncbi.nlm.nih.gov/10937729 DMOZ73L DI DMOZ73L DMOZ73L DN [2-(5-Ethyl-1H-indol-3-yl)-ethyl]-dimethyl-amine DMOZ73L TI TTK8CXU DMOZ73L TN 5-HT 1B receptor (HTR1B) DMOZ73L MA Inhibitor DMOZ73L RN 5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9. DMOZ73L RU https://pubmed.ncbi.nlm.nih.gov/10937729 DMOZ8E3 DI DMOZ8E3 DMOZ8E3 DN [11C]SB207145 DMOZ8E3 TI TT07C3Y DMOZ8E3 TN 5-HT 4 receptor (HTR4) DMOZ8E3 MA Antagonist DMOZ8E3 RN Mass dose effects and in vivo affinity in brain PET receptor studies--a study of cerebral 5-HT4 receptor binding with [11C]SB207145. Nucl Med Biol. 2011 Nov;38(8):1085-91. DMOZ8E3 RU https://pubmed.ncbi.nlm.nih.gov/21831646 DMOZ91H DI DMOZ91H DMOZ91H DN 1H-Indole-2,3-dione DMOZ91H TI TTGP7BY DMOZ91H TN Monoamine oxidase type B (MAO-B) DMOZ91H MA Inhibitor DMOZ91H RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMOZ91H RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMOZ9WC DI DMOZ9WC DMOZ9WC DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Ser13]SRIF DMOZ9WC TI TTIND6G DMOZ9WC TN Somatostatin receptor type 1 (SSTR1) DMOZ9WC MA Inhibitor DMOZ9WC RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMOZ9WC RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMOZAHB DI DMOZAHB DMOZAHB DN 3beta-acetoxyolean-12-en-27-oic acid DMOZAHB TI TTELIN2 DMOZAHB TN PTPN1 messenger RNA (PTPN1 mRNA) DMOZAHB MA Inhibitor DMOZAHB RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DMOZAHB RU https://pubmed.ncbi.nlm.nih.gov/16580200 DMOZAM6 DI DMOZAM6 DMOZAM6 DN 1-(4-Aminobenzyl)-1H-imidazole DMOZAM6 TI TTIQUX7 DMOZAM6 TN Steroid 11-beta-hydroxylase (CYP11B1) DMOZAM6 MA Inhibitor DMOZAM6 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMOZAM6 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMOZAQ6 DI DMOZAQ6 DMOZAQ6 DN ME36 DMOZAQ6 TI TT953CX DMOZAQ6 TN Motilin receptor (MLNR) DMOZAQ6 MA Agonist DMOZAQ6 RN Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. DMOZAQ6 RU https://pubmed.ncbi.nlm.nih.gov/15764739 DMOZARM DI DMOZARM DMOZARM DN N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide DMOZARM TI TT5ZKDI DMOZARM TN Histone deacetylase 6 (HDAC6) DMOZARM MA Inhibitor DMOZARM RN Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. DMOZARM RU https://pubmed.ncbi.nlm.nih.gov/19419863 DMOZARM DI DMOZARM DMOZARM DN N1-hydroxy-N8-(4-phenylthiazol-2-yl)octanediamide DMOZARM TI TT6R7JZ DMOZARM TN Histone deacetylase 1 (HDAC1) DMOZARM MA Inhibitor DMOZARM RN Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. DMOZARM RU https://pubmed.ncbi.nlm.nih.gov/19419863 DMOZATX DI DMOZATX DMOZATX DN WO2012007375C1 DMOZATX TI TTXAJWN DMOZATX TN IL-1 receptor-associated kinase 1 (IRAK1) DMOZATX MA Inhibitor DMOZATX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2042). DMOZATX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2042 DMOZATX DI DMOZATX DMOZATX DN WO2012007375C1 DMOZATX TI TTKFVXR DMOZATX TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMOZATX MA Inhibitor DMOZATX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045). DMOZATX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045 DMOZCDK DI DMOZCDK DMOZCDK DN 3,4-dichloroisocoumarin DMOZCDK TI TTPLTSQ DMOZCDK TN Neutrophil elastase (NE) DMOZCDK MA Inhibitor DMOZCDK RN Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and G... Antimicrob Agents Chemother. 2007 Feb;51(2):543-50. DMOZCDK RU https://pubmed.ncbi.nlm.nih.gov/17145787 DMOZEKQ DI DMOZEKQ DMOZEKQ DN 2,7-Bis[3-(piperazino)propionamido]anthraquinone DMOZEKQ TI TTQY2EJ DMOZEKQ TN TERT messenger RNA (TERT mRNA) DMOZEKQ MA Inhibitor DMOZEKQ RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMOZEKQ RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMOZEKU DI DMOZEKU DMOZEKU DN 1,3,8-Trimethyl-3,7-dihydro-purine-2,6-dione DMOZEKU TI TTM2AOE DMOZEKU TN Adenosine A2a receptor (ADORA2A) DMOZEKU MA Inhibitor DMOZEKU RN 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors. J Med Chem. 1985 Apr;28(4):487-92. DMOZEKU RU https://pubmed.ncbi.nlm.nih.gov/2984420 DMOZEW9 DI DMOZEW9 DMOZEW9 DN PD-0173955 DMOZEW9 TI TT8FYO9 DMOZEW9 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMOZEW9 MA Inhibitor DMOZEW9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMOZEW9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMOZEW9 DI DMOZEW9 DMOZEW9 DN PD-0173955 DMOZEW9 TI TT860QF DMOZEW9 TN LCK tyrosine protein kinase (LCK) DMOZEW9 MA Inhibitor DMOZEW9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMOZEW9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMOZEW9 DI DMOZEW9 DMOZEW9 DN PD-0173955 DMOZEW9 TI TT6PKBN DMOZEW9 TN Proto-oncogene c-Src (SRC) DMOZEW9 MA Inhibitor DMOZEW9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMOZEW9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMOZEW9 DI DMOZEW9 DMOZEW9 DN PD-0173955 DMOZEW9 TI TTS7G69 DMOZEW9 TN Fusion protein Bcr-Abl (Bcr-Abl) DMOZEW9 MA Inhibitor DMOZEW9 RN Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and hom... J Med Chem. 2006 Sep 21;49(19):5759-68. DMOZEW9 RU https://pubmed.ncbi.nlm.nih.gov/16970400 DMOZEW9 DI DMOZEW9 DMOZEW9 DN PD-0173955 DMOZEW9 TI TTRLW2X DMOZEW9 TN Fibroblast growth factor receptor 1 (FGFR1) DMOZEW9 MA Inhibitor DMOZEW9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMOZEW9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMOZEW9 DI DMOZEW9 DMOZEW9 DN PD-0173955 DMOZEW9 TI TTI7421 DMOZEW9 TN Platelet-derived growth factor receptor beta (PDGFRB) DMOZEW9 MA Inhibitor DMOZEW9 RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMOZEW9 RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMOZFU5 DI DMOZFU5 DMOZFU5 DN 6-(4-chlorophenylamino)-N,N-diethylnicotinamide DMOZFU5 TI TTHS256 DMOZFU5 TN Metabotropic glutamate receptor 5 (mGluR5) DMOZFU5 MA Inhibitor DMOZFU5 RN Piperidyl amides as novel, potent and orally active mGlu5 receptor antagonists with anxiolytic-like activity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):184-8. DMOZFU5 RU https://pubmed.ncbi.nlm.nih.gov/19931453 DMOZG0A DI DMOZG0A DMOZG0A DN PMID22533316C3 DMOZG0A TI TT7O8ZA DMOZG0A TN Lanosterol synthase (LSS) DMOZG0A MA Inhibitor DMOZG0A RN Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002. DMOZG0A RU https://pubmed.ncbi.nlm.nih.gov/22533316 DMOZGLM DI DMOZGLM DMOZGLM DN [123I]iodobenzovesamicol DMOZGLM TI TTV8KWS DMOZGLM TN Vesicular acetylcholine transporter (SLC18A3) DMOZGLM MA Modulator DMOZGLM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1013). DMOZGLM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1013 DMOZJA5 DI DMOZJA5 DMOZJA5 DN (+)-norfenfluramine DMOZJA5 TI TT0K1SC DMOZJA5 TN 5-HT 2B receptor (HTR2B) DMOZJA5 MA Agonist DMOZJA5 RN Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000 Dec 5;102(23):2836-41. DMOZJA5 RU https://pubmed.ncbi.nlm.nih.gov/11104741 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTTIBVP DMOZV7N TN Inward rectifier potassium channel Kir3.2 (KCNJ6) DMOZV7N MA Activator DMOZV7N RN Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature. 1998 Feb 19;391(6669):803-6. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/9486652 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTGM19J DMOZV7N TN Inward rectifier potassium channel Kir3.1 (KCNJ3) DMOZV7N MA Activator DMOZV7N RN Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by Gbetagamma. Nature. 1998 Feb 19;391(6669):803-6. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/9486652 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TT4VHL6 DMOZV7N TN Inward rectifier potassium channel Kir3.3 (KCNJ9) DMOZV7N MA Activator DMOZV7N RN Regulation of cardiac Na+,Ca2+ exchange and KATP potassium channels by PIP2. Science. 1996 Aug 16;273(5277):956-9. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/8688080 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TT8HGRW DMOZV7N TN Voltage-gated potassium channel Kv7.4 (KCNQ4) DMOZV7N MA Activator DMOZV7N RN Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/16251430 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTFPVZO DMOZV7N TN Long transient receptor potential channel 7 (TRPM7) DMOZV7N MA Activator DMOZV7N RN The TRPM7 channel is inactivated by PIP(2) hydrolysis. Nat Cell Biol. 2002 May;4(5):329-36. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/11941371 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TT5HWAT DMOZV7N TN IP3 receptor isoform 1 (ITPR1) DMOZV7N MA Antagonist DMOZV7N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 743). DMOZV7N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=743 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTRLMKF DMOZV7N TN Phospholipase D2 (PLD2) DMOZV7N MA Activator DMOZV7N RN Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2. J Biol Chem. 1998 May 22;273(21):12846-52. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/9582313 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTH7UO3 DMOZV7N TN Inward rectifier potassium channel Kir2.1 (KCNJ2) DMOZV7N MA Activator DMOZV7N RN Multiple PIP2 binding sites in Kir2.1 inwardly rectifying potassium channels. FEBS Lett. 2001 Feb 9;490(1-2):49-53. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/11172809 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTEO25X DMOZV7N TN Inward rectifier potassium channel Kir3.4 (KCNJ5) DMOZV7N MA Activator DMOZV7N RN PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science. 1998 Nov 6;282(5391):1141-4. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/9804555 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TT9EUT4 DMOZV7N TN Hyperpolarization cyclic nucleotide-gated channel 2 (HCN2) DMOZV7N MA Activator DMOZV7N RN Regulation of gating and rundown of HCN hyperpolarization-activated channels by exogenous and endogenous PIP2. J Gen Physiol. 2006 Nov;128(5):593-604. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/17074978 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTJ2HKA DMOZV7N TN Long transient receptor potential channel 4 (TRPM4) DMOZV7N MA Activator DMOZV7N RN Phosphatidylinositol 4,5-bisphosphate rescues TRPM4 channels from desensitization. J Biol Chem. 2005 Nov 25;280(47):39185-92. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/16186107 DMOZV7N DI DMOZV7N DMOZV7N DN PIP2 DMOZV7N TI TTPXI3S DMOZV7N TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DMOZV7N MA Activator DMOZV7N RN Regulation of Kv7 (KCNQ) K+ channel open probability by phosphatidylinositol 4,5-bisphosphate. J Neurosci. 2005 Oct 26;25(43):9825-35. DMOZV7N RU https://pubmed.ncbi.nlm.nih.gov/16251430 DMOZV9W DI DMOZV9W DMOZV9W DN 7-(1H-indol-5-yloxy)-N-hydroxyheptanamide DMOZV9W TI TT6R7JZ DMOZV9W TN Histone deacetylase 1 (HDAC1) DMOZV9W MA Inhibitor DMOZV9W RN Structure-activity relationships of aryloxyalkanoic acid hydroxyamides as potent inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2007 Jan 1;17(1):136-41. DMOZV9W RU https://pubmed.ncbi.nlm.nih.gov/17046252 DMOZX0D DI DMOZX0D DMOZX0D DN SB-0304 DMOZX0D TI TT27RFC DMOZX0D TN Opioid receptor delta (OPRD1) DMOZX0D MA Inhibitor DMOZX0D RN Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4. DMOZX0D RU https://pubmed.ncbi.nlm.nih.gov/18370374 DMOZX0D DI DMOZX0D DMOZX0D DN SB-0304 DMOZX0D TI TTKWM86 DMOZX0D TN Opioid receptor mu (MOP) DMOZX0D MA Inhibitor DMOZX0D RN Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4. DMOZX0D RU https://pubmed.ncbi.nlm.nih.gov/18370374 DMOZX8M DI DMOZX8M DMOZX8M DN Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys) DMOZX8M TI TT3ZTGU DMOZX8M TN Endothelin B receptor (EDNRB) DMOZX8M MA Inhibitor DMOZX8M RN Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994). DMOZX8M RU http://www.sciencedirect.com/science/article/pii/S0960894X01801566 DMOZX8M DI DMOZX8M DMOZX8M DN Trp-Ile-Ile-Asp-Leu-Hisc(Cys-Val-Tyr-Phe-Cys) DMOZX8M TI TTKRD0G DMOZX8M TN Endothelin A receptor (EDNRA) DMOZX8M MA Inhibitor DMOZX8M RN Structure-activity relationships in a series of monocyclic endothelin analogues, Bioorg. Med. Chem. Lett. 4(4):567-572 (1994). DMOZX8M RU http://www.sciencedirect.com/science/article/pii/S0960894X01801566 DMP0627 DI DMP0627 DMP0627 DN (D)Arg-Arg-Pro-Hyp-Gly-Thi-Ser-(D)Tic-Tic-Arg DMP0627 TI TTGY8IW DMP0627 TN B2 bradykinin receptor (BDKRB2) DMP0627 MA Inhibitor DMP0627 RN Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3. DMP0627 RU https://pubmed.ncbi.nlm.nih.gov/1848297 DMP06I3 DI DMP06I3 DMP06I3 DN Methyl 2-(7-phenylheptanoyl)oxazole-4-carboxylate DMP06I3 TI TTDP1UC DMP06I3 TN Fatty acid amide hydrolase (FAAH) DMP06I3 MA Inhibitor DMP06I3 RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMP06I3 RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMP089G DI DMP089G DMP089G DN ZK 756326 DMP089G TI TTE836A DMP089G TN C-C chemokine receptor type 8 (CCR8) DMP089G MA Agonist DMP089G RN Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol. 2006 Jan;69(1):309-16. DMP089G RU https://pubmed.ncbi.nlm.nih.gov/16221874 DMP08BY DI DMP08BY DMP08BY DN RGB-286147 DMP08BY TI TTQYF7G DMP08BY TN Cyclin-dependent kinase 7 (CDK7) DMP08BY MA Inhibitor DMP08BY RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMP08BY RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMP08BY DI DMP08BY DMP08BY DN RGB-286147 DMP08BY TI TTO0FDJ DMP08BY TN Cyclin-dependent kinase 6 (CDK6) DMP08BY MA Inhibitor DMP08BY RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMP08BY RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMP08BY DI DMP08BY DMP08BY DN RGB-286147 DMP08BY TI TTRSMW9 DMP08BY TN Glycogen synthase kinase-3 beta (GSK-3B) DMP08BY MA Inhibitor DMP08BY RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMP08BY RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMP08QO DI DMP08QO DMP08QO DN LUF-5767 DMP08QO TI TTJFY5U DMP08QO TN Adenosine A3 receptor (ADORA3) DMP08QO MA Inhibitor DMP08QO RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMP08QO RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMP08QO DI DMP08QO DMP08QO DN LUF-5767 DMP08QO TI TTK25J1 DMP08QO TN Adenosine A1 receptor (ADORA1) DMP08QO MA Inhibitor DMP08QO RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMP08QO RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMP08QO DI DMP08QO DMP08QO DN LUF-5767 DMP08QO TI TTM2AOE DMP08QO TN Adenosine A2a receptor (ADORA2A) DMP08QO MA Inhibitor DMP08QO RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMP08QO RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMP0A17 DI DMP0A17 DMP0A17 DN AS16 DMP0A17 TI TTNE7KG DMP0A17 TN Adenosine A2b receptor (ADORA2B) DMP0A17 MA Antagonist DMP0A17 RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DMP0A17 RU https://pubmed.ncbi.nlm.nih.gov/16219300 DMP0C7B DI DMP0C7B DMP0C7B DN CCNCSSKWCRDHARCC DMP0C7B TI TT84DRB DMP0C7B TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMP0C7B MA Inhibitor DMP0C7B RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DMP0C7B RU https://pubmed.ncbi.nlm.nih.gov/17724025 DMP0CRD DI DMP0CRD DMP0CRD DN H-Tyr-Pro-Ala-Phe-NH2 DMP0CRD TI TTKWM86 DMP0CRD TN Opioid receptor mu (MOP) DMP0CRD MA Inhibitor DMP0CRD RN Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. DMP0CRD RU https://pubmed.ncbi.nlm.nih.gov/18329886 DMP0CRD DI DMP0CRD DMP0CRD DN H-Tyr-Pro-Ala-Phe-NH2 DMP0CRD TI TTZPO1L DMP0CRD TN Substance-P receptor (TACR1) DMP0CRD MA Inhibitor DMP0CRD RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMP0CRD RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMP0DQE DI DMP0DQE DMP0DQE DN 3-(3-hydroxyphenyl)quinolin-7-ol DMP0DQE TI TTIWB6L DMP0DQE TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMP0DQE MA Inhibitor DMP0DQE RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DMP0DQE RU https://pubmed.ncbi.nlm.nih.gov/18324762 DMP0G1W DI DMP0G1W DMP0G1W DN 4-(4-benzenesulfonamidophenyl)piperazine DMP0G1W TI TTJS8PY DMP0G1W TN 5-HT 6 receptor (HTR6) DMP0G1W MA Inhibitor DMP0G1W RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMP0G1W RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMP0GA6 DI DMP0GA6 DMP0GA6 DN RO-5212651 DMP0GA6 TI TT7QNVC DMP0GA6 TN Glucose-dependent insulinotropic receptor (GPR119) DMP0GA6 MA Agonist DMP0GA6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DMP0GA6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DMP0GI8 DI DMP0GI8 DMP0GI8 DN 2-(4-aminophenoxy)-5-hexylphenol DMP0GI8 TI TTVTX4N DMP0GI8 TN Bacterial Fatty acid synthetase I (Bact inhA) DMP0GI8 MA Inhibitor DMP0GI8 RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMP0GI8 RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMP0N4U DI DMP0N4U DMP0N4U DN PD173074 DMP0N4U TI TT6PKBN DMP0N4U TN Proto-oncogene c-Src (SRC) DMP0N4U MA Inhibitor DMP0N4U RN Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs. 1999;17(2):121-35. DMP0N4U RU https://pubmed.ncbi.nlm.nih.gov/10638483 DMP0N4U DI DMP0N4U DMP0N4U DN PD173074 DMP0N4U TI TT0LF7H DMP0N4U TN Fibroblast growth factor receptor (FGFR) DMP0N4U MA Antagonist DMP0N4U RN Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. DMP0N4U RU https://pubmed.ncbi.nlm.nih.gov/11576867 DMP0N4U DI DMP0N4U DMP0N4U DN PD173074 DMP0N4U TI TTFPD8J DMP0N4U TN Fusion protein FGFR3-TACC3 (FGFR3-TACC3) DMP0N4U MA Inhibitor DMP0N4U RN Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.Cancer Biol Ther. 2014;15(12):1613-21. DMP0N4U RU https://pubmed.ncbi.nlm.nih.gov/25535896 DMP0NW3 DI DMP0NW3 DMP0NW3 DN 2-phenyl-N-(thiazol-2-yl)acetamide DMP0NW3 TI TTSJ6Q4 DMP0NW3 TN LOX-5 messenger RNA (ALOX5 mRNA) DMP0NW3 MA Inhibitor DMP0NW3 RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMP0NW3 RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMP0RYB DI DMP0RYB DMP0RYB DN 3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione DMP0RYB TI TTYPXQF DMP0RYB TN Protein kinase C beta (PRKCB) DMP0RYB MA Inhibitor DMP0RYB RN Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4. DMP0RYB RU https://pubmed.ncbi.nlm.nih.gov/15380221 DMP0RYB DI DMP0RYB DMP0RYB DN 3-(1H-Indol-3-yl)-4-phenylamino-pyrrole-2,5-dione DMP0RYB TI TTFJ8Q1 DMP0RYB TN Protein kinase C alpha (PRKCA) DMP0RYB MA Inhibitor DMP0RYB RN Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4. DMP0RYB RU https://pubmed.ncbi.nlm.nih.gov/15380221 DMP13VE DI DMP13VE DMP13VE DN ML9 DMP13VE TI TTRBT3W DMP13VE TN Short transient receptor potential channel 6 (TRPC6) DMP13VE MA Blocker (channel blocker) DMP13VE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 491). DMP13VE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=491 DMP168O DI DMP168O DMP168O DN 19alpha,24-dihydroxyurs-12-en-3-on-28-oic acid DMP168O TI TTELIN2 DMP168O TN PTPN1 messenger RNA (PTPN1 mRNA) DMP168O MA Inhibitor DMP168O RN Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8. DMP168O RU https://pubmed.ncbi.nlm.nih.gov/18798681 DMP1A3C DI DMP1A3C DMP1A3C DN KKHT-20818 DMP1A3C TI TT729IR DMP1A3C TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMP1A3C MA Inhibitor DMP1A3C RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DMP1A3C RU https://pubmed.ncbi.nlm.nih.gov/17035033 DMP1B9D DI DMP1B9D DMP1B9D DN JMV 1535 DMP1B9D TI TTC1MVT DMP1B9D TN Gastrin-releasing peptide receptor (GRPR) DMP1B9D MA Inhibitor DMP1B9D RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DMP1B9D RU https://pubmed.ncbi.nlm.nih.gov/10882361 DMP1D5Q DI DMP1D5Q DMP1D5Q DN Cudraxanthone L DMP1D5Q TI TT50QJ3 DMP1D5Q TN Influenza Neuraminidase (Influ NA) DMP1D5Q MA Inhibitor DMP1D5Q RN Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. DMP1D5Q RU https://pubmed.ncbi.nlm.nih.gov/19285413 DMP1D7Q DI DMP1D7Q DMP1D7Q DN [D-Gln3,D-Ncy(isopropyl)7]acyline DMP1D7Q TI TT8R70G DMP1D7Q TN Gonadotropin-releasing hormone receptor (GNRHR) DMP1D7Q MA Inhibitor DMP1D7Q RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMP1D7Q RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMP1DO4 DI DMP1DO4 DMP1DO4 DN GR100679 DMP1DO4 TI TTYO0A3 DMP1DO4 TN Substance-K receptor (TACR2) DMP1DO4 MA Antagonist DMP1DO4 RN Characterisation, CNS distribution and function of NK2 receptors studied using potent NK2 receptor antagonists. Regul Pept. 1993 Jul 2;46(1-2):9-19. DMP1DO4 RU https://pubmed.ncbi.nlm.nih.gov/8210508 DMP1EF6 DI DMP1EF6 DMP1EF6 DN N-Methyl-ETAV DMP1EF6 TI TT9PB26 DMP1EF6 TN Presynaptic density protein 95 (DLG4) DMP1EF6 MA Inhibitor DMP1EF6 RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMP1EF6 RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMP1EWV DI DMP1EWV DMP1EWV DN AR-C126313 DMP1EWV TI TTOZHQC DMP1EWV TN P2Y purinoceptor 2 (P2RY2) DMP1EWV MA Antagonist DMP1EWV RN Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate. J Med Chem. 2007 Mar 22;50(6):1166-76. DMP1EWV RU https://pubmed.ncbi.nlm.nih.gov/17302398 DMP1GQB DI DMP1GQB DMP1GQB DN KMJ-372 DMP1GQB TI TTMI6F5 DMP1GQB TN Transient receptor potential cation channel V1 (TRPV1) DMP1GQB MA Antagonist DMP1GQB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DMP1GQB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DMP1ICB DI DMP1ICB DMP1ICB DN N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide DMP1ICB TI TTQBR95 DMP1ICB TN Stress-activated protein kinase 2a (p38 alpha) DMP1ICB MA Inhibitor DMP1ICB RN Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2560-3. DMP1ICB RU https://pubmed.ncbi.nlm.nih.gov/20346659 DMP1KZW DI DMP1KZW DMP1KZW DN 2-(2-adamantyl) piperidine DMP1KZW TI TTXT3PU DMP1KZW TN Influenza M2 protein (Influ M) DMP1KZW MA Inhibitor DMP1KZW RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMP1KZW RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMP1LY4 DI DMP1LY4 DMP1LY4 DN 4-(2-(3-tert-Butylphenylamino)ethyl)-1H-imidazole DMP1LY4 TI TT9JNIC DMP1LY4 TN Histamine H3 receptor (H3R) DMP1LY4 MA Inhibitor DMP1LY4 RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMP1LY4 RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMP1V8Y DI DMP1V8Y DMP1V8Y DN LA-480 DMP1V8Y TI TTNDSF4 DMP1V8Y TN Proto-oncogene c-Met (MET) DMP1V8Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMP1V8Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMP2016 DI DMP2016 DMP2016 DN TA1-RTA DMP2016 TI TT6EO5L DMP2016 TN Erbb2 tyrosine kinase receptor (HER2) DMP2016 MA Binder DMP2016 RN Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res.2000 Aug;6(8):3334-41. DMP2016 RU https://pubmed.ncbi.nlm.nih.gov/10955821 DMP204G DI DMP204G DMP204G DN Methylenedioxyamphetamine DMP204G TI TTAWNKZ DMP204G TN Norepinephrine transporter (NET) DMP204G MA Inhibitor DMP204G RN Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31. DMP204G RU https://pubmed.ncbi.nlm.nih.gov/20466553 DMP204G DI DMP204G DMP204G DN Methylenedioxyamphetamine DMP204G TI TT3ROYC DMP204G TN Serotonin transporter (SERT) DMP204G MA Inhibitor DMP204G RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMP204G RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMP204G DI DMP204G DMP204G DN Methylenedioxyamphetamine DMP204G TI TTVBI8W DMP204G TN Dopamine transporter (DAT) DMP204G MA Inhibitor DMP204G RN Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31. DMP204G RU https://pubmed.ncbi.nlm.nih.gov/20466553 DMP21ST DI DMP21ST DMP21ST DN BHF-177 DMP21ST TI TTDCVZW DMP21ST TN Gamma-aminobutyric acid B receptor (GABBR) DMP21ST MA Modulator DMP21ST RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241). DMP21ST RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=241 DMP21ZO DI DMP21ZO DMP21ZO DN Beta-(2-Naphthyl)-Alanine DMP21ZO TI TTJNTSI DMP21ZO TN Rotamase Pin1 (PIN1) DMP21ZO MA Inhibitor DMP21ZO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMP21ZO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMP21ZO DI DMP21ZO DMP21ZO DN Beta-(2-Naphthyl)-Alanine DMP21ZO TI TT6L509 DMP21ZO TN Coagulation factor IIa (F2) DMP21ZO MA Inhibitor DMP21ZO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMP21ZO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMP26K9 DI DMP26K9 DMP26K9 DN Alx 1393 DMP26K9 TI TTI0138 DMP26K9 TN Glycine transporter-2 (SLC6A5) DMP26K9 MA Inhibitor DMP26K9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 936). DMP26K9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=936 DMP2DMB DI DMP2DMB DMP2DMB DN RAP-310 DMP2DMB TI TTFZYTO DMP2DMB TN C-C chemokine receptor type 2 (CCR2) DMP2DMB MA Modulator DMP2DMB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59). DMP2DMB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59 DMP2E3I DI DMP2E3I DMP2E3I DN KNI-10266 DMP2E3I TI TTXMNHO DMP2E3I TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMP2E3I MA Inhibitor DMP2E3I RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMP2E3I RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMP2EDX DI DMP2EDX DMP2EDX DN RP-1040 DMP2EDX TI TTNDSF4 DMP2EDX TN Proto-oncogene c-Met (MET) DMP2EDX MA Inhibitor DMP2EDX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMP2EDX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMP2G5W DI DMP2G5W DMP2G5W DN (3-amino-5-bromobenzofuran-2-yl)(phenyl)methanone DMP2G5W TI TTM2AOE DMP2G5W TN Adenosine A2a receptor (ADORA2A) DMP2G5W MA Inhibitor DMP2G5W RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DMP2G5W RU https://pubmed.ncbi.nlm.nih.gov/20095623 DMP2GN7 DI DMP2GN7 DMP2GN7 DN 4-aminobenzoic acid hydrazide DMP2GN7 TI TTVCZPI DMP2GN7 TN Myeloperoxidase (MPO) DMP2GN7 MA Inhibitor DMP2GN7 RN Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010 Nov;335(2):389-400. DMP2GN7 RU https://pubmed.ncbi.nlm.nih.gov/20699435 DMP2K1A DI DMP2K1A DMP2K1A DN 3-Amino-5,6-dihydro-2H-benzo[f]quinazolin-1-one DMP2K1A TI TTU6BFZ DMP2K1A TN Candida Thymidylate synthase (Candi TMP1) DMP2K1A MA Inhibitor DMP2K1A RN Benzoquinazoline inhibitors of thymidylate synthase: enzyme inhibitory activity and cytotoxicity of some sulfonamidobenzoylglutamate and related de... J Med Chem. 1993 Oct 29;36(22):3464-71. DMP2K1A RU https://pubmed.ncbi.nlm.nih.gov/8230138 DMP2QF0 DI DMP2QF0 DMP2QF0 DN EPO peptide mimetics DMP2QF0 TI TTAUX24 DMP2QF0 TN Erythropoietin Receptor (EPOR) DMP2QF0 MA Modulator DMP2QF0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DMP2QF0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DMP35OM DI DMP35OM DMP35OM DN CIFEA DMP35OM TI TT0WAIE DMP35OM TN Melatonin receptor type 1A (MTNR1A) DMP35OM MA Agonist DMP35OM RN 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT selective agonists. J Med Chem. 2011 May 12;54(9):3436-44. DMP35OM RU https://pubmed.ncbi.nlm.nih.gov/21473625 DMP35VS DI DMP35VS DMP35VS DN SGC0946 DMP35VS TI TTSZ8T1 DMP35VS TN Histone-lysine N-methyltransferase (HLNM) DMP35VS MA Inhibitor DMP35VS RN Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun. 2012;3:1288. DMP35VS RU https://pubmed.ncbi.nlm.nih.gov/23250418 DMP3BZH DI DMP3BZH DMP3BZH DN Fusion peptide EK1 DMP3BZH TI TT854FJ DMP3BZH TN MERS-CoV spike glycoprotein S2' HR1 region (S S2'HR1) DMP3BZH MA Inhibitor DMP3BZH RN A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 Apr 10;5(4):eaav4580. DMP3BZH RU https://pubmed.ncbi.nlm.nih.gov/30989115 DMP3BZH DI DMP3BZH DMP3BZH DN Fusion peptide EK1 DMP3BZH TI TTXMITO DMP3BZH TN SARS-CoV spike glycoprotein S2' HR1 region (S S2'HR1) DMP3BZH MA Inhibitor DMP3BZH RN A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 Apr 10;5(4):eaav4580. DMP3BZH RU https://pubmed.ncbi.nlm.nih.gov/30989115 DMP3EXG DI DMP3EXG DMP3EXG DN SDZ-205-557 DMP3EXG TI TT07C3Y DMP3EXG TN 5-HT 4 receptor (HTR4) DMP3EXG MA Modulator DMP3EXG RN SDZ 205-557, a selective antagonist at 5-HT4 receptors in the isolated guinea pig ileum. Eur J Pharmacol. 1991 Aug 6;200(2-3):373-4. DMP3EXG RU https://www.ncbi.nlm.nih.gov/pubmed/1782999 DMP3EZ8 DI DMP3EZ8 DMP3EZ8 DN 2,7-Bis(cyclopentanecarbonamido)anthraquinone DMP3EZ8 TI TTQY2EJ DMP3EZ8 TN TERT messenger RNA (TERT mRNA) DMP3EZ8 MA Inhibitor DMP3EZ8 RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMP3EZ8 RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMP3F0D DI DMP3F0D DMP3F0D DN Cis-1-adamantan-1-yl-3-(4-hydroxycyclohexyl)urea DMP3F0D TI TT7WVHI DMP3F0D TN Soluble epoxide hydrolase (EPHX2) DMP3F0D MA Inhibitor DMP3F0D RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DMP3F0D RU https://pubmed.ncbi.nlm.nih.gov/17616115 DMP3I6E DI DMP3I6E DMP3I6E DN [U-13C]ascomycin DMP3I6E TI TTQW87Y DMP3I6E TN Opioid receptor kappa (OPRK1) DMP3I6E MA Antagonist DMP3I6E RN NMR studies of an FK-506 analog, [U-13C]ascomycin, bound to FK-506-binding protein. J Med Chem. 1992 Jun 26;35(13):2467-73. DMP3I6E RU https://pubmed.ncbi.nlm.nih.gov/1377749 DMP3MDS DI DMP3MDS DMP3MDS DN CL82198 DMP3MDS TI TTHY57M DMP3MDS TN Matrix metalloproteinase-13 (MMP-13) DMP3MDS MA Inhibitor DMP3MDS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1637). DMP3MDS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1637 DMP3MOC DI DMP3MOC DMP3MOC DN Philanthotoxin-343 DMP3MOC TI TTVPQTF DMP3MOC TN Glutamate receptor AMPA 1 (GRIA1) DMP3MOC MA Inhibitor DMP3MOC RN Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7. DMP3MOC RU https://pubmed.ncbi.nlm.nih.gov/20096591 DMP43HI DI DMP43HI DMP43HI DN 4-(n-propyl)amino-3-nitrobenzoic acid DMP43HI TI TT8WFXV DMP43HI TN Hydroxycarboxylic acid receptor 3 (HCAR3) DMP43HI MA Agonist DMP43HI RN 3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6619-22. DMP43HI RU https://pubmed.ncbi.nlm.nih.gov/17931863 DMP4DLV DI DMP4DLV DMP4DLV DN 1,2,3,4-Tetrahydro-naphthalen-2-ylamine DMP4DLV TI TTJQOD7 DMP4DLV TN 5-HT 2A receptor (HTR2A) DMP4DLV MA Inhibitor DMP4DLV RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMP4DLV RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMP4DLV DI DMP4DLV DMP4DLV DN 1,2,3,4-Tetrahydro-naphthalen-2-ylamine DMP4DLV TI TTSQIFT DMP4DLV TN 5-HT 1A receptor (HTR1A) DMP4DLV MA Inhibitor DMP4DLV RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMP4DLV RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMP4DLV DI DMP4DLV DMP4DLV DN 1,2,3,4-Tetrahydro-naphthalen-2-ylamine DMP4DLV TI TT6MSOK DMP4DLV TN 5-HT 1D receptor (HTR1D) DMP4DLV MA Inhibitor DMP4DLV RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMP4DLV RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMP4HR2 DI DMP4HR2 DMP4HR2 DN TG003 DMP4HR2 TI TT85TPS DMP4HR2 TN CDC-like kinase 2 (CLK2) DMP4HR2 MA Inhibitor DMP4HR2 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMP4HR2 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMP4HR2 DI DMP4HR2 DMP4HR2 DN TG003 DMP4HR2 TI TTE6YDG DMP4HR2 TN CDC-like kinase 1 (CLK1) DMP4HR2 MA Inhibitor DMP4HR2 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMP4HR2 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMP4HR2 DI DMP4HR2 DMP4HR2 DN TG003 DMP4HR2 TI TTSBVFO DMP4HR2 TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMP4HR2 MA Inhibitor DMP4HR2 RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMP4HR2 RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMP4IJ6 DI DMP4IJ6 DMP4IJ6 DN SN429 DMP4IJ6 TI TTCIHJA DMP4IJ6 TN Coagulation factor Xa (F10) DMP4IJ6 MA Inhibitor DMP4IJ6 RN Pharmacological intervention at disparate sites in the coagulation cascade: comparison of anti-thrombotic efficacy vs bleeding propensity in a rat model of acute arterial thrombosis. J Thromb Thrombolysis. 2002 Oct;14(2):113-21. DMP4IJ6 RU https://pubmed.ncbi.nlm.nih.gov/12714830 DMP4NHD DI DMP4NHD DMP4NHD DN 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile DMP4NHD TI TTNE7KG DMP4NHD TN Adenosine A2b receptor (ADORA2B) DMP4NHD MA Inhibitor DMP4NHD RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMP4NHD RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMP4NHD DI DMP4NHD DMP4NHD DN 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile DMP4NHD TI TTM2AOE DMP4NHD TN Adenosine A2a receptor (ADORA2A) DMP4NHD MA Inhibitor DMP4NHD RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMP4NHD RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMP4NHD DI DMP4NHD DMP4NHD DN 2-Amino-4-furan-2-yl-6-phenyl-nicotinonitrile DMP4NHD TI TTK25J1 DMP4NHD TN Adenosine A1 receptor (ADORA1) DMP4NHD MA Inhibitor DMP4NHD RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMP4NHD RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMP4Q0J DI DMP4Q0J DMP4Q0J DN MK-2894 DMP4Q0J TI TT79WV3 DMP4Q0J TN Prostaglandin E2 receptor EP4 (PTGER4) DMP4Q0J MA Antagonist DMP4Q0J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). DMP4Q0J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343 DMP4QCJ DI DMP4QCJ DMP4QCJ DN L-671,480 DMP4QCJ TI TTDMBF5 DMP4QCJ TN Arachidonate 5-lipoxygenase activating protein (FLAP) DMP4QCJ MA Inhibitor DMP4QCJ RN 5-Lipoxygenase-activating protein is the target of a quinoline class of leukotriene synthesis inhibitors. Mol Pharmacol. 1991 Jul;40(1):22-7. DMP4QCJ RU https://pubmed.ncbi.nlm.nih.gov/1857337 DMP4RO3 DI DMP4RO3 DMP4RO3 DN 5-(phenylethynyl)pyrimidine DMP4RO3 TI TTHS256 DMP4RO3 TN Metabotropic glutamate receptor 5 (mGluR5) DMP4RO3 MA Inhibitor DMP4RO3 RN Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. DMP4RO3 RU https://pubmed.ncbi.nlm.nih.gov/18550372 DMP4T87 DI DMP4T87 DMP4T87 DN TRANSTORINE DMP4T87 TI TTLD29N DMP4T87 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMP4T87 MA Inhibitor DMP4T87 RN 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. DMP4T87 RU https://pubmed.ncbi.nlm.nih.gov/2146391 DMP4T87 DI DMP4T87 DMP4T87 DN TRANSTORINE DMP4T87 TI TTN9D8E DMP4T87 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMP4T87 MA Inhibitor DMP4T87 RN 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. DMP4T87 RU https://pubmed.ncbi.nlm.nih.gov/2146391 DMP4T87 DI DMP4T87 DMP4T87 DN TRANSTORINE DMP4T87 TI TTKJEMQ DMP4T87 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMP4T87 MA Inhibitor DMP4T87 RN 3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspart... J Med Chem. 1990 Nov;33(11):2944-6. DMP4T87 RU https://pubmed.ncbi.nlm.nih.gov/2146391 DMP4T9Z DI DMP4T9Z DMP4T9Z DN (E)-5-(3-Fluorostyryl)isatin DMP4T9Z TI TTGP7BY DMP4T9Z TN Monoamine oxidase type B (MAO-B) DMP4T9Z MA Inhibitor DMP4T9Z RN Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. DMP4T9Z RU https://pubmed.ncbi.nlm.nih.gov/19342233 DMP4T9Z DI DMP4T9Z DMP4T9Z DN (E)-5-(3-Fluorostyryl)isatin DMP4T9Z TI TT3WG5C DMP4T9Z TN Monoamine oxidase type A (MAO-A) DMP4T9Z MA Inhibitor DMP4T9Z RN Inhibition of monoamine oxidase by (E)-styrylisatin analogues. Bioorg Med Chem Lett. 2009 May 1;19(9):2509-13. DMP4T9Z RU https://pubmed.ncbi.nlm.nih.gov/19342233 DMP4UC1 DI DMP4UC1 DMP4UC1 DN (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine DMP4UC1 TI TTF10I9 DMP4UC1 TN Nitric-oxide synthase inducible (NOS2) DMP4UC1 MA Inhibitor DMP4UC1 RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMP4UC1 RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMP4UC1 DI DMP4UC1 DMP4UC1 DN (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine DMP4UC1 TI TTZUFI5 DMP4UC1 TN Nitric-oxide synthase brain (NOS1) DMP4UC1 MA Inhibitor DMP4UC1 RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMP4UC1 RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMP4UC1 DI DMP4UC1 DMP4UC1 DN (5S,6S)-[Octahydro-quinolin-(2E)-ylidene]amine DMP4UC1 TI TTCM4B3 DMP4UC1 TN Nitric-oxide synthase endothelial (NOS3) DMP4UC1 MA Inhibitor DMP4UC1 RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMP4UC1 RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMP4V8Y DI DMP4V8Y DMP4V8Y DN 6-chloro-5-hexylpyrimidine-2,4(1H,3H)-dione DMP4V8Y TI TTO0IB8 DMP4V8Y TN Thymidine phosphorylase (TYMP) DMP4V8Y MA Inhibitor DMP4V8Y RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DMP4V8Y RU https://pubmed.ncbi.nlm.nih.gov/17963370 DMP523A DI DMP523A DMP523A DN MCL-451 DMP523A TI TTQW87Y DMP523A TN Opioid receptor kappa (OPRK1) DMP523A MA Inhibitor DMP523A RN New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3. DMP523A RU https://pubmed.ncbi.nlm.nih.gov/16942040 DMP523A DI DMP523A DMP523A DN MCL-451 DMP523A TI TT27RFC DMP523A TN Opioid receptor delta (OPRD1) DMP523A MA Inhibitor DMP523A RN New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3. DMP523A RU https://pubmed.ncbi.nlm.nih.gov/16942040 DMP523A DI DMP523A DMP523A DN MCL-451 DMP523A TI TTKWM86 DMP523A TN Opioid receptor mu (MOP) DMP523A MA Inhibitor DMP523A RN New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3. DMP523A RU https://pubmed.ncbi.nlm.nih.gov/16942040 DMP543H DI DMP543H DMP543H DN INDOLACTUM DMP543H TI TT9WJ8U DMP543H TN Protein kinase C delta (PRKCD) DMP543H MA Inhibitor DMP543H RN Structural basis of RasGRP binding to high-affinity PKC ligands. J Med Chem. 2002 Feb 14;45(4):853-60. DMP543H RU https://pubmed.ncbi.nlm.nih.gov/11831896 DMP5A8K DI DMP5A8K DMP5A8K DN N-[5-(2-Ethyl-phenyl)-furan-2-carbonyl]-guanidine DMP5A8K TI TTGSEFH DMP5A8K TN Sodium/hydrogen exchanger 1 (SLC9A1) DMP5A8K MA Inhibitor DMP5A8K RN (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. DMP5A8K RU https://pubmed.ncbi.nlm.nih.gov/15828827 DMP5E1G DI DMP5E1G DMP5E1G DN N-phenyl-1H-pyrazole-3-carboxamide DMP5E1G TI TT7HF4W DMP5E1G TN Cyclin-dependent kinase 2 (CDK2) DMP5E1G MA Inhibitor DMP5E1G RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMP5E1G RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMP5I47 DI DMP5I47 DMP5I47 DN Dimethylallyl Diphosphate DMP5I47 TI TTIKWV4 DMP5I47 TN Geranyltranstransferase (FDPS) DMP5I47 MA Inhibitor DMP5I47 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMP5I47 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMP5JF8 DI DMP5JF8 DMP5JF8 DN 7-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole DMP5JF8 TI TTJQOD7 DMP5JF8 TN 5-HT 2A receptor (HTR2A) DMP5JF8 MA Inhibitor DMP5JF8 RN Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8. DMP5JF8 RU https://pubmed.ncbi.nlm.nih.gov/11755343 DMP5M9E DI DMP5M9E DMP5M9E DN 4,6-Dideoxyglucose DMP5M9E TI TTHCF4J DMP5M9E TN Alpha-glucosidase (GLA) DMP5M9E MA Inhibitor DMP5M9E RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMP5M9E RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMP5OSK DI DMP5OSK DMP5OSK DN CA-327 DMP5OSK TI TT8ZLTI DMP5OSK TN Programmed cell death 1 ligand 1 (PD-L1) DMP5OSK MA Inhibitor DMP5OSK RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMP5OSK RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMP5VN2 DI DMP5VN2 DMP5VN2 DN SPP-800 DMP5VN2 TI TTB2MXP DMP5VN2 TN Angiotensinogenase renin (REN) DMP5VN2 MA Inhibitor DMP5VN2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2413). DMP5VN2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2413 DMP5VZQ DI DMP5VZQ DMP5VZQ DN Anti-FGFR1 mab program DMP5VZQ TI TTRLW2X DMP5VZQ TN Fibroblast growth factor receptor 1 (FGFR1) DMP5VZQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). DMP5VZQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808 DMP5WNL DI DMP5WNL DMP5WNL DN Salvinorin B ethoxymethyl ether DMP5WNL TI TTQW87Y DMP5WNL TN Opioid receptor kappa (OPRK1) DMP5WNL MA Inhibitor DMP5WNL RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMP5WNL RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMP5YFQ DI DMP5YFQ DMP5YFQ DN 4-methoxyphenylboronic acid DMP5YFQ TI TTUNARX DMP5YFQ TN Carbonic anhydrase (CA) DMP5YFQ MA Inhibitor DMP5YFQ RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMP5YFQ RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMP5YFQ DI DMP5YFQ DMP5YFQ DN 4-methoxyphenylboronic acid DMP5YFQ TI TTDP1UC DMP5YFQ TN Fatty acid amide hydrolase (FAAH) DMP5YFQ MA Inhibitor DMP5YFQ RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMP5YFQ RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMP5YFQ DI DMP5YFQ DMP5YFQ DN 4-methoxyphenylboronic acid DMP5YFQ TI TTHQPL7 DMP5YFQ TN Carbonic anhydrase I (CA-I) DMP5YFQ MA Inhibitor DMP5YFQ RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMP5YFQ RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMP5YFQ DI DMP5YFQ DMP5YFQ DN 4-methoxyphenylboronic acid DMP5YFQ TI TTANPDJ DMP5YFQ TN Carbonic anhydrase II (CA-II) DMP5YFQ MA Inhibitor DMP5YFQ RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMP5YFQ RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMP60XE DI DMP60XE DMP60XE DN ISIS 133242 DMP60XE TI TTZN92A DMP60XE TN DUSP5 messenger RNA (DUSP5 mRNA) DMP60XE RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DMP60XE RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DMP64XH DI DMP64XH DMP64XH DN [Sar1,Bpa3]AngII DMP64XH TI TT8DBY3 DMP64XH TN Angiotensin II receptor type-1 (AGTR1) DMP64XH MA Inhibitor DMP64XH RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMP64XH RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMP65EI DI DMP65EI DMP65EI DN PD-149164 DMP65EI TI TTVFO0U DMP65EI TN Gastrin/cholecystokinin type B receptor (CCKBR) DMP65EI MA Antagonist DMP65EI RN Cholecystokinin B antagonists. Synthesis and quantitative structure-activity relationships of a series of C-terminal analogues of CI-988. Bioorg Med Chem. 1996 Oct;4(10):1733-45. DMP65EI RU https://pubmed.ncbi.nlm.nih.gov/8931944 DMP68CE DI DMP68CE DMP68CE DN 2-(N-Cyclopentylamino)-3'-chloropropiophenone DMP68CE TI TTAWNKZ DMP68CE TN Norepinephrine transporter (NET) DMP68CE MA Inhibitor DMP68CE RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMP68CE RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMP68CE DI DMP68CE DMP68CE DN 2-(N-Cyclopentylamino)-3'-chloropropiophenone DMP68CE TI TTVBI8W DMP68CE TN Dopamine transporter (DAT) DMP68CE MA Inhibitor DMP68CE RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMP68CE RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMP69QG DI DMP69QG DMP69QG DN [125I]LSD DMP69QG TI TTO9X1H DMP69QG TN 5-HT 7 receptor (HTR7) DMP69QG MA Agonist DMP69QG RN A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron. 1993 Sep;11(3):449-58. DMP69QG RU https://pubmed.ncbi.nlm.nih.gov/8398139 DMP69QG DI DMP69QG DMP69QG DN [125I]LSD DMP69QG TI TT9KJ1X DMP69QG TN 5-HT 5B receptor (HTR5B) DMP69QG MA Agonist DMP69QG RN Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization. Mol Pharmacol. 1993 Mar;43(3):313-9. DMP69QG RU https://pubmed.ncbi.nlm.nih.gov/8450829 DMP69QG DI DMP69QG DMP69QG DN [125I]LSD DMP69QG TI TT0MI3F DMP69QG TN 5-HT 1F receptor (HTR1F) DMP69QG MA Agonist DMP69QG RN Isolation of a mouse "5HT1E-like" serotonin receptor expressed predominantly in hippocampus. J Biol Chem. 1992 Oct 5;267(28):19761-4. DMP69QG RU https://pubmed.ncbi.nlm.nih.gov/1328180 DMP69QG DI DMP69QG DMP69QG DN [125I]LSD DMP69QG TI TTRUFDT DMP69QG TN 5-HT 5A receptor (HTR5A) DMP69QG MA Agonist DMP69QG RN Human 5-HT(5) receptors: the 5-HT(5A) receptor is functional but the 5-HT(5B) receptor was lost during mammalian evolution. Eur J Pharmacol. 2001 Apr 27;418(3):157-67. DMP69QG RU https://pubmed.ncbi.nlm.nih.gov/11343685 DMP6BSH DI DMP6BSH DMP6BSH DN Orotic acid DMP6BSH TI TT3PQ2Y DMP6BSH TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMP6BSH MA Inhibitor DMP6BSH RN Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16. DMP6BSH RU https://pubmed.ncbi.nlm.nih.gov/2847745 DMP6BU3 DI DMP6BU3 DMP6BU3 DN Ciclosporin DMP6BU3 TI TT95SAZ DMP6BU3 TN HUMAN cyclophilin D (CYP3) DMP6BU3 MA Inhibitor DMP6BU3 RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DMP6BU3 RU https://pubmed.ncbi.nlm.nih.gov/32127666 DMP6C4D DI DMP6C4D DMP6C4D DN JWH-364 DMP6C4D TI TTMSFAW DMP6C4D TN Cannabinoid receptor 2 (CB2) DMP6C4D MA Inhibitor DMP6C4D RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMP6C4D RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMP6C4D DI DMP6C4D DMP6C4D DN JWH-364 DMP6C4D TI TT6OEDT DMP6C4D TN Cannabinoid receptor 1 (CB1) DMP6C4D MA Inhibitor DMP6C4D RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMP6C4D RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMP6DBX DI DMP6DBX DMP6DBX DN GNF-PF-2307 DMP6DBX TI TT8DBY3 DMP6DBX TN Angiotensin II receptor type-1 (AGTR1) DMP6DBX MA Inhibitor DMP6DBX RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMP6DBX RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMP6E34 DI DMP6E34 DMP6E34 DN Isosorbide-2-benzylcarbamate-5-propionate DMP6E34 TI TTEB0GD DMP6E34 TN Cholinesterase (BCHE) DMP6E34 MA Inhibitor DMP6E34 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMP6E34 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMP6GNY DI DMP6GNY DMP6GNY DN Firocoxib DMP6GNY TI TTVKILB DMP6GNY TN Prostaglandin G/H synthase 2 (COX-2) DMP6GNY MA Inhibitor DMP6GNY RN SAR in the alkoxy lactone series: the discovery of DFP, a potent and orally active COX-2 inhibitor. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2207-12. DMP6GNY RU https://pubmed.ncbi.nlm.nih.gov/10465547 DMP6GXU DI DMP6GXU DMP6GXU DN Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid DMP6GXU TI TTHI19T DMP6GXU TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMP6GXU MA Inhibitor DMP6GXU RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMP6GXU RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMP6I98 DI DMP6I98 DMP6I98 DN CID16197121 DMP6I98 TI TT2AP5B DMP6I98 TN Ras converting CAAX endopeptidase 1 (RCE1) DMP6I98 MA Inhibitor DMP6I98 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2412). DMP6I98 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2412 DMP6IHR DI DMP6IHR DMP6IHR DN Diphenylacetic Acid DMP6IHR TI TTF2LRI DMP6IHR TN Cathepsin B (CTSB) DMP6IHR MA Inhibitor DMP6IHR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMP6IHR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMP6S0L DI DMP6S0L DMP6S0L DN KYS-05056 DMP6S0L TI TT729IR DMP6S0L TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMP6S0L MA Inhibitor DMP6S0L RN T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. DMP6S0L RU https://pubmed.ncbi.nlm.nih.gov/18585035 DMP6TLY DI DMP6TLY DMP6TLY DN 3-Carbamoyl-6-chloro-1H-indole-2-carboxylic acid DMP6TLY TI TTLD29N DMP6TLY TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMP6TLY MA Inhibitor DMP6TLY RN 2-carboxy indolines and indoles as potential glycine/NMDA antagonists: effect of five-membered ring conformation on affinity. Bioorg. Med. Chem. Lett. 2(12):1627-1630 (1992). DMP6TLY RU http://www.sciencedirect.com/science/article/pii/S0960894X00804448 DMP6U3L DI DMP6U3L DMP6U3L DN 5-hexyl-2-(pyridin-4-yloxy)phenol DMP6U3L TI TTVTX4N DMP6U3L TN Bacterial Fatty acid synthetase I (Bact inhA) DMP6U3L MA Inhibitor DMP6U3L RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMP6U3L RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMP6VOK DI DMP6VOK DMP6VOK DN 1-nitro-2-(2-nitrophenylsulfonyl)benzene DMP6VOK TI TT84ETX DMP6VOK TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMP6VOK MA Inhibitor DMP6VOK RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMP6VOK RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMP6WE0 DI DMP6WE0 DMP6WE0 DN ISIS 113907 DMP6WE0 TI TTIX0ZU DMP6WE0 TN MEKK2 messenger RNA (MAP3K2 mRNA) DMP6WE0 RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMP6WE0 RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMP6XL9 DI DMP6XL9 DMP6XL9 DN [3H](+)-cis-diltiazem DMP6XL9 TI TTZIFHC DMP6XL9 TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMP6XL9 MA Inhibitor (gating inhibitor) DMP6XL9 RN SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes. J Pharmacol Exp Ther. 1990 Nov;255(2):600-7. DMP6XL9 RU https://pubmed.ncbi.nlm.nih.gov/2147036 DMP6XL9 DI DMP6XL9 DMP6XL9 DN [3H](+)-cis-diltiazem DMP6XL9 TI TT94HRF DMP6XL9 TN Voltage-gated calcium channel alpha Cav1.1 (CACNA1S) DMP6XL9 MA Inhibitor (gating inhibitor) DMP6XL9 RN High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels. J Pharmacol Exp Ther. 1997 Apr;281(1):173-9. DMP6XL9 RU https://pubmed.ncbi.nlm.nih.gov/9103495 DMP6Z3R DI DMP6Z3R DMP6Z3R DN 8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine DMP6Z3R TI TTZ97H5 DMP6Z3R TN Phosphodiesterase 4A (PDE4A) DMP6Z3R MA Inhibitor DMP6Z3R RN Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phos... J Med Chem. 2000 Feb 24;43(4):675-82. DMP6Z3R RU https://pubmed.ncbi.nlm.nih.gov/10691693 DMP6Z3R DI DMP6Z3R DMP6Z3R DN 8-(3-Nitro-phenyl)-6-phenyl-[1,7]naphthyridine DMP6Z3R TI TTVIAT9 DMP6Z3R TN Phosphodiesterase 4B (PDE4B) DMP6Z3R MA Inhibitor DMP6Z3R RN Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phos... J Med Chem. 2000 Feb 24;43(4):675-82. DMP6Z3R RU https://pubmed.ncbi.nlm.nih.gov/10691693 DMP7246 DI DMP7246 DMP7246 DN N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine DMP7246 TI TTJFY5U DMP7246 TN Adenosine A3 receptor (ADORA3) DMP7246 MA Inhibitor DMP7246 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMP7246 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMP7246 DI DMP7246 DMP7246 DN N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine DMP7246 TI TTM2AOE DMP7246 TN Adenosine A2a receptor (ADORA2A) DMP7246 MA Inhibitor DMP7246 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMP7246 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMP7246 DI DMP7246 DMP7246 DN N6-methoxy-2-[(3-pyridinyl)ethynyl]-adenosine DMP7246 TI TTK25J1 DMP7246 TN Adenosine A1 receptor (ADORA1) DMP7246 MA Inhibitor DMP7246 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMP7246 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMP75YK DI DMP75YK DMP75YK DN L-741742 DMP75YK TI TTRK8B9 DMP75YK TN Sodium channel unspecific (NaC) DMP75YK MA Inhibitor DMP75YK RN 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) rece... J Med Chem. 1999 Jul 15;42(14):2706-15. DMP75YK RU https://pubmed.ncbi.nlm.nih.gov/10411491 DMP75YK DI DMP75YK DMP75YK DN L-741742 DMP75YK TI TT4C8EA DMP75YK TN Dopamine D3 receptor (D3R) DMP75YK MA Inhibitor DMP75YK RN 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5. DMP75YK RU https://pubmed.ncbi.nlm.nih.gov/8642551 DMP75YK DI DMP75YK DMP75YK DN L-741742 DMP75YK TI TTAXZ0K DMP75YK TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMP75YK MA Inhibitor DMP75YK RN 1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1, 3-dihydroimidazol-2-one: a selective high-affinity antagonist for the human dopamine D(4) rece... J Med Chem. 1999 Jul 15;42(14):2706-15. DMP75YK RU https://pubmed.ncbi.nlm.nih.gov/10411491 DMP75YK DI DMP75YK DMP75YK DN L-741742 DMP75YK TI TTE0A2F DMP75YK TN Dopamine D4 receptor (D4R) DMP75YK MA Inhibitor DMP75YK RN 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5. DMP75YK RU https://pubmed.ncbi.nlm.nih.gov/8642551 DMP761U DI DMP761U DMP761U DN WRR-112 DMP761U TI TTEAID7 DMP761U TN Trypanosoma Cruzipain (Trypano CYSP) DMP761U MA Inhibitor DMP761U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMP761U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMP761U DI DMP761U DMP761U DN WRR-112 DMP761U TI TTJOKD1 DMP761U TN Cathepsin F (CTSF) DMP761U MA Inhibitor DMP761U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMP761U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMP78JY DI DMP78JY DMP78JY DN A-770041 DMP78JY TI TT6PKBN DMP78JY TN Proto-oncogene c-Src (SRC) DMP78JY MA Inhibitor DMP78JY RN Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22. DMP78JY RU https://pubmed.ncbi.nlm.nih.gov/16216497 DMP78JY DI DMP78JY DMP78JY DN A-770041 DMP78JY TI TT860QF DMP78JY TN LCK tyrosine protein kinase (LCK) DMP78JY MA Inhibitor DMP78JY RN Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett. 2006 Jan 1;16(1):118-22. DMP78JY RU https://pubmed.ncbi.nlm.nih.gov/16216497 DMP7CF8 DI DMP7CF8 DMP7CF8 DN 2-(4-Butoxy-phenyl)-N-hydroxy-N-methyl-acetamide DMP7CF8 TI TT2J34L DMP7CF8 TN Arachidonate 5-lipoxygenase (5-LOX) DMP7CF8 MA Inhibitor DMP7CF8 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMP7CF8 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMP7IS0 DI DMP7IS0 DMP7IS0 DN ADS-0101 DMP7IS0 TI TTG043C DMP7IS0 TN Tumor necrosis factor receptor type I (TNF-R1) DMP7IS0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870). DMP7IS0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870 DMP7J0I DI DMP7J0I DMP7J0I DN Apigenin-7-O-beta-D-glucuronide methyl ester DMP7J0I TI TTFBNVI DMP7J0I TN Aldose reductase (AKR1B1) DMP7J0I MA Inhibitor DMP7J0I RN Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5. DMP7J0I RU https://pubmed.ncbi.nlm.nih.gov/18298080 DMP7LJH DI DMP7LJH DMP7LJH DN Thiocarbamate DMP7LJH TI TTE14XG DMP7LJH TN Squalene monooxygenase (SQLE) DMP7LJH MA Inhibitor DMP7LJH RN Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7. DMP7LJH RU https://pubmed.ncbi.nlm.nih.gov/8834895 DMP7M8O DI DMP7M8O DMP7M8O DN KNI-10313 DMP7M8O TI TTXMNHO DMP7M8O TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMP7M8O MA Inhibitor DMP7M8O RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMP7M8O RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMP7SI9 DI DMP7SI9 DMP7SI9 DN RWJ-140998 DMP7SI9 TI TTICX3S DMP7SI9 TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMP7SI9 MA Inhibitor DMP7SI9 RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMP7SI9 RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMP7TK0 DI DMP7TK0 DMP7TK0 DN (E)-Octadec-9-enoic acid phenylamide DMP7TK0 TI TTMF541 DMP7TK0 TN Liver carboxylesterase (CES1) DMP7TK0 MA Inhibitor DMP7TK0 RN Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas. Bioorg Med Chem Lett. 2004 Aug 16;14(16):4277-80. DMP7TK0 RU https://pubmed.ncbi.nlm.nih.gov/15261286 DMP7UZB DI DMP7UZB DMP7UZB DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) DMP7UZB TI TT6OEDT DMP7UZB TN Cannabinoid receptor 1 (CB1) DMP7UZB MA Inhibitor DMP7UZB RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMP7UZB RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMP7UZB DI DMP7UZB DMP7UZB DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYACETAMIDE (ENANTIOMERIC MIX) DMP7UZB TI TTMSFAW DMP7UZB TN Cannabinoid receptor 2 (CB2) DMP7UZB MA Inhibitor DMP7UZB RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMP7UZB RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMP7VJL DI DMP7VJL DMP7VJL DN ISIS 103621 DMP7VJL TI TTBWMKT DMP7VJL TN WWP1 messenger RNA (WWP1 mRNA) DMP7VJL RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMP7VJL RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMP84CS DI DMP84CS DMP84CS DN KOJIC ACID DMP84CS TI TTULVH8 DMP84CS TN Tyrosinase (TYR) DMP84CS MA Inhibitor DMP84CS RN A novel ring-expanded product with enhanced tyrosinase inhibitory activity from classical Fe-catalyzed oxidation of rosmarinic acid, a potent antio... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7393-6. DMP84CS RU https://pubmed.ncbi.nlm.nih.gov/21041086 DMP8547 DI DMP8547 DMP8547 DN N-(3-(2-aminoethyl)phenyl)benzenesulfonamide DMP8547 TI TTJS8PY DMP8547 TN 5-HT 6 receptor (HTR6) DMP8547 MA Inhibitor DMP8547 RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMP8547 RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMP86R3 DI DMP86R3 DMP86R3 DN 1,3-bis(1,3-benzothiazol-2-ylthio)acetone DMP86R3 TI TTHGL48 DMP86R3 TN AP endonuclease 1 (APEX1) DMP86R3 MA Inhibitor DMP86R3 RN Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63. DMP86R3 RU https://pubmed.ncbi.nlm.nih.gov/21266972 DMP87U4 DI DMP87U4 DMP87U4 DN KNI-10541 DMP87U4 TI TTXMNHO DMP87U4 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMP87U4 MA Inhibitor DMP87U4 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMP87U4 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMP89K4 DI DMP89K4 DMP89K4 DN Ac-w-F-F-N-Y-Y-W DMP89K4 TI TT3ZTGU DMP89K4 TN Endothelin B receptor (EDNRB) DMP89K4 MA Inhibitor DMP89K4 RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DMP89K4 RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DMP89K4 DI DMP89K4 DMP89K4 DN Ac-w-F-F-N-Y-Y-W DMP89K4 TI TTKRD0G DMP89K4 TN Endothelin A receptor (EDNRA) DMP89K4 MA Inhibitor DMP89K4 RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DMP89K4 RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DMP8A5R DI DMP8A5R DMP8A5R DN example 373 [WO2012093101] DMP8A5R TI TT8D13I DMP8A5R TN Complement factor D (CFD) DMP8A5R MA Inhibitor DMP8A5R RN Factor D Inhibitors for the Treatment of AMD: Patent Highlight. ACS Med Chem Lett. 2012 Aug 27;3(10):781-2. DMP8A5R RU https://pubmed.ncbi.nlm.nih.gov/24900375 DMP8G3C DI DMP8G3C DMP8G3C DN 2-phenyl-1,2'-spirobi[1H-indene]-5'-ol DMP8G3C TI TTOM3J0 DMP8G3C TN Estrogen receptor beta (ESR2) DMP8G3C MA Inhibitor DMP8G3C RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMP8G3C RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMP8G3C DI DMP8G3C DMP8G3C DN 2-phenyl-1,2'-spirobi[1H-indene]-5'-ol DMP8G3C TI TTZAYWL DMP8G3C TN Estrogen receptor (ESR) DMP8G3C MA Inhibitor DMP8G3C RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMP8G3C RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMP8HFA DI DMP8HFA DMP8HFA DN H-Dmt-Tic-Lys(Z)-NH-CH2-Ph DMP8HFA TI TTKWM86 DMP8HFA TN Opioid receptor mu (MOP) DMP8HFA MA Inhibitor DMP8HFA RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMP8HFA RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMP8HFA DI DMP8HFA DMP8HFA DN H-Dmt-Tic-Lys(Z)-NH-CH2-Ph DMP8HFA TI TT27RFC DMP8HFA TN Opioid receptor delta (OPRD1) DMP8HFA MA Inhibitor DMP8HFA RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMP8HFA RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMP8J7E DI DMP8J7E DMP8J7E DN 2-Propionyl-cyclohexane-1,3-dione DMP8J7E TI TT8DSFC DMP8J7E TN Hydroxyphenylpyruvate dioxygenase (HPD) DMP8J7E MA Inhibitor DMP8J7E RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DMP8J7E RU https://pubmed.ncbi.nlm.nih.gov/10853644 DMP8KMV DI DMP8KMV DMP8KMV DN H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2 DMP8KMV TI TT27RFC DMP8KMV TN Opioid receptor delta (OPRD1) DMP8KMV MA Inhibitor DMP8KMV RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMP8KMV RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMP8LSF DI DMP8LSF DMP8LSF DN THIQ DMP8LSF TI TTD0CIQ DMP8LSF TN Melanocortin receptor 4 (MC4R) DMP8LSF MA Agonist DMP8LSF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285). DMP8LSF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285 DMP8LXB DI DMP8LXB DMP8LXB DN 6,7-dimethoxy-N-m-tolylquinazolin-4-amine DMP8LXB TI TTGKNB4 DMP8LXB TN Epidermal growth factor receptor (EGFR) DMP8LXB MA Inhibitor DMP8LXB RN Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75. DMP8LXB RU https://pubmed.ncbi.nlm.nih.gov/19170633 DMP8M9Q DI DMP8M9Q DMP8M9Q DN K00024 DMP8M9Q TI TT7HF4W DMP8M9Q TN Cyclin-dependent kinase 2 (CDK2) DMP8M9Q MA Inhibitor DMP8M9Q RN Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30. DMP8M9Q RU https://pubmed.ncbi.nlm.nih.gov/12747775 DMP8M9Q DI DMP8M9Q DMP8M9Q DN K00024 DMP8M9Q TI TT0PG8F DMP8M9Q TN Cyclin-dependent kinase 4 (CDK4) DMP8M9Q MA Inhibitor DMP8M9Q RN Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30. DMP8M9Q RU https://pubmed.ncbi.nlm.nih.gov/12747775 DMP8M9Q DI DMP8M9Q DMP8M9Q DN K00024 DMP8M9Q TI TTH6V3D DMP8M9Q TN Cyclin-dependent kinase 1 (CDK1) DMP8M9Q MA Inhibitor DMP8M9Q RN Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem. 2003 May 22;46(11):2027-30. DMP8M9Q RU https://pubmed.ncbi.nlm.nih.gov/12747775 DMP8NSU DI DMP8NSU DMP8NSU DN ADRENOGLOMERULOTROPIN DMP8NSU TI TT0K1SC DMP8NSU TN 5-HT 2B receptor (HTR2B) DMP8NSU MA Inhibitor DMP8NSU RN Development, validation, and use of quantitative structure-activity relationship models of 5-hydroxytryptamine (2B) receptor ligands to identify no... J Med Chem. 2010 Nov 11;53(21):7573-86. DMP8NSU RU https://pubmed.ncbi.nlm.nih.gov/20958049 DMP8O6R DI DMP8O6R DMP8O6R DN L-Thiocitrulline DMP8O6R TI TTF10I9 DMP8O6R TN Nitric-oxide synthase inducible (NOS2) DMP8O6R MA Inhibitor DMP8O6R RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMP8O6R RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMP8OKA DI DMP8OKA DMP8OKA DN SCH-12679 DMP8OKA TI TTZFYLI DMP8OKA TN Dopamine D1 receptor (D1R) DMP8OKA MA Inhibitor DMP8OKA RN Modified ibogaine fragments: synthesis and preliminary pharmacological characterization of 3-ethyl-5-phenyl-1,2,3,4,5, 6-hexahydroazepino[4,5-b]ben... J Med Chem. 1998 Nov 5;41(23):4486-91. DMP8OKA RU https://pubmed.ncbi.nlm.nih.gov/9804688 DMP8OXG DI DMP8OXG DMP8OXG DN LY433222 DMP8OXG TI TTJQOD7 DMP8OXG TN 5-HT 2A receptor (HTR2A) DMP8OXG MA Inhibitor DMP8OXG RN Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. DMP8OXG RU https://pubmed.ncbi.nlm.nih.gov/17017959 DMP8OXL DI DMP8OXL DMP8OXL DN 2-Fluoro-6-(3-phenoxy-benzoylamino)-benzoic acid DMP8OXL TI TTRVTMX DMP8OXL TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMP8OXL MA Inhibitor DMP8OXL RN Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609. DMP8OXL RU https://pubmed.ncbi.nlm.nih.gov/15743201 DMP8VDT DI DMP8VDT DMP8VDT DN Elaidoylamide DMP8VDT TI TTO9X1H DMP8VDT TN 5-HT 7 receptor (HTR7) DMP8VDT MA Modulator (allosteric modulator) DMP8VDT RN Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochem Pharmacol. 1999 Dec 1;58(11):1807-13. DMP8VDT RU https://pubmed.ncbi.nlm.nih.gov/10571256 DMP8VDT DI DMP8VDT DMP8VDT DN Elaidoylamide DMP8VDT TI TTO8QRU DMP8VDT TN Group IIA phospholipase A2 (GIIA sPLA2) DMP8VDT MA Inhibitor DMP8VDT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMP8VDT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMP8VM2 DI DMP8VM2 DMP8VM2 DN 9-Cycloheptyl-9H-adenine DMP8VM2 TI TTM2AOE DMP8VM2 TN Adenosine A2a receptor (ADORA2A) DMP8VM2 MA Inhibitor DMP8VM2 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMP8VM2 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMP8VO6 DI DMP8VO6 DMP8VO6 DN SM-131 DMP8VO6 TI TTAIWZN DMP8VO6 TN Apoptosis-2 messenger RNA (BIRC3 mRNA) DMP8VO6 MA Inhibitor DMP8VO6 RN Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of ca... J Med Chem. 2008 Dec 11;51(23):7352-5. DMP8VO6 RU https://pubmed.ncbi.nlm.nih.gov/19012392 DMP8VO6 DI DMP8VO6 DMP8VO6 DN SM-131 DMP8VO6 TI TTK3WBU DMP8VO6 TN XIAP messenger RNA (XIAP mRNA) DMP8VO6 MA Inhibitor DMP8VO6 RN Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of ca... J Med Chem. 2008 Dec 11;51(23):7352-5. DMP8VO6 RU https://pubmed.ncbi.nlm.nih.gov/19012392 DMP8ZVS DI DMP8ZVS DMP8ZVS DN 6-Bromo-2-(3-nitro-phenyl)-chromen-4-one DMP8ZVS TI TT1MPAY DMP8ZVS TN GABA(A) receptor alpha-1 (GABRA1) DMP8ZVS MA Inhibitor DMP8ZVS RN 6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997). DMP8ZVS RU http://www.sciencedirect.com/science/article/pii/S0960894X97000206 DMP8ZVS DI DMP8ZVS DMP8ZVS DN 6-Bromo-2-(3-nitro-phenyl)-chromen-4-one DMP8ZVS TI TTNJYV2 DMP8ZVS TN Gamma-aminobutyric acid receptor (GAR) DMP8ZVS MA Inhibitor DMP8ZVS RN 6-Bromo-3 nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites, Bioorg. Med. Chem. Lett. 7(3):373-378 (1997). DMP8ZVS RU http://www.sciencedirect.com/science/article/pii/S0960894X97000206 DMP93E2 DI DMP93E2 DMP93E2 DN 1-(4-aminosulfonylphenyl)-2-(4-pyridyl)acetylene DMP93E2 TI TT8NGED DMP93E2 TN Prostaglandin G/H synthase 1 (COX-1) DMP93E2 MA Inhibitor DMP93E2 RN Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56. DMP93E2 RU https://pubmed.ncbi.nlm.nih.gov/18023187 DMP93HZ DI DMP93HZ DMP93HZ DN 1-(3,4-dihydronaphthalen-2-yl)-1H-imidazole DMP93HZ TI TTIQUX7 DMP93HZ TN Steroid 11-beta-hydroxylase (CYP11B1) DMP93HZ MA Inhibitor DMP93HZ RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMP93HZ RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMP98AQ DI DMP98AQ DMP98AQ DN [3H]PSB-0413 DMP98AQ TI TTZ1DT0 DMP98AQ TN P2Y purinoceptor 12 (P2RY12) DMP98AQ MA Antagonist DMP98AQ RN Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5450-2. DMP98AQ RU https://pubmed.ncbi.nlm.nih.gov/16213725 DMP9A7L DI DMP9A7L DMP9A7L DN N-(1-Benzyl-2-oxo-ethyl)-benzamide DMP9A7L TI TTG5QB7 DMP9A7L TN Calpain-2 (CAPN2) DMP9A7L MA Inhibitor DMP9A7L RN Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. J Med Chem. 1990 Jan;33(1):11-3. DMP9A7L RU https://pubmed.ncbi.nlm.nih.gov/2296008 DMP9AIH DI DMP9AIH DMP9AIH DN GNF-PF-5434 DMP9AIH TI TTDZN01 DMP9AIH TN Cathepsin K (CTSK) DMP9AIH MA Inhibitor DMP9AIH RN Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70. DMP9AIH RU https://pubmed.ncbi.nlm.nih.gov/18313933 DMP9AIH DI DMP9AIH DMP9AIH DN GNF-PF-5434 DMP9AIH TI TTF2LRI DMP9AIH TN Cathepsin B (CTSB) DMP9AIH MA Inhibitor DMP9AIH RN Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70. DMP9AIH RU https://pubmed.ncbi.nlm.nih.gov/18313933 DMP9AIH DI DMP9AIH DMP9AIH DN GNF-PF-5434 DMP9AIH TI TTUMQVO DMP9AIH TN Cathepsin S (CTSS) DMP9AIH MA Inhibitor DMP9AIH RN Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70. DMP9AIH RU https://pubmed.ncbi.nlm.nih.gov/18313933 DMP9AIH DI DMP9AIH DMP9AIH DN GNF-PF-5434 DMP9AIH TI TT4H0V2 DMP9AIH TN Dipeptidyl peptidase I (CTSC) DMP9AIH MA Inhibitor DMP9AIH RN Substrate optimization for monitoring cathepsin C activity in live cells. Bioorg Med Chem. 2009 Feb 1;17(3):1064-70. DMP9AIH RU https://pubmed.ncbi.nlm.nih.gov/18313933 DMP9BZU DI DMP9BZU DMP9BZU DN 2,4-dimethoxy-2'-hydroxychalcone DMP9BZU TI TTVKILB DMP9BZU TN Prostaglandin G/H synthase 2 (COX-2) DMP9BZU MA Inhibitor DMP9BZU RN Inhibitory activity of prostaglandin E2 production by the synthetic 2'-hydroxychalcone analogues: Synthesis and SAR study. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1650-3. DMP9BZU RU https://pubmed.ncbi.nlm.nih.gov/19233646 DMP9ECK DI DMP9ECK DMP9ECK DN 2,2,4-Trimethyl-6-phenyl-1,2-dihydro-quinoline DMP9ECK TI TTUV8G9 DMP9ECK TN Progesterone receptor (PGR) DMP9ECK MA Inhibitor DMP9ECK RN Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore. J Med Chem. 1998 Aug 27;41(18):3461-6. DMP9ECK RU https://pubmed.ncbi.nlm.nih.gov/9719599 DMP9IR2 DI DMP9IR2 DMP9IR2 DN ISIS 31982 DMP9IR2 TI TT9H4P3 DMP9IR2 TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMP9IR2 RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMP9IR2 RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMP9JVT DI DMP9JVT DMP9JVT DN N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile DMP9JVT TI TT36ETB DMP9JVT TN Cathepsin L (CTSL) DMP9JVT MA Inhibitor DMP9JVT RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMP9JVT RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMP9JVT DI DMP9JVT DMP9JVT DN N-(tert-butoxycarbonyl)-tyrosyl-glycine-nitrile DMP9JVT TI TTUMQVO DMP9JVT TN Cathepsin S (CTSS) DMP9JVT MA Inhibitor DMP9JVT RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMP9JVT RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMP9O7G DI DMP9O7G DMP9O7G DN 6-bromo-N-(3-bromophenyl)quinazolin-4-amine DMP9O7G TI TTHS256 DMP9O7G TN Metabotropic glutamate receptor 5 (mGluR5) DMP9O7G MA Inhibitor DMP9O7G RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMP9O7G RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMP9OGC DI DMP9OGC DMP9OGC DN GTx-878 DMP9OGC TI TTOM3J0 DMP9OGC TN Estrogen receptor beta (ESR2) DMP9OGC MA Agonist DMP9OGC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621). DMP9OGC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621 DMP9QW0 DI DMP9QW0 DMP9QW0 DN AGT-2000 DMP9QW0 TI TTGKNB4 DMP9QW0 TN Epidermal growth factor receptor (EGFR) DMP9QW0 MA Modulator DMP9QW0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMP9QW0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMP9RBK DI DMP9RBK DMP9RBK DN WZ4003 DMP9RBK TI TTHVOTQ DMP9RBK TN NUAK family SNF1-like kinase 2 (NUAK2) DMP9RBK MA Inhibitor DMP9RBK RN Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem J. 2014 Jan 1;457(1):215-25. DMP9RBK RU https://pubmed.ncbi.nlm.nih.gov/24171924 DMP9RBK DI DMP9RBK DMP9RBK DN WZ4003 DMP9RBK TI TT65FL0 DMP9RBK TN Omphalocele kinase 1 (NUAK1) DMP9RBK MA Inhibitor DMP9RBK RN Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases. Biochem J. 2014 Jan 1;457(1):215-25. DMP9RBK RU https://pubmed.ncbi.nlm.nih.gov/24171924 DMP9RLE DI DMP9RLE DMP9RLE DN RR(17)PZ DMP9RLE TI TTZ9SOR DMP9RLE TN Muscarinic acetylcholine receptor M1 (CHRM1) DMP9RLE MA Inhibitor DMP9RLE RN On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. J Med Chem. 2005 Dec 1;48(24):7847-59. DMP9RLE RU https://pubmed.ncbi.nlm.nih.gov/16302823 DMP9UHT DI DMP9UHT DMP9UHT DN CH4474 DMP9UHT TI TT6AZXG DMP9UHT TN TNF alpha converting enzyme (ADAM17) DMP9UHT MA Inhibitor DMP9UHT RN Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol. 2004 Jan;135(1):146-53. DMP9UHT RU https://pubmed.ncbi.nlm.nih.gov/14678276 DMP9V42 DI DMP9V42 DMP9V42 DN Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid DMP9V42 TI TTHI19T DMP9V42 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMP9V42 MA Inhibitor DMP9V42 RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMP9V42 RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMP9V7U DI DMP9V7U DMP9V7U DN RQ-00000008 DMP9V7U TI TT79WV3 DMP9V7U TN Prostaglandin E2 receptor EP4 (PTGER4) DMP9V7U MA Antagonist DMP9V7U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). DMP9V7U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343 DMP9WOZ DI DMP9WOZ DMP9WOZ DN ISIS 140180 DMP9WOZ TI TTWRN6M DMP9WOZ TN CRP messenger RNA (CRP mRNA) DMP9WOZ RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMP9WOZ RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMP9YD3 DI DMP9YD3 DMP9YD3 DN ISIS 188778 DMP9YD3 TI TTLRVIA DMP9YD3 TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DMP9YD3 RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DMP9YD3 RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DMP9ZVQ DI DMP9ZVQ DMP9ZVQ DN (L)-Phe-(D)-Phe-NH2 DMP9ZVQ TI TTZPO1L DMP9ZVQ TN Substance-P receptor (TACR1) DMP9ZVQ MA Inhibitor DMP9ZVQ RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMP9ZVQ RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMPA0BJ DI DMPA0BJ DMPA0BJ DN Uridine diphosphate galactose DMPA0BJ TI TTGRHIB DMPA0BJ TN UDP-glucose 4-epimerase (GALE) DMPA0BJ MA Inhibitor DMPA0BJ RN Crystal structure of beta1,4-galactosyltransferase complex with UDP-Gal reveals an oligosaccharide acceptor binding site. J Mol Biol. 2002 Apr 26;318(2):491-502. DMPA0BJ RU https://pubmed.ncbi.nlm.nih.gov/12051854 DMPA2E9 DI DMPA2E9 DMPA2E9 DN T-1106 DMPA2E9 TI TTSUKYD DMPA2E9 TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMPA2E9 MA Inhibitor DMPA2E9 RN Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9. DMPA2E9 RU https://pubmed.ncbi.nlm.nih.gov/18955536 DMPA2ON DI DMPA2ON DMPA2ON DN Isosorbide-di-(4-nitrophenyl carbamate) DMPA2ON TI TT1RS9F DMPA2ON TN Acetylcholinesterase (AChE) DMPA2ON MA Inhibitor DMPA2ON RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMPA2ON RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMPA4S0 DI DMPA4S0 DMPA4S0 DN 2-(2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one DMPA4S0 TI TT2WR1T DMPA4S0 TN Cationic trypsinogen (PRSS1) DMPA4S0 MA Inhibitor DMPA4S0 RN 2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease. J Med Chem. 1998 Mar 26;41(7):1060-7. DMPA4S0 RU https://pubmed.ncbi.nlm.nih.gov/9544206 DMPA534 DI DMPA534 DMPA534 DN 6-Phenylmethanesulfonyl-2H-pyridazin-3-one DMPA534 TI TTFBNVI DMPA534 TN Aldose reductase (AKR1B1) DMPA534 MA Inhibitor DMPA534 RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMPA534 RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMPA5WD DI DMPA5WD DMPA5WD DN Harmine DMPA5WD TI TT3WG5C DMPA5WD TN Monoamine oxidase type A (MAO-A) DMPA5WD MA Inhibitor DMPA5WD RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPA5WD RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPA5WD DI DMPA5WD DMPA5WD DN Harmine DMPA5WD TI TT84OS6 DMPA5WD TN Dual-specificity tyrosine-phosphorylation regulated kinase 2 (DYRK2) DMPA5WD MA Inhibitor DMPA5WD RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPA5WD RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPA5WD DI DMPA5WD DMPA5WD DN Harmine DMPA5WD TI TTSBVFO DMPA5WD TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMPA5WD MA Inhibitor DMPA5WD RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPA5WD RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPA5WD DI DMPA5WD DMPA5WD DN Harmine DMPA5WD TI TTV4EX0 DMPA5WD TN Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3) DMPA5WD MA Inhibitor DMPA5WD RN Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.Expert Opin Ther Pat. 2017 Nov;27(11):1183-1199. DMPA5WD RU https://www.ncbi.nlm.nih.gov/pubmed/28766366 DMPA91F DI DMPA91F DMPA91F DN N-(4-Phenyl-thiazol-2-yl)-benzamide DMPA91F TI TTK25J1 DMPA91F TN Adenosine A1 receptor (ADORA1) DMPA91F MA Inhibitor DMPA91F RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMPA91F RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMPAHJF DI DMPAHJF DMPAHJF DN Alpha,beta-methylene-dTTP DMPAHJF TI TTIU7X1 DMPAHJF TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMPAHJF MA Inhibitor DMPAHJF RN Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70. DMPAHJF RU https://pubmed.ncbi.nlm.nih.gov/18811136 DMPAKQV DI DMPAKQV DMPAKQV DN Lithospermic acid DMPAKQV TI TTLM12X DMPAKQV TN Matrix metalloproteinase-2 (MMP-2) DMPAKQV MA Inhibitor DMPAKQV RN Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84. DMPAKQV RU https://pubmed.ncbi.nlm.nih.gov/19711986 DMPAWFJ DI DMPAWFJ DMPAWFJ DN 1-(3-phenylpropyl)-1H-imidazole DMPAWFJ TI TTRA5BZ DMPAWFJ TN Steroid 17-alpha-monooxygenase (S17AH) DMPAWFJ MA Inhibitor DMPAWFJ RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DMPAWFJ RU https://pubmed.ncbi.nlm.nih.gov/16870430 DMPAXR4 DI DMPAXR4 DMPAXR4 DN ISIS 175510 DMPAXR4 TI TTSN6QU DMPAXR4 TN HIF1-alpha messenger RNA (HIF1A mRNA) DMPAXR4 RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMPAXR4 RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMPB3FH DI DMPB3FH DMPB3FH DN ISIS 156449 DMPB3FH TI TTILUKB DMPB3FH TN IRAK4 messenger RNA (IRAK4 mRNA) DMPB3FH RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMPB3FH RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMPB7EL DI DMPB7EL DMPB7EL DN ML169 DMPB7EL TI TTOXS3C DMPB7EL TN Muscarinic acetylcholine receptor (CHRM) DMPB7EL MA Modulator (allosteric modulator) DMPB7EL RN Targeting selective activation of M(1) for the treatment of Alzheimer's disease: further chemical optimization and pharmacological characterization of the M(1) positive allosteric modulator ML169. ACS Chem Neurosci. 2012 Nov 21;3(11):884-95. DMPB7EL RU https://pubmed.ncbi.nlm.nih.gov/23173069 DMPB7Z6 DI DMPB7Z6 DMPB7Z6 DN PMID15686941C13 DMPB7Z6 TI TTHS256 DMPB7Z6 TN Metabotropic glutamate receptor 5 (mGluR5) DMPB7Z6 MA Modulator (allosteric modulator) DMPB7Z6 RN Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1197-200. DMPB7Z6 RU https://pubmed.ncbi.nlm.nih.gov/15686941 DMPB9MY DI DMPB9MY DMPB9MY DN 6-Methoxy-4-morpholin-4-yl-chromen-2-one DMPB9MY TI TTK3PY9 DMPB9MY TN DNA-dependent protein kinase catalytic (PRKDC) DMPB9MY MA Inhibitor DMPB9MY RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMPB9MY RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMPBDW0 DI DMPBDW0 DMPBDW0 DN KF26777 DMPBDW0 TI TTNE7KG DMPBDW0 TN Adenosine A2b receptor (ADORA2B) DMPBDW0 MA Antagonist DMPBDW0 RN KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol. 2002 May 31;444(3):133-41. DMPBDW0 RU https://pubmed.ncbi.nlm.nih.gov/12063073 DMPBDW0 DI DMPBDW0 DMPBDW0 DN KF26777 DMPBDW0 TI TTK25J1 DMPBDW0 TN Adenosine A1 receptor (ADORA1) DMPBDW0 MA Antagonist DMPBDW0 RN KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol. 2002 May 31;444(3):133-41. DMPBDW0 RU https://pubmed.ncbi.nlm.nih.gov/12063073 DMPBDW0 DI DMPBDW0 DMPBDW0 DN KF26777 DMPBDW0 TI TTJFY5U DMPBDW0 TN Adenosine A3 receptor (ADORA3) DMPBDW0 MA Antagonist DMPBDW0 RN KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol. 2002 May 31;444(3):133-41. DMPBDW0 RU https://pubmed.ncbi.nlm.nih.gov/12063073 DMPBE5H DI DMPBE5H DMPBE5H DN 6-oxo-16-formyl-estrone DMPBE5H TI TTIWB6L DMPBE5H TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMPBE5H MA Inhibitor DMPBE5H RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMPBE5H RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMPBITK DI DMPBITK DMPBITK DN PMID21571530C7e DMPBITK TI TT4FX9Y DMPBITK TN Succinate receptor (SUCNR1) DMPBITK MA Antagonist DMPBITK RN Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3596-602. DMPBITK RU https://pubmed.ncbi.nlm.nih.gov/21571530 DMPBJ9L DI DMPBJ9L DMPBJ9L DN 1-((9H-Fluoren-2-yl)methyl)-1H-imidazole DMPBJ9L TI TTRA5BZ DMPBJ9L TN Steroid 17-alpha-monooxygenase (S17AH) DMPBJ9L MA Inhibitor DMPBJ9L RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMPBJ9L RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMPBLM2 DI DMPBLM2 DMPBLM2 DN 3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMPBLM2 TI TT1VAUK DMPBLM2 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMPBLM2 MA Inhibitor DMPBLM2 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMPBLM2 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMPBLM2 DI DMPBLM2 DMPBLM2 DN 3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMPBLM2 TI TTUTJGQ DMPBLM2 TN Vascular endothelial growth factor receptor 2 (KDR) DMPBLM2 MA Inhibitor DMPBLM2 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMPBLM2 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMPBLM2 DI DMPBLM2 DMPBLM2 DN 3-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMPBLM2 TI TTDCBX5 DMPBLM2 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMPBLM2 MA Inhibitor DMPBLM2 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMPBLM2 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMPBNYM DI DMPBNYM DMPBNYM DN (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone DMPBNYM TI TTI7421 DMPBNYM TN Platelet-derived growth factor receptor beta (PDGFRB) DMPBNYM MA Inhibitor DMPBNYM RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMPBNYM RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMPBNYM DI DMPBNYM DMPBNYM DN (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone DMPBNYM TI TTGJCWZ DMPBNYM TN Fms-like tyrosine kinase 3 (FLT-3) DMPBNYM MA Inhibitor DMPBNYM RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMPBNYM RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMPBNYM DI DMPBNYM DMPBNYM DN (5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone DMPBNYM TI TT8FYO9 DMPBNYM TN Platelet-derived growth factor receptor alpha (PDGFRA) DMPBNYM MA Inhibitor DMPBNYM RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMPBNYM RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMPC568 DI DMPC568 DMPC568 DN FORSYTHIASIDE DMPC568 TI TTFJ8Q1 DMPC568 TN Protein kinase C alpha (PRKCA) DMPC568 MA Inhibitor DMPC568 RN Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2. DMPC568 RU https://pubmed.ncbi.nlm.nih.gov/9834166 DMPC6YL DI DMPC6YL DMPC6YL DN Furan-3-yl(4-(methylsulfonyl)phenyl)methanone DMPC6YL TI TTVKILB DMPC6YL TN Prostaglandin G/H synthase 2 (COX-2) DMPC6YL MA Inhibitor DMPC6YL RN Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71. DMPC6YL RU https://pubmed.ncbi.nlm.nih.gov/20804197 DMPC9DV DI DMPC9DV DMPC9DV DN 5-(3'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid DMPC9DV TI TTXZ0KQ DMPC9DV TN Matrix metalloproteinase-12 (MMP-12) DMPC9DV MA Inhibitor DMPC9DV RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMPC9DV RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMPCBXT DI DMPCBXT DMPCBXT DN FR-166124 DMPCBXT TI TTM2AOE DMPCBXT TN Adenosine A2a receptor (ADORA2A) DMPCBXT MA Inhibitor DMPCBXT RN Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1979-84. DMPCBXT RU https://pubmed.ncbi.nlm.nih.gov/10450966 DMPCBXT DI DMPCBXT DMPCBXT DN FR-166124 DMPCBXT TI TTK25J1 DMPCBXT TN Adenosine A1 receptor (ADORA1) DMPCBXT MA Inhibitor DMPCBXT RN Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist. Bioorg Med Chem Lett. 1999 Jul 19;9(14):1979-84. DMPCBXT RU https://pubmed.ncbi.nlm.nih.gov/10450966 DMPCFA6 DI DMPCFA6 DMPCFA6 DN 5-(3-Phenyl-propyl)-1H-pyrazole-3-carboxylic acid DMPCFA6 TI TTWNV8U DMPCFA6 TN Nicotinic acid receptor (HCAR2) DMPCFA6 MA Inhibitor DMPCFA6 RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMPCFA6 RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMPCGSD DI DMPCGSD DMPCGSD DN 2,3-dichloro-1,4-naphthoquinone DMPCGSD TI TTZJYKH DMPCGSD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMPCGSD MA Inhibitor DMPCGSD RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMPCGSD RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMPCK7Y DI DMPCK7Y DMPCK7Y DN ISIS 29470 DMPCK7Y TI TTYMGWX DMPCK7Y TN PDK-1 messenger RNA (PDK-1 mRNA) DMPCK7Y RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMPCK7Y RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMPCLTW DI DMPCLTW DMPCLTW DN dodecylphosphate DMPCLTW TI TTB7Y8I DMPCLTW TN Lysophosphatidic acid receptor 2 (LPAR2) DMPCLTW MA Agonist DMPCLTW RN Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42. DMPCLTW RU https://pubmed.ncbi.nlm.nih.gov/12695531 DMPCLTW DI DMPCLTW DMPCLTW DN dodecylphosphate DMPCLTW TI TTE2YJR DMPCLTW TN Lysophosphatidate-3 receptor (LPAR3) DMPCLTW MA Antagonist DMPCLTW RN Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42. DMPCLTW RU https://pubmed.ncbi.nlm.nih.gov/12695531 DMPCRLY DI DMPCRLY DMPCRLY DN 2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine DMPCRLY TI TTK25J1 DMPCRLY TN Adenosine A1 receptor (ADORA1) DMPCRLY MA Inhibitor DMPCRLY RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMPCRLY RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMPCRLY DI DMPCRLY DMPCRLY DN 2-chloro-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine DMPCRLY TI TTM2AOE DMPCRLY TN Adenosine A2a receptor (ADORA2A) DMPCRLY MA Inhibitor DMPCRLY RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMPCRLY RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMPCRSY DI DMPCRSY DMPCRSY DN Detrothyronine DMPCRSY TI TTGER3L DMPCRSY TN Thyroid hormone receptor beta (THRB) DMPCRSY MA Inhibitor DMPCRSY RN Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1240-4. DMPCRSY RU https://pubmed.ncbi.nlm.nih.gov/16338239 DMPCRSY DI DMPCRSY DMPCRSY DN Detrothyronine DMPCRSY TI TTTSEPU DMPCRSY TN Thyroid hormone receptor alpha (THRA) DMPCRSY MA Inhibitor DMPCRSY RN Thyroid receptor ligands. Part 5: novel bicyclic agonist ligands selective for the thyroid hormone receptor beta. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1240-4. DMPCRSY RU https://pubmed.ncbi.nlm.nih.gov/16338239 DMPCT0A DI DMPCT0A DMPCT0A DN 3-Pyridin-4-yl-quinoline-5,7-diol DMPCT0A TI TT8FYO9 DMPCT0A TN Platelet-derived growth factor receptor alpha (PDGFRA) DMPCT0A MA Inhibitor DMPCT0A RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DMPCT0A RU https://pubmed.ncbi.nlm.nih.gov/8064792 DMPCT0A DI DMPCT0A DMPCT0A DN 3-Pyridin-4-yl-quinoline-5,7-diol DMPCT0A TI TTI7421 DMPCT0A TN Platelet-derived growth factor receptor beta (PDGFRB) DMPCT0A MA Inhibitor DMPCT0A RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DMPCT0A RU https://pubmed.ncbi.nlm.nih.gov/8064792 DMPCTED DI DMPCTED DMPCTED DN PMID23521020C7k DMPCTED TI TTI1FPZ DMPCTED TN Epithelial discoidin domain receptor 1 (DDR1) DMPCTED MA Inhibitor DMPCTED RN Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2013 Apr 25;56(8):3281-95. DMPCTED RU https://pubmed.ncbi.nlm.nih.gov/23521020 DMPCTED DI DMPCTED DMPCTED DN PMID23521020C7k DMPCTED TI TTX41N9 DMPCTED TN Tyrosine-protein kinase Kit (KIT) DMPCTED MA Inhibitor DMPCTED RN Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. J Med Chem. 2013 Apr 25;56(8):3281-95. DMPCTED RU https://pubmed.ncbi.nlm.nih.gov/23521020 DMPD16N DI DMPD16N DMPD16N DN FR-233118 DMPD16N TI TTY6EWA DMPD16N TN Neuropeptide Y receptor type 5 (NPY5R) DMPD16N MA Inhibitor DMPD16N RN Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802. DMPD16N RU https://pubmed.ncbi.nlm.nih.gov/11859006 DMPD2XF DI DMPD2XF DMPD2XF DN DLX-521 DMPD2XF TI TTPMQSO DMPD2XF TN ALK tyrosine kinase receptor (ALK) DMPD2XF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1839). DMPD2XF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1839 DMPD41Q DI DMPD41Q DMPD41Q DN prunetin DMPD41Q TI TTFLN4T DMPD41Q TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMPD41Q MA Inhibitor DMPD41Q RN Structure of daidzin, a naturally occurring anti-alcohol-addiction agent, in complex with human mitochondrial aldehyde dehydrogenase. J Med Chem. 2008 Aug 14;51(15):4482-7. DMPD41Q RU https://pubmed.ncbi.nlm.nih.gov/18613661 DMPD9GE DI DMPD9GE DMPD9GE DN 4-(6-Cyclohexyl-hex-3-ynyl)-1H-imidazole DMPD9GE TI TT9JNIC DMPD9GE TN Histamine H3 receptor (H3R) DMPD9GE MA Inhibitor DMPD9GE RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DMPD9GE RU https://pubmed.ncbi.nlm.nih.gov/9871722 DMPDJKG DI DMPDJKG DMPDJKG DN JWH-306 DMPDJKG TI TTMSFAW DMPDJKG TN Cannabinoid receptor 2 (CB2) DMPDJKG MA Inhibitor DMPDJKG RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMPDJKG RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMPDMFA DI DMPDMFA DMPDMFA DN F-G-G-F-T-G-A-R-K-S-A-R-K-L-Aib-N-Q-COOH DMPDMFA TI TTNT7K8 DMPDMFA TN Nociceptin receptor (OPRL1) DMPDMFA MA Inhibitor DMPDMFA RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMPDMFA RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMPDN63 DI DMPDN63 DMPDN63 DN 5-[5-Methoxy-indan-(1Z)-ylidenemethyl]-thiazole DMPDN63 TI TTSZLWK DMPDN63 TN Aromatase (CYP19A1) DMPDN63 MA Inhibitor DMPDN63 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMPDN63 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMPDO43 DI DMPDO43 DMPDO43 DN (R,S)-N-(R-phenylethyl)-1H-pyrrole-2-carboxamide DMPDO43 TI TT3WG5C DMPDO43 TN Monoamine oxidase type A (MAO-A) DMPDO43 MA Inhibitor DMPDO43 RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMPDO43 RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMPDO49 DI DMPDO49 DMPDO49 DN PSILOCIN DMPDO49 TI TTJQOD7 DMPDO49 TN 5-HT 2A receptor (HTR2A) DMPDO49 MA Inhibitor DMPDO49 RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DMPDO49 RU https://pubmed.ncbi.nlm.nih.gov/18296055 DMPDOY8 DI DMPDOY8 DMPDOY8 DN (S)-(+)-CBPG DMPDOY8 TI TTHS256 DMPDOY8 TN Metabotropic glutamate receptor 5 (mGluR5) DMPDOY8 MA Agonist DMPDOY8 RN Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo(1.1.1)pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity. Neuropharmacology. 1999 Jul;38(7):917-26. DMPDOY8 RU https://pubmed.ncbi.nlm.nih.gov/10428410 DMPDOY8 DI DMPDOY8 DMPDOY8 DN (S)-(+)-CBPG DMPDOY8 TI TTVBPDM DMPDOY8 TN Metabotropic glutamate receptor 1 (mGluR1) DMPDOY8 MA Antagonist DMPDOY8 RN Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo(1.1.1)pentyl)-glycine (CBPG), a novel mGlu5 receptor agonist endowed with mGlu1 receptor antagonist activity. Neuropharmacology. 1999 Jul;38(7):917-26. DMPDOY8 RU https://pubmed.ncbi.nlm.nih.gov/10428410 DMPDTWY DI DMPDTWY DMPDTWY DN JWH-369 DMPDTWY TI TT6OEDT DMPDTWY TN Cannabinoid receptor 1 (CB1) DMPDTWY MA Inhibitor DMPDTWY RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMPDTWY RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMPDTWY DI DMPDTWY DMPDTWY DN JWH-369 DMPDTWY TI TTMSFAW DMPDTWY TN Cannabinoid receptor 2 (CB2) DMPDTWY MA Inhibitor DMPDTWY RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMPDTWY RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMPDVG2 DI DMPDVG2 DMPDVG2 DN Phenethylboronic acid DMPDVG2 TI TTANPDJ DMPDVG2 TN Carbonic anhydrase II (CA-II) DMPDVG2 MA Inhibitor DMPDVG2 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMPDVG2 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMPDVG2 DI DMPDVG2 DMPDVG2 DN Phenethylboronic acid DMPDVG2 TI TTDP1UC DMPDVG2 TN Fatty acid amide hydrolase (FAAH) DMPDVG2 MA Inhibitor DMPDVG2 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMPDVG2 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMPDVG2 DI DMPDVG2 DMPDVG2 DN Phenethylboronic acid DMPDVG2 TI TTHQPL7 DMPDVG2 TN Carbonic anhydrase I (CA-I) DMPDVG2 MA Inhibitor DMPDVG2 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMPDVG2 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMPE1B2 DI DMPE1B2 DMPE1B2 DN [3H]PGF2alpha DMPE1B2 TI TTT2ZAR DMPE1B2 TN Prostaglandin F2-alpha receptor (PTGFR) DMPE1B2 MA Agonist DMPE1B2 RN Cloning and expression of a cDNA for the human prostanoid FP receptor. J Biol Chem. 1994 Jan 28;269(4):2632-6. DMPE1B2 RU https://pubmed.ncbi.nlm.nih.gov/8300593 DMPE8GX DI DMPE8GX DMPE8GX DN 2,7-Bis[2-(piperazino)acetamido]anthraquinone DMPE8GX TI TTQY2EJ DMPE8GX TN TERT messenger RNA (TERT mRNA) DMPE8GX MA Inhibitor DMPE8GX RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMPE8GX RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMPEIQT DI DMPEIQT DMPEIQT DN 1-(1-Biphenyl-4-yl-2-methyl-propyl)-1H-imidazole DMPEIQT TI TTRA5BZ DMPEIQT TN Steroid 17-alpha-monooxygenase (S17AH) DMPEIQT MA Inhibitor DMPEIQT RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMPEIQT RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMPEKTO DI DMPEKTO DMPEKTO DN P-toluenesulfonamide DMPEKTO TI TTUNARX DMPEKTO TN Carbonic anhydrase (CA) DMPEKTO MA Inhibitor DMPEKTO RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMPEKTO RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMPEKTO DI DMPEKTO DMPEKTO DN P-toluenesulfonamide DMPEKTO TI TTANPDJ DMPEKTO TN Carbonic anhydrase II (CA-II) DMPEKTO MA Inhibitor DMPEKTO RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMPEKTO RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMPEKTO DI DMPEKTO DMPEKTO DN P-toluenesulfonamide DMPEKTO TI TTSYM0R DMPEKTO TN Carbonic anhydrase XII (CA-XII) DMPEKTO MA Inhibitor DMPEKTO RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMPEKTO RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMPEKTO DI DMPEKTO DMPEKTO DN P-toluenesulfonamide DMPEKTO TI TTCFSPE DMPEKTO TN Carbonic anhydrase VI (CA-VI) DMPEKTO MA Inhibitor DMPEKTO RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMPEKTO RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMPEKTO DI DMPEKTO DMPEKTO DN P-toluenesulfonamide DMPEKTO TI TT2LVK8 DMPEKTO TN Carbonic anhydrase IX (CA-IX) DMPEKTO MA Inhibitor DMPEKTO RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMPEKTO RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMPEKWD DI DMPEKWD DMPEKWD DN 5-Methoxy-1-phenyl-1H-benzoimidazole DMPEKWD TI TTI7421 DMPEKWD TN Platelet-derived growth factor receptor beta (PDGFRB) DMPEKWD MA Inhibitor DMPEKWD RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DMPEKWD RU https://pubmed.ncbi.nlm.nih.gov/9876115 DMPEKWD DI DMPEKWD DMPEKWD DN 5-Methoxy-1-phenyl-1H-benzoimidazole DMPEKWD TI TT8FYO9 DMPEKWD TN Platelet-derived growth factor receptor alpha (PDGFRA) DMPEKWD MA Inhibitor DMPEKWD RN Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65. DMPEKWD RU https://pubmed.ncbi.nlm.nih.gov/9876115 DMPETL7 DI DMPETL7 DMPETL7 DN SLV-314 DMPETL7 TI TTEX248 DMPETL7 TN Dopamine D2 receptor (D2R) DMPETL7 MA Inhibitor DMPETL7 RN Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[omega-(1H-indol-3-yl)alkyl]piperazines, novel potential a... J Med Chem. 2005 Nov 3;48(22):6855-69. DMPETL7 RU https://pubmed.ncbi.nlm.nih.gov/16250644 DMPEV2W DI DMPEV2W DMPEV2W DN (R)-3-Prop-2-ynylamino-indan-5-ol DMPEV2W TI TTGP7BY DMPEV2W TN Monoamine oxidase type B (MAO-B) DMPEV2W MA Inhibitor DMPEV2W RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPEV2W RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPEV7S DI DMPEV7S DMPEV7S DN (E,E)-8-[4-(3-Bromophenyl)butadien-1-yl]caffeine DMPEV7S TI TTM2AOE DMPEV7S TN Adenosine A2a receptor (ADORA2A) DMPEV7S MA Inhibitor DMPEV7S RN Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84. DMPEV7S RU https://pubmed.ncbi.nlm.nih.gov/18723354 DMPEVQT DI DMPEVQT DMPEVQT DN PTosyl-Glu(OtBu)-Ala-LeuVSMe DMPEVQT TI TTF2LRI DMPEVQT TN Cathepsin B (CTSB) DMPEVQT MA Inhibitor DMPEVQT RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMPEVQT RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMPEXTB DI DMPEXTB DMPEXTB DN 7,9-tetradecadiynoic acid DMPEXTB TI TTPADOQ DMPEXTB TN HMG-CoA reductase (HMGCR) DMPEXTB MA Inhibitor DMPEXTB RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DMPEXTB RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DMPEZ1V DI DMPEZ1V DMPEZ1V DN 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPEZ1V TI TT3ROYC DMPEZ1V TN Serotonin transporter (SERT) DMPEZ1V MA Inhibitor DMPEZ1V RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMPEZ1V RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMPEZ1V DI DMPEZ1V DMPEZ1V DN 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPEZ1V TI TTVBI8W DMPEZ1V TN Dopamine transporter (DAT) DMPEZ1V MA Inhibitor DMPEZ1V RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMPEZ1V RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMPEZ1V DI DMPEZ1V DMPEZ1V DN 1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPEZ1V TI TTAWNKZ DMPEZ1V TN Norepinephrine transporter (NET) DMPEZ1V MA Inhibitor DMPEZ1V RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMPEZ1V RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMPEZHC DI DMPEZHC DMPEZHC DN N-glycylglycinehydroxamic acid DMPEZHC TI TTAS2UO DMPEZHC TN Bacterial Urease (Bact ureC) DMPEZHC MA Inhibitor DMPEZHC RN Design, synthesis, and evaluation of novel organophosphorus inhibitors of bacterial ureases. J Med Chem. 2008 Sep 25;51(18):5736-44. DMPEZHC RU https://pubmed.ncbi.nlm.nih.gov/18717581 DMPEZKT DI DMPEZKT DMPEZKT DN PF-04957325 DMPEZKT TI TTIS4OW DMPEZKT TN Phosphodiesterase 8 (PDE8) DMPEZKT MA Inhibitor DMPEZKT RN Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation.Front Pharmacol. 2016 Aug 23;7:259. DMPEZKT RU https://pubmed.ncbi.nlm.nih.gov/27601994 DMPF1VU DI DMPF1VU DMPF1VU DN UR-10324 DMPF1VU TI TTQL5VC DMPF1VU TN Platelet-activating factor receptor (PTAFR) DMPF1VU MA Modulator DMPF1VU RN Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents. Br J Pharmacol. 1991 Dec;104(4):990-4. DMPF1VU RU https://www.ncbi.nlm.nih.gov/pubmed/1810607 DMPF2N1 DI DMPF2N1 DMPF2N1 DN paxilline DMPF2N1 TI TT1AQ50 DMPF2N1 TN Charybdotoxin receptor beta-4 (BKbeta4) DMPF2N1 MA Blocker (channel blocker) DMPF2N1 RN Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology. 1996;35(7):963-8. DMPF2N1 RU https://pubmed.ncbi.nlm.nih.gov/8938726 DMPF2N1 DI DMPF2N1 DMPF2N1 DN paxilline DMPF2N1 TI TTECBXN DMPF2N1 TN Oxysterols receptor LXR-alpha (NR1H3) DMPF2N1 MA Agonist DMPF2N1 RN A natural product ligand of the oxysterol receptor, liver X receptor. J Pharmacol Exp Ther. 2003 Oct;307(1):291-6. DMPF2N1 RU https://pubmed.ncbi.nlm.nih.gov/12893846 DMPF598 DI DMPF598 DMPF598 DN 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline DMPF598 TI TT1MPAY DMPF598 TN GABA(A) receptor alpha-1 (GABRA1) DMPF598 MA Inhibitor DMPF598 RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMPF598 RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMPF598 DI DMPF598 DMPF598 DN 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline DMPF598 TI TT06RH5 DMPF598 TN GABA(A) receptor gamma-2 (GABRG2) DMPF598 MA Inhibitor DMPF598 RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMPF598 RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMPF598 DI DMPF598 DMPF598 DN 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline DMPF598 TI TTNJYV2 DMPF598 TN Gamma-aminobutyric acid receptor (GAR) DMPF598 MA Inhibitor DMPF598 RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMPF598 RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMPF598 DI DMPF598 DMPF598 DN 2-Thiophen-2-yl-3H-imidazo[4,5-c]quinoline DMPF598 TI TTZA1NY DMPF598 TN GABA(A) receptor beta-2 (GABRB2) DMPF598 MA Inhibitor DMPF598 RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMPF598 RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMPF5OX DI DMPF5OX DMPF5OX DN 3PO DMPF5OX TI TTTHMQJ DMPF5OX TN Renal carcinoma antigen NY-REN-56 (PFKFB3) DMPF5OX MA Antagonist DMPF5OX RN CPEB4 Increases Expression of PFKFB3 to Induce Glycolysis and Activate Mouse and Human Hepatic Stellate Cells, Promoting Liver Fibrosis. Gastroenterology. 2020 Jul;159(1):273-288. DMPF5OX RU https://pubmed.ncbi.nlm.nih.gov/32169429 DMPF6MD DI DMPF6MD DMPF6MD DN 7,8-Dimethoxy-1,4-dimethylquinolin-2(1H)-one DMPF6MD TI TTJLP0R DMPF6MD TN Quinone reductase 2 (NQO2) DMPF6MD MA Inhibitor DMPF6MD RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMPF6MD RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMPF7O2 DI DMPF7O2 DMPF7O2 DN 3-bromoboldine DMPF7O2 TI TTEX248 DMPF7O2 TN Dopamine D2 receptor (D2R) DMPF7O2 MA Inhibitor DMPF7O2 RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DMPF7O2 RU https://pubmed.ncbi.nlm.nih.gov/10785418 DMPF7O2 DI DMPF7O2 DMPF7O2 DN 3-bromoboldine DMPF7O2 TI TTZFYLI DMPF7O2 TN Dopamine D1 receptor (D1R) DMPF7O2 MA Inhibitor DMPF7O2 RN Halogenated boldine derivatives with enhanced monoamine receptor selectivity. J Nat Prod. 2000 Apr;63(4):480-4. DMPF7O2 RU https://pubmed.ncbi.nlm.nih.gov/10785418 DMPF7O2 DI DMPF7O2 DMPF7O2 DN 3-bromoboldine DMPF7O2 TI TTLA931 DMPF7O2 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMPF7O2 MA Inhibitor DMPF7O2 RN Aporphine metho salts as neuronal nicotinic acetylcholine receptor blockers. Bioorg Med Chem. 2007 May 15;15(10):3368-72. DMPF7O2 RU https://pubmed.ncbi.nlm.nih.gov/17391965 DMPFC5U DI DMPFC5U DMPFC5U DN NSC-640558 DMPFC5U TI TTJLP0R DMPFC5U TN Quinone reductase 2 (NQO2) DMPFC5U MA Inhibitor DMPFC5U RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMPFC5U RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMPFD6Y DI DMPFD6Y DMPFD6Y DN Oxindole 94 DMPFD6Y TI TTBJR4L DMPFD6Y TN Cyclin-dependent kinase 8 (CDK8) DMPFD6Y MA Inhibitor DMPFD6Y RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMPFD6Y RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMPFD6Y DI DMPFD6Y DMPFD6Y DN Oxindole 94 DMPFD6Y TI TTQBR95 DMPFD6Y TN Stress-activated protein kinase 2a (p38 alpha) DMPFD6Y MA Inhibitor DMPFD6Y RN Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. Cardiovasc Res. 2003 Oct 1;59(4):893-900. DMPFD6Y RU https://pubmed.ncbi.nlm.nih.gov/14553829 DMPFD6Y DI DMPFD6Y DMPFD6Y DN Oxindole 94 DMPFD6Y TI TTVKILB DMPFD6Y TN Prostaglandin G/H synthase 2 (COX-2) DMPFD6Y MA Inhibitor DMPFD6Y RN A selective inhibitor of p38 MAP kinase, SB202190, induced apoptotic cell death of a lipopolysaccharide-treated macrophage-like cell line, J774.1. Biochim Biophys Acta. 2000 Oct 18;1502(2):207-23. DMPFD6Y RU https://pubmed.ncbi.nlm.nih.gov/11040446 DMPFH15 DI DMPFH15 DMPFH15 DN 3-(Aminooxy)propan-1-amine hydrochloride DMPFH15 TI TTUMGNO DMPFH15 TN Ornithine decarboxylase (ODC1) DMPFH15 MA Inhibitor DMPFH15 RN Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4364-6. DMPFH15 RU https://pubmed.ncbi.nlm.nih.gov/20615694 DMPFH8U DI DMPFH8U DMPFH8U DN 3-(benzo[d]oxazol-2-yl)phenyl propylcarbamate DMPFH8U TI TTDP1UC DMPFH8U TN Fatty acid amide hydrolase (FAAH) DMPFH8U MA Inhibitor DMPFH8U RN Chiral 3-(4,5-dihydrooxazol-2-yl)phenyl alkylcarbamates as novel FAAH inhibitors: Insight into FAAH enantioselectivity by molecular docking and int... Eur J Med Chem. 2009 Oct;44(10):4179-91. DMPFH8U RU https://pubmed.ncbi.nlm.nih.gov/19539407 DMPFUBE DI DMPFUBE DMPFUBE DN [(R)-(+)-deoxytylophorinidine DMPFUBE TI TTS7IR5 DMPFUBE TN c-Jun messenger RNA (c-Jun mRNA) DMPFUBE MA Inhibitor DMPFUBE RN Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42. DMPFUBE RU https://pubmed.ncbi.nlm.nih.gov/17531481 DMPFX0S DI DMPFX0S DMPFX0S DN 5-(DIMETHYLAMINO)-2-NAPHTHALENESULFONIC ACID DMPFX0S TI TTXAGYU DMPFX0S TN Tissue-type plasminogen activator (PLAT) DMPFX0S MA Inhibitor DMPFX0S RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPFX0S RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPG0V7 DI DMPG0V7 DMPG0V7 DN 2-methoxyapomorphine DMPG0V7 TI TTZFYLI DMPG0V7 TN Dopamine D1 receptor (D1R) DMPG0V7 MA Inhibitor DMPG0V7 RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DMPG0V7 RU https://pubmed.ncbi.nlm.nih.gov/18313931 DMPG0V7 DI DMPG0V7 DMPG0V7 DN 2-methoxyapomorphine DMPG0V7 TI TTEX248 DMPG0V7 TN Dopamine D2 receptor (D2R) DMPG0V7 MA Inhibitor DMPG0V7 RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DMPG0V7 RU https://pubmed.ncbi.nlm.nih.gov/18313931 DMPG315 DI DMPG315 DMPG315 DN 3-Benzyloxy-6,7-dimethoxy-quinoline DMPG315 TI TT8FYO9 DMPG315 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMPG315 MA Inhibitor DMPG315 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMPG315 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMPG315 DI DMPG315 DMPG315 DN 3-Benzyloxy-6,7-dimethoxy-quinoline DMPG315 TI TTI7421 DMPG315 TN Platelet-derived growth factor receptor beta (PDGFRB) DMPG315 MA Inhibitor DMPG315 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMPG315 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMPG8NC DI DMPG8NC DMPG8NC DN FGGFTGARKSARKKRNQ DMPG8NC TI TTNT7K8 DMPG8NC TN Nociceptin receptor (OPRL1) DMPG8NC MA Inhibitor DMPG8NC RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMPG8NC RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMPGEO1 DI DMPGEO1 DMPGEO1 DN BrP-LPA DMPGEO1 TI TTQ6S1K DMPGEO1 TN Lysophosphatidic acid receptor 1 (LPAR1) DMPGEO1 MA Antagonist DMPGEO1 RN Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9. DMPGEO1 RU https://pubmed.ncbi.nlm.nih.gov/19509223 DMPGEO1 DI DMPGEO1 DMPGEO1 DN BrP-LPA DMPGEO1 TI TTB7Y8I DMPGEO1 TN Lysophosphatidic acid receptor 2 (LPAR2) DMPGEO1 MA Antagonist DMPGEO1 RN Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9. DMPGEO1 RU https://pubmed.ncbi.nlm.nih.gov/19509223 DMPGJE6 DI DMPGJE6 DMPGJE6 DN (-)-clusin DMPGJE6 TI TTXV4FI DMPGJE6 TN Albendazole monooxygenase (CYP3A4) DMPGJE6 MA Inhibitor DMPGJE6 RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMPGJE6 RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMPGM0V DI DMPGM0V DMPGM0V DN 1-(1-(benzo[b]thiophen-2-yl)cyclohexyl)piperidine DMPGM0V TI TTVBI8W DMPGM0V TN Dopamine transporter (DAT) DMPGM0V MA Inhibitor DMPGM0V RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMPGM0V RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMPGT80 DI DMPGT80 DMPGT80 DN L-Val-L-boroPro DMPGT80 TI TTDIGC1 DMPGT80 TN Dipeptidyl peptidase 4 (DPP-4) DMPGT80 MA Inhibitor DMPGT80 RN Synthesis and characterization of constrained peptidomimetic dipeptidyl peptidase IV inhibitors: amino-lactam boroalanines. J Med Chem. 2007 May 17;50(10):2391-8. DMPGT80 RU https://pubmed.ncbi.nlm.nih.gov/17458948 DMPGYDA DI DMPGYDA DMPGYDA DN 2-(3'-Ethylsulfanyl-biphenyl-4-yl)-propionic acid DMPGYDA TI TT8NGED DMPGYDA TN Prostaglandin G/H synthase 1 (COX-1) DMPGYDA MA Inhibitor DMPGYDA RN Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12. DMPGYDA RU https://pubmed.ncbi.nlm.nih.gov/10091674 DMPH1G0 DI DMPH1G0 DMPH1G0 DN Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMPH1G0 TI TTCG0AL DMPH1G0 TN Cholecystokinin receptor type A (CCKAR) DMPH1G0 MA Inhibitor DMPH1G0 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMPH1G0 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMPH1G0 DI DMPH1G0 DMPH1G0 DN Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMPH1G0 TI TT27RFC DMPH1G0 TN Opioid receptor delta (OPRD1) DMPH1G0 MA Inhibitor DMPH1G0 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMPH1G0 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMPH1G0 DI DMPH1G0 DMPH1G0 DN Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMPH1G0 TI TTKWM86 DMPH1G0 TN Opioid receptor mu (MOP) DMPH1G0 MA Inhibitor DMPH1G0 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMPH1G0 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMPH1G0 DI DMPH1G0 DMPH1G0 DN Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMPH1G0 TI TTVFO0U DMPH1G0 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMPH1G0 MA Inhibitor DMPH1G0 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMPH1G0 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMPH2W7 DI DMPH2W7 DMPH2W7 DN ISIS 156451 DMPH2W7 TI TTILUKB DMPH2W7 TN IRAK4 messenger RNA (IRAK4 mRNA) DMPH2W7 RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMPH2W7 RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMPH4C8 DI DMPH4C8 DMPH4C8 DN 4-Methanesulfonylamino-benzenesulfonamide DMPH4C8 TI TT2LVK8 DMPH4C8 TN Carbonic anhydrase IX (CA-IX) DMPH4C8 MA Inhibitor DMPH4C8 RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMPH4C8 RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMPH4C8 DI DMPH4C8 DMPH4C8 DN 4-Methanesulfonylamino-benzenesulfonamide DMPH4C8 TI TTANPDJ DMPH4C8 TN Carbonic anhydrase II (CA-II) DMPH4C8 MA Inhibitor DMPH4C8 RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMPH4C8 RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMPH4C8 DI DMPH4C8 DMPH4C8 DN 4-Methanesulfonylamino-benzenesulfonamide DMPH4C8 TI TTSYM0R DMPH4C8 TN Carbonic anhydrase XII (CA-XII) DMPH4C8 MA Inhibitor DMPH4C8 RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMPH4C8 RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMPH4C8 DI DMPH4C8 DMPH4C8 DN 4-Methanesulfonylamino-benzenesulfonamide DMPH4C8 TI TTHQPL7 DMPH4C8 TN Carbonic anhydrase I (CA-I) DMPH4C8 MA Inhibitor DMPH4C8 RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMPH4C8 RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMPH63G DI DMPH63G DMPH63G DN 2-(2-Methylpropanoyl)-1,3,5-benzenetriol DMPH63G TI TT8NGED DMPH63G TN Prostaglandin G/H synthase 1 (COX-1) DMPH63G MA Inhibitor DMPH63G RN Anti-inflammatory acylphloroglucinol derivatives from Hops (Humulus lupulus). J Nat Prod. 2005 Oct;68(10):1545-8. DMPH63G RU https://pubmed.ncbi.nlm.nih.gov/16252923 DMPH7A6 DI DMPH7A6 DMPH7A6 DN PMID18754614C9 DMPH7A6 TI TTFQEO5 DMPH7A6 TN Squalene synthetase (FDFT1) DMPH7A6 MA Inhibitor DMPH7A6 RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DMPH7A6 RU https://pubmed.ncbi.nlm.nih.gov/18754614 DMPH7EO DI DMPH7EO DMPH7EO DN Apomorphine SL DMPH7EO TI TT0R12H DMPH7EO TN Neuron-specific vesicular protein calcyon (CALY) DMPH7EO MA Activator DMPH7EO RN Dopamine and sexual function. Int J Impot Res. 2001 Aug;13 Suppl 3:S18-28. DMPH7EO RU https://pubmed.ncbi.nlm.nih.gov/11477488 DMPH8E9 DI DMPH8E9 DMPH8E9 DN ICT-037 DMPH8E9 TI TTY6DTE DMPH8E9 TN Carcinoembryonic antigen CEA (CD66e) DMPH8E9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2836). DMPH8E9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2836 DMPHCX7 DI DMPHCX7 DMPHCX7 DN (3-Amino-1-ethyl-propyl)-methyl-phosphinic acid DMPHCX7 TI TTDCVZW DMPHCX7 TN Gamma-aminobutyric acid B receptor (GABBR) DMPHCX7 MA Inhibitor DMPHCX7 RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DMPHCX7 RU https://pubmed.ncbi.nlm.nih.gov/7650684 DMPHIBZ DI DMPHIBZ DMPHIBZ DN F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-CONH2 DMPHIBZ TI TTNT7K8 DMPHIBZ TN Nociceptin receptor (OPRL1) DMPHIBZ MA Inhibitor DMPHIBZ RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMPHIBZ RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMPHJO2 DI DMPHJO2 DMPHJO2 DN (E,E)-8-[4-(3-Fluorophenyl)butadien-1-yl]caffeine DMPHJO2 TI TTM2AOE DMPHJO2 TN Adenosine A2a receptor (ADORA2A) DMPHJO2 MA Inhibitor DMPHJO2 RN Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84. DMPHJO2 RU https://pubmed.ncbi.nlm.nih.gov/18723354 DMPHJZU DI DMPHJZU DMPHJZU DN 7beta-hydroxycholesterol DMPHJZU TI TTME5YJ DMPHJZU TN EBV-induced G-protein coupled receptor 2 (GPR183) DMPHJZU MA Agonist DMPHJZU RN Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23. DMPHJZU RU https://pubmed.ncbi.nlm.nih.gov/21796211 DMPHKJI DI DMPHKJI DMPHKJI DN PMID23368907C16 DMPHKJI TI TTA93TL DMPHKJI TN P2Y purinoceptor 1 (P2RY1) DMPHKJI MA Antagonist DMPHKJI RN Two disparate ligand-binding sites in the human P2Y1 receptor. Nature. 2015 Apr 16;520(7547):317-21. DMPHKJI RU https://pubmed.ncbi.nlm.nih.gov/25822790 DMPHM23 DI DMPHM23 DMPHM23 DN (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid DMPHM23 TI TTTU72V DMPHM23 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMPHM23 MA Inhibitor DMPHM23 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMPHM23 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMPHM23 DI DMPHM23 DMPHM23 DN (3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid DMPHM23 TI TTT02K8 DMPHM23 TN Steroid 5-alpha-reductase 2 (SRD5A2) DMPHM23 MA Inhibitor DMPHM23 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMPHM23 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMPHRXQ DI DMPHRXQ DMPHRXQ DN spiroxatrine DMPHRXQ TI TTSQIFT DMPHRXQ TN 5-HT 1A receptor (HTR1A) DMPHRXQ MA Agonist DMPHRXQ RN Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol. 1998 Aug 21;355(2-3):245-56. DMPHRXQ RU https://pubmed.ncbi.nlm.nih.gov/9760039 DMPHRXQ DI DMPHRXQ DMPHRXQ DN spiroxatrine DMPHRXQ TI TT0K1SC DMPHRXQ TN 5-HT 2B receptor (HTR2B) DMPHRXQ MA Antagonist DMPHRXQ RN [3H]Rauwolscine: an antagonist radioligand for the cloned human 5-hydroxytryptamine2b (5-HT2B) receptor. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):17-24. DMPHRXQ RU https://pubmed.ncbi.nlm.nih.gov/9459568 DMPHRXQ DI DMPHRXQ DMPHRXQ DN spiroxatrine DMPHRXQ TI TTWM4TY DMPHRXQ TN Adrenergic receptor alpha-2B (ADRA2B) DMPHRXQ MA Antagonist DMPHRXQ RN The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994 Dec;271(3):1558-65. DMPHRXQ RU https://pubmed.ncbi.nlm.nih.gov/7996470 DMPHRXQ DI DMPHRXQ DMPHRXQ DN spiroxatrine DMPHRXQ TI TT2NUT5 DMPHRXQ TN Adrenergic receptor alpha-2C (ADRA2C) DMPHRXQ MA Antagonist DMPHRXQ RN Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95. DMPHRXQ RU https://pubmed.ncbi.nlm.nih.gov/11459121 DMPHRXQ DI DMPHRXQ DMPHRXQ DN spiroxatrine DMPHRXQ TI TTBRKXS DMPHRXQ TN Adrenergic receptor alpha-1B (ADRA1B) DMPHRXQ MA Antagonist DMPHRXQ RN Affinity of serotonin receptor antagonists and agonists to recombinant and native alpha1-adrenoceptor subtypes. Jpn J Pharmacol. 2001 Jun;86(2):189-95. DMPHRXQ RU https://pubmed.ncbi.nlm.nih.gov/11459121 DMPHSU8 DI DMPHSU8 DMPHSU8 DN ACTB-1003 DMPHSU8 TI TTST7KB DMPHSU8 TN Fibroblast growth factor receptor 3 (FGFR3) DMPHSU8 MA Inhibitor DMPHSU8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810). DMPHSU8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1810 DMPHSU8 DI DMPHSU8 DMPHSU8 DN ACTB-1003 DMPHSU8 TI TTGJVQM DMPHSU8 TN Fibroblast growth factor receptor 2 (FGFR2) DMPHSU8 MA Inhibitor DMPHSU8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1809). DMPHSU8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1809 DMPHSU8 DI DMPHSU8 DMPHSU8 DN ACTB-1003 DMPHSU8 TI TTG0U4H DMPHSU8 TN Ribosomal protein S6 kinase beta-1 (S6K1) DMPHSU8 MA Inhibitor DMPHSU8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1525). DMPHSU8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1525 DMPHSU8 DI DMPHSU8 DMPHSU8 DN ACTB-1003 DMPHSU8 TI TT5BR7T DMPHSU8 TN Fibroblast growth factor receptor 4 (FGFR4) DMPHSU8 MA Inhibitor DMPHSU8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1811). DMPHSU8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1811 DMPHSU8 DI DMPHSU8 DMPHSU8 DN ACTB-1003 DMPHSU8 TI TTRLW2X DMPHSU8 TN Fibroblast growth factor receptor 1 (FGFR1) DMPHSU8 MA Inhibitor DMPHSU8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1808). DMPHSU8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1808 DMPHTX0 DI DMPHTX0 DMPHTX0 DN AL-59640 DMPHTX0 TI TTSKMI8 DMPHTX0 TN Phosphodiesterase 4D (PDE4D) DMPHTX0 MA Modulator DMPHTX0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DMPHTX0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DMPHTX0 DI DMPHTX0 DMPHTX0 DN AL-59640 DMPHTX0 TI TTVIAT9 DMPHTX0 TN Phosphodiesterase 4B (PDE4B) DMPHTX0 MA Modulator DMPHTX0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DMPHTX0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DMPHTX0 DI DMPHTX0 DMPHTX0 DN AL-59640 DMPHTX0 TI TTZ97H5 DMPHTX0 TN Phosphodiesterase 4A (PDE4A) DMPHTX0 MA Inhibitor DMPHTX0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DMPHTX0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DMPHV7K DI DMPHV7K DMPHV7K DN AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH DMPHV7K TI TT6L509 DMPHV7K TN Coagulation factor IIa (F2) DMPHV7K MA Inhibitor DMPHV7K RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPHV7K RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPHWMO DI DMPHWMO DMPHWMO DN ISIS 1827 DMPHWMO TI TTSJ6Q4 DMPHWMO TN LOX-5 messenger RNA (ALOX5 mRNA) DMPHWMO RN US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism. DMPHWMO RU http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true DMPI0AX DI DMPI0AX DMPI0AX DN (S)-BULBOCAPNINE DMPI0AX TI TTZFYLI DMPI0AX TN Dopamine D1 receptor (D1R) DMPI0AX MA Inhibitor DMPI0AX RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMPI0AX RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMPI0AX DI DMPI0AX DMPI0AX DN (S)-BULBOCAPNINE DMPI0AX TI TTEX248 DMPI0AX TN Dopamine D2 receptor (D2R) DMPI0AX MA Inhibitor DMPI0AX RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMPI0AX RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMPI0YX DI DMPI0YX DMPI0YX DN A-304121 DMPI0YX TI TT9JNIC DMPI0YX TN Histamine H3 receptor (H3R) DMPI0YX MA Antagonist DMPI0YX RN Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol. 2004 Sep 1;68(5):933-45. DMPI0YX RU https://pubmed.ncbi.nlm.nih.gov/15294456 DMPI2MA DI DMPI2MA DMPI2MA DN WO2012007375C7 DMPI2MA TI TTKFVXR DMPI2MA TN Renal carcinoma antigen NY-REN-64 (IRAK-4) DMPI2MA MA Inhibitor DMPI2MA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2045). DMPI2MA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2045 DMPI2MA DI DMPI2MA DMPI2MA DN WO2012007375C7 DMPI2MA TI TTXAJWN DMPI2MA TN IL-1 receptor-associated kinase 1 (IRAK1) DMPI2MA MA Inhibitor DMPI2MA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2042). DMPI2MA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2042 DMPIFLA DI DMPIFLA DMPIFLA DN 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine DMPIFLA TI TTHS256 DMPIFLA TN Metabotropic glutamate receptor 5 (mGluR5) DMPIFLA MA Inhibitor DMPIFLA RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMPIFLA RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMPIFLA DI DMPIFLA DMPIFLA DN 6-chloro-N-(3-chlorophenyl)quinazolin-4-amine DMPIFLA TI TTGKNB4 DMPIFLA TN Epidermal growth factor receptor (EGFR) DMPIFLA MA Inhibitor DMPIFLA RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMPIFLA RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMPIH4L DI DMPIH4L DMPIH4L DN 4-Biphenyl-4-yl-2-hexyl-1H-imidazole DMPIH4L TI TTRK8B9 DMPIH4L TN Sodium channel unspecific (NaC) DMPIH4L MA Inhibitor DMPIH4L RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMPIH4L RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMPIH4L DI DMPIH4L DMPIH4L DN 4-Biphenyl-4-yl-2-hexyl-1H-imidazole DMPIH4L TI TTAXZ0K DMPIH4L TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMPIH4L MA Inhibitor DMPIH4L RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMPIH4L RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMPIHN6 DI DMPIHN6 DMPIHN6 DN AZD5582 DMPIHN6 TI TTQ5LRD DMPIHN6 TN Cellular inhibitor of apoptosis 1 (BIRC2) DMPIHN6 MA Antagonist DMPIHN6 RN Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919. DMPIHN6 RU https://pubmed.ncbi.nlm.nih.gov/24320998 DMPIHN6 DI DMPIHN6 DMPIHN6 DN AZD5582 DMPIHN6 TI TTK3WBU DMPIHN6 TN XIAP messenger RNA (XIAP mRNA) DMPIHN6 MA Antagonist DMPIHN6 RN Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919. DMPIHN6 RU https://pubmed.ncbi.nlm.nih.gov/24320998 DMPIHN6 DI DMPIHN6 DMPIHN6 DN AZD5582 DMPIHN6 TI TTIRY6K DMPIHN6 TN Cellular inhibitor of apoptosis 2 (BIRC3) DMPIHN6 MA Antagonist DMPIHN6 RN Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582). J Med Chem. 2013 Dec 27;56(24):9897-919. DMPIHN6 RU https://pubmed.ncbi.nlm.nih.gov/24320998 DMPIMRC DI DMPIMRC DMPIMRC DN N-Hydroxy-3-naphthalen-2-yl-propionamide DMPIMRC TI TT2J34L DMPIMRC TN Arachidonate 5-lipoxygenase (5-LOX) DMPIMRC MA Inhibitor DMPIMRC RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMPIMRC RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMPINBR DI DMPINBR DMPINBR DN 4-chlorophenyl 10H-phenothiazine-10-carboxylate DMPINBR TI TTEB0GD DMPINBR TN Cholinesterase (BCHE) DMPINBR MA Inhibitor DMPINBR RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMPINBR RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMPIQTE DI DMPIQTE DMPIQTE DN 2-Phenylheme DMPIQTE TI TTI6V2A DMPIQTE TN Heme oxygenase 1 (HMOX1) DMPIQTE MA Inhibitor DMPIQTE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPIQTE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPIRE0 DI DMPIRE0 DMPIRE0 DN GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2 DMPIRE0 TI TTBPW3J DMPIRE0 TN Galanin receptor type 2 (GAL2-R) DMPIRE0 MA Inhibitor DMPIRE0 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMPIRE0 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMPIRE0 DI DMPIRE0 DMPIRE0 DN GwTLNSAGYLLGPHAVGNHRSFSDKNGLTS-CONH2 DMPIRE0 TI TTX3HNZ DMPIRE0 TN Galanin receptor type 1 (GAL1-R) DMPIRE0 MA Inhibitor DMPIRE0 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMPIRE0 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMPITR9 DI DMPITR9 DMPITR9 DN 5-boronothiophene-2-carboxylic acid DMPITR9 TI TTLP6GN DMPITR9 TN Bacterial DD-carboxypeptidase (Bact vanYB) DMPITR9 MA Inhibitor DMPITR9 RN Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106. DMPITR9 RU https://pubmed.ncbi.nlm.nih.gov/19731939 DMPIUKZ DI DMPIUKZ DMPIUKZ DN (E,E)-8-(4-Phenylbutadien-1-yl)caffeine DMPIUKZ TI TTM2AOE DMPIUKZ TN Adenosine A2a receptor (ADORA2A) DMPIUKZ MA Inhibitor DMPIUKZ RN Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84. DMPIUKZ RU https://pubmed.ncbi.nlm.nih.gov/18723354 DMPIV1G DI DMPIV1G DMPIV1G DN Ilatreotide DMPIV1G TI TTOMNR9 DMPIV1G TN Somatostatin receptor (SSTR) DMPIV1G MA Modulator DMPIV1G RN Inhibitory effect of intraduodenal administration of somatostatin analogue SDZ CO 611 on rat pancreatic exocrine secretion. Pancreas. 1993 Jul;8(4):471-5. DMPIV1G RU https://www.ncbi.nlm.nih.gov/pubmed/8361968 DMPIV6J DI DMPIV6J DMPIV6J DN 4-hydroxysaprothoquinone DMPIV6J TI TTGTQHC DMPIV6J TN DNA topoisomerase I (TOP1) DMPIV6J MA Inhibitor DMPIV6J RN Bioactive abietane and seco-abietane diterpenoids from Salvia prionitis. J Nat Prod. 2002 Jul;65(7):1016-20. DMPIV6J RU https://pubmed.ncbi.nlm.nih.gov/12141863 DMPJ08G DI DMPJ08G DMPJ08G DN Cyclopiazonic acid DMPJ08G TI TTZVSJ2 DMPJ08G TN Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A) DMPJ08G MA Inhibitor DMPJ08G RN Expression and functional characterization of a Plasmodium falciparum Ca2+-ATPase (PfATP4) belonging to a subclass unique to apicomplexan organisms. J Biol Chem. 2001 Apr 6;276(14):10782-7. DMPJ08G RU https://pubmed.ncbi.nlm.nih.gov/11145964 DMPJ0O6 DI DMPJ0O6 DMPJ0O6 DN 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol DMPJ0O6 TI TT1MPAY DMPJ0O6 TN GABA(A) receptor alpha-1 (GABRA1) DMPJ0O6 MA Inhibitor DMPJ0O6 RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMPJ0O6 RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMPJ0O6 DI DMPJ0O6 DMPJ0O6 DN 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol DMPJ0O6 TI TTZA1NY DMPJ0O6 TN GABA(A) receptor beta-2 (GABRB2) DMPJ0O6 MA Inhibitor DMPJ0O6 RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMPJ0O6 RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMPJ0O6 DI DMPJ0O6 DMPJ0O6 DN 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol DMPJ0O6 TI TTNJYV2 DMPJ0O6 TN Gamma-aminobutyric acid receptor (GAR) DMPJ0O6 MA Inhibitor DMPJ0O6 RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMPJ0O6 RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMPJ0O6 DI DMPJ0O6 DMPJ0O6 DN 2-(9-Benzyl-9H-purin-6-ylamino)-ethanol DMPJ0O6 TI TT06RH5 DMPJ0O6 TN GABA(A) receptor gamma-2 (GABRG2) DMPJ0O6 MA Inhibitor DMPJ0O6 RN Benzodiazepine receptor binding activity of 6,9-disubstituted purines. J Med Chem. 1989 May;32(5):1020-4. DMPJ0O6 RU https://pubmed.ncbi.nlm.nih.gov/2540330 DMPJAB5 DI DMPJAB5 DMPJAB5 DN ISIS 113906 DMPJAB5 TI TTIX0ZU DMPJAB5 TN MEKK2 messenger RNA (MAP3K2 mRNA) DMPJAB5 RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMPJAB5 RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMPJAKL DI DMPJAKL DMPJAKL DN (Z)-5-Amino-3-(4-methoxybenzylidene)indolin-2-one DMPJAKL TI TT4DXQT DMPJAKL TN Proto-oncogene c-Ret (RET) DMPJAKL MA Inhibitor DMPJAKL RN Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. DMPJAKL RU https://pubmed.ncbi.nlm.nih.gov/20117004 DMPJBNC DI DMPJBNC DMPJBNC DN 3-mercapto-2-(piperidin-3-yl)propanoic acid DMPJBNC TI TTP18AY DMPJBNC TN Carboxypeptidase B2 (CPB2) DMPJBNC MA Inhibitor DMPJBNC RN 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54. DMPJBNC RU https://pubmed.ncbi.nlm.nih.gov/17189688 DMPJFGI DI DMPJFGI DMPJFGI DN L-AP4 DMPJFGI TI TTICZ1O DMPJFGI TN Metabotropic glutamate receptor 4 (mGluR4) DMPJFGI MA Agonist DMPJFGI RN Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13. DMPJFGI RU https://pubmed.ncbi.nlm.nih.gov/10187777 DMPJFGI DI DMPJFGI DMPJFGI DN L-AP4 DMPJFGI TI TTWRP2F DMPJFGI TN Metabotropic glutamate receptor 6 (mGluR6) DMPJFGI MA Agonist DMPJFGI RN Cloning, distribution and functional expression of the human mGlu6 metabotropic glutamate receptor. Neuropharmacology. 1997 Feb;36(2):145-52. DMPJFGI RU https://pubmed.ncbi.nlm.nih.gov/9144651 DMPJFGI DI DMPJFGI DMPJFGI DN L-AP4 DMPJFGI TI TT0IFKL DMPJFGI TN Metabotropic glutamate receptor 8 (mGluR8) DMPJFGI MA Agonist DMPJFGI RN Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10. DMPJFGI RU https://pubmed.ncbi.nlm.nih.gov/10216218 DMPJFGI DI DMPJFGI DMPJFGI DN L-AP4 DMPJFGI TI TT0I76D DMPJFGI TN Metabotropic glutamate receptor 7 (mGluR7) DMPJFGI MA Agonist DMPJFGI RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMPJFGI RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMPJKBV DI DMPJKBV DMPJKBV DN KJM429 DMPJKBV TI TTMI6F5 DMPJKBV TN Transient receptor potential cation channel V1 (TRPV1) DMPJKBV MA Antagonist DMPJKBV RN High affinity antagonists of the vanilloid receptor. Mol Pharmacol. 2002 Oct;62(4):947-56. DMPJKBV RU https://pubmed.ncbi.nlm.nih.gov/12237342 DMPJR98 DI DMPJR98 DMPJR98 DN Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2 DMPJR98 TI TTVFO0U DMPJR98 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMPJR98 MA Inhibitor DMPJR98 RN Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide ... J Med Chem. 1987 Aug;30(8):1366-73. DMPJR98 RU https://pubmed.ncbi.nlm.nih.gov/2441054 DMPJR98 DI DMPJR98 DMPJR98 DN Boc-Asp-Tyr(So3-)-Nle-Gly-Trp-Asp-Phe-NH2 DMPJR98 TI TTCG0AL DMPJR98 TN Cholecystokinin receptor type A (CCKAR) DMPJR98 MA Inhibitor DMPJR98 RN Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide ... J Med Chem. 1987 Aug;30(8):1366-73. DMPJR98 RU https://pubmed.ncbi.nlm.nih.gov/2441054 DMPJRHX DI DMPJRHX DMPJRHX DN ATF-HI-8 DMPJRHX TI TTGY7WI DMPJRHX TN Urokinase-type plasminogen activator (PLAU) DMPJRHX MA Modulator DMPJRHX RN Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361-6. DMPJRHX RU https://www.ncbi.nlm.nih.gov/pubmed/7713945 DMPJRHX DI DMPJRHX DMPJRHX DN ATF-HI-8 DMPJRHX TI TT2WR1T DMPJRHX TN Cationic trypsinogen (PRSS1) DMPJRHX MA Modulator DMPJRHX RN Inhibitory effect of a conjugate between human urokinase and urinary trypsin inhibitor on tumor cell invasion in vitro. J Biol Chem. 1995 Apr 7;270(14):8361-6. DMPJRHX RU https://www.ncbi.nlm.nih.gov/pubmed/7713945 DMPJT1C DI DMPJT1C DMPJT1C DN 2MD DMPJT1C TI TTK59TV DMPJT1C TN Vitamin D3 receptor (VDR) DMPJT1C MA Agonist DMPJT1C RN New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998 Nov 5;41(23):4662-74. DMPJT1C RU https://pubmed.ncbi.nlm.nih.gov/9804706 DMPJT3V DI DMPJT3V DMPJT3V DN 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione DMPJT3V TI TTMF541 DMPJT3V TN Liver carboxylesterase (CES1) DMPJT3V MA Inhibitor DMPJT3V RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMPJT3V RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMPJTLM DI DMPJTLM DMPJTLM DN RWJ-38063 DMPJTLM TI TTNGILX DMPJTLM TN Adrenergic receptor alpha-1A (ADRA1A) DMPJTLM MA Inhibitor DMPJTLM RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMPJTLM RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMPJTLM DI DMPJTLM DMPJTLM DN RWJ-38063 DMPJTLM TI TT34BHT DMPJTLM TN Adrenergic receptor alpha-1D (ADRA1D) DMPJTLM MA Inhibitor DMPJTLM RN Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6. DMPJTLM RU https://pubmed.ncbi.nlm.nih.gov/10843225 DMPJWIB DI DMPJWIB DMPJWIB DN 7-chloro-1,3-dihydroxyacridone DMPJWIB TI TT0IHXV DMPJWIB TN DNA topoisomerase II (TOP2) DMPJWIB MA Inhibitor DMPJWIB RN 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34. DMPJWIB RU https://pubmed.ncbi.nlm.nih.gov/10809021 DMPJXZN DI DMPJXZN DMPJXZN DN impentamine DMPJXZN TI TT9JNIC DMPJXZN TN Histamine H3 receptor (H3R) DMPJXZN MA Agonist DMPJXZN RN Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists. J Med Chem. 2003 Dec 4;46(25):5445-57. DMPJXZN RU https://pubmed.ncbi.nlm.nih.gov/14640553 DMPK2JO DI DMPK2JO DMPK2JO DN NI-105 DMPK2JO TI TTS87KH DMPK2JO TN Microtubule-associated protein tau (MAPT) DMPK2JO MA Modulator DMPK2JO RN Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7. DMPK2JO RU https://pubmed.ncbi.nlm.nih.gov/21902667 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTBZ7OD DMPK6YT TN Protein kinase C epsilon (PRKCE) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTR5TV4 DMPK6YT TN ERBB2 messenger RNA (HER2 mRNA) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TT7HF4W DMPK6YT TN Cyclin-dependent kinase 2 (CDK2) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTGKNB4 DMPK6YT TN Epidermal growth factor receptor (EGFR) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TT9P6OW DMPK6YT TN G2/mitotic-specific cyclin B1 (CCNB1) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTUTJGQ DMPK6YT TN Vascular endothelial growth factor receptor 2 (KDR) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TT0PG8F DMPK6YT TN Cyclin-dependent kinase 4 (CDK4) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTFJ8Q1 DMPK6YT TN Protein kinase C alpha (PRKCA) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TT9VGXW DMPK6YT TN Angiopoietin 1 receptor (TEK) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTH6V3D DMPK6YT TN Cyclin-dependent kinase 1 (CDK1) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTO0FDJ DMPK6YT TN Cyclin-dependent kinase 6 (CDK6) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTCEJ4F DMPK6YT TN G1/S-specific cyclin-E1 (CCNE1) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTFCJ7S DMPK6YT TN G1/S-specific cyclin-D1 (CCND1) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK6YT DI DMPK6YT DMPK6YT DN 3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT TI TTRFOXJ DMPK6YT TN Protein kinase C gamma (PRKCG) DMPK6YT MA Inhibitor DMPK6YT RN Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. DMPK6YT RU https://pubmed.ncbi.nlm.nih.gov/16480264 DMPK74W DI DMPK74W DMPK74W DN C[Glu21-Lys26][Gly8]GLP-1(7-37)-NH2 DMPK74W TI TTVIMDE DMPK74W TN Glucagon-like peptide 1 receptor (GLP1R) DMPK74W MA Inhibitor DMPK74W RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMPK74W RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMPK9LG DI DMPK9LG DMPK9LG DN Ac-ICVWQD(5fW)GAHRCT-NH2 DMPK9LG TI TTJGY7A DMPK9LG TN Complement C3 (CO3) DMPK9LG MA Inhibitor DMPK9LG RN Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22. DMPK9LG RU https://pubmed.ncbi.nlm.nih.gov/16854067 DMPKAEW DI DMPKAEW DMPKAEW DN BPH-676 DMPKAEW TI TTIKWV4 DMPKAEW TN Geranyltranstransferase (FDPS) DMPKAEW MA Inhibitor DMPKAEW RN Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10022-7. DMPKAEW RU https://pubmed.ncbi.nlm.nih.gov/17535895 DMPKBT1 DI DMPKBT1 DMPKBT1 DN N-[2-(4'-Nitrophenyl)ethyl]-imidazole DMPKBT1 TI TTSZLWK DMPKBT1 TN Aromatase (CYP19A1) DMPKBT1 MA Inhibitor DMPKBT1 RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMPKBT1 RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMPKBVR DI DMPKBVR DMPKBVR DN 2-acetamido-5-sulfonamidoindane DMPKBVR TI TT2LVK8 DMPKBVR TN Carbonic anhydrase IX (CA-IX) DMPKBVR MA Inhibitor DMPKBVR RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMPKBVR RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMPKBVR DI DMPKBVR DMPKBVR DN 2-acetamido-5-sulfonamidoindane DMPKBVR TI TTANPDJ DMPKBVR TN Carbonic anhydrase II (CA-II) DMPKBVR MA Inhibitor DMPKBVR RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMPKBVR RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMPKBVR DI DMPKBVR DMPKBVR DN 2-acetamido-5-sulfonamidoindane DMPKBVR TI TTHQPL7 DMPKBVR TN Carbonic anhydrase I (CA-I) DMPKBVR MA Inhibitor DMPKBVR RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMPKBVR RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMPKDJ4 DI DMPKDJ4 DMPKDJ4 DN KUR-CXCR4 DMPKDJ4 TI TTBID49 DMPKDJ4 TN C-X-C chemokine receptor type 4 (CXCR4) DMPKDJ4 MA Modulator DMPKDJ4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMPKDJ4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMPKE6G DI DMPKE6G DMPKE6G DN 4-(2,4-dichloro-phenoxy)-2'-methyl-biphenyl-3-ol DMPKE6G TI TTNX2CS DMPKE6G TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMPKE6G MA Inhibitor DMPKE6G RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DMPKE6G RU https://pubmed.ncbi.nlm.nih.gov/17567585 DMPKFYZ DI DMPKFYZ DMPKFYZ DN CACA DMPKFYZ TI TT6XFEU DMPKFYZ TN GABA(A) receptor rho1 (GABRR1) DMPKFYZ MA Agonist DMPKFYZ RN Characterization of bicuculline/baclofen-insensitive (rho-like) gamma-aminobutyric acid receptors expressed in Xenopus oocytes. II. Pharmacology of gamma-aminobutyric acidA and gamma-aminobutyric acidB receptor agonists and antagonists. Mol Pharmacol. 1993 Apr;43(4):609-25. DMPKFYZ RU https://pubmed.ncbi.nlm.nih.gov/8386310 DMPKGHB DI DMPKGHB DMPKGHB DN [3H]MDL105519 DMPKGHB TI TTLD29N DMPKGHB TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMPKGHB MA Antagonist DMPKGHB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMPKGHB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMPKGHB DI DMPKGHB DMPKGHB DN [3H]MDL105519 DMPKGHB TI TTKJEMQ DMPKGHB TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMPKGHB MA Antagonist DMPKGHB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMPKGHB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMPKGHB DI DMPKGHB DMPKGHB DN [3H]MDL105519 DMPKGHB TI TT5POTG DMPKGHB TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMPKGHB MA Antagonist DMPKGHB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMPKGHB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMPKGHB DI DMPKGHB DMPKGHB DN [3H]MDL105519 DMPKGHB TI TTN9D8E DMPKGHB TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMPKGHB MA Antagonist DMPKGHB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMPKGHB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMPKGHB DI DMPKGHB DMPKGHB DN [3H]MDL105519 DMPKGHB TI TT1M8OW DMPKGHB TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMPKGHB MA Antagonist DMPKGHB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMPKGHB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMPKGIU DI DMPKGIU DMPKGIU DN ISIS 32024 DMPKGIU TI TT9H4P3 DMPKGIU TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMPKGIU RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMPKGIU RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMPKGJC DI DMPKGJC DMPKGJC DN 5-(3-butylpyrrolidin-3-yl)-1H-indole DMPKGJC TI TTQ6VDM DMPKGJC TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMPKGJC MA Inhibitor DMPKGJC RN Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6. DMPKGJC RU https://pubmed.ncbi.nlm.nih.gov/18954985 DMPKI0N DI DMPKI0N DMPKI0N DN EBIO DMPKI0N TI TT9JH25 DMPKI0N TN Calcium-activated potassium channel KCa2.3 (KCNN3) DMPKI0N MA Activator DMPKI0N RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DMPKI0N RU https://pubmed.ncbi.nlm.nih.gov/20359520 DMPKI0N DI DMPKI0N DMPKI0N DN EBIO DMPKI0N TI TT2T5M0 DMPKI0N TN Calcium-activated potassium channel KCa2.2 (KCNN2) DMPKI0N MA Activator DMPKI0N RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DMPKI0N RU https://pubmed.ncbi.nlm.nih.gov/20359520 DMPKI0N DI DMPKI0N DMPKI0N DN EBIO DMPKI0N TI TT7M9I6 DMPKI0N TN Calcium-activated potassium channel KCa3.1 (KCNN4) DMPKI0N MA Activator DMPKI0N RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DMPKI0N RU https://pubmed.ncbi.nlm.nih.gov/20359520 DMPKI0N DI DMPKI0N DMPKI0N DN EBIO DMPKI0N TI TT9R6BE DMPKI0N TN Calcium-activated potassium channel KCa2.1 (KCNN1) DMPKI0N MA Activator DMPKI0N RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DMPKI0N RU https://pubmed.ncbi.nlm.nih.gov/20359520 DMPKM9B DI DMPKM9B DMPKM9B DN (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine DMPKM9B TI TT2NUT5 DMPKM9B TN Adrenergic receptor alpha-2C (ADRA2C) DMPKM9B MA Inhibitor DMPKM9B RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DMPKM9B RU https://pubmed.ncbi.nlm.nih.gov/9016324 DMPKM9B DI DMPKM9B DMPKM9B DN (1H-Benzoimidazol-5-yl)-(1H-imidazol-2-yl)-amine DMPKM9B TI TTWG9A4 DMPKM9B TN Adrenergic receptor alpha-2A (ADRA2A) DMPKM9B MA Inhibitor DMPKM9B RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DMPKM9B RU https://pubmed.ncbi.nlm.nih.gov/9016324 DMPKQ61 DI DMPKQ61 DMPKQ61 DN ISIS 104211 DMPKQ61 TI TTCQ2E5 DMPKQ61 TN RIP2 messenger RNA (RIP2 mRNA) DMPKQ61 RN US patent application no. 6,426,221, Antisense modulation of RIP2 expression. DMPKQ61 RU http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true DMPKQER DI DMPKQER DMPKQER DN Diketonitrile DMPKQER TI TT8DSFC DMPKQER TN Hydroxyphenylpyruvate dioxygenase (HPD) DMPKQER MA Inhibitor DMPKQER RN 4-Hydroxyphenylpyruvate dioxygenase as a drug discovery target. Drug News Perspect. 2003 Oct;16(8):493-6. DMPKQER RU https://pubmed.ncbi.nlm.nih.gov/14668946 DMPKSTD DI DMPKSTD DMPKSTD DN VU0155041 DMPKSTD TI TTICZ1O DMPKSTD TN Metabotropic glutamate receptor 4 (mGluR4) DMPKSTD MA Modulator (allosteric modulator) DMPKSTD RN Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol. 2008 Nov;74(5):1345-58. DMPKSTD RU https://pubmed.ncbi.nlm.nih.gov/18664603 DMPKTB4 DI DMPKTB4 DMPKTB4 DN DTD DMPKTB4 TI TTSXVID DMPKTB4 TN Nuclear factor NF-kappa-B (NFKB) DMPKTB4 MA Inhibitor DMPKTB4 RN A new ditriazine inhibitor of NF-kappaB modulates chronic inflammation and angiogenesis. Naunyn Schmiedebergs Arch Pharmacol. 2002 May;365(5):357-64. DMPKTB4 RU https://pubmed.ncbi.nlm.nih.gov/12012021 DMPKWIN DI DMPKWIN DMPKWIN DN (R)-N2-{4-[(3-chlorobenzyl)oxy]benzyl}alaninamide DMPKWIN TI TTGP7BY DMPKWIN TN Monoamine oxidase type B (MAO-B) DMPKWIN MA Inhibitor DMPKWIN RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMPKWIN RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMPKWUO DI DMPKWUO DMPKWUO DN imbutamine DMPKWUO TI TT9JNIC DMPKWUO TN Histamine H3 receptor (H3R) DMPKWUO MA Agonist DMPKWUO RN Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists. J Med Chem. 2003 Dec 4;46(25):5445-57. DMPKWUO RU https://pubmed.ncbi.nlm.nih.gov/14640553 DMPKXNZ DI DMPKXNZ DMPKXNZ DN PFI-4 DMPKXNZ TI TTT46BN DMPKXNZ TN Bromodomain and PHD finger containing 1 (BRPF1) DMPKXNZ MA Inhibitor DMPKXNZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2730). DMPKXNZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2730 DMPL0BA DI DMPL0BA DMPL0BA DN ANDROSTENEDONE DMPL0BA TI TTSZLWK DMPL0BA TN Aromatase (CYP19A1) DMPL0BA MA Inhibitor DMPL0BA RN Effects of steroid D-ring modification on suicide inactivation and competitive inhibition of aromatase by analogues of androsta-1,4-diene-3,17-dione. J Med Chem. 1989 Mar;32(3):651-8. DMPL0BA RU https://pubmed.ncbi.nlm.nih.gov/2918514 DMPL0BR DI DMPL0BR DMPL0BR DN H-Cxp-ala-Gly-Phe-leu-OH DMPL0BR TI TT27RFC DMPL0BR TN Opioid receptor delta (OPRD1) DMPL0BR MA Inhibitor DMPL0BR RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMPL0BR RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMPL26K DI DMPL26K DMPL26K DN N-(2,3-Dihydro-1H-phenalen-2-yl)-acetamide DMPL26K TI TT0WAIE DMPL26K TN Melatonin receptor type 1A (MTNR1A) DMPL26K MA Inhibitor DMPL26K RN Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. J Med Chem. 1996 Aug 2;39(16):3089-95. DMPL26K RU https://pubmed.ncbi.nlm.nih.gov/8759629 DMPL3UZ DI DMPL3UZ DMPL3UZ DN 1-(5-(furan-2-yl)oxazol-2-yl)octadec-9-en-1-one DMPL3UZ TI TTDP1UC DMPL3UZ TN Fatty acid amide hydrolase (FAAH) DMPL3UZ MA Inhibitor DMPL3UZ RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMPL3UZ RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMPL5XV DI DMPL5XV DMPL5XV DN 6-(4-Nitro-benzylsulfanyl)-9-phenethyl-9H-purine DMPL5XV TI TTLXAKE DMPL5XV TN Solute carrier family 29 member 1 (SLC29A1) DMPL5XV MA Inhibitor DMPL5XV RN Inhibition of nucleoside transport by new analogues of 4-nitrobenzylthioinosine: replacement of the ribose moiety by substituted benzyl groups. J Med Chem. 2004 Oct 21;47(22):5441-50. DMPL5XV RU https://pubmed.ncbi.nlm.nih.gov/15481982 DMPL80G DI DMPL80G DMPL80G DN (24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol DMPL80G TI TTEB0GD DMPL80G TN Cholinesterase (BCHE) DMPL80G MA Inhibitor DMPL80G RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMPL80G RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMPL80G DI DMPL80G DMPL80G DN (24S)-ethylcholesta-7,9(11),22(E)-triene-3b-ol DMPL80G TI TT1RS9F DMPL80G TN Acetylcholinesterase (AChE) DMPL80G MA Inhibitor DMPL80G RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMPL80G RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMPLB3S DI DMPLB3S DMPLB3S DN 5PAM523 DMPLB3S TI TTHS256 DMPLB3S TN Metabotropic glutamate receptor 5 (mGluR5) DMPLB3S MA Modulator (allosteric modulator) DMPLB3S RN Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target. Neuropharmacology. 2014 Jul;82:161-73. DMPLB3S RU https://pubmed.ncbi.nlm.nih.gov/23291536 DMPLEC0 DI DMPLEC0 DMPLEC0 DN 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPLEC0 TI TTAWNKZ DMPLEC0 TN Norepinephrine transporter (NET) DMPLEC0 MA Inhibitor DMPLEC0 RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMPLEC0 RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMPLEC0 DI DMPLEC0 DMPLEC0 DN 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPLEC0 TI TTVBI8W DMPLEC0 TN Dopamine transporter (DAT) DMPLEC0 MA Inhibitor DMPLEC0 RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMPLEC0 RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMPLEC0 DI DMPLEC0 DMPLEC0 DN 1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMPLEC0 TI TT3ROYC DMPLEC0 TN Serotonin transporter (SERT) DMPLEC0 MA Inhibitor DMPLEC0 RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMPLEC0 RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMPLFRC DI DMPLFRC DMPLFRC DN KSG-YEKLSSIESDV DMPLFRC TI TT9PB26 DMPLFRC TN Presynaptic density protein 95 (DLG4) DMPLFRC MA Inhibitor DMPLFRC RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMPLFRC RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMPLG4R DI DMPLG4R DMPLG4R DN HU-433 DMPLG4R TI TTMSFAW DMPLG4R TN Cannabinoid receptor 2 (CB2) DMPLG4R MA Activator DMPLG4R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DMPLG4R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DMPLG9Q DI DMPLG9Q DMPLG9Q DN 4-(2,6-dimethylphenylthio)-2-methoxybenzonitrile DMPLG9Q TI TTKPW01 DMPLG9Q TN Androgen receptor messenger RNA (AR mRNA) DMPLG9Q MA Inhibitor DMPLG9Q RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMPLG9Q RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMPLHEY DI DMPLHEY DMPLHEY DN 1-(2-Hydroxy-5-nitro-phenyl)-3-phenyl-urea DMPLHEY TI TT30C9G DMPLHEY TN C-X-C chemokine receptor type 2 (CXCR2) DMPLHEY MA Inhibitor DMPLHEY RN Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem. 2004 Mar 11;47(6):1319-21. DMPLHEY RU https://pubmed.ncbi.nlm.nih.gov/14998320 DMPLN58 DI DMPLN58 DMPLN58 DN 2-(3'-Ethyl-biphenyl-4-yl)-propionic acid DMPLN58 TI TT8NGED DMPLN58 TN Prostaglandin G/H synthase 1 (COX-1) DMPLN58 MA Inhibitor DMPLN58 RN Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12. DMPLN58 RU https://pubmed.ncbi.nlm.nih.gov/10091674 DMPLNTM DI DMPLNTM DMPLNTM DN ACI-636 DMPLNTM TI TTE4KHA DMPLNTM TN Amyloid beta A4 protein (APP) DMPLNTM MA Inhibitor DMPLNTM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMPLNTM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMPLUHT DI DMPLUHT DMPLUHT DN NSC-115890 DMPLUHT TI TTJLP0R DMPLUHT TN Quinone reductase 2 (NQO2) DMPLUHT MA Inhibitor DMPLUHT RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMPLUHT RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMPLV3A DI DMPLV3A DMPLV3A DN 2-(2-(2-chlorophenylamino)phenyl)acetic acid DMPLV3A TI TTCTE1G DMPLV3A TN Interleukin-8 (IL8) DMPLV3A MA Inhibitor DMPLV3A RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DMPLV3A RU https://pubmed.ncbi.nlm.nih.gov/19560921 DMPM8I5 DI DMPM8I5 DMPM8I5 DN Estradiol 3,17-O,O-bis-sulfamate DMPM8I5 TI TTHM0R1 DMPM8I5 TN Steryl-sulfatase (STS) DMPM8I5 MA Inhibitor DMPM8I5 RN 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96. DMPM8I5 RU https://pubmed.ncbi.nlm.nih.gov/17181151 DMPMAXI DI DMPMAXI DMPMAXI DN Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF DMPMAXI TI TTJX3UE DMPMAXI TN Somatostatin receptor type 3 (SSTR3) DMPMAXI MA Inhibitor DMPMAXI RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMPMAXI RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMPMAXI DI DMPMAXI DMPMAXI DN Des-AA1,4,5,13-[Tyr2,D-Trp8]-SRIF DMPMAXI TI TTIND6G DMPMAXI TN Somatostatin receptor type 1 (SSTR1) DMPMAXI MA Inhibitor DMPMAXI RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMPMAXI RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMPMBC2 DI DMPMBC2 DMPMBC2 DN N-(7-Benzyloxy-isoquinolin-1-yl)-guanidine DMPMBC2 TI TTXAGYU DMPMBC2 TN Tissue-type plasminogen activator (PLAT) DMPMBC2 MA Inhibitor DMPMBC2 RN Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30. DMPMBC2 RU https://pubmed.ncbi.nlm.nih.gov/15149680 DMPMGLO DI DMPMGLO DMPMGLO DN 1-Oxazolo[4,5-b]pyridin-2-yl-6-phenyl-hexan-1-one DMPMGLO TI TTDP1UC DMPMGLO TN Fatty acid amide hydrolase (FAAH) DMPMGLO MA Inhibitor DMPMGLO RN The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem. 2005 Aug 11;48(16):5059-87. DMPMGLO RU https://pubmed.ncbi.nlm.nih.gov/16078824 DMPMH7Z DI DMPMH7Z DMPMH7Z DN ACDPP DMPMH7Z TI TTHS256 DMPMH7Z TN Metabotropic glutamate receptor 5 (mGluR5) DMPMH7Z MA Antagonist DMPMH7Z RN Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1197-200. DMPMH7Z RU https://pubmed.ncbi.nlm.nih.gov/15686941 DMPMIN9 DI DMPMIN9 DMPMIN9 DN 1-Propyl-3-p-tolyl-piperidine hydrochloride DMPMIN9 TI TTEX248 DMPMIN9 TN Dopamine D2 receptor (D2R) DMPMIN9 MA Inhibitor DMPMIN9 RN New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8. DMPMIN9 RU https://pubmed.ncbi.nlm.nih.gov/12502370 DMPMJHV DI DMPMJHV DMPMJHV DN 8-(3-Methyl-cyclohexyloxy)-quinolin-2-ylamine DMPMJHV TI TTX4RTB DMPMJHV TN Melanin-concentrating hormone receptor 1 (MCHR1) DMPMJHV MA Inhibitor DMPMJHV RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMPMJHV RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMPML15 DI DMPML15 DMPML15 DN RAZAXABAN DMPML15 TI TTCIHJA DMPML15 TN Coagulation factor Xa (F10) DMPML15 MA Inhibitor DMPML15 RN Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS... J Med Chem. 2007 Nov 1;50(22):5339-56. DMPML15 RU https://pubmed.ncbi.nlm.nih.gov/17914785 DMPML15 DI DMPML15 DMPML15 DN RAZAXABAN DMPML15 TI TT1O264 DMPML15 TN Coagulation factor Va (F5) DMPML15 MA Inhibitor DMPML15 RN Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1795-8. DMPML15 RU https://pubmed.ncbi.nlm.nih.gov/16434195 DMPML15 DI DMPML15 DMPML15 DN RAZAXABAN DMPML15 TI TT6L509 DMPML15 TN Coagulation factor IIa (F2) DMPML15 MA Inhibitor DMPML15 RN Phenyltriazolinones as potent factor Xa inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1373-7. DMPML15 RU https://pubmed.ncbi.nlm.nih.gov/20100660 DMPML15 DI DMPML15 DMPML15 DN RAZAXABAN DMPML15 TI TTFEZ5Q DMPML15 TN Coagulation factor IX (F9) DMPML15 MA Inhibitor DMPML15 RN Aminobenzisoxazoles with biaryl P4 moieties as potent, selective, and orally bioavailable factor Xa inhibitors. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1795-8. DMPML15 RU https://pubmed.ncbi.nlm.nih.gov/16434195 DMPMLZF DI DMPMLZF DMPMLZF DN 1-(1,2,4-Oxadiazol-3-yl)-7-phenylheptan-1-one DMPMLZF TI TTDP1UC DMPMLZF TN Fatty acid amide hydrolase (FAAH) DMPMLZF MA Inhibitor DMPMLZF RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMPMLZF RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMPMOHQ DI DMPMOHQ DMPMOHQ DN 2,2'-bi(1,3,4-thiadiazole)-5,5'(4H,4'H)-dithione DMPMOHQ TI TTULVH8 DMPMOHQ TN Tyrosinase (TYR) DMPMOHQ MA Inhibitor DMPMOHQ RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMPMOHQ RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMPMX8R DI DMPMX8R DMPMX8R DN 3-Nitrophenylboronic Acid DMPMX8R TI TTHI19T DMPMX8R TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMPMX8R MA Inhibitor DMPMX8R RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPMX8R RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPN3Q0 DI DMPN3Q0 DMPN3Q0 DN SR-14136 DMPN3Q0 TI TTNT7K8 DMPN3Q0 TN Nociceptin receptor (OPRL1) DMPN3Q0 MA Binder DMPN3Q0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). DMPN3Q0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 DMPNGXE DI DMPNGXE DMPNGXE DN 2-(2-cyclohexylidenehydrazinyl)-4-phenylthiazole DMPNGXE TI TTGP7BY DMPNGXE TN Monoamine oxidase type B (MAO-B) DMPNGXE MA Inhibitor DMPNGXE RN Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. DMPNGXE RU https://pubmed.ncbi.nlm.nih.gov/20579890 DMPNQ27 DI DMPNQ27 DMPNQ27 DN Il-94 DMPNQ27 TI TTFN95D DMPNQ27 TN PAK-1 protein kinase (PAK1) DMPNQ27 MA Inhibitor DMPNQ27 RN PAK1: A Therapeutic Target for Cancer Treatment. ACS Med Chem Lett. 2013 Mar 19;4(5):431-2. DMPNQ27 RU https://pubmed.ncbi.nlm.nih.gov/24900689 DMPNQ27 DI DMPNQ27 DMPNQ27 DN Il-94 DMPNQ27 TI TT279WO DMPNQ27 TN PAK-2 protein kinase (PAK2) DMPNQ27 MA Inhibitor DMPNQ27 RN PAK1: A Therapeutic Target for Cancer Treatment. ACS Med Chem Lett. 2013 Mar 19;4(5):431-2. DMPNQ27 RU https://pubmed.ncbi.nlm.nih.gov/24900689 DMPNXFA DI DMPNXFA DMPNXFA DN 4-(Quinolinoxy)-3-pyridinesulfonamide DMPNXFA TI TTHQPL7 DMPNXFA TN Carbonic anhydrase I (CA-I) DMPNXFA MA Inhibitor DMPNXFA RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMPNXFA RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMPNXFA DI DMPNXFA DMPNXFA DN 4-(Quinolinoxy)-3-pyridinesulfonamide DMPNXFA TI TTSYM0R DMPNXFA TN Carbonic anhydrase XII (CA-XII) DMPNXFA MA Inhibitor DMPNXFA RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMPNXFA RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMPNXFA DI DMPNXFA DMPNXFA DN 4-(Quinolinoxy)-3-pyridinesulfonamide DMPNXFA TI TTANPDJ DMPNXFA TN Carbonic anhydrase II (CA-II) DMPNXFA MA Inhibitor DMPNXFA RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMPNXFA RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMPNXFA DI DMPNXFA DMPNXFA DN 4-(Quinolinoxy)-3-pyridinesulfonamide DMPNXFA TI TTEYTKG DMPNXFA TN Carbonic anhydrase XIV (CA-XIV) DMPNXFA MA Inhibitor DMPNXFA RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMPNXFA RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMPNXFA DI DMPNXFA DMPNXFA DN 4-(Quinolinoxy)-3-pyridinesulfonamide DMPNXFA TI TT2LVK8 DMPNXFA TN Carbonic anhydrase IX (CA-IX) DMPNXFA MA Inhibitor DMPNXFA RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMPNXFA RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMPO2RU DI DMPO2RU DMPO2RU DN NSC-679036 DMPO2RU TI TTML2WA DMPO2RU TN Tubulin (TUB) DMPO2RU MA Inhibitor DMPO2RU RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMPO2RU RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMPO2RU DI DMPO2RU DMPO2RU DN NSC-679036 DMPO2RU TI TTYFKSZ DMPO2RU TN Tubulin beta (TUBB) DMPO2RU MA Inhibitor DMPO2RU RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMPO2RU RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMPO3CJ DI DMPO3CJ DMPO3CJ DN 2-(N-tert-Butylamino)-3'-chlorohexanophenone DMPO3CJ TI TTAWNKZ DMPO3CJ TN Norepinephrine transporter (NET) DMPO3CJ MA Inhibitor DMPO3CJ RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMPO3CJ RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMPO3CJ DI DMPO3CJ DMPO3CJ DN 2-(N-tert-Butylamino)-3'-chlorohexanophenone DMPO3CJ TI TTVBI8W DMPO3CJ TN Dopamine transporter (DAT) DMPO3CJ MA Inhibitor DMPO3CJ RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMPO3CJ RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMPO4WX DI DMPO4WX DMPO4WX DN SR-33805A DMPO4WX TI TT5HONZ DMPO4WX TN Calcium channel unspecific (CaC) DMPO4WX MA Modulator DMPO4WX RN Vascular calcium overload produced by vitamin D3, in rats. Effect of treatment with SR 33805, a novel calcium entry blocker. Cardiovasc Res. 1995 Dec;30(6):1038-43. DMPO4WX RU https://pubmed.ncbi.nlm.nih.gov/8746222 DMPOAB7 DI DMPOAB7 DMPOAB7 DN 1,5-bis(4-hydroxyphenyl)penta-1,4-dien-3-one DMPOAB7 TI TTVG215 DMPOAB7 TN Debrisoquine 4-hydroxylase (CYP2D6) DMPOAB7 MA Inhibitor DMPOAB7 RN Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31. DMPOAB7 RU https://pubmed.ncbi.nlm.nih.gov/18249473 DMPOALD DI DMPOALD DMPOALD DN HELENALINMETHACRYLATE DMPOALD TI TTSXVID DMPOALD TN Nuclear factor NF-kappa-B (NFKB) DMPOALD MA Inhibitor DMPOALD RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMPOALD RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMPOFAR DI DMPOFAR DMPOFAR DN MCL-432 DMPOFAR TI TT27RFC DMPOFAR TN Opioid receptor delta (OPRD1) DMPOFAR MA Inhibitor DMPOFAR RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMPOFAR RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMPOFAR DI DMPOFAR DMPOFAR DN MCL-432 DMPOFAR TI TTQW87Y DMPOFAR TN Opioid receptor kappa (OPRK1) DMPOFAR MA Inhibitor DMPOFAR RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMPOFAR RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMPOFAR DI DMPOFAR DMPOFAR DN MCL-432 DMPOFAR TI TTKWM86 DMPOFAR TN Opioid receptor mu (MOP) DMPOFAR MA Inhibitor DMPOFAR RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMPOFAR RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMPOGXU DI DMPOGXU DMPOGXU DN XNT DMPOGXU TI TTUI5H7 DMPOGXU TN Angiotensin-converting enzyme 2 (ACE2) DMPOGXU MA Activator DMPOGXU RN Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008 May;51(5):1312-7. DMPOGXU RU https://pubmed.ncbi.nlm.nih.gov/18391097 DMPOIDK DI DMPOIDK DMPOIDK DN C[-Arg-Gly-Asp-Acpca19-] DMPOIDK TI TTT1R2L DMPOIDK TN Integrin alpha-V (ITGAV) DMPOIDK MA Inhibitor DMPOIDK RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMPOIDK RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMPOIDK DI DMPOIDK DMPOIDK DN C[-Arg-Gly-Asp-Acpca19-] DMPOIDK TI TTJA1ZO DMPOIDK TN ITGB3 messenger RNA (ITGB3 mRNA) DMPOIDK MA Inhibitor DMPOIDK RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMPOIDK RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMPOML4 DI DMPOML4 DMPOML4 DN GBR 12530 DMPOML4 TI TTVG215 DMPOML4 TN Debrisoquine 4-hydroxylase (CYP2D6) DMPOML4 MA Inhibitor DMPOML4 RN Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30. DMPOML4 RU https://pubmed.ncbi.nlm.nih.gov/16610785 DMPOU86 DI DMPOU86 DMPOU86 DN ADOCIAQUINONE B DMPOU86 TI TTR0SWN DMPOU86 TN M-phase inducer phosphatase 2 (MPIP2) DMPOU86 MA Inhibitor DMPOU86 RN Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9. DMPOU86 RU https://pubmed.ncbi.nlm.nih.gov/18789703 DMPOU86 DI DMPOU86 DMPOU86 DN ADOCIAQUINONE B DMPOU86 TI TTG8HIM DMPOU86 TN Dual specificity protein phosphatase 1 (DUSP1) DMPOU86 MA Inhibitor DMPOU86 RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMPOU86 RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMPOVUY DI DMPOVUY DMPOVUY DN 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one DMPOVUY TI TT3ROYC DMPOVUY TN Serotonin transporter (SERT) DMPOVUY MA Inhibitor DMPOVUY RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMPOVUY RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMPOVUY DI DMPOVUY DMPOVUY DN 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one DMPOVUY TI TTVBI8W DMPOVUY TN Dopamine transporter (DAT) DMPOVUY MA Inhibitor DMPOVUY RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMPOVUY RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMPOVUY DI DMPOVUY DMPOVUY DN 1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one DMPOVUY TI TTAWNKZ DMPOVUY TN Norepinephrine transporter (NET) DMPOVUY MA Inhibitor DMPOVUY RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMPOVUY RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMPOX4Q DI DMPOX4Q DMPOX4Q DN ML290 DMPOX4Q TI TTMAHD1 DMPOX4Q TN Relaxin receptor 1 (RXFP1) DMPOX4Q MA Modulator (allosteric modulator) DMPOX4Q RN Discovery, optimization, and biological activity of the first potent and selective small-molecule agonist series of human relaxin receptor 1 (RXFP1). Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010. DMPOX4Q RU https://pubmed.ncbi.nlm.nih.gov/23905199 DMPOYK2 DI DMPOYK2 DMPOYK2 DN (E)-3-(4-chlorophenylimino)indolin-2-one DMPOYK2 TI TTOPAY7 DMPOYK2 TN Galanin receptor (GAL-R) DMPOYK2 MA Inhibitor DMPOYK2 RN 3-arylimino-2-indolones are potent and selective galanin GAL3 receptor antagonists. J Med Chem. 2006 Jun 29;49(13):3757-8. DMPOYK2 RU https://pubmed.ncbi.nlm.nih.gov/16789730 DMPQ1HL DI DMPQ1HL DMPQ1HL DN NNC 92-1687 DMPQ1HL TI TT9O6WS DMPQ1HL TN Glucagon receptor (GCGR) DMPQ1HL MA Antagonist DMPQ1HL RN Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem. 1998 Dec 17;41(26):5150-7. DMPQ1HL RU https://pubmed.ncbi.nlm.nih.gov/9857085 DMPQ53V DI DMPQ53V DMPQ53V DN (S)-2-amino-1-(4-butylthiophenyl)-propane DMPQ53V TI TTGP7BY DMPQ53V TN Monoamine oxidase type B (MAO-B) DMPQ53V MA Inhibitor DMPQ53V RN Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206. DMPQ53V RU https://pubmed.ncbi.nlm.nih.gov/17521909 DMPQ53V DI DMPQ53V DMPQ53V DN (S)-2-amino-1-(4-butylthiophenyl)-propane DMPQ53V TI TT3WG5C DMPQ53V TN Monoamine oxidase type A (MAO-A) DMPQ53V MA Inhibitor DMPQ53V RN Human and rat monoamine oxidase-A are differentially inhibited by (S)-4-alkylthioamphetamine derivatives: insights from molecular modeling studies. Bioorg Med Chem. 2007 Aug 1;15(15):5198-206. DMPQ53V RU https://pubmed.ncbi.nlm.nih.gov/17521909 DMPQ8Z9 DI DMPQ8Z9 DMPQ8Z9 DN AcAsp-Glu-Dif-Glu-Cha-Fab DMPQ8Z9 TI TTWXB3E DMPQ8Z9 TN Hepatitis C virus NS3 helicase (HCV NS3) DMPQ8Z9 MA Inhibitor DMPQ8Z9 RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMPQ8Z9 RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMPQAGL DI DMPQAGL DMPQAGL DN (RS/SR)-2-[1-(4-chlorophenyl)propyl]piperidine DMPQAGL TI TTVBI8W DMPQAGL TN Dopamine transporter (DAT) DMPQAGL MA Inhibitor DMPQAGL RN Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter. J Med Chem. 2007 Jan 25;50(2):219-32. DMPQAGL RU https://pubmed.ncbi.nlm.nih.gov/17228864 DMPQBN0 DI DMPQBN0 DMPQBN0 DN Heptyl-Beta-D-Glucopyranoside DMPQBN0 TI TTMW94E DMPQBN0 TN FK506-binding protein 1A (FKBP1A) DMPQBN0 MA Inhibitor DMPQBN0 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMPQBN0 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMPQBN0 DI DMPQBN0 DMPQBN0 DN Heptyl-Beta-D-Glucopyranoside DMPQBN0 TI TT2JWF6 DMPQBN0 TN Peroxisome proliferator-activated receptor delta (PPARD) DMPQBN0 MA Inhibitor DMPQBN0 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMPQBN0 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMPQBWY DI DMPQBWY DMPQBWY DN (-)-englerin A DMPQBWY TI TT32NQ1 DMPQBWY TN Short transient receptor potential channel 5 (TRPC5) DMPQBWY MA Agonist DMPQBWY RN (-)-Englerin is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3787-91. DMPQBWY RU https://pubmed.ncbi.nlm.nih.gov/25707820 DMPQBWY DI DMPQBWY DMPQBWY DN (-)-englerin A DMPQBWY TI TTX0H5W DMPQBWY TN Short transient receptor potential channel 4 (TRPC4) DMPQBWY MA Agonist DMPQBWY RN (-)-Englerin is a potent and selective activator of TRPC4 and TRPC5 calcium channels. Angew Chem Int Ed Engl. 2015 Mar 16;54(12):3787-91. DMPQBWY RU https://pubmed.ncbi.nlm.nih.gov/25707820 DMPQGUL DI DMPQGUL DMPQGUL DN ORIPAVINE DMPQGUL TI TTKWM86 DMPQGUL TN Opioid receptor mu (MOP) DMPQGUL MA Inhibitor DMPQGUL RN Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32. DMPQGUL RU https://pubmed.ncbi.nlm.nih.gov/17616524 DMPQHRC DI DMPQHRC DMPQHRC DN D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP) DMPQHRC TI TT27RFC DMPQHRC TN Opioid receptor delta (OPRD1) DMPQHRC MA Inhibitor DMPQHRC RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMPQHRC RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMPQHRC DI DMPQHRC DMPQHRC DN D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP) DMPQHRC TI TTKWM86 DMPQHRC TN Opioid receptor mu (MOP) DMPQHRC MA Inhibitor DMPQHRC RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMPQHRC RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMPQKGY DI DMPQKGY DMPQKGY DN 4-methoxy-N-(thiazol-2-yl)benzamide DMPQKGY TI TTSJ6Q4 DMPQKGY TN LOX-5 messenger RNA (ALOX5 mRNA) DMPQKGY MA Inhibitor DMPQKGY RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMPQKGY RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMPQOS2 DI DMPQOS2 DMPQOS2 DN 3-bromo-5-(2-methylquinolin-7-yl)benzonitrile DMPQOS2 TI TTHS256 DMPQOS2 TN Metabotropic glutamate receptor 5 (mGluR5) DMPQOS2 MA Inhibitor DMPQOS2 RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMPQOS2 RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMPQSZN DI DMPQSZN DMPQSZN DN 5-(Biphenyl-4-yl)-pentanoic acid N-hydroxyamide DMPQSZN TI TTSHTOI DMPQSZN TN Histone deacetylase 2 (HDAC2) DMPQSZN MA Inhibitor DMPQSZN RN Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12. DMPQSZN RU https://pubmed.ncbi.nlm.nih.gov/19084294 DMPQTNK DI DMPQTNK DMPQTNK DN 6-hydroxy-7,9-octadecadiynoic acid DMPQTNK TI TTPADOQ DMPQTNK TN HMG-CoA reductase (HMGCR) DMPQTNK MA Inhibitor DMPQTNK RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DMPQTNK RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DMPR14J DI DMPR14J DMPR14J DN Bimetopyrole DMPR14J TI TTVKILB DMPR14J TN Prostaglandin G/H synthase 2 (COX-2) DMPR14J MA Inhibitor DMPR14J RN Current status of COX-2 inhibitors. Mini Rev Med Chem. 2008 Jan;8(1):73-90. DMPR14J RU https://pubmed.ncbi.nlm.nih.gov/18220987 DMPR7OD DI DMPR7OD DMPR7OD DN ISIS 107642 DMPR7OD TI TT6SZNG DMPR7OD TN Caspase 8 messenger RNA (CASP8 mRNA) DMPR7OD RN US patent application no. 6,258,600, Antisense modulation of caspase 8 expression. DMPR7OD RU http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true DMPRALC DI DMPRALC DMPRALC DN 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine DMPRALC TI TT3ROYC DMPRALC TN Serotonin transporter (SERT) DMPRALC MA Inhibitor DMPRALC RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMPRALC RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMPRALC DI DMPRALC DMPRALC DN 1-(2-(2-bromophenyl)-1-phenylethyl)piperazine DMPRALC TI TTAWNKZ DMPRALC TN Norepinephrine transporter (NET) DMPRALC MA Inhibitor DMPRALC RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMPRALC RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMPRBLH DI DMPRBLH DMPRBLH DN 3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol DMPRBLH TI TTZAYWL DMPRBLH TN Estrogen receptor (ESR) DMPRBLH MA Inhibitor DMPRBLH RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMPRBLH RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMPRBLH DI DMPRBLH DMPRBLH DN 3-(5-Hydroxy-benzooxazol-2-yl)-benzene-1,2-diol DMPRBLH TI TTOM3J0 DMPRBLH TN Estrogen receptor beta (ESR2) DMPRBLH MA Inhibitor DMPRBLH RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMPRBLH RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMPRBO1 DI DMPRBO1 DMPRBO1 DN 7-Allyl-1,3-dimethyl-3,7-dihydro-purine-2,6-dione DMPRBO1 TI TTM2AOE DMPRBO1 TN Adenosine A2a receptor (ADORA2A) DMPRBO1 MA Inhibitor DMPRBO1 RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DMPRBO1 RU https://pubmed.ncbi.nlm.nih.gov/3806581 DMPRCS0 DI DMPRCS0 DMPRCS0 DN 3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one DMPRCS0 TI TTDP1UC DMPRCS0 TN Fatty acid amide hydrolase (FAAH) DMPRCS0 MA Inhibitor DMPRCS0 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMPRCS0 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMPRCS0 DI DMPRCS0 DMPRCS0 DN 3-(dodecylsulfonyl)-1,1,1-trifluoropropan-2-one DMPRCS0 TI TTMF541 DMPRCS0 TN Liver carboxylesterase (CES1) DMPRCS0 MA Inhibitor DMPRCS0 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMPRCS0 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMPRDXO DI DMPRDXO DMPRDXO DN ISIS 113905 DMPRDXO TI TTIX0ZU DMPRDXO TN MEKK2 messenger RNA (MAP3K2 mRNA) DMPRDXO RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMPRDXO RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMPRF1X DI DMPRF1X DMPRF1X DN 2,3,4-Trimethoxy-4'-amino-trans-stilbene DMPRF1X TI TTSZLWK DMPRF1X TN Aromatase (CYP19A1) DMPRF1X MA Inhibitor DMPRF1X RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMPRF1X RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMPRMOD DI DMPRMOD DMPRMOD DN FSHR NAM DMPRMOD TI TTZFDBT DMPRMOD TN Follicle-stimulating hormone receptor (FSHR) DMPRMOD MA Modulator DMPRMOD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 253). DMPRMOD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=253 DMPROW5 DI DMPROW5 DMPROW5 DN ISIS 112002 DMPROW5 TI TTPJ9XK DMPROW5 TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMPROW5 RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMPROW5 RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMPRTVX DI DMPRTVX DMPRTVX DN JB 98064 DMPRTVX TI TT9JNIC DMPRTVX TN Histamine H3 receptor (H3R) DMPRTVX MA Antagonist DMPRTVX RN Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur J Pharmacol. 2002 Oct 18;453(1):33-41. DMPRTVX RU https://pubmed.ncbi.nlm.nih.gov/12393057 DMPRYTW DI DMPRYTW DMPRYTW DN DCB-3503 DMPRYTW TI TTS7IR5 DMPRYTW TN c-Jun messenger RNA (c-Jun mRNA) DMPRYTW MA Inhibitor DMPRYTW RN Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4338-42. DMPRYTW RU https://pubmed.ncbi.nlm.nih.gov/17531481 DMPRZ8N DI DMPRZ8N DMPRZ8N DN F-G-G-F-T-G-A-R-K-S-Aib-R-K-L-A-N-Q-COOH DMPRZ8N TI TTNT7K8 DMPRZ8N TN Nociceptin receptor (OPRL1) DMPRZ8N MA Inhibitor DMPRZ8N RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMPRZ8N RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMPS1GW DI DMPS1GW DMPS1GW DN 3-(4H-Imidazol-4-yl)benzenethiol DMPS1GW TI TTZJYKH DMPS1GW TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMPS1GW MA Inhibitor DMPS1GW RN Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77. DMPS1GW RU https://pubmed.ncbi.nlm.nih.gov/18665584 DMPS1Y2 DI DMPS1Y2 DMPS1Y2 DN P-hydroxyphenethyl trans-ferulate DMPS1Y2 TI TTO9X1H DMPS1Y2 TN 5-HT 7 receptor (HTR7) DMPS1Y2 MA Inhibitor DMPS1Y2 RN Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod. 2006 Apr;69(4):536-41. DMPS1Y2 RU https://pubmed.ncbi.nlm.nih.gov/16643021 DMPS2B1 DI DMPS2B1 DMPS2B1 DN Hydroxydimethylarsine Oxide DMPS2B1 TI TTCM4B3 DMPS2B1 TN Nitric-oxide synthase endothelial (NOS3) DMPS2B1 MA Inhibitor DMPS2B1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPS2B1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPS2B1 DI DMPS2B1 DMPS2B1 DN Hydroxydimethylarsine Oxide DMPS2B1 TI TTFBNVI DMPS2B1 TN Aldose reductase (AKR1B1) DMPS2B1 MA Inhibitor DMPS2B1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPS2B1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPS2GX DI DMPS2GX DMPS2GX DN 6,7-Dimethoxy-4-(3-methoxy-phenoxy)-quinoline DMPS2GX TI TTI7421 DMPS2GX TN Platelet-derived growth factor receptor beta (PDGFRB) DMPS2GX MA Inhibitor DMPS2GX RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMPS2GX RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMPS340 DI DMPS340 DMPS340 DN 3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMPS340 TI TTSZLWK DMPS340 TN Aromatase (CYP19A1) DMPS340 MA Inhibitor DMPS340 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMPS340 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMPS340 DI DMPS340 DMPS340 DN 3-[4-Fluoro-indan-(1Z)-ylidenemethyl]-pyridine DMPS340 TI TTRA5BZ DMPS340 TN Steroid 17-alpha-monooxygenase (S17AH) DMPS340 MA Inhibitor DMPS340 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMPS340 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMPS6OQ DI DMPS6OQ DMPS6OQ DN ISIS 29161 DMPS6OQ TI TTO6SGY DMPS6OQ TN AKT3 messenger RNA (AKT3 mRNA) DMPS6OQ RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMPS6OQ RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMPSAQW DI DMPSAQW DMPSAQW DN 3-(2,6-Dimethyl-phenyl)-1-propyl-piperidine DMPSAQW TI TTEX248 DMPSAQW TN Dopamine D2 receptor (D2R) DMPSAQW MA Inhibitor DMPSAQW RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DMPSAQW RU https://pubmed.ncbi.nlm.nih.gov/9836610 DMPSEZV DI DMPSEZV DMPSEZV DN (R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine DMPSEZV TI TTZFYLI DMPSEZV TN Dopamine D1 receptor (D1R) DMPSEZV MA Inhibitor DMPSEZV RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMPSEZV RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMPSEZV DI DMPSEZV DMPSEZV DN (R)-(-)-N-ethyl-2-methoxy-11-hydroxynoraporphine DMPSEZV TI TTEX248 DMPSEZV TN Dopamine D2 receptor (D2R) DMPSEZV MA Inhibitor DMPSEZV RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMPSEZV RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMPSI10 DI DMPSI10 DMPSI10 DN VU0119498 DMPSI10 TI TTH18TF DMPSI10 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMPSI10 MA Inhibitor DMPSI10 RN Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of ... J Med Chem. 2009 Jun 11;52(11):3445-8. DMPSI10 RU https://pubmed.ncbi.nlm.nih.gov/19438238 DMPSI26 DI DMPSI26 DMPSI26 DN Ac-ICVWQDWGAHRCT-NH2 DMPSI26 TI TTJGY7A DMPSI26 TN Complement C3 (CO3) DMPSI26 MA Inhibitor DMPSI26 RN Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22. DMPSI26 RU https://pubmed.ncbi.nlm.nih.gov/16854067 DMPSJ72 DI DMPSJ72 DMPSJ72 DN Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 DMPSJ72 TI TTVFO0U DMPSJ72 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMPSJ72 MA Inhibitor DMPSJ72 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMPSJ72 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMPSJ72 DI DMPSJ72 DMPSJ72 DN Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 DMPSJ72 TI TTKWM86 DMPSJ72 TN Opioid receptor mu (MOP) DMPSJ72 MA Inhibitor DMPSJ72 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMPSJ72 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMPSJ72 DI DMPSJ72 DMPSJ72 DN Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 DMPSJ72 TI TT27RFC DMPSJ72 TN Opioid receptor delta (OPRD1) DMPSJ72 MA Inhibitor DMPSJ72 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMPSJ72 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMPSM4O DI DMPSM4O DMPSM4O DN 1-tert-butyl-9H-carbazole DMPSM4O TI TTBGTCW DMPSM4O TN Kinesin spindle messenger RNA (KIF11 mRNA) DMPSM4O MA Inhibitor DMPSM4O RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMPSM4O RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMPSOIF DI DMPSOIF DMPSOIF DN 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE DMPSOIF TI TTANPDJ DMPSOIF TN Carbonic anhydrase II (CA-II) DMPSOIF MA Inhibitor DMPSOIF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPSOIF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPSOIF DI DMPSOIF DMPSOIF DN 6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE DMPSOIF TI TT2AST1 DMPSOIF TN Macrophage migration inhibitory factor (MIF) DMPSOIF MA Inhibitor DMPSOIF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPSOIF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPSR1O DI DMPSR1O DMPSR1O DN 2-(2,4-dichlorophenoxy)-5-ethylphenol DMPSR1O TI TTNX2CS DMPSR1O TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMPSR1O MA Inhibitor DMPSR1O RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DMPSR1O RU https://pubmed.ncbi.nlm.nih.gov/17567585 DMPSRAC DI DMPSRAC DMPSRAC DN 4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol DMPSRAC TI TTZAYWL DMPSRAC TN Estrogen receptor (ESR) DMPSRAC MA Inhibitor DMPSRAC RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMPSRAC RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMPSRAC DI DMPSRAC DMPSRAC DN 4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol DMPSRAC TI TTPNQAC DMPSRAC TN Estrogen-related receptor-alpha (ESRRA) DMPSRAC MA Inhibitor DMPSRAC RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMPSRAC RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMPSRAC DI DMPSRAC DMPSRAC DN 4-Bromo-2-(4-hydroxy-phenyl)-quinolin-6-ol DMPSRAC TI TTOM3J0 DMPSRAC TN Estrogen receptor beta (ESR2) DMPSRAC MA Inhibitor DMPSRAC RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMPSRAC RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMPSRZ0 DI DMPSRZ0 DMPSRZ0 DN AMXT-1501 DMPSRZ0 TI TTUMGNO DMPSRZ0 TN Ornithine decarboxylase (ODC1) DMPSRZ0 MA Inhibitor DMPSRZ0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1276). DMPSRZ0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1276 DMPSXR8 DI DMPSXR8 DMPSXR8 DN NF340 DMPSXR8 TI TTYXPCO DMPSXR8 TN P2Y purinoceptor 11 (P2RY11) DMPSXR8 MA Antagonist DMPSXR8 RN Invited Lectures : Overviews Purinergic signalling: past, present and future. Purinergic Signal. 2006 May;2(1):1-324. DMPSXR8 RU https://pubmed.ncbi.nlm.nih.gov/18404494 DMPSYRW DI DMPSYRW DMPSYRW DN N-Cyclohexyl-N'-(4-Iodophenyl)Urea DMPSYRW TI TT7WVHI DMPSYRW TN Soluble epoxide hydrolase (EPHX2) DMPSYRW MA Inhibitor DMPSYRW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPSYRW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPT01J DI DMPT01J DMPT01J DN Ro-66-1168 DMPT01J TI TTB2MXP DMPT01J TN Angiotensinogenase renin (REN) DMPT01J MA Inhibitor DMPT01J RN Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors. J Med Chem. 2009 Jun 25;52(12):3689-702. DMPT01J RU https://pubmed.ncbi.nlm.nih.gov/19358611 DMPT0MB DI DMPT0MB DMPT0MB DN 2-(cyclohexylamino)benzoic acid DMPT0MB TI TTTU902 DMPT0MB TN Checkpoint kinase-1 (CHK1) DMPT0MB MA Inhibitor DMPT0MB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPT0MB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPT1ME DI DMPT1ME DMPT1ME DN [Mpa1, D-Tic7]OT DMPT1ME TI TTSCIUP DMPT1ME TN Oxytocin receptor (OTR) DMPT1ME MA Inhibitor DMPT1ME RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMPT1ME RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMPT4WM DI DMPT4WM DMPT4WM DN Cytosine Arabinose-5'-Phosphate DMPT4WM TI TTMFYEC DMPT4WM TN Streptococcus Cytidylate kinase (Stre-coc cmk) DMPT4WM MA Inhibitor DMPT4WM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPT4WM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPT8JN DI DMPT8JN DMPT8JN DN HTMT DMPT8JN TI TTXJ178 DMPT8JN TN Histamine H4 receptor (H4R) DMPT8JN MA Agonist DMPT8JN RN Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol. 2001 Mar;59(3):434-41. DMPT8JN RU https://pubmed.ncbi.nlm.nih.gov/11179436 DMPTBJZ DI DMPTBJZ DMPTBJZ DN MLS1547 DMPTBJZ TI TTEX248 DMPTBJZ TN Dopamine D2 receptor (D2R) DMPTBJZ MA Agonist DMPTBJZ RN Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor. Mol Pharmacol. 2014 Jul;86(1):96-105. DMPTBJZ RU https://pubmed.ncbi.nlm.nih.gov/24755247 DMPTDHC DI DMPTDHC DMPTDHC DN ESCHOLTZINE DMPTDHC TI TTSQIFT DMPTDHC TN 5-HT 1A receptor (HTR1A) DMPTDHC MA Inhibitor DMPTDHC RN Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in ... J Nat Prod. 2006 Mar;69(3):432-5. DMPTDHC RU https://pubmed.ncbi.nlm.nih.gov/16562853 DMPTI1Z DI DMPTI1Z DMPTI1Z DN 3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol DMPTI1Z TI TTOM3J0 DMPTI1Z TN Estrogen receptor beta (ESR2) DMPTI1Z MA Inhibitor DMPTI1Z RN Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxypheny... J Med Chem. 1986 Sep;29(9):1668-74. DMPTI1Z RU https://pubmed.ncbi.nlm.nih.gov/3018243 DMPTI1Z DI DMPTI1Z DMPTI1Z DN 3-[1-ethyl-2-(3-hydroxyphenyl)butyl]phenol DMPTI1Z TI TTZAYWL DMPTI1Z TN Estrogen receptor (ESR) DMPTI1Z MA Inhibitor DMPTI1Z RN Influence of alkyl chain ramification on estradiol receptor binding affinity and intrinsic activity of 1,2-dialkylated 1,2-bis(4- or 3-hydroxypheny... J Med Chem. 1986 Sep;29(9):1668-74. DMPTI1Z RU https://pubmed.ncbi.nlm.nih.gov/3018243 DMPTM6V DI DMPTM6V DMPTM6V DN TOLSERINE DMPTM6V TI TT1RS9F DMPTM6V TN Acetylcholinesterase (AChE) DMPTM6V MA Inhibitor DMPTM6V RN Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based vi... J Med Chem. 2010 Sep 9;53(17):6490-505. DMPTM6V RU https://pubmed.ncbi.nlm.nih.gov/20684567 DMPTM6V DI DMPTM6V DMPTM6V DN TOLSERINE DMPTM6V TI TTEB0GD DMPTM6V TN Cholinesterase (BCHE) DMPTM6V MA Inhibitor DMPTM6V RN Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J Med Chem. 2006 Apr 6;49(7):2174-85. DMPTM6V RU https://pubmed.ncbi.nlm.nih.gov/16570913 DMPTMKH DI DMPTMKH DMPTMKH DN KN-93 DMPTMKH TI TTFYL58 DMPTMKH TN CaM-kinase II (CAMK2) DMPTMKH MA Inhibitor DMPTMKH RN Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound. J Med Chem. 2002 Jan 31;45(3):563-6. DMPTMKH RU https://pubmed.ncbi.nlm.nih.gov/11806708 DMPTMKU DI DMPTMKU DMPTMKU DN 1-benzyl-3,3-diethylazetidine-2,4-dione DMPTMKU TI TTPLTSQ DMPTMKU TN Neutrophil elastase (NE) DMPTMKU MA Inhibitor DMPTMKU RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMPTMKU RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMPTNI8 DI DMPTNI8 DMPTNI8 DN N-Ethyl-ETAV DMPTNI8 TI TT9PB26 DMPTNI8 TN Presynaptic density protein 95 (DLG4) DMPTNI8 MA Inhibitor DMPTNI8 RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMPTNI8 RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMPTNUQ DI DMPTNUQ DMPTNUQ DN MC-113 DMPTNUQ TI TT5TPI6 DMPTNUQ TN Opioid receptor sigma 1 (OPRS1) DMPTNUQ MA Agonist DMPTNUQ RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMPTNUQ RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMPTQEG DI DMPTQEG DMPTQEG DN TNFR1 NAM DMPTQEG TI TTG043C DMPTQEG TN Tumor necrosis factor receptor type I (TNF-R1) DMPTQEG MA Modulator DMPTQEG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1870). DMPTQEG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870 DMPTSN0 DI DMPTSN0 DMPTSN0 DN Thiocoumarin DMPTSN0 TI TTF10I9 DMPTSN0 TN Nitric-oxide synthase inducible (NOS2) DMPTSN0 MA Inhibitor DMPTSN0 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMPTSN0 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMPTVR2 DI DMPTVR2 DMPTVR2 DN 4-(2-nitrovinyl)phenol DMPTVR2 TI TTGKNB4 DMPTVR2 TN Epidermal growth factor receptor (EGFR) DMPTVR2 MA Inhibitor DMPTVR2 RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMPTVR2 RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMPTY8S DI DMPTY8S DMPTY8S DN Aloe-emodin DMPTY8S TI TTB6UM0 DMPTY8S TN Fatty aldehyde dehydrogenase (ALDH3A2) DMPTY8S MA Inhibitor DMPTY8S RN Elgonica-Dimers A and B, Two Potent Alcohol Metabolism Inhibitory Constituents of Aloe arborescens J. Nat. Prod. 60(11):1180-1182 (1997). DMPTY8S RU http://pubs.acs.org/doi/abs/10.1021/np9703104 DMPU3QR DI DMPU3QR DMPU3QR DN A-331440 DMPU3QR TI TT9JNIC DMPU3QR TN Histamine H3 receptor (H3R) DMPU3QR MA Antagonist DMPU3QR RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMPU3QR RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMPU5TC DI DMPU5TC DMPU5TC DN YM-96765 DMPU5TC TI TTCIHJA DMPU5TC TN Coagulation factor Xa (F10) DMPU5TC MA Inhibitor DMPU5TC RN Synthesis and biological activity of novel 1,4-diazepane derivatives as factor Xa inhibitor with potent anticoagulant and antithrombotic activity. Bioorg Med Chem. 2004 May 1;12(9):2179-91. DMPU5TC RU https://pubmed.ncbi.nlm.nih.gov/15080918 DMPU7KE DI DMPU7KE DMPU7KE DN (4-Methyl-2-oxo-2H-quinolin-1-yl)-acetic acid DMPU7KE TI TTFBNVI DMPU7KE TN Aldose reductase (AKR1B1) DMPU7KE MA Inhibitor DMPU7KE RN Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8. DMPU7KE RU https://pubmed.ncbi.nlm.nih.gov/3093680 DMPU90E DI DMPU90E DMPU90E DN 2-(4-Cyclopropyl-piperazin-1-yl)-quinoline DMPU90E TI TT9JNIC DMPU90E TN Histamine H3 receptor (H3R) DMPU90E MA Inhibitor DMPU90E RN 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11. DMPU90E RU https://pubmed.ncbi.nlm.nih.gov/15634025 DMPUAFC DI DMPUAFC DMPUAFC DN AdoC(beta-Ala)2AlaArg6 DMPUAFC TI TTW4Y2M DMPUAFC TN cAMP protein kinase type II-beta (PRKAR2B) DMPUAFC MA Inhibitor DMPUAFC RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMPUAFC RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMPUAFC DI DMPUAFC DMPUAFC DN AdoC(beta-Ala)2AlaArg6 DMPUAFC TI TTNAHEX DMPUAFC TN cAMP-dependent protein kinase A type I (PRKAR1A) DMPUAFC MA Inhibitor DMPUAFC RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMPUAFC RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMPUARE DI DMPUARE DMPUARE DN 2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine DMPUARE TI TT0EOB8 DMPUARE TN B-Raf messenger RNA (BRAF mRNA) DMPUARE MA Inhibitor DMPUARE RN Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem. 2006 Jan 12;49(1):407-16. DMPUARE RU https://pubmed.ncbi.nlm.nih.gov/16392826 DMPUCMV DI DMPUCMV DMPUCMV DN Ethyl 2beta-hydroxyolean-12-en-28-oate DMPUCMV TI TTZHY6R DMPUCMV TN Glycogen phosphorylase muscle form (GP) DMPUCMV MA Inhibitor DMPUCMV RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMPUCMV RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMPUFDS DI DMPUFDS DMPUFDS DN Glutarate DMPUFDS TI TTTQR47 DMPUFDS TN Solute carrier family 22 member 8 (SLC22A8) DMPUFDS MA Inhibitor DMPUFDS RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DMPUFDS RU https://pubmed.ncbi.nlm.nih.gov/17553798 DMPULH3 DI DMPULH3 DMPULH3 DN 6-cinnamoylhernandine DMPULH3 TI TT27RFC DMPULH3 TN Opioid receptor delta (OPRD1) DMPULH3 MA Inhibitor DMPULH3 RN Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91. DMPULH3 RU https://pubmed.ncbi.nlm.nih.gov/20426456 DMPURE8 DI DMPURE8 DMPURE8 DN S-(N-4chlorophenyl-N-hydroxycarbamoyl)glutathione DMPURE8 TI TTV9A7R DMPURE8 TN Lactoylglutathione lyase (GLO1) DMPURE8 MA Inhibitor DMPURE8 RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DMPURE8 RU https://pubmed.ncbi.nlm.nih.gov/11052803 DMPV0QN DI DMPV0QN DMPV0QN DN [1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one DMPV0QN TI TTJFY5U DMPV0QN TN Adenosine A3 receptor (ADORA3) DMPV0QN MA Inhibitor DMPV0QN RN 1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological eva... J Med Chem. 2005 Dec 15;48(25):7932-45. DMPV0QN RU https://pubmed.ncbi.nlm.nih.gov/16335918 DMPV1LU DI DMPV1LU DMPV1LU DN 2'-deoxyuridylic acid DMPV1LU TI TTU6BFZ DMPV1LU TN Candida Thymidylate synthase (Candi TMP1) DMPV1LU MA Inhibitor DMPV1LU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPV1LU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPV1LU DI DMPV1LU DMPV1LU DN 2'-deoxyuridylic acid DMPV1LU TI TTY8KJS DMPV1LU TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMPV1LU MA Inhibitor DMPV1LU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPV1LU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPV450 DI DMPV450 DMPV450 DN NIPECOTIC ACID DMPV450 TI TTPRKM0 DMPV450 TN GABA transporter GAT-1 (SLC6A1) DMPV450 MA Inhibitor DMPV450 RN Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94. DMPV450 RU https://pubmed.ncbi.nlm.nih.gov/6268788 DMPV450 DI DMPV450 DMPV450 DN NIPECOTIC ACID DMPV450 TI TT8RXO5 DMPV450 TN GABA transporter-3 (SLC6A11) DMPV450 MA Inhibitor DMPV450 RN Epimeric cis-decahydroquinoline-5-carboxylic acids: effects on gamma-aminobutyric acid uptake and receptor binding in vitro. J Med Chem. 1981 Jul;24(7):788-94. DMPV450 RU https://pubmed.ncbi.nlm.nih.gov/6268788 DMPV450 DI DMPV450 DMPV450 DN NIPECOTIC ACID DMPV450 TI TTT2LD9 DMPV450 TN GABA transaminase (ABAT) DMPV450 MA Inhibitor DMPV450 RN Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist. J Med Chem. 1982 Feb;25(2):113-6. DMPV450 RU https://pubmed.ncbi.nlm.nih.gov/6276545 DMPV450 DI DMPV450 DMPV450 DN NIPECOTIC ACID DMPV450 TI TTJFY5U DMPV450 TN Adenosine A3 receptor (ADORA3) DMPV450 MA Inhibitor DMPV450 RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMPV450 RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMPV450 DI DMPV450 DMPV450 DN NIPECOTIC ACID DMPV450 TI TTNJYV2 DMPV450 TN Gamma-aminobutyric acid receptor (GAR) DMPV450 MA Inhibitor DMPV450 RN Orally active and potent inhibitors of gamma-aminobutyric acid uptake. J Med Chem. 1985 May;28(5):653-60. DMPV450 RU https://pubmed.ncbi.nlm.nih.gov/2985785 DMPV5D0 DI DMPV5D0 DMPV5D0 DN L-Tryptophan-L-leucine DMPV5D0 TI TTT2SVW DMPV5D0 TN PPAR-gamma messenger RNA (PPARG mRNA) DMPV5D0 MA Inhibitor DMPV5D0 RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DMPV5D0 RU https://pubmed.ncbi.nlm.nih.gov/18329752 DMPV674 DI DMPV674 DMPV674 DN 7-(2-Amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one DMPV674 TI TTEX248 DMPV674 TN Dopamine D2 receptor (D2R) DMPV674 MA Inhibitor DMPV674 RN Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzot... J Med Chem. 1987 Jul;30(7):1166-76. DMPV674 RU https://pubmed.ncbi.nlm.nih.gov/2955118 DMPV6N9 DI DMPV6N9 DMPV6N9 DN LY-2318912 DMPV6N9 TI TTDP1UC DMPV6N9 TN Fatty acid amide hydrolase (FAAH) DMPV6N9 MA Inhibitor DMPV6N9 RN Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation. Eur J Med Chem. 2008 Jan;43(1):62-72. DMPV6N9 RU https://pubmed.ncbi.nlm.nih.gov/17452063 DMPVBC2 DI DMPVBC2 DMPVBC2 DN 5,5'-methylenebis(1,3,4-oxadiazole-2(3H)-thione) DMPVBC2 TI TTULVH8 DMPVBC2 TN Tyrosinase (TYR) DMPVBC2 MA Inhibitor DMPVBC2 RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMPVBC2 RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMPVCDN DI DMPVCDN DMPVCDN DN 2-(2-Methoxy-phenyl)-6-methyl-chromen-4-one DMPVCDN TI TTNJYV2 DMPVCDN TN Gamma-aminobutyric acid receptor (GAR) DMPVCDN MA Inhibitor DMPVCDN RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMPVCDN RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMPVG5Y DI DMPVG5Y DMPVG5Y DN [3H]AZ11637326 DMPVG5Y TI TTLA931 DMPVG5Y TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMPVG5Y MA Agonist DMPVG5Y RN In vitro binding characteristics of [3H]AZ11637326, a novel alpha7-selective neuronal nicotinic receptor agonist radioligand. Eur J Pharmacol. 2010 Oct 25;645(1-3):63-9. DMPVG5Y RU https://pubmed.ncbi.nlm.nih.gov/20674564 DMPVI3A DI DMPVI3A DMPVI3A DN Trisodium phosphate DMPVI3A TI TTZHA0O DMPVI3A TN Carbonic anhydrase IV (CA-IV) DMPVI3A MA Inhibitor DMPVI3A RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7. DMPVI3A RU https://pubmed.ncbi.nlm.nih.gov/15501037 DMPVI9W DI DMPVI9W DMPVI9W DN 3,5-dichlorobenzaldehyde thiosemicarbazone DMPVI9W TI TTEAID7 DMPVI9W TN Trypanosoma Cruzipain (Trypano CYSP) DMPVI9W MA Inhibitor DMPVI9W RN Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707. DMPVI9W RU https://pubmed.ncbi.nlm.nih.gov/12061873 DMPVKEA DI DMPVKEA DMPVKEA DN Ro-32-0557 DMPVKEA TI TT8QL1J DMPVKEA TN Protein kinase C theta (PRKCQ) DMPVKEA MA Inhibitor DMPVKEA RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMPVKEA RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMPVKEA DI DMPVKEA DMPVKEA DN Ro-32-0557 DMPVKEA TI TTRFOXJ DMPVKEA TN Protein kinase C gamma (PRKCG) DMPVKEA MA Inhibitor DMPVKEA RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMPVKEA RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMPVKEA DI DMPVKEA DMPVKEA DN Ro-32-0557 DMPVKEA TI TTUWGRA DMPVKEA TN Protein kinase C zeta (PRKCZ) DMPVKEA MA Inhibitor DMPVKEA RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMPVKEA RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMPVKEA DI DMPVKEA DMPVKEA DN Ro-32-0557 DMPVKEA TI TTFJ8Q1 DMPVKEA TN Protein kinase C alpha (PRKCA) DMPVKEA MA Inhibitor DMPVKEA RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMPVKEA RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMPVKEA DI DMPVKEA DMPVKEA DN Ro-32-0557 DMPVKEA TI TTYPXQF DMPVKEA TN Protein kinase C beta (PRKCB) DMPVKEA MA Inhibitor DMPVKEA RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMPVKEA RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMPVKEA DI DMPVKEA DMPVKEA DN Ro-32-0557 DMPVKEA TI TTBZ7OD DMPVKEA TN Protein kinase C epsilon (PRKCE) DMPVKEA MA Inhibitor DMPVKEA RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMPVKEA RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMPVKEA DI DMPVKEA DMPVKEA DN Ro-32-0557 DMPVKEA TI TT9WJ8U DMPVKEA TN Protein kinase C delta (PRKCD) DMPVKEA MA Inhibitor DMPVKEA RN Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994). DMPVKEA RU http://www.sciencedirect.com/science/article/pii/S0960894X01803498 DMPVKWG DI DMPVKWG DMPVKWG DN N-[4'-(trifluoromethyl)-4-biphenylyl]thiourea DMPVKWG TI TTBGTCW DMPVKWG TN Kinesin spindle messenger RNA (KIF11 mRNA) DMPVKWG MA Inhibitor DMPVKWG RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMPVKWG RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMPVNDK DI DMPVNDK DMPVNDK DN Distamycin A DMPVNDK TI TTOVXHF DMPVNDK TN Human Deoxyribonucleic acid minor groove (hDNA min) DMPVNDK MA Binder (minor groove binder) DMPVNDK RN Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14. DMPVNDK RU https://pubmed.ncbi.nlm.nih.gov/11772279 DMPVQN3 DI DMPVQN3 DMPVQN3 DN 8-(4-Methyl-cyclohexyloxy)-quinolin-2-ylamine DMPVQN3 TI TTX4RTB DMPVQN3 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMPVQN3 MA Inhibitor DMPVQN3 RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMPVQN3 RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMPVU7H DI DMPVU7H DMPVU7H DN 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMPVU7H TI TTLD29N DMPVU7H TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMPVU7H MA Inhibitor DMPVU7H RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMPVU7H RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMPVU7H DI DMPVU7H DMPVU7H DN 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMPVU7H TI TTN9D8E DMPVU7H TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMPVU7H MA Inhibitor DMPVU7H RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMPVU7H RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMPVU7H DI DMPVU7H DMPVU7H DN 8-Bromo-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMPVU7H TI TTKJEMQ DMPVU7H TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMPVU7H MA Inhibitor DMPVU7H RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMPVU7H RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMPVXTB DI DMPVXTB DMPVXTB DN 3-[3-(benzylmethylamino)propoxy]xanthen-9-one DMPVXTB TI TTEB0GD DMPVXTB TN Cholinesterase (BCHE) DMPVXTB MA Inhibitor DMPVXTB RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMPVXTB RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMPVXTB DI DMPVXTB DMPVXTB DN 3-[3-(benzylmethylamino)propoxy]xanthen-9-one DMPVXTB TI TT1RS9F DMPVXTB TN Acetylcholinesterase (AChE) DMPVXTB MA Inhibitor DMPVXTB RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMPVXTB RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMPW145 DI DMPW145 DMPW145 DN 4,5-Bis(4-methoxyphenyl)-3H-1,2-dithiole-3-thione DMPW145 TI TT8NGED DMPW145 TN Prostaglandin G/H synthase 1 (COX-1) DMPW145 MA Inhibitor DMPW145 RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMPW145 RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMPW75L DI DMPW75L DMPW75L DN 1-methyl-1H-indole-2,3-dione DMPW75L TI TTMF541 DMPW75L TN Liver carboxylesterase (CES1) DMPW75L MA Inhibitor DMPW75L RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMPW75L RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMPW9SD DI DMPW9SD DMPW9SD DN Cyclo(-D-Tyr-L-Ala-L-Arg-L-Nal-Gly-) DMPW9SD TI TTBID49 DMPW9SD TN C-X-C chemokine receptor type 4 (CXCR4) DMPW9SD MA Inhibitor DMPW9SD RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMPW9SD RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMPWART DI DMPWART DMPWART DN [18F]fluoroethylflumazenil DMPWART TI TT37EDJ DMPWART TN GABA(A) receptor alpha-3 (GABRA3) DMPWART MA Modulator (allosteric modulator) DMPWART RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMPWART RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMPWART DI DMPWART DMPWART DN [18F]fluoroethylflumazenil DMPWART TI TTEX6LM DMPWART TN GABA(A) receptor gamma-3 (GABRG3) DMPWART MA Modulator (allosteric modulator) DMPWART RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMPWART RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMPWART DI DMPWART DMPWART DN [18F]fluoroethylflumazenil DMPWART TI TTBMV1G DMPWART TN GABA(A) receptor alpha-2 (GABRA2) DMPWART MA Modulator (allosteric modulator) DMPWART RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMPWART RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMPWART DI DMPWART DMPWART DN [18F]fluoroethylflumazenil DMPWART TI TTNZPQ1 DMPWART TN GABA(A) receptor alpha-5 (GABRA5) DMPWART MA Modulator (allosteric modulator) DMPWART RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMPWART RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMPWB8G DI DMPWB8G DMPWB8G DN 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine DMPWB8G TI TTGP7BY DMPWB8G TN Monoamine oxidase type B (MAO-B) DMPWB8G MA Inhibitor DMPWB8G RN Further explorations of unnatural alkaloids. J Nat Prod. 1985 Nov-Dec;48(6):878-93. DMPWB8G RU https://pubmed.ncbi.nlm.nih.gov/3879267 DMPWEL8 DI DMPWEL8 DMPWEL8 DN 3-(2-Pyridin-2-yl-2H-tetrazol-5-yl)-benzonitrile DMPWEL8 TI TTHS256 DMPWEL8 TN Metabotropic glutamate receptor 5 (mGluR5) DMPWEL8 MA Inhibitor DMPWEL8 RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMPWEL8 RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMPWG21 DI DMPWG21 DMPWG21 DN 2-phenethylisoquinoline-1,3,4-trione DMPWG21 TI TTPF2QI DMPWG21 TN Caspase-3 (CASP3) DMPWG21 MA Inhibitor DMPWG21 RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMPWG21 RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMPWR90 DI DMPWR90 DMPWR90 DN 3-cyanophenylboronic acid DMPWR90 TI TTDP1UC DMPWR90 TN Fatty acid amide hydrolase (FAAH) DMPWR90 MA Inhibitor DMPWR90 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMPWR90 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMPWXI8 DI DMPWXI8 DMPWXI8 DN 6-fluoronorepinehprine DMPWXI8 TI TTBRKXS DMPWXI8 TN Adrenergic receptor alpha-1B (ADRA1B) DMPWXI8 MA Inhibitor DMPWXI8 RN Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. Bioorg Med Chem. 2009 Dec 1;17(23):7987-92. DMPWXI8 RU https://pubmed.ncbi.nlm.nih.gov/19857969 DMPWY6H DI DMPWY6H DMPWY6H DN KNI-10740 DMPWY6H TI TTXMNHO DMPWY6H TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMPWY6H MA Inhibitor DMPWY6H RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMPWY6H RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMPWZOK DI DMPWZOK DMPWZOK DN CRB-0022 DMPWZOK TI TTEDJN4 DMPWZOK TN Low-affinity nerve growth factor receptor (NGFR) DMPWZOK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMPWZOK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMPX1J9 DI DMPX1J9 DMPX1J9 DN 4-oxo-nonenal DMPX1J9 TI TTELV3W DMPX1J9 TN Transformation-sensitive protein p120 (TRPA1) DMPX1J9 MA Activator DMPX1J9 RN Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci. 2008 Mar 5;28(10):2485-94. DMPX1J9 RU https://pubmed.ncbi.nlm.nih.gov/18322093 DMPX3WT DI DMPX3WT DMPX3WT DN TMX-202 DMPX3WT TI TTRJ1K4 DMPX3WT TN Toll-like receptor 7 (TLR7) DMPX3WT MA Agonist DMPX3WT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757). DMPX3WT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757 DMPX5SJ DI DMPX5SJ DMPX5SJ DN AS-1397 DMPX5SJ TI TTEB0GD DMPX5SJ TN Cholinesterase (BCHE) DMPX5SJ MA Inhibitor DMPX5SJ RN Novel heterobivalent tacrine derivatives as cholinesterase inhibitors with notable selectivity toward butyrylcholinesterase. J Med Chem. 2006 Dec 14;49(25):7540-4. DMPX5SJ RU https://pubmed.ncbi.nlm.nih.gov/17149883 DMPX642 DI DMPX642 DMPX642 DN 2,2-diMeBut-RYYRIK-NH2 DMPX642 TI TTNT7K8 DMPX642 TN Nociceptin receptor (OPRL1) DMPX642 MA Inhibitor DMPX642 RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMPX642 RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMPX71O DI DMPX71O DMPX71O DN PT-106 DMPX71O TI TT84ETX DMPX71O TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMPX71O MA Inhibitor DMPX71O RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMPX71O RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMPX7FR DI DMPX7FR DMPX7FR DN Glutathionylspermidine Disulfide DMPX7FR TI TTEP6RV DMPX7FR TN Glutathione reductase (GR) DMPX7FR MA Inhibitor DMPX7FR RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMPX7FR RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMPX7QS DI DMPX7QS DMPX7QS DN TERRITREM B DMPX7QS TI TT1RS9F DMPX7QS TN Acetylcholinesterase (AChE) DMPX7QS MA Inhibitor DMPX7QS RN Acetylcholinesterase inhibition by territrem B derivatives. J Nat Prod. 1995 Jun;58(6):857-62. DMPX7QS RU https://pubmed.ncbi.nlm.nih.gov/7673929 DMPXC9L DI DMPXC9L DMPXC9L DN RO5101576 DMPXC9L TI TTVJX54 DMPXC9L TN Leukotriene B4 receptor 2 (LTB4R2) DMPXC9L MA Antagonist DMPXC9L RN Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates. Prostaglandins Other Lipid Mediat. 2010 Jun;92(1-4):33-43. DMPXC9L RU https://pubmed.ncbi.nlm.nih.gov/20214997 DMPXCZ7 DI DMPXCZ7 DMPXCZ7 DN ISIS 13812 DMPXCZ7 TI TT89Z17 DMPXCZ7 TN B7 translation initiation codon region messenger RNA (CD80 mRNA) DMPXCZ7 RN US patent application no. 6,319,906, Oligonucleotide compositions and methods for the modulation of the expression of B7 protein. DMPXCZ7 RU http://www.patentbuddy.com/Patent/6319906?ft=true&sr=true DMPXEIQ DI DMPXEIQ DMPXEIQ DN PMID19433355C11q DMPXEIQ TI TTVBPDM DMPXEIQ TN Metabotropic glutamate receptor 1 (mGluR1) DMPXEIQ MA Modulator (allosteric modulator) DMPXEIQ RN Tricyclic thienopyridine-pyrimidones/thienopyrimidine-pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3199-203. DMPXEIQ RU https://pubmed.ncbi.nlm.nih.gov/19433355 DMPXF5I DI DMPXF5I DMPXF5I DN androstanol DMPXF5I TI TTRANFM DMPXF5I TN Orphan nuclear receptor NR1I3 (NR1I3) DMPXF5I MA Antagonist DMPXF5I RN Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature. 1998 Oct 8;395(6702):612-5. DMPXF5I RU https://pubmed.ncbi.nlm.nih.gov/9783588 DMPXHO8 DI DMPXHO8 DMPXHO8 DN Cyclazosin DMPXHO8 TI TTBRKXS DMPXHO8 TN Adrenergic receptor alpha-1B (ADRA1B) DMPXHO8 MA Antagonist DMPXHO8 RN Identification of alpha1-adrenoceptor subtypes involved in contraction of young CD rat epididymal vas deferens. Eur J Pharmacol. 2009 Jan 14;602(2-3):388-94. DMPXHO8 RU https://pubmed.ncbi.nlm.nih.gov/19041301 DMPXHTY DI DMPXHTY DMPXHTY DN TRIMEDOXIME DMPXHTY TI TT1RS9F DMPXHTY TN Acetylcholinesterase (AChE) DMPXHTY MA Inhibitor DMPXHTY RN Synthesis of the novel series of bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against chlorpy... Bioorg Med Chem Lett. 2006 Feb;16(3):622-7. DMPXHTY RU https://pubmed.ncbi.nlm.nih.gov/16288867 DMPXKOE DI DMPXKOE DMPXKOE DN A839977 DMPXKOE TI TT473XN DMPXKOE TN P2X purinoceptor 7 (P2RX7) DMPXKOE MA Antagonist DMPXKOE RN The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav Brain Res. 2009 Dec 1;204(1):77-81. DMPXKOE RU https://pubmed.ncbi.nlm.nih.gov/19464323 DMPXLEU DI DMPXLEU DMPXLEU DN 9-N-ETHYL-8-ETHOXY-MANZAMINE A DMPXLEU TI TTRSMW9 DMPXLEU TN Glycogen synthase kinase-3 beta (GSK-3B) DMPXLEU MA Inhibitor DMPXLEU RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DMPXLEU RU https://pubmed.ncbi.nlm.nih.gov/17708655 DMPXS9F DI DMPXS9F DMPXS9F DN 6-cinnamoyl-N-methylstephasunoline DMPXS9F TI TT27RFC DMPXS9F TN Opioid receptor delta (OPRD1) DMPXS9F MA Inhibitor DMPXS9F RN Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91. DMPXS9F RU https://pubmed.ncbi.nlm.nih.gov/20426456 DMPY4G1 DI DMPY4G1 DMPY4G1 DN 4-phenyl-4-[1H-imidazol-2-yl]-piperidine DMPY4G1 TI TT27RFC DMPY4G1 TN Opioid receptor delta (OPRD1) DMPY4G1 MA Inhibitor DMPY4G1 RN 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):146-9. DMPY4G1 RU https://pubmed.ncbi.nlm.nih.gov/16236510 DMPY4G1 DI DMPY4G1 DMPY4G1 DN 4-phenyl-4-[1H-imidazol-2-yl]-piperidine DMPY4G1 TI TTQW87Y DMPY4G1 TN Opioid receptor kappa (OPRK1) DMPY4G1 MA Inhibitor DMPY4G1 RN 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):146-9. DMPY4G1 RU https://pubmed.ncbi.nlm.nih.gov/16236510 DMPY6IG DI DMPY6IG DMPY6IG DN Quipazine DMPY6IG TI TT6MSOK DMPY6IG TN 5-HT 1D receptor (HTR1D) DMPY6IG MA Inhibitor DMPY6IG RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMPY6IG RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMPY6IG DI DMPY6IG DMPY6IG DN Quipazine DMPY6IG TI TTR6K75 DMPY6IG TN 5-HT 3B receptor (HTR3B) DMPY6IG MA Inhibitor DMPY6IG RN Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75. DMPY6IG RU https://pubmed.ncbi.nlm.nih.gov/10229626 DMPY6IG DI DMPY6IG DMPY6IG DN Quipazine DMPY6IG TI TT3ROYC DMPY6IG TN Serotonin transporter (SERT) DMPY6IG MA Inhibitor DMPY6IG RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DMPY6IG RU https://pubmed.ncbi.nlm.nih.gov/10915050 DMPY6IG DI DMPY6IG DMPY6IG DN Quipazine DMPY6IG TI TTJQOD7 DMPY6IG TN 5-HT 2A receptor (HTR2A) DMPY6IG MA Inhibitor DMPY6IG RN Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50. DMPY6IG RU https://pubmed.ncbi.nlm.nih.gov/19831400 DMPY6IG DI DMPY6IG DMPY6IG DN Quipazine DMPY6IG TI TTSQIFT DMPY6IG TN 5-HT 1A receptor (HTR1A) DMPY6IG MA Inhibitor DMPY6IG RN Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50. DMPY6IG RU https://pubmed.ncbi.nlm.nih.gov/19831400 DMPY6IG DI DMPY6IG DMPY6IG DN Quipazine DMPY6IG TI TTJS8PY DMPY6IG TN 5-HT 6 receptor (HTR6) DMPY6IG MA Inhibitor DMPY6IG RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMPY6IG RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMPY6IG DI DMPY6IG DMPY6IG DN Quipazine DMPY6IG TI TTPC4TU DMPY6IG TN 5-HT 3A receptor (HTR3A) DMPY6IG MA Inhibitor DMPY6IG RN Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50. DMPY6IG RU https://pubmed.ncbi.nlm.nih.gov/19831400 DMPY8D3 DI DMPY8D3 DMPY8D3 DN 4-Amino-3-hydroxy-butyric acid DMPY8D3 TI TTNJYV2 DMPY8D3 TN Gamma-aminobutyric acid receptor (GAR) DMPY8D3 MA Inhibitor DMPY8D3 RN GABA agonists. Resolution, absolute stereochemistry, and enantioselectivity of (S)-(+)- and (R)-(-)-dihydromuscimol. J Med Chem. 1985 Nov;28(11):1612-7. DMPY8D3 RU https://pubmed.ncbi.nlm.nih.gov/2999396 DMPY9OI DI DMPY9OI DMPY9OI DN 8-furan-2-yl-2-morpholin-4-ylchromen-4-one DMPY9OI TI TTK3PY9 DMPY9OI TN DNA-dependent protein kinase catalytic (PRKDC) DMPY9OI MA Inhibitor DMPY9OI RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMPY9OI RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMPYAMU DI DMPYAMU DMPYAMU DN isopulegol DMPYAMU TI TTXDKTO DMPYAMU TN Long transient receptor potential channel 8 (TRPM8) DMPYAMU MA Activator DMPYAMU RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMPYAMU RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMPYB93 DI DMPYB93 DMPYB93 DN 2-Benzyl-2H-indazole-7-carboxamide DMPYB93 TI TTVDSZ0 DMPYB93 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMPYB93 MA Inhibitor DMPYB93 RN Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85. DMPYB93 RU https://pubmed.ncbi.nlm.nih.gov/19873981 DMPYBHI DI DMPYBHI DMPYBHI DN moexiprilat DMPYBHI TI TTL69WB DMPYBHI TN Angiotensin-converting enzyme (ACE) DMPYBHI MA Modulator DMPYBHI RN Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther. 1995 Nov;275(2):854-63. DMPYBHI RU https://www.ncbi.nlm.nih.gov/pubmed/7473177 DMPYCK5 DI DMPYCK5 DMPYCK5 DN 1-Aminopropane-1,2,3-tricarboxylic acid DMPYCK5 TI TTHI19T DMPYCK5 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMPYCK5 MA Inhibitor DMPYCK5 RN Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7. DMPYCK5 RU https://pubmed.ncbi.nlm.nih.gov/19467869 DMPYGK9 DI DMPYGK9 DMPYGK9 DN 6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline DMPYGK9 TI TT8FYO9 DMPYGK9 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMPYGK9 MA Inhibitor DMPYGK9 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMPYGK9 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMPYGMO DI DMPYGMO DMPYGMO DN WRR605 DMPYGMO TI TTPXTVS DMPYGMO TN Entamoeba Cysteine proteinase CP4 (Eh CP4) DMPYGMO MA Inhibitor DMPYGMO RN A novel Entamoeba histolytica cysteine proteinase, EhCP4, is key for invasive amebiasis and a therapeutic target. J Biol Chem. 2010 Jun 11;285(24):18516-27. DMPYGMO RU https://pubmed.ncbi.nlm.nih.gov/20378535 DMPYIA3 DI DMPYIA3 DMPYIA3 DN GNF-PF-4453 DMPYIA3 TI TTG5QB7 DMPYIA3 TN Calpain-2 (CAPN2) DMPYIA3 MA Inhibitor DMPYIA3 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMPYIA3 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMPYJEB DI DMPYJEB DMPYJEB DN ISIS 29237 DMPYJEB TI TTYMGWX DMPYJEB TN PDK-1 messenger RNA (PDK-1 mRNA) DMPYJEB RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMPYJEB RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMPYJLA DI DMPYJLA DMPYJLA DN Methotrexate gamma-L-proline-hydroxamic acid DMPYJLA TI TT6X50U DMPYJLA TN Matrix metalloproteinase-9 (MMP-9) DMPYJLA MA Inhibitor DMPYJLA RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMPYJLA RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMPYJLA DI DMPYJLA DMPYJLA DN Methotrexate gamma-L-proline-hydroxamic acid DMPYJLA TI TTLM12X DMPYJLA TN Matrix metalloproteinase-2 (MMP-2) DMPYJLA MA Inhibitor DMPYJLA RN Methotrexate gamma-hydroxamate derivatives as potential dual target antitumor drugs. Bioorg Med Chem. 2007 Feb 1;15(3):1266-74. DMPYJLA RU https://pubmed.ncbi.nlm.nih.gov/17127067 DMPYK1T DI DMPYK1T DMPYK1T DN (O10eq)-Benzyloxycarbonyl-beta-alanylryanodine DMPYK1T TI TTU5CIX DMPYK1T TN Ryanodine receptor 1 (RYR1) DMPYK1T MA Inhibitor DMPYK1T RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMPYK1T RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMPYM3J DI DMPYM3J DMPYM3J DN YM 218 DMPYM3J TI TTL9MHW DMPYM3J TN Vasopressin V1b receptor (V1BR) DMPYM3J MA Antagonist DMPYM3J RN Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res. 2005 Mar;51(3):275-81. DMPYM3J RU https://pubmed.ncbi.nlm.nih.gov/15661579 DMPYM3J DI DMPYM3J DMPYM3J DN YM 218 DMPYM3J TI TTK8R02 DMPYM3J TN Vasopressin V2 receptor (V2R) DMPYM3J MA Antagonist DMPYM3J RN Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res. 2005 Mar;51(3):275-81. DMPYM3J RU https://pubmed.ncbi.nlm.nih.gov/15661579 DMPYM3J DI DMPYM3J DMPYM3J DN YM 218 DMPYM3J TI TT4TFGN DMPYM3J TN Vasopressin V1a receptor (V1AR) DMPYM3J MA Antagonist DMPYM3J RN Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors. Pharmacol Res. 2005 Mar;51(3):275-81. DMPYM3J RU https://pubmed.ncbi.nlm.nih.gov/15661579 DMPYSIT DI DMPYSIT DMPYSIT DN levetimide DMPYSIT TI TTOXS3C DMPYSIT TN Muscarinic acetylcholine receptor (CHRM) DMPYSIT MA Antagonist DMPYSIT RN Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line. J Pharmacol Exp Ther. 1998 Feb;284(2):500-7. DMPYSIT RU https://pubmed.ncbi.nlm.nih.gov/9454790 DMPYTHV DI DMPYTHV DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide DMPYTHV TI TT6R7JZ DMPYTHV TN Histone deacetylase 1 (HDAC1) DMPYTHV MA Inhibitor DMPYTHV RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMPYTHV RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMPYTHV DI DMPYTHV DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide DMPYTHV TI TT5ZKDI DMPYTHV TN Histone deacetylase 6 (HDAC6) DMPYTHV MA Inhibitor DMPYTHV RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMPYTHV RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMPYTHV DI DMPYTHV DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide DMPYTHV TI TTTQGH8 DMPYTHV TN Histone deacetylase 4 (HDAC4) DMPYTHV MA Inhibitor DMPYTHV RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMPYTHV RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMPYTHV DI DMPYTHV DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide DMPYTHV TI TTBH0VX DMPYTHV TN Histone deacetylase (HDAC) DMPYTHV MA Inhibitor DMPYTHV RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMPYTHV RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMPYTHV DI DMPYTHV DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide DMPYTHV TI TTT6LFV DMPYTHV TN Histone deacetylase 8 (HDAC8) DMPYTHV MA Inhibitor DMPYTHV RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMPYTHV RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMPYTHV DI DMPYTHV DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide DMPYTHV TI TTSHTOI DMPYTHV TN Histone deacetylase 2 (HDAC2) DMPYTHV MA Inhibitor DMPYTHV RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMPYTHV RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMPYTHV DI DMPYTHV DMPYTHV DN 7-Mercapto-heptanoic acid benzothiazol-2-ylamide DMPYTHV TI TTYHPU6 DMPYTHV TN Histone deacetylase 10 (HDAC10) DMPYTHV MA Inhibitor DMPYTHV RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMPYTHV RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMPZ0XJ DI DMPZ0XJ DMPZ0XJ DN Merimepodib DMPZ0XJ TI TTTU6X1 DMPZ0XJ TN HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMPZ0XJ MA Inhibitor DMPZ0XJ RN The IMPDH inhibitor merimepodib suppresses SARS-CoV-2 replication in vitro. April 09, 2020. doi: https://doi.org/10.1101/2020.04.07.028589 DMPZ0XJ RU https://www.biorxiv.org/content/10.1101/2020.04.07.028589v1 DMPZ1LY DI DMPZ1LY DMPZ1LY DN Cis-2-(para-fluorophenyl)cyclopropylamine DMPZ1LY TI TTGP7BY DMPZ1LY TN Monoamine oxidase type B (MAO-B) DMPZ1LY MA Inhibitor DMPZ1LY RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMPZ1LY RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMPZ316 DI DMPZ316 DMPZ316 DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-MeNal-Gly-) DMPZ316 TI TTBID49 DMPZ316 TN C-X-C chemokine receptor type 4 (CXCR4) DMPZ316 MA Inhibitor DMPZ316 RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMPZ316 RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMPZ3AY DI DMPZ3AY DMPZ3AY DN PMID30247903-Compound-General structure40 DMPZ3AY TI TT23XQV DMPZ3AY TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMPZ3AY MA Inhibitor DMPZ3AY RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMPZ3AY RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMPZ4M8 DI DMPZ4M8 DMPZ4M8 DN 3-bromo-4,4',5-trimethoxy-(Z)-stilbene DMPZ4M8 TI TTYFKSZ DMPZ4M8 TN Tubulin beta (TUBB) DMPZ4M8 MA Inhibitor DMPZ4M8 RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMPZ4M8 RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMPZ4M8 DI DMPZ4M8 DMPZ4M8 DN 3-bromo-4,4',5-trimethoxy-(Z)-stilbene DMPZ4M8 TI TTJ2PTI DMPZ4M8 TN Tubulin beta-2 chain (TUBB2) DMPZ4M8 MA Inhibitor DMPZ4M8 RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMPZ4M8 RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMPZ4VB DI DMPZ4VB DMPZ4VB DN C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 DMPZ4VB TI TTEOSZT DMPZ4VB TN Melanocortin receptor (MCR) DMPZ4VB MA Inhibitor DMPZ4VB RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMPZ4VB RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMPZ4VB DI DMPZ4VB DMPZ4VB DN C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 DMPZ4VB TI TTNI91K DMPZ4VB TN Melanocortin receptor 3 (MC3R) DMPZ4VB MA Inhibitor DMPZ4VB RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMPZ4VB RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMPZ4VB DI DMPZ4VB DMPZ4VB DN C[Nle-Pro-D-Nal(2')-Arg-Trp-Glu]-NH2 DMPZ4VB TI TTD0CIQ DMPZ4VB TN Melanocortin receptor 4 (MC4R) DMPZ4VB MA Inhibitor DMPZ4VB RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMPZ4VB RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TT0IFKL DMPZ8XH TN Metabotropic glutamate receptor 8 (mGluR8) DMPZ8XH MA Agonist DMPZ8XH RN Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/10216218 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TTXJ47W DMPZ8XH TN Metabotropic glutamate receptor 2 (mGluR2) DMPZ8XH MA Agonist DMPZ8XH RN [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/10530814 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TT8A9EF DMPZ8XH TN Metabotropic glutamate receptor 3 (mGluR3) DMPZ8XH MA Agonist DMPZ8XH RN [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells. Neuropharmacology. 1999 Oct;38(10):1519-29. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/10530814 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TT0I76D DMPZ8XH TN Metabotropic glutamate receptor 7 (mGluR7) DMPZ8XH MA Agonist DMPZ8XH RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TTVBPDM DMPZ8XH TN Metabotropic glutamate receptor 1 (mGluR1) DMPZ8XH MA Agonist DMPZ8XH RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TTHS256 DMPZ8XH TN Metabotropic glutamate receptor 5 (mGluR5) DMPZ8XH MA Agonist DMPZ8XH RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TTICZ1O DMPZ8XH TN Metabotropic glutamate receptor 4 (mGluR4) DMPZ8XH MA Agonist DMPZ8XH RN Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells. Br J Pharmacol. 1992 Oct;107(2):539-43. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/1330184 DMPZ8XH DI DMPZ8XH DMPZ8XH DN L-CCG-I DMPZ8XH TI TTWRP2F DMPZ8XH TN Metabotropic glutamate receptor 6 (mGluR6) DMPZ8XH MA Agonist DMPZ8XH RN Comparative effect of L-CCG-I, DCG-IV and gamma-carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology. 1998 Aug;37(8):1043-51. DMPZ8XH RU https://pubmed.ncbi.nlm.nih.gov/9833633 DMPZ92X DI DMPZ92X DMPZ92X DN 6-fluoromevalonate 5-diphosphate DMPZ92X TI TTE5J6X DMPZ92X TN Diphosphomevalonate decarboxylase (MVD) DMPZ92X MA Inhibitor DMPZ92X RN Human mevalonate diphosphate decarboxylase: characterization, investigation of the mevalonate diphosphate binding site, and crystal structure. Arch Biochem Biophys. 2008 Dec 1;480(1):58-67. DMPZ92X RU https://pubmed.ncbi.nlm.nih.gov/18823933 DMPZ9D3 DI DMPZ9D3 DMPZ9D3 DN ISIS 17148 DMPZ9D3 TI TTHJT3X DMPZ9D3 TN STAT3 messenger RNA (STAT3 mRNA) DMPZ9D3 RN US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression. DMPZ9D3 RU http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true DMPZB31 DI DMPZB31 DMPZB31 DN NF546 DMPZB31 TI TTYXPCO DMPZB31 TN P2Y purinoceptor 11 (P2RY11) DMPZB31 MA Agonist DMPZB31 RN NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharmacol Exp Ther. 2010 Jan;332(1):238-47. DMPZB31 RU https://pubmed.ncbi.nlm.nih.gov/19815812 DMPZHIE DI DMPZHIE DMPZHIE DN (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K DMPZHIE TI TTBPW3J DMPZHIE TN Galanin receptor type 2 (GAL2-R) DMPZHIE MA Inhibitor DMPZHIE RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMPZHIE RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMPZHIE DI DMPZHIE DMPZHIE DN (Sar)WTLNSAGYLLGPKK(Lys-lauroyl)K DMPZHIE TI TTX3HNZ DMPZHIE TN Galanin receptor type 1 (GAL1-R) DMPZHIE MA Inhibitor DMPZHIE RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMPZHIE RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMPZIV0 DI DMPZIV0 DMPZIV0 DN 6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one DMPZIV0 TI TTNJYV2 DMPZIV0 TN Gamma-aminobutyric acid receptor (GAR) DMPZIV0 MA Inhibitor DMPZIV0 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMPZIV0 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMPZIV0 DI DMPZIV0 DMPZIV0 DN 6-Fluoro-2-(3-nitro-phenyl)-chromen-4-one DMPZIV0 TI TT1MPAY DMPZIV0 TN GABA(A) receptor alpha-1 (GABRA1) DMPZIV0 MA Inhibitor DMPZIV0 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMPZIV0 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMPZMS0 DI DMPZMS0 DMPZMS0 DN PMID19456099C15 DMPZMS0 TI TTFQEO5 DMPZMS0 TN Squalene synthetase (FDFT1) DMPZMS0 MA Inhibitor DMPZMS0 RN Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J Med Chem. 2009 Jul 9;52(13):3869-80. DMPZMS0 RU https://pubmed.ncbi.nlm.nih.gov/19456099 DMPZS80 DI DMPZS80 DMPZS80 DN Alpha,beta-methylene-dGTP DMPZS80 TI TTIU7X1 DMPZS80 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMPZS80 MA Inhibitor DMPZS80 RN Alpha,beta-methylene-2'-deoxynucleoside 5'-triphosphates as noncleavable substrates for DNA polymerases: isolation, characterization, and stability... J Med Chem. 2008 Oct 23;51(20):6460-70. DMPZS80 RU https://pubmed.ncbi.nlm.nih.gov/18811136 DMPZSGV DI DMPZSGV DMPZSGV DN PMID18752940C9n DMPZSGV TI TTWNV8U DMPZSGV TN Nicotinic acid receptor (HCAR2) DMPZSGV MA Modulator (allosteric modulator) DMPZSGV RN Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109A. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4948-51. DMPZSGV RU https://pubmed.ncbi.nlm.nih.gov/18752940 DMPZTG9 DI DMPZTG9 DMPZTG9 DN 9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide DMPZTG9 TI TTEB0GD DMPZTG9 TN Cholinesterase (BCHE) DMPZTG9 MA Inhibitor DMPZTG9 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DMPZTG9 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DMPZTG9 DI DMPZTG9 DMPZTG9 DN 9-O-[5-(Phenylol-1-yloxy)pentyl]berberine bromide DMPZTG9 TI TT1RS9F DMPZTG9 TN Acetylcholinesterase (AChE) DMPZTG9 MA Inhibitor DMPZTG9 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DMPZTG9 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DMPZURH DI DMPZURH DMPZURH DN Isoxazolecarboxylic acid DMPZURH TI TTELIN2 DMPZURH TN PTPN1 messenger RNA (PTPN1 mRNA) DMPZURH MA Inhibitor DMPZURH RN Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18. DMPZURH RU https://pubmed.ncbi.nlm.nih.gov/20627471 DMPZX8U DI DMPZX8U DMPZX8U DN 2-amino-2-(3-chlorophenyl)acetic acid DMPZX8U TI TTFK1JQ DMPZX8U TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMPZX8U MA Inhibitor DMPZX8U RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMPZX8U RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMQ05F2 DI DMQ05F2 DMQ05F2 DN 1-[7-(triphenylmethoxy)heptyl]thymine DMQ05F2 TI TTP3QRF DMQ05F2 TN Thymidine kinase 1 (TK1) DMQ05F2 MA Inhibitor DMQ05F2 RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DMQ05F2 RU https://pubmed.ncbi.nlm.nih.gov/17181158 DMQ09J8 DI DMQ09J8 DMQ09J8 DN 3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide DMQ09J8 TI TTHQPL7 DMQ09J8 TN Carbonic anhydrase I (CA-I) DMQ09J8 MA Inhibitor DMQ09J8 RN Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006 Sep 7;49(18):5544-51. DMQ09J8 RU https://pubmed.ncbi.nlm.nih.gov/16942027 DMQ09J8 DI DMQ09J8 DMQ09J8 DN 3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide DMQ09J8 TI TTANPDJ DMQ09J8 TN Carbonic anhydrase II (CA-II) DMQ09J8 MA Inhibitor DMQ09J8 RN Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006 Sep 7;49(18):5544-51. DMQ09J8 RU https://pubmed.ncbi.nlm.nih.gov/16942027 DMQ09J8 DI DMQ09J8 DMQ09J8 DN 3-mercapto-N-(4-sulfamoyl-phenyl)-propionamide DMQ09J8 TI TT2LVK8 DMQ09J8 TN Carbonic anhydrase IX (CA-IX) DMQ09J8 MA Inhibitor DMQ09J8 RN Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006 Sep 7;49(18):5544-51. DMQ09J8 RU https://pubmed.ncbi.nlm.nih.gov/16942027 DMQ0A8W DI DMQ0A8W DMQ0A8W DN 3-(2-N-Pyrrolyl-acetamino)-rutaecarpine DMQ0A8W TI TTEB0GD DMQ0A8W TN Cholinesterase (BCHE) DMQ0A8W MA Inhibitor DMQ0A8W RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DMQ0A8W RU https://pubmed.ncbi.nlm.nih.gov/20079560 DMQ0A8W DI DMQ0A8W DMQ0A8W DN 3-(2-N-Pyrrolyl-acetamino)-rutaecarpine DMQ0A8W TI TT1RS9F DMQ0A8W TN Acetylcholinesterase (AChE) DMQ0A8W MA Inhibitor DMQ0A8W RN Synthesis and evaluation of novel rutaecarpine derivatives and related alkaloids derivatives as selective acetylcholinesterase inhibitors. Eur J Med Chem. 2010 Apr;45(4):1415-23. DMQ0A8W RU https://pubmed.ncbi.nlm.nih.gov/20079560 DMQ0DMU DI DMQ0DMU DMQ0DMU DN N-(2,6-diphenylpyrimidin-4-yl)acetamide DMQ0DMU TI TTK25J1 DMQ0DMU TN Adenosine A1 receptor (ADORA1) DMQ0DMU MA Inhibitor DMQ0DMU RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMQ0DMU RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMQ0DMU DI DMQ0DMU DMQ0DMU DN N-(2,6-diphenylpyrimidin-4-yl)acetamide DMQ0DMU TI TTM2AOE DMQ0DMU TN Adenosine A2a receptor (ADORA2A) DMQ0DMU MA Inhibitor DMQ0DMU RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMQ0DMU RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMQ0DMU DI DMQ0DMU DMQ0DMU DN N-(2,6-diphenylpyrimidin-4-yl)acetamide DMQ0DMU TI TTJFY5U DMQ0DMU TN Adenosine A3 receptor (ADORA3) DMQ0DMU MA Inhibitor DMQ0DMU RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMQ0DMU RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMQ0EA7 DI DMQ0EA7 DMQ0EA7 DN cis-3-ACPBPA DMQ0EA7 TI TTQMXLS DMQ0EA7 TN GABA(A) receptor rho2 (GABRR2) DMQ0EA7 MA Antagonist DMQ0EA7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DMQ0EA7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DMQ0EA7 DI DMQ0EA7 DMQ0EA7 DN cis-3-ACPBPA DMQ0EA7 TI TT6XFEU DMQ0EA7 TN GABA(A) receptor rho1 (GABRR1) DMQ0EA7 MA Antagonist DMQ0EA7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DMQ0EA7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DMQ0EA7 DI DMQ0EA7 DMQ0EA7 DN cis-3-ACPBPA DMQ0EA7 TI TT4N6D8 DMQ0EA7 TN GABA(A) receptor rho3 (GABRR3) DMQ0EA7 MA Antagonist DMQ0EA7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DMQ0EA7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DMQ0F96 DI DMQ0F96 DMQ0F96 DN 2-Hydroxy-N,6-bis(3-hydroxyphenyl)-1-naphthamide DMQ0F96 TI TTIWB6L DMQ0F96 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMQ0F96 MA Inhibitor DMQ0F96 RN Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98. DMQ0F96 RU https://pubmed.ncbi.nlm.nih.gov/18630892 DMQ0FVJ DI DMQ0FVJ DMQ0FVJ DN (S)-3HPG DMQ0FVJ TI TTHS256 DMQ0FVJ TN Metabotropic glutamate receptor 5 (mGluR5) DMQ0FVJ MA Agonist DMQ0FVJ RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMQ0FVJ RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMQ0FVJ DI DMQ0FVJ DMQ0FVJ DN (S)-3HPG DMQ0FVJ TI TTVBPDM DMQ0FVJ TN Metabotropic glutamate receptor 1 (mGluR1) DMQ0FVJ MA Agonist DMQ0FVJ RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMQ0FVJ RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMQ0HCT DI DMQ0HCT DMQ0HCT DN CEM-301 DMQ0HCT TI TT953CX DMQ0HCT TN Motilin receptor (MLNR) DMQ0HCT MA Agonist DMQ0HCT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297). DMQ0HCT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=297 DMQ0JWZ DI DMQ0JWZ DMQ0JWZ DN 4-(4-phenoxybenzoyl)phenylacetic acid DMQ0JWZ TI TTT02K8 DMQ0JWZ TN Steroid 5-alpha-reductase 2 (SRD5A2) DMQ0JWZ MA Inhibitor DMQ0JWZ RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMQ0JWZ RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMQ0LF2 DI DMQ0LF2 DMQ0LF2 DN N-(3,5-dichlorophenyl)imidodicarbonimidic diamide DMQ0LF2 TI TTT1R2L DMQ0LF2 TN Integrin alpha-V (ITGAV) DMQ0LF2 MA Inhibitor DMQ0LF2 RN Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53. DMQ0LF2 RU https://pubmed.ncbi.nlm.nih.gov/20218623 DMQ0LF2 DI DMQ0LF2 DMQ0LF2 DN N-(3,5-dichlorophenyl)imidodicarbonimidic diamide DMQ0LF2 TI TTJA1ZO DMQ0LF2 TN ITGB3 messenger RNA (ITGB3 mRNA) DMQ0LF2 MA Inhibitor DMQ0LF2 RN Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53. DMQ0LF2 RU https://pubmed.ncbi.nlm.nih.gov/20218623 DMQ0NK8 DI DMQ0NK8 DMQ0NK8 DN [35S]ibutamoren DMQ0NK8 TI TTWDC17 DMQ0NK8 TN Growth hormone secretagogue receptor 1 (GHSR) DMQ0NK8 MA Agonist DMQ0NK8 RN Molecular analysis of rat pituitary and hypothalamic growth hormone secretagogue receptors. Mol Endocrinol. 1997 Apr;11(4):415-23. DMQ0NK8 RU https://pubmed.ncbi.nlm.nih.gov/9092793 DMQ0S4B DI DMQ0S4B DMQ0S4B DN NSC-66209 DMQ0S4B TI TTL53M6 DMQ0S4B TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMQ0S4B MA Inhibitor DMQ0S4B RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMQ0S4B RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQ0S4B DI DMQ0S4B DMQ0S4B DN NSC-66209 DMQ0S4B TI TT915ZD DMQ0S4B TN Candida Mannose-6-phosphate isomerase (Candi PMI1) DMQ0S4B MA Inhibitor DMQ0S4B RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMQ0S4B RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQ0TBX DI DMQ0TBX DMQ0TBX DN 4,4-Diphenylbutan-1-amine DMQ0TBX TI TTTIBOJ DMQ0TBX TN Histamine H1 receptor (H1R) DMQ0TBX MA Inhibitor DMQ0TBX RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMQ0TBX RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMQ0TBX DI DMQ0TBX DMQ0TBX DN 4,4-Diphenylbutan-1-amine DMQ0TBX TI TTJQOD7 DMQ0TBX TN 5-HT 2A receptor (HTR2A) DMQ0TBX MA Inhibitor DMQ0TBX RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMQ0TBX RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMQ0VZ8 DI DMQ0VZ8 DMQ0VZ8 DN ASN04885796 DMQ0VZ8 TI TTMPART DMQ0VZ8 TN Uracil nucleotide/cysteinyl leukotriene receptor (GPR17) DMQ0VZ8 MA Agonist DMQ0VZ8 RN In silico identification of new ligands for GPR17: a promising therapeutic target for neurodegenerative diseases. J Comput Aided Mol Des. 2011 Aug;25(8):743-52. DMQ0VZ8 RU https://pubmed.ncbi.nlm.nih.gov/21744154 DMQ0WKA DI DMQ0WKA DMQ0WKA DN 2-(2-(pyrrolidin-1-yl)ethyl)phenol DMQ0WKA TI TT9JNIC DMQ0WKA TN Histamine H3 receptor (H3R) DMQ0WKA MA Inhibitor DMQ0WKA RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMQ0WKA RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMQ0X7I DI DMQ0X7I DMQ0X7I DN IOX2 DMQ0X7I TI TT8XTY2 DMQ0X7I TN Lysine-specific demethylase 2A (KDM2A) DMQ0X7I MA Inhibitor DMQ0X7I RN Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol. 2013 Jul 19;8(7):1488-96. DMQ0X7I RU https://pubmed.ncbi.nlm.nih.gov/23683440 DMQ0X7I DI DMQ0X7I DMQ0X7I DN IOX2 DMQ0X7I TI TT94UCF DMQ0X7I TN Lysine-specific demethylase 5C (KDM5C) DMQ0X7I MA Inhibitor DMQ0X7I RN Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol. 2013 Jul 19;8(7):1488-96. DMQ0X7I RU https://pubmed.ncbi.nlm.nih.gov/23683440 DMQ0X7I DI DMQ0X7I DMQ0X7I DN IOX2 DMQ0X7I TI TT9ISBX DMQ0X7I TN HIF-prolyl hydroxylase 2 (HPH-2) DMQ0X7I MA Inhibitor DMQ0X7I RN Selective small molecule probes for the hypoxia inducible factor (HIF) prolyl hydroxylases. ACS Chem Biol. 2013 Jul 19;8(7):1488-96. DMQ0X7I RU https://pubmed.ncbi.nlm.nih.gov/23683440 DMQ0XYH DI DMQ0XYH DMQ0XYH DN Ethyl 1-[(1H-benzimidazol-5(6)-yl)sulfonyl]-1H-pyrrole-2-carboxylate DMQ0XYH TI TT84ETX DMQ0XYH TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQ0XYH MA Inhibitor DMQ0XYH RN Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg Med Chem. 2000 Sep;8(9):2305-9. DMQ0XYH RU https://pubmed.ncbi.nlm.nih.gov/11026542 DMQ0YB5 DI DMQ0YB5 DMQ0YB5 DN Thiethylperazine DMQ0YB5 TI TTAIY2U DMQ0YB5 TN HUMAN clathrin-mediated endocytosis (RME) DMQ0YB5 MA Inhibitor DMQ0YB5 RN Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. DMQ0YB5 RU https://pubmed.ncbi.nlm.nih.gov/24841273 DMQ0YW7 DI DMQ0YW7 DMQ0YW7 DN Acocantherin DMQ0YW7 TI TTWNK8B DMQ0YW7 TN HUMAN sodium pump subunit alpha-1 (ATP1A1) DMQ0YW7 MA Inhibitor DMQ0YW7 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMQ0YW7 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMQ13PZ DI DMQ13PZ DMQ13PZ DN Azocan-(2Z)-ylideneamine DMQ13PZ TI TTF10I9 DMQ13PZ TN Nitric-oxide synthase inducible (NOS2) DMQ13PZ MA Inhibitor DMQ13PZ RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMQ13PZ RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMQ13PZ DI DMQ13PZ DMQ13PZ DN Azocan-(2Z)-ylideneamine DMQ13PZ TI TTZUFI5 DMQ13PZ TN Nitric-oxide synthase brain (NOS1) DMQ13PZ MA Inhibitor DMQ13PZ RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMQ13PZ RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMQ13SI DI DMQ13SI DMQ13SI DN NSC-645836 DMQ13SI TI TTJLP0R DMQ13SI TN Quinone reductase 2 (NQO2) DMQ13SI MA Inhibitor DMQ13SI RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMQ13SI RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMQ13Z8 DI DMQ13Z8 DMQ13Z8 DN 3-Benzyl-2-ethylthio-6-nitro-quinazolin-4(3H)-one DMQ13Z8 TI TT9SL3Q DMQ13Z8 TN Polypeptide deformylase (PDF) DMQ13Z8 MA Inhibitor DMQ13Z8 RN Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63. DMQ13Z8 RU https://pubmed.ncbi.nlm.nih.gov/20350811 DMQ1B2Y DI DMQ1B2Y DMQ1B2Y DN WIN-64745 DMQ1B2Y TI TTZPO1L DMQ1B2Y TN Substance-P receptor (TACR1) DMQ1B2Y MA Modulator DMQ1B2Y RN DOI: 10.1021/jo00074a031 DMQ1B2Y RU http://pubs.acs.org/doi/abs/10.1021/jo00074a031 DMQ1BDZ DI DMQ1BDZ DMQ1BDZ DN MCL-139 DMQ1BDZ TI TTKWM86 DMQ1BDZ TN Opioid receptor mu (MOP) DMQ1BDZ MA Inhibitor DMQ1BDZ RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMQ1BDZ RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMQ1BDZ DI DMQ1BDZ DMQ1BDZ DN MCL-139 DMQ1BDZ TI TTQW87Y DMQ1BDZ TN Opioid receptor kappa (OPRK1) DMQ1BDZ MA Inhibitor DMQ1BDZ RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMQ1BDZ RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMQ1BDZ DI DMQ1BDZ DMQ1BDZ DN MCL-139 DMQ1BDZ TI TT27RFC DMQ1BDZ TN Opioid receptor delta (OPRD1) DMQ1BDZ MA Inhibitor DMQ1BDZ RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMQ1BDZ RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMQ1BE8 DI DMQ1BE8 DMQ1BE8 DN 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 TI TT3WG5C DMQ1BE8 TN Monoamine oxidase type A (MAO-A) DMQ1BE8 MA Inhibitor DMQ1BE8 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMQ1BE8 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMQ1BE8 DI DMQ1BE8 DMQ1BE8 DN 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 TI TT2NUT5 DMQ1BE8 TN Adrenergic receptor alpha-2C (ADRA2C) DMQ1BE8 MA Inhibitor DMQ1BE8 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMQ1BE8 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMQ1BE8 DI DMQ1BE8 DMQ1BE8 DN 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 TI TTGP7BY DMQ1BE8 TN Monoamine oxidase type B (MAO-B) DMQ1BE8 MA Inhibitor DMQ1BE8 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMQ1BE8 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMQ1BE8 DI DMQ1BE8 DMQ1BE8 DN 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 TI TTWM4TY DMQ1BE8 TN Adrenergic receptor alpha-2B (ADRA2B) DMQ1BE8 MA Inhibitor DMQ1BE8 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMQ1BE8 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMQ1BE8 DI DMQ1BE8 DMQ1BE8 DN 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 TI TTJQOD7 DMQ1BE8 TN 5-HT 2A receptor (HTR2A) DMQ1BE8 MA Inhibitor DMQ1BE8 RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMQ1BE8 RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMQ1BE8 DI DMQ1BE8 DMQ1BE8 DN 7-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMQ1BE8 TI TTWG9A4 DMQ1BE8 TN Adrenergic receptor alpha-2A (ADRA2A) DMQ1BE8 MA Inhibitor DMQ1BE8 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMQ1BE8 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMQ1D9A DI DMQ1D9A DMQ1D9A DN 4'-FLUORO-1,1'-BIPHENYL-4-CARBOXYLIC ACID DMQ1D9A TI TTU1E82 DMQ1D9A TN Apoptosis regulator Bcl-xL (BCL-xL) DMQ1D9A MA Inhibitor DMQ1D9A RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQ1D9A RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQ1DWU DI DMQ1DWU DMQ1DWU DN Argiotoxin-636 DMQ1DWU TI TTVPQTF DMQ1DWU TN Glutamate receptor AMPA 1 (GRIA1) DMQ1DWU MA Inhibitor DMQ1DWU RN Developing a complete pharmacology for AMPA receptors: a perspective on subtype-selective ligands. Bioorg Med Chem. 2010 Feb 15;18(4):1381-7. DMQ1DWU RU https://pubmed.ncbi.nlm.nih.gov/20096591 DMQ1EVT DI DMQ1EVT DMQ1EVT DN 1-benzene sulfonyl-cis-2,6-dimethyl piperidine DMQ1EVT TI TT1RS9F DMQ1EVT TN Acetylcholinesterase (AChE) DMQ1EVT MA Inhibitor DMQ1EVT RN Active site directed docking studies: synthesis and pharmacological evaluation of cis-2,6-dimethyl piperidine sulfonamides as inhibitors of acetylc... Eur J Med Chem. 2009 Oct;44(10):4057-62. DMQ1EVT RU https://pubmed.ncbi.nlm.nih.gov/19493592 DMQ1F7J DI DMQ1F7J DMQ1F7J DN ADP ribose DMQ1F7J TI TTEBMN7 DMQ1F7J TN Long transient receptor potential channel 2 (TRPM2) DMQ1F7J MA Activator DMQ1F7J RN ADP-ribose gating of the calcium-permeable LTRPC2 channel revealed by Nudix motif homology. Nature. 2001 May 31;411(6837):595-9. DMQ1F7J RU https://pubmed.ncbi.nlm.nih.gov/11385575 DMQ20A4 DI DMQ20A4 DMQ20A4 DN UCB-2892 DMQ20A4 TI TT9JNIC DMQ20A4 TN Histamine H3 receptor (H3R) DMQ20A4 MA Antagonist DMQ20A4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DMQ20A4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DMQ24TI DI DMQ24TI DMQ24TI DN BMS-740808 DMQ24TI TI TT6L509 DMQ24TI TN Coagulation factor IIa (F2) DMQ24TI MA Inhibitor DMQ24TI RN Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorg Med Chem Lett. 2008 Jan 15;18(2):749-54. DMQ24TI RU https://pubmed.ncbi.nlm.nih.gov/18054227 DMQ24TI DI DMQ24TI DMQ24TI DN BMS-740808 DMQ24TI TI TTCIHJA DMQ24TI TN Coagulation factor Xa (F10) DMQ24TI MA Inhibitor DMQ24TI RN Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS... J Med Chem. 2007 Nov 1;50(22):5339-56. DMQ24TI RU https://pubmed.ncbi.nlm.nih.gov/17914785 DMQ28L9 DI DMQ28L9 DMQ28L9 DN RTI-5989-25 DMQ28L9 TI TTQW87Y DMQ28L9 TN Opioid receptor kappa (OPRK1) DMQ28L9 MA Inhibitor DMQ28L9 RN Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90. DMQ28L9 RU https://pubmed.ncbi.nlm.nih.gov/9599247 DMQ28L9 DI DMQ28L9 DMQ28L9 DN RTI-5989-25 DMQ28L9 TI TT27RFC DMQ28L9 TN Opioid receptor delta (OPRD1) DMQ28L9 MA Inhibitor DMQ28L9 RN Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90. DMQ28L9 RU https://pubmed.ncbi.nlm.nih.gov/9599247 DMQ2C8X DI DMQ2C8X DMQ2C8X DN AdcAhxArg4Lys-PEGOMe DMQ2C8X TI TTW4Y2M DMQ2C8X TN cAMP protein kinase type II-beta (PRKAR2B) DMQ2C8X MA Inhibitor DMQ2C8X RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DMQ2C8X RU https://pubmed.ncbi.nlm.nih.gov/12941328 DMQ2C8X DI DMQ2C8X DMQ2C8X DN AdcAhxArg4Lys-PEGOMe DMQ2C8X TI TTNAHEX DMQ2C8X TN cAMP-dependent protein kinase A type I (PRKAR1A) DMQ2C8X MA Inhibitor DMQ2C8X RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DMQ2C8X RU https://pubmed.ncbi.nlm.nih.gov/12941328 DMQ2D09 DI DMQ2D09 DMQ2D09 DN 3-(4-chloro-2-cyclohexylphenoxy)propanoic acid DMQ2D09 TI TTQDMX5 DMQ2D09 TN Prostaglandin D2 receptor 2 (PTGDR2) DMQ2D09 MA Inhibitor DMQ2D09 RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMQ2D09 RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMQ2DFN DI DMQ2DFN DMQ2DFN DN LBQ657 DMQ2DFN TI TT5TKPM DMQ2DFN TN Neutral endopeptidase (MME) DMQ2DFN MA Inhibitor DMQ2DFN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1611). DMQ2DFN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1611 DMQ2EYJ DI DMQ2EYJ DMQ2EYJ DN YGWFL-NH2 DMQ2EYJ TI TTKWM86 DMQ2EYJ TN Opioid receptor mu (MOP) DMQ2EYJ MA Inhibitor DMQ2EYJ RN Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. DMQ2EYJ RU https://pubmed.ncbi.nlm.nih.gov/18329886 DMQ2FDA DI DMQ2FDA DMQ2FDA DN BS 9106 DMQ2FDA TI TTVG215 DMQ2FDA TN Debrisoquine 4-hydroxylase (CYP2D6) DMQ2FDA MA Inhibitor DMQ2FDA RN Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J Med Chem. 2006 Apr 20;49(8):2417-30. DMQ2FDA RU https://pubmed.ncbi.nlm.nih.gov/16610785 DMQ2INJ DI DMQ2INJ DMQ2INJ DN (R)-(-)-2-methoxy-11-hydroxyaporphine DMQ2INJ TI TTEX248 DMQ2INJ TN Dopamine D2 receptor (D2R) DMQ2INJ MA Inhibitor DMQ2INJ RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMQ2INJ RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMQ2INJ DI DMQ2INJ DMQ2INJ DN (R)-(-)-2-methoxy-11-hydroxyaporphine DMQ2INJ TI TTZFYLI DMQ2INJ TN Dopamine D1 receptor (D1R) DMQ2INJ MA Inhibitor DMQ2INJ RN Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selec... J Med Chem. 2008 Feb 28;51(4):983-7. DMQ2INJ RU https://pubmed.ncbi.nlm.nih.gov/18251489 DMQ2KF8 DI DMQ2KF8 DMQ2KF8 DN (R)-3-(4-Isobutyl-phenyl)-butan-2-one DMQ2KF8 TI TTMWT8Z DMQ2KF8 TN C-X-C chemokine receptor type 1 (CXCR1) DMQ2KF8 MA Inhibitor DMQ2KF8 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMQ2KF8 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMQ2KF8 DI DMQ2KF8 DMQ2KF8 DN (R)-3-(4-Isobutyl-phenyl)-butan-2-one DMQ2KF8 TI TT30C9G DMQ2KF8 TN C-X-C chemokine receptor type 2 (CXCR2) DMQ2KF8 MA Inhibitor DMQ2KF8 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMQ2KF8 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMQ2KPI DI DMQ2KPI DMQ2KPI DN 2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol DMQ2KPI TI TTZAYWL DMQ2KPI TN Estrogen receptor (ESR) DMQ2KPI MA Inhibitor DMQ2KPI RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DMQ2KPI RU https://pubmed.ncbi.nlm.nih.gov/15341953 DMQ2KPI DI DMQ2KPI DMQ2KPI DN 2-(4-Hydroxy-phenyl)-7-methyl-benzofuran-5-ol DMQ2KPI TI TTOM3J0 DMQ2KPI TN Estrogen receptor beta (ESR2) DMQ2KPI MA Inhibitor DMQ2KPI RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DMQ2KPI RU https://pubmed.ncbi.nlm.nih.gov/15341953 DMQ2SNL DI DMQ2SNL DMQ2SNL DN 2-(carboxymethylamino)-2-oxoacetic acid DMQ2SNL TI TTMHFRY DMQ2SNL TN HIF-prolyl hydroxylase 1 (HPH-1) DMQ2SNL MA Inhibitor DMQ2SNL RN Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone de... J Med Chem. 2010 Aug 12;53(15):5629-38. DMQ2SNL RU https://pubmed.ncbi.nlm.nih.gov/20684604 DMQ2TNL DI DMQ2TNL DMQ2TNL DN ANG-2864 DMQ2TNL TI TTVDSZ0 DMQ2TNL TN Poly [ADP-ribose] polymerase 1 (PARP1) DMQ2TNL MA Inhibitor DMQ2TNL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMQ2TNL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMQ2U4G DI DMQ2U4G DMQ2U4G DN D-219 DMQ2U4G TI TT4C8EA DMQ2U4G TN Dopamine D3 receptor (D3R) DMQ2U4G MA Inhibitor DMQ2U4G RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMQ2U4G RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMQ2U4G DI DMQ2U4G DMQ2U4G DN D-219 DMQ2U4G TI TTEX248 DMQ2U4G TN Dopamine D2 receptor (D2R) DMQ2U4G MA Inhibitor DMQ2U4G RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMQ2U4G RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMQ2XUE DI DMQ2XUE DMQ2XUE DN (2R)-1-(2,6-dimethylphenoxy)propan-2-amine DMQ2XUE TI TTGY7WI DMQ2XUE TN Urokinase-type plasminogen activator (PLAU) DMQ2XUE MA Inhibitor DMQ2XUE RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQ2XUE RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQ2ZTJ DI DMQ2ZTJ DMQ2ZTJ DN 7-fluorochromone-2-carboxamide DMQ2ZTJ TI TTX4RTB DMQ2ZTJ TN Melanin-concentrating hormone receptor 1 (MCHR1) DMQ2ZTJ MA Antagonist DMQ2ZTJ RN Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J Med Chem. 2006 Nov 2;49(22):6569-84. DMQ2ZTJ RU https://pubmed.ncbi.nlm.nih.gov/17064075 DMQ30UY DI DMQ30UY DMQ30UY DN 2-amino-N1-benzyl-N3-hydroxymalonamide DMQ30UY TI TTPHMWB DMQ30UY TN Aminopeptidase N (ANPEP) DMQ30UY MA Inhibitor DMQ30UY RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMQ30UY RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMQ3184 DI DMQ3184 DMQ3184 DN N-ethyl-2,2,2-triphenylacetamide DMQ3184 TI TTMNI76 DMQ3184 TN Calcium-activated potassium channel (KCN) DMQ3184 MA Inhibitor DMQ3184 RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMQ3184 RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMQ350F DI DMQ350F DMQ350F DN 5-chloro-1H-indole-2,3-dione DMQ350F TI TTMF541 DMQ350F TN Liver carboxylesterase (CES1) DMQ350F MA Inhibitor DMQ350F RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMQ350F RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMQ357C DI DMQ357C DMQ357C DN MQ1 DMQ357C TI TTX4RTB DMQ357C TN Melanin-concentrating hormone receptor 1 (MCHR1) DMQ357C MA Modulator (allosteric modulator) DMQ357C RN The MCH(1) receptor, an anti-obesity target, is allosterically inhibited by 8-methylquinoline derivatives possessing subnanomolar binding and long residence times. Br J Pharmacol. 2014 Mar;171(5):1287-98. DMQ357C RU https://pubmed.ncbi.nlm.nih.gov/24670150 DMQ369D DI DMQ369D DMQ369D DN L-367,773 DMQ369D TI TTSCIUP DMQ369D TN Oxytocin receptor (OTR) DMQ369D MA Antagonist DMQ369D RN Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells. Life Sci. 1995;57(24):2253-61. DMQ369D RU https://pubmed.ncbi.nlm.nih.gov/7475979 DMQ37OP DI DMQ37OP DMQ37OP DN clofilium DMQ37OP TI TTW0CMT DMQ37OP TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMQ37OP MA Blocker (channel blocker) DMQ37OP RN Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205. DMQ37OP RU https://pubmed.ncbi.nlm.nih.gov/7838129 DMQ37OP DI DMQ37OP DMQ37OP DN clofilium DMQ37OP TI TT9XKUC DMQ37OP TN Voltage-gated potassium channel Kv10.1 (KCNH1) DMQ37OP MA Blocker (channel blocker) DMQ37OP RN Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol. 2003 Jan;138(1):161-71. DMQ37OP RU https://pubmed.ncbi.nlm.nih.gov/12522086 DMQ385U DI DMQ385U DMQ385U DN 2,4-Dibenzylamino-6-isopentylpyrimidine DMQ385U TI TTZAYWL DMQ385U TN Estrogen receptor (ESR) DMQ385U MA Inhibitor DMQ385U RN Blocking estrogen signaling after the hormone: pyrimidine-core inhibitors of estrogen receptor-coactivator binding. J Med Chem. 2008 Oct 23;51(20):6512-30. DMQ385U RU https://pubmed.ncbi.nlm.nih.gov/18785725 DMQ391A DI DMQ391A DMQ391A DN Fmet-leu-phe DMQ391A TI TTOJ1NF DMQ391A TN FMLP-related receptor I (FPR2) DMQ391A MA Agonist DMQ391A RN Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors. J Biol Chem. 1993 Aug 25;268(24):18167-75. DMQ391A RU https://pubmed.ncbi.nlm.nih.gov/8349692 DMQ391A DI DMQ391A DMQ391A DN Fmet-leu-phe DMQ391A TI TT5Y4EM DMQ391A TN N-formyl peptide receptor (FPR1) DMQ391A MA Agonist DMQ391A RN Further studies on the structural requirements for synthetic peptide chemoattractants. Biochemistry. 1980 May 27;19(11):2404-10. DMQ391A RU https://pubmed.ncbi.nlm.nih.gov/7387981 DMQ3AC0 DI DMQ3AC0 DMQ3AC0 DN BW284C51 DMQ3AC0 TI TT1RS9F DMQ3AC0 TN Acetylcholinesterase (AChE) DMQ3AC0 MA Inhibitor DMQ3AC0 RN Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res. 2003 Apr;28(3-4):515-22. DMQ3AC0 RU https://pubmed.ncbi.nlm.nih.gov/12675140 DMQ3ER0 DI DMQ3ER0 DMQ3ER0 DN reglitazar DMQ3ER0 TI TTT2SVW DMQ3ER0 TN PPAR-gamma messenger RNA (PPARG mRNA) DMQ3ER0 MA Agonist DMQ3ER0 RN Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9. DMQ3ER0 RU https://pubmed.ncbi.nlm.nih.gov/9932726 DMQ3ER0 DI DMQ3ER0 DMQ3ER0 DN reglitazar DMQ3ER0 TI TTJ584C DMQ3ER0 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMQ3ER0 MA Agonist DMQ3ER0 RN Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Eur J Pharmacol. 1999 Jan 8;364(2-3):211-9. DMQ3ER0 RU https://pubmed.ncbi.nlm.nih.gov/9932726 DMQ3KUV DI DMQ3KUV DMQ3KUV DN ISIS 10311 DMQ3KUV TI TT7A1BO DMQ3KUV TN PKC-delta messenger RNA (PRKCD mRNA) DMQ3KUV RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMQ3KUV RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMQ3LMF DI DMQ3LMF DMQ3LMF DN Ethyl 4-(2-oxo-2H-chromene-3-carboxamido)benzoate DMQ3LMF TI TT3WG5C DMQ3LMF TN Monoamine oxidase type A (MAO-A) DMQ3LMF MA Inhibitor DMQ3LMF RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMQ3LMF RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMQ3RVK DI DMQ3RVK DMQ3RVK DN 7-hydroxy-6-propionyl-2H-chromen-2-one DMQ3RVK TI TT2LVK8 DMQ3RVK TN Carbonic anhydrase IX (CA-IX) DMQ3RVK MA Inhibitor DMQ3RVK RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMQ3RVK RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMQ3SAY DI DMQ3SAY DMQ3SAY DN CGNLSTCBLGTYTQDF[DKFHO]YPQTAIGVGAP-amide DMQ3SAY TI TTLWS2O DMQ3SAY TN Calcitonin receptor (CALCR) DMQ3SAY MA Inhibitor DMQ3SAY RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMQ3SAY RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMQ3VHR DI DMQ3VHR DMQ3VHR DN LUF-5764 DMQ3VHR TI TTK25J1 DMQ3VHR TN Adenosine A1 receptor (ADORA1) DMQ3VHR MA Inhibitor DMQ3VHR RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMQ3VHR RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMQ3Z17 DI DMQ3Z17 DMQ3Z17 DN Isosorbide-2-benzylcarbamate-5-isonicotinate DMQ3Z17 TI TTEB0GD DMQ3Z17 TN Cholinesterase (BCHE) DMQ3Z17 MA Inhibitor DMQ3Z17 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMQ3Z17 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMQ42KU DI DMQ42KU DMQ42KU DN lisinopril-tryptophan DMQ42KU TI TTL69WB DMQ42KU TN Angiotensin-converting enzyme (ACE) DMQ42KU MA Inhibitor DMQ42KU RN Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J. 2010 Apr 28;428(1):67-74. DMQ42KU RU https://pubmed.ncbi.nlm.nih.gov/20233165 DMQ45WH DI DMQ45WH DMQ45WH DN 3,5-dichlorosalicylic acid DMQ45WH TI TTFBNVI DMQ45WH TN Aldose reductase (AKR1B1) DMQ45WH MA Inhibitor DMQ45WH RN Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorg Med Chem. 2009 Feb 1;17(3):1244-50. DMQ45WH RU https://pubmed.ncbi.nlm.nih.gov/19121944 DMQ45WH DI DMQ45WH DMQ45WH DN 3,5-dichlorosalicylic acid DMQ45WH TI TTJS7O4 DMQ45WH TN Entamoeba Alcohol dehydrogenase 2 (Entamo ADH2) DMQ45WH MA Inhibitor DMQ45WH RN Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase. Bioorg Med Chem. 2009 Feb 1;17(3):1244-50. DMQ45WH RU https://pubmed.ncbi.nlm.nih.gov/19121944 DMQ48YZ DI DMQ48YZ DMQ48YZ DN ISIS 103701 DMQ48YZ TI TT6TU05 DMQ48YZ TN WWP2 messenger RNA (WWP2 mRNA) DMQ48YZ RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMQ48YZ RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMQ4GBO DI DMQ4GBO DMQ4GBO DN tirotundin DMQ4GBO TI TTT2SVW DMQ4GBO TN PPAR-gamma messenger RNA (PPARG mRNA) DMQ4GBO MA Agonist DMQ4GBO RN Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2954-8. DMQ4GBO RU https://pubmed.ncbi.nlm.nih.gov/22424975 DMQ4GL6 DI DMQ4GL6 DMQ4GL6 DN ISIS 113021 DMQ4GL6 TI TTASI04 DMQ4GL6 TN E2F1 messenger RNA (E2F1 mRNA) DMQ4GL6 RN US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression. DMQ4GL6 RU http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true DMQ4ICU DI DMQ4ICU DMQ4ICU DN improgan DMQ4ICU TI TTXJ178 DMQ4ICU TN Histamine H4 receptor (H4R) DMQ4ICU MA Agonist DMQ4ICU RN Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol. 2001 Mar;59(3):434-41. DMQ4ICU RU https://pubmed.ncbi.nlm.nih.gov/11179436 DMQ4ILK DI DMQ4ILK DMQ4ILK DN H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid DMQ4ILK TI TTKWM86 DMQ4ILK TN Opioid receptor mu (MOP) DMQ4ILK MA Inhibitor DMQ4ILK RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMQ4ILK RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMQ4ILK DI DMQ4ILK DMQ4ILK DN H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid DMQ4ILK TI TT27RFC DMQ4ILK TN Opioid receptor delta (OPRD1) DMQ4ILK MA Inhibitor DMQ4ILK RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMQ4ILK RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMQ4L1I DI DMQ4L1I DMQ4L1I DN Dansylamide DMQ4L1I TI TTANPDJ DMQ4L1I TN Carbonic anhydrase II (CA-II) DMQ4L1I MA Inhibitor DMQ4L1I RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQ4L1I RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQ4LRZ DI DMQ4LRZ DMQ4LRZ DN PD-115199 DMQ4LRZ TI TTM2AOE DMQ4LRZ TN Adenosine A2a receptor (ADORA2A) DMQ4LRZ MA Inhibitor DMQ4LRZ RN (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992 Jun 12;35(12):2342-5. DMQ4LRZ RU https://pubmed.ncbi.nlm.nih.gov/1613758 DMQ4LRZ DI DMQ4LRZ DMQ4LRZ DN PD-115199 DMQ4LRZ TI TTK25J1 DMQ4LRZ TN Adenosine A1 receptor (ADORA1) DMQ4LRZ MA Inhibitor DMQ4LRZ RN (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992 Jun 12;35(12):2342-5. DMQ4LRZ RU https://pubmed.ncbi.nlm.nih.gov/1613758 DMQ4LRZ DI DMQ4LRZ DMQ4LRZ DN PD-115199 DMQ4LRZ TI TTNE7KG DMQ4LRZ TN Adenosine A2b receptor (ADORA2B) DMQ4LRZ MA Inhibitor DMQ4LRZ RN (E)-1,3-dialkyl-7-methyl-8-(3,4,5-trimethoxystyryl)xanthines: potent and selective adenosine A2 antagonists. J Med Chem. 1992 Jun 12;35(12):2342-5. DMQ4LRZ RU https://pubmed.ncbi.nlm.nih.gov/1613758 DMQ4MFY DI DMQ4MFY DMQ4MFY DN BRL-26175 DMQ4MFY TI TTEX248 DMQ4MFY TN Dopamine D2 receptor (D2R) DMQ4MFY MA Inhibitor DMQ4MFY RN 18F-labeled benzamides for studying the dopamine D2 receptor with positron emission tomography. J Med Chem. 1993 Nov 12;36(23):3707-20. DMQ4MFY RU https://pubmed.ncbi.nlm.nih.gov/8246241 DMQ4MUF DI DMQ4MUF DMQ4MUF DN 1-(3-(benzyloxy)-2-methylphenyl)piperazine DMQ4MUF TI TTJS8PY DMQ4MUF TN 5-HT 6 receptor (HTR6) DMQ4MUF MA Inhibitor DMQ4MUF RN Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12. DMQ4MUF RU https://pubmed.ncbi.nlm.nih.gov/19346128 DMQ4OTJ DI DMQ4OTJ DMQ4OTJ DN VPC44116 DMQ4OTJ TI TTDZCKV DMQ4OTJ TN Sphingosine-1-phosphate receptor 5 (S1PR5) DMQ4OTJ MA Agonist DMQ4OTJ RN Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77. DMQ4OTJ RU https://pubmed.ncbi.nlm.nih.gov/17113298 DMQ4OTJ DI DMQ4OTJ DMQ4OTJ DN VPC44116 DMQ4OTJ TI TTDYP7I DMQ4OTJ TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMQ4OTJ MA Antagonist DMQ4OTJ RN Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77. DMQ4OTJ RU https://pubmed.ncbi.nlm.nih.gov/17113298 DMQ4OTJ DI DMQ4OTJ DMQ4OTJ DN VPC44116 DMQ4OTJ TI TT9JZCK DMQ4OTJ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMQ4OTJ MA Antagonist DMQ4OTJ RN Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77. DMQ4OTJ RU https://pubmed.ncbi.nlm.nih.gov/17113298 DMQ4ST2 DI DMQ4ST2 DMQ4ST2 DN N-Hydroxy-N-methyl-2,3,3-triphenyl-acrylamide DMQ4ST2 TI TT2J34L DMQ4ST2 TN Arachidonate 5-lipoxygenase (5-LOX) DMQ4ST2 MA Inhibitor DMQ4ST2 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMQ4ST2 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMQ4WNB DI DMQ4WNB DMQ4WNB DN KMI-494 DMQ4WNB TI TT8JRS7 DMQ4WNB TN Beta-secretase (BACE) DMQ4WNB MA Inhibitor DMQ4WNB RN Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1629-33. DMQ4WNB RU https://pubmed.ncbi.nlm.nih.gov/17251016 DMQ4Z6E DI DMQ4Z6E DMQ4Z6E DN ISORHAMNETIN DMQ4Z6E TI TTBE4IR DMQ4Z6E TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMQ4Z6E MA Inhibitor DMQ4Z6E RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMQ4Z6E RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMQ4Z6E DI DMQ4Z6E DMQ4Z6E DN ISORHAMNETIN DMQ4Z6E TI TTI84H7 DMQ4Z6E TN Cytochrome P450 1B1 (CYP1B1) DMQ4Z6E MA Inhibitor DMQ4Z6E RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMQ4Z6E RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMQ4Z6E DI DMQ4Z6E DMQ4Z6E DN ISORHAMNETIN DMQ4Z6E TI TTNX2CS DMQ4Z6E TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMQ4Z6E MA Inhibitor DMQ4Z6E RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMQ4Z6E RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMQ586T DI DMQ586T DMQ586T DN H-Dmt-Tic-NH-(CH2)6-NH-Tic-H DMQ586T TI TT27RFC DMQ586T TN Opioid receptor delta (OPRD1) DMQ586T MA Inhibitor DMQ586T RN New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. DMQ586T RU https://pubmed.ncbi.nlm.nih.gov/16183273 DMQ586T DI DMQ586T DMQ586T DN H-Dmt-Tic-NH-(CH2)6-NH-Tic-H DMQ586T TI TTKWM86 DMQ586T TN Opioid receptor mu (MOP) DMQ586T MA Inhibitor DMQ586T RN New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20. DMQ586T RU https://pubmed.ncbi.nlm.nih.gov/16183273 DMQ5A4Y DI DMQ5A4Y DMQ5A4Y DN ISIS 1820 DMQ5A4Y TI TTSJ6Q4 DMQ5A4Y TN LOX-5 messenger RNA (ALOX5 mRNA) DMQ5A4Y RN US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism. DMQ5A4Y RU http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true DMQ5AJW DI DMQ5AJW DMQ5AJW DN A-82186 DMQ5AJW TI TTGN1ZA DMQ5AJW TN Angiotensin II receptor (AGTR) DMQ5AJW MA Modulator DMQ5AJW RN WO patent application no. 2011,0583,31, Pemirolast for the treatment of systemic low grade inflammation. DMQ5AJW RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20110519&CC=WO&NR=2011058331A1&KC=A1 DMQ5CE1 DI DMQ5CE1 DMQ5CE1 DN CI-1015 DMQ5CE1 TI TTVFO0U DMQ5CE1 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMQ5CE1 MA Antagonist DMQ5CE1 RN Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem. 1998 Jan 1;41(1):38-45. DMQ5CE1 RU https://pubmed.ncbi.nlm.nih.gov/9438020 DMQ5CE1 DI DMQ5CE1 DMQ5CE1 DN CI-1015 DMQ5CE1 TI TTCG0AL DMQ5CE1 TN Cholecystokinin receptor type A (CCKAR) DMQ5CE1 MA Antagonist DMQ5CE1 RN Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantyloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem. 1998 Jan 1;41(1):38-45. DMQ5CE1 RU https://pubmed.ncbi.nlm.nih.gov/9438020 DMQ5GA9 DI DMQ5GA9 DMQ5GA9 DN IS20 DMQ5GA9 TI TTB9CIL DMQ5GA9 TN Prokineticin receptor-1 (PROKR1) DMQ5GA9 MA Agonist DMQ5GA9 RN Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS One. 2015 Apr 1;10(4):e0121027. DMQ5GA9 RU https://pubmed.ncbi.nlm.nih.gov/25831128 DMQ5GMV DI DMQ5GMV DMQ5GMV DN SUVN-1004028 DMQ5GMV TI TT07C3Y DMQ5GMV TN 5-HT 4 receptor (HTR4) DMQ5GMV MA Agonist DMQ5GMV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMQ5GMV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMQ5H2V DI DMQ5H2V DMQ5H2V DN AZ12260493 DMQ5H2V TI TTECBXN DMQ5H2V TN Oxysterols receptor LXR-alpha (NR1H3) DMQ5H2V MA Agonist DMQ5H2V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 602). DMQ5H2V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=602 DMQ5H2V DI DMQ5H2V DMQ5H2V DN AZ12260493 DMQ5H2V TI TTXA6PH DMQ5H2V TN Oxysterols receptor LXR-beta (NR1H2) DMQ5H2V MA Agonist DMQ5H2V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 601). DMQ5H2V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=601 DMQ5JNT DI DMQ5JNT DMQ5JNT DN ISIS 28465 DMQ5JNT TI TT0J32Z DMQ5JNT TN Smad7 messenger RNA (Smad7 mRNA) DMQ5JNT RN US patent application no. 6,159,697, Antisense modulation of Smad7 expression. DMQ5JNT RU http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true DMQ5JX8 DI DMQ5JX8 DMQ5JX8 DN CTT-54 DMQ5JX8 TI TT9G4N0 DMQ5JX8 TN Glutamate carboxypeptidase II (GCPII) DMQ5JX8 MA Modulator DMQ5JX8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMQ5JX8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMQ5K8R DI DMQ5K8R DMQ5K8R DN N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine DMQ5K8R TI TTJFY5U DMQ5K8R TN Adenosine A3 receptor (ADORA3) DMQ5K8R MA Inhibitor DMQ5K8R RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMQ5K8R RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMQ5K8R DI DMQ5K8R DMQ5K8R DN N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine DMQ5K8R TI TTM2AOE DMQ5K8R TN Adenosine A2a receptor (ADORA2A) DMQ5K8R MA Inhibitor DMQ5K8R RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMQ5K8R RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMQ5K8R DI DMQ5K8R DMQ5K8R DN N6-methoxy-2-[(4-pentylphenyl)ethynyl]adenosine DMQ5K8R TI TTK25J1 DMQ5K8R TN Adenosine A1 receptor (ADORA1) DMQ5K8R MA Inhibitor DMQ5K8R RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMQ5K8R RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMQ5S9C DI DMQ5S9C DMQ5S9C DN MEDI-552 DMQ5S9C TI TTUE541 DMQ5S9C TN Leukocyte surface antigen Leu-16 (CD20) DMQ5S9C MA Modulator DMQ5S9C RN Anti CD37 antibodies DMQ5S9C RU https://www.google.com/patents/US9078879 DMQ5UA3 DI DMQ5UA3 DMQ5UA3 DN ISIS 19659 DMQ5UA3 TI TTWALCO DMQ5UA3 TN HER4 messenger RNA (ERBB4 mRNA) DMQ5UA3 RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMQ5UA3 RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMQ5USA DI DMQ5USA DMQ5USA DN N-(3,4,5-trihydroxyphenethyl)oleamide DMQ5USA TI TTIQSC1 DMQ5USA TN Bacterial Lethal factor (Bact lef) DMQ5USA MA Inhibitor DMQ5USA RN Inhibitors of anthrax lethal factor. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4575-8. DMQ5USA RU https://pubmed.ncbi.nlm.nih.gov/17574849 DMQ63J2 DI DMQ63J2 DMQ63J2 DN EM-101 DMQ63J2 TI TTCJG29 DMQ63J2 TN Serine/threonine-protein kinase mTOR (mTOR) DMQ63J2 MA Inhibitor DMQ63J2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMQ63J2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMQ6AR5 DI DMQ6AR5 DMQ6AR5 DN [18F]MK-1312 DMQ6AR5 TI TTVBPDM DMQ6AR5 TN Metabotropic glutamate receptor 1 (mGluR1) DMQ6AR5 MA Modulator (allosteric modulator) DMQ6AR5 RN Synthesis, characterization, and monkey PET studies of [ ]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse. 2011 Feb;65(2):125-35. DMQ6AR5 RU https://pubmed.ncbi.nlm.nih.gov/20524178 DMQ6BS2 DI DMQ6BS2 DMQ6BS2 DN Cyclopentyl-(9-ethyl-9H-purin-6-yl)-amine DMQ6BS2 TI TTK25J1 DMQ6BS2 TN Adenosine A1 receptor (ADORA1) DMQ6BS2 MA Inhibitor DMQ6BS2 RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMQ6BS2 RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMQ6EBR DI DMQ6EBR DMQ6EBR DN 4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol DMQ6EBR TI TTMSFAW DMQ6EBR TN Cannabinoid receptor 2 (CB2) DMQ6EBR MA Inhibitor DMQ6EBR RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMQ6EBR RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMQ6EBR DI DMQ6EBR DMQ6EBR DN 4'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol DMQ6EBR TI TT6OEDT DMQ6EBR TN Cannabinoid receptor 1 (CB1) DMQ6EBR MA Inhibitor DMQ6EBR RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMQ6EBR RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMQ6GBX DI DMQ6GBX DMQ6GBX DN NSC-45592 DMQ6GBX TI TT9NVXQ DMQ6GBX TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMQ6GBX MA Inhibitor DMQ6GBX RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMQ6GBX RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMQ6P13 DI DMQ6P13 DMQ6P13 DN Phenylphosphate DMQ6P13 TI TT6PKBN DMQ6P13 TN Proto-oncogene c-Src (SRC) DMQ6P13 MA Inhibitor DMQ6P13 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMQ6P13 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMQ6POC DI DMQ6POC DMQ6POC DN Pyridoxamine-5'-Phosphate DMQ6POC TI TTN6GE9 DMQ6POC TN Staphylococcus D-amino acid aminotransferase (Stap-coc dat) DMQ6POC MA Inhibitor DMQ6POC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQ6POC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQ6POC DI DMQ6POC DMQ6POC DN Pyridoxamine-5'-Phosphate DMQ6POC TI TTF9OQ6 DMQ6POC TN Branched-chain-amino-acid transaminase 2 (BCAT2) DMQ6POC MA Inhibitor DMQ6POC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQ6POC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQ6POC DI DMQ6POC DMQ6POC DN Pyridoxamine-5'-Phosphate DMQ6POC TI TT6TMZU DMQ6POC TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMQ6POC MA Inhibitor DMQ6POC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQ6POC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQ6SJT DI DMQ6SJT DMQ6SJT DN ROSMARINIC ACID DMQ6SJT TI TTULVH8 DMQ6SJT TN Tyrosinase (TYR) DMQ6SJT MA Inhibitor DMQ6SJT RN A novel ring-expanded product with enhanced tyrosinase inhibitory activity from classical Fe-catalyzed oxidation of rosmarinic acid, a potent antio... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7393-6. DMQ6SJT RU https://pubmed.ncbi.nlm.nih.gov/21041086 DMQ6SJT DI DMQ6SJT DMQ6SJT DN ROSMARINIC ACID DMQ6SJT TI TTL53M6 DMQ6SJT TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMQ6SJT MA Inhibitor DMQ6SJT RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMQ6SJT RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMQ6TZE DI DMQ6TZE DMQ6TZE DN P-1116 DMQ6TZE TI TTAUX24 DMQ6TZE TN Erythropoietin Receptor (EPOR) DMQ6TZE MA Stimulator DMQ6TZE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718). DMQ6TZE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1718 DMQ6W4I DI DMQ6W4I DMQ6W4I DN Substance P DMQ6W4I TI TTZPO1L DMQ6W4I TN Substance-P receptor (TACR1) DMQ6W4I MA Inhibitor DMQ6W4I RN Synthesis and structure-activity relationships of CP-122,721, a second-generation NK-1 receptor antagonist. Bioorg Med Chem Lett. 1998 Feb 3;8(3):281-4. DMQ6W4I RU https://pubmed.ncbi.nlm.nih.gov/9871670 DMQ6YXF DI DMQ6YXF DMQ6YXF DN SKF-75670 DMQ6YXF TI TTZFYLI DMQ6YXF TN Dopamine D1 receptor (D1R) DMQ6YXF MA Agonist DMQ6YXF RN Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol. 1990 Jun 12;188(6):335-47. DMQ6YXF RU https://pubmed.ncbi.nlm.nih.gov/1973652 DMQ7I06 DI DMQ7I06 DMQ7I06 DN Benzofuran-2-ylboronic acid DMQ7I06 TI TTDP1UC DMQ7I06 TN Fatty acid amide hydrolase (FAAH) DMQ7I06 MA Inhibitor DMQ7I06 RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMQ7I06 RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMQ7KR1 DI DMQ7KR1 DMQ7KR1 DN Bis(2,3-dibromo-4,5-dihydroxyphenyl)ether DMQ7KR1 TI TT58ZYW DMQ7KR1 TN Mycobacterium Isocitrate lyase (MycB icl) DMQ7KR1 MA Inhibitor DMQ7KR1 RN Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8. DMQ7KR1 RU https://pubmed.ncbi.nlm.nih.gov/20888765 DMQ7PIL DI DMQ7PIL DMQ7PIL DN QwFwLL-NH2 DMQ7PIL TI TTWDC17 DMQ7PIL TN Growth hormone secretagogue receptor 1 (GHSR) DMQ7PIL MA Inhibitor DMQ7PIL RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DMQ7PIL RU https://pubmed.ncbi.nlm.nih.gov/17371869 DMQ7THK DI DMQ7THK DMQ7THK DN Methyl-pentyl-prop-2-ynyl-amine oxalic acid DMQ7THK TI TTGP7BY DMQ7THK TN Monoamine oxidase type B (MAO-B) DMQ7THK MA Inhibitor DMQ7THK RN Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem. 1992 Oct 2;35(20):3705-13. DMQ7THK RU https://pubmed.ncbi.nlm.nih.gov/1433183 DMQ7VDM DI DMQ7VDM DMQ7VDM DN TDI-0033 DMQ7VDM TI TTEDJN4 DMQ7VDM TN Low-affinity nerve growth factor receptor (NGFR) DMQ7VDM MA Agonist DMQ7VDM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMQ7VDM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMQ84J7 DI DMQ84J7 DMQ84J7 DN N-oxo-2-(phenylsulfonylamino)ethanamide DMQ84J7 TI TTXZ0KQ DMQ84J7 TN Matrix metalloproteinase-12 (MMP-12) DMQ84J7 MA Inhibitor DMQ84J7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQ84J7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQ890N DI DMQ890N DMQ890N DN MCL-449 DMQ890N TI TT27RFC DMQ890N TN Opioid receptor delta (OPRD1) DMQ890N MA Inhibitor DMQ890N RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMQ890N RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMQ890N DI DMQ890N DMQ890N DN MCL-449 DMQ890N TI TTQW87Y DMQ890N TN Opioid receptor kappa (OPRK1) DMQ890N MA Inhibitor DMQ890N RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMQ890N RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMQ890N DI DMQ890N DMQ890N DN MCL-449 DMQ890N TI TTKWM86 DMQ890N TN Opioid receptor mu (MOP) DMQ890N MA Inhibitor DMQ890N RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMQ890N RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMQ8ADE DI DMQ8ADE DMQ8ADE DN HTS-00213 DMQ8ADE TI TTGKNB4 DMQ8ADE TN Epidermal growth factor receptor (EGFR) DMQ8ADE MA Inhibitor DMQ8ADE RN Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75. DMQ8ADE RU https://pubmed.ncbi.nlm.nih.gov/19170633 DMQ8BIX DI DMQ8BIX DMQ8BIX DN 7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMQ8BIX TI TTOM3J0 DMQ8BIX TN Estrogen receptor beta (ESR2) DMQ8BIX MA Inhibitor DMQ8BIX RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMQ8BIX RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMQ8BIX DI DMQ8BIX DMQ8BIX DN 7-Butyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMQ8BIX TI TTZAYWL DMQ8BIX TN Estrogen receptor (ESR) DMQ8BIX MA Inhibitor DMQ8BIX RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMQ8BIX RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMQ8CD3 DI DMQ8CD3 DMQ8CD3 DN [Cyclopentyl-(2-nitro-benzoyl)-amino]-acetic acid DMQ8CD3 TI TTL69WB DMQ8CD3 TN Angiotensin-converting enzyme (ACE) DMQ8CD3 MA Inhibitor DMQ8CD3 RN Angiotensin converting enzyme inhibitors. (Mercaptoaroyl)amino acids. J Med Chem. 1985 Mar;28(3):328-32. DMQ8CD3 RU https://pubmed.ncbi.nlm.nih.gov/2983075 DMQ8H74 DI DMQ8H74 DMQ8H74 DN 3-Butoxy-9H-beta-carboline DMQ8H74 TI TTNJYV2 DMQ8H74 TN Gamma-aminobutyric acid receptor (GAR) DMQ8H74 MA Inhibitor DMQ8H74 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMQ8H74 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMQ8H74 DI DMQ8H74 DMQ8H74 DN 3-Butoxy-9H-beta-carboline DMQ8H74 TI TT1MPAY DMQ8H74 TN GABA(A) receptor alpha-1 (GABRA1) DMQ8H74 MA Inhibitor DMQ8H74 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMQ8H74 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMQ8H74 DI DMQ8H74 DMQ8H74 DN 3-Butoxy-9H-beta-carboline DMQ8H74 TI TTNZPQ1 DMQ8H74 TN GABA(A) receptor alpha-5 (GABRA5) DMQ8H74 MA Inhibitor DMQ8H74 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMQ8H74 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMQ8H74 DI DMQ8H74 DMQ8H74 DN 3-Butoxy-9H-beta-carboline DMQ8H74 TI TT06RH5 DMQ8H74 TN GABA(A) receptor gamma-2 (GABRG2) DMQ8H74 MA Inhibitor DMQ8H74 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMQ8H74 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMQ8H74 DI DMQ8H74 DMQ8H74 DN 3-Butoxy-9H-beta-carboline DMQ8H74 TI TTBMV1G DMQ8H74 TN GABA(A) receptor alpha-2 (GABRA2) DMQ8H74 MA Inhibitor DMQ8H74 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMQ8H74 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMQ8H74 DI DMQ8H74 DMQ8H74 DN 3-Butoxy-9H-beta-carboline DMQ8H74 TI TT37EDJ DMQ8H74 TN GABA(A) receptor alpha-3 (GABRA3) DMQ8H74 MA Inhibitor DMQ8H74 RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMQ8H74 RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMQ8J3M DI DMQ8J3M DMQ8J3M DN J-104118 DMQ8J3M TI TTFQEO5 DMQ8J3M TN Squalene synthetase (FDFT1) DMQ8J3M MA Inhibitor DMQ8J3M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645). DMQ8J3M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645 DMQ8K9J DI DMQ8K9J DMQ8K9J DN ISIS 109116 DMQ8K9J TI TTQSMFG DMQ8K9J TN Talin messenger RNA (TLN1 mRNA) DMQ8K9J RN US patent application no. 6,372,492, Antisense modulation of talin expression. DMQ8K9J RU http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true DMQ8VIU DI DMQ8VIU DMQ8VIU DN 3-epicorosolic acid methyl ester DMQ8VIU TI TTN7BL9 DMQ8VIU TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMQ8VIU MA Inhibitor DMQ8VIU RN 11beta-Hydroxysteroid dehydrogenase 1 inhibiting constituents from Eriobotrya japonica revealed by bioactivity-guided isolation and computational a... Bioorg Med Chem. 2010 Feb 15;18(4):1507-15. DMQ8VIU RU https://pubmed.ncbi.nlm.nih.gov/20100662 DMQ9018 DI DMQ9018 DMQ9018 DN ISIS 156453 DMQ9018 TI TTILUKB DMQ9018 TN IRAK4 messenger RNA (IRAK4 mRNA) DMQ9018 RN US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression. DMQ9018 RU http://www.patentbuddy.com/Patent/6692959?ft=true&sr=true DMQ918T DI DMQ918T DMQ918T DN PMID20483621C5g DMQ918T TI TTOHTCY DMQ918T TN Doublecortin-like kinase 1 (DCLK1) DMQ918T MA Inhibitor DMQ918T RN Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. DMQ918T RU https://pubmed.ncbi.nlm.nih.gov/20483621 DMQ918T DI DMQ918T DMQ918T DN PMID20483621C5g DMQ918T TI TTPMQSO DMQ918T TN ALK tyrosine kinase receptor (ALK) DMQ918T MA Inhibitor DMQ918T RN Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. DMQ918T RU https://pubmed.ncbi.nlm.nih.gov/20483621 DMQ94BX DI DMQ94BX DMQ94BX DN 5-oxo-1-tosyl-2,5-dihydro-1Hpyrrol-2-yl acetate DMQ94BX TI TTHQPL7 DMQ94BX TN Carbonic anhydrase I (CA-I) DMQ94BX MA Inhibitor DMQ94BX RN A novel and one-pot synthesis of new 1-tosyl pyrrol-2-one derivatives and analysis of carbonic anhydrase inhibitory potencies. Bioorg Med Chem. 2010 Jun 15;18(12):4468-74. DMQ94BX RU https://pubmed.ncbi.nlm.nih.gov/20554206 DMQ95EB DI DMQ95EB DMQ95EB DN AS-601245 DMQ95EB TI TT056SO DMQ95EB TN Stress-activated protein kinase JNK3 (JNK3) DMQ95EB MA Inhibitor DMQ95EB RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMQ95EB RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMQ95EB DI DMQ95EB DMQ95EB DN AS-601245 DMQ95EB TI TT3IVG2 DMQ95EB TN JNK2 messenger RNA (JNK2 mRNA) DMQ95EB MA Inhibitor DMQ95EB RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQ95EB RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQ95EB DI DMQ95EB DMQ95EB DN AS-601245 DMQ95EB TI TT0K6EO DMQ95EB TN Stress-activated protein kinase JNK1 (JNK1) DMQ95EB MA Inhibitor DMQ95EB RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQ95EB RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQ95EB DI DMQ95EB DMQ95EB DN AS-601245 DMQ95EB TI TTRSMW9 DMQ95EB TN Glycogen synthase kinase-3 beta (GSK-3B) DMQ95EB MA Inhibitor DMQ95EB RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMQ95EB RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMQ95EG DI DMQ95EG DMQ95EG DN 4-Iodyl-benzoic acid DMQ95EG TI TTELIN2 DMQ95EG TN PTPN1 messenger RNA (PTPN1 mRNA) DMQ95EG MA Inhibitor DMQ95EG RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DMQ95EG RU https://pubmed.ncbi.nlm.nih.gov/10091683 DMQ98H5 DI DMQ98H5 DMQ98H5 DN Bis-(5-pyridin-3-yl-thiophen-2-ylmethyl)-amine DMQ98H5 TI TTVG215 DMQ98H5 TN Debrisoquine 4-hydroxylase (CYP2D6) DMQ98H5 MA Inhibitor DMQ98H5 RN 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39. DMQ98H5 RU https://pubmed.ncbi.nlm.nih.gov/15634016 DMQ98RS DI DMQ98RS DMQ98RS DN ML277 DMQ98RS TI TT846HF DMQ98RS TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMQ98RS MA Activator DMQ98RS RN Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5936-41. DMQ98RS RU https://pubmed.ncbi.nlm.nih.gov/22910039 DMQ9IN4 DI DMQ9IN4 DMQ9IN4 DN 4-[4-benzyloxy)benzoyl]benzoic acid DMQ9IN4 TI TTT02K8 DMQ9IN4 TN Steroid 5-alpha-reductase 2 (SRD5A2) DMQ9IN4 MA Inhibitor DMQ9IN4 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMQ9IN4 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMQ9IN4 DI DMQ9IN4 DMQ9IN4 DN 4-[4-benzyloxy)benzoyl]benzoic acid DMQ9IN4 TI TTTU72V DMQ9IN4 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMQ9IN4 MA Inhibitor DMQ9IN4 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMQ9IN4 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMQ9ODG DI DMQ9ODG DMQ9ODG DN 2-(cycloheptylamino)-2-oxoethyl 2-aminonicotinate DMQ9ODG TI TTEAID7 DMQ9ODG TN Trypanosoma Cruzipain (Trypano CYSP) DMQ9ODG MA Inhibitor DMQ9ODG RN Divergent modes of enzyme inhibition in a homologous structure-activity series. J Med Chem. 2009 Aug 27;52(16):5005-8. DMQ9ODG RU https://pubmed.ncbi.nlm.nih.gov/19637873 DMQ9PLA DI DMQ9PLA DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide DMQ9PLA TI TTYHPU6 DMQ9PLA TN Histone deacetylase 10 (HDAC10) DMQ9PLA MA Inhibitor DMQ9PLA RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMQ9PLA RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMQ9PLA DI DMQ9PLA DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide DMQ9PLA TI TTSHTOI DMQ9PLA TN Histone deacetylase 2 (HDAC2) DMQ9PLA MA Inhibitor DMQ9PLA RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMQ9PLA RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMQ9PLA DI DMQ9PLA DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide DMQ9PLA TI TTBH0VX DMQ9PLA TN Histone deacetylase (HDAC) DMQ9PLA MA Inhibitor DMQ9PLA RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMQ9PLA RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMQ9PLA DI DMQ9PLA DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide DMQ9PLA TI TT6R7JZ DMQ9PLA TN Histone deacetylase 1 (HDAC1) DMQ9PLA MA Inhibitor DMQ9PLA RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMQ9PLA RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMQ9PLA DI DMQ9PLA DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide DMQ9PLA TI TT5ZKDI DMQ9PLA TN Histone deacetylase 6 (HDAC6) DMQ9PLA MA Inhibitor DMQ9PLA RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMQ9PLA RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMQ9PLA DI DMQ9PLA DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide DMQ9PLA TI TTTQGH8 DMQ9PLA TN Histone deacetylase 4 (HDAC4) DMQ9PLA MA Inhibitor DMQ9PLA RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMQ9PLA RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMQ9PLA DI DMQ9PLA DMQ9PLA DN 7-Mercapto-heptanoic acid pyridin-3-ylamide DMQ9PLA TI TTT6LFV DMQ9PLA TN Histone deacetylase 8 (HDAC8) DMQ9PLA MA Inhibitor DMQ9PLA RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMQ9PLA RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMQ9TNB DI DMQ9TNB DMQ9TNB DN 3,5-Dihydroxyl-4'-amino-trans-stilbene DMQ9TNB TI TTSZLWK DMQ9TNB TN Aromatase (CYP19A1) DMQ9TNB MA Inhibitor DMQ9TNB RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMQ9TNB RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMQ9TWD DI DMQ9TWD DMQ9TWD DN (E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone DMQ9TWD TI TTHS256 DMQ9TWD TN Metabotropic glutamate receptor 5 (mGluR5) DMQ9TWD MA Inhibitor DMQ9TWD RN Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15. DMQ9TWD RU https://pubmed.ncbi.nlm.nih.gov/19574055 DMQ9TWD DI DMQ9TWD DMQ9TWD DN (E)-1-Adamantan-1-yl-3-quinolin-3-yl-propenone DMQ9TWD TI TTVBPDM DMQ9TWD TN Metabotropic glutamate receptor 1 (mGluR1) DMQ9TWD MA Inhibitor DMQ9TWD RN Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate recepto... Bioorg Med Chem. 2009 Aug 1;17(15):5708-15. DMQ9TWD RU https://pubmed.ncbi.nlm.nih.gov/19574055 DMQA0EJ DI DMQA0EJ DMQA0EJ DN 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione DMQA0EJ TI TTR0SWN DMQA0EJ TN M-phase inducer phosphatase 2 (MPIP2) DMQA0EJ MA Inhibitor DMQA0EJ RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMQA0EJ RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMQA0EJ DI DMQA0EJ DMQA0EJ DN 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione DMQA0EJ TI TTLZS4Q DMQA0EJ TN M-phase inducer phosphatase 1 (MPIP1) DMQA0EJ MA Inhibitor DMQA0EJ RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMQA0EJ RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMQA0EJ DI DMQA0EJ DMQA0EJ DN 4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione DMQA0EJ TI TTELIN2 DMQA0EJ TN PTPN1 messenger RNA (PTPN1 mRNA) DMQA0EJ MA Inhibitor DMQA0EJ RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMQA0EJ RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMQA7ZI DI DMQA7ZI DMQA7ZI DN MCL-516 DMQA7ZI TI TTEX248 DMQA7ZI TN Dopamine D2 receptor (D2R) DMQA7ZI MA Inhibitor DMQA7ZI RN Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3. DMQA7ZI RU https://pubmed.ncbi.nlm.nih.gov/19058967 DMQA7ZI DI DMQA7ZI DMQA7ZI DN MCL-516 DMQA7ZI TI TTSQIFT DMQA7ZI TN 5-HT 1A receptor (HTR1A) DMQA7ZI MA Inhibitor DMQA7ZI RN Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem. 2008 Jul 15;16(14):6675-81. DMQA7ZI RU https://pubmed.ncbi.nlm.nih.gov/18562201 DMQA7ZI DI DMQA7ZI DMQA7ZI DN MCL-516 DMQA7ZI TI TTZFYLI DMQA7ZI TN Dopamine D1 receptor (D1R) DMQA7ZI MA Inhibitor DMQA7ZI RN Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3. DMQA7ZI RU https://pubmed.ncbi.nlm.nih.gov/19058967 DMQA7ZS DI DMQA7ZS DMQA7ZS DN Trisnorsqualene difluoromethylidene DMQA7ZS TI TTE14XG DMQA7ZS TN Squalene monooxygenase (SQLE) DMQA7ZS MA Inhibitor DMQA7ZS RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMQA7ZS RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMQA8N3 DI DMQA8N3 DMQA8N3 DN PAULLONE DMQA8N3 TI TTRSMW9 DMQA8N3 TN Glycogen synthase kinase-3 beta (GSK-3B) DMQA8N3 MA Inhibitor DMQA8N3 RN Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. DMQA8N3 RU https://pubmed.ncbi.nlm.nih.gov/20138512 DMQADXL DI DMQADXL DMQADXL DN 3,7-Bis(2-hydroxyethyl)icaritin DMQADXL TI TTJ0IQB DMQADXL TN Phosphodiesterase 5A (PDE5A) DMQADXL MA Inhibitor DMQADXL RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DMQADXL RU https://pubmed.ncbi.nlm.nih.gov/18778098 DMQAEOL DI DMQAEOL DMQAEOL DN Benzyl-methyl-[1-(1H-pyrrol-2-yl)-vinyl]-amine DMQAEOL TI TTGP7BY DMQAEOL TN Monoamine oxidase type B (MAO-B) DMQAEOL MA Inhibitor DMQAEOL RN Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B. J Med Chem. 2003 Mar 13;46(6):917-20. DMQAEOL RU https://pubmed.ncbi.nlm.nih.gov/12620068 DMQAEU8 DI DMQAEU8 DMQAEU8 DN EPIMER A DMQAEU8 TI TTY6O0Q DMQAEU8 TN Calcitonin gene-related peptide receptor (CGRPR) DMQAEU8 MA Inhibitor DMQAEU8 RN The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4740-2. DMQAEU8 RU https://pubmed.ncbi.nlm.nih.gov/19577468 DMQAEZP DI DMQAEZP DMQAEZP DN Isosorbide-2-(propylcarbamate)-5-mononitrate DMQAEZP TI TTEB0GD DMQAEZP TN Cholinesterase (BCHE) DMQAEZP MA Inhibitor DMQAEZP RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMQAEZP RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMQAG1B DI DMQAG1B DMQAG1B DN 6-tert-Butyl-2-morpholin-4-yl-4H-thiopyran-4-one DMQAG1B TI TTK3PY9 DMQAG1B TN DNA-dependent protein kinase catalytic (PRKDC) DMQAG1B MA Inhibitor DMQAG1B RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMQAG1B RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMQAO5B DI DMQAO5B DMQAO5B DN SB 203106 DMQAO5B TI TT85JO3 DMQAO5B TN 5-HT receptor (5HTR) DMQAO5B MA Antagonist DMQAO5B RN 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58. DMQAO5B RU https://pubmed.ncbi.nlm.nih.gov/11874527 DMQATPN DI DMQATPN DMQATPN DN CAA0225 DMQATPN TI TT36ETB DMQATPN TN Cathepsin L (CTSL) DMQATPN MA Inhibitor DMQATPN RN Characterization of CAA0225, a novel inhibitor specific for cathepsin L, as a probe for autophagic proteolysis. Biol Pharm Bull. 2009 Mar;32(3):475-9. DMQATPN RU https://pubmed.ncbi.nlm.nih.gov/19252298 DMQAVM4 DI DMQAVM4 DMQAVM4 DN 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid DMQAVM4 TI TTLM12X DMQAVM4 TN Matrix metalloproteinase-2 (MMP-2) DMQAVM4 MA Inhibitor DMQAVM4 RN Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100. DMQAVM4 RU https://pubmed.ncbi.nlm.nih.gov/16632358 DMQAVM4 DI DMQAVM4 DMQAVM4 DN 2-(4'-chloro-biphenyl-4-sulfonyl)-pentanoic acid DMQAVM4 TI TT6X50U DMQAVM4 TN Matrix metalloproteinase-9 (MMP-9) DMQAVM4 MA Inhibitor DMQAVM4 RN Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3096-100. DMQAVM4 RU https://pubmed.ncbi.nlm.nih.gov/16632358 DMQB1UI DI DMQB1UI DMQB1UI DN 5-(4-Chloro-phenyl)-1-methyl-piperidine-2-thione DMQB1UI TI TTTU72V DMQB1UI TN Steroid 5-alpha-reductase 1 (SRD5A1) DMQB1UI MA Inhibitor DMQB1UI RN Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11. DMQB1UI RU https://pubmed.ncbi.nlm.nih.gov/10987415 DMQB2CN DI DMQB2CN DMQB2CN DN Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O) DMQB2CN TI TTB2MXP DMQB2CN TN Angiotensinogenase renin (REN) DMQB2CN MA Inhibitor DMQB2CN RN Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42. DMQB2CN RU https://pubmed.ncbi.nlm.nih.gov/1995887 DMQB8C3 DI DMQB8C3 DMQB8C3 DN UCB35625 DMQB8C3 TI TT8KLPT DMQB8C3 TN C-C chemokine receptor (CCR) DMQB8C3 MA Antagonist DMQB8C3 RN A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. J Biol Chem. 2000 Aug 25;275(34):25985-92. DMQB8C3 RU https://pubmed.ncbi.nlm.nih.gov/10854442 DMQB9SC DI DMQB9SC DMQB9SC DN 2-(3-aminophenyl)-3-mercaptopropanoic acid DMQB9SC TI TTP18AY DMQB9SC TN Carboxypeptidase B2 (CPB2) DMQB9SC MA Inhibitor DMQB9SC RN 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54. DMQB9SC RU https://pubmed.ncbi.nlm.nih.gov/17189688 DMQBAM6 DI DMQBAM6 DMQBAM6 DN PIBTU DMQBAM6 TI TTF10I9 DMQBAM6 TN Nitric-oxide synthase inducible (NOS2) DMQBAM6 MA Inhibitor DMQBAM6 RN Potent and selective inhibition of human nitric oxide synthases. Inhibition by non-amino acid isothioureas. J Biol Chem. 1994 Oct 28;269(43):26669-76. DMQBAM6 RU https://pubmed.ncbi.nlm.nih.gov/7523409 DMQBCPK DI DMQBCPK DMQBCPK DN ADR58 DMQBCPK TI TTIVXSE DMQBCPK TN Oncostatin-M (OSM) DMQBCPK RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMQBCPK RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMQBD27 DI DMQBD27 DMQBD27 DN N-Hydroxy-N-methyl-3-phenanthren-9-yl-acrylamide DMQBD27 TI TT2J34L DMQBD27 TN Arachidonate 5-lipoxygenase (5-LOX) DMQBD27 MA Inhibitor DMQBD27 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMQBD27 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMQBEYX DI DMQBEYX DMQBEYX DN Phencyclidine DMQBEYX TI TTLD29N DMQBEYX TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMQBEYX MA Inhibitor DMQBEYX RN Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52. DMQBEYX RU https://pubmed.ncbi.nlm.nih.gov/8941398 DMQBEYX DI DMQBEYX DMQBEYX DN Phencyclidine DMQBEYX TI TTN9D8E DMQBEYX TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMQBEYX MA Inhibitor DMQBEYX RN Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52. DMQBEYX RU https://pubmed.ncbi.nlm.nih.gov/8941398 DMQBEYX DI DMQBEYX DMQBEYX DN Phencyclidine DMQBEYX TI TTKJEMQ DMQBEYX TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMQBEYX MA Inhibitor DMQBEYX RN Synthesis and biological activity of conformationally restricted analogs of milnacipran: (1S,2R)-1-phenyl-2-[(S)-1-aminopropyl]-N,N-diethylcyclopro... J Med Chem. 1996 Nov 22;39(24):4844-52. DMQBEYX RU https://pubmed.ncbi.nlm.nih.gov/8941398 DMQBF7J DI DMQBF7J DMQBF7J DN 2-Methyl-beta-carboline-2-ium iodide DMQBF7J TI TTEB0GD DMQBF7J TN Cholinesterase (BCHE) DMQBF7J MA Inhibitor DMQBF7J RN Bivalent beta-carbolines as potential multitarget anti-Alzheimer agents. J Med Chem. 2010 May 13;53(9):3611-7. DMQBF7J RU https://pubmed.ncbi.nlm.nih.gov/20361801 DMQBGH9 DI DMQBGH9 DMQBGH9 DN Metazamide DMQBGH9 TI TTKN8W0 DMQBGH9 TN Glucose-6-phosphate dehydrogenase (G6PD) DMQBGH9 MA Inhibitor DMQBGH9 RN Glucose utilization and activity of glucose-6-phosphate dehydrogenase, isocitrate dehydrogenase and malate dehydrogenase in rat erythrocytes after treatment with tuberculostatic agents. Vopr Med Khim. 1986 Sep-Oct;32(5):32-5. DMQBGH9 RU https://pubmed.ncbi.nlm.nih.gov/3776114 DMQBHF2 DI DMQBHF2 DMQBHF2 DN 4-(3-bromophenylthio)-2-(pyridin-2-yl)pyrimidine DMQBHF2 TI TTHS256 DMQBHF2 TN Metabotropic glutamate receptor 5 (mGluR5) DMQBHF2 MA Inhibitor DMQBHF2 RN Structure-activity relationship of thiopyrimidines as mGluR5 antagonists. Bioorg Med Chem Lett. 2006 May 1;16(9):2467-9. DMQBHF2 RU https://pubmed.ncbi.nlm.nih.gov/16481165 DMQBHGK DI DMQBHGK DMQBHGK DN 1-(1-(4-fluorophenyl)ethylidene)thiosemicarbazide DMQBHGK TI TTULVH8 DMQBHGK TN Tyrosinase (TYR) DMQBHGK MA Inhibitor DMQBHGK RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DMQBHGK RU https://pubmed.ncbi.nlm.nih.gov/18326070 DMQBRSM DI DMQBRSM DMQBRSM DN BQ 3020 DMQBRSM TI TT3ZTGU DMQBRSM TN Endothelin B receptor (EDNRB) DMQBRSM MA Agonist DMQBRSM RN Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun. 1995 Apr 17;209(2):506-12. DMQBRSM RU https://pubmed.ncbi.nlm.nih.gov/7733918 DMQBTL3 DI DMQBTL3 DMQBTL3 DN FMS586 DMQBTL3 TI TTY6EWA DMQBTL3 TN Neuropeptide Y receptor type 5 (NPY5R) DMQBTL3 MA Antagonist DMQBTL3 RN Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin... J Pharmacol Exp Ther. 2006 May;317(2):562-70. DMQBTL3 RU https://pubmed.ncbi.nlm.nih.gov/16436501 DMQC168 DI DMQC168 DMQC168 DN 3-(1,3 dodecadiynyl)-6-oxiranebutanoic acid DMQC168 TI TTPADOQ DMQC168 TN HMG-CoA reductase (HMGCR) DMQC168 MA Inhibitor DMQC168 RN Novel Acetylenic Acids from the Root Bark of Paramacrolobium caeruleum: Inhibitors of 3-Hydroxy-3-methyl-glutaryl Coenzyme A Reductase J. Nat. Prod. 52(1):153-161 (1989). DMQC168 RU http://pubs.acs.org/doi/abs/10.1021/np50061a020 DMQC4HV DI DMQC4HV DMQC4HV DN Isoindolinone Urea derivative DMQC4HV TI TTUTJGQ DMQC4HV TN Vascular endothelial growth factor receptor 2 (KDR) DMQC4HV MA Inhibitor DMQC4HV RN Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4505-9. DMQC4HV RU https://pubmed.ncbi.nlm.nih.gov/15357981 DMQC5EH DI DMQC5EH DMQC5EH DN 4-[4-(benzylamino)benzoyl]benzoic acid DMQC5EH TI TTT02K8 DMQC5EH TN Steroid 5-alpha-reductase 2 (SRD5A2) DMQC5EH MA Inhibitor DMQC5EH RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMQC5EH RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMQC9UB DI DMQC9UB DMQC9UB DN MC-116 DMQC9UB TI TT5TPI6 DMQC9UB TN Opioid receptor sigma 1 (OPRS1) DMQC9UB MA Agonist DMQC9UB RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMQC9UB RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMQC9WV DI DMQC9WV DMQC9WV DN 3-(2-phenylthiazol-4-yl)quinolin-2(1H)-one DMQC9WV TI TTL4Q97 DMQC9WV TN Cyclin-dependent kinase 5 (CDK5) DMQC9WV MA Inhibitor DMQC9WV RN Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5384-9. DMQC9WV RU https://pubmed.ncbi.nlm.nih.gov/17709247 DMQCDT1 DI DMQCDT1 DMQCDT1 DN 7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin DMQCDT1 TI TTGP7BY DMQCDT1 TN Monoamine oxidase type B (MAO-B) DMQCDT1 MA Inhibitor DMQCDT1 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMQCDT1 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMQCDT1 DI DMQCDT1 DMQCDT1 DN 7-Acetonyloxy-3,4-cyclohexene-8-methylcoumarin DMQCDT1 TI TT3WG5C DMQCDT1 TN Monoamine oxidase type A (MAO-A) DMQCDT1 MA Inhibitor DMQCDT1 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMQCDT1 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMQCGFL DI DMQCGFL DMQCGFL DN N-benzyl-2-morpholinopyrimidin-4-amine DMQCGFL TI TT1RS9F DMQCGFL TN Acetylcholinesterase (AChE) DMQCGFL MA Inhibitor DMQCGFL RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMQCGFL RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMQCGRI DI DMQCGRI DMQCGRI DN HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRG-NH2 DMQCGRI TI TTVIMDE DMQCGRI TN Glucagon-like peptide 1 receptor (GLP1R) DMQCGRI MA Inhibitor DMQCGRI RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMQCGRI RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMQCK5G DI DMQCK5G DMQCK5G DN N-Hydroxy-E-3-(biphenyl-4-yl)-acrylamide DMQCK5G TI TTSHTOI DMQCK5G TN Histone deacetylase 2 (HDAC2) DMQCK5G MA Inhibitor DMQCK5G RN Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12. DMQCK5G RU https://pubmed.ncbi.nlm.nih.gov/19084294 DMQCL6Y DI DMQCL6Y DMQCL6Y DN UR-PG146 DMQCL6Y TI TTTIBOJ DMQCL6Y TN Histamine H1 receptor (H1R) DMQCL6Y MA Agonist DMQCL6Y RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DMQCL6Y RU https://pubmed.ncbi.nlm.nih.gov/16394198 DMQCL6Y DI DMQCL6Y DMQCL6Y DN UR-PG146 DMQCL6Y TI TTQHJ1K DMQCL6Y TN Histamine H2 receptor (H2R) DMQCL6Y MA Agonist DMQCL6Y RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DMQCL6Y RU https://pubmed.ncbi.nlm.nih.gov/16394198 DMQCMFU DI DMQCMFU DMQCMFU DN 4-(methyl(4-phenylthiazol-2-yl)amino)phenol DMQCMFU TI TTHY57M DMQCMFU TN Matrix metalloproteinase-13 (MMP-13) DMQCMFU MA Inhibitor DMQCMFU RN High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. DMQCMFU RU https://pubmed.ncbi.nlm.nih.gov/18358729 DMQCPXL DI DMQCPXL DMQCPXL DN AR-C118925XX DMQCPXL TI TTOZHQC DMQCPXL TN P2Y purinoceptor 2 (P2RY2) DMQCPXL MA Antagonist DMQCPXL RN Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells. Am J Respir Cell Mol Biol. 2004 Oct;31(4):446-55. DMQCPXL RU https://pubmed.ncbi.nlm.nih.gov/15231488 DMQCRUG DI DMQCRUG DMQCRUG DN 15-isobutyrylmiguanin DMQCRUG TI TTSXVID DMQCRUG TN Nuclear factor NF-kappa-B (NFKB) DMQCRUG MA Inhibitor DMQCRUG RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMQCRUG RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMQCVKO DI DMQCVKO DMQCVKO DN 3-chlorophenyl 10H-phenothiazine-10-carboxylate DMQCVKO TI TTEB0GD DMQCVKO TN Cholinesterase (BCHE) DMQCVKO MA Inhibitor DMQCVKO RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMQCVKO RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMQCW7V DI DMQCW7V DMQCW7V DN Tanaproget DMQCW7V TI TTUV8G9 DMQCW7V TN Progesterone receptor (PGR) DMQCW7V MA Inhibitor DMQCW7V RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQCW7V RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQCYEK DI DMQCYEK DMQCYEK DN 5-(2-fluorobenzyloxy)quinazoline-2,4-diamine DMQCYEK TI TT9SL3Q DMQCYEK TN Polypeptide deformylase (PDF) DMQCYEK MA Inhibitor DMQCYEK RN Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal m... J Med Chem. 2008 Feb 14;51(3):449-69. DMQCYEK RU https://pubmed.ncbi.nlm.nih.gov/18205293 DMQD34N DI DMQD34N DMQD34N DN 7-fluoroindirubin-3-oxime DMQD34N TI TT9RTBL DMQD34N TN Aurora B messenger RNA (AURKB mRNA) DMQD34N MA Inhibitor DMQD34N RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMQD34N RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMQD34N DI DMQD34N DMQD34N DN 7-fluoroindirubin-3-oxime DMQD34N TI TTLYXIT DMQD34N TN Aurora kinase C (AURKC) DMQD34N MA Inhibitor DMQD34N RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMQD34N RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMQD34N DI DMQD34N DMQD34N DN 7-fluoroindirubin-3-oxime DMQD34N TI TTPS3C0 DMQD34N TN Aurora kinase A (AURKA) DMQD34N MA Inhibitor DMQD34N RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMQD34N RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMQDA5W DI DMQDA5W DMQDA5W DN CDRI-85/92 DMQDA5W TI TTF1QVM DMQDA5W TN Gastric H(+)/K(+) ATPase alpha (ATP4A) DMQDA5W MA Inhibitor DMQDA5W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 849). DMQDA5W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=849 DMQDH3N DI DMQDH3N DMQDH3N DN (2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime DMQDH3N TI TT7HF4W DMQDH3N TN Cyclin-dependent kinase 2 (CDK2) DMQDH3N MA Inhibitor DMQDH3N RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMQDH3N RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMQDH3N DI DMQDH3N DMQDH3N DN (2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime DMQDH3N TI TTCEJ4F DMQDH3N TN G1/S-specific cyclin-E1 (CCNE1) DMQDH3N MA Inhibitor DMQDH3N RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMQDH3N RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMQDI5H DI DMQDI5H DMQDI5H DN N-(4-(4-hexyl-2-hydroxyphenoxy)phenyl)acetamide DMQDI5H TI TTVTX4N DMQDI5H TN Bacterial Fatty acid synthetase I (Bact inhA) DMQDI5H MA Inhibitor DMQDI5H RN Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitors. Bioorg Med Chem Lett. 2008 May 15;18(10):3029-33. DMQDI5H RU https://pubmed.ncbi.nlm.nih.gov/18457948 DMQDKYI DI DMQDKYI DMQDKYI DN 3,4'-(1H-1,2,4-triazole-3,5-diyl)dipyridine DMQDKYI TI TT7RJY8 DMQDKYI TN Xanthine dehydrogenase/oxidase (XDH) DMQDKYI MA Inhibitor DMQDKYI RN Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9. DMQDKYI RU https://pubmed.ncbi.nlm.nih.gov/19783139 DMQDP23 DI DMQDP23 DMQDP23 DN FR-175985 DMQDP23 TI TTCG0AL DMQDP23 TN Cholecystokinin receptor type A (CCKAR) DMQDP23 MA Inhibitor DMQDP23 RN Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines, Bioorg. Med. Chem. Lett. 7(2):169-174 (1997). DMQDP23 RU http://www.sciencedirect.com/science/article/pii/S0960894X96006099 DMQDPHT DI DMQDPHT DMQDPHT DN 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid DMQDPHT TI TTYRF5E DMQDPHT TN Matrix metalloproteinase-21 (MMP-21) DMQDPHT MA Inhibitor DMQDPHT RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DMQDPHT RU https://pubmed.ncbi.nlm.nih.gov/16420030 DMQDPHT DI DMQDPHT DMQDPHT DN 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid DMQDPHT TI TTXZ0KQ DMQDPHT TN Matrix metalloproteinase-12 (MMP-12) DMQDPHT MA Inhibitor DMQDPHT RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DMQDPHT RU https://pubmed.ncbi.nlm.nih.gov/16420030 DMQDPHT DI DMQDPHT DMQDPHT DN 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid DMQDPHT TI TT6X50U DMQDPHT TN Matrix metalloproteinase-9 (MMP-9) DMQDPHT MA Inhibitor DMQDPHT RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DMQDPHT RU https://pubmed.ncbi.nlm.nih.gov/16420030 DMQDPHT DI DMQDPHT DMQDPHT DN 3-(4-(2-phenylethynyl)benzoyl)pentanoic acid DMQDPHT TI TTLM12X DMQDPHT TN Matrix metalloproteinase-2 (MMP-2) DMQDPHT MA Inhibitor DMQDPHT RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DMQDPHT RU https://pubmed.ncbi.nlm.nih.gov/16420030 DMQDV3U DI DMQDV3U DMQDV3U DN GARCINONE D DMQDV3U TI TT50QJ3 DMQDV3U TN Influenza Neuraminidase (Influ NA) DMQDV3U MA Inhibitor DMQDV3U RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMQDV3U RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMQDV3U DI DMQDV3U DMQDV3U DN GARCINONE D DMQDV3U TI TTSZLWK DMQDV3U TN Aromatase (CYP19A1) DMQDV3U MA Inhibitor DMQDV3U RN Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod. 2008 Jul;71(7):1161-6. DMQDV3U RU https://pubmed.ncbi.nlm.nih.gov/18558747 DMQDVNZ DI DMQDVNZ DMQDVNZ DN Testetrol DMQDVNZ TI TTS64P2 DMQDVNZ TN Androgen receptor (AR) DMQDVNZ MA Agonist DMQDVNZ RN Estetrol review: profile and potential clinical applications. Climacteric. 2008;11 Suppl 1:47-58. DMQDVNZ RU https://pubmed.ncbi.nlm.nih.gov/18464023 DMQDZF2 DI DMQDZF2 DMQDZF2 DN ISIS 9008 DMQDZF2 TI TTBSN0L DMQDZF2 TN PKC-zeta messenger RNA (PRKCZ mRNA) DMQDZF2 RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMQDZF2 RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMQE7BH DI DMQE7BH DMQE7BH DN ISIS 150452 DMQE7BH TI TTP9K3Q DMQE7BH TN SOD1 messenger RNA (SOD1 mRNA) DMQE7BH RN US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. DMQE7BH RU http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true DMQE89J DI DMQE89J DMQE89J DN LY593093 DMQE89J TI TTOXS3C DMQE89J TN Muscarinic acetylcholine receptor (CHRM) DMQE89J MA Agonist DMQE89J RN Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist. J Pharmacol Exp Ther. 2011 Aug;338(2):622-32. DMQE89J RU https://pubmed.ncbi.nlm.nih.gov/21558436 DMQEBKF DI DMQEBKF DMQEBKF DN RES-701-1-C-terminal analogue DMQEBKF TI TT3ZTGU DMQEBKF TN Endothelin B receptor (EDNRB) DMQEBKF MA Inhibitor DMQEBKF RN Analogs of an endothelin antagonist RES-701-1: substitutions of C-terminal amino acid, Bioorg. Med. Chem. Lett. 6(7):775-778 (1996). DMQEBKF RU http://www.sciencedirect.com/science/article/pii/0960894X96001278 DMQECWT DI DMQECWT DMQECWT DN 1-(4-tert-butylphenylsulfonyl)azepan-4-ol DMQECWT TI TTN7BL9 DMQECWT TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMQECWT MA Inhibitor DMQECWT RN The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5. DMQECWT RU https://pubmed.ncbi.nlm.nih.gov/19625185 DMQEDP5 DI DMQEDP5 DMQEDP5 DN H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid DMQEDP5 TI TT27RFC DMQEDP5 TN Opioid receptor delta (OPRD1) DMQEDP5 MA Inhibitor DMQEDP5 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMQEDP5 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMQEDP5 DI DMQEDP5 DMQEDP5 DN H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid DMQEDP5 TI TTKWM86 DMQEDP5 TN Opioid receptor mu (MOP) DMQEDP5 MA Inhibitor DMQEDP5 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMQEDP5 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMQEGJU DI DMQEGJU DMQEGJU DN N3-GHQMFYYPra-NH2 DMQEGJU TI TT1VAUK DMQEGJU TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMQEGJU MA Inhibitor DMQEGJU RN On-resin cyclization of peptide ligands of the Vascular Endothelial Growth Factor Receptor 1 by copper(I)-catalyzed 1,3-dipolar azide-alkyne cycloa... Bioorg Med Chem Lett. 2007 Oct 15;17(20):5590-4. DMQEGJU RU https://pubmed.ncbi.nlm.nih.gov/17826090 DMQEJVU DI DMQEJVU DMQEJVU DN 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole DMQEJVU TI TT7M9I6 DMQEJVU TN Calcium-activated potassium channel KCa3.1 (KCNN4) DMQEJVU MA Blocker (channel blocker) DMQEJVU RN Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25. DMQEJVU RU https://pubmed.ncbi.nlm.nih.gov/12939222 DMQEJVU DI DMQEJVU DMQEJVU DN 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole DMQEJVU TI TTMNI76 DMQEJVU TN Calcium-activated potassium channel (KCN) DMQEJVU MA Inhibitor DMQEJVU RN Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304. DMQEJVU RU https://pubmed.ncbi.nlm.nih.gov/19282171 DMQEO7F DI DMQEO7F DMQEO7F DN 9-Bromo-5,11-dimethyl-6H-pyrido[4,3-b]carbazole DMQEO7F TI TTX41N9 DMQEO7F TN Tyrosine-protein kinase Kit (KIT) DMQEO7F MA Inhibitor DMQEO7F RN Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201. DMQEO7F RU https://pubmed.ncbi.nlm.nih.gov/16190746 DMQEPV0 DI DMQEPV0 DMQEPV0 DN N-(3-chlorophenyl)-6-methoxyquinazolin-4-amine DMQEPV0 TI TTHS256 DMQEPV0 TN Metabotropic glutamate receptor 5 (mGluR5) DMQEPV0 MA Inhibitor DMQEPV0 RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMQEPV0 RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMQER8D DI DMQER8D DMQER8D DN Deschloroflavopiridol DMQER8D TI TT1LVF2 DMQER8D TN Cyclin-dependent kinase 9 (CDK9) DMQER8D MA Binder DMQER8D RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMQER8D RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMQER8D DI DMQER8D DMQER8D DN Deschloroflavopiridol DMQER8D TI TTO0FDJ DMQER8D TN Cyclin-dependent kinase 6 (CDK6) DMQER8D MA Inhibitor DMQER8D RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMQER8D RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMQETUY DI DMQETUY DMQETUY DN N'-(phenylsulfonyl)quinoline-6-carbohydrazide DMQETUY TI TTF9OQ6 DMQETUY TN Branched-chain-amino-acid transaminase 2 (BCAT2) DMQETUY MA Inhibitor DMQETUY RN The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases. Bioorg Med Chem Lett. 2006 May 1;16(9):2337-40. DMQETUY RU https://pubmed.ncbi.nlm.nih.gov/16143519 DMQF2N5 DI DMQF2N5 DMQF2N5 DN 1-(1-(4-thiophen-3-yl-phenyl)propyl)-1Himidazole DMQF2N5 TI TTRA5BZ DMQF2N5 TN Steroid 17-alpha-monooxygenase (S17AH) DMQF2N5 MA Inhibitor DMQF2N5 RN Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17alpha-hydroxyla... Bioorg Med Chem. 2008 Feb 15;16(4):1992-2010. DMQF2N5 RU https://pubmed.ncbi.nlm.nih.gov/18061460 DMQF8DY DI DMQF8DY DMQF8DY DN 1-(4-Cyanobenzyl)-5-phenyl-1H-imidazole DMQF8DY TI TTIQUX7 DMQF8DY TN Steroid 11-beta-hydroxylase (CYP11B1) DMQF8DY MA Inhibitor DMQF8DY RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMQF8DY RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMQF8JG DI DMQF8JG DMQF8JG DN 6-ile-ustiloxin DMQF8JG TI TTJ2PTI DMQF8JG TN Tubulin beta-2 chain (TUBB2) DMQF8JG MA Inhibitor DMQF8JG RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMQF8JG RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMQF8JG DI DMQF8JG DMQF8JG DN 6-ile-ustiloxin DMQF8JG TI TTYFKSZ DMQF8JG TN Tubulin beta (TUBB) DMQF8JG MA Inhibitor DMQF8JG RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMQF8JG RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMQF9H1 DI DMQF9H1 DMQF9H1 DN 2-Amino-6-m-tolylsulfanyl-benzonitrile DMQF9H1 TI TT84ETX DMQF9H1 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQF9H1 MA Inhibitor DMQF9H1 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMQF9H1 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMQFBH6 DI DMQFBH6 DMQFBH6 DN Hydroxyacetic acid DMQFBH6 TI TTKN8W0 DMQFBH6 TN Glucose-6-phosphate dehydrogenase (G6PD) DMQFBH6 MA Inhibitor DMQFBH6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQFBH6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQFBTW DI DMQFBTW DMQFBTW DN 7-(4,6-dimethylpyrimidin-2-yl)-2-methylquinoline DMQFBTW TI TTHS256 DMQFBTW TN Metabotropic glutamate receptor 5 (mGluR5) DMQFBTW MA Inhibitor DMQFBTW RN Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91. DMQFBTW RU https://pubmed.ncbi.nlm.nih.gov/17446071 DMQFKBI DI DMQFKBI DMQFKBI DN PMID20462760C22 DMQFKBI TI TTZN7RP DMQFKBI TN Rho-associated protein kinase 1 (ROCK1) DMQFKBI MA Inhibitor DMQFKBI RN Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9. DMQFKBI RU https://pubmed.ncbi.nlm.nih.gov/20462760 DMQFKBI DI DMQFKBI DMQFKBI DN PMID20462760C22 DMQFKBI TI TTJ5SWP DMQFKBI TN NIMA-related kinase 7 (NEK7) DMQFKBI MA Inhibitor DMQFKBI RN Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9. DMQFKBI RU https://pubmed.ncbi.nlm.nih.gov/20462760 DMQFKBI DI DMQFKBI DMQFKBI DN PMID20462760C22 DMQFKBI TI TTGWKQJ DMQFKBI TN Rho-associated protein kinase 2 (ROCK2) DMQFKBI MA Inhibitor DMQFKBI RN Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9. DMQFKBI RU https://pubmed.ncbi.nlm.nih.gov/20462760 DMQFKBI DI DMQFKBI DMQFKBI DN PMID20462760C22 DMQFKBI TI TTHOI91 DMQFKBI TN NIMA-related kinase 6 (NEK6) DMQFKBI MA Inhibitor DMQFKBI RN Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3235-9. DMQFKBI RU https://pubmed.ncbi.nlm.nih.gov/20462760 DMQFS2D DI DMQFS2D DMQFS2D DN 1-benzyl-2,3-dimethyl-1H-indole-7-carboxylic acid DMQFS2D TI TTHWMFZ DMQFS2D TN Fatty acid-binding protein 4 (FABP4) DMQFS2D MA Inhibitor DMQFS2D RN N-Benzyl-indolo carboxylic acids: Design and synthesis of potent and selective adipocyte fatty-acid binding protein (A-FABP) inhibitors. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1745-8. DMQFS2D RU https://pubmed.ncbi.nlm.nih.gov/19217286 DMQFSI5 DI DMQFSI5 DMQFSI5 DN Retagliptin DMQFSI5 TI TTDIGC1 DMQFSI5 TN Dipeptidyl peptidase 4 (DPP-4) DMQFSI5 MA Inhibitor DMQFSI5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DMQFSI5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DMQFTJ7 DI DMQFTJ7 DMQFTJ7 DN 4,5,6-trihydroxy-3-methylphthalide DMQFTJ7 TI TTWTSCV DMQFTJ7 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMQFTJ7 MA Inhibitor DMQFTJ7 RN A phthalide with in vitro growth inhibitory activity from an oidiodendron strain. J Nat Prod. 2004 Dec;67(12):2086-9. DMQFTJ7 RU https://pubmed.ncbi.nlm.nih.gov/15620258 DMQFWV7 DI DMQFWV7 DMQFWV7 DN VUF-8507 DMQFWV7 TI TTK25J1 DMQFWV7 TN Adenosine A1 receptor (ADORA1) DMQFWV7 MA Inhibitor DMQFWV7 RN Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. J Med Chem. 2000 Jun 1;43(11):2227-38. DMQFWV7 RU https://pubmed.ncbi.nlm.nih.gov/10841801 DMQFWV7 DI DMQFWV7 DMQFWV7 DN VUF-8507 DMQFWV7 TI TTJFY5U DMQFWV7 TN Adenosine A3 receptor (ADORA3) DMQFWV7 MA Inhibitor DMQFWV7 RN Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97. DMQFWV7 RU https://pubmed.ncbi.nlm.nih.gov/16821770 DMQFYM4 DI DMQFYM4 DMQFYM4 DN PMID18754614C4 DMQFYM4 TI TTFQEO5 DMQFYM4 TN Squalene synthetase (FDFT1) DMQFYM4 MA Inhibitor DMQFYM4 RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DMQFYM4 RU https://pubmed.ncbi.nlm.nih.gov/18754614 DMQG2MC DI DMQG2MC DMQG2MC DN Conotoxin DMQG2MC TI TT4FDG6 DMQG2MC TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMQG2MC MA Blocker DMQG2MC RN Treatment with conotoxin, an 'N-type' calcium channel blocker, in neuronal hypoxic-ischemic injury. Brain Res. 1990 Dec 24;537(1-2):256-62. DMQG2MC RU https://pubmed.ncbi.nlm.nih.gov/2085777 DMQG4L2 DI DMQG4L2 DMQG4L2 DN S-(-)-enantiomer of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) DMQG4L2 TI TTV5CGO DMQG4L2 TN Phosphodiesterase 4 (PDE4) DMQG4L2 MA Inhibitor DMQG4L2 RN Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. DMQG4L2 RU https://pubmed.ncbi.nlm.nih.gov/7925603 DMQG57D DI DMQG57D DMQG57D DN 4-(mesityloxy)-2-(trifluoromethyl)benzonitrile DMQG57D TI TTKPW01 DMQG57D TN Androgen receptor messenger RNA (AR mRNA) DMQG57D MA Inhibitor DMQG57D RN Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8. DMQG57D RU https://pubmed.ncbi.nlm.nih.gov/19286380 DMQGB70 DI DMQGB70 DMQGB70 DN 6-bromoaplysinopsin DMQGB70 TI TTJQOD7 DMQGB70 TN 5-HT 2A receptor (HTR2A) DMQGB70 MA Inhibitor DMQGB70 RN New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80. DMQGB70 RU https://pubmed.ncbi.nlm.nih.gov/11975483 DMQGB70 DI DMQGB70 DMQGB70 DN 6-bromoaplysinopsin DMQGB70 TI TTWJBZ5 DMQGB70 TN 5-HT 2C receptor (HTR2C) DMQGB70 MA Inhibitor DMQGB70 RN New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80. DMQGB70 RU https://pubmed.ncbi.nlm.nih.gov/11975483 DMQGCKX DI DMQGCKX DMQGCKX DN (S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)phenol DMQGCKX TI TT9JNIC DMQGCKX TN Histamine H3 receptor (H3R) DMQGCKX MA Inhibitor DMQGCKX RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMQGCKX RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMQGCM3 DI DMQGCM3 DMQGCM3 DN (S)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine DMQGCM3 TI TT9JNIC DMQGCM3 TN Histamine H3 receptor (H3R) DMQGCM3 MA Inhibitor DMQGCM3 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMQGCM3 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMQGPJE DI DMQGPJE DMQGPJE DN PMID1656041C4rr DMQGPJE TI TTPADOQ DMQGPJE TN HMG-CoA reductase (HMGCR) DMQGPJE MA Inhibitor DMQGPJE RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83. DMQGPJE RU https://pubmed.ncbi.nlm.nih.gov/1656041 DMQGRMO DI DMQGRMO DMQGRMO DN N-methyl-2,2,2-triphenylacetamide DMQGRMO TI TTMNI76 DMQGRMO TN Calcium-activated potassium channel (KCN) DMQGRMO MA Inhibitor DMQGRMO RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMQGRMO RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMQGX2Z DI DMQGX2Z DMQGX2Z DN 5-[5-Fluoro-indan-(1Z)-ylidenemethyl]-pyrimidine DMQGX2Z TI TTSZLWK DMQGX2Z TN Aromatase (CYP19A1) DMQGX2Z MA Inhibitor DMQGX2Z RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMQGX2Z RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMQH1MS DI DMQH1MS DMQH1MS DN 1-Acetoxylycorine DMQH1MS TI TTXV4FI DMQH1MS TN Albendazole monooxygenase (CYP3A4) DMQH1MS MA Inhibitor DMQH1MS RN Selective cytochrome P450 3A4 inhibitory activity of Amaryllidaceae alkaloids. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3233-7. DMQH1MS RU https://pubmed.ncbi.nlm.nih.gov/19428250 DMQH481 DI DMQH481 DMQH481 DN alkylbenzene sulfonate DMQH481 TI TTZ8EM9 DMQH481 TN Glycine receptor (GlyR) DMQH481 RN Selective actions of a detergent on ligand-gated ion channels expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1998 Jan;284(1):32-6. DMQH481 RU https://pubmed.ncbi.nlm.nih.gov/9435157 DMQH8PK DI DMQH8PK DMQH8PK DN GR-133686 DMQH8PK TI TT6L509 DMQH8PK TN Coagulation factor IIa (F2) DMQH8PK MA Inhibitor DMQH8PK RN 5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60. DMQH8PK RU https://pubmed.ncbi.nlm.nih.gov/9873654 DMQH8PK DI DMQH8PK DMQH8PK DN GR-133686 DMQH8PK TI TT2WR1T DMQH8PK TN Cationic trypsinogen (PRSS1) DMQH8PK MA Inhibitor DMQH8PK RN 5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60. DMQH8PK RU https://pubmed.ncbi.nlm.nih.gov/9873654 DMQHAIK DI DMQHAIK DMQHAIK DN PMID21627121C2 DMQHAIK TI TT3VZ24 DMQHAIK TN NIMA-related kinase 2 (NEK2) DMQHAIK MA Inhibitor DMQHAIK RN Irreversible Nek2 kinase inhibitors with cellular activity. J Med Chem. 2011 Jun 23;54(12):4133-46. DMQHAIK RU https://pubmed.ncbi.nlm.nih.gov/21627121 DMQHFOX DI DMQHFOX DMQHFOX DN 1-(3-Hydroxyphenyl)-4-propylpiperazine DMQHFOX TI TTEX248 DMQHFOX TN Dopamine D2 receptor (D2R) DMQHFOX MA Inhibitor DMQHFOX RN Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20. DMQHFOX RU https://pubmed.ncbi.nlm.nih.gov/20155917 DMQHG0R DI DMQHG0R DMQHG0R DN SU9516 DMQHG0R TI TT7HF4W DMQHG0R TN Cyclin-dependent kinase 2 (CDK2) DMQHG0R MA Inhibitor DMQHG0R RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMQHG0R RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMQHG0R DI DMQHG0R DMQHG0R DN SU9516 DMQHG0R TI TTL4Q97 DMQHG0R TN Cyclin-dependent kinase 5 (CDK5) DMQHG0R MA Inhibitor DMQHG0R RN Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci. 2002 Sep;23(9):417-25. DMQHG0R RU https://pubmed.ncbi.nlm.nih.gov/12237154 DMQHG0R DI DMQHG0R DMQHG0R DN SU9516 DMQHG0R TI TTH6V3D DMQHG0R TN Cyclin-dependent kinase 1 (CDK1) DMQHG0R MA Binder DMQHG0R RN SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun. 2003 Oct 24;310(3):1026-31. DMQHG0R RU https://pubmed.ncbi.nlm.nih.gov/14550307 DMQHJTF DI DMQHJTF DMQHJTF DN Green tea DMQHJTF TI TTYEG6Q DMQHJTF TN Muscarinic acetylcholine receptor M2 (CHRM2) DMQHJTF MA Agonist DMQHJTF RN Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93. DMQHJTF RU https://pubmed.ncbi.nlm.nih.gov/12391271 DMQHJTF DI DMQHJTF DMQHJTF DN Green tea DMQHJTF TI TTE14XG DMQHJTF TN Squalene monooxygenase (SQLE) DMQHJTF MA Inhibitor DMQHJTF RN Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50. DMQHJTF RU https://pubmed.ncbi.nlm.nih.gov/12467639 DMQHKIA DI DMQHKIA DMQHKIA DN A-432411 DMQHKIA TI TTTU902 DMQHKIA TN Checkpoint kinase-1 (CHK1) DMQHKIA MA Inhibitor DMQHKIA RN Synthesis of selenophene derivatives as novel CHK1 inhibitors. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5065-8. DMQHKIA RU https://pubmed.ncbi.nlm.nih.gov/20674356 DMQHM7R DI DMQHM7R DMQHM7R DN 2-Methyl-1,2-di-pyridin-3-yl-propylchloride DMQHM7R TI TTIQUX7 DMQHM7R TN Steroid 11-beta-hydroxylase (CYP11B1) DMQHM7R MA Inhibitor DMQHM7R RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMQHM7R RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMQHN43 DI DMQHN43 DMQHN43 DN ISIS 6432 DMQHN43 TI TTONI0R DMQHN43 TN PKC-eta messenger RNA (PRKCH mRNA) DMQHN43 RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMQHN43 RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMQHTR4 DI DMQHTR4 DMQHTR4 DN 1-(4-chlorophenyl)-2-(phenylsulfonyl)ethanone DMQHTR4 TI TTN7BL9 DMQHTR4 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMQHTR4 MA Inhibitor DMQHTR4 RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMQHTR4 RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMQHU0J DI DMQHU0J DMQHU0J DN 5-phenyl-2-(4-(piperidin-1-yl)butyl)oxazole DMQHU0J TI TT9JNIC DMQHU0J TN Histamine H3 receptor (H3R) DMQHU0J MA Inhibitor DMQHU0J RN Azole derivatives as histamine H3 receptor antagonists, part 2: C-C and C-S coupled heterocycles. Bioorg Med Chem Lett. 2010 Oct 1;20(19):5883-6. DMQHU0J RU https://pubmed.ncbi.nlm.nih.gov/20727744 DMQI7BA DI DMQI7BA DMQI7BA DN W54011 DMQI7BA TI TTHXFA1 DMQI7BA TN C5a anaphylatoxin chemotactic receptor (C5AR1) DMQI7BA MA Antagonist DMQI7BA RN Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem. 2002 Dec 20;277(51):49403-7. DMQI7BA RU https://pubmed.ncbi.nlm.nih.gov/12384495 DMQIBZD DI DMQIBZD DMQIBZD DN Silmitasertib DMQIBZD TI TTDT8RP DMQIBZD TN HUMAN casein kinase II (CSK2) DMQIBZD MA Inhibitor DMQIBZD RN News report, company report or official report of Senhwa Biosciences, Inc. Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy. 2020 March 31. DMQIBZD RU https://www.ptcommunity.com/wire/senhwa-biosciences-silmitasertib-named-potential-covid-19-therapy DMQIC3L DI DMQIC3L DMQIC3L DN 2-aminopyridine DMQIC3L TI TTZUFI5 DMQIC3L TN Nitric-oxide synthase brain (NOS1) DMQIC3L MA Inhibitor DMQIC3L RN L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors. J Med Chem. 2009 Jul 23;52(14):4533-7. DMQIC3L RU https://pubmed.ncbi.nlm.nih.gov/19537690 DMQIFJ9 DI DMQIFJ9 DMQIFJ9 DN 2-Furan-2-yl-4,5-dihydro-1H-imidazole DMQIFJ9 TI TT3WG5C DMQIFJ9 TN Monoamine oxidase type A (MAO-A) DMQIFJ9 MA Inhibitor DMQIFJ9 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMQIFJ9 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMQIFJ9 DI DMQIFJ9 DMQIFJ9 DN 2-Furan-2-yl-4,5-dihydro-1H-imidazole DMQIFJ9 TI TTGP7BY DMQIFJ9 TN Monoamine oxidase type B (MAO-B) DMQIFJ9 MA Inhibitor DMQIFJ9 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMQIFJ9 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMQIFZC DI DMQIFZC DMQIFZC DN 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline DMQIFZC TI TT6MSOK DMQIFZC TN 5-HT 1D receptor (HTR1D) DMQIFZC MA Inhibitor DMQIFZC RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMQIFZC RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMQIFZC DI DMQIFZC DMQIFZC DN 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline DMQIFZC TI TTJQOD7 DMQIFZC TN 5-HT 2A receptor (HTR2A) DMQIFZC MA Inhibitor DMQIFZC RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMQIFZC RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMQIFZC DI DMQIFZC DMQIFZC DN 8-Methoxy-2-(4-methyl-piperazin-1-yl)-quinoline DMQIFZC TI TTSQIFT DMQIFZC TN 5-HT 1A receptor (HTR1A) DMQIFZC MA Inhibitor DMQIFZC RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMQIFZC RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMQIGZ7 DI DMQIGZ7 DMQIGZ7 DN MCL-117 DMQIGZ7 TI TTKWM86 DMQIGZ7 TN Opioid receptor mu (MOP) DMQIGZ7 MA Inhibitor DMQIGZ7 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMQIGZ7 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMQIGZ7 DI DMQIGZ7 DMQIGZ7 DN MCL-117 DMQIGZ7 TI TT27RFC DMQIGZ7 TN Opioid receptor delta (OPRD1) DMQIGZ7 MA Inhibitor DMQIGZ7 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMQIGZ7 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMQIGZ7 DI DMQIGZ7 DMQIGZ7 DN MCL-117 DMQIGZ7 TI TTQW87Y DMQIGZ7 TN Opioid receptor kappa (OPRK1) DMQIGZ7 MA Inhibitor DMQIGZ7 RN Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62. DMQIGZ7 RU https://pubmed.ncbi.nlm.nih.gov/16392810 DMQIHZU DI DMQIHZU DMQIHZU DN (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K DMQIHZU TI TTX3HNZ DMQIHZU TN Galanin receptor type 1 (GAL1-R) DMQIHZU MA Inhibitor DMQIHZU RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMQIHZU RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMQIHZU DI DMQIHZU DMQIHZU DN (Sar)WTLNSAGYLLGPKK(Lys-MPEG4)K DMQIHZU TI TTBPW3J DMQIHZU TN Galanin receptor type 2 (GAL2-R) DMQIHZU MA Inhibitor DMQIHZU RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMQIHZU RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMQIK9S DI DMQIK9S DMQIK9S DN DOV-51892 DMQIK9S TI TTEX6LM DMQIK9S TN GABA(A) receptor gamma-3 (GABRG3) DMQIK9S MA Modulator DMQIK9S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMQIK9S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMQINY5 DI DMQINY5 DMQINY5 DN 5'-iodoresiniferatoxin DMQINY5 TI TTKP2SU DMQINY5 TN Transient receptor potential cation channel V4 (TRPV4) DMQINY5 MA Inhibitor DMQINY5 RN N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6. DMQINY5 RU https://pubmed.ncbi.nlm.nih.gov/15026052 DMQIRY7 DI DMQIRY7 DMQIRY7 DN 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one DMQIRY7 TI TTVKILB DMQIRY7 TN Prostaglandin G/H synthase 2 (COX-2) DMQIRY7 MA Inhibitor DMQIRY7 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMQIRY7 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMQIRY7 DI DMQIRY7 DMQIRY7 DN 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one DMQIRY7 TI TT2J34L DMQIRY7 TN Arachidonate 5-lipoxygenase (5-LOX) DMQIRY7 MA Inhibitor DMQIRY7 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMQIRY7 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMQIRY7 DI DMQIRY7 DMQIRY7 DN 2-Furan-2-ylmethyl-1,2-dihydro-indazol-3-one DMQIRY7 TI TT8NGED DMQIRY7 TN Prostaglandin G/H synthase 1 (COX-1) DMQIRY7 MA Inhibitor DMQIRY7 RN Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. J Med Chem. 1991 Mar;34(3):1028-36. DMQIRY7 RU https://pubmed.ncbi.nlm.nih.gov/1848292 DMQISG6 DI DMQISG6 DMQISG6 DN Ac-I[CV(2Igl)QDWGAHRC]T-NH2 DMQISG6 TI TTJGY7A DMQISG6 TN Complement C3 (CO3) DMQISG6 MA Inhibitor DMQISG6 RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMQISG6 RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMQIUOB DI DMQIUOB DMQIUOB DN (R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide DMQIUOB TI TT3ROYC DMQIUOB TN Serotonin transporter (SERT) DMQIUOB MA Inhibitor DMQIUOB RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMQIUOB RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMQIUOB DI DMQIUOB DMQIUOB DN (R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide DMQIUOB TI TTAWNKZ DMQIUOB TN Norepinephrine transporter (NET) DMQIUOB MA Inhibitor DMQIUOB RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMQIUOB RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMQIVPK DI DMQIVPK DMQIVPK DN JWH-348 DMQIVPK TI TTMSFAW DMQIVPK TN Cannabinoid receptor 2 (CB2) DMQIVPK MA Inhibitor DMQIVPK RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMQIVPK RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMQIVPK DI DMQIVPK DMQIVPK DN JWH-348 DMQIVPK TI TT6OEDT DMQIVPK TN Cannabinoid receptor 1 (CB1) DMQIVPK MA Inhibitor DMQIVPK RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMQIVPK RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMQJ26K DI DMQJ26K DMQJ26K DN 7-Pyrrolidin-1-yl-hept-5-yn-2-one DMQJ26K TI TTQ3JTF DMQJ26K TN Muscarinic acetylcholine receptor M4 (CHRM4) DMQJ26K MA Inhibitor DMQJ26K RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMQJ26K RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMQJ26K DI DMQJ26K DMQJ26K DN 7-Pyrrolidin-1-yl-hept-5-yn-2-one DMQJ26K TI TTH18TF DMQJ26K TN Muscarinic acetylcholine receptor M5 (CHRM5) DMQJ26K MA Inhibitor DMQJ26K RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMQJ26K RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMQJ26K DI DMQJ26K DMQJ26K DN 7-Pyrrolidin-1-yl-hept-5-yn-2-one DMQJ26K TI TTQ13Z5 DMQJ26K TN Muscarinic acetylcholine receptor M3 (CHRM3) DMQJ26K MA Inhibitor DMQJ26K RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMQJ26K RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMQJ26K DI DMQJ26K DMQJ26K DN 7-Pyrrolidin-1-yl-hept-5-yn-2-one DMQJ26K TI TTYEG6Q DMQJ26K TN Muscarinic acetylcholine receptor M2 (CHRM2) DMQJ26K MA Inhibitor DMQJ26K RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMQJ26K RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMQJ26K DI DMQJ26K DMQJ26K DN 7-Pyrrolidin-1-yl-hept-5-yn-2-one DMQJ26K TI TTZ9SOR DMQJ26K TN Muscarinic acetylcholine receptor M1 (CHRM1) DMQJ26K MA Inhibitor DMQJ26K RN Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5, Bioorg. Med. Chem. Lett. 2(8):803-808 (1992). DMQJ26K RU http://www.sciencedirect.com/science/article/pii/S0960894X00805351 DMQJ3T5 DI DMQJ3T5 DMQJ3T5 DN KF-A6 DMQJ3T5 TI TT3ROYC DMQJ3T5 TN Serotonin transporter (SERT) DMQJ3T5 MA Inhibitor DMQJ3T5 RN Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. DMQJ3T5 RU https://pubmed.ncbi.nlm.nih.gov/17846138 DMQJ3T5 DI DMQJ3T5 DMQJ3T5 DN KF-A6 DMQJ3T5 TI TTTIBOJ DMQJ3T5 TN Histamine H1 receptor (H1R) DMQJ3T5 MA Inhibitor DMQJ3T5 RN Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40. DMQJ3T5 RU https://pubmed.ncbi.nlm.nih.gov/17846138 DMQJ3ZL DI DMQJ3ZL DMQJ3ZL DN Anticalin DMQJ3ZL TI TTE4KHA DMQJ3ZL TN Amyloid beta A4 protein (APP) DMQJ3ZL MA Inhibitor DMQJ3ZL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMQJ3ZL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMQJ5RU DI DMQJ5RU DMQJ5RU DN (6-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid DMQJ5RU TI TTFBNVI DMQJ5RU TN Aldose reductase (AKR1B1) DMQJ5RU MA Inhibitor DMQJ5RU RN Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8. DMQJ5RU RU https://pubmed.ncbi.nlm.nih.gov/3093680 DMQJ9RZ DI DMQJ9RZ DMQJ9RZ DN 1-allyl-2-[3-(isopropylamino)propoxy]-9H-carbazole DMQJ9RZ TI TTFQEO5 DMQJ9RZ TN Squalene synthetase (FDFT1) DMQJ9RZ MA Inhibitor DMQJ9RZ RN Synthesis and biological evaluation of novel propylamine derivatives as orally active squalene synthase inhibitors. Bioorg Med Chem. 2004 Nov 15;12(22):5899-908. DMQJ9RZ RU https://pubmed.ncbi.nlm.nih.gov/15498666 DMQJA4F DI DMQJA4F DMQJA4F DN 8-Diazonium-naphthalene-1-sulfonic acid anion DMQJA4F TI TTNJYV2 DMQJA4F TN Gamma-aminobutyric acid receptor (GAR) DMQJA4F MA Inhibitor DMQJA4F RN Aryl diazo compounds and diazonium salts as potential irreversible probes of the gamma-aminobutyric acid receptor. J Med Chem. 1987 Dec;30(12):2222-7. DMQJA4F RU https://pubmed.ncbi.nlm.nih.gov/2824775 DMQJD4P DI DMQJD4P DMQJD4P DN D-166A DMQJD4P TI TTAWNKZ DMQJD4P TN Norepinephrine transporter (NET) DMQJD4P MA Inhibitor DMQJD4P RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMQJD4P RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMQJD4P DI DMQJD4P DMQJD4P DN D-166A DMQJD4P TI TTVBI8W DMQJD4P TN Dopamine transporter (DAT) DMQJD4P MA Inhibitor DMQJD4P RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMQJD4P RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMQJD4P DI DMQJD4P DMQJD4P DN D-166A DMQJD4P TI TT3ROYC DMQJD4P TN Serotonin transporter (SERT) DMQJD4P MA Inhibitor DMQJD4P RN Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78. DMQJD4P RU https://pubmed.ncbi.nlm.nih.gov/18249549 DMQJKSV DI DMQJKSV DMQJKSV DN 2-methyl-1-(thiophen-3-yl)pent-1-en-3-one oxime DMQJKSV TI TTELV3W DMQJKSV TN Transformation-sensitive protein p120 (TRPA1) DMQJKSV MA Inhibitor DMQJKSV RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DMQJKSV RU https://pubmed.ncbi.nlm.nih.gov/20356305 DMQJNDX DI DMQJNDX DMQJNDX DN L-759,633 DMQJNDX TI TTMSFAW DMQJNDX TN Cannabinoid receptor 2 (CB2) DMQJNDX MA Agonist DMQJNDX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DMQJNDX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DMQJYX7 DI DMQJYX7 DMQJYX7 DN 2-aminoquinazoline-4-carboxyanilide DMQJYX7 TI TTJFY5U DMQJYX7 TN Adenosine A3 receptor (ADORA3) DMQJYX7 MA Inhibitor DMQJYX7 RN Scouting human A3 adenosine receptor antagonist binding mode using a molecular simplification approach: from triazoloquinoxaline to a pyrimidine sk... J Med Chem. 2007 Dec 27;50(26):6596-606. DMQJYX7 RU https://pubmed.ncbi.nlm.nih.gov/18047262 DMQK0AL DI DMQK0AL DMQK0AL DN ISIS 19217 DMQK0AL TI TT1ERKL DMQK0AL TN CD40 messenger RNA (CD40 mRNA) DMQK0AL RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMQK0AL RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMQK32F DI DMQK32F DMQK32F DN 5-tert-Butyl-2-(4-fluoro-phenyl)-[1,3]dithiane DMQK32F TI TTNJYV2 DMQK32F TN Gamma-aminobutyric acid receptor (GAR) DMQK32F MA Inhibitor DMQK32F RN Synthesis of carbon-11-, fluorine-18-, and iodine-125-labeled GABAA-gated chloride ion channel blockers: substituted 5-tert-butyl-2-phenyl-1,3-dith... J Med Chem. 1995 Jul 7;38(14):2663-71. DMQK32F RU https://pubmed.ncbi.nlm.nih.gov/7629805 DMQK4I2 DI DMQK4I2 DMQK4I2 DN (S)-4C3HPG DMQK4I2 TI TTVBPDM DMQK4I2 TN Metabotropic glutamate receptor 1 (mGluR1) DMQK4I2 MA Antagonist DMQK4I2 RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMQK4I2 RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMQK4I2 DI DMQK4I2 DMQK4I2 DN (S)-4C3HPG DMQK4I2 TI TTHS256 DMQK4I2 TN Metabotropic glutamate receptor 5 (mGluR5) DMQK4I2 MA Antagonist DMQK4I2 RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMQK4I2 RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMQK4I2 DI DMQK4I2 DMQK4I2 DN (S)-4C3HPG DMQK4I2 TI TTXJ47W DMQK4I2 TN Metabotropic glutamate receptor 2 (mGluR2) DMQK4I2 MA Agonist DMQK4I2 RN Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes. Br J Pharmacol. 1998 Feb;123(3):497-504. DMQK4I2 RU https://pubmed.ncbi.nlm.nih.gov/9504391 DMQK5RM DI DMQK5RM DMQK5RM DN HI-240 DMQK5RM TI TT84ETX DMQK5RM TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMQK5RM MA Inhibitor DMQK5RM RN N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency vi... Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-6. DMQK5RM RU https://pubmed.ncbi.nlm.nih.gov/10617082 DMQKB6W DI DMQKB6W DMQKB6W DN 1-phenyl-3-(2-(pyridin-3-yl)quinazolin-4-yl)urea DMQKB6W TI TTJFY5U DMQKB6W TN Adenosine A3 receptor (ADORA3) DMQKB6W MA Inhibitor DMQKB6W RN Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97. DMQKB6W RU https://pubmed.ncbi.nlm.nih.gov/16821770 DMQKCGI DI DMQKCGI DMQKCGI DN 4-Benzyl-1-methyl-piperidine hydrochloride DMQKCGI TI TTJQOD7 DMQKCGI TN 5-HT 2A receptor (HTR2A) DMQKCGI MA Inhibitor DMQKCGI RN Ketanserin analogues: structure-affinity relationships for 5-HT2 and 5-HT1C serotonin receptor binding. J Med Chem. 1992 Dec 25;35(26):4903-10. DMQKCGI RU https://pubmed.ncbi.nlm.nih.gov/1479590 DMQKGL3 DI DMQKGL3 DMQKGL3 DN 2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX) DMQKGL3 TI TT0MYE2 DMQKGL3 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMQKGL3 MA Inhibitor DMQKGL3 RN 4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological charact... J Med Chem. 2010 May 27;53(10):4110-8. DMQKGL3 RU https://pubmed.ncbi.nlm.nih.gov/20408529 DMQKGL3 DI DMQKGL3 DMQKGL3 DN 2-AMINO-3-(4-HYDROXY-1,2,5-OXADIAZOL-3-YL)PROPIONIC ACID (STRUCTURAL MIX) DMQKGL3 TI TTAN6JD DMQKGL3 TN Glutamate receptor AMPA (GRIA) DMQKGL3 MA Inhibitor DMQKGL3 RN 4-hydroxy-1,2,5-oxadiazol-3-yl moiety as bioisoster of the carboxy function. Synthesis, ionization constants, and molecular pharmacological charact... J Med Chem. 2010 May 27;53(10):4110-8. DMQKGL3 RU https://pubmed.ncbi.nlm.nih.gov/20408529 DMQKHXN DI DMQKHXN DMQKHXN DN 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine DMQKHXN TI TTSZLWK DMQKHXN TN Aromatase (CYP19A1) DMQKHXN MA Inhibitor DMQKHXN RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMQKHXN RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMQKHXN DI DMQKHXN DMQKHXN DN 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine DMQKHXN TI TTIQUX7 DMQKHXN TN Steroid 11-beta-hydroxylase (CYP11B1) DMQKHXN MA Inhibitor DMQKHXN RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMQKHXN RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMQKHXN DI DMQKHXN DMQKHXN DN 4-[5-Bromo-indan-(1Z)-ylidenemethyl]-pyridine DMQKHXN TI TTRA5BZ DMQKHXN TN Steroid 17-alpha-monooxygenase (S17AH) DMQKHXN MA Inhibitor DMQKHXN RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMQKHXN RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMQKMCG DI DMQKMCG DMQKMCG DN 1-(4-nonylbenzyl)azetidine-3-carboxylic acid DMQKMCG TI TT9JZCK DMQKMCG TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMQKMCG MA Inhibitor DMQKMCG RN A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 re... J Med Chem. 2004 Dec 30;47(27):6662-5. DMQKMCG RU https://pubmed.ncbi.nlm.nih.gov/15615513 DMQKMX3 DI DMQKMX3 DMQKMX3 DN alpha-propyldopacetamide DMQKMX3 TI TTUHP71 DMQKMX3 TN Tyrosine 3-monooxygenase (TH) DMQKMX3 MA Inhibitor DMQKMX3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243). DMQKMX3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1243 DMQKMX3 DI DMQKMX3 DMQKMX3 DN alpha-propyldopacetamide DMQKMX3 TI TTZSJHV DMQKMX3 TN Tryptophan 5-hydroxylase 1 (TPH1) DMQKMX3 MA Inhibitor DMQKMX3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1241). DMQKMX3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1241 DMQKMX3 DI DMQKMX3 DMQKMX3 DN alpha-propyldopacetamide DMQKMX3 TI TT3KLDP DMQKMX3 TN L-Tryptophan hydroxylase 2 (TPH2) DMQKMX3 MA Inhibitor DMQKMX3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1242). DMQKMX3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1242 DMQKOUZ DI DMQKOUZ DMQKOUZ DN Tert-butyloxy carbonyl-D-Phe-pro-Arg-H DMQKOUZ TI TT2WR1T DMQKOUZ TN Cationic trypsinogen (PRSS1) DMQKOUZ MA Inhibitor DMQKOUZ RN Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitu... J Med Chem. 1995 Oct 27;38(22):4446-53. DMQKOUZ RU https://pubmed.ncbi.nlm.nih.gov/7473571 DMQKR2W DI DMQKR2W DMQKR2W DN 6-(2-Fluoro-benzenesulfonyl)-2H-pyridazin-3-one DMQKR2W TI TTFBNVI DMQKR2W TN Aldose reductase (AKR1B1) DMQKR2W MA Inhibitor DMQKR2W RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMQKR2W RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMQKU9H DI DMQKU9H DMQKU9H DN 5-(biphenyl-4-yl)-3-oxopentanoic acid DMQKU9H TI TTXZ0KQ DMQKU9H TN Matrix metalloproteinase-12 (MMP-12) DMQKU9H MA Inhibitor DMQKU9H RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMQKU9H RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMQLB3T DI DMQLB3T DMQLB3T DN KNI-10265 DMQLB3T TI TTXMNHO DMQLB3T TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMQLB3T MA Inhibitor DMQLB3T RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMQLB3T RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMQLGFH DI DMQLGFH DMQLGFH DN Cyclopentylcarbamic Acid Biphenyl-3-yl Ester DMQLGFH TI TTDP1UC DMQLGFH TN Fatty acid amide hydrolase (FAAH) DMQLGFH MA Inhibitor DMQLGFH RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMQLGFH RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMQLHE8 DI DMQLHE8 DMQLHE8 DN SB-410220 DMQLHE8 TI TT60Q8D DMQLHE8 TN Orexin receptor type 1 (HCRTR1) DMQLHE8 MA Antagonist DMQLHE8 RN Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol. 2004 Jan;141(2):340-6. DMQLHE8 RU https://pubmed.ncbi.nlm.nih.gov/14691055 DMQLJ3Y DI DMQLJ3Y DMQLJ3Y DN DQP-1105 DMQLJ3Y TI TTN9D8E DMQLJ3Y TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMQLJ3Y MA Modulator (allosteric modulator) DMQLJ3Y RN Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95. DMQLJ3Y RU https://pubmed.ncbi.nlm.nih.gov/21807990 DMQLJ3Y DI DMQLJ3Y DMQLJ3Y DN DQP-1105 DMQLJ3Y TI TT1M8OW DMQLJ3Y TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMQLJ3Y MA Modulator (allosteric modulator) DMQLJ3Y RN Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95. DMQLJ3Y RU https://pubmed.ncbi.nlm.nih.gov/21807990 DMQLJ3Y DI DMQLJ3Y DMQLJ3Y DN DQP-1105 DMQLJ3Y TI TT5POTG DMQLJ3Y TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMQLJ3Y MA Modulator (allosteric modulator) DMQLJ3Y RN Mechanism for noncompetitive inhibition by novel GluN2C/D N-methyl-D-aspartate receptor subunit-selective modulators. Mol Pharmacol. 2011 Nov;80(5):782-95. DMQLJ3Y RU https://pubmed.ncbi.nlm.nih.gov/21807990 DMQLJMC DI DMQLJMC DMQLJMC DN BL-6020 DMQLJMC TI TTD0CIQ DMQLJMC TN Melanocortin receptor 4 (MC4R) DMQLJMC MA Antagonist DMQLJMC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285). DMQLJMC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=285 DMQLNZC DI DMQLNZC DMQLNZC DN Empagli ozin DMQLNZC TI TTLWPVF DMQLNZC TN Sodium/glucose cotransporter 2 (SGLT2) DMQLNZC MA Modulator DMQLNZC RN 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. DMQLNZC RU https://pubmed.ncbi.nlm.nih.gov/25633781 DMQLPGA DI DMQLPGA DMQLPGA DN Ac-ICV(5fW)QDWGAHRCT-NH2 DMQLPGA TI TTJGY7A DMQLPGA TN Complement C3 (CO3) DMQLPGA MA Inhibitor DMQLPGA RN Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22. DMQLPGA RU https://pubmed.ncbi.nlm.nih.gov/16854067 DMQLT84 DI DMQLT84 DMQLT84 DN D-218 DMQLT84 TI TT4C8EA DMQLT84 TN Dopamine D3 receptor (D3R) DMQLT84 MA Inhibitor DMQLT84 RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMQLT84 RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMQLT84 DI DMQLT84 DMQLT84 DN D-218 DMQLT84 TI TTEX248 DMQLT84 TN Dopamine D2 receptor (D2R) DMQLT84 MA Inhibitor DMQLT84 RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMQLT84 RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMQM6IA DI DMQM6IA DMQM6IA DN 2-(2-Phosphonooxy-ethyl)-pentanedioic acid DMQM6IA TI TT9G4N0 DMQM6IA TN Glutamate carboxypeptidase II (GCPII) DMQM6IA MA Inhibitor DMQM6IA RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DMQM6IA RU https://pubmed.ncbi.nlm.nih.gov/12723961 DMQM8O5 DI DMQM8O5 DMQM8O5 DN (4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine DMQM8O5 TI TT4C8EA DMQM8O5 TN Dopamine D3 receptor (D3R) DMQM8O5 MA Inhibitor DMQM8O5 RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMQM8O5 RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMQM8O5 DI DMQM8O5 DMQM8O5 DN (4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine DMQM8O5 TI TTE0A2F DMQM8O5 TN Dopamine D4 receptor (D4R) DMQM8O5 MA Inhibitor DMQM8O5 RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMQM8O5 RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMQMDSG DI DMQMDSG DMQMDSG DN PO3 2-Ile-Trp-O-3K DMQMDSG TI TTQ9RYT DMQMDSG TN Endothelin-converting enzyme 1 (ECE1) DMQMDSG MA Inhibitor DMQMDSG RN Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994). DMQMDSG RU http://www.sciencedirect.com/science/article/pii/S0960894X01803413 DMQMH6S DI DMQMH6S DMQMH6S DN Iodotubercidin DMQMH6S TI TTL732K DMQMH6S TN Adenosine kinase (ADK) DMQMH6S MA Inhibitor DMQMH6S RN Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36. DMQMH6S RU https://pubmed.ncbi.nlm.nih.gov/21948793 DMQMR3P DI DMQMR3P DMQMR3P DN DECYL(DIMETHYL)PHOSPHINE OXIDE DMQMR3P TI TT3WG5C DMQMR3P TN Monoamine oxidase type A (MAO-A) DMQMR3P MA Inhibitor DMQMR3P RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQMR3P RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQMRGD DI DMQMRGD DMQMRGD DN 7-Phenyl-1-(1,3,4-thiadiazol-2-yl)-heptan-1-one DMQMRGD TI TTDP1UC DMQMRGD TN Fatty acid amide hydrolase (FAAH) DMQMRGD MA Inhibitor DMQMRGD RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMQMRGD RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMQMSW3 DI DMQMSW3 DMQMSW3 DN 4-Sulfamoyloxy-benzoic acid octyl ester DMQMSW3 TI TTHM0R1 DMQMSW3 TN Steryl-sulfatase (STS) DMQMSW3 MA Inhibitor DMQMSW3 RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMQMSW3 RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMQMSZR DI DMQMSZR DMQMSZR DN 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide DMQMSZR TI TT27RFC DMQMSZR TN Opioid receptor delta (OPRD1) DMQMSZR MA Inhibitor DMQMSZR RN SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. DMQMSZR RU https://pubmed.ncbi.nlm.nih.gov/20719509 DMQMSZR DI DMQMSZR DMQMSZR DN 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide DMQMSZR TI TTQW87Y DMQMSZR TN Opioid receptor kappa (OPRK1) DMQMSZR MA Inhibitor DMQMSZR RN SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. DMQMSZR RU https://pubmed.ncbi.nlm.nih.gov/20719509 DMQMSZR DI DMQMSZR DMQMSZR DN 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide DMQMSZR TI TTQ6VDM DMQMSZR TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMQMSZR MA Inhibitor DMQMSZR RN SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. DMQMSZR RU https://pubmed.ncbi.nlm.nih.gov/20719509 DMQMSZR DI DMQMSZR DMQMSZR DN 8-azabicyclo[3.2.1]octan-3-yloxy-benzamide DMQMSZR TI TTKWM86 DMQMSZR TN Opioid receptor mu (MOP) DMQMSZR MA Inhibitor DMQMSZR RN SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10. DMQMSZR RU https://pubmed.ncbi.nlm.nih.gov/20719509 DMQMT1A DI DMQMT1A DMQMT1A DN 3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium DMQMT1A TI TT1MPAY DMQMT1A TN GABA(A) receptor alpha-1 (GABRA1) DMQMT1A MA Inhibitor DMQMT1A RN N-2 methylated quaternary derivatives of beta-carboline-3-carboxylates inhibit acetylcholinesterase in vitroO, Bioorg. Med. Chem. Lett. 3(12):2831-2836 (1993). DMQMT1A RU http://www.sciencedirect.com/science/article/pii/S0960894X01807745 DMQMT1A DI DMQMT1A DMQMT1A DN 3-Methoxycarbonyl-2-methyl-9H-beta-carbolin-2-ium DMQMT1A TI TTNJYV2 DMQMT1A TN Gamma-aminobutyric acid receptor (GAR) DMQMT1A MA Inhibitor DMQMT1A RN N-2 methylated quaternary derivatives of beta-carboline-3-carboxylates inhibit acetylcholinesterase in vitroO, Bioorg. Med. Chem. Lett. 3(12):2831-2836 (1993). DMQMT1A RU http://www.sciencedirect.com/science/article/pii/S0960894X01807745 DMQMTSX DI DMQMTSX DMQMTSX DN 7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin DMQMTSX TI TTGP7BY DMQMTSX TN Monoamine oxidase type B (MAO-B) DMQMTSX MA Inhibitor DMQMTSX RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMQMTSX RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMQMTSX DI DMQMTSX DMQMTSX DN 7-Acetonyloxy-3,4-cyclopentene-8-methylcoumarin DMQMTSX TI TT3WG5C DMQMTSX TN Monoamine oxidase type A (MAO-A) DMQMTSX MA Inhibitor DMQMTSX RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMQMTSX RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMQMZ0Y DI DMQMZ0Y DMQMZ0Y DN 5'-phenylthio-ImmH DMQMZ0Y TI TTMCF1Y DMQMZ0Y TN Purine nucleoside phosphorylase (PNP) DMQMZ0Y MA Inhibitor DMQMZ0Y RN Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3. DMQMZ0Y RU https://pubmed.ncbi.nlm.nih.gov/18778937 DMQN14X DI DMQN14X DMQN14X DN (D)Phe-Gln-Trp-Ala-Val-Gly-His-Leu-Leu-NH2 DMQN14X TI TTC1MVT DMQN14X TN Gastrin-releasing peptide receptor (GRPR) DMQN14X MA Inhibitor DMQN14X RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DMQN14X RU https://pubmed.ncbi.nlm.nih.gov/10882361 DMQN6CL DI DMQN6CL DMQN6CL DN N-Hydroxy-4-(4-methoxy-phenyl)-4-oxo-butyramide DMQN6CL TI TTMX39J DMQN6CL TN Matrix metalloproteinase-1 (MMP-1) DMQN6CL MA Inhibitor DMQN6CL RN Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96. DMQN6CL RU https://pubmed.ncbi.nlm.nih.gov/16220975 DMQNA7V DI DMQNA7V DMQNA7V DN BC11-38 DMQNA7V TI TTTWC79 DMQNA7V TN Phosphodiesterase 11A (PDE11A) DMQNA7V MA Inhibitor DMQNA7V RN Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen. Chem Biol. 2012 Jan 27;19(1):155-63. DMQNA7V RU https://pubmed.ncbi.nlm.nih.gov/22284362 DMQNOFA DI DMQNOFA DMQNOFA DN BAY11-7082 DMQNOFA TI TTSXVID DMQNOFA TN Nuclear factor NF-kappa-B (NFKB) DMQNOFA MA Inhibitor DMQNOFA RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMQNOFA RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMQNT8D DI DMQNT8D DMQNT8D DN 4S-4,5-Diamino-N-(4-phenoxyphenyl)pentanamide DMQNT8D TI TTXZEAJ DMQNT8D TN Leukotriene A-4 hydrolase (LTA4H) DMQNT8D MA Inhibitor DMQNT8D RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMQNT8D RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMQNXL1 DI DMQNXL1 DMQNXL1 DN 4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin DMQNXL1 TI TT3WG5C DMQNXL1 TN Monoamine oxidase type A (MAO-A) DMQNXL1 MA Inhibitor DMQNXL1 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMQNXL1 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMQNXL1 DI DMQNXL1 DMQNXL1 DN 4,8-Dimethyl-7-(2'-oxocyclohexyloxy)coumarin DMQNXL1 TI TTGP7BY DMQNXL1 TN Monoamine oxidase type B (MAO-B) DMQNXL1 MA Inhibitor DMQNXL1 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMQNXL1 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMQO71C DI DMQO71C DMQO71C DN (R,S)-PHPNECA DMQO71C TI TTK25J1 DMQO71C TN Adenosine A1 receptor (ADORA1) DMQO71C MA Agonist DMQO71C RN N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9. DMQO71C RU https://pubmed.ncbi.nlm.nih.gov/12109910 DMQO71C DI DMQO71C DMQO71C DN (R,S)-PHPNECA DMQO71C TI TTJFY5U DMQO71C TN Adenosine A3 receptor (ADORA3) DMQO71C MA Agonist DMQO71C RN N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9. DMQO71C RU https://pubmed.ncbi.nlm.nih.gov/12109910 DMQO71C DI DMQO71C DMQO71C DN (R,S)-PHPNECA DMQO71C TI TTNE7KG DMQO71C TN Adenosine A2b receptor (ADORA2B) DMQO71C MA Agonist DMQO71C RN N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. J Med Chem. 2002 Jul 18;45(15):3271-9. DMQO71C RU https://pubmed.ncbi.nlm.nih.gov/12109910 DMQO8AF DI DMQO8AF DMQO8AF DN [3H]2,2,2-TEMPS DMQO8AF TI TTXJ47W DMQO8AF TN Metabotropic glutamate receptor 2 (mGluR2) DMQO8AF MA Modulator (allosteric modulator) DMQO8AF RN Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators. Br J Pharmacol. 2011 Sep;164(2b):521-37. DMQO8AF RU https://pubmed.ncbi.nlm.nih.gov/21470207 DMQOB0X DI DMQOB0X DMQOB0X DN Acacetin DMQOB0X TI TT2J34L DMQOB0X TN Arachidonate 5-lipoxygenase (5-LOX) DMQOB0X MA Inhibitor DMQOB0X RN Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J Nat Prod. 1999 Sep;62(9):1241-5. DMQOB0X RU https://pubmed.ncbi.nlm.nih.gov/10514305 DMQOB0X DI DMQOB0X DMQOB0X DN Acacetin DMQOB0X TI TTI84H7 DMQOB0X TN Cytochrome P450 1B1 (CYP1B1) DMQOB0X MA Inhibitor DMQOB0X RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMQOB0X RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMQOB0X DI DMQOB0X DMQOB0X DN Acacetin DMQOB0X TI TT7RJY8 DMQOB0X TN Xanthine dehydrogenase/oxidase (XDH) DMQOB0X MA Inhibitor DMQOB0X RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DMQOB0X RU https://pubmed.ncbi.nlm.nih.gov/3379415 DMQOCAY DI DMQOCAY DMQOCAY DN 2-amino-2,3-dihydro-1H-indene-5-sulfonamide DMQOCAY TI TTUNARX DMQOCAY TN Carbonic anhydrase (CA) DMQOCAY MA Inhibitor DMQOCAY RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMQOCAY RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMQOCAY DI DMQOCAY DMQOCAY DN 2-amino-2,3-dihydro-1H-indene-5-sulfonamide DMQOCAY TI TTSYM0R DMQOCAY TN Carbonic anhydrase XII (CA-XII) DMQOCAY MA Inhibitor DMQOCAY RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMQOCAY RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMQOCAY DI DMQOCAY DMQOCAY DN 2-amino-2,3-dihydro-1H-indene-5-sulfonamide DMQOCAY TI TTEYTKG DMQOCAY TN Carbonic anhydrase XIV (CA-XIV) DMQOCAY MA Inhibitor DMQOCAY RN Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem. 2008 Dec;43(12):2853-60. DMQOCAY RU https://pubmed.ncbi.nlm.nih.gov/18406497 DMQOFX2 DI DMQOFX2 DMQOFX2 DN 99mTc-MIP-1340 DMQOFX2 TI TT9G4N0 DMQOFX2 TN Glutamate carboxypeptidase II (GCPII) DMQOFX2 MA Modulator DMQOFX2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMQOFX2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMQOI5X DI DMQOI5X DMQOI5X DN 3-Methylphenylalanine DMQOI5X TI TTF2LRI DMQOI5X TN Cathepsin B (CTSB) DMQOI5X MA Inhibitor DMQOI5X RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQOI5X RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQOJBN DI DMQOJBN DMQOJBN DN 6-(2-phenethylisoindolin-5-yloxy)nicotinamide DMQOJBN TI TT27RFC DMQOJBN TN Opioid receptor delta (OPRD1) DMQOJBN MA Inhibitor DMQOJBN RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DMQOJBN RU https://pubmed.ncbi.nlm.nih.gov/17980586 DMQOJBN DI DMQOJBN DMQOJBN DN 6-(2-phenethylisoindolin-5-yloxy)nicotinamide DMQOJBN TI TTKWM86 DMQOJBN TN Opioid receptor mu (MOP) DMQOJBN MA Inhibitor DMQOJBN RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DMQOJBN RU https://pubmed.ncbi.nlm.nih.gov/17980586 DMQOJY2 DI DMQOJY2 DMQOJY2 DN OPC 4392 DMQOJY2 TI TTJS8PY DMQOJY2 TN 5-HT 6 receptor (HTR6) DMQOJY2 MA Agonist DMQOJY2 RN Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27. DMQOJY2 RU https://pubmed.ncbi.nlm.nih.gov/10327430 DMQOJY2 DI DMQOJY2 DMQOJY2 DN OPC 4392 DMQOJY2 TI TTO9X1H DMQOJY2 TN 5-HT 7 receptor (HTR7) DMQOJY2 MA Agonist DMQOJY2 RN Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27. DMQOJY2 RU https://pubmed.ncbi.nlm.nih.gov/10327430 DMQOL73 DI DMQOL73 DMQOL73 DN Des-AA1,2,5-[D-Nal8,(NalphaMe)IAmp9,Tyr11]SRIF DMQOL73 TI TTIND6G DMQOL73 TN Somatostatin receptor type 1 (SSTR1) DMQOL73 MA Inhibitor DMQOL73 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMQOL73 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMQONPU DI DMQONPU DMQONPU DN ISIS 6748 DMQONPU TI TTBLG3H DMQONPU TN P120 messenger RNA (NOP2 mRNA) DMQONPU RN US patent application no. 5,814,619, Oligonucleotide inhibition of P120. DMQONPU RU http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true DMQOUJ7 DI DMQOUJ7 DMQOUJ7 DN 10-CF3C(OH)2-DDACTHF DMQOUJ7 TI TTEXB9Z DMQOUJ7 TN Glycinamide ribonucleotide formyltransferase (GART) DMQOUJ7 MA Inhibitor DMQOUJ7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQOUJ7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQOY3J DI DMQOY3J DMQOY3J DN C[-Arg-Gly-Asp-Acpca35-] DMQOY3J TI TTJA1ZO DMQOY3J TN ITGB3 messenger RNA (ITGB3 mRNA) DMQOY3J MA Inhibitor DMQOY3J RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMQOY3J RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMQOY3J DI DMQOY3J DMQOY3J DN C[-Arg-Gly-Asp-Acpca35-] DMQOY3J TI TTT1R2L DMQOY3J TN Integrin alpha-V (ITGAV) DMQOY3J MA Inhibitor DMQOY3J RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMQOY3J RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMQP03A DI DMQP03A DMQP03A DN [11C]butylthio-TZTP DMQP03A TI TTOXS3C DMQP03A TN Muscarinic acetylcholine receptor (CHRM) DMQP03A MA Agonist DMQP03A RN PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. Dementia. 1996 Jul-Aug;7(4):187-95. DMQP03A RU https://pubmed.ncbi.nlm.nih.gov/8835881 DMQP4VG DI DMQP4VG DMQP4VG DN JG-365 DMQP4VG TI TT5FNQT DMQP4VG TN Human immunodeficiency virus Protease (HIV PR) DMQP4VG MA Modulator DMQP4VG RN [Mechanism of action of aspartic proteases. III. Conformational characteristics of HIV-1 protease inhibitor JG-365]. Bioorg Khim. 1999 Jun;25(6):418-22. DMQP4VG RU https://www.ncbi.nlm.nih.gov/pubmed/10505229 DMQP5U9 DI DMQP5U9 DMQP5U9 DN (+/-)-5'-deoxy-4'-fluoro-5'-methylthio-DADMe-ImmH DMQP5U9 TI TTMCF1Y DMQP5U9 TN Purine nucleoside phosphorylase (PNP) DMQP5U9 MA Inhibitor DMQP5U9 RN Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3. DMQP5U9 RU https://pubmed.ncbi.nlm.nih.gov/18778937 DMQPCDG DI DMQPCDG DMQPCDG DN Helenalin-2-methylbutyrate DMQPCDG TI TTSXVID DMQPCDG TN Nuclear factor NF-kappa-B (NFKB) DMQPCDG MA Inhibitor DMQPCDG RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMQPCDG RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMQPEA7 DI DMQPEA7 DMQPEA7 DN PRT-060318 DMQPEA7 TI TTOU65C DMQPEA7 TN Tyrosine-protein kinase SYK (SYK) DMQPEA7 MA Inhibitor DMQPEA7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230). DMQPEA7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2230 DMQPFT3 DI DMQPFT3 DMQPFT3 DN 1-[(Furan-2(5H)-one)-4-methyl]-desloratadine DMQPFT3 TI TTTIBOJ DMQPFT3 TN Histamine H1 receptor (H1R) DMQPFT3 MA Inhibitor DMQPFT3 RN Stereoselective synthesis of desloratadine derivatives as antagonist of histamine. Bioorg Med Chem. 2010 Feb 15;18(4):1626-32. DMQPFT3 RU https://pubmed.ncbi.nlm.nih.gov/20110173 DMQPHFU DI DMQPHFU DMQPHFU DN AB-MECA DMQPHFU TI TTNE7KG DMQPHFU TN Adenosine A2b receptor (ADORA2B) DMQPHFU MA Agonist DMQPHFU RN Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 1998 Jan;357(1):1-9. DMQPHFU RU https://pubmed.ncbi.nlm.nih.gov/9459566 DMQPHFU DI DMQPHFU DMQPHFU DN AB-MECA DMQPHFU TI TTJFY5U DMQPHFU TN Adenosine A3 receptor (ADORA3) DMQPHFU MA Agonist DMQPHFU RN [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol. 2000 May;57(5):968-75. DMQPHFU RU https://pubmed.ncbi.nlm.nih.gov/10779381 DMQPJXT DI DMQPJXT DMQPJXT DN OSU-53 DMQPJXT TI TTLAFZV DMQPJXT TN AMP-activated protein kinase (AMPK) DMQPJXT MA Activator DMQPJXT RN A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth. J Clin Endocrinol Metab. 2015 May;100(5):E748-56. DMQPJXT RU https://pubmed.ncbi.nlm.nih.gov/25710562 DMQPKWM DI DMQPKWM DMQPKWM DN 2,4-Diamino-6-Phenyl-5,6,7,8,-Tetrahydropteridine DMQPKWM TI TTCM4B3 DMQPKWM TN Nitric-oxide synthase endothelial (NOS3) DMQPKWM MA Inhibitor DMQPKWM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQPKWM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQPNUM DI DMQPNUM DMQPNUM DN 3-(2-Amino-propyl)-1H-indol-5-ol DMQPNUM TI TT0K1SC DMQPNUM TN 5-HT 2B receptor (HTR2B) DMQPNUM MA Inhibitor DMQPNUM RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMQPNUM RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMQPNUM DI DMQPNUM DMQPNUM DN 3-(2-Amino-propyl)-1H-indol-5-ol DMQPNUM TI TTWJBZ5 DMQPNUM TN 5-HT 2C receptor (HTR2C) DMQPNUM MA Inhibitor DMQPNUM RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMQPNUM RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMQPNUM DI DMQPNUM DMQPNUM DN 3-(2-Amino-propyl)-1H-indol-5-ol DMQPNUM TI TTJQOD7 DMQPNUM TN 5-HT 2A receptor (HTR2A) DMQPNUM MA Inhibitor DMQPNUM RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMQPNUM RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMQPNUM DI DMQPNUM DMQPNUM DN 3-(2-Amino-propyl)-1H-indol-5-ol DMQPNUM TI TTSQIFT DMQPNUM TN 5-HT 1A receptor (HTR1A) DMQPNUM MA Inhibitor DMQPNUM RN A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95. DMQPNUM RU https://pubmed.ncbi.nlm.nih.gov/12954071 DMQPTL5 DI DMQPTL5 DMQPTL5 DN 6-(Dihydroxy-Isobutyl)-Thymine DMQPTL5 TI TTP3QRF DMQPTL5 TN Thymidine kinase 1 (TK1) DMQPTL5 MA Inhibitor DMQPTL5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQPTL5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQPVGO DI DMQPVGO DMQPVGO DN Des-AA1,2,5-[(NalphaMe)D-Nal8,IAmp9]SRIF DMQPVGO TI TTIND6G DMQPVGO TN Somatostatin receptor type 1 (SSTR1) DMQPVGO MA Inhibitor DMQPVGO RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMQPVGO RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMQR6ZX DI DMQR6ZX DMQR6ZX DN L-054,522 DMQR6ZX TI TTZ6T9E DMQR6ZX TN Somatostatin receptor type 2 (SSTR2) DMQR6ZX MA Agonist DMQR6ZX RN Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41. DMQR6ZX RU https://pubmed.ncbi.nlm.nih.gov/9724791 DMQR7TZ DI DMQR7TZ DMQR7TZ DN GSK-3beta inhibitor II DMQR7TZ TI TTRSMW9 DMQR7TZ TN Glycogen synthase kinase-3 beta (GSK-3B) DMQR7TZ MA Inhibitor DMQR7TZ RN Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. Bioorg Med Chem Lett. 2002 Jun 3;12(11):1525-8. DMQR7TZ RU https://pubmed.ncbi.nlm.nih.gov/12031334 DMQRE5D DI DMQRE5D DMQRE5D DN N-(6-methylpyridin-2-yl)-5-phenylpicolinamide DMQRE5D TI TTHS256 DMQRE5D TN Metabotropic glutamate receptor 5 (mGluR5) DMQRE5D MA Inhibitor DMQRE5D RN Design and synthesis of novel heterobiaryl amides as metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Apr 1;17(7):2074-9. DMQRE5D RU https://pubmed.ncbi.nlm.nih.gov/17336520 DMQREP2 DI DMQREP2 DMQREP2 DN Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMQREP2 TI TT27RFC DMQREP2 TN Opioid receptor delta (OPRD1) DMQREP2 MA Inhibitor DMQREP2 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMQREP2 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMQREP2 DI DMQREP2 DMQREP2 DN Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMQREP2 TI TTCG0AL DMQREP2 TN Cholecystokinin receptor type A (CCKAR) DMQREP2 MA Inhibitor DMQREP2 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMQREP2 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMQREP2 DI DMQREP2 DMQREP2 DN Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMQREP2 TI TTVFO0U DMQREP2 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMQREP2 MA Inhibitor DMQREP2 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMQREP2 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMQREP2 DI DMQREP2 DMQREP2 DN Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 DMQREP2 TI TTKWM86 DMQREP2 TN Opioid receptor mu (MOP) DMQREP2 MA Inhibitor DMQREP2 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMQREP2 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMQRKZO DI DMQRKZO DMQRKZO DN 1-Ethylidenethiosemicarbazide DMQRKZO TI TTULVH8 DMQRKZO TN Tyrosinase (TYR) DMQRKZO MA Inhibitor DMQRKZO RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMQRKZO RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMQROC3 DI DMQROC3 DMQROC3 DN ML380 DMQROC3 TI TTOXS3C DMQROC3 TN Muscarinic acetylcholine receptor (CHRM) DMQROC3 MA Modulator (allosteric modulator) DMQROC3 RN Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380). J Med Chem. 2014 Sep 25;57(18):7804-10. DMQROC3 RU https://pubmed.ncbi.nlm.nih.gov/25147929 DMQRP32 DI DMQRP32 DMQRP32 DN ISIS 103473 DMQRP32 TI TT1GV6C DMQRP32 TN DUSP9 messenger RNA (DUSP9 mRNA) DMQRP32 RN US patent application no. 6,566,133, Antisense inhibition of dual specific phosphatase 9 expression. DMQRP32 RU http://www.patentbuddy.com/Patent/6566133?ft=true&sr=true DMQRSP7 DI DMQRSP7 DMQRSP7 DN [11C]MMTP DMQRSP7 TI TTVBPDM DMQRSP7 TN Metabotropic glutamate receptor 1 (mGluR1) DMQRSP7 MA Modulator (allosteric modulator) DMQRSP7 RN Synthesis, in vitro and in vivo evaluation of [11C]MMTP: a potential PET ligand for mGluR1 receptors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3499-501. DMQRSP7 RU https://pubmed.ncbi.nlm.nih.gov/20494576 DMQRUF6 DI DMQRUF6 DMQRUF6 DN Des-AA1,2,5-[IAmp9,Tyr11]-SRIF DMQRUF6 TI TTAE1BR DMQRUF6 TN Somatostatin receptor type 4 (SSTR4) DMQRUF6 MA Inhibitor DMQRUF6 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMQRUF6 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMQRUF6 DI DMQRUF6 DMQRUF6 DN Des-AA1,2,5-[IAmp9,Tyr11]-SRIF DMQRUF6 TI TTIND6G DMQRUF6 TN Somatostatin receptor type 1 (SSTR1) DMQRUF6 MA Inhibitor DMQRUF6 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMQRUF6 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMQRZX8 DI DMQRZX8 DMQRZX8 DN ISIS 191756 DMQRZX8 TI TT0GV3R DMQRZX8 TN DGAT1 messenger RNA (DGAT1 mRNA) DMQRZX8 RN US patent application no. 7,414,033, Modulation of diacylglycerol acyltransferase 1 expression. DMQRZX8 RU http://www.patentbuddy.com/Patent/7414033?ft=true&sr=true DMQS7BT DI DMQS7BT DMQS7BT DN WFwGG-NH2 DMQS7BT TI TTWDC17 DMQS7BT TN Growth hormone secretagogue receptor 1 (GHSR) DMQS7BT MA Inhibitor DMQS7BT RN Identification of an efficacy switch region in the ghrelin receptor responsible for interchange between agonism and inverse agonism. J Biol Chem. 2007 May 25;282(21):15799-811. DMQS7BT RU https://pubmed.ncbi.nlm.nih.gov/17371869 DMQS8VE DI DMQS8VE DMQS8VE DN 2-methoxyphenyl 10H-phenothiazine-10-carboxylate DMQS8VE TI TTEB0GD DMQS8VE TN Cholinesterase (BCHE) DMQS8VE MA Inhibitor DMQS8VE RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMQS8VE RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMQS9OH DI DMQS9OH DMQS9OH DN N-(4-phenylsulfamoyl-naphthalen-1-yl)-benzamide DMQS9OH TI TTE836A DMQS9OH TN C-C chemokine receptor type 8 (CCR8) DMQS9OH MA Inhibitor DMQS9OH RN Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8. J Med Chem. 2007 Feb 8;50(3):566-84. DMQS9OH RU https://pubmed.ncbi.nlm.nih.gov/17266208 DMQSC21 DI DMQSC21 DMQSC21 DN (S)-DHPA DMQSC21 TI TTM2AOE DMQSC21 TN Adenosine A2a receptor (ADORA2A) DMQSC21 MA Inhibitor DMQSC21 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMQSC21 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMQSDM7 DI DMQSDM7 DMQSDM7 DN FLUANISONE DMQSDM7 TI TTNGILX DMQSDM7 TN Adrenergic receptor alpha-1A (ADRA1A) DMQSDM7 MA Inhibitor DMQSDM7 RN 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104. DMQSDM7 RU https://pubmed.ncbi.nlm.nih.gov/2889830 DMQSDM7 DI DMQSDM7 DMQSDM7 DN FLUANISONE DMQSDM7 TI TTBRKXS DMQSDM7 TN Adrenergic receptor alpha-1B (ADRA1B) DMQSDM7 MA Inhibitor DMQSDM7 RN 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104. DMQSDM7 RU https://pubmed.ncbi.nlm.nih.gov/2889830 DMQSDM7 DI DMQSDM7 DMQSDM7 DN FLUANISONE DMQSDM7 TI TTJQOD7 DMQSDM7 TN 5-HT 2A receptor (HTR2A) DMQSDM7 MA Inhibitor DMQSDM7 RN 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104. DMQSDM7 RU https://pubmed.ncbi.nlm.nih.gov/2889830 DMQSDM7 DI DMQSDM7 DMQSDM7 DN FLUANISONE DMQSDM7 TI TTEX248 DMQSDM7 TN Dopamine D2 receptor (D2R) DMQSDM7 MA Inhibitor DMQSDM7 RN 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104. DMQSDM7 RU https://pubmed.ncbi.nlm.nih.gov/2889830 DMQSDM7 DI DMQSDM7 DMQSDM7 DN FLUANISONE DMQSDM7 TI TT34BHT DMQSDM7 TN Adrenergic receptor alpha-1D (ADRA1D) DMQSDM7 MA Inhibitor DMQSDM7 RN 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. J Med Chem. 1987 Nov;30(11):2099-104. DMQSDM7 RU https://pubmed.ncbi.nlm.nih.gov/2889830 DMQSEF6 DI DMQSEF6 DMQSEF6 DN 1-(1-(thiophen-2-yl)ethylidene)thiosemicarbazide DMQSEF6 TI TTULVH8 DMQSEF6 TN Tyrosinase (TYR) DMQSEF6 MA Inhibitor DMQSEF6 RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DMQSEF6 RU https://pubmed.ncbi.nlm.nih.gov/18326070 DMQSG6Y DI DMQSG6Y DMQSG6Y DN [Mpa1, D-Tyr(Et)2, Aib7]OT DMQSG6Y TI TTSCIUP DMQSG6Y TN Oxytocin receptor (OTR) DMQSG6Y MA Inhibitor DMQSG6Y RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMQSG6Y RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMQSK3H DI DMQSK3H DMQSK3H DN 1-benzhydryl-3-(isoquinolin-5-yl)urea DMQSK3H TI TTMI6F5 DMQSK3H TN Transient receptor potential cation channel V1 (TRPV1) DMQSK3H MA Inhibitor DMQSK3H RN Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9. DMQSK3H RU https://pubmed.ncbi.nlm.nih.gov/17507218 DMQSLJI DI DMQSLJI DMQSLJI DN N-(1-(4-phenylbutyl)piperidin-4-yl)-1-naphthamide DMQSLJI TI TTJQOD7 DMQSLJI TN 5-HT 2A receptor (HTR2A) DMQSLJI MA Inhibitor DMQSLJI RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9. DMQSLJI RU https://pubmed.ncbi.nlm.nih.gov/17254782 DMQSO7V DI DMQSO7V DMQSO7V DN THA-904 DMQSO7V TI TTVMWLP DMQSO7V TN Acid-sensing ion channel 2 (ASIC2) DMQSO7V MA Antagonist DMQSO7V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 685). DMQSO7V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=685 DMQSRPD DI DMQSRPD DMQSRPD DN H-Dmt-Tic-Glu-Dap(6DMN)-NH(2) DMQSRPD TI TT27RFC DMQSRPD TN Opioid receptor delta (OPRD1) DMQSRPD MA Inhibitor DMQSRPD RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DMQSRPD RU https://pubmed.ncbi.nlm.nih.gov/16759107 DMQSRPD DI DMQSRPD DMQSRPD DN H-Dmt-Tic-Glu-Dap(6DMN)-NH(2) DMQSRPD TI TTKWM86 DMQSRPD TN Opioid receptor mu (MOP) DMQSRPD MA Inhibitor DMQSRPD RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DMQSRPD RU https://pubmed.ncbi.nlm.nih.gov/16759107 DMQSTYZ DI DMQSTYZ DMQSTYZ DN 24-ethyl-cholest-7-ene-3,5,6-triol DMQSTYZ TI TT1RS9F DMQSTYZ TN Acetylcholinesterase (AChE) DMQSTYZ MA Inhibitor DMQSTYZ RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMQSTYZ RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMQSTYZ DI DMQSTYZ DMQSTYZ DN 24-ethyl-cholest-7-ene-3,5,6-triol DMQSTYZ TI TTEB0GD DMQSTYZ TN Cholinesterase (BCHE) DMQSTYZ MA Inhibitor DMQSTYZ RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMQSTYZ RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMQSWO8 DI DMQSWO8 DMQSWO8 DN N-Hydroxy-4-oxo-4-(4-phenoxy-phenyl)-butyramide DMQSWO8 TI TTMX39J DMQSWO8 TN Matrix metalloproteinase-1 (MMP-1) DMQSWO8 MA Inhibitor DMQSWO8 RN Receptor flexibility in de novo ligand design and docking. J Med Chem. 2005 Oct 20;48(21):6585-96. DMQSWO8 RU https://pubmed.ncbi.nlm.nih.gov/16220975 DMQT15Z DI DMQT15Z DMQT15Z DN (E)-8-(3-chlorostyryl)-caffeine DMQT15Z TI TTJFY5U DMQT15Z TN Adenosine A3 receptor (ADORA3) DMQT15Z MA Antagonist DMQT15Z RN A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol. 1994 Jun;45(6):1101-11. DMQT15Z RU https://pubmed.ncbi.nlm.nih.gov/8022403 DMQT15Z DI DMQT15Z DMQT15Z DN (E)-8-(3-chlorostyryl)-caffeine DMQT15Z TI TTK25J1 DMQT15Z TN Adenosine A1 receptor (ADORA1) DMQT15Z MA Antagonist DMQT15Z RN Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. J Med Chem. 1993 May 14;36(10):1333-42. DMQT15Z RU https://pubmed.ncbi.nlm.nih.gov/8496902 DMQT15Z DI DMQT15Z DMQT15Z DN (E)-8-(3-chlorostyryl)-caffeine DMQT15Z TI TTNE7KG DMQT15Z TN Adenosine A2b receptor (ADORA2B) DMQT15Z MA Antagonist DMQT15Z RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 20). DMQT15Z RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=20 DMQT15Z DI DMQT15Z DMQT15Z DN (E)-8-(3-chlorostyryl)-caffeine DMQT15Z TI TTGP7BY DMQT15Z TN Monoamine oxidase type B (MAO-B) DMQT15Z MA Inhibitor DMQT15Z RN Synthesis and in vitro evaluation of pteridine analogues as monoamine oxidase B and nitric oxide synthase inhibitors. Bioorg Med Chem. 2009 Nov 1;17(21):7523-30. DMQT15Z RU https://pubmed.ncbi.nlm.nih.gov/19804982 DMQT3WJ DI DMQT3WJ DMQT3WJ DN CHLORODEOXYURIDINE DMQT3WJ TI TT5B8AX DMQT3WJ TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMQT3WJ MA Inhibitor DMQT3WJ RN Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial ac... Bioorg Med Chem. 2008 Jun 1;16(11):6075-85. DMQT3WJ RU https://pubmed.ncbi.nlm.nih.gov/18467107 DMQT6AH DI DMQT6AH DMQT6AH DN U-89267 DMQT6AH TI TT1MPAY DMQT6AH TN GABA(A) receptor alpha-1 (GABRA1) DMQT6AH MA Inhibitor DMQT6AH RN Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68. DMQT6AH RU https://pubmed.ncbi.nlm.nih.gov/8145225 DMQT6AH DI DMQT6AH DMQT6AH DN U-89267 DMQT6AH TI TT06RH5 DMQT6AH TN GABA(A) receptor gamma-2 (GABRG2) DMQT6AH MA Inhibitor DMQT6AH RN Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68. DMQT6AH RU https://pubmed.ncbi.nlm.nih.gov/8145225 DMQT6AH DI DMQT6AH DMQT6AH DN U-89267 DMQT6AH TI TTNJYV2 DMQT6AH TN Gamma-aminobutyric acid receptor (GAR) DMQT6AH MA Inhibitor DMQT6AH RN Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68. DMQT6AH RU https://pubmed.ncbi.nlm.nih.gov/8145225 DMQT6AH DI DMQT6AH DMQT6AH DN U-89267 DMQT6AH TI TTZA1NY DMQT6AH TN GABA(A) receptor beta-2 (GABRB2) DMQT6AH MA Inhibitor DMQT6AH RN Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the GABAA/benzodiazepine receptor. J Med Chem. 1994 Mar 18;37(6):758-68. DMQT6AH RU https://pubmed.ncbi.nlm.nih.gov/8145225 DMQT9OK DI DMQT9OK DMQT9OK DN 2-Piperazin-1-yl-phenol DMQT9OK TI TT6MSOK DMQT9OK TN 5-HT 1D receptor (HTR1D) DMQT9OK MA Inhibitor DMQT9OK RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMQT9OK RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMQT9OK DI DMQT9OK DMQT9OK DN 2-Piperazin-1-yl-phenol DMQT9OK TI TTJQOD7 DMQT9OK TN 5-HT 2A receptor (HTR2A) DMQT9OK MA Inhibitor DMQT9OK RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMQT9OK RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMQT9OK DI DMQT9OK DMQT9OK DN 2-Piperazin-1-yl-phenol DMQT9OK TI TTSQIFT DMQT9OK TN 5-HT 1A receptor (HTR1A) DMQT9OK MA Inhibitor DMQT9OK RN Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents. J Med Chem. 1986 May;29(5):630-4. DMQT9OK RU https://pubmed.ncbi.nlm.nih.gov/3701781 DMQTBRM DI DMQTBRM DMQTBRM DN [3H]CGP27492 DMQTBRM TI TT1MPAY DMQTBRM TN GABA(A) receptor alpha-1 (GABRA1) DMQTBRM MA Inhibitor DMQTBRM RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DMQTBRM RU https://pubmed.ncbi.nlm.nih.gov/7650684 DMQTBRM DI DMQTBRM DMQTBRM DN [3H]CGP27492 DMQTBRM TI TTDCVZW DMQTBRM TN Gamma-aminobutyric acid B receptor (GABBR) DMQTBRM MA Inhibitor DMQTBRM RN Biological activity of 3-aminopropyl (methyl) phosphinic acid, a potent and selective GABAB agonist with CNS activity, Bioorg. Med. Chem. Lett. 3(4):515-518 (1993). DMQTBRM RU http://www.sciencedirect.com/science/article/pii/S0960894X0181218X DMQTBRM DI DMQTBRM DMQTBRM DN [3H]CGP27492 DMQTBRM TI TTNJYV2 DMQTBRM TN Gamma-aminobutyric acid receptor (GAR) DMQTBRM MA Inhibitor DMQTBRM RN Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists. J Med Chem. 1995 Aug 18;38(17):3297-312. DMQTBRM RU https://pubmed.ncbi.nlm.nih.gov/7650684 DMQTEDP DI DMQTEDP DMQTEDP DN ETHIOFENCARB DMQTEDP TI TTLUQ8E DMQTEDP TN Hormone sensitive lipase (LIPE) DMQTEDP MA Inhibitor DMQTEDP RN Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94. DMQTEDP RU https://pubmed.ncbi.nlm.nih.gov/18808096 DMQTEPY DI DMQTEPY DMQTEPY DN 9-Propyl-9H-adenine DMQTEPY TI TTM2AOE DMQTEPY TN Adenosine A2a receptor (ADORA2A) DMQTEPY MA Inhibitor DMQTEPY RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMQTEPY RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMQTEPY DI DMQTEPY DMQTEPY DN 9-Propyl-9H-adenine DMQTEPY TI TTNE7KG DMQTEPY TN Adenosine A2b receptor (ADORA2B) DMQTEPY MA Inhibitor DMQTEPY RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMQTEPY RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMQTEPY DI DMQTEPY DMQTEPY DN 9-Propyl-9H-adenine DMQTEPY TI TTK25J1 DMQTEPY TN Adenosine A1 receptor (ADORA1) DMQTEPY MA Inhibitor DMQTEPY RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMQTEPY RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMQTHV7 DI DMQTHV7 DMQTHV7 DN 6,7-dimethoxy-4-(2-phenylethynyl)quinazoline DMQTHV7 TI TTGKNB4 DMQTHV7 TN Epidermal growth factor receptor (EGFR) DMQTHV7 MA Inhibitor DMQTHV7 RN Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. DMQTHV7 RU https://pubmed.ncbi.nlm.nih.gov/17869510 DMQTPX2 DI DMQTPX2 DMQTPX2 DN 1,2-bis(3,5-difluorophenyl)-2-hydroxyethanone DMQTPX2 TI TTMF541 DMQTPX2 TN Liver carboxylesterase (CES1) DMQTPX2 MA Inhibitor DMQTPX2 RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMQTPX2 RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMQU2SV DI DMQU2SV DMQU2SV DN JWH-202 DMQU2SV TI TTMSFAW DMQU2SV TN Cannabinoid receptor 2 (CB2) DMQU2SV MA Inhibitor DMQU2SV RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMQU2SV RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMQU4XM DI DMQU4XM DMQU4XM DN 7,8-dihydrobiopterin DMQU4XM TI TTF10I9 DMQU4XM TN Nitric-oxide synthase inducible (NOS2) DMQU4XM MA Inhibitor DMQU4XM RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMQU4XM RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMQU4XM DI DMQU4XM DMQU4XM DN 7,8-dihydrobiopterin DMQU4XM TI TTG9CFY DMQU4XM TN Bacterial Dihydroneopterinaldolase (Bact folB) DMQU4XM MA Inhibitor DMQU4XM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQU4XM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQU4XM DI DMQU4XM DMQU4XM DN 7,8-dihydrobiopterin DMQU4XM TI TTUHP71 DMQU4XM TN Tyrosine 3-monooxygenase (TH) DMQU4XM MA Inhibitor DMQU4XM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQU4XM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQU9VD DI DMQU9VD DMQU9VD DN Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine DMQU9VD TI TTVG215 DMQU9VD TN Debrisoquine 4-hydroxylase (CYP2D6) DMQU9VD MA Inhibitor DMQU9VD RN 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39. DMQU9VD RU https://pubmed.ncbi.nlm.nih.gov/15634016 DMQU9VD DI DMQU9VD DMQU9VD DN Methyl-(5-pyridin-3-yl-thiophen-2-yl)-amine DMQU9VD TI TTXV4FI DMQU9VD TN Albendazole monooxygenase (CYP3A4) DMQU9VD MA Inhibitor DMQU9VD RN 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39. DMQU9VD RU https://pubmed.ncbi.nlm.nih.gov/15634016 DMQUAP2 DI DMQUAP2 DMQUAP2 DN 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine DMQUAP2 TI TTAWNKZ DMQUAP2 TN Norepinephrine transporter (NET) DMQUAP2 MA Inhibitor DMQUAP2 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMQUAP2 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMQUAP2 DI DMQUAP2 DMQUAP2 DN 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine DMQUAP2 TI TTSQIFT DMQUAP2 TN 5-HT 1A receptor (HTR1A) DMQUAP2 MA Inhibitor DMQUAP2 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMQUAP2 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMQUAP2 DI DMQUAP2 DMQUAP2 DN 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine DMQUAP2 TI TT3ROYC DMQUAP2 TN Serotonin transporter (SERT) DMQUAP2 MA Inhibitor DMQUAP2 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMQUAP2 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMQUAP2 DI DMQUAP2 DMQUAP2 DN 4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine DMQUAP2 TI TTVBI8W DMQUAP2 TN Dopamine transporter (DAT) DMQUAP2 MA Inhibitor DMQUAP2 RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMQUAP2 RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMQUB19 DI DMQUB19 DMQUB19 DN Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH DMQUB19 TI TT27RFC DMQUB19 TN Opioid receptor delta (OPRD1) DMQUB19 MA Inhibitor DMQUB19 RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMQUB19 RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMQUB19 DI DMQUB19 DMQUB19 DN Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH DMQUB19 TI TTQW87Y DMQUB19 TN Opioid receptor kappa (OPRK1) DMQUB19 MA Inhibitor DMQUB19 RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMQUB19 RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMQUB19 DI DMQUB19 DMQUB19 DN Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH DMQUB19 TI TTKWM86 DMQUB19 TN Opioid receptor mu (MOP) DMQUB19 MA Inhibitor DMQUB19 RN Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42. DMQUB19 RU https://pubmed.ncbi.nlm.nih.gov/17539621 DMQUDA9 DI DMQUDA9 DMQUDA9 DN 2-chloroadenosine-5-triphosphate DMQUDA9 TI TTA93TL DMQUDA9 TN P2Y purinoceptor 1 (P2RY1) DMQUDA9 MA Antagonist DMQUDA9 RN ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol. 1998 Apr;53(4):727-33. DMQUDA9 RU https://pubmed.ncbi.nlm.nih.gov/9547364 DMQUDR1 DI DMQUDR1 DMQUDR1 DN 3-[(2-methyl-4-thiazolyl)ethynyl]benzonitrile DMQUDR1 TI TTHS256 DMQUDR1 TN Metabotropic glutamate receptor 5 (mGluR5) DMQUDR1 MA Inhibitor DMQUDR1 RN Discovery of novel modulators of metabotropic glutamate receptor subtype-5. Bioorg Med Chem. 2004 Jan 2;12(1):17-21. DMQUDR1 RU https://pubmed.ncbi.nlm.nih.gov/14697765 DMQUG0K DI DMQUG0K DMQUG0K DN PS-154636-1 DMQUG0K TI TTXMNHO DMQUG0K TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMQUG0K MA Inhibitor DMQUG0K RN Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20. DMQUG0K RU https://pubmed.ncbi.nlm.nih.gov/9873534 DMQUKBG DI DMQUKBG DMQUKBG DN CARCININE DMQUKBG TI TT9JNIC DMQUKBG TN Histamine H3 receptor (H3R) DMQUKBG MA Inhibitor DMQUKBG RN The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem. 2008 Sep 11;51(17):5423-30. DMQUKBG RU https://pubmed.ncbi.nlm.nih.gov/18683917 DMQUNGC DI DMQUNGC DMQUNGC DN H-Tyr-Pro-Dap(6DMN)-Phe-NH2 DMQUNGC TI TTKWM86 DMQUNGC TN Opioid receptor mu (MOP) DMQUNGC MA Inhibitor DMQUNGC RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DMQUNGC RU https://pubmed.ncbi.nlm.nih.gov/16759107 DMQUNGC DI DMQUNGC DMQUNGC DN H-Tyr-Pro-Dap(6DMN)-Phe-NH2 DMQUNGC TI TT27RFC DMQUNGC TN Opioid receptor delta (OPRD1) DMQUNGC MA Inhibitor DMQUNGC RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DMQUNGC RU https://pubmed.ncbi.nlm.nih.gov/16759107 DMQUP7O DI DMQUP7O DMQUP7O DN Glyoxalate, Glyoxylate DMQUP7O TI TT58ZYW DMQUP7O TN Mycobacterium Isocitrate lyase (MycB icl) DMQUP7O MA Inhibitor DMQUP7O RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQUP7O RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQUSXK DI DMQUSXK DMQUSXK DN PTI-601 DMQUSXK TI TTKWM86 DMQUSXK TN Opioid receptor mu (MOP) DMQUSXK MA Modulator DMQUSXK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMQUSXK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMQUSXK DI DMQUSXK DMQUSXK DN PTI-601 DMQUSXK TI TTAWNKZ DMQUSXK TN Norepinephrine transporter (NET) DMQUSXK MA Inhibitor DMQUSXK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DMQUSXK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DMQUY08 DI DMQUY08 DMQUY08 DN [125I]DOI DMQUY08 TI TTJQOD7 DMQUY08 TN 5-HT 2A receptor (HTR2A) DMQUY08 MA Agonist DMQUY08 RN Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10. DMQUY08 RU https://pubmed.ncbi.nlm.nih.gov/11101361 DMQUY08 DI DMQUY08 DMQUY08 DN [125I]DOI DMQUY08 TI TT0K1SC DMQUY08 TN 5-HT 2B receptor (HTR2B) DMQUY08 MA Agonist DMQUY08 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7). DMQUY08 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7 DMQUY08 DI DMQUY08 DMQUY08 DN [125I]DOI DMQUY08 TI TTWJBZ5 DMQUY08 TN 5-HT 2C receptor (HTR2C) DMQUY08 MA Agonist DMQUY08 RN High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34. DMQUY08 RU https://pubmed.ncbi.nlm.nih.gov/10217294 DMQUZSJ DI DMQUZSJ DMQUZSJ DN 8-(2-methylpropyl)naringenin DMQUZSJ TI TTOM3J0 DMQUZSJ TN Estrogen receptor beta (ESR2) DMQUZSJ MA Inhibitor DMQUZSJ RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMQUZSJ RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMQUZSJ DI DMQUZSJ DMQUZSJ DN 8-(2-methylpropyl)naringenin DMQUZSJ TI TTZAYWL DMQUZSJ TN Estrogen receptor (ESR) DMQUZSJ MA Inhibitor DMQUZSJ RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMQUZSJ RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMQV974 DI DMQV974 DMQV974 DN L-372662 DMQV974 TI TTSCIUP DMQV974 TN Oxytocin receptor (OTR) DMQV974 MA Inhibitor DMQV974 RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DMQV974 RU https://pubmed.ncbi.nlm.nih.gov/20550119 DMQV974 DI DMQV974 DMQV974 DN L-372662 DMQV974 TI TT4TFGN DMQV974 TN Vasopressin V1a receptor (V1AR) DMQV974 MA Inhibitor DMQV974 RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DMQV974 RU https://pubmed.ncbi.nlm.nih.gov/20550119 DMQV974 DI DMQV974 DMQV974 DN L-372662 DMQV974 TI TTK8R02 DMQV974 TN Vasopressin V2 receptor (V2R) DMQV974 MA Inhibitor DMQV974 RN Oral oxytocin antagonists. J Med Chem. 2010 Sep 23;53(18):6525-38. DMQV974 RU https://pubmed.ncbi.nlm.nih.gov/20550119 DMQVF41 DI DMQVF41 DMQVF41 DN LY-593039 DMQVF41 TI TTZ9SOR DMQVF41 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMQVF41 MA Agonist DMQVF41 RN Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol. 2009 Mar 1;605(1-3):53-6. DMQVF41 RU https://pubmed.ncbi.nlm.nih.gov/19168056 DMQVFWJ DI DMQVFWJ DMQVFWJ DN Para-Mercury-Benzenesulfonic Acid DMQVFWJ TI TTOM3J0 DMQVFWJ TN Estrogen receptor beta (ESR2) DMQVFWJ MA Inhibitor DMQVFWJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQVFWJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQVH3J DI DMQVH3J DMQVH3J DN Trisnorsqualene alcohol DMQVH3J TI TTE14XG DMQVH3J TN Squalene monooxygenase (SQLE) DMQVH3J MA Inhibitor DMQVH3J RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMQVH3J RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMQVI5U DI DMQVI5U DMQVI5U DN PS-222036 DMQVI5U TI TTXMNHO DMQVI5U TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMQVI5U MA Inhibitor DMQVI5U RN Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20. DMQVI5U RU https://pubmed.ncbi.nlm.nih.gov/9873534 DMQVL2U DI DMQVL2U DMQVL2U DN BUDLEIN A DMQVL2U TI TTSXVID DMQVL2U TN Nuclear factor NF-kappa-B (NFKB) DMQVL2U MA Inhibitor DMQVL2U RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DMQVL2U RU https://pubmed.ncbi.nlm.nih.gov/15537359 DMQVOSU DI DMQVOSU DMQVOSU DN 4-(1H-indol-4-yloxy)-1-(isopropylamino)butan-2-ol DMQVOSU TI TTSQIFT DMQVOSU TN 5-HT 1A receptor (HTR1A) DMQVOSU MA Inhibitor DMQVOSU RN Indoloxypropanolamine analogues as 5-HT(1A) receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5600-4. DMQVOSU RU https://pubmed.ncbi.nlm.nih.gov/17804228 DMQVPK9 DI DMQVPK9 DMQVPK9 DN N-(4,6-diphenylpyrimidin-2-yl)-3-chlorobenzamide DMQVPK9 TI TTK25J1 DMQVPK9 TN Adenosine A1 receptor (ADORA1) DMQVPK9 MA Inhibitor DMQVPK9 RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMQVPK9 RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMQVRHG DI DMQVRHG DMQVRHG DN Bbs-Arg-(D-Pip)-Gly-(SPHYEKVS)-Gly-Hir DMQVRHG TI TT6L509 DMQVRHG TN Coagulation factor IIa (F2) DMQVRHG MA Inhibitor DMQVRHG RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMQVRHG RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMQVUZP DI DMQVUZP DMQVUZP DN 2-(4-bromo-2-formylphenoxy)acetic acid DMQVUZP TI TTQDMX5 DMQVUZP TN Prostaglandin D2 receptor 2 (PTGDR2) DMQVUZP MA Inhibitor DMQVUZP RN Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41. DMQVUZP RU https://pubmed.ncbi.nlm.nih.gov/17154491 DMQVW4E DI DMQVW4E DMQVW4E DN [125I]CGP 71872 DMQVW4E TI TTDCVZW DMQVW4E TN Gamma-aminobutyric acid B receptor (GABBR) DMQVW4E MA Antagonist DMQVW4E RN Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46. DMQVW4E RU https://pubmed.ncbi.nlm.nih.gov/9069281 DMQVXMZ DI DMQVXMZ DMQVXMZ DN 4-(3-chlorobenzylthio)-2-aminobutanoic acid DMQVXMZ TI TTFK1JQ DMQVXMZ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMQVXMZ MA Inhibitor DMQVXMZ RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMQVXMZ RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMQW3A9 DI DMQW3A9 DMQW3A9 DN [3H]naltrindole DMQW3A9 TI TT27RFC DMQW3A9 TN Opioid receptor delta (OPRD1) DMQW3A9 MA Antagonist DMQW3A9 RN Characterization of [3H]naltrindole binding to delta opioid receptors in rat brain. Life Sci. 1992;50(16):PL119-24. DMQW3A9 RU https://pubmed.ncbi.nlm.nih.gov/1313133 DMQW612 DI DMQW612 DMQW612 DN Ad5f35-LMPd1-2-transduced autologous dendritic cells DMQW612 TI TT0BI4Q DMQW612 TN Epstein-Barr virus Latent membrane protein 1 (EBV LMP1) DMQW612 RN CA patent application no. 876139, Nanotherapeutics for drug targeting. DMQW612 RU http://www.google.com/patents/CA2876139A1?cl=en DMQW612 DI DMQW612 DMQW612 DN Ad5f35-LMPd1-2-transduced autologous dendritic cells DMQW612 TI TTBK351 DMQW612 TN Epstein-Barr virus Latent membrane protein 2 (EBV LMP2) DMQW612 RN CA patent application no. 876139, Nanotherapeutics for drug targeting. DMQW612 RU http://www.google.com/patents/CA2876139A1?cl=en DMQW7JZ DI DMQW7JZ DMQW7JZ DN N-hydroxy-7-oxo-7-phenylheptanamide DMQW7JZ TI TT6R7JZ DMQW7JZ TN Histone deacetylase 1 (HDAC1) DMQW7JZ MA Inhibitor DMQW7JZ RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMQW7JZ RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMQWD75 DI DMQWD75 DMQWD75 DN (2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine DMQWD75 TI TTDCBX5 DMQWD75 TN Vascular endothelial growth factor receptor 3 (FLT-4) DMQWD75 MA Inhibitor DMQWD75 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMQWD75 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMQWD75 DI DMQWD75 DMQWD75 DN (2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine DMQWD75 TI TT1VAUK DMQWD75 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMQWD75 MA Inhibitor DMQWD75 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMQWD75 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMQWD75 DI DMQWD75 DMQWD75 DN (2-Methoxy-phenyl)-(5-phenyl-oxazol-2-yl)-amine DMQWD75 TI TTUTJGQ DMQWD75 TN Vascular endothelial growth factor receptor 2 (KDR) DMQWD75 MA Inhibitor DMQWD75 RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMQWD75 RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMQWFO1 DI DMQWFO1 DMQWFO1 DN Phenethyl-(3-phenyl-propyl)-amine DMQWFO1 TI TTLD29N DMQWFO1 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMQWFO1 MA Inhibitor DMQWFO1 RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMQWFO1 RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMQWFO1 DI DMQWFO1 DMQWFO1 DN Phenethyl-(3-phenyl-propyl)-amine DMQWFO1 TI TTN9D8E DMQWFO1 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMQWFO1 MA Inhibitor DMQWFO1 RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMQWFO1 RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMQWHLM DI DMQWHLM DMQWHLM DN 4'-Demethyl-4beta-amino-4-desoxypodophyllotoxin DMQWHLM TI TT0IHXV DMQWHLM TN DNA topoisomerase II (TOP2) DMQWHLM MA Inhibitor DMQWHLM RN Antitumor agents, 107. New cytotoxic 4-alkylamino analogues of 4'-demethyl-epipodophyllotoxin as inhibitors of human DNA topoisomerase II. J Nat Prod. 1989 May-Jun;52(3):606-13. DMQWHLM RU https://pubmed.ncbi.nlm.nih.gov/2550587 DMQWIEL DI DMQWIEL DMQWIEL DN AP-2238 DMQWIEL TI TT1RS9F DMQWIEL TN Acetylcholinesterase (AChE) DMQWIEL MA Inhibitor DMQWIEL RN Targeting Alzheimer's disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238. Bioorg Med Chem. 2010 Mar 1;18(5):1749-60. DMQWIEL RU https://pubmed.ncbi.nlm.nih.gov/20171894 DMQWKPM DI DMQWKPM DMQWKPM DN L-375378 DMQWKPM TI TT6L509 DMQWKPM TN Coagulation factor IIa (F2) DMQWKPM MA Inhibitor DMQWKPM RN Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4. DMQWKPM RU https://pubmed.ncbi.nlm.nih.gov/12482415 DMQWKPM DI DMQWKPM DMQWKPM DN L-375378 DMQWKPM TI TT2WR1T DMQWKPM TN Cationic trypsinogen (PRSS1) DMQWKPM MA Inhibitor DMQWKPM RN Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4. DMQWKPM RU https://pubmed.ncbi.nlm.nih.gov/12482415 DMQWLIC DI DMQWLIC DMQWLIC DN Cylopentenyl cytosine DMQWLIC TI TTN12BZ DMQWLIC TN CTP synthase (CTPS1) DMQWLIC MA Inhibitor DMQWLIC RN Comments on: cylopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: a promising target for chemotherapy. A.C. Verschuur et al. Eur J Cancer 2000, 36, 627-635. Eur J Cancer. 2001 Jan;37(2):290. DMQWLIC RU https://pubmed.ncbi.nlm.nih.gov/11243234 DMQWOIG DI DMQWOIG DMQWOIG DN 5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine DMQWOIG TI TTZUFI5 DMQWOIG TN Nitric-oxide synthase brain (NOS1) DMQWOIG MA Inhibitor DMQWOIG RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMQWOIG RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMQWOIG DI DMQWOIG DMQWOIG DN 5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine DMQWOIG TI TTF10I9 DMQWOIG TN Nitric-oxide synthase inducible (NOS2) DMQWOIG MA Inhibitor DMQWOIG RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMQWOIG RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMQWOIG DI DMQWOIG DMQWOIG DN 5-Ethyl-4-methyl-pyrrolidin-(2Z)-ylideneamine DMQWOIG TI TTCM4B3 DMQWOIG TN Nitric-oxide synthase endothelial (NOS3) DMQWOIG MA Inhibitor DMQWOIG RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMQWOIG RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMQWOZ5 DI DMQWOZ5 DMQWOZ5 DN BC-264 DMQWOZ5 TI TTVFO0U DMQWOZ5 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMQWOZ5 MA Agonist DMQWOZ5 RN Synthesis and biological characterisation of [3H]BBL454, a new CCK2 selective radiolabelled agonist displaying original pharmacological properties. Bioorg Med Chem Lett. 2004 Jan 19;14(2):369-72. DMQWOZ5 RU https://pubmed.ncbi.nlm.nih.gov/14698161 DMQWR69 DI DMQWR69 DMQWR69 DN 2-NONYL-4-HYDROXYQUINOLINE N-OXIDE DMQWR69 TI TTRAMF0 DMQWR69 TN Plasmodium Cytochrome B (Malaria MT-CYB) DMQWR69 MA Inhibitor DMQWR69 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQWR69 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQWS6U DI DMQWS6U DMQWS6U DN KU-0060648 DMQWS6U TI TTTHBCA DMQWS6U TN PI3-kinase beta (PIK3CB) DMQWS6U MA Inhibitor DMQWS6U RN 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401. DMQWS6U RU https://pubmed.ncbi.nlm.nih.gov/23855836 DMQWS6U DI DMQWS6U DMQWS6U DN KU-0060648 DMQWS6U TI TTK3PY9 DMQWS6U TN DNA-dependent protein kinase catalytic (PRKDC) DMQWS6U MA Inhibitor DMQWS6U RN 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401. DMQWS6U RU https://pubmed.ncbi.nlm.nih.gov/23855836 DMQWS6U DI DMQWS6U DMQWS6U DN KU-0060648 DMQWS6U TI TTHBTOP DMQWS6U TN PI3-kinase gamma (PIK3CG) DMQWS6U MA Inhibitor DMQWS6U RN 1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity. J Med Chem. 2013 Aug 22;56(16):6386-401. DMQWS6U RU https://pubmed.ncbi.nlm.nih.gov/23855836 DMQX2GK DI DMQX2GK DMQX2GK DN FGGFTGCRKSCRK DMQX2GK TI TTNT7K8 DMQX2GK TN Nociceptin receptor (OPRL1) DMQX2GK MA Inhibitor DMQX2GK RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DMQX2GK RU https://pubmed.ncbi.nlm.nih.gov/11689089 DMQX37R DI DMQX37R DMQX37R DN 1-(4-Cyanobenzyl)-5-(4-methylphenyl)-1H-imidazole DMQX37R TI TTIQUX7 DMQX37R TN Steroid 11-beta-hydroxylase (CYP11B1) DMQX37R MA Inhibitor DMQX37R RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMQX37R RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMQX3V9 DI DMQX3V9 DMQX3V9 DN 5-Methoxyflavone DMQX3V9 TI TTKPW01 DMQX3V9 TN Androgen receptor messenger RNA (AR mRNA) DMQX3V9 MA Inhibitor DMQX3V9 RN Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4706-10. DMQX3V9 RU https://pubmed.ncbi.nlm.nih.gov/19592245 DMQX3W6 DI DMQX3W6 DMQX3W6 DN I-CBP112 DMQX3W6 TI TTFRCTK DMQX3W6 TN CREB-binding protein (CREBBP) DMQX3W6 MA Inhibitor DMQX3W6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2734). DMQX3W6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2734 DMQX3W6 DI DMQX3W6 DMQX3W6 DN I-CBP112 DMQX3W6 TI TTH4VJL DMQX3W6 TN Histone acetyltransferase KAT6B (KAT6B) DMQX3W6 MA Inhibitor DMQX3W6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2735). DMQX3W6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2735 DMQX7FW DI DMQX7FW DMQX7FW DN 2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone DMQX7FW TI TTW0CMT DMQX7FW TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMQX7FW MA Inhibitor DMQX7FW RN Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4. DMQX7FW RU https://pubmed.ncbi.nlm.nih.gov/17095219 DMQX9PD DI DMQX9PD DMQX9PD DN 2-Benzoxy-5-(2-methylquinolin-7-yl)benzonitrile DMQX9PD TI TTHS256 DMQX9PD TN Metabotropic glutamate receptor 5 (mGluR5) DMQX9PD MA Inhibitor DMQX9PD RN Structure-activity relationships in a novel series of 7-substituted-aryl quinolines and 5-substituted-aryl benzothiazoles at the metabotropic gluta... Bioorg Med Chem. 2010 May 1;18(9):3026-35. DMQX9PD RU https://pubmed.ncbi.nlm.nih.gov/20382541 DMQXCIK DI DMQXCIK DMQXCIK DN 2-phenyl-2H-pyrazolo[4,3-d]pyrimidin-7(6H)-one DMQXCIK TI TTJFY5U DMQXCIK TN Adenosine A3 receptor (ADORA3) DMQXCIK MA Inhibitor DMQXCIK RN 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into ... J Med Chem. 2009 Dec 10;52(23):7640-52. DMQXCIK RU https://pubmed.ncbi.nlm.nih.gov/19743865 DMQXD0N DI DMQXD0N DMQXD0N DN 3-Benzenesulfinyl-heptanoic acid hydroxyamide DMQXD0N TI TTMX39J DMQXD0N TN Matrix metalloproteinase-1 (MMP-1) DMQXD0N MA Inhibitor DMQXD0N RN Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents. J Med Chem. 2000 Jun 15;43(12):2324-31. DMQXD0N RU https://pubmed.ncbi.nlm.nih.gov/10882358 DMQXEHJ DI DMQXEHJ DMQXEHJ DN CSNLSTCVLGKLSQELc[DKLHO]YPRTNTGSGTP-amide DMQXEHJ TI TTLWS2O DMQXEHJ TN Calcitonin receptor (CALCR) DMQXEHJ MA Inhibitor DMQXEHJ RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMQXEHJ RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMQXJA1 DI DMQXJA1 DMQXJA1 DN 3-Benzimidazol-2-ylhydroquinolin-2-one DMQXJA1 TI TTUTJGQ DMQXJA1 TN Vascular endothelial growth factor receptor 2 (KDR) DMQXJA1 MA Inhibitor DMQXJA1 RN Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92. DMQXJA1 RU https://pubmed.ncbi.nlm.nih.gov/19113866 DMQXJA1 DI DMQXJA1 DMQXJA1 DN 3-Benzimidazol-2-ylhydroquinolin-2-one DMQXJA1 TI TTI7421 DMQXJA1 TN Platelet-derived growth factor receptor beta (PDGFRB) DMQXJA1 MA Inhibitor DMQXJA1 RN Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92. DMQXJA1 RU https://pubmed.ncbi.nlm.nih.gov/19113866 DMQXJA1 DI DMQXJA1 DMQXJA1 DN 3-Benzimidazol-2-ylhydroquinolin-2-one DMQXJA1 TI TTRLW2X DMQXJA1 TN Fibroblast growth factor receptor 1 (FGFR1) DMQXJA1 MA Inhibitor DMQXJA1 RN Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor... J Med Chem. 2009 Jan 22;52(2):278-92. DMQXJA1 RU https://pubmed.ncbi.nlm.nih.gov/19113866 DMQXK4B DI DMQXK4B DMQXK4B DN PMID19800804C12 DMQXK4B TI TTE2YJR DMQXK4B TN Lysophosphatidate-3 receptor (LPAR3) DMQXK4B MA Antagonist DMQXK4B RN Structure-based drug design identifies novel LPA3 antagonists. Bioorg Med Chem. 2009 Nov 1;17(21):7457-64. DMQXK4B RU https://pubmed.ncbi.nlm.nih.gov/19800804 DMQXL1Y DI DMQXL1Y DMQXL1Y DN 6-Imidazol-1-yl-isoquinoline DMQXL1Y TI TTSZLWK DMQXL1Y TN Aromatase (CYP19A1) DMQXL1Y MA Inhibitor DMQXL1Y RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMQXL1Y RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMQXL1Y DI DMQXL1Y DMQXL1Y DN 6-Imidazol-1-yl-isoquinoline DMQXL1Y TI TTKNWZ4 DMQXL1Y TN Thromboxane-A synthase (TBXAS1) DMQXL1Y MA Inhibitor DMQXL1Y RN 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51. DMQXL1Y RU https://pubmed.ncbi.nlm.nih.gov/10794700 DMQXMKB DI DMQXMKB DMQXMKB DN Beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide DMQXMKB TI TT6L509 DMQXMKB TN Coagulation factor IIa (F2) DMQXMKB MA Inhibitor DMQXMKB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQXMKB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQXO5G DI DMQXO5G DMQXO5G DN ALD-805 DMQXO5G TI TTNDSF4 DMQXO5G TN Proto-oncogene c-Met (MET) DMQXO5G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMQXO5G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMQXP7C DI DMQXP7C DMQXP7C DN 3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine DMQXP7C TI TTF10I9 DMQXP7C TN Nitric-oxide synthase inducible (NOS2) DMQXP7C MA Inhibitor DMQXP7C RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMQXP7C RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMQXP7C DI DMQXP7C DMQXP7C DN 3-Isobutyl-[1,4]thiazepan-(5E)-ylideneamine DMQXP7C TI TTZUFI5 DMQXP7C TN Nitric-oxide synthase brain (NOS1) DMQXP7C MA Inhibitor DMQXP7C RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMQXP7C RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMQXPA5 DI DMQXPA5 DMQXPA5 DN DNQX DMQXPA5 TI TTVPQTF DMQXPA5 TN Glutamate receptor AMPA 1 (GRIA1) DMQXPA5 MA Inhibitor DMQXPA5 RN Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8. DMQXPA5 RU https://pubmed.ncbi.nlm.nih.gov/8893837 DMQXPA5 DI DMQXPA5 DMQXPA5 DN DNQX DMQXPA5 TI TT0MYE2 DMQXPA5 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMQXPA5 MA Inhibitor DMQXPA5 RN Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8. DMQXPA5 RU https://pubmed.ncbi.nlm.nih.gov/8893837 DMQXPA5 DI DMQXPA5 DMQXPA5 DN DNQX DMQXPA5 TI TTN9D8E DMQXPA5 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMQXPA5 MA Inhibitor DMQXPA5 RN Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52. DMQXPA5 RU https://pubmed.ncbi.nlm.nih.gov/1826744 DMQXPA5 DI DMQXPA5 DMQXPA5 DN DNQX DMQXPA5 TI TTAN6JD DMQXPA5 TN Glutamate receptor AMPA (GRIA) DMQXPA5 MA Inhibitor DMQXPA5 RN Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8. DMQXPA5 RU https://pubmed.ncbi.nlm.nih.gov/8893837 DMQXPA5 DI DMQXPA5 DMQXPA5 DN DNQX DMQXPA5 TI TTKJEMQ DMQXPA5 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMQXPA5 MA Inhibitor DMQXPA5 RN Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52. DMQXPA5 RU https://pubmed.ncbi.nlm.nih.gov/1826744 DMQXPA5 DI DMQXPA5 DMQXPA5 DN DNQX DMQXPA5 TI TTLD29N DMQXPA5 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMQXPA5 MA Inhibitor DMQXPA5 RN Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antago... J Med Chem. 1991 Apr;34(4):1243-52. DMQXPA5 RU https://pubmed.ncbi.nlm.nih.gov/1826744 DMQXPM3 DI DMQXPM3 DMQXPM3 DN 3-(2-Aminoethyl)-4-(Aminomethyl)Heptanedioic Acid DMQXPM3 TI TTJHKYD DMQXPM3 TN Delta-aminolevulinic acid dehydratase (ALAD) DMQXPM3 MA Inhibitor DMQXPM3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMQXPM3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMQXPMB DI DMQXPMB DMQXPMB DN Trimethyl-(3-nitro-phenyl)-ammonium iodide DMQXPMB TI TT1RS9F DMQXPMB TN Acetylcholinesterase (AChE) DMQXPMB MA Inhibitor DMQXPMB RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMQXPMB RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMQXRCW DI DMQXRCW DMQXRCW DN PMID22490048C(R)-10h DMQXRCW TI TTX4RTB DMQXRCW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMQXRCW MA Antagonist DMQXRCW RN Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities. J Med Chem. 2012 May 10;55(9):4336-51. DMQXRCW RU https://pubmed.ncbi.nlm.nih.gov/22490048 DMQXUYH DI DMQXUYH DMQXUYH DN SD-208 DMQXUYH TI TTP4520 DMQXUYH TN TGF-beta receptor type I (TGFBR1) DMQXUYH MA Inhibitor DMQXUYH RN Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1843-9. DMQXUYH RU https://pubmed.ncbi.nlm.nih.gov/17289388 DMQXYE9 DI DMQXYE9 DMQXYE9 DN PD-158780 DMQXYE9 TI TTGKNB4 DMQXYE9 TN Epidermal growth factor receptor (EGFR) DMQXYE9 MA Inhibitor DMQXYE9 RN Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35. DMQXYE9 RU https://pubmed.ncbi.nlm.nih.gov/8627606 DMQY1ST DI DMQY1ST DMQY1ST DN KNI-10232 DMQY1ST TI TTXMNHO DMQY1ST TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMQY1ST MA Inhibitor DMQY1ST RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMQY1ST RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMQY2EA DI DMQY2EA DMQY2EA DN ISIS 222035 DMQY2EA TI TTWPA54 DMQY2EA TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMQY2EA RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMQY2EA RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMQY3L0 DI DMQY3L0 DMQY3L0 DN Sulforaphane DMQY3L0 TI TTH1ZOP DMQY3L0 TN Inactive rhomboid protein 2 (RHBDF2) DMQY3L0 RN p63 is a key regulator of iRHOM2 signalling in the keratinocyte stress response.Nat Commun. 2018 Mar 9;9(1):1021. DMQY3L0 RU https://pubmed.ncbi.nlm.nih.gov/29523849 DMQY50A DI DMQY50A DMQY50A DN 3,3-(1,3-Thiazole-2,5-diyl)diphenol DMQY50A TI TTIWB6L DMQY50A TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMQY50A MA Inhibitor DMQY50A RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DMQY50A RU https://pubmed.ncbi.nlm.nih.gov/18855374 DMQY50A DI DMQY50A DMQY50A DN 3,3-(1,3-Thiazole-2,5-diyl)diphenol DMQY50A TI TTXV4FI DMQY50A TN Albendazole monooxygenase (CYP3A4) DMQY50A MA Inhibitor DMQY50A RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DMQY50A RU https://pubmed.ncbi.nlm.nih.gov/18855374 DMQY75B DI DMQY75B DMQY75B DN 1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene DMQY75B TI TTE4KHA DMQY75B TN Amyloid beta A4 protein (APP) DMQY75B MA Inhibitor DMQY75B RN Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4. DMQY75B RU https://pubmed.ncbi.nlm.nih.gov/16640346 DMQYB7A DI DMQYB7A DMQYB7A DN ISIS 7849 DMQYB7A TI TTAN5W2 DMQYB7A TN Raf messenger RNA (Raf mRNA) DMQYB7A RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMQYB7A RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMQYCFI DI DMQYCFI DMQYCFI DN 2,2-dimethyl-2H-benzo[g]chromene-5,10-dione DMQYCFI TI TTZJYKH DMQYCFI TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMQYCFI MA Inhibitor DMQYCFI RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMQYCFI RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMQYEZP DI DMQYEZP DMQYEZP DN 2,3,4-tribromo-6-(2,4-dibromophenoxy)phenol DMQYEZP TI TTCFP0V DMQYEZP TN Glutamine amidotransferase (GMPS) DMQYEZP MA Inhibitor DMQYEZP RN Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. J Nat Prod. 1995 Sep;58(9):1384-91. DMQYEZP RU https://pubmed.ncbi.nlm.nih.gov/7494145 DMQYIBC DI DMQYIBC DMQYIBC DN 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one DMQYIBC TI TTIQUX7 DMQYIBC TN Steroid 11-beta-hydroxylase (CYP11B1) DMQYIBC MA Inhibitor DMQYIBC RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMQYIBC RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMQYIBC DI DMQYIBC DMQYIBC DN 5-Pyridin-3-yl-2,3-dihydro-1H-inden-1-one DMQYIBC TI TTSZLWK DMQYIBC TN Aromatase (CYP19A1) DMQYIBC MA Inhibitor DMQYIBC RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMQYIBC RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMQYJB1 DI DMQYJB1 DMQYJB1 DN 16-(2',2'-Dimethyl)-propylidene-estrone DMQYJB1 TI TTIWB6L DMQYJB1 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMQYJB1 MA Inhibitor DMQYJB1 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMQYJB1 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMQYRAB DI DMQYRAB DMQYRAB DN Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,5-diol DMQYRAB TI TTRA5BZ DMQYRAB TN Steroid 17-alpha-monooxygenase (S17AH) DMQYRAB MA Inhibitor DMQYRAB RN Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75. DMQYRAB RU https://pubmed.ncbi.nlm.nih.gov/19211174 DMQZ0A7 DI DMQZ0A7 DMQZ0A7 DN 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one DMQZ0A7 TI TTEB0GD DMQZ0A7 TN Cholinesterase (BCHE) DMQZ0A7 MA Inhibitor DMQZ0A7 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMQZ0A7 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMQZ0A7 DI DMQZ0A7 DMQZ0A7 DN 3-[5-(benzylmethylamino)pentyloxy]xanthen-9-one DMQZ0A7 TI TT1RS9F DMQZ0A7 TN Acetylcholinesterase (AChE) DMQZ0A7 MA Inhibitor DMQZ0A7 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMQZ0A7 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMQZ0D6 DI DMQZ0D6 DMQZ0D6 DN 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine DMQZ0D6 TI TTN9D8E DMQZ0D6 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMQZ0D6 MA Inhibitor DMQZ0D6 RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DMQZ0D6 RU https://pubmed.ncbi.nlm.nih.gov/10425109 DMQZ0D6 DI DMQZ0D6 DMQZ0D6 DN 4-Benzyl-1-(2-phenoxy-ethyl)-piperidine DMQZ0D6 TI TTLD29N DMQZ0D6 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMQZ0D6 MA Inhibitor DMQZ0D6 RN 4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1/2B NMDA receptor antagonist. J Med Chem. 1999 Jul 29;42(15):2993-3000. DMQZ0D6 RU https://pubmed.ncbi.nlm.nih.gov/10425109 DMQZ13A DI DMQZ13A DMQZ13A DN L-valyl-L-proline benzylamide DMQZ13A TI TTQ7R2V DMQZ13A TN Tripeptidyl-peptidase II (TPP2) DMQZ13A MA Inhibitor DMQZ13A RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMQZ13A RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMQZ7JD DI DMQZ7JD DMQZ7JD DN BAY-60-7550 DMQZ7JD TI TTJGW1Z DMQZ7JD TN Phosphodiesterase 2A (PDE2A) DMQZ7JD MA Inhibitor DMQZ7JD RN The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem. 2005 May 19;48(10):3449-62. DMQZ7JD RU https://pubmed.ncbi.nlm.nih.gov/15887951 DMQZC0U DI DMQZC0U DMQZC0U DN MCL-129 DMQZC0U TI TTD0CIQ DMQZC0U TN Melanocortin receptor 4 (MC4R) DMQZC0U MA Inhibitor DMQZC0U RN Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem. 2007 Mar 1;15(5):1989-2005. DMQZC0U RU https://pubmed.ncbi.nlm.nih.gov/17234422 DMQZDMH DI DMQZDMH DMQZDMH DN LUF-5816 DMQZDMH TI TTJFY5U DMQZDMH TN Adenosine A3 receptor (ADORA3) DMQZDMH MA Inhibitor DMQZDMH RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMQZDMH RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMQZDMH DI DMQZDMH DMQZDMH DN LUF-5816 DMQZDMH TI TTK25J1 DMQZDMH TN Adenosine A1 receptor (ADORA1) DMQZDMH MA Inhibitor DMQZDMH RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMQZDMH RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMQZDMH DI DMQZDMH DMQZDMH DN LUF-5816 DMQZDMH TI TTNE7KG DMQZDMH TN Adenosine A2b receptor (ADORA2B) DMQZDMH MA Inhibitor DMQZDMH RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMQZDMH RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMQZGNJ DI DMQZGNJ DMQZGNJ DN Sulfamic acid 4-sulfamoyloxy-butyl ester DMQZGNJ TI TTHQPL7 DMQZGNJ TN Carbonic anhydrase I (CA-I) DMQZGNJ MA Inhibitor DMQZGNJ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMQZGNJ RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMQZGNJ DI DMQZGNJ DMQZGNJ DN Sulfamic acid 4-sulfamoyloxy-butyl ester DMQZGNJ TI TTANPDJ DMQZGNJ TN Carbonic anhydrase II (CA-II) DMQZGNJ MA Inhibitor DMQZGNJ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMQZGNJ RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMQZGNJ DI DMQZGNJ DMQZGNJ DN Sulfamic acid 4-sulfamoyloxy-butyl ester DMQZGNJ TI TT2LVK8 DMQZGNJ TN Carbonic anhydrase IX (CA-IX) DMQZGNJ MA Inhibitor DMQZGNJ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMQZGNJ RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMQZJYS DI DMQZJYS DMQZJYS DN 3-phenyl-CPP DMQZJYS TI TTR68GQ DMQZJYS TN Chloride channel protein ClC-Kb (ClC-K2) DMQZJYS MA Blocker (channel blocker) DMQZJYS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 701). DMQZJYS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=701 DMQZJYS DI DMQZJYS DMQZJYS DN 3-phenyl-CPP DMQZJYS TI TT823N1 DMQZJYS TN Chloride channel protein ClC-Ka (ClC-K1) DMQZJYS MA Blocker (channel blocker) DMQZJYS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 700). DMQZJYS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=700 DMQZMRG DI DMQZMRG DMQZMRG DN N-(6-methylpyridin-2-yl)-6-phenylnicotinamide DMQZMRG TI TTHS256 DMQZMRG TN Metabotropic glutamate receptor 5 (mGluR5) DMQZMRG MA Inhibitor DMQZMRG RN Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75. DMQZMRG RU https://pubmed.ncbi.nlm.nih.gov/19445453 DMQZTS3 DI DMQZTS3 DMQZTS3 DN 6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide DMQZTS3 TI TT6R7JZ DMQZTS3 TN Histone deacetylase 1 (HDAC1) DMQZTS3 MA Inhibitor DMQZTS3 RN Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21. DMQZTS3 RU https://pubmed.ncbi.nlm.nih.gov/20451378 DMQZU9G DI DMQZU9G DMQZU9G DN 3-(heptyloxy)benzoic acid DMQZU9G TI TT0OFWN DMQZU9G TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DMQZU9G MA Inhibitor DMQZU9G RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMQZU9G RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMQZUD9 DI DMQZUD9 DMQZUD9 DN [2-(Imidazol-1-yl)ethyl]-bisphosphonic acid DMQZUD9 TI TTIKWV4 DMQZUD9 TN Geranyltranstransferase (FDPS) DMQZUD9 MA Inhibitor DMQZUD9 RN Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocy... J Med Chem. 2008 Nov 13;51(21):6800-7. DMQZUD9 RU https://pubmed.ncbi.nlm.nih.gov/18937434 DMQZULR DI DMQZULR DMQZULR DN 3-Methylquinoline-8-carboxamide DMQZULR TI TTVDSZ0 DMQZULR TN Poly [ADP-ribose] polymerase 1 (PARP1) DMQZULR MA Inhibitor DMQZULR RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMQZULR RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMQZXMF DI DMQZXMF DMQZXMF DN PMID12238936C3a DMQZXMF TI TTFQEO5 DMQZXMF TN Squalene synthetase (FDFT1) DMQZXMF MA Inhibitor DMQZXMF RN Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. J Med Chem. 2002 Sep 26;45(20):4571-80. DMQZXMF RU https://pubmed.ncbi.nlm.nih.gov/12238936 DMQZYW6 DI DMQZYW6 DMQZYW6 DN Propan-2-one O-3-butoxyphenylcarbamoyl oxime DMQZYW6 TI TTDP1UC DMQZYW6 TN Fatty acid amide hydrolase (FAAH) DMQZYW6 MA Inhibitor DMQZYW6 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMQZYW6 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMR01O4 DI DMR01O4 DMR01O4 DN AS-9705 DMR01O4 TI TT4C8EA DMR01O4 TN Dopamine D3 receptor (D3R) DMR01O4 MA Antagonist DMR01O4 RN Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51. DMR01O4 RU https://pubmed.ncbi.nlm.nih.gov/16503832 DMR05YO DI DMR05YO DMR05YO DN ISIS 113872 DMR05YO TI TTIX0ZU DMR05YO TN MEKK2 messenger RNA (MAP3K2 mRNA) DMR05YO RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMR05YO RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMR0CNQ DI DMR0CNQ DMR0CNQ DN Calpastatin DMR0CNQ TI TTG5QB7 DMR0CNQ TN Calpain-2 (CAPN2) DMR0CNQ MA Inhibitor DMR0CNQ RN Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Brain Res Rev. 2003 May;42(2):169-85. DMR0CNQ RU https://pubmed.ncbi.nlm.nih.gov/12738057 DMR0EVN DI DMR0EVN DMR0EVN DN Alpha-D-Glucose-6-Phosphate DMR0EVN TI TTFBNVI DMR0EVN TN Aldose reductase (AKR1B1) DMR0EVN MA Inhibitor DMR0EVN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR0EVN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR0EVN DI DMR0EVN DMR0EVN DN Alpha-D-Glucose-6-Phosphate DMR0EVN TI TTZHY6R DMR0EVN TN Glycogen phosphorylase muscle form (GP) DMR0EVN MA Inhibitor DMR0EVN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR0EVN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR0EVN DI DMR0EVN DMR0EVN DN Alpha-D-Glucose-6-Phosphate DMR0EVN TI TTLP3GX DMR0EVN TN Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC) DMR0EVN MA Inhibitor DMR0EVN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR0EVN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR0EVN DI DMR0EVN DMR0EVN DN Alpha-D-Glucose-6-Phosphate DMR0EVN TI TTC67I0 DMR0EVN TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMR0EVN MA Inhibitor DMR0EVN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR0EVN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR0HDF DI DMR0HDF DMR0HDF DN 2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole DMR0HDF TI TTRK8B9 DMR0HDF TN Sodium channel unspecific (NaC) DMR0HDF MA Inhibitor DMR0HDF RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMR0HDF RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMR0HDF DI DMR0HDF DMR0HDF DN 2-(1-Pentyl-hexyl)-4-phenyl-1H-imidazole DMR0HDF TI TTAXZ0K DMR0HDF TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMR0HDF MA Inhibitor DMR0HDF RN 2-Alkyl-4-arylimidazoles: structurally novel sodium channel modulators. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3521-3. DMR0HDF RU https://pubmed.ncbi.nlm.nih.gov/15177465 DMR0ICB DI DMR0ICB DMR0ICB DN 1-(3-methoxyphenyl)-2-(phenylsulfonyl)ethanone DMR0ICB TI TTN7BL9 DMR0ICB TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMR0ICB MA Inhibitor DMR0ICB RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMR0ICB RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMR0IEK DI DMR0IEK DMR0IEK DN 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine DMR0IEK TI TTK25J1 DMR0IEK TN Adenosine A1 receptor (ADORA1) DMR0IEK MA Inhibitor DMR0IEK RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMR0IEK RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMR0IEK DI DMR0IEK DMR0IEK DN 2-ethyl-4-(furan-3-yl)thieno[3,2-d]pyrimidine DMR0IEK TI TTM2AOE DMR0IEK TN Adenosine A2a receptor (ADORA2A) DMR0IEK MA Inhibitor DMR0IEK RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMR0IEK RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMR0S8X DI DMR0S8X DMR0S8X DN 4-hydroxy-3-nitrobenzaldehyde DMR0S8X TI TTT2LD9 DMR0S8X TN GABA transaminase (ABAT) DMR0S8X MA Inhibitor DMR0S8X RN Inhibition of GABA shunt enzymes' activity by 4-hydroxybenzaldehyde derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):592-5. DMR0S8X RU https://pubmed.ncbi.nlm.nih.gov/16290145 DMR12KP DI DMR12KP DMR12KP DN 1-(2-nitrophenethyl)-1H-pyrrolo[3,2-b]pyridine DMR12KP TI TTNDSF4 DMR12KP TN Proto-oncogene c-Met (MET) DMR12KP MA Inhibitor DMR12KP RN Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorg Med Chem Lett. 2009 May 15;19(10):2780-4. DMR12KP RU https://pubmed.ncbi.nlm.nih.gov/19369077 DMR18YI DI DMR18YI DMR18YI DN N-(benzyloxycarbonyl)-leucyl-glycine-nitrile DMR18YI TI TT36ETB DMR18YI TN Cathepsin L (CTSL) DMR18YI MA Inhibitor DMR18YI RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMR18YI RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMR18YI DI DMR18YI DMR18YI DN N-(benzyloxycarbonyl)-leucyl-glycine-nitrile DMR18YI TI TTUMQVO DMR18YI TN Cathepsin S (CTSS) DMR18YI MA Inhibitor DMR18YI RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMR18YI RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMR18YI DI DMR18YI DMR18YI DN N-(benzyloxycarbonyl)-leucyl-glycine-nitrile DMR18YI TI TTDZN01 DMR18YI TN Cathepsin K (CTSK) DMR18YI MA Inhibitor DMR18YI RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMR18YI RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMR1G40 DI DMR1G40 DMR1G40 DN ST-1646 DMR1G40 TI TTJA1ZO DMR1G40 TN ITGB3 messenger RNA (ITGB3 mRNA) DMR1G40 MA Inhibitor DMR1G40 RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMR1G40 RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMR1G40 DI DMR1G40 DMR1G40 DN ST-1646 DMR1G40 TI TTT1R2L DMR1G40 TN Integrin alpha-V (ITGAV) DMR1G40 MA Inhibitor DMR1G40 RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMR1G40 RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMR1HQ3 DI DMR1HQ3 DMR1HQ3 DN (S)-tert-butyl 4-methyl-1-oxopentan-2-ylcarbamate DMR1HQ3 TI TTDZN01 DMR1HQ3 TN Cathepsin K (CTSK) DMR1HQ3 MA Inhibitor DMR1HQ3 RN Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83. DMR1HQ3 RU https://pubmed.ncbi.nlm.nih.gov/16290936 DMR1MCD DI DMR1MCD DMR1MCD DN PMID12723943C12 DMR1MCD TI TTGY8IW DMR1MCD TN B2 bradykinin receptor (BDKRB2) DMR1MCD MA Antagonist DMR1MCD RN Benzodiazepines as potent and selective bradykinin B1 antagonists. J Med Chem. 2003 May 8;46(10):1803-6. DMR1MCD RU https://pubmed.ncbi.nlm.nih.gov/12723943 DMR1MQE DI DMR1MQE DMR1MQE DN Phenyl 4-(dodecyloxy)phenylcarbamate DMR1MQE TI TTDP1UC DMR1MQE TN Fatty acid amide hydrolase (FAAH) DMR1MQE MA Inhibitor DMR1MQE RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMR1MQE RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMR1N53 DI DMR1N53 DMR1N53 DN Ac-WVTH[Cit]LAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 DMR1N53 TI TTVSFJW DMR1N53 TN Calcitonin gene-related peptide 1 (CALCA) DMR1N53 MA Inhibitor DMR1N53 RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMR1N53 RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMR1XJN DI DMR1XJN DMR1XJN DN N5-[4-(2-phenylethoxy)phenyl]-L-glutamine DMR1XJN TI TTXZEAJ DMR1XJN TN Leukotriene A-4 hydrolase (LTA4H) DMR1XJN MA Inhibitor DMR1XJN RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMR1XJN RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMR21YD DI DMR21YD DMR21YD DN PMID21444206C8g DMR21YD TI TT7QNVC DMR21YD TN Glucose-dependent insulinotropic receptor (GPR119) DMR21YD MA Agonist DMR21YD RN Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41. DMR21YD RU https://pubmed.ncbi.nlm.nih.gov/21444206 DMR24BS DI DMR24BS DMR24BS DN ISIS 28425 DMR24BS TI TT9GR53 DMR24BS TN Smad1 messenger RNA (SMAD1 mRNA) DMR24BS RN US patent application no. 6,159,697, Antisense modulation of Smad7 expression. DMR24BS RU http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true DMR251H DI DMR251H DMR251H DN FR233623 DMR251H TI TTLP57V DMR251H TN Adenosine deaminase (ADA) DMR251H MA Inhibitor DMR251H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMR251H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMR28HG DI DMR28HG DMR28HG DN 5'-Deoxy-5'-(Methylthio)-Tubercidin DMR28HG TI TTFSX6G DMR28HG TN Bacterial MTA/SAH nucleosidase (Bact mtnN) DMR28HG MA Inhibitor DMR28HG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR28HG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR28HG DI DMR28HG DMR28HG DN 5'-Deoxy-5'-(Methylthio)-Tubercidin DMR28HG TI TTDBX7N DMR28HG TN S-methyl-5'-thioadenosine phosphorylase (MTAP) DMR28HG MA Inhibitor DMR28HG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR28HG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR29IQ DI DMR29IQ DMR29IQ DN 3-Fluoren-9-ylidenemethyl-pyridine DMR29IQ TI TTSZLWK DMR29IQ TN Aromatase (CYP19A1) DMR29IQ MA Inhibitor DMR29IQ RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMR29IQ RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMR2B4O DI DMR2B4O DMR2B4O DN Phenyl-(5-phenyl-oxazol-2-yl)-amine DMR2B4O TI TT1VAUK DMR2B4O TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMR2B4O MA Inhibitor DMR2B4O RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMR2B4O RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMR2B4O DI DMR2B4O DMR2B4O DN Phenyl-(5-phenyl-oxazol-2-yl)-amine DMR2B4O TI TTUTJGQ DMR2B4O TN Vascular endothelial growth factor receptor 2 (KDR) DMR2B4O MA Inhibitor DMR2B4O RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMR2B4O RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMR2B4O DI DMR2B4O DMR2B4O DN Phenyl-(5-phenyl-oxazol-2-yl)-amine DMR2B4O TI TTDCBX5 DMR2B4O TN Vascular endothelial growth factor receptor 3 (FLT-4) DMR2B4O MA Inhibitor DMR2B4O RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMR2B4O RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMR2C94 DI DMR2C94 DMR2C94 DN N5-[4-(2-methylphenoxy)phenyl]-L-glutamamide DMR2C94 TI TTXZEAJ DMR2C94 TN Leukotriene A-4 hydrolase (LTA4H) DMR2C94 MA Inhibitor DMR2C94 RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMR2C94 RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMR2DTI DI DMR2DTI DMR2DTI DN NSC-106547 DMR2DTI TI TT8XK6L DMR2DTI TN Quinone reductase 1 (NQO1) DMR2DTI MA Inhibitor DMR2DTI RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMR2DTI RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMR2K4F DI DMR2K4F DMR2K4F DN MCL-445 DMR2K4F TI TTKWM86 DMR2K4F TN Opioid receptor mu (MOP) DMR2K4F MA Inhibitor DMR2K4F RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMR2K4F RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMR2K4F DI DMR2K4F DMR2K4F DN MCL-445 DMR2K4F TI TT27RFC DMR2K4F TN Opioid receptor delta (OPRD1) DMR2K4F MA Inhibitor DMR2K4F RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMR2K4F RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMR2K4F DI DMR2K4F DMR2K4F DN MCL-445 DMR2K4F TI TTQW87Y DMR2K4F TN Opioid receptor kappa (OPRK1) DMR2K4F MA Inhibitor DMR2K4F RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMR2K4F RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMR2L6X DI DMR2L6X DMR2L6X DN PMID14640538C3 DMR2L6X TI TTP18AY DMR2L6X TN Carboxypeptidase B2 (CPB2) DMR2L6X MA Inhibitor DMR2L6X RN Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7. DMR2L6X RU https://pubmed.ncbi.nlm.nih.gov/14640538 DMR2L6X DI DMR2L6X DMR2L6X DN PMID14640538C3 DMR2L6X TI TTVOH2M DMR2L6X TN Carboxypeptidase M (CPM) DMR2L6X MA Inhibitor DMR2L6X RN Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7. DMR2L6X RU https://pubmed.ncbi.nlm.nih.gov/14640538 DMR2L6X DI DMR2L6X DMR2L6X DN PMID14640538C3 DMR2L6X TI TT8V2KD DMR2L6X TN Arginine carboxypeptidase (CPN1) DMR2L6X MA Inhibitor DMR2L6X RN Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7. DMR2L6X RU https://pubmed.ncbi.nlm.nih.gov/14640538 DMR2L6X DI DMR2L6X DMR2L6X DN PMID14640538C3 DMR2L6X TI TT4UJX5 DMR2L6X TN Carboxypeptidase B1 (CPB1) DMR2L6X MA Inhibitor DMR2L6X RN Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem. 2003 Dec 4;46(25):5294-7. DMR2L6X RU https://pubmed.ncbi.nlm.nih.gov/14640538 DMR2LTC DI DMR2LTC DMR2LTC DN PGJ2 DMR2LTC TI TTNVEIR DMR2LTC TN Prostaglandin D2 receptor (PTGDR) DMR2LTC MA Agonist DMR2LTC RN Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24. DMR2LTC RU https://pubmed.ncbi.nlm.nih.gov/9579725 DMR2LTC DI DMR2LTC DMR2LTC DN PGJ2 DMR2LTC TI TTQDMX5 DMR2LTC TN Prostaglandin D2 receptor 2 (PTGDR2) DMR2LTC MA Agonist DMR2LTC RN Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol. 2002 Dec;137(8):1163-72. DMR2LTC RU https://pubmed.ncbi.nlm.nih.gov/12466225 DMR2M7L DI DMR2M7L DMR2M7L DN ATN-658 DMR2M7L TI TTGY7WI DMR2M7L TN Urokinase-type plasminogen activator (PLAU) DMR2M7L MA Activator DMR2M7L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393). DMR2M7L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393 DMR2MUG DI DMR2MUG DMR2MUG DN ACULEACIN A DMR2MUG TI TTZMS1L DMR2MUG TN Fungal Papulacandin B resistance protein 1 (Fung FKS1) DMR2MUG MA Inhibitor DMR2MUG RN Synthesis, anti-fungal and 1,3--D-glucan synthase inhibitory activities of caffeic and quinic acid derivatives. Bioorg Med Chem. 2010 Oct 1;18(19):7009-14. DMR2MUG RU https://pubmed.ncbi.nlm.nih.gov/20813534 DMR2NBK DI DMR2NBK DMR2NBK DN FPTQ DMR2NBK TI TTVBPDM DMR2NBK TN Metabotropic glutamate receptor 1 (mGluR1) DMR2NBK MA Modulator (allosteric modulator) DMR2NBK RN Synthesis and evaluation of 6-[1-(2-[(18)F]fluoro-3-pyridyl)-5-methyl-1H-1,2,3-triazol-4-yl]quinoline for positron emission tomography imaging of the metabotropic glutamate receptor type 1 in brain. Bioorg Med Chem. 2011 Jan 1;19(1):102-10. DMR2NBK RU https://pubmed.ncbi.nlm.nih.gov/21172734 DMR2OMU DI DMR2OMU DMR2OMU DN 5,6-Dichloro-N-(2-morpholinoethyl)nicotinamide DMR2OMU TI TT3WG5C DMR2OMU TN Monoamine oxidase type A (MAO-A) DMR2OMU MA Inhibitor DMR2OMU RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMR2OMU RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMR2SEB DI DMR2SEB DMR2SEB DN BIIE0246 DMR2SEB TI TTJ6WK9 DMR2SEB TN Neuropeptide Y receptor type 2 (NPY2R) DMR2SEB MA Antagonist DMR2SEB RN The peptide YY-preferring receptor mediating inhibition of small intestinal secretion is a peripheral Y(2) receptor: pharmacological evidence and molecular cloning. Mol Pharmacol. 2001 Jul;60(1):124-34. DMR2SEB RU https://pubmed.ncbi.nlm.nih.gov/11408607 DMR2SXL DI DMR2SXL DMR2SXL DN 1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol DMR2SXL TI TTWJBZ5 DMR2SXL TN 5-HT 2C receptor (HTR2C) DMR2SXL MA Inhibitor DMR2SXL RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMR2SXL RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMR2SXL DI DMR2SXL DMR2SXL DN 1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol DMR2SXL TI TTJQOD7 DMR2SXL TN 5-HT 2A receptor (HTR2A) DMR2SXL MA Inhibitor DMR2SXL RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMR2SXL RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMR2SXL DI DMR2SXL DMR2SXL DN 1-((S)-2-aminopropyl)-7-iodo-1H-indazol-6-ol DMR2SXL TI TT0K1SC DMR2SXL TN 5-HT 2B receptor (HTR2B) DMR2SXL MA Inhibitor DMR2SXL RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMR2SXL RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMR2WQE DI DMR2WQE DMR2WQE DN LOFENTANIL DMR2WQE TI TTKWM86 DMR2WQE TN Opioid receptor mu (MOP) DMR2WQE MA Inhibitor DMR2WQE RN Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9. DMR2WQE RU https://pubmed.ncbi.nlm.nih.gov/6288945 DMR2WQE DI DMR2WQE DMR2WQE DN LOFENTANIL DMR2WQE TI TTQW87Y DMR2WQE TN Opioid receptor kappa (OPRK1) DMR2WQE MA Inhibitor DMR2WQE RN Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9. DMR2WQE RU https://pubmed.ncbi.nlm.nih.gov/6288945 DMR2WQE DI DMR2WQE DMR2WQE DN LOFENTANIL DMR2WQE TI TT27RFC DMR2WQE TN Opioid receptor delta (OPRD1) DMR2WQE MA Inhibitor DMR2WQE RN Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9. DMR2WQE RU https://pubmed.ncbi.nlm.nih.gov/6288945 DMR31VO DI DMR31VO DMR31VO DN MCL-434 DMR31VO TI TT27RFC DMR31VO TN Opioid receptor delta (OPRD1) DMR31VO MA Inhibitor DMR31VO RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMR31VO RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMR31VO DI DMR31VO DMR31VO DN MCL-434 DMR31VO TI TTQW87Y DMR31VO TN Opioid receptor kappa (OPRK1) DMR31VO MA Inhibitor DMR31VO RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMR31VO RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMR31VO DI DMR31VO DMR31VO DN MCL-434 DMR31VO TI TTKWM86 DMR31VO TN Opioid receptor mu (MOP) DMR31VO MA Inhibitor DMR31VO RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMR31VO RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMR31Z9 DI DMR31Z9 DMR31Z9 DN Ac-His-DPhe(3,4-diCl)-Arg-Trp-NH2 DMR31Z9 TI TTEOSZT DMR31Z9 TN Melanocortin receptor (MCR) DMR31Z9 MA Inhibitor DMR31Z9 RN Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93. DMR31Z9 RU https://pubmed.ncbi.nlm.nih.gov/18800761 DMR3487 DI DMR3487 DMR3487 DN EU-C-001 DMR3487 TI TTZPO1L DMR3487 TN Substance-P receptor (TACR1) DMR3487 MA Modulator DMR3487 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360). DMR3487 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360 DMR35OM DI DMR35OM DMR35OM DN 5-(3-(4-fluorobenzyl)pyrrolidin-3-yl)-1H-indole DMR35OM TI TTQ6VDM DMR35OM TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMR35OM MA Inhibitor DMR35OM RN Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6. DMR35OM RU https://pubmed.ncbi.nlm.nih.gov/18954985 DMR37FN DI DMR37FN DMR37FN DN 4-(Acetylamino)-3-Amino Benzoic Acid DMR37FN TI TT50QJ3 DMR37FN TN Influenza Neuraminidase (Influ NA) DMR37FN MA Inhibitor DMR37FN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR37FN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR3A2O DI DMR3A2O DMR3A2O DN RU82209 DMR3A2O TI TT6PKBN DMR3A2O TN Proto-oncogene c-Src (SRC) DMR3A2O MA Inhibitor DMR3A2O RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR3A2O RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR3A5N DI DMR3A5N DMR3A5N DN 10-Propargyl-5,8-Dideazafolic Acid DMR3A5N TI TTU6BFZ DMR3A5N TN Candida Thymidylate synthase (Candi TMP1) DMR3A5N MA Inhibitor DMR3A5N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR3A5N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR3A5N DI DMR3A5N DMR3A5N DN 10-Propargyl-5,8-Dideazafolic Acid DMR3A5N TI TTJLP0R DMR3A5N TN Quinone reductase 2 (NQO2) DMR3A5N MA Inhibitor DMR3A5N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR3A5N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR3DSG DI DMR3DSG DMR3DSG DN (R)-1-(4-methoxyphenethyl)-2-methylpyrrolidine DMR3DSG TI TT9JNIC DMR3DSG TN Histamine H3 receptor (H3R) DMR3DSG MA Inhibitor DMR3DSG RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMR3DSG RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMR3IP5 DI DMR3IP5 DMR3IP5 DN NSC-368280 DMR3IP5 TI TTSZLWK DMR3IP5 TN Aromatase (CYP19A1) DMR3IP5 MA Inhibitor DMR3IP5 RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMR3IP5 RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMR3IVB DI DMR3IVB DMR3IVB DN Tyr-Pro-Tmp-Phe-NH DMR3IVB TI TTKWM86 DMR3IVB TN Opioid receptor mu (MOP) DMR3IVB MA Inhibitor DMR3IVB RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMR3IVB RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMR3IVB DI DMR3IVB DMR3IVB DN Tyr-Pro-Tmp-Phe-NH DMR3IVB TI TT27RFC DMR3IVB TN Opioid receptor delta (OPRD1) DMR3IVB MA Inhibitor DMR3IVB RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMR3IVB RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMR3J6S DI DMR3J6S DMR3J6S DN Cholesterol DMR3J6S TI TTUAIKM DMR3J6S TN Cholinephosphate cytidylyltransferase (PCYT1B) DMR3J6S MA Activator DMR3J6S RN Regulation of CTP: phosphocholine cytidylyltransferase activity by the physical properties of lipid membranes: an important role for stored curvature strain energy. Biochemistry. 2001 Sep 4;40(35):10522-31. DMR3J6S RU https://pubmed.ncbi.nlm.nih.gov/11523994 DMR3KLF DI DMR3KLF DMR3KLF DN ISIS 133207 DMR3KLF TI TTZN92A DMR3KLF TN DUSP5 messenger RNA (DUSP5 mRNA) DMR3KLF RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DMR3KLF RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DMR3T2D DI DMR3T2D DMR3T2D DN 4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol DMR3T2D TI TTOM3J0 DMR3T2D TN Estrogen receptor beta (ESR2) DMR3T2D MA Inhibitor DMR3T2D RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMR3T2D RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMR3T2D DI DMR3T2D DMR3T2D DN 4-(3-(4-hydroxyphenyl)-1H-indol-2-yl)phenol DMR3T2D TI TTZAYWL DMR3T2D TN Estrogen receptor (ESR) DMR3T2D MA Inhibitor DMR3T2D RN Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5562-6. DMR3T2D RU https://pubmed.ncbi.nlm.nih.gov/16219463 DMR3Z1D DI DMR3Z1D DMR3Z1D DN 2-(6-phenylhexyl)pyrido[2,3-d]pyrimidin-4(3H)-one DMR3Z1D TI TTWNV8U DMR3Z1D TN Nicotinic acid receptor (HCAR2) DMR3Z1D MA Inhibitor DMR3Z1D RN Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5426-30. DMR3Z1D RU https://pubmed.ncbi.nlm.nih.gov/20724150 DMR46C8 DI DMR46C8 DMR46C8 DN UPA-targeted oncolytic Sendai virus DMR46C8 TI TTGY7WI DMR46C8 TN Urokinase-type plasminogen activator (PLAU) DMR46C8 MA Inhibitor DMR46C8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393). DMR46C8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393 DMR48NG DI DMR48NG DMR48NG DN 5'-deoxythymidine DMR48NG TI TT5B8AX DMR48NG TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMR48NG MA Inhibitor DMR48NG RN Thymidylate kinase as target enzyme for 5'-deoxythymidine and various 5'-deoxy-5'-halogeno pyrimidine nucleosides. Acta Biol Med Ger. 1969;23(6):Suppl:K 19+. DMR48NG RU https://pubmed.ncbi.nlm.nih.gov/5375492 DMR4DJ1 DI DMR4DJ1 DMR4DJ1 DN 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine DMR4DJ1 TI TTQ6VDM DMR4DJ1 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMR4DJ1 MA Inhibitor DMR4DJ1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMR4DJ1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMR4DJ1 DI DMR4DJ1 DMR4DJ1 DN 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine DMR4DJ1 TI TT3ROYC DMR4DJ1 TN Serotonin transporter (SERT) DMR4DJ1 MA Inhibitor DMR4DJ1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMR4DJ1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMR4DJ1 DI DMR4DJ1 DMR4DJ1 DN 1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine DMR4DJ1 TI TTAWNKZ DMR4DJ1 TN Norepinephrine transporter (NET) DMR4DJ1 MA Inhibitor DMR4DJ1 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMR4DJ1 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMR4J8G DI DMR4J8G DMR4J8G DN N-hydroxybenzo[b]thiophene-2-carboxamide DMR4J8G TI TT6R7JZ DMR4J8G TN Histone deacetylase 1 (HDAC1) DMR4J8G MA Inhibitor DMR4J8G RN Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29. DMR4J8G RU https://pubmed.ncbi.nlm.nih.gov/18247554 DMR4LJY DI DMR4LJY DMR4LJY DN 2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL DMR4LJY TI TTUMQVO DMR4LJY TN Cathepsin S (CTSS) DMR4LJY MA Inhibitor DMR4LJY RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMR4LJY RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMR4O3I DI DMR4O3I DMR4O3I DN RP-66471 DMR4O3I TI TT1VOHK DMR4O3I TN Potassium channel unspecific (KC) DMR4O3I MA Modulator DMR4O3I RN Potassium channel opener, RP 66471, induces membrane depolarization of rat liver mitochondria. Biochem Biophys Res Commun. 1995 Feb 6;207(1):126-32. DMR4O3I RU https://www.ncbi.nlm.nih.gov/pubmed/7857254 DMR4TM1 DI DMR4TM1 DMR4TM1 DN RTI-5989-23 DMR4TM1 TI TT27RFC DMR4TM1 TN Opioid receptor delta (OPRD1) DMR4TM1 MA Inhibitor DMR4TM1 RN Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90. DMR4TM1 RU https://pubmed.ncbi.nlm.nih.gov/9599247 DMR4TM1 DI DMR4TM1 DMR4TM1 DN RTI-5989-23 DMR4TM1 TI TTQW87Y DMR4TM1 TN Opioid receptor kappa (OPRK1) DMR4TM1 MA Inhibitor DMR4TM1 RN Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90. DMR4TM1 RU https://pubmed.ncbi.nlm.nih.gov/9599247 DMR54SW DI DMR54SW DMR54SW DN 2-(4-pentylphenyl)-N-(pyridin-3-yl)acetamide DMR54SW TI TTMI6F5 DMR54SW TN Transient receptor potential cation channel V1 (TRPV1) DMR54SW MA Inhibitor DMR54SW RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMR54SW RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMR5D16 DI DMR5D16 DMR5D16 DN N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide DMR5D16 TI TTSHTOI DMR5D16 TN Histone deacetylase 2 (HDAC2) DMR5D16 MA Inhibitor DMR5D16 RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMR5D16 RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMR5DYK DI DMR5DYK DMR5DYK DN 2,4-Dichlorobenzenemethanethiol DMR5DYK TI TTZJYKH DMR5DYK TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMR5DYK MA Inhibitor DMR5DYK RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMR5DYK RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMR5FD9 DI DMR5FD9 DMR5FD9 DN Sib-1533A DMR5FD9 TI TTMT0HG DMR5FD9 TN Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3) DMR5FD9 MA Agonist DMR5FD9 RN Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. Arch Med Res. 2000 Mar-Apr;31(2):131-44. DMR5FD9 RU https://pubmed.ncbi.nlm.nih.gov/10880717 DMR5HNI DI DMR5HNI DMR5HNI DN 4-(isopropylthio)-2-methoxybenzonitrile DMR5HNI TI TTKPW01 DMR5HNI TN Androgen receptor messenger RNA (AR mRNA) DMR5HNI MA Inhibitor DMR5HNI RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMR5HNI RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMR5NLM DI DMR5NLM DMR5NLM DN 4-methylphenyl-difluoromethanesulfonamide DMR5NLM TI TTUNARX DMR5NLM TN Carbonic anhydrase (CA) DMR5NLM MA Inhibitor DMR5NLM RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMR5NLM RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMR5NLM DI DMR5NLM DMR5NLM DN 4-methylphenyl-difluoromethanesulfonamide DMR5NLM TI TTHQPL7 DMR5NLM TN Carbonic anhydrase I (CA-I) DMR5NLM MA Inhibitor DMR5NLM RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMR5NLM RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMR5NLM DI DMR5NLM DMR5NLM DN 4-methylphenyl-difluoromethanesulfonamide DMR5NLM TI TT2LVK8 DMR5NLM TN Carbonic anhydrase IX (CA-IX) DMR5NLM MA Inhibitor DMR5NLM RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMR5NLM RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMR5NLM DI DMR5NLM DMR5NLM DN 4-methylphenyl-difluoromethanesulfonamide DMR5NLM TI TTANPDJ DMR5NLM TN Carbonic anhydrase II (CA-II) DMR5NLM MA Inhibitor DMR5NLM RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMR5NLM RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMR5UBF DI DMR5UBF DMR5UBF DN [3H]CPP DMR5UBF TI TT1M8OW DMR5UBF TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMR5UBF MA Antagonist DMR5UBF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMR5UBF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMR5UBF DI DMR5UBF DMR5UBF DN [3H]CPP DMR5UBF TI TTN9D8E DMR5UBF TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMR5UBF MA Antagonist DMR5UBF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMR5UBF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMR5UBF DI DMR5UBF DMR5UBF DN [3H]CPP DMR5UBF TI TTLD29N DMR5UBF TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMR5UBF MA Antagonist DMR5UBF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMR5UBF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMR5UBF DI DMR5UBF DMR5UBF DN [3H]CPP DMR5UBF TI TTKJEMQ DMR5UBF TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMR5UBF MA Antagonist DMR5UBF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMR5UBF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMR5UBF DI DMR5UBF DMR5UBF DN [3H]CPP DMR5UBF TI TT5POTG DMR5UBF TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMR5UBF MA Antagonist DMR5UBF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMR5UBF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMR5YZG DI DMR5YZG DMR5YZG DN 2-methoxy-4-(p-tolyloxy)benzonitrile DMR5YZG TI TTKPW01 DMR5YZG TN Androgen receptor messenger RNA (AR mRNA) DMR5YZG MA Inhibitor DMR5YZG RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMR5YZG RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMR69K2 DI DMR69K2 DMR69K2 DN 4-(cyclobutylmethylthio)-2-methoxybenzonitrile DMR69K2 TI TTKPW01 DMR69K2 TN Androgen receptor messenger RNA (AR mRNA) DMR69K2 MA Inhibitor DMR69K2 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMR69K2 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMR6GJK DI DMR6GJK DMR6GJK DN Butirosin B DMR6GJK TI TT38DW5 DMR6GJK TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMR6GJK MA Inhibitor DMR6GJK RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMR6GJK RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMR6JTQ DI DMR6JTQ DMR6JTQ DN (3-(2-methylquinolin-7-yl)phenyl)methanol DMR6JTQ TI TTHS256 DMR6JTQ TN Metabotropic glutamate receptor 5 (mGluR5) DMR6JTQ MA Inhibitor DMR6JTQ RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMR6JTQ RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMR6LIE DI DMR6LIE DMR6LIE DN LUF-5962 DMR6LIE TI TTM2AOE DMR6LIE TN Adenosine A2a receptor (ADORA2A) DMR6LIE MA Inhibitor DMR6LIE RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMR6LIE RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMR6LIE DI DMR6LIE DMR6LIE DN LUF-5962 DMR6LIE TI TTK25J1 DMR6LIE TN Adenosine A1 receptor (ADORA1) DMR6LIE MA Inhibitor DMR6LIE RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMR6LIE RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMR6LIE DI DMR6LIE DMR6LIE DN LUF-5962 DMR6LIE TI TTJFY5U DMR6LIE TN Adenosine A3 receptor (ADORA3) DMR6LIE MA Inhibitor DMR6LIE RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMR6LIE RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMR6P9S DI DMR6P9S DMR6P9S DN NSC-106080 DMR6P9S TI TTJLP0R DMR6P9S TN Quinone reductase 2 (NQO2) DMR6P9S MA Inhibitor DMR6P9S RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMR6P9S RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMR6P9S DI DMR6P9S DMR6P9S DN NSC-106080 DMR6P9S TI TT8XK6L DMR6P9S TN Quinone reductase 1 (NQO1) DMR6P9S MA Inhibitor DMR6P9S RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMR6P9S RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMR6PJ5 DI DMR6PJ5 DMR6PJ5 DN sarafotoxin S6b DMR6PJ5 TI TTKRD0G DMR6PJ5 TN Endothelin A receptor (EDNRA) DMR6PJ5 MA Agonist DMR6PJ5 RN ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995 May;115(1):191-7. DMR6PJ5 RU https://pubmed.ncbi.nlm.nih.gov/7647976 DMR6QNA DI DMR6QNA DMR6QNA DN ISIS 18473 DMR6QNA TI TT405FP DMR6QNA TN FAP-1 messenger RNA (PTPN13 mRNA) DMR6QNA RN US patent application no. 6,204,055, Antisense inhibition of Fas mediated signaling. DMR6QNA RU http://www.patentbuddy.com/Patent/6204055?ft=true&sr=true DMR6VWL DI DMR6VWL DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide DMR6VWL TI TTEYTKG DMR6VWL TN Carbonic anhydrase XIV (CA-XIV) DMR6VWL MA Inhibitor DMR6VWL RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMR6VWL RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMR6VWL DI DMR6VWL DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide DMR6VWL TI TTCFSPE DMR6VWL TN Carbonic anhydrase VI (CA-VI) DMR6VWL MA Inhibitor DMR6VWL RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMR6VWL RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMR6VWL DI DMR6VWL DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide DMR6VWL TI TT2LVK8 DMR6VWL TN Carbonic anhydrase IX (CA-IX) DMR6VWL MA Inhibitor DMR6VWL RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMR6VWL RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMR6VWL DI DMR6VWL DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide DMR6VWL TI TTSYM0R DMR6VWL TN Carbonic anhydrase XII (CA-XII) DMR6VWL MA Inhibitor DMR6VWL RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMR6VWL RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMR6VWL DI DMR6VWL DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide DMR6VWL TI TTANPDJ DMR6VWL TN Carbonic anhydrase II (CA-II) DMR6VWL MA Inhibitor DMR6VWL RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMR6VWL RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMR6VWL DI DMR6VWL DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide DMR6VWL TI TTUNARX DMR6VWL TN Carbonic anhydrase (CA) DMR6VWL MA Inhibitor DMR6VWL RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMR6VWL RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMR6VWL DI DMR6VWL DMR6VWL DN 4-(hydroxymethyl)benzenesulfonamide DMR6VWL TI TTHQPL7 DMR6VWL TN Carbonic anhydrase I (CA-I) DMR6VWL MA Inhibitor DMR6VWL RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMR6VWL RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMR6Z2N DI DMR6Z2N DMR6Z2N DN Des-AA1,2,4,13-[D-Trp8]SRIF DMR6Z2N TI TT2BC4G DMR6Z2N TN Somatostatin receptor type 5 (SSTR5) DMR6Z2N MA Inhibitor DMR6Z2N RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMR6Z2N RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMR6Z2N DI DMR6Z2N DMR6Z2N DN Des-AA1,2,4,13-[D-Trp8]SRIF DMR6Z2N TI TTJX3UE DMR6Z2N TN Somatostatin receptor type 3 (SSTR3) DMR6Z2N MA Inhibitor DMR6Z2N RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMR6Z2N RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMR6Z2N DI DMR6Z2N DMR6Z2N DN Des-AA1,2,4,13-[D-Trp8]SRIF DMR6Z2N TI TTIND6G DMR6Z2N TN Somatostatin receptor type 1 (SSTR1) DMR6Z2N MA Inhibitor DMR6Z2N RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMR6Z2N RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMR6Z2N DI DMR6Z2N DMR6Z2N DN Des-AA1,2,4,13-[D-Trp8]SRIF DMR6Z2N TI TTZ6T9E DMR6Z2N TN Somatostatin receptor type 2 (SSTR2) DMR6Z2N MA Inhibitor DMR6Z2N RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMR6Z2N RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMR6Z2N DI DMR6Z2N DMR6Z2N DN Des-AA1,2,4,13-[D-Trp8]SRIF DMR6Z2N TI TTAE1BR DMR6Z2N TN Somatostatin receptor type 4 (SSTR4) DMR6Z2N MA Inhibitor DMR6Z2N RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMR6Z2N RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMR708D DI DMR708D DMR708D DN CGP 56999A DMR708D TI TTDCVZW DMR708D TN Gamma-aminobutyric acid B receptor (GABBR) DMR708D MA Antagonist DMR708D RN Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46. DMR708D RU https://pubmed.ncbi.nlm.nih.gov/9069281 DMR70ZO DI DMR70ZO DMR70ZO DN Bornyl (3,4,5-trihydroxy)-cinnamate DMR70ZO TI TTPLTSQ DMR70ZO TN Neutrophil elastase (NE) DMR70ZO MA Inhibitor DMR70ZO RN Bornyl (3,4,5-trihydroxy)-cinnamate--an optimized human neutrophil elastase inhibitor designed by free energy calculations. Bioorg Med Chem. 2008 Mar 1;16(5):2385-90. DMR70ZO RU https://pubmed.ncbi.nlm.nih.gov/18078761 DMR713M DI DMR713M DMR713M DN 7-Methoxy-2-morpholin-4-yl-chromen-4-one DMR713M TI TTK3PY9 DMR713M TN DNA-dependent protein kinase catalytic (PRKDC) DMR713M MA Inhibitor DMR713M RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMR713M RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMR74OM DI DMR74OM DMR74OM DN Cypate-[(RGD)4-NH2]2 DMR74OM TI TTJA1ZO DMR74OM TN ITGB3 messenger RNA (ITGB3 mRNA) DMR74OM MA Inhibitor DMR74OM RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMR74OM RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMR74OM DI DMR74OM DMR74OM DN Cypate-[(RGD)4-NH2]2 DMR74OM TI TTT1R2L DMR74OM TN Integrin alpha-V (ITGAV) DMR74OM MA Inhibitor DMR74OM RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMR74OM RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMR7GP6 DI DMR7GP6 DMR7GP6 DN 4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol DMR7GP6 TI TTOM3J0 DMR7GP6 TN Estrogen receptor beta (ESR2) DMR7GP6 MA Inhibitor DMR7GP6 RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMR7GP6 RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMR7GP6 DI DMR7GP6 DMR7GP6 DN 4-[1,2-bis(4-hydroxyphenyl)vinyl]phenol DMR7GP6 TI TTZAYWL DMR7GP6 TN Estrogen receptor (ESR) DMR7GP6 MA Inhibitor DMR7GP6 RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMR7GP6 RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMR7HV3 DI DMR7HV3 DMR7HV3 DN METHYL-PHE-PRO-AMINO-CYCLOHEXYLGLYCINE DMR7HV3 TI TT6L509 DMR7HV3 TN Coagulation factor IIa (F2) DMR7HV3 MA Inhibitor DMR7HV3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMR7HV3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMR7IGZ DI DMR7IGZ DMR7IGZ DN Abyssinin II DMR7IGZ TI TTELIN2 DMR7IGZ TN PTPN1 messenger RNA (PTPN1 mRNA) DMR7IGZ MA Inhibitor DMR7IGZ RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DMR7IGZ RU https://pubmed.ncbi.nlm.nih.gov/17489632 DMR7M82 DI DMR7M82 DMR7M82 DN 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine DMR7M82 TI TTSZLWK DMR7M82 TN Aromatase (CYP19A1) DMR7M82 MA Inhibitor DMR7M82 RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMR7M82 RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMR7M82 DI DMR7M82 DMR7M82 DN 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine DMR7M82 TI TTRA5BZ DMR7M82 TN Steroid 17-alpha-monooxygenase (S17AH) DMR7M82 MA Inhibitor DMR7M82 RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMR7M82 RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMR7M82 DI DMR7M82 DMR7M82 DN 3-(1-ethyl-3,4-dihydronaphthalen-2-yl)-pyridine DMR7M82 TI TTIQUX7 DMR7M82 TN Steroid 11-beta-hydroxylase (CYP11B1) DMR7M82 MA Inhibitor DMR7M82 RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMR7M82 RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMR7OHB DI DMR7OHB DMR7OHB DN 5-(2-oxoindolin-5-yl)-1H-pyrrole-2-carbonitrile DMR7OHB TI TTUV8G9 DMR7OHB TN Progesterone receptor (PGR) DMR7OHB MA Inhibitor DMR7OHB RN Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73. DMR7OHB RU https://pubmed.ncbi.nlm.nih.gov/18318463 DMR7TEQ DI DMR7TEQ DMR7TEQ DN [D-4Aph(CO-NH-OCH3)6]degarelix DMR7TEQ TI TT8R70G DMR7TEQ TN Gonadotropin-releasing hormone receptor (GNRHR) DMR7TEQ MA Inhibitor DMR7TEQ RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DMR7TEQ RU https://pubmed.ncbi.nlm.nih.gov/16759096 DMR7UBZ DI DMR7UBZ DMR7UBZ DN PMID15686947C(S)-3h DMR7UBZ TI TTBUYHA DMR7UBZ TN Extracellular calcium-sensing receptor (CASR) DMR7UBZ MA Antagonist DMR7UBZ RN Discovery and structure-activity relationships of 2-benzylpyrrolidine-substituted aryloxypropanols as calcium-sensing receptor antagonists. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1225-8. DMR7UBZ RU https://pubmed.ncbi.nlm.nih.gov/15686947 DMR82WI DI DMR82WI DMR82WI DN BMS compound 4c DMR82WI TI TTA93TL DMR82WI TN P2Y purinoceptor 1 (P2RY1) DMR82WI MA Antagonist DMR82WI RN New azole antagonists with high affinity for the P2Y(1) receptor. Bioorg Med Chem Lett. 2013 Jun 15;23(12):3519-22. DMR82WI RU https://pubmed.ncbi.nlm.nih.gov/23668989 DMR853M DI DMR853M DMR853M DN 5-amino-3,4-dihydroisoquinolin-1(2H)-one DMR853M TI TTVDSZ0 DMR853M TN Poly [ADP-ribose] polymerase 1 (PARP1) DMR853M MA Inhibitor DMR853M RN Discovery and SAR of novel, potent and selective hexahydrobenzonaphthyridinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett. 2010 Jan 15;20(2):448-52. DMR853M RU https://pubmed.ncbi.nlm.nih.gov/20015648 DMR8E0G DI DMR8E0G DMR8E0G DN (R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide DMR8E0G TI TTMWT8Z DMR8E0G TN C-X-C chemokine receptor type 1 (CXCR1) DMR8E0G MA Inhibitor DMR8E0G RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMR8E0G RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMR8E0G DI DMR8E0G DMR8E0G DN (R)-2-(4-Isobutyl-phenyl)-N-methoxy-propionamide DMR8E0G TI TT30C9G DMR8E0G TN C-X-C chemokine receptor type 2 (CXCR2) DMR8E0G MA Inhibitor DMR8E0G RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMR8E0G RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMR8HKC DI DMR8HKC DMR8HKC DN Chebulinic acid DMR8HKC TI TTE14XG DMR8HKC TN Squalene monooxygenase (SQLE) DMR8HKC MA Inhibitor DMR8HKC RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMR8HKC RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMR8I03 DI DMR8I03 DMR8I03 DN RU78262 DMR8I03 TI TT6PKBN DMR8I03 TN Proto-oncogene c-Src (SRC) DMR8I03 MA Inhibitor DMR8I03 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMR8I03 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMR8L6O DI DMR8L6O DMR8L6O DN Rac-cis-N-arachidonoylcyclopropanolamide DMR8L6O TI TTMSFAW DMR8L6O TN Cannabinoid receptor 2 (CB2) DMR8L6O MA Inhibitor DMR8L6O RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMR8L6O RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMR8L6O DI DMR8L6O DMR8L6O DN Rac-cis-N-arachidonoylcyclopropanolamide DMR8L6O TI TT6OEDT DMR8L6O TN Cannabinoid receptor 1 (CB1) DMR8L6O MA Inhibitor DMR8L6O RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMR8L6O RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMR8M19 DI DMR8M19 DMR8M19 DN DFGYVAE DMR8M19 TI TTPADOQ DMR8M19 TN HMG-CoA reductase (HMGCR) DMR8M19 MA Inhibitor DMR8M19 RN Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase. Bioorg Med Chem. 2010 Jun 15;18(12):4300-9. DMR8M19 RU https://pubmed.ncbi.nlm.nih.gov/20494585 DMR8M36 DI DMR8M36 DMR8M36 DN 2-Chloro-N-(2-morpholinoethyl)nicotinamide DMR8M36 TI TT3WG5C DMR8M36 TN Monoamine oxidase type A (MAO-A) DMR8M36 MA Inhibitor DMR8M36 RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMR8M36 RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMR8M36 DI DMR8M36 DMR8M36 DN 2-Chloro-N-(2-morpholinoethyl)nicotinamide DMR8M36 TI TTGP7BY DMR8M36 TN Monoamine oxidase type B (MAO-B) DMR8M36 MA Inhibitor DMR8M36 RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMR8M36 RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMR8N36 DI DMR8N36 DMR8N36 DN ML347 DMR8N36 TI TTJNBQA DMR8N36 TN Activin receptor-like kinase 2 (ALK-2) DMR8N36 MA Inhibitor DMR8N36 RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMR8N36 RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMR8N36 DI DMR8N36 DMR8N36 DN ML347 DMR8N36 TI TTGKF90 DMR8N36 TN Bone morphogenetic protein receptor (BMPR2) DMR8N36 MA Inhibitor DMR8N36 RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMR8N36 RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMR8N36 DI DMR8N36 DMR8N36 DN ML347 DMR8N36 TI TTGYPTC DMR8N36 TN Activin receptor-like kinase-1 (ACVRL1) DMR8N36 MA Inhibitor DMR8N36 RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMR8N36 RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMR8O1B DI DMR8O1B DMR8O1B DN 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine DMR8O1B TI TTSZLWK DMR8O1B TN Aromatase (CYP19A1) DMR8O1B MA Inhibitor DMR8O1B RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMR8O1B RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMR8O1B DI DMR8O1B DMR8O1B DN 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine DMR8O1B TI TTRA5BZ DMR8O1B TN Steroid 17-alpha-monooxygenase (S17AH) DMR8O1B MA Inhibitor DMR8O1B RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMR8O1B RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMR8O1B DI DMR8O1B DMR8O1B DN 4'-(Pyridin-4-ylmethyl)biphenyl-3-amine DMR8O1B TI TTIQUX7 DMR8O1B TN Steroid 11-beta-hydroxylase (CYP11B1) DMR8O1B MA Inhibitor DMR8O1B RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMR8O1B RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMR8PGZ DI DMR8PGZ DMR8PGZ DN 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine DMR8PGZ TI TTM2AOE DMR8PGZ TN Adenosine A2a receptor (ADORA2A) DMR8PGZ MA Inhibitor DMR8PGZ RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMR8PGZ RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMR8PGZ DI DMR8PGZ DMR8PGZ DN 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine DMR8PGZ TI TTK25J1 DMR8PGZ TN Adenosine A1 receptor (ADORA1) DMR8PGZ MA Inhibitor DMR8PGZ RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMR8PGZ RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMR8PGZ DI DMR8PGZ DMR8PGZ DN 2-(3''-(5''-bromo-indolyl)ethyloxy)adenosine DMR8PGZ TI TTJFY5U DMR8PGZ TN Adenosine A3 receptor (ADORA3) DMR8PGZ MA Inhibitor DMR8PGZ RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMR8PGZ RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMR8U1M DI DMR8U1M DMR8U1M DN CGP 64213 DMR8U1M TI TTDCVZW DMR8U1M TN Gamma-aminobutyric acid B receptor (GABBR) DMR8U1M MA Antagonist DMR8U1M RN Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature. 1997 Mar 20;386(6622):239-46. DMR8U1M RU https://pubmed.ncbi.nlm.nih.gov/9069281 DMR8ZBT DI DMR8ZBT DMR8ZBT DN Petrosaspongiolide M DMR8ZBT TI TT9V5JH DMR8ZBT TN Phospholipase A2 (PLA2G1B) DMR8ZBT MA Inhibitor DMR8ZBT RN Synthesis and pharmacological evaluation of a selected library of new potential anti-inflammatory agents bearing the gamma-hydroxybutenolide scaffo... J Med Chem. 2007 May 3;50(9):2176-84. DMR8ZBT RU https://pubmed.ncbi.nlm.nih.gov/17407277 DMR90HY DI DMR90HY DMR90HY DN Deoxythymidine DMR90HY TI TTP3QRF DMR90HY TN Thymidine kinase 1 (TK1) DMR90HY MA Inhibitor DMR90HY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR90HY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR90HY DI DMR90HY DMR90HY DN Deoxythymidine DMR90HY TI TT5B8AX DMR90HY TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMR90HY MA Inhibitor DMR90HY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMR90HY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMR92HV DI DMR92HV DMR92HV DN NE11808 DMR92HV TI TTIKWV4 DMR92HV TN Geranyltranstransferase (FDPS) DMR92HV MA Inhibitor DMR92HV RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMR92HV RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMR93MK DI DMR93MK DMR93MK DN GRL-7234 DMR93MK TI TTPT2QI DMR93MK TN Cathepsin D (CTSD) DMR93MK MA Inhibitor DMR93MK RN Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407. DMR93MK RU https://pubmed.ncbi.nlm.nih.gov/17432843 DMR93MK DI DMR93MK DMR93MK DN GRL-7234 DMR93MK TI TT8JRS7 DMR93MK TN Beta-secretase (BACE) DMR93MK MA Inhibitor DMR93MK RN Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407. DMR93MK RU https://pubmed.ncbi.nlm.nih.gov/17432843 DMR93WE DI DMR93WE DMR93WE DN APG-103 DMR93WE TI TTF0RCZ DMR93WE TN Apoptosis mediating surface antigen FAS (FAS) DMR93WE MA Inhibitor DMR93WE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1875). DMR93WE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875 DMR97FU DI DMR97FU DMR97FU DN 1-Benzo[b]thiophen-2-yl-cyclohexylamine DMR97FU TI TTVBI8W DMR97FU TN Dopamine transporter (DAT) DMR97FU MA Inhibitor DMR97FU RN Synthesis and biological evaluation of 1-[1-(2-benzo[b]thienyl)cyclohexyl]piperidine homologues at dopamine-uptake and phencyclidine- and sigma-bin... J Med Chem. 1993 Apr 30;36(9):1188-93. DMR97FU RU https://pubmed.ncbi.nlm.nih.gov/8098066 DMR97X3 DI DMR97X3 DMR97X3 DN NSC-368272 DMR97X3 TI TTSZLWK DMR97X3 TN Aromatase (CYP19A1) DMR97X3 MA Inhibitor DMR97X3 RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMR97X3 RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMR98ML DI DMR98ML DMR98ML DN 2-(2-carboxy-7-mercaptoheptyl)benzoic acid DMR98ML TI TT9G4N0 DMR98ML TN Glutamate carboxypeptidase II (GCPII) DMR98ML MA Inhibitor DMR98ML RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMR98ML RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMR9C4Q DI DMR9C4Q DMR9C4Q DN MK-6892 DMR9C4Q TI TTWNV8U DMR9C4Q TN Nicotinic acid receptor (HCAR2) DMR9C4Q MA Agonist DMR9C4Q RN Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8. DMR9C4Q RU https://pubmed.ncbi.nlm.nih.gov/24900372 DMR9GNW DI DMR9GNW DMR9GNW DN Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine DMR9GNW TI TTWG9A4 DMR9GNW TN Adrenergic receptor alpha-2A (ADRA2A) DMR9GNW MA Inhibitor DMR9GNW RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMR9GNW RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMR9GNW DI DMR9GNW DMR9GNW DN Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine DMR9GNW TI TTWM4TY DMR9GNW TN Adrenergic receptor alpha-2B (ADRA2B) DMR9GNW MA Inhibitor DMR9GNW RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMR9GNW RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMR9GNW DI DMR9GNW DMR9GNW DN Indol-1-yl-prop-2-ynyl-pyridin-4-yl-amine DMR9GNW TI TT2NUT5 DMR9GNW TN Adrenergic receptor alpha-2C (ADRA2C) DMR9GNW MA Inhibitor DMR9GNW RN Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeu... J Med Chem. 1996 Jan 19;39(2):570-81. DMR9GNW RU https://pubmed.ncbi.nlm.nih.gov/8558529 DMR9HYI DI DMR9HYI DMR9HYI DN PSB1114 DMR9HYI TI TTOZHQC DMR9HYI TN P2Y purinoceptor 2 (P2RY2) DMR9HYI MA Agonist DMR9HYI RN Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2011 Apr 28;54(8):2878-90. DMR9HYI RU https://pubmed.ncbi.nlm.nih.gov/21417463 DMR9M6H DI DMR9M6H DMR9M6H DN 4-amino-3-fluoro-5-iodobenzenesulfonamide DMR9M6H TI TTUNARX DMR9M6H TN Carbonic anhydrase (CA) DMR9M6H MA Inhibitor DMR9M6H RN Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. DMR9M6H RU https://pubmed.ncbi.nlm.nih.gov/17826101 DMR9OD1 DI DMR9OD1 DMR9OD1 DN Angiotensin IV DMR9OD1 TI TTPHMWB DMR9OD1 TN Aminopeptidase N (ANPEP) DMR9OD1 MA Inhibitor DMR9OD1 RN Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorg Med Chem. 2008 Jul 15;16(14):6924-35. DMR9OD1 RU https://pubmed.ncbi.nlm.nih.gov/18556208 DMR9Q4Y DI DMR9Q4Y DMR9Q4Y DN 2-(1H-indol-3-yl)-N,N-dimethylethanamine DMR9Q4Y TI TT5TPI6 DMR9Q4Y TN Opioid receptor sigma 1 (OPRS1) DMR9Q4Y MA Inhibitor DMR9Q4Y RN Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97. DMR9Q4Y RU https://pubmed.ncbi.nlm.nih.gov/8297216 DMR9Q4Y DI DMR9Q4Y DMR9Q4Y DN 2-(1H-indol-3-yl)-N,N-dimethylethanamine DMR9Q4Y TI TTJS8PY DMR9Q4Y TN 5-HT 6 receptor (HTR6) DMR9Q4Y MA Inhibitor DMR9Q4Y RN Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97. DMR9Q4Y RU https://pubmed.ncbi.nlm.nih.gov/8297216 DMR9Q4Y DI DMR9Q4Y DMR9Q4Y DN 2-(1H-indol-3-yl)-N,N-dimethylethanamine DMR9Q4Y TI TTJQOD7 DMR9Q4Y TN 5-HT 2A receptor (HTR2A) DMR9Q4Y MA Inhibitor DMR9Q4Y RN Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97. DMR9Q4Y RU https://pubmed.ncbi.nlm.nih.gov/8297216 DMR9SFM DI DMR9SFM DMR9SFM DN 15-deoxygoiazensolide DMR9SFM TI TTSXVID DMR9SFM TN Nuclear factor NF-kappa-B (NFKB) DMR9SFM MA Inhibitor DMR9SFM RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMR9SFM RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMR9TBW DI DMR9TBW DMR9TBW DN 4-(4-hexylphenyl)-4-oxobut-2-enoic acid DMR9TBW TI TTTSEPU DMR9TBW TN Thyroid hormone receptor alpha (THRA) DMR9TBW MA Inhibitor DMR9TBW RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMR9TBW RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMR9TBW DI DMR9TBW DMR9TBW DN 4-(4-hexylphenyl)-4-oxobut-2-enoic acid DMR9TBW TI TTGER3L DMR9TBW TN Thyroid hormone receptor beta (THRB) DMR9TBW MA Inhibitor DMR9TBW RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMR9TBW RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMR9TYV DI DMR9TYV DMR9TYV DN PMID17358052C5b DMR9TYV TI TT8WFXV DMR9TYV TN Hydroxycarboxylic acid receptor 3 (HCAR3) DMR9TYV MA Agonist DMR9TYV RN Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J Med Chem. 2007 Apr 5;50(7):1445-8. DMR9TYV RU https://pubmed.ncbi.nlm.nih.gov/17358052 DMR9WF7 DI DMR9WF7 DMR9WF7 DN 3,14-DIDEHYDROGINKGOLIDE A DMR9WF7 TI TTZ8EM9 DMR9WF7 TN Glycine receptor (GlyR) DMR9WF7 MA Inhibitor DMR9WF7 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMR9WF7 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMR9WF7 DI DMR9WF7 DMR9WF7 DN 3,14-DIDEHYDROGINKGOLIDE A DMR9WF7 TI TTF45NW DMR9WF7 TN Strychnine-binding glycine receptor (GLRA1) DMR9WF7 MA Inhibitor DMR9WF7 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMR9WF7 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMRA548 DI DMRA548 DMRA548 DN N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide DMRA548 TI TTGP7BY DMRA548 TN Monoamine oxidase type B (MAO-B) DMRA548 MA Inhibitor DMRA548 RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMRA548 RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMRA736 DI DMRA736 DMRA736 DN Saccharin DMRA736 TI TTUNARX DMRA736 TN Carbonic anhydrase (CA) DMRA736 MA Inhibitor DMRA736 RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMRA736 RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMRA736 DI DMRA736 DMRA736 DN Saccharin DMRA736 TI TTHQPL7 DMRA736 TN Carbonic anhydrase I (CA-I) DMRA736 MA Inhibitor DMRA736 RN Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503. DMRA736 RU https://pubmed.ncbi.nlm.nih.gov/20624682 DMRA736 DI DMRA736 DMRA736 DN Saccharin DMRA736 TI TT2LVK8 DMRA736 TN Carbonic anhydrase IX (CA-IX) DMRA736 MA Inhibitor DMRA736 RN Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of... Bioorg Med Chem Lett. 2008 Jan 15;18(2):836-41. DMRA736 RU https://pubmed.ncbi.nlm.nih.gov/18042384 DMRA736 DI DMRA736 DMRA736 DN Saccharin DMRA736 TI TTSYM0R DMRA736 TN Carbonic anhydrase XII (CA-XII) DMRA736 MA Inhibitor DMRA736 RN Carbonic anhydrase inhibitors: copper(II) complexes of polyamino-polycarboxylamido aromatic/heterocyclic sulfonamides are very potent inhibitors of... Bioorg Med Chem Lett. 2008 Jan 15;18(2):836-41. DMRA736 RU https://pubmed.ncbi.nlm.nih.gov/18042384 DMRA736 DI DMRA736 DMRA736 DN Saccharin DMRA736 TI TTANPDJ DMRA736 TN Carbonic anhydrase II (CA-II) DMRA736 MA Inhibitor DMRA736 RN Mutation of Phe91 to Asn in human carbonic anhydrase I unexpectedly enhanced both catalytic activity and affinity for sulfonamide inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5498-503. DMRA736 RU https://pubmed.ncbi.nlm.nih.gov/20624682 DMRA9VG DI DMRA9VG DMRA9VG DN 1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole DMRA9VG TI TTJS8PY DMRA9VG TN 5-HT 6 receptor (HTR6) DMRA9VG MA Inhibitor DMRA9VG RN N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Jan 17;15(2):379-83. DMRA9VG RU https://pubmed.ncbi.nlm.nih.gov/15603958 DMRAC6T DI DMRAC6T DMRAC6T DN (6s)-5,6,7,8-Tetrahydrofolate DMRAC6T TI TTU6BFZ DMRAC6T TN Candida Thymidylate synthase (Candi TMP1) DMRAC6T MA Inhibitor DMRAC6T RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRAC6T RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRADWB DI DMRADWB DMRADWB DN 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide DMRADWB TI TT2LVK8 DMRADWB TN Carbonic anhydrase IX (CA-IX) DMRADWB MA Inhibitor DMRADWB RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMRADWB RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMRADWB DI DMRADWB DMRADWB DN 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide DMRADWB TI TTANPDJ DMRADWB TN Carbonic anhydrase II (CA-II) DMRADWB MA Inhibitor DMRADWB RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMRADWB RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMRADWB DI DMRADWB DMRADWB DN 2-(4-chlorobenzyloxyamino)-N-hydroxypropanamide DMRADWB TI TTHQPL7 DMRADWB TN Carbonic anhydrase I (CA-I) DMRADWB MA Inhibitor DMRADWB RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMRADWB RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMRAFSB DI DMRAFSB DMRAFSB DN PMID30247903-Compound-General structure44 DMRAFSB TI TT23XQV DMRAFSB TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMRAFSB MA Inhibitor DMRAFSB RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMRAFSB RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMRAN5O DI DMRAN5O DMRAN5O DN Naltrexone-6-alpha-ol DMRAN5O TI TTKWM86 DMRAN5O TN Opioid receptor mu (MOP) DMRAN5O MA Inhibitor DMRAN5O RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMRAN5O RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMRAN5O DI DMRAN5O DMRAN5O DN Naltrexone-6-alpha-ol DMRAN5O TI TTQW87Y DMRAN5O TN Opioid receptor kappa (OPRK1) DMRAN5O MA Inhibitor DMRAN5O RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMRAN5O RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMRAN5O DI DMRAN5O DMRAN5O DN Naltrexone-6-alpha-ol DMRAN5O TI TT27RFC DMRAN5O TN Opioid receptor delta (OPRD1) DMRAN5O MA Inhibitor DMRAN5O RN Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8. DMRAN5O RU https://pubmed.ncbi.nlm.nih.gov/19027293 DMRAN9T DI DMRAN9T DMRAN9T DN 1-amino-2,4-bis(phenylthio)anthracene-9,10-dione DMRAN9T TI TTM2AOE DMRAN9T TN Adenosine A2a receptor (ADORA2A) DMRAN9T MA Inhibitor DMRAN9T RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DMRAN9T RU https://pubmed.ncbi.nlm.nih.gov/20095623 DMRATOH DI DMRATOH DMRATOH DN ISIS 5876 DMRATOH TI TTHCEF6 DMRATOH TN VCAM-1 messenger RNA (VCAM1 mRNA) DMRATOH RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMRATOH RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMRAZDW DI DMRAZDW DMRAZDW DN 7-epi-ginkgolide C DMRAZDW TI TTQL5VC DMRAZDW TN Platelet-activating factor receptor (PTAFR) DMRAZDW MA Antagonist DMRAZDW RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMRAZDW RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMRB1AT DI DMRB1AT DMRB1AT DN Kojic acid-phenylalanine amide DMRB1AT TI TTULVH8 DMRB1AT TN Tyrosinase (TYR) DMRB1AT MA Inhibitor DMRB1AT RN Kojic acid-amino acid conjugates as tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5586-9. DMRB1AT RU https://pubmed.ncbi.nlm.nih.gov/19700313 DMRB4YV DI DMRB4YV DMRB4YV DN M6G thiosaccharide analogue DMRB4YV TI TT27RFC DMRB4YV TN Opioid receptor delta (OPRD1) DMRB4YV MA Inhibitor DMRB4YV RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMRB4YV RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMRB4YV DI DMRB4YV DMRB4YV DN M6G thiosaccharide analogue DMRB4YV TI TTQW87Y DMRB4YV TN Opioid receptor kappa (OPRK1) DMRB4YV MA Inhibitor DMRB4YV RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMRB4YV RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMRB4YV DI DMRB4YV DMRB4YV DN M6G thiosaccharide analogue DMRB4YV TI TTKWM86 DMRB4YV TN Opioid receptor mu (MOP) DMRB4YV MA Inhibitor DMRB4YV RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMRB4YV RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMRBEZD DI DMRBEZD DMRBEZD DN 4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one DMRBEZD TI TTNGILX DMRBEZD TN Adrenergic receptor alpha-1A (ADRA1A) DMRBEZD MA Inhibitor DMRBEZD RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DMRBEZD RU https://pubmed.ncbi.nlm.nih.gov/16513345 DMRBEZD DI DMRBEZD DMRBEZD DN 4-(4-chlorobenzyl)-2-allylphthalazin-1(2H)-one DMRBEZD TI TT34BHT DMRBEZD TN Adrenergic receptor alpha-1D (ADRA1D) DMRBEZD MA Inhibitor DMRBEZD RN Vasorelaxant activity of phthalazinones and related compounds. Bioorg Med Chem Lett. 2006 May 15;16(10):2786-90. DMRBEZD RU https://pubmed.ncbi.nlm.nih.gov/16513345 DMRBJ4V DI DMRBJ4V DMRBJ4V DN [3-(Biphenyl-4-yloxy)-propyl]-dimethyl-amine DMRBJ4V TI TT7O8ZA DMRBJ4V TN Lanosterol synthase (LSS) DMRBJ4V MA Inhibitor DMRBJ4V RN Oxidosqualene cyclase inhibitors as antimicrobial agents. J Med Chem. 2003 Sep 25;46(20):4240-3. DMRBJ4V RU https://pubmed.ncbi.nlm.nih.gov/13678402 DMRBKW6 DI DMRBKW6 DMRBKW6 DN PD173212 DMRBKW6 TI TTXHYV6 DMRBKW6 TN Voltage-gated L-type calcium channel (L-CaC) DMRBKW6 MA Blocker DMRBKW6 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMRBKW6 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMRBS50 DI DMRBS50 DMRBS50 DN N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine DMRBS50 TI TTJFY5U DMRBS50 TN Adenosine A3 receptor (ADORA3) DMRBS50 MA Inhibitor DMRBS50 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMRBS50 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMRBS50 DI DMRBS50 DMRBS50 DN N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine DMRBS50 TI TTM2AOE DMRBS50 TN Adenosine A2a receptor (ADORA2A) DMRBS50 MA Inhibitor DMRBS50 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMRBS50 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMRBS50 DI DMRBS50 DMRBS50 DN N6-methoxy-2-[2-(trimethylsilyl)ethynyl]adenosine DMRBS50 TI TTK25J1 DMRBS50 TN Adenosine A1 receptor (ADORA1) DMRBS50 MA Inhibitor DMRBS50 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMRBS50 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMRBVFO DI DMRBVFO DMRBVFO DN 1-Adamantan-1-yl-3-(2-methoxy-phenyl)-urea DMRBVFO TI TT7WVHI DMRBVFO TN Soluble epoxide hydrolase (EPHX2) DMRBVFO MA Inhibitor DMRBVFO RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMRBVFO RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMRBX1D DI DMRBX1D DMRBX1D DN 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol DMRBX1D TI TTK25J1 DMRBX1D TN Adenosine A1 receptor (ADORA1) DMRBX1D MA Inhibitor DMRBX1D RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMRBX1D RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMRBX1D DI DMRBX1D DMRBX1D DN 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol DMRBX1D TI TTNE7KG DMRBX1D TN Adenosine A2b receptor (ADORA2B) DMRBX1D MA Inhibitor DMRBX1D RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMRBX1D RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMRBX1D DI DMRBX1D DMRBX1D DN 2-(6-amino-8-bromo-9H-purin-9-yl)ethanol DMRBX1D TI TTM2AOE DMRBX1D TN Adenosine A2a receptor (ADORA2A) DMRBX1D MA Inhibitor DMRBX1D RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMRBX1D RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMRBZ3X DI DMRBZ3X DMRBZ3X DN [14C]methylamine DMRBZ3X TI TTVHFE8 DMRBZ3X TN Ammonium transporter Rh type A (RHAG) DMRBZ3X MA Modulator DMRBZ3X RN The Rh complex exports ammonium from human red blood cells. Br J Haematol. 2003 Jul;122(2):333-40. DMRBZ3X RU https://pubmed.ncbi.nlm.nih.gov/12846905 DMRBZ3X DI DMRBZ3X DMRBZ3X DN [14C]methylamine DMRBZ3X TI TTN5MZ3 DMRBZ3X TN Ammonium transporter Rh type C (RHCG) DMRBZ3X MA Modulator DMRBZ3X RN Characterization of ammonia transport by the kidney Rh glycoproteins RhBG and RhCG. Am J Physiol Renal Physiol. 2006 Feb;290(2):F297-305. DMRBZ3X RU https://pubmed.ncbi.nlm.nih.gov/16131648 DMRC14X DI DMRC14X DMRC14X DN PMID23374867C24 DMRC14X TI TTHS256 DMRC14X TN Metabotropic glutamate receptor 5 (mGluR5) DMRC14X MA Modulator (allosteric modulator) DMRC14X RN Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator. Bioorg Med Chem Lett. 2013 Mar 1;23(5):1249-52. DMRC14X RU https://pubmed.ncbi.nlm.nih.gov/23374867 DMRC3A5 DI DMRC3A5 DMRC3A5 DN ABL127 DMRC3A5 TI TTXQ54R DMRC3A5 TN Protein phosphatase methylesterase 1 (PME-1) DMRC3A5 MA Inhibitor DMRC3A5 RN A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63. DMRC3A5 RU https://pubmed.ncbi.nlm.nih.gov/24997602 DMRC3OU DI DMRC3OU DMRC3OU DN Anthracene-2-carboxylic acid hydroxyamide DMRC3OU TI TT2J34L DMRC3OU TN Arachidonate 5-lipoxygenase (5-LOX) DMRC3OU MA Inhibitor DMRC3OU RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMRC3OU RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMRC3OZ DI DMRC3OZ DMRC3OZ DN methylglyoxal DMRC3OZ TI TTELV3W DMRC3OZ TN Transformation-sensitive protein p120 (TRPA1) DMRC3OZ MA Activator DMRC3OZ RN Inhibiting TRPA1 ion channel reduces loss of cutaneous nerve fiber function in diabetic animals: sustained activation of the TRPA1 channel contributes to the pathogenesis of peripheral diabetic neuropathy. Pharmacol Res. 2012 Jan;65(1):149-58. DMRC3OZ RU https://pubmed.ncbi.nlm.nih.gov/22133672 DMRC3OZ DI DMRC3OZ DMRC3OZ DN methylglyoxal DMRC3OZ TI TT9V5JH DMRC3OZ TN Phospholipase A2 (PLA2G1B) DMRC3OZ MA Inhibitor DMRC3OZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRC3OZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRC49E DI DMRC49E DMRC49E DN 4-fluoroselegiline DMRC49E TI TTGP7BY DMRC49E TN Monoamine oxidase type B (MAO-B) DMRC49E MA Modulator DMRC49E RN Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch Int Pharmacodyn Ther. 1994 Jul-Aug;328(1):1-15. DMRC49E RU https://pubmed.ncbi.nlm.nih.gov/7893186 DMRC4LE DI DMRC4LE DMRC4LE DN Sch 202596 DMRC4LE TI TTOPAY7 DMRC4LE TN Galanin receptor (GAL-R) DMRC4LE MA Antagonist DMRC4LE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 245). DMRC4LE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=245 DMRC60A DI DMRC60A DMRC60A DN 2-Methyl-4-phenylethynyl-thiazole DMRC60A TI TTHS256 DMRC60A TN Metabotropic glutamate receptor 5 (mGluR5) DMRC60A MA Inhibitor DMRC60A RN 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6. DMRC60A RU https://pubmed.ncbi.nlm.nih.gov/15225713 DMRC7V8 DI DMRC7V8 DMRC7V8 DN 1-(4-methoxyphenyl)-2-(phenylsulfonyl)ethanone DMRC7V8 TI TTN7BL9 DMRC7V8 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMRC7V8 MA Inhibitor DMRC7V8 RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMRC7V8 RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMRC8MT DI DMRC8MT DMRC8MT DN L-746233 DMRC8MT TI TTJA1ZO DMRC8MT TN ITGB3 messenger RNA (ITGB3 mRNA) DMRC8MT MA Inhibitor DMRC8MT RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DMRC8MT RU https://pubmed.ncbi.nlm.nih.gov/10999999 DMRC8SO DI DMRC8SO DMRC8SO DN 5-methyl-cyclosal-d4TMP DMRC8SO TI TTEB0GD DMRC8SO TN Cholinesterase (BCHE) DMRC8SO MA Inhibitor DMRC8SO RN Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46. DMRC8SO RU https://pubmed.ncbi.nlm.nih.gov/17328534 DMRCAEI DI DMRCAEI DMRCAEI DN PMID21939274C2 DMRCAEI TI TT7QNVC DMRCAEI TN Glucose-dependent insulinotropic receptor (GPR119) DMRCAEI MA Agonist DMRCAEI RN Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma. Chem Res Toxicol. 2011 Dec 19;24(12):2207-16. DMRCAEI RU https://pubmed.ncbi.nlm.nih.gov/21939274 DMRCD3O DI DMRCD3O DMRCD3O DN THEBAINE DMRCD3O TI TTKWM86 DMRCD3O TN Opioid receptor mu (MOP) DMRCD3O MA Inhibitor DMRCD3O RN Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem. 2007 Sep 14;282(37):27126-32. DMRCD3O RU https://pubmed.ncbi.nlm.nih.gov/17616524 DMRCJW0 DI DMRCJW0 DMRCJW0 DN 3-boronobenzoic acid DMRCJW0 TI TTLP6GN DMRCJW0 TN Bacterial DD-carboxypeptidase (Bact vanYB) DMRCJW0 MA Inhibitor DMRCJW0 RN Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106. DMRCJW0 RU https://pubmed.ncbi.nlm.nih.gov/19731939 DMRCM5O DI DMRCM5O DMRCM5O DN (4-Hydroxy-phenoxy)-acetic acid DMRCM5O TI TT8DSFC DMRCM5O TN Hydroxyphenylpyruvate dioxygenase (HPD) DMRCM5O MA Inhibitor DMRCM5O RN Design, synthesis, and evaluation of postulated transient intermediate and substrate analogues as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2002 Jul 8;12(13):1709-13. DMRCM5O RU https://pubmed.ncbi.nlm.nih.gov/12067543 DMRCM7Q DI DMRCM7Q DMRCM7Q DN 9-Phenyl-2,3-dihydro-1H-indeno[2,1-c]pyridine DMRCM7Q TI TTTIBOJ DMRCM7Q TN Histamine H1 receptor (H1R) DMRCM7Q MA Inhibitor DMRCM7Q RN Conformationally-restricted ligands for the histamine H1 receptor. Bioorg Med Chem Lett. 2000 Jun 5;10(11):1277-9. DMRCM7Q RU https://pubmed.ncbi.nlm.nih.gov/10866399 DMRCMIT DI DMRCMIT DMRCMIT DN (2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMRCMIT TI TT6OEDT DMRCMIT TN Cannabinoid receptor 1 (CB1) DMRCMIT MA Inhibitor DMRCMIT RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMRCMIT RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMRCMIT DI DMRCMIT DMRCMIT DN (2S)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMRCMIT TI TTMSFAW DMRCMIT TN Cannabinoid receptor 2 (CB2) DMRCMIT MA Inhibitor DMRCMIT RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMRCMIT RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMRCTBA DI DMRCTBA DMRCTBA DN 6-Nitro-2-(3-nitro-phenyl)-chromen-4-one DMRCTBA TI TT1MPAY DMRCTBA TN GABA(A) receptor alpha-1 (GABRA1) DMRCTBA MA Inhibitor DMRCTBA RN 6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995). DMRCTBA RU http://www.sciencedirect.com/science/article/pii/0960894X95004645 DMRCTBA DI DMRCTBA DMRCTBA DN 6-Nitro-2-(3-nitro-phenyl)-chromen-4-one DMRCTBA TI TT06RH5 DMRCTBA TN GABA(A) receptor gamma-2 (GABRG2) DMRCTBA MA Inhibitor DMRCTBA RN 6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995). DMRCTBA RU http://www.sciencedirect.com/science/article/pii/0960894X95004645 DMRCTBA DI DMRCTBA DMRCTBA DN 6-Nitro-2-(3-nitro-phenyl)-chromen-4-one DMRCTBA TI TTNJYV2 DMRCTBA TN Gamma-aminobutyric acid receptor (GAR) DMRCTBA MA Inhibitor DMRCTBA RN 6,3'-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties, Bioorg. Med. Chem. Lett. 5(22):2717-2720 (1995). DMRCTBA RU http://www.sciencedirect.com/science/article/pii/0960894X95004645 DMRCUKJ DI DMRCUKJ DMRCUKJ DN 1,2-bis(3,4-difluorophenyl)-2-hydroxyethanone DMRCUKJ TI TTMF541 DMRCUKJ TN Liver carboxylesterase (CES1) DMRCUKJ MA Inhibitor DMRCUKJ RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMRCUKJ RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMRCYB8 DI DMRCYB8 DMRCYB8 DN N-(biphenyl-3-yl)-6-(sulfamoylamino)hexanamide DMRCYB8 TI TT5ZKDI DMRCYB8 TN Histone deacetylase 6 (HDAC6) DMRCYB8 MA Inhibitor DMRCYB8 RN Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. DMRCYB8 RU https://pubmed.ncbi.nlm.nih.gov/19084395 DMRD83Q DI DMRD83Q DMRD83Q DN AMG-2504 DMRD83Q TI TTELV3W DMRD83Q TN Transformation-sensitive protein p120 (TRPA1) DMRD83Q MA Inhibitor DMRD83Q RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DMRD83Q RU https://pubmed.ncbi.nlm.nih.gov/20356305 DMRD8VM DI DMRD8VM DMRD8VM DN 3-cyano-N-(3-cyanophenyl)-5-fluorobenzamide DMRD8VM TI TTHS256 DMRD8VM TN Metabotropic glutamate receptor 5 (mGluR5) DMRD8VM MA Inhibitor DMRD8VM RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMRD8VM RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMRDF8Z DI DMRDF8Z DMRDF8Z DN Piridronic acid DMRDF8Z TI TTIKWV4 DMRDF8Z TN Geranyltranstransferase (FDPS) DMRDF8Z MA Inhibitor DMRDF8Z RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMRDF8Z RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMRDHL2 DI DMRDHL2 DMRDHL2 DN (1H-Imidazol-2-yl)-quinoxalin-6-yl-amine DMRDHL2 TI TTWG9A4 DMRDHL2 TN Adrenergic receptor alpha-2A (ADRA2A) DMRDHL2 MA Inhibitor DMRDHL2 RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DMRDHL2 RU https://pubmed.ncbi.nlm.nih.gov/9016324 DMRDHL2 DI DMRDHL2 DMRDHL2 DN (1H-Imidazol-2-yl)-quinoxalin-6-yl-amine DMRDHL2 TI TT2NUT5 DMRDHL2 TN Adrenergic receptor alpha-2C (ADRA2C) DMRDHL2 MA Inhibitor DMRDHL2 RN Synthesis and evaluation of 2-(arylamino)imidazoles as alpha 2-adrenergic agonists. J Med Chem. 1997 Jan 3;40(1):18-23. DMRDHL2 RU https://pubmed.ncbi.nlm.nih.gov/9016324 DMRDM9S DI DMRDM9S DMRDM9S DN SCH-602539 DMRDM9S TI TTL935N DMRDM9S TN Proteinase activated receptor 1 (F2R) DMRDM9S MA Antagonist DMRDM9S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 347). DMRDM9S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=347 DMRDOP0 DI DMRDOP0 DMRDOP0 DN 8-n-pentylnaringenin DMRDOP0 TI TTOM3J0 DMRDOP0 TN Estrogen receptor beta (ESR2) DMRDOP0 MA Inhibitor DMRDOP0 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMRDOP0 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMRDOP0 DI DMRDOP0 DMRDOP0 DN 8-n-pentylnaringenin DMRDOP0 TI TTZAYWL DMRDOP0 TN Estrogen receptor (ESR) DMRDOP0 MA Inhibitor DMRDOP0 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMRDOP0 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMRDQ1B DI DMRDQ1B DMRDQ1B DN N-(2-aminophenyl)nicotinamide DMRDQ1B TI TTSHTOI DMRDQ1B TN Histone deacetylase 2 (HDAC2) DMRDQ1B MA Inhibitor DMRDQ1B RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMRDQ1B RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMRDQ1B DI DMRDQ1B DMRDQ1B DN N-(2-aminophenyl)nicotinamide DMRDQ1B TI TT6R7JZ DMRDQ1B TN Histone deacetylase 1 (HDAC1) DMRDQ1B MA Inhibitor DMRDQ1B RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMRDQ1B RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMRDQ1B DI DMRDQ1B DMRDQ1B DN N-(2-aminophenyl)nicotinamide DMRDQ1B TI TTBH0VX DMRDQ1B TN Histone deacetylase (HDAC) DMRDQ1B MA Inhibitor DMRDQ1B RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMRDQ1B RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMRDS1U DI DMRDS1U DMRDS1U DN 3-(3-Methanesulfonyl-phenyl)-1-propyl-pyrrolidine DMRDS1U TI TTSQIFT DMRDS1U TN 5-HT 1A receptor (HTR1A) DMRDS1U MA Inhibitor DMRDS1U RN Regioselective synthesis of 3-aryl substituted pyrrolidines via palladium catalyzed arylation: pharmacological evaluation for central dopaminergic and serotonergic activity, Bioorg. Med. Chem. Lett. 7(3):241-246 (1997). DMRDS1U RU http://www.sciencedirect.com/science/article/pii/S0960894X9600618X DMRDWUT DI DMRDWUT DMRDWUT DN 4-(2-(3-fluorophenyl)ethynyl)-2-methylthiazole DMRDWUT TI TTHS256 DMRDWUT TN Metabotropic glutamate receptor 5 (mGluR5) DMRDWUT MA Inhibitor DMRDWUT RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMRDWUT RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMRDX8U DI DMRDX8U DMRDX8U DN dATPalphaS DMRDX8U TI TTA93TL DMRDX8U TN P2Y purinoceptor 1 (P2RY1) DMRDX8U MA Agonist DMRDX8U RN An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997 May;121(2):338-44. DMRDX8U RU https://pubmed.ncbi.nlm.nih.gov/9154346 DMRDZ7I DI DMRDZ7I DMRDZ7I DN KT6528 DMRDZ7I TI TTGTQHC DMRDZ7I TN DNA topoisomerase I (TOP1) DMRDZ7I MA Inducer DMRDZ7I RN Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 1992 Dec 8;31(48):12069-75. DMRDZ7I RU https://pubmed.ncbi.nlm.nih.gov/1333791 DMRE4ZI DI DMRE4ZI DMRE4ZI DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl DMRE4ZI TI TTZPO1L DMRE4ZI TN Substance-P receptor (TACR1) DMRE4ZI MA Inhibitor DMRE4ZI RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMRE4ZI RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMRE4ZI DI DMRE4ZI DMRE4ZI DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl DMRE4ZI TI TT27RFC DMRE4ZI TN Opioid receptor delta (OPRD1) DMRE4ZI MA Inhibitor DMRE4ZI RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMRE4ZI RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMRE4ZI DI DMRE4ZI DMRE4ZI DN H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl DMRE4ZI TI TTKWM86 DMRE4ZI TN Opioid receptor mu (MOP) DMRE4ZI MA Inhibitor DMRE4ZI RN A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76. DMRE4ZI RU https://pubmed.ncbi.nlm.nih.gov/18266313 DMRE7G3 DI DMRE7G3 DMRE7G3 DN Tyr-Pro-Mmp-Phe-NH DMRE7G3 TI TTKWM86 DMRE7G3 TN Opioid receptor mu (MOP) DMRE7G3 MA Inhibitor DMRE7G3 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMRE7G3 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMRE7G3 DI DMRE7G3 DMRE7G3 DN Tyr-Pro-Mmp-Phe-NH DMRE7G3 TI TT27RFC DMRE7G3 TN Opioid receptor delta (OPRD1) DMRE7G3 MA Inhibitor DMRE7G3 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMRE7G3 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMRE96F DI DMRE96F DMRE96F DN Benzomate DMRE96F TI TTHM0R1 DMRE96F TN Steryl-sulfatase (STS) DMRE96F MA Inhibitor DMRE96F RN Synthesis, in vitro and in vivo activity of benzophenone-based inhibitors of steroid sulfatase. Bioorg Med Chem. 2004 May 15;12(10):2759-72. DMRE96F RU https://pubmed.ncbi.nlm.nih.gov/15110857 DMREF31 DI DMREF31 DMREF31 DN 2,6-diamino-5-nitropyrimidin-4(3H)-one DMREF31 TI TT4ILYC DMREF31 TN Bacterial Dihydropteroate synthetase (Bact folP) DMREF31 MA Inhibitor DMREF31 RN Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem. 2010 Jan 14;53(1):166-77. DMREF31 RU https://pubmed.ncbi.nlm.nih.gov/19899766 DMREFCY DI DMREFCY DMREFCY DN ISIS 2324 DMREFCY TI TTF3I4E DMREFCY TN Human papillomavirus E2 region messenger RNA (HPV E2 mRNA) DMREFCY RN US patent application no. 5,457,189, Antisense oligonucleotide inhibition of papillomavirus. DMREFCY RU http://www.patentbuddy.com/Patent/5457189?ft=true&sr=true DMREJ69 DI DMREJ69 DMREJ69 DN Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 DMREJ69 TI TTVFO0U DMREJ69 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMREJ69 MA Inhibitor DMREJ69 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMREJ69 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMREJ69 DI DMREJ69 DMREJ69 DN Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 DMREJ69 TI TTKWM86 DMREJ69 TN Opioid receptor mu (MOP) DMREJ69 MA Inhibitor DMREJ69 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMREJ69 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMREJ69 DI DMREJ69 DMREJ69 DN Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 DMREJ69 TI TT27RFC DMREJ69 TN Opioid receptor delta (OPRD1) DMREJ69 MA Inhibitor DMREJ69 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMREJ69 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMREJ69 DI DMREJ69 DMREJ69 DN Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 DMREJ69 TI TTCG0AL DMREJ69 TN Cholecystokinin receptor type A (CCKAR) DMREJ69 MA Inhibitor DMREJ69 RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMREJ69 RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMREVX9 DI DMREVX9 DMREVX9 DN (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone DMREVX9 TI TT9W8GU DMREVX9 TN Gamma-secretase (GS) DMREVX9 MA Inhibitor DMREVX9 RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMREVX9 RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMREVX9 DI DMREVX9 DMREVX9 DN (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone DMREVX9 TI TTZ3S8C DMREVX9 TN Presenilin 1 (PSEN1) DMREVX9 MA Inhibitor DMREVX9 RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMREVX9 RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMREVX9 DI DMREVX9 DMREVX9 DN (5R,6S)-5,6-bis(benzyloxy)cyclohex-2-enone DMREVX9 TI TTWN3F4 DMREVX9 TN Presenilin 2 (PSEN2) DMREVX9 MA Inhibitor DMREVX9 RN Novel gamma-secretase inhibitors discovered by library screening of in-house synthetic natural product intermediates. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3813-6. DMREVX9 RU https://pubmed.ncbi.nlm.nih.gov/16682195 DMREZT7 DI DMREZT7 DMREZT7 DN D[Leu4]AVP DMREZT7 TI TT4TFGN DMREZT7 TN Vasopressin V1a receptor (V1AR) DMREZT7 MA Inhibitor DMREZT7 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMREZT7 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMREZT7 DI DMREZT7 DMREZT7 DN D[Leu4]AVP DMREZT7 TI TTSCIUP DMREZT7 TN Oxytocin receptor (OTR) DMREZT7 MA Inhibitor DMREZT7 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMREZT7 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMREZT7 DI DMREZT7 DMREZT7 DN D[Leu4]AVP DMREZT7 TI TTL9MHW DMREZT7 TN Vasopressin V1b receptor (V1BR) DMREZT7 MA Inhibitor DMREZT7 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMREZT7 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMREZT7 DI DMREZT7 DMREZT7 DN D[Leu4]AVP DMREZT7 TI TTK8R02 DMREZT7 TN Vasopressin V2 receptor (V2R) DMREZT7 MA Inhibitor DMREZT7 RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMREZT7 RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMRF0PS DI DMRF0PS DMRF0PS DN 5-(3,4-dichlorophenyl)-1H-pyrazol-3-ol DMRF0PS TI TTEAID7 DMRF0PS TN Trypanosoma Cruzipain (Trypano CYSP) DMRF0PS MA Inhibitor DMRF0PS RN Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51. DMRF0PS RU https://pubmed.ncbi.nlm.nih.gov/19908840 DMRF2Q8 DI DMRF2Q8 DMRF2Q8 DN 3-butoxycarbonyl-4-quinolone DMRF2Q8 TI TT1MPAY DMRF2Q8 TN GABA(A) receptor alpha-1 (GABRA1) DMRF2Q8 MA Inhibitor DMRF2Q8 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRF2Q8 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRF2Q8 DI DMRF2Q8 DMRF2Q8 DN 3-butoxycarbonyl-4-quinolone DMRF2Q8 TI TTNJYV2 DMRF2Q8 TN Gamma-aminobutyric acid receptor (GAR) DMRF2Q8 MA Inhibitor DMRF2Q8 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRF2Q8 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRF2Q8 DI DMRF2Q8 DMRF2Q8 DN 3-butoxycarbonyl-4-quinolone DMRF2Q8 TI TT06RH5 DMRF2Q8 TN GABA(A) receptor gamma-2 (GABRG2) DMRF2Q8 MA Inhibitor DMRF2Q8 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRF2Q8 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRF2Q8 DI DMRF2Q8 DMRF2Q8 DN 3-butoxycarbonyl-4-quinolone DMRF2Q8 TI TTZA1NY DMRF2Q8 TN GABA(A) receptor beta-2 (GABRB2) DMRF2Q8 MA Inhibitor DMRF2Q8 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRF2Q8 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRF5LU DI DMRF5LU DMRF5LU DN IC-041 DMRF5LU TI TT3ZS42 DMRF5LU TN Phosphodiesterase 1B (PDE1B) DMRF5LU MA Inhibitor DMRF5LU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1295). DMRF5LU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1295 DMRF73O DI DMRF73O DMRF73O DN HT-2678 DMRF73O TI TTNZPQ1 DMRF73O TN GABA(A) receptor alpha-5 (GABRA5) DMRF73O MA Agonist DMRF73O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMRF73O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMRFA5O DI DMRFA5O DMRFA5O DN CCNCASKWCRDHSRCC DMRFA5O TI TT84DRB DMRFA5O TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMRFA5O MA Inhibitor DMRFA5O RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DMRFA5O RU https://pubmed.ncbi.nlm.nih.gov/17724025 DMRFAVG DI DMRFAVG DMRFAVG DN TG-2001 DMRFAVG TI TTF89GD DMRFAVG TN Interleukin-2 (IL2) DMRFAVG MA Modulator DMRFAVG RN Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose le... Cancer Gene Ther. 2002 Mar;9(3):289-95. DMRFAVG RU https://www.ncbi.nlm.nih.gov/pubmed/11896446 DMRFBD0 DI DMRFBD0 DMRFBD0 DN Deprenyl DMRFBD0 TI TTGP7BY DMRFBD0 TN Monoamine oxidase type B (MAO-B) DMRFBD0 MA Inhibitor DMRFBD0 RN The effect of deprenyl washout in patients with long-standing Parkinson's disease. J Neural Transm. 2002 May;109(5-6):797-803. DMRFBD0 RU https://pubmed.ncbi.nlm.nih.gov/12111469 DMRFH9U DI DMRFH9U DMRFH9U DN 5'-deoxy-4'-hydroxy-5'-methylthio-DADMe-ImmH DMRFH9U TI TTMCF1Y DMRFH9U TN Purine nucleoside phosphorylase (PNP) DMRFH9U MA Inhibitor DMRFH9U RN Immucillins in custom catalytic-site cavities. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5900-3. DMRFH9U RU https://pubmed.ncbi.nlm.nih.gov/18778937 DMRFJNC DI DMRFJNC DMRFJNC DN 1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol DMRFJNC TI TTWJBZ5 DMRFJNC TN 5-HT 2C receptor (HTR2C) DMRFJNC MA Inhibitor DMRFJNC RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMRFJNC RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMRFJNC DI DMRFJNC DMRFJNC DN 1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol DMRFJNC TI TTJQOD7 DMRFJNC TN 5-HT 2A receptor (HTR2A) DMRFJNC MA Inhibitor DMRFJNC RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMRFJNC RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMRFJNC DI DMRFJNC DMRFJNC DN 1-((S)-2-aminopropyl)-7-chloro-1H-indazol-6-ol DMRFJNC TI TT0K1SC DMRFJNC TN 5-HT 2B receptor (HTR2B) DMRFJNC MA Inhibitor DMRFJNC RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMRFJNC RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMRFKZ6 DI DMRFKZ6 DMRFKZ6 DN S-(N-propyl-N-hydroxycarbamoyl)glutathione DMRFKZ6 TI TTV9A7R DMRFKZ6 TN Lactoylglutathione lyase (GLO1) DMRFKZ6 MA Inhibitor DMRFKZ6 RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DMRFKZ6 RU https://pubmed.ncbi.nlm.nih.gov/11052803 DMRFMVL DI DMRFMVL DMRFMVL DN ISIS 134532 DMRFMVL TI TTKW4ML DMRFMVL TN Caspase 6 messenger RNA (CASP6 mRNA) DMRFMVL RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMRFMVL RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMRFPNE DI DMRFPNE DMRFPNE DN 3-(pyridin-4-yl)-1H-indol-7-amine DMRFPNE TI TTTB4UP DMRFPNE TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMRFPNE MA Inhibitor DMRFPNE RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMRFPNE RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMRFQ1W DI DMRFQ1W DMRFQ1W DN PMID25050158C14 DMRFQ1W TI TTDCVZW DMRFQ1W TN Gamma-aminobutyric acid B receptor (GABBR) DMRFQ1W MA Modulator (allosteric modulator) DMRFQ1W RN Discovery of a Negative Allosteric Modulator of GABAB Receptors. ACS Med Chem Lett. 2014 May 27;5(7):742-7. DMRFQ1W RU https://pubmed.ncbi.nlm.nih.gov/25050158 DMRFTJX DI DMRFTJX DMRFTJX DN Daidzein DMRFTJX TI TT32NQ1 DMRFTJX TN Short transient receptor potential channel 5 (TRPC5) DMRFTJX MA Activator DMRFTJX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 490). DMRFTJX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=490 DMRFTJX DI DMRFTJX DMRFTJX DN Daidzein DMRFTJX TI TT9ZRHB DMRFTJX TN Estrogen-related receptor-gamma (ESRRG) DMRFTJX MA Agonist DMRFTJX RN Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. DMRFTJX RU https://pubmed.ncbi.nlm.nih.gov/14638870 DMRFTJX DI DMRFTJX DMRFTJX DN Daidzein DMRFTJX TI TTKF0XS DMRFTJX TN Estrogen-related receptor-beta (ESRRB) DMRFTJX MA Agonist DMRFTJX RN Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. DMRFTJX RU https://pubmed.ncbi.nlm.nih.gov/14638870 DMRFTJX DI DMRFTJX DMRFTJX DN Daidzein DMRFTJX TI TTPNQAC DMRFTJX TN Estrogen-related receptor-alpha (ESRRA) DMRFTJX MA Agonist DMRFTJX RN Flavone and isoflavone phytoestrogens are agonists of estrogen-related receptors. Mol Cancer Res. 2003 Nov;1(13):981-91. DMRFTJX RU https://pubmed.ncbi.nlm.nih.gov/14638870 DMRFTJX DI DMRFTJX DMRFTJX DN Daidzein DMRFTJX TI TTZAYWL DMRFTJX TN Estrogen receptor (ESR) DMRFTJX MA Inhibitor DMRFTJX RN Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53. DMRFTJX RU https://pubmed.ncbi.nlm.nih.gov/12502307 DMRFTJX DI DMRFTJX DMRFTJX DN Daidzein DMRFTJX TI TTOM3J0 DMRFTJX TN Estrogen receptor beta (ESR2) DMRFTJX MA Inhibitor DMRFTJX RN Isolation and structure elucidation of an isoflavone and a sesterterpenoic acid from Henriettella fascicularis. J Nat Prod. 2002 Dec;65(12):1749-53. DMRFTJX RU https://pubmed.ncbi.nlm.nih.gov/12502307 DMRFTJX DI DMRFTJX DMRFTJX DN Daidzein DMRFTJX TI TTFBNVI DMRFTJX TN Aldose reductase (AKR1B1) DMRFTJX MA Inhibitor DMRFTJX RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DMRFTJX RU https://pubmed.ncbi.nlm.nih.gov/10354396 DMRFWE1 DI DMRFWE1 DMRFWE1 DN 4'-(p-Toluenesulfonamide)-4-hydroxychalcone DMRFWE1 TI TTULVH8 DMRFWE1 TN Tyrosinase (TYR) DMRFWE1 MA Inhibitor DMRFWE1 RN Evaluation of anti-pigmentary effect of synthetic sulfonylamino chalcone. Eur J Med Chem. 2010 May;45(5):2010-7. DMRFWE1 RU https://pubmed.ncbi.nlm.nih.gov/20149498 DMRG1VI DI DMRG1VI DMRG1VI DN JWH-403 DMRG1VI TI TT6OEDT DMRG1VI TN Cannabinoid receptor 1 (CB1) DMRG1VI MA Inhibitor DMRG1VI RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMRG1VI RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMRG1VI DI DMRG1VI DMRG1VI DN JWH-403 DMRG1VI TI TTMSFAW DMRG1VI TN Cannabinoid receptor 2 (CB2) DMRG1VI MA Inhibitor DMRG1VI RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMRG1VI RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMRG2CU DI DMRG2CU DMRG2CU DN 1,6-bis-(Dmt-Tic-amino)hexane DMRG2CU TI TTKWM86 DMRG2CU TN Opioid receptor mu (MOP) DMRG2CU MA Inhibitor DMRG2CU RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMRG2CU RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMRG2CU DI DMRG2CU DMRG2CU DN 1,6-bis-(Dmt-Tic-amino)hexane DMRG2CU TI TT27RFC DMRG2CU TN Opioid receptor delta (OPRD1) DMRG2CU MA Inhibitor DMRG2CU RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMRG2CU RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMRG80O DI DMRG80O DMRG80O DN (S)-2-Amino-6-[(E)-ethylimino]-hexanoic acid DMRG80O TI TTF10I9 DMRG80O TN Nitric-oxide synthase inducible (NOS2) DMRG80O MA Inhibitor DMRG80O RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMRG80O RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMRGD8W DI DMRGD8W DMRGD8W DN 1-(phenylsulfonyl)butan-2-one DMRGD8W TI TTN7BL9 DMRGD8W TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMRGD8W MA Inhibitor DMRGD8W RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMRGD8W RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMRGFEM DI DMRGFEM DMRGFEM DN alphabeta-methyleneADP DMRGFEM TI TTK0O6Y DMRGFEM TN Ecto-5'-nucleotidase (CD73) DMRGFEM MA Inhibitor DMRGFEM RN 5'-Nucleotidase from smooth muscle of small intestine and from brain. Inhibition of nucleotides. Biochemistry. 1975 Jun 3;14(11):2362-6. DMRGFEM RU https://pubmed.ncbi.nlm.nih.gov/1169962 DMRGFEM DI DMRGFEM DMRGFEM DN alphabeta-methyleneADP DMRGFEM TI TTUTN1I DMRGFEM TN Human Deoxyribonucleic acid (hDNA) DMRGFEM MA Inhibitor DMRGFEM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRGFEM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRGIF3 DI DMRGIF3 DMRGIF3 DN (LTB4-(Csa)4)2-Glu-H Conjugate DMRGIF3 TI TTN53ZF DMRGIF3 TN Leukotriene B4 receptor 1 (LTB4R) DMRGIF3 MA Inhibitor DMRGIF3 RN Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci. J Med Chem. 2005 Oct 6;48(20):6442-53. DMRGIF3 RU https://pubmed.ncbi.nlm.nih.gov/16190770 DMRGM21 DI DMRGM21 DMRGM21 DN 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole DMRGM21 TI TTR5TV4 DMRGM21 TN ERBB2 messenger RNA (HER2 mRNA) DMRGM21 MA Inhibitor DMRGM21 RN Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. DMRGM21 RU https://pubmed.ncbi.nlm.nih.gov/17174554 DMRGNSQ DI DMRGNSQ DMRGNSQ DN Bis(6-hydroxybenzo[b]furan-2-yl)methanone DMRGNSQ TI TTI7421 DMRGNSQ TN Platelet-derived growth factor receptor beta (PDGFRB) DMRGNSQ MA Inhibitor DMRGNSQ RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMRGNSQ RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMRGNSQ DI DMRGNSQ DMRGNSQ DN Bis(6-hydroxybenzo[b]furan-2-yl)methanone DMRGNSQ TI TTGJCWZ DMRGNSQ TN Fms-like tyrosine kinase 3 (FLT-3) DMRGNSQ MA Inhibitor DMRGNSQ RN Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones. Bioorg Med Chem. 2007 Mar 1;15(5):2187-97. DMRGNSQ RU https://pubmed.ncbi.nlm.nih.gov/17210255 DMRGQTM DI DMRGQTM DMRGQTM DN N-(6-(furan-3-yl)-1H-indazol-3-yl)butyramide DMRGQTM TI TTRSMW9 DMRGQTM TN Glycogen synthase kinase-3 beta (GSK-3B) DMRGQTM MA Inhibitor DMRGQTM RN Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. DMRGQTM RU https://pubmed.ncbi.nlm.nih.gov/20167481 DMRGVNJ DI DMRGVNJ DMRGVNJ DN (-)-uniflorine A DMRGVNJ TI TTLPC70 DMRGVNJ TN Lysosomal alpha-glucosidase (GAA) DMRGVNJ MA Inhibitor DMRGVNJ RN Total synthesis of (-)-uniflorine A. J Nat Prod. 2009 Nov;72(11):2058-60. DMRGVNJ RU https://pubmed.ncbi.nlm.nih.gov/19835391 DMRGY2X DI DMRGY2X DMRGY2X DN PMID8246233C28 DMRGY2X TI TTPADOQ DMRGY2X TN HMG-CoA reductase (HMGCR) DMRGY2X MA Inhibitor DMRGY2X RN Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3646-57. DMRGY2X RU https://pubmed.ncbi.nlm.nih.gov/8246233 DMRH987 DI DMRH987 DMRH987 DN N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide DMRH987 TI TTJ2PTI DMRH987 TN Tubulin beta-2 chain (TUBB2) DMRH987 MA Inhibitor DMRH987 RN Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70. DMRH987 RU https://pubmed.ncbi.nlm.nih.gov/16970393 DMRH987 DI DMRH987 DMRH987 DN N-(4-(3-(pyridin-2-yl)acryloyl)phenyl)acetamide DMRH987 TI TTYFKSZ DMRH987 TN Tubulin beta (TUBB) DMRH987 MA Inhibitor DMRH987 RN Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006 Sep 21;49(19):5664-70. DMRH987 RU https://pubmed.ncbi.nlm.nih.gov/16970393 DMRHDGN DI DMRHDGN DMRHDGN DN TP003 DMRHDGN TI TTBMV1G DMRHDGN TN GABA(A) receptor alpha-2 (GABRA2) DMRHDGN MA Modulator (allosteric modulator) DMRHDGN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMRHDGN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMRHDGN DI DMRHDGN DMRHDGN DN TP003 DMRHDGN TI TT37EDJ DMRHDGN TN GABA(A) receptor alpha-3 (GABRA3) DMRHDGN MA Modulator (allosteric modulator) DMRHDGN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMRHDGN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMRHDGN DI DMRHDGN DMRHDGN DN TP003 DMRHDGN TI TTNZPQ1 DMRHDGN TN GABA(A) receptor alpha-5 (GABRA5) DMRHDGN MA Modulator (allosteric modulator) DMRHDGN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMRHDGN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMRHDGN DI DMRHDGN DMRHDGN DN TP003 DMRHDGN TI TTEX6LM DMRHDGN TN GABA(A) receptor gamma-3 (GABRG3) DMRHDGN MA Modulator (allosteric modulator) DMRHDGN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMRHDGN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMRHIMC DI DMRHIMC DMRHIMC DN PF-00212062 DMRHIMC TI TT1ZAVI DMRHIMC TN Prostaglandin E2 receptor EP2 (PTGER2) DMRHIMC MA Antagonist DMRHIMC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341). DMRHIMC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341 DMRHKF8 DI DMRHKF8 DMRHKF8 DN N-phenyl-6-(sulfamoylamino)hexanamide DMRHKF8 TI TT5ZKDI DMRHKF8 TN Histone deacetylase 6 (HDAC6) DMRHKF8 MA Inhibitor DMRHKF8 RN Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. DMRHKF8 RU https://pubmed.ncbi.nlm.nih.gov/19084395 DMRHSCQ DI DMRHSCQ DMRHSCQ DN ELAEOCARPENINE DMRHSCQ TI TTKWM86 DMRHSCQ TN Opioid receptor mu (MOP) DMRHSCQ MA Inhibitor DMRHSCQ RN Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3. DMRHSCQ RU https://pubmed.ncbi.nlm.nih.gov/20144865 DMRHSCQ DI DMRHSCQ DMRHSCQ DN ELAEOCARPENINE DMRHSCQ TI TT27RFC DMRHSCQ TN Opioid receptor delta (OPRD1) DMRHSCQ MA Inhibitor DMRHSCQ RN Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3. DMRHSCQ RU https://pubmed.ncbi.nlm.nih.gov/20144865 DMRHSCQ DI DMRHSCQ DMRHSCQ DN ELAEOCARPENINE DMRHSCQ TI TTQW87Y DMRHSCQ TN Opioid receptor kappa (OPRK1) DMRHSCQ MA Inhibitor DMRHSCQ RN Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3. DMRHSCQ RU https://pubmed.ncbi.nlm.nih.gov/20144865 DMRHSY6 DI DMRHSY6 DMRHSY6 DN ISIS 140161 DMRHSY6 TI TTAK0IN DMRHSY6 TN SOAT2 messenger RNA (SOAT2 mRNA) DMRHSY6 RN US patent application no. 7,202,357, Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression. DMRHSY6 RU http://www.patentbuddy.com/Patent/7202357?ft=true&sr=true DMRHY2M DI DMRHY2M DMRHY2M DN 1-(2-adamantyl)-3-benzylpyrrolidin-2-one DMRHY2M TI TTN7BL9 DMRHY2M TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMRHY2M MA Inhibitor DMRHY2M RN Discovery of orally active butyrolactam 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5555-60. DMRHY2M RU https://pubmed.ncbi.nlm.nih.gov/16931002 DMRI08C DI DMRI08C DMRI08C DN AL7099A DMRI08C TI TTANPDJ DMRI08C TN Carbonic anhydrase II (CA-II) DMRI08C MA Inhibitor DMRI08C RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMRI08C RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMRI1LF DI DMRI1LF DMRI1LF DN PV-1019 DMRI1LF TI TT9ABMF DMRI1LF TN Serine/threonine-protein kinase Chk2 (RAD53) DMRI1LF MA Inhibitor DMRI1LF RN Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. DMRI1LF RU https://pubmed.ncbi.nlm.nih.gov/19741151 DMRI49D DI DMRI49D DMRI49D DN BRL-36378 DMRI49D TI TTL69WB DMRI49D TN Angiotensin-converting enzyme (ACE) DMRI49D MA Modulator DMRI49D RN Antihypertensive and angiotensin converting enzyme inhibitory activities of a novel dihydrobenzofuran analogue. Arzneimittelforschung. 1988 Apr;38(4):531-6. DMRI49D RU https://www.ncbi.nlm.nih.gov/pubmed/2840917 DMRI503 DI DMRI503 DMRI503 DN 3-Butyl-[1,4]oxazepan-(5Z)-ylideneamine DMRI503 TI TTF10I9 DMRI503 TN Nitric-oxide synthase inducible (NOS2) DMRI503 MA Inhibitor DMRI503 RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMRI503 RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMRICV6 DI DMRICV6 DMRICV6 DN Demotensin 1 DMRICV6 TI TTTUMEP DMRICV6 TN Neurotensin receptor type 1 (NTSR1) DMRICV6 MA Inhibitor DMRICV6 RN Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76. DMRICV6 RU https://pubmed.ncbi.nlm.nih.gov/16854083 DMRIFCW DI DMRIFCW DMRIFCW DN 2-(phenylethynyl)pyrimidine DMRIFCW TI TTHS256 DMRIFCW TN Metabotropic glutamate receptor 5 (mGluR5) DMRIFCW MA Inhibitor DMRIFCW RN Discovery of molecular switches that modulate modes of metabotropic glutamate receptor subtype 5 (mGlu5) pharmacology in vitro and in vivo within a... J Med Chem. 2009 Jul 23;52(14):4103-6. DMRIFCW RU https://pubmed.ncbi.nlm.nih.gov/19537763 DMRIG3O DI DMRIG3O DMRIG3O DN iberiotoxin DMRIG3O TI TTI9XK6 DMRIG3O TN Calcium-activated potassium channel KCa5.1 (KCNU1) DMRIG3O MA Inhibitor DMRIG3O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 387). DMRIG3O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=387 DMRIG3O DI DMRIG3O DMRIG3O DN iberiotoxin DMRIG3O TI TTLU5FO DMRIG3O TN Calcium-activated potassium channel KCa4.2 (KCNT2) DMRIG3O MA Inhibitor DMRIG3O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 386). DMRIG3O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=386 DMRIG3O DI DMRIG3O DMRIG3O DN iberiotoxin DMRIG3O TI TT1AQ50 DMRIG3O TN Charybdotoxin receptor beta-4 (BKbeta4) DMRIG3O MA Inhibitor DMRIG3O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 380). DMRIG3O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=380 DMRIG3O DI DMRIG3O DMRIG3O DN iberiotoxin DMRIG3O TI TTGJFK1 DMRIG3O TN Calcium-activated potassium channel KCa4.1 (KCNT1) DMRIG3O MA Inhibitor DMRIG3O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 385). DMRIG3O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=385 DMRIGXA DI DMRIGXA DMRIGXA DN 5-Ethyl-3,4-diphenyl-isoxazole DMRIGXA TI TT8NGED DMRIGXA TN Prostaglandin G/H synthase 1 (COX-1) DMRIGXA MA Inhibitor DMRIGXA RN Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90. DMRIGXA RU https://pubmed.ncbi.nlm.nih.gov/15369392 DMRIGXA DI DMRIGXA DMRIGXA DN 5-Ethyl-3,4-diphenyl-isoxazole DMRIGXA TI TTVKILB DMRIGXA TN Prostaglandin G/H synthase 2 (COX-2) DMRIGXA MA Inhibitor DMRIGXA RN Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. J Med Chem. 2004 Sep 23;47(20):4881-90. DMRIGXA RU https://pubmed.ncbi.nlm.nih.gov/15369392 DMRIK7P DI DMRIK7P DMRIK7P DN N-(3-bromophenyl)-6-fluoroquinazolin-4-amine DMRIK7P TI TTVBPDM DMRIK7P TN Metabotropic glutamate receptor 1 (mGluR1) DMRIK7P MA Inhibitor DMRIK7P RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMRIK7P RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMRIK7P DI DMRIK7P DMRIK7P DN N-(3-bromophenyl)-6-fluoroquinazolin-4-amine DMRIK7P TI TTHS256 DMRIK7P TN Metabotropic glutamate receptor 5 (mGluR5) DMRIK7P MA Inhibitor DMRIK7P RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMRIK7P RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMRILJC DI DMRILJC DMRILJC DN 4-Sulfamoyloxy-benzoic acid propyl ester DMRILJC TI TTHM0R1 DMRILJC TN Steryl-sulfatase (STS) DMRILJC MA Inhibitor DMRILJC RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMRILJC RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMRIMLJ DI DMRIMLJ DMRIMLJ DN BX-795 DMRIMLJ TI TTYVI76 DMRIMLJ TN Fungal Protein kinase A (Fung ypkA) DMRIMLJ MA Inhibitor DMRIMLJ RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMRIMLJ RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMRIMLJ DI DMRIMLJ DMRIMLJ DN BX-795 DMRIMLJ TI TTTU902 DMRIMLJ TN Checkpoint kinase-1 (CHK1) DMRIMLJ MA Inhibitor DMRIMLJ RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMRIMLJ RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMRIMLJ DI DMRIMLJ DMRIMLJ DN BX-795 DMRIMLJ TI TT7HF4W DMRIMLJ TN Cyclin-dependent kinase 2 (CDK2) DMRIMLJ MA Inhibitor DMRIMLJ RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMRIMLJ RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMRIMLJ DI DMRIMLJ DMRIMLJ DN BX-795 DMRIMLJ TI TTUTJGQ DMRIMLJ TN Vascular endothelial growth factor receptor 2 (KDR) DMRIMLJ MA Inhibitor DMRIMLJ RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMRIMLJ RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMRIMLJ DI DMRIMLJ DMRIMLJ DN BX-795 DMRIMLJ TI TT9QBI6 DMRIMLJ TN Phosphoinositide dependent protein kinase-1 (PDPK1) DMRIMLJ MA Inhibitor DMRIMLJ RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMRIMLJ RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMRIMLJ DI DMRIMLJ DMRIMLJ DN BX-795 DMRIMLJ TI TTRSMW9 DMRIMLJ TN Glycogen synthase kinase-3 beta (GSK-3B) DMRIMLJ MA Inhibitor DMRIMLJ RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMRIMLJ RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMRIPU5 DI DMRIPU5 DMRIPU5 DN 8-Bromo-9-propyl-9H-adenine DMRIPU5 TI TTNE7KG DMRIPU5 TN Adenosine A2b receptor (ADORA2B) DMRIPU5 MA Inhibitor DMRIPU5 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMRIPU5 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMRIPU5 DI DMRIPU5 DMRIPU5 DN 8-Bromo-9-propyl-9H-adenine DMRIPU5 TI TTM2AOE DMRIPU5 TN Adenosine A2a receptor (ADORA2A) DMRIPU5 MA Inhibitor DMRIPU5 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMRIPU5 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMRIPU5 DI DMRIPU5 DMRIPU5 DN 8-Bromo-9-propyl-9H-adenine DMRIPU5 TI TTK25J1 DMRIPU5 TN Adenosine A1 receptor (ADORA1) DMRIPU5 MA Inhibitor DMRIPU5 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMRIPU5 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMRITFU DI DMRITFU DMRITFU DN GUANOSINE-2',3'-O-METHYLIDENEPHOSPHONATE DMRITFU TI TTMCF1Y DMRITFU TN Purine nucleoside phosphorylase (PNP) DMRITFU MA Inhibitor DMRITFU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMRITFU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMRITHA DI DMRITHA DMRITHA DN 1-(5-phenyloxazol-2-yl)octadec-9-en-1-one DMRITHA TI TTDP1UC DMRITHA TN Fatty acid amide hydrolase (FAAH) DMRITHA MA Inhibitor DMRITHA RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMRITHA RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMRIWDV DI DMRIWDV DMRIWDV DN Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid DMRIWDV TI TTHI19T DMRIWDV TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMRIWDV MA Inhibitor DMRIWDV RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMRIWDV RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMRIWH2 DI DMRIWH2 DMRIWH2 DN (4-Dipropylamino-cyclohexylidene)-acetonitrile DMRIWH2 TI TT4C8EA DMRIWH2 TN Dopamine D3 receptor (D3R) DMRIWH2 MA Inhibitor DMRIWH2 RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMRIWH2 RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMRIYX9 DI DMRIYX9 DMRIYX9 DN 1-adamantan-1-yl-3-(2-heptyloxyethyl)urea DMRIYX9 TI TT7WVHI DMRIYX9 TN Soluble epoxide hydrolase (EPHX2) DMRIYX9 MA Inhibitor DMRIYX9 RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMRIYX9 RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMRJ104 DI DMRJ104 DMRJ104 DN PAT5A DMRJ104 TI TTT2SVW DMRJ104 TN PPAR-gamma messenger RNA (PPARG mRNA) DMRJ104 MA Agonist DMRJ104 RN Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Metabolism. 2000 Nov;49(11):1417-23. DMRJ104 RU https://pubmed.ncbi.nlm.nih.gov/11092504 DMRJ1L6 DI DMRJ1L6 DMRJ1L6 DN ISIS 112004 DMRJ1L6 TI TTPJ9XK DMRJ1L6 TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMRJ1L6 RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMRJ1L6 RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMRJ2GK DI DMRJ2GK DMRJ2GK DN AL-37350A DMRJ2GK TI TTWJBZ5 DMRJ2GK TN 5-HT 2C receptor (HTR2C) DMRJ2GK MA Agonist DMRJ2GK RN A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95. DMRJ2GK RU https://pubmed.ncbi.nlm.nih.gov/12954071 DMRJ2GK DI DMRJ2GK DMRJ2GK DN AL-37350A DMRJ2GK TI TT0K1SC DMRJ2GK TN 5-HT 2B receptor (HTR2B) DMRJ2GK MA Agonist DMRJ2GK RN A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95. DMRJ2GK RU https://pubmed.ncbi.nlm.nih.gov/12954071 DMRJ2GK DI DMRJ2GK DMRJ2GK DN AL-37350A DMRJ2GK TI TTJQOD7 DMRJ2GK TN 5-HT 2A receptor (HTR2A) DMRJ2GK MA Agonist DMRJ2GK RN A novel and selective 5-HT2 receptor agonist with ocular hypotensive activity: (S)-(+)-1-(2-aminopropyl)-8,9-dihydropyrano[3,2-e]indole. J Med Chem. 2003 Sep 11;46(19):4188-95. DMRJ2GK RU https://pubmed.ncbi.nlm.nih.gov/12954071 DMRJ4B1 DI DMRJ4B1 DMRJ4B1 DN N-benzoyl-phenylalanyl-glycine-nitrile DMRJ4B1 TI TT36ETB DMRJ4B1 TN Cathepsin L (CTSL) DMRJ4B1 MA Inhibitor DMRJ4B1 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMRJ4B1 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMRJ4B1 DI DMRJ4B1 DMRJ4B1 DN N-benzoyl-phenylalanyl-glycine-nitrile DMRJ4B1 TI TTUMQVO DMRJ4B1 TN Cathepsin S (CTSS) DMRJ4B1 MA Inhibitor DMRJ4B1 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMRJ4B1 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMRJ4B1 DI DMRJ4B1 DMRJ4B1 DN N-benzoyl-phenylalanyl-glycine-nitrile DMRJ4B1 TI TTDZN01 DMRJ4B1 TN Cathepsin K (CTSK) DMRJ4B1 MA Inhibitor DMRJ4B1 RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMRJ4B1 RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMRJ5OD DI DMRJ5OD DMRJ5OD DN GPG-290 DMRJ5OD TI TT1290U DMRJ5OD TN Coagulation factor VIII (F8) DMRJ5OD MA Inhibitor DMRJ5OD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMRJ5OD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMRJBH4 DI DMRJBH4 DMRJBH4 DN ISIS 13730 DMRJBH4 TI TT0EOB8 DMRJBH4 TN B-Raf messenger RNA (BRAF mRNA) DMRJBH4 RN US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression. DMRJBH4 RU http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true DMRJD75 DI DMRJD75 DMRJD75 DN 4-(4-fluoro-benzylideneamino)-benzenesulfonamide DMRJD75 TI TTVKILB DMRJD75 TN Prostaglandin G/H synthase 2 (COX-2) DMRJD75 MA Inhibitor DMRJD75 RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMRJD75 RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMRJGOP DI DMRJGOP DMRJGOP DN His-DPhe-Arg-Trp DMRJGOP TI TTD0CIQ DMRJGOP TN Melanocortin receptor 4 (MC4R) DMRJGOP MA Inhibitor DMRJGOP RN Squalene-derived flexible linkers for bioactive peptides. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3310-3. DMRJGOP RU https://pubmed.ncbi.nlm.nih.gov/17448660 DMRJIP4 DI DMRJIP4 DMRJIP4 DN Septide DMRJIP4 TI TTZPO1L DMRJIP4 TN Substance-P receptor (TACR1) DMRJIP4 MA Agonist DMRJIP4 RN Septide: an agonist for the NK1 receptor acting at a site distinct from substance P. Mol Pharmacol. 1994 Feb;45(2):287-93. DMRJIP4 RU https://pubmed.ncbi.nlm.nih.gov/7509440 DMRJKIV DI DMRJKIV DMRJKIV DN Caffeic acid phenethyl ester DMRJKIV TI TTSXVID DMRJKIV TN Nuclear factor NF-kappa-B (NFKB) DMRJKIV MA Inhibitor DMRJKIV RN Beneficial effects of caffeic acid phenethyl ester in a rat model of vascular injury. Br J Pharmacol. 2002 Jun;136(3):353-60. DMRJKIV RU https://pubmed.ncbi.nlm.nih.gov/12023937 DMRJLAP DI DMRJLAP DMRJLAP DN 4-(4-Fluorophenoxy)-3-pyridinesulfonamide DMRJLAP TI TTHQPL7 DMRJLAP TN Carbonic anhydrase I (CA-I) DMRJLAP MA Inhibitor DMRJLAP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMRJLAP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMRJLAP DI DMRJLAP DMRJLAP DN 4-(4-Fluorophenoxy)-3-pyridinesulfonamide DMRJLAP TI TT2LVK8 DMRJLAP TN Carbonic anhydrase IX (CA-IX) DMRJLAP MA Inhibitor DMRJLAP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMRJLAP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMRJLAP DI DMRJLAP DMRJLAP DN 4-(4-Fluorophenoxy)-3-pyridinesulfonamide DMRJLAP TI TTSYM0R DMRJLAP TN Carbonic anhydrase XII (CA-XII) DMRJLAP MA Inhibitor DMRJLAP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMRJLAP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMRJLAP DI DMRJLAP DMRJLAP DN 4-(4-Fluorophenoxy)-3-pyridinesulfonamide DMRJLAP TI TTANPDJ DMRJLAP TN Carbonic anhydrase II (CA-II) DMRJLAP MA Inhibitor DMRJLAP RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMRJLAP RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMRJMGK DI DMRJMGK DMRJMGK DN N-benzyl-2-thiomorpholinopyrimidin-4-amine DMRJMGK TI TT1RS9F DMRJMGK TN Acetylcholinesterase (AChE) DMRJMGK MA Inhibitor DMRJMGK RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMRJMGK RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMRJMGK DI DMRJMGK DMRJMGK DN N-benzyl-2-thiomorpholinopyrimidin-4-amine DMRJMGK TI TTEB0GD DMRJMGK TN Cholinesterase (BCHE) DMRJMGK MA Inhibitor DMRJMGK RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMRJMGK RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMRJQ8X DI DMRJQ8X DMRJQ8X DN D-Pro-Phe-Arg chloromethyl ketone DMRJQ8X TI TTMF8H9 DMRJQ8X TN Plasma kallikrein (KLKB1) DMRJQ8X MA Inhibitor DMRJQ8X RN Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80. DMRJQ8X RU https://pubmed.ncbi.nlm.nih.gov/18459730 DMRJQ8X DI DMRJQ8X DMRJQ8X DN D-Pro-Phe-Arg chloromethyl ketone DMRJQ8X TI TT6L509 DMRJQ8X TN Coagulation factor IIa (F2) DMRJQ8X MA Inhibitor DMRJQ8X RN Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80. DMRJQ8X RU https://pubmed.ncbi.nlm.nih.gov/18459730 DMRJQ8X DI DMRJQ8X DMRJQ8X DN D-Pro-Phe-Arg chloromethyl ketone DMRJQ8X TI TTCIHJA DMRJQ8X TN Coagulation factor Xa (F10) DMRJQ8X MA Inhibitor DMRJQ8X RN Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80. DMRJQ8X RU https://pubmed.ncbi.nlm.nih.gov/18459730 DMRJQ8X DI DMRJQ8X DMRJQ8X DN D-Pro-Phe-Arg chloromethyl ketone DMRJQ8X TI TT38MDJ DMRJQ8X TN Tissue factor (F3) DMRJQ8X MA Inhibitor DMRJQ8X RN Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. J Med Chem. 2008 Jun 12;51(11):3077-80. DMRJQ8X RU https://pubmed.ncbi.nlm.nih.gov/18459730 DMRJQY3 DI DMRJQY3 DMRJQY3 DN KYS-05070 DMRJQY3 TI TT729IR DMRJQY3 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMRJQY3 MA Inhibitor DMRJQY3 RN Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5014-7. DMRJQY3 RU https://pubmed.ncbi.nlm.nih.gov/16876410 DMRJSG7 DI DMRJSG7 DMRJSG7 DN 1-adamantan-1-yl-3-((R)-1-phenyl-ethyl)-urea DMRJSG7 TI TT7WVHI DMRJSG7 TN Soluble epoxide hydrolase (EPHX2) DMRJSG7 MA Inhibitor DMRJSG7 RN Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5773-7. DMRJSG7 RU https://pubmed.ncbi.nlm.nih.gov/16949285 DMRJVE8 DI DMRJVE8 DMRJVE8 DN Dmt-Pro-Phe-D-2-Nal-NH2 DMRJVE8 TI TTKWM86 DMRJVE8 TN Opioid receptor mu (MOP) DMRJVE8 MA Inhibitor DMRJVE8 RN Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20. DMRJVE8 RU https://pubmed.ncbi.nlm.nih.gov/17266203 DMRJVE8 DI DMRJVE8 DMRJVE8 DN Dmt-Pro-Phe-D-2-Nal-NH2 DMRJVE8 TI TT27RFC DMRJVE8 TN Opioid receptor delta (OPRD1) DMRJVE8 MA Inhibitor DMRJVE8 RN Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20. DMRJVE8 RU https://pubmed.ncbi.nlm.nih.gov/17266203 DMRK0Z1 DI DMRK0Z1 DMRK0Z1 DN 1-(4-ethylpiperazin-1-yl)-2-phenylethanone DMRK0Z1 TI TTN7BL9 DMRK0Z1 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMRK0Z1 MA Inhibitor DMRK0Z1 RN Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43. DMRK0Z1 RU https://pubmed.ncbi.nlm.nih.gov/17350260 DMRK3HO DI DMRK3HO DMRK3HO DN RB-105 DMRK3HO TI TT5TKPM DMRK3HO TN Neutral endopeptidase (MME) DMRK3HO MA Modulator DMRK3HO RN Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000 Jun;18(6):749-55. DMRK3HO RU https://www.ncbi.nlm.nih.gov/pubmed/10872560 DMRK3HO DI DMRK3HO DMRK3HO DN RB-105 DMRK3HO TI TTL69WB DMRK3HO TN Angiotensin-converting enzyme (ACE) DMRK3HO MA Modulator DMRK3HO RN Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs. J Hypertens. 2000 Jun;18(6):749-55. DMRK3HO RU https://www.ncbi.nlm.nih.gov/pubmed/10872560 DMRK4FA DI DMRK4FA DMRK4FA DN N-(2-aminoethyl)-1-aziridine-ethanamine DMRK4FA TI TTYRG7F DMRK4FA TN HUMAN angiotensin-converting enzyme 2 (ACE2) DMRK4FA MA Inhibitor DMRK4FA RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMRK4FA RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMRKE6W DI DMRKE6W DMRKE6W DN VU0255035 DMRKE6W TI TTQ13Z5 DMRKE6W TN Muscarinic acetylcholine receptor M3 (CHRM3) DMRKE6W MA Antagonist DMRKE6W RN A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol. 2009 Aug;76(2):356-68. DMRKE6W RU https://pubmed.ncbi.nlm.nih.gov/19407080 DMRKE6W DI DMRKE6W DMRKE6W DN VU0255035 DMRKE6W TI TTOXS3C DMRKE6W TN Muscarinic acetylcholine receptor (CHRM) DMRKE6W MA Antagonist DMRKE6W RN A novel selective muscarinic acetylcholine receptor subtype 1 antagonist reduces seizures without impairing hippocampus-dependent learning. Mol Pharmacol. 2009 Aug;76(2):356-68. DMRKE6W RU https://pubmed.ncbi.nlm.nih.gov/19407080 DMRKO49 DI DMRKO49 DMRKO49 DN Ribose-5-Phosphate DMRKO49 TI TTVNA43 DMRKO49 TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DMRKO49 MA Inhibitor DMRKO49 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRKO49 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRKQLV DI DMRKQLV DMRKQLV DN 2-Amino-6-(2-cyano-benzenesulfonyl)-benzonitrile DMRKQLV TI TT84ETX DMRKQLV TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMRKQLV MA Inhibitor DMRKQLV RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMRKQLV RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMRKYD6 DI DMRKYD6 DMRKYD6 DN 2-acetyl-3-hydroxycyclohex-2-enone DMRKYD6 TI TT8DSFC DMRKYD6 TN Hydroxyphenylpyruvate dioxygenase (HPD) DMRKYD6 MA Inhibitor DMRKYD6 RN Enzyme inhibition potency enhancement by active site metal chelating and hydrogen bonding induced conformation-restricted cyclopropanecarbonyl deri... Bioorg Med Chem Lett. 2006 Dec 1;16(23):6024-7. DMRKYD6 RU https://pubmed.ncbi.nlm.nih.gov/16979340 DMRL3BK DI DMRL3BK DMRL3BK DN 8S-hydroxylobel-9-ene DMRL3BK TI TTVBI8W DMRL3BK TN Dopamine transporter (DAT) DMRL3BK MA Inhibitor DMRL3BK RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMRL3BK RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMRL3BK DI DMRL3BK DMRL3BK DN 8S-hydroxylobel-9-ene DMRL3BK TI TT3ROYC DMRL3BK TN Serotonin transporter (SERT) DMRL3BK MA Inhibitor DMRL3BK RN Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5018-21. DMRL3BK RU https://pubmed.ncbi.nlm.nih.gov/16905316 DMRL65E DI DMRL65E DMRL65E DN 2-(2-thiazolyl)ethanamine DMRL65E TI TTTIBOJ DMRL65E TN Histamine H1 receptor (H1R) DMRL65E MA Agonist DMRL65E RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DMRL65E RU https://pubmed.ncbi.nlm.nih.gov/12626648 DMRL9IN DI DMRL9IN DMRL9IN DN GW841819X DMRL9IN TI TTHE657 DMRL9IN TN Bromodomain-containing protein 3 (BRD3) DMRL9IN MA Inhibitor DMRL9IN RN Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38. DMRL9IN RU https://pubmed.ncbi.nlm.nih.gov/21568322 DMRL9IN DI DMRL9IN DMRL9IN DN GW841819X DMRL9IN TI TTRA6BO DMRL9IN TN Bromodomain-containing protein 4 (BRD4) DMRL9IN MA Inhibitor DMRL9IN RN Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38. DMRL9IN RU https://pubmed.ncbi.nlm.nih.gov/21568322 DMRL9IN DI DMRL9IN DMRL9IN DN GW841819X DMRL9IN TI TTDP48B DMRL9IN TN Bromodomain-containing protein 2 (BRD2) DMRL9IN MA Inhibitor DMRL9IN RN Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J Med Chem. 2011 Jun 9;54(11):3827-38. DMRL9IN RU https://pubmed.ncbi.nlm.nih.gov/21568322 DMRLAX8 DI DMRLAX8 DMRLAX8 DN 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol DMRLAX8 TI TTHY57M DMRLAX8 TN Matrix metalloproteinase-13 (MMP-13) DMRLAX8 MA Inhibitor DMRLAX8 RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DMRLAX8 RU https://pubmed.ncbi.nlm.nih.gov/10230616 DMRLAX8 DI DMRLAX8 DMRLAX8 DN 3-(4-Methoxy-benzenesulfonyl)-hexane-1-thiol DMRLAX8 TI TTMX39J DMRLAX8 TN Matrix metalloproteinase-1 (MMP-1) DMRLAX8 MA Inhibitor DMRLAX8 RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DMRLAX8 RU https://pubmed.ncbi.nlm.nih.gov/10230616 DMRLFJV DI DMRLFJV DMRLFJV DN PHENYLSULFAMATE DMRLFJV TI TTANPDJ DMRLFJV TN Carbonic anhydrase II (CA-II) DMRLFJV MA Inhibitor DMRLFJV RN Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500. DMRLFJV RU https://pubmed.ncbi.nlm.nih.gov/16759092 DMRLFJV DI DMRLFJV DMRLFJV DN PHENYLSULFAMATE DMRLFJV TI TT2LVK8 DMRLFJV TN Carbonic anhydrase IX (CA-IX) DMRLFJV MA Inhibitor DMRLFJV RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMRLFJV RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMRLFJV DI DMRLFJV DMRLFJV DN PHENYLSULFAMATE DMRLFJV TI TTHQPL7 DMRLFJV TN Carbonic anhydrase I (CA-I) DMRLFJV MA Inhibitor DMRLFJV RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMRLFJV RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMRLG7Z DI DMRLG7Z DMRLG7Z DN PMID22364337C48 DMRLG7Z TI TTXJ47W DMRLG7Z TN Metabotropic glutamate receptor 2 (mGluR2) DMRLG7Z MA Modulator (allosteric modulator) DMRLG7Z RN Discovery of 1,4-disubstituted 3-cyano-2-pyridones: a new class of positive allosteric modulators of the metabotropic glutamate 2 receptor. J Med Chem. 2012 Mar 8;55(5):2388-405. DMRLG7Z RU https://pubmed.ncbi.nlm.nih.gov/22364337 DMRLOGP DI DMRLOGP DMRLOGP DN Ac-[CEHdFRWC]-NH2 DMRLOGP TI TTNI91K DMRLOGP TN Melanocortin receptor 3 (MC3R) DMRLOGP MA Inhibitor DMRLOGP RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMRLOGP RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMRLOGP DI DMRLOGP DMRLOGP DN Ac-[CEHdFRWC]-NH2 DMRLOGP TI TTD0CIQ DMRLOGP TN Melanocortin receptor 4 (MC4R) DMRLOGP MA Inhibitor DMRLOGP RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMRLOGP RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMRLOGP DI DMRLOGP DMRLOGP DN Ac-[CEHdFRWC]-NH2 DMRLOGP TI TT0MV2T DMRLOGP TN Melanocortin receptor 1 (MC1R) DMRLOGP MA Inhibitor DMRLOGP RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMRLOGP RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMRLZKJ DI DMRLZKJ DMRLZKJ DN FGGFTGARKSARKWRNQ DMRLZKJ TI TTNT7K8 DMRLZKJ TN Nociceptin receptor (OPRL1) DMRLZKJ MA Inhibitor DMRLZKJ RN Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. DMRLZKJ RU https://pubmed.ncbi.nlm.nih.gov/19577933 DMRM0OW DI DMRM0OW DMRM0OW DN Dadle DMRM0OW TI TT27RFC DMRM0OW TN Opioid receptor delta (OPRD1) DMRM0OW MA Agonist DMRM0OW RN Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol. 2000 Dec;36(7):2296-302. DMRM0OW RU https://pubmed.ncbi.nlm.nih.gov/11127476 DMRM0OW DI DMRM0OW DMRM0OW DN Dadle DMRM0OW TI TTKWM86 DMRM0OW TN Opioid receptor mu (MOP) DMRM0OW MA Inhibitor DMRM0OW RN Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokini... J Med Chem. 2007 Jun 14;50(12):2779-86. DMRM0OW RU https://pubmed.ncbi.nlm.nih.gov/17516639 DMRM1QV DI DMRM1QV DMRM1QV DN Tenocyclidine DMRM1QV TI TTKJEMQ DMRM1QV TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMRM1QV MA Antagonist DMRM1QV RN The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7. DMRM1QV RU https://pubmed.ncbi.nlm.nih.gov/2538766 DMRM1QV DI DMRM1QV DMRM1QV DN Tenocyclidine DMRM1QV TI TTN9D8E DMRM1QV TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMRM1QV MA Antagonist DMRM1QV RN The binding of [3H]thienyl cyclohexylpiperidine ([3H]TCP) to the NMDA-phencyclidine receptor complex. Neuropharmacology. 1989 Jan;28(1):1-7. DMRM1QV RU https://pubmed.ncbi.nlm.nih.gov/2538766 DMRM5QH DI DMRM5QH DMRM5QH DN ISIS 6756 DMRM5QH TI TTBLG3H DMRM5QH TN P120 messenger RNA (NOP2 mRNA) DMRM5QH RN US patent application no. 5,814,619, Oligonucleotide inhibition of P120. DMRM5QH RU http://www.patentbuddy.com/Patent/5814619?ft=true&sr=true DMRMAOI DI DMRMAOI DMRMAOI DN 4-(2,4-dichlorophenyl)-1-tosylpyrrolidin-3-amine DMRMAOI TI TTDIGC1 DMRMAOI TN Dipeptidyl peptidase 4 (DPP-4) DMRMAOI MA Inhibitor DMRMAOI RN Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibito... Bioorg Med Chem Lett. 2007 Apr 1;17(7):2005-12. DMRMAOI RU https://pubmed.ncbi.nlm.nih.gov/17276063 DMRMF13 DI DMRMF13 DMRMF13 DN 3-MATIDA DMRMF13 TI TTVBPDM DMRMF13 TN Metabotropic glutamate receptor 1 (mGluR1) DMRMF13 MA Antagonist DMRMF13 RN The novel and systemically active metabotropic glutamate 1 (mGlu1) receptor antagonist 3-MATIDA reduces post-ischemic neuronal death. Neuropharmacology. 2002 May;42(6):741-51. DMRMF13 RU https://pubmed.ncbi.nlm.nih.gov/12015200 DMRMGWF DI DMRMGWF DMRMGWF DN 4-butyl-N-(quinolin-3-yl)benzamide DMRMGWF TI TTMI6F5 DMRMGWF TN Transient receptor potential cation channel V1 (TRPV1) DMRMGWF MA Inhibitor DMRMGWF RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMRMGWF RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMRMHE8 DI DMRMHE8 DMRMHE8 DN Dimepheptanol DMRMHE8 TI TTKWM86 DMRMHE8 TN Opioid receptor mu (MOP) DMRMHE8 MA Inhibitor DMRMHE8 RN Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6. DMRMHE8 RU https://pubmed.ncbi.nlm.nih.gov/6268789 DMRMHE8 DI DMRMHE8 DMRMHE8 DN Dimepheptanol DMRMHE8 TI TT27RFC DMRMHE8 TN Opioid receptor delta (OPRD1) DMRMHE8 MA Inhibitor DMRMHE8 RN Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6. DMRMHE8 RU https://pubmed.ncbi.nlm.nih.gov/6268789 DMRMHE8 DI DMRMHE8 DMRMHE8 DN Dimepheptanol DMRMHE8 TI TTQW87Y DMRMHE8 TN Opioid receptor kappa (OPRK1) DMRMHE8 MA Inhibitor DMRMHE8 RN Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6. DMRMHE8 RU https://pubmed.ncbi.nlm.nih.gov/6268789 DMRMI0V DI DMRMI0V DMRMI0V DN FAS-031 DMRMI0V TI TT7AOUD DMRMI0V TN Fatty acid synthase (FASN) DMRMI0V MA Inhibitor DMRMI0V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608). DMRMI0V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608 DMRMKXD DI DMRMKXD DMRMKXD DN 5-Methyl-5-phenyl-pyrimidine-2,4,6-trione DMRMKXD TI TT6X50U DMRMKXD TN Matrix metalloproteinase-9 (MMP-9) DMRMKXD MA Inhibitor DMRMKXD RN Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72. DMRMKXD RU https://pubmed.ncbi.nlm.nih.gov/11327602 DMRMSU5 DI DMRMSU5 DMRMSU5 DN 6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one DMRMSU5 TI TT06AWU DMRMSU5 TN Phosphodiesterase 3A (PDE3A) DMRMSU5 MA Inhibitor DMRMSU5 RN 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8. DMRMSU5 RU https://pubmed.ncbi.nlm.nih.gov/1311763 DMRMZLV DI DMRMZLV DMRMZLV DN 3-methoxy-5-(2-methylquinolin-7-yl)benzonitrile DMRMZLV TI TTHS256 DMRMZLV TN Metabotropic glutamate receptor 5 (mGluR5) DMRMZLV MA Inhibitor DMRMZLV RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMRMZLV RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMRN1C6 DI DMRN1C6 DMRN1C6 DN N-hydroxy-8-(naphthalen-2-yl)non-8-enamide DMRN1C6 TI TT6R7JZ DMRN1C6 TN Histone deacetylase 1 (HDAC1) DMRN1C6 MA Inhibitor DMRN1C6 RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMRN1C6 RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMRN7SC DI DMRN7SC DMRN7SC DN 1-benzhydryl-4-butylpiperidin-4-ol DMRN7SC TI TT27RFC DMRN7SC TN Opioid receptor delta (OPRD1) DMRN7SC MA Inhibitor DMRN7SC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRN7SC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRN7SC DI DMRN7SC DMRN7SC DN 1-benzhydryl-4-butylpiperidin-4-ol DMRN7SC TI TTQW87Y DMRN7SC TN Opioid receptor kappa (OPRK1) DMRN7SC MA Inhibitor DMRN7SC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRN7SC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRN7SC DI DMRN7SC DMRN7SC DN 1-benzhydryl-4-butylpiperidin-4-ol DMRN7SC TI TTNT7K8 DMRN7SC TN Nociceptin receptor (OPRL1) DMRN7SC MA Inhibitor DMRN7SC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRN7SC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRN7SC DI DMRN7SC DMRN7SC DN 1-benzhydryl-4-butylpiperidin-4-ol DMRN7SC TI TTKWM86 DMRN7SC TN Opioid receptor mu (MOP) DMRN7SC MA Inhibitor DMRN7SC RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRN7SC RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRNF96 DI DMRNF96 DMRNF96 DN PMID30247903-Compound-General structure42 DMRNF96 TI TT23XQV DMRNF96 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMRNF96 MA Inhibitor DMRNF96 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMRNF96 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMRNGK7 DI DMRNGK7 DMRNGK7 DN 2-Cinnamamido-N4-hexyl-N1-hydroxysuccinamide DMRNGK7 TI TTPHMWB DMRNGK7 TN Aminopeptidase N (ANPEP) DMRNGK7 MA Inhibitor DMRNGK7 RN Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404. DMRNGK7 RU https://pubmed.ncbi.nlm.nih.gov/19782572 DMRNGV0 DI DMRNGV0 DMRNGV0 DN N*6*-Benzyl-quinazoline-2,4,6-triamine DMRNGV0 TI TT9SL3Q DMRNGV0 TN Polypeptide deformylase (PDF) DMRNGV0 MA Inhibitor DMRNGV0 RN CoMFA and CoMSIA analyses of Pneumocystis carinii dihydrofolate reductase, Toxoplasma gondii dihydrofolate reductase, and rat liver dihydrofolate r... J Med Chem. 2005 Mar 10;48(5):1448-69. DMRNGV0 RU https://pubmed.ncbi.nlm.nih.gov/15743188 DMRNHXE DI DMRNHXE DMRNHXE DN 3-Phenylsulfanylmethyl-quinoxaline-5,7-diamine DMRNHXE TI TT9SL3Q DMRNHXE TN Polypeptide deformylase (PDF) DMRNHXE MA Inhibitor DMRNHXE RN New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii. J Med Chem. 1995 Nov 24;38(24):4739-59. DMRNHXE RU https://pubmed.ncbi.nlm.nih.gov/7490723 DMRNLGW DI DMRNLGW DMRNLGW DN VU0029767 DMRNLGW TI TTOXS3C DMRNLGW TN Muscarinic acetylcholine receptor (CHRM) DMRNLGW MA Modulator (allosteric modulator) DMRNLGW RN Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol. 2009 Mar;75(3):577-88. DMRNLGW RU https://pubmed.ncbi.nlm.nih.gov/19047481 DMRNMKG DI DMRNMKG DMRNMKG DN 3-methyl-N-(6-methylpyridin-2-yl)benzamide DMRNMKG TI TTHS256 DMRNMKG TN Metabotropic glutamate receptor 5 (mGluR5) DMRNMKG MA Inhibitor DMRNMKG RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DMRNMKG RU https://pubmed.ncbi.nlm.nih.gov/16678408 DMRNO5U DI DMRNO5U DMRNO5U DN 1-Hydroxy-8-methoxy-10H-anthracen-9-one DMRNO5U TI TT2J34L DMRNO5U TN Arachidonate 5-lipoxygenase (5-LOX) DMRNO5U MA Inhibitor DMRNO5U RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMRNO5U RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMRNOM6 DI DMRNOM6 DMRNOM6 DN 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid DMRNOM6 TI TTVKILB DMRNOM6 TN Prostaglandin G/H synthase 2 (COX-2) DMRNOM6 MA Inhibitor DMRNOM6 RN Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90. DMRNOM6 RU https://pubmed.ncbi.nlm.nih.gov/17517512 DMRNOM6 DI DMRNOM6 DMRNOM6 DN 2-(N-(2-Ffuorophenyl)pyrrol-3-yl) acetic acid DMRNOM6 TI TT8NGED DMRNOM6 TN Prostaglandin G/H synthase 1 (COX-1) DMRNOM6 MA Inhibitor DMRNOM6 RN Synthesis and biological activity of new anti-inflammatory compounds containing the 1,4-benzodioxine and/or pyrrole system. Bioorg Med Chem. 2007 Jul 15;15(14):4876-90. DMRNOM6 RU https://pubmed.ncbi.nlm.nih.gov/17517512 DMRNZ4X DI DMRNZ4X DMRNZ4X DN 2-phenyl-2,3-dihydrobenzo[h]chromen-4-one DMRNZ4X TI TTSZLWK DMRNZ4X TN Aromatase (CYP19A1) DMRNZ4X MA Inhibitor DMRNZ4X RN New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80. DMRNZ4X RU https://pubmed.ncbi.nlm.nih.gov/18042388 DMRNZD6 DI DMRNZD6 DMRNZD6 DN 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol DMRNZD6 TI TT27RFC DMRNZD6 TN Opioid receptor delta (OPRD1) DMRNZD6 MA Inhibitor DMRNZD6 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRNZD6 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRNZD6 DI DMRNZD6 DMRNZD6 DN 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol DMRNZD6 TI TTQW87Y DMRNZD6 TN Opioid receptor kappa (OPRK1) DMRNZD6 MA Inhibitor DMRNZD6 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRNZD6 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRNZD6 DI DMRNZD6 DMRNZD6 DN 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol DMRNZD6 TI TTKWM86 DMRNZD6 TN Opioid receptor mu (MOP) DMRNZD6 MA Inhibitor DMRNZD6 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRNZD6 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRNZD6 DI DMRNZD6 DMRNZD6 DN 1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol DMRNZD6 TI TTNT7K8 DMRNZD6 TN Nociceptin receptor (OPRL1) DMRNZD6 MA Inhibitor DMRNZD6 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMRNZD6 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMRNZYQ DI DMRNZYQ DMRNZYQ DN 7-chloro-6H-chromeno[4,3-b]quinoline-3,9-diol DMRNZYQ TI TTPNQAC DMRNZYQ TN Estrogen-related receptor-alpha (ESRRA) DMRNZYQ MA Inhibitor DMRNZYQ RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMRNZYQ RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMRO1IU DI DMRO1IU DMRO1IU DN 1-3 Sugar Ring of Pentamannosyl 6-Phosphate DMRO1IU TI TT95ICL DMRO1IU TN Mannose-6-phosphate receptor (M6PR) DMRO1IU MA Inhibitor DMRO1IU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRO1IU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRO7JX DI DMRO7JX DMRO7JX DN N1,N4-bis(5-chloro-2-methylphenyl)succinamide DMRO7JX TI TTEAID7 DMRO7JX TN Trypanosoma Cruzipain (Trypano CYSP) DMRO7JX MA Inhibitor DMRO7JX RN Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51. DMRO7JX RU https://pubmed.ncbi.nlm.nih.gov/19908840 DMRO9C7 DI DMRO9C7 DMRO9C7 DN (R)-2,6-Bis-hydroxymethyl-piperidine-3,4,5-triol DMRO9C7 TI TTLPC70 DMRO9C7 TN Lysosomal alpha-glucosidase (GAA) DMRO9C7 MA Inhibitor DMRO9C7 RN Homonojirimycin isomers and N-alkylated homonojirimycins: structural and conformational basis of inhibition of glycosidases. J Med Chem. 1998 Jul 2;41(14):2565-71. DMRO9C7 RU https://pubmed.ncbi.nlm.nih.gov/9651160 DMROD7Q DI DMROD7Q DMROD7Q DN A-943931 DMROD7Q TI TTXJ178 DMROD7Q TN Histamine H4 receptor (H4R) DMROD7Q MA Inhibitor DMROD7Q RN Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and... J Med Chem. 2008 Oct 23;51(20):6547-57. DMROD7Q RU https://pubmed.ncbi.nlm.nih.gov/18817367 DMROFX8 DI DMROFX8 DMROFX8 DN LY456236 DMROFX8 TI TTVBPDM DMROFX8 TN Metabotropic glutamate receptor 1 (mGluR1) DMROFX8 MA Modulator (allosteric modulator) DMROFX8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 289). DMROFX8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=289 DMROG71 DI DMROG71 DMROG71 DN Biphenyl-3-carboxylic acid hydroxyamide DMROG71 TI TT2J34L DMROG71 TN Arachidonate 5-lipoxygenase (5-LOX) DMROG71 MA Inhibitor DMROG71 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMROG71 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMROKJP DI DMROKJP DMROKJP DN [125I]PTA-OH DMROKJP TI TT2O84V DMROKJP TN Thromboxane A2 receptor (TBXA2R) DMROKJP MA Antagonist DMROKJP RN Binding of thromboxane A2/prostaglandin H2 agonists to human platelets. Br J Pharmacol. 1987 May;91(1):223-7. DMROKJP RU https://pubmed.ncbi.nlm.nih.gov/3594077 DMROP5Q DI DMROP5Q DMROP5Q DN Benzothiazole-2-sulfonic acid amide DMROP5Q TI TTANPDJ DMROP5Q TN Carbonic anhydrase II (CA-II) DMROP5Q MA Inhibitor DMROP5Q RN Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6. DMROP5Q RU https://pubmed.ncbi.nlm.nih.gov/15686895 DMROP5Q DI DMROP5Q DMROP5Q DN Benzothiazole-2-sulfonic acid amide DMROP5Q TI TTHQPL7 DMROP5Q TN Carbonic anhydrase I (CA-I) DMROP5Q MA Inhibitor DMROP5Q RN Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6. DMROP5Q RU https://pubmed.ncbi.nlm.nih.gov/15686895 DMROP5Q DI DMROP5Q DMROP5Q DN Benzothiazole-2-sulfonic acid amide DMROP5Q TI TTUNARX DMROP5Q TN Carbonic anhydrase (CA) DMROP5Q MA Inhibitor DMROP5Q RN Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):971-6. DMROP5Q RU https://pubmed.ncbi.nlm.nih.gov/15686895 DMROQP6 DI DMROQP6 DMROQP6 DN MRS2957 DMROQP6 TI TTNVSKA DMROQP6 TN P2Y purinoceptor 6 (P2RY6) DMROQP6 MA Agonist DMROQP6 RN Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. J Med Chem. 2010 Jun 10;53(11):4488-501. DMROQP6 RU https://pubmed.ncbi.nlm.nih.gov/20446735 DMROS5K DI DMROS5K DMROS5K DN TEPA (possesses cytotoxic activity) DMROS5K TI TTZFYLI DMROS5K TN Dopamine D1 receptor (D1R) DMROS5K MA Inhibitor DMROS5K RN N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies. J Med Chem. 1998 Oct 8;41(21):4165-70. DMROS5K RU https://pubmed.ncbi.nlm.nih.gov/9767652 DMROWV8 DI DMROWV8 DMROWV8 DN ZK-164015 DMROWV8 TI TTZAYWL DMROWV8 TN Estrogen receptor (ESR) DMROWV8 MA Inhibitor DMROWV8 RN Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63. DMROWV8 RU https://pubmed.ncbi.nlm.nih.gov/15324884 DMROWV8 DI DMROWV8 DMROWV8 DN ZK-164015 DMROWV8 TI TTOM3J0 DMROWV8 TN Estrogen receptor beta (ESR2) DMROWV8 MA Inhibitor DMROWV8 RN Synthesis and biological evaluation of stilbene-based pure estrogen antagonists. Bioorg Med Chem Lett. 2004 Sep 20;14(18):4659-63. DMROWV8 RU https://pubmed.ncbi.nlm.nih.gov/15324884 DMROYD7 DI DMROYD7 DMROYD7 DN CP-409092 DMROYD7 TI TTEX6LM DMROYD7 TN GABA(A) receptor gamma-3 (GABRG3) DMROYD7 MA Modulator DMROYD7 RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMROYD7 RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMROZL8 DI DMROZL8 DMROZL8 DN Tonazocine mesylate DMROZL8 TI TT27RFC DMROZL8 TN Opioid receptor delta (OPRD1) DMROZL8 MA Agonist DMROZL8 RN Antiparkinson potential of delta-opioid receptor agonists. Eur J Pharmacol. 2000 May 19;396(2-3):101-7. DMROZL8 RU https://pubmed.ncbi.nlm.nih.gov/10822062 DMROZUA DI DMROZUA DMROZUA DN Pyroglutamic acid DMROZUA TI TTCGSZ4 DMROZUA TN Pancreatic alpha-amylase (AMY2A) DMROZUA MA Inhibitor DMROZUA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMROZUA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMROZUA DI DMROZUA DMROZUA DN Pyroglutamic acid DMROZUA TI TTURHFP DMROZUA TN Angiogenin (ANG) DMROZUA MA Inhibitor DMROZUA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMROZUA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMROZUA DI DMROZUA DMROZUA DN Pyroglutamic acid DMROZUA TI TTU5HJP DMROZUA TN Orexin (HCRT) DMROZUA MA Inhibitor DMROZUA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMROZUA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRP03X DI DMRP03X DMRP03X DN 1,3,8-Trihydroxy-6-methyl-10H-anthracen-9-one DMRP03X TI TT2J34L DMRP03X TN Arachidonate 5-lipoxygenase (5-LOX) DMRP03X MA Inhibitor DMRP03X RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMRP03X RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMRP42B DI DMRP42B DMRP42B DN SQ 26655 DMRP42B TI TT2O84V DMRP42B TN Thromboxane A2 receptor (TBXA2R) DMRP42B MA Agonist DMRP42B RN Synthesis and in vitro pharmacology of 7-oxabicyclo[2.2.1]heptane analogues of thromboxane A2/PGH2. J Med Chem. 1985 Nov;28(11):1580-90. DMRP42B RU https://pubmed.ncbi.nlm.nih.gov/4067988 DMRP9K3 DI DMRP9K3 DMRP9K3 DN EG-10 DMRP9K3 TI TTJTRMK DMRP9K3 TN Interleukin 10 receptor (IL10RB) DMRP9K3 MA Modulator DMRP9K3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1900). DMRP9K3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1900 DMRPCL7 DI DMRPCL7 DMRPCL7 DN 2-(2-Hydroxyethyl)anthra[1,9-cd]pyrazol-6(2H)-one DMRPCL7 TI TT0IHXV DMRPCL7 TN DNA topoisomerase II (TOP2) DMRPCL7 MA Inhibitor DMRPCL7 RN Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer... Bioorg Med Chem. 2010 Jun 1;18(11):3974-84. DMRPCL7 RU https://pubmed.ncbi.nlm.nih.gov/20471276 DMRPFCS DI DMRPFCS DMRPFCS DN TEFLUDAZINE DMRPFCS TI TT3ROYC DMRPFCS TN Serotonin transporter (SERT) DMRPFCS MA Inhibitor DMRPFCS RN Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans. J Med Chem. 1983 Jul;26(7):935-47. DMRPFCS RU https://pubmed.ncbi.nlm.nih.gov/6134833 DMRPFNU DI DMRPFNU DMRPFNU DN 7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol DMRPFNU TI TTIQUX7 DMRPFNU TN Steroid 11-beta-hydroxylase (CYP11B1) DMRPFNU MA Inhibitor DMRPFNU RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMRPFNU RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMRPFNU DI DMRPFNU DMRPFNU DN 7-(1-(1H-imidazol-1-yl)ethyl)-9H-fluoren-2-ol DMRPFNU TI TTRA5BZ DMRPFNU TN Steroid 17-alpha-monooxygenase (S17AH) DMRPFNU MA Inhibitor DMRPFNU RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMRPFNU RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMRPMN6 DI DMRPMN6 DMRPMN6 DN ISIS 109502 DMRPMN6 TI TT3K9S2 DMRPMN6 TN RANK messenger RNA (RANK mRNA) DMRPMN6 RN US patent application no. 6,171,860, Antisense inhibition of rank expression. DMRPMN6 RU http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true DMRPS2X DI DMRPS2X DMRPS2X DN [3H](R)-NPTS DMRPS2X TI TTHJTF7 DMRPS2X TN Glycine transporter GlyT-1 (SLC6A9) DMRPS2X MA Modulator DMRPS2X RN [3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1291-2. DMRPS2X RU https://pubmed.ncbi.nlm.nih.gov/12657266 DMRPU0V DI DMRPU0V DMRPU0V DN 4-(6-Methoxy-3-methylnaphthalen-2-yl)isoquinoline DMRPU0V TI TTIQUX7 DMRPU0V TN Steroid 11-beta-hydroxylase (CYP11B1) DMRPU0V MA Inhibitor DMRPU0V RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMRPU0V RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMRPUCA DI DMRPUCA DMRPUCA DN N-isopropyl-5,6-dip-tolylpyrazine-2-carboxamide DMRPUCA TI TT6OEDT DMRPUCA TN Cannabinoid receptor 1 (CB1) DMRPUCA MA Inhibitor DMRPUCA RN Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3978-82. DMRPUCA RU https://pubmed.ncbi.nlm.nih.gov/17513109 DMRPV0A DI DMRPV0A DMRPV0A DN Concatameric LAG3Ig DMRPV0A TI TTNVXAW DMRPV0A TN Lymphocyte activation gene 3 protein (LAG3) DMRPV0A MA Modulator DMRPV0A RN IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5. DMRPV0A RU https://pubmed.ncbi.nlm.nih.gov/17394654 DMRPVO3 DI DMRPVO3 DMRPVO3 DN 4-(2,4-dichlorophenoxy)-4'-methylbiphenyl-3-ol DMRPVO3 TI TTNX2CS DMRPVO3 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMRPVO3 MA Inhibitor DMRPVO3 RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DMRPVO3 RU https://pubmed.ncbi.nlm.nih.gov/19217192 DMRPWGL DI DMRPWGL DMRPWGL DN Geranylcoumarin DMRPWGL TI TTXV4FI DMRPWGL TN Albendazole monooxygenase (CYP3A4) DMRPWGL MA Inhibitor DMRPWGL RN Radical scavenging and cytochrome P450 3A4 inhibitory activity of bergaptol and geranylcoumarin from grapefruit. Bioorg Med Chem. 2007 Jun 1;15(11):3684-91. DMRPWGL RU https://pubmed.ncbi.nlm.nih.gov/17400460 DMRPYGX DI DMRPYGX DMRPYGX DN RWJ-50353 DMRPYGX TI TT6L509 DMRPYGX TN Coagulation factor IIa (F2) DMRPYGX MA Inhibitor DMRPYGX RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMRPYGX RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMRPYGX DI DMRPYGX DMRPYGX DN RWJ-50353 DMRPYGX TI TT2WR1T DMRPYGX TN Cationic trypsinogen (PRSS1) DMRPYGX MA Inhibitor DMRPYGX RN In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications ... J Med Chem. 2005 Mar 24;48(6):1984-2008. DMRPYGX RU https://pubmed.ncbi.nlm.nih.gov/15771442 DMRPZD4 DI DMRPZD4 DMRPZD4 DN HPTE DMRPZD4 TI TTOM3J0 DMRPZD4 TN Estrogen receptor beta (ESR2) DMRPZD4 MA Antagonist DMRPZD4 RN Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha. Br J Pharmacol. 1999 Feb;126(3):810-8. DMRPZD4 RU https://pubmed.ncbi.nlm.nih.gov/10188995 DMRQ0ZF DI DMRQ0ZF DMRQ0ZF DN (10H-phenothiazin-10-yl)(p-tolyl)methanone DMRQ0ZF TI TTEB0GD DMRQ0ZF TN Cholinesterase (BCHE) DMRQ0ZF MA Inhibitor DMRQ0ZF RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMRQ0ZF RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMRQ24A DI DMRQ24A DMRQ24A DN 7alpha-F-ginkgolide B DMRQ24A TI TTQL5VC DMRQ24A TN Platelet-activating factor receptor (PTAFR) DMRQ24A MA Antagonist DMRQ24A RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMRQ24A RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMRQ6XD DI DMRQ6XD DMRQ6XD DN [18F]FPIT DMRQ6XD TI TTVBPDM DMRQ6XD TN Metabotropic glutamate receptor 1 (mGluR1) DMRQ6XD MA Modulator (allosteric modulator) DMRQ6XD RN Characterization of 1-(2-[18F] fluoro-3-pyridyl)-4-(2-isopropyl-1-oxo- isoindoline-5-yl)-5-methyl-1H-1,2,3-triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains. J Neurochem. 2012 Apr;121(1):115-24. DMRQ6XD RU https://pubmed.ncbi.nlm.nih.gov/21668889 DMRQ8T9 DI DMRQ8T9 DMRQ8T9 DN 4-(2-(diethylamino)ethylamino)-1-naphthol DMRQ8T9 TI TTZJYKH DMRQ8T9 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMRQ8T9 MA Inhibitor DMRQ8T9 RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMRQ8T9 RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMRQBEW DI DMRQBEW DMRQBEW DN VK-12 DMRQBEW TI TTE4KHA DMRQBEW TN Amyloid beta A4 protein (APP) DMRQBEW MA Inhibitor DMRQBEW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMRQBEW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMRQC1F DI DMRQC1F DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F TI TT9WJ8U DMRQC1F TN Protein kinase C delta (PRKCD) DMRQC1F MA Inhibitor DMRQC1F RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMRQC1F RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMRQC1F DI DMRQC1F DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F TI TTBZ7OD DMRQC1F TN Protein kinase C epsilon (PRKCE) DMRQC1F MA Inhibitor DMRQC1F RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMRQC1F RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMRQC1F DI DMRQC1F DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F TI TTUWGRA DMRQC1F TN Protein kinase C zeta (PRKCZ) DMRQC1F MA Inhibitor DMRQC1F RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMRQC1F RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMRQC1F DI DMRQC1F DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F TI TTYPXQF DMRQC1F TN Protein kinase C beta (PRKCB) DMRQC1F MA Inhibitor DMRQC1F RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMRQC1F RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMRQC1F DI DMRQC1F DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F TI TTFJ8Q1 DMRQC1F TN Protein kinase C alpha (PRKCA) DMRQC1F MA Inhibitor DMRQC1F RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMRQC1F RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMRQC1F DI DMRQC1F DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F TI TTRFOXJ DMRQC1F TN Protein kinase C gamma (PRKCG) DMRQC1F MA Inhibitor DMRQC1F RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMRQC1F RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMRQC1F DI DMRQC1F DMRQC1F DN [2,2':5',2'']Terthiophen-4-yl-methanol DMRQC1F TI TT8QL1J DMRQC1F TN Protein kinase C theta (PRKCQ) DMRQC1F MA Inhibitor DMRQC1F RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMRQC1F RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMRQCK3 DI DMRQCK3 DMRQCK3 DN Quinizarin DMRQCK3 TI TTGTQHC DMRQCK3 TN DNA topoisomerase I (TOP1) DMRQCK3 MA Binder DMRQCK3 RN Comparison of responses of DNA topoisomerase I from Candida albicans and human cells to four new agents which stimulate topoisomerase-dependent DNA nicking. FEMS Microbiol Lett. 1996 May 1;138(2-3):105-11. DMRQCK3 RU https://pubmed.ncbi.nlm.nih.gov/9026436 DMRQGWX DI DMRQGWX DMRQGWX DN 2,7-Bis[2-(isopropylamino)acetamido]anthraquinone DMRQGWX TI TTQY2EJ DMRQGWX TN TERT messenger RNA (TERT mRNA) DMRQGWX MA Inhibitor DMRQGWX RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMRQGWX RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMRQKYC DI DMRQKYC DMRQKYC DN N-(1-(3-bromobenzyl)piperidin-4-yl)-2-naphthamide DMRQKYC TI TTJQOD7 DMRQKYC TN 5-HT 2A receptor (HTR2A) DMRQKYC MA Inhibitor DMRQKYC RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4. DMRQKYC RU https://pubmed.ncbi.nlm.nih.gov/17251022 DMRQOKB DI DMRQOKB DMRQOKB DN 2-(biphenyl-4-yl)vinylboronic acid DMRQOKB TI TTHQPL7 DMRQOKB TN Carbonic anhydrase I (CA-I) DMRQOKB MA Inhibitor DMRQOKB RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMRQOKB RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMRQOKB DI DMRQOKB DMRQOKB DN 2-(biphenyl-4-yl)vinylboronic acid DMRQOKB TI TTDP1UC DMRQOKB TN Fatty acid amide hydrolase (FAAH) DMRQOKB MA Inhibitor DMRQOKB RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMRQOKB RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMRQOL5 DI DMRQOL5 DMRQOL5 DN JWH-237 DMRQOL5 TI TTMSFAW DMRQOL5 TN Cannabinoid receptor 2 (CB2) DMRQOL5 MA Inhibitor DMRQOL5 RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMRQOL5 RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMRQSD2 DI DMRQSD2 DMRQSD2 DN N-(2,4-dimethoxyphenethyl)oleamide DMRQSD2 TI TT6OEDT DMRQSD2 TN Cannabinoid receptor 1 (CB1) DMRQSD2 MA Inhibitor DMRQSD2 RN New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorg Med Chem Lett. 2006 Jan 1;16(1):138-41. DMRQSD2 RU https://pubmed.ncbi.nlm.nih.gov/16213718 DMRQSN2 DI DMRQSN2 DMRQSN2 DN IDN-1965 DMRQSN2 TI TTZY5KP DMRQSN2 TN Caspase (CASP) DMRQSN2 MA Inhibitor DMRQSN2 RN Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic ... Circulation. 2003 Dec 16;108(24):3036-41. DMRQSN2 RU https://pubmed.ncbi.nlm.nih.gov/14638549 DMRQVME DI DMRQVME DMRQVME DN Boc-cyclo-(Glu-Tyr-Nle-D-Lys)-Trp-Nle-Asp-Phe-NH2 DMRQVME TI TTCG0AL DMRQVME TN Cholecystokinin receptor type A (CCKAR) DMRQVME MA Inhibitor DMRQVME RN Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. J Med Chem. 1989 Jun;32(6):1184-90. DMRQVME RU https://pubmed.ncbi.nlm.nih.gov/2724293 DMRQVW9 DI DMRQVW9 DMRQVW9 DN Anthoptilide C DMRQVW9 TI TTK25J1 DMRQVW9 TN Adenosine A1 receptor (ADORA1) DMRQVW9 MA Inhibitor DMRQVW9 RN Anthoptilides A-E, new Briarane diterpenes from the Australian sea pen Anthoptilum cf. kukenthali. J Nat Prod. 2000 Mar;63(3):318-21. DMRQVW9 RU https://pubmed.ncbi.nlm.nih.gov/10757710 DMRQXHO DI DMRQXHO DMRQXHO DN Tyr-Pro-Phe-Phe-OCH3 DMRQXHO TI TTKWM86 DMRQXHO TN Opioid receptor mu (MOP) DMRQXHO MA Inhibitor DMRQXHO RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMRQXHO RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMRQXHO DI DMRQXHO DMRQXHO DN Tyr-Pro-Phe-Phe-OCH3 DMRQXHO TI TT27RFC DMRQXHO TN Opioid receptor delta (OPRD1) DMRQXHO MA Inhibitor DMRQXHO RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMRQXHO RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMRQZTS DI DMRQZTS DMRQZTS DN diphenylboronic anhydride DMRQZTS TI TTMI6F5 DMRQZTS TN Transient receptor potential cation channel V1 (TRPV1) DMRQZTS MA Activator DMRQZTS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DMRQZTS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DMRQZTS DI DMRQZTS DMRQZTS DN diphenylboronic anhydride DMRQZTS TI TTBECWA DMRQZTS TN Transient receptor potential cation channel V2 (TRPV2) DMRQZTS MA Activator DMRQZTS RN Pharmacological characterization and molecular determinants of the activation of transient receptor potential V2 channel orthologs by 2-aminoethoxy... Mol Pharmacol. 2007 Nov;72(5):1258-68. DMRQZTS RU https://pubmed.ncbi.nlm.nih.gov/17673572 DMRQZTS DI DMRQZTS DMRQZTS DN diphenylboronic anhydride DMRQZTS TI TT946IA DMRQZTS TN Transient receptor potential cation channel V3 (TRPV3) DMRQZTS MA Activator DMRQZTS RN Biphasic currents evoked by chemical or thermal activation of the heat-gated ion channel, TRPV3. J Biol Chem. 2005 Apr 22;280(16):15928-41. DMRQZTS RU https://pubmed.ncbi.nlm.nih.gov/15722340 DMRS0LA DI DMRS0LA DMRS0LA DN AN-207 DMRS0LA TI TT8R70G DMRS0LA TN Gonadotropin-releasing hormone receptor (GNRHR) DMRS0LA MA Inhibitor DMRS0LA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DMRS0LA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DMRS1Q5 DI DMRS1Q5 DMRS1Q5 DN 5-(2-(4-fluoro-3-methylphenyl)ethynyl)pyrimidine DMRS1Q5 TI TTHS256 DMRS1Q5 TN Metabotropic glutamate receptor 5 (mGluR5) DMRS1Q5 MA Inhibitor DMRS1Q5 RN Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: unexpected modulation of pharmacology with slight structural modifications to a 5... Bioorg Med Chem Lett. 2008 Jul 15;18(14):4098-101. DMRS1Q5 RU https://pubmed.ncbi.nlm.nih.gov/18550372 DMRS6LH DI DMRS6LH DMRS6LH DN 2-Cyclopropanecarbonyl-cyclohexane-1,3-dione DMRS6LH TI TT8DSFC DMRS6LH TN Hydroxyphenylpyruvate dioxygenase (HPD) DMRS6LH MA Inhibitor DMRS6LH RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DMRS6LH RU https://pubmed.ncbi.nlm.nih.gov/10853644 DMRS82Q DI DMRS82Q DMRS82Q DN 5-chloro-4-nitrothiophene-2-sulfonamide DMRS82Q TI TTSFWA7 DMRS82Q TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMRS82Q MA Inhibitor DMRS82Q RN Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010). DMRS82Q RU http://www.sciencedirect.com/science/article/pii/S0960894X10006803 DMRSBWT DI DMRSBWT DMRSBWT DN MJN228 DMRSBWT TI TT6A5ZL DMRSBWT TN Nucleobindin-1 (NUCB1) DMRSBWT MA Antagonist DMRSBWT RN A Global Map of Lipid-Binding Proteins and Their Ligandability in Cells. Cell. 2015 Jun 18;161(7):1668-80. DMRSBWT RU https://pubmed.ncbi.nlm.nih.gov/26091042 DMRSCO2 DI DMRSCO2 DMRSCO2 DN AdoC(Aoc)Arg6 DMRSCO2 TI TTNAHEX DMRSCO2 TN cAMP-dependent protein kinase A type I (PRKAR1A) DMRSCO2 MA Inhibitor DMRSCO2 RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMRSCO2 RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMRSCO2 DI DMRSCO2 DMRSCO2 DN AdoC(Aoc)Arg6 DMRSCO2 TI TTW4Y2M DMRSCO2 TN cAMP protein kinase type II-beta (PRKAR2B) DMRSCO2 MA Inhibitor DMRSCO2 RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMRSCO2 RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMRSGC5 DI DMRSGC5 DMRSGC5 DN 2-amino-8-methyl-7,8-dihydropteridin-4(3H)-one DMRSGC5 TI TT4ILYC DMRSGC5 TN Bacterial Dihydropteroate synthetase (Bact folP) DMRSGC5 MA Inhibitor DMRSGC5 RN Structural studies of pterin-based inhibitors of dihydropteroate synthase. J Med Chem. 2010 Jan 14;53(1):166-77. DMRSGC5 RU https://pubmed.ncbi.nlm.nih.gov/19899766 DMRSKGC DI DMRSKGC DMRSKGC DN bisandrographolide DMRSKGC TI TTKP2SU DMRSKGC TN Transient receptor potential cation channel V4 (TRPV4) DMRSKGC MA Activator DMRSKGC RN Bisandrographolide from Andrographis paniculata activates TRPV4 channels. J Biol Chem. 2006 Oct 6;281(40):29897-904. DMRSKGC RU https://pubmed.ncbi.nlm.nih.gov/16899456 DMRSKIY DI DMRSKIY DMRSKIY DN Ac-I[CVVQDWGAHRC]T-NH2 DMRSKIY TI TTJGY7A DMRSKIY TN Complement C3 (CO3) DMRSKIY MA Inhibitor DMRSKIY RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMRSKIY RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMRSU2K DI DMRSU2K DMRSU2K DN AcPYY(25-36) DMRSU2K TI TTJ6WK9 DMRSU2K TN Neuropeptide Y receptor type 2 (NPY2R) DMRSU2K MA Inhibitor DMRSU2K RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DMRSU2K RU https://pubmed.ncbi.nlm.nih.gov/17055726 DMRSZGB DI DMRSZGB DMRSZGB DN (O10eq)-beta-alanyl-anhydro-ryanodine DMRSZGB TI TTU5CIX DMRSZGB TN Ryanodine receptor 1 (RYR1) DMRSZGB MA Inhibitor DMRSZGB RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMRSZGB RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMRT13B DI DMRT13B DMRT13B DN 1,4-Dimethylquinolin-2(1H)-one DMRT13B TI TTJLP0R DMRT13B TN Quinone reductase 2 (NQO2) DMRT13B MA Inhibitor DMRT13B RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMRT13B RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMRT6OP DI DMRT6OP DMRT6OP DN kallidin DMRT6OP TI TTGY8IW DMRT6OP TN B2 bradykinin receptor (BDKRB2) DMRT6OP MA Agonist DMRT6OP RN Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol Pharmacol. 1994 Jan;45(1):1-8. DMRT6OP RU https://pubmed.ncbi.nlm.nih.gov/8302267 DMRT7G3 DI DMRT7G3 DMRT7G3 DN BMS641 DMRT7G3 TI TTISP28 DMRT7G3 TN Retinoic acid receptor beta (RARB) DMRT7G3 MA Agonist DMRT7G3 RN Rational design of RAR-selective ligands revealed by RARbeta crystal stucture. EMBO Rep. 2004 Sep;5(9):877-82. DMRT7G3 RU https://pubmed.ncbi.nlm.nih.gov/15319780 DMRTASL DI DMRTASL DMRTASL DN Trametinib DMRTASL TI TTWX403 DMRTASL TN HUMAN ERK activator kinase 2 (MEK2) DMRTASL MA Inhibitor DMRTASL RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMRTASL RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMRTASL DI DMRTASL DMRTASL DN Trametinib DMRTASL TI TTAW3TO DMRTASL TN HUMAN ERK activator kinase 1 (MEK1) DMRTASL MA Inhibitor DMRTASL RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMRTASL RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMRTHW1 DI DMRTHW1 DMRTHW1 DN PHENYLSULFAMIDE DMRTHW1 TI TTANPDJ DMRTHW1 TN Carbonic anhydrase II (CA-II) DMRTHW1 MA Inhibitor DMRTHW1 RN Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500. DMRTHW1 RU https://pubmed.ncbi.nlm.nih.gov/16759092 DMRU0IB DI DMRU0IB DMRU0IB DN (8-Hydroxy-2-oxo-2H-quinolin-1-yl)-acetic acid DMRU0IB TI TTFBNVI DMRU0IB TN Aldose reductase (AKR1B1) DMRU0IB MA Inhibitor DMRU0IB RN Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8. DMRU0IB RU https://pubmed.ncbi.nlm.nih.gov/3093680 DMRU21X DI DMRU21X DMRU21X DN N-oleoyl-N-(2-hydroxyethyl)hydroxylamine DMRU21X TI TTMSFAW DMRU21X TN Cannabinoid receptor 2 (CB2) DMRU21X MA Inhibitor DMRU21X RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DMRU21X RU https://pubmed.ncbi.nlm.nih.gov/16570929 DMRU3H0 DI DMRU3H0 DMRU3H0 DN Org27569 DMRU3H0 TI TT6OEDT DMRU3H0 TN Cannabinoid receptor 1 (CB1) DMRU3H0 MA Modulator (allosteric modulator) DMRU3H0 RN Indole-2-carboxamides as allosteric modulators of the cannabinoid CB receptor. J Med Chem. 2012 Jun 14;55(11):5627-31. DMRU3H0 RU https://pubmed.ncbi.nlm.nih.gov/22571451 DMRU8G7 DI DMRU8G7 DMRU8G7 DN CGS 24012 DMRU8G7 TI TTNE7KG DMRU8G7 TN Adenosine A2b receptor (ADORA2B) DMRU8G7 MA Agonist DMRU8G7 RN Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem. 1995 Jun 9;270(23):13987-97. DMRU8G7 RU https://pubmed.ncbi.nlm.nih.gov/7775460 DMRU8WT DI DMRU8WT DMRU8WT DN TDT-044 DMRU8WT TI TTPNQAC DMRU8WT TN Estrogen-related receptor-alpha (ESRRA) DMRU8WT MA Agonist DMRU8WT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 622). DMRU8WT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=622 DMRU963 DI DMRU963 DMRU963 DN 6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMRU963 TI TTZAYWL DMRU963 TN Estrogen receptor (ESR) DMRU963 MA Inhibitor DMRU963 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMRU963 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMRU963 DI DMRU963 DMRU963 DN 6-(2,5-Difluoro-4-hydroxy-phenyl)-naphthalen-2-ol DMRU963 TI TTOM3J0 DMRU963 TN Estrogen receptor beta (ESR2) DMRU963 MA Inhibitor DMRU963 RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMRU963 RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMRUA0Y DI DMRUA0Y DMRUA0Y DN AZ-11657312 DMRUA0Y TI TT473XN DMRUA0Y TN P2X purinoceptor 7 (P2RX7) DMRUA0Y MA Antagonist DMRUA0Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484). DMRUA0Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484 DMRUD37 DI DMRUD37 DMRUD37 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac DMRUD37 TI TTKWM86 DMRUD37 TN Opioid receptor mu (MOP) DMRUD37 MA Inhibitor DMRUD37 RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMRUD37 RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMRUD37 DI DMRUD37 DMRUD37 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac DMRUD37 TI TTVFO0U DMRUD37 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMRUD37 MA Inhibitor DMRUD37 RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMRUD37 RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMRUD37 DI DMRUD37 DMRUD37 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac DMRUD37 TI TT27RFC DMRUD37 TN Opioid receptor delta (OPRD1) DMRUD37 MA Inhibitor DMRUD37 RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMRUD37 RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMRUEM8 DI DMRUEM8 DMRUEM8 DN ISIS 2674 DMRUEM8 TI TT1PL7M DMRUEM8 TN E-selectin messenger RNA (SELE mRNA) DMRUEM8 RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMRUEM8 RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMRUIX3 DI DMRUIX3 DMRUIX3 DN GP515 DMRUIX3 TI TTT02K8 DMRUIX3 TN Steroid 5-alpha-reductase 2 (SRD5A2) DMRUIX3 MA Inhibitor DMRUIX3 RN 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29. DMRUIX3 RU https://pubmed.ncbi.nlm.nih.gov/9089333 DMRUIX3 DI DMRUIX3 DMRUIX3 DN GP515 DMRUIX3 TI TTTU72V DMRUIX3 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMRUIX3 MA Inhibitor DMRUIX3 RN 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29. DMRUIX3 RU https://pubmed.ncbi.nlm.nih.gov/9089333 DMRUIX3 DI DMRUIX3 DMRUIX3 DN GP515 DMRUIX3 TI TTL732K DMRUIX3 TN Adenosine kinase (ADK) DMRUIX3 MA Inhibitor DMRUIX3 RN Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 2001 Jan;296(1):99-105. DMRUIX3 RU https://pubmed.ncbi.nlm.nih.gov/11123368 DMRUJFZ DI DMRUJFZ DMRUJFZ DN PMID2153213C1e DMRUJFZ TI TTPADOQ DMRUJFZ TN HMG-CoA reductase (HMGCR) DMRUJFZ MA Inhibitor DMRUJFZ RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DMRUJFZ RU https://pubmed.ncbi.nlm.nih.gov/2153213 DMRUP0A DI DMRUP0A DMRUP0A DN 8-(3,3,3-trifluoropropoxy)quinolin-2-amine DMRUP0A TI TTX4RTB DMRUP0A TN Melanin-concentrating hormone receptor 1 (MCHR1) DMRUP0A MA Inhibitor DMRUP0A RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMRUP0A RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMRUTDY DI DMRUTDY DMRUTDY DN 2-(pyridin-2-yl)-1H-benzo[d]imidazole DMRUTDY TI TTZL0OI DMRUTDY TN Methionine aminopeptidase 2 (METAP2) DMRUTDY MA Inhibitor DMRUTDY RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMRUTDY RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMRUX93 DI DMRUX93 DMRUX93 DN 3-carboxy-6-ethyl-4-quinolone DMRUX93 TI TT1MPAY DMRUX93 TN GABA(A) receptor alpha-1 (GABRA1) DMRUX93 MA Inhibitor DMRUX93 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRUX93 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRUX93 DI DMRUX93 DMRUX93 DN 3-carboxy-6-ethyl-4-quinolone DMRUX93 TI TTNJYV2 DMRUX93 TN Gamma-aminobutyric acid receptor (GAR) DMRUX93 MA Inhibitor DMRUX93 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRUX93 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRUX93 DI DMRUX93 DMRUX93 DN 3-carboxy-6-ethyl-4-quinolone DMRUX93 TI TT06RH5 DMRUX93 TN GABA(A) receptor gamma-2 (GABRG2) DMRUX93 MA Inhibitor DMRUX93 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRUX93 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRUX93 DI DMRUX93 DMRUX93 DN 3-carboxy-6-ethyl-4-quinolone DMRUX93 TI TTZA1NY DMRUX93 TN GABA(A) receptor beta-2 (GABRB2) DMRUX93 MA Inhibitor DMRUX93 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMRUX93 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMRV16G DI DMRV16G DMRV16G DN NDP-SYSMEHFRWGKPVG DMRV16G TI TTEOSZT DMRV16G TN Melanocortin receptor (MCR) DMRV16G MA Inhibitor DMRV16G RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMRV16G RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMRV16G DI DMRV16G DMRV16G DN NDP-SYSMEHFRWGKPVG DMRV16G TI TTNI91K DMRV16G TN Melanocortin receptor 3 (MC3R) DMRV16G MA Inhibitor DMRV16G RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMRV16G RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMRV16G DI DMRV16G DMRV16G DN NDP-SYSMEHFRWGKPVG DMRV16G TI TTD0CIQ DMRV16G TN Melanocortin receptor 4 (MC4R) DMRV16G MA Inhibitor DMRV16G RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMRV16G RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMRV16G DI DMRV16G DMRV16G DN NDP-SYSMEHFRWGKPVG DMRV16G TI TT0MV2T DMRV16G TN Melanocortin receptor 1 (MC1R) DMRV16G MA Inhibitor DMRV16G RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMRV16G RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMRV5YE DI DMRV5YE DMRV5YE DN KURARINOL DMRV5YE TI TTZ97H5 DMRV5YE TN Phosphodiesterase 4A (PDE4A) DMRV5YE MA Inhibitor DMRV5YE RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMRV5YE RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMRV5YE DI DMRV5YE DMRV5YE DN KURARINOL DMRV5YE TI TTJ0IQB DMRV5YE TN Phosphodiesterase 5A (PDE5A) DMRV5YE MA Inhibitor DMRV5YE RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMRV5YE RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMRV5YE DI DMRV5YE DMRV5YE DN KURARINOL DMRV5YE TI TT06AWU DMRV5YE TN Phosphodiesterase 3A (PDE3A) DMRV5YE MA Inhibitor DMRV5YE RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMRV5YE RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMRV5YE DI DMRV5YE DMRV5YE DN KURARINOL DMRV5YE TI TTVIAT9 DMRV5YE TN Phosphodiesterase 4B (PDE4B) DMRV5YE MA Inhibitor DMRV5YE RN A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6. DMRV5YE RU https://pubmed.ncbi.nlm.nih.gov/12161123 DMRV89X DI DMRV89X DMRV89X DN Cl-amidine DMRV89X TI TTSCHFW DMRV89X TN Peptidyl arginine deiminase type III (PADI3) DMRV89X MA Inhibitor DMRV89X RN Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21. DMRV89X RU https://pubmed.ncbi.nlm.nih.gov/25742366 DMRV89X DI DMRV89X DMRV89X DN Cl-amidine DMRV89X TI TTQHAXM DMRV89X TN Peptidyl arginine deiminase type IV (PADI4) DMRV89X MA Inhibitor DMRV89X RN Identification of multiple structurally distinct, nonpeptidic small molecule inhibitors of protein arginine deiminase 3 using a substrate-based fragment method. J Am Chem Soc. 2015 Mar 18;137(10):3616-21. DMRV89X RU https://pubmed.ncbi.nlm.nih.gov/25742366 DMRVA94 DI DMRVA94 DMRVA94 DN 2-benzyl-N1-hydroxy-N3-(4-phenylbutyl)malonamide DMRVA94 TI TTPHMWB DMRVA94 TN Aminopeptidase N (ANPEP) DMRVA94 MA Inhibitor DMRVA94 RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMRVA94 RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMRVAH1 DI DMRVAH1 DMRVAH1 DN WRR-204 DMRVAH1 TI TTEAID7 DMRVAH1 TN Trypanosoma Cruzipain (Trypano CYSP) DMRVAH1 MA Inhibitor DMRVAH1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRVAH1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRVBCI DI DMRVBCI DMRVBCI DN 2-Mercapto-pentanedioic acid DMRVBCI TI TT9G4N0 DMRVBCI TN Glutamate carboxypeptidase II (GCPII) DMRVBCI MA Inhibitor DMRVBCI RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DMRVBCI RU https://pubmed.ncbi.nlm.nih.gov/12723961 DMRVHWZ DI DMRVHWZ DMRVHWZ DN PIPERROLEIN B DMRVHWZ TI TTA1L39 DMRVHWZ TN ICAM1 messenger RNA (ICAM1 mRNA) DMRVHWZ MA Inhibitor DMRVHWZ RN Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6. DMRVHWZ RU https://pubmed.ncbi.nlm.nih.gov/18672369 DMRVLZ4 DI DMRVLZ4 DMRVLZ4 DN G3139 + Fludarabine DMRVLZ4 TI TTFOUV4 DMRVLZ4 TN BCL-2 messenger RNA (BCL2 mRNA) DMRVLZ4 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMRVLZ4 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMRVMA5 DI DMRVMA5 DMRVMA5 DN NSC-66811 DMRVMA5 TI TT9TE0O DMRVMA5 TN Mdm2 messenger RNA (MDM2 mRNA) DMRVMA5 MA Inhibitor DMRVMA5 RN Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening str... J Med Chem. 2006 Jun 29;49(13):3759-62. DMRVMA5 RU https://pubmed.ncbi.nlm.nih.gov/16789731 DMRVOLN DI DMRVOLN DMRVOLN DN (R)-4-[2-[3-(4-methoxy-benzoylamino)-benzyl]-piperidin-1-ylmethyl]piperidine-1-carboxylic acid amide (Ro-320-6206) DMRVOLN TI TTYEG6Q DMRVOLN TN Muscarinic acetylcholine receptor M2 (CHRM2) DMRVOLN MA Antagonist DMRVOLN RN Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. DMRVOLN RU https://pubmed.ncbi.nlm.nih.gov/14769832 DMRVOT7 DI DMRVOT7 DMRVOT7 DN KYS-05055 DMRVOT7 TI TT729IR DMRVOT7 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMRVOT7 MA Inhibitor DMRVOT7 RN T-type Ca2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3899-901. DMRVOT7 RU https://pubmed.ncbi.nlm.nih.gov/18585035 DMRVPN1 DI DMRVPN1 DMRVPN1 DN [D-Dab(CO-NH-OH)3]degarelix DMRVPN1 TI TT8R70G DMRVPN1 TN Gonadotropin-releasing hormone receptor (GNRHR) DMRVPN1 MA Inhibitor DMRVPN1 RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DMRVPN1 RU https://pubmed.ncbi.nlm.nih.gov/16759096 DMRVQCB DI DMRVQCB DMRVQCB DN 13-n-Heptanamidotridec-5-ynoic acid DMRVQCB TI TT7WVHI DMRVQCB TN Soluble epoxide hydrolase (EPHX2) DMRVQCB MA Inhibitor DMRVQCB RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMRVQCB RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMRVS2D DI DMRVS2D DMRVS2D DN 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine DMRVS2D TI TTM2AOE DMRVS2D TN Adenosine A2a receptor (ADORA2A) DMRVS2D MA Inhibitor DMRVS2D RN Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4. DMRVS2D RU https://pubmed.ncbi.nlm.nih.gov/11459663 DMRVS2D DI DMRVS2D DMRVS2D DN 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine DMRVS2D TI TTK25J1 DMRVS2D TN Adenosine A1 receptor (ADORA1) DMRVS2D MA Inhibitor DMRVS2D RN Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4. DMRVS2D RU https://pubmed.ncbi.nlm.nih.gov/11459663 DMRVS2D DI DMRVS2D DMRVS2D DN 9-Ethyl-8-phenylethynyl-9H-purin-6-ylamine DMRVS2D TI TTJFY5U DMRVS2D TN Adenosine A3 receptor (ADORA3) DMRVS2D MA Inhibitor DMRVS2D RN Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor. Bioorg Med Chem Lett. 2001 Jul 23;11(14):1931-4. DMRVS2D RU https://pubmed.ncbi.nlm.nih.gov/11459663 DMRVSXG DI DMRVSXG DMRVSXG DN FGGFTGARKSARKLLNQ DMRVSXG TI TTNT7K8 DMRVSXG TN Nociceptin receptor (OPRL1) DMRVSXG MA Inhibitor DMRVSXG RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMRVSXG RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMRVTJ1 DI DMRVTJ1 DMRVTJ1 DN 2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile DMRVTJ1 TI TTM2AOE DMRVTJ1 TN Adenosine A2a receptor (ADORA2A) DMRVTJ1 MA Inhibitor DMRVTJ1 RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMRVTJ1 RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMRVTJ1 DI DMRVTJ1 DMRVTJ1 DN 2-Amino-4-phenyl-6-thiophen-2-yl-nicotinonitrile DMRVTJ1 TI TTK25J1 DMRVTJ1 TN Adenosine A1 receptor (ADORA1) DMRVTJ1 MA Inhibitor DMRVTJ1 RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMRVTJ1 RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMRVUCY DI DMRVUCY DMRVUCY DN S-111 DMRVUCY TI TTVDSZ0 DMRVUCY TN Poly [ADP-ribose] polymerase 1 (PARP1) DMRVUCY MA Inhibitor DMRVUCY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMRVUCY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMRVXFN DI DMRVXFN DMRVXFN DN Theliatinib DMRVXFN TI TTGKNB4 DMRVXFN TN Epidermal growth factor receptor (EGFR) DMRVXFN MA Inhibitor DMRVXFN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMRVXFN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMRVXH7 DI DMRVXH7 DMRVXH7 DN ThromboMer DMRVXH7 TI TTIHYA4 DMRVXH7 TN Thrombopoietin receptor (MPL) DMRVXH7 MA Modulator DMRVXH7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DMRVXH7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DMRVYKQ DI DMRVYKQ DMRVYKQ DN 2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol DMRVYKQ TI TTRA5BZ DMRVYKQ TN Steroid 17-alpha-monooxygenase (S17AH) DMRVYKQ MA Inhibitor DMRVYKQ RN Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5. DMRVYKQ RU https://pubmed.ncbi.nlm.nih.gov/2391687 DMRVYKQ DI DMRVYKQ DMRVYKQ DN 2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol DMRVYKQ TI TTT02K8 DMRVYKQ TN Steroid 5-alpha-reductase 2 (SRD5A2) DMRVYKQ MA Inhibitor DMRVYKQ RN Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5. DMRVYKQ RU https://pubmed.ncbi.nlm.nih.gov/2391687 DMRVYKQ DI DMRVYKQ DMRVYKQ DN 2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol DMRVYKQ TI TTTU72V DMRVYKQ TN Steroid 5-alpha-reductase 1 (SRD5A1) DMRVYKQ MA Inhibitor DMRVYKQ RN Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5. DMRVYKQ RU https://pubmed.ncbi.nlm.nih.gov/2391687 DMRW475 DI DMRW475 DMRW475 DN 2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine DMRW475 TI TTTIBOJ DMRW475 TN Histamine H1 receptor (H1R) DMRW475 MA Inhibitor DMRW475 RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMRW475 RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMRW475 DI DMRW475 DMRW475 DN 2-(9,10-dihydroanthracen-9-yl)-N-methylethanamine DMRW475 TI TTJQOD7 DMRW475 TN 5-HT 2A receptor (HTR2A) DMRW475 MA Inhibitor DMRW475 RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMRW475 RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMRW57G DI DMRW57G DMRW57G DN RS-14491 DMRW57G TI TTZ97H5 DMRW57G TN Phosphodiesterase 4A (PDE4A) DMRW57G MA Inhibitor DMRW57G RN Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997 May 9;40(10):1417-21. DMRW57G RU https://pubmed.ncbi.nlm.nih.gov/9154964 DMRW57G DI DMRW57G DMRW57G DN RS-14491 DMRW57G TI TTVIAT9 DMRW57G TN Phosphodiesterase 4B (PDE4B) DMRW57G MA Inhibitor DMRW57G RN Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997 May 9;40(10):1417-21. DMRW57G RU https://pubmed.ncbi.nlm.nih.gov/9154964 DMRW5J4 DI DMRW5J4 DMRW5J4 DN Benzyl-quinazolin-4-yl-amine DMRW5J4 TI TTGKNB4 DMRW5J4 TN Epidermal growth factor receptor (EGFR) DMRW5J4 MA Inhibitor DMRW5J4 RN Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7. DMRW5J4 RU https://pubmed.ncbi.nlm.nih.gov/7658435 DMRWD9M DI DMRWD9M DMRWD9M DN Diphthamide DMRWD9M TI TTCNGJ5 DMRWD9M TN Candida Elongation factor 2 (Candi EFT2) DMRWD9M MA Inhibitor DMRWD9M RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMRWD9M RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMRWG0C DI DMRWG0C DMRWG0C DN WAY-151693 DMRWG0C TI TTHY57M DMRWG0C TN Matrix metalloproteinase-13 (MMP-13) DMRWG0C MA Inhibitor DMRWG0C RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMRWG0C RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMRWLQM DI DMRWLQM DMRWLQM DN AL-8810 DMRWLQM TI TTT2ZAR DMRWLQM TN Prostaglandin F2-alpha receptor (PTGFR) DMRWLQM MA Agonist DMRWLQM RN AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84. DMRWLQM RU https://pubmed.ncbi.nlm.nih.gov/10454504 DMRWM24 DI DMRWM24 DMRWM24 DN PMID19632837C17f DMRWM24 TI TTIZQFJ DMRWM24 TN Histone-arginine methyltransferase CARM1 (CARM1) DMRWM24 MA Inhibitor DMRWM24 RN Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)--Hit to Lead studies. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5063-6. DMRWM24 RU https://pubmed.ncbi.nlm.nih.gov/19632837 DMRWOQH DI DMRWOQH DMRWOQH DN 2-methyl-1-(pyridin-3-yl)pent-1-en-3-one oxime DMRWOQH TI TTELV3W DMRWOQH TN Transformation-sensitive protein p120 (TRPA1) DMRWOQH MA Inhibitor DMRWOQH RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DMRWOQH RU https://pubmed.ncbi.nlm.nih.gov/20356305 DMRWSGO DI DMRWSGO DMRWSGO DN Bay K 8644 DMRWSGO TI TTXHYV6 DMRWSGO TN Voltage-gated L-type calcium channel (L-CaC) DMRWSGO MA Activator DMRWSGO RN Molecular determinants of drug binding and action on L-type calcium channels. Annu Rev Pharmacol Toxicol. 1997;37:361-96. DMRWSGO RU https://pubmed.ncbi.nlm.nih.gov/9131258 DMRWTHA DI DMRWTHA DMRWTHA DN PMID17888661C19 DMRWTHA TI TTE5J6X DMRWTHA TN Diphosphomevalonate decarboxylase (MVD) DMRWTHA MA Inhibitor DMRWTHA RN Mutation and inhibition studies of mevalonate 5-diphosphate decarboxylase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6164-8. DMRWTHA RU https://pubmed.ncbi.nlm.nih.gov/17888661 DMRWUQ5 DI DMRWUQ5 DMRWUQ5 DN Ala(1-naph)-Pro-CN DMRWUQ5 TI TTUA38Z DMRWUQ5 TN Retinoblastoma-binding protein 9 (RBBP9) DMRWUQ5 MA Inhibitor DMRWUQ5 RN A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nat Chem Biol. 2014 Aug;10(8):656-63. DMRWUQ5 RU https://pubmed.ncbi.nlm.nih.gov/24997602 DMRWXH4 DI DMRWXH4 DMRWXH4 DN Quinoxaline1 DMRWXH4 TI TTL4Q97 DMRWXH4 TN Cyclin-dependent kinase 5 (CDK5) DMRWXH4 MA Inhibitor DMRWXH4 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMRWXH4 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMRWXH4 DI DMRWXH4 DMRWXH4 DN Quinoxaline1 DMRWXH4 TI TTH6V3D DMRWXH4 TN Cyclin-dependent kinase 1 (CDK1) DMRWXH4 MA Inhibitor DMRWXH4 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMRWXH4 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMRWXH4 DI DMRWXH4 DMRWXH4 DN Quinoxaline1 DMRWXH4 TI TTRSMW9 DMRWXH4 TN Glycogen synthase kinase-3 beta (GSK-3B) DMRWXH4 MA Inhibitor DMRWXH4 RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMRWXH4 RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMRWZ6T DI DMRWZ6T DMRWZ6T DN 4-((1H-indol-1-yl)methyl)benzenamine DMRWZ6T TI TTJS8PY DMRWZ6T TN 5-HT 6 receptor (HTR6) DMRWZ6T MA Inhibitor DMRWZ6T RN Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1691-4. DMRWZ6T RU https://pubmed.ncbi.nlm.nih.gov/17239595 DMRWZX6 DI DMRWZX6 DMRWZX6 DN PMID20690647C5a DMRWZX6 TI TTG5QB7 DMRWZX6 TN Calpain-2 (CAPN2) DMRWZX6 MA Inhibitor DMRWZX6 RN Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors. J Med Chem. 2010 Sep 9;53(17):6326-36. DMRWZX6 RU https://pubmed.ncbi.nlm.nih.gov/20690647 DMRX4HM DI DMRX4HM DMRX4HM DN 2-(3-(3-bromophenyl)ureido)-4-chlorobenzoic acid DMRX4HM TI TT0MYE2 DMRX4HM TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMRX4HM MA Inhibitor DMRX4HM RN Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J Med Chem. 2004 Dec 30;47(27):6948-57. DMRX4HM RU https://pubmed.ncbi.nlm.nih.gov/15615543 DMRX9E3 DI DMRX9E3 DMRX9E3 DN POLYSIN DMRX9E3 TI TTHQ79V DMRX9E3 TN Trypanosoma Pyrophosphate-dependent phosphofructokinase (Trypano pfk) DMRX9E3 MA Inhibitor DMRX9E3 RN Antitrypanosomal alkaloids from Polyalthia suaveolens (Annonaceae): their effects on three selected glycolytic enzymes of Trypanosoma brucei. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3495-8. DMRX9E3 RU https://pubmed.ncbi.nlm.nih.gov/20529682 DMRXA8N DI DMRXA8N DMRXA8N DN N-ALLYLNORGALANTHAMINE DMRXA8N TI TT1RS9F DMRXA8N TN Acetylcholinesterase (AChE) DMRXA8N MA Inhibitor DMRXA8N RN N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2263-6. DMRXA8N RU https://pubmed.ncbi.nlm.nih.gov/18356045 DMRXD2P DI DMRXD2P DMRXD2P DN 1-(3,4-difluorobenzyl)-1H-imidazole DMRXD2P TI TTRA5BZ DMRXD2P TN Steroid 17-alpha-monooxygenase (S17AH) DMRXD2P MA Inhibitor DMRXD2P RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DMRXD2P RU https://pubmed.ncbi.nlm.nih.gov/16750362 DMRXD82 DI DMRXD82 DMRXD82 DN (R/S)-2-((4-benzylphenoxy)methyl)piperidine DMRXD82 TI TTXZEAJ DMRXD82 TN Leukotriene A-4 hydrolase (LTA4H) DMRXD82 MA Inhibitor DMRXD82 RN Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4. DMRXD82 RU https://pubmed.ncbi.nlm.nih.gov/20371179 DMRXDS2 DI DMRXDS2 DMRXDS2 DN 2np8 DMRXDS2 TI TTLYXIT DMRXDS2 TN Aurora kinase C (AURKC) DMRXDS2 MA Inhibitor DMRXDS2 RN Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. Bioorg Med Chem Lett. 2007 Feb 1;17(3):688-91. DMRXDS2 RU https://pubmed.ncbi.nlm.nih.gov/17157005 DMRXK5G DI DMRXK5G DMRXK5G DN BI6015 DMRXK5G TI TT2F3CD DMRXK5G TN Hepatocyte nuclear factor 4-alpha (HNF4A) DMRXK5G MA Antagonist DMRXK5G RN HNF4alpha antagonists discovered by a high-throughput screen for modulators of the human insulin promoter. Chem Biol. 2012 Jul 27;19(7):806-18. DMRXK5G RU https://pubmed.ncbi.nlm.nih.gov/22840769 DMRXKMP DI DMRXKMP DMRXKMP DN 4-(3-pyridylethynyl)-2-thiazolylamine DMRXKMP TI TTHS256 DMRXKMP TN Metabotropic glutamate receptor 5 (mGluR5) DMRXKMP MA Inhibitor DMRXKMP RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMRXKMP RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMRXPFM DI DMRXPFM DMRXPFM DN BZ5 DMRXPFM TI TTVDSZ0 DMRXPFM TN Poly [ADP-ribose] polymerase 1 (PARP1) DMRXPFM MA Inhibitor DMRXPFM RN Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8. DMRXPFM RU https://pubmed.ncbi.nlm.nih.gov/12855651 DMRXW3U DI DMRXW3U DMRXW3U DN 2-Hex-5-enyl-5-non-8-enyl-3,4-dihydro-2H-pyrrole DMRXW3U TI TT1RS9F DMRXW3U TN Acetylcholinesterase (AChE) DMRXW3U MA Inhibitor DMRXW3U RN Acetylcholinesterase inhibition by alkaloids of the ant's venom Monomorium minutum, Bioorg. Med. Chem. Lett. 5(11):1131-1132 (1995). DMRXW3U RU http://www.sciencedirect.com/science/article/pii/0960894X9500179W DMRY06D DI DMRY06D DMRY06D DN 2-Amino-N-[4-(phenylmethoxy)phenyl]-acetamide DMRY06D TI TTXZEAJ DMRY06D TN Leukotriene A-4 hydrolase (LTA4H) DMRY06D MA Inhibitor DMRY06D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMRY06D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMRY0OL DI DMRY0OL DMRY0OL DN 5-bromo-6-(cyclopropylamino)uracil hydrochloride DMRY0OL TI TTO0IB8 DMRY0OL TN Thymidine phosphorylase (TYMP) DMRY0OL MA Inhibitor DMRY0OL RN Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7. DMRY0OL RU https://pubmed.ncbi.nlm.nih.gov/16337119 DMRY2ZC DI DMRY2ZC DMRY2ZC DN 3'',5''-dimethoxy-[1,1':2',1'']-terphenyl-4-ol DMRY2ZC TI TTS7G69 DMRY2ZC TN Fusion protein Bcr-Abl (Bcr-Abl) DMRY2ZC MA Inhibitor DMRY2ZC RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMRY2ZC RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMRY6B4 DI DMRY6B4 DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide DMRY6B4 TI TTSHTOI DMRY6B4 TN Histone deacetylase 2 (HDAC2) DMRY6B4 MA Inhibitor DMRY6B4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMRY6B4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMRY6B4 DI DMRY6B4 DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide DMRY6B4 TI TTYHPU6 DMRY6B4 TN Histone deacetylase 10 (HDAC10) DMRY6B4 MA Inhibitor DMRY6B4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMRY6B4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMRY6B4 DI DMRY6B4 DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide DMRY6B4 TI TTT6LFV DMRY6B4 TN Histone deacetylase 8 (HDAC8) DMRY6B4 MA Inhibitor DMRY6B4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMRY6B4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMRY6B4 DI DMRY6B4 DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide DMRY6B4 TI TT6R7JZ DMRY6B4 TN Histone deacetylase 1 (HDAC1) DMRY6B4 MA Inhibitor DMRY6B4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMRY6B4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMRY6B4 DI DMRY6B4 DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide DMRY6B4 TI TT5ZKDI DMRY6B4 TN Histone deacetylase 6 (HDAC6) DMRY6B4 MA Inhibitor DMRY6B4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMRY6B4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMRY6B4 DI DMRY6B4 DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide DMRY6B4 TI TTTQGH8 DMRY6B4 TN Histone deacetylase 4 (HDAC4) DMRY6B4 MA Inhibitor DMRY6B4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMRY6B4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMRY6B4 DI DMRY6B4 DMRY6B4 DN 4-Butyrylamino-N-hydroxy-benzamide DMRY6B4 TI TTBH0VX DMRY6B4 TN Histone deacetylase (HDAC) DMRY6B4 MA Inhibitor DMRY6B4 RN Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors. J Med Chem. 2004 Jan 15;47(2):467-74. DMRY6B4 RU https://pubmed.ncbi.nlm.nih.gov/14711316 DMRY95I DI DMRY95I DMRY95I DN C[Thr-Tyr-Thr-His-DNaf-Arg-Trp-Thr-Ile-Pro] DMRY95I TI TTD0CIQ DMRY95I TN Melanocortin receptor 4 (MC4R) DMRY95I MA Inhibitor DMRY95I RN Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for... J Med Chem. 2006 Feb 9;49(3):911-22. DMRY95I RU https://pubmed.ncbi.nlm.nih.gov/16451057 DMRYBK6 DI DMRYBK6 DMRYBK6 DN NW-1772 DMRYBK6 TI TTGP7BY DMRYBK6 TN Monoamine oxidase type B (MAO-B) DMRYBK6 MA Inhibitor DMRYBK6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490). DMRYBK6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2490 DMRYCL6 DI DMRYCL6 DMRYCL6 DN 4-propyl-3,4-dihydroquinazolin-2-amine DMRYCL6 TI TTRUFDT DMRYCL6 TN 5-HT 5A receptor (HTR5A) DMRYCL6 MA Inhibitor DMRYCL6 RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMRYCL6 RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMRYJBA DI DMRYJBA DMRYJBA DN Phenanthrene-3-carboxylic acid hydroxyamide DMRYJBA TI TT2J34L DMRYJBA TN Arachidonate 5-lipoxygenase (5-LOX) DMRYJBA MA Inhibitor DMRYJBA RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMRYJBA RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMRYL9X DI DMRYL9X DMRYL9X DN AP-2243 DMRYL9X TI TT1RS9F DMRYL9X TN Acetylcholinesterase (AChE) DMRYL9X MA Inhibitor DMRYL9X RN Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6. DMRYL9X RU https://pubmed.ncbi.nlm.nih.gov/17998161 DMRYL9X DI DMRYL9X DMRYL9X DN AP-2243 DMRYL9X TI TT8JRS7 DMRYL9X TN Beta-secretase (BACE) DMRYL9X MA Inhibitor DMRYL9X RN Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett. 2008 Jan 1;18(1):423-6. DMRYL9X RU https://pubmed.ncbi.nlm.nih.gov/17998161 DMRYNJE DI DMRYNJE DMRYNJE DN RO3 DMRYNJE TI TT2THBD DMRYNJE TN P2X purinoceptor 3 (P2RX3) DMRYNJE MA Antagonist DMRYNJE RN Purinoceptors as therapeutic targets for lower urinary tract dysfunction. Br J Pharmacol. 2006 Feb;147 Suppl 2:S132-43. DMRYNJE RU https://pubmed.ncbi.nlm.nih.gov/16465177 DMRYQVJ DI DMRYQVJ DMRYQVJ DN DM-107 DMRYQVJ TI TTJLNAW DMRYQVJ TN Tissue kallikrein (KLK2) DMRYQVJ MA Inhibitor DMRYQVJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2372). DMRYQVJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2372 DMRYV9E DI DMRYV9E DMRYV9E DN 11-Hexanoyloxy-N-n-propylnoraporphine DMRYV9E TI TTJQOD7 DMRYV9E TN 5-HT 2A receptor (HTR2A) DMRYV9E MA Inhibitor DMRYV9E RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMRYV9E RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMRYV9E DI DMRYV9E DMRYV9E DN 11-Hexanoyloxy-N-n-propylnoraporphine DMRYV9E TI TTZFYLI DMRYV9E TN Dopamine D1 receptor (D1R) DMRYV9E MA Inhibitor DMRYV9E RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMRYV9E RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMRYWSN DI DMRYWSN DMRYWSN DN 4-((1H-Imidazol-4-yl)methyl)-1-phenylpiperidine DMRYWSN TI TT9JNIC DMRYWSN TN Histamine H3 receptor (H3R) DMRYWSN MA Inhibitor DMRYWSN RN Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor. Bioorg Med Chem. 2010 Jul 15;18(14):5441-8. DMRYWSN RU https://pubmed.ncbi.nlm.nih.gov/20541426 DMRYX1P DI DMRYX1P DMRYX1P DN CEL-1000 DMRYX1P TI TTN2JFW DMRYX1P TN T-cell surface glycoprotein CD4 (CD4) DMRYX1P RN A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother. 2004 Jul;48(7):2455-63. DMRYX1P RU https://pubmed.ncbi.nlm.nih.gov/15215094 DMRZAQW DI DMRZAQW DMRZAQW DN PAF DMRZAQW TI TTQL5VC DMRZAQW TN Platelet-activating factor receptor (PTAFR) DMRZAQW MA Agonist DMRZAQW RN Identification of transmembrane domain residues determinant in the structure-function relationship of the human platelet-activating factor receptor by site-directed mutagenesis. J Biol Chem. 1996 Sep20;271(38):23298-303. DMRZAQW RU https://pubmed.ncbi.nlm.nih.gov/8798529 DMRZDM0 DI DMRZDM0 DMRZDM0 DN (R)-3-(1'-Adamantanecarbonyl)amino-caprolactam DMRZDM0 TI TTFZYTO DMRZDM0 TN C-C chemokine receptor type 2 (CCR2) DMRZDM0 MA Inhibitor DMRZDM0 RN Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors. J Med Chem. 2009 Jun 11;52(11):3591-5. DMRZDM0 RU https://pubmed.ncbi.nlm.nih.gov/19425597 DMRZJL1 DI DMRZJL1 DMRZJL1 DN NSC-47729 DMRZJL1 TI TT9NVXQ DMRZJL1 TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMRZJL1 MA Inhibitor DMRZJL1 RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMRZJL1 RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMRZJU5 DI DMRZJU5 DMRZJU5 DN 2,6-dimethyl-8-ethyl-1-deazapurine DMRZJU5 TI TTK25J1 DMRZJU5 TN Adenosine A1 receptor (ADORA1) DMRZJU5 MA Inhibitor DMRZJU5 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMRZJU5 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMRZK9A DI DMRZK9A DMRZK9A DN 2-nitro-N-(2,4,5-trichlorophenyl)benzamide DMRZK9A TI TTVTX4N DMRZK9A TN Bacterial Fatty acid synthetase I (Bact inhA) DMRZK9A MA Inhibitor DMRZK9A RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMRZK9A RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMRZMKT DI DMRZMKT DMRZMKT DN AP-1189 DMRZMKT TI TT0MV2T DMRZMKT TN Melanocortin receptor 1 (MC1R) DMRZMKT MA Modulator DMRZMKT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 282). DMRZMKT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=282 DMRZOVP DI DMRZOVP DMRZOVP DN (+/-)-threo-Methylphenidate amide DMRZOVP TI TTVBI8W DMRZOVP TN Dopamine transporter (DAT) DMRZOVP MA Inhibitor DMRZOVP RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMRZOVP RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMRZY0B DI DMRZY0B DMRZY0B DN 4-(2,2'-bithiophen-5-ylmethyleneamino)phenol DMRZY0B TI TTHY57M DMRZY0B TN Matrix metalloproteinase-13 (MMP-13) DMRZY0B MA Inhibitor DMRZY0B RN High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem. 2009 Feb 1;17(3):990-1005. DMRZY0B RU https://pubmed.ncbi.nlm.nih.gov/18358729 DMS01IN DI DMS01IN DMS01IN DN PT-115 DMS01IN TI TT84ETX DMS01IN TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMS01IN MA Inhibitor DMS01IN RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DMS01IN RU https://pubmed.ncbi.nlm.nih.gov/8863804 DMS03TR DI DMS03TR DMS03TR DN ISIS 222041 DMS03TR TI TTWPA54 DMS03TR TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMS03TR RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMS03TR RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMS0FQC DI DMS0FQC DMS0FQC DN Sar-Arg-Val-Tyr-Ile-His-Pro-Ile DMS0FQC TI TTQVOEI DMS0FQC TN Angiotensin II receptor type-2 (AGTR2) DMS0FQC MA Inhibitor DMS0FQC RN Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 sub... J Med Chem. 1991 Nov;34(11):3248-60. DMS0FQC RU https://pubmed.ncbi.nlm.nih.gov/1956044 DMS0HV6 DI DMS0HV6 DMS0HV6 DN 4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol DMS0HV6 TI TTOM3J0 DMS0HV6 TN Estrogen receptor beta (ESR2) DMS0HV6 MA Inhibitor DMS0HV6 RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMS0HV6 RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMS0HV6 DI DMS0HV6 DMS0HV6 DN 4-[2,2-bis(4-hydroxyphenyl)-1-methylvinyl]phenol DMS0HV6 TI TTZAYWL DMS0HV6 TN Estrogen receptor (ESR) DMS0HV6 MA Inhibitor DMS0HV6 RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMS0HV6 RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMS0I5V DI DMS0I5V DMS0I5V DN 10-OBn-ginkgolide B DMS0I5V TI TTQL5VC DMS0I5V TN Platelet-activating factor receptor (PTAFR) DMS0I5V MA Antagonist DMS0I5V RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMS0I5V RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMS0JVE DI DMS0JVE DMS0JVE DN 4BP-TQS DMS0JVE TI TTLA931 DMS0JVE TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMS0JVE MA Agonist DMS0JVE RN Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5867-72. DMS0JVE RU https://pubmed.ncbi.nlm.nih.gov/21436053 DMS0LFT DI DMS0LFT DMS0LFT DN [D-Dap(CO-NH-OH)3]degarelix DMS0LFT TI TT8R70G DMS0LFT TN Gonadotropin-releasing hormone receptor (GNRHR) DMS0LFT MA Inhibitor DMS0LFT RN Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III. J Med Chem. 2006 Jun 15;49(12):3536-43. DMS0LFT RU https://pubmed.ncbi.nlm.nih.gov/16759096 DMS0NW3 DI DMS0NW3 DMS0NW3 DN 2-N-Cyclopropylamino-1-(4-methylthiophenyl)butane DMS0NW3 TI TT3ROYC DMS0NW3 TN Serotonin transporter (SERT) DMS0NW3 MA Inhibitor DMS0NW3 RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMS0NW3 RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMS0V84 DI DMS0V84 DMS0V84 DN Demotensin 3 DMS0V84 TI TTTUMEP DMS0V84 TN Neurotensin receptor type 1 (NTSR1) DMS0V84 MA Inhibitor DMS0V84 RN Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76. DMS0V84 RU https://pubmed.ncbi.nlm.nih.gov/16854083 DMS10LE DI DMS10LE DMS10LE DN 1-cyclohexyl-1-isopropyl-3,3-dimethylselenourea DMS10LE TI TTAS2UO DMS10LE TN Bacterial Urease (Bact ureC) DMS10LE MA Inhibitor DMS10LE RN Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91. DMS10LE RU https://pubmed.ncbi.nlm.nih.gov/17889535 DMS15A3 DI DMS15A3 DMS15A3 DN ISIS 12884 DMS15A3 TI TTR5TV4 DMS15A3 TN ERBB2 messenger RNA (HER2 mRNA) DMS15A3 RN US patent application no. 5,968,748, Antisense oligonucleotide modulation of human HER-2 expression. DMS15A3 RU http://www.patentbuddy.com/Patent/5968748?ft=true&sr=true DMS16BD DI DMS16BD DMS16BD DN CEP-6800 DMS16BD TI TTVDSZ0 DMS16BD TN Poly [ADP-ribose] polymerase 1 (PARP1) DMS16BD MA Inhibitor DMS16BD RN Novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2007 Jan 15;17(2):542-5. DMS16BD RU https://pubmed.ncbi.nlm.nih.gov/17074482 DMS16CO DI DMS16CO DMS16CO DN (4-benzylpiperidin-1-yl)(m-tolyl)methanone DMS16CO TI TTVTX4N DMS16CO TN Bacterial Fatty acid synthetase I (Bact inhA) DMS16CO MA Inhibitor DMS16CO RN Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. DMS16CO RU https://pubmed.ncbi.nlm.nih.gov/17723305 DMS172K DI DMS172K DMS172K DN ISIS 183897 DMS172K TI TTBGTCW DMS172K TN Kinesin spindle messenger RNA (KIF11 mRNA) DMS172K RN US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression. DMS172K RU http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true DMS192I DI DMS192I DMS192I DN 1-[3-(Methylsulfonyl)phenyl]-4-propylpiperazine DMS192I TI TTEX248 DMS192I TN Dopamine D2 receptor (D2R) DMS192I MA Inhibitor DMS192I RN Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabi... J Med Chem. 2010 Mar 25;53(6):2510-20. DMS192I RU https://pubmed.ncbi.nlm.nih.gov/20155917 DMS1AFL DI DMS1AFL DMS1AFL DN SNAP 398299 DMS1AFL TI TTOPAY7 DMS1AFL TN Galanin receptor (GAL-R) DMS1AFL MA Antagonist DMS1AFL RN Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17489-94. DMS1AFL RU https://pubmed.ncbi.nlm.nih.gov/16287967 DMS1AOK DI DMS1AOK DMS1AOK DN 2-((2-iodophenoxy)(phenyl)methyl)morpholine DMS1AOK TI TTVBI8W DMS1AOK TN Dopamine transporter (DAT) DMS1AOK MA Inhibitor DMS1AOK RN Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. DMS1AOK RU https://pubmed.ncbi.nlm.nih.gov/17095215 DMS1AOK DI DMS1AOK DMS1AOK DN 2-((2-iodophenoxy)(phenyl)methyl)morpholine DMS1AOK TI TTAWNKZ DMS1AOK TN Norepinephrine transporter (NET) DMS1AOK MA Inhibitor DMS1AOK RN Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. DMS1AOK RU https://pubmed.ncbi.nlm.nih.gov/17095215 DMS1DVA DI DMS1DVA DMS1DVA DN DAMGO DMS1DVA TI TTKWM86 DMS1DVA TN Opioid receptor mu (MOP) DMS1DVA MA Inhibitor DMS1DVA RN Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. DMS1DVA RU https://pubmed.ncbi.nlm.nih.gov/20599386 DMS1DVA DI DMS1DVA DMS1DVA DN DAMGO DMS1DVA TI TT27RFC DMS1DVA TN Opioid receptor delta (OPRD1) DMS1DVA MA Inhibitor DMS1DVA RN Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. DMS1DVA RU https://pubmed.ncbi.nlm.nih.gov/20599386 DMS1DVA DI DMS1DVA DMS1DVA DN DAMGO DMS1DVA TI TTQW87Y DMS1DVA TN Opioid receptor kappa (OPRK1) DMS1DVA MA Inhibitor DMS1DVA RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMS1DVA RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMS1LDH DI DMS1LDH DMS1LDH DN 3-(4-Amino-phenyl)-1-methyl-pyrrolidine-2,5-dione DMS1LDH TI TTSZLWK DMS1LDH TN Aromatase (CYP19A1) DMS1LDH MA Inhibitor DMS1LDH RN Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3. DMS1LDH RU https://pubmed.ncbi.nlm.nih.gov/3754286 DMS1LZI DI DMS1LZI DMS1LZI DN E[c(RGDyK)]2-PTX conjugate DMS1LZI TI TTT1R2L DMS1LZI TN Integrin alpha-V (ITGAV) DMS1LZI MA Inhibitor DMS1LZI RN Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106. DMS1LZI RU https://pubmed.ncbi.nlm.nih.gov/15715477 DMS1LZI DI DMS1LZI DMS1LZI DN E[c(RGDyK)]2-PTX conjugate DMS1LZI TI TTJA1ZO DMS1LZI TN ITGB3 messenger RNA (ITGB3 mRNA) DMS1LZI MA Inhibitor DMS1LZI RN Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery. J Med Chem. 2005 Feb 24;48(4):1098-106. DMS1LZI RU https://pubmed.ncbi.nlm.nih.gov/15715477 DMS1OYA DI DMS1OYA DMS1OYA DN 4-(1-butyl-7-chloro-1H-indazol-3-yl)phenol DMS1OYA TI TTZAYWL DMS1OYA TN Estrogen receptor (ESR) DMS1OYA MA Inhibitor DMS1OYA RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DMS1OYA RU https://pubmed.ncbi.nlm.nih.gov/15588074 DMS1P85 DI DMS1P85 DMS1P85 DN N1-(4-fluorobenzyl)-2-benzyl-N3-hydroxymalonamide DMS1P85 TI TTPHMWB DMS1P85 TN Aminopeptidase N (ANPEP) DMS1P85 MA Inhibitor DMS1P85 RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMS1P85 RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMS1QIJ DI DMS1QIJ DMS1QIJ DN 3',4'-dichloroacetophenonethiosemicarbazone DMS1QIJ TI TTEAID7 DMS1QIJ TN Trypanosoma Cruzipain (Trypano CYSP) DMS1QIJ MA Inhibitor DMS1QIJ RN Studies toward the structural optimization of novel thiazolylhydrazone-based potent antitrypanosomal agents. Bioorg Med Chem. 2010 Nov 15;18(22):7826-35. DMS1QIJ RU https://pubmed.ncbi.nlm.nih.gov/20961766 DMS1QM8 DI DMS1QM8 DMS1QM8 DN PMID17975902C5e DMS1QM8 TI TTIKWV4 DMS1QM8 TN Geranyltranstransferase (FDPS) DMS1QM8 MA Inhibitor DMS1QM8 RN Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate. J Med Chem. 2007 Nov 29;50(24):5967-75. DMS1QM8 RU https://pubmed.ncbi.nlm.nih.gov/17975902 DMS1T0V DI DMS1T0V DMS1T0V DN 2-Cyclohexylacetic acidbiphenyl-3-yl ester DMS1T0V TI TTDP1UC DMS1T0V TN Fatty acid amide hydrolase (FAAH) DMS1T0V MA Inhibitor DMS1T0V RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMS1T0V RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMS1YN3 DI DMS1YN3 DMS1YN3 DN [1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate DMS1YN3 TI TT7ZMY4 DMS1YN3 TN Lysophosphatidic acid receptor 4 (LPAR4) DMS1YN3 MA Antagonist DMS1YN3 RN LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31. DMS1YN3 RU https://pubmed.ncbi.nlm.nih.gov/18781939 DMS1YXL DI DMS1YXL DMS1YXL DN 2,4-diaminoquinozalines and quinoxaline-2,3-diones DMS1YXL TI TTNSXG2 DMS1YXL TN Human immunodeficiency virus TAR RNA (HIV TAR-RNA) DMS1YXL MA Inhibitor DMS1YXL RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMS1YXL RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMS21CR DI DMS21CR DMS21CR DN 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine DMS21CR TI TTAWNKZ DMS21CR TN Norepinephrine transporter (NET) DMS21CR MA Inhibitor DMS21CR RN Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. DMS21CR RU https://pubmed.ncbi.nlm.nih.gov/17095215 DMS21CR DI DMS21CR DMS21CR DN 2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine DMS21CR TI TTVBI8W DMS21CR TN Dopamine transporter (DAT) DMS21CR MA Inhibitor DMS21CR RN Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7. DMS21CR RU https://pubmed.ncbi.nlm.nih.gov/17095215 DMS21ZP DI DMS21ZP DMS21ZP DN PMID20598884C8 DMS21ZP TI TTHS256 DMS21ZP TN Metabotropic glutamate receptor 5 (mGluR5) DMS21ZP MA Modulator (allosteric modulator) DMS21ZP RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMS21ZP RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMS29M4 DI DMS29M4 DMS29M4 DN TWS-119 DMS29M4 TI TTZILNJ DMS29M4 TN Proto-oncogene c-Myc (MYC) DMS29M4 MA Inhibitor DMS29M4 RN Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84. DMS29M4 RU https://pubmed.ncbi.nlm.nih.gov/16408003 DMS29M4 DI DMS29M4 DMS29M4 DN TWS-119 DMS29M4 TI TTRSMW9 DMS29M4 TN Glycogen synthase kinase-3 beta (GSK-3B) DMS29M4 MA Inhibitor DMS29M4 RN Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84. DMS29M4 RU https://pubmed.ncbi.nlm.nih.gov/16408003 DMS29M4 DI DMS29M4 DMS29M4 DN TWS-119 DMS29M4 TI TTN3GBV DMS29M4 TN Transcription factor AP-1 (JUN) DMS29M4 MA Inhibitor DMS29M4 RN Diversity-oriented synthesis: exploring the intersections between chemistry and biology. Nat Chem Biol. 2005 Jul;1(2):74-84. DMS29M4 RU https://pubmed.ncbi.nlm.nih.gov/16408003 DMS2DI9 DI DMS2DI9 DMS2DI9 DN (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine DMS2DI9 TI TTJQOD7 DMS2DI9 TN 5-HT 2A receptor (HTR2A) DMS2DI9 MA Inhibitor DMS2DI9 RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMS2DI9 RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMS2DI9 DI DMS2DI9 DMS2DI9 DN (R,S)-1-(5-methyl-1H-indol-1-yl)propan-2-amine DMS2DI9 TI TTWJBZ5 DMS2DI9 TN 5-HT 2C receptor (HTR2C) DMS2DI9 MA Inhibitor DMS2DI9 RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMS2DI9 RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMS2NZA DI DMS2NZA DMS2NZA DN 7-Hydroxy-3-(3-hydroxyphenyl)-1-naphthonitrile DMS2NZA TI TTIWB6L DMS2NZA TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMS2NZA MA Inhibitor DMS2NZA RN Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98. DMS2NZA RU https://pubmed.ncbi.nlm.nih.gov/18630892 DMS2OY9 DI DMS2OY9 DMS2OY9 DN 3-(6-morpholino-9H-purin-2-yl)phenol DMS2OY9 TI TTCJG29 DMS2OY9 TN Serine/threonine-protein kinase mTOR (mTOR) DMS2OY9 MA Inhibitor DMS2OY9 RN Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. DMS2OY9 RU https://pubmed.ncbi.nlm.nih.gov/19969455 DMS2QUL DI DMS2QUL DMS2QUL DN WR-289010 DMS2QUL TI TTSFWA7 DMS2QUL TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMS2QUL MA Inhibitor DMS2QUL RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DMS2QUL RU https://pubmed.ncbi.nlm.nih.gov/19250824 DMS2RHE DI DMS2RHE DMS2RHE DN CP-470,711 DMS2RHE TI TTLSRBZ DMS2RHE TN Sorbitoldehydrogenase (SORD) DMS2RHE MA Inhibitor DMS2RHE RN Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium. FASEB J. 2003 Dec;17(15):2331-3. DMS2RHE RU https://pubmed.ncbi.nlm.nih.gov/14525943 DMS2V0P DI DMS2V0P DMS2V0P DN PSB-716 DMS2V0P TI TTOZHQC DMS2V0P TN P2Y purinoceptor 2 (P2RY2) DMS2V0P MA Inhibitor DMS2V0P RN Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7. DMS2V0P RU https://pubmed.ncbi.nlm.nih.gov/18006312 DMS2X69 DI DMS2X69 DMS2X69 DN N-(5-m-Tolyl-furan-2-carbonyl)-guanidine DMS2X69 TI TTGSEFH DMS2X69 TN Sodium/hydrogen exchanger 1 (SLC9A1) DMS2X69 MA Inhibitor DMS2X69 RN (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. DMS2X69 RU https://pubmed.ncbi.nlm.nih.gov/15828827 DMS30HQ DI DMS30HQ DMS30HQ DN 4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine DMS30HQ TI TTUTJGQ DMS30HQ TN Vascular endothelial growth factor receptor 2 (KDR) DMS30HQ MA Inhibitor DMS30HQ RN Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81. DMS30HQ RU https://pubmed.ncbi.nlm.nih.gov/16386418 DMS30HQ DI DMS30HQ DMS30HQ DN 4-(isoquinolin-5-yl)-N-o-tolylphthalazin-1-amine DMS30HQ TI TT1VAUK DMS30HQ TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMS30HQ MA Inhibitor DMS30HQ RN Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1579-81. DMS30HQ RU https://pubmed.ncbi.nlm.nih.gov/16386418 DMS30KU DI DMS30KU DMS30KU DN (R)-Norfluoxetine DMS30KU TI TTVBI8W DMS30KU TN Dopamine transporter (DAT) DMS30KU MA Inhibitor DMS30KU RN Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43. DMS30KU RU https://pubmed.ncbi.nlm.nih.gov/19014888 DMS30KU DI DMS30KU DMS30KU DN (R)-Norfluoxetine DMS30KU TI TT3ROYC DMS30KU TN Serotonin transporter (SERT) DMS30KU MA Inhibitor DMS30KU RN Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43. DMS30KU RU https://pubmed.ncbi.nlm.nih.gov/19014888 DMS30KU DI DMS30KU DMS30KU DN (R)-Norfluoxetine DMS30KU TI TTAWNKZ DMS30KU TN Norepinephrine transporter (NET) DMS30KU MA Inhibitor DMS30KU RN Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43. DMS30KU RU https://pubmed.ncbi.nlm.nih.gov/19014888 DMS31H9 DI DMS31H9 DMS31H9 DN 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol DMS31H9 TI TTMSFAW DMS31H9 TN Cannabinoid receptor 2 (CB2) DMS31H9 MA Inhibitor DMS31H9 RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMS31H9 RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMS31H9 DI DMS31H9 DMS31H9 DN 5-(1,1-dimethyl-heptyl)-2-pyridin-3-yl-phenol DMS31H9 TI TT6OEDT DMS31H9 TN Cannabinoid receptor 1 (CB1) DMS31H9 MA Inhibitor DMS31H9 RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMS31H9 RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMS325C DI DMS325C DMS325C DN 6-fluoropyridin-3-ylboronic acid DMS325C TI TTDP1UC DMS325C TN Fatty acid amide hydrolase (FAAH) DMS325C MA Inhibitor DMS325C RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMS325C RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMS32YA DI DMS32YA DMS32YA DN (D)-Phe-(L)-Phe-NH2 DMS32YA TI TTZPO1L DMS32YA TN Substance-P receptor (TACR1) DMS32YA MA Inhibitor DMS32YA RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMS32YA RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMS3AXK DI DMS3AXK DMS3AXK DN EDMT DMS3AXK TI TT6MSOK DMS3AXK TN 5-HT 1D receptor (HTR1D) DMS3AXK MA Agonist DMS3AXK RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMS3AXK RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMS3AXK DI DMS3AXK DMS3AXK DN EDMT DMS3AXK TI TTSQIFT DMS3AXK TN 5-HT 1A receptor (HTR1A) DMS3AXK MA Agonist DMS3AXK RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMS3AXK RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMS3AXK DI DMS3AXK DMS3AXK DN EDMT DMS3AXK TI TTO9X1H DMS3AXK TN 5-HT 7 receptor (HTR7) DMS3AXK MA Agonist DMS3AXK RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMS3AXK RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMS3AXK DI DMS3AXK DMS3AXK DN EDMT DMS3AXK TI TTRUFDT DMS3AXK TN 5-HT 5A receptor (HTR5A) DMS3AXK MA Agonist DMS3AXK RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMS3AXK RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMS3AXK DI DMS3AXK DMS3AXK DN EDMT DMS3AXK TI TTCPG9S DMS3AXK TN 5-HT 1E receptor (HTR1E) DMS3AXK MA Agonist DMS3AXK RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMS3AXK RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMS3AXK DI DMS3AXK DMS3AXK DN EDMT DMS3AXK TI TTJS8PY DMS3AXK TN 5-HT 6 receptor (HTR6) DMS3AXK MA Inhibitor DMS3AXK RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMS3AXK RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMS3CBD DI DMS3CBD DMS3CBD DN geraniol DMS3CBD TI TTXDKTO DMS3CBD TN Long transient receptor potential channel 8 (TRPM8) DMS3CBD MA Activator DMS3CBD RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMS3CBD RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMS3HNM DI DMS3HNM DMS3HNM DN Jte 013 DMS3HNM TI TTVSMOH DMS3HNM TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMS3HNM MA Inhibitor DMS3HNM RN Sphingosine 1-phosphate receptor antagonists. US9663511. DMS3HNM RU http://www.freepatentsonline.com/US9663511.html DMS3JCN DI DMS3JCN DMS3JCN DN 3-(1H-Indol-2-yl)-1H-quinolin-2-one DMS3JCN TI TTUTJGQ DMS3JCN TN Vascular endothelial growth factor receptor 2 (KDR) DMS3JCN MA Inhibitor DMS3JCN RN Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmaco... Bioorg Med Chem Lett. 2004 Jan 19;14(2):351-5. DMS3JCN RU https://pubmed.ncbi.nlm.nih.gov/14698157 DMS3JCN DI DMS3JCN DMS3JCN DN 3-(1H-Indol-2-yl)-1H-quinolin-2-one DMS3JCN TI TTTU902 DMS3JCN TN Checkpoint kinase-1 (CHK1) DMS3JCN MA Inhibitor DMS3JCN RN Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5907-12. DMS3JCN RU https://pubmed.ncbi.nlm.nih.gov/16990002 DMS3MZG DI DMS3MZG DMS3MZG DN ONO-AE1-329 DMS3MZG TI TT1ZAVI DMS3MZG TN Prostaglandin E2 receptor EP2 (PTGER2) DMS3MZG MA Agonist DMS3MZG RN The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9. DMS3MZG RU https://pubmed.ncbi.nlm.nih.gov/10746663 DMS3MZG DI DMS3MZG DMS3MZG DN ONO-AE1-329 DMS3MZG TI TTPNGDE DMS3MZG TN Prostaglandin E2 receptor EP3 (PTGER3) DMS3MZG MA Agonist DMS3MZG RN The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9. DMS3MZG RU https://pubmed.ncbi.nlm.nih.gov/10746663 DMS3MZG DI DMS3MZG DMS3MZG DN ONO-AE1-329 DMS3MZG TI TT79WV3 DMS3MZG TN Prostaglandin E2 receptor EP4 (PTGER4) DMS3MZG MA Agonist DMS3MZG RN The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology. 2000 Apr;141(4):1554-9. DMS3MZG RU https://pubmed.ncbi.nlm.nih.gov/10746663 DMS3N4X DI DMS3N4X DMS3N4X DN norzotepine DMS3N4X TI TTAWNKZ DMS3N4X TN Norepinephrine transporter (NET) DMS3N4X MA Inhibitor DMS3N4X RN Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81. DMS3N4X RU https://pubmed.ncbi.nlm.nih.gov/20223878 DMS3N4X DI DMS3N4X DMS3N4X DN norzotepine DMS3N4X TI TT3ROYC DMS3N4X TN Serotonin transporter (SERT) DMS3N4X MA Inhibitor DMS3N4X RN Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81. DMS3N4X RU https://pubmed.ncbi.nlm.nih.gov/20223878 DMS3O9H DI DMS3O9H DMS3O9H DN MSC2032964A DMS3O9H TI TTOQCD8 DMS3O9H TN Apoptosis signal-regulating kinase 1 (MAP3K5) DMS3O9H MA Inhibitor DMS3O9H RN Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med. 2010 Dec;2(12):504-15. DMS3O9H RU https://pubmed.ncbi.nlm.nih.gov/21064192 DMS3TZ5 DI DMS3TZ5 DMS3TZ5 DN XD1 DMS3TZ5 TI TTRA6BO DMS3TZ5 TN Bromodomain-containing protein 4 (BRD4) DMS3TZ5 MA Inhibitor DMS3TZ5 RN 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9. DMS3TZ5 RU https://pubmed.ncbi.nlm.nih.gov/24272870 DMS3WNG DI DMS3WNG DMS3WNG DN [3H]nisoxetine DMS3WNG TI TTAWNKZ DMS3WNG TN Norepinephrine transporter (NET) DMS3WNG MA Inhibitor DMS3WNG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926). DMS3WNG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=926 DMS3XUC DI DMS3XUC DMS3XUC DN 1-(cyclohexyl)methyl-5'-O-tritylinosine DMS3XUC TI TTO0IB8 DMS3XUC TN Thymidine phosphorylase (TYMP) DMS3XUC MA Inhibitor DMS3XUC RN 5'-O-tritylinosine and analogues as allosteric inhibitors of human thymidine phosphorylase. J Med Chem. 2006 Sep 7;49(18):5562-70. DMS3XUC RU https://pubmed.ncbi.nlm.nih.gov/16942029 DMS42CA DI DMS42CA DMS42CA DN 3,4,5-tribromo-2-(2', 4'-dibromo-phenoxy)phenol DMS42CA TI TTCFP0V DMS42CA TN Glutamine amidotransferase (GMPS) DMS42CA MA Inhibitor DMS42CA RN Enzyme inhibitors: new and known polybrominated phenols and diphenyl ethers from four Indo-Pacific Dysidea sponges. J Nat Prod. 1995 Sep;58(9):1384-91. DMS42CA RU https://pubmed.ncbi.nlm.nih.gov/7494145 DMS42TN DI DMS42TN DMS42TN DN 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile DMS42TN TI TTDZN01 DMS42TN TN Cathepsin K (CTSK) DMS42TN MA Inhibitor DMS42TN RN Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. DMS42TN RU https://pubmed.ncbi.nlm.nih.gov/20149657 DMS42TN DI DMS42TN DMS42TN DN 4-cyclooctyl-6-propylpyrimidine-2-carbonitrile DMS42TN TI TTUMQVO DMS42TN TN Cathepsin S (CTSS) DMS42TN MA Inhibitor DMS42TN RN Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1524-7. DMS42TN RU https://pubmed.ncbi.nlm.nih.gov/20149657 DMS4D96 DI DMS4D96 DMS4D96 DN imiloxan DMS4D96 TI TTWM4TY DMS4D96 TN Adrenergic receptor alpha-2B (ADRA2B) DMS4D96 MA Antagonist DMS4D96 RN Assessment of imiloxan as a selective alpha 2B-adrenoceptor antagonist. Br J Pharmacol. 1990 Mar;99(3):560-4. DMS4D96 RU https://pubmed.ncbi.nlm.nih.gov/1970500 DMS4F8O DI DMS4F8O DMS4F8O DN D[Thr4,Lys8(5/6C-Flu)]VT DMS4F8O TI TTL9MHW DMS4F8O TN Vasopressin V1b receptor (V1BR) DMS4F8O MA Inhibitor DMS4F8O RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMS4F8O RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMS4F8O DI DMS4F8O DMS4F8O DN D[Thr4,Lys8(5/6C-Flu)]VT DMS4F8O TI TTSCIUP DMS4F8O TN Oxytocin receptor (OTR) DMS4F8O MA Inhibitor DMS4F8O RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMS4F8O RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMS4F8O DI DMS4F8O DMS4F8O DN D[Thr4,Lys8(5/6C-Flu)]VT DMS4F8O TI TT4TFGN DMS4F8O TN Vasopressin V1a receptor (V1AR) DMS4F8O MA Inhibitor DMS4F8O RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMS4F8O RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMS4JAG DI DMS4JAG DMS4JAG DN (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMS4JAG TI TTWG9A4 DMS4JAG TN Adrenergic receptor alpha-2A (ADRA2A) DMS4JAG MA Inhibitor DMS4JAG RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMS4JAG RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMS4JAG DI DMS4JAG DMS4JAG DN (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMS4JAG TI TTWM4TY DMS4JAG TN Adrenergic receptor alpha-2B (ADRA2B) DMS4JAG MA Inhibitor DMS4JAG RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMS4JAG RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMS4JAG DI DMS4JAG DMS4JAG DN (S)-3-Methyl-1,2,3,4-tetrahydro-isoquinoline DMS4JAG TI TT2NUT5 DMS4JAG TN Adrenergic receptor alpha-2C (ADRA2C) DMS4JAG MA Inhibitor DMS4JAG RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMS4JAG RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMS4JGT DI DMS4JGT DMS4JGT DN 3-Ethynylquinoline-8-carboxamide DMS4JGT TI TTVDSZ0 DMS4JGT TN Poly [ADP-ribose] polymerase 1 (PARP1) DMS4JGT MA Inhibitor DMS4JGT RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMS4JGT RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMS4JVT DI DMS4JVT DMS4JVT DN 4-(3-Phenylethynyl-benzyl)-1H-imidazole DMS4JVT TI TTVG215 DMS4JVT TN Debrisoquine 4-hydroxylase (CYP2D6) DMS4JVT MA Inhibitor DMS4JVT RN 4-benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists. J Med Chem. 2008 May 22;51(10):2944-53. DMS4JVT RU https://pubmed.ncbi.nlm.nih.gov/18433114 DMS4P1E DI DMS4P1E DMS4P1E DN Tyr-Pro-Phe-Phe-OC(CH3)3 DMS4P1E TI TTKWM86 DMS4P1E TN Opioid receptor mu (MOP) DMS4P1E MA Inhibitor DMS4P1E RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMS4P1E RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMS4P1E DI DMS4P1E DMS4P1E DN Tyr-Pro-Phe-Phe-OC(CH3)3 DMS4P1E TI TT27RFC DMS4P1E TN Opioid receptor delta (OPRD1) DMS4P1E MA Inhibitor DMS4P1E RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMS4P1E RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMS4U68 DI DMS4U68 DMS4U68 DN dihydrocarveol DMS4U68 TI TT946IA DMS4U68 TN Transient receptor potential cation channel V3 (TRPV3) DMS4U68 MA Activator DMS4U68 RN Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40. DMS4U68 RU https://pubmed.ncbi.nlm.nih.gov/17420775 DMS4ZFU DI DMS4ZFU DMS4ZFU DN Pyrrolidin-(2Z)-ylideneamine DMS4ZFU TI TTF10I9 DMS4ZFU TN Nitric-oxide synthase inducible (NOS2) DMS4ZFU MA Inhibitor DMS4ZFU RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMS4ZFU RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMS4ZFU DI DMS4ZFU DMS4ZFU DN Pyrrolidin-(2Z)-ylideneamine DMS4ZFU TI TTZUFI5 DMS4ZFU TN Nitric-oxide synthase brain (NOS1) DMS4ZFU MA Inhibitor DMS4ZFU RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMS4ZFU RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMS4ZFU DI DMS4ZFU DMS4ZFU DN Pyrrolidin-(2Z)-ylideneamine DMS4ZFU TI TTCM4B3 DMS4ZFU TN Nitric-oxide synthase endothelial (NOS3) DMS4ZFU MA Inhibitor DMS4ZFU RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMS4ZFU RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMS4ZVK DI DMS4ZVK DMS4ZVK DN (Amino-phenyl-methyl)-phosphinic acid DMS4ZVK TI TTPHMWB DMS4ZVK TN Aminopeptidase N (ANPEP) DMS4ZVK MA Inhibitor DMS4ZVK RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMS4ZVK RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMS509U DI DMS509U DMS509U DN Ser-Tyr-Ser-Nle-Glu-His-Dphe-Arg DMS509U TI TTD0CIQ DMS509U TN Melanocortin receptor 4 (MC4R) DMS509U MA Inhibitor DMS509U RN Squalene-derived flexible linkers for bioactive peptides. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3310-3. DMS509U RU https://pubmed.ncbi.nlm.nih.gov/17448660 DMS527J DI DMS527J DMS527J DN Kazinol C DMS527J TI TTULVH8 DMS527J TN Tyrosinase (TYR) DMS527J MA Inhibitor DMS527J RN Tyrosinase inhibitory effects of 1,3-diphenylpropanes from Broussonetia kazinoki. Bioorg Med Chem. 2009 Jan 1;17(1):35-41. DMS527J RU https://pubmed.ncbi.nlm.nih.gov/19046886 DMS572H DI DMS572H DMS572H DN 2-(4-Methoxy-phenyl)-8-methyl-3H-quinazolin-4-one DMS572H TI TTVDSZ0 DMS572H TN Poly [ADP-ribose] polymerase 1 (PARP1) DMS572H MA Inhibitor DMS572H RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMS572H RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMS57HX DI DMS57HX DMS57HX DN Phosphoric acid mono-((E)-dec-4-enyl) ester DMS57HX TI TTQ6S1K DMS57HX TN Lysophosphatidic acid receptor 1 (LPAR1) DMS57HX MA Inhibitor DMS57HX RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMS57HX RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMS58P1 DI DMS58P1 DMS58P1 DN Clinopodic acid C DMS58P1 TI TTLM12X DMS58P1 TN Matrix metalloproteinase-2 (MMP-2) DMS58P1 MA Inhibitor DMS58P1 RN Matrix metalloproteinase-2 inhibitors from Clinopodium chinense var. parviflorum. J Nat Prod. 2009 Aug;72(8):1379-84. DMS58P1 RU https://pubmed.ncbi.nlm.nih.gov/19711986 DMS5AH4 DI DMS5AH4 DMS5AH4 DN FGGFTGARKSARKLADE DMS5AH4 TI TTNT7K8 DMS5AH4 TN Nociceptin receptor (OPRL1) DMS5AH4 MA Inhibitor DMS5AH4 RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DMS5AH4 RU https://pubmed.ncbi.nlm.nih.gov/11689089 DMS5AWP DI DMS5AWP DMS5AWP DN (+/-)-3-allyl-1-pent-4-enoylazetidin-2-one DMS5AWP TI TTDP1UC DMS5AWP TN Fatty acid amide hydrolase (FAAH) DMS5AWP MA Inhibitor DMS5AWP RN 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7. DMS5AWP RU https://pubmed.ncbi.nlm.nih.gov/18547805 DMS5DHY DI DMS5DHY DMS5DHY DN Cystamine DMS5DHY TI TTNFESW DMS5DHY TN Glutamate--cysteine ligase modifier (GCLM) DMS5DHY MA Inhibitor DMS5DHY RN The gamma-glutamylcysteine synthetase of Onchocerca volvulus. Mol Biochem Parasitol. 2000 Dec;111(2):243-51. DMS5DHY RU https://pubmed.ncbi.nlm.nih.gov/11163433 DMS5ICY DI DMS5ICY DMS5ICY DN 10,11-dihydro-5H-dibenzo[b,f]azepine DMS5ICY TI TTPC4TU DMS5ICY TN 5-HT 3A receptor (HTR3A) DMS5ICY MA Inhibitor DMS5ICY RN Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. Eur J Med Chem. 2009 Jun;44(6):2667-72. DMS5ICY RU https://pubmed.ncbi.nlm.nih.gov/19144451 DMS5IHX DI DMS5IHX DMS5IHX DN (S)-3-(1'-Adamantanecarbonyl)amino-caprolactam DMS5IHX TI TTFZYTO DMS5IHX TN C-C chemokine receptor type 2 (CCR2) DMS5IHX MA Inhibitor DMS5IHX RN Highly potent, orally available anti-inflammatory broad-spectrum chemokine inhibitors. J Med Chem. 2009 Jun 11;52(11):3591-5. DMS5IHX RU https://pubmed.ncbi.nlm.nih.gov/19425597 DMS5LKR DI DMS5LKR DMS5LKR DN 2-Amino-1-(4-ethylthiophenyl)propane DMS5LKR TI TT3ROYC DMS5LKR TN Serotonin transporter (SERT) DMS5LKR MA Inhibitor DMS5LKR RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMS5LKR RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMS5N6Y DI DMS5N6Y DMS5N6Y DN 3-(4-Hydroxyphenyl)-7-isobutoxychromen-4-one DMS5N6Y TI TTZAYWL DMS5N6Y TN Estrogen receptor (ESR) DMS5N6Y MA Inhibitor DMS5N6Y RN Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. J Med Chem. 2010 Aug 26;53(16):6153-63. DMS5N6Y RU https://pubmed.ncbi.nlm.nih.gov/20669983 DMS5PZ0 DI DMS5PZ0 DMS5PZ0 DN ISIS 19647 DMS5PZ0 TI TTWALCO DMS5PZ0 TN HER4 messenger RNA (ERBB4 mRNA) DMS5PZ0 RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMS5PZ0 RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMS5XRY DI DMS5XRY DMS5XRY DN PNU-107859 DMS5XRY TI TTLM12X DMS5XRY TN Matrix metalloproteinase-2 (MMP-2) DMS5XRY MA Inhibitor DMS5XRY RN A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74. DMS5XRY RU https://pubmed.ncbi.nlm.nih.gov/15163188 DMS5XRY DI DMS5XRY DMS5XRY DN PNU-107859 DMS5XRY TI TTUZ2L5 DMS5XRY TN Matrix metalloproteinase-3 (MMP-3) DMS5XRY MA Inhibitor DMS5XRY RN A molecular basis for the selectivity of thiadiazole urea inhibitors with stromelysin-1 and gelatinase-A from generalized born molecular dynamics s... J Med Chem. 2004 Jun 3;47(12):3065-74. DMS5XRY RU https://pubmed.ncbi.nlm.nih.gov/15163188 DMS61DB DI DMS61DB DMS61DB DN KNI-227 DMS61DB TI TTXMNHO DMS61DB TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMS61DB MA Inhibitor DMS61DB RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMS61DB RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMS61KA DI DMS61KA DMS61KA DN CGP-29030A DMS61KA TI TTDCVZW DMS61KA TN Gamma-aminobutyric acid B receptor (GABBR) DMS61KA MA Modulator DMS61KA RN Effects of a novel piperazine derivative (CGP 29030A) on nociceptive dorsal horn neurons in the rat. Drugs Exp Clin Res. 1992;18(11-12):447-59. DMS61KA RU https://pubmed.ncbi.nlm.nih.gov/1308469 DMS62T0 DI DMS62T0 DMS62T0 DN Cdk1/2 inhibitor III DMS62T0 TI TT1VAUK DMS62T0 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMS62T0 MA Inhibitor DMS62T0 RN 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11. DMS62T0 RU https://pubmed.ncbi.nlm.nih.gov/15974571 DMS62T0 DI DMS62T0 DMS62T0 DN Cdk1/2 inhibitor III DMS62T0 TI TTH6V3D DMS62T0 TN Cyclin-dependent kinase 1 (CDK1) DMS62T0 MA Inhibitor DMS62T0 RN 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11. DMS62T0 RU https://pubmed.ncbi.nlm.nih.gov/15974571 DMS62T0 DI DMS62T0 DMS62T0 DN Cdk1/2 inhibitor III DMS62T0 TI TT7HF4W DMS62T0 TN Cyclin-dependent kinase 2 (CDK2) DMS62T0 MA Inhibitor DMS62T0 RN 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. J Med Chem. 2005 Jun 30;48(13):4208-11. DMS62T0 RU https://pubmed.ncbi.nlm.nih.gov/15974571 DMS658R DI DMS658R DMS658R DN 3-hydroxyoctanoic acid DMS658R TI TT8WFXV DMS658R TN Hydroxycarboxylic acid receptor 3 (HCAR3) DMS658R MA Agonist DMS658R RN Deorphanization of GPR109B as a receptor for the beta-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J Biol Chem. 2009 Aug 14;284(33):21928-33. DMS658R RU https://pubmed.ncbi.nlm.nih.gov/19561068 DMS6IJ0 DI DMS6IJ0 DMS6IJ0 DN RHEIN DMS6IJ0 TI TT78R5H DMS6IJ0 TN Heat shock protein 90 alpha (HSP90A) DMS6IJ0 MA Inhibitor DMS6IJ0 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMS6IJ0 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMS6JD4 DI DMS6JD4 DMS6JD4 DN ISIS 101952 DMS6JD4 TI TTON5JB DMS6JD4 TN MADH6 messenger RNA (MADH6 mRNA) DMS6JD4 RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DMS6JD4 RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DMS6RHD DI DMS6RHD DMS6RHD DN 4-Fluorobenzenemethanethiol DMS6RHD TI TTZJYKH DMS6RHD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMS6RHD MA Inhibitor DMS6RHD RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMS6RHD RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMS6X1I DI DMS6X1I DMS6X1I DN DEOXYADENOSINE DMS6X1I TI TT2QM9D DMS6X1I TN Adenylate cyclase (ADCY) DMS6X1I MA Inhibitor DMS6X1I RN Synthesis of 2',5'-dideoxy-2-fluoroadenosine and 2',5'-dideoxy-2,5'-difluoroadenosine: potent P-site inhibitors of adenylyl cyclase. J Med Chem. 2004 Feb 26;47(5):1207-13. DMS6X1I RU https://pubmed.ncbi.nlm.nih.gov/14971900 DMS74F2 DI DMS74F2 DMS74F2 DN 4-(4-Morpholin-4-yl-butyl)-2H-phthalazin-1-one DMS74F2 TI TTVDSZ0 DMS74F2 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMS74F2 MA Inhibitor DMS74F2 RN 4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5. DMS74F2 RU https://pubmed.ncbi.nlm.nih.gov/16098744 DMS7B6T DI DMS7B6T DMS7B6T DN 3-Cyclopentyl-6,7-dimethoxy-quinoline DMS7B6T TI TT8FYO9 DMS7B6T TN Platelet-derived growth factor receptor alpha (PDGFRA) DMS7B6T MA Inhibitor DMS7B6T RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMS7B6T RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMS7B6T DI DMS7B6T DMS7B6T DN 3-Cyclopentyl-6,7-dimethoxy-quinoline DMS7B6T TI TTI7421 DMS7B6T TN Platelet-derived growth factor receptor beta (PDGFRB) DMS7B6T MA Inhibitor DMS7B6T RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMS7B6T RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMS7C6R DI DMS7C6R DMS7C6R DN MK-5046 DMS7C6R TI TTHYDUM DMS7C6R TN Bombesin receptor (BS) DMS7C6R MA Agonist DMS7C6R RN Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist. J Pharmacol Exp Ther. 2011 Feb;336(2):356-64. DMS7C6R RU https://pubmed.ncbi.nlm.nih.gov/21036912 DMS7C6R DI DMS7C6R DMS7C6R DN MK-5046 DMS7C6R TI TTC1MVT DMS7C6R TN Gastrin-releasing peptide receptor (GRPR) DMS7C6R MA Agonist DMS7C6R RN Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors. J Pharmacol Exp Ther. 2013 Oct;347(1):100-16. DMS7C6R RU https://pubmed.ncbi.nlm.nih.gov/23892571 DMS7DA3 DI DMS7DA3 DMS7DA3 DN 8-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine DMS7DA3 TI TT1RS9F DMS7DA3 TN Acetylcholinesterase (AChE) DMS7DA3 MA Inhibitor DMS7DA3 RN The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex ) derivaties, Bioorg. Med. Chem. Lett. 2(8):861-864 (1992). DMS7DA3 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805454 DMS7FC6 DI DMS7FC6 DMS7FC6 DN MR-1029 DMS7FC6 TI TTKWM86 DMS7FC6 TN Opioid receptor mu (MOP) DMS7FC6 MA Inhibitor DMS7FC6 RN Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44. DMS7FC6 RU https://pubmed.ncbi.nlm.nih.gov/1652019 DMS7FC6 DI DMS7FC6 DMS7FC6 DN MR-1029 DMS7FC6 TI TTQW87Y DMS7FC6 TN Opioid receptor kappa (OPRK1) DMS7FC6 MA Inhibitor DMS7FC6 RN Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44. DMS7FC6 RU https://pubmed.ncbi.nlm.nih.gov/1652019 DMS7HQN DI DMS7HQN DMS7HQN DN ISIS 16112 DMS7HQN TI TTHMYB1 DMS7HQN TN E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA) DMS7HQN RN US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression. DMS7HQN RU http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true DMS7KW8 DI DMS7KW8 DMS7KW8 DN LY341770 DMS7KW8 TI TTU6BFZ DMS7KW8 TN Candida Thymidylate synthase (Candi TMP1) DMS7KW8 MA Inhibitor DMS7KW8 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMS7KW8 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMS7PL3 DI DMS7PL3 DMS7PL3 DN 16-isobutylidene-estrone DMS7PL3 TI TTIWB6L DMS7PL3 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMS7PL3 MA Inhibitor DMS7PL3 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMS7PL3 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMS7POY DI DMS7POY DMS7POY DN 4-(2,4-dichlorophenoxy)-3-hydroxybenzonitrile DMS7POY TI TTNX2CS DMS7POY TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMS7POY MA Inhibitor DMS7POY RN X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalar... J Biol Chem. 2007 Aug 31;282(35):25436-44. DMS7POY RU https://pubmed.ncbi.nlm.nih.gov/17567585 DMS7UNR DI DMS7UNR DMS7UNR DN NE58043 DMS7UNR TI TTIKWV4 DMS7UNR TN Geranyltranstransferase (FDPS) DMS7UNR MA Inhibitor DMS7UNR RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMS7UNR RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMS7WQD DI DMS7WQD DMS7WQD DN 2-(ethoxycarbonyl)-1H-indole-5-carboxylic acid DMS7WQD TI TT9JNIC DMS7WQD TN Histamine H3 receptor (H3R) DMS7WQD MA Inhibitor DMS7WQD RN 5-hydroxyindole-2-carboxylic acid amides: novel histamine-3 receptor inverse agonists for the treatment of obesity. J Med Chem. 2009 Jul 9;52(13):3855-68. DMS7WQD RU https://pubmed.ncbi.nlm.nih.gov/19456097 DMS7YF6 DI DMS7YF6 DMS7YF6 DN 1-(2-(naphthalen-2-yl)ethyl)piperazine DMS7YF6 TI TT3ROYC DMS7YF6 TN Serotonin transporter (SERT) DMS7YF6 MA Inhibitor DMS7YF6 RN Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. DMS7YF6 RU https://pubmed.ncbi.nlm.nih.gov/19282174 DMS80DF DI DMS80DF DMS80DF DN ALDISIN DMS80DF TI TTIDAPM DMS80DF TN ERK activator kinase 1 (MEK1) DMS80DF MA Inhibitor DMS80DF RN Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32. DMS80DF RU https://pubmed.ncbi.nlm.nih.gov/11784156 DMS86PI DI DMS86PI DMS86PI DN AS-1892802 DMS86PI TI TTZN7RP DMS86PI TN Rho-associated protein kinase 1 (ROCK1) DMS86PI MA Inhibitor DMS86PI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503). DMS86PI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503 DMS87IF DI DMS87IF DMS87IF DN C2-MAD DMS87IF TI TTTB4UP DMS87IF TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMS87IF MA Inhibitor DMS87IF RN Novel mycophenolic adenine bis(phosphonate) analogues as potential differentiation agents against human leukemia. J Med Chem. 2002 Jan 31;45(3):703-12. DMS87IF RU https://pubmed.ncbi.nlm.nih.gov/11806722 DMS8H5Q DI DMS8H5Q DMS8H5Q DN NM-PP1 DMS8H5Q TI TTCQ2E5 DMS8H5Q TN RIP2 messenger RNA (RIP2 mRNA) DMS8H5Q MA Inhibitor DMS8H5Q RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMS8H5Q RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMS8H5Q DI DMS8H5Q DMS8H5Q DN NM-PP1 DMS8H5Q TI TT0K6EO DMS8H5Q TN Stress-activated protein kinase JNK1 (JNK1) DMS8H5Q MA Inhibitor DMS8H5Q RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMS8H5Q RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMS8H5Q DI DMS8H5Q DMS8H5Q DN NM-PP1 DMS8H5Q TI TT5U49F DMS8H5Q TN PRKACA messenger RNA (PRKACA mRNA) DMS8H5Q MA Inhibitor DMS8H5Q RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMS8H5Q RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMS8H5Q DI DMS8H5Q DMS8H5Q DN NM-PP1 DMS8H5Q TI TT6PKBN DMS8H5Q TN Proto-oncogene c-Src (SRC) DMS8H5Q MA Inhibitor DMS8H5Q RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMS8H5Q RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMS8H5Q DI DMS8H5Q DMS8H5Q DN NM-PP1 DMS8H5Q TI TT860QF DMS8H5Q TN LCK tyrosine protein kinase (LCK) DMS8H5Q MA Inhibitor DMS8H5Q RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMS8H5Q RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMS8I1E DI DMS8I1E DMS8I1E DN 2,4,4-triphenylimidazoline DMS8I1E TI TTY6EWA DMS8I1E TN Neuropeptide Y receptor type 5 (NPY5R) DMS8I1E MA Inhibitor DMS8I1E RN Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1670-4. DMS8I1E RU https://pubmed.ncbi.nlm.nih.gov/19233647 DMS8MBI DI DMS8MBI DMS8MBI DN Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate DMS8MBI TI TTML2WA DMS8MBI TN Tubulin (TUB) DMS8MBI MA Inhibitor DMS8MBI RN New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. J Med Chem. 2006 Feb 9;49(3):947-54. DMS8MBI RU https://pubmed.ncbi.nlm.nih.gov/16451061 DMS8MBI DI DMS8MBI DMS8MBI DN Isopropyl 3-(phenylthio)-1H-indole-2-carboxylate DMS8MBI TI TTYFKSZ DMS8MBI TN Tubulin beta (TUBB) DMS8MBI MA Inhibitor DMS8MBI RN New arylthioindoles: potent inhibitors of tubulin polymerization. 2. Structure-activity relationships and molecular modeling studies. J Med Chem. 2006 Feb 9;49(3):947-54. DMS8MBI RU https://pubmed.ncbi.nlm.nih.gov/16451061 DMS8WG3 DI DMS8WG3 DMS8WG3 DN (S)-sirtinol DMS8WG3 TI TTUF2HO DMS8WG3 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMS8WG3 MA Inhibitor DMS8WG3 RN Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95. DMS8WG3 RU https://pubmed.ncbi.nlm.nih.gov/16302818 DMS9125 DI DMS9125 DMS9125 DN (4-bromo-1H-pyrazol-1-yl)(m-tolyl)methanone DMS9125 TI TTPLTSQ DMS9125 TN Neutrophil elastase (NE) DMS9125 MA Inhibitor DMS9125 RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMS9125 RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMS91OR DI DMS91OR DMS91OR DN Go7874 DMS91OR TI TTOXS3C DMS91OR TN Muscarinic acetylcholine receptor (CHRM) DMS91OR MA Modulator (allosteric modulator) DMS91OR RN Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207. DMS91OR RU https://pubmed.ncbi.nlm.nih.gov/10860942 DMS91OR DI DMS91OR DMS91OR DN Go7874 DMS91OR TI TTQ13Z5 DMS91OR TN Muscarinic acetylcholine receptor M3 (CHRM3) DMS91OR MA Modulator (allosteric modulator) DMS91OR RN Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site. Mol Pharmacol. 2000 Jul;58(1):194-207. DMS91OR RU https://pubmed.ncbi.nlm.nih.gov/10860942 DMS947W DI DMS947W DMS947W DN 2-Cyclopentylaminomethyl-pyrrolidine-3,4-diol DMS947W TI TTXWASR DMS947W TN Intestinal maltase-glucoamylase (MGAM) DMS947W MA Inhibitor DMS947W RN Derivatives of (2R,3R,4S)-2-aminomethylpyrrolidine-3,4-diol are selective alpha-mannosidase inhibitors. Bioorg Med Chem Lett. 2001 Sep 17;11(18):2489-93. DMS947W RU https://pubmed.ncbi.nlm.nih.gov/11549453 DMS97A1 DI DMS97A1 DMS97A1 DN Gold trichloride sodium chloride DMS97A1 TI TTF2LRI DMS97A1 TN Cathepsin B (CTSB) DMS97A1 MA Inhibitor DMS97A1 RN Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au(I). Bioorg Med Chem Lett. 2004 Oct 18;14(20):5113-6. DMS97A1 RU https://pubmed.ncbi.nlm.nih.gov/15380210 DMS98WA DI DMS98WA DMS98WA DN 3-(2-adamantyl) pyrrolidine DMS98WA TI TTXT3PU DMS98WA TN Influenza M2 protein (Influ M) DMS98WA MA Inhibitor DMS98WA RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMS98WA RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMS9COH DI DMS9COH DMS9COH DN Acarbose Derived Hexasaccharide DMS9COH TI TTCGSZ4 DMS9COH TN Pancreatic alpha-amylase (AMY2A) DMS9COH MA Inhibitor DMS9COH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMS9COH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMS9DPO DI DMS9DPO DMS9DPO DN 3-(6-morpholino-4-oxo-4H-pyran-2-yl)benzaldehyde DMS9DPO TI TTK3PY9 DMS9DPO TN DNA-dependent protein kinase catalytic (PRKDC) DMS9DPO MA Inhibitor DMS9DPO RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMS9DPO RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMS9H2P DI DMS9H2P DMS9H2P DN ICA-105574 DMS9H2P TI TT9XKUC DMS9H2P TN Voltage-gated potassium channel Kv10.1 (KCNH1) DMS9H2P MA Inhibitor (gating inhibitor) DMS9H2P RN ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels. Mol Pharmacol. 2013 Apr;83(4):805-13. DMS9H2P RU https://pubmed.ncbi.nlm.nih.gov/23319419 DMS9H2P DI DMS9H2P DMS9H2P DN ICA-105574 DMS9H2P TI TTQ6VDM DMS9H2P TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMS9H2P MA Activator DMS9H2P RN Pharmacological removal of human ether- -go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574). Mol Pharmacol. 2010 Jan;77(1):58-68. DMS9H2P RU https://pubmed.ncbi.nlm.nih.gov/19805508 DMS9PZ7 DI DMS9PZ7 DMS9PZ7 DN 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMS9PZ7 TI TTVBI8W DMS9PZ7 TN Dopamine transporter (DAT) DMS9PZ7 MA Inhibitor DMS9PZ7 RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMS9PZ7 RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMS9PZ7 DI DMS9PZ7 DMS9PZ7 DN 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMS9PZ7 TI TTQ6VDM DMS9PZ7 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMS9PZ7 MA Inhibitor DMS9PZ7 RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMS9PZ7 RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMS9PZ7 DI DMS9PZ7 DMS9PZ7 DN 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMS9PZ7 TI TT3ROYC DMS9PZ7 TN Serotonin transporter (SERT) DMS9PZ7 MA Inhibitor DMS9PZ7 RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMS9PZ7 RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMS9PZ7 DI DMS9PZ7 DMS9PZ7 DN 1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMS9PZ7 TI TTAWNKZ DMS9PZ7 TN Norepinephrine transporter (NET) DMS9PZ7 MA Inhibitor DMS9PZ7 RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMS9PZ7 RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMS9QHI DI DMS9QHI DMS9QHI DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-L-Pic-) DMS9QHI TI TTBID49 DMS9QHI TN C-X-C chemokine receptor type 4 (CXCR4) DMS9QHI MA Inhibitor DMS9QHI RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMS9QHI RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMS9RDW DI DMS9RDW DMS9RDW DN N-(1-(4-bromobenzyl)piperidin-4-yl)-2-naphthamide DMS9RDW TI TTJQOD7 DMS9RDW TN 5-HT 2A receptor (HTR2A) DMS9RDW MA Inhibitor DMS9RDW RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4. DMS9RDW RU https://pubmed.ncbi.nlm.nih.gov/17251022 DMS9TFC DI DMS9TFC DMS9TFC DN 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine DMS9TFC TI TTCM4B3 DMS9TFC TN Nitric-oxide synthase endothelial (NOS3) DMS9TFC MA Inhibitor DMS9TFC RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMS9TFC RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMS9TFC DI DMS9TFC DMS9TFC DN 5-Ethyl-3-methyl-pyrrolidin-(2Z)-ylideneamine DMS9TFC TI TTZUFI5 DMS9TFC TN Nitric-oxide synthase brain (NOS1) DMS9TFC MA Inhibitor DMS9TFC RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMS9TFC RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMSA0IW DI DMSA0IW DMSA0IW DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-D-Ala-) DMSA0IW TI TTBID49 DMSA0IW TN C-X-C chemokine receptor type 4 (CXCR4) DMSA0IW MA Inhibitor DMSA0IW RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMSA0IW RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMSA367 DI DMSA367 DMSA367 DN 6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMSA367 TI TT3WG5C DMSA367 TN Monoamine oxidase type A (MAO-A) DMSA367 MA Inhibitor DMSA367 RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DMSA367 RU https://pubmed.ncbi.nlm.nih.gov/15013010 DMSA367 DI DMSA367 DMSA367 DN 6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMSA367 TI TTGP7BY DMSA367 TN Monoamine oxidase type B (MAO-B) DMSA367 MA Inhibitor DMSA367 RN Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I(2) receptor ligands. Bioorg Med Chem Lett. 2004 Feb 23;14(4):1003-5. DMSA367 RU https://pubmed.ncbi.nlm.nih.gov/15013010 DMSA367 DI DMSA367 DMSA367 DN 6-Methoxy-2,3,4,9-tetrahydro-1H-beta-carboline DMSA367 TI TTJQOD7 DMSA367 TN 5-HT 2A receptor (HTR2A) DMSA367 MA Inhibitor DMSA367 RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMSA367 RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMSA3U4 DI DMSA3U4 DMSA3U4 DN T1117 DMSA3U4 TI TTNET8J DMSA3U4 TN G-protein coupled receptor 55 (GPR55) DMSA3U4 MA Agonist DMSA3U4 RN Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol. 2010 Feb;159(4):787-96. DMSA3U4 RU https://pubmed.ncbi.nlm.nih.gov/20136833 DMSA6IY DI DMSA6IY DMSA6IY DN arecaidine propargyl ester DMSA6IY TI TTQ13Z5 DMSA6IY TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSA6IY MA Agonist DMSA6IY RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMSA6IY RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMSA6IY DI DMSA6IY DMSA6IY DN arecaidine propargyl ester DMSA6IY TI TTOXS3C DMSA6IY TN Muscarinic acetylcholine receptor (CHRM) DMSA6IY MA Agonist DMSA6IY RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMSA6IY RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMSA8X2 DI DMSA8X2 DMSA8X2 DN 5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine DMSA8X2 TI TTZUFI5 DMSA8X2 TN Nitric-oxide synthase brain (NOS1) DMSA8X2 MA Inhibitor DMSA8X2 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMSA8X2 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMSA8X2 DI DMSA8X2 DMSA8X2 DN 5-Ethyl-4-propyl-pyrrolidin-(2Z)-ylideneamine DMSA8X2 TI TTF10I9 DMSA8X2 TN Nitric-oxide synthase inducible (NOS2) DMSA8X2 MA Inhibitor DMSA8X2 RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMSA8X2 RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMSABD0 DI DMSABD0 DMSABD0 DN TTNPB DMSABD0 TI TTISP28 DMSABD0 TN Retinoic acid receptor beta (RARB) DMSABD0 MA Inhibitor DMSABD0 RN 9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6117-22. DMSABD0 RU https://pubmed.ncbi.nlm.nih.gov/15546741 DMSAD87 DI DMSAD87 DMSAD87 DN N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide DMSAD87 TI TT3IVG2 DMSAD87 TN JNK2 messenger RNA (JNK2 mRNA) DMSAD87 MA Inhibitor DMSAD87 RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMSAD87 RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMSAD87 DI DMSAD87 DMSAD87 DN N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide DMSAD87 TI TT0K6EO DMSAD87 TN Stress-activated protein kinase JNK1 (JNK1) DMSAD87 MA Inhibitor DMSAD87 RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMSAD87 RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMSAFUK DI DMSAFUK DMSAFUK DN 2-amino-2-(2,4-difluorophenyl)acetic acid DMSAFUK TI TTFK1JQ DMSAFUK TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMSAFUK MA Inhibitor DMSAFUK RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMSAFUK RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMSAJO8 DI DMSAJO8 DMSAJO8 DN ODQ DMSAJO8 TI TTWNFC2 DMSAJO8 TN Soluble guanylyl cyclase (GUCY2D) DMSAJO8 MA Inhibitor DMSAJO8 RN Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol. 1995 Aug;48(2):184-8. DMSAJO8 RU https://pubmed.ncbi.nlm.nih.gov/7544433 DMSB0JA DI DMSB0JA DMSB0JA DN 2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline DMSB0JA TI TT1MPAY DMSB0JA TN GABA(A) receptor alpha-1 (GABRA1) DMSB0JA MA Inhibitor DMSB0JA RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMSB0JA RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMSB0JA DI DMSB0JA DMSB0JA DN 2-(4-Chloro-phenyl)-3H-imidazo[4,5-c]quinoline DMSB0JA TI TTNJYV2 DMSB0JA TN Gamma-aminobutyric acid receptor (GAR) DMSB0JA MA Inhibitor DMSB0JA RN Synthesis and structure--activity relationships of fused imidazopyridines: a new series of benzodiazepine receptor ligands. J Med Chem. 1996 Jul 5;39(14):2844-51. DMSB0JA RU https://pubmed.ncbi.nlm.nih.gov/8709114 DMSB27R DI DMSB27R DMSB27R DN ISIS 148715 DMSB27R TI TTOJY1B DMSB27R TN Jagged2 messenger RNA (JAG2 mRNA) DMSB27R RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMSB27R RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMSB2YG DI DMSB2YG DMSB2YG DN NKY80 DMSB2YG TI TTN64VU DMSB2YG TN Adenylate cyclase type 5 (AC5) DMSB2YG MA Inhibitor DMSB2YG RN Type-specific regulation of adenylyl cyclase. Selective pharmacological stimulation and inhibition of adenylyl cyclase isoforms. J Biol Chem. 2001 Dec 21;276(51):47785-93. DMSB2YG RU https://pubmed.ncbi.nlm.nih.gov/11602596 DMSB4EW DI DMSB4EW DMSB4EW DN BRL-24682 DMSB4EW TI TTPC4TU DMSB4EW TN 5-HT 3A receptor (HTR3A) DMSB4EW MA Inhibitor DMSB4EW RN Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15. DMSB4EW RU https://pubmed.ncbi.nlm.nih.gov/12593651 DMSB4EW DI DMSB4EW DMSB4EW DN BRL-24682 DMSB4EW TI TTR6K75 DMSB4EW TN 5-HT 3B receptor (HTR3B) DMSB4EW MA Inhibitor DMSB4EW RN Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15. DMSB4EW RU https://pubmed.ncbi.nlm.nih.gov/12593651 DMSB4WO DI DMSB4WO DMSB4WO DN SEA DMSB4WO TI TT7QNVC DMSB4WO TN Glucose-dependent insulinotropic receptor (GPR119) DMSB4WO MA Agonist DMSB4WO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126). DMSB4WO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=126 DMSB5IQ DI DMSB5IQ DMSB5IQ DN 3-Chloro-4-hydrazino-benzenesulfonamide DMSB5IQ TI TTANPDJ DMSB5IQ TN Carbonic anhydrase II (CA-II) DMSB5IQ MA Inhibitor DMSB5IQ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMSB5IQ RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMSB5IQ DI DMSB5IQ DMSB5IQ DN 3-Chloro-4-hydrazino-benzenesulfonamide DMSB5IQ TI TT2LVK8 DMSB5IQ TN Carbonic anhydrase IX (CA-IX) DMSB5IQ MA Inhibitor DMSB5IQ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMSB5IQ RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMSB5IQ DI DMSB5IQ DMSB5IQ DN 3-Chloro-4-hydrazino-benzenesulfonamide DMSB5IQ TI TTHQPL7 DMSB5IQ TN Carbonic anhydrase I (CA-I) DMSB5IQ MA Inhibitor DMSB5IQ RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamide... J Med Chem. 2005 Mar 24;48(6):2121-5. DMSB5IQ RU https://pubmed.ncbi.nlm.nih.gov/15771455 DMSB8WQ DI DMSB8WQ DMSB8WQ DN 6,11-dihydro-5H-benzo[a]carbazole DMSB8WQ TI TT3WG5C DMSB8WQ TN Monoamine oxidase type A (MAO-A) DMSB8WQ MA Inhibitor DMSB8WQ RN Synthesis and monoamine oxidase inhibitory activity of new pyridazine-, pyrimidine- and 1,2,4-triazine-containing tricyclic derivatives. J Med Chem. 2007 Nov 1;50(22):5364-71. DMSB8WQ RU https://pubmed.ncbi.nlm.nih.gov/17910428 DMSBAC0 DI DMSBAC0 DMSBAC0 DN 18-methoxycoronaridinate 2-methoxyethylamide DMSBAC0 TI TTTVAFQ DMSBAC0 TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMSBAC0 MA Inhibitor DMSBAC0 RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DMSBAC0 RU https://pubmed.ncbi.nlm.nih.gov/12801235 DMSBCL6 DI DMSBCL6 DMSBCL6 DN Methyl 4-(4-tert-butylbenzylideneamino)benzoate DMSBCL6 TI TTANPDJ DMSBCL6 TN Carbonic anhydrase II (CA-II) DMSBCL6 MA Inhibitor DMSBCL6 RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DMSBCL6 RU https://pubmed.ncbi.nlm.nih.gov/19796939 DMSBJ4M DI DMSBJ4M DMSBJ4M DN 7-phenyloxyethoxy-2-morpholin-4-yl-chromen-4-one DMSBJ4M TI TTK3PY9 DMSBJ4M TN DNA-dependent protein kinase catalytic (PRKDC) DMSBJ4M MA Inhibitor DMSBJ4M RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMSBJ4M RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMSBNY8 DI DMSBNY8 DMSBNY8 DN 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine DMSBNY8 TI TTZFYLI DMSBNY8 TN Dopamine D1 receptor (D1R) DMSBNY8 MA Inhibitor DMSBNY8 RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMSBNY8 RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMSBNY8 DI DMSBNY8 DMSBNY8 DN 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine DMSBNY8 TI TTEX248 DMSBNY8 TN Dopamine D2 receptor (D2R) DMSBNY8 MA Inhibitor DMSBNY8 RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMSBNY8 RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMSBNY8 DI DMSBNY8 DMSBNY8 DN 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine DMSBNY8 TI TTE0A2F DMSBNY8 TN Dopamine D4 receptor (D4R) DMSBNY8 MA Inhibitor DMSBNY8 RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMSBNY8 RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMSBNY8 DI DMSBNY8 DMSBNY8 DN 1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine DMSBNY8 TI TT4C8EA DMSBNY8 TN Dopamine D3 receptor (D3R) DMSBNY8 MA Inhibitor DMSBNY8 RN Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6. DMSBNY8 RU https://pubmed.ncbi.nlm.nih.gov/10560741 DMSBQL0 DI DMSBQL0 DMSBQL0 DN FOLITENOL DMSBQL0 TI TTELIN2 DMSBQL0 TN PTPN1 messenger RNA (PTPN1 mRNA) DMSBQL0 MA Inhibitor DMSBQL0 RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DMSBQL0 RU https://pubmed.ncbi.nlm.nih.gov/19836230 DMSBZ29 DI DMSBZ29 DMSBZ29 DN Agmatine DMSBZ29 TI TTLGDIS DMSBZ29 TN Acid-sensing ion channel 3 (ASIC3) DMSBZ29 MA Activator DMSBZ29 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686). DMSBZ29 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686 DMSC862 DI DMSC862 DMSC862 DN N-(3-(aminomethyl)phenyl)benzenesulfonamide DMSC862 TI TTJS8PY DMSC862 TN 5-HT 6 receptor (HTR6) DMSC862 MA Inhibitor DMSC862 RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMSC862 RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMSC8ZW DI DMSC8ZW DMSC8ZW DN (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}serinamide DMSC8ZW TI TTGP7BY DMSC8ZW TN Monoamine oxidase type B (MAO-B) DMSC8ZW MA Inhibitor DMSC8ZW RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMSC8ZW RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMSC9FV DI DMSC9FV DMSC9FV DN N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2 DMSC9FV TI TT27RFC DMSC9FV TN Opioid receptor delta (OPRD1) DMSC9FV MA Inhibitor DMSC9FV RN Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. DMSC9FV RU https://pubmed.ncbi.nlm.nih.gov/17188879 DMSC9FV DI DMSC9FV DMSC9FV DN N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2 DMSC9FV TI TTKWM86 DMSC9FV TN Opioid receptor mu (MOP) DMSC9FV MA Inhibitor DMSC9FV RN Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702. DMSC9FV RU https://pubmed.ncbi.nlm.nih.gov/17188879 DMSCHL0 DI DMSCHL0 DMSCHL0 DN S-(Dimethylarsenic)Cysteine DMSCHL0 TI TTY7ZHS DMSCHL0 TN Toll-like receptor 2 (TLR2) DMSCHL0 MA Inhibitor DMSCHL0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSCHL0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSCHL0 DI DMSCHL0 DMSCHL0 DN S-(Dimethylarsenic)Cysteine DMSCHL0 TI TT5DOVB DMSCHL0 TN Cytomegalovirus Protease (CMV UL80) DMSCHL0 MA Inhibitor DMSCHL0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSCHL0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSCHL0 DI DMSCHL0 DMSCHL0 DN S-(Dimethylarsenic)Cysteine DMSCHL0 TI TTCM4B3 DMSCHL0 TN Nitric-oxide synthase endothelial (NOS3) DMSCHL0 MA Inhibitor DMSCHL0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSCHL0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSCIP2 DI DMSCIP2 DMSCIP2 DN 3-(2,2-Dimethyl-propoxy)-9H-beta-carboline DMSCIP2 TI TTNJYV2 DMSCIP2 TN Gamma-aminobutyric acid receptor (GAR) DMSCIP2 MA Inhibitor DMSCIP2 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMSCIP2 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMSCIP2 DI DMSCIP2 DMSCIP2 DN 3-(2,2-Dimethyl-propoxy)-9H-beta-carboline DMSCIP2 TI TT1MPAY DMSCIP2 TN GABA(A) receptor alpha-1 (GABRA1) DMSCIP2 MA Inhibitor DMSCIP2 RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMSCIP2 RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMSCN8J DI DMSCN8J DMSCN8J DN 1-[(prop-2-ylamino)ethyl]-1,1-bisphosphonicacid DMSCN8J TI TTIKWV4 DMSCN8J TN Geranyltranstransferase (FDPS) DMSCN8J MA Inhibitor DMSCN8J RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DMSCN8J RU https://pubmed.ncbi.nlm.nih.gov/18096393 DMSCQ64 DI DMSCQ64 DMSCQ64 DN (H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2) DMSCQ64 TI TT27RFC DMSCQ64 TN Opioid receptor delta (OPRD1) DMSCQ64 MA Inhibitor DMSCQ64 RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DMSCQ64 RU https://pubmed.ncbi.nlm.nih.gov/16759107 DMSCQ64 DI DMSCQ64 DMSCQ64 DN (H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2) DMSCQ64 TI TTKWM86 DMSCQ64 TN Opioid receptor mu (MOP) DMSCQ64 MA Inhibitor DMSCQ64 RN 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8. DMSCQ64 RU https://pubmed.ncbi.nlm.nih.gov/16759107 DMSCQ9U DI DMSCQ9U DMSCQ9U DN PD-0173952 DMSCQ9U TI TT8FYO9 DMSCQ9U TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSCQ9U MA Inhibitor DMSCQ9U RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMSCQ9U RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMSCQ9U DI DMSCQ9U DMSCQ9U DN PD-0173952 DMSCQ9U TI TT6PKBN DMSCQ9U TN Proto-oncogene c-Src (SRC) DMSCQ9U MA Inhibitor DMSCQ9U RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMSCQ9U RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMSCQ9U DI DMSCQ9U DMSCQ9U DN PD-0173952 DMSCQ9U TI TT860QF DMSCQ9U TN LCK tyrosine protein kinase (LCK) DMSCQ9U MA Inhibitor DMSCQ9U RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMSCQ9U RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMSCQ9U DI DMSCQ9U DMSCQ9U DN PD-0173952 DMSCQ9U TI TTI7421 DMSCQ9U TN Platelet-derived growth factor receptor beta (PDGFRB) DMSCQ9U MA Inhibitor DMSCQ9U RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMSCQ9U RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMSCQ9U DI DMSCQ9U DMSCQ9U DN PD-0173952 DMSCQ9U TI TTRLW2X DMSCQ9U TN Fibroblast growth factor receptor 1 (FGFR1) DMSCQ9U MA Inhibitor DMSCQ9U RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMSCQ9U RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMSD2U1 DI DMSD2U1 DMSD2U1 DN AL5424 DMSD2U1 TI TTANPDJ DMSD2U1 TN Carbonic anhydrase II (CA-II) DMSD2U1 MA Inhibitor DMSD2U1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSD2U1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSD51L DI DMSD51L DMSD51L DN [35S]TBPS DMSD51L TI TTEX6LM DMSD51L TN GABA(A) receptor gamma-3 (GABRG3) DMSD51L MA Blocker (channel blocker) DMSD51L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMSD51L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMSD51L DI DMSD51L DMSD51L DN [35S]TBPS DMSD51L TI TTBMV1G DMSD51L TN GABA(A) receptor alpha-2 (GABRA2) DMSD51L MA Blocker (channel blocker) DMSD51L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMSD51L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMSD51L DI DMSD51L DMSD51L DN [35S]TBPS DMSD51L TI TTNZPQ1 DMSD51L TN GABA(A) receptor alpha-5 (GABRA5) DMSD51L MA Blocker (channel blocker) DMSD51L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMSD51L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMSD51L DI DMSD51L DMSD51L DN [35S]TBPS DMSD51L TI TT37EDJ DMSD51L TN GABA(A) receptor alpha-3 (GABRA3) DMSD51L MA Blocker (channel blocker) DMSD51L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMSD51L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMSD7B1 DI DMSD7B1 DMSD7B1 DN FVPTDVGAFAF DMSD7B1 TI TTY6O0Q DMSD7B1 TN Calcitonin gene-related peptide receptor (CGRPR) DMSD7B1 MA Inhibitor DMSD7B1 RN Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24. DMSD7B1 RU https://pubmed.ncbi.nlm.nih.gov/16420047 DMSDCGV DI DMSDCGV DMSDCGV DN ISIS 104257 DMSDCGV TI TTCQ2E5 DMSDCGV TN RIP2 messenger RNA (RIP2 mRNA) DMSDCGV RN US patent application no. 6,426,221, Antisense modulation of RIP2 expression. DMSDCGV RU http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true DMSDFOC DI DMSDFOC DMSDFOC DN peptide III-BTD DMSDFOC TI TTNT7K8 DMSDFOC TN Nociceptin receptor (OPRL1) DMSDFOC MA Antagonist DMSDFOC RN Ligands for kappa-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library. J Biol Chem. 1999 Sep 24;274(39):27513-22. DMSDFOC RU https://pubmed.ncbi.nlm.nih.gov/10488086 DMSDH3A DI DMSDH3A DMSDH3A DN CCT244747 DMSDH3A TI TTV6WMQ DMSDH3A TN BR serine/threonine kinase 1 (BRSK1) DMSDH3A MA Inhibitor DMSDH3A RN Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40. DMSDH3A RU https://pubmed.ncbi.nlm.nih.gov/23082860 DMSDH3A DI DMSDH3A DMSDH3A DN CCT244747 DMSDH3A TI TTTU902 DMSDH3A TN Checkpoint kinase-1 (CHK1) DMSDH3A MA Inhibitor DMSDH3A RN Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40. DMSDH3A RU https://pubmed.ncbi.nlm.nih.gov/23082860 DMSDH3A DI DMSDH3A DMSDH3A DN CCT244747 DMSDH3A TI TTHZN4X DMSDH3A TN BR serine/threonine kinase 2 (BRSK2) DMSDH3A MA Inhibitor DMSDH3A RN Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. J Med Chem. 2012 Nov 26;55(22):10229-40. DMSDH3A RU https://pubmed.ncbi.nlm.nih.gov/23082860 DMSDINR DI DMSDINR DMSDINR DN 7beta, 27-dihydroxycholesterol DMSDINR TI TTME5YJ DMSDINR TN EBV-induced G-protein coupled receptor 2 (GPR183) DMSDINR MA Agonist DMSDINR RN Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23. DMSDINR RU https://pubmed.ncbi.nlm.nih.gov/21796211 DMSDVGQ DI DMSDVGQ DMSDVGQ DN N1,N2-bis(dihydrocaffeoyl)spermine DMSDVGQ TI TTRTKPV DMSDVGQ TN Trypanosoma Trypanothione reductase (Trypano TPR) DMSDVGQ MA Inhibitor DMSDVGQ RN The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem. 2008 Jul 15;16(14):6689-95. DMSDVGQ RU https://pubmed.ncbi.nlm.nih.gov/18558492 DMSDY2Z DI DMSDY2Z DMSDY2Z DN [3H]A-585539 DMSDY2Z TI TTLA931 DMSDY2Z TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMSDY2Z MA Agonist DMSDY2Z RN [3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]heptane], a novel high-affinity alpha7 neuronal nicotinic... J Pharmacol Exp Ther. 2008 Jan;324(1):179-87. DMSDY2Z RU https://pubmed.ncbi.nlm.nih.gov/17959745 DMSDYZQ DI DMSDYZQ DMSDYZQ DN 2-hydroxy-5-isopropyl-2,4,6-cycloheptatrien-1-one DMSDYZQ TI TTULVH8 DMSDYZQ TN Tyrosinase (TYR) DMSDYZQ MA Inhibitor DMSDYZQ RN Structural insights into the hot spot amino acid residues of mushroom tyrosinase for the bindings of thujaplicins. Bioorg Med Chem. 2010 Nov 15;18(22):8112-8. DMSDYZQ RU https://pubmed.ncbi.nlm.nih.gov/20947360 DMSE1C3 DI DMSE1C3 DMSE1C3 DN PMID19364658C33 DMSE1C3 TI TTYVI76 DMSE1C3 TN Fungal Protein kinase A (Fung ypkA) DMSE1C3 MA Inhibitor DMSE1C3 RN Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. DMSE1C3 RU https://pubmed.ncbi.nlm.nih.gov/19364658 DMSE1C3 DI DMSE1C3 DMSE1C3 DN PMID19364658C33 DMSE1C3 TI TTTU902 DMSE1C3 TN Checkpoint kinase-1 (CHK1) DMSE1C3 MA Inhibitor DMSE1C3 RN Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. DMSE1C3 RU https://pubmed.ncbi.nlm.nih.gov/19364658 DMSE1C3 DI DMSE1C3 DMSE1C3 DN PMID19364658C33 DMSE1C3 TI TTZN7RP DMSE1C3 TN Rho-associated protein kinase 1 (ROCK1) DMSE1C3 MA Inhibitor DMSE1C3 RN Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. DMSE1C3 RU https://pubmed.ncbi.nlm.nih.gov/19364658 DMSE1C3 DI DMSE1C3 DMSE1C3 DN PMID19364658C33 DMSE1C3 TI TTQR5YD DMSE1C3 TN Casein kinase I gamma-1 (CSNK1G1) DMSE1C3 MA Inhibitor DMSE1C3 RN Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. DMSE1C3 RU https://pubmed.ncbi.nlm.nih.gov/19364658 DMSE1C3 DI DMSE1C3 DMSE1C3 DN PMID19364658C33 DMSE1C3 TI TTIXKA4 DMSE1C3 TN Ribosomal protein S6 kinase alpha-1 (RSK1) DMSE1C3 MA Inhibitor DMSE1C3 RN Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. DMSE1C3 RU https://pubmed.ncbi.nlm.nih.gov/19364658 DMSE1C3 DI DMSE1C3 DMSE1C3 DN PMID19364658C33 DMSE1C3 TI TTMUG9D DMSE1C3 TN MAPK-activated protein kinase 2 (MAPKAPK2) DMSE1C3 MA Inhibitor DMSE1C3 RN Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51. DMSE1C3 RU https://pubmed.ncbi.nlm.nih.gov/19364658 DMSE20Y DI DMSE20Y DMSE20Y DN CCACSSKWCRDHSRCC DMSE20Y TI TT84DRB DMSE20Y TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMSE20Y MA Inhibitor DMSE20Y RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DMSE20Y RU https://pubmed.ncbi.nlm.nih.gov/17724025 DMSE29N DI DMSE29N DMSE29N DN Ac-Bth-Thr(PO3H2)-Pip-Nal-Gln-NH2 DMSE29N TI TTJNTSI DMSE29N TN Rotamase Pin1 (PIN1) DMSE29N MA Inhibitor DMSE29N RN Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries. J Med Chem. 2006 Apr 6;49(7):2147-50. DMSE29N RU https://pubmed.ncbi.nlm.nih.gov/16570909 DMSE56B DI DMSE56B DMSE56B DN [3H]JNJ-40068782 DMSE56B TI TTXJ47W DMSE56B TN Metabotropic glutamate receptor 2 (mGluR2) DMSE56B MA Modulator (allosteric modulator) DMSE56B RN Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782. J Pharmacol Exp Ther. 2013 Sep;346(3):514-27. DMSE56B RU https://pubmed.ncbi.nlm.nih.gov/23766542 DMSE8NU DI DMSE8NU DMSE8NU DN 4-ANDROSTENE-3-17-DIONE DMSE8NU TI TTZT9R2 DMSE8NU TN Hydroxysteroid dehydrogenase 3-beta (HSD3B) DMSE8NU MA Agonist DMSE8NU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSE8NU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSE8NU DI DMSE8NU DMSE8NU DN 4-ANDROSTENE-3-17-DIONE DMSE8NU TI TT5ZWB6 DMSE8NU TN Dihydrodiol dehydrogenase type I (AKR1C3) DMSE8NU MA Inhibitor DMSE8NU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSE8NU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSE8NU DI DMSE8NU DMSE8NU DN 4-ANDROSTENE-3-17-DIONE DMSE8NU TI TTSZLWK DMSE8NU TN Aromatase (CYP19A1) DMSE8NU MA Inhibitor DMSE8NU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMSE8NU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMSE8NU DI DMSE8NU DMSE8NU DN 4-ANDROSTENE-3-17-DIONE DMSE8NU TI TTIWB6L DMSE8NU TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMSE8NU MA Inhibitor DMSE8NU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSE8NU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSEAMU DI DMSEAMU DMSEAMU DN TMX-30X DMSEAMU TI TTRJ1K4 DMSEAMU TN Toll-like receptor 7 (TLR7) DMSEAMU MA Agonist DMSEAMU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757). DMSEAMU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757 DMSEHNV DI DMSEHNV DMSEHNV DN 1,1,1,2,2-Pentafluoro-9-phenyl-nonan-3-one DMSEHNV TI TTT1JVS DMSEHNV TN Cytosolic phospholipase A2 (GIVA cPLA2) DMSEHNV MA Inhibitor DMSEHNV RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMSEHNV RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMSEIUP DI DMSEIUP DMSEIUP DN 2-iodo-melatonin DMSEIUP TI TT0WAIE DMSEIUP TN Melatonin receptor type 1A (MTNR1A) DMSEIUP MA Agonist DMSEIUP RN Characterization of a retinal melatonin receptor. J Pharmacol Exp Ther. 1985 Aug;234(2):395-401. DMSEIUP RU https://pubmed.ncbi.nlm.nih.gov/2991499 DMSEIUP DI DMSEIUP DMSEIUP DN 2-iodo-melatonin DMSEIUP TI TT32JK8 DMSEIUP TN Melatonin receptor type 1B (MTNR1B) DMSEIUP MA Inhibitor DMSEIUP RN Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). J Med Chem. 2002 Apr 25;45(9):1853-9. DMSEIUP RU https://pubmed.ncbi.nlm.nih.gov/11960497 DMSEIUP DI DMSEIUP DMSEIUP DN 2-iodo-melatonin DMSEIUP TI TTJLP0R DMSEIUP TN Quinone reductase 2 (NQO2) DMSEIUP MA Inhibitor DMSEIUP RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMSEIUP RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMSEJZK DI DMSEJZK DMSEJZK DN ISIS 183901 DMSEJZK TI TTBGTCW DMSEJZK TN Kinesin spindle messenger RNA (KIF11 mRNA) DMSEJZK RN US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression. DMSEJZK RU http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true DMSEK5W DI DMSEK5W DMSEK5W DN CVT-313 DMSEK5W TI TTH6V3D DMSEK5W TN Cyclin-dependent kinase 1 (CDK1) DMSEK5W MA Inhibitor DMSEK5W RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMSEK5W RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMSEK5W DI DMSEK5W DMSEK5W DN CVT-313 DMSEK5W TI TT7HF4W DMSEK5W TN Cyclin-dependent kinase 2 (CDK2) DMSEK5W MA Inhibitor DMSEK5W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973). DMSEK5W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1973 DMSEL5W DI DMSEL5W DMSEL5W DN N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine DMSEL5W TI TTM2AOE DMSEL5W TN Adenosine A2a receptor (ADORA2A) DMSEL5W MA Inhibitor DMSEL5W RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMSEL5W RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMSEL5W DI DMSEL5W DMSEL5W DN N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine DMSEL5W TI TTK25J1 DMSEL5W TN Adenosine A1 receptor (ADORA1) DMSEL5W MA Inhibitor DMSEL5W RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMSEL5W RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMSEL5W DI DMSEL5W DMSEL5W DN N6-methoxy-2-[(2-pyridinyl)ethynyl]adenosine DMSEL5W TI TTJFY5U DMSEL5W TN Adenosine A3 receptor (ADORA3) DMSEL5W MA Inhibitor DMSEL5W RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMSEL5W RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMSEQ0W DI DMSEQ0W DMSEQ0W DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) DMSEQ0W TI TTTQGH8 DMSEQ0W TN Histone deacetylase 4 (HDAC4) DMSEQ0W MA Inhibitor DMSEQ0W RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMSEQ0W RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMSEQ0W DI DMSEQ0W DMSEQ0W DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) DMSEQ0W TI TT5ZKDI DMSEQ0W TN Histone deacetylase 6 (HDAC6) DMSEQ0W MA Inhibitor DMSEQ0W RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMSEQ0W RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMSEQ0W DI DMSEQ0W DMSEQ0W DN Cyclo(-L-Am7(S2Py)-Aib-L-Ser(Bzl)-D-Pro-) DMSEQ0W TI TT6R7JZ DMSEQ0W TN Histone deacetylase 1 (HDAC1) DMSEQ0W MA Inhibitor DMSEQ0W RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMSEQ0W RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMSEQ61 DI DMSEQ61 DMSEQ61 DN ISIS 114530 DMSEQ61 TI TTY3BRA DMSEQ61 TN ZNF217 messenger RNA (ZNF217 mRNA) DMSEQ61 RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DMSEQ61 RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DMSF3C8 DI DMSF3C8 DMSF3C8 DN 13-(n-Pentylcarbamoyloxy)tridec-8(Z)-enoic acid DMSF3C8 TI TT7WVHI DMSF3C8 TN Soluble epoxide hydrolase (EPHX2) DMSF3C8 MA Inhibitor DMSF3C8 RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMSF3C8 RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMSF4UI DI DMSF4UI DMSF4UI DN MDT-006 DMSF4UI TI TTOZHQC DMSF4UI TN P2Y purinoceptor 2 (P2RY2) DMSF4UI MA Agonist DMSF4UI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324). DMSF4UI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=324 DMSF5DR DI DMSF5DR DMSF5DR DN 4-Methyl-N-(4-phenyl-thiazol-2-yl)-benzamide DMSF5DR TI TTK25J1 DMSF5DR TN Adenosine A1 receptor (ADORA1) DMSF5DR MA Inhibitor DMSF5DR RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMSF5DR RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMSF5DW DI DMSF5DW DMSF5DW DN Sanggenon C DMSF5DW TI TTELIN2 DMSF5DW TN PTPN1 messenger RNA (PTPN1 mRNA) DMSF5DW MA Inhibitor DMSF5DW RN Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9. DMSF5DW RU https://pubmed.ncbi.nlm.nih.gov/16356713 DMSF8B9 DI DMSF8B9 DMSF8B9 DN GC-24 DMSF8B9 TI TTGER3L DMSF8B9 TN Thyroid hormone receptor beta (THRB) DMSF8B9 MA Inhibitor DMSF8B9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSF8B9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSF8UC DI DMSF8UC DMSF8UC DN MOL 6131 DMSF8UC TI TTM1TDX DMSF8UC TN Tryptase alpha/beta-1 (Tryptase) DMSF8UC MA Inhibitor DMSF8UC RN Tryptase inhibition blocks airway inflammation in a mouse asthma model. J Immunol. 2002 Feb 15;168(4):1992-2000. DMSF8UC RU https://pubmed.ncbi.nlm.nih.gov/11823536 DMSFA2D DI DMSFA2D DMSFA2D DN (R)-tacrine(10)-hupyridone DMSFA2D TI TT1RS9F DMSFA2D TN Acetylcholinesterase (AChE) DMSFA2D MA Inhibitor DMSFA2D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMSFA2D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMSFGRI DI DMSFGRI DMSFGRI DN 4-(1,2,3-thiadiazol-4-yl)phenyl hexylcarbamate DMSFGRI TI TTDP1UC DMSFGRI TN Fatty acid amide hydrolase (FAAH) DMSFGRI MA Inhibitor DMSFGRI RN The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008. DMSFGRI RU https://pubmed.ncbi.nlm.nih.gov/19232787 DMSFINY DI DMSFINY DMSFINY DN 1-Ethyl-3-methyl-3,7-dihydro-purine-2,6-dione DMSFINY TI TTM2AOE DMSFINY TN Adenosine A2a receptor (ADORA2A) DMSFINY MA Inhibitor DMSFINY RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DMSFINY RU https://pubmed.ncbi.nlm.nih.gov/3806581 DMSFJNE DI DMSFJNE DMSFJNE DN 3-methoxy-N-(6-methylpyridin-2-yl)benzamide DMSFJNE TI TTHS256 DMSFJNE TN Metabotropic glutamate receptor 5 (mGluR5) DMSFJNE MA Inhibitor DMSFJNE RN Design and synthesis of noncompetitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3371-5. DMSFJNE RU https://pubmed.ncbi.nlm.nih.gov/16678408 DMSFLTK DI DMSFLTK DMSFLTK DN astressin DMSFLTK TI TTIY658 DMSFLTK TN Corticotropin-releasing factor receptor 2 (CRHR2) DMSFLTK MA Antagonist DMSFLTK RN Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. J Pharmacol Exp Ther. 1999 Feb;288(2):729-34. DMSFLTK RU https://pubmed.ncbi.nlm.nih.gov/9918582 DMSFODU DI DMSFODU DMSFODU DN 7-ethyl-6H-chromeno[4,3-b]quinoline-3,9-diol DMSFODU TI TTPNQAC DMSFODU TN Estrogen-related receptor-alpha (ESRRA) DMSFODU MA Inhibitor DMSFODU RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMSFODU RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMSFQAZ DI DMSFQAZ DMSFQAZ DN 2-fluorophenyl 4-(decyloxy)phenylcarbamate DMSFQAZ TI TTDP1UC DMSFQAZ TN Fatty acid amide hydrolase (FAAH) DMSFQAZ MA Inhibitor DMSFQAZ RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMSFQAZ RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMSFQHO DI DMSFQHO DMSFQHO DN ON-24160 DMSFQHO TI TTYFKSZ DMSFQHO TN Tubulin beta (TUBB) DMSFQHO MA Inhibitor DMSFQHO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMSFQHO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMSFW9T DI DMSFW9T DMSFW9T DN 3-[5-(4-hydroxyphenyl)-2-thienyl]phenol DMSFW9T TI TTIWB6L DMSFW9T TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMSFW9T MA Inhibitor DMSFW9T RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMSFW9T RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMSFXA3 DI DMSFXA3 DMSFXA3 DN Salvinorin B isopropoxymethyl ether DMSFXA3 TI TTQW87Y DMSFXA3 TN Opioid receptor kappa (OPRK1) DMSFXA3 MA Inhibitor DMSFXA3 RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMSFXA3 RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMSFXEO DI DMSFXEO DMSFXEO DN (2R,5R)-delta-methyl-alpha-acetylenic putrescine DMSFXEO TI TTUMGNO DMSFXEO TN Ornithine decarboxylase (ODC1) DMSFXEO MA Inhibitor DMSFXEO RN Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. DMSFXEO RU https://pubmed.ncbi.nlm.nih.gov/3115816 DMSFXJ8 DI DMSFXJ8 DMSFXJ8 DN Cosalane derivative DMSFXJ8 TI TTC24WT DMSFXJ8 TN C-C chemokine receptor type 1 (CCR1) DMSFXJ8 MA Inhibitor DMSFXJ8 RN Inhibition of RANTES/CCR1-mediated chemotaxis by cosalane and related compounds. Bioorg Med Chem Lett. 2001 Jan 8;11(1):59-62. DMSFXJ8 RU https://pubmed.ncbi.nlm.nih.gov/11140734 DMSFXZU DI DMSFXZU DMSFXZU DN CB-1922 DMSFXZU TI TT26PHO DMSFXZU TN Mineralocorticoid receptor (MR) DMSFXZU MA Inhibitor DMSFXZU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626). DMSFXZU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=626 DMSG0TL DI DMSG0TL DMSG0TL DN TG-1022 DMSG0TL TI TTLAFZV DMSG0TL TN AMP-activated protein kinase (AMPK) DMSG0TL MA Stimulator DMSG0TL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1540). DMSG0TL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1540 DMSG1AY DI DMSG1AY DMSG1AY DN 6,7-Dimethoxy-3-pyridin-3-yl-quinoline DMSG1AY TI TTI7421 DMSG1AY TN Platelet-derived growth factor receptor beta (PDGFRB) DMSG1AY MA Inhibitor DMSG1AY RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMSG1AY RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMSG1AY DI DMSG1AY DMSG1AY DN 6,7-Dimethoxy-3-pyridin-3-yl-quinoline DMSG1AY TI TT8FYO9 DMSG1AY TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSG1AY MA Inhibitor DMSG1AY RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMSG1AY RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMSG1NI DI DMSG1NI DMSG1NI DN ISIS 173848 DMSG1NI TI TT9RTBL DMSG1NI TN Aurora B messenger RNA (AURKB mRNA) DMSG1NI RN US patent application no. 7,375,212, Modulation of Aurora B expression. DMSG1NI RU http://www.patentbuddy.com/Patent/7375212?ft=true&sr=true DMSG6F1 DI DMSG6F1 DMSG6F1 DN PF-4989216 DMSG6F1 TI TTHBTOP DMSG6F1 TN PI3-kinase gamma (PIK3CG) DMSG6F1 MA Inhibitor DMSG6F1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMSG6F1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMSG8RI DI DMSG8RI DMSG8RI DN example 131 [WO2009133348] DMSG8RI TI TT5T3P6 DMSG8RI TN Tissue kallikrein (KLK1) DMSG8RI MA Inhibitor DMSG8RI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2865). DMSG8RI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2865 DMSG91J DI DMSG91J DMSG91J DN ER819762 DMSG91J TI TT79WV3 DMSG91J TN Prostaglandin E2 receptor EP4 (PTGER4) DMSG91J MA Antagonist DMSG91J RN A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. Br J Pharmacol. 2010 May;160(2):292-310. DMSG91J RU https://pubmed.ncbi.nlm.nih.gov/20423341 DMSG9LV DI DMSG9LV DMSG9LV DN 4-(Carboxyvin-2-Yl)Phenylboronic Acid DMSG9LV TI TTHI19T DMSG9LV TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMSG9LV MA Inhibitor DMSG9LV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSG9LV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSGBQA DI DMSGBQA DMSGBQA DN chloropicrin DMSGBQA TI TTELV3W DMSGBQA TN Transformation-sensitive protein p120 (TRPA1) DMSGBQA MA Activator DMSGBQA RN Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14. DMSGBQA RU https://pubmed.ncbi.nlm.nih.gov/19036859 DMSGCKU DI DMSGCKU DMSGCKU DN 3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline DMSGCKU TI TT8FYO9 DMSGCKU TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSGCKU MA Inhibitor DMSGCKU RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMSGCKU RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMSGCKU DI DMSGCKU DMSGCKU DN 3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline DMSGCKU TI TTI7421 DMSGCKU TN Platelet-derived growth factor receptor beta (PDGFRB) DMSGCKU MA Inhibitor DMSGCKU RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMSGCKU RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMSGIXK DI DMSGIXK DMSGIXK DN BQCA DMSGIXK TI TTZ9SOR DMSGIXK TN Muscarinic acetylcholine receptor M1 (CHRM1) DMSGIXK MA Agonist DMSGIXK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5436). DMSGIXK RU http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5436 DMSGJM6 DI DMSGJM6 DMSGJM6 DN 6-ethyl-3-pentoxycarbonyl-4-quinolone DMSGJM6 TI TT1MPAY DMSGJM6 TN GABA(A) receptor alpha-1 (GABRA1) DMSGJM6 MA Inhibitor DMSGJM6 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMSGJM6 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMSGJM6 DI DMSGJM6 DMSGJM6 DN 6-ethyl-3-pentoxycarbonyl-4-quinolone DMSGJM6 TI TTZA1NY DMSGJM6 TN GABA(A) receptor beta-2 (GABRB2) DMSGJM6 MA Inhibitor DMSGJM6 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMSGJM6 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMSGJM6 DI DMSGJM6 DMSGJM6 DN 6-ethyl-3-pentoxycarbonyl-4-quinolone DMSGJM6 TI TTNJYV2 DMSGJM6 TN Gamma-aminobutyric acid receptor (GAR) DMSGJM6 MA Inhibitor DMSGJM6 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMSGJM6 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMSGJM6 DI DMSGJM6 DMSGJM6 DN 6-ethyl-3-pentoxycarbonyl-4-quinolone DMSGJM6 TI TT06RH5 DMSGJM6 TN GABA(A) receptor gamma-2 (GABRG2) DMSGJM6 MA Inhibitor DMSGJM6 RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMSGJM6 RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMSGMPU DI DMSGMPU DMSGMPU DN Tyr-Pro-Phg-Pro-NH2 DMSGMPU TI TTKWM86 DMSGMPU TN Opioid receptor mu (MOP) DMSGMPU MA Inhibitor DMSGMPU RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DMSGMPU RU https://pubmed.ncbi.nlm.nih.gov/16682191 DMSGNM1 DI DMSGNM1 DMSGNM1 DN Sideroxylonal C DMSGNM1 TI TTTO43N DMSGNM1 TN Endothelial plasminogen activator inhibitor (SERPINE1) DMSGNM1 MA Inhibitor DMSGNM1 RN Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens. J Nat Prod. 1999 Feb;62(2):324-6. DMSGNM1 RU https://pubmed.ncbi.nlm.nih.gov/10075775 DMSGU2L DI DMSGU2L DMSGU2L DN 9-Cyclopentyl-9H-adenine DMSGU2L TI TTJFY5U DMSGU2L TN Adenosine A3 receptor (ADORA3) DMSGU2L MA Inhibitor DMSGU2L RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMSGU2L RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMSGU2L DI DMSGU2L DMSGU2L DN 9-Cyclopentyl-9H-adenine DMSGU2L TI TTM2AOE DMSGU2L TN Adenosine A2a receptor (ADORA2A) DMSGU2L MA Inhibitor DMSGU2L RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMSGU2L RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMSGU2L DI DMSGU2L DMSGU2L DN 9-Cyclopentyl-9H-adenine DMSGU2L TI TTK25J1 DMSGU2L TN Adenosine A1 receptor (ADORA1) DMSGU2L MA Inhibitor DMSGU2L RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMSGU2L RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMSGW51 DI DMSGW51 DMSGW51 DN [D-Asp7,Lys10]N/OFQ(1-13)NH2 DMSGW51 TI TTNT7K8 DMSGW51 TN Nociceptin receptor (OPRL1) DMSGW51 MA Inhibitor DMSGW51 RN High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7. DMSGW51 RU https://pubmed.ncbi.nlm.nih.gov/18624395 DMSGWZE DI DMSGWZE DMSGWZE DN C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 DMSGWZE TI TTNI91K DMSGWZE TN Melanocortin receptor 3 (MC3R) DMSGWZE MA Inhibitor DMSGWZE RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMSGWZE RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMSGWZE DI DMSGWZE DMSGWZE DN C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 DMSGWZE TI TTEOSZT DMSGWZE TN Melanocortin receptor (MCR) DMSGWZE MA Inhibitor DMSGWZE RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMSGWZE RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMSGWZE DI DMSGWZE DMSGWZE DN C[Nle-Gln-D-Phe-Arg-Trp-Glu]-NH2 DMSGWZE TI TT0MV2T DMSGWZE TN Melanocortin receptor 1 (MC1R) DMSGWZE MA Inhibitor DMSGWZE RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMSGWZE RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMSGX7V DI DMSGX7V DMSGX7V DN 3-((2-Pyrrolidine-1-yl)-ethyl)uracil DMSGX7V TI TTMCF1Y DMSGX7V TN Purine nucleoside phosphorylase (PNP) DMSGX7V MA Inhibitor DMSGX7V RN Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase. Eur J Med Chem. 2010 Nov;45(11):5140-9. DMSGX7V RU https://pubmed.ncbi.nlm.nih.gov/20817362 DMSH107 DI DMSH107 DMSH107 DN 6-(Indan-5-ylamino)-1H-pyrimidine-2,4-dione DMSH107 TI TT2GPK3 DMSH107 TN DNA topoisomerase (TOP) DMSH107 MA Inhibitor DMSH107 RN Inhibitors of Bacillus subtilis DNA polymerase III. 6-Anilinouracils and 6-(alkylamino)uracils. J Med Chem. 1980 Jan;23(1):34-8. DMSH107 RU https://pubmed.ncbi.nlm.nih.gov/6767030 DMSH4WP DI DMSH4WP DMSH4WP DN 2-(4-Isopropyl-piperazin-1-yl)-quinoline DMSH4WP TI TT9JNIC DMSH4WP TN Histamine H3 receptor (H3R) DMSH4WP MA Inhibitor DMSH4WP RN 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11. DMSH4WP RU https://pubmed.ncbi.nlm.nih.gov/15634025 DMSHBLF DI DMSHBLF DMSHBLF DN PD-135188 DMSHBLF TI TTEX248 DMSHBLF TN Dopamine D2 receptor (D2R) DMSHBLF MA Inhibitor DMSHBLF RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DMSHBLF RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DMSHDNO DI DMSHDNO DMSHDNO DN (+/-)-2-Phenylthiomorpholin-5-one DMSHDNO TI TT3WG5C DMSHDNO TN Monoamine oxidase type A (MAO-A) DMSHDNO MA Inhibitor DMSHDNO RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMSHDNO RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMSHDNO DI DMSHDNO DMSHDNO DN (+/-)-2-Phenylthiomorpholin-5-one DMSHDNO TI TTGP7BY DMSHDNO TN Monoamine oxidase type B (MAO-B) DMSHDNO MA Inhibitor DMSHDNO RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMSHDNO RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMSHF0K DI DMSHF0K DMSHF0K DN Hexane-1,6-diamine DMSHF0K TI TTUNARX DMSHF0K TN Carbonic anhydrase (CA) DMSHF0K MA Inhibitor DMSHF0K RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMSHF0K RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMSHF0K DI DMSHF0K DMSHF0K DN Hexane-1,6-diamine DMSHF0K TI TTZHA0O DMSHF0K TN Carbonic anhydrase IV (CA-IV) DMSHF0K MA Inhibitor DMSHF0K RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMSHF0K RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMSHF0K DI DMSHF0K DMSHF0K DN Hexane-1,6-diamine DMSHF0K TI TTHQPL7 DMSHF0K TN Carbonic anhydrase I (CA-I) DMSHF0K MA Inhibitor DMSHF0K RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMSHF0K RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMSHF0K DI DMSHF0K DMSHF0K DN Hexane-1,6-diamine DMSHF0K TI TTCFSPE DMSHF0K TN Carbonic anhydrase VI (CA-VI) DMSHF0K MA Inhibitor DMSHF0K RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMSHF0K RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMSHF0K DI DMSHF0K DMSHF0K DN Hexane-1,6-diamine DMSHF0K TI TT2LVK8 DMSHF0K TN Carbonic anhydrase IX (CA-IX) DMSHF0K MA Inhibitor DMSHF0K RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMSHF0K RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMSHF0K DI DMSHF0K DMSHF0K DN Hexane-1,6-diamine DMSHF0K TI TTEYTKG DMSHF0K TN Carbonic anhydrase XIV (CA-XIV) DMSHF0K MA Inhibitor DMSHF0K RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMSHF0K RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMSHF0K DI DMSHF0K DMSHF0K DN Hexane-1,6-diamine DMSHF0K TI TTSYM0R DMSHF0K TN Carbonic anhydrase XII (CA-XII) DMSHF0K MA Inhibitor DMSHF0K RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMSHF0K RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMSHIQA DI DMSHIQA DMSHIQA DN CID755673 DMSHIQA TI TTSLUMT DMSHIQA TN Protein kinase D (PRKD1) DMSHIQA MA Inhibitor DMSHIQA RN Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92. DMSHIQA RU https://pubmed.ncbi.nlm.nih.gov/20580776 DMSHMIK DI DMSHMIK DMSHMIK DN R-65 DMSHMIK TI TT1ZAVI DMSHMIK TN Prostaglandin E2 receptor EP2 (PTGER2) DMSHMIK MA Modulator DMSHMIK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341). DMSHMIK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=341 DMSHOQ8 DI DMSHOQ8 DMSHOQ8 DN [35S]-non-peptide OT antagonist DMSHOQ8 TI TTSCIUP DMSHOQ8 TN Oxytocin receptor (OTR) DMSHOQ8 MA Antagonist DMSHOQ8 RN A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors. Eur J Pharmacol. 2002 Aug 16;450(1):19-28. DMSHOQ8 RU https://pubmed.ncbi.nlm.nih.gov/12176104 DMSHORK DI DMSHORK DMSHORK DN 3-(3,3-dimethyl-2-oxoindolin-5-yl)benzonitrile DMSHORK TI TTUV8G9 DMSHORK TN Progesterone receptor (PGR) DMSHORK MA Inhibitor DMSHORK RN Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73. DMSHORK RU https://pubmed.ncbi.nlm.nih.gov/18318463 DMSHPCW DI DMSHPCW DMSHPCW DN 2-(4-Amino-3'-chloro-biphenyl-3-yl)-propan-2-ol DMSHPCW TI TTUV8G9 DMSHPCW TN Progesterone receptor (PGR) DMSHPCW MA Inhibitor DMSHPCW RN Potent nonsteroidal progesterone receptor agonists: synthesis and SAR study of 6-aryl benzoxazines. Bioorg Med Chem Lett. 2002 Mar 11;12(5):787-90. DMSHPCW RU https://pubmed.ncbi.nlm.nih.gov/11859003 DMSHQE3 DI DMSHQE3 DMSHQE3 DN N-hydroxy-4-(naphthalen-1-yl)benzamide DMSHQE3 TI TTT6LFV DMSHQE3 TN Histone deacetylase 8 (HDAC8) DMSHQE3 MA Inhibitor DMSHQE3 RN Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. DMSHQE3 RU https://pubmed.ncbi.nlm.nih.gov/17346959 DMSHQE3 DI DMSHQE3 DMSHQE3 DN N-hydroxy-4-(naphthalen-1-yl)benzamide DMSHQE3 TI TT2J34L DMSHQE3 TN Arachidonate 5-lipoxygenase (5-LOX) DMSHQE3 MA Inhibitor DMSHQE3 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMSHQE3 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMSHW2E DI DMSHW2E DMSHW2E DN [3H]thiamine DMSHW2E TI TT9BTWM DMSHW2E TN Solute carrier family 19 member 3 (SLC19A3) DMSHW2E MA Modulator DMSHW2E RN SLC19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta. 2001 Nov 29;1537(3):175-8. DMSHW2E RU https://pubmed.ncbi.nlm.nih.gov/11731220 DMSHW2E DI DMSHW2E DMSHW2E DN [3H]thiamine DMSHW2E TI TT2A1DZ DMSHW2E TN Solute carrier family 19 member 2 (SLC19A2) DMSHW2E MA Modulator DMSHW2E RN Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem. 1999 Nov 5;274(45):31925-9. DMSHW2E RU https://pubmed.ncbi.nlm.nih.gov/10542220 DMSHWYU DI DMSHWYU DMSHWYU DN N-(1-PHENYL-PROPYL)-FORMAMIDE DMSHWYU TI TT5DOVB DMSHWYU TN Cytomegalovirus Protease (CMV UL80) DMSHWYU MA Inhibitor DMSHWYU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMSHWYU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMSHYQ3 DI DMSHYQ3 DMSHYQ3 DN HQL-79 DMSHYQ3 TI TTCYE56 DMSHYQ3 TN Glutathione-dependent PGD synthase (HPGDS) DMSHYQ3 MA Inhibitor DMSHYQ3 RN Structural and functional characterization of HQL-79, an orally selective inhibitor of human hematopoietic prostaglandin D synthase. J Biol Chem. 2006 Jun 2;281(22):15277-86. DMSHYQ3 RU https://pubmed.ncbi.nlm.nih.gov/16547010 DMSI07M DI DMSI07M DMSI07M DN 2-(2-cyclohexyl-4-methoxyphenoxy)acetic acid DMSI07M TI TTQDMX5 DMSI07M TN Prostaglandin D2 receptor 2 (PTGDR2) DMSI07M MA Inhibitor DMSI07M RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMSI07M RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMSI0HE DI DMSI0HE DMSI0HE DN TZI-41127 DMSI0HE TI TT2J34L DMSI0HE TN Arachidonate 5-lipoxygenase (5-LOX) DMSI0HE MA Inhibitor DMSI0HE RN Design of pyrrolo-1,4-benzoxazine derivatives as inhibitors of 5-lipoxygenase and PAF antagonists with anthihistaminic properties, Bioorg. Med. Chem. Lett. 4(20):2383-2388 (1994). DMSI0HE RU http://www.sciencedirect.com/science/article/pii/S0960894X01803954 DMSI3V4 DI DMSI3V4 DMSI3V4 DN 3-(3,5-Dimethyl-phenyl)-1-propyl-piperidine DMSI3V4 TI TTEX248 DMSI3V4 TN Dopamine D2 receptor (D2R) DMSI3V4 MA Inhibitor DMSI3V4 RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DMSI3V4 RU https://pubmed.ncbi.nlm.nih.gov/9836610 DMSI41E DI DMSI41E DMSI41E DN 2-(2-hexylphenyl)isoindoline-1,3-dione DMSI41E TI TTECBXN DMSI41E TN Oxysterols receptor LXR-alpha (NR1H3) DMSI41E MA Inhibitor DMSI41E RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DMSI41E RU https://pubmed.ncbi.nlm.nih.gov/18343126 DMSI4PE DI DMSI4PE DMSI4PE DN N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMSI4PE TI TTHQPL7 DMSI4PE TN Carbonic anhydrase I (CA-I) DMSI4PE MA Inhibitor DMSI4PE RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMSI4PE RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMSI4PE DI DMSI4PE DMSI4PE DN N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMSI4PE TI TTZHA0O DMSI4PE TN Carbonic anhydrase IV (CA-IV) DMSI4PE MA Inhibitor DMSI4PE RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMSI4PE RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMSI4PE DI DMSI4PE DMSI4PE DN N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMSI4PE TI TTUNARX DMSI4PE TN Carbonic anhydrase (CA) DMSI4PE MA Inhibitor DMSI4PE RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMSI4PE RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMSI4PE DI DMSI4PE DMSI4PE DN N-[5-(ethylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMSI4PE TI TTANPDJ DMSI4PE TN Carbonic anhydrase II (CA-II) DMSI4PE MA Inhibitor DMSI4PE RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMSI4PE RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMSI95J DI DMSI95J DMSI95J DN SMP-797 DMSI95J TI TTMF541 DMSI95J TN Liver carboxylesterase (CES1) DMSI95J MA Modulator DMSI95J RN Company report (Dainippon Sumitomo Pharma) DMSI95J RU http://www.ds-pharma.com/ir/library/presentation/pdf/eir20060314.pdf (A lowering of plasma cholesterol by ACAT inhibition and enhancing LDL receptor activity leads to the direct inhibition of the progress of arteriosclerosis by ACAT inhibition) DMSI9QM DI DMSI9QM DMSI9QM DN TDI-0059 DMSI9QM TI TTEDJN4 DMSI9QM TN Low-affinity nerve growth factor receptor (NGFR) DMSI9QM MA Modulator DMSI9QM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMSI9QM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMSIAMN DI DMSIAMN DMSIAMN DN 3-Benzyl-5-methoxychromen-2-one DMSIAMN TI TT6OEDT DMSIAMN TN Cannabinoid receptor 1 (CB1) DMSIAMN MA Inhibitor DMSIAMN RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMSIAMN RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMSIBWP DI DMSIBWP DMSIBWP DN ISIS 3308 DMSIBWP TI TTM27B5 DMSIBWP TN Influenza NA messenger RNA (Influenza NA mRNA) DMSIBWP RN US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides. DMSIBWP RU http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true DMSICYK DI DMSICYK DMSICYK DN JMV 1813 DMSICYK TI TTC1MVT DMSICYK TN Gastrin-releasing peptide receptor (GRPR) DMSICYK MA Inhibitor DMSICYK RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DMSICYK RU https://pubmed.ncbi.nlm.nih.gov/10882361 DMSIGJW DI DMSIGJW DMSIGJW DN C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW TI TTD0CIQ DMSIGJW TN Melanocortin receptor 4 (MC4R) DMSIGJW MA Inhibitor DMSIGJW RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMSIGJW RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMSIGJW DI DMSIGJW DMSIGJW DN C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW TI TT0MV2T DMSIGJW TN Melanocortin receptor 1 (MC1R) DMSIGJW MA Inhibitor DMSIGJW RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMSIGJW RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMSIGJW DI DMSIGJW DMSIGJW DN C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW TI TTEOSZT DMSIGJW TN Melanocortin receptor (MCR) DMSIGJW MA Inhibitor DMSIGJW RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMSIGJW RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMSIGJW DI DMSIGJW DMSIGJW DN C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2 DMSIGJW TI TTNI91K DMSIGJW TN Melanocortin receptor 3 (MC3R) DMSIGJW MA Inhibitor DMSIGJW RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMSIGJW RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMSIJ17 DI DMSIJ17 DMSIJ17 DN 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine DMSIJ17 TI TTK25J1 DMSIJ17 TN Adenosine A1 receptor (ADORA1) DMSIJ17 MA Inhibitor DMSIJ17 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMSIJ17 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMSIJ17 DI DMSIJ17 DMSIJ17 DN 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine DMSIJ17 TI TTM2AOE DMSIJ17 TN Adenosine A2a receptor (ADORA2A) DMSIJ17 MA Inhibitor DMSIJ17 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMSIJ17 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMSIJ17 DI DMSIJ17 DMSIJ17 DN 2-(5-cyano-1-pent-1-ynyl)-N6-methoxyadenosine DMSIJ17 TI TTJFY5U DMSIJ17 TN Adenosine A3 receptor (ADORA3) DMSIJ17 MA Inhibitor DMSIJ17 RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMSIJ17 RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMSIMKZ DI DMSIMKZ DMSIMKZ DN PD-83176 DMSIMKZ TI TTX20QP DMSIMKZ TN Geranylgeranyl transferase I (GGTase-I) DMSIMKZ MA Inhibitor DMSIMKZ RN Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem. 1997 Jan 17;40(2):192-200. DMSIMKZ RU https://pubmed.ncbi.nlm.nih.gov/9003517 DMSIMKZ DI DMSIMKZ DMSIMKZ DN PD-83176 DMSIMKZ TI TT7WZIJ DMSIMKZ TN CAAX farnesyltransferase beta (FNTB) DMSIMKZ MA Inhibitor DMSIMKZ RN Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem. 1997 Jan 17;40(2):192-200. DMSIMKZ RU https://pubmed.ncbi.nlm.nih.gov/9003517 DMSIMKZ DI DMSIMKZ DMSIMKZ DN PD-83176 DMSIMKZ TI TTXQKM3 DMSIMKZ TN Farnesyl protein transferase (Ftase) DMSIMKZ MA Inhibitor DMSIMKZ RN Structure-activity relationships of cysteine-lacking pentapeptide derivatives that inhibit ras farnesyltransferase. J Med Chem. 1997 Jan 17;40(2):192-200. DMSIMKZ RU https://pubmed.ncbi.nlm.nih.gov/9003517 DMSIMNR DI DMSIMNR DMSIMNR DN N-hydroxy-8-(2-methoxyphenyl)-8-oxooctanamide DMSIMNR TI TT6R7JZ DMSIMNR TN Histone deacetylase 1 (HDAC1) DMSIMNR MA Inhibitor DMSIMNR RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMSIMNR RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMSINGH DI DMSINGH DMSINGH DN Imino sugars DMSINGH TI TTXWASR DMSINGH TN Intestinal maltase-glucoamylase (MGAM) DMSINGH MA Modulator DMSINGH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627). DMSINGH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627 DMSJ06G DI DMSJ06G DMSJ06G DN NSC-640566 DMSJ06G TI TTJLP0R DMSJ06G TN Quinone reductase 2 (NQO2) DMSJ06G MA Inhibitor DMSJ06G RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMSJ06G RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMSJ6T1 DI DMSJ6T1 DMSJ6T1 DN Neuromed 2 DMSJ6T1 TI TTXHYV6 DMSJ6T1 TN Voltage-gated L-type calcium channel (L-CaC) DMSJ6T1 MA Blocker DMSJ6T1 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMSJ6T1 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMSJ94N DI DMSJ94N DMSJ94N DN PMID2296036C4i DMSJ94N TI TTPADOQ DMSJ94N TN HMG-CoA reductase (HMGCR) DMSJ94N MA Inhibitor DMSJ94N RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 1. Lactones of pyridine- and pyrimidine-substituted 3,5-dihydroxy-6-heptenoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):52-60. DMSJ94N RU https://pubmed.ncbi.nlm.nih.gov/2296036 DMSJBEH DI DMSJBEH DMSJBEH DN 2,4,5-Triarylimidazole analogue DMSJBEH TI TTSJ6Q4 DMSJBEH TN LOX-5 messenger RNA (ALOX5 mRNA) DMSJBEH MA Inhibitor DMSJBEH RN 2,4,5- triarylimidazole inhibitors of IL-1 biosynthesis, Bioorg. Med. Chem. Lett. 5(11):1171-1176 (1995). DMSJBEH RU http://www.sciencedirect.com/science/article/pii/0960894X9500189Z DMSJCKN DI DMSJCKN DMSJCKN DN PKR-A DMSJCKN TI TTM67AX DMSJCKN TN Prokineticin receptor 2 (PKR2) DMSJCKN MA Antagonist DMSJCKN RN Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5475-80. DMSJCKN RU https://pubmed.ncbi.nlm.nih.gov/22431614 DMSJGA9 DI DMSJGA9 DMSJGA9 DN MCL-448 DMSJGA9 TI TTKWM86 DMSJGA9 TN Opioid receptor mu (MOP) DMSJGA9 MA Inhibitor DMSJGA9 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMSJGA9 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMSJGA9 DI DMSJGA9 DMSJGA9 DN MCL-448 DMSJGA9 TI TTQW87Y DMSJGA9 TN Opioid receptor kappa (OPRK1) DMSJGA9 MA Inhibitor DMSJGA9 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMSJGA9 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMSJGA9 DI DMSJGA9 DMSJGA9 DN MCL-448 DMSJGA9 TI TT27RFC DMSJGA9 TN Opioid receptor delta (OPRD1) DMSJGA9 MA Inhibitor DMSJGA9 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMSJGA9 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMSJGQE DI DMSJGQE DMSJGQE DN 3-(3-Carboxy-propionylamino)-benzoic acid DMSJGQE TI TT1RS9F DMSJGQE TN Acetylcholinesterase (AChE) DMSJGQE MA Inhibitor DMSJGQE RN Synthesis, anticholinesterase activity and structure-activity relationships of m-Aminobenzoic acid derivatives. Bioorg Med Chem Lett. 2003 May 19;13(10):1825-7. DMSJGQE RU https://pubmed.ncbi.nlm.nih.gov/12729674 DMSJLWP DI DMSJLWP DMSJLWP DN Ro 41-5253 DMSJLWP TI TTW38KT DMSJLWP TN Retinoic acid receptor alpha (RARA) DMSJLWP MA Antagonist DMSJLWP RN A retinoic acid receptor alpha antagonist selectively counteracts retinoic acid effects. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7129-33. DMSJLWP RU https://pubmed.ncbi.nlm.nih.gov/1323127 DMSJLX0 DI DMSJLX0 DMSJLX0 DN UBP-302 DMSJLX0 TI TT0MYE2 DMSJLX0 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMSJLX0 MA Inhibitor DMSJLX0 RN Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26. DMSJLX0 RU https://pubmed.ncbi.nlm.nih.gov/17004715 DMSJP6T DI DMSJP6T DMSJP6T DN 6-Furan-2-yl-9-phenyl-9H-purin-2-ylamine DMSJP6T TI TTM2AOE DMSJP6T TN Adenosine A2a receptor (ADORA2A) DMSJP6T MA Inhibitor DMSJP6T RN 6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists. Bioorg Med Chem Lett. 2005 Apr 15;15(8):2119-22. DMSJP6T RU https://pubmed.ncbi.nlm.nih.gov/15808481 DMSJUOH DI DMSJUOH DMSJUOH DN 3-Dimethylaminomethyl-1H-indol-4-ol DMSJUOH TI TT0K1SC DMSJUOH TN 5-HT 2B receptor (HTR2B) DMSJUOH MA Inhibitor DMSJUOH RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMSJUOH RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMSJUOH DI DMSJUOH DMSJUOH DN 3-Dimethylaminomethyl-1H-indol-4-ol DMSJUOH TI TTJQOD7 DMSJUOH TN 5-HT 2A receptor (HTR2A) DMSJUOH MA Inhibitor DMSJUOH RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMSJUOH RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMSJUOH DI DMSJUOH DMSJUOH DN 3-Dimethylaminomethyl-1H-indol-4-ol DMSJUOH TI TTWJBZ5 DMSJUOH TN 5-HT 2C receptor (HTR2C) DMSJUOH MA Inhibitor DMSJUOH RN SAR of psilocybin analogs: discovery of a selective 5-HT 2C agonist. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4555-9. DMSJUOH RU https://pubmed.ncbi.nlm.nih.gov/16061378 DMSJX1H DI DMSJX1H DMSJX1H DN N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide DMSJX1H TI TTVKILB DMSJX1H TN Prostaglandin G/H synthase 2 (COX-2) DMSJX1H MA Inhibitor DMSJX1H RN Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71. DMSJX1H RU https://pubmed.ncbi.nlm.nih.gov/19791801 DMSJX1H DI DMSJX1H DMSJX1H DN N-(3-(phenylthio)pyridin-4-yl)methanesulfonamide DMSJX1H TI TT8NGED DMSJX1H TN Prostaglandin G/H synthase 1 (COX-1) DMSJX1H MA Inhibitor DMSJX1H RN Pyridine analogues of nimesulide: design, synthesis, and in vitro and in vivo pharmacological evaluation as promising cyclooxygenase 1 and 2 inhibi... J Med Chem. 2009 Oct 8;52(19):5864-71. DMSJX1H RU https://pubmed.ncbi.nlm.nih.gov/19791801 DMSK0QX DI DMSK0QX DMSK0QX DN Meta-sirtinol DMSK0QX TI TTUF2HO DMSK0QX TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMSK0QX MA Inhibitor DMSK0QX RN Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95. DMSK0QX RU https://pubmed.ncbi.nlm.nih.gov/16302818 DMSK6EM DI DMSK6EM DMSK6EM DN 3-ethoxy-5-(2-methylquinolin-7-yl)benzonitrile DMSK6EM TI TTHS256 DMSK6EM TN Metabotropic glutamate receptor 5 (mGluR5) DMSK6EM MA Inhibitor DMSK6EM RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMSK6EM RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMSKE1I DI DMSKE1I DMSKE1I DN AC261066 DMSKE1I TI TTISP28 DMSKE1I TN Retinoic acid receptor beta (RARB) DMSKE1I MA Agonist DMSKE1I RN Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist. J Med Chem. 2005 Dec 1;48(24):7517-9. DMSKE1I RU https://pubmed.ncbi.nlm.nih.gov/16302793 DMSKGEJ DI DMSKGEJ DMSKGEJ DN PMID19289283C32 DMSKGEJ TI TTVBPDM DMSKGEJ TN Metabotropic glutamate receptor 1 (mGluR1) DMSKGEJ MA Modulator (allosteric modulator) DMSKGEJ RN In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. DMSKGEJ RU https://pubmed.ncbi.nlm.nih.gov/19289283 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TT7HF4W DMSKJ1X TN Cyclin-dependent kinase 2 (CDK2) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTAMQ62 DMSKJ1X TN Cyclin A2 (CCNA2) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TT4TQBX DMSKJ1X TN Extracellular signal-regulated kinase 2 (ERK2) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTER6YH DMSKJ1X TN Casein kinase II alpha (CSNK2A1) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTYVI76 DMSKJ1X TN Fungal Protein kinase A (Fung ypkA) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTW4Y2M DMSKJ1X TN cAMP protein kinase type II-beta (PRKAR2B) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TT1LVF2 DMSKJ1X TN Cyclin-dependent kinase 9 (CDK9) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTTU902 DMSKJ1X TN Checkpoint kinase-1 (CHK1) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTG0U4H DMSKJ1X TN Ribosomal protein S6 kinase beta-1 (S6K1) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTFCJ7S DMSKJ1X TN G1/S-specific cyclin-D1 (CCND1) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTCEJ4F DMSKJ1X TN G1/S-specific cyclin-E1 (CCNE1) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TT5U49F DMSKJ1X TN PRKACA messenger RNA (PRKACA mRNA) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTRSMW9 DMSKJ1X TN Glycogen synthase kinase-3 beta (GSK-3B) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TT3PJMV DMSKJ1X TN Tyrosine-protein kinase ABL1 (ABL) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTQBR95 DMSKJ1X TN Stress-activated protein kinase 2a (p38 alpha) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TTWTSCV DMSKJ1X TN RAC-alpha serine/threonine-protein kinase (AKT1) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ1X DI DMSKJ1X DMSKJ1X DN 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X TI TT0PG8F DMSKJ1X TN Cyclin-dependent kinase 4 (CDK4) DMSKJ1X MA Inhibitor DMSKJ1X RN 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9. DMSKJ1X RU https://pubmed.ncbi.nlm.nih.gov/17064068 DMSKJ53 DI DMSKJ53 DMSKJ53 DN PMID8709131C23 DMSKJ53 TI TTFQEO5 DMSKJ53 TN Squalene synthetase (FDFT1) DMSKJ53 MA Inhibitor DMSKJ53 RN Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9. DMSKJ53 RU https://pubmed.ncbi.nlm.nih.gov/8709131 DMSKNBA DI DMSKNBA DMSKNBA DN 2-Thiomorpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one DMSKNBA TI TTK3PY9 DMSKNBA TN DNA-dependent protein kinase catalytic (PRKDC) DMSKNBA MA Inhibitor DMSKNBA RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMSKNBA RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMSKT8G DI DMSKT8G DMSKT8G DN Cartazolate DMSKT8G TI TTJ0IQB DMSKT8G TN Phosphodiesterase 5A (PDE5A) DMSKT8G MA Inhibitor DMSKT8G RN Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. J Med Chem. 2001 Mar 29;44(7):1025-7. DMSKT8G RU https://pubmed.ncbi.nlm.nih.gov/11297448 DMSKTVW DI DMSKTVW DMSKTVW DN 8-(2-Ethyl-1-methyl-butoxy)-quinolin-2-ylamine DMSKTVW TI TTX4RTB DMSKTVW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMSKTVW MA Inhibitor DMSKTVW RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMSKTVW RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMSKU4M DI DMSKU4M DMSKU4M DN ETHOXYCOUMARIN DMSKU4M TI TTUNARX DMSKU4M TN Carbonic anhydrase (CA) DMSKU4M MA Inhibitor DMSKU4M RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMSKU4M RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMSKU4M DI DMSKU4M DMSKU4M DN ETHOXYCOUMARIN DMSKU4M TI TT2LVK8 DMSKU4M TN Carbonic anhydrase IX (CA-IX) DMSKU4M MA Inhibitor DMSKU4M RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMSKU4M RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMSKU4M DI DMSKU4M DMSKU4M DN ETHOXYCOUMARIN DMSKU4M TI TTEYTKG DMSKU4M TN Carbonic anhydrase XIV (CA-XIV) DMSKU4M MA Inhibitor DMSKU4M RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMSKU4M RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMSKU4M DI DMSKU4M DMSKU4M DN ETHOXYCOUMARIN DMSKU4M TI TTSYM0R DMSKU4M TN Carbonic anhydrase XII (CA-XII) DMSKU4M MA Inhibitor DMSKU4M RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMSKU4M RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMSKVWG DI DMSKVWG DMSKVWG DN ISIS 29201 DMSKVWG TI TTO6SGY DMSKVWG TN AKT3 messenger RNA (AKT3 mRNA) DMSKVWG RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMSKVWG RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMSKW8H DI DMSKW8H DMSKW8H DN C[YYDEGLEE]-NH2 DMSKW8H TI TT1VAUK DMSKW8H TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMSKW8H MA Inhibitor DMSKW8H RN Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem. 2010 Jun 10;53(11):4428-40. DMSKW8H RU https://pubmed.ncbi.nlm.nih.gov/20462213 DMSKWL7 DI DMSKWL7 DMSKWL7 DN MRS1088 DMSKWL7 TI TTJFY5U DMSKWL7 TN Adenosine A3 receptor (ADORA3) DMSKWL7 MA Antagonist DMSKWL7 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMSKWL7 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMSKWL7 DI DMSKWL7 DMSKWL7 DN MRS1088 DMSKWL7 TI TTNE7KG DMSKWL7 TN Adenosine A2b receptor (ADORA2B) DMSKWL7 MA Antagonist DMSKWL7 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMSKWL7 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMSL2CM DI DMSL2CM DMSL2CM DN Ribavirin + interferon alfa-2a DMSL2CM TI TTOA6YT DMSL2CM TN MERS-CoV RNA-directed RNA polymerase (RdRp) DMSL2CM MA Inhibitor DMSL2CM RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMSL2CM RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMSL4FQ DI DMSL4FQ DMSL4FQ DN CFGGFTCARKSARK DMSL4FQ TI TTNT7K8 DMSL4FQ TN Nociceptin receptor (OPRL1) DMSL4FQ MA Inhibitor DMSL4FQ RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DMSL4FQ RU https://pubmed.ncbi.nlm.nih.gov/11689089 DMSLA8X DI DMSLA8X DMSLA8X DN NSFQ-105 DMSLA8X TI TTN6J5F DMSLA8X TN Bacterial DNA gyrase (Bact gyrase) DMSLA8X MA Modulator DMSLA8X RN Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target i... Antimicrob Agents Chemother. 2000 Feb;44(2):320-5. DMSLA8X RU https://www.ncbi.nlm.nih.gov/pubmed/10639357 DMSLA8X DI DMSLA8X DMSLA8X DN NSFQ-105 DMSLA8X TI TTIXTO3 DMSLA8X TN Staphylococcus Topoisomerase IV (Stap-coc parC) DMSLA8X MA Modulator DMSLA8X RN Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target i... Antimicrob Agents Chemother. 2000 Feb;44(2):320-5. DMSLA8X RU https://www.ncbi.nlm.nih.gov/pubmed/10639357 DMSLHDN DI DMSLHDN DMSLHDN DN EM-1424 DMSLHDN TI TT5ZWB6 DMSLHDN TN Dihydrodiol dehydrogenase type I (AKR1C3) DMSLHDN MA Inhibitor DMSLHDN RN Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem. 2007 Mar 16;282(11):8368-79. DMSLHDN RU https://pubmed.ncbi.nlm.nih.gov/17166832 DMSLMAN DI DMSLMAN DMSLMAN DN 2-isopropyl-9H-carbazole DMSLMAN TI TTBGTCW DMSLMAN TN Kinesin spindle messenger RNA (KIF11 mRNA) DMSLMAN MA Inhibitor DMSLMAN RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMSLMAN RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMSLNWA DI DMSLNWA DMSLNWA DN WAY-255348 DMSLNWA TI TTUV8G9 DMSLNWA TN Progesterone receptor (PGR) DMSLNWA MA Inhibitor DMSLNWA RN Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73. DMSLNWA RU https://pubmed.ncbi.nlm.nih.gov/18318463 DMSLNWA DI DMSLNWA DMSLNWA DN WAY-255348 DMSLNWA TI TTKPW01 DMSLNWA TN Androgen receptor messenger RNA (AR mRNA) DMSLNWA MA Inhibitor DMSLNWA RN Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73. DMSLNWA RU https://pubmed.ncbi.nlm.nih.gov/18318463 DMSLNWA DI DMSLNWA DMSLNWA DN WAY-255348 DMSLNWA TI TT26PHO DMSLNWA TN Mineralocorticoid receptor (MR) DMSLNWA MA Inhibitor DMSLNWA RN Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-... J Med Chem. 2008 Mar 27;51(6):1861-73. DMSLNWA RU https://pubmed.ncbi.nlm.nih.gov/18318463 DMSLO71 DI DMSLO71 DMSLO71 DN Isoelaeocarpine DMSLO71 TI TT27RFC DMSLO71 TN Opioid receptor delta (OPRD1) DMSLO71 MA Inhibitor DMSLO71 RN Indolizidine alkaloids with delta-opioid receptor binding affinity from the leaves of Elaeocarpus fuscoides. J Nat Prod. 2007 May;70(5):872-5. DMSLO71 RU https://pubmed.ncbi.nlm.nih.gov/17451272 DMSLOKM DI DMSLOKM DMSLOKM DN ISIS 110068 DMSLOKM TI TTK1V5Q DMSLOKM TN Nucleolin messenger RNA (NCL mRNA) DMSLOKM RN US patent application no. 6,165,786, Antisense modulation of nucleolin expression. DMSLOKM RU http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true DMSLPGZ DI DMSLPGZ DMSLPGZ DN 3-Isopropyl-3-methyl-dihydro-furan-2-one DMSLPGZ TI TT1MPAY DMSLPGZ TN GABA(A) receptor alpha-1 (GABRA1) DMSLPGZ MA Inhibitor DMSLPGZ RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMSLPGZ RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMSLPGZ DI DMSLPGZ DMSLPGZ DN 3-Isopropyl-3-methyl-dihydro-furan-2-one DMSLPGZ TI TTZA1NY DMSLPGZ TN GABA(A) receptor beta-2 (GABRB2) DMSLPGZ MA Inhibitor DMSLPGZ RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMSLPGZ RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMSLPGZ DI DMSLPGZ DMSLPGZ DN 3-Isopropyl-3-methyl-dihydro-furan-2-one DMSLPGZ TI TTNJYV2 DMSLPGZ TN Gamma-aminobutyric acid receptor (GAR) DMSLPGZ MA Inhibitor DMSLPGZ RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMSLPGZ RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMSLPGZ DI DMSLPGZ DMSLPGZ DN 3-Isopropyl-3-methyl-dihydro-furan-2-one DMSLPGZ TI TT06RH5 DMSLPGZ TN GABA(A) receptor gamma-2 (GABRG2) DMSLPGZ MA Inhibitor DMSLPGZ RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMSLPGZ RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMSLT3I DI DMSLT3I DMSLT3I DN 6-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine DMSLT3I TI TTF10I9 DMSLT3I TN Nitric-oxide synthase inducible (NOS2) DMSLT3I MA Inhibitor DMSLT3I RN Synthesis of biflavones having a 6-O-7'' linkage and effects on cyclooxygenase-2 and inducible nitric oxide synthase. Bioorg Med Chem Lett. 2009 Jan 1;19(1):74-6. DMSLT3I RU https://pubmed.ncbi.nlm.nih.gov/19041241 DMSLWBI DI DMSLWBI DMSLWBI DN PMID30247903-Compound-General structure31 DMSLWBI TI TT23XQV DMSLWBI TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMSLWBI MA Inhibitor DMSLWBI RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMSLWBI RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMSLYHQ DI DMSLYHQ DMSLYHQ DN C(his-D-phe-arg-trp-Abu) DMSLYHQ TI TTD0CIQ DMSLYHQ TN Melanocortin receptor 4 (MC4R) DMSLYHQ MA Inhibitor DMSLYHQ RN Design of cyclic peptides with agonist activity at melanocortin receptor-4. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3723-6. DMSLYHQ RU https://pubmed.ncbi.nlm.nih.gov/16678415 DMSM0QV DI DMSM0QV DMSM0QV DN 6,7-Dimethoxy-3-((E)-styryl)-quinoline DMSM0QV TI TTI7421 DMSM0QV TN Platelet-derived growth factor receptor beta (PDGFRB) DMSM0QV MA Inhibitor DMSM0QV RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMSM0QV RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMSM0QV DI DMSM0QV DMSM0QV DN 6,7-Dimethoxy-3-((E)-styryl)-quinoline DMSM0QV TI TT8FYO9 DMSM0QV TN Platelet-derived growth factor receptor alpha (PDGFRA) DMSM0QV MA Inhibitor DMSM0QV RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMSM0QV RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMSM1PV DI DMSM1PV DMSM1PV DN ARC-069 DMSM1PV TI TTE4KHA DMSM1PV TN Amyloid beta A4 protein (APP) DMSM1PV MA Inhibitor DMSM1PV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMSM1PV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMSMDQC DI DMSMDQC DMSMDQC DN 2-fluorophenyl 4-phenoxyphenylcarbamate DMSMDQC TI TTDP1UC DMSMDQC TN Fatty acid amide hydrolase (FAAH) DMSMDQC MA Inhibitor DMSMDQC RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMSMDQC RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMSMH6T DI DMSMH6T DMSMH6T DN Cyclo[Cys6,Cys10]N/OFQ(1-13)NH2 DMSMH6T TI TTNT7K8 DMSMH6T TN Nociceptin receptor (OPRL1) DMSMH6T MA Inhibitor DMSMH6T RN High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7. DMSMH6T RU https://pubmed.ncbi.nlm.nih.gov/18624395 DMSMJ37 DI DMSMJ37 DMSMJ37 DN ISIS 100749 DMSMJ37 TI TTVXEGU DMSMJ37 TN ADAM10 messenger RNA (ADAM10 mRNA) DMSMJ37 RN US patent application no. 6,228,648, Antisense modulation of ADAM10 expression. DMSMJ37 RU http://www.patentbuddy.com/Patent/6228648?ft=true&sr=true DMSMK70 DI DMSMK70 DMSMK70 DN FGGFTGARKSARKLARK DMSMK70 TI TTNT7K8 DMSMK70 TN Nociceptin receptor (OPRL1) DMSMK70 MA Inhibitor DMSMK70 RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMSMK70 RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMSMLRB DI DMSMLRB DMSMLRB DN Teijin-lead_cmp_5 DMSMLRB TI TTFZYTO DMSMLRB TN C-C chemokine receptor type 2 (CCR2) DMSMLRB MA Antagonist DMSMLRB RN CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach. J Med Chem. 2003 Sep 11;46(19):4070-86. DMSMLRB RU https://pubmed.ncbi.nlm.nih.gov/12954060 DMSMQE7 DI DMSMQE7 DMSMQE7 DN TMP269 DMSMQE7 TI TTUELN5 DMSMQE7 TN Histone deacetylase 5 (HDAC5) DMSMQE7 MA Inhibitor DMSMQE7 RN Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. DMSMQE7 RU https://pubmed.ncbi.nlm.nih.gov/23524983 DMSMQE7 DI DMSMQE7 DMSMQE7 DN TMP269 DMSMQE7 TI TTMUEK1 DMSMQE7 TN Histone deacetylase 7 (HDAC7) DMSMQE7 MA Inhibitor DMSMQE7 RN Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. DMSMQE7 RU https://pubmed.ncbi.nlm.nih.gov/23524983 DMSMQE7 DI DMSMQE7 DMSMQE7 DN TMP269 DMSMQE7 TI TT8M4E1 DMSMQE7 TN Histone deacetylase 9 (HDAC9) DMSMQE7 MA Inhibitor DMSMQE7 RN Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. DMSMQE7 RU https://pubmed.ncbi.nlm.nih.gov/23524983 DMSMQE7 DI DMSMQE7 DMSMQE7 DN TMP269 DMSMQE7 TI TTTQGH8 DMSMQE7 TN Histone deacetylase 4 (HDAC4) DMSMQE7 MA Inhibitor DMSMQE7 RN Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. DMSMQE7 RU https://pubmed.ncbi.nlm.nih.gov/23524983 DMSMQXZ DI DMSMQXZ DMSMQXZ DN Qcpac DMSMQXZ TI TT2UE56 DMSMQXZ TN Sodium/glucose cotransporter 1 (SGLT1) DMSMQXZ MA Inhibitor DMSMQXZ RN Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13. DMSMQXZ RU https://pubmed.ncbi.nlm.nih.gov/17686765 DMSMRF9 DI DMSMRF9 DMSMRF9 DN N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide DMSMRF9 TI TTQBR95 DMSMRF9 TN Stress-activated protein kinase 2a (p38 alpha) DMSMRF9 MA Inhibitor DMSMRF9 RN Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9. DMSMRF9 RU https://pubmed.ncbi.nlm.nih.gov/16169718 DMSMVCH DI DMSMVCH DMSMVCH DN 1,2-bis(2,6-difluorophenyl)-2-hydroxyethanone DMSMVCH TI TTMF541 DMSMVCH TN Liver carboxylesterase (CES1) DMSMVCH MA Inhibitor DMSMVCH RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMSMVCH RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMSMVK4 DI DMSMVK4 DMSMVK4 DN Ac-WVTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 DMSMVK4 TI TTVSFJW DMSMVK4 TN Calcitonin gene-related peptide 1 (CALCA) DMSMVK4 MA Inhibitor DMSMVK4 RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMSMVK4 RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMSN0ZE DI DMSN0ZE DMSN0ZE DN 8-Methoxy-2-(4-nitro-phenyl)-3H-quinazolin-4-one DMSN0ZE TI TTVDSZ0 DMSN0ZE TN Poly [ADP-ribose] polymerase 1 (PARP1) DMSN0ZE MA Inhibitor DMSN0ZE RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMSN0ZE RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMSN7GJ DI DMSN7GJ DMSN7GJ DN (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid DMSN7GJ TI TTHY57M DMSN7GJ TN Matrix metalloproteinase-13 (MMP-13) DMSN7GJ MA Inhibitor DMSN7GJ RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMSN7GJ RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMSN7GJ DI DMSN7GJ DMSN7GJ DN (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid DMSN7GJ TI TTXZ0KQ DMSN7GJ TN Matrix metalloproteinase-12 (MMP-12) DMSN7GJ MA Inhibitor DMSN7GJ RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMSN7GJ RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMSN7GJ DI DMSN7GJ DMSN7GJ DN (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid DMSN7GJ TI TT6X50U DMSN7GJ TN Matrix metalloproteinase-9 (MMP-9) DMSN7GJ MA Inhibitor DMSN7GJ RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMSN7GJ RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMSN7GJ DI DMSN7GJ DMSN7GJ DN (+/-)5-(biphenyl-4-yl)-3-hydroxypentanoic acid DMSN7GJ TI TTLM12X DMSN7GJ TN Matrix metalloproteinase-2 (MMP-2) DMSN7GJ MA Inhibitor DMSN7GJ RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMSN7GJ RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMSN814 DI DMSN814 DMSN814 DN 3,4,4',5-tetramethoxy-(Z)-stilbene DMSN814 TI TTYFKSZ DMSN814 TN Tubulin beta (TUBB) DMSN814 MA Inhibitor DMSN814 RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMSN814 RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMSN814 DI DMSN814 DMSN814 DN 3,4,4',5-tetramethoxy-(Z)-stilbene DMSN814 TI TTJ2PTI DMSN814 TN Tubulin beta-2 chain (TUBB2) DMSN814 MA Inhibitor DMSN814 RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMSN814 RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMSN87T DI DMSN87T DMSN87T DN Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 DMSN87T TI TTQW87Y DMSN87T TN Opioid receptor kappa (OPRK1) DMSN87T MA Inhibitor DMSN87T RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DMSN87T RU https://pubmed.ncbi.nlm.nih.gov/16913729 DMSN87T DI DMSN87T DMSN87T DN Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 DMSN87T TI TT27RFC DMSN87T TN Opioid receptor delta (OPRD1) DMSN87T MA Inhibitor DMSN87T RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DMSN87T RU https://pubmed.ncbi.nlm.nih.gov/16913729 DMSN87T DI DMSN87T DMSN87T DN Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 DMSN87T TI TTKWM86 DMSN87T TN Opioid receptor mu (MOP) DMSN87T MA Inhibitor DMSN87T RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DMSN87T RU https://pubmed.ncbi.nlm.nih.gov/16913729 DMSNBMQ DI DMSNBMQ DMSNBMQ DN ATH-90879 DMSNBMQ TI TT9JNIC DMSNBMQ TN Histamine H3 receptor (H3R) DMSNBMQ MA Antagonist DMSNBMQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DMSNBMQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DMSNCOW DI DMSNCOW DMSNCOW DN 2-(benzyloxyamino)-N-hydroxy-3-methylpentanamide DMSNCOW TI TT2LVK8 DMSNCOW TN Carbonic anhydrase IX (CA-IX) DMSNCOW MA Inhibitor DMSNCOW RN Carbonic anhydrase and matrix metalloproteinase inhibitors. Inhibition of human tumor-associated isozymes IX and cytosolic isozyme I and II with su... Bioorg Med Chem. 2007 Mar 15;15(6):2298-311. DMSNCOW RU https://pubmed.ncbi.nlm.nih.gov/17276072 DMSND8U DI DMSND8U DMSND8U DN 2-(2,4-difluorophenyl)-2,2-diphenylacetamide DMSND8U TI TTMNI76 DMSND8U TN Calcium-activated potassium channel (KCN) DMSND8U MA Inhibitor DMSND8U RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMSND8U RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMSNF7W DI DMSNF7W DMSNF7W DN N-(3-Phenyl)propyl-2-(4-bromophenylacetamide) DMSNF7W TI TT6OEDT DMSNF7W TN Cannabinoid receptor 1 (CB1) DMSNF7W MA Inhibitor DMSNF7W RN Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5. DMSNF7W RU https://pubmed.ncbi.nlm.nih.gov/18579386 DMSNF7W DI DMSNF7W DMSNF7W DN N-(3-Phenyl)propyl-2-(4-bromophenylacetamide) DMSNF7W TI TTMSFAW DMSNF7W TN Cannabinoid receptor 2 (CB2) DMSNF7W MA Inhibitor DMSNF7W RN Novel sterically hindered cannabinoid CB1 receptor ligands. Bioorg Med Chem. 2008 Aug 1;16(15):7510-5. DMSNF7W RU https://pubmed.ncbi.nlm.nih.gov/18579386 DMSNG7M DI DMSNG7M DMSNG7M DN 8-amino-9-benzylguanine DMSNG7M TI TTMCF1Y DMSNG7M TN Purine nucleoside phosphorylase (PNP) DMSNG7M MA Inhibitor DMSNG7M RN Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. J Biol Chem. 1986 Sep 5;261(25):11667-73. DMSNG7M RU https://pubmed.ncbi.nlm.nih.gov/3091593 DMSNIBO DI DMSNIBO DMSNIBO DN Phenyl 1-(4-butoxyphenyl)propylcarbamate DMSNIBO TI TTDP1UC DMSNIBO TN Fatty acid amide hydrolase (FAAH) DMSNIBO MA Inhibitor DMSNIBO RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMSNIBO RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMSNK98 DI DMSNK98 DMSNK98 DN 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione DMSNK98 TI TTNE7KG DMSNK98 TN Adenosine A2b receptor (ADORA2B) DMSNK98 MA Inhibitor DMSNK98 RN Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43. DMSNK98 RU https://pubmed.ncbi.nlm.nih.gov/14761205 DMSNK98 DI DMSNK98 DMSNK98 DN 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione DMSNK98 TI TTM2AOE DMSNK98 TN Adenosine A2a receptor (ADORA2A) DMSNK98 MA Inhibitor DMSNK98 RN Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43. DMSNK98 RU https://pubmed.ncbi.nlm.nih.gov/14761205 DMSNK98 DI DMSNK98 DMSNK98 DN 1-Butyl-8-phenyl-3,7-dihydro-purine-2,6-dione DMSNK98 TI TTK25J1 DMSNK98 TN Adenosine A1 receptor (ADORA1) DMSNK98 MA Inhibitor DMSNK98 RN Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43. DMSNK98 RU https://pubmed.ncbi.nlm.nih.gov/14761205 DMSNLFJ DI DMSNLFJ DMSNLFJ DN JWH-366 DMSNLFJ TI TTMSFAW DMSNLFJ TN Cannabinoid receptor 2 (CB2) DMSNLFJ MA Inhibitor DMSNLFJ RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMSNLFJ RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMSNLFJ DI DMSNLFJ DMSNLFJ DN JWH-366 DMSNLFJ TI TT6OEDT DMSNLFJ TN Cannabinoid receptor 1 (CB1) DMSNLFJ MA Inhibitor DMSNLFJ RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMSNLFJ RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMSNM5O DI DMSNM5O DMSNM5O DN ES-6864 DMSNM5O TI TTB2MXP DMSNM5O TN Angiotensinogenase renin (REN) DMSNM5O MA Inhibitor DMSNM5O RN A highly potent and long-acting oral inhibitor of human renin. Hypertension. 1988 Jun;11(6 Pt 2):708-12. DMSNM5O RU https://pubmed.ncbi.nlm.nih.gov/3134306 DMSNVKP DI DMSNVKP DMSNVKP DN CP 93129 DMSNVKP TI TTSQIFT DMSNVKP TN 5-HT 1A receptor (HTR1A) DMSNVKP MA Agonist DMSNVKP RN Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):682-8. DMSNVKP RU https://pubmed.ncbi.nlm.nih.gov/9205951 DMSNWA6 DI DMSNWA6 DMSNWA6 DN (+/-)-5-amino-2-(mercaptomethyl)pentanoic acid DMSNWA6 TI TTP18AY DMSNWA6 TN Carboxypeptidase B2 (CPB2) DMSNWA6 MA Inhibitor DMSNWA6 RN Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem. 2007 Nov 29;50(24):6095-103. DMSNWA6 RU https://pubmed.ncbi.nlm.nih.gov/17990866 DMSNZV1 DI DMSNZV1 DMSNZV1 DN N-(4-bromo-2-methylphenyl)-2-naphthamide DMSNZV1 TI TT3PQ2Y DMSNZV1 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMSNZV1 MA Inhibitor DMSNZV1 RN Design and synthesis of potent inhibitors of the malaria parasite dihydroorotate dehydrogenase. J Med Chem. 2007 Jan 25;50(2):186-91. DMSNZV1 RU https://pubmed.ncbi.nlm.nih.gov/17228860 DMSO215 DI DMSO215 DMSO215 DN NSC-645831 DMSO215 TI TTJLP0R DMSO215 TN Quinone reductase 2 (NQO2) DMSO215 MA Inhibitor DMSO215 RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMSO215 RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMSO2JW DI DMSO2JW DMSO2JW DN 6-(4-chlorophenyl)-2-morpholin-4-ylpyridin-4-ol DMSO2JW TI TTK3PY9 DMSO2JW TN DNA-dependent protein kinase catalytic (PRKDC) DMSO2JW MA Inhibitor DMSO2JW RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMSO2JW RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMSO3HM DI DMSO3HM DMSO3HM DN PDGF gene therapy DMSO3HM TI TTI2WET DMSO3HM TN Platelet-derived growth factor receptor (PDGFR) DMSO3HM MA Activator DMSO3HM RN Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. DMSO3HM RU https://pubmed.ncbi.nlm.nih.gov/17064227 DMSO7FW DI DMSO7FW DMSO7FW DN N-(Biphenyl-4-yl)-2-cyano-3-hydroxybut-2-enamide DMSO7FW TI TT3PQ2Y DMSO7FW TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMSO7FW MA Inhibitor DMSO7FW RN Structure-based design, synthesis, and characterization of inhibitors of human and Plasmodium falciparum dihydroorotate dehydrogenases. J Med Chem. 2009 May 14;52(9):2683-93. DMSO7FW RU https://pubmed.ncbi.nlm.nih.gov/19351152 DMSOB3U DI DMSOB3U DMSOB3U DN KH-CB19 DMSOB3U TI TTQPE1U DMSOB3U TN CDC-like kinase 3 (CLK3) DMSOB3U MA Inhibitor DMSOB3U RN Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. DMSOB3U RU https://pubmed.ncbi.nlm.nih.gov/21276940 DMSOB3U DI DMSOB3U DMSOB3U DN KH-CB19 DMSOB3U TI TTE6YDG DMSOB3U TN CDC-like kinase 1 (CLK1) DMSOB3U MA Inhibitor DMSOB3U RN Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. DMSOB3U RU https://pubmed.ncbi.nlm.nih.gov/21276940 DMSOB3U DI DMSOB3U DMSOB3U DN KH-CB19 DMSOB3U TI TTSBVFO DMSOB3U TN Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A) DMSOB3U MA Inhibitor DMSOB3U RN Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol. 2011 Jan 28;18(1):67-76. DMSOB3U RU https://pubmed.ncbi.nlm.nih.gov/21276940 DMSOJ6H DI DMSOJ6H DMSOJ6H DN ALLICIN DMSOJ6H TI TT2SUAQ DMSOJ6H TN Cysteine protease (CYP) DMSOJ6H MA Inhibitor DMSOJ6H RN Allicin and derivates are cysteine protease inhibitors with antiparasitic activity. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5541-3. DMSOJ6H RU https://pubmed.ncbi.nlm.nih.gov/20692829 DMSON1P DI DMSON1P DMSON1P DN D17.4 DMSON1P TI TTYJQTF DMSON1P TN Immunoglobulin E (IgE) DMSON1P RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMSON1P RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMSORHA DI DMSORHA DMSORHA DN N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP DMSORHA TI TTEB0GD DMSORHA TN Cholinesterase (BCHE) DMSORHA MA Inhibitor DMSORHA RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMSORHA RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMSORHA DI DMSORHA DMSORHA DN N,N'-(1',7'-heptylene)-bis-(-)-nor-MEP DMSORHA TI TT1RS9F DMSORHA TN Acetylcholinesterase (AChE) DMSORHA MA Inhibitor DMSORHA RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMSORHA RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMSOUI0 DI DMSOUI0 DMSOUI0 DN AG 9 DMSOUI0 TI TTGKNB4 DMSOUI0 TN Epidermal growth factor receptor (EGFR) DMSOUI0 MA Inhibitor DMSOUI0 RN Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52. DMSOUI0 RU https://pubmed.ncbi.nlm.nih.gov/2552117 DMSOVFD DI DMSOVFD DMSOVFD DN adenosine-3'-5'-bisphosphate DMSOVFD TI TTA93TL DMSOVFD TN P2Y purinoceptor 1 (P2RY1) DMSOVFD MA Antagonist DMSOVFD RN Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol. 1996 Nov;50(5):1323-9. DMSOVFD RU https://pubmed.ncbi.nlm.nih.gov/8913364 DMSOWPE DI DMSOWPE DMSOWPE DN GSK-894281 DMSOWPE TI TTWDC17 DMSOWPE TN Growth hormone secretagogue receptor 1 (GHSR) DMSOWPE MA Agonist DMSOWPE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246). DMSOWPE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246 DMSP4N5 DI DMSP4N5 DMSP4N5 DN 3-(1,8-naphthyridin-2-yl)benzonitrile DMSP4N5 TI TTHS256 DMSP4N5 TN Metabotropic glutamate receptor 5 (mGluR5) DMSP4N5 MA Inhibitor DMSP4N5 RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMSP4N5 RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMSP56N DI DMSP56N DMSP56N DN trihydroxycholestane DMSP56N TI TT7LCTF DMSP56N TN Pregnane X receptor (NR1I2) DMSP56N MA Agonist DMSP56N RN Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):223-8. DMSP56N RU https://pubmed.ncbi.nlm.nih.gov/12509506 DMSP7V8 DI DMSP7V8 DMSP7V8 DN GLAUCINE DMSP7V8 TI TTEX248 DMSP7V8 TN Dopamine D2 receptor (D2R) DMSP7V8 MA Inhibitor DMSP7V8 RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMSP7V8 RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMSP7V8 DI DMSP7V8 DMSP7V8 DN GLAUCINE DMSP7V8 TI TTZFYLI DMSP7V8 TN Dopamine D1 receptor (D1R) DMSP7V8 MA Inhibitor DMSP7V8 RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMSP7V8 RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMSPH30 DI DMSPH30 DMSPH30 DN PRX-111 DMSPH30 TI TTZFDBT DMSPH30 TN Follicle-stimulating hormone receptor (FSHR) DMSPH30 MA Modulator DMSPH30 RN A naturally occurring basically charged human follicle-stimulating hormone (FSH) variant inhibits FSH-induced androgen aromatization and tissue-type plasminogen activator enzyme activity in vitro. Neuroendocrinology. 1998 Mar;67(3):153-63. DMSPH30 RU https://pubmed.ncbi.nlm.nih.gov/9630432 DMSPIF2 DI DMSPIF2 DMSPIF2 DN EP 157 DMSPIF2 TI TTOFYT1 DMSPIF2 TN Prostacyclin receptor (PTGIR) DMSPIF2 MA Agonist DMSPIF2 RN Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics. Br J Pharmacol. 1986 Mar;87(3):543-51. DMSPIF2 RU https://pubmed.ncbi.nlm.nih.gov/3026540 DMSPKWD DI DMSPKWD DMSPKWD DN Cyclo(-D-Tyr-L-Arg-L-MeArg-L-Nal-Gly-) DMSPKWD TI TTBID49 DMSPKWD TN C-X-C chemokine receptor type 4 (CXCR4) DMSPKWD MA Inhibitor DMSPKWD RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMSPKWD RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMSPLYF DI DMSPLYF DMSPLYF DN 7alpha-NHMe-ginkgolide B DMSPLYF TI TTQL5VC DMSPLYF TN Platelet-activating factor receptor (PTAFR) DMSPLYF MA Antagonist DMSPLYF RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMSPLYF RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMSPMHE DI DMSPMHE DMSPMHE DN [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine DMSPMHE TI TT4C8EA DMSPMHE TN Dopamine D3 receptor (D3R) DMSPMHE MA Inhibitor DMSPMHE RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMSPMHE RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMSPMHE DI DMSPMHE DMSPMHE DN [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine DMSPMHE TI TTEX248 DMSPMHE TN Dopamine D2 receptor (D2R) DMSPMHE MA Inhibitor DMSPMHE RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMSPMHE RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMSPMHE DI DMSPMHE DMSPMHE DN [2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine DMSPMHE TI TTE0A2F DMSPMHE TN Dopamine D4 receptor (D4R) DMSPMHE MA Inhibitor DMSPMHE RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMSPMHE RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMSPOAT DI DMSPOAT DMSPOAT DN 2-(4-Phenoxy-phenyl)-1H-benzoimidazol-5-ylamine DMSPOAT TI TT9ABMF DMSPOAT TN Serine/threonine-protein kinase Chk2 (RAD53) DMSPOAT MA Inhibitor DMSPOAT RN Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. DMSPOAT RU https://pubmed.ncbi.nlm.nih.gov/15771432 DMSPQYV DI DMSPQYV DMSPQYV DN NSC-745798 DMSPQYV TI TTQY2EJ DMSPQYV TN TERT messenger RNA (TERT mRNA) DMSPQYV MA Inhibitor DMSPQYV RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMSPQYV RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMSPVLM DI DMSPVLM DMSPVLM DN dynorphin B DMSPVLM TI TTQW87Y DMSPVLM TN Opioid receptor kappa (OPRK1) DMSPVLM MA Agonist DMSPVLM RN Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6736-40. DMSPVLM RU https://pubmed.ncbi.nlm.nih.gov/8393575 DMSPVLM DI DMSPVLM DMSPVLM DN dynorphin B DMSPVLM TI TT27RFC DMSPVLM TN Opioid receptor delta (OPRD1) DMSPVLM MA Agonist DMSPVLM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMSPVLM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMSPVLM DI DMSPVLM DMSPVLM DN dynorphin B DMSPVLM TI TTKWM86 DMSPVLM TN Opioid receptor mu (MOP) DMSPVLM MA Agonist DMSPVLM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMSPVLM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMSPVXM DI DMSPVXM DMSPVXM DN 5-Propyl-1H-pyrazole-3-carboxylic acid DMSPVXM TI TTWNV8U DMSPVXM TN Nicotinic acid receptor (HCAR2) DMSPVXM MA Inhibitor DMSPVXM RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMSPVXM RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMSQ10I DI DMSQ10I DMSQ10I DN PHASEOLLIDIN DMSQ10I TI TT50QJ3 DMSQ10I TN Influenza Neuraminidase (Influ NA) DMSQ10I MA Inhibitor DMSQ10I RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMSQ10I RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMSQ3I9 DI DMSQ3I9 DMSQ3I9 DN Factor IX-XTEN DMSQ3I9 TI TTFEZ5Q DMSQ3I9 TN Coagulation factor IX (F9) DMSQ3I9 MA Modulator DMSQ3I9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364). DMSQ3I9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364 DMSQ49N DI DMSQ49N DMSQ49N DN AMG-JAK2-01 DMSQ49N TI TTRMX3V DMSQ49N TN Janus kinase 2 (JAK-2) DMSQ49N MA Inhibitor DMSQ49N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). DMSQ49N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048 DMSQ4TL DI DMSQ4TL DMSQ4TL DN NNC 11-1314 DMSQ4TL TI TTOXS3C DMSQ4TL TN Muscarinic acetylcholine receptor (CHRM) DMSQ4TL MA Agonist DMSQ4TL RN Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8. DMSQ4TL RU https://pubmed.ncbi.nlm.nih.gov/11504829 DMSQ4TL DI DMSQ4TL DMSQ4TL DN NNC 11-1314 DMSQ4TL TI TTQ13Z5 DMSQ4TL TN Muscarinic acetylcholine receptor M3 (CHRM3) DMSQ4TL MA Agonist DMSQ4TL RN Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8. DMSQ4TL RU https://pubmed.ncbi.nlm.nih.gov/11504829 DMSQ538 DI DMSQ538 DMSQ538 DN Isosorbide-2-benzylcarbamate-5-pentanoate DMSQ538 TI TTEB0GD DMSQ538 TN Cholinesterase (BCHE) DMSQ538 MA Inhibitor DMSQ538 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMSQ538 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMSQ6CV DI DMSQ6CV DMSQ6CV DN FR260010 DMSQ6CV TI TTWJBZ5 DMSQ6CV TN 5-HT 2C receptor (HTR2C) DMSQ6CV MA Antagonist DMSQ6CV RN Anxiolytic activity of a novel potent serotonin 5-HT2C receptor antagonist FR260010: a comparison with diazepam and buspirone. Eur J Pharmacol. 2006 Dec 28;553(1-3):171-84. DMSQ6CV RU https://pubmed.ncbi.nlm.nih.gov/17074317 DMSQEXP DI DMSQEXP DMSQEXP DN N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide DMSQEXP TI TTHQPL7 DMSQEXP TN Carbonic anhydrase I (CA-I) DMSQEXP MA Inhibitor DMSQEXP RN Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52. DMSQEXP RU https://pubmed.ncbi.nlm.nih.gov/15837323 DMSQEXP DI DMSQEXP DMSQEXP DN N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide DMSQEXP TI TTANPDJ DMSQEXP TN Carbonic anhydrase II (CA-II) DMSQEXP MA Inhibitor DMSQEXP RN Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52. DMSQEXP RU https://pubmed.ncbi.nlm.nih.gov/15837323 DMSQEXP DI DMSQEXP DMSQEXP DN N-(5-Mercapto-[1,3,4]thiadiazol-2-yl)-acetamide DMSQEXP TI TT2LVK8 DMSQEXP TN Carbonic anhydrase IX (CA-IX) DMSQEXP MA Inhibitor DMSQEXP RN Carbonic anhydrase inhibitors. Inhibition of the cytosolic and tumor-associated carbonic anhydrase isozymes I, II, and IX with a series of 1,3,4-th... Bioorg Med Chem Lett. 2005 May 2;15(9):2347-52. DMSQEXP RU https://pubmed.ncbi.nlm.nih.gov/15837323 DMSQL19 DI DMSQL19 DMSQL19 DN MAGGIEMYCIN DMSQL19 TI TTSJ542 DMSQL19 TN Integrin alpha-2 (ITGA2) DMSQL19 MA Inhibitor DMSQL19 RN Small molecule designed to target metal binding site in the alpha2I domain inhibits integrin function. J Med Chem. 2007 May 31;50(11):2742-6. DMSQL19 RU https://pubmed.ncbi.nlm.nih.gov/17447751 DMSQLZF DI DMSQLZF DMSQLZF DN A-315675 DMSQLZF TI TT50QJ3 DMSQLZF TN Influenza Neuraminidase (Influ NA) DMSQLZF MA Inhibitor DMSQLZF RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMSQLZF RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMSQPFM DI DMSQPFM DMSQPFM DN 8-Bromo-9-(sec-butyl)-9H-adenine DMSQPFM TI TTJFY5U DMSQPFM TN Adenosine A3 receptor (ADORA3) DMSQPFM MA Inhibitor DMSQPFM RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMSQPFM RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMSQPFM DI DMSQPFM DMSQPFM DN 8-Bromo-9-(sec-butyl)-9H-adenine DMSQPFM TI TTK25J1 DMSQPFM TN Adenosine A1 receptor (ADORA1) DMSQPFM MA Inhibitor DMSQPFM RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMSQPFM RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMSQPFM DI DMSQPFM DMSQPFM DN 8-Bromo-9-(sec-butyl)-9H-adenine DMSQPFM TI TTM2AOE DMSQPFM TN Adenosine A2a receptor (ADORA2A) DMSQPFM MA Inhibitor DMSQPFM RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMSQPFM RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMSQPFM DI DMSQPFM DMSQPFM DN 8-Bromo-9-(sec-butyl)-9H-adenine DMSQPFM TI TTNE7KG DMSQPFM TN Adenosine A2b receptor (ADORA2B) DMSQPFM MA Inhibitor DMSQPFM RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMSQPFM RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMSR2O3 DI DMSR2O3 DMSR2O3 DN 3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone DMSR2O3 TI TTVKILB DMSR2O3 TN Prostaglandin G/H synthase 2 (COX-2) DMSR2O3 MA Inhibitor DMSR2O3 RN Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4842-5. DMSR2O3 RU https://pubmed.ncbi.nlm.nih.gov/16143531 DMSR2O3 DI DMSR2O3 DMSR2O3 DN 3-(4-Methanesulfonyl-phenyl)-1-phenyl-propynone DMSR2O3 TI TT8NGED DMSR2O3 TN Prostaglandin G/H synthase 1 (COX-1) DMSR2O3 MA Inhibitor DMSR2O3 RN Synthesis and biological evaluation of 1,3-diphenylprop-2-yn-1-ones as dual inhibitors of cyclooxygenases and lipoxygenases. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4842-5. DMSR2O3 RU https://pubmed.ncbi.nlm.nih.gov/16143531 DMSR3OI DI DMSR3OI DMSR3OI DN MR-20814 DMSR3OI TI TTSZLWK DMSR3OI TN Aromatase (CYP19A1) DMSR3OI MA Inhibitor DMSR3OI RN Design and synthesis of a new type of non steroidal human aromatase inhibitors. Bioorg Med Chem Lett. 1998 May 5;8(9):1041-4. DMSR3OI RU https://pubmed.ncbi.nlm.nih.gov/9871704 DMSR4A6 DI DMSR4A6 DMSR4A6 DN N-adamantanemethyloxypentyl-1-deoxynojirimycin DMSR4A6 TI TTLPC70 DMSR4A6 TN Lysosomal alpha-glucosidase (GAA) DMSR4A6 MA Inhibitor DMSR4A6 RN Synthesis and evaluation of D-gluco-pyranocyclopropyl amines as potential glucosidase inhibitors. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6600-3. DMSR4A6 RU https://pubmed.ncbi.nlm.nih.gov/19853441 DMSRBUE DI DMSRBUE DMSRBUE DN 1-(4-nitro-2-phenoxybenzyl)-1H-imidazole DMSRBUE TI TTSZLWK DMSRBUE TN Aromatase (CYP19A1) DMSRBUE MA Inhibitor DMSRBUE RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DMSRBUE RU https://pubmed.ncbi.nlm.nih.gov/20568782 DMSREW5 DI DMSREW5 DMSREW5 DN N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide DMSREW5 TI TT3WG5C DMSREW5 TN Monoamine oxidase type A (MAO-A) DMSREW5 MA Inhibitor DMSREW5 RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMSREW5 RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMSRGTI DI DMSRGTI DMSRGTI DN 5-MPEP DMSRGTI TI TTHS256 DMSRGTI TN Metabotropic glutamate receptor 5 (mGluR5) DMSRGTI MA Modulator (allosteric modulator) DMSRGTI RN A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtyp... Mol Pharmacol. 2005 Dec;68(6):1793-802. DMSRGTI RU https://pubmed.ncbi.nlm.nih.gov/16155210 DMSRHJA DI DMSRHJA DMSRHJA DN N1-(3-phenoxybenzyl)-N3-hydroxymalonamide DMSRHJA TI TTPHMWB DMSRHJA TN Aminopeptidase N (ANPEP) DMSRHJA MA Inhibitor DMSRHJA RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMSRHJA RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMSRHLC DI DMSRHLC DMSRHLC DN 3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole DMSRHLC TI TTJS8PY DMSRHLC TN 5-HT 6 receptor (HTR6) DMSRHLC MA Inhibitor DMSRHLC RN 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60. DMSRHLC RU https://pubmed.ncbi.nlm.nih.gov/20138763 DMSRKF0 DI DMSRKF0 DMSRKF0 DN 7-(4-methoxypyrimidin-2-yl)-2-methylquinoline DMSRKF0 TI TTHS256 DMSRKF0 TN Metabotropic glutamate receptor 5 (mGluR5) DMSRKF0 MA Inhibitor DMSRKF0 RN Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91. DMSRKF0 RU https://pubmed.ncbi.nlm.nih.gov/17446071 DMSRM49 DI DMSRM49 DMSRM49 DN Sodium 2,3,5,6-tetrafluorobenzoate DMSRM49 TI TTANPDJ DMSRM49 TN Carbonic anhydrase II (CA-II) DMSRM49 MA Inhibitor DMSRM49 RN Carbonic anhydrase inhibitors. Inhibition of the beta-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with ali... Bioorg Med Chem. 2009 Apr 1;17(7):2654-7. DMSRM49 RU https://pubmed.ncbi.nlm.nih.gov/19297172 DMSRPI8 DI DMSRPI8 DMSRPI8 DN N-Hydroxy-N-methyl-3-naphthalen-1-yl-acrylamide DMSRPI8 TI TT2J34L DMSRPI8 TN Arachidonate 5-lipoxygenase (5-LOX) DMSRPI8 MA Inhibitor DMSRPI8 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMSRPI8 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMSRQ1L DI DMSRQ1L DMSRQ1L DN 7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMSRQ1L TI TTOM3J0 DMSRQ1L TN Estrogen receptor beta (ESR2) DMSRQ1L MA Inhibitor DMSRQ1L RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMSRQ1L RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMSRQ1L DI DMSRQ1L DMSRQ1L DN 7-Allyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMSRQ1L TI TTZAYWL DMSRQ1L TN Estrogen receptor (ESR) DMSRQ1L MA Inhibitor DMSRQ1L RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMSRQ1L RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMSRUKQ DI DMSRUKQ DMSRUKQ DN DPN-205-734 DMSRUKQ TI TTUST1O DMSRUKQ TN Phosphodiesterase (PDE) DMSRUKQ MA Inhibitor DMSRUKQ RN Pharmacological actions of DPN 205-734, a novel cardiotonic agent. J Cardiovasc Pharmacol. 1988 Oct;12(4):451-60. DMSRUKQ RU https://pubmed.ncbi.nlm.nih.gov/2465446 DMST0IN DI DMST0IN DMST0IN DN PMID21907142CJ DMST0IN TI TT8JRS7 DMST0IN TN Beta-secretase (BACE) DMST0IN MA Inhibitor DMST0IN RN Bace2 is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab. 2011 Sep 7;14(3):365-77. DMST0IN RU https://pubmed.ncbi.nlm.nih.gov/21907142 DMST0IN DI DMST0IN DMST0IN DN PMID21907142CJ DMST0IN TI TT69DB8 DMST0IN TN Beta-site APP-cleaving enzyme 2 (BACE2) DMST0IN MA Inhibitor DMST0IN RN Bace2 is a beta cell-enriched protease that regulates pancreatic beta cell function and mass. Cell Metab. 2011 Sep 7;14(3):365-77. DMST0IN RU https://pubmed.ncbi.nlm.nih.gov/21907142 DMST2LX DI DMST2LX DMST2LX DN 2-(pyridin-2-yl)-1H-benzo[d]imidazol-5-amine DMST2LX TI TTZL0OI DMST2LX TN Methionine aminopeptidase 2 (METAP2) DMST2LX MA Inhibitor DMST2LX RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMST2LX RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMST2QW DI DMST2QW DMST2QW DN ISIS 103624 DMST2QW TI TTBWMKT DMST2QW TN WWP1 messenger RNA (WWP1 mRNA) DMST2QW RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMST2QW RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMST5VW DI DMST5VW DMST5VW DN amidephrine DMST5VW TI TT2NUT5 DMST5VW TN Adrenergic receptor alpha-2C (ADRA2C) DMST5VW MA Agonist DMST5VW RN Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. DMST5VW RU https://pubmed.ncbi.nlm.nih.gov/7969082 DMST60D DI DMST60D DMST60D DN 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene DMST60D TI TTVKILB DMST60D TN Prostaglandin G/H synthase 2 (COX-2) DMST60D MA Inhibitor DMST60D RN 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18. DMST60D RU https://pubmed.ncbi.nlm.nih.gov/17604631 DMST60D DI DMST60D DMST60D DN 1,2-dihydro-3-(2,3,4-trimethoxyphenyl)naphthalene DMST60D TI TT8NGED DMST60D TN Prostaglandin G/H synthase 1 (COX-1) DMST60D MA Inhibitor DMST60D RN 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18. DMST60D RU https://pubmed.ncbi.nlm.nih.gov/17604631 DMST89H DI DMST89H DMST89H DN (S)-Piperidine-3-carboxylic acid DMST89H TI TTPRKM0 DMST89H TN GABA transporter GAT-1 (SLC6A1) DMST89H MA Inhibitor DMST89H RN Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9. DMST89H RU https://pubmed.ncbi.nlm.nih.gov/15509161 DMSTG03 DI DMSTG03 DMSTG03 DN 5-(4-Chlorophenyl)-4-(4-methoxyphenyl)isothiazole DMSTG03 TI TT8NGED DMSTG03 TN Prostaglandin G/H synthase 1 (COX-1) DMSTG03 MA Inhibitor DMSTG03 RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMSTG03 RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMSTGNH DI DMSTGNH DMSTGNH DN MCL-447 DMSTGNH TI TTQW87Y DMSTGNH TN Opioid receptor kappa (OPRK1) DMSTGNH MA Inhibitor DMSTGNH RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMSTGNH RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMSTGNH DI DMSTGNH DMSTGNH DN MCL-447 DMSTGNH TI TT27RFC DMSTGNH TN Opioid receptor delta (OPRD1) DMSTGNH MA Inhibitor DMSTGNH RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMSTGNH RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMSTGNH DI DMSTGNH DMSTGNH DN MCL-447 DMSTGNH TI TTKWM86 DMSTGNH TN Opioid receptor mu (MOP) DMSTGNH MA Inhibitor DMSTGNH RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMSTGNH RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMSTH24 DI DMSTH24 DMSTH24 DN 1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione DMSTH24 TI TTM2AOE DMSTH24 TN Adenosine A2a receptor (ADORA2A) DMSTH24 MA Inhibitor DMSTH24 RN Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic... J Med Chem. 2004 Feb 12;47(4):1031-43. DMSTH24 RU https://pubmed.ncbi.nlm.nih.gov/14761205 DMSTH24 DI DMSTH24 DMSTH24 DN 1-Methyl-8-phenyl-3,7-dihydro-purine-2,6-dione DMSTH24 TI TTK25J1 DMSTH24 TN Adenosine A1 receptor (ADORA1) DMSTH24 MA Inhibitor DMSTH24 RN Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-,... J Med Chem. 1989 Jun;32(6):1231-7. DMSTH24 RU https://pubmed.ncbi.nlm.nih.gov/2724296 DMSTL12 DI DMSTL12 DMSTL12 DN RG7232 DMSTL12 TI TTJW1GN DMSTL12 TN ATP-binding cassette transporter A1 (ABCA1) DMSTL12 MA Modulator DMSTL12 RN Analysis of "On/Off" Kinetics of a CETP Inhibitor Using a Mechanistic Model of Lipoprotein Metabolism and Kinetics. CPT Pharmacometrics Syst Pharmacol. 2015 Aug;4(8):465-73. DMSTL12 RU https://pubmed.ncbi.nlm.nih.gov/26380155 DMSTOB0 DI DMSTOB0 DMSTOB0 DN DSLET DMSTOB0 TI TT27RFC DMSTOB0 TN Opioid receptor delta (OPRD1) DMSTOB0 MA Agonist DMSTOB0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMSTOB0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMSTOB0 DI DMSTOB0 DMSTOB0 DN DSLET DMSTOB0 TI TTKWM86 DMSTOB0 TN Opioid receptor mu (MOP) DMSTOB0 MA Agonist DMSTOB0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMSTOB0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMSTQGH DI DMSTQGH DMSTQGH DN PMID23639540C13d DMSTQGH TI TTP4520 DMSTQGH TN TGF-beta receptor type I (TGFBR1) DMSTQGH MA Inhibitor DMSTQGH RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMSTQGH RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMSTQGH DI DMSTQGH DMSTQGH DN PMID23639540C13d DMSTQGH TI TTZE3P7 DMSTQGH TN TGF-beta receptor type II (TGFBR2) DMSTQGH MA Inhibitor DMSTQGH RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMSTQGH RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMSTQGH DI DMSTQGH DMSTQGH DN PMID23639540C13d DMSTQGH TI TTJNBQA DMSTQGH TN Activin receptor-like kinase 2 (ALK-2) DMSTQGH MA Inhibitor DMSTQGH RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMSTQGH RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMSTQGH DI DMSTQGH DMSTQGH DN PMID23639540C13d DMSTQGH TI TTPKHTZ DMSTQGH TN Activin receptor type IB (ACVR1B) DMSTQGH MA Inhibitor DMSTQGH RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMSTQGH RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMSTQGH DI DMSTQGH DMSTQGH DN PMID23639540C13d DMSTQGH TI TTGYPTC DMSTQGH TN Activin receptor-like kinase-1 (ACVRL1) DMSTQGH MA Inhibitor DMSTQGH RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMSTQGH RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMSTQGH DI DMSTQGH DMSTQGH DN PMID23639540C13d DMSTQGH TI TTGKF90 DMSTQGH TN Bone morphogenetic protein receptor (BMPR2) DMSTQGH MA Inhibitor DMSTQGH RN Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52. DMSTQGH RU https://pubmed.ncbi.nlm.nih.gov/23639540 DMSTV96 DI DMSTV96 DMSTV96 DN H-RYYRIK-NH2 DMSTV96 TI TTNT7K8 DMSTV96 TN Nociceptin receptor (OPRL1) DMSTV96 MA Inhibitor DMSTV96 RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMSTV96 RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMSTZ14 DI DMSTZ14 DMSTZ14 DN A-395 DMSTZ14 TI TTFNJ4R DMSTZ14 TN Embryonic ectoderm development protein (EED) DMSTZ14 MA Inhibitor DMSTZ14 RN The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. Nat Chem Biol. 2017 Apr;13(4):389-395. DMSTZ14 RU https://pubmed.ncbi.nlm.nih.gov/28135237 DMSTZF9 DI DMSTZF9 DMSTZF9 DN (-)-cubebinin DMSTZF9 TI TTXV4FI DMSTZF9 TN Albendazole monooxygenase (CYP3A4) DMSTZF9 MA Inhibitor DMSTZF9 RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMSTZF9 RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMSU06X DI DMSU06X DMSU06X DN 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) DMSU06X TI TT2J34L DMSU06X TN Arachidonate 5-lipoxygenase (5-LOX) DMSU06X MA Inhibitor DMSU06X RN Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol. 2008 Apr 28;14(16):2494-500. DMSU06X RU https://pubmed.ncbi.nlm.nih.gov/18442195 DMSU06X DI DMSU06X DMSU06X DN 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) DMSU06X TI TTMCF1Y DMSU06X TN Purine nucleoside phosphorylase (PNP) DMSU06X MA Inhibitor DMSU06X RN Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. J Biol Chem. 1986 Sep 5;261(25):11667-73. DMSU06X RU https://pubmed.ncbi.nlm.nih.gov/3091593 DMSU06X DI DMSU06X DMSU06X DN 7-tert-butyl-2, 3-dihydro-3, 3-dimethyl substituted dihydrofuran 30 (DHDMBF30) DMSU06X TI TTT1MCF DMSU06X TN Permeability pathway (NP pathway) DMSU06X MA Inhibitor DMSU06X RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMSU06X RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMSUB8D DI DMSUB8D DMSUB8D DN 4-(3-cyanobenzylthio)-2-aminobutanoic acid DMSUB8D TI TTFK1JQ DMSUB8D TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMSUB8D MA Inhibitor DMSUB8D RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMSUB8D RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMSUC85 DI DMSUC85 DMSUC85 DN 1-(1-phenyl-1H-tetrazol-5-ylthio)propan-2-one DMSUC85 TI TTN7BL9 DMSUC85 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMSUC85 MA Inhibitor DMSUC85 RN Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3265-71. DMSUC85 RU https://pubmed.ncbi.nlm.nih.gov/20452767 DMSUFJZ DI DMSUFJZ DMSUFJZ DN 4-(3-Methoxy-phenyl)-isoxazolidine-3,5-dione DMSUFJZ TI TTFBNVI DMSUFJZ TN Aldose reductase (AKR1B1) DMSUFJZ MA Inhibitor DMSUFJZ RN Isoxazolidine-3,5-diones as lens aldose reductase inhibitors. J Med Chem. 1982 Jun;25(6):745-7. DMSUFJZ RU https://pubmed.ncbi.nlm.nih.gov/6808134 DMSUJDH DI DMSUJDH DMSUJDH DN N-(4-amino-4'-vinylbiphenyl-3-yl)benzamide DMSUJDH TI TTSHTOI DMSUJDH TN Histone deacetylase 2 (HDAC2) DMSUJDH MA Inhibitor DMSUJDH RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMSUJDH RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMSUK2A DI DMSUK2A DMSUK2A DN N-Neopentyl-1'H-phenothiazine-1'-carboxamide DMSUK2A TI TTEB0GD DMSUK2A TN Cholinesterase (BCHE) DMSUK2A MA Inhibitor DMSUK2A RN Differential binding of phenothiazine urea derivatives to wild-type human cholinesterases and butyrylcholinesterase mutants. Bioorg Med Chem. 2010 Mar 15;18(6):2232-2244. DMSUK2A RU https://pubmed.ncbi.nlm.nih.gov/20181484 DMSUKAO DI DMSUKAO DMSUKAO DN ISIS 138648 DMSUKAO TI TTTEOPU DMSUKAO TN Helicase-moi messenger RNA (DICER1 mRNA) DMSUKAO RN US patent application no. 7,427,470, Antisense modulation of helicase-moi expression. DMSUKAO RU http://www.patentbuddy.com/Patent/7427470?ft=true&sr=true DMSUM3C DI DMSUM3C DMSUM3C DN 4-(thiazol-2-yl)phenyl butylcarbamate DMSUM3C TI TTDP1UC DMSUM3C TN Fatty acid amide hydrolase (FAAH) DMSUM3C MA Inhibitor DMSUM3C RN Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem. 2006 Jul 27;49(15):4650-6. DMSUM3C RU https://pubmed.ncbi.nlm.nih.gov/16854070 DMSUPCD DI DMSUPCD DMSUPCD DN 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol DMSUPCD TI TTR6W5O DMSUPCD TN Adrenergic receptor beta-1 (ADRB1) DMSUPCD MA Inhibitor DMSUPCD RN Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols. J Med Chem. 1986 Aug;29(8):1524-7. DMSUPCD RU https://pubmed.ncbi.nlm.nih.gov/2874227 DMSUPCD DI DMSUPCD DMSUPCD DN 1-(1H-Indol-4-yloxy)-3-phenethylamino-propan-2-ol DMSUPCD TI TTMXGCW DMSUPCD TN Adrenergic receptor beta-3 (ADRB3) DMSUPCD MA Inhibitor DMSUPCD RN Synthesis and beta-adrenergic receptor blocking potency of 1-(substituted amino)-3-(4-indolyloxy)propan-2-ols. J Med Chem. 1986 Aug;29(8):1524-7. DMSUPCD RU https://pubmed.ncbi.nlm.nih.gov/2874227 DMSUPVE DI DMSUPVE DMSUPVE DN (11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid DMSUPVE TI TT8NGED DMSUPVE TN Prostaglandin G/H synthase 1 (COX-1) DMSUPVE MA Inhibitor DMSUPVE RN Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41. DMSUPVE RU https://pubmed.ncbi.nlm.nih.gov/3488405 DMSUPVE DI DMSUPVE DMSUPVE DN (11H-Dibenzo[b,e][1,4]dioxepin-2-yl)-acetic acid DMSUPVE TI TTVKILB DMSUPVE TN Prostaglandin G/H synthase 2 (COX-2) DMSUPVE MA Inhibitor DMSUPVE RN Synthesis and antiinflammatory/analgesic activities of 11H-dibenzo[b, e,][1,4]dioxepinacetic acids. J Med Chem. 1986 Aug;29(8):1436-41. DMSUPVE RU https://pubmed.ncbi.nlm.nih.gov/3488405 DMSUW7M DI DMSUW7M DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide DMSUW7M TI TTBH0VX DMSUW7M TN Histone deacetylase (HDAC) DMSUW7M MA Inhibitor DMSUW7M RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMSUW7M RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMSUW7M DI DMSUW7M DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide DMSUW7M TI TT6R7JZ DMSUW7M TN Histone deacetylase 1 (HDAC1) DMSUW7M MA Inhibitor DMSUW7M RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMSUW7M RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMSUW7M DI DMSUW7M DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide DMSUW7M TI TT5ZKDI DMSUW7M TN Histone deacetylase 6 (HDAC6) DMSUW7M MA Inhibitor DMSUW7M RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMSUW7M RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMSUW7M DI DMSUW7M DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide DMSUW7M TI TTTQGH8 DMSUW7M TN Histone deacetylase 4 (HDAC4) DMSUW7M MA Inhibitor DMSUW7M RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMSUW7M RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMSUW7M DI DMSUW7M DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide DMSUW7M TI TTT6LFV DMSUW7M TN Histone deacetylase 8 (HDAC8) DMSUW7M MA Inhibitor DMSUW7M RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMSUW7M RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMSUW7M DI DMSUW7M DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide DMSUW7M TI TTYHPU6 DMSUW7M TN Histone deacetylase 10 (HDAC10) DMSUW7M MA Inhibitor DMSUW7M RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMSUW7M RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMSUW7M DI DMSUW7M DMSUW7M DN N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide DMSUW7M TI TTSHTOI DMSUW7M TN Histone deacetylase 2 (HDAC2) DMSUW7M MA Inhibitor DMSUW7M RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMSUW7M RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMSUWD8 DI DMSUWD8 DMSUWD8 DN HI-443 DMSUWD8 TI TT84ETX DMSUWD8 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMSUWD8 MA Inhibitor DMSUWD8 RN N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency vi... Bioorg Med Chem Lett. 1999 Dec 20;9(24):3411-6. DMSUWD8 RU https://pubmed.ncbi.nlm.nih.gov/10617082 DMSUWVE DI DMSUWVE DMSUWVE DN ISIS 29177 DMSUWVE TI TTO6SGY DMSUWVE TN AKT3 messenger RNA (AKT3 mRNA) DMSUWVE RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMSUWVE RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMSUZFO DI DMSUZFO DMSUZFO DN NH-4 DMSUZFO TI TTQWUPT DMSUZFO TN Thyroid hormone receptor (THR) DMSUZFO MA Antagonist DMSUZFO RN Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73. DMSUZFO RU https://pubmed.ncbi.nlm.nih.gov/12650702 DMSV6K5 DI DMSV6K5 DMSV6K5 DN 3,4,5,6-Tetrachloro-[1,2]benzoquinone DMSV6K5 TI TTEB0GD DMSV6K5 TN Cholinesterase (BCHE) DMSV6K5 MA Inhibitor DMSV6K5 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMSV6K5 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMSV6K5 DI DMSV6K5 DMSV6K5 DN 3,4,5,6-Tetrachloro-[1,2]benzoquinone DMSV6K5 TI TT1RS9F DMSV6K5 TN Acetylcholinesterase (AChE) DMSV6K5 MA Inhibitor DMSV6K5 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMSV6K5 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMSV6K5 DI DMSV6K5 DMSV6K5 DN 3,4,5,6-Tetrachloro-[1,2]benzoquinone DMSV6K5 TI TTMF541 DMSV6K5 TN Liver carboxylesterase (CES1) DMSV6K5 MA Inhibitor DMSV6K5 RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMSV6K5 RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMSV8XM DI DMSV8XM DMSV8XM DN (O10eq)-beta-guanidinopropionylryanodine DMSV8XM TI TTU5CIX DMSV8XM TN Ryanodine receptor 1 (RYR1) DMSV8XM MA Inhibitor DMSV8XM RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMSV8XM RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMSVB9D DI DMSVB9D DMSVB9D DN PMID18754614C17 DMSVB9D TI TTFQEO5 DMSVB9D TN Squalene synthetase (FDFT1) DMSVB9D MA Inhibitor DMSVB9D RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DMSVB9D RU https://pubmed.ncbi.nlm.nih.gov/18754614 DMSVBZO DI DMSVBZO DMSVBZO DN (Z)-1,1,1,2,2,3,3-heptafluorohenicos-12-en-4-one DMSVBZO TI TTT1JVS DMSVBZO TN Cytosolic phospholipase A2 (GIVA cPLA2) DMSVBZO MA Inhibitor DMSVBZO RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DMSVBZO RU https://pubmed.ncbi.nlm.nih.gov/20369880 DMSVCJM DI DMSVCJM DMSVCJM DN 5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine DMSVCJM TI TT34BHT DMSVCJM TN Adrenergic receptor alpha-1D (ADRA1D) DMSVCJM MA Inhibitor DMSVCJM RN Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57. DMSVCJM RU https://pubmed.ncbi.nlm.nih.gov/1359141 DMSVCJM DI DMSVCJM DMSVCJM DN 5-Bromo-8-piperazin-1-yl-imidazo[1,2-a]pyrazine DMSVCJM TI TTNGILX DMSVCJM TN Adrenergic receptor alpha-1A (ADRA1A) DMSVCJM MA Inhibitor DMSVCJM RN Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem. 1992 Oct 16;35(21):3845-57. DMSVCJM RU https://pubmed.ncbi.nlm.nih.gov/1359141 DMSVHU9 DI DMSVHU9 DMSVHU9 DN 2-(2-Iodo-benzoyl)-cyclohexane-1,3-dione DMSVHU9 TI TT8DSFC DMSVHU9 TN Hydroxyphenylpyruvate dioxygenase (HPD) DMSVHU9 MA Inhibitor DMSVHU9 RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DMSVHU9 RU https://pubmed.ncbi.nlm.nih.gov/10853644 DMSVJFG DI DMSVJFG DMSVJFG DN UCM-454 DMSVJFG TI TT32JK8 DMSVJFG TN Melatonin receptor type 1B (MTNR1B) DMSVJFG MA Inhibitor DMSVJFG RN 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33. DMSVJFG RU https://pubmed.ncbi.nlm.nih.gov/19193160 DMSVJFG DI DMSVJFG DMSVJFG DN UCM-454 DMSVJFG TI TT0WAIE DMSVJFG TN Melatonin receptor type 1A (MTNR1A) DMSVJFG MA Inhibitor DMSVJFG RN 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009 Feb 12;52(3):826-33. DMSVJFG RU https://pubmed.ncbi.nlm.nih.gov/19193160 DMSVLXQ DI DMSVLXQ DMSVLXQ DN T-0509 DMSVLXQ TI TTMXGCW DMSVLXQ TN Adrenergic receptor beta-3 (ADRB3) DMSVLXQ MA Agonist DMSVLXQ RN Molecular characterization of pharmacological properties of T-0509 for beta-adrenoceptors. Eur J Pharmacol. 1996 Nov 21;315(3):363-7. DMSVLXQ RU https://pubmed.ncbi.nlm.nih.gov/8982677 DMSVMI8 DI DMSVMI8 DMSVMI8 DN (Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K DMSVMI8 TI TTBPW3J DMSVMI8 TN Galanin receptor type 2 (GAL2-R) DMSVMI8 MA Inhibitor DMSVMI8 RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMSVMI8 RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMSVMI8 DI DMSVMI8 DMSVMI8 DN (Sar)WTLNSAGYLLGPKK(Lys-palmitoyl)K DMSVMI8 TI TTX3HNZ DMSVMI8 TN Galanin receptor type 1 (GAL1-R) DMSVMI8 MA Inhibitor DMSVMI8 RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMSVMI8 RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMSVN1B DI DMSVN1B DMSVN1B DN ISIS 29155 DMSVN1B TI TTO6SGY DMSVN1B TN AKT3 messenger RNA (AKT3 mRNA) DMSVN1B RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMSVN1B RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMSVP1K DI DMSVP1K DMSVP1K DN DSTBULET DMSVP1K TI TT27RFC DMSVP1K TN Opioid receptor delta (OPRD1) DMSVP1K MA Agonist DMSVP1K RN [3H][D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6 and [D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6(O-tert-butyl). Two new enkephalin analogs with both a good selectivity and a high affinity toward delta-opioid binding sites. J Biol Chem. 1988 Mar 25;263(9):4124-30. DMSVP1K RU https://pubmed.ncbi.nlm.nih.gov/2831220 DMSVQJP DI DMSVQJP DMSVQJP DN N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine DMSVQJP TI TTFZVPO DMSVQJP TN Sodium/hydrogen exchanger 3 (SLC9A3) DMSVQJP MA Inhibitor DMSVQJP RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMSVQJP RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMSVQJP DI DMSVQJP DMSVQJP DN N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine DMSVQJP TI TTGSEFH DMSVQJP TN Sodium/hydrogen exchanger 1 (SLC9A1) DMSVQJP MA Inhibitor DMSVQJP RN (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. J Med Chem. 1997 Jun 20;40(13):2017-34. DMSVQJP RU https://pubmed.ncbi.nlm.nih.gov/9207943 DMSW3KN DI DMSW3KN DMSW3KN DN 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine DMSW3KN TI TT7HF4W DMSW3KN TN Cyclin-dependent kinase 2 (CDK2) DMSW3KN MA Inhibitor DMSW3KN RN Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93. DMSW3KN RU https://pubmed.ncbi.nlm.nih.gov/12139449 DMSW3KN DI DMSW3KN DMSW3KN DN 6-(3-Methyl-benzyloxy)-9H-purin-2-ylamine DMSW3KN TI TTAMQ62 DMSW3KN TN Cyclin A2 (CCNA2) DMSW3KN MA Inhibitor DMSW3KN RN Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J Med Chem. 2002 Aug 1;45(16):3381-93. DMSW3KN RU https://pubmed.ncbi.nlm.nih.gov/12139449 DMSW89U DI DMSW89U DMSW89U DN 2-[1-(2-Chloro-phenyl)-1H-pyrrol-2-yl]-ethylamine DMSW89U TI TTO9X1H DMSW89U TN 5-HT 7 receptor (HTR7) DMSW89U MA Inhibitor DMSW89U RN Phenylpyrroles, a new chemolibrary virtual screening class of 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2005 Aug 15;15(16):3753-7. DMSW89U RU https://pubmed.ncbi.nlm.nih.gov/16002287 DMSWHMI DI DMSWHMI DMSWHMI DN S-(N-hexyl-N-hydroxycarbamoyl)glutathione DMSWHMI TI TTV9A7R DMSWHMI TN Lactoylglutathione lyase (GLO1) DMSWHMI MA Inhibitor DMSWHMI RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DMSWHMI RU https://pubmed.ncbi.nlm.nih.gov/11052803 DMSWI4D DI DMSWI4D DMSWI4D DN Ono 1 DMSWI4D TI TTXHYV6 DMSWI4D TN Voltage-gated L-type calcium channel (L-CaC) DMSWI4D MA Blocker DMSWI4D RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMSWI4D RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMSWJKZ DI DMSWJKZ DMSWJKZ DN 1-(4-Methoxybenzyl)-5-phenyl-1H-imidazole DMSWJKZ TI TTIQUX7 DMSWJKZ TN Steroid 11-beta-hydroxylase (CYP11B1) DMSWJKZ MA Inhibitor DMSWJKZ RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMSWJKZ RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMSWQED DI DMSWQED DMSWQED DN bag-1 DMSWQED TI TTHYDUM DMSWQED TN Bombesin receptor (BS) DMSWQED MA Agonist DMSWQED RN Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell Metab. 2010 Feb 3;11(2):101-12. DMSWQED RU https://pubmed.ncbi.nlm.nih.gov/20096642 DMSWQY7 DI DMSWQY7 DMSWQY7 DN 9-But-3-enyl-9H-adenine DMSWQY7 TI TTM2AOE DMSWQY7 TN Adenosine A2a receptor (ADORA2A) DMSWQY7 MA Inhibitor DMSWQY7 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMSWQY7 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMSWTPX DI DMSWTPX DMSWTPX DN Ac-Phe-Thr(PO3H2)-Pip-Nal-Gln-NH2 DMSWTPX TI TTJNTSI DMSWTPX TN Rotamase Pin1 (PIN1) DMSWTPX MA Inhibitor DMSWTPX RN Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries. J Med Chem. 2006 Apr 6;49(7):2147-50. DMSWTPX RU https://pubmed.ncbi.nlm.nih.gov/16570909 DMSX1NF DI DMSX1NF DMSX1NF DN BMS753 DMSX1NF TI TTW38KT DMSX1NF TN Retinoic acid receptor alpha (RARA) DMSX1NF MA Agonist DMSX1NF RN Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. Chem Biol. 1999 Aug;6(8):519-29. DMSX1NF RU https://pubmed.ncbi.nlm.nih.gov/10421757 DMSX5DI DI DMSX5DI DMSX5DI DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMSX5DI TI TTQ6VDM DMSX5DI TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMSX5DI MA Inhibitor DMSX5DI RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMSX5DI RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMSX5DI DI DMSX5DI DMSX5DI DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMSX5DI TI TT6OEDT DMSX5DI TN Cannabinoid receptor 1 (CB1) DMSX5DI MA Inhibitor DMSX5DI RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMSX5DI RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMSX5DI DI DMSX5DI DMSX5DI DN N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-3-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMSX5DI TI TTMSFAW DMSX5DI TN Cannabinoid receptor 2 (CB2) DMSX5DI MA Inhibitor DMSX5DI RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMSX5DI RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMSX8CH DI DMSX8CH DMSX8CH DN H-Tyr-D-Ala-Tic-Asp-Val-Val-Gly-NH2 DMSX8CH TI TTKWM86 DMSX8CH TN Opioid receptor mu (MOP) DMSX8CH MA Inhibitor DMSX8CH RN Phe3-substituted analogues of deltorphin C. Spatial conformation and topography of the aromatic ring in peptide recognition by delta opioid receptors. J Med Chem. 1993 Nov 26;36(24):3748-56. DMSX8CH RU https://pubmed.ncbi.nlm.nih.gov/8254604 DMSXD63 DI DMSXD63 DMSXD63 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H DMSXD63 TI TT27RFC DMSXD63 TN Opioid receptor delta (OPRD1) DMSXD63 MA Inhibitor DMSXD63 RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMSXD63 RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMSXD63 DI DMSXD63 DMSXD63 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H DMSXD63 TI TTCG0AL DMSXD63 TN Cholecystokinin receptor type A (CCKAR) DMSXD63 MA Inhibitor DMSXD63 RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMSXD63 RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMSXD63 DI DMSXD63 DMSXD63 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H DMSXD63 TI TTVFO0U DMSXD63 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMSXD63 MA Inhibitor DMSXD63 RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMSXD63 RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMSXD63 DI DMSXD63 DMSXD63 DN H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H DMSXD63 TI TTKWM86 DMSXD63 TN Opioid receptor mu (MOP) DMSXD63 MA Inhibitor DMSXD63 RN Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80. DMSXD63 RU https://pubmed.ncbi.nlm.nih.gov/16509592 DMSXFG0 DI DMSXFG0 DMSXFG0 DN 16-(pyridin-2-yl)methyl-estradiol DMSXFG0 TI TTIWB6L DMSXFG0 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMSXFG0 MA Inhibitor DMSXFG0 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMSXFG0 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMSXG23 DI DMSXG23 DMSXG23 DN 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole DMSXG23 TI TTR5TV4 DMSXG23 TN ERBB2 messenger RNA (HER2 mRNA) DMSXG23 MA Inhibitor DMSXG23 RN Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. DMSXG23 RU https://pubmed.ncbi.nlm.nih.gov/17174554 DMSXI6W DI DMSXI6W DMSXI6W DN DM-204 DMSXI6W TI TTRSMW9 DMSXI6W TN Glycogen synthase kinase-3 beta (GSK-3B) DMSXI6W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2030). DMSXI6W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2030 DMSXILZ DI DMSXILZ DMSXILZ DN Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275 DMSXILZ TI TTIND6G DMSXILZ TN Somatostatin receptor type 1 (SSTR1) DMSXILZ MA Inhibitor DMSXILZ RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMSXILZ RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMSXILZ DI DMSXILZ DMSXILZ DN Des-AA1,2,5-[D-Trp8,IAmp9]SRIF CH-275 DMSXILZ TI TTJX3UE DMSXILZ TN Somatostatin receptor type 3 (SSTR3) DMSXILZ MA Inhibitor DMSXILZ RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMSXILZ RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMSXJUW DI DMSXJUW DMSXJUW DN xylazine DMSXJUW TI TTWM4TY DMSXJUW TN Adrenergic receptor alpha-2B (ADRA2B) DMSXJUW MA Agonist DMSXJUW RN Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol. 1998 Apr 1;55(7):1035-43. DMSXJUW RU https://pubmed.ncbi.nlm.nih.gov/9605427 DMSXJUW DI DMSXJUW DMSXJUW DN xylazine DMSXJUW TI TT2NUT5 DMSXJUW TN Adrenergic receptor alpha-2C (ADRA2C) DMSXJUW MA Agonist DMSXJUW RN Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol. 1998 Apr 1;55(7):1035-43. DMSXJUW RU https://pubmed.ncbi.nlm.nih.gov/9605427 DMSXLKJ DI DMSXLKJ DMSXLKJ DN H-Arg-N-Me-Arg-Pro-Tyr-Ile-Leu-OH DMSXLKJ TI TTTUMEP DMSXLKJ TN Neurotensin receptor type 1 (NTSR1) DMSXLKJ MA Inhibitor DMSXLKJ RN Novel insights into GPCR-peptide interactions: mutations in extracellular loop 1, ligand backbone methylations and molecular modeling of neurotensi... Bioorg Med Chem. 2008 Oct 15;16(20):9359-68. DMSXLKJ RU https://pubmed.ncbi.nlm.nih.gov/18809332 DMSXT0H DI DMSXT0H DMSXT0H DN ONO-1581 DMSXT0H TI TTKNWZ4 DMSXT0H TN Thromboxane-A synthase (TBXAS1) DMSXT0H MA Inhibitor DMSXT0H RN Pharmacological evaluation of combined PGI2 agonists/thromboxane synthase inhibitors, Bioorg. Med. Chem. Lett. 5(10):1087-1090 (1995). DMSXT0H RU http://www.sciencedirect.com/science/article/pii/0960894X9500171O DMSXTRI DI DMSXTRI DMSXTRI DN ISIS 111997 DMSXTRI TI TTPJ9XK DMSXTRI TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMSXTRI RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMSXTRI RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMSXZ19 DI DMSXZ19 DMSXZ19 DN PB-28 DMSXZ19 TI TTSQIFT DMSXZ19 TN 5-HT 1A receptor (HTR1A) DMSXZ19 MA Inhibitor DMSXZ19 RN New sigma and 5-HT1A receptor ligands: omega-(tetralin-1-yl)-n-alkylamine derivatives. J Med Chem. 1996 Jan 5;39(1):176-82. DMSXZ19 RU https://pubmed.ncbi.nlm.nih.gov/8568804 DMSY4CK DI DMSY4CK DMSY4CK DN (R)-2-Amino-5-phosphono-pentanoic acid DMSY4CK TI TTKJEMQ DMSY4CK TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMSY4CK MA Inhibitor DMSY4CK RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DMSY4CK RU https://pubmed.ncbi.nlm.nih.gov/15801853 DMSY4CK DI DMSY4CK DMSY4CK DN (R)-2-Amino-5-phosphono-pentanoic acid DMSY4CK TI TTN9D8E DMSY4CK TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMSY4CK MA Inhibitor DMSY4CK RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DMSY4CK RU https://pubmed.ncbi.nlm.nih.gov/15801853 DMSY4CK DI DMSY4CK DMSY4CK DN (R)-2-Amino-5-phosphono-pentanoic acid DMSY4CK TI TTLD29N DMSY4CK TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMSY4CK MA Inhibitor DMSY4CK RN Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists. J Med Chem. 2005 Apr 7;48(7):2627-37. DMSY4CK RU https://pubmed.ncbi.nlm.nih.gov/15801853 DMSY571 DI DMSY571 DMSY571 DN N,N-diallyl[D-Pro-10]Dyn A-(1-11) DMSY571 TI TTQW87Y DMSY571 TN Opioid receptor kappa (OPRK1) DMSY571 MA Inhibitor DMSY571 RN Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution. J Med Chem. 1997 Aug 15;40(17):2733-9. DMSY571 RU https://pubmed.ncbi.nlm.nih.gov/9276018 DMSYE4W DI DMSYE4W DMSYE4W DN SAR-131675 DMSYE4W TI TTDCBX5 DMSYE4W TN Vascular endothelial growth factor receptor 3 (FLT-4) DMSYE4W MA Inhibitor DMSYE4W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814). DMSYE4W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1814 DMSYH8R DI DMSYH8R DMSYH8R DN 4-(4-cyclohexylthiosemicarbazono)methyl-phenol DMSYH8R TI TTHM0R1 DMSYH8R TN Steryl-sulfatase (STS) DMSYH8R MA Inhibitor DMSYH8R RN Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6. DMSYH8R RU https://pubmed.ncbi.nlm.nih.gov/17580843 DMSYLIJ DI DMSYLIJ DMSYLIJ DN LARGAZOLE DMSYLIJ TI TT6R7JZ DMSYLIJ TN Histone deacetylase 1 (HDAC1) DMSYLIJ MA Inhibitor DMSYLIJ RN Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67. DMSYLIJ RU https://pubmed.ncbi.nlm.nih.gov/20491440 DMSYLIJ DI DMSYLIJ DMSYLIJ DN LARGAZOLE DMSYLIJ TI TTTQGH8 DMSYLIJ TN Histone deacetylase 4 (HDAC4) DMSYLIJ MA Inhibitor DMSYLIJ RN Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues. J Med Chem. 2010 Jun 24;53(12):4654-67. DMSYLIJ RU https://pubmed.ncbi.nlm.nih.gov/20491440 DMSYMRJ DI DMSYMRJ DMSYMRJ DN AdcAhxArg4NH(CH2)6NH2 DMSYMRJ TI TTNAHEX DMSYMRJ TN cAMP-dependent protein kinase A type I (PRKAR1A) DMSYMRJ MA Inhibitor DMSYMRJ RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DMSYMRJ RU https://pubmed.ncbi.nlm.nih.gov/12941328 DMSYMRJ DI DMSYMRJ DMSYMRJ DN AdcAhxArg4NH(CH2)6NH2 DMSYMRJ TI TTW4Y2M DMSYMRJ TN cAMP protein kinase type II-beta (PRKAR2B) DMSYMRJ MA Inhibitor DMSYMRJ RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DMSYMRJ RU https://pubmed.ncbi.nlm.nih.gov/12941328 DMSYOHD DI DMSYOHD DMSYOHD DN NN-dimethyl-D-erythrosphingosine DMSYOHD TI TTO3TD8 DMSYOHD TN Long transient receptor potential channel 3 (TRPM3) DMSYOHD MA Activator DMSYOHD RN Activation of the melastatin-related cation channel TRPM3 by D-erythro-sphingosine [corrected]. Mol Pharmacol. 2005 Mar;67(3):798-805. DMSYOHD RU https://pubmed.ncbi.nlm.nih.gov/15550678 DMSYQP9 DI DMSYQP9 DMSYQP9 DN MF266-1 DMSYQP9 TI TTG1QMU DMSYQP9 TN Prostaglandin E2 receptor EP1 (PTGER1) DMSYQP9 MA Antagonist DMSYQP9 RN MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. J Pharmacol Exp Ther. 2008 May;325(2):425-34. DMSYQP9 RU https://pubmed.ncbi.nlm.nih.gov/18287210 DMSYT0A DI DMSYT0A DMSYT0A DN NSC-87509 DMSYT0A TI TT4FDG6 DMSYT0A TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMSYT0A MA Inhibitor DMSYT0A RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMSYT0A RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMSYT5P DI DMSYT5P DMSYT5P DN [125I]GTI DMSYT5P TI TTK8CXU DMSYT5P TN 5-HT 1B receptor (HTR1B) DMSYT5P MA Agonist DMSYT5P RN Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1993 Jun;347(6):569-82. DMSYT5P RU https://pubmed.ncbi.nlm.nih.gov/8361548 DMSYT5P DI DMSYT5P DMSYT5P DN [125I]GTI DMSYT5P TI TT6MSOK DMSYT5P TN 5-HT 1D receptor (HTR1D) DMSYT5P MA Agonist DMSYT5P RN Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1993 Jun;347(6):569-82. DMSYT5P RU https://pubmed.ncbi.nlm.nih.gov/8361548 DMSYXHF DI DMSYXHF DMSYXHF DN Sulfamic acid 4-(2-hydroxy-benzoyl)-phenyl ester DMSYXHF TI TTHM0R1 DMSYXHF TN Steryl-sulfatase (STS) DMSYXHF MA Inhibitor DMSYXHF RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMSYXHF RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMSZ03N DI DMSZ03N DMSZ03N DN N-(3-(3-methoxyphenyl)propyl)acetamide DMSZ03N TI TT0WAIE DMSZ03N TN Melatonin receptor type 1A (MTNR1A) DMSZ03N MA Inhibitor DMSZ03N RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMSZ03N RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMSZ03N DI DMSZ03N DMSZ03N DN N-(3-(3-methoxyphenyl)propyl)acetamide DMSZ03N TI TT32JK8 DMSZ03N TN Melatonin receptor type 1B (MTNR1B) DMSZ03N MA Inhibitor DMSZ03N RN Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. DMSZ03N RU https://pubmed.ncbi.nlm.nih.gov/20227878 DMSZ0H9 DI DMSZ0H9 DMSZ0H9 DN 2-(3,4-Dihydroxyphenyl)Acetic Acid DMSZ0H9 TI TTUTN1I DMSZ0H9 TN Human Deoxyribonucleic acid (hDNA) DMSZ0H9 MA Inhibitor DMSZ0H9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMSZ0H9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMSZ1RB DI DMSZ1RB DMSZ1RB DN Phytanic acid DMSZ1RB TI TT6PEUO DMSZ1RB TN Retinoic acid receptor RXR-alpha (RXRA) DMSZ1RB MA Agonist DMSZ1RB RN Phytanic acid is a retinoid X receptor ligand. Eur J Biochem. 1996 Feb 15;236(1):328-33. DMSZ1RB RU https://pubmed.ncbi.nlm.nih.gov/8617282 DMSZ1VC DI DMSZ1VC DMSZ1VC DN 3-(4-phenyl-2,4'-bipyridin-6-yl)phenol DMSZ1VC TI TTGTQHC DMSZ1VC TN DNA topoisomerase I (TOP1) DMSZ1VC MA Inhibitor DMSZ1VC RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMSZ1VC RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMSZ2CO DI DMSZ2CO DMSZ2CO DN Phenyl 4-(undecyloxy)phenylcarbamate DMSZ2CO TI TTDP1UC DMSZ2CO TN Fatty acid amide hydrolase (FAAH) DMSZ2CO MA Inhibitor DMSZ2CO RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMSZ2CO RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMSZ3T6 DI DMSZ3T6 DMSZ3T6 DN 5-{8(Z),11(Z),14-pentadecatrienyl}resorcinol DMSZ3T6 TI TTULVH8 DMSZ3T6 TN Tyrosinase (TYR) DMSZ3T6 MA Inhibitor DMSZ3T6 RN Tyrosinase inhibitors from Anacardium occidentale fruits. J Nat Prod. 1994 Apr;57(4):545-51. DMSZ3T6 RU https://pubmed.ncbi.nlm.nih.gov/8021657 DMSZ50N DI DMSZ50N DMSZ50N DN Sulfamic acid 3-(3-hydroxy-benzoyl)-phenyl ester DMSZ50N TI TTHM0R1 DMSZ50N TN Steryl-sulfatase (STS) DMSZ50N MA Inhibitor DMSZ50N RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMSZ50N RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMSZ7UE DI DMSZ7UE DMSZ7UE DN Dichloroisoproterenol DMSZ7UE TI TT2CJVK DMSZ7UE TN Adrenergic receptor beta-2 (ADRB2) DMSZ7UE MA Inhibitor DMSZ7UE RN The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists. J Med Chem. 1994 May 13;37(10):1518-25. DMSZ7UE RU https://pubmed.ncbi.nlm.nih.gov/7910217 DMSZ7UE DI DMSZ7UE DMSZ7UE DN Dichloroisoproterenol DMSZ7UE TI TTR6W5O DMSZ7UE TN Adrenergic receptor beta-1 (ADRB1) DMSZ7UE MA Inhibitor DMSZ7UE RN The [(methyloxy)imino]methyl moiety as a bioisoster of aryl. A novel class of completely aliphatic beta-adrenergic receptor antagonists. J Med Chem. 1994 May 13;37(10):1518-25. DMSZ7UE RU https://pubmed.ncbi.nlm.nih.gov/7910217 DMSZLNE DI DMSZLNE DMSZLNE DN 3'-(1-Benzothien-2-yl)biphenyl-3-ol DMSZLNE TI TTIWB6L DMSZLNE TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMSZLNE MA Inhibitor DMSZLNE RN Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505. DMSZLNE RU https://pubmed.ncbi.nlm.nih.gov/20413314 DMSZML2 DI DMSZML2 DMSZML2 DN 6-chloro-5-(2-thienyl)pyrimidine-2,4(1H,3H)-dione DMSZML2 TI TTO0IB8 DMSZML2 TN Thymidine phosphorylase (TYMP) DMSZML2 MA Inhibitor DMSZML2 RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DMSZML2 RU https://pubmed.ncbi.nlm.nih.gov/17963370 DMSZMQU DI DMSZMQU DMSZMQU DN 4-Hydrazino-3-pyridinesulfonamide DMSZMQU TI TT2LVK8 DMSZMQU TN Carbonic anhydrase IX (CA-IX) DMSZMQU MA Inhibitor DMSZMQU RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMSZMQU RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMSZMQU DI DMSZMQU DMSZMQU DN 4-Hydrazino-3-pyridinesulfonamide DMSZMQU TI TTEYTKG DMSZMQU TN Carbonic anhydrase XIV (CA-XIV) DMSZMQU MA Inhibitor DMSZMQU RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMSZMQU RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMSZMQU DI DMSZMQU DMSZMQU DN 4-Hydrazino-3-pyridinesulfonamide DMSZMQU TI TTANPDJ DMSZMQU TN Carbonic anhydrase II (CA-II) DMSZMQU MA Inhibitor DMSZMQU RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMSZMQU RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMSZMQU DI DMSZMQU DMSZMQU DN 4-Hydrazino-3-pyridinesulfonamide DMSZMQU TI TTSYM0R DMSZMQU TN Carbonic anhydrase XII (CA-XII) DMSZMQU MA Inhibitor DMSZMQU RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMSZMQU RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMSZMQU DI DMSZMQU DMSZMQU DN 4-Hydrazino-3-pyridinesulfonamide DMSZMQU TI TTHQPL7 DMSZMQU TN Carbonic anhydrase I (CA-I) DMSZMQU MA Inhibitor DMSZMQU RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMSZMQU RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMSZRY0 DI DMSZRY0 DMSZRY0 DN ISIS 25078 DMSZRY0 TI TT8H9GB DMSZRY0 TN MEK2 messenger RNA (MEK2 mRNA) DMSZRY0 RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMSZRY0 RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMSZT9G DI DMSZT9G DMSZT9G DN 2-(3-Butoxy-phenyl)-6-methyl-chromen-4-one DMSZT9G TI TTNJYV2 DMSZT9G TN Gamma-aminobutyric acid receptor (GAR) DMSZT9G MA Inhibitor DMSZT9G RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMSZT9G RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMSZWGN DI DMSZWGN DMSZWGN DN NOR-ROEFRACTINE DMSZWGN TI TTEX248 DMSZWGN TN Dopamine D2 receptor (D2R) DMSZWGN MA Inhibitor DMSZWGN RN Synthesis and dopamine receptor selectivity of the benzyltetrahydroisoquinoline, (R)-(+)-nor-roefractine. J Nat Prod. 1998 Jun 26;61(6):709-12. DMSZWGN RU https://pubmed.ncbi.nlm.nih.gov/9644051 DMT02B8 DI DMT02B8 DMT02B8 DN BMY 45778 DMT02B8 TI TTOFYT1 DMT02B8 TN Prostacyclin receptor (PTGIR) DMT02B8 MA Agonist DMT02B8 RN Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery. J Cardiovasc Pharmacol. 1997 Apr;29(4):525-35. DMT02B8 RU https://pubmed.ncbi.nlm.nih.gov/9156364 DMT03VB DI DMT03VB DMT03VB DN VP-343 DMT03VB TI TTK8R02 DMT03VB TN Vasopressin V2 receptor (V2R) DMT03VB MA Antagonist DMT03VB RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DMT03VB RU https://pubmed.ncbi.nlm.nih.gov/12436936 DMT08ZH DI DMT08ZH DMT08ZH DN WR-289016 DMT08ZH TI TTSFWA7 DMT08ZH TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMT08ZH MA Inhibitor DMT08ZH RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DMT08ZH RU https://pubmed.ncbi.nlm.nih.gov/19250824 DMT09YC DI DMT09YC DMT09YC DN 6,7'-oxybis(2-phenyl-4H-chromen-4-one) DMT09YC TI TTVKILB DMT09YC TN Prostaglandin G/H synthase 2 (COX-2) DMT09YC MA Inhibitor DMT09YC RN Synthesis of biflavones having a 6-O-7'' linkage and effects on cyclooxygenase-2 and inducible nitric oxide synthase. Bioorg Med Chem Lett. 2009 Jan 1;19(1):74-6. DMT09YC RU https://pubmed.ncbi.nlm.nih.gov/19041241 DMT0CR5 DI DMT0CR5 DMT0CR5 DN KST-5468 DMT0CR5 TI TTZPWGN DMT0CR5 TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMT0CR5 MA Antagonist DMT0CR5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536). DMT0CR5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536 DMT0DW4 DI DMT0DW4 DMT0DW4 DN Rotigitine DMT0DW4 TI TTEX248 DMT0DW4 TN Dopamine D2 receptor (D2R) DMT0DW4 MA Agonist DMT0DW4 RN Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. DMT0DW4 RU https://pubmed.ncbi.nlm.nih.gov/17016425 DMT0EK8 DI DMT0EK8 DMT0EK8 DN 4-(3-Benzoyl-1H-pyrrol-1-yl)butanoic acid DMT0EK8 TI TTFBNVI DMT0EK8 TN Aldose reductase (AKR1B1) DMT0EK8 MA Inhibitor DMT0EK8 RN Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisoste... Bioorg Med Chem. 2010 Mar 15;18(6):2107-2114. DMT0EK8 RU https://pubmed.ncbi.nlm.nih.gov/20189816 DMT0JXC DI DMT0JXC DMT0JXC DN LY134046 DMT0JXC TI TT0NZIC DMT0JXC TN Phenylethanolamine N-methyltransferase (PNMT) DMT0JXC MA Inhibitor DMT0JXC RN Properties of 8,9-dichloro-2,3,4,5-tetrahydro-1H-2-benzazepine, an inhibitor of norepinephrine N-methyltransferase. Biochem Pharmacol. 1981 Jun 1;30(11):1345-52. DMT0JXC RU https://pubmed.ncbi.nlm.nih.gov/6268095 DMT0M94 DI DMT0M94 DMT0M94 DN 3-(3-Adamantan-1-yl-ureido)-benzoic acid DMT0M94 TI TT7WVHI DMT0M94 TN Soluble epoxide hydrolase (EPHX2) DMT0M94 MA Inhibitor DMT0M94 RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMT0M94 RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMT0NQS DI DMT0NQS DMT0NQS DN ND-401 DMT0NQS TI TTBID49 DMT0NQS TN C-X-C chemokine receptor type 4 (CXCR4) DMT0NQS MA Inhibitor DMT0NQS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMT0NQS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMT0S7M DI DMT0S7M DMT0S7M DN BD-NP DMT0S7M TI TTY63XT DMT0S7M TN B-type natriuretic peptide (BNP) DMT0S7M MA Modulator DMT0S7M RN A Novel Designer Natriuretic and Diuretic Peptide Based Upon an Alternatively Spliced BNP Without Vascular Vasodilatory Actions. Circulation, 2006, 114:II_270. DMT0S7M RU http://circ.ahajournals.org/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_270-a DMT0UZ1 DI DMT0UZ1 DMT0UZ1 DN Z-Arg-Leu-Val-Agly-Ileu-Val-OMe DMT0UZ1 TI TTDZN01 DMT0UZ1 TN Cathepsin K (CTSK) DMT0UZ1 MA Inhibitor DMT0UZ1 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMT0UZ1 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMT0UZ1 DI DMT0UZ1 DMT0UZ1 DN Z-Arg-Leu-Val-Agly-Ileu-Val-OMe DMT0UZ1 TI TTF2LRI DMT0UZ1 TN Cathepsin B (CTSB) DMT0UZ1 MA Inhibitor DMT0UZ1 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMT0UZ1 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMT0X6Q DI DMT0X6Q DMT0X6Q DN BBT-007 DMT0X6Q TI TT6MP2Z DMT0X6Q TN GMCSFR-alpha (CSF2RA) DMT0X6Q MA Stimulator DMT0X6Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1707). DMT0X6Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1707 DMT13EW DI DMT13EW DMT13EW DN AMINOBENZTROPINE DMT13EW TI TTZ9SOR DMT13EW TN Muscarinic acetylcholine receptor M1 (CHRM1) DMT13EW MA Inhibitor DMT13EW RN 3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem. 1997 Mar 14;40(6):851-7. DMT13EW RU https://pubmed.ncbi.nlm.nih.gov/9083473 DMT13EW DI DMT13EW DMT13EW DN AMINOBENZTROPINE DMT13EW TI TTVBI8W DMT13EW TN Dopamine transporter (DAT) DMT13EW MA Inhibitor DMT13EW RN 3'-Chloro-3 alpha-(diphenylmethoxy)tropane but not 4'-chloro-3 alpha-(diphenylmethoxy)tropane produces a cocaine-like behavioral profile. J Med Chem. 1997 Mar 14;40(6):851-7. DMT13EW RU https://pubmed.ncbi.nlm.nih.gov/9083473 DMT14A7 DI DMT14A7 DMT14A7 DN DAU-5750 DMT14A7 TI TTZ9SOR DMT14A7 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMT14A7 MA Modulator DMT14A7 RN Synthesis, absolute configuration, conformational analysis and binding affinity properties of enantiomeric forms of DAU 5750, a novel M1-M3 muscari... Bioorg Med Chem. 1994 Dec;2(12):1375-83. DMT14A7 RU https://www.ncbi.nlm.nih.gov/pubmed/7788300 DMT14A7 DI DMT14A7 DMT14A7 DN DAU-5750 DMT14A7 TI TTQ13Z5 DMT14A7 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMT14A7 MA Modulator DMT14A7 RN Synthesis, absolute configuration, conformational analysis and binding affinity properties of enantiomeric forms of DAU 5750, a novel M1-M3 muscari... Bioorg Med Chem. 1994 Dec;2(12):1375-83. DMT14A7 RU https://www.ncbi.nlm.nih.gov/pubmed/7788300 DMT17H0 DI DMT17H0 DMT17H0 DN Alpha-Homonojirimycin DMT17H0 TI TTLPC70 DMT17H0 TN Lysosomal alpha-glucosidase (GAA) DMT17H0 MA Inhibitor DMT17H0 RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DMT17H0 RU https://pubmed.ncbi.nlm.nih.gov/18595718 DMT1CZ0 DI DMT1CZ0 DMT1CZ0 DN OL-135 DMT1CZ0 TI TTDP1UC DMT1CZ0 TN Fatty acid amide hydrolase (FAAH) DMT1CZ0 MA Inhibitor DMT1CZ0 RN X-ray crystallographic analysis of alpha-ketoheterocycle inhibitors bound to a humanized variant of fatty acid amide hydrolase. J Med Chem. 2010 Jan 14;53(1):230-40. DMT1CZ0 RU https://pubmed.ncbi.nlm.nih.gov/19924997 DMT1GJL DI DMT1GJL DMT1GJL DN SC-560 DMT1GJL TI TT8NGED DMT1GJL TN Prostaglandin G/H synthase 1 (COX-1) DMT1GJL MA Inhibitor DMT1GJL RN Synthesis and antiinflammatory activity of coumarin derivatives. J Med Chem. 2005 Oct 6;48(20):6400-8. DMT1GJL RU https://pubmed.ncbi.nlm.nih.gov/16190766 DMT1H9Z DI DMT1H9Z DMT1H9Z DN KOTALANOL DMT1H9Z TI TTXWASR DMT1H9Z TN Intestinal maltase-glucoamylase (MGAM) DMT1H9Z MA Inhibitor DMT1H9Z RN Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8. DMT1H9Z RU https://pubmed.ncbi.nlm.nih.gov/20970346 DMT1KFL DI DMT1KFL DMT1KFL DN SB-328872 DMT1KFL TI TTW5UDX DMT1KFL TN Urotensin II receptor (UTS2R) DMT1KFL MA Inhibitor DMT1KFL RN Urotensin-II receptor antagonists: synthesis and SAR of N-cyclic azaalkyl benzamides. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3950-4. DMT1KFL RU https://pubmed.ncbi.nlm.nih.gov/18573659 DMT1LS0 DI DMT1LS0 DMT1LS0 DN Ustiloxin F DMT1LS0 TI TTYFKSZ DMT1LS0 TN Tubulin beta (TUBB) DMT1LS0 MA Inhibitor DMT1LS0 RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMT1LS0 RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMT1LS0 DI DMT1LS0 DMT1LS0 DN Ustiloxin F DMT1LS0 TI TTJ2PTI DMT1LS0 TN Tubulin beta-2 chain (TUBB2) DMT1LS0 MA Inhibitor DMT1LS0 RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMT1LS0 RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMT1NP8 DI DMT1NP8 DMT1NP8 DN MM 11253 DMT1NP8 TI TT1Q3IE DMT1NP8 TN Retinoic acid receptor gamma (RARG) DMT1NP8 MA Antagonist DMT1NP8 RN Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids. Oncogene. 2000 Mar 9;19(11):1457-65. DMT1NP8 RU https://pubmed.ncbi.nlm.nih.gov/10723137 DMT1NW2 DI DMT1NW2 DMT1NW2 DN 8(S)-amino-2(R)-methyl-7-oxononanoic acid DMT1NW2 TI TTXZEAJ DMT1NW2 TN Leukotriene A-4 hydrolase (LTA4H) DMT1NW2 MA Inhibitor DMT1NW2 RN Isolation and structure of leukotriene-A4 hydrolase inhibitor: 8(S)-amino-2(R)-methyl-7-oxononanoic acid produced by Streptomyces diastaticus. J Nat Prod. 1996 Oct;59(10):962-4. DMT1NW2 RU https://pubmed.ncbi.nlm.nih.gov/8904845 DMT1OAH DI DMT1OAH DMT1OAH DN SCH-23390 DMT1OAH TI TTZFYLI DMT1OAH TN Dopamine D1 receptor (D1R) DMT1OAH MA Antagonist DMT1OAH RN Dopamine modulates effort-based decision making in rats. Behav Neurosci. 2009 Apr;123(2):242-51. DMT1OAH RU https://pubmed.ncbi.nlm.nih.gov/19331447 DMT1PM4 DI DMT1PM4 DMT1PM4 DN 4-[(diphenylmethyl)amino]-2-phenylquinazoline DMT1PM4 TI TT8DBY3 DMT1PM4 TN Angiotensin II receptor type-1 (AGTR1) DMT1PM4 MA Antagonist DMT1PM4 RN Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8. DMT1PM4 RU https://pubmed.ncbi.nlm.nih.gov/12127543 DMT1PM4 DI DMT1PM4 DMT1PM4 DN 4-[(diphenylmethyl)amino]-2-phenylquinazoline DMT1PM4 TI TTVBI8W DMT1PM4 TN Dopamine transporter (DAT) DMT1PM4 MA Inhibitor DMT1PM4 RN Identification of a novel partial inhibitor of dopamine transporter among 4-substituted 2-phenylquinazolines. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2225-8. DMT1PM4 RU https://pubmed.ncbi.nlm.nih.gov/12127543 DMT1ZGM DI DMT1ZGM DMT1ZGM DN Isosorbide-di-phenylcarbamate DMT1ZGM TI TT1RS9F DMT1ZGM TN Acetylcholinesterase (AChE) DMT1ZGM MA Inhibitor DMT1ZGM RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMT1ZGM RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMT21UX DI DMT21UX DMT21UX DN 2-Pyridin-3-yl-benzo[h]chromen-4-one DMT21UX TI TTK3PY9 DMT21UX TN DNA-dependent protein kinase catalytic (PRKDC) DMT21UX MA Inhibitor DMT21UX RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMT21UX RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMT27QD DI DMT27QD DMT27QD DN CHYMOSTATIN DMT27QD TI TT8VUE0 DMT27QD TN Chymase (CYM) DMT27QD MA Inhibitor DMT27QD RN Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4. DMT27QD RU https://pubmed.ncbi.nlm.nih.gov/17419055 DMT29SN DI DMT29SN DMT29SN DN 1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one DMT29SN TI TTMF541 DMT29SN TN Liver carboxylesterase (CES1) DMT29SN MA Inhibitor DMT29SN RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMT29SN RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMT29SN DI DMT29SN DMT29SN DN 1,1,1-trifluoro-3-(octylsulfonyl)propan-2-one DMT29SN TI TTDP1UC DMT29SN TN Fatty acid amide hydrolase (FAAH) DMT29SN MA Inhibitor DMT29SN RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMT29SN RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMT29VJ DI DMT29VJ DMT29VJ DN Cyclo-[-Arg-Gly-Asp-Amp23-] DMT29VJ TI TTT1R2L DMT29VJ TN Integrin alpha-V (ITGAV) DMT29VJ MA Inhibitor DMT29VJ RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMT29VJ RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMT29VJ DI DMT29VJ DMT29VJ DN Cyclo-[-Arg-Gly-Asp-Amp23-] DMT29VJ TI TTJA1ZO DMT29VJ TN ITGB3 messenger RNA (ITGB3 mRNA) DMT29VJ MA Inhibitor DMT29VJ RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMT29VJ RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMT2CZK DI DMT2CZK DMT2CZK DN Leucine-enkephalin DMT2CZK TI TT27RFC DMT2CZK TN Opioid receptor delta (OPRD1) DMT2CZK MA Agonist DMT2CZK RN Inverse agonist action of Leu-enkephalin at delta(2)-opioid receptors mediates spinal antianalgesia. J Pharmacol Exp Ther. 2001 May;297(2):582-9. DMT2CZK RU https://pubmed.ncbi.nlm.nih.gov/11303046 DMT2CZK DI DMT2CZK DMT2CZK DN Leucine-enkephalin DMT2CZK TI TTKWM86 DMT2CZK TN Opioid receptor mu (MOP) DMT2CZK MA Inhibitor DMT2CZK RN Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5. DMT2CZK RU https://pubmed.ncbi.nlm.nih.gov/2879914 DMT2GSI DI DMT2GSI DMT2GSI DN N-benzyl-N-(phenylsulfonyl)benzamide DMT2GSI TI TTN7BL9 DMT2GSI TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMT2GSI MA Inhibitor DMT2GSI RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMT2GSI RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMT2NVG DI DMT2NVG DMT2NVG DN (Sar)WTLNSAGYLLGPKKKK DMT2NVG TI TTBPW3J DMT2NVG TN Galanin receptor type 2 (GAL2-R) DMT2NVG MA Inhibitor DMT2NVG RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMT2NVG RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMT2NVG DI DMT2NVG DMT2NVG DN (Sar)WTLNSAGYLLGPKKKK DMT2NVG TI TTX3HNZ DMT2NVG TN Galanin receptor type 1 (GAL1-R) DMT2NVG MA Inhibitor DMT2NVG RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMT2NVG RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMT2RHV DI DMT2RHV DMT2RHV DN CP 4010 DMT2RHV TI TT51ZGC DMT2RHV TN Herpes simplex virus DNA polymerase POL (HSV POL) DMT2RHV MA Modulator DMT2RHV RN Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem. 1989 May 5;264(13):7405-11. DMT2RHV RU https://pubmed.ncbi.nlm.nih.gov/2540193 DMT2S9U DI DMT2S9U DMT2S9U DN 4-(4-benzyl-1H-1,2,3-triazol-1-yl)phenol DMT2S9U TI TT6804T DMT2S9U TN MIF messenger RNA (MIF mRNA) DMT2S9U MA Inhibitor DMT2S9U RN Receptor agonists of macrophage migration inhibitory factor. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7033-6. DMT2S9U RU https://pubmed.ncbi.nlm.nih.gov/20971005 DMT2UYR DI DMT2UYR DMT2UYR DN [HO1][Thr4,Lys8(5/6C-Flu)]VT DMT2UYR TI TTL9MHW DMT2UYR TN Vasopressin V1b receptor (V1BR) DMT2UYR MA Inhibitor DMT2UYR RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMT2UYR RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMT2UYR DI DMT2UYR DMT2UYR DN [HO1][Thr4,Lys8(5/6C-Flu)]VT DMT2UYR TI TTSCIUP DMT2UYR TN Oxytocin receptor (OTR) DMT2UYR MA Inhibitor DMT2UYR RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMT2UYR RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMT2UYR DI DMT2UYR DMT2UYR DN [HO1][Thr4,Lys8(5/6C-Flu)]VT DMT2UYR TI TT4TFGN DMT2UYR TN Vasopressin V1a receptor (V1AR) DMT2UYR MA Inhibitor DMT2UYR RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMT2UYR RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMT2X98 DI DMT2X98 DMT2X98 DN [D-Ncy(SO,methyl)10]acyline DMT2X98 TI TT8R70G DMT2X98 TN Gonadotropin-releasing hormone receptor (GNRHR) DMT2X98 MA Inhibitor DMT2X98 RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMT2X98 RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMT2YNG DI DMT2YNG DMT2YNG DN Pteroic Acid DMT2YNG TI TT4ILYC DMT2YNG TN Bacterial Dihydropteroate synthetase (Bact folP) DMT2YNG MA Inhibitor DMT2YNG RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMT2YNG RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMT2ZSV DI DMT2ZSV DMT2ZSV DN 1-(4-Fluorobenzyl)-5-phenyl-1H-imidazole DMT2ZSV TI TTIQUX7 DMT2ZSV TN Steroid 11-beta-hydroxylase (CYP11B1) DMT2ZSV MA Inhibitor DMT2ZSV RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMT2ZSV RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMT316S DI DMT316S DMT316S DN Tyr-(S)-spiro-Aba-Gly-Phe-NH2 DMT316S TI TTKWM86 DMT316S TN Opioid receptor mu (MOP) DMT316S MA Inhibitor DMT316S RN Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. DMT316S RU https://pubmed.ncbi.nlm.nih.gov/18062664 DMT316S DI DMT316S DMT316S DN Tyr-(S)-spiro-Aba-Gly-Phe-NH2 DMT316S TI TT27RFC DMT316S TN Opioid receptor delta (OPRD1) DMT316S MA Inhibitor DMT316S RN Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. DMT316S RU https://pubmed.ncbi.nlm.nih.gov/18062664 DMT36AB DI DMT36AB DMT36AB DN S-024 DMT36AB TI TTTU902 DMT36AB TN Checkpoint kinase-1 (CHK1) DMT36AB MA Inhibitor DMT36AB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1987). DMT36AB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1987 DMT3AW8 DI DMT3AW8 DMT3AW8 DN 3-(3,4-dichlorophenyl)-2-nortropene DMT3AW8 TI TTVBI8W DMT3AW8 TN Dopamine transporter (DAT) DMT3AW8 MA Inhibitor DMT3AW8 RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMT3AW8 RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMT3AW8 DI DMT3AW8 DMT3AW8 DN 3-(3,4-dichlorophenyl)-2-nortropene DMT3AW8 TI TT3ROYC DMT3AW8 TN Serotonin transporter (SERT) DMT3AW8 MA Inhibitor DMT3AW8 RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMT3AW8 RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMT3BX9 DI DMT3BX9 DMT3BX9 DN 4'-(trifluoromethyl)-4-biphenylyl carbamate DMT3BX9 TI TTBGTCW DMT3BX9 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMT3BX9 MA Inhibitor DMT3BX9 RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMT3BX9 RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMT3EU2 DI DMT3EU2 DMT3EU2 DN PMID16242323C26c DMT3EU2 TI TTK3C21 DMT3EU2 TN Acetoacetyl-CoA thiolase (ACAT1) DMT3EU2 MA Inhibitor DMT3EU2 RN Synthesis and biological activity of novel 4-phenyl-1,8-naphthyridin-2(1H)-on-3-yl ureas: potent acyl-CoA:cholesterol acyltransferase inhibitor wit... Bioorg Med Chem Lett. 2006 Jan 1;16(1):44-8. DMT3EU2 RU https://pubmed.ncbi.nlm.nih.gov/16242323 DMT3GAD DI DMT3GAD DMT3GAD DN (10H-phenothiazin-10-yl)(phenyl)methanone DMT3GAD TI TTEB0GD DMT3GAD TN Cholinesterase (BCHE) DMT3GAD MA Inhibitor DMT3GAD RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMT3GAD RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMT3H0K DI DMT3H0K DMT3H0K DN 1-(4-(benzyloxy)phenethyl)pyrrolidine DMT3H0K TI TT9JNIC DMT3H0K TN Histamine H3 receptor (H3R) DMT3H0K MA Inhibitor DMT3H0K RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMT3H0K RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMT3H2X DI DMT3H2X DMT3H2X DN 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one DMT3H2X TI TTN9D8E DMT3H2X TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMT3H2X MA Inhibitor DMT3H2X RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMT3H2X RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMT3H2X DI DMT3H2X DMT3H2X DN 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one DMT3H2X TI TTKJEMQ DMT3H2X TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMT3H2X MA Inhibitor DMT3H2X RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMT3H2X RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMT3H2X DI DMT3H2X DMT3H2X DN 4-hydroxy-5-phenylthieno[2,3-b]pyridin-6(7H)-one DMT3H2X TI TTLD29N DMT3H2X TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMT3H2X MA Inhibitor DMT3H2X RN Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. J Med Chem. 2006 Feb 9;49(3):864-71. DMT3H2X RU https://pubmed.ncbi.nlm.nih.gov/16451052 DMT3IOB DI DMT3IOB DMT3IOB DN 8-[(3-Trifluoromethyl)benzyloxy]caffeine DMT3IOB TI TTGP7BY DMT3IOB TN Monoamine oxidase type B (MAO-B) DMT3IOB MA Inhibitor DMT3IOB RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMT3IOB RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMT3IOB DI DMT3IOB DMT3IOB DN 8-[(3-Trifluoromethyl)benzyloxy]caffeine DMT3IOB TI TT3WG5C DMT3IOB TN Monoamine oxidase type A (MAO-A) DMT3IOB MA Inhibitor DMT3IOB RN Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues. Bioorg Med Chem. 2010 Feb;18(3):1018-28. DMT3IOB RU https://pubmed.ncbi.nlm.nih.gov/20093036 DMT3JYE DI DMT3JYE DMT3JYE DN Benzyl 2-hydroxyiminoolean-12-en-28-oate DMT3JYE TI TTZHY6R DMT3JYE TN Glycogen phosphorylase muscle form (GP) DMT3JYE MA Inhibitor DMT3JYE RN Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8. DMT3JYE RU https://pubmed.ncbi.nlm.nih.gov/19642687 DMT3KP0 DI DMT3KP0 DMT3KP0 DN 2-Amino-6-(3-chloro-phenylsulfanyl)-benzonitrile DMT3KP0 TI TT84ETX DMT3KP0 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMT3KP0 MA Inhibitor DMT3KP0 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMT3KP0 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMT3MBD DI DMT3MBD DMT3MBD DN CAY10583 DMT3MBD TI TTVJX54 DMT3MBD TN Leukotriene B4 receptor 2 (LTB4R2) DMT3MBD MA Agonist DMT3MBD RN Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation and cell migration of primary mouse keratinocytes. J Biol Chem. 2005 Jul 1;280(26):24816-23. DMT3MBD RU https://pubmed.ncbi.nlm.nih.gov/15866883 DMT3ML6 DI DMT3ML6 DMT3ML6 DN AG-213 DMT3ML6 TI TTGKNB4 DMT3ML6 TN Epidermal growth factor receptor (EGFR) DMT3ML6 MA Inhibitor DMT3ML6 RN Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88. DMT3ML6 RU https://pubmed.ncbi.nlm.nih.gov/17981366 DMT3ML6 DI DMT3ML6 DMT3ML6 DN AG-213 DMT3ML6 TI TTR5TV4 DMT3ML6 TN ERBB2 messenger RNA (HER2 mRNA) DMT3ML6 MA Inhibitor DMT3ML6 RN Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88. DMT3ML6 RU https://pubmed.ncbi.nlm.nih.gov/17981366 DMT3RUE DI DMT3RUE DMT3RUE DN PMID16451062C46 DMT3RUE TI TT9RTBL DMT3RUE TN Aurora B messenger RNA (AURKB mRNA) DMT3RUE MA Inhibitor DMT3RUE RN Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006 Feb 9;49(3):955-70. DMT3RUE RU https://pubmed.ncbi.nlm.nih.gov/16451062 DMT3RUE DI DMT3RUE DMT3RUE DN PMID16451062C46 DMT3RUE TI TTLYXIT DMT3RUE TN Aurora kinase C (AURKC) DMT3RUE MA Inhibitor DMT3RUE RN Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J Med Chem. 2006 Feb 9;49(3):955-70. DMT3RUE RU https://pubmed.ncbi.nlm.nih.gov/16451062 DMT3S72 DI DMT3S72 DMT3S72 DN (South)-Methanocarba-Thymidine DMT3S72 TI TTP3QRF DMT3S72 TN Thymidine kinase 1 (TK1) DMT3S72 MA Inhibitor DMT3S72 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT3S72 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT3U2D DI DMT3U2D DMT3U2D DN Sulfamic acid 6-sulfamoyloxy-hexyl ester DMT3U2D TI TT2LVK8 DMT3U2D TN Carbonic anhydrase IX (CA-IX) DMT3U2D MA Inhibitor DMT3U2D RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMT3U2D RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMT3U2D DI DMT3U2D DMT3U2D DN Sulfamic acid 6-sulfamoyloxy-hexyl ester DMT3U2D TI TTANPDJ DMT3U2D TN Carbonic anhydrase II (CA-II) DMT3U2D MA Inhibitor DMT3U2D RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMT3U2D RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMT3U2D DI DMT3U2D DMT3U2D DN Sulfamic acid 6-sulfamoyloxy-hexyl ester DMT3U2D TI TTHQPL7 DMT3U2D TN Carbonic anhydrase I (CA-I) DMT3U2D MA Inhibitor DMT3U2D RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMT3U2D RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMT3Y6E DI DMT3Y6E DMT3Y6E DN H-Dmt-Tic-Lys-NH-Ph DMT3Y6E TI TT27RFC DMT3Y6E TN Opioid receptor delta (OPRD1) DMT3Y6E MA Inhibitor DMT3Y6E RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMT3Y6E RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMT3Y6E DI DMT3Y6E DMT3Y6E DN H-Dmt-Tic-Lys-NH-Ph DMT3Y6E TI TTKWM86 DMT3Y6E TN Opioid receptor mu (MOP) DMT3Y6E MA Inhibitor DMT3Y6E RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMT3Y6E RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMT3YI5 DI DMT3YI5 DMT3YI5 DN ISIS 183882 DMT3YI5 TI TTBGTCW DMT3YI5 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMT3YI5 RN US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression. DMT3YI5 RU http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true DMT4856 DI DMT4856 DMT4856 DN 5-(4-bromophenyl)-2-furaldehyde thiosemicarbazone DMT4856 TI TTEAID7 DMT4856 TN Trypanosoma Cruzipain (Trypano CYSP) DMT4856 MA Inhibitor DMT4856 RN Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707. DMT4856 RU https://pubmed.ncbi.nlm.nih.gov/12061873 DMT4I2W DI DMT4I2W DMT4I2W DN Aom-0890 DMT4I2W TI TTJ0IQB DMT4I2W TN Phosphodiesterase 5A (PDE5A) DMT4I2W MA Inhibitor DMT4I2W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304). DMT4I2W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304 DMT4JCW DI DMT4JCW DMT4JCW DN Ribavirin + interferon alfa-2b DMT4JCW TI TTOA6YT DMT4JCW TN MERS-CoV RNA-directed RNA polymerase (RdRp) DMT4JCW MA Inhibitor DMT4JCW RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMT4JCW RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMT4NM5 DI DMT4NM5 DMT4NM5 DN BRL-48482 DMT4NM5 TI TTT2SVW DMT4NM5 TN PPAR-gamma messenger RNA (PPARG mRNA) DMT4NM5 MA Inhibitor DMT4NM5 RN Non thiazolidinedione antihyperglycaemic agents. 2: alpha-Carbon substituted beta-phenylpropanoic acids1, Bioorg. Med. Chem. Lett. 6(17):2127-2130 (1996). DMT4NM5 RU http://www.sciencedirect.com/science/article/pii/0960894X96003824 DMT4NWX DI DMT4NWX DMT4NWX DN TELUDIPINE HYDROCHLORIDE DMT4NWX TI TT5HONZ DMT4NWX TN Calcium channel unspecific (CaC) DMT4NWX MA Blocker DMT4NWX RN Effects of R-enantiomer (GR66234A) and L-enantiomer (GR66235A) of telupidine, a new dihydropyridine derivative, on cell lines displaying the multidrug resistant phenotype. Haematologica. 1994 Jul-Aug;79(4):328-33. DMT4NWX RU https://pubmed.ncbi.nlm.nih.gov/7806087 DMT4RI2 DI DMT4RI2 DMT4RI2 DN Isoquinoline-1,3,4(2H)-trione DMT4RI2 TI TTPF2QI DMT4RI2 TN Caspase-3 (CASP3) DMT4RI2 MA Inhibitor DMT4RI2 RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMT4RI2 RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMT4RI2 DI DMT4RI2 DMT4RI2 DN Isoquinoline-1,3,4(2H)-trione DMT4RI2 TI TTKW4ML DMT4RI2 TN Caspase 6 messenger RNA (CASP6 mRNA) DMT4RI2 MA Inhibitor DMT4RI2 RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMT4RI2 RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMT4RI2 DI DMT4RI2 DMT4RI2 DN Isoquinoline-1,3,4(2H)-trione DMT4RI2 TI TTZY5KP DMT4RI2 TN Caspase (CASP) DMT4RI2 MA Inhibitor DMT4RI2 RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMT4RI2 RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMT4RI2 DI DMT4RI2 DMT4RI2 DN Isoquinoline-1,3,4(2H)-trione DMT4RI2 TI TT6SZNG DMT4RI2 TN Caspase 8 messenger RNA (CASP8 mRNA) DMT4RI2 MA Inhibitor DMT4RI2 RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMT4RI2 RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMT4USP DI DMT4USP DMT4USP DN N,N'-Bis(4-Amino-2-Methylquinolin-6-Yl)Urea DMT4USP TI TTIQSC1 DMT4USP TN Bacterial Lethal factor (Bact lef) DMT4USP MA Inhibitor DMT4USP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT4USP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT4XJM DI DMT4XJM DMT4XJM DN ETHYL HYDROGEN DIETHYLAMIDOPHOSPHATE DMT4XJM TI TTEB0GD DMT4XJM TN Cholinesterase (BCHE) DMT4XJM MA Inhibitor DMT4XJM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMT4XJM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMT4YFR DI DMT4YFR DMT4YFR DN PS-662477 DMT4YFR TI TTXMNHO DMT4YFR TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMT4YFR MA Inhibitor DMT4YFR RN Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library. Bioorg Med Chem Lett. 1998 Sep 8;8(17):2315-20. DMT4YFR RU https://pubmed.ncbi.nlm.nih.gov/9873534 DMT51QD DI DMT51QD DMT51QD DN ETHYLPHENSERINE DMT51QD TI TT1RS9F DMT51QD TN Acetylcholinesterase (AChE) DMT51QD MA Inhibitor DMT51QD RN Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based vi... J Med Chem. 2010 Sep 9;53(17):6490-505. DMT51QD RU https://pubmed.ncbi.nlm.nih.gov/20684567 DMT53U6 DI DMT53U6 DMT53U6 DN SX-GLP1 DMT53U6 TI TTVIMDE DMT53U6 TN Glucagon-like peptide 1 receptor (GLP1R) DMT53U6 MA Agonist DMT53U6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMT53U6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMT56ER DI DMT56ER DMT56ER DN Mercuribenzoic Acid DMT56ER TI TTANPDJ DMT56ER TN Carbonic anhydrase II (CA-II) DMT56ER MA Inhibitor DMT56ER RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT56ER RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT59UG DI DMT59UG DMT59UG DN OCOPHYLLALS A DMT59UG TI TTVKILB DMT59UG TN Prostaglandin G/H synthase 2 (COX-2) DMT59UG MA Inhibitor DMT59UG RN COX, LOX and platelet aggregation inhibitory properties of Lauraceae neolignans. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6922-5. DMT59UG RU https://pubmed.ncbi.nlm.nih.gov/19880317 DMT5AGJ DI DMT5AGJ DMT5AGJ DN BCTC DMT5AGJ TI TTMI6F5 DMT5AGJ TN Transient receptor potential cation channel V1 (TRPV1) DMT5AGJ MA Blocker DMT5AGJ RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMT5AGJ RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMT5E36 DI DMT5E36 DMT5E36 DN Bicarbonate DMT5E36 TI TT2LVK8 DMT5E36 TN Carbonic anhydrase IX (CA-IX) DMT5E36 MA Inhibitor DMT5E36 RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V, and IX with anions isosteric and isoelectronic with sulfate, nitrate, and carbo... Bioorg Med Chem Lett. 2005 Feb 1;15(3):567-71. DMT5E36 RU https://pubmed.ncbi.nlm.nih.gov/15664814 DMT5FIP DI DMT5FIP DMT5FIP DN KNI-10760 DMT5FIP TI TTXMNHO DMT5FIP TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMT5FIP MA Inhibitor DMT5FIP RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMT5FIP RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMT5HOA DI DMT5HOA DMT5HOA DN amino-propylphosphinic acid DMT5HOA TI TTDCVZW DMT5HOA TN Gamma-aminobutyric acid B receptor (GABBR) DMT5HOA MA Agonist DMT5HOA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 242). DMT5HOA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=242 DMT5LJN DI DMT5LJN DMT5LJN DN ASC-JMZ1 DMT5LJN TI TTS64P2 DMT5LJN TN Androgen receptor (AR) DMT5LJN MA Modulator DMT5LJN RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMT5LJN RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMT5P8O DI DMT5P8O DMT5P8O DN Axogenesis Factor-1 DMT5P8O TI TTEDJN4 DMT5P8O TN Low-affinity nerve growth factor receptor (NGFR) DMT5P8O MA Modulator DMT5P8O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1888). DMT5P8O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888 DMT5R1Q DI DMT5R1Q DMT5R1Q DN CVS-2139 DMT5R1Q TI TT2WR1T DMT5R1Q TN Cationic trypsinogen (PRSS1) DMT5R1Q MA Inhibitor DMT5R1Q RN Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1203-8. DMT5R1Q RU https://pubmed.ncbi.nlm.nih.gov/11934589 DMT5S2O DI DMT5S2O DMT5S2O DN 1-(2-Butoxy-phenyl)-piperazine DMT5S2O TI TT6MSOK DMT5S2O TN 5-HT 1D receptor (HTR1D) DMT5S2O MA Inhibitor DMT5S2O RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DMT5S2O RU https://pubmed.ncbi.nlm.nih.gov/2565400 DMT5S2O DI DMT5S2O DMT5S2O DN 1-(2-Butoxy-phenyl)-piperazine DMT5S2O TI TTSQIFT DMT5S2O TN 5-HT 1A receptor (HTR1A) DMT5S2O MA Inhibitor DMT5S2O RN Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy. J Med Chem. 1989 May;32(5):1052-6. DMT5S2O RU https://pubmed.ncbi.nlm.nih.gov/2565400 DMT5SED DI DMT5SED DMT5SED DN CORDOIN DMT5SED TI TTGP7BY DMT5SED TN Monoamine oxidase type B (MAO-B) DMT5SED MA Inhibitor DMT5SED RN Chalcones: a valid scaffold for monoamine oxidases inhibitors. J Med Chem. 2009 May 14;52(9):2818-24. DMT5SED RU https://pubmed.ncbi.nlm.nih.gov/19378991 DMT5SXR DI DMT5SXR DMT5SXR DN WS-23 DMT5SXR TI TTXDKTO DMT5SXR TN Long transient receptor potential channel 8 (TRPM8) DMT5SXR MA Activator DMT5SXR RN Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol. 2004 Feb;141(4):737-45. DMT5SXR RU https://pubmed.ncbi.nlm.nih.gov/14757700 DMT5UMG DI DMT5UMG DMT5UMG DN UH-AH 37 DMT5UMG TI TTQ13Z5 DMT5UMG TN Muscarinic acetylcholine receptor M3 (CHRM3) DMT5UMG MA Antagonist DMT5UMG RN Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998 May 22;349(2-3):285-92. DMT5UMG RU https://pubmed.ncbi.nlm.nih.gov/9671109 DMT5UMG DI DMT5UMG DMT5UMG DN UH-AH 37 DMT5UMG TI TTOXS3C DMT5UMG TN Muscarinic acetylcholine receptor (CHRM) DMT5UMG MA Antagonist DMT5UMG RN Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol. 1998 May 22;349(2-3):285-92. DMT5UMG RU https://pubmed.ncbi.nlm.nih.gov/9671109 DMT60AM DI DMT60AM DMT60AM DN 5-(piperidin-1-ylsulfonyl)indoline-2,3-dione DMT60AM TI TTPF2QI DMT60AM TN Caspase-3 (CASP3) DMT60AM MA Inhibitor DMT60AM RN Design, synthesis, and discovery of novel non-peptide inhibitor of Caspase-3 using ligand based and structure based virtual screening approach. Bioorg Med Chem. 2009 Aug 15;17(16):6040-7. DMT60AM RU https://pubmed.ncbi.nlm.nih.gov/19631549 DMT62LS DI DMT62LS DMT62LS DN SHU9119 DMT62LS TI TTNI91K DMT62LS TN Melanocortin receptor 3 (MC3R) DMT62LS MA Antagonist DMT62LS RN Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum. 2002 Oct;46(10):2765-75. DMT62LS RU https://pubmed.ncbi.nlm.nih.gov/12384937 DMT68RG DI DMT68RG DMT68RG DN K252a DMT68RG TI TTSLUMT DMT68RG TN Protein kinase D (PRKD1) DMT68RG MA Inhibitor DMT68RG RN Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92. DMT68RG RU https://pubmed.ncbi.nlm.nih.gov/20580776 DMT6A7G DI DMT6A7G DMT6A7G DN A-690344 DMT6A7G TI TT4C8EA DMT6A7G TN Dopamine D3 receptor (D3R) DMT6A7G MA Inhibitor DMT6A7G RN Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):490-4. DMT6A7G RU https://pubmed.ncbi.nlm.nih.gov/16290141 DMT6A7G DI DMT6A7G DMT6A7G DN A-690344 DMT6A7G TI TTEX248 DMT6A7G TN Dopamine D2 receptor (D2R) DMT6A7G MA Inhibitor DMT6A7G RN Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: 1H-pyrimidin-2-one derivatives. Bioorg Med Chem Lett. 2006 Feb;16(3):490-4. DMT6A7G RU https://pubmed.ncbi.nlm.nih.gov/16290141 DMT6APV DI DMT6APV DMT6APV DN 2-Hydroxyethyl 18-methoxycoronaridinate DMT6APV TI TTTVAFQ DMT6APV TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMT6APV MA Inhibitor DMT6APV RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DMT6APV RU https://pubmed.ncbi.nlm.nih.gov/12801235 DMT6CV5 DI DMT6CV5 DMT6CV5 DN NSC-73613 DMT6CV5 TI TTNJYV2 DMT6CV5 TN Gamma-aminobutyric acid receptor (GAR) DMT6CV5 MA Inhibitor DMT6CV5 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMT6CV5 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMT6CV5 DI DMT6CV5 DMT6CV5 DN NSC-73613 DMT6CV5 TI TT1MPAY DMT6CV5 TN GABA(A) receptor alpha-1 (GABRA1) DMT6CV5 MA Inhibitor DMT6CV5 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMT6CV5 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMT6D5V DI DMT6D5V DMT6D5V DN 5'-([(Z)-4-amino-2-butenyl]methylamino)-5'-deoxyadenosine DMT6D5V TI TTBFROQ DMT6D5V TN S-adenosylmethionine decarboxylase proenzyme (AMD1) DMT6D5V MA Inhibitor DMT6D5V RN S-adenosylmethionine decarboxylase as an enzyme target for therapy. Pharmacol Ther. 1992 Dec;56(3):359-77. DMT6D5V RU https://pubmed.ncbi.nlm.nih.gov/1301596 DMT6H9S DI DMT6H9S DMT6H9S DN ISIS 10310 DMT6H9S TI TT7A1BO DMT6H9S TN PKC-delta messenger RNA (PRKCD mRNA) DMT6H9S RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMT6H9S RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMT6J51 DI DMT6J51 DMT6J51 DN (R)-zacopride DMT6J51 TI TT07C3Y DMT6J51 TN 5-HT 4 receptor (HTR4) DMT6J51 MA Modulator DMT6J51 RN R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):283-9. DMT6J51 RU https://www.ncbi.nlm.nih.gov/pubmed/11420096 DMT6J51 DI DMT6J51 DMT6J51 DN (R)-zacopride DMT6J51 TI TTNXLKE DMT6J51 TN 5-HT 3 receptor (5HT3R) DMT6J51 MA Modulator DMT6J51 RN R-zacopride, a 5-HT3 antagonist/5-HT4 agonist, reduces sleep apneas in rats. Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):283-9. DMT6J51 RU https://www.ncbi.nlm.nih.gov/pubmed/11420096 DMT6JH9 DI DMT6JH9 DMT6JH9 DN MRS-1220 DMT6JH9 TI TTJFY5U DMT6JH9 TN Adenosine A3 receptor (ADORA3) DMT6JH9 MA Antagonist DMT6JH9 RN A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol. 1999 Nov;277(5 Pt 2):H1895-905. DMT6JH9 RU https://pubmed.ncbi.nlm.nih.gov/10564145 DMT6KI7 DI DMT6KI7 DMT6KI7 DN Alpha-Phosphoribosylpyrophosphoric Acid DMT6KI7 TI TTAFJUD DMT6KI7 TN Orotidine 5'-monophosphate decarboxylase (UMPS) DMT6KI7 MA Inhibitor DMT6KI7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMT6KI7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMT6KI7 DI DMT6KI7 DMT6KI7 DN Alpha-Phosphoribosylpyrophosphoric Acid DMT6KI7 TI TTBL49X DMT6KI7 TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMT6KI7 MA Inhibitor DMT6KI7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMT6KI7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMT6LX9 DI DMT6LX9 DMT6LX9 DN N-[4-(1H-benzoimidazol-2-yl)-benzoyl]-guanidine DMT6LX9 TI TTGSEFH DMT6LX9 TN Sodium/hydrogen exchanger 1 (SLC9A1) DMT6LX9 MA Inhibitor DMT6LX9 RN Benzimidazol-2-yl or benzimidazol-2-ylthiomethyl benzoylguanidines as novel Na+/H+ exchanger inhibitors, synthesis and protection against ischemic-... Bioorg Med Chem Lett. 2007 May 1;17(9):2430-3. DMT6LX9 RU https://pubmed.ncbi.nlm.nih.gov/17346962 DMT6M5E DI DMT6M5E DMT6M5E DN CD-160130 DMT6M5E TI TTZ97H5 DMT6M5E TN Phosphodiesterase 4A (PDE4A) DMT6M5E MA Inhibitor DMT6M5E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DMT6M5E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DMT6M5E DI DMT6M5E DMT6M5E DN CD-160130 DMT6M5E TI TTSKMI8 DMT6M5E TN Phosphodiesterase 4D (PDE4D) DMT6M5E MA Inhibitor DMT6M5E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DMT6M5E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DMT6M5E DI DMT6M5E DMT6M5E DN CD-160130 DMT6M5E TI TTVIAT9 DMT6M5E TN Phosphodiesterase 4B (PDE4B) DMT6M5E MA Inhibitor DMT6M5E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DMT6M5E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DMT6YUF DI DMT6YUF DMT6YUF DN 8-propyl-2,6-diphenyl-9H-purine DMT6YUF TI TTJFY5U DMT6YUF TN Adenosine A3 receptor (ADORA3) DMT6YUF MA Inhibitor DMT6YUF RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMT6YUF RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMT6YUF DI DMT6YUF DMT6YUF DN 8-propyl-2,6-diphenyl-9H-purine DMT6YUF TI TTK25J1 DMT6YUF TN Adenosine A1 receptor (ADORA1) DMT6YUF MA Inhibitor DMT6YUF RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMT6YUF RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMT6YUF DI DMT6YUF DMT6YUF DN 8-propyl-2,6-diphenyl-9H-purine DMT6YUF TI TTM2AOE DMT6YUF TN Adenosine A2a receptor (ADORA2A) DMT6YUF MA Inhibitor DMT6YUF RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMT6YUF RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMT72FB DI DMT72FB DMT72FB DN 3-(aminomethyl)-4-(thiophen-2-yl)butanoic acid DMT72FB TI TTFK1JQ DMT72FB TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMT72FB MA Inhibitor DMT72FB RN Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32. DMT72FB RU https://pubmed.ncbi.nlm.nih.gov/16099652 DMT74F5 DI DMT74F5 DMT74F5 DN AcAsp-D-Gla-Leu-Ile-Cha-Cys DMT74F5 TI TTWXB3E DMT74F5 TN Hepatitis C virus NS3 helicase (HCV NS3) DMT74F5 MA Inhibitor DMT74F5 RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMT74F5 RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMT74N6 DI DMT74N6 DMT74N6 DN Thieno[3,2-e][1]benzothiophene-4,5-dione DMT74N6 TI TTMF541 DMT74N6 TN Liver carboxylesterase (CES1) DMT74N6 MA Inhibitor DMT74N6 RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMT74N6 RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMT76JS DI DMT76JS DMT76JS DN VU0092273 DMT76JS TI TTHS256 DMT76JS TN Metabotropic glutamate receptor 5 (mGluR5) DMT76JS MA Modulator (allosteric modulator) DMT76JS RN Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol.2012 Feb;81(2):120-33. DMT76JS RU https://pubmed.ncbi.nlm.nih.gov/22021324 DMT7G32 DI DMT7G32 DMT7G32 DN PT-310 DMT7G32 TI TT84ETX DMT7G32 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMT7G32 MA Inhibitor DMT7G32 RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMT7G32 RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMT7JUC DI DMT7JUC DMT7JUC DN N-(2-aminophenyl)-4-(chroman-3-ylmethyl)benzamide DMT7JUC TI TT6R7JZ DMT7JUC TN Histone deacetylase 1 (HDAC1) DMT7JUC MA Inhibitor DMT7JUC RN N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6729-33. DMT7JUC RU https://pubmed.ncbi.nlm.nih.gov/17977726 DMT7K0U DI DMT7K0U DMT7K0U DN Glutamine Hydroxamate DMT7K0U TI TTC67I0 DMT7K0U TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMT7K0U MA Inhibitor DMT7K0U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT7K0U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT7MVD DI DMT7MVD DMT7MVD DN 2-methyl-7-phenylquinoline DMT7MVD TI TTHS256 DMT7MVD TN Metabotropic glutamate receptor 5 (mGluR5) DMT7MVD MA Inhibitor DMT7MVD RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMT7MVD RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMT7P2Z DI DMT7P2Z DMT7P2Z DN 1-(oxazolo[4,5-b]pyridin-2-yl)dodecan-1-one DMT7P2Z TI TTDP1UC DMT7P2Z TN Fatty acid amide hydrolase (FAAH) DMT7P2Z MA Inhibitor DMT7P2Z RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMT7P2Z RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMT7RXZ DI DMT7RXZ DMT7RXZ DN E-pentenylbutanedioic acid 32 DMT7RXZ TI TT5VER7 DMT7RXZ TN Bacterial Undecaprenyl pyrophosphate synthetase (Bact ispU) DMT7RXZ MA Inhibitor DMT7RXZ RN Synthesis and biological activity of isopentenyl diphosphate analogues. Bioorg Med Chem. 2004 Feb 15;12(4):763-70. DMT7RXZ RU https://pubmed.ncbi.nlm.nih.gov/14759736 DMT7XYE DI DMT7XYE DMT7XYE DN Oxalylaminobenzoic acid DMT7XYE TI TTELIN2 DMT7XYE TN PTPN1 messenger RNA (PTPN1 mRNA) DMT7XYE MA Inhibitor DMT7XYE RN Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18. DMT7XYE RU https://pubmed.ncbi.nlm.nih.gov/20627471 DMT7YR3 DI DMT7YR3 DMT7YR3 DN 2-methoxy-4-(o-tolyloxy)benzonitrile DMT7YR3 TI TTKPW01 DMT7YR3 TN Androgen receptor messenger RNA (AR mRNA) DMT7YR3 MA Inhibitor DMT7YR3 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMT7YR3 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMT80IF DI DMT80IF DMT80IF DN 3570-0208 DMT80IF TI TT5Y4EM DMT80IF TN N-formyl peptide receptor (FPR1) DMT80IF MA Antagonist DMT80IF RN Discovery of selective probes and antagonists for G-protein-coupled receptors FPR/FPRL1 and GPR30. Curr Top Med Chem. 2009;9(13):1227-36. DMT80IF RU https://pubmed.ncbi.nlm.nih.gov/19807662 DMT81N3 DI DMT81N3 DMT81N3 DN 1-(4-(benzyloxy)phenyl)propan-2-amine DMT81N3 TI TTGP7BY DMT81N3 TN Monoamine oxidase type B (MAO-B) DMT81N3 MA Inhibitor DMT81N3 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMT81N3 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMT81N3 DI DMT81N3 DMT81N3 DN 1-(4-(benzyloxy)phenyl)propan-2-amine DMT81N3 TI TT3WG5C DMT81N3 TN Monoamine oxidase type A (MAO-A) DMT81N3 MA Inhibitor DMT81N3 RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMT81N3 RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMT81SD DI DMT81SD DMT81SD DN 4'-trifluoromethyl-biphenyl-4-ylamine DMT81SD TI TTBGTCW DMT81SD TN Kinesin spindle messenger RNA (KIF11 mRNA) DMT81SD MA Inhibitor DMT81SD RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMT81SD RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMT847Y DI DMT847Y DMT847Y DN 2-(4-hydroxyphenyl)-7-methoxychroman-4-one DMT847Y TI TTSZLWK DMT847Y TN Aromatase (CYP19A1) DMT847Y MA Inhibitor DMT847Y RN New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80. DMT847Y RU https://pubmed.ncbi.nlm.nih.gov/18042388 DMT893N DI DMT893N DMT893N DN N5-(1-iminobutyl)-L-ornithine DMT893N TI TTCM4B3 DMT893N TN Nitric-oxide synthase endothelial (NOS3) DMT893N MA Inhibitor DMT893N RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DMT893N RU https://pubmed.ncbi.nlm.nih.gov/19013076 DMT893N DI DMT893N DMT893N DN N5-(1-iminobutyl)-L-ornithine DMT893N TI TTZUFI5 DMT893N TN Nitric-oxide synthase brain (NOS1) DMT893N MA Inhibitor DMT893N RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DMT893N RU https://pubmed.ncbi.nlm.nih.gov/19013076 DMT893N DI DMT893N DMT893N DN N5-(1-iminobutyl)-L-ornithine DMT893N TI TTF10I9 DMT893N TN Nitric-oxide synthase inducible (NOS2) DMT893N MA Inhibitor DMT893N RN Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. DMT893N RU https://pubmed.ncbi.nlm.nih.gov/19013076 DMT8GWX DI DMT8GWX DMT8GWX DN ISIS 32005 DMT8GWX TI TT9H4P3 DMT8GWX TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMT8GWX RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMT8GWX RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMT8HP1 DI DMT8HP1 DMT8HP1 DN (R)-2-methyl-1-(2-m-tolyl-ethyl)-pyrrolidine DMT8HP1 TI TT9JNIC DMT8HP1 TN Histamine H3 receptor (H3R) DMT8HP1 MA Inhibitor DMT8HP1 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMT8HP1 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMT8KI6 DI DMT8KI6 DMT8KI6 DN d[Pen1,Tyr(Me)2]AVP DMT8KI6 TI TTK8R02 DMT8KI6 TN Vasopressin V2 receptor (V2R) DMT8KI6 MA Antagonist DMT8KI6 RN Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463. Kidney Int. 2000 Oct;58(4):1613-22. DMT8KI6 RU https://pubmed.ncbi.nlm.nih.gov/11012895 DMT8KI6 DI DMT8KI6 DMT8KI6 DN d[Pen1,Tyr(Me)2]AVP DMT8KI6 TI TTL9MHW DMT8KI6 TN Vasopressin V1b receptor (V1BR) DMT8KI6 MA Antagonist DMT8KI6 RN Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Dec;125(7):1463-70. DMT8KI6 RU https://pubmed.ncbi.nlm.nih.gov/9884074 DMT8KI6 DI DMT8KI6 DMT8KI6 DN d[Pen1,Tyr(Me)2]AVP DMT8KI6 TI TT4TFGN DMT8KI6 TN Vasopressin V1a receptor (V1AR) DMT8KI6 MA Antagonist DMT8KI6 RN Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Dec;125(7):1463-70. DMT8KI6 RU https://pubmed.ncbi.nlm.nih.gov/9884074 DMT8L5R DI DMT8L5R DMT8L5R DN 4-Hydroxy-Aconitate Ion DMT8L5R TI TTMTF2P DMT8L5R TN Citrate hydro-lyase (ACO2) DMT8L5R MA Inhibitor DMT8L5R RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMT8L5R RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMT8PKC DI DMT8PKC DMT8PKC DN SUVN-501 DMT8PKC TI TTJS8PY DMT8PKC TN 5-HT 6 receptor (HTR6) DMT8PKC MA Antagonist DMT8PKC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11). DMT8PKC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11 DMT8QAP DI DMT8QAP DMT8QAP DN 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- DMT8QAP TI TT78R5H DMT8QAP TN Heat shock protein 90 alpha (HSP90A) DMT8QAP MA Inhibitor DMT8QAP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMT8QAP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMT8VUS DI DMT8VUS DMT8VUS DN GNF-PF-5618 DMT8VUS TI TTZ9SOR DMT8VUS TN Muscarinic acetylcholine receptor M1 (CHRM1) DMT8VUS MA Inhibitor DMT8VUS RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMT8VUS RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMT8VUS DI DMT8VUS DMT8VUS DN GNF-PF-5618 DMT8VUS TI TTYEG6Q DMT8VUS TN Muscarinic acetylcholine receptor M2 (CHRM2) DMT8VUS MA Inhibitor DMT8VUS RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMT8VUS RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMT8VUS DI DMT8VUS DMT8VUS DN GNF-PF-5618 DMT8VUS TI TTH18TF DMT8VUS TN Muscarinic acetylcholine receptor M5 (CHRM5) DMT8VUS MA Inhibitor DMT8VUS RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMT8VUS RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMT8VUS DI DMT8VUS DMT8VUS DN GNF-PF-5618 DMT8VUS TI TTQ13Z5 DMT8VUS TN Muscarinic acetylcholine receptor M3 (CHRM3) DMT8VUS MA Inhibitor DMT8VUS RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMT8VUS RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMT8VUS DI DMT8VUS DMT8VUS DN GNF-PF-5618 DMT8VUS TI TTQ3JTF DMT8VUS TN Muscarinic acetylcholine receptor M4 (CHRM4) DMT8VUS MA Inhibitor DMT8VUS RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMT8VUS RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMT8X45 DI DMT8X45 DMT8X45 DN [Ncy(SO,methyl)10]acyline DMT8X45 TI TT8R70G DMT8X45 TN Gonadotropin-releasing hormone receptor (GNRHR) DMT8X45 MA Inhibitor DMT8X45 RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMT8X45 RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMT8Y65 DI DMT8Y65 DMT8Y65 DN ASIATIC ACID DMT8Y65 TI TTZHY6R DMT8Y65 TN Glycogen phosphorylase muscle form (GP) DMT8Y65 MA Inhibitor DMT8Y65 RN Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54. DMT8Y65 RU https://pubmed.ncbi.nlm.nih.gov/18517260 DMT967L DI DMT967L DMT967L DN VTT-201 DMT967L TI TTS78AZ DMT967L TN Prostate specific antigen (KLK3) DMT967L MA Modulator DMT967L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2373). DMT967L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2373 DMT97KV DI DMT97KV DMT97KV DN NS-1643 DMT97KV TI TTQ6VDM DMT97KV TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMT97KV MA Opener DMT97KV RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 572). DMT97KV RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=572 DMT98PA DI DMT98PA DMT98PA DN GSK-812397 DMT98PA TI TTBID49 DMT98PA TN C-X-C chemokine receptor type 4 (CXCR4) DMT98PA MA Antagonist DMT98PA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMT98PA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMT9BPN DI DMT9BPN DMT9BPN DN 8-hydroxyguanine DMT9BPN TI TTLSWP6 DMT9BPN TN GTP cyclohydrolase-I (GCH1) DMT9BPN MA Inhibitor DMT9BPN RN GTP cyclohydrolase I feedback regulatory protein-dependent and -independent inhibitors of GTP cyclohydrolase I. Arch Biochem Biophys. 2001 Apr 1;388(1):67-73. DMT9BPN RU https://pubmed.ncbi.nlm.nih.gov/11361142 DMT9CXD DI DMT9CXD DMT9CXD DN (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine DMT9CXD TI TTF10I9 DMT9CXD TN Nitric-oxide synthase inducible (NOS2) DMT9CXD MA Inhibitor DMT9CXD RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMT9CXD RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMT9CXD DI DMT9CXD DMT9CXD DN (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine DMT9CXD TI TTZUFI5 DMT9CXD TN Nitric-oxide synthase brain (NOS1) DMT9CXD MA Inhibitor DMT9CXD RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMT9CXD RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMT9CXD DI DMT9CXD DMT9CXD DN (5S,6R)-[Octahydro-quinolin-(2E)-ylidene]amine DMT9CXD TI TTCM4B3 DMT9CXD TN Nitric-oxide synthase endothelial (NOS3) DMT9CXD MA Inhibitor DMT9CXD RN Bicyclic amidine inhibitors of nitric oxide synthase: discovery of perhydro-iminopyrindine and perhydro-iminoquinoline as potent, orally active inh... Bioorg Med Chem Lett. 2005 Apr 15;15(8):1997-2001. DMT9CXD RU https://pubmed.ncbi.nlm.nih.gov/15808455 DMT9F15 DI DMT9F15 DMT9F15 DN ISIS 29154 DMT9F15 TI TTO6SGY DMT9F15 TN AKT3 messenger RNA (AKT3 mRNA) DMT9F15 RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMT9F15 RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMT9FJZ DI DMT9FJZ DMT9FJZ DN AGROCLAVINE DMT9FJZ TI TTSQIFT DMT9FJZ TN 5-HT 1A receptor (HTR1A) DMT9FJZ MA Inhibitor DMT9FJZ RN Ergolines as selective 5-HT1 agonists. J Med Chem. 1988 Aug;31(8):1512-9. DMT9FJZ RU https://pubmed.ncbi.nlm.nih.gov/2456389 DMT9FJZ DI DMT9FJZ DMT9FJZ DN AGROCLAVINE DMT9FJZ TI TT6MSOK DMT9FJZ TN 5-HT 1D receptor (HTR1D) DMT9FJZ MA Inhibitor DMT9FJZ RN Ergolines as selective 5-HT1 agonists. J Med Chem. 1988 Aug;31(8):1512-9. DMT9FJZ RU https://pubmed.ncbi.nlm.nih.gov/2456389 DMT9FQN DI DMT9FQN DMT9FQN DN 5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one DMT9FQN TI TTGP7BY DMT9FQN TN Monoamine oxidase type B (MAO-B) DMT9FQN MA Inhibitor DMT9FQN RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DMT9FQN RU https://pubmed.ncbi.nlm.nih.gov/11881986 DMT9FQN DI DMT9FQN DMT9FQN DN 5-Hydroxymethyl-3-pyrrol-1-yl-oxazolidin-2-one DMT9FQN TI TT3WG5C DMT9FQN TN Monoamine oxidase type A (MAO-A) DMT9FQN MA Inhibitor DMT9FQN RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DMT9FQN RU https://pubmed.ncbi.nlm.nih.gov/11881986 DMT9FZD DI DMT9FZD DMT9FZD DN (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone DMT9FZD TI TT6L509 DMT9FZD TN Coagulation factor IIa (F2) DMT9FZD MA Inhibitor DMT9FZD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMT9FZD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMT9FZD DI DMT9FZD DMT9FZD DN (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone DMT9FZD TI TTMF8H9 DMT9FZD TN Plasma kallikrein (KLKB1) DMT9FZD MA Inhibitor DMT9FZD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMT9FZD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMT9FZD DI DMT9FZD DMT9FZD DN (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone DMT9FZD TI TTGY7WI DMT9FZD TN Urokinase-type plasminogen activator (PLAU) DMT9FZD MA Inhibitor DMT9FZD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMT9FZD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMT9FZD DI DMT9FZD DMT9FZD DN (3-nitro-1H-pyrazol-1-yl)(p-tolyl)methanone DMT9FZD TI TTPLTSQ DMT9FZD TN Neutrophil elastase (NE) DMT9FZD MA Inhibitor DMT9FZD RN N-benzoylpyrazoles are novel small-molecule inhibitors of human neutrophil elastase. J Med Chem. 2007 Oct 4;50(20):4928-38. DMT9FZD RU https://pubmed.ncbi.nlm.nih.gov/17850059 DMT9JHV DI DMT9JHV DMT9JHV DN 2,7-Bis(3-chloropropionamido)anthraquinone DMT9JHV TI TTQY2EJ DMT9JHV TN TERT messenger RNA (TERT mRNA) DMT9JHV MA Inhibitor DMT9JHV RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMT9JHV RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMT9N1I DI DMT9N1I DMT9N1I DN A-76341 DMT9N1I TI TT3C1VN DMT9N1I TN Enzyme unspecific (Enz) DMT9N1I MA Modulator DMT9N1I RN WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting. DMT9N1I RU http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20131212&CC=WO&NR=2013185032A1&KC=A1 DMT9RAC DI DMT9RAC DMT9RAC DN 4-(2-Propynylthio)pyridine-3-sulfonamide DMT9RAC TI TTHQPL7 DMT9RAC TN Carbonic anhydrase I (CA-I) DMT9RAC MA Inhibitor DMT9RAC RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMT9RAC RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMT9RAC DI DMT9RAC DMT9RAC DN 4-(2-Propynylthio)pyridine-3-sulfonamide DMT9RAC TI TTSYM0R DMT9RAC TN Carbonic anhydrase XII (CA-XII) DMT9RAC MA Inhibitor DMT9RAC RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMT9RAC RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMT9RAC DI DMT9RAC DMT9RAC DN 4-(2-Propynylthio)pyridine-3-sulfonamide DMT9RAC TI TTANPDJ DMT9RAC TN Carbonic anhydrase II (CA-II) DMT9RAC MA Inhibitor DMT9RAC RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMT9RAC RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMT9RAC DI DMT9RAC DMT9RAC DN 4-(2-Propynylthio)pyridine-3-sulfonamide DMT9RAC TI TTEYTKG DMT9RAC TN Carbonic anhydrase XIV (CA-XIV) DMT9RAC MA Inhibitor DMT9RAC RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMT9RAC RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMT9RAC DI DMT9RAC DMT9RAC DN 4-(2-Propynylthio)pyridine-3-sulfonamide DMT9RAC TI TT2LVK8 DMT9RAC TN Carbonic anhydrase IX (CA-IX) DMT9RAC MA Inhibitor DMT9RAC RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMT9RAC RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMT9SAC DI DMT9SAC DMT9SAC DN 8S-HETE DMT9SAC TI TTJ584C DMT9SAC TN Peroxisome proliferator-activated receptor alpha (PPARA) DMT9SAC MA Agonist DMT9SAC RN Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem. 1995 Oct 13;270(41):23975-83. DMT9SAC RU https://pubmed.ncbi.nlm.nih.gov/7592593 DMT9WPJ DI DMT9WPJ DMT9WPJ DN WR-089120 DMT9WPJ TI TTSFWA7 DMT9WPJ TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMT9WPJ MA Inhibitor DMT9WPJ RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DMT9WPJ RU https://pubmed.ncbi.nlm.nih.gov/19250824 DMT9YKG DI DMT9YKG DMT9YKG DN CMI-936 DMT9YKG TI TTYEG6Q DMT9YKG TN Muscarinic acetylcholine receptor M2 (CHRM2) DMT9YKG MA Agonist DMT9YKG RN Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93. DMT9YKG RU https://pubmed.ncbi.nlm.nih.gov/12391271 DMT9YKG DI DMT9YKG DMT9YKG DN CMI-936 DMT9YKG TI TTQ3JTF DMT9YKG TN Muscarinic acetylcholine receptor M4 (CHRM4) DMT9YKG MA Agonist DMT9YKG RN Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93. DMT9YKG RU https://pubmed.ncbi.nlm.nih.gov/12391271 DMT9Z5A DI DMT9Z5A DMT9Z5A DN AP-Cav DMT9Z5A TI TTCM4B3 DMT9Z5A TN Nitric-oxide synthase endothelial (NOS3) DMT9Z5A MA Inhibitor DMT9Z5A RN Endothelial nitric oxide synthase: the Cinderella of inflammation Trends Pharmacol Sci. 2003 Feb;24(2):91-5. DMT9Z5A RU https://pubmed.ncbi.nlm.nih.gov/12559774 DMTA152 DI DMTA152 DMTA152 DN 2,4,6 trinitrobenzene sulfonate 1,3-bis (2-chlorethyl)-1-nitrosourea DMTA152 TI TTEP6RV DMTA152 TN Glutathione reductase (GR) DMTA152 MA Inhibitor DMTA152 RN The purification and properties of glutathione reductase from the cestode Moniezia expansa. Int J Biochem Cell Biol. 1995 Apr;27(4):393-401. DMTA152 RU https://pubmed.ncbi.nlm.nih.gov/7788561 DMTA6I5 DI DMTA6I5 DMTA6I5 DN Ac-His-DPhe(pCF3)-Arg-Trp-NH2 DMTA6I5 TI TTEOSZT DMTA6I5 TN Melanocortin receptor (MCR) DMTA6I5 MA Inhibitor DMTA6I5 RN Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93. DMTA6I5 RU https://pubmed.ncbi.nlm.nih.gov/18800761 DMTAB8W DI DMTAB8W DMTAB8W DN (E)-4-(2-(thiophen-3-yl)vinyl)benzenesulfonamide DMTAB8W TI TTVKILB DMTAB8W TN Prostaglandin G/H synthase 2 (COX-2) DMTAB8W MA Inhibitor DMTAB8W RN Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41. DMTAB8W RU https://pubmed.ncbi.nlm.nih.gov/20970329 DMTAGJ1 DI DMTAGJ1 DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide DMTAGJ1 TI TTSHTOI DMTAGJ1 TN Histone deacetylase 2 (HDAC2) DMTAGJ1 MA Inhibitor DMTAGJ1 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMTAGJ1 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMTAGJ1 DI DMTAGJ1 DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide DMTAGJ1 TI TTYHPU6 DMTAGJ1 TN Histone deacetylase 10 (HDAC10) DMTAGJ1 MA Inhibitor DMTAGJ1 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMTAGJ1 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMTAGJ1 DI DMTAGJ1 DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide DMTAGJ1 TI TT5ZKDI DMTAGJ1 TN Histone deacetylase 6 (HDAC6) DMTAGJ1 MA Inhibitor DMTAGJ1 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMTAGJ1 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMTAGJ1 DI DMTAGJ1 DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide DMTAGJ1 TI TT6R7JZ DMTAGJ1 TN Histone deacetylase 1 (HDAC1) DMTAGJ1 MA Inhibitor DMTAGJ1 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMTAGJ1 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMTAGJ1 DI DMTAGJ1 DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide DMTAGJ1 TI TTTQGH8 DMTAGJ1 TN Histone deacetylase 4 (HDAC4) DMTAGJ1 MA Inhibitor DMTAGJ1 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMTAGJ1 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMTAGJ1 DI DMTAGJ1 DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide DMTAGJ1 TI TTBH0VX DMTAGJ1 TN Histone deacetylase (HDAC) DMTAGJ1 MA Inhibitor DMTAGJ1 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMTAGJ1 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMTAGJ1 DI DMTAGJ1 DMTAGJ1 DN 7-Mercapto-heptanoic acid quinolin-3-ylamide DMTAGJ1 TI TTT6LFV DMTAGJ1 TN Histone deacetylase 8 (HDAC8) DMTAGJ1 MA Inhibitor DMTAGJ1 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMTAGJ1 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMTAJP7 DI DMTAJP7 DMTAJP7 DN Butanoic acid DMTAJP7 TI TTEB0GD DMTAJP7 TN Cholinesterase (BCHE) DMTAJP7 MA Inhibitor DMTAJP7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTAJP7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTANPG DI DMTANPG DMTANPG DN 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol DMTANPG TI TT27RFC DMTANPG TN Opioid receptor delta (OPRD1) DMTANPG MA Inhibitor DMTANPG RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMTANPG RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMTANPG DI DMTANPG DMTANPG DN 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol DMTANPG TI TTQW87Y DMTANPG TN Opioid receptor kappa (OPRK1) DMTANPG MA Inhibitor DMTANPG RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMTANPG RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMTANPG DI DMTANPG DMTANPG DN 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol DMTANPG TI TTKWM86 DMTANPG TN Opioid receptor mu (MOP) DMTANPG MA Inhibitor DMTANPG RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMTANPG RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMTANPG DI DMTANPG DMTANPG DN 1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol DMTANPG TI TTNT7K8 DMTANPG TN Nociceptin receptor (OPRL1) DMTANPG MA Inhibitor DMTANPG RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMTANPG RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMTASYN DI DMTASYN DMTASYN DN PMID19309152C2g DMTASYN TI TTWNV8U DMTASYN TN Nicotinic acid receptor (HCAR2) DMTASYN MA Agonist DMTASYN RN Discovery of novel tricyclic full agonists for the G-protein-coupled niacin receptor 109A with minimized flushing in rats. J Med Chem. 2009 Apr 23;52(8):2587-602. DMTASYN RU https://pubmed.ncbi.nlm.nih.gov/19309152 DMTAVU5 DI DMTAVU5 DMTAVU5 DN 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline DMTAVU5 TI TTM2AOE DMTAVU5 TN Adenosine A2a receptor (ADORA2A) DMTAVU5 MA Inhibitor DMTAVU5 RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DMTAVU5 RU https://pubmed.ncbi.nlm.nih.gov/16366607 DMTAVU5 DI DMTAVU5 DMTAVU5 DN 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline DMTAVU5 TI TTK25J1 DMTAVU5 TN Adenosine A1 receptor (ADORA1) DMTAVU5 MA Inhibitor DMTAVU5 RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DMTAVU5 RU https://pubmed.ncbi.nlm.nih.gov/16366607 DMTAVU5 DI DMTAVU5 DMTAVU5 DN 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline DMTAVU5 TI TTJFY5U DMTAVU5 TN Adenosine A3 receptor (ADORA3) DMTAVU5 MA Inhibitor DMTAVU5 RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DMTAVU5 RU https://pubmed.ncbi.nlm.nih.gov/16366607 DMTAWHL DI DMTAWHL DMTAWHL DN AM251 DMTAWHL TI TT6OEDT DMTAWHL TN Cannabinoid receptor 1 (CB1) DMTAWHL MA Antagonist DMTAWHL RN Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther. 2004 Apr;309(1):56-63. DMTAWHL RU https://pubmed.ncbi.nlm.nih.gov/14718591 DMTAXZI DI DMTAXZI DMTAXZI DN 16-(4-cyano-benzylidene)-estradiol DMTAXZI TI TTIWB6L DMTAXZI TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMTAXZI MA Inhibitor DMTAXZI RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMTAXZI RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMTAZ71 DI DMTAZ71 DMTAZ71 DN 5-Fluoro-6-ethyluridine-5'-O-monophosphate DMTAZ71 TI TTAFJUD DMTAZ71 TN Orotidine 5'-monophosphate decarboxylase (UMPS) DMTAZ71 MA Inhibitor DMTAZ71 RN Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58. DMTAZ71 RU https://pubmed.ncbi.nlm.nih.gov/19260677 DMTB1KV DI DMTB1KV DMTB1KV DN 2-Morpholin-4-yl-6-phenyl-chromen-4-one DMTB1KV TI TTK3PY9 DMTB1KV TN DNA-dependent protein kinase catalytic (PRKDC) DMTB1KV MA Inhibitor DMTB1KV RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMTB1KV RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMTB350 DI DMTB350 DMTB350 DN ISIS 183911 DMTB350 TI TTBGTCW DMTB350 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMTB350 RN US patent application no. 7,163,927, Antisense modulation of kinesin-like 1 expression. DMTB350 RU http://www.patentbuddy.com/Patent/7163927?ft=true&sr=true DMTB41W DI DMTB41W DMTB41W DN (3,4-DIHYDROXY-2-NITROPHENYL)(PHENYL)METHANONE DMTB41W TI TTKWFB8 DMTB41W TN Catechol-O-methyl-transferase (COMT) DMTB41W MA Inhibitor DMTB41W RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTB41W RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTB80W DI DMTB80W DMTB80W DN 4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one DMTB80W TI TT3WG5C DMTB80W TN Monoamine oxidase type A (MAO-A) DMTB80W MA Inhibitor DMTB80W RN Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706. DMTB80W RU https://pubmed.ncbi.nlm.nih.gov/19810674 DMTB80W DI DMTB80W DMTB80W DN 4-(Aminomethyl)-7-(benzyloxy)-2H-chromen-2-one DMTB80W TI TTGP7BY DMTB80W TN Monoamine oxidase type B (MAO-B) DMTB80W MA Inhibitor DMTB80W RN Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706. DMTB80W RU https://pubmed.ncbi.nlm.nih.gov/19810674 DMTB8D4 DI DMTB8D4 DMTB8D4 DN MCL-515 DMTB8D4 TI TTEX248 DMTB8D4 TN Dopamine D2 receptor (D2R) DMTB8D4 MA Inhibitor DMTB8D4 RN Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines. Bioorg Med Chem Lett. 2009 Jan 1;19(1):51-3. DMTB8D4 RU https://pubmed.ncbi.nlm.nih.gov/19058967 DMTB91D DI DMTB91D DMTB91D DN 5-tosyl-5H-dibenzo[b,d]azepin-7(6H)-one DMTB91D TI TTMNI76 DMTB91D TN Calcium-activated potassium channel (KCN) DMTB91D MA Inhibitor DMTB91D RN Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304. DMTB91D RU https://pubmed.ncbi.nlm.nih.gov/19282171 DMTB965 DI DMTB965 DMTB965 DN Cobalt Hexammine Ion DMTB965 TI TTQAOZR DMTB965 TN Bacterial Chorismate synthase (Bact aroC) DMTB965 MA Inhibitor DMTB965 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMTB965 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMTBAPH DI DMTBAPH DMTBAPH DN N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide DMTBAPH TI TT6R7JZ DMTBAPH TN Histone deacetylase 1 (HDAC1) DMTBAPH MA Inhibitor DMTBAPH RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMTBAPH RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMTBAPH DI DMTBAPH DMTBAPH DN N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide DMTBAPH TI TTBH0VX DMTBAPH TN Histone deacetylase (HDAC) DMTBAPH MA Inhibitor DMTBAPH RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMTBAPH RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMTBAUG DI DMTBAUG DMTBAUG DN 2,2-Diphenyl-ethylamine DMTBAUG TI TTJQOD7 DMTBAUG TN 5-HT 2A receptor (HTR2A) DMTBAUG MA Inhibitor DMTBAUG RN Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6. DMTBAUG RU https://pubmed.ncbi.nlm.nih.gov/11229772 DMTBAXD DI DMTBAXD DMTBAXD DN [3H]A317491 DMTBAXD TI TT2THBD DMTBAXD TN P2X purinoceptor 3 (P2RX3) DMTBAXD MA Antagonist DMTBAXD RN Crossing the pain barrier: P2 receptors as targets for novel analgesics. J Physiol. 2003 Dec 15;553(Pt 3):683-94. DMTBAXD RU https://pubmed.ncbi.nlm.nih.gov/14514872 DMTBG57 DI DMTBG57 DMTBG57 DN (S)-3-(aminomethyl)-4-(furan-2-yl)butanoic acid DMTBG57 TI TTFK1JQ DMTBG57 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMTBG57 MA Inhibitor DMTBG57 RN Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32. DMTBG57 RU https://pubmed.ncbi.nlm.nih.gov/16099652 DMTBO7F DI DMTBO7F DMTBO7F DN bromoacetone DMTBO7F TI TTELV3W DMTBO7F TN Transformation-sensitive protein p120 (TRPA1) DMTBO7F MA Activator DMTBO7F RN Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases. FASEB J. 2009 Apr;23(4):1102-14. DMTBO7F RU https://pubmed.ncbi.nlm.nih.gov/19036859 DMTBRLK DI DMTBRLK DMTBRLK DN 2-morpholino-6-(quinolin-8-yl)-4H-pyran-4-one DMTBRLK TI TTK3PY9 DMTBRLK TN DNA-dependent protein kinase catalytic (PRKDC) DMTBRLK MA Inhibitor DMTBRLK RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMTBRLK RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMTBX0D DI DMTBX0D DMTBX0D DN 3-Methoxy-9H-beta-carboline DMTBX0D TI TTNJYV2 DMTBX0D TN Gamma-aminobutyric acid receptor (GAR) DMTBX0D MA Inhibitor DMTBX0D RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMTBX0D RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMTBX0D DI DMTBX0D DMTBX0D DN 3-Methoxy-9H-beta-carboline DMTBX0D TI TT1MPAY DMTBX0D TN GABA(A) receptor alpha-1 (GABRA1) DMTBX0D MA Inhibitor DMTBX0D RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMTBX0D RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMTBZJL DI DMTBZJL DMTBZJL DN 1-Naphthalen-2-yl-1H-imidazole DMTBZJL TI TTSZLWK DMTBZJL TN Aromatase (CYP19A1) DMTBZJL MA Inhibitor DMTBZJL RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMTBZJL RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMTBZJL DI DMTBZJL DMTBZJL DN 1-Naphthalen-2-yl-1H-imidazole DMTBZJL TI TTIQUX7 DMTBZJL TN Steroid 11-beta-hydroxylase (CYP11B1) DMTBZJL MA Inhibitor DMTBZJL RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMTBZJL RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMTBZUC DI DMTBZUC DMTBZUC DN ASKENDOSIDE B DMTBZUC TI TTULVH8 DMTBZUC TN Tyrosinase (TYR) DMTBZUC MA Inhibitor DMTBZUC RN New tyrosinase inhibitors selected by atomic linear indices-based classification models. Bioorg Med Chem Lett. 2006 Jan 15;16(2):324-30. DMTBZUC RU https://pubmed.ncbi.nlm.nih.gov/16275084 DMTC25W DI DMTC25W DMTC25W DN 4-Sulfamoyloxy-benzoic acid heptyl ester DMTC25W TI TTHM0R1 DMTC25W TN Steryl-sulfatase (STS) DMTC25W MA Inhibitor DMTC25W RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMTC25W RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMTC4G0 DI DMTC4G0 DMTC4G0 DN Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine DMTC4G0 TI TT4C8EA DMTC4G0 TN Dopamine D3 receptor (D3R) DMTC4G0 MA Inhibitor DMTC4G0 RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMTC4G0 RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMTC4G0 DI DMTC4G0 DMTC4G0 DN Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine DMTC4G0 TI TTE0A2F DMTC4G0 TN Dopamine D4 receptor (D4R) DMTC4G0 MA Inhibitor DMTC4G0 RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMTC4G0 RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMTC4G0 DI DMTC4G0 DMTC4G0 DN Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine DMTC4G0 TI TTEX248 DMTC4G0 TN Dopamine D2 receptor (D2R) DMTC4G0 MA Inhibitor DMTC4G0 RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMTC4G0 RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMTC5VF DI DMTC5VF DMTC5VF DN (5-(pyridin-3-yl)furan-2-yl)methanamine DMTC5VF TI TTVG215 DMTC5VF TN Debrisoquine 4-hydroxylase (CYP2D6) DMTC5VF MA Inhibitor DMTC5VF RN Synthetic inhibitors of cytochrome P-450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006 Nov 30;49(24):6987-7001. DMTC5VF RU https://pubmed.ncbi.nlm.nih.gov/17125252 DMTC5Y9 DI DMTC5Y9 DMTC5Y9 DN 2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile DMTC5Y9 TI TTGKNB4 DMTC5Y9 TN Epidermal growth factor receptor (EGFR) DMTC5Y9 MA Inhibitor DMTC5Y9 RN Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907. DMTC5Y9 RU https://pubmed.ncbi.nlm.nih.gov/1676428 DMTC7J2 DI DMTC7J2 DMTC7J2 DN 4,5,6,7-tetrafluoro-3-methyl-1H-indazole DMTC7J2 TI TTF10I9 DMTC7J2 TN Nitric-oxide synthase inducible (NOS2) DMTC7J2 MA Inhibitor DMTC7J2 RN Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7. DMTC7J2 RU https://pubmed.ncbi.nlm.nih.gov/19679481 DMTC7J2 DI DMTC7J2 DMTC7J2 DN 4,5,6,7-tetrafluoro-3-methyl-1H-indazole DMTC7J2 TI TTZUFI5 DMTC7J2 TN Nitric-oxide synthase brain (NOS1) DMTC7J2 MA Inhibitor DMTC7J2 RN Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7. DMTC7J2 RU https://pubmed.ncbi.nlm.nih.gov/19679481 DMTC98X DI DMTC98X DMTC98X DN 1-(1,3-diphenylpropyl)piperazine DMTC98X TI TT3ROYC DMTC98X TN Serotonin transporter (SERT) DMTC98X MA Inhibitor DMTC98X RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DMTC98X RU https://pubmed.ncbi.nlm.nih.gov/16750363 DMTCA2Z DI DMTCA2Z DMTCA2Z DN N-(4-methylthiazol-2-yl)benzamide DMTCA2Z TI TTSJ6Q4 DMTCA2Z TN LOX-5 messenger RNA (ALOX5 mRNA) DMTCA2Z MA Inhibitor DMTCA2Z RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMTCA2Z RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMTCBLS DI DMTCBLS DMTCBLS DN NCI-159878 DMTCBLS TI TTLUQ8E DMTCBLS TN Hormone sensitive lipase (LIPE) DMTCBLS MA Inhibitor DMTCBLS RN Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of n... J Med Chem. 2008 Oct 23;51(20):6478-94. DMTCBLS RU https://pubmed.ncbi.nlm.nih.gov/18808096 DMTCEFV DI DMTCEFV DMTCEFV DN Glycinamid DMTCEFV TI TTGA1IV DMTCEFV TN Matrix metalloproteinase-8 (MMP-8) DMTCEFV MA Inhibitor DMTCEFV RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTCEFV RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTCG8M DI DMTCG8M DMTCG8M DN MR-20496 DMTCG8M TI TTSZLWK DMTCG8M TN Aromatase (CYP19A1) DMTCG8M MA Inhibitor DMTCG8M RN Design and synthesis of a new type of non steroidal human aromatase inhibitors. Bioorg Med Chem Lett. 1998 May 5;8(9):1041-4. DMTCG8M RU https://pubmed.ncbi.nlm.nih.gov/9871704 DMTCGLY DI DMTCGLY DMTCGLY DN PMID25259874C21 DMTCGLY TI TTI6B3F DMTCGLY TN C3a anaphylatoxin chemotactic receptor (C3AR1) DMTCGLY MA Agonist DMTCGLY RN Potent heterocyclic ligands for human complement c3a receptor. J Med Chem. 2014 Oct 23;57(20):8459-70. DMTCGLY RU https://pubmed.ncbi.nlm.nih.gov/25259874 DMTCMH7 DI DMTCMH7 DMTCMH7 DN 1,4-Naphthoquinone DMTCMH7 TI TT3PQ2Y DMTCMH7 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMTCMH7 MA Inhibitor DMTCMH7 RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMTCMH7 RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMTCMH7 DI DMTCMH7 DMTCMH7 DN 1,4-Naphthoquinone DMTCMH7 TI TTZJYKH DMTCMH7 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMTCMH7 MA Inhibitor DMTCMH7 RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMTCMH7 RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMTCMUG DI DMTCMUG DMTCMUG DN N-(4-Phenylbutyl)-1H-indole-2-carboxamide DMTCMUG TI TTGP7BY DMTCMUG TN Monoamine oxidase type B (MAO-B) DMTCMUG MA Inhibitor DMTCMUG RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMTCMUG RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMTCMUG DI DMTCMUG DMTCMUG DN N-(4-Phenylbutyl)-1H-indole-2-carboxamide DMTCMUG TI TT3WG5C DMTCMUG TN Monoamine oxidase type A (MAO-A) DMTCMUG MA Inhibitor DMTCMUG RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMTCMUG RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMTCNOM DI DMTCNOM DMTCNOM DN Fasudil DMTCNOM TI TTZN7RP DMTCNOM TN Rho-associated protein kinase 1 (ROCK1) DMTCNOM MA Inhibitor DMTCNOM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTCNOM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTCOY9 DI DMTCOY9 DMTCOY9 DN C3 DMTCOY9 TI TTX4RTB DMTCOY9 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMTCOY9 MA Agonist DMTCOY9 RN SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study. J Pharmacol Exp Ther. 2001 Oct;299(1):137-46. DMTCOY9 RU https://pubmed.ncbi.nlm.nih.gov/11561073 DMTCP8K DI DMTCP8K DMTCP8K DN propylpyrazoletriol DMTCP8K TI TTZAYWL DMTCP8K TN Estrogen receptor (ESR) DMTCP8K MA Agonist DMTCP8K RN Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology. 2000 Oct;141(10):3534-45. DMTCP8K RU https://pubmed.ncbi.nlm.nih.gov/11014206 DMTCYHM DI DMTCYHM DMTCYHM DN Benzylcysteine DMTCYHM TI TTJ8DV7 DMTCYHM TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DMTCYHM MA Inhibitor DMTCYHM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTCYHM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTD0IG DI DMTD0IG DMTD0IG DN 2-hexylphenyl acrylate DMTD0IG TI TTGER3L DMTD0IG TN Thyroid hormone receptor beta (THRB) DMTD0IG MA Inhibitor DMTD0IG RN Inhibitors of the interaction of a thyroid hormone receptor and coactivators: preliminary structure-activity relationships. J Med Chem. 2007 Nov 1;50(22):5269-80. DMTD0IG RU https://pubmed.ncbi.nlm.nih.gov/17918822 DMTD16H DI DMTD16H DMTD16H DN 3-(4-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile DMTD16H TI TTHS256 DMTD16H TN Metabotropic glutamate receptor 5 (mGluR5) DMTD16H MA Inhibitor DMTD16H RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMTD16H RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMTD3O8 DI DMTD3O8 DMTD3O8 DN RQ-00202730 DMTD3O8 TI TTMSFAW DMTD3O8 TN Cannabinoid receptor 2 (CB2) DMTD3O8 MA Agonist DMTD3O8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DMTD3O8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DMTD5AO DI DMTD5AO DMTD5AO DN 16-(pyridin-3-yl)methyl-estradiol DMTD5AO TI TTIWB6L DMTD5AO TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMTD5AO MA Inhibitor DMTD5AO RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMTD5AO RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMTD7VE DI DMTD7VE DMTD7VE DN 3-(1-Pyridin-2-yl-1H-pyrazol-3-yl)-benzonitrile DMTD7VE TI TTHS256 DMTD7VE TN Metabotropic glutamate receptor 5 (mGluR5) DMTD7VE MA Inhibitor DMTD7VE RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMTD7VE RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMTDB62 DI DMTDB62 DMTDB62 DN 3-(1,2,3,6-Tetrahydro-pyridin-4-yl)-1H-indole DMTDB62 TI TTSQIFT DMTDB62 TN 5-HT 1A receptor (HTR1A) DMTDB62 MA Inhibitor DMTDB62 RN 3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic a... J Med Chem. 1990 Aug;33(8):2087-93. DMTDB62 RU https://pubmed.ncbi.nlm.nih.gov/2374139 DMTDBMU DI DMTDBMU DMTDBMU DN N-hydroxysulfamide DMTDBMU TI TT2LVK8 DMTDBMU TN Carbonic anhydrase IX (CA-IX) DMTDBMU MA Inhibitor DMTDBMU RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMTDBMU RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMTDBMU DI DMTDBMU DMTDBMU DN N-hydroxysulfamide DMTDBMU TI TTANPDJ DMTDBMU TN Carbonic anhydrase II (CA-II) DMTDBMU MA Inhibitor DMTDBMU RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMTDBMU RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMTDBMU DI DMTDBMU DMTDBMU DN N-hydroxysulfamide DMTDBMU TI TTSYM0R DMTDBMU TN Carbonic anhydrase XII (CA-XII) DMTDBMU MA Inhibitor DMTDBMU RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMTDBMU RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMTDBMU DI DMTDBMU DMTDBMU DN N-hydroxysulfamide DMTDBMU TI TTHQPL7 DMTDBMU TN Carbonic anhydrase I (CA-I) DMTDBMU MA Inhibitor DMTDBMU RN Carbonic anhydrase inhibitors: crystallographic and solution binding studies for the interaction of a boron-containing aromatic sulfamide with mamm... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3601-5. DMTDBMU RU https://pubmed.ncbi.nlm.nih.gov/20472429 DMTDEYL DI DMTDEYL DMTDEYL DN 3-cyano-N-(6-methylpyridin-2-yl)benzamide DMTDEYL TI TTHS256 DMTDEYL TN Metabotropic glutamate receptor 5 (mGluR5) DMTDEYL MA Inhibitor DMTDEYL RN Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-met... J Med Chem. 2009 Jun 11;52(11):3563-75. DMTDEYL RU https://pubmed.ncbi.nlm.nih.gov/19445453 DMTDIM9 DI DMTDIM9 DMTDIM9 DN Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) DMTDIM9 TI TTTQGH8 DMTDIM9 TN Histone deacetylase 4 (HDAC4) DMTDIM9 MA Inhibitor DMTDIM9 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMTDIM9 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMTDIM9 DI DMTDIM9 DMTDIM9 DN Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) DMTDIM9 TI TT5ZKDI DMTDIM9 TN Histone deacetylase 6 (HDAC6) DMTDIM9 MA Inhibitor DMTDIM9 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMTDIM9 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMTDIM9 DI DMTDIM9 DMTDIM9 DN Cyclo(-L-Am7(S2Py)-D-A1in-L-Ala-D-Pro-) DMTDIM9 TI TT6R7JZ DMTDIM9 TN Histone deacetylase 1 (HDAC1) DMTDIM9 MA Inhibitor DMTDIM9 RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMTDIM9 RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMTDNX3 DI DMTDNX3 DMTDNX3 DN 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid DMTDNX3 TI TTHY57M DMTDNX3 TN Matrix metalloproteinase-13 (MMP-13) DMTDNX3 MA Inhibitor DMTDNX3 RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMTDNX3 RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMTDNX3 DI DMTDNX3 DMTDNX3 DN 5-(4'-cyanobiphenyl-4-yl)-3-hydroxypentanoic acid DMTDNX3 TI TTXZ0KQ DMTDNX3 TN Matrix metalloproteinase-12 (MMP-12) DMTDNX3 MA Inhibitor DMTDNX3 RN The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5760-3. DMTDNX3 RU https://pubmed.ncbi.nlm.nih.gov/19703773 DMTDRPM DI DMTDRPM DMTDRPM DN impromidine DMTDRPM TI TTQHJ1K DMTDRPM TN Histamine H2 receptor (H2R) DMTDRPM MA Agonist DMTDRPM RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DMTDRPM RU https://pubmed.ncbi.nlm.nih.gov/16394198 DMTDRPM DI DMTDRPM DMTDRPM DN impromidine DMTDRPM TI TTTIBOJ DMTDRPM TN Histamine H1 receptor (H1R) DMTDRPM MA Antagonist DMTDRPM RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DMTDRPM RU https://pubmed.ncbi.nlm.nih.gov/16394198 DMTDRPM DI DMTDRPM DMTDRPM DN impromidine DMTDRPM TI TTXJ178 DMTDRPM TN Histamine H4 receptor (H4R) DMTDRPM MA Agonist DMTDRPM RN Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first pote... J Pharmacol Exp Ther. 2005 Sep;314(3):1310-21. DMTDRPM RU https://pubmed.ncbi.nlm.nih.gov/15947036 DMTDRPM DI DMTDRPM DMTDRPM DN impromidine DMTDRPM TI TT9JNIC DMTDRPM TN Histamine H3 receptor (H3R) DMTDRPM MA Agonist DMTDRPM RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DMTDRPM RU https://pubmed.ncbi.nlm.nih.gov/11179434 DMTDX2S DI DMTDX2S DMTDX2S DN 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide DMTDX2S TI TT1VAUK DMTDX2S TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMTDX2S MA Inhibitor DMTDX2S RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMTDX2S RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMTDX2S DI DMTDX2S DMTDX2S DN 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide DMTDX2S TI TTUTJGQ DMTDX2S TN Vascular endothelial growth factor receptor 2 (KDR) DMTDX2S MA Inhibitor DMTDX2S RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMTDX2S RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMTDX2S DI DMTDX2S DMTDX2S DN 4-Chloro-N-(4-chloro-benzoyl)-benzenesulfonamide DMTDX2S TI TTDCBX5 DMTDX2S TN Vascular endothelial growth factor receptor 3 (FLT-4) DMTDX2S MA Inhibitor DMTDX2S RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMTDX2S RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMTDYHE DI DMTDYHE DMTDYHE DN 4-[4-(benzyloxy)piperidino]butyl benzoate DMTDYHE TI TTEB0GD DMTDYHE TN Cholinesterase (BCHE) DMTDYHE MA Inhibitor DMTDYHE RN Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abe... Bioorg Med Chem. 2007 Oct 15;15(20):6596-607. DMTDYHE RU https://pubmed.ncbi.nlm.nih.gov/17681794 DMTE0YJ DI DMTE0YJ DMTE0YJ DN WIN 64338 DMTE0YJ TI TTGY8IW DMTE0YJ TN B2 bradykinin receptor (BDKRB2) DMTE0YJ MA Antagonist DMTE0YJ RN Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor. J Med Chem. 1993 Aug 20;36(17):2583-4. DMTE0YJ RU https://pubmed.ncbi.nlm.nih.gov/8394936 DMTE3FJ DI DMTE3FJ DMTE3FJ DN ISIS 147919 DMTE3FJ TI TT6RIOV DMTE3FJ TN Acyl-CoA desaturase (SCD) DMTE3FJ RN US patent application no. 7,132,529, Antisense modulation of stearoyl-CoA desaturase expression. DMTE3FJ RU http://www.patentbuddy.com/Patent/7132529?ft=true&sr=true DMTE7BJ DI DMTE7BJ DMTE7BJ DN ISIS 29178 DMTE7BJ TI TTO6SGY DMTE7BJ TN AKT3 messenger RNA (AKT3 mRNA) DMTE7BJ RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMTE7BJ RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMTEACQ DI DMTEACQ DMTEACQ DN 13,14-dihydro-PGE1 DMTEACQ TI TT79WV3 DMTEACQ TN Prostaglandin E2 receptor EP4 (PTGER4) DMTEACQ MA Agonist DMTEACQ RN Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. Br J Pharmacol. 2000 Aug;130(8):1919-26. DMTEACQ RU https://pubmed.ncbi.nlm.nih.gov/10952683 DMTEBP0 DI DMTEBP0 DMTEBP0 DN 1-(2-(naphthalen-2-yl)-1-phenylethyl)piperazine DMTEBP0 TI TT3ROYC DMTEBP0 TN Serotonin transporter (SERT) DMTEBP0 MA Inhibitor DMTEBP0 RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DMTEBP0 RU https://pubmed.ncbi.nlm.nih.gov/16750363 DMTECXA DI DMTECXA DMTECXA DN CGP 23996 DMTECXA TI TTZ6T9E DMTECXA TN Somatostatin receptor type 2 (SSTR2) DMTECXA MA Agonist DMTECXA RN [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20. DMTECXA RU https://pubmed.ncbi.nlm.nih.gov/9652348 DMTECXA DI DMTECXA DMTECXA DN CGP 23996 DMTECXA TI TTAE1BR DMTECXA TN Somatostatin receptor type 4 (SSTR4) DMTECXA MA Agonist DMTECXA RN Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch Pharmacol. 1999 Nov;360(5):488-99. DMTECXA RU https://pubmed.ncbi.nlm.nih.gov/10598788 DMTECXA DI DMTECXA DMTECXA DN CGP 23996 DMTECXA TI TTIND6G DMTECXA TN Somatostatin receptor type 1 (SSTR1) DMTECXA MA Agonist DMTECXA RN Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch Pharmacol. 1999 Nov;360(5):488-99. DMTECXA RU https://pubmed.ncbi.nlm.nih.gov/10598788 DMTECXA DI DMTECXA DMTECXA DN CGP 23996 DMTECXA TI TTJX3UE DMTECXA TN Somatostatin receptor type 3 (SSTR3) DMTECXA MA Agonist DMTECXA RN Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies. Naunyn Schmiedebergs Arch Pharmacol. 1999 Nov;360(5):488-99. DMTECXA RU https://pubmed.ncbi.nlm.nih.gov/10598788 DMTECXA DI DMTECXA DMTECXA DN CGP 23996 DMTECXA TI TT2BC4G DMTECXA TN Somatostatin receptor type 5 (SSTR5) DMTECXA MA Agonist DMTECXA RN [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20. DMTECXA RU https://pubmed.ncbi.nlm.nih.gov/9652348 DMTEDHP DI DMTEDHP DMTEDHP DN isoamylamine DMTEDHP TI TTVX9SH DMTEDHP TN Trace amine receptor 3 (TAAR3) DMTEDHP MA Agonist DMTEDHP RN A second class of chemosensory receptors in the olfactory epithelium. Nature. 2006 Aug 10;442(7103):645-50. DMTEDHP RU https://pubmed.ncbi.nlm.nih.gov/16878137 DMTEGNB DI DMTEGNB DMTEGNB DN CNS-1169 DMTEGNB TI TT5TPI6 DMTEGNB TN Opioid receptor sigma 1 (OPRS1) DMTEGNB MA Modulator DMTEGNB RN Antitussives and substance abuse. Subst Abuse Rehabil. 2013 Nov 6;4:75-82. DMTEGNB RU https://pubmed.ncbi.nlm.nih.gov/24648790 DMTEJOY DI DMTEJOY DMTEJOY DN 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione DMTEJOY TI TTKJEMQ DMTEJOY TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMTEJOY MA Inhibitor DMTEJOY RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMTEJOY RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMTEJOY DI DMTEJOY DMTEJOY DN 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione DMTEJOY TI TTLD29N DMTEJOY TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMTEJOY MA Inhibitor DMTEJOY RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMTEJOY RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMTEJOY DI DMTEJOY DMTEJOY DN 3-Hydroxy-7-nitro-1H-benzo[b]azepine-2,5-dione DMTEJOY TI TTN9D8E DMTEJOY TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMTEJOY MA Inhibitor DMTEJOY RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMTEJOY RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMTEO35 DI DMTEO35 DMTEO35 DN FGGFTGARKCARKC DMTEO35 TI TTNT7K8 DMTEO35 TN Nociceptin receptor (OPRL1) DMTEO35 MA Inhibitor DMTEO35 RN Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nocic... J Med Chem. 2001 Nov 8;44(23):4015-8. DMTEO35 RU https://pubmed.ncbi.nlm.nih.gov/11689089 DMTEQU8 DI DMTEQU8 DMTEQU8 DN 2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde DMTEQU8 TI TTML2WA DMTEQU8 TN Tubulin (TUB) DMTEQU8 MA Inhibitor DMTEQU8 RN Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem. 1998 Dec 3;41(25):4965-72. DMTEQU8 RU https://pubmed.ncbi.nlm.nih.gov/9836614 DMTEQU8 DI DMTEQU8 DMTEQU8 DN 2-(4-Methoxy-phenyl)-1H-indole-3-carbaldehyde DMTEQU8 TI TTYFKSZ DMTEQU8 TN Tubulin beta (TUBB) DMTEQU8 MA Inhibitor DMTEQU8 RN Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J Med Chem. 1998 Dec 3;41(25):4965-72. DMTEQU8 RU https://pubmed.ncbi.nlm.nih.gov/9836614 DMTERF6 DI DMTERF6 DMTERF6 DN N-(3,4-Dichlorophenyl)propyl-ETAV DMTERF6 TI TT9PB26 DMTERF6 TN Presynaptic density protein 95 (DLG4) DMTERF6 MA Inhibitor DMTERF6 RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMTERF6 RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMTEU0L DI DMTEU0L DMTEU0L DN Sul-Pro-Phe-N-MeHis-LVA-Ile-Amp DMTEU0L TI TTB2MXP DMTEU0L TN Angiotensinogenase renin (REN) DMTEU0L MA Inhibitor DMTEU0L RN Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42. DMTEU0L RU https://pubmed.ncbi.nlm.nih.gov/1995887 DMTEUDL DI DMTEUDL DMTEUDL DN ISIS 113871 DMTEUDL TI TTIX0ZU DMTEUDL TN MEKK2 messenger RNA (MAP3K2 mRNA) DMTEUDL RN US patent application no. 6,287,860, Antisense inhibition of MEKK2 expression. DMTEUDL RU http://www.patentbuddy.com/Patent/6287860?ft=true&sr=true DMTF1HL DI DMTF1HL DMTF1HL DN 1-guanidino-N-phenyl-7-isoquinolinesulphonamide DMTF1HL TI TTP86E2 DMTF1HL TN Plasminogen (PLG) DMTF1HL MA Inhibitor DMTF1HL RN Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. DMTF1HL RU https://pubmed.ncbi.nlm.nih.gov/17447747 DMTF1HL DI DMTF1HL DMTF1HL DN 1-guanidino-N-phenyl-7-isoquinolinesulphonamide DMTF1HL TI TTXAGYU DMTF1HL TN Tissue-type plasminogen activator (PLAT) DMTF1HL MA Inhibitor DMTF1HL RN Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. DMTF1HL RU https://pubmed.ncbi.nlm.nih.gov/17447747 DMTF1HL DI DMTF1HL DMTF1HL DN 1-guanidino-N-phenyl-7-isoquinolinesulphonamide DMTF1HL TI TTGY7WI DMTF1HL TN Urokinase-type plasminogen activator (PLAU) DMTF1HL MA Inhibitor DMTF1HL RN Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines. J Med Chem. 2007 May 17;50(10):2341-51. DMTF1HL RU https://pubmed.ncbi.nlm.nih.gov/17447747 DMTF4VI DI DMTF4VI DMTF4VI DN TCPA DMTF4VI TI TTNE7KG DMTF4VI TN Adenosine A2b receptor (ADORA2B) DMTF4VI MA Agonist DMTF4VI RN Heterologous expression of rat epitope-tagged histamine H2 receptors in insect Sf9 cells. Br J Pharmacol. 1997 Nov;122(5):867-74. DMTF4VI RU https://pubmed.ncbi.nlm.nih.gov/9384502 DMTF4VI DI DMTF4VI DMTF4VI DN TCPA DMTF4VI TI TTK25J1 DMTF4VI TN Adenosine A1 receptor (ADORA1) DMTF4VI MA Agonist DMTF4VI RN N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem. 2003 Apr 10;46(8):1492-503. DMTF4VI RU https://pubmed.ncbi.nlm.nih.gov/12672250 DMTF4VI DI DMTF4VI DMTF4VI DN TCPA DMTF4VI TI TTJFY5U DMTF4VI TN Adenosine A3 receptor (ADORA3) DMTF4VI MA Agonist DMTF4VI RN N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem. 2003 Apr 10;46(8):1492-503. DMTF4VI RU https://pubmed.ncbi.nlm.nih.gov/12672250 DMTF520 DI DMTF520 DMTF520 DN 3-[3-Methyl-indan-(1Z)-ylidenemethyl]-pyridine DMTF520 TI TTSZLWK DMTF520 TN Aromatase (CYP19A1) DMTF520 MA Inhibitor DMTF520 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMTF520 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMTF7JA DI DMTF7JA DMTF7JA DN (E)-10-nitrooctadec-9-enoic acid DMTF7JA TI TTT2SVW DMTF7JA TN PPAR-gamma messenger RNA (PPARG mRNA) DMTF7JA MA Inhibitor DMTF7JA RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMTF7JA RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMTF8US DI DMTF8US DMTF8US DN N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide DMTF8US TI TTJFY5U DMTF8US TN Adenosine A3 receptor (ADORA3) DMTF8US MA Inhibitor DMTF8US RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMTF8US RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMTF8US DI DMTF8US DMTF8US DN N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide DMTF8US TI TTK25J1 DMTF8US TN Adenosine A1 receptor (ADORA1) DMTF8US MA Inhibitor DMTF8US RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMTF8US RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMTF8US DI DMTF8US DMTF8US DN N-(5-Benzoyl-4-phenylthiazol-2-yl)benzamide DMTF8US TI TTM2AOE DMTF8US TN Adenosine A2a receptor (ADORA2A) DMTF8US MA Inhibitor DMTF8US RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMTF8US RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMTFBCU DI DMTFBCU DMTFBCU DN 7-Methoxy-1H-indazole DMTFBCU TI TTZUFI5 DMTFBCU TN Nitric-oxide synthase brain (NOS1) DMTFBCU MA Inhibitor DMTFBCU RN Inhibition of neuronal nitric oxide synthase by 7-methoxyindazole and related substituted indazoles. Bioorg Med Chem Lett. 2001 May 7;11(9):1153-6. DMTFBCU RU https://pubmed.ncbi.nlm.nih.gov/11354365 DMTFGYH DI DMTFGYH DMTFGYH DN Org-231295 DMTFGYH TI TTDP1UC DMTFGYH TN Fatty acid amide hydrolase (FAAH) DMTFGYH MA Inhibitor DMTFGYH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400). DMTFGYH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1400 DMTFHPI DI DMTFHPI DMTFHPI DN Phosphonothreonine DMTFHPI TI TTPS3C0 DMTFHPI TN Aurora kinase A (AURKA) DMTFHPI MA Inhibitor DMTFHPI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTFHPI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTFHPI DI DMTFHPI DMTFHPI DN Phosphonothreonine DMTFHPI TI TTQYF7G DMTFHPI TN Cyclin-dependent kinase 7 (CDK7) DMTFHPI MA Inhibitor DMTFHPI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTFHPI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTFHPI DI DMTFHPI DMTFHPI DN Phosphonothreonine DMTFHPI TI TT8QL1J DMTFHPI TN Protein kinase C theta (PRKCQ) DMTFHPI MA Inhibitor DMTFHPI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTFHPI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTFHPI DI DMTFHPI DMTFHPI DN Phosphonothreonine DMTFHPI TI TT4TQBX DMTFHPI TN Extracellular signal-regulated kinase 2 (ERK2) DMTFHPI MA Inhibitor DMTFHPI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTFHPI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTFHPI DI DMTFHPI DMTFHPI DN Phosphonothreonine DMTFHPI TI TTH0KSX DMTFHPI TN Rhodopsin (RHO) DMTFHPI MA Inhibitor DMTFHPI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTFHPI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTFHPI DI DMTFHPI DMTFHPI DN Phosphonothreonine DMTFHPI TI TTYT93M DMTFHPI TN MAP kinase p38 (MAPK12) DMTFHPI MA Inhibitor DMTFHPI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTFHPI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTFHRI DI DMTFHRI DMTFHRI DN TANNIN DMTFHRI TI TTFJ8Q1 DMTFHRI TN Protein kinase C alpha (PRKCA) DMTFHRI MA Inhibitor DMTFHRI RN Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992). DMTFHRI RU http://www.sciencedirect.com/science/article/pii/S0960894X01810726 DMTFHRI DI DMTFHRI DMTFHRI DN TANNIN DMTFHRI TI TTYPXQF DMTFHRI TN Protein kinase C beta (PRKCB) DMTFHRI MA Inhibitor DMTFHRI RN Tannins as selective inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 2(3):239-244 (1992). DMTFHRI RU http://www.sciencedirect.com/science/article/pii/S0960894X01810726 DMTFIPZ DI DMTFIPZ DMTFIPZ DN 2-Hexadecynoic acid DMTFIPZ TI TTHPFTS DMTFIPZ TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DMTFIPZ MA Inhibitor DMTFIPZ RN 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85. DMTFIPZ RU https://pubmed.ncbi.nlm.nih.gov/20855214 DMTFIPZ DI DMTFIPZ DMTFIPZ DN 2-Hexadecynoic acid DMTFIPZ TI TTVTX4N DMTFIPZ TN Bacterial Fatty acid synthetase I (Bact inhA) DMTFIPZ MA Inhibitor DMTFIPZ RN 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85. DMTFIPZ RU https://pubmed.ncbi.nlm.nih.gov/20855214 DMTFIPZ DI DMTFIPZ DMTFIPZ DN 2-Hexadecynoic acid DMTFIPZ TI TT7AOUD DMTFIPZ TN Fatty acid synthase (FASN) DMTFIPZ MA Inhibitor DMTFIPZ RN 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85. DMTFIPZ RU https://pubmed.ncbi.nlm.nih.gov/20855214 DMTFIPZ DI DMTFIPZ DMTFIPZ DN 2-Hexadecynoic acid DMTFIPZ TI TTBE4IR DMTFIPZ TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMTFIPZ MA Inhibitor DMTFIPZ RN 2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections. Bioorg Med Chem. 2010 Nov 1;18(21):7475-85. DMTFIPZ RU https://pubmed.ncbi.nlm.nih.gov/20855214 DMTFL5J DI DMTFL5J DMTFL5J DN 4-Cyclohexyl-4-hydroxy-but-2-enoic acid DMTFL5J TI TT6TKEN DMTFL5J TN Gamma-hydroxybutyrate receptor (SLC52A2) DMTFL5J MA Inhibitor DMTFL5J RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DMTFL5J RU https://pubmed.ncbi.nlm.nih.gov/3361576 DMTFP0Z DI DMTFP0Z DMTFP0Z DN (2S)-aminobutyryl-L-proline (R)-sec-butylamide DMTFP0Z TI TTQ7R2V DMTFP0Z TN Tripeptidyl-peptidase II (TPP2) DMTFP0Z MA Inhibitor DMTFP0Z RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMTFP0Z RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMTFP5Q DI DMTFP5Q DMTFP5Q DN [125I]HEAT DMTFP5Q TI TT2NUT5 DMTFP5Q TN Adrenergic receptor alpha-2C (ADRA2C) DMTFP5Q MA Agonist DMTFP5Q RN KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995 Aug;48(2):250-8. DMTFP5Q RU https://pubmed.ncbi.nlm.nih.gov/7651358 DMTFP5Q DI DMTFP5Q DMTFP5Q DN [125I]HEAT DMTFP5Q TI TTBRKXS DMTFP5Q TN Adrenergic receptor alpha-1B (ADRA1B) DMTFP5Q MA Agonist DMTFP5Q RN KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues. Mol Pharmacol. 1995 Aug;48(2):250-8. DMTFP5Q RU https://pubmed.ncbi.nlm.nih.gov/7651358 DMTFQG3 DI DMTFQG3 DMTFQG3 DN DRF 2519 DMTFQG3 TI TTJ584C DMTFQG3 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMTFQG3 MA Agonist DMTFQG3 RN Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206. DMTFQG3 RU https://pubmed.ncbi.nlm.nih.gov/15140637 DMTFQG3 DI DMTFQG3 DMTFQG3 DN DRF 2519 DMTFQG3 TI TTT2SVW DMTFQG3 TN PPAR-gamma messenger RNA (PPARG mRNA) DMTFQG3 MA Agonist DMTFQG3 RN Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol. 2004 May 3;491(2-3):195-206. DMTFQG3 RU https://pubmed.ncbi.nlm.nih.gov/15140637 DMTFRLO DI DMTFRLO DMTFRLO DN MK-0343 DMTFRLO TI TTBMV1G DMTFRLO TN GABA(A) receptor alpha-2 (GABRA2) DMTFRLO MA Modulator DMTFRLO RN Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.J Psychopharmacol.2008 Jan;22(1):24-32. DMTFRLO RU https://www.ncbi.nlm.nih.gov/pubmed/18187530 DMTFRLO DI DMTFRLO DMTFRLO DN MK-0343 DMTFRLO TI TT37EDJ DMTFRLO TN GABA(A) receptor alpha-3 (GABRA3) DMTFRLO MA Modulator DMTFRLO RN Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA(A) alpha2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers.J Psychopharmacol.2008 Jan;22(1):24-32. DMTFRLO RU https://www.ncbi.nlm.nih.gov/pubmed/18187530 DMTFV65 DI DMTFV65 DMTFV65 DN IM-094261 DMTFV65 TI TT1VAUK DMTFV65 TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMTFV65 MA Inhibitor DMTFV65 RN Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8. DMTFV65 RU https://pubmed.ncbi.nlm.nih.gov/16143524 DMTFV65 DI DMTFV65 DMTFV65 DN IM-094261 DMTFV65 TI TTUTJGQ DMTFV65 TN Vascular endothelial growth factor receptor 2 (KDR) DMTFV65 MA Inhibitor DMTFV65 RN Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8. DMTFV65 RU https://pubmed.ncbi.nlm.nih.gov/16143524 DMTFWAQ DI DMTFWAQ DMTFWAQ DN 2-(2-cyclohexylidenehydrazinyl)-4-p-tolylthiazole DMTFWAQ TI TTGP7BY DMTFWAQ TN Monoamine oxidase type B (MAO-B) DMTFWAQ MA Inhibitor DMTFWAQ RN Synthesis, semipreparative HPLC separation, biological evaluation, and 3D-QSAR of hydrazothiazole derivatives as human monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Jul 15;18(14):5063-70. DMTFWAQ RU https://pubmed.ncbi.nlm.nih.gov/20579890 DMTFZBQ DI DMTFZBQ DMTFZBQ DN (S)(+)-7-fluoro-2-p-tolylchroman-4-one DMTFZBQ TI TTGP7BY DMTFZBQ TN Monoamine oxidase type B (MAO-B) DMTFZBQ MA Inhibitor DMTFZBQ RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMTFZBQ RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMTG17Q DI DMTG17Q DMTG17Q DN [Nphe(1)]-nociceptin (1-13)-NH(2) DMTG17Q TI TTNT7K8 DMTG17Q TN Nociceptin receptor (OPRL1) DMTG17Q MA Antagonist DMTG17Q RN Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test. Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):164-7. DMTG17Q RU https://pubmed.ncbi.nlm.nih.gov/11819035 DMTG8D0 DI DMTG8D0 DMTG8D0 DN 6'-methylepibatidine DMTG8D0 TI TT4H1MQ DMTG8D0 TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMTG8D0 MA Inhibitor DMTG8D0 RN Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91. DMTG8D0 RU https://pubmed.ncbi.nlm.nih.gov/17994682 DMTG8D0 DI DMTG8D0 DMTG8D0 DN 6'-methylepibatidine DMTG8D0 TI TT5KPZR DMTG8D0 TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMTG8D0 MA Inhibitor DMTG8D0 RN Synthesis and nicotinic acetylcholine receptor binding properties of bridged and fused ring analogues of epibatidine. J Med Chem. 2007 Dec 13;50(25):6383-91. DMTG8D0 RU https://pubmed.ncbi.nlm.nih.gov/17994682 DMTGFXI DI DMTGFXI DMTGFXI DN ISIS 133244 DMTGFXI TI TTZN92A DMTGFXI TN DUSP5 messenger RNA (DUSP5 mRNA) DMTGFXI RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DMTGFXI RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DMTGMB1 DI DMTGMB1 DMTGMB1 DN Metanephrine DMTGMB1 TI TTJ6ESR DMTGMB1 TN Catecholamine uptake (CA uptake) DMTGMB1 MA Inhibitor DMTGMB1 RN Catecholamine uptake blockade in anaesthetized dogs: influence on cardiovascular responses. J Pharm Pharmacol. 1979 Nov;31(11):761-6. DMTGMB1 RU https://pubmed.ncbi.nlm.nih.gov/41908 DMTGRAF DI DMTGRAF DMTGRAF DN Imidazolidin-2-ylidene-o-tolyl-amine DMTGRAF TI TTNGILX DMTGRAF TN Adrenergic receptor alpha-1A (ADRA1A) DMTGRAF MA Inhibitor DMTGRAF RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMTGRAF RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMTGRAF DI DMTGRAF DMTGRAF DN Imidazolidin-2-ylidene-o-tolyl-amine DMTGRAF TI TT34BHT DMTGRAF TN Adrenergic receptor alpha-1D (ADRA1D) DMTGRAF MA Inhibitor DMTGRAF RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMTGRAF RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMTGRAF DI DMTGRAF DMTGRAF DN Imidazolidin-2-ylidene-o-tolyl-amine DMTGRAF TI TTBRKXS DMTGRAF TN Adrenergic receptor alpha-1B (ADRA1B) DMTGRAF MA Inhibitor DMTGRAF RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMTGRAF RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMTGU0L DI DMTGU0L DMTGU0L DN H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669) DMTGU0L TI TTG5QIA DMTGU0L TN B1 bradykinin receptor (BDKRB1) DMTGU0L MA Inhibitor DMTGU0L RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DMTGU0L RU https://pubmed.ncbi.nlm.nih.gov/10882364 DMTGU0L DI DMTGU0L DMTGU0L DN H-Lys-Arg-Pro-Hyp-Gly-Thi-Ser-D-BT-OH(JMV1669) DMTGU0L TI TTGY8IW DMTGU0L TN B2 bradykinin receptor (BDKRB2) DMTGU0L MA Inhibitor DMTGU0L RN Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6. DMTGU0L RU https://pubmed.ncbi.nlm.nih.gov/10882364 DMTGVSU DI DMTGVSU DMTGVSU DN PMID22153340C20 DMTGVSU TI TTXZ0KQ DMTGVSU TN Matrix metalloproteinase-12 (MMP-12) DMTGVSU MA Inhibitor DMTGVSU RN Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorg Med Chem Lett. 2012 Jan 1;22(1):138-43. DMTGVSU RU https://pubmed.ncbi.nlm.nih.gov/22153340 DMTGZ3E DI DMTGZ3E DMTGZ3E DN PA451 DMTGZ3E TI TT6PEUO DMTGZ3E TN Retinoic acid receptor RXR-alpha (RXRA) DMTGZ3E MA Antagonist DMTGZ3E RN Novel retinoid X receptor antagonists: specific inhibition of retinoid synergism in RXR-RAR heterodimer actions. J Med Chem. 2002 Aug 1;45(16):3327-30. DMTGZ3E RU https://pubmed.ncbi.nlm.nih.gov/12139443 DMTH0PD DI DMTH0PD DMTH0PD DN PMID1875346C18 DMTH0PD TI TTPADOQ DMTH0PD TN HMG-CoA reductase (HMGCR) DMTH0PD MA Inhibitor DMTH0PD RN 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. 7. Modification of the hexahydronaphthalene moiety of simvastatin: 5-oxygenated and 5-oxa derivatives. J Med Chem. 1991 Aug;34(8):2489-95. DMTH0PD RU https://pubmed.ncbi.nlm.nih.gov/1875346 DMTH15E DI DMTH15E DMTH15E DN S-2,9-dioxo-9-(phenylamino)nonyl ethanethioate DMTH15E TI TTT6LFV DMTH15E TN Histone deacetylase 8 (HDAC8) DMTH15E MA Inhibitor DMTH15E RN Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29. DMTH15E RU https://pubmed.ncbi.nlm.nih.gov/18247554 DMTH1JQ DI DMTH1JQ DMTH1JQ DN BAS-450225 DMTH1JQ TI TT6PKBN DMTH1JQ TN Proto-oncogene c-Src (SRC) DMTH1JQ MA Inhibitor DMTH1JQ RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMTH1JQ RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMTH3BW DI DMTH3BW DMTH3BW DN 5-Naphthalen-2-yl-oxazole DMTH3BW TI TTIQUX7 DMTH3BW TN Steroid 11-beta-hydroxylase (CYP11B1) DMTH3BW MA Inhibitor DMTH3BW RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMTH3BW RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMTH4BG DI DMTH4BG DMTH4BG DN Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine DMTH4BG TI TTAWNKZ DMTH4BG TN Norepinephrine transporter (NET) DMTH4BG MA Inhibitor DMTH4BG RN Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. DMTH4BG RU https://pubmed.ncbi.nlm.nih.gov/18550369 DMTH4BG DI DMTH4BG DMTH4BG DN Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine DMTH4BG TI TTVBI8W DMTH4BG TN Dopamine transporter (DAT) DMTH4BG MA Inhibitor DMTH4BG RN Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. DMTH4BG RU https://pubmed.ncbi.nlm.nih.gov/18550369 DMTHB2Y DI DMTHB2Y DMTHB2Y DN nTzDpa DMTHB2Y TI TTT2SVW DMTHB2Y TN PPAR-gamma messenger RNA (PPARG mRNA) DMTHB2Y MA Agonist DMTHB2Y RN Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Mol Endocrinol. 2003 Apr;17(4):662-76. DMTHB2Y RU https://pubmed.ncbi.nlm.nih.gov/12554792 DMTHFSE DI DMTHFSE DMTHFSE DN Morphinan Cyclic Imine analogue DMTHFSE TI TTQW87Y DMTHFSE TN Opioid receptor kappa (OPRK1) DMTHFSE MA Inhibitor DMTHFSE RN Morphinan cyclic imines and pyrrolidines containing a constrained phenyl group: High affinity opioid agonists, Bioorg. Med. Chem. Lett. 5(24):2969-2974 (1995). DMTHFSE RU http://www.sciencedirect.com/science/article/pii/0960894X95005221 DMTHG0Y DI DMTHG0Y DMTHG0Y DN 4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol DMTHG0Y TI TTZAYWL DMTHG0Y TN Estrogen receptor (ESR) DMTHG0Y MA Inhibitor DMTHG0Y RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMTHG0Y RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMTHG0Y DI DMTHG0Y DMTHG0Y DN 4-[1,2-bis(4-hydroxyphenyl)pent-1-enyl]phenol DMTHG0Y TI TTOM3J0 DMTHG0Y TN Estrogen receptor beta (ESR2) DMTHG0Y MA Inhibitor DMTHG0Y RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMTHG0Y RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMTHGMR DI DMTHGMR DMTHGMR DN C[YYDEKLEE]-NH2 DMTHGMR TI TT1VAUK DMTHGMR TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMTHGMR MA Inhibitor DMTHGMR RN Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist. J Med Chem. 2010 Jun 10;53(11):4428-40. DMTHGMR RU https://pubmed.ncbi.nlm.nih.gov/20462213 DMTHJL4 DI DMTHJL4 DMTHJL4 DN N-(pyridin-3-yl)indoline-1-carboxamide DMTHJL4 TI TTWJBZ5 DMTHJL4 TN 5-HT 2C receptor (HTR2C) DMTHJL4 MA Inhibitor DMTHJL4 RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMTHJL4 RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMTHLUN DI DMTHLUN DMTHLUN DN L-731128 DMTHLUN TI TTFQEO5 DMTHLUN TN Squalene synthetase (FDFT1) DMTHLUN MA Inhibitor DMTHLUN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645). DMTHLUN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645 DMTHMF0 DI DMTHMF0 DMTHMF0 DN ISIS 102563 DMTHMF0 TI TT5U49F DMTHMF0 TN PRKACA messenger RNA (PRKACA mRNA) DMTHMF0 RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMTHMF0 RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMTHO4A DI DMTHO4A DMTHO4A DN ISIS 6957 DMTHO4A TI TTM8FR7 DMTHO4A TN KRAS messenger RNA (KRAS mRNA) DMTHO4A RN Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem. 1996 Nov 8;271(45):28259-65. DMTHO4A RU https://pubmed.ncbi.nlm.nih.gov/8910444 DMTHVCA DI DMTHVCA DMTHVCA DN CP-4497 DMTHVCA TI TT6OEDT DMTHVCA TN Cannabinoid receptor 1 (CB1) DMTHVCA MA Inhibitor DMTHVCA RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DMTHVCA RU https://pubmed.ncbi.nlm.nih.gov/20621488 DMTHVEL DI DMTHVEL DMTHVEL DN ISIS 29244 DMTHVEL TI TTYMGWX DMTHVEL TN PDK-1 messenger RNA (PDK-1 mRNA) DMTHVEL RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMTHVEL RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMTHVQD DI DMTHVQD DMTHVQD DN RIPAZEPAM DMTHVQD TI TT1MPAY DMTHVQD TN GABA(A) receptor alpha-1 (GABRA1) DMTHVQD MA Inhibitor DMTHVQD RN Synthesis and interaction of 5-(substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e] [1,4]diazepin-8(7H)-ones with benzodiazepine receptors in r... J Med Chem. 1985 May;28(5):683-5. DMTHVQD RU https://pubmed.ncbi.nlm.nih.gov/2985787 DMTHVQD DI DMTHVQD DMTHVQD DN RIPAZEPAM DMTHVQD TI TTNJYV2 DMTHVQD TN Gamma-aminobutyric acid receptor (GAR) DMTHVQD MA Inhibitor DMTHVQD RN Synthesis and interaction of 5-(substituted-phenyl)-3-methyl-6,7-dihydropyrazolo[4,3-e] [1,4]diazepin-8(7H)-ones with benzodiazepine receptors in r... J Med Chem. 1985 May;28(5):683-5. DMTHVQD RU https://pubmed.ncbi.nlm.nih.gov/2985787 DMTHW3F DI DMTHW3F DMTHW3F DN BPH-715 DMTHW3F TI TTIKWV4 DMTHW3F TN Geranyltranstransferase (FDPS) DMTHW3F MA Inhibitor DMTHW3F RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DMTHW3F RU https://pubmed.ncbi.nlm.nih.gov/18800762 DMTHWXO DI DMTHWXO DMTHWXO DN Isosorbide-di-(ethylcarbamate) DMTHWXO TI TTEB0GD DMTHWXO TN Cholinesterase (BCHE) DMTHWXO MA Inhibitor DMTHWXO RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMTHWXO RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMTHWXO DI DMTHWXO DMTHWXO DN Isosorbide-di-(ethylcarbamate) DMTHWXO TI TT1RS9F DMTHWXO TN Acetylcholinesterase (AChE) DMTHWXO MA Inhibitor DMTHWXO RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMTHWXO RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMTHZ3B DI DMTHZ3B DMTHZ3B DN DPI59 DMTHZ3B TI TT6PKBN DMTHZ3B TN Proto-oncogene c-Src (SRC) DMTHZ3B MA Inhibitor DMTHZ3B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTHZ3B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTI1VO DI DMTI1VO DMTI1VO DN 2-(6-Cyclopentylamino-purin-9-yl)-ethanol DMTI1VO TI TTK25J1 DMTI1VO TN Adenosine A1 receptor (ADORA1) DMTI1VO MA Inhibitor DMTI1VO RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMTI1VO RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMTIA27 DI DMTIA27 DMTIA27 DN 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline DMTIA27 TI TT7HF4W DMTIA27 TN Cyclin-dependent kinase 2 (CDK2) DMTIA27 MA Inhibitor DMTIA27 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMTIA27 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMTIA27 DI DMTIA27 DMTIA27 DN 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline DMTIA27 TI TTUTJGQ DMTIA27 TN Vascular endothelial growth factor receptor 2 (KDR) DMTIA27 MA Inhibitor DMTIA27 RN Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2126-33. DMTIA27 RU https://pubmed.ncbi.nlm.nih.gov/17306530 DMTIKF7 DI DMTIKF7 DMTIKF7 DN 3-(6-hydroxy-2-naphthyl)benzoic acid DMTIKF7 TI TTIWB6L DMTIKF7 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMTIKF7 MA Inhibitor DMTIKF7 RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DMTIKF7 RU https://pubmed.ncbi.nlm.nih.gov/18324762 DMTIY89 DI DMTIY89 DMTIY89 DN 4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMTIY89 TI TTPNQAC DMTIY89 TN Estrogen-related receptor-alpha (ESRRA) DMTIY89 MA Inhibitor DMTIY89 RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMTIY89 RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMTIY89 DI DMTIY89 DMTIY89 DN 4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMTIY89 TI TTOM3J0 DMTIY89 TN Estrogen receptor beta (ESR2) DMTIY89 MA Inhibitor DMTIY89 RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMTIY89 RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMTIY89 DI DMTIY89 DMTIY89 DN 4-Ethyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMTIY89 TI TTZAYWL DMTIY89 TN Estrogen receptor (ESR) DMTIY89 MA Inhibitor DMTIY89 RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMTIY89 RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TTWRP2F DMTJ1NH TN Metabotropic glutamate receptor 6 (mGluR6) DMTJ1NH MA Agonist DMTJ1NH RN Cloning, distribution and functional expression of the human mGlu6 metabotropic glutamate receptor. Neuropharmacology. 1997 Feb;36(2):145-52. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/9144651 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TTICZ1O DMTJ1NH TN Metabotropic glutamate receptor 4 (mGluR4) DMTJ1NH MA Agonist DMTJ1NH RN Serine-O-phosphate has affinity for type IV, but not type I, metabotropic glutamate receptor. Neuroreport. 1993 Sep;4(9):1099-101. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/8106006 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TT0I76D DMTJ1NH TN Metabotropic glutamate receptor 7 (mGluR7) DMTJ1NH MA Agonist DMTJ1NH RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TT0IFKL DMTJ1NH TN Metabotropic glutamate receptor 8 (mGluR8) DMTJ1NH MA Agonist DMTJ1NH RN Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res Mol Brain Res. 1999 Apr 20;67(2):201-10. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/10216218 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TT9QBI6 DMTJ1NH TN Phosphoinositide dependent protein kinase-1 (PDPK1) DMTJ1NH MA Inhibitor DMTJ1NH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TTLP3GX DMTJ1NH TN Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC) DMTJ1NH MA Inhibitor DMTJ1NH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TTZHY6R DMTJ1NH TN Glycogen phosphorylase muscle form (GP) DMTJ1NH MA Inhibitor DMTJ1NH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TTH0KSX DMTJ1NH TN Rhodopsin (RHO) DMTJ1NH MA Inhibitor DMTJ1NH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTJ1NH DI DMTJ1NH DMTJ1NH DN L-serine-O-phosphate DMTJ1NH TI TT8QL1J DMTJ1NH TN Protein kinase C theta (PRKCQ) DMTJ1NH MA Inhibitor DMTJ1NH RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTJ1NH RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTJ384 DI DMTJ384 DMTJ384 DN 18-Methoxycoronaridine DMTJ384 TI TTMT0HG DMTJ384 TN Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3) DMTJ384 MA Antagonist DMTJ384 RN Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol. 2002 Mar 1;438(1-2):99-105. DMTJ384 RU https://pubmed.ncbi.nlm.nih.gov/11906717 DMTJ3F9 DI DMTJ3F9 DMTJ3F9 DN 4-Nitrophenyl 4-Benzylpiperazine-1-carboxylate DMTJ3F9 TI TTDP1UC DMTJ3F9 TN Fatty acid amide hydrolase (FAAH) DMTJ3F9 MA Inhibitor DMTJ3F9 RN Characterization of tunable piperidine and piperazine carbamates as inhibitors of endocannabinoid hydrolases. J Med Chem. 2010 Feb 25;53(4):1830-42. DMTJ3F9 RU https://pubmed.ncbi.nlm.nih.gov/20099888 DMTJ5WL DI DMTJ5WL DMTJ5WL DN N-(propargyl),N-(pyrrol-2-ylmethyl)amine DMTJ5WL TI TTGP7BY DMTJ5WL TN Monoamine oxidase type B (MAO-B) DMTJ5WL MA Inhibitor DMTJ5WL RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMTJ5WL RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMTJ5WL DI DMTJ5WL DMTJ5WL DN N-(propargyl),N-(pyrrol-2-ylmethyl)amine DMTJ5WL TI TT3WG5C DMTJ5WL TN Monoamine oxidase type A (MAO-A) DMTJ5WL MA Inhibitor DMTJ5WL RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMTJ5WL RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMTJDXY DI DMTJDXY DMTJDXY DN ESI-09 DMTJDXY TI TTOS63B DMTJDXY TN Rap guanine nucleotide exchange factor 4 (EPAC2) DMTJDXY MA Inhibitor DMTJDXY RN A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion. Mol Pharmacol. 2013 Jan;83(1):122-8. DMTJDXY RU https://pubmed.ncbi.nlm.nih.gov/23066090 DMTJGBL DI DMTJGBL DMTJGBL DN 4-(2-(1H-indol-6-yl)-9H-purin-6-yl)morpholine DMTJGBL TI TTCJG29 DMTJGBL TN Serine/threonine-protein kinase mTOR (mTOR) DMTJGBL MA Inhibitor DMTJGBL RN Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. DMTJGBL RU https://pubmed.ncbi.nlm.nih.gov/19969455 DMTJI4F DI DMTJI4F DMTJI4F DN (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine DMTJI4F TI TTQ6VDM DMTJI4F TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMTJI4F MA Inhibitor DMTJI4F RN 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8. DMTJI4F RU https://pubmed.ncbi.nlm.nih.gov/17314044 DMTJI4F DI DMTJI4F DMTJI4F DN (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine DMTJI4F TI TTJQOD7 DMTJI4F TN 5-HT 2A receptor (HTR2A) DMTJI4F MA Inhibitor DMTJI4F RN 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8. DMTJI4F RU https://pubmed.ncbi.nlm.nih.gov/17314044 DMTJI4F DI DMTJI4F DMTJI4F DN (E)-2-(4-fluorostyryl)-5-(phenylsulfinyl)pyridine DMTJI4F TI TTWJBZ5 DMTJI4F TN 5-HT 2C receptor (HTR2C) DMTJI4F MA Inhibitor DMTJI4F RN 2,5-Disubstituted pyridines: the discovery of a novel series of 5-HT2A ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2643-8. DMTJI4F RU https://pubmed.ncbi.nlm.nih.gov/17314044 DMTJNY0 DI DMTJNY0 DMTJNY0 DN 5-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamine DMTJNY0 TI TT1RS9F DMTJNY0 TN Acetylcholinesterase (AChE) DMTJNY0 MA Inhibitor DMTJNY0 RN The synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory activity of tacrine (Cognex ) derivaties, Bioorg. Med. Chem. Lett. 2(8):861-864 (1992). DMTJNY0 RU http://www.sciencedirect.com/science/article/pii/S0960894X00805454 DMTJOWH DI DMTJOWH DMTJOWH DN CP-339818 DMTJOWH TI TTY3UE6 DMTJOWH TN Voltage-gated potassium channel Kv1.3 (KCNA3) DMTJOWH MA Inhibitor DMTJOWH RN Angular methoxy-substituted furo- and pyranoquinolinones as blockers of the voltage-gated potassium channel Kv1.3. J Med Chem. 2001 Apr 12;44(8):1249-56. DMTJOWH RU https://pubmed.ncbi.nlm.nih.gov/11312924 DMTJPZU DI DMTJPZU DMTJPZU DN 6-(3-Fluoropropyl)-4-methylpyridin-2-amine DMTJPZU TI TTF10I9 DMTJPZU TN Nitric-oxide synthase inducible (NOS2) DMTJPZU MA Inhibitor DMTJPZU RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DMTJPZU RU https://pubmed.ncbi.nlm.nih.gov/19323559 DMTJPZU DI DMTJPZU DMTJPZU DN 6-(3-Fluoropropyl)-4-methylpyridin-2-amine DMTJPZU TI TTZUFI5 DMTJPZU TN Nitric-oxide synthase brain (NOS1) DMTJPZU MA Inhibitor DMTJPZU RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DMTJPZU RU https://pubmed.ncbi.nlm.nih.gov/19323559 DMTJPZU DI DMTJPZU DMTJPZU DN 6-(3-Fluoropropyl)-4-methylpyridin-2-amine DMTJPZU TI TTCM4B3 DMTJPZU TN Nitric-oxide synthase endothelial (NOS3) DMTJPZU MA Inhibitor DMTJPZU RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DMTJPZU RU https://pubmed.ncbi.nlm.nih.gov/19323559 DMTJRF3 DI DMTJRF3 DMTJRF3 DN 6-Bromo-2-(3-bromo-phenyl)-chromen-4-one DMTJRF3 TI TTNJYV2 DMTJRF3 TN Gamma-aminobutyric acid receptor (GAR) DMTJRF3 MA Inhibitor DMTJRF3 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMTJRF3 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMTJRF3 DI DMTJRF3 DMTJRF3 DN 6-Bromo-2-(3-bromo-phenyl)-chromen-4-one DMTJRF3 TI TT1MPAY DMTJRF3 TN GABA(A) receptor alpha-1 (GABRA1) DMTJRF3 MA Inhibitor DMTJRF3 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMTJRF3 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMTJXOU DI DMTJXOU DMTJXOU DN 3-(5-methoxy-1H-inden-2-yl)pyridine DMTJXOU TI TTIQUX7 DMTJXOU TN Steroid 11-beta-hydroxylase (CYP11B1) DMTJXOU MA Inhibitor DMTJXOU RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMTJXOU RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMTJZQK DI DMTJZQK DMTJZQK DN pristanic acid DMTJZQK TI TTJ584C DMTJZQK TN Peroxisome proliferator-activated receptor alpha (PPARA) DMTJZQK MA Agonist DMTJZQK RN Pristanic acid and phytanic acid: naturally occurring ligands for the nuclear receptor peroxisome proliferator-activated receptor alpha. J Lipid Res. 2000 Nov;41(11):1801-7. DMTJZQK RU https://pubmed.ncbi.nlm.nih.gov/11060349 DMTK650 DI DMTK650 DMTK650 DN 1,2,3,4,6-penta-O-galloyl-beta-D-glucose DMTK650 TI TTCIHJA DMTK650 TN Coagulation factor Xa (F10) DMTK650 MA Inhibitor DMTK650 RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DMTK650 RU https://pubmed.ncbi.nlm.nih.gov/9834152 DMTK650 DI DMTK650 DMTK650 DN 1,2,3,4,6-penta-O-galloyl-beta-D-glucose DMTK650 TI TTE14XG DMTK650 TN Squalene monooxygenase (SQLE) DMTK650 MA Inhibitor DMTK650 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMTK650 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMTK650 DI DMTK650 DMTK650 DN 1,2,3,4,6-penta-O-galloyl-beta-D-glucose DMTK650 TI TT7RJY8 DMTK650 TN Xanthine dehydrogenase/oxidase (XDH) DMTK650 MA Inhibitor DMTK650 RN Pentagalloylglucose, a xanthine oxidase inhibitor from a Paraguayan crude drug, "Molle-i" (Schinus terebinthifolius). J Nat Prod. 1989 Jan-Feb;52(1):210-1. DMTK650 RU https://pubmed.ncbi.nlm.nih.gov/2723668 DMTK650 DI DMTK650 DMTK650 DN 1,2,3,4,6-penta-O-galloyl-beta-D-glucose DMTK650 TI TT6L509 DMTK650 TN Coagulation factor IIa (F2) DMTK650 MA Inhibitor DMTK650 RN Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60. DMTK650 RU https://pubmed.ncbi.nlm.nih.gov/9834152 DMTK9V7 DI DMTK9V7 DMTK9V7 DN [(3-Bromophenyl)-m-tolyl-ketone]thiosemicarbazone DMTK9V7 TI TT36ETB DMTK9V7 TN Cathepsin L (CTSL) DMTK9V7 MA Inhibitor DMTK9V7 RN Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9. DMTK9V7 RU https://pubmed.ncbi.nlm.nih.gov/20089402 DMTKCAL DI DMTKCAL DMTKCAL DN (E)-3-(4-tert-Butyl-phenyl)-N-phenyl-acrylamide DMTKCAL TI TTMI6F5 DMTKCAL TN Transient receptor potential cation channel V1 (TRPV1) DMTKCAL MA Inhibitor DMTKCAL RN Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides. J Med Chem. 2005 Jan 13;48(1):71-90. DMTKCAL RU https://pubmed.ncbi.nlm.nih.gov/15634002 DMTKCW6 DI DMTKCW6 DMTKCW6 DN HI-241 DMTKCW6 TI TT84ETX DMTKCW6 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMTKCW6 MA Inhibitor DMTKCW6 RN Antioxidant function of phenethyl-5-bromo-pyridyl thiourea compounds with potent anti-HIV activity. Bioorg Med Chem Lett. 2000 Jan 3;10(1):87-90. DMTKCW6 RU https://pubmed.ncbi.nlm.nih.gov/10636251 DMTKFPW DI DMTKFPW DMTKFPW DN 7-(benzyloxy)-2H-chromen-2-one DMTKFPW TI TTZHA0O DMTKFPW TN Carbonic anhydrase IV (CA-IV) DMTKFPW MA Inhibitor DMTKFPW RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMTKFPW RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMTKFPW DI DMTKFPW DMTKFPW DN 7-(benzyloxy)-2H-chromen-2-one DMTKFPW TI TTUNARX DMTKFPW TN Carbonic anhydrase (CA) DMTKFPW MA Inhibitor DMTKFPW RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMTKFPW RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMTKFPW DI DMTKFPW DMTKFPW DN 7-(benzyloxy)-2H-chromen-2-one DMTKFPW TI TT2LVK8 DMTKFPW TN Carbonic anhydrase IX (CA-IX) DMTKFPW MA Inhibitor DMTKFPW RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMTKFPW RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMTKFPW DI DMTKFPW DMTKFPW DN 7-(benzyloxy)-2H-chromen-2-one DMTKFPW TI TTEYTKG DMTKFPW TN Carbonic anhydrase XIV (CA-XIV) DMTKFPW MA Inhibitor DMTKFPW RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMTKFPW RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMTKFPW DI DMTKFPW DMTKFPW DN 7-(benzyloxy)-2H-chromen-2-one DMTKFPW TI TTSYM0R DMTKFPW TN Carbonic anhydrase XII (CA-XII) DMTKFPW MA Inhibitor DMTKFPW RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMTKFPW RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMTKGA3 DI DMTKGA3 DMTKGA3 DN GSC-1 DMTKGA3 TI TTXWASR DMTKGA3 TN Intestinal maltase-glucoamylase (MGAM) DMTKGA3 MA Inhibitor DMTKGA3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627). DMTKGA3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627 DMTKHR3 DI DMTKHR3 DMTKHR3 DN ShRNA molecule silencing DNAPK radiosensitizer DMTKHR3 TI TTK3PY9 DMTKHR3 TN DNA-dependent protein kinase catalytic (PRKDC) DMTKHR3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2800). DMTKHR3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2800 DMTKJA9 DI DMTKJA9 DMTKJA9 DN PMID21855335C19a DMTKJA9 TI TT860QF DMTKJA9 TN LCK tyrosine protein kinase (LCK) DMTKJA9 MA Inhibitor DMTKJA9 RN Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5. DMTKJA9 RU https://pubmed.ncbi.nlm.nih.gov/21855335 DMTKJA9 DI DMTKJA9 DMTKJA9 DN PMID21855335C19a DMTKJA9 TI TT6TH8V DMTKJA9 TN Tyrosine-protein kinase BRK (PTK6) DMTKJA9 MA Inhibitor DMTKJA9 RN Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors. Bioorg Med Chem Lett. 2011 Oct 1;21(19):5870-5. DMTKJA9 RU https://pubmed.ncbi.nlm.nih.gov/21855335 DMTKN4A DI DMTKN4A DMTKN4A DN Homoserine Lactone DMTKN4A TI TTGSEFH DMTKN4A TN Sodium/hydrogen exchanger 1 (SLC9A1) DMTKN4A MA Inhibitor DMTKN4A RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTKN4A RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTKO7P DI DMTKO7P DMTKO7P DN CP608,039 DMTKO7P TI TTJFY5U DMTKO7P TN Adenosine A3 receptor (ADORA3) DMTKO7P MA Agonist DMTKO7P RN Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2780-7. DMTKO7P RU https://pubmed.ncbi.nlm.nih.gov/12919933 DMTKO7P DI DMTKO7P DMTKO7P DN CP608,039 DMTKO7P TI TTK25J1 DMTKO7P TN Adenosine A1 receptor (ADORA1) DMTKO7P MA Agonist DMTKO7P RN Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006 Mar;5(3):247-64. DMTKO7P RU https://pubmed.ncbi.nlm.nih.gov/16518376 DMTKQNU DI DMTKQNU DMTKQNU DN 3-Ethenylquinoline-8-carboxamide DMTKQNU TI TTVDSZ0 DMTKQNU TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTKQNU MA Inhibitor DMTKQNU RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMTKQNU RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMTKREZ DI DMTKREZ DMTKREZ DN N-(cyanomethyl)cyclohex-1-ene-1-carboxamide DMTKREZ TI TTDZN01 DMTKREZ TN Cathepsin K (CTSK) DMTKREZ MA Inhibitor DMTKREZ RN Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J Med Chem. 2006 Feb 9;49(3):1066-79. DMTKREZ RU https://pubmed.ncbi.nlm.nih.gov/16451072 DMTKSVO DI DMTKSVO DMTKSVO DN T0070907 DMTKSVO TI TTT2SVW DMTKSVO TN PPAR-gamma messenger RNA (PPARG mRNA) DMTKSVO MA Antagonist DMTKSVO RN T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002 May 31;277(22):19649-57. DMTKSVO RU https://pubmed.ncbi.nlm.nih.gov/11877444 DMTKVDZ DI DMTKVDZ DMTKVDZ DN CI-1031 DMTKVDZ TI TTCIHJA DMTKVDZ TN Coagulation factor Xa (F10) DMTKVDZ MA Modulator DMTKVDZ RN Effects of ZK-807834, a novel inhibitor of factor Xa, on arterial and venous thrombosis in rabbits. J Cardiovasc Pharmacol. 2000 May;35(5):796-805. DMTKVDZ RU https://www.ncbi.nlm.nih.gov/pubmed/10813384 DMTKWUM DI DMTKWUM DMTKWUM DN N-(2-aminophenyl)-4-methoxybenzamide DMTKWUM TI TTSHTOI DMTKWUM TN Histone deacetylase 2 (HDAC2) DMTKWUM MA Inhibitor DMTKWUM RN Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. DMTKWUM RU https://pubmed.ncbi.nlm.nih.gov/17941625 DMTKWUM DI DMTKWUM DMTKWUM DN N-(2-aminophenyl)-4-methoxybenzamide DMTKWUM TI TTBH0VX DMTKWUM TN Histone deacetylase (HDAC) DMTKWUM MA Inhibitor DMTKWUM RN Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. DMTKWUM RU https://pubmed.ncbi.nlm.nih.gov/17941625 DMTKWUM DI DMTKWUM DMTKWUM DN N-(2-aminophenyl)-4-methoxybenzamide DMTKWUM TI TT6R7JZ DMTKWUM TN Histone deacetylase 1 (HDAC1) DMTKWUM MA Inhibitor DMTKWUM RN Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007 Nov 15;50(23):5543-6. DMTKWUM RU https://pubmed.ncbi.nlm.nih.gov/17941625 DMTKYFE DI DMTKYFE DMTKYFE DN 1,2,3,4,5,6-Hexahydro-benzo[c]azocine DMTKYFE TI TTWG9A4 DMTKYFE TN Adrenergic receptor alpha-2A (ADRA2A) DMTKYFE MA Inhibitor DMTKYFE RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMTKYFE RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMTKYFE DI DMTKYFE DMTKYFE DN 1,2,3,4,5,6-Hexahydro-benzo[c]azocine DMTKYFE TI TTWM4TY DMTKYFE TN Adrenergic receptor alpha-2B (ADRA2B) DMTKYFE MA Inhibitor DMTKYFE RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMTKYFE RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMTKYFE DI DMTKYFE DMTKYFE DN 1,2,3,4,5,6-Hexahydro-benzo[c]azocine DMTKYFE TI TT2NUT5 DMTKYFE TN Adrenergic receptor alpha-2C (ADRA2C) DMTKYFE MA Inhibitor DMTKYFE RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMTKYFE RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMTL2BA DI DMTL2BA DMTL2BA DN CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP-amide DMTL2BA TI TTLWS2O DMTL2BA TN Calcitonin receptor (CALCR) DMTL2BA MA Inhibitor DMTL2BA RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMTL2BA RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMTL4S9 DI DMTL4S9 DMTL4S9 DN 5,6,7-Trichloro-1,4-dihydro-quinoxaline-2,3-dione DMTL4S9 TI TTLD29N DMTL4S9 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMTL4S9 MA Inhibitor DMTL4S9 RN 1-Hydroxy-1,4-dihydroquinoxaline-2,3-diones: Novel antagonists at NMDA receptor glycine sites, Bioorg. Med. Chem. Lett. 6(4):439-440 (1996). DMTL4S9 RU http://www.sciencedirect.com/science/article/pii/0960894X96000364 DMTL6ES DI DMTL6ES DMTL6ES DN 4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol DMTL6ES TI TTOM3J0 DMTL6ES TN Estrogen receptor beta (ESR2) DMTL6ES MA Inhibitor DMTL6ES RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMTL6ES RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMTL6ES DI DMTL6ES DMTL6ES DN 4-[1,2-bis(4-hydroxyphenyl)hex-1-enyl]phenol DMTL6ES TI TTZAYWL DMTL6ES TN Estrogen receptor (ESR) DMTL6ES MA Inhibitor DMTL6ES RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMTL6ES RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMTLJMF DI DMTLJMF DMTLJMF DN 3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine DMTLJMF TI TTVG215 DMTLJMF TN Debrisoquine 4-hydroxylase (CYP2D6) DMTLJMF MA Inhibitor DMTLJMF RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DMTLJMF RU https://pubmed.ncbi.nlm.nih.gov/14698153 DMTLJMF DI DMTLJMF DMTLJMF DN 3-[3-(4-Imidazol-1-yl-phenoxy)-propyl]-pyridine DMTLJMF TI TTXV4FI DMTLJMF TN Albendazole monooxygenase (CYP3A4) DMTLJMF MA Inhibitor DMTLJMF RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DMTLJMF RU https://pubmed.ncbi.nlm.nih.gov/14698153 DMTLOU6 DI DMTLOU6 DMTLOU6 DN CLEBOPRIDE DMTLOU6 TI TTEX248 DMTLOU6 TN Dopamine D2 receptor (D2R) DMTLOU6 MA Inhibitor DMTLOU6 RN Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15. DMTLOU6 RU https://pubmed.ncbi.nlm.nih.gov/12593651 DMTLOU6 DI DMTLOU6 DMTLOU6 DN CLEBOPRIDE DMTLOU6 TI TT1RS9F DMTLOU6 TN Acetylcholinesterase (AChE) DMTLOU6 MA Inhibitor DMTLOU6 RN Efficient method for high-throughput virtual screening based on flexible docking: discovery of novel acetylcholinesterase inhibitors. J Med Chem. 2004 Sep 23;47(20):4818-28. DMTLOU6 RU https://pubmed.ncbi.nlm.nih.gov/15369385 DMTLPDZ DI DMTLPDZ DMTLPDZ DN N-(2,3-dihydro-1H-inden-2-yl)isoquinolin-1-amine DMTLPDZ TI TTVBPDM DMTLPDZ TN Metabotropic glutamate receptor 1 (mGluR1) DMTLPDZ MA Inhibitor DMTLPDZ RN In vitro and in vivo SAR of pyrido[3,4-d]pyramid-4-ylamine based mGluR1 antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2190-4. DMTLPDZ RU https://pubmed.ncbi.nlm.nih.gov/19289283 DMTLRGZ DI DMTLRGZ DMTLRGZ DN SGC-CBP30 DMTLRGZ TI TTH4VJL DMTLRGZ TN Histone acetyltransferase KAT6B (KAT6B) DMTLRGZ MA Inhibitor DMTLRGZ RN Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64. DMTLRGZ RU https://pubmed.ncbi.nlm.nih.gov/24497428 DMTLRGZ DI DMTLRGZ DMTLRGZ DN SGC-CBP30 DMTLRGZ TI TTFRCTK DMTLRGZ TN CREB-binding protein (CREBBP) DMTLRGZ MA Inhibitor DMTLRGZ RN Bromodomains and their pharmacological inhibitors. ChemMedChem. 2014 Mar;9(3):438-64. DMTLRGZ RU https://pubmed.ncbi.nlm.nih.gov/24497428 DMTLYDS DI DMTLYDS DMTLYDS DN 2-hydroxyisoquinoline-1,3(2H,4H)-dione DMTLYDS TI TT37KAF DMTLYDS TN Human immunodeficiency virus Ribonuclease H (HIV RNH) DMTLYDS MA Inhibitor DMTLYDS RN RNase H active site inhibitors of human immunodeficiency virus type 1 reverse transcriptase: design, biochemical activity, and structural information. J Med Chem. 2009 Oct 8;52(19):5781-4. DMTLYDS RU https://pubmed.ncbi.nlm.nih.gov/19791799 DMTM1VD DI DMTM1VD DMTM1VD DN 4-Ethyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine DMTM1VD TI TTCM4B3 DMTM1VD TN Nitric-oxide synthase endothelial (NOS3) DMTM1VD MA Inhibitor DMTM1VD RN Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4. DMTM1VD RU https://pubmed.ncbi.nlm.nih.gov/12161118 DMTM6B0 DI DMTM6B0 DMTM6B0 DN 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one DMTM6B0 TI TTNJYV2 DMTM6B0 TN Gamma-aminobutyric acid receptor (GAR) DMTM6B0 MA Inhibitor DMTM6B0 RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DMTM6B0 RU https://pubmed.ncbi.nlm.nih.gov/2826782 DMTM6B0 DI DMTM6B0 DMTM6B0 DN 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one DMTM6B0 TI TT06RH5 DMTM6B0 TN GABA(A) receptor gamma-2 (GABRG2) DMTM6B0 MA Inhibitor DMTM6B0 RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DMTM6B0 RU https://pubmed.ncbi.nlm.nih.gov/2826782 DMTM6B0 DI DMTM6B0 DMTM6B0 DN 3-Methyl-1-phenyl-1H-chromeno[4,3-c]pyrazol-4-one DMTM6B0 TI TT1MPAY DMTM6B0 TN GABA(A) receptor alpha-1 (GABRA1) DMTM6B0 MA Inhibitor DMTM6B0 RN Synthesis, binding studies, and structure-activity relationships of 1-aryl-and 2-aryl[1]benzopyranopyrazol-4-ones, central benzodiazepine receptor ... J Med Chem. 1988 Jan;31(1):1-3. DMTM6B0 RU https://pubmed.ncbi.nlm.nih.gov/2826782 DMTM7W0 DI DMTM7W0 DMTM7W0 DN BRL 43694A DMTM7W0 TI TTNXLKE DMTM7W0 TN 5-HT 3 receptor (5HT3R) DMTM7W0 MA Antagonist DMTM7W0 RN BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy. Schweiz Med Wochenschr. 1989 Jun 10;119(23):831-4. DMTM7W0 RU https://pubmed.ncbi.nlm.nih.gov/2549616 DMTMBEX DI DMTMBEX DMTMBEX DN ISIS 102486 DMTMBEX TI TT5U49F DMTMBEX TN PRKACA messenger RNA (PRKACA mRNA) DMTMBEX RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMTMBEX RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMTMDZ4 DI DMTMDZ4 DMTMDZ4 DN N1-(4-chlorobenzyl)-2-benzyl-N3-hydroxymalonamide DMTMDZ4 TI TTPHMWB DMTMDZ4 TN Aminopeptidase N (ANPEP) DMTMDZ4 MA Inhibitor DMTMDZ4 RN Novel selective inhibitors of the zinc plasmodial aminopeptidase PfA-M1 as potential antimalarial agents. J Med Chem. 2007 Mar 22;50(6):1322-34. DMTMDZ4 RU https://pubmed.ncbi.nlm.nih.gov/17326615 DMTMF8X DI DMTMF8X DMTMF8X DN JWH-294 DMTMF8X TI TTMSFAW DMTMF8X TN Cannabinoid receptor 2 (CB2) DMTMF8X MA Inhibitor DMTMF8X RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMTMF8X RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMTMHW2 DI DMTMHW2 DMTMHW2 DN NDP-alpha-MSH DMTMHW2 TI TTD0CIQ DMTMHW2 TN Melanocortin receptor 4 (MC4R) DMTMHW2 MA Inhibitor DMTMHW2 RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMTMHW2 RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMTMJAI DI DMTMJAI DMTMJAI DN C(-GRGDfL-) DMTMJAI TI TTT1R2L DMTMJAI TN Integrin alpha-V (ITGAV) DMTMJAI MA Inhibitor DMTMJAI RN Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81. DMTMJAI RU https://pubmed.ncbi.nlm.nih.gov/17973471 DMTMJAI DI DMTMJAI DMTMJAI DN C(-GRGDfL-) DMTMJAI TI TTBVIQC DMTMJAI TN Integrin beta-1 (ITGB1) DMTMJAI MA Inhibitor DMTMJAI RN Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81. DMTMJAI RU https://pubmed.ncbi.nlm.nih.gov/17973471 DMTMJAI DI DMTMJAI DMTMJAI DN C(-GRGDfL-) DMTMJAI TI TTHIZP9 DMTMJAI TN Integrin alpha-5 (ITGA5) DMTMJAI MA Inhibitor DMTMJAI RN Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81. DMTMJAI RU https://pubmed.ncbi.nlm.nih.gov/17973471 DMTMJAI DI DMTMJAI DMTMJAI DN C(-GRGDfL-) DMTMJAI TI TTJA1ZO DMTMJAI TN ITGB3 messenger RNA (ITGB3 mRNA) DMTMJAI MA Inhibitor DMTMJAI RN Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81. DMTMJAI RU https://pubmed.ncbi.nlm.nih.gov/17973471 DMTMLRN DI DMTMLRN DMTMLRN DN Microcystin-LR DMTMLRN TI TTFLH0E DMTMLRN TN Serine/threonine PP1-alpha (PPP1CA) DMTMLRN MA Inhibitor DMTMLRN RN Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J Med Chem. 2002 Mar 14;45(6):1151-75. DMTMLRN RU https://pubmed.ncbi.nlm.nih.gov/11881984 DMTMLXU DI DMTMLXU DMTMLXU DN 4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenol DMTMLXU TI TTZAYWL DMTMLXU TN Estrogen receptor (ESR) DMTMLXU MA Inhibitor DMTMLXU RN Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64. DMTMLXU RU https://pubmed.ncbi.nlm.nih.gov/12431063 DMTMNO7 DI DMTMNO7 DMTMNO7 DN 7-hydroxycoumarin DMTMNO7 TI TTFCJ7S DMTMNO7 TN G1/S-specific cyclin-D1 (CCND1) DMTMNO7 MA Inhibitor DMTMNO7 RN Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. Lung Cancer. 2001 Nov;34(2):185-94. DMTMNO7 RU https://pubmed.ncbi.nlm.nih.gov/11679177 DMTMNO7 DI DMTMNO7 DMTMNO7 DN 7-hydroxycoumarin DMTMNO7 TI TT2LVK8 DMTMNO7 TN Carbonic anhydrase IX (CA-IX) DMTMNO7 MA Inhibitor DMTMNO7 RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMTMNO7 RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMTMVYH DI DMTMVYH DMTMVYH DN ZM-39923 DMTMVYH TI TT6DM01 DMTMVYH TN Janus kinase 1 (JAK-1) DMTMVYH MA Inhibitor DMTMVYH RN Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9. DMTMVYH RU https://pubmed.ncbi.nlm.nih.gov/10741557 DMTMVYH DI DMTMVYH DMTMVYH DN ZM-39923 DMTMVYH TI TTT7PJU DMTMVYH TN Janus kinase 3 (JAK-3) DMTMVYH MA Inhibitor DMTMVYH RN Naphthyl ketones: a new class of Janus kinase 3 inhibitors. Bioorg Med Chem Lett. 2000 Mar 20;10(6):575-9. DMTMVYH RU https://pubmed.ncbi.nlm.nih.gov/10741557 DMTMXN4 DI DMTMXN4 DMTMXN4 DN 1-Pyridin-2-yl-3-quinolin-5-yl-urea DMTMXN4 TI TT0PG8F DMTMXN4 TN Cyclin-dependent kinase 4 (CDK4) DMTMXN4 MA Inhibitor DMTMXN4 RN Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27. DMTMXN4 RU https://pubmed.ncbi.nlm.nih.gov/11741479 DMTMZAJ DI DMTMZAJ DMTMZAJ DN 1-(but-2-ylamino)ethyl 1,I-bisphosphonic acid DMTMZAJ TI TTIKWV4 DMTMZAJ TN Geranyltranstransferase (FDPS) DMTMZAJ MA Inhibitor DMTMZAJ RN Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl... Bioorg Med Chem. 2008 Mar 15;16(6):3283-90. DMTMZAJ RU https://pubmed.ncbi.nlm.nih.gov/18096393 DMTN10D DI DMTN10D DMTN10D DN AR234960 DMTN10D TI TTOISYB DMTN10D TN Proto-oncogene Mas (MAS) DMTN10D MA Agonist DMTN10D RN Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol. 2012 Jan 1;302(1):H299-311. DMTN10D RU https://pubmed.ncbi.nlm.nih.gov/22003054 DMTN1D7 DI DMTN1D7 DMTN1D7 DN ISIS 7847 DMTN1D7 TI TTAN5W2 DMTN1D7 TN Raf messenger RNA (Raf mRNA) DMTN1D7 RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMTN1D7 RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMTN1P2 DI DMTN1P2 DMTN1P2 DN CSL-324 DMTN1P2 TI TTC70AJ DMTN1P2 TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMTN1P2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMTN1P2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMTN7IU DI DMTN7IU DMTN7IU DN Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-3,4-diol DMTN7IU TI TTRA5BZ DMTN7IU TN Steroid 17-alpha-monooxygenase (S17AH) DMTN7IU MA Inhibitor DMTN7IU RN Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75. DMTN7IU RU https://pubmed.ncbi.nlm.nih.gov/19211174 DMTNCXP DI DMTNCXP DMTNCXP DN 3-(3-Methyl-butoxy)-9H-beta-carboline DMTNCXP TI TT1MPAY DMTNCXP TN GABA(A) receptor alpha-1 (GABRA1) DMTNCXP MA Inhibitor DMTNCXP RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMTNCXP RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMTNCXP DI DMTNCXP DMTNCXP DN 3-(3-Methyl-butoxy)-9H-beta-carboline DMTNCXP TI TTNJYV2 DMTNCXP TN Gamma-aminobutyric acid receptor (GAR) DMTNCXP MA Inhibitor DMTNCXP RN Predictive binding of beta-carboline inverse agonists and antagonists via the CoMFA/GOLPE approach. J Med Chem. 1992 Oct 30;35(22):4001-10. DMTNCXP RU https://pubmed.ncbi.nlm.nih.gov/1331452 DMTNCXP DI DMTNCXP DMTNCXP DN 3-(3-Methyl-butoxy)-9H-beta-carboline DMTNCXP TI TT06RH5 DMTNCXP TN GABA(A) receptor gamma-2 (GABRG2) DMTNCXP MA Inhibitor DMTNCXP RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMTNCXP RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMTNCXP DI DMTNCXP DMTNCXP DN 3-(3-Methyl-butoxy)-9H-beta-carboline DMTNCXP TI TTNZPQ1 DMTNCXP TN GABA(A) receptor alpha-5 (GABRA5) DMTNCXP MA Inhibitor DMTNCXP RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMTNCXP RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMTNCXP DI DMTNCXP DMTNCXP DN 3-(3-Methyl-butoxy)-9H-beta-carboline DMTNCXP TI TTBMV1G DMTNCXP TN GABA(A) receptor alpha-2 (GABRA2) DMTNCXP MA Inhibitor DMTNCXP RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMTNCXP RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMTNCXP DI DMTNCXP DMTNCXP DN 3-(3-Methyl-butoxy)-9H-beta-carboline DMTNCXP TI TT37EDJ DMTNCXP TN GABA(A) receptor alpha-3 (GABRA3) DMTNCXP MA Inhibitor DMTNCXP RN Design, synthesis, and subtype selectivity of 3,6-disubstituted -carbolines at Bz/GABA(A)ergic receptors. SAR and studies directed toward agents f... Bioorg Med Chem. 2010 Nov 1;18(21):7548-64. DMTNCXP RU https://pubmed.ncbi.nlm.nih.gov/20888240 DMTNGCW DI DMTNGCW DMTNGCW DN [Sar1,Tdf8]AngII DMTNGCW TI TT8DBY3 DMTNGCW TN Angiotensin II receptor type-1 (AGTR1) DMTNGCW MA Inhibitor DMTNGCW RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMTNGCW RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMTNKBW DI DMTNKBW DMTNKBW DN ON-128 DMTNKBW TI TTGKNB4 DMTNKBW TN Epidermal growth factor receptor (EGFR) DMTNKBW MA Inhibitor DMTNKBW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMTNKBW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMTNPBH DI DMTNPBH DMTNPBH DN 1-adamantan-1-yl-3-piperidin-4-yl-urea DMTNPBH TI TT7WVHI DMTNPBH TN Soluble epoxide hydrolase (EPHX2) DMTNPBH MA Inhibitor DMTNPBH RN Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. DMTNPBH RU https://pubmed.ncbi.nlm.nih.gov/16870439 DMTNQ5E DI DMTNQ5E DMTNQ5E DN Alstiphyllanine E DMTNQ5E TI TT2UE56 DMTNQ5E TN Sodium/glucose cotransporter 1 (SGLT1) DMTNQ5E MA Inhibitor DMTNQ5E RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMTNQ5E RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMTNQ5E DI DMTNQ5E DMTNQ5E DN Alstiphyllanine E DMTNQ5E TI TTF8JAT DMTNQ5E TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMTNQ5E MA Inhibitor DMTNQ5E RN Alstiphyllanines E-H, picraline and ajmaline-type alkaloids from Alstonia macrophylla inhibiting sodium glucose cotransporter. Bioorg Med Chem. 2010 Mar 15;18(6):2152-2158. DMTNQ5E RU https://pubmed.ncbi.nlm.nih.gov/20189404 DMTNQCE DI DMTNQCE DMTNQCE DN L-betagamma-meATP DMTNQCE TI TTJW7B3 DMTNQCE TN P2X purinoceptor 1 (P2RX1) DMTNQCE MA Agonist DMTNQCE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478). DMTNQCE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=478 DMTNQCE DI DMTNQCE DMTNQCE DN L-betagamma-meATP DMTNQCE TI TTCBFJO DMTNQCE TN Insulin receptor (INSR) DMTNQCE MA Inhibitor DMTNQCE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTNQCE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTNQCE DI DMTNQCE DMTNQCE DN L-betagamma-meATP DMTNQCE TI TTXI3KF DMTNQCE TN Pyridoxal kinase (PDXK) DMTNQCE MA Inhibitor DMTNQCE RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTNQCE RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTNQZU DI DMTNQZU DMTNQZU DN 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine DMTNQZU TI TTM2AOE DMTNQZU TN Adenosine A2a receptor (ADORA2A) DMTNQZU MA Inhibitor DMTNQZU RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMTNQZU RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMTNQZU DI DMTNQZU DMTNQZU DN 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine DMTNQZU TI TTK25J1 DMTNQZU TN Adenosine A1 receptor (ADORA1) DMTNQZU MA Inhibitor DMTNQZU RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMTNQZU RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMTNQZU DI DMTNQZU DMTNQZU DN 2-[(4-fluorophenyl)ethynyl]-N6-methoxyadenosine DMTNQZU TI TTJFY5U DMTNQZU TN Adenosine A3 receptor (ADORA3) DMTNQZU MA Inhibitor DMTNQZU RN N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. J Med Chem. 2007 Mar 22;50(6):1222-30. DMTNQZU RU https://pubmed.ncbi.nlm.nih.gov/17309246 DMTNRG7 DI DMTNRG7 DMTNRG7 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine DMTNRG7 TI TTEX248 DMTNRG7 TN Dopamine D2 receptor (D2R) DMTNRG7 MA Inhibitor DMTNRG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMTNRG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMTNRG7 DI DMTNRG7 DMTNRG7 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine DMTNRG7 TI TTE0A2F DMTNRG7 TN Dopamine D4 receptor (D4R) DMTNRG7 MA Inhibitor DMTNRG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMTNRG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMTNRG7 DI DMTNRG7 DMTNRG7 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine DMTNRG7 TI TTZFYLI DMTNRG7 TN Dopamine D1 receptor (D1R) DMTNRG7 MA Inhibitor DMTNRG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMTNRG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMTNRG7 DI DMTNRG7 DMTNRG7 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine DMTNRG7 TI TTS2PH3 DMTNRG7 TN Dopamine D5 receptor (D5R) DMTNRG7 MA Inhibitor DMTNRG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMTNRG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMTNRG7 DI DMTNRG7 DMTNRG7 DN 1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine DMTNRG7 TI TT4C8EA DMTNRG7 TN Dopamine D3 receptor (D3R) DMTNRG7 MA Inhibitor DMTNRG7 RN Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8. DMTNRG7 RU https://pubmed.ncbi.nlm.nih.gov/15293986 DMTNVFZ DI DMTNVFZ DMTNVFZ DN 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine DMTNVFZ TI TTWJBZ5 DMTNVFZ TN 5-HT 2C receptor (HTR2C) DMTNVFZ MA Inhibitor DMTNVFZ RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DMTNVFZ RU https://pubmed.ncbi.nlm.nih.gov/19914063 DMTNVP4 DI DMTNVP4 DMTNVP4 DN LY97241 DMTNVP4 TI TT9XKUC DMTNVP4 TN Voltage-gated potassium channel Kv10.1 (KCNH1) DMTNVP4 MA Blocker (channel blocker) DMTNVP4 RN Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol. 2003 Jan;138(1):161-71. DMTNVP4 RU https://pubmed.ncbi.nlm.nih.gov/12522086 DMTNVP4 DI DMTNVP4 DMTNVP4 DN LY97241 DMTNVP4 TI TTX8LQ0 DMTNVP4 TN Voltage-gated potassium channel Kv10.2 (KCNH5) DMTNVP4 MA Blocker (channel blocker) DMTNVP4 RN Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. Mol Pharmacol. 2004 May;65(5):1120-9. DMTNVP4 RU https://pubmed.ncbi.nlm.nih.gov/15102940 DMTNZKU DI DMTNZKU DMTNZKU DN 6-MORPHOLIN-4-YL-9H-PURINE DMTNZKU TI TTTU902 DMTNZKU TN Checkpoint kinase-1 (CHK1) DMTNZKU MA Inhibitor DMTNZKU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTNZKU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTO1EJ DI DMTO1EJ DMTO1EJ DN 2-Allylthio-3-benzyl-6-nitro-quinazolin-4(3H)-one DMTO1EJ TI TT9SL3Q DMTO1EJ TN Polypeptide deformylase (PDF) DMTO1EJ MA Inhibitor DMTO1EJ RN Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones. Bioorg Med Chem. 2010 Apr 15;18(8):2849-63. DMTO1EJ RU https://pubmed.ncbi.nlm.nih.gov/20350811 DMTO2L3 DI DMTO2L3 DMTO2L3 DN 5-hydroxy-2-(pentylthiomethyl)-4H-pyran-4-one DMTO2L3 TI TTULVH8 DMTO2L3 TN Tyrosinase (TYR) DMTO2L3 MA Inhibitor DMTO2L3 RN Kojyl thioether derivatives having both tyrosinase inhibitory and anti-inflammatory properties. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6569-71. DMTO2L3 RU https://pubmed.ncbi.nlm.nih.gov/20934336 DMTO8KS DI DMTO8KS DMTO8KS DN N5-[4-(3-methylphenoxy)phenyl]-L-glutamamide DMTO8KS TI TTXZEAJ DMTO8KS TN Leukotriene A-4 hydrolase (LTA4H) DMTO8KS MA Inhibitor DMTO8KS RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMTO8KS RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMTO8NV DI DMTO8NV DMTO8NV DN 4-Amino-3-(5-bromo-thiophen-2-yl)-butyric acid DMTO8NV TI TTDCVZW DMTO8NV TN Gamma-aminobutyric acid B receptor (GABBR) DMTO8NV MA Inhibitor DMTO8NV RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DMTO8NV RU https://pubmed.ncbi.nlm.nih.gov/1652022 DMTO95J DI DMTO95J DMTO95J DN PMID26161824C70 DMTO95J TI TT6OEDT DMTO95J TN Cannabinoid receptor 1 (CB1) DMTO95J MA Antagonist DMTO95J RN A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents. Expert Opin Ther Pat. 2015 Oct;25(10):1093-116. DMTO95J RU https://pubmed.ncbi.nlm.nih.gov/26161824 DMTOCXZ DI DMTOCXZ DMTOCXZ DN GLYCYLRYANODINE DMTOCXZ TI TTU5CIX DMTOCXZ TN Ryanodine receptor 1 (RYR1) DMTOCXZ MA Inhibitor DMTOCXZ RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMTOCXZ RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMTODR2 DI DMTODR2 DMTODR2 DN 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide DMTODR2 TI TTBH0VX DMTODR2 TN Histone deacetylase (HDAC) DMTODR2 MA Inhibitor DMTODR2 RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DMTODR2 RU https://pubmed.ncbi.nlm.nih.gov/19699639 DMTODR2 DI DMTODR2 DMTODR2 DN 2,2-bis(3-fluorophenyl)-N-hydroxyacetamide DMTODR2 TI TTTQGH8 DMTODR2 TN Histone deacetylase 4 (HDAC4) DMTODR2 MA Inhibitor DMTODR2 RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DMTODR2 RU https://pubmed.ncbi.nlm.nih.gov/19699639 DMTOEJX DI DMTOEJX DMTOEJX DN Acid-activated omeprazole DMTOEJX TI TT30NW6 DMTOEJX TN Chloride channel protein 2 (CLC-2) DMTOEJX MA Activator DMTOEJX RN ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell Physiol. 2001 Jul;281(1):C46-54. DMTOEJX RU https://pubmed.ncbi.nlm.nih.gov/11401826 DMTOEJX DI DMTOEJX DMTOEJX DN Acid-activated omeprazole DMTOEJX TI TTZN7RP DMTOEJX TN Rho-associated protein kinase 1 (ROCK1) DMTOEJX MA Inhibitor DMTOEJX RN Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. Circ Res. 2004 Jan 9;94(1):46-52. DMTOEJX RU https://pubmed.ncbi.nlm.nih.gov/14615290 DMTOFS7 DI DMTOFS7 DMTOFS7 DN NSC-93358 DMTOFS7 TI TTSZLWK DMTOFS7 TN Aromatase (CYP19A1) DMTOFS7 MA Inhibitor DMTOFS7 RN An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7. DMTOFS7 RU https://pubmed.ncbi.nlm.nih.gov/19500885 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTJ2HKA DMTOK1D TN Long transient receptor potential channel 4 (TRPM4) DMTOK1D MA Inhibitor (gating inhibitor) DMTOK1D RN Intracellular nucleotides and polyamines inhibit the Ca2+-activated cation channel TRPM4b. Pflugers Arch. 2004 Apr;448(1):70-5. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/14758478 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTKPV6O DMTOK1D TN Ephrin type-B receptor 2 (EPHB2) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTYT93M DMTOK1D TN MAP kinase p38 (MAPK12) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TT056SO DMTOK1D TN Stress-activated protein kinase JNK3 (JNK3) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TT0IHXV DMTOK1D TN DNA topoisomerase II (TOP2) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TT5B8AX DMTOK1D TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTHRID2 DMTOK1D TN Insulin-like growth factor I receptor (IGF1R) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TT4NVEM DMTOK1D TN DNA topoisomerase II beta (TOP2B) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTSEOPJ DMTOK1D TN Bacterial Pantothenate kinase (Bact coaA) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTC0G1L DMTOK1D TN DNA repair protein RAD51 homolog 1 (RAD51) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TT860QF DMTOK1D TN LCK tyrosine protein kinase (LCK) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTRSMW9 DMTOK1D TN Glycogen synthase kinase-3 beta (GSK-3B) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOK1D DI DMTOK1D DMTOK1D DN AMP-PNP DMTOK1D TI TTRJB2G DMTOK1D TN Ephrin type-A receptor 2 (EPHA2) DMTOK1D MA Inhibitor DMTOK1D RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTOK1D RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTOM3E DI DMTOM3E DMTOM3E DN PMID21310611C3 DMTOM3E TI TT7QNVC DMTOM3E TN Glucose-dependent insulinotropic receptor (GPR119) DMTOM3E MA Agonist DMTOM3E RN Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1306-9. DMTOM3E RU https://pubmed.ncbi.nlm.nih.gov/21310611 DMTOSXF DI DMTOSXF DMTOSXF DN 12-dehydroxyriccardin C DMTOSXF TI TTECBXN DMTOSXF TN Oxysterols receptor LXR-alpha (NR1H3) DMTOSXF MA Inhibitor DMTOSXF RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DMTOSXF RU https://pubmed.ncbi.nlm.nih.gov/18343126 DMTOSXF DI DMTOSXF DMTOSXF DN 12-dehydroxyriccardin C DMTOSXF TI TTXA6PH DMTOSXF TN Oxysterols receptor LXR-beta (NR1H2) DMTOSXF MA Inhibitor DMTOSXF RN Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85. DMTOSXF RU https://pubmed.ncbi.nlm.nih.gov/18343126 DMTOUCL DI DMTOUCL DMTOUCL DN JWH-249 DMTOUCL TI TTMSFAW DMTOUCL TN Cannabinoid receptor 2 (CB2) DMTOUCL MA Inhibitor DMTOUCL RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMTOUCL RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMTP3LD DI DMTP3LD DMTP3LD DN 2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol DMTP3LD TI TTMSFAW DMTP3LD TN Cannabinoid receptor 2 (CB2) DMTP3LD MA Inhibitor DMTP3LD RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMTP3LD RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMTP3LD DI DMTP3LD DMTP3LD DN 2'-amino-4-(1,1-dimethyl-heptyl)-biphenyl-2-ol DMTP3LD TI TT6OEDT DMTP3LD TN Cannabinoid receptor 1 (CB1) DMTP3LD MA Inhibitor DMTP3LD RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMTP3LD RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMTP4S2 DI DMTP4S2 DMTP4S2 DN OXYMORPHINDOLE DMTP4S2 TI TT27RFC DMTP4S2 TN Opioid receptor delta (OPRD1) DMTP4S2 MA Inhibitor DMTP4S2 RN Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15. DMTP4S2 RU https://pubmed.ncbi.nlm.nih.gov/18403056 DMTP4S2 DI DMTP4S2 DMTP4S2 DN OXYMORPHINDOLE DMTP4S2 TI TTQW87Y DMTP4S2 TN Opioid receptor kappa (OPRK1) DMTP4S2 MA Inhibitor DMTP4S2 RN Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15. DMTP4S2 RU https://pubmed.ncbi.nlm.nih.gov/18403056 DMTP4S2 DI DMTP4S2 DMTP4S2 DN OXYMORPHINDOLE DMTP4S2 TI TTKWM86 DMTP4S2 TN Opioid receptor mu (MOP) DMTP4S2 MA Inhibitor DMTP4S2 RN Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15. DMTP4S2 RU https://pubmed.ncbi.nlm.nih.gov/18403056 DMTP5OY DI DMTP5OY DMTP5OY DN PMID17963374C31 DMTP5OY TI TTIKWV4 DMTP5OY TN Geranyltranstransferase (FDPS) DMTP5OY MA Inhibitor DMTP5OY RN Activity of sulfonium bisphosphonates on tumor cell lines. J Med Chem. 2007 Nov 29;50(24):6067-79. DMTP5OY RU https://pubmed.ncbi.nlm.nih.gov/17963374 DMTP5YZ DI DMTP5YZ DMTP5YZ DN C[hGlu22-Lys26][Gly8]GLP-1(7-37)-NH2 DMTP5YZ TI TTVIMDE DMTP5YZ TN Glucagon-like peptide 1 receptor (GLP1R) DMTP5YZ MA Inhibitor DMTP5YZ RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMTP5YZ RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMTP9DB DI DMTP9DB DMTP9DB DN 5-Aminomethyl-naphthalen-2-ol DMTP9DB TI TT2NUT5 DMTP9DB TN Adrenergic receptor alpha-2C (ADRA2C) DMTP9DB MA Inhibitor DMTP9DB RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMTP9DB RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMTP9DB DI DMTP9DB DMTP9DB DN 5-Aminomethyl-naphthalen-2-ol DMTP9DB TI TTWM4TY DMTP9DB TN Adrenergic receptor alpha-2B (ADRA2B) DMTP9DB MA Inhibitor DMTP9DB RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMTP9DB RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMTP9DB DI DMTP9DB DMTP9DB DN 5-Aminomethyl-naphthalen-2-ol DMTP9DB TI TTWG9A4 DMTP9DB TN Adrenergic receptor alpha-2A (ADRA2A) DMTP9DB MA Inhibitor DMTP9DB RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMTP9DB RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMTPAMS DI DMTPAMS DMTPAMS DN 6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol DMTPAMS TI TTZAYWL DMTPAMS TN Estrogen receptor (ESR) DMTPAMS MA Inhibitor DMTPAMS RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMTPAMS RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMTPAMS DI DMTPAMS DMTPAMS DN 6-(2-Chloro-4-hydroxy-phenyl)-naphthalen-2-ol DMTPAMS TI TTOM3J0 DMTPAMS TN Estrogen receptor beta (ESR2) DMTPAMS MA Inhibitor DMTPAMS RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMTPAMS RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMTPB8A DI DMTPB8A DMTPB8A DN INT-777 DMTPB8A TI TTSDVTR DMTPB8A TN G-protein coupled bile acid receptor 1 (GPBAR1) DMTPB8A MA Agonist DMTPB8A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 37). DMTPB8A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=37 DMTPD4R DI DMTPD4R DMTPD4R DN 1-(4-Bromo-benzyl)-3-quinazolin-8-yl-urea DMTPD4R TI TTMI6F5 DMTPD4R TN Transient receptor potential cation channel V1 (TRPV1) DMTPD4R MA Inhibitor DMTPD4R RN Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: structure-activity relationships for ureas with quin... J Med Chem. 2005 Feb 10;48(3):744-52. DMTPD4R RU https://pubmed.ncbi.nlm.nih.gov/15689158 DMTPFLU DI DMTPFLU DMTPFLU DN Quinoline-8-sulfonamide DMTPFLU TI TT2LVK8 DMTPFLU TN Carbonic anhydrase IX (CA-IX) DMTPFLU MA Inhibitor DMTPFLU RN Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7. DMTPFLU RU https://pubmed.ncbi.nlm.nih.gov/19097911 DMTPFLU DI DMTPFLU DMTPFLU DN Quinoline-8-sulfonamide DMTPFLU TI TTANPDJ DMTPFLU TN Carbonic anhydrase II (CA-II) DMTPFLU MA Inhibitor DMTPFLU RN Ligand-based and structure-based virtual screening to identify carbonic anhydrase IX inhibitors. Bioorg Med Chem. 2009 Jan 15;17(2):553-7. DMTPFLU RU https://pubmed.ncbi.nlm.nih.gov/19097911 DMTPGQ3 DI DMTPGQ3 DMTPGQ3 DN MS1943 DMTPGQ3 TI TT9MZCQ DMTPGQ3 TN Enhancer of zeste homolog 2 (EZH2) DMTPGQ3 MA Degrader DMTPGQ3 RN Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286. DMTPGQ3 RU https://pubmed.ncbi.nlm.nih.gov/33469207 DMTPKU8 DI DMTPKU8 DMTPKU8 DN 2-chloro-4-(o-tolyloxy)benzonitrile DMTPKU8 TI TTKPW01 DMTPKU8 TN Androgen receptor messenger RNA (AR mRNA) DMTPKU8 MA Inhibitor DMTPKU8 RN Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8. DMTPKU8 RU https://pubmed.ncbi.nlm.nih.gov/19286380 DMTPL0C DI DMTPL0C DMTPL0C DN 4-(3-methoxybenzylthio)-2-aminobutanoic acid DMTPL0C TI TTFK1JQ DMTPL0C TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMTPL0C MA Inhibitor DMTPL0C RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMTPL0C RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMTPLNZ DI DMTPLNZ DMTPLNZ DN Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2 DMTPLNZ TI TTKWM86 DMTPLNZ TN Opioid receptor mu (MOP) DMTPLNZ MA Inhibitor DMTPLNZ RN Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52. DMTPLNZ RU https://pubmed.ncbi.nlm.nih.gov/9288177 DMTPLNZ DI DMTPLNZ DMTPLNZ DN Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2 DMTPLNZ TI TT27RFC DMTPLNZ TN Opioid receptor delta (OPRD1) DMTPLNZ MA Inhibitor DMTPLNZ RN Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52. DMTPLNZ RU https://pubmed.ncbi.nlm.nih.gov/9288177 DMTPNI4 DI DMTPNI4 DMTPNI4 DN BMS-480404 DMTPNI4 TI TTHWMFZ DMTPNI4 TN Fatty acid-binding protein 4 (FABP4) DMTPNI4 MA Inhibitor DMTPNI4 RN NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7. DMTPNI4 RU https://pubmed.ncbi.nlm.nih.gov/16884313 DMTPNI4 DI DMTPNI4 DMTPNI4 DN BMS-480404 DMTPNI4 TI TTNT2S6 DMTPNI4 TN Fatty acid-binding protein 5 (FABP5) DMTPNI4 MA Inhibitor DMTPNI4 RN NMR structure of a potent small molecule inhibitor bound to human keratinocyte fatty acid-binding protein. J Med Chem. 2006 Aug 10;49(16):5013-7. DMTPNI4 RU https://pubmed.ncbi.nlm.nih.gov/16884313 DMTPQ84 DI DMTPQ84 DMTPQ84 DN (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE DMTPQ84 TI TTOZRK6 DMTPQ84 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMTPQ84 MA Agonist DMTPQ84 RN Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9. DMTPQ84 RU https://pubmed.ncbi.nlm.nih.gov/10747884 DMTPQ84 DI DMTPQ84 DMTPQ84 DN (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE DMTPQ84 TI TTN7BL9 DMTPQ84 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMTPQ84 MA Inhibitor DMTPQ84 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTPQ84 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTPQ84 DI DMTPQ84 DMTPQ84 DN (11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE DMTPQ84 TI TT26PHO DMTPQ84 TN Mineralocorticoid receptor (MR) DMTPQ84 MA Inhibitor DMTPQ84 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTPQ84 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTPRBX DI DMTPRBX DMTPRBX DN CGI-1316 DMTPRBX TI TTGM6VW DMTPRBX TN Tyrosine-protein kinase BTK (ATK) DMTPRBX MA Inhibitor DMTPRBX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1948). DMTPRBX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1948 DMTPRIW DI DMTPRIW DMTPRIW DN 5-Bromo-6-p-tolylamino-1H-pyrimidine-2,4-dione DMTPRIW TI TT2GPK3 DMTPRIW TN DNA topoisomerase (TOP) DMTPRIW MA Inhibitor DMTPRIW RN Inhibitors of Bacillus subtilis DNA polymerase III. Influence of modifications in the pyrimidine ring of anilino- and (benzylamino)pyrimidines. J Med Chem. 1986 May;29(5):676-81. DMTPRIW RU https://pubmed.ncbi.nlm.nih.gov/3084785 DMTPRXI DI DMTPRXI DMTPRXI DN NSC-316158 DMTPRXI TI TT8XK6L DMTPRXI TN Quinone reductase 1 (NQO1) DMTPRXI MA Inhibitor DMTPRXI RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMTPRXI RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMTPV4Y DI DMTPV4Y DMTPV4Y DN AGN 191976 DMTPV4Y TI TT2O84V DMTPV4Y TN Thromboxane A2 receptor (TBXA2R) DMTPV4Y MA Agonist DMTPV4Y RN Evidence for human thromboxane receptor heterogeneity using a novel series of 9,11-cyclic carbonate derivatives of prostaglandin F2 alpha. Br J Pharmacol. 1996 Mar;117(6):1171-80. DMTPV4Y RU https://pubmed.ncbi.nlm.nih.gov/8882612 DMTPXB6 DI DMTPXB6 DMTPXB6 DN Huprine X DMTPXB6 TI TT1RS9F DMTPXB6 TN Acetylcholinesterase (AChE) DMTPXB6 MA Inhibitor DMTPXB6 RN Exploiting protein fluctuations at the active-site gorge of human cholinesterases: further optimization of the design strategy to develop extremely... J Med Chem. 2008 Jun 12;51(11):3154-70. DMTPXB6 RU https://pubmed.ncbi.nlm.nih.gov/18479118 DMTPXB6 DI DMTPXB6 DMTPXB6 DN Huprine X DMTPXB6 TI TTEB0GD DMTPXB6 TN Cholinesterase (BCHE) DMTPXB6 MA Inhibitor DMTPXB6 RN Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites. J Med Chem. 2006 Jun 1;49(11):3421-5. DMTPXB6 RU https://pubmed.ncbi.nlm.nih.gov/16722663 DMTPZ8D DI DMTPZ8D DMTPZ8D DN 2,7-Bis(cyclohexanecarbonamido)anthraquinone DMTPZ8D TI TTQY2EJ DMTPZ8D TN TERT messenger RNA (TERT mRNA) DMTPZ8D MA Inhibitor DMTPZ8D RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMTPZ8D RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMTQ4FV DI DMTQ4FV DMTQ4FV DN 2-methyl-1-(pyridin-4-yl)pent-1-en-3-one oxime DMTQ4FV TI TTELV3W DMTQ4FV TN Transformation-sensitive protein p120 (TRPA1) DMTQ4FV MA Inhibitor DMTQ4FV RN Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. J Med Chem. 2010 Jul 22;53(14):5085-107. DMTQ4FV RU https://pubmed.ncbi.nlm.nih.gov/20356305 DMTQEDA DI DMTQEDA DMTQEDA DN UCPH-101 DMTQEDA TI TT8WRDA DMTQEDA TN Excitatory amino acid transporter 1 (SLC1A3) DMTQEDA MA Inhibitor DMTQEDA RN Discovery of the first selective inhibitor of excitatory amino acid transporter subtype 1. J Med Chem. 2009 Feb 26;52(4):912-5. DMTQEDA RU https://pubmed.ncbi.nlm.nih.gov/19161278 DMTQERW DI DMTQERW DMTQERW DN 3-Indan-(1Z)-ylidenemethyl-pyridine DMTQERW TI TTIQUX7 DMTQERW TN Steroid 11-beta-hydroxylase (CYP11B1) DMTQERW MA Inhibitor DMTQERW RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMTQERW RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMTQERW DI DMTQERW DMTQERW DN 3-Indan-(1Z)-ylidenemethyl-pyridine DMTQERW TI TTSZLWK DMTQERW TN Aromatase (CYP19A1) DMTQERW MA Inhibitor DMTQERW RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMTQERW RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMTQF2G DI DMTQF2G DMTQF2G DN (2S,4R)-4-(3-Methoxy-3-oxopropyl)glutamic Acid DMTQF2G TI TT0MYE2 DMTQF2G TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMTQF2G MA Inhibitor DMTQF2G RN Chemo-enzymatic synthesis of a series of 2,4-syn-functionalized (S)-glutamate analogues: new insight into the structure-activity relation of ionotr... J Med Chem. 2008 Jul 24;51(14):4093-103. DMTQF2G RU https://pubmed.ncbi.nlm.nih.gov/18578478 DMTQP0K DI DMTQP0K DMTQP0K DN Ro 5-4864 DMTQP0K TI TT9SL3Q DMTQP0K TN Polypeptide deformylase (PDF) DMTQP0K MA Inhibitor DMTQP0K RN Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. DMTQP0K RU https://pubmed.ncbi.nlm.nih.gov/15934867 DMTQP0K DI DMTQP0K DMTQP0K DN Ro 5-4864 DMTQP0K TI TTPTXIN DMTQP0K TN Translocator protein (TSPO) DMTQP0K MA Binder DMTQP0K RN Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001 Nov 30;85(11):1771-80. DMTQP0K RU https://pubmed.ncbi.nlm.nih.gov/11742501 DMTQP3V DI DMTQP3V DMTQP3V DN NSC-50187 DMTQP3V TI TTGP7BY DMTQP3V TN Monoamine oxidase type B (MAO-B) DMTQP3V MA Inhibitor DMTQP3V RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMTQP3V RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMTQSNK DI DMTQSNK DMTQSNK DN Azonan-(2Z)-ylideneamine DMTQSNK TI TTF10I9 DMTQSNK TN Nitric-oxide synthase inducible (NOS2) DMTQSNK MA Inhibitor DMTQSNK RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMTQSNK RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMTQSNK DI DMTQSNK DMTQSNK DN Azonan-(2Z)-ylideneamine DMTQSNK TI TTZUFI5 DMTQSNK TN Nitric-oxide synthase brain (NOS1) DMTQSNK MA Inhibitor DMTQSNK RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMTQSNK RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMTQWI8 DI DMTQWI8 DMTQWI8 DN ML-3403 DMTQWI8 TI TTYT93M DMTQWI8 TN MAP kinase p38 (MAPK12) DMTQWI8 MA Inhibitor DMTQWI8 RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMTQWI8 RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMTQWI8 DI DMTQWI8 DMTQWI8 DN ML-3403 DMTQWI8 TI TTXV4FI DMTQWI8 TN Albendazole monooxygenase (CYP3A4) DMTQWI8 MA Inhibitor DMTQWI8 RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMTQWI8 RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMTQWI8 DI DMTQWI8 DMTQWI8 DN ML-3403 DMTQWI8 TI TTQBR95 DMTQWI8 TN Stress-activated protein kinase 2a (p38 alpha) DMTQWI8 MA Inhibitor DMTQWI8 RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMTQWI8 RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMTQWI8 DI DMTQWI8 DMTQWI8 DN ML-3403 DMTQWI8 TI TT73U6C DMTQWI8 TN Stress-activated protein kinase 2b (p38 beta) DMTQWI8 MA Inhibitor DMTQWI8 RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMTQWI8 RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMTQX1G DI DMTQX1G DMTQX1G DN Batimistat DMTQX1G TI TT6AZXG DMTQX1G TN TNF alpha converting enzyme (ADAM17) DMTQX1G MA Inhibitor DMTQX1G RN The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-alpha convertase. FEBS Lett. 1998 Jul 10;431(1):63-5. DMTQX1G RU https://pubmed.ncbi.nlm.nih.gov/9684866 DMTQX92 DI DMTQX92 DMTQX92 DN 3,4-dihydroxyxanthone DMTQX92 TI TTVKILB DMTQX92 TN Prostaglandin G/H synthase 2 (COX-2) DMTQX92 MA Inhibitor DMTQX92 RN Selective cyclooxygenase-2 inhibitors from Calophyllum membranaceum. J Nat Prod. 2005 Oct;68(10):1514-8. DMTQX92 RU https://pubmed.ncbi.nlm.nih.gov/16252917 DMTR8SZ DI DMTR8SZ DMTR8SZ DN 3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol DMTR8SZ TI TT0IHXV DMTR8SZ TN DNA topoisomerase II (TOP2) DMTR8SZ MA Inhibitor DMTR8SZ RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMTR8SZ RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMTR8SZ DI DMTR8SZ DMTR8SZ DN 3-(4-phenyl-6-(thiophen-3-yl)pyridin-2-yl)-phenol DMTR8SZ TI TTGTQHC DMTR8SZ TN DNA topoisomerase I (TOP1) DMTR8SZ MA Inhibitor DMTR8SZ RN Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl ... Bioorg Med Chem. 2010 May 1;18(9):3066-77. DMTR8SZ RU https://pubmed.ncbi.nlm.nih.gov/20392646 DMTRBDP DI DMTRBDP DMTRBDP DN 8-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one DMTRBDP TI TTVDSZ0 DMTRBDP TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTRBDP MA Inhibitor DMTRBDP RN Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3. DMTRBDP RU https://pubmed.ncbi.nlm.nih.gov/16078828 DMTRCSV DI DMTRCSV DMTRCSV DN Isosorbide-2-(benzylcarbamate)-5-benzoate DMTRCSV TI TTEB0GD DMTRCSV TN Cholinesterase (BCHE) DMTRCSV MA Inhibitor DMTRCSV RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMTRCSV RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMTRDPI DI DMTRDPI DMTRDPI DN Bicine DMTRDPI TI TTP86E2 DMTRDPI TN Plasminogen (PLG) DMTRDPI MA Inhibitor DMTRDPI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTRDPI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTRGAP DI DMTRGAP DMTRGAP DN isovelleral DMTRGAP TI TTELV3W DMTRGAP TN Transformation-sensitive protein p120 (TRPA1) DMTRGAP MA Activator DMTRGAP RN TRPA1 mediates the noxious effects of natural sesquiterpene deterrents. J Biol Chem. 2008 Aug 29;283(35):24136-44. DMTRGAP RU https://pubmed.ncbi.nlm.nih.gov/18550530 DMTRL0X DI DMTRL0X DMTRL0X DN PMID19502059C25d DMTRL0X TI TTPADOQ DMTRL0X TN HMG-CoA reductase (HMGCR) DMTRL0X MA Inhibitor DMTRL0X RN Application of a 3,3-diphenylpentane skeleton as a multi-template for creation of HMG-CoA reductase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4228-31. DMTRL0X RU https://pubmed.ncbi.nlm.nih.gov/19502059 DMTRMX8 DI DMTRMX8 DMTRMX8 DN Sanfetrinem cilexetil DMTRMX8 TI TTJP4SM DMTRMX8 TN Bacterial Penicillin binding protein (Bact PBP) DMTRMX8 MA Modulator DMTRMX8 RN Entry of Sanfetrinem into Human Polymorphonuclear Granulocytes and Its Cell-Associated Activity against Intracellular, Penicillin-Resistant Streptococcus pneumoniae DMTRMX8 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC105677 DMTRYCI DI DMTRYCI DMTRYCI DN tryptanthrin DMTRYCI TI TTZJYKH DMTRYCI TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMTRYCI MA Inhibitor DMTRYCI RN Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31. DMTRYCI RU https://pubmed.ncbi.nlm.nih.gov/24099220 DMTS06Z DI DMTS06Z DMTS06Z DN 5-Nitro-1H-indole-2,3-dione DMTS06Z TI TTSFWA7 DMTS06Z TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMTS06Z MA Inhibitor DMTS06Z RN A three-dimensional in silico pharmacophore model for inhibition of Plasmodium falciparum cyclin-dependent kinases and discovery of different class... J Med Chem. 2004 Oct 21;47(22):5418-26. DMTS06Z RU https://pubmed.ncbi.nlm.nih.gov/15481979 DMTS4YD DI DMTS4YD DMTS4YD DN 3-(2,3-Dihydro-1,4-benzodioxin-6-yl)pyridine DMTS4YD TI TTIQUX7 DMTS4YD TN Steroid 11-beta-hydroxylase (CYP11B1) DMTS4YD MA Inhibitor DMTS4YD RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMTS4YD RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMTS8D5 DI DMTS8D5 DMTS8D5 DN CYLINDOL A DMTS8D5 TI TT2J34L DMTS8D5 TN Arachidonate 5-lipoxygenase (5-LOX) DMTS8D5 MA Inhibitor DMTS8D5 RN Cylindol A, a novel biphenyl ether with 5-lipoxygenase inhibitory activity, and a related compound from Imperata Cylindrica. J Nat Prod. 1994 Sep;57(9):1290-3. DMTS8D5 RU https://pubmed.ncbi.nlm.nih.gov/7798964 DMTSBJL DI DMTSBJL DMTSBJL DN 2-phenyl-2H-benzo[d][1,2,3]triazole-4-carboxamide DMTSBJL TI TTVDSZ0 DMTSBJL TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTSBJL MA Inhibitor DMTSBJL RN Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85. DMTSBJL RU https://pubmed.ncbi.nlm.nih.gov/19873981 DMTSEXB DI DMTSEXB DMTSEXB DN Bis-(5-hydroxy-1H-indol-2-yl)-methanone DMTSEXB TI TTGJCWZ DMTSEXB TN Fms-like tyrosine kinase 3 (FLT-3) DMTSEXB MA Inhibitor DMTSEXB RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMTSEXB RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMTSEXB DI DMTSEXB DMTSEXB DN Bis-(5-hydroxy-1H-indol-2-yl)-methanone DMTSEXB TI TTI7421 DMTSEXB TN Platelet-derived growth factor receptor beta (PDGFRB) DMTSEXB MA Inhibitor DMTSEXB RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMTSEXB RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMTSEXB DI DMTSEXB DMTSEXB DN Bis-(5-hydroxy-1H-indol-2-yl)-methanone DMTSEXB TI TT8FYO9 DMTSEXB TN Platelet-derived growth factor receptor alpha (PDGFRA) DMTSEXB MA Inhibitor DMTSEXB RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMTSEXB RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMTSEXB DI DMTSEXB DMTSEXB DN Bis-(5-hydroxy-1H-indol-2-yl)-methanone DMTSEXB TI TTX41N9 DMTSEXB TN Tyrosine-protein kinase Kit (KIT) DMTSEXB MA Inhibitor DMTSEXB RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMTSEXB RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMTSEXB DI DMTSEXB DMTSEXB DN Bis-(5-hydroxy-1H-indol-2-yl)-methanone DMTSEXB TI TT3PJMV DMTSEXB TN Tyrosine-protein kinase ABL1 (ABL) DMTSEXB MA Inhibitor DMTSEXB RN Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15. DMTSEXB RU https://pubmed.ncbi.nlm.nih.gov/16722630 DMTSF6A DI DMTSF6A DMTSF6A DN 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one DMTSF6A TI TTML2WA DMTSF6A TN Tubulin (TUB) DMTSF6A MA Inhibitor DMTSF6A RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMTSF6A RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMTSF6A DI DMTSF6A DMTSF6A DN 2-Naphthalen-1-yl-1H-[1,8]naphthyridin-4-one DMTSF6A TI TTYFKSZ DMTSF6A TN Tubulin beta (TUBB) DMTSF6A MA Inhibitor DMTSF6A RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMTSF6A RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMTSGOW DI DMTSGOW DMTSGOW DN [3H]methyltrienolone DMTSGOW TI TTKPW01 DMTSGOW TN Androgen receptor messenger RNA (AR mRNA) DMTSGOW MA Agonist DMTSGOW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 628). DMTSGOW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=628 DMTSGOW DI DMTSGOW DMTSGOW DN [3H]methyltrienolone DMTSGOW TI TTUV8G9 DMTSGOW TN Progesterone receptor (PGR) DMTSGOW MA Inhibitor DMTSGOW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTSGOW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTSGOW DI DMTSGOW DMTSGOW DN [3H]methyltrienolone DMTSGOW TI TTS64P2 DMTSGOW TN Androgen receptor (AR) DMTSGOW MA Inhibitor DMTSGOW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTSGOW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTSKQZ DI DMTSKQZ DMTSKQZ DN ISIS 133208 DMTSKQZ TI TTZN92A DMTSKQZ TN DUSP5 messenger RNA (DUSP5 mRNA) DMTSKQZ RN US patent application no. 6,867,039, Antisense modulation of dual specific phosphatase 5 expression. DMTSKQZ RU http://www.patentbuddy.com/Patent/6867039?ft=true&sr=true DMTSLGF DI DMTSLGF DMTSLGF DN LDN-91946 DMTSLGF TI TTX9IFP DMTSLGF TN Ubiquitin thioesterase L1 (UCHL1) DMTSLGF MA Inhibitor DMTSLGF RN Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3729-32. DMTSLGF RU https://pubmed.ncbi.nlm.nih.gov/17449248 DMTSM61 DI DMTSM61 DMTSM61 DN Oxymorphone semicarbazone hydrochloride DMTSM61 TI TTQW87Y DMTSM61 TN Opioid receptor kappa (OPRK1) DMTSM61 MA Inhibitor DMTSM61 RN Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5. DMTSM61 RU https://pubmed.ncbi.nlm.nih.gov/2879914 DMTSM61 DI DMTSM61 DMTSM61 DN Oxymorphone semicarbazone hydrochloride DMTSM61 TI TTKWM86 DMTSM61 TN Opioid receptor mu (MOP) DMTSM61 MA Inhibitor DMTSM61 RN Peptides as receptor selectivity modulators of opiate pharmacophores. J Med Chem. 1986 Jul;29(7):1222-5. DMTSM61 RU https://pubmed.ncbi.nlm.nih.gov/2879914 DMTSPLX DI DMTSPLX DMTSPLX DN 4alpha-PDD DMTSPLX TI TTKP2SU DMTSPLX TN Transient receptor potential cation channel V4 (TRPV4) DMTSPLX MA Activator DMTSPLX RN Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem. 2002 Apr 19;277(16):13569-77. DMTSPLX RU https://pubmed.ncbi.nlm.nih.gov/11827975 DMTSZFB DI DMTSZFB DMTSZFB DN JWH-342 DMTSZFB TI TT6OEDT DMTSZFB TN Cannabinoid receptor 1 (CB1) DMTSZFB MA Inhibitor DMTSZFB RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMTSZFB RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMTSZFB DI DMTSZFB DMTSZFB DN JWH-342 DMTSZFB TI TTMSFAW DMTSZFB TN Cannabinoid receptor 2 (CB2) DMTSZFB MA Inhibitor DMTSZFB RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMTSZFB RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMTU05Y DI DMTU05Y DMTU05Y DN ISOPENTENYL PYROPHOSPHATE DMTU05Y TI TT5VER7 DMTU05Y TN Bacterial Undecaprenyl pyrophosphate synthetase (Bact ispU) DMTU05Y MA Inhibitor DMTU05Y RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTU05Y RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTU05Y DI DMTU05Y DMTU05Y DN ISOPENTENYL PYROPHOSPHATE DMTU05Y TI TTIKWV4 DMTU05Y TN Geranyltranstransferase (FDPS) DMTU05Y MA Inhibitor DMTU05Y RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMTU05Y RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMTU0HR DI DMTU0HR DMTU0HR DN Bbs-Arg-(D-Pip)-Gly-S-(GS)1-Gly-Hir DMTU0HR TI TT6L509 DMTU0HR TN Coagulation factor IIa (F2) DMTU0HR MA Inhibitor DMTU0HR RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMTU0HR RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMTU0IG DI DMTU0IG DMTU0IG DN MLN-0905 DMTU0IG TI TTIYVQP DMTU0IG TN Polo-like kinase 1 (PLK1) DMTU0IG MA Inhibitor DMTU0IG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168). DMTU0IG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168 DMTU5QR DI DMTU5QR DMTU5QR DN alpha5IA DMTU5QR TI TT37EDJ DMTU5QR TN GABA(A) receptor alpha-3 (GABRA3) DMTU5QR MA Modulator (allosteric modulator) DMTU5QR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 406). DMTU5QR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=406 DMTU5QR DI DMTU5QR DMTU5QR DN alpha5IA DMTU5QR TI TTBMV1G DMTU5QR TN GABA(A) receptor alpha-2 (GABRA2) DMTU5QR MA Modulator (allosteric modulator) DMTU5QR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 405). DMTU5QR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=405 DMTU5QR DI DMTU5QR DMTU5QR DN alpha5IA DMTU5QR TI TTEX6LM DMTU5QR TN GABA(A) receptor gamma-3 (GABRG3) DMTU5QR MA Modulator (allosteric modulator) DMTU5QR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMTU5QR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMTU5QR DI DMTU5QR DMTU5QR DN alpha5IA DMTU5QR TI TTNZPQ1 DMTU5QR TN GABA(A) receptor alpha-5 (GABRA5) DMTU5QR MA Modulator (allosteric modulator) DMTU5QR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMTU5QR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMTUFI1 DI DMTUFI1 DMTUFI1 DN XR-9456 DMTUFI1 TI TT3OT40 DMTUFI1 TN Multidrug resistance protein 1 (ABCB1) DMTUFI1 MA Inhibitor DMTUFI1 RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DMTUFI1 RU https://pubmed.ncbi.nlm.nih.gov/18083034 DMTUFI1 DI DMTUFI1 DMTUFI1 DN XR-9456 DMTUFI1 TI TTOI92F DMTUFI1 TN Multidrug resistance-associated protein 1 (ABCC1) DMTUFI1 MA Inhibitor DMTUFI1 RN Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors. Bioorg Med Chem. 2008 Mar 1;16(5):2448-62. DMTUFI1 RU https://pubmed.ncbi.nlm.nih.gov/18083034 DMTUFOE DI DMTUFOE DMTUFOE DN (+/-)-2-(4-methoxyphenyl)-7-methylchroman-4-one DMTUFOE TI TTGP7BY DMTUFOE TN Monoamine oxidase type B (MAO-B) DMTUFOE MA Inhibitor DMTUFOE RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMTUFOE RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMTUHFX DI DMTUHFX DMTUHFX DN D-Phenylalanine DMTUHFX TI TTA7YIZ DMTUHFX TN Corticoliberin (CRH) DMTUHFX MA Inhibitor DMTUHFX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTUHFX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTUJWN DI DMTUJWN DMTUJWN DN D-220 DMTUJWN TI TT4C8EA DMTUJWN TN Dopamine D3 receptor (D3R) DMTUJWN MA Inhibitor DMTUJWN RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMTUJWN RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMTUJWN DI DMTUJWN DMTUJWN DN D-220 DMTUJWN TI TTEX248 DMTUJWN TN Dopamine D2 receptor (D2R) DMTUJWN MA Inhibitor DMTUJWN RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMTUJWN RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMTUL9J DI DMTUL9J DMTUL9J DN Adamantan-1-yl-piperidin-1-yl-methanone DMTUL9J TI TTN7BL9 DMTUL9J TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMTUL9J MA Inhibitor DMTUL9J RN Discovery and biological evaluation of adamantyl amide 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2838-43. DMTUL9J RU https://pubmed.ncbi.nlm.nih.gov/17350260 DMTUM78 DI DMTUM78 DMTUM78 DN 2-Amino-6-(3-bromo-benzenesulfonyl)-benzonitrile DMTUM78 TI TT84ETX DMTUM78 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMTUM78 MA Inhibitor DMTUM78 RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMTUM78 RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMTUR6C DI DMTUR6C DMTUR6C DN Rac-2-amino-4-phenylbutanoic acid DMTUR6C TI TTFK1JQ DMTUR6C TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMTUR6C MA Inhibitor DMTUR6C RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMTUR6C RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMTURQZ DI DMTURQZ DMTURQZ DN PMID8426367C18 DMTURQZ TI TTPADOQ DMTURQZ TN HMG-CoA reductase (HMGCR) DMTURQZ MA Inhibitor DMTURQZ RN 32-Methyl-32-oxylanosterols: dual-action inhibitors of cholesterol biosynthesis. J Med Chem. 1993 Feb 5;36(3):410-6. DMTURQZ RU https://pubmed.ncbi.nlm.nih.gov/8426367 DMTURZ6 DI DMTURZ6 DMTURZ6 DN YS110 mAb clone DMTURZ6 TI TTF928K DMTURZ6 TN HUMAN dipeptidyl peptidase 4 (DPP-4) DMTURZ6 MA Blocker DMTURZ6 RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMTURZ6 RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMTUZIN DI DMTUZIN DMTUZIN DN (S)-alpha-methylhistamine DMTUZIN TI TT9JNIC DMTUZIN TN Histamine H3 receptor (H3R) DMTUZIN MA Agonist DMTUZIN RN Characteristics of recombinantly expressed rat and human histamine H3 receptors. Eur J Pharmacol. 2002 Oct 18;453(1):33-41. DMTUZIN RU https://pubmed.ncbi.nlm.nih.gov/12393057 DMTUZIN DI DMTUZIN DMTUZIN DN (S)-alpha-methylhistamine DMTUZIN TI TTXJ178 DMTUZIN TN Histamine H4 receptor (H4R) DMTUZIN MA Agonist DMTUZIN RN Cloning and characterization of a novel human histamine receptor. J Pharmacol Exp Ther. 2001 Mar;296(3):1058-66. DMTUZIN RU https://pubmed.ncbi.nlm.nih.gov/11181941 DMTV1B9 DI DMTV1B9 DMTV1B9 DN JWH-309 DMTV1B9 TI TT6OEDT DMTV1B9 TN Cannabinoid receptor 1 (CB1) DMTV1B9 MA Inhibitor DMTV1B9 RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMTV1B9 RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMTV1B9 DI DMTV1B9 DMTV1B9 DN JWH-309 DMTV1B9 TI TTMSFAW DMTV1B9 TN Cannabinoid receptor 2 (CB2) DMTV1B9 MA Inhibitor DMTV1B9 RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMTV1B9 RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMTV4L0 DI DMTV4L0 DMTV4L0 DN Myricetin DMTV4L0 TI TTHBTOP DMTV4L0 TN PI3-kinase gamma (PIK3CG) DMTV4L0 MA Inhibitor DMTV4L0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTV4L0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTV753 DI DMTV753 DMTV753 DN 6-(4-Methylpyridin-3-yl)-2-naphthonitrile DMTV753 TI TTIQUX7 DMTV753 TN Steroid 11-beta-hydroxylase (CYP11B1) DMTV753 MA Inhibitor DMTV753 RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMTV753 RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMTV9P3 DI DMTV9P3 DMTV9P3 DN Mulberrofuran W DMTV9P3 TI TTELIN2 DMTV9P3 TN PTPN1 messenger RNA (PTPN1 mRNA) DMTV9P3 MA Inhibitor DMTV9P3 RN Protein tyrosine phosphatase 1B inhibitors isolated from Morus bombycis. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6759-61. DMTV9P3 RU https://pubmed.ncbi.nlm.nih.gov/19846295 DMTVA49 DI DMTVA49 DMTVA49 DN Dimethyl 2,2,2-trifluoro-1-phenylethyl phosphate DMTVA49 TI TTMF541 DMTVA49 TN Liver carboxylesterase (CES1) DMTVA49 MA Inhibitor DMTVA49 RN Synthesis of organophosphates with fluorine-containing leaving groups as serine esterase inhibitors with potential for Alzheimer disease therapeutics. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5528-30. DMTVA49 RU https://pubmed.ncbi.nlm.nih.gov/19717305 DMTVL9N DI DMTVL9N DMTVL9N DN 2,4,6-Trihydroxy-3-nitro-N-tridecyl-benzamide DMTVL9N TI TTWXB3E DMTVL9N TN Hepatitis C virus NS3 helicase (HCV NS3) DMTVL9N MA Inhibitor DMTVL9N RN Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20. DMTVL9N RU https://pubmed.ncbi.nlm.nih.gov/15633995 DMTVMWA DI DMTVMWA DMTVMWA DN Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) DMTVMWA TI TTTQGH8 DMTVMWA TN Histone deacetylase 4 (HDAC4) DMTVMWA MA Inhibitor DMTVMWA RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMTVMWA RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMTVMWA DI DMTVMWA DMTVMWA DN Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) DMTVMWA TI TT5ZKDI DMTVMWA TN Histone deacetylase 6 (HDAC6) DMTVMWA MA Inhibitor DMTVMWA RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMTVMWA RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMTVMWA DI DMTVMWA DMTVMWA DN Cyclo(-L-Am7(S2Py)-Aib-L-Phe-D-Pro-) DMTVMWA TI TT6R7JZ DMTVMWA TN Histone deacetylase 1 (HDAC1) DMTVMWA MA Inhibitor DMTVMWA RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMTVMWA RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMTVNO3 DI DMTVNO3 DMTVNO3 DN 1-(bis(4-chlorophenyl)methyl)-3-phenylurea DMTVNO3 TI TT6OEDT DMTVNO3 TN Cannabinoid receptor 1 (CB1) DMTVNO3 MA Inhibitor DMTVNO3 RN 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90. DMTVNO3 RU https://pubmed.ncbi.nlm.nih.gov/16279809 DMTVOWC DI DMTVOWC DMTVOWC DN MDL-18962 DMTVOWC TI TTSZLWK DMTVOWC TN Aromatase (CYP19A1) DMTVOWC MA Inhibitor DMTVOWC RN 6 beta-Propynyl-substituted steroids: mechanism-based enzyme-activated irreversible inhibitors of aromatase. J Med Chem. 1997 Sep 26;40(20):3263-70. DMTVOWC RU https://pubmed.ncbi.nlm.nih.gov/9379446 DMTVPZC DI DMTVPZC DMTVPZC DN 1-(1-phenyl-2-(pyridin-4-yl)ethyl)piperazine DMTVPZC TI TT3ROYC DMTVPZC TN Serotonin transporter (SERT) DMTVPZC MA Inhibitor DMTVPZC RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DMTVPZC RU https://pubmed.ncbi.nlm.nih.gov/16750363 DMTVQSL DI DMTVQSL DMTVQSL DN Abyssinoflavanone VII DMTVQSL TI TTELIN2 DMTVQSL TN PTPN1 messenger RNA (PTPN1 mRNA) DMTVQSL MA Inhibitor DMTVQSL RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DMTVQSL RU https://pubmed.ncbi.nlm.nih.gov/17489632 DMTVRKG DI DMTVRKG DMTVRKG DN EDP-18 DMTVRKG TI TT946IA DMTVRKG TN Transient receptor potential cation channel V3 (TRPV3) DMTVRKG MA Agonist DMTVRKG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 509). DMTVRKG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=509 DMTVY6K DI DMTVY6K DMTVY6K DN PGI-02749 DMTVY6K TI TT9G4N0 DMTVY6K TN Glutamate carboxypeptidase II (GCPII) DMTVY6K MA Inhibitor DMTVY6K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMTVY6K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMTVYLM DI DMTVYLM DMTVYLM DN 3-(5,6,7,8-Tetrahydronaphthalen-2-yl)pyridine DMTVYLM TI TTIQUX7 DMTVYLM TN Steroid 11-beta-hydroxylase (CYP11B1) DMTVYLM MA Inhibitor DMTVYLM RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMTVYLM RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMTW0GD DI DMTW0GD DMTW0GD DN (2-biphenyl-3-yl-ethyl)-dimethyl-amine DMTW0GD TI TTO9X1H DMTW0GD TN 5-HT 7 receptor (HTR7) DMTW0GD MA Inhibitor DMTW0GD RN Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22. DMTW0GD RU https://pubmed.ncbi.nlm.nih.gov/17419056 DMTW4Q1 DI DMTW4Q1 DMTW4Q1 DN KKHT-20918 DMTW4Q1 TI TT729IR DMTW4Q1 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMTW4Q1 MA Inhibitor DMTW4Q1 RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DMTW4Q1 RU https://pubmed.ncbi.nlm.nih.gov/17035033 DMTW571 DI DMTW571 DMTW571 DN F(4-Fluoro)VAE DMTW571 TI TTPADOQ DMTW571 TN HMG-CoA reductase (HMGCR) DMTW571 MA Inhibitor DMTW571 RN Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone. Bioorg Med Chem. 2008 Feb 1;16(3):1309-18. DMTW571 RU https://pubmed.ncbi.nlm.nih.gov/17977732 DMTW82E DI DMTW82E DMTW82E DN Procyanidin B-2 3,3'-di-O-gallate DMTW82E TI TTE14XG DMTW82E TN Squalene monooxygenase (SQLE) DMTW82E MA Inhibitor DMTW82E RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMTW82E RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMTW9B7 DI DMTW9B7 DMTW9B7 DN 2-(4-chlorobenzylidene)cyclopentylmethyl ether DMTW9B7 TI TT5ZWB6 DMTW9B7 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMTW9B7 MA Inhibitor DMTW9B7 RN New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3. Eur J Med Chem. 2009 Jun;44(6):2563-71. DMTW9B7 RU https://pubmed.ncbi.nlm.nih.gov/19237229 DMTW9GM DI DMTW9GM DMTW9GM DN GW-2580 DMTW9GM TI TTVW6QL DMTW9GM TN CSF1R messenger RNA (CSF1R mRNA) DMTW9GM MA Inhibitor DMTW9GM RN Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83. DMTW9GM RU https://pubmed.ncbi.nlm.nih.gov/16249345 DMTWB54 DI DMTWB54 DMTWB54 DN Ala-Pro-Glu DMTWB54 TI TTN9D8E DMTWB54 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMTWB54 MA Inhibitor DMTWB54 RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMTWB54 RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMTWB54 DI DMTWB54 DMTWB54 DN Ala-Pro-Glu DMTWB54 TI TTKJEMQ DMTWB54 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMTWB54 MA Inhibitor DMTWB54 RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMTWB54 RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMTWB54 DI DMTWB54 DMTWB54 DN Ala-Pro-Glu DMTWB54 TI TTLD29N DMTWB54 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMTWB54 MA Inhibitor DMTWB54 RN New Gly-Pro-Glu (GPE) analogues: expedite solid-phase synthesis and biological activity. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1392-6. DMTWB54 RU https://pubmed.ncbi.nlm.nih.gov/16321525 DMTWBOV DI DMTWBOV DMTWBOV DN 6-Chloro-2-(3-nitro-phenyl)-chromen-4-one DMTWBOV TI TT1MPAY DMTWBOV TN GABA(A) receptor alpha-1 (GABRA1) DMTWBOV MA Inhibitor DMTWBOV RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMTWBOV RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMTWBOV DI DMTWBOV DMTWBOV DN 6-Chloro-2-(3-nitro-phenyl)-chromen-4-one DMTWBOV TI TTNJYV2 DMTWBOV TN Gamma-aminobutyric acid receptor (GAR) DMTWBOV MA Inhibitor DMTWBOV RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMTWBOV RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMTWEQP DI DMTWEQP DMTWEQP DN Naphthyridinomycin DMTWEQP TI TTJP4SM DMTWEQP TN Bacterial Penicillin binding protein (Bact PBP) DMTWEQP RN Naphthyridinomycin-DNA adducts: a molecular modeling study. J Antibiot (Tokyo). 1991 Aug;44(8):885-94. DMTWEQP RU https://pubmed.ncbi.nlm.nih.gov/1917702 DMTWJMN DI DMTWJMN DMTWJMN DN 2-morpholino-6-(thiophen-2-yl)-4H-pyran-4-one DMTWJMN TI TTK3PY9 DMTWJMN TN DNA-dependent protein kinase catalytic (PRKDC) DMTWJMN MA Inhibitor DMTWJMN RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMTWJMN RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMTWK7L DI DMTWK7L DMTWK7L DN N,Ndimethyl milnacipran DMTWK7L TI TTVBI8W DMTWK7L TN Dopamine transporter (DAT) DMTWK7L MA Inhibitor DMTWK7L RN Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9. DMTWK7L RU https://pubmed.ncbi.nlm.nih.gov/18207394 DMTWNH7 DI DMTWNH7 DMTWNH7 DN Z-Arg-Leu-Val-Agly-Val-Ala-NH2 DMTWNH7 TI TTDZN01 DMTWNH7 TN Cathepsin K (CTSK) DMTWNH7 MA Inhibitor DMTWNH7 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMTWNH7 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMTWNH7 DI DMTWNH7 DMTWNH7 DN Z-Arg-Leu-Val-Agly-Val-Ala-NH2 DMTWNH7 TI TTF2LRI DMTWNH7 TN Cathepsin B (CTSB) DMTWNH7 MA Inhibitor DMTWNH7 RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMTWNH7 RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMTWRQI DI DMTWRQI DMTWRQI DN crotylaldehyde DMTWRQI TI TTELV3W DMTWRQI TN Transformation-sensitive protein p120 (TRPA1) DMTWRQI MA Activator DMTWRQI RN Cigarette smoke-induced neurogenic inflammation is mediated by alpha,beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest. 2008 Jul;118(7):2574-82. DMTWRQI RU https://pubmed.ncbi.nlm.nih.gov/18568077 DMTWRQI DI DMTWRQI DMTWRQI DN crotylaldehyde DMTWRQI TI TTFLN4T DMTWRQI TN Mitochondrial aldehyde dehydrogenase (ALDH2) DMTWRQI MA Inhibitor DMTWRQI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTWRQI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTWY94 DI DMTWY94 DMTWY94 DN MCL-149 DMTWY94 TI TTKWM86 DMTWY94 TN Opioid receptor mu (MOP) DMTWY94 MA Inhibitor DMTWY94 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMTWY94 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMTWY94 DI DMTWY94 DMTWY94 DN MCL-149 DMTWY94 TI TT27RFC DMTWY94 TN Opioid receptor delta (OPRD1) DMTWY94 MA Inhibitor DMTWY94 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMTWY94 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMTWY94 DI DMTWY94 DMTWY94 DN MCL-149 DMTWY94 TI TTQW87Y DMTWY94 TN Opioid receptor kappa (OPRK1) DMTWY94 MA Inhibitor DMTWY94 RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMTWY94 RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMTX0ZJ DI DMTX0ZJ DMTX0ZJ DN PMID19743866C51 DMTX0ZJ TI TTA0P7K DMTX0ZJ TN Complement factor B (CFB) DMTX0ZJ MA Inhibitor DMTX0ZJ RN Structure-activity relationships for substrate-based inhibitors of human complement factor B. J Med Chem. 2009 Oct 8;52(19):6042-52. DMTX0ZJ RU https://pubmed.ncbi.nlm.nih.gov/19743866 DMTX694 DI DMTX694 DMTX694 DN JMV 1801 DMTX694 TI TTC1MVT DMTX694 TN Gastrin-releasing peptide receptor (GRPR) DMTX694 MA Inhibitor DMTX694 RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DMTX694 RU https://pubmed.ncbi.nlm.nih.gov/10882361 DMTXJ5S DI DMTXJ5S DMTXJ5S DN Tin protoporphyrin DMTXJ5S TI TTI6V2A DMTXJ5S TN Heme oxygenase 1 (HMOX1) DMTXJ5S MA Inhibitor DMTXJ5S RN Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation. 2001 Nov 27;104(22):2710-5. DMTXJ5S RU https://pubmed.ncbi.nlm.nih.gov/11723024 DMTXPJI DI DMTXPJI DMTXPJI DN Al7089a DMTXPJI TI TTANPDJ DMTXPJI TN Carbonic anhydrase II (CA-II) DMTXPJI MA Inhibitor DMTXPJI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTXPJI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTXWCZ DI DMTXWCZ DMTXWCZ DN LFM-A13 DMTXWCZ TI TTGM6VW DMTXWCZ TN Tyrosine-protein kinase BTK (ATK) DMTXWCZ MA Inhibitor DMTXWCZ RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMTXWCZ RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMTY3N6 DI DMTY3N6 DMTY3N6 DN ISIS 188761 DMTY3N6 TI TTLRVIA DMTY3N6 TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DMTY3N6 RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DMTY3N6 RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DMTY41F DI DMTY41F DMTY41F DN 1-(3-benzyl-6,7-dichloroquinoxalin-2-yl)hydrazine DMTY41F TI TT3WG5C DMTY41F TN Monoamine oxidase type A (MAO-A) DMTY41F MA Inhibitor DMTY41F RN Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6. DMTY41F RU https://pubmed.ncbi.nlm.nih.gov/16356714 DMTY43L DI DMTY43L DMTY43L DN Nortropinyl-arylsulfonylurea 3 DMTY43L TI TTHM0R1 DMTY43L TN Steryl-sulfatase (STS) DMTY43L MA Inhibitor DMTY43L RN Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulfatase. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3673-7. DMTY43L RU https://pubmed.ncbi.nlm.nih.gov/14552755 DMTY5HP DI DMTY5HP DMTY5HP DN QNEQCPQVSac DMTY5HP TI TT2UE56 DMTY5HP TN Sodium/glucose cotransporter 1 (SGLT1) DMTY5HP MA Inhibitor DMTY5HP RN Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-glucose cotransporter SGLT1 with high affinity. J Biol Chem. 2007 Sep 28;282(39):28501-13. DMTY5HP RU https://pubmed.ncbi.nlm.nih.gov/17686765 DMTY63G DI DMTY63G DMTY63G DN Olterodine DMTY63G TI TTQ13Z5 DMTY63G TN Muscarinic acetylcholine receptor M3 (CHRM3) DMTY63G MA Antagonist DMTY63G RN Which muscarinic receptor is important in the bladder World J Urol. 2001 Nov;19(5):299-306. DMTY63G RU https://pubmed.ncbi.nlm.nih.gov/11760777 DMTY6O9 DI DMTY6O9 DMTY6O9 DN ISIS 106008 DMTY6O9 TI TTT2SVW DMTY6O9 TN PPAR-gamma messenger RNA (PPARG mRNA) DMTY6O9 RN US patent application no. 6,159,734, Antisense modulation of peroxisome proliferator-activated receptor gamma expression. DMTY6O9 RU http://www.patentbuddy.com/Patent/6159734?ft=true&sr=true DMTY92S DI DMTY92S DMTY92S DN 3-Fluoro-2-(Phosphonooxy)Propanoic Acid DMTY92S TI TTVNA43 DMTY92S TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DMTY92S MA Inhibitor DMTY92S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTY92S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTYBC9 DI DMTYBC9 DMTYBC9 DN OXAMATE DMTYBC9 TI TTAZHU0 DMTYBC9 TN L-lactate dehydrogenase (LDH) DMTYBC9 MA Inhibitor DMTYBC9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTYBC9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTYBC9 DI DMTYBC9 DMTYBC9 DN OXAMATE DMTYBC9 TI TTT2LD9 DMTYBC9 TN GABA transaminase (ABAT) DMTYBC9 MA Inhibitor DMTYBC9 RN Aminomethyl-1,2,4-benzothiadiazines as potential analogues of gamma-aminobutyric acid. Unexpected discovery of a taurine antagonist. J Med Chem. 1982 Feb;25(2):113-6. DMTYBC9 RU https://pubmed.ncbi.nlm.nih.gov/6276545 DMTYDX2 DI DMTYDX2 DMTYDX2 DN 2-(2-Chlorophenyl)-2H-indazole-7-carboxamide DMTYDX2 TI TTVDSZ0 DMTYDX2 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMTYDX2 MA Inhibitor DMTYDX2 RN Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85. DMTYDX2 RU https://pubmed.ncbi.nlm.nih.gov/19873981 DMTYKMR DI DMTYKMR DMTYKMR DN 1-benzhydryl-4-(3,3-diphenylpropyl)piperazine DMTYKMR TI TTFK1JQ DMTYKMR TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMTYKMR MA Inhibitor DMTYKMR RN Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. DMTYKMR RU https://pubmed.ncbi.nlm.nih.gov/19815411 DMTYQDO DI DMTYQDO DMTYQDO DN ANNULIN C DMTYQDO TI TTZJYKH DMTYQDO TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMTYQDO MA Inhibitor DMTYQDO RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DMTYQDO RU https://pubmed.ncbi.nlm.nih.gov/17067170 DMTYSUN DI DMTYSUN DMTYSUN DN YM49598 DMTYSUN TI TTYO0A3 DMTYSUN TN Substance-K receptor (TACR2) DMTYSUN MA Antagonist DMTYSUN RN Effect of YM-44781, YM-44778 and YM-49598, novel tachykinin antagonists, in a drug-induced bladder contraction model. Pharmacology. 2002 May;65(2):96-102. DMTYSUN RU https://pubmed.ncbi.nlm.nih.gov/11937780 DMTYWCS DI DMTYWCS DMTYWCS DN 6-(4-hydroxyphenyl)-2-morpholino-4H-chromen-4-one DMTYWCS TI TTK3PY9 DMTYWCS TN DNA-dependent protein kinase catalytic (PRKDC) DMTYWCS MA Inhibitor DMTYWCS RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMTYWCS RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMTYX5G DI DMTYX5G DMTYX5G DN 2-fluorophenyl 4-(undecyloxy)phenylcarbamate DMTYX5G TI TTDP1UC DMTYX5G TN Fatty acid amide hydrolase (FAAH) DMTYX5G MA Inhibitor DMTYX5G RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMTYX5G RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMTYXFU DI DMTYXFU DMTYXFU DN (6-Methoxy-2-oxo-2H-quinolin-1-yl)-acetic acid DMTYXFU TI TTFBNVI DMTYXFU TN Aldose reductase (AKR1B1) DMTYXFU MA Inhibitor DMTYXFU RN Synthesis and aldose reductase inhibitory activity of substituted 2-oxoquinoline-1-acetic acid derivatives. J Med Chem. 1986 Oct;29(10):2024-8. DMTYXFU RU https://pubmed.ncbi.nlm.nih.gov/3093680 DMTYXH1 DI DMTYXH1 DMTYXH1 DN 3-Aminomethyl-5-methyl-hexanoic acid DMTYXH1 TI TTU8P3M DMTYXH1 TN Voltage-gated calcium channel alpha-2/delta-2 (CACNA2D2) DMTYXH1 MA Inhibitor DMTYXH1 RN Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994). DMTYXH1 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808556 DMTYXH1 DI DMTYXH1 DMTYXH1 DN 3-Aminomethyl-5-methyl-hexanoic acid DMTYXH1 TI TTFK1JQ DMTYXH1 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMTYXH1 MA Inhibitor DMTYXH1 RN Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994). DMTYXH1 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808556 DMTYXH1 DI DMTYXH1 DMTYXH1 DN 3-Aminomethyl-5-methyl-hexanoic acid DMTYXH1 TI TTN7T29 DMTYXH1 TN Voltage-gated calcium channel alpha-2/delta-3 (CACNA2D3) DMTYXH1 MA Inhibitor DMTYXH1 RN Enantioselective synthesis of PD144723: a potent stereospecific anticonvulsant, Bioorg. Med. Chem. Lett. 4(6):823-826 (1994). DMTYXH1 RU http://www.sciencedirect.com/science/article/pii/S0960894X01808556 DMTZ17V DI DMTZ17V DMTZ17V DN Laevulinic Acid DMTZ17V TI TTJHKYD DMTZ17V TN Delta-aminolevulinic acid dehydratase (ALAD) DMTZ17V MA Inhibitor DMTZ17V RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMTZ17V RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMTZ1XV DI DMTZ1XV DMTZ1XV DN NBBCC DMTZ1XV TI TTZ8EM9 DMTZ1XV TN Glycine receptor (GlyR) DMTZ1XV RN Developmental regulation of beta-carboline-induced inhibition of glycine-evoked responses depends on glycine receptor beta subunit expression. Mol Pharmacol. 2005 May;67(5):1783-96. DMTZ1XV RU https://pubmed.ncbi.nlm.nih.gov/15722459 DMTZ540 DI DMTZ540 DMTZ540 DN 2-(N-tert-Butylamino)-3'-chloropentanophenone DMTZ540 TI TTVBI8W DMTZ540 TN Dopamine transporter (DAT) DMTZ540 MA Inhibitor DMTZ540 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMTZ540 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMTZ540 DI DMTZ540 DMTZ540 DN 2-(N-tert-Butylamino)-3'-chloropentanophenone DMTZ540 TI TTAWNKZ DMTZ540 TN Norepinephrine transporter (NET) DMTZ540 MA Inhibitor DMTZ540 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMTZ540 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMTZ71K DI DMTZ71K DMTZ71K DN 1-(bis(3-bromophenyl)methylene)thiosemicarbazide DMTZ71K TI TTEAID7 DMTZ71K TN Trypanosoma Cruzipain (Trypano CYSP) DMTZ71K MA Inhibitor DMTZ71K RN Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas' disease. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4405-9. DMTZ71K RU https://pubmed.ncbi.nlm.nih.gov/16781147 DMTZ8RQ DI DMTZ8RQ DMTZ8RQ DN N-hydroxy-3-phenoxybenzamide DMTZ8RQ TI TTT6LFV DMTZ8RQ TN Histone deacetylase 8 (HDAC8) DMTZ8RQ MA Inhibitor DMTZ8RQ RN Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. DMTZ8RQ RU https://pubmed.ncbi.nlm.nih.gov/17346959 DMTZ943 DI DMTZ943 DMTZ943 DN 7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene DMTZ943 TI TT1MPAY DMTZ943 TN GABA(A) receptor alpha-1 (GABRA1) DMTZ943 MA Inhibitor DMTZ943 RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMTZ943 RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMTZ943 DI DMTZ943 DMTZ943 DN 7,12-Dihydro-7,12-diaza-indeno[1,2-a]fluorene DMTZ943 TI TTNJYV2 DMTZ943 TN Gamma-aminobutyric acid receptor (GAR) DMTZ943 MA Inhibitor DMTZ943 RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMTZ943 RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMTZ9G3 DI DMTZ9G3 DMTZ9G3 DN 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone DMTZ9G3 TI TT8DBY3 DMTZ9G3 TN Angiotensin II receptor type-1 (AGTR1) DMTZ9G3 MA Antagonist DMTZ9G3 RN Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J Med Chem. 2000 Feb 10;43(3):351-60. DMTZ9G3 RU https://pubmed.ncbi.nlm.nih.gov/10669562 DMTZDAJ DI DMTZDAJ DMTZDAJ DN (R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine DMTZDAJ TI TTWJBZ5 DMTZDAJ TN 5-HT 2C receptor (HTR2C) DMTZDAJ MA Inhibitor DMTZDAJ RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMTZDAJ RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMTZDAJ DI DMTZDAJ DMTZDAJ DN (R,S)-1-(5-chloro-1H-indol-1-yl)propan-2-amine DMTZDAJ TI TTJQOD7 DMTZDAJ TN 5-HT 2A receptor (HTR2A) DMTZDAJ MA Inhibitor DMTZDAJ RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMTZDAJ RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMTZG68 DI DMTZG68 DMTZG68 DN 16-isobutylidene-estradiol DMTZG68 TI TTIWB6L DMTZG68 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMTZG68 MA Inhibitor DMTZG68 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMTZG68 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMTZQUJ DI DMTZQUJ DMTZQUJ DN PMID18068976C25 DMTZQUJ TI TTVXEGU DMTZQUJ TN ADAM10 messenger RNA (ADAM10 mRNA) DMTZQUJ MA Inhibitor DMTZQUJ RN Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations. Bioorg Med Chem Lett. 2008 Jan 15;18(2):560-4. DMTZQUJ RU https://pubmed.ncbi.nlm.nih.gov/18068976 DMTZYQ3 DI DMTZYQ3 DMTZYQ3 DN LP99 DMTZYQ3 TI TTR7L5Y DMTZYQ3 TN Bromodomain-containing protein 9 (BRD9) DMTZYQ3 MA Inhibitor DMTZYQ3 RN LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl. 2015 May 18;54(21):6217-21. DMTZYQ3 RU https://pubmed.ncbi.nlm.nih.gov/25864491 DMTZYQ3 DI DMTZYQ3 DMTZYQ3 DN LP99 DMTZYQ3 TI TT07ZS1 DMTZYQ3 TN Bromodomain-containing protein 7 (BRD7) DMTZYQ3 MA Inhibitor DMTZYQ3 RN LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl. 2015 May 18;54(21):6217-21. DMTZYQ3 RU https://pubmed.ncbi.nlm.nih.gov/25864491 DMU04ZQ DI DMU04ZQ DMU04ZQ DN 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one DMU04ZQ TI TTVBI8W DMU04ZQ TN Dopamine transporter (DAT) DMU04ZQ MA Inhibitor DMU04ZQ RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMU04ZQ RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMU04ZQ DI DMU04ZQ DMU04ZQ DN 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one DMU04ZQ TI TT3ROYC DMU04ZQ TN Serotonin transporter (SERT) DMU04ZQ MA Inhibitor DMU04ZQ RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMU04ZQ RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMU04ZQ DI DMU04ZQ DMU04ZQ DN 1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one DMU04ZQ TI TTAWNKZ DMU04ZQ TN Norepinephrine transporter (NET) DMU04ZQ MA Inhibitor DMU04ZQ RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMU04ZQ RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMU0746 DI DMU0746 DMU0746 DN Rac-2-amino-5-cyclohexylpentanoic acid DMU0746 TI TTFK1JQ DMU0746 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMU0746 MA Inhibitor DMU0746 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMU0746 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMU075F DI DMU075F DMU075F DN Leupeptin DMU075F TI TT7EASG DMU075F TN Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) DMU075F MA Inhibitor DMU075F RN Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97. DMU075F RU https://pubmed.ncbi.nlm.nih.gov/18298458 DMU075F DI DMU075F DMU075F DN Leupeptin DMU075F TI TTH9VL3 DMU075F TN Plasmodium Plasmepsin 1 (Malaria PLA1) DMU075F MA Inhibitor DMU075F RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DMU075F RU https://pubmed.ncbi.nlm.nih.gov/17339102 DMU075F DI DMU075F DMU075F DN Leupeptin DMU075F TI TTXMNHO DMU075F TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMU075F MA Inhibitor DMU075F RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DMU075F RU https://pubmed.ncbi.nlm.nih.gov/17339102 DMU075F DI DMU075F DMU075F DN Leupeptin DMU075F TI TTJNPTK DMU075F TN Plasmodium Cysteine protease falcipain (Malaria CPF) DMU075F MA Inhibitor DMU075F RN Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10. DMU075F RU https://pubmed.ncbi.nlm.nih.gov/17339102 DMU082P DI DMU082P DMU082P DN 1-(2-(4-fluorophenoxy)phenyl)piperazine DMU082P TI TTSQIFT DMU082P TN 5-HT 1A receptor (HTR1A) DMU082P MA Inhibitor DMU082P RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMU082P RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMU082P DI DMU082P DMU082P DN 1-(2-(4-fluorophenoxy)phenyl)piperazine DMU082P TI TT3ROYC DMU082P TN Serotonin transporter (SERT) DMU082P MA Inhibitor DMU082P RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMU082P RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMU082P DI DMU082P DMU082P DN 1-(2-(4-fluorophenoxy)phenyl)piperazine DMU082P TI TTVBI8W DMU082P TN Dopamine transporter (DAT) DMU082P MA Inhibitor DMU082P RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMU082P RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMU082P DI DMU082P DMU082P DN 1-(2-(4-fluorophenoxy)phenyl)piperazine DMU082P TI TTAWNKZ DMU082P TN Norepinephrine transporter (NET) DMU082P MA Inhibitor DMU082P RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMU082P RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMU08A4 DI DMU08A4 DMU08A4 DN 3-(6-Amino-purin-9-yl)-4-p-tolyl-butan-2-ol DMU08A4 TI TTLP57V DMU08A4 TN Adenosine deaminase (ADA) DMU08A4 MA Inhibitor DMU08A4 RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMU08A4 RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMU08MN DI DMU08MN DMU08MN DN 3'-Azido-3'-Deoxythymidine-5'-Monophosphate DMU08MN TI TT5B8AX DMU08MN TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMU08MN MA Inhibitor DMU08MN RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMU08MN RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMU08WO DI DMU08WO DMU08WO DN (+/-)-threo-N-(3-Chlorobenzyl)methylphenidate DMU08WO TI TTVBI8W DMU08WO TN Dopamine transporter (DAT) DMU08WO MA Inhibitor DMU08WO RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMU08WO RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMU09E4 DI DMU09E4 DMU09E4 DN BIIL 260 DMU09E4 TI TTVJX54 DMU09E4 TN Leukotriene B4 receptor 2 (LTB4R2) DMU09E4 MA Antagonist DMU09E4 RN Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis. 2007 May;66(5):628-32. DMU09E4 RU https://pubmed.ncbi.nlm.nih.gov/17170051 DMU0AGE DI DMU0AGE DMU0AGE DN PMID11934595C2 DMU0AGE TI TT0L58T DMU0AGE TN Bone morphogenetic protein 1 (BMP1) DMU0AGE MA Inhibitor DMU0AGE RN Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase. Part 2: Solid-phase optimization of side chains. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1233-5. DMU0AGE RU https://pubmed.ncbi.nlm.nih.gov/11934595 DMU0BMQ DI DMU0BMQ DMU0BMQ DN NIBR-785 DMU0BMQ TI TT9JZCK DMU0BMQ TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMU0BMQ MA Modulator DMU0BMQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275). DMU0BMQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275 DMU0BW9 DI DMU0BW9 DMU0BW9 DN sulfonamide-01 DMU0BW9 TI TTRLZHP DMU0BW9 TN cAMP-dependent chloride channel (CFTR) DMU0BW9 MA Activator DMU0BW9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 707). DMU0BW9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=707 DMU0GDY DI DMU0GDY DMU0GDY DN 2-(Biphenyl-3-ylthio)-N,N-dimethylethanamine DMU0GDY TI TTSQIFT DMU0GDY TN 5-HT 1A receptor (HTR1A) DMU0GDY MA Inhibitor DMU0GDY RN SAR studies on new bis-aryls 5-HT7 ligands: Synthesis and molecular modeling. Bioorg Med Chem. 2010 Mar 1;18(5):1958-67. DMU0GDY RU https://pubmed.ncbi.nlm.nih.gov/20138771 DMU0HQF DI DMU0HQF DMU0HQF DN ISIS 9070 DMU0HQF TI TT5TURO DMU0HQF TN A-Raf messenger RNA (ARAF mRNA) DMU0HQF RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DMU0HQF RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DMU0NHX DI DMU0NHX DMU0NHX DN YK-3237 DMU0NHX TI TTUF2HO DMU0NHX TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMU0NHX MA Inhibitor DMU0NHX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2707). DMU0NHX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2707 DMU10CY DI DMU10CY DMU10CY DN 1-(phenyl(p-tolyl)methylene)thiosemicarbazide DMU10CY TI TTF2LRI DMU10CY TN Cathepsin B (CTSB) DMU10CY MA Inhibitor DMU10CY RN Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5. DMU10CY RU https://pubmed.ncbi.nlm.nih.gov/18420405 DMU10CY DI DMU10CY DMU10CY DN 1-(phenyl(p-tolyl)methylene)thiosemicarbazide DMU10CY TI TT36ETB DMU10CY TN Cathepsin L (CTSL) DMU10CY MA Inhibitor DMU10CY RN Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5. DMU10CY RU https://pubmed.ncbi.nlm.nih.gov/18420405 DMU10FE DI DMU10FE DMU10FE DN THZ1 DMU10FE TI TTQYF7G DMU10FE TN Cyclin-dependent kinase 7 (CDK7) DMU10FE MA Inhibitor DMU10FE RN Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20. DMU10FE RU https://pubmed.ncbi.nlm.nih.gov/25043025 DMU13BY DI DMU13BY DMU13BY DN BzT-7 DMU13BY TI TTRA6BO DMU13BY TN Bromodomain-containing protein 4 (BRD4) DMU13BY MA Inhibitor DMU13BY RN Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family. Bioorg Med Chem. 2012 Mar 15;20(6):1878-86. DMU13BY RU https://pubmed.ncbi.nlm.nih.gov/22137933 DMU15YV DI DMU15YV DMU15YV DN 6,7-Dimethoxy-4-(2-methoxy-phenoxy)-quinoline DMU15YV TI TTI7421 DMU15YV TN Platelet-derived growth factor receptor beta (PDGFRB) DMU15YV MA Inhibitor DMU15YV RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMU15YV RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMU1ATH DI DMU1ATH DMU1ATH DN N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide DMU1ATH TI TT4C8EA DMU1ATH TN Dopamine D3 receptor (D3R) DMU1ATH MA Inhibitor DMU1ATH RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMU1ATH RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMU1ATH DI DMU1ATH DMU1ATH DN N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide DMU1ATH TI TTZFYLI DMU1ATH TN Dopamine D1 receptor (D1R) DMU1ATH MA Inhibitor DMU1ATH RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMU1ATH RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMU1ATH DI DMU1ATH DMU1ATH DN N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide DMU1ATH TI TTEX248 DMU1ATH TN Dopamine D2 receptor (D2R) DMU1ATH MA Inhibitor DMU1ATH RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMU1ATH RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMU1ATH DI DMU1ATH DMU1ATH DN N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide DMU1ATH TI TTE0A2F DMU1ATH TN Dopamine D4 receptor (D4R) DMU1ATH MA Inhibitor DMU1ATH RN Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38. DMU1ATH RU https://pubmed.ncbi.nlm.nih.gov/18834111 DMU1CGD DI DMU1CGD DMU1CGD DN 6-Hydroxy-2-(4-hydroxy-benzyl)-chromen-4-one DMU1CGD TI TTFBNVI DMU1CGD TN Aldose reductase (AKR1B1) DMU1CGD MA Inhibitor DMU1CGD RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DMU1CGD RU https://pubmed.ncbi.nlm.nih.gov/10354396 DMU1CV4 DI DMU1CV4 DMU1CV4 DN 6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one DMU1CV4 TI TTGP7BY DMU1CV4 TN Monoamine oxidase type B (MAO-B) DMU1CV4 MA Inhibitor DMU1CV4 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMU1CV4 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMU1CV4 DI DMU1CV4 DMU1CV4 DN 6-amino-9-methoxy-7H-furo[3,2-g]chromen-7-one DMU1CV4 TI TT3WG5C DMU1CV4 TN Monoamine oxidase type A (MAO-A) DMU1CV4 MA Inhibitor DMU1CV4 RN Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem. 2008 Nov 13;51(21):6740-51. DMU1CV4 RU https://pubmed.ncbi.nlm.nih.gov/18834112 DMU1DHM DI DMU1DHM DMU1DHM DN Haloxysterol C DMU1DHM TI TTEB0GD DMU1DHM TN Cholinesterase (BCHE) DMU1DHM MA Inhibitor DMU1DHM RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMU1DHM RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMU1DHM DI DMU1DHM DMU1DHM DN Haloxysterol C DMU1DHM TI TT1RS9F DMU1DHM TN Acetylcholinesterase (AChE) DMU1DHM MA Inhibitor DMU1DHM RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMU1DHM RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMU1HA7 DI DMU1HA7 DMU1HA7 DN JWH-385 DMU1HA7 TI TT6OEDT DMU1HA7 TN Cannabinoid receptor 1 (CB1) DMU1HA7 MA Inhibitor DMU1HA7 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMU1HA7 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMU1HA7 DI DMU1HA7 DMU1HA7 DN JWH-385 DMU1HA7 TI TTMSFAW DMU1HA7 TN Cannabinoid receptor 2 (CB2) DMU1HA7 MA Inhibitor DMU1HA7 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMU1HA7 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMU1HFM DI DMU1HFM DMU1HFM DN (4-Bromo-butyl)-trimethyl-ammonium DMU1HFM TI TT1RS9F DMU1HFM TN Acetylcholinesterase (AChE) DMU1HFM MA Inhibitor DMU1HFM RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMU1HFM RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMU1P3T DI DMU1P3T DMU1P3T DN SK&F 107649 DMU1P3T TI TT2J34L DMU1P3T TN Arachidonate 5-lipoxygenase (5-LOX) DMU1P3T MA Inhibitor DMU1P3T RN Selective inhibition of 5-lipoxygenase attenuates glomerulonephritis in the rat. Kidney Int. 1994 May;45(5):1301-10. DMU1P3T RU https://pubmed.ncbi.nlm.nih.gov/8072241 DMU1SGX DI DMU1SGX DMU1SGX DN 3-(Octahydro-quinolizin-1-yl)-phenol DMU1SGX TI TTEX248 DMU1SGX TN Dopamine D2 receptor (D2R) DMU1SGX MA Inhibitor DMU1SGX RN Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). ... J Med Chem. 1990 Mar;33(3):1015-22. DMU1SGX RU https://pubmed.ncbi.nlm.nih.gov/1968512 DMU25HZ DI DMU25HZ DMU25HZ DN example 2 (WO2013004676) DMU25HZ TI TT69DB8 DMU25HZ TN Beta-site APP-cleaving enzyme 2 (BACE2) DMU25HZ MA Inhibitor DMU25HZ RN Cyclopropyl-Fused 1,3-Thiazepines as BACE1 and BACE2 Inhibitors. ACS Med Chem Lett. 2013 Mar 15;4(4):379-80. DMU25HZ RU https://pubmed.ncbi.nlm.nih.gov/24900681 DMU25HZ DI DMU25HZ DMU25HZ DN example 2 (WO2013004676) DMU25HZ TI TT8JRS7 DMU25HZ TN Beta-secretase (BACE) DMU25HZ MA Inhibitor DMU25HZ RN Cyclopropyl-Fused 1,3-Thiazepines as BACE1 and BACE2 Inhibitors. ACS Med Chem Lett. 2013 Mar 15;4(4):379-80. DMU25HZ RU https://pubmed.ncbi.nlm.nih.gov/24900681 DMU287Q DI DMU287Q DMU287Q DN Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 DMU287Q TI TT27RFC DMU287Q TN Opioid receptor delta (OPRD1) DMU287Q MA Inhibitor DMU287Q RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DMU287Q RU https://pubmed.ncbi.nlm.nih.gov/16913729 DMU287Q DI DMU287Q DMU287Q DN Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 DMU287Q TI TTQW87Y DMU287Q TN Opioid receptor kappa (OPRK1) DMU287Q MA Inhibitor DMU287Q RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DMU287Q RU https://pubmed.ncbi.nlm.nih.gov/16913729 DMU287Q DI DMU287Q DMU287Q DN Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 DMU287Q TI TTKWM86 DMU287Q TN Opioid receptor mu (MOP) DMU287Q MA Inhibitor DMU287Q RN Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5. DMU287Q RU https://pubmed.ncbi.nlm.nih.gov/16913729 DMU2C9W DI DMU2C9W DMU2C9W DN SC-19220 DMU2C9W TI TTG1QMU DMU2C9W TN Prostaglandin E2 receptor EP1 (PTGER1) DMU2C9W MA Antagonist DMU2C9W RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMU2C9W RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMU2EFH DI DMU2EFH DMU2EFH DN 2,8-Dimethyl-3H-quinazolin-4-one DMU2EFH TI TTVDSZ0 DMU2EFH TN Poly [ADP-ribose] polymerase 1 (PARP1) DMU2EFH MA Inhibitor DMU2EFH RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMU2EFH RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMU2EKN DI DMU2EKN DMU2EKN DN Ro 40-6055 DMU2EKN TI TTW38KT DMU2EKN TN Retinoic acid receptor alpha (RARA) DMU2EKN MA Agonist DMU2EKN RN Selective high affinity retinoic acid receptor alpha or beta-gamma ligands. Mol Pharmacol. 1991 Oct;40(4):556-62. DMU2EKN RU https://pubmed.ncbi.nlm.nih.gov/1656191 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TTG0U4H DMU2H4K TN Ribosomal protein S6 kinase beta-1 (S6K1) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TTZC6DR DMU2H4K TN cGMP-dependent protein kinase (cGK) DMU2H4K MA Inhibitor DMU2H4K RN Non-glycosidic/non-aminoalkyl-substituted indolocarbazoles as inhibitors of protein kinase C, Bioorg. Med. Chem. Lett. 3(10):1959-1964 (1993). DMU2H4K RU http://www.sciencedirect.com/science/article/pii/S0960894X01809951 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TT860QF DMU2H4K TN LCK tyrosine protein kinase (LCK) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TTQBR95 DMU2H4K TN Stress-activated protein kinase 2a (p38 alpha) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TT73U6C DMU2H4K TN Stress-activated protein kinase 2b (p38 beta) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TTFJ8Q1 DMU2H4K TN Protein kinase C alpha (PRKCA) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TT0K6EO DMU2H4K TN Stress-activated protein kinase JNK1 (JNK1) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TTYT93M DMU2H4K TN MAP kinase p38 (MAPK12) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TTWTSCV DMU2H4K TN RAC-alpha serine/threonine-protein kinase (AKT1) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2H4K DI DMU2H4K DMU2H4K DN STAUROSPORINONE DMU2H4K TI TTRSMW9 DMU2H4K TN Glycogen synthase kinase-3 beta (GSK-3B) DMU2H4K MA Inhibitor DMU2H4K RN Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. DMU2H4K RU https://pubmed.ncbi.nlm.nih.gov/10998351 DMU2J3K DI DMU2J3K DMU2J3K DN SB-298 DMU2J3K TI TTM2AOE DMU2J3K TN Adenosine A2a receptor (ADORA2A) DMU2J3K MA Inhibitor DMU2J3K RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMU2J3K RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMU2J3K DI DMU2J3K DMU2J3K DN SB-298 DMU2J3K TI TTNE7KG DMU2J3K TN Adenosine A2b receptor (ADORA2B) DMU2J3K MA Inhibitor DMU2J3K RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMU2J3K RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMU2J3K DI DMU2J3K DMU2J3K DN SB-298 DMU2J3K TI TTK25J1 DMU2J3K TN Adenosine A1 receptor (ADORA1) DMU2J3K MA Inhibitor DMU2J3K RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMU2J3K RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMU2J3K DI DMU2J3K DMU2J3K DN SB-298 DMU2J3K TI TTJFY5U DMU2J3K TN Adenosine A3 receptor (ADORA3) DMU2J3K MA Inhibitor DMU2J3K RN 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with... J Med Chem. 2009 Jul 9;52(13):3994-4006. DMU2J3K RU https://pubmed.ncbi.nlm.nih.gov/19569717 DMU2PSQ DI DMU2PSQ DMU2PSQ DN 1-Bromo-6-(3-hydroxyphenyl)-2-naphthol DMU2PSQ TI TTIWB6L DMU2PSQ TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMU2PSQ MA Inhibitor DMU2PSQ RN Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design,... J Med Chem. 2008 Aug 14;51(15):4685-98. DMU2PSQ RU https://pubmed.ncbi.nlm.nih.gov/18630892 DMU2PT1 DI DMU2PT1 DMU2PT1 DN Ac-Cys-Ile-Tyr-Lys-Phe(4-NO2)-Tyr-Phe DMU2PT1 TI TT6PKBN DMU2PT1 TN Proto-oncogene c-Src (SRC) DMU2PT1 MA Inhibitor DMU2PT1 RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMU2PT1 RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMU2WIS DI DMU2WIS DMU2WIS DN SC-50073 DMU2WIS TI TTN53ZF DMU2WIS TN Leukotriene B4 receptor 1 (LTB4R) DMU2WIS MA Inhibitor DMU2WIS RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DMU2WIS RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DMU2X59 DI DMU2X59 DMU2X59 DN PMID16539403C15b DMU2X59 TI TTP4520 DMU2X59 TN TGF-beta receptor type I (TGFBR1) DMU2X59 MA Inhibitor DMU2X59 RN Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity vers... J Med Chem. 2006 Mar 23;49(6):2138-42. DMU2X59 RU https://pubmed.ncbi.nlm.nih.gov/16539403 DMU2X59 DI DMU2X59 DMU2X59 DN PMID16539403C15b DMU2X59 TI TTTUZ3O DMU2X59 TN MLK-related kinase (MLTK) DMU2X59 MA Inhibitor DMU2X59 RN Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity vers... J Med Chem. 2006 Mar 23;49(6):2138-42. DMU2X59 RU https://pubmed.ncbi.nlm.nih.gov/16539403 DMU2X59 DI DMU2X59 DMU2X59 DN PMID16539403C15b DMU2X59 TI TTZE3P7 DMU2X59 TN TGF-beta receptor type II (TGFBR2) DMU2X59 MA Inhibitor DMU2X59 RN Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity vers... J Med Chem. 2006 Mar 23;49(6):2138-42. DMU2X59 RU https://pubmed.ncbi.nlm.nih.gov/16539403 DMU30IO DI DMU30IO DMU30IO DN Phylomers DMU30IO TI TT0K6EO DMU30IO TN Stress-activated protein kinase JNK1 (JNK1) DMU30IO MA Inhibitor DMU30IO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496). DMU30IO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1496 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTJQOD7 DMU34BK TN 5-HT 2A receptor (HTR2A) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTSQIFT DMU34BK TN 5-HT 1A receptor (HTR1A) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTQ3JTF DMU34BK TN Muscarinic acetylcholine receptor M4 (CHRM4) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TT0K1SC DMU34BK TN 5-HT 2B receptor (HTR2B) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTPC4TU DMU34BK TN 5-HT 3A receptor (HTR3A) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TT4C8EA DMU34BK TN Dopamine D3 receptor (D3R) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTQ13Z5 DMU34BK TN Muscarinic acetylcholine receptor M3 (CHRM3) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTC24WT DMU34BK TN C-C chemokine receptor type 1 (CCR1) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTYO0A3 DMU34BK TN Substance-K receptor (TACR2) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTK25J1 DMU34BK TN Adenosine A1 receptor (ADORA1) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TT4TFGN DMU34BK TN Vasopressin V1a receptor (V1AR) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTK8CXU DMU34BK TN 5-HT 1B receptor (HTR1B) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTZ9SOR DMU34BK TN Muscarinic acetylcholine receptor M1 (CHRM1) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU34BK DI DMU34BK DMU34BK DN A-987306 DMU34BK TI TTYEG6Q DMU34BK TN Muscarinic acetylcholine receptor M2 (CHRM2) DMU34BK MA Inhibitor DMU34BK RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMU34BK RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMU36HT DI DMU36HT DMU36HT DN Alpha-D-Glucose-1-Phosphate DMU36HT TI TTLP3GX DMU36HT TN Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC) DMU36HT MA Inhibitor DMU36HT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMU36HT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMU36HT DI DMU36HT DMU36HT DN Alpha-D-Glucose-1-Phosphate DMU36HT TI TTZHY6R DMU36HT TN Glycogen phosphorylase muscle form (GP) DMU36HT MA Inhibitor DMU36HT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMU36HT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMU3A57 DI DMU3A57 DMU3A57 DN AR-C70484XX DMU3A57 TI TTDP1UC DMU3A57 TN Fatty acid amide hydrolase (FAAH) DMU3A57 MA Inhibitor DMU3A57 RN 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52. DMU3A57 RU https://pubmed.ncbi.nlm.nih.gov/20005725 DMU3A57 DI DMU3A57 DMU3A57 DN AR-C70484XX DMU3A57 TI TTT1JVS DMU3A57 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMU3A57 MA Inhibitor DMU3A57 RN 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52. DMU3A57 RU https://pubmed.ncbi.nlm.nih.gov/20005725 DMU3D2O DI DMU3D2O DMU3D2O DN BARETTIN DMU3D2O TI TTWJBZ5 DMU3D2O TN 5-HT 2C receptor (HTR2C) DMU3D2O MA Inhibitor DMU3D2O RN Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4. DMU3D2O RU https://pubmed.ncbi.nlm.nih.gov/17067154 DMU3D2O DI DMU3D2O DMU3D2O DN BARETTIN DMU3D2O TI TT07C3Y DMU3D2O TN 5-HT 4 receptor (HTR4) DMU3D2O MA Inhibitor DMU3D2O RN Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4. DMU3D2O RU https://pubmed.ncbi.nlm.nih.gov/17067154 DMU3D2O DI DMU3D2O DMU3D2O DN BARETTIN DMU3D2O TI TTJQOD7 DMU3D2O TN 5-HT 2A receptor (HTR2A) DMU3D2O MA Inhibitor DMU3D2O RN Brominated cyclodipeptides from the marine sponge Geodia barretti as selective 5-HT ligands. J Nat Prod. 2006 Oct;69(10):1421-4. DMU3D2O RU https://pubmed.ncbi.nlm.nih.gov/17067154 DMU3DMH DI DMU3DMH DMU3DMH DN ACENAPHTHOQUINONE DMU3DMH TI TTEB0GD DMU3DMH TN Cholinesterase (BCHE) DMU3DMH MA Inhibitor DMU3DMH RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMU3DMH RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMU3DMH DI DMU3DMH DMU3DMH DN ACENAPHTHOQUINONE DMU3DMH TI TTMF541 DMU3DMH TN Liver carboxylesterase (CES1) DMU3DMH MA Inhibitor DMU3DMH RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMU3DMH RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMU3E1M DI DMU3E1M DMU3E1M DN TRL-382 DMU3E1M TI TT8NGED DMU3E1M TN Prostaglandin G/H synthase 1 (COX-1) DMU3E1M MA Inhibitor DMU3E1M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1375). DMU3E1M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1375 DMU3F7H DI DMU3F7H DMU3F7H DN (S)-N2-{4-[(4-chlorobenzyl)oxy]benzyl}alaninamide DMU3F7H TI TTGP7BY DMU3F7H TN Monoamine oxidase type B (MAO-B) DMU3F7H MA Inhibitor DMU3F7H RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMU3F7H RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMU3IJL DI DMU3IJL DMU3IJL DN F-G-G-F-T-G-Aib-R-K-S-A-R-K-L-A-N-Q-COOH DMU3IJL TI TTNT7K8 DMU3IJL TN Nociceptin receptor (OPRL1) DMU3IJL MA Inhibitor DMU3IJL RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMU3IJL RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMU3O5H DI DMU3O5H DMU3O5H DN malic acid DMU3O5H TI TTAHD89 DMU3O5H TN Polycystic kidney disease 2-like 1 (TRPP2) DMU3O5H MA Activator DMU3O5H RN Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12569-74. DMU3O5H RU https://pubmed.ncbi.nlm.nih.gov/16891422 DMU3OR1 DI DMU3OR1 DMU3OR1 DN PD-169469 DMU3OR1 TI TTLM12X DMU3OR1 TN Matrix metalloproteinase-2 (MMP-2) DMU3OR1 MA Inhibitor DMU3OR1 RN Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31. DMU3OR1 RU https://pubmed.ncbi.nlm.nih.gov/16451058 DMU3OR1 DI DMU3OR1 DMU3OR1 DN PD-169469 DMU3OR1 TI TTUZ2L5 DMU3OR1 TN Matrix metalloproteinase-3 (MMP-3) DMU3OR1 MA Inhibitor DMU3OR1 RN Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem. 2006 Feb 9;49(3):923-31. DMU3OR1 RU https://pubmed.ncbi.nlm.nih.gov/16451058 DMU3VWA DI DMU3VWA DMU3VWA DN 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine DMU3VWA TI TTP3QRF DMU3VWA TN Thymidine kinase 1 (TK1) DMU3VWA MA Inhibitor DMU3VWA RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DMU3VWA RU https://pubmed.ncbi.nlm.nih.gov/17181158 DMU3VWA DI DMU3VWA DMU3VWA DN 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine DMU3VWA TI TT7KNZQ DMU3VWA TN Thymidine kinase 2 (Mt-TK2) DMU3VWA MA Inhibitor DMU3VWA RN N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors. J Med Chem. 2006 Dec 28;49(26):7766-73. DMU3VWA RU https://pubmed.ncbi.nlm.nih.gov/17181158 DMU3Y4J DI DMU3Y4J DMU3Y4J DN AM-411 DMU3Y4J TI TTMSFAW DMU3Y4J TN Cannabinoid receptor 2 (CB2) DMU3Y4J MA Inhibitor DMU3Y4J RN Heteroadamantyl cannabinoids. J Med Chem. 2010 Aug 12;53(15):5656-66. DMU3Y4J RU https://pubmed.ncbi.nlm.nih.gov/20593789 DMU3Y4J DI DMU3Y4J DMU3Y4J DN AM-411 DMU3Y4J TI TT6OEDT DMU3Y4J TN Cannabinoid receptor 1 (CB1) DMU3Y4J MA Inhibitor DMU3Y4J RN Heteroadamantyl cannabinoids. J Med Chem. 2010 Aug 12;53(15):5656-66. DMU3Y4J RU https://pubmed.ncbi.nlm.nih.gov/20593789 DMU3YRH DI DMU3YRH DMU3YRH DN VU0240551 DMU3YRH TI TTH6UZY DMU3YRH TN Solute carrier family 12 member 5 (SLC12A5) DMU3YRH MA Inhibitor DMU3YRH RN Small-molecule screen identifies inhibitors of the neuronal K-Cl cotransporter KCC2. Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5383-8. DMU3YRH RU https://pubmed.ncbi.nlm.nih.gov/19279215 DMU3YXR DI DMU3YXR DMU3YXR DN beta-ergocriptine DMU3YXR TI TTS2PH3 DMU3YXR TN Dopamine D5 receptor (D5R) DMU3YXR MA Agonist DMU3YXR RN Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9. DMU3YXR RU https://pubmed.ncbi.nlm.nih.gov/1826762 DMU426Z DI DMU426Z DMU426Z DN NPC-349 DMU426Z TI TTGY8IW DMU426Z TN B2 bradykinin receptor (BDKRB2) DMU426Z MA Antagonist DMU426Z RN Differential pharmacology of cloned human and mouse B2 bradykinin receptors. Mol Pharmacol. 1994 Jan;45(1):1-8. DMU426Z RU https://pubmed.ncbi.nlm.nih.gov/8302267 DMU42C1 DI DMU42C1 DMU42C1 DN DYSINOSIN A DMU42C1 TI TT6L509 DMU42C1 TN Coagulation factor IIa (F2) DMU42C1 MA Inhibitor DMU42C1 RN From natural products to achiral drug prototypes: potent thrombin inhibitors based on P2/P3 dihydropyrid-2-one core motifs. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5429-32. DMU42C1 RU https://pubmed.ncbi.nlm.nih.gov/19674897 DMU42CR DI DMU42CR DMU42CR DN example 92 (WO2012095521) DMU42CR TI TT69DB8 DMU42CR TN Beta-site APP-cleaving enzyme 2 (BACE2) DMU42CR MA Inhibitor DMU42CR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2331). DMU42CR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2331 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TTE4KHA DMU48OD TN Amyloid beta A4 protein (APP) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TT6X50U DMU48OD TN Matrix metalloproteinase-9 (MMP-9) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TTLM12X DMU48OD TN Matrix metalloproteinase-2 (MMP-2) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TTHY57M DMU48OD TN Matrix metalloproteinase-13 (MMP-13) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TT6AZXG DMU48OD TN TNF alpha converting enzyme (ADAM17) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TTMTWOS DMU48OD TN Matrix metalloproteinase-7 (MMP-7) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TTMX39J DMU48OD TN Matrix metalloproteinase-1 (MMP-1) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TTJ4QE7 DMU48OD TN Matrix metalloproteinase-14 (MMP-14) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU48OD DI DMU48OD DMU48OD DN SR-973 DMU48OD TI TTYRF5E DMU48OD TN Matrix metalloproteinase-21 (MMP-21) DMU48OD MA Inhibitor DMU48OD RN Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63. DMU48OD RU https://pubmed.ncbi.nlm.nih.gov/16473009 DMU49H6 DI DMU49H6 DMU49H6 DN 4-amino-1,8-naphthalimide DMU49H6 TI TTVDSZ0 DMU49H6 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMU49H6 MA Inhibitor DMU49H6 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMU49H6 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMU49JN DI DMU49JN DMU49JN DN (R)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide DMU49JN TI TTGP7BY DMU49JN TN Monoamine oxidase type B (MAO-B) DMU49JN MA Inhibitor DMU49JN RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMU49JN RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMU4BIW DI DMU4BIW DMU4BIW DN N,N'-(1',6-hexylene)-bis-(-)-nor-MEP DMU4BIW TI TTEB0GD DMU4BIW TN Cholinesterase (BCHE) DMU4BIW MA Inhibitor DMU4BIW RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMU4BIW RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMU4BIW DI DMU4BIW DMU4BIW DN N,N'-(1',6-hexylene)-bis-(-)-nor-MEP DMU4BIW TI TT1RS9F DMU4BIW TN Acetylcholinesterase (AChE) DMU4BIW MA Inhibitor DMU4BIW RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMU4BIW RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMU4BL2 DI DMU4BL2 DMU4BL2 DN PMID24900428C14 DMU4BL2 TI TTFQEMX DMU4BL2 TN Casein kinase I alpha (CSNK1A1) DMU4BL2 MA Inhibitor DMU4BL2 RN Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64. DMU4BL2 RU https://pubmed.ncbi.nlm.nih.gov/24900428 DMU4BL2 DI DMU4BL2 DMU4BL2 DN PMID24900428C14 DMU4BL2 TI TTH30UI DMU4BL2 TN Casein kinase I delta (CSNK1D) DMU4BL2 MA Inhibitor DMU4BL2 RN Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64. DMU4BL2 RU https://pubmed.ncbi.nlm.nih.gov/24900428 DMU4BL2 DI DMU4BL2 DMU4BL2 DN PMID24900428C14 DMU4BL2 TI TT0UZJ9 DMU4BL2 TN Casein kinase I gamma-2 (CSNK1G2) DMU4BL2 MA Inhibitor DMU4BL2 RN Structure-Based Design of Potent and Selective CK1gamma Inhibitors. ACS Med Chem Lett. 2012 Oct 18;3(12):1059-64. DMU4BL2 RU https://pubmed.ncbi.nlm.nih.gov/24900428 DMU4EJW DI DMU4EJW DMU4EJW DN 1,1,1-trifluoro-3-(octylthio)propan-2-one DMU4EJW TI TTMF541 DMU4EJW TN Liver carboxylesterase (CES1) DMU4EJW MA Inhibitor DMU4EJW RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMU4EJW RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMU4EJW DI DMU4EJW DMU4EJW DN 1,1,1-trifluoro-3-(octylthio)propan-2-one DMU4EJW TI TTDP1UC DMU4EJW TN Fatty acid amide hydrolase (FAAH) DMU4EJW MA Inhibitor DMU4EJW RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMU4EJW RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMU4I8R DI DMU4I8R DMU4I8R DN NE58027 DMU4I8R TI TTIKWV4 DMU4I8R TN Geranyltranstransferase (FDPS) DMU4I8R MA Inhibitor DMU4I8R RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMU4I8R RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMU4JWM DI DMU4JWM DMU4JWM DN monomethylfumarate DMU4JWM TI TTWNV8U DMU4JWM TN Nicotinic acid receptor (HCAR2) DMU4JWM MA Agonist DMU4JWM RN The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5. DMU4JWM RU https://pubmed.ncbi.nlm.nih.gov/18722346 DMU4K7O DI DMU4K7O DMU4K7O DN KNI-10527 DMU4K7O TI TTXMNHO DMU4K7O TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMU4K7O MA Inhibitor DMU4K7O RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMU4K7O RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMU4MCK DI DMU4MCK DMU4MCK DN 5'-Deoxy-5'-phenyladenophostin A DMU4MCK TI TTC9IZL DMU4MCK TN Inositol 1,4,5-trisphosphate receptor (ITPR) DMU4MCK MA Inhibitor DMU4MCK RN Synthesis of adenophostin A analogues conjugating an aromatic group at the 5'-position as potent IP3 receptor ligands. J Med Chem. 2006 Sep 21;49(19):5750-8. DMU4MCK RU https://pubmed.ncbi.nlm.nih.gov/16970399 DMU4MIC DI DMU4MIC DMU4MIC DN 2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran DMU4MIC TI TTAWNKZ DMU4MIC TN Norepinephrine transporter (NET) DMU4MIC MA Inhibitor DMU4MIC RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMU4MIC RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMU4MIC DI DMU4MIC DMU4MIC DN 2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran DMU4MIC TI TT3ROYC DMU4MIC TN Serotonin transporter (SERT) DMU4MIC MA Inhibitor DMU4MIC RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMU4MIC RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMU4Q8C DI DMU4Q8C DMU4Q8C DN 2beta,3alpha-dihydroxyurs-12-en-28-oic acid DMU4Q8C TI TTZHY6R DMU4Q8C TN Glycogen phosphorylase muscle form (GP) DMU4Q8C MA Inhibitor DMU4Q8C RN Practical synthesis of bredemolic acid, a natural inhibitor of glycogen phosphorylase. J Nat Prod. 2008 Nov;71(11):1877-80. DMU4Q8C RU https://pubmed.ncbi.nlm.nih.gov/18847277 DMU52WA DI DMU52WA DMU52WA DN 3-(3-Pyridin-2-yl-pyrazol-1-yl)-benzonitrile DMU52WA TI TTHS256 DMU52WA TN Metabotropic glutamate receptor 5 (mGluR5) DMU52WA MA Inhibitor DMU52WA RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMU52WA RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMU53NZ DI DMU53NZ DMU53NZ DN 3-(3-methoxybenzyl)-1H-pyrrolo[2,3-b]pyridine DMU53NZ TI TTRLW2X DMU53NZ TN Fibroblast growth factor receptor 1 (FGFR1) DMU53NZ MA Inhibitor DMU53NZ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMU53NZ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMU5984 DI DMU5984 DMU5984 DN CGP74514A DMU5984 TI TTH6V3D DMU5984 TN Cyclin-dependent kinase 1 (CDK1) DMU5984 MA Inhibitor DMU5984 RN 2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors. Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6. DMU5984 RU https://pubmed.ncbi.nlm.nih.gov/9990463 DMU5A2B DI DMU5A2B DMU5A2B DN 4-(tert-butylamino)naphthalen-1-ol DMU5A2B TI TTZJYKH DMU5A2B TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMU5A2B MA Inhibitor DMU5A2B RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMU5A2B RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMU5BOW DI DMU5BOW DMU5BOW DN 1-(2-(diethylamino)quinazolin-4-yl)-3-phenylurea DMU5BOW TI TTJFY5U DMU5BOW TN Adenosine A3 receptor (ADORA3) DMU5BOW MA Inhibitor DMU5BOW RN Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97. DMU5BOW RU https://pubmed.ncbi.nlm.nih.gov/16821770 DMU5GKN DI DMU5GKN DMU5GKN DN 2,5-bis(2-methoxyphenyl)thiophene DMU5GKN TI TTE4KHA DMU5GKN TN Amyloid beta A4 protein (APP) DMU5GKN MA Inhibitor DMU5GKN RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DMU5GKN RU https://pubmed.ncbi.nlm.nih.gov/16325402 DMU5H4K DI DMU5H4K DMU5H4K DN RU78783 DMU5H4K TI TT6PKBN DMU5H4K TN Proto-oncogene c-Src (SRC) DMU5H4K MA Inhibitor DMU5H4K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMU5H4K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMU5HMC DI DMU5HMC DMU5HMC DN 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine DMU5HMC TI TTSZLWK DMU5HMC TN Aromatase (CYP19A1) DMU5HMC MA Inhibitor DMU5HMC RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMU5HMC RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMU5HMC DI DMU5HMC DMU5HMC DN 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine DMU5HMC TI TTRA5BZ DMU5HMC TN Steroid 17-alpha-monooxygenase (S17AH) DMU5HMC MA Inhibitor DMU5HMC RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMU5HMC RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMU5HMC DI DMU5HMC DMU5HMC DN 3-(1-methyl-3,4-dihydronaphthalen-2-yl)-pyridine DMU5HMC TI TTIQUX7 DMU5HMC TN Steroid 11-beta-hydroxylase (CYP11B1) DMU5HMC MA Inhibitor DMU5HMC RN Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B... J Med Chem. 2006 Apr 6;49(7):2222-31. DMU5HMC RU https://pubmed.ncbi.nlm.nih.gov/16570918 DMU5J8Y DI DMU5J8Y DMU5J8Y DN 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide DMU5J8Y TI TTAMQ62 DMU5J8Y TN Cyclin A2 (CCNA2) DMU5J8Y MA Inhibitor DMU5J8Y RN Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010). DMU5J8Y RU http://www.sciencedirect.com/science/article/pii/S0960894X10006803 DMU5J8Y DI DMU5J8Y DMU5J8Y DN 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide DMU5J8Y TI TTQYF7G DMU5J8Y TN Cyclin-dependent kinase 7 (CDK7) DMU5J8Y MA Inhibitor DMU5J8Y RN Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010). DMU5J8Y RU http://www.sciencedirect.com/science/article/pii/S0960894X10006803 DMU5J8Y DI DMU5J8Y DMU5J8Y DN 2,5-dichloro-N-p-tolylthiophene-3-sulfonamide DMU5J8Y TI TTSFWA7 DMU5J8Y TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMU5J8Y MA Inhibitor DMU5J8Y RN Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010). DMU5J8Y RU http://www.sciencedirect.com/science/article/pii/S0960894X10006803 DMU5NRA DI DMU5NRA DMU5NRA DN 3,4,5-trimethoxy-N-(thiazol-2-yl)benzamide DMU5NRA TI TTSJ6Q4 DMU5NRA TN LOX-5 messenger RNA (ALOX5 mRNA) DMU5NRA MA Inhibitor DMU5NRA RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMU5NRA RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMU5P8O DI DMU5P8O DMU5P8O DN [2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine DMU5P8O TI TTJS8PY DMU5P8O TN 5-HT 6 receptor (HTR6) DMU5P8O MA Inhibitor DMU5P8O RN Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4569-73. DMU5P8O RU https://pubmed.ncbi.nlm.nih.gov/15357994 DMU5QRX DI DMU5QRX DMU5QRX DN ISIS 112590 DMU5QRX TI TT6804T DMU5QRX TN MIF messenger RNA (MIF mRNA) DMU5QRX RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DMU5QRX RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DMU5R2O DI DMU5R2O DMU5R2O DN N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide DMU5R2O TI TTMSFAW DMU5R2O TN Cannabinoid receptor 2 (CB2) DMU5R2O MA Inhibitor DMU5R2O RN New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10. DMU5R2O RU https://pubmed.ncbi.nlm.nih.gov/17942307 DMU5R2O DI DMU5R2O DMU5R2O DN N-(2-chloroethyl)icosa-5,8,11,14-tetraenamide DMU5R2O TI TT6OEDT DMU5R2O TN Cannabinoid receptor 1 (CB1) DMU5R2O MA Inhibitor DMU5R2O RN New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6505-10. DMU5R2O RU https://pubmed.ncbi.nlm.nih.gov/17942307 DMU5SAF DI DMU5SAF DMU5SAF DN Fructose-6-phosphate DMU5SAF TI TTWHDVK DMU5SAF TN Fructose-1,6-bisphosphatase (FBP) DMU5SAF MA Inhibitor DMU5SAF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMU5SAF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMU5T28 DI DMU5T28 DMU5T28 DN (+/-)-threo-4'-Ethylmethylphenidate DMU5T28 TI TTVBI8W DMU5T28 TN Dopamine transporter (DAT) DMU5T28 MA Inhibitor DMU5T28 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMU5T28 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMU618S DI DMU618S DMU618S DN 5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DMU618S TI TTYFKSZ DMU618S TN Tubulin beta (TUBB) DMU618S MA Inhibitor DMU618S RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMU618S RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMU618S DI DMU618S DMU618S DN 5,7-Dimethyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one DMU618S TI TTML2WA DMU618S TN Tubulin (TUB) DMU618S MA Inhibitor DMU618S RN Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. DMU618S RU https://pubmed.ncbi.nlm.nih.gov/9301667 DMU64W8 DI DMU64W8 DMU64W8 DN ISO24 DMU64W8 TI TT6PKBN DMU64W8 TN Proto-oncogene c-Src (SRC) DMU64W8 MA Inhibitor DMU64W8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMU64W8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMU65NK DI DMU65NK DMU65NK DN Mycophenolic acid DMU65NK TI TTYJOLE DMU65NK TN MERS-CoV papain-like proteinase (PL-PRO) DMU65NK MA Inhibitor DMU65NK RN SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. DMU65NK RU https://pubmed.ncbi.nlm.nih.gov/27344959 DMU67CE DI DMU67CE DMU67CE DN MSOPPE DMU67CE TI TT0I76D DMU67CE TN Metabotropic glutamate receptor 7 (mGluR7) DMU67CE MA Antagonist DMU67CE RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMU67CE RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMU6972 DI DMU6972 DMU6972 DN PMBA DMU6972 TI TTZ8EM9 DMU6972 TN Glycine receptor (GlyR) DMU6972 MA Antagonist DMU6972 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 425). DMU6972 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=425 DMU6A3W DI DMU6A3W DMU6A3W DN [3H]GSK931145 DMU6A3W TI TTHJTF7 DMU6A3W TN Glycine transporter GlyT-1 (SLC6A9) DMU6A3W MA Modulator DMU6A3W RN Pharmacological characterisation of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology. 2010 Nov;59(6):558-65. DMU6A3W RU https://pubmed.ncbi.nlm.nih.gov/20691713 DMU6AMP DI DMU6AMP DMU6AMP DN IL-2 antibody (anti-tumor) DMU6AMP TI TTF89GD DMU6AMP TN Interleukin-2 (IL2) DMU6AMP MA Modulator DMU6AMP RN An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2. Immunopharmacology. 1994 Nov-Dec;28(3):223-32. DMU6AMP RU https://www.ncbi.nlm.nih.gov/pubmed/7852053 DMU6FOG DI DMU6FOG DMU6FOG DN Clorsulon DMU6FOG TI TTHJWVK DMU6FOG TN Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI) DMU6FOG MA Inhibitor DMU6FOG RN Modes of action of anthelmintic drugs. Vet J. 1997 Jul;154(1):11-34. DMU6FOG RU https://pubmed.ncbi.nlm.nih.gov/9265850 DMU6FPL DI DMU6FPL DMU6FPL DN N-(2-nonyloxy-4-nitrophenyl)methanesulfonamide DMU6FPL TI TTSZLWK DMU6FPL TN Aromatase (CYP19A1) DMU6FPL MA Inhibitor DMU6FPL RN Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9. DMU6FPL RU https://pubmed.ncbi.nlm.nih.gov/16480277 DMU6JOK DI DMU6JOK DMU6JOK DN cirazoline DMU6JOK TI TT2NUT5 DMU6JOK TN Adrenergic receptor alpha-2C (ADRA2C) DMU6JOK MA Agonist DMU6JOK RN Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. DMU6JOK RU https://pubmed.ncbi.nlm.nih.gov/7969082 DMU6OB4 DI DMU6OB4 DMU6OB4 DN Costunolide DMU6OB4 TI TT1EDJZ DMU6OB4 TN Microtubule-associated protein (MAP) DMU6OB4 MA Binder DMU6OB4 RN A sesquiterpene lactone, costunolide, interacts with microtubule protein and inhibits the growth of MCF-7 cells. Chem Biol Interact. 2004 Jan 15;147(1):79-86. DMU6OB4 RU https://pubmed.ncbi.nlm.nih.gov/14726154 DMU6PV8 DI DMU6PV8 DMU6PV8 DN H-Cpa-Gly-Gly-Phe-Met-NH2 DMU6PV8 TI TTKWM86 DMU6PV8 TN Opioid receptor mu (MOP) DMU6PV8 MA Inhibitor DMU6PV8 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMU6PV8 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMU6PV8 DI DMU6PV8 DMU6PV8 DN H-Cpa-Gly-Gly-Phe-Met-NH2 DMU6PV8 TI TTQW87Y DMU6PV8 TN Opioid receptor kappa (OPRK1) DMU6PV8 MA Inhibitor DMU6PV8 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMU6PV8 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMU6PV8 DI DMU6PV8 DMU6PV8 DN H-Cpa-Gly-Gly-Phe-Met-NH2 DMU6PV8 TI TT27RFC DMU6PV8 TN Opioid receptor delta (OPRD1) DMU6PV8 MA Inhibitor DMU6PV8 RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMU6PV8 RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMU6QXV DI DMU6QXV DMU6QXV DN ISA-2011B DMU6QXV TI TTA7DU1 DMU6QXV TN PtdIns(4)P-5-kinase 1 alpha (PIP5K1A) DMU6QXV MA Inhibitor DMU6QXV RN The role of PI3K/AKT-related PIP5K1alpha and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3689-98. DMU6QXV RU https://pubmed.ncbi.nlm.nih.gov/25071204 DMU6WR9 DI DMU6WR9 DMU6WR9 DN AMG-247 DMU6WR9 TI TT9JZCK DMU6WR9 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMU6WR9 MA Antagonist DMU6WR9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275). DMU6WR9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275 DMU70ND DI DMU70ND DMU70ND DN ISIS 102478 DMU70ND TI TT5U49F DMU70ND TN PRKACA messenger RNA (PRKACA mRNA) DMU70ND RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMU70ND RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMU70YP DI DMU70YP DMU70YP DN ARPFAQK-FAM DMU70YP TI TTK3WBU DMU70YP TN XIAP messenger RNA (XIAP mRNA) DMU70YP MA Inhibitor DMU70YP RN Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional... J Med Chem. 2004 May 6;47(10):2430-40. DMU70YP RU https://pubmed.ncbi.nlm.nih.gov/15115387 DMU74R8 DI DMU74R8 DMU74R8 DN 7-(naphthalen-2-yl)benzo[e][1,2,4]triazin-3-amine DMU74R8 TI TT6PKBN DMU74R8 TN Proto-oncogene c-Src (SRC) DMU74R8 MA Inhibitor DMU74R8 RN Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5546-50. DMU74R8 RU https://pubmed.ncbi.nlm.nih.gov/16931012 DMU784M DI DMU784M DMU784M DN 4-Sulfamoyloxy-benzoic acid hexyl ester DMU784M TI TTHM0R1 DMU784M TN Steryl-sulfatase (STS) DMU784M MA Inhibitor DMU784M RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMU784M RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMU79FD DI DMU79FD DMU79FD DN ISIS 122986 DMU79FD TI TTJZNIG DMU79FD TN MEKK3 messenger RNA (MAP3K3 mRNA) DMU79FD RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DMU79FD RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DMU7BJA DI DMU7BJA DMU7BJA DN (+)-(5S,8S,10S)-20-methoxypuupehenol DMU7BJA TI TTN9T81 DMU7BJA TN Arachidonate 15-lipoxygenase (15-LOX) DMU7BJA MA Inhibitor DMU7BJA RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMU7BJA RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMU7BJA DI DMU7BJA DMU7BJA DN (+)-(5S,8S,10S)-20-methoxypuupehenol DMU7BJA TI TT12ABZ DMU7BJA TN Arachidonate 12-lipoxygenase (12-LOX) DMU7BJA MA Inhibitor DMU7BJA RN Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. J Nat Prod. 2003 Feb;66(2):230-5. DMU7BJA RU https://pubmed.ncbi.nlm.nih.gov/12608855 DMU7E3O DI DMU7E3O DMU7E3O DN 6-Methyl-4-(4-phenylpiperazin-1-yl)coumarin DMU7E3O TI TT1RS9F DMU7E3O TN Acetylcholinesterase (AChE) DMU7E3O MA Inhibitor DMU7E3O RN Design, synthesis, and acetylcholinesterase inhibitory activity of novel coumarin analogues. Bioorg Med Chem. 2008 Sep 1;16(17):8011-21. DMU7E3O RU https://pubmed.ncbi.nlm.nih.gov/18701305 DMU7E6A DI DMU7E6A DMU7E6A DN JWH-146 DMU7E6A TI TTMSFAW DMU7E6A TN Cannabinoid receptor 2 (CB2) DMU7E6A MA Inhibitor DMU7E6A RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMU7E6A RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMU7E6A DI DMU7E6A DMU7E6A DN JWH-146 DMU7E6A TI TT6OEDT DMU7E6A TN Cannabinoid receptor 1 (CB1) DMU7E6A MA Inhibitor DMU7E6A RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMU7E6A RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMU7EQV DI DMU7EQV DMU7EQV DN S-(N-butyl-N-hydroxycarbamoyl)glutathione DMU7EQV TI TTV9A7R DMU7EQV TN Lactoylglutathione lyase (GLO1) DMU7EQV MA Inhibitor DMU7EQV RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DMU7EQV RU https://pubmed.ncbi.nlm.nih.gov/11052803 DMU7FC5 DI DMU7FC5 DMU7FC5 DN [3H]CP55940 DMU7FC5 TI TTMSFAW DMU7FC5 TN Cannabinoid receptor 2 (CB2) DMU7FC5 MA Agonist DMU7FC5 RN Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem. 1996 May1;237(3):704-11. DMU7FC5 RU https://pubmed.ncbi.nlm.nih.gov/8647116 DMU7FC5 DI DMU7FC5 DMU7FC5 DN [3H]CP55940 DMU7FC5 TI TTNET8J DMU7FC5 TN G-protein coupled receptor 55 (GPR55) DMU7FC5 MA Agonist DMU7FC5 RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DMU7FC5 RU https://pubmed.ncbi.nlm.nih.gov/17876302 DMU7FC5 DI DMU7FC5 DMU7FC5 DN [3H]CP55940 DMU7FC5 TI TT6OEDT DMU7FC5 TN Cannabinoid receptor 1 (CB1) DMU7FC5 MA Agonist DMU7FC5 RN Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J Biol Chem. 1996 Mar 22;271(12):6941-6. DMU7FC5 RU https://pubmed.ncbi.nlm.nih.gov/8636122 DMU7INH DI DMU7INH DMU7INH DN Benzaldehyde O-4-(heptyloxy)phenylcarbamoyl oxime DMU7INH TI TTDP1UC DMU7INH TN Fatty acid amide hydrolase (FAAH) DMU7INH MA Inhibitor DMU7INH RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMU7INH RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMU7SBD DI DMU7SBD DMU7SBD DN Ac-hPhe-Leu-Ala-LeuVSMe DMU7SBD TI TTF2LRI DMU7SBD TN Cathepsin B (CTSB) DMU7SBD MA Inhibitor DMU7SBD RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMU7SBD RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMU7SBD DI DMU7SBD DMU7SBD DN Ac-hPhe-Leu-Ala-LeuVSMe DMU7SBD TI TTUMQVO DMU7SBD TN Cathepsin S (CTSS) DMU7SBD MA Inhibitor DMU7SBD RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMU7SBD RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMU82JV DI DMU82JV DMU82JV DN GG-818 DMU82JV TI TTNGILX DMU82JV TN Adrenergic receptor alpha-1A (ADRA1A) DMU82JV MA Antagonist DMU82JV RN In situ salt screening--a useful technique for discovery support and preformulation studies. Pharm Dev Technol. 1998 May;3(2):215-23. DMU82JV RU https://pubmed.ncbi.nlm.nih.gov/9653759 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TT6MSOK DMU83KP TN 5-HT 1D receptor (HTR1D) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TT2NUT5 DMU83KP TN Adrenergic receptor alpha-2C (ADRA2C) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TT0K1SC DMU83KP TN 5-HT 2B receptor (HTR2B) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TTJQOD7 DMU83KP TN 5-HT 2A receptor (HTR2A) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TTSQIFT DMU83KP TN 5-HT 1A receptor (HTR1A) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TTWJBZ5 DMU83KP TN 5-HT 2C receptor (HTR2C) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TTWG9A4 DMU83KP TN Adrenergic receptor alpha-2A (ADRA2A) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83KP DI DMU83KP DMU83KP DN 1-((S)-2-aminopropyl)-1H-indazol-6-ol DMU83KP TI TT07C3Y DMU83KP TN 5-HT 4 receptor (HTR4) DMU83KP MA Inhibitor DMU83KP RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMU83KP RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMU83T7 DI DMU83T7 DMU83T7 DN D-193 DMU83T7 TI TT4C8EA DMU83T7 TN Dopamine D3 receptor (D3R) DMU83T7 MA Inhibitor DMU83T7 RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMU83T7 RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMU83T7 DI DMU83T7 DMU83T7 DN D-193 DMU83T7 TI TTEX248 DMU83T7 TN Dopamine D2 receptor (D2R) DMU83T7 MA Inhibitor DMU83T7 RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMU83T7 RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMU89FH DI DMU89FH DMU89FH DN N-[3-(2-Ethyl-benzooxazol-7-yl)-propyl]-acetamide DMU89FH TI TT32JK8 DMU89FH TN Melatonin receptor type 1B (MTNR1B) DMU89FH MA Inhibitor DMU89FH RN Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802. DMU89FH RU https://pubmed.ncbi.nlm.nih.gov/15203165 DMU8BJH DI DMU8BJH DMU8BJH DN D-189 DMU8BJH TI TT4C8EA DMU8BJH TN Dopamine D3 receptor (D3R) DMU8BJH MA Inhibitor DMU8BJH RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMU8BJH RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMU8BJH DI DMU8BJH DMU8BJH DN D-189 DMU8BJH TI TTEX248 DMU8BJH TN Dopamine D2 receptor (D2R) DMU8BJH MA Inhibitor DMU8BJH RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMU8BJH RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMU8KGB DI DMU8KGB DMU8KGB DN SBB007833 DMU8KGB TI TT6PKBN DMU8KGB TN Proto-oncogene c-Src (SRC) DMU8KGB MA Inhibitor DMU8KGB RN Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11. DMU8KGB RU https://pubmed.ncbi.nlm.nih.gov/17601492 DMU8KGB DI DMU8KGB DMU8KGB DN SBB007833 DMU8KGB TI TTOU65C DMU8KGB TN Tyrosine-protein kinase SYK (SYK) DMU8KGB MA Inhibitor DMU8KGB RN Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007 Aug 15;74(4):601-11. DMU8KGB RU https://pubmed.ncbi.nlm.nih.gov/17601492 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TTK3PY9 DMU8KTO TN DNA-dependent protein kinase catalytic (PRKDC) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TTCJG29 DMU8KTO TN Serine/threonine-protein kinase mTOR (mTOR) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TT6PKBN DMU8KTO TN Proto-oncogene c-Src (SRC) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TTUTJGQ DMU8KTO TN Vascular endothelial growth factor receptor 2 (KDR) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TTHBTOP DMU8KTO TN PI3-kinase gamma (PIK3CG) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TT8FYO9 DMU8KTO TN Platelet-derived growth factor receptor alpha (PDGFRA) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TT6B75U DMU8KTO TN ABL messenger RNA (ABL mRNA) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TT42OGM DMU8KTO TN Hematopoietic cell kinase (HCK) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TTTHBCA DMU8KTO TN PI3-kinase beta (PIK3CB) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8KTO DI DMU8KTO DMU8KTO DN PP121 DMU8KTO TI TTGKNB4 DMU8KTO TN Epidermal growth factor receptor (EGFR) DMU8KTO MA Inhibitor DMU8KTO RN Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. DMU8KTO RU https://pubmed.ncbi.nlm.nih.gov/18849971 DMU8L7C DI DMU8L7C DMU8L7C DN Mepacrine DMU8L7C TI TT9V5JH DMU8L7C TN Phospholipase A2 (PLA2G1B) DMU8L7C MA Inhibitor DMU8L7C RN Involvement of protein kinase C activation in L-leucine-induced stimulation of protein synthesis in l6 myotubes. Cytotechnology. 2003 Nov;43(1-3):97-103. DMU8L7C RU https://pubmed.ncbi.nlm.nih.gov/19003213 DMU8M0I DI DMU8M0I DMU8M0I DN AMG-8563 DMU8M0I TI TTMI6F5 DMU8M0I TN Transient receptor potential cation channel V1 (TRPV1) DMU8M0I MA Blocker DMU8M0I RN Analgesic potential of TRPV1 antagonists. Biochem Pharmacol. 2009 Aug 1;78(3):211-6. DMU8M0I RU https://pubmed.ncbi.nlm.nih.gov/19481638 DMU8VRB DI DMU8VRB DMU8VRB DN MK-5435 DMU8VRB TI TTVBPDM DMU8VRB TN Metabotropic glutamate receptor 1 (mGluR1) DMU8VRB MA Modulator (allosteric modulator) DMU8VRB RN Synthesis, characterization, and monkey PET studies of [ ]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435. Synapse. 2011 Feb;65(2):125-35. DMU8VRB RU https://pubmed.ncbi.nlm.nih.gov/20524178 DMU92RC DI DMU92RC DMU92RC DN GI-3000 DMU92RC TI TTGKNB4 DMU92RC TN Epidermal growth factor receptor (EGFR) DMU92RC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMU92RC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMU965M DI DMU965M DMU965M DN A-794282 DMU965M TI TTVBPDM DMU965M TN Metabotropic glutamate receptor 1 (mGluR1) DMU965M MA Modulator (allosteric modulator) DMU965M RN Structure-activity relationship of triazafluorenone derivatives as potent and selective mGluR1 antagonists. J Med Chem. 2005 Nov 17;48(23):7374-88. DMU965M RU https://pubmed.ncbi.nlm.nih.gov/16279797 DMU98ES DI DMU98ES DMU98ES DN Affinitak + Gemcitabine DMU98ES TI TT2MI95 DMU98ES TN PKC-alpha messenger RNA (PRKCA mRNA) DMU98ES RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMU98ES RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMU9F2P DI DMU9F2P DMU9F2P DN [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, DMU9F2P TI TTELIN2 DMU9F2P TN PTPN1 messenger RNA (PTPN1 mRNA) DMU9F2P MA Inhibitor DMU9F2P RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMU9F2P RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMU9F7K DI DMU9F7K DMU9F7K DN S-2-(o-toluidino)-2-oxoethyl carbamothioate DMU9F7K TI TTULVH8 DMU9F7K TN Tyrosinase (TYR) DMU9F7K MA Inhibitor DMU9F7K RN Discovery of small-molecule inhibitors of tyrosinase. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6871-5. DMU9F7K RU https://pubmed.ncbi.nlm.nih.gov/17964155 DMU9LQW DI DMU9LQW DMU9LQW DN BWA868C DMU9LQW TI TTNVEIR DMU9LQW TN Prostaglandin D2 receptor (PTGDR) DMU9LQW MA Antagonist DMU9LQW RN Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Br J Pharmacol. 2000 Nov;131(6):1025-38. DMU9LQW RU https://pubmed.ncbi.nlm.nih.gov/11082108 DMU9O7K DI DMU9O7K DMU9O7K DN Acenanthrene-9,10-dione DMU9O7K TI TTMF541 DMU9O7K TN Liver carboxylesterase (CES1) DMU9O7K MA Inhibitor DMU9O7K RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMU9O7K RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMU9T3A DI DMU9T3A DMU9T3A DN 1-(2-bromophenyl)-3-(4-cyano-2-hydroxyphenyl)urea DMU9T3A TI TT30C9G DMU9T3A TN C-X-C chemokine receptor type 2 (CXCR2) DMU9T3A MA Inhibitor DMU9T3A RN Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1713-7. DMU9T3A RU https://pubmed.ncbi.nlm.nih.gov/17236763 DMU9VQJ DI DMU9VQJ DMU9VQJ DN VL-1499 DMU9VQJ TI TTCG0AL DMU9VQJ TN Cholecystokinin receptor type A (CCKAR) DMU9VQJ MA Inhibitor DMU9VQJ RN 2D-QSAR and 3D-QSAR/CoMFA analyses of the N-terminal substituted anthranilic acid based CCK(1) receptor antagonists: 'Hic Rhodus, hic saltus'. Bioorg Med Chem. 2009 Jul 15;17(14):5198-206. DMU9VQJ RU https://pubmed.ncbi.nlm.nih.gov/19523833 DMU9WG0 DI DMU9WG0 DMU9WG0 DN 6-bromo-1H-indazole DMU9WG0 TI TTZUFI5 DMU9WG0 TN Nitric-oxide synthase brain (NOS1) DMU9WG0 MA Inhibitor DMU9WG0 RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DMU9WG0 RU https://pubmed.ncbi.nlm.nih.gov/17395463 DMU9WGT DI DMU9WGT DMU9WGT DN 3-Phenyl-1,2-Propandiol DMU9WGT TI TTB2MXP DMU9WGT TN Angiotensinogenase renin (REN) DMU9WGT MA Inhibitor DMU9WGT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMU9WGT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMU9YF6 DI DMU9YF6 DMU9YF6 DN N-(1-phenethylpiperidin-4-yl)-1-naphthamide DMU9YF6 TI TTJQOD7 DMU9YF6 TN 5-HT 2A receptor (HTR2A) DMU9YF6 MA Inhibitor DMU9YF6 RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9. DMU9YF6 RU https://pubmed.ncbi.nlm.nih.gov/17254782 DMUA485 DI DMUA485 DMUA485 DN EUGENIIN DMUA485 TI TTE14XG DMUA485 TN Squalene monooxygenase (SQLE) DMUA485 MA Inhibitor DMUA485 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMUA485 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMUA72F DI DMUA72F DMUA72F DN 1-phenyl-3-aza-bicyclo[3.1.0]hexane DMUA72F TI TTVBI8W DMUA72F TN Dopamine transporter (DAT) DMUA72F MA Inhibitor DMUA72F RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMUA72F RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMUA72F DI DMUA72F DMUA72F DN 1-phenyl-3-aza-bicyclo[3.1.0]hexane DMUA72F TI TT3ROYC DMUA72F TN Serotonin transporter (SERT) DMUA72F MA Inhibitor DMUA72F RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMUA72F RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMUA751 DI DMUA751 DMUA751 DN VUF5574 DMUA751 TI TTJFY5U DMUA751 TN Adenosine A3 receptor (ADORA3) DMUA751 MA Antagonist DMUA751 RN Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. J Med Chem. 2000 Jun 1;43(11):2227-38. DMUA751 RU https://pubmed.ncbi.nlm.nih.gov/10841801 DMUA751 DI DMUA751 DMUA751 DN VUF5574 DMUA751 TI TTK25J1 DMUA751 TN Adenosine A1 receptor (ADORA1) DMUA751 MA Antagonist DMUA751 RN A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J Med Chem. 1998 Oct 8;41(21):3987-93. DMUA751 RU https://pubmed.ncbi.nlm.nih.gov/9767636 DMUA751 DI DMUA751 DMUA751 DN VUF5574 DMUA751 TI TTNE7KG DMUA751 TN Adenosine A2b receptor (ADORA2B) DMUA751 MA Antagonist DMUA751 RN A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J Med Chem. 1998 Oct 8;41(21):3987-93. DMUA751 RU https://pubmed.ncbi.nlm.nih.gov/9767636 DMUACDH DI DMUACDH DMUACDH DN (+/-)-threo-N-Benzylmethylphenidate amide DMUACDH TI TTVBI8W DMUACDH TN Dopamine transporter (DAT) DMUACDH MA Inhibitor DMUACDH RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMUACDH RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMUACZF DI DMUACZF DMUACZF DN (1-Amino-ethyl)-phosphinic acid DMUACZF TI TTPHMWB DMUACZF TN Aminopeptidase N (ANPEP) DMUACZF MA Inhibitor DMUACZF RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMUACZF RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMUADN4 DI DMUADN4 DMUADN4 DN 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione DMUADN4 TI TTLD29N DMUADN4 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMUADN4 MA Inhibitor DMUADN4 RN 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. DMUADN4 RU https://pubmed.ncbi.nlm.nih.gov/15081038 DMUADN4 DI DMUADN4 DMUADN4 DN 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione DMUADN4 TI TTN9D8E DMUADN4 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMUADN4 MA Inhibitor DMUADN4 RN 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. DMUADN4 RU https://pubmed.ncbi.nlm.nih.gov/15081038 DMUADN4 DI DMUADN4 DMUADN4 DN 5,7-Dichloro-3-hydroxy-1H-quinazoline-2,4-dione DMUADN4 TI TTKJEMQ DMUADN4 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMUADN4 MA Inhibitor DMUADN4 RN 3-hydroxy-quinazoline-2,4-dione as a useful scaffold to obtain selective Gly/NMDA and AMPA receptor antagonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2345-9. DMUADN4 RU https://pubmed.ncbi.nlm.nih.gov/15081038 DMUANX1 DI DMUANX1 DMUANX1 DN 2-(4-amino-2-chlorophenoxy)-5-chlorophenol DMUANX1 TI TTNX2CS DMUANX1 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMUANX1 MA Inhibitor DMUANX1 RN Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52. DMUANX1 RU https://pubmed.ncbi.nlm.nih.gov/16198563 DMUAQYZ DI DMUAQYZ DMUAQYZ DN sakuranetin DMUAQYZ TI TTNE7KG DMUAQYZ TN Adenosine A2b receptor (ADORA2B) DMUAQYZ MA Antagonist DMUAQYZ RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMUAQYZ RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMUAQYZ DI DMUAQYZ DMUAQYZ DN sakuranetin DMUAQYZ TI TTK25J1 DMUAQYZ TN Adenosine A1 receptor (ADORA1) DMUAQYZ MA Antagonist DMUAQYZ RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMUAQYZ RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMUAQYZ DI DMUAQYZ DMUAQYZ DN sakuranetin DMUAQYZ TI TTJFY5U DMUAQYZ TN Adenosine A3 receptor (ADORA3) DMUAQYZ MA Antagonist DMUAQYZ RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMUAQYZ RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMUAYWX DI DMUAYWX DMUAYWX DN FUB 349 DMUAYWX TI TT9JNIC DMUAYWX TN Histamine H3 receptor (H3R) DMUAYWX MA Antagonist DMUAYWX RN Distinct pharmacology of rat and human histamine H(3) receptors: role of two amino acids in the third transmembrane domain. Br J Pharmacol. 2000 Dec;131(7):1247-50. DMUAYWX RU https://pubmed.ncbi.nlm.nih.gov/11090094 DMUAYZJ DI DMUAYZJ DMUAYZJ DN (S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMUAYZJ TI TTAWNKZ DMUAYZJ TN Norepinephrine transporter (NET) DMUAYZJ MA Inhibitor DMUAYZJ RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMUAYZJ RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMUAYZJ DI DMUAYZJ DMUAYZJ DN (S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide DMUAYZJ TI TT3ROYC DMUAYZJ TN Serotonin transporter (SERT) DMUAYZJ MA Inhibitor DMUAYZJ RN Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. DMUAYZJ RU https://pubmed.ncbi.nlm.nih.gov/19740658 DMUB0EJ DI DMUB0EJ DMUB0EJ DN Pyrazolo[1,5-a]pyrimidine 3G DMUB0EJ TI TTUTJGQ DMUB0EJ TN Vascular endothelial growth factor receptor 2 (KDR) DMUB0EJ MA Inhibitor DMUB0EJ RN Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharm... Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41. DMUB0EJ RU https://pubmed.ncbi.nlm.nih.gov/12443771 DMUB187 DI DMUB187 DMUB187 DN Isochroman mono-carboxylic acid DMUB187 TI TTELIN2 DMUB187 TN PTPN1 messenger RNA (PTPN1 mRNA) DMUB187 MA Inhibitor DMUB187 RN Synthesis and evaluation of some novel dibenzo[b,d]furan carboxylic acids as potential anti-diabetic agents. Eur J Med Chem. 2010 Sep;45(9):3709-18. DMUB187 RU https://pubmed.ncbi.nlm.nih.gov/20627471 DMUB5E8 DI DMUB5E8 DMUB5E8 DN 7,8-dihydroxy-4-phenyl-2H-chromen-2-one DMUB5E8 TI TTKWFB8 DMUB5E8 TN Catechol-O-methyl-transferase (COMT) DMUB5E8 MA Inhibitor DMUB5E8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUB5E8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUB7KH DI DMUB7KH DMUB7KH DN 2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol DMUB7KH TI TTOM3J0 DMUB7KH TN Estrogen receptor beta (ESR2) DMUB7KH MA Inhibitor DMUB7KH RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMUB7KH RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMUB7KH DI DMUB7KH DMUB7KH DN 2-(4-Hydroxy-phenyl)-7-phenyl-benzooxazol-5-ol DMUB7KH TI TTZAYWL DMUB7KH TN Estrogen receptor (ESR) DMUB7KH MA Inhibitor DMUB7KH RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMUB7KH RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMUB9XW DI DMUB9XW DMUB9XW DN 3-cyano-N-(6-ethylpyridin-2-yl)-5-fluorobenzamide DMUB9XW TI TTHS256 DMUB9XW TN Metabotropic glutamate receptor 5 (mGluR5) DMUB9XW MA Inhibitor DMUB9XW RN 3-Cyano-5-fluoro-N-arylbenzamides as negative allosteric modulators of mGlu(5): Identification of easily prepared tool compounds with CNS exposure ... Bioorg Med Chem Lett. 2010 Aug 1;20(15):4390-4. DMUB9XW RU https://pubmed.ncbi.nlm.nih.gov/20598884 DMUBCVL DI DMUBCVL DMUBCVL DN 5-Phenyl-6-thia-10b-aza-benzo[e]azulene DMUBCVL TI TTPTXIN DMUBCVL TN Translocator protein (TSPO) DMUBCVL MA Inhibitor DMUBCVL RN A concerted study using binding measurements, X-ray structural data, and molecular modeling on the stereochemical features responsible for the affi... J Med Chem. 1995 Nov 10;38(23):4730-8. DMUBCVL RU https://pubmed.ncbi.nlm.nih.gov/7473601 DMUBF53 DI DMUBF53 DMUBF53 DN LS-192629 DMUBF53 TI TT4TFGN DMUBF53 TN Vasopressin V1a receptor (V1AR) DMUBF53 MA Antagonist DMUBF53 RN Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a ... J Pharmacol Exp Ther. 2003 Jul;306(1):253-61. DMUBF53 RU https://pubmed.ncbi.nlm.nih.gov/12660315 DMUBF53 DI DMUBF53 DMUBF53 DN LS-192629 DMUBF53 TI TTSCIUP DMUBF53 TN Oxytocin receptor (OTR) DMUBF53 MA Antagonist DMUBF53 RN Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a ... J Pharmacol Exp Ther. 2003 Jul;306(1):253-61. DMUBF53 RU https://pubmed.ncbi.nlm.nih.gov/12660315 DMUBHRF DI DMUBHRF DMUBHRF DN 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine DMUBHRF TI TTAWNKZ DMUBHRF TN Norepinephrine transporter (NET) DMUBHRF MA Inhibitor DMUBHRF RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMUBHRF RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMUBHRF DI DMUBHRF DMUBHRF DN 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine DMUBHRF TI TTSQIFT DMUBHRF TN 5-HT 1A receptor (HTR1A) DMUBHRF MA Inhibitor DMUBHRF RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMUBHRF RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMUBHRF DI DMUBHRF DMUBHRF DN 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine DMUBHRF TI TT3ROYC DMUBHRF TN Serotonin transporter (SERT) DMUBHRF MA Inhibitor DMUBHRF RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMUBHRF RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMUBHRF DI DMUBHRF DMUBHRF DN 4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine DMUBHRF TI TTVBI8W DMUBHRF TN Dopamine transporter (DAT) DMUBHRF MA Inhibitor DMUBHRF RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMUBHRF RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMUBM8X DI DMUBM8X DMUBM8X DN A438079 DMUBM8X TI TT473XN DMUBM8X TN P2X purinoceptor 7 (P2RX7) DMUBM8X MA Antagonist DMUBM8X RN Discovery of P2X7 receptor-selective antagonists offers new insights into P2X7 receptor function and indicates a role in chronic pain states. Br J Pharmacol. 2007 Jul;151(5):571-9. DMUBM8X RU https://pubmed.ncbi.nlm.nih.gov/17471177 DMUBO3E DI DMUBO3E DMUBO3E DN fenclonine DMUBO3E TI TT3KLDP DMUBO3E TN L-Tryptophan hydroxylase 2 (TPH2) DMUBO3E MA Inhibitor DMUBO3E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1242). DMUBO3E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1242 DMUBO3E DI DMUBO3E DMUBO3E DN fenclonine DMUBO3E TI TTGSVH2 DMUBO3E TN Phenylalanine hydroxylase (PAH) DMUBO3E MA Inhibitor DMUBO3E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1240). DMUBO3E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1240 DMUBO3E DI DMUBO3E DMUBO3E DN fenclonine DMUBO3E TI TTZSJHV DMUBO3E TN Tryptophan 5-hydroxylase 1 (TPH1) DMUBO3E MA Inhibitor DMUBO3E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1241). DMUBO3E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1241 DMUC0F5 DI DMUC0F5 DMUC0F5 DN G(D-Pen)-G-H-R-G-D-L-R-C-A DMUC0F5 TI TTT1R2L DMUC0F5 TN Integrin alpha-V (ITGAV) DMUC0F5 MA Inhibitor DMUC0F5 RN Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin alpha IIb beta 3 antagonists. J Med Chem. 1994 Jan 7;37(1):1-8. DMUC0F5 RU https://pubmed.ncbi.nlm.nih.gov/7507165 DMUC3L0 DI DMUC3L0 DMUC3L0 DN ISIS 104258 DMUC3L0 TI TTCQ2E5 DMUC3L0 TN RIP2 messenger RNA (RIP2 mRNA) DMUC3L0 RN US patent application no. 6,426,221, Antisense modulation of RIP2 expression. DMUC3L0 RU http://www.patentbuddy.com/Patent/6426221?ft=true&sr=true DMUCAXT DI DMUCAXT DMUCAXT DN [Aib7]OT DMUCAXT TI TTSCIUP DMUCAXT TN Oxytocin receptor (OTR) DMUCAXT MA Inhibitor DMUCAXT RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMUCAXT RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMUCE93 DI DMUCE93 DMUCE93 DN MAP4 DMUCE93 TI TT0IFKL DMUCE93 TN Metabotropic glutamate receptor 8 (mGluR8) DMUCE93 MA Antagonist DMUCE93 RN Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors. Brain Res Mol Brain Res. 2000 Mar 10;76(1):180-90. DMUCE93 RU https://pubmed.ncbi.nlm.nih.gov/10719229 DMUCE93 DI DMUCE93 DMUCE93 DN MAP4 DMUCE93 TI TT0I76D DMUCE93 TN Metabotropic glutamate receptor 7 (mGluR7) DMUCE93 MA Antagonist DMUCE93 RN Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes. Naunyn Schmiedebergs Arch Pharmacol. 2000 Dec;362(6):546-54. DMUCE93 RU https://pubmed.ncbi.nlm.nih.gov/11138847 DMUCE93 DI DMUCE93 DMUCE93 DN MAP4 DMUCE93 TI TTWRP2F DMUCE93 TN Metabotropic glutamate receptor 6 (mGluR6) DMUCE93 MA Antagonist DMUCE93 RN The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):297-317. DMUCE93 RU https://pubmed.ncbi.nlm.nih.gov/12769621 DMUCE93 DI DMUCE93 DMUCE93 DN MAP4 DMUCE93 TI TTICZ1O DMUCE93 TN Metabotropic glutamate receptor 4 (mGluR4) DMUCE93 MA Antagonist DMUCE93 RN Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13. DMUCE93 RU https://pubmed.ncbi.nlm.nih.gov/10187777 DMUCGK8 DI DMUCGK8 DMUCGK8 DN WR-080539 DMUCGK8 TI TTSFWA7 DMUCGK8 TN Plasmodium CDK Pfmrk (Malaria Pfmrk) DMUCGK8 MA Inhibitor DMUCGK8 RN Selective inhibition of Pfmrk, a Plasmodium falciparum CDK, by antimalarial 1,3-diaryl-2-propenones. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1982-5. DMUCGK8 RU https://pubmed.ncbi.nlm.nih.gov/19250824 DMUCHNP DI DMUCHNP DMUCHNP DN SB-213068 DMUCHNP TI TTT2SVW DMUCHNP TN PPAR-gamma messenger RNA (PPARG mRNA) DMUCHNP MA Inhibitor DMUCHNP RN Non thiazolidinedione antihyperglycaemic agents. 2: alpha-Carbon substituted beta-phenylpropanoic acids1, Bioorg. Med. Chem. Lett. 6(17):2127-2130 (1996). DMUCHNP RU http://www.sciencedirect.com/science/article/pii/0960894X96003824 DMUCJA6 DI DMUCJA6 DMUCJA6 DN 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMUCJA6 TI TTZUFI5 DMUCJA6 TN Nitric-oxide synthase brain (NOS1) DMUCJA6 MA Inhibitor DMUCJA6 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMUCJA6 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMUCJA6 DI DMUCJA6 DMUCJA6 DN 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMUCJA6 TI TTF10I9 DMUCJA6 TN Nitric-oxide synthase inducible (NOS2) DMUCJA6 MA Inhibitor DMUCJA6 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMUCJA6 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMUCJA6 DI DMUCJA6 DMUCJA6 DN 7-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMUCJA6 TI TTCM4B3 DMUCJA6 TN Nitric-oxide synthase endothelial (NOS3) DMUCJA6 MA Inhibitor DMUCJA6 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMUCJA6 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMUCLAV DI DMUCLAV DMUCLAV DN 5-Fluoro-2-sulfanyl-phenylphosphonic acid DMUCLAV TI TTHI19T DMUCLAV TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMUCLAV MA Inhibitor DMUCLAV RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMUCLAV RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMUCZ3F DI DMUCZ3F DMUCZ3F DN Kaempferol-3-O-(2''-O-galloyl)-glucoside DMUCZ3F TI TTL69WB DMUCZ3F TN Angiotensin-converting enzyme (ACE) DMUCZ3F MA Inhibitor DMUCZ3F RN Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3. DMUCZ3F RU https://pubmed.ncbi.nlm.nih.gov/3430165 DMUCZPJ DI DMUCZPJ DMUCZPJ DN ENDG-4010 DMUCZPJ TI TT3ZTGU DMUCZPJ TN Endothelin B receptor (EDNRB) DMUCZPJ MA Modulator DMUCZPJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 220). DMUCZPJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220 DMUD0LA DI DMUD0LA DMUD0LA DN [Sar1Ala]GAL-B2 DMUD0LA TI TTX3HNZ DMUD0LA TN Galanin receptor type 1 (GAL1-R) DMUD0LA MA Inhibitor DMUD0LA RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMUD0LA RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMUD0LA DI DMUD0LA DMUD0LA DN [Sar1Ala]GAL-B2 DMUD0LA TI TTBPW3J DMUD0LA TN Galanin receptor type 2 (GAL2-R) DMUD0LA MA Inhibitor DMUD0LA RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMUD0LA RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMUD1CG DI DMUD1CG DMUD1CG DN 6-Hydroxy-1,6-Dihydro Purine Nucleoside DMUD1CG TI TTLP57V DMUD1CG TN Adenosine deaminase (ADA) DMUD1CG MA Inhibitor DMUD1CG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUD1CG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUD2R9 DI DMUD2R9 DMUD2R9 DN 6-(2-benzylisoindolin-5-yloxy)nicotinamide DMUD2R9 TI TTKWM86 DMUD2R9 TN Opioid receptor mu (MOP) DMUD2R9 MA Inhibitor DMUD2R9 RN Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6. DMUD2R9 RU https://pubmed.ncbi.nlm.nih.gov/17980586 DMUD3A8 DI DMUD3A8 DMUD3A8 DN [125I]resiniferatoxin DMUD3A8 TI TTMI6F5 DMUD3A8 TN Transient receptor potential cation channel V1 (TRPV1) DMUD3A8 MA Blocker (channel blocker) DMUD3A8 RN Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol. 2001 Jan;59(1):9-15. DMUD3A8 RU https://pubmed.ncbi.nlm.nih.gov/11125018 DMUD85N DI DMUD85N DMUD85N DN N-Benzyl-4-(2,5-dihydroxy-benzylamino)-benzamide DMUD85N TI TTOU65C DMUD85N TN Tyrosine-protein kinase SYK (SYK) DMUD85N MA Inhibitor DMUD85N RN Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin ... J Med Chem. 2001 Feb 1;44(3):441-52. DMUD85N RU https://pubmed.ncbi.nlm.nih.gov/11462983 DMUDFZN DI DMUDFZN DMUDFZN DN ISIS 109114 DMUDFZN TI TTQSMFG DMUDFZN TN Talin messenger RNA (TLN1 mRNA) DMUDFZN RN US patent application no. 6,372,492, Antisense modulation of talin expression. DMUDFZN RU http://www.patentbuddy.com/Patent/6372492?ft=true&sr=true DMUDGSN DI DMUDGSN DMUDGSN DN THYMELEATOXIN DMUDGSN TI TT9WJ8U DMUDGSN TN Protein kinase C delta (PRKCD) DMUDGSN MA Inhibitor DMUDGSN RN Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method a... J Med Chem. 2001 May 24;44(11):1690-701. DMUDGSN RU https://pubmed.ncbi.nlm.nih.gov/11356104 DMUDS12 DI DMUDS12 DMUDS12 DN Isosorbide-2-(butylcarbamate)-5-mononitrate DMUDS12 TI TTEB0GD DMUDS12 TN Cholinesterase (BCHE) DMUDS12 MA Inhibitor DMUDS12 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMUDS12 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMUDVRM DI DMUDVRM DMUDVRM DN 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine DMUDVRM TI TT4C8EA DMUDVRM TN Dopamine D3 receptor (D3R) DMUDVRM MA Inhibitor DMUDVRM RN Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9. DMUDVRM RU https://pubmed.ncbi.nlm.nih.gov/16563764 DMUDVRM DI DMUDVRM DMUDVRM DN 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine DMUDVRM TI TTEX248 DMUDVRM TN Dopamine D2 receptor (D2R) DMUDVRM MA Inhibitor DMUDVRM RN Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9. DMUDVRM RU https://pubmed.ncbi.nlm.nih.gov/16563764 DMUDVRM DI DMUDVRM DMUDVRM DN 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine DMUDVRM TI TTE0A2F DMUDVRM TN Dopamine D4 receptor (D4R) DMUDVRM MA Inhibitor DMUDVRM RN Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9. DMUDVRM RU https://pubmed.ncbi.nlm.nih.gov/16563764 DMUDVRM DI DMUDVRM DMUDVRM DN 1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine DMUDVRM TI TTZFYLI DMUDVRM TN Dopamine D1 receptor (D1R) DMUDVRM MA Inhibitor DMUDVRM RN Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9. DMUDVRM RU https://pubmed.ncbi.nlm.nih.gov/16563764 DMUDW1J DI DMUDW1J DMUDW1J DN 3-(2,5-dimethyl-1H-pyrrol-1-yl)benzoic acid DMUDW1J TI TTIQSC1 DMUDW1J TN Bacterial Lethal factor (Bact lef) DMUDW1J MA Inhibitor DMUDW1J RN Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening. J Med Chem. 2006 Aug 24;49(17):5232-44. DMUDW1J RU https://pubmed.ncbi.nlm.nih.gov/16913712 DMUDY7H DI DMUDY7H DMUDY7H DN PDC-31 DMUDY7H TI TTT2ZAR DMUDY7H TN Prostaglandin F2-alpha receptor (PTGFR) DMUDY7H MA Antagonist DMUDY7H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 344). DMUDY7H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=344 DMUE0D6 DI DMUE0D6 DMUE0D6 DN 2-(1,1'-Biphenyl-4-Yl)Propanoic Acid DMUE0D6 TI TT8NGED DMUE0D6 TN Prostaglandin G/H synthase 1 (COX-1) DMUE0D6 MA Inhibitor DMUE0D6 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUE0D6 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUE0W6 DI DMUE0W6 DMUE0W6 DN 2MeSATP DMUE0W6 TI TTYXPCO DMUE0W6 TN P2Y purinoceptor 11 (P2RY11) DMUE0W6 MA Agonist DMUE0W6 RN Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206. DMUE0W6 RU https://pubmed.ncbi.nlm.nih.gov/10578132 DMUE0W6 DI DMUE0W6 DMUE0W6 DN 2MeSATP DMUE0W6 TI TTNVSKA DMUE0W6 TN P2Y purinoceptor 6 (P2RY6) DMUE0W6 MA Agonist DMUE0W6 RN Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8. DMUE0W6 RU https://pubmed.ncbi.nlm.nih.gov/8670200 DMUE0W6 DI DMUE0W6 DMUE0W6 DN 2MeSATP DMUE0W6 TI TTA93TL DMUE0W6 TN P2Y purinoceptor 1 (P2RY1) DMUE0W6 MA Agonist DMUE0W6 RN Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57. DMUE0W6 RU https://pubmed.ncbi.nlm.nih.gov/12391289 DMUE0W6 DI DMUE0W6 DMUE0W6 DN 2MeSATP DMUE0W6 TI TT1FE3L DMUE0W6 TN P2Y purinoceptor 13 (P2RY13) DMUE0W6 MA Agonist DMUE0W6 RN Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. DMUE0W6 RU https://pubmed.ncbi.nlm.nih.gov/12815166 DMUE15B DI DMUE15B DMUE15B DN 8-(1,2-Dimethyl-propoxy)-quinolin-2-ylamine DMUE15B TI TTX4RTB DMUE15B TN Melanin-concentrating hormone receptor 1 (MCHR1) DMUE15B MA Inhibitor DMUE15B RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMUE15B RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMUE4K3 DI DMUE4K3 DMUE4K3 DN 4,5,6,7-tetrabromo-1H-benzimidazole DMUE4K3 TI TTER6YH DMUE4K3 TN Casein kinase II alpha (CSNK2A1) DMUE4K3 MA Inhibitor DMUE4K3 RN Synthesis of new analogs of benzotriazole, benzimidazole and phthalimide--potential inhibitors of human protein kinase CK2. Bioorg Med Chem. 2009 Feb 15;17(4):1573-8. DMUE4K3 RU https://pubmed.ncbi.nlm.nih.gov/19168362 DMUE64H DI DMUE64H DMUE64H DN ISIS 107676 DMUE64H TI TT6SZNG DMUE64H TN Caspase 8 messenger RNA (CASP8 mRNA) DMUE64H RN US patent application no. 6,258,600, Antisense modulation of caspase 8 expression. DMUE64H RU http://www.patentbuddy.com/Patent/6258600?ft=true&sr=true DMUEBRN DI DMUEBRN DMUEBRN DN Ac-His-DNal(2)-Arg-Trp-NH2 DMUEBRN TI TTEOSZT DMUEBRN TN Melanocortin receptor (MCR) DMUEBRN MA Inhibitor DMUEBRN RN Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93. DMUEBRN RU https://pubmed.ncbi.nlm.nih.gov/18800761 DMUEDBP DI DMUEDBP DMUEDBP DN PMID25815140C48 DMUEDBP TI TTVP9IQ DMUEDBP TN Solute carrier family 28 member 2 (SLC28A2) DMUEDBP MA Inhibitor DMUEDBP RN Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors. ACS Med Chem Lett. 2015 Jan 28;6(3):244-8. DMUEDBP RU https://pubmed.ncbi.nlm.nih.gov/25815140 DMUEFDM DI DMUEFDM DMUEFDM DN 6,8-Dichloro-1,2,3,4-tetrahydro-acridin-9-ylamine DMUEFDM TI TT1RS9F DMUEFDM TN Acetylcholinesterase (AChE) DMUEFDM MA Inhibitor DMUEFDM RN Novel and potent tacrine-related hetero- and homobivalent ligands for acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1779-82. DMUEFDM RU https://pubmed.ncbi.nlm.nih.gov/11425559 DMUEG8O DI DMUEG8O DMUEG8O DN PMID7966163C6c DMUEG8O TI TTFQEO5 DMUEG8O TN Squalene synthetase (FDFT1) DMUEG8O MA Inhibitor DMUEG8O RN Structure-activity relationships of C1 and C6 side chains of zaragozic acid A derivatives. J Med Chem. 1994 Nov 11;37(23):4031-51. DMUEG8O RU https://pubmed.ncbi.nlm.nih.gov/7966163 DMUEK1N DI DMUEK1N DMUEK1N DN Palodesangren E DMUEK1N TI TTS64P2 DMUEK1N TN Androgen receptor (AR) DMUEK1N MA Inhibitor DMUEK1N RN Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002. DMUEK1N RU https://pubmed.ncbi.nlm.nih.gov/9358642 DMUEKB3 DI DMUEKB3 DMUEKB3 DN pyrrolopyrimidine 48 DMUEKB3 TI TT4G2JS DMUEKB3 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUEKB3 MA Blocker (channel blocker) DMUEKB3 RN Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists. Bioorg Med Chem Lett. 2012 Mar 1;22(5):2052-62. DMUEKB3 RU https://pubmed.ncbi.nlm.nih.gov/22318156 DMUEQC8 DI DMUEQC8 DMUEQC8 DN 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane DMUEQC8 TI TT3ROYC DMUEQC8 TN Serotonin transporter (SERT) DMUEQC8 MA Inhibitor DMUEQC8 RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMUEQC8 RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMUEQC8 DI DMUEQC8 DMUEQC8 DN 1-(naphthalen-2-yl)-3-aza-bicyclo[3.1.0]hexane DMUEQC8 TI TTVBI8W DMUEQC8 TN Dopamine transporter (DAT) DMUEQC8 MA Inhibitor DMUEQC8 RN Studies on the structure-activity relationship of bicifadine analogs as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Jul 1;18(13):3682-6. DMUEQC8 RU https://pubmed.ncbi.nlm.nih.gov/18539031 DMUESCH DI DMUESCH DMUESCH DN C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 DMUESCH TI TTNI91K DMUESCH TN Melanocortin receptor 3 (MC3R) DMUESCH MA Inhibitor DMUESCH RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMUESCH RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMUESCH DI DMUESCH DMUESCH DN C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 DMUESCH TI TTEOSZT DMUESCH TN Melanocortin receptor (MCR) DMUESCH MA Inhibitor DMUESCH RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMUESCH RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMUESCH DI DMUESCH DMUESCH DN C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 DMUESCH TI TT0MV2T DMUESCH TN Melanocortin receptor 1 (MC1R) DMUESCH MA Inhibitor DMUESCH RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMUESCH RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMUESCH DI DMUESCH DMUESCH DN C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2 DMUESCH TI TTD0CIQ DMUESCH TN Melanocortin receptor 4 (MC4R) DMUESCH MA Inhibitor DMUESCH RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMUESCH RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMUESP8 DI DMUESP8 DMUESP8 DN ANTIOQUINE DMUESP8 TI TTVBI8W DMUESP8 TN Dopamine transporter (DAT) DMUESP8 MA Inhibitor DMUESP8 RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DMUESP8 RU https://pubmed.ncbi.nlm.nih.gov/8676127 DMUEVAQ DI DMUEVAQ DMUEVAQ DN 3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine DMUEVAQ TI TTIQUX7 DMUEVAQ TN Steroid 11-beta-hydroxylase (CYP11B1) DMUEVAQ MA Inhibitor DMUEVAQ RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMUEVAQ RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMUEVAQ DI DMUEVAQ DMUEVAQ DN 3-[5-Bromo-indan-(1E)-ylidenemethyl]-pyridine DMUEVAQ TI TTSZLWK DMUEVAQ TN Aromatase (CYP19A1) DMUEVAQ MA Inhibitor DMUEVAQ RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMUEVAQ RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMUF16A DI DMUF16A DMUF16A DN (9H-beta-Carbolin-3-yl)-methanol DMUF16A TI TT1MPAY DMUF16A TN GABA(A) receptor alpha-1 (GABRA1) DMUF16A MA Inhibitor DMUF16A RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMUF16A RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMUF16A DI DMUF16A DMUF16A DN (9H-beta-Carbolin-3-yl)-methanol DMUF16A TI TTNJYV2 DMUF16A TN Gamma-aminobutyric acid receptor (GAR) DMUF16A MA Inhibitor DMUF16A RN Synthesis of 6-substituted beta-carbolines that behave as benzodiazepine receptor antagonists or inverse agonists. J Med Chem. 1987 Apr;30(4):750-3. DMUF16A RU https://pubmed.ncbi.nlm.nih.gov/3031296 DMUF28Q DI DMUF28Q DMUF28Q DN BAS-00387347 DMUF28Q TI TT6PKBN DMUF28Q TN Proto-oncogene c-Src (SRC) DMUF28Q MA Inhibitor DMUF28Q RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMUF28Q RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMUF28Q DI DMUF28Q DMUF28Q DN BAS-00387347 DMUF28Q TI TT3PJMV DMUF28Q TN Tyrosine-protein kinase ABL1 (ABL) DMUF28Q MA Inhibitor DMUF28Q RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMUF28Q RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMUF7DP DI DMUF7DP DMUF7DP DN [Sar,D-Phe8,des-Arg9]bradykinin DMUF7DP TI TTGY8IW DMUF7DP TN B2 bradykinin receptor (BDKRB2) DMUF7DP MA Agonist DMUF7DP RN Molecular characterisation of cloned bradykinin B1 receptors from rat and human. Eur J Pharmacol. 1999 Jun 25;374(3):423-33. DMUF7DP RU https://pubmed.ncbi.nlm.nih.gov/10422787 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TTANOZH DMUF8JZ TN SCN1A messenger RNA (SCN1A mRNA) DMUF8JZ MA Activator DMUF8JZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 578). DMUF8JZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=578 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TTAXZ0K DMUF8JZ TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMUF8JZ MA Activator DMUF8JZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580). DMUF8JZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=580 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TTLJTUF DMUF8JZ TN Voltage-gated sodium channel alpha Nav1.2 (SCN2A) DMUF8JZ MA Activator DMUF8JZ RN Binding of batrachotoxinin A 20-alpha-benzoate to a receptor site associated with sodium channels in synaptic nerve ending particles. J Biol Chem. 1981 Sep 10;256(17):8922-7. DMUF8JZ RU https://pubmed.ncbi.nlm.nih.gov/6114956 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TT54ERL DMUF8JZ TN Voltage-gated sodium channel alpha Nav1.6 (SCN8A) DMUF8JZ MA Activator DMUF8JZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 583). DMUF8JZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=583 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TTZOVE0 DMUF8JZ TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMUF8JZ MA Activator DMUF8JZ RN Sodium channel comodification with full activator reveals veratridine reaction dynamics. Mol Pharmacol. 1990 Feb;37(2):144-8. DMUF8JZ RU https://pubmed.ncbi.nlm.nih.gov/2154667 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TT84DRB DMUF8JZ TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMUF8JZ MA Activator DMUF8JZ RN Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8. DMUF8JZ RU https://pubmed.ncbi.nlm.nih.gov/9482942 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TT90XZ8 DMUF8JZ TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMUF8JZ MA Activator DMUF8JZ RN A comparison of the effects of veratridine on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels in isolated rat dorsal root ganglio... Pflugers Arch. 2008 Feb;455(5):929-38. DMUF8JZ RU https://pubmed.ncbi.nlm.nih.gov/17962978 DMUF8JZ DI DMUF8JZ DMUF8JZ DN Veratridine DMUF8JZ TI TT4G2JS DMUF8JZ TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMUF8JZ MA Activator DMUF8JZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 584). DMUF8JZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=584 DMUFC6V DI DMUFC6V DMUFC6V DN PT-113 DMUFC6V TI TT84ETX DMUFC6V TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMUFC6V MA Inhibitor DMUFC6V RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DMUFC6V RU https://pubmed.ncbi.nlm.nih.gov/8863804 DMUFDR6 DI DMUFDR6 DMUFDR6 DN Octahydrocurcumin DMUFDR6 TI TTCJUR4 DMUFDR6 TN Exportin-1 (XPO1) DMUFDR6 MA Inhibitor DMUFDR6 RN Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021 Jan;20(1):21-38. DMUFDR6 RU https://pubmed.ncbi.nlm.nih.gov/33173189 DMUFLNT DI DMUFLNT DMUFLNT DN RP-71483 DMUFLNT TI TTVFO0U DMUFLNT TN Gastrin/cholecystokinin type B receptor (CCKBR) DMUFLNT MA Modulator DMUFLNT RN Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233-45. DMUFLNT RU https://pubmed.ncbi.nlm.nih.gov/7813588 DMUFP7W DI DMUFP7W DMUFP7W DN (R)-3-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine DMUFP7W TI TT9JNIC DMUFP7W TN Histamine H3 receptor (H3R) DMUFP7W MA Inhibitor DMUFP7W RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMUFP7W RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMUFR62 DI DMUFR62 DMUFR62 DN N-benzyl-4-cyclopentylpiperazine-1-carboxamide DMUFR62 TI TT9JNIC DMUFR62 TN Histamine H3 receptor (H3R) DMUFR62 MA Inhibitor DMUFR62 RN Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5303-8. DMUFR62 RU https://pubmed.ncbi.nlm.nih.gov/16908150 DMUFSE2 DI DMUFSE2 DMUFSE2 DN 6-Benzyloxy-5-nitroso-pyrimidine-2,4-diamine DMUFSE2 TI TTJ8DV7 DMUFSE2 TN O-6-methylguanine-DNA-alkyltransferase (MGMT) DMUFSE2 MA Inhibitor DMUFSE2 RN Inhibition of human O6-alkylguanine-DNA alkyltransferase and potentiation of the cytotoxicity of chloroethylnitrosourea by 4(6)-(benzyloxy)-2,6(4)-... J Med Chem. 1998 Feb 12;41(4):503-8. DMUFSE2 RU https://pubmed.ncbi.nlm.nih.gov/9484500 DMUFV4O DI DMUFV4O DMUFV4O DN SB452533 DMUFV4O TI TTMI6F5 DMUFV4O TN Transient receptor potential cation channel V1 (TRPV1) DMUFV4O MA Blocker (channel blocker) DMUFV4O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DMUFV4O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DMUFVM6 DI DMUFVM6 DMUFVM6 DN N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 TI TT3IVG2 DMUFVM6 TN JNK2 messenger RNA (JNK2 mRNA) DMUFVM6 MA Inhibitor DMUFVM6 RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMUFVM6 RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMUFVM6 DI DMUFVM6 DMUFVM6 DN N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 TI TT7HF4W DMUFVM6 TN Cyclin-dependent kinase 2 (CDK2) DMUFVM6 MA Inhibitor DMUFVM6 RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMUFVM6 RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMUFVM6 DI DMUFVM6 DMUFVM6 DN N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 TI TT056SO DMUFVM6 TN Stress-activated protein kinase JNK3 (JNK3) DMUFVM6 MA Inhibitor DMUFVM6 RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMUFVM6 RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMUFVM6 DI DMUFVM6 DMUFVM6 DN N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 TI TT0K6EO DMUFVM6 TN Stress-activated protein kinase JNK1 (JNK1) DMUFVM6 MA Inhibitor DMUFVM6 RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMUFVM6 RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMUFVM6 DI DMUFVM6 DMUFVM6 DN N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 TI TT1F8OQ DMUFVM6 TN IKKA messenger RNA (IKKA mRNA) DMUFVM6 MA Inhibitor DMUFVM6 RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMUFVM6 RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMUFZ18 DI DMUFZ18 DMUFZ18 DN Garveatin E DMUFZ18 TI TTZJYKH DMUFZ18 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMUFZ18 MA Inhibitor DMUFZ18 RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DMUFZ18 RU https://pubmed.ncbi.nlm.nih.gov/17067170 DMUG2L9 DI DMUG2L9 DMUG2L9 DN PD-138917 DMUG2L9 TI TTVFO0U DMUG2L9 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMUG2L9 MA Inhibitor DMUG2L9 RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMUG2L9 RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMUG2PN DI DMUG2PN DMUG2PN DN ISIS 1821 DMUG2PN TI TTSJ6Q4 DMUG2PN TN LOX-5 messenger RNA (ALOX5 mRNA) DMUG2PN RN US patent application no. 5,530,114, Oligonucleotide modulation of arachidonic acid metabolism. DMUG2PN RU http://www.patentbuddy.com/Patent/5530114?ft=true&sr=true DMUG451 DI DMUG451 DMUG451 DN (R,S)-homoaromaline hydrochloride DMUG451 TI TTZFYLI DMUG451 TN Dopamine D1 receptor (D1R) DMUG451 MA Inhibitor DMUG451 RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMUG451 RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMUG4HJ DI DMUG4HJ DMUG4HJ DN ISIS 110073 DMUG4HJ TI TTK1V5Q DMUG4HJ TN Nucleolin messenger RNA (NCL mRNA) DMUG4HJ RN US patent application no. 6,165,786, Antisense modulation of nucleolin expression. DMUG4HJ RU http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true DMUG7X1 DI DMUG7X1 DMUG7X1 DN H-Dmt-Tic-D-Asp-NH-Ph DMUG7X1 TI TT27RFC DMUG7X1 TN Opioid receptor delta (OPRD1) DMUG7X1 MA Inhibitor DMUG7X1 RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMUG7X1 RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMUG7X1 DI DMUG7X1 DMUG7X1 DN H-Dmt-Tic-D-Asp-NH-Ph DMUG7X1 TI TTKWM86 DMUG7X1 TN Opioid receptor mu (MOP) DMUG7X1 MA Inhibitor DMUG7X1 RN Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17. DMUG7X1 RU https://pubmed.ncbi.nlm.nih.gov/18680274 DMUGAT8 DI DMUGAT8 DMUGAT8 DN 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol DMUGAT8 TI TTIWB6L DMUGAT8 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMUGAT8 MA Inhibitor DMUGAT8 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMUGAT8 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMUGAT8 DI DMUGAT8 DMUGAT8 DN 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol DMUGAT8 TI TTXV4FI DMUGAT8 TN Albendazole monooxygenase (CYP3A4) DMUGAT8 MA Inhibitor DMUGAT8 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMUGAT8 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMUGAT8 DI DMUGAT8 DMUGAT8 DN 2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol DMUGAT8 TI TTVG215 DMUGAT8 TN Debrisoquine 4-hydroxylase (CYP2D6) DMUGAT8 MA Inhibitor DMUGAT8 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMUGAT8 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMUGAYT DI DMUGAYT DMUGAYT DN CGNLSTCMLGTYTQDFc[DKFHK]FPQTAIGVGAP-amide DMUGAYT TI TTLWS2O DMUGAYT TN Calcitonin receptor (CALCR) DMUGAYT MA Inhibitor DMUGAYT RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMUGAYT RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMUGFS3 DI DMUGFS3 DMUGFS3 DN 4r-Fluoro-N6-Ethanimidoyl-L-Lysine DMUGFS3 TI TTF10I9 DMUGFS3 TN Nitric-oxide synthase inducible (NOS2) DMUGFS3 MA Inhibitor DMUGFS3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUGFS3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUGH6J DI DMUGH6J DMUGH6J DN 2-Phenyl-cyclopropylamine hydrochloride DMUGH6J TI TTGP7BY DMUGH6J TN Monoamine oxidase type B (MAO-B) DMUGH6J MA Inhibitor DMUGH6J RN Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxi... J Med Chem. 2004 Nov 18;47(24):5860-71. DMUGH6J RU https://pubmed.ncbi.nlm.nih.gov/15537343 DMUGHF6 DI DMUGHF6 DMUGHF6 DN 2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol DMUGHF6 TI TTZAYWL DMUGHF6 TN Estrogen receptor (ESR) DMUGHF6 MA Inhibitor DMUGHF6 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMUGHF6 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMUGHF6 DI DMUGHF6 DMUGHF6 DN 2-(4-Hydroxy-naphthalen-1-yl)-benzooxazol-6-ol DMUGHF6 TI TTOM3J0 DMUGHF6 TN Estrogen receptor beta (ESR2) DMUGHF6 MA Inhibitor DMUGHF6 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMUGHF6 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMUGMVI DI DMUGMVI DMUGMVI DN 4-Thiocyanato-benzenesulfonamide DMUGMVI TI TTANPDJ DMUGMVI TN Carbonic anhydrase II (CA-II) DMUGMVI MA Inhibitor DMUGMVI RN Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. DMUGMVI RU https://pubmed.ncbi.nlm.nih.gov/15482952 DMUGMVI DI DMUGMVI DMUGMVI DN 4-Thiocyanato-benzenesulfonamide DMUGMVI TI TTUNARX DMUGMVI TN Carbonic anhydrase (CA) DMUGMVI MA Inhibitor DMUGMVI RN Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. DMUGMVI RU https://pubmed.ncbi.nlm.nih.gov/15482952 DMUGO9M DI DMUGO9M DMUGO9M DN Ac-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 DMUGO9M TI TTC1MVT DMUGO9M TN Gastrin-releasing peptide receptor (GRPR) DMUGO9M MA Inhibitor DMUGO9M RN Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7. DMUGO9M RU https://pubmed.ncbi.nlm.nih.gov/2066982 DMUGPD1 DI DMUGPD1 DMUGPD1 DN DM-PPP DMUGPD1 TI TTVBPDM DMUGPD1 TN Metabotropic glutamate receptor 1 (mGluR1) DMUGPD1 MA Modulator (allosteric modulator) DMUGPD1 RN Synthesis and pharmacological characterisation of 2,4-dicarboxy-pyrroles as selective non-competitive mGluR1 antagonists. Bioorg Med Chem. 2003 Jan 17;11(2):171-83. DMUGPD1 RU https://pubmed.ncbi.nlm.nih.gov/12470711 DMUGQIV DI DMUGQIV DMUGQIV DN 2-chloro-5-nitro-N-phenylbenzamide DMUGQIV TI TT6PEUO DMUGQIV TN Retinoic acid receptor RXR-alpha (RXRA) DMUGQIV MA Inhibitor DMUGQIV RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUGQIV RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUGQIV DI DMUGQIV DMUGQIV DN 2-chloro-5-nitro-N-phenylbenzamide DMUGQIV TI TTZMAO3 DMUGQIV TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMUGQIV MA Inhibitor DMUGQIV RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUGQIV RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUGQIV DI DMUGQIV DMUGQIV DN 2-chloro-5-nitro-N-phenylbenzamide DMUGQIV TI TTT2SVW DMUGQIV TN PPAR-gamma messenger RNA (PPARG mRNA) DMUGQIV MA Inhibitor DMUGQIV RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DMUGQIV RU https://pubmed.ncbi.nlm.nih.gov/18329752 DMUGWO6 DI DMUGWO6 DMUGWO6 DN PMID20936789C31 DMUGWO6 TI TT3VZ24 DMUGWO6 TN NIMA-related kinase 2 (NEK2) DMUGWO6 MA Inhibitor DMUGWO6 RN Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem. 2010 Nov 11;53(21):7682-98. DMUGWO6 RU https://pubmed.ncbi.nlm.nih.gov/20936789 DMUGWO6 DI DMUGWO6 DMUGWO6 DN PMID20936789C31 DMUGWO6 TI TTO5QT2 DMUGWO6 TN NIMA-related kinase 1 (NEK1) DMUGWO6 MA Inhibitor DMUGWO6 RN Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem. 2010 Nov 11;53(21):7682-98. DMUGWO6 RU https://pubmed.ncbi.nlm.nih.gov/20936789 DMUH1JX DI DMUH1JX DMUH1JX DN EMC-0901 DMUH1JX TI TTDIGC1 DMUH1JX TN Dipeptidyl peptidase 4 (DPP-4) DMUH1JX MA Inhibitor DMUH1JX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612). DMUH1JX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1612 DMUH203 DI DMUH203 DMUH203 DN PA-1637 DMUH203 TI TTE4KHA DMUH203 TN Amyloid beta A4 protein (APP) DMUH203 MA Modulator DMUH203 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMUH203 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMUH4OV DI DMUH4OV DMUH4OV DN 3,6-Dihydroxy-2-(4-hydroxy-phenyl)-inden-1-one DMUH4OV TI TTOM3J0 DMUH4OV TN Estrogen receptor beta (ESR2) DMUH4OV MA Inhibitor DMUH4OV RN Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3137-42. DMUH4OV RU https://pubmed.ncbi.nlm.nih.gov/15876535 DMUH526 DI DMUH526 DMUH526 DN 2-[4-(1-Ethyl-propyl)-piperazin-1-yl]-quinoline DMUH526 TI TT9JNIC DMUH526 TN Histamine H3 receptor (H3R) DMUH526 MA Inhibitor DMUH526 RN 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11. DMUH526 RU https://pubmed.ncbi.nlm.nih.gov/15634025 DMUH59X DI DMUH59X DMUH59X DN 1-(1-Propionylpiperidin-4-yl)-3-o-tolylurea DMUH59X TI TT7WVHI DMUH59X TN Soluble epoxide hydrolase (EPHX2) DMUH59X MA Inhibitor DMUH59X RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DMUH59X RU https://pubmed.ncbi.nlm.nih.gov/20812725 DMUH9PF DI DMUH9PF DMUH9PF DN 3-{3-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate DMUH9PF TI TTHM0R1 DMUH9PF TN Steryl-sulfatase (STS) DMUH9PF MA Inhibitor DMUH9PF RN 4,4'-Benzophenone-O,O'-disulfamate: a potent inhibitor of steroid sulfatase. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2093-5. DMUH9PF RU https://pubmed.ncbi.nlm.nih.gov/12127511 DMUHBGC DI DMUHBGC DMUHBGC DN H-Tyr-Ala-Phe-Phe-NH2 DMUHBGC TI TTZPO1L DMUHBGC TN Substance-P receptor (TACR1) DMUHBGC MA Inhibitor DMUHBGC RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMUHBGC RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMUHCO8 DI DMUHCO8 DMUHCO8 DN 6-(4-methoxyphenyl)-4-morpholino-2H-pyran-2-one DMUHCO8 TI TTK3PY9 DMUHCO8 TN DNA-dependent protein kinase catalytic (PRKDC) DMUHCO8 MA Inhibitor DMUHCO8 RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMUHCO8 RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMUHECR DI DMUHECR DMUHECR DN 2-[4-(1H-Indol-5-yl)-phenyl]-propionic acid DMUHECR TI TT8NGED DMUHECR TN Prostaglandin G/H synthase 1 (COX-1) DMUHECR MA Inhibitor DMUHECR RN Structure-based design of COX-2 selectivity into flurbiprofen. Bioorg Med Chem Lett. 1999 Feb 8;9(3):307-12. DMUHECR RU https://pubmed.ncbi.nlm.nih.gov/10091674 DMUHEJ3 DI DMUHEJ3 DMUHEJ3 DN Very low dose (VLD) cyclobenzaprine DMUHEJ3 TI TTJQOD7 DMUHEJ3 TN 5-HT 2A receptor (HTR2A) DMUHEJ3 MA Modulator DMUHEJ3 RN Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. DMUHEJ3 RU https://pubmed.ncbi.nlm.nih.gov/1370538 DMUHJ2C DI DMUHJ2C DMUHJ2C DN MDL-28163 DMUHJ2C TI TTZPO1L DMUHJ2C TN Substance-P receptor (TACR1) DMUHJ2C MA Inhibitor DMUHJ2C RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMUHJ2C RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMUHJ2C DI DMUHJ2C DMUHJ2C DN MDL-28163 DMUHJ2C TI TTTIBOJ DMUHJ2C TN Histamine H1 receptor (H1R) DMUHJ2C MA Inhibitor DMUHJ2C RN Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43. DMUHJ2C RU https://pubmed.ncbi.nlm.nih.gov/16220969 DMUHKYW DI DMUHKYW DMUHKYW DN N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide DMUHKYW TI TTBH0VX DMUHKYW TN Histone deacetylase (HDAC) DMUHKYW MA Inhibitor DMUHKYW RN Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79. DMUHKYW RU https://pubmed.ncbi.nlm.nih.gov/10579829 DMUHOF4 DI DMUHOF4 DMUHOF4 DN 6-Ethyl-2-phenyl-chromen-4-one DMUHOF4 TI TTNJYV2 DMUHOF4 TN Gamma-aminobutyric acid receptor (GAR) DMUHOF4 MA Inhibitor DMUHOF4 RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMUHOF4 RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMUHQ0J DI DMUHQ0J DMUHQ0J DN 4-(5-Nitro-indol-1-ylmethyl)-benzamidine DMUHQ0J TI TT2WR1T DMUHQ0J TN Cationic trypsinogen (PRSS1) DMUHQ0J MA Inhibitor DMUHQ0J RN Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8. DMUHQ0J RU https://pubmed.ncbi.nlm.nih.gov/6219223 DMUHQS9 DI DMUHQS9 DMUHQS9 DN SR48527 DMUHQS9 TI TTTUMEP DMUHQS9 TN Neurotensin receptor type 1 (NTSR1) DMUHQS9 MA Antagonist DMUHQS9 RN [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor. Mol Pharmacol. 1995 May;47(5):1050-6. DMUHQS9 RU https://pubmed.ncbi.nlm.nih.gov/7746272 DMUHXRA DI DMUHXRA DMUHXRA DN NCX-1067 DMUHXRA TI TTPADOQ DMUHXRA TN HMG-CoA reductase (HMGCR) DMUHXRA MA Modulator DMUHXRA RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 639). DMUHXRA RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=639 DMUHZ23 DI DMUHZ23 DMUHZ23 DN N-N-diethyl estradiol-16-methyl carboxamide DMUHZ23 TI TTIWB6L DMUHZ23 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMUHZ23 MA Inhibitor DMUHZ23 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMUHZ23 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMUHZ2V DI DMUHZ2V DMUHZ2V DN NT-69-L DMUHZ2V TI TTTUMEP DMUHZ2V TN Neurotensin receptor type 1 (NTSR1) DMUHZ2V MA Modulator DMUHZ2V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309). DMUHZ2V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=309 DMUI0XV DI DMUI0XV DMUI0XV DN [Sar1Gly]GAL-B2 DMUI0XV TI TTBPW3J DMUI0XV TN Galanin receptor type 2 (GAL2-R) DMUI0XV MA Inhibitor DMUI0XV RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMUI0XV RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMUI0XV DI DMUI0XV DMUI0XV DN [Sar1Gly]GAL-B2 DMUI0XV TI TTX3HNZ DMUI0XV TN Galanin receptor type 1 (GAL1-R) DMUI0XV MA Inhibitor DMUI0XV RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMUI0XV RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMUI1YZ DI DMUI1YZ DMUI1YZ DN 8-methyl-2-morpholino-7-phenyl-4H-chromen-4-one DMUI1YZ TI TT06AWU DMUI1YZ TN Phosphodiesterase 3A (PDE3A) DMUI1YZ MA Inhibitor DMUI1YZ RN Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73. DMUI1YZ RU https://pubmed.ncbi.nlm.nih.gov/16290931 DMUI8RC DI DMUI8RC DMUI8RC DN N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine DMUI8RC TI TTGKNB4 DMUI8RC TN Epidermal growth factor receptor (EGFR) DMUI8RC MA Inhibitor DMUI8RC RN Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a n... J Med Chem. 2003 Dec 4;46(25):5546-51. DMUI8RC RU https://pubmed.ncbi.nlm.nih.gov/14640561 DMUIFJY DI DMUIFJY DMUIFJY DN 8-(2-Methyl-cyclohexyloxy)-quinolin-2-ylamine DMUIFJY TI TTX4RTB DMUIFJY TN Melanin-concentrating hormone receptor 1 (MCHR1) DMUIFJY MA Inhibitor DMUIFJY RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMUIFJY RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMUILX8 DI DMUILX8 DMUILX8 DN N-(2-phenylimidazo[1,2-a]pyridin-3-yl)benzamide DMUILX8 TI TTHS256 DMUILX8 TN Metabotropic glutamate receptor 5 (mGluR5) DMUILX8 MA Inhibitor DMUILX8 RN Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat... J Med Chem. 2006 Jun 1;49(11):3332-44. DMUILX8 RU https://pubmed.ncbi.nlm.nih.gov/16722652 DMUINVT DI DMUINVT DMUINVT DN Ac-His-Trp-Ala-Val-D-Ala-His-Leu-Met-NH2 DMUINVT TI TTC1MVT DMUINVT TN Gastrin-releasing peptide receptor (GRPR) DMUINVT MA Inhibitor DMUINVT RN Gastrin releasing peptide antagonists with improved potency and stability. J Med Chem. 1991 Jul;34(7):2102-7. DMUINVT RU https://pubmed.ncbi.nlm.nih.gov/2066982 DMUIOAP DI DMUIOAP DMUIOAP DN (2'Z,3'E)-7-Azaindirubin-3'-oxime DMUIOAP TI TTRSMW9 DMUIOAP TN Glycogen synthase kinase-3 beta (GSK-3B) DMUIOAP MA Inhibitor DMUIOAP RN Synthesis and antiproliferative activity of 7-azaindirubin-3'-oxime, a 7-aza isostere of the natural indirubin pharmacophore. J Nat Prod. 2009 Dec;72(12):2199-202. DMUIOAP RU https://pubmed.ncbi.nlm.nih.gov/19994845 DMUIRS1 DI DMUIRS1 DMUIRS1 DN 9-(3-n-Pentylureido)non-4(Z)-enoic acid DMUIRS1 TI TT7WVHI DMUIRS1 TN Soluble epoxide hydrolase (EPHX2) DMUIRS1 MA Inhibitor DMUIRS1 RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMUIRS1 RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMUIVCX DI DMUIVCX DMUIVCX DN LIPOCRINE DMUIVCX TI TT1RS9F DMUIVCX TN Acetylcholinesterase (AChE) DMUIVCX MA Inhibitor DMUIVCX RN Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6. DMUIVCX RU https://pubmed.ncbi.nlm.nih.gov/19813747 DMUIVCX DI DMUIVCX DMUIVCX DN LIPOCRINE DMUIVCX TI TTEB0GD DMUIVCX TN Cholinesterase (BCHE) DMUIVCX MA Inhibitor DMUIVCX RN Toward a rational design of multitarget-directed antioxidants: merging memoquin and lipoic acid molecular frameworks. J Med Chem. 2009 Dec 10;52(23):7883-6. DMUIVCX RU https://pubmed.ncbi.nlm.nih.gov/19813747 DMUIVS9 DI DMUIVS9 DMUIVS9 DN 2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine DMUIVS9 TI TTVG215 DMUIVS9 TN Debrisoquine 4-hydroxylase (CYP2D6) DMUIVS9 MA Inhibitor DMUIVS9 RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DMUIVS9 RU https://pubmed.ncbi.nlm.nih.gov/14698153 DMUIVS9 DI DMUIVS9 DMUIVS9 DN 2-(4-Imidazol-1-yl-phenoxymethyl)-pyridine DMUIVS9 TI TTXV4FI DMUIVS9 TN Albendazole monooxygenase (CYP3A4) DMUIVS9 MA Inhibitor DMUIVS9 RN Imidazole derivatives as new potent and selective 20-HETE synthase inhibitors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):333-6. DMUIVS9 RU https://pubmed.ncbi.nlm.nih.gov/14698153 DMUIXNS DI DMUIXNS DMUIXNS DN 3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine DMUIXNS TI TTIQUX7 DMUIXNS TN Steroid 11-beta-hydroxylase (CYP11B1) DMUIXNS MA Inhibitor DMUIXNS RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMUIXNS RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMUIXNS DI DMUIXNS DMUIXNS DN 3-(5-Bromo-6-methoxy-naphthalen-2-yl)-pyridine DMUIXNS TI TTSZLWK DMUIXNS TN Aromatase (CYP19A1) DMUIXNS MA Inhibitor DMUIXNS RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMUIXNS RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMUIYZB DI DMUIYZB DMUIYZB DN 2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline DMUIYZB TI TTNJYV2 DMUIYZB TN Gamma-aminobutyric acid receptor (GAR) DMUIYZB MA Inhibitor DMUIYZB RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMUIYZB RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMUIYZB DI DMUIYZB DMUIYZB DN 2-Phenyl-5,6-dihydro-pyrazolo[1,5-c]quinazoline DMUIYZB TI TT1MPAY DMUIYZB TN GABA(A) receptor alpha-1 (GABRA1) DMUIYZB MA Inhibitor DMUIYZB RN Synthesis and binding activity of some pyrazolo[1,5-c]quinazolines as tools to verify an optional binding site of a benzodiazepine receptor ligand. J Med Chem. 1996 Jul 19;39(15):2915-21. DMUIYZB RU https://pubmed.ncbi.nlm.nih.gov/8709126 DMUJ18K DI DMUJ18K DMUJ18K DN (3-Bromo-propyl)-trimethyl-ammonium DMUJ18K TI TT1RS9F DMUJ18K TN Acetylcholinesterase (AChE) DMUJ18K MA Inhibitor DMUJ18K RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMUJ18K RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMUJ18P DI DMUJ18P DMUJ18P DN N-methyl-1-(2-thiophen-2-ylphenyl)methanamine DMUJ18P TI TTXZEAJ DMUJ18P TN Leukotriene A-4 hydrolase (LTA4H) DMUJ18P MA Inhibitor DMUJ18P RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUJ18P RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUJ2WB DI DMUJ2WB DMUJ2WB DN 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMUJ2WB TI TTAWNKZ DMUJ2WB TN Norepinephrine transporter (NET) DMUJ2WB MA Inhibitor DMUJ2WB RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMUJ2WB RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMUJ2WB DI DMUJ2WB DMUJ2WB DN 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMUJ2WB TI TTQ6VDM DMUJ2WB TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMUJ2WB MA Inhibitor DMUJ2WB RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMUJ2WB RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMUJ2WB DI DMUJ2WB DMUJ2WB DN 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMUJ2WB TI TTVBI8W DMUJ2WB TN Dopamine transporter (DAT) DMUJ2WB MA Inhibitor DMUJ2WB RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMUJ2WB RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMUJ2WB DI DMUJ2WB DMUJ2WB DN 1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX) DMUJ2WB TI TT3ROYC DMUJ2WB TN Serotonin transporter (SERT) DMUJ2WB MA Inhibitor DMUJ2WB RN Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92. DMUJ2WB RU https://pubmed.ncbi.nlm.nih.gov/20471260 DMUJ7ZE DI DMUJ7ZE DMUJ7ZE DN (1R,5R)-30-OXO-19-OXA-2,6,10,12-TETRAAZAHEXACYCLO[18.6.2.1^{2,5}.1^{14,18}.0^{8,12}.0^{23,27}]TRIACONTA-8,10,14(29),15,17,20(28),21,23(27)-OCTAENE-17-CARBONITRILE (STRUCTURAL MIX) DMUJ7ZE TI TTQ6VDM DMUJ7ZE TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMUJ7ZE MA Inhibitor DMUJ7ZE RN Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new ... J Med Chem. 2009 Jul 23;52(14):4266-76. DMUJ7ZE RU https://pubmed.ncbi.nlm.nih.gov/19534531 DMUJ9F7 DI DMUJ9F7 DMUJ9F7 DN PMID8246233C35 DMUJ9F7 TI TTPADOQ DMUJ9F7 TN HMG-CoA reductase (HMGCR) DMUJ9F7 MA Inhibitor DMUJ9F7 RN Inhibitors of cholesterol biosynthesis. 1. 3,5-Dihydroxy-7-(N-imidazolyl)-6-heptenoates and -heptanoates, a novel series of HMG-CoA reductase inhibitors. J Med Chem. 1993 Nov 12;36(23):3646-57. DMUJ9F7 RU https://pubmed.ncbi.nlm.nih.gov/8246233 DMUJC2E DI DMUJC2E DMUJC2E DN 2'-aminoimidazolylmethyluracils DMUJC2E TI TTO0IB8 DMUJC2E TN Thymidine phosphorylase (TYMP) DMUJC2E MA Inhibitor DMUJC2E RN Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem. 2003 Jan 16;46(2):207-9. DMUJC2E RU https://pubmed.ncbi.nlm.nih.gov/12519058 DMUJC97 DI DMUJC97 DMUJC97 DN D-Phe-Cys-Tyr--Trp-Lys-Thr-Pen-Thr-NH2 DMUJC97 TI TTKWM86 DMUJC97 TN Opioid receptor mu (MOP) DMUJC97 MA Inhibitor DMUJC97 RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMUJC97 RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMUJEA4 DI DMUJEA4 DMUJEA4 DN PMID8576905C4 DMUJEA4 TI TTFQEO5 DMUJEA4 TN Squalene synthetase (FDFT1) DMUJEA4 MA Inhibitor DMUJEA4 RN Alpha-Phosphonosulfonic acids: potent and selective inhibitors of squalene synthase. J Med Chem. 1996 Feb 2;39(3):657-60. DMUJEA4 RU https://pubmed.ncbi.nlm.nih.gov/8576905 DMUJEA9 DI DMUJEA9 DMUJEA9 DN MRS2567 DMUJEA9 TI TTNVSKA DMUJEA9 TN P2Y purinoceptor 6 (P2RY6) DMUJEA9 MA Antagonist DMUJEA9 RN Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70. DMUJEA9 RU https://pubmed.ncbi.nlm.nih.gov/15081875 DMUJQX1 DI DMUJQX1 DMUJQX1 DN 2-(2-Nitro-benzoyl)-cyclohexane-1,3-dione DMUJQX1 TI TT8DSFC DMUJQX1 TN Hydroxyphenylpyruvate dioxygenase (HPD) DMUJQX1 MA Inhibitor DMUJQX1 RN SAR studies of 2-o-substituted-benzoyl- and 2-alkanoyl-cyclohexane-1,3-diones as inhibitors of 4-hydroxyphenylpyruvate dioxygenase. Bioorg Med Chem Lett. 2000 May 1;10(9):843-5. DMUJQX1 RU https://pubmed.ncbi.nlm.nih.gov/10853644 DMUJS4R DI DMUJS4R DMUJS4R DN 4'-cyano-3-(imidazolylmethyl)flavone DMUJS4R TI TTSZLWK DMUJS4R TN Aromatase (CYP19A1) DMUJS4R MA Inhibitor DMUJS4R RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DMUJS4R RU https://pubmed.ncbi.nlm.nih.gov/16854084 DMUJS4Y DI DMUJS4Y DMUJS4Y DN N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile DMUJS4Y TI TTDZN01 DMUJS4Y TN Cathepsin K (CTSK) DMUJS4Y MA Inhibitor DMUJS4Y RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMUJS4Y RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMUJS4Y DI DMUJS4Y DMUJS4Y DN N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile DMUJS4Y TI TT36ETB DMUJS4Y TN Cathepsin L (CTSL) DMUJS4Y MA Inhibitor DMUJS4Y RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMUJS4Y RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMUJS4Y DI DMUJS4Y DMUJS4Y DN N-(4-phenylbenzoyl)-phenylalanyl-glycine-nitrile DMUJS4Y TI TTUMQVO DMUJS4Y TN Cathepsin S (CTSS) DMUJS4Y MA Inhibitor DMUJS4Y RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMUJS4Y RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMUJSP7 DI DMUJSP7 DMUJSP7 DN 6-chloro-5-pentylpyrimidine-2,4(1H,3H)-dione DMUJSP7 TI TTO0IB8 DMUJSP7 TN Thymidine phosphorylase (TYMP) DMUJSP7 MA Inhibitor DMUJSP7 RN Discovery of 5-substituted-6-chlorouracils as efficient inhibitors of human thymidine phosphorylase. J Med Chem. 2007 Nov 29;50(24):6016-23. DMUJSP7 RU https://pubmed.ncbi.nlm.nih.gov/17963370 DMUK1PA DI DMUK1PA DMUK1PA DN MRE 2029F20 DMUK1PA TI TTJFY5U DMUK1PA TN Adenosine A3 receptor (ADORA3) DMUK1PA MA Antagonist DMUK1PA RN Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem. 2004 Mar 11;47(6):1434-47. DMUK1PA RU https://pubmed.ncbi.nlm.nih.gov/14998332 DMUK1PA DI DMUK1PA DMUK1PA DN MRE 2029F20 DMUK1PA TI TTNE7KG DMUK1PA TN Adenosine A2b receptor (ADORA2B) DMUK1PA MA Antagonist DMUK1PA RN Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem. 2004 Mar 11;47(6):1434-47. DMUK1PA RU https://pubmed.ncbi.nlm.nih.gov/14998332 DMUK1PA DI DMUK1PA DMUK1PA DN MRE 2029F20 DMUK1PA TI TTK25J1 DMUK1PA TN Adenosine A1 receptor (ADORA1) DMUK1PA MA Antagonist DMUK1PA RN Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem. 2004 Mar 11;47(6):1434-47. DMUK1PA RU https://pubmed.ncbi.nlm.nih.gov/14998332 DMUK1VX DI DMUK1VX DMUK1VX DN 3,3'-(3-Phenylthiene-2,5-diyl)diphenol DMUK1VX TI TTIWB6L DMUK1VX TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMUK1VX MA Inhibitor DMUK1VX RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMUK1VX RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMUK7IT DI DMUK7IT DMUK7IT DN PT-315 DMUK7IT TI TT84ETX DMUK7IT TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMUK7IT MA Inhibitor DMUK7IT RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMUK7IT RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMUK7LX DI DMUK7LX DMUK7LX DN RWJ-68157 DMUK7LX TI TTBRKXS DMUK7LX TN Adrenergic receptor alpha-1B (ADRA1B) DMUK7LX MA Inhibitor DMUK7LX RN Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6. DMUK7LX RU https://pubmed.ncbi.nlm.nih.gov/10843225 DMUK7LX DI DMUK7LX DMUK7LX DN RWJ-68157 DMUK7LX TI TT34BHT DMUK7LX TN Adrenergic receptor alpha-1D (ADRA1D) DMUK7LX MA Inhibitor DMUK7LX RN Novel arylpiperazines as selective alpha1-adrenergic receptor antagonists. Bioorg Med Chem Lett. 2000 May 15;10(10):1093-6. DMUK7LX RU https://pubmed.ncbi.nlm.nih.gov/10843225 DMUK7LX DI DMUK7LX DMUK7LX DN RWJ-68157 DMUK7LX TI TTNGILX DMUK7LX TN Adrenergic receptor alpha-1A (ADRA1A) DMUK7LX MA Inhibitor DMUK7LX RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMUK7LX RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMUK95S DI DMUK95S DMUK95S DN 1-benzhydryl-4-hexylpiperidin-4-ol DMUK95S TI TTKWM86 DMUK95S TN Opioid receptor mu (MOP) DMUK95S MA Inhibitor DMUK95S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMUK95S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMUK95S DI DMUK95S DMUK95S DN 1-benzhydryl-4-hexylpiperidin-4-ol DMUK95S TI TTNT7K8 DMUK95S TN Nociceptin receptor (OPRL1) DMUK95S MA Inhibitor DMUK95S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMUK95S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMUK95S DI DMUK95S DMUK95S DN 1-benzhydryl-4-hexylpiperidin-4-ol DMUK95S TI TTQW87Y DMUK95S TN Opioid receptor kappa (OPRK1) DMUK95S MA Inhibitor DMUK95S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMUK95S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMUK95S DI DMUK95S DMUK95S DN 1-benzhydryl-4-hexylpiperidin-4-ol DMUK95S TI TT27RFC DMUK95S TN Opioid receptor delta (OPRD1) DMUK95S MA Inhibitor DMUK95S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMUK95S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMUKAH6 DI DMUKAH6 DMUKAH6 DN 1-methyl-1H-indole-3-carboxamide DMUKAH6 TI TTTB4UP DMUKAH6 TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMUKAH6 MA Inhibitor DMUKAH6 RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMUKAH6 RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMUKE43 DI DMUKE43 DMUKE43 DN Tyr-Pro-Emp-Phe-NH2 DMUKE43 TI TT27RFC DMUKE43 TN Opioid receptor delta (OPRD1) DMUKE43 MA Inhibitor DMUKE43 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMUKE43 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMUKE43 DI DMUKE43 DMUKE43 DN Tyr-Pro-Emp-Phe-NH2 DMUKE43 TI TTKWM86 DMUKE43 TN Opioid receptor mu (MOP) DMUKE43 MA Inhibitor DMUKE43 RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMUKE43 RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMUKGEA DI DMUKGEA DMUKGEA DN Cebutolol DMUKGEA TI TTR6W5O DMUKGEA TN Adrenergic receptor beta-1 (ADRB1) DMUKGEA MA Antagonist DMUKGEA RN Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404. DMUKGEA RU https://pubmed.ncbi.nlm.nih.gov/9551698 DMUKPO3 DI DMUKPO3 DMUKPO3 DN Duo3 DMUKPO3 TI TTOXS3C DMUKPO3 TN Muscarinic acetylcholine receptor (CHRM) DMUKPO3 MA Modulator (allosteric modulator) DMUKPO3 RN Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric... Mol Pharmacol. 2005 Dec;68(6):1597-610. DMUKPO3 RU https://pubmed.ncbi.nlm.nih.gov/16157694 DMUKVHQ DI DMUKVHQ DMUKVHQ DN SRT1720 DMUKVHQ TI TTUF2HO DMUKVHQ TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMUKVHQ MA Activator DMUKVHQ RN Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6. DMUKVHQ RU https://pubmed.ncbi.nlm.nih.gov/18046409 DMUKWJ2 DI DMUKWJ2 DMUKWJ2 DN MST-400 DMUKWJ2 TI TT7ALZG DMUKWJ2 TN Integrin-linked protein kinase 1 (ILK) DMUKWJ2 MA Inhibitor DMUKWJ2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2041). DMUKWJ2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2041 DMUL2B3 DI DMUL2B3 DMUL2B3 DN 1,3-Dipropyl-3,7-dihydro-purine-2,6-dione DMUL2B3 TI TTNE7KG DMUL2B3 TN Adenosine A2b receptor (ADORA2B) DMUL2B3 MA Inhibitor DMUL2B3 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMUL2B3 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMUL2B3 DI DMUL2B3 DMUL2B3 DN 1,3-Dipropyl-3,7-dihydro-purine-2,6-dione DMUL2B3 TI TTK25J1 DMUL2B3 TN Adenosine A1 receptor (ADORA1) DMUL2B3 MA Inhibitor DMUL2B3 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMUL2B3 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMUL2B3 DI DMUL2B3 DMUL2B3 DN 1,3-Dipropyl-3,7-dihydro-purine-2,6-dione DMUL2B3 TI TTM2AOE DMUL2B3 TN Adenosine A2a receptor (ADORA2A) DMUL2B3 MA Inhibitor DMUL2B3 RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMUL2B3 RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMUL2FW DI DMUL2FW DMUL2FW DN Thieno[2,3-B]Pyridine-2-Carboxamidine DMUL2FW TI TTGY7WI DMUL2FW TN Urokinase-type plasminogen activator (PLAU) DMUL2FW MA Inhibitor DMUL2FW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUL2FW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUL4AP DI DMUL4AP DMUL4AP DN Erythribyssin L DMUL4AP TI TT50QJ3 DMUL4AP TN Influenza Neuraminidase (Influ NA) DMUL4AP MA Inhibitor DMUL4AP RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMUL4AP RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMUL4PE DI DMUL4PE DMUL4PE DN MMB-4 DMUL4PE TI TT1RS9F DMUL4PE TN Acetylcholinesterase (AChE) DMUL4PE MA Activator DMUL4PE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMUL4PE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMUL6QR DI DMUL6QR DMUL6QR DN 9-Amino-6H,11H-indeno[1,2-c]isoquinolin-5-one DMUL6QR TI TTVDSZ0 DMUL6QR TN Poly [ADP-ribose] polymerase 1 (PARP1) DMUL6QR MA Inhibitor DMUL6QR RN Discovery of potent poly(ADP-ribose) polymerase-1 inhibitors from the modification of indeno[1,2-c]isoquinolinone. J Med Chem. 2005 Aug 11;48(16):5100-3. DMUL6QR RU https://pubmed.ncbi.nlm.nih.gov/16078828 DMULBO9 DI DMULBO9 DMULBO9 DN N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide DMULBO9 TI TTZA1NY DMULBO9 TN GABA(A) receptor beta-2 (GABRB2) DMULBO9 MA Inhibitor DMULBO9 RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMULBO9 RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMULBO9 DI DMULBO9 DMULBO9 DN N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide DMULBO9 TI TT06RH5 DMULBO9 TN GABA(A) receptor gamma-2 (GABRG2) DMULBO9 MA Inhibitor DMULBO9 RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMULBO9 RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMULBO9 DI DMULBO9 DMULBO9 DN N-(p-methylbenzyl)-5-nitroindol-3-ylglyoxylamide DMULBO9 TI TT1MPAY DMULBO9 TN GABA(A) receptor alpha-1 (GABRA1) DMULBO9 MA Inhibitor DMULBO9 RN Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1/L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-... J Med Chem. 2007 Apr 5;50(7):1627-34. DMULBO9 RU https://pubmed.ncbi.nlm.nih.gov/17335185 DMULFYA DI DMULFYA DMULFYA DN (S)-NORDULOXETINE DMULFYA TI TT3ROYC DMULFYA TN Serotonin transporter (SERT) DMULFYA MA Inhibitor DMULFYA RN Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. DMULFYA RU https://pubmed.ncbi.nlm.nih.gov/19740668 DMULFYA DI DMULFYA DMULFYA DN (S)-NORDULOXETINE DMULFYA TI TTAWNKZ DMULFYA TN Norepinephrine transporter (NET) DMULFYA MA Inhibitor DMULFYA RN Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7. DMULFYA RU https://pubmed.ncbi.nlm.nih.gov/19740668 DMULMWK DI DMULMWK DMULMWK DN Phenyl 4-(octyloxy)phenylcarbamate DMULMWK TI TTDP1UC DMULMWK TN Fatty acid amide hydrolase (FAAH) DMULMWK MA Inhibitor DMULMWK RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMULMWK RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMULO0V DI DMULO0V DMULO0V DN TMX-201 DMULO0V TI TTRJ1K4 DMULO0V TN Toll-like receptor 7 (TLR7) DMULO0V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1757). DMULO0V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1757 DMULOHZ DI DMULOHZ DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide DMULOHZ TI TT5ZKDI DMULOHZ TN Histone deacetylase 6 (HDAC6) DMULOHZ MA Inhibitor DMULOHZ RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMULOHZ RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMULOHZ DI DMULOHZ DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide DMULOHZ TI TT6R7JZ DMULOHZ TN Histone deacetylase 1 (HDAC1) DMULOHZ MA Inhibitor DMULOHZ RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMULOHZ RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMULOHZ DI DMULOHZ DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide DMULOHZ TI TTTQGH8 DMULOHZ TN Histone deacetylase 4 (HDAC4) DMULOHZ MA Inhibitor DMULOHZ RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMULOHZ RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMULOHZ DI DMULOHZ DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide DMULOHZ TI TTBH0VX DMULOHZ TN Histone deacetylase (HDAC) DMULOHZ MA Inhibitor DMULOHZ RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMULOHZ RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMULOHZ DI DMULOHZ DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide DMULOHZ TI TTT6LFV DMULOHZ TN Histone deacetylase 8 (HDAC8) DMULOHZ MA Inhibitor DMULOHZ RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMULOHZ RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMULOHZ DI DMULOHZ DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide DMULOHZ TI TTSHTOI DMULOHZ TN Histone deacetylase 2 (HDAC2) DMULOHZ MA Inhibitor DMULOHZ RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMULOHZ RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMULOHZ DI DMULOHZ DMULOHZ DN 4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide DMULOHZ TI TTYHPU6 DMULOHZ TN Histone deacetylase 10 (HDAC10) DMULOHZ MA Inhibitor DMULOHZ RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMULOHZ RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMULSNQ DI DMULSNQ DMULSNQ DN 2-amino-4-(2-methyl-benzylsulfanyl)-butyric acid DMULSNQ TI TTFK1JQ DMULSNQ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMULSNQ MA Inhibitor DMULSNQ RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMULSNQ RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMULW35 DI DMULW35 DMULW35 DN (E)-9-Nitrohexadec-9-enoicAcid DMULW35 TI TTT2SVW DMULW35 TN PPAR-gamma messenger RNA (PPARG mRNA) DMULW35 MA Inhibitor DMULW35 RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMULW35 RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMULWOG DI DMULWOG DMULWOG DN AEZS-115 DMULWOG TI TT8R70G DMULWOG TN Gonadotropin-releasing hormone receptor (GNRHR) DMULWOG MA Antagonist DMULWOG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 256). DMULWOG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=256 DMULX9O DI DMULX9O DMULX9O DN 3-(3,4-dimethylphenyl)-1,5-naphthyridine DMULX9O TI TTHS256 DMULX9O TN Metabotropic glutamate receptor 5 (mGluR5) DMULX9O MA Inhibitor DMULX9O RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMULX9O RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMULXO3 DI DMULXO3 DMULXO3 DN alpha-Emtbl DMULXO3 TI TTZ8EM9 DMULXO3 TN Glycine receptor (GlyR) DMULXO3 RN Subunit-specific action of an anticonvulsant thiobutyrolactone on recombinant glycine receptors involves a residue in the M2 membrane-spanning region. Mol Pharmacol. 2000 Jul;58(1):11-7. DMULXO3 RU https://pubmed.ncbi.nlm.nih.gov/10860922 DMULZOP DI DMULZOP DMULZOP DN BVT173187 DMULZOP TI TT5Y4EM DMULZOP TN N-formyl peptide receptor (FPR1) DMULZOP MA Antagonist DMULZOP RN A non-peptide receptor inhibitor with selectivity for one of the neutrophil formyl peptide receptors, FPR 1. Biochem Pharmacol. 2012 Jun 15;83(12):1655-62. DMULZOP RU https://pubmed.ncbi.nlm.nih.gov/22410002 DMUM2H1 DI DMUM2H1 DMUM2H1 DN ISIS 29257 DMUM2H1 TI TTYMGWX DMUM2H1 TN PDK-1 messenger RNA (PDK-1 mRNA) DMUM2H1 RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMUM2H1 RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMUM4YQ DI DMUM4YQ DMUM4YQ DN 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine DMUM4YQ TI TTAWNKZ DMUM4YQ TN Norepinephrine transporter (NET) DMUM4YQ MA Inhibitor DMUM4YQ RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMUM4YQ RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMUM4YQ DI DMUM4YQ DMUM4YQ DN 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine DMUM4YQ TI TTVBI8W DMUM4YQ TN Dopamine transporter (DAT) DMUM4YQ MA Inhibitor DMUM4YQ RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMUM4YQ RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMUM4YQ DI DMUM4YQ DMUM4YQ DN 1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine DMUM4YQ TI TT3ROYC DMUM4YQ TN Serotonin transporter (SERT) DMUM4YQ MA Inhibitor DMUM4YQ RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMUM4YQ RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMUM5LV DI DMUM5LV DMUM5LV DN WIN-66306 DMUM5LV TI TTZPO1L DMUM5LV TN Substance-P receptor (TACR1) DMUM5LV MA Modulator DMUM5LV RN WIN 66306, a new neurokinin antagonist produced by an Aspergillus species: fermentation, isolation and physico-chemical properties. J Antibiot (Tokyo). 1994 Nov;47(11):1182-7. DMUM5LV RU https://www.ncbi.nlm.nih.gov/pubmed/7528191 DMUM84K DI DMUM84K DMUM84K DN DFU DMUM84K TI TTVKILB DMUM84K TN Prostaglandin G/H synthase 2 (COX-2) DMUM84K MA Inhibitor DMUM84K RN Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem Biophys Res Commun. 2000 Jul 5;273(2):772-5. DMUM84K RU https://pubmed.ncbi.nlm.nih.gov/10873679 DMUMACD DI DMUMACD DMUMACD DN XD14 DMUMACD TI TTHE657 DMUMACD TN Bromodomain-containing protein 3 (BRD3) DMUMACD MA Inhibitor DMUMACD RN 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9. DMUMACD RU https://pubmed.ncbi.nlm.nih.gov/24272870 DMUMACD DI DMUMACD DMUMACD DN XD14 DMUMACD TI TT7CPI5 DMUMACD TN Bromodomain testis-specific protein (BRDT) DMUMACD MA Inhibitor DMUMACD RN 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9. DMUMACD RU https://pubmed.ncbi.nlm.nih.gov/24272870 DMUMACD DI DMUMACD DMUMACD DN XD14 DMUMACD TI TTDP48B DMUMACD TN Bromodomain-containing protein 2 (BRD2) DMUMACD MA Inhibitor DMUMACD RN 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9. DMUMACD RU https://pubmed.ncbi.nlm.nih.gov/24272870 DMUMACD DI DMUMACD DMUMACD DN XD14 DMUMACD TI TTRA6BO DMUMACD TN Bromodomain-containing protein 4 (BRD4) DMUMACD MA Inhibitor DMUMACD RN 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew Chem Int Ed Engl. 2013 Dec 23;52(52):14055-9. DMUMACD RU https://pubmed.ncbi.nlm.nih.gov/24272870 DMUMD8L DI DMUMD8L DMUMD8L DN 4'-(1,1-dimethyl-heptyl)-3,5-dimethyl-biphenyl DMUMD8L TI TTMSFAW DMUMD8L TN Cannabinoid receptor 2 (CB2) DMUMD8L MA Inhibitor DMUMD8L RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMUMD8L RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMUME74 DI DMUME74 DMUME74 DN 3-hydroxy-4,7-dimethyl-6H-benzo[c]chromen-6-one DMUME74 TI TTOM3J0 DMUME74 TN Estrogen receptor beta (ESR2) DMUME74 MA Inhibitor DMUME74 RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMUME74 RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMUMEST DI DMUMEST DMUMEST DN ISIS 25073 DMUMEST TI TT8H9GB DMUMEST TN MEK2 messenger RNA (MEK2 mRNA) DMUMEST RN US patent application no. 5,959,097, Antisense modulation of MEK2 expression. DMUMEST RU http://www.patentbuddy.com/Patent/5959097?ft=true&sr=true DMUMF0B DI DMUMF0B DMUMF0B DN ADS-103214 DMUMF0B TI TTX4RTB DMUMF0B TN Melanin-concentrating hormone receptor 1 (MCHR1) DMUMF0B MA Inhibitor DMUMF0B RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMUMF0B RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMUMJ7B DI DMUMJ7B DMUMJ7B DN Poly-ICR DMUMJ7B TI TTD24Y0 DMUMJ7B TN Toll-like receptor 3 (TLR3) DMUMJ7B MA Agonist DMUMJ7B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753). DMUMJ7B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753 DMUMJGD DI DMUMJGD DMUMJGD DN JWH-295 DMUMJGD TI TTMSFAW DMUMJGD TN Cannabinoid receptor 2 (CB2) DMUMJGD MA Inhibitor DMUMJGD RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMUMJGD RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMUMN4B DI DMUMN4B DMUMN4B DN 7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMUMN4B TI TTOM3J0 DMUMN4B TN Estrogen receptor beta (ESR2) DMUMN4B MA Inhibitor DMUMN4B RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMUMN4B RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMUMN4B DI DMUMN4B DMUMN4B DN 7-Ethyl-2-(4-hydroxy-phenyl)-benzooxazol-5-ol DMUMN4B TI TTZAYWL DMUMN4B TN Estrogen receptor (ESR) DMUMN4B MA Inhibitor DMUMN4B RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMUMN4B RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMUMNSW DI DMUMNSW DMUMNSW DN D-190 DMUMNSW TI TT4C8EA DMUMNSW TN Dopamine D3 receptor (D3R) DMUMNSW MA Inhibitor DMUMNSW RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMUMNSW RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMUMNSW DI DMUMNSW DMUMNSW DN D-190 DMUMNSW TI TTEX248 DMUMNSW TN Dopamine D2 receptor (D2R) DMUMNSW MA Inhibitor DMUMNSW RN Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly... J Med Chem. 2008 May 22;51(10):3005-19. DMUMNSW RU https://pubmed.ncbi.nlm.nih.gov/18410082 DMUMNYZ DI DMUMNYZ DMUMNYZ DN 1-(4-bromooxazol-2-yl)-7-phenylheptan-1-one DMUMNYZ TI TTDP1UC DMUMNYZ TN Fatty acid amide hydrolase (FAAH) DMUMNYZ MA Inhibitor DMUMNYZ RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMUMNYZ RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMUMOE2 DI DMUMOE2 DMUMOE2 DN 9-benzyl-6-(benzylamino)-9H-purine-2-carbonitrile DMUMOE2 TI TT36ETB DMUMOE2 TN Cathepsin L (CTSL) DMUMOE2 MA Inhibitor DMUMOE2 RN Development of potent purine-derived nitrile inhibitors of the trypanosomal protease TbcatB. J Med Chem. 2008 Feb 14;51(3):545-52. DMUMOE2 RU https://pubmed.ncbi.nlm.nih.gov/18173229 DMUMOV1 DI DMUMOV1 DMUMOV1 DN VU0080241 DMUMOV1 TI TTVBPDM DMUMOV1 TN Metabotropic glutamate receptor 1 (mGluR1) DMUMOV1 MA Inhibitor DMUMOV1 RN Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel ... Bioorg Med Chem Lett. 2008 Oct 15;18(20):5626-30. DMUMOV1 RU https://pubmed.ncbi.nlm.nih.gov/18793851 DMUMVIF DI DMUMVIF DMUMVIF DN ISIS 100929 DMUMVIF TI TTW8TJI DMUMVIF TN MEKK1 messenger RNA (MAP3K1 mRNA) DMUMVIF RN US patent application no. 6,168,950, Antisense modulation of MEKK1 expression. DMUMVIF RU http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true DMUMYTB DI DMUMYTB DMUMYTB DN PMID2153213C13b DMUMYTB TI TTPADOQ DMUMYTB TN HMG-CoA reductase (HMGCR) DMUMYTB MA Inhibitor DMUMYTB RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DMUMYTB RU https://pubmed.ncbi.nlm.nih.gov/2153213 DMUN2CS DI DMUN2CS DMUN2CS DN 2-(2-cyclohexyl-4-fluorophenoxy)acetic acid DMUN2CS TI TTQDMX5 DMUN2CS TN Prostaglandin D2 receptor 2 (PTGDR2) DMUN2CS MA Inhibitor DMUN2CS RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMUN2CS RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMUN3LV DI DMUN3LV DMUN3LV DN 2-Methylquinoline-8-carboxamide DMUN3LV TI TTVDSZ0 DMUN3LV TN Poly [ADP-ribose] polymerase 1 (PARP1) DMUN3LV MA Inhibitor DMUN3LV RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMUN3LV RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMUN50H DI DMUN50H DMUN50H DN Bis(3-bromo-4,5-dihydroxyphenyl)methanone DMUN50H TI TT58ZYW DMUN50H TN Mycobacterium Isocitrate lyase (MycB icl) DMUN50H MA Inhibitor DMUN50H RN Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8. DMUN50H RU https://pubmed.ncbi.nlm.nih.gov/20888765 DMUN54G DI DMUN54G DMUN54G DN Aminohippuric acid DMUN54G TI TTTQR47 DMUN54G TN Solute carrier family 22 member 8 (SLC22A8) DMUN54G MA Inhibitor DMUN54G RN Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53. DMUN54G RU https://pubmed.ncbi.nlm.nih.gov/17553798 DMUN7KC DI DMUN7KC DMUN7KC DN 4-ethoxynaphthalene-1,2-dione DMUN7KC TI TTG8HIM DMUN7KC TN Dual specificity protein phosphatase 1 (DUSP1) DMUN7KC MA Inhibitor DMUN7KC RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMUN7KC RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMUN7KC DI DMUN7KC DMUN7KC DN 4-ethoxynaphthalene-1,2-dione DMUN7KC TI TTR0SWN DMUN7KC TN M-phase inducer phosphatase 2 (MPIP2) DMUN7KC MA Inhibitor DMUN7KC RN Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. DMUN7KC RU https://pubmed.ncbi.nlm.nih.gov/19028102 DMUN8CG DI DMUN8CG DMUN8CG DN TB-102 DMUN8CG TI TT6L509 DMUN8CG TN Coagulation factor IIa (F2) DMUN8CG MA Modulator DMUN8CG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362). DMUN8CG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2362 DMUNCFQ DI DMUNCFQ DMUNCFQ DN N-Acetyl-N'-Beta-D-Glucopyranosyl Urea DMUNCFQ TI TTZHY6R DMUNCFQ TN Glycogen phosphorylase muscle form (GP) DMUNCFQ MA Inhibitor DMUNCFQ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMUNCFQ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMUNIWE DI DMUNIWE DMUNIWE DN NSC-270718 DMUNIWE TI TT2QM9D DMUNIWE TN Adenylate cyclase (ADCY) DMUNIWE MA Inhibitor DMUNIWE RN Structure-based development of novel adenylyl cyclase inhibitors. J Med Chem. 2008 Aug 14;51(15):4456-64. DMUNIWE RU https://pubmed.ncbi.nlm.nih.gov/18630896 DMUNK59 DI DMUNK59 DMUNK59 DN Bafilomycin A1 DMUNK59 TI TTTK3BH DMUNK59 TN Vacuolar-type proton ATPase (v-ATPase) DMUNK59 MA Inhibitor DMUNK59 RN Molecular basis of V-ATPase inhibition by bafilomycin A1. Nat Commun. 2021 Mar 19;12(1):1782. DMUNK59 RU https://pubmed.ncbi.nlm.nih.gov/33741963 DMUNL5Q DI DMUNL5Q DMUNL5Q DN N-benzyl-4-bromo-3-(morpholinosulfonyl)benzamide DMUNL5Q TI TTMSFAW DMUNL5Q TN Cannabinoid receptor 2 (CB2) DMUNL5Q MA Inhibitor DMUNL5Q RN CB2 selective sulfamoyl benzamides: optimization of the amide functionality. Bioorg Med Chem Lett. 2009 Jan 15;19(2):309-13. DMUNL5Q RU https://pubmed.ncbi.nlm.nih.gov/19091565 DMUNO4R DI DMUNO4R DMUNO4R DN ER-21018 DMUNO4R TI TT07C3Y DMUNO4R TN 5-HT 4 receptor (HTR4) DMUNO4R MA Agonist DMUNO4R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 9). DMUNO4R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=9 DMUNQY7 DI DMUNQY7 DMUNQY7 DN (S)-(-)-(4,5,6-trimethoxyindan-1-yl)methanamine DMUNQY7 TI TTJQOD7 DMUNQY7 TN 5-HT 2A receptor (HTR2A) DMUNQY7 MA Inhibitor DMUNQY7 RN C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor. J Med Chem. 2006 Jul 13;49(14):4269-74. DMUNQY7 RU https://pubmed.ncbi.nlm.nih.gov/16821786 DMUNSLJ DI DMUNSLJ DMUNSLJ DN Go-Y026 DMUNSLJ TI TTXV4FI DMUNSLJ TN Albendazole monooxygenase (CYP3A4) DMUNSLJ MA Inhibitor DMUNSLJ RN Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31. DMUNSLJ RU https://pubmed.ncbi.nlm.nih.gov/18249473 DMUNWJR DI DMUNWJR DMUNWJR DN 6-(piperazin-1-yl)-9-propyl-9H-purine DMUNWJR TI TTWJBZ5 DMUNWJR TN 5-HT 2C receptor (HTR2C) DMUNWJR MA Inhibitor DMUNWJR RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DMUNWJR RU https://pubmed.ncbi.nlm.nih.gov/19914063 DMUOB3S DI DMUOB3S DMUOB3S DN ISIS 116648 DMUOB3S TI TTQWAU1 DMUOB3S TN GSK3A messenger RNA (GSK3A mRNA) DMUOB3S RN US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression. DMUOB3S RU http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true DMUOCQB DI DMUOCQB DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide DMUOCQB TI TTSHTOI DMUOCQB TN Histone deacetylase 2 (HDAC2) DMUOCQB MA Inhibitor DMUOCQB RN Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetyla... Eur J Med Chem. 2009 Nov;44(11):4470-6. DMUOCQB RU https://pubmed.ncbi.nlm.nih.gov/19608304 DMUOCQB DI DMUOCQB DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide DMUOCQB TI TTYHPU6 DMUOCQB TN Histone deacetylase 10 (HDAC10) DMUOCQB MA Inhibitor DMUOCQB RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMUOCQB RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMUOCQB DI DMUOCQB DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide DMUOCQB TI TTT6LFV DMUOCQB TN Histone deacetylase 8 (HDAC8) DMUOCQB MA Inhibitor DMUOCQB RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMUOCQB RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMUOCQB DI DMUOCQB DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide DMUOCQB TI TT6R7JZ DMUOCQB TN Histone deacetylase 1 (HDAC1) DMUOCQB MA Inhibitor DMUOCQB RN Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetyla... Eur J Med Chem. 2009 Nov;44(11):4470-6. DMUOCQB RU https://pubmed.ncbi.nlm.nih.gov/19608304 DMUOCQB DI DMUOCQB DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide DMUOCQB TI TT5ZKDI DMUOCQB TN Histone deacetylase 6 (HDAC6) DMUOCQB MA Inhibitor DMUOCQB RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMUOCQB RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMUOCQB DI DMUOCQB DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide DMUOCQB TI TTTQGH8 DMUOCQB TN Histone deacetylase 4 (HDAC4) DMUOCQB MA Inhibitor DMUOCQB RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMUOCQB RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMUOCQB DI DMUOCQB DMUOCQB DN N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide DMUOCQB TI TTBH0VX DMUOCQB TN Histone deacetylase (HDAC) DMUOCQB MA Inhibitor DMUOCQB RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMUOCQB RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMUOFT0 DI DMUOFT0 DMUOFT0 DN PF-5177624 DMUOFT0 TI TT9QBI6 DMUOFT0 TN Phosphoinositide dependent protein kinase-1 (PDPK1) DMUOFT0 MA Inhibitor DMUOFT0 RN Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402. DMUOFT0 RU https://pubmed.ncbi.nlm.nih.gov/23119004 DMUOFW8 DI DMUOFW8 DMUOFW8 DN (4-(6-morpholino-9H-purin-2-yl)phenyl)methanol DMUOFW8 TI TTCJG29 DMUOFW8 TN Serine/threonine-protein kinase mTOR (mTOR) DMUOFW8 MA Inhibitor DMUOFW8 RN Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. DMUOFW8 RU https://pubmed.ncbi.nlm.nih.gov/19969455 DMUOHVL DI DMUOHVL DMUOHVL DN FLUTROLINE DMUOHVL TI TTE0A2F DMUOHVL TN Dopamine D4 receptor (D4R) DMUOHVL MA Inhibitor DMUOHVL RN Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43. DMUOHVL RU https://pubmed.ncbi.nlm.nih.gov/6104732 DMUOHVL DI DMUOHVL DMUOHVL DN FLUTROLINE DMUOHVL TI TTEX248 DMUOHVL TN Dopamine D2 receptor (D2R) DMUOHVL MA Inhibitor DMUOHVL RN Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43. DMUOHVL RU https://pubmed.ncbi.nlm.nih.gov/6104732 DMUOHVL DI DMUOHVL DMUOHVL DN FLUTROLINE DMUOHVL TI TTZFYLI DMUOHVL TN Dopamine D1 receptor (D1R) DMUOHVL MA Inhibitor DMUOHVL RN Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43. DMUOHVL RU https://pubmed.ncbi.nlm.nih.gov/6104732 DMUOHVL DI DMUOHVL DMUOHVL DN FLUTROLINE DMUOHVL TI TT4C8EA DMUOHVL TN Dopamine D3 receptor (D3R) DMUOHVL MA Inhibitor DMUOHVL RN Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43. DMUOHVL RU https://pubmed.ncbi.nlm.nih.gov/6104732 DMUOHVL DI DMUOHVL DMUOHVL DN FLUTROLINE DMUOHVL TI TTS2PH3 DMUOHVL TN Dopamine D5 receptor (D5R) DMUOHVL MA Inhibitor DMUOHVL RN Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43. DMUOHVL RU https://pubmed.ncbi.nlm.nih.gov/6104732 DMUOLES DI DMUOLES DMUOLES DN 4alpha-PDH DMUOLES TI TTKP2SU DMUOLES TN Transient receptor potential cation channel V4 (TRPV4) DMUOLES MA Activator DMUOLES RN Modulation of the transient receptor potential vanilloid channel TRPV4 by 4alpha-phorbol esters: a structure-activity study. J Med Chem. 2009 May 14;52(9):2933-9. DMUOLES RU https://pubmed.ncbi.nlm.nih.gov/19361196 DMUOMP1 DI DMUOMP1 DMUOMP1 DN Ginkgolide J DMUOMP1 TI TTF45NW DMUOMP1 TN Strychnine-binding glycine receptor (GLRA1) DMUOMP1 MA Inhibitor DMUOMP1 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMUOMP1 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMUOMP1 DI DMUOMP1 DMUOMP1 DN Ginkgolide J DMUOMP1 TI TTZ8EM9 DMUOMP1 TN Glycine receptor (GlyR) DMUOMP1 MA Inhibitor DMUOMP1 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMUOMP1 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMUONK5 DI DMUONK5 DMUONK5 DN amg-1 DMUONK5 TI TTZJYKH DMUONK5 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMUONK5 MA Inhibitor DMUONK5 RN Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors. Biochim Biophys Acta. 2011 Dec;1814(12):1947-54. DMUONK5 RU https://pubmed.ncbi.nlm.nih.gov/21835273 DMUOPRT DI DMUOPRT DMUOPRT DN L-703,606 DMUOPRT TI TTZPO1L DMUOPRT TN Substance-P receptor (TACR1) DMUOPRT MA Antagonist DMUOPRT RN The unpredicted high affinities of a large number of naturally occurring tachykinins for chimeric NK1/NK3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J BiolChem. 1996 Aug 23;271(34):20250-7. DMUOPRT RU https://pubmed.ncbi.nlm.nih.gov/8702757 DMUOQN7 DI DMUOQN7 DMUOQN7 DN 4-(Cyclohexylamino)-1-naphthol DMUOQN7 TI TTZJYKH DMUOQN7 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMUOQN7 MA Inhibitor DMUOQN7 RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMUOQN7 RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMUOQZD DI DMUOQZD DMUOQZD DN Arachidonic acid DMUOQZD TI TT8NGED DMUOQZD TN Prostaglandin G/H synthase 1 (COX-1) DMUOQZD MA Inhibitor DMUOQZD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUOQZD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUOS3G DI DMUOS3G DMUOS3G DN BPH-252 DMUOS3G TI TTIKWV4 DMUOS3G TN Geranyltranstransferase (FDPS) DMUOS3G MA Inhibitor DMUOS3G RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DMUOS3G RU https://pubmed.ncbi.nlm.nih.gov/18800762 DMUOSJG DI DMUOSJG DMUOSJG DN 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole DMUOSJG TI TTRA5BZ DMUOSJG TN Steroid 17-alpha-monooxygenase (S17AH) DMUOSJG MA Inhibitor DMUOSJG RN New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6. DMUOSJG RU https://pubmed.ncbi.nlm.nih.gov/10091679 DMUOSJG DI DMUOSJG DMUOSJG DN 1-Ethyl-5-(imidazol-1-yl-phenyl-methyl)-1H-indole DMUOSJG TI TTSZLWK DMUOSJG TN Aromatase (CYP19A1) DMUOSJG MA Inhibitor DMUOSJG RN New selective nonsteroidal aromatase inhibitors: synthesis and inhibitory activity of 2,3 or 5-(alpha-azolylbenzyl)-1H-indoles. Bioorg Med Chem Lett. 1999 Feb 8;9(3):333-6. DMUOSJG RU https://pubmed.ncbi.nlm.nih.gov/10091679 DMUOWNE DI DMUOWNE DMUOWNE DN 2-(3-Isopropyl-phenyl)-propionic acid DMUOWNE TI TTMWT8Z DMUOWNE TN C-X-C chemokine receptor type 1 (CXCR1) DMUOWNE MA Inhibitor DMUOWNE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMUOWNE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMUOWNE DI DMUOWNE DMUOWNE DN 2-(3-Isopropyl-phenyl)-propionic acid DMUOWNE TI TT30C9G DMUOWNE TN C-X-C chemokine receptor type 2 (CXCR2) DMUOWNE MA Inhibitor DMUOWNE RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMUOWNE RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMUOXHP DI DMUOXHP DMUOXHP DN 3,4-dihydroquinazolin-2-amine hydrobromide DMUOXHP TI TTRUFDT DMUOXHP TN 5-HT 5A receptor (HTR5A) DMUOXHP MA Inhibitor DMUOXHP RN Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61. DMUOXHP RU https://pubmed.ncbi.nlm.nih.gov/17998160 DMUP34S DI DMUP34S DMUP34S DN TGF-beta Shield DMUP34S TI TTP4520 DMUP34S TN TGF-beta receptor type I (TGFBR1) DMUP34S MA Antagonist DMUP34S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788). DMUP34S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788 DMUP516 DI DMUP516 DMUP516 DN L-873724 DMUP516 TI TTDZN01 DMUP516 TN Cathepsin K (CTSK) DMUP516 MA Inhibitor DMUP516 RN The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. DMUP516 RU https://pubmed.ncbi.nlm.nih.gov/18226527 DMUP516 DI DMUP516 DMUP516 DN L-873724 DMUP516 TI TT36ETB DMUP516 TN Cathepsin L (CTSL) DMUP516 MA Inhibitor DMUP516 RN The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33. DMUP516 RU https://pubmed.ncbi.nlm.nih.gov/17590332 DMUP516 DI DMUP516 DMUP516 DN L-873724 DMUP516 TI TTF2LRI DMUP516 TN Cathepsin B (CTSB) DMUP516 MA Inhibitor DMUP516 RN The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33. DMUP516 RU https://pubmed.ncbi.nlm.nih.gov/17590332 DMUP516 DI DMUP516 DMUP516 DN L-873724 DMUP516 TI TTUMQVO DMUP516 TN Cathepsin S (CTSS) DMUP516 MA Inhibitor DMUP516 RN The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33. DMUP516 RU https://pubmed.ncbi.nlm.nih.gov/17590332 DMUP8NS DI DMUP8NS DMUP8NS DN 4-Methyl-5,6-dihydro-1H-pyridin-(2Z)-ylideneamine DMUP8NS TI TTCM4B3 DMUP8NS TN Nitric-oxide synthase endothelial (NOS3) DMUP8NS MA Inhibitor DMUP8NS RN Design and synthesis of orally bioavailable inhibitors of inducible nitric oxide synthase. Part 1: synthesis and biological evaluation of dihydropy... Bioorg Med Chem Lett. 2002 Sep 2;12(17):2291-4. DMUP8NS RU https://pubmed.ncbi.nlm.nih.gov/12161118 DMUPAR1 DI DMUPAR1 DMUPAR1 DN 1-Adamantan-1-yl-3-(4-hydroxy-phenyl)-urea DMUPAR1 TI TT7WVHI DMUPAR1 TN Soluble epoxide hydrolase (EPHX2) DMUPAR1 MA Inhibitor DMUPAR1 RN Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9. DMUPAR1 RU https://pubmed.ncbi.nlm.nih.gov/19216074 DMUPB9H DI DMUPB9H DMUPB9H DN 3-(2-methylquinolin-7-yl)benzonitrile DMUPB9H TI TTHS256 DMUPB9H TN Metabotropic glutamate receptor 5 (mGluR5) DMUPB9H MA Inhibitor DMUPB9H RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMUPB9H RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMUPCA6 DI DMUPCA6 DMUPCA6 DN s-allylglycine DMUPCA6 TI TT7UY6K DMUPCA6 TN Glutamate decarboxylase 2 (GAD2) DMUPCA6 MA Inhibitor DMUPCA6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1273). DMUPCA6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1273 DMUPCA6 DI DMUPCA6 DMUPCA6 DN s-allylglycine DMUPCA6 TI TTKGEP3 DMUPCA6 TN Glutamic acid decarboxylase 1 (GAD1) DMUPCA6 MA Inhibitor DMUPCA6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1272). DMUPCA6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1272 DMUPL3J DI DMUPL3J DMUPL3J DN Aplysinopsin DMUPL3J TI TTJQOD7 DMUPL3J TN 5-HT 2A receptor (HTR2A) DMUPL3J MA Inhibitor DMUPL3J RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMUPL3J RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMUPL3J DI DMUPL3J DMUPL3J DN Aplysinopsin DMUPL3J TI TTWJBZ5 DMUPL3J TN 5-HT 2C receptor (HTR2C) DMUPL3J MA Inhibitor DMUPL3J RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMUPL3J RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMUPMCZ DI DMUPMCZ DMUPMCZ DN Dodecane-Trimethylamine DMUPMCZ TI TT7WUAV DMUPMCZ TN Protein-tyrosine phosphatase SHP-2 (PTPN11) DMUPMCZ MA Inhibitor DMUPMCZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUPMCZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUPQED DI DMUPQED DMUPQED DN LUF-5417 DMUPQED TI TTM2AOE DMUPQED TN Adenosine A2a receptor (ADORA2A) DMUPQED MA Inhibitor DMUPQED RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMUPQED RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMUPQED DI DMUPQED DMUPQED DN LUF-5417 DMUPQED TI TTK25J1 DMUPQED TN Adenosine A1 receptor (ADORA1) DMUPQED MA Inhibitor DMUPQED RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMUPQED RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMUPQED DI DMUPQED DMUPQED DN LUF-5417 DMUPQED TI TTJFY5U DMUPQED TN Adenosine A3 receptor (ADORA3) DMUPQED MA Inhibitor DMUPQED RN 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203. DMUPQED RU https://pubmed.ncbi.nlm.nih.gov/20188574 DMUPS48 DI DMUPS48 DMUPS48 DN HMS3229G13 DMUPS48 TI TTK0FEA DMUPS48 TN Leucine-rich repeat kinase 2 (LRRK2) DMUPS48 MA Inhibitor DMUPS48 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2059). DMUPS48 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2059 DMUPWQT DI DMUPWQT DMUPWQT DN PGF1alpha DMUPWQT TI TT5CISB DMUPWQT TN Cation channel sperm-associated protein 1 (CatSper1) DMUPWQT MA Activator DMUPWQT RN Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91. DMUPWQT RU https://pubmed.ncbi.nlm.nih.gov/21412339 DMUPWQT DI DMUPWQT DMUPWQT DN PGF1alpha DMUPWQT TI TTWOCZI DMUPWQT TN Cation channel sperm-associated protein (CatSper) DMUPWQT MA Activator DMUPWQT RN Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91. DMUPWQT RU https://pubmed.ncbi.nlm.nih.gov/21412339 DMUPWQT DI DMUPWQT DMUPWQT DN PGF1alpha DMUPWQT TI TTOEGC4 DMUPWQT TN Cation channel sperm-associated protein 2 (CatSper2) DMUPWQT MA Activator DMUPWQT RN Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91. DMUPWQT RU https://pubmed.ncbi.nlm.nih.gov/21412339 DMUPWQT DI DMUPWQT DMUPWQT DN PGF1alpha DMUPWQT TI TTP52ZV DMUPWQT TN Cation channel sperm-associated protein 3 (CatSper3) DMUPWQT MA Activator DMUPWQT RN Progesterone activates the principal Ca2+ channel of human sperm. Nature. 2011 Mar 17;471(7338):387-91. DMUPWQT RU https://pubmed.ncbi.nlm.nih.gov/21412339 DMUPXBJ DI DMUPXBJ DMUPXBJ DN 7-fluoro-2-(4-methoxyphenyl)-4H-chromen-4-one DMUPXBJ TI TTGP7BY DMUPXBJ TN Monoamine oxidase type B (MAO-B) DMUPXBJ MA Inhibitor DMUPXBJ RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMUPXBJ RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMUPYN1 DI DMUPYN1 DMUPYN1 DN (+/-)-2-(4'-Propoxyphenyl)thiomorpholine DMUPYN1 TI TT3WG5C DMUPYN1 TN Monoamine oxidase type A (MAO-A) DMUPYN1 MA Inhibitor DMUPYN1 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMUPYN1 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMUPYN1 DI DMUPYN1 DMUPYN1 DN (+/-)-2-(4'-Propoxyphenyl)thiomorpholine DMUPYN1 TI TTGP7BY DMUPYN1 TN Monoamine oxidase type B (MAO-B) DMUPYN1 MA Inhibitor DMUPYN1 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMUPYN1 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMUQ0WI DI DMUQ0WI DMUQ0WI DN 3-(6-Ethoxy-naphthalen-2-yl)-pyridine DMUQ0WI TI TTSZLWK DMUQ0WI TN Aromatase (CYP19A1) DMUQ0WI MA Inhibitor DMUQ0WI RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMUQ0WI RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMUQ0WI DI DMUQ0WI DMUQ0WI DN 3-(6-Ethoxy-naphthalen-2-yl)-pyridine DMUQ0WI TI TTIQUX7 DMUQ0WI TN Steroid 11-beta-hydroxylase (CYP11B1) DMUQ0WI MA Inhibitor DMUQ0WI RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMUQ0WI RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMUQ0WI DI DMUQ0WI DMUQ0WI DN 3-(6-Ethoxy-naphthalen-2-yl)-pyridine DMUQ0WI TI TTRA5BZ DMUQ0WI TN Steroid 17-alpha-monooxygenase (S17AH) DMUQ0WI MA Inhibitor DMUQ0WI RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMUQ0WI RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMUQ6FW DI DMUQ6FW DMUQ6FW DN Rac-4'-(1-Imidazol-1-yl-propyl)-biphenyl-4-ol DMUQ6FW TI TTRA5BZ DMUQ6FW TN Steroid 17-alpha-monooxygenase (S17AH) DMUQ6FW MA Inhibitor DMUQ6FW RN Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyl... Eur J Med Chem. 2009 Jul;44(7):2765-75. DMUQ6FW RU https://pubmed.ncbi.nlm.nih.gov/19211174 DMUQ6P4 DI DMUQ6P4 DMUQ6P4 DN N-(1-benzylpiperidine-4-yl)-2-naphthamide DMUQ6P4 TI TTJQOD7 DMUQ6P4 TN 5-HT 2A receptor (HTR2A) DMUQ6P4 MA Inhibitor DMUQ6P4 RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part II: Influence of the substitution on the benzyl moiety on the a... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1570-4. DMUQ6P4 RU https://pubmed.ncbi.nlm.nih.gov/17251022 DMUQ6XH DI DMUQ6XH DMUQ6XH DN AIKO-151 DMUQ6XH TI TTKWM86 DMUQ6XH TN Opioid receptor mu (MOP) DMUQ6XH MA Antagonist DMUQ6XH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMUQ6XH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMUQAP7 DI DMUQAP7 DMUQAP7 DN 29-methylidene-2,3-oxidosqualene DMUQAP7 TI TT7O8ZA DMUQAP7 TN Lanosterol synthase (LSS) DMUQAP7 MA Inhibitor DMUQAP7 RN Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9. DMUQAP7 RU https://pubmed.ncbi.nlm.nih.gov/9003518 DMUQBOP DI DMUQBOP DMUQBOP DN N-(tert-butoxycarbonyl)-valyl-glycine-nitrile DMUQBOP TI TTUMQVO DMUQBOP TN Cathepsin S (CTSS) DMUQBOP MA Inhibitor DMUQBOP RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMUQBOP RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMUQBOP DI DMUQBOP DMUQBOP DN N-(tert-butoxycarbonyl)-valyl-glycine-nitrile DMUQBOP TI TT36ETB DMUQBOP TN Cathepsin L (CTSL) DMUQBOP MA Inhibitor DMUQBOP RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMUQBOP RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMUQBOP DI DMUQBOP DMUQBOP DN N-(tert-butoxycarbonyl)-valyl-glycine-nitrile DMUQBOP TI TTDZN01 DMUQBOP TN Cathepsin K (CTSK) DMUQBOP MA Inhibitor DMUQBOP RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMUQBOP RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMUQHMP DI DMUQHMP DMUQHMP DN Inhibitor 1 [Colombo et al., 2012] DMUQHMP TI TTL9KE7 DMUQHMP TN Transmembrane protease serine 6 (TMPRSS6) DMUQHMP MA Inhibitor DMUQHMP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2422). DMUQHMP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2422 DMUQHMP DI DMUQHMP DMUQHMP DN Inhibitor 1 [Colombo et al., 2012] DMUQHMP TI TTPRO7W DMUQHMP TN Suppressor of tumorigenicity 14 protein (ST14) DMUQHMP MA Inhibitor DMUQHMP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2418). DMUQHMP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2418 DMUQHMP DI DMUQHMP DMUQHMP DN Inhibitor 1 [Colombo et al., 2012] DMUQHMP TI TTWHYC8 DMUQHMP TN Airway trypsin-like protease (TMPRSS11D) DMUQHMP MA Inhibitor DMUQHMP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2420). DMUQHMP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2420 DMUQJ6X DI DMUQJ6X DMUQJ6X DN CCG-50014 DMUQJ6X TI TTGTKX9 DMUQJ6X TN Regulator of G-protein signaling 4 (RGS4) DMUQJ6X MA Inhibitor DMUQJ6X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2811). DMUQJ6X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2811 DMUQJ6X DI DMUQJ6X DMUQJ6X DN CCG-50014 DMUQJ6X TI TTWME23 DMUQJ6X TN Regulator of G-protein signaling 8 (RGS8) DMUQJ6X MA Inhibitor DMUQJ6X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2813). DMUQJ6X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2813 DMUQLRN DI DMUQLRN DMUQLRN DN H-Tyr-Pro-Phe-Phe-OH DMUQLRN TI TTZPO1L DMUQLRN TN Substance-P receptor (TACR1) DMUQLRN MA Inhibitor DMUQLRN RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMUQLRN RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMUQO86 DI DMUQO86 DMUQO86 DN IM-491 DMUQO86 TI TT6AZXG DMUQO86 TN TNF alpha converting enzyme (ADAM17) DMUQO86 MA Inhibitor DMUQO86 RN Discovery of beta-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):241-6. DMUQO86 RU https://pubmed.ncbi.nlm.nih.gov/18032037 DMUQP3J DI DMUQP3J DMUQP3J DN Mycophenolic bis(sulfonamide) DMUQP3J TI TTTB4UP DMUQP3J TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMUQP3J MA Inhibitor DMUQP3J RN Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 1;16(15):7462-9. DMUQP3J RU https://pubmed.ncbi.nlm.nih.gov/18583139 DMUQP3J DI DMUQP3J DMUQP3J DN Mycophenolic bis(sulfonamide) DMUQP3J TI TTZFTY4 DMUQP3J TN Amidophosphoribosyltransferase (PPAT) DMUQP3J MA Inhibitor DMUQP3J RN Bis(sulfonamide) isosters of mycophenolic adenine dinucleotide analogues: inhibition of inosine monophosphate dehydrogenase. Bioorg Med Chem. 2008 Aug 1;16(15):7462-9. DMUQP3J RU https://pubmed.ncbi.nlm.nih.gov/18583139 DMUQWJZ DI DMUQWJZ DMUQWJZ DN 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol DMUQWJZ TI TT34BHT DMUQWJZ TN Adrenergic receptor alpha-1D (ADRA1D) DMUQWJZ MA Inhibitor DMUQWJZ RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DMUQWJZ RU https://pubmed.ncbi.nlm.nih.gov/1313109 DMUQWJZ DI DMUQWJZ DMUQWJZ DN 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol DMUQWJZ TI TTBRKXS DMUQWJZ TN Adrenergic receptor alpha-1B (ADRA1B) DMUQWJZ MA Inhibitor DMUQWJZ RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DMUQWJZ RU https://pubmed.ncbi.nlm.nih.gov/1313109 DMUQWJZ DI DMUQWJZ DMUQWJZ DN 4-(3-Hydroxy-piperidin-3-yl)-benzene-1,2-diol DMUQWJZ TI TTNGILX DMUQWJZ TN Adrenergic receptor alpha-1A (ADRA1A) DMUQWJZ MA Inhibitor DMUQWJZ RN Conformational effects on the activity of drugs. 13. A revision of previously proposed models for the activation of alpha- and beta-adrenergic rece... J Med Chem. 1992 Mar 20;35(6):1009-18. DMUQWJZ RU https://pubmed.ncbi.nlm.nih.gov/1313109 DMUQWP1 DI DMUQWP1 DMUQWP1 DN Zaragozic Acid C DMUQWP1 TI TTFQEO5 DMUQWP1 TN Squalene synthetase (FDFT1) DMUQWP1 MA Inhibitor DMUQWP1 RN Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9. DMUQWP1 RU https://pubmed.ncbi.nlm.nih.gov/8289063 DMUQWPZ DI DMUQWPZ DMUQWPZ DN 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine DMUQWPZ TI TTQW87Y DMUQWPZ TN Opioid receptor kappa (OPRK1) DMUQWPZ MA Inhibitor DMUQWPZ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMUQWPZ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMUQWPZ DI DMUQWPZ DMUQWPZ DN 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine DMUQWPZ TI TT27RFC DMUQWPZ TN Opioid receptor delta (OPRD1) DMUQWPZ MA Inhibitor DMUQWPZ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMUQWPZ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMUQWPZ DI DMUQWPZ DMUQWPZ DN 17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine DMUQWPZ TI TTKWM86 DMUQWPZ TN Opioid receptor mu (MOP) DMUQWPZ MA Inhibitor DMUQWPZ RN Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18. DMUQWPZ RU https://pubmed.ncbi.nlm.nih.gov/19928862 DMUR0TF DI DMUR0TF DMUR0TF DN Tu-514 DMUR0TF TI TT0OFWN DMUR0TF TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DMUR0TF MA Inhibitor DMUR0TF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUR0TF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUR2TH DI DMUR2TH DMUR2TH DN ISIS 25566 DMUR2TH TI TTP2U16 DMUR2TH TN RhoA messenger RNA (RHOA mRNA) DMUR2TH RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMUR2TH RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMUR97N DI DMUR97N DMUR97N DN 8-dibenzofuran-4-yl-2-morpholin-4-ylchromen-4-one DMUR97N TI TTK3PY9 DMUR97N TN DNA-dependent protein kinase catalytic (PRKDC) DMUR97N MA Inhibitor DMUR97N RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMUR97N RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMUR9LM DI DMUR9LM DMUR9LM DN RG-50810 DMUR9LM TI TTGKNB4 DMUR9LM TN Epidermal growth factor receptor (EGFR) DMUR9LM MA Inhibitor DMUR9LM RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMUR9LM RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMURB4Y DI DMURB4Y DMURB4Y DN pobilukast DMURB4Y TI TT0PZR5 DMURB4Y TN Leukotriene CysLT2 receptor (CYSLTR2) DMURB4Y MA Antagonist DMURB4Y RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 270). DMURB4Y RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=270 DMURB4Y DI DMURB4Y DMURB4Y DN pobilukast DMURB4Y TI TTGKOY9 DMURB4Y TN Leukotriene CysLT1 receptor (CYSLTR1) DMURB4Y MA Antagonist DMURB4Y RN Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol. 1999 Sep;56(3):657-63. DMURB4Y RU https://pubmed.ncbi.nlm.nih.gov/10462554 DMURC6X DI DMURC6X DMURC6X DN NBI-74330 DMURC6X TI TT1UCIJ DMURC6X TN C-X-C chemokine receptor type 3 (CXCR3) DMURC6X MA Antagonist DMURC6X RN Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther. 2005 Jun;313(3):1263-71. DMURC6X RU https://pubmed.ncbi.nlm.nih.gov/15761110 DMURD2E DI DMURD2E DMURD2E DN CYM5442 DMURD2E TI TT9JZCK DMURD2E TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMURD2E MA Agonist DMURD2E RN Full pharmacological efficacy of a novel S1P1 agonist that does not require S1P-like headgroup interactions. Mol Pharmacol. 2008 Nov;74(5):1308-18. DMURD2E RU https://pubmed.ncbi.nlm.nih.gov/18708635 DMURJ34 DI DMURJ34 DMURJ34 DN 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione DMURJ34 TI TTN9D8E DMURJ34 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMURJ34 MA Inhibitor DMURJ34 RN 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. DMURJ34 RU https://pubmed.ncbi.nlm.nih.gov/9357535 DMURJ34 DI DMURJ34 DMURJ34 DN 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione DMURJ34 TI TTKJEMQ DMURJ34 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMURJ34 MA Inhibitor DMURJ34 RN 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. DMURJ34 RU https://pubmed.ncbi.nlm.nih.gov/9357535 DMURJ34 DI DMURJ34 DMURJ34 DN 6-Chloro-1,4-dihydro-quinoxaline-2,3-dione DMURJ34 TI TTLD29N DMURJ34 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMURJ34 MA Inhibitor DMURJ34 RN 5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and... J Med Chem. 1997 Oct 24;40(22):3679-86. DMURJ34 RU https://pubmed.ncbi.nlm.nih.gov/9357535 DMURKL9 DI DMURKL9 DMURKL9 DN 9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine DMURKL9 TI TTK25J1 DMURKL9 TN Adenosine A1 receptor (ADORA1) DMURKL9 MA Inhibitor DMURKL9 RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DMURKL9 RU https://pubmed.ncbi.nlm.nih.gov/18411049 DMURKL9 DI DMURKL9 DMURKL9 DN 9-(4-nitrobenzyl)-6-(furan-2-yl)-9H-purin-2-amine DMURKL9 TI TTM2AOE DMURKL9 TN Adenosine A2a receptor (ADORA2A) DMURKL9 MA Inhibitor DMURKL9 RN Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpu... Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. DMURKL9 RU https://pubmed.ncbi.nlm.nih.gov/18411049 DMURL8D DI DMURL8D DMURL8D DN JWH-248 DMURL8D TI TTMSFAW DMURL8D TN Cannabinoid receptor 2 (CB2) DMURL8D MA Inhibitor DMURL8D RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMURL8D RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMUROGX DI DMUROGX DMUROGX DN Methyl 4-(4-hydroxybenzylideneamino)benzoate DMUROGX TI TTANPDJ DMUROGX TN Carbonic anhydrase II (CA-II) DMUROGX MA Inhibitor DMUROGX RN Carbonic anhydrase II-induced selection of inhibitors from a dynamic combinatorial library of Schiff's bases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6014-7. DMUROGX RU https://pubmed.ncbi.nlm.nih.gov/19796939 DMUROIY DI DMUROIY DMUROIY DN PSN-101 DMUROIY TI TTDLNGZ DMUROIY TN Glucokinase (GCK) DMUROIY MA Activator DMUROIY RN CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008. DMUROIY RU http://www.centerwatch.com/ DMURP5Y DI DMURP5Y DMURP5Y DN PMID23084894C10i DMURP5Y TI TTVBPDM DMURP5Y TN Metabotropic glutamate receptor 1 (mGluR1) DMURP5Y MA Modulator (allosteric modulator) DMURP5Y RN Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7223-6. DMURP5Y RU https://pubmed.ncbi.nlm.nih.gov/23084894 DMURTHE DI DMURTHE DMURTHE DN 5-Azido-6-benzyl-2-methyl-[1,8]naphthyridine DMURTHE TI TTM2AOE DMURTHE TN Adenosine A2a receptor (ADORA2A) DMURTHE MA Inhibitor DMURTHE RN 1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4604-10. DMURTHE RU https://pubmed.ncbi.nlm.nih.gov/16099648 DMUS0A4 DI DMUS0A4 DMUS0A4 DN 3,3-dimethyl-5-m-tolyl-2,3-dihydro-1H-inden-1-one DMUS0A4 TI TTUV8G9 DMUS0A4 TN Progesterone receptor (PGR) DMUS0A4 MA Inhibitor DMUS0A4 RN 5-Aryl indanones and derivatives as non-steroidal progesterone receptor modulators. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6666-9. DMUS0A4 RU https://pubmed.ncbi.nlm.nih.gov/19864132 DMUS0D8 DI DMUS0D8 DMUS0D8 DN (E)-3-(4-(methylsulfonyl)styryl)thiophene DMUS0D8 TI TTVKILB DMUS0D8 TN Prostaglandin G/H synthase 2 (COX-2) DMUS0D8 MA Inhibitor DMUS0D8 RN Sulfonamide derivatives of styrylheterocycles as a potent inhibitor of COX-2-mediated prostaglandin E2 production. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6938-41. DMUS0D8 RU https://pubmed.ncbi.nlm.nih.gov/20970329 DMUS7EH DI DMUS7EH DMUS7EH DN [3H]SB-733993 DMUS7EH TI TTHJTF7 DMUS7EH TN Glycine transporter GlyT-1 (SLC6A9) DMUS7EH MA Modulator DMUS7EH RN Pharmacological characterisation of the GlyT-1 glycine transporter using two novel radioligands. Neuropharmacology. 2010 Nov;59(6):558-65. DMUS7EH RU https://pubmed.ncbi.nlm.nih.gov/20691713 DMUS9Z3 DI DMUS9Z3 DMUS9Z3 DN 1-(6-Amino-4-methylpyridin-2-yl)propan-2-ol DMUS9Z3 TI TTF10I9 DMUS9Z3 TN Nitric-oxide synthase inducible (NOS2) DMUS9Z3 MA Inhibitor DMUS9Z3 RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DMUS9Z3 RU https://pubmed.ncbi.nlm.nih.gov/19323559 DMUSAYG DI DMUSAYG DMUSAYG DN GNF-PF-173 DMUSAYG TI TT9SL3Q DMUSAYG TN Polypeptide deformylase (PDF) DMUSAYG MA Inhibitor DMUSAYG RN Synthesis and biological evaluation of poly-gamma-glutamyl metabolites of 10-deazaaminopterin and 10-ethyl-10-deazaaminopterin. J Med Chem. 1988 Jan;31(1):181-5. DMUSAYG RU https://pubmed.ncbi.nlm.nih.gov/2447278 DMUSEDF DI DMUSEDF DMUSEDF DN Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) DMUSEDF TI TT5ZKDI DMUSEDF TN Histone deacetylase 6 (HDAC6) DMUSEDF MA Inhibitor DMUSEDF RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMUSEDF RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMUSEDF DI DMUSEDF DMUSEDF DN Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) DMUSEDF TI TT6R7JZ DMUSEDF TN Histone deacetylase 1 (HDAC1) DMUSEDF MA Inhibitor DMUSEDF RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMUSEDF RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMUSEDF DI DMUSEDF DMUSEDF DN Cyclo(-L-Am7(S2Py)-Aib-L-Phg-D-Pro-) DMUSEDF TI TTTQGH8 DMUSEDF TN Histone deacetylase 4 (HDAC4) DMUSEDF MA Inhibitor DMUSEDF RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMUSEDF RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMUSEOW DI DMUSEOW DMUSEOW DN 1-(2-Bromo-phenyl)-3-(2,4-dihydroxy-phenyl)-urea DMUSEOW TI TTMWT8Z DMUSEOW TN C-X-C chemokine receptor type 1 (CXCR1) DMUSEOW MA Inhibitor DMUSEOW RN Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleuki... Bioorg Med Chem Lett. 2004 Aug 16;14(16):4307-11. DMUSEOW RU https://pubmed.ncbi.nlm.nih.gov/15261292 DMUSGYQ DI DMUSGYQ DMUSGYQ DN Carinatumins B (2) DMUSGYQ TI TT1RS9F DMUSGYQ TN Acetylcholinesterase (AChE) DMUSGYQ MA Inhibitor DMUSGYQ RN Carinatumins A-C, new alkaloids from Lycopodium carinatum inhibiting acetylcholinesterase. Bioorg Med Chem. 2007 Feb 15;15(4):1703-7. DMUSGYQ RU https://pubmed.ncbi.nlm.nih.gov/17188496 DMUSHZK DI DMUSHZK DMUSHZK DN N-hydroxy-4-(oleamidomethyl)benzamide DMUSHZK TI TTIQSC1 DMUSHZK TN Bacterial Lethal factor (Bact lef) DMUSHZK MA Inhibitor DMUSHZK RN Inhibitors of anthrax lethal factor based upon N-oleoyldopamine. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2467-70. DMUSHZK RU https://pubmed.ncbi.nlm.nih.gov/18314330 DMUSJ96 DI DMUSJ96 DMUSJ96 DN Geldanamycin-estradiol hybrid DMUSJ96 TI TTR5TV4 DMUSJ96 TN ERBB2 messenger RNA (HER2 mRNA) DMUSJ96 MA Inhibitor DMUSJ96 RN Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. DMUSJ96 RU https://pubmed.ncbi.nlm.nih.gov/10340605 DMUSJ96 DI DMUSJ96 DMUSJ96 DN Geldanamycin-estradiol hybrid DMUSJ96 TI TTOM3J0 DMUSJ96 TN Estrogen receptor beta (ESR2) DMUSJ96 MA Inhibitor DMUSJ96 RN Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. DMUSJ96 RU https://pubmed.ncbi.nlm.nih.gov/10340605 DMUSJ96 DI DMUSJ96 DMUSJ96 DN Geldanamycin-estradiol hybrid DMUSJ96 TI TT78R5H DMUSJ96 TN Heat shock protein 90 alpha (HSP90A) DMUSJ96 MA Inhibitor DMUSJ96 RN Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. DMUSJ96 RU https://pubmed.ncbi.nlm.nih.gov/10340605 DMUSJ96 DI DMUSJ96 DMUSJ96 DN Geldanamycin-estradiol hybrid DMUSJ96 TI TTZAYWL DMUSJ96 TN Estrogen receptor (ESR) DMUSJ96 MA Inhibitor DMUSJ96 RN Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8. DMUSJ96 RU https://pubmed.ncbi.nlm.nih.gov/10340605 DMUSPIC DI DMUSPIC DMUSPIC DN 3,4-dichlorobenzaldehyde thiosemicarbazone DMUSPIC TI TTEAID7 DMUSPIC TN Trypanosoma Cruzipain (Trypano CYSP) DMUSPIC MA Inhibitor DMUSPIC RN Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707. DMUSPIC RU https://pubmed.ncbi.nlm.nih.gov/12061873 DMUSRJ8 DI DMUSRJ8 DMUSRJ8 DN IBZM DMUSRJ8 TI TTZFYLI DMUSRJ8 TN Dopamine D1 receptor (D1R) DMUSRJ8 MA Inhibitor DMUSRJ8 RN In vitro affinities of various halogenated benzamide derivatives as potential radioligands for non-invasive quantification of D(2)-like dopamine re... Bioorg Med Chem. 2007 Nov 1;15(21):6819-29. DMUSRJ8 RU https://pubmed.ncbi.nlm.nih.gov/17765546 DMUSRJ8 DI DMUSRJ8 DMUSRJ8 DN IBZM DMUSRJ8 TI TTEX248 DMUSRJ8 TN Dopamine D2 receptor (D2R) DMUSRJ8 MA Inhibitor DMUSRJ8 RN Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8. DMUSRJ8 RU https://pubmed.ncbi.nlm.nih.gov/8093734 DMUSYKG DI DMUSYKG DMUSYKG DN AR-129330 DMUSYKG TI TTX4RTB DMUSYKG TN Melanin-concentrating hormone receptor 1 (MCHR1) DMUSYKG MA Inhibitor DMUSYKG RN Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6. DMUSYKG RU https://pubmed.ncbi.nlm.nih.gov/16002290 DMUSYKG DI DMUSYKG DMUSYKG DN AR-129330 DMUSYKG TI TTWG9A4 DMUSYKG TN Adrenergic receptor alpha-2A (ADRA2A) DMUSYKG MA Inhibitor DMUSYKG RN Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6. DMUSYKG RU https://pubmed.ncbi.nlm.nih.gov/16002290 DMUSYKG DI DMUSYKG DMUSYKG DN AR-129330 DMUSYKG TI TTY6EWA DMUSYKG TN Neuropeptide Y receptor type 5 (NPY5R) DMUSYKG MA Inhibitor DMUSYKG RN Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6. DMUSYKG RU https://pubmed.ncbi.nlm.nih.gov/16002290 DMUTBZ8 DI DMUTBZ8 DMUTBZ8 DN SK554 DMUTBZ8 TI TTCIHJA DMUTBZ8 TN Coagulation factor Xa (F10) DMUTBZ8 MA Inhibitor DMUTBZ8 RN Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32. DMUTBZ8 RU https://pubmed.ncbi.nlm.nih.gov/11804648 DMUTC9Z DI DMUTC9Z DMUTC9Z DN ST-1535 DMUTC9Z TI TTNE7KG DMUTC9Z TN Adenosine A2b receptor (ADORA2B) DMUTC9Z MA Inhibitor DMUTC9Z RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMUTC9Z RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMUTC9Z DI DMUTC9Z DMUTC9Z DN ST-1535 DMUTC9Z TI TTM2AOE DMUTC9Z TN Adenosine A2a receptor (ADORA2A) DMUTC9Z MA Inhibitor DMUTC9Z RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMUTC9Z RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMUTC9Z DI DMUTC9Z DMUTC9Z DN ST-1535 DMUTC9Z TI TTK25J1 DMUTC9Z TN Adenosine A1 receptor (ADORA1) DMUTC9Z MA Inhibitor DMUTC9Z RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMUTC9Z RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMUTDNV DI DMUTDNV DMUTDNV DN N-Propyl-ETAV DMUTDNV TI TT9PB26 DMUTDNV TN Presynaptic density protein 95 (DLG4) DMUTDNV MA Inhibitor DMUTDNV RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMUTDNV RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMUTEWI DI DMUTEWI DMUTEWI DN PD-135118 DMUTEWI TI TTVFO0U DMUTEWI TN Gastrin/cholecystokinin type B receptor (CCKBR) DMUTEWI MA Inhibitor DMUTEWI RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMUTEWI RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMUTEWI DI DMUTEWI DMUTEWI DN PD-135118 DMUTEWI TI TTCG0AL DMUTEWI TN Cholecystokinin receptor type A (CCKAR) DMUTEWI MA Inhibitor DMUTEWI RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMUTEWI RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMUTV5P DI DMUTV5P DMUTV5P DN POLYGALATENOSIDE B DMUTV5P TI TTAWNKZ DMUTV5P TN Norepinephrine transporter (NET) DMUTV5P MA Inhibitor DMUTV5P RN Antidepressant principles of the roots of Polygala tenuifolia. J Nat Prod. 2006 Sep;69(9):1305-9. DMUTV5P RU https://pubmed.ncbi.nlm.nih.gov/16989524 DMUTV76 DI DMUTV76 DMUTV76 DN 8-Bromo-9-cyclobutyl-9H-adenine DMUTV76 TI TTJFY5U DMUTV76 TN Adenosine A3 receptor (ADORA3) DMUTV76 MA Inhibitor DMUTV76 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMUTV76 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMUTV76 DI DMUTV76 DMUTV76 DN 8-Bromo-9-cyclobutyl-9H-adenine DMUTV76 TI TTK25J1 DMUTV76 TN Adenosine A1 receptor (ADORA1) DMUTV76 MA Inhibitor DMUTV76 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMUTV76 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMUTV76 DI DMUTV76 DMUTV76 DN 8-Bromo-9-cyclobutyl-9H-adenine DMUTV76 TI TTNE7KG DMUTV76 TN Adenosine A2b receptor (ADORA2B) DMUTV76 MA Inhibitor DMUTV76 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMUTV76 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMUTV76 DI DMUTV76 DMUTV76 DN 8-Bromo-9-cyclobutyl-9H-adenine DMUTV76 TI TTM2AOE DMUTV76 TN Adenosine A2a receptor (ADORA2A) DMUTV76 MA Inhibitor DMUTV76 RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMUTV76 RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMUV3ZW DI DMUV3ZW DMUV3ZW DN Tyr-Pro-Imp-Phe-NH2 DMUV3ZW TI TTKWM86 DMUV3ZW TN Opioid receptor mu (MOP) DMUV3ZW MA Inhibitor DMUV3ZW RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMUV3ZW RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMUV3ZW DI DMUV3ZW DMUV3ZW DN Tyr-Pro-Imp-Phe-NH2 DMUV3ZW TI TT27RFC DMUV3ZW TN Opioid receptor delta (OPRD1) DMUV3ZW MA Inhibitor DMUV3ZW RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMUV3ZW RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMUVAFO DI DMUVAFO DMUVAFO DN SKLB-010 DMUVAFO TI TTF10I9 DMUVAFO TN Nitric-oxide synthase inducible (NOS2) DMUVAFO MA Modulator DMUVAFO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1250). DMUVAFO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1250 DMUVAIF DI DMUVAIF DMUVAIF DN ISONICOTINIC ACID DMUVAIF TI TTWNV8U DMUVAIF TN Nicotinic acid receptor (HCAR2) DMUVAIF MA Inhibitor DMUVAIF RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMUVAIF RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMUVCRQ DI DMUVCRQ DMUVCRQ DN Hydroxyaminovaline DMUVCRQ TI TTHY57M DMUVCRQ TN Matrix metalloproteinase-13 (MMP-13) DMUVCRQ MA Inhibitor DMUVCRQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUVCRQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUVCRQ DI DMUVCRQ DMUVCRQ DN Hydroxyaminovaline DMUVCRQ TI TTUZ2L5 DMUVCRQ TN Matrix metalloproteinase-3 (MMP-3) DMUVCRQ MA Inhibitor DMUVCRQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUVCRQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUVCWY DI DMUVCWY DMUVCWY DN Pyridoxyl-Alanine-5-Phosphate DMUVCWY TI TT6TMZU DMUVCWY TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMUVCWY MA Inhibitor DMUVCWY RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUVCWY RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUVHGS DI DMUVHGS DMUVHGS DN Tyr-Pro-L-Phe-D-Pro-NH2 DMUVHGS TI TTKWM86 DMUVHGS TN Opioid receptor mu (MOP) DMUVHGS MA Inhibitor DMUVHGS RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMUVHGS RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMUVHGS DI DMUVHGS DMUVHGS DN Tyr-Pro-L-Phe-D-Pro-NH2 DMUVHGS TI TT27RFC DMUVHGS TN Opioid receptor delta (OPRD1) DMUVHGS MA Inhibitor DMUVHGS RN A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19. DMUVHGS RU https://pubmed.ncbi.nlm.nih.gov/8384662 DMUVKX5 DI DMUVKX5 DMUVKX5 DN SOPHORAFLAVANONE B DMUVKX5 TI TTZAYWL DMUVKX5 TN Estrogen receptor (ESR) DMUVKX5 MA Inhibitor DMUVKX5 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMUVKX5 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMUVKX5 DI DMUVKX5 DMUVKX5 DN SOPHORAFLAVANONE B DMUVKX5 TI TTOM3J0 DMUVKX5 TN Estrogen receptor beta (ESR2) DMUVKX5 MA Inhibitor DMUVKX5 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMUVKX5 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMUVKX5 DI DMUVKX5 DMUVKX5 DN SOPHORAFLAVANONE B DMUVKX5 TI TTJ0IQB DMUVKX5 TN Phosphodiesterase 5A (PDE5A) DMUVKX5 MA Inhibitor DMUVKX5 RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DMUVKX5 RU https://pubmed.ncbi.nlm.nih.gov/18778098 DMUVP5L DI DMUVP5L DMUVP5L DN N5-[4-(Phenylmethoxy)phenyl]-D-glutamine DMUVP5L TI TTXZEAJ DMUVP5L TN Leukotriene A-4 hydrolase (LTA4H) DMUVP5L MA Inhibitor DMUVP5L RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMUVP5L RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMUVQFW DI DMUVQFW DMUVQFW DN CT301 DMUVQFW TI TT4BT06 DMUVQFW TN Integrin alpha-4 (ITGA4) DMUVQFW MA Antagonist DMUVQFW RN Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of alpha4 integrin. J Neuroimmunol. 2002 Oct;131(1-2):147-59. DMUVQFW RU https://pubmed.ncbi.nlm.nih.gov/12458046 DMUVR5T DI DMUVR5T DMUVR5T DN DEMETHYLMEDICARPIN DMUVR5T TI TT50QJ3 DMUVR5T TN Influenza Neuraminidase (Influ NA) DMUVR5T MA Inhibitor DMUVR5T RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMUVR5T RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMUVS0E DI DMUVS0E DMUVS0E DN ISIS 114170 DMUVS0E TI TTWIJYH DMUVS0E TN E2F3 messenger RNA (E2F3 mRNA) DMUVS0E RN US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression. DMUVS0E RU http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true DMUVSM1 DI DMUVSM1 DMUVSM1 DN N-(2,5-dichlorophenyl)-4-methoxy-3-nitrobenzamide DMUVSM1 TI TTVTX4N DMUVSM1 TN Bacterial Fatty acid synthetase I (Bact inhA) DMUVSM1 MA Inhibitor DMUVSM1 RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMUVSM1 RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMUVXZQ DI DMUVXZQ DMUVXZQ DN FVPTDVGPFAF DMUVXZQ TI TTY6O0Q DMUVXZQ TN Calcitonin gene-related peptide receptor (CGRPR) DMUVXZQ MA Inhibitor DMUVXZQ RN Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24. DMUVXZQ RU https://pubmed.ncbi.nlm.nih.gov/16420047 DMUW07J DI DMUW07J DMUW07J DN 16-beta-hydroxymethyl-estradiol DMUW07J TI TTIWB6L DMUW07J TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMUW07J MA Inhibitor DMUW07J RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMUW07J RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMUW1GI DI DMUW1GI DMUW1GI DN 1-(4-Chloro-phenyl)-3-(3-pentyl-oct-2-enyl)-urea DMUW1GI TI TTCG0AL DMUW1GI TN Cholecystokinin receptor type A (CCKAR) DMUW1GI MA Inhibitor DMUW1GI RN Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9. DMUW1GI RU https://pubmed.ncbi.nlm.nih.gov/1552499 DMUW2EJ DI DMUW2EJ DMUW2EJ DN 1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione DMUW2EJ TI TTMF541 DMUW2EJ TN Liver carboxylesterase (CES1) DMUW2EJ MA Inhibitor DMUW2EJ RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMUW2EJ RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMUW3MT DI DMUW3MT DMUW3MT DN PMID23849879C3 DMUW3MT TI TTPRO7W DMUW3MT TN Suppressor of tumorigenicity 14 protein (ST14) DMUW3MT MA Inhibitor DMUW3MT RN 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51. DMUW3MT RU https://pubmed.ncbi.nlm.nih.gov/23849879 DMUW3MT DI DMUW3MT DMUW3MT DN PMID23849879C3 DMUW3MT TI TTULSEW DMUW3MT TN Kallikrein-5 (KLK5) DMUW3MT MA Inhibitor DMUW3MT RN 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51. DMUW3MT RU https://pubmed.ncbi.nlm.nih.gov/23849879 DMUW3MT DI DMUW3MT DMUW3MT DN PMID23849879C3 DMUW3MT TI TTE6GTB DMUW3MT TN Kallikrein-7 (KLK7) DMUW3MT MA Inhibitor DMUW3MT RN 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51. DMUW3MT RU https://pubmed.ncbi.nlm.nih.gov/23849879 DMUW3MT DI DMUW3MT DMUW3MT DN PMID23849879C3 DMUW3MT TI TTDA81R DMUW3MT TN Kallikrein-14 (KLK14) DMUW3MT MA Inhibitor DMUW3MT RN 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases. Bioorg Med Chem Lett. 2013 Aug 15;23(16):4547-51. DMUW3MT RU https://pubmed.ncbi.nlm.nih.gov/23849879 DMUW3T4 DI DMUW3T4 DMUW3T4 DN Ac-I[CVWQDWG(Abu)HRC]T-NH2 DMUW3T4 TI TTJGY7A DMUW3T4 TN Complement C3 (CO3) DMUW3T4 MA Inhibitor DMUW3T4 RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMUW3T4 RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMUW4KG DI DMUW4KG DMUW4KG DN YAWF-NH2 DMUW4KG TI TTKWM86 DMUW4KG TN Opioid receptor mu (MOP) DMUW4KG MA Inhibitor DMUW4KG RN Internalisation of the mu-opioid receptor by endomorphin-1 and leu-enkephalin is dependant on aromatic amino acid residues. Bioorg Med Chem. 2008 Apr 15;16(8):4341-6. DMUW4KG RU https://pubmed.ncbi.nlm.nih.gov/18329886 DMUW87A DI DMUW87A DMUW87A DN Bz--RYYRIK-NH2 DMUW87A TI TTNT7K8 DMUW87A TN Nociceptin receptor (OPRL1) DMUW87A MA Inhibitor DMUW87A RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMUW87A RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMUW94S DI DMUW94S DMUW94S DN 2,3-dihydrobenzo[d]thiazole-2-thiol DMUW94S TI TTZJYKH DMUW94S TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMUW94S MA Inhibitor DMUW94S RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMUW94S RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMUWA2G DI DMUWA2G DMUWA2G DN KAEMPFERIDE DMUWA2G TI TTI84H7 DMUWA2G TN Cytochrome P450 1B1 (CYP1B1) DMUWA2G MA Inhibitor DMUWA2G RN Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem. 2010 Sep 1;18(17):6310-5. DMUWA2G RU https://pubmed.ncbi.nlm.nih.gov/20696580 DMUWC5O DI DMUWC5O DMUWC5O DN Cyclo(-D-Tyr-D-Arg-L-MeArg-L-Nal-Gly-) DMUWC5O TI TTBID49 DMUWC5O TN C-X-C chemokine receptor type 4 (CXCR4) DMUWC5O MA Inhibitor DMUWC5O RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMUWC5O RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMUWE81 DI DMUWE81 DMUWE81 DN Bip-tyr-thr-ala-pro-phe DMUWE81 TI TTVBI8W DMUWE81 TN Dopamine transporter (DAT) DMUWE81 MA Inhibitor DMUWE81 RN Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction. J Med Chem. 2006 Jul 13;49(14):4048-51. DMUWE81 RU https://pubmed.ncbi.nlm.nih.gov/16821765 DMUWI2F DI DMUWI2F DMUWI2F DN Ac-Cys-Ile-Tyr-Lys-Phe(4-Cl)-Tyr DMUWI2F TI TT6PKBN DMUWI2F TN Proto-oncogene c-Src (SRC) DMUWI2F MA Inhibitor DMUWI2F RN Synthesis and structure-activity relationships of linear and conformationally constrained peptide analogues of CIYKYY as Src tyrosine kinase inhibi... J Med Chem. 2006 Jun 1;49(11):3395-401. DMUWI2F RU https://pubmed.ncbi.nlm.nih.gov/16722659 DMUWKMN DI DMUWKMN DMUWKMN DN 3-(3,5-Dimethyl-phenyl)-piperidine DMUWKMN TI TTEX248 DMUWKMN TN Dopamine D2 receptor (D2R) DMUWKMN MA Inhibitor DMUWKMN RN N-n-Propyl-substituted 3-(dimethylphenyl)piperidines display novel discriminative properties between dopamine receptor subtypes: synthesis and rece... J Med Chem. 1998 Dec 3;41(25):4933-8. DMUWKMN RU https://pubmed.ncbi.nlm.nih.gov/9836610 DMUWKNX DI DMUWKNX DMUWKNX DN (+/-)-threo-3',5'-Dimethylmethylphenidate DMUWKNX TI TTVBI8W DMUWKNX TN Dopamine transporter (DAT) DMUWKNX MA Inhibitor DMUWKNX RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMUWKNX RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMUWO6D DI DMUWO6D DMUWO6D DN BIBF100 DMUWO6D TI TTGKIED DMUWO6D TN Fibroblast growth factor-2 (FGF2) DMUWO6D MA Inhibitor DMUWO6D RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMUWO6D RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMUWO6D DI DMUWO6D DMUWO6D DN BIBF100 DMUWO6D TI TT9HKJA DMUWO6D TN Vascular endothelial growth factor (VEGF) DMUWO6D MA Inhibitor DMUWO6D RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMUWO6D RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMUWTPX DI DMUWTPX DMUWTPX DN 4-tert-butyl-N-hydroxybenzamide DMUWTPX TI TT6R7JZ DMUWTPX TN Histone deacetylase 1 (HDAC1) DMUWTPX MA Inhibitor DMUWTPX RN Design of novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4619-24. DMUWTPX RU https://pubmed.ncbi.nlm.nih.gov/17555962 DMUWVGP DI DMUWVGP DMUWVGP DN MMDA DMUWVGP TI TTAWNKZ DMUWVGP TN Norepinephrine transporter (NET) DMUWVGP MA Modulator DMUWVGP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUWVGP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUWVGP DI DMUWVGP DMUWVGP DN MMDA DMUWVGP TI TTNZRI3 DMUWVGP TN Synaptic vesicle amine transporter (SLC18A2) DMUWVGP MA Antagonist DMUWVGP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUWVGP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUWVGP DI DMUWVGP DMUWVGP DN MMDA DMUWVGP TI TTGP7BY DMUWVGP TN Monoamine oxidase type B (MAO-B) DMUWVGP MA Antagonist DMUWVGP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUWVGP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUWVGP DI DMUWVGP DMUWVGP DN MMDA DMUWVGP TI TTVBI8W DMUWVGP TN Dopamine transporter (DAT) DMUWVGP MA Modulator DMUWVGP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUWVGP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUWVGP DI DMUWVGP DMUWVGP DN MMDA DMUWVGP TI TT3WG5C DMUWVGP TN Monoamine oxidase type A (MAO-A) DMUWVGP MA Antagonist DMUWVGP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUWVGP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUWVGP DI DMUWVGP DMUWVGP DN MMDA DMUWVGP TI TT3ROYC DMUWVGP TN Serotonin transporter (SERT) DMUWVGP MA Modulator DMUWVGP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUWVGP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUWVGP DI DMUWVGP DMUWVGP DN MMDA DMUWVGP TI TTJQOD7 DMUWVGP TN 5-HT 2A receptor (HTR2A) DMUWVGP MA Agonist DMUWVGP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMUWVGP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMUWYA2 DI DMUWYA2 DMUWYA2 DN PMID19191557C8 DMUWYA2 TI TTFQEO5 DMUWYA2 TN Squalene synthetase (FDFT1) DMUWYA2 MA Inhibitor DMUWYA2 RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DMUWYA2 RU https://pubmed.ncbi.nlm.nih.gov/19191557 DMUX702 DI DMUX702 DMUX702 DN Fibronectin extra domain A DMUX702 TI TTISGCA DMUX702 TN Toll-like receptor 4 (TLR4) DMUX702 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754). DMUX702 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1754 DMUXFZQ DI DMUXFZQ DMUXFZQ DN LY-3390334 DMUXFZQ TI TTVBPDM DMUXFZQ TN Metabotropic glutamate receptor 1 (mGluR1) DMUXFZQ MA Modulator DMUXFZQ RN Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagon... Neurosci Lett. 2002 Sep 20;330(2):127-30. DMUXFZQ RU https://www.ncbi.nlm.nih.gov/pubmed/12231428 DMUXFZQ DI DMUXFZQ DMUXFZQ DN LY-3390334 DMUXFZQ TI TTHS256 DMUXFZQ TN Metabotropic glutamate receptor 5 (mGluR5) DMUXFZQ MA Modulator DMUXFZQ RN Inhibition of group I metabotropic glutamate receptor responses in vivo in rats by a new generation of carboxyphenylglycine-like amino acid antagon... Neurosci Lett. 2002 Sep 20;330(2):127-30. DMUXFZQ RU https://www.ncbi.nlm.nih.gov/pubmed/12231428 DMUXMVQ DI DMUXMVQ DMUXMVQ DN Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 DMUXMVQ TI TTCG0AL DMUXMVQ TN Cholecystokinin receptor type A (CCKAR) DMUXMVQ MA Inhibitor DMUXMVQ RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMUXMVQ RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMUXMVQ DI DMUXMVQ DMUXMVQ DN Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 DMUXMVQ TI TT27RFC DMUXMVQ TN Opioid receptor delta (OPRD1) DMUXMVQ MA Inhibitor DMUXMVQ RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMUXMVQ RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMUXMVQ DI DMUXMVQ DMUXMVQ DN Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 DMUXMVQ TI TTKWM86 DMUXMVQ TN Opioid receptor mu (MOP) DMUXMVQ MA Inhibitor DMUXMVQ RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMUXMVQ RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMUXMVQ DI DMUXMVQ DMUXMVQ DN Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 DMUXMVQ TI TTVFO0U DMUXMVQ TN Gastrin/cholecystokinin type B receptor (CCKBR) DMUXMVQ MA Inhibitor DMUXMVQ RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMUXMVQ RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMUXN8P DI DMUXN8P DMUXN8P DN ISIS 113020 DMUXN8P TI TTASI04 DMUXN8P TN E2F1 messenger RNA (E2F1 mRNA) DMUXN8P RN US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression. DMUXN8P RU http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true DMUXSH5 DI DMUXSH5 DMUXSH5 DN 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide DMUXSH5 TI TTSYM0R DMUXSH5 TN Carbonic anhydrase XII (CA-XII) DMUXSH5 MA Inhibitor DMUXSH5 RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMUXSH5 RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMUXSH5 DI DMUXSH5 DMUXSH5 DN 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide DMUXSH5 TI TTANPDJ DMUXSH5 TN Carbonic anhydrase II (CA-II) DMUXSH5 MA Inhibitor DMUXSH5 RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMUXSH5 RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMUXSH5 DI DMUXSH5 DMUXSH5 DN 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide DMUXSH5 TI TTHQPL7 DMUXSH5 TN Carbonic anhydrase I (CA-I) DMUXSH5 MA Inhibitor DMUXSH5 RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMUXSH5 RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMUXSH5 DI DMUXSH5 DMUXSH5 DN 1-Benzyl-1,4-dihydro-4-oxo-3-pyridinesulfonamide DMUXSH5 TI TT2LVK8 DMUXSH5 TN Carbonic anhydrase IX (CA-IX) DMUXSH5 MA Inhibitor DMUXSH5 RN Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the... Eur J Med Chem. 2010 Sep;45(9):3656-61. DMUXSH5 RU https://pubmed.ncbi.nlm.nih.gov/20554082 DMUXTWC DI DMUXTWC DMUXTWC DN 5-methoxy-luzindole DMUXTWC TI TT0WAIE DMUXTWC TN Melatonin receptor type 1A (MTNR1A) DMUXTWC MA Agonist DMUXTWC RN Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75. DMUXTWC RU https://pubmed.ncbi.nlm.nih.gov/9089668 DMUXZL1 DI DMUXZL1 DMUXZL1 DN N-hydroxy-7-(4-methoxyphenyl)-7-oxoheptanamide DMUXZL1 TI TT6R7JZ DMUXZL1 TN Histone deacetylase 1 (HDAC1) DMUXZL1 MA Inhibitor DMUXZL1 RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMUXZL1 RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMUXZOM DI DMUXZOM DMUXZOM DN 4-(7-chloro-1-cyclohexyl-1H-indazol-3-yl)phenol DMUXZOM TI TTZAYWL DMUXZOM TN Estrogen receptor (ESR) DMUXZOM MA Inhibitor DMUXZOM RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DMUXZOM RU https://pubmed.ncbi.nlm.nih.gov/15588074 DMUY75A DI DMUY75A DMUY75A DN 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol DMUY75A TI TT78R5H DMUY75A TN Heat shock protein 90 alpha (HSP90A) DMUY75A MA Inhibitor DMUY75A RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUY75A RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUY8MP DI DMUY8MP DMUY8MP DN L-746530 DMUY8MP TI TTSJ6Q4 DMUY8MP TN LOX-5 messenger RNA (ALOX5 mRNA) DMUY8MP MA Inhibitor DMUY8MP RN Substituted coumarins as potent 5-lipoxygenase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2528-31. DMUY8MP RU https://pubmed.ncbi.nlm.nih.gov/16464579 DMUY9TF DI DMUY9TF DMUY9TF DN 6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide DMUY9TF TI TTJQOD7 DMUY9TF TN 5-HT 2A receptor (HTR2A) DMUY9TF MA Inhibitor DMUY9TF RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMUY9TF RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMUY9TF DI DMUY9TF DMUY9TF DN 6-chloro-N-(pyridin-3-yl)indoline-1-carboxamide DMUY9TF TI TTWJBZ5 DMUY9TF TN 5-HT 2C receptor (HTR2C) DMUY9TF MA Inhibitor DMUY9TF RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMUY9TF RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMUYDXT DI DMUYDXT DMUYDXT DN YM298198 DMUYDXT TI TTVBPDM DMUYDXT TN Metabotropic glutamate receptor 1 (mGluR1) DMUYDXT MA Modulator (allosteric modulator) DMUYDXT RN Radioligand binding properties and pharmacological characterization of 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzimidazole-2-carboxamide ... J Pharmacol Exp Ther. 2005 Oct;315(1):163-9. DMUYDXT RU https://pubmed.ncbi.nlm.nih.gov/15976016 DMUYELJ DI DMUYELJ DMUYELJ DN 3-(6-Amino-purin-9-yl)-7-phenyl-heptan-2-ol DMUYELJ TI TTLP57V DMUYELJ TN Adenosine deaminase (ADA) DMUYELJ MA Inhibitor DMUYELJ RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMUYELJ RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMUYKIE DI DMUYKIE DMUYKIE DN Acetic acid 2-phenyl-5-propyl-thiazol-4-yl ester DMUYKIE TI TT2J34L DMUYKIE TN Arachidonate 5-lipoxygenase (5-LOX) DMUYKIE MA Inhibitor DMUYKIE RN 4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65. DMUYKIE RU https://pubmed.ncbi.nlm.nih.gov/2066989 DMUYPMO DI DMUYPMO DMUYPMO DN 4-(2-(aminomethyl)phenyl)-1-benzylpiperidin-4-ol DMUYPMO TI TTNT7K8 DMUYPMO TN Nociceptin receptor (OPRL1) DMUYPMO MA Inhibitor DMUYPMO RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMUYPMO RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMUYTXS DI DMUYTXS DMUYTXS DN 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile DMUYTXS TI TTM2AOE DMUYTXS TN Adenosine A2a receptor (ADORA2A) DMUYTXS MA Inhibitor DMUYTXS RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMUYTXS RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMUYTXS DI DMUYTXS DMUYTXS DN 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile DMUYTXS TI TTNE7KG DMUYTXS TN Adenosine A2b receptor (ADORA2B) DMUYTXS MA Inhibitor DMUYTXS RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMUYTXS RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMUYTXS DI DMUYTXS DMUYTXS DN 2-Amino-6-furan-2-yl-4-phenyl-nicotinonitrile DMUYTXS TI TTK25J1 DMUYTXS TN Adenosine A1 receptor (ADORA1) DMUYTXS MA Inhibitor DMUYTXS RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMUYTXS RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMUYZA8 DI DMUYZA8 DMUYZA8 DN 2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene DMUYZA8 TI TTYFKSZ DMUYZA8 TN Tubulin beta (TUBB) DMUYZA8 MA Inhibitor DMUYZA8 RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMUYZA8 RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMUYZA8 DI DMUYZA8 DMUYZA8 DN 2'-amino-3,4,4',5-tetramethoxy-(Z)-stillbene DMUYZA8 TI TTJ2PTI DMUYZA8 TN Tubulin beta-2 chain (TUBB2) DMUYZA8 MA Inhibitor DMUYZA8 RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMUYZA8 RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMUZ3OS DI DMUZ3OS DMUZ3OS DN 1-adamantan-1-yl-3-(4-pentyloxycylclohexyl)urea DMUZ3OS TI TT7WVHI DMUZ3OS TN Soluble epoxide hydrolase (EPHX2) DMUZ3OS MA Inhibitor DMUZ3OS RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMUZ3OS RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMUZ9LX DI DMUZ9LX DMUZ9LX DN [3H]L655708 DMUZ9LX TI TTNZPQ1 DMUZ9LX TN GABA(A) receptor alpha-5 (GABRA5) DMUZ9LX MA Modulator (allosteric modulator) DMUZ9LX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 408). DMUZ9LX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=408 DMUZDSC DI DMUZDSC DMUZDSC DN 2-[1-(4-CHLORO-PHENYL)-ETHYL]-4,6-DINITRO-PHENOL DMUZDSC TI TTHDSE2 DMUZDSC TN Bacterial Fumarate reductase flavoprotein (Bact frdA) DMUZDSC MA Inhibitor DMUZDSC RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUZDSC RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUZHPS DI DMUZHPS DMUZHPS DN 1,2-bis(2,4-difluorophenyl)ethane-1,2-dione DMUZHPS TI TTMF541 DMUZHPS TN Liver carboxylesterase (CES1) DMUZHPS MA Inhibitor DMUZHPS RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMUZHPS RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMUZIDT DI DMUZIDT DMUZIDT DN 7-Methoxy-3-pyridin-4-yl-quinoline DMUZIDT TI TTI7421 DMUZIDT TN Platelet-derived growth factor receptor beta (PDGFRB) DMUZIDT MA Inhibitor DMUZIDT RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DMUZIDT RU https://pubmed.ncbi.nlm.nih.gov/8064792 DMUZIDT DI DMUZIDT DMUZIDT DN 7-Methoxy-3-pyridin-4-yl-quinoline DMUZIDT TI TT8FYO9 DMUZIDT TN Platelet-derived growth factor receptor alpha (PDGFRA) DMUZIDT MA Inhibitor DMUZIDT RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DMUZIDT RU https://pubmed.ncbi.nlm.nih.gov/8064792 DMUZJCD DI DMUZJCD DMUZJCD DN ISIS 101997 DMUZJCD TI TTON5JB DMUZJCD TN MADH6 messenger RNA (MADH6 mRNA) DMUZJCD RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DMUZJCD RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DMUZL3J DI DMUZL3J DMUZL3J DN N-(2,3-DIFLUORO-BENZYL)-4-SULFAMOYL-BENZAMIDE DMUZL3J TI TTANPDJ DMUZL3J TN Carbonic anhydrase II (CA-II) DMUZL3J MA Inhibitor DMUZL3J RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMUZL3J RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMUZOYN DI DMUZOYN DMUZOYN DN 6-amino-uridine monophosphate DMUZOYN TI TTV7Y40 DMUZOYN TN Mycobacterium Orotidine phosphate decarboxylase (MycB pyrF) DMUZOYN MA Inhibitor DMUZOYN RN Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics. J Med Chem. 2006 Aug 10;49(16):4937-45. DMUZOYN RU https://pubmed.ncbi.nlm.nih.gov/16884305 DMUZP9V DI DMUZP9V DMUZP9V DN Src kinase inhibitor I DMUZP9V TI TTCQ2E5 DMUZP9V TN RIP2 messenger RNA (RIP2 mRNA) DMUZP9V MA Inhibitor DMUZP9V RN The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. DMUZP9V RU https://pubmed.ncbi.nlm.nih.gov/17850214 DMUZSJ2 DI DMUZSJ2 DMUZSJ2 DN KP772 DMUZSJ2 TI TT0JLSD DMUZSJ2 TN Multidrug resistance protein (MDR) DMUZSJ2 MA Inhibitor DMUZSJ2 RN Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. DMUZSJ2 RU https://pubmed.ncbi.nlm.nih.gov/19442032 DMUZW80 DI DMUZW80 DMUZW80 DN RWJ-68141 DMUZW80 TI TTNGILX DMUZW80 TN Adrenergic receptor alpha-1A (ADRA1A) DMUZW80 MA Inhibitor DMUZW80 RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMUZW80 RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMUZYXQ DI DMUZYXQ DMUZYXQ DN 6,7-Difluoro-3-thiophen-3-yl-quinoline DMUZYXQ TI TTI7421 DMUZYXQ TN Platelet-derived growth factor receptor beta (PDGFRB) DMUZYXQ MA Inhibitor DMUZYXQ RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMUZYXQ RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMUZYXQ DI DMUZYXQ DMUZYXQ DN 6,7-Difluoro-3-thiophen-3-yl-quinoline DMUZYXQ TI TT8FYO9 DMUZYXQ TN Platelet-derived growth factor receptor alpha (PDGFRA) DMUZYXQ MA Inhibitor DMUZYXQ RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMUZYXQ RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMV03NS DI DMV03NS DMV03NS DN A-192558 DMV03NS TI TT50QJ3 DMV03NS TN Influenza Neuraminidase (Influ NA) DMV03NS MA Inhibitor DMV03NS RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMV03NS RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMV0C69 DI DMV0C69 DMV0C69 DN 6-chlorotacrine hydrochloride DMV0C69 TI TTEB0GD DMV0C69 TN Cholinesterase (BCHE) DMV0C69 MA Inhibitor DMV0C69 RN Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79. DMV0C69 RU https://pubmed.ncbi.nlm.nih.gov/19663388 DMV0C69 DI DMV0C69 DMV0C69 DN 6-chlorotacrine hydrochloride DMV0C69 TI TT1RS9F DMV0C69 TN Acetylcholinesterase (AChE) DMV0C69 MA Inhibitor DMV0C69 RN Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79. DMV0C69 RU https://pubmed.ncbi.nlm.nih.gov/19663388 DMV0C6F DI DMV0C6F DMV0C6F DN 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine DMV0C6F TI TTJQOD7 DMV0C6F TN 5-HT 2A receptor (HTR2A) DMV0C6F MA Inhibitor DMV0C6F RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DMV0C6F RU https://pubmed.ncbi.nlm.nih.gov/18296055 DMV0CXN DI DMV0CXN DMV0CXN DN 1,1,1,3-Tetrafluoro-7-phenylheptan-2-one DMV0CXN TI TTT1JVS DMV0CXN TN Cytosolic phospholipase A2 (GIVA cPLA2) DMV0CXN MA Inhibitor DMV0CXN RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DMV0CXN RU https://pubmed.ncbi.nlm.nih.gov/20369880 DMV0CZ5 DI DMV0CZ5 DMV0CZ5 DN Threo-ritalinol methyl ether hydrochloride DMV0CZ5 TI TTVBI8W DMV0CZ5 TN Dopamine transporter (DAT) DMV0CZ5 MA Inhibitor DMV0CZ5 RN Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31. DMV0CZ5 RU https://pubmed.ncbi.nlm.nih.gov/17489581 DMV0EDM DI DMV0EDM DMV0EDM DN PD-152255 DMV0EDM TI TT4C8EA DMV0EDM TN Dopamine D3 receptor (D3R) DMV0EDM MA Modulator DMV0EDM RN Pharmacological characterization of PD 152255, a novel dimeric benzimidazole dopamine D3 antagonist. Pharmacol Biochem Behav. 1998 Feb;59(2):487-93. DMV0EDM RU https://www.ncbi.nlm.nih.gov/pubmed/9476999 DMV0JQG DI DMV0JQG DMV0JQG DN DD7 DMV0JQG TI TTPLTSQ DMV0JQG TN Neutrophil elastase (NE) DMV0JQG RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMV0JQG RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMV0KTW DI DMV0KTW DMV0KTW DN oxo-arpromidine DMV0KTW TI TTTIBOJ DMV0KTW TN Histamine H1 receptor (H1R) DMV0KTW MA Agonist DMV0KTW RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DMV0KTW RU https://pubmed.ncbi.nlm.nih.gov/16394198 DMV0KTW DI DMV0KTW DMV0KTW DN oxo-arpromidine DMV0KTW TI TTQHJ1K DMV0KTW TN Histamine H2 receptor (H2R) DMV0KTW MA Agonist DMV0KTW RN Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther. 2006 Apr;317(1):139-46. DMV0KTW RU https://pubmed.ncbi.nlm.nih.gov/16394198 DMV0PT8 DI DMV0PT8 DMV0PT8 DN 7-hydroxycostunolide DMV0PT8 TI TTSXVID DMV0PT8 TN Nuclear factor NF-kappa-B (NFKB) DMV0PT8 MA Inhibitor DMV0PT8 RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMV0PT8 RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMV0S4U DI DMV0S4U DMV0S4U DN 4-(4-methyl-phenyliminomethyl)-benzenesulfonamide DMV0S4U TI TTVKILB DMV0S4U TN Prostaglandin G/H synthase 2 (COX-2) DMV0S4U MA Inhibitor DMV0S4U RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMV0S4U RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMV0UIR DI DMV0UIR DMV0UIR DN 2,5-Dimethoxy-4'-amino-trans-stilbene DMV0UIR TI TTSZLWK DMV0UIR TN Aromatase (CYP19A1) DMV0UIR MA Inhibitor DMV0UIR RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMV0UIR RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMV0UM2 DI DMV0UM2 DMV0UM2 DN FR-73966 DMV0UM2 TI TTY6EWA DMV0UM2 TN Neuropeptide Y receptor type 5 (NPY5R) DMV0UM2 MA Inhibitor DMV0UM2 RN Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802. DMV0UM2 RU https://pubmed.ncbi.nlm.nih.gov/11859006 DMV10UH DI DMV10UH DMV10UH DN GNF-PF-4421 DMV10UH TI TT1MPAY DMV10UH TN GABA(A) receptor alpha-1 (GABRA1) DMV10UH MA Inhibitor DMV10UH RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMV10UH RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMV10UH DI DMV10UH DMV10UH DN GNF-PF-4421 DMV10UH TI TTZA1NY DMV10UH TN GABA(A) receptor beta-2 (GABRB2) DMV10UH MA Inhibitor DMV10UH RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMV10UH RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMV10UH DI DMV10UH DMV10UH DN GNF-PF-4421 DMV10UH TI TTNJYV2 DMV10UH TN Gamma-aminobutyric acid receptor (GAR) DMV10UH MA Inhibitor DMV10UH RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMV10UH RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMV10UH DI DMV10UH DMV10UH DN GNF-PF-4421 DMV10UH TI TT06RH5 DMV10UH TN GABA(A) receptor gamma-2 (GABRG2) DMV10UH MA Inhibitor DMV10UH RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMV10UH RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMV13MO DI DMV13MO DMV13MO DN Propan-2-one O-4-butoxybenzylcarbamoyl oxime DMV13MO TI TTDP1UC DMV13MO TN Fatty acid amide hydrolase (FAAH) DMV13MO MA Inhibitor DMV13MO RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMV13MO RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMV1408 DI DMV1408 DMV1408 DN SU5403 DMV1408 TI TT0LF7H DMV1408 TN Fibroblast growth factor receptor (FGFR) DMV1408 MA Antagonist DMV1408 RN Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. DMV1408 RU https://pubmed.ncbi.nlm.nih.gov/11576867 DMV19HC DI DMV19HC DMV19HC DN 4-Methyl-5-(4-piperidyl)isothiazol-3-ol DMV19HC TI TT1MPAY DMV19HC TN GABA(A) receptor alpha-1 (GABRA1) DMV19HC MA Inhibitor DMV19HC RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMV19HC RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMV19HC DI DMV19HC DMV19HC DN 4-Methyl-5-(4-piperidyl)isothiazol-3-ol DMV19HC TI TTNJYV2 DMV19HC TN Gamma-aminobutyric acid receptor (GAR) DMV19HC MA Inhibitor DMV19HC RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMV19HC RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMV19HC DI DMV19HC DMV19HC DN 4-Methyl-5-(4-piperidyl)isothiazol-3-ol DMV19HC TI TT06RH5 DMV19HC TN GABA(A) receptor gamma-2 (GABRG2) DMV19HC MA Inhibitor DMV19HC RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMV19HC RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMV19K7 DI DMV19K7 DMV19K7 DN TRYPTOLINE DMV19K7 TI TTWG9A4 DMV19K7 TN Adrenergic receptor alpha-2A (ADRA2A) DMV19K7 MA Inhibitor DMV19K7 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMV19K7 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMV19K7 DI DMV19K7 DMV19K7 DN TRYPTOLINE DMV19K7 TI TTGP7BY DMV19K7 TN Monoamine oxidase type B (MAO-B) DMV19K7 MA Inhibitor DMV19K7 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMV19K7 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMV19K7 DI DMV19K7 DMV19K7 DN TRYPTOLINE DMV19K7 TI TTWM4TY DMV19K7 TN Adrenergic receptor alpha-2B (ADRA2B) DMV19K7 MA Inhibitor DMV19K7 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMV19K7 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMV19K7 DI DMV19K7 DMV19K7 DN TRYPTOLINE DMV19K7 TI TTJQOD7 DMV19K7 TN 5-HT 2A receptor (HTR2A) DMV19K7 MA Inhibitor DMV19K7 RN Binding of beta-carbolines at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4421-5. DMV19K7 RU https://pubmed.ncbi.nlm.nih.gov/14643338 DMV19K7 DI DMV19K7 DMV19K7 DN TRYPTOLINE DMV19K7 TI TT3WG5C DMV19K7 TN Monoamine oxidase type A (MAO-A) DMV19K7 MA Inhibitor DMV19K7 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMV19K7 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMV19K7 DI DMV19K7 DMV19K7 DN TRYPTOLINE DMV19K7 TI TT2NUT5 DMV19K7 TN Adrenergic receptor alpha-2C (ADRA2C) DMV19K7 MA Inhibitor DMV19K7 RN Binding of an imidazopyridoindole at imidazoline I2 receptors. Bioorg Med Chem Lett. 2004 Jan 19;14(2):527-9. DMV19K7 RU https://pubmed.ncbi.nlm.nih.gov/14698196 DMV1AL5 DI DMV1AL5 DMV1AL5 DN Methyl 14-(3-n-butylureido)tetradec-8(Z)-enoate DMV1AL5 TI TT7WVHI DMV1AL5 TN Soluble epoxide hydrolase (EPHX2) DMV1AL5 MA Inhibitor DMV1AL5 RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMV1AL5 RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMV1CX0 DI DMV1CX0 DMV1CX0 DN 2,3,4,11-tetrahydro-1H-benzo[a]carbazole DMV1CX0 TI TTBGTCW DMV1CX0 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMV1CX0 MA Inhibitor DMV1CX0 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMV1CX0 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMV1F7U DI DMV1F7U DMV1F7U DN PD-128763 DMV1F7U TI TTVDSZ0 DMV1F7U TN Poly [ADP-ribose] polymerase 1 (PARP1) DMV1F7U MA Inhibitor DMV1F7U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV1F7U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV1GLP DI DMV1GLP DMV1GLP DN Isosorbide-di-(propylcarbamate) DMV1GLP TI TTEB0GD DMV1GLP TN Cholinesterase (BCHE) DMV1GLP MA Inhibitor DMV1GLP RN Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability. Bioorg Med Chem. 2010 Feb;18(3):1045-53. DMV1GLP RU https://pubmed.ncbi.nlm.nih.gov/20093035 DMV1HMX DI DMV1HMX DMV1HMX DN 3r-Hydroxydecanoyl-Coa DMV1HMX TI TTL1WGS DMV1HMX TN Estradiol 17 beta-dehydrogenase 4 (HSD17B4) DMV1HMX MA Inhibitor DMV1HMX RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMV1HMX RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMV1IS8 DI DMV1IS8 DMV1IS8 DN (R)-sirtinol DMV1IS8 TI TTUF2HO DMV1IS8 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMV1IS8 MA Inhibitor DMV1IS8 RN Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem. 2005 Dec 1;48(24):7789-95. DMV1IS8 RU https://pubmed.ncbi.nlm.nih.gov/16302818 DMV1KI2 DI DMV1KI2 DMV1KI2 DN KNI-10092 DMV1KI2 TI TTXMNHO DMV1KI2 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMV1KI2 MA Inhibitor DMV1KI2 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMV1KI2 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMV1W4M DI DMV1W4M DMV1W4M DN Sp-722 DMV1W4M TI TTU6BFZ DMV1W4M TN Candida Thymidylate synthase (Candi TMP1) DMV1W4M MA Inhibitor DMV1W4M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV1W4M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV23XD DI DMV23XD DMV23XD DN Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) DMV23XD TI TTTQGH8 DMV23XD TN Histone deacetylase 4 (HDAC4) DMV23XD MA Inhibitor DMV23XD RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMV23XD RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMV23XD DI DMV23XD DMV23XD DN Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) DMV23XD TI TT6R7JZ DMV23XD TN Histone deacetylase 1 (HDAC1) DMV23XD MA Inhibitor DMV23XD RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMV23XD RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMV23XD DI DMV23XD DMV23XD DN Cyclo(-L-Am7(S2Py)-L-2MePhe-L-Ala-D-Pro-) DMV23XD TI TT5ZKDI DMV23XD TN Histone deacetylase 6 (HDAC6) DMV23XD MA Inhibitor DMV23XD RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMV23XD RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMV275G DI DMV275G DMV275G DN 1,2-indanedione DMV275G TI TTMF541 DMV275G TN Liver carboxylesterase (CES1) DMV275G MA Inhibitor DMV275G RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMV275G RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMV275G DI DMV275G DMV275G DN 1,2-indanedione DMV275G TI TTEB0GD DMV275G TN Cholinesterase (BCHE) DMV275G MA Inhibitor DMV275G RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMV275G RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMV2CKN DI DMV2CKN DMV2CKN DN (4-(thiophen-2-yl)phenyl)methanamine DMV2CKN TI TTXZEAJ DMV2CKN TN Leukotriene A-4 hydrolase (LTA4H) DMV2CKN MA Inhibitor DMV2CKN RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMV2CKN RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMV2D8F DI DMV2D8F DMV2D8F DN NSC-275420 DMV2D8F TI TT8XK6L DMV2D8F TN Quinone reductase 1 (NQO1) DMV2D8F MA Inhibitor DMV2D8F RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMV2D8F RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMV2OJX DI DMV2OJX DMV2OJX DN Guanosine-5'-Triphosphate DMV2OJX TI TTO3MV6 DMV2OJX TN Bacterial GTP-binding protein YihA (Bact engB) DMV2OJX MA Inhibitor DMV2OJX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV2OJX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV2OJX DI DMV2OJX DMV2OJX DN Guanosine-5'-Triphosphate DMV2OJX TI TTLSWP6 DMV2OJX TN GTP cyclohydrolase-I (GCH1) DMV2OJX MA Inhibitor DMV2OJX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV2OJX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV2OJX DI DMV2OJX DMV2OJX DN Guanosine-5'-Triphosphate DMV2OJX TI TTSUKYD DMV2OJX TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMV2OJX MA Inhibitor DMV2OJX RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV2OJX RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV2X1B DI DMV2X1B DMV2X1B DN Farnesol DMV2X1B TI TTGP7BY DMV2X1B TN Monoamine oxidase type B (MAO-B) DMV2X1B MA Inhibitor DMV2X1B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMV2X1B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMV2XUM DI DMV2XUM DMV2XUM DN BRL50481 DMV2XUM TI TTWIEY9 DMV2XUM TN Phosphodiesterase 7B (PDE7B) DMV2XUM MA Inhibitor DMV2XUM RN New classes of PDE7 inhibitors identified by a fission yeast-based HTS. J Biomol Screen. 2010 Apr;15(4):359-67. DMV2XUM RU https://pubmed.ncbi.nlm.nih.gov/20228279 DMV30N2 DI DMV30N2 DMV30N2 DN [(D)MeSer]3-[(40-OH) MeLeu]4-Cyclosporin A DMV30N2 TI TT84ETX DMV30N2 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMV30N2 MA Inhibitor DMV30N2 RN Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4415-9. DMV30N2 RU https://pubmed.ncbi.nlm.nih.gov/14643337 DMV34KQ DI DMV34KQ DMV34KQ DN FGGFTGARKSARKLWNQ DMV34KQ TI TTNT7K8 DMV34KQ TN Nociceptin receptor (OPRL1) DMV34KQ MA Inhibitor DMV34KQ RN Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activa... Bioorg Med Chem. 2009 Aug 1;17(15):5683-7. DMV34KQ RU https://pubmed.ncbi.nlm.nih.gov/19577933 DMV34O2 DI DMV34O2 DMV34O2 DN Platelet factor 4 (PF-4) DMV34O2 TI TTGJVQM DMV34O2 TN Fibroblast growth factor receptor 2 (FGFR2) DMV34O2 MA Inhibitor DMV34O2 RN A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2. FASEB J. 2001 Mar;15(3):550-2. DMV34O2 RU https://pubmed.ncbi.nlm.nih.gov/11259363 DMV39AW DI DMV39AW DMV39AW DN ADENOPHOSTIN A DMV39AW TI TTC9IZL DMV39AW TN Inositol 1,4,5-trisphosphate receptor (ITPR) DMV39AW MA Inhibitor DMV39AW RN Synthesis of adenophostin A analogues conjugating an aromatic group at the 5'-position as potent IP3 receptor ligands. J Med Chem. 2006 Sep 21;49(19):5750-8. DMV39AW RU https://pubmed.ncbi.nlm.nih.gov/16970399 DMV39XT DI DMV39XT DMV39XT DN 7-Hydroxy-Pyrazolo[4,3-D]Pyrimidine DMV39XT TI TTBL49X DMV39XT TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMV39XT MA Inhibitor DMV39XT RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMV39XT RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMV3FSH DI DMV3FSH DMV3FSH DN 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol DMV3FSH TI TTNT7K8 DMV3FSH TN Nociceptin receptor (OPRL1) DMV3FSH MA Inhibitor DMV3FSH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMV3FSH RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMV3FSH DI DMV3FSH DMV3FSH DN 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol DMV3FSH TI TTKWM86 DMV3FSH TN Opioid receptor mu (MOP) DMV3FSH MA Inhibitor DMV3FSH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMV3FSH RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMV3FSH DI DMV3FSH DMV3FSH DN 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol DMV3FSH TI TT27RFC DMV3FSH TN Opioid receptor delta (OPRD1) DMV3FSH MA Inhibitor DMV3FSH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMV3FSH RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMV3FSH DI DMV3FSH DMV3FSH DN 1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol DMV3FSH TI TTQW87Y DMV3FSH TN Opioid receptor kappa (OPRK1) DMV3FSH MA Inhibitor DMV3FSH RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMV3FSH RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMV3H0C DI DMV3H0C DMV3H0C DN B3C DMV3H0C TI TTT4N0Q DMV3H0C TN Channel-activating protease 1 (CAP1) DMV3H0C MA Inhibitor DMV3H0C RN Discovery of inhibitors of the channel-activating protease prostasin (CAP1/PRSS8) utilizing structure-based design. Bioorg Med Chem Lett. 2008 Nov 15;18(22):5895-9. DMV3H0C RU https://pubmed.ncbi.nlm.nih.gov/18752942 DMV3KBE DI DMV3KBE DMV3KBE DN 5-(2-methylpiperazin-1-ylsulfonyl)isoquinoline DMV3KBE TI TTNAHEX DMV3KBE TN cAMP-dependent protein kinase A type I (PRKAR1A) DMV3KBE MA Inhibitor DMV3KBE RN Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and... J Biol Chem. 1996 Oct 18;271(42):26157-64. DMV3KBE RU https://pubmed.ncbi.nlm.nih.gov/8824261 DMV3MF4 DI DMV3MF4 DMV3MF4 DN 6-(Toluene-4-sulfonyl)-2H-pyridazin-3-one DMV3MF4 TI TTFBNVI DMV3MF4 TN Aldose reductase (AKR1B1) DMV3MF4 MA Inhibitor DMV3MF4 RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMV3MF4 RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMV3PC7 DI DMV3PC7 DMV3PC7 DN Ac-I[CVWQDWGAHRC]T DMV3PC7 TI TTJGY7A DMV3PC7 TN Complement C3 (CO3) DMV3PC7 MA Inhibitor DMV3PC7 RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMV3PC7 RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMV3RYK DI DMV3RYK DMV3RYK DN Cis-[PtCl(NH3)2(N7-acyclovir)]+ DMV3RYK TI TTJP4SM DMV3RYK TN Bacterial Penicillin binding protein (Bact PBP) DMV3RYK RN DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+. Mol Pharmacol. 1998 May;53(5):846-55. DMV3RYK RU https://pubmed.ncbi.nlm.nih.gov/9584210 DMV3U9Z DI DMV3U9Z DMV3U9Z DN KNI-10255 DMV3U9Z TI TTXMNHO DMV3U9Z TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMV3U9Z MA Inhibitor DMV3U9Z RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMV3U9Z RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMV3ZF1 DI DMV3ZF1 DMV3ZF1 DN F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-CONH2 DMV3ZF1 TI TTNT7K8 DMV3ZF1 TN Nociceptin receptor (OPRL1) DMV3ZF1 MA Inhibitor DMV3ZF1 RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMV3ZF1 RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMV40XH DI DMV40XH DMV40XH DN leualacin DMV40XH TI TT5HONZ DMV40XH TN Calcium channel unspecific (CaC) DMV40XH MA Modulator DMV40XH RN Leualacin, a novel calcium blocker from Hapsidospora irregularis. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties. J Antibiot (Tokyo). 1992 Jun;45(6):899-905. DMV40XH RU https://www.ncbi.nlm.nih.gov/pubmed/1500357 DMV43GY DI DMV43GY DMV43GY DN CEP-5104 DMV43GY TI TTTDVOJ DMV43GY TN Tropomyosin-related kinase A (TrkA) DMV43GY MA Inhibitor DMV43GY RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMV43GY RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMV43GY DI DMV43GY DMV43GY DN CEP-5104 DMV43GY TI TT2B9KF DMV43GY TN Fyn tyrosine protein kinase (FYN) DMV43GY MA Inhibitor DMV43GY RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMV43GY RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMV43GY DI DMV43GY DMV43GY DN CEP-5104 DMV43GY TI TTUNSIX DMV43GY TN Mixed lineage kinase 1 (MAP3K9) DMV43GY MA Inhibitor DMV43GY RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMV43GY RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMV43GY DI DMV43GY DMV43GY DN CEP-5104 DMV43GY TI TT9FN4J DMV43GY TN Mixed lineage kinase 2 (MAP3K10) DMV43GY MA Inhibitor DMV43GY RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMV43GY RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMV43GY DI DMV43GY DMV43GY DN CEP-5104 DMV43GY TI TTUTJGQ DMV43GY TN Vascular endothelial growth factor receptor 2 (KDR) DMV43GY MA Inhibitor DMV43GY RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMV43GY RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMV43GY DI DMV43GY DMV43GY DN CEP-5104 DMV43GY TI TT860QF DMV43GY TN LCK tyrosine protein kinase (LCK) DMV43GY MA Inhibitor DMV43GY RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMV43GY RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMV43GY DI DMV43GY DMV43GY DN CEP-5104 DMV43GY TI TTETX6Q DMV43GY TN Mixed lineage kinase 3 (MAP3K11) DMV43GY MA Inhibitor DMV43GY RN Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: optimization, mixed-linea... J Med Chem. 2008 Sep 25;51(18):5680-9. DMV43GY RU https://pubmed.ncbi.nlm.nih.gov/18714982 DMV43NF DI DMV43NF DMV43NF DN PF-00356231 DMV43NF TI TTXZ0KQ DMV43NF TN Matrix metalloproteinase-12 (MMP-12) DMV43NF MA Inhibitor DMV43NF RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMV43NF RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMV486E DI DMV486E DMV486E DN polyIC DMV486E TI TTD24Y0 DMV486E TN Toll-like receptor 3 (TLR3) DMV486E MA Agonist DMV486E RN Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001 Oct 18;413(6857):732-8. DMV486E RU https://pubmed.ncbi.nlm.nih.gov/11607032 DMV48L3 DI DMV48L3 DMV48L3 DN AD5-10 DMV48L3 TI TTW20TU DMV48L3 TN TRAIL receptor 2 (TRAIL-R2) DMV48L3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1880). DMV48L3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1880 DMV48S2 DI DMV48S2 DMV48S2 DN Pyrovalerone DMV48S2 TI TTAWNKZ DMV48S2 TN Norepinephrine transporter (NET) DMV48S2 MA Inhibitor DMV48S2 RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMV48S2 RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMV48S2 DI DMV48S2 DMV48S2 DN Pyrovalerone DMV48S2 TI TTVBI8W DMV48S2 TN Dopamine transporter (DAT) DMV48S2 MA Inhibitor DMV48S2 RN A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg Med Chem. 2009 Jun 1;17(11):3770-4. DMV48S2 RU https://pubmed.ncbi.nlm.nih.gov/19442525 DMV48S2 DI DMV48S2 DMV48S2 DN Pyrovalerone DMV48S2 TI TT3ROYC DMV48S2 TN Serotonin transporter (SERT) DMV48S2 MA Inhibitor DMV48S2 RN 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32. DMV48S2 RU https://pubmed.ncbi.nlm.nih.gov/16480278 DMV4GDI DI DMV4GDI DMV4GDI DN Heptane-1,2,3-Triol DMV4GDI TI TTH0KSX DMV4GDI TN Rhodopsin (RHO) DMV4GDI MA Inhibitor DMV4GDI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV4GDI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV4ICS DI DMV4ICS DMV4ICS DN 5-p-Tolylsulfanyl-quinazoline-2,4-diamine DMV4ICS TI TT9SL3Q DMV4ICS TN Polypeptide deformylase (PDF) DMV4ICS MA Inhibitor DMV4ICS RN X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of ... J Med Chem. 2001 Aug 30;44(18):2928-32. DMV4ICS RU https://pubmed.ncbi.nlm.nih.gov/11520201 DMV4OKR DI DMV4OKR DMV4OKR DN L-erythro-3-hydroxyaspartate DMV4OKR TI TTZFUY6 DMV4OKR TN Serine Racemase (SRR) DMV4OKR MA Inhibitor DMV4OKR RN Inhibition of human serine racemase, an emerging target for medicinal chemistry. Curr Drug Targets. 2011 Jun;12(7):1037-55. DMV4OKR RU https://pubmed.ncbi.nlm.nih.gov/21291385 DMV4OY2 DI DMV4OY2 DMV4OY2 DN 2beta,3alpha-dihydroxyolean-12-en-28-oic acid DMV4OY2 TI TTZHY6R DMV4OY2 TN Glycogen phosphorylase muscle form (GP) DMV4OY2 MA Inhibitor DMV4OY2 RN Practical synthesis of bredemolic acid, a natural inhibitor of glycogen phosphorylase. J Nat Prod. 2008 Nov;71(11):1877-80. DMV4OY2 RU https://pubmed.ncbi.nlm.nih.gov/18847277 DMV4P7S DI DMV4P7S DMV4P7S DN PF-4957325-00 DMV4P7S TI TTIS4OW DMV4P7S TN Phosphodiesterase 8 (PDE8) DMV4P7S MA Inhibitor DMV4P7S RN PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER. PLoS One. 2010 Aug 9;5(8):e12011. DMV4P7S RU https://pubmed.ncbi.nlm.nih.gov/20711499 DMV4QRF DI DMV4QRF DMV4QRF DN 4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol DMV4QRF TI TT6OEDT DMV4QRF TN Cannabinoid receptor 1 (CB1) DMV4QRF MA Inhibitor DMV4QRF RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMV4QRF RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMV4QRF DI DMV4QRF DMV4QRF DN 4-(1,1-dimethyl-heptyl)-2'-methoxy-biphenyl-2-ol DMV4QRF TI TTMSFAW DMV4QRF TN Cannabinoid receptor 2 (CB2) DMV4QRF MA Inhibitor DMV4QRF RN Biaryl cannabinoid mimetics--synthesis and structure-activity relationship. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3652-6. DMV4QRF RU https://pubmed.ncbi.nlm.nih.gov/17507224 DMV4XGT DI DMV4XGT DMV4XGT DN 3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid DMV4XGT TI TTHI19T DMV4XGT TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMV4XGT MA Inhibitor DMV4XGT RN Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7. DMV4XGT RU https://pubmed.ncbi.nlm.nih.gov/19467869 DMV4ZWD DI DMV4ZWD DMV4ZWD DN PMID22465637C1 DMV4ZWD TI TTICZ1O DMV4ZWD TN Metabotropic glutamate receptor 4 (mGluR4) DMV4ZWD MA Modulator (allosteric modulator) DMV4ZWD RN 4-(1-Phenyl-1H-pyrazol-4-yl)quinolines as novel, selective and brain penetrant metabotropic glutamate receptor 4 positive allosteric modulators. Bioorg Med Chem Lett. 2012 May 1;22(9):3235-9. DMV4ZWD RU https://pubmed.ncbi.nlm.nih.gov/22465637 DMV53PH DI DMV53PH DMV53PH DN NIP-142 DMV53PH TI TTW0CMT DMV53PH TN Voltage-gated potassium channel Kv1.5 (KCNA5) DMV53PH MA Blocker DMV53PH RN New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22. DMV53PH RU https://pubmed.ncbi.nlm.nih.gov/15934869 DMV54MT DI DMV54MT DMV54MT DN 7-Biphenyl-4-yl-heptanoic acid hydroxyamide DMV54MT TI TTSHTOI DMV54MT TN Histone deacetylase 2 (HDAC2) DMV54MT MA Inhibitor DMV54MT RN A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. DMV54MT RU https://pubmed.ncbi.nlm.nih.gov/14552787 DMV54MT DI DMV54MT DMV54MT DN 7-Biphenyl-4-yl-heptanoic acid hydroxyamide DMV54MT TI TT6R7JZ DMV54MT TN Histone deacetylase 1 (HDAC1) DMV54MT MA Inhibitor DMV54MT RN A novel series of histone deacetylase inhibitors incorporating hetero aromatic ring systems as connection units. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3817-20. DMV54MT RU https://pubmed.ncbi.nlm.nih.gov/14552787 DMV57OZ DI DMV57OZ DMV57OZ DN Quinoline-8-carboxamide DMV57OZ TI TTVDSZ0 DMV57OZ TN Poly [ADP-ribose] polymerase 1 (PARP1) DMV57OZ MA Inhibitor DMV57OZ RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMV57OZ RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMV58GQ DI DMV58GQ DMV58GQ DN Ac-HSDAVFTDQYTRLRKQVAAKKYLQSIKQKRYC DMV58GQ TI TTZC9FV DMV58GQ TN Vasoactive intestinal polypeptide receptor (VIPR) DMV58GQ MA Inhibitor DMV58GQ RN Engineering of a VPAC2 receptor peptide agonist to impart dipeptidyl peptidase IV stability and enhance in vivo glucose disposal. J Med Chem. 2006 Dec 14;49(25):7545-8. DMV58GQ RU https://pubmed.ncbi.nlm.nih.gov/17149884 DMV5ASE DI DMV5ASE DMV5ASE DN JWH-308 DMV5ASE TI TT6OEDT DMV5ASE TN Cannabinoid receptor 1 (CB1) DMV5ASE MA Inhibitor DMV5ASE RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMV5ASE RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMV5ASE DI DMV5ASE DMV5ASE DN JWH-308 DMV5ASE TI TTMSFAW DMV5ASE TN Cannabinoid receptor 2 (CB2) DMV5ASE MA Inhibitor DMV5ASE RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMV5ASE RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMV5FZO DI DMV5FZO DMV5FZO DN 8-(2,2-dimethylpropyl)naringenin DMV5FZO TI TTZAYWL DMV5FZO TN Estrogen receptor (ESR) DMV5FZO MA Inhibitor DMV5FZO RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMV5FZO RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMV5FZO DI DMV5FZO DMV5FZO DN 8-(2,2-dimethylpropyl)naringenin DMV5FZO TI TTOM3J0 DMV5FZO TN Estrogen receptor beta (ESR2) DMV5FZO MA Inhibitor DMV5FZO RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMV5FZO RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMV5RZM DI DMV5RZM DMV5RZM DN N-dodecylgallate DMV5RZM TI TTE14XG DMV5RZM TN Squalene monooxygenase (SQLE) DMV5RZM MA Inhibitor DMV5RZM RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMV5RZM RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMV5T1I DI DMV5T1I DMV5T1I DN MP-529 DMV5T1I TI TTLYXIT DMV5T1I TN Aurora kinase C (AURKC) DMV5T1I MA Inhibitor DMV5T1I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936). DMV5T1I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1936 DMV6018 DI DMV6018 DMV6018 DN L-269,289 DMV6018 TI TTX20QP DMV6018 TN Geranylgeranyl transferase I (GGTase-I) DMV6018 MA Inhibitor DMV6018 RN Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes. J Bacteriol. 2000 Feb;182(3):704-13. DMV6018 RU https://pubmed.ncbi.nlm.nih.gov/10633104 DMV6154 DI DMV6154 DMV6154 DN N-(4-amino-3'-methoxybiphenyl-3-yl)benzamide DMV6154 TI TTSHTOI DMV6154 TN Histone deacetylase 2 (HDAC2) DMV6154 MA Inhibitor DMV6154 RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMV6154 RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMV63G1 DI DMV63G1 DMV63G1 DN 8-(3,4,5-trimethoxyphenyl)-9H-purine-2,6-diamine DMV63G1 TI TT9SL3Q DMV63G1 TN Polypeptide deformylase (PDF) DMV63G1 MA Inhibitor DMV63G1 RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DMV63G1 RU https://pubmed.ncbi.nlm.nih.gov/20117005 DMV63IP DI DMV63IP DMV63IP DN SPANTIDE DMV63IP TI TTZPO1L DMV63IP TN Substance-P receptor (TACR1) DMV63IP MA Inhibitor DMV63IP RN Synthesis and substance P antagonist activity of naphthimidazolium derivatives. J Med Chem. 1992 Apr 3;35(7):1273-9. DMV63IP RU https://pubmed.ncbi.nlm.nih.gov/1373191 DMV6824 DI DMV6824 DMV6824 DN 1-adamantan-1-yl-3-(5-hydroxypentyl)urea DMV6824 TI TT7WVHI DMV6824 TN Soluble epoxide hydrolase (EPHX2) DMV6824 MA Inhibitor DMV6824 RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMV6824 RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMV6C9N DI DMV6C9N DMV6C9N DN Cyclo(-D-Tyr-L-Arg-L-Arg-L-Nal-D-Ala-) DMV6C9N TI TTBID49 DMV6C9N TN C-X-C chemokine receptor type 4 (CXCR4) DMV6C9N MA Inhibitor DMV6C9N RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMV6C9N RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMV6DAO DI DMV6DAO DMV6DAO DN abnormal cannabidiol DMV6DAO TI TTSLJAR DMV6DAO TN N-arachidonyl glycine receptor (GPR18) DMV6DAO MA Agonist DMV6DAO RN Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012 Apr;165(8):2414-24. DMV6DAO RU https://pubmed.ncbi.nlm.nih.gov/21595653 DMV6DAO DI DMV6DAO DMV6DAO DN abnormal cannabidiol DMV6DAO TI TTNET8J DMV6DAO TN G-protein coupled receptor 55 (GPR55) DMV6DAO MA Agonist DMV6DAO RN The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101. DMV6DAO RU https://pubmed.ncbi.nlm.nih.gov/17876302 DMV6DY7 DI DMV6DY7 DMV6DY7 DN Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine DMV6DY7 TI TTEX248 DMV6DY7 TN Dopamine D2 receptor (D2R) DMV6DY7 MA Inhibitor DMV6DY7 RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMV6DY7 RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMV6DY7 DI DMV6DY7 DMV6DY7 DN Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine DMV6DY7 TI TTE0A2F DMV6DY7 TN Dopamine D4 receptor (D4R) DMV6DY7 MA Inhibitor DMV6DY7 RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMV6DY7 RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMV6DY7 DI DMV6DY7 DMV6DY7 DN Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine DMV6DY7 TI TT4C8EA DMV6DY7 TN Dopamine D3 receptor (D3R) DMV6DY7 MA Inhibitor DMV6DY7 RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMV6DY7 RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMV6EMN DI DMV6EMN DMV6EMN DN (-)-(R)-efonidipine DMV6EMN TI TT729IR DMV6EMN TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMV6EMN MA Blocker (channel blocker) DMV6EMN RN Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br J Pharmacol. 2004 Dec;143(8):1050-7. DMV6EMN RU https://pubmed.ncbi.nlm.nih.gov/15545287 DMV6EMN DI DMV6EMN DMV6EMN DN (-)-(R)-efonidipine DMV6EMN TI TTZIFHC DMV6EMN TN Voltage-gated calcium channel alpha Cav1.2 (CACNA1C) DMV6EMN MA Blocker (channel blocker) DMV6EMN RN Identification of R(-)-isomer of efonidipine as a selective blocker of T-type Ca2+ channels. Br J Pharmacol. 2004 Dec;143(8):1050-7. DMV6EMN RU https://pubmed.ncbi.nlm.nih.gov/15545287 DMV6H5S DI DMV6H5S DMV6H5S DN Conantokins T DMV6H5S TI TTN9D8E DMV6H5S TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMV6H5S MA Antagonist DMV6H5S RN Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain. 2003 Jan;101(1-2):109-16. DMV6H5S RU https://pubmed.ncbi.nlm.nih.gov/12507705 DMV6I7H DI DMV6I7H DMV6I7H DN [125I]BOP DMV6I7H TI TT2O84V DMV6I7H TN Thromboxane A2 receptor (TBXA2R) DMV6I7H MA Agonist DMV6I7H RN Characterization of an 125I-labeled thromboxane A2/prostaglandin H2 receptor agonist. J Pharmacol Exp Ther. 1989 Nov;251(2):557-62. DMV6I7H RU https://pubmed.ncbi.nlm.nih.gov/2530338 DMV6M5U DI DMV6M5U DMV6M5U DN 4-fluoro-N-(4-(methylsulfonyl)phenyl)aniline DMV6M5U TI TTVKILB DMV6M5U TN Prostaglandin G/H synthase 2 (COX-2) DMV6M5U MA Inhibitor DMV6M5U RN Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71. DMV6M5U RU https://pubmed.ncbi.nlm.nih.gov/20804197 DMV6NP1 DI DMV6NP1 DMV6NP1 DN [Cu(CN)2]- DMV6NP1 TI TTHQPL7 DMV6NP1 TN Carbonic anhydrase I (CA-I) DMV6NP1 MA Inhibitor DMV6NP1 RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13. DMV6NP1 RU https://pubmed.ncbi.nlm.nih.gov/15780631 DMV6NP1 DI DMV6NP1 DMV6NP1 DN [Cu(CN)2]- DMV6NP1 TI TTZHA0O DMV6NP1 TN Carbonic anhydrase IV (CA-IV) DMV6NP1 MA Inhibitor DMV6NP1 RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13. DMV6NP1 RU https://pubmed.ncbi.nlm.nih.gov/15780631 DMV6OPB DI DMV6OPB DMV6OPB DN 3alpha-Hydroxyurs-12-en-28-oic Acid DMV6OPB TI TTZHY6R DMV6OPB TN Glycogen phosphorylase muscle form (GP) DMV6OPB MA Inhibitor DMV6OPB RN Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54. DMV6OPB RU https://pubmed.ncbi.nlm.nih.gov/18517260 DMV6T1Q DI DMV6T1Q DMV6T1Q DN S-(N-heptyl-N-hydroxycarbamoyl)glutathione DMV6T1Q TI TTV9A7R DMV6T1Q TN Lactoylglutathione lyase (GLO1) DMV6T1Q MA Inhibitor DMV6T1Q RN Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I. J Med Chem. 2000 Oct 19;43(21):3981-6. DMV6T1Q RU https://pubmed.ncbi.nlm.nih.gov/11052803 DMV6UJ5 DI DMV6UJ5 DMV6UJ5 DN Infractopicrin DMV6UJ5 TI TT1RS9F DMV6UJ5 TN Acetylcholinesterase (AChE) DMV6UJ5 MA Inhibitor DMV6UJ5 RN Acetylcholinesterase inhibitors from the toadstool Cortinarius infractus. Bioorg Med Chem. 2010 Mar 15;18(6):2173-2177. DMV6UJ5 RU https://pubmed.ncbi.nlm.nih.gov/20176490 DMV6WC4 DI DMV6WC4 DMV6WC4 DN 4-phenyl-1,2,3,6-tetrahydropyridine DMV6WC4 TI TTGP7BY DMV6WC4 TN Monoamine oxidase type B (MAO-B) DMV6WC4 MA Inhibitor DMV6WC4 RN Further explorations of unnatural alkaloids. J Nat Prod. 1985 Nov-Dec;48(6):878-93. DMV6WC4 RU https://pubmed.ncbi.nlm.nih.gov/3879267 DMV70YA DI DMV70YA DMV70YA DN (Z)-5-Hexylidene-2-thioxothiazolidin-4-one DMV70YA TI TT1K6Q4 DMV70YA TN Arylamine N-acetyltransferase (NAT) DMV70YA MA Inhibitor DMV70YA RN Selective small molecule inhibitors of the potential breast cancer marker, human arylamine N-acetyltransferase 1, and its murine homologue, mouse a... Bioorg Med Chem. 2009 Jan 15;17(2):905-18. DMV70YA RU https://pubmed.ncbi.nlm.nih.gov/19059786 DMV751G DI DMV751G DMV751G DN H-Cdp-ala-Gly-Phe-leu-OH DMV751G TI TTKWM86 DMV751G TN Opioid receptor mu (MOP) DMV751G MA Inhibitor DMV751G RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMV751G RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMV751G DI DMV751G DMV751G DN H-Cdp-ala-Gly-Phe-leu-OH DMV751G TI TT27RFC DMV751G TN Opioid receptor delta (OPRD1) DMV751G MA Inhibitor DMV751G RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMV751G RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMV751G DI DMV751G DMV751G DN H-Cdp-ala-Gly-Phe-leu-OH DMV751G TI TTQW87Y DMV751G TN Opioid receptor kappa (OPRK1) DMV751G MA Inhibitor DMV751G RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMV751G RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMV761D DI DMV761D DMV761D DN ADC-5510 DMV761D TI TTKWM86 DMV761D TN Opioid receptor mu (MOP) DMV761D MA Antagonist DMV761D RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMV761D RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMV7HA1 DI DMV7HA1 DMV7HA1 DN 5-(4-chlorophenyl)-N-(2-methylbenzyl)nicotinamide DMV7HA1 TI TT90XZ8 DMV7HA1 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMV7HA1 MA Inhibitor DMV7HA1 RN Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5. DMV7HA1 RU https://pubmed.ncbi.nlm.nih.gov/20855211 DMV7IAK DI DMV7IAK DMV7IAK DN Delta-Amino Valeric Acid DMV7IAK TI TTJHKYD DMV7IAK TN Delta-aminolevulinic acid dehydratase (ALAD) DMV7IAK MA Inhibitor DMV7IAK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV7IAK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV7IWE DI DMV7IWE DMV7IWE DN 2-Benzyl-1-hydroxy-3H-benzo[f]chromen-3-one DMV7IWE TI TT8XK6L DMV7IWE TN Quinone reductase 1 (NQO1) DMV7IWE MA Inhibitor DMV7IWE RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DMV7IWE RU https://pubmed.ncbi.nlm.nih.gov/19877692 DMV7MPL DI DMV7MPL DMV7MPL DN BENZOTHIAZOLE DMV7MPL TI TT6L509 DMV7MPL TN Coagulation factor IIa (F2) DMV7MPL MA Inhibitor DMV7MPL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMV7MPL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMV7NGS DI DMV7NGS DMV7NGS DN Myristoyl-Coa DMV7NGS TI TTBAF05 DMV7NGS TN Candida Peptide N-myristoyltransferase (Candi NMT1) DMV7NGS MA Inhibitor DMV7NGS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV7NGS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV7ORJ DI DMV7ORJ DMV7ORJ DN N4-[4-(Phenylmethoxy)phenyl]-L-aspartamine DMV7ORJ TI TTXZEAJ DMV7ORJ TN Leukotriene A-4 hydrolase (LTA4H) DMV7ORJ MA Inhibitor DMV7ORJ RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMV7ORJ RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMV7QU3 DI DMV7QU3 DMV7QU3 DN 5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole DMV7QU3 TI TTIQUX7 DMV7QU3 TN Steroid 11-beta-hydroxylase (CYP11B1) DMV7QU3 MA Inhibitor DMV7QU3 RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMV7QU3 RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMV7QU3 DI DMV7QU3 DMV7QU3 DN 5-[5-Bromo-indan-(1E)-ylidenemethyl]-1H-imidazole DMV7QU3 TI TTSZLWK DMV7QU3 TN Aromatase (CYP19A1) DMV7QU3 MA Inhibitor DMV7QU3 RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMV7QU3 RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMV7TE4 DI DMV7TE4 DMV7TE4 DN CGNLSTCMLGTYTQDFNPFHTFPQTAIGVGAP-amide DMV7TE4 TI TTLWS2O DMV7TE4 TN Calcitonin receptor (CALCR) DMV7TE4 MA Inhibitor DMV7TE4 RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMV7TE4 RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMV7UC0 DI DMV7UC0 DMV7UC0 DN 1-Benzyl-3-phenylquinazoline-2,4(1H,3H)-dione DMV7UC0 TI TTUV8G9 DMV7UC0 TN Progesterone receptor (PGR) DMV7UC0 MA Inhibitor DMV7UC0 RN Progesterone receptor antagonists with a 3-phenylquinazoline-2,4-dione/2-phenylisoquinoline-1,3-dione skeleton. Bioorg Med Chem. 2008 Jul 15;16(14):7046-54. DMV7UC0 RU https://pubmed.ncbi.nlm.nih.gov/18586498 DMV84PQ DI DMV84PQ DMV84PQ DN N-(2-iodoethyl)linoleoylamide DMV84PQ TI TTDP1UC DMV84PQ TN Fatty acid amide hydrolase (FAAH) DMV84PQ MA Inhibitor DMV84PQ RN Radiosynthesis, in vitro and in vivo evaluation of 123I-labeled anandamide analogues for mapping brain FAAH. Bioorg Med Chem. 2009 Jan 1;17(1):49-56. DMV84PQ RU https://pubmed.ncbi.nlm.nih.gov/19054678 DMV859W DI DMV859W DMV859W DN 3,5-bis(2-methylpyridin-4-yl)-1H-1,2,4-triazole DMV859W TI TT7RJY8 DMV859W TN Xanthine dehydrogenase/oxidase (XDH) DMV859W MA Inhibitor DMV859W RN Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [... Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9. DMV859W RU https://pubmed.ncbi.nlm.nih.gov/19783139 DMV865Q DI DMV865Q DMV865Q DN methylcarbamyl PAF DMV865Q TI TTQL5VC DMV865Q TN Platelet-activating factor receptor (PTAFR) DMV865Q MA Agonist DMV865Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 334). DMV865Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=334 DMV87MP DI DMV87MP DMV87MP DN ISIS 107792 DMV87MP TI TTELIN2 DMV87MP TN PTPN1 messenger RNA (PTPN1 mRNA) DMV87MP RN US patent application no. 6,261,840, Antisense modulation of PTP1B expression. DMV87MP RU http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true DMV89B4 DI DMV89B4 DMV89B4 DN YGRKKRRQRRR-KLSSIESDV DMV89B4 TI TT9PB26 DMV89B4 TN Presynaptic density protein 95 (DLG4) DMV89B4 MA Inhibitor DMV89B4 RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMV89B4 RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMV8AH6 DI DMV8AH6 DMV8AH6 DN A192621 DMV8AH6 TI TT3ZTGU DMV8AH6 TN Endothelin B receptor (EDNRB) DMV8AH6 MA Antagonist DMV8AH6 RN Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ET(B) selectivity. J Med Chem. 1999 Sep 9;42(18):3668-78. DMV8AH6 RU https://pubmed.ncbi.nlm.nih.gov/10479298 DMV8C7I DI DMV8C7I DMV8C7I DN 1-(4-CHLOROPHENYL)-2-(2,4-DICHLOROPHENYL)-5-(METHYLSULFINYL)-N-(PIPERIDIN-1-YL)-1H-IMIDAZOLE-4-CARBOXAMIDE (ENANTIOMERIC MIX) DMV8C7I TI TT6OEDT DMV8C7I TN Cannabinoid receptor 1 (CB1) DMV8C7I MA Inhibitor DMV8C7I RN Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern. Bioorg Med Chem Lett. 2010 May 1;20(9):2770-5. DMV8C7I RU https://pubmed.ncbi.nlm.nih.gov/20363132 DMV8CJK DI DMV8CJK DMV8CJK DN Cbz-Ile-hPhe-Ala-LeuVSMe DMV8CJK TI TTUMQVO DMV8CJK TN Cathepsin S (CTSS) DMV8CJK MA Inhibitor DMV8CJK RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMV8CJK RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMV8EWF DI DMV8EWF DMV8EWF DN Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF DMV8EWF TI TTIND6G DMV8EWF TN Somatostatin receptor type 1 (SSTR1) DMV8EWF MA Inhibitor DMV8EWF RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMV8EWF RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMV8EWF DI DMV8EWF DMV8EWF DN Des-AA1,5-[Tyr2,D-Trp8,IAmp9]Cbm-SRIF DMV8EWF TI TTJX3UE DMV8EWF TN Somatostatin receptor type 3 (SSTR3) DMV8EWF MA Inhibitor DMV8EWF RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMV8EWF RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMV8MKP DI DMV8MKP DMV8MKP DN A-315456 DMV8MKP TI TTNGILX DMV8MKP TN Adrenergic receptor alpha-1A (ADRA1A) DMV8MKP MA Inhibitor DMV8MKP RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMV8MKP RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMV8OCF DI DMV8OCF DMV8OCF DN IsoBu-RYYRIK-NH2 DMV8OCF TI TTNT7K8 DMV8OCF TN Nociceptin receptor (OPRL1) DMV8OCF MA Inhibitor DMV8OCF RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMV8OCF RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMV8PB4 DI DMV8PB4 DMV8PB4 DN Epostane DMV8PB4 TI TTZT9R2 DMV8PB4 TN Hydroxysteroid dehydrogenase 3-beta (HSD3B) DMV8PB4 MA Inhibitor DMV8PB4 RN Termination of early pregnancy by the 3 beta-hydroxysteroid dehydrogenase inhibitor epostane. N Engl J Med. 1988 Sep 29;319(13):813-7. DMV8PB4 RU https://pubmed.ncbi.nlm.nih.gov/3166108 DMV8QTR DI DMV8QTR DMV8QTR DN N,N-Dihexyl-2-(2-phenyl-1H-indol-3-yl)-acetamide DMV8QTR TI TTPTXIN DMV8QTR TN Translocator protein (TSPO) DMV8QTR MA Inhibitor DMV8QTR RN Chemistry, binding affinities, and behavioral properties of a new class of "antineophobic" mitochondrial DBI receptor complex (mDRC) ligands. J Med Chem. 1993 Oct 1;36(20):2908-20. DMV8QTR RU https://pubmed.ncbi.nlm.nih.gov/8411007 DMV8SUM DI DMV8SUM DMV8SUM DN Desmosterol DMV8SUM TI TTXA6PH DMV8SUM TN Oxysterols receptor LXR-beta (NR1H2) DMV8SUM MA Agonist DMV8SUM RN Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26. DMV8SUM RU https://pubmed.ncbi.nlm.nih.gov/16857673 DMV8SUM DI DMV8SUM DMV8SUM DN Desmosterol DMV8SUM TI TTS4UGC DMV8SUM TN Farnesoid X-activated receptor (FXR) DMV8SUM MA Agonist DMV8SUM RN Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol Cell Biol. 2003 Feb;23(3):864-72. DMV8SUM RU https://pubmed.ncbi.nlm.nih.gov/12529392 DMV8SUM DI DMV8SUM DMV8SUM DN Desmosterol DMV8SUM TI TTECBXN DMV8SUM TN Oxysterols receptor LXR-alpha (NR1H3) DMV8SUM MA Agonist DMV8SUM RN Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26. DMV8SUM RU https://pubmed.ncbi.nlm.nih.gov/16857673 DMV8TNO DI DMV8TNO DMV8TNO DN 3-chloro-N-(3-isobutyramidophenyl)benzamide DMV8TNO TI TTHS256 DMV8TNO TN Metabotropic glutamate receptor 5 (mGluR5) DMV8TNO MA Inhibitor DMV8TNO RN Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6. DMV8TNO RU https://pubmed.ncbi.nlm.nih.gov/19875287 DMV8UCK DI DMV8UCK DMV8UCK DN N-Hydroxy-N-methyl-3-phenanthren-3-yl-acrylamide DMV8UCK TI TT2J34L DMV8UCK TN Arachidonate 5-lipoxygenase (5-LOX) DMV8UCK MA Inhibitor DMV8UCK RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMV8UCK RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMV8UK1 DI DMV8UK1 DMV8UK1 DN PMID16099654C4b DMV8UK1 TI TTVBPDM DMV8UK1 TN Metabotropic glutamate receptor 1 (mGluR1) DMV8UK1 MA Modulator (allosteric modulator) DMV8UK1 RN 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4628-31. DMV8UK1 RU https://pubmed.ncbi.nlm.nih.gov/16099654 DMV8YHQ DI DMV8YHQ DMV8YHQ DN prenalterol DMV8YHQ TI TTMXGCW DMV8YHQ TN Adrenergic receptor beta-3 (ADRB3) DMV8YHQ MA Agonist DMV8YHQ RN Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 1989 Mar;35(3):295-303. DMV8YHQ RU https://pubmed.ncbi.nlm.nih.gov/2564629 DMV8YIZ DI DMV8YIZ DMV8YIZ DN 2-methyl-3-(pyridin-4-yl)-1H-indol-6-amine DMV8YIZ TI TTTB4UP DMV8YIZ TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMV8YIZ MA Inhibitor DMV8YIZ RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMV8YIZ RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMV8ZFA DI DMV8ZFA DMV8ZFA DN PMID20080612C1 DMV8ZFA TI TT1ZAVI DMV8ZFA TN Prostaglandin E2 receptor EP2 (PTGER2) DMV8ZFA MA Modulator (allosteric modulator) DMV8ZFA RN Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2307-12. DMV8ZFA RU https://pubmed.ncbi.nlm.nih.gov/20080612 DMV8ZQG DI DMV8ZQG DMV8ZQG DN DIMEBOLIN DMV8ZQG TI TTJS8PY DMV8ZQG TN 5-HT 6 receptor (HTR6) DMV8ZQG MA Inhibitor DMV8ZQG RN 8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists. Eur J Med Chem. 2010 Feb;45(2):782-9. DMV8ZQG RU https://pubmed.ncbi.nlm.nih.gov/19939513 DMV8ZQG DI DMV8ZQG DMV8ZQG DN DIMEBOLIN DMV8ZQG TI TTTIBOJ DMV8ZQG TN Histamine H1 receptor (H1R) DMV8ZQG MA Inhibitor DMV8ZQG RN Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles. Bioorg Med Chem Lett. 2010 Jan 1;20(1):78-82. DMV8ZQG RU https://pubmed.ncbi.nlm.nih.gov/19945877 DMV940C DI DMV940C DMV940C DN PT-320 DMV940C TI TT84ETX DMV940C TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMV940C MA Inhibitor DMV940C RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMV940C RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMV9M57 DI DMV9M57 DMV9M57 DN 2-(3-hydroxyphenyl)quinolin-6-ol DMV9M57 TI TTIWB6L DMV9M57 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMV9M57 MA Inhibitor DMV9M57 RN Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69. DMV9M57 RU https://pubmed.ncbi.nlm.nih.gov/18324762 DMV9NP6 DI DMV9NP6 DMV9NP6 DN LSN2814617 DMV9NP6 TI TTHS256 DMV9NP6 TN Metabotropic glutamate receptor 5 (mGluR5) DMV9NP6 MA Modulator (allosteric modulator) DMV9NP6 RN In vitro characterisation of the novel positive allosteric modulators of the mGlu receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39. DMV9NP6 RU https://pubmed.ncbi.nlm.nih.gov/22884720 DMV9OCU DI DMV9OCU DMV9OCU DN Ethylisothiourea DMV9OCU TI TTF10I9 DMV9OCU TN Nitric-oxide synthase inducible (NOS2) DMV9OCU MA Inhibitor DMV9OCU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV9OCU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV9OCU DI DMV9OCU DMV9OCU DN Ethylisothiourea DMV9OCU TI TTCM4B3 DMV9OCU TN Nitric-oxide synthase endothelial (NOS3) DMV9OCU MA Inhibitor DMV9OCU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMV9OCU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMV9PI7 DI DMV9PI7 DMV9PI7 DN ISIS 101983 DMV9PI7 TI TTON5JB DMV9PI7 TN MADH6 messenger RNA (MADH6 mRNA) DMV9PI7 RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DMV9PI7 RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DMV9RAN DI DMV9RAN DMV9RAN DN D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide DMV9RAN TI TT6L509 DMV9RAN TN Coagulation factor IIa (F2) DMV9RAN MA Inhibitor DMV9RAN RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMV9RAN RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVA2D0 DI DMVA2D0 DMVA2D0 DN L-740093 DMVA2D0 TI TTCG0AL DMVA2D0 TN Cholecystokinin receptor type A (CCKAR) DMVA2D0 MA Inhibitor DMVA2D0 RN C5-piperazinyl-1,4-benzodiazepines, water-soluble, orally bioa vailable CCKB/gastrin receptor antagonists, Bioorg. Med. Chem. Lett. 5(24):3023-3026 (1995). DMVA2D0 RU http://www.sciencedirect.com/science/article/pii/0960894X95005300 DMVA4XC DI DMVA4XC DMVA4XC DN 2-(3-bromophenyl)pyrido[2,3-d]pyrimidine DMVA4XC TI TTHS256 DMVA4XC TN Metabotropic glutamate receptor 5 (mGluR5) DMVA4XC MA Inhibitor DMVA4XC RN Synthesis and SAR of 2-aryl pyrido[2,3-d]pyrimidines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5396-9. DMVA4XC RU https://pubmed.ncbi.nlm.nih.gov/17723296 DMVA5FE DI DMVA5FE DMVA5FE DN SA-6541 DMVA5FE TI TTXZEAJ DMVA5FE TN Leukotriene A-4 hydrolase (LTA4H) DMVA5FE MA Inhibitor DMVA5FE RN Synthesis and biological evaluation of N-mercaptoacylcysteine derivatives as leukotriene A4 hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):442-6. DMVA5FE RU https://pubmed.ncbi.nlm.nih.gov/19042128 DMVA6LH DI DMVA6LH DMVA6LH DN KYS-05041 DMVA6LH TI TT729IR DMVA6LH TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMVA6LH MA Inhibitor DMVA6LH RN 3D pharmacophore based virtual screening of T-type calcium channel blockers. Bioorg Med Chem. 2007 Jan 15;15(2):1091-105. DMVA6LH RU https://pubmed.ncbi.nlm.nih.gov/17074493 DMVA6LH DI DMVA6LH DMVA6LH DN KYS-05041 DMVA6LH TI TTZPWGN DMVA6LH TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMVA6LH MA Inhibitor DMVA6LH RN 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84. DMVA6LH RU https://pubmed.ncbi.nlm.nih.gov/15177437 DMVA6R0 DI DMVA6R0 DMVA6R0 DN NSC-745883 DMVA6R0 TI TTQY2EJ DMVA6R0 TN TERT messenger RNA (TERT mRNA) DMVA6R0 MA Inhibitor DMVA6R0 RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMVA6R0 RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMVA9F7 DI DMVA9F7 DMVA9F7 DN Erysubin D DMVA9F7 TI TT50QJ3 DMVA9F7 TN Influenza Neuraminidase (Influ NA) DMVA9F7 MA Inhibitor DMVA9F7 RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMVA9F7 RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMVAB7U DI DMVAB7U DMVAB7U DN 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole DMVAB7U TI TTEX248 DMVAB7U TN Dopamine D2 receptor (D2R) DMVAB7U MA Inhibitor DMVAB7U RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMVAB7U RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMVAB7U DI DMVAB7U DMVAB7U DN 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole DMVAB7U TI TTE0A2F DMVAB7U TN Dopamine D4 receptor (D4R) DMVAB7U MA Inhibitor DMVAB7U RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMVAB7U RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMVAB7U DI DMVAB7U DMVAB7U DN 4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole DMVAB7U TI TT4C8EA DMVAB7U TN Dopamine D3 receptor (D3R) DMVAB7U MA Inhibitor DMVAB7U RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMVAB7U RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMVADTP DI DMVADTP DMVADTP DN 6-fluoro-N-m-tolylquinazolin-4-amine DMVADTP TI TTHS256 DMVADTP TN Metabotropic glutamate receptor 5 (mGluR5) DMVADTP MA Inhibitor DMVADTP RN Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. DMVADTP RU https://pubmed.ncbi.nlm.nih.gov/19854049 DMVAOIG DI DMVAOIG DMVAOIG DN 8-Methyl-4-morpholin-4-yl-chromen-2-one DMVAOIG TI TTK3PY9 DMVAOIG TN DNA-dependent protein kinase catalytic (PRKDC) DMVAOIG MA Inhibitor DMVAOIG RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMVAOIG RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMVAP4T DI DMVAP4T DMVAP4T DN Camrelizumab DMVAP4T TI TTVLU5N DMVAP4T TN HUMAN programmed cell death protein 1 (PD-1) DMVAP4T MA Inhibitor DMVAP4T RN ClinicalTrials.gov (NCT04268537) Immunoregulatory Therapy for 2019-nCoV. U.S. National Institutes of Health. DMVAP4T RU https://clinicaltrials.gov/ct2/show/NCT04268537 DMVAP9U DI DMVAP9U DMVAP9U DN 4-hydroxy-N-isopropyl-N-phenylbenzenesulfonamide DMVAP9U TI TTZAYWL DMVAP9U TN Estrogen receptor (ESR) DMVAP9U MA Inhibitor DMVAP9U RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DMVAP9U RU https://pubmed.ncbi.nlm.nih.gov/16300947 DMVAQOZ DI DMVAQOZ DMVAQOZ DN 2-Pyridinethiol DMVAQOZ TI TTF2LRI DMVAQOZ TN Cathepsin B (CTSB) DMVAQOZ MA Inhibitor DMVAQOZ RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMVAQOZ RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMVB5U0 DI DMVB5U0 DMVB5U0 DN 2-(3-cyanobenzyl)-5-mercaptopentanoic acid DMVB5U0 TI TT9G4N0 DMVB5U0 TN Glutamate carboxypeptidase II (GCPII) DMVB5U0 MA Inhibitor DMVB5U0 RN Structural optimization of thiol-based inhibitors of glutamate carboxypeptidase II by modification of the P1' side chain. J Med Chem. 2006 May 18;49(10):2876-85. DMVB5U0 RU https://pubmed.ncbi.nlm.nih.gov/16686531 DMVB6UG DI DMVB6UG DMVB6UG DN BOLINAQUINONE DMVB6UG TI TT9V5JH DMVB6UG TN Phospholipase A2 (PLA2G1B) DMVB6UG MA Inhibitor DMVB6UG RN New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5. DMVB6UG RU https://pubmed.ncbi.nlm.nih.gov/11374954 DMVB6UG DI DMVB6UG DMVB6UG DN BOLINAQUINONE DMVB6UG TI TTO8QRU DMVB6UG TN Group IIA phospholipase A2 (GIIA sPLA2) DMVB6UG MA Inhibitor DMVB6UG RN New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5. DMVB6UG RU https://pubmed.ncbi.nlm.nih.gov/11374954 DMVB7P3 DI DMVB7P3 DMVB7P3 DN 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene DMVB7P3 TI TTSQIFT DMVB7P3 TN 5-HT 1A receptor (HTR1A) DMVB7P3 MA Inhibitor DMVB7P3 RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DMVB7P3 RU https://pubmed.ncbi.nlm.nih.gov/17064079 DMVB7P3 DI DMVB7P3 DMVB7P3 DN 1-(benzyloxy)-2-[2-(3-methoxyphenyl)ethyl]benzene DMVB7P3 TI TTEX248 DMVB7P3 TN Dopamine D2 receptor (D2R) DMVB7P3 MA Inhibitor DMVB7P3 RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DMVB7P3 RU https://pubmed.ncbi.nlm.nih.gov/17064079 DMVBCID DI DMVBCID DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID TI TTT6LFV DMVBCID TN Histone deacetylase 8 (HDAC8) DMVBCID MA Inhibitor DMVBCID RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMVBCID RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMVBCID DI DMVBCID DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID TI TTTQGH8 DMVBCID TN Histone deacetylase 4 (HDAC4) DMVBCID MA Inhibitor DMVBCID RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMVBCID RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMVBCID DI DMVBCID DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID TI TT6R7JZ DMVBCID TN Histone deacetylase 1 (HDAC1) DMVBCID MA Inhibitor DMVBCID RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DMVBCID RU https://pubmed.ncbi.nlm.nih.gov/12419380 DMVBCID DI DMVBCID DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID TI TT5ZKDI DMVBCID TN Histone deacetylase 6 (HDAC6) DMVBCID MA Inhibitor DMVBCID RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMVBCID RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMVBCID DI DMVBCID DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID TI TTBH0VX DMVBCID TN Histone deacetylase (HDAC) DMVBCID MA Inhibitor DMVBCID RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMVBCID RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMVBCID DI DMVBCID DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID TI TTSHTOI DMVBCID TN Histone deacetylase 2 (HDAC2) DMVBCID MA Inhibitor DMVBCID RN Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2002 Dec 2;12(23):3443-7. DMVBCID RU https://pubmed.ncbi.nlm.nih.gov/12419380 DMVBCID DI DMVBCID DMVBCID DN 9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide DMVBCID TI TTYHPU6 DMVBCID TN Histone deacetylase 10 (HDAC10) DMVBCID MA Inhibitor DMVBCID RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMVBCID RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMVBD6H DI DMVBD6H DMVBD6H DN (S)(+)-7-methyl-2-p-tolylchroman-4-one DMVBD6H TI TTGP7BY DMVBD6H TN Monoamine oxidase type B (MAO-B) DMVBD6H MA Inhibitor DMVBD6H RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMVBD6H RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMVBFJP DI DMVBFJP DMVBFJP DN MK-0668 DMVBFJP TI TTBVIQC DMVBFJP TN Integrin beta-1 (ITGB1) DMVBFJP MA Inhibitor DMVBFJP RN Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6. DMVBFJP RU https://pubmed.ncbi.nlm.nih.gov/19713111 DMVBFJP DI DMVBFJP DMVBFJP DN MK-0668 DMVBFJP TI TTJMF9P DMVBFJP TN ITGA4 messenger RNA (ITGA4 mRNA) DMVBFJP MA Inhibitor DMVBFJP RN Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6. DMVBFJP RU https://pubmed.ncbi.nlm.nih.gov/19713111 DMVBGAT DI DMVBGAT DMVBGAT DN For-RYYRIK-NH2 DMVBGAT TI TTNT7K8 DMVBGAT TN Nociceptin receptor (OPRL1) DMVBGAT MA Inhibitor DMVBGAT RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMVBGAT RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMVBI2C DI DMVBI2C DMVBI2C DN 1,3-propanediphosphonic acid DMVBI2C TI TTU6BFZ DMVBI2C TN Candida Thymidylate synthase (Candi TMP1) DMVBI2C MA Inhibitor DMVBI2C RN Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs. J Med Chem. 2010 Sep 23;53(18):6539-49. DMVBI2C RU https://pubmed.ncbi.nlm.nih.gov/20527892 DMVBO78 DI DMVBO78 DMVBO78 DN VARIECOLIN DMVBO78 TI TT2CEJG DMVBO78 TN C-C chemokine receptor type 5 (CCR5) DMVBO78 MA Inhibitor DMVBO78 RN Inhibition of the human chemokine receptor CCR5 by variecolin and variecolol and isolation of four new variecolin analogues, emericolins A-D, from ... J Nat Prod. 2004 Oct;67(10):1681-4. DMVBO78 RU https://pubmed.ncbi.nlm.nih.gov/15497939 DMVBPRO DI DMVBPRO DMVBPRO DN CP-673451 DMVBPRO TI TTX41N9 DMVBPRO TN Tyrosine-protein kinase Kit (KIT) DMVBPRO MA Inhibitor DMVBPRO RN Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66. DMVBPRO RU https://pubmed.ncbi.nlm.nih.gov/15705896 DMVBPRO DI DMVBPRO DMVBPRO DN CP-673451 DMVBPRO TI TT8FYO9 DMVBPRO TN Platelet-derived growth factor receptor alpha (PDGFRA) DMVBPRO MA Inhibitor DMVBPRO RN Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66. DMVBPRO RU https://pubmed.ncbi.nlm.nih.gov/15705896 DMVBPRO DI DMVBPRO DMVBPRO DN CP-673451 DMVBPRO TI TTI7421 DMVBPRO TN Platelet-derived growth factor receptor beta (PDGFRB) DMVBPRO MA Inhibitor DMVBPRO RN Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66. DMVBPRO RU https://pubmed.ncbi.nlm.nih.gov/15705896 DMVBR36 DI DMVBR36 DMVBR36 DN 1-benzhydryl-4-benzylpiperidin-4-ol DMVBR36 TI TT27RFC DMVBR36 TN Opioid receptor delta (OPRD1) DMVBR36 MA Inhibitor DMVBR36 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVBR36 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVBR36 DI DMVBR36 DMVBR36 DN 1-benzhydryl-4-benzylpiperidin-4-ol DMVBR36 TI TTQW87Y DMVBR36 TN Opioid receptor kappa (OPRK1) DMVBR36 MA Inhibitor DMVBR36 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVBR36 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVBR36 DI DMVBR36 DMVBR36 DN 1-benzhydryl-4-benzylpiperidin-4-ol DMVBR36 TI TTNT7K8 DMVBR36 TN Nociceptin receptor (OPRL1) DMVBR36 MA Inhibitor DMVBR36 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVBR36 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVBR36 DI DMVBR36 DMVBR36 DN 1-benzhydryl-4-benzylpiperidin-4-ol DMVBR36 TI TTKWM86 DMVBR36 TN Opioid receptor mu (MOP) DMVBR36 MA Inhibitor DMVBR36 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVBR36 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVBRMF DI DMVBRMF DMVBRMF DN 8-(2-Methyl-butoxy)-quinolin-2-ylamine DMVBRMF TI TTX4RTB DMVBRMF TN Melanin-concentrating hormone receptor 1 (MCHR1) DMVBRMF MA Inhibitor DMVBRMF RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMVBRMF RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMVBTAM DI DMVBTAM DMVBTAM DN [D-Ncy(isopropyl)7]acyline DMVBTAM TI TT8R70G DMVBTAM TN Gonadotropin-releasing hormone receptor (GNRHR) DMVBTAM MA Inhibitor DMVBTAM RN Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized deriv... J Med Chem. 2007 May 3;50(9):2067-77. DMVBTAM RU https://pubmed.ncbi.nlm.nih.gov/17402723 DMVBTHA DI DMVBTHA DMVBTHA DN HOMOPHENYLALANINYLMETHANE DMVBTHA TI TTJOKD1 DMVBTHA TN Cathepsin F (CTSF) DMVBTHA MA Inhibitor DMVBTHA RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVBTHA RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVCFQ5 DI DMVCFQ5 DMVCFQ5 DN ISIS 29469 DMVCFQ5 TI TTYMGWX DMVCFQ5 TN PDK-1 messenger RNA (PDK-1 mRNA) DMVCFQ5 RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMVCFQ5 RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMVCHOX DI DMVCHOX DMVCHOX DN TZD18 DMVCHOX TI TTT2SVW DMVCHOX TN PPAR-gamma messenger RNA (PPARG mRNA) DMVCHOX MA Agonist DMVCHOX RN A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8. DMVCHOX RU https://pubmed.ncbi.nlm.nih.gov/14701675 DMVCHOX DI DMVCHOX DMVCHOX DN TZD18 DMVCHOX TI TTJ584C DMVCHOX TN Peroxisome proliferator-activated receptor alpha (PPARA) DMVCHOX MA Agonist DMVCHOX RN A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8. DMVCHOX RU https://pubmed.ncbi.nlm.nih.gov/14701675 DMVCHSI DI DMVCHSI DMVCHSI DN 1-(4-chlorophenyl)-4-phenyl-1H-imidazole DMVCHSI TI TT1MPAY DMVCHSI TN GABA(A) receptor alpha-1 (GABRA1) DMVCHSI MA Inhibitor DMVCHSI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMVCHSI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMVCHSI DI DMVCHSI DMVCHSI DN 1-(4-chlorophenyl)-4-phenyl-1H-imidazole DMVCHSI TI TTNJYV2 DMVCHSI TN Gamma-aminobutyric acid receptor (GAR) DMVCHSI MA Inhibitor DMVCHSI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMVCHSI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMVCHSI DI DMVCHSI DMVCHSI DN 1-(4-chlorophenyl)-4-phenyl-1H-imidazole DMVCHSI TI TT06RH5 DMVCHSI TN GABA(A) receptor gamma-2 (GABRG2) DMVCHSI MA Inhibitor DMVCHSI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMVCHSI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMVCHSI DI DMVCHSI DMVCHSI DN 1-(4-chlorophenyl)-4-phenyl-1H-imidazole DMVCHSI TI TTZA1NY DMVCHSI TN GABA(A) receptor beta-2 (GABRB2) DMVCHSI MA Inhibitor DMVCHSI RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMVCHSI RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMVCIJB DI DMVCIJB DMVCIJB DN 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol DMVCIJB TI TTNT7K8 DMVCIJB TN Nociceptin receptor (OPRL1) DMVCIJB MA Inhibitor DMVCIJB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMVCIJB RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMVCIJB DI DMVCIJB DMVCIJB DN 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol DMVCIJB TI TTKWM86 DMVCIJB TN Opioid receptor mu (MOP) DMVCIJB MA Inhibitor DMVCIJB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMVCIJB RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMVCIJB DI DMVCIJB DMVCIJB DN 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol DMVCIJB TI TTQW87Y DMVCIJB TN Opioid receptor kappa (OPRK1) DMVCIJB MA Inhibitor DMVCIJB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMVCIJB RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMVCIJB DI DMVCIJB DMVCIJB DN 4-phenyl-1-(1-phenylbutyl)piperidin-4-ol DMVCIJB TI TT27RFC DMVCIJB TN Opioid receptor delta (OPRD1) DMVCIJB MA Inhibitor DMVCIJB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMVCIJB RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMVCLP8 DI DMVCLP8 DMVCLP8 DN 4-Chloro-N-(2-morpholinoethyl)nicotinamide DMVCLP8 TI TT3WG5C DMVCLP8 TN Monoamine oxidase type A (MAO-A) DMVCLP8 MA Inhibitor DMVCLP8 RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMVCLP8 RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMVCM0I DI DMVCM0I DMVCM0I DN 1-(4-Phenoxyphenyl)piperazine DMVCM0I TI TTXZEAJ DMVCM0I TN Leukotriene A-4 hydrolase (LTA4H) DMVCM0I MA Inhibitor DMVCM0I RN Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of ... J Med Chem. 2010 Jan 28;53(2):573-85. DMVCM0I RU https://pubmed.ncbi.nlm.nih.gov/19950900 DMVCNBH DI DMVCNBH DMVCNBH DN MMP-408 DMVCNBH TI TTXZ0KQ DMVCNBH TN Matrix metalloproteinase-12 (MMP-12) DMVCNBH MA Inhibitor DMVCNBH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1636). DMVCNBH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1636 DMVCP6X DI DMVCP6X DMVCP6X DN Docosapentaenoic acid DMVCP6X TI TTSZLWK DMVCP6X TN Aromatase (CYP19A1) DMVCP6X MA Inhibitor DMVCP6X RN Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod. 2006 Apr;69(4):700-3. DMVCP6X RU https://pubmed.ncbi.nlm.nih.gov/16643058 DMVCPLU DI DMVCPLU DMVCPLU DN N-(6-phenyl-1H-indazol-3-yl)butyramide DMVCPLU TI TTRSMW9 DMVCPLU TN Glycogen synthase kinase-3 beta (GSK-3B) DMVCPLU MA Inhibitor DMVCPLU RN Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9. DMVCPLU RU https://pubmed.ncbi.nlm.nih.gov/20189807 DMVCY42 DI DMVCY42 DMVCY42 DN 2-(2-cyclohexyl-4-methylphenoxy)acetic acid DMVCY42 TI TTQDMX5 DMVCY42 TN Prostaglandin D2 receptor 2 (PTGDR2) DMVCY42 MA Inhibitor DMVCY42 RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMVCY42 RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMVCYBG DI DMVCYBG DMVCYBG DN ISIS 113019 DMVCYBG TI TTASI04 DMVCYBG TN E2F1 messenger RNA (E2F1 mRNA) DMVCYBG RN US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression. DMVCYBG RU http://www.patentbuddy.com/Patent/6187587?ft=true&sr=true DMVD05E DI DMVD05E DMVD05E DN (S)-2-amino-2-cyclohexylacetic acid DMVD05E TI TTFK1JQ DMVD05E TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMVD05E MA Inhibitor DMVD05E RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMVD05E RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMVD481 DI DMVD481 DMVD481 DN Carzenide DMVD481 TI TTEYTKG DMVD481 TN Carbonic anhydrase XIV (CA-XIV) DMVD481 MA Inhibitor DMVD481 RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMVD481 RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMVD481 DI DMVD481 DMVD481 DN Carzenide DMVD481 TI TT2LVK8 DMVD481 TN Carbonic anhydrase IX (CA-IX) DMVD481 MA Inhibitor DMVD481 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMVD481 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMVD481 DI DMVD481 DMVD481 DN Carzenide DMVD481 TI TTCFSPE DMVD481 TN Carbonic anhydrase VI (CA-VI) DMVD481 MA Inhibitor DMVD481 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMVD481 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMVD481 DI DMVD481 DMVD481 DN Carzenide DMVD481 TI TTSYM0R DMVD481 TN Carbonic anhydrase XII (CA-XII) DMVD481 MA Inhibitor DMVD481 RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMVD481 RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMVD481 DI DMVD481 DMVD481 DN Carzenide DMVD481 TI TTANPDJ DMVD481 TN Carbonic anhydrase II (CA-II) DMVD481 MA Inhibitor DMVD481 RN Synthesis and structure-activity relationships of novel benzene sulfonamides with potent binding affinity for bovine carbonic anhydrase II. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5429-33. DMVD481 RU https://pubmed.ncbi.nlm.nih.gov/16213706 DMVD481 DI DMVD481 DMVD481 DN Carzenide DMVD481 TI TTUNARX DMVD481 TN Carbonic anhydrase (CA) DMVD481 MA Inhibitor DMVD481 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMVD481 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMVD481 DI DMVD481 DMVD481 DN Carzenide DMVD481 TI TTHQPL7 DMVD481 TN Carbonic anhydrase I (CA-I) DMVD481 MA Inhibitor DMVD481 RN Ligand-directed tosyl chemistry for protein labeling in vivo. Nat Chem Biol. 2009 May;5(5):341-3. DMVD481 RU https://pubmed.ncbi.nlm.nih.gov/19330012 DMVD6HE DI DMVD6HE DMVD6HE DN 2-(4-(methylsulfonyl)phenyl)-3-phenylquinoline DMVD6HE TI TTVKILB DMVD6HE TN Prostaglandin G/H synthase 2 (COX-2) DMVD6HE MA Inhibitor DMVD6HE RN Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1029-33. DMVD6HE RU https://pubmed.ncbi.nlm.nih.gov/20061161 DMVD702 DI DMVD702 DMVD702 DN 1,2,3,4,5,6-hexabromocyclohexane DMVD702 TI TTRMX3V DMVD702 TN Janus kinase 2 (JAK-2) DMVD702 MA Inhibitor DMVD702 RN Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem. 2005 Apr 7;48(7):2526-33. DMVD702 RU https://pubmed.ncbi.nlm.nih.gov/15801842 DMVDB7S DI DMVDB7S DMVDB7S DN chroman 28 DMVDB7S TI TTGY8IW DMVDB7S TN B2 bradykinin receptor (BDKRB2) DMVDB7S MA Antagonist DMVDB7S RN Identification of a nonpeptidic and conformationally restricted bradykinin B1 receptor antagonist with anti-inflammatory activity. J Med Chem. 2007 Feb 22;50(4):607-10. DMVDB7S RU https://pubmed.ncbi.nlm.nih.gov/17243660 DMVDF9Q DI DMVDF9Q DMVDF9Q DN 4-(4-Chlorophenyl)-5-p-tolyl-3H-1,2-dithiol-3-one DMVDF9Q TI TT8NGED DMVDF9Q TN Prostaglandin G/H synthase 1 (COX-1) DMVDF9Q MA Inhibitor DMVDF9Q RN Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem. 2009 Jan 15;17(2):558-68. DMVDF9Q RU https://pubmed.ncbi.nlm.nih.gov/19097798 DMVDH4I DI DMVDH4I DMVDH4I DN Ac-D-pro-L-Phe-D-trp-L-Phe-NH2 DMVDH4I TI TTKWM86 DMVDH4I TN Opioid receptor mu (MOP) DMVDH4I MA Inhibitor DMVDH4I RN Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. DMVDH4I RU https://pubmed.ncbi.nlm.nih.gov/19464172 DMVDHBT DI DMVDHBT DMVDHBT DN SUVN-G1031 DMVDHBT TI TT9JNIC DMVDHBT TN Histamine H3 receptor (H3R) DMVDHBT MA Antagonist DMVDHBT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 264). DMVDHBT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=264 DMVDHX1 DI DMVDHX1 DMVDHX1 DN 4-(isopropylthio)-2-(trifluoromethyl)benzonitrile DMVDHX1 TI TTKPW01 DMVDHX1 TN Androgen receptor messenger RNA (AR mRNA) DMVDHX1 MA Inhibitor DMVDHX1 RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMVDHX1 RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMVDM0Q DI DMVDM0Q DMVDM0Q DN NITRAQUAZONE DMVDM0Q TI TTZ97H5 DMVDM0Q TN Phosphodiesterase 4A (PDE4A) DMVDM0Q MA Inhibitor DMVDM0Q RN Synthesis and biological evaluation of 2,5-dihydropyrazol. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2661-4. DMVDM0Q RU https://pubmed.ncbi.nlm.nih.gov/11128646 DMVDM0Q DI DMVDM0Q DMVDM0Q DN NITRAQUAZONE DMVDM0Q TI TTVIAT9 DMVDM0Q TN Phosphodiesterase 4B (PDE4B) DMVDM0Q MA Inhibitor DMVDM0Q RN Synthesis and biological evaluation of 2,5-dihydropyrazol. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2661-4. DMVDM0Q RU https://pubmed.ncbi.nlm.nih.gov/11128646 DMVDM73 DI DMVDM73 DMVDM73 DN Tyr-Pro-Phg-Phe-NH2 DMVDM73 TI TTKWM86 DMVDM73 TN Opioid receptor mu (MOP) DMVDM73 MA Inhibitor DMVDM73 RN Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. DMVDM73 RU https://pubmed.ncbi.nlm.nih.gov/16682191 DMVDS8B DI DMVDS8B DMVDS8B DN Cyclo(1,12)PenIYDTKGKNVLC-OH DMVDS8B TI TTJDUNO DMVDS8B TN T-cell surface antigen CD2 (CD2) DMVDS8B MA Inhibitor DMVDS8B RN Structure-activity studies of peptides from the "hot-spot" region of human CD2 protein: development of peptides for immunomodulation. J Med Chem. 2005 Oct 6;48(20):6236-49. DMVDS8B RU https://pubmed.ncbi.nlm.nih.gov/16190751 DMVDZCE DI DMVDZCE DMVDZCE DN 3,4-Dimethoxy-4'-amino-trans-stilbene DMVDZCE TI TTSZLWK DMVDZCE TN Aromatase (CYP19A1) DMVDZCE MA Inhibitor DMVDZCE RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMVDZCE RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMVE34H DI DMVE34H DMVE34H DN (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate DMVE34H TI TTDNFMT DMVE34H TN Platelet-activating factor acetylhydrolase (PLA2G7) DMVE34H MA Inhibitor DMVE34H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVE34H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVE34H DI DMVE34H DMVE34H DN (1r)-1,2,2-trimethylpropyl (r)-methylphosphinate DMVE34H TI TTMF541 DMVE34H TN Liver carboxylesterase (CES1) DMVE34H MA Inhibitor DMVE34H RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVE34H RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVE5UH DI DMVE5UH DMVE5UH DN ISIS 116505 DMVE5UH TI TTUI35N DMVE5UH TN C/EBP beta messenger RNA (CEBPB mRNA) DMVE5UH RN US patent application no. 6,271,030, Antisense inhibition of C/EBP beta expression. DMVE5UH RU http://www.patentbuddy.com/Patent/6271030?ft=true&sr=true DMVE69Y DI DMVE69Y DMVE69Y DN NSC-119913 DMVE69Y TI TTHYBIX DMVE69Y TN Heat shock protein 70 (HSP70) DMVE69Y MA Inhibitor DMVE69Y RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMVE69Y RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMVE69Y DI DMVE69Y DMVE69Y DN NSC-119913 DMVE69Y TI TTMQL3K DMVE69Y TN Lipopolysaccharide-associated protein 1 (HSPA8) DMVE69Y MA Inhibitor DMVE69Y RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMVE69Y RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMVE95S DI DMVE95S DMVE95S DN MERIOLIN 3 DMVE95S TI TT1LVF2 DMVE95S TN Cyclin-dependent kinase 9 (CDK9) DMVE95S MA Inhibitor DMVE95S RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMVE95S RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMVE95S DI DMVE95S DMVE95S DN MERIOLIN 3 DMVE95S TI TT7HF4W DMVE95S TN Cyclin-dependent kinase 2 (CDK2) DMVE95S MA Inhibitor DMVE95S RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMVE95S RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMVE95S DI DMVE95S DMVE95S DN MERIOLIN 3 DMVE95S TI TTAMQ62 DMVE95S TN Cyclin A2 (CCNA2) DMVE95S MA Inhibitor DMVE95S RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMVE95S RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMVEB8C DI DMVEB8C DMVEB8C DN H-Cdp-Gly-Gly-Phe-Leu-OH DMVEB8C TI TTKWM86 DMVEB8C TN Opioid receptor mu (MOP) DMVEB8C MA Inhibitor DMVEB8C RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMVEB8C RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMVEB8C DI DMVEB8C DMVEB8C DN H-Cdp-Gly-Gly-Phe-Leu-OH DMVEB8C TI TT27RFC DMVEB8C TN Opioid receptor delta (OPRD1) DMVEB8C MA Inhibitor DMVEB8C RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMVEB8C RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMVEB8C DI DMVEB8C DMVEB8C DN H-Cdp-Gly-Gly-Phe-Leu-OH DMVEB8C TI TTQW87Y DMVEB8C TN Opioid receptor kappa (OPRK1) DMVEB8C MA Inhibitor DMVEB8C RN Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60. DMVEB8C RU https://pubmed.ncbi.nlm.nih.gov/17350835 DMVEBT6 DI DMVEBT6 DMVEBT6 DN CHIR-98014 DMVEBT6 TI TTQWAU1 DMVEBT6 TN GSK3A messenger RNA (GSK3A mRNA) DMVEBT6 MA Inhibitor DMVEBT6 RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMVEBT6 RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMVEBT6 DI DMVEBT6 DMVEBT6 DN CHIR-98014 DMVEBT6 TI TTRSMW9 DMVEBT6 TN Glycogen synthase kinase-3 beta (GSK-3B) DMVEBT6 MA Inhibitor DMVEBT6 RN Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95. DMVEBT6 RU https://pubmed.ncbi.nlm.nih.gov/12606497 DMVEH40 DI DMVEH40 DMVEH40 DN Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMVEH40 TI TTQ3JTF DMVEH40 TN Muscarinic acetylcholine receptor M4 (CHRM4) DMVEH40 MA Inhibitor DMVEH40 RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMVEH40 RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMVEH40 DI DMVEH40 DMVEH40 DN Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMVEH40 TI TTH18TF DMVEH40 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMVEH40 MA Inhibitor DMVEH40 RN 6beta-Acyloxy(nor)tropanes: affinities for antagonist/agonist binding sites on transfected and native muscarinic receptors. J Med Chem. 2000 Jun 29;43(13):2514-22. DMVEH40 RU https://pubmed.ncbi.nlm.nih.gov/10891110 DMVEH40 DI DMVEH40 DMVEH40 DN Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMVEH40 TI TTQ13Z5 DMVEH40 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMVEH40 MA Inhibitor DMVEH40 RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMVEH40 RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMVEH40 DI DMVEH40 DMVEH40 DN Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMVEH40 TI TTZ9SOR DMVEH40 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMVEH40 MA Inhibitor DMVEH40 RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMVEH40 RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMVEH40 DI DMVEH40 DMVEH40 DN Acetic acid 8-aza-bicyclo[3.2.1]oct-6-yl ester DMVEH40 TI TTYEG6Q DMVEH40 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMVEH40 MA Inhibitor DMVEH40 RN 6beta-Acetoxynortropane: a potent muscarinic agonist with apparent selectivity toward M2-receptors. J Med Chem. 1998 Jun 4;41(12):2047-55. DMVEH40 RU https://pubmed.ncbi.nlm.nih.gov/9622546 DMVEHI7 DI DMVEHI7 DMVEHI7 DN [125I]IRL1620 DMVEHI7 TI TT3ZTGU DMVEHI7 TN Endothelin B receptor (EDNRB) DMVEHI7 MA Agonist DMVEHI7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 220). DMVEHI7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220 DMVELYW DI DMVELYW DMVELYW DN ML321 DMVELYW TI TTEX248 DMVELYW TN Dopamine D2 receptor (D2R) DMVELYW MA Antagonist DMVELYW RN Discovery, optimization, and characterization of a novel series of dopamine D2 versus D3 receptor selective antagonists. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010. DMVELYW RU https://pubmed.ncbi.nlm.nih.gov/24260782 DMVEMNA DI DMVEMNA DMVEMNA DN (R)-2-(2-naphthamido)-3-m-tolylpropanoic acid DMVEMNA TI TTJNTSI DMVEMNA TN Rotamase Pin1 (PIN1) DMVEMNA MA Inhibitor DMVEMNA RN Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. DMVEMNA RU https://pubmed.ncbi.nlm.nih.gov/20207139 DMVEOBY DI DMVEOBY DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide DMVEOBY TI TTYHPU6 DMVEOBY TN Histone deacetylase 10 (HDAC10) DMVEOBY MA Inhibitor DMVEOBY RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVEOBY RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVEOBY DI DMVEOBY DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide DMVEOBY TI TTSHTOI DMVEOBY TN Histone deacetylase 2 (HDAC2) DMVEOBY MA Inhibitor DMVEOBY RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVEOBY RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVEOBY DI DMVEOBY DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide DMVEOBY TI TTT6LFV DMVEOBY TN Histone deacetylase 8 (HDAC8) DMVEOBY MA Inhibitor DMVEOBY RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVEOBY RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVEOBY DI DMVEOBY DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide DMVEOBY TI TTBH0VX DMVEOBY TN Histone deacetylase (HDAC) DMVEOBY MA Inhibitor DMVEOBY RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVEOBY RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVEOBY DI DMVEOBY DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide DMVEOBY TI TTTQGH8 DMVEOBY TN Histone deacetylase 4 (HDAC4) DMVEOBY MA Inhibitor DMVEOBY RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVEOBY RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVEOBY DI DMVEOBY DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide DMVEOBY TI TT5ZKDI DMVEOBY TN Histone deacetylase 6 (HDAC6) DMVEOBY MA Inhibitor DMVEOBY RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVEOBY RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVEOBY DI DMVEOBY DMVEOBY DN N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide DMVEOBY TI TT6R7JZ DMVEOBY TN Histone deacetylase 1 (HDAC1) DMVEOBY MA Inhibitor DMVEOBY RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVEOBY RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVESO2 DI DMVESO2 DMVESO2 DN NE10790 DMVESO2 TI TTIKWV4 DMVESO2 TN Geranyltranstransferase (FDPS) DMVESO2 MA Inhibitor DMVESO2 RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMVESO2 RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMVEUOL DI DMVEUOL DMVEUOL DN Z-Ala-Leu-lle-Agly-Ile-Val-OMe DMVEUOL TI TTF2LRI DMVEUOL TN Cathepsin B (CTSB) DMVEUOL MA Inhibitor DMVEUOL RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMVEUOL RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMVEUOL DI DMVEUOL DMVEUOL DN Z-Ala-Leu-lle-Agly-Ile-Val-OMe DMVEUOL TI TTDZN01 DMVEUOL TN Cathepsin K (CTSK) DMVEUOL MA Inhibitor DMVEUOL RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMVEUOL RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMVEZH1 DI DMVEZH1 DMVEZH1 DN N-benzylnorlitebamine DMVEZH1 TI TT1RS9F DMVEZH1 TN Acetylcholinesterase (AChE) DMVEZH1 MA Inhibitor DMVEZH1 RN Litebamine N-homologues: preparation and anti-acetylcholinesterase activity. J Nat Prod. 1998 Jan;61(1):46-50. DMVEZH1 RU https://pubmed.ncbi.nlm.nih.gov/9461651 DMVF2YH DI DMVF2YH DMVF2YH DN Antileukoprotease (ALP) DMVF2YH TI TTE6GTB DMVF2YH TN Kallikrein-7 (KLK7) DMVF2YH MA Inhibitor DMVF2YH RN Expression of the protease inhibitor antileukoprotease and the serine protease stratum corneum chymotryptic enzyme (SCCE) is coordinated in ovarian tumors. Int J Gynecol Cancer. 2001 Nov-Dec;11(6):454-61. DMVF2YH RU https://pubmed.ncbi.nlm.nih.gov/11906548 DMVF420 DI DMVF420 DMVF420 DN NBTGR DMVF420 TI TTLXAKE DMVF420 TN Solute carrier family 29 member 1 (SLC29A1) DMVF420 MA Inhibitor DMVF420 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1117). DMVF420 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1117 DMVF6OQ DI DMVF6OQ DMVF6OQ DN 3-Imidazol-1-yl-quinoline DMVF6OQ TI TTIQUX7 DMVF6OQ TN Steroid 11-beta-hydroxylase (CYP11B1) DMVF6OQ MA Inhibitor DMVF6OQ RN Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart fa... J Med Chem. 2005 Oct 20;48(21):6632-42. DMVF6OQ RU https://pubmed.ncbi.nlm.nih.gov/16220979 DMVFAD5 DI DMVFAD5 DMVFAD5 DN L-Tryptophan-L-aspartic acid DMVFAD5 TI TTT2SVW DMVFAD5 TN PPAR-gamma messenger RNA (PPARG mRNA) DMVFAD5 MA Inhibitor DMVFAD5 RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DMVFAD5 RU https://pubmed.ncbi.nlm.nih.gov/18329752 DMVFB93 DI DMVFB93 DMVFB93 DN Nitrate DMVFB93 TI TTANPDJ DMVFB93 TN Carbonic anhydrase II (CA-II) DMVFB93 MA Inhibitor DMVFB93 RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMVFB93 RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMVFB93 DI DMVFB93 DMVFB93 DN Nitrate DMVFB93 TI TTHQPL7 DMVFB93 TN Carbonic anhydrase I (CA-I) DMVFB93 MA Inhibitor DMVFB93 RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMVFB93 RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMVFCLO DI DMVFCLO DMVFCLO DN 1-butyryl-1H-indole-2,3-dione DMVFCLO TI TTMF541 DMVFCLO TN Liver carboxylesterase (CES1) DMVFCLO MA Inhibitor DMVFCLO RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMVFCLO RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMVFDYU DI DMVFDYU DMVFDYU DN G-CSF DMVFDYU TI TTC70AJ DMVFDYU TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMVFDYU MA Stimulator DMVFDYU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMVFDYU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMVFHNM DI DMVFHNM DMVFHNM DN [N40,Pro1,Tyr4]BB DMVFHNM TI TTC1MVT DMVFHNM TN Gastrin-releasing peptide receptor (GRPR) DMVFHNM MA Inhibitor DMVFHNM RN Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10. DMVFHNM RU https://pubmed.ncbi.nlm.nih.gov/15634004 DMVFITX DI DMVFITX DMVFITX DN ITP DMVFITX TI TT24DGP DMVFITX TN P2Y purinoceptor 4 (P2RY4) DMVFITX MA Agonist DMVFITX RN ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor. Mol Pharmacol. 2000 May;57(5):926-31. DMVFITX RU https://pubmed.ncbi.nlm.nih.gov/10779375 DMVFJAH DI DMVFJAH DMVFJAH DN Diisopropyl 2-(sulfanylmethyl)phenylphosphonate DMVFJAH TI TTHI19T DMVFJAH TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMVFJAH MA Inhibitor DMVFJAH RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMVFJAH RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMVFJR4 DI DMVFJR4 DMVFJR4 DN VUF 5681 DMVFJR4 TI TT9JNIC DMVFJR4 TN Histamine H3 receptor (H3R) DMVFJR4 MA Antagonist DMVFJR4 RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMVFJR4 RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMVFK3J DI DMVFK3J DMVFK3J DN PFI-1 DMVFK3J TI TTRA6BO DMVFK3J TN Bromodomain-containing protein 4 (BRD4) DMVFK3J MA Inhibitor DMVFK3J RN Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem. 2012 Nov 26;55(22):9831-7. DMVFK3J RU https://pubmed.ncbi.nlm.nih.gov/23095041 DMVFKO4 DI DMVFKO4 DMVFKO4 DN N-Hydroxy-E-3-(4'-cyanobiphenyl-4-yl)-acrylamide DMVFKO4 TI TTSHTOI DMVFKO4 TN Histone deacetylase 2 (HDAC2) DMVFKO4 MA Inhibitor DMVFKO4 RN Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12. DMVFKO4 RU https://pubmed.ncbi.nlm.nih.gov/19084294 DMVFKSX DI DMVFKSX DMVFKSX DN 4-Hydroxy-5-methoxy-10H-anthracen-9-one DMVFKSX TI TT2J34L DMVFKSX TN Arachidonate 5-lipoxygenase (5-LOX) DMVFKSX MA Inhibitor DMVFKSX RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMVFKSX RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMVFLCM DI DMVFLCM DMVFLCM DN 4-Methoxybenzenemethanethiol DMVFLCM TI TTZJYKH DMVFLCM TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMVFLCM MA Inhibitor DMVFLCM RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMVFLCM RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMVFZKQ DI DMVFZKQ DMVFZKQ DN NSC-669977 DMVFZKQ TI TTJLP0R DMVFZKQ TN Quinone reductase 2 (NQO2) DMVFZKQ MA Inhibitor DMVFZKQ RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMVFZKQ RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMVG3K1 DI DMVG3K1 DMVG3K1 DN APA DMVG3K1 TI TTUMGNO DMVG3K1 TN Ornithine decarboxylase (ODC1) DMVG3K1 MA Inhibitor DMVG3K1 RN 2-substituted 3-(aminooxy)propanamines as inhibitors of ornithine decarboxylase: synthesis and biological activity. J Med Chem. 1992 Apr 17;35(8):1339-44. DMVG3K1 RU https://pubmed.ncbi.nlm.nih.gov/1573631 DMVGAFR DI DMVGAFR DMVGAFR DN Trans-2-fluoro-2-phenylcyclopropylamin DMVGAFR TI TTGP7BY DMVGAFR TN Monoamine oxidase type B (MAO-B) DMVGAFR MA Inhibitor DMVGAFR RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMVGAFR RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMVGAFR DI DMVGAFR DMVGAFR DN Trans-2-fluoro-2-phenylcyclopropylamin DMVGAFR TI TT3WG5C DMVGAFR TN Monoamine oxidase type A (MAO-A) DMVGAFR MA Inhibitor DMVGAFR RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMVGAFR RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMVGARN DI DMVGARN DMVGARN DN (O10eq)-beta-alanylryanodine DMVGARN TI TTU5CIX DMVGARN TN Ryanodine receptor 1 (RYR1) DMVGARN MA Inhibitor DMVGARN RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMVGARN RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMVGC7H DI DMVGC7H DMVGC7H DN 6-Thia-10b-aza-benzo[e]azulen-4-one DMVGC7H TI TTPTXIN DMVGC7H TN Translocator protein (TSPO) DMVGC7H MA Inhibitor DMVGC7H RN Novel ligands specific for mitochondrial benzodiazepine receptors: 6-arylpyrrolo[2,1-d][1,5]benzothiazepine derivatives. Synthesis, structure-activ... J Med Chem. 1994 May 13;37(10):1427-38. DMVGC7H RU https://pubmed.ncbi.nlm.nih.gov/8182701 DMVGDSM DI DMVGDSM DMVGDSM DN 3S,4R-293B DMVGDSM TI TT846HF DMVGDSM TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMVGDSM MA Blocker (channel blocker) DMVGDSM RN A kinetic study on the stereospecific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 2001 Dec;134(8):1647-54. DMVGDSM RU https://pubmed.ncbi.nlm.nih.gov/11739240 DMVGIO5 DI DMVGIO5 DMVGIO5 DN AUY954 DMVGIO5 TI TTZ8C5Q DMVGIO5 TN Sphingosine-1-phosphate receptor 4 (S1PR4) DMVGIO5 MA Agonist DMVGIO5 RN A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34. DMVGIO5 RU https://pubmed.ncbi.nlm.nih.gov/17114004 DMVGIO5 DI DMVGIO5 DMVGIO5 DN AUY954 DMVGIO5 TI TT9JZCK DMVGIO5 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMVGIO5 MA Agonist DMVGIO5 RN A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34. DMVGIO5 RU https://pubmed.ncbi.nlm.nih.gov/17114004 DMVGIO5 DI DMVGIO5 DMVGIO5 DN AUY954 DMVGIO5 TI TTDZCKV DMVGIO5 TN Sphingosine-1-phosphate receptor 5 (S1PR5) DMVGIO5 MA Agonist DMVGIO5 RN A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34. DMVGIO5 RU https://pubmed.ncbi.nlm.nih.gov/17114004 DMVGIO5 DI DMVGIO5 DMVGIO5 DN AUY954 DMVGIO5 TI TTVSMOH DMVGIO5 TN Sphingosine-1-phosphate receptor 2 (S1PR2) DMVGIO5 MA Agonist DMVGIO5 RN A monoselective sphingosine-1-phosphate receptor-1 agonist prevents allograft rejection in a stringent rat heart transplantation model. Chem Biol. 2006 Nov;13(11):1227-34. DMVGIO5 RU https://pubmed.ncbi.nlm.nih.gov/17114004 DMVGIO5 DI DMVGIO5 DMVGIO5 DN AUY954 DMVGIO5 TI TTDYP7I DMVGIO5 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMVGIO5 MA Agonist DMVGIO5 RN Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem. 2007 Jan 15;15(2):663-77. DMVGIO5 RU https://pubmed.ncbi.nlm.nih.gov/17113298 DMVGITD DI DMVGITD DMVGITD DN Ro48-8071 DMVGITD TI TT7O8ZA DMVGITD TN Lanosterol synthase (LSS) DMVGITD MA Inhibitor DMVGITD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVGITD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVGLH7 DI DMVGLH7 DMVGLH7 DN NSC-341622 DMVGLH7 TI TTGTQHC DMVGLH7 TN DNA topoisomerase I (TOP1) DMVGLH7 MA Inhibitor DMVGLH7 RN Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of share... Bioorg Med Chem. 2009 Oct 15;17(20):7145-55. DMVGLH7 RU https://pubmed.ncbi.nlm.nih.gov/19783447 DMVGNZJ DI DMVGNZJ DMVGNZJ DN KO-286011 DMVGNZJ TI TTQL5VC DMVGNZJ TN Platelet-activating factor receptor (PTAFR) DMVGNZJ MA Modulator DMVGNZJ RN Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1990 Dec;342(6):713-8. DMVGNZJ RU https://www.ncbi.nlm.nih.gov/pubmed/2096302 DMVGP02 DI DMVGP02 DMVGP02 DN N-(2-oxazolemethyl)milnacipran DMVGP02 TI TT3ROYC DMVGP02 TN Serotonin transporter (SERT) DMVGP02 MA Inhibitor DMVGP02 RN Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9. DMVGP02 RU https://pubmed.ncbi.nlm.nih.gov/18207394 DMVGP02 DI DMVGP02 DMVGP02 DN N-(2-oxazolemethyl)milnacipran DMVGP02 TI TTAWNKZ DMVGP02 TN Norepinephrine transporter (NET) DMVGP02 MA Inhibitor DMVGP02 RN Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9. DMVGP02 RU https://pubmed.ncbi.nlm.nih.gov/18207394 DMVGX7Z DI DMVGX7Z DMVGX7Z DN L-152,804 DMVGX7Z TI TTY6EWA DMVGX7Z TN Neuropeptide Y receptor type 5 (NPY5R) DMVGX7Z MA Antagonist DMVGX7Z RN L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist. Biochem Biophys Res Commun. 2000 May 27;272(1):169-73. DMVGX7Z RU https://pubmed.ncbi.nlm.nih.gov/10872822 DMVGY6K DI DMVGY6K DMVGY6K DN KU-58684 DMVGY6K TI TTVDSZ0 DMVGY6K TN Poly [ADP-ribose] polymerase 1 (PARP1) DMVGY6K MA Inhibitor DMVGY6K RN Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem. 2009 Feb 12;52(3):718-25. DMVGY6K RU https://pubmed.ncbi.nlm.nih.gov/19125579 DMVH4LK DI DMVH4LK DMVH4LK DN Bhg-F-N-Y-Y-W DMVH4LK TI TT3ZTGU DMVH4LK TN Endothelin B receptor (EDNRB) DMVH4LK MA Inhibitor DMVH4LK RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DMVH4LK RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DMVH4LK DI DMVH4LK DMVH4LK DN Bhg-F-N-Y-Y-W DMVH4LK TI TTKRD0G DMVH4LK TN Endothelin A receptor (EDNRA) DMVH4LK MA Inhibitor DMVH4LK RN Res-701-1, synthesis and a reevaluation of its effects on the endothelin receptors, Bioorg. Med. Chem. Lett. 5(6):621-626 (1995). DMVH4LK RU http://www.sciencedirect.com/science/article/pii/0960894X95000847 DMVH5WK DI DMVH5WK DMVH5WK DN SIGMOIDIN B DMVH5WK TI TTELIN2 DMVH5WK TN PTPN1 messenger RNA (PTPN1 mRNA) DMVH5WK MA Inhibitor DMVH5WK RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DMVH5WK RU https://pubmed.ncbi.nlm.nih.gov/17489632 DMVHDF4 DI DMVHDF4 DMVHDF4 DN (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K DMVHDF4 TI TTX3HNZ DMVHDF4 TN Galanin receptor type 1 (GAL1-R) DMVHDF4 MA Inhibitor DMVHDF4 RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMVHDF4 RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMVHDF4 DI DMVHDF4 DMVHDF4 DN (Sar)WTLNSAGYLLGPKK(Lys-myristoyl)K DMVHDF4 TI TTBPW3J DMVHDF4 TN Galanin receptor type 2 (GAL2-R) DMVHDF4 MA Inhibitor DMVHDF4 RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMVHDF4 RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMVHE1P DI DMVHE1P DMVHE1P DN 1,8,9-Trimethoxy-9,10-dihydro-anthracene DMVHE1P TI TT2J34L DMVHE1P TN Arachidonate 5-lipoxygenase (5-LOX) DMVHE1P MA Inhibitor DMVHE1P RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMVHE1P RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMVHKZT DI DMVHKZT DMVHKZT DN 1,4-Butanediol DMVHKZT TI TTO8QRU DMVHKZT TN Group IIA phospholipase A2 (GIIA sPLA2) DMVHKZT MA Inhibitor DMVHKZT RN Drosophila metabolize 1,4-butanediol into gamma-hydroxybutyric acid in vivo. Eur J Pharmacol. 2003 Jul 25;473(2-3):149-52. DMVHKZT RU https://pubmed.ncbi.nlm.nih.gov/12892832 DMVHMGA DI DMVHMGA DMVHMGA DN D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT DMVHMGA TI TT4TFGN DMVHMGA TN Vasopressin V1a receptor (V1AR) DMVHMGA MA Inhibitor DMVHMGA RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMVHMGA RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMVHMGA DI DMVHMGA DMVHMGA DN D(CH2)5[Tyr(Me)2,Thr4,Orn8(5/6C-Flu),Tyr-NH29]VT DMVHMGA TI TTSCIUP DMVHMGA TN Oxytocin receptor (OTR) DMVHMGA MA Inhibitor DMVHMGA RN Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. J Med Chem. 2002 Jun 6;45(12):2579-88. DMVHMGA RU https://pubmed.ncbi.nlm.nih.gov/12036367 DMVHMPC DI DMVHMPC DMVHMPC DN (9H-beta-Carbolin-3-yl)-ethyl-amine DMVHMPC TI TT1MPAY DMVHMPC TN GABA(A) receptor alpha-1 (GABRA1) DMVHMPC MA Inhibitor DMVHMPC RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DMVHMPC RU https://pubmed.ncbi.nlm.nih.gov/2989520 DMVHMPC DI DMVHMPC DMVHMPC DN (9H-beta-Carbolin-3-yl)-ethyl-amine DMVHMPC TI TTNJYV2 DMVHMPC TN Gamma-aminobutyric acid receptor (GAR) DMVHMPC MA Inhibitor DMVHMPC RN 3-Amino-beta-carboline derivatives and the benzodiazepine receptor. Synthesis of a selective antagonist of the sedative action of diazepam. J Med Chem. 1985 Jun;28(6):824-8. DMVHMPC RU https://pubmed.ncbi.nlm.nih.gov/2989520 DMVHOQE DI DMVHOQE DMVHOQE DN AMPPL DMVHOQE TI TT0HD6V DMVHOQE TN Leptin receptor (LEPR) DMVHOQE MA Modulator DMVHOQE RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DMVHOQE RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DMVHQB8 DI DMVHQB8 DMVHQB8 DN 3-DIPHENOL-6-NITRO-3H-BENZO[DE]ISOCHROMEN-1-ONE DMVHQB8 TI TTU6BFZ DMVHQB8 TN Candida Thymidylate synthase (Candi TMP1) DMVHQB8 MA Inhibitor DMVHQB8 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVHQB8 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVHQGF DI DMVHQGF DMVHQGF DN LY2033298 DMVHQGF TI TTOXS3C DMVHQGF TN Muscarinic acetylcholine receptor (CHRM) DMVHQGF MA Modulator (allosteric modulator) DMVHQGF RN Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. DMVHQGF RU https://pubmed.ncbi.nlm.nih.gov/18678919 DMVHQM9 DI DMVHQM9 DMVHQM9 DN 2-(4-Hydroxy-phenyl)-8-methyl-3H-quinazolin-4-one DMVHQM9 TI TTVDSZ0 DMVHQM9 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMVHQM9 MA Inhibitor DMVHQM9 RN Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymeras... J Med Chem. 1998 Dec 17;41(26):5247-56. DMVHQM9 RU https://pubmed.ncbi.nlm.nih.gov/9857092 DMVHR3Z DI DMVHR3Z DMVHR3Z DN PMID20873740C18 DMVHR3Z TI TTQY9DH DMVHR3Z TN TAO kinase 1 (TAOK1) DMVHR3Z MA Inhibitor DMVHR3Z RN Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315. DMVHR3Z RU https://pubmed.ncbi.nlm.nih.gov/20873740 DMVHR3Z DI DMVHR3Z DMVHR3Z DN PMID20873740C18 DMVHR3Z TI TT1LVF2 DMVHR3Z TN Cyclin-dependent kinase 9 (CDK9) DMVHR3Z MA Inhibitor DMVHR3Z RN Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315. DMVHR3Z RU https://pubmed.ncbi.nlm.nih.gov/20873740 DMVHR3Z DI DMVHR3Z DMVHR3Z DN PMID20873740C18 DMVHR3Z TI TTSMTDI DMVHR3Z TN CDC7-related kinase (CDC7) DMVHR3Z MA Inhibitor DMVHR3Z RN Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315. DMVHR3Z RU https://pubmed.ncbi.nlm.nih.gov/20873740 DMVHX5T DI DMVHX5T DMVHX5T DN CPPG DMVHX5T TI TTICZ1O DMVHX5T TN Metabotropic glutamate receptor 4 (mGluR4) DMVHX5T MA Antagonist DMVHX5T RN Ligand binding to the amino-terminal domain of the mGluR4 subtype of metabotropic glutamate receptor. J Biol Chem. 1999 Apr 9;274(15):10008-13. DMVHX5T RU https://pubmed.ncbi.nlm.nih.gov/10187777 DMVHX5T DI DMVHX5T DMVHX5T DN CPPG DMVHX5T TI TT0IFKL DMVHX5T TN Metabotropic glutamate receptor 8 (mGluR8) DMVHX5T MA Antagonist DMVHX5T RN Constraints on proper folding of the amino terminal domains of group III metabotropic glutamate receptors. Brain Res Mol Brain Res. 2000 Mar 10;76(1):180-90. DMVHX5T RU https://pubmed.ncbi.nlm.nih.gov/10719229 DMVI1D0 DI DMVI1D0 DMVI1D0 DN ISIS 2491 DMVI1D0 TI TTWMK2G DMVI1D0 TN Human papillomavirus-18 E7 region messenger RNA (HPV-18 E7 mRNA) DMVI1D0 RN US patent application no. 5,457,189, Antisense oligonucleotide inhibition of papillomavirus. DMVI1D0 RU http://www.patentbuddy.com/Patent/5457189?ft=true&sr=true DMVI2H9 DI DMVI2H9 DMVI2H9 DN SF-11 DMVI2H9 TI TT0NLAQ DMVI2H9 TN Mucolipin-3 (TRPML3) DMVI2H9 MA Activator DMVI2H9 RN Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48. DMVI2H9 RU https://pubmed.ncbi.nlm.nih.gov/20189104 DMVI2PM DI DMVI2PM DMVI2PM DN 1-(4-methyloxazol-2-yl)-7-phenylheptan-1-one DMVI2PM TI TTDP1UC DMVI2PM TN Fatty acid amide hydrolase (FAAH) DMVI2PM MA Inhibitor DMVI2PM RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMVI2PM RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMVI4JG DI DMVI4JG DMVI4JG DN GNF-PF-5188 DMVI4JG TI TTMSFAW DMVI4JG TN Cannabinoid receptor 2 (CB2) DMVI4JG MA Inhibitor DMVI4JG RN Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow. J Med Chem. 2009 Jan 22;52(2):369-78. DMVI4JG RU https://pubmed.ncbi.nlm.nih.gov/19143566 DMVI6EX DI DMVI6EX DMVI6EX DN PMID2231594C3j DMVI6EX TI TTPADOQ DMVI6EX TN HMG-CoA reductase (HMGCR) DMVI6EX MA Inhibitor DMVI6EX RN Phosphorus-containing inhibitors of HMG-CoA reductase. 1. 4-[(2-arylethyl)hydroxyphosphinyl]-3-hydroxy-butanoic acids: a new class of cell-selective inhibitors of cholesterol biosynthesis. J Med Chem. 1990 Nov;33(11):2952-6. DMVI6EX RU https://pubmed.ncbi.nlm.nih.gov/2231594 DMVI8R2 DI DMVI8R2 DMVI8R2 DN Parke-Davis 1 DMVI8R2 TI TTXHYV6 DMVI8R2 TN Voltage-gated L-type calcium channel (L-CaC) DMVI8R2 MA Blocker DMVI8R2 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMVI8R2 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMVI93X DI DMVI93X DMVI93X DN ANG-3407 DMVI93X TI TTRA5BZ DMVI93X TN Steroid 17-alpha-monooxygenase (S17AH) DMVI93X MA Inhibitor DMVI93X RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1361). DMVI93X RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1361 DMVI9DM DI DMVI9DM DMVI9DM DN ETIOCHOLANOLONE DMVI9DM TI TTNJYV2 DMVI9DM TN Gamma-aminobutyric acid receptor (GAR) DMVI9DM MA Inhibitor DMVI9DM RN Neurosteroid analogues. 11. Alternative ring system scaffolds: gamma-aminobutyric acid receptor modulation and anesthetic actions of benz[f]indenes. J Med Chem. 2006 Jul 27;49(15):4595-605. DMVI9DM RU https://pubmed.ncbi.nlm.nih.gov/16854065 DMVIDQL DI DMVIDQL DMVIDQL DN D-alanine DMVIDQL TI TTLP6GN DMVIDQL TN Bacterial DD-carboxypeptidase (Bact vanYB) DMVIDQL MA Inhibitor DMVIDQL RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVIDQL RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVIGCJ DI DMVIGCJ DMVIGCJ DN N1,N14-Bis((S-Methyl)Isothioureido)Tetradecane DMVIGCJ TI TTCM4B3 DMVIGCJ TN Nitric-oxide synthase endothelial (NOS3) DMVIGCJ MA Inhibitor DMVIGCJ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVIGCJ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVIHTF DI DMVIHTF DMVIHTF DN (8R,8'R,9'S)-5-methoxyclusin DMVIHTF TI TTXV4FI DMVIHTF TN Albendazole monooxygenase (CYP3A4) DMVIHTF MA Inhibitor DMVIHTF RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMVIHTF RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMVIQ7F DI DMVIQ7F DMVIQ7F DN 4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole DMVIQ7F TI TTBRKXS DMVIQ7F TN Adrenergic receptor alpha-1B (ADRA1B) DMVIQ7F MA Inhibitor DMVIQ7F RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMVIQ7F RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMVIQ7F DI DMVIQ7F DMVIQ7F DN 4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole DMVIQ7F TI TT34BHT DMVIQ7F TN Adrenergic receptor alpha-1D (ADRA1D) DMVIQ7F MA Inhibitor DMVIQ7F RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMVIQ7F RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMVIQ7F DI DMVIQ7F DMVIQ7F DN 4-(2,3-Dihydro-1H-phenalen-1-yl)-1H-imidazole DMVIQ7F TI TTNGILX DMVIQ7F TN Adrenergic receptor alpha-1A (ADRA1A) DMVIQ7F MA Inhibitor DMVIQ7F RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMVIQ7F RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMVIRLX DI DMVIRLX DMVIRLX DN 3-Oximo-olean-12-en-29-oic acid DMVIRLX TI TTIU7X1 DMVIRLX TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMVIRLX MA Inhibitor DMVIRLX RN DNA polymerase beta inhibitors from Sandoricum koetjape. J Nat Prod. 1999 Aug;62(8):1110-3. DMVIRLX RU https://pubmed.ncbi.nlm.nih.gov/10479314 DMVIXND DI DMVIXND DMVIXND DN ISIS 298701 DMVIXND TI TTSN6QU DMVIXND TN HIF1-alpha messenger RNA (HIF1A mRNA) DMVIXND RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMVIXND RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMVIZ1S DI DMVIZ1S DMVIZ1S DN 3-O-METHYLQUERCETIN DMVIZ1S TI TT7RJY8 DMVIZ1S TN Xanthine dehydrogenase/oxidase (XDH) DMVIZ1S MA Inhibitor DMVIZ1S RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DMVIZ1S RU https://pubmed.ncbi.nlm.nih.gov/3379415 DMVJ61A DI DMVJ61A DMVJ61A DN 4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide DMVJ61A TI TT1VAUK DMVJ61A TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMVJ61A MA Inhibitor DMVJ61A RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMVJ61A RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMVJ61A DI DMVJ61A DMVJ61A DN 4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide DMVJ61A TI TTUTJGQ DMVJ61A TN Vascular endothelial growth factor receptor 2 (KDR) DMVJ61A MA Inhibitor DMVJ61A RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMVJ61A RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMVJ61A DI DMVJ61A DMVJ61A DN 4-Chloro-N-(2-chloro-benzoyl)-benzenesulfonamide DMVJ61A TI TTDCBX5 DMVJ61A TN Vascular endothelial growth factor receptor 3 (FLT-4) DMVJ61A MA Inhibitor DMVJ61A RN Acyl sulfonamide anti-proliferatives: benzene substituent structure-activity relationships for a novel class of antitumor agents. J Med Chem. 2004 Oct 21;47(22):5367-80. DMVJ61A RU https://pubmed.ncbi.nlm.nih.gov/15481975 DMVJDCM DI DMVJDCM DMVJDCM DN PSX-4206 DMVJDCM TI TT7HC21 DMVJDCM TN Membrane copper amine oxidase (AOC3) DMVJDCM MA Inhibitor DMVJDCM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767). DMVJDCM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767 DMVJH1S DI DMVJH1S DMVJH1S DN 1-benzhydryl-4-m-tolylpiperidin-4-ol DMVJH1S TI TTKWM86 DMVJH1S TN Opioid receptor mu (MOP) DMVJH1S MA Inhibitor DMVJH1S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVJH1S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVJH1S DI DMVJH1S DMVJH1S DN 1-benzhydryl-4-m-tolylpiperidin-4-ol DMVJH1S TI TTNT7K8 DMVJH1S TN Nociceptin receptor (OPRL1) DMVJH1S MA Inhibitor DMVJH1S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVJH1S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVJH1S DI DMVJH1S DMVJH1S DN 1-benzhydryl-4-m-tolylpiperidin-4-ol DMVJH1S TI TTQW87Y DMVJH1S TN Opioid receptor kappa (OPRK1) DMVJH1S MA Inhibitor DMVJH1S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVJH1S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVJH1S DI DMVJH1S DMVJH1S DN 1-benzhydryl-4-m-tolylpiperidin-4-ol DMVJH1S TI TT27RFC DMVJH1S TN Opioid receptor delta (OPRD1) DMVJH1S MA Inhibitor DMVJH1S RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVJH1S RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVJKCH DI DMVJKCH DMVJKCH DN [3H]A778317 DMVJKCH TI TTMI6F5 DMVJKCH TN Transient receptor potential cation channel V1 (TRPV1) DMVJKCH MA Blocker (channel blocker) DMVJKCH RN [3H]A-778317 [1-((R)-5-tert-butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a novel, stereoselective, high-affinity antagonist is a useful radioligand ... J Pharmacol Exp Ther. 2007 Oct;323(1):285-93. DMVJKCH RU https://pubmed.ncbi.nlm.nih.gov/17660385 DMVJL8H DI DMVJL8H DMVJL8H DN cyclic CMP DMVJL8H TI TT9EUT4 DMVJL8H TN Hyperpolarization cyclic nucleotide-gated channel 2 (HCN2) DMVJL8H MA Activator DMVJL8H RN Regulation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel activity by cCMP. J Biol Chem. 2012 Aug 3;287(32):26506-12. DMVJL8H RU https://pubmed.ncbi.nlm.nih.gov/22715094 DMVJLR3 DI DMVJLR3 DMVJLR3 DN Recombinant human pro-urokinase DMVJLR3 TI TTGY7WI DMVJLR3 TN Urokinase-type plasminogen activator (PLAU) DMVJLR3 MA Inhibitor DMVJLR3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393). DMVJLR3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2393 DMVJLSM DI DMVJLSM DMVJLSM DN Pyrazofurin DMVJLSM TI TTAFJUD DMVJLSM TN Orotidine 5'-monophosphate decarboxylase (UMPS) DMVJLSM MA Inhibitor DMVJLSM RN Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75. DMVJLSM RU https://pubmed.ncbi.nlm.nih.gov/8250543 DMVJMG8 DI DMVJMG8 DMVJMG8 DN Cholecystokinin-9 DMVJMG8 TI TTVFO0U DMVJMG8 TN Gastrin/cholecystokinin type B receptor (CCKBR) DMVJMG8 MA Inhibitor DMVJMG8 RN 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectiv... J Med Chem. 2004 Oct 7;47(21):5318-29. DMVJMG8 RU https://pubmed.ncbi.nlm.nih.gov/15456276 DMVJN4B DI DMVJN4B DMVJN4B DN ISIS 114197 DMVJN4B TI TTWIJYH DMVJN4B TN E2F3 messenger RNA (E2F3 mRNA) DMVJN4B RN US patent application no. 6,165,791, Antisense inhibition of E2F transcription factor 3 expression. DMVJN4B RU http://www.patentbuddy.com/Patent/6165791?ft=true&sr=true DMVJORE DI DMVJORE DMVJORE DN 2-trityl-4,5-dihydrooxazole DMVJORE TI TTMNI76 DMVJORE TN Calcium-activated potassium channel (KCN) DMVJORE MA Inhibitor DMVJORE RN Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82. DMVJORE RU https://pubmed.ncbi.nlm.nih.gov/18232633 DMVJX21 DI DMVJX21 DMVJX21 DN CP-99,994 DMVJX21 TI TTZPO1L DMVJX21 TN Substance-P receptor (TACR1) DMVJX21 MA Antagonist DMVJX21 RN Gabapentin and the neurokinin(1) receptor antagonist CI-1021 act synergistically in two rat models of neuropathic pain. J Pharmacol Exp Ther. 2002 Nov;303(2):730-5. DMVJX21 RU https://pubmed.ncbi.nlm.nih.gov/12388658 DMVJXQ9 DI DMVJXQ9 DMVJXQ9 DN 2-amino-4,6-dimethylpyridine DMVJXQ9 TI TTZUFI5 DMVJXQ9 TN Nitric-oxide synthase brain (NOS1) DMVJXQ9 MA Inhibitor DMVJXQ9 RN L337H mutant of rat neuronal nitric oxide synthase resembles human neuronal nitric oxide synthase toward inhibitors. J Med Chem. 2009 Jul 23;52(14):4533-7. DMVJXQ9 RU https://pubmed.ncbi.nlm.nih.gov/19537690 DMVJZ0C DI DMVJZ0C DMVJZ0C DN 1-(9-phenyl-9H-fluoren-9-yl)-1H-1,2,4-triazole DMVJZ0C TI TTSZLWK DMVJZ0C TN Aromatase (CYP19A1) DMVJZ0C MA Inhibitor DMVJZ0C RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMVJZ0C RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMVK1GT DI DMVK1GT DMVK1GT DN PMID22802221C21 DMVK1GT TI TTQVOEI DMVK1GT TN Angiotensin II receptor type-2 (AGTR2) DMVK1GT MA Agonist DMVK1GT RN Compound 21 induces vasorelaxation via an endothelium- and angiotensin II type 2 receptor-independent mechanism. Hypertension. 2012 Sep;60(3):722-9. DMVK1GT RU https://pubmed.ncbi.nlm.nih.gov/22802221 DMVK2Y3 DI DMVK2Y3 DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide DMVK2Y3 TI TT5ZKDI DMVK2Y3 TN Histone deacetylase 6 (HDAC6) DMVK2Y3 MA Inhibitor DMVK2Y3 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVK2Y3 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVK2Y3 DI DMVK2Y3 DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide DMVK2Y3 TI TT6R7JZ DMVK2Y3 TN Histone deacetylase 1 (HDAC1) DMVK2Y3 MA Inhibitor DMVK2Y3 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVK2Y3 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVK2Y3 DI DMVK2Y3 DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide DMVK2Y3 TI TTTQGH8 DMVK2Y3 TN Histone deacetylase 4 (HDAC4) DMVK2Y3 MA Inhibitor DMVK2Y3 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVK2Y3 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVK2Y3 DI DMVK2Y3 DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide DMVK2Y3 TI TTBH0VX DMVK2Y3 TN Histone deacetylase (HDAC) DMVK2Y3 MA Inhibitor DMVK2Y3 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVK2Y3 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVK2Y3 DI DMVK2Y3 DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide DMVK2Y3 TI TTT6LFV DMVK2Y3 TN Histone deacetylase 8 (HDAC8) DMVK2Y3 MA Inhibitor DMVK2Y3 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVK2Y3 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVK2Y3 DI DMVK2Y3 DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide DMVK2Y3 TI TTSHTOI DMVK2Y3 TN Histone deacetylase 2 (HDAC2) DMVK2Y3 MA Inhibitor DMVK2Y3 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVK2Y3 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVK2Y3 DI DMVK2Y3 DMVK2Y3 DN N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide DMVK2Y3 TI TTYHPU6 DMVK2Y3 TN Histone deacetylase 10 (HDAC10) DMVK2Y3 MA Inhibitor DMVK2Y3 RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMVK2Y3 RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMVKJ0H DI DMVKJ0H DMVKJ0H DN (H-261)Boc-His-Pro-Phe-His-Leu(OH)-Val-Ile-His-OH DMVKJ0H TI TTB2MXP DMVKJ0H TN Angiotensinogenase renin (REN) DMVKJ0H MA Inhibitor DMVKJ0H RN Renin inhibitors. Dipeptide analogues of angiotensinogen incorporating transition-state, nonpeptidic replacements at the scissile bond. J Med Chem. 1987 Oct;30(10):1729-37. DMVKJ0H RU https://pubmed.ncbi.nlm.nih.gov/3309313 DMVKL84 DI DMVKL84 DMVKL84 DN (S)-2-(2-(2-methylpyrrolidin-1-yl)ethyl)pyridine DMVKL84 TI TT9JNIC DMVKL84 TN Histamine H3 receptor (H3R) DMVKL84 MA Inhibitor DMVKL84 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMVKL84 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMVKO5N DI DMVKO5N DMVKO5N DN 3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole DMVKO5N TI TTJS8PY DMVKO5N TN 5-HT 6 receptor (HTR6) DMVKO5N MA Inhibitor DMVKO5N RN 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60. DMVKO5N RU https://pubmed.ncbi.nlm.nih.gov/20138763 DMVKPF1 DI DMVKPF1 DMVKPF1 DN 4-Amino-3-(4-fluoro-phenyl)-butyric acid DMVKPF1 TI TTDCVZW DMVKPF1 TN Gamma-aminobutyric acid B receptor (GABBR) DMVKPF1 MA Inhibitor DMVKPF1 RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DMVKPF1 RU https://pubmed.ncbi.nlm.nih.gov/1652022 DMVKU4L DI DMVKU4L DMVKU4L DN 4-Chloro-N-(4-phenyl-thiazol-2-yl)-benzamide DMVKU4L TI TTK25J1 DMVKU4L TN Adenosine A1 receptor (ADORA1) DMVKU4L MA Inhibitor DMVKU4L RN Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor. Bioorg Med Chem Lett. 2001 Aug 6;11(15):2017-9. DMVKU4L RU https://pubmed.ncbi.nlm.nih.gov/11454470 DMVKZ5I DI DMVKZ5I DMVKZ5I DN GW9508 DMVKZ5I TI TT08JVB DMVKZ5I TN G-protein coupled receptor 120 (GPR120) DMVKZ5I MA Agonist DMVKZ5I RN Free fatty acid receptors and drug discovery. Biol Pharm Bull. 2008 Oct;31(10):1847-51. DMVKZ5I RU https://pubmed.ncbi.nlm.nih.gov/18827341 DMVKZ5I DI DMVKZ5I DMVKZ5I DN GW9508 DMVKZ5I TI TTB8FUC DMVKZ5I TN Free fatty acid receptor 1 (GPR40) DMVKZ5I MA Agonist DMVKZ5I RN Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small... Br J Pharmacol. 2006 Jul;148(5):619-28. DMVKZ5I RU https://pubmed.ncbi.nlm.nih.gov/16702987 DMVL1SN DI DMVL1SN DMVL1SN DN ISIS 222039 DMVL1SN TI TTWPA54 DMVL1SN TN HIF2-alpha messenger RNA (EPAS1 mRNA) DMVL1SN RN US patent application no. 7,217,572, Modulation of HIF1.alpha. and HIF2.alpha. expression. DMVL1SN RU http://www.patentbuddy.com/Patent/7217572?ft=true&sr=true DMVL218 DI DMVL218 DMVL218 DN 6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole DMVL218 TI TTJS8PY DMVL218 TN 5-HT 6 receptor (HTR6) DMVL218 MA Inhibitor DMVL218 RN A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3929-31. DMVL218 RU https://pubmed.ncbi.nlm.nih.gov/18583130 DMVL51I DI DMVL51I DMVL51I DN NSC-354279 DMVL51I TI TT8XK6L DMVL51I TN Quinone reductase 1 (NQO1) DMVL51I MA Inhibitor DMVL51I RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMVL51I RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMVL5KS DI DMVL5KS DMVL5KS DN NS3763 DMVL5KS TI TT0MYE2 DMVL5KS TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMVL5KS MA Antagonist DMVL5KS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMVL5KS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMVL8O0 DI DMVL8O0 DMVL8O0 DN ISIS 103803 DMVL8O0 TI TT6TU05 DMVL8O0 TN WWP2 messenger RNA (WWP2 mRNA) DMVL8O0 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMVL8O0 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMVLHN9 DI DMVLHN9 DMVLHN9 DN ISIS 112024 DMVLHN9 TI TTPJ9XK DMVLHN9 TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMVLHN9 RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMVLHN9 RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMVLID9 DI DMVLID9 DMVLID9 DN 6-Nitro-2-phenyl-chromen-4-one DMVLID9 TI TT1MPAY DMVLID9 TN GABA(A) receptor alpha-1 (GABRA1) DMVLID9 MA Inhibitor DMVLID9 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMVLID9 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMVLID9 DI DMVLID9 DMVLID9 DN 6-Nitro-2-phenyl-chromen-4-one DMVLID9 TI TTNJYV2 DMVLID9 TN Gamma-aminobutyric acid receptor (GAR) DMVLID9 MA Inhibitor DMVLID9 RN Synthesis of halogenated/nitrated flavone derivatives and evaluation of their affinity for the central benzodiazepine receptor, Bioorg. Med. Chem. Lett. 7(15):2003-2008 (1997). DMVLID9 RU http://www.sciencedirect.com/science/article/pii/S0960894X97003430 DMVLMBQ DI DMVLMBQ DMVLMBQ DN 1,2-bis(2,5-difluorophenyl)ethane-1,2-dione DMVLMBQ TI TTMF541 DMVLMBQ TN Liver carboxylesterase (CES1) DMVLMBQ MA Inhibitor DMVLMBQ RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMVLMBQ RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMVLQUP DI DMVLQUP DMVLQUP DN Grandisine C DMVLQUP TI TT27RFC DMVLQUP TN Opioid receptor delta (OPRD1) DMVLQUP MA Inhibitor DMVLQUP RN Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9. DMVLQUP RU https://pubmed.ncbi.nlm.nih.gov/16989522 DMVLRHW DI DMVLRHW DMVLRHW DN [3H]cytisine DMVLRHW TI TTF4E0J DMVLRHW TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMVLRHW MA Agonist DMVLRHW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 463). DMVLRHW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=463 DMVLRHW DI DMVLRHW DMVLRHW DN [3H]cytisine DMVLRHW TI TTH18TF DMVLRHW TN Muscarinic acetylcholine receptor M5 (CHRM5) DMVLRHW MA Agonist DMVLRHW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMVLRHW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMVLRHW DI DMVLRHW DMVLRHW DN [3H]cytisine DMVLRHW TI TT5KPZR DMVLRHW TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMVLRHW MA Agonist DMVLRHW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 465). DMVLRHW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=465 DMVLU5J DI DMVLU5J DMVLU5J DN ISIS 29176 DMVLU5J TI TTO6SGY DMVLU5J TN AKT3 messenger RNA (AKT3 mRNA) DMVLU5J RN US patent application no. 6,187,586, Antisense modulation of AKT-3 expression. DMVLU5J RU http://www.patentbuddy.com/Patent/6187586?ft=true&sr=true DMVLW6R DI DMVLW6R DMVLW6R DN IMPERATORIN DMVLW6R TI TTO9X1H DMVLW6R TN 5-HT 7 receptor (HTR7) DMVLW6R MA Inhibitor DMVLW6R RN Serotonergic activity-guided phytochemical investigation of the roots of Angelica sinensis. J Nat Prod. 2006 Apr;69(4):536-41. DMVLW6R RU https://pubmed.ncbi.nlm.nih.gov/16643021 DMVLX1T DI DMVLX1T DMVLX1T DN 2-N-Methylamino-1-(4-methylthiophenyl)propane DMVLX1T TI TT3ROYC DMVLX1T TN Serotonin transporter (SERT) DMVLX1T MA Inhibitor DMVLX1T RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMVLX1T RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMVM2XD DI DMVM2XD DMVM2XD DN PMID16439120C26 DMVM2XD TI TTHS256 DMVM2XD TN Metabotropic glutamate receptor 5 (mGluR5) DMVM2XD MA Modulator (allosteric modulator) DMVM2XD RN Arylmethoxypyridines as novel, potent and orally active mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1892-7. DMVM2XD RU https://pubmed.ncbi.nlm.nih.gov/16439120 DMVM78Q DI DMVM78Q DMVM78Q DN Olean-12-en-3beta,15alpha-diol DMVM78Q TI TT0IHXV DMVM78Q TN DNA topoisomerase II (TOP2) DMVM78Q MA Inhibitor DMVM78Q RN Screening of triterpenoids isolated from Phyllanthus flexuosus for DNA topoisomerase inhibitory activity. J Nat Prod. 2001 Dec;64(12):1545-7. DMVM78Q RU https://pubmed.ncbi.nlm.nih.gov/11754608 DMVM7B2 DI DMVM7B2 DMVM7B2 DN C-[-Arg-Gly-Asp-Acpca32-] DMVM7B2 TI TTJA1ZO DMVM7B2 TN ITGB3 messenger RNA (ITGB3 mRNA) DMVM7B2 MA Inhibitor DMVM7B2 RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMVM7B2 RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMVM7B2 DI DMVM7B2 DMVM7B2 DN C-[-Arg-Gly-Asp-Acpca32-] DMVM7B2 TI TTT1R2L DMVM7B2 TN Integrin alpha-V (ITGAV) DMVM7B2 MA Inhibitor DMVM7B2 RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMVM7B2 RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMVMBG0 DI DMVMBG0 DMVMBG0 DN 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one DMVMBG0 TI TTI7421 DMVMBG0 TN Platelet-derived growth factor receptor beta (PDGFRB) DMVMBG0 MA Inhibitor DMVMBG0 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMVMBG0 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMVMBG0 DI DMVMBG0 DMVMBG0 DN 5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one DMVMBG0 TI TT8FYO9 DMVMBG0 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMVMBG0 MA Inhibitor DMVMBG0 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMVMBG0 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMVMDAZ DI DMVMDAZ DMVMDAZ DN ISIS 111993 DMVMDAZ TI TTPJ9XK DMVMDAZ TN hnRNP A1 messenger RNA (HNRNPA1 mRNA) DMVMDAZ RN US patent application no. 6,165,789, Antisense modulation of hnRNP A1 expression. DMVMDAZ RU http://www.patentbuddy.com/Patent/6165789?ft=true&sr=true DMVMDJ3 DI DMVMDJ3 DMVMDJ3 DN 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide DMVMDJ3 TI TT5ZKDI DMVMDJ3 TN Histone deacetylase 6 (HDAC6) DMVMDJ3 MA Inhibitor DMVMDJ3 RN Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70. DMVMDJ3 RU https://pubmed.ncbi.nlm.nih.gov/20947351 DMVMDJ3 DI DMVMDJ3 DMVMDJ3 DN 6-(9H-carbazol-9-yl)-N-hydroxyhexanamide DMVMDJ3 TI TT6R7JZ DMVMDJ3 TN Histone deacetylase 1 (HDAC1) DMVMDJ3 MA Inhibitor DMVMDJ3 RN Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010 Dec 1;20(23):7067-70. DMVMDJ3 RU https://pubmed.ncbi.nlm.nih.gov/20947351 DMVMF5X DI DMVMF5X DMVMF5X DN ISIS 2919 DMVMF5X TI TT4SCBE DMVMF5X TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMVMF5X RN US patent application no. 5,442,049, Oligonucleotides for modulating the effects of cytomegalovirus infections. DMVMF5X RU http://www.patentbuddy.com/Patent/5442049?ft=true&sr=true DMVMHBL DI DMVMHBL DMVMHBL DN 4-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione DMVMHBL TI TTVDSZ0 DMVMHBL TN Poly [ADP-ribose] polymerase 1 (PARP1) DMVMHBL MA Inhibitor DMVMHBL RN Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42. DMVMHBL RU https://pubmed.ncbi.nlm.nih.gov/16290935 DMVMW9S DI DMVMW9S DMVMW9S DN AZ3971 DMVMW9S TI TT8JRS7 DMVMW9S TN Beta-secretase (BACE) DMVMW9S MA Inhibitor DMVMW9S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2330). DMVMW9S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2330 DMVMXKP DI DMVMXKP DMVMXKP DN VU0092145 DMVMXKP TI TTICZ1O DMVMXKP TN Metabotropic glutamate receptor 4 (mGluR4) DMVMXKP MA Modulator (allosteric modulator) DMVMXKP RN Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4). Part II: Challenges in hit-to-lead. Bioorg Med Chem Lett. 2009 Feb 1;19(3):962-6. DMVMXKP RU https://pubmed.ncbi.nlm.nih.gov/19097893 DMVN0EC DI DMVN0EC DMVN0EC DN 2-Amino-4,6-di-furan-2-yl-nicotinonitrile DMVN0EC TI TTNE7KG DMVN0EC TN Adenosine A2b receptor (ADORA2B) DMVN0EC MA Inhibitor DMVN0EC RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMVN0EC RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMVN0EC DI DMVN0EC DMVN0EC DN 2-Amino-4,6-di-furan-2-yl-nicotinonitrile DMVN0EC TI TTM2AOE DMVN0EC TN Adenosine A2a receptor (ADORA2A) DMVN0EC MA Inhibitor DMVN0EC RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMVN0EC RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMVN0EC DI DMVN0EC DMVN0EC DN 2-Amino-4,6-di-furan-2-yl-nicotinonitrile DMVN0EC TI TTK25J1 DMVN0EC TN Adenosine A1 receptor (ADORA1) DMVN0EC MA Inhibitor DMVN0EC RN 2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem. 2008 Aug 14;51(15):4449-55. DMVN0EC RU https://pubmed.ncbi.nlm.nih.gov/18637670 DMVN0O5 DI DMVN0O5 DMVN0O5 DN 3-(4-Amino-phenyl)-pyrrolidine-2,5-dione DMVN0O5 TI TTSZLWK DMVN0O5 TN Aromatase (CYP19A1) DMVN0O5 MA Inhibitor DMVN0O5 RN Synthesis and biochemical evaluation of analogues of aminoglutethimide based on phenylpyrrolidine-2,5-dione. J Med Chem. 1986 Apr;29(4):520-3. DMVN0O5 RU https://pubmed.ncbi.nlm.nih.gov/3754286 DMVN1UI DI DMVN1UI DMVN1UI DN 2-(N-Cyclopentylamino)-3'-methoxypropiophenone DMVN1UI TI TT3ROYC DMVN1UI TN Serotonin transporter (SERT) DMVN1UI MA Inhibitor DMVN1UI RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMVN1UI RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMVN1UI DI DMVN1UI DMVN1UI DN 2-(N-Cyclopentylamino)-3'-methoxypropiophenone DMVN1UI TI TTVBI8W DMVN1UI TN Dopamine transporter (DAT) DMVN1UI MA Inhibitor DMVN1UI RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMVN1UI RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMVN1UI DI DMVN1UI DMVN1UI DN 2-(N-Cyclopentylamino)-3'-methoxypropiophenone DMVN1UI TI TTAWNKZ DMVN1UI TN Norepinephrine transporter (NET) DMVN1UI MA Inhibitor DMVN1UI RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMVN1UI RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMVN374 DI DMVN374 DMVN374 DN Ginkgolide C DMVN374 TI TTZ8EM9 DMVN374 TN Glycine receptor (GlyR) DMVN374 MA Inhibitor DMVN374 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMVN374 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMVN374 DI DMVN374 DMVN374 DN Ginkgolide C DMVN374 TI TTF45NW DMVN374 TN Strychnine-binding glycine receptor (GLRA1) DMVN374 MA Inhibitor DMVN374 RN Probing the pharmacophore of ginkgolides as glycine receptor antagonists. J Med Chem. 2007 Apr 5;50(7):1610-7. DMVN374 RU https://pubmed.ncbi.nlm.nih.gov/17352465 DMVN38H DI DMVN38H DMVN38H DN 2-morpholin-4-yl-8-phenoxathiin-4-ylchromen-4-one DMVN38H TI TTK3PY9 DMVN38H TN DNA-dependent protein kinase catalytic (PRKDC) DMVN38H MA Inhibitor DMVN38H RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMVN38H RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMVN50D DI DMVN50D DMVN50D DN (R)(+)-7-methyl-2-p-tolylchroman-4-one DMVN50D TI TTGP7BY DMVN50D TN Monoamine oxidase type B (MAO-B) DMVN50D MA Inhibitor DMVN50D RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMVN50D RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMVN7GC DI DMVN7GC DMVN7GC DN 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole DMVN7GC TI TTR5TV4 DMVN7GC TN ERBB2 messenger RNA (HER2 mRNA) DMVN7GC MA Inhibitor DMVN7GC RN Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem. 2007 Feb 1;15(3):1533-8. DMVN7GC RU https://pubmed.ncbi.nlm.nih.gov/17174554 DMVN93B DI DMVN93B DMVN93B DN D-leucyl-N-(3-chlorobenzyl)-L-prolinamide DMVN93B TI TT6L509 DMVN93B TN Coagulation factor IIa (F2) DMVN93B MA Inhibitor DMVN93B RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVN93B RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVNC1R DI DMVNC1R DMVNC1R DN Bis-7-tacrine DMVNC1R TI TT1RS9F DMVNC1R TN Acetylcholinesterase (AChE) DMVNC1R MA Inhibitor DMVNC1R RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMVNC1R RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMVNC1R DI DMVNC1R DMVNC1R DN Bis-7-tacrine DMVNC1R TI TT8JRS7 DMVNC1R TN Beta-secretase (BACE) DMVNC1R MA Inhibitor DMVNC1R RN Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds. J Med Chem. 2009 Sep 10;52(17):5365-79. DMVNC1R RU https://pubmed.ncbi.nlm.nih.gov/19663388 DMVNC1R DI DMVNC1R DMVNC1R DN Bis-7-tacrine DMVNC1R TI TTEB0GD DMVNC1R TN Cholinesterase (BCHE) DMVNC1R MA Inhibitor DMVNC1R RN Design, synthesis and evaluation of 2,4-disubstituted pyrimidines as cholinesterase inhibitors. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3606-9. DMVNC1R RU https://pubmed.ncbi.nlm.nih.gov/20472431 DMVNHTE DI DMVNHTE DMVNHTE DN PQ401 DMVNHTE TI TTQFBMY DMVNHTE TN IGF1R messenger RNA (IGF1R mRNA) DMVNHTE MA Inhibitor DMVNHTE RN Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol Cancer Ther. 2006 Apr;5(4):1079-86. DMVNHTE RU https://pubmed.ncbi.nlm.nih.gov/16648580 DMVNLPF DI DMVNLPF DMVNLPF DN N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine DMVNLPF TI TTM2AOE DMVNLPF TN Adenosine A2a receptor (ADORA2A) DMVNLPF MA Inhibitor DMVNLPF RN N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47. DMVNLPF RU https://pubmed.ncbi.nlm.nih.gov/18045744 DMVNLPF DI DMVNLPF DMVNLPF DN N6-[(4-Nitro)-phenyl]-9-benzyl-2-phenyladenine DMVNLPF TI TTK25J1 DMVNLPF TN Adenosine A1 receptor (ADORA1) DMVNLPF MA Inhibitor DMVNLPF RN N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A... Eur J Med Chem. 2008 Aug;43(8):1639-47. DMVNLPF RU https://pubmed.ncbi.nlm.nih.gov/18045744 DMVO8P5 DI DMVO8P5 DMVO8P5 DN SB 272844 DMVO8P5 TI TT30C9G DMVO8P5 TN C-X-C chemokine receptor type 2 (CXCR2) DMVO8P5 MA Antagonist DMVO8P5 RN The selective CXCR2 antagonist SB272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis. Pulm Pharmacol Ther. 2002;15(2):103-10. DMVO8P5 RU https://pubmed.ncbi.nlm.nih.gov/12090783 DMVOCWY DI DMVOCWY DMVOCWY DN 8-(4-bromophenyl)-N-hydroxy-8-oxooctanamide DMVOCWY TI TT6R7JZ DMVOCWY TN Histone deacetylase 1 (HDAC1) DMVOCWY MA Inhibitor DMVOCWY RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMVOCWY RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMVOD03 DI DMVOD03 DMVOD03 DN Eplerenone DMVOD03 TI TT9P1CK DMVOD03 TN HUMAN mineralocorticoid receptor (MR) DMVOD03 MA Antagonist DMVOD03 RN Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020 Mar 16;6:14. DMVOD03 RU https://pubmed.ncbi.nlm.nih.gov/32194980 DMVOGT4 DI DMVOGT4 DMVOGT4 DN PREMETREXED DMVOGT4 TI TTY8Z2E DMVOGT4 TN Proton-coupled folate transporter (SLC46A1) DMVOGT4 MA Modulator DMVOGT4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1213). DMVOGT4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1213 DMVOGT4 DI DMVOGT4 DMVOGT4 DN PREMETREXED DMVOGT4 TI TT9SL3Q DMVOGT4 TN Polypeptide deformylase (PDF) DMVOGT4 MA Inhibitor DMVOGT4 RN Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J Med Chem. 2001 Jun 7;44(12):1993-2003. DMVOGT4 RU https://pubmed.ncbi.nlm.nih.gov/11384244 DMVOGT4 DI DMVOGT4 DMVOGT4 DN PREMETREXED DMVOGT4 TI TTU6BFZ DMVOGT4 TN Candida Thymidylate synthase (Candi TMP1) DMVOGT4 MA Inhibitor DMVOGT4 RN Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical ... J Med Chem. 2006 Feb 9;49(3):1055-65. DMVOGT4 RU https://pubmed.ncbi.nlm.nih.gov/16451071 DMVOIL5 DI DMVOIL5 DMVOIL5 DN SB-656104 DMVOIL5 TI TTO9X1H DMVOIL5 TN 5-HT 7 receptor (HTR7) DMVOIL5 MA Inhibitor DMVOIL5 RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMVOIL5 RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMVOIL5 DI DMVOIL5 DMVOIL5 DN SB-656104 DMVOIL5 TI TTSQIFT DMVOIL5 TN 5-HT 1A receptor (HTR1A) DMVOIL5 MA Inhibitor DMVOIL5 RN Novel 3-aminochromans as potential pharmacological tools for the serotonin 5-HT(7) receptor. Bioorg Med Chem Lett. 2005 Feb 1;15(3):747-50. DMVOIL5 RU https://pubmed.ncbi.nlm.nih.gov/15664850 DMVOJ0X DI DMVOJ0X DMVOJ0X DN BioVant DMVOJ0X TI TT3J5ZI DMVOJ0X TN Cell mediated immunity response (CMIR) DMVOJ0X RN Calcium Phosphate Nanoparticle Adjuvant. Clin Diagn Lab Immunol. 2000 November; 7(6): 899-903. DMVOJ0X RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC95982/ DMVOJ7K DI DMVOJ7K DMVOJ7K DN 1-(3,4-dichlorophenyl)-3-hydroxyurea DMVOJ7K TI TTUNARX DMVOJ7K TN Carbonic anhydrase (CA) DMVOJ7K MA Inhibitor DMVOJ7K RN N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20. DMVOJ7K RU https://pubmed.ncbi.nlm.nih.gov/16759856 DMVOJ7K DI DMVOJ7K DMVOJ7K DN 1-(3,4-dichlorophenyl)-3-hydroxyurea DMVOJ7K TI TTZHA0O DMVOJ7K TN Carbonic anhydrase IV (CA-IV) DMVOJ7K MA Inhibitor DMVOJ7K RN N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20. DMVOJ7K RU https://pubmed.ncbi.nlm.nih.gov/16759856 DMVOJ7K DI DMVOJ7K DMVOJ7K DN 1-(3,4-dichlorophenyl)-3-hydroxyurea DMVOJ7K TI TT2LVK8 DMVOJ7K TN Carbonic anhydrase IX (CA-IX) DMVOJ7K MA Inhibitor DMVOJ7K RN N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20. DMVOJ7K RU https://pubmed.ncbi.nlm.nih.gov/16759856 DMVOJ7K DI DMVOJ7K DMVOJ7K DN 1-(3,4-dichlorophenyl)-3-hydroxyurea DMVOJ7K TI TTANPDJ DMVOJ7K TN Carbonic anhydrase II (CA-II) DMVOJ7K MA Inhibitor DMVOJ7K RN N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20. DMVOJ7K RU https://pubmed.ncbi.nlm.nih.gov/16759856 DMVOJFW DI DMVOJFW DMVOJFW DN N-[(4-methoxyphenyl)sulfonyl]-D-alanine DMVOJFW TI TTXZ0KQ DMVOJFW TN Matrix metalloproteinase-12 (MMP-12) DMVOJFW MA Inhibitor DMVOJFW RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVOJFW RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVOPXE DI DMVOPXE DMVOPXE DN N-Hydroxy-3-naphthalen-2-yl-N-phenyl-acrylamide DMVOPXE TI TT2J34L DMVOPXE TN Arachidonate 5-lipoxygenase (5-LOX) DMVOPXE MA Inhibitor DMVOPXE RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMVOPXE RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMVOS2C DI DMVOS2C DMVOS2C DN BCX-1827 DMVOS2C TI TT50QJ3 DMVOS2C TN Influenza Neuraminidase (Influ NA) DMVOS2C MA Inhibitor DMVOS2C RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMVOS2C RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMVOSN1 DI DMVOSN1 DMVOSN1 DN ISIS 19634 DMVOSN1 TI TTWALCO DMVOSN1 TN HER4 messenger RNA (ERBB4 mRNA) DMVOSN1 RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMVOSN1 RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMVOX4L DI DMVOX4L DMVOX4L DN [6,4''']biflavone DMVOX4L TI TTT1JVS DMVOX4L TN Cytosolic phospholipase A2 (GIVA cPLA2) DMVOX4L MA Inhibitor DMVOX4L RN Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43. DMVOX4L RU https://pubmed.ncbi.nlm.nih.gov/17826099 DMVOY4D DI DMVOY4D DMVOY4D DN [1,1':2',1'']-terphenyl-4,3'',5''-triol DMVOY4D TI TT3PJMV DMVOY4D TN Tyrosine-protein kinase ABL1 (ABL) DMVOY4D MA Inhibitor DMVOY4D RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMVOY4D RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMVOY4D DI DMVOY4D DMVOY4D DN [1,1':2',1'']-terphenyl-4,3'',5''-triol DMVOY4D TI TT3OT40 DMVOY4D TN Multidrug resistance protein 1 (ABCB1) DMVOY4D MA Inhibitor DMVOY4D RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMVOY4D RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMVP0Z9 DI DMVP0Z9 DMVP0Z9 DN PMID24900824C2-3-2 DMVP0Z9 TI TT78309 DMVP0Z9 TN BUB1 mitotic checkpoint serine/threonine kinase (BUB1) DMVP0Z9 MA Inhibitor DMVP0Z9 RN Novel cycloalkenepyrazoles as inhibitors of bub1 kinase. ACS Med Chem Lett. 2014 Feb 12;5(4):280-1. DMVP0Z9 RU https://pubmed.ncbi.nlm.nih.gov/24900824 DMVP183 DI DMVP183 DMVP183 DN (+/-)-threo-N-(3-Phenylpropyl)ritalinol DMVP183 TI TTVBI8W DMVP183 TN Dopamine transporter (DAT) DMVP183 MA Inhibitor DMVP183 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMVP183 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMVP39I DI DMVP39I DMVP39I DN 12,13-DEHYDRO-8-O-ACETYLMANZAMINE A DMVP39I TI TTRSMW9 DMVP39I TN Glycogen synthase kinase-3 beta (GSK-3B) DMVP39I MA Inhibitor DMVP39I RN Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for ... J Nat Prod. 2007 Sep;70(9):1397-405. DMVP39I RU https://pubmed.ncbi.nlm.nih.gov/17708655 DMVP6CW DI DMVP6CW DMVP6CW DN 2-Cyclopent-1-enylethynyl-pyridine DMVP6CW TI TTHS256 DMVP6CW TN Metabotropic glutamate receptor 5 (mGluR5) DMVP6CW MA Inhibitor DMVP6CW RN Cyclohexenyl- and dehydropiperidinyl-alkynyl pyridines as potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4589-93. DMVP6CW RU https://pubmed.ncbi.nlm.nih.gov/16115767 DMVP74I DI DMVP74I DMVP74I DN BAY 367620 DMVP74I TI TTVBPDM DMVP74I TN Metabotropic glutamate receptor 1 (mGluR1) DMVP74I MA Modulator (allosteric modulator) DMVP74I RN BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol. 2001 May;59(5):965-73. DMVP74I RU https://pubmed.ncbi.nlm.nih.gov/11306677 DMVPIF8 DI DMVPIF8 DMVPIF8 DN NP-506 DMVPIF8 TI TTRLW2X DMVPIF8 TN Fibroblast growth factor receptor 1 (FGFR1) DMVPIF8 MA Inhibitor DMVPIF8 RN 5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases. Bioorg Med Chem Lett. 2009 Feb 1;19(3):745-50. DMVPIF8 RU https://pubmed.ncbi.nlm.nih.gov/19110422 DMVPIYG DI DMVPIYG DMVPIYG DN 8-Br-adenine DMVPIYG TI TTM2AOE DMVPIYG TN Adenosine A2a receptor (ADORA2A) DMVPIYG MA Inhibitor DMVPIYG RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMVPIYG RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMVPSXW DI DMVPSXW DMVPSXW DN 5-aminoisoquinolin-1(2H)-one DMVPSXW TI TTVDSZ0 DMVPSXW TN Poly [ADP-ribose] polymerase 1 (PARP1) DMVPSXW MA Inhibitor DMVPSXW RN Design, synthesis, and evaluation in vitro of quinoline-8-carboxamides, a new class of poly(adenosine-diphosphate-ribose)polymerase-1 (PARP-1) inhi... J Med Chem. 2009 Feb 12;52(3):868-77. DMVPSXW RU https://pubmed.ncbi.nlm.nih.gov/19117416 DMVPW1G DI DMVPW1G DMVPW1G DN PMID21123062C27 DMVPW1G TI TTNM4ZH DMVPW1G TN NDR2 protein kinase (STK38L) DMVPW1G MA Inhibitor DMVPW1G RN Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7. DMVPW1G RU https://pubmed.ncbi.nlm.nih.gov/21123062 DMVPW1G DI DMVPW1G DMVPW1G DN PMID21123062C27 DMVPW1G TI TTFGN19 DMVPW1G TN TGF-beta-stimulated factor 1 (STK16) DMVPW1G MA Inhibitor DMVPW1G RN Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7. DMVPW1G RU https://pubmed.ncbi.nlm.nih.gov/21123062 DMVPW1G DI DMVPW1G DMVPW1G DN PMID21123062C27 DMVPW1G TI TTNDSF4 DMVPW1G TN Proto-oncogene c-Met (MET) DMVPW1G MA Inhibitor DMVPW1G RN Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7. DMVPW1G RU https://pubmed.ncbi.nlm.nih.gov/21123062 DMVPWML DI DMVPWML DMVPWML DN 2,4'-Diacetoxy-5,3'-di-(2-propenyl)-biphenyl DMVPWML TI TTSJ6Q4 DMVPWML TN LOX-5 messenger RNA (ALOX5 mRNA) DMVPWML MA Inhibitor DMVPWML RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMVPWML RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TTUNARX DMVPZG9 TN Carbonic anhydrase (CA) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TTZHA0O DMVPZG9 TN Carbonic anhydrase IV (CA-IV) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TTHQPL7 DMVPZG9 TN Carbonic anhydrase I (CA-I) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TTCFSPE DMVPZG9 TN Carbonic anhydrase VI (CA-VI) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TT2LVK8 DMVPZG9 TN Carbonic anhydrase IX (CA-IX) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TTEYTKG DMVPZG9 TN Carbonic anhydrase XIV (CA-XIV) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TTANPDJ DMVPZG9 TN Carbonic anhydrase II (CA-II) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVPZG9 DI DMVPZG9 DMVPZG9 DN Pentane-1,5-diamine DMVPZG9 TI TTSYM0R DMVPZG9 TN Carbonic anhydrase XII (CA-XII) DMVPZG9 MA Inhibitor DMVPZG9 RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMVPZG9 RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMVQ30P DI DMVQ30P DMVQ30P DN Acerogenin B DMVQ30P TI TTF8JAT DMVQ30P TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMVQ30P MA Inhibitor DMVQ30P RN Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4. DMVQ30P RU https://pubmed.ncbi.nlm.nih.gov/20036535 DMVQ30P DI DMVQ30P DMVQ30P DN Acerogenin B DMVQ30P TI TT2UE56 DMVQ30P TN Sodium/glucose cotransporter 1 (SGLT1) DMVQ30P MA Inhibitor DMVQ30P RN Cyclic diarylheptanoids as Na+-glucose cotransporter (SGLT) inhibitors from Acer nikoense. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1070-4. DMVQ30P RU https://pubmed.ncbi.nlm.nih.gov/20036535 DMVQ4KG DI DMVQ4KG DMVQ4KG DN Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 DMVQ4KG TI TTEOSZT DMVQ4KG TN Melanocortin receptor (MCR) DMVQ4KG MA Inhibitor DMVQ4KG RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMVQ4KG RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMVQ4KG DI DMVQ4KG DMVQ4KG DN Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 DMVQ4KG TI TTNI91K DMVQ4KG TN Melanocortin receptor 3 (MC3R) DMVQ4KG MA Inhibitor DMVQ4KG RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMVQ4KG RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMVQ4KG DI DMVQ4KG DMVQ4KG DN Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 DMVQ4KG TI TTD0CIQ DMVQ4KG TN Melanocortin receptor 4 (MC4R) DMVQ4KG MA Inhibitor DMVQ4KG RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMVQ4KG RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMVQ4KG DI DMVQ4KG DMVQ4KG DN Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2 DMVQ4KG TI TT0MV2T DMVQ4KG TN Melanocortin receptor 1 (MC1R) DMVQ4KG MA Inhibitor DMVQ4KG RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMVQ4KG RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMVQ68F DI DMVQ68F DMVQ68F DN 2-(2-(2-fluorophenylamino)phenyl)acetic acid DMVQ68F TI TTCTE1G DMVQ68F TN Interleukin-8 (IL8) DMVQ68F MA Inhibitor DMVQ68F RN Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4026-30. DMVQ68F RU https://pubmed.ncbi.nlm.nih.gov/19560921 DMVQ6RN DI DMVQ6RN DMVQ6RN DN (5BETA)-PREGNANE-3,20-DIONE DMVQ6RN TI TT6PEUO DMVQ6RN TN Retinoic acid receptor RXR-alpha (RXRA) DMVQ6RN MA Inhibitor DMVQ6RN RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVQ6RN RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVQ6RN DI DMVQ6RN DMVQ6RN DN (5BETA)-PREGNANE-3,20-DIONE DMVQ6RN TI TTRANFM DMVQ6RN TN Orphan nuclear receptor NR1I3 (NR1I3) DMVQ6RN MA Inhibitor DMVQ6RN RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVQ6RN RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVQDNR DI DMVQDNR DMVQDNR DN kuwanon H DMVQDNR TI TTC1MVT DMVQDNR TN Gastrin-releasing peptide receptor (GRPR) DMVQDNR MA Antagonist DMVQDNR RN Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9. DMVQDNR RU https://pubmed.ncbi.nlm.nih.gov/7646517 DMVQDNR DI DMVQDNR DMVQDNR DN kuwanon H DMVQDNR TI TTHYDUM DMVQDNR TN Bombesin receptor (BS) DMVQDNR MA Antagonist DMVQDNR RN Non-peptide bombesin receptor antagonists, kuwanon G and H, isolated from mulberry. Biochem Biophys Res Commun. 1995 Aug 15;213(2):594-9. DMVQDNR RU https://pubmed.ncbi.nlm.nih.gov/7646517 DMVQFY4 DI DMVQFY4 DMVQFY4 DN VPC23019 DMVQFY4 TI TT9JZCK DMVQFY4 TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMVQFY4 MA Antagonist DMVQFY4 RN Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005 Mar 18;280(11):9833-41. DMVQFY4 RU https://pubmed.ncbi.nlm.nih.gov/15590668 DMVQFY4 DI DMVQFY4 DMVQFY4 DN VPC23019 DMVQFY4 TI TTDYP7I DMVQFY4 TN Sphingosine-1-phosphate receptor 3 (S1PR3) DMVQFY4 MA Antagonist DMVQFY4 RN Sphingosine 1-phosphate analogs as receptor antagonists. J Biol Chem. 2005 Mar 18;280(11):9833-41. DMVQFY4 RU https://pubmed.ncbi.nlm.nih.gov/15590668 DMVQJP0 DI DMVQJP0 DMVQJP0 DN AdoCGlyArg6 DMVQJP0 TI TTW4Y2M DMVQJP0 TN cAMP protein kinase type II-beta (PRKAR2B) DMVQJP0 MA Inhibitor DMVQJP0 RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMVQJP0 RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMVQJP0 DI DMVQJP0 DMVQJP0 DN AdoCGlyArg6 DMVQJP0 TI TTNAHEX DMVQJP0 TN cAMP-dependent protein kinase A type I (PRKAR1A) DMVQJP0 MA Inhibitor DMVQJP0 RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMVQJP0 RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMVQK4Y DI DMVQK4Y DMVQK4Y DN 2-methyl-6-(phenylethynyl)pyridine DMVQK4Y TI TTICZ1O DMVQK4Y TN Metabotropic glutamate receptor 4 (mGluR4) DMVQK4Y MA Modulator (allosteric modulator) DMVQK4Y RN Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br J Pharmacol. 2003 Mar;138(6):1026-30. DMVQK4Y RU https://pubmed.ncbi.nlm.nih.gov/12684257 DMVQK4Y DI DMVQK4Y DMVQK4Y DN 2-methyl-6-(phenylethynyl)pyridine DMVQK4Y TI TTHS256 DMVQK4Y TN Metabotropic glutamate receptor 5 (mGluR5) DMVQK4Y MA Inhibitor DMVQK4Y RN 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999 Oct;38(10):1493-503. DMVQK4Y RU https://pubmed.ncbi.nlm.nih.gov/10530811 DMVQK4Y DI DMVQK4Y DMVQK4Y DN 2-methyl-6-(phenylethynyl)pyridine DMVQK4Y TI TTVBPDM DMVQK4Y TN Metabotropic glutamate receptor 1 (mGluR1) DMVQK4Y MA Inhibitor DMVQK4Y RN Carbamoyloximes as novel non-competitive mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4371-5. DMVQK4Y RU https://pubmed.ncbi.nlm.nih.gov/20615697 DMVQKMC DI DMVQKMC DMVQKMC DN SB-207710 DMVQKMC TI TT07C3Y DMVQKMC TN 5-HT 4 receptor (HTR4) DMVQKMC MA Inhibitor DMVQKMC RN Synthesis, structure-affinity relationships, and radiolabeling of selective high-affinity 5-HT4 receptor ligands as prospective imaging probes for ... J Med Chem. 2010 Oct 14;53(19):7035-47. DMVQKMC RU https://pubmed.ncbi.nlm.nih.gov/20812727 DMVQL3J DI DMVQL3J DMVQL3J DN UBP310 DMVQL3J TI TT0MYE2 DMVQL3J TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMVQL3J MA Antagonist DMVQL3J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMVQL3J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMVQL3J DI DMVQL3J DMVQL3J DN UBP310 DMVQL3J TI TTNP6O2 DMVQL3J TN Glutamate receptor ionotropic kainate 3 (GluK3) DMVQL3J MA Antagonist DMVQL3J RN Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310. Mol Pharmacol. 2010 Dec;78(6):1036-45. DMVQL3J RU https://pubmed.ncbi.nlm.nih.gov/20837679 DMVQLFB DI DMVQLFB DMVQLFB DN 5-Chloro-N-phenylbenzo[d]oxazol-2-amine DMVQLFB TI TT2J34L DMVQLFB TN Arachidonate 5-lipoxygenase (5-LOX) DMVQLFB MA Inhibitor DMVQLFB RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DMVQLFB RU https://pubmed.ncbi.nlm.nih.gov/20870413 DMVQSEH DI DMVQSEH DMVQSEH DN Methimepip DMVQSEH TI TT9JNIC DMVQSEH TN Histamine H3 receptor (H3R) DMVQSEH MA Agonist DMVQSEH RN The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov. 2005 Feb;4(2):107-20. DMVQSEH RU https://pubmed.ncbi.nlm.nih.gov/15665857 DMVQU1M DI DMVQU1M DMVQU1M DN 2-(4-methoxyphenyl)-6-morpholino-4H-pyran-4-one DMVQU1M TI TTK3PY9 DMVQU1M TN DNA-dependent protein kinase catalytic (PRKDC) DMVQU1M MA Inhibitor DMVQU1M RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMVQU1M RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMVQYWS DI DMVQYWS DMVQYWS DN quin-C1 DMVQYWS TI TTOJ1NF DMVQYWS TN FMLP-related receptor I (FPR2) DMVQYWS MA Agonist DMVQYWS RN A novel nonpeptide ligand for formyl peptide receptor-like 1. Mol Pharmacol. 2004 Nov;66(5):1213-22. DMVQYWS RU https://pubmed.ncbi.nlm.nih.gov/15308762 DMVR248 DI DMVR248 DMVR248 DN 2-(N,N-Diethylamino)-3'-chloropropiophenone DMVR248 TI TTVBI8W DMVR248 TN Dopamine transporter (DAT) DMVR248 MA Inhibitor DMVR248 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMVR248 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMVR248 DI DMVR248 DMVR248 DN 2-(N,N-Diethylamino)-3'-chloropropiophenone DMVR248 TI TTAWNKZ DMVR248 TN Norepinephrine transporter (NET) DMVR248 MA Inhibitor DMVR248 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMVR248 RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMVR4OW DI DMVR4OW DMVR4OW DN 6,7-diethoxy-4-styrylquinazoline DMVR4OW TI TTGKNB4 DMVR4OW TN Epidermal growth factor receptor (EGFR) DMVR4OW MA Inhibitor DMVR4OW RN Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. DMVR4OW RU https://pubmed.ncbi.nlm.nih.gov/17869510 DMVR4QH DI DMVR4QH DMVR4QH DN PMID30247903-Compound-General structure16 DMVR4QH TI TTNBFWK DMVR4QH TN Programmed cell death protein 1 (PD-1) DMVR4QH MA Inhibitor DMVR4QH RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMVR4QH RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMVR51Z DI DMVR51Z DMVR51Z DN MCL-183 DMVR51Z TI TT27RFC DMVR51Z TN Opioid receptor delta (OPRD1) DMVR51Z MA Inhibitor DMVR51Z RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMVR51Z RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMVR51Z DI DMVR51Z DMVR51Z DN MCL-183 DMVR51Z TI TTQW87Y DMVR51Z TN Opioid receptor kappa (OPRK1) DMVR51Z MA Inhibitor DMVR51Z RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMVR51Z RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMVR51Z DI DMVR51Z DMVR51Z DN MCL-183 DMVR51Z TI TTKWM86 DMVR51Z TN Opioid receptor mu (MOP) DMVR51Z MA Inhibitor DMVR51Z RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMVR51Z RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMVR9G0 DI DMVR9G0 DMVR9G0 DN AG-14 DMVR9G0 TI TT5Y4EM DMVR9G0 TN N-formyl peptide receptor (FPR1) DMVR9G0 MA Agonist DMVR9G0 RN High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists. Mol Pharmacol. 2007 Apr;71(4):1061-74. DMVR9G0 RU https://pubmed.ncbi.nlm.nih.gov/17229869 DMVRF9H DI DMVRF9H DMVRF9H DN Cis-2-(4-chlorophenyl)-2-fluorocyclopropanamine DMVRF9H TI TTGP7BY DMVRF9H TN Monoamine oxidase type B (MAO-B) DMVRF9H MA Inhibitor DMVRF9H RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMVRF9H RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMVRFU5 DI DMVRFU5 DMVRFU5 DN 6-Hydroxypropylthymine DMVRFU5 TI TTP3QRF DMVRFU5 TN Thymidine kinase 1 (TK1) DMVRFU5 MA Inhibitor DMVRFU5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVRFU5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVRJEL DI DMVRJEL DMVRJEL DN T13 DMVRJEL TI TTE2YJR DMVRJEL TN Lysophosphatidate-3 receptor (LPAR3) DMVRJEL MA Agonist DMVRJEL RN LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31. DMVRJEL RU https://pubmed.ncbi.nlm.nih.gov/18781939 DMVRJEL DI DMVRJEL DMVRJEL DN T13 DMVRJEL TI TTQ6S1K DMVRJEL TN Lysophosphatidic acid receptor 1 (LPAR1) DMVRJEL MA Agonist DMVRJEL RN Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin. 2010 Sep;31(9):1213-22. DMVRJEL RU https://pubmed.ncbi.nlm.nih.gov/20729877 DMVRN0I DI DMVRN0I DMVRN0I DN 1-(piperidin-3-ylmethyl)pyridin-2(1H)-one DMVRN0I TI TTF4E0J DMVRN0I TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMVRN0I MA Inhibitor DMVRN0I RN Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity. J Med Chem. 2006 May 4;49(9):2673-6. DMVRN0I RU https://pubmed.ncbi.nlm.nih.gov/16640326 DMVRWL6 DI DMVRWL6 DMVRWL6 DN propargylglycine DMVRWL6 TI TTLQUZS DMVRWL6 TN Cystathionine gamma-lyase (CTH) DMVRWL6 MA Inhibitor DMVRWL6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1444). DMVRWL6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1444 DMVRXH3 DI DMVRXH3 DMVRXH3 DN Bishydroxy[2h-1-Benzopyran-2-One,1,2-Benzopyrone] DMVRXH3 TI TT8XK6L DMVRXH3 TN Quinone reductase 1 (NQO1) DMVRXH3 MA Inhibitor DMVRXH3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVRXH3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVS4D5 DI DMVS4D5 DMVS4D5 DN 1-(4-Cyanobenzyl)-5-(3-fluorophenyl)-1H-imidazole DMVS4D5 TI TTIQUX7 DMVS4D5 TN Steroid 11-beta-hydroxylase (CYP11B1) DMVS4D5 MA Inhibitor DMVS4D5 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMVS4D5 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMVS6DW DI DMVS6DW DMVS6DW DN NOX-S91 DMVS6DW TI TT9JZCK DMVS6DW TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMVS6DW MA Inhibitor DMVS6DW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 275). DMVS6DW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=275 DMVSAUL DI DMVSAUL DMVSAUL DN L-isoleucyl-L-prolinamide DMVSAUL TI TTQ7R2V DMVSAUL TN Tripeptidyl-peptidase II (TPP2) DMVSAUL MA Inhibitor DMVSAUL RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMVSAUL RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMVSBHU DI DMVSBHU DMVSBHU DN 5-Imidazol-1-yl-5,6,7,8-tetrahydro-quinoline DMVSBHU TI TTKNWZ4 DMVSBHU TN Thromboxane-A synthase (TBXAS1) DMVSBHU MA Inhibitor DMVSBHU RN 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthas... J Med Chem. 2000 May 4;43(9):1841-51. DMVSBHU RU https://pubmed.ncbi.nlm.nih.gov/10794700 DMVSC3O DI DMVSC3O DMVSC3O DN 1-(benzyloxy)-2-(2-phenylethyl)benzene DMVSC3O TI TTSQIFT DMVSC3O TN 5-HT 1A receptor (HTR1A) DMVSC3O MA Inhibitor DMVSC3O RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DMVSC3O RU https://pubmed.ncbi.nlm.nih.gov/17064079 DMVSC3O DI DMVSC3O DMVSC3O DN 1-(benzyloxy)-2-(2-phenylethyl)benzene DMVSC3O TI TTEX248 DMVSC3O TN Dopamine D2 receptor (D2R) DMVSC3O MA Inhibitor DMVSC3O RN Arylmethyloxyphenyl derivatives: small molecules displaying P-glycoprotein inhibition. J Med Chem. 2006 Nov 2;49(22):6607-13. DMVSC3O RU https://pubmed.ncbi.nlm.nih.gov/17064079 DMVSF0O DI DMVSF0O DMVSF0O DN 7-Isopropyl-7H-adenine DMVSF0O TI TTM2AOE DMVSF0O TN Adenosine A2a receptor (ADORA2A) DMVSF0O MA Inhibitor DMVSF0O RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMVSF0O RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMVSI6R DI DMVSI6R DMVSI6R DN 2-[(Dioxidophosphino)Oxy]Benzoate DMVSI6R TI TTLP6GN DMVSI6R TN Bacterial DD-carboxypeptidase (Bact vanYB) DMVSI6R MA Inhibitor DMVSI6R RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVSI6R RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVSL49 DI DMVSL49 DMVSL49 DN 2-(7-phenylheptanoyl)oxazole-4-carbonitrile DMVSL49 TI TTDP1UC DMVSL49 TN Fatty acid amide hydrolase (FAAH) DMVSL49 MA Inhibitor DMVSL49 RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMVSL49 RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMVSNPB DI DMVSNPB DMVSNPB DN 4-benzhydryl-N-butylpiperazine-1-carboxamide DMVSNPB TI TTMSFAW DMVSNPB TN Cannabinoid receptor 2 (CB2) DMVSNPB MA Inhibitor DMVSNPB RN Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9. DMVSNPB RU https://pubmed.ncbi.nlm.nih.gov/20047779 DMVSNPB DI DMVSNPB DMVSNPB DN 4-benzhydryl-N-butylpiperazine-1-carboxamide DMVSNPB TI TT6OEDT DMVSNPB TN Cannabinoid receptor 1 (CB1) DMVSNPB MA Inhibitor DMVSNPB RN Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. Eur J Med Chem. 2010 Mar;45(3):1133-9. DMVSNPB RU https://pubmed.ncbi.nlm.nih.gov/20047779 DMVSQFI DI DMVSQFI DMVSQFI DN 3-Phenethyl-2-phenyl-3H-quinazolin-4-one DMVSQFI TI TTBUYHA DMVSQFI TN Extracellular calcium-sensing receptor (CASR) DMVSQFI MA Inhibitor DMVSQFI RN 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1557-60. DMVSQFI RU https://pubmed.ncbi.nlm.nih.gov/15745796 DMVSRYH DI DMVSRYH DMVSRYH DN NE-28345 DMVSRYH TI TTMI6F5 DMVSRYH TN Transient receptor potential cation channel V1 (TRPV1) DMVSRYH MA Modulator DMVSRYH RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMVSRYH RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMVSTG7 DI DMVSTG7 DMVSTG7 DN 2-[(2,2-diphenylacetyl)amino]benzoic acid DMVSTG7 TI TT5ZWB6 DMVSTG7 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMVSTG7 MA Inhibitor DMVSTG7 RN Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of ant... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5170-5. DMVSTG7 RU https://pubmed.ncbi.nlm.nih.gov/16183274 DMVT0JO DI DMVT0JO DMVT0JO DN FUROSIN DMVT0JO TI TTE14XG DMVT0JO TN Squalene monooxygenase (SQLE) DMVT0JO MA Inhibitor DMVT0JO RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMVT0JO RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMVT2CJ DI DMVT2CJ DMVT2CJ DN ISIS 2922 + Ganciclovir DMVT2CJ TI TT4SCBE DMVT2CJ TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMVT2CJ RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMVT2CJ RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMVT2LW DI DMVT2LW DMVT2LW DN 5-iodo,5'-deoxytubercidin DMVT2LW TI TTL732K DMVT2LW TN Adenosine kinase (ADK) DMVT2LW MA Inhibitor DMVT2LW RN Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes. J Med Chem. 2006 Nov 16;49(23):6726-31. DMVT2LW RU https://pubmed.ncbi.nlm.nih.gov/17154503 DMVT6Y3 DI DMVT6Y3 DMVT6Y3 DN AP-24163 DMVT6Y3 TI TTIV39N DMVT6Y3 TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMVT6Y3 MA Inhibitor DMVT6Y3 RN Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP2453... J Med Chem. 2010 Jun 24;53(12):4701-19. DMVT6Y3 RU https://pubmed.ncbi.nlm.nih.gov/20513156 DMVT6Y3 DI DMVT6Y3 DMVT6Y3 DN AP-24163 DMVT6Y3 TI TT6PKBN DMVT6Y3 TN Proto-oncogene c-Src (SRC) DMVT6Y3 MA Inhibitor DMVT6Y3 RN 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13;52(15):4743-56. DMVT6Y3 RU https://pubmed.ncbi.nlm.nih.gov/19572547 DMVT865 DI DMVT865 DMVT865 DN MRS1042 DMVT865 TI TTK25J1 DMVT865 TN Adenosine A1 receptor (ADORA1) DMVT865 MA Antagonist DMVT865 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMVT865 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMVT865 DI DMVT865 DMVT865 DN MRS1042 DMVT865 TI TTNE7KG DMVT865 TN Adenosine A2b receptor (ADORA2B) DMVT865 MA Antagonist DMVT865 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMVT865 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMVT865 DI DMVT865 DMVT865 DN MRS1042 DMVT865 TI TTJFY5U DMVT865 TN Adenosine A3 receptor (ADORA3) DMVT865 MA Antagonist DMVT865 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMVT865 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMVTCGP DI DMVTCGP DMVTCGP DN 1-(3-Cyano-phenyl)-1H-pyrazole-4-carboxylic acid DMVTCGP TI TT7RJY8 DMVTCGP TN Xanthine dehydrogenase/oxidase (XDH) DMVTCGP MA Inhibitor DMVTCGP RN Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. Bioorg Med Chem Lett. 2001 Apr 9;11(7):879-82. DMVTCGP RU https://pubmed.ncbi.nlm.nih.gov/11294382 DMVTCZ1 DI DMVTCZ1 DMVTCZ1 DN XEP-018 DMVTCZ1 TI TT84DRB DMVTCZ1 TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMVTCZ1 MA Modulator DMVTCZ1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 581). DMVTCZ1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=581 DMVTD1F DI DMVTD1F DMVTD1F DN 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran DMVTD1F TI TTAWNKZ DMVTD1F TN Norepinephrine transporter (NET) DMVTD1F MA Inhibitor DMVTD1F RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMVTD1F RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMVTD1F DI DMVTD1F DMVTD1F DN 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran DMVTD1F TI TTVBI8W DMVTD1F TN Dopamine transporter (DAT) DMVTD1F MA Inhibitor DMVTD1F RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMVTD1F RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMVTD1F DI DMVTD1F DMVTD1F DN 2-(2'-Aminoethyl)-5-benzyltetrahydrofuran DMVTD1F TI TT3ROYC DMVTD1F TN Serotonin transporter (SERT) DMVTD1F MA Inhibitor DMVTD1F RN 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68. DMVTD1F RU https://pubmed.ncbi.nlm.nih.gov/19201198 DMVTEOQ DI DMVTEOQ DMVTEOQ DN 4-Isopropyl-pyrrolidin-(2Z)-ylideneamine DMVTEOQ TI TTF10I9 DMVTEOQ TN Nitric-oxide synthase inducible (NOS2) DMVTEOQ MA Inhibitor DMVTEOQ RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMVTEOQ RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMVTEOQ DI DMVTEOQ DMVTEOQ DN 4-Isopropyl-pyrrolidin-(2Z)-ylideneamine DMVTEOQ TI TTZUFI5 DMVTEOQ TN Nitric-oxide synthase brain (NOS1) DMVTEOQ MA Inhibitor DMVTEOQ RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMVTEOQ RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMVTH0Q DI DMVTH0Q DMVTH0Q DN 7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMVTH0Q TI TT3WG5C DMVTH0Q TN Monoamine oxidase type A (MAO-A) DMVTH0Q MA Inhibitor DMVTH0Q RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMVTH0Q RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMVTH0Q DI DMVTH0Q DMVTH0Q DN 7-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMVTH0Q TI TTGP7BY DMVTH0Q TN Monoamine oxidase type B (MAO-B) DMVTH0Q MA Inhibitor DMVTH0Q RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMVTH0Q RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMVTK0A DI DMVTK0A DMVTK0A DN 7-Butyl-azepan-(2Z)-ylideneamine DMVTK0A TI TTZUFI5 DMVTK0A TN Nitric-oxide synthase brain (NOS1) DMVTK0A MA Inhibitor DMVTK0A RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMVTK0A RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMVTK0A DI DMVTK0A DMVTK0A DN 7-Butyl-azepan-(2Z)-ylideneamine DMVTK0A TI TTF10I9 DMVTK0A TN Nitric-oxide synthase inducible (NOS2) DMVTK0A MA Inhibitor DMVTK0A RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMVTK0A RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMVTKCX DI DMVTKCX DMVTKCX DN POP-1 DMVTKCX TI TT2WR1T DMVTKCX TN Cationic trypsinogen (PRSS1) DMVTKCX MA Modulator DMVTKCX RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DMVTKCX RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DMVTKCX DI DMVTKCX DMVTKCX DN POP-1 DMVTKCX TI TTHCF4J DMVTKCX TN Alpha-glucosidase (GLA) DMVTKCX MA Modulator DMVTKCX RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DMVTKCX RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DMVTKCX DI DMVTKCX DMVTKCX DN POP-1 DMVTKCX TI TT7MRGU DMVTKCX TN Chymotrypsin (CTR) DMVTKCX MA Modulator DMVTKCX RN US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. DMVTKCX RU http://www.patentbuddy.com/Patent/20120251516?ft=true&sr=true DMVTLF9 DI DMVTLF9 DMVTLF9 DN (10r)-10-Formyl-5,8,10-Trideazafolic Acid DMVTLF9 TI TTEXB9Z DMVTLF9 TN Glycinamide ribonucleotide formyltransferase (GART) DMVTLF9 MA Inhibitor DMVTLF9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVTLF9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVTLO0 DI DMVTLO0 DMVTLO0 DN PMID18754614C7 DMVTLO0 TI TTFQEO5 DMVTLO0 TN Squalene synthetase (FDFT1) DMVTLO0 MA Inhibitor DMVTLO0 RN Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity. J Med Chem. 2008 Sep 25;51(18):5861-5. DMVTLO0 RU https://pubmed.ncbi.nlm.nih.gov/18754614 DMVTU63 DI DMVTU63 DMVTU63 DN ISIS 107791 DMVTU63 TI TTELIN2 DMVTU63 TN PTPN1 messenger RNA (PTPN1 mRNA) DMVTU63 RN US patent application no. 6,261,840, Antisense modulation of PTP1B expression. DMVTU63 RU http://www.patentbuddy.com/Patent/6261840?ft=true&sr=true DMVTXKI DI DMVTXKI DMVTXKI DN PMID19111466C7d DMVTXKI TI TT5ZKDI DMVTXKI TN Histone deacetylase 6 (HDAC6) DMVTXKI MA Inhibitor DMVTXKI RN Novel HDAC6 isoform selective chiral small molecule histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Feb 1;19(3):688-92. DMVTXKI RU https://pubmed.ncbi.nlm.nih.gov/19111466 DMVUBGF DI DMVUBGF DMVUBGF DN GNF-PF-1550 DMVUBGF TI TTX4RTB DMVUBGF TN Melanin-concentrating hormone receptor 1 (MCHR1) DMVUBGF MA Inhibitor DMVUBGF RN 6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and ... J Med Chem. 2005 Sep 8;48(18):5684-97. DMVUBGF RU https://pubmed.ncbi.nlm.nih.gov/16134937 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TTHQPL7 DMVUCZK TN Carbonic anhydrase I (CA-I) DMVUCZK MA Inhibitor DMVUCZK RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TTZHA0O DMVUCZK TN Carbonic anhydrase IV (CA-IV) DMVUCZK MA Inhibitor DMVUCZK RN Carbonic anhydrase inhibitors. Inhibition of the membrane-bound human and bovine isozymes IV with sulfonamides. Bioorg Med Chem Lett. 2005 Feb 15;15(4):1149-54. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/15686931 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TTUNARX DMVUCZK TN Carbonic anhydrase (CA) DMVUCZK MA Inhibitor DMVUCZK RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TTANPDJ DMVUCZK TN Carbonic anhydrase II (CA-II) DMVUCZK MA Inhibitor DMVUCZK RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TTSYM0R DMVUCZK TN Carbonic anhydrase XII (CA-XII) DMVUCZK MA Inhibitor DMVUCZK RN Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglauc... Bioorg Med Chem Lett. 2005 Feb 15;15(4):963-9. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/15686894 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TT2LVK8 DMVUCZK TN Carbonic anhydrase IX (CA-IX) DMVUCZK MA Inhibitor DMVUCZK RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TTCFSPE DMVUCZK TN Carbonic anhydrase VI (CA-VI) DMVUCZK MA Inhibitor DMVUCZK RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMVUCZK DI DMVUCZK DMVUCZK DN 4-Amino-3-bromo-benzenesulfonamide DMVUCZK TI TTEYTKG DMVUCZK TN Carbonic anhydrase XIV (CA-XIV) DMVUCZK MA Inhibitor DMVUCZK RN Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3828-33. DMVUCZK RU https://pubmed.ncbi.nlm.nih.gov/16039848 DMVUEW5 DI DMVUEW5 DMVUEW5 DN (-)-Phenethylcymserine DMVUEW5 TI TTEB0GD DMVUEW5 TN Cholinesterase (BCHE) DMVUEW5 MA Inhibitor DMVUEW5 RN Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. Bioorg Med Chem. 2010 Jul 1;18(13):4687-93. DMVUEW5 RU https://pubmed.ncbi.nlm.nih.gov/20627738 DMVUEYM DI DMVUEYM DMVUEYM DN [35S]ACPPB DMVUEYM TI TTHJTF7 DMVUEYM TN Glycine transporter GlyT-1 (SLC6A9) DMVUEYM MA Modulator DMVUEYM RN A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol. 2008 Apr;35(3):315-25. DMVUEYM RU https://pubmed.ncbi.nlm.nih.gov/18355687 DMVUEZI DI DMVUEZI DMVUEZI DN PMID20684608C35 DMVUEZI TI TTML7FG DMVUEZI TN Large tumor suppressor homolog 2 (LATS2) DMVUEZI MA Inhibitor DMVUEZI RN Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37. DMVUEZI RU https://pubmed.ncbi.nlm.nih.gov/20684608 DMVUEZI DI DMVUEZI DMVUEZI DN PMID20684608C35 DMVUEZI TI TTGWKQJ DMVUEZI TN Rho-associated protein kinase 2 (ROCK2) DMVUEZI MA Inhibitor DMVUEZI RN Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37. DMVUEZI RU https://pubmed.ncbi.nlm.nih.gov/20684608 DMVUEZI DI DMVUEZI DMVUEZI DN PMID20684608C35 DMVUEZI TI TT27XFN DMVUEZI TN NDR1 protein kinase (STK38) DMVUEZI MA Inhibitor DMVUEZI RN Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37. DMVUEZI RU https://pubmed.ncbi.nlm.nih.gov/20684608 DMVUEZI DI DMVUEZI DMVUEZI DN PMID20684608C35 DMVUEZI TI TTZN7RP DMVUEZI TN Rho-associated protein kinase 1 (ROCK1) DMVUEZI MA Inhibitor DMVUEZI RN Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors. J Med Chem. 2010 Aug 12;53(15):5727-37. DMVUEZI RU https://pubmed.ncbi.nlm.nih.gov/20684608 DMVUF71 DI DMVUF71 DMVUF71 DN [14C]histidine DMVUF71 TI TTG2XRE DMVUF71 TN Solute carrier family 15 member 4 (SLC15A4) DMVUF71 MA Modulator DMVUF71 RN Cloning and functional expression of a brain peptide/histidine transporter. J Biol Chem. 1997 Apr 11;272(15):10205-11. DMVUF71 RU https://pubmed.ncbi.nlm.nih.gov/9092568 DMVUF71 DI DMVUF71 DMVUF71 DN [14C]histidine DMVUF71 TI TTC8YPT DMVUF71 TN Solute carrier family 38 member 5 (SLC38A5) DMVUF71 MA Modulator DMVUF71 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1173). DMVUF71 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1173 DMVUF71 DI DMVUF71 DMVUF71 DN [14C]histidine DMVUF71 TI TTAYPWS DMVUF71 TN Solute carrier family 15 member 3 (SLC15A3) DMVUF71 MA Modulator DMVUF71 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 986). DMVUF71 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=986 DMVUK96 DI DMVUK96 DMVUK96 DN 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline DMVUK96 TI TT8FYO9 DMVUK96 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMVUK96 MA Inhibitor DMVUK96 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMVUK96 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMVUK96 DI DMVUK96 DMVUK96 DN 3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline DMVUK96 TI TTI7421 DMVUK96 TN Platelet-derived growth factor receptor beta (PDGFRB) DMVUK96 MA Inhibitor DMVUK96 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMVUK96 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMVUMSF DI DMVUMSF DMVUMSF DN 1-benzhydryl-4-o-tolylpiperidin-4-ol DMVUMSF TI TT27RFC DMVUMSF TN Opioid receptor delta (OPRD1) DMVUMSF MA Inhibitor DMVUMSF RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVUMSF RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVUMSF DI DMVUMSF DMVUMSF DN 1-benzhydryl-4-o-tolylpiperidin-4-ol DMVUMSF TI TTQW87Y DMVUMSF TN Opioid receptor kappa (OPRK1) DMVUMSF MA Inhibitor DMVUMSF RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVUMSF RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVUMSF DI DMVUMSF DMVUMSF DN 1-benzhydryl-4-o-tolylpiperidin-4-ol DMVUMSF TI TTKWM86 DMVUMSF TN Opioid receptor mu (MOP) DMVUMSF MA Inhibitor DMVUMSF RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVUMSF RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVUMSF DI DMVUMSF DMVUMSF DN 1-benzhydryl-4-o-tolylpiperidin-4-ol DMVUMSF TI TTNT7K8 DMVUMSF TN Nociceptin receptor (OPRL1) DMVUMSF MA Inhibitor DMVUMSF RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMVUMSF RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMVUMWZ DI DMVUMWZ DMVUMWZ DN PS-1145 DMVUMWZ TI TTRPDBG DMVUMWZ TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMVUMWZ MA Inhibitor DMVUMWZ RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMVUMWZ RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMVUMWZ DI DMVUMWZ DMVUMWZ DN PS-1145 DMVUMWZ TI TTSXVID DMVUMWZ TN Nuclear factor NF-kappa-B (NFKB) DMVUMWZ MA Activator DMVUMWZ RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMVUMWZ RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMVUSMP DI DMVUSMP DMVUSMP DN 4-Imidazol-1-ylmethylthioxanthen-9-one DMVUSMP TI TTSZLWK DMVUSMP TN Aromatase (CYP19A1) DMVUSMP MA Inhibitor DMVUSMP RN Novel highly potent and selective nonsteroidal aromatase inhibitors: synthesis, biological evaluation and structure-activity relationships investigation. J Med Chem. 2010 Jul 22;53(14):5347-51. DMVUSMP RU https://pubmed.ncbi.nlm.nih.gov/20568782 DMVUTJ5 DI DMVUTJ5 DMVUTJ5 DN HTS-02876 DMVUTJ5 TI TTGKNB4 DMVUTJ5 TN Epidermal growth factor receptor (EGFR) DMVUTJ5 MA Inhibitor DMVUTJ5 RN Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75. DMVUTJ5 RU https://pubmed.ncbi.nlm.nih.gov/19170633 DMVW7N3 DI DMVW7N3 DMVW7N3 DN Taurine DMVW7N3 TI TTZ8EM9 DMVW7N3 TN Glycine receptor (GlyR) DMVW7N3 MA Agonist DMVW7N3 RN Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. EMBO J. 1997 Jan 2;16(1):110-20. DMVW7N3 RU https://pubmed.ncbi.nlm.nih.gov/9009272 DMVW7N5 DI DMVW7N5 DMVW7N5 DN ISIS 103635 DMVW7N5 TI TTBWMKT DMVW7N5 TN WWP1 messenger RNA (WWP1 mRNA) DMVW7N5 RN US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression. DMVW7N5 RU http://www.patentbuddy.com/Patent/6258601?ft=true&sr=true DMVW8KN DI DMVW8KN DMVW8KN DN 4-methoxyphenylsulfamide DMVW8KN TI TTANPDJ DMVW8KN TN Carbonic anhydrase II (CA-II) DMVW8KN MA Inhibitor DMVW8KN RN Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements. J Med Chem. 2006 Jun 15;49(12):3496-500. DMVW8KN RU https://pubmed.ncbi.nlm.nih.gov/16759092 DMVWCTL DI DMVWCTL DMVWCTL DN [(N4-Bzdig)0,Nle14]BB(7-14) DMVWCTL TI TTC1MVT DMVWCTL TN Gastrin-releasing peptide receptor (GRPR) DMVWCTL MA Inhibitor DMVWCTL RN Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. J Med Chem. 2005 Jan 13;48(1):100-10. DMVWCTL RU https://pubmed.ncbi.nlm.nih.gov/15634004 DMVWDHM DI DMVWDHM DMVWDHM DN glucagon-(1-6) DMVWDHM TI TT9O6WS DMVWDHM TN Glucagon receptor (GCGR) DMVWDHM MA Agonist DMVWDHM RN Glucagon1-6 binds to the glucagon receptor and activates hepatic adenylate cyclase. J Biol Chem. 1979 Jan 25;254(2):268-9. DMVWDHM RU https://pubmed.ncbi.nlm.nih.gov/216670 DMVWEN3 DI DMVWEN3 DMVWEN3 DN Sulfamic acid 7-sulfamoyloxy-heptyl ester DMVWEN3 TI TTHQPL7 DMVWEN3 TN Carbonic anhydrase I (CA-I) DMVWEN3 MA Inhibitor DMVWEN3 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMVWEN3 RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMVWEN3 DI DMVWEN3 DMVWEN3 DN Sulfamic acid 7-sulfamoyloxy-heptyl ester DMVWEN3 TI TT2LVK8 DMVWEN3 TN Carbonic anhydrase IX (CA-IX) DMVWEN3 MA Inhibitor DMVWEN3 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMVWEN3 RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMVWEN3 DI DMVWEN3 DMVWEN3 DN Sulfamic acid 7-sulfamoyloxy-heptyl ester DMVWEN3 TI TTANPDJ DMVWEN3 TN Carbonic anhydrase II (CA-II) DMVWEN3 MA Inhibitor DMVWEN3 RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with bis-sulfamates. Bioorg Med Chem Lett. 2005 Feb 1;15(3):579-84. DMVWEN3 RU https://pubmed.ncbi.nlm.nih.gov/15664816 DMVWGM2 DI DMVWGM2 DMVWGM2 DN GWTLNSAGYLLGPPPGFSPFR-CONH2 DMVWGM2 TI TTBPW3J DMVWGM2 TN Galanin receptor type 2 (GAL2-R) DMVWGM2 MA Inhibitor DMVWGM2 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMVWGM2 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMVWGM2 DI DMVWGM2 DMVWGM2 DN GWTLNSAGYLLGPPPGFSPFR-CONH2 DMVWGM2 TI TTX3HNZ DMVWGM2 TN Galanin receptor type 1 (GAL1-R) DMVWGM2 MA Inhibitor DMVWGM2 RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMVWGM2 RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMVWIE5 DI DMVWIE5 DMVWIE5 DN 1-(4-methoxyphenyl)-3-(5-methylthiazol-2-yl)urea DMVWIE5 TI TTSJ6Q4 DMVWIE5 TN LOX-5 messenger RNA (ALOX5 mRNA) DMVWIE5 MA Inhibitor DMVWIE5 RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMVWIE5 RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMVWIQ2 DI DMVWIQ2 DMVWIQ2 DN 3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine DMVWIQ2 TI TTIQUX7 DMVWIQ2 TN Steroid 11-beta-hydroxylase (CYP11B1) DMVWIQ2 MA Inhibitor DMVWIQ2 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMVWIQ2 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMVWIQ2 DI DMVWIQ2 DMVWIQ2 DN 3-[7-Methoxy-indan-(1E)-ylidenemethyl]-pyridine DMVWIQ2 TI TTSZLWK DMVWIQ2 TN Aromatase (CYP19A1) DMVWIQ2 MA Inhibitor DMVWIQ2 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMVWIQ2 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMVWM75 DI DMVWM75 DMVWM75 DN Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMVWM75 TI TTW4N16 DMVWM75 TN Neuropeptide Y receptor type 4 (NPY4R) DMVWM75 MA Inhibitor DMVWM75 RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMVWM75 RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMVWM75 DI DMVWM75 DMVWM75 DN Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMVWM75 TI TTJ6WK9 DMVWM75 TN Neuropeptide Y receptor type 2 (NPY2R) DMVWM75 MA Inhibitor DMVWM75 RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMVWM75 RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMVWM75 DI DMVWM75 DMVWM75 DN Adp[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMVWM75 TI TTRK9JT DMVWM75 TN Neuropeptide Y receptor type 1 (NPY1R) DMVWM75 MA Inhibitor DMVWM75 RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMVWM75 RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMVWOPG DI DMVWOPG DMVWOPG DN C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2 DMVWOPG TI TTEOSZT DMVWOPG TN Melanocortin receptor (MCR) DMVWOPG MA Inhibitor DMVWOPG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMVWOPG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMVWOPG DI DMVWOPG DMVWOPG DN C[Nle-Glu-D-Phe-Arg-Trp-Glu]-NH2 DMVWOPG TI TTNI91K DMVWOPG TN Melanocortin receptor 3 (MC3R) DMVWOPG MA Inhibitor DMVWOPG RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMVWOPG RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMVWQ26 DI DMVWQ26 DMVWQ26 DN (beta-CCE)9H-beta-Carboline-3-carboxylic acid DMVWQ26 TI TT1MPAY DMVWQ26 TN GABA(A) receptor alpha-1 (GABRA1) DMVWQ26 MA Inhibitor DMVWQ26 RN Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20. DMVWQ26 RU https://pubmed.ncbi.nlm.nih.gov/1319492 DMVWQ26 DI DMVWQ26 DMVWQ26 DN (beta-CCE)9H-beta-Carboline-3-carboxylic acid DMVWQ26 TI TT06RH5 DMVWQ26 TN GABA(A) receptor gamma-2 (GABRG2) DMVWQ26 MA Inhibitor DMVWQ26 RN Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20. DMVWQ26 RU https://pubmed.ncbi.nlm.nih.gov/1319492 DMVWQ26 DI DMVWQ26 DMVWQ26 DN (beta-CCE)9H-beta-Carboline-3-carboxylic acid DMVWQ26 TI TTNJYV2 DMVWQ26 TN Gamma-aminobutyric acid receptor (GAR) DMVWQ26 MA Inhibitor DMVWQ26 RN Benzodiazepine receptor affinity and interaction of some N-(indol-3-ylglyoxylyl)amine derivatives. J Med Chem. 1992 Jun 12;35(12):2214-20. DMVWQ26 RU https://pubmed.ncbi.nlm.nih.gov/1319492 DMVWUCF DI DMVWUCF DMVWUCF DN Sucrose DMVWUCF TI TTHI19T DMVWUCF TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMVWUCF MA Inhibitor DMVWUCF RN Ten S, Maclaren N: Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39. DMVWUCF RU https://pubmed.ncbi.nlm.nih.gov/15181020 DMVWUME DI DMVWUME DMVWUME DN 2-Propyl-pentanoic acid 4-sulfamoyl-benzylamide DMVWUME TI TTZHA0O DMVWUME TN Carbonic anhydrase IV (CA-IV) DMVWUME MA Inhibitor DMVWUME RN Carbonic anhydrase inhibitors: anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties. J Med Chem. 2002 Jan 17;45(2):312-20. DMVWUME RU https://pubmed.ncbi.nlm.nih.gov/11784136 DMVWX62 DI DMVWX62 DMVWX62 DN 6-bromo-3-(pyridin-4-yl)-1H-indole DMVWX62 TI TTTB4UP DMVWX62 TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMVWX62 MA Inhibitor DMVWX62 RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMVWX62 RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMVX063 DI DMVX063 DMVX063 DN 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE DMVX063 TI TTHBTOP DMVX063 TN PI3-kinase gamma (PIK3CG) DMVX063 MA Inhibitor DMVX063 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMVX063 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMVX063 DI DMVX063 DMVX063 DN 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE DMVX063 TI TTGP7BY DMVX063 TN Monoamine oxidase type B (MAO-B) DMVX063 MA Inhibitor DMVX063 RN Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5295-8. DMVX063 RU https://pubmed.ncbi.nlm.nih.gov/20650633 DMVX19Q DI DMVX19Q DMVX19Q DN LYCOGARUBIN B DMVX19Q TI TT1VAUK DMVX19Q TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMVX19Q MA Inhibitor DMVX19Q RN New cytotoxic bisindole alkaloids with protein tyrosine kinase inhibitory activity from a myxomycete Lycogala epidendrum. Bioorg Med Chem Lett. 2005 Jun 2;15(11):2776-80. DMVX19Q RU https://pubmed.ncbi.nlm.nih.gov/15911254 DMVX8LO DI DMVX8LO DMVX8LO DN AZ11657312 (salt free) DMVX8LO TI TT473XN DMVX8LO TN P2X purinoceptor 7 (P2RX7) DMVX8LO MA Antagonist DMVX8LO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 484). DMVX8LO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=484 DMVX9I0 DI DMVX9I0 DMVX9I0 DN Des-Arg(9)-[Leu(8)]-BK DMVX9I0 TI TT7EFHR DMVX9I0 TN Corticotropin-releasing factor receptor 1 (CRHR1) DMVX9I0 MA Antagonist DMVX9I0 RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DMVX9I0 RU https://pubmed.ncbi.nlm.nih.gov/17109611 DMVX9I0 DI DMVX9I0 DMVX9I0 DN Des-Arg(9)-[Leu(8)]-BK DMVX9I0 TI TTG5QIA DMVX9I0 TN B1 bradykinin receptor (BDKRB1) DMVX9I0 MA Antagonist DMVX9I0 RN Evidence for the participation of kinins in Freund's adjuvant-induced inflammatory and nociceptive responses in kinin B1 and B2 receptor knockout mice. Neuropharmacology. 2001 Dec;41(8):1006-12. DMVX9I0 RU https://pubmed.ncbi.nlm.nih.gov/11747905 DMVX9IT DI DMVX9IT DMVX9IT DN ISIS 134608 DMVX9IT TI TTKW4ML DMVX9IT TN Caspase 6 messenger RNA (CASP6 mRNA) DMVX9IT RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMVX9IT RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMVXC7W DI DMVXC7W DMVXC7W DN ISIS 6603 DMVXC7W TI TTONI0R DMVXC7W TN PKC-eta messenger RNA (PRKCH mRNA) DMVXC7W RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMVXC7W RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMVXCPE DI DMVXCPE DMVXCPE DN 1-(3-(4-(fluoromethyl)phenoxy)propyl)piperidine DMVXCPE TI TT9JNIC DMVXCPE TN Histamine H3 receptor (H3R) DMVXCPE MA Inhibitor DMVXCPE RN Fluorinated non-imidazole histamine H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2172-5. DMVXCPE RU https://pubmed.ncbi.nlm.nih.gov/19286376 DMVXJU6 DI DMVXJU6 DMVXJU6 DN 4-(4-(thiophen-2-yl)benzyl)pyridine DMVXJU6 TI TTIQUX7 DMVXJU6 TN Steroid 11-beta-hydroxylase (CYP11B1) DMVXJU6 MA Inhibitor DMVXJU6 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMVXJU6 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMVXJU6 DI DMVXJU6 DMVXJU6 DN 4-(4-(thiophen-2-yl)benzyl)pyridine DMVXJU6 TI TTRA5BZ DMVXJU6 TN Steroid 17-alpha-monooxygenase (S17AH) DMVXJU6 MA Inhibitor DMVXJU6 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMVXJU6 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMVXKLF DI DMVXKLF DMVXKLF DN CALOPOCARPIN DMVXKLF TI TT50QJ3 DMVXKLF TN Influenza Neuraminidase (Influ NA) DMVXKLF MA Inhibitor DMVXKLF RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMVXKLF RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMVXN01 DI DMVXN01 DMVXN01 DN 2-(10-Imidazol-1-yl-decyl)-isoindole-1,3-dione DMVXN01 TI TTKNWZ4 DMVXN01 TN Thromboxane-A synthase (TBXAS1) DMVXN01 MA Inhibitor DMVXN01 RN Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-... J Med Chem. 1986 May;29(5):816-9. DMVXN01 RU https://pubmed.ncbi.nlm.nih.gov/3517332 DMVXPUB DI DMVXPUB DMVXPUB DN Cyclo-[-Arg-Gly-Asp-Amp21-] DMVXPUB TI TTT1R2L DMVXPUB TN Integrin alpha-V (ITGAV) DMVXPUB MA Inhibitor DMVXPUB RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMVXPUB RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMVXPUB DI DMVXPUB DMVXPUB DN Cyclo-[-Arg-Gly-Asp-Amp21-] DMVXPUB TI TTJA1ZO DMVXPUB TN ITGB3 messenger RNA (ITGB3 mRNA) DMVXPUB MA Inhibitor DMVXPUB RN Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008 Mar 27;51(6):1771-82. DMVXPUB RU https://pubmed.ncbi.nlm.nih.gov/18303826 DMVXW4L DI DMVXW4L DMVXW4L DN MYRIOCIN DMVXW4L TI TTWTSCV DMVXW4L TN RAC-alpha serine/threonine-protein kinase (AKT1) DMVXW4L MA Inhibitor DMVXW4L RN Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat Chem Biol. 2008 Sep;4(9):538-47. DMVXW4L RU https://pubmed.ncbi.nlm.nih.gov/18641634 DMVXYZL DI DMVXYZL DMVXYZL DN 1,11-bis(pyridinium)-undecane dibromide DMVXYZL TI TTEB0GD DMVXYZL TN Cholinesterase (BCHE) DMVXYZL MA Inhibitor DMVXYZL RN Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6. DMVXYZL RU https://pubmed.ncbi.nlm.nih.gov/20138518 DMVXYZL DI DMVXYZL DMVXYZL DN 1,11-bis(pyridinium)-undecane dibromide DMVXYZL TI TT1RS9F DMVXYZL TN Acetylcholinesterase (AChE) DMVXYZL MA Inhibitor DMVXYZL RN Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6. DMVXYZL RU https://pubmed.ncbi.nlm.nih.gov/20138518 DMVY271 DI DMVY271 DMVY271 DN 24-hydroxyursolic acid DMVY271 TI TTELIN2 DMVY271 TN PTPN1 messenger RNA (PTPN1 mRNA) DMVY271 MA Inhibitor DMVY271 RN Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8. DMVY271 RU https://pubmed.ncbi.nlm.nih.gov/18798681 DMVY7RX DI DMVY7RX DMVY7RX DN N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) DMVY7RX TI TTQ6VDM DMVY7RX TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMVY7RX MA Inhibitor DMVY7RX RN Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37. DMVY7RX RU https://pubmed.ncbi.nlm.nih.gov/20423086 DMVY7RX DI DMVY7RX DMVY7RX DN N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) DMVY7RX TI TT6OEDT DMVY7RX TN Cannabinoid receptor 1 (CB1) DMVY7RX MA Inhibitor DMVY7RX RN Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37. DMVY7RX RU https://pubmed.ncbi.nlm.nih.gov/20423086 DMVY7RX DI DMVY7RX DMVY7RX DN N-[6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDINE-4-YL]-4,4,4-TRIFLUORO-3-HYDROXYBUTANAMIDE (DIASTEREOMERIC MIX) DMVY7RX TI TTMSFAW DMVY7RX TN Cannabinoid receptor 2 (CB2) DMVY7RX MA Inhibitor DMVY7RX RN Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carbox... J Med Chem. 2010 May 27;53(10):4028-37. DMVY7RX RU https://pubmed.ncbi.nlm.nih.gov/20423086 DMVY89X DI DMVY89X DMVY89X DN Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) DMVY89X TI TTTQGH8 DMVY89X TN Histone deacetylase 4 (HDAC4) DMVY89X MA Inhibitor DMVY89X RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMVY89X RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMVY89X DI DMVY89X DMVY89X DN Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) DMVY89X TI TT6R7JZ DMVY89X TN Histone deacetylase 1 (HDAC1) DMVY89X MA Inhibitor DMVY89X RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMVY89X RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMVY89X DI DMVY89X DMVY89X DN Cyclo(-L-Am7(S2Py)-D-2MePhe-L-Ala-D-Pro-) DMVY89X TI TT5ZKDI DMVY89X TN Histone deacetylase 6 (HDAC6) DMVY89X MA Inhibitor DMVY89X RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMVY89X RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMVYALJ DI DMVYALJ DMVYALJ DN 4-(2,5-Diphenyl-furan-3-yl)-morpholine DMVYALJ TI TTZ97H5 DMVYALJ TN Phosphodiesterase 4A (PDE4A) DMVYALJ MA Inhibitor DMVYALJ RN Substituted furans as inhibitors of the PDE4 enzyme. Bioorg Med Chem Lett. 1999 Feb 8;9(3):323-6. DMVYALJ RU https://pubmed.ncbi.nlm.nih.gov/10091677 DMVYB6Q DI DMVYB6Q DMVYB6Q DN PMID2153213C1a DMVYB6Q TI TTPADOQ DMVYB6Q TN HMG-CoA reductase (HMGCR) DMVYB6Q MA Inhibitor DMVYB6Q RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 2. Derivatives of 7-(1H-pyrrol-3-yl)-substituted-3,5-dihydroxyhept-6(E)-enoic (-heptanoic) acids. J Med Chem. 1990 Jan;33(1):61-70. DMVYB6Q RU https://pubmed.ncbi.nlm.nih.gov/2153213 DMVYEZ1 DI DMVYEZ1 DMVYEZ1 DN Furo[2,3d]Pyrimidine Antifolate DMVYEZ1 TI TT9SL3Q DMVYEZ1 TN Polypeptide deformylase (PDF) DMVYEZ1 MA Inhibitor DMVYEZ1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMVYEZ1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMVYGBU DI DMVYGBU DMVYGBU DN Methyl 2-(2-oxohexadecanamido)acetate DMVYGBU TI TTT1JVS DMVYGBU TN Cytosolic phospholipase A2 (GIVA cPLA2) DMVYGBU MA Inhibitor DMVYGBU RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMVYGBU RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMVYHGI DI DMVYHGI DMVYHGI DN Des-AA1,2,5-[(NalphaMe)Cys3,D-Nal8,IAmp9]SRIF DMVYHGI TI TTIND6G DMVYHGI TN Somatostatin receptor type 1 (SSTR1) DMVYHGI MA Inhibitor DMVYHGI RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMVYHGI RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMVYIN2 DI DMVYIN2 DMVYIN2 DN 6-Phenoxy-hexane-1-thiol DMVYIN2 TI TTT6LFV DMVYIN2 TN Histone deacetylase 8 (HDAC8) DMVYIN2 MA Inhibitor DMVYIN2 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMVYIN2 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMVYIN2 DI DMVYIN2 DMVYIN2 DN 6-Phenoxy-hexane-1-thiol DMVYIN2 TI TTTQGH8 DMVYIN2 TN Histone deacetylase 4 (HDAC4) DMVYIN2 MA Inhibitor DMVYIN2 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMVYIN2 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMVYIN2 DI DMVYIN2 DMVYIN2 DN 6-Phenoxy-hexane-1-thiol DMVYIN2 TI TT6R7JZ DMVYIN2 TN Histone deacetylase 1 (HDAC1) DMVYIN2 MA Inhibitor DMVYIN2 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMVYIN2 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMVYIN2 DI DMVYIN2 DMVYIN2 DN 6-Phenoxy-hexane-1-thiol DMVYIN2 TI TT5ZKDI DMVYIN2 TN Histone deacetylase 6 (HDAC6) DMVYIN2 MA Inhibitor DMVYIN2 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMVYIN2 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMVYIN2 DI DMVYIN2 DMVYIN2 DN 6-Phenoxy-hexane-1-thiol DMVYIN2 TI TTBH0VX DMVYIN2 TN Histone deacetylase (HDAC) DMVYIN2 MA Inhibitor DMVYIN2 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMVYIN2 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMVYIN2 DI DMVYIN2 DMVYIN2 DN 6-Phenoxy-hexane-1-thiol DMVYIN2 TI TTSHTOI DMVYIN2 TN Histone deacetylase 2 (HDAC2) DMVYIN2 MA Inhibitor DMVYIN2 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMVYIN2 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMVYIN2 DI DMVYIN2 DMVYIN2 DN 6-Phenoxy-hexane-1-thiol DMVYIN2 TI TTYHPU6 DMVYIN2 TN Histone deacetylase 10 (HDAC10) DMVYIN2 MA Inhibitor DMVYIN2 RN Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxama... J Med Chem. 2005 Feb 24;48(4):1019-32. DMVYIN2 RU https://pubmed.ncbi.nlm.nih.gov/15715470 DMVYNJZ DI DMVYNJZ DMVYNJZ DN BUTAPROST DMVYNJZ TI TTT2ZAR DMVYNJZ TN Prostaglandin F2-alpha receptor (PTGFR) DMVYNJZ MA Antagonist DMVYNJZ RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMVYNJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMVYNJZ DI DMVYNJZ DMVYNJZ DN BUTAPROST DMVYNJZ TI TTG1QMU DMVYNJZ TN Prostaglandin E2 receptor EP1 (PTGER1) DMVYNJZ MA Antagonist DMVYNJZ RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMVYNJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMVYNJZ DI DMVYNJZ DMVYNJZ DN BUTAPROST DMVYNJZ TI TT79WV3 DMVYNJZ TN Prostaglandin E2 receptor EP4 (PTGER4) DMVYNJZ MA Antagonist DMVYNJZ RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMVYNJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMVYNJZ DI DMVYNJZ DMVYNJZ DN BUTAPROST DMVYNJZ TI TTPNGDE DMVYNJZ TN Prostaglandin E2 receptor EP3 (PTGER3) DMVYNJZ MA Antagonist DMVYNJZ RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMVYNJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMVYNJZ DI DMVYNJZ DMVYNJZ DN BUTAPROST DMVYNJZ TI TT1ZAVI DMVYNJZ TN Prostaglandin E2 receptor EP2 (PTGER2) DMVYNJZ MA Antagonist DMVYNJZ RN Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44. DMVYNJZ RU https://www.ncbi.nlm.nih.gov/pubmed/25772215 DMVYNTB DI DMVYNTB DMVYNTB DN Piv-RYYRIK-NH2 DMVYNTB TI TTNT7K8 DMVYNTB TN Nociceptin receptor (OPRL1) DMVYNTB MA Inhibitor DMVYNTB RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMVYNTB RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMVYSAZ DI DMVYSAZ DMVYSAZ DN CRT-0004592 DMVYSAZ TI TTWJTHX DMVYSAZ TN Protein kinase C iota (PRKCI) DMVYSAZ MA Inhibitor DMVYSAZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1490). DMVYSAZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1490 DMVYWJS DI DMVYWJS DMVYWJS DN MEZILAMINE DMVYWJS TI TT2NUT5 DMVYWJS TN Adrenergic receptor alpha-2C (ADRA2C) DMVYWJS MA Inhibitor DMVYWJS RN 4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors. J Med Chem. 1986 Aug;29(8):1394-8. DMVYWJS RU https://pubmed.ncbi.nlm.nih.gov/3016265 DMVYWJS DI DMVYWJS DMVYWJS DN MEZILAMINE DMVYWJS TI TTWG9A4 DMVYWJS TN Adrenergic receptor alpha-2A (ADRA2A) DMVYWJS MA Inhibitor DMVYWJS RN 4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors. J Med Chem. 1986 Aug;29(8):1394-8. DMVYWJS RU https://pubmed.ncbi.nlm.nih.gov/3016265 DMVYWJS DI DMVYWJS DMVYWJS DN MEZILAMINE DMVYWJS TI TTWM4TY DMVYWJS TN Adrenergic receptor alpha-2B (ADRA2B) DMVYWJS MA Inhibitor DMVYWJS RN 4-Amino-6-chloro-2-piperazinopyrimidines with selective affinity for alpha 2-adrenoceptors. J Med Chem. 1986 Aug;29(8):1394-8. DMVYWJS RU https://pubmed.ncbi.nlm.nih.gov/3016265 DMVZ9Q0 DI DMVZ9Q0 DMVZ9Q0 DN Sc-43076 DMVZ9Q0 TI TTSJIRP DMVZ9Q0 TN Connexin 32 messenger RNA (GJB1 mRNA) DMVZ9Q0 RN Connexin Antibodies. Report from santa cruz biotechnology, inc. Santa cruz biotechnology. 2009. DMVZ9Q0 RU http://www.scbt.com/table-connexin.html DMVZA27 DI DMVZA27 DMVZA27 DN 7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine DMVZA27 TI TTWJBZ5 DMVZA27 TN 5-HT 2C receptor (HTR2C) DMVZA27 MA Inhibitor DMVZA27 RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DMVZA27 RU https://pubmed.ncbi.nlm.nih.gov/18083579 DMVZA27 DI DMVZA27 DMVZA27 DN 7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine DMVZA27 TI TTJQOD7 DMVZA27 TN 5-HT 2A receptor (HTR2A) DMVZA27 MA Inhibitor DMVZA27 RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DMVZA27 RU https://pubmed.ncbi.nlm.nih.gov/18083579 DMVZA27 DI DMVZA27 DMVZA27 DN 7,8,9,10-tetrahydro-6H-furo-[3,2-g][3]benzazepine DMVZA27 TI TT0K1SC DMVZA27 TN 5-HT 2B receptor (HTR2B) DMVZA27 MA Inhibitor DMVZA27 RN Synthesis and structure-activity relationships of a series of benzazepine derivatives as 5-HT2C receptor agonists. Bioorg Med Chem. 2008 Mar 15;16(6):3309-20. DMVZA27 RU https://pubmed.ncbi.nlm.nih.gov/18083579 DMVZB8U DI DMVZB8U DMVZB8U DN WVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2 DMVZB8U TI TTVSFJW DMVZB8U TN Calcitonin gene-related peptide 1 (CALCA) DMVZB8U MA Inhibitor DMVZB8U RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMVZB8U RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMVZLIB DI DMVZLIB DMVZLIB DN AHL DMVZLIB TI TT12KOD DMVZLIB TN P53 messenger RNA (TP53 mRNA) DMVZLIB RN Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer. 2012 Jan 15;118(2):418-27. DMVZLIB RU https://pubmed.ncbi.nlm.nih.gov/21717444 DMVZMBU DI DMVZMBU DMVZMBU DN Indan-2-ylcarbamic Acid Biphenyl-3-yl Ester DMVZMBU TI TTDP1UC DMVZMBU TN Fatty acid amide hydrolase (FAAH) DMVZMBU MA Inhibitor DMVZMBU RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMVZMBU RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMVZQ47 DI DMVZQ47 DMVZQ47 DN UR-12519 DMVZQ47 TI TTQL5VC DMVZQ47 TN Platelet-activating factor receptor (PTAFR) DMVZQ47 MA Modulator DMVZQ47 RN Evidence for the autocrine induction of capacitation of mammalian spermatozoa.J Biol Chem.2001 Jul 20;276(29):26962-8. DMVZQ47 RU https://www.ncbi.nlm.nih.gov/pubmed/11350972 DMVZQ6U DI DMVZQ6U DMVZQ6U DN PMID22545772C42 DMVZQ6U TI TT7QNVC DMVZQ6U TN Glucose-dependent insulinotropic receptor (GPR119) DMVZQ6U MA Agonist DMVZQ6U RN Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation. J Med Chem. 2012 Jun 14;55(11):5361-79. DMVZQ6U RU https://pubmed.ncbi.nlm.nih.gov/22545772 DMVZS1D DI DMVZS1D DMVZS1D DN ISIS 122984 DMVZS1D TI TTJZNIG DMVZS1D TN MEKK3 messenger RNA (MAP3K3 mRNA) DMVZS1D RN US patent application no. 6,498,035, Antisense modulation of MEKK3 expression. DMVZS1D RU http://www.patentbuddy.com/Patent/6498035?ft=true&sr=true DMVZTU0 DI DMVZTU0 DMVZTU0 DN ISIS 188780 DMVZTU0 TI TTLRVIA DMVZTU0 TN Forkhead box O1A messenger RNA (FOXO1 mRNA) DMVZTU0 RN US patent application no. 7,229,976, Modulation of forkhead box O1A expression. DMVZTU0 RU http://www.patentbuddy.com/Patent/7229976?ft=true&sr=true DMVZW92 DI DMVZW92 DMVZW92 DN Epierenone DMVZW92 TI TT26PHO DMVZW92 TN Mineralocorticoid receptor (MR) DMVZW92 MA Inhibitor DMVZW92 RN (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5. DMVZW92 RU https://pubmed.ncbi.nlm.nih.gov/18038968 DMVZW92 DI DMVZW92 DMVZW92 DN Epierenone DMVZW92 TI TTOZRK6 DMVZW92 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMVZW92 MA Inhibitor DMVZW92 RN (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5. DMVZW92 RU https://pubmed.ncbi.nlm.nih.gov/18038968 DMVZW92 DI DMVZW92 DMVZW92 DN Epierenone DMVZW92 TI TTKPW01 DMVZW92 TN Androgen receptor messenger RNA (AR mRNA) DMVZW92 MA Inhibitor DMVZW92 RN (S)-N-{3-[1-cyclopropyl-1-(2,4-difluoro-phenyl)-ethyl]-1H-indol-7-yl}-methanesulfonamide: a potent, nonsteroidal, functional antagonist of the mine... J Med Chem. 2007 Dec 27;50(26):6443-5. DMVZW92 RU https://pubmed.ncbi.nlm.nih.gov/18038968 DMVZWCI DI DMVZWCI DMVZWCI DN super cinnamaldehyde DMVZWCI TI TTELV3W DMVZWCI TN Transformation-sensitive protein p120 (TRPA1) DMVZWCI MA Activator DMVZWCI RN Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 1;445(7127):541-5. DMVZWCI RU https://pubmed.ncbi.nlm.nih.gov/17237762 DMVZY0X DI DMVZY0X DMVZY0X DN TNP-ATP DMVZY0X TI TTJW7B3 DMVZY0X TN P2X purinoceptor 1 (P2RX1) DMVZY0X MA Antagonist DMVZY0X RN Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73. DMVZY0X RU https://pubmed.ncbi.nlm.nih.gov/9614197 DMVZY0X DI DMVZY0X DMVZY0X DN TNP-ATP DMVZY0X TI TT2THBD DMVZY0X TN P2X purinoceptor 3 (P2RX3) DMVZY0X MA Antagonist DMVZY0X RN Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73. DMVZY0X RU https://pubmed.ncbi.nlm.nih.gov/9614197 DMVZYNH DI DMVZYNH DMVZYNH DN (Z)-1-(4-phenyloxazol-2-yl)octadec-9-en-1-one DMVZYNH TI TTDP1UC DMVZYNH TN Fatty acid amide hydrolase (FAAH) DMVZYNH MA Inhibitor DMVZYNH RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMVZYNH RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMW02H7 DI DMW02H7 DMW02H7 DN Ac-DEVD-CHO DMW02H7 TI TTPF2QI DMW02H7 TN Caspase-3 (CASP3) DMW02H7 MA Inhibitor DMW02H7 RN Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. Eur J Med Chem. 2010 Sep;45(9):3858-63. DMW02H7 RU https://pubmed.ncbi.nlm.nih.gov/20541849 DMW02H7 DI DMW02H7 DMW02H7 DN Ac-DEVD-CHO DMW02H7 TI TTZY5KP DMW02H7 TN Caspase (CASP) DMW02H7 MA Inhibitor DMW02H7 RN Synthesis and evaluation of vinyl sulfones as caspase-3 inhibitors. A structure-activity study. Eur J Med Chem. 2010 Sep;45(9):3858-63. DMW02H7 RU https://pubmed.ncbi.nlm.nih.gov/20541849 DMW09LB DI DMW09LB DMW09LB DN LTK-14 DMW09LB TI TTVK7SB DMW09LB TN Histone acetyltransferase KAT2B (KAT2B) DMW09LB MA Inhibitor DMW09LB RN Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol. 2007 Jun;14(6):645-57. DMW09LB RU https://pubmed.ncbi.nlm.nih.gov/17584612 DMW0B4H DI DMW0B4H DMW0B4H DN 3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one DMW0B4H TI TTOM3J0 DMW0B4H TN Estrogen receptor beta (ESR2) DMW0B4H MA Inhibitor DMW0B4H RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMW0B4H RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMW0B4H DI DMW0B4H DMW0B4H DN 3,8-dihydroxy-7-methyl-6H-benzo[c]chromen-6-one DMW0B4H TI TTZAYWL DMW0B4H TN Estrogen receptor (ESR) DMW0B4H MA Inhibitor DMW0B4H RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMW0B4H RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTE0A2F DMW0HOG TN Dopamine D4 receptor (D4R) DMW0HOG MA Inhibitor DMW0HOG RN Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/6128416 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTEX248 DMW0HOG TN Dopamine D2 receptor (D2R) DMW0HOG MA Inhibitor DMW0HOG RN Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/2573732 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTZFYLI DMW0HOG TN Dopamine D1 receptor (D1R) DMW0HOG MA Inhibitor DMW0HOG RN Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/6128416 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTQ3JTF DMW0HOG TN Muscarinic acetylcholine receptor M4 (CHRM4) DMW0HOG MA Inhibitor DMW0HOG RN Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/2573732 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTH18TF DMW0HOG TN Muscarinic acetylcholine receptor M5 (CHRM5) DMW0HOG MA Inhibitor DMW0HOG RN Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/2573732 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTYEG6Q DMW0HOG TN Muscarinic acetylcholine receptor M2 (CHRM2) DMW0HOG MA Inhibitor DMW0HOG RN Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/2573732 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTZ9SOR DMW0HOG TN Muscarinic acetylcholine receptor M1 (CHRM1) DMW0HOG MA Inhibitor DMW0HOG RN Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/2573732 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTQ13Z5 DMW0HOG TN Muscarinic acetylcholine receptor M3 (CHRM3) DMW0HOG MA Inhibitor DMW0HOG RN Synthesis and pharmacological evaluation of a series of 4-piperazinylpyrazolo[3,4-b]- and -[4,3-b][1,5]benzodiazepines as potential anxiolytics. J Med Chem. 1989 Dec;32(12):2573-82. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/2573732 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TT4C8EA DMW0HOG TN Dopamine D3 receptor (D3R) DMW0HOG MA Inhibitor DMW0HOG RN Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/6128416 DMW0HOG DI DMW0HOG DMW0HOG DN FLUMEZAPINE DMW0HOG TI TTS2PH3 DMW0HOG TN Dopamine D5 receptor (D5R) DMW0HOG MA Inhibitor DMW0HOG RN Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40. DMW0HOG RU https://pubmed.ncbi.nlm.nih.gov/6128416 DMW0HXO DI DMW0HXO DMW0HXO DN Azithromycin-N-benzyltriazolylnonahydroxamic Acid DMW0HXO TI TT6R7JZ DMW0HXO TN Histone deacetylase 1 (HDAC1) DMW0HXO MA Inhibitor DMW0HXO RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DMW0HXO RU https://pubmed.ncbi.nlm.nih.gov/19093884 DMW0HXO DI DMW0HXO DMW0HXO DN Azithromycin-N-benzyltriazolylnonahydroxamic Acid DMW0HXO TI TTT6LFV DMW0HXO TN Histone deacetylase 8 (HDAC8) DMW0HXO MA Inhibitor DMW0HXO RN Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem. 2009 Jan 22;52(2):456-68. DMW0HXO RU https://pubmed.ncbi.nlm.nih.gov/19093884 DMW0J3D DI DMW0J3D DMW0J3D DN Ethyl Dihydrogen Phosphate DMW0J3D TI TTEB0GD DMW0J3D TN Cholinesterase (BCHE) DMW0J3D MA Inhibitor DMW0J3D RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW0J3D RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW0M14 DI DMW0M14 DMW0M14 DN 2-phenylamino-9-(4-hydroxy-butyl)-6-oxopurine DMW0M14 TI TTP3QRF DMW0M14 TN Thymidine kinase 1 (TK1) DMW0M14 MA Inhibitor DMW0M14 RN Sensitivity of monkey B virus (Cercopithecine herpesvirus 1) to antiviral drugs: role of thymidine kinase in antiviral activities of substrate anal... Antimicrob Agents Chemother. 2007 Jun;51(6):2028-34. DMW0M14 RU https://pubmed.ncbi.nlm.nih.gov/17438061 DMW0MTV DI DMW0MTV DMW0MTV DN DIMETHYLGRISABINE DMW0MTV TI TTVBI8W DMW0MTV TN Dopamine transporter (DAT) DMW0MTV MA Inhibitor DMW0MTV RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DMW0MTV RU https://pubmed.ncbi.nlm.nih.gov/8676127 DMW0Y29 DI DMW0Y29 DMW0Y29 DN 4-methylstyrylboronic acid DMW0Y29 TI TTHQPL7 DMW0Y29 TN Carbonic anhydrase I (CA-I) DMW0Y29 MA Inhibitor DMW0Y29 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMW0Y29 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMW0Y75 DI DMW0Y75 DMW0Y75 DN ISIS 150454 DMW0Y75 TI TTP9K3Q DMW0Y75 TN SOD1 messenger RNA (SOD1 mRNA) DMW0Y75 RN US patent application no. 7,132,530, Antisense modulation of superoxide dismutase 1, soluble expression. DMW0Y75 RU http://www.patentbuddy.com/Patent/7132530?ft=true&sr=true DMW0Y92 DI DMW0Y92 DMW0Y92 DN 1-Benzyl-1H-indole-5-carboxamidine DMW0Y92 TI TT2WR1T DMW0Y92 TN Cationic trypsinogen (PRSS1) DMW0Y92 MA Inhibitor DMW0Y92 RN Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin... J Med Chem. 1983 Feb;26(2):294-8. DMW0Y92 RU https://pubmed.ncbi.nlm.nih.gov/6219223 DMW0ZBF DI DMW0ZBF DMW0ZBF DN Sulfate DMW0ZBF TI TTHQPL7 DMW0ZBF TN Carbonic anhydrase I (CA-I) DMW0ZBF MA Inhibitor DMW0ZBF RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMW0ZBF RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMW13SO DI DMW13SO DMW13SO DN 5,5'-methylenebis(1,3,4-thiadiazole-2(3H)-thione) DMW13SO TI TTULVH8 DMW13SO TN Tyrosinase (TYR) DMW13SO MA Inhibitor DMW13SO RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMW13SO RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMW15DS DI DMW15DS DMW15DS DN (1H-indol-2-yl)(piperazin-1-yl)methanone DMW15DS TI TTXJ178 DMW15DS TN Histamine H4 receptor (H4R) DMW15DS MA Inhibitor DMW15DS RN Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists. J Med Chem. 2005 Dec 29;48(26):8289-98. DMW15DS RU https://pubmed.ncbi.nlm.nih.gov/16366610 DMW15DS DI DMW15DS DMW15DS DN (1H-indol-2-yl)(piperazin-1-yl)methanone DMW15DS TI TT9JNIC DMW15DS TN Histamine H3 receptor (H3R) DMW15DS MA Inhibitor DMW15DS RN Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists. J Med Chem. 2005 Dec 29;48(26):8289-98. DMW15DS RU https://pubmed.ncbi.nlm.nih.gov/16366610 DMW167A DI DMW167A DMW167A DN Benzyl-(9H-beta-carbolin-6-yl)-amine DMW167A TI TT1MPAY DMW167A TN GABA(A) receptor alpha-1 (GABRA1) DMW167A MA Inhibitor DMW167A RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMW167A RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMW167A DI DMW167A DMW167A DN Benzyl-(9H-beta-carbolin-6-yl)-amine DMW167A TI TTNJYV2 DMW167A TN Gamma-aminobutyric acid receptor (GAR) DMW167A MA Inhibitor DMW167A RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMW167A RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMW16X2 DI DMW16X2 DMW16X2 DN UDP-glucuronic acid DMW16X2 TI TT72OKI DMW16X2 TN P2Y purinoceptor 14 (P2RY14) DMW16X2 MA Agonist DMW16X2 RN Gi-dependent cell signaling responses of the human P2Y14 receptor in model cell systems. J Pharmacol Exp Ther. 2009 Jul;330(1):162-8. DMW16X2 RU https://pubmed.ncbi.nlm.nih.gov/19339661 DMW172Q DI DMW172Q DMW172Q DN 123I-DRM-106 DMW172Q TI TTE4KHA DMW172Q TN Amyloid beta A4 protein (APP) DMW172Q MA Modulator DMW172Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMW172Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMW180Y DI DMW180Y DMW180Y DN Glycinamide Ribonucleotide DMW180Y TI TTEXB9Z DMW180Y TN Glycinamide ribonucleotide formyltransferase (GART) DMW180Y MA Inhibitor DMW180Y RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW180Y RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW198G DI DMW198G DMW198G DN 4-pentyl-N-pyridin-3-yl benzamide DMW198G TI TTMI6F5 DMW198G TN Transient receptor potential cation channel V1 (TRPV1) DMW198G MA Inhibitor DMW198G RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMW198G RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMW19LB DI DMW19LB DMW19LB DN PSB-0952 DMW19LB TI TTK0O6Y DMW19LB TN Ecto-5'-nucleotidase (CD73) DMW19LB MA Inhibitor DMW19LB RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMW19LB RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMW19LB DI DMW19LB DMW19LB DN PSB-0952 DMW19LB TI TTNVSKA DMW19LB TN P2Y purinoceptor 6 (P2RY6) DMW19LB MA Inhibitor DMW19LB RN Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86. DMW19LB RU https://pubmed.ncbi.nlm.nih.gov/20146483 DMW1ALX DI DMW1ALX DMW1ALX DN DIHYDROAKUAMMINE DMW1ALX TI TTKWM86 DMW1ALX TN Opioid receptor mu (MOP) DMW1ALX MA Inhibitor DMW1ALX RN Akuammine and dihydroakuammine, two indolomonoterpene alkaloids displaying affinity for opioid receptors. J Nat Prod. 1992 Mar;55(3):380-4. DMW1ALX RU https://pubmed.ncbi.nlm.nih.gov/1317407 DMW1H6C DI DMW1H6C DMW1H6C DN 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline DMW1H6C TI TTI7421 DMW1H6C TN Platelet-derived growth factor receptor beta (PDGFRB) DMW1H6C MA Inhibitor DMW1H6C RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMW1H6C RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMW1H6C DI DMW1H6C DMW1H6C DN 4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline DMW1H6C TI TT8FYO9 DMW1H6C TN Platelet-derived growth factor receptor alpha (PDGFRA) DMW1H6C MA Inhibitor DMW1H6C RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMW1H6C RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMW1IXY DI DMW1IXY DMW1IXY DN 4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol DMW1IXY TI TTZAYWL DMW1IXY TN Estrogen receptor (ESR) DMW1IXY MA Inhibitor DMW1IXY RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMW1IXY RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMW1IXY DI DMW1IXY DMW1IXY DN 4-[1,2-bis(4-hydroxyphenyl)but-1-enyl]phenol DMW1IXY TI TTOM3J0 DMW1IXY TN Estrogen receptor beta (ESR2) DMW1IXY MA Inhibitor DMW1IXY RN Antiestrogenically active 1,1,2-tris(4-hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med Chem. 2003 Apr 10;46(8):1484-91. DMW1IXY RU https://pubmed.ncbi.nlm.nih.gov/12672249 DMW1LF0 DI DMW1LF0 DMW1LF0 DN Alpha-Aminobutyric Acid DMW1LF0 TI TT3DQUT DMW1LF0 TN Bacterial Lantibiotic mersacidin (Bact glmM) DMW1LF0 MA Inhibitor DMW1LF0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW1LF0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW1PSO DI DMW1PSO DMW1PSO DN Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2 DMW1PSO TI TT860QF DMW1PSO TN LCK tyrosine protein kinase (LCK) DMW1PSO MA Inhibitor DMW1PSO RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DMW1PSO RU https://pubmed.ncbi.nlm.nih.gov/9632358 DMW1PSO DI DMW1PSO DMW1PSO DN Y-c[D-Pen-(3-I)Tyr-GSFC]KR-NH2 DMW1PSO TI TT6PKBN DMW1PSO TN Proto-oncogene c-Src (SRC) DMW1PSO MA Inhibitor DMW1PSO RN Discovery of a novel series of potent and selective substrate-based inhibitors of p60c-src protein tyrosine kinase: conformational and topographica... J Med Chem. 1998 Jun 18;41(13):2252-60. DMW1PSO RU https://pubmed.ncbi.nlm.nih.gov/9632358 DMW1T93 DI DMW1T93 DMW1T93 DN 4-isopropyl-N-(naphthalen-1-yl)thiazol-2-amine DMW1T93 TI TT7HQD0 DMW1T93 TN C-C chemokine receptor type 4 (CCR4) DMW1T93 MA Inhibitor DMW1T93 RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMW1T93 RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMW1VOB DI DMW1VOB DMW1VOB DN rHuB-D2 DMW1VOB TI TTIVY12 DMW1VOB TN Beta-defensin 4A (DEFB4A) DMW1VOB MA Modulator DMW1VOB RN Bioactive coating of titanium surfaces with recombinant human -defensin-2 (rHuD2) may prevent bacterial colonization in orthopaedic surgery.J Bone Joint Surg Am.2011 May 4;93(9):840-6. DMW1VOB RU https://www.ncbi.nlm.nih.gov/pubmed/21543673 DMW1XY4 DI DMW1XY4 DMW1XY4 DN PO3 2-Nle-Trp-O-3K DMW1XY4 TI TTQ9RYT DMW1XY4 TN Endothelin-converting enzyme 1 (ECE1) DMW1XY4 MA Inhibitor DMW1XY4 RN Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994). DMW1XY4 RU http://www.sciencedirect.com/science/article/pii/S0960894X01803413 DMW1Y2G DI DMW1Y2G DMW1Y2G DN Abietic acid DMW1Y2G TI TTN7BL9 DMW1Y2G TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMW1Y2G MA Inhibitor DMW1Y2G RN A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol. 2003 Dec 30;212(1-2):41-9. DMW1Y2G RU https://pubmed.ncbi.nlm.nih.gov/14654249 DMW1YK3 DI DMW1YK3 DMW1YK3 DN Lysine Nz-Carboxylic Acid DMW1YK3 TI TT09NOX DMW1YK3 TN Plasmodium Dihydroorotase (Malaria dho) DMW1YK3 MA Inhibitor DMW1YK3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW1YK3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW1YK3 DI DMW1YK3 DMW1YK3 DN Lysine Nz-Carboxylic Acid DMW1YK3 TI TT6TMZU DMW1YK3 TN Mycobacterium Biosynthetic alanine racemase (MycB alr) DMW1YK3 MA Inhibitor DMW1YK3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW1YK3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW1YK3 DI DMW1YK3 DMW1YK3 DN Lysine Nz-Carboxylic Acid DMW1YK3 TI TT7HF4W DMW1YK3 TN Cyclin-dependent kinase 2 (CDK2) DMW1YK3 MA Inhibitor DMW1YK3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW1YK3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW23Y9 DI DMW23Y9 DMW23Y9 DN GTP-14564 DMW23Y9 TI TTX41N9 DMW23Y9 TN Tyrosine-protein kinase Kit (KIT) DMW23Y9 MA Inhibitor DMW23Y9 RN Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8. DMW23Y9 RU https://pubmed.ncbi.nlm.nih.gov/12815052 DMW23Y9 DI DMW23Y9 DMW23Y9 DN GTP-14564 DMW23Y9 TI TTGJCWZ DMW23Y9 TN Fms-like tyrosine kinase 3 (FLT-3) DMW23Y9 MA Inhibitor DMW23Y9 RN Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8. DMW23Y9 RU https://pubmed.ncbi.nlm.nih.gov/12815052 DMW23Y9 DI DMW23Y9 DMW23Y9 DN GTP-14564 DMW23Y9 TI TTI7421 DMW23Y9 TN Platelet-derived growth factor receptor beta (PDGFRB) DMW23Y9 MA Inhibitor DMW23Y9 RN Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8. DMW23Y9 RU https://pubmed.ncbi.nlm.nih.gov/12815052 DMW23Y9 DI DMW23Y9 DMW23Y9 DN GTP-14564 DMW23Y9 TI TTVW6QL DMW23Y9 TN CSF1R messenger RNA (CSF1R mRNA) DMW23Y9 MA Inhibitor DMW23Y9 RN Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosin... J Biol Chem. 2003 Aug 29;278(35):32892-8. DMW23Y9 RU https://pubmed.ncbi.nlm.nih.gov/12815052 DMW24JP DI DMW24JP DMW24JP DN TALAROFLAVONE DMW24JP TI TTIU7X1 DMW24JP TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMW24JP MA Inhibitor DMW24JP RN 1-deoxyrubralactone, a novel specific inhibitor of families X and Y of eukaryotic DNA polymerases from a fungal strain derived from sea algae. Bioorg Med Chem. 2008 Mar 15;16(6):2939-44. DMW24JP RU https://pubmed.ncbi.nlm.nih.gov/18178092 DMW24UH DI DMW24UH DMW24UH DN Ac-[CFWkYC]-NH2 DMW24UH TI TTW5UDX DMW24UH TN Urotensin II receptor (UTS2R) DMW24UH MA Inhibitor DMW24UH RN Urotensin-II receptor modulators as potential drugs. J Med Chem. 2010 Apr 8;53(7):2695-708. DMW24UH RU https://pubmed.ncbi.nlm.nih.gov/20043680 DMW271Q DI DMW271Q DMW271Q DN epipregnanolone sulphate DMW271Q TI TTO3TD8 DMW271Q TN Long transient receptor potential channel 3 (TRPM3) DMW271Q MA Activator DMW271Q RN Cis-isomerism and other chemical requirements of steroidal agonists and partial agonists acting at TRPM3 channels. Br J Pharmacol. 2010 Sep;161(2):430-41. DMW271Q RU https://pubmed.ncbi.nlm.nih.gov/20735426 DMW27AC DI DMW27AC DMW27AC DN 2-(benzylamino)-5,5-diethyloxazol-4(5H)-one DMW27AC TI TTN7BL9 DMW27AC TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMW27AC MA Inhibitor DMW27AC RN Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40. DMW27AC RU https://pubmed.ncbi.nlm.nih.gov/17600707 DMW2FTP DI DMW2FTP DMW2FTP DN TPI-1361-17 DMW2FTP TI TTX4RTB DMW2FTP TN Melanin-concentrating hormone receptor 1 (MCHR1) DMW2FTP MA Antagonist DMW2FTP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 280). DMW2FTP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=280 DMW2GA4 DI DMW2GA4 DMW2GA4 DN Demotensin 2 DMW2GA4 TI TTTUMEP DMW2GA4 TN Neurotensin receptor type 1 (NTSR1) DMW2GA4 MA Inhibitor DMW2GA4 RN Toward stable N4-modified neurotensins for NTS1-receptor-targeted tumor imaging with 99mTc. J Med Chem. 2006 Jul 27;49(15):4767-76. DMW2GA4 RU https://pubmed.ncbi.nlm.nih.gov/16854083 DMW2KI5 DI DMW2KI5 DMW2KI5 DN 24(S), 25-epoxycholesterol DMW2KI5 TI TTXA6PH DMW2KI5 TN Oxysterols receptor LXR-beta (NR1H2) DMW2KI5 MA Agonist DMW2KI5 RN Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol. 2013 Feb;9(2):126-33. DMW2KI5 RU https://pubmed.ncbi.nlm.nih.gov/23292650 DMW2KI5 DI DMW2KI5 DMW2KI5 DN 24(S), 25-epoxycholesterol DMW2KI5 TI TTECBXN DMW2KI5 TN Oxysterols receptor LXR-alpha (NR1H3) DMW2KI5 MA Agonist DMW2KI5 RN Brain endogenous liver X receptor ligands selectively promote midbrain neurogenesis. Nat Chem Biol. 2013 Feb;9(2):126-33. DMW2KI5 RU https://pubmed.ncbi.nlm.nih.gov/23292650 DMW2MRP DI DMW2MRP DMW2MRP DN 4-Morpholin-4-yl-benzo[h]chromen-2-one DMW2MRP TI TTK3PY9 DMW2MRP TN DNA-dependent protein kinase catalytic (PRKDC) DMW2MRP MA Inhibitor DMW2MRP RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMW2MRP RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMW2NJR DI DMW2NJR DMW2NJR DN 8-(3-Benzoyl-ureido)-octanoic acid hydroxyamide DMW2NJR TI TT6R7JZ DMW2NJR TN Histone deacetylase 1 (HDAC1) DMW2NJR MA Inhibitor DMW2NJR RN Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3314-21. DMW2NJR RU https://pubmed.ncbi.nlm.nih.gov/20451378 DMW2NY9 DI DMW2NY9 DMW2NY9 DN 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine DMW2NY9 TI TTQBR95 DMW2NY9 TN Stress-activated protein kinase 2a (p38 alpha) DMW2NY9 MA Inhibitor DMW2NY9 RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMW2NY9 RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMW2Q4T DI DMW2Q4T DMW2Q4T DN ISIS 116632 DMW2Q4T TI TTQWAU1 DMW2Q4T TN GSK3A messenger RNA (GSK3A mRNA) DMW2Q4T RN US patent application no. 6,316,259, Antisense inhibition of glycogen synthase kinase 3 alpha expression. DMW2Q4T RU http://www.patentbuddy.com/Patent/6316259?ft=true&sr=true DMW2Q6N DI DMW2Q6N DMW2Q6N DN NSC-54162 DMW2Q6N TI TTHVCUP DMW2Q6N TN DNA [cytosine-5]-methyltransferase (DNMT) DMW2Q6N MA Inhibitor DMW2Q6N RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMW2Q6N RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMW2Q6N DI DMW2Q6N DMW2Q6N DN NSC-54162 DMW2Q6N TI TT6VZ78 DMW2Q6N TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMW2Q6N MA Inhibitor DMW2Q6N RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMW2Q6N RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMW2R3M DI DMW2R3M DMW2R3M DN Methyl piperate DMW2R3M TI TTGP7BY DMW2R3M TN Monoamine oxidase type B (MAO-B) DMW2R3M MA Inhibitor DMW2R3M RN Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40. DMW2R3M RU https://pubmed.ncbi.nlm.nih.gov/19969454 DMW2VOX DI DMW2VOX DMW2VOX DN FITC-LMNNAEHINQFYMFI DMW2VOX TI TT7EASG DMW2VOX TN Plasmodium Cysteine protease falcipain-2 (Malaria CPF2) DMW2VOX MA Inhibitor DMW2VOX RN A prodomain peptide of Plasmodium falciparum cysteine protease (falcipain-2) inhibits malaria parasite development. J Med Chem. 2008 Jun 12;51(11):3116-23. DMW2VOX RU https://pubmed.ncbi.nlm.nih.gov/18461922 DMW2VZ1 DI DMW2VZ1 DMW2VZ1 DN 2,6-diphenyl-1-deazapurine DMW2VZ1 TI TTM2AOE DMW2VZ1 TN Adenosine A2a receptor (ADORA2A) DMW2VZ1 MA Inhibitor DMW2VZ1 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMW2VZ1 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMW2VZ1 DI DMW2VZ1 DMW2VZ1 DN 2,6-diphenyl-1-deazapurine DMW2VZ1 TI TTK25J1 DMW2VZ1 TN Adenosine A1 receptor (ADORA1) DMW2VZ1 MA Inhibitor DMW2VZ1 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMW2VZ1 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMW2VZ1 DI DMW2VZ1 DMW2VZ1 DN 2,6-diphenyl-1-deazapurine DMW2VZ1 TI TTJFY5U DMW2VZ1 TN Adenosine A3 receptor (ADORA3) DMW2VZ1 MA Inhibitor DMW2VZ1 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMW2VZ1 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMW2X5V DI DMW2X5V DMW2X5V DN Tert-butyl 10H-phenothiazine-10-carboxylate DMW2X5V TI TTEB0GD DMW2X5V TN Cholinesterase (BCHE) DMW2X5V MA Inhibitor DMW2X5V RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMW2X5V RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMW2Z4I DI DMW2Z4I DMW2Z4I DN Multiform PI3K inhibitors DMW2Z4I TI TTHBTOP DMW2Z4I TN PI3-kinase gamma (PIK3CG) DMW2Z4I MA Inhibitor DMW2Z4I RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMW2Z4I RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMW3145 DI DMW3145 DMW3145 DN ISIS 11219 DMW3145 TI TTRE6AX DMW3145 TN Bcl-x messenger RNA (BCL2L1 mRNA) DMW3145 RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMW3145 RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMW378C DI DMW378C DMW378C DN N-(naphthalen-1-yl)-4-neopentylthiazol-2-amine DMW378C TI TT7HQD0 DMW378C TN C-C chemokine receptor type 4 (CCR4) DMW378C MA Inhibitor DMW378C RN Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. DMW378C RU https://pubmed.ncbi.nlm.nih.gov/16497499 DMW3F5C DI DMW3F5C DMW3F5C DN 2-phenylethylyl-adenosine derivative DMW3F5C TI TTJFY5U DMW3F5C TN Adenosine A3 receptor (ADORA3) DMW3F5C MA Agonist DMW3F5C RN Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. J Med Chem. 2009 Dec 10;52(23):7897-900. DMW3F5C RU https://pubmed.ncbi.nlm.nih.gov/19839592 DMW3QAK DI DMW3QAK DMW3QAK DN NSC-654077 DMW3QAK TI TTHQPL7 DMW3QAK TN Carbonic anhydrase I (CA-I) DMW3QAK MA Inhibitor DMW3QAK RN Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6. DMW3QAK RU https://pubmed.ncbi.nlm.nih.gov/18348513 DMW3QAK DI DMW3QAK DMW3QAK DN NSC-654077 DMW3QAK TI TTANPDJ DMW3QAK TN Carbonic anhydrase II (CA-II) DMW3QAK MA Inhibitor DMW3QAK RN Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6. DMW3QAK RU https://pubmed.ncbi.nlm.nih.gov/18348513 DMW3QAK DI DMW3QAK DMW3QAK DN NSC-654077 DMW3QAK TI TT2LVK8 DMW3QAK TN Carbonic anhydrase IX (CA-IX) DMW3QAK MA Inhibitor DMW3QAK RN Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6. DMW3QAK RU https://pubmed.ncbi.nlm.nih.gov/18348513 DMW3RJL DI DMW3RJL DMW3RJL DN (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n DMW3RJL TI TT8DBY3 DMW3RJL TN Angiotensin II receptor type-1 (AGTR1) DMW3RJL MA Antagonist DMW3RJL RN Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter. J Pharmacol Exp Ther. 1999 Nov;291(2):648-54. DMW3RJL RU https://pubmed.ncbi.nlm.nih.gov/10525084 DMW3RLB DI DMW3RLB DMW3RLB DN CL-301 DMW3RLB TI TTS087L DMW3RLB TN Solute carrier family 12 member 1 (SLC12A1) DMW3RLB MA Modulator DMW3RLB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 969). DMW3RLB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=969 DMW3UHO DI DMW3UHO DMW3UHO DN PMID22533316C4 DMW3UHO TI TT7O8ZA DMW3UHO TN Lanosterol synthase (LSS) DMW3UHO MA Inhibitor DMW3UHO RN Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002. DMW3UHO RU https://pubmed.ncbi.nlm.nih.gov/22533316 DMW40NK DI DMW40NK DMW40NK DN ISIS 17252 DMW40NK TI TT7A1BO DMW40NK TN PKC-delta messenger RNA (PRKCD mRNA) DMW40NK RN US patent application no. 6,235,723, Antisense oligonucleotide modulation of human protein kinase C-.delta. expression. DMW40NK RU http://www.patentbuddy.com/Patent/6235723?ft=true&sr=true DMW437Z DI DMW437Z DMW437Z DN NSC-623548 DMW437Z TI TT6VZ78 DMW437Z TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMW437Z MA Inhibitor DMW437Z RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMW437Z RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMW437Z DI DMW437Z DMW437Z DN NSC-623548 DMW437Z TI TTHVCUP DMW437Z TN DNA [cytosine-5]-methyltransferase (DNMT) DMW437Z MA Inhibitor DMW437Z RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMW437Z RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMW45GK DI DMW45GK DMW45GK DN APNEA DMW45GK TI TTNE7KG DMW45GK TN Adenosine A2b receptor (ADORA2B) DMW45GK MA Agonist DMW45GK RN Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem Pharmacol. 1999 Jan 1;57(1):65-75. DMW45GK RU https://pubmed.ncbi.nlm.nih.gov/9920286 DMW460V DI DMW460V DMW460V DN N-(14-methylallyl)norgalanthamine DMW460V TI TT1RS9F DMW460V TN Acetylcholinesterase (AChE) DMW460V MA Inhibitor DMW460V RN N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum. Bioorg Med Chem Lett. 2008 Apr 1;18(7):2263-6. DMW460V RU https://pubmed.ncbi.nlm.nih.gov/18356045 DMW46GY DI DMW46GY DMW46GY DN CAMBINOL DMW46GY TI TTUF2HO DMW46GY TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMW46GY MA Inhibitor DMW46GY RN Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem. 2009 May 14;52(9):2673-82. DMW46GY RU https://pubmed.ncbi.nlm.nih.gov/19419202 DMW46K7 DI DMW46K7 DMW46K7 DN 4-Phenylspiro[chromene-2,4'-piperidine] DMW46K7 TI TTQW87Y DMW46K7 TN Opioid receptor kappa (OPRK1) DMW46K7 MA Inhibitor DMW46K7 RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DMW46K7 RU https://pubmed.ncbi.nlm.nih.gov/18788723 DMW46K7 DI DMW46K7 DMW46K7 DN 4-Phenylspiro[chromene-2,4'-piperidine] DMW46K7 TI TT27RFC DMW46K7 TN Opioid receptor delta (OPRD1) DMW46K7 MA Inhibitor DMW46K7 RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DMW46K7 RU https://pubmed.ncbi.nlm.nih.gov/18788723 DMW46K7 DI DMW46K7 DMW46K7 DN 4-Phenylspiro[chromene-2,4'-piperidine] DMW46K7 TI TTQ6VDM DMW46K7 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMW46K7 MA Inhibitor DMW46K7 RN Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6. DMW46K7 RU https://pubmed.ncbi.nlm.nih.gov/18788723 DMW47VA DI DMW47VA DMW47VA DN 2-(N-tert-Butylamino)-3'-chlorooctanophenone DMW47VA TI TTAWNKZ DMW47VA TN Norepinephrine transporter (NET) DMW47VA MA Inhibitor DMW47VA RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMW47VA RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMW47VA DI DMW47VA DMW47VA DN 2-(N-tert-Butylamino)-3'-chlorooctanophenone DMW47VA TI TTVBI8W DMW47VA TN Dopamine transporter (DAT) DMW47VA MA Inhibitor DMW47VA RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMW47VA RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMW4850 DI DMW4850 DMW4850 DN RY796 DMW4850 TI TT5PFNG DMW4850 TN Voltage-gated potassium channel Kv2.2 (KCNB2) DMW4850 MA Inhibitor (gating inhibitor) DMW4850 RN Identification of novel and selective Kv2 channel inhibitors. Mol Pharmacol. 2011 Dec;80(6):959-64. DMW4850 RU https://pubmed.ncbi.nlm.nih.gov/21948463 DMW4850 DI DMW4850 DMW4850 DN RY796 DMW4850 TI TT5OEKU DMW4850 TN Voltage-gated potassium channel Kv2.1 (KCNB1) DMW4850 MA Inhibitor (gating inhibitor) DMW4850 RN Identification of novel and selective Kv2 channel inhibitors. Mol Pharmacol. 2011 Dec;80(6):959-64. DMW4850 RU https://pubmed.ncbi.nlm.nih.gov/21948463 DMW48JD DI DMW48JD DMW48JD DN Spiro[pyrrolidine-2,2-adamantane] DMW48JD TI TTXT3PU DMW48JD TN Influenza M2 protein (Influ M) DMW48JD MA Inhibitor DMW48JD RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMW48JD RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMW4ARM DI DMW4ARM DMW4ARM DN (2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine DMW4ARM TI TTJQOD7 DMW4ARM TN 5-HT 2A receptor (HTR2A) DMW4ARM MA Inhibitor DMW4ARM RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DMW4ARM RU https://pubmed.ncbi.nlm.nih.gov/18035544 DMW4ARM DI DMW4ARM DMW4ARM DN (2S)-1-(5-fluoro-1H-indazol-1-yl)propan-2-amine DMW4ARM TI TTWJBZ5 DMW4ARM TN 5-HT 2C receptor (HTR2C) DMW4ARM MA Inhibitor DMW4ARM RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DMW4ARM RU https://pubmed.ncbi.nlm.nih.gov/18035544 DMW4KXQ DI DMW4KXQ DMW4KXQ DN 4-phospho-D-erythronate DMW4KXQ TI TTZ3IFB DMW4KXQ TN Phosphogluconate dehydrogenase (PGD) DMW4KXQ MA Inhibitor DMW4KXQ RN Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorg Med Chem. 2010 Jul 15;18(14):5056-62. DMW4KXQ RU https://pubmed.ncbi.nlm.nih.gov/20598892 DMW4L3K DI DMW4L3K DMW4L3K DN ICI-198583 DMW4L3K TI TT5FOMZ DMW4L3K TN Thymidylate synthase (TYMS) DMW4L3K MA Modulator DMW4L3K RN The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol. 1991 Oct 24;42(10):1885-95. DMW4L3K RU https://www.ncbi.nlm.nih.gov/pubmed/1741766 DMW4O31 DI DMW4O31 DMW4O31 DN 4-(furan-3-yl)-2,6-di(thiophen-2-yl)pyridine DMW4O31 TI TT0IHXV DMW4O31 TN DNA topoisomerase II (TOP2) DMW4O31 MA Inhibitor DMW4O31 RN 2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study. Bioorg Med Chem Lett. 2010 Jan 1;20(1):42-7. DMW4O31 RU https://pubmed.ncbi.nlm.nih.gov/19954977 DMW4XKQ DI DMW4XKQ DMW4XKQ DN 7-nitro-1H-indazole DMW4XKQ TI TTF10I9 DMW4XKQ TN Nitric-oxide synthase inducible (NOS2) DMW4XKQ MA Inhibitor DMW4XKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW4XKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW4XKQ DI DMW4XKQ DMW4XKQ DN 7-nitro-1H-indazole DMW4XKQ TI TTCM4B3 DMW4XKQ TN Nitric-oxide synthase endothelial (NOS3) DMW4XKQ MA Inhibitor DMW4XKQ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW4XKQ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMW4XKQ DI DMW4XKQ DMW4XKQ DN 7-nitro-1H-indazole DMW4XKQ TI TTZUFI5 DMW4XKQ TN Nitric-oxide synthase brain (NOS1) DMW4XKQ MA Inhibitor DMW4XKQ RN Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7. DMW4XKQ RU https://pubmed.ncbi.nlm.nih.gov/19679481 DMW50ZQ DI DMW50ZQ DMW50ZQ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo DMW50ZQ TI TT27RFC DMW50ZQ TN Opioid receptor delta (OPRD1) DMW50ZQ MA Inhibitor DMW50ZQ RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMW50ZQ RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMW50ZQ DI DMW50ZQ DMW50ZQ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo DMW50ZQ TI TTVFO0U DMW50ZQ TN Gastrin/cholecystokinin type B receptor (CCKBR) DMW50ZQ MA Inhibitor DMW50ZQ RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMW50ZQ RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMW50ZQ DI DMW50ZQ DMW50ZQ DN H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo DMW50ZQ TI TTKWM86 DMW50ZQ TN Opioid receptor mu (MOP) DMW50ZQ MA Inhibitor DMW50ZQ RN Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8. DMW50ZQ RU https://pubmed.ncbi.nlm.nih.gov/17201419 DMW56NI DI DMW56NI DMW56NI DN Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF DMW56NI TI TTIND6G DMW56NI TN Somatostatin receptor type 1 (SSTR1) DMW56NI MA Inhibitor DMW56NI RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMW56NI RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMW56NI DI DMW56NI DMW56NI DN Des-AA1,5-[Tyr2,D-Trp8,(NalphaMe)IAmp9]SRIF DMW56NI TI TTAE1BR DMW56NI TN Somatostatin receptor type 4 (SSTR4) DMW56NI MA Inhibitor DMW56NI RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMW56NI RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMW579R DI DMW579R DMW579R DN PMID23083103C4 DMW579R TI TTZ1DT0 DMW579R TN P2Y purinoceptor 12 (P2RY12) DMW579R MA Antagonist DMW579R RN Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec;10(12):2573-80. DMW579R RU https://pubmed.ncbi.nlm.nih.gov/23083103 DMW59AY DI DMW59AY DMW59AY DN N-(3-(3-aminopropyl)phenyl)benzenesulfonamide DMW59AY TI TTJS8PY DMW59AY TN 5-HT 6 receptor (HTR6) DMW59AY MA Inhibitor DMW59AY RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMW59AY RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMW59XA DI DMW59XA DMW59XA DN 1-benzyl-3,3-dimethylazetidine-2,4-dione DMW59XA TI TTPLTSQ DMW59XA TN Neutrophil elastase (NE) DMW59XA MA Inhibitor DMW59XA RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMW59XA RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMW5AXC DI DMW5AXC DMW5AXC DN MERIOLIN 6 DMW5AXC TI TT1LVF2 DMW5AXC TN Cyclin-dependent kinase 9 (CDK9) DMW5AXC MA Inhibitor DMW5AXC RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMW5AXC RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMW5AXC DI DMW5AXC DMW5AXC DN MERIOLIN 6 DMW5AXC TI TTAMQ62 DMW5AXC TN Cyclin A2 (CCNA2) DMW5AXC MA Inhibitor DMW5AXC RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMW5AXC RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMW5AXC DI DMW5AXC DMW5AXC DN MERIOLIN 6 DMW5AXC TI TT7HF4W DMW5AXC TN Cyclin-dependent kinase 2 (CDK2) DMW5AXC MA Inhibitor DMW5AXC RN Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin com... J Med Chem. 2008 Feb 28;51(4):737-51. DMW5AXC RU https://pubmed.ncbi.nlm.nih.gov/18232649 DMW5HO0 DI DMW5HO0 DMW5HO0 DN AdoC(Ahx)Arg6 DMW5HO0 TI TTW4Y2M DMW5HO0 TN cAMP protein kinase type II-beta (PRKAR2B) DMW5HO0 MA Inhibitor DMW5HO0 RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMW5HO0 RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMW5HO0 DI DMW5HO0 DMW5HO0 DN AdoC(Ahx)Arg6 DMW5HO0 TI TTNAHEX DMW5HO0 TN cAMP-dependent protein kinase A type I (PRKAR1A) DMW5HO0 MA Inhibitor DMW5HO0 RN Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52. DMW5HO0 RU https://pubmed.ncbi.nlm.nih.gov/10360754 DMW5SIQ DI DMW5SIQ DMW5SIQ DN SEMIPLENAMIDE A DMW5SIQ TI TT6OEDT DMW5SIQ TN Cannabinoid receptor 1 (CB1) DMW5SIQ MA Inhibitor DMW5SIQ RN Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J Nat Prod. 2003 Oct;66(10):1364-8. DMW5SIQ RU https://pubmed.ncbi.nlm.nih.gov/14575438 DMW5V9U DI DMW5V9U DMW5V9U DN FMP-825 DMW5V9U TI TTMXGCW DMW5V9U TN Adrenergic receptor beta-3 (ADRB3) DMW5V9U MA Agonist DMW5V9U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 30). DMW5V9U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=30 DMW5XLG DI DMW5XLG DMW5XLG DN N-(2-benzyloxy-4-nitrophenyl)methanesulfonamide DMW5XLG TI TTSZLWK DMW5XLG TN Aromatase (CYP19A1) DMW5XLG MA Inhibitor DMW5XLG RN Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem. 2007 Apr 5;50(7):1635-44. DMW5XLG RU https://pubmed.ncbi.nlm.nih.gov/17315855 DMW5ZK7 DI DMW5ZK7 DMW5ZK7 DN (S)-N2-[4-(benzyloxy)benzyl]serinamide DMW5ZK7 TI TTGP7BY DMW5ZK7 TN Monoamine oxidase type B (MAO-B) DMW5ZK7 MA Inhibitor DMW5ZK7 RN Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoa... J Med Chem. 2007 Oct 4;50(20):4909-16. DMW5ZK7 RU https://pubmed.ncbi.nlm.nih.gov/17824599 DMW613U DI DMW613U DMW613U DN 1,9-dideoxyforskolin DMW613U TI TT0FC1V DMW613U TN Volume regulated chloride channel (VRAC) DMW613U MA Blocker (channel blocker) DMW613U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 710). DMW613U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=710 DMW61UK DI DMW61UK DMW61UK DN CRX-526 DMW61UK TI TTISGCA DMW61UK TN Toll-like receptor 4 (TLR4) DMW61UK MA Inhibitor DMW61UK RN The 'Ethereal' nature of TLR4 agonism and antagonism in the AGP class of lipid A mimetics. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5350-4. DMW61UK RU https://pubmed.ncbi.nlm.nih.gov/18835160 DMW625B DI DMW625B DMW625B DN BAY-85-3474 DMW625B TI TTNDSF4 DMW625B TN Proto-oncogene c-Met (MET) DMW625B MA Inhibitor DMW625B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMW625B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMW62U8 DI DMW62U8 DMW62U8 DN 3-(4-Amino-phenyl)-3-hexyl-piperidine-2,6-dione DMW62U8 TI TTSZLWK DMW62U8 TN Aromatase (CYP19A1) DMW62U8 MA Inhibitor DMW62U8 RN Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9. DMW62U8 RU https://pubmed.ncbi.nlm.nih.gov/3735304 DMW6320 DI DMW6320 DMW6320 DN 6-Chloro-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole DMW6320 TI TTJQOD7 DMW6320 TN 5-HT 2A receptor (HTR2A) DMW6320 MA Inhibitor DMW6320 RN Evaluation of isotryptamine derivatives at 5-HT(2) serotonin receptors. Bioorg Med Chem Lett. 2002 Jan 21;12(2):155-8. DMW6320 RU https://pubmed.ncbi.nlm.nih.gov/11755343 DMW6CQV DI DMW6CQV DMW6CQV DN 1,1,1-trifluorododecan-2-one DMW6CQV TI TTDP1UC DMW6CQV TN Fatty acid amide hydrolase (FAAH) DMW6CQV MA Inhibitor DMW6CQV RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMW6CQV RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMW6CQV DI DMW6CQV DMW6CQV DN 1,1,1-trifluorododecan-2-one DMW6CQV TI TTMF541 DMW6CQV TN Liver carboxylesterase (CES1) DMW6CQV MA Inhibitor DMW6CQV RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMW6CQV RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMW6K80 DI DMW6K80 DMW6K80 DN Oximidine II DMW6K80 TI TTTK3BH DMW6K80 TN Vacuolar-type proton ATPase (v-ATPase) DMW6K80 MA Inhibitor DMW6K80 RN Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001 Apr;297(1):114-20. DMW6K80 RU https://pubmed.ncbi.nlm.nih.gov/11259534 DMW6L38 DI DMW6L38 DMW6L38 DN 2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol DMW6L38 TI TTOM3J0 DMW6L38 TN Estrogen receptor beta (ESR2) DMW6L38 MA Inhibitor DMW6L38 RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMW6L38 RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMW6L38 DI DMW6L38 DMW6L38 DN 2-(4-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol DMW6L38 TI TTZAYWL DMW6L38 TN Estrogen receptor (ESR) DMW6L38 MA Inhibitor DMW6L38 RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMW6L38 RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMW6LCH DI DMW6LCH DMW6LCH DN 7-(3-methoxyphenyl)-2-methylquinoline DMW6LCH TI TTHS256 DMW6LCH TN Metabotropic glutamate receptor 5 (mGluR5) DMW6LCH MA Inhibitor DMW6LCH RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMW6LCH RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMW6LIJ DI DMW6LIJ DMW6LIJ DN [N-Ac,des-Sar]Gal-B2 DMW6LIJ TI TTX3HNZ DMW6LIJ TN Galanin receptor type 1 (GAL1-R) DMW6LIJ MA Inhibitor DMW6LIJ RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMW6LIJ RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMW6LIJ DI DMW6LIJ DMW6LIJ DN [N-Ac,des-Sar]Gal-B2 DMW6LIJ TI TTBPW3J DMW6LIJ TN Galanin receptor type 2 (GAL2-R) DMW6LIJ MA Inhibitor DMW6LIJ RN Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic de... J Med Chem. 2010 Feb 25;53(4):1871-5. DMW6LIJ RU https://pubmed.ncbi.nlm.nih.gov/20121116 DMW6P4A DI DMW6P4A DMW6P4A DN casp 4 inhib DMW6P4A TI TT3VZ8D DMW6P4A TN Caspase-4 (CASP4) DMW6P4A MA Inhibitor DMW6P4A RN Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001 Jun 7;44(12):2015-26. DMW6P4A RU https://pubmed.ncbi.nlm.nih.gov/11384246 DMW6U7K DI DMW6U7K DMW6U7K DN CHOLINE IODIDE DMW6U7K TI TT1RS9F DMW6U7K TN Acetylcholinesterase (AChE) DMW6U7K MA Inhibitor DMW6U7K RN Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors. J Med Chem. 1996 Dec 20;39(26):5064-71. DMW6U7K RU https://pubmed.ncbi.nlm.nih.gov/8978837 DMW6YDK DI DMW6YDK DMW6YDK DN 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one DMW6YDK TI TTVBI8W DMW6YDK TN Dopamine transporter (DAT) DMW6YDK MA Inhibitor DMW6YDK RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMW6YDK RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMW6YDK DI DMW6YDK DMW6YDK DN 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one DMW6YDK TI TT3ROYC DMW6YDK TN Serotonin transporter (SERT) DMW6YDK MA Inhibitor DMW6YDK RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMW6YDK RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMW6YDK DI DMW6YDK DMW6YDK DN 1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one DMW6YDK TI TTAWNKZ DMW6YDK TN Norepinephrine transporter (NET) DMW6YDK MA Inhibitor DMW6YDK RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMW6YDK RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMW6YLS DI DMW6YLS DMW6YLS DN Deoxycorticosterone DMW6YLS TI TTOZRK6 DMW6YLS TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMW6YLS MA Agonist DMW6YLS RN Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. J Biol Chem. 2000Jun 23;275(25):19041-9. DMW6YLS RU https://pubmed.ncbi.nlm.nih.gov/10747884 DMW6YLS DI DMW6YLS DMW6YLS DN Deoxycorticosterone DMW6YLS TI TT26PHO DMW6YLS TN Mineralocorticoid receptor (MR) DMW6YLS MA Agonist DMW6YLS RN Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145-54. DMW6YLS RU https://pubmed.ncbi.nlm.nih.gov/8282004 DMW704S DI DMW704S DMW704S DN KKHT-10618 DMW704S TI TT729IR DMW704S TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMW704S MA Inhibitor DMW704S RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DMW704S RU https://pubmed.ncbi.nlm.nih.gov/17035033 DMW73A8 DI DMW73A8 DMW73A8 DN AA-123 DMW73A8 TI TTGKF90 DMW73A8 TN Bone morphogenetic protein receptor (BMPR2) DMW73A8 MA Agonist DMW73A8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1794). DMW73A8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1794 DMW740T DI DMW740T DMW740T DN desulfated cholecystokinin-8 DMW740T TI TTVFO0U DMW740T TN Gastrin/cholecystokinin type B receptor (CCKBR) DMW740T MA Agonist DMW740T RN The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem. 1993 Apr 15;268(11):8164-9. DMW740T RU https://pubmed.ncbi.nlm.nih.gov/7681836 DMW75IF DI DMW75IF DMW75IF DN 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide DMW75IF TI TTQW87Y DMW75IF TN Opioid receptor kappa (OPRK1) DMW75IF MA Inhibitor DMW75IF RN Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic ... Bioorg Med Chem. 2009 Aug 15;17(16):5782-90. DMW75IF RU https://pubmed.ncbi.nlm.nih.gov/19640720 DMW75IF DI DMW75IF DMW75IF DN 2-(2-methylquinolin-4-ylamino)-N-phenylacetamide DMW75IF TI TTKWM86 DMW75IF TN Opioid receptor mu (MOP) DMW75IF MA Inhibitor DMW75IF RN Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic ... Bioorg Med Chem. 2009 Aug 15;17(16):5782-90. DMW75IF RU https://pubmed.ncbi.nlm.nih.gov/19640720 DMW7BZT DI DMW7BZT DMW7BZT DN N-Butylcarbamic Acid Biphenyl-3-yl Ester DMW7BZT TI TTDP1UC DMW7BZT TN Fatty acid amide hydrolase (FAAH) DMW7BZT MA Inhibitor DMW7BZT RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMW7BZT RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMW7E32 DI DMW7E32 DMW7E32 DN SHA 68 DMW7E32 TI TTV1C0Z DMW7E32 TN Neuropeptide S receptor (NPSR) DMW7E32 MA Antagonist DMW7E32 RN Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides. 2010 May;31(5):915-25. DMW7E32 RU https://pubmed.ncbi.nlm.nih.gov/20172007 DMW7H28 DI DMW7H28 DMW7H28 DN AG-09/1 DMW7H28 TI TT5Y4EM DMW7H28 TN N-formyl peptide receptor (FPR1) DMW7H28 MA Agonist DMW7H28 RN Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition. Mol Pharmacol. 2010 Feb;77(2):159-70. DMW7H28 RU https://pubmed.ncbi.nlm.nih.gov/19903830 DMW7IXL DI DMW7IXL DMW7IXL DN 5-methoxy-2-(4-aminophenyl)benzofuran DMW7IXL TI TTE4KHA DMW7IXL TN Amyloid beta A4 protein (APP) DMW7IXL MA Inhibitor DMW7IXL RN Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. DMW7IXL RU https://pubmed.ncbi.nlm.nih.gov/16640332 DMW7K5P DI DMW7K5P DMW7K5P DN 6,7-Dimethoxy-3-pyridin-4-yl-quinoline DMW7K5P TI TTI7421 DMW7K5P TN Platelet-derived growth factor receptor beta (PDGFRB) DMW7K5P MA Inhibitor DMW7K5P RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DMW7K5P RU https://pubmed.ncbi.nlm.nih.gov/8064792 DMW7K5P DI DMW7K5P DMW7K5P DN 6,7-Dimethoxy-3-pyridin-4-yl-quinoline DMW7K5P TI TT8FYO9 DMW7K5P TN Platelet-derived growth factor receptor alpha (PDGFRA) DMW7K5P MA Inhibitor DMW7K5P RN 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9. DMW7K5P RU https://pubmed.ncbi.nlm.nih.gov/8064792 DMW7N3H DI DMW7N3H DMW7N3H DN 2-Amino-1-(4-methylthiophenyl)butane DMW7N3H TI TT3ROYC DMW7N3H TN Serotonin transporter (SERT) DMW7N3H MA Inhibitor DMW7N3H RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMW7N3H RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMW7PQ8 DI DMW7PQ8 DMW7PQ8 DN PMID18445527C11 DMW7PQ8 TI TTA93TL DMW7PQ8 TN P2Y purinoceptor 1 (P2RY1) DMW7PQ8 MA Antagonist DMW7PQ8 RN P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3338-43. DMW7PQ8 RU https://pubmed.ncbi.nlm.nih.gov/18445527 DMW7XFQ DI DMW7XFQ DMW7XFQ DN 3,3'-Thiene-2,4-diyldiphenol DMW7XFQ TI TTIWB6L DMW7XFQ TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMW7XFQ MA Inhibitor DMW7XFQ RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DMW7XFQ RU https://pubmed.ncbi.nlm.nih.gov/18855374 DMW7XN5 DI DMW7XN5 DMW7XN5 DN 3-(1H-Indol-3-yl)-quinoline DMW7XN5 TI TTI7421 DMW7XN5 TN Platelet-derived growth factor receptor beta (PDGFRB) DMW7XN5 MA Inhibitor DMW7XN5 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMW7XN5 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMW7XN5 DI DMW7XN5 DMW7XN5 DN 3-(1H-Indol-3-yl)-quinoline DMW7XN5 TI TT8FYO9 DMW7XN5 TN Platelet-derived growth factor receptor alpha (PDGFRA) DMW7XN5 MA Inhibitor DMW7XN5 RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMW7XN5 RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMW7Y9L DI DMW7Y9L DMW7Y9L DN SQ-24798 DMW7Y9L TI TTP18AY DMW7Y9L TN Carboxypeptidase B2 (CPB2) DMW7Y9L MA Inhibitor DMW7Y9L RN 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54. DMW7Y9L RU https://pubmed.ncbi.nlm.nih.gov/17189688 DMW7YHS DI DMW7YHS DMW7YHS DN 4-Methyl-6-(2-methylprop-1-enyl)pyridin-2-amine DMW7YHS TI TTF10I9 DMW7YHS TN Nitric-oxide synthase inducible (NOS2) DMW7YHS MA Inhibitor DMW7YHS RN Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53. DMW7YHS RU https://pubmed.ncbi.nlm.nih.gov/19323559 DMW7ZF8 DI DMW7ZF8 DMW7ZF8 DN MCL-144 DMW7ZF8 TI TTKWM86 DMW7ZF8 TN Opioid receptor mu (MOP) DMW7ZF8 MA Inhibitor DMW7ZF8 RN Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96. DMW7ZF8 RU https://pubmed.ncbi.nlm.nih.gov/19634902 DMW7ZF8 DI DMW7ZF8 DMW7ZF8 DN MCL-144 DMW7ZF8 TI TT27RFC DMW7ZF8 TN Opioid receptor delta (OPRD1) DMW7ZF8 MA Inhibitor DMW7ZF8 RN Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96. DMW7ZF8 RU https://pubmed.ncbi.nlm.nih.gov/19634902 DMW7ZF8 DI DMW7ZF8 DMW7ZF8 DN MCL-144 DMW7ZF8 TI TTQW87Y DMW7ZF8 TN Opioid receptor kappa (OPRK1) DMW7ZF8 MA Inhibitor DMW7ZF8 RN Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96. DMW7ZF8 RU https://pubmed.ncbi.nlm.nih.gov/19634902 DMW82SA DI DMW82SA DMW82SA DN NSC-154957 DMW82SA TI TT6VZ78 DMW82SA TN DNA [cytosine-5]-methyltransferase 3B (DNMT3B) DMW82SA MA Inhibitor DMW82SA RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMW82SA RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMW82SA DI DMW82SA DMW82SA DN NSC-154957 DMW82SA TI TTHVCUP DMW82SA TN DNA [cytosine-5]-methyltransferase (DNMT) DMW82SA MA Inhibitor DMW82SA RN Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem. 2010 Jan 15;18(2):822-9. DMW82SA RU https://pubmed.ncbi.nlm.nih.gov/20006515 DMW82ZT DI DMW82ZT DMW82ZT DN [Val4]AVP DMW82ZT TI TTL9MHW DMW82ZT TN Vasopressin V1b receptor (V1BR) DMW82ZT MA Agonist DMW82ZT RN [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology. 2002 Dec;143(12):4655-64. DMW82ZT RU https://pubmed.ncbi.nlm.nih.gov/12446593 DMW82ZT DI DMW82ZT DMW82ZT DN [Val4]AVP DMW82ZT TI TT4TFGN DMW82ZT TN Vasopressin V1a receptor (V1AR) DMW82ZT MA Agonist DMW82ZT RN [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology. 2002 Dec;143(12):4655-64. DMW82ZT RU https://pubmed.ncbi.nlm.nih.gov/12446593 DMW82ZT DI DMW82ZT DMW82ZT DN [Val4]AVP DMW82ZT TI TTK8R02 DMW82ZT TN Vasopressin V2 receptor (V2R) DMW82ZT MA Agonist DMW82ZT RN [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors. Endocrinology. 2002 Dec;143(12):4655-64. DMW82ZT RU https://pubmed.ncbi.nlm.nih.gov/12446593 DMW85CH DI DMW85CH DMW85CH DN 1-(1-Biphenyl-4-yl-ethyl)-1H-imidazole DMW85CH TI TTRA5BZ DMW85CH TN Steroid 17-alpha-monooxygenase (S17AH) DMW85CH MA Inhibitor DMW85CH RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMW85CH RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMW85FP DI DMW85FP DMW85FP DN Anti-EGFR mab DMW85FP TI TTGKNB4 DMW85FP TN Epidermal growth factor receptor (EGFR) DMW85FP RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMW85FP RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMW87OE DI DMW87OE DMW87OE DN (R)-5-Amino-3-(4-chloro-phenyl)-pentanoic acid DMW87OE TI TTDCVZW DMW87OE TN Gamma-aminobutyric acid B receptor (GABBR) DMW87OE MA Inhibitor DMW87OE RN Synthesis and pharmacology of the baclofen homologues 5-amino-4-(4-chlorophenyl)pentanoic acid and the R- and S-enantiomers of 5-amino-3-(4-chlorop... J Med Chem. 1999 Jun 3;42(11):2053-9. DMW87OE RU https://pubmed.ncbi.nlm.nih.gov/10354414 DMW8AOM DI DMW8AOM DMW8AOM DN 5-Indan-(1E)-ylidenemethyl-1H-imidazole DMW8AOM TI TTSZLWK DMW8AOM TN Aromatase (CYP19A1) DMW8AOM MA Inhibitor DMW8AOM RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMW8AOM RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMW8AOM DI DMW8AOM DMW8AOM DN 5-Indan-(1E)-ylidenemethyl-1H-imidazole DMW8AOM TI TTIQUX7 DMW8AOM TN Steroid 11-beta-hydroxylase (CYP11B1) DMW8AOM MA Inhibitor DMW8AOM RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMW8AOM RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMW8BXG DI DMW8BXG DMW8BXG DN Naphthalen-2-yl(10H-phenothiazin-10-yl)methanone DMW8BXG TI TTEB0GD DMW8BXG TN Cholinesterase (BCHE) DMW8BXG MA Inhibitor DMW8BXG RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMW8BXG RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMW8GIT DI DMW8GIT DMW8GIT DN ISIS 103387 DMW8GIT TI TTK0TF2 DMW8GIT TN DUSP8 messenger RNA (DUSP8 mRNA) DMW8GIT RN US patent application no. 6,482,644, Antisense modulation of dual specific phosphatase 8 expression. DMW8GIT RU http://www.patentbuddy.com/Patent/6482644?ft=true&sr=true DMW8IN3 DI DMW8IN3 DMW8IN3 DN 4-(4-FLUOROBENZYL)PIPERIDINE DMW8IN3 TI TT8JRS7 DMW8IN3 TN Beta-secretase (BACE) DMW8IN3 MA Inhibitor DMW8IN3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMW8IN3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMW8ORN DI DMW8ORN DMW8ORN DN DR-4004 DMW8ORN TI TTO9X1H DMW8ORN TN 5-HT 7 receptor (HTR7) DMW8ORN MA Antagonist DMW8ORN RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMW8ORN RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMW8RLN DI DMW8RLN DMW8RLN DN 5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole DMW8RLN TI TTRA5BZ DMW8RLN TN Steroid 17-alpha-monooxygenase (S17AH) DMW8RLN MA Inhibitor DMW8RLN RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMW8RLN RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMW8RLN DI DMW8RLN DMW8RLN DN 5-[4-(Pyridin-4-ylmethyl)phenyl]-1H-indole DMW8RLN TI TTIQUX7 DMW8RLN TN Steroid 11-beta-hydroxylase (CYP11B1) DMW8RLN MA Inhibitor DMW8RLN RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMW8RLN RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMW8S2D DI DMW8S2D DMW8S2D DN N-(4-cyanophenyl)sulfamide DMW8S2D TI TT2LVK8 DMW8S2D TN Carbonic anhydrase IX (CA-IX) DMW8S2D MA Inhibitor DMW8S2D RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DMW8S2D RU https://pubmed.ncbi.nlm.nih.gov/15837324 DMW8S2D DI DMW8S2D DMW8S2D DN N-(4-cyanophenyl)sulfamide DMW8S2D TI TTSYM0R DMW8S2D TN Carbonic anhydrase XII (CA-XII) DMW8S2D MA Inhibitor DMW8S2D RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DMW8S2D RU https://pubmed.ncbi.nlm.nih.gov/15837324 DMW8S2D DI DMW8S2D DMW8S2D DN N-(4-cyanophenyl)sulfamide DMW8S2D TI TTANPDJ DMW8S2D TN Carbonic anhydrase II (CA-II) DMW8S2D MA Inhibitor DMW8S2D RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DMW8S2D RU https://pubmed.ncbi.nlm.nih.gov/15837324 DMW8S2D DI DMW8S2D DMW8S2D DN N-(4-cyanophenyl)sulfamide DMW8S2D TI TTHQPL7 DMW8S2D TN Carbonic anhydrase I (CA-I) DMW8S2D MA Inhibitor DMW8S2D RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with N-hydroxy... Bioorg Med Chem Lett. 2005 May 2;15(9):2353-8. DMW8S2D RU https://pubmed.ncbi.nlm.nih.gov/15837324 DMW8XME DI DMW8XME DMW8XME DN 7-Pyridin-3-yl-2H-1,4-benzothiazin-3(4H)-one DMW8XME TI TTIQUX7 DMW8XME TN Steroid 11-beta-hydroxylase (CYP11B1) DMW8XME MA Inhibitor DMW8XME RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMW8XME RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMW8YDR DI DMW8YDR DMW8YDR DN GR138676 DMW8YDR TI TTBPGLU DMW8YDR TN Neuromedin-K receptor (TACR3) DMW8YDR MA Antagonist DMW8YDR RN GR138676, a novel peptidic tachykinin antagonist which is potent at NK3 receptors. Neuropeptides. 1994 Dec;27(6):333-41. DMW8YDR RU https://pubmed.ncbi.nlm.nih.gov/7534879 DMW905K DI DMW905K DMW905K DN 9-mercapto-8-oxo-N-phenylnonanamide DMW905K TI TTT6LFV DMW905K TN Histone deacetylase 8 (HDAC8) DMW905K MA Inhibitor DMW905K RN Histone deacetylase inhibitors: from bench to clinic. J Med Chem. 2008 Mar 27;51(6):1505-29. DMW905K RU https://pubmed.ncbi.nlm.nih.gov/18247554 DMW90GD DI DMW90GD DMW90GD DN PMID1656041C4ff DMW90GD TI TTPADOQ DMW90GD TN HMG-CoA reductase (HMGCR) DMW90GD MA Inhibitor DMW90GD RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83. DMW90GD RU https://pubmed.ncbi.nlm.nih.gov/1656041 DMW93IO DI DMW93IO DMW93IO DN GNF-PF-2322 DMW93IO TI TTX4RTB DMW93IO TN Melanin-concentrating hormone receptor 1 (MCHR1) DMW93IO MA Inhibitor DMW93IO RN 6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and ... J Med Chem. 2005 Sep 8;48(18):5684-97. DMW93IO RU https://pubmed.ncbi.nlm.nih.gov/16134937 DMW9AN1 DI DMW9AN1 DMW9AN1 DN GSK-9578 DMW9AN1 TI TTJ584C DMW9AN1 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMW9AN1 MA Inhibitor DMW9AN1 RN Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42. DMW9AN1 RU https://pubmed.ncbi.nlm.nih.gov/10828060 DMW9AST DI DMW9AST DMW9AST DN [N-[2-[(3'-N'-PROPYL-3''ALPHA-(BIS(4-FLUORORPHENYL)METHOXY)TROPANE-2''BETA-CARBOXYLIC ACID METHYL ESTER)(2-MERCAPTOETHYL)AMINO]ACETYL]-2-AMINOETHANETHIOLATO]RHENIUM(V) OXIDE (DIASTEREOMERIC MIX) DMW9AST TI TTVBI8W DMW9AST TN Dopamine transporter (DAT) DMW9AST MA Inhibitor DMW9AST RN A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem. 1997 Jun 6;40(12):1835-44. DMW9AST RU https://pubmed.ncbi.nlm.nih.gov/9191960 DMW9CRT DI DMW9CRT DMW9CRT DN 1-Phenyl-2-p-tolyl-ethane-1,2-dione DMW9CRT TI TTMF541 DMW9CRT TN Liver carboxylesterase (CES1) DMW9CRT MA Inhibitor DMW9CRT RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMW9CRT RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMW9D30 DI DMW9D30 DMW9D30 DN 5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one DMW9D30 TI TT6OEDT DMW9D30 TN Cannabinoid receptor 1 (CB1) DMW9D30 MA Inhibitor DMW9D30 RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMW9D30 RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMW9D30 DI DMW9D30 DMW9D30 DN 5-Methoxy-3-(2-methoxybenzyl)-2H-chromen-2-one DMW9D30 TI TTMSFAW DMW9D30 TN Cannabinoid receptor 2 (CB2) DMW9D30 MA Inhibitor DMW9D30 RN Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. DMW9D30 RU https://pubmed.ncbi.nlm.nih.gov/19278853 DMW9ERM DI DMW9ERM DMW9ERM DN AM-1714 DMW9ERM TI TTMSFAW DMW9ERM TN Cannabinoid receptor 2 (CB2) DMW9ERM MA Inhibitor DMW9ERM RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMW9ERM RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMW9ERM DI DMW9ERM DMW9ERM DN AM-1714 DMW9ERM TI TT6OEDT DMW9ERM TN Cannabinoid receptor 1 (CB1) DMW9ERM MA Inhibitor DMW9ERM RN Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem. 2007 Dec 27;50(26):6493-500. DMW9ERM RU https://pubmed.ncbi.nlm.nih.gov/18038967 DMW9G7H DI DMW9G7H DMW9G7H DN TPN-729 DMW9G7H TI TTJ0IQB DMW9G7H TN Phosphodiesterase 5A (PDE5A) DMW9G7H MA Inhibitor DMW9G7H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1304). DMW9G7H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1304 DMW9GT7 DI DMW9GT7 DMW9GT7 DN DwLIP-GCGRrx DMW9GT7 TI TT9O6WS DMW9GT7 TN Glucagon receptor (GCGR) DMW9GT7 MA Binder DMW9GT7 RN Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). DMW9GT7 RU http://www.isispharm.com/Pipeline/index.htm DMW9HTL DI DMW9HTL DMW9HTL DN HYP-10 DMW9HTL TI TTZPWGN DMW9HTL TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMW9HTL MA Blocker DMW9HTL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536). DMW9HTL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536 DMW9I1X DI DMW9I1X DMW9I1X DN 4-Fluoren-9-ylidenemethyl-pyridine DMW9I1X TI TTSZLWK DMW9I1X TN Aromatase (CYP19A1) DMW9I1X MA Inhibitor DMW9I1X RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMW9I1X RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMW9MRO DI DMW9MRO DMW9MRO DN EGTA DMW9MRO TI TTBLN9S DMW9MRO TN Sulfur mustard-stimulated protease (SMSP) DMW9MRO MA Inhibitor DMW9MRO RN Sulfur mustard-stimulated protease: a target for antivesicant drugs. J Appl Toxicol. 2002 Mar-Apr;22(2):139-40. DMW9MRO RU https://pubmed.ncbi.nlm.nih.gov/11920939 DMW9TRD DI DMW9TRD DMW9TRD DN AMA-237 DMW9TRD TI TTGWKQJ DMW9TRD TN Rho-associated protein kinase 2 (ROCK2) DMW9TRD MA Inhibitor DMW9TRD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504). DMW9TRD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504 DMW9TRD DI DMW9TRD DMW9TRD DN AMA-237 DMW9TRD TI TTZN7RP DMW9TRD TN Rho-associated protein kinase 1 (ROCK1) DMW9TRD MA Inhibitor DMW9TRD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503). DMW9TRD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503 DMW9Z7N DI DMW9Z7N DMW9Z7N DN Lipid Fragment DMW9Z7N TI TTUTN1I DMW9Z7N TN Human Deoxyribonucleic acid (hDNA) DMW9Z7N MA Inhibitor DMW9Z7N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMW9Z7N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWA0MN DI DMWA0MN DMWA0MN DN 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine DMWA0MN TI TTJFY5U DMWA0MN TN Adenosine A3 receptor (ADORA3) DMWA0MN MA Inhibitor DMWA0MN RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMWA0MN RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMWA0MN DI DMWA0MN DMWA0MN DN 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine DMWA0MN TI TTM2AOE DMWA0MN TN Adenosine A2a receptor (ADORA2A) DMWA0MN MA Inhibitor DMWA0MN RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMWA0MN RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMWA0MN DI DMWA0MN DMWA0MN DN 2-(3''-(5''-methoxy-indolyl)ethyloxy)adenosine DMWA0MN TI TTK25J1 DMWA0MN TN Adenosine A1 receptor (ADORA1) DMWA0MN MA Inhibitor DMWA0MN RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMWA0MN RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMWA6G1 DI DMWA6G1 DMWA6G1 DN 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene DMWA6G1 TI TT8NGED DMWA6G1 TN Prostaglandin G/H synthase 1 (COX-1) DMWA6G1 MA Inhibitor DMWA6G1 RN Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56. DMWA6G1 RU https://pubmed.ncbi.nlm.nih.gov/18023187 DMWA6G1 DI DMWA6G1 DMWA6G1 DN 1-(4-aminosulfonylphenyl)-2-(2-pyridyl)acetylene DMWA6G1 TI TTVKILB DMWA6G1 TN Prostaglandin G/H synthase 2 (COX-2) DMWA6G1 MA Inhibitor DMWA6G1 RN Synthesis and cyclooxygenase inhibitory activities of linear 1-(methanesulfonylphenyl or benzenesulfonamido)-2-(pyridyl)acetylene regioisomers. Bioorg Med Chem. 2008 Feb 15;16(4):1948-56. DMWA6G1 RU https://pubmed.ncbi.nlm.nih.gov/18023187 DMWA8B0 DI DMWA8B0 DMWA8B0 DN JZL184 DMWA8B0 TI TTZ963I DMWA8B0 TN Monoglyceride lipase (MAGL) DMWA8B0 MA Inhibitor DMWA8B0 RN Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009 Jan;5(1):37-44. DMWA8B0 RU https://pubmed.ncbi.nlm.nih.gov/19029917 DMWAB7F DI DMWAB7F DMWAB7F DN 7alpha-NHEt-ginkgolide B DMWAB7F TI TTQL5VC DMWAB7F TN Platelet-activating factor receptor (PTAFR) DMWAB7F MA Antagonist DMWAB7F RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMWAB7F RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMWADOY DI DMWADOY DMWADOY DN M3S DMWADOY TI TTKWM86 DMWADOY TN Opioid receptor mu (MOP) DMWADOY MA Inhibitor DMWADOY RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMWADOY RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMWAEJ3 DI DMWAEJ3 DMWAEJ3 DN GW803430 DMWAEJ3 TI TTX4RTB DMWAEJ3 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMWAEJ3 MA Antagonist DMWAEJ3 RN The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4723-7. DMWAEJ3 RU https://pubmed.ncbi.nlm.nih.gov/16870432 DMWAEJ3 DI DMWAEJ3 DMWAEJ3 DN GW803430 DMWAEJ3 TI TTQ6VDM DMWAEJ3 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMWAEJ3 MA Inhibitor DMWAEJ3 RN Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concen... J Med Chem. 2009 Apr 9;52(7):2076-89. DMWAEJ3 RU https://pubmed.ncbi.nlm.nih.gov/19290642 DMWAF5Z DI DMWAF5Z DMWAF5Z DN MANGIFERIN DMWAF5Z TI TT50QJ3 DMWAF5Z TN Influenza Neuraminidase (Influ NA) DMWAF5Z MA Inhibitor DMWAF5Z RN Characteristic of neuraminidase inhibitory xanthones from Cudrania tricuspidata. Bioorg Med Chem. 2009 Apr 1;17(7):2744-50. DMWAF5Z RU https://pubmed.ncbi.nlm.nih.gov/19285413 DMWAF5Z DI DMWAF5Z DMWAF5Z DN MANGIFERIN DMWAF5Z TI TTFBNVI DMWAF5Z TN Aldose reductase (AKR1B1) DMWAF5Z MA Inhibitor DMWAF5Z RN Structures of new friedelane-type triterpenes and eudesmane-type sesquiterpene and aldose reductase inhibitors from Salacia chinensis. J Nat Prod. 2003 Sep;66(9):1191-6. DMWAF5Z RU https://pubmed.ncbi.nlm.nih.gov/14510595 DMWAHYX DI DMWAHYX DMWAHYX DN LY314228 DMWAHYX TI TTJQOD7 DMWAHYX TN 5-HT 2A receptor (HTR2A) DMWAHYX MA Antagonist DMWAHYX RN A novel class of 5-HT2A receptor antagonists: aryl aminoguanidines. Life Sci. 1996;59(15):1259-68. DMWAHYX RU https://pubmed.ncbi.nlm.nih.gov/8845011 DMWAK1R DI DMWAK1R DMWAK1R DN PHENYLPIPERAZINE DMWAK1R TI TTSQIFT DMWAK1R TN 5-HT 1A receptor (HTR1A) DMWAK1R MA Inhibitor DMWAK1R RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMWAK1R RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMWAK1R DI DMWAK1R DMWAK1R DN PHENYLPIPERAZINE DMWAK1R TI TTJQOD7 DMWAK1R TN 5-HT 2A receptor (HTR2A) DMWAK1R MA Inhibitor DMWAK1R RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMWAK1R RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMWAK1R DI DMWAK1R DMWAK1R DN PHENYLPIPERAZINE DMWAK1R TI TT6MSOK DMWAK1R TN 5-HT 1D receptor (HTR1D) DMWAK1R MA Inhibitor DMWAK1R RN 5-HT1 and 5-HT2 binding characteristics of some quipazine analogues. J Med Chem. 1986 Nov;29(11):2375-80. DMWAK1R RU https://pubmed.ncbi.nlm.nih.gov/3783595 DMWAK5V DI DMWAK5V DMWAK5V DN N-n-pentyl-7-methoxytacrine hydrochloride DMWAK5V TI TT1RS9F DMWAK5V TN Acetylcholinesterase (AChE) DMWAK5V MA Inhibitor DMWAK5V RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMWAK5V RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMWAK5V DI DMWAK5V DMWAK5V DN N-n-pentyl-7-methoxytacrine hydrochloride DMWAK5V TI TTEB0GD DMWAK5V TN Cholinesterase (BCHE) DMWAK5V MA Inhibitor DMWAK5V RN Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett. 2010 Oct 15;20(20):6093-5. DMWAK5V RU https://pubmed.ncbi.nlm.nih.gov/20817518 DMWAKFM DI DMWAKFM DMWAKFM DN 2-(trifluoromethyl)benzaldehyde thiosemicarbazone DMWAKFM TI TTEAID7 DMWAKFM TN Trypanosoma Cruzipain (Trypano CYSP) DMWAKFM MA Inhibitor DMWAKFM RN Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruz... J Med Chem. 2002 Jun 20;45(13):2695-707. DMWAKFM RU https://pubmed.ncbi.nlm.nih.gov/12061873 DMWAKHD DI DMWAKHD DMWAKHD DN GNF-PF-3464 DMWAKHD TI TTWXB3E DMWAKHD TN Hepatitis C virus NS3 helicase (HCV NS3) DMWAKHD MA Inhibitor DMWAKHD RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMWAKHD RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMWAKHD DI DMWAKHD DMWAKHD DN GNF-PF-3464 DMWAKHD TI TT4FDG6 DMWAKHD TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMWAKHD MA Inhibitor DMWAKHD RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMWAKHD RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMWALXQ DI DMWALXQ DMWALXQ DN bongkrek acid DMWALXQ TI TTU5A6Q DMWALXQ TN Adenine nucleotide translocator 1 (SLC25A4) DMWALXQ MA Inhibitor DMWALXQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1062). DMWALXQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1062 DMWAPGI DI DMWAPGI DMWAPGI DN Hexane-1,6-Diol DMWAPGI TI TT9V5JH DMWAPGI TN Phospholipase A2 (PLA2G1B) DMWAPGI MA Inhibitor DMWAPGI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWAPGI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWAPGI DI DMWAPGI DMWAPGI DN Hexane-1,6-Diol DMWAPGI TI TTYRL6O DMWAPGI TN Glucocorticoid receptor (NR3C1) DMWAPGI MA Inhibitor DMWAPGI RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWAPGI RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWAS4Q DI DMWAS4Q DMWAS4Q DN BIS(12)-HUPERZINE B DMWAS4Q TI TT1RS9F DMWAS4Q TN Acetylcholinesterase (AChE) DMWAS4Q MA Inhibitor DMWAS4Q RN Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7. DMWAS4Q RU https://pubmed.ncbi.nlm.nih.gov/15689148 DMWAT5S DI DMWAT5S DMWAT5S DN [3H]PD140376 DMWAT5S TI TTVFO0U DMWAT5S TN Gastrin/cholecystokinin type B receptor (CCKBR) DMWAT5S MA Antagonist DMWAT5S RN [3H]PD 140376: a novel and highly selective antagonist radioligand for the cholecystokininB/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol Pharmacol. 1993 Apr;43(4):595-602. DMWAT5S RU https://pubmed.ncbi.nlm.nih.gov/8474432 DMWB07I DI DMWB07I DMWB07I DN Alpha-Sulfanylbenzylphosphonic acid DMWB07I TI TTHI19T DMWB07I TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMWB07I MA Inhibitor DMWB07I RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMWB07I RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMWB43U DI DMWB43U DMWB43U DN 6-Chloropurine Riboside, 5'-Monophosphate DMWB43U TI TTZFTY4 DMWB43U TN Amidophosphoribosyltransferase (PPAT) DMWB43U MA Inhibitor DMWB43U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWB43U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWB43U DI DMWB43U DMWB43U DN 6-Chloropurine Riboside, 5'-Monophosphate DMWB43U TI TTTB4UP DMWB43U TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMWB43U MA Inhibitor DMWB43U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWB43U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWBH9N DI DMWBH9N DMWBH9N DN (S)-2-Amino-1-azetidin-1-yl-2-cyclohexyl-ethanone DMWBH9N TI TTDIGC1 DMWBH9N TN Dipeptidyl peptidase 4 (DPP-4) DMWBH9N MA Inhibitor DMWBH9N RN New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4770-3. DMWBH9N RU https://pubmed.ncbi.nlm.nih.gov/16115768 DMWBHZL DI DMWBHZL DMWBHZL DN JWH-313 DMWBHZL TI TTMSFAW DMWBHZL TN Cannabinoid receptor 2 (CB2) DMWBHZL MA Inhibitor DMWBHZL RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMWBHZL RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMWBKH1 DI DMWBKH1 DMWBKH1 DN ALD-806 DMWBKH1 TI TTNDSF4 DMWBKH1 TN Proto-oncogene c-Met (MET) DMWBKH1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMWBKH1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMWBPOJ DI DMWBPOJ DMWBPOJ DN PMID8709131C15 DMWBPOJ TI TTFQEO5 DMWBPOJ TN Squalene synthetase (FDFT1) DMWBPOJ MA Inhibitor DMWBPOJ RN Synthesis and activity of a novel series of 3-biarylquinuclidine squalene synthase inhibitors. J Med Chem. 1996 Jul 19;39(15):2971-9. DMWBPOJ RU https://pubmed.ncbi.nlm.nih.gov/8709131 DMWBQHS DI DMWBQHS DMWBQHS DN ISIS 116361 DMWBQHS TI TTGECUM DMWBQHS TN Cot oncogene messenger RNA (MAP3K8 mRNA) DMWBQHS RN US patent application no. 6,265,216, Antisense modulation of cot oncogene expression. DMWBQHS RU http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true DMWBRDK DI DMWBRDK DMWBRDK DN L-803,087 DMWBRDK TI TTAE1BR DMWBRDK TN Somatostatin receptor type 4 (SSTR4) DMWBRDK MA Agonist DMWBRDK RN Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 1998 Oct 23;282(5389):737-40. DMWBRDK RU https://pubmed.ncbi.nlm.nih.gov/9784130 DMWBV1P DI DMWBV1P DMWBV1P DN borneol DMWBV1P TI TT946IA DMWBV1P TN Transient receptor potential cation channel V3 (TRPV3) DMWBV1P MA Activator DMWBV1P RN Monoterpenoid agonists of TRPV3. Br J Pharmacol. 2007 Jun;151(4):530-40. DMWBV1P RU https://pubmed.ncbi.nlm.nih.gov/17420775 DMWBVMH DI DMWBVMH DMWBVMH DN 4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid DMWBVMH TI TTGKNB4 DMWBVMH TN Epidermal growth factor receptor (EGFR) DMWBVMH MA Inhibitor DMWBVMH RN Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. DMWBVMH RU https://pubmed.ncbi.nlm.nih.gov/1479375 DMWBYNF DI DMWBYNF DMWBYNF DN PMID22017539C15 DMWBYNF TI TTHY57M DMWBYNF TN Matrix metalloproteinase-13 (MMP-13) DMWBYNF MA Inhibitor DMWBYNF RN Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. J Med Chem. 2011 Dec 8;54(23):8174-87. DMWBYNF RU https://pubmed.ncbi.nlm.nih.gov/22017539 DMWC10R DI DMWC10R DMWC10R DN [Sar1,Bpa8]AngII DMWC10R TI TT8DBY3 DMWC10R TN Angiotensin II receptor type-1 (AGTR1) DMWC10R MA Inhibitor DMWC10R RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMWC10R RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMWC2F9 DI DMWC2F9 DMWC2F9 DN (E)-9-nitrooctadec-9-enoic acid DMWC2F9 TI TTT2SVW DMWC2F9 TN PPAR-gamma messenger RNA (PPARG mRNA) DMWC2F9 MA Inhibitor DMWC2F9 RN Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9. DMWC2F9 RU https://pubmed.ncbi.nlm.nih.gov/19719236 DMWC34B DI DMWC34B DMWC34B DN BAG956 DMWC34B TI TTHBTOP DMWC34B TN PI3-kinase gamma (PIK3CG) DMWC34B MA Inhibitor DMWC34B RN The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. DMWC34B RU https://pubmed.ncbi.nlm.nih.gov/19519296 DMWC4X8 DI DMWC4X8 DMWC4X8 DN Prostaglandin A2 DMWC4X8 TI TTELV3W DMWC4X8 TN Transformation-sensitive protein p120 (TRPA1) DMWC4X8 MA Activator DMWC4X8 RN Cox-dependent fatty acid metabolites cause pain through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):12045-50. DMWC4X8 RU https://pubmed.ncbi.nlm.nih.gov/18687886 DMWC6RU DI DMWC6RU DMWC6RU DN SKF-83959 DMWC6RU TI TTZFYLI DMWC6RU TN Dopamine D1 receptor (D1R) DMWC6RU MA Agonist DMWC6RU RN Identification of G protein-biased agonists that fail to recruit beta-arrestin or promote internalization of the D1 dopamine receptor. ACS Chem Neurosci. 2015 Apr 15;6(4):681-92. DMWC6RU RU https://pubmed.ncbi.nlm.nih.gov/25660762 DMWC70I DI DMWC70I DMWC70I DN N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide DMWC70I TI TT32JK8 DMWC70I TN Melatonin receptor type 1B (MTNR1B) DMWC70I MA Inhibitor DMWC70I RN Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994). DMWC70I RU http://www.sciencedirect.com/science/article/pii/S0960894X01805667 DMWC70I DI DMWC70I DMWC70I DN N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamide DMWC70I TI TT0WAIE DMWC70I TN Melatonin receptor type 1A (MTNR1A) DMWC70I MA Inhibitor DMWC70I RN Mapping the melatonin receptor. 2. synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain, Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994). DMWC70I RU http://www.sciencedirect.com/science/article/pii/S0960894X01805667 DMWC7QE DI DMWC7QE DMWC7QE DN 1,9-bis(pyridinium)-nonane dibromide DMWC7QE TI TTEB0GD DMWC7QE TN Cholinesterase (BCHE) DMWC7QE MA Inhibitor DMWC7QE RN Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6. DMWC7QE RU https://pubmed.ncbi.nlm.nih.gov/20138518 DMWC7QE DI DMWC7QE DMWC7QE DN 1,9-bis(pyridinium)-nonane dibromide DMWC7QE TI TT1RS9F DMWC7QE TN Acetylcholinesterase (AChE) DMWC7QE MA Inhibitor DMWC7QE RN Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for My... Bioorg Med Chem Lett. 2010 Mar 1;20(5):1763-6. DMWC7QE RU https://pubmed.ncbi.nlm.nih.gov/20138518 DMWCDM8 DI DMWCDM8 DMWCDM8 DN artepillin C DMWCDM8 TI TTELV3W DMWCDM8 TN Transformation-sensitive protein p120 (TRPA1) DMWCDM8 MA Activator DMWCDM8 RN Artepillin C, a major ingredient of Brazilian propolis, induces a pungent taste by activating TRPA1 channels. PLoS One. 2012;7(11):e48072. DMWCDM8 RU https://pubmed.ncbi.nlm.nih.gov/23133611 DMWCGE8 DI DMWCGE8 DMWCGE8 DN 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine DMWCGE8 TI TTJFY5U DMWCGE8 TN Adenosine A3 receptor (ADORA3) DMWCGE8 MA Inhibitor DMWCGE8 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMWCGE8 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMWCGE8 DI DMWCGE8 DMWCGE8 DN 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine DMWCGE8 TI TTK25J1 DMWCGE8 TN Adenosine A1 receptor (ADORA1) DMWCGE8 MA Inhibitor DMWCGE8 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMWCGE8 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMWCGE8 DI DMWCGE8 DMWCGE8 DN 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine DMWCGE8 TI TTNE7KG DMWCGE8 TN Adenosine A2b receptor (ADORA2B) DMWCGE8 MA Inhibitor DMWCGE8 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMWCGE8 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMWCGE8 DI DMWCGE8 DMWCGE8 DN 2-ethyl-4-(thiazol-2-yl)thieno[3,2-d]pyrimidine DMWCGE8 TI TTM2AOE DMWCGE8 TN Adenosine A2a receptor (ADORA2A) DMWCGE8 MA Inhibitor DMWCGE8 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMWCGE8 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMWCK8Q DI DMWCK8Q DMWCK8Q DN ISIS 101987 DMWCK8Q TI TTON5JB DMWCK8Q TN MADH6 messenger RNA (MADH6 mRNA) DMWCK8Q RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DMWCK8Q RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DMWCLQ5 DI DMWCLQ5 DMWCLQ5 DN Fexaramine DMWCLQ5 TI TTS4UGC DMWCLQ5 TN Farnesoid X-activated receptor (FXR) DMWCLQ5 MA Inhibitor DMWCLQ5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWCLQ5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWCS4Y DI DMWCS4Y DMWCS4Y DN [Sar1,Tdf3]AngII DMWCS4Y TI TT8DBY3 DMWCS4Y TN Angiotensin II receptor type-1 (AGTR1) DMWCS4Y MA Inhibitor DMWCS4Y RN The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1. J Med Chem. 2010 Mar 11;53(5):2063-75. DMWCS4Y RU https://pubmed.ncbi.nlm.nih.gov/20146480 DMWCSQH DI DMWCSQH DMWCSQH DN SN-1 DMWCSQH TI TT0NLAQ DMWCSQH TN Mucolipin-3 (TRPML3) DMWCSQH MA Activator DMWCSQH RN Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48. DMWCSQH RU https://pubmed.ncbi.nlm.nih.gov/20189104 DMWCTZ7 DI DMWCTZ7 DMWCTZ7 DN Decynium 22 DMWCTZ7 TI TTTR957 DMWCTZ7 TN Solute carrier family 29 member 4 (SLC29A4) DMWCTZ7 MA Inhibitor DMWCTZ7 RN Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol. 2005 Nov;68(5):1397-407. DMWCTZ7 RU https://pubmed.ncbi.nlm.nih.gov/16099839 DMWCTZ7 DI DMWCTZ7 DMWCTZ7 DN Decynium 22 DMWCTZ7 TI TTJLP0R DMWCTZ7 TN Quinone reductase 2 (NQO2) DMWCTZ7 MA Inhibitor DMWCTZ7 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMWCTZ7 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMWCV48 DI DMWCV48 DMWCV48 DN Nitroflurbiprofen DMWCV48 TI TT8NGED DMWCV48 TN Prostaglandin G/H synthase 1 (COX-1) DMWCV48 MA Modulator DMWCV48 RN The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann N Y Acad Sci. 2004 Dec;1030:37-42. DMWCV48 RU https://www.ncbi.nlm.nih.gov/pubmed/15659778 DMWCV48 DI DMWCV48 DMWCV48 DN Nitroflurbiprofen DMWCV48 TI TTVKILB DMWCV48 TN Prostaglandin G/H synthase 2 (COX-2) DMWCV48 MA Modulator DMWCV48 RN The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann N Y Acad Sci. 2004 Dec;1030:37-42. DMWCV48 RU https://www.ncbi.nlm.nih.gov/pubmed/15659778 DMWCXM4 DI DMWCXM4 DMWCXM4 DN 1-amino-2-phenoxyanthracene-9,10-dione DMWCXM4 TI TTM2AOE DMWCXM4 TN Adenosine A2a receptor (ADORA2A) DMWCXM4 MA Inhibitor DMWCXM4 RN Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem. 2010 Feb 25;53(4):1799-809. DMWCXM4 RU https://pubmed.ncbi.nlm.nih.gov/20095623 DMWCXPK DI DMWCXPK DMWCXPK DN Haloperidol DMWCXPK TI TTTPE1L DMWCXPK TN HUMAN opioid receptor sigma 1 (OPRS1) DMWCXPK MA Modulator DMWCXPK RN A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DMWCXPK RU https://www.nature.com/articles/s41586-020-2286-9 DMWCXPK DI DMWCXPK DMWCXPK DN Haloperidol DMWCXPK TI TTIS0R2 DMWCXPK TN HUMAN sigma intracellular receptor 2 (TMEM97) DMWCXPK MA Modulator DMWCXPK RN A SARS-CoV-2 protein interaction map reveals targets for drug repurposing DMWCXPK RU https://www.nature.com/articles/s41586-020-2286-9 DMWCZLT DI DMWCZLT DMWCZLT DN Haloxysterol D DMWCZLT TI TTEB0GD DMWCZLT TN Cholinesterase (BCHE) DMWCZLT MA Inhibitor DMWCZLT RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMWCZLT RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMWCZLT DI DMWCZLT DMWCZLT DN Haloxysterol D DMWCZLT TI TT1RS9F DMWCZLT TN Acetylcholinesterase (AChE) DMWCZLT MA Inhibitor DMWCZLT RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMWCZLT RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMWD1XH DI DMWD1XH DMWD1XH DN ISIS 3306 DMWD1XH TI TTZSY8Q DMWD1XH TN Influenza HA messenger RNA (Influ HA mRNA) DMWD1XH RN US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides. DMWD1XH RU http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true DMWD42N DI DMWD42N DMWD42N DN 4-fluorobenzoyl-Phe-Gly-Leu-Arg-Trp-NH2 DMWD42N TI TT3KBZY DMWD42N TN G-protein coupled receptor 54 (KISS1R) DMWD42N MA Inhibitor DMWD42N RN Development of novel G-protein-coupled receptor 54 agonists with resistance to degradation by matrix metalloproteinase. J Med Chem. 2008 Dec 11;51(23):7645-9. DMWD42N RU https://pubmed.ncbi.nlm.nih.gov/19007202 DMWD5RK DI DMWD5RK DMWD5RK DN Cyclo-[Asp6,Lys10]N/OFQ(1-13)NH2 DMWD5RK TI TTNT7K8 DMWD5RK TN Nociceptin receptor (OPRL1) DMWD5RK MA Inhibitor DMWD5RK RN High affinity conformationally constrained nociceptin/orphanin FQ(1-13) amide analogues. J Med Chem. 2008 Aug 14;51(15):4385-7. DMWD5RK RU https://pubmed.ncbi.nlm.nih.gov/18624395 DMWD7I3 DI DMWD7I3 DMWD7I3 DN NGD 96-3 DMWD7I3 TI TTEX6LM DMWD7I3 TN GABA(A) receptor gamma-3 (GABRG3) DMWD7I3 MA Modulator DMWD7I3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMWD7I3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMWDBHC DI DMWDBHC DMWDBHC DN 4-Hydroxy-3-methyl-but-2-enoic acid DMWDBHC TI TT6TKEN DMWDBHC TN Gamma-hydroxybutyrate receptor (SLC52A2) DMWDBHC MA Inhibitor DMWDBHC RN Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies. J Med Chem. 1988 May;31(5):893-7. DMWDBHC RU https://pubmed.ncbi.nlm.nih.gov/3361576 DMWDCV1 DI DMWDCV1 DMWDCV1 DN N-[3H]alpha-methylhistamine DMWDCV1 TI TT9JNIC DMWDCV1 TN Histamine H3 receptor (H3R) DMWDCV1 MA Agonist DMWDCV1 RN Molecular and pharmacological characterization of the mouse histamine H3 receptor. Eur J Pharmacol. 2003 Apr 25;467(1-3):57-65. DMWDCV1 RU https://pubmed.ncbi.nlm.nih.gov/12706455 DMWDCV1 DI DMWDCV1 DMWDCV1 DN N-[3H]alpha-methylhistamine DMWDCV1 TI TTXJ178 DMWDCV1 TN Histamine H4 receptor (H4R) DMWDCV1 MA Agonist DMWDCV1 RN Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor. Br J Pharmacol. 2003 Nov;140(6):1117-27. DMWDCV1 RU https://pubmed.ncbi.nlm.nih.gov/14530216 DMWDE9A DI DMWDE9A DMWDE9A DN PMID15300839C17 DMWDE9A TI TTBUYHA DMWDE9A TN Extracellular calcium-sensing receptor (CASR) DMWDE9A MA Antagonist DMWDE9A RN N(1)-Arylsulfonyl-N(2)-(1-(1-naphthyl)ethyl)-1,2-diaminocyclohexanes: a new class of calcilytic agents acting at the calcium-sensing receptor. Chembiochem. 2004 Aug 6;5(8):1131-6. DMWDE9A RU https://pubmed.ncbi.nlm.nih.gov/15300839 DMWDENZ DI DMWDENZ DMWDENZ DN 2-amino-2-(2,3-difluorophenyl)acetic acid DMWDENZ TI TTFK1JQ DMWDENZ TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMWDENZ MA Inhibitor DMWDENZ RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMWDENZ RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMWDJ0H DI DMWDJ0H DMWDJ0H DN LEVONORDEFRIN DMWDJ0H TI TT34BHT DMWDJ0H TN Adrenergic receptor alpha-1D (ADRA1D) DMWDJ0H MA Inhibitor DMWDJ0H RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMWDJ0H RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMWDJ0H DI DMWDJ0H DMWDJ0H DN LEVONORDEFRIN DMWDJ0H TI TTBRKXS DMWDJ0H TN Adrenergic receptor alpha-1B (ADRA1B) DMWDJ0H MA Inhibitor DMWDJ0H RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMWDJ0H RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMWDJ0H DI DMWDJ0H DMWDJ0H DN LEVONORDEFRIN DMWDJ0H TI TTNGILX DMWDJ0H TN Adrenergic receptor alpha-1A (ADRA1A) DMWDJ0H MA Inhibitor DMWDJ0H RN Medetomidine analogs as alpha 2-adrenergic ligands. 2. Design, synthesis, and biological activity of conformationally restricted naphthalene deriva... J Med Chem. 1996 Jul 19;39(15):3001-13. DMWDJ0H RU https://pubmed.ncbi.nlm.nih.gov/8709134 DMWDMJ3 DI DMWDMJ3 DMWDMJ3 DN OLEANOLIC_ACID DMWDMJ3 TI TTELIN2 DMWDMJ3 TN PTPN1 messenger RNA (PTPN1 mRNA) DMWDMJ3 MA Inhibitor DMWDMJ3 RN Chemical Constituents of the Roots of Euphorbia micractina. J Nat Prod. 2009 Sep;72(9):1620-6. DMWDMJ3 RU https://pubmed.ncbi.nlm.nih.gov/19702283 DMWDMJ3 DI DMWDMJ3 DMWDMJ3 DN OLEANOLIC_ACID DMWDMJ3 TI TTZHY6R DMWDMJ3 TN Glycogen phosphorylase muscle form (GP) DMWDMJ3 MA Inhibitor DMWDMJ3 RN Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54. DMWDMJ3 RU https://pubmed.ncbi.nlm.nih.gov/18517260 DMWDMJ3 DI DMWDMJ3 DMWDMJ3 DN OLEANOLIC_ACID DMWDMJ3 TI TTIU7X1 DMWDMJ3 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMWDMJ3 MA Inhibitor DMWDMJ3 RN DNA polymerase beta inhibitors from Baeckea gunniana. J Nat Prod. 1999 Dec;62(12):1624-6. DMWDMJ3 RU https://pubmed.ncbi.nlm.nih.gov/10654412 DMWDNLI DI DMWDNLI DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI TI TTBZ7OD DMWDNLI TN Protein kinase C epsilon (PRKCE) DMWDNLI MA Inhibitor DMWDNLI RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMWDNLI RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMWDNLI DI DMWDNLI DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI TI TT9WJ8U DMWDNLI TN Protein kinase C delta (PRKCD) DMWDNLI MA Inhibitor DMWDNLI RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMWDNLI RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMWDNLI DI DMWDNLI DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI TI TT8QL1J DMWDNLI TN Protein kinase C theta (PRKCQ) DMWDNLI MA Inhibitor DMWDNLI RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMWDNLI RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMWDNLI DI DMWDNLI DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI TI TTUWGRA DMWDNLI TN Protein kinase C zeta (PRKCZ) DMWDNLI MA Inhibitor DMWDNLI RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMWDNLI RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMWDNLI DI DMWDNLI DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI TI TTYPXQF DMWDNLI TN Protein kinase C beta (PRKCB) DMWDNLI MA Inhibitor DMWDNLI RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMWDNLI RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMWDNLI DI DMWDNLI DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI TI TTFJ8Q1 DMWDNLI TN Protein kinase C alpha (PRKCA) DMWDNLI MA Inhibitor DMWDNLI RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMWDNLI RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMWDNLI DI DMWDNLI DMWDNLI DN [2,2':5',2'']Terthiophene-4,5''-dicarbaldehyde DMWDNLI TI TTRFOXJ DMWDNLI TN Protein kinase C gamma (PRKCG) DMWDNLI MA Inhibitor DMWDNLI RN Novel protein kinase C inhibitors: synthesis and PKC inhibition of beta-substituted polythiophene derivatives. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2279-82. DMWDNLI RU https://pubmed.ncbi.nlm.nih.gov/10465561 DMWDNOK DI DMWDNOK DMWDNOK DN REVERSINE DMWDNOK TI TTJFY5U DMWDNOK TN Adenosine A3 receptor (ADORA3) DMWDNOK MA Inhibitor DMWDNOK RN Reversine and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists. J Med Chem. 2005 Jul 28;48(15):4910-8. DMWDNOK RU https://pubmed.ncbi.nlm.nih.gov/16033270 DMWDNOK DI DMWDNOK DMWDNOK DN REVERSINE DMWDNOK TI TTIDAPM DMWDNOK TN ERK activator kinase 1 (MEK1) DMWDNOK MA Inhibitor DMWDNOK RN Reversine increases the plasticity of lineage-committed mammalian cells. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10482-7. DMWDNOK RU https://pubmed.ncbi.nlm.nih.gov/17566101 DMWDQ90 DI DMWDQ90 DMWDQ90 DN Isosorbide-2-benzylcarbamate-5-cyclopentanoate DMWDQ90 TI TT1RS9F DMWDQ90 TN Acetylcholinesterase (AChE) DMWDQ90 MA Inhibitor DMWDQ90 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMWDQ90 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMWDQ90 DI DMWDQ90 DMWDQ90 DN Isosorbide-2-benzylcarbamate-5-cyclopentanoate DMWDQ90 TI TTEB0GD DMWDQ90 TN Cholinesterase (BCHE) DMWDQ90 MA Inhibitor DMWDQ90 RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMWDQ90 RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMWDUCH DI DMWDUCH DMWDUCH DN 1,1,1-trifluoro-3-(hexylsulfonyl)propan-2-one DMWDUCH TI TTMF541 DMWDUCH TN Liver carboxylesterase (CES1) DMWDUCH MA Inhibitor DMWDUCH RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMWDUCH RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMWDUVC DI DMWDUVC DMWDUVC DN 5-Aminomethyl-3-pyrrol-1-yl-oxazolidin-2-one DMWDUVC TI TTGP7BY DMWDUVC TN Monoamine oxidase type B (MAO-B) DMWDUVC MA Inhibitor DMWDUVC RN 3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A. J Med Chem. 2002 Mar 14;45(6):1180-3. DMWDUVC RU https://pubmed.ncbi.nlm.nih.gov/11881986 DMWDV71 DI DMWDV71 DMWDV71 DN 2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol DMWDV71 TI TTZAYWL DMWDV71 TN Estrogen receptor (ESR) DMWDV71 MA Inhibitor DMWDV71 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMWDV71 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMWDV71 DI DMWDV71 DMWDV71 DN 2-(2-Chloro-4-hydroxy-phenyl)-benzooxazol-5-ol DMWDV71 TI TTOM3J0 DMWDV71 TN Estrogen receptor beta (ESR2) DMWDV71 MA Inhibitor DMWDV71 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMWDV71 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMWDXPN DI DMWDXPN DMWDXPN DN rT3 DMWDXPN TI TTTSEPU DMWDXPN TN Thyroid hormone receptor alpha (THRA) DMWDXPN MA Agonist DMWDXPN RN Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34. DMWDXPN RU https://pubmed.ncbi.nlm.nih.gov/2158622 DMWDXPN DI DMWDXPN DMWDXPN DN rT3 DMWDXPN TI TTGER3L DMWDXPN TN Thyroid hormone receptor beta (THRB) DMWDXPN MA Agonist DMWDXPN RN Binding of 3,5,3'-triiodothyronine (T3) and its analogs to the in vitro translational products of c-erbA protooncogenes: differences in the affinity of the alpha- and beta-forms for the acetic acid analog and failure of the human testis and kidney alpha-2 products to bind T3. Mol Endocrinol. 1990 Feb;4(2):227-34. DMWDXPN RU https://pubmed.ncbi.nlm.nih.gov/2158622 DMWDYLR DI DMWDYLR DMWDYLR DN 4,6-dinitrobenzo[c][1,2,5]thiadiazole DMWDYLR TI TTR7UJ3 DMWDYLR TN Cytoplasmic thioredoxin reductase (TXNRD1) DMWDYLR MA Inhibitor DMWDYLR RN Specific inhibitors of Plasmodium falciparum thioredoxin reductase as potential antimalarial agents. Bioorg Med Chem Lett. 2006 Apr 15;16(8):2283-92. DMWDYLR RU https://pubmed.ncbi.nlm.nih.gov/16458512 DMWE1N8 DI DMWE1N8 DMWE1N8 DN Cibacron blue DMWE1N8 TI TTCYE56 DMWE1N8 TN Glutathione-dependent PGD synthase (HPGDS) DMWE1N8 MA Inhibitor DMWE1N8 RN A novel method for screening the glutathione transferase inhibitors. BMC Biochem. 2009 Mar 16;10:6. DMWE1N8 RU https://pubmed.ncbi.nlm.nih.gov/19291299 DMWE42T DI DMWE42T DMWE42T DN (D)Arg-Arg-Pro-Hyp-Gly-Phe-Ser-(d)Phe-Phe-Arg DMWE42T TI TTGY8IW DMWE42T TN B2 bradykinin receptor (BDKRB2) DMWE42T MA Inhibitor DMWE42T RN Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3. DMWE42T RU https://pubmed.ncbi.nlm.nih.gov/1848297 DMWEK8I DI DMWEK8I DMWEK8I DN Erythribyssin M DMWEK8I TI TT50QJ3 DMWEK8I TN Influenza Neuraminidase (Influ NA) DMWEK8I MA Inhibitor DMWEK8I RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMWEK8I RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMWEKBD DI DMWEKBD DMWEKBD DN Phenyl-1,4-bismaleimide DMWEKBD TI TTDP1UC DMWEKBD TN Fatty acid amide hydrolase (FAAH) DMWEKBD MA Inhibitor DMWEKBD RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DMWEKBD RU https://pubmed.ncbi.nlm.nih.gov/19583260 DMWELVK DI DMWELVK DMWELVK DN 4-(cyclohexylamino)-N-(quinolin-3-yl)benzamide DMWELVK TI TTMI6F5 DMWELVK TN Transient receptor potential cation channel V1 (TRPV1) DMWELVK MA Inhibitor DMWELVK RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMWELVK RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMWEXOY DI DMWEXOY DMWEXOY DN Benzaldehyde O-4-(pentyloxy)phenylcarbamoyl oxime DMWEXOY TI TTDP1UC DMWEXOY TN Fatty acid amide hydrolase (FAAH) DMWEXOY MA Inhibitor DMWEXOY RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMWEXOY RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMWF4HX DI DMWF4HX DMWF4HX DN 5-phenyl-1H-1,2,3-triazole DMWF4HX TI TTZJYKH DMWF4HX TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMWF4HX MA Inhibitor DMWF4HX RN Rational design of indoleamine 2,3-dioxygenase inhibitors. J Med Chem. 2010 Feb 11;53(3):1172-89. DMWF4HX RU https://pubmed.ncbi.nlm.nih.gov/20055453 DMWF7RO DI DMWF7RO DMWF7RO DN J-104123 DMWF7RO TI TTFQEO5 DMWF7RO TN Squalene synthetase (FDFT1) DMWF7RO MA Inhibitor DMWF7RO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645). DMWF7RO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645 DMWF82O DI DMWF82O DMWF82O DN FUKUGETIN DMWF82O TI TT7RJY8 DMWF82O TN Xanthine dehydrogenase/oxidase (XDH) DMWF82O MA Inhibitor DMWF82O RN Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8. DMWF82O RU https://pubmed.ncbi.nlm.nih.gov/3379415 DMWF8GN DI DMWF8GN DMWF8GN DN Ala7-SRIF-14-amide DMWF8GN TI TTZ6T9E DMWF8GN TN Somatostatin receptor type 2 (SSTR2) DMWF8GN MA Inhibitor DMWF8GN RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DMWF8GN RU https://pubmed.ncbi.nlm.nih.gov/15943475 DMWF8U5 DI DMWF8U5 DMWF8U5 DN EX-1314 DMWF8U5 TI TTWDC17 DMWF8U5 TN Growth hormone secretagogue receptor 1 (GHSR) DMWF8U5 MA Agonist DMWF8U5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246). DMWF8U5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=246 DMWF9GQ DI DMWF9GQ DMWF9GQ DN DVD-Ig DMWF9GQ TI TTRYK0X DMWF9GQ TN Interleukin-1 beta (IL1B) DMWF9GQ MA Modulator DMWF9GQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2623). DMWF9GQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2623 DMWFAPJ DI DMWFAPJ DMWFAPJ DN LONCHOCARPUSONE DMWFAPJ TI TTUMGNO DMWFAPJ TN Ornithine decarboxylase (ODC1) DMWFAPJ MA Inhibitor DMWFAPJ RN New bioactive flavonoids and stilbenes in cub resin insecticide. J Nat Prod. 1999 Feb;62(2):205-10. DMWFAPJ RU https://pubmed.ncbi.nlm.nih.gov/10075742 DMWFCYN DI DMWFCYN DMWFCYN DN 1-(2-phenoxyphenyl)piperazine DMWFCYN TI TTAWNKZ DMWFCYN TN Norepinephrine transporter (NET) DMWFCYN MA Inhibitor DMWFCYN RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMWFCYN RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMWFCYN DI DMWFCYN DMWFCYN DN 1-(2-phenoxyphenyl)piperazine DMWFCYN TI TTSQIFT DMWFCYN TN 5-HT 1A receptor (HTR1A) DMWFCYN MA Inhibitor DMWFCYN RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMWFCYN RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMWFCYN DI DMWFCYN DMWFCYN DN 1-(2-phenoxyphenyl)piperazine DMWFCYN TI TT3ROYC DMWFCYN TN Serotonin transporter (SERT) DMWFCYN MA Inhibitor DMWFCYN RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMWFCYN RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMWFCYN DI DMWFCYN DMWFCYN DN 1-(2-phenoxyphenyl)piperazine DMWFCYN TI TTVBI8W DMWFCYN TN Dopamine transporter (DAT) DMWFCYN MA Inhibitor DMWFCYN RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMWFCYN RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMWFD5C DI DMWFD5C DMWFD5C DN 3,3-Diethyl-1-(pyridin-3-yl)azetidine-2,4-dione DMWFD5C TI TTPLTSQ DMWFD5C TN Neutrophil elastase (NE) DMWFD5C MA Inhibitor DMWFD5C RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMWFD5C RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMWFGBC DI DMWFGBC DMWFGBC DN [Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMWFGBC TI TTRK9JT DMWFGBC TN Neuropeptide Y receptor type 1 (NPY1R) DMWFGBC MA Inhibitor DMWFGBC RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMWFGBC RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMWFGBC DI DMWFGBC DMWFGBC DN [Cys-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMWFGBC TI TTW4N16 DMWFGBC TN Neuropeptide Y receptor type 4 (NPY4R) DMWFGBC MA Inhibitor DMWFGBC RN Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5. DMWFGBC RU https://pubmed.ncbi.nlm.nih.gov/16610810 DMWFGY4 DI DMWFGY4 DMWFGY4 DN PMID18800762C51 DMWFGY4 TI TTIKWV4 DMWFGY4 TN Geranyltranstransferase (FDPS) DMWFGY4 MA Inhibitor DMWFGY4 RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DMWFGY4 RU https://pubmed.ncbi.nlm.nih.gov/18800762 DMWFITM DI DMWFITM DMWFITM DN Cyclo(-D-Tyr-D-Arg-L-Arg-L-Nal-beta-Ala-) DMWFITM TI TTBID49 DMWFITM TN C-X-C chemokine receptor type 4 (CXCR4) DMWFITM MA Inhibitor DMWFITM RN Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone... J Med Chem. 2007 Jan 25;50(2):192-8. DMWFITM RU https://pubmed.ncbi.nlm.nih.gov/17228861 DMWFR16 DI DMWFR16 DMWFR16 DN 2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine DMWFR16 TI TTK25J1 DMWFR16 TN Adenosine A1 receptor (ADORA1) DMWFR16 MA Inhibitor DMWFR16 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMWFR16 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMWFR16 DI DMWFR16 DMWFR16 DN 2-ethyl-4-(pyridin-2-yl)thieno[3,2-d]pyrimidine DMWFR16 TI TTM2AOE DMWFR16 TN Adenosine A2a receptor (ADORA2A) DMWFR16 MA Inhibitor DMWFR16 RN Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives. Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. DMWFR16 RU https://pubmed.ncbi.nlm.nih.gov/18407496 DMWFU3T DI DMWFU3T DMWFU3T DN 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine DMWFU3T TI TTWG9A4 DMWFU3T TN Adrenergic receptor alpha-2A (ADRA2A) DMWFU3T MA Inhibitor DMWFU3T RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMWFU3T RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMWFU3T DI DMWFU3T DMWFU3T DN 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine DMWFU3T TI TTWM4TY DMWFU3T TN Adrenergic receptor alpha-2B (ADRA2B) DMWFU3T MA Inhibitor DMWFU3T RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMWFU3T RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMWFU3T DI DMWFU3T DMWFU3T DN 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine DMWFU3T TI TT34BHT DMWFU3T TN Adrenergic receptor alpha-1D (ADRA1D) DMWFU3T MA Inhibitor DMWFU3T RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMWFU3T RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMWFU3T DI DMWFU3T DMWFU3T DN 1-(3-Fluoro-pyridin-2-yl)-4-methyl-piperazine DMWFU3T TI TTNGILX DMWFU3T TN Adrenergic receptor alpha-1A (ADRA1A) DMWFU3T MA Inhibitor DMWFU3T RN Adrenoceptor and tetrabenazine antagonism activities of some pyridinyltetrahydropyridines. J Med Chem. 1984 Sep;27(9):1182-5. DMWFU3T RU https://pubmed.ncbi.nlm.nih.gov/6088770 DMWFYJ4 DI DMWFYJ4 DMWFYJ4 DN GB110 DMWFYJ4 TI TTQR74A DMWFYJ4 TN Proteinase activated receptor 2 (PAR2) DMWFYJ4 MA Agonist DMWFYJ4 RN Novel agonists and antagonists for human protease activated receptor 2. J Med Chem. 2010 Oct 28;53(20):7428-40. DMWFYJ4 RU https://pubmed.ncbi.nlm.nih.gov/20873792 DMWG0P3 DI DMWG0P3 DMWG0P3 DN Formycin DMWG0P3 TI TTFSX6G DMWG0P3 TN Bacterial MTA/SAH nucleosidase (Bact mtnN) DMWG0P3 MA Inhibitor DMWG0P3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWG0P3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWG0P3 DI DMWG0P3 DMWG0P3 DN Formycin DMWG0P3 TI TTDBX7N DMWG0P3 TN S-methyl-5'-thioadenosine phosphorylase (MTAP) DMWG0P3 MA Inhibitor DMWG0P3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWG0P3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWG706 DI DMWG706 DMWG706 DN 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide DMWG706 TI TTUNARX DMWG706 TN Carbonic anhydrase (CA) DMWG706 MA Inhibitor DMWG706 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMWG706 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMWG706 DI DMWG706 DMWG706 DN 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide DMWG706 TI TTHQPL7 DMWG706 TN Carbonic anhydrase I (CA-I) DMWG706 MA Inhibitor DMWG706 RN Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides. Bioorg Med Chem. 2009 Jul 15;17(14):5054-8. DMWG706 RU https://pubmed.ncbi.nlm.nih.gov/19520577 DMWG706 DI DMWG706 DMWG706 DN 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide DMWG706 TI TT2LVK8 DMWG706 TN Carbonic anhydrase IX (CA-IX) DMWG706 MA Inhibitor DMWG706 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMWG706 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMWG706 DI DMWG706 DMWG706 DN 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide DMWG706 TI TTCFSPE DMWG706 TN Carbonic anhydrase VI (CA-VI) DMWG706 MA Inhibitor DMWG706 RN Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV. J Med Chem. 2009 Feb 12;52(3):646-54. DMWG706 RU https://pubmed.ncbi.nlm.nih.gov/19193158 DMWG706 DI DMWG706 DMWG706 DN 4-(2-aminopyrimidin-4-ylamino)benzenesulfonamide DMWG706 TI TTANPDJ DMWG706 TN Carbonic anhydrase II (CA-II) DMWG706 MA Inhibitor DMWG706 RN Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, ... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6649-54. DMWG706 RU https://pubmed.ncbi.nlm.nih.gov/19846301 DMWG9BE DI DMWG9BE DMWG9BE DN Methyl 3beta-hydroxyolean-12-en-28-oate DMWG9BE TI TTELIN2 DMWG9BE TN PTPN1 messenger RNA (PTPN1 mRNA) DMWG9BE MA Inhibitor DMWG9BE RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DMWG9BE RU https://pubmed.ncbi.nlm.nih.gov/16580200 DMWGADP DI DMWGADP DMWGADP DN [Fe(CN)6]4- DMWGADP TI TTZHA0O DMWGADP TN Carbonic anhydrase IV (CA-IV) DMWGADP MA Inhibitor DMWGADP RN Carbonic anhydrase inhibitors. Inhibition of isozymes I, II, IV, V and IX with complex fluorides, chlorides and cyanides. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1909-13. DMWGADP RU https://pubmed.ncbi.nlm.nih.gov/15780631 DMWGB40 DI DMWGB40 DMWGB40 DN (R)-nipecotic acid DMWGB40 TI TTV9MQG DMWGB40 TN Gamma-aminobutyric acid uptake (GABAU) DMWGB40 MA Inhibitor DMWGB40 RN GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects. Curr Pharm Des. 2000 Aug;6(12):1193-209. DMWGB40 RU https://pubmed.ncbi.nlm.nih.gov/10903390 DMWGB40 DI DMWGB40 DMWGB40 DN (R)-nipecotic acid DMWGB40 TI TTPRKM0 DMWGB40 TN GABA transporter GAT-1 (SLC6A1) DMWGB40 MA Inhibitor DMWGB40 RN Novel secoergoline derivatives inhibit both GABA and glutamate uptake in rat brain homogenates: synthesis, in vitro pharmacology, and modeling. J Med Chem. 2004 Nov 4;47(23):5620-9. DMWGB40 RU https://pubmed.ncbi.nlm.nih.gov/15509161 DMWGDXF DI DMWGDXF DMWGDXF DN TDI-0107 DMWGDXF TI TT6RVLG DMWGDXF TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMWGDXF MA Inhibitor DMWGDXF RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DMWGDXF RU https://pubmed.ncbi.nlm.nih.gov/16914587 DMWGE3U DI DMWGE3U DMWGE3U DN 2-Amino-6-(toluene-2-sulfonyl)-benzonitrile DMWGE3U TI TT84ETX DMWGE3U TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMWGE3U MA Inhibitor DMWGE3U RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMWGE3U RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMWGF9R DI DMWGF9R DMWGF9R DN 4'-cyano-3-(imidazolylmethyl)-7-methoxyflavone DMWGF9R TI TTSZLWK DMWGF9R TN Aromatase (CYP19A1) DMWGF9R MA Inhibitor DMWGF9R RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DMWGF9R RU https://pubmed.ncbi.nlm.nih.gov/16854084 DMWGN3F DI DMWGN3F DMWGN3F DN 1,2,6-tri-O-galloyl-beta-D-glucose DMWGN3F TI TTE14XG DMWGN3F TN Squalene monooxygenase (SQLE) DMWGN3F MA Inhibitor DMWGN3F RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMWGN3F RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMWGPO6 DI DMWGPO6 DMWGPO6 DN L-aspartic acid DMWGPO6 TI TTKJEMQ DMWGPO6 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMWGPO6 MA Agonist DMWGPO6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMWGPO6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMWGPO6 DI DMWGPO6 DMWGPO6 DN L-aspartic acid DMWGPO6 TI TTN9D8E DMWGPO6 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMWGPO6 MA Agonist DMWGPO6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMWGPO6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMWGPO6 DI DMWGPO6 DMWGPO6 DN L-aspartic acid DMWGPO6 TI TTLD29N DMWGPO6 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMWGPO6 MA Agonist DMWGPO6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMWGPO6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMWGPO6 DI DMWGPO6 DMWGPO6 DN L-aspartic acid DMWGPO6 TI TT5POTG DMWGPO6 TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMWGPO6 MA Agonist DMWGPO6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMWGPO6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMWGPO6 DI DMWGPO6 DMWGPO6 DN L-aspartic acid DMWGPO6 TI TT1M8OW DMWGPO6 TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMWGPO6 MA Agonist DMWGPO6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMWGPO6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMWGRL8 DI DMWGRL8 DMWGRL8 DN A-803467 DMWGRL8 TI TT90XZ8 DMWGRL8 TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMWGRL8 MA Inhibitor DMWGRL8 RN Sensory neuron voltage-gated sodium channels as analgesic drug targets. Curr Opin Neurobiol. 2008 Aug;18(4):383-8. DMWGRL8 RU https://pubmed.ncbi.nlm.nih.gov/18824099 DMWGSP6 DI DMWGSP6 DMWGSP6 DN 1,1,1-trifluoro-3-(hexylthio)propan-2-one DMWGSP6 TI TTMF541 DMWGSP6 TN Liver carboxylesterase (CES1) DMWGSP6 MA Inhibitor DMWGSP6 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMWGSP6 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMWGSP6 DI DMWGSP6 DMWGSP6 DN 1,1,1-trifluoro-3-(hexylthio)propan-2-one DMWGSP6 TI TTDP1UC DMWGSP6 TN Fatty acid amide hydrolase (FAAH) DMWGSP6 MA Inhibitor DMWGSP6 RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMWGSP6 RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMWGSQO DI DMWGSQO DMWGSQO DN JWH-156 DMWGSQO TI TT6OEDT DMWGSQO TN Cannabinoid receptor 1 (CB1) DMWGSQO MA Inhibitor DMWGSQO RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMWGSQO RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMWGSQO DI DMWGSQO DMWGSQO DN JWH-156 DMWGSQO TI TTMSFAW DMWGSQO TN Cannabinoid receptor 2 (CB2) DMWGSQO MA Inhibitor DMWGSQO RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMWGSQO RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMWGXBF DI DMWGXBF DMWGXBF DN GNF-PF-600 DMWGXBF TI TTIQSC1 DMWGXBF TN Bacterial Lethal factor (Bact lef) DMWGXBF MA Inhibitor DMWGXBF RN Anthrax lethal factor protease inhibitors: synthesis, SAR, and structure-based 3D QSAR studies. J Med Chem. 2006 Jan 12;49(1):27-30. DMWGXBF RU https://pubmed.ncbi.nlm.nih.gov/16392787 DMWGY61 DI DMWGY61 DMWGY61 DN [3H]ETB-TBOA DMWGY61 TI TT2F078 DMWGY61 TN Excitatory amino acid transporter 2 (SLC1A2) DMWGY61 MA Modulator DMWGY61 RN Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302. DMWGY61 RU https://pubmed.ncbi.nlm.nih.gov/17047096 DMWGY61 DI DMWGY61 DMWGY61 DN [3H]ETB-TBOA DMWGY61 TI TT6KMPN DMWGY61 TN Excitatory amino acid transporter 4 (SLC1A6) DMWGY61 MA Modulator DMWGY61 RN Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302. DMWGY61 RU https://pubmed.ncbi.nlm.nih.gov/17047096 DMWGY61 DI DMWGY61 DMWGY61 DN [3H]ETB-TBOA DMWGY61 TI TT8WRDA DMWGY61 TN Excitatory amino acid transporter 1 (SLC1A3) DMWGY61 MA Modulator DMWGY61 RN Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302. DMWGY61 RU https://pubmed.ncbi.nlm.nih.gov/17047096 DMWGY61 DI DMWGY61 DMWGY61 DN [3H]ETB-TBOA DMWGY61 TI TTK41DM DMWGY61 TN Excitatory amino acid transporter 5 (SLC1A7) DMWGY61 MA Modulator DMWGY61 RN Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302. DMWGY61 RU https://pubmed.ncbi.nlm.nih.gov/17047096 DMWGY61 DI DMWGY61 DMWGY61 DN [3H]ETB-TBOA DMWGY61 TI TTG2A6F DMWGY61 TN Excitatory amino acid transporter 3 (SLC1A1) DMWGY61 MA Modulator DMWGY61 RN Characterization of the tritium-labeled analog of L-threo-beta-benzyloxyaspartate binding to glutamate transporters. Mol Pharmacol. 2007 Jan;71(1):294-302. DMWGY61 RU https://pubmed.ncbi.nlm.nih.gov/17047096 DMWH0ER DI DMWH0ER DMWH0ER DN 3,3'-thiene-2,5-diyldiphenol DMWH0ER TI TTIWB6L DMWH0ER TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMWH0ER MA Inhibitor DMWH0ER RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMWH0ER RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMWH2NT DI DMWH2NT DMWH2NT DN 4-Sulfamoyloxy-benzoic acid butyl ester DMWH2NT TI TTHM0R1 DMWH2NT TN Steryl-sulfatase (STS) DMWH2NT MA Inhibitor DMWH2NT RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMWH2NT RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMWH86J DI DMWH86J DMWH86J DN N-phenyl-3-(2-aminoethyl)benzenesulfonamide DMWH86J TI TTJS8PY DMWH86J TN 5-HT 6 receptor (HTR6) DMWH86J MA Inhibitor DMWH86J RN Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25. DMWH86J RU https://pubmed.ncbi.nlm.nih.gov/16913710 DMWH92F DI DMWH92F DMWH92F DN Hydrolyzed Cephalothin DMWH92F TI TTHI19T DMWH92F TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMWH92F MA Inhibitor DMWH92F RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWH92F RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TT4C8EA DMWHEV8 TN Dopamine D3 receptor (D3R) DMWHEV8 MA Antagonist DMWHEV8 RN Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol. 2000 Jul;130(5):1045-59. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/10882389 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TTE0A2F DMWHEV8 TN Dopamine D4 receptor (D4R) DMWHEV8 MA Antagonist DMWHEV8 RN Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci Lett. 1995 Feb 17;186(2-3):145-8. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/7777184 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TTEX248 DMWHEV8 TN Dopamine D2 receptor (D2R) DMWHEV8 MA Antagonist DMWHEV8 RN Regulation of human D(1), d(2(long)), d(2(short)), D(3) and D(4) dopamine receptors by amiloride and amiloride analogues. Br J Pharmacol. 2000 Jul;130(5):1045-59. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/10882389 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TTO9X1H DMWHEV8 TN 5-HT 7 receptor (HTR7) DMWHEV8 MA Inhibitor DMWHEV8 RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TTNGILX DMWHEV8 TN Adrenergic receptor alpha-1A (ADRA1A) DMWHEV8 MA Inhibitor DMWHEV8 RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TTJQOD7 DMWHEV8 TN 5-HT 2A receptor (HTR2A) DMWHEV8 MA Inhibitor DMWHEV8 RN Activity of Parthenolide at 5HT2A receptors. J Nat Prod. 1997 Jun;60(6):651-3. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/9214741 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TTSQIFT DMWHEV8 TN 5-HT 1A receptor (HTR1A) DMWHEV8 MA Inhibitor DMWHEV8 RN Synthesis of (R,S)-trans-8-hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetral in (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J Med Chem. 1993 Oct 15;36(21):3161-5. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/8230102 DMWHEV8 DI DMWHEV8 DMWHEV8 DN [3H]spiperone DMWHEV8 TI TTJS8PY DMWHEV8 TN 5-HT 6 receptor (HTR6) DMWHEV8 MA Inhibitor DMWHEV8 RN Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812. DMWHEV8 RU https://pubmed.ncbi.nlm.nih.gov/12825922 DMWHK35 DI DMWHK35 DMWHK35 DN 2,3,4-trihydroxybenzoic acid DMWHK35 TI TT2IYXF DMWHK35 TN L-selectin (SELL) DMWHK35 MA Inhibitor DMWHK35 RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DMWHK35 RU https://pubmed.ncbi.nlm.nih.gov/17302397 DMWHK35 DI DMWHK35 DMWHK35 DN 2,3,4-trihydroxybenzoic acid DMWHK35 TI TTE5VG0 DMWHK35 TN P-selectin (SELP) DMWHK35 MA Inhibitor DMWHK35 RN Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15. DMWHK35 RU https://pubmed.ncbi.nlm.nih.gov/17302397 DMWHKLA DI DMWHKLA DMWHKLA DN 4-[1-(4-hydroxyphenyl)-2-phenylpent-1-enyl]phenol DMWHKLA TI TTZAYWL DMWHKLA TN Estrogen receptor (ESR) DMWHKLA MA Inhibitor DMWHKLA RN Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkyl-substituted 1,1-bis(4-hydroxyphen... J Med Chem. 2002 Nov 21;45(24):5358-64. DMWHKLA RU https://pubmed.ncbi.nlm.nih.gov/12431063 DMWHMNY DI DMWHMNY DMWHMNY DN 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol DMWHMNY TI TTKWM86 DMWHMNY TN Opioid receptor mu (MOP) DMWHMNY MA Inhibitor DMWHMNY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWHMNY RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWHMNY DI DMWHMNY DMWHMNY DN 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol DMWHMNY TI TTNT7K8 DMWHMNY TN Nociceptin receptor (OPRL1) DMWHMNY MA Inhibitor DMWHMNY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWHMNY RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWHMNY DI DMWHMNY DMWHMNY DN 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol DMWHMNY TI TTQW87Y DMWHMNY TN Opioid receptor kappa (OPRK1) DMWHMNY MA Inhibitor DMWHMNY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWHMNY RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWHMNY DI DMWHMNY DMWHMNY DN 1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol DMWHMNY TI TT27RFC DMWHMNY TN Opioid receptor delta (OPRD1) DMWHMNY MA Inhibitor DMWHMNY RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWHMNY RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWHN2J DI DMWHN2J DMWHN2J DN 1,1,1,2,2,3,3,5-octafluoro-8-phenyloctan-4-one DMWHN2J TI TTT1JVS DMWHN2J TN Cytosolic phospholipase A2 (GIVA cPLA2) DMWHN2J MA Inhibitor DMWHN2J RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DMWHN2J RU https://pubmed.ncbi.nlm.nih.gov/20369880 DMWHN3T DI DMWHN3T DMWHN3T DN PPADS DMWHN3T TI TTA93TL DMWHN3T TN P2Y purinoceptor 1 (P2RY1) DMWHN3T MA Antagonist DMWHN3T RN Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist. Mol Pharmacol. 2002 Nov;62(5):1249-57. DMWHN3T RU https://pubmed.ncbi.nlm.nih.gov/12391289 DMWHN3T DI DMWHN3T DMWHN3T DN PPADS DMWHN3T TI TT1FE3L DMWHN3T TN P2Y purinoceptor 13 (P2RY13) DMWHN3T MA Antagonist DMWHN3T RN Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. DMWHN3T RU https://pubmed.ncbi.nlm.nih.gov/12815166 DMWHN3T DI DMWHN3T DMWHN3T DN PPADS DMWHN3T TI TT24DGP DMWHN3T TN P2Y purinoceptor 4 (P2RY4) DMWHN3T MA Antagonist DMWHN3T RN Development of selective agonists and antagonists of P2Y receptors. Purinergic Signal. 2009 Mar;5(1):75-89. DMWHN3T RU https://pubmed.ncbi.nlm.nih.gov/18600475 DMWHN56 DI DMWHN56 DMWHN56 DN JWH-315 DMWHN56 TI TTMSFAW DMWHN56 TN Cannabinoid receptor 2 (CB2) DMWHN56 MA Inhibitor DMWHN56 RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMWHN56 RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMWHNZ4 DI DMWHNZ4 DMWHNZ4 DN Plantainoside D DMWHNZ4 TI TTFJ8Q1 DMWHNZ4 TN Protein kinase C alpha (PRKCA) DMWHNZ4 MA Inhibitor DMWHNZ4 RN Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2. DMWHNZ4 RU https://pubmed.ncbi.nlm.nih.gov/9834166 DMWHP52 DI DMWHP52 DMWHP52 DN CAT-2200 DMWHP52 TI TT69OHW DMWHP52 TN Interleukin 17 receptor (IL17R) DMWHP52 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2294). DMWHP52 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2294 DMWHUKZ DI DMWHUKZ DMWHUKZ DN AR-XYZ DMWHUKZ TI TTMSFAW DMWHUKZ TN Cannabinoid receptor 2 (CB2) DMWHUKZ MA Agonist DMWHUKZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DMWHUKZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DMWHYND DI DMWHYND DMWHYND DN NSC-745888 DMWHYND TI TTQY2EJ DMWHYND TN TERT messenger RNA (TERT mRNA) DMWHYND MA Inhibitor DMWHYND RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMWHYND RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMWHYOJ DI DMWHYOJ DMWHYOJ DN N-(4'-bromo-3,3'-difluoro-4-biphenylyl)urea DMWHYOJ TI TTBGTCW DMWHYOJ TN Kinesin spindle messenger RNA (KIF11 mRNA) DMWHYOJ MA Inhibitor DMWHYOJ RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMWHYOJ RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMWI06H DI DMWI06H DMWI06H DN N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP DMWI06H TI TTEB0GD DMWI06H TN Cholinesterase (BCHE) DMWI06H MA Inhibitor DMWI06H RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMWI06H RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMWI06H DI DMWI06H DMWI06H DN N,N'-(1',12'-dodecydene)-bis-(-)-nor-MEP DMWI06H TI TT1RS9F DMWI06H TN Acetylcholinesterase (AChE) DMWI06H MA Inhibitor DMWI06H RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMWI06H RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMWI0M8 DI DMWI0M8 DMWI0M8 DN ISOPPADS DMWI0M8 TI TT2THBD DMWI0M8 TN P2X purinoceptor 3 (P2RX3) DMWI0M8 MA Inhibitor DMWI0M8 RN Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001 Feb 1;44(3):340-9. DMWI0M8 RU https://pubmed.ncbi.nlm.nih.gov/11462975 DMWI0M8 DI DMWI0M8 DMWI0M8 DN ISOPPADS DMWI0M8 TI TT473XN DMWI0M8 TN P2X purinoceptor 7 (P2RX7) DMWI0M8 MA Inhibitor DMWI0M8 RN Structure-activity relationship studies of spinorphin as a potent and selective human P2X(3) receptor antagonist. J Med Chem. 2007 Sep 6;50(18):4543-7. DMWI0M8 RU https://pubmed.ncbi.nlm.nih.gov/17676725 DMWI37C DI DMWI37C DMWI37C DN 3-(1-Pyridin-2-yl-1H-pyrazol-4-yl)-benzonitrile DMWI37C TI TTHS256 DMWI37C TN Metabotropic glutamate receptor 5 (mGluR5) DMWI37C MA Inhibitor DMWI37C RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMWI37C RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMWI7XJ DI DMWI7XJ DMWI7XJ DN 5-Phenethyl-quinazoline-2,4-diamine DMWI7XJ TI TT9SL3Q DMWI7XJ TN Polypeptide deformylase (PDF) DMWI7XJ MA Inhibitor DMWI7XJ RN 2,4-Diamino-5-substituted-quinazolines as inhibitors of a human dihydrofolate reductase with a site-directed mutation at position 22 and of the dih... J Med Chem. 1995 Mar 3;38(5):745-52. DMWI7XJ RU https://pubmed.ncbi.nlm.nih.gov/7877140 DMWI9XS DI DMWI9XS DMWI9XS DN 2,3-Dihydro-1H-isoindole DMWI9XS TI TT2NUT5 DMWI9XS TN Adrenergic receptor alpha-2C (ADRA2C) DMWI9XS MA Inhibitor DMWI9XS RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMWI9XS RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMWI9XS DI DMWI9XS DMWI9XS DN 2,3-Dihydro-1H-isoindole DMWI9XS TI TTWG9A4 DMWI9XS TN Adrenergic receptor alpha-2A (ADRA2A) DMWI9XS MA Inhibitor DMWI9XS RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMWI9XS RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMWI9XS DI DMWI9XS DMWI9XS DN 2,3-Dihydro-1H-isoindole DMWI9XS TI TTWM4TY DMWI9XS TN Adrenergic receptor alpha-2B (ADRA2B) DMWI9XS MA Inhibitor DMWI9XS RN Effect of ring size or an additional heteroatom on the potency and selectivity of bicyclic benzylamine-type inhibitors of phenylethanolamine N-meth... J Med Chem. 1996 Aug 30;39(18):3539-46. DMWI9XS RU https://pubmed.ncbi.nlm.nih.gov/8784452 DMWIABE DI DMWIABE DMWIABE DN (+/-)-3-(pent-4-enyl)azetidin-2-one DMWIABE TI TTDP1UC DMWIABE TN Fatty acid amide hydrolase (FAAH) DMWIABE MA Inhibitor DMWIABE RN 3-Alkenyl-2-azetidinones as fatty acid amide hydrolase inhibitors. Bioorg Med Chem Lett. 2008 Jul 15;18(14):4163-7. DMWIABE RU https://pubmed.ncbi.nlm.nih.gov/18547805 DMWIALU DI DMWIALU DMWIALU DN 4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid DMWIALU TI TTGP7BY DMWIALU TN Monoamine oxidase type B (MAO-B) DMWIALU MA Inhibitor DMWIALU RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMWIALU RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMWIALU DI DMWIALU DMWIALU DN 4-(2-oxo-2H-chromene-3-carboxamido)benzoic acid DMWIALU TI TT3WG5C DMWIALU TN Monoamine oxidase type A (MAO-A) DMWIALU MA Inhibitor DMWIALU RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMWIALU RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMWIB0V DI DMWIB0V DMWIB0V DN Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate DMWIB0V TI TTZHA0O DMWIB0V TN Carbonic anhydrase IV (CA-IV) DMWIB0V MA Inhibitor DMWIB0V RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMWIB0V RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMWIB0V DI DMWIB0V DMWIB0V DN Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate DMWIB0V TI TTUNARX DMWIB0V TN Carbonic anhydrase (CA) DMWIB0V MA Inhibitor DMWIB0V RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMWIB0V RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMWIB0V DI DMWIB0V DMWIB0V DN Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate DMWIB0V TI TTSYM0R DMWIB0V TN Carbonic anhydrase XII (CA-XII) DMWIB0V MA Inhibitor DMWIB0V RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMWIB0V RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMWIB0V DI DMWIB0V DMWIB0V DN Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate DMWIB0V TI TTEYTKG DMWIB0V TN Carbonic anhydrase XIV (CA-XIV) DMWIB0V MA Inhibitor DMWIB0V RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMWIB0V RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMWIB0V DI DMWIB0V DMWIB0V DN Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate DMWIB0V TI TTCFSPE DMWIB0V TN Carbonic anhydrase VI (CA-VI) DMWIB0V MA Inhibitor DMWIB0V RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMWIB0V RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMWIB0V DI DMWIB0V DMWIB0V DN Ethyl 7-methoxy-2-oxo-2H-chromene-3-carboxylate DMWIB0V TI TT2LVK8 DMWIB0V TN Carbonic anhydrase IX (CA-IX) DMWIB0V MA Inhibitor DMWIB0V RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMWIB0V RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMWIBFM DI DMWIBFM DMWIBFM DN EXP3174 DMWIBFM TI TT8DBY3 DMWIBFM TN Angiotensin II receptor type-1 (AGTR1) DMWIBFM MA Antagonist DMWIBFM RN Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993 Jun;45(2):205-51. DMWIBFM RU https://pubmed.ncbi.nlm.nih.gov/8372104 DMWIEDN DI DMWIEDN DMWIEDN DN 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol DMWIEDN TI TT3ROYC DMWIEDN TN Serotonin transporter (SERT) DMWIEDN MA Inhibitor DMWIEDN RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DMWIEDN RU https://pubmed.ncbi.nlm.nih.gov/15115403 DMWIEDN DI DMWIEDN DMWIEDN DN 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol DMWIEDN TI TTVBI8W DMWIEDN TN Dopamine transporter (DAT) DMWIEDN MA Inhibitor DMWIEDN RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DMWIEDN RU https://pubmed.ncbi.nlm.nih.gov/15115403 DMWIEDN DI DMWIEDN DMWIEDN DN 1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol DMWIEDN TI TTAWNKZ DMWIEDN TN Norepinephrine transporter (NET) DMWIEDN MA Inhibitor DMWIEDN RN Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34. DMWIEDN RU https://pubmed.ncbi.nlm.nih.gov/15115403 DMWIHRX DI DMWIHRX DMWIHRX DN inhibitor 19 DMWIHRX TI TTY2KP7 DMWIHRX TN Leucyl-cysteinyl aminopeptidase (LNPEP) DMWIHRX MA Inhibitor DMWIHRX RN Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis. J Med Chem. 2011 Jun 9;54(11):3779-92. DMWIHRX RU https://pubmed.ncbi.nlm.nih.gov/21476495 DMWIKD5 DI DMWIKD5 DMWIKD5 DN ISIS 14144 DMWIKD5 TI TT0EOB8 DMWIKD5 TN B-Raf messenger RNA (BRAF mRNA) DMWIKD5 RN US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression. DMWIKD5 RU http://www.patentbuddy.com/Patent/5981731?ft=true&sr=true DMWIMR4 DI DMWIMR4 DMWIMR4 DN N-hydroxy-2,2'-bithiophene-5-carboxamide DMWIMR4 TI TT6R7JZ DMWIMR4 TN Histone deacetylase 1 (HDAC1) DMWIMR4 MA Inhibitor DMWIMR4 RN Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. DMWIMR4 RU https://pubmed.ncbi.nlm.nih.gov/17107790 DMWIMUZ DI DMWIMUZ DMWIMUZ DN Isoquinoline-3-carboxylic acid methyl ester DMWIMUZ TI TT1MPAY DMWIMUZ TN GABA(A) receptor alpha-1 (GABRA1) DMWIMUZ MA Inhibitor DMWIMUZ RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMWIMUZ RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMWIMUZ DI DMWIMUZ DMWIMUZ DN Isoquinoline-3-carboxylic acid methyl ester DMWIMUZ TI TTNJYV2 DMWIMUZ TN Gamma-aminobutyric acid receptor (GAR) DMWIMUZ MA Inhibitor DMWIMUZ RN Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J Med Chem. 1988 Sep;31(9):1854-61. DMWIMUZ RU https://pubmed.ncbi.nlm.nih.gov/2842507 DMWINK5 DI DMWINK5 DMWINK5 DN Cypate-[(RGD)3-NH2]1 DMWINK5 TI TTJA1ZO DMWINK5 TN ITGB3 messenger RNA (ITGB3 mRNA) DMWINK5 MA Inhibitor DMWINK5 RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMWINK5 RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMWINK5 DI DMWINK5 DMWINK5 DN Cypate-[(RGD)3-NH2]1 DMWINK5 TI TTT1R2L DMWINK5 TN Integrin alpha-V (ITGAV) DMWINK5 MA Inhibitor DMWINK5 RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMWINK5 RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMWIOCY DI DMWIOCY DMWIOCY DN HJP-272 DMWIOCY TI TTKRD0G DMWIOCY TN Endothelin A receptor (EDNRA) DMWIOCY MA Antagonist DMWIOCY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 219). DMWIOCY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=219 DMWITYU DI DMWITYU DMWITYU DN 6-(4-Methylpiperazin-1-yl)-9H-purin-2-amine DMWITYU TI TTXJ178 DMWITYU TN Histamine H4 receptor (H4R) DMWITYU MA Inhibitor DMWITYU RN 2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96. DMWITYU RU https://pubmed.ncbi.nlm.nih.gov/19773175 DMWIUR0 DI DMWIUR0 DMWIUR0 DN 2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid DMWIUR0 TI TTMWT8Z DMWIUR0 TN C-X-C chemokine receptor type 1 (CXCR1) DMWIUR0 MA Inhibitor DMWIUR0 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMWIUR0 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMWIUR0 DI DMWIUR0 DMWIUR0 DN 2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid DMWIUR0 TI TT30C9G DMWIUR0 TN C-X-C chemokine receptor type 2 (CXCR2) DMWIUR0 MA Inhibitor DMWIUR0 RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMWIUR0 RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMWIVM3 DI DMWIVM3 DMWIVM3 DN PF-06454589 DMWIVM3 TI TTK0FEA DMWIVM3 TN Leucine-rich repeat kinase 2 (LRRK2) DMWIVM3 MA Inhibitor DMWIVM3 RN Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem. 2015 Jan 8;58(1):419-32. DMWIVM3 RU https://pubmed.ncbi.nlm.nih.gov/25353650 DMWIVS9 DI DMWIVS9 DMWIVS9 DN ISIS 330012 DMWIVS9 TI TTWRN6M DMWIVS9 TN CRP messenger RNA (CRP mRNA) DMWIVS9 RN US patent application no. 7,425,545, Modulation of C-reactive protein expression. DMWIVS9 RU http://www.patentbuddy.com/Patent/7425545?ft=true&sr=true DMWIXQS DI DMWIXQS DMWIXQS DN RP-72540 DMWIXQS TI TTVFO0U DMWIXQS TN Gastrin/cholecystokinin type B receptor (CCKBR) DMWIXQS MA Modulator DMWIXQS RN Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233-45. DMWIXQS RU https://pubmed.ncbi.nlm.nih.gov/7813588 DMWJ2M5 DI DMWJ2M5 DMWJ2M5 DN Ac-VTHRLAGLLSRSGGVVRKNFVPTDVGPFAF-NH2 DMWJ2M5 TI TTVSFJW DMWJ2M5 TN Calcitonin gene-related peptide 1 (CALCA) DMWJ2M5 MA Inhibitor DMWJ2M5 RN Identification of potent, selective, and metabolically stable peptide antagonists to the calcitonin gene-related peptide (CGRP) receptor. J Med Chem. 2008 Dec 25;51(24):7889-97. DMWJ2M5 RU https://pubmed.ncbi.nlm.nih.gov/19053766 DMWJ2PM DI DMWJ2PM DMWJ2PM DN N,N-Dimethylaminoethyl 18-methoxycoronaridinate DMWJ2PM TI TTTVAFQ DMWJ2PM TN Neuronal acetylcholine receptor beta-4 (CHRNB4) DMWJ2PM MA Inhibitor DMWJ2PM RN Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19;46(13):2716-30. DMWJ2PM RU https://pubmed.ncbi.nlm.nih.gov/12801235 DMWJ6UD DI DMWJ6UD DMWJ6UD DN 3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one DMWJ6UD TI TTMF541 DMWJ6UD TN Liver carboxylesterase (CES1) DMWJ6UD MA Inhibitor DMWJ6UD RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMWJ6UD RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMWJ6UD DI DMWJ6UD DMWJ6UD DN 3-(decylsulfinyl)-1,1,1-trifluoropropan-2-one DMWJ6UD TI TTDP1UC DMWJ6UD TN Fatty acid amide hydrolase (FAAH) DMWJ6UD MA Inhibitor DMWJ6UD RN Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hy... Bioorg Med Chem. 2008 Feb 15;16(4):2114-30. DMWJ6UD RU https://pubmed.ncbi.nlm.nih.gov/18023188 DMWJ70Q DI DMWJ70Q DMWJ70Q DN Small molecule 34 DMWJ70Q TI TTQBR95 DMWJ70Q TN Stress-activated protein kinase 2a (p38 alpha) DMWJ70Q MA Inhibitor DMWJ70Q RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWJ70Q RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWJ8UR DI DMWJ8UR DMWJ8UR DN Ac-YRC(Me)*EHdFRWC(Me)NH2 DMWJ8UR TI TTNI91K DMWJ8UR TN Melanocortin receptor 3 (MC3R) DMWJ8UR MA Inhibitor DMWJ8UR RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMWJ8UR RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMWJ8UR DI DMWJ8UR DMWJ8UR DN Ac-YRC(Me)*EHdFRWC(Me)NH2 DMWJ8UR TI TTEOSZT DMWJ8UR TN Melanocortin receptor (MCR) DMWJ8UR MA Inhibitor DMWJ8UR RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMWJ8UR RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMWJ8UR DI DMWJ8UR DMWJ8UR DN Ac-YRC(Me)*EHdFRWC(Me)NH2 DMWJ8UR TI TT0MV2T DMWJ8UR TN Melanocortin receptor 1 (MC1R) DMWJ8UR MA Inhibitor DMWJ8UR RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMWJ8UR RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMWJ8UR DI DMWJ8UR DMWJ8UR DN Ac-YRC(Me)*EHdFRWC(Me)NH2 DMWJ8UR TI TTD0CIQ DMWJ8UR TN Melanocortin receptor 4 (MC4R) DMWJ8UR MA Inhibitor DMWJ8UR RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMWJ8UR RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMWJCST DI DMWJCST DMWJCST DN phytosphingosine 1-phosphate DMWJCST TI TTZ8C5Q DMWJCST TN Sphingosine-1-phosphate receptor 4 (S1PR4) DMWJCST MA Agonist DMWJCST RN Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun. 2002 Sep 27;297(3):600-6. DMWJCST RU https://pubmed.ncbi.nlm.nih.gov/12270137 DMWJDYZ DI DMWJDYZ DMWJDYZ DN N-(Sulfanylacetyl)Tyrosylprolylmethioninamide DMWJDYZ TI TTIQSC1 DMWJDYZ TN Bacterial Lethal factor (Bact lef) DMWJDYZ MA Inhibitor DMWJDYZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWJDYZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWJE2X DI DMWJE2X DMWJE2X DN S-(4-Chlorobenzyl)isothiourea hydrochloride DMWJE2X TI TTZJYKH DMWJE2X TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMWJE2X MA Inhibitor DMWJE2X RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMWJE2X RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMWJN73 DI DMWJN73 DMWJN73 DN 4-(Hydroxymercury)Benzoic Acid DMWJN73 TI TTANPDJ DMWJN73 TN Carbonic anhydrase II (CA-II) DMWJN73 MA Inhibitor DMWJN73 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWJN73 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWJNFC DI DMWJNFC DMWJNFC DN (9-Methyl-9H-purin-6-yl)-phenyl-amine DMWJNFC TI TTK25J1 DMWJNFC TN Adenosine A1 receptor (ADORA1) DMWJNFC MA Inhibitor DMWJNFC RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMWJNFC RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMWJNV5 DI DMWJNV5 DMWJNV5 DN 16-beta-ethoxymethyl-estrone DMWJNV5 TI TTIWB6L DMWJNV5 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMWJNV5 MA Inhibitor DMWJNV5 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMWJNV5 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMWK0Z6 DI DMWK0Z6 DMWK0Z6 DN FGGFTGARKSARKRKRK DMWK0Z6 TI TTNT7K8 DMWK0Z6 TN Nociceptin receptor (OPRL1) DMWK0Z6 MA Inhibitor DMWK0Z6 RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMWK0Z6 RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMWK1XC DI DMWK1XC DMWK1XC DN ISIS 109352 DMWK1XC TI TT1MS7X DMWK1XC TN PKC-theta messenger RNA (PRKCQ mRNA) DMWK1XC RN US patent application no. 6,190,869, Antisense inhibition of protein kinase C-theta expression. DMWK1XC RU http://www.patentbuddy.com/Patent/6190869?ft=true&sr=true DMWK3LU DI DMWK3LU DMWK3LU DN RU84687 DMWK3LU TI TT6PKBN DMWK3LU TN Proto-oncogene c-Src (SRC) DMWK3LU MA Inhibitor DMWK3LU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMWK3LU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMWK3RO DI DMWK3RO DMWK3RO DN (1-Benzyl-2-oxo-ethyl)-carbamic acid benzyl ester DMWK3RO TI TTG5QB7 DMWK3RO TN Calpain-2 (CAPN2) DMWK3RO MA Inhibitor DMWK3RO RN Alpha-diketone and alpha-keto ester derivatives of N-protected amino acids and peptides as novel inhibitors of cysteine and serine proteinases. J Med Chem. 1990 Jan;33(1):11-3. DMWK3RO RU https://pubmed.ncbi.nlm.nih.gov/2296008 DMWK91T DI DMWK91T DMWK91T DN N,N-dimethyl(2-phenoxyphenyl)methanamine DMWK91T TI TTAWNKZ DMWK91T TN Norepinephrine transporter (NET) DMWK91T MA Inhibitor DMWK91T RN 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9. DMWK91T RU https://pubmed.ncbi.nlm.nih.gov/18240382 DMWK91T DI DMWK91T DMWK91T DN N,N-dimethyl(2-phenoxyphenyl)methanamine DMWK91T TI TT3ROYC DMWK91T TN Serotonin transporter (SERT) DMWK91T MA Inhibitor DMWK91T RN 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9. DMWK91T RU https://pubmed.ncbi.nlm.nih.gov/18240382 DMWKPJH DI DMWKPJH DMWKPJH DN AK198 DMWKPJH TI TTFBNVI DMWKPJH TN Aldose reductase (AKR1B1) DMWKPJH MA Inhibitor DMWKPJH RN The Effect of Halogen-to-Hydrogen Bond Substitution on Human Aldose Reductase Inhibition. ACS Chem Biol. 2015 Jul 17;10(7):1637-42. DMWKPJH RU https://pubmed.ncbi.nlm.nih.gov/25919404 DMWKRJX DI DMWKRJX DMWKRJX DN N',2-diphenylquinoline-4-carbohydrazide DMWKRJX TI TTBPGLU DMWKRJX TN Neuromedin-K receptor (TACR3) DMWKRJX MA Antagonist DMWKRJX RN N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5748-51. DMWKRJX RU https://pubmed.ncbi.nlm.nih.gov/16950620 DMWKS29 DI DMWKS29 DMWKS29 DN ECOPLADIB DMWKS29 TI TTT1JVS DMWKS29 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMWKS29 MA Inhibitor DMWKS29 RN Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71. DMWKS29 RU https://pubmed.ncbi.nlm.nih.gov/19178292 DMWKTYC DI DMWKTYC DMWKTYC DN RU79073 DMWKTYC TI TT6PKBN DMWKTYC TN Proto-oncogene c-Src (SRC) DMWKTYC MA Inhibitor DMWKTYC RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMWKTYC RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMWKXGP DI DMWKXGP DMWKXGP DN MRS4062 DMWKXGP TI TT24DGP DMWKXGP TN P2Y purinoceptor 4 (P2RY4) DMWKXGP MA Agonist DMWKXGP RN Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate delta-ester modifications as selective agonists of the P2Y(4) receptor. J Med Chem. 2011 Jun 23;54(12):4018-33. DMWKXGP RU https://pubmed.ncbi.nlm.nih.gov/21528910 DMWKXZ2 DI DMWKXZ2 DMWKXZ2 DN 1-(3-(4-fluorophenyl)propyl)-1H-imidazole DMWKXZ2 TI TTRA5BZ DMWKXZ2 TN Steroid 17-alpha-monooxygenase (S17AH) DMWKXZ2 MA Inhibitor DMWKXZ2 RN Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitor... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4752-6. DMWKXZ2 RU https://pubmed.ncbi.nlm.nih.gov/16870430 DMWKXZ2 DI DMWKXZ2 DMWKXZ2 DN 1-(3-(4-fluorophenyl)propyl)-1H-imidazole DMWKXZ2 TI TTSZLWK DMWKXZ2 TN Aromatase (CYP19A1) DMWKXZ2 MA Inhibitor DMWKXZ2 RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMWKXZ2 RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMWKYFO DI DMWKYFO DMWKYFO DN LY382884 DMWKYFO TI TT0MYE2 DMWKYFO TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMWKYFO MA Antagonist DMWKYFO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMWKYFO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMWKZCY DI DMWKZCY DMWKZCY DN MRS2802 DMWKZCY TI TT72OKI DMWKZCY TN P2Y purinoceptor 14 (P2RY14) DMWKZCY MA Agonist DMWKZCY RN Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J Med Chem. 2010 Jan 14;53(1):471-80. DMWKZCY RU https://pubmed.ncbi.nlm.nih.gov/19902968 DMWL172 DI DMWL172 DMWL172 DN Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid DMWL172 TI TTHI19T DMWL172 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMWL172 MA Inhibitor DMWL172 RN Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76. DMWL172 RU https://pubmed.ncbi.nlm.nih.gov/20527888 DMWL1UY DI DMWL1UY DMWL1UY DN 5,5-diethyl-2-(phenethylamino)oxazol-4(5H)-one DMWL1UY TI TTN7BL9 DMWL1UY TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMWL1UY MA Inhibitor DMWL1UY RN Oxazolones as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4837-40. DMWL1UY RU https://pubmed.ncbi.nlm.nih.gov/17600707 DMWL9CU DI DMWL9CU DMWL9CU DN PF-00614435 DMWL9CU TI TTNDSF4 DMWL9CU TN Proto-oncogene c-Met (MET) DMWL9CU MA Inhibitor DMWL9CU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815). DMWL9CU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815 DMWLDRJ DI DMWLDRJ DMWLDRJ DN PIROTIODECANE DMWLDRJ TI TTXLO8T DMWLDRJ TN Potential penetration (PP) DMWLDRJ MA Modulator DMWLDRJ RN Effectiveness of pirotiodecane, absorption enhancer, on nasal absorption in rabbits. Drug Metab Pharmacokinet. 2005 Feb;20(1):65-71. DMWLDRJ RU https://pubmed.ncbi.nlm.nih.gov/15770076 DMWLHBQ DI DMWLHBQ DMWLHBQ DN D-264 DMWLHBQ TI TT4C8EA DMWLHBQ TN Dopamine D3 receptor (D3R) DMWLHBQ MA Inhibitor DMWLHBQ RN Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-... Bioorg Med Chem. 2009 Jun 1;17(11):3923-33. DMWLHBQ RU https://pubmed.ncbi.nlm.nih.gov/19427222 DMWLHBQ DI DMWLHBQ DMWLHBQ DN D-264 DMWLHBQ TI TTEX248 DMWLHBQ TN Dopamine D2 receptor (D2R) DMWLHBQ MA Inhibitor DMWLHBQ RN Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-... Bioorg Med Chem. 2009 Jun 1;17(11):3923-33. DMWLHBQ RU https://pubmed.ncbi.nlm.nih.gov/19427222 DMWLI4U DI DMWLI4U DMWLI4U DN N-Ethyl-2-methylnorapomorphine hydrochloride DMWLI4U TI TTEX248 DMWLI4U TN Dopamine D2 receptor (D2R) DMWLI4U MA Inhibitor DMWLI4U RN N-Substituted-2-alkyl- and 2-arylnorapomorphines: novel, highly active D2 agonists. Bioorg Med Chem. 2009 Jul 1;17(13):4756-62. DMWLI4U RU https://pubmed.ncbi.nlm.nih.gov/19454369 DMWLIK1 DI DMWLIK1 DMWLIK1 DN 3-benzofuran-2-yl-2-benzothiazol-2-yl-3-oxo-propanenitrile DMWLIK1 TI TTHGL48 DMWLIK1 TN AP endonuclease 1 (APEX1) DMWLIK1 MA Inhibitor DMWLIK1 RN Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63. DMWLIK1 RU https://pubmed.ncbi.nlm.nih.gov/21266972 DMWLJ5S DI DMWLJ5S DMWLJ5S DN Hyrtiosulawesine DMWLJ5S TI TT9V5JH DMWLJ5S TN Phospholipase A2 (PLA2G1B) DMWLJ5S MA Inhibitor DMWLJ5S RN Hyrtiazepine, an azepino-indole-type alkaloid from the Red Sea marine sponge Hyrtios erectus. J Nat Prod. 2006 Dec;69(12):1676-9. DMWLJ5S RU https://pubmed.ncbi.nlm.nih.gov/17190441 DMWLMTD DI DMWLMTD DMWLMTD DN LM-4108 DMWLMTD TI TTVKILB DMWLMTD TN Prostaglandin G/H synthase 2 (COX-2) DMWLMTD MA Inhibitor DMWLMTD RN Discovery of 3-(4-bromophenyl)-6-nitrobenzo[1.3.2]dithiazolium ylide 1,1-dioxide as a novel dual cyclooxygenase/5-lipoxygenase inhibitor that also ... Bioorg Med Chem. 2010 Jan 15;18(2):597-604. DMWLMTD RU https://pubmed.ncbi.nlm.nih.gov/20056549 DMWLMV2 DI DMWLMV2 DMWLMV2 DN Anti-EGFR humanized mabs DMWLMV2 TI TTGKNB4 DMWLMV2 TN Epidermal growth factor receptor (EGFR) DMWLMV2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMWLMV2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMWLN2Y DI DMWLN2Y DMWLN2Y DN 6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium DMWLN2Y TI TT1RS9F DMWLN2Y TN Acetylcholinesterase (AChE) DMWLN2Y MA Inhibitor DMWLN2Y RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMWLN2Y RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMWLN2Y DI DMWLN2Y DMWLN2Y DN 6-hydroxy-1,2,9-trimethyl-9H-beta-carbolin-2-ium DMWLN2Y TI TTEB0GD DMWLN2Y TN Cholinesterase (BCHE) DMWLN2Y MA Inhibitor DMWLN2Y RN 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5840-3. DMWLN2Y RU https://pubmed.ncbi.nlm.nih.gov/16945529 DMWLQV8 DI DMWLQV8 DMWLQV8 DN NV-07a DMWLQV8 TI TTXPQW1 DMWLQV8 TN Hormone unspecific (HOM) DMWLQV8 MA Modulator DMWLQV8 RN UV radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J Invest Dermatol. 2008 Feb;128(2):447-54. DMWLQV8 RU https://pubmed.ncbi.nlm.nih.gov/17882270 DMWM1UL DI DMWM1UL DMWM1UL DN 8-Oxo-8-phenyl-octanoic acid hydroxyamide DMWM1UL TI TTSHTOI DMWM1UL TN Histone deacetylase 2 (HDAC2) DMWM1UL MA Inhibitor DMWM1UL RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMWM1UL RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMWM1UL DI DMWM1UL DMWM1UL DN 8-Oxo-8-phenyl-octanoic acid hydroxyamide DMWM1UL TI TTBH0VX DMWM1UL TN Histone deacetylase (HDAC) DMWM1UL MA Inhibitor DMWM1UL RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMWM1UL RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMWM1UL DI DMWM1UL DMWM1UL DN 8-Oxo-8-phenyl-octanoic acid hydroxyamide DMWM1UL TI TT5ZKDI DMWM1UL TN Histone deacetylase 6 (HDAC6) DMWM1UL MA Inhibitor DMWM1UL RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMWM1UL RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMWM1UL DI DMWM1UL DMWM1UL DN 8-Oxo-8-phenyl-octanoic acid hydroxyamide DMWM1UL TI TT6R7JZ DMWM1UL TN Histone deacetylase 1 (HDAC1) DMWM1UL MA Inhibitor DMWM1UL RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMWM1UL RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMWM1UL DI DMWM1UL DMWM1UL DN 8-Oxo-8-phenyl-octanoic acid hydroxyamide DMWM1UL TI TTTQGH8 DMWM1UL TN Histone deacetylase 4 (HDAC4) DMWM1UL MA Inhibitor DMWM1UL RN Histone deacetylase inhibitors. J Med Chem. 2003 Nov 20;46(24):5097-116. DMWM1UL RU https://pubmed.ncbi.nlm.nih.gov/14613312 DMWM814 DI DMWM814 DMWM814 DN Methyl 3-(1-Benzyl-1H-imidazol-5-yl)-propanoate DMWM814 TI TTIQUX7 DMWM814 TN Steroid 11-beta-hydroxylase (CYP11B1) DMWM814 MA Inhibitor DMWM814 RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMWM814 RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMWMBP3 DI DMWMBP3 DMWMBP3 DN PheTQS DMWMBP3 TI TTLA931 DMWMBP3 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMWMBP3 MA Modulator DMWMBP3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468). DMWMBP3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468 DMWME7I DI DMWME7I DMWME7I DN 1-(1-Biphenyl-4-yl-3-methyl-butyl)-1H-imidazole DMWME7I TI TTRA5BZ DMWME7I TN Steroid 17-alpha-monooxygenase (S17AH) DMWME7I MA Inhibitor DMWME7I RN Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxyl... Bioorg Med Chem. 2008 Aug 15;16(16):7715-27. DMWME7I RU https://pubmed.ncbi.nlm.nih.gov/18674917 DMWMFTJ DI DMWMFTJ DMWMFTJ DN 2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE DMWMFTJ TI TTICO5G DMWMFTJ TN Staphylococcus Peptide deformylase (Stap-coc def) DMWMFTJ MA Inhibitor DMWMFTJ RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMWMFTJ RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMWMFZ3 DI DMWMFZ3 DMWMFZ3 DN 3-Cyclohexyl-1-propyl-piperidine hydrochloride DMWMFZ3 TI TTEX248 DMWMFZ3 TN Dopamine D2 receptor (D2R) DMWMFZ3 MA Inhibitor DMWMFZ3 RN New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8. DMWMFZ3 RU https://pubmed.ncbi.nlm.nih.gov/12502370 DMWMIRL DI DMWMIRL DMWMIRL DN Alisporivir DMWMIRL TI TTS41ER DMWMIRL TN HUMAN cyclophilin A (CYPA) DMWMIRL MA Inhibitor DMWMIRL RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DMWMIRL RU https://pubmed.ncbi.nlm.nih.gov/32127666 DMWMRLS DI DMWMRLS DMWMRLS DN UNC1215 DMWMRLS TI TTQDMJN DMWMRLS TN Lethal(3)malignant brain tumor-like 3 (L3MBTL3) DMWMRLS MA Agonist DMWMRLS RN Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nat Chem Biol. 2013 Mar;9(3):184-91. DMWMRLS RU https://pubmed.ncbi.nlm.nih.gov/23292653 DMWMRO2 DI DMWMRO2 DMWMRO2 DN JM-1232(-) DMWMRO2 TI TTEX6LM DMWMRO2 TN GABA(A) receptor gamma-3 (GABRG3) DMWMRO2 MA Agonist DMWMRO2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 415). DMWMRO2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=415 DMWMVI3 DI DMWMVI3 DMWMVI3 DN 8-n-heptylnaringenin DMWMVI3 TI TTZAYWL DMWMVI3 TN Estrogen receptor (ESR) DMWMVI3 MA Inhibitor DMWMVI3 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMWMVI3 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMWMVI3 DI DMWMVI3 DMWMVI3 DN 8-n-heptylnaringenin DMWMVI3 TI TTOM3J0 DMWMVI3 TN Estrogen receptor beta (ESR2) DMWMVI3 MA Inhibitor DMWMVI3 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMWMVI3 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMWMZL7 DI DMWMZL7 DMWMZL7 DN MMPIP DMWMZL7 TI TT0I76D DMWMZL7 TN Metabotropic glutamate receptor 7 (mGluR7) DMWMZL7 MA Modulator (allosteric modulator) DMWMZL7 RN Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol Pharmacol. 2010 Mar;77(3):459-68. DMWMZL7 RU https://pubmed.ncbi.nlm.nih.gov/20026717 DMWN1CM DI DMWN1CM DMWN1CM DN 4-(2-(thiophen-2-yl)-9H-purin-6-yl)morpholine DMWN1CM TI TTCJG29 DMWN1CM TN Serine/threonine-protein kinase mTOR (mTOR) DMWN1CM MA Inhibitor DMWN1CM RN Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. DMWN1CM RU https://pubmed.ncbi.nlm.nih.gov/19969455 DMWN8FU DI DMWN8FU DMWN8FU DN NS9283 DMWN8FU TI TT5KPZR DMWN8FU TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMWN8FU MA Modulator (allosteric modulator) DMWN8FU RN alpha4beta2 neuronal nicotinic receptor positive allosteric modulation: an approach for improving the therapeutic index of alpha4beta2 nAChR agonists in pain. Biochem Pharmacol. 2011 Oct 15;82(8):959-66. DMWN8FU RU https://pubmed.ncbi.nlm.nih.gov/21763685 DMWN9XU DI DMWN9XU DMWN9XU DN Phenyl 7-methoxy-4-phenylbenzofuran-2-ylcarbamate DMWN9XU TI TTM2AOE DMWN9XU TN Adenosine A2a receptor (ADORA2A) DMWN9XU MA Inhibitor DMWN9XU RN Synthetic studies on selective adenosine A2A receptor antagonists: synthesis and structure-activity relationships of novel benzofuran derivatives. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1090-3. DMWN9XU RU https://pubmed.ncbi.nlm.nih.gov/20034788 DMWNCLJ DI DMWNCLJ DMWNCLJ DN PGD3 DMWNCLJ TI TTQDMX5 DMWNCLJ TN Prostaglandin D2 receptor 2 (PTGDR2) DMWNCLJ MA Agonist DMWNCLJ RN Expression and molecular pharmacology of the mouse CRTH2 receptor. J Pharmacol Exp Ther. 2003 Aug;306(2):463-70. DMWNCLJ RU https://pubmed.ncbi.nlm.nih.gov/12721327 DMWNEA1 DI DMWNEA1 DMWNEA1 DN (S)-enastron DMWNEA1 TI TTBGTCW DMWNEA1 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMWNEA1 MA Inhibitor DMWNEA1 RN Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. J Med Chem. 2010 Aug 12;53(15):5676-83. DMWNEA1 RU https://pubmed.ncbi.nlm.nih.gov/20597485 DMWNJ84 DI DMWNJ84 DMWNJ84 DN 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl DMWNJ84 TI TTVKILB DMWNJ84 TN Prostaglandin G/H synthase 2 (COX-2) DMWNJ84 MA Inhibitor DMWNJ84 RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMWNJ84 RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMWNJ84 DI DMWNJ84 DMWNJ84 DN 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl DMWNJ84 TI TT8NGED DMWNJ84 TN Prostaglandin G/H synthase 1 (COX-1) DMWNJ84 MA Inhibitor DMWNJ84 RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMWNJ84 RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMWNJ84 DI DMWNJ84 DMWNJ84 DN 2,4'-Dimethoxy-5,3'-di-(2-propenyl)-biphenyl DMWNJ84 TI TTSJ6Q4 DMWNJ84 TN LOX-5 messenger RNA (ALOX5 mRNA) DMWNJ84 MA Inhibitor DMWNJ84 RN Design and synthesis of ten biphenyl-neolignan derivatives and their in vitro inhibitory potency against cyclooxygenase-1/2 activity and 5-lipoxyge... Bioorg Med Chem. 2009 Jul 1;17(13):4459-65. DMWNJ84 RU https://pubmed.ncbi.nlm.nih.gov/19481465 DMWNJV0 DI DMWNJV0 DMWNJV0 DN L-136662 DMWNJV0 TI TTGP7BY DMWNJV0 TN Monoamine oxidase type B (MAO-B) DMWNJV0 MA Inhibitor DMWNJV0 RN Identification of novel monoamine oxidase B inhibitors by structure-based virtual screening. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5295-8. DMWNJV0 RU https://pubmed.ncbi.nlm.nih.gov/20650633 DMWNO4D DI DMWNO4D DMWNO4D DN 3-Methoxyl-4'-amino-trans-stilbene DMWNO4D TI TTSZLWK DMWNO4D TN Aromatase (CYP19A1) DMWNO4D MA Inhibitor DMWNO4D RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMWNO4D RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMWNYBV DI DMWNYBV DMWNYBV DN PMID17276684C22 DMWNYBV TI TTVBPDM DMWNYBV TN Metabotropic glutamate receptor 1 (mGluR1) DMWNYBV MA Modulator (allosteric modulator) DMWNYBV RN From pyrroles to 1-oxo-2,3,4,9-tetrahydro-1H-beta-carbolines: a new class of orally bioavailable mGluR1 antagonists. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2254-9. DMWNYBV RU https://pubmed.ncbi.nlm.nih.gov/17276684 DMWO1Z7 DI DMWO1Z7 DMWO1Z7 DN 3-(aminomethyl)-4-(thiophen-3-yl)butanoic acid DMWO1Z7 TI TTFK1JQ DMWO1Z7 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMWO1Z7 MA Inhibitor DMWO1Z7 RN Heteroaromatic side-chain analogs of pregabalin. Bioorg Med Chem Lett. 2006 May 1;16(9):2329-32. DMWO1Z7 RU https://pubmed.ncbi.nlm.nih.gov/16099652 DMWO4EI DI DMWO4EI DMWO4EI DN Des-Arg10-Leu9-Kallidin DMWO4EI TI TTG5QIA DMWO4EI TN B1 bradykinin receptor (BDKRB1) DMWO4EI MA Inhibitor DMWO4EI RN Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6045-8. DMWO4EI RU https://pubmed.ncbi.nlm.nih.gov/15546726 DMWO85H DI DMWO85H DMWO85H DN TMPyP4 DMWO85H TI TTUJFD0 DMWO85H TN Telomerase reverse transcriptase (TERT) DMWO85H MA Inhibitor DMWO85H RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMWO85H RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMWOB7Q DI DMWOB7Q DMWOB7Q DN 3,5-Di-tert-butyl-[1,2]benzoquinone DMWOB7Q TI TTMF541 DMWOB7Q TN Liver carboxylesterase (CES1) DMWOB7Q MA Inhibitor DMWOB7Q RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMWOB7Q RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMWOBAE DI DMWOBAE DMWOBAE DN tetralin_urea analogue (7o) DMWOBAE TI TTX4RTB DMWOBAE TN Melanin-concentrating hormone receptor 1 (MCHR1) DMWOBAE MA Antagonist DMWOBAE RN Discovery of tetralin ureas as potent melanin concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1718-21. DMWOBAE RU https://pubmed.ncbi.nlm.nih.gov/17251014 DMWODHR DI DMWODHR DMWODHR DN SKF 89748 DMWODHR TI TT2NUT5 DMWODHR TN Adrenergic receptor alpha-2C (ADRA2C) DMWODHR MA Agonist DMWODHR RN Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36. DMWODHR RU https://pubmed.ncbi.nlm.nih.gov/7969082 DMWOHAE DI DMWOHAE DMWOHAE DN PMID24099220C5i DMWOHAE TI TTZJYKH DMWOHAE TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMWOHAE MA Inhibitor DMWOHAE RN Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. J Med Chem. 2013 Nov 14;56(21):8321-31. DMWOHAE RU https://pubmed.ncbi.nlm.nih.gov/24099220 DMWOHDV DI DMWOHDV DMWOHDV DN ON-044580 DMWOHDV TI TTIV39N DMWOHDV TN Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) DMWOHDV MA Inhibitor DMWOHDV RN A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45. DMWOHDV RU https://pubmed.ncbi.nlm.nih.gov/20717479 DMWOHDV DI DMWOHDV DMWOHDV DN ON-044580 DMWOHDV TI TTRMX3V DMWOHDV TN Janus kinase 2 (JAK-2) DMWOHDV MA Inhibitor DMWOHDV RN A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45. DMWOHDV RU https://pubmed.ncbi.nlm.nih.gov/20717479 DMWOJ5N DI DMWOJ5N DMWOJ5N DN 2-Biphenyl-4-yl-N-hydroxy-N-methyl-acetamide DMWOJ5N TI TT2J34L DMWOJ5N TN Arachidonate 5-lipoxygenase (5-LOX) DMWOJ5N MA Inhibitor DMWOJ5N RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMWOJ5N RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMWOMVF DI DMWOMVF DMWOMVF DN 3,4-Dichloro-N-(3,3-diphenyl-allyl)-benzamide DMWOMVF TI TTCG0AL DMWOMVF TN Cholecystokinin receptor type A (CCKAR) DMWOMVF MA Inhibitor DMWOMVF RN Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718. J Med Chem. 1992 Mar 20;35(6):1042-9. DMWOMVF RU https://pubmed.ncbi.nlm.nih.gov/1552499 DMWOP9N DI DMWOP9N DMWOP9N DN Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl DMWOP9N TI TTZPO1L DMWOP9N TN Substance-P receptor (TACR1) DMWOP9N MA Inhibitor DMWOP9N RN The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47. DMWOP9N RU https://pubmed.ncbi.nlm.nih.gov/18821747 DMWOP9N DI DMWOP9N DMWOP9N DN Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl DMWOP9N TI TT27RFC DMWOP9N TN Opioid receptor delta (OPRD1) DMWOP9N MA Inhibitor DMWOP9N RN The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47. DMWOP9N RU https://pubmed.ncbi.nlm.nih.gov/18821747 DMWOP9N DI DMWOP9N DMWOP9N DN Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl DMWOP9N TI TTKWM86 DMWOP9N TN Opioid receptor mu (MOP) DMWOP9N MA Inhibitor DMWOP9N RN The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47. DMWOP9N RU https://pubmed.ncbi.nlm.nih.gov/18821747 DMWOSFJ DI DMWOSFJ DMWOSFJ DN QLT-091382 DMWOSFJ TI TTY84UG DMWOSFJ TN Acetyl-CoA carboxylase 2 (ACACB) DMWOSFJ MA Inhibitor DMWOSFJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1264). DMWOSFJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1264 DMWOTD3 DI DMWOTD3 DMWOTD3 DN 3-amino-benzo[b]thiophene-2-carboxylic acid amide DMWOTD3 TI TTJ3E9X DMWOTD3 TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMWOTD3 MA Inhibitor DMWOTD3 RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DMWOTD3 RU https://pubmed.ncbi.nlm.nih.gov/16686533 DMWOYCZ DI DMWOYCZ DMWOYCZ DN Ac-VEID-CHO DMWOYCZ TI TTKW4ML DMWOYCZ TN Caspase 6 messenger RNA (CASP6 mRNA) DMWOYCZ MA Inhibitor DMWOYCZ RN Synthesis and in vitro evaluation of sulfonamide isatin Michael acceptors as small molecule inhibitors of caspase-6. J Med Chem. 2009 Apr 23;52(8):2188-91. DMWOYCZ RU https://pubmed.ncbi.nlm.nih.gov/19326941 DMWP09B DI DMWP09B DMWP09B DN RHIIP DMWP09B TI TTCBFJO DMWP09B TN Insulin receptor (INSR) DMWP09B MA Modulator DMWP09B RN PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler. Diabetes Obes Metab. 2009 May;11(5):455-9. DMWP09B RU https://pubmed.ncbi.nlm.nih.gov/19236443 DMWP0BX DI DMWP0BX DMWP0BX DN PG-120 DMWP0BX TI TTN6Y9A DMWP0BX TN CD40L receptor (CD40) DMWP0BX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874). DMWP0BX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874 DMWP0LZ DI DMWP0LZ DMWP0LZ DN 3-isobutoxy-5-(2-methylquinolin-7-yl)benzonitrile DMWP0LZ TI TTHS256 DMWP0LZ TN Metabotropic glutamate receptor 5 (mGluR5) DMWP0LZ MA Inhibitor DMWP0LZ RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMWP0LZ RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMWP0VK DI DMWP0VK DMWP0VK DN 3-(1-Benzyl-piperidin-4-yl)-2-phenyl-1H-indole DMWP0VK TI TTJQOD7 DMWP0VK TN 5-HT 2A receptor (HTR2A) DMWP0VK MA Inhibitor DMWP0VK RN 3-(4-Piperidinyl)- and 3-(8-aza-bicyclo[3.2.1]oct-3-yl)-2-phenyl-1H-indoles as bioavailable h5-HT2A antagonists. Bioorg Med Chem Lett. 2000 Dec 18;10(24):2701-3. DMWP0VK RU https://pubmed.ncbi.nlm.nih.gov/11133072 DMWP63C DI DMWP63C DMWP63C DN CD79-targeted immunotoxins DMWP63C TI TTBN5I7 DMWP63C TN B-cell-specific glycoprotein B29 (CD79B) DMWP63C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852). DMWP63C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2852 DMWP6OZ DI DMWP6OZ DMWP6OZ DN N-(1,3,4-thiadiazol-2-yl)benzamide DMWP6OZ TI TTSJ6Q4 DMWP6OZ TN LOX-5 messenger RNA (ALOX5 mRNA) DMWP6OZ MA Inhibitor DMWP6OZ RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMWP6OZ RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMWP84R DI DMWP84R DMWP84R DN JWH-373 DMWP84R TI TTMSFAW DMWP84R TN Cannabinoid receptor 2 (CB2) DMWP84R MA Inhibitor DMWP84R RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMWP84R RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMWP84R DI DMWP84R DMWP84R DN JWH-373 DMWP84R TI TT6OEDT DMWP84R TN Cannabinoid receptor 1 (CB1) DMWP84R MA Inhibitor DMWP84R RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMWP84R RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMWPB0G DI DMWPB0G DMWPB0G DN 3-(4-Benzyl-piperazin-1-yl)-phenol DMWPB0G TI TT4C8EA DMWPB0G TN Dopamine D3 receptor (D3R) DMWPB0G MA Inhibitor DMWPB0G RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMWPB0G RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMWPB0G DI DMWPB0G DMWPB0G DN 3-(4-Benzyl-piperazin-1-yl)-phenol DMWPB0G TI TTEX248 DMWPB0G TN Dopamine D2 receptor (D2R) DMWPB0G MA Inhibitor DMWPB0G RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMWPB0G RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMWPBKU DI DMWPBKU DMWPBKU DN N-methyllaurotetanine DMWPBKU TI TTSQIFT DMWPBKU TN 5-HT 1A receptor (HTR1A) DMWPBKU MA Inhibitor DMWPBKU RN Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in ... J Nat Prod. 2006 Mar;69(3):432-5. DMWPBKU RU https://pubmed.ncbi.nlm.nih.gov/16562853 DMWPELS DI DMWPELS DMWPELS DN 6-Amino-benzothiazole-2-sulfonic acid amide DMWPELS TI TTANPDJ DMWPELS TN Carbonic anhydrase II (CA-II) DMWPELS MA Inhibitor DMWPELS RN Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides co... J Med Chem. 1999 Jul 15;42(14):2641-50. DMWPELS RU https://pubmed.ncbi.nlm.nih.gov/10411484 DMWPELS DI DMWPELS DMWPELS DN 6-Amino-benzothiazole-2-sulfonic acid amide DMWPELS TI TTHQPL7 DMWPELS TN Carbonic anhydrase I (CA-I) DMWPELS MA Inhibitor DMWPELS RN Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides co... J Med Chem. 1999 Jul 15;42(14):2641-50. DMWPELS RU https://pubmed.ncbi.nlm.nih.gov/10411484 DMWPM9L DI DMWPM9L DMWPM9L DN 2-(4-Propyl-piperazin-1-yl)-quinoline DMWPM9L TI TT9JNIC DMWPM9L TN Histamine H3 receptor (H3R) DMWPM9L MA Inhibitor DMWPM9L RN 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists. J Med Chem. 2005 Jan 13;48(1):306-11. DMWPM9L RU https://pubmed.ncbi.nlm.nih.gov/15634025 DMWPZCS DI DMWPZCS DMWPZCS DN N-(2,6-diphenylpyrimidin-4-yl)isobutyramide DMWPZCS TI TTM2AOE DMWPZCS TN Adenosine A2a receptor (ADORA2A) DMWPZCS MA Inhibitor DMWPZCS RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMWPZCS RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMWPZCS DI DMWPZCS DMWPZCS DN N-(2,6-diphenylpyrimidin-4-yl)isobutyramide DMWPZCS TI TTK25J1 DMWPZCS TN Adenosine A1 receptor (ADORA1) DMWPZCS MA Inhibitor DMWPZCS RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMWPZCS RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMWPZCS DI DMWPZCS DMWPZCS DN N-(2,6-diphenylpyrimidin-4-yl)isobutyramide DMWPZCS TI TTJFY5U DMWPZCS TN Adenosine A3 receptor (ADORA3) DMWPZCS MA Inhibitor DMWPZCS RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMWPZCS RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMWQ3RH DI DMWQ3RH DMWQ3RH DN bufrudin DMWQ3RH TI TT6L509 DMWQ3RH TN Coagulation factor IIa (F2) DMWQ3RH MA Modulator DMWQ3RH RN Leech therapeutic applications.Indian J Pharm Sci.2013 Mar;75(2):127-37. DMWQ3RH RU https://www.ncbi.nlm.nih.gov/pubmed/24019559 DMWQ480 DI DMWQ480 DMWQ480 DN schisandrin A DMWQ480 TI TT7LCTF DMWQ480 TN Pregnane X receptor (NR1I2) DMWQ480 MA Agonist DMWQ480 RN Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and inc... J Pharmacol Exp Ther. 2006 Mar;316(3):1369-77. DMWQ480 RU https://pubmed.ncbi.nlm.nih.gov/16267138 DMWQ9ZP DI DMWQ9ZP DMWQ9ZP DN 1-(5-methyloxazol-2-yl)-7-phenylheptan-1-one DMWQ9ZP TI TTDP1UC DMWQ9ZP TN Fatty acid amide hydrolase (FAAH) DMWQ9ZP MA Inhibitor DMWQ9ZP RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMWQ9ZP RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMWQCRD DI DMWQCRD DMWQCRD DN L-2-Amino-4-(Guanidinooxy)Butyric Acid DMWQCRD TI TTCM4B3 DMWQCRD TN Nitric-oxide synthase endothelial (NOS3) DMWQCRD MA Inhibitor DMWQCRD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWQCRD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWQFY6 DI DMWQFY6 DMWQFY6 DN Tert-Butyl 2-(2-oxohexadecanamido)acetate DMWQFY6 TI TTT1JVS DMWQFY6 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMWQFY6 MA Inhibitor DMWQFY6 RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMWQFY6 RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMWQK86 DI DMWQK86 DMWQK86 DN (2S)-aminobutyryl-(R)-pipecolinic acid amide DMWQK86 TI TTQ7R2V DMWQK86 TN Tripeptidyl-peptidase II (TPP2) DMWQK86 MA Inhibitor DMWQK86 RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMWQK86 RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMWR0AS DI DMWR0AS DMWR0AS DN 4-(4-Benzyl-piperazin-1-yl)-1H-indole DMWR0AS TI TT4C8EA DMWR0AS TN Dopamine D3 receptor (D3R) DMWR0AS MA Inhibitor DMWR0AS RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMWR0AS RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMWR0AS DI DMWR0AS DMWR0AS DN 4-(4-Benzyl-piperazin-1-yl)-1H-indole DMWR0AS TI TTEX248 DMWR0AS TN Dopamine D2 receptor (D2R) DMWR0AS MA Inhibitor DMWR0AS RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMWR0AS RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMWR0AS DI DMWR0AS DMWR0AS DN 4-(4-Benzyl-piperazin-1-yl)-1H-indole DMWR0AS TI TTE0A2F DMWR0AS TN Dopamine D4 receptor (D4R) DMWR0AS MA Inhibitor DMWR0AS RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMWR0AS RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMWR0J1 DI DMWR0J1 DMWR0J1 DN MORACHALCONE A DMWR0J1 TI TTSZLWK DMWR0J1 TN Aromatase (CYP19A1) DMWR0J1 MA Inhibitor DMWR0J1 RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DMWR0J1 RU https://pubmed.ncbi.nlm.nih.gov/11678652 DMWR3XL DI DMWR3XL DMWR3XL DN DAEDALIN A DMWR3XL TI TTULVH8 DMWR3XL TN Tyrosinase (TYR) DMWR3XL MA Inhibitor DMWR3XL RN Asymmetric syntheses of daedalin A and quercinol and their tyrosinase inhibitory activity. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1063-4. DMWR3XL RU https://pubmed.ncbi.nlm.nih.gov/20036119 DMWRCFY DI DMWRCFY DMWRCFY DN 2-Methyl-4-p-tolylethynyl-thiazole DMWRCFY TI TTHS256 DMWRCFY TN Metabotropic glutamate receptor 5 (mGluR5) DMWRCFY MA Inhibitor DMWRCFY RN 5-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-2,3'-bipyridine: a highly potent, orally active metabotropic glutamate subtype 5 (mGlu5) receptor antagonist... Bioorg Med Chem Lett. 2004 Aug 2;14(15):3993-6. DMWRCFY RU https://pubmed.ncbi.nlm.nih.gov/15225713 DMWRCM1 DI DMWRCM1 DMWRCM1 DN (2,6-Diamino-pyridin-3-yl)-phenyl-methanone DMWRCM1 TI TTH6V3D DMWRCM1 TN Cyclin-dependent kinase 1 (CDK1) DMWRCM1 MA Inhibitor DMWRCM1 RN 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation. Bioorg Med Chem Lett. 2005 May 2;15(9):2221-4. DMWRCM1 RU https://pubmed.ncbi.nlm.nih.gov/15837297 DMWRIQG DI DMWRIQG DMWRIQG DN (R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide DMWRIQG TI TTMWT8Z DMWRIQG TN C-X-C chemokine receptor type 1 (CXCR1) DMWRIQG MA Inhibitor DMWRIQG RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMWRIQG RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMWRIQG DI DMWRIQG DMWRIQG DN (R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide DMWRIQG TI TT30C9G DMWRIQG TN C-X-C chemokine receptor type 2 (CXCR2) DMWRIQG MA Inhibitor DMWRIQG RN 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31. DMWRIQG RU https://pubmed.ncbi.nlm.nih.gov/15974585 DMWRVGE DI DMWRVGE DMWRVGE DN IC86621 DMWRVGE TI TTK3PY9 DMWRVGE TN DNA-dependent protein kinase catalytic (PRKDC) DMWRVGE MA Inhibitor DMWRVGE RN Modulation of DNA repair by pharmacological inhibitors of the PIKK protein kinase family. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5352-9. DMWRVGE RU https://pubmed.ncbi.nlm.nih.gov/22835870 DMWRX4T DI DMWRX4T DMWRX4T DN VULM-1457 DMWRX4T TI TTMF541 DMWRX4T TN Liver carboxylesterase (CES1) DMWRX4T MA Inhibitor DMWRX4T RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2592). DMWRX4T RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2592 DMWRYA1 DI DMWRYA1 DMWRYA1 DN ISIS 134563 DMWRYA1 TI TTKW4ML DMWRYA1 TN Caspase 6 messenger RNA (CASP6 mRNA) DMWRYA1 RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMWRYA1 RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMWRZJX DI DMWRZJX DMWRZJX DN TETRAHYDROQUINOLINE A DMWRZJX TI TTFQAYR DMWRZJX TN Cholesteryl ester transfer protein (CETP) DMWRZJX MA Inhibitor DMWRZJX RN Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett. 2009 May 1;19(9):2456-60. DMWRZJX RU https://pubmed.ncbi.nlm.nih.gov/19339179 DMWS2HL DI DMWS2HL DMWS2HL DN 1,2-bis(2,3,6-trifluorophenyl)ethane-1,2-dione DMWS2HL TI TTMF541 DMWS2HL TN Liver carboxylesterase (CES1) DMWS2HL MA Inhibitor DMWS2HL RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMWS2HL RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMWS35F DI DMWS35F DMWS35F DN (4-((1H-imidazol-1-yl)methyl)phenyl)methanol DMWS35F TI TTIQUX7 DMWS35F TN Steroid 11-beta-hydroxylase (CYP11B1) DMWS35F MA Inhibitor DMWS35F RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMWS35F RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMWS3D6 DI DMWS3D6 DMWS3D6 DN 5-Chloryl-2,4,6-Quinazolinetriamine DMWS3D6 TI TT9SL3Q DMWS3D6 TN Polypeptide deformylase (PDF) DMWS3D6 MA Inhibitor DMWS3D6 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWS3D6 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWS7O9 DI DMWS7O9 DMWS7O9 DN PMID23099093C17d DMWS7O9 TI TT3DCYJ DMWS7O9 TN Microtubule affinity regulating kinase 3 (MARK3) DMWS7O9 MA Inhibitor DMWS7O9 RN Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73. DMWS7O9 RU https://pubmed.ncbi.nlm.nih.gov/23099093 DMWS7O9 DI DMWS7O9 DMWS7O9 DN PMID23099093C17d DMWS7O9 TI TTRPDBG DMWS7O9 TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMWS7O9 MA Inhibitor DMWS7O9 RN Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73. DMWS7O9 RU https://pubmed.ncbi.nlm.nih.gov/23099093 DMWS7O9 DI DMWS7O9 DMWS7O9 DN PMID23099093C17d DMWS7O9 TI TTJQT60 DMWS7O9 TN TGF-beta-activated kinase 1 (MAP3K7) DMWS7O9 MA Inhibitor DMWS7O9 RN Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73. DMWS7O9 RU https://pubmed.ncbi.nlm.nih.gov/23099093 DMWS7O9 DI DMWS7O9 DMWS7O9 DN PMID23099093C17d DMWS7O9 TI TTH5TC2 DMWS7O9 TN NF-kappa-B-activating kinase (TBK1) DMWS7O9 MA Inhibitor DMWS7O9 RN Synthesis and structure-activity relationships of a novel series of pyrimidines as potent inhibitors of TBK1/IKKepsilon kinases. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7169-73. DMWS7O9 RU https://pubmed.ncbi.nlm.nih.gov/23099093 DMWSDZ9 DI DMWSDZ9 DMWSDZ9 DN N-bis-(3-phenyl-propyl)9-oxo-fluorene-2,7-diamide DMWSDZ9 TI TT39J16 DMWSDZ9 TN Poly [ADP-ribose] glycohydrolase (PARG) DMWSDZ9 MA Inhibitor DMWSDZ9 RN Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat. Brain Res. 2003 Jul 18;978(1-2):99-103. DMWSDZ9 RU https://pubmed.ncbi.nlm.nih.gov/12834903 DMWSFIR DI DMWSFIR DMWSFIR DN 3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMWSFIR TI TTSZLWK DMWSFIR TN Aromatase (CYP19A1) DMWSFIR MA Inhibitor DMWSFIR RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMWSFIR RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMWSFIR DI DMWSFIR DMWSFIR DN 3-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMWSFIR TI TTIQUX7 DMWSFIR TN Steroid 11-beta-hydroxylase (CYP11B1) DMWSFIR MA Inhibitor DMWSFIR RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMWSFIR RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMWSLTB DI DMWSLTB DMWSLTB DN 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol DMWSLTB TI TT8FYO9 DMWSLTB TN Platelet-derived growth factor receptor alpha (PDGFRA) DMWSLTB MA Inhibitor DMWSLTB RN Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201. DMWSLTB RU https://pubmed.ncbi.nlm.nih.gov/16190746 DMWSLTB DI DMWSLTB DMWSLTB DN 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol DMWSLTB TI TTST7KB DMWSLTB TN Fibroblast growth factor receptor 3 (FGFR3) DMWSLTB MA Inhibitor DMWSLTB RN Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201. DMWSLTB RU https://pubmed.ncbi.nlm.nih.gov/16190746 DMWSLTB DI DMWSLTB DMWSLTB DN 5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol DMWSLTB TI TTX41N9 DMWSLTB TN Tyrosine-protein kinase Kit (KIT) DMWSLTB MA Inhibitor DMWSLTB RN Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201. DMWSLTB RU https://pubmed.ncbi.nlm.nih.gov/16190746 DMWSP6H DI DMWSP6H DMWSP6H DN L-162782 DMWSP6H TI TT8DBY3 DMWSP6H TN Angiotensin II receptor type-1 (AGTR1) DMWSP6H MA Inhibitor DMWSP6H RN Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem. 2008 Jul 15;16(14):6841-9. DMWSP6H RU https://pubmed.ncbi.nlm.nih.gov/18599297 DMWSR13 DI DMWSR13 DMWSR13 DN 2-Hydroxy-N-(3-phenyl-propyl)-benzamide DMWSR13 TI TT64EPS DMWSR13 TN Fungal Scytalone dehydratase (Fung SDH1) DMWSR13 MA Inhibitor DMWSR13 RN A diazine heterocycle replaces a six-membered hydrogen-bonded array in the active site of scytalone dehydratase, Bioorg. Med. Chem. Lett. 3(8):1605-1608 (1993). DMWSR13 RU http://www.sciencedirect.com/science/article/pii/S0960894X00800268 DMWT7BK DI DMWT7BK DMWT7BK DN ISIS 102633 DMWT7BK TI TT5U49F DMWT7BK TN PRKACA messenger RNA (PRKACA mRNA) DMWT7BK RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMWT7BK RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMWTBG8 DI DMWTBG8 DMWTBG8 DN Clostridial collagenase DMWTBG8 TI TTK982E DMWTBG8 TN Collagen (CO) DMWTBG8 MA Binder DMWTBG8 RN Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2002 Sep;27(5):788-98. DMWTBG8 RU https://pubmed.ncbi.nlm.nih.gov/12239666 DMWTDS8 DI DMWTDS8 DMWTDS8 DN ITRI-305 DMWTDS8 TI TT4DXQT DMWTDS8 TN Proto-oncogene c-Ret (RET) DMWTDS8 MA Inhibitor DMWTDS8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2185). DMWTDS8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2185 DMWTGQM DI DMWTGQM DMWTGQM DN L-796449 DMWTGQM TI TT2JWF6 DMWTGQM TN Peroxisome proliferator-activated receptor delta (PPARD) DMWTGQM MA Inhibitor DMWTGQM RN Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80. DMWTGQM RU https://pubmed.ncbi.nlm.nih.gov/12657263 DMWTGQM DI DMWTGQM DMWTGQM DN L-796449 DMWTGQM TI TTT2SVW DMWTGQM TN PPAR-gamma messenger RNA (PPARG mRNA) DMWTGQM MA Inhibitor DMWTGQM RN Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80. DMWTGQM RU https://pubmed.ncbi.nlm.nih.gov/12657263 DMWTGQM DI DMWTGQM DMWTGQM DN L-796449 DMWTGQM TI TTJ584C DMWTGQM TN Peroxisome proliferator-activated receptor alpha (PPARA) DMWTGQM MA Inhibitor DMWTGQM RN Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80. DMWTGQM RU https://pubmed.ncbi.nlm.nih.gov/12657263 DMWTJ3E DI DMWTJ3E DMWTJ3E DN LP-0067 DMWTJ3E TI TTBID49 DMWTJ3E TN C-X-C chemokine receptor type 4 (CXCR4) DMWTJ3E MA Antagonist DMWTJ3E RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMWTJ3E RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMWTOJN DI DMWTOJN DMWTOJN DN PD-140723 DMWTOJN TI TTVFO0U DMWTOJN TN Gastrin/cholecystokinin type B receptor (CCKBR) DMWTOJN MA Inhibitor DMWTOJN RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMWTOJN RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMWTOJN DI DMWTOJN DMWTOJN DN PD-140723 DMWTOJN TI TTCG0AL DMWTOJN TN Cholecystokinin receptor type A (CCKAR) DMWTOJN MA Inhibitor DMWTOJN RN Selective ligands for cholecystokinin receptor subtypes CCK-A and CCK-B within a single structural class, Bioorg. Med. Chem. Lett. 3(5):881-884 (1993). DMWTOJN RU http://www.sciencedirect.com/science/article/pii/S0960894X0080685X DMWTP7Y DI DMWTP7Y DMWTP7Y DN 3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone DMWTP7Y TI TT27RFC DMWTP7Y TN Opioid receptor delta (OPRD1) DMWTP7Y MA Inhibitor DMWTP7Y RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMWTP7Y RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMWTP7Y DI DMWTP7Y DMWTP7Y DN 3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone DMWTP7Y TI TTKWM86 DMWTP7Y TN Opioid receptor mu (MOP) DMWTP7Y MA Inhibitor DMWTP7Y RN Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44. DMWTP7Y RU https://pubmed.ncbi.nlm.nih.gov/16335927 DMWTPJH DI DMWTPJH DMWTPJH DN N-propynyl amidebenzenesulphonide DMWTPJH TI TTHQPL7 DMWTPJH TN Carbonic anhydrase I (CA-I) DMWTPJH MA Inhibitor DMWTPJH RN A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48. DMWTPJH RU https://pubmed.ncbi.nlm.nih.gov/17064072 DMWTPJH DI DMWTPJH DMWTPJH DN N-propynyl amidebenzenesulphonide DMWTPJH TI TTSYM0R DMWTPJH TN Carbonic anhydrase XII (CA-XII) DMWTPJH MA Inhibitor DMWTPJH RN Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92. DMWTPJH RU https://pubmed.ncbi.nlm.nih.gov/17157501 DMWTPJH DI DMWTPJH DMWTPJH DN N-propynyl amidebenzenesulphonide DMWTPJH TI TTANPDJ DMWTPJH TN Carbonic anhydrase II (CA-II) DMWTPJH MA Inhibitor DMWTPJH RN A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48. DMWTPJH RU https://pubmed.ncbi.nlm.nih.gov/17064072 DMWTPJH DI DMWTPJH DMWTPJH DN N-propynyl amidebenzenesulphonide DMWTPJH TI TTEYTKG DMWTPJH TN Carbonic anhydrase XIV (CA-XIV) DMWTPJH MA Inhibitor DMWTPJH RN Inhibition of membrane-associated carbonic anhydrase isozymes IX, XII and XIV with a library of glycoconjugate benzenesulfonamides. Bioorg Med Chem Lett. 2007 Feb 15;17(4):987-92. DMWTPJH RU https://pubmed.ncbi.nlm.nih.gov/17157501 DMWTPJH DI DMWTPJH DMWTPJH DN N-propynyl amidebenzenesulphonide DMWTPJH TI TT2LVK8 DMWTPJH TN Carbonic anhydrase IX (CA-IX) DMWTPJH MA Inhibitor DMWTPJH RN A novel class of carbonic anhydrase inhibitors: glycoconjugate benzene sulfonamides prepared by "click-tailing". J Med Chem. 2006 Nov 2;49(22):6539-48. DMWTPJH RU https://pubmed.ncbi.nlm.nih.gov/17064072 DMWTVJH DI DMWTVJH DMWTVJH DN N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide DMWTVJH TI TTGP7BY DMWTVJH TN Monoamine oxidase type B (MAO-B) DMWTVJH MA Inhibitor DMWTVJH RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMWTVJH RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMWTVJH DI DMWTVJH DMWTVJH DN N-(4-Ethylphenyl)-2-oxo-2H-chromene-3-carboxamide DMWTVJH TI TT3WG5C DMWTVJH TN Monoamine oxidase type A (MAO-A) DMWTVJH MA Inhibitor DMWTVJH RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMWTVJH RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMWU17O DI DMWU17O DMWU17O DN (E,E)-1,7-Diphenyl-4,6-heptadien-3-one DMWU17O TI TT50QJ3 DMWU17O TN Influenza Neuraminidase (Influ NA) DMWU17O MA Inhibitor DMWU17O RN Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem. 2010 Jan 28;53(2):778-86. DMWU17O RU https://pubmed.ncbi.nlm.nih.gov/20014777 DMWU5PK DI DMWU5PK DMWU5PK DN WDuo3 DMWU5PK TI TTOXS3C DMWU5PK TN Muscarinic acetylcholine receptor (CHRM) DMWU5PK MA Modulator (allosteric modulator) DMWU5PK RN Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003 Jul;64(1):180-90. DMWU5PK RU https://pubmed.ncbi.nlm.nih.gov/12815174 DMWU9PV DI DMWU9PV DMWU9PV DN Spiro[piperidine-2,2-adamantane] DMWU9PV TI TTXT3PU DMWU9PV TN Influenza M2 protein (Influ M) DMWU9PV MA Inhibitor DMWU9PV RN Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25. DMWU9PV RU https://pubmed.ncbi.nlm.nih.gov/17139286 DMWUAMQ DI DMWUAMQ DMWUAMQ DN ROXIFIBAN DMWUAMQ TI TTJA1ZO DMWUAMQ TN ITGB3 messenger RNA (ITGB3 mRNA) DMWUAMQ MA Inhibitor DMWUAMQ RN Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. J Med Chem. 2000 Sep 21;43(19):3453-73. DMWUAMQ RU https://pubmed.ncbi.nlm.nih.gov/10999999 DMWUBI4 DI DMWUBI4 DMWUBI4 DN 1-(1-Propionylpiperidin-4-yl)-3-p-tolylurea DMWUBI4 TI TT7WVHI DMWUBI4 TN Soluble epoxide hydrolase (EPHX2) DMWUBI4 MA Inhibitor DMWUBI4 RN 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75. DMWUBI4 RU https://pubmed.ncbi.nlm.nih.gov/20812725 DMWUGSV DI DMWUGSV DMWUGSV DN (+/-)-threo-N-(2-Methylthiopene)methylphenidate DMWUGSV TI TTVBI8W DMWUGSV TN Dopamine transporter (DAT) DMWUGSV MA Inhibitor DMWUGSV RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMWUGSV RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMWUK9G DI DMWUK9G DMWUK9G DN MPrP DMWUK9G TI TTZAYWL DMWUK9G TN Estrogen receptor (ESR) DMWUK9G MA Inhibitor DMWUK9G RN Analogs of methyl-piperidinopyrazole (MPP): antiestrogens with estrogen receptor alpha selective activity. Bioorg Med Chem Lett. 2009 Jan 1;19(1):108-10. DMWUK9G RU https://pubmed.ncbi.nlm.nih.gov/19014882 DMWUS5Q DI DMWUS5Q DMWUS5Q DN 7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DMWUS5Q TI TT06AWU DMWUS5Q TN Phosphodiesterase 3A (PDE3A) DMWUS5Q MA Inhibitor DMWUS5Q RN 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16. DMWUS5Q RU https://pubmed.ncbi.nlm.nih.gov/1654430 DMWUXDZ DI DMWUXDZ DMWUXDZ DN Hexadecanoic acid DMWUXDZ TI TTH0KSX DMWUXDZ TN Rhodopsin (RHO) DMWUXDZ MA Inhibitor DMWUXDZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWUXDZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWUXDZ DI DMWUXDZ DMWUXDZ DN Hexadecanoic acid DMWUXDZ TI TTHWMFZ DMWUXDZ TN Fatty acid-binding protein 4 (FABP4) DMWUXDZ MA Inhibitor DMWUXDZ RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMWUXDZ RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMWUXDZ DI DMWUXDZ DMWUXDZ DN Hexadecanoic acid DMWUXDZ TI TTNT2S6 DMWUXDZ TN Fatty acid-binding protein 5 (FABP5) DMWUXDZ MA Inhibitor DMWUXDZ RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMWUXDZ RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMWUZP1 DI DMWUZP1 DMWUZP1 DN PMID24157366C35 DMWUZP1 TI TTTJZ4M DMWUZP1 TN Prolylcarboxypeptidase (PRCP) DMWUZP1 MA Inhibitor DMWUZP1 RN Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors. Bioorg Med Chem Lett. 2013 Dec 1;23(23):6228-33. DMWUZP1 RU https://pubmed.ncbi.nlm.nih.gov/24157366 DMWV5C3 DI DMWV5C3 DMWV5C3 DN [3H]alphabeta-meATP DMWV5C3 TI TT2QM9D DMWV5C3 TN Adenylate cyclase (ADCY) DMWV5C3 MA Inhibitor DMWV5C3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWV5C3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWV5C3 DI DMWV5C3 DMWV5C3 DN [3H]alphabeta-meATP DMWV5C3 TI TT38ECI DMWV5C3 TN Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) DMWV5C3 MA Inhibitor DMWV5C3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWV5C3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWV5C3 DI DMWV5C3 DMWV5C3 DN [3H]alphabeta-meATP DMWV5C3 TI TT8WCXO DMWV5C3 TN Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE) DMWV5C3 MA Inhibitor DMWV5C3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWV5C3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWV8YX DI DMWV8YX DMWV8YX DN 9-Ethyl-9H-adenine DMWV8YX TI TTM2AOE DMWV8YX TN Adenosine A2a receptor (ADORA2A) DMWV8YX MA Inhibitor DMWV8YX RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMWV8YX RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMWV8YX DI DMWV8YX DMWV8YX DN 9-Ethyl-9H-adenine DMWV8YX TI TTK25J1 DMWV8YX TN Adenosine A1 receptor (ADORA1) DMWV8YX MA Inhibitor DMWV8YX RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMWV8YX RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMWVBD9 DI DMWVBD9 DMWVBD9 DN RTU-1096 DMWVBD9 TI TT7HC21 DMWVBD9 TN Membrane copper amine oxidase (AOC3) DMWVBD9 MA Inhibitor DMWVBD9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2767). DMWVBD9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2767 DMWVCJ1 DI DMWVCJ1 DMWVCJ1 DN 5-Hydroxymethyluridine-2'-Deoxy-5'-Monophosphate DMWVCJ1 TI TT5B8AX DMWVCJ1 TN Mycobacterium Thymidine monophosphate kinase (MycB tmk) DMWVCJ1 MA Inhibitor DMWVCJ1 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWVCJ1 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWVH62 DI DMWVH62 DMWVH62 DN SCH772984 DMWVH62 TI TT4TQBX DMWVH62 TN Extracellular signal-regulated kinase 2 (ERK2) DMWVH62 MA Inhibitor DMWVH62 RN Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 2013 Jul;3(7):742-50. DMWVH62 RU https://pubmed.ncbi.nlm.nih.gov/23614898 DMWVLG1 DI DMWVLG1 DMWVLG1 DN Oxametacin DMWVLG1 TI TTVKILB DMWVLG1 TN Prostaglandin G/H synthase 2 (COX-2) DMWVLG1 MA Inhibitor DMWVLG1 RN Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem. 2007 Dec 13;50(25):6367-82. DMWVLG1 RU https://pubmed.ncbi.nlm.nih.gov/17994684 DMWVLG1 DI DMWVLG1 DMWVLG1 DN Oxametacin DMWVLG1 TI TT8NGED DMWVLG1 TN Prostaglandin G/H synthase 1 (COX-1) DMWVLG1 MA Inhibitor DMWVLG1 RN Structure-based design, synthesis, and biological evaluation of indomethacin derivatives as cyclooxygenase-2 inhibiting nitric oxide donors. J Med Chem. 2007 Dec 13;50(25):6367-82. DMWVLG1 RU https://pubmed.ncbi.nlm.nih.gov/17994684 DMWVN8R DI DMWVN8R DMWVN8R DN SU4984 DMWVN8R TI TT0LF7H DMWVN8R TN Fibroblast growth factor receptor (FGFR) DMWVN8R MA Antagonist DMWVN8R RN Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024. DMWVN8R RU https://pubmed.ncbi.nlm.nih.gov/11576867 DMWVPSM DI DMWVPSM DMWVPSM DN PARCETASAL DMWVPSM TI TTGSRBC DMWVPSM TN Prostaglandin synthetase (PGS) DMWVPSM MA Modulator DMWVPSM RN Paracetamol effectively reduces prostaglandin E2 synthesis in brain macrophages by inhibiting enzymatic activity of cyclooxygenase but not phospholipase and prostaglandin E synthase. J Neurosci Res. 2003 Mar 15;71(6):844-52. DMWVPSM RU https://pubmed.ncbi.nlm.nih.gov/12605411 DMWVS5X DI DMWVS5X DMWVS5X DN JWH-250 DMWVS5X TI TTMSFAW DMWVS5X TN Cannabinoid receptor 2 (CB2) DMWVS5X MA Inhibitor DMWVS5X RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMWVS5X RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMWVSPH DI DMWVSPH DMWVSPH DN 9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide DMWVSPH TI TT1RS9F DMWVSPH TN Acetylcholinesterase (AChE) DMWVSPH MA Inhibitor DMWVSPH RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMWVSPH RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMWVSPH DI DMWVSPH DMWVSPH DN 9-O-[3-(4-Nitro-phenoxyl)butyl]-berberine bromide DMWVSPH TI TTEB0GD DMWVSPH TN Cholinesterase (BCHE) DMWVSPH MA Inhibitor DMWVSPH RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMWVSPH RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMWVTAE DI DMWVTAE DMWVTAE DN PMID22902653C31 DMWVTAE TI TTWKT3Y DMWVTAE TN Testis-specific kinase 1 (TESK1) DMWVTAE MA Inhibitor DMWVTAE RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMWVTAE RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMWVTAE DI DMWVTAE DMWVTAE DN PMID22902653C31 DMWVTAE TI TTASMD8 DMWVTAE TN LIM domain kinase-2 (LIMK-2) DMWVTAE MA Inhibitor DMWVTAE RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMWVTAE RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMWVTAE DI DMWVTAE DMWVTAE DN PMID22902653C31 DMWVTAE TI TTRMD8U DMWVTAE TN Testis-specific kinase 2 (TESK2) DMWVTAE MA Inhibitor DMWVTAE RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMWVTAE RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMWVTAE DI DMWVTAE DMWVTAE DN PMID22902653C31 DMWVTAE TI TTWL9TY DMWVTAE TN LIM domain kinase-1 (LIMK-1) DMWVTAE MA Inhibitor DMWVTAE RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMWVTAE RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMWVTS3 DI DMWVTS3 DMWVTS3 DN LSN2463359 DMWVTS3 TI TTHS256 DMWVTS3 TN Metabotropic glutamate receptor 5 (mGluR5) DMWVTS3 MA Modulator (allosteric modulator) DMWVTS3 RN In vitro characterisation of the novel positive allosteric modulators of the mGlu receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39. DMWVTS3 RU https://pubmed.ncbi.nlm.nih.gov/22884720 DMWVULN DI DMWVULN DMWVULN DN AR-C102222 DMWVULN TI TTZUFI5 DMWVULN TN Nitric-oxide synthase brain (NOS1) DMWVULN MA Inhibitor DMWVULN RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DMWVULN RU https://pubmed.ncbi.nlm.nih.gov/18849972 DMWVULN DI DMWVULN DMWVULN DN AR-C102222 DMWVULN TI TTF10I9 DMWVULN TN Nitric-oxide synthase inducible (NOS2) DMWVULN MA Inhibitor DMWVULN RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DMWVULN RU https://pubmed.ncbi.nlm.nih.gov/18849972 DMWVZFK DI DMWVZFK DMWVZFK DN PPAHV DMWVZFK TI TTMI6F5 DMWVZFK TN Transient receptor potential cation channel V1 (TRPV1) DMWVZFK MA Activator DMWVZFK RN Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br J Pharmacol. 2001 Mar;132(5):1084-94. DMWVZFK RU https://pubmed.ncbi.nlm.nih.gov/11226139 DMWX3HT DI DMWX3HT DMWX3HT DN ACEA DMWX3HT TI TT6OEDT DMWX3HT TN Cannabinoid receptor 1 (CB1) DMWX3HT MA Agonist DMWX3HT RN Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33. DMWX3HT RU https://pubmed.ncbi.nlm.nih.gov/10336536 DMWX4L5 DI DMWX4L5 DMWX4L5 DN 3-(trifluoromethyl)-9H-carbazole DMWX4L5 TI TTBGTCW DMWX4L5 TN Kinesin spindle messenger RNA (KIF11 mRNA) DMWX4L5 MA Inhibitor DMWX4L5 RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMWX4L5 RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMWX5Q6 DI DMWX5Q6 DMWX5Q6 DN Propan-2-one O-4-propoxyphenylcarbamoyl oxime DMWX5Q6 TI TTDP1UC DMWX5Q6 TN Fatty acid amide hydrolase (FAAH) DMWX5Q6 MA Inhibitor DMWX5Q6 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMWX5Q6 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMWX6J0 DI DMWX6J0 DMWX6J0 DN Cis-(+/-)-2-Fluoro-1,2-diphenylcyclopropylamine DMWX6J0 TI TT3WG5C DMWX6J0 TN Monoamine oxidase type A (MAO-A) DMWX6J0 MA Inhibitor DMWX6J0 RN Fluorinated phenylcyclopropylamines. Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases... Bioorg Med Chem. 2008 Aug 1;16(15):7148-66. DMWX6J0 RU https://pubmed.ncbi.nlm.nih.gov/18640844 DMWXBYC DI DMWXBYC DMWXBYC DN N-Aminoethylmorpholine DMWXBYC TI TTPT2QI DMWXBYC TN Cathepsin D (CTSD) DMWXBYC MA Inhibitor DMWXBYC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMWXBYC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMWXCYA DI DMWXCYA DMWXCYA DN VEGF receptor 2 kinase inhibitor I DMWXCYA TI TTUTJGQ DMWXCYA TN Vascular endothelial growth factor receptor 2 (KDR) DMWXCYA MA Inhibitor DMWXCYA RN Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 1998 Jul 2;41(14):2588-603. DMWXCYA RU https://pubmed.ncbi.nlm.nih.gov/9651163 DMWXGLE DI DMWXGLE DMWXGLE DN 7-(2-Dipropylamino-ethyl)-3H-benzothiazol-2-one DMWXGLE TI TTEX248 DMWXGLE TN Dopamine D2 receptor (D2R) DMWXGLE MA Inhibitor DMWXGLE RN Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzot... J Med Chem. 1987 Jul;30(7):1166-76. DMWXGLE RU https://pubmed.ncbi.nlm.nih.gov/2955118 DMWXI06 DI DMWXI06 DMWXI06 DN 2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid DMWXI06 TI TTY84UG DMWXI06 TN Acetyl-CoA carboxylase 2 (ACACB) DMWXI06 MA Inhibitor DMWXI06 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMWXI06 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMWXI6C DI DMWXI6C DMWXI6C DN 2-oxo-N-p-tolyl-2H-chromene-3-carboxamide DMWXI6C TI TTGP7BY DMWXI6C TN Monoamine oxidase type B (MAO-B) DMWXI6C MA Inhibitor DMWXI6C RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMWXI6C RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMWXI6C DI DMWXI6C DMWXI6C DN 2-oxo-N-p-tolyl-2H-chromene-3-carboxamide DMWXI6C TI TT3WG5C DMWXI6C TN Monoamine oxidase type A (MAO-A) DMWXI6C MA Inhibitor DMWXI6C RN Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009 Apr 9;52(7):1935-42. DMWXI6C RU https://pubmed.ncbi.nlm.nih.gov/19267475 DMWXNOI DI DMWXNOI DMWXNOI DN NSC-238146 DMWXNOI TI TTJLP0R DMWXNOI TN Quinone reductase 2 (NQO2) DMWXNOI MA Inhibitor DMWXNOI RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMWXNOI RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMWXQPG DI DMWXQPG DMWXQPG DN ISIS 25549 DMWXQPG TI TTP2U16 DMWXQPG TN RhoA messenger RNA (RHOA mRNA) DMWXQPG RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMWXQPG RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMWXTM8 DI DMWXTM8 DMWXTM8 DN ST-2987 DMWXTM8 TI TTSHTOI DMWXTM8 TN Histone deacetylase 2 (HDAC2) DMWXTM8 MA Inhibitor DMWXTM8 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMWXTM8 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMWXTM8 DI DMWXTM8 DMWXTM8 DN ST-2987 DMWXTM8 TI TTYHPU6 DMWXTM8 TN Histone deacetylase 10 (HDAC10) DMWXTM8 MA Inhibitor DMWXTM8 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMWXTM8 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMWXTM8 DI DMWXTM8 DMWXTM8 DN ST-2987 DMWXTM8 TI TTT6LFV DMWXTM8 TN Histone deacetylase 8 (HDAC8) DMWXTM8 MA Inhibitor DMWXTM8 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMWXTM8 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMWXTM8 DI DMWXTM8 DMWXTM8 DN ST-2987 DMWXTM8 TI TTTQGH8 DMWXTM8 TN Histone deacetylase 4 (HDAC4) DMWXTM8 MA Inhibitor DMWXTM8 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMWXTM8 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMWXTM8 DI DMWXTM8 DMWXTM8 DN ST-2987 DMWXTM8 TI TT5ZKDI DMWXTM8 TN Histone deacetylase 6 (HDAC6) DMWXTM8 MA Inhibitor DMWXTM8 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMWXTM8 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMWXTM8 DI DMWXTM8 DMWXTM8 DN ST-2987 DMWXTM8 TI TT6R7JZ DMWXTM8 TN Histone deacetylase 1 (HDAC1) DMWXTM8 MA Inhibitor DMWXTM8 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMWXTM8 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMWXTM8 DI DMWXTM8 DMWXTM8 DN ST-2987 DMWXTM8 TI TTBH0VX DMWXTM8 TN Histone deacetylase (HDAC) DMWXTM8 MA Inhibitor DMWXTM8 RN N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. DMWXTM8 RU https://pubmed.ncbi.nlm.nih.gov/19285395 DMWXUCT DI DMWXUCT DMWXUCT DN N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide DMWXUCT TI TTLM12X DMWXUCT TN Matrix metalloproteinase-2 (MMP-2) DMWXUCT MA Inhibitor DMWXUCT RN Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. DMWXUCT RU https://pubmed.ncbi.nlm.nih.gov/17936631 DMWXUCT DI DMWXUCT DMWXUCT DN N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide DMWXUCT TI TT6X50U DMWXUCT TN Matrix metalloproteinase-9 (MMP-9) DMWXUCT MA Inhibitor DMWXUCT RN Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. DMWXUCT RU https://pubmed.ncbi.nlm.nih.gov/17936631 DMWXUCT DI DMWXUCT DMWXUCT DN N-hydroxy-3-(2-oxo-2H-chromen-3-yl)propanamide DMWXUCT TI TT6AZXG DMWXUCT TN TNF alpha converting enzyme (ADAM17) DMWXUCT MA Inhibitor DMWXUCT RN Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation. Bioorg Med Chem. 2008 Jan 1;16(1):530-5. DMWXUCT RU https://pubmed.ncbi.nlm.nih.gov/17936631 DMWY0TN DI DMWY0TN DMWY0TN DN LICOAGROCHACONE A DMWY0TN TI TTELIN2 DMWY0TN TN PTPN1 messenger RNA (PTPN1 mRNA) DMWY0TN MA Inhibitor DMWY0TN RN Inhibitory effect of chalcones and their derivatives from Glycyrrhiza inflata on protein tyrosine phosphatase 1B. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5155-7. DMWY0TN RU https://pubmed.ncbi.nlm.nih.gov/19632832 DMWY1QN DI DMWY1QN DMWY1QN DN 1,2-Bis-(3-methoxy-phenyl)-ethane-1,2-dione DMWY1QN TI TTMF541 DMWY1QN TN Liver carboxylesterase (CES1) DMWY1QN MA Inhibitor DMWY1QN RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMWY1QN RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMWY2XB DI DMWY2XB DMWY2XB DN ISIS 9071 DMWY2XB TI TT5TURO DMWY2XB TN A-Raf messenger RNA (ARAF mRNA) DMWY2XB RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DMWY2XB RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DMWY39L DI DMWY39L DMWY39L DN NSC-651016 DMWY39L TI TTFZYTO DMWY39L TN C-C chemokine receptor type 2 (CCR2) DMWY39L MA Inhibitor DMWY39L RN Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemo... J Med Chem. 1998 Jun 18;41(13):2184-93. DMWY39L RU https://pubmed.ncbi.nlm.nih.gov/9632350 DMWYCOB DI DMWYCOB DMWYCOB DN PMID30247903-Compound-General structure46 DMWYCOB TI TT23XQV DMWYCOB TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMWYCOB MA Inhibitor DMWYCOB RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMWYCOB RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMWYE7A DI DMWYE7A DMWYE7A DN Protoporphyrin IX DMWYE7A TI TTCYE56 DMWYE7A TN Glutathione-dependent PGD synthase (HPGDS) DMWYE7A MA Inhibitor DMWYE7A RN Inhibition of glutathione-S-transferase from Plasmodium yoelii by protoporphyrin IX, cibacron blue and menadione: implications and therapeutic bene... Parasitol Res. 2008 Mar;102(4):805-7. DMWYE7A RU https://pubmed.ncbi.nlm.nih.gov/18180958 DMWYESB DI DMWYESB DMWYESB DN 4-(cyclohexylmethylcarbamoyloxy)benzoic acid DMWYESB TI TTDP1UC DMWYESB TN Fatty acid amide hydrolase (FAAH) DMWYESB MA Inhibitor DMWYESB RN Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43. DMWYESB RU https://pubmed.ncbi.nlm.nih.gov/18983142 DMWYFLD DI DMWYFLD DMWYFLD DN Cyclo[RGDfK(cypate)] DMWYFLD TI TTJA1ZO DMWYFLD TN ITGB3 messenger RNA (ITGB3 mRNA) DMWYFLD MA Inhibitor DMWYFLD RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMWYFLD RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMWYFLD DI DMWYFLD DMWYFLD DN Cyclo[RGDfK(cypate)] DMWYFLD TI TTT1R2L DMWYFLD TN Integrin alpha-V (ITGAV) DMWYFLD MA Inhibitor DMWYFLD RN Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem. 2006 Apr 6;49(7):2268-75. DMWYFLD RU https://pubmed.ncbi.nlm.nih.gov/16570923 DMWYG8K DI DMWYG8K DMWYG8K DN 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol DMWYG8K TI TTNT7K8 DMWYG8K TN Nociceptin receptor (OPRL1) DMWYG8K MA Inhibitor DMWYG8K RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWYG8K RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWYG8K DI DMWYG8K DMWYG8K DN 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol DMWYG8K TI TTKWM86 DMWYG8K TN Opioid receptor mu (MOP) DMWYG8K MA Inhibitor DMWYG8K RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWYG8K RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWYG8K DI DMWYG8K DMWYG8K DN 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol DMWYG8K TI TT27RFC DMWYG8K TN Opioid receptor delta (OPRD1) DMWYG8K MA Inhibitor DMWYG8K RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWYG8K RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWYG8K DI DMWYG8K DMWYG8K DN 1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol DMWYG8K TI TTQW87Y DMWYG8K TN Opioid receptor kappa (OPRK1) DMWYG8K MA Inhibitor DMWYG8K RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMWYG8K RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMWYIJ3 DI DMWYIJ3 DMWYIJ3 DN L-708,906 DMWYIJ3 TI TT5FH9Y DMWYIJ3 TN Human immunodeficiency virus Integrase (HIV IN) DMWYIJ3 MA Inhibitor DMWYIJ3 RN Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6. DMWYIJ3 RU https://pubmed.ncbi.nlm.nih.gov/11502522 DMWYN87 DI DMWYN87 DMWYN87 DN C[Glu23-Lys27][Gly8]GLP-1(7-37)-NH2 DMWYN87 TI TTVIMDE DMWYN87 TN Glucagon-like peptide 1 receptor (GLP1R) DMWYN87 MA Inhibitor DMWYN87 RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMWYN87 RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMWYS0Z DI DMWYS0Z DMWYS0Z DN Aminobenzolamide derivative DMWYS0Z TI TTANPDJ DMWYS0Z TN Carbonic anhydrase II (CA-II) DMWYS0Z MA Inhibitor DMWYS0Z RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides d... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5775-80. DMWYS0Z RU https://pubmed.ncbi.nlm.nih.gov/15501039 DMWYS0Z DI DMWYS0Z DMWYS0Z DN Aminobenzolamide derivative DMWYS0Z TI TT2LVK8 DMWYS0Z TN Carbonic anhydrase IX (CA-IX) DMWYS0Z MA Inhibitor DMWYS0Z RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides d... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5775-80. DMWYS0Z RU https://pubmed.ncbi.nlm.nih.gov/15501039 DMWYS0Z DI DMWYS0Z DMWYS0Z DN Aminobenzolamide derivative DMWYS0Z TI TTHQPL7 DMWYS0Z TN Carbonic anhydrase I (CA-I) DMWYS0Z MA Inhibitor DMWYS0Z RN Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides d... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5775-80. DMWYS0Z RU https://pubmed.ncbi.nlm.nih.gov/15501039 DMWYU5C DI DMWYU5C DMWYU5C DN JNJ-5207787 DMWYU5C TI TTJ6WK9 DMWYU5C TN Neuropeptide Y receptor type 2 (NPY2R) DMWYU5C MA Antagonist DMWYU5C RN Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a ... J Pharmacol Exp Ther. 2004 Mar;308(3):1130-7. DMWYU5C RU https://pubmed.ncbi.nlm.nih.gov/14617685 DMWZ093 DI DMWZ093 DMWZ093 DN ANTHRONE DMWZ093 TI TT2J34L DMWZ093 TN Arachidonate 5-lipoxygenase (5-LOX) DMWZ093 MA Inhibitor DMWZ093 RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMWZ093 RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMWZ27A DI DMWZ27A DMWZ27A DN 8-methyl-2-morpholino-7-phenoxy-4H-chromen-4-one DMWZ27A TI TT06AWU DMWZ27A TN Phosphodiesterase 3A (PDE3A) DMWZ27A MA Inhibitor DMWZ27A RN Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73. DMWZ27A RU https://pubmed.ncbi.nlm.nih.gov/16290931 DMWZ4KN DI DMWZ4KN DMWZ4KN DN 2beta-methoxy-2-deethoxyphantomolin DMWZ4KN TI TTSXVID DMWZ4KN TN Nuclear factor NF-kappa-B (NFKB) DMWZ4KN MA Inhibitor DMWZ4KN RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMWZ4KN RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMWZ5FB DI DMWZ5FB DMWZ5FB DN tripitramine DMWZ5FB TI TTOXS3C DMWZ5FB TN Muscarinic acetylcholine receptor (CHRM) DMWZ5FB MA Antagonist DMWZ5FB RN Binding profile of the selective muscarinic receptor antagonist tripitramine. Eur J Pharmacol. 1994 Aug 16;268(3):459-62. DMWZ5FB RU https://pubmed.ncbi.nlm.nih.gov/7805774 DMWZ5FB DI DMWZ5FB DMWZ5FB DN tripitramine DMWZ5FB TI TTQ13Z5 DMWZ5FB TN Muscarinic acetylcholine receptor M3 (CHRM3) DMWZ5FB MA Antagonist DMWZ5FB RN Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics. Bioorg Med Chem. 2008 Aug 1;16(15):7311-20. DMWZ5FB RU https://pubmed.ncbi.nlm.nih.gov/18595721 DMWZDA1 DI DMWZDA1 DMWZDA1 DN 3-Ethoxy-5-(6-methoxynaphthalen-2-yl)pyridine DMWZDA1 TI TTIQUX7 DMWZDA1 TN Steroid 11-beta-hydroxylase (CYP11B1) DMWZDA1 MA Inhibitor DMWZDA1 RN Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on pote... J Med Chem. 2008 Aug 28;51(16):5064-74. DMWZDA1 RU https://pubmed.ncbi.nlm.nih.gov/18672861 DMWZJG6 DI DMWZJG6 DMWZJG6 DN K00248 DMWZJG6 TI TTYPXQF DMWZJG6 TN Protein kinase C beta (PRKCB) DMWZJG6 MA Inhibitor DMWZJG6 RN Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4. DMWZJG6 RU https://pubmed.ncbi.nlm.nih.gov/15380221 DMWZJT0 DI DMWZJT0 DMWZJT0 DN PMID25489658C4d DMWZJT0 TI TTE6GTB DMWZJT0 TN Kallikrein-7 (KLK7) DMWZJT0 MA Inhibitor DMWZJT0 RN Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612. DMWZJT0 RU https://pubmed.ncbi.nlm.nih.gov/25489658 DMWZJT0 DI DMWZJT0 DMWZJT0 DN PMID25489658C4d DMWZJT0 TI TTULSEW DMWZJT0 TN Kallikrein-5 (KLK5) DMWZJT0 MA Inhibitor DMWZJT0 RN Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612. DMWZJT0 RU https://pubmed.ncbi.nlm.nih.gov/25489658 DMWZJT0 DI DMWZJT0 DMWZJT0 DN PMID25489658C4d DMWZJT0 TI TTPRO7W DMWZJT0 TN Suppressor of tumorigenicity 14 protein (ST14) DMWZJT0 MA Inhibitor DMWZJT0 RN Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612. DMWZJT0 RU https://pubmed.ncbi.nlm.nih.gov/25489658 DMWZJT0 DI DMWZJT0 DMWZJT0 DN PMID25489658C4d DMWZJT0 TI TTDA81R DMWZJT0 TN Kallikrein-14 (KLK14) DMWZJT0 MA Inhibitor DMWZJT0 RN Toward the first class of suicide inhibitors of kallikreins involved in skin diseases. J Med Chem. 2015 Jan 22;58(2):598-612. DMWZJT0 RU https://pubmed.ncbi.nlm.nih.gov/25489658 DMWZK9U DI DMWZK9U DMWZK9U DN PMID20684603C24dd DMWZK9U TI TTDIGC1 DMWZK9U TN Dipeptidyl peptidase 4 (DPP-4) DMWZK9U MA Inhibitor DMWZK9U RN Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8. DMWZK9U RU https://pubmed.ncbi.nlm.nih.gov/20684603 DMWZK9U DI DMWZK9U DMWZK9U DN PMID20684603C24dd DMWZK9U TI TTNDUL7 DMWZK9U TN Dipeptidyl peptidase 9 (DPP-9) DMWZK9U MA Inhibitor DMWZK9U RN Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8. DMWZK9U RU https://pubmed.ncbi.nlm.nih.gov/20684603 DMWZK9U DI DMWZK9U DMWZK9U DN PMID20684603C24dd DMWZK9U TI TTJGLZF DMWZK9U TN Dipeptidyl peptidase 8 (DPP-8) DMWZK9U MA Inhibitor DMWZK9U RN Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8. DMWZK9U RU https://pubmed.ncbi.nlm.nih.gov/20684603 DMWZMCA DI DMWZMCA DMWZMCA DN L-Tryptophan-L-asparagine DMWZMCA TI TTT2SVW DMWZMCA TN PPAR-gamma messenger RNA (PPARG mRNA) DMWZMCA MA Inhibitor DMWZMCA RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DMWZMCA RU https://pubmed.ncbi.nlm.nih.gov/18329752 DMWZOQJ DI DMWZOQJ DMWZOQJ DN ISIS 6729 DMWZOQJ TI TTAN5W2 DMWZOQJ TN Raf messenger RNA (Raf mRNA) DMWZOQJ RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMWZOQJ RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMWZTKD DI DMWZTKD DMWZTKD DN N-3'-ethylaplysinopsin DMWZTKD TI TTJQOD7 DMWZTKD TN 5-HT 2A receptor (HTR2A) DMWZTKD MA Inhibitor DMWZTKD RN New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80. DMWZTKD RU https://pubmed.ncbi.nlm.nih.gov/11975483 DMWZTKD DI DMWZTKD DMWZTKD DN N-3'-ethylaplysinopsin DMWZTKD TI TTWJBZ5 DMWZTKD TN 5-HT 2C receptor (HTR2C) DMWZTKD MA Inhibitor DMWZTKD RN New antiinfective and human 5-HT2 receptor binding natural and semisynthetic compounds from the Jamaican sponge Smenospongia aurea. J Nat Prod. 2002 Apr;65(4):476-80. DMWZTKD RU https://pubmed.ncbi.nlm.nih.gov/11975483 DMWZXH6 DI DMWZXH6 DMWZXH6 DN O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine DMWZXH6 TI TT6OEDT DMWZXH6 TN Cannabinoid receptor 1 (CB1) DMWZXH6 MA Inhibitor DMWZXH6 RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DMWZXH6 RU https://pubmed.ncbi.nlm.nih.gov/16570929 DMWZXH6 DI DMWZXH6 DMWZXH6 DN O-arachidonoyl-N-(2-hydroxyethyl)hydroxylamine DMWZXH6 TI TTMSFAW DMWZXH6 TN Cannabinoid receptor 2 (CB2) DMWZXH6 MA Inhibitor DMWZXH6 RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DMWZXH6 RU https://pubmed.ncbi.nlm.nih.gov/16570929 DMX07BG DI DMX07BG DMX07BG DN Cis-4-hydroxynipecotic acid DMX07BG TI TTV9MQG DMX07BG TN Gamma-aminobutyric acid uptake (GABAU) DMX07BG MA Inhibitor DMX07BG RN GABA uptake inhibitors. Synthesis and effects on audiogenic seizures of ester prodrugs of nipecotic acid, guvacine and cis-4-hydroxynipecotic acid. Drug Des Deliv. 1987 Sep;2(1):9-21. DMX07BG RU https://pubmed.ncbi.nlm.nih.gov/3509345 DMX08FL DI DMX08FL DMX08FL DN H-Tyr(OMe)-Phe(2-Me)-NH2 DMX08FL TI TTZPO1L DMX08FL TN Substance-P receptor (TACR1) DMX08FL MA Inhibitor DMX08FL RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMX08FL RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMX09KI DI DMX09KI DMX09KI DN CRT0066101 DMX09KI TI TTSLUMT DMX09KI TN Protein kinase D (PRKD1) DMX09KI MA Inhibitor DMX09KI RN Protein kinase D as a potential new target for cancer therapy. Biochim Biophys Acta. 2010 Dec;1806(2):183-92. DMX09KI RU https://pubmed.ncbi.nlm.nih.gov/20580776 DMX0EAK DI DMX0EAK DMX0EAK DN 5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine DMX0EAK TI TTBL49X DMX0EAK TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMX0EAK MA Inhibitor DMX0EAK RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX0EAK RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX0G4F DI DMX0G4F DMX0G4F DN Phenethylamine DMX0G4F TI TTJQOD7 DMX0G4F TN 5-HT 2A receptor (HTR2A) DMX0G4F MA Inhibitor DMX0G4F RN Exploring the relationship between binding modes of 9-(aminomethyl)-9,10-dihydroanthracene and cyproheptadine analogues at the 5-HT2A serotonin rec... Bioorg Med Chem Lett. 2001 Feb 26;11(4):563-6. DMX0G4F RU https://pubmed.ncbi.nlm.nih.gov/11229772 DMX0G7E DI DMX0G7E DMX0G7E DN [(125)I] RB129 DMX0G7E TI TTPHMWB DMX0G7E TN Aminopeptidase N (ANPEP) DMX0G7E MA Inhibitor DMX0G7E RN Ontogenic and adult whole body distribution of aminopeptidase N in rat investigated by in vitro autoradiography. Biochimie. 2004 Feb;86(2):105-13. DMX0G7E RU https://pubmed.ncbi.nlm.nih.gov/15016448 DMX0G7E DI DMX0G7E DMX0G7E DN [(125)I] RB129 DMX0G7E TI TTN7BL9 DMX0G7E TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMX0G7E MA Inhibitor DMX0G7E RN Rapid hepatic metabolism of 7-ketocholesterol by 11beta-hydroxysteroid dehydrogenase type 1: species-specific differences between the rat, human, a... J Biol Chem. 2004 Apr 30;279(18):18415-24. DMX0G7E RU https://pubmed.ncbi.nlm.nih.gov/14973125 DMX0G7E DI DMX0G7E DMX0G7E DN [(125)I] RB129 DMX0G7E TI TT9H85R DMX0G7E TN Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) DMX0G7E MA Inhibitor DMX0G7E RN Abnormal expression of 11 beta-hydroxysteroid dehydrogenase type 2 in human pituitary adenomas: a prereceptor determinant of pituitary cell proliferation. Oncogene. 2003 Mar 20;22(11):1663-7. DMX0G7E RU https://pubmed.ncbi.nlm.nih.gov/12642869 DMX0TAM DI DMX0TAM DMX0TAM DN NSC-95397 DMX0TAM TI TTR0SWN DMX0TAM TN M-phase inducer phosphatase 2 (MPIP2) DMX0TAM MA Inhibitor DMX0TAM RN Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9. DMX0TAM RU https://pubmed.ncbi.nlm.nih.gov/18789703 DMX0TAM DI DMX0TAM DMX0TAM DN NSC-95397 DMX0TAM TI TTLZS4Q DMX0TAM TN M-phase inducer phosphatase 1 (MPIP1) DMX0TAM MA Inhibitor DMX0TAM RN Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4330-4. DMX0TAM RU https://pubmed.ncbi.nlm.nih.gov/19497739 DMX0VQN DI DMX0VQN DMX0VQN DN NSC-73410 DMX0VQN TI TT8XK6L DMX0VQN TN Quinone reductase 1 (NQO1) DMX0VQN MA Inhibitor DMX0VQN RN In silico identification and biochemical characterization of novel inhibitors of NQO1. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6246-54. DMX0VQN RU https://pubmed.ncbi.nlm.nih.gov/17011189 DMX0Y79 DI DMX0Y79 DMX0Y79 DN N-BENZOYL-D-ALANINE DMX0Y79 TI TT329FH DMX0Y79 TN Bacterial Penicillin-binding protein 1B (Bact mrcB) DMX0Y79 MA Inhibitor DMX0Y79 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMX0Y79 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMX0YIV DI DMX0YIV DMX0YIV DN (2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMX0YIV TI TTMSFAW DMX0YIV TN Cannabinoid receptor 2 (CB2) DMX0YIV MA Inhibitor DMX0YIV RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMX0YIV RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMX0YIV DI DMX0YIV DMX0YIV DN (2R)-N-(7'-(2-CHLOROPHENYL)-6'-(4-CHLOROPHENYL)-3',4'-DIHYDROSPIRO[CYCLOHEXANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMX0YIV TI TT6OEDT DMX0YIV TN Cannabinoid receptor 1 (CB1) DMX0YIV MA Inhibitor DMX0YIV RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMX0YIV RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMX0ZBC DI DMX0ZBC DMX0ZBC DN WK-X-34 DMX0ZBC TI TT0JLSD DMX0ZBC TN Multidrug resistance protein (MDR) DMX0ZBC MA Inhibitor DMX0ZBC RN Thiazolides: a new class of antiviral drugs. Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):667-74. DMX0ZBC RU https://pubmed.ncbi.nlm.nih.gov/19442032 DMX1AY4 DI DMX1AY4 DMX1AY4 DN PD-168077 DMX1AY4 TI TTEX248 DMX1AY4 TN Dopamine D2 receptor (D2R) DMX1AY4 MA Inhibitor DMX1AY4 RN New N-n-propyl-substituted 3-aryl- and 3-cyclohexylpiperidines as partial agonists at the D4 dopamine receptor. J Med Chem. 2003 Jan 2;46(1):161-8. DMX1AY4 RU https://pubmed.ncbi.nlm.nih.gov/12502370 DMX1HKU DI DMX1HKU DMX1HKU DN 4-(2-(Phenylamino)ethyl)-1H-imidazole DMX1HKU TI TT9JNIC DMX1HKU TN Histamine H3 receptor (H3R) DMX1HKU MA Inhibitor DMX1HKU RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMX1HKU RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMX1IC4 DI DMX1IC4 DMX1IC4 DN 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMX1IC4 TI TTCM4B3 DMX1IC4 TN Nitric-oxide synthase endothelial (NOS3) DMX1IC4 MA Inhibitor DMX1IC4 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX1IC4 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX1IC4 DI DMX1IC4 DMX1IC4 DN 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMX1IC4 TI TTF10I9 DMX1IC4 TN Nitric-oxide synthase inducible (NOS2) DMX1IC4 MA Inhibitor DMX1IC4 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX1IC4 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX1IC4 DI DMX1IC4 DMX1IC4 DN 2-Methyl-[1,4]thiazepan-(5E)-ylideneamine DMX1IC4 TI TTZUFI5 DMX1IC4 TN Nitric-oxide synthase brain (NOS1) DMX1IC4 MA Inhibitor DMX1IC4 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX1IC4 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX1IYO DI DMX1IYO DMX1IYO DN D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP) DMX1IYO TI TT27RFC DMX1IYO TN Opioid receptor delta (OPRD1) DMX1IYO MA Inhibitor DMX1IYO RN Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5. DMX1IYO RU https://pubmed.ncbi.nlm.nih.gov/2878079 DMX1JR0 DI DMX1JR0 DMX1JR0 DN WS-5 DMX1JR0 TI TTXDKTO DMX1JR0 TN Long transient receptor potential channel 8 (TRPM8) DMX1JR0 MA Activator DMX1JR0 RN Characterization of selective TRPM8 ligands and their structure activity response (S.A.R) relationship. J Pharm Pharm Sci. 2010;13(2):242-53. DMX1JR0 RU https://pubmed.ncbi.nlm.nih.gov/20816009 DMX1LY3 DI DMX1LY3 DMX1LY3 DN 5-methoxy-2-(2-(pyrrolidin-1-yl)ethyl)-1H-indole DMX1LY3 TI TT9JNIC DMX1LY3 TN Histamine H3 receptor (H3R) DMX1LY3 MA Inhibitor DMX1LY3 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMX1LY3 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMX1OI8 DI DMX1OI8 DMX1OI8 DN ISIS 11158 DMX1OI8 TI TTA1L39 DMX1OI8 TN ICAM1 messenger RNA (ICAM1 mRNA) DMX1OI8 RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DMX1OI8 RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DMX1POR DI DMX1POR DMX1POR DN MYOSEVERIN DMX1POR TI TTYFKSZ DMX1POR TN Tubulin beta (TUBB) DMX1POR MA Inhibitor DMX1POR RN Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J Med Chem. 2001 Dec 20;44(26):4497-500. DMX1POR RU https://pubmed.ncbi.nlm.nih.gov/11741468 DMX1POR DI DMX1POR DMX1POR DN MYOSEVERIN DMX1POR TI TTML2WA DMX1POR TN Tubulin (TUB) DMX1POR MA Inhibitor DMX1POR RN Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J Med Chem. 2001 Dec 20;44(26):4497-500. DMX1POR RU https://pubmed.ncbi.nlm.nih.gov/11741468 DMX1TIU DI DMX1TIU DMX1TIU DN 2-[2-(3,5-Dimethoxy-phenyl)-vinyl]-thiophene DMX1TIU TI TTI84H7 DMX1TIU TN Cytochrome P450 1B1 (CYP1B1) DMX1TIU MA Inhibitor DMX1TIU RN Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. DMX1TIU RU https://pubmed.ncbi.nlm.nih.gov/11754588 DMX2084 DI DMX2084 DMX2084 DN GALLOCATECHIN GALLATE DMX2084 TI TT7AOUD DMX2084 TN Fatty acid synthase (FASN) DMX2084 MA Inhibitor DMX2084 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMX2084 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMX2084 DI DMX2084 DMX2084 DN GALLOCATECHIN GALLATE DMX2084 TI TTHPFTS DMX2084 TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DMX2084 MA Inhibitor DMX2084 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMX2084 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMX2084 DI DMX2084 DMX2084 DN GALLOCATECHIN GALLATE DMX2084 TI TTNX2CS DMX2084 TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMX2084 MA Inhibitor DMX2084 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMX2084 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMX2084 DI DMX2084 DMX2084 DN GALLOCATECHIN GALLATE DMX2084 TI TTBE4IR DMX2084 TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMX2084 MA Inhibitor DMX2084 RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMX2084 RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMX294V DI DMX294V DMX294V DN PD-135385 DMX294V TI TTEX248 DMX294V TN Dopamine D2 receptor (D2R) DMX294V MA Inhibitor DMX294V RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DMX294V RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DMX2DQ5 DI DMX2DQ5 DMX2DQ5 DN CHLOROCYCLINONE C DMX2DQ5 TI TTT2SVW DMX2DQ5 TN PPAR-gamma messenger RNA (PPARG mRNA) DMX2DQ5 MA Inhibitor DMX2DQ5 RN Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8. DMX2DQ5 RU https://pubmed.ncbi.nlm.nih.gov/18044841 DMX2FWN DI DMX2FWN DMX2FWN DN 1-Methyl-5-oxa-spiro[2.4]heptan-4-one DMX2FWN TI TT1MPAY DMX2FWN TN GABA(A) receptor alpha-1 (GABRA1) DMX2FWN MA Inhibitor DMX2FWN RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMX2FWN RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMX2FWN DI DMX2FWN DMX2FWN DN 1-Methyl-5-oxa-spiro[2.4]heptan-4-one DMX2FWN TI TTNJYV2 DMX2FWN TN Gamma-aminobutyric acid receptor (GAR) DMX2FWN MA Inhibitor DMX2FWN RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMX2FWN RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMX2FWN DI DMX2FWN DMX2FWN DN 1-Methyl-5-oxa-spiro[2.4]heptan-4-one DMX2FWN TI TT06RH5 DMX2FWN TN GABA(A) receptor gamma-2 (GABRG2) DMX2FWN MA Inhibitor DMX2FWN RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMX2FWN RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMX2FWN DI DMX2FWN DMX2FWN DN 1-Methyl-5-oxa-spiro[2.4]heptan-4-one DMX2FWN TI TTZA1NY DMX2FWN TN GABA(A) receptor beta-2 (GABRB2) DMX2FWN MA Inhibitor DMX2FWN RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMX2FWN RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMX2I4P DI DMX2I4P DMX2I4P DN Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF DMX2I4P TI TTIND6G DMX2I4P TN Somatostatin receptor type 1 (SSTR1) DMX2I4P MA Inhibitor DMX2I4P RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMX2I4P RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMX2I4P DI DMX2I4P DMX2I4P DN Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF DMX2I4P TI TTAE1BR DMX2I4P TN Somatostatin receptor type 4 (SSTR4) DMX2I4P MA Inhibitor DMX2I4P RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMX2I4P RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMX2I4P DI DMX2I4P DMX2I4P DN Des-AA1,2,5-[D-Trp8,(NalphaMe)IAmp9]SRIF DMX2I4P TI TTJX3UE DMX2I4P TN Somatostatin receptor type 3 (SSTR3) DMX2I4P MA Inhibitor DMX2I4P RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMX2I4P RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMX2IRY DI DMX2IRY DMX2IRY DN Ac-I[CV(2Nal)QDWGAHRC]T-NH2 DMX2IRY TI TTJGY7A DMX2IRY TN Complement C3 (CO3) DMX2IRY MA Inhibitor DMX2IRY RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMX2IRY RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMX2JKQ DI DMX2JKQ DMX2JKQ DN 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine DMX2JKQ TI TTF10I9 DMX2JKQ TN Nitric-oxide synthase inducible (NOS2) DMX2JKQ MA Inhibitor DMX2JKQ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX2JKQ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX2JKQ DI DMX2JKQ DMX2JKQ DN 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine DMX2JKQ TI TTZUFI5 DMX2JKQ TN Nitric-oxide synthase brain (NOS1) DMX2JKQ MA Inhibitor DMX2JKQ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX2JKQ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX2JKQ DI DMX2JKQ DMX2JKQ DN 3-Ethyl-[1,4]thiazepan-(5E)-ylideneamine DMX2JKQ TI TTCM4B3 DMX2JKQ TN Nitric-oxide synthase endothelial (NOS3) DMX2JKQ MA Inhibitor DMX2JKQ RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX2JKQ RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX2K8R DI DMX2K8R DMX2K8R DN 4-(7-methyl-1-propyl-1H-indazol-3-yl)phenol DMX2K8R TI TTZAYWL DMX2K8R TN Estrogen receptor (ESR) DMX2K8R MA Inhibitor DMX2K8R RN Synthesis and activity of substituted 4-(indazol-3-yl)phenols as pathway-selective estrogen receptor ligands useful in the treatment of rheumatoid ... J Med Chem. 2004 Dec 16;47(26):6435-8. DMX2K8R RU https://pubmed.ncbi.nlm.nih.gov/15588074 DMX2LT5 DI DMX2LT5 DMX2LT5 DN 3-(imidazolylmethyl)-4'-nitroflavone DMX2LT5 TI TTSZLWK DMX2LT5 TN Aromatase (CYP19A1) DMX2LT5 MA Inhibitor DMX2LT5 RN Lead optimization providing a series of flavone derivatives as potent nonsteroidal inhibitors of the cytochrome P450 aromatase enzyme. J Med Chem. 2006 Jul 27;49(15):4777-80. DMX2LT5 RU https://pubmed.ncbi.nlm.nih.gov/16854084 DMX2NKO DI DMX2NKO DMX2NKO DN Immucillin-G DMX2NKO TI TTMCF1Y DMX2NKO TN Purine nucleoside phosphorylase (PNP) DMX2NKO MA Inhibitor DMX2NKO RN Exploring structure-activity relationships of transition state analogues of human purine nucleoside phosphorylase. J Med Chem. 2003 Jul 17;46(15):3412-23. DMX2NKO RU https://pubmed.ncbi.nlm.nih.gov/12852771 DMX2QD5 DI DMX2QD5 DMX2QD5 DN 4-((1H-imidazol-4-yl)methyl)-1-heptylpiperidine DMX2QD5 TI TT9JNIC DMX2QD5 TN Histamine H3 receptor (H3R) DMX2QD5 MA Inhibitor DMX2QD5 RN Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorg Med Chem Lett. 2006 Jan 15;16(2):395-9. DMX2QD5 RU https://pubmed.ncbi.nlm.nih.gov/16246552 DMX2SFW DI DMX2SFW DMX2SFW DN 1,1,1-Trifluoro-undecan-2-one DMX2SFW TI TTDP1UC DMX2SFW TN Fatty acid amide hydrolase (FAAH) DMX2SFW MA Inhibitor DMX2SFW RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DMX2SFW RU https://pubmed.ncbi.nlm.nih.gov/15771430 DMX2SU9 DI DMX2SU9 DMX2SU9 DN [Mpa1, D-Tyr(Et)2, Gly(But)7]OT DMX2SU9 TI TTSCIUP DMX2SU9 TN Oxytocin receptor (OTR) DMX2SU9 MA Inhibitor DMX2SU9 RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMX2SU9 RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMX2TGD DI DMX2TGD DMX2TGD DN H-Gly-D-dmP-Glu-OH DMX2TGD TI TTLD29N DMX2TGD TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMX2TGD MA Inhibitor DMX2TGD RN The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. DMX2TGD RU https://pubmed.ncbi.nlm.nih.gov/16650992 DMX2TGD DI DMX2TGD DMX2TGD DN H-Gly-D-dmP-Glu-OH DMX2TGD TI TTN9D8E DMX2TGD TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMX2TGD MA Inhibitor DMX2TGD RN The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. DMX2TGD RU https://pubmed.ncbi.nlm.nih.gov/16650992 DMX2TGD DI DMX2TGD DMX2TGD DN H-Gly-D-dmP-Glu-OH DMX2TGD TI TTKJEMQ DMX2TGD TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMX2TGD MA Inhibitor DMX2TGD RN The neuroprotective activity of GPE tripeptide analogues does not correlate with glutamate receptor binding affinity. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3396-400. DMX2TGD RU https://pubmed.ncbi.nlm.nih.gov/16650992 DMX2TZD DI DMX2TZD DMX2TZD DN DR-5/DR-4 cross reactive mabs DMX2TZD TI TTW20TU DMX2TZD TN TRAIL receptor 2 (TRAIL-R2) DMX2TZD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1880). DMX2TZD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1880 DMX2TZD DI DMX2TZD DMX2TZD DN DR-5/DR-4 cross reactive mabs DMX2TZD TI TT5WLRX DMX2TZD TN TRAIL receptor 1 (TRAIL-R1) DMX2TZD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1879). DMX2TZD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1879 DMX2U7G DI DMX2U7G DMX2U7G DN bromo-deaza-SAH DMX2U7G TI TTSZ8T1 DMX2U7G TN Histone-lysine N-methyltransferase (HLNM) DMX2U7G MA Inhibitor DMX2U7G RN Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg Med Chem. 2013 Apr 1;21(7):1787-94. DMX2U7G RU https://pubmed.ncbi.nlm.nih.gov/23433670 DMX2VFP DI DMX2VFP DMX2VFP DN 6,7-Dimethoxy-4-(4-methoxy-phenoxy)-quinoline DMX2VFP TI TTI7421 DMX2VFP TN Platelet-derived growth factor receptor beta (PDGFRB) DMX2VFP MA Inhibitor DMX2VFP RN A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997). DMX2VFP RU http://www.sciencedirect.com/science/article/pii/S0960894X97101172 DMX2WCZ DI DMX2WCZ DMX2WCZ DN C[Glu26-Lys30][Gly8]GLP-1(7-37)-NH2 DMX2WCZ TI TTVIMDE DMX2WCZ TN Glucagon-like peptide 1 receptor (GLP1R) DMX2WCZ MA Inhibitor DMX2WCZ RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMX2WCZ RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMX32JY DI DMX32JY DMX32JY DN ED45 DMX32JY TI TTPLTSQ DMX32JY TN Neutrophil elastase (NE) DMX32JY RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMX32JY RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMX34F1 DI DMX34F1 DMX34F1 DN SKA-31 DMX34F1 TI TT7M9I6 DMX34F1 TN Calcium-activated potassium channel KCa3.1 (KCNN4) DMX34F1 MA Activator DMX34F1 RN Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009 Feb;75(2):281-95. DMX34F1 RU https://pubmed.ncbi.nlm.nih.gov/18955585 DMX34TL DI DMX34TL DMX34TL DN 2-fluoronorepinehprine DMX34TL TI TT2CJVK DMX34TL TN Adrenergic receptor beta-2 (ADRB2) DMX34TL MA Inhibitor DMX34TL RN Structural basis of the selectivity of the beta(2)-adrenergic receptor for fluorinated catecholamines. Bioorg Med Chem. 2009 Dec 1;17(23):7987-92. DMX34TL RU https://pubmed.ncbi.nlm.nih.gov/19857969 DMX37ZC DI DMX37ZC DMX37ZC DN 5-amino-2-phenyl-oxazole-4-carboxylic acid amide DMX37ZC TI TTJ3E9X DMX37ZC TN Inhibitor of nuclear factor kappa-B kinase beta (IKKB) DMX37ZC MA Inhibitor DMX37ZC RN Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J Med Chem. 2006 May 18;49(10):2898-908. DMX37ZC RU https://pubmed.ncbi.nlm.nih.gov/16686533 DMX3AMB DI DMX3AMB DMX3AMB DN 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline DMX3AMB TI TTI7421 DMX3AMB TN Platelet-derived growth factor receptor beta (PDGFRB) DMX3AMB MA Inhibitor DMX3AMB RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMX3AMB RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMX3AMB DI DMX3AMB DMX3AMB DN 3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline DMX3AMB TI TT8FYO9 DMX3AMB TN Platelet-derived growth factor receptor alpha (PDGFRA) DMX3AMB MA Inhibitor DMX3AMB RN A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37. DMX3AMB RU https://pubmed.ncbi.nlm.nih.gov/8035419 DMX3ANZ DI DMX3ANZ DMX3ANZ DN 3-Mercuri-4-Aminobenzenesulfonamide DMX3ANZ TI TTANPDJ DMX3ANZ TN Carbonic anhydrase II (CA-II) DMX3ANZ MA Inhibitor DMX3ANZ RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX3ANZ RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX3CYG DI DMX3CYG DMX3CYG DN PMID17532216C2f DMX3CYG TI TTVBPDM DMX3CYG TN Metabotropic glutamate receptor 1 (mGluR1) DMX3CYG MA Modulator (allosteric modulator) DMX3CYG RN Rapid hit to lead evaluation of pyrazolo[3,4-d]pyrimidin-4-one as selective and orally bioavailable mGluR1 antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4303-7. DMX3CYG RU https://pubmed.ncbi.nlm.nih.gov/17532216 DMX3K4E DI DMX3K4E DMX3K4E DN (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K DMX3K4E TI TTX3HNZ DMX3K4E TN Galanin receptor type 1 (GAL1-R) DMX3K4E MA Inhibitor DMX3K4E RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMX3K4E RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMX3K4E DI DMX3K4E DMX3K4E DN (Sar)WTLNSAGYLLGPKK(Lys-octanoyl)K DMX3K4E TI TTBPW3J DMX3K4E TN Galanin receptor type 2 (GAL2-R) DMX3K4E MA Inhibitor DMX3K4E RN Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem. 2009 Mar 12;52(5):1310-6. DMX3K4E RU https://pubmed.ncbi.nlm.nih.gov/19199479 DMX3KRQ DI DMX3KRQ DMX3KRQ DN N-hydroxy-2,2-diphenylacetamide DMX3KRQ TI TTTQGH8 DMX3KRQ TN Histone deacetylase 4 (HDAC4) DMX3KRQ MA Inhibitor DMX3KRQ RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DMX3KRQ RU https://pubmed.ncbi.nlm.nih.gov/19699639 DMX3KRQ DI DMX3KRQ DMX3KRQ DN N-hydroxy-2,2-diphenylacetamide DMX3KRQ TI TTBH0VX DMX3KRQ TN Histone deacetylase (HDAC) DMX3KRQ MA Inhibitor DMX3KRQ RN Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. DMX3KRQ RU https://pubmed.ncbi.nlm.nih.gov/19699639 DMX3P68 DI DMX3P68 DMX3P68 DN JMV 1799 DMX3P68 TI TTC1MVT DMX3P68 TN Gastrin-releasing peptide receptor (GRPR) DMX3P68 MA Inhibitor DMX3P68 RN Synthesis and biological evaluation of bombesin constrained analogues. J Med Chem. 2000 Jun 15;43(12):2356-61. DMX3P68 RU https://pubmed.ncbi.nlm.nih.gov/10882361 DMX3UV1 DI DMX3UV1 DMX3UV1 DN 7-Nitro-1,2,3,4-tetrahydro-isoquinoline DMX3UV1 TI TTWG9A4 DMX3UV1 TN Adrenergic receptor alpha-2A (ADRA2A) DMX3UV1 MA Inhibitor DMX3UV1 RN Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoqui... Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7. DMX3UV1 RU https://pubmed.ncbi.nlm.nih.gov/15686930 DMX40NM DI DMX40NM DMX40NM DN SCANDENOLIDE DMX40NM TI TTSXVID DMX40NM TN Nuclear factor NF-kappa-B (NFKB) DMX40NM MA Inhibitor DMX40NM RN Quantitative structure-activity relationship of sesquiterpene lactones as inhibitors of the transcription factor NF-kappaB. J Med Chem. 2004 Nov 18;47(24):6042-54. DMX40NM RU https://pubmed.ncbi.nlm.nih.gov/15537359 DMX41ZF DI DMX41ZF DMX41ZF DN T863 DMX41ZF TI TTF8P9I DMX41ZF TN Diacylglycerol acyltransferase 1 (DGAT1) DMX41ZF MA Inhibitor DMX41ZF RN Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58. DMX41ZF RU https://www.ncbi.nlm.nih.gov/pubmed/25470667 DMX45WE DI DMX45WE DMX45WE DN 2-Heptyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione DMX45WE TI TTQY2EJ DMX45WE TN TERT messenger RNA (TERT mRNA) DMX45WE MA Inhibitor DMX45WE RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMX45WE RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMX4B36 DI DMX4B36 DMX4B36 DN RO-147437 DMX4B36 TI TTZA1NY DMX4B36 TN GABA(A) receptor beta-2 (GABRB2) DMX4B36 MA Inhibitor DMX4B36 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMX4B36 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMX4B36 DI DMX4B36 DMX4B36 DN RO-147437 DMX4B36 TI TT06RH5 DMX4B36 TN GABA(A) receptor gamma-2 (GABRG2) DMX4B36 MA Inhibitor DMX4B36 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMX4B36 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMX4B36 DI DMX4B36 DMX4B36 DN RO-147437 DMX4B36 TI TTNJYV2 DMX4B36 TN Gamma-aminobutyric acid receptor (GAR) DMX4B36 MA Inhibitor DMX4B36 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMX4B36 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMX4B36 DI DMX4B36 DMX4B36 DN RO-147437 DMX4B36 TI TT1MPAY DMX4B36 TN GABA(A) receptor alpha-1 (GABRA1) DMX4B36 MA Inhibitor DMX4B36 RN Synthesis and evaluation of imidazo[1,5-a][1,4]benzodiazepine esters with high affinities and selectivities at "diazepam-insensitive" benzodiazepin... J Med Chem. 1993 Apr 16;36(8):1001-6. DMX4B36 RU https://pubmed.ncbi.nlm.nih.gov/8386769 DMX4D1Q DI DMX4D1Q DMX4D1Q DN Kuwanon L DMX4D1Q TI TTELIN2 DMX4D1Q TN PTPN1 messenger RNA (PTPN1 mRNA) DMX4D1Q MA Inhibitor DMX4D1Q RN Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9. DMX4D1Q RU https://pubmed.ncbi.nlm.nih.gov/16356713 DMX4DRV DI DMX4DRV DMX4DRV DN L-valyl-L-proline hexylamide DMX4DRV TI TTQ7R2V DMX4DRV TN Tripeptidyl-peptidase II (TPP2) DMX4DRV MA Inhibitor DMX4DRV RN Inhibitors of tripeptidyl peptidase II. 3. Derivation of butabindide by successive structure optimizations leading to a potential general approach ... J Med Chem. 2005 Nov 17;48(23):7333-42. DMX4DRV RU https://pubmed.ncbi.nlm.nih.gov/16279793 DMX4DT7 DI DMX4DT7 DMX4DT7 DN NSC 665564 DMX4DT7 TI TT3PQ2Y DMX4DT7 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMX4DT7 MA Inhibitor DMX4DT7 RN Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar. Biochem Biophys Res Commun. 1996 Jun 25;223(3):654-9. DMX4DT7 RU https://pubmed.ncbi.nlm.nih.gov/8687451 DMX4DUR DI DMX4DUR DMX4DUR DN 2-(3-bromobenzoylamino)-4-chlorobenzoic acid DMX4DUR TI TT0MYE2 DMX4DUR TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMX4DUR MA Inhibitor DMX4DUR RN Bioisosteric modifications of 2-arylureidobenzoic acids: selective noncompetitive antagonists for the homomeric kainate receptor subtype GluR5. J Med Chem. 2004 Dec 30;47(27):6948-57. DMX4DUR RU https://pubmed.ncbi.nlm.nih.gov/15615543 DMX4I5A DI DMX4I5A DMX4I5A DN ISIS 19218 DMX4I5A TI TT1ERKL DMX4I5A TN CD40 messenger RNA (CD40 mRNA) DMX4I5A RN US patent application no. 6,197,584, Antisense modulation of CD40 expression. DMX4I5A RU http://www.patentbuddy.com/Patent/6197584?ft=true&sr=true DMX4I9D DI DMX4I9D DMX4I9D DN 11-Heptanoyloxy-N-n-propylnoraporphine DMX4I9D TI TTZFYLI DMX4I9D TN Dopamine D1 receptor (D1R) DMX4I9D MA Inhibitor DMX4I9D RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMX4I9D RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMX4I9D DI DMX4I9D DMX4I9D DN 11-Heptanoyloxy-N-n-propylnoraporphine DMX4I9D TI TTJQOD7 DMX4I9D TN 5-HT 2A receptor (HTR2A) DMX4I9D MA Inhibitor DMX4I9D RN N-Propylnoraporphin-11-O-yl carboxylic esters as potent dopamine D(2) and serotonin 5-HT(1A) receptor dual ligands. Bioorg Med Chem. 2008 Sep 15;16(18):8335-8. DMX4I9D RU https://pubmed.ncbi.nlm.nih.gov/18783955 DMX4JN6 DI DMX4JN6 DMX4JN6 DN RGDechi DMX4JN6 TI TTT1R2L DMX4JN6 TN Integrin alpha-V (ITGAV) DMX4JN6 MA Inhibitor DMX4JN6 RN Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20. DMX4JN6 RU https://pubmed.ncbi.nlm.nih.gov/16722662 DMX4JN6 DI DMX4JN6 DMX4JN6 DN RGDechi DMX4JN6 TI TTJA1ZO DMX4JN6 TN ITGB3 messenger RNA (ITGB3 mRNA) DMX4JN6 MA Inhibitor DMX4JN6 RN Novel and selective alpha(v)beta3 receptor peptide antagonist: design, synthesis, and biological behavior. J Med Chem. 2006 Jun 1;49(11):3416-20. DMX4JN6 RU https://pubmed.ncbi.nlm.nih.gov/16722662 DMX4P5A DI DMX4P5A DMX4P5A DN andarine DMX4P5A TI TTKPW01 DMX4P5A TN Androgen receptor messenger RNA (AR mRNA) DMX4P5A MA Agonist DMX4P5A RN Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. J Med Chem. 2009 Jun 25;52(12):3597-617. DMX4P5A RU https://pubmed.ncbi.nlm.nih.gov/19432422 DMX4QKU DI DMX4QKU DMX4QKU DN N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE DMX4QKU TI TTANPDJ DMX4QKU TN Carbonic anhydrase II (CA-II) DMX4QKU MA Inhibitor DMX4QKU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMX4QKU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMX4QKU DI DMX4QKU DMX4QKU DN N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE DMX4QKU TI TTHQPL7 DMX4QKU TN Carbonic anhydrase I (CA-I) DMX4QKU MA Inhibitor DMX4QKU RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMX4QKU RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMX4RJ8 DI DMX4RJ8 DMX4RJ8 DN [3H]N-methyl-SSR504734 DMX4RJ8 TI TTHJTF7 DMX4RJ8 TN Glycine transporter GlyT-1 (SLC6A9) DMX4RJ8 MA Modulator DMX4RJ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 935). DMX4RJ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=935 DMX4U9L DI DMX4U9L DMX4U9L DN (E)-3-(4-hydroxybenzylidene)indolin-2-one DMX4U9L TI TT4DXQT DMX4U9L TN Proto-oncogene c-Ret (RET) DMX4U9L MA Inhibitor DMX4U9L RN Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. DMX4U9L RU https://pubmed.ncbi.nlm.nih.gov/20117004 DMX4VY9 DI DMX4VY9 DMX4VY9 DN isobutyric acid DMX4VY9 TI TT0FYAN DMX4VY9 TN Free fatty acid receptor 2 (FFAR2) DMX4VY9 MA Agonist DMX4VY9 RN Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J Biol Chem. 2003 Jul 11;278(28):25481-9. DMX4VY9 RU https://pubmed.ncbi.nlm.nih.gov/12711604 DMX4VY9 DI DMX4VY9 DMX4VY9 DN isobutyric acid DMX4VY9 TI TTXDOHN DMX4VY9 TN Free fatty acid receptor 3 (FFAR3) DMX4VY9 MA Agonist DMX4VY9 RN Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1045-50. DMX4VY9 RU https://pubmed.ncbi.nlm.nih.gov/14722361 DMX4WI7 DI DMX4WI7 DMX4WI7 DN BPH-652 DMX4WI7 TI TTFQEO5 DMX4WI7 TN Squalene synthetase (FDFT1) DMX4WI7 MA Inhibitor DMX4WI7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 645). DMX4WI7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=645 DMX4ZGL DI DMX4ZGL DMX4ZGL DN NMS-1 DMX4ZGL TI TTIYVQP DMX4ZGL TN Polo-like kinase 1 (PLK1) DMX4ZGL MA Inhibitor DMX4ZGL RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMX4ZGL RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMX53OY DI DMX53OY DMX53OY DN {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid DMX53OY TI TTTU72V DMX53OY TN Steroid 5-alpha-reductase 1 (SRD5A1) DMX53OY MA Inhibitor DMX53OY RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMX53OY RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMX53OY DI DMX53OY DMX53OY DN {4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid DMX53OY TI TTT02K8 DMX53OY TN Steroid 5-alpha-reductase 2 (SRD5A2) DMX53OY MA Inhibitor DMX53OY RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMX53OY RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMX58NK DI DMX58NK DMX58NK DN [1,4]Oxazepan-(3E)-ylideneamine DMX58NK TI TTF10I9 DMX58NK TN Nitric-oxide synthase inducible (NOS2) DMX58NK MA Inhibitor DMX58NK RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX58NK RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX58NK DI DMX58NK DMX58NK DN [1,4]Oxazepan-(3E)-ylideneamine DMX58NK TI TTZUFI5 DMX58NK TN Nitric-oxide synthase brain (NOS1) DMX58NK MA Inhibitor DMX58NK RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX58NK RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX58NK DI DMX58NK DMX58NK DN [1,4]Oxazepan-(3E)-ylideneamine DMX58NK TI TTCM4B3 DMX58NK TN Nitric-oxide synthase endothelial (NOS3) DMX58NK MA Inhibitor DMX58NK RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMX58NK RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMX59A0 DI DMX59A0 DMX59A0 DN GW-637185X DMX59A0 TI TTVKILB DMX59A0 TN Prostaglandin G/H synthase 2 (COX-2) DMX59A0 MA Inhibitor DMX59A0 RN Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhib... Bioorg Med Chem Lett. 2009 Aug 1;19(15):4504-8. DMX59A0 RU https://pubmed.ncbi.nlm.nih.gov/19520573 DMX5CY3 DI DMX5CY3 DMX5CY3 DN (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid DMX5CY3 TI TTTU72V DMX5CY3 TN Steroid 5-alpha-reductase 1 (SRD5A1) DMX5CY3 MA Inhibitor DMX5CY3 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMX5CY3 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMX5CY3 DI DMX5CY3 DMX5CY3 DN (3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid DMX5CY3 TI TTT02K8 DMX5CY3 TN Steroid 5-alpha-reductase 2 (SRD5A2) DMX5CY3 MA Inhibitor DMX5CY3 RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMX5CY3 RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMX5H3T DI DMX5H3T DMX5H3T DN LY-266111 DMX5H3T TI TTTU72V DMX5H3T TN Steroid 5-alpha-reductase 1 (SRD5A1) DMX5H3T MA Inhibitor DMX5H3T RN Simple bi- and tricyclic inhibitors of human steroid 5alpha-reductase. Bioorg Med Chem Lett. 2000 Sep 4;10(17):1909-11. DMX5H3T RU https://pubmed.ncbi.nlm.nih.gov/10987415 DMX5MAU DI DMX5MAU DMX5MAU DN Tetrabutylammonium Ion DMX5MAU TI TTYOMFZ DMX5MAU TN Voltage-gated potassium channel (VGKC) DMX5MAU MA Inhibitor DMX5MAU RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX5MAU RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX5N3V DI DMX5N3V DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V TI TTK8CXU DMX5N3V TN 5-HT 1B receptor (HTR1B) DMX5N3V MA Inhibitor DMX5N3V RN The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66. DMX5N3V RU https://pubmed.ncbi.nlm.nih.gov/17765553 DMX5N3V DI DMX5N3V DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V TI TTJS8PY DMX5N3V TN 5-HT 6 receptor (HTR6) DMX5N3V MA Inhibitor DMX5N3V RN The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66. DMX5N3V RU https://pubmed.ncbi.nlm.nih.gov/17765553 DMX5N3V DI DMX5N3V DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V TI TTSQIFT DMX5N3V TN 5-HT 1A receptor (HTR1A) DMX5N3V MA Inhibitor DMX5N3V RN The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66. DMX5N3V RU https://pubmed.ncbi.nlm.nih.gov/17765553 DMX5N3V DI DMX5N3V DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V TI TTJQOD7 DMX5N3V TN 5-HT 2A receptor (HTR2A) DMX5N3V MA Inhibitor DMX5N3V RN The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66. DMX5N3V RU https://pubmed.ncbi.nlm.nih.gov/17765553 DMX5N3V DI DMX5N3V DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V TI TT0K1SC DMX5N3V TN 5-HT 2B receptor (HTR2B) DMX5N3V MA Inhibitor DMX5N3V RN The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66. DMX5N3V RU https://pubmed.ncbi.nlm.nih.gov/17765553 DMX5N3V DI DMX5N3V DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V TI TTO9X1H DMX5N3V TN 5-HT 7 receptor (HTR7) DMX5N3V MA Inhibitor DMX5N3V RN The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66. DMX5N3V RU https://pubmed.ncbi.nlm.nih.gov/17765553 DMX5N3V DI DMX5N3V DMX5N3V DN 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine DMX5N3V TI TT6MSOK DMX5N3V TN 5-HT 1D receptor (HTR1D) DMX5N3V MA Inhibitor DMX5N3V RN The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66. DMX5N3V RU https://pubmed.ncbi.nlm.nih.gov/17765553 DMX5UKA DI DMX5UKA DMX5UKA DN PMID22115617C2c DMX5UKA TI TTR93NU DMX5UKA TN Casein kinase II alpha prime (CSNK2A2) DMX5UKA MA Inhibitor DMX5UKA RN CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50. DMX5UKA RU https://pubmed.ncbi.nlm.nih.gov/22115617 DMX5UKA DI DMX5UKA DMX5UKA DN PMID22115617C2c DMX5UKA TI TTER6YH DMX5UKA TN Casein kinase II alpha (CSNK2A1) DMX5UKA MA Inhibitor DMX5UKA RN CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50. DMX5UKA RU https://pubmed.ncbi.nlm.nih.gov/22115617 DMX5V9T DI DMX5V9T DMX5V9T DN 4-(3-(Dimethylamino)propanoyl)-N-hexylbenzamide DMX5V9T TI TTGER3L DMX5V9T TN Thyroid hormone receptor beta (THRB) DMX5V9T MA Inhibitor DMX5V9T RN Improvement of pharmacological properties of irreversible thyroid receptor coactivator binding inhibitors. J Med Chem. 2009 Jul 9;52(13):3892-901. DMX5V9T RU https://pubmed.ncbi.nlm.nih.gov/19469546 DMX64E3 DI DMX64E3 DMX64E3 DN 5-ethyl-2-(2-(pyrrolidin-1-yl)ethyl)pyridine DMX64E3 TI TT9JNIC DMX64E3 TN Histamine H3 receptor (H3R) DMX64E3 MA Inhibitor DMX64E3 RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMX64E3 RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMX681M DI DMX681M DMX681M DN 4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole DMX681M TI TTNX2CS DMX681M TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMX681M MA Inhibitor DMX681M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX681M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX681M DI DMX681M DMX681M DN 4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole DMX681M TI TTVTX4N DMX681M TN Bacterial Fatty acid synthetase I (Bact inhA) DMX681M MA Inhibitor DMX681M RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX681M RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX6F1L DI DMX6F1L DMX6F1L DN JWH-442 DMX6F1L TI TT6OEDT DMX6F1L TN Cannabinoid receptor 1 (CB1) DMX6F1L MA Inhibitor DMX6F1L RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DMX6F1L RU https://pubmed.ncbi.nlm.nih.gov/20621488 DMX6F1L DI DMX6F1L DMX6F1L DN JWH-442 DMX6F1L TI TTMSFAW DMX6F1L TN Cannabinoid receptor 2 (CB2) DMX6F1L MA Inhibitor DMX6F1L RN Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. Bioorg Med Chem. 2010 Aug 1;18(15):5475-82. DMX6F1L RU https://pubmed.ncbi.nlm.nih.gov/20621488 DMX6GH5 DI DMX6GH5 DMX6GH5 DN 2-Phosphoglyceric Acid DMX6GH5 TI TTHJWVK DMX6GH5 TN Mycobacterium Bisphosphoglycerate phosphoglycerate mutase (MycB gpmI) DMX6GH5 MA Inhibitor DMX6GH5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX6GH5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX6GH5 DI DMX6GH5 DMX6GH5 DN 2-Phosphoglyceric Acid DMX6GH5 TI TTVNA43 DMX6GH5 TN Bacterial Deoxy-D-manno-octulosonate 8-phosphate synthase (Bact kdsA) DMX6GH5 MA Inhibitor DMX6GH5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX6GH5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX6GH5 DI DMX6GH5 DMX6GH5 DN 2-Phosphoglyceric Acid DMX6GH5 TI TTNS6X4 DMX6GH5 TN Bacterial Triosephosphate isomerase (Bact TPI) DMX6GH5 MA Inhibitor DMX6GH5 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX6GH5 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX6KTO DI DMX6KTO DMX6KTO DN BAN-2203 DMX6KTO TI TTE4KHA DMX6KTO TN Amyloid beta A4 protein (APP) DMX6KTO MA Modulator DMX6KTO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402). DMX6KTO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2402 DMX6LV3 DI DMX6LV3 DMX6LV3 DN Recombinant Factor X DMX6LV3 TI TTCIHJA DMX6LV3 TN Coagulation factor Xa (F10) DMX6LV3 MA Modulator DMX6LV3 RN Semuloparin for the prevention of venous thromboembolic events in cancer patients. Drugs Today (Barc). 2012 Jul;48(7):451-7. DMX6LV3 RU https://pubmed.ncbi.nlm.nih.gov/22844656 DMX6PKO DI DMX6PKO DMX6PKO DN 1-(3,4-dichlorobenzyl)-1H-imidazole DMX6PKO TI TTRA5BZ DMX6PKO TN Steroid 17-alpha-monooxygenase (S17AH) DMX6PKO MA Inhibitor DMX6PKO RN Synthesis and biochemical evaluation of a range of potent benzyl imidazole-based compounds as potential inhibitors of the enzyme complex 17alpha-hy... Bioorg Med Chem Lett. 2006 Aug 1;16(15):4011-5. DMX6PKO RU https://pubmed.ncbi.nlm.nih.gov/16750362 DMX6PLV DI DMX6PLV DMX6PLV DN Sodium valproate DMX6PLV TI TTT2LD9 DMX6PLV TN GABA transaminase (ABAT) DMX6PLV MA Inhibitor DMX6PLV RN Influence of a GABA transaminase inhibitor on central nervous system oxygen toxicity. Aviat Space Environ Med. 1978 Jul;49(7):877-9. DMX6PLV RU https://pubmed.ncbi.nlm.nih.gov/352331 DMX6QMT DI DMX6QMT DMX6QMT DN 2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMX6QMT TI TTDCBX5 DMX6QMT TN Vascular endothelial growth factor receptor 3 (FLT-4) DMX6QMT MA Inhibitor DMX6QMT RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMX6QMT RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMX6QMT DI DMX6QMT DMX6QMT DN 2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMX6QMT TI TTUTJGQ DMX6QMT TN Vascular endothelial growth factor receptor 2 (KDR) DMX6QMT MA Inhibitor DMX6QMT RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMX6QMT RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMX6QMT DI DMX6QMT DMX6QMT DN 2-(5-Phenyl-oxazol-2-ylamino)-benzonitrile DMX6QMT TI TT1VAUK DMX6QMT TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMX6QMT MA Inhibitor DMX6QMT RN Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. DMX6QMT RU https://pubmed.ncbi.nlm.nih.gov/15743202 DMX6R0H DI DMX6R0H DMX6R0H DN 5-phenylamino-4-cyano-3-hydroxy-isothiazole DMX6R0H TI TTIDAPM DMX6R0H TN ERK activator kinase 1 (MEK1) DMX6R0H MA Inhibitor DMX6R0H RN Discovery of 3-hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles as potent MEK1 inhibitors. Bioorg Med Chem Lett. 2006 Aug 1;16(15):3975-80. DMX6R0H RU https://pubmed.ncbi.nlm.nih.gov/16725322 DMX6UYN DI DMX6UYN DMX6UYN DN (+)-BUTACLAMOL DMX6UYN TI TT4C8EA DMX6UYN TN Dopamine D3 receptor (D3R) DMX6UYN MA Inhibitor DMX6UYN RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMX6UYN RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMX6UYN DI DMX6UYN DMX6UYN DN (+)-BUTACLAMOL DMX6UYN TI TTEX248 DMX6UYN TN Dopamine D2 receptor (D2R) DMX6UYN MA Inhibitor DMX6UYN RN Synthesis and structure-activity relationships of 1-aralkyl-4-benzylpiperidine and 1-aralkyl-4-benzylpiperazine derivatives as potent sigma ligands. J Med Chem. 2005 Jan 13;48(1):266-73. DMX6UYN RU https://pubmed.ncbi.nlm.nih.gov/15634021 DMX6UYN DI DMX6UYN DMX6UYN DN (+)-BUTACLAMOL DMX6UYN TI TTZFYLI DMX6UYN TN Dopamine D1 receptor (D1R) DMX6UYN MA Inhibitor DMX6UYN RN 7-Methyl-6,7,8,9,14,15-hexahydro-5H-benz[d]indolo[2,3-g]azecine: a new heterocyclic system and a new lead compound for dopamine receptor antagonists. J Med Chem. 2000 May 18;43(10):2079-81. DMX6UYN RU https://pubmed.ncbi.nlm.nih.gov/10821720 DMX6UYN DI DMX6UYN DMX6UYN DN (+)-BUTACLAMOL DMX6UYN TI TTJFY5U DMX6UYN TN Adenosine A3 receptor (ADORA3) DMX6UYN MA Inhibitor DMX6UYN RN 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacolog... J Med Chem. 2005 Nov 3;48(22):6887-96. DMX6UYN RU https://pubmed.ncbi.nlm.nih.gov/16250647 DMX6ZHQ DI DMX6ZHQ DMX6ZHQ DN 3-(4-(o-toluidino)pyrimidin-2-ylamino)benzamide DMX6ZHQ TI TT860QF DMX6ZHQ TN LCK tyrosine protein kinase (LCK) DMX6ZHQ MA Inhibitor DMX6ZHQ RN N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4363-8. DMX6ZHQ RU https://pubmed.ncbi.nlm.nih.gov/17600705 DMX71K9 DI DMX71K9 DMX71K9 DN 1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione DMX71K9 TI TTEB0GD DMX71K9 TN Cholinesterase (BCHE) DMX71K9 MA Inhibitor DMX71K9 RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMX71K9 RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMX71K9 DI DMX71K9 DMX71K9 DN 1-(3,4-dichlorobenzyl)-1H-indole-2,3-dione DMX71K9 TI TTMF541 DMX71K9 TN Liver carboxylesterase (CES1) DMX71K9 MA Inhibitor DMX71K9 RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMX71K9 RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMX71N9 DI DMX71N9 DMX71N9 DN 3-Methylfentanyl DMX71N9 TI TT27RFC DMX71N9 TN Opioid receptor delta (OPRD1) DMX71N9 MA Agonist DMX71N9 RN Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91. DMX71N9 RU https://pubmed.ncbi.nlm.nih.gov/10669565 DMX71N9 DI DMX71N9 DMX71N9 DN 3-Methylfentanyl DMX71N9 TI TTQW87Y DMX71N9 TN Opioid receptor kappa (OPRK1) DMX71N9 MA Agonist DMX71N9 RN Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91. DMX71N9 RU https://pubmed.ncbi.nlm.nih.gov/10669565 DMX71N9 DI DMX71N9 DMX71N9 DN 3-Methylfentanyl DMX71N9 TI TTKWM86 DMX71N9 TN Opioid receptor mu (MOP) DMX71N9 MA Agonist DMX71N9 RN Subramanian G, Paterlini MG, Portoghese PS, Ferguson DM: Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor. J Med Chem. 2000 Feb 10;43(3):381-91. DMX71N9 RU https://pubmed.ncbi.nlm.nih.gov/10669565 DMX72T6 DI DMX72T6 DMX72T6 DN ISIS 25567 DMX72T6 TI TTP2U16 DMX72T6 TN RhoA messenger RNA (RHOA mRNA) DMX72T6 RN US patent application no. 5,945,290, Antisense modulation of RhoA expression. DMX72T6 RU http://www.patentbuddy.com/Patent/5945290?ft=true&sr=true DMX768L DI DMX768L DMX768L DN (+/-)-2-Amino-1,2,3,4-tetrahydro-2-naphthoic acid DMX768L TI TTPH2JB DMX768L TN Large neutral amino acids transporter 1 (SLC7A5) DMX768L MA Inhibitor DMX768L RN Regiospecific and conformationally restrained analogs of melphalan and DL-2-NAM-7 and their affinities for the large neutral amino acid transporter... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3688-91. DMX768L RU https://pubmed.ncbi.nlm.nih.gov/20466543 DMX7ECD DI DMX7ECD DMX7ECD DN (+)-S-14297 DMX7ECD TI TT4C8EA DMX7ECD TN Dopamine D3 receptor (D3R) DMX7ECD MA Antagonist DMX7ECD RN S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol. 1994 Aug 1;260(2-3):R3-5. DMX7ECD RU https://pubmed.ncbi.nlm.nih.gov/7988633 DMX7ECD DI DMX7ECD DMX7ECD DN (+)-S-14297 DMX7ECD TI TTEX248 DMX7ECD TN Dopamine D2 receptor (D2R) DMX7ECD MA Antagonist DMX7ECD RN Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther. 1995 Nov;275(2):885-98. DMX7ECD RU https://pubmed.ncbi.nlm.nih.gov/7473180 DMX7IVO DI DMX7IVO DMX7IVO DN C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO TI TT0MV2T DMX7IVO TN Melanocortin receptor 1 (MC1R) DMX7IVO MA Inhibitor DMX7IVO RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMX7IVO RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMX7IVO DI DMX7IVO DMX7IVO DN C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO TI TTD0CIQ DMX7IVO TN Melanocortin receptor 4 (MC4R) DMX7IVO MA Inhibitor DMX7IVO RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMX7IVO RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMX7IVO DI DMX7IVO DMX7IVO DN C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO TI TTNI91K DMX7IVO TN Melanocortin receptor 3 (MC3R) DMX7IVO MA Inhibitor DMX7IVO RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMX7IVO RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMX7IVO DI DMX7IVO DMX7IVO DN C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2 DMX7IVO TI TTEOSZT DMX7IVO TN Melanocortin receptor (MCR) DMX7IVO MA Inhibitor DMX7IVO RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMX7IVO RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMX7PJH DI DMX7PJH DMX7PJH DN 1-(4-HEXYLPHENYL)PROP-2-EN-1-ONE DMX7PJH TI TTGER3L DMX7PJH TN Thyroid hormone receptor beta (THRB) DMX7PJH MA Inhibitor DMX7PJH RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMX7PJH RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMX7WU9 DI DMX7WU9 DMX7WU9 DN PB-1120 DMX7WU9 TI TT4O5P0 DMX7WU9 TN Helodermin-preferring VIP receptor (VIPR2) DMX7WU9 MA Modulator DMX7WU9 RN Company report (PhaseBio) DMX7WU9 RU http://phasebio.com/clinical-development-pipeline/pb1046-pb1120/ DMX7ZI0 DI DMX7ZI0 DMX7ZI0 DN RU82129 DMX7ZI0 TI TT6PKBN DMX7ZI0 TN Proto-oncogene c-Src (SRC) DMX7ZI0 MA Inhibitor DMX7ZI0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX7ZI0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX80BL DI DMX80BL DMX80BL DN R214127 DMX80BL TI TTVBPDM DMX80BL TN Metabotropic glutamate receptor 1 (mGluR1) DMX80BL MA Modulator (allosteric modulator) DMX80BL RN [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93. DMX80BL RU https://pubmed.ncbi.nlm.nih.gov/12695537 DMX80JF DI DMX80JF DMX80JF DN N-Carboxymethionine DMX80JF TI TTU6BFZ DMX80JF TN Candida Thymidylate synthase (Candi TMP1) DMX80JF MA Inhibitor DMX80JF RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX80JF RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX835E DI DMX835E DMX835E DN ISIS 103375 DMX835E TI TTK0TF2 DMX835E TN DUSP8 messenger RNA (DUSP8 mRNA) DMX835E RN US patent application no. 6,482,644, Antisense modulation of dual specific phosphatase 8 expression. DMX835E RU http://www.patentbuddy.com/Patent/6482644?ft=true&sr=true DMX85E7 DI DMX85E7 DMX85E7 DN Ca(2+) chelator DMX85E7 TI TTBLN9S DMX85E7 TN Sulfur mustard-stimulated protease (SMSP) DMX85E7 MA Inhibitor DMX85E7 RN Sulfur mustard-stimulated protease: a target for antivesicant drugs. J Appl Toxicol. 2002 Mar-Apr;22(2):139-40. DMX85E7 RU https://pubmed.ncbi.nlm.nih.gov/11920939 DMX85IF DI DMX85IF DMX85IF DN 7-bromo-6H-chromeno[4,3-b]quinoline-3,9-diol DMX85IF TI TTPNQAC DMX85IF TN Estrogen-related receptor-alpha (ESRRA) DMX85IF MA Inhibitor DMX85IF RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMX85IF RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTSYM0R DMX8BS5 TN Carbonic anhydrase XII (CA-XII) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTHYBIX DMX8BS5 TN Heat shock protein 70 (HSP70) DMX8BS5 MA Inhibitor DMX8BS5 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTANPDJ DMX8BS5 TN Carbonic anhydrase II (CA-II) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTEYTKG DMX8BS5 TN Carbonic anhydrase XIV (CA-XIV) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTRSMW9 DMX8BS5 TN Glycogen synthase kinase-3 beta (GSK-3B) DMX8BS5 MA Inhibitor DMX8BS5 RN Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/16610779 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTHQZV7 DMX8BS5 TN Mothers against decapentaplegic homolog 3 (SMAD3) DMX8BS5 MA Inhibitor DMX8BS5 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTCFSPE DMX8BS5 TN Carbonic anhydrase VI (CA-VI) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTOU65C DMX8BS5 TN Tyrosine-protein kinase SYK (SYK) DMX8BS5 MA Inhibitor DMX8BS5 RN Identification of ellagic acid as potent inhibitor of protein kinase CK2: a successful example of a virtual screening application. J Med Chem. 2006 Apr 20;49(8):2363-6. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/16610779 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TT2LVK8 DMX8BS5 TN Carbonic anhydrase IX (CA-IX) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTHQPL7 DMX8BS5 TN Carbonic anhydrase I (CA-I) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTE14XG DMX8BS5 TN Squalene monooxygenase (SQLE) DMX8BS5 MA Inhibitor DMX8BS5 RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTUNARX DMX8BS5 TN Carbonic anhydrase (CA) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTZHA0O DMX8BS5 TN Carbonic anhydrase IV (CA-IV) DMX8BS5 MA Inhibitor DMX8BS5 RN Carbonic anhydrase inhibitors. Inhibition of mammalian isoforms I-XIV with a series of natural product polyphenols and phenolic acids. Bioorg Med Chem. 2010 Mar 15;18(6):2159-2164. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/20185318 DMX8BS5 DI DMX8BS5 DMX8BS5 DN ELLAGIC ACID DMX8BS5 TI TTER6YH DMX8BS5 TN Casein kinase II alpha (CSNK2A1) DMX8BS5 MA Inhibitor DMX8BS5 RN Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3. DMX8BS5 RU https://pubmed.ncbi.nlm.nih.gov/19414254 DMX8DC2 DI DMX8DC2 DMX8DC2 DN Homorisedronate DMX8DC2 TI TTIKWV4 DMX8DC2 TN Geranyltranstransferase (FDPS) DMX8DC2 MA Inhibitor DMX8DC2 RN Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem. 2001 Sep 7;276(36):33930-7. DMX8DC2 RU https://pubmed.ncbi.nlm.nih.gov/11435429 DMX8DZM DI DMX8DZM DMX8DZM DN 7-chloro-1H-indazole DMX8DZM TI TTZUFI5 DMX8DZM TN Nitric-oxide synthase brain (NOS1) DMX8DZM MA Inhibitor DMX8DZM RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DMX8DZM RU https://pubmed.ncbi.nlm.nih.gov/17395463 DMX8NYD DI DMX8NYD DMX8NYD DN 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole DMX8NYD TI TT3WG5C DMX8NYD TN Monoamine oxidase type A (MAO-A) DMX8NYD MA Inhibitor DMX8NYD RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMX8NYD RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMX8NYD DI DMX8NYD DMX8NYD DN 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indole DMX8NYD TI TTGP7BY DMX8NYD TN Monoamine oxidase type B (MAO-B) DMX8NYD MA Inhibitor DMX8NYD RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMX8NYD RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMX8QK0 DI DMX8QK0 DMX8QK0 DN Methoxy arachidonyl fluorophosphonate DMX8QK0 TI TTDP1UC DMX8QK0 TN Fatty acid amide hydrolase (FAAH) DMX8QK0 MA Inhibitor DMX8QK0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMX8QK0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMX8U32 DI DMX8U32 DMX8U32 DN 2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene DMX8U32 TI TTE4KHA DMX8U32 TN Amyloid beta A4 protein (APP) DMX8U32 MA Inhibitor DMX8U32 RN Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2. DMX8U32 RU https://pubmed.ncbi.nlm.nih.gov/16325402 DMX8W4G DI DMX8W4G DMX8W4G DN Benzyl derivative of M6G DMX8W4G TI TTKWM86 DMX8W4G TN Opioid receptor mu (MOP) DMX8W4G MA Inhibitor DMX8W4G RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMX8W4G RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMX8W4G DI DMX8W4G DMX8W4G DN Benzyl derivative of M6G DMX8W4G TI TTQW87Y DMX8W4G TN Opioid receptor kappa (OPRK1) DMX8W4G MA Inhibitor DMX8W4G RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMX8W4G RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMX8W4G DI DMX8W4G DMX8W4G DN Benzyl derivative of M6G DMX8W4G TI TT27RFC DMX8W4G TN Opioid receptor delta (OPRD1) DMX8W4G MA Inhibitor DMX8W4G RN Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6. DMX8W4G RU https://pubmed.ncbi.nlm.nih.gov/15745801 DMX8YCK DI DMX8YCK DMX8YCK DN 16-(4-dimethylamino-benzylidene)-estrone DMX8YCK TI TTIWB6L DMX8YCK TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMX8YCK MA Inhibitor DMX8YCK RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMX8YCK RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMX927V DI DMX927V DMX927V DN ISIS 3805 DMX927V TI TTHCEF6 DMX927V TN VCAM-1 messenger RNA (VCAM1 mRNA) DMX927V RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMX927V RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMX94EK DI DMX94EK DMX94EK DN 4,5-dichloro-1H-indole-2,3-dione DMX94EK TI TTMF541 DMX94EK TN Liver carboxylesterase (CES1) DMX94EK MA Inhibitor DMX94EK RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMX94EK RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMX9EA7 DI DMX9EA7 DMX9EA7 DN KMI-538 DMX9EA7 TI TT8JRS7 DMX9EA7 TN Beta-secretase (BACE) DMX9EA7 MA Inhibitor DMX9EA7 RN Design and synthesis of BACE1 inhibitors containing a novel norstatine derivative (2R,3R)-3-amino-2-hydroxy-4-(phenylthio)butyric acid. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1629-33. DMX9EA7 RU https://pubmed.ncbi.nlm.nih.gov/17251016 DMX9ED1 DI DMX9ED1 DMX9ED1 DN VU591 DMX9ED1 TI TTJ13ST DMX9ED1 TN Inward rectifier potassium channel Kir1.1 (KCNJ1) DMX9ED1 MA Blocker (channel blocker) DMX9ED1 RN Development of a selective small-molecule inhibitor of Kir1.1, the renal outer medullary potassium channel. Mol Pharmacol. 2011 Jan;79(1):42-50. DMX9ED1 RU https://pubmed.ncbi.nlm.nih.gov/20926757 DMX9FOB DI DMX9FOB DMX9FOB DN DC6S DMX9FOB TI TTKWM86 DMX9FOB TN Opioid receptor mu (MOP) DMX9FOB MA Inhibitor DMX9FOB RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMX9FOB RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMX9U7S DI DMX9U7S DMX9U7S DN N,N-dimethyl-4,4-diphenylbutan-1-amine DMX9U7S TI TTTIBOJ DMX9U7S TN Histamine H1 receptor (H1R) DMX9U7S MA Inhibitor DMX9U7S RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMX9U7S RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMX9U7S DI DMX9U7S DMX9U7S DN N,N-dimethyl-4,4-diphenylbutan-1-amine DMX9U7S TI TTJQOD7 DMX9U7S TN 5-HT 2A receptor (HTR2A) DMX9U7S MA Inhibitor DMX9U7S RN Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity. Bioorg Med Chem. 2009 Sep 15;17(18):6496-504. DMX9U7S RU https://pubmed.ncbi.nlm.nih.gov/19700330 DMX9W0T DI DMX9W0T DMX9W0T DN RS 116 0086 DMX9W0T TI TT07C3Y DMX9W0T TN 5-HT 4 receptor (HTR4) DMX9W0T MA Antagonist DMX9W0T RN A 5-HT4 receptor transmembrane network implicated in the activity of inverse agonists but not agonists. J Biol Chem. 2002 Jul 12;277(28):25502-11. DMX9W0T RU https://pubmed.ncbi.nlm.nih.gov/11976337 DMXA0JB DI DMXA0JB DMXA0JB DN C[RGDf-(R)-alpha-TfmF] DMXA0JB TI TTT1R2L DMXA0JB TN Integrin alpha-V (ITGAV) DMXA0JB MA Inhibitor DMXA0JB RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMXA0JB RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMXA0JB DI DMXA0JB DMXA0JB DN C[RGDf-(R)-alpha-TfmF] DMXA0JB TI TTJA1ZO DMXA0JB TN ITGB3 messenger RNA (ITGB3 mRNA) DMXA0JB MA Inhibitor DMXA0JB RN Incorporation of the unusual C(alpha)-fluoroalkylamino acids into cyclopeptides: synthesis of arginine-glycine-aspartate (RGD) analogues and study ... J Med Chem. 2006 Mar 9;49(5):1808-17. DMXA0JB RU https://pubmed.ncbi.nlm.nih.gov/16509596 DMXA1LK DI DMXA1LK DMXA1LK DN 2-[(2-methoxy-5-methylphenoxy)methyl]pyridine DMXA1LK TI TTQO71U DMXA1LK TN Hemoglobin (HB) DMXA1LK MA Inhibitor DMXA1LK RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXA1LK RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXA20E DI DMXA20E DMXA20E DN 2-(1H-imidazo[4,5-c]pyridin-2-yl)quinoxaline DMXA20E TI TTJFY5U DMXA20E TN Adenosine A3 receptor (ADORA3) DMXA20E MA Inhibitor DMXA20E RN 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database search... J Med Chem. 2005 Dec 29;48(26):8253-60. DMXA20E RU https://pubmed.ncbi.nlm.nih.gov/16366607 DMXA4HY DI DMXA4HY DMXA4HY DN Poly IC-poly arginine DMXA4HY TI TTD24Y0 DMXA4HY TN Toll-like receptor 3 (TLR3) DMXA4HY RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1753). DMXA4HY RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1753 DMXA5M9 DI DMXA5M9 DMXA5M9 DN GW848687X DMXA5M9 TI TTG1QMU DMXA5M9 TN Prostaglandin E2 receptor EP1 (PTGER1) DMXA5M9 MA Antagonist DMXA5M9 RN The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and s... Bioorg Med Chem Lett. 2007 Jan 15;17(2):385-9. DMXA5M9 RU https://pubmed.ncbi.nlm.nih.gov/17084082 DMXA6LU DI DMXA6LU DMXA6LU DN SC-52892 DMXA6LU TI TTQVOEI DMXA6LU TN Angiotensin II receptor type-2 (AGTR2) DMXA6LU MA Inhibitor DMXA6LU RN N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists, Bioorg. Med. Chem. Lett. 3(6):1055-1060 (1993). DMXA6LU RU http://www.sciencedirect.com/science/article/pii/S0960894X00802863 DMXA8K1 DI DMXA8K1 DMXA8K1 DN CM-352 DMXA8K1 TI TTXLEG7 DMXA8K1 TN Matrix metalloproteinase-10 (MMP-10) DMXA8K1 MA Inhibitor DMXA8K1 RN Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem. 2015 Apr 9;58(7):2941-57. DMXA8K1 RU https://pubmed.ncbi.nlm.nih.gov/25686022 DMXA8K1 DI DMXA8K1 DMXA8K1 DN CM-352 DMXA8K1 TI TTUZ2L5 DMXA8K1 TN Matrix metalloproteinase-3 (MMP-3) DMXA8K1 MA Inhibitor DMXA8K1 RN Discovery and safety profiling of a potent preclinical candidate, (4-[4-[[(3R)-3-(hydroxycarbamoyl)-8-azaspiro[4.5]decan-3-yl]sulfonyl]phenoxy]-N-methylbenzamide) (CM-352), for the prevention and treatment of hemorrhage. J Med Chem. 2015 Apr 9;58(7):2941-57. DMXA8K1 RU https://pubmed.ncbi.nlm.nih.gov/25686022 DMXA9MR DI DMXA9MR DMXA9MR DN N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide DMXA9MR TI TTBH0VX DMXA9MR TN Histone deacetylase (HDAC) DMXA9MR MA Inhibitor DMXA9MR RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMXA9MR RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMXA9MR DI DMXA9MR DMXA9MR DN N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide DMXA9MR TI TT6R7JZ DMXA9MR TN Histone deacetylase 1 (HDAC1) DMXA9MR MA Inhibitor DMXA9MR RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMXA9MR RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMXACM2 DI DMXACM2 DMXACM2 DN Anti-RON receptor mabs DMXACM2 TI TTBQ3OC DMXACM2 TN Macrophage-stimulating protein receptor (RON) DMXACM2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1816). DMXACM2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1816 DMXAD0R DI DMXAD0R DMXAD0R DN 3-(3-methylphenylethynyl)-5-methyl[1,2,4]triazine DMXAD0R TI TTHS256 DMXAD0R TN Metabotropic glutamate receptor 5 (mGluR5) DMXAD0R MA Inhibitor DMXAD0R RN Synthesis and pharmacological evaluation of phenylethynyl[1,2,4]methyltriazines as analogues of 3-methyl-6-(phenylethynyl)pyridine. J Med Chem. 2007 Jul 12;50(14):3388-91. DMXAD0R RU https://pubmed.ncbi.nlm.nih.gov/17569516 DMXAD8E DI DMXAD8E DMXAD8E DN Isoxazol DMXAD8E TI TT3PQ2Y DMXAD8E TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMXAD8E MA Inhibitor DMXAD8E RN Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76. DMXAD8E RU https://pubmed.ncbi.nlm.nih.gov/10658902 DMXAEGF DI DMXAEGF DMXAEGF DN 4-iodobenzo[b]thiophene 2-carboxamidine DMXAEGF TI TT6L509 DMXAEGF TN Coagulation factor IIa (F2) DMXAEGF MA Inhibitor DMXAEGF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXAEGF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXAEGF DI DMXAEGF DMXAEGF DN 4-iodobenzo[b]thiophene 2-carboxamidine DMXAEGF TI TTGY7WI DMXAEGF TN Urokinase-type plasminogen activator (PLAU) DMXAEGF MA Inhibitor DMXAEGF RN Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator. Chem Biol. 2000 Apr;7(4):299-312. DMXAEGF RU https://pubmed.ncbi.nlm.nih.gov/10779411 DMXAEGF DI DMXAEGF DMXAEGF DN 4-iodobenzo[b]thiophene 2-carboxamidine DMXAEGF TI TTFEZ5Q DMXAEGF TN Coagulation factor IX (F9) DMXAEGF MA Inhibitor DMXAEGF RN Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis. J Med Chem. 2010 Feb 25;53(4):1465-72. DMXAEGF RU https://pubmed.ncbi.nlm.nih.gov/20121198 DMXAEW9 DI DMXAEW9 DMXAEW9 DN 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole DMXAEW9 TI TTEX248 DMXAEW9 TN Dopamine D2 receptor (D2R) DMXAEW9 MA Inhibitor DMXAEW9 RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMXAEW9 RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMXAEW9 DI DMXAEW9 DMXAEW9 DN 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole DMXAEW9 TI TTE0A2F DMXAEW9 TN Dopamine D4 receptor (D4R) DMXAEW9 MA Inhibitor DMXAEW9 RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMXAEW9 RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMXAEW9 DI DMXAEW9 DMXAEW9 DN 4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole DMXAEW9 TI TT4C8EA DMXAEW9 TN Dopamine D3 receptor (D3R) DMXAEW9 MA Inhibitor DMXAEW9 RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMXAEW9 RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMXAF7Y DI DMXAF7Y DMXAF7Y DN 5-(2-(pyrrolidin-1-yl)ethyl)isothiazole DMXAF7Y TI TT9JNIC DMXAF7Y TN Histamine H3 receptor (H3R) DMXAF7Y MA Inhibitor DMXAF7Y RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMXAF7Y RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMXAK75 DI DMXAK75 DMXAK75 DN KAR-1880 DMXAK75 TI TTSHTOI DMXAK75 TN Histone deacetylase 2 (HDAC2) DMXAK75 MA Inhibitor DMXAK75 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2616). DMXAK75 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2616 DMXAK92 DI DMXAK92 DMXAK92 DN RU78299 DMXAK92 TI TT6PKBN DMXAK92 TN Proto-oncogene c-Src (SRC) DMXAK92 MA Inhibitor DMXAK92 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXAK92 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXANES DI DMXANES DMXANES DN N-Phenylbenzo[d]oxazol-2-amine DMXANES TI TT2J34L DMXANES TN Arachidonate 5-lipoxygenase (5-LOX) DMXANES MA Inhibitor DMXANES RN Synthesis and evaluation of benzoxazole derivatives as 5-lipoxygenase inhibitors. Bioorg Med Chem. 2010 Nov 1;18(21):7580-5. DMXANES RU https://pubmed.ncbi.nlm.nih.gov/20870413 DMXAQZ0 DI DMXAQZ0 DMXAQZ0 DN 2-(4-bromo-2-tert-butylphenoxy)acetic acid DMXAQZ0 TI TTQDMX5 DMXAQZ0 TN Prostaglandin D2 receptor 2 (PTGDR2) DMXAQZ0 MA Inhibitor DMXAQZ0 RN Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. J Med Chem. 2006 Nov 16;49(23):6638-41. DMXAQZ0 RU https://pubmed.ncbi.nlm.nih.gov/17154491 DMXAS25 DI DMXAS25 DMXAS25 DN 2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide DMXAS25 TI TTUF2HO DMXAS25 TN NAD-dependent deacetylase sirtuin-1 (SIRT1) DMXAS25 MA Inhibitor DMXAS25 RN Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem. 2005 Dec 15;48(25):8045-54. DMXAS25 RU https://pubmed.ncbi.nlm.nih.gov/16335928 DMXAVHT DI DMXAVHT DMXAVHT DN 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol DMXAVHT TI TTOM3J0 DMXAVHT TN Estrogen receptor beta (ESR2) DMXAVHT MA Inhibitor DMXAVHT RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMXAVHT RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMXAVHT DI DMXAVHT DMXAVHT DN 2-(6-Hydroxy-naphthalen-1-yl)-benzooxazol-5-ol DMXAVHT TI TTZAYWL DMXAVHT TN Estrogen receptor (ESR) DMXAVHT MA Inhibitor DMXAVHT RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMXAVHT RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMXB7G5 DI DMXB7G5 DMXB7G5 DN L-054852 DMXB7G5 TI TTZ6T9E DMXB7G5 TN Somatostatin receptor type 2 (SSTR2) DMXB7G5 MA Agonist DMXB7G5 RN Treatment strategies for acromegaly. Expert Opin Emerg Drugs. 2005 Nov;10(4):875-90. DMXB7G5 RU https://pubmed.ncbi.nlm.nih.gov/16262568 DMXBEYQ DI DMXBEYQ DMXBEYQ DN 4-[3-(4-Ethynyl-phenoxy)-propyl]-1H-imidazole DMXBEYQ TI TT9JNIC DMXBEYQ TN Histamine H3 receptor (H3R) DMXBEYQ MA Inhibitor DMXBEYQ RN Analogues and derivatives of ciproxifan, a novel prototype for generating potent histamine H3-receptor antagonists. Bioorg Med Chem Lett. 2000 Oct 16;10(20):2379-82. DMXBEYQ RU https://pubmed.ncbi.nlm.nih.gov/11055360 DMXBGSL DI DMXBGSL DMXBGSL DN EUSYNSTYELAMIDE B DMXBGSL TI TTZUFI5 DMXBGSL TN Nitric-oxide synthase brain (NOS1) DMXBGSL MA Inhibitor DMXBGSL RN Eusynstyelamides A, B, and C, nNOS inhibitors, from the ascidian Eusynstyela latericius. J Nat Prod. 2009 Jun;72(6):1115-20. DMXBGSL RU https://pubmed.ncbi.nlm.nih.gov/19505081 DMXBHE4 DI DMXBHE4 DMXBHE4 DN MCL-428 DMXBHE4 TI TTKWM86 DMXBHE4 TN Opioid receptor mu (MOP) DMXBHE4 MA Inhibitor DMXBHE4 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMXBHE4 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMXBHE4 DI DMXBHE4 DMXBHE4 DN MCL-428 DMXBHE4 TI TT27RFC DMXBHE4 TN Opioid receptor delta (OPRD1) DMXBHE4 MA Inhibitor DMXBHE4 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMXBHE4 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMXBHE4 DI DMXBHE4 DMXBHE4 DN MCL-428 DMXBHE4 TI TTQW87Y DMXBHE4 TN Opioid receptor kappa (OPRK1) DMXBHE4 MA Inhibitor DMXBHE4 RN High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. DMXBHE4 RU https://pubmed.ncbi.nlm.nih.gov/17276685 DMXBITO DI DMXBITO DMXBITO DN KSP-BCS-1-alpha-CHF2-1624F2-2 DMXBITO TI TTK59TV DMXBITO TN Vitamin D3 receptor (VDR) DMXBITO MA Inhibitor DMXBITO RN Low-calcemic, highly antiproliferative, 1-difluoromethyl hybrid analogs of the natural hormone 1alpha,25-dihydroxyvitamin D3: design, synthesis, an... J Med Chem. 2006 Dec 14;49(25):7513-7. DMXBITO RU https://pubmed.ncbi.nlm.nih.gov/17149880 DMXBQRJ DI DMXBQRJ DMXBQRJ DN Glu-Leu-Asp-Leu-(CHOH-CH2)-Ala-Ala-Glu-Phe DMXBQRJ TI TT8JRS7 DMXBQRJ TN Beta-secretase (BACE) DMXBQRJ MA Inhibitor DMXBQRJ RN Efficient evaluation of binding free energy using continuum electrostatics solvation. J Med Chem. 2004 Nov 4;47(23):5791-7. DMXBQRJ RU https://pubmed.ncbi.nlm.nih.gov/15509178 DMXBRCI DI DMXBRCI DMXBRCI DN NSC-180246 DMXBRCI TI TT4FDG6 DMXBRCI TN Voltage-gated calcium channel alpha Cav2.2 (CACNA1B) DMXBRCI MA Inhibitor DMXBRCI RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMXBRCI RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMXBRCI DI DMXBRCI DMXBRCI DN NSC-180246 DMXBRCI TI TTL53M6 DMXBRCI TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMXBRCI MA Inhibitor DMXBRCI RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMXBRCI RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMXBUNV DI DMXBUNV DMXBUNV DN 7-hydroxy-2-(3-hydroxyphenyl)chroman-4-one DMXBUNV TI TTSZLWK DMXBUNV TN Aromatase (CYP19A1) DMXBUNV MA Inhibitor DMXBUNV RN New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80. DMXBUNV RU https://pubmed.ncbi.nlm.nih.gov/18042388 DMXC20R DI DMXC20R DMXC20R DN 2-(4-propylphenylsulfonyl)naphthalene-1,4-diol DMXC20R TI TTRVTMX DMXC20R TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMXC20R MA Inhibitor DMXC20R RN Synthesis and biological evaluation of novel sulfonyl-naphthalene-1,4-diols as FabH inhibitors. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6402-5. DMXC20R RU https://pubmed.ncbi.nlm.nih.gov/18996691 DMXC30P DI DMXC30P DMXC30P DN MS417 DMXC30P TI TTRA6BO DMXC30P TN Bromodomain-containing protein 4 (BRD4) DMXC30P MA Inhibitor DMXC30P RN Down-regulation of NF- B transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012 Aug 17;287(34):28840-51. DMXC30P RU https://pubmed.ncbi.nlm.nih.gov/22645123 DMXC319 DI DMXC319 DMXC319 DN J591-Ac-225 DMXC319 TI TT9G4N0 DMXC319 TN Glutamate carboxypeptidase II (GCPII) DMXC319 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1606). DMXC319 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1606 DMXC5S0 DI DMXC5S0 DMXC5S0 DN 4-(2'-(trifluoromethyl)biphenyl-3-yl)oxazole DMXC5S0 TI TT4G2JS DMXC5S0 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMXC5S0 MA Inhibitor DMXC5S0 RN Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5536-40. DMXC5S0 RU https://pubmed.ncbi.nlm.nih.gov/20709552 DMXC98D DI DMXC98D DMXC98D DN Trans-(R(S))-2-Hydroxy-1-phenylethyl nitrate DMXC98D TI TTEP6RV DMXC98D TN Glutathione reductase (GR) DMXC98D MA Inhibitor DMXC98D RN In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3661-3. DMXC98D RU https://pubmed.ncbi.nlm.nih.gov/19447620 DMXCAKO DI DMXCAKO DMXCAKO DN 2-methoxy-9-aminomethyl-9,10-dihydroanthracene DMXCAKO TI TTJQOD7 DMXCAKO TN 5-HT 2A receptor (HTR2A) DMXCAKO MA Inhibitor DMXCAKO RN Methoxy-substituted 9-aminomethyl-9,10-dihydroanthracene (AMDA) derivatives exhibit differential binding affinities at the 5-HT(2A) receptor. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5268-71. DMXCAKO RU https://pubmed.ncbi.nlm.nih.gov/18774714 DMXCF9T DI DMXCF9T DMXCF9T DN Ac-YR[CEH(pF-dF)RWC]-NH2 DMXCF9T TI TTEOSZT DMXCF9T TN Melanocortin receptor (MCR) DMXCF9T MA Inhibitor DMXCF9T RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMXCF9T RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMXCF9T DI DMXCF9T DMXCF9T DN Ac-YR[CEH(pF-dF)RWC]-NH2 DMXCF9T TI TTNI91K DMXCF9T TN Melanocortin receptor 3 (MC3R) DMXCF9T MA Inhibitor DMXCF9T RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMXCF9T RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMXCF9T DI DMXCF9T DMXCF9T DN Ac-YR[CEH(pF-dF)RWC]-NH2 DMXCF9T TI TTD0CIQ DMXCF9T TN Melanocortin receptor 4 (MC4R) DMXCF9T MA Inhibitor DMXCF9T RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMXCF9T RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMXCF9T DI DMXCF9T DMXCF9T DN Ac-YR[CEH(pF-dF)RWC]-NH2 DMXCF9T TI TT0MV2T DMXCF9T TN Melanocortin receptor 1 (MC1R) DMXCF9T MA Inhibitor DMXCF9T RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMXCF9T RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMXCID6 DI DMXCID6 DMXCID6 DN 2-(1-tosyl-1H-indol-3-yl)ethanamine DMXCID6 TI TTJS8PY DMXCID6 TN 5-HT 6 receptor (HTR6) DMXCID6 MA Inhibitor DMXCID6 RN Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. J Med Chem. 2007 Nov 15;50(23):5535-8. DMXCID6 RU https://pubmed.ncbi.nlm.nih.gov/17948978 DMXCJ7O DI DMXCJ7O DMXCJ7O DN Prostacyclin analog DMXCJ7O TI TTOFYT1 DMXCJ7O TN Prostacyclin receptor (PTGIR) DMXCJ7O MA Modulator DMXCJ7O RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 345). DMXCJ7O RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=345 DMXCSVH DI DMXCSVH DMXCSVH DN Oleic acid anilide DMXCSVH TI TTMF541 DMXCSVH TN Liver carboxylesterase (CES1) DMXCSVH MA Inhibitor DMXCSVH RN Phenolic compounds from the roots of Lindera fruticosa. J Nat Prod. 2006 May;69(5):853-5. DMXCSVH RU https://pubmed.ncbi.nlm.nih.gov/16724860 DMXCSVH DI DMXCSVH DMXCSVH DN Oleic acid anilide DMXCSVH TI TTAK0IN DMXCSVH TN SOAT2 messenger RNA (SOAT2 mRNA) DMXCSVH MA Inhibitor DMXCSVH RN Anti-atherosclerotic and anti-inflammatory activities of catecholic xanthones and flavonoids isolated from Cudrania tricuspidata. Bioorg Med Chem Lett. 2006 Nov 1;16(21):5580-3. DMXCSVH RU https://pubmed.ncbi.nlm.nih.gov/16919944 DMXCUDV DI DMXCUDV DMXCUDV DN C[-Arg-Gly-Asp-Acpca21-] DMXCUDV TI TTJA1ZO DMXCUDV TN ITGB3 messenger RNA (ITGB3 mRNA) DMXCUDV MA Inhibitor DMXCUDV RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMXCUDV RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMXCUDV DI DMXCUDV DMXCUDV DN C[-Arg-Gly-Asp-Acpca21-] DMXCUDV TI TTT1R2L DMXCUDV TN Integrin alpha-V (ITGAV) DMXCUDV MA Inhibitor DMXCUDV RN Grafting aminocyclopentane carboxylic acids onto the RGD tripeptide sequence generates low nanomolar alphaVbeta3/alphaVbeta5 integrin dual binders. J Med Chem. 2005 Dec 1;48(24):7675-87. DMXCUDV RU https://pubmed.ncbi.nlm.nih.gov/16302808 DMXCZAK DI DMXCZAK DMXCZAK DN 3'',5''-dimethoxy-[1,1':3',1'']-terphenyl-4-ol DMXCZAK TI TTS7G69 DMXCZAK TN Fusion protein Bcr-Abl (Bcr-Abl) DMXCZAK MA Inhibitor DMXCZAK RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMXCZAK RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMXD0C3 DI DMXD0C3 DMXD0C3 DN ADS-102891 DMXD0C3 TI TTX4RTB DMXD0C3 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMXD0C3 MA Inhibitor DMXD0C3 RN Quinazoline and benzimidazole MCH-1R antagonists. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1403-7. DMXD0C3 RU https://pubmed.ncbi.nlm.nih.gov/17178222 DMXD1IN DI DMXD1IN DMXD1IN DN CX-5011 DMXD1IN TI TTER6YH DMXD1IN TN Casein kinase II alpha (CSNK2A1) DMXD1IN MA Inhibitor DMXD1IN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1549). DMXD1IN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1549 DMXD3T7 DI DMXD3T7 DMXD3T7 DN VU0010010 DMXD3T7 TI TTOXS3C DMXD3T7 TN Muscarinic acetylcholine receptor (CHRM) DMXD3T7 MA Modulator (allosteric modulator) DMXD3T7 RN Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci. 2009 Mar;30(3):148-55. DMXD3T7 RU https://pubmed.ncbi.nlm.nih.gov/19201489 DMXD592 DI DMXD592 DMXD592 DN N-(1H-Indol-2-ylmethyl)-N-phenylamine DMXD592 TI TTGP7BY DMXD592 TN Monoamine oxidase type B (MAO-B) DMXD592 MA Inhibitor DMXD592 RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMXD592 RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMXD592 DI DMXD592 DMXD592 DN N-(1H-Indol-2-ylmethyl)-N-phenylamine DMXD592 TI TT3WG5C DMXD592 TN Monoamine oxidase type A (MAO-A) DMXD592 MA Inhibitor DMXD592 RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMXD592 RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMXD60K DI DMXD60K DMXD60K DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Cys14]SRIF DMXD60K TI TTIND6G DMXD60K TN Somatostatin receptor type 1 (SSTR1) DMXD60K MA Inhibitor DMXD60K RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMXD60K RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMXD697 DI DMXD697 DMXD697 DN (1-Amino-3-phenyl-propyl)-phosphinic acid DMXD697 TI TTPHMWB DMXD697 TN Aminopeptidase N (ANPEP) DMXD697 MA Inhibitor DMXD697 RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMXD697 RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMXD8H1 DI DMXD8H1 DMXD8H1 DN (1-Amino-2-phenyl-ethyl)-phosphinic acid DMXD8H1 TI TTPHMWB DMXD8H1 TN Aminopeptidase N (ANPEP) DMXD8H1 MA Inhibitor DMXD8H1 RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMXD8H1 RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMXDG13 DI DMXDG13 DMXDG13 DN CP-810123 DMXDG13 TI TTLA931 DMXDG13 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMXDG13 MA Inhibitor DMXDG13 RN Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor ag... J Med Chem. 2010 Feb 11;53(3):1222-37. DMXDG13 RU https://pubmed.ncbi.nlm.nih.gov/20043678 DMXDG13 DI DMXDG13 DMXDG13 DN CP-810123 DMXDG13 TI TTPC4TU DMXDG13 TN 5-HT 3A receptor (HTR3A) DMXDG13 MA Inhibitor DMXDG13 RN Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor ag... J Med Chem. 2010 Feb 11;53(3):1222-37. DMXDG13 RU https://pubmed.ncbi.nlm.nih.gov/20043678 DMXDGEF DI DMXDGEF DMXDGEF DN 2-(2-allyl-4-chlorophenoxy)acetic acid DMXDGEF TI TTQDMX5 DMXDGEF TN Prostaglandin D2 receptor 2 (PTGDR2) DMXDGEF MA Inhibitor DMXDGEF RN 2-Cycloalkyl phenoxyacetic acid CRTh2 receptor antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4347-50. DMXDGEF RU https://pubmed.ncbi.nlm.nih.gov/17531480 DMXDNQ6 DI DMXDNQ6 DMXDNQ6 DN NSC-660838 DMXDNQ6 TI TTJLP0R DMXDNQ6 TN Quinone reductase 2 (NQO2) DMXDNQ6 MA Inhibitor DMXDNQ6 RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMXDNQ6 RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMXDQ25 DI DMXDQ25 DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid DMXDQ25 TI TTT6LFV DMXDQ25 TN Histone deacetylase 8 (HDAC8) DMXDQ25 MA Inhibitor DMXDQ25 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMXDQ25 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMXDQ25 DI DMXDQ25 DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid DMXDQ25 TI TTBH0VX DMXDQ25 TN Histone deacetylase (HDAC) DMXDQ25 MA Inhibitor DMXDQ25 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMXDQ25 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMXDQ25 DI DMXDQ25 DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid DMXDQ25 TI TTTQGH8 DMXDQ25 TN Histone deacetylase 4 (HDAC4) DMXDQ25 MA Inhibitor DMXDQ25 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMXDQ25 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMXDQ25 DI DMXDQ25 DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid DMXDQ25 TI TT5ZKDI DMXDQ25 TN Histone deacetylase 6 (HDAC6) DMXDQ25 MA Inhibitor DMXDQ25 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMXDQ25 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMXDQ25 DI DMXDQ25 DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid DMXDQ25 TI TT6R7JZ DMXDQ25 TN Histone deacetylase 1 (HDAC1) DMXDQ25 MA Inhibitor DMXDQ25 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMXDQ25 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMXDQ25 DI DMXDQ25 DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid DMXDQ25 TI TTYHPU6 DMXDQ25 TN Histone deacetylase 10 (HDAC10) DMXDQ25 MA Inhibitor DMXDQ25 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMXDQ25 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMXDQ25 DI DMXDQ25 DMXDQ25 DN 8-Oxo-8-phenyl-octanoic acid DMXDQ25 TI TTSHTOI DMXDQ25 TN Histone deacetylase 2 (HDAC2) DMXDQ25 MA Inhibitor DMXDQ25 RN Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J Med Chem. 2002 Feb 14;45(4):753-7. DMXDQ25 RU https://pubmed.ncbi.nlm.nih.gov/11831887 DMXDTPL DI DMXDTPL DMXDTPL DN PMID22902653C30 DMXDTPL TI TTRMD8U DMXDTPL TN Testis-specific kinase 2 (TESK2) DMXDTPL MA Inhibitor DMXDTPL RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMXDTPL RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMXDTPL DI DMXDTPL DMXDTPL DN PMID22902653C30 DMXDTPL TI TTWL9TY DMXDTPL TN LIM domain kinase-1 (LIMK-1) DMXDTPL MA Inhibitor DMXDTPL RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMXDTPL RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMXDTPL DI DMXDTPL DMXDTPL DN PMID22902653C30 DMXDTPL TI TTASMD8 DMXDTPL TN LIM domain kinase-2 (LIMK-2) DMXDTPL MA Inhibitor DMXDTPL RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMXDTPL RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMXDTPL DI DMXDTPL DMXDTPL DN PMID22902653C30 DMXDTPL TI TTWKT3Y DMXDTPL TN Testis-specific kinase 1 (TESK1) DMXDTPL MA Inhibitor DMXDTPL RN Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg Med Chem Lett. 2012 Sep 15;22(18):5995-8. DMXDTPL RU https://pubmed.ncbi.nlm.nih.gov/22902653 DMXDUCP DI DMXDUCP DMXDUCP DN AMN082 DMXDUCP TI TT0I76D DMXDUCP TN Metabotropic glutamate receptor 7 (mGluR7) DMXDUCP MA Modulator (allosteric modulator) DMXDUCP RN A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18712-7. DMXDUCP RU https://pubmed.ncbi.nlm.nih.gov/16339898 DMXDWO7 DI DMXDWO7 DMXDWO7 DN PSB-10 DMXDWO7 TI TTJFY5U DMXDWO7 TN Adenosine A3 receptor (ADORA3) DMXDWO7 MA Antagonist DMXDWO7 RN Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3440-50. DMXDWO7 RU https://pubmed.ncbi.nlm.nih.gov/12139454 DMXDWO7 DI DMXDWO7 DMXDWO7 DN PSB-10 DMXDWO7 TI TTK25J1 DMXDWO7 TN Adenosine A1 receptor (ADORA1) DMXDWO7 MA Antagonist DMXDWO7 RN 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. Bioorg Med Chem. 2003 Feb 6;11(3):347-56. DMXDWO7 RU https://pubmed.ncbi.nlm.nih.gov/12517430 DMXDWO7 DI DMXDWO7 DMXDWO7 DN PSB-10 DMXDWO7 TI TTNE7KG DMXDWO7 TN Adenosine A2b receptor (ADORA2B) DMXDWO7 MA Antagonist DMXDWO7 RN Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3440-50. DMXDWO7 RU https://pubmed.ncbi.nlm.nih.gov/12139454 DMXE1LC DI DMXE1LC DMXE1LC DN 3-[2-(3,5-Dimethoxy-phenyl)-vinyl]-furan DMXE1LC TI TTI84H7 DMXE1LC TN Cytochrome P450 1B1 (CYP1B1) DMXE1LC MA Inhibitor DMXE1LC RN Design, synthesis, and discovery of novel trans-stilbene analogues as potent and selective human cytochrome P450 1B1 inhibitors. J Med Chem. 2002 Jan 3;45(1):160-4. DMXE1LC RU https://pubmed.ncbi.nlm.nih.gov/11754588 DMXE8CB DI DMXE8CB DMXE8CB DN N1-guanyl-1,7-diaminoheptane DMXE8CB TI TTBO2A9 DMXE8CB TN Deoxyhypusine synthase (DHPS) DMXE8CB MA Inhibitor DMXE8CB RN Effects of N1-guanyl-1,7-diaminoheptane, an inhibitor of deoxyhypusine synthase, on the growth of tumorigenic cell lines in culture. Biochim Biophys Acta. 1996 Jan 10;1310(1):119-26. DMXE8CB RU https://pubmed.ncbi.nlm.nih.gov/9244184 DMXECFJ DI DMXECFJ DMXECFJ DN Bbs-Arg-(D-Pip)-Gly-S-(GS)11-Gly-Hir DMXECFJ TI TT6L509 DMXECFJ TN Coagulation factor IIa (F2) DMXECFJ MA Inhibitor DMXECFJ RN Transforming bivalent ligands into retractable enzyme inhibitors through polypeptide-protein interactions. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5120-3. DMXECFJ RU https://pubmed.ncbi.nlm.nih.gov/16202582 DMXELBI DI DMXELBI DMXELBI DN Sodium phenylarsonate DMXELBI TI TTZHA0O DMXELBI TN Carbonic anhydrase IV (CA-IV) DMXELBI MA Inhibitor DMXELBI RN Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions. Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8. DMXELBI RU https://pubmed.ncbi.nlm.nih.gov/19128966 DMXERWD DI DMXERWD DMXERWD DN Selenazole-4-Carboxyamide-Adenine Dinucleotide DMXERWD TI TTTB4UP DMXERWD TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMXERWD MA Inhibitor DMXERWD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXERWD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXEUDM DI DMXEUDM DMXEUDM DN 2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide DMXEUDM TI TTANPDJ DMXEUDM TN Carbonic anhydrase II (CA-II) DMXEUDM MA Inhibitor DMXEUDM RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXEUDM RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXEUDM DI DMXEUDM DMXEUDM DN 2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide DMXEUDM TI TTHQPL7 DMXEUDM TN Carbonic anhydrase I (CA-I) DMXEUDM MA Inhibitor DMXEUDM RN Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6. DMXEUDM RU https://pubmed.ncbi.nlm.nih.gov/18348513 DMXEUDM DI DMXEUDM DMXEUDM DN 2-Mercapto-N-(4-sulfamoyl-phenyl)-benzamide DMXEUDM TI TT2LVK8 DMXEUDM TN Carbonic anhydrase IX (CA-IX) DMXEUDM MA Inhibitor DMXEUDM RN Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem. 2008 Jun 12;51(11):3051-6. DMXEUDM RU https://pubmed.ncbi.nlm.nih.gov/18348513 DMXEVA2 DI DMXEVA2 DMXEVA2 DN DP-3005 DMXEVA2 TI TTZPWGN DMXEVA2 TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMXEVA2 MA Blocker DMXEVA2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 536). DMXEVA2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=536 DMXF32O DI DMXF32O DMXF32O DN PMID21823616C22 DMXF32O TI TT7ALZG DMXF32O TN Integrin-linked protein kinase 1 (ILK) DMXF32O MA Inhibitor DMXF32O RN Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem. 2011 Sep 22;54(18):6364-74. DMXF32O RU https://pubmed.ncbi.nlm.nih.gov/21823616 DMXF46V DI DMXF46V DMXF46V DN N-(3-phenoxy-4-pyridinyl)ethanesulfonamide DMXF46V TI TTVKILB DMXF46V TN Prostaglandin G/H synthase 2 (COX-2) DMXF46V MA Inhibitor DMXF46V RN Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59. DMXF46V RU https://pubmed.ncbi.nlm.nih.gov/15615524 DMXF46V DI DMXF46V DMXF46V DN N-(3-phenoxy-4-pyridinyl)ethanesulfonamide DMXF46V TI TT8NGED DMXF46V TN Prostaglandin G/H synthase 1 (COX-1) DMXF46V MA Inhibitor DMXF46V RN Design, synthesis, and pharmacological evaluation of pyridinic analogues of nimesulide as cyclooxygenase-2 selective inhibitors. J Med Chem. 2004 Dec 30;47(27):6749-59. DMXF46V RU https://pubmed.ncbi.nlm.nih.gov/15615524 DMXF73G DI DMXF73G DMXF73G DN MCL-446 DMXF73G TI TTKWM86 DMXF73G TN Opioid receptor mu (MOP) DMXF73G MA Inhibitor DMXF73G RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMXF73G RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMXF73G DI DMXF73G DMXF73G DN MCL-446 DMXF73G TI TT27RFC DMXF73G TN Opioid receptor delta (OPRD1) DMXF73G MA Inhibitor DMXF73G RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMXF73G RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMXF73G DI DMXF73G DMXF73G DN MCL-446 DMXF73G TI TTQW87Y DMXF73G TN Opioid receptor kappa (OPRK1) DMXF73G MA Inhibitor DMXF73G RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMXF73G RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMXF8M0 DI DMXF8M0 DMXF8M0 DN 3-butyl-1-(naphthalen-1-yl)piperidin-4-amine DMXF8M0 TI TTDIGC1 DMXF8M0 TN Dipeptidyl peptidase 4 (DPP-4) DMXF8M0 MA Inhibitor DMXF8M0 RN 1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2966-70. DMXF8M0 RU https://pubmed.ncbi.nlm.nih.gov/17418568 DMXFBER DI DMXFBER DMXFBER DN KRH-102053 DMXFBER TI TT9ISBX DMXFBER TN HIF-prolyl hydroxylase 2 (HPH-2) DMXFBER MA Activator DMXFBER RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2833). DMXFBER RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2833 DMXFD3S DI DMXFD3S DMXFD3S DN LUF-5737 DMXFD3S TI TTK25J1 DMXFD3S TN Adenosine A1 receptor (ADORA1) DMXFD3S MA Inhibitor DMXFD3S RN 2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem. 2004 Dec 16;47(26):6529-40. DMXFD3S RU https://pubmed.ncbi.nlm.nih.gov/15588088 DMXFLMK DI DMXFLMK DMXFLMK DN 4-(3-cyclohexylureido)butanoic acid DMXFLMK TI TT7WVHI DMXFLMK TN Soluble epoxide hydrolase (EPHX2) DMXFLMK MA Inhibitor DMXFLMK RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXFLMK RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXFN6H DI DMXFN6H DMXFN6H DN BROUSSONIN A DMXFN6H TI TTOM3J0 DMXFN6H TN Estrogen receptor beta (ESR2) DMXFN6H MA Inhibitor DMXFN6H RN New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. DMXFN6H RU https://pubmed.ncbi.nlm.nih.gov/20493686 DMXFN6H DI DMXFN6H DMXFN6H DN BROUSSONIN A DMXFN6H TI TTZAYWL DMXFN6H TN Estrogen receptor (ESR) DMXFN6H MA Inhibitor DMXFN6H RN New estrogenic compounds isolated from Broussonetia kazinoki. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3764-7. DMXFN6H RU https://pubmed.ncbi.nlm.nih.gov/20493686 DMXFRW9 DI DMXFRW9 DMXFRW9 DN 6-(2-aminophenoxy)benzo[d]isothiazol-3-amine DMXFRW9 TI TTISGCA DMXFRW9 TN Toll-like receptor 4 (TLR4) DMXFRW9 MA Inhibitor DMXFRW9 RN Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6. DMXFRW9 RU https://pubmed.ncbi.nlm.nih.gov/18828583 DMXFVD1 DI DMXFVD1 DMXFVD1 DN 3-demethoxy-3-D-xylopyranosylaminothiocolchicine DMXFVD1 TI TT1MPAY DMXFVD1 TN GABA(A) receptor alpha-1 (GABRA1) DMXFVD1 MA Inhibitor DMXFVD1 RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMXFVD1 RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMXFVD1 DI DMXFVD1 DMXFVD1 DN 3-demethoxy-3-D-xylopyranosylaminothiocolchicine DMXFVD1 TI TTF45NW DMXFVD1 TN Strychnine-binding glycine receptor (GLRA1) DMXFVD1 MA Inhibitor DMXFVD1 RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMXFVD1 RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMXFVD1 DI DMXFVD1 DMXFVD1 DN 3-demethoxy-3-D-xylopyranosylaminothiocolchicine DMXFVD1 TI TT06RH5 DMXFVD1 TN GABA(A) receptor gamma-2 (GABRG2) DMXFVD1 MA Inhibitor DMXFVD1 RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMXFVD1 RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMXFVD1 DI DMXFVD1 DMXFVD1 DN 3-demethoxy-3-D-xylopyranosylaminothiocolchicine DMXFVD1 TI TTNJYV2 DMXFVD1 TN Gamma-aminobutyric acid receptor (GAR) DMXFVD1 MA Inhibitor DMXFVD1 RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMXFVD1 RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMXFVD1 DI DMXFVD1 DMXFVD1 DN 3-demethoxy-3-D-xylopyranosylaminothiocolchicine DMXFVD1 TI TTZ8EM9 DMXFVD1 TN Glycine receptor (GlyR) DMXFVD1 MA Inhibitor DMXFVD1 RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMXFVD1 RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMXFVD1 DI DMXFVD1 DMXFVD1 DN 3-demethoxy-3-D-xylopyranosylaminothiocolchicine DMXFVD1 TI TTZA1NY DMXFVD1 TN GABA(A) receptor beta-2 (GABRB2) DMXFVD1 MA Inhibitor DMXFVD1 RN 3-demethoxy-3-glycosylaminothiocolchicines: Synthesis of a new class of putative muscle relaxant compounds. J Med Chem. 2006 Sep 7;49(18):5571-7. DMXFVD1 RU https://pubmed.ncbi.nlm.nih.gov/16942030 DMXFY4P DI DMXFY4P DMXFY4P DN PMID12614873C2b-1 DMXFY4P TI TT8KLPT DMXFY4P TN C-C chemokine receptor (CCR) DMXFY4P MA Antagonist DMXFY4P RN Structure-activity relationships of xanthene carboxamides, novel CCR1 receptor antagonists. Bioorg Med Chem. 2003 Mar 20;11(6):875-84. DMXFY4P RU https://pubmed.ncbi.nlm.nih.gov/12614873 DMXFYN8 DI DMXFYN8 DMXFYN8 DN 2-(2-methoxyphenyl)-1H-indene DMXFYN8 TI TT8NGED DMXFYN8 TN Prostaglandin G/H synthase 1 (COX-1) DMXFYN8 MA Inhibitor DMXFYN8 RN 'Bridged' stilbene derivatives as selective cyclooxygenase-1 inhibitors. Bioorg Med Chem. 2007 Sep 15;15(18):6109-18. DMXFYN8 RU https://pubmed.ncbi.nlm.nih.gov/17604631 DMXG029 DI DMXG029 DMXG029 DN 2-Adamantan-2-ylidenemethyl-benzooxazol-6-ol DMXG029 TI TTHM0R1 DMXG029 TN Steryl-sulfatase (STS) DMXG029 MA Inhibitor DMXG029 RN Estrone formate: a novel type of irreversible inhibitor of human steroid sulfatase. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4999-5002. DMXG029 RU https://pubmed.ncbi.nlm.nih.gov/15341968 DMXG10E DI DMXG10E DMXG10E DN 1-(2-Phenyl-propyl)-3-thiazol-2-yl-thiourea DMXG10E TI TT84ETX DMXG10E TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMXG10E MA Inhibitor DMXG10E RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMXG10E RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMXGA12 DI DMXGA12 DMXGA12 DN OGX-427 + Paclitaxel DMXGA12 TI TT9AZWY DMXGA12 TN HSPB1 messenger RNA (HSPB1 mRNA) DMXGA12 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMXGA12 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMXGA56 DI DMXGA56 DMXGA56 DN Org-30850 DMXGA56 TI TT8R70G DMXGA56 TN Gonadotropin-releasing hormone receptor (GNRHR) DMXGA56 MA Modulator DMXGA56 RN In vivo effects of a potent GnRH antagonist ORG 30850: physiologic evidence that down-regulation of GnRH receptors does not occur. J Soc Gynecol Investig. 1994 Oct-Dec;1(4):290-6. DMXGA56 RU https://www.ncbi.nlm.nih.gov/pubmed/9419786 DMXGB38 DI DMXGB38 DMXGB38 DN 1-(4-chlorooxazol-2-yl)-7-phenylheptan-1-one DMXGB38 TI TTDP1UC DMXGB38 TN Fatty acid amide hydrolase (FAAH) DMXGB38 MA Inhibitor DMXGB38 RN Exploration of a fundamental substituent effect of alpha-ketoheterocycle enzyme inhibitors: Potent and selective inhibitors of fatty acid amide hyd... Bioorg Med Chem Lett. 2008 Nov 15;18(22):5842-6. DMXGB38 RU https://pubmed.ncbi.nlm.nih.gov/18639454 DMXGCYZ DI DMXGCYZ DMXGCYZ DN (R)-2-(2-naphthamido)-3-p-tolylpropanoic acid DMXGCYZ TI TTJNTSI DMXGCYZ TN Rotamase Pin1 (PIN1) DMXGCYZ MA Inhibitor DMXGCYZ RN Structure-based design of novel human Pin1 inhibitors (II). Bioorg Med Chem Lett. 2010 Apr 1;20(7):2210-4. DMXGCYZ RU https://pubmed.ncbi.nlm.nih.gov/20207139 DMXGP2I DI DMXGP2I DMXGP2I DN 2-methoxy-4-(propylthio)benzonitrile DMXGP2I TI TTKPW01 DMXGP2I TN Androgen receptor messenger RNA (AR mRNA) DMXGP2I MA Inhibitor DMXGP2I RN 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1310-3. DMXGP2I RU https://pubmed.ncbi.nlm.nih.gov/19201190 DMXGRMB DI DMXGRMB DMXGRMB DN 5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole DMXGRMB TI TT6MSOK DMXGRMB TN 5-HT 1D receptor (HTR1D) DMXGRMB MA Inhibitor DMXGRMB RN 5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9. DMXGRMB RU https://pubmed.ncbi.nlm.nih.gov/10937729 DMXGRMB DI DMXGRMB DMXGRMB DN 5-Isopropyl-3-(2-pyrrolidin-1-yl-ethyl)-1H-indole DMXGRMB TI TTK8CXU DMXGRMB TN 5-HT 1B receptor (HTR1B) DMXGRMB MA Inhibitor DMXGRMB RN 5-Alkyltryptamine derivatives as highly selective and potent 5-HT1D receptor agonists. Bioorg Med Chem Lett. 2000 Aug 7;10(15):1707-9. DMXGRMB RU https://pubmed.ncbi.nlm.nih.gov/10937729 DMXGV63 DI DMXGV63 DMXGV63 DN Dichloroallyl lawsone DMXGV63 TI TT3PQ2Y DMXGV63 TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMXGV63 MA Inhibitor DMXGV63 RN Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J Biol Chem. 2002 Nov 1;277(44):41827-34. DMXGV63 RU https://pubmed.ncbi.nlm.nih.gov/12189151 DMXGWOT DI DMXGWOT DMXGWOT DN 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine DMXGWOT TI TTM2AOE DMXGWOT TN Adenosine A2a receptor (ADORA2A) DMXGWOT MA Inhibitor DMXGWOT RN Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. J Med Chem. 2008 Feb 14;51(3):400-6. DMXGWOT RU https://pubmed.ncbi.nlm.nih.gov/18189346 DMXGWOT DI DMXGWOT DMXGWOT DN 2-(2-furyl)-6-(1H-pyrazol-1-yl)pyrimidin-4-amine DMXGWOT TI TTK25J1 DMXGWOT TN Adenosine A1 receptor (ADORA1) DMXGWOT MA Inhibitor DMXGWOT RN Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy. J Med Chem. 2008 Feb 14;51(3):400-6. DMXGWOT RU https://pubmed.ncbi.nlm.nih.gov/18189346 DMXGY4F DI DMXGY4F DMXGY4F DN N-methyl ryanodine-succinamidate DMXGY4F TI TTU5CIX DMXGY4F TN Ryanodine receptor 1 (RYR1) DMXGY4F MA Inhibitor DMXGY4F RN Amino- and guanidinoacylryanodines: basic ryanodine esters with enhanced affinity for the sarcoplasmic reticulum Ca(2+)-release channel. J Med Chem. 1993 May 14;36(10):1319-23. DMXGY4F RU https://pubmed.ncbi.nlm.nih.gov/8388466 DMXH0FO DI DMXH0FO DMXH0FO DN 2-(4-Dipropylamino-cyclohexylidene)-malononitrile DMXH0FO TI TTEX248 DMXH0FO TN Dopamine D2 receptor (D2R) DMXH0FO MA Inhibitor DMXH0FO RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMXH0FO RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMXH0FO DI DMXH0FO DMXH0FO DN 2-(4-Dipropylamino-cyclohexylidene)-malononitrile DMXH0FO TI TT4C8EA DMXH0FO TN Dopamine D3 receptor (D3R) DMXH0FO MA Inhibitor DMXH0FO RN Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62. DMXH0FO RU https://pubmed.ncbi.nlm.nih.gov/10691700 DMXH2D8 DI DMXH2D8 DMXH2D8 DN F-G-G-F-T-G-MeA-R-K-S-A-R-K-L-A-N-Q-COOH DMXH2D8 TI TTNT7K8 DMXH2D8 TN Nociceptin receptor (OPRL1) DMXH2D8 MA Inhibitor DMXH2D8 RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMXH2D8 RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMXH2R3 DI DMXH2R3 DMXH2R3 DN CGP 77675 DMXH2R3 TI TT6PKBN DMXH2R3 TN Proto-oncogene c-Src (SRC) DMXH2R3 MA Inhibitor DMXH2R3 RN A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo. Bone. 1999 May;24(5):437-49. DMXH2R3 RU https://pubmed.ncbi.nlm.nih.gov/10321903 DMXH6DL DI DMXH6DL DMXH6DL DN XN-0502 DMXH6DL TI TTYFKSZ DMXH6DL TN Tubulin beta (TUBB) DMXH6DL MA Modulator DMXH6DL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMXH6DL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMXH9IT DI DMXH9IT DMXH9IT DN ISIS 102619 DMXH9IT TI TT5U49F DMXH9IT TN PRKACA messenger RNA (PRKACA mRNA) DMXH9IT RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMXH9IT RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMXHIFZ DI DMXHIFZ DMXHIFZ DN CR-4892 DMXHIFZ TI TT90XZ8 DMXHIFZ TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMXHIFZ MA Blocker DMXHIFZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 585). DMXHIFZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=585 DMXHIK5 DI DMXHIK5 DMXHIK5 DN 4-(5-Morpholin-4-yl-pentyl)-2H-phthalazin-1-one DMXHIK5 TI TTVDSZ0 DMXHIK5 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMXHIK5 MA Inhibitor DMXHIK5 RN 4-Phenyl-1,2,3,6-tetrahydropyridine, an excellent fragment to improve the potency of PARP-1 inhibitors. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4221-5. DMXHIK5 RU https://pubmed.ncbi.nlm.nih.gov/16098744 DMXHKE3 DI DMXHKE3 DMXHKE3 DN F-12458 DMXHKE3 TI TT7WZIJ DMXHKE3 TN CAAX farnesyltransferase beta (FNTB) DMXHKE3 MA Inhibitor DMXHKE3 RN Recent progress in protein farnesyltransferase inhibition. IDrugs. 2000 Nov;3(11):1336-45. DMXHKE3 RU https://pubmed.ncbi.nlm.nih.gov/16047255 DMXHO6J DI DMXHO6J DMXHO6J DN Uridine-Diphosphate-N-Acetylgalactosamine DMXHO6J TI TTP8UCK DMXHO6J TN Bacterial Glycosyltransferase MurG (Bact murG) DMXHO6J MA Inhibitor DMXHO6J RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXHO6J RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXHO6J DI DMXHO6J DMXHO6J DN Uridine-Diphosphate-N-Acetylgalactosamine DMXHO6J TI TTGRHIB DMXHO6J TN UDP-glucose 4-epimerase (GALE) DMXHO6J MA Inhibitor DMXHO6J RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXHO6J RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXHPV0 DI DMXHPV0 DMXHPV0 DN NSC-660841 DMXHPV0 TI TTJLP0R DMXHPV0 TN Quinone reductase 2 (NQO2) DMXHPV0 MA Inhibitor DMXHPV0 RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMXHPV0 RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMXHQIN DI DMXHQIN DMXHQIN DN ATPgammaS DMXHQIN TI TT1FE3L DMXHQIN TN P2Y purinoceptor 13 (P2RY13) DMXHQIN MA Agonist DMXHQIN RN Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol. 2003 Jul;64(1):104-12. DMXHQIN RU https://pubmed.ncbi.nlm.nih.gov/12815166 DMXHQIN DI DMXHQIN DMXHQIN DN ATPgammaS DMXHQIN TI TTA93TL DMXHQIN TN P2Y purinoceptor 1 (P2RY1) DMXHQIN MA Agonist DMXHQIN RN An examination of deoxyadenosine 5'(alpha-thio)triphosphate as a ligand to define P2Y receptors and its selectivity as a low potency partial agonist of the P2Y1 receptor. Br J Pharmacol. 1997 May;121(2):338-44. DMXHQIN RU https://pubmed.ncbi.nlm.nih.gov/9154346 DMXHQIN DI DMXHQIN DMXHQIN DN ATPgammaS DMXHQIN TI TTYXPCO DMXHQIN TN P2Y purinoceptor 11 (P2RY11) DMXHQIN MA Agonist DMXHQIN RN Pharmacological characterization of the human P2Y11 receptor. Br J Pharmacol. 1999 Nov;128(6):1199-206. DMXHQIN RU https://pubmed.ncbi.nlm.nih.gov/10578132 DMXHQSG DI DMXHQSG DMXHQSG DN ISIS 112580 DMXHQSG TI TT6804T DMXHQSG TN MIF messenger RNA (MIF mRNA) DMXHQSG RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DMXHQSG RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DMXHS4L DI DMXHS4L DMXHS4L DN PMID17280833C30 DMXHS4L TI TT860QF DMXHS4L TN LCK tyrosine protein kinase (LCK) DMXHS4L MA Inhibitor DMXHS4L RN Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and prelimin... Bioorg Med Chem Lett. 2007 Apr 15;17(8):2305-9. DMXHS4L RU https://pubmed.ncbi.nlm.nih.gov/17280833 DMXHS4L DI DMXHS4L DMXHS4L DN PMID17280833C30 DMXHS4L TI TTIET93 DMXHS4L TN Activated CDC42 kinase 1 (ACK-1) DMXHS4L MA Inhibitor DMXHS4L RN Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and prelimin... Bioorg Med Chem Lett. 2007 Apr 15;17(8):2305-9. DMXHS4L RU https://pubmed.ncbi.nlm.nih.gov/17280833 DMXHWAY DI DMXHWAY DMXHWAY DN TDI-0060 DMXHWAY TI TT6RVLG DMXHWAY TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMXHWAY MA Modulator DMXHWAY RN Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82. DMXHWAY RU https://pubmed.ncbi.nlm.nih.gov/16914587 DMXI4V8 DI DMXI4V8 DMXI4V8 DN N-(Propylamide-acetophenone)-1-deoxynojirimycin DMXI4V8 TI TT1B5PU DMXI4V8 TN Glucosylceramidase (GBA) DMXI4V8 MA Inhibitor DMXI4V8 RN Nanomolar affinity, iminosugar-based chemical probes for specific labeling of lysosomal glucocerebrosidase. Bioorg Med Chem. 2010 Jan 1;18(1):267-73. DMXI4V8 RU https://pubmed.ncbi.nlm.nih.gov/19931460 DMXI8FP DI DMXI8FP DMXI8FP DN Cysteinesulfonic Acid DMXI8FP TI TTR0SWN DMXI8FP TN M-phase inducer phosphatase 2 (MPIP2) DMXI8FP MA Inhibitor DMXI8FP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXI8FP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXI8FP DI DMXI8FP DMXI8FP DN Cysteinesulfonic Acid DMXI8FP TI TTELIN2 DMXI8FP TN PTPN1 messenger RNA (PTPN1 mRNA) DMXI8FP MA Inhibitor DMXI8FP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXI8FP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXI8FP DI DMXI8FP DMXI8FP DN Cysteinesulfonic Acid DMXI8FP TI TT36ETB DMXI8FP TN Cathepsin L (CTSL) DMXI8FP MA Inhibitor DMXI8FP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXI8FP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXI8FP DI DMXI8FP DMXI8FP DN Cysteinesulfonic Acid DMXI8FP TI TTICO5G DMXI8FP TN Staphylococcus Peptide deformylase (Stap-coc def) DMXI8FP MA Inhibitor DMXI8FP RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXI8FP RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXIDS9 DI DMXIDS9 DMXIDS9 DN ACTINOPLANIC ACID A DMXIDS9 TI TT7WZIJ DMXIDS9 TN CAAX farnesyltransferase beta (FNTB) DMXIDS9 MA Inhibitor DMXIDS9 RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DMXIDS9 RU https://pubmed.ncbi.nlm.nih.gov/9301658 DMXIDS9 DI DMXIDS9 DMXIDS9 DN ACTINOPLANIC ACID A DMXIDS9 TI TTXQKM3 DMXIDS9 TN Farnesyl protein transferase (Ftase) DMXIDS9 MA Inhibitor DMXIDS9 RN Ras farnesyltransferase: a new therapeutic target. J Med Chem. 1997 Sep 12;40(19):2971-90. DMXIDS9 RU https://pubmed.ncbi.nlm.nih.gov/9301658 DMXIEA1 DI DMXIEA1 DMXIEA1 DN [11C]WAY100635 DMXIEA1 TI TTSQIFT DMXIEA1 TN 5-HT 1A receptor (HTR1A) DMXIEA1 MA Antagonist DMXIEA1 RN [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain. 2005 Apr;128(Pt 4):896-905. DMXIEA1 RU https://pubmed.ncbi.nlm.nih.gov/15689356 DMXIGWC DI DMXIGWC DMXIGWC DN 4-(2-fluoro-6-phenoxyphenyl)piperidine DMXIGWC TI TTAWNKZ DMXIGWC TN Norepinephrine transporter (NET) DMXIGWC MA Inhibitor DMXIGWC RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMXIGWC RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMXIGWC DI DMXIGWC DMXIGWC DN 4-(2-fluoro-6-phenoxyphenyl)piperidine DMXIGWC TI TTSQIFT DMXIGWC TN 5-HT 1A receptor (HTR1A) DMXIGWC MA Inhibitor DMXIGWC RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMXIGWC RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMXIGWC DI DMXIGWC DMXIGWC DN 4-(2-fluoro-6-phenoxyphenyl)piperidine DMXIGWC TI TT3ROYC DMXIGWC TN Serotonin transporter (SERT) DMXIGWC MA Inhibitor DMXIGWC RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMXIGWC RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMXIGWC DI DMXIGWC DMXIGWC DN 4-(2-fluoro-6-phenoxyphenyl)piperidine DMXIGWC TI TTVBI8W DMXIGWC TN Dopamine transporter (DAT) DMXIGWC MA Inhibitor DMXIGWC RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMXIGWC RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMXIO84 DI DMXIO84 DMXIO84 DN [18F]SPA-RQ DMXIO84 TI TTZPO1L DMXIO84 TN Substance-P receptor (TACR1) DMXIO84 MA Antagonist DMXIO84 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360). DMXIO84 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=360 DMXIU6W DI DMXIU6W DMXIU6W DN Quercetin 3-O-neohesperidoside DMXIU6W TI TTFBNVI DMXIU6W TN Aldose reductase (AKR1B1) DMXIU6W MA Inhibitor DMXIU6W RN New flavonol oligoglycosides and polyacylated sucroses with inhibitory effects on aldose reductase and platelet aggregation from the flowers of Pru... J Nat Prod. 2002 Aug;65(8):1151-5. DMXIU6W RU https://pubmed.ncbi.nlm.nih.gov/12193020 DMXIUO5 DI DMXIUO5 DMXIUO5 DN KT6006 DMXIUO5 TI TTGTQHC DMXIUO5 TN DNA topoisomerase I (TOP1) DMXIUO5 MA Inducer DMXIUO5 RN Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry. 1992 Dec 8;31(48):12069-75. DMXIUO5 RU https://pubmed.ncbi.nlm.nih.gov/1333791 DMXJ2SM DI DMXJ2SM DMXJ2SM DN OM00-3 DMXJ2SM TI TT8JRS7 DMXJ2SM TN Beta-secretase (BACE) DMXJ2SM MA Inhibitor DMXJ2SM RN Synthesis and biological evaluation of phosphino dipeptide isostere inhibitor of human beta-secretase (BACE1). Bioorg Med Chem. 2007 Jun 15;15(12):4136-43. DMXJ2SM RU https://pubmed.ncbi.nlm.nih.gov/17433698 DMXJ4SO DI DMXJ4SO DMXJ4SO DN ISIS 6445 DMXJ4SO TI TTONI0R DMXJ4SO TN PKC-eta messenger RNA (PRKCH mRNA) DMXJ4SO RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMXJ4SO RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMXJ58Z DI DMXJ58Z DMXJ58Z DN 1-(1-(4-bromophenyl)ethylidene)thiosemicarbazide DMXJ58Z TI TTULVH8 DMXJ58Z TN Tyrosinase (TYR) DMXJ58Z MA Inhibitor DMXJ58Z RN 1-(1-Arylethylidene)thiosemicarbazide derivatives: a new class of tyrosinase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1096-102. DMXJ58Z RU https://pubmed.ncbi.nlm.nih.gov/18326070 DMXJAOI DI DMXJAOI DMXJAOI DN C[Nle-Asp-D-Phe-Arg-Trp-Glu]-NH2 DMXJAOI TI TTD0CIQ DMXJAOI TN Melanocortin receptor 4 (MC4R) DMXJAOI MA Inhibitor DMXJAOI RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMXJAOI RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMXJASC DI DMXJASC DMXJASC DN ML375 DMXJASC TI TTOXS3C DMXJASC TN Muscarinic acetylcholine receptor (CHRM) DMXJASC MA Modulator (allosteric modulator) DMXJASC RN Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375). J Med Chem. 2013 Nov 27;56(22):9351-5. DMXJASC RU https://pubmed.ncbi.nlm.nih.gov/24164599 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TT8FYO9 DMXJB4N TN Platelet-derived growth factor receptor alpha (PDGFRA) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTWTSCV DMXJB4N TN RAC-alpha serine/threonine-protein kinase (AKT1) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTUTJGQ DMXJB4N TN Vascular endothelial growth factor receptor 2 (KDR) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TT860QF DMXJB4N TN LCK tyrosine protein kinase (LCK) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTNDSF4 DMXJB4N TN Proto-oncogene c-Met (MET) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTXV4FI DMXJB4N TN Albendazole monooxygenase (CYP3A4) DMXJB4N MA Inhibitor DMXJB4N RN Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/18763755 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTCEJ4F DMXJB4N TN G1/S-specific cyclin-E1 (CCNE1) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTON5IT DMXJB4N TN Focal adhesion kinase 1 (FAK) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTI7421 DMXJB4N TN Platelet-derived growth factor receptor beta (PDGFRB) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTHRID2 DMXJB4N TN Insulin-like growth factor I receptor (IGF1R) DMXJB4N MA Inhibitor DMXJB4N RN SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1744-8. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/20153189 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TT4TQBX DMXJB4N TN Extracellular signal-regulated kinase 2 (ERK2) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TT7HF4W DMXJB4N TN Cyclin-dependent kinase 2 (CDK2) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJB4N DI DMXJB4N DMXJB4N DN BMS-536924 DMXJB4N TI TTR5TV4 DMXJB4N TN ERBB2 messenger RNA (HER2 mRNA) DMXJB4N MA Inhibitor DMXJB4N RN Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43. DMXJB4N RU https://pubmed.ncbi.nlm.nih.gov/16134929 DMXJDEA DI DMXJDEA DMXJDEA DN [Pip7]OT DMXJDEA TI TTSCIUP DMXJDEA TN Oxytocin receptor (OTR) DMXJDEA MA Inhibitor DMXJDEA RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMXJDEA RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMXJFCQ DI DMXJFCQ DMXJFCQ DN 6-n-octylaminouracil DMXJFCQ TI TTG0MQD DMXJFCQ TN Inflammation-related GPCR EX33 (GPR84) DMXJFCQ MA Agonist DMXJFCQ RN Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J Biol Chem. 2013 Apr 12;288(15):10684-91. DMXJFCQ RU https://pubmed.ncbi.nlm.nih.gov/23449982 DMXJOYH DI DMXJOYH DMXJOYH DN DOM-0215 DMXJOYH TI TTF8CQI DMXJOYH TN Tumor necrosis factor (TNF) DMXJOYH MA Modulator DMXJOYH RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMXJOYH RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMXJY6W DI DMXJY6W DMXJY6W DN ML-3375 DMXJY6W TI TTYT93M DMXJY6W TN MAP kinase p38 (MAPK12) DMXJY6W MA Inhibitor DMXJY6W RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMXJY6W RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMXJY6W DI DMXJY6W DMXJY6W DN ML-3375 DMXJY6W TI TTXV4FI DMXJY6W TN Albendazole monooxygenase (CYP3A4) DMXJY6W MA Inhibitor DMXJY6W RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMXJY6W RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMXJY6W DI DMXJY6W DMXJY6W DN ML-3375 DMXJY6W TI TTQBR95 DMXJY6W TN Stress-activated protein kinase 2a (p38 alpha) DMXJY6W MA Inhibitor DMXJY6W RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMXJY6W RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMXJY6W DI DMXJY6W DMXJY6W DN ML-3375 DMXJY6W TI TT73U6C DMXJY6W TN Stress-activated protein kinase 2b (p38 beta) DMXJY6W MA Inhibitor DMXJY6W RN Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44. DMXJY6W RU https://pubmed.ncbi.nlm.nih.gov/12852754 DMXK4HR DI DMXK4HR DMXK4HR DN (+/-)-2-(4-fluorophenyl)chroman-4-one DMXK4HR TI TTGP7BY DMXK4HR TN Monoamine oxidase type B (MAO-B) DMXK4HR MA Inhibitor DMXK4HR RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMXK4HR RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMXK56P DI DMXK56P DMXK56P DN 4-(p-tolyloxy)-2-(trifluoromethyl)benzonitrile DMXK56P TI TTKPW01 DMXK56P TN Androgen receptor messenger RNA (AR mRNA) DMXK56P MA Inhibitor DMXK56P RN Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2176-8. DMXK56P RU https://pubmed.ncbi.nlm.nih.gov/19286380 DMXK6D2 DI DMXK6D2 DMXK6D2 DN 13-(N-Isopropylheptanamido)tridec-8(Z)-enoic acid DMXK6D2 TI TT7WVHI DMXK6D2 TN Soluble epoxide hydrolase (EPHX2) DMXK6D2 MA Inhibitor DMXK6D2 RN 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75. DMXK6D2 RU https://pubmed.ncbi.nlm.nih.gov/19653681 DMXK6EI DI DMXK6EI DMXK6EI DN FM-101 DMXK6EI TI TT0E5SK DMXK6EI TN Interleukin 6 receptor (IL6R) DMXK6EI MA Modulator DMXK6EI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2310). DMXK6EI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2310 DMXK8BH DI DMXK8BH DMXK8BH DN digeranyl bisphosphonate DMXK8BH TI TTIKWV4 DMXK8BH TN Geranyltranstransferase (FDPS) DMXK8BH MA Inhibitor DMXK8BH RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DMXK8BH RU https://pubmed.ncbi.nlm.nih.gov/18800762 DMXKAJP DI DMXKAJP DMXKAJP DN ISIS 116363 DMXKAJP TI TTGECUM DMXKAJP TN Cot oncogene messenger RNA (MAP3K8 mRNA) DMXKAJP RN US patent application no. 6,265,216, Antisense modulation of cot oncogene expression. DMXKAJP RU http://www.patentbuddy.com/Patent/6265216?ft=true&sr=true DMXKJOC DI DMXKJOC DMXKJOC DN 3-(4-methoxyphenyl)-6-methyl-2H-chromen-2-one DMXKJOC TI TTGP7BY DMXKJOC TN Monoamine oxidase type B (MAO-B) DMXKJOC MA Inhibitor DMXKJOC RN Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5053-5. DMXKJOC RU https://pubmed.ncbi.nlm.nih.gov/19628387 DMXKL75 DI DMXKL75 DMXKL75 DN 3-(3-Benzoyl-1H-pyrrol-1-yl)propanoic acid DMXKL75 TI TTFBNVI DMXKL75 TN Aldose reductase (AKR1B1) DMXKL75 MA Inhibitor DMXKL75 RN Design and synthesis of novel series of pyrrole based chemotypes and their evaluation as selective aldose reductase inhibitors. A case of bioisoste... Bioorg Med Chem. 2010 Mar 15;18(6):2107-2114. DMXKL75 RU https://pubmed.ncbi.nlm.nih.gov/20189816 DMXKPQR DI DMXKPQR DMXKPQR DN H-Pro-Phe-Phe-NH2 DMXKPQR TI TTZPO1L DMXKPQR TN Substance-P receptor (TACR1) DMXKPQR MA Inhibitor DMXKPQR RN Discovery of dipeptides with high affinity to the specific binding site for substance P1-7. J Med Chem. 2010 Mar 25;53(6):2383-9. DMXKPQR RU https://pubmed.ncbi.nlm.nih.gov/20178322 DMXKQFM DI DMXKQFM DMXKQFM DN 5-Butyl-1H-pyrazole-3-carboxylic acid DMXKQFM TI TTWNV8U DMXKQFM TN Nicotinic acid receptor (HCAR2) DMXKQFM MA Inhibitor DMXKQFM RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMXKQFM RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMXKRWN DI DMXKRWN DMXKRWN DN ISIS 28407 DMXKRWN TI TT9GR53 DMXKRWN TN Smad1 messenger RNA (SMAD1 mRNA) DMXKRWN RN US patent application no. 6,159,697, Antisense modulation of Smad7 expression. DMXKRWN RU http://www.patentbuddy.com/Patent/6159697?ft=true&sr=true DMXKT45 DI DMXKT45 DMXKT45 DN Neuromed 5 DMXKT45 TI TTXHYV6 DMXKT45 TN Voltage-gated L-type calcium channel (L-CaC) DMXKT45 MA Blocker DMXKT45 RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMXKT45 RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMXKT6M DI DMXKT6M DMXKT6M DN 4-[(METHYLSULFONYL)AMINO]BENZOIC ACID DMXKT6M TI TTHI19T DMXKT6M TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMXKT6M MA Inhibitor DMXKT6M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXKT6M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXKU73 DI DMXKU73 DMXKU73 DN CHR-4125 DMXKU73 TI TTIYVQP DMXKU73 TN Polo-like kinase 1 (PLK1) DMXKU73 MA Inhibitor DMXKU73 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168). DMXKU73 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2168 DMXL0J5 DI DMXL0J5 DMXL0J5 DN 3-(4-Phenylethynylbenzoyl)nonanoic acid DMXL0J5 TI TTXZ0KQ DMXL0J5 TN Matrix metalloproteinase-12 (MMP-12) DMXL0J5 MA Inhibitor DMXL0J5 RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DMXL0J5 RU https://pubmed.ncbi.nlm.nih.gov/16420030 DMXL0J5 DI DMXL0J5 DMXL0J5 DN 3-(4-Phenylethynylbenzoyl)nonanoic acid DMXL0J5 TI TT6X50U DMXL0J5 TN Matrix metalloproteinase-9 (MMP-9) DMXL0J5 MA Inhibitor DMXL0J5 RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DMXL0J5 RU https://pubmed.ncbi.nlm.nih.gov/16420030 DMXL0J5 DI DMXL0J5 DMXL0J5 DN 3-(4-Phenylethynylbenzoyl)nonanoic acid DMXL0J5 TI TTLM12X DMXL0J5 TN Matrix metalloproteinase-2 (MMP-2) DMXL0J5 MA Inhibitor DMXL0J5 RN Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids. J Med Chem. 2006 Jan 26;49(2):456-8. DMXL0J5 RU https://pubmed.ncbi.nlm.nih.gov/16420030 DMXL3CD DI DMXL3CD DMXL3CD DN NVP-ADW742 DMXL3CD TI TTHRID2 DMXL3CD TN Insulin-like growth factor I receptor (IGF1R) DMXL3CD MA Inhibitor DMXL3CD RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMXL3CD RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMXL5R7 DI DMXL5R7 DMXL5R7 DN 1,2,3-benzenetricarboxylic acid DMXL5R7 TI TTTD730 DMXL5R7 TN Mitochondrial citrate transporter (SLC25A1) DMXL5R7 MA Inhibitor DMXL5R7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1051). DMXL5R7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1051 DMXL70A DI DMXL70A DMXL70A DN N-(3-(3-cyanobenzamido)phenyl)-2-methoxybenzamide DMXL70A TI TTHS256 DMXL70A TN Metabotropic glutamate receptor 5 (mGluR5) DMXL70A MA Inhibitor DMXL70A RN Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6502-6. DMXL70A RU https://pubmed.ncbi.nlm.nih.gov/19875287 DMXL7Z5 DI DMXL7Z5 DMXL7Z5 DN 1-(2-(naphthalen-1-yl)-1-phenylethyl)piperazine DMXL7Z5 TI TT3ROYC DMXL7Z5 TN Serotonin transporter (SERT) DMXL7Z5 MA Inhibitor DMXL7Z5 RN Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53. DMXL7Z5 RU https://pubmed.ncbi.nlm.nih.gov/16750363 DMXL9IY DI DMXL9IY DMXL9IY DN ISIS 32020 DMXL9IY TI TT9H4P3 DMXL9IY TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMXL9IY RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMXL9IY RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMXLC94 DI DMXLC94 DMXLC94 DN 4-(3-fluorobenzylthio)-2-aminobutanoic acid DMXLC94 TI TTFK1JQ DMXLC94 TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMXLC94 MA Inhibitor DMXLC94 RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMXLC94 RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMXLDHR DI DMXLDHR DMXLDHR DN 6-(Benzothiazole-2-sulfonyl)-2H-pyridazin-3-one DMXLDHR TI TTFBNVI DMXLDHR TN Aldose reductase (AKR1B1) DMXLDHR MA Inhibitor DMXLDHR RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMXLDHR RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMXLGUS DI DMXLGUS DMXLGUS DN OCTYL_GALLATE DMXLGUS TI TTE14XG DMXLGUS TN Squalene monooxygenase (SQLE) DMXLGUS MA Inhibitor DMXLGUS RN Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4. DMXLGUS RU https://pubmed.ncbi.nlm.nih.gov/11520216 DMXLHIO DI DMXLHIO DMXLHIO DN V158411 DMXLHIO TI TTTU902 DMXLHIO TN Checkpoint kinase-1 (CHK1) DMXLHIO MA Inhibitor DMXLHIO RN Cell Density Affects the Detection of Chk1 Target Engagement by the Selective Inhibitor V158411. SLAS Discov. 2018 Feb;23(2):144-153. DMXLHIO RU https://pubmed.ncbi.nlm.nih.gov/29048945 DMXLJGR DI DMXLJGR DMXLJGR DN N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMXLJGR TI TTANPDJ DMXLJGR TN Carbonic anhydrase II (CA-II) DMXLJGR MA Inhibitor DMXLJGR RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMXLJGR RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMXLJGR DI DMXLJGR DMXLJGR DN N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMXLJGR TI TTHQPL7 DMXLJGR TN Carbonic anhydrase I (CA-I) DMXLJGR MA Inhibitor DMXLJGR RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMXLJGR RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMXLJGR DI DMXLJGR DMXLJGR DN N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMXLJGR TI TTZHA0O DMXLJGR TN Carbonic anhydrase IV (CA-IV) DMXLJGR MA Inhibitor DMXLJGR RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMXLJGR RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMXLJGR DI DMXLJGR DMXLJGR DN N-[5-(methylthio)-1,3,4-thiadiazol-2-yl]sulfamide DMXLJGR TI TTUNARX DMXLJGR TN Carbonic anhydrase (CA) DMXLJGR MA Inhibitor DMXLJGR RN Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes ... Bioorg Med Chem Lett. 2008 Dec 15;18(24):6332-5. DMXLJGR RU https://pubmed.ncbi.nlm.nih.gov/18990571 DMXLPO6 DI DMXLPO6 DMXLPO6 DN PQ-1 DMXLPO6 TI TTJ7ATH DMXLPO6 TN Gap junction alpha-8 protein (Cx50) DMXLPO6 MA Modulator DMXLPO6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 732). DMXLPO6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=732 DMXLS78 DI DMXLS78 DMXLS78 DN ATPO DMXLS78 TI TT9HLZ0 DMXLS78 TN Glutamate receptor AMPA 2 (GRIA2) DMXLS78 MA Antagonist DMXLS78 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445). DMXLS78 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=445 DMXLS78 DI DMXLS78 DMXLS78 DN ATPO DMXLS78 TI TTPJR0G DMXLS78 TN Glutamate receptor AMPA 4 (GRIA4) DMXLS78 MA Antagonist DMXLS78 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447). DMXLS78 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447 DMXLS78 DI DMXLS78 DMXLS78 DN ATPO DMXLS78 TI TT82EZV DMXLS78 TN Glutamate receptor AMPA 3 (GRIA3) DMXLS78 MA Antagonist DMXLS78 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446). DMXLS78 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446 DMXLS78 DI DMXLS78 DMXLS78 DN ATPO DMXLS78 TI TTVPQTF DMXLS78 TN Glutamate receptor AMPA 1 (GRIA1) DMXLS78 MA Antagonist DMXLS78 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444). DMXLS78 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444 DMXLVEC DI DMXLVEC DMXLVEC DN PMID19191557C19 DMXLVEC TI TTFQEO5 DMXLVEC TN Squalene synthetase (FDFT1) DMXLVEC MA Inhibitor DMXLVEC RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DMXLVEC RU https://pubmed.ncbi.nlm.nih.gov/19191557 DMXLVG6 DI DMXLVG6 DMXLVG6 DN 3-(5-methoxy-1H-indol-3-yl)propanoic acid DMXLVG6 TI TTZMAO3 DMXLVG6 TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMXLVG6 MA Inhibitor DMXLVG6 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXLVG6 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXLVJW DI DMXLVJW DMXLVJW DN 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol DMXLVJW TI TTLD29N DMXLVJW TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMXLVJW MA Inhibitor DMXLVJW RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMXLVJW RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMXLVJW DI DMXLVJW DMXLVJW DN 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol DMXLVJW TI TTN9D8E DMXLVJW TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMXLVJW MA Inhibitor DMXLVJW RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMXLVJW RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMXLVJW DI DMXLVJW DMXLVJW DN 4-[2-(4-Phenyl-butylamino)-ethyl]-phenol DMXLVJW TI TTKJEMQ DMXLVJW TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMXLVJW MA Inhibitor DMXLVJW RN Structure-activity relationships for a series of bis(phenylalkyl)amines: potent subtype-selective inhibitors of N-methyl-D-aspartate receptors. J Med Chem. 1998 Aug 27;41(18):3499-506. DMXLVJW RU https://pubmed.ncbi.nlm.nih.gov/9719603 DMXLW4F DI DMXLW4F DMXLW4F DN PD182905 DMXLW4F TI TTGKNB4 DMXLW4F TN Epidermal growth factor receptor (EGFR) DMXLW4F MA Inhibitor DMXLW4F RN Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22. DMXLW4F RU https://pubmed.ncbi.nlm.nih.gov/11502465 DMXLWOK DI DMXLWOK DMXLWOK DN 11-deoxy-PGE2 DMXLWOK TI TT79WV3 DMXLWOK TN Prostaglandin E2 receptor EP4 (PTGER4) DMXLWOK MA Agonist DMXLWOK RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMXLWOK RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMXLZAT DI DMXLZAT DMXLZAT DN 4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMXLZAT TI TTZAYWL DMXLZAT TN Estrogen receptor (ESR) DMXLZAT MA Inhibitor DMXLZAT RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMXLZAT RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMXLZAT DI DMXLZAT DMXLZAT DN 4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMXLZAT TI TTPNQAC DMXLZAT TN Estrogen-related receptor-alpha (ESRRA) DMXLZAT MA Inhibitor DMXLZAT RN ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Bioorg Med Chem Lett. 2007 Jul 15;17(14):4053-6. DMXLZAT RU https://pubmed.ncbi.nlm.nih.gov/17482813 DMXLZAT DI DMXLZAT DMXLZAT DN 4-Ethynyl-2-(4-hydroxy-phenyl)-quinolin-6-ol DMXLZAT TI TTOM3J0 DMXLZAT TN Estrogen receptor beta (ESR2) DMXLZAT MA Inhibitor DMXLZAT RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMXLZAT RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMXLZUA DI DMXLZUA DMXLZUA DN 2-Amino-3-Oxo-4-Sulfo-Butyric Acid DMXLZUA TI TTHM0R1 DMXLZUA TN Steryl-sulfatase (STS) DMXLZUA MA Inhibitor DMXLZUA RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMXLZUA RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMXM2G7 DI DMXM2G7 DMXM2G7 DN 7-ethyloxyethoxy-2-morpholin-4-yl-chromen-4-one DMXM2G7 TI TTK3PY9 DMXM2G7 TN DNA-dependent protein kinase catalytic (PRKDC) DMXM2G7 MA Inhibitor DMXM2G7 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMXM2G7 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMXM6NT DI DMXM6NT DMXM6NT DN PT-316 DMXM6NT TI TT84ETX DMXM6NT TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMXM6NT MA Inhibitor DMXM6NT RN Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relati... J Med Chem. 1995 Dec 8;38(25):4929-36. DMXM6NT RU https://pubmed.ncbi.nlm.nih.gov/8523406 DMXM7JR DI DMXM7JR DMXM7JR DN daminozide DMXM7JR TI TT81PFE DMXM7JR TN Histone lysine demethylase PHF8 (PHF8) DMXM7JR MA Inhibitor DMXM7JR RN Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43. DMXM7JR RU https://pubmed.ncbi.nlm.nih.gov/22724510 DMXM7JR DI DMXM7JR DMXM7JR DN daminozide DMXM7JR TI TT0NYMP DMXM7JR TN Lysine-specific demethylase 7A (KDM7A) DMXM7JR MA Inhibitor DMXM7JR RN Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43. DMXM7JR RU https://pubmed.ncbi.nlm.nih.gov/22724510 DMXM7JR DI DMXM7JR DMXM7JR DN daminozide DMXM7JR TI TT8XTY2 DMXM7JR TN Lysine-specific demethylase 2A (KDM2A) DMXM7JR MA Inhibitor DMXM7JR RN Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J Med Chem. 2012 Jul 26;55(14):6639-43. DMXM7JR RU https://pubmed.ncbi.nlm.nih.gov/22724510 DMXMATS DI DMXMATS DMXMATS DN 1-butoxy-4-phenoxybenzene DMXMATS TI TTXZEAJ DMXMATS TN Leukotriene A-4 hydrolase (LTA4H) DMXMATS MA Inhibitor DMXMATS RN Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52. DMXMATS RU https://pubmed.ncbi.nlm.nih.gov/18952425 DMXMBEF DI DMXMBEF DMXMBEF DN 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE DMXMBEF TI TTQBR95 DMXMBEF TN Stress-activated protein kinase 2a (p38 alpha) DMXMBEF MA Inhibitor DMXMBEF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXMBEF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXMF39 DI DMXMF39 DMXMF39 DN PMID7629799C6 DMXMF39 TI TTFQEO5 DMXMF39 TN Squalene synthetase (FDFT1) DMXMF39 MA Inhibitor DMXMF39 RN Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem. 2009 Feb 26;52(4):976-88. DMXMF39 RU https://pubmed.ncbi.nlm.nih.gov/19191557 DMXMHJV DI DMXMHJV DMXMHJV DN ISIS 17020 DMXMHJV TI TT7LTUJ DMXMHJV TN Fas messenger RNA (FAS mRNA) DMXMHJV RN US patent application no. 6,204,055, Antisense inhibition of Fas mediated signaling. DMXMHJV RU http://www.patentbuddy.com/Patent/6204055?ft=true&sr=true DMXMI5E DI DMXMI5E DMXMI5E DN 6-benzyl-3-propoxycarbonyl-4-quinolone DMXMI5E TI TT1MPAY DMXMI5E TN GABA(A) receptor alpha-1 (GABRA1) DMXMI5E MA Inhibitor DMXMI5E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMXMI5E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMXMI5E DI DMXMI5E DMXMI5E DN 6-benzyl-3-propoxycarbonyl-4-quinolone DMXMI5E TI TTZA1NY DMXMI5E TN GABA(A) receptor beta-2 (GABRB2) DMXMI5E MA Inhibitor DMXMI5E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMXMI5E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMXMI5E DI DMXMI5E DMXMI5E DN 6-benzyl-3-propoxycarbonyl-4-quinolone DMXMI5E TI TTNJYV2 DMXMI5E TN Gamma-aminobutyric acid receptor (GAR) DMXMI5E MA Inhibitor DMXMI5E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMXMI5E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMXMI5E DI DMXMI5E DMXMI5E DN 6-benzyl-3-propoxycarbonyl-4-quinolone DMXMI5E TI TT06RH5 DMXMI5E TN GABA(A) receptor gamma-2 (GABRG2) DMXMI5E MA Inhibitor DMXMI5E RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMXMI5E RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMXMIT4 DI DMXMIT4 DMXMIT4 DN CX-02 DMXMIT4 TI TTBID49 DMXMIT4 TN C-X-C chemokine receptor type 4 (CXCR4) DMXMIT4 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 71). DMXMIT4 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=71 DMXMRK7 DI DMXMRK7 DMXMRK7 DN Ethyl octylfluorophosphonate DMXMRK7 TI TTDP1UC DMXMRK7 TN Fatty acid amide hydrolase (FAAH) DMXMRK7 MA Inhibitor DMXMRK7 RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DMXMRK7 RU https://pubmed.ncbi.nlm.nih.gov/18438404 DMXMRK7 DI DMXMRK7 DMXMRK7 DN Ethyl octylfluorophosphonate DMXMRK7 TI TT1RS9F DMXMRK7 TN Acetylcholinesterase (AChE) DMXMRK7 MA Inhibitor DMXMRK7 RN Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8. DMXMRK7 RU https://pubmed.ncbi.nlm.nih.gov/18438404 DMXMRVG DI DMXMRVG DMXMRVG DN RP-69758 DMXMRVG TI TTVFO0U DMXMRVG TN Gastrin/cholecystokinin type B receptor (CCKBR) DMXMRVG MA Antagonist DMXMRVG RN Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists. Eur J Pharmacol. 1994 Sep 12;262(3):233-45. DMXMRVG RU https://pubmed.ncbi.nlm.nih.gov/7813588 DMXMSYB DI DMXMSYB DMXMSYB DN Ro 46-8443 DMXMSYB TI TT3ZTGU DMXMSYB TN Endothelin B receptor (EDNRB) DMXMSYB MA Antagonist DMXMSYB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 220). DMXMSYB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=220 DMXMTA9 DI DMXMTA9 DMXMTA9 DN HMR-1556 DMXMTA9 TI TT846HF DMXMTA9 TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMXMTA9 MA Inhibitor DMXMTA9 RN Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004 Mar 11;47(6):1303-14. DMXMTA9 RU https://pubmed.ncbi.nlm.nih.gov/14998318 DMXMZRE DI DMXMZRE DMXMZRE DN 3-(4-bromophenyl)-1,1-dimethylthiourea DMXMZRE TI TTAS2UO DMXMZRE TN Bacterial Urease (Bact ureC) DMXMZRE MA Inhibitor DMXMZRE RN Facile one-pot synthesis of thio and selenourea derivatives: a new class of potent urease inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6387-91. DMXMZRE RU https://pubmed.ncbi.nlm.nih.gov/17889535 DMXNBGP DI DMXNBGP DMXNBGP DN ISIS 4719 DMXNBGP TI TT1PL7M DMXNBGP TN E-selectin messenger RNA (SELE mRNA) DMXNBGP RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMXNBGP RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMXNC0B DI DMXNC0B DMXNC0B DN ISIS 102462 DMXNC0B TI TT5U49F DMXNC0B TN PRKACA messenger RNA (PRKACA mRNA) DMXNC0B RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMXNC0B RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMXNF3V DI DMXNF3V DMXNF3V DN 8-Bromo-9-(but-3-enyl)-9H-adenine DMXNF3V TI TTK25J1 DMXNF3V TN Adenosine A1 receptor (ADORA1) DMXNF3V MA Inhibitor DMXNF3V RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMXNF3V RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMXNF3V DI DMXNF3V DMXNF3V DN 8-Bromo-9-(but-3-enyl)-9H-adenine DMXNF3V TI TTM2AOE DMXNF3V TN Adenosine A2a receptor (ADORA2A) DMXNF3V MA Inhibitor DMXNF3V RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMXNF3V RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMXNFU5 DI DMXNFU5 DMXNFU5 DN JNJ-16567083 DMXNFU5 TI TTVBPDM DMXNFU5 TN Metabotropic glutamate receptor 1 (mGluR1) DMXNFU5 MA Modulator (allosteric modulator) DMXNFU5 RN A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-ethyl-2-[11C]methyl-6-quinolinyl)(cis- 4-methoxycyclohexyl)methanone. J Med Chem. 2005 Aug11;48(16):5096-9. DMXNFU5 RU https://pubmed.ncbi.nlm.nih.gov/16078827 DMXNG1S DI DMXNG1S DMXNG1S DN ISIS 110064 DMXNG1S TI TTK1V5Q DMXNG1S TN Nucleolin messenger RNA (NCL mRNA) DMXNG1S RN US patent application no. 6,165,786, Antisense modulation of nucleolin expression. DMXNG1S RU http://www.patentbuddy.com/Patent/6165786?ft=true&sr=true DMXNMTD DI DMXNMTD DMXNMTD DN N-(4'-methyl-piperazinyl) estradiol-16-carboxamide DMXNMTD TI TTIWB6L DMXNMTD TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMXNMTD MA Inhibitor DMXNMTD RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMXNMTD RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMXNP2W DI DMXNP2W DMXNP2W DN 4,5-ISOBUDLEIN A DMXNP2W TI TTSXVID DMXNP2W TN Nuclear factor NF-kappa-B (NFKB) DMXNP2W MA Inhibitor DMXNP2W RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMXNP2W RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMXNPSB DI DMXNPSB DMXNPSB DN 5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol DMXNPSB TI TTZAYWL DMXNPSB TN Estrogen receptor (ESR) DMXNPSB MA Inhibitor DMXNPSB RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMXNPSB RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMXNPSB DI DMXNPSB DMXNPSB DN 5-Chloro-2-(4-hydroxy-phenyl)-quinolin-6-ol DMXNPSB TI TTOM3J0 DMXNPSB TN Estrogen receptor beta (ESR2) DMXNPSB MA Inhibitor DMXNPSB RN ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Bioorg Med Chem Lett. 2005 Oct 15;15(20):4520-5. DMXNPSB RU https://pubmed.ncbi.nlm.nih.gov/16098741 DMXNQ15 DI DMXNQ15 DMXNQ15 DN Garveatin C DMXNQ15 TI TTZJYKH DMXNQ15 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMXNQ15 MA Inhibitor DMXNQ15 RN Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod. 2006 Oct;69(10):1496-9. DMXNQ15 RU https://pubmed.ncbi.nlm.nih.gov/17067170 DMXNSTF DI DMXNSTF DMXNSTF DN TRN-101 DMXNSTF TI TTZN7RP DMXNSTF TN Rho-associated protein kinase 1 (ROCK1) DMXNSTF MA Inhibitor DMXNSTF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1503). DMXNSTF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1503 DMXNSTF DI DMXNSTF DMXNSTF DN TRN-101 DMXNSTF TI TTGWKQJ DMXNSTF TN Rho-associated protein kinase 2 (ROCK2) DMXNSTF MA Inhibitor DMXNSTF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1504). DMXNSTF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1504 DMXO98C DI DMXO98C DMXO98C DN 3-hydroxy-N,N,N-trimethylbenzenaminium iodide DMXO98C TI TT1RS9F DMXO98C TN Acetylcholinesterase (AChE) DMXO98C MA Inhibitor DMXO98C RN Homo- and hetero-bivalent edrophonium-like ammonium salts as highly potent, dual binding site AChE inhibitors. Bioorg Med Chem. 2008 Aug 1;16(15):7450-6. DMXO98C RU https://pubmed.ncbi.nlm.nih.gov/18585045 DMXOB2K DI DMXOB2K DMXOB2K DN 6-acetyl-7-methoxy-2H-chromen-2-one DMXOB2K TI TT2LVK8 DMXOB2K TN Carbonic anhydrase IX (CA-IX) DMXOB2K MA Inhibitor DMXOB2K RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMXOB2K RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMXOF4Z DI DMXOF4Z DMXOF4Z DN Noccardimicin E DMXOF4Z TI TTQ13Z5 DMXOF4Z TN Muscarinic acetylcholine receptor M3 (CHRM3) DMXOF4Z MA Inhibitor DMXOF4Z RN Nocardimicins A, B, C, D, E, and F, siderophores with muscarinic M3 receptor inhibiting activity from Nocardia sp. TP-A0674. J Nat Prod. 2005 Jul;68(7):1061-5. DMXOF4Z RU https://pubmed.ncbi.nlm.nih.gov/16038549 DMXOGE8 DI DMXOGE8 DMXOGE8 DN AZUMAMIDE B DMXOGE8 TI TT6R7JZ DMXOGE8 TN Histone deacetylase 1 (HDAC1) DMXOGE8 MA Inhibitor DMXOGE8 RN Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4. DMXOGE8 RU https://pubmed.ncbi.nlm.nih.gov/18397826 DMXOGE8 DI DMXOGE8 DMXOGE8 DN AZUMAMIDE B DMXOGE8 TI TTTQGH8 DMXOGE8 TN Histone deacetylase 4 (HDAC4) DMXOGE8 MA Inhibitor DMXOGE8 RN Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells. Bioorg Med Chem Lett. 2008 May 1;18(9):2982-4. DMXOGE8 RU https://pubmed.ncbi.nlm.nih.gov/18397826 DMXOJIB DI DMXOJIB DMXOJIB DN YRFB DMXOJIB TI TTKWM86 DMXOJIB TN Opioid receptor mu (MOP) DMXOJIB MA Inhibitor DMXOJIB RN Synthesis and receptor binding properties of chimeric peptides containing a mu-opioid receptor ligand and nociceptin/orphanin FQ receptor ligand Ac... Bioorg Med Chem Lett. 2006 Sep 15;16(18):4839-41. DMXOJIB RU https://pubmed.ncbi.nlm.nih.gov/16814543 DMXON4L DI DMXON4L DMXON4L DN CB-676475 DMXON4L TI TT1VAUK DMXON4L TN VEGFR1 messenger RNA (VEGFR1 mRNA) DMXON4L MA Inhibitor DMXON4L RN Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endo... Bioorg Med Chem. 2010 May 15;18(10):3575-87. DMXON4L RU https://pubmed.ncbi.nlm.nih.gov/20403700 DMXON4L DI DMXON4L DMXON4L DN CB-676475 DMXON4L TI TTUTJGQ DMXON4L TN Vascular endothelial growth factor receptor 2 (KDR) DMXON4L MA Inhibitor DMXON4L RN Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jan 1;16(1):129-33. DMXON4L RU https://pubmed.ncbi.nlm.nih.gov/16216503 DMXON4L DI DMXON4L DMXON4L DN CB-676475 DMXON4L TI TTDCBX5 DMXON4L TN Vascular endothelial growth factor receptor 3 (FLT-4) DMXON4L MA Inhibitor DMXON4L RN Synthesis of a novel biotin-tagged photoaffinity probe for VEGF receptor tyrosine kinases. Bioorg Med Chem Lett. 2006 Jan 1;16(1):129-33. DMXON4L RU https://pubmed.ncbi.nlm.nih.gov/16216503 DMXOPFU DI DMXOPFU DMXOPFU DN A-706149 DMXOPFU TI TT4C8EA DMXOPFU TN Dopamine D3 receptor (D3R) DMXOPFU MA Inhibitor DMXOPFU RN Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.genes... Bioorg Med Chem Lett. 2006 Feb;16(3):658-62. DMXOPFU RU https://pubmed.ncbi.nlm.nih.gov/16271293 DMXOPFU DI DMXOPFU DMXOPFU DN A-706149 DMXOPFU TI TTEX248 DMXOPFU TN Dopamine D2 receptor (D2R) DMXOPFU MA Inhibitor DMXOPFU RN Synthesis and SAR of highly potent and selective dopamine D(3)-receptor antagonists: Quinolin(di)one and benzazepin(di)one derivatives. herve.genes... Bioorg Med Chem Lett. 2006 Feb;16(3):658-62. DMXOPFU RU https://pubmed.ncbi.nlm.nih.gov/16271293 DMXOTHC DI DMXOTHC DMXOTHC DN Ro64-5229 DMXOTHC TI TTXJ47W DMXOTHC TN Metabotropic glutamate receptor 2 (mGluR2) DMXOTHC MA Modulator (allosteric modulator) DMXOTHC RN Synthesis of heterocyclic enol ethers and their use as group 2 metabotropic glutamate receptor antagonists. Bioorg Med Chem Lett. 1999 Aug 2;9(15):2173-6. DMXOTHC RU https://pubmed.ncbi.nlm.nih.gov/10465539 DMXOUFI DI DMXOUFI DMXOUFI DN 1-Propylidenethiosemicarbazide DMXOUFI TI TTULVH8 DMXOUFI TN Tyrosinase (TYR) DMXOUFI MA Inhibitor DMXOUFI RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMXOUFI RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMXOYK0 DI DMXOYK0 DMXOYK0 DN Arcaine DMXOYK0 TI TTLGDIS DMXOYK0 TN Acid-sensing ion channel 3 (ASIC3) DMXOYK0 MA Activator DMXOYK0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686). DMXOYK0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=686 DMXP03H DI DMXP03H DMXP03H DN NRC-2694 DMXP03H TI TTGKNB4 DMXP03H TN Epidermal growth factor receptor (EGFR) DMXP03H MA Inhibitor DMXP03H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMXP03H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMXP276 DI DMXP276 DMXP276 DN Hemi-Babim DMXP276 TI TT6L509 DMXP276 TN Coagulation factor IIa (F2) DMXP276 MA Inhibitor DMXP276 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXP276 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXP72F DI DMXP72F DMXP72F DN OTS964 DMXP72F TI TTMY6BZ DMXP72F TN PDZ binding kinase (PBK) DMXP72F MA Inhibitor DMXP72F RN TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145. DMXP72F RU https://pubmed.ncbi.nlm.nih.gov/25338756 DMXPFYZ DI DMXPFYZ DMXPFYZ DN 2-fluorophenylboronic acid DMXPFYZ TI TTDP1UC DMXPFYZ TN Fatty acid amide hydrolase (FAAH) DMXPFYZ MA Inhibitor DMXPFYZ RN Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Nov 27;51(22):7057-60. DMXPFYZ RU https://pubmed.ncbi.nlm.nih.gov/18983140 DMXPIKT DI DMXPIKT DMXPIKT DN M-tolyl 10H-phenothiazine-10-carboxylate DMXPIKT TI TTEB0GD DMXPIKT TN Cholinesterase (BCHE) DMXPIKT MA Inhibitor DMXPIKT RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMXPIKT RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMXPJF3 DI DMXPJF3 DMXPJF3 DN 2-(4-Mercapto-butyl)-pentanedioic acid DMXPJF3 TI TT9G4N0 DMXPJF3 TN Glutamate carboxypeptidase II (GCPII) DMXPJF3 MA Inhibitor DMXPJF3 RN Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem. 2003 May 8;46(10):1989-96. DMXPJF3 RU https://pubmed.ncbi.nlm.nih.gov/12723961 DMXPJHB DI DMXPJHB DMXPJHB DN H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 DMXPJHB TI TTKWM86 DMXPJHB TN Opioid receptor mu (MOP) DMXPJHB MA Inhibitor DMXPJHB RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DMXPJHB RU https://pubmed.ncbi.nlm.nih.gov/17315860 DMXPJHB DI DMXPJHB DMXPJHB DN H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 DMXPJHB TI TTQW87Y DMXPJHB TN Opioid receptor kappa (OPRK1) DMXPJHB MA Inhibitor DMXPJHB RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DMXPJHB RU https://pubmed.ncbi.nlm.nih.gov/17315860 DMXPJHB DI DMXPJHB DMXPJHB DN H-Tyr-c[D-Allylgly-Gly-Phe-L-Allylgly]NH2 DMXPJHB TI TT27RFC DMXPJHB TN Opioid receptor delta (OPRD1) DMXPJHB MA Inhibitor DMXPJHB RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DMXPJHB RU https://pubmed.ncbi.nlm.nih.gov/17315860 DMXPMA6 DI DMXPMA6 DMXPMA6 DN IS20I DMXPMA6 TI TT69TQN DMXPMA6 TN Integrin alpha-V/beta-3 (ITGAV/B3) DMXPMA6 MA Antagonist DMXPMA6 RN IS20I, a specific alphavbeta3 integrin inhibitor, reduces glioma growth in vivo. Neurosurgery. 2003 Jan;52(1):177-85; discussion 185-6. DMXPMA6 RU https://pubmed.ncbi.nlm.nih.gov/12493116 DMXPQ5H DI DMXPQ5H DMXPQ5H DN 4-hydroxy-N,N-diphenylbenzenesulfonamide DMXPQ5H TI TTZAYWL DMXPQ5H TN Estrogen receptor (ESR) DMXPQ5H MA Inhibitor DMXPQ5H RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DMXPQ5H RU https://pubmed.ncbi.nlm.nih.gov/16300947 DMXPQU6 DI DMXPQU6 DMXPQU6 DN (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMXPQU6 TI TTQ6VDM DMXPQU6 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMXPQU6 MA Inhibitor DMXPQU6 RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMXPQU6 RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMXPQU6 DI DMXPQU6 DMXPQU6 DN (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMXPQU6 TI TT6OEDT DMXPQU6 TN Cannabinoid receptor 1 (CB1) DMXPQU6 MA Inhibitor DMXPQU6 RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMXPQU6 RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMXPQU6 DI DMXPQU6 DMXPQU6 DN (2R)-N-(6-(4-CHLOROPHENYL)-7-(2,4-DICHLOROPHENYL)-2,2-DIMETHYL-3,4-DIHYDRO-2H-PYRANO[2,3-B]PYRIDIN-4-YL)-2-HYDROXYPROPANAMIDE (ENANTIOMERIC MIX) DMXPQU6 TI TTMSFAW DMXPQU6 TN Cannabinoid receptor 2 (CB2) DMXPQU6 MA Inhibitor DMXPQU6 RN Dihydro-pyrano[2,3-b]pyridines and tetrahydro-1,8-naphthyridines as CB1 receptor inverse agonists: synthesis, SAR and biological evaluation. Bioorg Med Chem Lett. 2010 Jun 15;20(12):3750-4. DMXPQU6 RU https://pubmed.ncbi.nlm.nih.gov/20483606 DMXPWHF DI DMXPWHF DMXPWHF DN 2-Amino-6-(naphthalene-1-sulfonyl)-benzonitrile DMXPWHF TI TT84ETX DMXPWHF TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMXPWHF MA Inhibitor DMXPWHF RN 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem. 2001 Jun 7;44(12):1866-82. DMXPWHF RU https://pubmed.ncbi.nlm.nih.gov/11384233 DMXQ14V DI DMXQ14V DMXQ14V DN BAYu9773 DMXQ14V TI TTGKOY9 DMXQ14V TN Leukotriene CysLT1 receptor (CYSLTR1) DMXQ14V MA Antagonist DMXQ14V RN Molecular cloning and characterization of a second human cysteinyl leukotriene receptor: discovery of a subtype selective agonist. Mol Pharmacol. 2000 Dec;58(6):1601-8. DMXQ14V RU https://pubmed.ncbi.nlm.nih.gov/11093801 DMXQ14V DI DMXQ14V DMXQ14V DN BAYu9773 DMXQ14V TI TT0PZR5 DMXQ14V TN Leukotriene CysLT2 receptor (CYSLTR2) DMXQ14V MA Antagonist DMXQ14V RN BAY u9773, a novel antagonist of cysteinyl-leukotrienes with activity against two receptor subtypes. Eur J Pharmacol. 1994 Nov 3;264(3):317-23. DMXQ14V RU https://pubmed.ncbi.nlm.nih.gov/7698171 DMXQ1K0 DI DMXQ1K0 DMXQ1K0 DN 7,4'-Dihydroxyflavone DMXQ1K0 TI TTSZLWK DMXQ1K0 TN Aromatase (CYP19A1) DMXQ1K0 MA Inhibitor DMXQ1K0 RN Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64. DMXQ1K0 RU https://pubmed.ncbi.nlm.nih.gov/20413308 DMXQ3MO DI DMXQ3MO DMXQ3MO DN AF353 DMXQ3MO TI TT2THBD DMXQ3MO TN P2X purinoceptor 3 (P2RX3) DMXQ3MO MA Antagonist DMXQ3MO RN AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist. Br J Pharmacol. 2010 Jul;160(6):1387-98. DMXQ3MO RU https://pubmed.ncbi.nlm.nih.gov/20590629 DMXQ47M DI DMXQ47M DMXQ47M DN (S)-WILLARDIINE DMXQ47M TI TTVPQTF DMXQ47M TN Glutamate receptor AMPA 1 (GRIA1) DMXQ47M MA Inhibitor DMXQ47M RN Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem. 1997 Oct 24;40(22):3645-50. DMXQ47M RU https://pubmed.ncbi.nlm.nih.gov/9357531 DMXQ47M DI DMXQ47M DMXQ47M DN (S)-WILLARDIINE DMXQ47M TI TTAN6JD DMXQ47M TN Glutamate receptor AMPA (GRIA) DMXQ47M MA Inhibitor DMXQ47M RN Synthesis of willardiine and 6-azawillardiine analogs: pharmacological characterization on cloned homomeric human AMPA and kainate receptor subtypes. J Med Chem. 1997 Oct 24;40(22):3645-50. DMXQ47M RU https://pubmed.ncbi.nlm.nih.gov/9357531 DMXQ8K1 DI DMXQ8K1 DMXQ8K1 DN 6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMXQ8K1 TI TT3WG5C DMXQ8K1 TN Monoamine oxidase type A (MAO-A) DMXQ8K1 MA Inhibitor DMXQ8K1 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMXQ8K1 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMXQ8K1 DI DMXQ8K1 DMXQ8K1 DN 6-Bromo-2,3,4,9-tetrahydro-1H-beta-carboline DMXQ8K1 TI TTGP7BY DMXQ8K1 TN Monoamine oxidase type B (MAO-B) DMXQ8K1 MA Inhibitor DMXQ8K1 RN Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002. DMXQ8K1 RU https://pubmed.ncbi.nlm.nih.gov/15013009 DMXQATR DI DMXQATR DMXQATR DN AcAsp-Gla-Leu-Ile-Cha-Cys DMXQATR TI TTWXB3E DMXQATR TN Hepatitis C virus NS3 helicase (HCV NS3) DMXQATR MA Inhibitor DMXQATR RN Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6. DMXQATR RU https://pubmed.ncbi.nlm.nih.gov/11206459 DMXQC6H DI DMXQC6H DMXQC6H DN FV-Hyp-TDVGPFAF DMXQC6H TI TTY6O0Q DMXQC6H TN Calcitonin gene-related peptide receptor (CGRPR) DMXQC6H MA Inhibitor DMXQC6H RN Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem. 2006 Jan 26;49(2):616-24. DMXQC6H RU https://pubmed.ncbi.nlm.nih.gov/16420047 DMXQICK DI DMXQICK DMXQICK DN N-hydroxy-8-(naphthalen-2-yl)octanamide DMXQICK TI TT6R7JZ DMXQICK TN Histone deacetylase 1 (HDAC1) DMXQICK MA Inhibitor DMXQICK RN 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur J Med Chem. 2009 Jul;44(7):2868-76. DMXQICK RU https://pubmed.ncbi.nlm.nih.gov/19136179 DMXQROU DI DMXQROU DMXQROU DN 3-(2,4-dihydroxyphenyl)propionic acid DMXQROU TI TTULVH8 DMXQROU TN Tyrosinase (TYR) DMXQROU MA Inhibitor DMXQROU RN Enhanced substituted resorcinol hydrophobicity augments tyrosinase inhibition potency. J Med Chem. 2007 May 31;50(11):2676-81. DMXQROU RU https://pubmed.ncbi.nlm.nih.gov/17447749 DMXQUKJ DI DMXQUKJ DMXQUKJ DN H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H DMXQUKJ TI TT27RFC DMXQUKJ TN Opioid receptor delta (OPRD1) DMXQUKJ MA Inhibitor DMXQUKJ RN A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. DMXQUKJ RU https://pubmed.ncbi.nlm.nih.gov/17851080 DMXQUKJ DI DMXQUKJ DMXQUKJ DN H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H DMXQUKJ TI TTKWM86 DMXQUKJ TN Opioid receptor mu (MOP) DMXQUKJ MA Inhibitor DMXQUKJ RN A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. DMXQUKJ RU https://pubmed.ncbi.nlm.nih.gov/17851080 DMXQVRD DI DMXQVRD DMXQVRD DN 3,4-Dibromo-2-(5-bromo-2-hydroxy-phenoxy)-phenol DMXQVRD TI TTN9T81 DMXQVRD TN Arachidonate 15-lipoxygenase (15-LOX) DMXQVRD MA Inhibitor DMXQVRD RN Probing the activity differences of simple and complex brominated aryl compounds against 15-soybean, 15-human, and 12-human lipoxygenase. J Med Chem. 2004 Jul 29;47(16):4060-5. DMXQVRD RU https://pubmed.ncbi.nlm.nih.gov/15267244 DMXR3V4 DI DMXR3V4 DMXR3V4 DN KYS-05050 DMXR3V4 TI TTZPWGN DMXR3V4 TN Voltage-gated calcium channel alpha Cav3.2 (CACNA1H) DMXR3V4 MA Inhibitor DMXR3V4 RN Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. DMXR3V4 RU https://pubmed.ncbi.nlm.nih.gov/17064894 DMXR3V4 DI DMXR3V4 DMXR3V4 DN KYS-05050 DMXR3V4 TI TT729IR DMXR3V4 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMXR3V4 MA Inhibitor DMXR3V4 RN Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5. DMXR3V4 RU https://pubmed.ncbi.nlm.nih.gov/17064894 DMXRAE3 DI DMXRAE3 DMXRAE3 DN 2-(3''-indolylethyloxy)adenosine DMXRAE3 TI TTJFY5U DMXRAE3 TN Adenosine A3 receptor (ADORA3) DMXRAE3 MA Inhibitor DMXRAE3 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMXRAE3 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMXRAE3 DI DMXRAE3 DMXRAE3 DN 2-(3''-indolylethyloxy)adenosine DMXRAE3 TI TTM2AOE DMXRAE3 TN Adenosine A2a receptor (ADORA2A) DMXRAE3 MA Inhibitor DMXRAE3 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMXRAE3 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMXRAE3 DI DMXRAE3 DMXRAE3 DN 2-(3''-indolylethyloxy)adenosine DMXRAE3 TI TTK25J1 DMXRAE3 TN Adenosine A1 receptor (ADORA1) DMXRAE3 MA Inhibitor DMXRAE3 RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMXRAE3 RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMXRHKQ DI DMXRHKQ DMXRHKQ DN 1-adamantan-1-yl-3-[4-(4-fluorophenoxy)butyl]urea DMXRHKQ TI TT7WVHI DMXRHKQ TN Soluble epoxide hydrolase (EPHX2) DMXRHKQ MA Inhibitor DMXRHKQ RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DMXRHKQ RU https://pubmed.ncbi.nlm.nih.gov/17616115 DMXRHOY DI DMXRHOY DMXRHOY DN 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine DMXRHOY TI TTM2AOE DMXRHOY TN Adenosine A2a receptor (ADORA2A) DMXRHOY MA Inhibitor DMXRHOY RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMXRHOY RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMXRHOY DI DMXRHOY DMXRHOY DN 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine DMXRHOY TI TTK25J1 DMXRHOY TN Adenosine A1 receptor (ADORA1) DMXRHOY MA Inhibitor DMXRHOY RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMXRHOY RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMXRHOY DI DMXRHOY DMXRHOY DN 2-(3''-(4''-bromo-indolyl)ethyloxy)adenosine DMXRHOY TI TTJFY5U DMXRHOY TN Adenosine A3 receptor (ADORA3) DMXRHOY MA Inhibitor DMXRHOY RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMXRHOY RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMXRIUT DI DMXRIUT DMXRIUT DN AMPSL DMXRIUT TI TT0HD6V DMXRIUT TN Leptin receptor (LEPR) DMXRIUT MA Modulator DMXRIUT RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DMXRIUT RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DMXRL2J DI DMXRL2J DMXRL2J DN ISIS 3307 DMXRL2J TI TTRG72O DMXRL2J TN Influenza NP messenger RNA (Influ NP mRNA) DMXRL2J RN US patent application no. 5,580,767, Inhibition of influenza viruses by antisense oligonucleotides. DMXRL2J RU http://www.patentbuddy.com/Patent/5580767?ft=true&sr=true DMXRSM1 DI DMXRSM1 DMXRSM1 DN N-(2-methyl-2-phenylpropyl)pyrazine-2-carboxamide DMXRSM1 TI TTVBPDM DMXRSM1 TN Metabotropic glutamate receptor 1 (mGluR1) DMXRSM1 MA Inhibitor DMXRSM1 RN Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain. Bioorg Med Chem Lett. 2007 Jan 15;17(2):486-90. DMXRSM1 RU https://pubmed.ncbi.nlm.nih.gov/17064898 DMXRYDL DI DMXRYDL DMXRYDL DN 2-(5-Bromo-indole-1-sulfonyl)-benzoic acid DMXRYDL TI TTHWMFZ DMXRYDL TN Fatty acid-binding protein 4 (FABP4) DMXRYDL MA Inhibitor DMXRYDL RN Discovery of inhibitors of human adipocyte fatty acid-binding protein, a potential type 2 diabetes target. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4445-8. DMXRYDL RU https://pubmed.ncbi.nlm.nih.gov/15357969 DMXRZ6N DI DMXRZ6N DMXRZ6N DN YM-35278 DMXRZ6N TI TTK8R02 DMXRZ6N TN Vasopressin V2 receptor (V2R) DMXRZ6N MA Inhibitor DMXRZ6N RN Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists. Bioorg Med Chem. 2008 Nov 1;16(21):9524-35. DMXRZ6N RU https://pubmed.ncbi.nlm.nih.gov/18835174 DMXS43P DI DMXS43P DMXS43P DN N-methyl-2-(pyridin-3-yloxy)ethanamine DMXS43P TI TT5KPZR DMXS43P TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMXS43P MA Inhibitor DMXS43P RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMXS43P RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMXS43P DI DMXS43P DMXS43P DN N-methyl-2-(pyridin-3-yloxy)ethanamine DMXS43P TI TT4H1MQ DMXS43P TN Neuronal acetylcholine receptor alpha-4 (CHRNA4) DMXS43P MA Inhibitor DMXS43P RN Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2013-6. DMXS43P RU https://pubmed.ncbi.nlm.nih.gov/16412637 DMXS72J DI DMXS72J DMXS72J DN AC-710 DMXS72J TI TTC70AJ DMXS72J TN Granulocyte colony-stimulating factor receptor (G-CSF-R) DMXS72J MA Inhibitor DMXS72J RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1719). DMXS72J RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1719 DMXS8LN DI DMXS8LN DMXS8LN DN Trans-hydroxytamoxifen DMXS8LN TI TTOM3J0 DMXS8LN TN Estrogen receptor beta (ESR2) DMXS8LN MA Antagonist DMXS8LN RN Antagonists selective for estrogen receptor alpha. Endocrinology. 2002 Mar;143(3):941-7. DMXS8LN RU https://pubmed.ncbi.nlm.nih.gov/11861516 DMXS8LN DI DMXS8LN DMXS8LN DN Trans-hydroxytamoxifen DMXS8LN TI TTZAYWL DMXS8LN TN Estrogen receptor (ESR) DMXS8LN MA Antagonist DMXS8LN RN Antagonists selective for estrogen receptor alpha. Endocrinology. 2002 Mar;143(3):941-7. DMXS8LN RU https://pubmed.ncbi.nlm.nih.gov/11861516 DMXS9V8 DI DMXS9V8 DMXS9V8 DN SKL-18287 DMXS9V8 TI TTVIMDE DMXS9V8 TN Glucagon-like peptide 1 receptor (GLP1R) DMXS9V8 MA Modulator DMXS9V8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMXS9V8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMXSCEA DI DMXSCEA DMXSCEA DN PMID21692504C8 DMXSCEA TI TT3HYDO DMXSCEA TN Prolyl endopeptidase-like (PREPL) DMXSCEA MA Inhibitor DMXSCEA RN A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors. J Am Chem Soc. 2011 Aug 3;133(30):11665-74. DMXSCEA RU https://pubmed.ncbi.nlm.nih.gov/21692504 DMXSCQE DI DMXSCQE DMXSCQE DN 6-(Naphthalene-1-sulfonyl)-2H-pyridazin-3-one DMXSCQE TI TTFBNVI DMXSCQE TN Aldose reductase (AKR1B1) DMXSCQE MA Inhibitor DMXSCQE RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMXSCQE RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMXSFWK DI DMXSFWK DMXSFWK DN N1-benzyl-N3-hydroxy-2-isobutylmalonamide DMXSFWK TI TTPHMWB DMXSFWK TN Aminopeptidase N (ANPEP) DMXSFWK MA Inhibitor DMXSFWK RN A library of novel hydroxamic acids targeting the metallo-protease family: design, parallel synthesis and screening. Bioorg Med Chem. 2007 Jan 1;15(1):63-76. DMXSFWK RU https://pubmed.ncbi.nlm.nih.gov/17070058 DMXSJH0 DI DMXSJH0 DMXSJH0 DN N-Methylnaloxonium DMXSJH0 TI TTMF541 DMXSJH0 TN Liver carboxylesterase (CES1) DMXSJH0 MA Inhibitor DMXSJH0 RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMXSJH0 RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMXSTF2 DI DMXSTF2 DMXSTF2 DN UNC0006 DMXSTF2 TI TTEX248 DMXSTF2 TN Dopamine D2 receptor (D2R) DMXSTF2 MA Agonist DMXSTF2 RN Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18488-93. DMXSTF2 RU https://pubmed.ncbi.nlm.nih.gov/22025698 DMXSWF6 DI DMXSWF6 DMXSWF6 DN grayanotoxin III DMXSWF6 TI TT84DRB DMXSWF6 TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMXSWF6 MA Activator DMXSWF6 RN Novel site on sodium channel alpha-subunit responsible for the differential sensitivity of grayanotoxin in skeletal and cardiac muscle. Mol Pharmacol. 2001 Oct;60(4):865-72. DMXSWF6 RU https://pubmed.ncbi.nlm.nih.gov/11562450 DMXSYTA DI DMXSYTA DMXSYTA DN CPI-203 DMXSYTA TI TTRA6BO DMXSYTA TN Bromodomain-containing protein 4 (BRD4) DMXSYTA MA Inhibitor DMXSYTA RN BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32. DMXSYTA RU https://pubmed.ncbi.nlm.nih.gov/22509028 DMXSZ1A DI DMXSZ1A DMXSZ1A DN N6 benzyl-cAMP DMXSZ1A TI TTYVI76 DMXSZ1A TN Fungal Protein kinase A (Fung ypkA) DMXSZ1A MA Activator DMXSZ1A RN cAMP analog mapping of Epac1 and cAMP kinase. Discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cel... J Biol Chem. 2003 Sep 12;278(37):35394-402. DMXSZ1A RU https://pubmed.ncbi.nlm.nih.gov/12819211 DMXT1EK DI DMXT1EK DMXT1EK DN NSC-356819 DMXT1EK TI TTJLP0R DMXT1EK TN Quinone reductase 2 (NQO2) DMXT1EK MA Inhibitor DMXT1EK RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMXT1EK RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMXT2ZL DI DMXT2ZL DMXT2ZL DN 1-(oxazol-2-yl)-3-(4-phenoxyphenyl)propan-1-one DMXT2ZL TI TTDP1UC DMXT2ZL TN Fatty acid amide hydrolase (FAAH) DMXT2ZL MA Inhibitor DMXT2ZL RN Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Feb 28;51(4):937-47. DMXT2ZL RU https://pubmed.ncbi.nlm.nih.gov/18247553 DMXT34V DI DMXT34V DMXT34V DN Ro 10-4548 DMXT34V TI TTE0A2F DMXT34V TN Dopamine D4 receptor (D4R) DMXT34V MA Antagonist DMXT34V RN Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9. DMXT34V RU https://pubmed.ncbi.nlm.nih.gov/15448188 DMXT7WG DI DMXT7WG DMXT7WG DN Deguelin DMXT7WG TI TT5LS6T DMXT7WG TN Aurora kinase B (AURKB) DMXT7WG MA Inhibitor DMXT7WG RN An Electrophilic Deguelin Analogue Inhibits STAT3 Signaling in H- Ras-Transformed Human Mammary Epithelial Cells: The Cysteine 259 Residue as a Potential Target. Biomedicines. 2020 Oct 12;8(10):407. DMXT7WG RU https://pubmed.ncbi.nlm.nih.gov/33053804 DMXT87E DI DMXT87E DMXT87E DN M3P6S DMXT87E TI TTKWM86 DMXT87E TN Opioid receptor mu (MOP) DMXT87E MA Inhibitor DMXT87E RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMXT87E RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMXT87E DI DMXT87E DMXT87E DN M3P6S DMXT87E TI TTQW87Y DMXT87E TN Opioid receptor kappa (OPRK1) DMXT87E MA Inhibitor DMXT87E RN Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. DMXT87E RU https://pubmed.ncbi.nlm.nih.gov/16777416 DMXT894 DI DMXT894 DMXT894 DN 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol DMXT894 TI TT27RFC DMXT894 TN Opioid receptor delta (OPRD1) DMXT894 MA Inhibitor DMXT894 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXT894 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXT894 DI DMXT894 DMXT894 DN 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol DMXT894 TI TTQW87Y DMXT894 TN Opioid receptor kappa (OPRK1) DMXT894 MA Inhibitor DMXT894 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXT894 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXT894 DI DMXT894 DMXT894 DN 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol DMXT894 TI TTKWM86 DMXT894 TN Opioid receptor mu (MOP) DMXT894 MA Inhibitor DMXT894 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXT894 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXT894 DI DMXT894 DMXT894 DN 1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol DMXT894 TI TTNT7K8 DMXT894 TN Nociceptin receptor (OPRL1) DMXT894 MA Inhibitor DMXT894 RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXT894 RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXTCE7 DI DMXTCE7 DMXTCE7 DN Carvedilol DMXTCE7 TI TTJB8UY DMXTCE7 TN HUMAN beta adrenergic receptor (BAR) DMXTCE7 MA Antagonist DMXTCE7 RN Can beta-adrenergic blockers be used in the treatment of COVID-19 Med Hypotheses. 2020 May 5;142:109809. DMXTCE7 RU https://pubmed.ncbi.nlm.nih.gov/32388480 DMXTCE7 DI DMXTCE7 DMXTCE7 DN Carvedilol DMXTCE7 TI TTDBOI7 DMXTCE7 TN HUAMN alpha-1 adrenergic receptor (ADRA1) DMXTCE7 MA Inhibitor DMXTCE7 RN Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol. 2003 Jan 15;41(2):340-5. DMXTCE7 RU https://pubmed.ncbi.nlm.nih.gov/12535832 DMXTCJ1 DI DMXTCJ1 DMXTCJ1 DN Drug 311951 DMXTCJ1 TI TT9W8GU DMXTCJ1 TN Gamma-secretase (GS) DMXTCJ1 MA Inhibitor DMXTCJ1 RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DMXTCJ1 RU https://pubmed.ncbi.nlm.nih.gov/15267231 DMXTCJ1 DI DMXTCJ1 DMXTCJ1 DN Drug 311951 DMXTCJ1 TI TTWN3F4 DMXTCJ1 TN Presenilin 2 (PSEN2) DMXTCJ1 MA Inhibitor DMXTCJ1 RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DMXTCJ1 RU https://pubmed.ncbi.nlm.nih.gov/15267231 DMXTCJ1 DI DMXTCJ1 DMXTCJ1 DN Drug 311951 DMXTCJ1 TI TTZ3S8C DMXTCJ1 TN Presenilin 1 (PSEN1) DMXTCJ1 MA Inhibitor DMXTCJ1 RN Discovery of a Subnanomolar helical D-tridecapeptide inhibitor of gamma-secretase. J Med Chem. 2004 Jul 29;47(16):3931-3. DMXTCJ1 RU https://pubmed.ncbi.nlm.nih.gov/15267231 DMXTHOV DI DMXTHOV DMXTHOV DN 2-(4-methoxyphenyl)-6-phenyl-9H-purine DMXTHOV TI TTK25J1 DMXTHOV TN Adenosine A1 receptor (ADORA1) DMXTHOV MA Inhibitor DMXTHOV RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMXTHOV RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMXTHOV DI DMXTHOV DMXTHOV DN 2-(4-methoxyphenyl)-6-phenyl-9H-purine DMXTHOV TI TTJFY5U DMXTHOV TN Adenosine A3 receptor (ADORA3) DMXTHOV MA Inhibitor DMXTHOV RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMXTHOV RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMXTLJE DI DMXTLJE DMXTLJE DN Ethyl estrone-16-methylcarboxylate DMXTLJE TI TTIWB6L DMXTLJE TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMXTLJE MA Inhibitor DMXTLJE RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMXTLJE RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMXTV1B DI DMXTV1B DMXTV1B DN 6-phenylpyridazin-3-yl thiophene-2-carboxylate DMXTV1B TI TT6804T DMXTV1B TN MIF messenger RNA (MIF mRNA) DMXTV1B MA Inhibitor DMXTV1B RN An integrative in silico methodology for the identification of modulators of macrophage migration inhibitory factor (MIF) tautomerase activity. Bioorg Med Chem. 2010 Jul 15;18(14):5425-40. DMXTV1B RU https://pubmed.ncbi.nlm.nih.gov/20639113 DMXTVZ8 DI DMXTVZ8 DMXTVZ8 DN bromocresol green DMXTVZ8 TI TTKVTQO DMXTVZ8 TN Prostaglandin transporter (SLC21A2) DMXTVZ8 MA Inhibitor DMXTVZ8 RN Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. DMXTVZ8 RU https://pubmed.ncbi.nlm.nih.gov/7754369 DMXTY6L DI DMXTY6L DMXTY6L DN [Leu13]motilin (human) DMXTY6L TI TT953CX DMXTY6L TN Motilin receptor (MLNR) DMXTY6L MA Agonist DMXTY6L RN Receptor for motilin identified in the human gastrointestinal system. Science. 1999 Jun 25;284(5423):2184-8. DMXTY6L RU https://pubmed.ncbi.nlm.nih.gov/10381885 DMXTYCU DI DMXTYCU DMXTYCU DN 5,6-epoxyeicosatrienoic acid DMXTYCU TI TTKP2SU DMXTYCU TN Transient receptor potential cation channel V4 (TRPV4) DMXTYCU MA Activator DMXTYCU RN Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature. 2003 Jul 24;424(6947):434-8. DMXTYCU RU https://pubmed.ncbi.nlm.nih.gov/12879072 DMXU1EF DI DMXU1EF DMXU1EF DN 1-(Butan-2-ylidene)thiosemicarbazide DMXU1EF TI TTULVH8 DMXU1EF TN Tyrosinase (TYR) DMXU1EF MA Inhibitor DMXU1EF RN A class of potent tyrosinase inhibitors: alkylidenethiosemicarbazide compounds. Eur J Med Chem. 2009 Apr;44(4):1773-8. DMXU1EF RU https://pubmed.ncbi.nlm.nih.gov/18524420 DMXU5IS DI DMXU5IS DMXU5IS DN N-{4-[2-(4-Hydroxyphenyl)ethyl]phenyl}phthalimide DMXU5IS TI TTECBXN DMXU5IS TN Oxysterols receptor LXR-alpha (NR1H3) DMXU5IS MA Inhibitor DMXU5IS RN Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. DMXU5IS RU https://pubmed.ncbi.nlm.nih.gov/19539483 DMXU5ZP DI DMXU5ZP DMXU5ZP DN Ac-His-DPhe(pBr)-Arg-Trp-NH2 DMXU5ZP TI TTEOSZT DMXU5ZP TN Melanocortin receptor (MCR) DMXU5ZP MA Inhibitor DMXU5ZP RN Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-... J Med Chem. 2008 Sep 25;51(18):5585-93. DMXU5ZP RU https://pubmed.ncbi.nlm.nih.gov/18800761 DMXU90T DI DMXU90T DMXU90T DN 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine DMXU90T TI TT78R5H DMXU90T TN Heat shock protein 90 alpha (HSP90A) DMXU90T MA Inhibitor DMXU90T RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXU90T RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXUBIK DI DMXUBIK DMXUBIK DN S-(-)CPB DMXUBIK TI TTUYAF3 DMXUBIK TN Chloride channel protein 1 (ClC-1) DMXUBIK MA Blocker (channel blocker) DMXUBIK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 698). DMXUBIK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=698 DMXUETW DI DMXUETW DMXUETW DN KMI-596 DMXUETW TI TT8JRS7 DMXUETW TN Beta-secretase (BACE) DMXUETW MA Inhibitor DMXUETW RN Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at P1' and P4 positions. Bioorg Med Chem. 2010 May 1;18(9):3175-86. DMXUETW RU https://pubmed.ncbi.nlm.nih.gov/20381362 DMXUHV3 DI DMXUHV3 DMXUHV3 DN (R)-2-((4-benzylphenoxy)methyl)piperidine DMXUHV3 TI TTXZEAJ DMXUHV3 TN Leukotriene A-4 hydrolase (LTA4H) DMXUHV3 MA Inhibitor DMXUHV3 RN Discovery of novel leukotriene A4 hydrolase inhibitors based on piperidine and piperazine scaffolds. Bioorg Med Chem Lett. 2010 May 1;20(9):2851-4. DMXUHV3 RU https://pubmed.ncbi.nlm.nih.gov/20371179 DMXUI1J DI DMXUI1J DMXUI1J DN Dmt-Pro-Imp-Phe-NH2 DMXUI1J TI TTKWM86 DMXUI1J TN Opioid receptor mu (MOP) DMXUI1J MA Inhibitor DMXUI1J RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMXUI1J RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMXUI1J DI DMXUI1J DMXUI1J DN Dmt-Pro-Imp-Phe-NH2 DMXUI1J TI TTQW87Y DMXUI1J TN Opioid receptor kappa (OPRK1) DMXUI1J MA Inhibitor DMXUI1J RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMXUI1J RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMXUI1J DI DMXUI1J DMXUI1J DN Dmt-Pro-Imp-Phe-NH2 DMXUI1J TI TT27RFC DMXUI1J TN Opioid receptor delta (OPRD1) DMXUI1J MA Inhibitor DMXUI1J RN Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66. DMXUI1J RU https://pubmed.ncbi.nlm.nih.gov/17497839 DMXUIS2 DI DMXUIS2 DMXUIS2 DN 1-(4-ethylphenylsulfonyl)-4-phenylazepan-4-ol DMXUIS2 TI TTN7BL9 DMXUIS2 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMXUIS2 MA Inhibitor DMXUIS2 RN The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5. DMXUIS2 RU https://pubmed.ncbi.nlm.nih.gov/19625185 DMXULGK DI DMXULGK DMXULGK DN Neplanocin A DMXULGK TI TTE2KUJ DMXULGK TN Adenosylhomocysteinase (AHCY) DMXULGK MA Inhibitor DMXULGK RN Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75. DMXULGK RU https://pubmed.ncbi.nlm.nih.gov/8250543 DMXULGK DI DMXULGK DMXULGK DN Neplanocin A DMXULGK TI TTQWUPT DMXULGK TN Thyroid hormone receptor (THR) DMXULGK MA Antagonist DMXULGK RN Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73. DMXULGK RU https://pubmed.ncbi.nlm.nih.gov/12650702 DMXUNMW DI DMXUNMW DMXUNMW DN 1-(3-(phenylthio)propyl)-4-m-tolylpiperazine DMXUNMW TI TTJQOD7 DMXUNMW TN 5-HT 2A receptor (HTR2A) DMXUNMW MA Inhibitor DMXUNMW RN Synthesis and QSAR studies on hypotensive 1-[3-(4-substituted phenylthio) propyl]-4-(substituted phenyl) piperazines. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1708-12. DMXUNMW RU https://pubmed.ncbi.nlm.nih.gov/17234413 DMXUODT DI DMXUODT DMXUODT DN N5-[(4-Phenoxy)-3-pyridyl]-L-glutamamide DMXUODT TI TTXZEAJ DMXUODT TN Leukotriene A-4 hydrolase (LTA4H) DMXUODT MA Inhibitor DMXUODT RN Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorg Med Chem. 2008 May 1;16(9):4963-83. DMXUODT RU https://pubmed.ncbi.nlm.nih.gov/18394906 DMXURM8 DI DMXURM8 DMXURM8 DN 8-n-undecylnaringenin DMXURM8 TI TTZAYWL DMXURM8 TN Estrogen receptor (ESR) DMXURM8 MA Inhibitor DMXURM8 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMXURM8 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMXURM8 DI DMXURM8 DMXURM8 DN 8-n-undecylnaringenin DMXURM8 TI TTOM3J0 DMXURM8 TN Estrogen receptor beta (ESR2) DMXURM8 MA Inhibitor DMXURM8 RN Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen re... J Med Chem. 2006 Dec 14;49(25):7357-65. DMXURM8 RU https://pubmed.ncbi.nlm.nih.gov/17149865 DMXUTWZ DI DMXUTWZ DMXUTWZ DN KNI-10761 DMXUTWZ TI TTXMNHO DMXUTWZ TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMXUTWZ MA Inhibitor DMXUTWZ RN Improvement of both plasmepsin inhibitory activity and antimalarial activity by 2-aminoethylamino substitution. Bioorg Med Chem Lett. 2010 Aug 15;20(16):4836-9. DMXUTWZ RU https://pubmed.ncbi.nlm.nih.gov/20634066 DMXV27U DI DMXV27U DMXV27U DN 2'-deoxyuridine 5'-alpha,beta-imido-diphosphate DMXV27U TI TTY8KJS DMXV27U TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMXV27U MA Inhibitor DMXV27U RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMXV27U RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMXV2KQ DI DMXV2KQ DMXV2KQ DN 1-(2-(3-fluorophenoxy)phenyl)piperazine DMXV2KQ TI TTSQIFT DMXV2KQ TN 5-HT 1A receptor (HTR1A) DMXV2KQ MA Inhibitor DMXV2KQ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMXV2KQ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMXV2KQ DI DMXV2KQ DMXV2KQ DN 1-(2-(3-fluorophenoxy)phenyl)piperazine DMXV2KQ TI TT3ROYC DMXV2KQ TN Serotonin transporter (SERT) DMXV2KQ MA Inhibitor DMXV2KQ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMXV2KQ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMXV2KQ DI DMXV2KQ DMXV2KQ DN 1-(2-(3-fluorophenoxy)phenyl)piperazine DMXV2KQ TI TTAWNKZ DMXV2KQ TN Norepinephrine transporter (NET) DMXV2KQ MA Inhibitor DMXV2KQ RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMXV2KQ RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMXV379 DI DMXV379 DMXV379 DN HTS-00798 DMXV379 TI TTDP1UC DMXV379 TN Fatty acid amide hydrolase (FAAH) DMXV379 MA Inhibitor DMXV379 RN Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system. J Med Chem. 2006 Jul 27;49(15):4650-6. DMXV379 RU https://pubmed.ncbi.nlm.nih.gov/16854070 DMXV5PM DI DMXV5PM DMXV5PM DN EZN-3920 DMXV5PM TI TTSINU2 DMXV5PM TN ERBB3 messenger RNA (ERBB3 mRNA) DMXV5PM MA Inhibitor DMXV5PM RN Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models. Mol Cancer Ther. 2013 Apr;12(4):427-37. DMXV5PM RU https://pubmed.ncbi.nlm.nih.gov/23395887 DMXV6RD DI DMXV6RD DMXV6RD DN CGP 46381 DMXV6RD TI TTDCVZW DMXV6RD TN Gamma-aminobutyric acid B receptor (GABBR) DMXV6RD MA Antagonist DMXV6RD RN The human GABA(B1b) and GABA(B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Br J Pharmacol. 2000 Nov;131(6):1050-4. DMXV6RD RU https://pubmed.ncbi.nlm.nih.gov/11082110 DMXV9S7 DI DMXV9S7 DMXV9S7 DN 1-(4-Benzylsulfanyl-phenyl)-propylamine DMXV9S7 TI TT3ROYC DMXV9S7 TN Serotonin transporter (SERT) DMXV9S7 MA Inhibitor DMXV9S7 RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMXV9S7 RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMXVCL0 DI DMXVCL0 DMXVCL0 DN 2-(2-methoxyphenyl)-6-morpholino-4H-pyran-4-one DMXVCL0 TI TTK3PY9 DMXVCL0 TN DNA-dependent protein kinase catalytic (PRKDC) DMXVCL0 MA Inhibitor DMXVCL0 RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMXVCL0 RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMXVPL1 DI DMXVPL1 DMXVPL1 DN 5-ketodihydromevinolin DMXVPL1 TI TTPADOQ DMXVPL1 TN HMG-CoA reductase (HMGCR) DMXVPL1 MA Inhibitor DMXVPL1 RN Total synthesis and biological evaluation of structural analogues of compactin and dihydromevinolin. J Med Chem. 1987 Oct;30(10):1858-73. DMXVPL1 RU https://pubmed.ncbi.nlm.nih.gov/3656359 DMXVQJI DI DMXVQJI DMXVQJI DN (S)-pyrrolidin-1-yl(pyrrolidin-2-yl)methanone DMXVQJI TI TTDIGC1 DMXVQJI TN Dipeptidyl peptidase 4 (DPP-4) DMXVQJI MA Inhibitor DMXVQJI RN Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group. Bioorg Med Chem. 2008 Feb 15;16(4):1613-31. DMXVQJI RU https://pubmed.ncbi.nlm.nih.gov/18039579 DMXVZIY DI DMXVZIY DMXVZIY DN N-(4-aminobiphenyl-3-yl)nicotinamide DMXVZIY TI TTSHTOI DMXVZIY TN Histone deacetylase 2 (HDAC2) DMXVZIY MA Inhibitor DMXVZIY RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMXVZIY RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMXVZIY DI DMXVZIY DMXVZIY DN N-(4-aminobiphenyl-3-yl)nicotinamide DMXVZIY TI TT6R7JZ DMXVZIY TN Histone deacetylase 1 (HDAC1) DMXVZIY MA Inhibitor DMXVZIY RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMXVZIY RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMXVZIY DI DMXVZIY DMXVZIY DN N-(4-aminobiphenyl-3-yl)nicotinamide DMXVZIY TI TTBH0VX DMXVZIY TN Histone deacetylase (HDAC) DMXVZIY MA Inhibitor DMXVZIY RN Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2). DMXVZIY RU https://pubmed.ncbi.nlm.nih.gov/18951790 DMXWCVY DI DMXWCVY DMXWCVY DN (+)-ADTN DMXWCVY TI TTZFYLI DMXWCVY TN Dopamine D1 receptor (D1R) DMXWCVY MA Agonist DMXWCVY RN Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9. DMXWCVY RU https://pubmed.ncbi.nlm.nih.gov/1826762 DMXWCVY DI DMXWCVY DMXWCVY DN (+)-ADTN DMXWCVY TI TTS2PH3 DMXWCVY TN Dopamine D5 receptor (D5R) DMXWCVY MA Agonist DMXWCVY RN Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature. 1991 Apr 18;350(6319):614-9. DMXWCVY RU https://pubmed.ncbi.nlm.nih.gov/1826762 DMXWF2Z DI DMXWF2Z DMXWF2Z DN Des-AA1,2,5-[D-Trp8,IAmp9,Tyr11]Cbm-SRIF DMXWF2Z TI TTIND6G DMXWF2Z TN Somatostatin receptor type 1 (SSTR1) DMXWF2Z MA Inhibitor DMXWF2Z RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMXWF2Z RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMXWHDC DI DMXWHDC DMXWHDC DN Anti-Fas mabs DMXWHDC TI TT7AOUD DMXWHDC TN Fatty acid synthase (FASN) DMXWHDC RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608). DMXWHDC RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2608 DMXWK1A DI DMXWK1A DMXWK1A DN Erysubin E DMXWK1A TI TT50QJ3 DMXWK1A TN Influenza Neuraminidase (Influ NA) DMXWK1A MA Inhibitor DMXWK1A RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMXWK1A RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMXWK1A DI DMXWK1A DMXWK1A DN Erysubin E DMXWK1A TI TTELIN2 DMXWK1A TN PTPN1 messenger RNA (PTPN1 mRNA) DMXWK1A MA Inhibitor DMXWK1A RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DMXWK1A RU https://pubmed.ncbi.nlm.nih.gov/19836230 DMXWOBE DI DMXWOBE DMXWOBE DN ISOLONGIFOLOL DMXWOBE TI TTO69J7 DMXWOBE TN UDP-glucuronosyltransferase 2B7 (UGT2B7) DMXWOBE MA Inhibitor DMXWOBE RN Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives. J Med Chem. 2007 May 31;50(11):2655-64. DMXWOBE RU https://pubmed.ncbi.nlm.nih.gov/17474732 DMXWSIU DI DMXWSIU DMXWSIU DN MR-2266 DMXWSIU TI TTQW87Y DMXWSIU TN Opioid receptor kappa (OPRK1) DMXWSIU MA Inhibitor DMXWSIU RN Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44. DMXWSIU RU https://pubmed.ncbi.nlm.nih.gov/1652019 DMXWSIU DI DMXWSIU DMXWSIU DN MR-2266 DMXWSIU TI TTKWM86 DMXWSIU TN Opioid receptor mu (MOP) DMXWSIU MA Inhibitor DMXWSIU RN Electrophilic gamma-lactone kappa-opioid receptor probes. Analogues of 2'-hydroxy-2-tetrahydrofurfuryl-5,9-dimethyl-6,7-benzomorphan diastereomers. J Med Chem. 1991 Aug;34(8):2438-44. DMXWSIU RU https://pubmed.ncbi.nlm.nih.gov/1652019 DMXWUHA DI DMXWUHA DMXWUHA DN Ribostamycin DMXWUHA TI TT38DW5 DMXWUHA TN Bacterial 16S ribosomal RNA (Bact 16S rRNA) DMXWUHA MA Inhibitor DMXWUHA RN RNA as a target for small molecules. Curr Opin Chem Biol. 2000 Dec;4(6):678-86. DMXWUHA RU https://pubmed.ncbi.nlm.nih.gov/11102874 DMXWYMH DI DMXWYMH DMXWYMH DN GNF-PF-4292 DMXWYMH TI TTVG215 DMXWYMH TN Debrisoquine 4-hydroxylase (CYP2D6) DMXWYMH MA Inhibitor DMXWYMH RN Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. 1993 Apr 30;36(9):1136-45. DMXWYMH RU https://pubmed.ncbi.nlm.nih.gov/8487254 DMXWZCB DI DMXWZCB DMXWZCB DN [125I]SB-258585 DMXWZCB TI TTJS8PY DMXWZCB TN 5-HT 6 receptor (HTR6) DMXWZCB MA Antagonist DMXWZCB RN 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse. 2002 Sep 1;45(3):191-9. DMXWZCB RU https://pubmed.ncbi.nlm.nih.gov/12112397 DMXY574 DI DMXY574 DMXY574 DN BN-82002 DMXY574 TI TTESBNC DMXY574 TN M-phase inducer phosphatase 3 (MPIP3) DMXY574 MA Inhibitor DMXY574 RN Synthesis of small molecule CDC25 phosphatases inhibitors. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5809-12. DMXY574 RU https://pubmed.ncbi.nlm.nih.gov/15501045 DMXY980 DI DMXY980 DMXY980 DN VU0364770 DMXY980 TI TTICZ1O DMXY980 TN Metabotropic glutamate receptor 4 (mGluR4) DMXY980 MA Modulator (allosteric modulator) DMXY980 RN The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J Pharmacol Exp Ther. 2012 Feb;340(2):404-21. DMXY980 RU https://pubmed.ncbi.nlm.nih.gov/22088953 DMXY9R5 DI DMXY9R5 DMXY9R5 DN (1-Phenethyl-piperidin-4-yl)-phenyl-methanone DMXY9R5 TI TTJQOD7 DMXY9R5 TN 5-HT 2A receptor (HTR2A) DMXY9R5 MA Inhibitor DMXY9R5 RN Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501. DMXY9R5 RU https://pubmed.ncbi.nlm.nih.gov/11170639 DMXYAIQ DI DMXYAIQ DMXYAIQ DN (E)-Octadec-9-enal DMXYAIQ TI TTMI6F5 DMXYAIQ TN Transient receptor potential cation channel V1 (TRPV1) DMXYAIQ MA Inhibitor DMXYAIQ RN The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J Med Chem. 2005 Jul 14;48(14):4663-9. DMXYAIQ RU https://pubmed.ncbi.nlm.nih.gov/16000002 DMXYFMB DI DMXYFMB DMXYFMB DN IODOSULPIRIDE DMXYFMB TI TTEX248 DMXYFMB TN Dopamine D2 receptor (D2R) DMXYFMB MA Inhibitor DMXYFMB RN Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT. J Med Chem. 1993 Jan 22;36(2):221-8. DMXYFMB RU https://pubmed.ncbi.nlm.nih.gov/8093734 DMXYQWG DI DMXYQWG DMXYQWG DN N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile DMXYQWG TI TT36ETB DMXYQWG TN Cathepsin L (CTSL) DMXYQWG MA Inhibitor DMXYQWG RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMXYQWG RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMXYQWG DI DMXYQWG DMXYQWG DN N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile DMXYQWG TI TTUMQVO DMXYQWG TN Cathepsin S (CTSS) DMXYQWG MA Inhibitor DMXYQWG RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMXYQWG RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMXYQWG DI DMXYQWG DMXYQWG DN N-(tert-butoxycarbonyl)-leucyl-glycine-nitrile DMXYQWG TI TTDZN01 DMXYQWG TN Cathepsin K (CTSK) DMXYQWG MA Inhibitor DMXYQWG RN Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J Med Chem. 2005 Dec 1;48(24):7688-707. DMXYQWG RU https://pubmed.ncbi.nlm.nih.gov/16302809 DMXYTGU DI DMXYTGU DMXYTGU DN 2-Cinnamamido-N1-hydroxy-N4-octylsuccinamide DMXYTGU TI TTPHMWB DMXYTGU TN Aminopeptidase N (ANPEP) DMXYTGU MA Inhibitor DMXYTGU RN Design, synthesis, and preliminary studies of the activity of novel derivatives of N-cinnamoyl-L-aspartic acid as inhibitors of aminopeptidase N/CD13. Bioorg Med Chem. 2009 Oct 15;17(20):7398-404. DMXYTGU RU https://pubmed.ncbi.nlm.nih.gov/19782572 DMXYWD7 DI DMXYWD7 DMXYWD7 DN FARNESYL DMXYWD7 TI TTXQKM3 DMXYWD7 TN Farnesyl protein transferase (Ftase) DMXYWD7 MA Inhibitor DMXYWD7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXYWD7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXYWD7 DI DMXYWD7 DMXYWD7 DN FARNESYL DMXYWD7 TI TT7WZIJ DMXYWD7 TN CAAX farnesyltransferase beta (FNTB) DMXYWD7 MA Inhibitor DMXYWD7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMXYWD7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMXZ1HL DI DMXZ1HL DMXZ1HL DN 2-Benzhydryl-7-hydroxy-chromen-4-one DMXZ1HL TI TTFBNVI DMXZ1HL TN Aldose reductase (AKR1B1) DMXZ1HL MA Inhibitor DMXZ1HL RN 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. J Med Chem. 1999 Jun 3;42(11):1881-93. DMXZ1HL RU https://pubmed.ncbi.nlm.nih.gov/10354396 DMXZ2UC DI DMXZ2UC DMXZ2UC DN (2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime DMXZ2UC TI TT7HF4W DMXZ2UC TN Cyclin-dependent kinase 2 (CDK2) DMXZ2UC MA Inhibitor DMXZ2UC RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMXZ2UC RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMXZ2UC DI DMXZ2UC DMXZ2UC DN (2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime DMXZ2UC TI TTCEJ4F DMXZ2UC TN G1/S-specific cyclin-E1 (CCNE1) DMXZ2UC MA Inhibitor DMXZ2UC RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMXZ2UC RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMXZ8RJ DI DMXZ8RJ DMXZ8RJ DN 3,9-dihydroxy-2,10-diprenylpterocap-6a-ene DMXZ8RJ TI TT9V5JH DMXZ8RJ TN Phospholipase A2 (PLA2G1B) DMXZ8RJ MA Inhibitor DMXZ8RJ RN Phospholipase A2 Inhibitors from an Erythrina Species from Samoa J. Nat. Prod. 60(6):537-539 (1997). DMXZ8RJ RU http://pubs.acs.org/doi/abs/10.1021/np960533e DMXZ8S9 DI DMXZ8S9 DMXZ8S9 DN AS100 DMXZ8S9 TI TTNE7KG DMXZ8S9 TN Adenosine A2b receptor (ADORA2B) DMXZ8S9 MA Antagonist DMXZ8S9 RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DMXZ8S9 RU https://pubmed.ncbi.nlm.nih.gov/16219300 DMXZ8S9 DI DMXZ8S9 DMXZ8S9 DN AS100 DMXZ8S9 TI TTK25J1 DMXZ8S9 TN Adenosine A1 receptor (ADORA1) DMXZ8S9 MA Antagonist DMXZ8S9 RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DMXZ8S9 RU https://pubmed.ncbi.nlm.nih.gov/16219300 DMXZ9PI DI DMXZ9PI DMXZ9PI DN 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one DMXZ9PI TI TTLD29N DMXZ9PI TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMXZ9PI MA Inhibitor DMXZ9PI RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMXZ9PI RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMXZ9PI DI DMXZ9PI DMXZ9PI DN 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one DMXZ9PI TI TTN9D8E DMXZ9PI TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMXZ9PI MA Inhibitor DMXZ9PI RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMXZ9PI RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMXZ9PI DI DMXZ9PI DMXZ9PI DN 4,5,7-Trichloro-3-hydroxy-1H-quinolin-2-one DMXZ9PI TI TTKJEMQ DMXZ9PI TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMXZ9PI MA Inhibitor DMXZ9PI RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMXZ9PI RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMXZ9RF DI DMXZ9RF DMXZ9RF DN JWB-1-84-1 DMXZ9RF TI TTH18TF DMXZ9RF TN Muscarinic acetylcholine receptor M5 (CHRM5) DMXZ9RF MA Modulator DMXZ9RF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMXZ9RF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMXZ9T6 DI DMXZ9T6 DMXZ9T6 DN 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol DMXZ9T6 TI TTZAYWL DMXZ9T6 TN Estrogen receptor (ESR) DMXZ9T6 MA Inhibitor DMXZ9T6 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMXZ9T6 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMXZ9T6 DI DMXZ9T6 DMXZ9T6 DN 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-5-ol DMXZ9T6 TI TTOM3J0 DMXZ9T6 TN Estrogen receptor beta (ESR2) DMXZ9T6 MA Inhibitor DMXZ9T6 RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMXZ9T6 RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMXZAH6 DI DMXZAH6 DMXZAH6 DN Trapoxin DMXZAH6 TI TTBH0VX DMXZAH6 TN Histone deacetylase (HDAC) DMXZAH6 MA Inhibitor DMXZAH6 RN Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6. DMXZAH6 RU https://pubmed.ncbi.nlm.nih.gov/11587361 DMXZAIG DI DMXZAIG DMXZAIG DN NSC-99528 DMXZAIG TI TTJLP0R DMXZAIG TN Quinone reductase 2 (NQO2) DMXZAIG MA Inhibitor DMXZAIG RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMXZAIG RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMXZAIG DI DMXZAIG DMXZAIG DN NSC-99528 DMXZAIG TI TT8XK6L DMXZAIG TN Quinone reductase 1 (NQO1) DMXZAIG MA Inhibitor DMXZAIG RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMXZAIG RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMXZB5C DI DMXZB5C DMXZB5C DN 3-Bromo-6-nitro-2-piperazin-1-yl-quinoline DMXZB5C TI TT3ROYC DMXZB5C TN Serotonin transporter (SERT) DMXZB5C MA Inhibitor DMXZB5C RN Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1. Bioorg Med Chem Lett. 2000 Jul 17;10(14):1559-62. DMXZB5C RU https://pubmed.ncbi.nlm.nih.gov/10915050 DMXZBQL DI DMXZBQL DMXZBQL DN 3-(1,2-dihydroacenaphthylen-3-yl)pyridine DMXZBQL TI TTIQUX7 DMXZBQL TN Steroid 11-beta-hydroxylase (CYP11B1) DMXZBQL MA Inhibitor DMXZBQL RN Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg Med Chem Lett. 2006 Jan 1;16(1):25-30. DMXZBQL RU https://pubmed.ncbi.nlm.nih.gov/16246562 DMXZFPB DI DMXZFPB DMXZFPB DN 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol DMXZFPB TI TTQW87Y DMXZFPB TN Opioid receptor kappa (OPRK1) DMXZFPB MA Inhibitor DMXZFPB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXZFPB RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXZFPB DI DMXZFPB DMXZFPB DN 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol DMXZFPB TI TT27RFC DMXZFPB TN Opioid receptor delta (OPRD1) DMXZFPB MA Inhibitor DMXZFPB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXZFPB RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXZFPB DI DMXZFPB DMXZFPB DN 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol DMXZFPB TI TTKWM86 DMXZFPB TN Opioid receptor mu (MOP) DMXZFPB MA Inhibitor DMXZFPB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXZFPB RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXZFPB DI DMXZFPB DMXZFPB DN 1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol DMXZFPB TI TTNT7K8 DMXZFPB TN Nociceptin receptor (OPRL1) DMXZFPB MA Inhibitor DMXZFPB RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMXZFPB RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMXZGKI DI DMXZGKI DMXZGKI DN G009 DMXZGKI TI TTV0YFR DMXZGKI TN Lipid peroxidation (LPO) DMXZGKI MA Inhibitor DMXZGKI RN Inhibition of lipid peroxidation and oxidative DNA damage by Ganoderma lucidum. Phytother Res. 2001 May;15(3):245-9. DMXZGKI RU https://pubmed.ncbi.nlm.nih.gov/11351361 DMXZRND DI DMXZRND DMXZRND DN EFFUSOL DMXZRND TI TTOM3J0 DMXZRND TN Estrogen receptor beta (ESR2) DMXZRND MA Inhibitor DMXZRND RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMXZRND RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMXZRND DI DMXZRND DMXZRND DN EFFUSOL DMXZRND TI TTZAYWL DMXZRND TN Estrogen receptor (ESR) DMXZRND MA Inhibitor DMXZRND RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMXZRND RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMXZS4Y DI DMXZS4Y DMXZS4Y DN ISIS 112696 DMXZS4Y TI TT6804T DMXZS4Y TN MIF messenger RNA (MIF mRNA) DMXZS4Y RN US patent application no. 6,268,151, Antisense modulation of macrophage migration inhibitory factor expression. DMXZS4Y RU http://www.patentbuddy.com/Patent/6268151?ft=true&sr=true DMXZW3R DI DMXZW3R DMXZW3R DN 3-bromophenyl-difluoromethanesulfonamide DMXZW3R TI TT2LVK8 DMXZW3R TN Carbonic anhydrase IX (CA-IX) DMXZW3R MA Inhibitor DMXZW3R RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMXZW3R RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMXZW3R DI DMXZW3R DMXZW3R DN 3-bromophenyl-difluoromethanesulfonamide DMXZW3R TI TTANPDJ DMXZW3R TN Carbonic anhydrase II (CA-II) DMXZW3R MA Inhibitor DMXZW3R RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMXZW3R RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMXZW3R DI DMXZW3R DMXZW3R DN 3-bromophenyl-difluoromethanesulfonamide DMXZW3R TI TTUNARX DMXZW3R TN Carbonic anhydrase (CA) DMXZW3R MA Inhibitor DMXZW3R RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMXZW3R RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMXZW3R DI DMXZW3R DMXZW3R DN 3-bromophenyl-difluoromethanesulfonamide DMXZW3R TI TTHQPL7 DMXZW3R TN Carbonic anhydrase I (CA-I) DMXZW3R MA Inhibitor DMXZW3R RN Carbonic anhydrase inhibitors: inhibition of the human isozymes I, II, VA, and IX with a library of substituted difluoromethanesulfonamides. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5192-6. DMXZW3R RU https://pubmed.ncbi.nlm.nih.gov/16203142 DMXZWOA DI DMXZWOA DMXZWOA DN 6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one DMXZWOA TI TT06AWU DMXZWOA TN Phosphodiesterase 3A (PDE3A) DMXZWOA MA Inhibitor DMXZWOA RN 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8. DMXZWOA RU https://pubmed.ncbi.nlm.nih.gov/1311763 DMY027P DI DMY027P DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one DMY027P TI TTYHPU6 DMY027P TN Histone deacetylase 10 (HDAC10) DMY027P MA Inhibitor DMY027P RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMY027P RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMY027P DI DMY027P DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one DMY027P TI TTSHTOI DMY027P TN Histone deacetylase 2 (HDAC2) DMY027P MA Inhibitor DMY027P RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMY027P RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMY027P DI DMY027P DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one DMY027P TI TTBH0VX DMY027P TN Histone deacetylase (HDAC) DMY027P MA Inhibitor DMY027P RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMY027P RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMY027P DI DMY027P DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one DMY027P TI TTTQGH8 DMY027P TN Histone deacetylase 4 (HDAC4) DMY027P MA Inhibitor DMY027P RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMY027P RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMY027P DI DMY027P DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one DMY027P TI TT6R7JZ DMY027P TN Histone deacetylase 1 (HDAC1) DMY027P MA Inhibitor DMY027P RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMY027P RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMY027P DI DMY027P DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one DMY027P TI TT5ZKDI DMY027P TN Histone deacetylase 6 (HDAC6) DMY027P MA Inhibitor DMY027P RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMY027P RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMY027P DI DMY027P DMY027P DN 7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one DMY027P TI TTT6LFV DMY027P TN Histone deacetylase 8 (HDAC8) DMY027P MA Inhibitor DMY027P RN Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13. DMY027P RU https://pubmed.ncbi.nlm.nih.gov/14592473 DMY02IR DI DMY02IR DMY02IR DN PTBE DMY02IR TI TTXJ47W DMY02IR TN Metabotropic glutamate receptor 2 (mGluR2) DMY02IR MA Modulator (allosteric modulator) DMY02IR RN Phenyl-tetrazolyl acetophenones: discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor. J Med Chem. 2004 Aug 26;47(18):4595-9. DMY02IR RU https://pubmed.ncbi.nlm.nih.gov/15317469 DMY04D1 DI DMY04D1 DMY04D1 DN 4-methyl-6-propylpyridin-2-amine DMY04D1 TI TTZUFI5 DMY04D1 TN Nitric-oxide synthase brain (NOS1) DMY04D1 MA Inhibitor DMY04D1 RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DMY04D1 RU https://pubmed.ncbi.nlm.nih.gov/18849972 DMY04D1 DI DMY04D1 DMY04D1 DN 4-methyl-6-propylpyridin-2-amine DMY04D1 TI TTF10I9 DMY04D1 TN Nitric-oxide synthase inducible (NOS2) DMY04D1 MA Inhibitor DMY04D1 RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DMY04D1 RU https://pubmed.ncbi.nlm.nih.gov/18849972 DMY04D1 DI DMY04D1 DMY04D1 DN 4-methyl-6-propylpyridin-2-amine DMY04D1 TI TTCM4B3 DMY04D1 TN Nitric-oxide synthase endothelial (NOS3) DMY04D1 MA Inhibitor DMY04D1 RN Anchored plasticity opens doors for selective inhibitor design in nitric oxide synthase. Nat Chem Biol. 2008 Nov;4(11):700-7. DMY04D1 RU https://pubmed.ncbi.nlm.nih.gov/18849972 DMY07CA DI DMY07CA DMY07CA DN THRX160209 DMY07CA TI TTOXS3C DMY07CA TN Muscarinic acetylcholine receptor (CHRM) DMY07CA MA Antagonist DMY07CA RN A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Mol Pharmacol. 2007 Aug;72(2):291-302. DMY07CA RU https://pubmed.ncbi.nlm.nih.gov/17478612 DMY08FE DI DMY08FE DMY08FE DN 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE TI TTRA5BZ DMY08FE TN Steroid 17-alpha-monooxygenase (S17AH) DMY08FE MA Inhibitor DMY08FE RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMY08FE RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMY08FE DI DMY08FE DMY08FE DN 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE TI TTIQUX7 DMY08FE TN Steroid 11-beta-hydroxylase (CYP11B1) DMY08FE MA Inhibitor DMY08FE RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMY08FE RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMY08FE DI DMY08FE DMY08FE DN 4-[5-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMY08FE TI TTSZLWK DMY08FE TN Aromatase (CYP19A1) DMY08FE MA Inhibitor DMY08FE RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMY08FE RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMY0A9E DI DMY0A9E DMY0A9E DN Hydroxycitric acid DMY0A9E TI TTCGSZ4 DMY0A9E TN Pancreatic alpha-amylase (AMY2A) DMY0A9E MA Inhibitor DMY0A9E RN Chemistry, physiological properties, and microbial production of hydroxycitric acid. Appl Microbiol Biotechnol. 2007 Jul;75(5):977-82. DMY0A9E RU https://pubmed.ncbi.nlm.nih.gov/17476502 DMY0FVU DI DMY0FVU DMY0FVU DN dimethylhistaprodifen DMY0FVU TI TTTIBOJ DMY0FVU TN Histamine H1 receptor (H1R) DMY0FVU MA Agonist DMY0FVU RN Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther. 2003 Jun;305(3):1104-15. DMY0FVU RU https://pubmed.ncbi.nlm.nih.gov/12626648 DMY0GXM DI DMY0GXM DMY0GXM DN CRISNATOL MESILATE DMY0GXM TI TTGTQHC DMY0GXM TN DNA topoisomerase I (TOP1) DMY0GXM MA Modulator DMY0GXM RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMY0GXM RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMY0I8P DI DMY0I8P DMY0I8P DN 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol DMY0I8P TI TTOM3J0 DMY0I8P TN Estrogen receptor beta (ESR2) DMY0I8P MA Inhibitor DMY0I8P RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DMY0I8P RU https://pubmed.ncbi.nlm.nih.gov/15341953 DMY0I8P DI DMY0I8P DMY0I8P DN 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol DMY0I8P TI TTZAYWL DMY0I8P TN Estrogen receptor (ESR) DMY0I8P MA Inhibitor DMY0I8P RN 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4925-9. DMY0I8P RU https://pubmed.ncbi.nlm.nih.gov/15341953 DMY0IQ6 DI DMY0IQ6 DMY0IQ6 DN L-658,758 DMY0IQ6 TI TTPLTSQ DMY0IQ6 TN Neutrophil elastase (NE) DMY0IQ6 MA Inhibitor DMY0IQ6 RN Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am J Physiol. 1998 Aug;275(2 Pt 2):H385-92. DMY0IQ6 RU https://pubmed.ncbi.nlm.nih.gov/9683424 DMY0O7X DI DMY0O7X DMY0O7X DN METHOXYUNDECYLPHOSPHINIC ACID DMY0O7X TI TTXMY0J DMY0O7X TN Pancreatic triacylglycerol lipase (PNLIP) DMY0O7X MA Inhibitor DMY0O7X RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMY0O7X RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMY0P86 DI DMY0P86 DMY0P86 DN 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole DMY0P86 TI TTVKILB DMY0P86 TN Prostaglandin G/H synthase 2 (COX-2) DMY0P86 MA Inhibitor DMY0P86 RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMY0P86 RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMY0P86 DI DMY0P86 DMY0P86 DN 5-(4-Chlorophenyl)-4-p-tolyl-1,2-selenazole DMY0P86 TI TT8NGED DMY0P86 TN Prostaglandin G/H synthase 1 (COX-1) DMY0P86 MA Inhibitor DMY0P86 RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMY0P86 RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMY13UR DI DMY13UR DMY13UR DN Kushenol N DMY13UR TI TTF8JAT DMY13UR TN SLC5A2 messenger RNA (SLC5A2 mRNA) DMY13UR MA Inhibitor DMY13UR RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMY13UR RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMY13UR DI DMY13UR DMY13UR DN Kushenol N DMY13UR TI TT2UE56 DMY13UR TN Sodium/glucose cotransporter 1 (SGLT1) DMY13UR MA Inhibitor DMY13UR RN Na+-glucose cotransporter (SGLT) inhibitory flavonoids from the roots of Sophora flavescens. Bioorg Med Chem. 2007 May 15;15(10):3445-9. DMY13UR RU https://pubmed.ncbi.nlm.nih.gov/17374486 DMY16VG DI DMY16VG DMY16VG DN Heparin Pentasaccharide DMY16VG TI TT4QPUL DMY16VG TN Antithrombin-III (ATIII) DMY16VG MA Inhibitor DMY16VG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMY16VG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMY1807 DI DMY1807 DMY1807 DN LRHYLNLLTRQRY-NH2 DMY1807 TI TTRK9JT DMY1807 TN Neuropeptide Y receptor type 1 (NPY1R) DMY1807 MA Inhibitor DMY1807 RN A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1916-9. DMY1807 RU https://pubmed.ncbi.nlm.nih.gov/17292607 DMY1807 DI DMY1807 DMY1807 DN LRHYLNLLTRQRY-NH2 DMY1807 TI TTJ6WK9 DMY1807 TN Neuropeptide Y receptor type 2 (NPY2R) DMY1807 MA Inhibitor DMY1807 RN A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice. Bioorg Med Chem Lett. 2007 Apr 1;17(7):1916-9. DMY1807 RU https://pubmed.ncbi.nlm.nih.gov/17292607 DMY18ET DI DMY18ET DMY18ET DN Ac-I[CV(Yphs)QDWGAHRC]I-NH2 DMY18ET TI TTJGY7A DMY18ET TN Complement C3 (CO3) DMY18ET MA Inhibitor DMY18ET RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMY18ET RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMY1FMG DI DMY1FMG DMY1FMG DN N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide DMY1FMG TI TT056SO DMY1FMG TN Stress-activated protein kinase JNK3 (JNK3) DMY1FMG MA Inhibitor DMY1FMG RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMY1FMG RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMY1FMG DI DMY1FMG DMY1FMG DN N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide DMY1FMG TI TT3IVG2 DMY1FMG TN JNK2 messenger RNA (JNK2 mRNA) DMY1FMG MA Inhibitor DMY1FMG RN Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. DMY1FMG RU https://pubmed.ncbi.nlm.nih.gov/16759099 DMY1FMG DI DMY1FMG DMY1FMG DN N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide DMY1FMG TI TT0K6EO DMY1FMG TN Stress-activated protein kinase JNK1 (JNK1) DMY1FMG MA Inhibitor DMY1FMG RN Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. J Med Chem. 2006 Jul 27;49(15):4455-8. DMY1FMG RU https://pubmed.ncbi.nlm.nih.gov/16854050 DMY1OG7 DI DMY1OG7 DMY1OG7 DN ALM-301 DMY1OG7 TI TTWTSCV DMY1OG7 TN RAC-alpha serine/threonine-protein kinase (AKT1) DMY1OG7 MA Inhibitor DMY1OG7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479). DMY1OG7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1479 DMY1R0Q DI DMY1R0Q DMY1R0Q DN ISIS 32039 DMY1R0Q TI TT9H4P3 DMY1R0Q TN PI3K p110 beta messenger RNA (PIK3CB mRNA) DMY1R0Q RN US patent application no. 6,133,032, Antisense modulation of PI3 kinase p110 beta expression. DMY1R0Q RU http://www.patentbuddy.com/Patent/6133032?ft=true&sr=true DMY1W20 DI DMY1W20 DMY1W20 DN (+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one DMY1W20 TI TTGP7BY DMY1W20 TN Monoamine oxidase type B (MAO-B) DMY1W20 MA Inhibitor DMY1W20 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMY1W20 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMY1W20 DI DMY1W20 DMY1W20 DN (+/-)-2-(4'-Propoxyphenyl)thiomorpholin-5-one DMY1W20 TI TT3WG5C DMY1W20 TN Monoamine oxidase type A (MAO-A) DMY1W20 MA Inhibitor DMY1W20 RN 2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1388-95. DMY1W20 RU https://pubmed.ncbi.nlm.nih.gov/20123154 DMY1WEM DI DMY1WEM DMY1WEM DN CU-906 DMY1WEM TI TTCJG29 DMY1WEM TN Serine/threonine-protein kinase mTOR (mTOR) DMY1WEM MA Inhibitor DMY1WEM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMY1WEM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMY1WEM DI DMY1WEM DMY1WEM DN CU-906 DMY1WEM TI TTHBTOP DMY1WEM TN PI3-kinase gamma (PIK3CG) DMY1WEM MA Inhibitor DMY1WEM RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2155). DMY1WEM RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2155 DMY1Z2X DI DMY1Z2X DMY1Z2X DN 1-adamantan-1-yl-3-(1-ethyl-piperidin-4-yl)-urea DMY1Z2X TI TT7WVHI DMY1Z2X TN Soluble epoxide hydrolase (EPHX2) DMY1Z2X MA Inhibitor DMY1Z2X RN Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5212-6. DMY1Z2X RU https://pubmed.ncbi.nlm.nih.gov/16870439 DMY267E DI DMY267E DMY267E DN PMID2296027C29 DMY267E TI TTPADOQ DMY267E TN HMG-CoA reductase (HMGCR) DMY267E MA Inhibitor DMY267E RN Inhibitors of cholesterol biosynthesis. 2. 1,3,5-trisubstituted [2-(tetrahydro-4-hydroxy-2-oxopyran-6-yl)ethyl]pyrazoles. J Med Chem. 1990 Jan;33(1):31-8. DMY267E RU https://pubmed.ncbi.nlm.nih.gov/2296027 DMY26JI DI DMY26JI DMY26JI DN 3,6,9,12,15,18-HEXAOXAICOSANE DMY26JI TI TTJNTSI DMY26JI TN Rotamase Pin1 (PIN1) DMY26JI MA Inhibitor DMY26JI RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMY26JI RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMY28QM DI DMY28QM DMY28QM DN PMID9871507C14 DMY28QM TI TTFQEO5 DMY28QM TN Squalene synthetase (FDFT1) DMY28QM MA Inhibitor DMY28QM RN Cyclopentanedi- and tricarboxylic acids as squalene synthase inhibitors: syntheses and evaluation. Bioorg Med Chem Lett. 1998 Apr 21;8(8):891-6. DMY28QM RU https://pubmed.ncbi.nlm.nih.gov/9871507 DMY293M DI DMY293M DMY293M DN PEG-LPA-2 DMY293M TI TT0HD6V DMY293M TN Leptin receptor (LEPR) DMY293M MA Antagonist DMY293M RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DMY293M RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DMY29Q8 DI DMY29Q8 DMY29Q8 DN Calyculin-A DMY29Q8 TI TTS087L DMY29Q8 TN Solute carrier family 12 member 1 (SLC12A1) DMY29Q8 MA Blocker DMY29Q8 RN Involvement of K(+)-Cl(-)-cotransport in the apoptosis induced by N-ethylmaleimide in HepG2 human hepatoblastoma cells. Eur J Pharmacol. 2001 Apr 20;418(1-2):1-5. DMY29Q8 RU https://pubmed.ncbi.nlm.nih.gov/11334858 DMY2API DI DMY2API DMY2API DN NSC-640584 DMY2API TI TTJLP0R DMY2API TN Quinone reductase 2 (NQO2) DMY2API MA Inhibitor DMY2API RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMY2API RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMY2F6T DI DMY2F6T DMY2F6T DN Pumiliotoxin 251D DMY2F6T TI TT1WJCI DMY2F6T TN Streptococcus Topoisomerase IV A (Stre-coc parC) DMY2F6T MA Inhibitor DMY2F6T RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMY2F6T RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMY2F6T DI DMY2F6T DMY2F6T DN Pumiliotoxin 251D DMY2F6T TI TT0IHXV DMY2F6T TN DNA topoisomerase II (TOP2) DMY2F6T MA Inhibitor DMY2F6T RN How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73. DMY2F6T RU https://pubmed.ncbi.nlm.nih.gov/18621146 DMY2FX8 DI DMY2FX8 DMY2FX8 DN (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine DMY2FX8 TI TTVBI8W DMY2FX8 TN Dopamine transporter (DAT) DMY2FX8 MA Inhibitor DMY2FX8 RN Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. DMY2FX8 RU https://pubmed.ncbi.nlm.nih.gov/19640707 DMY2FX8 DI DMY2FX8 DMY2FX8 DN (2R,3S)-2-[(2-Iodophenoxy)phenylmethyl]morpholine DMY2FX8 TI TT3ROYC DMY2FX8 TN Serotonin transporter (SERT) DMY2FX8 MA Inhibitor DMY2FX8 RN Design and synthesis of (2R,3S)-iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2009 Sep 1;19(17):4996-8. DMY2FX8 RU https://pubmed.ncbi.nlm.nih.gov/19640707 DMY2GXT DI DMY2GXT DMY2GXT DN 2'-Me-tecadenoson DMY2GXT TI TTNE7KG DMY2GXT TN Adenosine A2b receptor (ADORA2B) DMY2GXT MA Inhibitor DMY2GXT RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMY2GXT RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMY2GXT DI DMY2GXT DMY2GXT DN 2'-Me-tecadenoson DMY2GXT TI TTK25J1 DMY2GXT TN Adenosine A1 receptor (ADORA1) DMY2GXT MA Inhibitor DMY2GXT RN 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 ... Bioorg Med Chem. 2008 Jan 1;16(1):336-53. DMY2GXT RU https://pubmed.ncbi.nlm.nih.gov/17933541 DMY2NU8 DI DMY2NU8 DMY2NU8 DN C-[2-(1H-Imidazol-4-yl)-cyclopropyl]-methylamine DMY2NU8 TI TT9JNIC DMY2NU8 TN Histamine H3 receptor (H3R) DMY2NU8 MA Inhibitor DMY2NU8 RN Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist f... J Med Chem. 2003 May 8;46(10):1980-8. DMY2NU8 RU https://pubmed.ncbi.nlm.nih.gov/12723960 DMY2OVL DI DMY2OVL DMY2OVL DN 4-(3-hydroxy-benzylideneamino)-benzenesulfonamide DMY2OVL TI TTVKILB DMY2OVL TN Prostaglandin G/H synthase 2 (COX-2) DMY2OVL MA Inhibitor DMY2OVL RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMY2OVL RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMY2P5C DI DMY2P5C DMY2P5C DN CR-5790 DMY2P5C TI TT79WV3 DMY2P5C TN Prostaglandin E2 receptor EP4 (PTGER4) DMY2P5C MA Antagonist DMY2P5C RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 343). DMY2P5C RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=343 DMY2PBO DI DMY2PBO DMY2PBO DN 2-(N-tert-Butylamino)-3'-chloroheptanophenone DMY2PBO TI TTVBI8W DMY2PBO TN Dopamine transporter (DAT) DMY2PBO MA Inhibitor DMY2PBO RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMY2PBO RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMY2PBO DI DMY2PBO DMY2PBO DN 2-(N-tert-Butylamino)-3'-chloroheptanophenone DMY2PBO TI TTAWNKZ DMY2PBO TN Norepinephrine transporter (NET) DMY2PBO MA Inhibitor DMY2PBO RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81. DMY2PBO RU https://pubmed.ncbi.nlm.nih.gov/19821577 DMY2V37 DI DMY2V37 DMY2V37 DN ZNCCNCSSKWCRDHSRCC DMY2V37 TI TT84DRB DMY2V37 TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMY2V37 MA Inhibitor DMY2V37 RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DMY2V37 RU https://pubmed.ncbi.nlm.nih.gov/17724025 DMY2XV3 DI DMY2XV3 DMY2XV3 DN GSK2193874 DMY2XV3 TI TTKP2SU DMY2XV3 TN Transient receptor potential cation channel V4 (TRPV4) DMY2XV3 MA Blocker (channel blocker) DMY2XV3 RN An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci Transl Med. 2012 Nov 7;4(159):159ra148. DMY2XV3 RU https://pubmed.ncbi.nlm.nih.gov/23136043 DMY347Q DI DMY347Q DMY347Q DN FGGFTGARKSARKKKNQ DMY347Q TI TTNT7K8 DMY347Q TN Nociceptin receptor (OPRL1) DMY347Q MA Inhibitor DMY347Q RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMY347Q RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMY34RB DI DMY34RB DMY34RB DN ISIS 144396 DMY34RB TI TT5S8DR DMY34RB TN APOA1 messenger RNA (APOA1 mRNA) DMY34RB RN US patent application no. 7,259,150, Modulation of apolipoprotein (a) expression. DMY34RB RU http://www.patentbuddy.com/Patent/7259150?ft=true&sr=true DMY35HG DI DMY35HG DMY35HG DN 2-(1-o-tolyl-1H-pyrrol-3-yl)ethanamine DMY35HG TI TTO9X1H DMY35HG TN 5-HT 7 receptor (HTR7) DMY35HG MA Inhibitor DMY35HG RN Novel aminoethylbiphenyls as 5-HT7 receptor ligands. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3018-22. DMY35HG RU https://pubmed.ncbi.nlm.nih.gov/17419056 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TTANPDJ DMY38SB TN Carbonic anhydrase II (CA-II) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TTSYM0R DMY38SB TN Carbonic anhydrase XII (CA-XII) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TTCFSPE DMY38SB TN Carbonic anhydrase VI (CA-VI) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TT2LVK8 DMY38SB TN Carbonic anhydrase IX (CA-IX) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TTEYTKG DMY38SB TN Carbonic anhydrase XIV (CA-XIV) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TTHQPL7 DMY38SB TN Carbonic anhydrase I (CA-I) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TT8NGED DMY38SB TN Prostaglandin G/H synthase 1 (COX-1) DMY38SB MA Inhibitor DMY38SB RN Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/15568761 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TTUNARX DMY38SB TN Carbonic anhydrase (CA) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY38SB DI DMY38SB DMY38SB DN CATECHIN DMY38SB TI TTZHA0O DMY38SB TN Carbonic anhydrase IV (CA-IV) DMY38SB MA Inhibitor DMY38SB RN Carbonic anhydrase inhibitors. Antioxidant polyphenols effectively inhibit mammalian isoforms I-XV. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5050-3. DMY38SB RU https://pubmed.ncbi.nlm.nih.gov/20674354 DMY3C78 DI DMY3C78 DMY3C78 DN 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine DMY3C78 TI TTNE7KG DMY3C78 TN Adenosine A2b receptor (ADORA2B) DMY3C78 MA Inhibitor DMY3C78 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMY3C78 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMY3C78 DI DMY3C78 DMY3C78 DN 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine DMY3C78 TI TTM2AOE DMY3C78 TN Adenosine A2a receptor (ADORA2A) DMY3C78 MA Inhibitor DMY3C78 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMY3C78 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMY3C78 DI DMY3C78 DMY3C78 DN 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine DMY3C78 TI TTK25J1 DMY3C78 TN Adenosine A1 receptor (ADORA1) DMY3C78 MA Inhibitor DMY3C78 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMY3C78 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMY3C78 DI DMY3C78 DMY3C78 DN 2,6-diphenyl-8-(1-ethylpropyl)-1-deazapurine DMY3C78 TI TTJFY5U DMY3C78 TN Adenosine A3 receptor (ADORA3) DMY3C78 MA Inhibitor DMY3C78 RN 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem. 2007 Feb 22;50(4):828-34. DMY3C78 RU https://pubmed.ncbi.nlm.nih.gov/17300165 DMY3CKG DI DMY3CKG DMY3CKG DN example 166 (WO2014154727) DMY3CKG TI TT5NILS DMY3CKG TN Cathepsin A (CTSA) DMY3CKG MA Inhibitor DMY3CKG RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1581). DMY3CKG RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1581 DMY3HEF DI DMY3HEF DMY3HEF DN N-Butyl-ETAV DMY3HEF TI TT9PB26 DMY3HEF TN Presynaptic density protein 95 (DLG4) DMY3HEF MA Inhibitor DMY3HEF RN Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. DMY3HEF RU https://pubmed.ncbi.nlm.nih.gov/18811137 DMY3J0B DI DMY3J0B DMY3J0B DN (+/-)-cis-2-CAMP DMY3J0B TI TT4N6D8 DMY3J0B TN GABA(A) receptor rho3 (GABRR3) DMY3J0B MA Agonist DMY3J0B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 422). DMY3J0B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=422 DMY3J0B DI DMY3J0B DMY3J0B DN (+/-)-cis-2-CAMP DMY3J0B TI TT6XFEU DMY3J0B TN GABA(A) receptor rho1 (GABRR1) DMY3J0B MA Agonist DMY3J0B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 420). DMY3J0B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=420 DMY3J0B DI DMY3J0B DMY3J0B DN (+/-)-cis-2-CAMP DMY3J0B TI TTQMXLS DMY3J0B TN GABA(A) receptor rho2 (GABRR2) DMY3J0B MA Agonist DMY3J0B RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 421). DMY3J0B RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=421 DMY3O6N DI DMY3O6N DMY3O6N DN N5-(1-Imino-3-Butenyl)-L-Ornithine DMY3O6N TI TTZUFI5 DMY3O6N TN Nitric-oxide synthase brain (NOS1) DMY3O6N MA Inhibitor DMY3O6N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMY3O6N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMY3OHK DI DMY3OHK DMY3OHK DN 4-Hydroxy-3-(1-naphthylmethyl)-2H-chromen-2-one DMY3OHK TI TT8XK6L DMY3OHK TN Quinone reductase 1 (NQO1) DMY3OHK MA Inhibitor DMY3OHK RN Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. DMY3OHK RU https://pubmed.ncbi.nlm.nih.gov/19877692 DMY3SEN DI DMY3SEN DMY3SEN DN GSK-J1 DMY3SEN TI TTDIJUQ DMY3SEN TN Lysine-specific demethylase 6B (KDM6B) DMY3SEN MA Inhibitor DMY3SEN RN A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature. 2012 Aug 16;488(7411):404-8. DMY3SEN RU https://pubmed.ncbi.nlm.nih.gov/22842901 DMY3SUZ DI DMY3SUZ DMY3SUZ DN ZK110841 DMY3SUZ TI TTNVEIR DMY3SUZ TN Prostaglandin D2 receptor (PTGDR) DMY3SUZ MA Agonist DMY3SUZ RN Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24. DMY3SUZ RU https://pubmed.ncbi.nlm.nih.gov/9579725 DMY3SUZ DI DMY3SUZ DMY3SUZ DN ZK110841 DMY3SUZ TI TTG1QMU DMY3SUZ TN Prostaglandin E2 receptor EP1 (PTGER1) DMY3SUZ MA Agonist DMY3SUZ RN Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47. DMY3SUZ RU https://pubmed.ncbi.nlm.nih.gov/11999132 DMY3UZH DI DMY3UZH DMY3UZH DN N-(1-Methyl-1H-indol-2-ylmethyl)-N-phenylamine DMY3UZH TI TT3WG5C DMY3UZH TN Monoamine oxidase type A (MAO-A) DMY3UZH MA Inhibitor DMY3UZH RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMY3UZH RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMY3V2B DI DMY3V2B DMY3V2B DN 2,7-Bis(cyclopropanecarbonamido)anthraquinone DMY3V2B TI TTQY2EJ DMY3V2B TN TERT messenger RNA (TERT mRNA) DMY3V2B MA Inhibitor DMY3V2B RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMY3V2B RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMY3VGC DI DMY3VGC DMY3VGC DN Promethazine DMY3VGC TI TTAIY2U DMY3VGC TN HUMAN clathrin-mediated endocytosis (RME) DMY3VGC MA Inhibitor DMY3VGC RN Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150. DMY3VGC RU https://pubmed.ncbi.nlm.nih.gov/32127666 DMY3X6I DI DMY3X6I DMY3X6I DN RU81843 DMY3X6I TI TT6PKBN DMY3X6I TN Proto-oncogene c-Src (SRC) DMY3X6I MA Inhibitor DMY3X6I RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMY3X6I RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMY40UG DI DMY40UG DMY40UG DN ML297 DMY40UG TI TTGM19J DMY40UG TN Inward rectifier potassium channel Kir3.1 (KCNJ3) DMY40UG MA Activator DMY40UG RN ML297 (VU0456810), the first potent and selective activator of the GIRK potassium channel, displays antiepileptic properties in mice. ACS Chem Neurosci. 2013 Sep 18;4(9):1278-86. DMY40UG RU https://pubmed.ncbi.nlm.nih.gov/23730969 DMY43FU DI DMY43FU DMY43FU DN PO3 2-Leu-Nal-O-3K DMY43FU TI TTQ9RYT DMY43FU TN Endothelin-converting enzyme 1 (ECE1) DMY43FU MA Inhibitor DMY43FU RN Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon, Bioorg. Med. Chem. Lett. 4(10):1257-1262 (1994). DMY43FU RU http://www.sciencedirect.com/science/article/pii/S0960894X01803413 DMY45K1 DI DMY45K1 DMY45K1 DN PF 5208766 DMY45K1 TI TTGKNB4 DMY45K1 TN Epidermal growth factor receptor (EGFR) DMY45K1 MA Modulator DMY45K1 RN Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31. DMY45K1 RU https://www.ncbi.nlm.nih.gov/pubmed/15715478 DMY45K1 DI DMY45K1 DMY45K1 DN PF 5208766 DMY45K1 TI TT6EO5L DMY45K1 TN Erbb2 tyrosine kinase receptor (HER2) DMY45K1 MA Modulator DMY45K1 RN Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31. DMY45K1 RU https://www.ncbi.nlm.nih.gov/pubmed/15715478 DMY49DN DI DMY49DN DMY49DN DN Isosorbide-2-benzylcarbamate-5-nicotinate DMY49DN TI TTEB0GD DMY49DN TN Cholinesterase (BCHE) DMY49DN MA Inhibitor DMY49DN RN Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J Med Chem. 2008 Oct 23;51(20):6400-9. DMY49DN RU https://pubmed.ncbi.nlm.nih.gov/18817366 DMY4C0G DI DMY4C0G DMY4C0G DN MRS1132 DMY4C0G TI TTNE7KG DMY4C0G TN Adenosine A2b receptor (ADORA2B) DMY4C0G MA Antagonist DMY4C0G RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMY4C0G RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMY4C0G DI DMY4C0G DMY4C0G DN MRS1132 DMY4C0G TI TTK25J1 DMY4C0G TN Adenosine A1 receptor (ADORA1) DMY4C0G MA Antagonist DMY4C0G RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMY4C0G RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMY4M3J DI DMY4M3J DMY4M3J DN Cbz-Ile-MetO2-Ala-LeuVSMe DMY4M3J TI TTUMQVO DMY4M3J TN Cathepsin S (CTSS) DMY4M3J MA Inhibitor DMY4M3J RN Optimization of subsite binding to the beta5 subunit of the human 20S proteasome using vinyl sulfones and 2-keto-1,3,4-oxadiazoles: syntheses and c... J Med Chem. 2006 May 18;49(10):2953-68. DMY4M3J RU https://pubmed.ncbi.nlm.nih.gov/16686537 DMY4MPG DI DMY4MPG DMY4MPG DN NSC-676468 DMY4MPG TI TTJLP0R DMY4MPG TN Quinone reductase 2 (NQO2) DMY4MPG MA Inhibitor DMY4MPG RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMY4MPG RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMY4PMN DI DMY4PMN DMY4PMN DN OBABERINE DMY4PMN TI TTVBI8W DMY4PMN TN Dopamine transporter (DAT) DMY4PMN MA Inhibitor DMY4PMN RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DMY4PMN RU https://pubmed.ncbi.nlm.nih.gov/8676127 DMY4QE6 DI DMY4QE6 DMY4QE6 DN H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 DMY4QE6 TI TT27RFC DMY4QE6 TN Opioid receptor delta (OPRD1) DMY4QE6 MA Inhibitor DMY4QE6 RN Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80. DMY4QE6 RU https://pubmed.ncbi.nlm.nih.gov/10691683 DMY4QE6 DI DMY4QE6 DMY4QE6 DN H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 DMY4QE6 TI TTKWM86 DMY4QE6 TN Opioid receptor mu (MOP) DMY4QE6 MA Inhibitor DMY4QE6 RN Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80. DMY4QE6 RU https://pubmed.ncbi.nlm.nih.gov/10691683 DMY4VOI DI DMY4VOI DMY4VOI DN 3-ethoxycarbonyl-4-quinolone DMY4VOI TI TT1MPAY DMY4VOI TN GABA(A) receptor alpha-1 (GABRA1) DMY4VOI MA Inhibitor DMY4VOI RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMY4VOI RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMY4VOI DI DMY4VOI DMY4VOI DN 3-ethoxycarbonyl-4-quinolone DMY4VOI TI TTZA1NY DMY4VOI TN GABA(A) receptor beta-2 (GABRB2) DMY4VOI MA Inhibitor DMY4VOI RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMY4VOI RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMY4VOI DI DMY4VOI DMY4VOI DN 3-ethoxycarbonyl-4-quinolone DMY4VOI TI TTNJYV2 DMY4VOI TN Gamma-aminobutyric acid receptor (GAR) DMY4VOI MA Inhibitor DMY4VOI RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMY4VOI RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMY4VOI DI DMY4VOI DMY4VOI DN 3-ethoxycarbonyl-4-quinolone DMY4VOI TI TT06RH5 DMY4VOI TN GABA(A) receptor gamma-2 (GABRG2) DMY4VOI MA Inhibitor DMY4VOI RN 4-quinolone derivatives: high-affinity ligands at the benzodiazepine site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore mod... J Med Chem. 2006 Apr 20;49(8):2526-33. DMY4VOI RU https://pubmed.ncbi.nlm.nih.gov/16610795 DMY4VX2 DI DMY4VX2 DMY4VX2 DN 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid DMY4VX2 TI TTSJ542 DMY4VX2 TN Integrin alpha-2 (ITGA2) DMY4VX2 MA Inhibitor DMY4VX2 RN Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. DMY4VX2 RU https://pubmed.ncbi.nlm.nih.gov/16919941 DMY4VX2 DI DMY4VX2 DMY4VX2 DN 3-(3-(benzamido)-5-nitrobenzamido)propanoic acid DMY4VX2 TI TTJA1ZO DMY4VX2 TN ITGB3 messenger RNA (ITGB3 mRNA) DMY4VX2 MA Inhibitor DMY4VX2 RN Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5294-7. DMY4VX2 RU https://pubmed.ncbi.nlm.nih.gov/16919941 DMY4W25 DI DMY4W25 DMY4W25 DN (E,E)-8-[4-(3-Chlorophenyl)butadien-1-yl]caffeine DMY4W25 TI TTM2AOE DMY4W25 TN Adenosine A2a receptor (ADORA2A) DMY4W25 MA Inhibitor DMY4W25 RN Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem. 2008 Sep 15;16(18):8676-84. DMY4W25 RU https://pubmed.ncbi.nlm.nih.gov/18723354 DMY50UR DI DMY50UR DMY50UR DN 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline DMY50UR TI TT2NUT5 DMY50UR TN Adrenergic receptor alpha-2C (ADRA2C) DMY50UR MA Inhibitor DMY50UR RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMY50UR RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMY50UR DI DMY50UR DMY50UR DN 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline DMY50UR TI TTWG9A4 DMY50UR TN Adrenergic receptor alpha-2A (ADRA2A) DMY50UR MA Inhibitor DMY50UR RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMY50UR RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMY50UR DI DMY50UR DMY50UR DN 8-Methoxy-1,2,3,4-tetrahydro-benzo[h]isoquinoline DMY50UR TI TTWM4TY DMY50UR TN Adrenergic receptor alpha-2B (ADRA2B) DMY50UR MA Inhibitor DMY50UR RN Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inh... J Med Chem. 1997 Dec 5;40(25):3997-4005. DMY50UR RU https://pubmed.ncbi.nlm.nih.gov/9406590 DMY57CV DI DMY57CV DMY57CV DN 3-tert-butyl-9H-carbazole DMY57CV TI TTBGTCW DMY57CV TN Kinesin spindle messenger RNA (KIF11 mRNA) DMY57CV MA Inhibitor DMY57CV RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMY57CV RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMY57L0 DI DMY57L0 DMY57L0 DN melanin-concentrating hormone DMY57L0 TI TTS17MG DMY57L0 TN Melanin-concentrating hormone receptor 2 (MCHR2) DMY57L0 MA Agonist DMY57L0 RN Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7564-9. DMY57L0 RU https://pubmed.ncbi.nlm.nih.gov/11404457 DMY57L0 DI DMY57L0 DMY57L0 DN melanin-concentrating hormone DMY57L0 TI TTX4RTB DMY57L0 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMY57L0 MA Agonist DMY57L0 RN [125I]-S36057: a new and highly potent radioligand for the melanin-concentrating hormone receptor. Br J Pharmacol. 2001 Jun;133(3):371-8. DMY57L0 RU https://pubmed.ncbi.nlm.nih.gov/11375253 DMY590Q DI DMY590Q DMY590Q DN Glucosamine 6-Phosphate DMY590Q TI TTC67I0 DMY590Q TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMY590Q MA Inhibitor DMY590Q RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMY590Q RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMY59KQ DI DMY59KQ DMY59KQ DN Nitracrine DMY59KQ TI TTUTN1I DMY59KQ TN Human Deoxyribonucleic acid (hDNA) DMY59KQ MA Breaker DMY59KQ RN Crosslinking of cellular DNA by nitracrine and furocoumarin derivatives. Neoplasma. 1999;46(1):50-3. DMY59KQ RU https://pubmed.ncbi.nlm.nih.gov/10355534 DMY5HX6 DI DMY5HX6 DMY5HX6 DN Tyr-Pro-Trp-D-Val-Bn DMY5HX6 TI TTKWM86 DMY5HX6 TN Opioid receptor mu (MOP) DMY5HX6 MA Inhibitor DMY5HX6 RN Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor. Bioorg Med Chem Lett. 2009 Sep 15;19(18):5387-91. DMY5HX6 RU https://pubmed.ncbi.nlm.nih.gov/19679474 DMY5JFB DI DMY5JFB DMY5JFB DN NSC-645834 DMY5JFB TI TTJLP0R DMY5JFB TN Quinone reductase 2 (NQO2) DMY5JFB MA Inhibitor DMY5JFB RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMY5JFB RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMY5LOB DI DMY5LOB DMY5LOB DN WIN 51,708 DMY5LOB TI TTOXS3C DMY5LOB TN Muscarinic acetylcholine receptor (CHRM) DMY5LOB MA Modulator (allosteric modulator) DMY5LOB RN Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505. DMY5LOB RU https://pubmed.ncbi.nlm.nih.gov/12435818 DMY5LOB DI DMY5LOB DMY5LOB DN WIN 51,708 DMY5LOB TI TTQ13Z5 DMY5LOB TN Muscarinic acetylcholine receptor M3 (CHRM3) DMY5LOB MA Modulator (allosteric modulator) DMY5LOB RN Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002 Dec;62(6):1492-505. DMY5LOB RU https://pubmed.ncbi.nlm.nih.gov/12435818 DMY5O1U DI DMY5O1U DMY5O1U DN BENZOYLENUREA DMY5O1U TI TT06AWU DMY5O1U TN Phosphodiesterase 3A (PDE3A) DMY5O1U MA Inhibitor DMY5O1U RN CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem. 2008 Jul;43(7):1349-59. DMY5O1U RU https://pubmed.ncbi.nlm.nih.gov/18082290 DMY5OTN DI DMY5OTN DMY5OTN DN d-AP5 DMY5OTN TI TT1M8OW DMY5OTN TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMY5OTN MA Antagonist DMY5OTN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMY5OTN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMY5OTN DI DMY5OTN DMY5OTN DN d-AP5 DMY5OTN TI TT5POTG DMY5OTN TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMY5OTN MA Antagonist DMY5OTN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMY5OTN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMY5OTN DI DMY5OTN DMY5OTN DN d-AP5 DMY5OTN TI TTN9D8E DMY5OTN TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMY5OTN MA Antagonist DMY5OTN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMY5OTN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMY5OTN DI DMY5OTN DMY5OTN DN d-AP5 DMY5OTN TI TTKJEMQ DMY5OTN TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMY5OTN MA Antagonist DMY5OTN RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMY5OTN RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMY5QBF DI DMY5QBF DMY5QBF DN 4-(1H-indol-1-ylsulfonyl)benzenamine DMY5QBF TI TTJS8PY DMY5QBF TN 5-HT 6 receptor (HTR6) DMY5QBF MA Inhibitor DMY5QBF RN Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302. DMY5QBF RU https://pubmed.ncbi.nlm.nih.gov/16183286 DMY5RDI DI DMY5RDI DMY5RDI DN HYDAMTIQ DMY5RDI TI TTVDSZ0 DMY5RDI TN Poly [ADP-ribose] polymerase 1 (PARP1) DMY5RDI MA Inhibitor DMY5RDI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMY5RDI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMY5STK DI DMY5STK DMY5STK DN 2-(4-bromophenylsulfonamido)-N-hydroxyacetamide DMY5STK TI TT6AZXG DMY5STK TN TNF alpha converting enzyme (ADAM17) DMY5STK MA Inhibitor DMY5STK RN Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35. DMY5STK RU https://pubmed.ncbi.nlm.nih.gov/20180536 DMY5STK DI DMY5STK DMY5STK DN 2-(4-bromophenylsulfonamido)-N-hydroxyacetamide DMY5STK TI TTJ4QE7 DMY5STK TN Matrix metalloproteinase-14 (MMP-14) DMY5STK MA Inhibitor DMY5STK RN Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule sheddi... J Med Chem. 2010 Mar 25;53(6):2622-35. DMY5STK RU https://pubmed.ncbi.nlm.nih.gov/20180536 DMY5SX9 DI DMY5SX9 DMY5SX9 DN PD-156 DMY5SX9 TI TTHY57M DMY5SX9 TN Matrix metalloproteinase-13 (MMP-13) DMY5SX9 MA Inhibitor DMY5SX9 RN Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7. DMY5SX9 RU https://pubmed.ncbi.nlm.nih.gov/16428338 DMY60K3 DI DMY60K3 DMY60K3 DN 2-(3-biphenyl-4-yl-propionylamino)-benzoic acid DMY60K3 TI TTWNV8U DMY60K3 TN Nicotinic acid receptor (HCAR2) DMY60K3 MA Inhibitor DMY60K3 RN Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor. J Med Chem. 2007 Dec 13;50(25):6303-6. DMY60K3 RU https://pubmed.ncbi.nlm.nih.gov/17994679 DMY60MG DI DMY60MG DMY60MG DN L-735,821 DMY60MG TI TT846HF DMY60MG TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMY60MG MA Blocker DMY60MG RN Molecular determinants of KCNQ1 channel block by a benzodiazepine. Mol Pharmacol. 2003 Jul;64(1):70-7. DMY60MG RU https://pubmed.ncbi.nlm.nih.gov/12815162 DMY64HE DI DMY64HE DMY64HE DN Alpha-linolenic acid DMY64HE TI TTB8FUC DMY64HE TN Free fatty acid receptor 1 (GPR40) DMY64HE MA Agonist DMY64HE RN Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003 Mar 13;422(6928):173-6. DMY64HE RU https://pubmed.ncbi.nlm.nih.gov/12629551 DMY64HE DI DMY64HE DMY64HE DN Alpha-linolenic acid DMY64HE TI TT08JVB DMY64HE TN G-protein coupled receptor 120 (GPR120) DMY64HE MA Agonist DMY64HE RN Cloning and characterization of the rat free fatty acid receptor GPR120: in vivo effect of the natural ligand on GLP-1 secretion and proliferation of pancreatic beta cells. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):515-22. DMY64HE RU https://pubmed.ncbi.nlm.nih.gov/18320172 DMY64HE DI DMY64HE DMY64HE DN Alpha-linolenic acid DMY64HE TI TTVKILB DMY64HE TN Prostaglandin G/H synthase 2 (COX-2) DMY64HE MA Inhibitor DMY64HE RN Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9. DMY64HE RU https://pubmed.ncbi.nlm.nih.gov/11421736 DMY65CX DI DMY65CX DMY65CX DN 2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline DMY65CX TI TTZFYLI DMY65CX TN Dopamine D1 receptor (D1R) DMY65CX MA Inhibitor DMY65CX RN Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists. J Med Chem. 1981 Sep;24(9):1107-10. DMY65CX RU https://pubmed.ncbi.nlm.nih.gov/7288826 DMY65CX DI DMY65CX DMY65CX DN 2-Methyl-8-phenyl-1,2,3,4-tetrahydro-isoquinoline DMY65CX TI TTEX248 DMY65CX TN Dopamine D2 receptor (D2R) DMY65CX MA Inhibitor DMY65CX RN Synthesis and evaluation of 1,2,3,4-tetrahydro[1]benzothieno[2,3-h]isoquinolines as dopamine antagonists. J Med Chem. 1981 Sep;24(9):1107-10. DMY65CX RU https://pubmed.ncbi.nlm.nih.gov/7288826 DMY65ZP DI DMY65ZP DMY65ZP DN LICOAGROCHALCONE A DMY65ZP TI TTELIN2 DMY65ZP TN PTPN1 messenger RNA (PTPN1 mRNA) DMY65ZP MA Inhibitor DMY65ZP RN Isoprenylated flavonoids from the stem bark of Erythrina abyssinica. J Nat Prod. 2007 Jun;70(6):1039-42. DMY65ZP RU https://pubmed.ncbi.nlm.nih.gov/17489632 DMY689Z DI DMY689Z DMY689Z DN NSC-527035 DMY689Z TI TTB6UM0 DMY689Z TN Fatty aldehyde dehydrogenase (ALDH3A2) DMY689Z MA Inhibitor DMY689Z RN Exploring the structural requirements for inhibition of the ubiquitin E3 ligase breast cancer associated protein 2 (BCA2) as a treatment for breast... J Med Chem. 2010 Apr 8;53(7):2757-65. DMY689Z RU https://pubmed.ncbi.nlm.nih.gov/20222671 DMY6DM5 DI DMY6DM5 DMY6DM5 DN E-758 DMY6DM5 TI TTGTQHC DMY6DM5 TN DNA topoisomerase I (TOP1) DMY6DM5 MA Inhibitor DMY6DM5 RN Lycobetaine acts as a selective topoisomerase IIbeta poison and inhibits the growth of human tumour cells. Br J Cancer. 2001 November; 85(10): 1585-1591. DMY6DM5 RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363954/ DMY6FUD DI DMY6FUD DMY6FUD DN (Hydroxyethyloxy)Tri(Ethyloxy)Octane DMY6FUD TI TTXMY0J DMY6FUD TN Pancreatic triacylglycerol lipase (PNLIP) DMY6FUD MA Inhibitor DMY6FUD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMY6FUD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMY6FUD DI DMY6FUD DMY6FUD DN (Hydroxyethyloxy)Tri(Ethyloxy)Octane DMY6FUD TI TTH0KSX DMY6FUD TN Rhodopsin (RHO) DMY6FUD MA Inhibitor DMY6FUD RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMY6FUD RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMY6GWF DI DMY6GWF DMY6GWF DN 4-(2,4-dichlorophenoxy)-3'-methylbiphenyl-3-ol DMY6GWF TI TTNX2CS DMY6GWF TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMY6GWF MA Inhibitor DMY6GWF RN Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier pr... Eur J Med Chem. 2009 Jul;44(7):3009-19. DMY6GWF RU https://pubmed.ncbi.nlm.nih.gov/19217192 DMY6K2A DI DMY6K2A DMY6K2A DN LA22-radioimmunoconjugates DMY6K2A TI TTGKNB4 DMY6K2A TN Epidermal growth factor receptor (EGFR) DMY6K2A MA Modulator DMY6K2A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797). DMY6K2A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1797 DMY6NID DI DMY6NID DMY6NID DN Des-AA1,2,5-[(NalphaMe)Cys3,D-Trp8,IAmp9]SRIF DMY6NID TI TTIND6G DMY6NID TN Somatostatin receptor type 1 (SSTR1) DMY6NID MA Inhibitor DMY6NID RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMY6NID RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMY6NIT DI DMY6NIT DMY6NIT DN 2-Phenyl-3-piperidin-3-yl-1H-indole DMY6NIT TI TTQ6VDM DMY6NIT TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMY6NIT MA Inhibitor DMY6NIT RN 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT(2A) receptor antagonists. J Med Chem. 2001 May 10;44(10):1603-14. DMY6NIT RU https://pubmed.ncbi.nlm.nih.gov/11334570 DMY6NRC DI DMY6NRC DMY6NRC DN Palodesangren D DMY6NRC TI TTS64P2 DMY6NRC TN Androgen receptor (AR) DMY6NRC MA Inhibitor DMY6NRC RN Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. J Nat Prod. 1997 Oct;60(10):997-1002. DMY6NRC RU https://pubmed.ncbi.nlm.nih.gov/9358642 DMY6PMJ DI DMY6PMJ DMY6PMJ DN ADC-9971 DMY6PMJ TI TTQDMX5 DMY6PMJ TN Prostaglandin D2 receptor 2 (PTGDR2) DMY6PMJ MA Antagonist DMY6PMJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339). DMY6PMJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=339 DMY6QOR DI DMY6QOR DMY6QOR DN KC-12291 DMY6QOR TI TTZOVE0 DMY6QOR TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMY6QOR MA Inhibitor DMY6QOR RN Sodium late current blockers in ischemia reperfusion: is the bullet magic J Med Chem. 2008 Jul 10;51(13):3856-66. DMY6QOR RU https://pubmed.ncbi.nlm.nih.gov/18529044 DMY6V9R DI DMY6V9R DMY6V9R DN Tyr-Pro-Phe-Phe-NHNH2 DMY6V9R TI TTKWM86 DMY6V9R TN Opioid receptor mu (MOP) DMY6V9R MA Inhibitor DMY6V9R RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMY6V9R RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMY6V9R DI DMY6V9R DMY6V9R DN Tyr-Pro-Phe-Phe-NHNH2 DMY6V9R TI TT27RFC DMY6V9R TN Opioid receptor delta (OPRD1) DMY6V9R MA Inhibitor DMY6V9R RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMY6V9R RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMY6Z0U DI DMY6Z0U DMY6Z0U DN N-hydroxy-3-(naphthalen-1-yl)acrylamide DMY6Z0U TI TTT6LFV DMY6Z0U TN Histone deacetylase 8 (HDAC8) DMY6Z0U MA Inhibitor DMY6Z0U RN Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. DMY6Z0U RU https://pubmed.ncbi.nlm.nih.gov/17346959 DMY7035 DI DMY7035 DMY7035 DN 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine DMY7035 TI TTK25J1 DMY7035 TN Adenosine A1 receptor (ADORA1) DMY7035 MA Inhibitor DMY7035 RN Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47. DMY7035 RU https://pubmed.ncbi.nlm.nih.gov/19072055 DMY7035 DI DMY7035 DMY7035 DN 4-(furan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine DMY7035 TI TTM2AOE DMY7035 TN Adenosine A2a receptor (ADORA2A) DMY7035 MA Inhibitor DMY7035 RN Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem. 2009 Jan 8;52(1):33-47. DMY7035 RU https://pubmed.ncbi.nlm.nih.gov/19072055 DMY729C DI DMY729C DMY729C DN NK314 DMY729C TI TTCGY2K DMY729C TN DNA topoisomerase II alpha (TOP2A) DMY729C MA Inhibitor DMY729C RN NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. DMY729C RU https://pubmed.ncbi.nlm.nih.gov/18596031 DMY782R DI DMY782R DMY782R DN 3-(2-methylbenzo[d]thiazol-5-yl)benzonitrile DMY782R TI TTHS256 DMY782R TN Metabotropic glutamate receptor 5 (mGluR5) DMY782R MA Inhibitor DMY782R RN Discovery of heterobicyclic templates for novel metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Jun 1;17(11):2987-91. DMY782R RU https://pubmed.ncbi.nlm.nih.gov/17446071 DMY7CN3 DI DMY7CN3 DMY7CN3 DN BODIPY-pirenzepine DMY7CN3 TI TTOXS3C DMY7CN3 TN Muscarinic acetylcholine receptor (CHRM) DMY7CN3 MA Antagonist DMY7CN3 RN Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. J Biol Chem. 2009 Jul 17;284(29):19533-43. DMY7CN3 RU https://pubmed.ncbi.nlm.nih.gov/19451648 DMY7EAF DI DMY7EAF DMY7EAF DN NSC-637991 DMY7EAF TI TTJLP0R DMY7EAF TN Quinone reductase 2 (NQO2) DMY7EAF MA Inhibitor DMY7EAF RN Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett. 2010 May 1;20(9):2832-6. DMY7EAF RU https://pubmed.ncbi.nlm.nih.gov/20356739 DMY7IVZ DI DMY7IVZ DMY7IVZ DN Seco-exiguamine DMY7IVZ TI TTZJYKH DMY7IVZ TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMY7IVZ MA Inhibitor DMY7IVZ RN Biomimetic synthesis of the IDO inhibitors exiguamine A and B. Nat Chem Biol. 2008 Sep;4(9):535-7. DMY7IVZ RU https://pubmed.ncbi.nlm.nih.gov/18677305 DMY7RM8 DI DMY7RM8 DMY7RM8 DN 2-Butyl-1(3)H-anthra[1,2-d]imidazole-6,11-dione DMY7RM8 TI TTQY2EJ DMY7RM8 TN TERT messenger RNA (TERT mRNA) DMY7RM8 MA Inhibitor DMY7RM8 RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMY7RM8 RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMY7TDZ DI DMY7TDZ DMY7TDZ DN 1-(4-aminophenyl)-2-pyrrolidin-1-yl-pentan-1-one DMY7TDZ TI TTVBI8W DMY7TDZ TN Dopamine transporter (DAT) DMY7TDZ MA Inhibitor DMY7TDZ RN A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone. Bioorg Med Chem. 2009 Jun 1;17(11):3770-4. DMY7TDZ RU https://pubmed.ncbi.nlm.nih.gov/19442525 DMY7W2U DI DMY7W2U DMY7W2U DN PMID12127536C20 DMY7W2U TI TTKEPHX DMY7W2U TN Granzyme B (GZMB) DMY7W2U MA Inhibitor DMY7W2U RN Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg Med Chem Lett. 2002 Aug 19;12(16):2197-200. DMY7W2U RU https://pubmed.ncbi.nlm.nih.gov/12127536 DMY87QX DI DMY87QX DMY87QX DN ISIS 102668 DMY87QX TI TT5U49F DMY87QX TN PRKACA messenger RNA (PRKACA mRNA) DMY87QX RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMY87QX RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMY8GZP DI DMY8GZP DMY8GZP DN 2-(4-Bromo-3-phenoxy-benzoylamino)-benzoic acid DMY8GZP TI TTRVTMX DMY8GZP TN Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH) DMY8GZP MA Inhibitor DMY8GZP RN Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial age... J Med Chem. 2005 Mar 10;48(5):1596-609. DMY8GZP RU https://pubmed.ncbi.nlm.nih.gov/15743201 DMY8IOP DI DMY8IOP DMY8IOP DN 3,6,9,12,15-Pentaoxaheptadecane DMY8IOP TI TT1RS9F DMY8IOP TN Acetylcholinesterase (AChE) DMY8IOP MA Inhibitor DMY8IOP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMY8IOP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMY8IOP DI DMY8IOP DMY8IOP DN 3,6,9,12,15-Pentaoxaheptadecane DMY8IOP TI TTWQM3J DMY8IOP TN Kynureninase (KYNU) DMY8IOP MA Inhibitor DMY8IOP RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMY8IOP RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMY8LBO DI DMY8LBO DMY8LBO DN Ceplene/Peg-Intron/Rebetol DMY8LBO TI TTSYFMA DMY8LBO TN Interferon alpha/beta receptor 1 (IFNAR1) DMY8LBO MA Modulator DMY8LBO RN Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase. Antivir Ther. 2012;17(3):411-23. DMY8LBO RU https://pubmed.ncbi.nlm.nih.gov/22402762 DMY8LDT DI DMY8LDT DMY8LDT DN 2,6-di-t-butylphenol DMY8LDT TI TTANPDJ DMY8LDT TN Carbonic anhydrase II (CA-II) DMY8LDT MA Inhibitor DMY8LDT RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMY8LDT RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMY8O0B DI DMY8O0B DMY8O0B DN CP-320626 DMY8O0B TI TTTSOUD DMY8O0B TN Candida Cytochrome P450 51 (Candi ERG11) DMY8O0B MA Inhibitor DMY8O0B RN Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500. DMY8O0B RU https://pubmed.ncbi.nlm.nih.gov/17194716 DMY8RT9 DI DMY8RT9 DMY8RT9 DN NCGC00167772-01 DMY8RT9 TI TTTN5QW DMY8RT9 TN Serine/threonine-protein kinase pim-1 (PIM1) DMY8RT9 MA Inhibitor DMY8RT9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2158). DMY8RT9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2158 DMY8S94 DI DMY8S94 DMY8S94 DN 3,3-Diethyl-1-o-tolylazetidine-2,4-dione DMY8S94 TI TTPLTSQ DMY8S94 TN Neutrophil elastase (NE) DMY8S94 MA Inhibitor DMY8S94 RN 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. DMY8S94 RU https://pubmed.ncbi.nlm.nih.gov/19904934 DMY8TLO DI DMY8TLO DMY8TLO DN 4-Bromo-2,6-diisopropyl-phenol DMY8TLO TI TTNJYV2 DMY8TLO TN Gamma-aminobutyric acid receptor (GAR) DMY8TLO MA Inhibitor DMY8TLO RN Propofol analogues. Synthesis, relationships between structure and affinity at GABAA receptor in rat brain, and differential electrophysiological p... J Med Chem. 1998 May 21;41(11):1846-54. DMY8TLO RU https://pubmed.ncbi.nlm.nih.gov/9599235 DMY8W0K DI DMY8W0K DMY8W0K DN 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMY8W0K TI TTLD29N DMY8W0K TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMY8W0K MA Inhibitor DMY8W0K RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMY8W0K RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMY8W0K DI DMY8W0K DMY8W0K DN 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMY8W0K TI TTN9D8E DMY8W0K TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMY8W0K MA Inhibitor DMY8W0K RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMY8W0K RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMY8W0K DI DMY8W0K DMY8W0K DN 8-Ethyl-3-hydroxy-1H-benzo[b]azepine-2,5-dione DMY8W0K TI TTKJEMQ DMY8W0K TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMY8W0K MA Inhibitor DMY8W0K RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMY8W0K RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMY8ZLM DI DMY8ZLM DMY8ZLM DN 4-Pyridin-2-yl-5-quinolin-2-yl-thiazol-2-ylamine DMY8ZLM TI TTP4520 DMY8ZLM TN TGF-beta receptor type I (TGFBR1) DMY8ZLM MA Inhibitor DMY8ZLM RN Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem. 2004 Aug 26;47(18):4494-506. DMY8ZLM RU https://pubmed.ncbi.nlm.nih.gov/15317461 DMY93GJ DI DMY93GJ DMY93GJ DN PF-592379 DMY93GJ TI TTE0A2F DMY93GJ TN Dopamine D4 receptor (D4R) DMY93GJ MA Agonist DMY93GJ RN Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol. 2012 Jun;23(3):280-91. DMY93GJ RU https://pubmed.ncbi.nlm.nih.gov/22470105 DMY93GJ DI DMY93GJ DMY93GJ DN PF-592379 DMY93GJ TI TT4C8EA DMY93GJ TN Dopamine D3 receptor (D3R) DMY93GJ MA Agonist DMY93GJ RN Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol. 2012 Jun;23(3):280-91. DMY93GJ RU https://pubmed.ncbi.nlm.nih.gov/22470105 DMY96KO DI DMY96KO DMY96KO DN EXRD-4605 DMY96KO TI TT7WVHI DMY96KO TN Soluble epoxide hydrolase (EPHX2) DMY96KO MA Inhibitor DMY96KO RN Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice. J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301. DMY96KO RU https://pubmed.ncbi.nlm.nih.gov/23232840 DMY971M DI DMY971M DMY971M DN PMID30247903-Compound-General structure43 DMY971M TI TT23XQV DMY971M TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMY971M MA Inhibitor DMY971M RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMY971M RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMY97TN DI DMY97TN DMY97TN DN H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2 DMY97TN TI TTKWM86 DMY97TN TN Opioid receptor mu (MOP) DMY97TN MA Inhibitor DMY97TN RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMY97TN RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMY97TN DI DMY97TN DMY97TN DN H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2 DMY97TN TI TT27RFC DMY97TN TN Opioid receptor delta (OPRD1) DMY97TN MA Inhibitor DMY97TN RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMY97TN RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMY9ERA DI DMY9ERA DMY9ERA DN 2-Phenyl-6-propyl-chromen-4-one DMY9ERA TI TTNJYV2 DMY9ERA TN Gamma-aminobutyric acid receptor (GAR) DMY9ERA MA Inhibitor DMY9ERA RN Refinement and evaluation of a pharmacophore model for flavone derivatives binding to the benzodiazepine site of the GABA(A) receptor. J Med Chem. 2002 Sep 12;45(19):4188-201. DMY9ERA RU https://pubmed.ncbi.nlm.nih.gov/12213060 DMY9FDT DI DMY9FDT DMY9FDT DN 2'-Deoxyguanosine-5'-Monophosphate DMY9FDT TI TTU6BFZ DMY9FDT TN Candida Thymidylate synthase (Candi TMP1) DMY9FDT MA Inhibitor DMY9FDT RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMY9FDT RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMY9HO8 DI DMY9HO8 DMY9HO8 DN N-(2-amino-5-(furan-2-yl)phenyl)benzamide DMY9HO8 TI TTSHTOI DMY9HO8 TN Histone deacetylase 2 (HDAC2) DMY9HO8 MA Inhibitor DMY9HO8 RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMY9HO8 RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMY9IK8 DI DMY9IK8 DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide DMY9IK8 TI TT5ZKDI DMY9IK8 TN Histone deacetylase 6 (HDAC6) DMY9IK8 MA Inhibitor DMY9IK8 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DMY9IK8 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DMY9IK8 DI DMY9IK8 DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide DMY9IK8 TI TT6R7JZ DMY9IK8 TN Histone deacetylase 1 (HDAC1) DMY9IK8 MA Inhibitor DMY9IK8 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DMY9IK8 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DMY9IK8 DI DMY9IK8 DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide DMY9IK8 TI TTTQGH8 DMY9IK8 TN Histone deacetylase 4 (HDAC4) DMY9IK8 MA Inhibitor DMY9IK8 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DMY9IK8 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DMY9IK8 DI DMY9IK8 DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide DMY9IK8 TI TTBH0VX DMY9IK8 TN Histone deacetylase (HDAC) DMY9IK8 MA Inhibitor DMY9IK8 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DMY9IK8 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DMY9IK8 DI DMY9IK8 DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide DMY9IK8 TI TTT6LFV DMY9IK8 TN Histone deacetylase 8 (HDAC8) DMY9IK8 MA Inhibitor DMY9IK8 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DMY9IK8 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DMY9IK8 DI DMY9IK8 DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide DMY9IK8 TI TTSHTOI DMY9IK8 TN Histone deacetylase 2 (HDAC2) DMY9IK8 MA Inhibitor DMY9IK8 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DMY9IK8 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DMY9IK8 DI DMY9IK8 DMY9IK8 DN 6-benzenesulfonylhexanoic acid hydroxamide DMY9IK8 TI TTYHPU6 DMY9IK8 TN Histone deacetylase 10 (HDAC10) DMY9IK8 MA Inhibitor DMY9IK8 RN Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides. J Med Chem. 2006 Jan 26;49(2):800-5. DMY9IK8 RU https://pubmed.ncbi.nlm.nih.gov/16420064 DMY9NIJ DI DMY9NIJ DMY9NIJ DN Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 DMY9NIJ TI TTKWM86 DMY9NIJ TN Opioid receptor mu (MOP) DMY9NIJ MA Inhibitor DMY9NIJ RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMY9NIJ RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMY9NIJ DI DMY9NIJ DMY9NIJ DN Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 DMY9NIJ TI TTVFO0U DMY9NIJ TN Gastrin/cholecystokinin type B receptor (CCKBR) DMY9NIJ MA Inhibitor DMY9NIJ RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMY9NIJ RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMY9NIJ DI DMY9NIJ DMY9NIJ DN Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 DMY9NIJ TI TT27RFC DMY9NIJ TN Opioid receptor delta (OPRD1) DMY9NIJ MA Inhibitor DMY9NIJ RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMY9NIJ RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMY9P6E DI DMY9P6E DMY9P6E DN calindol DMY9P6E TI TTBUYHA DMY9P6E TN Extracellular calcium-sensing receptor (CASR) DMY9P6E MA Modulator (allosteric modulator) DMY9P6E RN N2-benzyl-N1-(1-(1-naphthyl)ethyl)-3-phenylpropane-1,2-diamines and conformationally restrained indole analogues: development of calindol as a new calcimimetic acting at the calcium sensing receptor.Bioorg Med Chem Lett. 2004 Jun 21;14(12):3345-9. DMY9P6E RU https://pubmed.ncbi.nlm.nih.gov/15149704 DMY9P6E DI DMY9P6E DMY9P6E DN calindol DMY9P6E TI TTI1PRE DMY9P6E TN G-protein coupled receptor GPCR33 (GPRC6A) DMY9P6E MA Modulator (allosteric modulator) DMY9P6E RN Molecular determinants of non-competitive antagonist binding to the mouse GPRC6A receptor. Cell Calcium. 2009 Nov-Dec;46(5-6):323-32. DMY9P6E RU https://pubmed.ncbi.nlm.nih.gov/19836834 DMY9P85 DI DMY9P85 DMY9P85 DN RU-43044 DMY9P85 TI TTOZRK6 DMY9P85 TN Glucocorticoid receptor messenger RNA (GCR mRNA) DMY9P85 MA Inhibitor DMY9P85 RN Virtual screening for the identification of novel nonsteroidal glucocorticoid modulators. J Med Chem. 2010 Apr 22;53(8):3065-74. DMY9P85 RU https://pubmed.ncbi.nlm.nih.gov/20334371 DMY9P85 DI DMY9P85 DMY9P85 DN RU-43044 DMY9P85 TI TTKPW01 DMY9P85 TN Androgen receptor messenger RNA (AR mRNA) DMY9P85 MA Inhibitor DMY9P85 RN Discovery of potent, nonsteroidal, and highly selective glucocorticoid receptor antagonists. J Med Chem. 2002 Jun 6;45(12):2417-24. DMY9P85 RU https://pubmed.ncbi.nlm.nih.gov/12036351 DMY9WTE DI DMY9WTE DMY9WTE DN LY303336 DMY9WTE TI TT8DBY3 DMY9WTE TN Angiotensin II receptor type-1 (AGTR1) DMY9WTE MA Antagonist DMY9WTE RN Inhibition of angiotensin II-induced inositol phosphate production by triacid nonpeptide antagonists in CHO cells expressing human AT1 receptors. Pharm Res. 2000 Dec;17(12):1482-8. DMY9WTE RU https://pubmed.ncbi.nlm.nih.gov/11303957 DMY9ZT8 DI DMY9ZT8 DMY9ZT8 DN 15(R)-15-methyl-PGD2 DMY9ZT8 TI TTQDMX5 DMY9ZT8 TN Prostaglandin D2 receptor 2 (PTGDR2) DMY9ZT8 MA Agonist DMY9ZT8 RN CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. DMY9ZT8 RU https://pubmed.ncbi.nlm.nih.gov/16256979 DMYA25G DI DMYA25G DMYA25G DN 1,5-Dihydro-imidazo[2,1-b]quinazolin-2-one DMYA25G TI TT06AWU DMYA25G TN Phosphodiesterase 3A (PDE3A) DMYA25G MA Inhibitor DMYA25G RN Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoim... J Med Chem. 1988 Nov;31(11):2136-45. DMYA25G RU https://pubmed.ncbi.nlm.nih.gov/2846839 DMYA4D2 DI DMYA4D2 DMYA4D2 DN 6-(3-aminopropyl)benzo[h]isoquinolin-1(2H)-one DMYA4D2 TI TTTU902 DMYA4D2 TN Checkpoint kinase-1 (CHK1) DMYA4D2 MA Inhibitor DMYA4D2 RN Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6280-5. DMYA4D2 RU https://pubmed.ncbi.nlm.nih.gov/17900896 DMYA50U DI DMYA50U DMYA50U DN Phloretin DMYA50U TI TTQEI32 DMYA50U TN Aquaporin-9 (AQP9) DMYA50U MA Inhibitor DMYA50U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 696). DMYA50U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=696 DMYA50U DI DMYA50U DMYA50U DN Phloretin DMYA50U TI TT8XNZ7 DMYA50U TN Chloride channel protein 3 (CLC-3) DMYA50U MA Blocker (channel blocker) DMYA50U RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 702). DMYA50U RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=702 DMYA50U DI DMYA50U DMYA50U DN Phloretin DMYA50U TI TT6XAGK DMYA50U TN Solute carrier family 23 member 1 (SLC23A1) DMYA50U MA Inhibitor DMYA50U RN A family of mammalian Na+-dependent L-ascorbic acid transporters. Nature. 1999 May 6;399(6731):70-5. DMYA50U RU https://pubmed.ncbi.nlm.nih.gov/10331392 DMYA5CB DI DMYA5CB DMYA5CB DN PP1-Pro-Phe-N-MeHis-LVA-Ile-Amp-(O) DMYA5CB TI TTB2MXP DMYA5CB TN Angiotensinogenase renin (REN) DMYA5CB MA Inhibitor DMYA5CB RN Renin inhibitory peptides. Incorporation of polar, hydrophilic end groups into an active renin inhibitory peptide template and their evaluation in ... J Med Chem. 1991 Feb;34(2):633-42. DMYA5CB RU https://pubmed.ncbi.nlm.nih.gov/1995887 DMYAB79 DI DMYAB79 DMYAB79 DN NH-3 DMYAB79 TI TTQWUPT DMYAB79 TN Thyroid hormone receptor (THR) DMYAB79 MA Antagonist DMYAB79 RN Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73. DMYAB79 RU https://pubmed.ncbi.nlm.nih.gov/12650702 DMYACO7 DI DMYACO7 DMYACO7 DN 3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DMYACO7 TI TTF10I9 DMYACO7 TN Nitric-oxide synthase inducible (NOS2) DMYACO7 MA Inhibitor DMYACO7 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMYACO7 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMYACO7 DI DMYACO7 DMYACO7 DN 3-Propyl-[1,4]thiazepan-(5E)-ylideneamine DMYACO7 TI TTZUFI5 DMYACO7 TN Nitric-oxide synthase brain (NOS1) DMYACO7 MA Inhibitor DMYACO7 RN Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases. Bioorg Med Chem Lett. 2004 Dec 6;14(23):5907-11. DMYACO7 RU https://pubmed.ncbi.nlm.nih.gov/15501067 DMYAHU3 DI DMYAHU3 DMYAHU3 DN MRS1065 DMYAHU3 TI TTNE7KG DMYAHU3 TN Adenosine A2b receptor (ADORA2B) DMYAHU3 MA Antagonist DMYAHU3 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMYAHU3 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMYAHU3 DI DMYAHU3 DMYAHU3 DN MRS1065 DMYAHU3 TI TTK25J1 DMYAHU3 TN Adenosine A1 receptor (ADORA1) DMYAHU3 MA Antagonist DMYAHU3 RN Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists. J Med Chem. 1996 Jun 7;39(12):2293-301. DMYAHU3 RU https://pubmed.ncbi.nlm.nih.gov/8691424 DMYAJCG DI DMYAJCG DMYAJCG DN Deoxy-Bigchap DMYAJCG TI TTJ584C DMYAJCG TN Peroxisome proliferator-activated receptor alpha (PPARA) DMYAJCG MA Inhibitor DMYAJCG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYAJCG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYAJQU DI DMYAJQU DMYAJQU DN (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine DMYAJQU TI TT4TQBX DMYAJQU TN Extracellular signal-regulated kinase 2 (ERK2) DMYAJQU MA Inhibitor DMYAJQU RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMYAJQU RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMYALON DI DMYALON DMYALON DN (2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine DMYALON TI TT0K1SC DMYALON TN 5-HT 2B receptor (HTR2B) DMYALON MA Inhibitor DMYALON RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMYALON RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMYALON DI DMYALON DMYALON DN (2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine DMYALON TI TTJQOD7 DMYALON TN 5-HT 2A receptor (HTR2A) DMYALON MA Inhibitor DMYALON RN 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem. 2006 Jan 12;49(1):318-28. DMYALON RU https://pubmed.ncbi.nlm.nih.gov/16392816 DMYALON DI DMYALON DMYALON DN (2S)-1-(6-methoxy-1H-indazol-1-yl)propan-2-amine DMYALON TI TTWJBZ5 DMYALON TN 5-HT 2C receptor (HTR2C) DMYALON MA Inhibitor DMYALON RN Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor a... Bioorg Med Chem. 2008 Feb 15;16(4):1966-82. DMYALON RU https://pubmed.ncbi.nlm.nih.gov/18035544 DMYAPG5 DI DMYAPG5 DMYAPG5 DN BMS-687453 DMYAPG5 TI TTJ584C DMYAPG5 TN Peroxisome proliferator-activated receptor alpha (PPARA) DMYAPG5 MA Inhibitor DMYAPG5 RN Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol... J Med Chem. 2010 Apr 8;53(7):2854-64. DMYAPG5 RU https://pubmed.ncbi.nlm.nih.gov/20218621 DMYAPLT DI DMYAPLT DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate DMYAPLT TI TTZA1NY DMYAPLT TN GABA(A) receptor beta-2 (GABRB2) DMYAPLT MA Inhibitor DMYAPLT RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMYAPLT RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMYAPLT DI DMYAPLT DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate DMYAPLT TI TT1MPAY DMYAPLT TN GABA(A) receptor alpha-1 (GABRA1) DMYAPLT MA Inhibitor DMYAPLT RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMYAPLT RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMYAPLT DI DMYAPLT DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate DMYAPLT TI TTNZPQ1 DMYAPLT TN GABA(A) receptor alpha-5 (GABRA5) DMYAPLT MA Inhibitor DMYAPLT RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMYAPLT RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMYAPLT DI DMYAPLT DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate DMYAPLT TI TT37EDJ DMYAPLT TN GABA(A) receptor alpha-3 (GABRA3) DMYAPLT MA Inhibitor DMYAPLT RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMYAPLT RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMYAPLT DI DMYAPLT DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate DMYAPLT TI TTNJYV2 DMYAPLT TN Gamma-aminobutyric acid receptor (GAR) DMYAPLT MA Inhibitor DMYAPLT RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMYAPLT RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMYAPLT DI DMYAPLT DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate DMYAPLT TI TT06RH5 DMYAPLT TN GABA(A) receptor gamma-2 (GABRG2) DMYAPLT MA Inhibitor DMYAPLT RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMYAPLT RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMYAPLT DI DMYAPLT DMYAPLT DN 5-[(1S)-1-ammonioethyl]isoxazol-3-olate DMYAPLT TI TTBMV1G DMYAPLT TN GABA(A) receptor alpha-2 (GABRA2) DMYAPLT MA Inhibitor DMYAPLT RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMYAPLT RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMYAS2V DI DMYAS2V DMYAS2V DN 6-(4-Methylpiperazin-1-yl)pyrimidine-2,4-diamine DMYAS2V TI TTXJ178 DMYAS2V TN Histamine H4 receptor (H4R) DMYAS2V MA Inhibitor DMYAS2V RN 2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization. Bioorg Med Chem. 2009 Oct 15;17(20):7186-96. DMYAS2V RU https://pubmed.ncbi.nlm.nih.gov/19773175 DMYB2EZ DI DMYB2EZ DMYB2EZ DN NPRx-30 DMYB2EZ TI TT1RS9F DMYB2EZ TN Acetylcholinesterase (AChE) DMYB2EZ MA Modulator DMYB2EZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465). DMYB2EZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2465 DMYBC24 DI DMYBC24 DMYBC24 DN (R)-1-(1H-indazol-4-yl)-3-(1-p-tolylethyl)urea DMYBC24 TI TTMI6F5 DMYBC24 TN Transient receptor potential cation channel V1 (TRPV1) DMYBC24 MA Inhibitor DMYBC24 RN Alpha-methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher effic... Bioorg Med Chem Lett. 2007 Jul 15;17(14):3894-9. DMYBC24 RU https://pubmed.ncbi.nlm.nih.gov/17507218 DMYBCEG DI DMYBCEG DMYBCEG DN S-P-Nitrobenzyloxycarbonylglutathione DMYBCEG TI TTV9A7R DMYBCEG TN Lactoylglutathione lyase (GLO1) DMYBCEG MA Inhibitor DMYBCEG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYBCEG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYBH91 DI DMYBH91 DMYBH91 DN Propan-2-one O-4-(nonyloxy)phenylcarbamoyl oxime DMYBH91 TI TTDP1UC DMYBH91 TN Fatty acid amide hydrolase (FAAH) DMYBH91 MA Inhibitor DMYBH91 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMYBH91 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMYBJ4K DI DMYBJ4K DMYBJ4K DN joro toxin DMYBJ4K TI TTPJR0G DMYBJ4K TN Glutamate receptor AMPA 4 (GRIA4) DMYBJ4K MA Blocker (channel blocker) DMYBJ4K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447). DMYBJ4K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=447 DMYBJ4K DI DMYBJ4K DMYBJ4K DN joro toxin DMYBJ4K TI TTVPQTF DMYBJ4K TN Glutamate receptor AMPA 1 (GRIA1) DMYBJ4K MA Blocker (channel blocker) DMYBJ4K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444). DMYBJ4K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=444 DMYBJ4K DI DMYBJ4K DMYBJ4K DN joro toxin DMYBJ4K TI TT82EZV DMYBJ4K TN Glutamate receptor AMPA 3 (GRIA3) DMYBJ4K MA Blocker (channel blocker) DMYBJ4K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446). DMYBJ4K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=446 DMYBL5G DI DMYBL5G DMYBL5G DN CZC-19091 DMYBL5G TI TTHBTOP DMYBL5G TN PI3-kinase gamma (PIK3CG) DMYBL5G MA Inhibitor DMYBL5G RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2156). DMYBL5G RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2156 DMYBNCO DI DMYBNCO DMYBNCO DN 7-bromo-1H-indazole DMYBNCO TI TTZUFI5 DMYBNCO TN Nitric-oxide synthase brain (NOS1) DMYBNCO MA Inhibitor DMYBNCO RN 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3177-80. DMYBNCO RU https://pubmed.ncbi.nlm.nih.gov/17395463 DMYBPFS DI DMYBPFS DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide DMYBPFS TI TTBH0VX DMYBPFS TN Histone deacetylase (HDAC) DMYBPFS MA Inhibitor DMYBPFS RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMYBPFS RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMYBPFS DI DMYBPFS DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide DMYBPFS TI TTTQGH8 DMYBPFS TN Histone deacetylase 4 (HDAC4) DMYBPFS MA Inhibitor DMYBPFS RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMYBPFS RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMYBPFS DI DMYBPFS DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide DMYBPFS TI TT5ZKDI DMYBPFS TN Histone deacetylase 6 (HDAC6) DMYBPFS MA Inhibitor DMYBPFS RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMYBPFS RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMYBPFS DI DMYBPFS DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide DMYBPFS TI TT6R7JZ DMYBPFS TN Histone deacetylase 1 (HDAC1) DMYBPFS MA Inhibitor DMYBPFS RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMYBPFS RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMYBPFS DI DMYBPFS DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide DMYBPFS TI TTT6LFV DMYBPFS TN Histone deacetylase 8 (HDAC8) DMYBPFS MA Inhibitor DMYBPFS RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMYBPFS RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMYBPFS DI DMYBPFS DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide DMYBPFS TI TTYHPU6 DMYBPFS TN Histone deacetylase 10 (HDAC10) DMYBPFS MA Inhibitor DMYBPFS RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMYBPFS RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMYBPFS DI DMYBPFS DMYBPFS DN 4-Benzoylamino-N-hydroxy-benzamide DMYBPFS TI TTSHTOI DMYBPFS TN Histone deacetylase 2 (HDAC2) DMYBPFS MA Inhibitor DMYBPFS RN Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. J Med Chem. 2005 Aug 25;48(17):5530-5. DMYBPFS RU https://pubmed.ncbi.nlm.nih.gov/16107152 DMYBPGA DI DMYBPGA DMYBPGA DN 8-aza-11-deoxyprostaglandin E1 DMYBPGA TI TT79WV3 DMYBPGA TN Prostaglandin E2 receptor EP4 (PTGER4) DMYBPGA MA Inhibitor DMYBPGA RN Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents. J Med Chem. 2004 Dec 2;47(25):6124-7. DMYBPGA RU https://pubmed.ncbi.nlm.nih.gov/15566283 DMYBQM7 DI DMYBQM7 DMYBQM7 DN PNU-120596 DMYBQM7 TI TTLA931 DMYBQM7 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMYBQM7 MA Modulator (allosteric modulator) DMYBQM7 RN A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci. 2005 Apr 27;25(17):4396-405. DMYBQM7 RU https://pubmed.ncbi.nlm.nih.gov/15858066 DMYBQN9 DI DMYBQN9 DMYBQN9 DN FP0429 DMYBQN9 TI TTICZ1O DMYBQN9 TN Metabotropic glutamate receptor 4 (mGluR4) DMYBQN9 MA Agonist DMYBQN9 RN Amino-pyrrolidine tricarboxylic acids give new insight into group III metabotropic glutamate receptor activation mechanism. Mol Pharmacol. 2007 Mar;71(3):704-12. DMYBQN9 RU https://pubmed.ncbi.nlm.nih.gov/17167031 DMYBQOG DI DMYBQOG DMYBQOG DN [125I]-BDZ2 DMYBQOG TI TTVFO0U DMYBQOG TN Gastrin/cholecystokinin type B receptor (CCKBR) DMYBQOG MA Antagonist DMYBQOG RN Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. J Med Chem. 2009 Apr 9;52(7):2138-47. DMYBQOG RU https://pubmed.ncbi.nlm.nih.gov/19271701 DMYBV8Q DI DMYBV8Q DMYBV8Q DN PMID21277783C7 DMYBV8Q TI TTSD9T1 DMYBV8Q TN Cathepsin V (CTSV) DMYBV8Q MA Inhibitor DMYBV8Q RN Acridone alkaloids as potent inhibitors of cathepsin V. Bioorg Med Chem. 2011 Feb 15;19(4):1477-81. DMYBV8Q RU https://pubmed.ncbi.nlm.nih.gov/21277783 DMYBWXR DI DMYBWXR DMYBWXR DN NCX-125 DMYBWXR TI TTT2ZAR DMYBWXR TN Prostaglandin F2-alpha receptor (PTGFR) DMYBWXR MA Modulator DMYBWXR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 344). DMYBWXR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=344 DMYBXHF DI DMYBXHF DMYBXHF DN (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid DMYBXHF TI TTZMAO3 DMYBXHF TN Peroxisome proliferator-activated receptor gamma (PPAR-gamma) DMYBXHF MA Inhibitor DMYBXHF RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYBXHF RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYC1DW DI DMYC1DW DMYC1DW DN CVT-6694 DMYC1DW TI TTNE7KG DMYC1DW TN Adenosine A2b receptor (ADORA2B) DMYC1DW MA Inhibitor DMYC1DW RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMYC1DW RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMYC1T6 DI DMYC1T6 DMYC1T6 DN 4-AMINOPHENOL DMYC1T6 TI TTUNARX DMYC1T6 TN Carbonic anhydrase (CA) DMYC1T6 MA Inhibitor DMYC1T6 RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMYC1T6 RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMYC1T6 DI DMYC1T6 DMYC1T6 DN 4-AMINOPHENOL DMYC1T6 TI TTEYTKG DMYC1T6 TN Carbonic anhydrase XIV (CA-XIV) DMYC1T6 MA Inhibitor DMYC1T6 RN Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem. 2008 Aug 1;16(15):7424-8. DMYC1T6 RU https://pubmed.ncbi.nlm.nih.gov/18579385 DMYC51H DI DMYC51H DMYC51H DN PD 128907 DMYC51H TI TTEX248 DMYC51H TN Dopamine D2 receptor (D2R) DMYC51H MA Agonist DMYC51H RN Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66. DMYC51H RU https://pubmed.ncbi.nlm.nih.gov/8531103 DMYC51H DI DMYC51H DMYC51H DN PD 128907 DMYC51H TI TT4C8EA DMYC51H TN Dopamine D3 receptor (D3R) DMYC51H MA Agonist DMYC51H RN Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther. 1995 Dec;275(3):1355-66. DMYC51H RU https://pubmed.ncbi.nlm.nih.gov/8531103 DMYC7AK DI DMYC7AK DMYC7AK DN L-163,101 DMYC7AK TI TT8DBY3 DMYC7AK TN Angiotensin II receptor type-1 (AGTR1) DMYC7AK MA Agonist DMYC7AK RN Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor. Chem Biol. 1994 Dec;1(4):211-21. DMYC7AK RU https://pubmed.ncbi.nlm.nih.gov/9383393 DMYCENM DI DMYCENM DMYCENM DN 2-Bromo-N-(2-morpholinoethyl)nicotinamide DMYCENM TI TT3WG5C DMYCENM TN Monoamine oxidase type A (MAO-A) DMYCENM MA Inhibitor DMYCENM RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMYCENM RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMYCENM DI DMYCENM DMYCENM DN 2-Bromo-N-(2-morpholinoethyl)nicotinamide DMYCENM TI TTGP7BY DMYCENM TN Monoamine oxidase type B (MAO-B) DMYCENM MA Inhibitor DMYCENM RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMYCENM RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMYCHTD DI DMYCHTD DMYCHTD DN PHENMEDIPHAM DMYCHTD TI TTDP1UC DMYCHTD TN Fatty acid amide hydrolase (FAAH) DMYCHTD MA Inhibitor DMYCHTD RN Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inh... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6793-6. DMYCHTD RU https://pubmed.ncbi.nlm.nih.gov/19850474 DMYCKGH DI DMYCKGH DMYCKGH DN Biphenyl-3-ylcarbamic Acid Biphenyl-3-yl Ester DMYCKGH TI TTDP1UC DMYCKGH TN Fatty acid amide hydrolase (FAAH) DMYCKGH MA Inhibitor DMYCKGH RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMYCKGH RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMYCS0B DI DMYCS0B DMYCS0B DN ALTENUSIN DMYCS0B TI TTL53M6 DMYCS0B TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMYCS0B MA Inhibitor DMYCS0B RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMYCS0B RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMYCV7U DI DMYCV7U DMYCV7U DN N,O6-Disulfo-Glucosamine DMYCV7U TI TT4V2JM DMYCV7U TN Hepatocyte growth factor (HGF) DMYCV7U MA Inhibitor DMYCV7U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYCV7U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYCV7U DI DMYCV7U DMYCV7U DN N,O6-Disulfo-Glucosamine DMYCV7U TI TTMY81X DMYCV7U TN Heparin-binding growth factor 1 (FGF1) DMYCV7U MA Inhibitor DMYCV7U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYCV7U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYCV7U DI DMYCV7U DMYCV7U DN N,O6-Disulfo-Glucosamine DMYCV7U TI TTGKIED DMYCV7U TN Fibroblast growth factor-2 (FGF2) DMYCV7U MA Inhibitor DMYCV7U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYCV7U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYCV8E DI DMYCV8E DMYCV8E DN 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide DMYCV8E TI TTHQPL7 DMYCV8E TN Carbonic anhydrase I (CA-I) DMYCV8E MA Inhibitor DMYCV8E RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMYCV8E RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMYCV8E DI DMYCV8E DMYCV8E DN 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide DMYCV8E TI TT2LVK8 DMYCV8E TN Carbonic anhydrase IX (CA-IX) DMYCV8E MA Inhibitor DMYCV8E RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMYCV8E RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMYCV8E DI DMYCV8E DMYCV8E DN 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide DMYCV8E TI TTANPDJ DMYCV8E TN Carbonic anhydrase II (CA-II) DMYCV8E MA Inhibitor DMYCV8E RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMYCV8E RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMYCV8E DI DMYCV8E DMYCV8E DN 4-(N-Oxide-2-pyridylthio)pyridine-3-sulfonamide DMYCV8E TI TTSYM0R DMYCV8E TN Carbonic anhydrase XII (CA-XII) DMYCV8E MA Inhibitor DMYCV8E RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMYCV8E RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMYD4PC DI DMYD4PC DMYD4PC DN N-(4-Phenyl-pyridin-2-yl)-guanidine DMYD4PC TI TTXAGYU DMYD4PC TN Tissue-type plasminogen activator (PLAT) DMYD4PC MA Inhibitor DMYD4PC RN Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 1: 2-Pyridinylguanidines. Bioorg Med Chem Lett. 2002 Jan 21;12(2):181-4. DMYD4PC RU https://pubmed.ncbi.nlm.nih.gov/11755349 DMYD7P5 DI DMYD7P5 DMYD7P5 DN VER-54505 DMYD7P5 TI TT7HF4W DMYD7P5 TN Cyclin-dependent kinase 2 (CDK2) DMYD7P5 MA Inhibitor DMYD7P5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1973). DMYD7P5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1973 DMYD8GP DI DMYD8GP DMYD8GP DN 5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione DMYD8GP TI TTRK8B9 DMYD8GP TN Sodium channel unspecific (NaC) DMYD8GP MA Inhibitor DMYD8GP RN Sodium channel binding and anticonvulsant activities for the enantiomers of a bicyclic 2,4-oxazolidinedione and monocyclic models. J Med Chem. 1989 Jul;32(7):1577-80. DMYD8GP RU https://pubmed.ncbi.nlm.nih.gov/2544727 DMYD8GP DI DMYD8GP DMYD8GP DN 5-Ethyl-3-methyl-5-phenyl-oxazolidine-2,4-dione DMYD8GP TI TTAXZ0K DMYD8GP TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMYD8GP MA Inhibitor DMYD8GP RN Sodium channel binding and anticonvulsant activities for the enantiomers of a bicyclic 2,4-oxazolidinedione and monocyclic models. J Med Chem. 1989 Jul;32(7):1577-80. DMYD8GP RU https://pubmed.ncbi.nlm.nih.gov/2544727 DMYDG27 DI DMYDG27 DMYDG27 DN (R/S) EF-1500 DMYDG27 TI TTPRKM0 DMYDG27 TN GABA transporter GAT-1 (SLC6A1) DMYDG27 MA Inhibitor DMYDG27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 929). DMYDG27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=929 DMYDG27 DI DMYDG27 DMYDG27 DN (R/S) EF-1500 DMYDG27 TI TTQBMPI DMYDG27 TN Na(+)/Cl(-) betaine/GABA transporter (SLC6A12) DMYDG27 MA Inhibitor DMYDG27 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 932). DMYDG27 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=932 DMYDGA7 DI DMYDGA7 DMYDGA7 DN KOS1326 DMYDGA7 TI TT953CX DMYDGA7 TN Motilin receptor (MLNR) DMYDGA7 MA Agonist DMYDGA7 RN Desensitization of the human motilin receptor by motilides. J Pharmacol Exp Ther. 2005 Jun;313(3):1397-405. DMYDGA7 RU https://pubmed.ncbi.nlm.nih.gov/15764739 DMYDGAZ DI DMYDGAZ DMYDGAZ DN 1,2,3,7,12,12a-hexahydro-1-aza-pleiaden-5-ol DMYDGAZ TI TTZFYLI DMYDGAZ TN Dopamine D1 receptor (D1R) DMYDGAZ MA Inhibitor DMYDGAZ RN Advances in development of dopaminergic aporphinoids. J Med Chem. 2007 Jan 25;50(2):171-81. DMYDGAZ RU https://pubmed.ncbi.nlm.nih.gov/17228858 DMYDGCI DI DMYDGCI DMYDGCI DN Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine DMYDGCI TI TTZ97H5 DMYDGCI TN Phosphodiesterase 4A (PDE4A) DMYDGCI MA Inhibitor DMYDGCI RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMYDGCI RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMYDGCI DI DMYDGCI DMYDGCI DN Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine DMYDGCI TI TTVIAT9 DMYDGCI TN Phosphodiesterase 4B (PDE4B) DMYDGCI MA Inhibitor DMYDGCI RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMYDGCI RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMYDGCI DI DMYDGCI DMYDGCI DN Benzyl-(2-pyridin-3-yl-quinazolin-4-yl)-amine DMYDGCI TI TTJGW1Z DMYDGCI TN Phosphodiesterase 2A (PDE2A) DMYDGCI MA Inhibitor DMYDGCI RN Discovery of potent cyclic GMP phosphodiesterase inhibitors. 2-Pyridyl- and 2-imidazolylquinazolines possessing cyclic GMP phosphodiesterase and th... J Med Chem. 1995 Sep 1;38(18):3547-57. DMYDGCI RU https://pubmed.ncbi.nlm.nih.gov/7658441 DMYDGH4 DI DMYDGH4 DMYDGH4 DN 4-((1H-imidazol-1-yl)methyl)phenol DMYDGH4 TI TTRA5BZ DMYDGH4 TN Steroid 17-alpha-monooxygenase (S17AH) DMYDGH4 MA Inhibitor DMYDGH4 RN Synthesis and biochemical evaluation of a range of (4-substituted phenyl)sulfonate derivatives of 4-hydroxybenzyl imidazole-based compounds as pote... Bioorg Med Chem Lett. 2010 Sep 1;20(17):5345-8. DMYDGH4 RU https://pubmed.ncbi.nlm.nih.gov/20675132 DMYDHLN DI DMYDHLN DMYDHLN DN 6-(2-Bromo-benzenesulfonyl)-2H-pyridazin-3-one DMYDHLN TI TTFBNVI DMYDHLN TN Aldose reductase (AKR1B1) DMYDHLN MA Inhibitor DMYDHLN RN A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3... J Med Chem. 2005 Oct 6;48(20):6326-39. DMYDHLN RU https://pubmed.ncbi.nlm.nih.gov/16190759 DMYDR2N DI DMYDR2N DMYDR2N DN L-97-1 intravenous DMYDR2N TI TTK25J1 DMYDR2N TN Adenosine A1 receptor (ADORA1) DMYDR2N MA Modulator DMYDR2N RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 18). DMYDR2N RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18 DMYDRB7 DI DMYDRB7 DMYDRB7 DN Naphthalen-1-yl 10H-phenothiazine-10-carboxylate DMYDRB7 TI TTEB0GD DMYDRB7 TN Cholinesterase (BCHE) DMYDRB7 MA Inhibitor DMYDRB7 RN Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase. J Med Chem. 2008 Jul 24;51(14):4200-12. DMYDRB7 RU https://pubmed.ncbi.nlm.nih.gov/18570368 DMYDS5Z DI DMYDS5Z DMYDS5Z DN Sc-43077 DMYDS5Z TI TTSJIRP DMYDS5Z TN Connexin 32 messenger RNA (GJB1 mRNA) DMYDS5Z RN Connexin Antibodies. Report from santa cruz biotechnology, inc. Santa cruz biotechnology. 2009. DMYDS5Z RU http://www.scbt.com/table-connexin.html DMYDS6F DI DMYDS6F DMYDS6F DN (S,S)-oxandrine hydrochloride DMYDS6F TI TTZFYLI DMYDS6F TN Dopamine D1 receptor (D1R) DMYDS6F MA Inhibitor DMYDS6F RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMYDS6F RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMYDS6F DI DMYDS6F DMYDS6F DN (S,S)-oxandrine hydrochloride DMYDS6F TI TTEX248 DMYDS6F TN Dopamine D2 receptor (D2R) DMYDS6F MA Inhibitor DMYDS6F RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMYDS6F RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMYDTO8 DI DMYDTO8 DMYDTO8 DN CSNLSTCVLGKLSQELc[DKLHK]YPRTNTGSGTP-amide DMYDTO8 TI TTLWS2O DMYDTO8 TN Calcitonin receptor (CALCR) DMYDTO8 MA Inhibitor DMYDTO8 RN Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept fo... J Med Chem. 2002 Feb 28;45(5):1108-21. DMYDTO8 RU https://pubmed.ncbi.nlm.nih.gov/11855991 DMYDW6J DI DMYDW6J DMYDW6J DN PGD2 DMYDW6J TI TTNVEIR DMYDW6J TN Prostaglandin D2 receptor (PTGDR) DMYDW6J MA Agonist DMYDW6J RN A novel biological role for prostaglandin D2 is suggested by distribution studies of the rat DP prostanoid receptor. Eur J Pharmacol. 1999 Jul 14;377(1):101-15. DMYDW6J RU https://pubmed.ncbi.nlm.nih.gov/10448933 DMYDW6J DI DMYDW6J DMYDW6J DN PGD2 DMYDW6J TI TT79WV3 DMYDW6J TN Prostaglandin E2 receptor EP4 (PTGER4) DMYDW6J MA Agonist DMYDW6J RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMYDW6J RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMYDW6J DI DMYDW6J DMYDW6J DN PGD2 DMYDW6J TI TTQDMX5 DMYDW6J TN Prostaglandin D2 receptor 2 (PTGDR2) DMYDW6J MA Agonist DMYDW6J RN CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. DMYDW6J RU https://pubmed.ncbi.nlm.nih.gov/16256979 DMYDW6J DI DMYDW6J DMYDW6J DN PGD2 DMYDW6J TI TTT2ZAR DMYDW6J TN Prostaglandin F2-alpha receptor (PTGFR) DMYDW6J MA Agonist DMYDW6J RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMYDW6J RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMYDW6J DI DMYDW6J DMYDW6J DN PGD2 DMYDW6J TI TTG1QMU DMYDW6J TN Prostaglandin E2 receptor EP1 (PTGER1) DMYDW6J MA Agonist DMYDW6J RN Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47. DMYDW6J RU https://pubmed.ncbi.nlm.nih.gov/11999132 DMYDW6J DI DMYDW6J DMYDW6J DN PGD2 DMYDW6J TI TTPNGDE DMYDW6J TN Prostaglandin E2 receptor EP3 (PTGER3) DMYDW6J MA Agonist DMYDW6J RN Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. DMYDW6J RU https://pubmed.ncbi.nlm.nih.gov/9537820 DMYDW6J DI DMYDW6J DMYDW6J DN PGD2 DMYDW6J TI TT1ZAVI DMYDW6J TN Prostaglandin E2 receptor EP2 (PTGER2) DMYDW6J MA Agonist DMYDW6J RN Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999 Sep;56(3):545-51. DMYDW6J RU https://pubmed.ncbi.nlm.nih.gov/10462542 DMYDWH1 DI DMYDWH1 DMYDWH1 DN AZ13483342 DMYDWH1 TI TTX4RTB DMYDWH1 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMYDWH1 MA Antagonist DMYDWH1 RN Discovery of cyclopentane- and cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4232-41. DMYDWH1 RU https://pubmed.ncbi.nlm.nih.gov/17532215 DMYDX34 DI DMYDX34 DMYDX34 DN N-Hydroxy-2-naphthalen-2-yl-acetamide DMYDX34 TI TT2J34L DMYDX34 TN Arachidonate 5-lipoxygenase (5-LOX) DMYDX34 MA Inhibitor DMYDX34 RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMYDX34 RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMYE0MZ DI DMYE0MZ DMYE0MZ DN (+/-)-threo-N-Propargylmethylphenidate DMYE0MZ TI TTVBI8W DMYE0MZ TN Dopamine transporter (DAT) DMYE0MZ MA Inhibitor DMYE0MZ RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMYE0MZ RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMYE1P8 DI DMYE1P8 DMYE1P8 DN PT-114 DMYE1P8 TI TT84ETX DMYE1P8 TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMYE1P8 MA Inhibitor DMYE1P8 RN Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity r... J Med Chem. 1996 Oct 11;39(21):4261-74. DMYE1P8 RU https://pubmed.ncbi.nlm.nih.gov/8863804 DMYE1X2 DI DMYE1X2 DMYE1X2 DN 8-Methoxy-2-morpholin-4-yl-chromen-4-one DMYE1X2 TI TTK3PY9 DMYE1X2 TN DNA-dependent protein kinase catalytic (PRKDC) DMYE1X2 MA Inhibitor DMYE1X2 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMYE1X2 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMYE64O DI DMYE64O DMYE64O DN PMID9003518C4 DMYE64O TI TT7O8ZA DMYE64O TN Lanosterol synthase (LSS) DMYE64O MA Inhibitor DMYE64O RN Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9. DMYE64O RU https://pubmed.ncbi.nlm.nih.gov/9003518 DMYEC3M DI DMYEC3M DMYEC3M DN ISIS 2490 DMYEC3M TI TT7OU0X DMYEC3M TN Human papillomavirus-18 E6 region messenger RNA (HPV-18 E6 mRNA) DMYEC3M RN US patent application no. 5,457,189, Antisense oligonucleotide inhibition of papillomavirus. DMYEC3M RU http://www.patentbuddy.com/Patent/5457189?ft=true&sr=true DMYEFAV DI DMYEFAV DMYEFAV DN PD-135111 DMYEFAV TI TTEX248 DMYEFAV TN Dopamine D2 receptor (D2R) DMYEFAV MA Inhibitor DMYEFAV RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DMYEFAV RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DMYEGBC DI DMYEGBC DMYEGBC DN ISOLICOFLAVONOL DMYEGBC TI TTSZLWK DMYEGBC TN Aromatase (CYP19A1) DMYEGBC MA Inhibitor DMYEGBC RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DMYEGBC RU https://pubmed.ncbi.nlm.nih.gov/11678652 DMYEIRH DI DMYEIRH DMYEIRH DN 6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol DMYEIRH TI TTZAYWL DMYEIRH TN Estrogen receptor (ESR) DMYEIRH MA Inhibitor DMYEIRH RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMYEIRH RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMYEIRH DI DMYEIRH DMYEIRH DN 6-(4-Hydroxy-2-methyl-phenyl)-naphthalen-2-ol DMYEIRH TI TTOM3J0 DMYEIRH TN Estrogen receptor beta (ESR2) DMYEIRH MA Inhibitor DMYEIRH RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMYEIRH RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMYEMST DI DMYEMST DMYEMST DN ISIS 19676 DMYEMST TI TTWALCO DMYEMST TN HER4 messenger RNA (ERBB4 mRNA) DMYEMST RN US patent application no. 6,255,111, Antisense modulation of Her-4 expression. DMYEMST RU http://www.patentbuddy.com/Patent/6255111?ft=true&sr=true DMYEMWB DI DMYEMWB DMYEMWB DN PMID22533316C1 DMYEMWB TI TT7O8ZA DMYEMWB TN Lanosterol synthase (LSS) DMYEMWB MA Inhibitor DMYEMWB RN Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002. DMYEMWB RU https://pubmed.ncbi.nlm.nih.gov/22533316 DMYENI7 DI DMYENI7 DMYENI7 DN 1,1,1-Trifluoro-8-phenyl-octan-2-one DMYENI7 TI TTT1JVS DMYENI7 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMYENI7 MA Inhibitor DMYENI7 RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMYENI7 RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMYENI7 DI DMYENI7 DMYENI7 DN 1,1,1-Trifluoro-8-phenyl-octan-2-one DMYENI7 TI TTDP1UC DMYENI7 TN Fatty acid amide hydrolase (FAAH) DMYENI7 MA Inhibitor DMYENI7 RN Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as a... J Med Chem. 2005 Mar 24;48(6):1849-56. DMYENI7 RU https://pubmed.ncbi.nlm.nih.gov/15771430 DMYEPV8 DI DMYEPV8 DMYEPV8 DN ISIS 232828 DMYEPV8 TI TTNBTCW DMYEPV8 TN eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA) DMYEPV8 RN US patent application no. 7,468,431, Modulation of eIF4E-BP2 expression. DMYEPV8 RU http://www.patentbuddy.com/Patent/7468431?ft=true&sr=true DMYEQXH DI DMYEQXH DMYEQXH DN N-(quinolin-3-yl)-6-(sulfamoylamino)hexanamide DMYEQXH TI TT5ZKDI DMYEQXH TN Histone deacetylase 6 (HDAC6) DMYEQXH MA Inhibitor DMYEQXH RN Sulfamides as novel histone deacetylase inhibitors. Bioorg Med Chem Lett. 2009 Jan 15;19(2):336-40. DMYEQXH RU https://pubmed.ncbi.nlm.nih.gov/19084395 DMYERNM DI DMYERNM DMYERNM DN 5-methylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione DMYERNM TI TTVDSZ0 DMYERNM TN Poly [ADP-ribose] polymerase 1 (PARP1) DMYERNM MA Inhibitor DMYERNM RN Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors. Bioorg Med Chem Lett. 2006 Feb 15;16(4):938-42. DMYERNM RU https://pubmed.ncbi.nlm.nih.gov/16290935 DMYERNW DI DMYERNW DMYERNW DN 8-(1-Ethyl-propoxy)-quinolin-2-ylamine DMYERNW TI TTX4RTB DMYERNW TN Melanin-concentrating hormone receptor 1 (MCHR1) DMYERNW MA Inhibitor DMYERNW RN Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHr1 antagonists. Part 1. Bioorg Med Chem Lett. 2004 Oct 4;14(19):4873-7. DMYERNW RU https://pubmed.ncbi.nlm.nih.gov/15341942 DMYESXB DI DMYESXB DMYESXB DN 4-[2-(2-Thienyl)acetamido]benzenesulfonamide DMYESXB TI TTANPDJ DMYESXB TN Carbonic anhydrase II (CA-II) DMYESXB MA Inhibitor DMYESXB RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMYESXB RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMYESXB DI DMYESXB DMYESXB DN 4-[2-(2-Thienyl)acetamido]benzenesulfonamide DMYESXB TI TTHQPL7 DMYESXB TN Carbonic anhydrase I (CA-I) DMYESXB MA Inhibitor DMYESXB RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMYESXB RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMYESXB DI DMYESXB DMYESXB DN 4-[2-(2-Thienyl)acetamido]benzenesulfonamide DMYESXB TI TTUNARX DMYESXB TN Carbonic anhydrase (CA) DMYESXB MA Inhibitor DMYESXB RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMYESXB RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMYEWA4 DI DMYEWA4 DMYEWA4 DN 3-[3-Phenyl-indan-(1E)-ylidenemethyl]-pyridine DMYEWA4 TI TTSZLWK DMYEWA4 TN Aromatase (CYP19A1) DMYEWA4 MA Inhibitor DMYEWA4 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMYEWA4 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMYF243 DI DMYF243 DMYF243 DN N-Cyclohexyl-N'-(Propyl)Phenyl Urea DMYF243 TI TT7WVHI DMYF243 TN Soluble epoxide hydrolase (EPHX2) DMYF243 MA Inhibitor DMYF243 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYF243 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYF60K DI DMYF60K DMYF60K DN 6-Hydroxymethyl-7,8-Dihydropterin DMYF60K TI TT38ECI DMYF60K TN Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK) DMYF60K MA Inhibitor DMYF60K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYF60K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYF60K DI DMYF60K DMYF60K DN 6-Hydroxymethyl-7,8-Dihydropterin DMYF60K TI TTG9CFY DMYF60K TN Bacterial Dihydroneopterinaldolase (Bact folB) DMYF60K MA Inhibitor DMYF60K RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYF60K RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYF7AE DI DMYF7AE DMYF7AE DN JCF 109 DMYF7AE TI TTY6EWA DMYF7AE TN Neuropeptide Y receptor type 5 (NPY5R) DMYF7AE MA Antagonist DMYF7AE RN Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY. Br J Pharmacol. 2003 Aug;139(7):1360-8. DMYF7AE RU https://pubmed.ncbi.nlm.nih.gov/12890716 DMYF85Q DI DMYF85Q DMYF85Q DN [Sar9,Met(O2)11]-SP DMYF85Q TI TTZPO1L DMYF85Q TN Substance-P receptor (TACR1) DMYF85Q MA Inhibitor DMYF85Q RN cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8. DMYF85Q RU https://pubmed.ncbi.nlm.nih.gov/18983139 DMYF8ES DI DMYF8ES DMYF8ES DN 1-(2-bromoethyl)-1H-indole-2,3-dione DMYF8ES TI TTMF541 DMYF8ES TN Liver carboxylesterase (CES1) DMYF8ES MA Inhibitor DMYF8ES RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMYF8ES RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMYFAQV DI DMYFAQV DMYFAQV DN N-(pyridin-4-ylmethyl) estradiol-16-carboxamide DMYFAQV TI TTIWB6L DMYFAQV TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMYFAQV MA Inhibitor DMYFAQV RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMYFAQV RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMYFBRQ DI DMYFBRQ DMYFBRQ DN 1-(4-(methylsulfonyl)phenyl)-1H-pyrrole DMYFBRQ TI TTVKILB DMYFBRQ TN Prostaglandin G/H synthase 2 (COX-2) DMYFBRQ MA Inhibitor DMYFBRQ RN Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones. J Med Chem. 2010 Sep 23;53(18):6560-71. DMYFBRQ RU https://pubmed.ncbi.nlm.nih.gov/20804197 DMYFCB0 DI DMYFCB0 DMYFCB0 DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF DMYFCB0 TI TTAE1BR DMYFCB0 TN Somatostatin receptor type 4 (SSTR4) DMYFCB0 MA Inhibitor DMYFCB0 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMYFCB0 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMYFCB0 DI DMYFCB0 DMYFCB0 DN Des-AA1,2,5-[D-Nal8,IAmp9,(NalphaMe)Thr12]SRIF DMYFCB0 TI TTIND6G DMYFCB0 TN Somatostatin receptor type 1 (SSTR1) DMYFCB0 MA Inhibitor DMYFCB0 RN Somatostatin receptor 1 selective analogues: 2. N(alpha)-Methylated scan. J Med Chem. 2005 Jan 27;48(2):507-14. DMYFCB0 RU https://pubmed.ncbi.nlm.nih.gov/15658864 DMYFK4L DI DMYFK4L DMYFK4L DN Ethyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine DMYFK4L TI TTEX248 DMYFK4L TN Dopamine D2 receptor (D2R) DMYFK4L MA Inhibitor DMYFK4L RN Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity. J Med Chem. 1989 Oct;32(10):2388-96. DMYFK4L RU https://pubmed.ncbi.nlm.nih.gov/2571732 DMYFKID DI DMYFKID DMYFKID DN 1-(2-(naphthalen-2-yl)ethyl)pyrrolidine DMYFKID TI TT9JNIC DMYFKID TN Histamine H3 receptor (H3R) DMYFKID MA Inhibitor DMYFKID RN In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series. Bioorg Med Chem Lett. 2008 Jan 1;18(1):355-9. DMYFKID RU https://pubmed.ncbi.nlm.nih.gov/18077160 DMYFNW9 DI DMYFNW9 DMYFNW9 DN JATRORRHIZINE DMYFNW9 TI TTXV4FI DMYFNW9 TN Albendazole monooxygenase (CYP3A4) DMYFNW9 MA Inhibitor DMYFNW9 RN Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. J Nat Prod. 2007 Dec;70(12):1930-3. DMYFNW9 RU https://pubmed.ncbi.nlm.nih.gov/17994701 DMYFQDT DI DMYFQDT DMYFQDT DN 2-(tert-butylamino)-1-p-tolylpropan-1-one DMYFQDT TI TTAWNKZ DMYFQDT TN Norepinephrine transporter (NET) DMYFQDT MA Inhibitor DMYFQDT RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMYFQDT RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMYFQDT DI DMYFQDT DMYFQDT DN 2-(tert-butylamino)-1-p-tolylpropan-1-one DMYFQDT TI TTVBI8W DMYFQDT TN Dopamine transporter (DAT) DMYFQDT MA Inhibitor DMYFQDT RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMYFQDT RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMYG0M5 DI DMYG0M5 DMYG0M5 DN IOX1 DMYG0M5 TI TTDIJUQ DMYG0M5 TN Lysine-specific demethylase 6B (KDM6B) DMYG0M5 MA Inhibitor DMYG0M5 RN A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71. DMYG0M5 RU https://pubmed.ncbi.nlm.nih.gov/24504543 DMYG0M5 DI DMYG0M5 DMYG0M5 DN IOX1 DMYG0M5 TI TT9ISBX DMYG0M5 TN HIF-prolyl hydroxylase 2 (HPH-2) DMYG0M5 MA Inhibitor DMYG0M5 RN A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71. DMYG0M5 RU https://pubmed.ncbi.nlm.nih.gov/24504543 DMYG0M5 DI DMYG0M5 DMYG0M5 DN IOX1 DMYG0M5 TI TTV8CRH DMYG0M5 TN Lysine-specific demethylase 4C (KDM4C) DMYG0M5 MA Inhibitor DMYG0M5 RN A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71. DMYG0M5 RU https://pubmed.ncbi.nlm.nih.gov/24504543 DMYG0M5 DI DMYG0M5 DMYG0M5 DN IOX1 DMYG0M5 TI TTKXS4A DMYG0M5 TN Lysine-specific demethylase 3A (KDM3A) DMYG0M5 MA Inhibitor DMYG0M5 RN A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem. 2014 Mar;9(3):566-71. DMYG0M5 RU https://pubmed.ncbi.nlm.nih.gov/24504543 DMYG5IO DI DMYG5IO DMYG5IO DN ISIS 10707 DMYG5IO TI TTAN5W2 DMYG5IO TN Raf messenger RNA (Raf mRNA) DMYG5IO RN US patent application no. 5,952,229, Antisense oligonucleotide modulation of raf gene expression. DMYG5IO RU http://www.patentbuddy.com/Patent/5952229?ft=true&sr=true DMYG7BM DI DMYG7BM DMYG7BM DN Erybreadin D DMYG7BM TI TTELIN2 DMYG7BM TN PTPN1 messenger RNA (PTPN1 mRNA) DMYG7BM MA Inhibitor DMYG7BM RN Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9. DMYG7BM RU https://pubmed.ncbi.nlm.nih.gov/19836230 DMYG8EV DI DMYG8EV DMYG8EV DN (S)-2-Amino-propane-1-thiol DMYG8EV TI TTPHMWB DMYG8EV TN Aminopeptidase N (ANPEP) DMYG8EV MA Inhibitor DMYG8EV RN Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor. Bioorg Med Chem Lett. 1999 Jun 7;9(11):1511-6. DMYG8EV RU https://pubmed.ncbi.nlm.nih.gov/10386926 DMYGCSV DI DMYGCSV DMYGCSV DN N1-(naphthalen-1-yl)ethane-1,2-diamine DMYGCSV TI TTUNARX DMYGCSV TN Carbonic anhydrase (CA) DMYGCSV MA Inhibitor DMYGCSV RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMYGCSV RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMYGCSV DI DMYGCSV DMYGCSV DN N1-(naphthalen-1-yl)ethane-1,2-diamine DMYGCSV TI TTZHA0O DMYGCSV TN Carbonic anhydrase IV (CA-IV) DMYGCSV MA Inhibitor DMYGCSV RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMYGCSV RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMYGCSV DI DMYGCSV DMYGCSV DN N1-(naphthalen-1-yl)ethane-1,2-diamine DMYGCSV TI TTCFSPE DMYGCSV TN Carbonic anhydrase VI (CA-VI) DMYGCSV MA Inhibitor DMYGCSV RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMYGCSV RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMYGCSV DI DMYGCSV DMYGCSV DN N1-(naphthalen-1-yl)ethane-1,2-diamine DMYGCSV TI TT2LVK8 DMYGCSV TN Carbonic anhydrase IX (CA-IX) DMYGCSV MA Inhibitor DMYGCSV RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMYGCSV RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMYGCSV DI DMYGCSV DMYGCSV DN N1-(naphthalen-1-yl)ethane-1,2-diamine DMYGCSV TI TTEYTKG DMYGCSV TN Carbonic anhydrase XIV (CA-XIV) DMYGCSV MA Inhibitor DMYGCSV RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMYGCSV RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMYGCSV DI DMYGCSV DMYGCSV DN N1-(naphthalen-1-yl)ethane-1,2-diamine DMYGCSV TI TTSYM0R DMYGCSV TN Carbonic anhydrase XII (CA-XII) DMYGCSV MA Inhibitor DMYGCSV RN Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. J Med Chem. 2010 Aug 12;53(15):5511-22. DMYGCSV RU https://pubmed.ncbi.nlm.nih.gov/20590092 DMYGE3K DI DMYGE3K DMYGE3K DN 11C-PBR-170 DMYGE3K TI TTPTXIN DMYGE3K TN Translocator protein (TSPO) DMYGE3K MA Binder DMYGE3K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879). DMYGE3K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2879 DMYGKW5 DI DMYGKW5 DMYGKW5 DN 2-Benzyl-4-piperazin-1-yl-1H-benzimidazole DMYGKW5 TI TTJS8PY DMYGKW5 TN 5-HT 6 receptor (HTR6) DMYGKW5 MA Inhibitor DMYGKW5 RN Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation. J Med Chem. 2010 Feb 11;53(3):1357-69. DMYGKW5 RU https://pubmed.ncbi.nlm.nih.gov/20078106 DMYGKW7 DI DMYGKW7 DMYGKW7 DN APH-0911 DMYGKW7 TI TTYFKSZ DMYGKW7 TN Tubulin beta (TUBB) DMYGKW7 MA Modulator DMYGKW7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2640). DMYGKW7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2640 DMYGN1K DI DMYGN1K DMYGN1K DN 4-[6-Methyl-indan-(1E)-ylidenemethyl]-pyridine DMYGN1K TI TTSZLWK DMYGN1K TN Aromatase (CYP19A1) DMYGN1K MA Inhibitor DMYGN1K RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMYGN1K RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMYGNZA DI DMYGNZA DMYGNZA DN KNI-10314 DMYGNZA TI TTXMNHO DMYGNZA TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMYGNZA MA Inhibitor DMYGNZA RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMYGNZA RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMYGOT7 DI DMYGOT7 DMYGOT7 DN ISIS 16124 DMYGOT7 TI TTHMYB1 DMYGOT7 TN E2A-Pbx1 messenger RNA (E2A-Pbx1 mRNA) DMYGOT7 RN US patent application no. 6,607,915, Antisense inhibition of E2A-Pbx1 expression. DMYGOT7 RU http://www.patentbuddy.com/Patent/6607915?ft=true&sr=true DMYGRS9 DI DMYGRS9 DMYGRS9 DN 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one DMYGRS9 TI TT1MPAY DMYGRS9 TN GABA(A) receptor alpha-1 (GABRA1) DMYGRS9 MA Inhibitor DMYGRS9 RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMYGRS9 RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMYGRS9 DI DMYGRS9 DMYGRS9 DN 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one DMYGRS9 TI TTNJYV2 DMYGRS9 TN Gamma-aminobutyric acid receptor (GAR) DMYGRS9 MA Inhibitor DMYGRS9 RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMYGRS9 RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMYGRS9 DI DMYGRS9 DMYGRS9 DN 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one DMYGRS9 TI TT06RH5 DMYGRS9 TN GABA(A) receptor gamma-2 (GABRG2) DMYGRS9 MA Inhibitor DMYGRS9 RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMYGRS9 RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMYGRS9 DI DMYGRS9 DMYGRS9 DN 2-(4-chlorophenyl)-5-phenyl-4-isoxazolin-3-one DMYGRS9 TI TTZA1NY DMYGRS9 TN GABA(A) receptor beta-2 (GABRB2) DMYGRS9 MA Inhibitor DMYGRS9 RN Synthesis, pharmacology, and structure-activity relationships of novel imidazolones and pyrrolones as modulators of GABAA receptors. J Med Chem. 2006 Mar 23;49(6):1855-66. DMYGRS9 RU https://pubmed.ncbi.nlm.nih.gov/16539371 DMYGULD DI DMYGULD DMYGULD DN S-(4-Cyanobenzyl)isothiourea hydrobromide DMYGULD TI TTZJYKH DMYGULD TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMYGULD MA Inhibitor DMYGULD RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMYGULD RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMYGXHK DI DMYGXHK DMYGXHK DN T-kinin DMYGXHK TI TTGY8IW DMYGXHK TN B2 bradykinin receptor (BDKRB2) DMYGXHK MA Agonist DMYGXHK RN Molecular characterisation of cloned bradykinin B1 receptors from rat and human. Eur J Pharmacol. 1999 Jun 25;374(3):423-33. DMYGXHK RU https://pubmed.ncbi.nlm.nih.gov/10422787 DMYGZ8V DI DMYGZ8V DMYGZ8V DN 1-Benzyl-1H-1,3,4b,9-tetraaza-fluorene-2,4-dione DMYGZ8V TI TTJFY5U DMYGZ8V TN Adenosine A3 receptor (ADORA3) DMYGZ8V MA Inhibitor DMYGZ8V RN Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists. J Med Chem. 2002 Aug 1;45(16):3337-44. DMYGZ8V RU https://pubmed.ncbi.nlm.nih.gov/12139445 DMYH0XQ DI DMYH0XQ DMYH0XQ DN Huprine Y DMYH0XQ TI TT1RS9F DMYH0XQ TN Acetylcholinesterase (AChE) DMYH0XQ MA Inhibitor DMYH0XQ RN Synthesis and structure-activity relationship of Huprine derivatives as human acetylcholinesterase inhibitors. Bioorg Med Chem. 2009 Jul 1;17(13):4523-36. DMYH0XQ RU https://pubmed.ncbi.nlm.nih.gov/19473849 DMYH12X DI DMYH12X DMYH12X DN SC-53229 DMYH12X TI TTN53ZF DMYH12X TN Leukotriene B4 receptor 1 (LTB4R) DMYH12X MA Inhibitor DMYH12X RN Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity, Bioorg. Med. Chem. Lett. 4(6):811-816 (1994). DMYH12X RU http://www.sciencedirect.com/science/article/pii/S0960894X01808532 DMYH36T DI DMYH36T DMYH36T DN PMID17942791C3 DMYH36T TI TT2AP5B DMYH36T TN Ras converting CAAX endopeptidase 1 (RCE1) DMYH36T MA Inhibitor DMYH36T RN Small-molecule inhibitors of the Rce1p CaaX protease. J Biomol Screen. 2007 Oct;12(7):983-93. DMYH36T RU https://pubmed.ncbi.nlm.nih.gov/17942791 DMYH3A0 DI DMYH3A0 DMYH3A0 DN VLTS-582 DMYH3A0 TI TT6RVLG DMYH3A0 TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMYH3A0 MA Modulator DMYH3A0 RN A Phase I Study of Concurrent Chemotherapy (Paclitaxel and Carboplatin) and Thoracic Radiotherapy with Swallowed Manganese Superoxide Dismutase Plasmid Liposome Protection in Patients with Locally Advanced Stage III Non-Small-Cell Lung Cancer DMYH3A0 RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057216 DMYH6A2 DI DMYH6A2 DMYH6A2 DN 3-Indan-(1E)-ylidenemethyl-pyridine DMYH6A2 TI TTSZLWK DMYH6A2 TN Aromatase (CYP19A1) DMYH6A2 MA Inhibitor DMYH6A2 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMYH6A2 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMYH6A2 DI DMYH6A2 DMYH6A2 DN 3-Indan-(1E)-ylidenemethyl-pyridine DMYH6A2 TI TTIQUX7 DMYH6A2 TN Steroid 11-beta-hydroxylase (CYP11B1) DMYH6A2 MA Inhibitor DMYH6A2 RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMYH6A2 RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMYH9BC DI DMYH9BC DMYH9BC DN (Z)-2-Methyl-1-oxazol-2-yl-octadec-9-en-1-one DMYH9BC TI TTDP1UC DMYH9BC TN Fatty acid amide hydrolase (FAAH) DMYH9BC MA Inhibitor DMYH9BC RN alpha-Keto heterocycle inhibitors of fatty acid amide hydrolase: carbonyl group modification and alpha-substitution. Bioorg Med Chem Lett. 2001 Jun 18;11(12):1517-20. DMYH9BC RU https://pubmed.ncbi.nlm.nih.gov/11412972 DMYH9M0 DI DMYH9M0 DMYH9M0 DN 1-(3-methylpyridin-2-yl)-4-tosylpiperazine DMYH9M0 TI TTN7BL9 DMYH9M0 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMYH9M0 MA Inhibitor DMYH9M0 RN Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1). Bioorg Med Chem Lett. 2008 Jun 15;18(12):3513-6. DMYH9M0 RU https://pubmed.ncbi.nlm.nih.gov/18511278 DMYH9Q5 DI DMYH9Q5 DMYH9Q5 DN Salvinorin A (ester) DMYH9Q5 TI TTQW87Y DMYH9Q5 TN Opioid receptor kappa (OPRK1) DMYH9Q5 MA Inhibitor DMYH9Q5 RN Synthesis and in vitro evaluation of salvinorin A analogues: effect of configuration at C(2) and substitution at C(18). Bioorg Med Chem Lett. 2006 Sep 1;16(17):4679-85. DMYH9Q5 RU https://pubmed.ncbi.nlm.nih.gov/16777411 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TT54ERL DMYH9SU TN Voltage-gated sodium channel alpha Nav1.6 (SCN8A) DMYH9SU MA Activator DMYH9SU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 583). DMYH9SU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=583 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TTLJTUF DMYH9SU TN Voltage-gated sodium channel alpha Nav1.2 (SCN2A) DMYH9SU MA Activator DMYH9SU RN Interaction of batrachotoxin with the local anesthetic receptor site in transmembrane segment IVS6 of the voltage-gated sodium channel. Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13947-52. DMYH9SU RU https://pubmed.ncbi.nlm.nih.gov/9811906 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TTAXZ0K DMYH9SU TN Voltage-gated sodium channel alpha Nav1.3 (SCN3A) DMYH9SU MA Activator DMYH9SU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 580). DMYH9SU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=580 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TTANOZH DMYH9SU TN SCN1A messenger RNA (SCN1A mRNA) DMYH9SU MA Activator DMYH9SU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 578). DMYH9SU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=578 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TT4G2JS DMYH9SU TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMYH9SU MA Activator DMYH9SU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 584). DMYH9SU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=584 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TT90XZ8 DMYH9SU TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMYH9SU MA Activator DMYH9SU RN The poison Dart frog's batrachotoxin modulates Nav1.8. FEBS Lett. 2004 Nov 5;577(1-2):245-8. DMYH9SU RU https://pubmed.ncbi.nlm.nih.gov/15527793 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TT84DRB DMYH9SU TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMYH9SU MA Activator DMYH9SU RN Point mutations in segment I-S6 render voltage-gated Na+ channels resistant to batrachotoxin. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2653-8. DMYH9SU RU https://pubmed.ncbi.nlm.nih.gov/9482942 DMYH9SU DI DMYH9SU DMYH9SU DN Batrachotoxin DMYH9SU TI TTZOVE0 DMYH9SU TN Voltage-gated sodium channel alpha Nav1.5 (SCN5A) DMYH9SU MA Activator DMYH9SU RN Binding of [3H]batrachotoxinin A benzoate to specific sites on rat cardiac sodium channels. Mol Pharmacol. 1986 Dec;30(6):617-23. DMYH9SU RU https://pubmed.ncbi.nlm.nih.gov/2431264 DMYHADT DI DMYHADT DMYHADT DN Ac-Asp-Arg-Leu-Asp-Ser-OH DMYHADT TI TTT1R2L DMYHADT TN Integrin alpha-V (ITGAV) DMYHADT MA Inhibitor DMYHADT RN Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90. DMYHADT RU https://pubmed.ncbi.nlm.nih.gov/17869121 DMYHADT DI DMYHADT DMYHADT DN Ac-Asp-Arg-Leu-Asp-Ser-OH DMYHADT TI TTJA1ZO DMYHADT TN ITGB3 messenger RNA (ITGB3 mRNA) DMYHADT MA Inhibitor DMYHADT RN Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one sc... Bioorg Med Chem. 2007 Dec 1;15(23):7380-90. DMYHADT RU https://pubmed.ncbi.nlm.nih.gov/17869121 DMYHC3S DI DMYHC3S DMYHC3S DN 3,4',5-trimethoxy-(Z)-stilbene DMYHC3S TI TTYFKSZ DMYHC3S TN Tubulin beta (TUBB) DMYHC3S MA Inhibitor DMYHC3S RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMYHC3S RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMYHC3S DI DMYHC3S DMYHC3S DN 3,4',5-trimethoxy-(Z)-stilbene DMYHC3S TI TTJ2PTI DMYHC3S TN Tubulin beta-2 chain (TUBB2) DMYHC3S MA Inhibitor DMYHC3S RN 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents. J Med Chem. 2006 Oct 19;49(21):6412-5. DMYHC3S RU https://pubmed.ncbi.nlm.nih.gov/17034147 DMYHFUO DI DMYHFUO DMYHFUO DN 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine DMYHFUO TI TT1RS9F DMYHFUO TN Acetylcholinesterase (AChE) DMYHFUO MA Inhibitor DMYHFUO RN Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem. 2006 Sep 7;49(18):5411-3. DMYHFUO RU https://pubmed.ncbi.nlm.nih.gov/16942014 DMYHFUO DI DMYHFUO DMYHFUO DN 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-imine DMYHFUO TI TTEB0GD DMYHFUO TN Cholinesterase (BCHE) DMYHFUO MA Inhibitor DMYHFUO RN Homobivalent quinazolinimines as novel nanomolar inhibitors of cholinesterases with dirigible selectivity toward butyrylcholinesterase. J Med Chem. 2006 Sep 7;49(18):5411-3. DMYHFUO RU https://pubmed.ncbi.nlm.nih.gov/16942014 DMYHMEK DI DMYHMEK DMYHMEK DN 1-OH-PGE1 DMYHMEK TI TT79WV3 DMYHMEK TN Prostaglandin E2 receptor EP4 (PTGER4) DMYHMEK MA Agonist DMYHMEK RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMYHMEK RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMYHR74 DI DMYHR74 DMYHR74 DN CP154,526 DMYHR74 TI TT7EFHR DMYHR74 TN Corticotropin-releasing factor receptor 1 (CRHR1) DMYHR74 MA Antagonist DMYHR74 RN A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68. DMYHR74 RU https://pubmed.ncbi.nlm.nih.gov/17109611 DMYHV9P DI DMYHV9P DMYHV9P DN (+/-)-7-fluoro-2-(4-methoxyphenyl)chroman-4-one DMYHV9P TI TTGP7BY DMYHV9P TN Monoamine oxidase type B (MAO-B) DMYHV9P MA Inhibitor DMYHV9P RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMYHV9P RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMYHWS1 DI DMYHWS1 DMYHWS1 DN WHI-P154 DMYHWS1 TI TTRMX3V DMYHWS1 TN Janus kinase 2 (JAK-2) DMYHWS1 MA Inhibitor DMYHWS1 RN The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. DMYHWS1 RU https://pubmed.ncbi.nlm.nih.gov/18094329 DMYHWS1 DI DMYHWS1 DMYHWS1 DN WHI-P154 DMYHWS1 TI TTGKNB4 DMYHWS1 TN Epidermal growth factor receptor (EGFR) DMYHWS1 MA Inhibitor DMYHWS1 RN The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. DMYHWS1 RU https://pubmed.ncbi.nlm.nih.gov/18094329 DMYHWS1 DI DMYHWS1 DMYHWS1 DN WHI-P154 DMYHWS1 TI TTT7PJU DMYHWS1 TN Janus kinase 3 (JAK-3) DMYHWS1 MA Inhibitor DMYHWS1 RN The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. DMYHWS1 RU https://pubmed.ncbi.nlm.nih.gov/18094329 DMYHWS1 DI DMYHWS1 DMYHWS1 DN WHI-P154 DMYHWS1 TI TT6DM01 DMYHWS1 TN Janus kinase 1 (JAK-1) DMYHWS1 MA Inhibitor DMYHWS1 RN The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. DMYHWS1 RU https://pubmed.ncbi.nlm.nih.gov/18094329 DMYI3F5 DI DMYI3F5 DMYI3F5 DN 1-(1,3-diphenylpropylidene)thiosemicarbazide DMYI3F5 TI TT36ETB DMYI3F5 TN Cathepsin L (CTSL) DMYI3F5 MA Inhibitor DMYI3F5 RN Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbcatB. Bioorg Med Chem Lett. 2008 May 1;18(9):2883-5. DMYI3F5 RU https://pubmed.ncbi.nlm.nih.gov/18420405 DMYI5GU DI DMYI5GU DMYI5GU DN 6-amino-N-(3,3-diphenylpropyl)nicotinamide DMYI5GU TI TT7WVHI DMYI5GU TN Soluble epoxide hydrolase (EPHX2) DMYI5GU MA Inhibitor DMYI5GU RN Design and synthesis of substituted nicotinamides as inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5864-8. DMYI5GU RU https://pubmed.ncbi.nlm.nih.gov/19758802 DMYI87T DI DMYI87T DMYI87T DN N-ethylhistamine DMYI87T TI TTXJ178 DMYI87T TN Histamine H4 receptor (H4R) DMYI87T MA Agonist DMYI87T RN Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. Br J Pharmacol. 2006 Apr;147(7):744-54. DMYI87T RU https://pubmed.ncbi.nlm.nih.gov/16432504 DMYIEOJ DI DMYIEOJ DMYIEOJ DN Petrosamine DMYIEOJ TI TT1RS9F DMYIEOJ TN Acetylcholinesterase (AChE) DMYIEOJ MA Inhibitor DMYIEOJ RN Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp. Bioorg Med Chem. 2008 Jul 1;16(13):6560-7. DMYIEOJ RU https://pubmed.ncbi.nlm.nih.gov/18538575 DMYIGCU DI DMYIGCU DMYIGCU DN JWH-312 DMYIGCU TI TTMSFAW DMYIGCU TN Cannabinoid receptor 2 (CB2) DMYIGCU MA Inhibitor DMYIGCU RN 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Bioorg Med Chem Lett. 2005 Sep 15;15(18):4110-3. DMYIGCU RU https://pubmed.ncbi.nlm.nih.gov/16005223 DMYIJT1 DI DMYIJT1 DMYIJT1 DN C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2 DMYIJT1 TI TTVIMDE DMYIJT1 TN Glucagon-like peptide 1 receptor (GLP1R) DMYIJT1 MA Inhibitor DMYIJT1 RN Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. DMYIJT1 RU https://pubmed.ncbi.nlm.nih.gov/18412318 DMYIK9W DI DMYIK9W DMYIK9W DN 1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea DMYIK9W TI TT7WVHI DMYIK9W TN Soluble epoxide hydrolase (EPHX2) DMYIK9W MA Inhibitor DMYIK9W RN Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63. DMYIK9W RU https://pubmed.ncbi.nlm.nih.gov/19520575 DMYIQDE DI DMYIQDE DMYIQDE DN 1-Iodyl-3-nitro-benzene DMYIQDE TI TTELIN2 DMYIQDE TN PTPN1 messenger RNA (PTPN1 mRNA) DMYIQDE MA Inhibitor DMYIQDE RN Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6. DMYIQDE RU https://pubmed.ncbi.nlm.nih.gov/10091683 DMYIQRK DI DMYIQRK DMYIQRK DN RIPA-56 DMYIQRK TI TTAIQSN DMYIQRK TN Receptor-interacting protein 1 (RIPK1) DMYIQRK MA Inhibitor DMYIQRK RN Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol. 2020 Apr;72(4):627-635. DMYIQRK RU https://pubmed.ncbi.nlm.nih.gov/31760070 DMYISTE DI DMYISTE DMYISTE DN EPZ005687 DMYISTE TI TT9MZCQ DMYISTE TN Enhancer of zeste homolog 2 (EZH2) DMYISTE MA Inhibitor DMYISTE RN A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012 Nov;8(11):890-6. DMYISTE RU https://pubmed.ncbi.nlm.nih.gov/23023262 DMYIWAH DI DMYIWAH DMYIWAH DN 4-Ethyl-pyrrolidin-(2Z)-ylideneamine DMYIWAH TI TTF10I9 DMYIWAH TN Nitric-oxide synthase inducible (NOS2) DMYIWAH MA Inhibitor DMYIWAH RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMYIWAH RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMYIWAH DI DMYIWAH DMYIWAH DN 4-Ethyl-pyrrolidin-(2Z)-ylideneamine DMYIWAH TI TTZUFI5 DMYIWAH TN Nitric-oxide synthase brain (NOS1) DMYIWAH MA Inhibitor DMYIWAH RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMYIWAH RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMYIWAH DI DMYIWAH DMYIWAH DN 4-Ethyl-pyrrolidin-(2Z)-ylideneamine DMYIWAH TI TTCM4B3 DMYIWAH TN Nitric-oxide synthase endothelial (NOS3) DMYIWAH MA Inhibitor DMYIWAH RN Evaluation of pyrrolidin-2-imines and 1,3-thiazolidin-2-imines as inhibitors of nitric oxide synthase. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4539-44. DMYIWAH RU https://pubmed.ncbi.nlm.nih.gov/15357988 DMYIWBD DI DMYIWBD DMYIWBD DN Pellitorin DMYIWBD TI TTA1L39 DMYIWBD TN ICAM1 messenger RNA (ICAM1 mRNA) DMYIWBD MA Inhibitor DMYIWBD RN Alkamides from the fruits of Piper longum and Piper nigrum displaying potent cell adhesion inhibition. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4544-6. DMYIWBD RU https://pubmed.ncbi.nlm.nih.gov/18672369 DMYIZBK DI DMYIZBK DMYIZBK DN 3-(6-Amino-purin-9-yl)-6-o-tolyl-hexan-2-ol DMYIZBK TI TTLP57V DMYIZBK TN Adenosine deaminase (ADA) DMYIZBK MA Inhibitor DMYIZBK RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMYIZBK RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMYJ1M4 DI DMYJ1M4 DMYJ1M4 DN 2-fluorophenyl 4-butoxyphenylcarbamate DMYJ1M4 TI TTDP1UC DMYJ1M4 TN Fatty acid amide hydrolase (FAAH) DMYJ1M4 MA Inhibitor DMYJ1M4 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMYJ1M4 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMYJ28G DI DMYJ28G DMYJ28G DN Propan-2-one O-4-butoxyphenylcarbamoyl oxime DMYJ28G TI TTDP1UC DMYJ28G TN Fatty acid amide hydrolase (FAAH) DMYJ28G MA Inhibitor DMYJ28G RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMYJ28G RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMYJ4EG DI DMYJ4EG DMYJ4EG DN 1-(3,5-dimethylphenyl)-2-(phenylsulfonyl)ethanone DMYJ4EG TI TTN7BL9 DMYJ4EG TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMYJ4EG MA Inhibitor DMYJ4EG RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMYJ4EG RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMYJ6QZ DI DMYJ6QZ DMYJ6QZ DN L-826266 DMYJ6QZ TI TTPNGDE DMYJ6QZ TN Prostaglandin E2 receptor EP3 (PTGER3) DMYJ6QZ MA Antagonist DMYJ6QZ RN Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations. Br J Pharmacol. 2011 Feb;162(4):863-79. DMYJ6QZ RU https://pubmed.ncbi.nlm.nih.gov/20973775 DMYJ87C DI DMYJ87C DMYJ87C DN ASC-JMX2 DMYJ87C TI TTS64P2 DMYJ87C TN Androgen receptor (AR) DMYJ87C MA Antagonist DMYJ87C RN The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. DMYJ87C RU https://www.ncbi.nlm.nih.gov/pubmed/27899562 DMYJ8ZB DI DMYJ8ZB DMYJ8ZB DN Enoxaprin DMYJ8ZB TI TT6L509 DMYJ8ZB TN Coagulation factor IIa (F2) DMYJ8ZB MA Inhibitor DMYJ8ZB RN Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv. 1994 Jun;49(6):424-31. DMYJ8ZB RU https://pubmed.ncbi.nlm.nih.gov/8090379 DMYJAM5 DI DMYJAM5 DMYJAM5 DN (R)-(-)-10-methyl-11-hydroxyaporphine DMYJAM5 TI TTSQIFT DMYJAM5 TN 5-HT 1A receptor (HTR1A) DMYJAM5 MA Inhibitor DMYJAM5 RN R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. DMYJAM5 RU https://pubmed.ncbi.nlm.nih.gov/17543523 DMYJAM5 DI DMYJAM5 DMYJAM5 DN (R)-(-)-10-methyl-11-hydroxyaporphine DMYJAM5 TI TTZFYLI DMYJAM5 TN Dopamine D1 receptor (D1R) DMYJAM5 MA Inhibitor DMYJAM5 RN R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. DMYJAM5 RU https://pubmed.ncbi.nlm.nih.gov/17543523 DMYJAM5 DI DMYJAM5 DMYJAM5 DN (R)-(-)-10-methyl-11-hydroxyaporphine DMYJAM5 TI TTEX248 DMYJAM5 TN Dopamine D2 receptor (D2R) DMYJAM5 MA Inhibitor DMYJAM5 RN R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4128-30. DMYJAM5 RU https://pubmed.ncbi.nlm.nih.gov/17543523 DMYJAW4 DI DMYJAW4 DMYJAW4 DN H-Dmt-Tic-NH-CH2-CH2-NH2 DMYJAW4 TI TT27RFC DMYJAW4 TN Opioid receptor delta (OPRD1) DMYJAW4 MA Inhibitor DMYJAW4 RN A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. DMYJAW4 RU https://pubmed.ncbi.nlm.nih.gov/17851080 DMYJAW4 DI DMYJAW4 DMYJAW4 DN H-Dmt-Tic-NH-CH2-CH2-NH2 DMYJAW4 TI TTKWM86 DMYJAW4 TN Opioid receptor mu (MOP) DMYJAW4 MA Inhibitor DMYJAW4 RN A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81. DMYJAW4 RU https://pubmed.ncbi.nlm.nih.gov/17851080 DMYJB1A DI DMYJB1A DMYJB1A DN N-(3'-acetyl-4-aminobiphenyl-3-yl)benzamide DMYJB1A TI TTSHTOI DMYJB1A TN Histone deacetylase 2 (HDAC2) DMYJB1A MA Inhibitor DMYJB1A RN Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5. DMYJB1A RU https://pubmed.ncbi.nlm.nih.gov/20392638 DMYJBPI DI DMYJBPI DMYJBPI DN 7-ethoxy-8-propionyl-2H-chromen-2-one DMYJBPI TI TT2LVK8 DMYJBPI TN Carbonic anhydrase IX (CA-IX) DMYJBPI MA Inhibitor DMYJBPI RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMYJBPI RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMYJGDK DI DMYJGDK DMYJGDK DN (+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one DMYJGDK TI TTSZLWK DMYJGDK TN Aromatase (CYP19A1) DMYJGDK MA Inhibitor DMYJGDK RN Synthesis and biological evaluation of (+/-)-abyssinone II and its analogues as aromatase inhibitors for chemoprevention of breast cancer. J Med Chem. 2007 Jun 14;50(12):2799-806. DMYJGDK RU https://pubmed.ncbi.nlm.nih.gov/17511439 DMYJGDK DI DMYJGDK DMYJGDK DN (+/-)-7-methoxy-2-(4-methoxyphenyl)chroman-4-one DMYJGDK TI TTGP7BY DMYJGDK TN Monoamine oxidase type B (MAO-B) DMYJGDK MA Inhibitor DMYJGDK RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMYJGDK RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMYJGZ4 DI DMYJGZ4 DMYJGZ4 DN (+/-)-2-p-tolylchroman-4-one DMYJGZ4 TI TTGP7BY DMYJGZ4 TN Monoamine oxidase type B (MAO-B) DMYJGZ4 MA Inhibitor DMYJGZ4 RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMYJGZ4 RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMYJHRV DI DMYJHRV DMYJHRV DN N-[(5-chloro-1-benzothien-3-yl)methyl]sulfamide DMYJHRV TI TTANPDJ DMYJHRV TN Carbonic anhydrase II (CA-II) DMYJHRV MA Inhibitor DMYJHRV RN Novel, broad-spectrum anticonvulsants containing a sulfamide group: advancement of N-((benzo[b]thien-3-yl)methyl)sulfamide (JNJ-26990990) into huma... J Med Chem. 2009 Dec 10;52(23):7528-36. DMYJHRV RU https://pubmed.ncbi.nlm.nih.gov/19388676 DMYJI90 DI DMYJI90 DMYJI90 DN MEK inhibitor I DMYJI90 TI TTROQ37 DMYJI90 TN MAPK/ERK kinase kinase (MAP3K) DMYJI90 MA Inhibitor DMYJI90 RN Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitors. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1483-6. DMYJI90 RU https://pubmed.ncbi.nlm.nih.gov/15006386 DMYJNS9 DI DMYJNS9 DMYJNS9 DN NSC-131736 DMYJNS9 TI TTSZLWK DMYJNS9 TN Aromatase (CYP19A1) DMYJNS9 MA Inhibitor DMYJNS9 RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMYJNS9 RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMYJO13 DI DMYJO13 DMYJO13 DN GNF-5837 DMYJO13 TI TTKN7QR DMYJO13 TN BDNF/NT-3 growth factors receptor (TrkB) DMYJO13 MA Inhibitor DMYJO13 RN Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5. DMYJO13 RU https://pubmed.ncbi.nlm.nih.gov/24900443 DMYJO13 DI DMYJO13 DMYJO13 DN GNF-5837 DMYJO13 TI TTXABCW DMYJO13 TN NT-3 growth factor receptor (TrkC) DMYJO13 MA Inhibitor DMYJO13 RN Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Med Chem Lett. 2012 Jan 1;3(2):140-5. DMYJO13 RU https://pubmed.ncbi.nlm.nih.gov/24900443 DMYJO7T DI DMYJO7T DMYJO7T DN ISIS 102558 DMYJO7T TI TT5U49F DMYJO7T TN PRKACA messenger RNA (PRKACA mRNA) DMYJO7T RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMYJO7T RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMYJTZ7 DI DMYJTZ7 DMYJTZ7 DN FGGFTGARKSARKFANQ DMYJTZ7 TI TTNT7K8 DMYJTZ7 TN Nociceptin receptor (OPRL1) DMYJTZ7 MA Inhibitor DMYJTZ7 RN Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation. Bioorg Med Chem. 2008 Oct 15;16(20):9261-7. DMYJTZ7 RU https://pubmed.ncbi.nlm.nih.gov/18818087 DMYJV4I DI DMYJV4I DMYJV4I DN SL-327 DMYJV4I TI TTROQ37 DMYJV4I TN MAPK/ERK kinase kinase (MAP3K) DMYJV4I MA Inhibitor DMYJV4I RN A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. DMYJV4I RU https://pubmed.ncbi.nlm.nih.gov/18077363 DMYJXV7 DI DMYJXV7 DMYJXV7 DN [3H]5-HT DMYJXV7 TI TT6MSOK DMYJXV7 TN 5-HT 1D receptor (HTR1D) DMYJXV7 MA Agonist DMYJXV7 RN Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65. DMYJXV7 RU https://pubmed.ncbi.nlm.nih.gov/9605573 DMYJXV7 DI DMYJXV7 DMYJXV7 DN [3H]5-HT DMYJXV7 TI TTCPG9S DMYJXV7 TN 5-HT 1E receptor (HTR1E) DMYJXV7 MA Agonist DMYJXV7 RN Molecular cloning of a serotonin receptor from human brain (5HT1E): a fifth 5HT1-like subtype. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5517-21. DMYJXV7 RU https://pubmed.ncbi.nlm.nih.gov/1608964 DMYJXV7 DI DMYJXV7 DMYJXV7 DN [3H]5-HT DMYJXV7 TI TTO9X1H DMYJXV7 TN 5-HT 7 receptor (HTR7) DMYJXV7 MA Agonist DMYJXV7 RN Cloning of a novel human serotonin receptor (5-HT7) positively linked to adenylate cyclase. J Biol Chem. 1993 Nov 5;268(31):23422-6. DMYJXV7 RU https://pubmed.ncbi.nlm.nih.gov/8226867 DMYJXV7 DI DMYJXV7 DMYJXV7 DN [3H]5-HT DMYJXV7 TI TT0K1SC DMYJXV7 TN 5-HT 2B receptor (HTR2B) DMYJXV7 MA Agonist DMYJXV7 RN Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor. Mol Pharmacol. 1993 Mar;43(3):419-26. DMYJXV7 RU https://pubmed.ncbi.nlm.nih.gov/8450835 DMYK0Z9 DI DMYK0Z9 DMYK0Z9 DN angiotensin III DMYK0Z9 TI TT8DBY3 DMYK0Z9 TN Angiotensin II receptor type-1 (AGTR1) DMYK0Z9 MA Agonist DMYK0Z9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 34). DMYK0Z9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34 DMYK0Z9 DI DMYK0Z9 DMYK0Z9 DN angiotensin III DMYK0Z9 TI TTQVOEI DMYK0Z9 TN Angiotensin II receptor type-2 (AGTR2) DMYK0Z9 MA Agonist DMYK0Z9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 35). DMYK0Z9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=35 DMYK6OU DI DMYK6OU DMYK6OU DN RQ-00310941 DMYK6OU TI TT0K1SC DMYK6OU TN 5-HT 2B receptor (HTR2B) DMYK6OU MA Antagonist DMYK6OU RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7). DMYK6OU RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=7 DMYKB0S DI DMYKB0S DMYKB0S DN SCH-725739 DMYKB0S TI TT90XZ8 DMYKB0S TN Voltage-gated sodium channel alpha Nav1.8 (SCN10A) DMYKB0S MA Inhibitor DMYKB0S RN Novel steroidal saponins, Sch 725737 and Sch 725739, from a marine starfish, Novodinia antillensis. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5543-7. DMYKB0S RU https://pubmed.ncbi.nlm.nih.gov/17804230 DMYKJZ2 DI DMYKJZ2 DMYKJZ2 DN N-hydroxy-5-(pyridin-2-yl)thiophene-2-carboxamide DMYKJZ2 TI TT6R7JZ DMYKJZ2 TN Histone deacetylase 1 (HDAC1) DMYKJZ2 MA Inhibitor DMYKJZ2 RN Identification and optimisation of a series of substituted 5-pyridin-2-yl-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibit... Bioorg Med Chem Lett. 2007 Jan 15;17(2):363-9. DMYKJZ2 RU https://pubmed.ncbi.nlm.nih.gov/17107790 DMYKNSP DI DMYKNSP DMYKNSP DN MLN-120B DMYKNSP TI TTRPDBG DMYKNSP TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMYKNSP MA Inhibitor DMYKNSP RN A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like syno... J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001. DMYKNSP RU https://pubmed.ncbi.nlm.nih.gov/16525037 DMYKSTZ DI DMYKSTZ DMYKSTZ DN 6,8-Dimethoxy-4-methylquinolin-2(1H)-one DMYKSTZ TI TTJLP0R DMYKSTZ TN Quinone reductase 2 (NQO2) DMYKSTZ MA Inhibitor DMYKSTZ RN Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities. J Med Chem. 2009 Apr 9;52(7):1873-84. DMYKSTZ RU https://pubmed.ncbi.nlm.nih.gov/19265439 DMYKTF6 DI DMYKTF6 DMYKTF6 DN Anti-TNF human mabs DMYKTF6 TI TTG043C DMYKTF6 TN Tumor necrosis factor receptor type I (TNF-R1) DMYKTF6 RN Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. DMYKTF6 RU https://pubmed.ncbi.nlm.nih.gov/15507622 DMYKVRF DI DMYKVRF DMYKVRF DN 3-Isopropyl-1-methyl-3,7-dihydro-purine-2,6-dione DMYKVRF TI TTM2AOE DMYKVRF TN Adenosine A2a receptor (ADORA2A) DMYKVRF MA Inhibitor DMYKVRF RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DMYKVRF RU https://pubmed.ncbi.nlm.nih.gov/3806581 DMYKXWE DI DMYKXWE DMYKXWE DN 7beta, 25-dihydroxycholesterol DMYKXWE TI TTME5YJ DMYKXWE TN EBV-induced G-protein coupled receptor 2 (GPR183) DMYKXWE MA Agonist DMYKXWE RN Oxysterols direct B-cell migration through EBI2. Nature. 2011 Jul 27;475(7357):519-23. DMYKXWE RU https://pubmed.ncbi.nlm.nih.gov/21796211 DMYKZ6U DI DMYKZ6U DMYKZ6U DN NMS-873 DMYKZ6U TI TTYWTI0 DMYKZ6U TN HUMAN valosin-containing protein p97 (VCP) DMYKZ6U MA Inhibitor DMYKZ6U RN A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing. Nature. 2020 Apr 30. doi: 10.1038/s41586-020-2286-9. DMYKZ6U RU https://pubmed.ncbi.nlm.nih.gov/32353859 DMYL0ZF DI DMYL0ZF DMYL0ZF DN 5-hydroxy-2-(4-dimethylaminophenyl)benzofuran DMYL0ZF TI TTE4KHA DMYL0ZF TN Amyloid beta A4 protein (APP) DMYL0ZF MA Inhibitor DMYL0ZF RN Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30. DMYL0ZF RU https://pubmed.ncbi.nlm.nih.gov/16640332 DMYL3ST DI DMYL3ST DMYL3ST DN 3-bromopyruvate DMYL3ST TI TT58ZYW DMYL3ST TN Mycobacterium Isocitrate lyase (MycB icl) DMYL3ST MA Inhibitor DMYL3ST RN Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat Struct Biol. 2000 Aug;7(8):663-8. DMYL3ST RU https://pubmed.ncbi.nlm.nih.gov/10932251 DMYL56F DI DMYL56F DMYL56F DN SB-782443 DMYL56F TI TTMI6F5 DMYL56F TN Transient receptor potential cation channel V1 (TRPV1) DMYL56F MA Inhibitor DMYL56F RN Design and synthesis of 6-phenylnicotinamide derivatives as antagonists of TRPV1. Bioorg Med Chem Lett. 2008 Oct 15;18(20):5609-13. DMYL56F RU https://pubmed.ncbi.nlm.nih.gov/18809327 DMYLA29 DI DMYLA29 DMYLA29 DN AD10-1025 DMYLA29 TI TTCBFJO DMYLA29 TN Insulin receptor (INSR) DMYLA29 MA Agonist DMYLA29 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800). DMYLA29 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1800 DMYLA7F DI DMYLA7F DMYLA7F DN Cyclobutylcarbamic Acid Biphenyl-3-yl Ester DMYLA7F TI TTDP1UC DMYLA7F TN Fatty acid amide hydrolase (FAAH) DMYLA7F MA Inhibitor DMYLA7F RN Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl a... J Med Chem. 2008 Jun 26;51(12):3487-98. DMYLA7F RU https://pubmed.ncbi.nlm.nih.gov/18507372 DMYLDFG DI DMYLDFG DMYLDFG DN 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol DMYLDFG TI TTOM3J0 DMYLDFG TN Estrogen receptor beta (ESR2) DMYLDFG MA Inhibitor DMYLDFG RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMYLDFG RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMYLDFG DI DMYLDFG DMYLDFG DN 3-(4-Hydroxy-phenyl)-benzo[d]isoxazol-6-ol DMYLDFG TI TTZAYWL DMYLDFG TN Estrogen receptor (ESR) DMYLDFG MA Inhibitor DMYLDFG RN Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem. 2004 Oct 7;47(21):5021-40. DMYLDFG RU https://pubmed.ncbi.nlm.nih.gov/15456246 DMYLIX9 DI DMYLIX9 DMYLIX9 DN 5-(methylthio)thiophene-2-carboxylic acid DMYLIX9 TI TTGX0HR DMYLIX9 TN Bacterial DNA ligase (Bact ligA) DMYLIX9 MA Inhibitor DMYLIX9 RN Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J Med Chem. 2008 Aug 14;51(15):4553-62. DMYLIX9 RU https://pubmed.ncbi.nlm.nih.gov/18630893 DMYLONS DI DMYLONS DMYLONS DN L-Tryptophan-L-2-aminoadipic acid DMYLONS TI TTT2SVW DMYLONS TN PPAR-gamma messenger RNA (PPARG mRNA) DMYLONS MA Inhibitor DMYLONS RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DMYLONS RU https://pubmed.ncbi.nlm.nih.gov/18329752 DMYLPV1 DI DMYLPV1 DMYLPV1 DN (1R,2R)-N-Arachidonoylcyclopropanolamide DMYLPV1 TI TT6OEDT DMYLPV1 TN Cannabinoid receptor 1 (CB1) DMYLPV1 MA Inhibitor DMYLPV1 RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMYLPV1 RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMYLPV1 DI DMYLPV1 DMYLPV1 DN (1R,2R)-N-Arachidonoylcyclopropanolamide DMYLPV1 TI TTMSFAW DMYLPV1 TN Cannabinoid receptor 2 (CB2) DMYLPV1 MA Inhibitor DMYLPV1 RN Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9. DMYLPV1 RU https://pubmed.ncbi.nlm.nih.gov/19361197 DMYLVQF DI DMYLVQF DMYLVQF DN indirubin deriv. 8a DMYLVQF TI TTQWAU1 DMYLVQF TN GSK3A messenger RNA (GSK3A mRNA) DMYLVQF MA Inhibitor DMYLVQF RN Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46. DMYLVQF RU https://pubmed.ncbi.nlm.nih.gov/14761195 DMYLVQF DI DMYLVQF DMYLVQF DN indirubin deriv. 8a DMYLVQF TI TTRSMW9 DMYLVQF TN Glycogen synthase kinase-3 beta (GSK-3B) DMYLVQF MA Inhibitor DMYLVQF RN Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46. DMYLVQF RU https://pubmed.ncbi.nlm.nih.gov/14761195 DMYLX0U DI DMYLX0U DMYLX0U DN (2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime DMYLX0U TI TTCEJ4F DMYLX0U TN G1/S-specific cyclin-E1 (CCNE1) DMYLX0U MA Inhibitor DMYLX0U RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMYLX0U RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMYLX0U DI DMYLX0U DMYLX0U DN (2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime DMYLX0U TI TT7HF4W DMYLX0U TN Cyclin-dependent kinase 2 (CDK2) DMYLX0U MA Inhibitor DMYLX0U RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMYLX0U RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMYM3EW DI DMYM3EW DMYM3EW DN 6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol DMYM3EW TI TTZAYWL DMYM3EW TN Estrogen receptor (ESR) DMYM3EW MA Inhibitor DMYM3EW RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMYM3EW RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMYM3EW DI DMYM3EW DMYM3EW DN 6-(4-Hydroxy-2-methoxy-phenyl)-naphthalen-2-ol DMYM3EW TI TTOM3J0 DMYM3EW TN Estrogen receptor beta (ESR2) DMYM3EW MA Inhibitor DMYM3EW RN ERbeta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERbeta selectivity. J Med Chem. 2005 Jun 16;48(12):3953-79. DMYM3EW RU https://pubmed.ncbi.nlm.nih.gov/15943471 DMYM72T DI DMYM72T DMYM72T DN 4-(2-(4-Methylphenylamino)ethyl)-1H-imidazole DMYM72T TI TT9JNIC DMYM72T TN Histamine H3 receptor (H3R) DMYM72T MA Inhibitor DMYM72T RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMYM72T RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMYM91S DI DMYM91S DMYM91S DN Arg-Pro-Lys-Pro-Ala-Ser-Phe-Phe-Gly-Leu-Met-NH2 DMYM91S TI TTZPO1L DMYM91S TN Substance-P receptor (TACR1) DMYM91S MA Inhibitor DMYM91S RN Conformational comparisons of a series of tachykinin peptide analogs. J Med Chem. 2007 Dec 27;50(26):6501-6. DMYM91S RU https://pubmed.ncbi.nlm.nih.gov/18067242 DMYMB4A DI DMYMB4A DMYMB4A DN NSC-122427 DMYMB4A TI TTSZLWK DMYMB4A TN Aromatase (CYP19A1) DMYMB4A MA Inhibitor DMYMB4A RN An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors. Eur J Med Chem. 2009 Oct;44(10):4121-7. DMYMB4A RU https://pubmed.ncbi.nlm.nih.gov/19500885 DMYMCQA DI DMYMCQA DMYMCQA DN ATL802 DMYMCQA TI TTJFY5U DMYMCQA TN Adenosine A3 receptor (ADORA3) DMYMCQA MA Antagonist DMYMCQA RN Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72. DMYMCQA RU https://pubmed.ncbi.nlm.nih.gov/10737749 DMYMCQA DI DMYMCQA DMYMCQA DN ATL802 DMYMCQA TI TTK25J1 DMYMCQA TN Adenosine A1 receptor (ADORA1) DMYMCQA MA Antagonist DMYMCQA RN Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72. DMYMCQA RU https://pubmed.ncbi.nlm.nih.gov/10737749 DMYMCQA DI DMYMCQA DMYMCQA DN ATL802 DMYMCQA TI TTNE7KG DMYMCQA TN Adenosine A2b receptor (ADORA2B) DMYMCQA MA Antagonist DMYMCQA RN Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem. 2000 Mar 23;43(6):1165-72. DMYMCQA RU https://pubmed.ncbi.nlm.nih.gov/10737749 DMYMFSE DI DMYMFSE DMYMFSE DN PD-137821 DMYMFSE TI TTEX248 DMYMFSE TN Dopamine D2 receptor (D2R) DMYMFSE MA Inhibitor DMYMFSE RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DMYMFSE RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DMYMGBA DI DMYMGBA DMYMGBA DN GC-14 DMYMGBA TI TTQWUPT DMYMGBA TN Thyroid hormone receptor (THR) DMYMGBA MA Antagonist DMYMGBA RN Design of thyroid hormone receptor antagonists from first principles. J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):59-73. DMYMGBA RU https://pubmed.ncbi.nlm.nih.gov/12650702 DMYMJHF DI DMYMJHF DMYMJHF DN 6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol DMYMJHF TI TT27RFC DMYMJHF TN Opioid receptor delta (OPRD1) DMYMJHF MA Inhibitor DMYMJHF RN Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6. DMYMJHF RU https://pubmed.ncbi.nlm.nih.gov/6268789 DMYMJHF DI DMYMJHF DMYMJHF DN 6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol DMYMJHF TI TTQW87Y DMYMJHF TN Opioid receptor kappa (OPRK1) DMYMJHF MA Inhibitor DMYMJHF RN Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6. DMYMJHF RU https://pubmed.ncbi.nlm.nih.gov/6268789 DMYMJHF DI DMYMJHF DMYMJHF DN 6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol DMYMJHF TI TTKWM86 DMYMJHF TN Opioid receptor mu (MOP) DMYMJHF MA Inhibitor DMYMJHF RN Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6. DMYMJHF RU https://pubmed.ncbi.nlm.nih.gov/6268789 DMYMNBL DI DMYMNBL DMYMNBL DN Phenyl-phosphonic acid DMYMNBL TI TTANPDJ DMYMNBL TN Carbonic anhydrase II (CA-II) DMYMNBL MA Inhibitor DMYMNBL RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6. DMYMNBL RU https://pubmed.ncbi.nlm.nih.gov/15745821 DMYMNBL DI DMYMNBL DMYMNBL DN Phenyl-phosphonic acid DMYMNBL TI TTZHA0O DMYMNBL TN Carbonic anhydrase IV (CA-IV) DMYMNBL MA Inhibitor DMYMNBL RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6. DMYMNBL RU https://pubmed.ncbi.nlm.nih.gov/15745821 DMYN25U DI DMYN25U DMYN25U DN 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol DMYN25U TI TTZAYWL DMYN25U TN Estrogen receptor (ESR) DMYN25U MA Inhibitor DMYN25U RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMYN25U RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMYN25U DI DMYN25U DMYN25U DN 4,6,7,10-tetramethyl-6H-benzo[c]chromene-3,8-diol DMYN25U TI TTOM3J0 DMYN25U TN Estrogen receptor beta (ESR2) DMYN25U MA Inhibitor DMYN25U RN 6H-Benzo[c]chromen-6-one derivatives as selective ERbeta agonists. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1468-72. DMYN25U RU https://pubmed.ncbi.nlm.nih.gov/16412638 DMYN2U4 DI DMYN2U4 DMYN2U4 DN KNI-10087 DMYN2U4 TI TTXMNHO DMYN2U4 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMYN2U4 MA Inhibitor DMYN2U4 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMYN2U4 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMYN6Z9 DI DMYN6Z9 DMYN6Z9 DN 3-(3-benzylamino)-piperidin-2-one DMYN6Z9 TI TTH18TF DMYN6Z9 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMYN6Z9 MA Inhibitor DMYN6Z9 RN Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32. DMYN6Z9 RU https://pubmed.ncbi.nlm.nih.gov/17367122 DMYN6Z9 DI DMYN6Z9 DMYN6Z9 DN 3-(3-benzylamino)-piperidin-2-one DMYN6Z9 TI TTQ3JTF DMYN6Z9 TN Muscarinic acetylcholine receptor M4 (CHRM4) DMYN6Z9 MA Inhibitor DMYN6Z9 RN Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32. DMYN6Z9 RU https://pubmed.ncbi.nlm.nih.gov/17367122 DMYN6Z9 DI DMYN6Z9 DMYN6Z9 DN 3-(3-benzylamino)-piperidin-2-one DMYN6Z9 TI TTQ13Z5 DMYN6Z9 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMYN6Z9 MA Inhibitor DMYN6Z9 RN Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32. DMYN6Z9 RU https://pubmed.ncbi.nlm.nih.gov/17367122 DMYN6Z9 DI DMYN6Z9 DMYN6Z9 DN 3-(3-benzylamino)-piperidin-2-one DMYN6Z9 TI TTYEG6Q DMYN6Z9 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMYN6Z9 MA Inhibitor DMYN6Z9 RN Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32. DMYN6Z9 RU https://pubmed.ncbi.nlm.nih.gov/17367122 DMYN6Z9 DI DMYN6Z9 DMYN6Z9 DN 3-(3-benzylamino)-piperidin-2-one DMYN6Z9 TI TTZ9SOR DMYN6Z9 TN Muscarinic acetylcholine receptor M1 (CHRM1) DMYN6Z9 MA Inhibitor DMYN6Z9 RN Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32. DMYN6Z9 RU https://pubmed.ncbi.nlm.nih.gov/17367122 DMYNASR DI DMYNASR DMYNASR DN 4-AMBA DMYNASR TI TT5LF3C DMYNASR TN Solute carrier family 15 member 1 (SLC15A1) DMYNASR MA Inhibitor DMYNASR RN Activation of vagal afferents in the rat duodenum by protein digests requires PepT1. J Nutr. 2005 Jun;135(6):1491-5. DMYNASR RU https://pubmed.ncbi.nlm.nih.gov/15930458 DMYNBK5 DI DMYNBK5 DMYNBK5 DN Apamin DMYNBK5 TI TT9R6BE DMYNBK5 TN Calcium-activated potassium channel KCa2.1 (KCNN1) DMYNBK5 MA Blocker (channel blocker) DMYNBK5 RN Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9. DMYNBK5 RU https://pubmed.ncbi.nlm.nih.gov/10696100 DMYNBK5 DI DMYNBK5 DMYNBK5 DN Apamin DMYNBK5 TI TT2T5M0 DMYNBK5 TN Calcium-activated potassium channel KCa2.2 (KCNN2) DMYNBK5 MA Blocker (channel blocker) DMYNBK5 RN SK2 encodes the apamin-sensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat. FEBS Lett. 2000 Mar 10;469(2-3):196-202. DMYNBK5 RU https://pubmed.ncbi.nlm.nih.gov/10713270 DMYNBK5 DI DMYNBK5 DMYNBK5 DN Apamin DMYNBK5 TI TT9JH25 DMYNBK5 TN Calcium-activated potassium channel KCa2.3 (KCNN3) DMYNBK5 MA Blocker (channel blocker) DMYNBK5 RN SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34. DMYNBK5 RU https://pubmed.ncbi.nlm.nih.gov/11533126 DMYNCQR DI DMYNCQR DMYNCQR DN LY108742 DMYNCQR TI TTJQOD7 DMYNCQR TN 5-HT 2A receptor (HTR2A) DMYNCQR MA Antagonist DMYNCQR RN Species variations in transmembrane region V of the 5-hydroxytryptamine type 2A receptor alter the structure-activity relationship of certain ergolines and tryptamines. Mol Pharmacol. 1994 Feb;45(2):277-86. DMYNCQR RU https://pubmed.ncbi.nlm.nih.gov/8114677 DMYNFIP DI DMYNFIP DMYNFIP DN 5-methyl orotate DMYNFIP TI TT09NOX DMYNFIP TN Plasmodium Dihydroorotase (Malaria dho) DMYNFIP MA Inhibitor DMYNFIP RN Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301. DMYNFIP RU https://pubmed.ncbi.nlm.nih.gov/1348618 DMYNIG5 DI DMYNIG5 DMYNIG5 DN WS-070117 DMYNIG5 TI TTOF3WZ DMYNIG5 TN Lipoprotein lipase (LPL) DMYNIG5 MA Modulator DMYNIG5 RN Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. Drugs Today (Barc). 2013 Mar;49(3):161-70. DMYNIG5 RU https://pubmed.ncbi.nlm.nih.gov/23527320 DMYNKLR DI DMYNKLR DMYNKLR DN Allyl 4-(aminosulfonyl)benzoate DMYNKLR TI TTANPDJ DMYNKLR TN Carbonic anhydrase II (CA-II) DMYNKLR MA Inhibitor DMYNKLR RN Synthesis and structure-activity relationships of novel benzene sulfonamides with potent binding affinity for bovine carbonic anhydrase II. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5429-33. DMYNKLR RU https://pubmed.ncbi.nlm.nih.gov/16213706 DMYNL40 DI DMYNL40 DMYNL40 DN LASSBio-881 DMYNL40 TI TTMI6F5 DMYNL40 TN Transient receptor potential cation channel V1 (TRPV1) DMYNL40 MA Agonist DMYNL40 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 507). DMYNL40 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=507 DMYNLOI DI DMYNLOI DMYNLOI DN 7-(3-(methoxymethyl)phenyl)-2-methylquinoline DMYNLOI TI TTHS256 DMYNLOI TN Metabotropic glutamate receptor 5 (mGluR5) DMYNLOI MA Inhibitor DMYNLOI RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMYNLOI RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMYNO71 DI DMYNO71 DMYNO71 DN (+/-)-threo-N-Allylmethylphenidate DMYNO71 TI TTVBI8W DMYNO71 TN Dopamine transporter (DAT) DMYNO71 MA Inhibitor DMYNO71 RN Quantitative structure-activity relationship studies of threo-methylphenidate analogs. Bioorg Med Chem. 2010 Oct 15;18(20):7221-38. DMYNO71 RU https://pubmed.ncbi.nlm.nih.gov/20846865 DMYNTJ0 DI DMYNTJ0 DMYNTJ0 DN 4-Hex-3-ynyl-1H-imidazole DMYNTJ0 TI TT9JNIC DMYNTJ0 TN Histamine H3 receptor (H3R) DMYNTJ0 MA Inhibitor DMYNTJ0 RN New acetylene based histamine H3 receptor antagonists derived from the marine natural product verongamine. Bioorg Med Chem Lett. 1998 May 19;8(10):1133-8. DMYNTJ0 RU https://pubmed.ncbi.nlm.nih.gov/9871722 DMYNVLZ DI DMYNVLZ DMYNVLZ DN 4-iodo-6-phenylpyrimidine DMYNVLZ TI TT6804T DMYNVLZ TN MIF messenger RNA (MIF mRNA) DMYNVLZ MA Inhibitor DMYNVLZ RN Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4. DMYNVLZ RU https://pubmed.ncbi.nlm.nih.gov/20728358 DMYNZXC DI DMYNZXC DMYNZXC DN Pyrrolidin-1-yl-thiourea DMYNZXC TI TTMI6F5 DMYNZXC TN Transient receptor potential cation channel V1 (TRPV1) DMYNZXC MA Inhibitor DMYNZXC RN N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6. DMYNZXC RU https://pubmed.ncbi.nlm.nih.gov/15026052 DMYNZXC DI DMYNZXC DMYNZXC DN Pyrrolidin-1-yl-thiourea DMYNZXC TI TTKP2SU DMYNZXC TN Transient receptor potential cation channel V4 (TRPV4) DMYNZXC MA Inhibitor DMYNZXC RN N-4-methansulfonamidobenzyl-N'-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands. Bioorg Med Chem Lett. 2004 Apr 5;14(7):1693-6. DMYNZXC RU https://pubmed.ncbi.nlm.nih.gov/15026052 DMYO2GP DI DMYO2GP DMYO2GP DN 4-Ethyl-5-piperidin-4-yl-isoxazol-3-ol DMYO2GP TI TTNJYV2 DMYO2GP TN Gamma-aminobutyric acid receptor (GAR) DMYO2GP MA Inhibitor DMYO2GP RN A novel class of potent 3-isoxazolol GABA(A) antagonists: design, synthesis, and pharmacology. J Med Chem. 2000 Dec 28;43(26):4930-3. DMYO2GP RU https://pubmed.ncbi.nlm.nih.gov/11150163 DMYO4A3 DI DMYO4A3 DMYO4A3 DN Sri-9662 DMYO4A3 TI TT9SL3Q DMYO4A3 TN Polypeptide deformylase (PDF) DMYO4A3 MA Inhibitor DMYO4A3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYO4A3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYO8D3 DI DMYO8D3 DMYO8D3 DN 1-(bis(4-bromophenyl)methyl)-3-phenylurea DMYO8D3 TI TT6OEDT DMYO8D3 TN Cannabinoid receptor 1 (CB1) DMYO8D3 MA Inhibitor DMYO8D3 RN 1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists. J Med Chem. 2005 Nov 17;48(23):7486-90. DMYO8D3 RU https://pubmed.ncbi.nlm.nih.gov/16279809 DMYO8T6 DI DMYO8T6 DMYO8T6 DN MK-212 DMYO8T6 TI TTWJBZ5 DMYO8T6 TN 5-HT 2C receptor (HTR2C) DMYO8T6 MA Modulator DMYO8T6 RN [Agonists of 5HT2C-receptors SCH 23390 and MK 212 incresase the force of rat aorta contraction in the presence of vasopressin and angiotensin II].Patol Fiziol Eksp Ter.2014 Oct-Dec;(4):17-29. DMYO8T6 RU https://www.ncbi.nlm.nih.gov/pubmed/25980223 DMYOADQ DI DMYOADQ DMYOADQ DN H-2',6'-dimethyltyrosine-Tic-OH DMYOADQ TI TTKWM86 DMYOADQ TN Opioid receptor mu (MOP) DMYOADQ MA Inhibitor DMYOADQ RN Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5. DMYOADQ RU https://pubmed.ncbi.nlm.nih.gov/19827750 DMYOADQ DI DMYOADQ DMYOADQ DN H-2',6'-dimethyltyrosine-Tic-OH DMYOADQ TI TT27RFC DMYOADQ TN Opioid receptor delta (OPRD1) DMYOADQ MA Inhibitor DMYOADQ RN Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5. DMYOADQ RU https://pubmed.ncbi.nlm.nih.gov/19827750 DMYOCFX DI DMYOCFX DMYOCFX DN 4-Bromo-3-hydroxy-1H-quinolin-2-one DMYOCFX TI TTKJEMQ DMYOCFX TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMYOCFX MA Inhibitor DMYOCFX RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMYOCFX RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMYOCFX DI DMYOCFX DMYOCFX DN 4-Bromo-3-hydroxy-1H-quinolin-2-one DMYOCFX TI TTN9D8E DMYOCFX TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMYOCFX MA Inhibitor DMYOCFX RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMYOCFX RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMYOCFX DI DMYOCFX DMYOCFX DN 4-Bromo-3-hydroxy-1H-quinolin-2-one DMYOCFX TI TTLD29N DMYOCFX TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMYOCFX MA Inhibitor DMYOCFX RN 3-Hydroxy-quinolin-2-ones: Inhibitors of [3H]-glycine binding to the site associated with the NMDA receptor, Bioorg. Med. Chem. Lett. 6(5):499-504 (1996). DMYOCFX RU http://www.sciencedirect.com/science/article/pii/0960894X96000315 DMYODMN DI DMYODMN DMYODMN DN ISIS 134609 DMYODMN TI TTKW4ML DMYODMN TN Caspase 6 messenger RNA (CASP6 mRNA) DMYODMN RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMYODMN RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMYOJ01 DI DMYOJ01 DMYOJ01 DN 1-Morpholin-4-yl-benzo[f]chromen-3-one DMYOJ01 TI TTK3PY9 DMYOJ01 TN DNA-dependent protein kinase catalytic (PRKDC) DMYOJ01 MA Inhibitor DMYOJ01 RN Selective benzopyranone and pyrimido[2,1-a]isoquinolin-4-one inhibitors of DNA-dependent protein kinase: synthesis, structure-activity studies, and... J Med Chem. 2005 Jan 27;48(2):569-85. DMYOJ01 RU https://pubmed.ncbi.nlm.nih.gov/15658870 DMYONVF DI DMYONVF DMYONVF DN LC-445 DMYONVF TI TTIYVQP DMYONVF TN Polo-like kinase 1 (PLK1) DMYONVF MA Inhibitor DMYONVF RN Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. DMYONVF RU https://pubmed.ncbi.nlm.nih.gov/19474163 DMYOP45 DI DMYOP45 DMYOP45 DN Piceatannol DMYOP45 TI TTYR7OH DMYOP45 TN Interferon regulatory factor 3 (IRF3) DMYOP45 MA Inhibitor DMYOP45 RN Inhibition of lipopolysaccharide-induced interferon regulatory factor 3 activation and protection from septic shock by hydroxystilbenes. Shock. 2004 May;21(5):470-5. DMYOP45 RU https://pubmed.ncbi.nlm.nih.gov/15087825 DMYOTMP DI DMYOTMP DMYOTMP DN (2-(2-chlorophenyl)pyridin-3-yl)methanamine DMYOTMP TI TTDIGC1 DMYOTMP TN Dipeptidyl peptidase 4 (DPP-4) DMYOTMP MA Inhibitor DMYOTMP RN In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1405-9. DMYOTMP RU https://pubmed.ncbi.nlm.nih.gov/16321524 DMYOXJ4 DI DMYOXJ4 DMYOXJ4 DN Thiophosphoric acid (E)-tetradec-9-enyl ester DMYOXJ4 TI TTQ6S1K DMYOXJ4 TN Lysophosphatidic acid receptor 1 (LPAR1) DMYOXJ4 MA Inhibitor DMYOXJ4 RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMYOXJ4 RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMYP0DE DI DMYP0DE DMYP0DE DN HI-445 DMYP0DE TI TT84ETX DMYP0DE TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMYP0DE MA Inhibitor DMYP0DE RN Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistan... Bioorg Med Chem Lett. 1999 Jun 7;9(11):1593-8. DMYP0DE RU https://pubmed.ncbi.nlm.nih.gov/10386942 DMYP0UI DI DMYP0UI DMYP0UI DN 2-morpholinobenzo[h]quinolin-4(1H)-one DMYP0UI TI TTK3PY9 DMYP0UI TN DNA-dependent protein kinase catalytic (PRKDC) DMYP0UI MA Inhibitor DMYP0UI RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMYP0UI RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMYP7UG DI DMYP7UG DMYP7UG DN 6-Nitro-benzothiazole-2-sulfonic acid amide DMYP7UG TI TTANPDJ DMYP7UG TN Carbonic anhydrase II (CA-II) DMYP7UG MA Inhibitor DMYP7UG RN Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. DMYP7UG RU https://pubmed.ncbi.nlm.nih.gov/15482952 DMYPC0W DI DMYPC0W DMYPC0W DN 1-(4-methoxyphenyl)-3-(4-methylthiazol-2-yl)urea DMYPC0W TI TTSJ6Q4 DMYPC0W TN LOX-5 messenger RNA (ALOX5 mRNA) DMYPC0W MA Inhibitor DMYPC0W RN Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. J Med Chem. 2007 May 31;50(11):2640-6. DMYPC0W RU https://pubmed.ncbi.nlm.nih.gov/17461565 DMYPD5L DI DMYPD5L DMYPD5L DN 99mTc-MIP-1407 DMYPD5L TI TTIND6G DMYPD5L TN Somatostatin receptor type 1 (SSTR1) DMYPD5L MA Modulator DMYPD5L RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMYPD5L RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMYPD5L DI DMYPD5L DMYPD5L DN 99mTc-MIP-1407 DMYPD5L TI TTJX3UE DMYPD5L TN Somatostatin receptor type 3 (SSTR3) DMYPD5L MA Modulator DMYPD5L RN Nat Rev Drug Discov. 2013 Feb;12(2):87-90. DMYPD5L RU https://pubmed.ncbi.nlm.nih.gov/23370234 DMYPD5L DI DMYPD5L DMYPD5L DN 99mTc-MIP-1407 DMYPD5L TI TTZ6T9E DMYPD5L TN Somatostatin receptor type 2 (SSTR2) DMYPD5L MA Modulator DMYPD5L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 356). DMYPD5L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=356 DMYPD5L DI DMYPD5L DMYPD5L DN 99mTc-MIP-1407 DMYPD5L TI TTAE1BR DMYPD5L TN Somatostatin receptor type 4 (SSTR4) DMYPD5L MA Modulator DMYPD5L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 358). DMYPD5L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=358 DMYPD5L DI DMYPD5L DMYPD5L DN 99mTc-MIP-1407 DMYPD5L TI TT2BC4G DMYPD5L TN Somatostatin receptor type 5 (SSTR5) DMYPD5L MA Modulator DMYPD5L RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 359). DMYPD5L RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=359 DMYPEX3 DI DMYPEX3 DMYPEX3 DN N-Methyl-N-(Methylbenzyl)Formamide DMYPEX3 TI TTB2MXP DMYPEX3 TN Angiotensinogenase renin (REN) DMYPEX3 MA Inhibitor DMYPEX3 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYPEX3 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYPG01 DI DMYPG01 DMYPG01 DN CMI-1145 DMYPG01 TI TTYEG6Q DMYPG01 TN Muscarinic acetylcholine receptor M2 (CHRM2) DMYPG01 MA Agonist DMYPG01 RN Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93. DMYPG01 RU https://pubmed.ncbi.nlm.nih.gov/12391271 DMYPG01 DI DMYPG01 DMYPG01 DN CMI-1145 DMYPG01 TI TTQ3JTF DMYPG01 TN Muscarinic acetylcholine receptor M4 (CHRM4) DMYPG01 MA Agonist DMYPG01 RN Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol. 2002 Nov;62(5):1084-93. DMYPG01 RU https://pubmed.ncbi.nlm.nih.gov/12391271 DMYPHVC DI DMYPHVC DMYPHVC DN C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMYPHVC TI TTD0CIQ DMYPHVC TN Melanocortin receptor 4 (MC4R) DMYPHVC MA Inhibitor DMYPHVC RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMYPHVC RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMYPHVC DI DMYPHVC DMYPHVC DN C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMYPHVC TI TTNI91K DMYPHVC TN Melanocortin receptor 3 (MC3R) DMYPHVC MA Inhibitor DMYPHVC RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMYPHVC RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMYPHVC DI DMYPHVC DMYPHVC DN C[CO-(CH2)3-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2 DMYPHVC TI TTEOSZT DMYPHVC TN Melanocortin receptor (MCR) DMYPHVC MA Inhibitor DMYPHVC RN Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95. DMYPHVC RU https://pubmed.ncbi.nlm.nih.gov/18088090 DMYPJC3 DI DMYPJC3 DMYPJC3 DN Oleanonic acid DMYPJC3 TI TTELIN2 DMYPJC3 TN PTPN1 messenger RNA (PTPN1 mRNA) DMYPJC3 MA Inhibitor DMYPJC3 RN Triterpenoids from the leaves of Diospyros kaki (persimmon) and their inhibitory effects on protein tyrosine phosphatase 1B. J Nat Prod. 2008 Oct;71(10):1775-8. DMYPJC3 RU https://pubmed.ncbi.nlm.nih.gov/18798681 DMYPJC3 DI DMYPJC3 DMYPJC3 DN Oleanonic acid DMYPJC3 TI TTZHY6R DMYPJC3 TN Glycogen phosphorylase muscle form (GP) DMYPJC3 MA Inhibitor DMYPJC3 RN Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54. DMYPJC3 RU https://pubmed.ncbi.nlm.nih.gov/18517260 DMYPLZ8 DI DMYPLZ8 DMYPLZ8 DN Cristacarpin DMYPLZ8 TI TT50QJ3 DMYPLZ8 TN Influenza Neuraminidase (Influ NA) DMYPLZ8 MA Inhibitor DMYPLZ8 RN Prenylated pterocarpans as bacterial neuraminidase inhibitors. Bioorg Med Chem. 2010 May 1;18(9):3335-44. DMYPLZ8 RU https://pubmed.ncbi.nlm.nih.gov/20363636 DMYPM2D DI DMYPM2D DMYPM2D DN SULFURETIN DMYPM2D TI TTL53M6 DMYPM2D TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMYPM2D MA Inhibitor DMYPM2D RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMYPM2D RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMYPOC5 DI DMYPOC5 DMYPOC5 DN 2-(N-Pyrrolidinyl)-3'-fluoropropiophenone DMYPOC5 TI TTVBI8W DMYPOC5 TN Dopamine transporter (DAT) DMYPOC5 MA Inhibitor DMYPOC5 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMYPOC5 RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMYPOC5 DI DMYPOC5 DMYPOC5 DN 2-(N-Pyrrolidinyl)-3'-fluoropropiophenone DMYPOC5 TI TTAWNKZ DMYPOC5 TN Norepinephrine transporter (NET) DMYPOC5 MA Inhibitor DMYPOC5 RN Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14. DMYPOC5 RU https://pubmed.ncbi.nlm.nih.gov/20158204 DMYPQEW DI DMYPQEW DMYPQEW DN 2-chloroadenosine DMYPQEW TI TTNE7KG DMYPQEW TN Adenosine A2b receptor (ADORA2B) DMYPQEW MA Agonist DMYPQEW RN Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol. 1980 Jun;58(6):673-91. DMYPQEW RU https://pubmed.ncbi.nlm.nih.gov/6253037 DMYPQEW DI DMYPQEW DMYPQEW DN 2-chloroadenosine DMYPQEW TI TTK25J1 DMYPQEW TN Adenosine A1 receptor (ADORA1) DMYPQEW MA Agonist DMYPQEW RN Identification of the adenine binding site of the human A1 adenosine receptor. J Biol Chem. 1999 Feb 5;274(6):3617-21. DMYPQEW RU https://pubmed.ncbi.nlm.nih.gov/9920910 DMYPQEW DI DMYPQEW DMYPQEW DN 2-chloroadenosine DMYPQEW TI TTJFY5U DMYPQEW TN Adenosine A3 receptor (ADORA3) DMYPQEW MA Agonist DMYPQEW RN A binding site model and structure-activity relationships for the rat A3 adenosine receptor. Mol Pharmacol. 1994 Jun;45(6):1101-11. DMYPQEW RU https://pubmed.ncbi.nlm.nih.gov/8022403 DMYPVO0 DI DMYPVO0 DMYPVO0 DN domoic acid DMYPVO0 TI TT0K5RG DMYPVO0 TN Glutamate receptor ionotropic kainate 2 (GRIK2) DMYPVO0 MA Agonist DMYPVO0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451). DMYPVO0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451 DMYPVO0 DI DMYPVO0 DMYPVO0 DN domoic acid DMYPVO0 TI TT0MYE2 DMYPVO0 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMYPVO0 MA Agonist DMYPVO0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMYPVO0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMYPVO0 DI DMYPVO0 DMYPVO0 DN domoic acid DMYPVO0 TI TTQV6BO DMYPVO0 TN Glutamate receptor ionotropic kainate 4 (GluK4) DMYPVO0 MA Agonist DMYPVO0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 453). DMYPVO0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=453 DMYPVO0 DI DMYPVO0 DMYPVO0 DN domoic acid DMYPVO0 TI TTO6LI7 DMYPVO0 TN Glutamate receptor ionotropic kainate 5 (GRIK5) DMYPVO0 MA Agonist DMYPVO0 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 454). DMYPVO0 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=454 DMYPVSJ DI DMYPVSJ DMYPVSJ DN UFP-512 DMYPVSJ TI TT27RFC DMYPVSJ TN Opioid receptor delta (OPRD1) DMYPVSJ MA Inhibitor DMYPVSJ RN Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. DMYPVSJ RU https://pubmed.ncbi.nlm.nih.gov/20637637 DMYPVSJ DI DMYPVSJ DMYPVSJ DN UFP-512 DMYPVSJ TI TTKWM86 DMYPVSJ TN Opioid receptor mu (MOP) DMYPVSJ MA Inhibitor DMYPVSJ RN Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30. DMYPVSJ RU https://pubmed.ncbi.nlm.nih.gov/20637637 DMYPZMO DI DMYPZMO DMYPZMO DN N4-(N,N-diphenylcarbamoyl)-aminoguanidine DMYPZMO TI TT6L509 DMYPZMO TN Coagulation factor IIa (F2) DMYPZMO MA Inhibitor DMYPZMO RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYPZMO RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYQB5R DI DMYQB5R DMYQB5R DN 6-(4-Decyloxy-phenyl)-1,1,1-trifluoro-hexan-2-one DMYQB5R TI TTT1JVS DMYQB5R TN Cytosolic phospholipase A2 (GIVA cPLA2) DMYQB5R MA Inhibitor DMYQB5R RN Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37. DMYQB5R RU https://pubmed.ncbi.nlm.nih.gov/19053783 DMYQBSV DI DMYQBSV DMYQBSV DN 2-(3-Chlorophenyl)-2H-indazole-7-carboxamide DMYQBSV TI TTVDSZ0 DMYQBSV TN Poly [ADP-ribose] polymerase 1 (PARP1) DMYQBSV MA Inhibitor DMYQBSV RN Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica... J Med Chem. 2009 Nov 26;52(22):7170-85. DMYQBSV RU https://pubmed.ncbi.nlm.nih.gov/19873981 DMYQDPM DI DMYQDPM DMYQDPM DN SB236057 DMYQDPM TI TTK8CXU DMYQDPM TN 5-HT 1B receptor (HTR1B) DMYQDPM MA Antagonist DMYQDPM RN SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. Eur J Pharmacol. 1999 Jun 30;375(1-3):359-65. DMYQDPM RU https://pubmed.ncbi.nlm.nih.gov/10443589 DMYQDXO DI DMYQDXO DMYQDXO DN PMID22521646C12 DMYQDXO TI TTQBR95 DMYQDXO TN Stress-activated protein kinase 2a (p38 alpha) DMYQDXO MA Inhibitor DMYQDXO RN Novel triazolopyridylbenzamides as potent and selective p38alpha inhibitors. Bioorg Med Chem Lett. 2012 May 15;22(10):3431-6. DMYQDXO RU https://pubmed.ncbi.nlm.nih.gov/22521646 DMYQG7A DI DMYQG7A DMYQG7A DN 3-mercapto-2-(piperidin-4-yl)propanoic acid DMYQG7A TI TTP18AY DMYQG7A TN Carboxypeptidase B2 (CPB2) DMYQG7A MA Inhibitor DMYQG7A RN 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54. DMYQG7A RU https://pubmed.ncbi.nlm.nih.gov/17189688 DMYQGDV DI DMYQGDV DMYQGDV DN MANGOSTIN DMYQGDV TI TT12ABZ DMYQGDV TN Arachidonate 12-lipoxygenase (12-LOX) DMYQGDV MA Inhibitor DMYQGDV RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DMYQGDV RU https://pubmed.ncbi.nlm.nih.gov/17826100 DMYQGDV DI DMYQGDV DMYQGDV DN MANGOSTIN DMYQGDV TI TTN9T81 DMYQGDV TN Arachidonate 15-lipoxygenase (15-LOX) DMYQGDV MA Inhibitor DMYQGDV RN Discovery of platelet-type 12-human lipoxygenase selective inhibitors by high-throughput screening of structurally diverse libraries. Bioorg Med Chem. 2007 Nov 15;15(22):6900-8. DMYQGDV RU https://pubmed.ncbi.nlm.nih.gov/17826100 DMYQGDV DI DMYQGDV DMYQGDV DN MANGOSTIN DMYQGDV TI TT50QJ3 DMYQGDV TN Influenza Neuraminidase (Influ NA) DMYQGDV MA Inhibitor DMYQGDV RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMYQGDV RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMYQGFJ DI DMYQGFJ DMYQGFJ DN normorphine DMYQGFJ TI TTKWM86 DMYQGFJ TN Opioid receptor mu (MOP) DMYQGFJ MA Agonist DMYQGFJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319). DMYQGFJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=319 DMYQGFJ DI DMYQGFJ DMYQGFJ DN normorphine DMYQGFJ TI TTQW87Y DMYQGFJ TN Opioid receptor kappa (OPRK1) DMYQGFJ MA Agonist DMYQGFJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 318). DMYQGFJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=318 DMYQGFJ DI DMYQGFJ DMYQGFJ DN normorphine DMYQGFJ TI TT27RFC DMYQGFJ TN Opioid receptor delta (OPRD1) DMYQGFJ MA Agonist DMYQGFJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317). DMYQGFJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=317 DMYQH2N DI DMYQH2N DMYQH2N DN Cyclohexylammonium Ion DMYQH2N TI TTICX3S DMYQH2N TN Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA) DMYQH2N MA Inhibitor DMYQH2N RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYQH2N RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYQM3B DI DMYQM3B DMYQM3B DN BIS(16)-HUPERZINE B DMYQM3B TI TT1RS9F DMYQM3B TN Acetylcholinesterase (AChE) DMYQM3B MA Inhibitor DMYQM3B RN Bis-huperzine B: highly potent and selective acetylcholinesterase inhibitors. J Med Chem. 2005 Feb 10;48(3):655-7. DMYQM3B RU https://pubmed.ncbi.nlm.nih.gov/15689148 DMYQNK0 DI DMYQNK0 DMYQNK0 DN 2,6-bis(4-chlorophenyl)-9H-purine DMYQNK0 TI TTJFY5U DMYQNK0 TN Adenosine A3 receptor (ADORA3) DMYQNK0 MA Inhibitor DMYQNK0 RN 2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists. J Med Chem. 2006 May 18;49(10):2861-7. DMYQNK0 RU https://pubmed.ncbi.nlm.nih.gov/16686529 DMYQOKX DI DMYQOKX DMYQOKX DN MeBut-RYYRIK-NH2 DMYQOKX TI TTNT7K8 DMYQOKX TN Nociceptin receptor (OPRL1) DMYQOKX MA Inhibitor DMYQOKX RN Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. DMYQOKX RU https://pubmed.ncbi.nlm.nih.gov/18068993 DMYQR3A DI DMYQR3A DMYQR3A DN ISIS 119285 DMYQR3A TI TTKS60G DMYQR3A TN STXBP4 messenger RNA (STXBP4 mRNA) DMYQR3A RN US patent application no. 6,503,756, Antisense modulation of syntaxin 4 interacting protein expression. DMYQR3A RU http://www.patentbuddy.com/Patent/6503756?ft=true&sr=true DMYQXPB DI DMYQXPB DMYQXPB DN Tert-Butyl 3-(2-oxohexadecanamido)propanoate DMYQXPB TI TTT1JVS DMYQXPB TN Cytosolic phospholipase A2 (GIVA cPLA2) DMYQXPB MA Inhibitor DMYQXPB RN Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69. DMYQXPB RU https://pubmed.ncbi.nlm.nih.gov/18993078 DMYR350 DI DMYR350 DMYR350 DN 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione DMYR350 TI TTKJEMQ DMYR350 TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMYR350 MA Inhibitor DMYR350 RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMYR350 RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMYR350 DI DMYR350 DMYR350 DN 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione DMYR350 TI TTN9D8E DMYR350 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMYR350 MA Inhibitor DMYR350 RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMYR350 RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMYR350 DI DMYR350 DMYR350 DN 3-Hydroxy-6-methyl-1H-benzo[b]azepine-2,5-dione DMYR350 TI TTLD29N DMYR350 TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMYR350 MA Inhibitor DMYR350 RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMYR350 RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMYR8SG DI DMYR8SG DMYR8SG DN Tubacin DMYR8SG TI TT5ZKDI DMYR8SG TN Histone deacetylase 6 (HDAC6) DMYR8SG MA Inhibitor DMYR8SG RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMYR8SG RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMYRBO0 DI DMYRBO0 DMYRBO0 DN S-(4-Nitrobenzyl)isothiourea hydrochloride DMYRBO0 TI TTZJYKH DMYRBO0 TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMYRBO0 MA Inhibitor DMYRBO0 RN S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg Med Chem Lett. 2010 Sep 1;20(17):5126-9. DMYRBO0 RU https://pubmed.ncbi.nlm.nih.gov/20688518 DMYRC2M DI DMYRC2M DMYRC2M DN N-Hydroxy-N'-(3-methylphenyl)octanediamide DMYRC2M TI TT6R7JZ DMYRC2M TN Histone deacetylase 1 (HDAC1) DMYRC2M MA Inhibitor DMYRC2M RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMYRC2M RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMYRC2M DI DMYRC2M DMYRC2M DN N-Hydroxy-N'-(3-methylphenyl)octanediamide DMYRC2M TI TTBH0VX DMYRC2M TN Histone deacetylase (HDAC) DMYRC2M MA Inhibitor DMYRC2M RN Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short al... J Med Chem. 2010 Mar 11;53(5):1937-50. DMYRC2M RU https://pubmed.ncbi.nlm.nih.gov/20143840 DMYRCHG DI DMYRCHG DMYRCHG DN MRT67307 DMYRCHG TI TTRPDBG DMYRCHG TN Inhibitor of nuclear factor kappa-B kinase (IKK) DMYRCHG MA Inhibitor DMYRCHG RN Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104. DMYRCHG RU https://pubmed.ncbi.nlm.nih.gov/21138416 DMYRCHG DI DMYRCHG DMYRCHG DN MRT67307 DMYRCHG TI TTH5TC2 DMYRCHG TN NF-kappa-B-activating kinase (TBK1) DMYRCHG MA Inhibitor DMYRCHG RN Novel cross-talk within the IKK family controls innate immunity. Biochem J. 2011 Feb 15;434(1):93-104. DMYRCHG RU https://pubmed.ncbi.nlm.nih.gov/21138416 DMYRCHV DI DMYRCHV DMYRCHV DN LUFFARIELLOLIDE DMYRCHV TI TTO8QRU DMYRCHV TN Group IIA phospholipase A2 (GIIA sPLA2) DMYRCHV MA Inhibitor DMYRCHV RN Phospholipase A2 inhibitors from marine organisms. J Nat Prod. 1992 Dec;55(12):1701-17. DMYRCHV RU https://pubmed.ncbi.nlm.nih.gov/1294693 DMYRDBX DI DMYRDBX DMYRDBX DN ERB-002 DMYRDBX TI TTOM3J0 DMYRDBX TN Estrogen receptor beta (ESR2) DMYRDBX MA Agonist DMYRDBX RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 621). DMYRDBX RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=621 DMYRHFI DI DMYRHFI DMYRHFI DN (2R,3R)-iodoreboxetine DMYRHFI TI TT3ROYC DMYRHFI TN Serotonin transporter (SERT) DMYRHFI MA Inhibitor DMYRHFI RN New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3. DMYRHFI RU https://pubmed.ncbi.nlm.nih.gov/18762424 DMYRHFI DI DMYRHFI DMYRHFI DN (2R,3R)-iodoreboxetine DMYRHFI TI TTVBI8W DMYRHFI TN Dopamine transporter (DAT) DMYRHFI MA Inhibitor DMYRHFI RN New iodoreboxetine analogues for SPECT imaging of the noradrenaline transporter. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4940-3. DMYRHFI RU https://pubmed.ncbi.nlm.nih.gov/18762424 DMYRHK6 DI DMYRHK6 DMYRHK6 DN ZK159222 DMYRHK6 TI TTK59TV DMYRHK6 TN Vitamin D3 receptor (VDR) DMYRHK6 MA Antagonist DMYRHK6 RN Carboxylic ester antagonists of 1alpha,25-dihydroxyvitamin D(3) show cell-specific actions. Chem Biol. 2000 Nov;7(11):885-94. DMYRHK6 RU https://pubmed.ncbi.nlm.nih.gov/11094341 DMYRILU DI DMYRILU DMYRILU DN ICI-211965 DMYRILU TI TT2J34L DMYRILU TN Arachidonate 5-lipoxygenase (5-LOX) DMYRILU MA Modulator DMYRILU RN DOI: 10.1517/13543776.2.11.1817 DMYRILU RU http://www.tandfonline.com/doi/abs/10.1517/13543776.2.11.1817?journalCode=ietp19 DMYRJAB DI DMYRJAB DMYRJAB DN 3-(6-methoxynaphthalen-2-yl)pyridine DMYRJAB TI TTSZLWK DMYRJAB TN Aromatase (CYP19A1) DMYRJAB MA Inhibitor DMYRJAB RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMYRJAB RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMYRJAB DI DMYRJAB DMYRJAB DN 3-(6-methoxynaphthalen-2-yl)pyridine DMYRJAB TI TTIQUX7 DMYRJAB TN Steroid 11-beta-hydroxylase (CYP11B1) DMYRJAB MA Inhibitor DMYRJAB RN Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008 Oct 9;51(19):6138-49. DMYRJAB RU https://pubmed.ncbi.nlm.nih.gov/18763754 DMYRJAB DI DMYRJAB DMYRJAB DN 3-(6-methoxynaphthalen-2-yl)pyridine DMYRJAB TI TTRA5BZ DMYRJAB TN Steroid 17-alpha-monooxygenase (S17AH) DMYRJAB MA Inhibitor DMYRJAB RN In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. DMYRJAB RU https://pubmed.ncbi.nlm.nih.gov/19049427 DMYRKEJ DI DMYRKEJ DMYRKEJ DN SK&F-105854 DMYRKEJ TI TT34BHT DMYRKEJ TN Adrenergic receptor alpha-1D (ADRA1D) DMYRKEJ MA Inhibitor DMYRKEJ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMYRKEJ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMYRKEJ DI DMYRKEJ DMYRKEJ DN SK&F-105854 DMYRKEJ TI TTNGILX DMYRKEJ TN Adrenergic receptor alpha-1A (ADRA1A) DMYRKEJ MA Inhibitor DMYRKEJ RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMYRKEJ RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMYRKEJ DI DMYRKEJ DMYRKEJ DN SK&F-105854 DMYRKEJ TI TTBRKXS DMYRKEJ TN Adrenergic receptor alpha-1B (ADRA1B) DMYRKEJ MA Inhibitor DMYRKEJ RN Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J Med Chem. 1995 Sep 15;38(19):3681-716. DMYRKEJ RU https://pubmed.ncbi.nlm.nih.gov/7562902 DMYRLA0 DI DMYRLA0 DMYRLA0 DN ZARAGOZIC ACID B DMYRLA0 TI TTFQEO5 DMYRLA0 TN Squalene synthetase (FDFT1) DMYRLA0 MA Inhibitor DMYRLA0 RN Zaragozic acids D and D2: potent inhibitors of squalene synthase and of Ras farnesyl-protein transferase. J Nat Prod. 1993 Nov;56(11):1923-9. DMYRLA0 RU https://pubmed.ncbi.nlm.nih.gov/8289063 DMYRUH2 DI DMYRUH2 DMYRUH2 DN I-BET151 DMYRUH2 TI TTRA6BO DMYRUH2 TN Bromodomain-containing protein 4 (BRD4) DMYRUH2 MA Inhibitor DMYRUH2 RN Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33. DMYRUH2 RU https://pubmed.ncbi.nlm.nih.gov/21964340 DMYRUH2 DI DMYRUH2 DMYRUH2 DN I-BET151 DMYRUH2 TI TTDP48B DMYRUH2 TN Bromodomain-containing protein 2 (BRD2) DMYRUH2 MA Inhibitor DMYRUH2 RN Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33. DMYRUH2 RU https://pubmed.ncbi.nlm.nih.gov/21964340 DMYRUH2 DI DMYRUH2 DMYRUH2 DN I-BET151 DMYRUH2 TI TTHE657 DMYRUH2 TN Bromodomain-containing protein 3 (BRD3) DMYRUH2 MA Inhibitor DMYRUH2 RN Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011 Oct 2;478(7370):529-33. DMYRUH2 RU https://pubmed.ncbi.nlm.nih.gov/21964340 DMYRVZ8 DI DMYRVZ8 DMYRVZ8 DN CTEP DMYRVZ8 TI TTHS256 DMYRVZ8 TN Metabotropic glutamate receptor 5 (mGluR5) DMYRVZ8 MA Antagonist DMYRVZ8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293). DMYRVZ8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=293 DMYRWQ3 DI DMYRWQ3 DMYRWQ3 DN KYS-05074 DMYRWQ3 TI TT729IR DMYRWQ3 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMYRWQ3 MA Inhibitor DMYRWQ3 RN Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5014-7. DMYRWQ3 RU https://pubmed.ncbi.nlm.nih.gov/16876410 DMYS6DB DI DMYS6DB DMYS6DB DN 18alpha-Glycyrrhetic acid DMYS6DB TI TTELIN2 DMYS6DB TN PTPN1 messenger RNA (PTPN1 mRNA) DMYS6DB MA Inhibitor DMYS6DB RN Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6. DMYS6DB RU https://pubmed.ncbi.nlm.nih.gov/16580200 DMYSCQU DI DMYSCQU DMYSCQU DN Alpha-eudesmol DMYSCQU TI TTX4QDJ DMYSCQU TN Voltage-gated calcium channel alpha Cav2.1 (CACNA1A) DMYSCQU MA Blocker DMYSCQU RN Alpha-eudesmol, a P/Q-type Ca(2+) channel blocker, inhibits neurogenic vasodilation and extravasation following electrical stimulation of trigeminal ganglion. Brain Res. 2000 Aug 4;873(1):94-101. DMYSCQU RU https://pubmed.ncbi.nlm.nih.gov/10915814 DMYSDN4 DI DMYSDN4 DMYSDN4 DN KNI-10062 DMYSDN4 TI TTXMNHO DMYSDN4 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMYSDN4 MA Inhibitor DMYSDN4 RN Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3048-52. DMYSDN4 RU https://pubmed.ncbi.nlm.nih.gov/17400453 DMYSE3O DI DMYSE3O DMYSE3O DN (D)Arg-Arg-Pro-Hyp-Gly-Thi-Cys-(D)Phe-Phe-Cys-Arg DMYSE3O TI TTGY8IW DMYSE3O TN B2 bradykinin receptor (BDKRB2) DMYSE3O MA Inhibitor DMYSE3O RN Design and conformational analysis of several highly potent bradykinin receptor antagonists. J Med Chem. 1991 Mar;34(3):1230-3. DMYSE3O RU https://pubmed.ncbi.nlm.nih.gov/1848297 DMYSG9J DI DMYSG9J DMYSG9J DN Chemosensitizers DMYSG9J TI TT0JLSD DMYSG9J TN Multidrug resistance protein (MDR) DMYSG9J MA Inhibitor DMYSG9J RN P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2000 Jul;1(1):85-99. DMYSG9J RU https://pubmed.ncbi.nlm.nih.gov/11475537 DMYSKI0 DI DMYSKI0 DMYSKI0 DN SE RNA DMYSKI0 TI TTWXB3E DMYSKI0 TN Hepatitis C virus NS3 helicase (HCV NS3) DMYSKI0 RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMYSKI0 RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMYSM9L DI DMYSM9L DMYSM9L DN 2-(3-bromophenyl)-7-methyl-1,8-naphthyridine DMYSM9L TI TTHS256 DMYSM9L TN Metabotropic glutamate receptor 5 (mGluR5) DMYSM9L MA Inhibitor DMYSM9L RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMYSM9L RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMYSMWI DI DMYSMWI DMYSMWI DN K-454 DMYSMWI TI TTRMX3V DMYSMWI TN Janus kinase 2 (JAK-2) DMYSMWI MA Inhibitor DMYSMWI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). DMYSMWI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048 DMYSNQO DI DMYSNQO DMYSNQO DN 7-acetonyloxy-3-acetylamino-8-methoxycoumarin DMYSNQO TI TT3WG5C DMYSNQO TN Monoamine oxidase type A (MAO-A) DMYSNQO MA Inhibitor DMYSNQO RN A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins. J Med Chem. 2006 Feb 9;49(3):1149-56. DMYSNQO RU https://pubmed.ncbi.nlm.nih.gov/16451079 DMYSPMH DI DMYSPMH DMYSPMH DN Dihydropyrone DMYSPMH TI TT84ETX DMYSPMH TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMYSPMH MA Inhibitor DMYSPMH RN Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416. DMYSPMH RU https://pubmed.ncbi.nlm.nih.gov/18764719 DMYSQ2B DI DMYSQ2B DMYSQ2B DN Bis-{[R-(-)-apomorphine-2-oxy]ethyl} ether DMYSQ2B TI TTEX248 DMYSQ2B TN Dopamine D2 receptor (D2R) DMYSQ2B MA Inhibitor DMYSQ2B RN Synthesis and neuropharmacological characterization of 2-O-substituted apomorphines. Bioorg Med Chem. 2008 Apr 15;16(8):4563-8. DMYSQ2B RU https://pubmed.ncbi.nlm.nih.gov/18313931 DMYSURL DI DMYSURL DMYSURL DN N-(3-Benzooxazol-7-yl-propyl)-acetamide DMYSURL TI TT32JK8 DMYSURL TN Melatonin receptor type 1B (MTNR1B) DMYSURL MA Inhibitor DMYSURL RN Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004 Jul 16;14(14):3799-802. DMYSURL RU https://pubmed.ncbi.nlm.nih.gov/15203165 DMYSWAZ DI DMYSWAZ DMYSWAZ DN PF-271836 DMYSWAZ TI TTSCIUP DMYSWAZ TN Oxytocin receptor (OTR) DMYSWAZ MA Antagonist DMYSWAZ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 369). DMYSWAZ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369 DMYSWO4 DI DMYSWO4 DMYSWO4 DN PMID30247903-Compound-General structure27 DMYSWO4 TI TT23XQV DMYSWO4 TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMYSWO4 MA Inhibitor DMYSWO4 RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMYSWO4 RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMYSX0K DI DMYSX0K DMYSX0K DN Tribenzyl 2-aminopropane-1,2,3-tricarboxylate DMYSX0K TI TTHI19T DMYSX0K TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMYSX0K MA Inhibitor DMYSX0K RN Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7. DMYSX0K RU https://pubmed.ncbi.nlm.nih.gov/19467869 DMYT381 DI DMYT381 DMYT381 DN KKHT-10608 DMYT381 TI TT729IR DMYT381 TN Voltage-gated calcium channel alpha Cav3.1 (CACNA1G) DMYT381 MA Inhibitor DMYT381 RN Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives. Bioorg Med Chem. 2007 Jan 1;15(1):365-73. DMYT381 RU https://pubmed.ncbi.nlm.nih.gov/17035033 DMYT5DI DI DMYT5DI DMYT5DI DN XB-05 DMYT5DI TI TT6S2FE DMYT5DI TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMYT5DI MA Inhibitor DMYT5DI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605). DMYT5DI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2605 DMYT8UG DI DMYT8UG DMYT8UG DN Phenanthrene-2-carboxylic acid hydroxyamide DMYT8UG TI TT2J34L DMYT8UG TN Arachidonate 5-lipoxygenase (5-LOX) DMYT8UG MA Inhibitor DMYT8UG RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMYT8UG RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMYTEXB DI DMYTEXB DMYTEXB DN Syn-1020 DMYTEXB TI TTNT7K8 DMYTEXB TN Nociceptin receptor (OPRL1) DMYTEXB MA Agonist DMYTEXB RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 320). DMYTEXB RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=320 DMYTJX4 DI DMYTJX4 DMYTJX4 DN 2-(o-toluidino)-5-isopropylthiazol-4(5H)-one DMYTJX4 TI TTN7BL9 DMYTJX4 TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMYTJX4 MA Inhibitor DMYTJX4 RN The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2007 Nov 15;17(22):6056-61. DMYTJX4 RU https://pubmed.ncbi.nlm.nih.gov/17919905 DMYTS73 DI DMYTS73 DMYTS73 DN Phenyl-N,N-bis(tosylmethyl)methanamine DMYTS73 TI TTX4RTB DMYTS73 TN Melanin-concentrating hormone receptor 1 (MCHR1) DMYTS73 MA Inhibitor DMYTS73 RN Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. J Med Chem. 2008 Feb 14;51(3):581-8. DMYTS73 RU https://pubmed.ncbi.nlm.nih.gov/18198821 DMYTUNE DI DMYTUNE DMYTUNE DN 5-AMINO-NAPHTALENE-2-MONOSULFONATE DMYTUNE TI TTMY81X DMYTUNE TN Heparin-binding growth factor 1 (FGF1) DMYTUNE MA Inhibitor DMYTUNE RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYTUNE RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYTXBS DI DMYTXBS DMYTXBS DN ISIS 2502 DMYTXBS TI TT28ZON DMYTXBS TN H-ras messenger RNA (HRAS mRNA) DMYTXBS RN US patent application no. 5,965,722, Antisense inhibition of ras gene with chimeric and alternating oligonucleotides. DMYTXBS RU http://www.patentbuddy.com/Patent/5965722?ft=true&sr=true DMYU348 DI DMYU348 DMYU348 DN 1-Methyl-2-(4-phenylsulfanyl-phenyl)-ethylamine DMYU348 TI TT3ROYC DMYU348 TN Serotonin transporter (SERT) DMYU348 MA Inhibitor DMYU348 RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMYU348 RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMYU3Z7 DI DMYU3Z7 DMYU3Z7 DN M372049 DMYU3Z7 TI TTWVLS6 DMYU3Z7 TN Natriuretic peptide receptor (NPR3) DMYU3Z7 MA Antagonist DMYU3Z7 RN Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for e... Circulation. 2004 Sep 7;110(10):1231-5. DMYU3Z7 RU https://pubmed.ncbi.nlm.nih.gov/15337698 DMYU65F DI DMYU65F DMYU65F DN L-Tryptophan-L-arginine DMYU65F TI TTT2SVW DMYU65F TN PPAR-gamma messenger RNA (PPARG mRNA) DMYU65F MA Inhibitor DMYU65F RN Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716. DMYU65F RU https://pubmed.ncbi.nlm.nih.gov/18329752 DMYUAXR DI DMYUAXR DMYUAXR DN N-((1H-indol-2-yl)methyl)-2-phenylethanamine DMYUAXR TI TT3WG5C DMYUAXR TN Monoamine oxidase type A (MAO-A) DMYUAXR MA Inhibitor DMYUAXR RN Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B. Bioorg Med Chem. 2008 Nov 15;16(22):9729-40. DMYUAXR RU https://pubmed.ncbi.nlm.nih.gov/18951803 DMYUH62 DI DMYUH62 DMYUH62 DN SNEWIQPRLPQH DMYUH62 TI TTKPV6O DMYUH62 TN Ephrin type-B receptor 2 (EPHB2) DMYUH62 MA Inhibitor DMYUH62 RN Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007 Dec 14;282(50):36505-13. DMYUH62 RU https://pubmed.ncbi.nlm.nih.gov/17897949 DMYUL9J DI DMYUL9J DMYUL9J DN 4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline DMYUL9J TI TTGKNB4 DMYUL9J TN Epidermal growth factor receptor (EGFR) DMYUL9J MA Inhibitor DMYUL9J RN Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. DMYUL9J RU https://pubmed.ncbi.nlm.nih.gov/17869510 DMYUMHG DI DMYUMHG DMYUMHG DN 9-(2-Hydroxyethyl)-9H-adenine DMYUMHG TI TTM2AOE DMYUMHG TN Adenosine A2a receptor (ADORA2A) DMYUMHG MA Inhibitor DMYUMHG RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMYUMHG RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMYUQDK DI DMYUQDK DMYUQDK DN N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine DMYUQDK TI TTJS8PY DMYUQDK TN 5-HT 6 receptor (HTR6) DMYUQDK MA Inhibitor DMYUQDK RN Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1691-4. DMYUQDK RU https://pubmed.ncbi.nlm.nih.gov/17239595 DMYV49C DI DMYV49C DMYV49C DN Mulberrofuran C DMYV49C TI TTELIN2 DMYV49C TN PTPN1 messenger RNA (PTPN1 mRNA) DMYV49C MA Inhibitor DMYV49C RN Protein tyrosine phosphatase 1B inhibitors from Morus root bark. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1426-9. DMYV49C RU https://pubmed.ncbi.nlm.nih.gov/16356713 DMYVBD2 DI DMYVBD2 DMYVBD2 DN 1,10-(methylenedi-4,1-phenylene)bismaleimide DMYVBD2 TI TTDP1UC DMYVBD2 TN Fatty acid amide hydrolase (FAAH) DMYVBD2 MA Inhibitor DMYVBD2 RN Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. J Med Chem. 2009 Dec 10;52(23):7410-20. DMYVBD2 RU https://pubmed.ncbi.nlm.nih.gov/19583260 DMYVBHT DI DMYVBHT DMYVBHT DN (2S)-5,7,2',4'-tetrahydroxyflavanone DMYVBHT TI TTSZLWK DMYVBHT TN Aromatase (CYP19A1) DMYVBHT MA Inhibitor DMYVBHT RN Aromatase inhibitors from Broussonetia papyrifera. J Nat Prod. 2001 Oct;64(10):1286-93. DMYVBHT RU https://pubmed.ncbi.nlm.nih.gov/11678652 DMYVD2E DI DMYVD2E DMYVD2E DN 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one DMYVD2E TI TT4C8EA DMYVD2E TN Dopamine D3 receptor (D3R) DMYVD2E MA Inhibitor DMYVD2E RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMYVD2E RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMYVD2E DI DMYVD2E DMYVD2E DN 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one DMYVD2E TI TTEX248 DMYVD2E TN Dopamine D2 receptor (D2R) DMYVD2E MA Inhibitor DMYVD2E RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMYVD2E RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMYVD2E DI DMYVD2E DMYVD2E DN 4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one DMYVD2E TI TTE0A2F DMYVD2E TN Dopamine D4 receptor (D4R) DMYVD2E MA Inhibitor DMYVD2E RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMYVD2E RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMYVDJQ DI DMYVDJQ DMYVDJQ DN 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine DMYVDJQ TI TTAWNKZ DMYVDJQ TN Norepinephrine transporter (NET) DMYVDJQ MA Inhibitor DMYVDJQ RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMYVDJQ RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMYVDJQ DI DMYVDJQ DMYVDJQ DN 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine DMYVDJQ TI TT3ROYC DMYVDJQ TN Serotonin transporter (SERT) DMYVDJQ MA Inhibitor DMYVDJQ RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMYVDJQ RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMYVDJQ DI DMYVDJQ DMYVDJQ DN 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine DMYVDJQ TI TTSQIFT DMYVDJQ TN 5-HT 1A receptor (HTR1A) DMYVDJQ MA Inhibitor DMYVDJQ RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMYVDJQ RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMYVDJQ DI DMYVDJQ DMYVDJQ DN 2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine DMYVDJQ TI TTVBI8W DMYVDJQ TN Dopamine transporter (DAT) DMYVDJQ MA Inhibitor DMYVDJQ RN Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7. DMYVDJQ RU https://pubmed.ncbi.nlm.nih.gov/20031410 DMYVIBW DI DMYVIBW DMYVIBW DN SN-2 DMYVIBW TI TT0NLAQ DMYVIBW TN Mucolipin-3 (TRPML3) DMYVIBW MA Activator DMYVIBW RN Small molecule activators of TRPML3. Chem Biol. 2010 Feb 26;17(2):135-48. DMYVIBW RU https://pubmed.ncbi.nlm.nih.gov/20189104 DMYVJHN DI DMYVJHN DMYVJHN DN Trans-(1S(R),2S(R))-2-Hydroxycyclooctyl nitrate DMYVJHN TI TTEP6RV DMYVJHN TN Glutathione reductase (GR) DMYVJHN MA Inhibitor DMYVJHN RN In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3661-3. DMYVJHN RU https://pubmed.ncbi.nlm.nih.gov/19447620 DMYVOL9 DI DMYVOL9 DMYVOL9 DN icilin DMYVOL9 TI TTELV3W DMYVOL9 TN Transformation-sensitive protein p120 (TRPA1) DMYVOL9 MA Activator DMYVOL9 RN ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell. 2003 Mar 21;112(6):819-29. DMYVOL9 RU https://pubmed.ncbi.nlm.nih.gov/12654248 DMYVOL9 DI DMYVOL9 DMYVOL9 DN icilin DMYVOL9 TI TTXDKTO DMYVOL9 TN Long transient receptor potential channel 8 (TRPM8) DMYVOL9 MA Activator DMYVOL9 RN Evolution of thermal response properties in a cold-activated TRP channel. PLoS One. 2009 May 29;4(5):e5741. DMYVOL9 RU https://pubmed.ncbi.nlm.nih.gov/19492038 DMYVQF5 DI DMYVQF5 DMYVQF5 DN Ro 63-1908 DMYVQF5 TI TTN9D8E DMYVQF5 TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMYVQF5 MA Antagonist DMYVQF5 RN Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther. 2002 Sep;302(3):940-8. DMYVQF5 RU https://pubmed.ncbi.nlm.nih.gov/12183650 DMYVQFN DI DMYVQFN DMYVQFN DN AM7 DMYVQFN TI TTNDSF4 DMYVQFN TN Proto-oncogene c-Met (MET) DMYVQFN MA Inhibitor DMYVQFN RN c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008 Feb 1;283(5):2675-83. DMYVQFN RU https://pubmed.ncbi.nlm.nih.gov/18055465 DMYVST6 DI DMYVST6 DMYVST6 DN ISIS 5874 DMYVST6 TI TTHCEF6 DMYVST6 TN VCAM-1 messenger RNA (VCAM1 mRNA) DMYVST6 RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMYVST6 RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMYVU47 DI DMYVU47 DMYVU47 DN Methylenedioxymethamphetamine DMYVU47 TI TTWJBZ5 DMYVU47 TN 5-HT 2C receptor (HTR2C) DMYVU47 MA Agonist DMYVU47 RN The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. DMYVU47 RU https://pubmed.ncbi.nlm.nih.gov/16911722 DMYVU47 DI DMYVU47 DMYVU47 DN Methylenedioxymethamphetamine DMYVU47 TI TTNZRI3 DMYVU47 TN Synaptic vesicle amine transporter (SLC18A2) DMYVU47 MA Antagonist DMYVU47 RN The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. DMYVU47 RU https://pubmed.ncbi.nlm.nih.gov/16911722 DMYVU47 DI DMYVU47 DMYVU47 DN Methylenedioxymethamphetamine DMYVU47 TI TTJQOD7 DMYVU47 TN 5-HT 2A receptor (HTR2A) DMYVU47 MA Agonist DMYVU47 RN The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. DMYVU47 RU https://pubmed.ncbi.nlm.nih.gov/16911722 DMYVU47 DI DMYVU47 DMYVU47 DN Methylenedioxymethamphetamine DMYVU47 TI TT0K1SC DMYVU47 TN 5-HT 2B receptor (HTR2B) DMYVU47 MA Agonist DMYVU47 RN The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. DMYVU47 RU https://pubmed.ncbi.nlm.nih.gov/16911722 DMYVU47 DI DMYVU47 DMYVU47 DN Methylenedioxymethamphetamine DMYVU47 TI TT3ROYC DMYVU47 TN Serotonin transporter (SERT) DMYVU47 MA Inhibitor DMYVU47 RN The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. DMYVU47 RU https://pubmed.ncbi.nlm.nih.gov/16911722 DMYVU47 DI DMYVU47 DMYVU47 DN Methylenedioxymethamphetamine DMYVU47 TI TTVBI8W DMYVU47 TN Dopamine transporter (DAT) DMYVU47 MA Inhibitor DMYVU47 RN The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. DMYVU47 RU https://pubmed.ncbi.nlm.nih.gov/16911722 DMYVU47 DI DMYVU47 DMYVU47 DN Methylenedioxymethamphetamine DMYVU47 TI TTAWNKZ DMYVU47 TN Norepinephrine transporter (NET) DMYVU47 MA Inhibitor DMYVU47 RN The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5. DMYVU47 RU https://pubmed.ncbi.nlm.nih.gov/16911722 DMYVUCE DI DMYVUCE DMYVUCE DN MESCALINE DMYVUCE TI TTJQOD7 DMYVUCE TN 5-HT 2A receptor (HTR2A) DMYVUCE MA Inhibitor DMYVUCE RN The role of lipophilicity in determining binding affinity and functional activity for 5-HT2A receptor ligands. Bioorg Med Chem. 2008 Apr 15;16(8):4661-9. DMYVUCE RU https://pubmed.ncbi.nlm.nih.gov/18296055 DMYW1VP DI DMYW1VP DMYW1VP DN U50,488H DMYW1VP TI TTQW87Y DMYW1VP TN Opioid receptor kappa (OPRK1) DMYW1VP MA Agonist DMYW1VP RN The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav Brain Res. 2001 May;120(2):137-46. DMYW1VP RU https://pubmed.ncbi.nlm.nih.gov/11182162 DMYW3ZG DI DMYW3ZG DMYW3ZG DN Cephalosporin C DMYW3ZG TI TTLP6GN DMYW3ZG TN Bacterial DD-carboxypeptidase (Bact vanYB) DMYW3ZG MA Inhibitor DMYW3ZG RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMYW3ZG RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMYW3ZG DI DMYW3ZG DMYW3ZG DN Cephalosporin C DMYW3ZG TI TT85JMW DMYW3ZG TN Bacterial Penicillin binding protein 3 (Bact mrcA) DMYW3ZG MA Antagonist DMYW3ZG RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMYW3ZG RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMYW3ZG DI DMYW3ZG DMYW3ZG DN Cephalosporin C DMYW3ZG TI TT329FH DMYW3ZG TN Bacterial Penicillin-binding protein 1B (Bact mrcB) DMYW3ZG MA Antagonist DMYW3ZG RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMYW3ZG RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMYW40T DI DMYW40T DMYW40T DN (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate DMYW40T TI TTXJ47W DMYW40T TN Metabotropic glutamate receptor 2 (mGluR2) DMYW40T MA Agonist DMYW40T RN Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci. 2002 Dec;116(6):1075-83. DMYW40T RU https://pubmed.ncbi.nlm.nih.gov/12492306 DMYW5JX DI DMYW5JX DMYW5JX DN ANALOG OF DYNORPHIN A DMYW5JX TI TT27RFC DMYW5JX TN Opioid receptor delta (OPRD1) DMYW5JX MA Inhibitor DMYW5JX RN Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7. DMYW5JX RU https://pubmed.ncbi.nlm.nih.gov/8096246 DMYWD6C DI DMYWD6C DMYWD6C DN L000021649 DMYWD6C TI TTUTJGQ DMYWD6C TN Vascular endothelial growth factor receptor 2 (KDR) DMYWD6C MA Inhibitor DMYWD6C RN Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharm... Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41. DMYWD6C RU https://pubmed.ncbi.nlm.nih.gov/12443771 DMYWEO6 DI DMYWEO6 DMYWEO6 DN BMN-103 DMYWEO6 TI TTXWASR DMYWEO6 TN Intestinal maltase-glucoamylase (MGAM) DMYWEO6 MA Modulator DMYWEO6 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627). DMYWEO6 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2627 DMYWERO DI DMYWERO DMYWERO DN F-9TG DMYWERO TI TTFEZ5Q DMYWERO TN Coagulation factor IX (F9) DMYWERO MA Modulator DMYWERO RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2364). DMYWERO RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2364 DMYWG7D DI DMYWG7D DMYWG7D DN 1-(10H-phenothiazin-10-yl)-2-phenylpropan-1-one DMYWG7D TI TTEB0GD DMYWG7D TN Cholinesterase (BCHE) DMYWG7D MA Inhibitor DMYWG7D RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMYWG7D RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMYWGCS DI DMYWGCS DMYWGCS DN [3H]methyllycaconitine DMYWGCS TI TTLA931 DMYWGCS TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMYWGCS MA Antagonist DMYWGCS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468). DMYWGCS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468 DMYWGCS DI DMYWGCS DMYWGCS DN [3H]methyllycaconitine DMYWGCS TI TTQACP9 DMYWGCS TN Neuronal acetylcholine receptor alpha-9 (CHRNA9) DMYWGCS MA Antagonist DMYWGCS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 469). DMYWGCS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=469 DMYWGCS DI DMYWGCS DMYWGCS DN [3H]methyllycaconitine DMYWGCS TI TTJ49OM DMYWGCS TN Neuronal acetylcholine receptor alpha-10 (CHRNA10) DMYWGCS MA Antagonist DMYWGCS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 470). DMYWGCS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=470 DMYWINR DI DMYWINR DMYWINR DN ISIS 11665 DMYWINR TI TTA1L39 DMYWINR TN ICAM1 messenger RNA (ICAM1 mRNA) DMYWINR RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DMYWINR RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DMYWL89 DI DMYWL89 DMYWL89 DN diphosphoric acid DMYWL89 TI TTIKWV4 DMYWL89 TN Geranyltranstransferase (FDPS) DMYWL89 MA Inhibitor DMYWL89 RN Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95. DMYWL89 RU https://pubmed.ncbi.nlm.nih.gov/18327899 DMYWM56 DI DMYWM56 DMYWM56 DN GNE-7915 DMYWM56 TI TTP7EGM DMYWM56 TN Dual specificity protein kinase TTK (MPS1) DMYWM56 MA Inhibitor DMYWM56 RN Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36. DMYWM56 RU https://pubmed.ncbi.nlm.nih.gov/24354345 DMYWM56 DI DMYWM56 DMYWM56 DN GNE-7915 DMYWM56 TI TTK0FEA DMYWM56 TN Leucine-rich repeat kinase 2 (LRRK2) DMYWM56 MA Inhibitor DMYWM56 RN Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors. J Med Chem. 2014 Feb 13;57(3):921-36. DMYWM56 RU https://pubmed.ncbi.nlm.nih.gov/24354345 DMYWRL6 DI DMYWRL6 DMYWRL6 DN Purpurin DMYWRL6 TI TT5FH9Y DMYWRL6 TN Human immunodeficiency virus Integrase (HIV IN) DMYWRL6 MA Inhibitor DMYWRL6 RN Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir Chem Chemother. 1998 Nov;9(6):461-72. DMYWRL6 RU https://pubmed.ncbi.nlm.nih.gov/9865384 DMYWV81 DI DMYWV81 DMYWV81 DN EPI-001 DMYWV81 TI TTS64P2 DMYWV81 TN Androgen receptor (AR) DMYWV81 MA Modulator DMYWV81 RN EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget. 2015 Feb 28;6(6):3811-24. DMYWV81 RU https://pubmed.ncbi.nlm.nih.gov/25669987 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TT4NXYM DMYX0BL TN Human immunodeficiency virus Negative factor (HIV nef) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TT3PJMV DMYX0BL TN Tyrosine-protein kinase ABL1 (ABL) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TT0OFWN DMYX0BL TN Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TT2F3CD DMYX0BL TN Hepatocyte nuclear factor 4-alpha (HNF4A) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TTV3NH6 DMYX0BL TN Calmodulin (CALM) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TTISGCA DMYX0BL TN Toll-like receptor 4 (TLR4) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TTDQTEY DMYX0BL TN Recoverin (RCVRN) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TTVBE0F DMYX0BL TN Virus Genome polyprotein (Viru POL) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TT8S9AV DMYX0BL TN Lymphocyte antigen 96 (LY96) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX0BL DI DMYX0BL DMYX0BL DN MYRISTIC ACID DMYX0BL TI TTMW94E DMYX0BL TN FK506-binding protein 1A (FKBP1A) DMYX0BL MA Inhibitor DMYX0BL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYX0BL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYX2NJ DI DMYX2NJ DMYX2NJ DN Leukotoxin DMYX2NJ TI TT48WR6 DMYX2NJ TN Integrin alpha-L (ITGAL) DMYX2NJ MA Modulator DMYX2NJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2451). DMYX2NJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2451 DMYX30S DI DMYX30S DMYX30S DN JWH-051 DMYX30S TI TTMSFAW DMYX30S TN Cannabinoid receptor 2 (CB2) DMYX30S MA Agonist DMYX30S RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 57). DMYX30S RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57 DMYX31S DI DMYX31S DMYX31S DN MPDT DMYX31S TI TTJQOD7 DMYX31S TN 5-HT 2A receptor (HTR2A) DMYX31S MA Antagonist DMYX31S RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMYX31S RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMYX31S DI DMYX31S DMYX31S DN MPDT DMYX31S TI TTSQIFT DMYX31S TN 5-HT 1A receptor (HTR1A) DMYX31S MA Antagonist DMYX31S RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMYX31S RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMYX31S DI DMYX31S DMYX31S DN MPDT DMYX31S TI TT6MSOK DMYX31S TN 5-HT 1D receptor (HTR1D) DMYX31S MA Antagonist DMYX31S RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMYX31S RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMYX31S DI DMYX31S DMYX31S DN MPDT DMYX31S TI TTRUFDT DMYX31S TN 5-HT 5A receptor (HTR5A) DMYX31S MA Antagonist DMYX31S RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMYX31S RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMYX31S DI DMYX31S DMYX31S DN MPDT DMYX31S TI TTWJBZ5 DMYX31S TN 5-HT 2C receptor (HTR2C) DMYX31S MA Antagonist DMYX31S RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMYX31S RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMYX31S DI DMYX31S DMYX31S DN MPDT DMYX31S TI TTO9X1H DMYX31S TN 5-HT 7 receptor (HTR7) DMYX31S MA Antagonist DMYX31S RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMYX31S RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMYX31S DI DMYX31S DMYX31S DN MPDT DMYX31S TI TTJS8PY DMYX31S TN 5-HT 6 receptor (HTR6) DMYX31S MA Antagonist DMYX31S RN 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8. DMYX31S RU https://pubmed.ncbi.nlm.nih.gov/10715164 DMYX34S DI DMYX34S DMYX34S DN 4-Amino Hexanoic Acid DMYX34S TI TTT2LD9 DMYX34S TN GABA transaminase (ABAT) DMYX34S MA Inhibitor DMYX34S RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMYX34S RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMYXA7E DI DMYXA7E DMYXA7E DN FdG DMYXA7E TI TTSUKYD DMYXA7E TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMYXA7E MA Inhibitor DMYXA7E RN Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9. DMYXA7E RU https://pubmed.ncbi.nlm.nih.gov/18955536 DMYXDK5 DI DMYXDK5 DMYXDK5 DN PMID12812482C11 DMYXDK5 TI TTGY8IW DMYXDK5 TN B2 bradykinin receptor (BDKRB2) DMYXDK5 MA Antagonist DMYXDK5 RN Discovery of a potent, non-peptide bradykinin B1 receptor antagonist. J Am Chem Soc. 2003 Jun 25;125(25):7516-7. DMYXDK5 RU https://pubmed.ncbi.nlm.nih.gov/12812482 DMYXE39 DI DMYXE39 DMYXE39 DN CGP 62349 DMYXE39 TI TTDCVZW DMYXE39 TN Gamma-aminobutyric acid B receptor (GABBR) DMYXE39 MA Antagonist DMYXE39 RN Characterisation and partial purification of the GABA(B) receptor from the rat cerebellum using the novel antagonist [3H]CGP 62349. Brain Res Mol Brain Res. 1999 Aug 25;71(2):279-89. DMYXE39 RU https://pubmed.ncbi.nlm.nih.gov/10521582 DMYXEJ8 DI DMYXEJ8 DMYXEJ8 DN 9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide DMYXEJ8 TI TTEB0GD DMYXEJ8 TN Cholinesterase (BCHE) DMYXEJ8 MA Inhibitor DMYXEJ8 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DMYXEJ8 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DMYXEJ8 DI DMYXEJ8 DMYXEJ8 DN 9-O-[2-(Phenylol-1-yloxy)ethyl]berberine bromide DMYXEJ8 TI TT1RS9F DMYXEJ8 TN Acetylcholinesterase (AChE) DMYXEJ8 MA Inhibitor DMYXEJ8 RN Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1244-51. DMYXEJ8 RU https://pubmed.ncbi.nlm.nih.gov/20056426 DMYXELH DI DMYXELH DMYXELH DN 1,2-NAPHTHOQUINONE DMYXELH TI TT1RS9F DMYXELH TN Acetylcholinesterase (AChE) DMYXELH MA Inhibitor DMYXELH RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMYXELH RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMYXELH DI DMYXELH DMYXELH DN 1,2-NAPHTHOQUINONE DMYXELH TI TTZJYKH DMYXELH TN Indoleamine 2,3-dioxygenase 1 (IDO1) DMYXELH MA Inhibitor DMYXELH RN Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18. DMYXELH RU https://pubmed.ncbi.nlm.nih.gov/18318466 DMYXELH DI DMYXELH DMYXELH DN 1,2-NAPHTHOQUINONE DMYXELH TI TTMF541 DMYXELH TN Liver carboxylesterase (CES1) DMYXELH MA Inhibitor DMYXELH RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMYXELH RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMYXELH DI DMYXELH DMYXELH DN 1,2-NAPHTHOQUINONE DMYXELH TI TTELIN2 DMYXELH TN PTPN1 messenger RNA (PTPN1 mRNA) DMYXELH MA Inhibitor DMYXELH RN Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1941-6. DMYXELH RU https://pubmed.ncbi.nlm.nih.gov/12113814 DMYXELH DI DMYXELH DMYXELH DN 1,2-NAPHTHOQUINONE DMYXELH TI TTEB0GD DMYXELH TN Cholinesterase (BCHE) DMYXELH MA Inhibitor DMYXELH RN Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. J Med Chem. 2007 Nov 15;50(23):5727-34. DMYXELH RU https://pubmed.ncbi.nlm.nih.gov/17941623 DMYXHUO DI DMYXHUO DMYXHUO DN 4-(4-(pentyloxy)phenoxy)phenol DMYXHUO TI TTXZEAJ DMYXHUO TN Leukotriene A-4 hydrolase (LTA4H) DMYXHUO MA Inhibitor DMYXHUO RN Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. Bioorg Med Chem Lett. 2008 Dec 15;18(24):6549-52. DMYXHUO RU https://pubmed.ncbi.nlm.nih.gov/18952425 DMYXI2V DI DMYXI2V DMYXI2V DN (E)-4-(3,5-dimethoxystyryl)phenol DMYXI2V TI TTJ584C DMYXI2V TN Peroxisome proliferator-activated receptor alpha (PPARA) DMYXI2V MA Agonist DMYXI2V RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 593). DMYXI2V RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=593 DMYXI2V DI DMYXI2V DMYXI2V DN (E)-4-(3,5-dimethoxystyryl)phenol DMYXI2V TI TTS7G69 DMYXI2V TN Fusion protein Bcr-Abl (Bcr-Abl) DMYXI2V MA Inhibitor DMYXI2V RN Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem. 2006 May 18;49(10):3012-8. DMYXI2V RU https://pubmed.ncbi.nlm.nih.gov/16686543 DMYXJG7 DI DMYXJG7 DMYXJG7 DN 8-AMINOGUANINE DMYXJG7 TI TTMCF1Y DMYXJG7 TN Purine nucleoside phosphorylase (PNP) DMYXJG7 MA Inhibitor DMYXJG7 RN Nucleosides. 5. Synthesis of guanine and formycin B derivatives as potential inhibitors of purine nucleoside phosphorylase. J Med Chem. 1993 Apr 16;36(8):1024-31. DMYXJG7 RU https://pubmed.ncbi.nlm.nih.gov/8478902 DMYXMT6 DI DMYXMT6 DMYXMT6 DN 4'-(Pyridin-4-ylmethyl)biphenyl-4-carboxamide DMYXMT6 TI TTRA5BZ DMYXMT6 TN Steroid 17-alpha-monooxygenase (S17AH) DMYXMT6 MA Inhibitor DMYXMT6 RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMYXMT6 RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMYXPF8 DI DMYXPF8 DMYXPF8 DN QO-58 DMYXPF8 TI TTPXI3S DMYXPF8 TN Voltage-gated potassium channel Kv7.2 (KCNQ2) DMYXPF8 MA Activator DMYXPF8 RN Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58. Br J Pharmacol. 2013 Feb;168(4):1030-42. DMYXPF8 RU https://pubmed.ncbi.nlm.nih.gov/23013484 DMYXQ7L DI DMYXQ7L DMYXQ7L DN 3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine DMYXQ7L TI TTZUFI5 DMYXQ7L TN Nitric-oxide synthase brain (NOS1) DMYXQ7L MA Inhibitor DMYXQ7L RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMYXQ7L RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMYXQ7L DI DMYXQ7L DMYXQ7L DN 3-(2-Nitro-ethyl)-[1,4]oxazepan-(5Z)-ylideneamine DMYXQ7L TI TTF10I9 DMYXQ7L TN Nitric-oxide synthase inducible (NOS2) DMYXQ7L MA Inhibitor DMYXQ7L RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMYXQ7L RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMYZ2U0 DI DMYZ2U0 DMYZ2U0 DN 3-[5-(4-Fluorophenyl)-2-thienyl]phenol DMYZ2U0 TI TTIWB6L DMYZ2U0 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMYZ2U0 MA Inhibitor DMYZ2U0 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMYZ2U0 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMYZ548 DI DMYZ548 DMYZ548 DN 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) DMYZ548 TI TTVG215 DMYZ548 TN Debrisoquine 4-hydroxylase (CYP2D6) DMYZ548 MA Inhibitor DMYZ548 RN 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001. DMYZ548 RU https://pubmed.ncbi.nlm.nih.gov/20527970 DMYZ548 DI DMYZ548 DMYZ548 DN 1-(3,4-DICHLOROPHENYL)-6-(METHOXYMETHYL)-3-AZABICYCLO[4.1.0]HEPTANE (ENANTIOMERIC MIX) DMYZ548 TI TTXV4FI DMYZ548 TN Albendazole monooxygenase (CYP3A4) DMYZ548 MA Inhibitor DMYZ548 RN 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001. DMYZ548 RU https://pubmed.ncbi.nlm.nih.gov/20527970 DMYZ5CX DI DMYZ5CX DMYZ5CX DN ISIS 101984 DMYZ5CX TI TTON5JB DMYZ5CX TN MADH6 messenger RNA (MADH6 mRNA) DMYZ5CX RN US patent application no. 6,277,636, Antisense inhibition of MADH6 expression. DMYZ5CX RU http://www.patentbuddy.com/Patent/6277636?ft=true&sr=true DMYZ72J DI DMYZ72J DMYZ72J DN CGP-57698 DMYZ72J TI TTGKOY9 DMYZ72J TN Leukotriene CysLT1 receptor (CYSLTR1) DMYZ72J MA Modulator DMYZ72J RN A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lun... Mol Pharmacol. 2000 Jun;57(6):1182-9. DMYZ72J RU https://www.ncbi.nlm.nih.gov/pubmed/10825389 DMYZ72J DI DMYZ72J DMYZ72J DN CGP-57698 DMYZ72J TI TT0PZR5 DMYZ72J TN Leukotriene CysLT2 receptor (CYSLTR2) DMYZ72J MA Modulator DMYZ72J RN A kinetic binding study to evaluate the pharmacological profile of a specific leukotriene C(4) binding site not coupled to contraction in human lun... Mol Pharmacol. 2000 Jun;57(6):1182-9. DMYZ72J RU https://www.ncbi.nlm.nih.gov/pubmed/10825389 DMYZ792 DI DMYZ792 DMYZ792 DN Tyr-(S)-Aba-Gly-Phe-NH2 DMYZ792 TI TTKWM86 DMYZ792 TN Opioid receptor mu (MOP) DMYZ792 MA Inhibitor DMYZ792 RN Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. DMYZ792 RU https://pubmed.ncbi.nlm.nih.gov/18062664 DMYZ792 DI DMYZ792 DMYZ792 DN Tyr-(S)-Aba-Gly-Phe-NH2 DMYZ792 TI TT27RFC DMYZ792 TN Opioid receptor delta (OPRD1) DMYZ792 MA Inhibitor DMYZ792 RN Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7. DMYZ792 RU https://pubmed.ncbi.nlm.nih.gov/18062664 DMYZC3I DI DMYZC3I DMYZC3I DN 8-(3,4-dimethoxyphenyl)-9H-purine-2,6-diamine DMYZC3I TI TT9SL3Q DMYZC3I TN Polypeptide deformylase (PDF) DMYZC3I MA Inhibitor DMYZC3I RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DMYZC3I RU https://pubmed.ncbi.nlm.nih.gov/20117005 DMYZCRF DI DMYZCRF DMYZCRF DN (RS)-(tetrazol-5-yl)glycine DMYZCRF TI TTKJEMQ DMYZCRF TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMYZCRF MA Agonist DMYZCRF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 456). DMYZCRF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=456 DMYZCRF DI DMYZCRF DMYZCRF DN (RS)-(tetrazol-5-yl)glycine DMYZCRF TI TT5POTG DMYZCRF TN Glutamate receptor ionotropic NMDA 2D (GluN2D) DMYZCRF MA Agonist DMYZCRF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 459). DMYZCRF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=459 DMYZCRF DI DMYZCRF DMYZCRF DN (RS)-(tetrazol-5-yl)glycine DMYZCRF TI TTLD29N DMYZCRF TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMYZCRF MA Agonist DMYZCRF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 455). DMYZCRF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=455 DMYZCRF DI DMYZCRF DMYZCRF DN (RS)-(tetrazol-5-yl)glycine DMYZCRF TI TTN9D8E DMYZCRF TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMYZCRF MA Agonist DMYZCRF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457). DMYZCRF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=457 DMYZCRF DI DMYZCRF DMYZCRF DN (RS)-(tetrazol-5-yl)glycine DMYZCRF TI TT1M8OW DMYZCRF TN Glutamate receptor ionotropic NMDA 2C (GluN2C) DMYZCRF MA Agonist DMYZCRF RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 458). DMYZCRF RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=458 DMYZCWX DI DMYZCWX DMYZCWX DN 3-isopropyl-4-phenylnaphthalene-1,2-dione DMYZCWX TI TTLZS4Q DMYZCWX TN M-phase inducer phosphatase 1 (MPIP1) DMYZCWX MA Inhibitor DMYZCWX RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMYZCWX RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMYZCWX DI DMYZCWX DMYZCWX DN 3-isopropyl-4-phenylnaphthalene-1,2-dione DMYZCWX TI TTR0SWN DMYZCWX TN M-phase inducer phosphatase 2 (MPIP2) DMYZCWX MA Inhibitor DMYZCWX RN Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8. DMYZCWX RU https://pubmed.ncbi.nlm.nih.gov/16434190 DMYZE8R DI DMYZE8R DMYZE8R DN ISIS 7948 DMYZE8R TI TT57MT2 DMYZE8R TN PKC-epsilon messenger RNA (PRKCE mRNA) DMYZE8R RN US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C. DMYZE8R RU http://www.patentbuddy.com/Patent/5959096?ft=true&sr=true DMYZFNH DI DMYZFNH DMYZFNH DN Sapanisertib DMYZFNH TI TT7HQAF DMYZFNH TN HUMAN mammalian target of rapamycin (mTOR) DMYZFNH MA Inhibitor DMYZFNH RN Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020 DMYZFNH RU https://www.preprints.org/manuscript/202004.0060/v1 DMYZGIK DI DMYZGIK DMYZGIK DN LUF5831 DMYZGIK TI TTK25J1 DMYZGIK TN Adenosine A1 receptor (ADORA1) DMYZGIK MA Agonist DMYZGIK RN Allosteric modulation, thermodynamics and binding to wild-type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine-like agonist. Br J Pharmacol. 2006 Mar;147(5):533-41. DMYZGIK RU https://pubmed.ncbi.nlm.nih.gov/16444290 DMYZHXR DI DMYZHXR DMYZHXR DN 4-(4-Methyl-indan-1-yl)-1H-imidazole DMYZHXR TI TT34BHT DMYZHXR TN Adrenergic receptor alpha-1D (ADRA1D) DMYZHXR MA Inhibitor DMYZHXR RN Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24. DMYZHXR RU https://pubmed.ncbi.nlm.nih.gov/9301663 DMYZHXR DI DMYZHXR DMYZHXR DN 4-(4-Methyl-indan-1-yl)-1H-imidazole DMYZHXR TI TTWM4TY DMYZHXR TN Adrenergic receptor alpha-2B (ADRA2B) DMYZHXR MA Inhibitor DMYZHXR RN Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24. DMYZHXR RU https://pubmed.ncbi.nlm.nih.gov/9301663 DMYZHXR DI DMYZHXR DMYZHXR DN 4-(4-Methyl-indan-1-yl)-1H-imidazole DMYZHXR TI TTWG9A4 DMYZHXR TN Adrenergic receptor alpha-2A (ADRA2A) DMYZHXR MA Inhibitor DMYZHXR RN Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24. DMYZHXR RU https://pubmed.ncbi.nlm.nih.gov/9301663 DMYZHXR DI DMYZHXR DMYZHXR DN 4-(4-Methyl-indan-1-yl)-1H-imidazole DMYZHXR TI TTBRKXS DMYZHXR TN Adrenergic receptor alpha-1B (ADRA1B) DMYZHXR MA Inhibitor DMYZHXR RN Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24. DMYZHXR RU https://pubmed.ncbi.nlm.nih.gov/9301663 DMYZHXR DI DMYZHXR DMYZHXR DN 4-(4-Methyl-indan-1-yl)-1H-imidazole DMYZHXR TI TTNGILX DMYZHXR TN Adrenergic receptor alpha-1A (ADRA1A) DMYZHXR MA Inhibitor DMYZHXR RN Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24. DMYZHXR RU https://pubmed.ncbi.nlm.nih.gov/9301663 DMYZHXR DI DMYZHXR DMYZHXR DN 4-(4-Methyl-indan-1-yl)-1H-imidazole DMYZHXR TI TT2NUT5 DMYZHXR TN Adrenergic receptor alpha-2C (ADRA2C) DMYZHXR MA Inhibitor DMYZHXR RN Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potent... J Med Chem. 1997 Sep 12;40(19):3014-24. DMYZHXR RU https://pubmed.ncbi.nlm.nih.gov/9301663 DMYZIG3 DI DMYZIG3 DMYZIG3 DN 3-[5-(3,4-Difluorophenyl)-2-thienyl]phenol DMYZIG3 TI TTIWB6L DMYZIG3 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMYZIG3 MA Inhibitor DMYZIG3 RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMYZIG3 RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMYZNIW DI DMYZNIW DMYZNIW DN ISIS 134528 DMYZNIW TI TTKW4ML DMYZNIW TN Caspase 6 messenger RNA (CASP6 mRNA) DMYZNIW RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMYZNIW RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMYZO37 DI DMYZO37 DMYZO37 DN Glu-Pro-Gln-pTyr-Glu-Glu-Ile-Pro-Ile-Tyr-Leu DMYZO37 TI TT6PKBN DMYZO37 TN Proto-oncogene c-Src (SRC) DMYZO37 MA Inhibitor DMYZO37 RN The Role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands, Bioorg. Med. Chem. Lett. 7(14):1909-1914 (1997). DMYZO37 RU http://www.sciencedirect.com/science/article/pii/S0960894X9700334X DMYZRTB DI DMYZRTB DMYZRTB DN Nojirimycine Tetrazole DMYZRTB TI TTZHY6R DMYZRTB TN Glycogen phosphorylase muscle form (GP) DMYZRTB MA Inhibitor DMYZRTB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYZRTB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYZRTB DI DMYZRTB DMYZRTB DN Nojirimycine Tetrazole DMYZRTB TI TTA0OSE DMYZRTB TN Lactase-phlorizin hydrolase (LCT) DMYZRTB MA Inhibitor DMYZRTB RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMYZRTB RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMYZVLN DI DMYZVLN DMYZVLN DN EC-SOD DMYZVLN TI TT6RVLG DMYZVLN TN Superoxide dismutase Cu-Zn (SOD Cu-Zn) DMYZVLN MA Modulator DMYZVLN RN Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD.Transl Res.2008 Feb;151(2):68-78. DMYZVLN RU https://www.ncbi.nlm.nih.gov/pubmed/18201674 DMYZXEO DI DMYZXEO DMYZXEO DN Des-AA1,2,4,5,13-[D-Trp8]-SRIF DMYZXEO TI TTIND6G DMYZXEO TN Somatostatin receptor type 1 (SSTR1) DMYZXEO MA Inhibitor DMYZXEO RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMYZXEO RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMYZXEO DI DMYZXEO DMYZXEO DN Des-AA1,2,4,5,13-[D-Trp8]-SRIF DMYZXEO TI TTZ6T9E DMYZXEO TN Somatostatin receptor type 2 (SSTR2) DMYZXEO MA Inhibitor DMYZXEO RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMYZXEO RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMYZXEO DI DMYZXEO DMYZXEO DN Des-AA1,2,4,5,13-[D-Trp8]-SRIF DMYZXEO TI TTAE1BR DMYZXEO TN Somatostatin receptor type 4 (SSTR4) DMYZXEO MA Inhibitor DMYZXEO RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMYZXEO RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMYZXEO DI DMYZXEO DMYZXEO DN Des-AA1,2,4,5,13-[D-Trp8]-SRIF DMYZXEO TI TT2BC4G DMYZXEO TN Somatostatin receptor type 5 (SSTR5) DMYZXEO MA Inhibitor DMYZXEO RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMYZXEO RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMYZXEO DI DMYZXEO DMYZXEO DN Des-AA1,2,4,5,13-[D-Trp8]-SRIF DMYZXEO TI TTJX3UE DMYZXEO TN Somatostatin receptor type 3 (SSTR3) DMYZXEO MA Inhibitor DMYZXEO RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMYZXEO RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMZ01PS DI DMZ01PS DMZ01PS DN PEGylated leptin DMZ01PS TI TT0HD6V DMZ01PS TN Leptin receptor (LEPR) DMZ01PS MA Modulator DMZ01PS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712). DMZ01PS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1712 DMZ01SV DI DMZ01SV DMZ01SV DN 4beta,15-epoxy-miller-9Z-enolide DMZ01SV TI TTSXVID DMZ01SV TN Nuclear factor NF-kappa-B (NFKB) DMZ01SV MA Inhibitor DMZ01SV RN Development of a structural model for NF-kappaB inhibition of sesquiterpene lactones using self-organizing neural networks. J Med Chem. 2006 Apr 6;49(7):2241-52. DMZ01SV RU https://pubmed.ncbi.nlm.nih.gov/16570920 DMZ03DT DI DMZ03DT DMZ03DT DN Phenyl 4-(decyloxy)phenylcarbamate DMZ03DT TI TTDP1UC DMZ03DT TN Fatty acid amide hydrolase (FAAH) DMZ03DT MA Inhibitor DMZ03DT RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMZ03DT RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMZ07H6 DI DMZ07H6 DMZ07H6 DN Phenyl 4-(hexyloxy)phenylcarbamate DMZ07H6 TI TTDP1UC DMZ07H6 TN Fatty acid amide hydrolase (FAAH) DMZ07H6 MA Inhibitor DMZ07H6 RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMZ07H6 RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMZ0AKP DI DMZ0AKP DMZ0AKP DN 4-(trifluoromethyl)biphenyl DMZ0AKP TI TTBGTCW DMZ0AKP TN Kinesin spindle messenger RNA (KIF11 mRNA) DMZ0AKP MA Inhibitor DMZ0AKP RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMZ0AKP RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMZ0D5W DI DMZ0D5W DMZ0D5W DN 1,2-bis(2,3-difluorophenyl)-2-hydroxyethanone DMZ0D5W TI TTMF541 DMZ0D5W TN Liver carboxylesterase (CES1) DMZ0D5W MA Inhibitor DMZ0D5W RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMZ0D5W RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMZ0F7E DI DMZ0F7E DMZ0F7E DN 3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate DMZ0F7E TI TTCIHJA DMZ0F7E TN Coagulation factor Xa (F10) DMZ0F7E MA Inhibitor DMZ0F7E RN 3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem. 2005 Dec 1;48(24):7592-603. DMZ0F7E RU https://pubmed.ncbi.nlm.nih.gov/16302799 DMZ0F7E DI DMZ0F7E DMZ0F7E DN 3-chlorophenyl 2-oxo-2H-chromene-3-carboxylate DMZ0F7E TI TT6L509 DMZ0F7E TN Coagulation factor IIa (F2) DMZ0F7E MA Inhibitor DMZ0F7E RN 3,6-disubstituted coumarins as mechanism-based inhibitors of thrombin and factor Xa. J Med Chem. 2005 Dec 1;48(24):7592-603. DMZ0F7E RU https://pubmed.ncbi.nlm.nih.gov/16302799 DMZ0H5X DI DMZ0H5X DMZ0H5X DN 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine DMZ0H5X TI TTIQUX7 DMZ0H5X TN Steroid 11-beta-hydroxylase (CYP11B1) DMZ0H5X MA Inhibitor DMZ0H5X RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMZ0H5X RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMZ0H5X DI DMZ0H5X DMZ0H5X DN 4'-(Pyridin-4-ylmethyl)biphenyl-3,4-diamine DMZ0H5X TI TTRA5BZ DMZ0H5X TN Steroid 17-alpha-monooxygenase (S17AH) DMZ0H5X MA Inhibitor DMZ0H5X RN Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prosta... J Med Chem. 2010 Aug 12;53(15):5749-58. DMZ0H5X RU https://pubmed.ncbi.nlm.nih.gov/20684610 DMZ0O1X DI DMZ0O1X DMZ0O1X DN Lactoquinomycin DMZ0O1X TI TTWTSCV DMZ0O1X TN RAC-alpha serine/threonine-protein kinase (AKT1) DMZ0O1X MA Inhibitor DMZ0O1X RN The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9. DMZ0O1X RU https://pubmed.ncbi.nlm.nih.gov/19519296 DMZ0RP5 DI DMZ0RP5 DMZ0RP5 DN AC-(D)PHE-PRO-BOROHOMOLYS-OH DMZ0RP5 TI TT6L509 DMZ0RP5 TN Coagulation factor IIa (F2) DMZ0RP5 MA Inhibitor DMZ0RP5 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZ0RP5 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZ0TDL DI DMZ0TDL DMZ0TDL DN X-387 DMZ0TDL TI TTCJG29 DMZ0TDL TN Serine/threonine-protein kinase mTOR (mTOR) DMZ0TDL MA Inhibitor DMZ0TDL RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMZ0TDL RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMZ0TGY DI DMZ0TGY DMZ0TGY DN CGS 21680 DMZ0TGY TI TTNE7KG DMZ0TGY TN Adenosine A2b receptor (ADORA2B) DMZ0TGY MA Agonist DMZ0TGY RN [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther. 1989 Dec;251(3):888-93. DMZ0TGY RU https://pubmed.ncbi.nlm.nih.gov/2600819 DMZ0TGY DI DMZ0TGY DMZ0TGY DN CGS 21680 DMZ0TGY TI TTM2AOE DMZ0TGY TN Adenosine A2a receptor (ADORA2A) DMZ0TGY MA Agonist DMZ0TGY RN Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol. 2002 Mar 8;438(3):183-8. DMZ0TGY RU https://pubmed.ncbi.nlm.nih.gov/11909610 DMZ0V6G DI DMZ0V6G DMZ0V6G DN (2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime DMZ0V6G TI TT7HF4W DMZ0V6G TN Cyclin-dependent kinase 2 (CDK2) DMZ0V6G MA Inhibitor DMZ0V6G RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMZ0V6G RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMZ0V6G DI DMZ0V6G DMZ0V6G DN (2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime DMZ0V6G TI TTCEJ4F DMZ0V6G TN G1/S-specific cyclin-E1 (CCNE1) DMZ0V6G MA Inhibitor DMZ0V6G RN 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706. DMZ0V6G RU https://pubmed.ncbi.nlm.nih.gov/20361800 DMZ0V8O DI DMZ0V8O DMZ0V8O DN N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide DMZ0V8O TI TTQBR95 DMZ0V8O TN Stress-activated protein kinase 2a (p38 alpha) DMZ0V8O MA Inhibitor DMZ0V8O RN Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9. DMZ0V8O RU https://pubmed.ncbi.nlm.nih.gov/16169718 DMZ12GE DI DMZ12GE DMZ12GE DN MESUAGENIN A DMZ12GE TI TT1RS9F DMZ12GE TN Acetylcholinesterase (AChE) DMZ12GE MA Inhibitor DMZ12GE RN 4-Phenylcoumarins from Mesua elegans with acetylcholinesterase inhibitory activity. Bioorg Med Chem. 2010 Nov 15;18(22):7873-7. DMZ12GE RU https://pubmed.ncbi.nlm.nih.gov/20943395 DMZ18OJ DI DMZ18OJ DMZ18OJ DN 4-benzyl-5-(4-piperidyl)isothiazol-3-ol DMZ18OJ TI TT1MPAY DMZ18OJ TN GABA(A) receptor alpha-1 (GABRA1) DMZ18OJ MA Inhibitor DMZ18OJ RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMZ18OJ RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMZ18OJ DI DMZ18OJ DMZ18OJ DN 4-benzyl-5-(4-piperidyl)isothiazol-3-ol DMZ18OJ TI TTNJYV2 DMZ18OJ TN Gamma-aminobutyric acid receptor (GAR) DMZ18OJ MA Inhibitor DMZ18OJ RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMZ18OJ RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMZ18OJ DI DMZ18OJ DMZ18OJ DN 4-benzyl-5-(4-piperidyl)isothiazol-3-ol DMZ18OJ TI TT06RH5 DMZ18OJ TN GABA(A) receptor gamma-2 (GABRG2) DMZ18OJ MA Inhibitor DMZ18OJ RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMZ18OJ RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMZ1DW0 DI DMZ1DW0 DMZ1DW0 DN 4-(5-tert-Butyl-[1,3]dithian-2-yl)-benzonitrile DMZ1DW0 TI TTNJYV2 DMZ1DW0 TN Gamma-aminobutyric acid receptor (GAR) DMZ1DW0 MA Inhibitor DMZ1DW0 RN Synthesis of carbon-11-, fluorine-18-, and iodine-125-labeled GABAA-gated chloride ion channel blockers: substituted 5-tert-butyl-2-phenyl-1,3-dith... J Med Chem. 1995 Jul 7;38(14):2663-71. DMZ1DW0 RU https://pubmed.ncbi.nlm.nih.gov/7629805 DMZ1FCJ DI DMZ1FCJ DMZ1FCJ DN EU-517 DMZ1FCJ TI TTL53M6 DMZ1FCJ TN Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) DMZ1FCJ MA Inhibitor DMZ1FCJ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2847). DMZ1FCJ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2847 DMZ1FRS DI DMZ1FRS DMZ1FRS DN Propidium DMZ1FRS TI TT1RS9F DMZ1FRS TN Acetylcholinesterase (AChE) DMZ1FRS MA Inhibitor DMZ1FRS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZ1FRS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZ1GH0 DI DMZ1GH0 DMZ1GH0 DN 1-(1,3,4-oxadiazol-2-yl)octadec-9-en-1-one DMZ1GH0 TI TTDP1UC DMZ1GH0 TN Fatty acid amide hydrolase (FAAH) DMZ1GH0 MA Inhibitor DMZ1GH0 RN Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem. 2008 Aug 14;51(15):4392-403. DMZ1GH0 RU https://pubmed.ncbi.nlm.nih.gov/18630870 DMZ1TNM DI DMZ1TNM DMZ1TNM DN 4-(3'-furyl)-aniline DMZ1TNM TI TTAWNKZ DMZ1TNM TN Norepinephrine transporter (NET) DMZ1TNM MA Inhibitor DMZ1TNM RN Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32. DMZ1TNM RU https://pubmed.ncbi.nlm.nih.gov/17367122 DMZ1VSI DI DMZ1VSI DMZ1VSI DN COCLAURINE DMZ1VSI TI TTVBI8W DMZ1VSI TN Dopamine transporter (DAT) DMZ1VSI MA Inhibitor DMZ1VSI RN Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes. J Nat Prod. 1995 Oct;58(10):1475-84. DMZ1VSI RU https://pubmed.ncbi.nlm.nih.gov/8676127 DMZ1YGI DI DMZ1YGI DMZ1YGI DN MCI DMZ1YGI TI TT85JO3 DMZ1YGI TN 5-HT receptor (5HTR) DMZ1YGI MA Antagonist DMZ1YGI RN Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest. 2001 Feb;119(2):554-61. DMZ1YGI RU https://pubmed.ncbi.nlm.nih.gov/11171737 DMZ20A5 DI DMZ20A5 DMZ20A5 DN SGI-1252 DMZ20A5 TI TTRMX3V DMZ20A5 TN Janus kinase 2 (JAK-2) DMZ20A5 MA Inhibitor DMZ20A5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). DMZ20A5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2048 DMZ21HU DI DMZ21HU DMZ21HU DN LEACHIANONE A DMZ21HU TI TT8JRS7 DMZ21HU TN Beta-secretase (BACE) DMZ21HU MA Inhibitor DMZ21HU RN BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74. DMZ21HU RU https://pubmed.ncbi.nlm.nih.gov/18565755 DMZ24LN DI DMZ24LN DMZ24LN DN Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 DMZ24LN TI TTVFO0U DMZ24LN TN Gastrin/cholecystokinin type B receptor (CCKBR) DMZ24LN MA Inhibitor DMZ24LN RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZ24LN RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZ24LN DI DMZ24LN DMZ24LN DN Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 DMZ24LN TI TTKWM86 DMZ24LN TN Opioid receptor mu (MOP) DMZ24LN MA Inhibitor DMZ24LN RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZ24LN RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZ24LN DI DMZ24LN DMZ24LN DN Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 DMZ24LN TI TTCG0AL DMZ24LN TN Cholecystokinin receptor type A (CCKAR) DMZ24LN MA Inhibitor DMZ24LN RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZ24LN RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZ24LN DI DMZ24LN DMZ24LN DN Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 DMZ24LN TI TT27RFC DMZ24LN TN Opioid receptor delta (OPRD1) DMZ24LN MA Inhibitor DMZ24LN RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZ24LN RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZ24P1 DI DMZ24P1 DMZ24P1 DN XEN-907 DMZ24P1 TI TT4G2JS DMZ24P1 TN Voltage-gated sodium channel alpha Nav1.7 (SCN9A) DMZ24P1 MA Inhibitor DMZ24P1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 584). DMZ24P1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=584 DMZ24XT DI DMZ24XT DMZ24XT DN N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine DMZ24XT TI TT3WG5C DMZ24XT TN Monoamine oxidase type A (MAO-A) DMZ24XT MA Inhibitor DMZ24XT RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMZ24XT RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMZ24XT DI DMZ24XT DMZ24XT DN N-methyl,N-(propargyl),N-(pyrrol-2-ylmethyl)amine DMZ24XT TI TTGP7BY DMZ24XT TN Monoamine oxidase type B (MAO-B) DMZ24XT MA Inhibitor DMZ24XT RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMZ24XT RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMZ26LS DI DMZ26LS DMZ26LS DN 6-fluoromevalonate pyrophosphate DMZ26LS TI TTE5J6X DMZ26LS TN Diphosphomevalonate decarboxylase (MVD) DMZ26LS MA Inhibitor DMZ26LS RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 642). DMZ26LS RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=642 DMZ2BR9 DI DMZ2BR9 DMZ2BR9 DN Beta-D-Glucopyranose Spirohydantoin DMZ2BR9 TI TTZHY6R DMZ2BR9 TN Glycogen phosphorylase muscle form (GP) DMZ2BR9 MA Inhibitor DMZ2BR9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZ2BR9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZ2DSK DI DMZ2DSK DMZ2DSK DN Non-peptide TPO mimics DMZ2DSK TI TTIHYA4 DMZ2DSK TN Thrombopoietin receptor (MPL) DMZ2DSK MA Modulator DMZ2DSK RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). DMZ2DSK RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1722 DMZ2EL1 DI DMZ2EL1 DMZ2EL1 DN EM1396 DMZ2EL1 TI TT5ZWB6 DMZ2EL1 TN Dihydrodiol dehydrogenase type I (AKR1C3) DMZ2EL1 MA Inhibitor DMZ2EL1 RN Structure-based inhibitor design for an enzyme that binds different steroids: a potent inhibitor for human type 5 17beta-hydroxysteroid dehydrogenase. J Biol Chem. 2007 Mar 16;282(11):8368-79. DMZ2EL1 RU https://pubmed.ncbi.nlm.nih.gov/17166832 DMZ2KUB DI DMZ2KUB DMZ2KUB DN NSC-683634 DMZ2KUB TI TTSZLWK DMZ2KUB TN Aromatase (CYP19A1) DMZ2KUB MA Inhibitor DMZ2KUB RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMZ2KUB RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMZ2LPO DI DMZ2LPO DMZ2LPO DN CD564 DMZ2LPO TI TT1Q3IE DMZ2LPO TN Retinoic acid receptor gamma (RARG) DMZ2LPO MA Inhibitor DMZ2LPO RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZ2LPO RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZ2R1O DI DMZ2R1O DMZ2R1O DN [3H]methoxy-PEPy DMZ2R1O TI TTHS256 DMZ2R1O TN Metabotropic glutamate receptor 5 (mGluR5) DMZ2R1O MA Modulator (allosteric modulator) DMZ2R1O RN [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett. 2003 Feb 10;13(3):351-4. DMZ2R1O RU https://pubmed.ncbi.nlm.nih.gov/12565928 DMZ2T59 DI DMZ2T59 DMZ2T59 DN N-hydroxy-1-naphthamide DMZ2T59 TI TTT6LFV DMZ2T59 TN Histone deacetylase 8 (HDAC8) DMZ2T59 MA Inhibitor DMZ2T59 RN Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8. DMZ2T59 RU https://pubmed.ncbi.nlm.nih.gov/17346959 DMZ2TD9 DI DMZ2TD9 DMZ2TD9 DN GSK2194069 DMZ2TD9 TI TT7AOUD DMZ2TD9 TN Fatty acid synthase (FASN) DMZ2TD9 MA Inhibitor DMZ2TD9 RN A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9. DMZ2TD9 RU https://pubmed.ncbi.nlm.nih.gov/25086508 DMZ2V0A DI DMZ2V0A DMZ2V0A DN VER-5593 DMZ2V0A TI TTWJBZ5 DMZ2V0A TN 5-HT 2C receptor (HTR2C) DMZ2V0A MA Inhibitor DMZ2V0A RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DMZ2V0A RU https://pubmed.ncbi.nlm.nih.gov/15081042 DMZ2V0A DI DMZ2V0A DMZ2V0A DN VER-5593 DMZ2V0A TI TT0K1SC DMZ2V0A TN 5-HT 2B receptor (HTR2B) DMZ2V0A MA Inhibitor DMZ2V0A RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DMZ2V0A RU https://pubmed.ncbi.nlm.nih.gov/15081042 DMZ2V0A DI DMZ2V0A DMZ2V0A DN VER-5593 DMZ2V0A TI TTJQOD7 DMZ2V0A TN 5-HT 2A receptor (HTR2A) DMZ2V0A MA Inhibitor DMZ2V0A RN Indoline derivatives as 5-HT(2C) receptor agonists. Bioorg Med Chem Lett. 2004 May 3;14(9):2367-70. DMZ2V0A RU https://pubmed.ncbi.nlm.nih.gov/15081042 DMZ2VE3 DI DMZ2VE3 DMZ2VE3 DN 1,1,1-Trifluoro-6-(naphthalen-2-yl)hexan-2-one DMZ2VE3 TI TTT1JVS DMZ2VE3 TN Cytosolic phospholipase A2 (GIVA cPLA2) DMZ2VE3 MA Inhibitor DMZ2VE3 RN Potent and selective fluoroketone inhibitors of group VIA calcium-independent phospholipase A2. J Med Chem. 2010 May 13;53(9):3602-10. DMZ2VE3 RU https://pubmed.ncbi.nlm.nih.gov/20369880 DMZ2VYG DI DMZ2VYG DMZ2VYG DN burimamide DMZ2VYG TI TTXJ178 DMZ2VYG TN Histamine H4 receptor (H4R) DMZ2VYG MA Antagonist DMZ2VYG RN Comparison of human, mouse, rat, and guinea pig histamine H4 receptors reveals substantial pharmacological species variation. J Pharmacol Exp Ther. 2001 Oct;299(1):121-30. DMZ2VYG RU https://pubmed.ncbi.nlm.nih.gov/11561071 DMZ2VYG DI DMZ2VYG DMZ2VYG DN burimamide DMZ2VYG TI TT9JNIC DMZ2VYG TN Histamine H3 receptor (H3R) DMZ2VYG MA Antagonist DMZ2VYG RN Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6. DMZ2VYG RU https://pubmed.ncbi.nlm.nih.gov/11179434 DMZ2VYG DI DMZ2VYG DMZ2VYG DN burimamide DMZ2VYG TI TTQHJ1K DMZ2VYG TN Histamine H2 receptor (H2R) DMZ2VYG MA Agonist DMZ2VYG RN Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem. 1998 Aug;71(2):799-807. DMZ2VYG RU https://pubmed.ncbi.nlm.nih.gov/9681472 DMZ2WS9 DI DMZ2WS9 DMZ2WS9 DN CIP-137401 DMZ2WS9 TI TTROQ37 DMZ2WS9 TN MAPK/ERK kinase kinase (MAP3K) DMZ2WS9 MA Inhibitor DMZ2WS9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2063). DMZ2WS9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2063 DMZ2XOH DI DMZ2XOH DMZ2XOH DN EFPPEA DMZ2XOH TI TT0WAIE DMZ2XOH TN Melatonin receptor type 1A (MTNR1A) DMZ2XOH MA Agonist DMZ2XOH RN Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands. J Med Chem. 2011 Jun 23;54(12):4207-18. DMZ2XOH RU https://pubmed.ncbi.nlm.nih.gov/21568291 DMZ30AM DI DMZ30AM DMZ30AM DN S-Isopropyl-Isothiourea DMZ30AM TI TTCM4B3 DMZ30AM TN Nitric-oxide synthase endothelial (NOS3) DMZ30AM MA Inhibitor DMZ30AM RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZ30AM RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZ318I DI DMZ318I DMZ318I DN methylfurmethide DMZ318I TI TTQ13Z5 DMZ318I TN Muscarinic acetylcholine receptor M3 (CHRM3) DMZ318I MA Agonist DMZ318I RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMZ318I RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMZ318I DI DMZ318I DMZ318I DN methylfurmethide DMZ318I TI TTOXS3C DMZ318I TN Muscarinic acetylcholine receptor (CHRM) DMZ318I MA Agonist DMZ318I RN Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9. DMZ318I RU https://pubmed.ncbi.nlm.nih.gov/9224827 DMZ34P1 DI DMZ34P1 DMZ34P1 DN CGP-62464 DMZ34P1 TI TT6PKBN DMZ34P1 TN Proto-oncogene c-Src (SRC) DMZ34P1 MA Inhibitor DMZ34P1 RN Substituted 5,7-diphenyl-pyrrolo[2,3d]pyrimidines: potent inhibitors of the tyrosine kinase c-Src. Bioorg Med Chem Lett. 2000 May 1;10(9):945-9. DMZ34P1 RU https://pubmed.ncbi.nlm.nih.gov/10853665 DMZ3DMX DI DMZ3DMX DMZ3DMX DN (1R,2S)-2-(1H-Imidazol-4-yl)-1-methyl-propylamine DMZ3DMX TI TT9JNIC DMZ3DMX TN Histamine H3 receptor (H3R) DMZ3DMX MA Inhibitor DMZ3DMX RN A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9. DMZ3DMX RU https://pubmed.ncbi.nlm.nih.gov/7752184 DMZ3EA1 DI DMZ3EA1 DMZ3EA1 DN N,N-diethyl estrone-16-methyl carboxamide DMZ3EA1 TI TTIWB6L DMZ3EA1 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMZ3EA1 MA Inhibitor DMZ3EA1 RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMZ3EA1 RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMZ3EML DI DMZ3EML DMZ3EML DN Di(2,6-dimethylphenol) DMZ3EML TI TTANPDJ DMZ3EML TN Carbonic anhydrase II (CA-II) DMZ3EML MA Inhibitor DMZ3EML RN Carbonic anhydrase inhibitors. Inhibition of human erythrocyte isozymes I and II with a series of antioxidant phenols. Bioorg Med Chem. 2009 Apr 15;17(8):3207-11. DMZ3EML RU https://pubmed.ncbi.nlm.nih.gov/19231207 DMZ3I6U DI DMZ3I6U DMZ3I6U DN N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide DMZ3I6U TI TT3WG5C DMZ3I6U TN Monoamine oxidase type A (MAO-A) DMZ3I6U MA Inhibitor DMZ3I6U RN New pyrrole inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. J Med Chem. 2007 Mar 8;50(5):922-31. DMZ3I6U RU https://pubmed.ncbi.nlm.nih.gov/17256833 DMZ3INJ DI DMZ3INJ DMZ3INJ DN N-Hydroxy-3-naphthalen-2-yl-acrylamide DMZ3INJ TI TT2J34L DMZ3INJ TN Arachidonate 5-lipoxygenase (5-LOX) DMZ3INJ MA Inhibitor DMZ3INJ RN Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships. J Med Chem. 1990 Mar;33(3):992-8. DMZ3INJ RU https://pubmed.ncbi.nlm.nih.gov/2308149 DMZ3N8A DI DMZ3N8A DMZ3N8A DN 10-Propyl-10H-dibenzo[b,f][1,4]thiazepin-11-one DMZ3N8A TI TT84ETX DMZ3N8A TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMZ3N8A MA Inhibitor DMZ3N8A RN Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97. DMZ3N8A RU https://pubmed.ncbi.nlm.nih.gov/1375293 DMZ3WPN DI DMZ3WPN DMZ3WPN DN Penciclovir DMZ3WPN TI TTV1095 DMZ3WPN TN COVID-19 RNA-directed RNA polymerase (RdRp) DMZ3WPN MA Inhibitor DMZ3WPN RN Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. DMZ3WPN RU https://pubmed.ncbi.nlm.nih.gov/32020029 DMZ3YTO DI DMZ3YTO DMZ3YTO DN ABT-341 DMZ3YTO TI TTDIGC1 DMZ3YTO TN Dipeptidyl peptidase 4 (DPP-4) DMZ3YTO MA Inhibitor DMZ3YTO RN Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)... J Med Chem. 2006 Nov 2;49(22):6439-42. DMZ3YTO RU https://pubmed.ncbi.nlm.nih.gov/17064063 DMZ40RQ DI DMZ40RQ DMZ40RQ DN Propyl-(4,5,6,7-tetrahydro-2H-indazol-5-yl)-amine DMZ40RQ TI TTEX248 DMZ40RQ TN Dopamine D2 receptor (D2R) DMZ40RQ MA Inhibitor DMZ40RQ RN Substituted 5-amino-4,5,6,7-tetrahydroindazoles as partial ergoline structures with dopaminergic activity. J Med Chem. 1989 Oct;32(10):2388-96. DMZ40RQ RU https://pubmed.ncbi.nlm.nih.gov/2571732 DMZ4237 DI DMZ4237 DMZ4237 DN 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole DMZ4237 TI TT4C8EA DMZ4237 TN Dopamine D3 receptor (D3R) DMZ4237 MA Inhibitor DMZ4237 RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMZ4237 RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMZ4237 DI DMZ4237 DMZ4237 DN 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole DMZ4237 TI TTE0A2F DMZ4237 TN Dopamine D4 receptor (D4R) DMZ4237 MA Inhibitor DMZ4237 RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMZ4237 RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMZ4237 DI DMZ4237 DMZ4237 DN 4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole DMZ4237 TI TTEX248 DMZ4237 TN Dopamine D2 receptor (D2R) DMZ4237 MA Inhibitor DMZ4237 RN New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80. DMZ4237 RU https://pubmed.ncbi.nlm.nih.gov/9873601 DMZ43N1 DI DMZ43N1 DMZ43N1 DN N-adamantyl-N'-cyclohexylurea DMZ43N1 TI TT7WVHI DMZ43N1 TN Soluble epoxide hydrolase (EPHX2) DMZ43N1 MA Inhibitor DMZ43N1 RN Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40. DMZ43N1 RU https://pubmed.ncbi.nlm.nih.gov/17616115 DMZ45M6 DI DMZ45M6 DMZ45M6 DN calcitriol-26,23-lactone DMZ45M6 TI TTK59TV DMZ45M6 TN Vitamin D3 receptor (VDR) DMZ45M6 MA Agonist DMZ45M6 RN Biological activity of 24,24-difluoro-1 alpha, 25-dihydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3-26,23-lactone in inducing differentiation of human myeloid leukemia cells. Arch Biochem Biophys. 1983 Jan;220(1):90-4. DMZ45M6 RU https://pubmed.ncbi.nlm.nih.gov/6572492 DMZ46GI DI DMZ46GI DMZ46GI DN AM-2S DMZ46GI TI TTUZ2L5 DMZ46GI TN Matrix metalloproteinase-3 (MMP-3) DMZ46GI MA Inhibitor DMZ46GI RN Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship. Bioorg Med Chem Lett. 2009 Apr 1;19(7):1970-6. DMZ46GI RU https://pubmed.ncbi.nlm.nih.gov/19261472 DMZ4A0R DI DMZ4A0R DMZ4A0R DN Hebervis DMZ4A0R TI TTED8JB DMZ4A0R TN Epidermal growth factor (EGF) DMZ4A0R MA Modulator DMZ4A0R RN Leadership in BioBusiness. Dr Gurinder S Shahi. Page(36). DMZ4A0R RU https://books.google.com.hk/books?id=6qF0AgAAQBAJ&pg=PA36&lpg=PA36&dq=Hebervis++++Epidermal+growth+factor&source=bl&ots=RD745hdy84&sig=5Z2dTG5PlEIIoiJHRtoqvbq5ny8&hl=zh-CN&sa=X&ved=0CB4Q6AEwAWoVChMI6tqlvJDCyAIVUZGOCh1qkgCl#v=onepage&q=Hebervis%20%20%20%20Epidermal%20growth%20factor&f=false DMZ4A2X DI DMZ4A2X DMZ4A2X DN N-(2-Diethylamino-ethyl)-4-hexyloxy-benzamide DMZ4A2X TI TT846HF DMZ4A2X TN Voltage-gated potassium channel Kv7.1 (KCNQ1) DMZ4A2X MA Inhibitor DMZ4A2X RN Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable I(Ks) blockers. J Med Chem. 2001 Nov 8;44(23):3764-7. DMZ4A2X RU https://pubmed.ncbi.nlm.nih.gov/11689063 DMZ4FCB DI DMZ4FCB DMZ4FCB DN Thiophosphoric acid (E)-dodec-9-enyl ester DMZ4FCB TI TTQ6S1K DMZ4FCB TN Lysophosphatidic acid receptor 1 (LPAR1) DMZ4FCB MA Inhibitor DMZ4FCB RN Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30. DMZ4FCB RU https://pubmed.ncbi.nlm.nih.gov/16033271 DMZ4KO0 DI DMZ4KO0 DMZ4KO0 DN L17 DMZ4KO0 TI TT5FH9Y DMZ4KO0 TN Human immunodeficiency virus Integrase (HIV IN) DMZ4KO0 MA Inhibitor DMZ4KO0 RN Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase. Antimicrob Agents Chemother. 2001 Sep;45(9):2510-6. DMZ4KO0 RU https://pubmed.ncbi.nlm.nih.gov/11502522 DMZ4LDC DI DMZ4LDC DMZ4LDC DN PD-135146 DMZ4LDC TI TTEX248 DMZ4LDC TN Dopamine D2 receptor (D2R) DMZ4LDC MA Inhibitor DMZ4LDC RN Synthesis and pharmacological evaluation of the enantiomers of the dopamine autoreceptor agonist PD 135385, Bioorg. Med. Chem. Lett. 3(4):639-644 (1993). DMZ4LDC RU http://www.sciencedirect.com/science/article/pii/S0960894X01812452 DMZ4LJ7 DI DMZ4LJ7 DMZ4LJ7 DN 2-NAPHTHALENESULFONIC ACID DMZ4LJ7 TI TT6L509 DMZ4LJ7 TN Coagulation factor IIa (F2) DMZ4LJ7 MA Inhibitor DMZ4LJ7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZ4LJ7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZ4N7Q DI DMZ4N7Q DMZ4N7Q DN N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide DMZ4N7Q TI TTXA6PH DMZ4N7Q TN Oxysterols receptor LXR-beta (NR1H2) DMZ4N7Q MA Inhibitor DMZ4N7Q RN Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. DMZ4N7Q RU https://pubmed.ncbi.nlm.nih.gov/19539483 DMZ4N7Q DI DMZ4N7Q DMZ4N7Q DN N-{4-[2-(3-Methoxyphenyl)ethyl]phenyl}phthalimide DMZ4N7Q TI TTECBXN DMZ4N7Q TN Oxysterols receptor LXR-alpha (NR1H3) DMZ4N7Q MA Inhibitor DMZ4N7Q RN Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LX... Bioorg Med Chem. 2009 Jul 15;17(14):5001-14. DMZ4N7Q RU https://pubmed.ncbi.nlm.nih.gov/19539483 DMZ4Q0B DI DMZ4Q0B DMZ4Q0B DN Dasatinib DMZ4Q0B TI TTE63HY DMZ4Q0B TN HUMAN fusion protein Bcr-Abl (Bcr-Abl) DMZ4Q0B MA Inhibitor DMZ4Q0B RN Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. DMZ4Q0B RU https://pubmed.ncbi.nlm.nih.gov/26868298 DMZ51IE DI DMZ51IE DMZ51IE DN Salvinorin B methoxymethyl ether DMZ51IE TI TTQW87Y DMZ51IE TN Opioid receptor kappa (OPRK1) DMZ51IE MA Inhibitor DMZ51IE RN Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers. Bioorg Med Chem. 2008 Feb 1;16(3):1279-86. DMZ51IE RU https://pubmed.ncbi.nlm.nih.gov/17981041 DMZ51UJ DI DMZ51UJ DMZ51UJ DN A-123189 DMZ51UJ TI TTNGILX DMZ51UJ TN Adrenergic receptor alpha-1A (ADRA1A) DMZ51UJ MA Inhibitor DMZ51UJ RN Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64. DMZ51UJ RU https://pubmed.ncbi.nlm.nih.gov/15664832 DMZ51UJ DI DMZ51UJ DMZ51UJ DN A-123189 DMZ51UJ TI TTBRKXS DMZ51UJ TN Adrenergic receptor alpha-1B (ADRA1B) DMZ51UJ MA Inhibitor DMZ51UJ RN Two novel and potent 3-[(o-methoxyphenyl)piperazinylethyl]-5-phenylthien. Bioorg Med Chem Lett. 2001 May 7;11(9):1119-21. DMZ51UJ RU https://pubmed.ncbi.nlm.nih.gov/11354357 DMZ53N4 DI DMZ53N4 DMZ53N4 DN 3-(7-methyl-1,8-naphthyridin-2-yl)benzonitrile DMZ53N4 TI TTHS256 DMZ53N4 TN Metabotropic glutamate receptor 5 (mGluR5) DMZ53N4 MA Inhibitor DMZ53N4 RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMZ53N4 RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMZ57O1 DI DMZ57O1 DMZ57O1 DN CNTO-736 DMZ57O1 TI TTVIMDE DMZ57O1 TN Glucagon-like peptide 1 receptor (GLP1R) DMZ57O1 MA Modulator DMZ57O1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMZ57O1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMZ5AD8 DI DMZ5AD8 DMZ5AD8 DN GARTANIN DMZ5AD8 TI TT50QJ3 DMZ5AD8 TN Influenza Neuraminidase (Influ NA) DMZ5AD8 MA Inhibitor DMZ5AD8 RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMZ5AD8 RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMZ5BHX DI DMZ5BHX DMZ5BHX DN PMID22123324C38 DMZ5BHX TI TTS17MG DMZ5BHX TN Melanin-concentrating hormone receptor 2 (MCHR2) DMZ5BHX MA Antagonist DMZ5BHX RN Discovery and characterization of a potent and selective antagonist of melanin-concentrating hormone receptor 2. Bioorg Med Chem Lett. 2012 Jan 1;22(1):363-6. DMZ5BHX RU https://pubmed.ncbi.nlm.nih.gov/22123324 DMZ5H8O DI DMZ5H8O DMZ5H8O DN 2-(3-Piperidin-1-yl-propyl)-3H-quinazolin-4-one DMZ5H8O TI TTVDSZ0 DMZ5H8O TN Poly [ADP-ribose] polymerase 1 (PARP1) DMZ5H8O MA Inhibitor DMZ5H8O RN Rational approaches to discovery of orally active and brain-penetrable quinazolinone inhibitors of poly(ADP-ribose)polymerase. J Med Chem. 2004 Aug 12;47(17):4151-4. DMZ5H8O RU https://pubmed.ncbi.nlm.nih.gov/15293985 DMZ5ISH DI DMZ5ISH DMZ5ISH DN Imidazolidin-2-ylidene-quinoxalin-6-yl-amine DMZ5ISH TI TTBRKXS DMZ5ISH TN Adrenergic receptor alpha-1B (ADRA1B) DMZ5ISH MA Inhibitor DMZ5ISH RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMZ5ISH RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMZ5ISH DI DMZ5ISH DMZ5ISH DN Imidazolidin-2-ylidene-quinoxalin-6-yl-amine DMZ5ISH TI TTNGILX DMZ5ISH TN Adrenergic receptor alpha-1A (ADRA1A) DMZ5ISH MA Inhibitor DMZ5ISH RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMZ5ISH RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMZ5ISH DI DMZ5ISH DMZ5ISH DN Imidazolidin-2-ylidene-quinoxalin-6-yl-amine DMZ5ISH TI TT34BHT DMZ5ISH TN Adrenergic receptor alpha-1D (ADRA1D) DMZ5ISH MA Inhibitor DMZ5ISH RN Analogs of UK 14,304: Structural features responsible for alpha2 adrenoceptor activity, Bioorg. Med. Chem. Lett. 5(15):1745-1750 (1995). DMZ5ISH RU http://www.sciencedirect.com/science/article/pii/0960894X95002955 DMZ5JFG DI DMZ5JFG DMZ5JFG DN 3-chloro-4-(4-chloro-2-hydroxyphenoxy)benzamide DMZ5JFG TI TTNX2CS DMZ5JFG TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMZ5JFG MA Inhibitor DMZ5JFG RN Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. ... Bioorg Med Chem Lett. 2005 Dec 1;15(23):5247-52. DMZ5JFG RU https://pubmed.ncbi.nlm.nih.gov/16198563 DMZ5JNT DI DMZ5JNT DMZ5JNT DN PF-02367982 DMZ5JNT TI TTUV8G9 DMZ5JNT TN Progesterone receptor (PGR) DMZ5JNT MA Inhibitor DMZ5JNT RN Optimisation of a pyrazole series of progesterone antagonists; Part 1. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3384-6. DMZ5JNT RU https://pubmed.ncbi.nlm.nih.gov/20430618 DMZ5MDY DI DMZ5MDY DMZ5MDY DN 5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide DMZ5MDY TI TTJQOD7 DMZ5MDY TN 5-HT 2A receptor (HTR2A) DMZ5MDY MA Inhibitor DMZ5MDY RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMZ5MDY RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMZ5MDY DI DMZ5MDY DMZ5MDY DN 5-chloro-N-(pyridin-3-yl)indoline-1-carboxamide DMZ5MDY TI TTWJBZ5 DMZ5MDY TN 5-HT 2C receptor (HTR2C) DMZ5MDY MA Inhibitor DMZ5MDY RN Synthesis and structure-affinity relationships of novel small molecule natural product derivatives capable of discriminating between serotonin 5-HT1A, 5-HT2A, 5-HT2C receptor subtypes. Bioorg Med Chem. 2010 Jul 1;18(13):4783-92. DMZ5MDY RU https://pubmed.ncbi.nlm.nih.gov/20570529 DMZ5ODC DI DMZ5ODC DMZ5ODC DN Indirubin-3-methoxime DMZ5ODC TI TT9RTBL DMZ5ODC TN Aurora B messenger RNA (AURKB mRNA) DMZ5ODC MA Inhibitor DMZ5ODC RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMZ5ODC RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMZ5ODC DI DMZ5ODC DMZ5ODC DN Indirubin-3-methoxime DMZ5ODC TI TTPS3C0 DMZ5ODC TN Aurora kinase A (AURKA) DMZ5ODC MA Inhibitor DMZ5ODC RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMZ5ODC RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMZ5ODC DI DMZ5ODC DMZ5ODC DN Indirubin-3-methoxime DMZ5ODC TI TTLYXIT DMZ5ODC TN Aurora kinase C (AURKC) DMZ5ODC MA Inhibitor DMZ5ODC RN An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37. DMZ5ODC RU https://pubmed.ncbi.nlm.nih.gov/17665890 DMZ5P2K DI DMZ5P2K DMZ5P2K DN PMID24900446C5 DMZ5P2K TI TTLPF4X DMZ5P2K TN Kallikrein-6 (KLK6) DMZ5P2K MA Inhibitor DMZ5P2K RN Virtual Screening and X-ray Crystallography for Human Kallikrein 6 Inhibitors with an Amidinothiophene P1 Group. ACS Med Chem Lett. 2012 Jan 11;3(2):159-64. DMZ5P2K RU https://pubmed.ncbi.nlm.nih.gov/24900446 DMZ5Q7J DI DMZ5Q7J DMZ5Q7J DN Patuletin 3-O-beta-D-robinobioside DMZ5Q7J TI TTFBNVI DMZ5Q7J TN Aldose reductase (AKR1B1) DMZ5Q7J MA Inhibitor DMZ5Q7J RN Flavonoids with anti-cataract activity from Brickellia arguta. J Nat Prod. 1984 Mar-Apr;47(2):316-9. DMZ5Q7J RU https://pubmed.ncbi.nlm.nih.gov/6429283 DMZ5Y94 DI DMZ5Y94 DMZ5Y94 DN Des-Arg10-Kallidin DMZ5Y94 TI TTG5QIA DMZ5Y94 TN B1 bradykinin receptor (BDKRB1) DMZ5Y94 MA Inhibitor DMZ5Y94 RN Development of an efficient and selective radioligand for bradykinin B1 receptor occupancy studies. Bioorg Med Chem Lett. 2004 Dec 20;14(24):6045-8. DMZ5Y94 RU https://pubmed.ncbi.nlm.nih.gov/15546726 DMZ5YMH DI DMZ5YMH DMZ5YMH DN (11E)-OCTADEC-11-ENOIC ACID DMZ5YMH TI TT2JWF6 DMZ5YMH TN Peroxisome proliferator-activated receptor delta (PPARD) DMZ5YMH MA Inhibitor DMZ5YMH RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMZ5YMH RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMZ62L3 DI DMZ62L3 DMZ62L3 DN 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide DMZ62L3 TI TTANPDJ DMZ62L3 TN Carbonic anhydrase II (CA-II) DMZ62L3 MA Inhibitor DMZ62L3 RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMZ62L3 RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMZ62L3 DI DMZ62L3 DMZ62L3 DN 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide DMZ62L3 TI TTUNARX DMZ62L3 TN Carbonic anhydrase (CA) DMZ62L3 MA Inhibitor DMZ62L3 RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMZ62L3 RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMZ62L3 DI DMZ62L3 DMZ62L3 DN 4-(2-Phenylacetamido)-3-bromobenzenesulfonamide DMZ62L3 TI TTHQPL7 DMZ62L3 TN Carbonic anhydrase I (CA-I) DMZ62L3 MA Inhibitor DMZ62L3 RN Carbonic anhydrase inhibitors. Aromatic/heterocyclic sulfonamides incorporating phenacetyl, pyridylacetyl and thienylacetyl tails act as potent inh... Bioorg Med Chem. 2009 Jul 15;17(14):4894-9. DMZ62L3 RU https://pubmed.ncbi.nlm.nih.gov/19539481 DMZ693W DI DMZ693W DMZ693W DN 5,5'-methylenebis(3,4-dibromobenzene-1,2-diol) DMZ693W TI TT58ZYW DMZ693W TN Mycobacterium Isocitrate lyase (MycB icl) DMZ693W MA Inhibitor DMZ693W RN Bromophenols as Candida albicans isocitrate lyase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6644-8. DMZ693W RU https://pubmed.ncbi.nlm.nih.gov/20888765 DMZ6EGA DI DMZ6EGA DMZ6EGA DN MRS2298 DMZ6EGA TI TTA93TL DMZ6EGA TN P2Y purinoceptor 1 (P2RY1) DMZ6EGA MA Antagonist DMZ6EGA RN Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol. 2004 Nov 15;68(10):1995-2002. DMZ6EGA RU https://pubmed.ncbi.nlm.nih.gov/15476670 DMZ6H1X DI DMZ6H1X DMZ6H1X DN Molecule 11 DMZ6H1X TI TTCIHJA DMZ6H1X TN Coagulation factor Xa (F10) DMZ6H1X MA Inhibitor DMZ6H1X RN Role of tissue factor pathway inhibitor in the regulation of tissue factor-dependent blood coagulation. Cardiovasc Drug Rev. 2002 Winter;20(1):67-80. DMZ6H1X RU https://pubmed.ncbi.nlm.nih.gov/12070535 DMZ6HQL DI DMZ6HQL DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid DMZ6HQL TI TTUNARX DMZ6HQL TN Carbonic anhydrase (CA) DMZ6HQL MA Inhibitor DMZ6HQL RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZ6HQL RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZ6HQL DI DMZ6HQL DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid DMZ6HQL TI TTZHA0O DMZ6HQL TN Carbonic anhydrase IV (CA-IV) DMZ6HQL MA Inhibitor DMZ6HQL RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZ6HQL RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZ6HQL DI DMZ6HQL DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid DMZ6HQL TI TTHQPL7 DMZ6HQL TN Carbonic anhydrase I (CA-I) DMZ6HQL MA Inhibitor DMZ6HQL RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZ6HQL RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZ6HQL DI DMZ6HQL DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid DMZ6HQL TI TTEYTKG DMZ6HQL TN Carbonic anhydrase XIV (CA-XIV) DMZ6HQL MA Inhibitor DMZ6HQL RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZ6HQL RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZ6HQL DI DMZ6HQL DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid DMZ6HQL TI TT2LVK8 DMZ6HQL TN Carbonic anhydrase IX (CA-IX) DMZ6HQL MA Inhibitor DMZ6HQL RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZ6HQL RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZ6HQL DI DMZ6HQL DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid DMZ6HQL TI TTSYM0R DMZ6HQL TN Carbonic anhydrase XII (CA-XII) DMZ6HQL MA Inhibitor DMZ6HQL RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZ6HQL RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZ6HQL DI DMZ6HQL DMZ6HQL DN 6-methyl-2-oxo-2H-chromene-3-carboxylic acid DMZ6HQL TI TTANPDJ DMZ6HQL TN Carbonic anhydrase II (CA-II) DMZ6HQL MA Inhibitor DMZ6HQL RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZ6HQL RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZ6QX0 DI DMZ6QX0 DMZ6QX0 DN 1-(1-phenyl-2-o-tolylethyl)piperazine DMZ6QX0 TI TT3ROYC DMZ6QX0 TN Serotonin transporter (SERT) DMZ6QX0 MA Inhibitor DMZ6QX0 RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMZ6QX0 RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMZ6QX0 DI DMZ6QX0 DMZ6QX0 DN 1-(1-phenyl-2-o-tolylethyl)piperazine DMZ6QX0 TI TTAWNKZ DMZ6QX0 TN Norepinephrine transporter (NET) DMZ6QX0 MA Inhibitor DMZ6QX0 RN N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8. DMZ6QX0 RU https://pubmed.ncbi.nlm.nih.gov/16750359 DMZ6TRV DI DMZ6TRV DMZ6TRV DN 5-phenyl-1,3,4-oxadiazole-2(3H)-thione DMZ6TRV TI TTULVH8 DMZ6TRV TN Tyrosinase (TYR) DMZ6TRV MA Inhibitor DMZ6TRV RN New potent inhibitors of tyrosinase: novel clues to binding of 1,3,4-thiadiazole-2(3H)-thiones, 1,3,4-oxadiazole-2(3H)-thiones, 4-amino-1,2,4-triaz... Bioorg Med Chem. 2010 Jun 1;18(11):4042-8. DMZ6TRV RU https://pubmed.ncbi.nlm.nih.gov/20452224 DMZ6X9B DI DMZ6X9B DMZ6X9B DN ISIS 102604 DMZ6X9B TI TT5U49F DMZ6X9B TN PRKACA messenger RNA (PRKACA mRNA) DMZ6X9B RN US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression. DMZ6X9B RU http://www.patentbuddy.com/Patent/6248586?ft=true&sr=true DMZ6YPV DI DMZ6YPV DMZ6YPV DN Cyamemazine DMZ6YPV TI TTJQOD7 DMZ6YPV TN 5-HT 2A receptor (HTR2A) DMZ6YPV MA Antagonist DMZ6YPV RN Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40. DMZ6YPV RU https://pubmed.ncbi.nlm.nih.gov/12527336 DMZ6YPV DI DMZ6YPV DMZ6YPV DN Cyamemazine DMZ6YPV TI TTSQIFT DMZ6YPV TN 5-HT 1A receptor (HTR1A) DMZ6YPV MA Antagonist DMZ6YPV RN Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40. DMZ6YPV RU https://pubmed.ncbi.nlm.nih.gov/12527336 DMZ6YPV DI DMZ6YPV DMZ6YPV DN Cyamemazine DMZ6YPV TI TTO9X1H DMZ6YPV TN 5-HT 7 receptor (HTR7) DMZ6YPV MA Antagonist DMZ6YPV RN Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40. DMZ6YPV RU https://pubmed.ncbi.nlm.nih.gov/12527336 DMZ6YPV DI DMZ6YPV DMZ6YPV DN Cyamemazine DMZ6YPV TI TTWJBZ5 DMZ6YPV TN 5-HT 2C receptor (HTR2C) DMZ6YPV MA Antagonist DMZ6YPV RN Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes. Biochem Pharmacol. 2003 Feb 1;65(3):435-40. DMZ6YPV RU https://pubmed.ncbi.nlm.nih.gov/12527336 DMZ703W DI DMZ703W DMZ703W DN WilVent DMZ703W TI TTP4520 DMZ703W TN TGF-beta receptor type I (TGFBR1) DMZ703W MA Modulator DMZ703W RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788). DMZ703W RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1788 DMZ76NQ DI DMZ76NQ DMZ76NQ DN 6-Phenylsulfanyl-9H-purine DMZ76NQ TI TTQBR95 DMZ76NQ TN Stress-activated protein kinase 2a (p38 alpha) DMZ76NQ MA Inhibitor DMZ76NQ RN Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22. DMZ76NQ RU https://pubmed.ncbi.nlm.nih.gov/15689155 DMZ78WB DI DMZ78WB DMZ78WB DN 3-[(2-methyl-4-thiazolyl)ethynyl]-5-vinylpyridine DMZ78WB TI TTHS256 DMZ78WB TN Metabotropic glutamate receptor 5 (mGluR5) DMZ78WB MA Inhibitor DMZ78WB RN Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic g... J Med Chem. 2006 Feb 9;49(3):1080-100. DMZ78WB RU https://pubmed.ncbi.nlm.nih.gov/16451073 DMZ7EAC DI DMZ7EAC DMZ7EAC DN 2,7-Bis[2-(ethylamino)acetamido]anthraquinone DMZ7EAC TI TTQY2EJ DMZ7EAC TN TERT messenger RNA (TERT mRNA) DMZ7EAC MA Inhibitor DMZ7EAC RN Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86. DMZ7EAC RU https://pubmed.ncbi.nlm.nih.gov/18571928 DMZ7FJN DI DMZ7FJN DMZ7FJN DN AS99 DMZ7FJN TI TTK25J1 DMZ7FJN TN Adenosine A1 receptor (ADORA1) DMZ7FJN MA Antagonist DMZ7FJN RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DMZ7FJN RU https://pubmed.ncbi.nlm.nih.gov/16219300 DMZ7FJN DI DMZ7FJN DMZ7FJN DN AS99 DMZ7FJN TI TTNE7KG DMZ7FJN TN Adenosine A2b receptor (ADORA2B) DMZ7FJN MA Antagonist DMZ7FJN RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DMZ7FJN RU https://pubmed.ncbi.nlm.nih.gov/16219300 DMZ7GUP DI DMZ7GUP DMZ7GUP DN 1-hydroxy-3-(4-nitrophenyl)urea DMZ7GUP TI TTULVH8 DMZ7GUP TN Tyrosinase (TYR) DMZ7GUP MA Inhibitor DMZ7GUP RN Analogues of N-hydroxy-N'-phenylthiourea and N-hydroxy-N'-phenylurea as inhibitors of tyrosinase and melanin formation. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3607-10. DMZ7GUP RU https://pubmed.ncbi.nlm.nih.gov/18501598 DMZ7K5G DI DMZ7K5G DMZ7K5G DN 5-(4-piperidyl)-4-propylisothiazol-3-ol DMZ7K5G TI TT1MPAY DMZ7K5G TN GABA(A) receptor alpha-1 (GABRA1) DMZ7K5G MA Inhibitor DMZ7K5G RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMZ7K5G RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMZ7K5G DI DMZ7K5G DMZ7K5G DN 5-(4-piperidyl)-4-propylisothiazol-3-ol DMZ7K5G TI TT06RH5 DMZ7K5G TN GABA(A) receptor gamma-2 (GABRG2) DMZ7K5G MA Inhibitor DMZ7K5G RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMZ7K5G RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMZ7K5G DI DMZ7K5G DMZ7K5G DN 5-(4-piperidyl)-4-propylisothiazol-3-ol DMZ7K5G TI TTNJYV2 DMZ7K5G TN Gamma-aminobutyric acid receptor (GAR) DMZ7K5G MA Inhibitor DMZ7K5G RN Potent 4-arylalkyl-substituted 3-isothiazolol GABA(A) competitive/noncompetitive antagonists: synthesis and pharmacology. J Med Chem. 2006 Feb 23;49(4):1388-96. DMZ7K5G RU https://pubmed.ncbi.nlm.nih.gov/16480274 DMZ7N8D DI DMZ7N8D DMZ7N8D DN XCT790 DMZ7N8D TI TTPNQAC DMZ7N8D TN Estrogen-related receptor-alpha (ESRRA) DMZ7N8D MA Antagonist DMZ7N8D RN Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7. DMZ7N8D RU https://pubmed.ncbi.nlm.nih.gov/15184675 DMZ7OHP DI DMZ7OHP DMZ7OHP DN Lecanindole D DMZ7OHP TI TTUV8G9 DMZ7OHP TN Progesterone receptor (PGR) DMZ7OHP MA Inhibitor DMZ7OHP RN The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144. J Nat Prod. 2009 Nov;72(11):1944-8. DMZ7OHP RU https://pubmed.ncbi.nlm.nih.gov/19863083 DMZ7UM2 DI DMZ7UM2 DMZ7UM2 DN ISIS 29243 DMZ7UM2 TI TTYMGWX DMZ7UM2 TN PDK-1 messenger RNA (PDK-1 mRNA) DMZ7UM2 RN US patent application no. 6,124,272, Antisense modulation of PDK-1 expression. DMZ7UM2 RU http://www.patentbuddy.com/Patent/6124272?ft=true&sr=true DMZ80CT DI DMZ80CT DMZ80CT DN 1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione DMZ80CT TI TTM2AOE DMZ80CT TN Adenosine A2a receptor (ADORA2A) DMZ80CT MA Inhibitor DMZ80CT RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DMZ80CT RU https://pubmed.ncbi.nlm.nih.gov/3806581 DMZ80CT DI DMZ80CT DMZ80CT DN 1,3-Diisobutyl-3,7-dihydro-purine-2,6-dione DMZ80CT TI TTK25J1 DMZ80CT TN Adenosine A1 receptor (ADORA1) DMZ80CT MA Inhibitor DMZ80CT RN Benzo[1,2-c:5,4-c']dipyrazoles: non-xanthine adenosine antagonists. J Med Chem. 1988 Oct;31(10):2034-9. DMZ80CT RU https://pubmed.ncbi.nlm.nih.gov/3172141 DMZ83G9 DI DMZ83G9 DMZ83G9 DN 2-(1,4'-bipiperidin-1'-yl)thiazolo[4,5-b]pyridine DMZ83G9 TI TT9JNIC DMZ83G9 TN Histamine H3 receptor (H3R) DMZ83G9 MA Inhibitor DMZ83G9 RN Synthesis and structure-activity relationships of 2-(1,4'-bipiperidin-1'-yl)thiazolopyridine as H3 receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6176-80. DMZ83G9 RU https://pubmed.ncbi.nlm.nih.gov/19773164 DMZ84JH DI DMZ84JH DMZ84JH DN N-(1-(4-phenylbutyl)piperidin-4-yl)-2-naphthamide DMZ84JH TI TTJQOD7 DMZ84JH TN 5-HT 2A receptor (HTR2A) DMZ84JH MA Inhibitor DMZ84JH RN Synthesis and in vitro binding studies of substituted piperidine naphthamides. Part I: Influence of the substitution on the basic nitrogen and the ... Bioorg Med Chem Lett. 2007 Mar 15;17(6):1565-9. DMZ84JH RU https://pubmed.ncbi.nlm.nih.gov/17254782 DMZ85NC DI DMZ85NC DMZ85NC DN 3-benzyl-5-fluorobenzo[d]oxazol-2(3H)-one DMZ85NC TI TT6804T DMZ85NC TN MIF messenger RNA (MIF mRNA) DMZ85NC MA Inhibitor DMZ85NC RN Optimization of N-benzyl-benzoxazol-2-ones as receptor antagonists of macrophage migration inhibitory factor (MIF). Bioorg Med Chem Lett. 2010 Oct 1;20(19):5811-4. DMZ85NC RU https://pubmed.ncbi.nlm.nih.gov/20728358 DMZ86CS DI DMZ86CS DMZ86CS DN 3-(4-Amino-phenyl)-3-heptyl-piperidine-2,6-dione DMZ86CS TI TTSZLWK DMZ86CS TN Aromatase (CYP19A1) DMZ86CS MA Inhibitor DMZ86CS RN Aromatase inhibitors. Synthesis and evaluation of mammary tumor inhibiting activity of 3-alkylated 3-(4-aminophenyl)piperidine-2,6-diones. J Med Chem. 1986 Aug;29(8):1362-9. DMZ86CS RU https://pubmed.ncbi.nlm.nih.gov/3735304 DMZ8C0U DI DMZ8C0U DMZ8C0U DN H-Dmt-Tic-NH-CH2-Bta DMZ8C0U TI TTKWM86 DMZ8C0U TN Opioid receptor mu (MOP) DMZ8C0U MA Inhibitor DMZ8C0U RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMZ8C0U RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMZ8C0U DI DMZ8C0U DMZ8C0U DN H-Dmt-Tic-NH-CH2-Bta DMZ8C0U TI TT27RFC DMZ8C0U TN Opioid receptor delta (OPRD1) DMZ8C0U MA Inhibitor DMZ8C0U RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMZ8C0U RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMZ8IL9 DI DMZ8IL9 DMZ8IL9 DN 1-Hydroxy-3-Methylbutane DMZ8IL9 TI TTB2MXP DMZ8IL9 TN Angiotensinogenase renin (REN) DMZ8IL9 MA Inhibitor DMZ8IL9 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZ8IL9 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZ8M0K DI DMZ8M0K DMZ8M0K DN JNJ-10397049 DMZ8M0K TI TT9N02I DMZ8M0K TN Orexin receptor type 2 (HCRTR2) DMZ8M0K MA Modulator DMZ8M0K RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 322). DMZ8M0K RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=322 DMZ8PBE DI DMZ8PBE DMZ8PBE DN 6beta-naltrexol HCl DMZ8PBE TI TTQW87Y DMZ8PBE TN Opioid receptor kappa (OPRK1) DMZ8PBE MA Inhibitor DMZ8PBE RN Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4. DMZ8PBE RU https://pubmed.ncbi.nlm.nih.gov/19364645 DMZ8PBE DI DMZ8PBE DMZ8PBE DN 6beta-naltrexol HCl DMZ8PBE TI TT27RFC DMZ8PBE TN Opioid receptor delta (OPRD1) DMZ8PBE MA Inhibitor DMZ8PBE RN Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4. DMZ8PBE RU https://pubmed.ncbi.nlm.nih.gov/19364645 DMZ8PBE DI DMZ8PBE DMZ8PBE DN 6beta-naltrexol HCl DMZ8PBE TI TTKWM86 DMZ8PBE TN Opioid receptor mu (MOP) DMZ8PBE MA Inhibitor DMZ8PBE RN Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4. DMZ8PBE RU https://pubmed.ncbi.nlm.nih.gov/19364645 DMZ8SV3 DI DMZ8SV3 DMZ8SV3 DN AEKKDEGPYRMEHFRWGSPPKD DMZ8SV3 TI TTEOSZT DMZ8SV3 TN Melanocortin receptor (MCR) DMZ8SV3 MA Inhibitor DMZ8SV3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMZ8SV3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMZ8SV3 DI DMZ8SV3 DMZ8SV3 DN AEKKDEGPYRMEHFRWGSPPKD DMZ8SV3 TI TTNI91K DMZ8SV3 TN Melanocortin receptor 3 (MC3R) DMZ8SV3 MA Inhibitor DMZ8SV3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMZ8SV3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMZ8SV3 DI DMZ8SV3 DMZ8SV3 DN AEKKDEGPYRMEHFRWGSPPKD DMZ8SV3 TI TTD0CIQ DMZ8SV3 TN Melanocortin receptor 4 (MC4R) DMZ8SV3 MA Inhibitor DMZ8SV3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMZ8SV3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMZ8SV3 DI DMZ8SV3 DMZ8SV3 DN AEKKDEGPYRMEHFRWGSPPKD DMZ8SV3 TI TT0MV2T DMZ8SV3 TN Melanocortin receptor 1 (MC1R) DMZ8SV3 MA Inhibitor DMZ8SV3 RN Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8. DMZ8SV3 RU https://pubmed.ncbi.nlm.nih.gov/15857110 DMZ8WMA DI DMZ8WMA DMZ8WMA DN 3-bicyclo[2.2.1]hept-2-yl-benzene-1,2-diol DMZ8WMA TI TT5OEKU DMZ8WMA TN Voltage-gated potassium channel Kv2.1 (KCNB1) DMZ8WMA MA Blocker (channel blocker) DMZ8WMA RN Novel neuroprotective K+ channel inhibitor identified by high-throughput screening in yeast. Mol Pharmacol. 2004 Jan;65(1):214-9. DMZ8WMA RU https://pubmed.ncbi.nlm.nih.gov/14722253 DMZ8X3H DI DMZ8X3H DMZ8X3H DN 5-Bromothienyldeoxyuridine DMZ8X3H TI TTP3QRF DMZ8X3H TN Thymidine kinase 1 (TK1) DMZ8X3H MA Inhibitor DMZ8X3H RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZ8X3H RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZ8Y67 DI DMZ8Y67 DMZ8Y67 DN Beta-naphthylboronic acid DMZ8Y67 TI TTHQPL7 DMZ8Y67 TN Carbonic anhydrase I (CA-I) DMZ8Y67 MA Inhibitor DMZ8Y67 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMZ8Y67 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMZ8Y67 DI DMZ8Y67 DMZ8Y67 DN Beta-naphthylboronic acid DMZ8Y67 TI TTUNARX DMZ8Y67 TN Carbonic anhydrase (CA) DMZ8Y67 MA Inhibitor DMZ8Y67 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMZ8Y67 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMZ8Y67 DI DMZ8Y67 DMZ8Y67 DN Beta-naphthylboronic acid DMZ8Y67 TI TTANPDJ DMZ8Y67 TN Carbonic anhydrase II (CA-II) DMZ8Y67 MA Inhibitor DMZ8Y67 RN Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. Bioorg Med Chem Lett. 2009 May 15;19(10):2642-5. DMZ8Y67 RU https://pubmed.ncbi.nlm.nih.gov/19375309 DMZ9024 DI DMZ9024 DMZ9024 DN NORARISTEROMYCIN DMZ9024 TI TTE2KUJ DMZ9024 TN Adenosylhomocysteinase (AHCY) DMZ9024 MA Inhibitor DMZ9024 RN Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocystein... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2615-8. DMZ9024 RU https://pubmed.ncbi.nlm.nih.gov/18374570 DMZ956E DI DMZ956E DMZ956E DN CHPG DMZ956E TI TTHS256 DMZ956E TN Metabotropic glutamate receptor 5 (mGluR5) DMZ956E MA Agonist DMZ956E RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMZ956E RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMZ9A6U DI DMZ9A6U DMZ9A6U DN 2-(4-Methoxy-phenyl)-5-phenyl-thiazol-4-ol DMZ9A6U TI TT2J34L DMZ9A6U TN Arachidonate 5-lipoxygenase (5-LOX) DMZ9A6U MA Inhibitor DMZ9A6U RN 4-hydroxythiazole inhibitors of 5-lipoxygenase. J Med Chem. 1991 Jul;34(7):2158-65. DMZ9A6U RU https://pubmed.ncbi.nlm.nih.gov/2066989 DMZ9GQR DI DMZ9GQR DMZ9GQR DN ASP-3258 DMZ9GQR TI TTSKMI8 DMZ9GQR TN Phosphodiesterase 4D (PDE4D) DMZ9GQR MA Inhibitor DMZ9GQR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1303). DMZ9GQR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1303 DMZ9GQR DI DMZ9GQR DMZ9GQR DN ASP-3258 DMZ9GQR TI TTZ97H5 DMZ9GQR TN Phosphodiesterase 4A (PDE4A) DMZ9GQR MA Inhibitor DMZ9GQR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1300). DMZ9GQR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1300 DMZ9GQR DI DMZ9GQR DMZ9GQR DN ASP-3258 DMZ9GQR TI TTVIAT9 DMZ9GQR TN Phosphodiesterase 4B (PDE4B) DMZ9GQR MA Inhibitor DMZ9GQR RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1301). DMZ9GQR RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1301 DMZ9L6Q DI DMZ9L6Q DMZ9L6Q DN 3-((1H-imidazol-1-yl)methyl)aniline DMZ9L6Q TI TTIQUX7 DMZ9L6Q TN Steroid 11-beta-hydroxylase (CYP11B1) DMZ9L6Q MA Inhibitor DMZ9L6Q RN Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem. 2010 Feb 25;53(4):1712-25. DMZ9L6Q RU https://pubmed.ncbi.nlm.nih.gov/20121113 DMZ9MCR DI DMZ9MCR DMZ9MCR DN MHL cyclohexylthiosemicarbazone DMZ9MCR TI TTHM0R1 DMZ9MCR TN Steryl-sulfatase (STS) DMZ9MCR MA Inhibitor DMZ9MCR RN Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6. DMZ9MCR RU https://pubmed.ncbi.nlm.nih.gov/17580843 DMZ9MQ5 DI DMZ9MQ5 DMZ9MQ5 DN 3-methoxy-N',2-diphenylquinoline-4-carbohydrazide DMZ9MQ5 TI TTBPGLU DMZ9MQ5 TN Neuromedin-K receptor (TACR3) DMZ9MQ5 MA Inhibitor DMZ9MQ5 RN N',2-diphenylquinoline-4-carbohydrazide based NK3 receptor antagonists. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5748-51. DMZ9MQ5 RU https://pubmed.ncbi.nlm.nih.gov/16950620 DMZ9NCA DI DMZ9NCA DMZ9NCA DN 2-pentafluorophenylamido-5-sulfonamidoindane DMZ9NCA TI TTANPDJ DMZ9NCA TN Carbonic anhydrase II (CA-II) DMZ9NCA MA Inhibitor DMZ9NCA RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMZ9NCA RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMZ9NCA DI DMZ9NCA DMZ9NCA DN 2-pentafluorophenylamido-5-sulfonamidoindane DMZ9NCA TI TT2LVK8 DMZ9NCA TN Carbonic anhydrase IX (CA-IX) DMZ9NCA MA Inhibitor DMZ9NCA RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMZ9NCA RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMZ9NCA DI DMZ9NCA DMZ9NCA DN 2-pentafluorophenylamido-5-sulfonamidoindane DMZ9NCA TI TTHQPL7 DMZ9NCA TN Carbonic anhydrase I (CA-I) DMZ9NCA MA Inhibitor DMZ9NCA RN Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX. J Med Chem. 2006 May 4;49(9):2743-9. DMZ9NCA RU https://pubmed.ncbi.nlm.nih.gov/16640335 DMZ9PW3 DI DMZ9PW3 DMZ9PW3 DN 12-EPI-SALVINORIN A DMZ9PW3 TI TTQW87Y DMZ9PW3 TN Opioid receptor kappa (OPRK1) DMZ9PW3 MA Inhibitor DMZ9PW3 RN Modification of the furan ring of salvinorin A: identification of a selective partial agonist at the kappa opioid receptor. Bioorg Med Chem. 2009 Feb 1;17(3):1370-80. DMZ9PW3 RU https://pubmed.ncbi.nlm.nih.gov/19147366 DMZ9TSR DI DMZ9TSR DMZ9TSR DN 4-(2-bromobenzylthio)-2-aminobutanoic acid DMZ9TSR TI TTFK1JQ DMZ9TSR TN Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1) DMZ9TSR MA Inhibitor DMZ9TSR RN Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1138-41. DMZ9TSR RU https://pubmed.ncbi.nlm.nih.gov/16380257 DMZ9UIL DI DMZ9UIL DMZ9UIL DN (S)-4CPG DMZ9UIL TI TTVBPDM DMZ9UIL TN Metabotropic glutamate receptor 1 (mGluR1) DMZ9UIL MA Antagonist DMZ9UIL RN [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol Pharmacol. 2003 May;63(5):1082-93. DMZ9UIL RU https://pubmed.ncbi.nlm.nih.gov/12695537 DMZ9UIL DI DMZ9UIL DMZ9UIL DN (S)-4CPG DMZ9UIL TI TTHS256 DMZ9UIL TN Metabotropic glutamate receptor 5 (mGluR5) DMZ9UIL MA Antagonist DMZ9UIL RN Characterization of [(3)H]Quisqualate binding to recombinant rat metabotropic glutamate 1a and 5a receptors and to rat and human brain sections. J Neurochem. 2000 Dec;75(6):2590-601. DMZ9UIL RU https://pubmed.ncbi.nlm.nih.gov/11080213 DMZ9V18 DI DMZ9V18 DMZ9V18 DN N-[5-(2-Nitro-phenyl)-furan-2-carbonyl]-guanidine DMZ9V18 TI TTGSEFH DMZ9V18 TN Sodium/hydrogen exchanger 1 (SLC9A1) DMZ9V18 MA Inhibitor DMZ9V18 RN (5-Arylfuran-2-ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-1. J Med Chem. 2005 Apr 21;48(8):2882-91. DMZ9V18 RU https://pubmed.ncbi.nlm.nih.gov/15828827 DMZA0VD DI DMZA0VD DMZA0VD DN Perillaldehyde DMZA0VD TI TTXDKTO DMZA0VD TN Long transient receptor potential channel 8 (TRPM8) DMZA0VD MA Inhibitor DMZA0VD RN Taste-guided identification of high potency TRPA1 agonists from Perilla frutescens. Bioorg Med Chem. 2009 Feb 15;17(4):1636-9. DMZA0VD RU https://pubmed.ncbi.nlm.nih.gov/19162486 DMZA394 DI DMZA394 DMZA394 DN CHLOROCYCLINONE A DMZA394 TI TTT2SVW DMZA394 TN PPAR-gamma messenger RNA (PPARG mRNA) DMZA394 MA Inhibitor DMZA394 RN Chlorocyclinones A-D, chlorinated angucyclinones from Streptomyces sp. strongly antagonizing rosiglitazone-induced PPAR-gamma activation. J Nat Prod. 2007 Dec;70(12):1934-8. DMZA394 RU https://pubmed.ncbi.nlm.nih.gov/18044841 DMZA45C DI DMZA45C DMZA45C DN BX-912 DMZA45C TI TT9QBI6 DMZA45C TN Phosphoinositide dependent protein kinase-1 (PDPK1) DMZA45C MA Inhibitor DMZA45C RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMZA45C RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMZA45C DI DMZA45C DMZA45C DN BX-912 DMZA45C TI TTRSMW9 DMZA45C TN Glycogen synthase kinase-3 beta (GSK-3B) DMZA45C MA Inhibitor DMZA45C RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMZA45C RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMZA45C DI DMZA45C DMZA45C DN BX-912 DMZA45C TI TTUTJGQ DMZA45C TN Vascular endothelial growth factor receptor 2 (KDR) DMZA45C MA Inhibitor DMZA45C RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMZA45C RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMZA45C DI DMZA45C DMZA45C DN BX-912 DMZA45C TI TT7HF4W DMZA45C TN Cyclin-dependent kinase 2 (CDK2) DMZA45C MA Inhibitor DMZA45C RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMZA45C RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMZA45C DI DMZA45C DMZA45C DN BX-912 DMZA45C TI TTYVI76 DMZA45C TN Fungal Protein kinase A (Fung ypkA) DMZA45C MA Inhibitor DMZA45C RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMZA45C RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMZA45C DI DMZA45C DMZA45C DN BX-912 DMZA45C TI TTTU902 DMZA45C TN Checkpoint kinase-1 (CHK1) DMZA45C MA Inhibitor DMZA45C RN Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74. DMZA45C RU https://pubmed.ncbi.nlm.nih.gov/15772071 DMZA6X3 DI DMZA6X3 DMZA6X3 DN TQX-173 DMZA6X3 TI TT0MYE2 DMZA6X3 TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMZA6X3 MA Inhibitor DMZA6X3 RN Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heteroaryl-4-oxo-1,2,... J Med Chem. 2001 Sep 13;44(19):3157-65. DMZA6X3 RU https://pubmed.ncbi.nlm.nih.gov/11543685 DMZA8M7 DI DMZA8M7 DMZA8M7 DN 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid DMZA8M7 TI TT0K6EO DMZA8M7 TN Stress-activated protein kinase JNK1 (JNK1) DMZA8M7 MA Inhibitor DMZA8M7 RN Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. DMZA8M7 RU https://pubmed.ncbi.nlm.nih.gov/17107797 DMZA8NC DI DMZA8NC DMZA8NC DN N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide DMZA8NC TI TT6R7JZ DMZA8NC TN Histone deacetylase 1 (HDAC1) DMZA8NC MA Inhibitor DMZA8NC RN Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. DMZA8NC RU https://pubmed.ncbi.nlm.nih.gov/19419863 DMZA8NC DI DMZA8NC DMZA8NC DN N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide DMZA8NC TI TT5ZKDI DMZA8NC TN Histone deacetylase 6 (HDAC6) DMZA8NC MA Inhibitor DMZA8NC RN Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. DMZA8NC RU https://pubmed.ncbi.nlm.nih.gov/19419863 DMZA8NC DI DMZA8NC DMZA8NC DN N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide DMZA8NC TI TTBH0VX DMZA8NC TN Histone deacetylase (HDAC) DMZA8NC MA Inhibitor DMZA8NC RN Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity. Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. DMZA8NC RU https://pubmed.ncbi.nlm.nih.gov/19419863 DMZACXG DI DMZACXG DMZACXG DN 5-Iodo-2'-Deoxyuridine-5'-Monophosphate DMZACXG TI TTP3QRF DMZACXG TN Thymidine kinase 1 (TK1) DMZACXG MA Inhibitor DMZACXG RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZACXG RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZAE97 DI DMZAE97 DMZAE97 DN PF-05094037 DMZAE97 TI TTCJG29 DMZAE97 TN Serine/threonine-protein kinase mTOR (mTOR) DMZAE97 MA Inhibitor DMZAE97 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMZAE97 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMZAM3G DI DMZAM3G DMZAM3G DN D-366 DMZAM3G TI TTEX248 DMZAM3G TN Dopamine D2 receptor (D2R) DMZAM3G MA Inhibitor DMZAM3G RN Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37. DMZAM3G RU https://pubmed.ncbi.nlm.nih.gov/20038106 DMZAM3G DI DMZAM3G DMZAM3G DN D-366 DMZAM3G TI TT4C8EA DMZAM3G TN Dopamine D3 receptor (D3R) DMZAM3G MA Inhibitor DMZAM3G RN Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37. DMZAM3G RU https://pubmed.ncbi.nlm.nih.gov/20038106 DMZAOVG DI DMZAOVG DMZAOVG DN N-(4-(diethylamino)phenyl)-2-nitrobenzamide DMZAOVG TI TTVTX4N DMZAOVG TN Bacterial Fatty acid synthetase I (Bact inhA) DMZAOVG MA Inhibitor DMZAOVG RN Discovery of potential new InhA direct inhibitors based on pharmacophore and 3D-QSAR analysis followed by in silico screening. Eur J Med Chem. 2009 Sep;44(9):3718-30. DMZAOVG RU https://pubmed.ncbi.nlm.nih.gov/19428156 DMZARSD DI DMZARSD DMZARSD DN 3-(pyridin-4-yl)-1H-indol-6-amine DMZARSD TI TTTB4UP DMZARSD TN Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) DMZARSD MA Inhibitor DMZARSD RN Low molecular weight indole fragments as IMPDH inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2535-8. DMZARSD RU https://pubmed.ncbi.nlm.nih.gov/16483769 DMZB0C3 DI DMZB0C3 DMZB0C3 DN (Carboxyhydroxyamino)Ethanoic Acid DMZB0C3 TI TTYQ4AE DMZB0C3 TN Plasmodium Adenylosuccinate synthetase (Malaria Adss) DMZB0C3 MA Inhibitor DMZB0C3 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZB0C3 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZB804 DI DMZB804 DMZB804 DN 3-(4-Trifluoromethylphenyl)-2-nortropene DMZB804 TI TT3ROYC DMZB804 TN Serotonin transporter (SERT) DMZB804 MA Inhibitor DMZB804 RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMZB804 RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMZB804 DI DMZB804 DMZB804 DN 3-(4-Trifluoromethylphenyl)-2-nortropene DMZB804 TI TTVBI8W DMZB804 TN Dopamine transporter (DAT) DMZB804 MA Inhibitor DMZB804 RN Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6865-8. DMZB804 RU https://pubmed.ncbi.nlm.nih.gov/19896846 DMZBDO1 DI DMZBDO1 DMZBDO1 DN CYANIDIN DMZBDO1 TI TTV9A7R DMZBDO1 TN Lactoylglutathione lyase (GLO1) DMZBDO1 MA Inhibitor DMZBDO1 RN Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I. Bioorg Med Chem. 2010 Oct 1;18(19):7029-33. DMZBDO1 RU https://pubmed.ncbi.nlm.nih.gov/20801663 DMZBEYO DI DMZBEYO DMZBEYO DN 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole DMZBEYO TI TTVKILB DMZBEYO TN Prostaglandin G/H synthase 2 (COX-2) DMZBEYO MA Inhibitor DMZBEYO RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMZBEYO RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMZBEYO DI DMZBEYO DMZBEYO DN 4-(4-Chlorophenyl)-5-p-tolyl-1,2-selenazole DMZBEYO TI TT8NGED DMZBEYO TN Prostaglandin G/H synthase 1 (COX-1) DMZBEYO MA Inhibitor DMZBEYO RN Investigations concerning the COX/5-LOX inhibiting and hydroxyl radical scavenging potencies of novel 4,5-diaryl isoselenazoles. Eur J Med Chem. 2008 Jun;43(6):1152-9. DMZBEYO RU https://pubmed.ncbi.nlm.nih.gov/17976864 DMZBFJ5 DI DMZBFJ5 DMZBFJ5 DN H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH DMZBFJ5 TI TT27RFC DMZBFJ5 TN Opioid receptor delta (OPRD1) DMZBFJ5 MA Inhibitor DMZBFJ5 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMZBFJ5 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMZBFJ5 DI DMZBFJ5 DMZBFJ5 DN H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH DMZBFJ5 TI TTKWM86 DMZBFJ5 TN Opioid receptor mu (MOP) DMZBFJ5 MA Inhibitor DMZBFJ5 RN Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33. DMZBFJ5 RU https://pubmed.ncbi.nlm.nih.gov/17228874 DMZBIC3 DI DMZBIC3 DMZBIC3 DN BAS-01373578 DMZBIC3 TI TT6PKBN DMZBIC3 TN Proto-oncogene c-Src (SRC) DMZBIC3 MA Inhibitor DMZBIC3 RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMZBIC3 RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMZBIC3 DI DMZBIC3 DMZBIC3 DN BAS-01373578 DMZBIC3 TI TT3PJMV DMZBIC3 TN Tyrosine-protein kinase ABL1 (ABL) DMZBIC3 MA Inhibitor DMZBIC3 RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMZBIC3 RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMZBLQD DI DMZBLQD DMZBLQD DN Met-Lys-bradykinin DMZBLQD TI TTGY8IW DMZBLQD TN B2 bradykinin receptor (BDKRB2) DMZBLQD MA Agonist DMZBLQD RN Expression cloning of a human B1 bradykinin receptor. J Biol Chem. 1994 Aug 26;269(34):21583-6. DMZBLQD RU https://pubmed.ncbi.nlm.nih.gov/8063797 DMZBNH0 DI DMZBNH0 DMZBNH0 DN Nisoxetine DMZBNH0 TI TTAWNKZ DMZBNH0 TN Norepinephrine transporter (NET) DMZBNH0 MA Inhibitor DMZBNH0 RN Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31. DMZBNH0 RU https://pubmed.ncbi.nlm.nih.gov/18771916 DMZBNH0 DI DMZBNH0 DMZBNH0 DN Nisoxetine DMZBNH0 TI TTVBI8W DMZBNH0 TN Dopamine transporter (DAT) DMZBNH0 MA Inhibitor DMZBNH0 RN Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7. DMZBNH0 RU https://pubmed.ncbi.nlm.nih.gov/18550369 DMZBNH0 DI DMZBNH0 DMZBNH0 DN Nisoxetine DMZBNH0 TI TT3ROYC DMZBNH0 TN Serotonin transporter (SERT) DMZBNH0 MA Inhibitor DMZBNH0 RN 1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors. Bioorg Med Chem Lett. 2009 Jan 1;19(1):58-61. DMZBNH0 RU https://pubmed.ncbi.nlm.nih.gov/19038547 DMZBNK9 DI DMZBNK9 DMZBNK9 DN [125I]ABOPX DMZBNK9 TI TTNE7KG DMZBNK9 TN Adenosine A2b receptor (ADORA2B) DMZBNK9 MA Antagonist DMZBNK9 RN Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol Pharmacol. 1999 Oct;56(4):705-13. DMZBNK9 RU https://pubmed.ncbi.nlm.nih.gov/10496952 DMZBOQW DI DMZBOQW DMZBOQW DN AcNPY(25-36) DMZBOQW TI TTJ6WK9 DMZBOQW TN Neuropeptide Y receptor type 2 (NPY2R) DMZBOQW MA Inhibitor DMZBOQW RN Identification of selective neuropeptide Y2 peptide agonists. Bioorg Med Chem Lett. 2007 Jan 15;17(2):538-41. DMZBOQW RU https://pubmed.ncbi.nlm.nih.gov/17055726 DMZBQ5R DI DMZBQ5R DMZBQ5R DN PMID30247903-Compound-General structure18 DMZBQ5R TI TT23XQV DMZBQ5R TN PD-1-PD-L1 interaction (PD-1/PD-L1 PPI) DMZBQ5R MA Inhibitor DMZBQ5R RN Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730. DMZBQ5R RU https://pubmed.ncbi.nlm.nih.gov/30247903 DMZBUE7 DI DMZBUE7 DMZBUE7 DN CORONARIDINE DMZBUE7 TI TT1RS9F DMZBUE7 TN Acetylcholinesterase (AChE) DMZBUE7 MA Inhibitor DMZBUE7 RN Indole alkaloids from Ervatamia hainanensis with potent acetylcholinesterase inhibition activities. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6185-7. DMZBUE7 RU https://pubmed.ncbi.nlm.nih.gov/20850311 DMZC1SV DI DMZC1SV DMZC1SV DN 8-prenylquercetin DMZC1SV TI TTJ0IQB DMZC1SV TN Phosphodiesterase 5A (PDE5A) DMZC1SV MA Inhibitor DMZC1SV RN Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7. DMZC1SV RU https://pubmed.ncbi.nlm.nih.gov/18778098 DMZC2BT DI DMZC2BT DMZC2BT DN SMEATHXANTHONE A DMZC2BT TI TT50QJ3 DMZC2BT TN Influenza Neuraminidase (Influ NA) DMZC2BT MA Inhibitor DMZC2BT RN Xanthones with neuraminidase inhibitory activity from the seedcases of Garcinia mangostana. Bioorg Med Chem. 2010 Sep 1;18(17):6258-64. DMZC2BT RU https://pubmed.ncbi.nlm.nih.gov/20696581 DMZC90M DI DMZC90M DMZC90M DN PD98059 DMZC90M TI TTIDAPM DMZC90M TN ERK activator kinase 1 (MEK1) DMZC90M MA Inhibitor DMZC90M RN The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9. DMZC90M RU https://pubmed.ncbi.nlm.nih.gov/11254111 DMZC90M DI DMZC90M DMZC90M DN PD98059 DMZC90M TI TTTW2NY DMZC90M TN ERK activator kinase 2 (MEK2) DMZC90M MA Inhibitor DMZC90M RN The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 2001 Feb;11(1):11-9. DMZC90M RU https://pubmed.ncbi.nlm.nih.gov/11254111 DMZCA15 DI DMZCA15 DMZCA15 DN Cynooxide anion DMZCA15 TI TTHQPL7 DMZCA15 TN Carbonic anhydrase I (CA-I) DMZCA15 MA Inhibitor DMZCA15 RN Carbonic anhydrase inhibitors. Inhibition of the beta-class enzyme from the methanoarchaeon Methanobacterium thermoautotrophicum (Cab) with anions. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4563-7. DMZCA15 RU https://pubmed.ncbi.nlm.nih.gov/15357993 DMZCE18 DI DMZCE18 DMZCE18 DN 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol DMZCE18 TI TTZAYWL DMZCE18 TN Estrogen receptor (ESR) DMZCE18 MA Inhibitor DMZCE18 RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMZCE18 RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMZCE18 DI DMZCE18 DMZCE18 DN 2-(3-hydroxyphenyl)-1,2'-spirobi[1H-indene]-5-ol DMZCE18 TI TTOM3J0 DMZCE18 TN Estrogen receptor beta (ESR2) DMZCE18 MA Inhibitor DMZCE18 RN 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs). Bioorg Med Chem Lett. 2003 Feb 10;13(3):479-83. DMZCE18 RU https://pubmed.ncbi.nlm.nih.gov/12565955 DMZCHSD DI DMZCHSD DMZCHSD DN INCB-10820 DMZCHSD TI TTFZYTO DMZCHSD TN C-C chemokine receptor type 2 (CCR2) DMZCHSD MA Antagonist DMZCHSD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 59). DMZCHSD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=59 DMZCKDH DI DMZCKDH DMZCKDH DN SUVN-504 DMZCKDH TI TTJS8PY DMZCKDH TN 5-HT 6 receptor (HTR6) DMZCKDH MA Antagonist DMZCKDH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11). DMZCKDH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=11 DMZCO83 DI DMZCO83 DMZCO83 DN 3-[4-(5-Chloro-2-thienyl)pyridin-2-yl]phenol DMZCO83 TI TTIWB6L DMZCO83 TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMZCO83 MA Inhibitor DMZCO83 RN Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem. 2010 May 15;18(10):3494-505. DMZCO83 RU https://pubmed.ncbi.nlm.nih.gov/20413314 DMZCPAQ DI DMZCPAQ DMZCPAQ DN 1-(10H-phenothiazin-10-yl)-3-phenylbutan-1-one DMZCPAQ TI TTEB0GD DMZCPAQ TN Cholinesterase (BCHE) DMZCPAQ MA Inhibitor DMZCPAQ RN Selective reversible inhibition of human butyrylcholinesterase by aryl amide derivatives of phenothiazine. Bioorg Med Chem. 2007 Oct 1;15(19):6367-78. DMZCPAQ RU https://pubmed.ncbi.nlm.nih.gov/17681768 DMZCS2K DI DMZCS2K DMZCS2K DN (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopentylamine DMZCS2K TI TT9JNIC DMZCS2K TN Histamine H3 receptor (H3R) DMZCS2K MA Inhibitor DMZCS2K RN A novel pyrrolidine analog of histamine as a potent, highly selective histamine H3 receptor agonist. J Med Chem. 1995 May 12;38(10):1593-9. DMZCS2K RU https://pubmed.ncbi.nlm.nih.gov/7752184 DMZCSF1 DI DMZCSF1 DMZCSF1 DN PMX-700 DMZCSF1 TI TT6S2FE DMZCSF1 TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMZCSF1 MA Modulator DMZCSF1 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605). DMZCSF1 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2605 DMZCTGF DI DMZCTGF DMZCTGF DN 3-(2-Benzylamino-ethoxy)-phenol DMZCTGF TI TT4C8EA DMZCTGF TN Dopamine D3 receptor (D3R) DMZCTGF MA Inhibitor DMZCTGF RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMZCTGF RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMZCTGF DI DMZCTGF DMZCTGF DN 3-(2-Benzylamino-ethoxy)-phenol DMZCTGF TI TTEX248 DMZCTGF TN Dopamine D2 receptor (D2R) DMZCTGF MA Inhibitor DMZCTGF RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMZCTGF RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMZCTGF DI DMZCTGF DMZCTGF DN 3-(2-Benzylamino-ethoxy)-phenol DMZCTGF TI TTE0A2F DMZCTGF TN Dopamine D4 receptor (D4R) DMZCTGF MA Inhibitor DMZCTGF RN New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8. DMZCTGF RU https://pubmed.ncbi.nlm.nih.gov/10498215 DMZCTGF DI DMZCTGF DMZCTGF DN 3-(2-Benzylamino-ethoxy)-phenol DMZCTGF TI TTSQIFT DMZCTGF TN 5-HT 1A receptor (HTR1A) DMZCTGF MA Inhibitor DMZCTGF RN New generation dopaminergic agents. 2. Discovery of 3-OH-phenoxyethylamine and 3-OH-N1-phenylpiperazine dopaminergic templates. Bioorg Med Chem Lett. 1998 Feb 3;8(3):295-300. DMZCTGF RU https://pubmed.ncbi.nlm.nih.gov/9871673 DMZCYM1 DI DMZCYM1 DMZCYM1 DN NSC-640353 DMZCYM1 TI TTJLP0R DMZCYM1 TN Quinone reductase 2 (NQO2) DMZCYM1 MA Inhibitor DMZCYM1 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMZCYM1 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMZD0KG DI DMZD0KG DMZD0KG DN (4-methoxyphenyl)(4-phenylazepan-1-yl)methanone DMZD0KG TI TTN7BL9 DMZD0KG TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMZD0KG MA Inhibitor DMZD0KG RN The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors. Bioorg Med Chem Lett. 2009 Aug 15;19(16):4563-5. DMZD0KG RU https://pubmed.ncbi.nlm.nih.gov/19625185 DMZD0NA DI DMZD0NA DMZD0NA DN torin 1 DMZD0NA TI TTCJG29 DMZD0NA TN Serine/threonine-protein kinase mTOR (mTOR) DMZD0NA MA Inhibitor DMZD0NA RN Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem. 2010 Oct 14;53(19):7146-55. DMZD0NA RU https://pubmed.ncbi.nlm.nih.gov/20860370 DMZD348 DI DMZD348 DMZD348 DN 2LM20-4 DMZD348 TI TTUE541 DMZD348 TN Leukocyte surface antigen Leu-16 (CD20) DMZD348 MA Modulator DMZD348 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DMZD348 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DMZDACT DI DMZDACT DMZDACT DN N-(4-Sulfamoyl-phenyl)-benzamide DMZDACT TI TTANPDJ DMZDACT TN Carbonic anhydrase II (CA-II) DMZDACT MA Inhibitor DMZDACT RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMZDACT RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMZDACT DI DMZDACT DMZDACT DN N-(4-Sulfamoyl-phenyl)-benzamide DMZDACT TI TTSYM0R DMZDACT TN Carbonic anhydrase XII (CA-XII) DMZDACT MA Inhibitor DMZDACT RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMZDACT RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMZDACT DI DMZDACT DMZDACT DN N-(4-Sulfamoyl-phenyl)-benzamide DMZDACT TI TT2LVK8 DMZDACT TN Carbonic anhydrase IX (CA-IX) DMZDACT MA Inhibitor DMZDACT RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMZDACT RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMZDACT DI DMZDACT DMZDACT DN N-(4-Sulfamoyl-phenyl)-benzamide DMZDACT TI TTHQPL7 DMZDACT TN Carbonic anhydrase I (CA-I) DMZDACT MA Inhibitor DMZDACT RN Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4862-6. DMZDACT RU https://pubmed.ncbi.nlm.nih.gov/16168653 DMZDC14 DI DMZDC14 DMZDC14 DN PMID18800762C47 DMZDC14 TI TTIKWV4 DMZDC14 TN Geranyltranstransferase (FDPS) DMZDC14 MA Inhibitor DMZDC14 RN Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J Med Chem. 2008 Sep 25;51(18):5594-607. DMZDC14 RU https://pubmed.ncbi.nlm.nih.gov/18800762 DMZDFRI DI DMZDFRI DMZDFRI DN Acanthus ilicifolius Linn DMZDFRI TI TT2J34L DMZDFRI TN Arachidonate 5-lipoxygenase (5-LOX) DMZDFRI MA Inhibitor DMZDFRI RN Anti-inflammatory activity of Acanthus ilicifolius. J Ethnopharmacol. 2008 Oct 30;120(1):7-12. DMZDFRI RU https://pubmed.ncbi.nlm.nih.gov/18703126 DMZDFRI DI DMZDFRI DMZDFRI DN Acanthus ilicifolius Linn DMZDFRI TI TTCGSZ4 DMZDFRI TN Pancreatic alpha-amylase (AMY2A) DMZDFRI MA Inhibitor DMZDFRI RN Four acarviosin-containing oligosaccharides identified from Streptomyces coelicoflavus ZG0656 are potent inhibitors of alpha-amylase. Carbohydr Res. 2008 Apr 7;343(5):882-92. DMZDFRI RU https://pubmed.ncbi.nlm.nih.gov/18294624 DMZDGB3 DI DMZDGB3 DMZDGB3 DN 2-(4-fluorophenyl)-7-methoxy-4H-chromen-4-one DMZDGB3 TI TTGP7BY DMZDGB3 TN Monoamine oxidase type B (MAO-B) DMZDGB3 MA Inhibitor DMZDGB3 RN A new series of flavones, thioflavones, and flavanones as selective monoamine oxidase-B inhibitors. Bioorg Med Chem. 2010 Feb;18(3):1273-9. DMZDGB3 RU https://pubmed.ncbi.nlm.nih.gov/20045650 DMZDGJO DI DMZDGJO DMZDGJO DN Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2 DMZDGJO TI TTDZN01 DMZDGJO TN Cathepsin K (CTSK) DMZDGJO MA Inhibitor DMZDGJO RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMZDGJO RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMZDGJO DI DMZDGJO DMZDGJO DN Z-Arg-Leu-Val-Agly-Ile-Val-Trp-NH2 DMZDGJO TI TTF2LRI DMZDGJO TN Cathepsin B (CTSB) DMZDGJO MA Inhibitor DMZDGJO RN Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. DMZDGJO RU https://pubmed.ncbi.nlm.nih.gov/12213061 DMZDIVL DI DMZDIVL DMZDIVL DN VU0424465 DMZDIVL TI TTHS256 DMZDIVL TN Metabotropic glutamate receptor 5 (mGluR5) DMZDIVL MA Modulator (allosteric modulator) DMZDIVL RN Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol Psychiatry. 2013 Mar 15;73(6):501-9. DMZDIVL RU https://pubmed.ncbi.nlm.nih.gov/23140665 DMZDJF3 DI DMZDJF3 DMZDJF3 DN ISIS 134607 DMZDJF3 TI TTKW4ML DMZDJF3 TN Caspase 6 messenger RNA (CASP6 mRNA) DMZDJF3 RN US patent application no. 6,566,135, Antisense modulation of caspase 6 expression. DMZDJF3 RU http://www.patentbuddy.com/Patent/6566135?ft=true&sr=true DMZDNHQ DI DMZDNHQ DMZDNHQ DN 2-(6-morpholino-9H-purin-2-yl)phenol DMZDNHQ TI TTCJG29 DMZDNHQ TN Serine/threonine-protein kinase mTOR (mTOR) DMZDNHQ MA Inhibitor DMZDNHQ RN Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-alpha: Hit to lead studies. Bioorg Med Chem Lett. 2010 Jan 15;20(2):636-9. DMZDNHQ RU https://pubmed.ncbi.nlm.nih.gov/19969455 DMZDP5S DI DMZDP5S DMZDP5S DN 7-benzoyloxy-2-(morpholin-4-yl)-chromen-4-one DMZDP5S TI TTK3PY9 DMZDP5S TN DNA-dependent protein kinase catalytic (PRKDC) DMZDP5S MA Inhibitor DMZDP5S RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMZDP5S RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMZDUSA DI DMZDUSA DMZDUSA DN 1,1-diphenyl-2-(3-tropanyl)ethanol DMZDUSA TI TTZ9SOR DMZDUSA TN Muscarinic acetylcholine receptor M1 (CHRM1) DMZDUSA MA Inhibitor DMZDUSA RN Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2. DMZDUSA RU https://pubmed.ncbi.nlm.nih.gov/19616944 DMZDUSA DI DMZDUSA DMZDUSA DN 1,1-diphenyl-2-(3-tropanyl)ethanol DMZDUSA TI TTYEG6Q DMZDUSA TN Muscarinic acetylcholine receptor M2 (CHRM2) DMZDUSA MA Inhibitor DMZDUSA RN Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2. DMZDUSA RU https://pubmed.ncbi.nlm.nih.gov/19616944 DMZDUSA DI DMZDUSA DMZDUSA DN 1,1-diphenyl-2-(3-tropanyl)ethanol DMZDUSA TI TTQ13Z5 DMZDUSA TN Muscarinic acetylcholine receptor M3 (CHRM3) DMZDUSA MA Inhibitor DMZDUSA RN Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylch... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4560-2. DMZDUSA RU https://pubmed.ncbi.nlm.nih.gov/19616944 DMZDUXG DI DMZDUXG DMZDUXG DN cinnamaldehyde DMZDUXG TI TT946IA DMZDUXG TN Transient receptor potential cation channel V3 (TRPV3) DMZDUXG MA Activator DMZDUXG RN More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci. 2006 Aug;32(4):335-43. DMZDUXG RU https://pubmed.ncbi.nlm.nih.gov/16829128 DMZDUXG DI DMZDUXG DMZDUXG DN cinnamaldehyde DMZDUXG TI TTELV3W DMZDUXG TN Transformation-sensitive protein p120 (TRPA1) DMZDUXG MA Activator DMZDUXG RN Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron. 2004 Mar 25;41(6):849-57. DMZDUXG RU https://pubmed.ncbi.nlm.nih.gov/15046718 DMZDYCW DI DMZDYCW DMZDYCW DN 2-N-Hydroxyamino-1-(4-methylthiophenyl)propane DMZDYCW TI TT3ROYC DMZDYCW TN Serotonin transporter (SERT) DMZDYCW MA Inhibitor DMZDYCW RN Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88. DMZDYCW RU https://pubmed.ncbi.nlm.nih.gov/19717215 DMZE45V DI DMZE45V DMZE45V DN Ajinomoto 2 DMZE45V TI TTXHYV6 DMZE45V TN Voltage-gated L-type calcium channel (L-CaC) DMZE45V MA Blocker DMZE45V RN Recent updates of N-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem. 2009;9(4):377-95. DMZE45V RU https://pubmed.ncbi.nlm.nih.gov/19442208 DMZE5GX DI DMZE5GX DMZE5GX DN 1-Allyl-3,7-dimethyl-3,7-dihydro-purine-2,6-dione DMZE5GX TI TTM2AOE DMZE5GX TN Adenosine A2a receptor (ADORA2A) DMZE5GX MA Inhibitor DMZE5GX RN Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors. J Med Chem. 1986 Jul;29(7):1305-8. DMZE5GX RU https://pubmed.ncbi.nlm.nih.gov/3806581 DMZE9TW DI DMZE9TW DMZE9TW DN T0156 DMZE9TW TI TTJ0IQB DMZE9TW TN Phosphodiesterase 5A (PDE5A) DMZE9TW MA Inhibitor DMZE9TW RN Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol. 2002 Dec 5;456(1-3):91-8. DMZE9TW RU https://pubmed.ncbi.nlm.nih.gov/12450574 DMZENGX DI DMZENGX DMZENGX DN PMID24793884C77 DMZENGX TI TTUMFAR DMZENGX TN Cyclin-dependent kinase 18 (CDK18) DMZENGX MA Inhibitor DMZENGX RN Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82. DMZENGX RU https://pubmed.ncbi.nlm.nih.gov/24793884 DMZENGX DI DMZENGX DMZENGX DN PMID24793884C77 DMZENGX TI TTSMTDI DMZENGX TN CDC7-related kinase (CDC7) DMZENGX MA Inhibitor DMZENGX RN Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82. DMZENGX RU https://pubmed.ncbi.nlm.nih.gov/24793884 DMZEXY9 DI DMZEXY9 DMZEXY9 DN INO-1002 DMZEXY9 TI TTVDSZ0 DMZEXY9 TN Poly [ADP-ribose] polymerase 1 (PARP1) DMZEXY9 MA Inhibitor DMZEXY9 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2771). DMZEXY9 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2771 DMZEY31 DI DMZEY31 DMZEY31 DN 4,5,6,7-tetrafluoro-3-perfluorophenyl-1H-indazole DMZEY31 TI TTF10I9 DMZEY31 TN Nitric-oxide synthase inducible (NOS2) DMZEY31 MA Inhibitor DMZEY31 RN Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. Bioorg Med Chem. 2009 Sep 1;17(17):6180-7. DMZEY31 RU https://pubmed.ncbi.nlm.nih.gov/19679481 DMZF0D3 DI DMZF0D3 DMZF0D3 DN 1-(2-morpholinoethyl)-1H-indol-3-yl acetate DMZF0D3 TI TT6OEDT DMZF0D3 TN Cannabinoid receptor 1 (CB1) DMZF0D3 MA Inhibitor DMZF0D3 RN Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. Eur J Med Chem. 2008 Mar;43(3):513-39. DMZF0D3 RU https://pubmed.ncbi.nlm.nih.gov/17582659 DMZF35W DI DMZF35W DMZF35W DN Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) DMZF35W TI TTTQGH8 DMZF35W TN Histone deacetylase 4 (HDAC4) DMZF35W MA Inhibitor DMZF35W RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMZF35W RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMZF35W DI DMZF35W DMZF35W DN Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) DMZF35W TI TT6R7JZ DMZF35W TN Histone deacetylase 1 (HDAC1) DMZF35W MA Inhibitor DMZF35W RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMZF35W RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMZF35W DI DMZF35W DMZF35W DN Cyclo(-L-Am7(S2Py)-A2in-L-Ala-D-Pro-) DMZF35W TI TT5ZKDI DMZF35W TN Histone deacetylase 6 (HDAC6) DMZF35W MA Inhibitor DMZF35W RN Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework. Bioorg Med Chem. 2007 Dec 15;15(24):7830-9. DMZF35W RU https://pubmed.ncbi.nlm.nih.gov/17881232 DMZF3E9 DI DMZF3E9 DMZF3E9 DN KNT-5 DMZF3E9 TI TTKWM86 DMZF3E9 TN Opioid receptor mu (MOP) DMZF3E9 MA Inhibitor DMZF3E9 RN Investigation of Beckett-Casy model 1: synthesis of novel 16,17-seco-naltrexone derivatives and their pharmacology. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1055-8. DMZF3E9 RU https://pubmed.ncbi.nlm.nih.gov/20056539 DMZF3UN DI DMZF3UN DMZF3UN DN 8-bromo-9-isobutyl-9H-purin-6-amine DMZF3UN TI TTJFY5U DMZF3UN TN Adenosine A3 receptor (ADORA3) DMZF3UN MA Inhibitor DMZF3UN RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMZF3UN RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMZF3UN DI DMZF3UN DMZF3UN DN 8-bromo-9-isobutyl-9H-purin-6-amine DMZF3UN TI TTNE7KG DMZF3UN TN Adenosine A2b receptor (ADORA2B) DMZF3UN MA Inhibitor DMZF3UN RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMZF3UN RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMZF3UN DI DMZF3UN DMZF3UN DN 8-bromo-9-isobutyl-9H-purin-6-amine DMZF3UN TI TTM2AOE DMZF3UN TN Adenosine A2a receptor (ADORA2A) DMZF3UN MA Inhibitor DMZF3UN RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMZF3UN RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMZF3UN DI DMZF3UN DMZF3UN DN 8-bromo-9-isobutyl-9H-purin-6-amine DMZF3UN TI TTK25J1 DMZF3UN TN Adenosine A1 receptor (ADORA1) DMZF3UN MA Inhibitor DMZF3UN RN Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods. Eur J Med Chem. 2010 Aug;45(8):3459-71. DMZF3UN RU https://pubmed.ncbi.nlm.nih.gov/20537438 DMZF4IC DI DMZF4IC DMZF4IC DN 1,2-Bis-(2-chloro-phenyl)-ethane-1,2-dione DMZF4IC TI TTMF541 DMZF4IC TN Liver carboxylesterase (CES1) DMZF4IC MA Inhibitor DMZF4IC RN Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem. 2005 Apr 21;48(8):2906-15. DMZF4IC RU https://pubmed.ncbi.nlm.nih.gov/15828829 DMZFHL0 DI DMZFHL0 DMZFHL0 DN NSC-180969 DMZFHL0 TI TTJLP0R DMZFHL0 TN Quinone reductase 2 (NQO2) DMZFHL0 MA Inhibitor DMZFHL0 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMZFHL0 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMZFK4R DI DMZFK4R DMZFK4R DN 2-methyl-7-m-tolyl-1,8-naphthyridine DMZFK4R TI TTHS256 DMZFK4R TN Metabotropic glutamate receptor 5 (mGluR5) DMZFK4R MA Inhibitor DMZFK4R RN Synthesis and SAR comparison of regioisomeric aryl naphthyridines as potent mGlu5 receptor antagonists. Bioorg Med Chem Lett. 2007 Dec 1;17(23):6525-8. DMZFK4R RU https://pubmed.ncbi.nlm.nih.gov/17936624 DMZFKDW DI DMZFKDW DMZFKDW DN 2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide DMZFKDW TI TT3WG5C DMZFKDW TN Monoamine oxidase type A (MAO-A) DMZFKDW MA Inhibitor DMZFKDW RN Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706. DMZFKDW RU https://pubmed.ncbi.nlm.nih.gov/19810674 DMZFKDW DI DMZFKDW DMZFKDW DN 2-[7-(Benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide DMZFKDW TI TTGP7BY DMZFKDW TN Monoamine oxidase type B (MAO-B) DMZFKDW MA Inhibitor DMZFKDW RN Discovery of a novel class of potent coumarin monoamine oxidase B inhibitors: development and biopharmacological profiling of 7-[(3-chlorobenzyl)ox... J Med Chem. 2009 Nov 12;52(21):6685-706. DMZFKDW RU https://pubmed.ncbi.nlm.nih.gov/19810674 DMZFTI4 DI DMZFTI4 DMZFTI4 DN (4R)-4-ammoniopentanoate DMZFTI4 TI TTZA1NY DMZFTI4 TN GABA(A) receptor beta-2 (GABRB2) DMZFTI4 MA Inhibitor DMZFTI4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMZFTI4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMZFTI4 DI DMZFTI4 DMZFTI4 DN (4R)-4-ammoniopentanoate DMZFTI4 TI TT1MPAY DMZFTI4 TN GABA(A) receptor alpha-1 (GABRA1) DMZFTI4 MA Inhibitor DMZFTI4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMZFTI4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMZFTI4 DI DMZFTI4 DMZFTI4 DN (4R)-4-ammoniopentanoate DMZFTI4 TI TTNZPQ1 DMZFTI4 TN GABA(A) receptor alpha-5 (GABRA5) DMZFTI4 MA Inhibitor DMZFTI4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMZFTI4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMZFTI4 DI DMZFTI4 DMZFTI4 DN (4R)-4-ammoniopentanoate DMZFTI4 TI TT37EDJ DMZFTI4 TN GABA(A) receptor alpha-3 (GABRA3) DMZFTI4 MA Inhibitor DMZFTI4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMZFTI4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMZFTI4 DI DMZFTI4 DMZFTI4 DN (4R)-4-ammoniopentanoate DMZFTI4 TI TTNJYV2 DMZFTI4 TN Gamma-aminobutyric acid receptor (GAR) DMZFTI4 MA Inhibitor DMZFTI4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMZFTI4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMZFTI4 DI DMZFTI4 DMZFTI4 DN (4R)-4-ammoniopentanoate DMZFTI4 TI TT06RH5 DMZFTI4 TN GABA(A) receptor gamma-2 (GABRG2) DMZFTI4 MA Inhibitor DMZFTI4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMZFTI4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMZFTI4 DI DMZFTI4 DMZFTI4 DN (4R)-4-ammoniopentanoate DMZFTI4 TI TTBMV1G DMZFTI4 TN GABA(A) receptor alpha-2 (GABRA2) DMZFTI4 MA Inhibitor DMZFTI4 RN gamma-Aminobutyric acid agonists, antagonists, and uptake inhibitors. Design and therapeutic aspects. J Med Chem. 1981 Dec;24(12):1377-83. DMZFTI4 RU https://pubmed.ncbi.nlm.nih.gov/6118436 DMZFULS DI DMZFULS DMZFULS DN NSC-37173 DMZFULS TI TT9NVXQ DMZFULS TN Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC) DMZFULS MA Inhibitor DMZFULS RN Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identif... J Med Chem. 2004 Dec 30;47(27):6681-90. DMZFULS RU https://pubmed.ncbi.nlm.nih.gov/15615517 DMZFVGC DI DMZFVGC DMZFVGC DN PGH2 DMZFVGC TI TT2O84V DMZFVGC TN Thromboxane A2 receptor (TBXA2R) DMZFVGC MA Agonist DMZFVGC RN Effects of KW-3635, a novel dibenzoxepin derivative of a selective thromboxane A2 antagonist, on human, guinea pig and rat platelets. Jpn J Pharmacol. 1992 Jul;59(3):357-64. DMZFVGC RU https://pubmed.ncbi.nlm.nih.gov/1434130 DMZFVHT DI DMZFVHT DMZFVHT DN KNI-10256 DMZFVHT TI TTXMNHO DMZFVHT TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMZFVHT MA Inhibitor DMZFVHT RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMZFVHT RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMZG1L5 DI DMZG1L5 DMZG1L5 DN PLX-ORI3 DMZG1L5 TI TT0EOB8 DMZG1L5 TN B-Raf messenger RNA (BRAF mRNA) DMZG1L5 MA Inhibitor DMZG1L5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943). DMZG1L5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1943 DMZG1L5 DI DMZG1L5 DMZG1L5 DN PLX-ORI3 DMZG1L5 TI TTAN5W2 DMZG1L5 TN Raf messenger RNA (Raf mRNA) DMZG1L5 MA Inhibitor DMZG1L5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184). DMZG1L5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2184 DMZG46O DI DMZG46O DMZG46O DN Ac-I[CV(Bpa)QDWGAHRC]T-NH2 DMZG46O TI TTJGY7A DMZG46O TN Complement C3 (CO3) DMZG46O MA Inhibitor DMZG46O RN Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86. DMZG46O RU https://pubmed.ncbi.nlm.nih.gov/15634022 DMZG5I7 DI DMZG5I7 DMZG5I7 DN TERT-BUTYL 2-CYANO-2-METHYLHYDRAZINECARBOXYLATE DMZG5I7 TI TTDZN01 DMZG5I7 TN Cathepsin K (CTSK) DMZG5I7 MA Inhibitor DMZG5I7 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZG5I7 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZG7TH DI DMZG7TH DMZG7TH DN [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone DMZG7TH TI TT36ETB DMZG7TH TN Cathepsin L (CTSL) DMZG7TH MA Inhibitor DMZG7TH RN Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9. DMZG7TH RU https://pubmed.ncbi.nlm.nih.gov/20089402 DMZG7TH DI DMZG7TH DMZG7TH DN [(3-Bromophenyl)-p-tolyl-ketone]thiosemicarbazone DMZG7TH TI TTF2LRI DMZG7TH TN Cathepsin B (CTSB) DMZG7TH MA Inhibitor DMZG7TH RN Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1415-9. DMZG7TH RU https://pubmed.ncbi.nlm.nih.gov/20089402 DMZGCEQ DI DMZGCEQ DMZGCEQ DN 1,2,3,4-tetrahydroisoquinoline DMZGCEQ TI TTWM4TY DMZGCEQ TN Adrenergic receptor alpha-2B (ADRA2B) DMZGCEQ MA Inhibitor DMZGCEQ RN Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33. DMZGCEQ RU https://pubmed.ncbi.nlm.nih.gov/16942016 DMZGCEQ DI DMZGCEQ DMZGCEQ DN 1,2,3,4-tetrahydroisoquinoline DMZGCEQ TI TTWG9A4 DMZGCEQ TN Adrenergic receptor alpha-2A (ADRA2A) DMZGCEQ MA Inhibitor DMZGCEQ RN Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33. DMZGCEQ RU https://pubmed.ncbi.nlm.nih.gov/16942016 DMZGCEQ DI DMZGCEQ DMZGCEQ DN 1,2,3,4-tetrahydroisoquinoline DMZGCEQ TI TT2NUT5 DMZGCEQ TN Adrenergic receptor alpha-2C (ADRA2C) DMZGCEQ MA Inhibitor DMZGCEQ RN Comparison of the binding of 3-fluoromethyl-7-sulfonyl-1,2,3,4-tetrahydroisoquinolines with their isosteric sulfonamides to the active site of phen... J Med Chem. 2006 Sep 7;49(18):5424-33. DMZGCEQ RU https://pubmed.ncbi.nlm.nih.gov/16942016 DMZGFE8 DI DMZGFE8 DMZGFE8 DN PTR-3046 DMZGFE8 TI TT2BC4G DMZGFE8 TN Somatostatin receptor type 5 (SSTR5) DMZGFE8 MA Inhibitor DMZGFE8 RN Highly potent 4-amino-indolo[2,3-c]azepin-3-one-containing somatostatin mimetics with a range of sst receptor selectivities. J Med Chem. 2009 Jan 8;52(1):95-104. DMZGFE8 RU https://pubmed.ncbi.nlm.nih.gov/19067538 DMZGKHO DI DMZGKHO DMZGKHO DN ISIS 12659 DMZGKHO TI TT4SCBE DMZGKHO TN Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA) DMZGKHO RN US patent application no. 5,767,102, Antisense composition and method for treatment of CMV infection. DMZGKHO RU http://www.patentbuddy.com/Patent/5767102?ft=true&sr=true DMZGLHJ DI DMZGLHJ DMZGLHJ DN BAS-0338868 DMZGLHJ TI TT6PKBN DMZGLHJ TN Proto-oncogene c-Src (SRC) DMZGLHJ MA Inhibitor DMZGLHJ RN Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11. DMZGLHJ RU https://pubmed.ncbi.nlm.nih.gov/18078752 DMZGMQJ DI DMZGMQJ DMZGMQJ DN N-isopropyl estrone-16-methyl carboxamide DMZGMQJ TI TTIWB6L DMZGMQJ TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMZGMQJ MA Inhibitor DMZGMQJ RN Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem. 2006 Feb 23;49(4):1325-45. DMZGMQJ RU https://pubmed.ncbi.nlm.nih.gov/16480268 DMZGWL2 DI DMZGWL2 DMZGWL2 DN 3-Bromo-1H-indazole-7-carbonitrile DMZGWL2 TI TTCM4B3 DMZGWL2 TN Nitric-oxide synthase endothelial (NOS3) DMZGWL2 MA Inhibitor DMZGWL2 RN Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73. DMZGWL2 RU https://pubmed.ncbi.nlm.nih.gov/18502134 DMZGWL2 DI DMZGWL2 DMZGWL2 DN 3-Bromo-1H-indazole-7-carbonitrile DMZGWL2 TI TTF10I9 DMZGWL2 TN Nitric-oxide synthase inducible (NOS2) DMZGWL2 MA Inhibitor DMZGWL2 RN Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73. DMZGWL2 RU https://pubmed.ncbi.nlm.nih.gov/18502134 DMZGWL2 DI DMZGWL2 DMZGWL2 DN 3-Bromo-1H-indazole-7-carbonitrile DMZGWL2 TI TTZUFI5 DMZGWL2 TN Nitric-oxide synthase brain (NOS1) DMZGWL2 MA Inhibitor DMZGWL2 RN Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem. 2008 Jun 1;16(11):5962-73. DMZGWL2 RU https://pubmed.ncbi.nlm.nih.gov/18502134 DMZGWQA DI DMZGWQA DMZGWQA DN DS-AH-14 DMZGWQA TI TTOXS3C DMZGWQA TN Muscarinic acetylcholine receptor (CHRM) DMZGWQA MA Modulator DMZGWQA RN US patent application no. 5,446,057, Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists. DMZGWQA RU http://www.google.com/patents/US5446057 DMZGX48 DI DMZGX48 DMZGX48 DN SX-517 DMZGX48 TI TT30C9G DMZGX48 TN C-X-C chemokine receptor type 2 (CXCR2) DMZGX48 MA Antagonist DMZGX48 RN Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2. J Med Chem. 2014 Oct 23;57(20):8378-97. DMZGX48 RU https://pubmed.ncbi.nlm.nih.gov/25254640 DMZH0K8 DI DMZH0K8 DMZH0K8 DN JNJ-10392980 DMZH0K8 TI TTQ6VDM DMZH0K8 TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMZH0K8 MA Inhibitor DMZH0K8 RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMZH0K8 RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMZH0K8 DI DMZH0K8 DMZH0K8 DN JNJ-10392980 DMZH0K8 TI TTXZEAJ DMZH0K8 TN Leukotriene A-4 hydrolase (LTA4H) DMZH0K8 MA Inhibitor DMZH0K8 RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMZH0K8 RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMZH0K8 DI DMZH0K8 DMZH0K8 DN JNJ-10392980 DMZH0K8 TI TTSQIFT DMZH0K8 TN 5-HT 1A receptor (HTR1A) DMZH0K8 MA Inhibitor DMZH0K8 RN Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity. J Med Chem. 2008 Jul 24;51(14):4150-69. DMZH0K8 RU https://pubmed.ncbi.nlm.nih.gov/18588282 DMZH0KY DI DMZH0KY DMZH0KY DN Pro-His-Pro-His-Leu-Phe-Val-Tyr DMZH0KY TI TTB2MXP DMZH0KY TN Angiotensinogenase renin (REN) DMZH0KY MA Inhibitor DMZH0KY RN Inhibition of the renin-angiotensin system. A new approach to the therapy of hypertension. J Med Chem. 1981 Apr;24(4):355-61. DMZH0KY RU https://pubmed.ncbi.nlm.nih.gov/6267277 DMZH4NQ DI DMZH4NQ DMZH4NQ DN Ala11-SRIF-14-amide DMZH4NQ TI TTZ6T9E DMZH4NQ TN Somatostatin receptor type 2 (SSTR2) DMZH4NQ MA Inhibitor DMZH4NQ RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DMZH4NQ RU https://pubmed.ncbi.nlm.nih.gov/15943475 DMZH4NQ DI DMZH4NQ DMZH4NQ DN Ala11-SRIF-14-amide DMZH4NQ TI TTAE1BR DMZH4NQ TN Somatostatin receptor type 4 (SSTR4) DMZH4NQ MA Inhibitor DMZH4NQ RN Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSS... J Med Chem. 2005 Jun 16;48(12):4025-30. DMZH4NQ RU https://pubmed.ncbi.nlm.nih.gov/15943475 DMZH9P5 DI DMZH9P5 DMZH9P5 DN H-Dmt-Tic-Lys(Ac)-NH-Ph DMZH9P5 TI TT27RFC DMZH9P5 TN Opioid receptor delta (OPRD1) DMZH9P5 MA Inhibitor DMZH9P5 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMZH9P5 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMZH9P5 DI DMZH9P5 DMZH9P5 DN H-Dmt-Tic-Lys(Ac)-NH-Ph DMZH9P5 TI TTKWM86 DMZH9P5 TN Opioid receptor mu (MOP) DMZH9P5 MA Inhibitor DMZH9P5 RN Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7. DMZH9P5 RU https://pubmed.ncbi.nlm.nih.gov/16942034 DMZH9PW DI DMZH9PW DMZH9PW DN Isohelenin DMZH9PW TI TTSXVID DMZH9PW TN Nuclear factor NF-kappa-B (NFKB) DMZH9PW MA Inhibitor DMZH9PW RN Protective effects of isohelenin, an inhibitor of nuclear factor kappaB, in endotoxic shock in rats. J Endotoxin Res. 2002;8(2):99-107. DMZH9PW RU https://pubmed.ncbi.nlm.nih.gov/12028749 DMZHBTA DI DMZHBTA DMZHBTA DN N,N'-(1',4'-butylene)-bis-(-)-nor-MEP DMZHBTA TI TTEB0GD DMZHBTA TN Cholinesterase (BCHE) DMZHBTA MA Inhibitor DMZHBTA RN Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation. J Med Chem. 2008 Apr 10;51(7):2027-36. DMZHBTA RU https://pubmed.ncbi.nlm.nih.gov/18333606 DMZHDFM DI DMZHDFM DMZHDFM DN 6,7-dichloro-1H-indole-2,3-dione DMZHDFM TI TTMF541 DMZHDFM TN Liver carboxylesterase (CES1) DMZHDFM MA Inhibitor DMZHDFM RN Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. J Med Chem. 2007 Apr 19;50(8):1876-85. DMZHDFM RU https://pubmed.ncbi.nlm.nih.gov/17378546 DMZHDWN DI DMZHDWN DMZHDWN DN A-357300 DMZHDWN TI TTZL0OI DMZHDWN TN Methionine aminopeptidase 2 (METAP2) DMZHDWN MA Inhibitor DMZHDWN RN Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9. DMZHDWN RU https://pubmed.ncbi.nlm.nih.gov/14633714 DMZHFWX DI DMZHFWX DMZHFWX DN 6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX) DMZHFWX TI TTVG215 DMZHFWX TN Debrisoquine 4-hydroxylase (CYP2D6) DMZHFWX MA Inhibitor DMZHFWX RN 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001. DMZHFWX RU https://pubmed.ncbi.nlm.nih.gov/20527970 DMZHFWX DI DMZHFWX DMZHFWX DN 6-(3,4-DICHLOROPHENYL)-1-[1-(METHYLOXY)-3-BUTEN-1-YL]-3-AZABICYCLO[4.1.0]HEPTANE (DIASTEREOMERIC MIX) DMZHFWX TI TTXV4FI DMZHFWX TN Albendazole monooxygenase (CYP3A4) DMZHFWX MA Inhibitor DMZHFWX RN 6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J Med Chem. 2010 Jul 8;53(13):4989-5001. DMZHFWX RU https://pubmed.ncbi.nlm.nih.gov/20527970 DMZHGP6 DI DMZHGP6 DMZHGP6 DN 4-butyl-N-(7-hydroxynaphthalen-1-yl)benzamide DMZHGP6 TI TTMI6F5 DMZHGP6 TN Transient receptor potential cation channel V1 (TRPV1) DMZHGP6 MA Inhibitor DMZHGP6 RN N-pyridin-3-yl- and N-quinolin-3-yl-benzamides: modulators of human vanilloid receptor 1 (TRPV1). Bioorg Med Chem Lett. 2008 Apr 15;18(8):2730-4. DMZHGP6 RU https://pubmed.ncbi.nlm.nih.gov/18359227 DMZHO3S DI DMZHO3S DMZHO3S DN CHO793076 DMZHO3S TI TTGTQHC DMZHO3S TN DNA topoisomerase I (TOP1) DMZHO3S MA Inhibitor DMZHO3S RN Synthesis of new camptothecin analogs with improved antitumor activities. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21. DMZHO3S RU https://pubmed.ncbi.nlm.nih.gov/19254843 DMZHV39 DI DMZHV39 DMZHV39 DN Azepan-(2Z)-ylideneamine DMZHV39 TI TTCM4B3 DMZHV39 TN Nitric-oxide synthase endothelial (NOS3) DMZHV39 MA Inhibitor DMZHV39 RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMZHV39 RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMZHV39 DI DMZHV39 DMZHV39 DN Azepan-(2Z)-ylideneamine DMZHV39 TI TTZUFI5 DMZHV39 TN Nitric-oxide synthase brain (NOS1) DMZHV39 MA Inhibitor DMZHV39 RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMZHV39 RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMZHV39 DI DMZHV39 DMZHV39 DN Azepan-(2Z)-ylideneamine DMZHV39 TI TTF10I9 DMZHV39 TN Nitric-oxide synthase inducible (NOS2) DMZHV39 MA Inhibitor DMZHV39 RN Selective heterocyclic amidine inhibitors of human inducible nitric oxide synthase. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2651-3. DMZHV39 RU https://pubmed.ncbi.nlm.nih.gov/11551770 DMZHVFO DI DMZHVFO DMZHVFO DN 4-[5-(3-Hydroxyphenyl)-2-thienyl]benzene-1,2-diol DMZHVFO TI TTIWB6L DMZHVFO TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMZHVFO MA Inhibitor DMZHVFO RN New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43. DMZHVFO RU https://pubmed.ncbi.nlm.nih.gov/19831396 DMZHVRW DI DMZHVRW DMZHVRW DN 5-Hydroxymethyl-Chonduritol DMZHVRW TI TTCGSZ4 DMZHVRW TN Pancreatic alpha-amylase (AMY2A) DMZHVRW MA Inhibitor DMZHVRW RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZHVRW RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZHWAV DI DMZHWAV DMZHWAV DN 1,2-bis(2,3,5-trifluorophenyl)ethane-1,2-dione DMZHWAV TI TTMF541 DMZHWAV TN Liver carboxylesterase (CES1) DMZHWAV MA Inhibitor DMZHWAV RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMZHWAV RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMZHWPG DI DMZHWPG DMZHWPG DN ASTRAGALIN DMZHWPG TI TTL69WB DMZHWPG TN Angiotensin-converting enzyme (ACE) DMZHWPG MA Inhibitor DMZHWPG RN Inhibitory effects of various flavonoids isolated from leaves of persimmon on angiotensin-converting enzyme activity. J Nat Prod. 1987 Jul-Aug;50(4):680-3. DMZHWPG RU https://pubmed.ncbi.nlm.nih.gov/3430165 DMZHWPG DI DMZHWPG DMZHWPG DN ASTRAGALIN DMZHWPG TI TTFBNVI DMZHWPG TN Aldose reductase (AKR1B1) DMZHWPG MA Inhibitor DMZHWPG RN Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. J Nat Prod. 2008 Apr;71(4):713-5. DMZHWPG RU https://pubmed.ncbi.nlm.nih.gov/18298080 DMZI6RD DI DMZI6RD DMZI6RD DN F-G-G-F-T-G-A-R-K-S-MeA-R-K-L-A-N-Q-COOH DMZI6RD TI TTNT7K8 DMZI6RD TN Nociceptin receptor (OPRL1) DMZI6RD MA Inhibitor DMZI6RD RN Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem. 2002 Nov 21;45(24):5280-6. DMZI6RD RU https://pubmed.ncbi.nlm.nih.gov/12431054 DMZI7O1 DI DMZI7O1 DMZI7O1 DN 2-phenyl-1H-imidazole-4-carboxylic acid DMZI7O1 TI TTHI19T DMZI7O1 TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMZI7O1 MA Inhibitor DMZI7O1 RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZI7O1 RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZI8QW DI DMZI8QW DMZI8QW DN P-2281 DMZI8QW TI TTCJG29 DMZI8QW TN Serine/threonine-protein kinase mTOR (mTOR) DMZI8QW MA Inhibitor DMZI8QW RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2109). DMZI8QW RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2109 DMZIA1R DI DMZIA1R DMZIA1R DN mercaptoacrylate inhibitor of calpain 1 DMZIA1R TI TTG5QB7 DMZIA1R TN Calpain-2 (CAPN2) DMZIA1R MA Inhibitor DMZIA1R RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336). DMZIA1R RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2336 DMZICL8 DI DMZICL8 DMZICL8 DN 5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole DMZICL8 TI TTIQUX7 DMZICL8 TN Steroid 11-beta-hydroxylase (CYP11B1) DMZICL8 MA Inhibitor DMZICL8 RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMZICL8 RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMZICL8 DI DMZICL8 DMZICL8 DN 5-[5-Bromo-indan-(1Z)-ylidenemethyl]-1H-imidazole DMZICL8 TI TTSZLWK DMZICL8 TN Aromatase (CYP19A1) DMZICL8 MA Inhibitor DMZICL8 RN Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 24;48(6):1796-805. DMZICL8 RU https://pubmed.ncbi.nlm.nih.gov/15771425 DMZID0W DI DMZID0W DMZID0W DN ISIS 16010 DMZID0W TI TTRE6AX DMZID0W TN Bcl-x messenger RNA (BCL2L1 mRNA) DMZID0W RN US patent application no. 7,148,204, Antisense modulation of bcl-x expression. DMZID0W RU http://www.patentbuddy.com/Patent/7148204?ft=true&sr=true DMZIFW7 DI DMZIFW7 DMZIFW7 DN 4-Sulfamoyloxy-benzoic acid pentyl ester DMZIFW7 TI TTHM0R1 DMZIFW7 TN Steryl-sulfatase (STS) DMZIFW7 MA Inhibitor DMZIFW7 RN Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9. DMZIFW7 RU https://pubmed.ncbi.nlm.nih.gov/14741252 DMZIHKY DI DMZIHKY DMZIHKY DN XMD8-92 DMZIHKY TI TTWS7I3 DMZIHKY TN Non-receptor tyrosine-protein kinase TNK1 (TNK1) DMZIHKY MA Inhibitor DMZIHKY RN Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67. DMZIHKY RU https://pubmed.ncbi.nlm.nih.gov/20832753 DMZIHKY DI DMZIHKY DMZIHKY DN XMD8-92 DMZIHKY TI TTU6FSC DMZIHKY TN Extracellular signal-regulated kinase 5 (ERK5) DMZIHKY MA Inhibitor DMZIHKY RN Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67. DMZIHKY RU https://pubmed.ncbi.nlm.nih.gov/20832753 DMZIHKY DI DMZIHKY DMZIHKY DN XMD8-92 DMZIHKY TI TTGPNZQ DMZIHKY TN Polo-like kinase 4 (PLK4) DMZIHKY MA Inhibitor DMZIHKY RN Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67. DMZIHKY RU https://pubmed.ncbi.nlm.nih.gov/20832753 DMZIHKY DI DMZIHKY DMZIHKY DN XMD8-92 DMZIHKY TI TTHK3MO DMZIHKY TN Doublecortin-like kinase 2 (DCLK2) DMZIHKY MA Inhibitor DMZIHKY RN Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67. DMZIHKY RU https://pubmed.ncbi.nlm.nih.gov/20832753 DMZILNC DI DMZILNC DMZILNC DN 3,3'-Pyridine-2,5-diyldiphenol DMZILNC TI TTIWB6L DMZILNC TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMZILNC MA Inhibitor DMZILNC RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DMZILNC RU https://pubmed.ncbi.nlm.nih.gov/18855374 DMZINUY DI DMZINUY DMZINUY DN AG-11/03 DMZINUY TI TT5Y4EM DMZINUY TN N-formyl peptide receptor (FPR1) DMZINUY MA Agonist DMZINUY RN Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1. J Mol Model. 2012 Jun;18(6):2831-43. DMZINUY RU https://pubmed.ncbi.nlm.nih.gov/22127612 DMZIOJS DI DMZIOJS DMZIOJS DN 3-benzyl-N-(2-morpholinoethyl)quinoxalin-2-amine DMZIOJS TI TT3WG5C DMZIOJS TN Monoamine oxidase type A (MAO-A) DMZIOJS MA Inhibitor DMZIOJS RN Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1753-6. DMZIOJS RU https://pubmed.ncbi.nlm.nih.gov/16356714 DMZIQ56 DI DMZIQ56 DMZIQ56 DN 24-ethylcholest-6-ene-3,5-diol DMZIQ56 TI TTEB0GD DMZIQ56 TN Cholinesterase (BCHE) DMZIQ56 MA Inhibitor DMZIQ56 RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMZIQ56 RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMZIQ56 DI DMZIQ56 DMZIQ56 DN 24-ethylcholest-6-ene-3,5-diol DMZIQ56 TI TT1RS9F DMZIQ56 TN Acetylcholinesterase (AChE) DMZIQ56 MA Inhibitor DMZIQ56 RN Isolation and cholinesterase-inhibition studies of sterols from Haloxylon recurvum. Bioorg Med Chem Lett. 2006 Feb;16(3):573-80. DMZIQ56 RU https://pubmed.ncbi.nlm.nih.gov/16274989 DMZIUQ2 DI DMZIUQ2 DMZIUQ2 DN 4-DAMP DMZIUQ2 TI TTQ13Z5 DMZIUQ2 TN Muscarinic acetylcholine receptor M3 (CHRM3) DMZIUQ2 MA Antagonist DMZIUQ2 RN An increase in intracelluar free calcium ions modulated by cholinergic receptors in rat facial nucleus. Chin Med J (Engl). 2009 May 5;122(9):1049-55. DMZIUQ2 RU https://pubmed.ncbi.nlm.nih.gov/19493439 DMZJ4VL DI DMZJ4VL DMZJ4VL DN 3,4-dihydroxybenzaldehyde-O-ethyloxime DMZJ4VL TI TTULVH8 DMZJ4VL TN Tyrosinase (TYR) DMZJ4VL MA Inhibitor DMZJ4VL RN Discovery of 4-functionalized phenyl-O-beta-D-glycosides as a new class of mushroom tyrosinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6157-60. DMZJ4VL RU https://pubmed.ncbi.nlm.nih.gov/19800229 DMZJ6M8 DI DMZJ6M8 DMZJ6M8 DN 6-bromo-8-(piperazin-1-yl)imidazo[1,2-a]pyrazine DMZJ6M8 TI TTWJBZ5 DMZJ6M8 TN 5-HT 2C receptor (HTR2C) DMZJ6M8 MA Inhibitor DMZJ6M8 RN Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. Bioorg Med Chem Lett. 2010 Jan 1;20(1):266-71. DMZJ6M8 RU https://pubmed.ncbi.nlm.nih.gov/19914063 DMZJE6M DI DMZJE6M DMZJE6M DN 5-bromo-6-hydrazinouracil hydrochloride DMZJE6M TI TTO0IB8 DMZJE6M TN Thymidine phosphorylase (TYMP) DMZJE6M MA Inhibitor DMZJE6M RN Design and synthesis of novel 5,6-disubstituted uracil derivatives as potent inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1335-7. DMZJE6M RU https://pubmed.ncbi.nlm.nih.gov/16337119 DMZJKIU DI DMZJKIU DMZJKIU DN 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one DMZJKIU TI TTN9D8E DMZJKIU TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMZJKIU MA Inhibitor DMZJKIU RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMZJKIU RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMZJKIU DI DMZJKIU DMZJKIU DN 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one DMZJKIU TI TTKJEMQ DMZJKIU TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMZJKIU MA Inhibitor DMZJKIU RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMZJKIU RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMZJKIU DI DMZJKIU DMZJKIU DN 5,7-Dichloro-4-hydroxy-3-phenyl-1H-quinolin-2-one DMZJKIU TI TTLD29N DMZJKIU TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMZJKIU MA Inhibitor DMZJKIU RN Amino acid bioisosteres: design of 2-quinolone derivatives as glycine-site N-methyl-D-aspartate receptor antagonists, Bioorg. Med. Chem. Lett. 3(2):299-304 (1993). DMZJKIU RU http://www.sciencedirect.com/science/article/pii/S0960894X01808970 DMZJO5V DI DMZJO5V DMZJO5V DN Phenoxyarsonous acid DMZJO5V TI TTANPDJ DMZJO5V TN Carbonic anhydrase II (CA-II) DMZJO5V MA Inhibitor DMZJO5V RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMZJO5V RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMZJO5V DI DMZJO5V DMZJO5V DN Phenoxyarsonous acid DMZJO5V TI TTHQPL7 DMZJO5V TN Carbonic anhydrase I (CA-I) DMZJO5V MA Inhibitor DMZJO5V RN Carbonic anhydrase inhibitors. Inhibition of the newly isolated murine isozyme XIII with anions. Bioorg Med Chem Lett. 2004 Nov 1;14(21):5435-9. DMZJO5V RU https://pubmed.ncbi.nlm.nih.gov/15454240 DMZJPOB DI DMZJPOB DMZJPOB DN MDDR 287569 DMZJPOB TI TT07C3Y DMZJPOB TN 5-HT 4 receptor (HTR4) DMZJPOB MA Modulator DMZJPOB RN Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF Prostate Cancer Clinical Trials Consortium. Invest New Drugs. 2012 April; 30(2): 749-757. DMZJPOB RU http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175265/ DMZJQ1D DI DMZJQ1D DMZJQ1D DN SC-58272 DMZJQ1D TI TTBAF05 DMZJQ1D TN Candida Peptide N-myristoyltransferase (Candi NMT1) DMZJQ1D MA Inhibitor DMZJQ1D RN Crystal structures of Saccharomyces cerevisiae N-myristoyltransferase with bound myristoyl-CoA and inhibitors reveal the functional roles of the N-... J Biol Chem. 2007 Jul 27;282(30):22185-94. DMZJQ1D RU https://pubmed.ncbi.nlm.nih.gov/17513302 DMZJQC0 DI DMZJQC0 DMZJQC0 DN [18F](R,R)-quinuclidinyl-4-fluoromethyl-benzilate DMZJQC0 TI TTOXS3C DMZJQC0 TN Muscarinic acetylcholine receptor (CHRM) DMZJQC0 MA Antagonist DMZJQC0 RN In vivo muscarinic binding selectivity of (R,S)- and (R,R)-[18F]-fluoromethyl QNB. Bioorg Med Chem. 1997 Aug;5(8):1555-67. DMZJQC0 RU https://pubmed.ncbi.nlm.nih.gov/9313861 DMZJS2E DI DMZJS2E DMZJS2E DN 4-Amino-3-thiophen-2-yl-butyric acid DMZJS2E TI TTDCVZW DMZJS2E TN Gamma-aminobutyric acid B receptor (GABBR) DMZJS2E MA Inhibitor DMZJS2E RN 3-Thienyl- and 3-furylaminobutyric acids. Synthesis and binding GABAB receptor studies. J Med Chem. 1991 Aug;34(8):2557-60. DMZJS2E RU https://pubmed.ncbi.nlm.nih.gov/1652022 DMZJSWI DI DMZJSWI DMZJSWI DN NNC 11-1607 DMZJSWI TI TTOXS3C DMZJSWI TN Muscarinic acetylcholine receptor (CHRM) DMZJSWI MA Agonist DMZJSWI RN Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8. DMZJSWI RU https://pubmed.ncbi.nlm.nih.gov/11504829 DMZJSWI DI DMZJSWI DMZJSWI DN NNC 11-1607 DMZJSWI TI TTQ13Z5 DMZJSWI TN Muscarinic acetylcholine receptor M3 (CHRM3) DMZJSWI MA Agonist DMZJSWI RN Synthesis and pharmacological evaluation of dimeric muscarinic acetylcholine receptor agonists. J Pharmacol Exp Ther. 2001 Sep;298(3):1260-8. DMZJSWI RU https://pubmed.ncbi.nlm.nih.gov/11504829 DMZK0JV DI DMZK0JV DMZK0JV DN 2-O-ethyl-PAF C-16 DMZK0JV TI TTQL5VC DMZK0JV TN Platelet-activating factor receptor (PTAFR) DMZK0JV MA Agonist DMZK0JV RN A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J Immunol Methods. 1995 Oct 26;186(2):225-31. DMZK0JV RU https://pubmed.ncbi.nlm.nih.gov/7594622 DMZK0SC DI DMZK0SC DMZK0SC DN BAS-0338872 DMZK0SC TI TT6PKBN DMZK0SC TN Proto-oncogene c-Src (SRC) DMZK0SC MA Inhibitor DMZK0SC RN Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11. DMZK0SC RU https://pubmed.ncbi.nlm.nih.gov/18078752 DMZK0SC DI DMZK0SC DMZK0SC DN BAS-0338872 DMZK0SC TI TT3PJMV DMZK0SC TN Tyrosine-protein kinase ABL1 (ABL) DMZK0SC MA Inhibitor DMZK0SC RN Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1207-11. DMZK0SC RU https://pubmed.ncbi.nlm.nih.gov/18078752 DMZK13I DI DMZK13I DMZK13I DN 3-Ethyl-3-isopropyl-dihydro-furan-2-one DMZK13I TI TTZA1NY DMZK13I TN GABA(A) receptor beta-2 (GABRB2) DMZK13I MA Inhibitor DMZK13I RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMZK13I RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMZK13I DI DMZK13I DMZK13I DN 3-Ethyl-3-isopropyl-dihydro-furan-2-one DMZK13I TI TTNJYV2 DMZK13I TN Gamma-aminobutyric acid receptor (GAR) DMZK13I MA Inhibitor DMZK13I RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMZK13I RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMZK13I DI DMZK13I DMZK13I DN 3-Ethyl-3-isopropyl-dihydro-furan-2-one DMZK13I TI TT06RH5 DMZK13I TN GABA(A) receptor gamma-2 (GABRG2) DMZK13I MA Inhibitor DMZK13I RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMZK13I RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMZK13I DI DMZK13I DMZK13I DN 3-Ethyl-3-isopropyl-dihydro-furan-2-one DMZK13I TI TT1MPAY DMZK13I TN GABA(A) receptor alpha-1 (GABRA1) DMZK13I MA Inhibitor DMZK13I RN Alpha-spirocyclopentyl- and alpha-spirocyclopropyl-gamma-butyrolactones: conformationally constrained derivatives of anticonvulsant and convulsant ... J Med Chem. 1994 Jan 21;37(2):275-86. DMZK13I RU https://pubmed.ncbi.nlm.nih.gov/8295215 DMZK4AH DI DMZK4AH DMZK4AH DN 5-(3-benzylpyrrolidin-3-yl)-1h-indole (structural mix) DMZK4AH TI TTQ6VDM DMZK4AH TN Voltage-gated potassium channel Kv11.1 (KCNH2) DMZK4AH MA Inhibitor DMZK4AH RN Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6062-6. DMZK4AH RU https://pubmed.ncbi.nlm.nih.gov/18954985 DMZK4DL DI DMZK4DL DMZK4DL DN 1,8-Dichloro-10H-anthracen-9-one DMZK4DL TI TT2J34L DMZK4DL TN Arachidonate 5-lipoxygenase (5-LOX) DMZK4DL MA Inhibitor DMZK4DL RN Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. J Med Chem. 1997 Nov 7;40(23):3773-80. DMZK4DL RU https://pubmed.ncbi.nlm.nih.gov/9371243 DMZK8V5 DI DMZK8V5 DMZK8V5 DN 5-Aminomethyl-4,5-dihydro-isoxazol-3-ol DMZK8V5 TI TTNJYV2 DMZK8V5 TN Gamma-aminobutyric acid receptor (GAR) DMZK8V5 MA Inhibitor DMZK8V5 RN GABA agonists. Resolution, absolute stereochemistry, and enantioselectivity of (S)-(+)- and (R)-(-)-dihydromuscimol. J Med Chem. 1985 Nov;28(11):1612-7. DMZK8V5 RU https://pubmed.ncbi.nlm.nih.gov/2999396 DMZKC7S DI DMZKC7S DMZKC7S DN Ankinara DMZKC7S TI TTT0Q1F DMZKC7S TN Interleukin-10 (IL10) DMZKC7S MA Activator DMZKC7S RN Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. DMZKC7S RU https://pubmed.ncbi.nlm.nih.gov/16634702 DMZKEIH DI DMZKEIH DMZKEIH DN PMID25259874C4 DMZKEIH TI TTI6B3F DMZKEIH TN C3a anaphylatoxin chemotactic receptor (C3AR1) DMZKEIH MA Antagonist DMZKEIH RN Potent heterocyclic ligands for human complement c3a receptor. J Med Chem. 2014 Oct 23;57(20):8459-70. DMZKEIH RU https://pubmed.ncbi.nlm.nih.gov/25259874 DMZKH4R DI DMZKH4R DMZKH4R DN Cyclohexyl biphenyl-4-ylcarbamate DMZKH4R TI TTDP1UC DMZKH4R TN Fatty acid amide hydrolase (FAAH) DMZKH4R MA Inhibitor DMZKH4R RN The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors. Eur J Med Chem. 2009 Jul;44(7):2994-3008. DMZKH4R RU https://pubmed.ncbi.nlm.nih.gov/19232787 DMZKJ37 DI DMZKJ37 DMZKJ37 DN CCNCSAKWCRDHSRCC DMZKJ37 TI TT84DRB DMZKJ37 TN Voltage-gated sodium channel alpha Nav1.4 (SCN4A) DMZKJ37 MA Inhibitor DMZKJ37 RN Structure/function characterization of micro-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem. 2007 Oct 19;282(42):30699-706. DMZKJ37 RU https://pubmed.ncbi.nlm.nih.gov/17724025 DMZKJF8 DI DMZKJF8 DMZKJF8 DN 5-Phenethyl-1H-pyrazole-3-carboxylic acid DMZKJF8 TI TTWNV8U DMZKJF8 TN Nicotinic acid receptor (HCAR2) DMZKJF8 MA Inhibitor DMZKJF8 RN Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51. DMZKJF8 RU https://pubmed.ncbi.nlm.nih.gov/12930155 DMZKO14 DI DMZKO14 DMZKO14 DN 7-Methyl-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine DMZKO14 TI TT9SL3Q DMZKO14 TN Polypeptide deformylase (PDF) DMZKO14 MA Inhibitor DMZKO14 RN High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines w... J Med Chem. 1996 Feb 16;39(4):892-903. DMZKO14 RU https://pubmed.ncbi.nlm.nih.gov/8632413 DMZKPSQ DI DMZKPSQ DMZKPSQ DN Y-26763 DMZKPSQ TI TT1VOHK DMZKPSQ TN Potassium channel unspecific (KC) DMZKPSQ MA Modulator DMZKPSQ RN Y-26763: ATP-sensitive K+ channel activation and the inhibition of insulin release from human pancreatic beta-cells. Eur J Pharmacol. 2004 Feb 20;486(2):133-9. DMZKPSQ RU https://www.ncbi.nlm.nih.gov/pubmed/14975702 DMZKS6Q DI DMZKS6Q DMZKS6Q DN CGS-7181 DMZKS6Q TI TT1VOHK DMZKS6Q TN Potassium channel unspecific (KC) DMZKS6Q MA Modulator DMZKS6Q RN Molecular mechanism of pharmacological activation of BK channels DMZKS6Q RU https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295268 DMZKUOX DI DMZKUOX DMZKUOX DN 1,3-Di(berberine-9-O-yl)ethane dibromide DMZKUOX TI TT1RS9F DMZKUOX TN Acetylcholinesterase (AChE) DMZKUOX MA Inhibitor DMZKUOX RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMZKUOX RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMZKUOX DI DMZKUOX DMZKUOX DN 1,3-Di(berberine-9-O-yl)ethane dibromide DMZKUOX TI TTEB0GD DMZKUOX TN Cholinesterase (BCHE) DMZKUOX MA Inhibitor DMZKUOX RN Synthesis and biological evaluation of a new series of berberine derivatives as dual inhibitors of acetylcholinesterase and butyrylcholinesterase. Bioorg Med Chem. 2010 Jun 15;18(12):4475-84. DMZKUOX RU https://pubmed.ncbi.nlm.nih.gov/20471843 DMZL6Q1 DI DMZL6Q1 DMZL6Q1 DN 2-morpholino-6-(naphthalen-1-yl)-4H-chromen-4-one DMZL6Q1 TI TTK3PY9 DMZL6Q1 TN DNA-dependent protein kinase catalytic (PRKDC) DMZL6Q1 MA Inhibitor DMZL6Q1 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMZL6Q1 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMZL7R6 DI DMZL7R6 DMZL7R6 DN DIHYDROCUBEBIN DMZL7R6 TI TTVG215 DMZL7R6 TN Debrisoquine 4-hydroxylase (CYP2D6) DMZL7R6 MA Inhibitor DMZL7R6 RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMZL7R6 RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMZL7R6 DI DMZL7R6 DMZL7R6 DN DIHYDROCUBEBIN DMZL7R6 TI TTXV4FI DMZL7R6 TN Albendazole monooxygenase (CYP3A4) DMZL7R6 MA Inhibitor DMZL7R6 RN Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod. 2005 Jan;68(1):64-8. DMZL7R6 RU https://pubmed.ncbi.nlm.nih.gov/15679319 DMZL7SW DI DMZL7SW DMZL7SW DN ISIS 9060 DMZL7SW TI TT5TURO DMZL7SW TN A-Raf messenger RNA (ARAF mRNA) DMZL7SW RN US patent application no. 5,563,255, Antisense oligonucleotide modulation of raf gene expression. DMZL7SW RU http://www.patentbuddy.com/Patent/5563255?ft=true&sr=true DMZL87A DI DMZL87A DMZL87A DN 5,6-Dichloro-N-(3-morpholinopropyl)nicotinamide DMZL87A TI TT3WG5C DMZL87A TN Monoamine oxidase type A (MAO-A) DMZL87A MA Inhibitor DMZL87A RN Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1659-64. DMZL87A RU https://pubmed.ncbi.nlm.nih.gov/20117937 DMZL8KN DI DMZL8KN DMZL8KN DN 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine DMZL8KN TI TTIQUX7 DMZL8KN TN Steroid 11-beta-hydroxylase (CYP11B1) DMZL8KN MA Inhibitor DMZL8KN RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMZL8KN RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMZL8KN DI DMZL8KN DMZL8KN DN 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine DMZL8KN TI TTRA5BZ DMZL8KN TN Steroid 17-alpha-monooxygenase (S17AH) DMZL8KN MA Inhibitor DMZL8KN RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMZL8KN RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMZL8KN DI DMZL8KN DMZL8KN DN 4-[5-Chloro-indan-(1E)-ylidenemethyl]-pyridine DMZL8KN TI TTSZLWK DMZL8KN TN Aromatase (CYP19A1) DMZL8KN MA Inhibitor DMZL8KN RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMZL8KN RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMZLE0U DI DMZLE0U DMZLE0U DN BMS-269223 DMZLE0U TI TTCIHJA DMZLE0U TN Coagulation factor Xa (F10) DMZLE0U MA Inhibitor DMZLE0U RN Aroylguanidine-based factor Xa inhibitors: the discovery of BMS-344577. Bioorg Med Chem Lett. 2009 Dec 15;19(24):6882-9. DMZLE0U RU https://pubmed.ncbi.nlm.nih.gov/19896847 DMZLFVG DI DMZLFVG DMZLFVG DN Pyrrolopyrimidine DMZLFVG TI TTOI92F DMZLFVG TN Multidrug resistance-associated protein 1 (ABCC1) DMZLFVG MA Inhibitor DMZLFVG RN Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4967-72. DMZLFVG RU https://pubmed.ncbi.nlm.nih.gov/16168641 DMZLJ21 DI DMZLJ21 DMZLJ21 DN G3139 + Irinotecan DMZLJ21 TI TTFOUV4 DMZLJ21 TN BCL-2 messenger RNA (BCL2 mRNA) DMZLJ21 RN Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207. DMZLJ21 RU http://www.informahealthcare.com/doi/abs/10.1517/17460441.3.10.1177 DMZLJRS DI DMZLJRS DMZLJRS DN 5-fluoro-6-azido-UMP DMZLJRS TI TTAFJUD DMZLJRS TN Orotidine 5'-monophosphate decarboxylase (UMPS) DMZLJRS MA Inhibitor DMZLJRS RN Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents. J Med Chem. 2009 Mar 26;52(6):1648-58. DMZLJRS RU https://pubmed.ncbi.nlm.nih.gov/19260677 DMZLMJH DI DMZLMJH DMZLMJH DN Clocinnamox DMZLMJH TI TTQW87Y DMZLMJH TN Opioid receptor kappa (OPRK1) DMZLMJH MA Inhibitor DMZLMJH RN 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7. DMZLMJH RU https://pubmed.ncbi.nlm.nih.gov/19253983 DMZLMJH DI DMZLMJH DMZLMJH DN Clocinnamox DMZLMJH TI TT27RFC DMZLMJH TN Opioid receptor delta (OPRD1) DMZLMJH MA Inhibitor DMZLMJH RN 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7. DMZLMJH RU https://pubmed.ncbi.nlm.nih.gov/19253983 DMZLMJH DI DMZLMJH DMZLMJH DN Clocinnamox DMZLMJH TI TTKWM86 DMZLMJH TN Opioid receptor mu (MOP) DMZLMJH MA Inhibitor DMZLMJH RN 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7. DMZLMJH RU https://pubmed.ncbi.nlm.nih.gov/19253983 DMZLNAP DI DMZLNAP DMZLNAP DN 1-(4-fluorophenyl)-2-(phenylsulfonyl)ethanone DMZLNAP TI TTN7BL9 DMZLNAP TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMZLNAP MA Inhibitor DMZLNAP RN beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action. Bioorg Med Chem. 2007 Jul 1;15(13):4396-405. DMZLNAP RU https://pubmed.ncbi.nlm.nih.gov/17490884 DMZLOVB DI DMZLOVB DMZLOVB DN 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol DMZLOVB TI TTJFY5U DMZLOVB TN Adenosine A3 receptor (ADORA3) DMZLOVB MA Inhibitor DMZLOVB RN Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30. DMZLOVB RU https://pubmed.ncbi.nlm.nih.gov/18262425 DMZLOVB DI DMZLOVB DMZLOVB DN 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol DMZLOVB TI TTM2AOE DMZLOVB TN Adenosine A2a receptor (ADORA2A) DMZLOVB MA Inhibitor DMZLOVB RN Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30. DMZLOVB RU https://pubmed.ncbi.nlm.nih.gov/18262425 DMZLOVB DI DMZLOVB DMZLOVB DN 5,7-dibromo-9H-pyrido[3,4-b]indol-6-ol DMZLOVB TI TTK25J1 DMZLOVB TN Adenosine A1 receptor (ADORA1) DMZLOVB MA Inhibitor DMZLOVB RN Synthesis of eudistomin D analogues and its effects on adenosine receptors. Bioorg Med Chem. 2008 Apr 1;16(7):3825-30. DMZLOVB RU https://pubmed.ncbi.nlm.nih.gov/18262425 DMZLQ5W DI DMZLQ5W DMZLQ5W DN S-34324 DMZLQ5W TI TTWG9A4 DMZLQ5W TN Adrenergic receptor alpha-2A (ADRA2A) DMZLQ5W MA Inhibitor DMZLQ5W RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMZLQ5W RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMZLQ5W DI DMZLQ5W DMZLQ5W DN S-34324 DMZLQ5W TI TTAWNKZ DMZLQ5W TN Norepinephrine transporter (NET) DMZLQ5W MA Inhibitor DMZLQ5W RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMZLQ5W RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMZLQ5W DI DMZLQ5W DMZLQ5W DN S-34324 DMZLQ5W TI TT2NUT5 DMZLQ5W TN Adrenergic receptor alpha-2C (ADRA2C) DMZLQ5W MA Inhibitor DMZLQ5W RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMZLQ5W RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMZLQ5W DI DMZLQ5W DMZLQ5W DN S-34324 DMZLQ5W TI TT3ROYC DMZLQ5W TN Serotonin transporter (SERT) DMZLQ5W MA Inhibitor DMZLQ5W RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMZLQ5W RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMZLQ5W DI DMZLQ5W DMZLQ5W DN S-34324 DMZLQ5W TI TTWM4TY DMZLQ5W TN Adrenergic receptor alpha-2B (ADRA2B) DMZLQ5W MA Inhibitor DMZLQ5W RN Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71. DMZLQ5W RU https://pubmed.ncbi.nlm.nih.gov/15771448 DMZLRY2 DI DMZLRY2 DMZLRY2 DN Glucagon-like peptide-1 analog DMZLRY2 TI TTVIMDE DMZLRY2 TN Glucagon-like peptide 1 receptor (GLP1R) DMZLRY2 MA Modulator DMZLRY2 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 249). DMZLRY2 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=249 DMZLT24 DI DMZLT24 DMZLT24 DN 3-(3-Pyridin-2-yl-pyrrol-1-yl)-benzonitrile DMZLT24 TI TTHS256 DMZLT24 TN Metabotropic glutamate receptor 5 (mGluR5) DMZLT24 MA Inhibitor DMZLT24 RN Discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity. J Med Chem. 2004 Sep 9;47(19):4645-8. Letter DMZLT24 RU https://pubmed.ncbi.nlm.nih.gov/15341479 DMZLUAK DI DMZLUAK DMZLUAK DN Ro0711401 DMZLUAK TI TTVBPDM DMZLUAK TN Metabotropic glutamate receptor 1 (mGluR1) DMZLUAK MA Modulator (allosteric modulator) DMZLUAK RN Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9. DMZLUAK RU https://pubmed.ncbi.nlm.nih.gov/19233648 DMZLVIF DI DMZLVIF DMZLVIF DN 4-Imidazol-1-ylmethyl-1-nitro-xanthen-9-one DMZLVIF TI TTSZLWK DMZLVIF TN Aromatase (CYP19A1) DMZLVIF MA Inhibitor DMZLVIF RN A new class of nonsteroidal aromatase inhibitors: design and synthesis of chromone and xanthone derivatives and inhibition of the P450 enzymes aromatase and 17 alpha-hydroxylase/C17,20-lyase. J Med Chem. 2001 Mar 1;44(5):672-80. DMZLVIF RU https://pubmed.ncbi.nlm.nih.gov/11262078 DMZM3CH DI DMZM3CH DMZM3CH DN N-oleoyl-O-(2-hydroxyethyl)hydroxylamine DMZM3CH TI TTMSFAW DMZM3CH TN Cannabinoid receptor 2 (CB2) DMZM3CH MA Inhibitor DMZM3CH RN Oxyhomologues of anandamide and related endolipids: chemoselective synthesis and biological activity. J Med Chem. 2006 Apr 6;49(7):2333-8. DMZM3CH RU https://pubmed.ncbi.nlm.nih.gov/16570929 DMZM3GB DI DMZM3GB DMZM3GB DN [Gly(But)7]OT DMZM3GB TI TTSCIUP DMZM3GB TN Oxytocin receptor (OTR) DMZM3GB MA Inhibitor DMZM3GB RN Synthesis and biological activity of oxytocin analogues containing conformationally-restricted residues in position 7. Eur J Med Chem. 2007 Jun;42(6):799-806. DMZM3GB RU https://pubmed.ncbi.nlm.nih.gov/17316912 DMZM5KE DI DMZM5KE DMZM5KE DN arachidonylcyclopropylamide DMZM5KE TI TT6OEDT DMZM5KE TN Cannabinoid receptor 1 (CB1) DMZM5KE MA Agonist DMZM5KE RN Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999 Jun;289(3):1427-33. DMZM5KE RU https://pubmed.ncbi.nlm.nih.gov/10336536 DMZM5KE DI DMZM5KE DMZM5KE DN arachidonylcyclopropylamide DMZM5KE TI TTSLJAR DMZM5KE TN N-arachidonyl glycine receptor (GPR18) DMZM5KE MA Agonist DMZM5KE RN Delta(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012 Apr;165(8):2414-24. DMZM5KE RU https://pubmed.ncbi.nlm.nih.gov/21595653 DMZM9AI DI DMZM9AI DMZM9AI DN 1-phenyl-2-(1-phenyl-1H-tetrazol-5-yloxy)ethanone DMZM9AI TI TTN7BL9 DMZM9AI TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMZM9AI MA Inhibitor DMZM9AI RN Modulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by 1,5-substituted 1H-tetrazoles. Bioorg Med Chem Lett. 2010 Jun 1;20(11):3265-71. DMZM9AI RU https://pubmed.ncbi.nlm.nih.gov/20452767 DMZMCT0 DI DMZMCT0 DMZMCT0 DN Gamma-Carboxy-Glutamic Acid DMZMCT0 TI TT6L509 DMZMCT0 TN Coagulation factor IIa (F2) DMZMCT0 MA Inhibitor DMZMCT0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZMCT0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZMCT0 DI DMZMCT0 DMZMCT0 DN Gamma-Carboxy-Glutamic Acid DMZMCT0 TI TTFEZ5Q DMZMCT0 TN Coagulation factor IX (F9) DMZMCT0 MA Inhibitor DMZMCT0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZMCT0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZMCT0 DI DMZMCT0 DMZMCT0 DN Gamma-Carboxy-Glutamic Acid DMZMCT0 TI TTCIHJA DMZMCT0 TN Coagulation factor Xa (F10) DMZMCT0 MA Inhibitor DMZMCT0 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZMCT0 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZME4N DI DMZME4N DMZME4N DN BN-82685 DMZME4N TI TTESBNC DMZME4N TN M-phase inducer phosphatase 3 (MPIP3) DMZME4N MA Inhibitor DMZME4N RN Synthesis and biological evaluation of novel heterocyclic quinones as inhibitors of the dual specificity protein phosphatase CDC25C. Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5. DMZME4N RU https://pubmed.ncbi.nlm.nih.gov/16216500 DMZMEOG DI DMZMEOG DMZMEOG DN 4-(2-(3-fluorophenoxy)phenyl)piperidine DMZMEOG TI TTAWNKZ DMZMEOG TN Norepinephrine transporter (NET) DMZMEOG MA Inhibitor DMZMEOG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMZMEOG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMZMEOG DI DMZMEOG DMZMEOG DN 4-(2-(3-fluorophenoxy)phenyl)piperidine DMZMEOG TI TTVBI8W DMZMEOG TN Dopamine transporter (DAT) DMZMEOG MA Inhibitor DMZMEOG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMZMEOG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMZMEOG DI DMZMEOG DMZMEOG DN 4-(2-(3-fluorophenoxy)phenyl)piperidine DMZMEOG TI TTSQIFT DMZMEOG TN 5-HT 1A receptor (HTR1A) DMZMEOG MA Inhibitor DMZMEOG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMZMEOG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMZMEOG DI DMZMEOG DMZMEOG DN 4-(2-(3-fluorophenoxy)phenyl)piperidine DMZMEOG TI TT3ROYC DMZMEOG TN Serotonin transporter (SERT) DMZMEOG MA Inhibitor DMZMEOG RN Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. DMZMEOG RU https://pubmed.ncbi.nlm.nih.gov/19854053 DMZMKAQ DI DMZMKAQ DMZMKAQ DN CP-4200 DMZMKAQ TI TT6S2FE DMZMKAQ TN DNA [cytosine-5]-methyltransferase 1 (DNMT1) DMZMKAQ MA Inhibitor DMZMKAQ RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2605). DMZMKAQ RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2605 DMZMTLB DI DMZMTLB DMZMTLB DN OHIOENSIN A DMZMTLB TI TTELIN2 DMZMTLB TN PTPN1 messenger RNA (PTPN1 mRNA) DMZMTLB MA Inhibitor DMZMTLB RN Ohioensins F and G: protein tyrosine phosphatase 1B inhibitory benzonaphthoxanthenones from the Antarctic moss Polytrichastrum alpinum. Bioorg Med Chem Lett. 2008 Jan 15;18(2):772-5. DMZMTLB RU https://pubmed.ncbi.nlm.nih.gov/18053716 DMZN0RW DI DMZN0RW DMZN0RW DN S 3025 DMZN0RW TI TT1KPBZ DMZN0RW TN Glucose-6-phosphate translocase (SLC37A4) DMZN0RW MA Inhibitor DMZN0RW RN Prolonged blood glucose reduction in mrp-2 deficient rats (GY/TR(-)) by the glucose-6-phosphate translocase inhibitor S 3025. Biochim Biophys Acta. 2002 Jan 15;1569(1-3):105-10. DMZN0RW RU https://pubmed.ncbi.nlm.nih.gov/11853963 DMZN1A3 DI DMZN1A3 DMZN1A3 DN [3H]CGP12177 DMZN1A3 TI TTMXGCW DMZN1A3 TN Adrenergic receptor beta-3 (ADRB3) DMZN1A3 MA Agonist DMZN1A3 RN Effects of several putative beta 3-adrenoceptor agonists on lipolysis in human omental adipocytes. Int J Obes Relat Metab Disord. 1996 May;20(5):428-34. DMZN1A3 RU https://pubmed.ncbi.nlm.nih.gov/8696421 DMZN1A3 DI DMZN1A3 DMZN1A3 DN [3H]CGP12177 DMZN1A3 TI TTR6W5O DMZN1A3 TN Adrenergic receptor beta-1 (ADRB1) DMZN1A3 MA Inhibitor DMZN1A3 RN (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66. DMZN1A3 RU https://pubmed.ncbi.nlm.nih.gov/11311069 DMZN1A3 DI DMZN1A3 DMZN1A3 DN [3H]CGP12177 DMZN1A3 TI TT2CJVK DMZN1A3 TN Adrenergic receptor beta-2 (ADRB2) DMZN1A3 MA Inhibitor DMZN1A3 RN (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66. DMZN1A3 RU https://pubmed.ncbi.nlm.nih.gov/11311069 DMZN60F DI DMZN60F DMZN60F DN ISIS 109526 DMZN60F TI TT3K9S2 DMZN60F TN RANK messenger RNA (RANK mRNA) DMZN60F RN US patent application no. 6,171,860, Antisense inhibition of rank expression. DMZN60F RU http://www.patentbuddy.com/Patent/6171860?ft=true&sr=true DMZN7YT DI DMZN7YT DMZN7YT DN SC-795 DMZN7YT TI TTFQAYR DMZN7YT TN Cholesteryl ester transfer protein (CETP) DMZN7YT MA Inhibitor DMZN7YT RN Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic expl... Eur J Med Chem. 2010 Apr;45(4):1598-617. DMZN7YT RU https://pubmed.ncbi.nlm.nih.gov/20116902 DMZN93Y DI DMZN93Y DMZN93Y DN MCL-458 DMZN93Y TI TTQW87Y DMZN93Y TN Opioid receptor kappa (OPRK1) DMZN93Y MA Inhibitor DMZN93Y RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMZN93Y RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMZN93Y DI DMZN93Y DMZN93Y DN MCL-458 DMZN93Y TI TT27RFC DMZN93Y TN Opioid receptor delta (OPRD1) DMZN93Y MA Inhibitor DMZN93Y RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMZN93Y RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMZN93Y DI DMZN93Y DMZN93Y DN MCL-458 DMZN93Y TI TTKWM86 DMZN93Y TN Opioid receptor mu (MOP) DMZN93Y MA Inhibitor DMZN93Y RN In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. DMZN93Y RU https://pubmed.ncbi.nlm.nih.gov/17433695 DMZNAEQ DI DMZNAEQ DMZNAEQ DN GNF-PF-5411 DMZNAEQ TI TTVG215 DMZNAEQ TN Debrisoquine 4-hydroxylase (CYP2D6) DMZNAEQ MA Inhibitor DMZNAEQ RN Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J Med Chem. 1993 Apr 30;36(9):1136-45. DMZNAEQ RU https://pubmed.ncbi.nlm.nih.gov/8487254 DMZNEIB DI DMZNEIB DMZNEIB DN 1-(5-(pyridin-2-yl)oxazol-2-yl)octan-1-one DMZNEIB TI TTDP1UC DMZNEIB TN Fatty acid amide hydrolase (FAAH) DMZNEIB MA Inhibitor DMZNEIB RN Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality. Bioorg Med Chem. 2008 Feb 15;16(4):1562-95. DMZNEIB RU https://pubmed.ncbi.nlm.nih.gov/18053726 DMZNFT2 DI DMZNFT2 DMZNFT2 DN Phenylalanylmethane DMZNFT2 TI TT8VUE0 DMZNFT2 TN Chymase (CYM) DMZNFT2 MA Inhibitor DMZNFT2 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZNFT2 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZNHEC DI DMZNHEC DMZNHEC DN Tyr-Pro-Phe-Phe-OCH2CH3 DMZNHEC TI TTKWM86 DMZNHEC TN Opioid receptor mu (MOP) DMZNHEC MA Inhibitor DMZNHEC RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMZNHEC RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMZNHEC DI DMZNHEC DMZNHEC DN Tyr-Pro-Phe-Phe-OCH2CH3 DMZNHEC TI TT27RFC DMZNHEC TN Opioid receptor delta (OPRD1) DMZNHEC MA Inhibitor DMZNHEC RN Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22. DMZNHEC RU https://pubmed.ncbi.nlm.nih.gov/18490168 DMZNJFU DI DMZNJFU DMZNJFU DN UCL1684 DMZNJFU TI TT9R6BE DMZNJFU TN Calcium-activated potassium channel KCa2.1 (KCNN1) DMZNJFU MA Blocker (channel blocker) DMZNJFU RN Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55. DMZNJFU RU https://pubmed.ncbi.nlm.nih.gov/20359520 DMZNJFU DI DMZNJFU DMZNJFU DN UCL1684 DMZNJFU TI TT2T5M0 DMZNJFU TN Calcium-activated potassium channel KCa2.2 (KCNN2) DMZNJFU MA Blocker (channel blocker) DMZNJFU RN Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9. DMZNJFU RU https://pubmed.ncbi.nlm.nih.gov/10696100 DMZNJFU DI DMZNJFU DMZNJFU DN UCL1684 DMZNJFU TI TT9JH25 DMZNJFU TN Calcium-activated potassium channel KCa2.3 (KCNN3) DMZNJFU MA Blocker (channel blocker) DMZNJFU RN SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34. DMZNJFU RU https://pubmed.ncbi.nlm.nih.gov/11533126 DMZNML4 DI DMZNML4 DMZNML4 DN 2-(1H-indol-5-yl)-6-morpholino-4H-pyran-4-one DMZNML4 TI TTK3PY9 DMZNML4 TN DNA-dependent protein kinase catalytic (PRKDC) DMZNML4 MA Inhibitor DMZNML4 RN Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependen... J Med Chem. 2007 Apr 19;50(8):1958-72. DMZNML4 RU https://pubmed.ncbi.nlm.nih.gov/17371003 DMZNPMQ DI DMZNPMQ DMZNPMQ DN 2-(4-methoxybenzylthio)-6-methylpyrimidin-4-ol DMZNPMQ TI TTHY57M DMZNPMQ TN Matrix metalloproteinase-13 (MMP-13) DMZNPMQ MA Inhibitor DMZNPMQ RN Ranking the selectivity of PubChem screening hits by activity-based protein profiling: MMP13 as a case study. Bioorg Med Chem. 2009 Feb 1;17(3):1101-8. DMZNPMQ RU https://pubmed.ncbi.nlm.nih.gov/18364257 DMZNRFG DI DMZNRFG DMZNRFG DN 2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol DMZNRFG TI TTSQIFT DMZNRFG TN 5-HT 1A receptor (HTR1A) DMZNRFG MA Inhibitor DMZNRFG RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMZNRFG RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMZNRFG DI DMZNRFG DMZNRFG DN 2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol DMZNRFG TI TTJQOD7 DMZNRFG TN 5-HT 2A receptor (HTR2A) DMZNRFG MA Inhibitor DMZNRFG RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMZNRFG RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMZNRFG DI DMZNRFG DMZNRFG DN 2-(2-Amino-propyl)-5-bromo-4-methoxy-phenol DMZNRFG TI TT6MSOK DMZNRFG TN 5-HT 1D receptor (HTR1D) DMZNRFG MA Inhibitor DMZNRFG RN 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogues. J Med Chem. 1986 Feb;29(2):194-9. DMZNRFG RU https://pubmed.ncbi.nlm.nih.gov/3950904 DMZNUAD DI DMZNUAD DMZNUAD DN Go-Y022 DMZNUAD TI TTVG215 DMZNUAD TN Debrisoquine 4-hydroxylase (CYP2D6) DMZNUAD MA Inhibitor DMZNUAD RN Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31. DMZNUAD RU https://pubmed.ncbi.nlm.nih.gov/18249473 DMZO0EI DI DMZO0EI DMZO0EI DN 2,4-Deoxy-4-Guanidino-5-N-Acetyl-Neuraminic Acid DMZO0EI TI TT50QJ3 DMZO0EI TN Influenza Neuraminidase (Influ NA) DMZO0EI MA Inhibitor DMZO0EI RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMZO0EI RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMZO1FJ DI DMZO1FJ DMZO1FJ DN TIP DMZO1FJ TI TT27RFC DMZO1FJ TN Opioid receptor delta (OPRD1) DMZO1FJ MA Antagonist DMZO1FJ RN The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers. 1999;51(6):411-25. DMZO1FJ RU https://pubmed.ncbi.nlm.nih.gov/10797230 DMZO1QC DI DMZO1QC DMZO1QC DN RTI-5989-31 DMZO1QC TI TT27RFC DMZO1QC TN Opioid receptor delta (OPRD1) DMZO1QC MA Inhibitor DMZO1QC RN Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76. DMZO1QC RU https://pubmed.ncbi.nlm.nih.gov/17625813 DMZO1QC DI DMZO1QC DMZO1QC DN RTI-5989-31 DMZO1QC TI TTQW87Y DMZO1QC TN Opioid receptor kappa (OPRK1) DMZO1QC MA Inhibitor DMZO1QC RN Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76. DMZO1QC RU https://pubmed.ncbi.nlm.nih.gov/17625813 DMZO1QC DI DMZO1QC DMZO1QC DN RTI-5989-31 DMZO1QC TI TTKWM86 DMZO1QC TN Opioid receptor mu (MOP) DMZO1QC MA Inhibitor DMZO1QC RN Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76. DMZO1QC RU https://pubmed.ncbi.nlm.nih.gov/17625813 DMZO5Y7 DI DMZO5Y7 DMZO5Y7 DN ACHP DMZO5Y7 TI TTSXVID DMZO5Y7 TN Nuclear factor NF-kappa-B (NFKB) DMZO5Y7 MA Inhibitor DMZO5Y7 RN Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. DMZO5Y7 RU https://pubmed.ncbi.nlm.nih.gov/19249983 DMZOEQY DI DMZOEQY DMZOEQY DN 1-phenyl-3-(quinazolin-4-yl)urea DMZOEQY TI TTJFY5U DMZOEQY TN Adenosine A3 receptor (ADORA3) DMZOEQY MA Inhibitor DMZOEQY RN Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models. J Med Chem. 2006 Jul 13;49(14):4085-97. DMZOEQY RU https://pubmed.ncbi.nlm.nih.gov/16821770 DMZOGSK DI DMZOGSK DMZOGSK DN (-)-CATECHINGALLATE DMZOGSK TI TT7AOUD DMZOGSK TN Fatty acid synthase (FASN) DMZOGSK MA Inhibitor DMZOGSK RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMZOGSK RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMZOGSK DI DMZOGSK DMZOGSK DN (-)-CATECHINGALLATE DMZOGSK TI TT8JRS7 DMZOGSK TN Beta-secretase (BACE) DMZOGSK MA Inhibitor DMZOGSK RN Green tea catechins as a BACE1 (beta-secretase) inhibitor. Bioorg Med Chem Lett. 2003 Nov 17;13(22):3905-8. DMZOGSK RU https://pubmed.ncbi.nlm.nih.gov/14592472 DMZOGSK DI DMZOGSK DMZOGSK DN (-)-CATECHINGALLATE DMZOGSK TI TTHPFTS DMZOGSK TN Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ) DMZOGSK MA Inhibitor DMZOGSK RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMZOGSK RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMZOGSK DI DMZOGSK DMZOGSK DN (-)-CATECHINGALLATE DMZOGSK TI TTNX2CS DMZOGSK TN Plasmodium Enoyl-ACP reductase (Malaria fabI) DMZOGSK MA Inhibitor DMZOGSK RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMZOGSK RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMZOGSK DI DMZOGSK DMZOGSK DN (-)-CATECHINGALLATE DMZOGSK TI TTBE4IR DMZOGSK TN Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG) DMZOGSK MA Inhibitor DMZOGSK RN Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006 Jun 1;49(11):3345-53. DMZOGSK RU https://pubmed.ncbi.nlm.nih.gov/16722653 DMZON3T DI DMZON3T DMZON3T DN (2s)-Pyrrolidin-2-Ylmethylamine DMZON3T TI TTDIGC1 DMZON3T TN Dipeptidyl peptidase 4 (DPP-4) DMZON3T MA Inhibitor DMZON3T RN DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41. DMZON3T RU https://pubmed.ncbi.nlm.nih.gov/21059682 DMZOTGM DI DMZOTGM DMZOTGM DN Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 DMZOTGM TI TT27RFC DMZOTGM TN Opioid receptor delta (OPRD1) DMZOTGM MA Inhibitor DMZOTGM RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZOTGM RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZOTGM DI DMZOTGM DMZOTGM DN Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 DMZOTGM TI TTCG0AL DMZOTGM TN Cholecystokinin receptor type A (CCKAR) DMZOTGM MA Inhibitor DMZOTGM RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZOTGM RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZOTGM DI DMZOTGM DMZOTGM DN Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 DMZOTGM TI TTVFO0U DMZOTGM TN Gastrin/cholecystokinin type B receptor (CCKBR) DMZOTGM MA Inhibitor DMZOTGM RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZOTGM RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZOTGM DI DMZOTGM DMZOTGM DN Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 DMZOTGM TI TTKWM86 DMZOTGM TN Opioid receptor mu (MOP) DMZOTGM MA Inhibitor DMZOTGM RN Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75. DMZOTGM RU https://pubmed.ncbi.nlm.nih.gov/16686530 DMZOW96 DI DMZOW96 DMZOW96 DN L-162313 DMZOW96 TI TTQVOEI DMZOW96 TN Angiotensin II receptor type-2 (AGTR2) DMZOW96 MA Inhibitor DMZOW96 RN Selective angiotensin II AT(2) receptor agonists with reduced CYP 450 inhibition. Bioorg Med Chem. 2010 Jun 15;18(12):4570-90. DMZOW96 RU https://pubmed.ncbi.nlm.nih.gov/20493713 DMZOW96 DI DMZOW96 DMZOW96 DN L-162313 DMZOW96 TI TT8DBY3 DMZOW96 TN Angiotensin II receptor type-1 (AGTR1) DMZOW96 MA Inhibitor DMZOW96 RN Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships. Bioorg Med Chem. 2008 Jul 15;16(14):6841-9. DMZOW96 RU https://pubmed.ncbi.nlm.nih.gov/18599297 DMZOX43 DI DMZOX43 DMZOX43 DN (2S)-2'-methoxy kurarinone DMZOX43 TI TT8JRS7 DMZOX43 TN Beta-secretase (BACE) DMZOX43 MA Inhibitor DMZOX43 RN BACE1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem. 2008 Jul 15;16(14):6669-74. DMZOX43 RU https://pubmed.ncbi.nlm.nih.gov/18565755 DMZP20H DI DMZP20H DMZP20H DN 4-(Cyanomethylthio)pyridine-3-sulfonamide DMZP20H TI TTEYTKG DMZP20H TN Carbonic anhydrase XIV (CA-XIV) DMZP20H MA Inhibitor DMZP20H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMZP20H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMZP20H DI DMZP20H DMZP20H DN 4-(Cyanomethylthio)pyridine-3-sulfonamide DMZP20H TI TT2LVK8 DMZP20H TN Carbonic anhydrase IX (CA-IX) DMZP20H MA Inhibitor DMZP20H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMZP20H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMZP20H DI DMZP20H DMZP20H DN 4-(Cyanomethylthio)pyridine-3-sulfonamide DMZP20H TI TTSYM0R DMZP20H TN Carbonic anhydrase XII (CA-XII) DMZP20H MA Inhibitor DMZP20H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMZP20H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMZP20H DI DMZP20H DMZP20H DN 4-(Cyanomethylthio)pyridine-3-sulfonamide DMZP20H TI TTANPDJ DMZP20H TN Carbonic anhydrase II (CA-II) DMZP20H MA Inhibitor DMZP20H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMZP20H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMZP20H DI DMZP20H DMZP20H DN 4-(Cyanomethylthio)pyridine-3-sulfonamide DMZP20H TI TTHQPL7 DMZP20H TN Carbonic anhydrase I (CA-I) DMZP20H MA Inhibitor DMZP20H RN Carbonic anhydrase inhibitors: synthesis and inhibition of the human cytosolic isozymes I and II and transmembrane isozymes IX, XII (cancer-associa... Eur J Med Chem. 2010 Jun;45(6):2396-404. DMZP20H RU https://pubmed.ncbi.nlm.nih.gov/20202722 DMZP32O DI DMZP32O DMZP32O DN USTILOXIN A DMZP32O TI TTJ2PTI DMZP32O TN Tubulin beta-2 chain (TUBB2) DMZP32O MA Inhibitor DMZP32O RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMZP32O RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMZP32O DI DMZP32O DMZP32O DN USTILOXIN A DMZP32O TI TTYFKSZ DMZP32O TN Tubulin beta (TUBB) DMZP32O MA Inhibitor DMZP32O RN Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7. DMZP32O RU https://pubmed.ncbi.nlm.nih.gov/16837194 DMZP3XJ DI DMZP3XJ DMZP3XJ DN 6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole DMZP3XJ TI TTN9D8E DMZP3XJ TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMZP3XJ MA Inhibitor DMZP3XJ RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMZP3XJ RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMZP3XJ DI DMZP3XJ DMZP3XJ DN 6-Methoxy-2-(4-phenoxy-benzyl)-1H-benzoimidazole DMZP3XJ TI TTLD29N DMZP3XJ TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMZP3XJ MA Inhibitor DMZP3XJ RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMZP3XJ RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMZP5VG DI DMZP5VG DMZP5VG DN ISIS 2678 DMZP5VG TI TT1PL7M DMZP5VG TN E-selectin messenger RNA (SELE mRNA) DMZP5VG RN US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion. DMZP5VG RU http://www.patentbuddy.com/Patent/5843738?ft=true&sr=true DMZP7YM DI DMZP7YM DMZP7YM DN L-165041 DMZP7YM TI TT2JWF6 DMZP7YM TN Peroxisome proliferator-activated receptor delta (PPARD) DMZP7YM MA Agonist DMZP7YM RN Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25. DMZP7YM RU https://pubmed.ncbi.nlm.nih.gov/10037770 DMZPGBT DI DMZPGBT DMZPGBT DN 3-isopr-sal-cyclosal-d4TMP DMZPGBT TI TTEB0GD DMZPGBT TN Cholinesterase (BCHE) DMZPGBT MA Inhibitor DMZPGBT RN Bis-cycloSal-d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem. 2007 Mar 22;50(6):1335-46. DMZPGBT RU https://pubmed.ncbi.nlm.nih.gov/17328534 DMZPHKG DI DMZPHKG DMZPHKG DN AS74 DMZPHKG TI TTNE7KG DMZPHKG TN Adenosine A2b receptor (ADORA2B) DMZPHKG MA Antagonist DMZPHKG RN Pharmacological characterization of novel adenosine ligands in recombinant and native human A2B receptors. Biochem Pharmacol. 2005 Nov 25;70(11):1601-12. DMZPHKG RU https://pubmed.ncbi.nlm.nih.gov/16219300 DMZPJM4 DI DMZPJM4 DMZPJM4 DN 1-(3-tritylaminopropyl)uracil DMZPJM4 TI TTY8KJS DMZPJM4 TN Bacterial Deoxyuridine triphosphate nucleotidohydrolase (Bact dut) DMZPJM4 MA Inhibitor DMZPJM4 RN Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. J Med Chem. 2006 Jul 13;49(14):4183-95. DMZPJM4 RU https://pubmed.ncbi.nlm.nih.gov/16821778 DMZPKGS DI DMZPKGS DMZPKGS DN BAS-00387275 DMZPKGS TI TT3PJMV DMZPKGS TN Tyrosine-protein kinase ABL1 (ABL) DMZPKGS MA Inhibitor DMZPKGS RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMZPKGS RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMZPKGS DI DMZPKGS DMZPKGS DN BAS-00387275 DMZPKGS TI TT6PKBN DMZPKGS TN Proto-oncogene c-Src (SRC) DMZPKGS MA Inhibitor DMZPKGS RN A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors. J Med Chem. 2006 Jun 1;49(11):3278-86. DMZPKGS RU https://pubmed.ncbi.nlm.nih.gov/16722646 DMZPL63 DI DMZPL63 DMZPL63 DN BB-823 DMZPL63 TI TTQL5VC DMZPL63 TN Platelet-activating factor receptor (PTAFR) DMZPL63 MA Modulator DMZPL63 RN Platelet-activating factor: the effector of protein-rich plasma extravasation and nitric oxide synthase induction in rat immune complex peritonitis. Br J Pharmacol. 1995 Feb;114(4):895-901. DMZPL63 RU https://pubmed.ncbi.nlm.nih.gov/7539698 DMZPRIG DI DMZPRIG DMZPRIG DN GWTLNSAGYLLGPHAV-NH2 DMZPRIG TI TTX3HNZ DMZPRIG TN Galanin receptor type 1 (GAL1-R) DMZPRIG MA Inhibitor DMZPRIG RN Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem. 2008 Dec 25;51(24):8038-47. DMZPRIG RU https://pubmed.ncbi.nlm.nih.gov/19053761 DMZPRIG DI DMZPRIG DMZPRIG DN GWTLNSAGYLLGPHAV-NH2 DMZPRIG TI TTBPW3J DMZPRIG TN Galanin receptor type 2 (GAL2-R) DMZPRIG MA Inhibitor DMZPRIG RN Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem. 2008 Dec 25;51(24):8038-47. DMZPRIG RU https://pubmed.ncbi.nlm.nih.gov/19053761 DMZPULH DI DMZPULH DMZPULH DN 3-[4-(benzylmethylamino)butoxy]xanthen-9-one DMZPULH TI TT1RS9F DMZPULH TN Acetylcholinesterase (AChE) DMZPULH MA Inhibitor DMZPULH RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMZPULH RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMZPULH DI DMZPULH DMZPULH DN 3-[4-(benzylmethylamino)butoxy]xanthen-9-one DMZPULH TI TTEB0GD DMZPULH TN Cholinesterase (BCHE) DMZPULH MA Inhibitor DMZPULH RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMZPULH RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMZPUSO DI DMZPUSO DMZPUSO DN PMID24900749C1a DMZPUSO TI TTER6YH DMZPUSO TN Casein kinase II alpha (CSNK2A1) DMZPUSO MA Inhibitor DMZPUSO RN Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5. DMZPUSO RU https://pubmed.ncbi.nlm.nih.gov/24900749 DMZPUSO DI DMZPUSO DMZPUSO DN PMID24900749C1a DMZPUSO TI TTCGOIN DMZPUSO TN PIM-3 protein kinase (PIM3) DMZPUSO MA Inhibitor DMZPUSO RN Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5. DMZPUSO RU https://pubmed.ncbi.nlm.nih.gov/24900749 DMZPUSO DI DMZPUSO DMZPUSO DN PMID24900749C1a DMZPUSO TI TTV4EX0 DMZPUSO TN Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3) DMZPUSO MA Inhibitor DMZPUSO RN Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5. DMZPUSO RU https://pubmed.ncbi.nlm.nih.gov/24900749 DMZPUSO DI DMZPUSO DMZPUSO DN PMID24900749C1a DMZPUSO TI TTOB49C DMZPUSO TN Homeodomain interacting protein kinase 2 (HIPK2) DMZPUSO MA Inhibitor DMZPUSO RN Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5. DMZPUSO RU https://pubmed.ncbi.nlm.nih.gov/24900749 DMZPXGY DI DMZPXGY DMZPXGY DN Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF DMZPXGY TI TTJX3UE DMZPXGY TN Somatostatin receptor type 3 (SSTR3) DMZPXGY MA Inhibitor DMZPXGY RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMZPXGY RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMZPXGY DI DMZPXGY DMZPXGY DN Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF DMZPXGY TI TTIND6G DMZPXGY TN Somatostatin receptor type 1 (SSTR1) DMZPXGY MA Inhibitor DMZPXGY RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMZPXGY RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMZPXGY DI DMZPXGY DMZPXGY DN Des-AA1,2,5,12,13-[D-Trp8,IAmp9]SRIF DMZPXGY TI TTAE1BR DMZPXGY TN Somatostatin receptor type 4 (SSTR4) DMZPXGY MA Inhibitor DMZPXGY RN Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides. J Med Chem. 2005 Jan 27;48(2):515-22. DMZPXGY RU https://pubmed.ncbi.nlm.nih.gov/15658865 DMZPY69 DI DMZPY69 DMZPY69 DN 6-biphenyl-2-yl-2-morpholin-4-yl-chromen-4-one DMZPY69 TI TTK3PY9 DMZPY69 TN DNA-dependent protein kinase catalytic (PRKDC) DMZPY69 MA Inhibitor DMZPY69 RN Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem. 2005 Dec 1;48(24):7829-46. DMZPY69 RU https://pubmed.ncbi.nlm.nih.gov/16302822 DMZPYN2 DI DMZPYN2 DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 TI TT8QL1J DMZPYN2 TN Protein kinase C theta (PRKCQ) DMZPYN2 MA Inhibitor DMZPYN2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMZPYN2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMZPYN2 DI DMZPYN2 DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 TI TTUWGRA DMZPYN2 TN Protein kinase C zeta (PRKCZ) DMZPYN2 MA Inhibitor DMZPYN2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMZPYN2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMZPYN2 DI DMZPYN2 DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 TI TTYPXQF DMZPYN2 TN Protein kinase C beta (PRKCB) DMZPYN2 MA Inhibitor DMZPYN2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMZPYN2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMZPYN2 DI DMZPYN2 DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 TI TTFJ8Q1 DMZPYN2 TN Protein kinase C alpha (PRKCA) DMZPYN2 MA Inhibitor DMZPYN2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMZPYN2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMZPYN2 DI DMZPYN2 DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 TI TTRFOXJ DMZPYN2 TN Protein kinase C gamma (PRKCG) DMZPYN2 MA Inhibitor DMZPYN2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMZPYN2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMZPYN2 DI DMZPYN2 DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 TI TT9WJ8U DMZPYN2 TN Protein kinase C delta (PRKCD) DMZPYN2 MA Inhibitor DMZPYN2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMZPYN2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMZPYN2 DI DMZPYN2 DMZPYN2 DN 3,3-Bis-(4-methoxy-phenyl)-2-phenyl-acrylonitrile DMZPYN2 TI TTBZ7OD DMZPYN2 TN Protein kinase C epsilon (PRKCE) DMZPYN2 MA Inhibitor DMZPYN2 RN Multivariate analysis by the minimum spanning tree method of the structural determinants of diphenylethylenes and triphenylacrylonitriles implicate... J Med Chem. 1992 Feb 7;35(3):573-83. DMZPYN2 RU https://pubmed.ncbi.nlm.nih.gov/1738150 DMZQ0V9 DI DMZQ0V9 DMZQ0V9 DN JWH-407 DMZQ0V9 TI TT6OEDT DMZQ0V9 TN Cannabinoid receptor 1 (CB1) DMZQ0V9 MA Inhibitor DMZQ0V9 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMZQ0V9 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMZQ0V9 DI DMZQ0V9 DMZQ0V9 DN JWH-407 DMZQ0V9 TI TTMSFAW DMZQ0V9 TN Cannabinoid receptor 2 (CB2) DMZQ0V9 MA Inhibitor DMZQ0V9 RN Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem. 2008 Jan 1;16(1):322-35. DMZQ0V9 RU https://pubmed.ncbi.nlm.nih.gov/17919913 DMZQ2CJ DI DMZQ2CJ DMZQ2CJ DN 3-(3-methoxyphenyl)-6-methyl-2H-chromen-2-one DMZQ2CJ TI TTGP7BY DMZQ2CJ TN Monoamine oxidase type B (MAO-B) DMZQ2CJ MA Inhibitor DMZQ2CJ RN Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors. Bioorg Med Chem Lett. 2009 Sep 1;19(17):5053-5. DMZQ2CJ RU https://pubmed.ncbi.nlm.nih.gov/19628387 DMZQ31O DI DMZQ31O DMZQ31O DN JWH-145 DMZQ31O TI TTMSFAW DMZQ31O TN Cannabinoid receptor 2 (CB2) DMZQ31O MA Inhibitor DMZQ31O RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMZQ31O RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMZQ31O DI DMZQ31O DMZQ31O DN JWH-145 DMZQ31O TI TT6OEDT DMZQ31O TN Cannabinoid receptor 1 (CB1) DMZQ31O MA Inhibitor DMZQ31O RN 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors. Bioorg Med Chem Lett. 2006 Oct 15;16(20):5432-5. DMZQ31O RU https://pubmed.ncbi.nlm.nih.gov/16889960 DMZQ75M DI DMZQ75M DMZQ75M DN Pyrophosphate 2- DMZQ75M TI TT8WCXO DMZQ75M TN Bacterial NH(3)-dependent NAD(+) synthetase (Bact nadE) DMZQ75M MA Inhibitor DMZQ75M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZQ75M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZQ75M DI DMZQ75M DMZQ75M DN Pyrophosphate 2- DMZQ75M TI TTSUKYD DMZQ75M TN Virus RNA-dependent RNA polymerase (Viru RdRP) DMZQ75M MA Inhibitor DMZQ75M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZQ75M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZQ75M DI DMZQ75M DMZQ75M DN Pyrophosphate 2- DMZQ75M TI TTOY91U DMZQ75M TN Plasmodium Hypoxanthine-guanine-xanthine phosphoribosyltransferase (Malaria LACZ) DMZQ75M MA Inhibitor DMZQ75M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZQ75M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZQ75M DI DMZQ75M DMZQ75M DN Pyrophosphate 2- DMZQ75M TI TTZ3IFB DMZQ75M TN Phosphogluconate dehydrogenase (PGD) DMZQ75M MA Inhibitor DMZQ75M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZQ75M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZQ75M DI DMZQ75M DMZQ75M DN Pyrophosphate 2- DMZQ75M TI TTURHFP DMZQ75M TN Angiogenin (ANG) DMZQ75M MA Inhibitor DMZQ75M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZQ75M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZQ75M DI DMZQ75M DMZQ75M DN Pyrophosphate 2- DMZQ75M TI TTBL49X DMZQ75M TN Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ) DMZQ75M MA Inhibitor DMZQ75M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZQ75M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZQ75M DI DMZQ75M DMZQ75M DN Pyrophosphate 2- DMZQ75M TI TTCFP0V DMZQ75M TN Glutamine amidotransferase (GMPS) DMZQ75M MA Inhibitor DMZQ75M RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZQ75M RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZQ7DP DI DMZQ7DP DMZQ7DP DN 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol DMZQ7DP TI TTNT7K8 DMZQ7DP TN Nociceptin receptor (OPRL1) DMZQ7DP MA Inhibitor DMZQ7DP RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMZQ7DP RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMZQ7DP DI DMZQ7DP DMZQ7DP DN 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol DMZQ7DP TI TTKWM86 DMZQ7DP TN Opioid receptor mu (MOP) DMZQ7DP MA Inhibitor DMZQ7DP RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMZQ7DP RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMZQ7DP DI DMZQ7DP DMZQ7DP DN 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol DMZQ7DP TI TT27RFC DMZQ7DP TN Opioid receptor delta (OPRD1) DMZQ7DP MA Inhibitor DMZQ7DP RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMZQ7DP RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMZQ7DP DI DMZQ7DP DMZQ7DP DN 4-phenyl-1-(1-phenylpentyl)piperidin-4-ol DMZQ7DP TI TTQW87Y DMZQ7DP TN Opioid receptor kappa (OPRK1) DMZQ7DP MA Inhibitor DMZQ7DP RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. DMZQ7DP RU https://pubmed.ncbi.nlm.nih.gov/17428659 DMZQ803 DI DMZQ803 DMZQ803 DN NSC-745885 DMZQ803 TI TTQY2EJ DMZQ803 TN TERT messenger RNA (TERT mRNA) DMZQ803 MA Inhibitor DMZQ803 RN Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28. DMZQ803 RU https://pubmed.ncbi.nlm.nih.gov/19804981 DMZQ8YV DI DMZQ8YV DMZQ8YV DN PD-0173958 DMZQ8YV TI TTRLW2X DMZQ8YV TN Fibroblast growth factor receptor 1 (FGFR1) DMZQ8YV MA Inhibitor DMZQ8YV RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMZQ8YV RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMZQ8YV DI DMZQ8YV DMZQ8YV DN PD-0173958 DMZQ8YV TI TTI7421 DMZQ8YV TN Platelet-derived growth factor receptor beta (PDGFRB) DMZQ8YV MA Inhibitor DMZQ8YV RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMZQ8YV RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMZQ8YV DI DMZQ8YV DMZQ8YV DN PD-0173958 DMZQ8YV TI TT8FYO9 DMZQ8YV TN Platelet-derived growth factor receptor alpha (PDGFRA) DMZQ8YV MA Inhibitor DMZQ8YV RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMZQ8YV RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMZQ8YV DI DMZQ8YV DMZQ8YV DN PD-0173958 DMZQ8YV TI TT6PKBN DMZQ8YV TN Proto-oncogene c-Src (SRC) DMZQ8YV MA Inhibitor DMZQ8YV RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMZQ8YV RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMZQ8YV DI DMZQ8YV DMZQ8YV DN PD-0173958 DMZQ8YV TI TT860QF DMZQ8YV TN LCK tyrosine protein kinase (LCK) DMZQ8YV MA Inhibitor DMZQ8YV RN Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. DMZQ8YV RU https://pubmed.ncbi.nlm.nih.gov/10974196 DMZQCEP DI DMZQCEP DMZQCEP DN 2-phenylpropoxyadenosine DMZQCEP TI TTJFY5U DMZQCEP TN Adenosine A3 receptor (ADORA3) DMZQCEP MA Inhibitor DMZQCEP RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMZQCEP RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMZQCEP DI DMZQCEP DMZQCEP DN 2-phenylpropoxyadenosine DMZQCEP TI TTM2AOE DMZQCEP TN Adenosine A2a receptor (ADORA2A) DMZQCEP MA Inhibitor DMZQCEP RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMZQCEP RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMZQCEP DI DMZQCEP DMZQCEP DN 2-phenylpropoxyadenosine DMZQCEP TI TTK25J1 DMZQCEP TN Adenosine A1 receptor (ADORA1) DMZQCEP MA Inhibitor DMZQCEP RN Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor. J Med Chem. 2007 Apr 19;50(8):1810-27. DMZQCEP RU https://pubmed.ncbi.nlm.nih.gov/17378544 DMZQETV DI DMZQETV DMZQETV DN GTPL8662 DMZQETV TI TTUV8G9 DMZQETV TN Progesterone receptor (PGR) DMZQETV MA Antagonist DMZQETV RN A new strategy for selective targeting of progesterone receptor with passive antagonists. Mol Endocrinol. 2013 Jun;27(6):909-24. DMZQETV RU https://pubmed.ncbi.nlm.nih.gov/23579486 DMZQLBD DI DMZQLBD DMZQLBD DN 9-Butyl-9H-adenine DMZQLBD TI TTM2AOE DMZQLBD TN Adenosine A2a receptor (ADORA2A) DMZQLBD MA Inhibitor DMZQLBD RN 8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands. Bioorg Med Chem. 2009 Apr 1;17(7):2812-22. DMZQLBD RU https://pubmed.ncbi.nlm.nih.gov/19282184 DMZQPTU DI DMZQPTU DMZQPTU DN 5-Pyridin-3-yl-thiophene-2-carbaldehyde oxime DMZQPTU TI TTXV4FI DMZQPTU TN Albendazole monooxygenase (CYP3A4) DMZQPTU MA Inhibitor DMZQPTU RN 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J Med Chem. 2005 Jan 13;48(1):224-39. DMZQPTU RU https://pubmed.ncbi.nlm.nih.gov/15634016 DMZQU90 DI DMZQU90 DMZQU90 DN LUF-5853 DMZQU90 TI TTK25J1 DMZQU90 TN Adenosine A1 receptor (ADORA1) DMZQU90 MA Inhibitor DMZQU90 RN A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines. Bioorg Med Chem. 2008 Mar 15;16(6):2741-52. DMZQU90 RU https://pubmed.ncbi.nlm.nih.gov/18258439 DMZQUMB DI DMZQUMB DMZQUMB DN N-allyl-4-hydroxy-N-phenylbenzenesulfonamide DMZQUMB TI TTZAYWL DMZQUMB TN Estrogen receptor (ESR) DMZQUMB MA Inhibitor DMZQUMB RN Substituted 4-hydroxyphenyl sulfonamides as pathway-selective estrogen receptor ligands. Bioorg Med Chem Lett. 2006 Feb 15;16(4):854-8. DMZQUMB RU https://pubmed.ncbi.nlm.nih.gov/16300947 DMZQUY4 DI DMZQUY4 DMZQUY4 DN Isorhamnetin 3-O-rhamnoside DMZQUY4 TI TTFBNVI DMZQUY4 TN Aldose reductase (AKR1B1) DMZQUY4 MA Inhibitor DMZQUY4 RN New flavonol oligoglycosides and polyacylated sucroses with inhibitory effects on aldose reductase and platelet aggregation from the flowers of Pru... J Nat Prod. 2002 Aug;65(8):1151-5. DMZQUY4 RU https://pubmed.ncbi.nlm.nih.gov/12193020 DMZQVDI DI DMZQVDI DMZQVDI DN T0901317 DMZQVDI TI TTM1EQF DMZQVDI TN Oxysterols receptor LXR (NR1H) DMZQVDI MA Binder DMZQVDI RN The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J Lipid Res. 2003 Nov;44(11):2039-48. DMZQVDI RU https://pubmed.ncbi.nlm.nih.gov/12923232 DMZQXLS DI DMZQXLS DMZQXLS DN N-Trimethyllysine DMZQXLS TI TTV3NH6 DMZQXLS TN Calmodulin (CALM) DMZQXLS MA Inhibitor DMZQXLS RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZQXLS RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZR02J DI DMZR02J DMZR02J DN Benzo[c][1,2]oxaborol-1(3H)-ol DMZR02J TI TTLP6GN DMZR02J TN Bacterial DD-carboxypeptidase (Bact vanYB) DMZR02J MA Inhibitor DMZR02J RN Synthesis and evaluation of 3-(dihydroxyboryl)benzoic acids as D,D-carboxypeptidase R39 inhibitors. J Med Chem. 2009 Oct 8;52(19):6097-106. DMZR02J RU https://pubmed.ncbi.nlm.nih.gov/19731939 DMZR4FX DI DMZR4FX DMZR4FX DN Sarcodictyin A DMZR4FX TI TTML2WA DMZR4FX TN Tubulin (TUB) DMZR4FX MA Inducer DMZR4FX RN The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry. 1999 Apr 27;38(17):5490-8. DMZR4FX RU https://pubmed.ncbi.nlm.nih.gov/10220336 DMZR7W6 DI DMZR7W6 DMZR7W6 DN isocarbacyclin DMZR7W6 TI TTOFYT1 DMZR7W6 TN Prostacyclin receptor (PTGIR) DMZR7W6 MA Agonist DMZR7W6 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMZR7W6 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMZR7W6 DI DMZR7W6 DMZR7W6 DN isocarbacyclin DMZR7W6 TI TTPNGDE DMZR7W6 TN Prostaglandin E2 receptor EP3 (PTGER3) DMZR7W6 MA Agonist DMZR7W6 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMZR7W6 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMZR7W6 DI DMZR7W6 DMZR7W6 DN isocarbacyclin DMZR7W6 TI TT1ZAVI DMZR7W6 TN Prostaglandin E2 receptor EP2 (PTGER2) DMZR7W6 MA Agonist DMZR7W6 RN Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. DMZR7W6 RU https://pubmed.ncbi.nlm.nih.gov/9313928 DMZR94D DI DMZR94D DMZR94D DN 1-(4-ethoxyphenyl)propan-2-amine DMZR94D TI TT3WG5C DMZR94D TN Monoamine oxidase type A (MAO-A) DMZR94D MA Inhibitor DMZR94D RN Naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors. Bioorg Med Chem. 2009 Mar 15;17(6):2452-60. DMZR94D RU https://pubmed.ncbi.nlm.nih.gov/19243954 DMZRE6X DI DMZRE6X DMZRE6X DN VU0404251 DMZRE6X TI TTHS256 DMZRE6X TN Metabotropic glutamate receptor 5 (mGluR5) DMZRE6X MA Modulator (allosteric modulator) DMZRE6X RN Optimization of an ether series of mGlu5 positive allosteric modulators: molecular determinants of MPEP-site interaction crossover. Bioorg Med Chem Lett. 2012 Oct 15;22(20):6481-5. DMZRE6X RU https://pubmed.ncbi.nlm.nih.gov/22981332 DMZRI6H DI DMZRI6H DMZRI6H DN FM-303 DMZRI6H TI TT6H4QR DMZRI6H TN Interleukin 23 receptor (IL23R) DMZRI6H RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2293). DMZRI6H RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2293 DMZRM0Q DI DMZRM0Q DMZRM0Q DN 4-amino-6-(4-octylphenyl)hexanoic acid DMZRM0Q TI TT9JZCK DMZRM0Q TN Sphingosine-1-phosphate receptor 1 (S1PR1) DMZRM0Q MA Inhibitor DMZRM0Q RN S1P receptor mediated activity of FTY720 phosphate mimics. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1485-7. DMZRM0Q RU https://pubmed.ncbi.nlm.nih.gov/20153186 DMZRNOT DI DMZRNOT DMZRNOT DN 3-Nitro-4'-nitro-trans-stilbene DMZRNOT TI TTSZLWK DMZRNOT TN Aromatase (CYP19A1) DMZRNOT MA Inhibitor DMZRNOT RN Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer. Bioorg Med Chem. 2010 Jul 15;18(14):5352-66. DMZRNOT RU https://pubmed.ncbi.nlm.nih.gov/20558073 DMZRPM5 DI DMZRPM5 DMZRPM5 DN HT1042 DMZRPM5 TI TTEAD9J DMZRPM5 TN Proteasome beta-8 (PS beta-8) DMZRPM5 MA Inhibitor DMZRPM5 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2408). DMZRPM5 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2408 DMZRQEF DI DMZRQEF DMZRQEF DN 6-Benzyl-2-cyclopentylsulfanyl-3H-pyrimidin-4-one DMZRQEF TI TT84ETX DMZRQEF TN Human immunodeficiency virus Reverse transcriptase (HIV RT) DMZRQEF MA Inhibitor DMZRQEF RN 5-Alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine d... J Med Chem. 1999 Feb 25;42(4):619-27. DMZRQEF RU https://pubmed.ncbi.nlm.nih.gov/10052969 DMZRQU7 DI DMZRQU7 DMZRQU7 DN [3H]cAMP DMZRQU7 TI TTYVI76 DMZRQU7 TN Fungal Protein kinase A (Fung ypkA) DMZRQU7 MA Activator DMZRQU7 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694). DMZRQU7 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1694 DMZRQU7 DI DMZRQU7 DMZRQU7 DN [3H]cAMP DMZRQU7 TI TTNAHEX DMZRQU7 TN cAMP-dependent protein kinase A type I (PRKAR1A) DMZRQU7 MA Inhibitor DMZRQU7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZRQU7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZRQU7 DI DMZRQU7 DMZRQU7 DN [3H]cAMP DMZRQU7 TI TT2QM9D DMZRQU7 TN Adenylate cyclase (ADCY) DMZRQU7 MA Inhibitor DMZRQU7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZRQU7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZRQU7 DI DMZRQU7 DMZRQU7 DN [3H]cAMP DMZRQU7 TI TTW4Y2M DMZRQU7 TN cAMP protein kinase type II-beta (PRKAR2B) DMZRQU7 MA Inhibitor DMZRQU7 RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZRQU7 RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZRS7A DI DMZRS7A DMZRS7A DN BHT-3034 DMZRS7A TI TTH18TF DMZRS7A TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZRS7A MA Modulator DMZRS7A RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMZRS7A RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMZRY0Q DI DMZRY0Q DMZRY0Q DN 2,4-epi-neodysiherbaine DMZRY0Q TI TT0MYE2 DMZRY0Q TN Glutamate receptor ionotropic kainate 1 (GRIK1) DMZRY0Q MA Antagonist DMZRY0Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 450). DMZRY0Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=450 DMZRY0Q DI DMZRY0Q DMZRY0Q DN 2,4-epi-neodysiherbaine DMZRY0Q TI TT0K5RG DMZRY0Q TN Glutamate receptor ionotropic kainate 2 (GRIK2) DMZRY0Q MA Antagonist DMZRY0Q RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 451). DMZRY0Q RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=451 DMZS20Y DI DMZS20Y DMZS20Y DN 3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMZS20Y TI TTIQUX7 DMZS20Y TN Steroid 11-beta-hydroxylase (CYP11B1) DMZS20Y MA Inhibitor DMZS20Y RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMZS20Y RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMZS20Y DI DMZS20Y DMZS20Y DN 3-[4-Fluoro-indan-(1E)-ylidenemethyl]-pyridine DMZS20Y TI TTSZLWK DMZS20Y TN Aromatase (CYP19A1) DMZS20Y MA Inhibitor DMZS20Y RN Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75. DMZS20Y RU https://pubmed.ncbi.nlm.nih.gov/15743198 DMZS4P7 DI DMZS4P7 DMZS4P7 DN 3-hydroxy-5-(2-methylquinolin-7-yl)benzonitrile DMZS4P7 TI TTHS256 DMZS4P7 TN Metabotropic glutamate receptor 5 (mGluR5) DMZS4P7 MA Inhibitor DMZS4P7 RN Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4415-8. DMZS4P7 RU https://pubmed.ncbi.nlm.nih.gov/17590335 DMZSBU5 DI DMZSBU5 DMZSBU5 DN 3-[9-(benzylmethylamino)nonyloxy]xanthen-9-one DMZSBU5 TI TTEB0GD DMZSBU5 TN Cholinesterase (BCHE) DMZSBU5 MA Inhibitor DMZSBU5 RN Cholinesterase inhibitors: SAR and enzyme inhibitory activity of 3-[omega-(benzylmethylamino)alkoxy]xanthen-9-ones. Bioorg Med Chem. 2007 Jan 1;15(1):575-85. DMZSBU5 RU https://pubmed.ncbi.nlm.nih.gov/17008100 DMZSFEP DI DMZSFEP DMZSFEP DN FR161282 DMZSFEP TI TTK8R02 DMZSFEP TN Vasopressin V2 receptor (V2R) DMZSFEP MA Antagonist DMZSFEP RN Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. DMZSFEP RU https://pubmed.ncbi.nlm.nih.gov/12436936 DMZSGPB DI DMZSGPB DMZSGPB DN N-(5-Hydroxycarbamoyl-pentyl)-benzamide DMZSGPB TI TTBH0VX DMZSGPB TN Histone deacetylase (HDAC) DMZSGPB MA Inhibitor DMZSGPB RN Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J Med Chem. 1999 Nov 4;42(22):4669-79. DMZSGPB RU https://pubmed.ncbi.nlm.nih.gov/10579829 DMZSHDR DI DMZSHDR DMZSHDR DN 2-(4-fluoro-benzyl)isoquinoline-1,3,4-trione DMZSHDR TI TTPF2QI DMZSHDR TN Caspase-3 (CASP3) DMZSHDR MA Inhibitor DMZSHDR RN Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors. J Med Chem. 2006 Mar 9;49(5):1613-23. DMZSHDR RU https://pubmed.ncbi.nlm.nih.gov/16509578 DMZSJRC DI DMZSJRC DMZSJRC DN 8-acetyl-7-methoxy-2H-chromen-2-one DMZSJRC TI TT2LVK8 DMZSJRC TN Carbonic anhydrase IX (CA-IX) DMZSJRC MA Inhibitor DMZSJRC RN 7,8-disubstituted- but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumor-associated carbonic anhydrase isoforms IX and X... Bioorg Med Chem Lett. 2010 Dec 15;20(24):7255-8. DMZSJRC RU https://pubmed.ncbi.nlm.nih.gov/21067924 DMZSL7H DI DMZSL7H DMZSL7H DN 1,2-bis(2,3,4-trifluorophenyl)-2-hydroxyethanone DMZSL7H TI TTMF541 DMZSL7H TN Liver carboxylesterase (CES1) DMZSL7H MA Inhibitor DMZSL7H RN Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. Bioorg Med Chem. 2007 Jun 1;15(11):3801-17. DMZSL7H RU https://pubmed.ncbi.nlm.nih.gov/17399985 DMZSN1Y DI DMZSN1Y DMZSN1Y DN 4-(2-aminoethyl)-2-cyclohexylphenol DMZSN1Y TI TT8JRS7 DMZSN1Y TN Beta-secretase (BACE) DMZSN1Y MA Inhibitor DMZSN1Y RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZSN1Y RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZSO4R DI DMZSO4R DMZSO4R DN MRS2782 DMZSO4R TI TTNVSKA DMZSO4R TN P2Y purinoceptor 6 (P2RY6) DMZSO4R MA Agonist DMZSO4R RN Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32. DMZSO4R RU https://pubmed.ncbi.nlm.nih.gov/18514530 DMZSOG2 DI DMZSOG2 DMZSOG2 DN STO609 DMZSOG2 TI TTV298Y DMZSOG2 TN Calmodulin-dependent kinase II (CAMKK2) DMZSOG2 MA Inhibitor DMZSOG2 RN STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002 May 3;277(18):15813-8. DMZSOG2 RU https://pubmed.ncbi.nlm.nih.gov/11867640 DMZSOG2 DI DMZSOG2 DMZSOG2 DN STO609 DMZSOG2 TI TTGLQWZ DMZSOG2 TN CaM-kinase IV kinase (CAMKK1) DMZSOG2 MA Inhibitor DMZSOG2 RN STO-609, a specific inhibitor of the Ca(2+)/calmodulin-dependent protein kinase kinase. J Biol Chem. 2002 May 3;277(18):15813-8. DMZSOG2 RU https://pubmed.ncbi.nlm.nih.gov/11867640 DMZSOPU DI DMZSOPU DMZSOPU DN 3-Hydroxy-1H-benzo[b]azepine-2,5-dione DMZSOPU TI TTLD29N DMZSOPU TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMZSOPU MA Inhibitor DMZSOPU RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMZSOPU RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMZSOPU DI DMZSOPU DMZSOPU DN 3-Hydroxy-1H-benzo[b]azepine-2,5-dione DMZSOPU TI TTN9D8E DMZSOPU TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMZSOPU MA Inhibitor DMZSOPU RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMZSOPU RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMZSOPU DI DMZSOPU DMZSOPU DN 3-Hydroxy-1H-benzo[b]azepine-2,5-dione DMZSOPU TI TTKJEMQ DMZSOPU TN Glutamate receptor ionotropic NMDA 2A (NMDAR2A) DMZSOPU MA Inhibitor DMZSOPU RN Analogs of 3-hydroxy-1H-1-benzazepine-2,5-dione: structure-activity relationship at N-methyl-D-aspartate receptor glycine sites. J Med Chem. 1996 Nov 8;39(23):4643-53. DMZSOPU RU https://pubmed.ncbi.nlm.nih.gov/8917653 DMZSP7F DI DMZSP7F DMZSP7F DN (2-BROMOETHYL)(2-'FORMYL-4'-AMINOPHENYL) ACETATE DMZSP7F TI TT3NKIB DMZSP7F TN Pancreatic elastase 1 (CELA1) DMZSP7F MA Inhibitor DMZSP7F RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZSP7F RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZSQ04 DI DMZSQ04 DMZSQ04 DN 4-(4-methyl-benzylideneamino)-benzenesulfonamide DMZSQ04 TI TTVKILB DMZSQ04 TN Prostaglandin G/H synthase 2 (COX-2) DMZSQ04 MA Inhibitor DMZSQ04 RN Selective COX-2 inhibitors. Part 2: synthesis and biological evaluation of 4-benzylideneamino- and 4-phenyliminomethyl-benzenesulfonamides. Bioorg Med Chem. 2008 Mar 1;16(5):2697-706. DMZSQ04 RU https://pubmed.ncbi.nlm.nih.gov/18063374 DMZSTL5 DI DMZSTL5 DMZSTL5 DN H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 DMZSTL5 TI TTQW87Y DMZSTL5 TN Opioid receptor kappa (OPRK1) DMZSTL5 MA Inhibitor DMZSTL5 RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DMZSTL5 RU https://pubmed.ncbi.nlm.nih.gov/17315860 DMZSTL5 DI DMZSTL5 DMZSTL5 DN H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 DMZSTL5 TI TT27RFC DMZSTL5 TN Opioid receptor delta (OPRD1) DMZSTL5 MA Inhibitor DMZSTL5 RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DMZSTL5 RU https://pubmed.ncbi.nlm.nih.gov/17315860 DMZSTL5 DI DMZSTL5 DMZSTL5 DN H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 DMZSTL5 TI TTKWM86 DMZSTL5 TN Opioid receptor mu (MOP) DMZSTL5 MA Inhibitor DMZSTL5 RN Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7. DMZSTL5 RU https://pubmed.ncbi.nlm.nih.gov/17315860 DMZSUA9 DI DMZSUA9 DMZSUA9 DN ISIS 114531 DMZSUA9 TI TTY3BRA DMZSUA9 TN ZNF217 messenger RNA (ZNF217 mRNA) DMZSUA9 RN US patent application no. 6,242,590, Antisense modulation of zinc finger protein-217 expression. DMZSUA9 RU http://www.patentbuddy.com/Patent/6242590?ft=true&sr=true DMZSUHY DI DMZSUHY DMZSUHY DN Antanal 2 DMZSUHY TI TT27RFC DMZSUHY TN Opioid receptor delta (OPRD1) DMZSUHY MA Inhibitor DMZSUHY RN Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70. DMZSUHY RU https://pubmed.ncbi.nlm.nih.gov/18800771 DMZSUHY DI DMZSUHY DMZSUHY DN Antanal 2 DMZSUHY TI TTKWM86 DMZSUHY TN Opioid receptor mu (MOP) DMZSUHY MA Inhibitor DMZSUHY RN Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70. DMZSUHY RU https://pubmed.ncbi.nlm.nih.gov/18800771 DMZSWDM DI DMZSWDM DMZSWDM DN (S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid DMZSWDM TI TTZUFI5 DMZSWDM TN Nitric-oxide synthase brain (NOS1) DMZSWDM MA Inhibitor DMZSWDM RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMZSWDM RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMZSWDM DI DMZSWDM DMZSWDM DN (S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid DMZSWDM TI TTF10I9 DMZSWDM TN Nitric-oxide synthase inducible (NOS2) DMZSWDM MA Inhibitor DMZSWDM RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMZSWDM RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMZSWDM DI DMZSWDM DMZSWDM DN (S)-2-Amino-5-(N-methyl-guanidino)-pentanoic acid DMZSWDM TI TTCM4B3 DMZSWDM TN Nitric-oxide synthase endothelial (NOS3) DMZSWDM MA Inhibitor DMZSWDM RN 2-Iminopiperidine and other 2-iminoazaheterocycles as potent inhibitors of human nitric oxide synthase isoforms. J Med Chem. 1996 Feb 2;39(3):669-72. DMZSWDM RU https://pubmed.ncbi.nlm.nih.gov/8576908 DMZSYKC DI DMZSYKC DMZSYKC DN KM-233 DMZSYKC TI TTMSFAW DMZSYKC TN Cannabinoid receptor 2 (CB2) DMZSYKC MA Inhibitor DMZSYKC RN Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500. DMZSYKC RU https://pubmed.ncbi.nlm.nih.gov/18524604 DMZSYKC DI DMZSYKC DMZSYKC DN KM-233 DMZSYKC TI TT6OEDT DMZSYKC TN Cannabinoid receptor 1 (CB1) DMZSYKC MA Inhibitor DMZSYKC RN Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs. Bioorg Med Chem. 2008 Jul 1;16(13):6489-500. DMZSYKC RU https://pubmed.ncbi.nlm.nih.gov/18524604 DMZT6HL DI DMZT6HL DMZT6HL DN 4-(4-HYDROXYPHENYL)-1-NAPHTHALDEHYDE OXIME DMZT6HL TI TTOM3J0 DMZT6HL TN Estrogen receptor beta (ESR2) DMZT6HL MA Inhibitor DMZT6HL RN The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. DMZT6HL RU https://pubmed.ncbi.nlm.nih.gov/10592235 DMZT6JR DI DMZT6JR DMZT6JR DN 5-OH-DPAT DMZT6JR TI TTK8CXU DMZT6JR TN 5-HT 1B receptor (HTR1B) DMZT6JR MA Antagonist DMZT6JR RN Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3020-4. DMZT6JR RU https://pubmed.ncbi.nlm.nih.gov/1557407 DMZT6JR DI DMZT6JR DMZT6JR DN 5-OH-DPAT DMZT6JR TI TT4C8EA DMZT6JR TN Dopamine D3 receptor (D3R) DMZT6JR MA Inhibitor DMZT6JR RN Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37. DMZT6JR RU https://pubmed.ncbi.nlm.nih.gov/20038106 DMZT6JR DI DMZT6JR DMZT6JR DN 5-OH-DPAT DMZT6JR TI TTEX248 DMZT6JR TN Dopamine D2 receptor (D2R) DMZT6JR MA Inhibitor DMZT6JR RN Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a... J Med Chem. 2010 Feb 11;53(3):1023-37. DMZT6JR RU https://pubmed.ncbi.nlm.nih.gov/20038106 DMZT7C1 DI DMZT7C1 DMZT7C1 DN CP-481,715 DMZT7C1 TI TT8KLPT DMZT7C1 TN C-C chemokine receptor (CCR) DMZT7C1 MA Antagonist DMZT7C1 RN CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases. J Biol Chem. 2003 Oct 17;278(42):40473-80. DMZT7C1 RU https://pubmed.ncbi.nlm.nih.gov/12909630 DMZT8LI DI DMZT8LI DMZT8LI DN WAY170523 DMZT8LI TI TTHY57M DMZT8LI TN Matrix metalloproteinase-13 (MMP-13) DMZT8LI MA Inhibitor DMZT8LI RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1637). DMZT8LI RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1637 DMZT8QX DI DMZT8QX DMZT8QX DN 3-(6-Amino-purin-9-yl)-6-phenyl-hexan-2-ol DMZT8QX TI TTLP57V DMZT8QX TN Adenosine deaminase (ADA) DMZT8QX MA Inhibitor DMZT8QX RN Adenosine deaminase inhibitors: synthesis and biological evaluation of unsaturated, aromatic, and oxo derivatives of (+)-erythro-9-(2'S-hydroxy-3'R... J Med Chem. 2000 Nov 30;43(24):4694-700. DMZT8QX RU https://pubmed.ncbi.nlm.nih.gov/11101360 DMZT8UD DI DMZT8UD DMZT8UD DN [3H]JNJ 7777120 DMZT8UD TI TTXJ178 DMZT8UD TN Histamine H4 receptor (H4R) DMZT8UD MA Antagonist DMZT8UD RN A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004 Apr;309(1):404-13. DMZT8UD RU https://pubmed.ncbi.nlm.nih.gov/14722321 DMZTCOM DI DMZTCOM DMZTCOM DN 2-oxo-2H-thiochromene-3-carboxylic acid DMZTCOM TI TTEYTKG DMZTCOM TN Carbonic anhydrase XIV (CA-XIV) DMZTCOM MA Inhibitor DMZTCOM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZTCOM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZTCOM DI DMZTCOM DMZTCOM DN 2-oxo-2H-thiochromene-3-carboxylic acid DMZTCOM TI TT2LVK8 DMZTCOM TN Carbonic anhydrase IX (CA-IX) DMZTCOM MA Inhibitor DMZTCOM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZTCOM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZTCOM DI DMZTCOM DMZTCOM DN 2-oxo-2H-thiochromene-3-carboxylic acid DMZTCOM TI TTSYM0R DMZTCOM TN Carbonic anhydrase XII (CA-XII) DMZTCOM MA Inhibitor DMZTCOM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZTCOM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZTCOM DI DMZTCOM DMZTCOM DN 2-oxo-2H-thiochromene-3-carboxylic acid DMZTCOM TI TTANPDJ DMZTCOM TN Carbonic anhydrase II (CA-II) DMZTCOM MA Inhibitor DMZTCOM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZTCOM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZTCOM DI DMZTCOM DMZTCOM DN 2-oxo-2H-thiochromene-3-carboxylic acid DMZTCOM TI TTUNARX DMZTCOM TN Carbonic anhydrase (CA) DMZTCOM MA Inhibitor DMZTCOM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZTCOM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZTCOM DI DMZTCOM DMZTCOM DN 2-oxo-2H-thiochromene-3-carboxylic acid DMZTCOM TI TTHQPL7 DMZTCOM TN Carbonic anhydrase I (CA-I) DMZTCOM MA Inhibitor DMZTCOM RN Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J Med Chem. 2010 Jan 14;53(1):335-44. DMZTCOM RU https://pubmed.ncbi.nlm.nih.gov/19911821 DMZTDCL DI DMZTDCL DMZTDCL DN 3-Bromo-5-phenylsalicylc acid DMZTDCL TI TT5ZWB6 DMZTDCL TN Dihydrodiol dehydrogenase type I (AKR1C3) DMZTDCL MA Inhibitor DMZTDCL RN Structure-guided design, synthesis, and evaluation of salicylic acid-based inhibitors targeting a selectivity pocket in the active site of human 20... J Med Chem. 2009 May 28;52(10):3259-64. DMZTDCL RU https://pubmed.ncbi.nlm.nih.gov/19397269 DMZTIPJ DI DMZTIPJ DMZTIPJ DN 3,3'-pyrazine-2,5-diyldiphenol DMZTIPJ TI TTIWB6L DMZTIPJ TN Estradiol 17 beta-dehydrogenase 1 (17-beta-HSD1) DMZTIPJ MA Inhibitor DMZTIPJ RN Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as p... J Med Chem. 2008 Nov 13;51(21):6725-39. DMZTIPJ RU https://pubmed.ncbi.nlm.nih.gov/18855374 DMZTIU3 DI DMZTIU3 DMZTIU3 DN Iva-His-Pro-Phe-His-AHPPA-Leu-Phe-NH2 DMZTIU3 TI TTB2MXP DMZTIU3 TN Angiotensinogenase renin (REN) DMZTIU3 MA Inhibitor DMZTIU3 RN Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analogue inhibitors containing a novel analogue of statine. J Med Chem. 1985 Dec;28(12):1779-90. DMZTIU3 RU https://pubmed.ncbi.nlm.nih.gov/3906131 DMZTRQ0 DI DMZTRQ0 DMZTRQ0 DN [Tyr-Pro-Phe-NH-CH2-]2 DMZTRQ0 TI TTKWM86 DMZTRQ0 TN Opioid receptor mu (MOP) DMZTRQ0 MA Inhibitor DMZTRQ0 RN Structure-activity relationship of the novel bivalent and C-terminal modified analogues of endomorphin-2. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1847-50. DMZTRQ0 RU https://pubmed.ncbi.nlm.nih.gov/15780619 DMZTXDV DI DMZTXDV DMZTXDV DN 6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole DMZTXDV TI TTN9D8E DMZTXDV TN Glutamate receptor ionotropic NMDA 2B (NMDAR2B) DMZTXDV MA Inhibitor DMZTXDV RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMZTXDV RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMZTXDV DI DMZTXDV DMZTXDV DN 6-Nitro-2-(4-phenoxy-benzyl)-1H-benzoimidazole DMZTXDV TI TTLD29N DMZTXDV TN Glutamate receptor ionotropic NMDA 1 (NMDAR1) DMZTXDV MA Inhibitor DMZTXDV RN NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles. J Med Chem. 2004 Apr 8;47(8):2089-96. DMZTXDV RU https://pubmed.ncbi.nlm.nih.gov/15056006 DMZU0YF DI DMZU0YF DMZU0YF DN 8-(3,4-dichlorophenyl)-9H-purine-2,6-diamine DMZU0YF TI TT9SL3Q DMZU0YF TN Polypeptide deformylase (PDF) DMZU0YF MA Inhibitor DMZU0YF RN CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified c... Bioorg Med Chem. 2010 Feb 15;18(4):1684-701. DMZU0YF RU https://pubmed.ncbi.nlm.nih.gov/20117005 DMZU1GD DI DMZU1GD DMZU1GD DN 1,5-Dideoxy-1,5-imino-D-xylitol DMZU1GD TI TT1B5PU DMZU1GD TN Glucosylceramidase (GBA) DMZU1GD MA Inhibitor DMZU1GD RN In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. Bioorg Med Chem. 2008 Aug 1;16(15):7330-6. DMZU1GD RU https://pubmed.ncbi.nlm.nih.gov/18595718 DMZU1L0 DI DMZU1L0 DMZU1L0 DN NSC-289311 DMZU1L0 TI TTSZLWK DMZU1L0 TN Aromatase (CYP19A1) DMZU1L0 MA Inhibitor DMZU1L0 RN Fast three dimensional pharmacophore virtual screening of new potent non-steroid aromatase inhibitors. J Med Chem. 2009 Jan 8;52(1):143-50. DMZU1L0 RU https://pubmed.ncbi.nlm.nih.gov/19072235 DMZU23D DI DMZU23D DMZU23D DN 4-[3-(benzyloxy)benzoyl]benzoic acid DMZU23D TI TTT02K8 DMZU23D TN Steroid 5-alpha-reductase 2 (SRD5A2) DMZU23D MA Inhibitor DMZU23D RN Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59. DMZU23D RU https://pubmed.ncbi.nlm.nih.gov/16420060 DMZU2VG DI DMZU2VG DMZU2VG DN (1-Phenyl-propyl)-(9-phenyl-9H-purin-6-yl)-amine DMZU2VG TI TTK25J1 DMZU2VG TN Adenosine A1 receptor (ADORA1) DMZU2VG MA Inhibitor DMZU2VG RN N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. DMZU2VG RU https://pubmed.ncbi.nlm.nih.gov/1895305 DMZU4O8 DI DMZU4O8 DMZU4O8 DN TKP-1002 DMZU4O8 TI TTE0A2F DMZU4O8 TN Dopamine D4 receptor (D4R) DMZU4O8 MA Modulator DMZU4O8 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 217). DMZU4O8 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=217 DMZU74I DI DMZU74I DMZU74I DN 3-((S)-Azetidin-2-yloxy)-5-iodo-pyridine DMZU74I TI TTF4E0J DMZU74I TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMZU74I MA Inhibitor DMZU74I RN Pharmacology of the agonist binding sites of rat neuronal nicotinic receptor subtypes expressed in HEK 293 cells. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1845-8. DMZU74I RU https://pubmed.ncbi.nlm.nih.gov/15050613 DMZUES2 DI DMZUES2 DMZUES2 DN PENICILLIOL A DMZUES2 TI TTIU7X1 DMZUES2 TN Herpes simplex virus DNA polymerase UL30 (HSV UL30) DMZUES2 MA Inhibitor DMZUES2 RN Penicilliols A and B, novel inhibitors specific to mammalian Y-family DNA polymerases. Bioorg Med Chem. 2009 Mar 1;17(5):1811-6. DMZUES2 RU https://pubmed.ncbi.nlm.nih.gov/19223184 DMZUM95 DI DMZUM95 DMZUM95 DN 4-{4-[(aminosulfonyl)oxy]benzoyl}phenyl sulfamate DMZUM95 TI TTHM0R1 DMZUM95 TN Steryl-sulfatase (STS) DMZUM95 MA Inhibitor DMZUM95 RN Chiral aromatase and dual aromatase-steroid sulfatase inhibitors from the letrozole template: synthesis, absolute configuration, and in vitro activ... J Med Chem. 2008 Jul 24;51(14):4226-38. DMZUM95 RU https://pubmed.ncbi.nlm.nih.gov/18590272 DMZUQ7X DI DMZUQ7X DMZUQ7X DN PMID23428964CI3 DMZUQ7X TI TTPHMWB DMZUQ7X TN Aminopeptidase N (ANPEP) DMZUQ7X MA Inhibitor DMZUQ7X RN Selective aminopeptidase-N (CD13) inhibitors with relevance to cancer chemotherapy. Bioorg Med Chem. 2013 Apr 1;21(7):2135-44. DMZUQ7X RU https://pubmed.ncbi.nlm.nih.gov/23428964 DMZURA2 DI DMZURA2 DMZURA2 DN PB-27 DMZURA2 TI TTXQKM3 DMZURA2 TN Farnesyl protein transferase (Ftase) DMZURA2 MA Inhibitor DMZURA2 RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DMZURA2 RU https://pubmed.ncbi.nlm.nih.gov/15916422 DMZURA2 DI DMZURA2 DMZURA2 DN PB-27 DMZURA2 TI TT7WZIJ DMZURA2 TN CAAX farnesyltransferase beta (FNTB) DMZURA2 MA Inhibitor DMZURA2 RN Protein farnesyltransferase inhibitors exhibit potent antimalarial activity. J Med Chem. 2005 Jun 2;48(11):3704-13. DMZURA2 RU https://pubmed.ncbi.nlm.nih.gov/15916422 DMZUSJD DI DMZUSJD DMZUSJD DN Long-acting factor VIII DMZUSJD TI TT1290U DMZUSJD TN Coagulation factor VIII (F8) DMZUSJD MA Modulator DMZUSJD RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607). DMZUSJD RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2607 DMZUTXW DI DMZUTXW DMZUTXW DN GSK1511931 DMZUTXW TI TTQFBMY DMZUTXW TN IGF1R messenger RNA (IGF1R mRNA) DMZUTXW MA Inhibitor DMZUTXW RN Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway. Bioorg Med Chem Lett. 2009 Jan 15;19(2):373-7. DMZUTXW RU https://pubmed.ncbi.nlm.nih.gov/19081716 DMZUY93 DI DMZUY93 DMZUY93 DN Abyssinone-VI-4-O-methyl ether DMZUY93 TI TTELIN2 DMZUY93 TN PTPN1 messenger RNA (PTPN1 mRNA) DMZUY93 MA Inhibitor DMZUY93 RN Protein tyrosine phosphatase-1B inhibitory activity of isoprenylated flavonoids isolated from Erythrina mildbraedii. J Nat Prod. 2006 Nov;69(11):1572-6. DMZUY93 RU https://pubmed.ncbi.nlm.nih.gov/17125223 DMZUYX1 DI DMZUYX1 DMZUYX1 DN 7alpha-NH2-ginkgolide B DMZUYX1 TI TTQL5VC DMZUYX1 TN Platelet-activating factor receptor (PTAFR) DMZUYX1 MA Antagonist DMZUYX1 RN Preparation of 7-substituted ginkgolide derivatives: potent platelet activating factor (PAF) receptor antagonists. J Med Chem. 2003 Feb 13;46(4):601-8. DMZUYX1 RU https://pubmed.ncbi.nlm.nih.gov/12570381 DMZV3MD DI DMZV3MD DMZV3MD DN 4-fluorophenyl 1-(4-butoxyphenyl)propylcarbamate DMZV3MD TI TTDP1UC DMZV3MD TN Fatty acid amide hydrolase (FAAH) DMZV3MD MA Inhibitor DMZV3MD RN Oxime carbamate--discovery of a series of novel FAAH inhibitors. Bioorg Med Chem Lett. 2010 Feb 1;20(3):1272-7. DMZV3MD RU https://pubmed.ncbi.nlm.nih.gov/20036536 DMZV52W DI DMZV52W DMZV52W DN (S,R)-isotetrandrine hydrochloride DMZV52W TI TTEX248 DMZV52W TN Dopamine D2 receptor (D2R) DMZV52W MA Inhibitor DMZV52W RN Displacement activity of bisbenzylisoquinoline alkaloids at striatal 3H-SCH 23390 and 3H-raclopride binding sites. J Nat Prod. 1992 Sep;55(9):1281-6. DMZV52W RU https://pubmed.ncbi.nlm.nih.gov/1431946 DMZV5A7 DI DMZV5A7 DMZV5A7 DN ISIS 100913 DMZV5A7 TI TTW8TJI DMZV5A7 TN MEKK1 messenger RNA (MAP3K1 mRNA) DMZV5A7 RN US patent application no. 6,168,950, Antisense modulation of MEKK1 expression. DMZV5A7 RU http://www.patentbuddy.com/Patent/6168950?ft=true&sr=true DMZVBLT DI DMZVBLT DMZVBLT DN Methyl[4'-(trifluoromethyl)-4-biphenylyl]amine DMZVBLT TI TTBGTCW DMZVBLT TN Kinesin spindle messenger RNA (KIF11 mRNA) DMZVBLT MA Inhibitor DMZVBLT RN Novel ATP-competitive kinesin spindle protein inhibitors. J Med Chem. 2007 Oct 4;50(20):4939-52. DMZVBLT RU https://pubmed.ncbi.nlm.nih.gov/17725339 DMZVBPG DI DMZVBPG DMZVBPG DN 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG TI TTXJ178 DMZVBPG TN Histamine H4 receptor (H4R) DMZVBPG MA Inhibitor DMZVBPG RN Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor. Bioorg Med Chem. 2010 Jul 15;18(14):5441-8. DMZVBPG RU https://pubmed.ncbi.nlm.nih.gov/20541426 DMZVBPG DI DMZVBPG DMZVBPG DN 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG TI TT9JNIC DMZVBPG TN Histamine H3 receptor (H3R) DMZVBPG MA Inhibitor DMZVBPG RN Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. J Med Chem. 2010 Sep 9;53(17):6445-56. DMZVBPG RU https://pubmed.ncbi.nlm.nih.gov/20690643 DMZVBPG DI DMZVBPG DMZVBPG DN 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG TI TTVG215 DMZVBPG TN Debrisoquine 4-hydroxylase (CYP2D6) DMZVBPG MA Inhibitor DMZVBPG RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMZVBPG RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMZVBPG DI DMZVBPG DMZVBPG DN 2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole DMZVBPG TI TTXV4FI DMZVBPG TN Albendazole monooxygenase (CYP3A4) DMZVBPG MA Inhibitor DMZVBPG RN Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4. DMZVBPG RU https://pubmed.ncbi.nlm.nih.gov/20384344 DMZVDLS DI DMZVDLS DMZVDLS DN NOX 2149 DMZVDLS TI TTNT7K8 DMZVDLS TN Nociceptin receptor (OPRL1) DMZVDLS RN Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60. DMZVDLS RU https://pubmed.ncbi.nlm.nih.gov/18095918 DMZVE0S DI DMZVE0S DMZVE0S DN ISIS 114399 DMZVE0S TI TT8OY02 DMZVE0S TN ARA70 messenger RNA (NCOA4 mRNA) DMZVE0S RN US patent application no. 6,255,110, Antisense modulation of ARA70 expression. DMZVE0S RU http://www.patentbuddy.com/Patent/6255110?ft=true&sr=true DMZVF6M DI DMZVF6M DMZVF6M DN Methanandamide DMZVF6M TI TT6OEDT DMZVF6M TN Cannabinoid receptor 1 (CB1) DMZVF6M MA Antagonist DMZVF6M RN Methanandamide attenuates cocaine-induced hyperthermia in rats by a cannabinoid CB1-dopamine D2 receptor mechanism. Brain Res. 2009 Mar 13;1260:7-14. DMZVF6M RU https://pubmed.ncbi.nlm.nih.gov/19401177 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TTN7BL9 DMZVHSB TN Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TTHI19T DMZVHSB TN Staphylococcus Beta-lactamase (Stap-coc blaZ) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TTNAW8S DMZVHSB TN Bacterial Flavohemoglobin (Bact hmp) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TT9SL3Q DMZVHSB TN Polypeptide deformylase (PDF) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TT1RS9F DMZVHSB TN Acetylcholinesterase (AChE) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TTC67I0 DMZVHSB TN Bacterial Glucosamine-6-phosphate synthase (Bact glmS) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TT8VUE0 DMZVHSB TN Chymase (CYM) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVHSB DI DMZVHSB DMZVHSB DN 2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB TI TTEB0GD DMZVHSB TN Cholinesterase (BCHE) DMZVHSB MA Inhibitor DMZVHSB RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZVHSB RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZVJYL DI DMZVJYL DMZVJYL DN PcTx1 DMZVJYL TI TTRJYB6 DMZVJYL TN Acid-sensing ion channel 1 (ASIC1) DMZVJYL MA Blocker DMZVJYL RN Challenges in analgesic drug development. Clin Pharmacol Ther. 2009 Oct;86(4):447-50. DMZVJYL RU https://pubmed.ncbi.nlm.nih.gov/19675542 DMZVK16 DI DMZVK16 DMZVK16 DN PMID1656041C74 DMZVK16 TI TTPADOQ DMZVK16 TN HMG-CoA reductase (HMGCR) DMZVK16 MA Inhibitor DMZVK16 RN Synthesis and biological activity of new HMG-CoA reductase inhibitors. 3. Lactones of 6-phenoxy-3,5-dihydroxyhexanoic acids. J Med Chem. 1991 Oct;34(10):2962-83. DMZVK16 RU https://pubmed.ncbi.nlm.nih.gov/1656041 DMZVLJH DI DMZVLJH DMZVLJH DN AM-3701 DMZVLJH TI TTDZN01 DMZVLJH TN Cathepsin K (CTSK) DMZVLJH MA Inhibitor DMZVLJH RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2350). DMZVLJH RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2350 DMZVMDO DI DMZVMDO DMZVMDO DN 2-(difluoromethyl)-9H-carbazole DMZVMDO TI TTBGTCW DMZVMDO TN Kinesin spindle messenger RNA (KIF11 mRNA) DMZVMDO MA Inhibitor DMZVMDO RN Kinesin spindle protein (KSP) inhibitors with 2,3-fused indole scaffolds. J Med Chem. 2010 Jul 8;53(13):5054-8. DMZVMDO RU https://pubmed.ncbi.nlm.nih.gov/20521839 DMZVS9Y DI DMZVS9Y DMZVS9Y DN OXYQUINOLINE DMZVS9Y TI TTZL0OI DMZVS9Y TN Methionine aminopeptidase 2 (METAP2) DMZVS9Y MA Inhibitor DMZVS9Y RN Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010). DMZVS9Y RU http://www.sciencedirect.com/science/article/pii/S0960894X10007468 DMZVSYD DI DMZVSYD DMZVSYD DN 1-benzhydryl-4-cyclohexylpiperidin-4-ol DMZVSYD TI TTKWM86 DMZVSYD TN Opioid receptor mu (MOP) DMZVSYD MA Inhibitor DMZVSYD RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMZVSYD RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMZVSYD DI DMZVSYD DMZVSYD DN 1-benzhydryl-4-cyclohexylpiperidin-4-ol DMZVSYD TI TTNT7K8 DMZVSYD TN Nociceptin receptor (OPRL1) DMZVSYD MA Inhibitor DMZVSYD RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMZVSYD RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMZVSYD DI DMZVSYD DMZVSYD DN 1-benzhydryl-4-cyclohexylpiperidin-4-ol DMZVSYD TI TT27RFC DMZVSYD TN Opioid receptor delta (OPRD1) DMZVSYD MA Inhibitor DMZVSYD RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMZVSYD RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMZVSYD DI DMZVSYD DMZVSYD DN 1-benzhydryl-4-cyclohexylpiperidin-4-ol DMZVSYD TI TTQW87Y DMZVSYD TN Opioid receptor kappa (OPRK1) DMZVSYD MA Inhibitor DMZVSYD RN Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. DMZVSYD RU https://pubmed.ncbi.nlm.nih.gov/17420123 DMZVWCG DI DMZVWCG DMZVWCG DN 13,14-dihydro-15-keto-PGD2 DMZVWCG TI TTQDMX5 DMZVWCG TN Prostaglandin D2 receptor 2 (PTGDR2) DMZVWCG MA Agonist DMZVWCG RN CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. DMZVWCG RU https://pubmed.ncbi.nlm.nih.gov/16256979 DMZW0YO DI DMZW0YO DMZW0YO DN IM-023911 DMZW0YO TI TTUTJGQ DMZW0YO TN Vascular endothelial growth factor receptor 2 (KDR) DMZW0YO MA Inhibitor DMZW0YO RN Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4696-8. DMZW0YO RU https://pubmed.ncbi.nlm.nih.gov/16143524 DMZW9AC DI DMZW9AC DMZW9AC DN N-Acetylalanine DMZW9AC TI TTFBNVI DMZW9AC TN Aldose reductase (AKR1B1) DMZW9AC MA Inhibitor DMZW9AC RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZW9AC RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZWAQ3 DI DMZWAQ3 DMZWAQ3 DN DXL-625 DMZWAQ3 TI TTUE541 DMZWAQ3 TN Leukocyte surface antigen Leu-16 (CD20) DMZWAQ3 MA Modulator DMZWAQ3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2628). DMZWAQ3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2628 DMZWGVP DI DMZWGVP DMZWGVP DN Saframycin A DMZWGVP TI TTUGSWA DMZWGVP TN Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) DMZWGVP MA Binder DMZWGVP RN Identification of GAPDH as a protein target of the saframycin antiproliferative agents. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5862-6. DMZWGVP RU https://pubmed.ncbi.nlm.nih.gov/15079082 DMZWH6E DI DMZWH6E DMZWH6E DN ISIS 113210 DMZWH6E TI TTHJT3X DMZWH6E TN STAT3 messenger RNA (STAT3 mRNA) DMZWH6E RN US patent application no. 7,098,192, Antisense oligonucleotide modulation of STAT3 expression. DMZWH6E RU http://www.patentbuddy.com/Patent/7098192?ft=true&sr=true DMZWIVJ DI DMZWIVJ DMZWIVJ DN N-hydroxy-2,3-bis(phenylsulfonamido)propanamide DMZWIVJ TI TTYRF5E DMZWIVJ TN Matrix metalloproteinase-21 (MMP-21) DMZWIVJ MA Inhibitor DMZWIVJ RN Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7. DMZWIVJ RU https://pubmed.ncbi.nlm.nih.gov/18442906 DMZWIVJ DI DMZWIVJ DMZWIVJ DN N-hydroxy-2,3-bis(phenylsulfonamido)propanamide DMZWIVJ TI TT6X50U DMZWIVJ TN Matrix metalloproteinase-9 (MMP-9) DMZWIVJ MA Inhibitor DMZWIVJ RN Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7. DMZWIVJ RU https://pubmed.ncbi.nlm.nih.gov/18442906 DMZWIVJ DI DMZWIVJ DMZWIVJ DN N-hydroxy-2,3-bis(phenylsulfonamido)propanamide DMZWIVJ TI TTMTWOS DMZWIVJ TN Matrix metalloproteinase-7 (MMP-7) DMZWIVJ MA Inhibitor DMZWIVJ RN Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3333-7. DMZWIVJ RU https://pubmed.ncbi.nlm.nih.gov/18442906 DMZWMV0 DI DMZWMV0 DMZWMV0 DN C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 DMZWMV0 TI TTNI91K DMZWMV0 TN Melanocortin receptor 3 (MC3R) DMZWMV0 MA Inhibitor DMZWMV0 RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMZWMV0 RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMZWMV0 DI DMZWMV0 DMZWMV0 DN C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 DMZWMV0 TI TTEOSZT DMZWMV0 TN Melanocortin receptor (MCR) DMZWMV0 MA Inhibitor DMZWMV0 RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMZWMV0 RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMZWMV0 DI DMZWMV0 DMZWMV0 DN C[Nle-Pro-D-Phe-Arg-Trp-Glu]-NH2 DMZWMV0 TI TTD0CIQ DMZWMV0 TN Melanocortin receptor 4 (MC4R) DMZWMV0 MA Inhibitor DMZWMV0 RN Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52. DMZWMV0 RU https://pubmed.ncbi.nlm.nih.gov/16539382 DMZWNO9 DI DMZWNO9 DMZWNO9 DN BMS614 DMZWNO9 TI TTW38KT DMZWNO9 TN Retinoic acid receptor alpha (RARA) DMZWNO9 MA Antagonist DMZWNO9 RN Co-regulator recruitment and the mechanism of retinoic acid receptor synergy. Nature. 2002 Jan 10;415(6868):187-92. DMZWNO9 RU https://pubmed.ncbi.nlm.nih.gov/11805839 DMZWQH3 DI DMZWQH3 DMZWQH3 DN [125I]epibatidine DMZWQH3 TI TTF4E0J DMZWQH3 TN Neuronal acetylcholine receptor alpha-2 (CHRNA2) DMZWQH3 MA Agonist DMZWQH3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 463). DMZWQH3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=463 DMZWQH3 DI DMZWQH3 DMZWQH3 DN [125I]epibatidine DMZWQH3 TI TT5KPZR DMZWQH3 TN Neuronal acetylcholine receptor beta-2 (CHRNB2) DMZWQH3 MA Agonist DMZWQH3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 465). DMZWQH3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=465 DMZWQH3 DI DMZWQH3 DMZWQH3 DN [125I]epibatidine DMZWQH3 TI TTH18TF DMZWQH3 TN Muscarinic acetylcholine receptor M5 (CHRM5) DMZWQH3 MA Agonist DMZWQH3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467). DMZWQH3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=467 DMZWQH3 DI DMZWQH3 DMZWQH3 DN [125I]epibatidine DMZWQH3 TI TTLA931 DMZWQH3 TN Neuronal acetylcholine receptor alpha-7 (CHRNA7) DMZWQH3 MA Agonist DMZWQH3 RN URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 468). DMZWQH3 RU http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=468 DMZWRU7 DI DMZWRU7 DMZWRU7 DN 1-(4-Methoxy-benzenesulfonyl)-heptane-3-thiol DMZWRU7 TI TTHY57M DMZWRU7 TN Matrix metalloproteinase-13 (MMP-13) DMZWRU7 MA Inhibitor DMZWRU7 RN Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols. Bioorg Med Chem Lett. 1999 Apr 5;9(7):943-8. DMZWRU7 RU https://pubmed.ncbi.nlm.nih.gov/10230616 DMZWTJK DI DMZWTJK DMZWTJK DN D[Cha4,Orn8]VP DMZWTJK TI TT4TFGN DMZWTJK TN Vasopressin V1a receptor (V1AR) DMZWTJK MA Inhibitor DMZWTJK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMZWTJK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMZWTJK DI DMZWTJK DMZWTJK DN D[Cha4,Orn8]VP DMZWTJK TI TTSCIUP DMZWTJK TN Oxytocin receptor (OTR) DMZWTJK MA Inhibitor DMZWTJK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMZWTJK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMZWTJK DI DMZWTJK DMZWTJK DN D[Cha4,Orn8]VP DMZWTJK TI TTL9MHW DMZWTJK TN Vasopressin V1b receptor (V1BR) DMZWTJK MA Inhibitor DMZWTJK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMZWTJK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMZWTJK DI DMZWTJK DMZWTJK DN D[Cha4,Orn8]VP DMZWTJK TI TTK8R02 DMZWTJK TN Vasopressin V2 receptor (V2R) DMZWTJK MA Inhibitor DMZWTJK RN Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47. DMZWTJK RU https://pubmed.ncbi.nlm.nih.gov/17300166 DMZWTY7 DI DMZWTY7 DMZWTY7 DN Phorbol 12,13-butyrate DMZWTY7 TI TT9WJ8U DMZWTY7 TN Protein kinase C delta (PRKCD) DMZWTY7 MA Inhibitor DMZWTY7 RN Conformationally constrained analogues of diacylglycerol (DAG). 28. DAG-dioxolanones reveal a new additional interaction site in the C1b domain of ... J Med Chem. 2007 Jul 26;50(15):3465-81. DMZWTY7 RU https://pubmed.ncbi.nlm.nih.gov/17591763 DMZWUFK DI DMZWUFK DMZWUFK DN H-Dmt-Tic-NH-CH2-Indn DMZWUFK TI TT27RFC DMZWUFK TN Opioid receptor delta (OPRD1) DMZWUFK MA Inhibitor DMZWUFK RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMZWUFK RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMZWUFK DI DMZWUFK DMZWUFK DN H-Dmt-Tic-NH-CH2-Indn DMZWUFK TI TTKWM86 DMZWUFK TN Opioid receptor mu (MOP) DMZWUFK MA Inhibitor DMZWUFK RN Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8. DMZWUFK RU https://pubmed.ncbi.nlm.nih.gov/18178091 DMZX2BH DI DMZX2BH DMZX2BH DN N-(4-methyl-benzyl)-4-phenoxy-benzamide DMZX2BH TI TTQBR95 DMZX2BH TN Stress-activated protein kinase 2a (p38 alpha) DMZX2BH MA Inhibitor DMZX2BH RN Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5274-9. DMZX2BH RU https://pubmed.ncbi.nlm.nih.gov/16169718 DMZX2GE DI DMZX2GE DMZX2GE DN 2-(3-guanidinophenyl)-3-mercaptopropanoic acid DMZX2GE TI TTP18AY DMZX2GE TN Carboxypeptidase B2 (CPB2) DMZX2GE MA Inhibitor DMZX2GE RN 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett. 2007 Mar 1;17(5):1349-54. DMZX2GE RU https://pubmed.ncbi.nlm.nih.gov/17189688 DMZX430 DI DMZX430 DMZX430 DN KNI-1293 DMZX430 TI TTXMNHO DMZX430 TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMZX430 MA Inhibitor DMZX430 RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMZX430 RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMZX57Y DI DMZX57Y DMZX57Y DN befetupitant DMZX57Y TI TTZPO1L DMZX57Y TN Substance-P receptor (TACR1) DMZX57Y MA Antagonist DMZX57Y RN Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1362-5. DMZX57Y RU https://pubmed.ncbi.nlm.nih.gov/16332435 DMZX72E DI DMZX72E DMZX72E DN 1-adamantan-1-yl-3-(3-hydroxypropyl)urea DMZX72E TI TT7WVHI DMZX72E TN Soluble epoxide hydrolase (EPHX2) DMZX72E MA Inhibitor DMZX72E RN 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26. DMZX72E RU https://pubmed.ncbi.nlm.nih.gov/17894481 DMZXE6O DI DMZXE6O DMZXE6O DN C-16-(S)-3-methylindolerapamycin DMZXE6O TI TTCJG29 DMZXE6O TN Serine/threonine-protein kinase mTOR (mTOR) DMZXE6O MA Inhibitor DMZXE6O RN The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain. J Biol Chem. 2007 May 4;282(18):13395-401. DMZXE6O RU https://pubmed.ncbi.nlm.nih.gov/17350953 DMZXF36 DI DMZXF36 DMZXF36 DN N,8-diphenyl-9H-purin-6-amine DMZXF36 TI TTRSMW9 DMZXF36 TN Glycogen synthase kinase-3 beta (GSK-3B) DMZXF36 MA Inhibitor DMZXF36 RN Novel 8-arylated purines as inhibitors of glycogen synthase kinase. Eur J Med Chem. 2010 Aug;45(8):3389-93. DMZXF36 RU https://pubmed.ncbi.nlm.nih.gov/20472330 DMZXFT9 DI DMZXFT9 DMZXFT9 DN CCT-241533 DMZXFT9 TI TT9ABMF DMZXFT9 TN Serine/threonine-protein kinase Chk2 (RAD53) DMZXFT9 MA Inhibitor DMZXFT9 RN CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors. Cancer Res. 2011 Jan 15;71(2):463-72. DMZXFT9 RU https://pubmed.ncbi.nlm.nih.gov/21239475 DMZXI6U DI DMZXI6U DMZXI6U DN KNI-10260 DMZXI6U TI TTXMNHO DMZXI6U TN Plasmodium Plasmepsin 2 (Malaria PLA2) DMZXI6U MA Inhibitor DMZXI6U RN Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin. Bioorg Med Chem. 2008 Dec 1;16(23):10049-60. DMZXI6U RU https://pubmed.ncbi.nlm.nih.gov/18952439 DMZXIW0 DI DMZXIW0 DMZXIW0 DN 2-EPI-2-THIOSALVINORIN B DMZXIW0 TI TTQW87Y DMZXIW0 TN Opioid receptor kappa (OPRK1) DMZXIW0 MA Inhibitor DMZXIW0 RN Convenient synthesis and in vitro pharmacological activity of 2-thioanalogs of salvinorins A and B. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2229-32. DMZXIW0 RU https://pubmed.ncbi.nlm.nih.gov/17303418 DMZXMB7 DI DMZXMB7 DMZXMB7 DN 7-hydroxycholesterol DMZXMB7 TI TT1TYN7 DMZXMB7 TN Nuclear receptor ROR-alpha (RORA) DMZXMB7 MA Agonist DMZXMB7 RN Identification of natural ligands of retinoic acid receptor-related orphan receptor alpha ligand-binding domain expressed in Sf9 cells--a mass spectrometry approach. Anal Biochem. 2003 Dec 1;323(1):139-49. DMZXMB7 RU https://pubmed.ncbi.nlm.nih.gov/14622968 DMZXT34 DI DMZXT34 DMZXT34 DN (R)-2-amino-3-(4-octylphenylamino)propan-1-ol DMZXT34 TI TTCN0M9 DMZXT34 TN Sphingosine kinase 2 (SPHK2) DMZXT34 MA Inhibitor DMZXT34 RN Discovery of novel sphingosine kinase 1 inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6119-21. DMZXT34 RU https://pubmed.ncbi.nlm.nih.gov/19800228 DMZY41U DI DMZY41U DMZY41U DN Para-Isopropylaniline DMZY41U TI TT3NKIB DMZY41U TN Pancreatic elastase 1 (CELA1) DMZY41U MA Inhibitor DMZY41U RN How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. DMZY41U RU https://pubmed.ncbi.nlm.nih.gov/17139284 DMZY6VX DI DMZY6VX DMZY6VX DN 3-Methyl-7-nitro-1,2,3,4-tetrahydro-isoquinoline DMZY6VX TI TTWG9A4 DMZY6VX TN Adrenergic receptor alpha-2A (ADRA2A) DMZY6VX MA Inhibitor DMZY6VX RN Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoqui... Bioorg Med Chem Lett. 2005 Feb 15;15(4):1143-7. DMZY6VX RU https://pubmed.ncbi.nlm.nih.gov/15686930 DMZY72I DI DMZY72I DMZY72I DN 2-Methyl-1-phenyl-2-pyridin-3-yl-propan-1-one DMZY72I TI TTIQUX7 DMZY72I TN Steroid 11-beta-hydroxylase (CYP11B1) DMZY72I MA Inhibitor DMZY72I RN Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984 Jan;27(1):15-9. DMZY72I RU https://pubmed.ncbi.nlm.nih.gov/6606707 DMZY8UW DI DMZY8UW DMZY8UW DN 4-Nitro-benzenesulfonamide DMZY8UW TI TTUNARX DMZY8UW TN Carbonic anhydrase (CA) DMZY8UW MA Inhibitor DMZY8UW RN Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. DMZY8UW RU https://pubmed.ncbi.nlm.nih.gov/15482952 DMZY8UW DI DMZY8UW DMZY8UW DN 4-Nitro-benzenesulfonamide DMZY8UW TI TTANPDJ DMZY8UW TN Carbonic anhydrase II (CA-II) DMZY8UW MA Inhibitor DMZY8UW RN Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5703-7. DMZY8UW RU https://pubmed.ncbi.nlm.nih.gov/15482952 DMZYE8W DI DMZYE8W DMZYE8W DN 5-(4-((phenethylamino)methyl)phenoxy)picolinamide DMZYE8W TI TT27RFC DMZYE8W TN Opioid receptor delta (OPRD1) DMZYE8W MA Inhibitor DMZYE8W RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMZYE8W RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMZYE8W DI DMZYE8W DMZYE8W DN 5-(4-((phenethylamino)methyl)phenoxy)picolinamide DMZYE8W TI TTQW87Y DMZYE8W TN Opioid receptor kappa (OPRK1) DMZYE8W MA Inhibitor DMZYE8W RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMZYE8W RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMZYE8W DI DMZYE8W DMZYE8W DN 5-(4-((phenethylamino)methyl)phenoxy)picolinamide DMZYE8W TI TTKWM86 DMZYE8W TN Opioid receptor mu (MOP) DMZYE8W MA Inhibitor DMZYE8W RN Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52. DMZYE8W RU https://pubmed.ncbi.nlm.nih.gov/17720493 DMZYIKR DI DMZYIKR DMZYIKR DN PD-160946 DMZYIKR TI TTBPGLU DMZYIKR TN Neuromedin-K receptor (TACR3) DMZYIKR MA Inhibitor DMZYIKR RN The development of a novel series of non-peptide tachykinin NK3 receptor selective antagonists, Bioorg. Med. Chem. Lett. 5(16):1773-1778 (1995). DMZYIKR RU http://www.sciencedirect.com/science/article/pii/0960894X9500313I DMZYJHV DI DMZYJHV DMZYJHV DN AdcAhxArg4Lys(biotin)-PEG-OMe DMZYJHV TI TTW4Y2M DMZYJHV TN cAMP protein kinase type II-beta (PRKAR2B) DMZYJHV MA Inhibitor DMZYJHV RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DMZYJHV RU https://pubmed.ncbi.nlm.nih.gov/12941328 DMZYJHV DI DMZYJHV DMZYJHV DN AdcAhxArg4Lys(biotin)-PEG-OMe DMZYJHV TI TTNAHEX DMZYJHV TN cAMP-dependent protein kinase A type I (PRKAR1A) DMZYJHV MA Inhibitor DMZYJHV RN Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9. DMZYJHV RU https://pubmed.ncbi.nlm.nih.gov/12941328 DMZYJU0 DI DMZYJU0 DMZYJU0 DN NSC-306843 DMZYJU0 TI TTJLP0R DMZYJU0 TN Quinone reductase 2 (NQO2) DMZYJU0 MA Inhibitor DMZYJU0 RN In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. DMZYJU0 RU https://pubmed.ncbi.nlm.nih.gov/21074425 DMZYK1W DI DMZYK1W DMZYK1W DN Carbamoyl phosphate disodium DMZYK1W TI TTZHA0O DMZYK1W TN Carbonic anhydrase IV (CA-IV) DMZYK1W MA Inhibitor DMZYK1W RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7. DMZYK1W RU https://pubmed.ncbi.nlm.nih.gov/15501037 DMZYK1W DI DMZYK1W DMZYK1W DN Carbamoyl phosphate disodium DMZYK1W TI TTHQPL7 DMZYK1W TN Carbonic anhydrase I (CA-I) DMZYK1W MA Inhibitor DMZYK1W RN Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with phosphates, carbamoyl phosphate, and the phosphonate antiviral dru... Bioorg Med Chem Lett. 2004 Dec 6;14(23):5763-7. DMZYK1W RU https://pubmed.ncbi.nlm.nih.gov/15501037 DMZYOPD DI DMZYOPD DMZYOPD DN ISIS 11929 DMZYOPD TI TT1PL7M DMZYOPD TN E-selectin messenger RNA (SELE mRNA) DMZYOPD RN US patent application no. 5,789,573, Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2. DMZYOPD RU http://www.patentbuddy.com/Patent/5789573?ft=true&sr=true DMZYQOB DI DMZYQOB DMZYQOB DN DSM2 DMZYQOB TI TT3PQ2Y DMZYQOB TN Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase) DMZYQOB MA Inhibitor DMZYQOB RN Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010 Jun;10(3):226-39. DMZYQOB RU https://pubmed.ncbi.nlm.nih.gov/20334617 DMZYSM1 DI DMZYSM1 DMZYSM1 DN N-methylstephisoferulin DMZYSM1 TI TT27RFC DMZYSM1 TN Opioid receptor delta (OPRD1) DMZYSM1 MA Inhibitor DMZYSM1 RN Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91. DMZYSM1 RU https://pubmed.ncbi.nlm.nih.gov/20426456